[{"id":"961a0adf518c4617bdb51ea976b4d471","type":"TRIAL","name":"\"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients.\"","canonical_id":"clinicaltrials.gov:NCT05855629","description":"Acne Vulgaris","metadata":null},{"id":"f6fe7cf9673d4c7cb8ef1a3162a8cef0","type":"TRIAL","name":"\"Effect of CPA/EE Drug on Periodontal Tissue and hsCRP Levels in PCOS Patients With Gingivitis","canonical_id":"clinicaltrials.gov:NCT05657171","description":"Periodontal Diseases","metadata":null},{"id":"1713ed6fc7fc4f08b54980774256b6ea","type":"TRIAL","name":"\"Efficacy and Safety of Linaclotide in Chronic Constipation\"","canonical_id":"clinicaltrials.gov:NCT07431957","description":"Chronic Idiopathic Constipation; Irritable Bowel Syndrome (IBS-C); Chronic Constipation; CIC; Constipation Predominant Irritable Bowel Syndrome","metadata":null},{"id":"01a746ab43644f6a82a92c1cbdb6e46f","type":"TRIAL","name":"\"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention\"","canonical_id":"clinicaltrials.gov:NCT01023139","description":"Obesity","metadata":null},{"id":"587acb1c1ec7473e9351ccdb9f5b8c2f","type":"TRIAL","name":"\"Extended\" (Alternate Day) Antipsychotic Dosing","canonical_id":"clinicaltrials.gov:NCT04478838","description":"Schizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic Agents","metadata":null},{"id":"1602d51de7804b5d83bfe4ce1254bb9d","type":"TRIAL","name":"\"MILNACIPRAN\" in Subjects With Chronic Shoulder Pain","canonical_id":"clinicaltrials.gov:NCT01289236","description":"Chronic Shoulder Pain","metadata":null},{"id":"a6f35b944e3846858e5c088c6a3b5110","type":"TRIAL","name":"\"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes\"","canonical_id":"clinicaltrials.gov:NCT00792376","description":"Achilles Tendinopathy","metadata":null},{"id":"f0fea5e88263443ba5fd5336180e728e","type":"TRIAL","name":"\"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)\"","canonical_id":"clinicaltrials.gov:NCT03219710","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"87937e48ab9d4b138564807e0c851486","type":"TRIAL","name":"\"SALT Trial\" Study of Ascending Levels of Tolvaptan in Hyponatremia","canonical_id":"clinicaltrials.gov:NCT00072683","description":"Hyponatremias; Water Intoxication; Inappropriate ADH Syndrome; Water-Electrolyte Imbalances","metadata":null},{"id":"8f7c8c8631af412fb7e627a57380e81c","type":"TRIAL","name":"\"Supracondylar Radial Nerve Block Guided by Ultrasound Versus Hematoma Block for Analgesic Management in Closed Reduction of Distal Radius Fractures\"","canonical_id":"clinicaltrials.gov:NCT06857110","description":"Distal Radius Fracture","metadata":null},{"id":"d6b88b96120e4ccd995f82f102f344b0","type":"DRUG","name":"&Delta;9-tetrahydrocannabinol","canonical_id":"gtopdb:2424","description":null,"metadata":null},{"id":"017f0c9a5d684cde8ebbef2af17963c3","type":"GO_TERM","name":"'de novo' AMP biosynthetic process","canonical_id":"go:GO:0044208","description":"\"The chemical reactions and pathways resulting in the formation of adenosine monophosphate (AMP) from inosine 5'-monophosphate (IMP).\" [GOC:ecd, PMID:10888601]","metadata":null},{"id":"532a63a1636f4eda8c1c32345cdfc1b6","type":"GO_TERM","name":"'de novo' CTP biosynthetic process","canonical_id":"go:GO:0044210","description":"\"The chemical reactions and pathways resulting in the formation of cytidine 5'-triphosphate (CTP) from simpler components.\" [GOC:ecd, GOC:jl, PMID:11912132, PMID:18439916]","metadata":null},{"id":"ffb8aee5eb004e478e23326bf762b79a","type":"GO_TERM","name":"'de novo' GDP-L-fucose biosynthetic process","canonical_id":"go:GO:0042351","description":"\"The chemical reactions and pathways resulting in the formation of GDP-L-fucose from GDP-D-mannose via GDP-4-dehydro-6-deoxy-D-mannose, requiring the functions of GDP-mannose 4,6-dehydratase (EC:4.2.1.47) and GDP-L-fucose synthase (EC:1.1.1.271).\" [PMID:11030750]","metadata":null},{"id":"03c15a0967d04707800e599480999b01","type":"GO_TERM","name":"'de novo' GMP biosynthetic process","canonical_id":"go:GO:0106387","description":"\"The chemical reactions and pathways resulting in the formation of guanosine 5'-monophosphate (GMP) through an inosine 5'-monophosphate (IMP) intermediate.\" [PMID:25605736]","metadata":null},{"id":"923c69c2907d4b259ceebb2a429902ce","type":"GO_TERM","name":"'de novo' IMP biosynthetic process","canonical_id":"go:GO:0006189","description":"\"The chemical reactions and pathways resulting in the formation of IMP, inosine monophosphate, by the stepwise assembly of a purine ring on ribose 5-phosphate.\" [GOC:mah, ISBN:0716720094]","metadata":null},{"id":"1836c301cd13480bbd15fca702a38a90","type":"GO_TERM","name":"'de novo' L-methionine biosynthetic process","canonical_id":"go:GO:0071266","description":"\"The chemical reactions and pathways resulting in the formation of L-methionine, the L-enantiomer of (2S)-2-amino-4-(methylsulfanyl)butanoic acid, from simpler components such as L-aspartate or L-homoserine. This process occurs in plants, bacteria, archae and fungi.\" [PMID:12818659, PMID:24939187]","metadata":null},{"id":"1c22b88c19884016a4af7cf6eee28a53","type":"GO_TERM","name":"'de novo' NAD+ biosynthetic process from L-aspartate","canonical_id":"go:GO:0034628","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide (NAD+), beginning with the catabolism of L-aspartate into the precursor quinolinate. NAD+ is a coenzyme that interconverts with its reduced form, NADH, in many redox and catabolic reactions.\" [GOC:curators]","metadata":null},{"id":"e11449e69cf6436591ba1f8a8e1c0c6b","type":"GO_TERM","name":"'de novo' NAD+ biosynthetic process from L-tryptophan","canonical_id":"go:GO:0034354","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide (NAD+), beginning with the catabolism of L-tryptophan into the precursor quinolinate. NAD+ is a coenzyme that interconverts with its reduced form, NADH, in many redox and catabolic reactions.\" [PMID:17161604]","metadata":null},{"id":"a28cd71093624578b13f7201544339ae","type":"GO_TERM","name":"'de novo' UMP biosynthetic process","canonical_id":"go:GO:0044205","description":"\"The chemical reactions and pathways resulting in the formation of UMP, uridine monophosphate, starting with the synthesis of (S)-dihydroorotate from bicarbonate; UMP biosynthesis may either occur via reduction by quinone, NAD+ or oxygen.\" [GOC:ecd, GOC:jl]","metadata":null},{"id":"a7d15ffcc09d41a0931c9bdb207ec195","type":"GO_TERM","name":"'de novo' XMP biosynthetic process","canonical_id":"go:GO:0097294","description":"\"The chemical reactions and pathways resulting in the formation of XMP, xanthosine monophosphate, from simpler precursors.\" [GOC:yaf, PMID:27590927]","metadata":null},{"id":"f95f27482504443bb1572bfad41757b4","type":"GO_TERM","name":"'de novo' actin filament nucleation","canonical_id":"go:GO:0070060","description":"\"The actin nucleation process in which actin monomers combine in the absence of any existing actin filaments; elongation of the actin oligomer formed by nucleation leads to the formation of an unbranched filament.\" [GOC:mah, PMID:17477841]","metadata":null},{"id":"47e574a8cea54fc3ad7f36a19b63bcd6","type":"GO_TERM","name":"'de novo' cotranslational protein folding","canonical_id":"go:GO:0051083","description":"\"The process of assisting in the correct noncovalent assembly of the ribosome-bound nascent chains of a multidomain protein whilst other parts of the protein are still being translated.\" [GOC:rb]","metadata":null},{"id":"41aa39ef2ec34d4798fdb63593326387","type":"GO_TERM","name":"'de novo' post-translational protein folding","canonical_id":"go:GO:0051084","description":"\"The process of assisting in the correct noncovalent folding of newly formed polypeptides or folding intermediates of polypeptides that have exited the ribosome and/or have been stabilized and transferred by other chaperone proteins. This process could involve several cycles of ATP hydrolysis.\" [GOC:rb]","metadata":null},{"id":"a03e6b09a1514a71926901952d898529","type":"GO_TERM","name":"'de novo' protein folding","canonical_id":"go:GO:0006458","description":"\"The process of assisting in the folding of a nascent peptide chain into its correct tertiary structure.\" [GOC:mb]","metadata":null},{"id":"89bb4d30813648278fc688682e0fa597","type":"GO_TERM","name":"'de novo' pyridoxal 5'-phosphate biosynthetic process","canonical_id":"go:GO:0036001","description":"\"The chemical reactions and pathways resulting in the formation of pyridoxal 5'-phosphate, the active form of vitamin B6, from simpler components.\" [GOC:bf, GOC:yaf, MetaCyc:PYRIDOXSYN-PWY]","metadata":null},{"id":"ac29bfbd94d84a33a4a92221d2e6e7a5","type":"GO_TERM","name":"'de novo' pyrimidine nucleobase biosynthetic process","canonical_id":"go:GO:0006207","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine nucleobases, 1,3-diazine, organic nitrogenous bases, beginning with the synthesis of a pyrimidine ring from simpler precursors.\" [GOC:mah, ISBN:0716720094]","metadata":null},{"id":"a7d4755fceca4133aa1cefb6c8265581","type":"GO_TERM","name":"(+)-2-epi-prezizaene synthase activity","canonical_id":"go:GO:0102201","description":"\"Catalysis of the reaction: (2Z,6E)-farnesyl diphosphate = (+)-2-epi-prezizaene + diphosphate.\" [PMID:20175559, PMID:20201526, RHEA:31415]","metadata":null},{"id":"5f16dc7447e54ed18a4f7282da094445","type":"GO_TERM","name":"(+)-3'-hydroxylarreatricin biosynthetic process","canonical_id":"go:GO:1901708","description":"\"The chemical reactions and pathways resulting in the formation of (+)-3'-hydroxylarreatricin.\" [GOC:TermGenie, PMID:12960376]","metadata":null},{"id":"22f4049741b645b3a937a4c47cff8727","type":"GO_TERM","name":"(+)-abscisic acid 8'-hydroxylase activity","canonical_id":"go:GO:0010295","description":"\"Catalysis of the reaction: (+)-abscisate + H+ + NADPH + O2 = (+)-8'-hydroxyabscisate + H2O + NADP+.\" [EC:1.14.14.137, RHEA:12897]","metadata":null},{"id":"21034cb560884ba4a2c333ca1619fc3c","type":"GO_TERM","name":"(+)-abscisic acid D-glucopyranosyl ester transmembrane transport","canonical_id":"go:GO:1902418","description":"\"The process in which (+)-abscisic acid D-glucopyranosyl este is transported across a membrane.\" [GOC:TermGenie, PMID:24028845]","metadata":null},{"id":"bab64bb2fca64ddf8fb9e1626d4178f1","type":"GO_TERM","name":"(+)-abscisic acid D-glucopyranosyl ester transmembrane transporter activity","canonical_id":"go:GO:1902417","description":"\"Enables the transfer of (+)-abscisic acid D-glucopyranosyl ester from one side of a membrane to the other.\" [GOC:TermGenie, PMID:24028845]","metadata":null},{"id":"c7852927319a4a65a5a0d63f47788952","type":"GO_TERM","name":"(+)-alpha-barbatene synthase activity","canonical_id":"go:GO:0102878","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (+)-alpha-barbatene + diphosphate.\" [RHEA:29499]","metadata":null},{"id":"293035151b124349a4c7ab1ab28ed9c1","type":"GO_TERM","name":"(+)-beta-barbatene synthase activity","canonical_id":"go:GO:0102881","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (-)-beta-barbatene + diphosphate.\" [PMID:15918888, PMID:16297850, RHEA:73983]","metadata":null},{"id":"b429e2a7d40643d0890534330c7a8298","type":"GO_TERM","name":"(+)-beta-chamigrene synthase activity","canonical_id":"go:GO:0102883","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (+)-beta-chamigrene + diphosphate.\" [RHEA:30379]","metadata":null},{"id":"e9cb6e9506bc4ae58dcabd7e0e0fc2ae","type":"GO_TERM","name":"(+)-borneol dehydrogenase activity","canonical_id":"go:GO:0047500","description":"\"Catalysis of the reaction: (+)-borneol + NAD+ = (1R, 4R)-camphor + H+ + NADH.\" [RHEA:17329]","metadata":null},{"id":"bf08953fd8e042f9a5318bfc8600bad7","type":"GO_TERM","name":"(+)-camphor biosynthetic process","canonical_id":"go:GO:0046211","description":"\"The chemical reactions and pathways resulting in the formation of (+)-camphor, a bicyclic monoterpene ketone. Consists of the three reactions: (2E)-geranyl diphosphate = (2S,4R)-bornyl diphosphate, which is converted to (1R,2S,4R)-borneol + diphosphate, and then to (1R,4R)-camphor.\" [GOC:ai, PMID:42357]","metadata":null},{"id":"3a89bf8e7a9f498e96fc6e568e464841","type":"GO_TERM","name":"(+)-camphor catabolic process","canonical_id":"go:GO:0019383","description":"\"The chemical reactions and pathways resulting in the breakdown of (+)-camphor, a bicyclic monoterpene ketone.\" [MetaCyc:P601-PWY]","metadata":null},{"id":"92208e713dca4bf3933f11a586ebe3e8","type":"GO_TERM","name":"(+)-delta-cadinene synthase activity","canonical_id":"go:GO:0047461","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = diphosphate + (+)-delta-cadinene.\" [EC:4.2.3.13, MetaCyc:4.6.1.11-RXN]","metadata":null},{"id":"c106289f99c74327897ecf6daa666702","type":"GO_TERM","name":"(+)-epi-alpha-bisabolol biosynthetic process","canonical_id":"go:GO:1901943","description":"\"The chemical reactions and pathways resulting in the formation of (+)-epi-alpha-bisabolol.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"055df3d18cfa49eaa286d31dbc28c37e","type":"GO_TERM","name":"(+)-epi-alpha-bisabolol catabolic process","canonical_id":"go:GO:1901942","description":"\"The chemical reactions and pathways resulting in the breakdown of (+)-epi-alpha-bisabolol.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"ee89fa0bc5414a52b281564d5d92034d","type":"GO_TERM","name":"(+)-kotanin biosynthetic process","canonical_id":"go:GO:1900596","description":"\"The chemical reactions and pathways resulting in the formation of (+)-kotanin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3876e3194a3247abb82ab62f57a49bd9","type":"GO_TERM","name":"(+)-kotanin catabolic process","canonical_id":"go:GO:1900595","description":"\"The chemical reactions and pathways resulting in the breakdown of (+)-kotanin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"500c230d739a46b39e1db8feefb0dc8f","type":"GO_TERM","name":"(+)-lariciresinol biosynthetic process","canonical_id":"go:GO:1902132","description":"\"The chemical reactions and pathways resulting in the formation of (+)-lariciresinol.\" [GOC:TermGenie, PMID:8910615, PMID:9872995]","metadata":null},{"id":"dea35daae331496bacc7486a2c39886b","type":"GO_TERM","name":"(+)-lariciresinol catabolic process","canonical_id":"go:GO:1902131","description":"\"The chemical reactions and pathways resulting in the breakdown of (+)-lariciresinol.\" [GOC:TermGenie, PMID:8910615, PMID:9872995]","metadata":null},{"id":"509c587977824bbdb59cf33a60ce9a3d","type":"GO_TERM","name":"(+)-larreatricin biosynthetic process","canonical_id":"go:GO:1901709","description":"\"The chemical reactions and pathways resulting in the formation of (+)-larreatricin.\" [GOC:TermGenie, PMID:12960376, PMID:30113748]","metadata":null},{"id":"47cd772b70cb4e72a8d550fca492a558","type":"GO_TERM","name":"(+)-menthofuran synthase activity","canonical_id":"go:GO:0052582","description":"\"Catalysis of the reaction: (R)-pulegone + reduced [NADPH--hemoprotein reductase] + O2 = (R)-menthofuran + 2 H2O + +H+ + oxidized [NADPH--hemoprotein reductase].\" [RHEA:25658]","metadata":null},{"id":"53e17a851777405b816e72d0c0abb7c2","type":"GO_TERM","name":"(+)-neomenthol dehydrogenase activity","canonical_id":"go:GO:0047501","description":"\"Catalysis of the reaction: (+)-neomenthol + NADP+ = (2S,5R)-menthone + H+ + NADPH.\" [EC:1.1.1.208, RHEA:23812]","metadata":null},{"id":"b7af9d28c16b4527a8c32f31fb7d5dd8","type":"GO_TERM","name":"(+)-pinoresinol biosynthetic process","canonical_id":"go:GO:1902126","description":"\"The chemical reactions and pathways resulting in the formation of (+)-pinoresinol.\" [GOC:TermGenie, PMID:8910615, PMID:9872995]","metadata":null},{"id":"1a4f233b2ac841aa96bf5d988bc795a2","type":"GO_TERM","name":"(+)-pinoresinol catabolic process","canonical_id":"go:GO:1902125","description":"\"The chemical reactions and pathways resulting in the breakdown of (+)-pinoresinol.\" [GOC:TermGenie, PMID:8910615, PMID:9872995]","metadata":null},{"id":"9e6cea58ed8a47fda01e7bd2f89eccc3","type":"GO_TERM","name":"(+)-pulegone reductase (NADP+) activity","canonical_id":"go:GO:0052579","description":"\"Catalysis of the reaction: (1R,4S)-menthone + NADP+ = (R)-pulegone + H+ + NADPH. Also converts (2R,5R)-isomenthone into (R)-pulegone.\" [EC:1.3.1.81]","metadata":null},{"id":"82c01039aacf45818f9197744682840c","type":"GO_TERM","name":"(+)-sabinol dehydrogenase activity","canonical_id":"go:GO:0047502","description":"\"Catalysis of the reaction: (+)-cis-sabinol + NAD+ = (1S,5S)-sabinone + H+ + NADH.\" [EC:1.1.1.228, RHEA:18329]","metadata":null},{"id":"aec882321f704b0187e73654b2a2a769","type":"GO_TERM","name":"(+)-secoisolariciresinol biosynthetic process","canonical_id":"go:GO:1902135","description":"\"The chemical reactions and pathways resulting in the formation of (+)-secoisolariciresinol.\" [GOC:TermGenie, PMID:15949826, PMID:9872995]","metadata":null},{"id":"2ba8a595618b4be7aba1f3402fa0d428","type":"GO_TERM","name":"(+)-secoisolariciresinol catabolic process","canonical_id":"go:GO:1902134","description":"\"The chemical reactions and pathways resulting in the breakdown of (+)-secoisolariciresinol.\" [GOC:TermGenie, PMID:15949826, PMID:9872995]","metadata":null},{"id":"e3dc191ec6434c35af3dbb0f46433f84","type":"GO_TERM","name":"(+)-secoisolariciresinol glucosyltransferase activity","canonical_id":"go:GO:0102610","description":"\"Catalysis of the reaction: (+)-secoisolariciresinol + UDP-alpha-D-glucose = (+)-secoisolariciresinol monoglucoside + UDP + H+.\" [GOC:pz, PMID:24678929]","metadata":null},{"id":"7b7f98ed5a424433bc49303e5c48c151","type":"GO_TERM","name":"(+)-secoisolariciresinol monoglucoside glucosyltransferase activity","canonical_id":"go:GO:0102611","description":"\"Catalysis of the reaction: (+)-secoisolariciresinol monoglucoside + UDP-alpha-D-glucose = (+)-secoisolariciresinol diglucoside + UDP + H+.\" [GOC:pz, PMID:24678929]","metadata":null},{"id":"021eb24d068540299e514e820fa3a63c","type":"GO_TERM","name":"(+)-sesaminol 2-O-glucosyltransferase activity","canonical_id":"go:GO:0102423","description":"\"Catalysis of the reaction: (+)-sesaminol + UDP-alpha-D-glucose = (+)-sesaminol 2-O-beta-D-glucoside + UDP + H+.\" [GOC:pz, PMID:18248594, PMID:19561332]","metadata":null},{"id":"1ffca0b72df9463e85415c1b6b4e2562","type":"GO_TERM","name":"(+)-taxifolin 5'-hydroxylase activity","canonical_id":"go:GO:0102405","description":"\"Catalysis of the reaction: (+)-taxifolin(1-) + O2 + NADPH(4-) + H+ = (+)-dihydromyricetin + NADP(3-) + H2O.\" [GOC:pz]","metadata":null},{"id":"f1191e9dd1cb45f98fe07d46784638cc","type":"GO_TERM","name":"(+)-thujopsene synthase activity","canonical_id":"go:GO:0102879","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (+)-thujopsene + diphosphoric acid.\" [GOC:pz, RHEA:30375]","metadata":null},{"id":"1126d1fd6f4c4c1aa5d988c509a98ee1","type":"GO_TERM","name":"(+)-trans-carveol dehydrogenase activity","canonical_id":"go:GO:0033702","description":"\"Catalysis of the reaction: (1R,5S)-carveol + NAD+ = (S)-carvone + H+ + NADH.\" [EC:1.1.1.275, RHEA:14825]","metadata":null},{"id":"8a64bf6d7282417aab41217ff3506a27","type":"GO_TERM","name":"(-)-E-beta-caryophyllene synthase activity","canonical_id":"go:GO:0080016","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (-)-E-beta-caryophyllene + diphosphate.\" [MetaCyc:RXN-8414, PMID:12566586, PMID:9442047]","metadata":null},{"id":"13f316581f7041a6815c8e2050979137","type":"DRUG","name":"(-)-adrenaline","canonical_id":"gtopdb:479","description":null,"metadata":null},{"id":"bc93f8cad6b84dcca71063e907f0fcdf","type":"GO_TERM","name":"(-)-borneol dehydrogenase activity","canonical_id":"go:GO:0047503","description":"\"Catalysis of the reaction: (-)-borneol + NAD+ = (1S,4S)-camphor + H+ + NADH.\" [EC:1.1.1.227, RHEA:22128]","metadata":null},{"id":"394e9dadca234ac984bb41a71b0154e0","type":"GO_TERM","name":"(-)-endo-fenchol synthase activity","canonical_id":"go:GO:0050437","description":"\"Catalysis of the reaction: geranyl diphosphate + H2O = (-)-endo-fenchol + diphosphate.\" [EC:4.2.3.10, RHEA:20565]","metadata":null},{"id":"72cb7f6f456d4474a709c702f6d85fee","type":"GO_TERM","name":"(-)-exo-alpha-bergamotene biosynthetic process","canonical_id":"go:GO:1901940","description":"\"The chemical reactions and pathways resulting in the formation of (-)-exo-alpha-bergamotene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"f35be485d6ff4751a6df45939e9fe04a","type":"GO_TERM","name":"(-)-exo-alpha-bergamotene catabolic process","canonical_id":"go:GO:1901939","description":"\"The chemical reactions and pathways resulting in the breakdown of (-)-exo-alpha-bergamotene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"d451ab0460e1442691cbb34fc2ae8af3","type":"GO_TERM","name":"(-)-isopiperitenone reductase activity","canonical_id":"go:GO:0052581","description":"\"Catalysis of the reaction: (6R)-isoperitenone + H+ + NADPH = (2R,5R)-isopulegone + NADP+.\" [EC:1.3.1.82, RHEA:25649]","metadata":null},{"id":"2d6b793a1193434da6ec53d11ecf021f","type":"GO_TERM","name":"(-)-lariciresinol biosynthetic process","canonical_id":"go:GO:1902129","description":"\"The chemical reactions and pathways resulting in the formation of (-)-lariciresinol.\" [GOC:TermGenie, PMID:15949826, PMID:9872995]","metadata":null},{"id":"283fc1bfb7ea4eafa13f3653689d7b0a","type":"GO_TERM","name":"(-)-lariciresinol catabolic process","canonical_id":"go:GO:1902128","description":"\"The chemical reactions and pathways resulting in the breakdown of (-)-lariciresinol.\" [GOC:TermGenie, PMID:15949826, PMID:9872995]","metadata":null},{"id":"af51702bdcb64a4cb926c880b02b45d8","type":"DRUG","name":"(-)-menthol","canonical_id":"gtopdb:2430","description":null,"metadata":null},{"id":"ffb0e98a3d3c43248cc454b0b0881af4","type":"DRUG","name":"(-)-menthol","canonical_id":"chembl:CHEMBL256087","description":null,"metadata":null},{"id":"2cd220afb3a64c428a815bc7d2a208a5","type":"GO_TERM","name":"(-)-menthol dehydrogenase activity","canonical_id":"go:GO:0047504","description":"\"Catalysis of the reaction: (-)-menthol + NADP+ = (2S,5R)-menthone + H+ + NADPH.\" [EC:1.1.1.207, RHEA:13917]","metadata":null},{"id":"5cfc70463d85450a9f6d20f8a04f5c89","type":"GO_TERM","name":"(-)-menthol monooxygenase activity","canonical_id":"go:GO:0047505","description":"\"Catalysis of the reaction: (-)-menthol + H+ + NADPH + O2 = 1,4-menthane-3,8-diol + H2O + NADP+.\" [EC:1.14.13.46, RHEA:11648]","metadata":null},{"id":"581a5eec14e24a60b784098af6ef8728","type":"GO_TERM","name":"(-)-microperfuranone biosynthetic process","canonical_id":"go:GO:1901512","description":"\"The chemical reactions and pathways resulting in the formation of (-)-microperfuranone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"52feda87cf054bcb8011953c79f4666d","type":"GO_TERM","name":"(-)-microperfuranone catabolic process","canonical_id":"go:GO:1901511","description":"\"The chemical reactions and pathways resulting in the breakdown of (-)-microperfuranone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"260ee802b1044b94b2af0d58e0f98048","type":"DRUG","name":"(-)-noradrenaline","canonical_id":"gtopdb:505","description":null,"metadata":null},{"id":"13f5c2dc08ef498bae7deda02d88a462","type":"DRUG","name":"(-)-pentazocine","canonical_id":"gtopdb:1606","description":null,"metadata":null},{"id":"f71eec3c8d2446b39e34b402bc52750c","type":"DRUG","name":"(-)-pentazocine","canonical_id":"chembl:CHEMBL3989510","description":null,"metadata":null},{"id":"33e9b4b4cb114f09b3049aeb4a8c14ef","type":"GO_TERM","name":"(-)-pinoresinol biosynthetic process","canonical_id":"go:GO:1901599","description":"\"The chemical reactions and pathways resulting in the formation of (-)-pinoresinol.\" [GOC:TermGenie]","metadata":null},{"id":"00ab85b2cc45420fbd751034fdc195c7","type":"GO_TERM","name":"(-)-pinoresinol catabolic process","canonical_id":"go:GO:1902123","description":"\"The chemical reactions and pathways resulting in the breakdown of (-)-pinoresinol.\" [GOC:TermGenie, PMID:15949826, PMID:9872995]","metadata":null},{"id":"c986b4ac90c947a0a953c607eacfcdc0","type":"GO_TERM","name":"(-)-pinoresinol metabolic process","canonical_id":"go:GO:1901598","description":"\"The chemical reactions and pathways involving (-)-pinoresinol.\" [GOC:TermGenie]","metadata":null},{"id":"c760eb90c1e247e3ab383c875ce73288","type":"GO_TERM","name":"(-)-secoisolariciresinol biosynthetic process","canonical_id":"go:GO:1902138","description":"\"The chemical reactions and pathways resulting in the formation of (-)-secoisolariciresinol.\" [GOC:TermGenie, PMID:8910615, PMID:9872995]","metadata":null},{"id":"1bdf21143d634ceeb581c1b00ec57d38","type":"GO_TERM","name":"(-)-secoisolariciresinol catabolic process","canonical_id":"go:GO:1902137","description":"\"The chemical reactions and pathways resulting in the breakdown of (-)-secoisolariciresinol.\" [GOC:TermGenie, PMID:8910615, PMID:9872995]","metadata":null},{"id":"aaa4fcbee7824dab8ec032f1e5f10ace","type":"GO_TERM","name":"(-)-secologanin biosynthetic process","canonical_id":"go:GO:1900994","description":"\"The chemical reactions and pathways resulting in the formation of (-)-secologanin.\" [GOC:TermGenie, GOC:yaf, PMID:24104568]","metadata":null},{"id":"00d0aba9ae004c69b7ba45b526c6c295","type":"DRUG","name":"(-)-sulpiride","canonical_id":"gtopdb:958","description":null,"metadata":null},{"id":"d9a8503a860a41718d5090e6d9bd53c3","type":"DRUG","name":"(-)-sulpiride","canonical_id":"chembl:CHEMBL26","description":null,"metadata":null},{"id":"44e81268593147bda3002c2ee9e935b7","type":"GO_TERM","name":"(1,4)-alpha-D-glucan 1-alpha-D-glucosylmutase activity","canonical_id":"go:GO:0047470","description":"\"Catalysis of the reaction: 4-[(1->4)-alpha-D-glucosyl](n-1)-D-glucose = 1-alpha-D-[(1->4)-alpha-D-glucosyl](n-1)-alpha-D-glucopyranoside.\" [EC:5.4.99.15, MetaCyc:5.4.99.15-RXN]","metadata":null},{"id":"e8d22e7ad0ab40f4be5b593691f36766","type":"GO_TERM","name":"(1->3),(1->4)-beta-glucan binding","canonical_id":"go:GO:2001077","description":"\"Binding to (1->3),(1->4)-beta-glucan.\" [GOC:mengo_curators]","metadata":null},{"id":"2a4c9a831db14d0fb0b45ee700240ca2","type":"GO_TERM","name":"(1->3)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070596","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-alpha-D-glucans, compounds composed of glucose residues linked by (1->3)-alpha-D-glucosidic bonds.\" [GOC:mah]","metadata":null},{"id":"69ccc206adf54b74be946550ea7e691a","type":"GO_TERM","name":"(1->3)-beta-D-glucan binding","canonical_id":"go:GO:0001872","description":"\"Binding to a (1->3)-beta-D-glucan.\" [PMID:14707091]","metadata":null},{"id":"20ec5cbb114041b2b999645d3733698a","type":"GO_TERM","name":"(1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0006075","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds.\" [GOC:ai]","metadata":null},{"id":"e38e3449e92341a9a0de8adad8eb5e87","type":"GO_TERM","name":"(1->3)-beta-D-glucan catabolic process","canonical_id":"go:GO:0006076","description":"\"The chemical reactions and pathways resulting in the breakdown of (1->3)-beta-D-glucans.\" [GOC:ai]","metadata":null},{"id":"95efca251747400593fe7402f01d8f1e","type":"GO_TERM","name":"(1->3)-beta-D-glucan immune receptor activity","canonical_id":"go:GO:0001874","description":"\"Combining with (1->3)-beta-D-glucans to initiate an innate immune response.\" [PMID:14707091]","metadata":null},{"id":"feca4399e95b4a779bcaac592f11654d","type":"GO_TERM","name":"(1->3)-beta-D-glucan metabolic process","canonical_id":"go:GO:0006074","description":"\"The chemical reactions and pathways involving (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds.\" [ISBN:0198506732]","metadata":null},{"id":"c604afe3e9b542ad957164565ba049cf","type":"GO_TERM","name":"(1->4)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070630","description":"\"The chemical reactions and pathways resulting in the formation of (1->4)-alpha-glucans, compounds composed of glucose residues linked by (1->4)-alpha-D-glucosidic bonds.\" [GOC:mah]","metadata":null},{"id":"86512bd5421a4d51831c71de82d21e15","type":"GO_TERM","name":"(1->4)-beta-D-galactan binding","canonical_id":"go:GO:2001081","description":"\"Binding to (1->4)-beta-D-galactan.\" [GOC:mengo_curators]","metadata":null},{"id":"fd301a338d5f499fb35525b8d909acce","type":"GO_TERM","name":"(1->6)-beta-D-glucan binding","canonical_id":"go:GO:2001078","description":"\"Binding to (1->6)-beta-D-glucan.\" [GOC:mengo_curators]","metadata":null},{"id":"e6b62186aac840728b534574a93e4e90","type":"GO_TERM","name":"(1->6)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0006078","description":"\"The chemical reactions and pathways resulting in the formation of (1->6)-beta-D-glucans.\" [GOC:ai]","metadata":null},{"id":"16ae76fec9854d76a045ffcad1f7f5ca","type":"GO_TERM","name":"(1->6)-beta-D-glucan catabolic process","canonical_id":"go:GO:0006079","description":"\"The chemical reactions and pathways resulting in the breakdown of (1->6)-beta-D-glucans.\" [GOC:ai]","metadata":null},{"id":"bf150922b8704e749fe4a08b7b80b0e2","type":"GO_TERM","name":"(1->6)-beta-D-glucan metabolic process","canonical_id":"go:GO:0006077","description":"\"The chemical reactions and pathways involving (1->6)-beta-D-glucans, compounds composed of glucose residues linked by (1->6)-beta-D-glucosidic bonds.\" [ISBN:0198506732]","metadata":null},{"id":"723b7a7950f74fdd96b4a0b8d8984da3","type":"GO_TERM","name":"(1-hydroxycyclohexan-1-yl)acetyl-CoA lyase activity","canonical_id":"go:GO:0047446","description":"\"Catalysis of the reaction: (1-hydroxycyclohexan-1-yl)acetyl-CoA = acetyl-CoA + cyclohexanone.\" [EC:4.1.3.35, RHEA:23868]","metadata":null},{"id":"a1e7b033ee364b38b86aa9a820fbcf49","type":"GO_TERM","name":"(13E)-labda-7,13-dien-15-ol synthase activity","canonical_id":"go:GO:0102305","description":"\"Catalysis of the reaction: geranylgeranyl diphosphate + H2O = (13E)-labda-7,13-dien-15-ol + diphosphate.\" [RHEA:32075]","metadata":null},{"id":"416973ea57424f498fcb10bb1fcefce2","type":"GO_TERM","name":"(13S)-vitexifolin A synthase activity","canonical_id":"go:GO:0062204","description":"\"Catalysis of the reaction:9alpha-copalyl diphosphate + H2O = (13S)-vitexifolin A + diphosphate.\" [PMID:29315936, RHEA:40027]","metadata":null},{"id":"2f66088943424e1bb35888c61658559d","type":"GO_TERM","name":"(17Z)-protosta-17(20),24-dien-3beta-ol biosynthetic process","canonical_id":"go:GO:1900581","description":"\"The chemical reactions and pathways resulting in the formation of (17Z)-protosta-17(20),24-dien-3beta-ol.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b562132526144a19b6e98f6930d1d697","type":"GO_TERM","name":"(17Z)-protosta-17(20),24-dien-3beta-ol catabolic process","canonical_id":"go:GO:1900580","description":"\"The chemical reactions and pathways resulting in the breakdown of (17Z)-protosta-17(20),24-dien-3beta-ol.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4c0afb8116c3403392912d5a4ba47d44","type":"GO_TERM","name":"(25S)-Delta(4)-dafachronate binding","canonical_id":"go:GO:1902051","description":"\"Binding to (25S)-Delta(4)-dafachronate.\" [GOC:TermGenie, PMID:16529801]","metadata":null},{"id":"cf27b5fba99d412ca254e758598a6f33","type":"GO_TERM","name":"(25S)-Delta(7)-dafachronate binding","canonical_id":"go:GO:1902052","description":"\"Binding to (25S)-Delta(7)-dafachronate.\" [GOC:TermGenie, PMID:16529801]","metadata":null},{"id":"6d29256e561a46a2b5fcc7494fafc868","type":"GO_TERM","name":"(25S)-Delta(7)-dafachronate biosynthetic process","canonical_id":"go:GO:1902056","description":"\"The chemical reactions and pathways resulting in the formation of (25S)-Delta(7)-dafachronate.\" [GOC:TermGenie, PMID:22505847]","metadata":null},{"id":"e3c9a2d4d52e44f38980ab08677274cd","type":"GO_TERM","name":"(2E)-butenoyl-CoA hydratase activity","canonical_id":"go:GO:0120092","description":"\"Catalysis of the reaction: 3-hydroxybutanoyl-CoA = (2E)-butenoyl-CoA + H2O. (2E)-butenoyl-CoA is also known as crotonoyl-CoA.\" [PMID:28803779, RHEA:45584]","metadata":null},{"id":"e45e88d616a545b6af6e5bf71eae2730","type":"GO_TERM","name":"(2E)-enoyl-CoA hydratase activity","canonical_id":"go:GO:0080023","description":"\"Catalysis of the reaction: a (3R)-3-hydroxyacyl-CoA = a (2E)-enoyl-CoA + H2O.\" [PMID:16982622, RHEA:26526]","metadata":null},{"id":"cf3c68664f894e55ab215907e2e2a0c9","type":"GO_TERM","name":"(2E,6E)-farnesyl diphosphate synthase activity","canonical_id":"go:GO:0004337","description":"\"Catalysis of the reaction: (2E)-geranyl diphosphate + isopentenyl diphosphate = (2E,6E)-farnesyl diphosphate + diphosphate.\" [RHEA:19361]","metadata":null},{"id":"1a4c68b32747434a892a2243d4fb9bad","type":"GO_TERM","name":"(2R)-2-hydroxyacid dehydrogenase (NAD+) activity","canonical_id":"go:GO:0140175","description":"\"Catalysis of the reaction: a (2R)-2-hydroxycarboxylate + NAD+ = a 2-oxocarboxylate + NADH + H+.\" [RHEA:35643]","metadata":null},{"id":"95890eb9b21845259bbb0abd88bc3241","type":"GO_TERM","name":"(2R)-2-hydroxyacid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050578","description":"\"Catalysis of the reaction: a (2R)-2-hydroxycarboxylate + NADP+ = a 2-oxocarboxylate + NADPH + H+.\" [RHEA:35735]","metadata":null},{"id":"a6440a8d249f441690469396fc359002","type":"GO_TERM","name":"(2R)-2-hydroxycarboxylate dehydrogenase activity","canonical_id":"go:GO:0140174","description":"\"Catalysis of the activity: a (2R)-2-hydroxycarboxylate + FAD + H+ = a 2-oxocarboxylate + FADH2.\" [PMID:37863926, RHEA:82511]","metadata":null},{"id":"7466d82938954aa7ac4c44c779314372","type":"GO_TERM","name":"(2R)-hydroxyacid dehydrogenase (quinone) activity","canonical_id":"go:GO:1990464","description":"\"Catalysis of the reaction: a (2R)-2-hydroxycarboxylate + a quinone = a 2-oxocarboxylate + a quinol.\" [PMID:3013300, PMID:4582730, RHEA:11272]","metadata":null},{"id":"4ccbba17bd6c4eb6ac514d26cc886b60","type":"GO_TERM","name":"(2R)-hydroxyphenylpyruvate reductase [NAD(P)H] activity","canonical_id":"go:GO:0047995","description":"\"Catalysis of the reaction: (2R)-2-hydroxy-3-(4-hydroxyphenyl)propanoate + NAD(P)+ = 3-(4-hydroxyphenyl)pyruvate + NAD(P)H + H+.\" [EC:1.1.1.237]","metadata":null},{"id":"18e8b58b3a0f46498c690060a0efa0d9","type":"GO_TERM","name":"(2R)-oxo-acid reductase activity","canonical_id":"go:GO:0033719","description":"\"Catalysis of the reaction: a (2R)-hydroxycarboxylate + acceptor = a 2-oxocarboxylate + reduced acceptor.\" [RHEA:23664]","metadata":null},{"id":"fe5722c426e046f8a307a19d8d929771","type":"GO_TERM","name":"(2S)-2-aminobutanoate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0120554","description":"\"Catalysis of the reaction: (2S)-2-aminobutanoate + 2-oxoglutarate = 2-oxobutanoate + L-glutamate.\" [PMID:27827456, RHEA:70223]","metadata":null},{"id":"5ca066fbb1d44bfab02910071fca6d54","type":"GO_TERM","name":"(2S)-2-hydroxyphytanate oxidase activity","canonical_id":"go:GO:0047996","description":"\"Catalysis of the reaction: (2S)-2-hydroxyphytanate + O2 = 2-oxophytanate + H2O2.\" [RHEA:21680]","metadata":null},{"id":"d0abb9c8afcc4751ae63bedb09024604","type":"GO_TERM","name":"(2S,3R,6S,9S)-(-)-protoillud-7-ene synthase activity","canonical_id":"go:GO:0061923","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (2S,3R,6S,9S)-(-)-protoillud-7-ene + diphosphate.\" [PMID:27862766, RHEA:53628]","metadata":null},{"id":"eb8420f66644498383e581e11392ff38","type":"GO_TERM","name":"(2Z,6Z)-farnesyl diphosphate synthase activity","canonical_id":"go:GO:0102059","description":"\"Catalysis of the reaction: 2 isopentenyl diphosphate + dimethylallyl diphosphate = (2Z,6Z)-farnesyl diphosphate + 2 diphosphate.\" [RHEA:27810]","metadata":null},{"id":"df9a7dda5e404861b8175386a5b3d16a","type":"GO_TERM","name":"(3E)-4,8-dimethyl-1,3,7-nonatriene synthase activity","canonical_id":"go:GO:0097008","description":"\"Catalysis of the reaction: (E)-nerolidol + NADPH + O2 = (3E)-4,8-dimethylnona-1,3,7-triene + NADP+ + 2 H2O. It is unknown whether this reaction proceeds by the direct release of the 4-carbon compound but-1-en-3-one, or whether the substrate is first degraded to C11-geranylacetone and then cleaved to produce (3E)-4,8-dimethylnona-1,3,7-triene (DMNT) and acetone.\" [GOC:kad, MetaCyc:RXN-8619, PMID:21088219]","metadata":null},{"id":"ab646113177f4eea8551f023395428f1","type":"GO_TERM","name":"(3R)-(E)-nerolidol synthase activity","canonical_id":"go:GO:0102145","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate + H2O = (3R,6E)-nerolidol + diphosphoric acid.\" [GOC:pz, RHEA:27534]","metadata":null},{"id":"44e88939eceb4178a533dce84073165b","type":"GO_TERM","name":"(3R)-2'-hydroxyisoflavanone reductase (NADP+) activity","canonical_id":"go:GO:0140860","description":"\"Catalysis of the reaction: a (3R,4R)-4,2'-dihydroxyisoflavan + NADP+ = a (3R)-2'-hydroxyisoflavanone + H+ + NADPH.\" [PMID:7625843, RHEA:56284]","metadata":null},{"id":"20bc5582f87c4ca2ba021cf0e67d0af4","type":"GO_TERM","name":"(3R)-3-hydroxyacyl-CoA dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106386","description":"\"Catalysis of the reaction: a (3R)-3-hydroxyacyl-CoA + NAD+ = a 3-oxoacyl-CoA + NADH + H+.\" [PMID:19571038, PMID:25203508, RHEA:32711]","metadata":null},{"id":"56656b9584a341abb87a303a5631ac82","type":"GO_TERM","name":"(3R)-citramalyl-CoA lyase activity","canonical_id":"go:GO:0044101","description":"\"Catalysis of the reaction: (3R)-citramalyl-CoA = pyruvate + acetyl-CoA.\" [GOC:jl]","metadata":null},{"id":"b9682416d7f04951a8fae54a6ae2518f","type":"GO_TERM","name":"(3R)-hydroxyacyl-[acyl-carrier-protein] dehydratase activity","canonical_id":"go:GO:0019171","description":"\"Catalysis of the reaction: a (3R)-hydroxyacyl-[acyl-carrier-protein] = a (2E)-enoyl-[acyl-carrier-protein] + H2O.\" [RHEA:13097]","metadata":null},{"id":"4d57f272d2724664ad6a704dc830f0f7","type":"GO_TERM","name":"(3S)-(+)-asterisca-2(9),6-diene synthase activity","canonical_id":"go:GO:0120086","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (3S)-(+)-asterisca-2(9),6-diene + diphosphate.\" [PMID:27862766, RHEA:53632]","metadata":null},{"id":"da27c7a7b2954c778df3849865a84861","type":"GO_TERM","name":"(3S)-3-hydroxyacyl-CoA dehydrogenase (NAD+) activity","canonical_id":"go:GO:0003857","description":"\"Catalysis of the reaction: a (3S)-3-hydroxyacyl-CoA + NAD+ = a 3-oxoacyl-CoA + NADH + H+.\" [RHEA:22432]","metadata":null},{"id":"c5f8c61b8d8c4691b053aae825cc413f","type":"GO_TERM","name":"(3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase activity","canonical_id":"go:GO:0047120","description":"\"Catalysis of the reaction: (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate + NAD+ = 3,4-dihydroxybenzoate + CO2 + NADH.\" [EC:1.3.1.53, RHEA:10744]","metadata":null},{"id":"9313b4fa14644dd2bf9d43d084058024","type":"GO_TERM","name":"(4S)-4-hydroxy-2-oxoglutarate aldolase activity","canonical_id":"go:GO:0106009","description":"\"Catalysis of the reaction:(4S)-4-hydroxy-2-oxoglutarate = pyruvate + glyoxylate. Specific for the (4S) enantiomer of 4-hydroxy-2-oxoglutarate.\" [PMID:1098660, PMID:1339418, RHEA:35639]","metadata":null},{"id":"1ea35404149d4c57bb39d57827e66ed4","type":"GO_TERM","name":"(4S)-4-hydroxy-5-phosphonooxypentane-2,3-dione isomerase activity","canonical_id":"go:GO:0002952","description":"\"Catalysis of the reaction: (2S)-2-hydroxy-3,4-dioxopentyl phosphate = 3-hydroxy-2,4-dioxopentyl phosphate.\" [RHEA:44360]","metadata":null},{"id":"2865f103d9594433b478edafa6cb7cde","type":"GO_TERM","name":"(4S)-4-hydroxy-L-glutamate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047578","description":"\"Catalysis of the reaction: (4S)-4-hydroxy-L-glutamate + 2-oxoglutarate = (4R)-4-hydroxy-2-oxoglutarate + L-glutamate.\" [RHEA:31235]","metadata":null},{"id":"d6b15a3e145e46db9e0f47d86db7f85c","type":"GO_TERM","name":"(4S)-limonene synthase activity","canonical_id":"go:GO:0050552","description":"\"Catalysis of the reaction: geranyl diphosphate = (4S)-limonene + diphosphate.\" [EC:4.2.3.16, MetaCyc:4.2.3.16-RXN]","metadata":null},{"id":"d81f10a311054c04b1716782112ce666","type":"GO_TERM","name":"(5alpha)-campestan-3-one hydroxylase activity","canonical_id":"go:GO:0102679","description":"\"Catalysis of the reaction: H+ + (5alpha)-campestan-3-one + O2 + NADPH = (5alpha,22S,24R)-22-hydroxyergostan-3-one + H2O + NADP.\" [GOC:pz, PMID:10377996]","metadata":null},{"id":"aad8affea50341518055b003a8ef24c7","type":"DRUG","name":"(<i>R</i>)-cetirizine","canonical_id":"chembl:CHEMBL1607273","description":null,"metadata":null},{"id":"dd61f82dd0ed4c318c944b3f12bf30b3","type":"TRIAL","name":"(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF","canonical_id":"clinicaltrials.gov:NCT00768300","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"1fae2e38e3dc47308d78f007bdd7eee9","type":"TRIAL","name":"(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT05923502","description":"Follicular Lymphoma; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Richter Syndrome; Marginal Zone Lymphoma; Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma","metadata":null},{"id":"a5f25fc68fe14a7da404d1c07c8fe6e9","type":"GO_TERM","name":"(E)-beta-ocimene synthase activity","canonical_id":"go:GO:0034768","description":"\"Catalysis of the reaction: geranyl diphosphate = (E)-beta-ocimene + diphosphate.\" [EC:4.2.3.106, PMID:12624761]","metadata":null},{"id":"492c45e7594f4e74ba7ef22b97289a86","type":"GO_TERM","name":"(E)-caffeate-CoA ligase activity","canonical_id":"go:GO:0106286","description":"\"Catalysis of the reaction: (E)-caffeate + ATP + CoA = (E)-caffeoyl-CoA + AMP + diphosphate.\" [PMID:22649270, RHEA:36299]","metadata":null},{"id":"333f79aca6384dbda5e7158c435f12ca","type":"GO_TERM","name":"(E,E)-geranyllinalool synthase activity","canonical_id":"go:GO:0080013","description":"\"Catalysis of the reaction: (2E,6E,10E)-geranylgeranyl diphosphate + H2O = (6E,10E)-geranyllinalool + diphosphate.\" [PMID:18398052, RHEA:38155]","metadata":null},{"id":"4e68b55aecf245b2a80606c331f39c93","type":"GO_TERM","name":"(M)-viriditoxin biosynthetic process","canonical_id":"go:GO:0140783","description":"\"The chemical reactions and pathways resulting in the formation of (M)-viriditoxin, a fungal secondary metabolite with antibacterial activity.\" [PMID:31045362, PMID:31304040]","metadata":null},{"id":"9205ed9e38974a23b2fa730ce6e8edaf","type":"GO_TERM","name":"(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0003947","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-galactosamine + (N-acetylneuraminyl)-D-galactosyl-D-glucosylceramide = UDP + N-acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-D-glucosylceramide.\" [EC:2.4.1.92]","metadata":null},{"id":"e57f3cec8c9f41b29baa530fd461014e","type":"TRIAL","name":"(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma","canonical_id":"clinicaltrials.gov:NCT05767879","description":"Melanoma Stage III; In-Transit Metastasis of Cutaneous Melanoma","metadata":null},{"id":"9b5afd1977e34e65bf565accc29a1e5d","type":"TRIAL","name":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","canonical_id":"clinicaltrials.gov:NCT02039726","description":"AML","metadata":null},{"id":"f2b959852ea7475ea40288cd72489b1b","type":"GO_TERM","name":"(R)-2-haloacid dehalogenase activity","canonical_id":"go:GO:0033975","description":"\"Catalysis of the reaction: (R)-2-haloacid + H2O = (S)-2-hydroxyacid + halide.\" [EC:3.8.1.9]","metadata":null},{"id":"56eb8a4a2af6402d9acc66a55c8f55cc","type":"GO_TERM","name":"(R)-2-hydroxy-4-methylpentanoate CoA-transferase activity","canonical_id":"go:GO:0043712","description":"\"Catalysis of the reaction: 4-methylpentanoyl-CoA + (2R)-hydroxy-4-methylpentanoate = (R)-2-hydroxy-4-methylpentanoyl-CoA + 4-methylpentanoate.\" [PMID:16957230, RHEA:49440]","metadata":null},{"id":"e88ede12a4b9434ca385ced92b81c5f1","type":"GO_TERM","name":"(R)-2-hydroxy-alpha-linolenic acid biosynthetic process","canonical_id":"go:GO:1902609","description":"\"The chemical reactions and pathways resulting in the formation of (R)-2-hydroxy-alpha-linolenic acid.\" [GO_REF:0000068, GOC:TermGenie, PMID:24214535]","metadata":null},{"id":"b153b235081a4b34becb76d12956c03b","type":"GO_TERM","name":"(R)-2-hydroxy-fatty acid dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047049","description":"\"Catalysis of the reaction: (R)-2-hydroxystearate + NAD+ = 2-oxostearate + H+ + NADH.\" [EC:1.1.1.98, RHEA:15949]","metadata":null},{"id":"d174e74ffc2946728b68432aee6a757a","type":"GO_TERM","name":"(R)-2-hydroxyglutarate (NAD+) dehydrogenase activity","canonical_id":"go:GO:0120568","description":"\"Catalysis of the reaction: (R)-2-hydroxyglutarate + NAD+ = 2-oxoglutarate + NADH + H+.\" [PMID:26774271, RHEA:49612]","metadata":null},{"id":"1c1d87db362748eab1cebaea34daf65d","type":"GO_TERM","name":"(R)-2-hydroxyglutarate dehydrogenase activity","canonical_id":"go:GO:0051990","description":"\"Catalysis of the reaction: (R)-2-hydroxyglutarate + acceptor = 2-oxoglutarate + reduced acceptor.\" [RHEA:38295]","metadata":null},{"id":"e32ab3769b1b4f1cad1654a7a5bce2be","type":"GO_TERM","name":"(R)-2-hydroxyglutarate-pyruvate transhydrogenase activity","canonical_id":"go:GO:0099615","description":"\"Catalysis of the reaction: (R)-2-hydroxyglutarate + pyruvate = (R)-lactate + 2-oxoglutarate.\" [PMID:26774271, RHEA:51608]","metadata":null},{"id":"c3a47fc4e3814595aaead3dda14bf727","type":"GO_TERM","name":"(R)-2-methylmalate dehydratase activity","canonical_id":"go:GO:0047508","description":"\"Catalysis of the reaction: (R)-citramalate = 2-methylmaleate + H2O.\" [EC:4.2.1.35]","metadata":null},{"id":"db140526a2b94369936324d06540d231","type":"GO_TERM","name":"(R)-3-amino-2-methylpropionate:pyruvate transaminase activity","canonical_id":"go:GO:0047305","description":"\"Catalysis of the reaction: (R)-3-amino-2-methylpropanoate + pyruvate = 2-methyl-3-oxopropanoate + L-alanine.\" [RHEA:18393]","metadata":null},{"id":"2d643d4b958546f4a85175397afac4ba","type":"GO_TERM","name":"(R)-3-hydroxyacid-ester dehydrogenase activity","canonical_id":"go:GO:0047108","description":"\"Catalysis of the reaction: ethyl (R)-3-hydroxyhexanoate + NADP+ = ethyl 3-oxohexanoate + H+ + NADPH.\" [EC:1.1.1.279, RHEA:24352]","metadata":null},{"id":"da7713f378254668b94ee7f79cf6dafe","type":"GO_TERM","name":"(R)-4-hydroxymandelate catabolic process","canonical_id":"go:GO:0019599","description":"\"The chemical reactions and pathways resulting in the breakdown of (R)-4-hydroxymandelate, the anion of (R)-4-hydroxymandelic acid.\" [GOC:ai]","metadata":null},{"id":"1f2d0c1a0db946a1a0c93bf7c0a31c22","type":"GO_TERM","name":"(R)-4-hydroxyphenyllactate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047029","description":"\"Catalysis of the reaction: NADP+ + (R)-3-(4-hydroxyphenyl)lactate = NADPH + H+ + 3-(4-hydroxyphenyl)pyruvate.\" [RHEA:52692]","metadata":null},{"id":"c23829f23f3d4db1bf4e290bdccec986","type":"GO_TERM","name":"(R)-6-hydroxynicotine oxidase activity","canonical_id":"go:GO:0018530","description":"\"Catalysis of the reaction: (R)-6-hydroxynicotine + H2O + O2 = 6-hydroxypseudooxynicotine + H2O2.\" [EC:1.5.3.6, RHEA:10012]","metadata":null},{"id":"7e087297907c41b5b1240d021b979965","type":"GO_TERM","name":"(R)-aminopropanol dehydrogenase activity","canonical_id":"go:GO:0019147","description":"\"Catalysis of the reaction: (R)-1-aminopropan-2-ol + NAD+ = aminoacetone + H+ + NADH.\" [EC:1.1.1.75, RHEA:16517]","metadata":null},{"id":"99f253293c824293b5958d1157994510","type":"GO_TERM","name":"(R)-benzylsuccinyl-CoA dehydrogenase activity","canonical_id":"go:GO:0033734","description":"\"Catalysis of the reaction: (R)-2-benzylsuccinyl-CoA + 2 electron-transferring flavoprotein = (E)-2-benzylidenesuccinyl-CoA + 2 reduced electron-transferring flavoprotein.\" [EC:1.3.8.3]","metadata":null},{"id":"271c718666d74cb1b86124cf049b8787","type":"GO_TERM","name":"(R)-carnitine transmembrane transport","canonical_id":"go:GO:1902270","description":"\"The process in which (R)-carnitine is transported across a membrane.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"2de65ffaf25745da8571be5074782ddf","type":"GO_TERM","name":"(R)-carnitine transmembrane transporter activity","canonical_id":"go:GO:1901235","description":"\"Enables the transfer of (R)-carnitine from one side of a membrane to the other.\" [GOC:TermGenie, PMID:16365042, PMID:20357772, PMID:20829798]","metadata":null},{"id":"f1f3587764604921b1b5a654d16bde3b","type":"GO_TERM","name":"(R)-carnitine transport","canonical_id":"go:GO:1900749","description":"\"The directed movement of a (R)-carnitine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie, PMID:16365044, PMID:20357772, PMID:20829798]","metadata":null},{"id":"24ce8013b6c04d8f80ad384f09323e90","type":"GO_TERM","name":"(R)-carnitine:4-(trimethylammonio)butanoate antiporter activity","canonical_id":"go:GO:0044667","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: (R)-carnitine(out) + 4-(trimethylammonio)butanoate(in) = (R)-carnitine(in) + 4-(trimethylammonio)butanoate(out).\" [GOC:crds]","metadata":null},{"id":"13550c00e26649398fba6522b6c79150","type":"DRUG","name":"(R)-cetirizine","canonical_id":"gtopdb:1214","description":null,"metadata":null},{"id":"b5b265df3e674838bdea172f19c20621","type":"GO_TERM","name":"(R)-citramalate synthase activity","canonical_id":"go:GO:0043714","description":"\"Catalysis of the reaction: pyruvate + acetyl-CoA + H2O = (R)-citramalate + CoA.\" [GOC:jl, PMID:9864346, RHEA:19045]","metadata":null},{"id":"bcb79f18e43148478e05686ac6e95000","type":"GO_TERM","name":"(R)-dehydropantoate dehydrogenase activity","canonical_id":"go:GO:0047509","description":"\"Catalysis of the reaction: (R)-4-dehydropantoate + NAD+ + H2O = (R)-3,3-dimethylmalate + NADH + 2 H+.\" [RHEA:19349]","metadata":null},{"id":"027aa3c80d854ce19df766cbf1125cd1","type":"GO_TERM","name":"(R)-limonene 6-monooxygenase activity","canonical_id":"go:GO:0052741","description":"\"Catalysis of the reaction: (4R)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1R,5S)-carveol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:18957]","metadata":null},{"id":"7b7a31bbcd58469bb4d081102d7d62ea","type":"GO_TERM","name":"(R)-limonene synthase activity","canonical_id":"go:GO:0034002","description":"\"Catalysis of the reaction: geranyl diphosphate = (4R)-limonene + diphosphate.\" [EC:4.2.3.20, RHEA:10940]","metadata":null},{"id":"c2f893b58605440bb24e206b41b1e652","type":"GO_TERM","name":"(R)-mandelate catabolic process","canonical_id":"go:GO:0019596","description":"\"The chemical reactions and pathways resulting in the breakdown of (R)-mandelate, the anion of (R)-mandelic acid. Mandelic acid (alpha-hydroxybenzeneacetic acid) is an 8-carbon alpha-hydroxy acid (AHA) that is used in organic chemistry and as a urinary antiseptic.\" [GOC:curators]","metadata":null},{"id":"6f91f15a45014ee4897e533ae1cea92b","type":"GO_TERM","name":"(R)-mandelate dehydrogenase activity","canonical_id":"go:GO:0097620","description":"\"Catalysis of the reaction: (R)-mandelate + NAD+ = phenylglyoxylate + NADH + H+.\" [PMID:1731758, RHEA:43112]","metadata":null},{"id":"043580cad01d41038277f228889d6efa","type":"GO_TERM","name":"(R)-mevalonic acid biosynthetic process","canonical_id":"go:GO:1901737","description":"\"The chemical reactions and pathways resulting in the formation of (R)-mevalonic acid.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00058]","metadata":null},{"id":"0c1f14eaf7d443e68a63711a807860c0","type":"GO_TERM","name":"(R)-mevalonic acid catabolic process","canonical_id":"go:GO:1901736","description":"\"The chemical reactions and pathways resulting in the breakdown of (R)-mevalonic acid.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00058]","metadata":null},{"id":"eed45a380acf44cca65aa6c7c501be37","type":"GO_TERM","name":"(R)-pantolactone dehydrogenase (flavin) activity","canonical_id":"go:GO:0047060","description":"\"Catalysis of the reaction: (R)-pantolactone + A = 2-dehydropantolactone + AH(2).\" [EC:1.1.99.27, RHEA:21004]","metadata":null},{"id":"decece7c83f44e7f805c4e3660753f6b","type":"GO_TERM","name":"(R,R)-butanediol dehydrogenase activity","canonical_id":"go:GO:0000721","description":"\"Catalysis of the reversible reaction: (R,R)-butane-2,3-diol + NAD+ = (R)-acetoin + NADH + H+.\" [EC:1.1.1.4]","metadata":null},{"id":"749e3bf60dce480a9163c2839a92fd7f","type":"GO_TERM","name":"(R,S)-4-hydroxy-2-oxoglutarate aldolase activity","canonical_id":"go:GO:0008700","description":"\"Catalysis of the reaction: 4-hydroxy-2-oxoglutarate = pyruvate + glyoxylate. Can act on both the (4R) and the (4S) enantiomers of 4-hydroxy-2-oxoglutarate.\" [EC:4.1.3.16, RHEA:18169]","metadata":null},{"id":"e8120dbfd265421c84cbe079174021ac","type":"GO_TERM","name":"(R,S)-reticuline 7-O-methyltransferase activity","canonical_id":"go:GO:0102917","description":"\"Catalysis of the reaction: (S)- or (R)-reticuline + S-adenosyl-L-methionine = (S)- or (R)-laudanine + H+ + S-adenosyl-L-homocysteine.\" [EC:2.1.1.291]","metadata":null},{"id":"5fbff23eabba4d579194433f9cd6495f","type":"TRIAL","name":"(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)","canonical_id":"clinicaltrials.gov:NCT03362047","description":"Pulmonary Arterial Hypertension (PAH)","metadata":null},{"id":"378e811a2fcf43d98830d9e2da91c79d","type":"GO_TERM","name":"(RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline N-methyltransferase activity","canonical_id":"go:GO:0030776","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline = S-adenosyl-L-homocysteine + N-methyl-(RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline.\" [EC:2.1.1.115]","metadata":null},{"id":"e0dbdd6f784b45b7a9538354de7487fa","type":"GO_TERM","name":"(RS)-norcoclaurine 6-O-methyltransferase activity","canonical_id":"go:GO:0030786","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (RS)-norcoclaurine = S-adenosyl-L-homocysteine + (RS)-coclaurine.\" [EC:2.1.1.128]","metadata":null},{"id":"7898d0650839420d86459233e9204fc5","type":"GO_TERM","name":"(S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido) succinate lyase (fumarate-forming) activity","canonical_id":"go:GO:0070626","description":"\"Catalysis of the reaction: (S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate = fumarate + 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide.\" [RHEA:23920]","metadata":null},{"id":"62bae5759b444093a6677b295c69e087","type":"GO_TERM","name":"(S)-2-haloacid dehalogenase activity","canonical_id":"go:GO:0018784","description":"\"Catalysis of the reaction: (S)-2-haloacid + H2O = (R)-2-hydroxyacid + halide.\" [EC:3.8.1.2]","metadata":null},{"id":"84d53cad95a544a8aae43c4e47ef70cd","type":"GO_TERM","name":"(S)-2-hydroxy-acid oxidase activity","canonical_id":"go:GO:0003973","description":"\"Catalysis of the reaction: (S)-2-hydroxy-acid + O2 = 2-oxo acid + H2O2.\" [RHEA:16789]","metadata":null},{"id":"8f796e8a66714de1a1dcd3b941eb0259","type":"GO_TERM","name":"(S)-2-hydroxy-fatty acid dehydrogenase activity","canonical_id":"go:GO:0047050","description":"\"Catalysis of the reaction: (S)-2-hydroxystearate + NAD+ = 2-oxostearate + H+ + NADH.\" [EC:1.1.1.99, RHEA:11384]","metadata":null},{"id":"959a270f26144258aa7185c0d65da608","type":"GO_TERM","name":"(S)-2-hydroxyglutarate dehydrogenase (quinone) activity","canonical_id":"go:GO:0140696","description":"\"Catalysis of the reaction: (S)-2-hydroxyglutarate + a quinone = 2-oxoglutarate + a quinol.\" [PMID:30498244, RHEA:58664]","metadata":null},{"id":"c6a1b6dde1b547738e05a657bec8ddb0","type":"GO_TERM","name":"(S)-2-hydroxyglutarate dehydrogenase activity","canonical_id":"go:GO:0047545","description":"\"Catalysis of the reaction: (S)-2-hydroxyglutarate + acceptor = 2-oxoglutarate + reduced acceptor.\" [RHEA:21252]","metadata":null},{"id":"7d78214dbb764a9a8e6fd0d1a1cf43e7","type":"GO_TERM","name":"(S)-2-methylmalate dehydratase activity","canonical_id":"go:GO:0047510","description":"\"Catalysis of the reaction: S-citramalate = H2O + mesaconate.\" [RHEA:13529]","metadata":null},{"id":"8cc35fb9b0e14b9f90eb8c6a508d2ad3","type":"GO_TERM","name":"(S)-3-amino-2-methylpropionate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047298","description":"\"Catalysis of the reaction: (S)-3-amino-2-methylpropanoate + 2-oxoglutarate = 2-methyl-3-oxopropanoate + L-glutamate.\" [RHEA:13993]","metadata":null},{"id":"e8514cc1cf7b4ca9be175e4b664b15bb","type":"GO_TERM","name":"(S)-3-hydroxyacid-ester dehydrogenase activity","canonical_id":"go:GO:0047109","description":"\"Catalysis of the reaction: ethyl (S)-3-hydroxyhexanoate + NADP+ = ethyl 3-oxohexanoate + H+ + NADPH.\" [EC:1.1.1.280, RHEA:18269]","metadata":null},{"id":"5766501d9bf64957b2a91b2bc8eca63f","type":"GO_TERM","name":"(S)-6-hydroxynicotine oxidase activity","canonical_id":"go:GO:0018531","description":"\"Catalysis of the reaction: (S)-6-hydroxynicotine + H2O + O2 = 6-hydroxypseudooxynicotine + H2O2.\" [EC:1.5.3.5, RHEA:11880]","metadata":null},{"id":"e68181ceeb944a44a254b5558d79d55c","type":"GO_TERM","name":"(S)-N-acetyl-1-phenylethylamine hydrolase activity","canonical_id":"go:GO:0050536","description":"\"Catalysis of the reaction: N-acetylphenylethylamine + H2O = acetate + phenylethylamine.\" [EC:3.5.1.85, RHEA:23952]","metadata":null},{"id":"479721162915458a9db3beb892f6717a","type":"GO_TERM","name":"(S)-canadine synthase activity","canonical_id":"go:GO:0047056","description":"\"Catalysis of the reaction: (S)-tetrahydrocolumbamine + reduced [NADPH--hemoprotein reductase] + O2 = (S)-canadine + oxidized [NADPH--hemoprotein reductase] + 2 H2O + H+.\" [RHEA:21456]","metadata":null},{"id":"1e68c578d5034ea38e90fc17a7cb63f1","type":"GO_TERM","name":"(S)-carnitine 3-dehydrogenase activity","canonical_id":"go:GO:0047041","description":"\"Catalysis of the reaction: (S)-carnitine + NAD+ = 3-dehydrocarnitine + H+ + NADH.\" [EC:1.1.1.254, RHEA:11556]","metadata":null},{"id":"8d0a4b6add684c54bce63ad5b8c4e032","type":"GO_TERM","name":"(S)-cheilanthifoline synthase activity","canonical_id":"go:GO:0047053","description":"\"Catalysis of the reaction: (S)-scoulerine + [reduced NADPH--hemoprotein reductase] + O2 = (S)-cheilanthifoline + [oxidized NADPH--hemoprotein reductase] + 2 H2O.\" [RHEA:20485]","metadata":null},{"id":"06cbd97fd68746c9b639e175f57e9d07","type":"GO_TERM","name":"(S)-citramalyl-CoA lyase activity","canonical_id":"go:GO:0047777","description":"\"Catalysis of the reaction: (3S)-citramalyl-CoA = acetyl-CoA + pyruvate.\" [EC:4.1.3.25, RHEA:22612]","metadata":null},{"id":"f8b4e79dc2c149959c79db43b9990f18","type":"GO_TERM","name":"(S)-coclaurine-N-methyltransferase activity","canonical_id":"go:GO:0030794","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (S)-coclaurine = S-adenosyl-L-homocysteine + (S)-N-methylcoclaurine.\" [EC:2.1.1.140]","metadata":null},{"id":"bc4e88cf6dfd47de94896d10123bb793","type":"GO_TERM","name":"(S)-corytuberine synthase activity","canonical_id":"go:GO:0102963","description":"\"Catalysis of the reaction: H+ + (S)-reticulinium(1+) + NADPH + O2 = (S)-corytuberine + NADP + 2 H2O.\" [PMID:18230623, RHEA:51540]","metadata":null},{"id":"9cc373d04a1a4bf8a8365b7b4baefe55","type":"GO_TERM","name":"(S)-hydroxynitrile lyase activity","canonical_id":"go:GO:0047606","description":"\"Catalysis of the reaction: a (S)-hydroxynitrile = hydrogen cyanide + an aldehyde or ketone.\" [EC:4.1.2.47, PMID:3377504]","metadata":null},{"id":"432b190976c1449f954e4d7ba23cb70c","type":"GO_TERM","name":"(S)-limonene 3-monooxygenase activity","canonical_id":"go:GO:0018674","description":"\"Catalysis of the reaction: (4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1S,6R)-isopiperitenol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:15129]","metadata":null},{"id":"6b762a4588454551bd40ef73238533ad","type":"GO_TERM","name":"(S)-limonene 6-monooxygenase activity","canonical_id":"go:GO:0018675","description":"\"Catalysis of the reaction: (4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1S,5R)-carveol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:17945]","metadata":null},{"id":"16ee6792feff44129c0a192971f5848a","type":"GO_TERM","name":"(S)-limonene 7-monooxygenase activity","canonical_id":"go:GO:0018676","description":"\"Catalysis of the reaction: (4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (4S)-perillyl alcohol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:23432]","metadata":null},{"id":"555c35b2c62441beb6cdf9f58da117cf","type":"GO_TERM","name":"(S)-mandelate dehydrogenase activity","canonical_id":"go:GO:0033720","description":"\"Catalysis of the reaction: (S)-2-hydroxy-2-phenylacetate + acceptor = 2-oxo-2-phenylacetate + reduced acceptor.\" [EC:1.1.99.31]","metadata":null},{"id":"1ad96ada5546412493c9c6bb7127bed9","type":"GO_TERM","name":"(S)-methylmalonyl-CoA hydrolase activity","canonical_id":"go:GO:0047511","description":"\"Catalysis of the reaction: (S)-methylmalonyl-CoA + H2O = CoA + H+ + methylmalonate.\" [EC:3.1.2.17, RHEA:17345]","metadata":null},{"id":"d4a2f3093f5c4b99a88b617bbb9c884e","type":"GO_TERM","name":"(S)-nandinine synthase activity","canonical_id":"go:GO:0102632","description":"\"Catalysis of the reaction: (S)-scoulerine + reduced [NADPH--hemoprotein reductase] + O2 = (S)-nandinine + oxidized [NADPH--hemoprotein reductase] + 2 H2O + H+.\" [PMID:17250743, PMID:21094631, RHEA:50364]","metadata":null},{"id":"e19e106e86344e43b0b303df8eefff91","type":"GO_TERM","name":"(S)-norcoclaurine synthase activity","canonical_id":"go:GO:0050474","description":"\"Catalysis of the reaction: 4-(2-aminoethyl)benzene-1,2-diol + 4-hydroxyphenylacetaldehyde = (S)-norcoclaurine + H2O.\" [RHEA:16173]","metadata":null},{"id":"30e9b15c839541dda9e64ea7560bdf57","type":"GO_TERM","name":"(S)-reticuline biosynthetic process","canonical_id":"go:GO:1901012","description":"\"The chemical reactions and pathways resulting in the formation of (S)-reticuline.\" [GOC:TermGenie, GOC:yaf, PMID:22725256]","metadata":null},{"id":"b877ddcc966b4ccd9ab9eab24b68c012","type":"GO_TERM","name":"(S)-scoulerine 9-O-methyltransferase activity","canonical_id":"go:GO:0030777","description":"\"Catalysis of the reaction: (S)-scoulerine + S-adenosyl-L-methionine(1+) = (S)-tetrahydrocolumbamine + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.117, RHEA:23808]","metadata":null},{"id":"fb20201bb287439e8132050371f2f0de","type":"GO_TERM","name":"(S)-scoulerine biosynthetic process","canonical_id":"go:GO:1901009","description":"\"The chemical reactions and pathways resulting in the formation of (S)-scoulerine.\" [GOC:TermGenie, GOC:yaf, PMID:15672841]","metadata":null},{"id":"0af862e1e16d4783b93bff347caeeadf","type":"GO_TERM","name":"(S)-stylopine synthase activity","canonical_id":"go:GO:0047052","description":"\"Catalysis of the reaction: (S)-cheilanthifoline + reduced [NADPH--hemoprotein reductase] + O2 = (S)-stylopine + oxidized [NADPH--hemoprotein reductase] + 2 H2O + H+.\" [RHEA:13773]","metadata":null},{"id":"dfac590e84d140bf82838e19120cbacb","type":"GO_TERM","name":"(S)-tetrahydroprotoberberine N-methyltransferase activity","canonical_id":"go:GO:0030782","description":"\"Catalysis of the reaction: an (S)-7,8,13,14-tetrahydroprotoberberine + S-adenosyl-L-methionine = an (S)-cis-N-methyl-7,8,13,14-tetrahydroprotoberberine + S-adenosyl-L-homocysteine.\" [RHEA:76067]","metadata":null},{"id":"da31a13a67a644a892331de93daa42bf","type":"GO_TERM","name":"(S)-usnate reductase activity","canonical_id":"go:GO:0046998","description":"\"Catalysis of the reaction: (6R)-2-acetyl-6-(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)-3-hydroxy-6-methylcyclohexa-2,4-dien-1-one + NAD+ = (S)-usnate + 2 H+ + NADH.\" [EC:1.1.1.199, RHEA:21876]","metadata":null},{"id":"f0f373ef2ace4067b6e9cea85704e02e","type":"GO_TERM","name":"(S,S)-butanediol dehydrogenase activity","canonical_id":"go:GO:0047512","description":"\"Catalysis of the reaction: (S,S)-butane-2,3-diol + NAD+ = acetoin + H+ + NADH.\" [EC:1.1.1.76, RHEA:12184]","metadata":null},{"id":"b8f05662e00e44f8b5bbfedc8a3a093a","type":"TRIAL","name":"(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?","canonical_id":"clinicaltrials.gov:NCT02310789","description":"Cystic Fibrosis","metadata":null},{"id":"664a6701b1224e91bb18beb35f615436","type":"TRIAL","name":"(VELA) Study of BLU-222 in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05252416","description":"Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma","metadata":null},{"id":"bbd2075b53f14d03858757354663825f","type":"GO_TERM","name":"(Z)-3-hexen-1-ol acetyltransferase activity","canonical_id":"go:GO:0102165","description":"\"Catalysis of the reaction: acetyl-CoA + (Z)-hex-3-en-1-ol = (3Z)-hex-3-en-1-yl acetate + coenzyme A.\" [GOC:pz, RHEA:28254]","metadata":null},{"id":"9913373a4e184382acd8b82f511df7fc","type":"GO_TERM","name":"(Z)-gamma-bisabolene synthase activity","canonical_id":"go:GO:0052683","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (Z)-gamma-bisabolene + diphosphate.\" [RHEA:26081]","metadata":null},{"id":"9a60dac4aebe478081bd397ac828add3","type":"GO_TERM","name":"(Z,E)-alpha- farnesene synthase activity","canonical_id":"go:GO:0102931","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (Z,E)-alpha-farnesene + diphosphoric acid.\" [GOC:pz, PMID:17140613]","metadata":null},{"id":"eda3c9c2f3f14c319a839584d47ecb0d","type":"GO_TERM","name":"(carboxyethyl)arginine beta-lactam-synthase activity","canonical_id":"go:GO:0034027","description":"\"Catalysis of the reaction: N(2)-(2-carboxyethyl)-L-arginine + ATP = AMP + deoxyamidinoproclavaminate + diphosphate + 2 H+.\" [EC:6.3.3.4, RHEA:23620]","metadata":null},{"id":"5a7848d226a64ac5a2619b78e8627069","type":"GO_TERM","name":"(hydroxyamino)benzene mutase activity","canonical_id":"go:GO:0018824","description":"\"Catalysis of the reaction: N-phenylhydroxylamine = 2-aminophenol.\" [RHEA:19245]","metadata":null},{"id":"77f9226f5cb246da96d179005a5cc8ec","type":"GO_TERM","name":"(iso)eugenol O-methyltransferase activity","canonical_id":"go:GO:0050630","description":"\"Catalysis of the reaction: (E)-isoeugenol + S-adenosyl-L-methionine = (E)-isomethyleugenol + H+ + S-adenosyl-L-homocysteine.\" [RHEA:17081]","metadata":null},{"id":"122679db4430496bbfe2e1552338174b","type":"TRIAL","name":"1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients","canonical_id":"clinicaltrials.gov:NCT02334722","description":"Brain Neoplasms; Brain Cancer; Brain Tumors; Cancer of the Brain; Cancer of Brain; Seizure","metadata":null},{"id":"c9c40e94a0f44453b584d6222c07425d","type":"TRIAL","name":"1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","canonical_id":"clinicaltrials.gov:NCT00767481","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"5c90bc91a0a34cf69c7d366d6619d382","type":"TRIAL","name":"1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers","canonical_id":"clinicaltrials.gov:NCT02168543","description":"Chronic Periodontitis","metadata":null},{"id":"c5d7b2864f414abdbca028c670c197a8","type":"TRIAL","name":"1% Clascoterone Cream for the Treatment Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT07457294","description":"Acne Vulgaris","metadata":null},{"id":"c9b16f319dad4bcfad8c096facd5e652","type":"TRIAL","name":"1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX","canonical_id":"clinicaltrials.gov:NCT01692626","description":"Rash","metadata":null},{"id":"f099b92f20774ea2aa96b51a5cdff9e0","type":"GO_TERM","name":"1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane catabolic process","canonical_id":"go:GO:0042188","description":"\"The chemical reactions and pathways resulting in the breakdown of 1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane (DDT), a chlorinated broad spectrum contact insecticide.\" [GOC:jl]","metadata":null},{"id":"1f1c88ca0ca7454aa26880373c08de0e","type":"GO_TERM","name":"1,2,4-trichlorobenzene catabolic process","canonical_id":"go:GO:0018911","description":"\"The chemical reactions and pathways resulting in the breakdown of 1,2,4-trichlorobenzene, a derivative of benzene with chlorine atoms attached to positions 1, 2 and 4 of the ring. It is a colorless liquid used as a solvent in chemical manufacturing, in dyes and intermediates, dielectric fluid, synthetic transformer oils, lubricants, heat-transfer medium and insecticides.\" [PMID:1987135]","metadata":null},{"id":"a054068762f246c780bc35cfbf9dbfd6","type":"GO_TERM","name":"1,2-alpha-L-fucosidase activity","canonical_id":"go:GO:0047513","description":"\"Catalysis of the reaction: H2O + methyl-2-alpha-L-fucopyranosyl-beta-D-galactoside = L-fucose + methyl beta-D-galactoside.\" [EC:3.2.1.63, MetaCyc:12-ALPHA-L-FUCOSIDASE-RXN]","metadata":null},{"id":"0afcf8dfa70b4752a9e4baf4f5cfcad9","type":"GO_TERM","name":"1,2-beta-fructan 1F-fructosyltransferase activity","canonical_id":"go:GO:0047207","description":"\"Catalysis of the reaction: [(1->2)-beta-D-fructosyl](n) + [(1->2)-beta-D-fructosyl](m) = [(1->2)-beta-D-fructosyl](n+1) + [(1->2)-beta-D-fructosyl](m-1).\" [EC:2.4.1.100, MetaCyc:2.4.1.100-RXN]","metadata":null},{"id":"d63b27e6f8b7439f8ebc070f4386a749","type":"GO_TERM","name":"1,2-dehydro-N-acetyldopamine biosynthetic process","canonical_id":"go:GO:0120577","description":"\"The chemical reactions and pathways resulting in the formation of 1,2-dehydro-N-acetyldopamine via N-acetyldopamine (NADA). In insects, these sclerotizing precursors are involved in the cross-linking of cuticular proteins hardening (sclerotizing) and pigmenting the cuticle.\" [PMID:19932179, PMID:32709620]","metadata":null},{"id":"5a50fee38e2f444a901bb8102fff7a96","type":"GO_TERM","name":"1,2-dehydro-N-beta-alanyldopamine biosynthetic process","canonical_id":"go:GO:0120576","description":"\"The chemical reactions and pathways resulting in the formation of 1,2-dehydro-N-beta-alanyldopamine via N-beta-alanyldopamine (NBAD). In insects, these sclerotizing precursors are involved in the cross-linking of cuticular proteins hardening (sclerotizing) and pigmenting the cuticle.\" [PMID:19932179, PMID:32709620]","metadata":null},{"id":"7573f2e0199246bc96ec7c1871381407","type":"GO_TERM","name":"1,2-dehydroreticulinium reductase (NADPH) activity","canonical_id":"go:GO:0047128","description":"\"Catalysis of the reaction: (R)-reticuline + NADP+ = 1,2-dehydroreticuline + H+ + NADPH.\" [EC:1.5.1.27, RHEA:17569]","metadata":null},{"id":"b546365925224fca81dc65f47b65c93a","type":"GO_TERM","name":"1,2-diacyl-sn-glycero-3-phosphocholine metabolic process","canonical_id":"go:GO:0006653","description":"\"The chemical reactions and pathways involving any 1,2-diacyl-sn-glycero-3-phosphocholine, the compounds most commonly designated lecithin.\" [ISBN:0198506732]","metadata":null},{"id":"7c20ce687a5348e3bbede43d197aac78","type":"GO_TERM","name":"1,2-diacylglycerol 3-beta-galactosyltransferase activity","canonical_id":"go:GO:0046509","description":"\"Catalysis of the reaction: 1,2-diacyl-sn-glycerol + UDP-D-galactose = 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol + H+ + UDP.\" [EC:2.4.1.46, RHEA:14945]","metadata":null},{"id":"9fab466f95e6426d986d48aebc0d2f19","type":"GO_TERM","name":"1,2-diacylglycerol 3-glucosyltransferase activity","canonical_id":"go:GO:0047228","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycerol + UDP-alpha-D-glucose = a 1,2-diacyl-3-O-(alpha-D-glucopyranosyl)-sn-glycerol + H+ + UDP.\" [RHEA:47612]","metadata":null},{"id":"a347a717ec674886813ecd9d5da5a911","type":"GO_TERM","name":"1,2-dichloroethane catabolic process","canonical_id":"go:GO:0019260","description":"\"The chemical reactions and pathways resulting in the breakdown of 1,2-dichloroethane, a major commodity chemical used, for example, in the manufacture of vinyl chloride.\" [GOC:curators]","metadata":null},{"id":"21e3c7a05eb341f0ad1a9b89e1b8fd37","type":"GO_TERM","name":"1,2-dihydrovomilenine reductase activity","canonical_id":"go:GO:0050615","description":"\"Catalysis of the reaction: 17-O-acetylnorajmaline + NADP+ = 1,2-dihydrovomilenine + H+ + NADPH.\" [EC:1.3.1.73, RHEA:12320]","metadata":null},{"id":"cd7f010505ed410a99e445857119cab5","type":"GO_TERM","name":"1,2-dihydroxy-6-methylcyclohexa-3,5-dienecarboxylate dehydrogenase activity","canonical_id":"go:GO:0018521","description":"\"Catalysis of the reaction: 1,6-dihydroxy-2-methylcyclohexa-2,4-dienecarboxylate + NAD+ = 3-methylcatechol + CO2 + NADH.\" [EC:1.3.1.68, RHEA:15657]","metadata":null},{"id":"08e0e356857d400f901b6c9ce295bd7b","type":"GO_TERM","name":"1,2-dihydroxynaphthalene dioxygenase activity","canonical_id":"go:GO:0018554","description":"\"Catalysis of the reaction: naphthalene-1,2-diol + O2 = 2-hydroxychromene-2-carboxylate + H+.\" [RHEA:27310]","metadata":null},{"id":"c76d4e8e5e5545cda2b7e49489363f6f","type":"GO_TERM","name":"1,2-propanediol catabolic process","canonical_id":"go:GO:0051144","description":"\"The chemical reactions and pathways resulting in the breakdown of propanediol, a sweet, colorless, viscous, hygroscopic liquid with the formula CH3-CHOH-CH2OH.\" [PMID:12700259]","metadata":null},{"id":"7a0edde9e5064a03968fd2bb9c9bb813","type":"GO_TERM","name":"1,2-rhamnosyltransferase activity","canonical_id":"go:GO:0102949","description":"\"Catalysis of the reaction: isoorientin + an L-rhamonsylated rhamnosyl acceptor = isoorientin 2'-O-rhamnoside + a non rhamnosylated rhamnosyl acceptor.\" [GOC:pz, PMID:15220389]","metadata":null},{"id":"2c8c8efaf4014acfb7887f17bd59c2ad","type":"DRUG","name":"1,25-dihydroxyvitamin D3","canonical_id":"gtopdb:2779","description":null,"metadata":null},{"id":"bf64c31c53fd4577b6be349a72853096","type":"GO_TERM","name":"1,3,6,8-tetrahydroxynaphthalene monooxygenase (quinone-forming) activity","canonical_id":"go:GO:0102634","description":"\"Catalysis of the reaction: naphthalene-1,3,6,8-tetrol + O2 = flaviolin-2-olate + H2O + H+.\" [GOC:pz, PMID:15701630]","metadata":null},{"id":"b43264f99db04956b81a90872def342e","type":"PROTEIN","name":"1,3-Beta-glucan synthase","canonical_id":"uniprot:IPR003440","description":null,"metadata":null},{"id":"f29c726e480043c681649ecb2923a646","type":"GO_TERM","name":"1,3-alpha-L-fucosidase activity","canonical_id":"go:GO:0033932","description":"\"Catalysis of the hydrolysis of (1->3) linkages between alpha-L-fucose and N-acetylglucosamine residues in glycoproteins.\" [EC:3.2.1.111]","metadata":null},{"id":"059a8f362b3a404f83b7b66c74d6ca2b","type":"GO_TERM","name":"1,3-beta-D-glucan phosphorylase activity","canonical_id":"go:GO:0047514","description":"\"Catalysis of the reaction: [(1->3)-beta-D-glucosyl](n) + phosphate = [(1->3)-beta-D-glucosyl](n-1) + alpha-D-glucose 1-phosphate; substrates include laminarin.\" [EC:2.4.1.97, MetaCyc:13-BETA-GLUCAN-PHOSPHORYLASE-RXN]","metadata":null},{"id":"ceb900d36ad64eb098bf2e35a468ce07","type":"GO_TERM","name":"1,3-beta-D-glucan synthase activity","canonical_id":"go:GO:0003843","description":"\"Catalysis of the reaction: UDP-glucose + [(1->3)-beta-D-glucosyl](n) = UDP + [(1->3)-beta-D-glucosyl](n+1).\" [EC:2.4.1.34]","metadata":null},{"id":"51df1b6746ab41f2aab36e17eff96ac4","type":"GO_TERM","name":"1,3-beta-D-glucan synthase complex","canonical_id":"go:GO:0000148","description":"\"A protein complex that catalyzes the transfer of a glucose group from UDP-glucose to a (1->3)-beta-D-glucan chain.\" [PMID:7983071]","metadata":null},{"id":"7012c3d0cedf4caaa984d88e6743c8de","type":"GO_TERM","name":"1,3-beta-galactosyl-N-acetylhexosamine phosphorylase activity","canonical_id":"go:GO:0050500","description":"\"Catalysis of the reaction: phosphate + beta-D-galactopyranosyl-(1->3)-N-acetyl-D-glucosamine = N-acetyl-D-glucosamine + alpha-D-galactopyranose 1-phosphate.\" [EC:2.4.1.211, MetaCyc:2.4.1.211-RXN]","metadata":null},{"id":"1eb5752c9ef24f81a3848e42ab199532","type":"PROTEIN","name":"1,3-beta-glucan synthase component FKS1","canonical_id":"uniprot:A2QLK4","description":null,"metadata":null},{"id":"5dccb49af2f54623b646e43f9c624f89","type":"GO_TERM","name":"1,3-beta-glucanosyltransferase activity","canonical_id":"go:GO:0042124","description":"\"Catalysis of the splitting and linkage of (1->3)-beta-D-glucan molecules, resulting in (1->3)-beta-D-glucan chain elongation.\" [GOC:jl, PMID:10809732]","metadata":null},{"id":"03dbd4337f2246729aa4b0e1ca8640e9","type":"GO_TERM","name":"1,3-beta-oligoglucan phosphorylase activity","canonical_id":"go:GO:0047515","description":"\"Catalysis of the reaction: [oligomeric (1->3)-beta-D-glucosyl](n) + phosphate = [(1->3)-beta-D-glucosyl](n-1) + alpha-D-glucose 1-phosphate.\" [EC:2.4.1.30, MetaCyc:13-BETA-OLIGOGLUCAN-PHOSPHORYLASE-RXN]","metadata":null},{"id":"3c95241a2a3144b796a4642a9f4c9624","type":"GO_TERM","name":"1,3-propanediol dehydrogenase activity","canonical_id":"go:GO:0047516","description":"\"Catalysis of the reaction: propane-1,3-diol + NAD+ = 3-hydroxypropanal + NADH + H+.\" [EC:1.1.1.202, MetaCyc:13-PROPANEDIOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"ef0ff3333524428d9145c3918d495ccb","type":"GO_TERM","name":"1,4-alpha-glucan 6-alpha-glucosyltransferase activity","canonical_id":"go:GO:0032001","description":"\"Catalysis of the transfer an alpha-D-glucosyl residue in a (1->4)-alpha-D-glucan to the primary hydroxy group of glucose, free or combined in a (1->4)-alpha-D-glucan.\" [EC:2.4.1.24]","metadata":null},{"id":"61defbf681d84770b4a6799555a14139","type":"GO_TERM","name":"1,4-alpha-glucan branching enzyme activity","canonical_id":"go:GO:0003844","description":"\"Catalysis of the transfer of a segment of a (1->4)-alpha-D-glucan chain to a primary hydroxyl group in a similar glucan chain.\" [EC:2.4.1.18]","metadata":null},{"id":"18f0874f6bbf45f081e9bddc6797a73f","type":"GO_TERM","name":"1,4-alpha-oligoglucan phosphorylase activity","canonical_id":"go:GO:0004645","description":"\"Catalysis of the reaction: 1,4-alpha-D-glucosyl(n) + phosphate = 1,4-alpha-D-glucosyl(n-1) + alpha-D-glucose 1-phosphate.\" [RHEA:41732]","metadata":null},{"id":"bdd0ab18d75940b68818d1454e6991e3","type":"GO_TERM","name":"1,4-beta-D-xylan synthase activity","canonical_id":"go:GO:0047517","description":"\"Catalysis of the reaction: UDP-D-xylose + [(1->4)-beta-D-xylan](n) = UDP + [(1->4)-beta-D-xylan](n+1).\" [EC:2.4.2.24]","metadata":null},{"id":"5366b028cc304ec1b4d0415a3bd00e7c","type":"GO_TERM","name":"1,4-dichlorobenzene catabolic process","canonical_id":"go:GO:0019261","description":"\"The chemical reactions and pathways resulting in the breakdown of 1,4-dichlorobenzene (p-dichlorobenzene or paramoth), a derivative of benzene with two chlorine atoms attached at opposite positions on the ring.\" [GOC:ai, PMID:9148781]","metadata":null},{"id":"69f91ffaf1f64175a0a7ebf6d503894a","type":"GO_TERM","name":"1,4-dihydroxy-2-naphthoate polyprenyltransferase activity","canonical_id":"go:GO:0046428","description":"\"Catalysis of the reaction: 1,4-dihydroxy-2-naphthoate + an all-trans-polyprenyl diphosphate + H+ = a 2-demethylmenaquinol + CO2 + diphosphate.\" [RHEA:26478]","metadata":null},{"id":"331d05ac5a0544b089920b50bbe440e9","type":"GO_TERM","name":"1,4-dihydroxy-2-naphthoyl-CoA synthase activity","canonical_id":"go:GO:0008935","description":"\"Catalysis of the reaction: 2-succinylbenzoyl-CoA + H+ = 1,4-dihydroxy-2-naphthoyl-CoA + H2O.\" [RHEA:26562]","metadata":null},{"id":"39f5e4f79a374ec1a3b6b43b80722d1f","type":"GO_TERM","name":"1,4-dihydroxy-2-naphthoyl-CoA thioesterase activity","canonical_id":"go:GO:0061522","description":"\"Catalysis of the reaction 1,4-dihydroxy-2-naphthoyl-CoA + H2O = 1,4-dihydroxy-2-naphthoate + CoA + H+.\" [RHEA:26309]","metadata":null},{"id":"32af41440f3d4c9399fb5f16beadd7fd","type":"GO_TERM","name":"1,4-lactonase activity","canonical_id":"go:GO:0050490","description":"\"Catalysis of the reaction: H2O + a 1,4-lactone = a 4-hydroxyacid.\" [EC:3.1.1.25, MetaCyc:14-LACTONASE-RXN]","metadata":null},{"id":"5f9c417420354a3c85854618e5eeb9a5","type":"GO_TERM","name":"1,5-anhydro-D-fructose catabolic process","canonical_id":"go:GO:1901802","description":"\"The chemical reactions and pathways resulting in the breakdown of 1,5-anhydro-D-fructose.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-6992, PMID:15716041, UniPathway:UPA00738]","metadata":null},{"id":"a5dda90e34a64beaa11c7cdf95db2e17","type":"GO_TERM","name":"1,5-anhydro-D-fructose dehydratase activity","canonical_id":"go:GO:0033992","description":"\"Catalysis of the reaction: 1,5-anhydro-D-fructose = 1,5-anhydro-4-deoxy-D-glycero-hex-3-en-2-ulose + H2O.\" [EC:4.2.1.111]","metadata":null},{"id":"60422e23cdb74b8bbf3db1150b88f00e","type":"GO_TERM","name":"1,5-anhydro-D-fructose reductase (1,5-anhydro-D-mannitol-forming) activity","canonical_id":"go:GO:0033712","description":"\"Catalysis of the reaction: 1,5-anhydro-D-mannitol + NADP+ = 1,5-anhydro-D-fructose + H+ + NADPH.\" [EC:1.1.1.292, RHEA:24208]","metadata":null},{"id":"ade594ffa52b4cfdb6852bf445afe08e","type":"GO_TERM","name":"1,5-anhydro-D-fructose reductase activity","canonical_id":"go:GO:0050571","description":"\"Catalysis of the reaction: 1,5-anhydro-D-glucitol + NADP+ = 1,5-anhydro-D-fructose + H+ + NADPH.\" [EC:1.1.1.263, RHEA:20665]","metadata":null},{"id":"d177072bd18d40ac96bdba8b8f04e562","type":"GO_TERM","name":"1,6-alpha-L-fucosidase activity","canonical_id":"go:GO:0033938","description":"\"Catalysis of the hydrolysis of (1->6) linkages between alpha-L-fucose and N-acetyl-D-glucosamine in glycopeptides such as immunoglobulin G glycopeptide and fucosyl-asialo-agalacto-fetuin.\" [EC:3.2.1.127]","metadata":null},{"id":"031a4658073b4ec2804f49b0bf0335fa","type":"GO_TERM","name":"1,6-anhydro-N-acetyl-beta-muramic acid catabolic process","canonical_id":"go:GO:0097175","description":"\"The chemical reactions and pathways resulting in the breakdown of 1,6-anhydro-N-acetylmuramic acid, the 1,6-anhydro-derivative of N-acetyl-beta-muramic acid.\" [GOC:yaf, PMID:15901686]","metadata":null},{"id":"93f25a8bb2b548f397b09a97f4897bec","type":"GO_TERM","name":"1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase activity","canonical_id":"go:GO:0047116","description":"\"Catalysis of the reaction: NAD+ + 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate = NADH + CO2 + catechol.\" [EC:1.3.1.25, MetaCyc:1.3.1.25-RXN]","metadata":null},{"id":"5f5a434b01d84ea493d7ce197db54393","type":"GO_TERM","name":"1,8-cineole 2-exo-monooxygenase activity","canonical_id":"go:GO:0102320","description":"\"Catalysis of the reaction: 1,8-cineole + NADPH + H+ + O2 = 2-exo-hydroxy-1,8-cineole + NADP + H2O.\" [GOC:pz, RHEA:32895]","metadata":null},{"id":"1b12147547b04152b13bec44d677f0f5","type":"GO_TERM","name":"1,8-cineole synthase activity","canonical_id":"go:GO:0102313","description":"\"Catalysis of the reaction: geranyl diphosphate(3-) + H2O = 1,8-cineole + diphosphoric acid.\" [RHEA:32543]","metadata":null},{"id":"273fabc191fb4b88a029696fcc33f875","type":"GO_TERM","name":"1,8-dihydroxynaphthalene-melanin biosynthetic process","canonical_id":"go:GO:0140614","description":"\"The chemical reactions and pathways resulting in the formation of dihydroxy naphthalene (DHN)-melanin.\" [PMID:12788746, PMID:23998343]","metadata":null},{"id":"b76b2a59e8e54911b2a8c24a55179ca7","type":"GO_TERM","name":"1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one metabolic process","canonical_id":"go:GO:0031147","description":"\"The chemical reactions and pathways involving 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one, also known as DIF-1, differentiation-inducing factor-1. DIF-1 is a secreted chlorinated molecule that controls cell fate during development of Dictyostelium cells.\" [GOC:mah, PMID:10706822]","metadata":null},{"id":"cefb24f3638b4d98933f21ecf7cadd4d","type":"GO_TERM","name":"1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding","canonical_id":"go:GO:0071886","description":"\"Binding to the amine 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine, a serotonin receptor agonist that can act as a psychedelic drug.\" [GOC:yaf, PMID:19057895]","metadata":null},{"id":"6a9c590e25ca431b80af2f7b2a39dbc0","type":"GO_TERM","name":"1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino]imidazole-4-carboxamide isomerase activity","canonical_id":"go:GO:0003949","description":"\"Catalysis of the reaction: 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino]imidazole-4-carboxamide = 5-[(5-phospho-1-deoxy-D-ribulos-1-ylimino)methylamino]-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide.\" [EC:5.3.1.16, RHEA:15469]","metadata":null},{"id":"f313efaad4cf4b29b441b965d2810da5","type":"GO_TERM","name":"1-acylglycerol-3-phosphate O-acyltransferase activity","canonical_id":"go:GO:0003841","description":"\"Catalysis of the reaction: acyl-CoA + 1-acyl-sn-glycerol-3-phosphate = CoA + 1,2-diacyl-sn-glycerol-3-phosphate.\" [EC:2.3.1.51, GOC:ab]","metadata":null},{"id":"4bfd149a7ddd4cb6afb327b79969c073","type":"GO_TERM","name":"1-acylglycerophosphocholine O-acyltransferase activity","canonical_id":"go:GO:0047184","description":"\"Catalysis of the reaction: 1-acyl-sn-glycero-3-phosphocholine + acyl-CoA = phosphatidylcholine + CoA.\" [EC:2.3.1.23, MetaCyc:2.3.1.23-RXN]","metadata":null},{"id":"9abfe03fb4134c0c8b8276ceba5f697c","type":"GO_TERM","name":"1-acylglycerophosphoethanolamine O-acyltransferase activity","canonical_id":"go:GO:0106262","description":"\"Catalysis of the reaction: a 1-acyl-sn-glycero-3-phosphoethanolamine + an acyl-CoA = a 1,2-diacyl-sn-glycero-3-phosphoethanolamine + CoA.\" [PMID:18287005, RHEA:32995]","metadata":null},{"id":"ea359f99e1914132a0a8aa0f55e8bbc8","type":"GO_TERM","name":"1-acylglycerophosphoserine O-acyltransferase activity","canonical_id":"go:GO:0106263","description":"\"Catalysis of the reaction:a 1-acyl-sn-glycero-3-phospho-L-serine + an acyl-CoA = a 1,2-diacyl-sn-glycero-3-phospho-L-serine + CoA.\" [PMID:18287005, RHEA:33191]","metadata":null},{"id":"d72a1f8c779e46ecb7aa59e332a94116","type":"GO_TERM","name":"1-alkenyl-2-acylglycerol choline phosphotransferase activity","canonical_id":"go:GO:0047359","description":"\"Catalysis of the reaction: 1-alkenyl-2-acylglycerol + CDP-choline = plasmenylcholine + CMP.\" [EC:2.7.8.22, MetaCyc:2.7.8.22-RXN]","metadata":null},{"id":"4d10e6150e8e4a43859f598a9891a692","type":"GO_TERM","name":"1-alkenylglycerophosphoethanolamine O-acyltransferase activity","canonical_id":"go:GO:0047166","description":"\"Catalysis of the reaction: 1-alkenylglycerophosphoethanolamine + acyl-CoA = 1-alkenyl-2-acyl-glycerophosphoethanolamine + CoA.\" [EC:2.3.1.121, MetaCyc:2.3.1.121-RXN]","metadata":null},{"id":"eeae9138af7b4e2c96316879d22173bd","type":"GO_TERM","name":"1-alkyl-2-acetylglycerol O-acyltransferase activity","canonical_id":"go:GO:0047167","description":"\"Catalysis of the reaction: 1-O-alkyl-2-acetyl-sn-glycerol + acyl-CoA = 1-O-alkyl-2-acetyl-3-acyl-sn-glycerol + CoA.\" [EC:2.3.1.125, MetaCyc:2.3.1.125-RXN]","metadata":null},{"id":"da2daf10748746309fa8b9434a11a4e4","type":"GO_TERM","name":"1-alkyl-2-acetylglycerophosphocholine esterase activity","canonical_id":"go:GO:0003847","description":"\"Catalysis of the reaction: a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O-alkyl-sn-glycero-3-phosphocholine + acetate + H+.\" [RHEA:17777]","metadata":null},{"id":"b6663d719fe540d9b185c2adebc3ec64","type":"GO_TERM","name":"1-alkyl-2-acetylglycerophosphocholine esterase complex","canonical_id":"go:GO:0008247","description":"\"An enzyme complex composed of two catalytic alpha subunits, which form a catalytic dimer, and a non-catalytic, regulatory beta subunit; the catalytic dimer may be an alpha1/alpha1 or alpha2/alpha2 homodimer, or an alpha1/alpha2 heterodimer. Modulates the action of platelet-activating factor (PAF).\" [GOC:jl, PMID:10542206]","metadata":null},{"id":"523df9c2c09c44c38434c231a3d3d982","type":"GO_TERM","name":"1-alkylglycerophosphocholine O-acetyltransferase activity","canonical_id":"go:GO:0047192","description":"\"Catalysis of the reaction: 1-alkyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine + CoA.\" [EC:2.3.1.67, MetaCyc:2.3.1.67-RXN]","metadata":null},{"id":"cf7d69de2786499abd8ffd1fa0f279fd","type":"GO_TERM","name":"1-alkylglycerophosphocholine O-acyltransferase activity","canonical_id":"go:GO:0047191","description":"\"Catalysis of the reaction: 1-alkyl-sn-glycero-3-phosphocholine + acyl-CoA = 1-alkyl-2-acyl-sn-glycero-3-phosphocholine + CoA.\" [EC:2.3.1.63, MetaCyc:2.3.1.63-RXN]","metadata":null},{"id":"5efd756ac65544c1871fa9c504f75167","type":"GO_TERM","name":"1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity","canonical_id":"go:GO:0062181","description":"\"Catatlysis of the reaction: calcitriol + 2 H+ + O2 + 2 reduced [adrenodoxin] = 1alpha,23S,25-trihydroxycholecalciferol + H2O + 2 oxidized [adrenodoxin].\" [PMID:22100522, PMID:30205156, RHEA:49192]","metadata":null},{"id":"163c65c206fc469385aec6e6e0cf9975","type":"GO_TERM","name":"1-alpha,25-dihydroxyvitamin D3 24-hydroxylase activity","canonical_id":"go:GO:0030342","description":"\"Catalysis of the hydroxylation of C-24 of 1-alpha,25-hydroxycholecalciferol (25-hydroxyvitamin D3; calcitriol).\" [PMID:8506296]","metadata":null},{"id":"e53263504db84a0584394e5d6443f7a9","type":"GO_TERM","name":"1-aminocyclopropane-1-carboxylate catabolic process","canonical_id":"go:GO:0042217","description":"\"The chemical reactions and pathways resulting in the breakdown of 1-aminocyclopropane-1-carboxylate, a natural product found in plant tissues. It is a key intermediate in the biosynthesis of ethylene (ethene), a fruit-ripening hormone in plants.\" [UM-BBD_pathwayID:acp]","metadata":null},{"id":"6a60787f61be4522a805a7f25700ec8e","type":"GO_TERM","name":"1-aminocyclopropane-1-carboxylate deaminase activity","canonical_id":"go:GO:0008660","description":"\"Catalysis of the reaction: 1-aminocyclopropane-1-carboxylate + H2O = 2-oxobutanate + NH4.\" [RHEA:16933]","metadata":null},{"id":"19220ea4f89b4ca58a8707a6b8c1ffaf","type":"GO_TERM","name":"1-aminocyclopropane-1-carboxylate oxidase activity","canonical_id":"go:GO:0009815","description":"\"Catalysis of the reaction: 1-aminocyclopropane-1-carboxylate + L-ascorbate + O2 = CO2 + dehydroascorbate + ethylene + 2 H2O + hydrogen cyanide. Ethene is also known as ethylene.\" [RHEA:23640]","metadata":null},{"id":"7ce57499ffce4bfa81714c5f4aea7d22","type":"GO_TERM","name":"1-aminocyclopropane-1-carboxylate synthase activity","canonical_id":"go:GO:0016847","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine = 1-aminocyclopropane-1-carboxylate + S-methyl-5'-thioadenosine + H+. 1-aminocyclopropane-1-carboxylate (ACC) is a direct precursor of ethylene biosynthesis.\" [RHEA:21744]","metadata":null},{"id":"20922376f639426bb17d0aba3f9d8229","type":"GO_TERM","name":"1-butanol biosynthetic process","canonical_id":"go:GO:0071271","description":"\"The chemical reactions and pathways resulting in the formation of 1-butanol, an alkyl primary alcohol with the formula C4H10O.\" [GOC:ecd, GOC:mah]","metadata":null},{"id":"36e4bfc8e8ce4ec3b405eff847763ece","type":"GO_TERM","name":"1-deoxy-11-oxopentalenate oxygenase activity","canonical_id":"go:GO:0102285","description":"\"Catalysis of the reaction: 1-deoxy-11-oxopentalenate + O2 + NADPH + H+ = pentalenolactone D + H2O + NADP.\" [GOC:pz, RHEA:34635]","metadata":null},{"id":"f3fcad6a56d44b7a977fe390982e0bd0","type":"GO_TERM","name":"1-deoxy-D-xylulose kinase activity","canonical_id":"go:GO:0103020","description":"\"Catalysis of the reaction: 1-deoxy-D-xylulose + ATP = H+ + 1-deoxy-D-xylulose 5-phosphate + ADP.\" [GOC:pz, PMID:11168365, PMID:16920870]","metadata":null},{"id":"07cf11c741c24978acf65cf8109add4e","type":"GO_TERM","name":"1-deoxy-D-xylulose-5-phosphate reductoisomerase activity","canonical_id":"go:GO:0030604","description":"\"Catalysis of the reaction: 2-C-methyl-D-erythritol 4-phosphate + NADP+ = 1-deoxy-D-xylulose 5-phosphate + H+ + NADPH.\" [EC:1.1.1.267, RHEA:13717]","metadata":null},{"id":"ea2eda6d588c4556936061ba9456a396","type":"GO_TERM","name":"1-deoxy-D-xylulose-5-phosphate synthase activity","canonical_id":"go:GO:0008661","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + H+ + pyruvate = 1-deoxy-D-xylulose 5-phosphate + CO2.\" [EC:2.2.1.7, RHEA:12605]","metadata":null},{"id":"ed1c30fb557f4be6bbb644d7126c7ca1","type":"GO_TERM","name":"1-hydroxy-2-naphthoate 1,2-dioxygenase activity","canonical_id":"go:GO:0018582","description":"\"Catalysis of the reaction: 1-hydroxy-2-naphthoate + O2 = (3E)-4-(2-carboxyphenyl)-2-oxobut-3-enoate.\" [EC:1.13.11.38]","metadata":null},{"id":"fd0d8b6e6ce741329c22757aaf9d1484","type":"GO_TERM","name":"1-hydroxy-2-naphthoate hydroxylase activity","canonical_id":"go:GO:0018637","description":"\"Catalysis of the reaction: 1-hydroxy-2-naphthoate + O2 + NAD(P)H + 2 H+ = NAD(P)+ + H2O + CO2 + 1,2-dihydroxynaphthalene.\" [EC:1.14.13.135, PMID:20727010, PMID:21545490, UM-BBD_reactionID:r0491]","metadata":null},{"id":"b010453a8ee645ccb7ec5df430e14cc8","type":"GO_TERM","name":"1-methyladenosine nucleosidase activity","canonical_id":"go:GO:0047518","description":"\"Catalysis of the reaction: 1-methyladenosine + H2O = 1-methyladenine + ribofuranose.\" [EC:3.2.2.13, RHEA:12865]","metadata":null},{"id":"052e6c073b3d43869baee21bf4284a3e","type":"GO_TERM","name":"1-methylguanosine metabolic process","canonical_id":"go:GO:0080179","description":"\"The chemical reactions and pathways involving 1-methylguanosine.\" [GOC:tb]","metadata":null},{"id":"9640c3333283488696fed3add3062c12","type":"GO_TERM","name":"1-phenylethanol dehydrogenase activity","canonical_id":"go:GO:0018449","description":"\"Catalysis of the reaction: (S)-1-phenylethanol + NAD+ = acetophenone + H+ + NADH.\" [RHEA:28198]","metadata":null},{"id":"5304b58d28a443029b243030caae44a5","type":"GO_TERM","name":"1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate biosynthetic process","canonical_id":"go:GO:1903102","description":"\"The chemical reactions and pathways resulting in the formation of 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate.\" [GO_REF:0000068, GOC:bhm, GOC:TermGenie, PMID:19037259]","metadata":null},{"id":"b4444bf38e124e3799f1df3248a94c28","type":"GO_TERM","name":"1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate catabolic process","canonical_id":"go:GO:1903101","description":"\"The chemical reactions and pathways resulting in the breakdown of 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate.\" [GO_REF:0000068, GOC:bhm, GOC:TermGenie, PMID:19037259]","metadata":null},{"id":"5126db4348b4490880dcd3a6bd84ff1f","type":"GO_TERM","name":"1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate metabolic process","canonical_id":"go:GO:1903100","description":"\"The chemical reactions and pathways involving 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate.\" [GO_REF:0000068, GOC:bhm, GOC:TermGenie, PMID:19037259]","metadata":null},{"id":"7c4d65948da546348ae06d90b30b4e01","type":"GO_TERM","name":"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process","canonical_id":"go:GO:1902635","description":"\"The chemical reactions and pathways resulting in the formation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate.\" [GO_REF:0000068, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"448c5e8d4fb4449c984db84108518f63","type":"GO_TERM","name":"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process","canonical_id":"go:GO:1902634","description":"\"The chemical reactions and pathways resulting in the breakdown of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate.\" [GO_REF:0000068, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"541fff812c4e461f8f6f6668dfaf465c","type":"GO_TERM","name":"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate metabolic process","canonical_id":"go:GO:1902633","description":"\"The chemical reactions and pathways involving 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate.\" [GO_REF:0000068, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"35a442b04ce242ffa14172bf203756da","type":"GO_TERM","name":"1-phosphatidylinositol 4-kinase activator activity","canonical_id":"go:GO:0098744","description":"\"Binds to and increases the activity of 1-phosphatidylinositol 4-kinase.\" [PMID:21288895]","metadata":null},{"id":"7ce9cb51538b484497d7ce0bd353e87b","type":"GO_TERM","name":"1-phosphatidylinositol 4-kinase activity","canonical_id":"go:GO:0004430","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol + ATP = a 1-phosphatidyl-1D-myo-inositol 4-phosphate + ADP + H+.\" [EC:2.7.1.67, RHEA:19877]","metadata":null},{"id":"87056e80f29e40cf8260514d6fd42b57","type":"GO_TERM","name":"1-phosphatidylinositol binding","canonical_id":"go:GO:0005545","description":"\"Binding to a phosphatidylinositol, a glycophospholipid with its sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.\" [ISBN:0198506732]","metadata":null},{"id":"d280ab4339424489b1113d9ac04f2e30","type":"GO_TERM","name":"1-phosphatidylinositol-3-kinase activity","canonical_id":"go:GO:0016303","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol + ATP = a 1-phosphatidyl-1D-myo-inositol 3-phosphate + ADP + H+.\" [EC:2.7.1.137, RHEA:12709]","metadata":null},{"id":"8dfdde3bfabb439ba15d2315e8a52f24","type":"GO_TERM","name":"1-phosphatidylinositol-3-kinase regulator activity","canonical_id":"go:GO:0046935","description":"\"Modulates the activity of the enzyme 1-phosphatidylinositol-3-kinase activity.\" [GOC:ai]","metadata":null},{"id":"8b924a4172ce4fbf9b9cb350e35f85d6","type":"GO_TERM","name":"1-phosphatidylinositol-3-phosphate 4-kinase activity","canonical_id":"go:GO:0052811","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol 3-phosphate + ATP = a 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate + ADP + H+.\" [PMID:9211928, PMID:9367159, PMID:9660759, RHEA:63688]","metadata":null},{"id":"719490db39e8463ea0a7d9e330fcf102","type":"GO_TERM","name":"1-phosphatidylinositol-3-phosphate 5-kinase activity","canonical_id":"go:GO:0000285","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol 3-phosphate + ATP = a 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate + ADP + H+.\" [EC:2.7.1.150, RHEA:13609]","metadata":null},{"id":"c3c570c0489f4e7bb1b258803ee8b1d7","type":"GO_TERM","name":"1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity","canonical_id":"go:GO:0046934","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + ATP = a 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate + ADP + H+.\" [EC:2.7.1.153, RHEA:21292]","metadata":null},{"id":"d56916cc99894fc78af565a7cd96a9ed","type":"GO_TERM","name":"1-phosphatidylinositol-4-phosphate 3-kinase activity","canonical_id":"go:GO:0035005","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol 4-phosphate + ATP = a 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate + ADP + H+.\" [EC:2.7.1.154, RHEA:18373]","metadata":null},{"id":"01715b33d1df491d814c92a245d32e07","type":"GO_TERM","name":"1-phosphatidylinositol-4-phosphate 5-kinase activity","canonical_id":"go:GO:0016308","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol 4-phosphate + ATP = a 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + ADP + H+.\" [EC:2.7.1.68, RHEA:14425]","metadata":null},{"id":"3c3f93aaf09e48ee825c71c29b0db884","type":"GO_TERM","name":"1-phosphatidylinositol-5-kinase activity","canonical_id":"go:GO:0052810","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol + ATP = a 1-phosphatidyl-1D-myo-inositol 5-phosphate + ADP + H+.\" [PMID:12270933, PMID:9660759, RHEA:44680]","metadata":null},{"id":"84ca4f0113044bb9833f7c37e41572e4","type":"GO_TERM","name":"1-phosphatidylinositol-5-phosphate 4-kinase activity","canonical_id":"go:GO:0016309","description":"\"Catalysis of the reaction: a 1-phosphatidyl-1D-myo-inositol 5-phosphate + ATP = a 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + ADP + H+.\" [EC:2.7.1.149]","metadata":null},{"id":"0800775f97864876bb0d6d78947b2ad1","type":"GO_TERM","name":"1-phosphofructokinase activity","canonical_id":"go:GO:0008662","description":"\"Catalysis of the reaction: ATP + D-fructose 1-phosphate = ADP + D-fructose 1,6-bisphosphate.\" [EC:2.7.1.56]","metadata":null},{"id":"8c726a7cf0aa4ab5b667f37401dcb820","type":"GO_TERM","name":"1-pyrroline-4-hydroxy-2-carboxylate deaminase activity","canonical_id":"go:GO:0047425","description":"\"Catalysis of the reaction: 4-hydroxy-1-pyrroline-2-carboxylate + H2O + H+ = 2,5-dioxopentanoate + NH4.\" [EC:3.5.4.22, RHEA:10560]","metadata":null},{"id":"4bb1ca5414e042b5bdae2a685a9c106b","type":"GO_TERM","name":"1-undecene biosynthetic process","canonical_id":"go:GO:1902821","description":"\"The chemical reactions and pathways resulting in the formation of 1-undecene.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:16013377]","metadata":null},{"id":"4edde78f3b09449f8ce630fa87fd6e8d","type":"TRIAL","name":"10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus","canonical_id":"clinicaltrials.gov:NCT00568997","description":"Atopic Dermatitis","metadata":null},{"id":"39a29eed09ae41f58ca2162ca60efb65","type":"TRIAL","name":"10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00024245","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"76d2c68ad75f4eac952c03123728653e","type":"TRIAL","name":"10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00052442","description":"Lymphoma","metadata":null},{"id":"c2042e27a8c34276a845e5440190a142","type":"TRIAL","name":"10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00004238","description":"Lung Cancer","metadata":null},{"id":"d53d5747f7454c9b99c3699873d8bc60","type":"GO_TERM","name":"10-deacetylbaccatin III 10-O-acetyltransferase activity","canonical_id":"go:GO:0050643","description":"\"Catalysis of the reaction: 10-deacetylbaccatin III + acetyl-CoA = baccatin III + CoA.\" [EC:2.3.1.167, RHEA:20137]","metadata":null},{"id":"6558eb412ba148f684432a4e55d793e8","type":"GO_TERM","name":"10-formyltetrahydrofolate biosynthetic process","canonical_id":"go:GO:0009257","description":"\"The chemical reactions and pathways resulting in the formation of 10-formyltetrahydrofolate, the formylated derivative of tetrahydrofolate.\" [GOC:ai]","metadata":null},{"id":"f2d05c314a934e9fbea9d0dfdfa7e7ed","type":"GO_TERM","name":"10-formyltetrahydrofolate catabolic process","canonical_id":"go:GO:0009258","description":"\"The chemical reactions and pathways resulting in the breakdown of 10-formyltetrahydrofolate, the formylated derivative of tetrahydrofolate.\" [GOC:ai]","metadata":null},{"id":"156a235c1f894897b892ab651ae836dd","type":"GO_TERM","name":"10-formyltetrahydrofolate metabolic process","canonical_id":"go:GO:0009256","description":"\"The chemical reactions and pathways involving 10-formyltetrahydrofolate, the formylated derivative of tetrahydrofolate.\" [GOC:ai]","metadata":null},{"id":"6dfcabdb1be2461f8f931ef5fc856b8b","type":"GO_TERM","name":"10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activity","canonical_id":"go:GO:0033885","description":"\"Catalysis of the reaction: (9S,10S)-10-hydroxy-9-(phosphonooxy)octadecanoate + H2O = (9S,10S)-9,10-dihydroxyoctadecanoate + phosphate.\" [EC:3.1.3.76, RHEA:16537]","metadata":null},{"id":"225edfba29884a16b1496a0f2fc8d00a","type":"GO_TERM","name":"10-hydroxydihydrosanguinarine 10-O-methyltransferase activity","canonical_id":"go:GO:0030779","description":"\"Catalysis of the reaction: 10-hydroxydihydrosanguinarine + S-adenosyl-L-methionine(1+) = S-adenosyl-L-homocysteine + dihydrochelirubine + H+.\" [EC:2.1.1.119, RHEA:18541]","metadata":null},{"id":"48f7639903b64b8a954a7420a7e87830","type":"GO_TERM","name":"10-hydroxygeranial oxidoreductase activity","canonical_id":"go:GO:0102968","description":"\"Catalysis of the reaction: (6E)-8-hydroxygeranial + NADP = (6E)-8-oxogeranial + NADPH + H+.\" [GOC:pz, RHEA:32611]","metadata":null},{"id":"33c7284e74cc4ece9cc021a3adb475e0","type":"GO_TERM","name":"10-hydroxygeraniol oxidoreductase activity","canonical_id":"go:GO:0102967","description":"\"Catalysis of the reaction: (6E)-8-hydroxygeraniol + NADP = (6E)-8-hydroxygeranial + NADPH + H+.\" [GOC:pz, RHEA:32607]","metadata":null},{"id":"1880df1e29b142229252c705d110005d","type":"GO_TERM","name":"10-hydroxytaxane O-acetyltransferase activity","canonical_id":"go:GO:0050639","description":"\"Catalysis of the reaction: 10-desacetyltaxuyunnanin C + acetyl-CoA = CoA + taxuyunnanin C.\" [EC:2.3.1.163, RHEA:18837]","metadata":null},{"id":"f95e36628d08493093a9f36d18908383","type":"GO_TERM","name":"10-oxogeraniol oxidoreductase activity","canonical_id":"go:GO:0102969","description":"\"Catalysis of the reaction: (6E)-8-oxogeraniol + NADP = (6E)-8-oxogeranial + NADPH + H+.\" [GOC:pz, RHEA:32615]","metadata":null},{"id":"8c3fcb8746504d279027eec4057a33e9","type":"GO_TERM","name":"11-O-demethyl-17-O-deacetylvindoline O-methyltransferase activity","canonical_id":"go:GO:0030766","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 11-O-demethyl-17-O-deacetylvindoline = S-adenosyl-L-homocysteine + 17-O-deacetylvindoline.\" [EC:2.1.1.94]","metadata":null},{"id":"3c673d0720674c4289ba8d8666d95638","type":"GO_TERM","name":"11-beta-hydroxysteroid dehydrogenase (NAD+) activity","canonical_id":"go:GO:0070523","description":"\"Catalysis of the reaction: an 11-beta-hydroxysteroid + NAD+ = an 11-oxosteroid + NADH + H+.\" [PMID:15761036, RHEA:53116]","metadata":null},{"id":"f8984fdd9fe34d49a48f9c030951bbf0","type":"GO_TERM","name":"11-beta-hydroxysteroid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0070524","description":"\"Catalysis of the reaction: an 11-beta-hydroxysteroid + NADP+ = an 11-oxosteroid + NADPH + H+.\" [PMID:16216911, RHEA:11388]","metadata":null},{"id":"f91532b2f62e40fca5825c3e7bc88b71","type":"GO_TERM","name":"11-cis retinal binding","canonical_id":"go:GO:0005502","description":"\"Binding to 11-cis retinal, an isomer of retinal that plays an important role in the visual process in most vertebrates. 11-cis retinal combines with opsin in the rods (scotopsin) to form rhodopsin or visual purple. Retinal is one of the three compounds that makes up vitamin A.\" [PMID:24403072]","metadata":null},{"id":"b18da5f40aee4fcab1455fc23ed32184","type":"GO_TERM","name":"11-cis-retinal 3,4-desaturase activity","canonical_id":"go:GO:0061899","description":"\"Catalysis of the reaction: 11-cis-retinal + 2 H+ + O2 + 2 reduced [adrenodoxin] = 11-cis-3,4-didehydro-retinal + 2 H2O + 2 oxidized [adrenodoxin].\" [PMID:27059013]","metadata":null},{"id":"cecf7567d9c149ac8acdbecf602bde73","type":"GO_TERM","name":"11-cis-retinol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106429","description":"\"Catalysis of the reaction: 11-cis-retinol--[retinol-binding protein] + NAD+ = 11-cis-retinal--[retinol-binding protein] + NADH + H+.\" [RHEA:55668]","metadata":null},{"id":"aa80e6e5d0aa4748bacd1f945df9857d","type":"GO_TERM","name":"11-cis-retinol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0102354","description":"\"Catalysis of the reaction: 11-cis-retinol + NADP+ = 11-cis-retinal + NADPH + H+.\" [RHEA:54912]","metadata":null},{"id":"898a9e2adca34e3fad99d7be70100648","type":"GO_TERM","name":"11-cis-retinyl-palmitate hydrolase activity","canonical_id":"go:GO:0047520","description":"\"Catalysis of the reaction: 11-cis-retinyl palmitate + H2O = 11-cis-retinol + H+ + palmitate.\" [EC:3.1.1.63, RHEA:19697]","metadata":null},{"id":"ead0bcd7e04b4cb194fb555bd1e018a7","type":"GO_TERM","name":"11-deoxycorticosterone binding","canonical_id":"go:GO:1903878","description":"\"Binding to 11-deoxycorticosterone.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10802282]","metadata":null},{"id":"f0649e57cbb74ce6a86efb4315a6590b","type":"GO_TERM","name":"11-deoxycorticosterone reductase activity","canonical_id":"go:GO:0102635","description":"\"Catalysis of the reaction: 11-deoxycorticosterone + NADH + H+ = 4-pregnen-20,21-diol-3-one + NAD.\" [GOC:pz, HEA:47716]","metadata":null},{"id":"3bd12fef29b64bc89c030bcbb2f611fa","type":"GO_TERM","name":"11-deoxycortisol binding","canonical_id":"go:GO:1903876","description":"\"Binding to 11-deoxycortisol.\" [GO_REF:0000067, GOC:TermGenie, PMID:10802282]","metadata":null},{"id":"a07de14a74f54e639372efb92c575735","type":"GO_TERM","name":"11-hydroxythromboxane B2 dehydrogenase activity","canonical_id":"go:GO:0036133","description":"\"Catalysis of the reaction: thromboxane B2 + NAD+ = 11-dehydro-thromboxane B2 + NADH + H+.\" [GOC:mw, KEGG_REACTION:R05060, PMID:3461463, PMID:3823488, PMID:8200461]","metadata":null},{"id":"052357b3f1f84ff3a318056cc1dede1b","type":"GO_TERM","name":"11-oxo-beta-amyrin 30-oxidase activity","canonical_id":"go:GO:0102375","description":"\"Catalysis of the reaction: 11-oxo-beta-amyrin + 3 NADPH + 3 O2 + 2 H+ = glycyrrhetinic acid + 3 NADP + 4 H2O.\" [GOC:pz, RHEA:35499]","metadata":null},{"id":"54aba38cdad04a3ba5bac33c36be506b","type":"GO_TERM","name":"11-oxo-beta-amyrin biosynthetic process","canonical_id":"go:GO:1902383","description":"\"The chemical reactions and pathways resulting in the formation of 11-oxo-beta-amyrin.\" [GOC:TermGenie, PMID:22128119]","metadata":null},{"id":"d0ce8204e12f43e2a23f3fe9950db808","type":"GO_TERM","name":"11-oxo-beta-amyrin catabolic process","canonical_id":"go:GO:1902382","description":"\"The chemical reactions and pathways resulting in the breakdown of 11-oxo-beta-amyrin.\" [GOC:TermGenie, PMID:22128119]","metadata":null},{"id":"fa2b63890f96457087a29dfe42d04b1d","type":"GO_TERM","name":"11beta-hydroxyprogesterone binding","canonical_id":"go:GO:1903879","description":"\"Binding to 11beta-hydroxyprogesterone.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10802282]","metadata":null},{"id":"17b7955a791c42b883d905d1f69193cd","type":"TRIAL","name":"12 / 48 Week Pivotal PFT vs PBO in COPD I","canonical_id":"clinicaltrials.gov:NCT00782210","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"feee2c009a464cdaa1a35f2ed4e877aa","type":"TRIAL","name":"12 / 48 wk Pivotal PFT vs PBO in COPD II","canonical_id":"clinicaltrials.gov:NCT00782509","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"c54acf3c2acd478c836838b3cc5a2ff0","type":"TRIAL","name":"12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)","canonical_id":"clinicaltrials.gov:NCT02025179","description":"Spinal Cord Injury; Bone Loss; Osteoporosis","metadata":null},{"id":"4a119f489ca648e58cab11823cc17520","type":"TRIAL","name":"12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD","canonical_id":"clinicaltrials.gov:NCT00240435","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"5869da0edf4349a888c0c4a9d0fa864d","type":"TRIAL","name":"12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress","canonical_id":"clinicaltrials.gov:NCT01040208","description":"Sexual Dysfunctions, Psychological; Depression","metadata":null},{"id":"89366cffb0ec4aa994f9ce8631c2922e","type":"TRIAL","name":"12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)","canonical_id":"clinicaltrials.gov:NCT00145470","description":"Bipolar Disorder","metadata":null},{"id":"6b383b4b848546168d0a5ad7731d48b6","type":"TRIAL","name":"12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device","canonical_id":"clinicaltrials.gov:NCT01623310","description":"Nasal Polyps","metadata":null},{"id":"230685d0f98240df9f3ed573cc628184","type":"GO_TERM","name":"12-beta-hydroxysteroid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047521","description":"\"Catalysis of the reaction: 3-alpha,7-alpha,12-beta-trihydroxy-5-beta-cholanate + NADP+ = 3-alpha,7-alpha-dihydroxy-12-oxo-5-beta-cholanate + H+ + NADPH.\" [RHEA:21424]","metadata":null},{"id":"538c5c824af24b9f99aad9bffe342db8","type":"GO_TERM","name":"12-hydroxydihydrochelirubine 12-O-methyltransferase activity","canonical_id":"go:GO:0030780","description":"\"Catalysis of the reaction: 12-hydroxydihydrochelirubine + S-adenosyl-L-methionine(1+) = S-adenosyl-L-homocysteine + dihydromacarpine + H+.\" [EC:2.1.1.120, RHEA:21092]","metadata":null},{"id":"b6720902ccba42fdb95f97a2a5f87ec7","type":"GO_TERM","name":"12-hydroxyheptadecatrienoic acid synthase activity","canonical_id":"go:GO:0036134","description":"\"Catalysis of the reaction: prostaglandin H2 = 12-hydroxyheptadecatrienoic acid (HHT) + malonaldehyde (MDA).\" [GOC:mw, PMID:11297515]","metadata":null},{"id":"9f4b93bf08ec48a59a1bfb962223d2ad","type":"GO_TERM","name":"12-oxophytodienoate reductase activity","canonical_id":"go:GO:0016629","description":"\"Catalysis of the reaction: 8-[(1R,2R)-3-oxo-2-{(Z)-pent-2-en-1-yl}cyclopentyl]octanoate + NADP+ = (15Z)-12-oxophyto-10,15-dienoate + H+ + NADPH.\" [EC:1.3.1.42, RHEA:21888]","metadata":null},{"id":"275207ba2d7c4b6cb3270565c049df5e","type":"TRIAL","name":"12-week Open-label Evaluation of Efficacy and Safety of Indacaterol","canonical_id":"clinicaltrials.gov:NCT01232894","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"4784b9fc49334bc29d4479984124711a","type":"TRIAL","name":"12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00373542","description":"Restless Legs Syndrome (RLS); Restless Legs Syndrome","metadata":null},{"id":"63832262c6914821a399408e3422fc62","type":"GO_TERM","name":"13-hydroxydocosanoate 13-beta-glucosyltransferase activity","canonical_id":"go:GO:0047229","description":"\"Catalysis of the reaction: 13-hydroxydocosanoate + UDP-D-glucose = 13-beta-D-glucosyloxydocosanoate + UDP.\" [EC:2.4.1.158]","metadata":null},{"id":"d9403914dd5d4a9f9123d69e68f5b503","type":"GO_TERM","name":"13-hydroxylupinine O-tigloyltransferase activity","canonical_id":"go:GO:0047203","description":"\"Catalysis of the reaction: 13-hydroxylupanine + 2-methylcrotonoyl-CoA = 13-(2-methylcrotonoyloxy)lupanine + CoA.\" [RHEA:12360]","metadata":null},{"id":"57a6e26ca46049e5a5fd2bd349c43f95","type":"GO_TERM","name":"13-lipoxin reductase activity","canonical_id":"go:GO:0036185","description":"\"Catalysis of the reaction: 15-oxo-(5S,6R)-dihydroxy-(7E,9E,11Z,13E)-eicosatetraenoate + NADH + H+ = 15-oxo-(5S,6R)-dihydroxy-(7E,9E,11Z)-eicosatrienoate + NAD+.\" [PMID:10837478, RHEA:41592]","metadata":null},{"id":"339af06c76cc4c859febe25518f677db","type":"GO_TERM","name":"13-series resolvin biosynthetic process","canonical_id":"go:GO:0106298","description":"\"The chemical reactions and pathways resulting in the formation of resolvin family 13-series, hydroxy fatty acids derived from docosapentaenoic acid.\" [PMID:26236990]","metadata":null},{"id":"08eef483509c436fbd5fad8b2c6c8cc0","type":"GO_TERM","name":"14-3-3 protein binding","canonical_id":"go:GO:0071889","description":"\"Binding to a 14-3-3 protein. A 14-3-3 protein is any of a large family of approximately 30kDa acidic proteins which exist primarily as homo- and heterodimers within all eukaryotic cells, and have been implicated in the modulation of distinct biological processes by binding to specific phosphorylated sites on diverse target proteins, thereby forcing conformational changes or influencing interactions between their targets and other molecules. Each 14-3-3 protein sequence can be roughly divided into three sections: a divergent amino terminus, the conserved core region and a divergent carboxy-terminus. The conserved middle core region of the 14-3-3s encodes an amphipathic groove that forms the main functional domain, a cradle for interacting with client proteins.\" [GOC:cna, GOC:mah, PMID:15167810, PMID:19575580]","metadata":null},{"id":"d48ee29a519048c3a6d3ccb5d33362fb","type":"GO_TERM","name":"14betaH-scalarane-17alpha-19-diol synthase activity","canonical_id":"go:GO:0102646","description":"\"Catalysis of the reaction: 14betaH-scalarane-17alpha-19-diol = all-trans-geranylfarnesol + H2O.\" [GOC:pz, PMID:24200803]","metadata":null},{"id":"13c3b17a59b94fe29474a669c88eab38","type":"TRIAL","name":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","canonical_id":"clinicaltrials.gov:NCT01157351","description":"Schizophrenia","metadata":null},{"id":"12c016ff686949809dfb58fe6bcabe9a","type":"TRIAL","name":"15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting","canonical_id":"clinicaltrials.gov:NCT00834197","description":"Healthy","metadata":null},{"id":"8a50a46fec534b419b807b911d09cc0c","type":"GO_TERM","name":"15,16-dihydrobiliverdin:ferredoxin oxidoreductase activity","canonical_id":"go:GO:0050617","description":"\"Catalysis of the reaction: 15,16-dihydrobiliverdin + oxidized ferredoxin = biliverdin IXa + reduced ferredoxin.\" [EC:1.3.7.2, MetaCyc:1.3.7.2-RXN]","metadata":null},{"id":"a97b2741151c48d8ba3b86606b54944b","type":"TRIAL","name":"15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.","canonical_id":"clinicaltrials.gov:NCT00495729","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"d8c17b5e531d4d1dba1a16e896ba3459","type":"GO_TERM","name":"15-cis-phytoene synthase activity","canonical_id":"go:GO:0046905","description":"\"Catalysis of the reaction: 2 geranylgeranyl diphosphate = 15-cis-phytoene + 2 diphosphate.\" [PMID:12641468, RHEA:34475]","metadata":null},{"id":"86916a6910074449bf63fb0d6d867f69","type":"GO_TERM","name":"15-hydroxyicosatetraenoate dehydrogenase activity","canonical_id":"go:GO:0047034","description":"\"Catalysis of the reaction: NAD(P)+ + (15S)-15-hydroxy-5,8,11-cis-13-trans-icosatetraenoate = NAD(P)H + H+ + 15-oxo-5,8,11-cis-13-trans-icosatetraenoate.\" [EC:1.1.1.232, MetaCyc:1.1.1.232-RXN]","metadata":null},{"id":"6578775c0d66423f8566266472c7c57c","type":"PROTEIN","name":"15-hydroxyprostaglandin dehydrogenase","canonical_id":"uniprot:P15428","description":null,"metadata":null},{"id":"7eba966f3feb44bdab61fe19394d0cee","type":"GO_TERM","name":"15-hydroxyprostaglandin dehydrogenase (NAD+) activity","canonical_id":"go:GO:0016404","description":"\"Catalysis of the reaction: (5Z,13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate + NAD+ = (5Z,13E)-11-alpha-hydroxy-9,15-dioxoprost-13-enoate + NADH + H+.\" [EC:1.1.1.141]","metadata":null},{"id":"e530561ac5434190a190fa84b7555212","type":"GO_TERM","name":"15-hydroxyprostaglandin dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047021","description":"\"Catalysis of the reaction: NADP+ + prostaglandin E(1) = 15-dehydro-prostaglandin E1 + H+ + NADPH.\" [EC:1.1.1.197, RHEA:11636]","metadata":null},{"id":"9fdecd04d85e43f0b1d4017b19e36b9a","type":"GO_TERM","name":"15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047020","description":"\"Catalysis of the reaction: NADP+ + (5Z,13E)-(15S)-9-alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate = NADPH + H+ + (5Z,13E)-9-alpha-hydroxy-11,15-dioxoprosta-5,13-dienoate.\" [EC:1.1.1.196, MetaCyc:1.1.1.196-RXN]","metadata":null},{"id":"75e5fbe3b08d46f3b735287a2cdebabd","type":"GO_TERM","name":"15-hydroxyprostaglandin-I dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047033","description":"\"Catalysis of the reaction: NADP+ + prostaglandin I(2) = 15-dehydro-prostaglandin I(2) + H+ + NADPH.\" [EC:1.1.1.231, RHEA:21420]","metadata":null},{"id":"0ce82e7a18b44b5984e76dbb64e3e81a","type":"GO_TERM","name":"15-oxoprostaglandin 13-reductase [NAD(P)+] activity","canonical_id":"go:GO:0047522","description":"\"Catalysis of the reaction: 13,14-dihydro-15-oxo-prostaglandin E2 + NAD(P)+ = 15-oxoprostaglandin E2 + H+ + NAD(P)H.\" [EC:1.3.1.48]","metadata":null},{"id":"193d6316eace45fb8f47f6057b5bdb0a","type":"TRIAL","name":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07779694","description":"pMMR/MSS; Locally Advanced Rectal Carcinoma; Fasting, Intermittent","metadata":null},{"id":"aa7727fc7af548ecb20aeb8a74a79733","type":"GO_TERM","name":"16-alpha-hydroxyprogesterone dehydratase activity","canonical_id":"go:GO:0047455","description":"\"Catalysis of the reaction: 16-alpha-hydroxyprogesterone = H2O + 16-dehydroprogesterone.\" [EC:4.2.1.98, MetaCyc:4.2.1.98-RXN]","metadata":null},{"id":"f4a2ecd905f54455ae9adfe8d259c160","type":"GO_TERM","name":"16-hydroxypalmitate dehydrogenase activity","canonical_id":"go:GO:0103002","description":"\"Catalysis of the reaction: 16-hydroxypalmitate + NADP = H+ + 16-oxo-palmitate + NADPH.\" [GOC:pz]","metadata":null},{"id":"1e11a95444d8432e94be5d4f9b53ec9a","type":"GO_TERM","name":"16-hydroxysteroid epimerase activity","canonical_id":"go:GO:0047524","description":"\"Catalysis of the reaction: 16-alpha-hydroxysteroid = 16-beta-hydroxysteroid.\" [RHEA:15829]","metadata":null},{"id":"b43f66039de84d1eb464ea7733c308f4","type":"GO_TERM","name":"16-methoxy-2,3-dihydro-3-hydroxytabersonine N-methyltransferase activity","canonical_id":"go:GO:0030768","description":"\"Catalysis of the reaction: (3R)-3-hydroxy-16-methoxy-2,3-dihydrotabersonine + S-adenosyl-L-methionine = S-adenosyl-L-homocysteine + deacetoxyvindoline + H+.\" [EC:2.1.1.99, RHEA:11336]","metadata":null},{"id":"41d5eaf51e174fc380d4ebade146c52c","type":"TRIAL","name":"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","canonical_id":"clinicaltrials.gov:NCT02008916","description":"Spondylitis, Ankylosing","metadata":null},{"id":"d11a1a42fe954a7d8af91eef6c6434b9","type":"GO_TERM","name":"16S rRNA (adenine(1518)-N(6)/adenine(1519)-N(6))-dimethyltransferase activity","canonical_id":"go:GO:0052908","description":"\"Catalysis of the reaction: 4 S-adenosyl-L-methionine + adenine(1518)/adenine(1519) in 16S rRNA = 4 S-adenosyl-L-homocysteine + N(6)-dimethyladenine(1518)/N(6)-dimethyladenine(1519) in 16S rRNA.\" [RHEA:19609]","metadata":null},{"id":"e010f10d88f0470eb6b03b1ddb666ace","type":"GO_TERM","name":"16S rRNA (guanine(1207)-N(2))-methyltransferase activity","canonical_id":"go:GO:0052914","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanosine(1207) in 16S rRNA = N(2)-methylguanosine(1207) in 16S rRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.172]","metadata":null},{"id":"808f5ac3c40c46c8bc705f5f0d3b5269","type":"GO_TERM","name":"16S rRNA (guanine(1516)-N(2))-methyltransferase activity","canonical_id":"go:GO:0036308","description":"\"Catalysis of the reaction: guanosine(1516) in 16S rRNA + S-adenosyl-L-methionine = N(2)-methylguanosine(1516) in 16S rRNA + S-adenosyl-L-homocysteine + H+.\" [PMID:22079366, RHEA:43220]","metadata":null},{"id":"a15f929e82754c23a5223c5d69118fd5","type":"GO_TERM","name":"16S rRNA (guanine(966)-N(2))-methyltransferase activity","canonical_id":"go:GO:0052913","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanosine(966) in 16S rRNA = N(2)-methylguanosine(966) in 16S rRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.171]","metadata":null},{"id":"3c468fb8724e4376af99c633cd77ab01","type":"GO_TERM","name":"16S rRNA pseudouridine(516) synthase activity","canonical_id":"go:GO:0160136","description":"\"Catalysis of the reaction: uridine(516) in 16S rRNA = pseudouridine(516) in 16S rRNA.\" [EC:5.4.99.19, RHEA:38867]","metadata":null},{"id":"2b0ba3cad7db4760a5daf0fb7c541432","type":"DRUG","name":"17&beta;-estradiol","canonical_id":"gtopdb:1013","description":null,"metadata":null},{"id":"d5c4035f9ea44885ba76dbbcd23760f4","type":"DRUG","name":"17&beta;-estradiol","canonical_id":"chembl:CHEMBL1200430","description":null,"metadata":null},{"id":"8a4950738a954f489fd8e532ce85ebbe","type":"GO_TERM","name":"17(E)-cheilanthenediol synthase activity","canonical_id":"go:GO:0102645","description":"\"Catalysis of the reaction: 17(E)-cheilanthenediol = all-trans-geranylfarnesol + H2O.\" [GOC:pz, PMID:24200803]","metadata":null},{"id":"16d523267a4a475888be62ddff141959","type":"GO_TERM","name":"17-O-deacetylvindoline O-acetyltransferase activity","canonical_id":"go:GO:0047162","description":"\"Catalysis of the reaction: (1R,9R,10S,11R,12R,19R)-12-ethyl-10,11-dihydroxy-5-methoxy-10-(methoxycarbonyl)-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraen-16-ium + acetyl-CoA = (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-10-hydroxy-5-methoxy-10-(methoxycarbonyl)-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraen-16-ium + CoA.\" [EC:2.3.1.107, RHEA:24496]","metadata":null},{"id":"2e8ea7f210894a2d8e8d6308b44835e9","type":"GO_TERM","name":"17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0047006","description":"\"Catalysis of the reaction: NAD(P)+ + 17-alpha,20-alpha-dihydroxypregn-4-en-3-one = NAD(P)H + H+ + 17-alpha-hydroxyprogesterone.\" [EC:1.1.1.149]","metadata":null},{"id":"e18988f996f64511a19eba89b9892501","type":"GO_TERM","name":"17-beta-hydroxysteroid dehydrogenase (NAD+) activity","canonical_id":"go:GO:0044594","description":"\"Catalysis of the reaction: a 17-beta-hydroxysteroid + NAD+ = a 17-oxosteroid + NADH + H+.\" [PMID:17074428, RHEA:81599]","metadata":null},{"id":"cef954a9710644d4b9d538ad82491777","type":"GO_TERM","name":"17-beta-hydroxysteroid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0072582","description":"\"Catalysis of the reaction: a 17-beta-hydroxysteroid + NADP+ = a 17-oxosteroid + NADPH + H+.\" [GOC:kad, PMID:17074428]","metadata":null},{"id":"cab04d3a011d40559de505f3dab9ca55","type":"GO_TERM","name":"17-hydroxyprogesterone 21-hydroxylase activity","canonical_id":"go:GO:0103069","description":"\"Catalysis of the reaction: 17alpha-hydroxyprogesterone + O2 + reduced [NADPH--hemoprotein reductase] = 11-deoxycortisol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:50308]","metadata":null},{"id":"9c7460932fbc4d65b6900642f90744a6","type":"TRIAL","name":"177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours","canonical_id":"clinicaltrials.gov:NCT04375267","description":"Clinical Trial, Phase I; Neuroendocrine Tumors; Thymoma; Mesothelioma","metadata":null},{"id":"c7c8f1d5b26c49f887cdc083e21d5c35","type":"GO_TERM","name":"17alpha-hydroxyprogesterone binding","canonical_id":"go:GO:1903880","description":"\"Binding to 17alpha-hydroxyprogesterone.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10802282]","metadata":null},{"id":"25f5cd5cd4714efab88bfbb4e4dee7a3","type":"TRIAL","name":"18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics","canonical_id":"clinicaltrials.gov:NCT00654745","description":"Type 2 Diabetes; Hypertension","metadata":null},{"id":"a9dcaf1a075e43b6be5960028875d106","type":"TRIAL","name":"18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD","canonical_id":"clinicaltrials.gov:NCT01286935","description":"Parkinson's Disease","metadata":null},{"id":"59c04a3952a848d4bd3a4fab03fa15eb","type":"TRIAL","name":"18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)","canonical_id":"clinicaltrials.gov:NCT00666458","description":"Type 2 Diabetes","metadata":null},{"id":"61b497494c00498e989ffa219d13900a","type":"TRIAL","name":"18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study","canonical_id":"clinicaltrials.gov:NCT02556502","description":"Amyloid PET Imaging","metadata":null},{"id":"1bcb003a622e46aab488200daff3913b","type":"TRIAL","name":"18F-Flutemetamol and Plaque Vulnerability","canonical_id":"clinicaltrials.gov:NCT03291093","description":"Atherosclerosis","metadata":null},{"id":"a632bc2fe242419b8b066c6e3e0c659c","type":"TRIAL","name":"18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT06048601","description":"Amyloid; Amyloid Cardiomyopathy","metadata":null},{"id":"668e9cca083643dda6a475a3a6d78763","type":"GO_TERM","name":"18S rRNA (adenine(1779)-N(6)/adenine(1780)-N(6))-dimethyltransferase activity","canonical_id":"go:GO:0052909","description":"\"Catalysis of the reaction: 4 S-adenosyl-L-methionine + adenine(1779)/adenine(1780) in 18S rRNA = 4 S-adenosyl-L-homocysteine + N(6)-dimethyladenine(1779)/N(6)-dimethyladenine(1780) in 18S rRNA.\" [RHEA:42780]","metadata":null},{"id":"85cc1b03877c43cf86df8799a011427d","type":"GO_TERM","name":"18S rRNA cytidine N-acetyltransferase activity","canonical_id":"go:GO:1990883","description":"\"Catalysis of the reaction: a cytidine in 18S rRNA + acetyl-CoA + ATP + H2O = an N(4)-acetylcytidine in 18S rRNA + ADP + phosphate + CoA + H+.\" [PMID:25402480, RHEA:51424]","metadata":null},{"id":"64260d033e3e42e580cebbd0f352c2e3","type":"GO_TERM","name":"1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol:pyruvate transaminase activity","canonical_id":"go:GO:0047311","description":"\"Catalysis of the reaction: 1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol + pyruvate = 1D-1-guanidino-1-deoxy-3-dehydro-scyllo-inositol + L-alanine.\" [RHEA:15497]","metadata":null},{"id":"f1239d36247b431784f716104eb80884","type":"TRIAL","name":"2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT05155098","description":"Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Ankylosing Spondylitis; Non-radiographic Axial Spondyloarthritis","metadata":null},{"id":"058e598fe7ae4d2cacb82bf60b61ea21","type":"GO_TERM","name":"2 iron, 2 sulfur cluster binding","canonical_id":"go:GO:0051537","description":"\"Binding to a 2 iron, 2 sulfur (2Fe-2S) cluster; this cluster consists of two iron atoms, with two inorganic sulfur atoms found between the irons and acting as bridging ligands.\" [GOC:ai, PMID:15952888, Wikipedia:Iron-sulfur_cluster]","metadata":null},{"id":"afcc9a409e6146578c13b07757a469ae","type":"GO_TERM","name":"2',3'-cyclic GMP-AMP binding","canonical_id":"go:GO:0061507","description":"\"Binding to 2',3' cyclic GMP-AMP (cGAMP) nucleotide, a cyclic purine dinucleotide that consists of AMP and GMP units cyclized via 2',5' and 3',5' linkages.\" [GOC:dph, PMID:23258412, PMID:23910378]","metadata":null},{"id":"508df623e1054a06aadc5c0d0219f9bc","type":"GO_TERM","name":"2',3'-cyclic GMP-AMP synthase activity","canonical_id":"go:GO:0061501","description":"\"Catalysis of the reaction: ATP + GTP = 2 diphosphate + cyclic G-P(2'-5')A-P(3'-5') (cyclic 2',3' GAMP).\" [GOC:dph, PMID:23258413, RHEA:42064]","metadata":null},{"id":"b6ba3623b1dd4584bbee4ffe6015b7ea","type":"GO_TERM","name":"2',3'-cyclic-nucleotide 2'-phosphodiesterase activity","canonical_id":"go:GO:0008663","description":"\"Catalysis of the reaction: nucleoside 2',3'-cyclic phosphate + H2O = nucleoside 3'-phosphate.\" [EC:3.1.4.16]","metadata":null},{"id":"06b4c2f13f424be0a6fc31aee4f3913e","type":"GO_TERM","name":"2',3'-cyclic-nucleotide 3'-phosphodiesterase activity","canonical_id":"go:GO:0004113","description":"\"Catalysis of the reaction: nucleoside 2',3'-cyclic phosphate + H2O = nucleoside 2'-phosphate.\" [EC:3.1.4.37]","metadata":null},{"id":"e85fa6c7ad3b481ba0e0f571fb82c1aa","type":"GO_TERM","name":"2'-(5''-triphosphoribosyl)-3'-dephospho-CoA biosynthetic process","canonical_id":"go:GO:0019361","description":"\"The chemical reactions and pathways resulting in the formation of 2'-(5''-triphosphoribosyl)-3'-dephospho-CoA, a derivative of coenzyme A.\" [GOC:ai]","metadata":null},{"id":"6a20bc29472b4ec2a2f07b67a87a5684","type":"GO_TERM","name":"2'-5'-oligoadenylate synthetase activity","canonical_id":"go:GO:0001730","description":"\"Catalysis of the reaction: ATP = pppA(2'p5'A)n oligomers. This reaction requires the binding of double-stranded RNA.\" [ISBN:0198506732]","metadata":null},{"id":"af14696eb0ce48a89f48fe0556d26280","type":"GO_TERM","name":"2'-deoxyadenosine deaminase activity","canonical_id":"go:GO:0046936","description":"\"Catalysis of the reaction: 2'-deoxyadenosine + H+ + H2O = 2'-deoxyinosine + NH4+.\" [GOC:ai, RHEA:28190]","metadata":null},{"id":"13fe2ff571274dc5aa019f256399c968","type":"GO_TERM","name":"2'-deoxyguanosine DNA ADP-ribosyltransferase activity","canonical_id":"go:GO:0030591","description":"\"Catalysis of the transfer of the ADP-ribose group of NAD+ to the amino group at N2 of 2'-deoxyguanosine to yield N2-(alpha-ADP-ribos-1-yl)-2'-deoxyguanosine and its beta form.\" [PMID:11592983]","metadata":null},{"id":"c4a1056a4f3e4009bf3dfe69b5518c96","type":"GO_TERM","name":"2'-deoxymugineic-acid 2'-dioxygenase activity","canonical_id":"go:GO:0033760","description":"\"Catalysis of the reaction: 2'-deoxymugineate + 2-oxoglutarate + O2 = CO2 + H+ + mugineate + succinate.\" [EC:1.14.11.24, RHEA:12200]","metadata":null},{"id":"958d4d4c63754594bae91dc39ce38105","type":"GO_TERM","name":"2'-deoxyribonucleoside biosynthetic process","canonical_id":"go:GO:0046120","description":"\"The chemical reactions and pathways resulting in the formation of any one of a family of organic molecules consisting of a purine or pyrimidine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"7d336086fc2940fd9ec4d5e0316a2043","type":"GO_TERM","name":"2'-deoxyribonucleoside catabolic process","canonical_id":"go:GO:0046121","description":"\"The chemical reactions and pathways resulting in the breakdown of any one of a family of organic molecules consisting of a purine or pyrimidine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"8109a65e733d44049973abe673d4c625","type":"GO_TERM","name":"2'-deoxyribonucleoside metabolic process","canonical_id":"go:GO:0009120","description":"\"The chemical reactions and pathways involving any one of a family of organic molecules consisting of a purine or pyrimidine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:jl, ISBN:0140512713]","metadata":null},{"id":"73fc1e92ed7f4518af86bce11073331d","type":"GO_TERM","name":"2'-deoxyribonucleotide biosynthetic process","canonical_id":"go:GO:0009265","description":"\"The chemical reactions and pathways resulting in the formation of a 2'-deoxyribonucleotide, a compound consisting of 2'-deoxyribonucleoside (a base linked to a 2'-deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:mah]","metadata":null},{"id":"3bf7b0bbeb6f4c768ca541756b1291bb","type":"GO_TERM","name":"2'-deoxyribonucleotide metabolic process","canonical_id":"go:GO:0009394","description":"\"The chemical reactions and pathways involving a 2'-deoxyribonucleotide, a compound consisting of 2'-deoxyribonucleoside (a base linked to a 2'-deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:mah]","metadata":null},{"id":"d850ffd25697472e823359e9f804560c","type":"GO_TERM","name":"2'-hydroxybiphenyl-2-sulfinate desulfinase activity","canonical_id":"go:GO:0018740","description":"\"Catalysis of the reaction: 2'-hydroxybiphenyl-2-sulfinate + H2O = biphenyl-2-ol + sulfite.\" [EC:3.13.1.3, RHEA:12945]","metadata":null},{"id":"f66b7b1641b64e2e8204930683406e52","type":"GO_TERM","name":"2'-hydroxydaidzein reductase activity","canonical_id":"go:GO:0047525","description":"\"Catalysis of the reaction: 2'-hydroxydihydrodaidzein + NADP+ = 2'-hydroxydaidzein + NADPH + H+.\" [EC:1.3.1.51]","metadata":null},{"id":"7f91d73867414c9eacf0e92d9e808fe7","type":"GO_TERM","name":"2'-hydroxyisoflavone reductase activity","canonical_id":"go:GO:0047526","description":"\"Catalysis of the reaction: vestitone + NADP+ = 2'-hydroxyformononetin + NADPH + H+.\" [RHEA:22560]","metadata":null},{"id":"c5e0759469514455b54a945eeadc2372","type":"GO_TERM","name":"2,2',3-trihydroxybiphenyl monooxygenase activity","canonical_id":"go:GO:0102325","description":"\"Catalysis of the reaction: biphenyl-2,2',3-triol + O2 + NADH + H+ = 2,2',3,3'-tetrahydroxybiphenyl + NAD + H2O.\" [GOC:pz, RHEA:63516]","metadata":null},{"id":"ecf1b4b67aa14e3c9b8b0d1a708de50f","type":"GO_TERM","name":"2,2-dialkylglycine decarboxylase (pyruvate) activity","canonical_id":"go:GO:0047432","description":"\"Catalysis of the reaction: 2,2-dialkylglycine + H+ + pyruvate = L-alanine + CO2 + dialkyl ketone.\" [EC:4.1.1.64, RHEA:16073]","metadata":null},{"id":"abe3f0105e7c4548bd326cfddcffc77c","type":"GO_TERM","name":"2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase activity","canonical_id":"go:GO:0008666","description":"\"Catalysis of the reaction: (S)-2,3,4,5-tetrahydrodipicolinate + H2O + succinyl-CoA = L-2-succinylamino-6-oxopimelate + CoA.\" [EC:2.3.1.117, RHEA:17325]","metadata":null},{"id":"59d96edba9b84d3c85ade7b1454dd1de","type":"GO_TERM","name":"2,3-diaminopropionate N-oxalyltransferase activity","canonical_id":"go:GO:0047189","description":"\"Catalysis of the reaction: 3-amino-L-alanine + oxalyl-CoA = N(3)-oxalyl-L-2,3-diaminopropanoate + CoA.\" [RHEA:13465]","metadata":null},{"id":"93d5e3c04db34cf49db4a3fde70f9206","type":"GO_TERM","name":"2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase activity","canonical_id":"go:GO:0008667","description":"\"Catalysis of the reaction: (2S,3S)-2,3-dihydroxy-2,3-dihydrobenzoate + NAD+ = 2,3-dihydroxybenzoate + H+ + NADH.\" [EC:1.3.1.28, RHEA:23824]","metadata":null},{"id":"d2eca55bfe8d461bb482f73f65a85c21","type":"GO_TERM","name":"2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase activity","canonical_id":"go:GO:0018511","description":"\"Catalysis of the reaction: cis-2,3-dihydroxy-2,3-dihydro-p-cumate + NAD+ = 2,3-dihydroxy-p-cumate + H+ + NADH.\" [EC:1.3.1.58, RHEA:23772]","metadata":null},{"id":"27345c92e774462aa8a7f4af55e7e5a0","type":"GO_TERM","name":"2,3-dihydroxy-2,3-dihydro-phenylpropionate dehydrogenase activity","canonical_id":"go:GO:0018498","description":"\"Catalysis of the reaction: 3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)propanoate + NAD+ = 3-(2,3-dihydroxyphenyl)propanoate + H+ + NADH. Also converts (2E)-3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)prop-2-enoate to (2E)-3-(2,3-dihydroxyphenyl)prop-2-enoate.\" [EC:1.3.1.87]","metadata":null},{"id":"fb0d099232a94c0a85ceeca930137946","type":"GO_TERM","name":"2,3-dihydroxy-p-cumate dioxygenase activity","canonical_id":"go:GO:0018571","description":"\"Catalysis of the reaction: 2,3-dihydroxy-p-cumate + O2 = 2-hydroxy-3-carboxy-6-oxo-7-methylocta-2,4-dienoate.\" [RHEA:42568]","metadata":null},{"id":"16f8b70b0f2f4a9cac440be1c7e70677","type":"GO_TERM","name":"2,3-dihydroxybenzoate 2,3-dioxygenase activity","canonical_id":"go:GO:0047072","description":"\"Catalysis of the reaction: 2,3-dihydroxybenzoate + O2 = 2-carboxy-cis,cis-muconate + 2 H+.\" [EC:1.13.11.28, RHEA:15369]","metadata":null},{"id":"751e6fbce67e4c3c9d260c22482eb391","type":"GO_TERM","name":"2,3-dihydroxybenzoate 3,4-dioxygenase activity","canonical_id":"go:GO:0045133","description":"\"Catalysis of the reaction: 2,3-dihydroxybenzoate + O2 = 2-hydroxy-3-(3-oxoprop-1-enyl)but-2-enedioate + H+.\" [EC:1.13.11.14, RHEA:18477]","metadata":null},{"id":"4edc6cc8a5cb4b98bc01e28873679524","type":"GO_TERM","name":"2,3-dihydroxybenzoate--[aryl-carrier protein] ligase activity","canonical_id":"go:GO:0008668","description":"\"Catalysis of the reaction: 2,3-dihydroxybenzoate + ATP + holo-[ACP] = 2,3-dihydroxybenzoyl-[ACP] + AMP + diphosphate.\" [RHEA:61652]","metadata":null},{"id":"0e561bd6228944048e01ccf4a77504e3","type":"GO_TERM","name":"2,3-dihydroxybenzoate-serine ligase activity","canonical_id":"go:GO:0047527","description":"\"Catalysis of the reaction: ATP + 2,3-dihydroxybenzoate + L-serine = products of ATP breakdown + N-(2,3-dihydroxybenzoyl)-L-serine.\" [EC:6.3.2.14]","metadata":null},{"id":"4a256453b94848efa94968a2c9c44213","type":"GO_TERM","name":"2,3-dihydroxybiphenyl 1,2-dioxygenase activity","canonical_id":"go:GO:0043898","description":"\"Catalysis of the reaction: 2,3-dihydroxybiphenyl + O2 = 2-hydroxy-6-phenylhexa-2,4-dienoic acid.\" [GOC:jl, PMID:15715866]","metadata":null},{"id":"4993b1f08e1a4bec98eef0ae7ae70120","type":"GO_TERM","name":"2,3-dihydroxyindole 2,3-dioxygenase activity","canonical_id":"go:GO:0047528","description":"\"Catalysis of the reaction: 2,3-dihydroxyindole + O2 = anthranilate + CO2 + H+.\" [EC:1.13.11.23, RHEA:19445]","metadata":null},{"id":"b1290fd7f8ad4ded854ff42c3533b23c","type":"GO_TERM","name":"2,3-diketo-5-methylthiopentyl-1-phosphate enolase activity","canonical_id":"go:GO:0043715","description":"\"Catalysis of the reaction: 2,3-diketo-5-methylthiopentyl-1-phosphate = H+ + 2-hydroxy 3-keto-5-methylthiopentenyl-1-phosphate. 2,3-diketo-5-methylthiopentyl-1-phosphate is also known as DK-MTP-1-P, and 2-hydroxy 3-keto-5-methylthiopentenyl-1-phosphate as HK-MTPenyl-1-P.\" [MetaCyc:R82-RXN]","metadata":null},{"id":"bdb7584746ec4cc095eac03f95fff328","type":"GO_TERM","name":"2,3-dimethylmalate lyase activity","canonical_id":"go:GO:0047529","description":"\"Catalysis of the reaction: (2R,3S)-2,3-dimethylmalate = propanoate + pyruvate.\" [EC:4.1.3.32, RHEA:10472]","metadata":null},{"id":"c4172c61e80542a2b4467daffb9893b6","type":"GO_TERM","name":"2,4'-dihydroxyacetophenone dioxygenase activity","canonical_id":"go:GO:0047073","description":"\"Catalysis of the reaction: 2,4'-dihydroxyacetophenone + O2 = 4-hydroxybenzoate + formate + 2 H+.\" [EC:1.13.11.41, RHEA:24416]","metadata":null},{"id":"6623155cdca54143b6a2ffca17232d59","type":"GO_TERM","name":"2,4,5-trichlorophenoxyacetic acid catabolic process","canonical_id":"go:GO:0046228","description":"\"The chemical reactions and pathways resulting in the breakdown of 2,4,5-trichlorophenoxyacetic acid, a chlorinated aromatic compound widely used as a herbicide.\" [GOC:ai]","metadata":null},{"id":"ddc96369056542619f6f2293aa83041f","type":"GO_TERM","name":"2,4,6-trinitrotoluene catabolic process","canonical_id":"go:GO:0046256","description":"\"The chemical reactions and pathways resulting in the breakdown of 2,4,6-trinitrotoluene, 1-methyl-2,4,6-trinitrobenzene, a highly explosive pale yellow crystalline solid.\" [GOC:ai]","metadata":null},{"id":"f25e6bfc656647d0abf48c103d24243c","type":"GO_TERM","name":"2,4-diaminopentanoate dehydrogenase activity","canonical_id":"go:GO:0047530","description":"\"Catalysis of the reaction: (2R,4S)-2,4-diaminopentanoate + NADP+ + H2O = (2R)-2-amino-4-oxopentanoate + NH4+ + NADPH + H+.\" [EC:1.4.1.12]","metadata":null},{"id":"43f91a73bf5846e69fd484fa42f95e7c","type":"GO_TERM","name":"2,4-dichlorobenzoate catabolic process","canonical_id":"go:GO:0046298","description":"\"The chemical reactions and pathways resulting in the breakdown of 2,4-dichlorobenzoate, a chlorinated aromatic compound which is a key intermediate in the aerobic degradation of polychlorinated biphenyls (PCBs).\" [GOC:ai]","metadata":null},{"id":"a9cac4ce2fd84d46a07eecbfe2f19327","type":"GO_TERM","name":"2,4-dichlorobenzoyl-CoA reductase activity","canonical_id":"go:GO:0018516","description":"\"Catalysis of the reaction: 4-chlorobenzoyl-CoA + chloride + NADP+ = 2,4-dichlorobenzoyl-CoA + NADPH.\" [RHEA:23076]","metadata":null},{"id":"193394f97cd64b629c769a2e459d2fec","type":"GO_TERM","name":"2,4-dichlorophenol 6-monooxygenase activity","canonical_id":"go:GO:0018666","description":"\"Catalysis of the reaction: 2,4-dichlorophenol + NADPH + H+ + O2 = 3,5-dichlorocatechol + NADP+ + H2O.\" [EC:1.14.13.20]","metadata":null},{"id":"e1bb23963c79474788b1d1f9bfe41665","type":"GO_TERM","name":"2,4-dichlorophenoxyacetate alpha-ketoglutarate dioxygenase activity","canonical_id":"go:GO:0018602","description":"\"Catalysis of the reaction: 2,4-dichlorophenoxyacetate + 2-oxoglutarate + oxygen = 2,4-dichlorophenol + glyoxylate + succinate + CO2.\" [UM-BBD_reactionID:r0274]","metadata":null},{"id":"5ea8800e72ff427a8f1571f6395cb8f3","type":"GO_TERM","name":"2,4-dichlorophenoxyacetic acid catabolic process","canonical_id":"go:GO:0046300","description":"\"The chemical reactions and pathways resulting in the breakdown of 2,4-dichlorophenoxyacetic acid, a chlorinated phenoxy compound which functions as a systemic herbicide and is used to control many types of broadleaf weeds.\" [GOC:ai, UM-BBD_pathwayID:2\\,4-d]","metadata":null},{"id":"7884d88035ed4f188ff20489c748c8d6","type":"GO_TERM","name":"2,4-dichlorophenoxyacetic acid metabolic process","canonical_id":"go:GO:0018901","description":"\"The chemical reactions and pathways involving 2,4-dichlorophenoxyacetic acid, a chlorinated phenoxy compound which functions as a systemic herbicide and is used to control many types of broadleaf weeds.\" [GOC:curators]","metadata":null},{"id":"22c1c9901b1746e7ad186810dc065c3d","type":"GO_TERM","name":"2,4-dienoyl-CoA reductase (NADPH) activity","canonical_id":"go:GO:0008670","description":"\"Catalysis of the reactions: a 4,5-saturated-(2E)-enoyl-CoA + NADP+ = a (2E,4E)-dienoyl-CoA + H+ + NADPH, and a (2E,4Z)-dienoyl-CoA + H+ + NADPH = a 4,5-saturated-(2E)-enoyl-CoA + NADP+.\" [EC:1.3.1.34]","metadata":null},{"id":"ddbbaaf79a9b49cf9e83ae7141ed597b","type":"GO_TERM","name":"2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase activity","canonical_id":"go:GO:0047254","description":"\"Catalysis of the reaction: 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one + UDP-D-glucose = 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucoside + UDP.\" [EC:2.4.1.202]","metadata":null},{"id":"8a211be91bd240e9ae9efc71db04128e","type":"GO_TERM","name":"2,5-dichloro-2,5-cyclohexadiene-1,4-diol dehydrogenase activity","canonical_id":"go:GO:0018502","description":"\"Catalysis of the reaction: 2,5-dichloro-2,5-cyclohexadiene-1,4-diol + NAD+ = NADH + H+ + 2,5-dichlorohydroquinone.\" [UM-BBD_reactionID:r0553]","metadata":null},{"id":"1f0cb23a920d4c3f9d78a970e4ac182d","type":"GO_TERM","name":"2,5-didehydrogluconate reductase activity","canonical_id":"go:GO:0050580","description":"\"Catalysis of the reaction: 2-dehydro-D-gluconate + NADP+ = 2,5-didehydro-D-gluconate + NADPH + H+.\" [EC:1.1.1.274, MetaCyc:1.1.1.274-RXN]","metadata":null},{"id":"a062ccc8d72b473ca0c7a4f382c3164b","type":"GO_TERM","name":"2,5-dihydroxypyridine 5,6-dioxygenase activity","canonical_id":"go:GO:0047075","description":"\"Catalysis of the reaction: H2O + O2 + 2,5-dihydroxypyridine = formate + maleamate.\" [EC:1.13.11.9, MetaCyc:1.13.11.9-RXN]","metadata":null},{"id":"70a487f2d392485498353b83d649957f","type":"GO_TERM","name":"2,5-diketocamphane 1,2-monooxygenase activity","canonical_id":"go:GO:0018684","description":"\"Catalysis of the reaction: 1R,4R)-bornane-2,5-dione + FMNH2 + O2 = (1R,4R)-5-oxo-1,2-campholide + FMN + H+ + H2O.\" [PMID:3944058, PMID:8515237, RHEA:34415]","metadata":null},{"id":"920a3c4326364290b80e15921b5dbdff","type":"GO_TERM","name":"2,5-dioxopiperazine hydrolase activity","canonical_id":"go:GO:0047532","description":"\"Catalysis of the reaction: 2,5-dioxopiperazine + H2O = glycylglycine.\" [EC:3.5.2.13, RHEA:21808]","metadata":null},{"id":"800ccad6c1e345ec9e82239893e48afa","type":"GO_TERM","name":"2,5-dioxovalerate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0044104","description":"\"Catalysis of the reaction: 2,5-dioxopentanoate + NAD+ + H2O = 2-oxoglutarate + NADH + 2 H+.\" [PMID:16835232, PMID:17202142, RHEA:47152]","metadata":null},{"id":"f1b3a24d76b54b9b9be14e12050671b0","type":"GO_TERM","name":"2,5-dioxovalerate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047533","description":"\"Catalysis of the reaction: 2,5-dioxopentanoate + NADP+ + H2O = 2-oxoglutarate + NADPH + H+.\" [RHEA:11296]","metadata":null},{"id":"9e92877e9f0044f689b002ae527da311","type":"GO_TERM","name":"2,6-beta-fructan 6-levanbiohydrolase activity","canonical_id":"go:GO:0033912","description":"\"Catalysis of the hydrolysis of (2->6)-beta-D-fructofuranan, to remove successive disaccharide residues as levanbiose, i.e. 6-(beta-D-fructofuranosyl)-D-fructose, from the end of the chain.\" [EC:3.2.1.64]","metadata":null},{"id":"e8abbcd5f8c44afd9ff29028ad40f844","type":"GO_TERM","name":"2,6-dihydroxypyridine 3-monooxygenase activity","canonical_id":"go:GO:0018663","description":"\"Catalysis of the reaction: 2,6-dihydroxypyridine + H+ + NADH + O2 = 2,3,6-trihydroxypyridine + H2O + NAD+.\" [EC:1.14.13.10, RHEA:16917]","metadata":null},{"id":"5d7757f85dfc418998748053e9bf7ef1","type":"GO_TERM","name":"2,6-dioxo-6-phenylhexa-3-enoate hydrolase activity","canonical_id":"go:GO:0018774","description":"\"Catalysis of the reaction: 2,6-dioxo-6-phenylhexa-3-enoate + H2O = 2-oxopent-4-enoate + benzoate + H+.\" [RHEA:17161]","metadata":null},{"id":"9eafa90ac7ba4d0dad7c0259b823b051","type":"GO_TERM","name":"2,7,4'-trihydroxyisoflavanone-4'-O-methyltransferase activity","canonical_id":"go:GO:0102670","description":"\"Catalysis of the reaction: 2,4',7-trihydroxyisoflavanone + S-adenosyl-L-methionine = H+ + 2,7-dihydroxy-4'-methoxyisoflavanone + S-adenosyl-L-homocysteine.\" [EC:2.1.1.212, GOC:pz]","metadata":null},{"id":"8cb156d3fec848d5afa45953b098c380","type":"GO_TERM","name":"2-(3-amino-3-carboxypropyl)histidine synthase activity","canonical_id":"go:GO:0090560","description":"\"Catalysis of the reaction S-adenosyl-L-methionine + L-histidine-[translation elongation factor 2] = S-methyl-5-thioadenosine + 2-[(3S)-3-amino-3-carboxypropyl]-L-histidine-[translation elongation factor 2].\" [GOC:pde, PMID:15485916, RHEA:36783]","metadata":null},{"id":"9416894477554d60904d2820ea32ed6e","type":"GO_TERM","name":"2-(3-amino-3-carboxypropyl)histidine synthase complex","canonical_id":"go:GO:0120513","description":"\"A protein complex capable of catalysing the transfer of the 3-amino-3-carboxypropyl group from S-adenosyl-L-methionine (SAM) to the histidine residue of translation elongation factor 2 (EF2), which is the first step in the biosynthesis of diphthamide. The complex is a Dph2 homodimer in archaea and a Dph1-Dph2 heterodimer in eukaryotes.\" [GOC:sjm, PMID:24422557, PMID:31463593]","metadata":null},{"id":"562580176700453db354270c2272fd58","type":"GO_TERM","name":"2-(R)-hydroxypropyl-CoM dehydrogenase activity","canonical_id":"go:GO:0050574","description":"\"Catalysis of the reaction: 2-(R)-hydroxypropyl-coenzyme M + NAD+ = 2-oxopropyl-coenzyme M + H+ + NADH.\" [EC:1.1.1.268, RHEA:13249]","metadata":null},{"id":"2136bbcce2d6473b94fb192bc7224943","type":"GO_TERM","name":"2-(S)-hydroxypropyl-CoM dehydrogenase activity","canonical_id":"go:GO:0050575","description":"\"Catalysis of the reaction: 2-(S)-hydroxypropyl-coenzyme M + NAD+ = 2-oxopropyl-coenzyme M + H+ + NADH.\" [EC:1.1.1.269, RHEA:21052]","metadata":null},{"id":"897086c373ff465397ea8cbe78d05df3","type":"GO_TERM","name":"2-(acetamidomethylene)succinate hydrolase activity","canonical_id":"go:GO:0047411","description":"\"Catalysis of the reaction: 2-(acetamidomethylene)succinate + 2 H2O + H+ = succinate semialdehyde + acetate + NH4+ + CO2.\" [RHEA:10432]","metadata":null},{"id":"dd213220b9944f12a2915e7843b31bbf","type":"GO_TERM","name":"2-(hydroxymethyl)-3-(acetamidomethylene)succinate hydrolase activity","canonical_id":"go:GO:0047414","description":"\"Catalysis of the reaction: (2Z)-2-(acetamidomethylene)-3-(hydroxymethyl)succinate + 2 H2O + H+ = 2-(hydroxymethyl)-4-oxobutanoate + acetate + CO2 + NH4.\" [EC:3.5.1.66, RHEA:17677]","metadata":null},{"id":"76ca86e969844b0c9856dd3a70bdcef0","type":"GO_TERM","name":"2-(omega-methylthio)alkylmalate dehydratase activity","canonical_id":"go:GO:0120528","description":"\"Catalysis of the reactions: a 2-(omega-methylsulfanyl)alkylmalate = a 2-(omega-methylsulfanyl)alkylmaleate + H2O and a 3-(omega-methylsulfanyl)alkylmalate = a 2-(omega-methylsulfanyl)alkylmaleate + H2O.\" [EC:4.2.1.170]","metadata":null},{"id":"b3a685e249994560a4c7973687544ac2","type":"GO_TERM","name":"2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase activity","canonical_id":"go:GO:0008685","description":"\"Catalysis of the reaction: 4-CDP-2-C-methyl-D-erythritol 2-phosphate = 2-C-methyl-D-erythritol 2,4-cyclic diphosphate + CMP.\" [EC:4.6.1.12, RHEA:23864]","metadata":null},{"id":"4476c471482f49d59aa4fe8032320a8a","type":"GO_TERM","name":"2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase activity","canonical_id":"go:GO:0050518","description":"\"Catalysis of the reaction: 2-C-methyl-D-erythritol 4-phosphate + CTP = 4-CDP-2-C-methyl-D-erythritol + diphosphate.\" [EC:2.7.7.60, RHEA:13429]","metadata":null},{"id":"3b41f0354161458e911abe0392426dde","type":"GO_TERM","name":"2-acetamido-4-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-2-deoxy-D-glucose exo-beta-D-glucosaminidase activity","canonical_id":"go:GO:0102277","description":"\"Catalysis of the reaction: beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine + H2O = D-glucosamine + N-acetyl-D-glucosamine.\" [RHEA:62164]","metadata":null},{"id":"ab9c4785eb15479c8888968e58be8321","type":"GO_TERM","name":"2-acetolactate mutase activity","canonical_id":"go:GO:0047534","description":"\"Catalysis of the reaction: 2-acetolactate = 3-hydroxy-3-methyl-2-oxobutanoate.\" [EC:5.4.99.3, MetaCyc:2-ACETOLACTATE-MUTASE-RXN]","metadata":null},{"id":"d7f88e5cd6404ab8aa0f54abf118a927","type":"GO_TERM","name":"2-acylglycerol O-acyltransferase activity","canonical_id":"go:GO:0003846","description":"\"Catalysis of the reaction: acyl-CoA + 2-acylglycerol = CoA + diacylglycerol.\" [PMID:4016575, RHEA:16741]","metadata":null},{"id":"407924c4a9f344b0869c4bdd780d073d","type":"GO_TERM","name":"2-acylglycerol-3-phosphate O-acyltransferase activity","canonical_id":"go:GO:0047144","description":"\"Catalysis of the reaction: 2-acyl-sn-glycerol 3-phosphate + acyl-CoA = L-phosphatidate + CoA.\" [GOC:ab, RHEA:14233]","metadata":null},{"id":"c33933c20a684a41ae762db1cd302146","type":"GO_TERM","name":"2-acylglycerophosphocholine O-acyltransferase activity","canonical_id":"go:GO:0047190","description":"\"Catalysis of the reaction: 2-acyl-sn-glycero-3-phosphocholine + acyl-CoA = 1,2-diacyl-sn-glycero-3-phosphocholine + CoA.\" [RHEA:10332]","metadata":null},{"id":"ab0ea0c93fd447478ddd8414071ee156","type":"GO_TERM","name":"2-alkenal reductase (NADPH) activity","canonical_id":"go:GO:0035798","description":"\"Catalysis of the reaction: n-alkanal + NADP+ = alk-2-enal + NADPH + H+.\" [PMID:16299173, RHEA:13737]","metadata":null},{"id":"458fba36ce8b4f37942f1e5bcde877a8","type":"GO_TERM","name":"2-alkenal reductase [NAD(P)H] activity","canonical_id":"go:GO:0032440","description":"\"Catalysis of the reaction: n-alkanal + NAD(P)+ = alk-2-enal + NAD(P)H + H+.\" [EC:1.3.1.74, PMID:16299173]","metadata":null},{"id":"7bfe538b8f3e441a88da7cef0a094245","type":"GO_TERM","name":"2-alkyn-1-ol dehydrogenase activity","canonical_id":"go:GO:0047535","description":"\"Catalysis of the reaction: 2-butyne-1,4-diol + NAD+ = 4-hydroxy-2-butynal + H+ + NADH.\" [EC:1.1.1.165, RHEA:19101]","metadata":null},{"id":"0131840a199347b6a0c187097acb74f1","type":"GO_TERM","name":"2-alpha-hydroxytaxane 2-O-benzoyltransferase activity","canonical_id":"go:GO:0050642","description":"\"Catalysis of the reaction: 10-deacetyl-2-debenzoylbaccatin III + benzoyl-CoA = 10-deacetylbaccatin III + CoA.\" [RHEA:18741]","metadata":null},{"id":"ce532496bad343e689685356997f4e84","type":"GO_TERM","name":"2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity","canonical_id":"go:GO:0003848","description":"\"Catalysis of the reaction: 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine + ATP = (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + AMP + 2 H+.\" [EC:2.7.6.3, RHEA:11412]","metadata":null},{"id":"9d5784f0ddcc4616aa5450acb36b88d6","type":"GO_TERM","name":"2-amino-5-formylamino-6-(5-phosphoribosylamino)pyrimidin-4(3H)-one formate-lyase activity","canonical_id":"go:GO:0043729","description":"\"Catalysis of the reaction: 2-amino-5-formylamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one + H2O = 2,5-diamino-6-(1-D-ribosylamino)pyrimidin-4(3H)-one 5'-phosphate + formate + H+.\" [RHEA:27282]","metadata":null},{"id":"471be6ba7bd342b2af79d963e0ee725c","type":"GO_TERM","name":"2-aminobenzenesulfonate 2,3-dioxygenase activity","canonical_id":"go:GO:0018627","description":"\"Catalysis of the reaction: 2-aminobenzenesulfonate + 2 H+ + NADH + O2 = 2,3-dihydroxybenzenesulfonate + NAD+ + NH4. 2,3-dihydroxybenzenesulfonate is also known as 3-sulfocatechol.\" [RHEA:23468]","metadata":null},{"id":"6e77e8f9a6874d16844cde9bbc4a4a36","type":"GO_TERM","name":"2-aminobenzenesulfonate catabolic process","canonical_id":"go:GO:0046230","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-aminobenzenesulfonate, an aromatic sulfonate used in organic synthesis and in the manufacture of various dyes and medicines.\" [GOC:ai]","metadata":null},{"id":"eb747b41048a4f9c85d1f68719e715a7","type":"GO_TERM","name":"2-aminobenzenesulfonate desulfonation","canonical_id":"go:GO:0019490","description":"\"The removal of the sulfonate group from 2-aminobenzenesulfonate, an aromatic sulfonate used in organic synthesis and in the manufacture of various dyes and medicines.\" [MetaCyc:2ASDEG-PWY]","metadata":null},{"id":"e7d2655b12004903a89288cc0810839b","type":"GO_TERM","name":"2-aminoethylphosphonate binding","canonical_id":"go:GO:0033226","description":"\"Binding to 2-aminoethylphosphonate.\" [GOC:mlg]","metadata":null},{"id":"e00828f5b8f742e998f0ddf16b61caf6","type":"GO_TERM","name":"2-aminoethylphosphonate catabolic process","canonical_id":"go:GO:0019635","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-aminoethylphosphonate, also known as ciliatine.\" [GOC:ai]","metadata":null},{"id":"e084c9a5a0c648d8bf333b5e0d084fcd","type":"GO_TERM","name":"2-aminoethylphosphonate transport","canonical_id":"go:GO:0033223","description":"\"The directed movement of 2-aminoethylphosphonate, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mlg]","metadata":null},{"id":"662ccb1a648c462785e1ce0f5c292661","type":"GO_TERM","name":"2-aminoethylphosphonate:pyruvate transaminase activity","canonical_id":"go:GO:0047304","description":"\"Catalysis of the reaction: (2-aminoethyl)phosphonate + pyruvate = L-alanine + phosphonoacetaldehyde.\" [RHEA:17021]","metadata":null},{"id":"d1da74d477914180bf582cc7267224c4","type":"GO_TERM","name":"2-aminohexano-6-lactam racemase activity","canonical_id":"go:GO:0047463","description":"\"Catalysis of the reaction: L-2-aminohexano-6-lactam = D-2-aminohexano-6-lactam.\" [EC:5.1.1.15, RHEA:14813]","metadata":null},{"id":"919d0360d2e24b9e854465c0ba9267ec","type":"GO_TERM","name":"2-aminomuconate deaminase activity","canonical_id":"go:GO:0050540","description":"\"Catalysis of the reaction: 2-aminomuconate + H2O + H+ = (Z)-5-oxohex-2-enedioate + NH4.\" [EC:3.5.99.5, RHEA:20996]","metadata":null},{"id":"6549918847374f7cbde6379a8329994a","type":"GO_TERM","name":"2-carboxy-D-arabinitol-1-phosphatase activity","canonical_id":"go:GO:0047538","description":"\"Catalysis of the reaction: 2-carboxy-D-arabinitol 1-phosphate + H2O = 2-carboxy-D-arabinitol + phosphate.\" [EC:3.1.3.63, RHEA:17837]","metadata":null},{"id":"bb2b7e67472e499992edd517e5257fc9","type":"GO_TERM","name":"2-carene synthase activity","canonical_id":"go:GO:0102702","description":"\"Catalysis of the reaction: geranyl diphosphate = (+)-2-carene + diphosphoric acid.\" [GOC:pz, PMID:10700382]","metadata":null},{"id":"732aceaefc4d478eb57816e1a62d887e","type":"GO_TERM","name":"2-chloro-4-carboxymethylenebut-2-en-1,4-olide isomerase activity","canonical_id":"go:GO:0047466","description":"\"Catalysis of the reaction: cis-2-chloro-4-carboxymethylenebut-2-en-1,4-olide = trans-2-chloro-4-carboxymethylenebut-2-en-1,4-olide.\" [EC:5.2.1.10, RHEA:10924]","metadata":null},{"id":"27da0c83796741f2b92ef2bd510a0574","type":"GO_TERM","name":"2-chloro-N-isopropylacetanilide catabolic process","canonical_id":"go:GO:0046302","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-chloro-N-isopropylacetanilide, an acylanide herbicide widely used to protect corn, onion, cabbage, rose bushes, and ornamental plants.\" [GOC:ai]","metadata":null},{"id":"65183166a3164782a24b7359e78587f5","type":"GO_TERM","name":"2-chloroacrylate reductase activity","canonical_id":"go:GO:0102523","description":"\"Catalysis of the reaction: (S)-2-chloropropanoate + NADP = 2-chloroacrylate + NADPH + H+.\" [EC:1.3.1.103, GOC:pz]","metadata":null},{"id":"ec40c046201b47a7ad98be78fdaf9cf0","type":"GO_TERM","name":"2-coumarate O-beta-glucosyltransferase activity","canonical_id":"go:GO:0047212","description":"\"Catalysis of the reaction: trans-2-coumarate + UDP-D-glucose = trans-beta-D-glucosyl-2-hydroxycinnamate + H+ + UDP.\" [EC:2.4.1.114, RHEA:10236]","metadata":null},{"id":"dc753ece86ff442d9752bb00793e2542","type":"GO_TERM","name":"2-coumarate reductase activity","canonical_id":"go:GO:0047788","description":"\"Catalysis of the reaction: 3-(2-hydroxyphenyl)propanoate + NAD+ = trans-2-coumarate + H+ + NADH.\" [EC:1.3.1.11, RHEA:21444]","metadata":null},{"id":"9ec73812837a4a82add2e5f9e9f659e4","type":"GO_TERM","name":"2-dehydro-3-deoxy-6-phosphogalactonate aldolase activity","canonical_id":"go:GO:0008674","description":"\"Catalysis of the reaction: 6-phospho-2-dehydro-3-deoxy-D-galactonate = D-glyceraldehyde 3-phosphate + pyruvate.\" [EC:4.1.2.21, RHEA:24464]","metadata":null},{"id":"9eb1f16b43414c7cb6343de6ef844b3f","type":"GO_TERM","name":"2-dehydro-3-deoxy-D-gluconate 5-dehydrogenase activity","canonical_id":"go:GO:0047001","description":"\"Catalysis of the reaction: NAD+ + 2-dehydro-3-deoxy-D-gluconate = NADH + (4S)-4,6-dihydroxy-2,5-dioxohexanoate.\" [EC:1.1.1.127, MetaCyc:1.1.1.127-RXN]","metadata":null},{"id":"bc14b393f18a4b82b331a2644ee77d96","type":"GO_TERM","name":"2-dehydro-3-deoxy-D-gluconate 6-dehydrogenase activity","canonical_id":"go:GO:0047000","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-gluconate + NADP+ = (4S,5S)-4,5-dihydroxy-2,6-dioxohexanoate + H+ + NADPH.\" [EC:1.1.1.126, RHEA:15109]","metadata":null},{"id":"b6730510f197427a851c5eb20a419d4a","type":"GO_TERM","name":"2-dehydro-3-deoxy-D-gluconate aldolase activity","canonical_id":"go:GO:0061677","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-gluconate = pyruvate + D-glyceraldehyde.\" [GOC:dph, PMID:12824170, RHEA:35583]","metadata":null},{"id":"f687da1369d94225ae63a97ddfc59f03","type":"GO_TERM","name":"2-dehydro-3-deoxy-D-gluconic acid biosynthetic process","canonical_id":"go:GO:1901274","description":"\"The chemical reactions and pathways resulting in the formation of 2-dehydro-3-deoxy-D-gluconic acid.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00856]","metadata":null},{"id":"fae8d50745ce47298b0602012bcfda55","type":"GO_TERM","name":"2-dehydro-3-deoxy-D-gluconic acid catabolic process","canonical_id":"go:GO:1901273","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-dehydro-3-deoxy-D-gluconic acid.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00856]","metadata":null},{"id":"b5010c8f6a444bcb945be96f6b380e97","type":"GO_TERM","name":"2-dehydro-3-deoxy-D-pentonate aldolase activity","canonical_id":"go:GO:0047440","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-arabinonate = glycolaldehyde + pyruvate.\" [EC:4.1.2.28, RHEA:20609]","metadata":null},{"id":"20b2255fd12341a698403fbcc3a67d25","type":"GO_TERM","name":"2-dehydro-3-deoxy-L-arabinonate dehydratase activity","canonical_id":"go:GO:0047449","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-L-arabinonate = 2,5-dioxopentanoate + H2O.\" [EC:4.2.1.43, RHEA:17201]","metadata":null},{"id":"2fe0062e65174f3fa2bc422fc5cd5ec0","type":"GO_TERM","name":"2-dehydro-3-deoxy-L-pentonate aldolase activity","canonical_id":"go:GO:0047438","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-L-pentonate = glycolaldehyde + pyruvate.\" [EC:4.1.2.18, MetaCyc:4.1.2.18-RXN]","metadata":null},{"id":"d23168372a1045b09bc71fbc54a1f03c","type":"GO_TERM","name":"2-dehydro-3-deoxy-phosphogluconate aldolase activity","canonical_id":"go:GO:0008675","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-gluconate 6-phosphate = pyruvate + D-glyceraldehyde 3-phosphate.\" [EC:4.1.2.14]","metadata":null},{"id":"204ef8b0727d4806ae61e6d53befa3ba","type":"GO_TERM","name":"2-dehydro-3-deoxygalactonokinase activity","canonical_id":"go:GO:0008671","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-galactonate + ATP = 6-phospho-2-dehydro-3-deoxy-D-galactonate + ADP + 2 H+.\" [EC:2.7.1.58, RHEA:16525]","metadata":null},{"id":"c52e3aaa47e94a73843ef71ed2fa71ed","type":"GO_TERM","name":"2-dehydro-3-deoxyglucarate aldolase activity","canonical_id":"go:GO:0008672","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-glucarate = pyruvate + tartronate semialdehyde.\" [EC:4.1.2.20]","metadata":null},{"id":"4a1c4cb5ccd14d4cb7e58088a0838aa6","type":"GO_TERM","name":"2-dehydro-3-deoxygluconokinase activity","canonical_id":"go:GO:0008673","description":"\"Catalysis of the reaction: 2-dehydro-3-deoxy-D-gluconate + ATP = 2-dehydro-3-deoxy-6-phospho-D-gluconate + ADP + 2 H+.\" [EC:2.7.1.45, RHEA:14797]","metadata":null},{"id":"363573512c09454daaaa3f87b595aa98","type":"GO_TERM","name":"2-dehydropantoate 2-reductase activity","canonical_id":"go:GO:0008677","description":"\"Catalysis of the reaction: (R)-pantoate + NADP+ = 2-dehydropantoate + H+ + NADPH.\" [EC:1.1.1.169, RHEA:16233]","metadata":null},{"id":"62cf9834e7b542cc8e7a0e9812f7bccc","type":"GO_TERM","name":"2-dehydropantoate aldolase activity","canonical_id":"go:GO:0050013","description":"\"Catalysis of the reaction: 2-dehydropantoate = 3-methyl-2-oxobutanoate + formaldehyde.\" [EC:4.1.2.12, MetaCyc:KETOPANTOALDOLASE-RXN]","metadata":null},{"id":"7c97877fa0b1450bb4f5decd6c25967e","type":"GO_TERM","name":"2-dehydropantolactone reductase (A-specific) activity","canonical_id":"go:GO:0047011","description":"\"Catalysis of the reaction: (R)-pantolactone + NADP+ = 2-dehydropantolactone + NADPH + H+. The reaction is A-specific (i.e. the pro-R hydrogen is transferred from the 4-position of reduced nicotinamide cofactor) with respect to NADP+.\" [EC:1.1.1.168, MetaCyc:1.1.1.168-RXN]","metadata":null},{"id":"86f0ffec8065405d9c2da079a45f06b0","type":"GO_TERM","name":"2-dehydropantolactone reductase (B-specific) activity","canonical_id":"go:GO:0019141","description":"\"Catalysis of the reaction: (R)-pantolactone + NADP+ = 2-dehydropantolactone + NADPH + H+. The reaction is B-specific (i.e. the pro-S hydrogen is transferred from the 4-position of reduced nicotinamide cofactor) with respect to NADP+.\" [EC:1.1.1.214]","metadata":null},{"id":"8e02761d744e4963bf934ea3dd1a61cd","type":"GO_TERM","name":"2-dehydropantolactone reductase activity","canonical_id":"go:GO:0036441","description":"\"Catalysis of the reaction: (R)-pantolactone + NADP+ = 2-dehydropantolactone + NADPH + H+.\" [RHEA:18981]","metadata":null},{"id":"3ee0b6bd85f548afa762ceafc853359b","type":"GO_TERM","name":"2-deoxy-D-gluconate 3-dehydrogenase activity","canonical_id":"go:GO:0008678","description":"\"Catalysis of the reaction: 2-deoxy-D-gluconate + NAD+ = 3-dehydro-2-deoxy-D-gluconate + NADH + H+.\" [EC:1.1.1.125]","metadata":null},{"id":"63f1e4298fbc4ed4a9a95d7e66e3bd6e","type":"GO_TERM","name":"2-deoxyglucose-6-phosphatase activity","canonical_id":"go:GO:0003850","description":"\"Catalysis of the reaction: 2-deoxy-D-glucose-6-phosphate + H2O = 2-deoxy-D-glucose + phosphate.\" [EC:3.1.3.68]","metadata":null},{"id":"70381ec641ad43fea10932ce4f4f57e1","type":"GO_TERM","name":"2-deoxyglucosidase activity","canonical_id":"go:GO:0047539","description":"\"Catalysis of the reaction: H2O + a 2-deoxy-alpha-D-glucoside = 2-deoxy-D-glucose + an alcohol.\" [EC:3.2.1.112, MetaCyc:2-DEOXYGLUCOSIDASE-RXN]","metadata":null},{"id":"345406fc6f5e4e04bbbb2ce6151fc158","type":"GO_TERM","name":"2-deoxyribose 1-phosphate biosynthetic process","canonical_id":"go:GO:0006016","description":"\"The chemical reactions and pathways resulting in the formation of 2-deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose.\" [ISBN:0198506732]","metadata":null},{"id":"bc4d96d752cf40fba89c1bf4e9e000c6","type":"GO_TERM","name":"2-deoxyribose 1-phosphate catabolic process","canonical_id":"go:GO:0006018","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxyribose 1-phosphate, the phosphorylated sugar 1-phospho-2-deoxyribose.\" [GOC:ai]","metadata":null},{"id":"fa652c445fe643149834aa2388648b62","type":"GO_TERM","name":"2-deoxystreptamine N-acetyl-D-glucosaminyltransferase activity","canonical_id":"go:GO:0102319","description":"\"Catalysis of the reaction: 2-deoxystreptamine(2+) + UDP-N-acetyl-alpha-D-glucosamine = H+ + 2'-N-acetylparomamine(2+) + UDP(3-).\" [EC:2.4.1.283, GOC:pz]","metadata":null},{"id":"84c707bec4654c54b424e4655af6dd4e","type":"GO_TERM","name":"2-deoxystreptamine biosynthetic process","canonical_id":"go:GO:1901744","description":"\"The chemical reactions and pathways resulting in the formation of 2-deoxystreptamine.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00907]","metadata":null},{"id":"6ced748f5ca64e8ab1dfeb1b942f658f","type":"GO_TERM","name":"2-deoxystreptamine catabolic process","canonical_id":"go:GO:1901743","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-deoxystreptamine.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"26ed7734ac6147ecb61639f0ac46666d","type":"GO_TERM","name":"2-deoxystreptamine glucosyltransferase activity","canonical_id":"go:GO:0102318","description":"\"Catalysis of the reaction: 2-deoxystreptamine + UDP-alpha-D-glucose = 2'-deamino-2'-hydroxyparomamine + UDP(3-) + H+.\" [EC:2.4.1.284, GOC:pz]","metadata":null},{"id":"27db82bb008e429fbea46c9fd4f37a30","type":"GO_TERM","name":"2-deoxystreptamine metabolic process","canonical_id":"go:GO:1901742","description":"\"The chemical reactions and pathways involving 2-deoxystreptamine.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"4020d36cf8e143b0b465c47863019281","type":"GO_TERM","name":"2-enoate reductase activity","canonical_id":"go:GO:0047540","description":"\"Catalysis of the reaction: butanoate + NAD+ = 2-butenoate + NADH + H+.\" [EC:1.3.1.31, MetaCyc:2-ENOATE-REDUCTASE-RXN]","metadata":null},{"id":"e76c9363389c4951b10ef932db2ba6a0","type":"GO_TERM","name":"2-ethylmalate synthase activity","canonical_id":"go:GO:0050438","description":"\"Catalysis of the reaction: 2-oxobutanate + acetyl-CoA + H2O = (R)-2-ethylmalate + CoA + H+.\" [RHEA:23040]","metadata":null},{"id":"888c0587f97d4eac883d51623f614d2d","type":"GO_TERM","name":"2-formylbenzoate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018474","description":"\"Catalysis of the reaction: 2-formylbenzoate + H2O + NAD+ = 2 H+ + NADH + phthalate.\" [RHEA:27298]","metadata":null},{"id":"25bc1b67cf7d48d88f516388050c1e80","type":"GO_TERM","name":"2-furoate-CoA ligase activity","canonical_id":"go:GO:0047541","description":"\"Catalysis of the reaction: 2-furoate + ATP + CoA = 2-furoyl-CoA + AMP + diphosphate + H+.\" [EC:6.2.1.31, RHEA:19269]","metadata":null},{"id":"387a4020dbb940f4b1a167bb64316b51","type":"GO_TERM","name":"2-furoyl-CoA dehydrogenase activity","canonical_id":"go:GO:0047542","description":"\"Catalysis of the reaction: 2-furoyl-CoA + A + H2O = 5-hydroxy-2-furoyl-CoA + AH(2) + H+.\" [EC:1.3.99.8, RHEA:21480]","metadata":null},{"id":"351b3525e5504d03858082959481eee6","type":"GO_TERM","name":"2-haloacid dehalogenase (configuration-inverting) activity","canonical_id":"go:GO:0033976","description":"\"Catalysis of the reactions: an (S)-2-haloacid + H2O = a (2R)-2-hydroxycarboxylate + a halide anion + H+, and an (R)-2-haloacid + H2O = a (2S)-2-hydroxycarboxylate + a halide anion + H+.\" [EC:3.8.1.10]","metadata":null},{"id":"dddb8ba73d074a26a5307f7df3585a13","type":"GO_TERM","name":"2-haloacid dehalogenase (configuration-retaining) activity","canonical_id":"go:GO:0033977","description":"\"Catalysis of the reactions: (S)-2-haloacid + H2O = (S)-2-hydroxyacid + halide, and (R)-2-haloacid + H2O = (R)-2-hydroxyacid + halide.\" [RHEA:12072]","metadata":null},{"id":"9346da73fa3b4ee9b784e31467d5fa7e","type":"GO_TERM","name":"2-halobenzoate 1,2-dioxygenase activity","canonical_id":"go:GO:0018626","description":"\"Catalysis of the reaction: a 2-halobenzoate + NADH + O2 + H+ = a halide anion + catechol + CO2 + NAD+.\" [RHEA:53736]","metadata":null},{"id":"90a4afc511ff4333aa01988a49f1cb84","type":"GO_TERM","name":"2-heptyl-3-hydroxy-4(1H)-quinolone synthase activity","canonical_id":"go:GO:0102164","description":"\"Catalysis of the reaction: 2-heptyl-4-quinolone + NADH + O2 + H+ = 2-heptyl-3-hydroxy-4-quinolone + NAD + H2O.\" [EC:1.14.13.182, GOC:pz]","metadata":null},{"id":"12983e4206164e199db60098bd659cb5","type":"GO_TERM","name":"2-hexadecenal reductase activity","canonical_id":"go:GO:0047543","description":"\"Catalysis of the reaction: NADP+ + palmitaldehyde = trans-hexadec-2-enal + H+ + NADPH.\" [EC:1.3.1.27, RHEA:12444]","metadata":null},{"id":"8efd3e95757a4743a9f2019ddaa7a16b","type":"GO_TERM","name":"2-hydroxy-1,4-benzoquinone reductase (NADH) activity","canonical_id":"go:GO:0050625","description":"\"Catalysis of the reaction: 2-hydroxy-1,4-benzoquinone + 2 H+ + NADH = benzene-1,2,4-triol + NAD+.\" [RHEA:12428]","metadata":null},{"id":"2e6fdb96395145d8a04aa97e36f8efba","type":"GO_TERM","name":"2-hydroxy-1,4-benzoxazin-3-one monooxygenase activity","canonical_id":"go:GO:0036193","description":"\"Catalysis of the reaction: 2-hydroxy-2H-1,4-benzoxazin-3(4H)-one + O2 + reduced [NADPH--hemoprotein reductase] = DIBOA + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:31939]","metadata":null},{"id":"7c32f12064624bc1b57c42062eea3800","type":"GO_TERM","name":"2-hydroxy-3-keto-5-methylthiopentenyl-1-phosphate phosphatase activity","canonical_id":"go:GO:0043716","description":"\"Catalysis of the reaction: 2-hydroxy-5-methylsulfanyl-3-oxopent-1-enyl phosphate + H2O = 1,2-dihydroxy-5-(methylsulfanyl)pent-1-en-3-one + phosphate.\" [RHEA:14481]","metadata":null},{"id":"4f9dcda453624fc7ae4a716e7b688424","type":"GO_TERM","name":"2-hydroxy-3-oxoadipate synthase activity","canonical_id":"go:GO:0050439","description":"\"Catalysis of the reaction: 2-oxoglutarate + glyoxylate + H+ = 2-hydroxy-3-oxoadipate + CO2.\" [EC:2.2.1.5, RHEA:14341]","metadata":null},{"id":"b9c202fcc35b419aac42ee6446d615a8","type":"GO_TERM","name":"2-hydroxy-3-oxopropionate reductase activity","canonical_id":"go:GO:0008679","description":"\"Catalysis of the reaction: (R)-glycerate + NADP+ = 2-hydroxy-3-oxopropanoate + NADPH + H+.\" [EC:1.1.1.60]","metadata":null},{"id":"6cfa87443dd84d199bdc644b639fb3dc","type":"GO_TERM","name":"2-hydroxy-6-oxo-6-(2'-aminophenyl)hexa-2,4-dienoate hydrolase activity","canonical_id":"go:GO:0018768","description":"\"Catalysis of the reaction: (2E,4E)-6-(2-aminophenyl)-2-hydroxy-6-oxohexa-2,4-dienoate + H2O = (2E)-2-hydroxypenta-2,4-dienoate + anthranilate + H+.\" [RHEA:27870]","metadata":null},{"id":"f9280ce27e4c4dd88d27e2b7f3020fb1","type":"GO_TERM","name":"2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate reductase activity","canonical_id":"go:GO:0047118","description":"\"Catalysis of the reaction: 2,6-dioxo-6-phenylhexanoate + NADP+ = 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate + H+ + NADPH.\" [EC:1.3.1.40, RHEA:24268]","metadata":null},{"id":"b9c3d4dfb9e84ca9aa4a439d8914e13a","type":"GO_TERM","name":"2-hydroxy-6-oxohepta-2,4-dienoate hydrolase activity","canonical_id":"go:GO:0018765","description":"\"Catalysis of the reaction: (2Z,4E)-2-hydroxy-6-oxohepta-2,4-dienoate + H2O = (2Z)-2-hydroxypenta-2,4-dienoate + acetate + H+.\" [RHEA:59220]","metadata":null},{"id":"e7db0a0f010343778a78d600eac06a9d","type":"GO_TERM","name":"2-hydroxy-6-oxonona-2,4,7-trienedioate hydrolase activity","canonical_id":"go:GO:0052823","description":"\"Catalysis of the reaction: (2Z,4E,7E)-2-hydroxy-6-oxonona-2,4,7-trienedioate + H2O = (2Z)-2-hydroxypenta-2,4-dienoate + fumarate + H+.\" [RHEA:34191]","metadata":null},{"id":"a808c97d3bf0406085c630bdd9906b63","type":"GO_TERM","name":"2-hydroxy-6-oxonona-2,4-dienedioate hydrolase activity","canonical_id":"go:GO:0018771","description":"\"Catalysis of the reaction: (2Z,4E)-2-hydroxy-6-oxonona-2,4-dienedioate + H2O = (2Z)-2-hydroxypenta-2,4-dienoate + H+ + succinate.\" [RHEA:34187]","metadata":null},{"id":"aff8b4f74ecd4334a180e41271c33e3d","type":"GO_TERM","name":"2-hydroxy-ATP hydrolase activity","canonical_id":"go:GO:0106377","description":"\"Catalysis of the reaction: 2-hydroxy-ATP + H2O = 2-hydroxy-AMP + H+ + diphosphate.\" [PMID:11139615, RHEA:67392]","metadata":null},{"id":"f6c807560ee240e398ee9f95bb552a3c","type":"GO_TERM","name":"2-hydroxy-but-3-enyl glucosinolate biosynthetic process","canonical_id":"go:GO:0080035","description":"\"The chemical reactions and pathways resulting in the formation of progoitrin, a 2-hydroxy-but-3-enyl glucosinolate. Glucosinolates are substituted thioglucosides found in rapeseed products and related cruciferae, and progoitrin has been implicated in causing goiters in mammals and bitter taste in cruciferous vegetables.\" [PMID:11560911, PMID:18945935]","metadata":null},{"id":"e85f446b6b144695a61829490e302a96","type":"GO_TERM","name":"2-hydroxy-dATP hydrolase activity","canonical_id":"go:GO:0106378","description":"\"Catalysis of the reaction: 2-hydroxy-dATP + H2O = 2-hydroxy-dAMP + H+ + diphosphate.\" [PMID:11139615, RHEA:31583]","metadata":null},{"id":"2398c519ba2643ad96c172fbff35a08a","type":"GO_TERM","name":"2-hydroxyacyl-CoA lyase activity","canonical_id":"go:GO:0106359","description":"\"Catalysis of the reaction: a 2-hydroxy fatty acyl-CoA = a fatty aldehyde + formyl-CoA. The reaction acts on 2-hydroxy-3-methyl-branched fatty acyl-CoA and 2-hydroxy-long-chain fatty acyl-CoA.\" [EC:4.1.2.63, PMID:21708296, PMID:28289220]","metadata":null},{"id":"acffd687d92745629bc5ec92b677ad18","type":"GO_TERM","name":"2-hydroxybenzoyl-CoA biosynthetic process","canonical_id":"go:GO:1901887","description":"\"The chemical reactions and pathways resulting in the formation of 2-hydroxybenzoyl-CoA.\" [GOC:TermGenie, PMID:19757094]","metadata":null},{"id":"ca8cff14a37f408d8fc694c914a36735","type":"GO_TERM","name":"2-hydroxybenzoyl-CoA catabolic process","canonical_id":"go:GO:1901886","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-hydroxybenzoyl-CoA.\" [GOC:TermGenie, PMID:19757094]","metadata":null},{"id":"77ad22549ad94dceade3efc432499e15","type":"GO_TERM","name":"2-hydroxybiphenyl 3-monooxygenase (NADH) activity","canonical_id":"go:GO:0047544","description":"\"Catalysis of the reaction: biphenyl-2-ol + H+ + NADH + O2 = biphenyl-2,3-diol + H2O + NAD+. Also converts 2,2'-dihydroxybiphenyl into 2,2',3-trihydroxy-biphenyl.\" [EC:1.14.13.44]","metadata":null},{"id":"525a5f6ed24440d39be4501a4bff30f4","type":"GO_TERM","name":"2-hydroxychromene-2-carboxylate isomerase activity","canonical_id":"go:GO:0018845","description":"\"Catalysis of the reaction: 2-hydroxychromene-2-carboxylate = (3E)-4-(2-hydroxyphenyl)-2-oxobut-3-enoate. (3E)-4-(2-hydroxyphenyl)-2-oxobut-3-enoate is also known as trans-o-hydroxybenzylidenepyruvate.\" [RHEA:27401]","metadata":null},{"id":"2e68560499c247a8b94e8d599448d926","type":"GO_TERM","name":"2-hydroxycyclohexanone 2-monooxygenase activity","canonical_id":"go:GO:0047095","description":"\"Catalysis of the reaction: 2-hydroxycyclohexan-1-one + NADPH + O2 = 6-oxohexanoate + H2O + NADP+.\" [EC:1.14.13.66, RHEA:33283]","metadata":null},{"id":"96f9c2afd4ef4b73a338c8ef5f8b85d7","type":"GO_TERM","name":"2-hydroxyflavanone C-glucosyltransferase activity","canonical_id":"go:GO:0120514","description":"\"Catalysis of the reaction: a 3'-hydro-2'-hydroxy-beta-oxodihydrochalcone + UDP-alpha-D-glucose = a 3'-(beta-D-glucopyranosyl)-2'-hydroxy-beta-oxodihydrochalcone + H+ + UDP.\" [RHEA:51504]","metadata":null},{"id":"f4c110fc039f4b2a9ff6fc5eeb7f8a07","type":"GO_TERM","name":"2-hydroxyglutarate synthase activity","canonical_id":"go:GO:0019142","description":"\"Catalysis of the reaction: glyoxylate + H2O + propanoyl-CoA = 2-hydroxyglutarate + CoA + H+.\" [RHEA:19185]","metadata":null},{"id":"45f973bd079e453db4a334cf47a31119","type":"GO_TERM","name":"2-hydroxyglutaryl-CoA dehydratase activity","canonical_id":"go:GO:0043717","description":"\"Catalysis of the reaction: (R)-2-hydroxyglutaryl-CoA = H2O + glutaconyl-CoA.\" [MetaCyc:RXN-1083]","metadata":null},{"id":"76c76650561e479583ded3a70737ab01","type":"GO_TERM","name":"2-hydroxyhexa-2,4-dienoate hydratase activity","canonical_id":"go:GO:0034856","description":"\"Catalysis of the reaction: (2E,4E)-2-hydroxyhexa-2,4-dienoate + H2O = 4-hydroxy-2-oxohexanoate.\" [UM-BBD_reactionID:r1281]","metadata":null},{"id":"e2c105a57a6344299b0194cb2aed73b6","type":"GO_TERM","name":"2-hydroxyisoflavanone dehydratase activity","canonical_id":"go:GO:0033987","description":"\"Catalysis of the reactions: (2R,3S)-2,4',7-trihydroxyisoflavanone = daidzein + H+ + H2O, and 2-hydroxy-2,3-dihydrogenistein = genistein + H+ + H2O.\" [EC:4.2.1.105]","metadata":null},{"id":"a92529fd53334a5cbc915f315501dafd","type":"GO_TERM","name":"2-hydroxyisoflavanone synthase activity","canonical_id":"go:GO:0033770","description":"\"Catalysis of the reactions: liquiritigenin + O2 + [reduced NADPH--hemoprotein reductase] = 2,4',7-trihydroxyisoflavanone + H2O + [oxidized NADPH--hemoprotein reductase] and (2S)-naringenin + O2 + [reduced NADPH--hemoprotein reductase] = 2,4',5,7-tetrahydroxyisoflavanone + H2O + [oxidized NADPH--hemoprotein reductase].\" [EC:1.14.14.87]","metadata":null},{"id":"7099c0ebdb4340a3b70ab5e6a62b3474","type":"GO_TERM","name":"2-hydroxymethylglutarate dehydrogenase activity","canonical_id":"go:GO:0043718","description":"\"Catalysis of the reaction: 2-(hydroxymethyl)glutarate + NAD+ = 2-formylglutarate + H+ + NADH.\" [EC:1.1.1.291, RHEA:15505]","metadata":null},{"id":"1a4a5c6ebce9497397d295d501e11680","type":"GO_TERM","name":"2-hydroxymuconate-semialdehyde hydrolase activity","canonical_id":"go:GO:0018775","description":"\"Catalysis of the reaction: (2Z,4E)-2-hydroxy-6-oxohexa-2,4-dienoate + H2O = 2-oxopent-4-enoate + formate + H+.\" [RHEA:14549]","metadata":null},{"id":"5a8b36d249ce45ea89d7ddc7b529272a","type":"GO_TERM","name":"2-hydroxyphytanoyl-CoA lyase activity","canonical_id":"go:GO:0106376","description":"\"Catalysis of the reaction: 2-hydroxyphytanoyl-CoA = 2,6,10,14-tetramethylpentadecanal + formyl-CoA.\" [PMID:10468558, RHEA:25355]","metadata":null},{"id":"a5f704e57e4641e4ba41da8a78f322a9","type":"GO_TERM","name":"2-hydroxypropyl-CoM lyase activity","canonical_id":"go:GO:0050555","description":"\"Catalysis of the reactions: (R)-2-hydroxypropyl-CoM = H-S-CoM + (R)-1,2-epoxypropane, and (S)-2-hydroxypropyl-CoM = H-S-CoM + (S)-1,2-epoxypropane.\" [EC:4.4.1.23]","metadata":null},{"id":"f0e089aad38c4f78a94fdd0d9320a5ee","type":"GO_TERM","name":"2-hydroxypyridine 5-monooxygenase activity","canonical_id":"go:GO:0047546","description":"\"Catalysis of the reaction: 2-hydroxypyridine + AH(2) + O2 = 2,5-dihydroxypyridine + A + H2O.\" [EC:1.14.99.26, RHEA:16973]","metadata":null},{"id":"ab0e23d6a185479a8c8927f6cc14d01f","type":"GO_TERM","name":"2-hydroxyquinoline 5,6-dioxygenase activity","canonical_id":"go:GO:0018629","description":"\"Catalysis of the reaction: quinolin-2-ol + NADH + O2 + H+ = 5,6-dihydroquinoline-2,5,6-triol + NAD+.\" [RHEA:10976]","metadata":null},{"id":"79882be16a7841eda954bcbffb4dd9fc","type":"GO_TERM","name":"2-hydroxyquinoline 8-monooxygenase activity","canonical_id":"go:GO:0033766","description":"\"Catalysis of the reaction: H+ + NADH + O2 + quinolin-2-ol = H2O + NAD+ + quinoline-2,8-diol.\" [EC:1.14.13.61, RHEA:22080]","metadata":null},{"id":"8ffdf1e939eb4fc4a117ae1f9b7e2ed6","type":"GO_TERM","name":"2-iminoacetate synthase activity","canonical_id":"go:GO:0036355","description":"\"Catalysis of the reaction: L-tyrosine + S-adenosyl-L-methionine + reduced acceptor = 2-iminoacetate + 4-methylphenol + 5'-deoxyadenosine + L-methionine + acceptor + 2 H+.\" [EC:4.1.99.19, GOC:crds, MetaCyc:RXN-11319, PMID:17403671]","metadata":null},{"id":"0fe05ca294374b49abd1f1ce446908b5","type":"GO_TERM","name":"2-iminoacetate synthase complex","canonical_id":"go:GO:1902508","description":"\"A protein complex which is capable of 2-iminoacetate synthase activity.\" [GOC:bhm, GOC:TermGenie, PMID:12650933]","metadata":null},{"id":"824b6fb8b3e540d5a1d4994d9a6574f7","type":"GO_TERM","name":"2-iminobutanoate deaminase activity","canonical_id":"go:GO:0120242","description":"\"Catalysis of the reaction: 2-iminobutanoate + H2O = 2-oxobutanoate + NH4+.\" [RHEA:39975]","metadata":null},{"id":"1f89838fb29548959b4cd497d01f36de","type":"GO_TERM","name":"2-iminobutanoate/2-iminopropanoate deaminase activity","canonical_id":"go:GO:0120241","description":"\"Catalyzes the hydrolytic deamination of imine intermediates formed by several types of pyridoxal-5'-phosphate-dependent dehydratases, such as EC 4.3.1.19 and EC 4.3.1.17.\" [EC:3.5.99.10]","metadata":null},{"id":"63ae42ff22774b958de385d10a4bdfba","type":"GO_TERM","name":"2-iminopropanoate deaminase activity","canonical_id":"go:GO:0120243","description":"\"Catalysis of the reaction: 2-iminopropanoate + H2O = NH4+ + pyruvate.\" [RHEA:40671]","metadata":null},{"id":"1b1493b6961a40b09c2f8c64660d399a","type":"GO_TERM","name":"2-isopropylmalate synthase activity","canonical_id":"go:GO:0003852","description":"\"Catalysis of the reaction: 3-methyl-2-oxobutanoate + acetyl-CoA + H2O = (2S)-2-isopropylmalate + CoA + H+.\" [RHEA:21524]","metadata":null},{"id":"01c310749c3b473caa7910009e176759","type":"GO_TERM","name":"2-isopropylmalate(2-) transmembrane transport","canonical_id":"go:GO:1902357","description":"\"The process in which 2-isopropylmalate(2-) is transported across a membrane.\" [GOC:dph, GOC:TermGenie, GOC:vw, PMID:18682385]","metadata":null},{"id":"e59fd099d661448fa3b6ca7b3e9c1200","type":"GO_TERM","name":"2-isopropylphenol monooxygenase activity","canonical_id":"go:GO:0102323","description":"\"Catalysis of the reaction: 2-isopropylphenol + O2 + NADH + H+ = 3-isopropylcatechol + H2O + NAD.\" [GOC:pz, RHEA:63520]","metadata":null},{"id":"bc2587baa9d24ffc89ab77c7c85fc79e","type":"GO_TERM","name":"2-keto-3-deoxy-L-rhamnonate aldolase activity","canonical_id":"go:GO:0106099","description":"\"Catalysis of the reaction 2-dehydro-3-deoxy-L-rhamnonate = pyruvate + (S)-lactaldehyde.\" [EC:4.1.2.53, GOC:imk, PMID:18754683]","metadata":null},{"id":"a061144496c04102b6f1a718a6b8d885","type":"GO_TERM","name":"2-keto-3-deoxygalactonate aldolase activity","canonical_id":"go:GO:0043724","description":"\"Catalysis of the reaction: 2-keto-3-deoxygalactonate = D-glyceraldehyde + pyruvate.\" [PMID:12824170]","metadata":null},{"id":"42c9632fdb9847c4a036ea5a19d03814","type":"GO_TERM","name":"2-keto-3-deoxygluconate transmembrane transport","canonical_id":"go:GO:0046411","description":"\"The process in which 2-keto-3-deoxygluconate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"5bd070b745f34225a671663cfd64b8d8","type":"GO_TERM","name":"2-keto-3-deoxygluconate:proton symporter activity","canonical_id":"go:GO:0015649","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: 2-keto-3-deoxygluconate(out) + H+(out) = 2-keto-3-deoxygluconate(in) + H+(in).\" [RHEA:29943, TC:2.A.10.1.1]","metadata":null},{"id":"52b76caa7d4f4530adfcf7dc4ee2112f","type":"GO_TERM","name":"2-ketobutyrate formate-lyase activity","canonical_id":"go:GO:0043875","description":"\"Catalysis of the reaction: 2-oxobutanoate + coenzyme A = propionyl-CoA + formate.\" [PMID:9484901, RHEA:28054]","metadata":null},{"id":"bb0910f481d74be9ad3ad0f481e86083","type":"GO_TERM","name":"2-methoxy-6-polyprenolphenol 4-hydroxylase activity","canonical_id":"go:GO:0120538","description":"\"Catalysis of the reaction: 2-methoxy-6-(all-trans-polyprenyl)phenol + 2 reduced [2Fe-2S]-[ferredoxin] + O2 + 2 H+ = 2-methoxy-6-(all-trans-polyprenyl)benzene-1,4-diol + 2 oxidized [2Fe-2S]-[ferredoxin] + H2O.\" [PMID:38425362, RHEA:81183]","metadata":null},{"id":"a71f37247ab2485dad257a6bf3d46cb3","type":"GO_TERM","name":"2-methoxy-6-polyprenyl-1,4-benzoquinol methyltransferase activity","canonical_id":"go:GO:0008425","description":"\"Catalysis of the reaction: a 2-methoxy-6-all-trans-polyprenyl-1,4-benzoquinol + S-adenosyl-L-methionine = a 6-methoxy-3-methyl-2-all-trans-polyprenyl-1,4-benzoquinol + S-adenosyl-L-homocysteine + H+.\" [PMID:23190198, PMID:9083048, RHEA:28286]","metadata":null},{"id":"fc61804ba56343abaa24e37e905c8001","type":"GO_TERM","name":"2-methyl-6-geranylgeranyl-1,4-benzoquinol methyltransferase activity","canonical_id":"go:GO:0102550","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 2-methyl-6-geranylgeranyl-1,4-benzoquinol = S-adenosyl-L-homocysteine + 2,3-dimethyl-6-geranylgeranyl-1,4-benzoquinol + H+.\" [EC:2.1.1.295, GOC:pz]","metadata":null},{"id":"ccc7fb6a109b47dfb373493f26c37c7a","type":"GO_TERM","name":"2-methyl-6-phytyl-1,4-benzoquinone methyltransferase activity","canonical_id":"go:GO:0051741","description":"\"Catalysis of the reaction: 2-methyl-6-phytyl-1,4-benzoquinone + S-adenosyl-methionine = 2,3-dimethyl-6-phytyl-1,4-benzoquinone + S-adenosyl-homocysteine.\" [MetaCyc:RXN-2542]","metadata":null},{"id":"6ee08d7ab9da4250bd647728e7af0c93","type":"GO_TERM","name":"2-methyl-6-solanyl-1,4-benzoquinone methyltransferase activity","canonical_id":"go:GO:0051742","description":"\"Catalysis of the reaction: 2-methyl-6-solanyl-1,4-benzoquinone + S-adenosyl-methionine = 2,3-dimethyl-6-solanyl-1,4-benzoquinone + S-adenosyl-homocysteine.\" [MetaCyc:RXN-2762]","metadata":null},{"id":"30e253ac5a274694bbdf94f3352a91cf","type":"GO_TERM","name":"2-methylbut-2-enoyl-CoA(4-) biosynthetic process","canonical_id":"go:GO:1902194","description":"\"The chemical reactions and pathways resulting in the formation of 2-methylbut-2-enoyl-CoA(4-).\" [GOC:TermGenie, PMID:15574432]","metadata":null},{"id":"9fa25ca640854b0a816a4cdc2a683283","type":"GO_TERM","name":"2-methylbut-2-enoyl-CoA(4-) catabolic process","canonical_id":"go:GO:1902193","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-methylbut-2-enoyl-CoA(4-).\" [GOC:TermGenie, PMID:15574432]","metadata":null},{"id":"3ba0b3777cc04d4fac6b39eca77cb93e","type":"GO_TERM","name":"2-methylbut-2-enoyl-CoA(4-) metabolic process","canonical_id":"go:GO:1902192","description":"\"The chemical reactions and pathways involving 2-methylbut-2-enoyl-CoA(4-).\" [GOC:TermGenie, PMID:15574432]","metadata":null},{"id":"5e4d0887c79a4d8591c25c6cf4231af7","type":"GO_TERM","name":"2-methylbutanal reductase (NADPH) activity","canonical_id":"go:GO:0032018","description":"\"Catalysis of the reaction: 2-methylbutan-1-ol + NADP+ = 2-methylbutanal + NADPH + H+.\" [PMID:12210903, RHEA:84375]","metadata":null},{"id":"e604c928c16c45fb97046e6df1bd2de4","type":"GO_TERM","name":"2-methylbutanoate-CoA ligase activity","canonical_id":"go:GO:0043759","description":"\"Catalysis of the reaction: ATP + 2-methylbutanoate + CoA = AMP + diphosphate + 2-methylbutanoyl-CoA.\" [RHEA:46180]","metadata":null},{"id":"f40ede3f6ad646879945f2a55a3331e4","type":"GO_TERM","name":"2-methylbutanoyl-CoA(4-) biosynthetic process","canonical_id":"go:GO:1902191","description":"\"The chemical reactions and pathways resulting in the formation of 2-methylbutanoyl-CoA(4-).\" [GOC:TermGenie, PMID:15574432]","metadata":null},{"id":"b47ff4ff26eb4c97a5cb8339a3f1dc2a","type":"GO_TERM","name":"2-methylbutanoyl-CoA(4-) catabolic process","canonical_id":"go:GO:1902190","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-methylbutanoyl-CoA(4-).\" [GOC:TermGenie, PMID:15574432]","metadata":null},{"id":"19566a9ca8164204b3063330d68c6e0b","type":"GO_TERM","name":"2-methylcitrate dehydratase activity","canonical_id":"go:GO:0047547","description":"\"Catalysis of the reaction: (2S,3S)-2-methylcitrate = cis-2-methylaconitate + H2O.\" [EC:4.2.1.79, RHEA:17725]","metadata":null},{"id":"f93138b41c0348de8cbfc329f82a98c6","type":"GO_TERM","name":"2-methylcitrate synthase activity","canonical_id":"go:GO:0050440","description":"\"Catalysis of the reaction: H2O + oxaloacetate + propanoyl-CoA = (2R,3S)-2-methylcitrate + CoA + H+.\" [RHEA:23780]","metadata":null},{"id":"b0f74435d11c4889aa42d8385aa23e21","type":"GO_TERM","name":"2-methyleneglutarate mutase activity","canonical_id":"go:GO:0047548","description":"\"Catalysis of the reaction: 2-methyleneglutarate = 2-methylene-3-methylsuccinate.\" [EC:5.4.99.4, RHEA:13793]","metadata":null},{"id":"eeef5116f96d4df09ca961fff09cb2f6","type":"GO_TERM","name":"2-methylguanosine metabolic process","canonical_id":"go:GO:0080180","description":"\"The chemical reactions and pathways involving 2-methylguanosine.\" [GOC:tb]","metadata":null},{"id":"64c9acd4e86245c496c86fcf548452ed","type":"GO_TERM","name":"2-methylisocitrate dehydratase activity","canonical_id":"go:GO:0047456","description":"\"Catalysis of the reaction: (2S,3R)-3-hydroxybutane-1,2,3-tricarboxylate = cis-2-methylaconitate + H2O.\" [EC:4.2.1.99, RHEA:17941]","metadata":null},{"id":"dfa2cd592a8a40bbbe7e53c1b32c2e97","type":"GO_TERM","name":"2-micrometer circle DNA","canonical_id":"go:GO:0005729","description":"\"A plasmid commonly found in Saccharomyces, inherited in a non-Mendelian manner and often present in 100-400 copies.\" [PMID:12073320]","metadata":null},{"id":"00eb7e5c33d84334a97a9bf25eb6eeeb","type":"GO_TERM","name":"2-micrometer plasmid partitioning","canonical_id":"go:GO:0030543","description":"\"The process in which copies of the 2-micrometer plasmid, found in fungi such as Saccharomyces, are distributed to daughter cells upon cell division.\" [GOC:mah]","metadata":null},{"id":"6e0ac7d98c1b41b1bf4908de61070ab8","type":"GO_TERM","name":"2-nitrophenol 2-monooxygenase activity","canonical_id":"go:GO:0047549","description":"\"Catalysis of the reaction: 2-nitrophenol + 2 H+ + 2 NADPH + O2 = catechol + H2O + 2 NADP+ + nitrite.\" [EC:1.14.13.31, RHEA:19457]","metadata":null},{"id":"feeb972cee6547899733e205eb6bf6f0","type":"GO_TERM","name":"2-nitropropane catabolic process","canonical_id":"go:GO:0046304","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-nitropropane, a clear, colorless liquid with a mild, fruity odor.\" [GOC:ai]","metadata":null},{"id":"e6486d3664524d37b1064752899f4184","type":"GO_TERM","name":"2-octaprenyl-6-methoxyphenol hydroxylase activity","canonical_id":"go:GO:0008681","description":"\"Catalysis of the reaction: 2-methoxy-6-(all-trans-octaprenyl)phenol + H+ + NADPH + O2 = 2-methoxy-6-all-trans-octaprenyl-1,4-benzoquinol + H2O + NADP+.\" [PMID:27822549, PMID:4572721, RHEA:29407]","metadata":null},{"id":"b475766396d24a698f2d6394972c7997","type":"GO_TERM","name":"2-oxo-3-(5-oxofuran-2-ylidene)propanoate lactonase activity","canonical_id":"go:GO:0102355","description":"\"Catalysis of the reaction: 2-oxo-3-(5-oxofuran-2-ylidene)propanoate + H2O = 3-maleylpyruvate + H+.\" [EC:3.1.1.91, GOC:pz]","metadata":null},{"id":"c2520ce924fa48eba8af27a60f6bcedb","type":"GO_TERM","name":"2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity","canonical_id":"go:GO:0051997","description":"\"Catalysis of the reaction: 5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H imidazole-5-carboxylate + H+ = S-allantoin + CO2.\" [MetaCyc:RXN-6201]","metadata":null},{"id":"5a5152f176074bacbbb3b1310359848a","type":"GO_TERM","name":"2-oxo-delta3-4,5,5-trimethylcyclopentenylacetyl-CoA synthetase activity","canonical_id":"go:GO:0018855","description":"\"Catalysis of the reaction: 2-oxo-delta3-4,5,5-trimethylcyclopentenylacetate + ATP + CoA = AMP + diphosphate + 2-oxo-delta3-4,5,5-trimethylcyclopentenylacetyl-CoA.\" [UM-BBD_reactionID:r0429]","metadata":null},{"id":"e85794b9c41b44f4a9d2c0d49a2477fb","type":"GO_TERM","name":"2-oxo-hept-3-ene-1,7-dioate hydratase activity","canonical_id":"go:GO:0018817","description":"\"Catalysis of the reaction: cis-2-oxohept-3-ene-1,7-dioate + H2O = 2,4-dihydroxy-hept-trans-2-ene-1,7-dioate.\" [UM-BBD_reactionID:r0369]","metadata":null},{"id":"c9f53ca32b2e4600aa7c928acba7f371","type":"GO_TERM","name":"2-oxoadipate dehydrogenase activity","canonical_id":"go:GO:0160166","description":"\"Catalysis of the reaction: 2-oxoadipate + H+ + N(6)-[(R)-lipoyl]-L-lysyl-[dihydrolipoyllysine-residue succinyltransferase] = CO2 + N(6)-[(R)-S(8)-glutaryldihydrolipoyl]-L-lysyl-[dihydrolipoyllysine-residue succinyltransferase].\" [PMID:29191460, PMID:32695416, RHEA:69576]","metadata":null},{"id":"c0ac4136b4b14574ab8095aeffb7168c","type":"GO_TERM","name":"2-oxoadipate reductase activity","canonical_id":"go:GO:0047550","description":"\"Catalysis of the reaction: 2-hydroxyadipate + NAD+ = 2-oxoadipate + H+ + NADH.\" [EC:1.1.1.172, RHEA:14793]","metadata":null},{"id":"d99232ea5680491687115606f3a7dadb","type":"GO_TERM","name":"2-oxoaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047551","description":"\"Catalysis of the reaction: a 2-oxoaldehyde + NAD+ + H2O = a 2-oxo acid + NADH + H+.\" [EC:1.2.1.23, MetaCyc:2-OXOALDEHYDE-DEHYDROGENASE-NAD+-RXN]","metadata":null},{"id":"76b67efa06fe45b2bae4047f61cd9cfa","type":"GO_TERM","name":"2-oxoaldehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047552","description":"\"Catalysis of the reaction: a 2-oxoaldehyde + NADP+ + H2O = a 2-oxo acid + NADPH + H+.\" [RHEA:18129]","metadata":null},{"id":"29cde91bc0a542d88ae7aec686ee8966","type":"GO_TERM","name":"2-oxobutyrate biosynthetic process","canonical_id":"go:GO:0046360","description":"\"The chemical reactions and pathways resulting in the formation of 2-oxobutyrate, the anion of the organic acid 2-oxobutyric acid, which contains a ketone group on carbon 2.\" [ISBN:0198506732]","metadata":null},{"id":"16dcca6caa9d44419fa0a1010c2ad6ed","type":"GO_TERM","name":"2-oxobutyrate catabolic process","canonical_id":"go:GO:0019606","description":"\"The chemical reactions and pathways resulting in the breakdown of 2-oxobutyrate, the anion of the organic acid 2-oxobutyric acid, which contains a ketone group on carbon 2.\" [ISBN:0198506732]","metadata":null},{"id":"3f4f056429c646c28ab75aae2b1bcdca","type":"GO_TERM","name":"2-oxoglutaramate amidase activity","canonical_id":"go:GO:0106008","description":"\"Catalysis of the reaction: 2-oxoglutaramate + H2O = 2-oxoglutarate + NH3.\" [PMID:21288482, RHEA:32963]","metadata":null},{"id":"0a4f9eb0794d4063955aaecff1c401a4","type":"GO_TERM","name":"2-oxoglutarate carboxylase activity","canonical_id":"go:GO:0034029","description":"\"Catalysis of the reaction: 2-oxoglutarate + ATP + bicarbonate = ADP + 2 H+ + oxalosuccinate + phosphate.\" [EC:6.4.1.7, RHEA:20425]","metadata":null},{"id":"cc909dc1e8674bafb8cbcdbb3c69b017","type":"GO_TERM","name":"2-oxoglutarate decarboxylase activity","canonical_id":"go:GO:0008683","description":"\"Catalysis of the reaction: 2-oxoglutarate + H+ = CO2 + succinate semialdehyde.\" [EC:4.1.1.71, RHEA:10524]","metadata":null},{"id":"00edb2247c294f4d8885487fe52fbf83","type":"GO_TERM","name":"2-oxoglutarate decarboxylation to succinyl-CoA","canonical_id":"go:GO:0120551","description":"\"The chemical reactions and pathways resulting in the formation of succinyl-CoA from 2-oxoglutarate.  In most organisms, this pathway is part of the TCA cycle and comprises a series of three reactions carried out by a multisubunit complex called the '2-oxoglutarate dehydrogenase complex', even though 2-oxoglutarate dehydrogenase activity describes only one of those reactions. The combination of the three reactions can be summarized as: 2-oxoglutarate + coenzyme A + NAD+ -> succinyl-CoA + CO2 + NADH.\" [MetaCyc:PWY-5084]","metadata":null},{"id":"c5c6b8b2fba141298d2a8af4e3d2565e","type":"GO_TERM","name":"2-oxoglutarate metabolic process","canonical_id":"go:GO:0006103","description":"\"The chemical reactions and pathways involving oxoglutarate, the dianion of 2-oxoglutaric acid. It is a key constituent of the TCA cycle and a key intermediate in amino-acid metabolism.\" [ISBN:0198506732]","metadata":null},{"id":"d841e4437bfe4ea8b685fb12e7604d59","type":"GO_TERM","name":"2-oxoglutarate oxygenase/decarboxylase (ethylene-forming) activity","canonical_id":"go:GO:0102276","description":"\"Catalysis of the reaction: 2-oxoglutarate(2-) + O2 + 2 H+ = ethene + 3 carbon dioxide + H2O.\" [EC:1.13.12.19, GOC:pz]","metadata":null},{"id":"71675ea08295479db60b132981dd64ff","type":"GO_TERM","name":"2-oxoglutarate synthase activity","canonical_id":"go:GO:0047553","description":"\"Catalysis of the reaction: 2-oxoglutarate + CoA + oxidized ferredoxin = succinyl-CoA + CO2 + reduced ferredoxin.\" [EC:1.2.7.3, MetaCyc:2-OXOGLUTARATE-SYNTHASE-RXN]","metadata":null},{"id":"f0751799a13340a8923603a14f3bee57","type":"GO_TERM","name":"2-oxoglutarate, L-arginine oxygenase (succinate-forming) activity","canonical_id":"go:GO:0102525","description":"\"Catalysis of the reaction: L-argininium(1+) + 2-oxoglutarate + O2 = (3S)-3-hydroxy-L-arginine(1+) + succinate + carbon dioxide.\" [GOC:pz, RHEA:36607]","metadata":null},{"id":"b4a069b0c8fb421c8facacfce677b5e4","type":"GO_TERM","name":"2-oxoglutarate-dependent dioxygenase activity","canonical_id":"go:GO:0016706","description":"\"Catalysis of the reaction: A + 2-oxoglutarate + O2 = B + succinate + CO2. This is an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from 2-oxoglutarate and one other donor, and one atom of oxygen is incorporated into each donor.\" [GOC:mah]","metadata":null},{"id":"25a49e214d414b3cb5f39168cf802215","type":"GO_TERM","name":"2-oxoglutarate-dependent tRNA 5-methylcytidine formyltransferase activity","canonical_id":"go:GO:0160290","description":"\"Catalysis of the reaction: 5-methylcytidine(34) in mitochondrial tRNA(Met) + 2 2-oxoglutarate + 2 O2 = 5-formylcytidine(34) in mitochondrial tRNA(Met) + 2 succinate + 2 CO2 + H2O.\" [PMID:27497299, PMID:28472312, RHEA:54144]","metadata":null},{"id":"b90b57dd98f04d23b95ca94f69832c27","type":"GO_TERM","name":"2-oxopent-4-enoate hydratase activity","canonical_id":"go:GO:0008684","description":"\"Catalysis of the reaction: 4-hydroxy-2-oxopentanoate = 2-oxopent-4-enoate + H2O.\" [EC:4.2.1.80]","metadata":null},{"id":"fa1e844430114866b69ea4a800af0e4c","type":"GO_TERM","name":"2-oxopropyl-CoM reductase (carboxylating) activity","canonical_id":"go:GO:0050628","description":"\"Catalysis of the reaction: acetoacetate + coenzyme M + NADP+ = 2-oxopropyl-coenzyme M + CO2 + NADPH.\" [EC:1.8.1.5, RHEA:16977]","metadata":null},{"id":"4eb0e634113c4196a79e46dfc4c60083","type":"GO_TERM","name":"2-phenylethylamine receptor activity","canonical_id":"go:GO:1990080","description":"\"Combining with the biogenic amine 2-phenylethylamine to initiate a change in cell activity.\" [PMID:16878137]","metadata":null},{"id":"d5f4d2a762214d5d9df720ad0a8d3ab7","type":"GO_TERM","name":"2-phosphosulfolactate phosphatase activity","canonical_id":"go:GO:0050532","description":"\"Catalysis of the reaction: (2R)-O-phospho-3-sulfolactate + H2O = (R)-3-sulfolactate + phosphate.\" [EC:3.1.3.71, RHEA:23416]","metadata":null},{"id":"380a9f1554ee442ab8ee727421c63796","type":"GO_TERM","name":"2-phytyl-1,4-naphthoquinone methyltransferase activity","canonical_id":"go:GO:0052624","description":"\"Catalysis of the reaction: demethylphylloquinol + S-adenosyl-L-methionine = H+ + phylloquinol + S-adenosyl-L-homocysteine.\" [PMID:14617060, RHEA:40551]","metadata":null},{"id":"2b2652a939484d6ea87498d37b3f4bfd","type":"GO_TERM","name":"2-polyprenyl-6-hydroxyphenol O-methyltransferase activity","canonical_id":"go:GO:1990888","description":"\"Catalysis of the reaction: 2-polyprenyl-6-hydroxyphenol + S-adenosyl-L-methionine = 2-polyprenyl-6-methoxyphenol + S-adenosyl-L-homocysteine + H+.\" [PMID:10419476]","metadata":null},{"id":"c6409aa8dd7f4acdb481acfa8d0af4b1","type":"GO_TERM","name":"2-polyprenyl-6-hydroxyphenol methylase activity","canonical_id":"go:GO:0102208","description":"\"Catalysis of the reaction: a 3-(all-trans-polyprenyl)benzene-1,2-diol + S-adenosyl-L-methionine = a 2-methoxy-6-(all-trans-polyprenyl)phenol + H+ + S-adenosyl-L-homocysteine.\" [GOC:pz, RHEA:31411]","metadata":null},{"id":"45fe006601a74bbf80046792313c368d","type":"GO_TERM","name":"2-polyprenylphenol 6-hydroxylase activity","canonical_id":"go:GO:0019168","description":"\"Catalysis of the reaction: a 2-(all-trans-polyprenyl)phenol + NADPH + O2 + H+ = a 3-(all-trans-polyprenyl)benzene-1,2-diol + NADP+ + H2O.\" [RHEA:55892]","metadata":null},{"id":"a47b6349ee724a9f80fe3fcbb42e4142","type":"GO_TERM","name":"2-propylphenol monooxygenase activity","canonical_id":"go:GO:0102322","description":"\"Catalysis of the reaction: 2-propylphenol + O2 + NADH + H+ = 3-propylcatechol + H2O + NAD.\" [GOC:pz]","metadata":null},{"id":"0bc9c87db3a74ddaa192f2f75f86312d","type":"GO_TERM","name":"2-pyrone-4,6-dicarboxylate lactonase activity","canonical_id":"go:GO:0047554","description":"\"Catalysis of the reaction: 2-oxo-2H-pyran-4,6-dicarboxylate + H2O = 4-carboxy-2-hydroxyhexa-2,4-dienedioate + H+.\" [EC:3.1.1.57, RHEA:10644]","metadata":null},{"id":"99ff9c95a6b8472c838d458450f143ff","type":"GO_TERM","name":"2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase activity","canonical_id":"go:GO:0070204","description":"\"Catalysis of the reaction: 2-oxoglutarate + H+ + isochorismate = 5-enolpyruvoyl-6-hydroxy-2-succinyl-cyclohex-3-ene-1-carboxylate + CO2.\" [RHEA:25593]","metadata":null},{"id":"4f48736f30844917b6ce97dba46e1edd","type":"GO_TERM","name":"2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase activity","canonical_id":"go:GO:0070205","description":"\"Catalysis of the reaction: 5-enolpyruvoyl-6-hydroxy-2-succinyl-cyclohex-3-ene-1-carboxylate = (1R,6R)-2-succinyl-6-hydroxycyclohexa-2,4-diene-1-carboxylate + pyruvate.\" [EC:4.2.99.20, RHEA:25597]","metadata":null},{"id":"c1afb32ce32149febdb9188e02674481","type":"GO_TERM","name":"20-aldehyde-leukotriene B4 20-monooxygenase activity","canonical_id":"go:GO:0097259","description":"\"Catalysis of the reaction: 20-oxo-leukotriene B4 + O2 + reduced [NADPH-hemoprotein reductase] = 20-carboxy-leukotriene B4 + 2 H+ + H2O + oxidized [NADPH-hemoprotein reductase].\" [GOC:mw, PMID:2549038, PMID:2836406, PMID:9675028, RHEA:48672]","metadata":null},{"id":"a58e0069045d46449537eb6705225330","type":"GO_TERM","name":"20-hydroxy-leukotriene B4 omega oxidase activity","canonical_id":"go:GO:0097258","description":"\"Catalysis of the reaction: 20-hydroxy-leukotriene B4 + O2 + reduced [NADPH-hemoprotein reductase] = 20-oxo-leukotriene B4 + H+ + 2 H2O + oxidized [NADPH-hemoprotein reductase].\" [GOC:mw, PMID:2836406, PMID:9675028, RHEA:48668]","metadata":null},{"id":"a7b11701ad884657969d4e3fd8e26488","type":"TRIAL","name":"20070360 Incident Dialysis","canonical_id":"clinicaltrials.gov:NCT00803712","description":"Chronic Kidney Disease; Secondary Hyperparathyroidism","metadata":null},{"id":"999d5e1ffee7491588a7c2903eed5437","type":"TRIAL","name":"2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy","canonical_id":"clinicaltrials.gov:NCT03000634","description":"Multiple Myeloma","metadata":null},{"id":"496b85bbc81e4f05be66e37c457c0902","type":"TRIAL","name":"2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)","canonical_id":"clinicaltrials.gov:NCT03003728","description":"Multiple Myeloma","metadata":null},{"id":"4ec53b0b2e094dad96fb8a134c2590b3","type":"TRIAL","name":"2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03168100","description":"Multiple Myeloma","metadata":null},{"id":"86f888a8dec44550afbeb5ef72d62acc","type":"GO_TERM","name":"21-deoxycortisol binding","canonical_id":"go:GO:1903877","description":"\"Binding to 21-deoxycortisol.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10802282]","metadata":null},{"id":"f45e81b90b5145c9aeb9cf8df768e15a","type":"GO_TERM","name":"21S rRNA pseudouridine(2819) synthase activity","canonical_id":"go:GO:0160143","description":"\"Catalysis of the reaction: uridine(2819) in 21S rRNA = pseudouridine(2819) in 21S rRNA.\" [EC:5.4.99.43, RHEA:42556]","metadata":null},{"id":"381f1c2e3cf141c58def66fc286384fd","type":"GO_TERM","name":"21U-RNA binding","canonical_id":"go:GO:0034583","description":"\"Binding to a 21U-RNA, a 21-nucleotide RNA characterized by a uridine 5'-monophosphate and a modified 3' end resistant to periodate degradation. 21U-RNAs are derived from distinct, autonomously expressed loci within the genome.\" [GOC:kmv]","metadata":null},{"id":"f9cca93f9ab14ca186a1ee4d1358acd5","type":"GO_TERM","name":"21U-RNA catabolic process","canonical_id":"go:GO:0034586","description":"\"The chemical reactions and pathways resulting in the breakdown of 21U-RNAs, a class of single-stranded RNA molecules of about 21 nucleotides in length characterized by a uridine 5'-monophosphate and a modified 3' end resistant to periodate degradation. 21U-RNAs are derived from distinct, autonomously expressed loci within the genome.\" [GOC:kmv]","metadata":null},{"id":"0f66d4d5ed3846f08efded8125b8af61","type":"GO_TERM","name":"21U-RNA metabolic process","canonical_id":"go:GO:0034585","description":"\"The chemical reactions and pathways involving 21U-RNAs, a class of single-stranded RNA molecules of about 21 nucleotides in length characterized by a uridine 5'-monophosphate and a modified 3' end resistant to periodate degradation. 21U-RNAs are derived from distinct, autonomously expressed loci within the genome.\" [GOC:kmv]","metadata":null},{"id":"5cded04e1eca45c98c76c3586452c389","type":"TRIAL","name":"221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02477800","description":"Alzheimer's Disease","metadata":null},{"id":"087112601a7c422db439372cf4ee1e94","type":"TRIAL","name":"221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02484547","description":"Alzheimer's Disease","metadata":null},{"id":"7a3401ac018f452bb79978444a14d2d2","type":"GO_TERM","name":"22alpha-hydroxysteroid 23-monooxygenase activity","canonical_id":"go:GO:0102097","description":"\"Catalysis of the reaction: (22S,24R)-22-hydroxy-5alpha-ergostan-3-one + O2 + reduced [NADPH--hemoprotein reductase] = 3-dehydro-6-deoxoteasterone + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. Also converts 3-epi-6-deoxocathasterone to 6-deoxotyphasterol.\" [EC:1.14.14.147]","metadata":null},{"id":"d790db117fb8432ba9465df5ce46e072","type":"GO_TERM","name":"23S rRNA (adenine(1618)-N(6))-methyltransferase activity","canonical_id":"go:GO:0052907","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + adenine(1618) in 23S rRNA = S-adenosyl-L-homocysteine + rRNA containing N(6)-methyladenine(1618) in 23S rRNA.\" [RHEA:16497]","metadata":null},{"id":"31b942214bd44acc9acd80b12e0341de","type":"GO_TERM","name":"23S rRNA (adenine(2030)-N(6))-methyltransferase activity","canonical_id":"go:GO:0036307","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + adenine(2030) in 23S rRNA = S-adenosyl-L-homocysteine + rRNA containing N(6)-methyladenine(2030) in 23S rRNA.\" [GOC:imk, PMID:22847818, RHEA:43736]","metadata":null},{"id":"f766fe0c76a0430ca3efe5512236477a","type":"GO_TERM","name":"23S rRNA (adenine(2085)-N(6))-dimethyltransferase activity","canonical_id":"go:GO:0052910","description":"\"Catalysis of the reaction: 2 S-adenosyl-L-methionine + adenine(2085) in 23S rRNA = 2 S-adenosyl-L-homocysteine + N(6)-dimethyladenine(2085) in 23S rRNA.\" [RHEA:42784]","metadata":null},{"id":"7bc89b040ec64ef785a6bc9d6bd535ab","type":"GO_TERM","name":"23S rRNA (adenosine(1067)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0030743","description":"\"Catalysis of the reaction: adenosine(1067) in 23S rRNA + S-adenosyl-L-methionine = 2'-O-methyladenosine(1067) in 23S rRNA + H+ + S-adenosyl-L-homocysteine.\" [EC:2.1.1.230]","metadata":null},{"id":"64b90b15283249adb553f77edefbab81","type":"GO_TERM","name":"23S rRNA (guanine(1835)-N(2))-methyltransferase activity","canonical_id":"go:GO:0052916","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanosine(1835) in 23S rRNA = N(2)-methylguanosine(1835) in 23S rRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.174]","metadata":null},{"id":"36bdf6c4d29c45ce85b3459f90252e9b","type":"GO_TERM","name":"23S rRNA (guanine(2445)-N(2))-methyltransferase activity","canonical_id":"go:GO:0052915","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanosine(2445) in 23S rRNA = N(2)-methylguanosine(2445) in 23S rRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.173]","metadata":null},{"id":"4c91bce2491049ec84b445b1149dd988","type":"GO_TERM","name":"23S rRNA (guanine(745)-N(1))-methyltransferase activity","canonical_id":"go:GO:0052911","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanine(745) in 23S rRNA = N(1)-methylguanine(745) in 23S rRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.187]","metadata":null},{"id":"41024f3a926d41b189e3b257a7295502","type":"GO_TERM","name":"23S rRNA (guanine(748)-N(1))-methyltransferase activity","canonical_id":"go:GO:0052912","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanine(748) in 23S rRNA = N(1)-methylguanine(748) in 23S rRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.188]","metadata":null},{"id":"93d1f5bb8bf24e5c8b180ec4059f0c20","type":"GO_TERM","name":"23S rRNA pseudouridine(1911/1915/1917) synthase activity","canonical_id":"go:GO:0160140","description":"\"Catalysis of the reaction: uridine(1911/1915/1917) in 23S rRNA = pseudouridine(1911/1915/1917) in 23S rRNA.\" [EC:5.4.99.23, RHEA:42524]","metadata":null},{"id":"45610278fc124b45b271362875a709f7","type":"GO_TERM","name":"23S rRNA pseudouridine(2457) synthase activity","canonical_id":"go:GO:0160137","description":"\"Catalysis of the reaction: uridine(2457) in 23S rRNA = pseudouridine(2457) in 23S rRNA.\" [EC:5.4.99.20, RHEA:38871]","metadata":null},{"id":"b1111728542747949e86e1f571e3f656","type":"GO_TERM","name":"23S rRNA pseudouridine(2604) synthase activity","canonical_id":"go:GO:0160138","description":"\"Catalysis of the reaction: uridine(2604) in 23S rRNA = pseudouridine(2604) in 23S rRNA.\" [EC:5.4.99.21, RHEA:38875]","metadata":null},{"id":"9c91e1b94e6f4c64b51454f841f55f5c","type":"GO_TERM","name":"23S rRNA pseudouridine(2605) synthase activity","canonical_id":"go:GO:0160139","description":"\"Catalysis of the reaction: uridine(2605) in 23S rRNA = pseudouridine(2605) in 23S rRNA.\" [EC:5.4.99.22, RHEA:42520]","metadata":null},{"id":"f153be656ce645afb2f490f3e9fe1ff6","type":"GO_TERM","name":"23S rRNA pseudouridine(746) synthase activity","canonical_id":"go:GO:0160142","description":"\"Catalysis of the reaction: uridine(746) in 23S rRNA = pseudouridine(746) in 23S rRNA.\" [EC:5.4.99.29, RHEA:42548]","metadata":null},{"id":"d3425d081e7041febe2481d72abb0d7a","type":"GO_TERM","name":"23S rRNA pseudouridine(955/2504/2580) synthase activity","canonical_id":"go:GO:0160141","description":"\"Catalysis of the reaction: uridine(955/2504/2580) in 23S rRNA = pseudouridine(955/2504/2580) in 23S rRNA.\" [EC:5.4.99.24, RHEA:42528]","metadata":null},{"id":"74d68c2e646649339c016e77f6e54d34","type":"TRIAL","name":"24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00318656","description":"Non-Insulin-Dependent Diabetes Mellitus","metadata":null},{"id":"a4d3ef98176942c0a504b78436828720","type":"TRIAL","name":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","canonical_id":"clinicaltrials.gov:NCT00981786","description":"Glaucoma","metadata":null},{"id":"d7215895ae7d45b49999f29711b3b014","type":"TRIAL","name":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","canonical_id":"clinicaltrials.gov:NCT02802137","description":"Glaucoma; Ocular Surface Disease","metadata":null},{"id":"badf926a228b4f118022014f11fde3bb","type":"TRIAL","name":"24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.","canonical_id":"clinicaltrials.gov:NCT05299593","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"a3ea4f5dd4b549bca6cfc59aa767e77a","type":"TRIAL","name":"24-hour IOP-lowering Effect of 0.01% Bimatoprost","canonical_id":"clinicaltrials.gov:NCT01271686","description":"Intraocular Pressure; Glaucoma; Ocular Hypertension","metadata":null},{"id":"77430a08f6994f34a8b798b11c9c1eee","type":"TRIAL","name":"24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination","canonical_id":"clinicaltrials.gov:NCT00486486","description":"Glaucoma","metadata":null},{"id":"bdf3f41dae3641ffbbd2ea6960820d87","type":"TRIAL","name":"24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost","canonical_id":"clinicaltrials.gov:NCT00444184","description":"Glaucoma","metadata":null},{"id":"65a40cd8ebde4a2f9a8aa17e77dd0222","type":"TRIAL","name":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","canonical_id":"clinicaltrials.gov:NCT00757835","description":"Glaucoma","metadata":null},{"id":"ad7f4eed56924158aa8e0ac39b532361","type":"TRIAL","name":"24-hr Intraocular Pressure Control With SIMBRINZA \u00ae","canonical_id":"clinicaltrials.gov:NCT02770248","description":"Glaucoma","metadata":null},{"id":"1b634947354f4205b423fba5aed6f078","type":"GO_TERM","name":"24-methylenesterol C-methyltransferase activity","canonical_id":"go:GO:0030797","description":"\"Catalysis of the reaction: 24-methylidenelophenol + S-adenosyl-L-methionine(1+) = (Z)-24-ethylidenelophenol + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.143, RHEA:21044]","metadata":null},{"id":"cb6608a7bb074af6afb6fcfb10f452fc","type":"TRIAL","name":"24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder","canonical_id":"clinicaltrials.gov:NCT00360529","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"05215180163742ceaa2a30c1db73729f","type":"TRIAL","name":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","canonical_id":"clinicaltrials.gov:NCT00976937","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"962bef0d61994e508ea2ebbbeced9bd9","type":"TRIAL","name":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","canonical_id":"clinicaltrials.gov:NCT00975286","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"442593f8720545c2aa77d5231db7166a","type":"GO_TERM","name":"24S-hydroxycholesterol 7-alpha-hydroxylase activity","canonical_id":"go:GO:0033782","description":"\"Catalysis of the reaction: (24S)-hydroxycholesterol + O2 + reduced [NADPH-hemoprotein reductase] = (24S)-7alpha-dihydroxycholesterol + H+ + H2O + oxidized [NADPH-hemoprotein reductase].\" [PMID:10748047, PMID:11013305, RHEA:46124]","metadata":null},{"id":"2b837f9efbe34e628aabc8eefde65e81","type":"GO_TERM","name":"25-hydroxycholecalciferol-23-hydroxylase activity","canonical_id":"go:GO:0062180","description":"\"Catalysis of the reaction: calcidiol + 2 H+ + O2 + 2 reduced [adrenodoxin] = (23S)-23,25-dihydroxycalciol + H2O + 2 oxidized [adrenodoxin].\" [PMID:22100522, PMID:30205156, RHEA:46616]","metadata":null},{"id":"7bd54d0e304c4edf8daaeb5d7cfc7b52","type":"GO_TERM","name":"25-hydroxycholecalciferol-24-hydroxylase activity","canonical_id":"go:GO:0008403","description":"\"Catalysis of the hydroxylation of C-24 of 25-hydroxycholecalciferol (25-hydroxyvitamin D3) to form 24(R),25-dihydroxycholecalciferol.\" [ISBN:0471331309]","metadata":null},{"id":"72e97c75573e4ad1999d5519ba6ea1dd","type":"GO_TERM","name":"25-hydroxycholesterol 7-alpha-hydroxylase activity","canonical_id":"go:GO:0033783","description":"\"Catalysis of the reactions: 25-hydroxycholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 7alpha,25-dihydroxycholesterol + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. Also converts (25R)-cholest-5-ene-3beta,26-diol to (25R)-cholest-5-en-3beta,7alpha,26-triol.\" [EC:1.14.14.29]","metadata":null},{"id":"d6b260aeec90410b80d113aa9edd22a0","type":"PROTEIN","name":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","canonical_id":"uniprot:O15528","description":null,"metadata":null},{"id":"dc0d7c6d0256476295bd19cc264358d0","type":"TRIAL","name":"2nd-line Treatment of Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01532804","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"4ceb506d18fc406ba2e2d34f20e2bc3f","type":"PROTEIN","name":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1","canonical_id":"uniprot:P14060","description":null,"metadata":null},{"id":"8b52163958174f0a86b375bd77427276","type":"GO_TERM","name":"3 iron, 4 sulfur cluster binding","canonical_id":"go:GO:0051538","description":"\"Binding to a 3 iron, 4 sulfur (3Fe-4S) cluster; this cluster consists of three iron atoms, with the inorganic sulfur atoms found between the irons and acting as bridging ligands. It is essentially a 4Fe-4S cluster with one iron missing.\" [GOC:ai, PMID:15952888, Wikipedia:Iron-sulfur_cluster]","metadata":null},{"id":"7c370f47ac3249daa0bba03cc9c6d624","type":"TRIAL","name":"3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00153049","description":"Hypertension","metadata":null},{"id":"924f66b8db9d4b2da09751f9d02d5061","type":"GO_TERM","name":"3' overhang single-stranded DNA endonuclease activity","canonical_id":"go:GO:1990599","description":"\"Catalysis of the hydrolysis of ester linkages within 3' overhang single-stranded deoxyribonucleic acid by creating internal breaks.\" [PMID:25203555]","metadata":null},{"id":"0d465ae955984f9289ffbf54ccc5d99d","type":"GO_TERM","name":"3' transitive RNA interference","canonical_id":"go:GO:1990515","description":"\"An RNA interference where the silencing signal spreads 3' along the target mRNA, outside of the initial target sequence. Typically involves the formation of secondary siRNAs formed when the initial mRNA target sequence functions as a template for 5' to 3' synthesis of new dsRNA.\" [GOC:pf, PMID:24369430]","metadata":null},{"id":"de32b3fb30564fcaa668f10f3ae640d4","type":"GO_TERM","name":"3''-deamino-3''-oxonicotianamine reductase activity","canonical_id":"go:GO:0033707","description":"\"Catalysis of the reaction: 2'-deoxymugineic acid + NAD(P)+ = 3''-deamino-3''-oxonicotianamine + NAD(P)H + H+.\" [EC:1.1.1.285]","metadata":null},{"id":"346916ba23ab4d1fbd58829c9372a4cc","type":"GO_TERM","name":"3'(2'),5'-bisphosphate nucleotidase activity","canonical_id":"go:GO:0008441","description":"\"Catalysis of the reaction: adenosine 3',5'-bisphosphate + H2O = adenosine 5'-phosphate + phosphate.\" [EC:3.1.3.7]","metadata":null},{"id":"64060749375d4939a2a2b42f2cfce98f","type":"GO_TERM","name":"3',2'-cyclic GMP-AMP binding","canonical_id":"go:GO:0140704","description":"\"Binding to 3',2' cyclic GMP-AMP (cGAMP) nucleotide, a cyclic purine dinucleotide that consists of AMP and GMP units cyclized via 3',5' and 2',5' linkages.\" [PMID:34261127]","metadata":null},{"id":"e6f8f76d406b4ba5ba5f32b2b0ceb8a2","type":"GO_TERM","name":"3',2'-cyclic GMP-AMP synthase activity","canonical_id":"go:GO:0140700","description":"\"Catalysis of the reaction: GTP + ATP = 3',2'-cGAMP + 2 diphosphate.\" [PMID:34261127, RHEA:68344]","metadata":null},{"id":"41342032c40142f5aee31bebf4c79196","type":"GO_TERM","name":"3',3'-cyclic GMP-AMP binding","canonical_id":"go:GO:0140703","description":"\"Binding to 3',3' cyclic GMP-AMP (cGAMP) nucleotide, a cyclic purine dinucleotide that consists of AMP and GMP units cyclized via 3',5' and 3',5' linkages.\" [PMID:30787435]","metadata":null},{"id":"d0a8b8cb55bc45f3a271f5763551e4aa","type":"GO_TERM","name":"3',3'-cyclic GMP-AMP synthase activity","canonical_id":"go:GO:0140701","description":"\"Catalysis of the reaction: ATP + GTP = 2 diphosphate + cyclic G-P(3'-5')A-P(3'-5') (cyclic 3',3' GAMP).\" [PMID:30787435, RHEA:35647]","metadata":null},{"id":"98766f57d6a0428e97059edaadbcd391","type":"GO_TERM","name":"3',4',5'-trimethylmyricetin 3-O-methyltransferase activity","canonical_id":"go:GO:0102440","description":"\"Catalysis of the reaction: 3',4',5'-O-trimethylmyricetin + S-adenosyl-L-methionine = 3,3',4',5'-O-tetramethylmyricetin + S-adenosyl-L-homocysteine.\" [RHEA:74771]","metadata":null},{"id":"9cf22195f3804ac3b1054fa1b9911a62","type":"GO_TERM","name":"3',4',5'-trimethylmyricetin 7-O-methyltransferase activity","canonical_id":"go:GO:0102439","description":"\"Catalysis of the reaction: 3',4',5'-O-trimethylmyricetin + S-adenosyl-L-methionine = 7,3',4',5'-O-tetramethylmyricetin + S-adenosyl-L-homocysteine.\" [RHEA:74739]","metadata":null},{"id":"280506627c0f4085bd2b36f68ebb7845","type":"GO_TERM","name":"3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity","canonical_id":"go:GO:0004119","description":"\"Catalysis of the reaction: nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate; catalytic activity is decreased in the presence of cGMP.\" [GOC:mah, PMID:35216259]","metadata":null},{"id":"fc094bebc328492bad19ee46a13acd8e","type":"GO_TERM","name":"3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity","canonical_id":"go:GO:0004118","description":"\"Catalysis of the reaction: nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate; catalytic activity is increased in the presence of cGMP.\" [GOC:mah, PMID:15210692, PMID:35216259]","metadata":null},{"id":"85dda1bbfbc04a73a25bab14f9ef2022","type":"GO_TERM","name":"3',5'-cyclic-AMP phosphodiesterase activity","canonical_id":"go:GO:0004115","description":"\"Catalysis of the reaction: 3',5'-cyclic AMP + H2O = AMP + H+.\" [GOC:ai, RHEA:25277]","metadata":null},{"id":"9e9f1464fe114f9e8165163963de62ca","type":"GO_TERM","name":"3',5'-cyclic-GMP phosphodiesterase activity","canonical_id":"go:GO:0047555","description":"\"Catalysis of the reaction: 3',5'-cyclic GMP + H2O = GMP + H+.\" [RHEA:16957]","metadata":null},{"id":"647b464bb91044b6bd0ea3924998350e","type":"GO_TERM","name":"3',5'-cyclic-nucleotide phosphodiesterase activity","canonical_id":"go:GO:0004114","description":"\"Catalysis of the reaction: a nucleoside 3',5'-cyclic phosphate + H2O = a nucleoside 5'-phosphate.\" [PMID:35216259, RHEA:14653]","metadata":null},{"id":"604b55e3d65f404ab5edba22081b7777","type":"GO_TERM","name":"3',5'-nucleotide bisphosphate phosphatase activity","canonical_id":"go:GO:0097657","description":"\"Catalysis of the reaction: 3',5'-nucleoside bisphosphate + H20 = 5'-nucleoside monophosphate + phosphate.\" [GOC:jh2, PMID:24401123, RHEA:43532]","metadata":null},{"id":"edd226b906fe4773abb865fede98ba1d","type":"GO_TERM","name":"3'-5' DNA helicase activity","canonical_id":"go:GO:0043138","description":"\"Unwinding a DNA helix in the direction 5' to 3', driven by ATP hydrolysis.\" [EC:5.6.2.4, GOC:jl]","metadata":null},{"id":"a79b78b701864e9cb71db8c4df5146d2","type":"GO_TERM","name":"3'-5' DNA/RNA helicase activity","canonical_id":"go:GO:0033679","description":"\"Unwinding of a DNA/RNA duplex in the 3' to 5' direction, driven by ATP hydrolysis.\" [GOC:mah]","metadata":null},{"id":"21c8bb63132245299f4f439c3a7189a5","type":"GO_TERM","name":"3'-5' RNA helicase activity","canonical_id":"go:GO:0034458","description":"\"Unwinding of an RNA helix in the 3' to 5' direction, driven by ATP hydrolysis.\" [GOC:jp]","metadata":null},{"id":"a1ee684a70d14d368ee98600f6f4f830","type":"GO_TERM","name":"3'-5' RNA polymerase activity","canonical_id":"go:GO:0097748","description":"\"Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); the synthesis of RNA from ribonucleotide triphosphates in the presence of a nucleic acid template, via extension of the 5'-end.\" [GOC:pf, PMID:22456265, PMID:27484477, PMID:30917604]","metadata":null},{"id":"236a2f2e13a141d7881a3d08ba1f7c0b","type":"GO_TERM","name":"3'-5' exonuclease activity","canonical_id":"go:GO:0008408","description":"\"Catalysis of the hydrolysis of ester linkages within nucleic acids by removing nucleotide residues from the 3' end.\" [GOC:ai]","metadata":null},{"id":"68d9525fcc0e4f18be09f0d7455dceb3","type":"GO_TERM","name":"3'-5'-DNA exonuclease activity","canonical_id":"go:GO:0008296","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 3' terminus of a DNA molecule.\" [GOC:mah]","metadata":null},{"id":"1a710dd71dec478dad5b3688ac41526b","type":"GO_TERM","name":"3'-5'-RNA exonuclease activity","canonical_id":"go:GO:0000175","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 3' terminus of an RNA molecule.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"104f71324e29438e91fc33833582bf61","type":"GO_TERM","name":"3'-5'-exoribonuclease activity involved in mature miRNA 3'-end processing","canonical_id":"go:GO:0044748","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 3' terminus of an RNA molecule that contributes to forming distinct miRNA isoforms from a mature miRNA.\" [GOC:sart]","metadata":null},{"id":"6f97f114bc5143dd89266580e1a37212","type":"GO_TERM","name":"3'-N-debenzoyl-2'-deoxytaxol N-benzoyltransferase activity","canonical_id":"go:GO:0102923","description":"\"Catalysis of the reaction: 3'-N-debenzoyltaxol + benzoyl-CoA = CoA + H+ + taxol.\" [RHEA:33687]","metadata":null},{"id":"622cb44d649946b08d6c80b7da3aae14","type":"GO_TERM","name":"3'-UTR-mediated mRNA destabilization","canonical_id":"go:GO:0061158","description":"\"An mRNA destabilization process in which one or more RNA-binding proteins associate with the 3'-untranslated region (UTR) of an mRNA.\" [GOC:dph, GOC:jh]","metadata":null},{"id":"f41b5ac21dc94e02a04c539513f3b2fb","type":"GO_TERM","name":"3'-UTR-mediated mRNA stabilization","canonical_id":"go:GO:0070935","description":"\"An mRNA stabilization process in which one or more RNA-binding proteins associate with the 3'-untranslated region (UTR) of an mRNA.\" [GOC:mah, PMID:19029303]","metadata":null},{"id":"862b10a087d149caab0d09a293a41c72","type":"GO_TERM","name":"3'-demethylstaurosporine O-methyltransferase activity","canonical_id":"go:GO:0030793","description":"\"Catalysis of the reaction: 3'-demethylstaurosporine + S-adenosyl-L-methionine = S-adenosyl-L-homocysteine + H+ + staurosporine.\" [EC:2.1.1.139, RHEA:11696]","metadata":null},{"id":"b37beabe482344da90115425279f193d","type":"GO_TERM","name":"3'-deoxyribose phosphate lyase activity","canonical_id":"go:GO:0106334","description":"\"Catalysis of the conversion of a 3'-deoxyribose phosphate in DNA to a 3'-phosphate.\" [GOC:mah, PMID:21276450, PMID:22084197, PMID:22375014, RHEA:65764]","metadata":null},{"id":"7b3133db84f3400fb6de47ef9a13f9d8","type":"GO_TERM","name":"3'-flap endonuclease activity","canonical_id":"go:GO:0048257","description":"\"Catalysis of the cleavage of a 3' flap structure in DNA, but not other DNA structures; processes the 3' ends of Okazaki fragments in lagging strand DNA synthesis.\" [GOC:jid, PMID:10635319]","metadata":null},{"id":"0d345e7e4d11443e98f18968899ada59","type":"GO_TERM","name":"3'-flap-structured DNA binding","canonical_id":"go:GO:0070337","description":"\"Binding to a 3'-flap structure in DNA. A DNA flap structure is one in which a single-stranded 3'-end of DNA or RNA protrudes from a double-stranded DNA molecule.\" [GOC:mah, PMID:15189154]","metadata":null},{"id":"e7c8c1f54bc64b7bb5dffe1b863d6fde","type":"GO_TERM","name":"3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase activity","canonical_id":"go:GO:0030784","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 3'-hydroxy-N-methyl-(S)-coclaurine = S-adenosyl-L-homocysteine + (S)-reticuline.\" [EC:2.1.1.116]","metadata":null},{"id":"9b1d534bacc8419b8209f57a0f8bd3ea","type":"GO_TERM","name":"3'-nucleotidase activity","canonical_id":"go:GO:0008254","description":"\"Catalysis of the reaction: a 3'-ribonucleotide + H2O = a ribonucleoside + phosphate.\" [EC:3.1.3.6]","metadata":null},{"id":"d6672eeeafb340fdb8f5b8c505f6358d","type":"GO_TERM","name":"3'-phospho-5'-adenylyl sulfate transmembrane transport","canonical_id":"go:GO:1902559","description":"\"The process in which 3'-phospho-5'-adenylyl sulfate is transported across a membrane.\" [GOC:TermGenie, PMID:24296033]","metadata":null},{"id":"6c0725d6f97448e9b3292aee24c60798","type":"GO_TERM","name":"3'-phosphoadenosine 5'-phosphosulfate binding","canonical_id":"go:GO:0050656","description":"\"Binding to 3'-phosphoadenosine 5'-phosphosulfate (PAPS), a naturally occurring mixed anhydride. It is an intermediate in the formation of a variety of sulfo compounds in biological systems.\" [GOC:ai]","metadata":null},{"id":"56314fa01931456bb45b56e3d693ea84","type":"GO_TERM","name":"3'-phosphoadenosine 5'-phosphosulfate biosynthetic process","canonical_id":"go:GO:0050428","description":"\"The chemical reactions and pathways resulting in the formation of 3'-phosphoadenosine 5'-phosphosulfate, a naturally occurring mixed anhydride. It is an intermediate in the formation of a variety of sulfo compounds in biological systems.\" [ISBN:0198506732]","metadata":null},{"id":"52ba5eed583a4ab580d77b10c397a044","type":"GO_TERM","name":"3'-phosphoadenosine 5'-phosphosulfate metabolic process","canonical_id":"go:GO:0050427","description":"\"The chemical reactions and pathways involving 3'-phosphoadenosine 5'-phosphosulfate, a naturally occurring mixed anhydride. It is an intermediate in the formation of a variety of sulfo compounds in biological systems.\" [ISBN:0198506732]","metadata":null},{"id":"160b1a14162e4b33aacf9aec52e77097","type":"GO_TERM","name":"3'-phosphoadenosine 5'-phosphosulfate transmembrane transporter activity","canonical_id":"go:GO:0046964","description":"\"Enables the transfer of 3'-phosphoadenosine 5'-phosphosulfate, a naturally occurring mixed anhydride synthesized from adenosine 5'-phosphosulfate, from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"fd3ff540720a43f9a4033acd40f54401","type":"GO_TERM","name":"3'-phosphoadenosine 5'-phosphosulfate transport","canonical_id":"go:GO:0046963","description":"\"The directed movement of 3'-phosphoadenosine 5'-phosphosulfate, a naturally occurring mixed anhydride synthesized from adenosine 5'-phosphosulfate, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [ISBN:0198506732]","metadata":null},{"id":"ffa76a363a6940e9862abd071423530d","type":"GO_TERM","name":"3'-phosphoadenylylselenate reductase activity","canonical_id":"go:GO:0098624","description":"\"Catalysis of the reaction: 3'-phosphoadenylylselenate + NADPH = adenosine 3',5'-bisphosphate + selenite + NADP+ + H+.\" [PMID:14723223]","metadata":null},{"id":"d29466e410b040019ad7e5c369b4bce9","type":"GO_TERM","name":"3'-tRNA processing endoribonuclease activity","canonical_id":"go:GO:0042781","description":"\"Catalysis of the endonucleolytic cleavage of RNA, removing extra 3' nucleotides from tRNA precursor, generating 3' termini of tRNAs. A 3'-hydroxy group is left at the tRNA terminus and a 5'-phosphoryl group is left at the trailer molecule.\" [EC:3.1.26.11, PMID:12032089, PMID:21208191]","metadata":null},{"id":"49f9bbce331446668bbaaf4eb7791088","type":"GO_TERM","name":"3'-tyrosyl-DNA phosphodiesterase activity","canonical_id":"go:GO:0017005","description":"\"Catalysis of the hydrolysis of 3'-phosphotyrosyl groups formed as covalent intermediates (in DNA backbone breakage) between DNA topoisomerase I and DNA.\" [PMID:10521354, PMID:16751265]","metadata":null},{"id":"a30ba1de1d9c4ff4a0537a545ce98168","type":"GO_TERM","name":"3,4-dichloroaniline N-malonyltransferase activity","canonical_id":"go:GO:0047163","description":"\"Catalysis of the reaction: 3,4-dichloroaniline + malonyl-CoA = N-(3,4-dichlorophenyl)malonamate + CoA.\" [EC:2.3.1.114, RHEA:21060]","metadata":null},{"id":"9bd6114ed57e4d31a6174f30005b560a","type":"GO_TERM","name":"3,4-dichlorobenzoate-4,5-oxygenase activity","canonical_id":"go:GO:0102046","description":"\"Catalysis of the reaction: 3,4-dichlorobenzoate + O2 + a reduced electron acceptor = 3,4-dichlorobenzoate-cis-4,5-diol + an oxidized electron acceptor.\" [GOC:pz, PMID:9322760]","metadata":null},{"id":"0d21e41455384fa19299aecf567f2950","type":"GO_TERM","name":"3,4-didehydroretinal binding","canonical_id":"go:GO:0046876","description":"\"Binding to 3,4-didehydroretinal, a form of retinal that plays a role in the visual process in freshwater fish and some amphibians analogous to that of all-trans retinal in other vertebrates. 3,4-didehydro-11-cis-retinal combines with an opsin to form cyanopsin (cone) or porphyropsin (rod).\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"572381be29c248edb36f0a22618ad7cc","type":"GO_TERM","name":"3,4-dihydroxy-2-butanone-4-phosphate synthase activity","canonical_id":"go:GO:0008686","description":"\"Catalysis of the reaction: D-ribulose 5-phosphate = (2S)-2-hydroxy-3-oxobutyl phosphate + formate + H+.\" [EC:4.1.99.12, RHEA:18457]","metadata":null},{"id":"827d2516eef145fe8de71876104feb82","type":"GO_TERM","name":"3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 4,5-dioxygenase activity","canonical_id":"go:GO:0047071","description":"\"Catalysis of the reaction: 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione + O2 = 3-hydroxy-5,9,17-trioxo-4,5:9,10-disecoandrosta-1(10),2-dien-4-oate + H+.\" [EC:1.13.11.25, RHEA:21352]","metadata":null},{"id":"fee5b67449e74487bb254ef1228d2e19","type":"GO_TERM","name":"3,4-dihydroxybenzoate biosynthetic process","canonical_id":"go:GO:0046279","description":"\"The chemical reactions and pathways resulting in the formation of 3,4-dihydroxybenzoate.\" [GOC:ai]","metadata":null},{"id":"730bf7a52ab34ee4a9ac7722f15f9dd2","type":"GO_TERM","name":"3,4-dihydroxybenzoate catabolic process","canonical_id":"go:GO:0019619","description":"\"The chemical reactions and pathways resulting in the breakdown of 3,4-dihydroxybenzoate.\" [GOC:ai]","metadata":null},{"id":"8710590580ae4350822ce6c88b58bf04","type":"GO_TERM","name":"3,4-dihydroxybenzoate metabolic process","canonical_id":"go:GO:0046278","description":"\"The chemical reactions and pathways involving protocatechuate, the anion of protocatechuic acid (3,4-dihydroxybenzoic acid).\" [GOC:ai, PMID:24359411]","metadata":null},{"id":"48594f679bf24b9d8ad701298d40e362","type":"GO_TERM","name":"3,4-dihydroxyphenylacetaldehyde synthase activity","canonical_id":"go:GO:0106425","description":"\"Catalysis of the reaction: L-dopa + O2 + H2O + H+ = 3,4-dihydroxyphenylacetaldehyde + CO2 + NH(4)+ + H2O2.\" [PMID:21283636, RHEA:55524]","metadata":null},{"id":"868b3ef990384041af56a1070e69b775","type":"GO_TERM","name":"3,4-dihydroxyphenylacetate 2,3-dioxygenase activity","canonical_id":"go:GO:0008687","description":"\"Catalysis of the reaction: 3,4-dihydroxyphenylacetate + O2 = 5-formyl-2-hydroxyhepta-2,4-dienedioate + H+.\" [RHEA:15633]","metadata":null},{"id":"b56a1d2f505b42fb91c621b0c6e3d88c","type":"GO_TERM","name":"3,4-dihydroxyphthalate decarboxylase activity","canonical_id":"go:GO:0047556","description":"\"Catalysis of the reaction: 3,4-dihydroxyphthalate + H+ = 3,4-dihydroxybenzoate + CO2.\" [EC:4.1.1.69, RHEA:18601]","metadata":null},{"id":"e7dbb300b960457dbfb66a8337a9292e","type":"GO_TERM","name":"3,5 dichloro-THPH synthase activity","canonical_id":"go:GO:0106267","description":"\"Catalysis of the reaction: (3-chloro-2,4,6-trihydroxyphenyl)hexan-1-one + chloride + FADH2 + O2 = (3,5-dichloro-2,4,6-trihydroxyphenyl)hexan-1-one + FAD + 2 H2O.\" [PMID:20231486, RHEA:64360]","metadata":null},{"id":"6a661f2938714a71a3da50d12a86a12f","type":"GO_TERM","name":"3,5-dichloro-THPH methyl transferase activity","canonical_id":"go:GO:0106268","description":"\"Catalysis of the reaction: (3,5-dichloro-2,4,6-trihydroxyphenyl)hexan-1-one + S-adenosyl-L-methionine = 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one + H+ + S-adenosyl-L-homocysteine.\" [PMID:20231486, RHEA:48396]","metadata":null},{"id":"ec1cba9a5398489f8176e28bf47ed153","type":"GO_TERM","name":"3,5-diiodo-L-tyrosine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047861","description":"\"Catalysis of the reaction: 2-oxoglutarate + 3,5-diiodo-L-tyrosine = 3-(3,5-diiodo-4-hydroxyphenyl)pyruvate + L-glutamate.\" [RHEA:19781]","metadata":null},{"id":"0fa189096686424589ef389278cb1745","type":"GO_TERM","name":"3,7-dimethylquercitin 4'-O-methyltransferase activity","canonical_id":"go:GO:0030758","description":"\"Catalysis of the reaction: 3',4',5-trihydroxy-3,7-dimethoxyflavone + S-adenosyl-L-methionine(1+) = 3',5-dihydroxy-3,4',7-trimethoxyflavone + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.83, RHEA:21832]","metadata":null},{"id":"01d4fa1b183148318feb3d08da7cbaf9","type":"GO_TERM","name":"3,8-divinyl protochlorophyllide a 8-vinyl-reductase (NADPH) activity","canonical_id":"go:GO:0033728","description":"\"Catalysis of the reaction: protochlorophyllide a + NADP+ = 3,8-divinyl protochlorophyllide a + NADPH + H+, and chlorophyllide a + NADP+ = 3,8-divinyl chlorophyllide a + NADPH + H+.\" [EC:1.3.1.75]","metadata":null},{"id":"ddaedd6b31974f2a9d90c3c001817f57","type":"GO_TERM","name":"3,9-dihydroxypterocarpan 6a-monooxygenase activity","canonical_id":"go:GO:0047082","description":"\"Catalysis of the reaction: (6aR,11aR)-3,9-dihydroxypterocarpan + H+ + NADPH + O2 = (6aS,11aS)-3,6a,9-trihydroxypterocarpan + H2O + NADP+. (6aS,11aS)-3,6a,9-trihydroxypterocarpan is also known as (-)-glycinol.\" [EC:1.14.14.93, RHEA:15321]","metadata":null},{"id":"168d7187e274401db1a20ffc32849d8b","type":"GO_TERM","name":"3-(2,3-dihydroxyphenyl)propanoate biosynthetic process","canonical_id":"go:GO:1901792","description":"\"The chemical reactions and pathways resulting in the formation of 3-(2,3-dihydroxyphenyl)propanoate.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"22db79926ccf49aea182b6ac979c0a3d","type":"GO_TERM","name":"3-(3-hydroxy)phenylpropionate catabolic process","canonical_id":"go:GO:0019622","description":"\"The chemical reactions and pathways resulting in the breakdown of 3-(3-hydroxy)phenylpropionate, a hydroxylated derivative of phenylpropionate.\" [GOC:ai]","metadata":null},{"id":"cbc9547226e44766b1c0f65c3fe86a46","type":"GO_TERM","name":"3-(3-hydroxyphenyl)propanoate biosynthetic process","canonical_id":"go:GO:1901795","description":"\"The chemical reactions and pathways resulting in the formation of 3-(3-hydroxyphenyl)propanoate.\" [GOC:TermGenie, GOC:yaf, PMID:10537203]","metadata":null},{"id":"d0e492e2d52743d9920ef73ea083d3d3","type":"GO_TERM","name":"3-(3-hydroxyphenyl)propanoate catabolic process","canonical_id":"go:GO:1901794","description":"\"The chemical reactions and pathways resulting in the breakdown of 3-(3-hydroxyphenyl)propanoate.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY0-1277, PMID:10537203, UniPathway:UPA00835]","metadata":null},{"id":"575c0ccc6955433e865c93215bd42069","type":"GO_TERM","name":"3-(3-hydroxyphenyl)propionate hydroxylase activity","canonical_id":"go:GO:0008688","description":"\"Catalysis of the reaction: 3-(3-hydroxyphenyl)propionate + NADH + oxygen + H+ = 3-(2,3-dihydroxyphenyl)propionate + NAD+ + H2O.\" [RHEA:24785]","metadata":null},{"id":"26fc1e2c2e794a3b92dc65e893725f47","type":"GO_TERM","name":"3-(hydroxyamino)phenol mutase activity","canonical_id":"go:GO:0034022","description":"\"Catalysis of the reaction: 3-hydroxyaminophenol = aminohydroquinone.\" [EC:5.4.4.3, RHEA:20577]","metadata":null},{"id":"b07174d62af84f88adb955008fe1d94f","type":"GO_TERM","name":"3-(imidazol-5-yl)lactate dehydrogenase activity","canonical_id":"go:GO:0019155","description":"\"Catalysis of the reaction: (S)-3-(imidazol-5-yl)lactate + NADP+ = 3-(imidazol-5-yl)pyruvate + NADPH + H+.\" [EC:1.1.1.111]","metadata":null},{"id":"d9ba602366d04f858bad13bcdb162b78","type":"TRIAL","name":"3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)","canonical_id":"clinicaltrials.gov:NCT00159744","description":"Bipolar Disorder","metadata":null},{"id":"c11a4b172738431f9765e42878527650","type":"GO_TERM","name":"3-aci-nitropropanoate oxidase activity","canonical_id":"go:GO:0047557","description":"\"Catalysis of the reaction: 3-aci-nitropropanoate + H2O + O2 = 3-oxopropanoate + H2O2 + nitrite.\" [EC:1.7.3.5, RHEA:22372]","metadata":null},{"id":"085b8053c61b47768dd6c352b3d0893d","type":"GO_TERM","name":"3-alpha,7-alpha-dihydroxy-5-beta-cholestanate-CoA ligase activity","canonical_id":"go:GO:0047476","description":"\"Catalysis of the reaction: CoA + 3-alpha,7-alpha-dihydroxy-5-beta-cholestanate + ATP = 3-alpha,7-alpha-dihydroxy-5-beta-cholestanoyl-CoA + diphosphate + AMP.\" [EC:6.2.1.28, MetaCyc:6.2.1.28-RXN]","metadata":null},{"id":"8cd9ea0233c64e5c96acbb15d215a132","type":"GO_TERM","name":"3-alpha-hydroxy-5-beta-androstane-17-one 3-alpha-dehydrogenase activity","canonical_id":"go:GO:0047009","description":"\"Catalysis of the reaction: NAD+ + 3-alpha-hydroxy-5-beta-androstane-17-one = NADH + H+ + 5-beta-androstane-3,17-dione.\" [EC:1.1.1.152, MetaCyc:1.1.1.152-RXN]","metadata":null},{"id":"ddaddf007ebe40fc89c7c8049a2689f7","type":"GO_TERM","name":"3-alpha-hydroxycholanate dehydrogenase activity","canonical_id":"go:GO:0047043","description":"\"Catalysis of the reaction: lithocholate + NAD+ = 3-oxo-5beta-cholanate + H+ + NADH.\" [EC:1.1.1.52, RHEA:19585]","metadata":null},{"id":"fc31c7c0ad56411b93c867971b956e4d","type":"GO_TERM","name":"3-alpha-hydroxyglycyrrhetinate dehydrogenase activity","canonical_id":"go:GO:0047032","description":"\"Catalysis of the reaction: 3alpha-hydroxyglycyrrhetinate + NADP+ = 3-oxoglycyrrhetinate + H+ + NADPH.\" [EC:1.1.1.230, RHEA:20816]","metadata":null},{"id":"2710e6b143484c2785982d72adaa6f11","type":"GO_TERM","name":"3-alpha-hydroxysteroid 3-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0140169","description":"\"Catalysis of the reaction: a 3alpha-hydroxysteroid + NAD(P)+ = a 3-oxosteroid + NAD(P)H + H+.\" [EC:1.1.1.357]","metadata":null},{"id":"0a18852018c44aefa005a6f7dfa5cb33","type":"GO_TERM","name":"3-aminobutyryl-CoA ammonia-lyase activity","canonical_id":"go:GO:0047459","description":"\"Catalysis of the reaction: (S)-3-aminobutanoyl-CoA = crotonoyl-CoA + NH4.\" [EC:4.3.1.14, RHEA:10056]","metadata":null},{"id":"fdfc9fb597c5499992e05d6f1a25cd71","type":"GO_TERM","name":"3-aminomethylindole N-methyltransferase activity","canonical_id":"go:GO:0102913","description":"\"Catalysis of the reaction: 3-(aminomethyl)indole + 2 S-adenosyl-L-methionine = gramine + 2 S-adenosyl-L-homocysteine + 2 H+.\" [RHEA:52264]","metadata":null},{"id":"6f9049ddad7945258eecc32c0cf7aaa0","type":"GO_TERM","name":"3-aminopropanal dehydrogenase (NAD+) activity","canonical_id":"go:GO:0102244","description":"\"Catalysis of the reaction: 3-aminopropanal + H2O + NAD+ = beta-alanine + 2 H+ + NADH.\" [RHEA:30695]","metadata":null},{"id":"8f302ba5c77841aea1272872fbf8f9e8","type":"TRIAL","name":"3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial","canonical_id":"clinicaltrials.gov:NCT01563354","description":"Neuroendocrine Carcinoma of the Lung and Thymus","metadata":null},{"id":"3580b3420ca544fc83d8960a2dc2271e","type":"GO_TERM","name":"3-beta-hydroxy-5-alpha-steroid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0033704","description":"\"Catalysis of the reaction: -3beta-hydroxy-5alpha-pregnane-20-one + NADP+ = 5-alpha-pregnane-3,20-dione + H+ + NADPH.\" [RHEA:18137]","metadata":null},{"id":"6b0a52ec3bc443dba83279e46c748669","type":"GO_TERM","name":"3-beta-hydroxy-5-beta-steroid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0033703","description":"\"Catalysis of the reaction: 3-beta-hydroxy-5-beta-pregnane-20-one + NADP+ = 5-beta-pregnan-3,20-dione + H+ + NADPH.\" [RHEA:22944]","metadata":null},{"id":"a1f402be85e641b3829ac169b9922f7f","type":"GO_TERM","name":"3-beta-hydroxy-Delta5-steroid dehydrogenase (NAD+) activity","canonical_id":"go:GO:0003854","description":"\"Catalysis of the reaction: a 3-beta-hydroxy-Delta(5)-steroid + NAD+ = a 3-oxo-Delta(5)-steroid + NADH + H+. Also acts on on 3-beta-hydroxypregn-5-en-20-one to form progesterone.\" [EC:1.1.1.145]","metadata":null},{"id":"89d6008790514ad5a9afcaa6a730d97e","type":"GO_TERM","name":"3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0000253","description":"\"Catalysis of the reaction: a 3-betahydroxyl sterol + NADP+ = a 3-oxosterol sterol + NADPH + H+.\" [EC:1.1.1.270, PMID:9811880]","metadata":null},{"id":"7655603c4f114fe89a8c3109a2c98d86","type":"GO_TERM","name":"3-beta-hydroxysteroid dehydrogenase (NAD+)/C4-decarboxylase activity","canonical_id":"go:GO:0102175","description":"\"Catalysis of the reaction: a 3-beta-hydroxysteroid-4-alpha-carboxylate + NAD+ = a 3-oxosteroid + CO2 + NADH.\" [RHEA:34775]","metadata":null},{"id":"802c54989f5d41cfbdd07db4892aa728","type":"GO_TERM","name":"3-beta-hydroxysteroid dehydrogenase [NAD(P)+]/C4-decarboxylase activity","canonical_id":"go:GO:0000252","description":"\"Catalysis of the reaction: a 3-beta-hydroxysteroid-4-alpha-carboxylate + NADP+ = a 3-oxosteroid + CO2 + NADPH.\" [EC:1.1.1.170, PMID:9811880]","metadata":null},{"id":"3216517a1b6348d5b2717d55b7cc7978","type":"GO_TERM","name":"3-butenylglucosinolate 2-hydroxylase activity","canonical_id":"go:GO:0062131","description":"\"Catalysis of the reaction: gluconapin + a reduced electron acceptor + O2 = progoitrin + an oxidized electron acceptor + H2O.\" [PMID:18945935, RHEA:60628]","metadata":null},{"id":"13b33adfda514b578b4b84ce2f89a4b0","type":"GO_TERM","name":"3-carboxy-cis,cis-muconate cycloisomerase activity","canonical_id":"go:GO:0047472","description":"\"Catalysis of the reaction: 2-(carboxymethyl)-5-oxo-2,5-dihydro-2-furoate = 3-carboxy-cis,cis-muconate + H+.\" [PMID:15301541, PMID:17054713, RHEA:23656]","metadata":null},{"id":"0d5d6cfad41447e49ba20c2cac14ff13","type":"GO_TERM","name":"3-carboxyethylcatechol 2,3-dioxygenase activity","canonical_id":"go:GO:0047070","description":"\"Catalysis of the reaction: O2 + 3-(2,3-dihydroxyphenyl)propanoate = 2-hydroxy-6-oxonona-2,4-diene-1,9-dioate.\" [EC:1.13.11.16, MetaCyc:1.13.11.16-RXN]","metadata":null},{"id":"3c284102e70a4cbfbb683c80b72c7f77","type":"GO_TERM","name":"3-chloro THPH synthase activity","canonical_id":"go:GO:0106266","description":"\"Catalysis of the reaction: 2,4,6-trihydroxyphenylhexan-1-one + chloride + FADH2 + O2 = (3-chloro-2,4,6-trihydroxyphenyl)hexan-1-one + FAD + H+ + 2 H2O.\" [PMID:20231486, RHEA:64356]","metadata":null},{"id":"27d1606cbffd496fba5df446543b3316","type":"GO_TERM","name":"3-chloro-D-alanine dehydrochlorinase activity","canonical_id":"go:GO:0019149","description":"\"Catalysis of the reaction: 3-chloro-D-alanine + H2O = chloride + pyruvate + NH4+ + H+.\" [RHEA:18873]","metadata":null},{"id":"097fc78e32d54505b115c1efb3d87c2d","type":"GO_TERM","name":"3-chloroallyl aldehyde dehydrogenase activity","canonical_id":"go:GO:0004028","description":"\"Catalysis of the reaction: 3-chloroallyl aldehyde + H2O = 2 H+ + 2 e- + 3-chloroacrylic acid.\" [GOC:curators]","metadata":null},{"id":"b881048ea5b04859a8871cffe828918c","type":"GO_TERM","name":"3-chlorobenzoate-3,4-oxygenase activity","canonical_id":"go:GO:0102045","description":"\"Catalysis of the reaction: 3-chlorobenzoate + O2 + a reduced electron acceptor = 3-chlorobenzoate-cis-3,4-diol + an oxidized electron acceptor.\" [PMID:38488372, PMID:8285670]","metadata":null},{"id":"9d4d9457fbed4dd8ac58e7cb288fa23d","type":"GO_TERM","name":"3-chlorocatechol biosynthetic process","canonical_id":"go:GO:1901169","description":"\"The chemical reactions and pathways resulting in the formation of 3-chlorocatechol.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00083]","metadata":null},{"id":"715d793e25ac4f399b23f2dc483f9f7b","type":"GO_TERM","name":"3-chlorocatechol catabolic process","canonical_id":"go:GO:1901168","description":"\"The chemical reactions and pathways resulting in the breakdown of 3-chlorocatechol.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00083]","metadata":null},{"id":"4fb36870a4984549acb42ccd5c82ae1f","type":"GO_TERM","name":"3-cyanoalanine hydratase activity","canonical_id":"go:GO:0047558","description":"\"Catalysis of the reaction: L-asparagine = 3-cyano-L-alanine + H2O + H+.\" [EC:4.2.1.65, RHEA:15385]","metadata":null},{"id":"78e965177eaa47e19e360e4547be2b4e","type":"GO_TERM","name":"3-dehydro-L-gulonate 2-dehydrogenase activity","canonical_id":"go:GO:0047559","description":"\"Catalysis of the reaction: 3-dehydro-L-gulonate + NAD(P)+ = (4R,5S)-4,5,6-trihydroxy-2,3-dioxohexanoate + NAD(P)H + H+.\" [EC:1.1.1.130, MetaCyc:3-DEHYDRO-L-GULONATE-2-DEHYDROGENASE-RXN]","metadata":null},{"id":"a26a7caa72214c5d9a214bfa14782e09","type":"GO_TERM","name":"3-dehydro-L-gulonate-6-phosphate decarboxylase activity","canonical_id":"go:GO:0033982","description":"\"Catalysis of the reaction: 3-dehydro-L-gulonate 6-phosphate + H+ = L-xylulose 5-phosphate + CO2.\" [EC:4.1.1.85, RHEA:14353]","metadata":null},{"id":"14c91d0313f141fe92add2c3f8997380","type":"GO_TERM","name":"3-dehydroquinate dehydratase activity","canonical_id":"go:GO:0003855","description":"\"Catalysis of the reaction: 3-dehydroquinate = 3-dehydroshikimate + H2O.\" [EC:4.2.1.10, RHEA:21096]","metadata":null},{"id":"719bf26cb8924029b74d29e1e448b8d5","type":"GO_TERM","name":"3-dehydroquinate synthase activity","canonical_id":"go:GO:0003856","description":"\"Catalysis of the reaction: 7-phospho-2-dehydro-3-deoxy-D-arabino-heptonate = 3-dehydroquinate + phosphate.\" [EC:4.2.3.4, RHEA:21968]","metadata":null},{"id":"f191ec847e9c41d08ef212ec9247b344","type":"GO_TERM","name":"3-dehydroshikimate dehydratase activity","canonical_id":"go:GO:0046565","description":"\"Catalysis of the reaction: 3-dehydroshikimate = 3,4-dihydroxybenzoate + H2O. 3,4-dihydroxybenzoate is also known as protocatechuate.\" [EC:4.2.1.118, MetaCyc:DHSHIKIMATE-DEHYDRO-RXN]","metadata":null},{"id":"3c7931479d1a4b77bee494463f4d4181","type":"GO_TERM","name":"3-dehydrosphinganine reductase activity","canonical_id":"go:GO:0047560","description":"\"Catalysis of the reaction: NADP+ + sphinganine = 3-dehydrosphinganine + H+ + NADPH.\" [EC:1.1.1.102, RHEA:22640]","metadata":null},{"id":"8f035cb952b541379104da6e32f360c2","type":"GO_TERM","name":"3-demethoxyubiquinol 3-hydroxylase activity","canonical_id":"go:GO:0008682","description":"\"Catalysis of the reaction: a 6-methoxy-3-methyl-2-all-trans-polyprenyl-1,4-benzoquinol + donor-H2 + O2 = acceptor + a 3-demethylubiquinol + H2O.\" [RHEA:50908]","metadata":null},{"id":"7a0dc229a6c547dfa7cbd9f10ff0af7f","type":"GO_TERM","name":"3-demethoxyubiquinone 3-hydroxylase (NADH) activity","canonical_id":"go:GO:0160224","description":"\"Catalysis of the reaction: a 5-methoxy-2-methyl-3-(all-trans-polyprenyl)benzoquinone + NADH + O2 = a 3-demethylubiquinone + NAD+ + H2O.\" [PMID:23445365, PMID:38425362, RHEA:81211]","metadata":null},{"id":"e00080314cd04661a793043762cf1382","type":"GO_TERM","name":"3-demethylubiquinol 3-O-methyltransferase activity","canonical_id":"go:GO:0061542","description":"\"Catalysis of the reaction: a 3-demethylubiquinol + S-adenosyl-L-methionine = a ubiquinol + S-adenosyl-L-homocysteine + H+.\" [PMID:10777520, PMID:23190198, RHEA:44380]","metadata":null},{"id":"3b4d0697549544ebb9208c8282bcf9e2","type":"GO_TERM","name":"3-demethylubiquinone 3-O-methyltransferase activity","canonical_id":"go:GO:0120537","description":"\"Catalysis of the reaction: a 3-demethylubiquinone + S-adenosyl-L-methionine = a ubiquinone + S-adenosyl-L-homocysteine.\" [PMID:38425362, RHEA:81215]","metadata":null},{"id":"bc5fafb9b5a94451bdeb32f199158578","type":"GO_TERM","name":"3-deoxy-2-octulosonidase activity","canonical_id":"go:GO:0033937","description":"\"Catalysis of the endohydrolysis of the beta-ketopyranosidic linkages of 3-deoxy-D-manno-2-octulosonate in capsular polysaccharides.\" [EC:3.2.1.124]","metadata":null},{"id":"5360f68b211f4c59b1b0a0e4ad5a65ab","type":"GO_TERM","name":"3-deoxy-7-phosphoheptulonate synthase activity","canonical_id":"go:GO:0003849","description":"\"Catalysis of the reaction: D-erythrose 4-phosphate + H2O + phosphoenolpyruvate = 7-phospho-2-dehydro-3-deoxy-D-arabino-heptonate + phosphate.\" [EC:2.5.1.54, RHEA:14717]","metadata":null},{"id":"3f6a37df547949b78cf5c7be37813765","type":"GO_TERM","name":"3-deoxy-8-phosphooctulonate synthase activity","canonical_id":"go:GO:0008676","description":"\"Catalysis of the reaction: D-arabinose 5-phosphate + H2O + phosphoenolpyruvate = 8-phospho-3-deoxy-D-manno-oct-2-ulosonate + 2 H+ + phosphate.\" [EC:2.5.1.55, RHEA:14053]","metadata":null},{"id":"0ffdcd9acbee411483bfafff6ba889a7","type":"GO_TERM","name":"3-deoxy-D-glycero-D-galacto-2-nonulosonic acid hydrolase activity","canonical_id":"go:GO:0052791","description":"\"Catalysis of the reaction: (2-keto-3-deoxynononic acid)n + H2O = (2-keto-3-deoxynononic acid)n-1 + 2-keto-3-deoxynononic acid. This reaction is the hydrolysis of a 2-keto-3-deoxynononic acid residue from a poly-2-keto-3-deoxynononic acid chain.\" [GOC:mengo_curators, PMID:21247893]","metadata":null},{"id":"6351522d60924538830ff262ddc980cd","type":"GO_TERM","name":"3-deoxy-D-manno-octulosonate aldolase activity","canonical_id":"go:GO:0047439","description":"\"Catalysis of the reaction: 3-deoxy-D-manno-octulosonate = D-arabinose + pyruvate.\" [EC:4.1.2.23, RHEA:23340]","metadata":null},{"id":"b80193c4e4db4d428f0d5aa0e703d41d","type":"GO_TERM","name":"3-deoxy-manno-octulosonate cytidylyltransferase activity","canonical_id":"go:GO:0008690","description":"\"Catalysis of the reaction: CTP + 3-deoxy-D-manno-octulosonate = diphosphate + CMP-3-deoxy-D-manno-octulosonate.\" [EC:2.7.7.38]","metadata":null},{"id":"60af0dd9341e48b4a4550574137fac4c","type":"GO_TERM","name":"3-deoxy-manno-octulosonate-8-phosphatase activity","canonical_id":"go:GO:0019143","description":"\"Catalysis of the reaction: 8-phospho-3-deoxy-D-manno-oct-2-ulosonate + H2O = 3-deoxy-D-manno-octulosonate + phosphate.\" [EC:3.1.3.45, RHEA:11500]","metadata":null},{"id":"018f08c816cf44d2bc2813b0a054acdc","type":"GO_TERM","name":"3-deoxyglucosone dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106373","description":"\"Catalysis of the reaction: 3-deoxyglucosone + H2O + NAD+ = 2-dehydro-3-deoxy-D-gluconate + 2 H+ + NADH.\" [PMID:17175089, RHEA:67244]","metadata":null},{"id":"3e30a162d6444f1d9c6c4e528ccd7ce6","type":"GO_TERM","name":"3-deoxyoctulosonase activity","canonical_id":"go:GO:0050534","description":"\"Catalysis of the reaction: 3-deoxyoctulosonyl-lipopolysaccharide + H2O = 3-deoxyoctulosonic acid + lipopolysaccharide.\" [EC:3.2.1.144]","metadata":null},{"id":"661fc0b52bce485493797088ee5027c8","type":"GO_TERM","name":"3-ethylmalate synthase activity","canonical_id":"go:GO:0050441","description":"\"Catalysis of the reaction: butanoyl-CoA + glyoxylate + H2O = 3-ethylmalate + CoA + H+.\" [RHEA:10500]","metadata":null},{"id":"585d295e38a048af88fae6a80573ac1a","type":"GO_TERM","name":"3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity","canonical_id":"go:GO:0017060","description":"\"Catalysis of the reaction: GDP-L-fucose + beta-D-galactosyl-(1,3)-N-acetyl-D-glucosaminyl-R = GDP + beta-D-galactosyl-(1,3)-[alpha-L-fucosyl-(1,4)]-N-acetyl-D-glucosaminyl-R.\" [EC:2.4.1.65]","metadata":null},{"id":"78fbae0a0c54464382f653bed781ce15","type":"GO_TERM","name":"3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity","canonical_id":"go:GO:0047015","description":"\"Catalysis of the reaction: NAD+ + 2-methyl-3-hydroxybutyryl-CoA = NADH + H+ + 2-methylaceto-acetyl-CoA.\" [EC:1.1.1.178, MetaCyc:1.1.1.178-RXN]","metadata":null},{"id":"8cdb2c7a56d249ef9b4874aed4ce1b1e","type":"GO_TERM","name":"3-hydroxy-2-methylpyridine-4,5-dicarboxylate 4-decarboxylase activity","canonical_id":"go:GO:0047431","description":"\"Catalysis of the reaction: 5-hydroxy-6-methylpyridine-3,4-dicarboxylate + H+ = 5-hydroxy-6-methylpyridine-3-carboxylate + CO2.\" [EC:4.1.1.51, RHEA:13669]","metadata":null},{"id":"9c1a413b979047a4bf1121febd572cd7","type":"GO_TERM","name":"3-hydroxy-2-methylpyridine-5-carboxylate monooxygenase [NAD(P)H] activity","canonical_id":"go:GO:0047081","description":"\"Catalysis of the reaction: 3-hydroxy-2-methylpyridine-5-carboxylate + NAD(P)H + O2 = 2-(acetamidomethylene)succinate + NAD(P)+.\" [EC:1.14.13.242]","metadata":null},{"id":"37187b9e29094c3a85d8da3d17233cb8","type":"GO_TERM","name":"3-hydroxy-2-methylquinolin-4-one 2,4-dioxygenase activity","canonical_id":"go:GO:0050586","description":"\"Catalysis of the reaction: 3-hydroxy-2-methylquinolin-4(1H)-one + H+ + O2 = N-acetylanthranilate + CO.\" [EC:1.13.11.48, RHEA:21572]","metadata":null},{"id":"f9f4feae186c4a7da4916babcb9e89c9","type":"GO_TERM","name":"3-hydroxy-3-isohexenylglutaryl-CoA lyase activity","canonical_id":"go:GO:0047445","description":"\"Catalysis of the reaction: 3-hydroxy-3-(4-methylpent-3-en-1-yl)glutaryl-CoA + 4 H+ = 7-methyl-3-oxooct-6-enoyl-CoA + acetate.\" [EC:4.1.3.26, RHEA:23084]","metadata":null},{"id":"e4e46bccbb0c438ca14470852dce845a","type":"GO_TERM","name":"3-hydroxy-4-oxoquinoline 2,4-dioxygenase activity","canonical_id":"go:GO:0047078","description":"\"Catalysis of the reaction: O2 + 3-hydroxy-1H-quinolin-4-one = carbon monoxide + N-formylanthranilate.\" [EC:1.13.11.47, MetaCyc:1.13.11.47-RXN]","metadata":null},{"id":"9116d080c24746cf98897320b155b600","type":"GO_TERM","name":"3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione monooxygenase activity","canonical_id":"go:GO:0036383","description":"\"Catalysis of the reaction: 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione + FMNH2 + O2 = 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione + FMN + H2O.\" [EC:1.14.14.12, GOC:rs]","metadata":null},{"id":"8033dad0afc646659f2da30fe830ef26","type":"GO_TERM","name":"3-hydroxyacyl-CoA dehydratase activity","canonical_id":"go:GO:0018812","description":"\"Catalysis of the reaction: a 3-hydroxy-fatty acyl-CoA = a (2E)-enoyl-CoA + H2O.\" [RHEA:33767]","metadata":null},{"id":"8b80276090864ec7ad588be37694f3f0","type":"GO_TERM","name":"3-hydroxyanthranilate 3,4-dioxygenase activity","canonical_id":"go:GO:0000334","description":"\"Catalysis of the reaction: 3-hydroxyanthranilate + O2 = cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate + H+.\" [EC:1.13.11.6, RHEA:17953]","metadata":null},{"id":"8283b8842f9d4001a30375c82bae8573","type":"GO_TERM","name":"3-hydroxyanthranilate 4-C-methyltransferase activity","canonical_id":"go:GO:0030767","description":"\"Catalysis of the reaction: 3-hydroxyanthranilate + S-adenosyl-L-methionine = 3-hydroxy-4-methylanthranilate + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.97, RHEA:17833]","metadata":null},{"id":"8d1f9ba211a741a9b953794a9713dd70","type":"GO_TERM","name":"3-hydroxyanthranilate oxidase activity","canonical_id":"go:GO:0047561","description":"\"Catalysis of the reaction: 3-hydroxyanthranilate + O2 = 6-imino-5-oxocyclohexa-1,3-dienecarboxylate + H2O2.\" [EC:1.10.3.5, RHEA:17245]","metadata":null},{"id":"2e838a91a5c5474d9dca57f19a53c69f","type":"GO_TERM","name":"3-hydroxyaspartate aldolase activity","canonical_id":"go:GO:0047562","description":"\"Catalysis of the reaction: (3R)-3-hydroxy-L-aspartate = glycine + glyoxylate.\" [EC:4.1.3.14, RHEA:14377]","metadata":null},{"id":"389f7d527dc44085b9531c3b64b4a8b0","type":"GO_TERM","name":"3-hydroxybenzoate 2-monooxygenase activity","canonical_id":"go:GO:0047563","description":"\"Catalysis of the reaction: 3-hydroxybenzoate + AH(2) + O2 = 2,3-dihydroxybenzoate + A + H2O.\" [EC:1.14.99.23, RHEA:14193]","metadata":null},{"id":"ed6f3d2ad04c47e9aa4de01221c94e72","type":"GO_TERM","name":"3-hydroxybenzoate 4-monooxygenase activity","canonical_id":"go:GO:0018668","description":"\"Catalysis of the reaction: 3-hydroxybenzoate + H+ + NADPH + O2 = 3,4-dihydroxybenzoate + H2O + NADP+.\" [EC:1.14.13.23, RHEA:11480]","metadata":null},{"id":"37f7d74e6e87444790cd5974a12f9ba7","type":"GO_TERM","name":"3-hydroxybenzoate 6-monooxygenase activity","canonical_id":"go:GO:0018669","description":"\"Catalysis of the reaction: 3-hydroxybenzoate + H+ + NADH + O2 = 2,5-dihydroxybenzoate + H2O + NAD+.\" [EC:1.14.13.24, RHEA:22692]","metadata":null},{"id":"74a101a0215244e98fbd6d0dc2b58e46","type":"GO_TERM","name":"3-hydroxybenzyl-alcohol dehydrogenase activity","canonical_id":"go:GO:0047048","description":"\"Catalysis of the reaction: 3-hydroxybenzyl alcohol + NADP+ = 3-hydroxybenzaldehyde + H+ + NADPH.\" [EC:1.1.1.97, RHEA:22340]","metadata":null},{"id":"96089f3ec67e4639a677e631914db8ec","type":"GO_TERM","name":"3-hydroxybutyrate dehydrogenase activity","canonical_id":"go:GO:0003858","description":"\"Catalysis of the reaction: (R)-3-hydroxybutanoate + NAD+ = acetoacetate + H+ + NADH.\" [EC:1.1.1.30, RHEA:20521]","metadata":null},{"id":"90782fb0c82044f79086a13997f564ef","type":"GO_TERM","name":"3-hydroxybutyryl-CoA dehydrogenase activity","canonical_id":"go:GO:0008691","description":"\"Catalysis of the reaction: (S)-3-hydroxybutanoyl-CoA + NADP+ = 3-acetoacetyl-CoA + NADPH + H+.\" [EC:1.1.1.157]","metadata":null},{"id":"fc81f7f24d88481e8c899cbe4eda6763","type":"GO_TERM","name":"3-hydroxybutyryl-CoA epimerase activity","canonical_id":"go:GO:0008692","description":"\"Catalysis of the reaction: (S)-3-hydroxybutanoyl-CoA = (R)-3-hydroxybutanoyl-CoA.\" [EC:5.1.2.3]","metadata":null},{"id":"223f651d16914c60ba82e49cade8f07c","type":"GO_TERM","name":"3-hydroxycyclohexanone dehydrogenase activity","canonical_id":"go:GO:0047564","description":"\"Catalysis of the reaction: 3-hydroxycyclohexanone + A = AH(2) + cyclohexane-1,3-dione.\" [EC:1.1.99.26, RHEA:15905]","metadata":null},{"id":"d523860eebb848fbba2391c0dc8a8666","type":"GO_TERM","name":"3-hydroxyindolin-2-one monooxygenase activity","canonical_id":"go:GO:0036192","description":"\"Catalysis of the reaction: 3-hydroxyindolin-2-one + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxy-2H-1,4-benzoxazin-3(4H)-one + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:31927]","metadata":null},{"id":"b237904ad39f40f99ade2f9b55e2f6c3","type":"GO_TERM","name":"3-hydroxyisobutyrate dehydrogenase activity","canonical_id":"go:GO:0008442","description":"\"Catalysis of the reaction: 3-hydroxy-2-methylpropanoate + NAD+ = 2-methyl-3-oxopropanoate + NADH + H+.\" [EC:1.1.1.31]","metadata":null},{"id":"dc7ed899bd7f449bbdde5bc3b84277a6","type":"GO_TERM","name":"3-hydroxyisobutyryl-CoA hydrolase activity","canonical_id":"go:GO:0003860","description":"\"Catalysis of the reaction: 3-hydroxy-2-methylpropanoyl-CoA + H2O = CoA + 3-hydroxy-2-methylpropanoate.\" [EC:3.1.2.4]","metadata":null},{"id":"21925dae08d545679bc90ff2b5b4d08f","type":"GO_TERM","name":"3-hydroxymethylcephem carbamoyltransferase activity","canonical_id":"go:GO:0047155","description":"\"Catalysis of the reaction: a 3-hydroxymethylceph-3-em-4-carboxylate + carbamoyl-phosphate = phosphate + a 3-carbamoyloxymethylcephem.\" [EC:2.1.3.7, MetaCyc:2.1.3.7-RXN]","metadata":null},{"id":"574af9ca3abf4c6c950bc5196abda4aa","type":"GO_TERM","name":"3-hydroxyphenyl propanoate transmembrane transporter activity","canonical_id":"go:GO:0015551","description":"\"Enables the transfer of 3-hydroxyphenyl propanoate from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"8a4c47cd1b58423e820b55d064f5938f","type":"GO_TERM","name":"3-hydroxyphenyl propanoate transport","canonical_id":"go:GO:0015731","description":"\"The directed movement of 3-hydroxyphenyl propanoate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"b5bf80c4f19a4485a4963c6deaba566b","type":"GO_TERM","name":"3-hydroxyphenyl propionate:proton symporter activity","canonical_id":"go:GO:0015540","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: 3-hydroxyphenyl propionate(out) + H+(out) = 3-hydroxyphenyl propionate(in) + H+(in).\" [TC:2.A.1.15.2]","metadata":null},{"id":"6db01535e8e34791877895018de6637c","type":"GO_TERM","name":"3-hydroxyphenylacetate 6-hydroxylase activity","canonical_id":"go:GO:0047094","description":"\"Catalysis of the reaction: O2 + NAD(P)H + 3-hydroxyphenylacetate = H2O + NAD(P)+ + homogentisate.\" [EC:1.14.13.63]","metadata":null},{"id":"cc8a9415e9034b88ac384d4a63ac4d81","type":"GO_TERM","name":"3-hydroxyphenylacetate catabolic process","canonical_id":"go:GO:0019610","description":"\"The chemical reactions and pathways resulting in the breakdown of 3-hydroxyphenylacetate, 1,3-benzenediol monoacetate, also known as resorcinol monoacetate.\" [PMID:6995433]","metadata":null},{"id":"62e074a83f9c4a669f5e7fc78e338532","type":"GO_TERM","name":"3-hydroxyphenylpropionic acid transmembrane transport","canonical_id":"go:GO:0042920","description":"\"The directed movement of 3-hydroxyphenylpropionic acid across a lipid bilayer, from one side of a membrane to the other.\" [GOC:curators, PMID:9098055]","metadata":null},{"id":"3bb37037403f466c8242fc59b136ce11","type":"GO_TERM","name":"3-hydroxyphenylpropionic acid transmembrane transporter activity","canonical_id":"go:GO:0042926","description":"\"Enables the directed movement of 3-hydroxyphenylpropionic acid from one side of a membrane to the other.\" [GOC:jl, PMID:9098055]","metadata":null},{"id":"08892fbae436481b9d5a5530e004b524","type":"GO_TERM","name":"3-hydroxypimeloyl-CoA dehydrogenase activity","canonical_id":"go:GO:0018464","description":"\"Catalysis of the reaction: 3-hydroxypimelyl-CoA + NAD+ = 3-oxopimelyl-CoA + H+ + NADH.\" [EC:1.1.1.259, RHEA:11168]","metadata":null},{"id":"5b9d7595ad46494db0b66c2c2e4034db","type":"GO_TERM","name":"3-hydroxypropionate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047565","description":"\"Catalysis of the reaction: 3-hydroxypropanoate + NAD+ = 3-oxopropanoate + H+ + NADH.\" [EC:1.1.1.59, RHEA:13357]","metadata":null},{"id":"31ea5df55e274f9a9be9a012dc52df63","type":"GO_TERM","name":"3-hydroxypropionate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0035527","description":"\"Catalysis of the reaction: 3-hydroxypropanoate + NADP+ = 3-oxopropanoate + H+ + NADPH.\" [RHEA:26438]","metadata":null},{"id":"83926dcb31724b0ea8548a0793ef6e05","type":"GO_TERM","name":"3-hydroxypropionyl-CoA dehydratase activity","canonical_id":"go:GO:0043956","description":"\"Catalysis of the reaction: 3-hydroxypropionyl-CoA = acryloyl-CoA + H2O.\" [GOC:jl, PMID:11821399]","metadata":null},{"id":"f5c95b1657ad40a3bb98fca36cec5a48","type":"GO_TERM","name":"3-hydroxypropionyl-CoA synthetase activity","canonical_id":"go:GO:0043955","description":"\"Catalysis of the reaction: 3-hydroxypropionate + ATP + CoA = 3-hydroxypropionyl-CoA + AMP + diphosphate.\" [GOC:jl, PMID:11821399]","metadata":null},{"id":"298714832ae24d78a61bd8d8945dfbc5","type":"GO_TERM","name":"3-isopropylmalate dehydratase activity","canonical_id":"go:GO:0003861","description":"\"Catalysis of the reaction: (2R,3S)-3-isopropylmalate = (2S)-2-isopropylmalate.\" [EC:4.2.1.33]","metadata":null},{"id":"cbe03026c5814ad09a33929980a5758a","type":"GO_TERM","name":"3-isopropylmalate dehydratase complex","canonical_id":"go:GO:0009316","description":"\"A heterodimeric enzyme complex composed of subunits leuC and leuD. Catalyzes the isomerization between 2-isopropylmalate and 3-isopropylmalate, via the formation of 2-isopropylmaleate.\" [GOC:jl, MetaCyc:3-ISOPROPYLMALISOM-CPLX, PMID:7026530]","metadata":null},{"id":"7cc39ffbad994e7fa4b21e6f5e865e0c","type":"GO_TERM","name":"3-isopropylmalate dehydrogenase activity","canonical_id":"go:GO:0003862","description":"\"Catalysis of the reaction: (2R,3S)-3-isopropylmalate + NAD+ = 4-methyl-2-oxopentanoate + CO2 + NADH.\" [RHEA:32271]","metadata":null},{"id":"e7973916f48440869c81a779c57a4a8f","type":"GO_TERM","name":"3-keto-5-aminohexanoate cleavage activity","canonical_id":"go:GO:0043720","description":"\"Catalysis of the reaction: 3-keto-5-aminohexanoate + acetyl-CoA = L-3-aminobutyryl-CoA + acetoacetate.\" [MetaCyc:R125-RXN, PMID:13064]","metadata":null},{"id":"6d7ec43b7f72451f9bf42489ccc05eb5","type":"PROTEIN","name":"3-ketoacyl-CoA thiolase, mitochondrial","canonical_id":"uniprot:P42765","description":null,"metadata":null},{"id":"aff6697e994a42d6950caf775e33ec56","type":"GO_TERM","name":"3-ketosteroid 9-alpha-monooxygenase activity","canonical_id":"go:GO:0036200","description":"\"Catalysis of the reaction: androsta-1,4-diene-3,17-dione + 2 H+ + O2 + 2 reduced [2Fe-2S]-[ferredoxin] = 9alpha-hydroxyandrosta-1,4-diene-3,17-dione + H2O + 2 oxidized [2Fe-2S]-[ferredoxin].\" [EC:1.14.15.30]","metadata":null},{"id":"ef0bb89881ad4d7aa494a05bc15dd805","type":"GO_TERM","name":"3-ketovalidoxylamine C-N-lyase activity","canonical_id":"go:GO:0047566","description":"\"Catalysis of the reaction: 4-nitrophenyl-3-ketovalidamine = 4-nitroaniline + 5-D-(5/6)-5-C-(hydroxymethyl)-2,6-dihydroxycyclohex-2-en-1-one + H+.\" [EC:4.3.3.1, RHEA:22768]","metadata":null},{"id":"a41df2ce24b3404b92bb179ae6326aec","type":"GO_TERM","name":"3-mercaptopyruvate sulfurtransferase activity","canonical_id":"go:GO:0016784","description":"\"Catalysis of the reaction: 2-oxo-3-sulfanylpropanoate + [thioredoxin]-dithiol = [thioredoxin]-disulfide + hydrogen sulfide + pyruvate + H+. Note that 2-oxo-3-sulfanylpropanoate is also known as 3-mercaptopyruvate.\" [RHEA:21740]","metadata":null},{"id":"e2db9425a7ba4dd0b240dac6ca56603b","type":"GO_TERM","name":"3-methyl-2-oxobutanoate dehydrogenase (ferredoxin) activity","canonical_id":"go:GO:0043807","description":"\"Catalysis of the reaction: 3-methyl-2-oxobutanoate + CoA + oxidized ferredoxin = S-(2-methylpropanoyl)-CoA + CO2 + reduced ferredoxin.\" [EC:1.2.7.7]","metadata":null},{"id":"ce407c5e8b544d76be63490a87def6d5","type":"GO_TERM","name":"3-methyl-2-oxobutanoate hydroxymethyltransferase activity","canonical_id":"go:GO:0003864","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + 3-methyl-2-oxobutanoate = tetrahydrofolate + 2-dehydropantoate.\" [EC:2.1.2.11]","metadata":null},{"id":"ff1abdba51884456bc5ec58f49880602","type":"GO_TERM","name":"3-methylbut-2-enoyl-CoA(4-) biosynthetic process","canonical_id":"go:GO:1902200","description":"\"The chemical reactions and pathways resulting in the formation of 3-methylbut-2-enoyl-CoA(4-).\" [GOC:TermGenie, PMID:11231285]","metadata":null},{"id":"a211fa254818414196e7a877e620cffa","type":"GO_TERM","name":"3-methylbut-2-enoyl-CoA(4-) catabolic process","canonical_id":"go:GO:1902199","description":"\"The chemical reactions and pathways resulting in the breakdown of 3-methylbut-2-enoyl-CoA(4-).\" [GOC:TermGenie, PMID:11231285]","metadata":null},{"id":"55d31c77972b4d78aa61c1ef0632ffb6","type":"GO_TERM","name":"3-methylbut-2-enoyl-CoA(4-) metabolic process","canonical_id":"go:GO:1902198","description":"\"The chemical reactions and pathways involving 3-methylbut-2-enoyl-CoA(4-).\" [GOC:TermGenie, PMID:11231285]","metadata":null},{"id":"d242eb60f8e14ba4b077fd59d793f668","type":"GO_TERM","name":"3-methylbutanal reductase (NADH) activity","canonical_id":"go:GO:0052676","description":"\"Catalysis of the reaction: 3-methylbutanol + NAD+ = 3-methylbutanal + NADH + H+. 3-methylbutanal is also known as isovaleraldehyde.\" [KEGG_REACTION:R05685, RHEA:18529]","metadata":null},{"id":"506bb7a7a07c4a7281edf71c52215903","type":"GO_TERM","name":"3-methylbutanal reductase (NADPH) activity","canonical_id":"go:GO:0052675","description":"\"Catalysis of the reaction: 3-methylbutanol + NADP+ = 3-methylbutanal + NADPH + H+. 3-methylbutanal is also known as isovaleraldehyde.\" [RHEA:18525]","metadata":null},{"id":"209e0856e6894c64b7c43b4703141c89","type":"GO_TERM","name":"3-methylbutanal reductase [NAD(P)H] activity","canonical_id":"go:GO:0046568","description":"\"Catalysis of the reaction: 3-methylbutanol + NAD(P)+ = 3-methylbutanal + NAD(P)H + H+. 3-methylbutanal is also known as isovaleraldehyde.\" [EC:1.1.1.265]","metadata":null},{"id":"c9efd484368b4b128746e72870eff9ce","type":"GO_TERM","name":"3-methylbutanoyl-CoA dehydrogenase activity","canonical_id":"go:GO:0008470","description":"\"Catalysis of the reaction: 3-methylbutanoyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = 3-methyl-(2E)-butenoyl-CoA + reduced [electron-transfer flavoprotein].\" [PMID:25450250, PMID:7640268, RHEA:12276]","metadata":null},{"id":"1c5d4090326c485da52de23d55ae87a6","type":"GO_TERM","name":"3-methyleneoxindole reductase activity","canonical_id":"go:GO:0047567","description":"\"Catalysis of the reaction: 3-methyloxindole + NADP+ = 3-methyleneoxindole + H+ + NADPH.\" [EC:1.3.1.17, RHEA:20257]","metadata":null},{"id":"1a89cb616bcf452da6afcad4fed4be49","type":"GO_TERM","name":"3-methylquercetin 3'-O-methyltransferase activity","canonical_id":"go:GO:0102445","description":"\"Catalysis of the reaction: 3',4',5,7-tetrahydroxy-3-methoxyflavone + S-adenosyl-L-methionine = 3,3'-O-dimethylquercetin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74715]","metadata":null},{"id":"8d47417326b64b44a13d54140070625a","type":"GO_TERM","name":"3-methylquercitin 7-O-methyltransferase activity","canonical_id":"go:GO:0030757","description":"\"Catalysis of the reaction: 3',4',5,7-tetrahydroxy-3-methoxyflavone + S-adenosyl-L-methionine(1+) = 3',4',5-trihydroxy-3,7-dimethoxyflavone + S-adenosyl-L-homocysteine.\" [EC:2.1.1.82, RHEA:16181]","metadata":null},{"id":"0d8bc24c2dea45bb868843cb06337476","type":"GO_TERM","name":"3-methylthiopropyl glucosinolate S-oxygenase activity","canonical_id":"go:GO:0080102","description":"\"Catalysis of the reaction: 3-methylthiopropyl-glucosinolate = 3-methylsulfinylpropyl-glucosinolate.\" [PMID:18799661]","metadata":null},{"id":"666d930e81d8452d9ee734da8b85ea7e","type":"GO_TERM","name":"3-oxo-5-alpha-steroid 4-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047751","description":"\"Catalysis of the reaction: 3-oxo-5alpha-steroid + NADP+ = a 3-oxo-delta(4)-steroid + H+ + NADPH.\" [RHEA:54384]","metadata":null},{"id":"016cc77ade6d47ad9bab095726b2cca9","type":"GO_TERM","name":"3-oxo-5-alpha-steroid 4-dehydrogenase activity","canonical_id":"go:GO:0003865","description":"\"Catalysis of the reaction: a 3-oxo-5-alpha-steroid + acceptor = a 3-oxo-delta(4)-steroid + reduced acceptor.\" [EC:1.3.99.5]","metadata":null},{"id":"52089252126047b080813b331e54d0da","type":"GO_TERM","name":"3-oxo-5-beta-steroid 4-dehydrogenase activity","canonical_id":"go:GO:0047568","description":"\"Catalysis of the reaction: a 3-oxo-5-beta-steroid + acceptor = a 3-oxo-D4-steroid + reduced acceptor.\" [EC:1.3.99.6]","metadata":null},{"id":"338faae0e4d244c382d1b88c2ca28f44","type":"GO_TERM","name":"3-oxoacyl-[acyl-carrier-protein] reductase (NADH) activity","canonical_id":"go:GO:0047025","description":"\"Catalysis of the reaction: NAD+ + OH-acyl-[acyl-carrier protein] = NADH + H+ + B-ketoacyl-[acyl-carrier protein].\" [EC:1.1.1.212, MetaCyc:1.1.1.212-RXN]","metadata":null},{"id":"3d975fc5adc7465eb444743ccf04942c","type":"GO_TERM","name":"3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity","canonical_id":"go:GO:0004316","description":"\"Catalysis of the reaction: (3R)-3-hydroxyacyl-[acyl-carrier protein] + NADP+ = 3-oxoacyl-[acyl-carrier protein] + NADPH + H+.\" [RHEA:17397]","metadata":null},{"id":"128e1daa594b4915a6d00328f6c0fc61","type":"GO_TERM","name":"3-oxoacyl-[acyl-carrier-protein] synthase activity","canonical_id":"go:GO:0004315","description":"\"Catalysis of the reaction: acyl-[acyl-carrier protein] + malonyl-[acyl-carrier protein] = 3-oxoacyl-[acyl-carrier protein] + CO2 + [acyl-carrier protein].\" [RHEA:22836]","metadata":null},{"id":"90969787a84543449c9263d66b879838","type":"GO_TERM","name":"3-oxoadipate CoA-transferase activity","canonical_id":"go:GO:0047569","description":"\"Catalysis of the reaction: 3-oxoadipate + succinyl-CoA = 3-oxoadipyl-CoA + succinate.\" [RHEA:12048]","metadata":null},{"id":"af1328afa33d48d199defe4cd919cda4","type":"GO_TERM","name":"3-oxoadipate enol-lactonase activity","canonical_id":"go:GO:0047570","description":"\"Catalysis of the reaction: 3-oxoadipate enol-lactone + H2O = 3-oxoadipate.\" [EC:3.1.1.24, MetaCyc:3-OXOADIPATE-ENOL-LACTONASE-RXN]","metadata":null},{"id":"741e3f5647474199ad18822188741d05","type":"GO_TERM","name":"3-oxoadipyl-CoA thiolase activity","canonical_id":"go:GO:0033812","description":"\"Catalysis of the reaction: succinyl-CoA + acetyl-CoA = CoA + 3-oxoadipyl-CoA.\" [RHEA:19481]","metadata":null},{"id":"b57546bcf2814c01942936dedb4e1851","type":"GO_TERM","name":"3-oxolaurate decarboxylase activity","canonical_id":"go:GO:0050410","description":"\"Catalysis of the reaction: 3-oxododecanoate + H+ = 2-undecanone + CO2. Also decarboxylates other C14 to C16 oxo acids.\" [EC:4.1.1.56, RHEA:13385]","metadata":null},{"id":"b44732f6c94642e5be39765d1251c44e","type":"GO_TERM","name":"3-oxosteroid 1-dehydrogenase activity","canonical_id":"go:GO:0047571","description":"\"Catalysis of the reaction: a 3-oxosteroid + acceptor = a 3-oxo-D1-steroid + reduced acceptor.\" [EC:1.3.99.4]","metadata":null},{"id":"dee944b9a062451d8314394dc93873ce","type":"GO_TERM","name":"3-phenylpropionate catabolic process","canonical_id":"go:GO:0019380","description":"\"The chemical reactions and pathways resulting in the breakdown of 3-phenylpropionate, the anion of phenylpropanoic acid.\" [GOC:ai]","metadata":null},{"id":"4d115bf35d1d4c648500dd6c938fec6f","type":"GO_TERM","name":"3-phenylpropionate dioxygenase activity","canonical_id":"go:GO:0008695","description":"\"Catalysis of the reaction: 3-phenylpropanoate + NADH + O2 + H+ = 3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)propanoate + NAD+.\" [RHEA:20357]","metadata":null},{"id":"af337f37f7fc4972b0a7906f339eb1f4","type":"GO_TERM","name":"3-phenylpropionate dioxygenase complex","canonical_id":"go:GO:0009334","description":"\"Enzyme complex consisting of four proteins: the two subunits of the hydroxylase component (hcaE and hcaF), a ferredoxin (hcaC) and a ferredoxin reductase (hcaD). Converts 3-phenylpropionic acid (PP) into cis-3-(3-carboxyethyl)-3,5-cyclohexadiene-1,2-diol (PP-dihydrodiol).\" [GOC:jl, MetaCyc:HCAMULTI-CPLX, PMID:9603882]","metadata":null},{"id":"71c4997d09ec4cfdb925731675d3338a","type":"GO_TERM","name":"3-phosphoglycerate phosphatase activity","canonical_id":"go:GO:0047572","description":"\"Catalysis of the reaction: 3-phospho-D-glycerate + H2O = D-glycerate + phosphate.\" [EC:3.1.3.38, RHEA:12412]","metadata":null},{"id":"c38b38f34e894cff88ffebc155fdfba8","type":"GO_TERM","name":"3-phosphoglyceroyl-phosphate-polyphosphate phosphotransferase activity","canonical_id":"go:GO:0047335","description":"\"Catalysis of the reaction: long-chain-polyphosphate + 3-phospho-D-glyceroyl-phosphate = long-chain-polyphosphate + 3-phosphoglycerate.\" [EC:2.7.4.17, MetaCyc:2.7.4.17-RXN]","metadata":null},{"id":"05bee79fb8734a269816f7d1241e35c3","type":"GO_TERM","name":"3-phosphoinositide-dependent protein kinase activity","canonical_id":"go:GO:0004676","description":"\"Phosphatidylinositol-3-phosphate-dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein.\" [GOC:mah]","metadata":null},{"id":"2d84122a546340fd9ba38256531a1da7","type":"GO_TERM","name":"3-phosphoinositide-dependent protein kinase binding","canonical_id":"go:GO:0043423","description":"\"Binding to a 3-phosphoinositide-dependent protein kinase.\" [GOC:jl]","metadata":null},{"id":"1bea176724d645bb905eaea34e6e029b","type":"GO_TERM","name":"3-phosphoshikimate 1-carboxyvinyltransferase activity","canonical_id":"go:GO:0003866","description":"\"Catalysis of the reaction: 3-phosphoshikimate + phosphoenolpyruvate = 5-O-(1-carboxyvinyl)-3-phosphoshikimate + phosphate.\" [EC:2.5.1.19, RHEA:21256]","metadata":null},{"id":"3039b65289a44c818a5e98fd8da7337e","type":"GO_TERM","name":"3-propylmalate synthase activity","canonical_id":"go:GO:0050442","description":"\"Catalysis of the reaction: glyoxylate + H2O + pentanoyl-CoA = 3-propylmalate + CoA + H+.\" [RHEA:14457]","metadata":null},{"id":"a8e67c72b1e248f8bfa46b52171fe08c","type":"GO_TERM","name":"3-sulfino-L-alanine binding","canonical_id":"go:GO:0036127","description":"\"Binding to 3-sulfino-L-alanine (cysteine sulfinate).\" [GOC:al, PMID:8346915]","metadata":null},{"id":"6e32c5646d1147428127c53d25c0951a","type":"GO_TERM","name":"3-sulfino-L-alanine: proton, glutamate antiporter activity","canonical_id":"go:GO:0000514","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: 3-sulfino-L-alanine (cysteinesulfinate) (out) + H+(in) + L-glutamate(in) = 3-sulfino-L-alanine(in) + H+(out) + L-glutamate(out).\" [PMID:11566871, RHEA:70967]","metadata":null},{"id":"7c187da7ca9a419dadbd76c684001d45","type":"GO_TERM","name":"3-sulfolactaldehyde reductase activity","canonical_id":"go:GO:0061596","description":"\"Catalysis of the reaction 2,3-dihydroxypropane-1-sulfonate + NAD+ = 3-sulfolactaldehyde + NADH + H+.\" [EC:1.1.1.373, GOC:dph, PMID:24463506]","metadata":null},{"id":"d558390e700b4d4aa286b26fa8dcd50d","type":"TRIAL","name":"3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)","canonical_id":"clinicaltrials.gov:NCT00159796","description":"Bipolar Disorder","metadata":null},{"id":"854b3ef346ae46ea9839f760a0b2e421","type":"TRIAL","name":"3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women","canonical_id":"clinicaltrials.gov:NCT00310531","description":"Osteopenia","metadata":null},{"id":"94dad8364103472091d3dcb256990350","type":"PROTEIN","name":"30S Ribosomal Subunit","canonical_id":"uniprot:P0A7S3","description":null,"metadata":null},{"id":"18cd082f2c714b4a80e998b4590aa26a","type":"PROTEIN","name":"30S ribosomal protein S12","canonical_id":"uniprot:P0A0H0","description":null,"metadata":null},{"id":"489c802b7d0f4fc8a4aeddb92de450bb","type":"PROTEIN","name":"30S ribosomal protein S12","canonical_id":"uniprot:A4WFD5","description":null,"metadata":null},{"id":"47ae88d6908041f49afd04ce6af1c31f","type":"PROTEIN","name":"30S ribosomal protein S12","canonical_id":"uniprot:B5XN85","description":null,"metadata":null},{"id":"733bac34bf974903bcceda48c0bf90bc","type":"PROTEIN","name":"30S ribosomal protein S12","canonical_id":"uniprot:Q155P6","description":null,"metadata":null},{"id":"354b05bb80184ee18b6f6e2ef45a8b43","type":"PROTEIN","name":"30S ribosomal protein S12 (Neisseria gonorrhoeae)","canonical_id":"uniprot:Q5F5S1","description":null,"metadata":null},{"id":"174466a176294ec4afb6e43248a0233d","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:S2ZP52","description":null,"metadata":null},{"id":"0b1d789620214d5c8aed464edc52f5c9","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:C3PBC1","description":null,"metadata":null},{"id":"2b7285ad89d648428ed0605c7fdef6ba","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:P0A7V8","description":null,"metadata":null},{"id":"1888cd8ccf6342a6854b226691cd2548","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:D0RGZ2","description":null,"metadata":null},{"id":"436c4d9bc07047b19db778e38843eb96","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:O84631","description":null,"metadata":null},{"id":"666bf811f07d419daf283a80d56e9e07","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:S7IK33","description":null,"metadata":null},{"id":"df3194a925f348d3be52ee615fc3b1f1","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q83EQ3","description":null,"metadata":null},{"id":"60a2f07346f24e679bcf2f166841ebe1","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:B5RMG4","description":null,"metadata":null},{"id":"e044c7ba34d1467db72e0931141c1b72","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:B0BX57","description":null,"metadata":null},{"id":"2f7a6c89634f433f811d38dc4c7862e3","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:O83328","description":null,"metadata":null},{"id":"c96f859b28c34120a50c983b08394c50","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q6A6R0","description":null,"metadata":null},{"id":"6289b5f00a0a4af68c4d15d3e9951b82","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q6FZU4","description":null,"metadata":null},{"id":"6086af4dc586406d8c3bd42a342fba92","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:P46775","description":null,"metadata":null},{"id":"9768b3d6615d4500bdb116c7e551d8c5","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q7VKF7","description":null,"metadata":null},{"id":"7a51312baea0482eb05bc12f6b64374f","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q9KP07","description":null,"metadata":null},{"id":"35e219dafe08441cbbce4fa428f42697","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q5F5V1","description":null,"metadata":null},{"id":"a5392494ff104042984e747e02bece20","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q71Z71","description":null,"metadata":null},{"id":"7d8bd357b40b43e288d8a92cb201b47a","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:X2JRY4","description":null,"metadata":null},{"id":"ffaf04dfd2d44ad4a51b2b79e4dd7a4b","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:A2RGZ8","description":null,"metadata":null},{"id":"b4ce08c0917249c6b980f34ddce15141","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q8ZJ88","description":null,"metadata":null},{"id":"7e82f8e6dab14a4e9a6dba5a53f5df46","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:C1CHZ1","description":null,"metadata":null},{"id":"fbae80cc0bfa4cc0bfe4741ea2b0cbdf","type":"PROTEIN","name":"30S ribosomal protein S4","canonical_id":"uniprot:Q5NHU4","description":null,"metadata":null},{"id":"2c34bc9ee743484681c3214154bba166","type":"GO_TERM","name":"3D-(3,5/4)-trihydroxycyclohexane-1,2-dione hydrolase activity","canonical_id":"go:GO:0102481","description":"\"Catalysis of the reaction: 3D-3,5/4-trihydroxycyclohexane-1,2-dione + H2O = 5-deoxy-D-glucuronate + H+.\" [GOC:pz, RHEA:25836]","metadata":null},{"id":"eb5548ed8a614f33a6b0c676bdcfe202","type":"GO_TERM","name":"3M complex","canonical_id":"go:GO:1990393","description":"\"A protein complex, at least composed of CUL7, CCDC8 and OBSL1, that is required for maintaining microtubule and genome integrity.\" [PMID:24793695, PMID:24793696]","metadata":null},{"id":"9ba802c62be241dfbc5789ce193b0c52","type":"GO_TERM","name":"3alpha(S)-strictosidine biosynthetic process","canonical_id":"go:GO:1901015","description":"\"The chemical reactions and pathways resulting in the formation of 3alpha(S)-strictosidine.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"af1e9ada698e4c9f91269fc16990ea4e","type":"GO_TERM","name":"3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-enoyl-CoA hydratase activity","canonical_id":"go:GO:0033989","description":"\"Catalysis of the reaction: (24R,25R)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestanoyl-CoA = (24E)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-enoyl-CoA + H2O.\" [EC:4.2.1.107]","metadata":null},{"id":"5d6f3cbb859a4ac682794ff457e60c3b","type":"GO_TERM","name":"3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA 24-hydroxylase activity","canonical_id":"go:GO:0033791","description":"\"Catalysis of the reaction: (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-CoA + H2O + acceptor = (24R,25R)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oyl-CoA + reduced acceptor.\" [EC:1.17.99.3]","metadata":null},{"id":"c7df374302a54a978eba94a9350040f4","type":"GO_TERM","name":"3alpha-hydroxy bile acid-CoA-ester 3-dehydrogenase activity","canonical_id":"go:GO:0033792","description":"\"Catalysis of the reactions: a 3alpha-hydroxy bile acid CoA + NAD+ = a 3-oxo bile acid CoA + H+ + NADH.\" [PMID:23836456, RHEA:55380]","metadata":null},{"id":"6d5d1a988ba84bb3810e3813002d83a5","type":"GO_TERM","name":"3alpha-hydroxy-ent-sandaracopimardiene 7-beta-monooxygenase activity","canonical_id":"go:GO:0102598","description":"\"Catalysis of the reaction: ent-sandaracopimaradien-3-beta-ol + NADPH + H+ + O2 = oryzalexin D + NADP + H2O.\" [EC:1.14.14.123, GOC:pz]","metadata":null},{"id":"5aa3550b9be942e7a1578c9da636b6ad","type":"GO_TERM","name":"3alpha-hydroxy-ent-sandaracopimardiene 9-beta-monooxygenase activity","canonical_id":"go:GO:0102597","description":"\"Catalysis of the reaction: ent-sandaracopimaradien-3-beta-ol + NADPH + H+ + O2 = oryzalexin E + NADP + H2O.\" [EC:1.14.14.122, GOC:pz]","metadata":null},{"id":"c042d5b3bd29452bb9baba41cf7a3b35","type":"GO_TERM","name":"4 iron, 3 sulfur cluster binding","canonical_id":"go:GO:1990655","description":"\"Binding to a 4 iron, 3 sulfur (4Fe-3S) cluster, an uncommon iron-sulfur cluster with unique properties found in oxygen-tolerant Ni-Fe hydrogenases of various bacteria.\" [GOC:am, PMID:23267108]","metadata":null},{"id":"45e4b2ef36964a3891cff8bd915620bb","type":"GO_TERM","name":"4 iron, 4 sulfur cluster binding","canonical_id":"go:GO:0051539","description":"\"Binding to a 4 iron, 4 sulfur (4Fe-4S) cluster; this cluster consists of four iron atoms, with the inorganic sulfur atoms found between the irons and acting as bridging ligands.\" [GOC:ai, PMID:15952888, Wikipedia:Iron-sulfur_cluster]","metadata":null},{"id":"173c0ab738234fb69a40c9613a616b7e","type":"GO_TERM","name":"4'-methoxyisoflavone 2'-hydroxylase activity","canonical_id":"go:GO:0047957","description":"\"Catalysis of the reaction: formononetin + NADPH + O2 = 2'-hydroxyformononetin + NADP+ + H2O.\" [EC:1.14.14.89, MetaCyc:ISOFLAVONE-2-HYDROXYLASE-RXN]","metadata":null},{"id":"f5c1c17678e04ca888a5ec791272a42f","type":"GO_TERM","name":"4,4'-diapophytoene desaturase (4,4'-diaponeurosporene-forming) activity","canonical_id":"go:GO:0102223","description":"\"Catalysis of the reaction: 4 H+ + 15-cis-4,4'-diapophytoene + 4 FAD = 4,4'-diapolycopene + 4 FADH2. This reaction consists of four successive dehydrogenations that lead to the introduction of three double bonds into 4,4'-diapophytoene (dehydrosqualene), with 4,4'-diapophytofluene, 4,4'-diapo-zeta-carotene and 4,4'-diapolycopene as intermediates, and 4,4'-diapolycopene as the end product.\" [PMID:8002598, RHEA:31391]","metadata":null},{"id":"be7ad46f15d44622ba3e9d508fb36219","type":"GO_TERM","name":"4,4-dimethyl-9beta,19-cyclopropylsterol oxidation","canonical_id":"go:GO:0080064","description":"\"A lipid oxidation process proceeding through a series of three successive monooxygenations of the alpha methyl group on the C4 carbon (CH3 to CH2OH to CHO to COOH) and resulting in this overall reaction: 4,4-dimethyl-9beta,19-cyclopropylsterol + 3 NADPH + 3 H+ + 3 O2 = 4-alpha-carboxy, 4-beta-methyl-9beta,19-cyclopropylsterol + 3 NADP+ + 3 H2O.\" [GOC:pr, PMID:14653780]","metadata":null},{"id":"192e94b5e7aa4762ac4c015b803f5afc","type":"GO_TERM","name":"4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase activity","canonical_id":"go:GO:0102296","description":"\"Catalysis of the reaction: (1E,2Z)-3-hydroxy-5,9,17-trioxo-4,5:9,10-disecoandrosta-1(10),2-dien-4-oate + H2O = 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate + (2Z,4Z)-2-hydroxyhexa-2,4-dienoate + H+.\" [GOC:pz, RHEA:32035]","metadata":null},{"id":"0326d33f1aac43e3ab0b4852a417b97c","type":"GO_TERM","name":"4,5-dihydroxyphthalate decarboxylase activity","canonical_id":"go:GO:0018796","description":"\"Catalysis of the reaction: 4,5-dihydroxyphthalate = 3,4-dihydroxybenzoate + CO2.\" [EC:4.1.1.55]","metadata":null},{"id":"62ea546fe305499e9111ae1fec41583e","type":"GO_TERM","name":"4,6-pyruvylated galactose residue biosynthetic process","canonical_id":"go:GO:0051072","description":"\"The chemical reactions and pathways resulting in the formation of the pyruvylated galactose residue 4-6-O-[(R)(1-carboxyethylidine)]-Gal-beta-1,3-. The galactose residue is part of a larger polysaccharide chain.\" [GOC:ai, PMID:15173185]","metadata":null},{"id":"2e2790aaf13a4865b02506c6d120cb4d","type":"GO_TERM","name":"4,8,12-trimethyltrideca-1,3,7,11-tetraene synthase activity","canonical_id":"go:GO:0097007","description":"\"Catalysis of the reaction: (EE)-geranyllinalool + NADPH + O2 = 4,8,12-trimethyl-1,3,7,11-tridecatetraene + NADP+ + 2 H2O. It is unknown whether this reaction proceeds by the direct release of the 4-carbon compound but-1-en-3-one, or whether the substrate is first degraded to C18-farnesylacetone and then cleaved to produce 4,8,12-trimethyl-1,3,7,11-tridecatetraene (TMTT) and acetone.\" [GOC:kad, MetaCyc:RXN-8620, PMID:21088219]","metadata":null},{"id":"1c699e4a03c2429dbff3b39eebf5d91e","type":"GO_TERM","name":"4-(2-carboxyphenyl)-2-oxobut-3-enoate aldolase activity","canonical_id":"go:GO:0018803","description":"\"Catalysis of the reaction: (3Z)-4-(2-carboxyphenyl)-2-oxobut-3-enoate + H2O = 2-formylbenzoate + pyruvate.\" [RHEA:16453]","metadata":null},{"id":"c446b63bfb7242a3aa681ddeb5293f6f","type":"GO_TERM","name":"4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase activity","canonical_id":"go:GO:0050515","description":"\"Catalysis of the reaction: 4-CDP-2-C-methyl-D-erythritol + ATP = 4-CDP-2-C-methyl-D-erythritol 2-phosphate + ADP + 2 H+.\" [EC:2.7.1.148, RHEA:18437]","metadata":null},{"id":"95cd24a8a04b4befa0e0afa13993e42a","type":"GO_TERM","name":"4-(dimethylamino)phenylazoxybenzene reductase activity","canonical_id":"go:GO:0047136","description":"\"Catalysis of the reaction: 4-(dimethylamino)azobenzene + H2O + NADP+ = 4-(dimethylamino)phenylazoxybenzene + H+ + NADPH.\" [EC:1.7.1.11, RHEA:19789]","metadata":null},{"id":"4d8ac3876e9845b6bf3167ae93859097","type":"GO_TERM","name":"4-(hydroxymethyl)benzenesulfonate dehydrogenase activity","canonical_id":"go:GO:0018462","description":"\"Catalysis of the reaction: 4-(hydroxymethyl)benzenesulfonate + NAD+ = 4-formylbenzenesulfonate + H+ + NADH.\" [EC:1.1.1.257, RHEA:24412]","metadata":null},{"id":"8b39a513d4544901bfdb487a29529f43","type":"GO_TERM","name":"4-(trimethylammonio)butanoate transmembrane transporter activity","canonical_id":"go:GO:1901236","description":"\"Enables the transfer of 4-(trimethylammonio)butanoate from one side of a membrane to the other.\" [GOC:TermGenie, PMID:16952940, PMID:21784948]","metadata":null},{"id":"dc80475034b648c781b0dfbb68985184","type":"GO_TERM","name":"4-(trimethylammonio)butanoate transport","canonical_id":"go:GO:1900751","description":"\"The directed movement of a 4-(trimethylammonio)butanoate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie, PMID:16365044, PMID:20357772, PMID:20829798]","metadata":null},{"id":"4deb9cc155ee427ba693f8cee03ad990","type":"TRIAL","name":"4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine","canonical_id":"clinicaltrials.gov:NCT03578354","description":"Vestibular Migraine; Migraine Disorders; Vestibular Diseases","metadata":null},{"id":"2352877b731d458e8ccf2ddc17c8b484","type":"GO_TERM","name":"4-O-methyl-glucuronoyl methylesterase activity","canonical_id":"go:GO:0052797","description":"\"Catalysis of the reaction: a 4-O-methyl-alpha-D-glucuronosyl ester derivative + H2O = 4-O-methyl-alpha-D-glucuronate derivative + an alcohol + H+.\" [PMID:16876163, RHEA:67452]","metadata":null},{"id":"ca05b93207ed4d67b02935b5a74fa237","type":"GO_TERM","name":"4-acetamido-4,6-dideoxy-D-galactose transferase activity","canonical_id":"go:GO:0102031","description":"\"Catalysis of the reaction: dTDP-4-acetamido-4,6-dideoxy-alpha-D-galactose + beta-D-ManNAcA-(1->4)-alpha-D-GlcNAc-1-diphospho-ditrans,polycis-undecaprenol = H+ + alpha-D-FucNAc4-(1->4)-beta-D-ManNAcA-(1->4)-D-GlcNAc-undecaprenyl diphosphate + dTDP.\" [EC:2.4.1.325, GOC:pz]","metadata":null},{"id":"d01d0921acd24865a304942826fca9c6","type":"GO_TERM","name":"4-acetamidobutyrate deacetylase activity","canonical_id":"go:GO:0047573","description":"\"Catalysis of the reaction: 4-acetamidobutanoate + H2O = acetate + 4-aminobutanoate.\" [EC:3.5.1.63]","metadata":null},{"id":"b6dc2bc0a8b14f04b52eb28a1a7d713d","type":"GO_TERM","name":"4-acetamidobutyryl-CoA deacetylase activity","canonical_id":"go:GO:0047574","description":"\"Catalysis of the reaction: 4-acetamidobutanoyl-CoA + H2O = 4-aminobutanoyl-CoA + acetate.\" [EC:3.5.1.51, RHEA:22928]","metadata":null},{"id":"43d4b35484cc47469d828b9ae8dc03a3","type":"GO_TERM","name":"4-alpha-D-(1->4)-alpha-D-glucanotrehalose trehalohydrolase activity","canonical_id":"go:GO:0033942","description":"\"Catalysis of the hydrolysis of alpha-(1->4)-D-glucosidic linkage in 4-alpha-D-{(1->4)-alpha-D-glucanosyl}n trehalose to yield trehalose and alpha-(1->4)-D-glucan.\" [EC:3.2.1.141]","metadata":null},{"id":"40f66b2f5ef04b24b18b952043b6f7b7","type":"GO_TERM","name":"4-alpha-glucanotransferase activity","canonical_id":"go:GO:0004134","description":"\"Catalysis of the transfer of a segment of a (1->4)-alpha-D-glucan to a new 4-position in an acceptor, which may be glucose or (1->4)-alpha-D-glucan.\" [EC:2.4.1.25]","metadata":null},{"id":"8bd5293b092747bc832a42753e00a40a","type":"GO_TERM","name":"4-alpha-hydroxytetrahydrobiopterin dehydratase activity","canonical_id":"go:GO:0008124","description":"\"Catalysis of the reaction: (6R)-6-(L-erythro-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4a-hydroxypterin = (6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin + H2O.\" [EC:4.2.1.96, RHEA:11920]","metadata":null},{"id":"3bf35f6c7e934504a8cab9a1002f3bb2","type":"GO_TERM","name":"4-alpha-methyl-delta7-sterol oxidation","canonical_id":"go:GO:0080065","description":"\"A lipid oxidation process proceeding through a series of three successive monooxygenations of the alpha methyl group on the C4 carbon (CH3 to CH2OH to CHO to COOH) and resulting in this overall reaction: 4-alpha-methyl-delta7-sterol + 3 NADPH + 3 H+ + 3 O2 = 4-alpha-carboxy,delta7-sterol + 3 NADP+ + 3 H2O.\" [GOC:pr, PMID:14653780]","metadata":null},{"id":"c08d80ed62c44e3f9cd88cef9bf0e8c9","type":"GO_TERM","name":"4-amino-3-isothiazolidinone biosynthetic process","canonical_id":"go:GO:0048107","description":"\"The chemical reactions and pathways resulting in the formation of 4-amino-3-isothiazolinone, five-membered saturated heterocyclic ring structures containing a sulfur and a nitrogen in the 1-position and 2-positions respectively.\" [GOC:jid]","metadata":null},{"id":"f9de58e9af294862a05ace29591bbd3d","type":"GO_TERM","name":"4-amino-4-deoxy-L-arabinose transferase activity","canonical_id":"go:GO:0103015","description":"\"Catalysis of the reaction: (Kdo)2-lipid A + 2 4-amino-4-deoxy-alpha-L-arabinopyranosyl di-trans,poly-cis-undecaprenyl phosphate = (beta-L-Ara4N)2-(KDO)2-lipid A + 2 ditrans,polycis-undecaprenyl phosphate.\" [EC:2.4.2.43, GOC:pz]","metadata":null},{"id":"0daca5cae2574d66a1f6414e1caab827","type":"GO_TERM","name":"4-amino-4-deoxy-alpha-L-arabinopyranosyl undecaprenyl phosphate biosynthetic process","canonical_id":"go:GO:0036108","description":"\"The chemical reactions and pathways resulting in the formation of 4-amino-4-deoxy-alpha-L-arabinopyranosyl undecaprenyl phosphate, a precursor of 4-amino-4-deoxy-L-arabinose (L-Ara4N).\" [GOC:yaf, PMID:15695810]","metadata":null},{"id":"901687b6c43d4073891cda644b18e4b8","type":"GO_TERM","name":"4-amino-4-deoxychorismate lyase activity","canonical_id":"go:GO:0008696","description":"\"Catalysis of the reaction: 4-amino-4-deoxychorismate = 4-aminobenzoate + H+ + pyruvate.\" [EC:4.1.3.38, RHEA:16201]","metadata":null},{"id":"659efcb7e02544b5ad7a86df09525751","type":"GO_TERM","name":"4-amino-5-hydroxymethyl-2-methylpyrimidine diphosphatase activity","canonical_id":"go:GO:0002145","description":"\"Catalysis of the reaction: 4-amino-5-hydroxymethyl-2-methylpyrimidine pyrophosphate + H2O = hydroxymethylpyrimidine phosphate + phosphate + H+.\" [MetaCyc:RXN0-3543]","metadata":null},{"id":"1e7c1099ca7245018514b814fac4f06a","type":"GO_TERM","name":"4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase activity from histidine and PLP","canonical_id":"go:GO:0106344","description":"\"Catalysis of the reaction: 2 Fe(3+) + 4 H2O + L-histidyl-[4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase] + N(6)-(pyridoxal phosphate)-L-lysyl-[4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase] = (2S)-2-amino-5-hydroxy-4-oxopentanoyl-[4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase] + 3-oxopropanoate + 4-amino-2-methyl-5-(phosphooxymethyl)pyrimidine + 2 Fe(2+) + 2 H+ + L-lysyl-[4-amino-5-hydroxymethyl-2-methylpyrimidine phosphate synthase].\" [PMID:22568620, RHEA:65756]","metadata":null},{"id":"f6b899a898ce4b3abd63de1d2e1c17cc","type":"GO_TERM","name":"4-aminobenzoate 1-monooxygenase activity","canonical_id":"go:GO:0018670","description":"\"Catalysis of the reaction: 4-aminobenzoate + NADPH + H+ + O2 = 4-hydroxyaniline + NADP+ + H2O + CO2.\" [EC:1.14.13.27]","metadata":null},{"id":"1cb12a0d93104862a50750760cf273c0","type":"GO_TERM","name":"4-aminobenzoate biosynthetic process","canonical_id":"go:GO:0008153","description":"\"The chemical reactions and pathways resulting in the formation of 4-aminobenzoate, an intermediate in the synthesis of folic acid, a compound which some organisms, e.g. prokaryotes, eukaryotic microbes, and plants, can synthesize de novo. Others, notably mammals, cannot. In yeast, it is present as a factor in the B complex of vitamins.\" [MetaCyc:PWY-6543, PMID:11377864, PMID:11960743]","metadata":null},{"id":"7818886d928c436d879c30c79a866ad8","type":"GO_TERM","name":"4-aminobutyrate transaminase complex","canonical_id":"go:GO:0032144","description":"\"A homodimeric protein complex that possesses 4-aminobutyrate transaminase activity.\" [GOC:mah, PMID:15528998]","metadata":null},{"id":"7944cd9b60664587ac779f40cce95a2e","type":"GO_TERM","name":"4-aminobutyrate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0034386","description":"\"Catalysis of the reaction: 2-oxoglutarate + 4-aminobutanoate = L-glutamate + succinate semialdehyde.\" [RHEA:23352]","metadata":null},{"id":"7d6b60b038a34a6f83b5bbe9d3281c96","type":"GO_TERM","name":"4-aminobutyrate:pyruvate transaminase activity","canonical_id":"go:GO:0034387","description":"\"Catalysis of the reaction: 4-aminobutanoate + pyruvate = succinate semialdehyde + alanine. Also converts glyoxylate to glycine.\" [EC:2.6.1.96]","metadata":null},{"id":"f1783780963f459ab495a74c2b342561","type":"GO_TERM","name":"4-carboxy-2-hydroxymuconate semialdehyde hemiacetal dehydrogenase activity","canonical_id":"go:GO:0050606","description":"\"Catalysis of the reaction: 4-carboxy-2-hydroxymuconate semialdehyde hemiacetal + NADP+ = 2-oxo-2H-pyran-4,6-dicarboxylate + H+ + NADPH.\" [RHEA:29587]","metadata":null},{"id":"0a77e06ca8614d228743cb68b6ca02af","type":"GO_TERM","name":"4-carboxymethyl-4-methylbutenolide mutase activity","canonical_id":"go:GO:0047469","description":"\"Catalysis of the reaction: 4-carboxymethyl-4-methylbut-2-en-1,4-olide = 4-carboxymethyl-3-methylbut-2-en-1,4-olide.\" [EC:5.4.99.14, RHEA:19237]","metadata":null},{"id":"ea9559a83bf14be983b57b447b4062bf","type":"GO_TERM","name":"4-carboxymuconolactone decarboxylase activity","canonical_id":"go:GO:0047575","description":"\"Catalysis of the reaction: (R)-2-(carboxymethyl)-5-oxo-2,5-dihydro-2-furoate + H+ = 5-oxo-4,5-dihydro-2-furylacetate + CO2.\" [EC:4.1.1.44, RHEA:23348]","metadata":null},{"id":"5d4d8eb74ee54a379d61c9288e9de740","type":"GO_TERM","name":"4-chloro-allylglycine synthase activity","canonical_id":"go:GO:0062146","description":"\"Catalysis of the reaction: 4-chloro-L-lysine + AH2 + O2 = A + formaldehyde + H2O + L-2-amino-4-chloropent-4-enoate + NH4+.\" [PMID:30867596, RHEA:59888]","metadata":null},{"id":"132f63c3c83f41fcae04368a42eec062","type":"GO_TERM","name":"4-chlorobenzoate dehalogenase activity","canonical_id":"go:GO:0047576","description":"\"Catalysis of the reaction: 4-chlorobenzoate + H2O = 4-hydroxybenzoate + chloride + H+.\" [RHEA:23440]","metadata":null},{"id":"02f3c86a60f04af48610988fdbd461a3","type":"GO_TERM","name":"4-chlorobenzoate-CoA ligase activity","canonical_id":"go:GO:0018861","description":"\"Catalysis of the reaction: 4-chlorobenzoate + CoA + ATP = 4-chlorobenzoyl-CoA + AMP + diphosphate. This reaction requires magnesium and is part of the bacterial 2,4-dichlorobenzoate degradation pathway.\" [EC:6.2.1.33]","metadata":null},{"id":"b7ff5374aec744dda717627333ae28ff","type":"GO_TERM","name":"4-chlorobenzoyl-CoA dehalogenase activity","canonical_id":"go:GO:0018787","description":"\"Catalysis of the reaction: 4-chlorobenzoyl-CoA + H2O = 4-hydroxybenzoyl-CoA + chloride + H+.\" [RHEA:14853]","metadata":null},{"id":"43fd34f7a408480da9c4bbd48921ac00","type":"GO_TERM","name":"4-chlorobiphenyl metabolic process","canonical_id":"go:GO:0018880","description":"\"The chemical reactions and pathways involving 4-chlorobiphenyl, a member of the polychlorinated biphenyl (PCB) group of compounds, a very stable group of synthetic organic compounds composed of a biphenyl nucleus with 1-10 chlorine substituents. 4-chlorobiphenyl has been used as a model substrate to investigate PCB degradation.\" [GOC:jl]","metadata":null},{"id":"baa2b0914a884fa6855ac8fae486cd10","type":"GO_TERM","name":"4-chlorophenylacetate 3,4-dioxygenase activity","canonical_id":"go:GO:0018622","description":"\"Catalysis of the reaction: 4-chlorophenylacetate + NADH + O2 = 3,4-dihydroxyphenylacetate + chloride + NAD+.\" [RHEA:14689]","metadata":null},{"id":"fc8caf228ff3459dbde0b865e2e81c52","type":"GO_TERM","name":"4-coumarate-CoA ligase activity","canonical_id":"go:GO:0016207","description":"\"Catalysis of the reaction: ATP + 4-coumarate + CoA = AMP + diphosphate + 4-coumaroyl-CoA.\" [EC:6.2.1.12]","metadata":null},{"id":"00257a2ae5c0472788f20c4122f0a6e8","type":"GO_TERM","name":"4-coumaroyl 2'-hydroxylase activity","canonical_id":"go:GO:0102312","description":"\"Catalysis of the reaction: 4-coumaryl-CoA + 2-oxoglutarate + O2 = 2,4-dihydroxycinnamoyl-CoA + succinate + carbon dioxide.\" [GOC:pz, PMID:22168819, PMID:22169019]","metadata":null},{"id":"80eab7e0700e4ca4901b4d0975c87712","type":"GO_TERM","name":"4-cresol dehydrogenase (hydroxylating) activity","canonical_id":"go:GO:0018695","description":"\"Catalysis of the reaction: 4-cresol + acceptor + H2O = 4-hydroxybenzaldehyde + reduced acceptor.\" [EC:1.17.9.1]","metadata":null},{"id":"703ffb98fb724c2aa89cd2d1986f7f34","type":"GO_TERM","name":"4-deoxy-L-threo-5-hexosulose-uronate ketol-isomerase activity","canonical_id":"go:GO:0008697","description":"\"Catalysis of the reaction: 5-dehydro-4-deoxy-D-glucuronate = 3-deoxy-D-glycero-2,5-hexodiulosonate.\" [EC:5.3.1.17, RHEA:23896]","metadata":null},{"id":"0120c28896f1499c9866adc58998b22e","type":"GO_TERM","name":"4-formylbenzenesulfonate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018482","description":"\"Catalysis of the reaction: 4-formylbenzenesulfonate + NAD+ + H2O = 4-sulfobenzoate + NADH + 2 H+.\" [RHEA:18833]","metadata":null},{"id":"f5f9130899fc4d9794c8e74c27a5b48c","type":"GO_TERM","name":"4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity","canonical_id":"go:GO:0017083","description":"\"Catalysis of the reaction: GDP-beta-L-fucose + beta-D-galactosyl-(1,4)-N-acetyl-D-glucosaminyl-R = GDP + 1,4-beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-D-glucosaminyl-R.\" [EC:2.4.1.152, RHEA:14257]","metadata":null},{"id":"bb691e60499c47e5b29281a6966d49b3","type":"GO_TERM","name":"4-hydroxy-2-ketopimelate aldolase activity","canonical_id":"go:GO:0043863","description":"\"Catalysis of the reaction: 4-hydroxy-2-ketopimelate = succinate semialdehyde + pyruvate.\" [MetaCyc:4-HYDROXY-2-KETOPIMELATE-LYSIS-RXN]","metadata":null},{"id":"ed053b88ea7e4b3bb900e4d30ca8adf1","type":"GO_TERM","name":"4-hydroxy-2-oxovalerate aldolase activity","canonical_id":"go:GO:0008701","description":"\"Catalysis of the reaction: 4-hydroxy-2-oxopentanoate = acetaldehyde + pyruvate.\" [EC:4.1.3.39, RHEA:22624]","metadata":null},{"id":"0b8e6c88dc1c422ea5b02df0ea121d9f","type":"GO_TERM","name":"4-hydroxy-3-all-trans-polyprenylbenzoate oxygenase activity","canonical_id":"go:GO:0106364","description":"\"Catalysis of the reaction: 4-hydroxy-3-all-trans-polyprenylbenzoate + 2 H+ + O2 + 2 reduced [2Fe-2S]-[ferredoxin] = 3,4-dihydroxy-5-all-trans-polyprenylbenzoate + H2O + 2 oxidized [2Fe-2S]-[ferredoxin].\" [PMID:38425362, RHEA:81195]","metadata":null},{"id":"8f640f878ec54160812a13fd2f6703c4","type":"GO_TERM","name":"4-hydroxy-3-methoxy-5-polyprenylbenzoate decarboxylase activity","canonical_id":"go:GO:0120539","description":"\"Catalysis of the reaction: a 4-hydroxy-3-methoxy-5-(all-trans-polyprenyl)benzoate + H+ = a 2-methoxy-6-(all-trans-polyprenyl)phenol + CO2.\" [PMID:38295803, PMID:38425362, RHEA:81179]","metadata":null},{"id":"2781bcb8e24d4e5f8e45f213fbb6ce20","type":"GO_TERM","name":"4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase activity (ferredoxin)","canonical_id":"go:GO:0046429","description":"\"Catalysis of the reaction: (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate + H2O + 2 oxidized ferredoxin = 2-C-methyl-D-erythritol 2,4-cyclodiphosphate + 2 reduced ferredoxin.\" [EC:1.17.7.1, PMID:11752431]","metadata":null},{"id":"42388c981bf842d7839aeebc60cdcaff","type":"GO_TERM","name":"4-hydroxy-3-methylbut-2-enyl diphosphate reductase activity","canonical_id":"go:GO:0051745","description":"\"Catalyzes the conversion of (2E)-4-hydroxy-3-methylbut-2-enyl diphosphate + 2 H+ + 2 reduced [2Fe-2S]-[ferredoxin] to isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) releasing H2O + 2 oxidized [2Fe-2S]-[ferredoxin]. Note that (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate is an alternative name for 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate.\" [EC:1.17.7.4, GOC:pg]","metadata":null},{"id":"d6e10b6b10b149e0ac55100f8e1039fa","type":"GO_TERM","name":"4-hydroxy-3-methylbut-2-enyl-diphosphate synthase activity (flavodoxin)","canonical_id":"go:GO:0141197","description":"\"Catalysis of the reaction: (2E)-4-hydroxy-3-methylbut-2-enyl diphosphate + 2 H+ + H2O + oxidized [flavodoxin] = 2-C-methyl-D-erythritol 2,4-cyclic diphosphate + reduced [flavodoxin].\" [RHEA:43604]","metadata":null},{"id":"e50703ee4e5741a3afb0dce06d7f3ce8","type":"GO_TERM","name":"4-hydroxy-3-polyprenylbenzoate decarboxylase activity","canonical_id":"go:GO:0008694","description":"\"Catalysis of the reaction: a 4-hydroxy-3-(all-trans-polyprenyl)benzoate + H+ = a 2-(all-trans-polyprenyl)phenol + CO2.\" [RHEA:41680]","metadata":null},{"id":"53d5d0d88e2847fead85fa2937ea4f15","type":"GO_TERM","name":"4-hydroxy-4-methyl-2-oxoglutarate aldolase activity","canonical_id":"go:GO:0047443","description":"\"Catalysis of the reactions: 4-hydroxy-4-methyl-2-oxoglutarate = 2 pyruvate, and 2-hydroxy-4-oxobutane-1,2,4-tricarboxylate = oxaloacetate + pyruvate.\" [EC:4.1.3.17]","metadata":null},{"id":"440adee7580e4aa88b22b6d79db74752","type":"GO_TERM","name":"4-hydroxy-L-threonine aldolase activity","canonical_id":"go:GO:0103042","description":"\"Catalysis of the reaction: 4-hydroxy-L-threonine = glycolaldehyde + glycine.\" [GOC:pz, RHEA:28779]","metadata":null},{"id":"346b20d742bf4841ba35389e6611f505","type":"GO_TERM","name":"4-hydroxy-tetrahydrodipicolinate reductase activity","canonical_id":"go:GO:0008839","description":"\"Catalysis of the reaction: (S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + NAD(P)+ + H2O = (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + NAD(P)H + H+.\" [EC:1.17.1.8]","metadata":null},{"id":"fe92c620124645139c0fdd6d36ddac4b","type":"GO_TERM","name":"4-hydroxy-tetrahydrodipicolinate synthase activity","canonical_id":"go:GO:0008840","description":"\"Catalysis of the reaction: L-aspartate 4-semialdehyde + pyruvate = (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + H2O + H+.\" [PMID:8993314, RHEA:34171]","metadata":null},{"id":"92431800bd2e4a1e97a1739190a1d944","type":"GO_TERM","name":"4-hydroxyacetophenone monooxygenase activity","canonical_id":"go:GO:0033767","description":"\"Catalysis of the reaction: 4'-hydroxyacetophenone + H+ + NADPH + O2 = 4-hydroxyphenyl acetate + H2O + NADP+.\" [EC:1.14.13.84, RHEA:22916]","metadata":null},{"id":"c76540dcdd5d444995d65e1498e94c4c","type":"GO_TERM","name":"4-hydroxybenzaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018484","description":"\"Catalysis of the reaction: 4-hydroxybenzaldehyde + NAD+ + H2O = 4-hydroxybenzoate + NADH + H+.\" [EC:1.2.1.64]","metadata":null},{"id":"e9e56345131748d68046f1440a1905e6","type":"GO_TERM","name":"4-hydroxybenzoate 1-hydroxylase activity","canonical_id":"go:GO:0018678","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + NADPH + H+ + O2 = hydroquinone + NADP+ + H2O + CO2.\" [EC:1.14.13.64]","metadata":null},{"id":"a54a4d806fba4f3eb43d046d09ddd80a","type":"GO_TERM","name":"4-hydroxybenzoate 3-monooxygenase (NADH) activity","canonical_id":"go:GO:0106355","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + H+ + NADH + O2 = 3,4-dihydroxybenzoate + H2O + NAD+.\" [RHEA:19473]","metadata":null},{"id":"ae31a7f1bfcc4dd996f5ad6ad914485d","type":"GO_TERM","name":"4-hydroxybenzoate 3-monooxygenase (NADPH) activity","canonical_id":"go:GO:0106356","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + H+ + NADPH + O2 = 3,4-dihydroxybenzoate + H2O + NADP+.\" [RHEA:19477]","metadata":null},{"id":"528ee15dd75a46fc9deff35dce5e5f84","type":"GO_TERM","name":"4-hydroxybenzoate 3-monooxygenase [NAD(P)H] activity","canonical_id":"go:GO:0018671","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + NAD(P)H + H+ + O2 = 3,4-dihydroxybenzoate + NAD(P)+ + H2O.\" [EC:1.14.13.33]","metadata":null},{"id":"5b123d94b489458db869f14fc6618eed","type":"GO_TERM","name":"4-hydroxybenzoate 3-monooxygenase activity","canonical_id":"go:GO:0018659","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + NADPH + H+ + O2 = protocatechuate + NADP+ + H2O.\" [EC:1.14.13.2]","metadata":null},{"id":"c0eacfa6de2649cfb1ab4fa3b6e404ca","type":"GO_TERM","name":"4-hydroxybenzoate 4-O-beta-D-glucosyltransferase activity","canonical_id":"go:GO:0047250","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + UDP-D-glucose = 4-(beta-D-glucosyloxy)benzoate + H+ + UDP.\" [EC:2.4.1.194, RHEA:15153]","metadata":null},{"id":"9da04c90d5f8482e91e9103278f267a9","type":"GO_TERM","name":"4-hydroxybenzoate decarboxylase activity","canonical_id":"go:GO:0018799","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + H+ = CO2 + phenol.\" [EC:4.1.1.61, RHEA:10876]","metadata":null},{"id":"aa960efe12844ed9b9290b452727ba24","type":"GO_TERM","name":"4-hydroxybenzoate geranyltransferase activity","canonical_id":"go:GO:0102930","description":"\"Catalysis of the reaction: geranyl diphosphate + 4-hydroxybenzoic acid = 3-geranyl-4-hydroxybenzoate + diphosphoric acid.\" [GOC:pz, RHEA:27854]","metadata":null},{"id":"cbbb764c11c24ca79ffeea5a9305981d","type":"GO_TERM","name":"4-hydroxybenzoate polyprenyltransferase activity","canonical_id":"go:GO:0008412","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + an all-trans-polyprenyl diphosphate = a 4-hydroxy-3-all-trans-polyprenylbenzoate + diphosphate.\" [RHEA:44504]","metadata":null},{"id":"596dfe528055465a9dfe5d7e0d08df52","type":"GO_TERM","name":"4-hydroxybenzoate-CoA ligase activity","canonical_id":"go:GO:0018859","description":"\"Catalysis of the reaction: ATP + 4-hydroxybenzoate + CoA = AMP + diphosphate + 4-hydroxybenzoyl-CoA.\" [EC:6.2.1.27]","metadata":null},{"id":"84aa92cc6ce9428da7b8573abb7bc67d","type":"GO_TERM","name":"4-hydroxybenzoyl-CoA reductase activity","canonical_id":"go:GO:0018525","description":"\"Catalysis of the reaction: oxidized 2[4Fe-4S]-[ferredoxin] + benzoyl-CoA + H2O = 4-hydroxybenzoyl-CoA + reduced 2[4Fe-4S]-[ferredoxin] + 2 H+.\" [RHEA:29603]","metadata":null},{"id":"87a0b79fff0f4c619be2d91e5944a1c4","type":"GO_TERM","name":"4-hydroxybenzoyl-CoA thioesterase activity","canonical_id":"go:GO:0018739","description":"\"Catalysis of the reaction: 4-hydroxybenzoyl-CoA + H2O = 4-hydroxybenzoate + CoA + H+.\" [EC:3.1.2.23, RHEA:11948]","metadata":null},{"id":"30a04bc27a2b4315b7bbfc3920a903dc","type":"GO_TERM","name":"4-hydroxybutanoyl-CoA dehydratase activity","canonical_id":"go:GO:0043721","description":"\"Catalysis of the reaction: 4-hydroxybutanoyl-CoA = (2E)-butenoyl-CoA + H2O.\" [RHEA:26530]","metadata":null},{"id":"1c1184c901f643e49597ec1145311d12","type":"GO_TERM","name":"4-hydroxybutyrate dehydrogenase activity","canonical_id":"go:GO:0047577","description":"\"Catalysis of the reaction: 4-hydroxybutanoate + NAD+ = H+ + NADH + succinate semialdehyde.\" [EC:1.1.1.61, RHEA:23948]","metadata":null},{"id":"0ac42856e3324573a62e0c2ae9474b88","type":"GO_TERM","name":"4-hydroxybutyrate receptor activity","canonical_id":"go:GO:0062124","description":"\"Combining with 4-hydroxybutyrte to initiate a change in cell activity.\" [PMID:17197387]","metadata":null},{"id":"9c8a36dae7414387b96258d532b4caa6","type":"GO_TERM","name":"4-hydroxycoumarin biosynthetic process","canonical_id":"go:GO:1901884","description":"\"The chemical reactions and pathways resulting in the formation of 4-hydroxycoumarin.\" [GOC:TermGenie, PMID:19757094]","metadata":null},{"id":"d235f3f10e174ec080cdcc1090ee5e40","type":"GO_TERM","name":"4-hydroxycoumarin catabolic process","canonical_id":"go:GO:1901883","description":"\"The chemical reactions and pathways resulting in the breakdown of 4-hydroxycoumarin.\" [GOC:TermGenie, PMID:19757094]","metadata":null},{"id":"03167895ebb148748ccb4c668b4b1ce5","type":"GO_TERM","name":"4-hydroxycyclohexanecarboxylate dehydrogenase activity","canonical_id":"go:GO:0047030","description":"\"Catalysis of the reaction: trans-4-hydroxycyclohexanecarboxylate + NAD+ = 4-oxocyclohexanecarboxylate + H+ + NADH.\" [EC:1.1.1.226, RHEA:17429]","metadata":null},{"id":"b44d3b21fb1c4a9088dc956f18798258","type":"GO_TERM","name":"4-hydroxyindole-3- carbonyl nitrile biosynthesis","canonical_id":"go:GO:0106148","description":"\"The chemical reactions and pathways resulting in the formation of 4-hydroxyindole-3- carbonyl nitrile (4-OH-ICN), a cyanogenic glucoside.\" [GOC:lr, PMID:26352477]","metadata":null},{"id":"6c5e3c96306a4eeeb7a082b3ac4ea654","type":"GO_TERM","name":"4-hydroxymandelate oxidase activity","canonical_id":"go:GO:0047579","description":"\"Catalysis of the reaction: (S)-4-hydroxymandelate + H+ + O2 = 4-hydroxybenzaldehyde + CO2 + H2O2.\" [EC:1.1.3.19, RHEA:15833]","metadata":null},{"id":"971b129cceb348668e00151d2f498fc2","type":"GO_TERM","name":"4-hydroxymandelate synthase activity","canonical_id":"go:GO:0050585","description":"\"Catalysis of the reaction: 4-hydroxyphenylpyruvate + O2 = 4-hydroxymandelate + CO2.\" [EC:1.13.11.46, MetaCyc:1.13.11.46-RXN]","metadata":null},{"id":"13479308d576484fb8d72974c545aa65","type":"GO_TERM","name":"4-hydroxymuconic-semialdehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018481","description":"\"Catalysis of the reaction: cis,trans-4-hydroxymuconate semialdehyde + NAD+ + H2O = maleylacetate + NADH + 2 H+.\" [RHEA:22420]","metadata":null},{"id":"2ab9e84177ce40cdbe9c7ed12b478d6e","type":"GO_TERM","name":"4-hydroxyphenylacetaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047106","description":"\"Catalysis of the reaction: (4-hydroxyphenyl)acetaldehyde + H2O + NAD+ = 4-hydroxyphenylacetate + 2 H+ + NADH.\" [RHEA:17273]","metadata":null},{"id":"6eb7901d3f7543b09e3436222566e8c9","type":"GO_TERM","name":"4-hydroxyphenylacetaldehyde oxime monooxygenase activity","canonical_id":"go:GO:0050592","description":"\"Catalysis of the reaction: (Z)-(4-hydroxyphenyl)acetaldehyde oxime + H+ + NADPH + O2 = (S)-4-hydroxymandelonitrile + 2 H2O + NADP+.\" [EC:1.14.14.37, RHEA:18401]","metadata":null},{"id":"2d788bc3703c418494651eca42252aaf","type":"GO_TERM","name":"4-hydroxyphenylacetate 1-monooxygenase activity","canonical_id":"go:GO:0018665","description":"\"Catalysis of the reaction: 4-hydroxyphenylacetate + NADPH + H+ + O2 = homogentisate + NADP+ + H2O.\" [EC:1.14.13.18]","metadata":null},{"id":"d8d371b8f43d480b97a45a89b19ee1c7","type":"GO_TERM","name":"4-hydroxyphenylacetate 3-monooxygenase activity","canonical_id":"go:GO:0052881","description":"\"Catalysis of the reaction: (4-hydroxyphenyl)acetate + FADH(2) + O2 = 3,4-dihydroxyphenylacetate + FAD + H+ + H2O.\" [RHEA:30595]","metadata":null},{"id":"b1e12bf288f24c3b8b8b4973b167fc15","type":"GO_TERM","name":"4-hydroxyphenylacetate biosynthetic process","canonical_id":"go:GO:1901024","description":"\"The chemical reactions and pathways resulting in the formation of 4-hydroxyphenylacetate.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"0faf5c3cb9544d948815c9396ac17933","type":"GO_TERM","name":"4-hydroxyphenylacetate catabolic process","canonical_id":"go:GO:1901023","description":"\"The chemical reactions and pathways resulting in the breakdown of 4-hydroxyphenylacetate.\" [GOC:TermGenie, GOC:yaf, PMID:8550403]","metadata":null},{"id":"cc84d22a80b8417b955e547b25fc99f7","type":"GO_TERM","name":"4-hydroxyphenylacetate decarboxylase activity","canonical_id":"go:GO:0043722","description":"\"Catalysis of the reaction: (4-hydroxyphenyl)acetate + H+ = 4-cresol + CO2.\" [EC:4.1.1.83, RHEA:22732]","metadata":null},{"id":"2914328d412a497482568d14326297d9","type":"GO_TERM","name":"4-hydroxyphenylacetate metabolic process","canonical_id":"go:GO:1901022","description":"\"The chemical reactions and pathways involving 4-hydroxyphenylacetate.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"8c1f44e67a414233a0b974742d5c9750","type":"GO_TERM","name":"4-hydroxyphenylacetate transmembrane transporter activity","canonical_id":"go:GO:1901241","description":"\"Enables the transfer of 4-hydroxyphenylacetate from one side of a membrane to the other.\" [GOC:TermGenie, PMID:9315705]","metadata":null},{"id":"30abaebbed40481885fd28fa87bfa0c8","type":"GO_TERM","name":"4-hydroxyphenylacetate transport","canonical_id":"go:GO:1900754","description":"\"The directed movement of a 4-hydroxyphenylacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie, PMID:9315705]","metadata":null},{"id":"2d11c0c5c6524cc8ad8a6650a33c7169","type":"GO_TERM","name":"4-hydroxyphenylpyruvate decarboxylase activity","canonical_id":"go:GO:0050546","description":"\"Catalysis of the reaction: (4-hydroxyphenyl)pyruvate + H+ = (4-hydroxyphenyl)acetaldehyde + CO2.\" [EC:4.1.1.80, RHEA:18697]","metadata":null},{"id":"505754a6ad064943a28d60fbbcecb759","type":"GO_TERM","name":"4-hydroxyphenylpyruvate dioxygenase activity","canonical_id":"go:GO:0003868","description":"\"Catalysis of the reaction: 4-hydroxyphenylpyruvate + O2 = homogentisate + CO2.\" [EC:1.13.11.27]","metadata":null},{"id":"8cf72ba2b979453c94add72d12edf23b","type":"GO_TERM","name":"4-hydroxyphenylpyruvate oxidase activity","canonical_id":"go:GO:0018490","description":"\"Catalysis of the reaction: 2 3-(4-hydroxyphenyl)pyruvate + O2 = 2 4-hydroxyphenylacetate + 2 CO2.\" [RHEA:17197]","metadata":null},{"id":"4b0fe341dad147a3b236e169611fd7de","type":"GO_TERM","name":"4-hydroxyproline epimerase activity","canonical_id":"go:GO:0047580","description":"\"Catalysis of the reaction: trans-4-hydroxy-L-proline = cis-4-hydroxy-D-proline.\" [EC:5.1.1.8, RHEA:21152]","metadata":null},{"id":"986874b8c29e460fab033dbe3ccfb5ae","type":"GO_TERM","name":"4-hydroxyquinoline 3-monooxygenase activity","canonical_id":"go:GO:0047093","description":"\"Catalysis of the reaction: H+ + NADH + O2 + quinolin-4-ol = H2O + NAD+ + quinoline-3,4-diol.\" [EC:1.14.13.62, RHEA:19325]","metadata":null},{"id":"3ccbfa35b0bb4c939c3e16b501fe64f3","type":"GO_TERM","name":"4-hydroxysphinganine ceramide fatty acyl 2-hydroxylase activity","canonical_id":"go:GO:0120521","description":"\"Catalysis of the reaction: an N-(1,2 saturated acyl)-(4R)-hydroxysphinganine + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = an N-(2R-hydroxyacyl)-4R-hydroxysphinganine + 2 Fe(III)-[cytochrome b5] + H2O.\" [RHEA:46520]","metadata":null},{"id":"f3597c0fd2cc4e299153ff9f12141643","type":"GO_TERM","name":"4-hydroxythreonine-4-phosphate dehydrogenase activity","canonical_id":"go:GO:0050570","description":"\"Catalysis of the reaction: 4-(phosphooxy)-L-threonine + NAD+ = 3-amino-2-oxopropyl phosphate + CO2 + NADH.\" [EC:1.1.1.262, RHEA:32275]","metadata":null},{"id":"4e67e09b3b974d2f82cc37d0b4ce3844","type":"GO_TERM","name":"4-hydroxytryptamine 4-phosphate methyltransferase activity","canonical_id":"go:GO:0140381","description":"\"Catalysis of the reaction: 2 S-adenosyl-L-methionine (SAM) + 4-hydroxytryptamine 4-phosphate (norbaeocystin) = 2 S-adenosyl-L-homocysteine + psilocybin.\" [PMID:28763571]","metadata":null},{"id":"03e82154e66c4992920c404333f11824","type":"GO_TERM","name":"4-hydroxytryptamine kinase activity","canonical_id":"go:GO:0140383","description":"\"Catalysis of the reaction: 4-hydroxytryptamine + ATP = 4-hydoxytryptamine 4-phosphate + ADP + H+.\" [PMID:28763571]","metadata":null},{"id":"eb03b4b6ba154fb9a0b6a8a3e5bdb624","type":"GO_TERM","name":"4-methoxybenzoate monooxygenase (O-demethylating) activity","canonical_id":"go:GO:0018690","description":"\"Catalysis of the reaction: 4-methoxybenzoate + AH(2) + O2 = 4-hydroxybenzoate + A + formaldehyde + H2O.\" [EC:1.14.99.15, RHEA:18613]","metadata":null},{"id":"bb680fbd7e804dac902a38718b659f25","type":"GO_TERM","name":"4-methylaminobutyrate oxidase (demethylating) activity","canonical_id":"go:GO:0102317","description":"\"Catalysis of the reaction: 4-(methylamino)butanoate + O2 + H2O = 4-aminobutanoate + formaldehyde + H2O2.\" [RHEA:33907]","metadata":null},{"id":"4dcb7b029b2b46289178c12ae06fa1d8","type":"GO_TERM","name":"4-methyleneglutamate-ammonia ligase activity","canonical_id":"go:GO:0047581","description":"\"Catalysis of the reaction: 4-methylene-L-glutamate + ATP + NH4 = 4-methylene-L-glutamine + AMP + diphosphate + 2 H+.\" [EC:6.3.1.7, RHEA:13853]","metadata":null},{"id":"b962d7e9875a4106b013ea7360936576","type":"GO_TERM","name":"4-methyleneglutaminase activity","canonical_id":"go:GO:0047582","description":"\"Catalysis of the reaction: 4-methylene-L-glutamine + H2O = 4-methylene-L-glutamate + NH4.\" [EC:3.5.1.67, RHEA:14741]","metadata":null},{"id":"8f5a2e990a75498fa5353c63ef0e9add","type":"GO_TERM","name":"4-methyloxaloacetate esterase activity","canonical_id":"go:GO:0047583","description":"\"Catalysis of the reaction: 4-methoxy-2,4-dioxobutanoate + H2O = H+ + methanol + oxaloacetate.\" [EC:3.1.1.44, RHEA:10564]","metadata":null},{"id":"411287bc85a547f3b4d3a2da74aacd90","type":"GO_TERM","name":"4-methylthiopropyl glucosinolate S-oxygenase activity","canonical_id":"go:GO:0080103","description":"\"Catalysis of the reaction: 4-methylthiopropyl-glucosinolate = 4-methylsulfinylpropyl-glucosinolate.\" [PMID:18799661]","metadata":null},{"id":"13d137c060dc4b71b51eb28d59345276","type":"GO_TERM","name":"4-methylumbelliferyl-beta-D-glucopyranoside beta-glucosidase activity","canonical_id":"go:GO:0080081","description":"\"Catalysis of the hydrolysis of glucosidic link in 4-methylumbelliferyl-beta-D-glucopyranoside.\" [PMID:15604686]","metadata":null},{"id":"14ce2b868f264ca1be45b06f3d9a0837","type":"GO_TERM","name":"4-nitrocatechol 4-monooxygenase activity","canonical_id":"go:GO:0018592","description":"\"Catalysis of the reaction: 4-nitrocatechol + NAD(P)H + O2 = 2-hydroxy-1,4-benzoquinone + nitrite + NAD(P)+ + H2O.\" [EC:1.14.13.166]","metadata":null},{"id":"e5b30f8164154077bfe89a8d2ce08da7","type":"GO_TERM","name":"4-nitrophenol 2-monooxygenase activity","canonical_id":"go:GO:0018601","description":"\"Catalysis of the reaction: 4-nitrophenol + H+ + NADH + O2 = 4-nitrocatechol + H2O + NAD+.\" [EC:1.14.13.29, RHEA:12568]","metadata":null},{"id":"751fca354e9b44d78a4b427cde41edc5","type":"GO_TERM","name":"4-nitrophenol 4-monooxygenase activity","canonical_id":"go:GO:0018632","description":"\"Catalysis of the reaction: p-nitrophenol + O2 + NADPH = H2O + NADP+ + nitrite + p-benzoquinone.\" [RHEA:34327]","metadata":null},{"id":"aed7d573a917436d84a5c76fe82fe414","type":"GO_TERM","name":"4-nitrophenol catabolic process","canonical_id":"go:GO:0046196","description":"\"The chemical reactions and pathways resulting in the breakdown of 4-nitrophenol, a nitroaromatic compound which is used in the production of dyes, leather treatment agents, fungicides and as an intermediate in the production of the insecticide parathion.\" [GOC:ai]","metadata":null},{"id":"f22df5e48bc44ebb85030dfe2338e7fc","type":"GO_TERM","name":"4-nitrophenol metabolic process","canonical_id":"go:GO:0018960","description":"\"The chemical reactions and pathways involving 4-nitrophenol, a nitroaromatic compound which is used in the production of dyes, leather treatment agents, fungicides and as an intermediate in the production of the insecticide parathion.\" [GOC:jl]","metadata":null},{"id":"66975ee5b2564a6db5c4af81a1681a48","type":"GO_TERM","name":"4-nitrotoluene catabolic process","canonical_id":"go:GO:0019258","description":"\"The chemical reactions and pathways resulting in the breakdown of 4-nitrotoluene, 1-methyl-4-nitrobenzene.\" [GOC:ai]","metadata":null},{"id":"5f8434f219794d9ea09b817381afa3d0","type":"GO_TERM","name":"4-oxalmesaconate hydratase activity","canonical_id":"go:GO:0047584","description":"\"Catalysis of the reaction: 2-hydroxy-4-oxobutane-1,2,4-tricarboxylate = (1E)-4-oxobut-1-ene-1,2,4-tricarboxylate + H2O.\" [EC:4.2.1.83, RHEA:17401]","metadata":null},{"id":"9ef2c3c3e2cb4e6ba203bdf65146464c","type":"GO_TERM","name":"4-oxalocrotonate decarboxylase activity","canonical_id":"go:GO:0047437","description":"\"Catalysis of the reaction: 4-oxalocrotonate = CO2 + 2-oxopent-4-enoate.\" [EC:4.1.1.77, MetaCyc:4.1.1.77-RXN]","metadata":null},{"id":"3420057fcd6e46859f03631f351c08f7","type":"GO_TERM","name":"4-oxoproline reductase activity","canonical_id":"go:GO:0016617","description":"\"Catalysis of the reaction: 4-hydroxy-L-proline + NAD+ = 4-oxoproline + NADH + H+.\" [EC:1.1.1.104]","metadata":null},{"id":"5f8e0c698f26480a924df8500089066a","type":"GO_TERM","name":"4-phosphoerythronate dehydrogenase activity","canonical_id":"go:GO:0033711","description":"\"Catalysis of the reaction: 4-phospho-D-erythronate + NAD+ = (R)-3-hydroxy-2-oxo-4-phosphonooxybutanoate + H+ + NADH.\" [EC:1.1.1.290, RHEA:18829]","metadata":null},{"id":"05cda434032b4b239084e39ff71d30cb","type":"GO_TERM","name":"4-phosphoerythronate phosphatase activity","canonical_id":"go:GO:0140401","description":"\"Catalysis of the reaction: 4-phospho-D-erythronate + H2O = D-erythronate + phosphate.\" [PMID:27294321, RHEA:86555]","metadata":null},{"id":"eb90f718776147fba49b99aaacb2a33d","type":"GO_TERM","name":"4-pyridoxolactonase activity","canonical_id":"go:GO:0047585","description":"\"Catalysis of the reaction: 4-pyridoxolactone + H2O = 4-pyridoxate + H+.\" [EC:3.1.1.27, RHEA:14301]","metadata":null},{"id":"11663b86360145d5a68998c718f4a49a","type":"GO_TERM","name":"4-sulfobenzoate 3,4-dioxygenase activity","canonical_id":"go:GO:0018621","description":"\"Catalysis of the reaction: 4-sulfobenzoate + H+ + NADH + O2 = 3,4-dihydroxybenzoate + NAD+ + sulfite.\" [RHEA:13937]","metadata":null},{"id":"a215170e6c40419cb705c9f6e455020b","type":"GO_TERM","name":"4-sulfomuconolactone hydrolase activity","canonical_id":"go:GO:0102998","description":"\"Catalysis of the reaction: (5-oxo-2-sulfonato-2,5-dihydrofuran-2-yl)acetate + H2O = maleylacetate + sulfite + 2 H+.\" [EC:3.1.1.92]","metadata":null},{"id":"2679a4fdd893438e94c2e814c555bd23","type":"GO_TERM","name":"4-toluenecarboxylate catabolic process","canonical_id":"go:GO:0019612","description":"\"The chemical reactions and pathways resulting in the breakdown of 4-toluenecarboxylate, 4-methylbenzenecarboxylate, the anion of carboxylic acid attached to a methylbenzene molecule.\" [GOC:ai]","metadata":null},{"id":"7d04b034559e4dd7ac9c1822ff0e3e1b","type":"GO_TERM","name":"4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047105","description":"\"Catalysis of the reaction: 4-(trimethylamino)butanal + NAD+ + H2O = 4-(trimethylamino)butanoate + NADH + 2 H+.\" [RHEA:17985]","metadata":null},{"id":"c693595bd25d4e6b9c0eb79d473b66cb","type":"GO_TERM","name":"4-vinylanisole biosynthetic process","canonical_id":"go:GO:0160305","description":"\"The chemical reactions and pathways resulting in the formation of 4-vinylanisole. 4-vinylanisole derived from food plant phenylalanin is the aggregation pheromone specifically released by gregarious migratory locusts.\" [PMID:40562929]","metadata":null},{"id":"d7660ec680a44304a5223c8e4ccaa9c5","type":"GO_TERM","name":"4-vinylphenol methyltransferase activity","canonical_id":"go:GO:0160304","description":"\"Catalysis of the reaction: 4-vinylphenol + S-adenosyl-L-methionine = 4-vinylanisole + S-adenosyl-L-homocysteine + H+.\" [PMID:40562929, RHEA:86075]","metadata":null},{"id":"dfb670e2e66e4ee2abbb8305d5a3cc38","type":"TRIAL","name":"40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)","canonical_id":"clinicaltrials.gov:NCT00159783","description":"Bipolar Disorder","metadata":null},{"id":"362c835b0c914cd7b4b0da4a24758115","type":"TRIAL","name":"40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)","canonical_id":"clinicaltrials.gov:NCT00145509","description":"Bipolar Disorder","metadata":null},{"id":"9911d631575a47879ef3829eeed9ec2f","type":"DISEASE","name":"46 XX gonadal dysgenesis","canonical_id":"mondo:0009299","description":null,"metadata":null},{"id":"9845bf94c05b4b0bb2fac70c202d3dfd","type":"DISEASE","name":"46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency","canonical_id":"mondo:0009923","description":null,"metadata":null},{"id":"14b6914c21c94932856982e6b6a6e215","type":"TRIAL","name":"480 Biomedical Sinus Drug Depot","canonical_id":"clinicaltrials.gov:NCT02967731","description":"Chronic Sinusitis","metadata":null},{"id":"3e263b33be4e458f8c7de01ae9c6f3bb","type":"TRIAL","name":"4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT00005047","description":"Bladder Cancer","metadata":null},{"id":"241145e92e41452aa8a995de47a80cf4","type":"GO_TERM","name":"4alpha-hydroxymethyl,4beta,14alpha-dimethyl-9beta,19-cyclo-5alpha-ergost-24(241)-en-3beta-ol-4alpha-methyl oxidase activity","canonical_id":"go:GO:0102172","description":"\"Catalysis of the reaction: 4alpha-hydroxymethyl,4beta,14alpha-dimethyl-9beta,19-cyclo-5alpha-ergost-24(241)-en-3beta-ol + NADH + O2 + H+ = 4alpha-formyl,4beta,14alpha-dimethyl-9beta,19-cyclo-5alpha-ergost-24(241)-en-3beta-ol + NAD + 2 H2O.\" [GOC:pz, RHEA:58860]","metadata":null},{"id":"b1dd0f039bac47ae9805a53ab77aa686","type":"GO_TERM","name":"4alpha-hydroxymethyl-stigmasta-7,24(241)-dien-3beta-ol-methyl oxidase activity","canonical_id":"go:GO:0102180","description":"\"Catalysis of the reaction: 4alpha-hydroxymethyl-stigmasta-7,24(241)-dien-3beta-ol + NADH + O2 + H+ = 4alpha-formyl-stigmasta-7,24(241)-dien-3beta-ol + NAD + 2 H2O.\" [GOC:pz, RHEA:59036]","metadata":null},{"id":"fe320b4a614f4c5d91b470f2019d51c1","type":"GO_TERM","name":"4alpha-monomethylsterol monooxygenase activity","canonical_id":"go:GO:0102177","description":"\"Catalysis of the reaction: 24-methylidenelophenol + 6 Fe(II)-[cytochrome b5] + 3 O2 + 5 H+ = 4alpha-carboxy-ergosta-7,24(24(1))-dien-3beta-ol + 6 Fe(III)-[cytochrome b5] + 4 H2O.\" [PMID:11707264, RHEA:58868]","metadata":null},{"id":"4f9bc7cdb6c74b2b801825e9672d7ca6","type":"GO_TERM","name":"5' overhang single-stranded DNA endonuclease activity","canonical_id":"go:GO:1990601","description":"\"Catalysis of the hydrolysis of ester linkages within 5' overhang single-stranded deoxyribonucleic acid by creating internal breaks.\" [PMID:25203555]","metadata":null},{"id":"7c585a19960242939d93c1c1994b6823","type":"GO_TERM","name":"5' transitive RNA interference","canonical_id":"go:GO:1990514","description":"\"An RNA interference where the silencing signal spreads 5' along the target mRNA, outside of the initial target sequence. Typically involves the formation of secondary siRNAs formed when the initial mRNA target sequence functions as a template for 5' to 3' synthesis of new dsRNA.\" [GOC:pf, PMID:24369430]","metadata":null},{"id":"685fd2b332bf4cffb794a58b3ff21e79","type":"GO_TERM","name":"5'-(N(7)-methyl 5'-triphosphoguanosine)-[mRNA] diphosphatase activity","canonical_id":"go:GO:0140932","description":"\"Catalysis of the reaction: a 5'-end (N2,N2,N7-trimethyl 5'-triphosphoguanosine)-ribonucleoside in mRNA + H2O = a 5'-end diphospho-ribonucleoside in mRNA + 2 H+ + N7-methyl-GMP. Can also use (N7-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA as a substrate.\" [PMID:24742626, PMID:32723815]","metadata":null},{"id":"12d6b1bece1a4d8082d096238c17a2c8","type":"GO_TERM","name":"5'-(N(7)-methylguanosine 5'-triphospho)-[mRNA] hydrolase activity","canonical_id":"go:GO:0140933","description":"\"Catalysis of the reaction: a 5'-end (N7-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA + H2O = a 5'-end phospho-ribonucleoside in mRNA + N7-methyl-GDP + H+.\" [PMID:18820299, PMID:29483298]","metadata":null},{"id":"3d4a60326e154637b13ce51645abd462","type":"GO_TERM","name":"5'-3' DNA exonuclease activity","canonical_id":"go:GO:0035312","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' terminus of a DNA molecule.\" [ISBN:0198547684]","metadata":null},{"id":"dc7596f924a241e5813a37e0fd31f122","type":"GO_TERM","name":"5'-3' DNA helicase activity","canonical_id":"go:GO:0043139","description":"\"Unwinding a DNA helix in the 5' to 3' direction, driven by ATP hydrolysis.\" [EC:5.6.2.3, GOC:jl]","metadata":null},{"id":"6e37efed07c7427f9bedf81cca43ce49","type":"GO_TERM","name":"5'-3' DNA/RNA helicase activity","canonical_id":"go:GO:0033678","description":"\"Unwinding of a DNA/RNA duplex in the 5' to 3' direction, driven by ATP hydrolysis.\" [GOC:mah]","metadata":null},{"id":"e7ee5d644b4b4b99a707f2375345a1ec","type":"GO_TERM","name":"5'-3' RNA exonuclease activity","canonical_id":"go:GO:0004534","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' terminus of an RNA molecule.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"f553d290a1394804b2b7536d8440eb94","type":"GO_TERM","name":"5'-3' RNA helicase activity","canonical_id":"go:GO:0032574","description":"\"Unwinding of an RNA helix in the 5' to 3' direction, driven by ATP hydrolysis.\" [GOC:jp]","metadata":null},{"id":"317e44eb61f54b8b9ad5b00a99d1caf3","type":"GO_TERM","name":"5'-3' RNA polymerase activity","canonical_id":"go:GO:0034062","description":"\"Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); the synthesis of RNA from ribonucleotide triphosphates in the presence of a nucleic acid template, via extension of the 3'-end.\" [GOC:mah, GOC:pf, RHEA:21248]","metadata":null},{"id":"970c7500ba174c56aa6a3cb9018274ae","type":"GO_TERM","name":"5'-3' exonuclease activity","canonical_id":"go:GO:0008409","description":"\"Catalysis of the hydrolysis of ester linkages within nucleic acids by removing nucleotide residues from the 5' end.\" [GOC:ai]","metadata":null},{"id":"fad56d4230964befb95e8dfc5a28c791","type":"GO_TERM","name":"5'-acylphosphoadenosine hydrolase activity","canonical_id":"go:GO:0047586","description":"\"Catalysis of the reaction: 5'-acylphosphoadenosine + H2O = AMP + a carboxylate.\" [EC:3.6.1.20, MetaCyc:5-ACYLPHOSPHOADENOSINE-HYDROLASE-RXN]","metadata":null},{"id":"e145322c812b4797b92ac1a5fe81cb12","type":"GO_TERM","name":"5'-adenylyl sulfate transmembrane transport","canonical_id":"go:GO:1902558","description":"\"The process in which 5'-adenylyl sulfate is transported across a membrane.\" [GOC:TermGenie, PMID:24296033]","metadata":null},{"id":"eda24a6bb4bd4767acf01f265e28b7d4","type":"GO_TERM","name":"5'-adenylyl sulfate transmembrane transporter activity","canonical_id":"go:GO:1902557","description":"\"Enables the transfer of 5'-adenylyl sulfate from one side of a membrane to the other.\" [GOC:TermGenie, PMID:24296033]","metadata":null},{"id":"78a9d355f35e4067921b3200513bbeb6","type":"GO_TERM","name":"5'-deoxyadenosine deaminase activity","canonical_id":"go:GO:0090613","description":"\"Catalysis of the reaction: 5'-deoxyadenosine + H2O + H+ = 5'-deoxyinosine + NH4+.\" [PMID:23968233, RHEA:42892]","metadata":null},{"id":"480f3e5930ea4f359d9b18c9f28e2318","type":"GO_TERM","name":"5'-deoxynucleotidase activity","canonical_id":"go:GO:0002953","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-phosphate + H2O = a 2'-deoxyribonucleoside + phosphate.\" [RHEA:36167]","metadata":null},{"id":"98a2ef9e22c841fb845a6c3f02a393a4","type":"GO_TERM","name":"5'-deoxyribose-5-phosphate lyase activity","canonical_id":"go:GO:0051575","description":"\"Catalysis of the reaction: a 5'-end 2'-deoxyribose-2'-deoxyribonucleotide-DNA = (2E,4S)-4-hydroxypenten-2-al-5-phosphate + a 5'-end 5'-phospho-2'-deoxyribonucleoside-DNA + H+.\" [PMID:11251121, PMID:16120966, PMID:9614142, RHEA:76255]","metadata":null},{"id":"90a82b643191494bb7d2783aa523cc5c","type":"GO_TERM","name":"5'-flap endonuclease activity","canonical_id":"go:GO:0017108","description":"\"Catalysis of the cleavage of a 5' flap structure in DNA, but not other DNA structures; processes the 5' ends of Okazaki fragments in lagging strand DNA synthesis.\" [PMID:9778254]","metadata":null},{"id":"b5257b93acb74edaad6910f0208c04b2","type":"GO_TERM","name":"5'-flap-structured DNA binding","canonical_id":"go:GO:0070338","description":"\"Binding to a 5'-flap structure in DNA. A DNA flap structure is one in which a single-stranded 5'-end of DNA or RNA protrudes from a double-stranded DNA molecule. 5'-flap structures can be formed during DNA repair or lagging strand synthesis; in the latter case RNA flaps form from lagging strand RNA primers.\" [GOC:mah, PMID:15189154]","metadata":null},{"id":"fc1494bd54fc4ca8bee15bc91f5058f0","type":"GO_TERM","name":"5'-hydroxyaverantin dehydrogenase activity","canonical_id":"go:GO:0140396","description":"\"Catalyzes the reaction: (1'S,5'S)-hydroxyaverantin + NAD+ = 5'-oxoaverantin + NADH.\" [EC:1.1.1.352, PMID:14602595]","metadata":null},{"id":"bb2a2dd289364712ac5f14003b3c269f","type":"GO_TERM","name":"5'-hydroxyl dinucleotide hydrolase activity","canonical_id":"go:GO:0140432","description":"\"Catalysis of the hydrolysis of phosphodiester bonds in 5'OH-RNA according to the reaction 5'OH-NpN-RNA + H20 = 5'OH-NpN + 5'P-RNA, where NpN represents a dinucleotide.\" [PMID:31777937]","metadata":null},{"id":"8e04ee4e370c4f449074e59380520e28","type":"GO_TERM","name":"5'-methylthioadenosine deaminase activity","canonical_id":"go:GO:0090614","description":"\"Catalysis of the reaction: S-methyl-5'-thioadenosine + H2O + H+ = S-methyl-5'-thioinosine + NH4+.\" [PMID:23968233, RHEA:25025]","metadata":null},{"id":"b99138efb42b44c29d84a6203948b79d","type":"GO_TERM","name":"5'-nucleotidase activity","canonical_id":"go:GO:0008253","description":"\"Catalysis of the reaction: a nucleoside 5'-phosphate + H2O = a nucleoside + phosphate.\" [EC:3.1.3.5, PMID:27907199]","metadata":null},{"id":"9846958439464190ae7c9f8bb79e0f6d","type":"GO_TERM","name":"5'-tyrosyl-DNA phosphodiesterase activity","canonical_id":"go:GO:0070260","description":"\"Catalysis of the hydrolysis of 5'-phosphotyrosyl groups formed as covalent intermediates (in DNA backbone breakage) between DNA topoisomerase II and DNA.\" [PMID:16751265]","metadata":null},{"id":"b3a7507c35614e3cba54569bcf1737c4","type":"GO_TERM","name":"5(S)-hydroxyeicosatetraenoic acid dehydrogenase activity","canonical_id":"go:GO:0097265","description":"\"Catalysis of the reaction: 5-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate (5-HETE) + reduced [NADPH-hemoprotein reductase] + O2 = 5,20-dihydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate (5-oxo-ETE) + oxidized [NADPH-hemoprotein reductase] + H2O + H+.\" [PMID:1326548, PMID:9675028, RHEA:48656]","metadata":null},{"id":"d9bd2c56af5e417db27a1a6f1bf6792b","type":"GO_TERM","name":"5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-icosatetraenoic acid binding","canonical_id":"go:GO:0050648","description":"\"Binding to 5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-icosatetraenoic acid, a straight-chain fatty acid with twenty carbon atoms and four double bonds.\" [GOC:ai]","metadata":null},{"id":"6afe47a6777148d88ab5913fff62a429","type":"GO_TERM","name":"5,10-methylenetetrahydrofolate-dependent methyltransferase activity","canonical_id":"go:GO:0042083","description":"\"Catalysis of the transfer of a methyl group to an acceptor molecule; dependent on the presence of 5,10-methylenetetrahydrofolate.\" [GOC:ai]","metadata":null},{"id":"3f3e469d822d4747abc09eca4bdafafe","type":"GO_TERM","name":"5,6,7,8-tetrahydromethanopterin biosynthetic process","canonical_id":"go:GO:1901285","description":"\"The chemical reactions and pathways resulting in the formation of 5,6,7,8-tetrahydromethanopterin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00065]","metadata":null},{"id":"60703a2cc7ab45ada9343c16a62c6e23","type":"GO_TERM","name":"5,6,7,8-tetrahydromethanopterin catabolic process","canonical_id":"go:GO:1901284","description":"\"The chemical reactions and pathways resulting in the breakdown of 5,6,7,8-tetrahydromethanopterin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00065]","metadata":null},{"id":"98218998cf124cb7814a401a9717f236","type":"GO_TERM","name":"5,6,7,8-tetrahydrosarcinapterin biosynthetic process","canonical_id":"go:GO:1901855","description":"\"The chemical reactions and pathways resulting in the formation of 5,6,7,8-tetrahydrosarcinapterin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00069]","metadata":null},{"id":"1d55784eaeff462da59fd6fefab14319","type":"GO_TERM","name":"5,6,7,8-tetrahydrosarcinapterin catabolic process","canonical_id":"go:GO:1901854","description":"\"The chemical reactions and pathways resulting in the breakdown of 5,6,7,8-tetrahydrosarcinapterin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00069]","metadata":null},{"id":"522377ce2dae43218c268b3052f6a95f","type":"GO_TERM","name":"5,6-dihydroxy-3-methyl-2-oxo-1,2,5,6-tetrahydroquinoline dehydrogenase activity","canonical_id":"go:GO:0018518","description":"\"Catalysis of the reaction: 5,6-dihydroxy-3-methyl-5,6-dihydroquinolin-2(1H)-one + NAD+ = 5,6-dihydroxy-3-methyl-2-oxo-1,2-dihydroquinoline + H+ + NADH.\" [EC:1.3.1.65, RHEA:24556]","metadata":null},{"id":"372838c51a5649e087fe19baf72b56a5","type":"GO_TERM","name":"5,6-dimethylbenzimidazole synthase activity","canonical_id":"go:GO:0102919","description":"\"Catalysis of the reaction: FMNH2 + O2 = 5,6-dimethylbenzimidazole + D-erythrose 4-phosphate + dialuric acid.\" [EC:1.13.11.79]","metadata":null},{"id":"b8c30a8a3a2140afa5f27c68e5bf67cf","type":"GO_TERM","name":"5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase activity","canonical_id":"go:GO:0047377","description":"\"Catalysis of the reaction: 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene + H2O = 5-(3-hydroxy-4-acetoxybut-1-ynyl)-2,2'-bithiophene + acetate + H+.\" [EC:3.1.1.66, RHEA:16313]","metadata":null},{"id":"2dacaa8b08f44a988fc8e89a650897da","type":"GO_TERM","name":"5-(carboxyamino)imidazole ribonucleotide mutase activity","canonical_id":"go:GO:0034023","description":"\"Catalysis of the reaction: 5-carboxyamino-1-(5-phospho-D-ribosyl)imidazole = 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate.\" [EC:5.4.99.18]","metadata":null},{"id":"404b5cde00ad45a1bc95c820fa17a54c","type":"GO_TERM","name":"5-(carboxyamino)imidazole ribonucleotide synthase activity","canonical_id":"go:GO:0034028","description":"\"Catalysis of the reaction: 5-amino-1-(5-phospho-D-ribosyl)imidazole + ATP + bicarbonate = 5-carboxyamino-1-(5-phospho-D-ribosyl)imidazole + ADP + 3 H+ + phosphate.\" [EC:6.3.4.18, RHEA:19317]","metadata":null},{"id":"b636a40d049e4df2a6fa9a5335dc7297","type":"TRIAL","name":"5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","canonical_id":"clinicaltrials.gov:NCT04288427","description":"Benign Prostatic Hyperplasia; Prostate Hyperplasia; Prostate Disease; Prostate Hypertrophy; Prostate Pain; Lower Urinary Tract Symptoms; Urinary Obstruction; Urinary Tract Disease","metadata":null},{"id":"d4ca5d9c5a7844198dd133ebf203d52f","type":"TRIAL","name":"5-Alpha Reductase and Anabolic Effects of Testosterone","canonical_id":"clinicaltrials.gov:NCT00475501","description":"Male Hypogonadism; Muscle Atrophy; Sarcopenia; Benign Prostate Hypertrophy","metadata":null},{"id":"38f7c22f14ab4d79990f3f4d52072b3a","type":"TRIAL","name":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","canonical_id":"clinicaltrials.gov:NCT03300609","description":"Colorectal Adenocarcinoma; RAS Wild Type; Stage III Colorectal Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7","metadata":null},{"id":"cfff6696b251440daa26e18b8af03aab","type":"PROTEIN","name":"5-Hydroxytryptamine receptor 2B","canonical_id":"uniprot:P41595","description":null,"metadata":null},{"id":"34c2156fb6484737b096e9cbde2fc27b","type":"GO_TERM","name":"5-O-(4-coumaroyl)-D-quinate 3'-monooxygenase activity","canonical_id":"go:GO:0047083","description":"\"Catalysis of the reaction: O2 + NADPH + H+ + trans-5-O-(4-coumaroyl)-D-quinate = H2O + NADP+ + trans-5-O-caffeoyl-D-quinate.\" [EC:1.14.14.96, MetaCyc:1.14.13.36-RXN]","metadata":null},{"id":"e07c65541b1445b7a3f91194fbbf2860","type":"GO_TERM","name":"5-O-phosphono-alpha-D-ribofuranosyl diphosphate binding","canonical_id":"go:GO:1902248","description":"\"Binding to 5-O-phosphono-alpha-D-ribofuranosyl diphosphate.\" [GOC:mah, GOC:TermGenie, PMID:4314233]","metadata":null},{"id":"bfdd55775f9b4b16af523bacf49659fc","type":"TRIAL","name":"5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00120523","description":"Atopic Dermatitis","metadata":null},{"id":"d793436ea87f4fffaf028e54fff67189","type":"GO_TERM","name":"5-alpha-androstane-3-beta,17-beta-diol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047024","description":"\"Catalysis of the reaction: 5-alpha-androstane-3-beta,17-beta-diol + NADP+ = 17-beta-hydroxy-5-alpha-androstan-3-one + H+ + NADPH.\" [RHEA:16297]","metadata":null},{"id":"97bff8037fee4841b6716df095ab4543","type":"GO_TERM","name":"5-alpha-hydroxysteroid dehydratase activity","canonical_id":"go:GO:0047587","description":"\"Catalysis of the reaction: 5alpha-ergosta-7,22-diene-3beta,5-diol = ergosterol + H2O.\" [EC:4.2.1.62, RHEA:22064]","metadata":null},{"id":"fd006a3baa9e4e29aed1cd67fd15c5fc","type":"GO_TERM","name":"5-amino-1-ribofuranosylimidazole-4-carboxamide transmembrane transport","canonical_id":"go:GO:1903088","description":"\"The process in which 5-amino-1-ribofuranosylimidazole-4-carboxamide is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:24778186]","metadata":null},{"id":"e130cbb5dc974a6ca538a30d81bea9e9","type":"GO_TERM","name":"5-amino-1-ribofuranosylimidazole-4-carboxamide transmembrane transporter activity","canonical_id":"go:GO:1903089","description":"\"Enables the transfer of 5-amino-1-ribofuranosylimidazole-4-carboxamide from one side of a membrane to the other.\" [GO_REF:0000066, GOC:TermGenie, PMID:24778186]","metadata":null},{"id":"6f96e74acb154191b2883ae837d515f4","type":"GO_TERM","name":"5-amino-6-(5-phosphoribitylamino)uracil phosphatase activity","canonical_id":"go:GO:0043726","description":"\"Catalysis of the reaction: 5-amino-6-(5-phospho-D-ribitylamino)uracil + H2O = 5-amino-6-(D-ribitylamino)uracil + phosphate.\" [GOC:jl]","metadata":null},{"id":"7fddd33997ad4ec0878cae95f7200981","type":"GO_TERM","name":"5-amino-6-(5-phosphoribosylamino)uracil reductase activity","canonical_id":"go:GO:0008703","description":"\"Catalysis of the reaction: 5-amino-6-(5-phosphoribitylamino)uracil + NADP+ = 5-amino-6-(5-phosphoribosylamino)uracil + H+ + NADPH.\" [EC:1.1.1.193, RHEA:17845]","metadata":null},{"id":"91c171cb8c4b4d3da370b9c43889648a","type":"GO_TERM","name":"5-amino-6-(D-ribitylamino)uracil--L-tyrosine 4-hydroxyphenyl transferase activity","canonical_id":"go:GO:0141093","description":"\"Catalysis of the reaction: 5-amino-6-(D-ribitylamino)uracil + L-tyrosine + S-adenosyl-L-methionine = 2-iminoacetate + 5'-deoxyadenosine + 5-amino-5-(4-hydroxybenzyl)-6-(D-ribitylimino)-5,6-dihydrouracil + H+ + L-methionine.\" [PMID:11948155, PMID:23072415, PMID:25781338, RHEA:55200]","metadata":null},{"id":"cc7fb99fc1484ca889281a2993700353","type":"GO_TERM","name":"5-aminolevulinate synthase activity","canonical_id":"go:GO:0003870","description":"\"Catalysis of the reaction: glycine + H+ + succinyl-CoA = 5-aminolevulinate + CO2 + CoA.\" [EC:2.3.1.37, RHEA:12921]","metadata":null},{"id":"c550d7b6e76a4476ba9aff623873ea2f","type":"GO_TERM","name":"5-aminolevulinic acid import across plasma membrane","canonical_id":"go:GO:0140484","description":"\"The directed movement of 5-aminolevulinic acid from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:31989647]","metadata":null},{"id":"3422c05396fc4dbab8c758a832ef9e9d","type":"GO_TERM","name":"5-aminolevulinic acid transmembrane transporter activity","canonical_id":"go:GO:0140485","description":"\"Enables the transfer of 5-aminolevulinic acid from one side of a membrane to the other.\" [PMID:31989647]","metadata":null},{"id":"535071043a644d0086a92d05b85bd40e","type":"GO_TERM","name":"5-aminopentanamidase activity","canonical_id":"go:GO:0047588","description":"\"Catalysis of the reaction: 5-aminopentanamide + H2O = 5-aminopentanoate + NH4+.\" [RHEA:15677]","metadata":null},{"id":"507f6fee6f0c4859a51e33679b4c4084","type":"GO_TERM","name":"5-aminovalerate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047589","description":"\"Catalysis of the reaction: 5-aminopentanoate + 2-oxoglutarate = 5-oxopentanoate + L-glutamate.\" [RHEA:10212]","metadata":null},{"id":"e8feb141ebb84aeba78b1873c73b01ab","type":"GO_TERM","name":"5-carbamoylmethyl uridine residue modification","canonical_id":"go:GO:0080178","description":"\"The chemical reactions and pathways involving the addition of a 5-carbamoylmethyl group to a uridine residue in RNA.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"942cc9b0b1ad47bba03f48e4064a200b","type":"GO_TERM","name":"5-carboxymethyl-2-hydroxymuconate delta-isomerase activity","canonical_id":"go:GO:0008704","description":"\"Catalysis of the reaction: 5-carboxymethyl-2-hydroxymuconate = 5-carboxy-2-oxohept-3-enedioate.\" [EC:5.3.3.10]","metadata":null},{"id":"44d98c8e9f484339bf77a1e6e03ea093","type":"GO_TERM","name":"5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018480","description":"\"Catalysis of the reaction: 2-hydroxy-5-carboxymethylmuconate semialdehyde + NAD+ + H2O = (2E,4Z)-5-hydroxypenta-2,4-diene-1,2,5-tricarboxylate + NADH + 2 H+.\" [RHEA:15681]","metadata":null},{"id":"108e2d0367fa46a990dd930ef8a9cbea","type":"GO_TERM","name":"5-dehydro-2-deoxygluconokinase activity","canonical_id":"go:GO:0047590","description":"\"Catalysis of the reaction: ATP + 5-dehydro-2-deoxy-D-gluconate = ADP + 6-phospho-5-dehydro-2-deoxy-D-gluconate.\" [EC:2.7.1.92, MetaCyc:5-DEHYDRO-2-DEOXYGLUCONOKINASE-RXN]","metadata":null},{"id":"d0085e56a34448e09b25ac9e43c93453","type":"GO_TERM","name":"5-dehydro-2-deoxyphosphogluconate aldolase activity","canonical_id":"go:GO:0047441","description":"\"Catalysis of the reaction: 6-phospho-5-dehydro-2-deoxy-D-gluconate = 3-oxopropanoate + glycerone phosphate.\" [EC:4.1.2.29, RHEA:13177]","metadata":null},{"id":"af3107eacd4941d6b84fc5abbdf10bc8","type":"GO_TERM","name":"5-dehydro-4-deoxyglucarate dehydratase activity","canonical_id":"go:GO:0047448","description":"\"Catalysis of the reaction: 5-dehydro-4-deoxy-D-glucarate + H+ = 2,5-dioxopentanoate + CO2 + H2O.\" [EC:4.2.1.41, RHEA:24608]","metadata":null},{"id":"876bb888777d407c9f5bbbec0de62b33","type":"GO_TERM","name":"5-deoxy-D-glucuronate isomerase activity","canonical_id":"go:GO:0102482","description":"\"Catalysis of the reaction: 5-deoxy-D-glucuronate = 5-dehydro-2-deoxy-D-gluconate.\" [GOC:pz, RHEA:25840]","metadata":null},{"id":"481875507a2d468b812b2a1f2bdcd3d5","type":"GO_TERM","name":"5-diphosphoinositol pentakisphosphate 1-kinase activity","canonical_id":"go:GO:0033857","description":"\"Catalysis of the reaction: ATP + 1D-myo-inositol 5-diphosphate pentakisphosphate = ADP + 1D-myo-inositol bisdiphosphate tetrakisphosphate.\" [EC:2.7.4.24]","metadata":null},{"id":"8749bb22a6004b06a542356bcf2d8492","type":"GO_TERM","name":"5-diphosphoinositol pentakisphosphate 4-kinase activity","canonical_id":"go:GO:0000833","description":"\"Catalysis of the reaction: ATP + 5-diphospho-1D-myo-inositol (1,2,3,4,6)pentakisphosphate = ADP + 4,5-bis(diphospho)-1D-myo-inositol (1,2,3,6)tetrakisphosphate.\" [GOC:elh, PMID:16429326]","metadata":null},{"id":"84654c3a3b684726b9b8381d87ccb2c7","type":"GO_TERM","name":"5-diphosphoinositol pentakisphosphate 6-kinase activity","canonical_id":"go:GO:0000834","description":"\"Catalysis of the reaction: ATP + 5-diphospho-1D-myo-inositol (1,2,3,4,6)pentakisphosphate = ADP + 5,6-bisdiphosphoinositol-1D-myo-inositol (1,2,3,4)tetrakisphosphate.\" [GOC:elh, PMID:16429326]","metadata":null},{"id":"5f966548974c40b7abdc2a633e0d1c02","type":"GO_TERM","name":"5-epi-aristolochene synthase activity","canonical_id":"go:GO:0102698","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (+)-5-epi-aristolochene + diphosphoric acid.\" [EC:4.2.3.61, GOC:pz]","metadata":null},{"id":"f2ca13931d9a4b14a2ca077dd92d6a45","type":"GO_TERM","name":"5-epi-aristolochene-1,3-dihydroxylase activity","canonical_id":"go:GO:0102170","description":"\"Catalysis of the reaction: (+)-5-epi-aristolochene + 2 NADPH + 2 H+ + 2 O2 = capsidiol + 2 NADP + 2 H2O.\" [EC:1.14.14.149, GOC:pz]","metadata":null},{"id":"d57957334bf240c2b4c9dd7d028b2bbb","type":"GO_TERM","name":"5-exo-hydroxycamphor dehydrogenase activity","canonical_id":"go:GO:0018452","description":"\"Catalysis of the reaction: 5-exo-hydroxycamphor + NAD+ = NADH + H+ + 2,5-diketocamphane.\" [UM-BBD_reactionID:r0427]","metadata":null},{"id":"0713bc9762ff4d10864739d9cdf474d3","type":"TRIAL","name":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","canonical_id":"clinicaltrials.gov:NCT07124884","description":"Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer","metadata":null},{"id":"4948ac7d15064bef9c576b8b8d0a5eef","type":"GO_TERM","name":"5-formyltetrahydrofolate cyclo-ligase activity","canonical_id":"go:GO:0030272","description":"\"Catalysis of the reaction: 5-formyltetrahydrofolate + ATP = 5,10-methenyltetrahydrofolate + ADP + H+ + phosphate.\" [EC:6.3.3.2, RHEA:10488]","metadata":null},{"id":"7c085d2247214cabb26cf3d23491d170","type":"GO_TERM","name":"5-formyltetrahydrofolate transmembrane transporter activity","canonical_id":"go:GO:0015231","description":"\"Enables the transfer of 5-formyltetrahydrofolate, the formylated derivative of tetrahydrofolate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"81e001cb277a48a8bbaed87c2cb83f25","type":"GO_TERM","name":"5-formyltetrahydrofolate transport","canonical_id":"go:GO:0015885","description":"\"The directed movement of 5-formyltetrahydrofolate, the formylated derivative of tetrahydrofolate, into, out of, within, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"0f9207e3a27b44759a2659c86a71471d","type":"GO_TERM","name":"5-formyluracil DNA N-glycosylase activity","canonical_id":"go:GO:0034042","description":"\"Catalysis of the removal of 5-formyluracil bases by cleaving the N-C1' glycosidic bond between the oxidized pyrimidine and the deoxyribose sugar.\" [GOC:mah, PMID:17641464]","metadata":null},{"id":"8a6fdea8e57548e797524b2c07114a98","type":"GO_TERM","name":"5-guanidino-2-oxopentanoate decarboxylase activity","canonical_id":"go:GO:0047435","description":"\"Catalysis of the reaction: 5-guanidino-2-oxopentanoate + H+ = 4-guanidinobutanal + CO2.\" [EC:4.1.1.75, RHEA:11340]","metadata":null},{"id":"022efc7cdb204a61a1c2bf55570cc531","type":"GO_TERM","name":"5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid binding","canonical_id":"go:GO:0050647","description":"\"Binding to 5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid, a straight-chain fatty acid with twenty carbon atoms and four double bonds.\" [GOC:ai]","metadata":null},{"id":"3600954db175441e969fb2d8bd7d0d2f","type":"GO_TERM","name":"5-hydroxy-L-tryptophan decarboxylase activity","canonical_id":"go:GO:0036467","description":"\"Catalysis of the reaction: 5-hydroxy-L-tryptophan + H+ = CO2 + serotonin.\" [GOC:bf, GOC:PARL, RHEA:18533]","metadata":null},{"id":"519676e1de63416785fef9397573768d","type":"GO_TERM","name":"5-hydroxyfuranocoumarin 5-O-methyltransferase activity","canonical_id":"go:GO:0030752","description":"\"Catalysis of the reaction: a 5-hydroxyfurocoumarin + S-adenosyl-L-methionine = a 5-methoxyfurocoumarin + S-adenosyl-L-homocysteine + H+.\" [RHEA:18861]","metadata":null},{"id":"1cf68238f92642819245485a5ec7a599","type":"GO_TERM","name":"5-hydroxymethyl-dUMP N-hydrolase activity","canonical_id":"go:GO:0070694","description":"\"Catalysis of the reaction: 5-hydroxymethyl-dUMP + H2O = 2-deoxy-D-ribose 5-phosphate + 5-hydroxymethyluracil.\" [PMID:17234634, RHEA:77099]","metadata":null},{"id":"f93f4007d07e4cadb2cbe886bda38d5f","type":"GO_TERM","name":"5-hydroxymethyluracil DNA N-glycosylase activity","canonical_id":"go:GO:0034043","description":"\"Catalysis of the removal of 5-hydroxymethyluracil bases by cleaving the N-C1' glycosidic bond between the oxidized pyrimidine and the deoxyribose sugar.\" [GOC:mah, PMID:17641464]","metadata":null},{"id":"a29a54e54b4f4d7390dad6bb5469b860","type":"GO_TERM","name":"5-hydroxypentanoate CoA-transferase activity","canonical_id":"go:GO:0047591","description":"\"Catalysis of the reaction: 5-hydroxypentanoate + acetyl-CoA = 5-hydroxy-pentanoyl-CoA + acetate.\" [RHEA:23496]","metadata":null},{"id":"9b9a093b373c46609966e6dff191883d","type":"PROTEIN","name":"5-hydroxytryptamine receptor 4","canonical_id":"uniprot:Q13639","description":null,"metadata":null},{"id":"03b45f0938814d21916ea16a063a6c1b","type":"GO_TERM","name":"5-lipoxygenase complex","canonical_id":"go:GO:0002180","description":"\"An nuclear membrane protein complex having arachidonate 5-lipoxygenase activity.\" [PMID:19075240]","metadata":null},{"id":"7bc854ed2f554157bf6df72653455991","type":"GO_TERM","name":"5-methyl-5,6,7,8-tetrahydromethanopterin-dependent methyltransferase activity","canonical_id":"go:GO:0042086","description":"\"Catalysis of the transfer of a methyl group to an acceptor molecule, dependent on the presence of 5-methyl-5,6,7,8-tetrahydromethanopterin.\" [GOC:ai]","metadata":null},{"id":"c40325567e484dc7ba6466b6a943b54e","type":"GO_TERM","name":"5-methyl-phenazine-1-carboxylate N-methyltransferase activity","canonical_id":"go:GO:0102168","description":"\"Catalysis of the reaction: phenazine-1-carboxylate + S-adenosyl-L-methionine = 5-methyl-phenazine-1-carboxylate + S-adenosyl-L-homocysteine.\" [RHEA:49112]","metadata":null},{"id":"7a57b96fe7024e1d9215c1412ed8d444","type":"GO_TERM","name":"5-methyldeoxycytidine-5'-phosphate kinase activity","canonical_id":"go:GO:0047336","description":"\"Catalysis of the reaction: 2'-deoxy-5-methyl-5'-cytidylate + ATP = 5-methyldeoxycytidine diphosphate + ADP + H+.\" [EC:2.7.4.19, RHEA:11396]","metadata":null},{"id":"23dcbe0db229496189df9123fff8cc44","type":"GO_TERM","name":"5-methylphenazine-1-carboxylate 1-monooxygenase (NADH) activity","canonical_id":"go:GO:0102169","description":"\"Catalysis of the reaction: 5-methyl-phenazine-1-carboxylate + 2 H+ + NADH + O2 = CO2 + H2O + NAD+ + pyocyanin. Also converts phenazine-1-carboxylate into 1-hydroxyphenazine.\" [EC:1.14.13.218, PMID:11591691]","metadata":null},{"id":"7025ec3f8a8c4991acdb556f2b2006f9","type":"GO_TERM","name":"5-methyltetrahydropteroyltriglutamate-homocysteine S-methyltransferase activity","canonical_id":"go:GO:0003871","description":"\"Catalysis of the reaction: 5-methyltetrahydropteroyltri-L-glutamate + L-homocysteine = L-methionine + tetrahydropteroyltri-L-glutamate.\" [EC:2.1.1.14, RHEA:21196]","metadata":null},{"id":"144e7330643c448793981561bd06a5f6","type":"GO_TERM","name":"5-methylthiopropyl glucosinolate S-oxygenase activity","canonical_id":"go:GO:0080104","description":"\"Catalysis of the reaction: 5-methylthiopropyl-glucosinolate = 5-methylsulfinylpropyl-glucosinolate.\" [PMID:18799661]","metadata":null},{"id":"86edb0862efa4fd1abbfacbab13e195a","type":"GO_TERM","name":"5-n-alk(en)ylresorcinol O-methyltransferase activity","canonical_id":"go:GO:0102990","description":"\"Catalysis of the reaction: (8Z,11Z)-5-(pentadeca-8,11,14-trien-1-yl)resorcinol + S-adenosyl-L-methionine = (8Z,11Z)-5-(pentadeca- 8,11,14-trien-1-yl)resorcinol-3-methyl ether + H+ + S-adenosyl-L-homocysteine.\" [RHEA:26325]","metadata":null},{"id":"3571d2fad48d4179a02e30555d29719c","type":"GO_TERM","name":"5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid binding","canonical_id":"go:GO:0050646","description":"\"Binding to 5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid, a straight-chain fatty acid with twenty carbon atoms and four double bonds.\" [GOC:ai]","metadata":null},{"id":"040dec21c33b4cb9a31f0f5a338bf5e4","type":"GO_TERM","name":"5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase activity","canonical_id":"go:GO:0018800","description":"\"Catalysis of the reaction: 5-oxopent-3-ene-1,2,5-tricarboxylate = 2-oxohept-3-enedioate + CO2.\" [EC:4.1.1.68]","metadata":null},{"id":"ef44d9f13dce4b03b17324756bcf0734","type":"GO_TERM","name":"5-oxoprolinase (ATP-hydrolyzing) activity","canonical_id":"go:GO:0017168","description":"\"Catalysis of the reaction: 5-oxo-L-proline + ATP + 2 H2O = L-glutamate + ADP + 2 H+ + phosphate.\" [EC:3.5.2.9, RHEA:10348]","metadata":null},{"id":"80424209a8c54c0990e454287db8eaa7","type":"GO_TERM","name":"5-phosphoribose 1-diphosphate biosynthetic process","canonical_id":"go:GO:0006015","description":"\"The chemical reactions and pathways resulting in the formation of 5-phosphoribose 1-diphosphate, also known as 5-phosphoribosyl-1-pyrophosphate.\" [GOC:ai]","metadata":null},{"id":"5fc987bea3484fbba952f2ad4557201c","type":"GO_TERM","name":"5-phosphoribose 1-diphosphate metabolic process","canonical_id":"go:GO:0046391","description":"\"The chemical reactions and pathways involving 5-phosphoribose 1-diphosphate, also known as 5-phosphoribosyl-1-pyrophosphate.\" [GOC:ai]","metadata":null},{"id":"499e5e4a3c4b41b69126881ccf27aba3","type":"GO_TERM","name":"5-phosphoribosyl 1-pyrophosphate pyrophosphatase activity","canonical_id":"go:GO:0043135","description":"\"Catalysis of the reaction: 5-phospho-alpha-D-ribose 1-diphosphate + H2O = ribose 1,5 bisphosphate + phosphate + H+.\" [MetaCyc:RXN-10969, PMID:12370170]","metadata":null},{"id":"cd84bdf6e41745e58d04cb5ee8646e64","type":"GO_TERM","name":"5-pyridoxate dioxygenase activity","canonical_id":"go:GO:0047592","description":"\"Catalysis of the reaction: 5-pyridoxate + NADPH + O2 = 2-(acetamidomethylene)-3-(hydroxymethyl)succinate) + NADP+.\" [RHEA:11152]","metadata":null},{"id":"119e385a560e46429d861995f7a7f5d3","type":"GO_TERM","name":"5.8S rRNA binding","canonical_id":"go:GO:1990932","description":"\"Binding to 5.8S ribosomal RNA, a eukaryotic ribosomal RNA which forms a complex with 28S RNA.\" [PMID:11716358, PMID:15527424]","metadata":null},{"id":"778d00a54932427db4337829f817b673","type":"PROTEIN","name":"50S Ribosomal protein l-10","canonical_id":"uniprot:P44350","description":null,"metadata":null},{"id":"23d52ed3c1f54e8d8ae68ca709ed2ae4","type":"PROTEIN","name":"50S ribosomal protein L10","canonical_id":"uniprot:P0A7J6","description":null,"metadata":null},{"id":"ad43e930782747428f17ea66bd5c04fd","type":"PROTEIN","name":"50S ribosomal protein L16","canonical_id":"uniprot:Q8XET6","description":null,"metadata":null},{"id":"aa3a990008d148279702c37307f90dce","type":"PROTEIN","name":"50S ribosomal protein L3 (Streptococcus pyogenes)","canonical_id":"uniprot:Q9A1X4","description":null,"metadata":null},{"id":"2a23ae9c3bdb4bf9aa96f963438b2622","type":"PROTEIN","name":"50S ribosomal subunit","canonical_id":"uniprot:P0A298","description":null,"metadata":null},{"id":"bec97b97299343edb96fb73d788087b7","type":"TRIAL","name":"52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine","canonical_id":"clinicaltrials.gov:NCT00145301","description":"Osteoarthritis","metadata":null},{"id":"14d3efb164024a5393e32066303c097f","type":"TRIAL","name":"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","canonical_id":"clinicaltrials.gov:NCT00575588","description":"Type 2 Diabetes","metadata":null},{"id":"5a8edf602357497a9ce06169518fbd7b","type":"TRIAL","name":"5G-EMERALD: Amivantamab in Malignant Brain Tumours","canonical_id":"clinicaltrials.gov:NCT06632236","description":"Malignant Primary Gliomas; Glioblastoma Multiform (Grade IV Astrocytoma); Diffuse Hemispheric Glioma, H3 G34-Mutant; Glioblastoma Multiforme (GBM)","metadata":null},{"id":"fd10ef613a3d4a91afa2ab510a2b511f","type":"TRIAL","name":"5HT3 Antagonism and Auditory Gating in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00018850","description":"Schizophrenia","metadata":null},{"id":"78075d4091f643bd85f3b071d0882127","type":"GO_TERM","name":"5S class rRNA transcription by RNA polymerase III","canonical_id":"go:GO:0042791","description":"\"The synthesis of 5S ribosomal RNA (rRNA), or an equivalent rRNA, from a DNA template by RNA polymerase III (Pol III), originating at a type 1 RNA polymerase III promoter.\" [GOC:jl, GOC:txnOH, ISBN:0321000382, PMID:12381659]","metadata":null},{"id":"dd36c45a7afb46198563732a9d3fb7e0","type":"GO_TERM","name":"5S rDNA binding","canonical_id":"go:GO:0080084","description":"\"Binding to a 5S rDNA sequence, encoding ribosomal 5S rRNA, which is individually transcribed by RNA polymerase III, rather than by RNA polymerase I, in species where it exists.\" [PMID:12711688]","metadata":null},{"id":"cb180937b5cd4478946406a9d53d7a87","type":"GO_TERM","name":"5S rRNA binding","canonical_id":"go:GO:0008097","description":"\"Binding to a 5S ribosomal RNA, the smallest RNA constituent of a ribosome.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"2ac0a99c05624688b7752093c4f58954","type":"GO_TERM","name":"5S rRNA primary transcript binding","canonical_id":"go:GO:0008098","description":"\"Binding to an unprocessed 5S ribosomal RNA transcript.\" [GOC:jl]","metadata":null},{"id":"c83364b95a2f4eadaf6047ffc0a185af","type":"GO_TERM","name":"5alpha,9alpha,10beta-labda-8(20),13-dien-15-yl diphosphate biosynthetic process","canonical_id":"go:GO:1901949","description":"\"The chemical reactions and pathways resulting in the formation of 5alpha,9alpha,10beta-labda-8(20),13-dien-15-yl diphosphate.\" [GOC:TermGenie, PMID:22027823]","metadata":null},{"id":"00370215d36343dbb93d40cb5a0949af","type":"GO_TERM","name":"5alpha,9alpha,10beta-labda-8(20),13-dien-15-yl diphosphate catabolic process","canonical_id":"go:GO:1901948","description":"\"The chemical reactions and pathways resulting in the breakdown of 5alpha,9alpha,10beta-labda-8(20),13-dien-15-yl diphosphate.\" [GOC:TermGenie, PMID:22027823]","metadata":null},{"id":"cc54917598db4ebb993bdb48bda331d8","type":"TRIAL","name":"6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00170872","description":"Osteoarthritis; Rheumatoid Arthritis","metadata":null},{"id":"54807120536b44c2b14b03965ddcf016","type":"GO_TERM","name":"6'-deoxychalcone synthase activity","canonical_id":"go:GO:0033808","description":"\"Catalysis of the reaction: 3 malonyl-CoA + 4-coumaroyl-CoA + NADPH + H+ = 4 CoA + isoliquiritigenin + 3 CO2 + NADP+ + H2O.\" [EC:2.3.1.170]","metadata":null},{"id":"04609438a6f14865bedcb7ef6fb2c11a","type":"GO_TERM","name":"6,7-dihydropteridine reductase activity","canonical_id":"go:GO:0004155","description":"\"Catalysis of the reaction: NAD(P)+ + 5,6,7,8-tetrahydropteridine = NAD(P)H + H+ + 6,7-dihydropteridine.\" [EC:1.5.1.34]","metadata":null},{"id":"46a568c32cf44b7283b440862093a2df","type":"GO_TERM","name":"6,7-dimethyl-8-ribityllumazine synthase activity","canonical_id":"go:GO:0000906","description":"\"Catalysis of the reaction: 3,4-dihydroxy-2-butanone-4-phosphate + 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione = 6,7-dimethyl-8-ribityllumazine + phosphate.\" [PMID:7559556]","metadata":null},{"id":"3f1a4ce8337e4cd8b6bc90606ec53fb2","type":"TRIAL","name":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)","canonical_id":"clinicaltrials.gov:NCT00265343","description":"Schizophrenia","metadata":null},{"id":"7864d6d3a1f443d5b2631660ad239b36","type":"TRIAL","name":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)","canonical_id":"clinicaltrials.gov:NCT00174265","description":"Schizophrenia","metadata":null},{"id":"e38b3d63649847f18bbc91d1c7461f21","type":"GO_TERM","name":"6-O-methyl-deacetylisoipecoside beta-glucosidase activity","canonical_id":"go:GO:0102413","description":"\"Catalysis of the reaction: 6-O-methyl-N-deacetylisoipecoside + H2O = 6-O-methyl-N-deacetylisoipecoside aglycon + D-glucose.\" [RHEA:78891]","metadata":null},{"id":"973a0fae09874b9eb7b18899bdf571fc","type":"GO_TERM","name":"6-O-methylnorlaudanosoline 5'-O-methyltransferase activity","canonical_id":"go:GO:0030781","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 6-O-methylnorlaudanosoline = S-adenosyl-L-homocysteine + nororientaline.\" [EC:2.1.1.121]","metadata":null},{"id":"51b202387d754ae5a42b4229d17a1349","type":"TRIAL","name":"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients","canonical_id":"clinicaltrials.gov:NCT00504660","description":"Anaplastic Glioma of Brain; Glioblastoma Multiforme; Brain Cancer","metadata":null},{"id":"94729ff0ed6a4beba52a42dccde8b26b","type":"TRIAL","name":"6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT02140060","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"f1526d9fbf7249e5871c33005e1c4780","type":"GO_TERM","name":"6-acetylglucose deacetylase activity","canonical_id":"go:GO:0047593","description":"\"Catalysis of the reaction: 6-acetyl-D-glucose + H2O = D-glucose + acetate + H+.\" [EC:3.1.1.33, RHEA:18485]","metadata":null},{"id":"63551d4aa3744c819f2194b059c3621c","type":"GO_TERM","name":"6-alpha-maltosylglucose biosynthetic process","canonical_id":"go:GO:0051680","description":"\"The chemical reactions and pathways resulting in the formation of 6-alpha-maltosylglucose, also known as isopanose.\" [GOC:ai]","metadata":null},{"id":"1c4a35a594d1446d93d6d539db1b0e0c","type":"GO_TERM","name":"6-alpha-maltosylglucose catabolic process","canonical_id":"go:GO:0051681","description":"\"The chemical reactions and pathways resulting in the breakdown of 6-alpha-maltosylglucose, also known as isopanose.\" [GOC:ai]","metadata":null},{"id":"3872ec9402fd45fd984c756f3b192023","type":"GO_TERM","name":"6-amino-6-deoxyfutalosine hydrolase activity","canonical_id":"go:GO:0102246","description":"\"Catalysis of the reaction: aminodeoxyfutalosinate + H2O = dehypoxanthine futalosine + adenine.\" [EC:3.2.2.30, GOC:pz]","metadata":null},{"id":"24c3b44563b34e8996052ea0614ae020","type":"DRUG","name":"6-aminocaproic acid","canonical_id":"gtopdb:6574","description":null,"metadata":null},{"id":"f53cce0d156f4da194993094d4e3d164","type":"DRUG","name":"6-aminocaproic acid","canonical_id":"chembl:CHEMBL1046","description":null,"metadata":null},{"id":"40d81527d7004369b6858da8365a8111","type":"GO_TERM","name":"6-aminohexanoate-cyclic-dimer hydrolase activity","canonical_id":"go:GO:0019874","description":"\"Catalysis of the reaction: 1,8-diazacyclotetradecane-2,9-dione + H2O = N-(6-aminohexanoyl)-6-aminohexanoate.\" [EC:3.5.2.12, RHEA:16225]","metadata":null},{"id":"2ade3df961ff4975bf5784746449eb53","type":"GO_TERM","name":"6-aminohexanoate-dimer hydrolase activity","canonical_id":"go:GO:0019875","description":"\"Catalysis of the reaction: N-(6-aminohexanoyl)-6-aminohexanoate + H2O = 2 6-aminohexanoate.\" [EC:3.5.1.46]","metadata":null},{"id":"d34491ca8406420698263a005d2c0de7","type":"GO_TERM","name":"6-aminohexanoate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0018719","description":"\"Catalysis of the reaction: 6-aminohexanoate + 2-oxoglutarate = 6-oxohexanoate + L-glutamate.\" [RHEA:58200]","metadata":null},{"id":"e32b366522d0482aaba6aad360628789","type":"GO_TERM","name":"6-beta-hydroxyhyoscyamine epoxidase activity","canonical_id":"go:GO:0047594","description":"\"Catalysis of the reaction: (6S)-6-hydroxyhyoscyamine + 2-oxoglutarate + O2 = CO2 + H2O + H+ + scopolamine + succinate.\" [EC:1.14.20.13, RHEA:12797]","metadata":null},{"id":"2dff99bafc684d12acd7a0721cf79eb8","type":"GO_TERM","name":"6-carboxyhexanoate-CoA ligase activity","canonical_id":"go:GO:0042410","description":"\"Catalysis of the reaction: ATP + CoA + pimelate = AMP + diphosphate + H+ + pimelyl-CoA.\" [EC:6.2.1.14, RHEA:14781]","metadata":null},{"id":"95394adabd2b4b1d82a286c865ad33f3","type":"GO_TERM","name":"6-carboxymethyl-5-methyl-4-hydroxypyridin-2-ol 3-C-methyltransferase activity","canonical_id":"go:GO:0160302","description":"\"Catalysis of the reaction: 6-carboxymethyl-5-methyl-4-hydroxypyridin-2-ol + S-adenosyl-L-methionine = 6-carboxymethyl-3,5-dimethyl-4-hydroxypyridin-2-ol + S-adenosyl-L-homocysteine + H+.\" [PMID:27391308, RHEA:85483]","metadata":null},{"id":"b1f6ecafada54e4b952301ca8d635475","type":"GO_TERM","name":"6-carboxytetrahydropterin synthase activity","canonical_id":"go:GO:0070497","description":"\"Catalysis of the reaction: 7,8-dihydroneopterin 3'-triphosphate + H2O = 6-carboxy-5,6,7,8-tetrahydropterin + triphosphate + acetaldehyde + 2 H+.\" [PMID:19231875, RHEA:27966]","metadata":null},{"id":"825ec164bd3248a5aad6516fdd0aa466","type":"GO_TERM","name":"6-deoxy-6-sulfofructose kinase activity","canonical_id":"go:GO:0061594","description":"\"Catalysis of the reaction 6-deoxy-6-sulfofructose + ATP = 6-deoxy-6-sulfofructose-1-phosphate + ADP.\" [PMID:24463506]","metadata":null},{"id":"f8fde3bc51c04dad967fa7192561129d","type":"GO_TERM","name":"6-deoxy-6-sulfofructose-1-phosphate aldolase activity","canonical_id":"go:GO:0061595","description":"\"Catalysis of the reaction 6-deoxy-6-sulfofructose-1-phosphate = 3-sulfolactaldehyde + dihydroxyacetone phosphate.\" [PMID:24463506]","metadata":null},{"id":"0b15bf67d1364580b01755b9e1e51b01","type":"GO_TERM","name":"6-endo-hydroxycineole dehydrogenase activity","canonical_id":"go:GO:0045481","description":"\"Catalysis of the reaction: 6-endo-hydroxycineole + NAD+ = 6-oxocineole + H+ + NADH.\" [EC:1.1.1.241, RHEA:11736]","metadata":null},{"id":"d98b6b0a5fca46c2b205c79ab5c1301d","type":"GO_TERM","name":"6-hydroxycineole catabolic process","canonical_id":"go:GO:0019639","description":"\"The chemical reactions and pathways resulting in the breakdown of 6-hydroxycineole (6-hydroxy-1,8-epoxy-p-menthane), a hydrocarbon with the formula C10H18O2.\" [GOC:ai]","metadata":null},{"id":"43faf8ed3a2f4a29950489d0bf072800","type":"GO_TERM","name":"6-hydroxycyclohex-1-ene-1-carboxyl-CoA hydratase activity","canonical_id":"go:GO:0018807","description":"\"Catalysis of the reaction: 6-hydroxycyclohex-1-ene-1-carboxyl-CoA + H2O = 2,6-dihydroxycyclohexane-1-carboxyl-CoA.\" [UM-BBD_reactionID:r0204]","metadata":null},{"id":"a46efa7974dd4413b10fc4fa7f2d38e5","type":"GO_TERM","name":"6-hydroxyhexanoate dehydrogenase activity","canonical_id":"go:GO:0018463","description":"\"Catalysis of the reaction: 6-hydroxyhexanoate + NAD+ = 6-oxohexanoate + H+ + NADH.\" [EC:1.1.1.258, RHEA:14225]","metadata":null},{"id":"ee230b2cdc1f4955a72ccca36378d75c","type":"GO_TERM","name":"6-hydroxymellein O-methyltransferase activity","canonical_id":"go:GO:0030773","description":"\"Catalysis of the reaction: 6-hydroxymellein + S-adenosyl-L-methionine = 6-methoxymellein + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.108, RHEA:15201]","metadata":null},{"id":"4781016ca2a9408c98dad2dc3f01b744","type":"GO_TERM","name":"6-hydroxynicotinate 3-monooxygenase activity","canonical_id":"go:GO:0043731","description":"\"Catalysis of the oxidative decarboxylation of 6-hydroxynicotinate to 2,5-dihydroxypyridine, dependent on O2, NADH +H+ and FAD.\" [GOC:jl, PMID:10091591]","metadata":null},{"id":"943e10afb3e84845adefcd7729aaec3d","type":"GO_TERM","name":"6-hydroxynicotinate dehydrogenase activity","canonical_id":"go:GO:0043732","description":"\"Catalysis of the reaction: 6-hydroxynicotinate + H2O + O2 = 2,6-dihydroxynicotinate + H2O2.\" [EC:1.17.3.3, RHEA:22808]","metadata":null},{"id":"50ae94dbb92f42cf86174651cf5c35f8","type":"GO_TERM","name":"6-hydroxynicotinate reductase activity","canonical_id":"go:GO:0047595","description":"\"Catalysis of the reaction: 1,4,5,6-tetrahydro-6-oxonicotinate + oxidized ferredoxin = 6-hydroxynicotinate + reduced ferredoxin.\" [EC:1.3.7.1, MetaCyc:6-HYDROXYNICOTINATE-REDUCTASE-RXN]","metadata":null},{"id":"5139e3a9317d490e9ce08deffd7af42c","type":"GO_TERM","name":"6-hydroxypseudooxynicotine dehydrogenase activity","canonical_id":"go:GO:0034909","description":"\"Catalysis of the reaction: 6-hydroxypseudooxynicotine + H2O + OH- = 6-hydroxy-3-succinoylpyridine + 4 H+ + 4 e- + methylamine.\" [UM-BBD_reactionID:r1441]","metadata":null},{"id":"fb9f0a7f40304b5682b43f3a69482123","type":"GO_TERM","name":"6-methylsalicylate decarboxylase activity","canonical_id":"go:GO:0047596","description":"\"Catalysis of the reaction: 6-methylsalicylate + H+ = 3-cresol + CO2.\" [EC:4.1.1.52, RHEA:23112]","metadata":null},{"id":"129e6d48373a401d9f8aada75473171a","type":"GO_TERM","name":"6-methylsalicylic acid synthase activity","canonical_id":"go:GO:0050641","description":"\"Catalysis of the reaction: acetyl-CoA + 3 H+ + 3 malonyl-CoA + NADPH = 6-methylsalicylate + 3 CO2 + 4 CoA + H2O + NADP+.\" [EC:2.3.1.165, RHEA:12240]","metadata":null},{"id":"5e0007668e26490b85903e17c51d5104","type":"GO_TERM","name":"6-methylthiopropyl glucosinolate S-oxygenase activity","canonical_id":"go:GO:0080105","description":"\"Catalysis of the reaction: 6-methylthiopropyl-glucosinolate = 6-methylsulfinylpropyl-glucosinolate.\" [PMID:18799661]","metadata":null},{"id":"0c879a798a204e398022503663412b98","type":"TRIAL","name":"6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA","canonical_id":"clinicaltrials.gov:NCT00360243","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"af3788a104e84b39833e4eba54f73ce8","type":"GO_TERM","name":"6-oxocineole dehydrogenase activity","canonical_id":"go:GO:0047597","description":"\"Catalysis of the reaction: 6-oxocineole + H+ + NADPH + O2 = 1,6,6-trimethyl-2,7-dioxabicyclo[3.2.2]nonan-3-one + H2O + NADP+.\" [EC:1.14.13.51, RHEA:24324]","metadata":null},{"id":"2f59e4565c334c46b95cba4945db0789","type":"GO_TERM","name":"6-oxohexanoate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0018483","description":"\"Catalysis of the reaction: 6-oxohexanoate + NADP+ + H2O = hexanedioate + NADPH + 2 H+.\" [RHEA:13397]","metadata":null},{"id":"099ea2c9fd5f487ca73502ebcfb9db44","type":"GO_TERM","name":"6-phospho-3-hexuloisomerase activity","canonical_id":"go:GO:0043800","description":"\"Catalysis of the reaction: D-arabino-hex-3-ulose 6-phosphate = beta-D-fructose 6-phosphate.\" [PMID:11839305, RHEA:25900]","metadata":null},{"id":"84e6504ae0f8467cab7a32082eddc87b","type":"GO_TERM","name":"6-phospho-beta-galactosidase activity","canonical_id":"go:GO:0033920","description":"\"Catalysis of the reaction: a 6-phospho-beta-D-galactoside + H2O = 6-phospho-D-galactose + an alcohol.\" [RHEA:24568]","metadata":null},{"id":"bbd0a600679e4b0a9f8971cfc0897a38","type":"GO_TERM","name":"6-phospho-beta-glucosidase activity","canonical_id":"go:GO:0008706","description":"\"Catalysis of the reaction: 6-phospho-beta-D-glucoside-(1,4)-D-glucose + H2O = D-glucose 6-phosphate + glucose.\" [EC:3.2.1.86]","metadata":null},{"id":"d69312f4a4e4404f920a5e22902b803b","type":"GO_TERM","name":"6-phosphofructo-2-kinase activity","canonical_id":"go:GO:0003873","description":"\"Catalysis of the reaction: beta-D-fructose 6-phosphate + ATP = beta-D-fructose 2,6-bisphosphate + ADP + 2 H+.\" [EC:2.7.1.105, RHEA:15653]","metadata":null},{"id":"2b0fd93878a94c0aae2109c6bdeb39e6","type":"GO_TERM","name":"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex","canonical_id":"go:GO:0043540","description":"\"A homodimeric, bifunctional enzyme complex which catalyzes the synthesis and degradation of fructose 2,6-bisphosphate, and is required for both glycolysis and gluconeogenesis.\" [GOC:jl, GOC:so]","metadata":null},{"id":"f191e65c58fb46d6bd661b826687e809","type":"GO_TERM","name":"6-phosphofructokinase activity","canonical_id":"go:GO:0003872","description":"\"Catalysis of the reaction: ATP + D-fructose-6-phosphate = ADP + D-fructose 1,6-bisphosphate.\" [EC:2.7.1.11]","metadata":null},{"id":"4d5d13cc5ea544008387ed3695ea4378","type":"GO_TERM","name":"6-phosphofructokinase complex","canonical_id":"go:GO:0005945","description":"\"A protein complex that possesses 6-phosphofructokinase activity; homodimeric, homooctameric, and allosteric homotetrameric forms are known.\" [GOC:mah, GOC:vw, ISBN:0198506732]","metadata":null},{"id":"ed910374791c43d59e8b47b1f420ad3e","type":"GO_TERM","name":"6-phosphogluconolactonase activity","canonical_id":"go:GO:0017057","description":"\"Catalysis of the reaction: 6-O-phosphono-D-glucono-1,5-lactone + H2O = 6-phospho-D-gluconate + H+.\" [EC:3.1.1.31, RHEA:12556]","metadata":null},{"id":"c1cd204f66114606a8bcbcda3e11f9fc","type":"GO_TERM","name":"6-pyruvoyltetrahydropterin 2'-reductase activity","canonical_id":"go:GO:0047028","description":"\"Catalysis of the reaction: NADP+ + 6-lactoyl-5,6,7,8-tetrahydropterin = NADPH + H+ + 6-pyruvoyltetrahydropterin.\" [EC:1.1.1.220, MetaCyc:1.1.1.220-RXN]","metadata":null},{"id":"87a901ea5d6c4b639bada045ebe731f8","type":"GO_TERM","name":"6-pyruvoyltetrahydropterin synthase activity","canonical_id":"go:GO:0003874","description":"\"Catalysis of the reaction: 7,8-dihydroneopterin 3'-triphosphate = 6-pyruvoyl-5,6,7,8-tetrahydropterin + H+ + triphosphate.\" [EC:4.2.3.12, RHEA:22048]","metadata":null},{"id":"f9ef7dc154b44225b487c5adfb0d7359","type":"GO_TERM","name":"6-sulfoquinovose(1-) catabolic process","canonical_id":"go:GO:1902777","description":"\"The chemical reactions and pathways resulting in the breakdown of 6-sulfoquinovose(1-).\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:24463506]","metadata":null},{"id":"30e5c55905714b40bc4c34fe96df4446","type":"TRIAL","name":"6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)","canonical_id":"clinicaltrials.gov:NCT01098110","description":"Schizophrenia","metadata":null},{"id":"b20be33628194da1a090b7a5d8d7b497","type":"TRIAL","name":"601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)","canonical_id":"clinicaltrials.gov:NCT04922151","description":"Pathological Myopic Choroidal Neovascularization","metadata":null},{"id":"ff4cfc5871ac43568b0b66f6173f1ea7","type":"PROTEIN","name":"60S ribosomal protein L3","canonical_id":"uniprot:P39023","description":null,"metadata":null},{"id":"6b4fc6c30aea4ba18c96546f1bfd8e64","type":"TRIAL","name":"64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy","canonical_id":"clinicaltrials.gov:NCT03542695","description":"Breast Carcinoma; Calcification","metadata":null},{"id":"27547ae398fa47e299fc677eedf4f0ac","type":"GO_TERM","name":"6G-fructosyltransferase activity","canonical_id":"go:GO:0033841","description":"\"Catalysis of the reaction: [1-beta-D-fructofuranosyl-(2->1)-]m+1 alpha-D-glucopyranoside + [1-beta-D-fructofuranosyl-(2->1)-]n+1 alpha-D-glucopyranoside = [1-beta-D-fructofuranosyl-(2->1)-]m alpha-D-glucopyranoside + [1-beta-D-fructofuranosyl-(2->1)-]n+1 beta-D-fructofuranosyl-(2->6)-alpha-D-glucopyranoside (m > 0; n >= 0).\" [EC:2.4.1.243]","metadata":null},{"id":"a2f7c710550846308e923021fe04df24","type":"GO_TERM","name":"6a-hydroxymaackiain-3-O-methyltransferase activity","canonical_id":"go:GO:0102671","description":"\"Catalysis of the reaction: (+)-6a-hydroxymaackiain + S-adenosyl-L-methionine = H+ + (+)-pisatin + S-adenosyl-L-homocysteine.\" [EC:2.1.1.270, GOC:pz]","metadata":null},{"id":"54db059d3c5a4f4a842e841e90bba1cf","type":"GO_TERM","name":"7,8-didemethyl-8-hydroxy-5-deazariboflavin biosynthetic process","canonical_id":"go:GO:1901852","description":"\"The chemical reactions and pathways resulting in the formation of 7,8-didemethyl-8-hydroxy-5-deazariboflavin.\" [GOC:TermGenie, GOC:yaf, PMID:14593448, UniPathway:UPA00072]","metadata":null},{"id":"939870ecab344ff5b3d2336cbc24694a","type":"GO_TERM","name":"7,8-didemethyl-8-hydroxy-5-deazariboflavin catabolic process","canonical_id":"go:GO:1901851","description":"\"The chemical reactions and pathways resulting in the breakdown of 7,8-didemethyl-8-hydroxy-5-deazariboflavin.\" [GOC:TermGenie, GOC:yaf, PMID:14593448, UniPathway:UPA00072]","metadata":null},{"id":"fd6ad442f1444476a6b36b11ce0b66de","type":"GO_TERM","name":"7,8-didemethyl-8-hydroxy-5-deazariboflavin synthase activity","canonical_id":"go:GO:0044689","description":"\"Catalysis of the reaction: 5-amino-5-(4-hydroxybenzyl)-6-(D-ribitylimino)-5,6-dihydrouracil + S-adenosyl-L-methionine = 5'-deoxyadenosine + 7,8-didemethyl-8-hydroxy-5-deazariboflavin + H+ + L-methionine + NH4+.\" [PMID:14593448, RHEA:55204]","metadata":null},{"id":"9d715633b8cc43839f209d5213284ebe","type":"GO_TERM","name":"7,8-didemethyl-8-hydroxy-5-deazariboflavin synthase complex","canonical_id":"go:GO:0044673","description":"\"A heterodimer which catalyses the reaction of 5-amino-6-(D-ribitylamino)uracil and 4-hydroxyphenylpyruvate to form 7,8-didemethyl-8-hydroxy-5-deazariboflavin (FO), an intermediate of coenzyme F420.\" [GOC:mengo_curators, PMID:14593448]","metadata":null},{"id":"94d7911eaaef4cb6a5c49e38fbcdcba0","type":"GO_TERM","name":"7,8-dihydro-D-neopterin 2',3'-cyclic phosphate phosphodiesterase activity","canonical_id":"go:GO:0044688","description":"\"Catalysis of the reaction: 7,8-dihydro-D-neopterin 2',3'-cyclic phosphate + H2O = 7,8-dihydroneopterin 3'-phosphate or 7,8-dihydroneopterin 2'-phosphate + H+.\" [EC:3.1.4.56]","metadata":null},{"id":"801661a4a5eb40ef965e0faf5efde9f4","type":"GO_TERM","name":"7,8-dihydromonapterin aldolase activity","canonical_id":"go:GO:0102083","description":"\"Catalysis of the reaction: 7,8-dihydromonapterin = glycolaldehyde + 2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-ol.\" [GOC:pz, PMID:15107504]","metadata":null},{"id":"e51874599b144960a63e7f6d8979d046","type":"GO_TERM","name":"7,8-dihydropterin-6-yl-methyl-4-(beta-D-ribofuranosyl)aminobenzene 5'-phosphate synthase activity","canonical_id":"go:GO:0102041","description":"\"Catalysis of the reaction: 4-(beta-D-ribofuranosyl)aminobenzene 5'-phosphate + (2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate = N-[(7,8-dihydropterin-6-yl)methyl]-4-(beta-D-ribofuranosyl)aniline 5'-phosphate + diphosphoric acid.\" [RHEA:35951]","metadata":null},{"id":"7946a71ce309457681a12ca963329f59","type":"GO_TERM","name":"7,8-dihydroxykynurenate 8,8a-dioxygenase activity","canonical_id":"go:GO:0047069","description":"\"Catalysis of the reaction: 7,8-dihydroxykynurenate + O2 = 5-(3-carboxylato-3-oxoprop-1-en-1-yl)-4,6-dihydroxypyridine-2-carboxylate + H+.\" [EC:1.13.11.10, RHEA:23400]","metadata":null},{"id":"e5a00d20bf2140529505e919411ef13d","type":"GO_TERM","name":"7-beta-hydroxysteroid dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047022","description":"\"Catalysis of the reaction: a 7-beta-hydroxysteroid + NADP+ = a 7-oxosteroid + NADPH + H+.\" [RHEA:20233]","metadata":null},{"id":"0583d1aee21a4402b220a51ff9dc6be0","type":"GO_TERM","name":"7-cyano-7-deazaguanine biosynthetic process","canonical_id":"go:GO:0097288","description":"\"The chemical reactions and pathways resulting in the formation of the Q nucleoside precursor 7-cyano-7-deazaguanine, also known as 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile or preQo.\" [GOC:yaf, PMID:364423]","metadata":null},{"id":"eeee511179b14d078ae128883aef1b8e","type":"GO_TERM","name":"7-cyano-7-deazaguanine tRNA-ribosyltransferase activity","canonical_id":"go:GO:0043867","description":"\"Catalysis of the reaction: tRNA guanine + 7-cyano-7-deazaguanine = tRNA 7-cyano-7-deazaguanine + guanine.\" [PMID:16407303, PMID:7748953]","metadata":null},{"id":"fe6d5c704dbd4872a0b9c7a273642c42","type":"GO_TERM","name":"7-dehydrocholesterol reductase activity","canonical_id":"go:GO:0047598","description":"\"Catalysis of the reaction: cholesterol + NADP+ = 7-dehydrocholesterol + H+ + NADPH.\" [RHEA:23984]","metadata":null},{"id":"53cc3af0403a4fe796fb1635f0baaf49","type":"GO_TERM","name":"7-deoxyloganate 7-hydroxylase activity","canonical_id":"go:GO:0140989","description":"\"Catalysis of the reaction: 7-deoxyloganate + O2 + reduced [NADPH-hemoprotein reductase] = H+ + H2O + loganate + oxidized [NADPH-hemoprotein reductase].\" [PMID:24710322, RHEA:57576]","metadata":null},{"id":"2c9891b89a7c49ff8d915bdb8dfd4cb0","type":"GO_TERM","name":"7-deoxyloganetic acid glucosyltransferase activity","canonical_id":"go:GO:0102970","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + 7-deoxyloganetate = H+ + 7-deoxyloganate + UDP.\" [EC:2.4.1.323, GOC:pz]","metadata":null},{"id":"eaa284068c50477db307dd37024eb08a","type":"GO_TERM","name":"7-deoxyloganin 7-hydroxylase activity","canonical_id":"go:GO:0050595","description":"\"Catalysis of the reaction: 7-deoxyloganin + O2 + reduced [NADPH-hemoprotein reductase] = H+ + H2O + loganin + oxidized [NADPH-hemoprotein reductase].\" [PMID:11524113, RHEA:11452]","metadata":null},{"id":"0a73e9f2586b4b17bbbdda7f12d7bc96","type":"GO_TERM","name":"7-epi-alpha-selinene synthase activity","canonical_id":"go:GO:0102906","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate(3-) = (-)-7-epi-alpha-selinene + diphosphoric acid.\" [EC:4.2.3.86, GOC:pz]","metadata":null},{"id":"a0acf066875547868daf71b82af7436b","type":"GO_TERM","name":"7-hydroxymethyl chlorophyll a reductase activity","canonical_id":"go:GO:0090415","description":"\"Catalysis of the reaction: 7-hydroxymethyl chlorophyll a + 2 reduced ferredoxin + 2 H+ chlorophyll a + 2 oxidized ferredoxin + H2O.\" [GOC:kad, PMID:21934147, RHEA:53544]","metadata":null},{"id":"3d875dec1fa04df3a91e43711610c746","type":"GO_TERM","name":"7-methylguanosine RNA capping","canonical_id":"go:GO:0009452","description":"\"The sequence of enzymatic reactions by which the RNA 5' cap structure, an inverted 7-methylguanosine linked via a 5'-5' triphosphate bridge (m7G(5')ppp(5')X) to the first transcribed residue, is added to a nascent transcript. Additional methylation can occur on the ribose sugars of the first and second nucleotides adjacent to the m7G nRNA cap. These methylations are often referred to as N6,2'-O-dimethyladenosine (m6,2A) and N6,2'-O-dimethylguanosine (m6,2G), respectively.\" [GOC:vw, PMID:9266685]","metadata":null},{"id":"205933d135794500808da72a49bf318e","type":"GO_TERM","name":"7-methylguanosine biosynthetic process","canonical_id":"go:GO:0046118","description":"\"The chemical reactions and pathways resulting in the formation of 7-methylguanosine, a modified nucleoside that forms a cap at the 5'-terminus of eukaryotic mRNA.\" [ISBN:0198506732]","metadata":null},{"id":"e71b64a68ea348e1aec46dcae059085a","type":"GO_TERM","name":"7-methylguanosine cap hypermethylation","canonical_id":"go:GO:0036261","description":"\"Hypermethylation of the 7-(mono)methylguanosine (m(7)G) cap structure at the 2' position of the guanosine residue to convert a mono-methylated cap to a 2,2,7-trimethylguanosine cap structure. This type of cap modification occurs on small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs) and is dependent on prior guanine-N7 methylation.\" [GOC:bf, GOC:BHF, GOC:krc, GOC:mah, GOC:rl, PMID:11983179, PMID:18775984]","metadata":null},{"id":"ce3cea54bb514456b6537c4fbea345cf","type":"GO_TERM","name":"7-methylguanosine catabolic process","canonical_id":"go:GO:0046119","description":"\"The chemical reactions and pathways resulting in the breakdown of 7-methylguanosine, a modified nucleoside that forms a cap at the 5'-terminus of eukaryotic mRNA.\" [ISBN:0198506732]","metadata":null},{"id":"ac545276e746468794db2e4e10f6106e","type":"GO_TERM","name":"7-methylguanosine mRNA capping","canonical_id":"go:GO:0006370","description":"\"The sequence of enzymatic reactions by which the mRNA 5' cap structure, an inverted 7-methylguanosine linked via a 5'-5' triphosphate bridge (m7G(5')ppp(5')X) to the first transcribed residue, is added to a nascent transcript. Additional methylation can occur on the ribose sugars of the first and second nucleotides adjacent to the m7G nRNA cap. These methylations are often referred to as N6,2'-O-dimethyladenosine (m6,2A) and N6,2'-O-dimethylguanosine (m6,2G), respectively.\" [GOC:mah, PMID:9266685]","metadata":null},{"id":"15a62a35678b47d980f2cf4ec3886e15","type":"GO_TERM","name":"7-methylguanosine metabolic process","canonical_id":"go:GO:0008618","description":"\"The chemical reactions and pathways involving 7-methylguanosine, a modified nucleoside that forms a cap at the 5'-terminus of eukaryotic mRNA.\" [ISBN:0198506732]","metadata":null},{"id":"3a6b5b9ac6b3496aa9eeed8c08aa46a3","type":"GO_TERM","name":"7-methylthiopropyl glucosinolate S-oxygenase activity","canonical_id":"go:GO:0080106","description":"\"Catalysis of the reaction: 7-methylthiopropyl-glucosinolate = 7-methylsulfinylpropyl-glucosinolate.\" [PMID:18799661]","metadata":null},{"id":"72aa740cb69e4b5093dd8bcd21246dee","type":"TRIAL","name":"723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover","canonical_id":"clinicaltrials.gov:NCT00972504","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"02db4bd444c74e1a912215604a947aea","type":"GO_TERM","name":"7S RNA binding","canonical_id":"go:GO:0008312","description":"\"Binding to a 7S RNA, the RNA component of the signal recognition particle (SRP).\" [GOC:jl, PMID:6181418]","metadata":null},{"id":"09cfc0787cc74bbf9f98818e986663e1","type":"GO_TERM","name":"7SK snRNA binding","canonical_id":"go:GO:0097322","description":"\"Binding to a 7SK small nuclear RNA (7SK snRNA).\" [GOC:nhn, PMID:21853533]","metadata":null},{"id":"ce1c82538cfe434982c19677b48a8d7f","type":"GO_TERM","name":"7SK snRNP","canonical_id":"go:GO:0120259","description":"\"A ribonucleoprotein complex that contains the 7SK snRNA. The 7SK snRNP plays a central role in RNA polymerase II elongation control by regulating the availability of active P-TEFb.\" [PMID:18249148, PMID:28431135]","metadata":null},{"id":"0daf2eb016ab477f897d5a36ac979c16","type":"TRIAL","name":"8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension","canonical_id":"clinicaltrials.gov:NCT00809926","description":"Stage 2 Hypertension","metadata":null},{"id":"d881ba18d4f94e6e87461ecae7cd2455","type":"GO_TERM","name":"8-amino-7-oxononanoate synthase activity","canonical_id":"go:GO:0008710","description":"\"Catalysis of the reaction: L-alanine + H+ + pimelyl-CoA = 8-amino-7-oxononanoate + CO2 + CoA.\" [EC:2.3.1.47, RHEA:20712]","metadata":null},{"id":"f316e31818cf49a8a32abb7522d247a5","type":"GO_TERM","name":"8-demethylnovobiocate synthase activity","canonical_id":"go:GO:0102527","description":"\"Catalysis of the reaction: 3-amino-4,7-dihydroxycoumarin + 3-dimethylallyl-4-hydroxybenzoate + ATP(4-) = H+ + 8-desmethylnovobiocic acid(1-) + AMP(2-) + diphosphoric acid.\" [EC:6.3.1.15, GOC:pz]","metadata":null},{"id":"4f71afe5c1b9446fbf9eecf6593cb88a","type":"GO_TERM","name":"8-demethylnovobiocic acid C8-methyltransferase activity","canonical_id":"go:GO:0102526","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 8-desmethylnovobiocic acid = S-adenosyl-L-homocysteine + novobiocic acid + H+.\" [EC:2.1.1.284, GOC:pz]","metadata":null},{"id":"aded8098fd4a425599576f353eeb4cc7","type":"GO_TERM","name":"8-hydroxy-2'-deoxyguanosine DNA binding","canonical_id":"go:GO:1905773","description":"\"Binding to 8-hydroxy-2'-deoxyguanosine an oxidized purine residue found in damaged DNA.\" [GO_REF:0000067, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:19734539]","metadata":null},{"id":"17b28327c1264deabdb1a6e69daf7d93","type":"GO_TERM","name":"8-hydroxy-5-deazaflavin:NADPH oxidoreductase activity","canonical_id":"go:GO:0102261","description":"\"Catalysis of the reaction: NADP+ + reduced coenzyme F420-(gamma-L-Glu)(n) = 2 H+ + NADPH + oxidized coenzyme F420-(gamma-L-Glu)(n).\" [PMID:11726492, RHEA:31363]","metadata":null},{"id":"50d1af9bdd8747db8afb1e35ea7030a3","type":"GO_TERM","name":"8-hydroxy-dADP phosphatase activity","canonical_id":"go:GO:0044717","description":"\"Catalysis of the reaction: 8-hydroxy-dADP + H2O = 8-hydroxy-dAMP + phosphate.\" [GOC:pde, PMID:22556419]","metadata":null},{"id":"03c66d9cd23a4ffda4256d86c3c9703d","type":"GO_TERM","name":"8-hydroxyfuranocoumarin 8-O-methyltransferase activity","canonical_id":"go:GO:0030753","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + xanthotoxol = S-adenosyl-L-homocysteine + xanthotoxin. Xanthotoxol is also known as 8-hydroxyfuranocoumarin and xanthotoxin as 8-methoxyfuranocoumarin.\" [EC:2.1.1.70]","metadata":null},{"id":"ed145a644caf47839d3b46a1e1e5d39b","type":"GO_TERM","name":"8-hydroxygeraniol dehydrogenase activity","canonical_id":"go:GO:0102311","description":"\"Catalysis of the reaction: (6E)-8-hydroxygeraniol + 2 NADP = (6E)-8-oxogeranial + 2 NADPH + 2 H+.\" [EC:1.1.1.324, GOC:pz]","metadata":null},{"id":"a2658f8bb63f4edf9ccbbff2f08e6012","type":"GO_TERM","name":"8-hydroxyquercitin 8-O-methyltransferase activity","canonical_id":"go:GO:0030761","description":"\"Catalysis of the reaction: 3,3',4',5,7,8-hexahydroxyflavone + S-adenosyl-L-methionine(1+) = 3,3',4',5,7-pentahydroxy-8-methoxyflavone + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.88, RHEA:16593]","metadata":null},{"id":"c408ff22155b4dc08062602b974fec71","type":"GO_TERM","name":"8-methylthiopropyl glucosinolate S-oxygenase activity","canonical_id":"go:GO:0080107","description":"\"Catalysis of the reaction: 8-methylthiopropyl-glucosinolate = 8-methylsulfinylpropyl-glucosinolate.\" [PMID:18799661]","metadata":null},{"id":"96dc5d1e40a7403fab539373d8cfb261","type":"GO_TERM","name":"8-oxo-(d)RTP hydrolase activity","canonical_id":"go:GO:0106379","description":"\"Catalysis of the reaction: 8-oxo-(d)RTP + H20 = 8-oxo-(d)RMP + diphosphate + H+.\" [PMID:11139615]","metadata":null},{"id":"2006590a287348d1b475356f546afbc8","type":"GO_TERM","name":"8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity","canonical_id":"go:GO:0035539","description":"\"Catalysis of the reaction: 8-oxo-7,8-dihydrodeoxyguanosine-triphosphate (8-oxo-dGTP) + H2O = 8-oxo-7,8-dihydrodeoxyguanosine phosphate (8-oxo-dGMP) + diphosphate. 8-oxo-dGTP is the oxidised form of the free guanine nucleotide and can act as a potent mutagenic substrate for DNA synthesis causing transversion mutations. 8-oxo-dGTPase hydrolyses 8-oxo-dGTP to its monophosphate form to prevent the misincorporation of 8-oxo-dGTP into cellular DNA.\" [PMID:17804481, PMID:7782328, PMID:7859359, RHEA:31575]","metadata":null},{"id":"79f9a261e5b248b492ea0609c6673f2c","type":"GO_TERM","name":"8-oxo-7,8-dihydroguanine DNA N-glycosylase activity","canonical_id":"go:GO:0034039","description":"\"Catalysis of the removal of 8-oxo-7,8-dihydroguanine bases by cleaving the N-C1' glycosidic bond between the oxidized purine and the deoxyribose sugar.\" [GOC:mah, PMID:17641464]","metadata":null},{"id":"a19279927b0748a3be7cd5f28caae55c","type":"GO_TERM","name":"8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity","canonical_id":"go:GO:0008413","description":"\"Catalysis of the reaction: 8-oxo-7,8-dihydroguanosine triphosphate (8-oxo-GTP) + H2O = 8-oxo-7,8-dihydroguanosine diphosphate (8-oxo-GDP) + phosphate. 8-oxo-7,8-dihydroguanosine triphosphate (8-oxo-GTP) is the oxidised form of the free guanine nucleotide and can act as a potent mutagenic substrate for transcription.\" [PMID:15878881, RHEA:60032]","metadata":null},{"id":"cb4d6985f56246b7a140153546f4abf3","type":"GO_TERM","name":"8-oxo-GDP phosphatase activity","canonical_id":"go:GO:0044716","description":"\"Catalysis of the reaction 8-oxo-GDP + H2O = 8-oxo-GMP + phosphate.\" [GOC:pde, PMID:22556419, RHEA:62356]","metadata":null},{"id":"b0dd1c4c4a764edb9cf8c8456a970a2b","type":"GO_TERM","name":"8-oxo-dGDP phosphatase activity","canonical_id":"go:GO:0044715","description":"\"Catalysis of the reaction 8-oxo-dGDP + H2O = 8-oxo-dGMP + phosphate.\" [GOC:pde, PMID:22556419, RHEA:32063]","metadata":null},{"id":"01acb579afd3494c9e1230b3d5c3ee36","type":"GO_TERM","name":"8-oxocoformycin reductase activity","canonical_id":"go:GO:0047599","description":"\"Catalysis of the reaction: coformycin + NADP+ = 8-oxocoformycin + 2 H+ + NADPH.\" [EC:1.1.1.235, RHEA:23168]","metadata":null},{"id":"3701660122a44383ababd6d62eaaace1","type":"GO_TERM","name":"8-oxoguanine deaminase activity","canonical_id":"go:GO:0102127","description":"\"Catalysis of the reaction: H+ + 7,8-dihydro-8-oxoguanine + H2O = 7,9-dihydro-1H-purine-2,6,8(3H)-trione + ammonium.\" [EC:3.5.4.32, GOC:pz]","metadata":null},{"id":"9b1ac0c57bcc4da8a6d50c3072429b89","type":"TRIAL","name":"8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00327587","description":"Hypertension","metadata":null},{"id":"07dc28340e9342e3962331926456d3ed","type":"TRIAL","name":"89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC","canonical_id":"clinicaltrials.gov:NCT05423197","description":"Head-and-neck Squamous Cell Carcinoma","metadata":null},{"id":"9c53e7a197e64d49b9c7e6a539bfc7f1","type":"TRIAL","name":"89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT06537596","description":"Soft Tissue Sarcoma; PDGFR Alpha Positive Solid Tumours","metadata":null},{"id":"45a235beb0d44cde9135d612cf76a93d","type":"TRIAL","name":"8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding","canonical_id":"clinicaltrials.gov:NCT02477384","description":"Portal Hypertension","metadata":null},{"id":"14736f6257f64b5eb1665d3b5c8002f2","type":"TRIAL","name":"9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00143182","description":"Bipolar Disorder","metadata":null},{"id":"72afd95d614449209c9b7a5945c49d9e","type":"GO_TERM","name":"9+0 motile cilium","canonical_id":"go:GO:0097728","description":"\"A motile cilium where the axoneme has a ring of nine outer microtubule doublets but no central microtubules (and is therefore called a 9+0 axoneme).\" [GOC:cilia, PMID:10330409, PMID:22118931]","metadata":null},{"id":"a5b5d6bf58f6404180c7755c1d269b08","type":"GO_TERM","name":"9+0 non-motile cilium","canonical_id":"go:GO:0097731","description":"\"A non-motile cilium where the axoneme has a ring of nine outer microtubule doublets but no central microtubules (and is therefore called a 9+0 axoneme).\" [GOC:cilia, PMID:22118931]","metadata":null},{"id":"875a57ecb84747ffa8c408c734c18345","type":"GO_TERM","name":"9+2 motile cilium","canonical_id":"go:GO:0097729","description":"\"A motile cilium where the axoneme has a ring of nine outer microtubule doublets plus two central microtubules (and is therefore called a 9+2 axoneme).\" [GOC:cilia, PMID:22118931]","metadata":null},{"id":"b83ab869764346f38e5a51aba44cadfd","type":"GO_TERM","name":"9+2 non-motile cilium","canonical_id":"go:GO:0097732","description":"\"A non-motile cilium where the axoneme has a ring of nine outer microtubule doublets plus two central microtubules (and is therefore called a 9+2 axoneme).\" [GOC:cilia, PMID:21307074, PMID:22118931]","metadata":null},{"id":"031999457c27429384afe13eaf92aeae","type":"GO_TERM","name":"9,10 (9', 10')-carotenoid-cleaving dioxygenase activity","canonical_id":"go:GO:0010437","description":"\"Catalysis of the oxidative cleavage of carotenoids at the (9, 10) and/or (9', 10') double bond.\" [PMID:16459333]","metadata":null},{"id":"8df3f772f5494460acdf808a0b25325a","type":"GO_TERM","name":"9,12-octadecadienoate 8-hydroperoxide 8S-isomerase activity","canonical_id":"go:GO:0052879","description":"\"Catalysis of the reaction: (8R,9Z,12Z)-8-hydroperoxyoctadeca-9,12-dienoate = (7S,8S,9Z,12Z)-7,8-dihydroxyoctadeca-9,12-dienoate.\" [RHEA:25399]","metadata":null},{"id":"cb904b2080a74917a44ebf6c7334830e","type":"GO_TERM","name":"9,13-epoxylabda-14-ene synthase activity","canonical_id":"go:GO:0106239","description":"\"Catalysis of the reaction:peregrinol diphosphate = (13R)-9,13-epoxylabd-14-ene + diphosphate.\" [GOC:emb, PMID:24990389, RHEA:54512]","metadata":null},{"id":"2110726b76154ec8a70646a78115abf7","type":"GO_TERM","name":"9,15,9'-tri-cis-zeta-carotene isomerase activity","canonical_id":"go:GO:0090471","description":"\"Catalysis of the reaction: 9,9',15-tri-cis-zeta-carotene = 9,9'-di-cis-zeta-carotene.\" [RHEA:30967]","metadata":null},{"id":"a1be8615613f479984ee6455cbd05e5e","type":"GO_TERM","name":"9,9'-di-cis-zeta-carotene desaturase activity","canonical_id":"go:GO:0016719","description":"\"Catalysis of the reaction: 9,9'-di-cis-zeta-carotene + 2 a quinone = 7,7',9,9'-tetra-cis-lycopene + 2 a quinol.\" [RHEA:30955]","metadata":null},{"id":"a47f933a02fc4b819518537efe35f08c","type":"GO_TERM","name":"9-cis-10'-apo-beta-carotenal cleavage oxygenase activity","canonical_id":"go:GO:0102396","description":"\"Catalysis of the reaction: 9-cis-10'-apo-beta-carotenal + 2 O2 = carlactone + (2E,4E,6E)-7-hydroxy-4-methylhepta-2,4,6-trienal.\" [EC:1.13.11.69, GOC:pz]","metadata":null},{"id":"79572116fcc446698dbc36e1c4b4b46d","type":"GO_TERM","name":"9-cis-beta-carotene 9',10'-cleavage oxygenase activity","canonical_id":"go:GO:0102395","description":"\"Catalysis of the reaction: 9-cis-beta-carotene + O2 = 9-cis-10'-apo-beta-carotenal + beta-ionone.\" [EC:1.13.11.68, GOC:pz]","metadata":null},{"id":"92b87eabdb494c6e9be1274c4b7968c6","type":"GO_TERM","name":"9-cis-epoxycarotenoid dioxygenase activity","canonical_id":"go:GO:0045549","description":"\"Catalysis of the reactions: a 9-cis-epoxycarotenoid + O2 = 2-cis,4-trans-xanthoxin + a 12'-apo-carotenal; 9-cis-violaxanthin + O2 = 2-cis,4-trans-xanthoxin + (3S,5R,6S)-5,6-epoxy-3-hydroxy-5,6-dihydro-12'-apo-beta-caroten-12'-al; and 9'-cis-neoxanthin + O2 = 2-cis,4-trans-xanthoxin + (3S,5R,6R)-5,6-dihydroxy-6,7-didehydro-5,6-dihydro-12'-apo-beta-caroten-12'-al.\" [EC:1.13.11.51]","metadata":null},{"id":"252031c6b0dd45a3a00552ae159eb30f","type":"GO_TERM","name":"9-cis-retinoic acid biosynthetic process","canonical_id":"go:GO:0042904","description":"\"The chemical reactions and pathways resulting in the formation of 9-cis-retinoic acid, a metabolically active vitamin A derivative.\" [GOC:jl, PMID:11279029]","metadata":null},{"id":"96604679689f42a88bb5138958e0ce81","type":"GO_TERM","name":"9-cis-retinoic acid metabolic process","canonical_id":"go:GO:0042905","description":"\"The chemical reactions and pathways involving 9-cis-retinoic acid, a metabolically active vitamin A derivative.\" [GOC:jl, PMID:11279029]","metadata":null},{"id":"4f4135564e514e2781591680d71a4cb3","type":"GO_TERM","name":"90S preribosome","canonical_id":"go:GO:0030686","description":"\"A large ribonucleoprotein complex considered to be the earliest preribosomal complex. In S. cerevisiae, it has a size of 90S and consists of the 35S pre-rRNA, early-associating ribosomal proteins most of which are part of the small ribosomal subunit, the U3 snoRNA and associated proteins.\" [GOC:krc, GOC:vw, PMID:12150911, PMID:12957375, PMID:15120992]","metadata":null},{"id":"70522069ddd74df4818760774acdbdec","type":"GO_TERM","name":"90S preribosome assembly","canonical_id":"go:GO:0034463","description":"\"The aggregation, arrangement and bonding together of proteins and RNA molecules to form a 90S preribosome. The 90S preribosome represents the complex that forms on the primary rRNA transcript before it splits into the small subunit and large subunit portions.\" [GOC:krc, GOC:mah, GOC:tb]","metadata":null},{"id":"e22d49207de44e50be96bc16ed05a4a8","type":"TRIAL","name":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT05139004","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia","metadata":null},{"id":"5e967c2efc3346e49f8b82a376ff763e","type":"TRIAL","name":"90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL","canonical_id":"clinicaltrials.gov:NCT00186589","description":"Lymphoma, Non-Hodgkin; Blood and Marrow Transplant (BMT)","metadata":null},{"id":"5206c92f31894f62b70872e8e27b841e","type":"TRIAL","name":"90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01157988","description":"Lymphoma, Large B-Cell, Diffuse","metadata":null},{"id":"004bf1046445412c86ad6a1b5dd365eb","type":"GO_TERM","name":"9beta-pimara-7,15-diene oxidase activity","canonical_id":"go:GO:0036209","description":"\"Catalysis of the reaction: 9beta-pimara-7,15-diene + 3 O2 + 3 reduced [NADPH-hemoprotein reductase] = 9beta-pimara-7,15-dien-19-oate + 4 H+ + 4 H2O + 3 oxidized [NADPH-hemoprotein reductase].\" [RHEA:31951]","metadata":null},{"id":"d1ead734507349169947b8167b6a840a","type":"TRIAL","name":": Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery","canonical_id":"clinicaltrials.gov:NCT02474212","description":"Venous Thromboembolism; Pulmonary Embolism; Thromboprophylaxis","metadata":null},{"id":"c50513c8852740c097c774dffd5cc7a6","type":"TRIAL","name":": Vascular Function in Health and Disease","canonical_id":"clinicaltrials.gov:NCT02966665","description":"Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension","metadata":null},{"id":"80b71521e7b24983b8ba72c10d800347","type":"TRIAL","name":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","canonical_id":"clinicaltrials.gov:NCT01794780","description":"COPD","metadata":null},{"id":"b54fff1ad9684634bb34d7e8e7cb2acc","type":"TRIAL","name":"A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)","canonical_id":"clinicaltrials.gov:NCT05064397","description":"Chronic Cluster Headache","metadata":null},{"id":"b0fc4bda99e042b2a144ab5e5b0d414a","type":"TRIAL","name":"A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)","canonical_id":"clinicaltrials.gov:NCT00658762","description":"Generalized Anxiety Disorder","metadata":null},{"id":"ea3c2dcc26394bc09c31746e23842425","type":"TRIAL","name":"A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2","canonical_id":"clinicaltrials.gov:NCT06072183","description":"Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo","metadata":null},{"id":"04ffec538b0b4ed3926a8f04a3241927","type":"TRIAL","name":"A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720","canonical_id":"clinicaltrials.gov:NCT01578330","description":"Multiple Sclerosis; Relapsing-Remitting","metadata":null},{"id":"eb44c5a4e7ab406a9ca41b5c53867e9b","type":"TRIAL","name":"A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma","canonical_id":"clinicaltrials.gov:NCT00887029","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"29324e48b0c949c9ad30f79045cf9b78","type":"TRIAL","name":"A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients","canonical_id":"clinicaltrials.gov:NCT03560739","description":"Multiple Sclerosis","metadata":null},{"id":"c8d1269d9f1344e294e42447542ba37c","type":"TRIAL","name":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","canonical_id":"clinicaltrials.gov:NCT00132717","description":"Hypercholesterolemia","metadata":null},{"id":"8dff2ced714d455f8be2bb396bc4cf1b","type":"TRIAL","name":"A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD","canonical_id":"clinicaltrials.gov:NCT01834885","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"f3b32cb4a44c46e7b503a4ffd8582776","type":"TRIAL","name":"A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT01292265","description":"Rheumatoid Arthritis","metadata":null},{"id":"a254bbab63fd4bf7b99742887e0d93d4","type":"TRIAL","name":"A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT04786340","description":"Painful Diabetic Neuropathy; Diabetes Mellitus","metadata":null},{"id":"df2725d1428d4a5fa0ba206eb219b007","type":"TRIAL","name":"A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.","canonical_id":"clinicaltrials.gov:NCT00171145","description":"Overactive Bladder Syndrome","metadata":null},{"id":"2fecdc7ef1fc424ea144f7061719bed1","type":"TRIAL","name":"A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.","canonical_id":"clinicaltrials.gov:NCT00612170","description":"Fibromyalgia","metadata":null},{"id":"4686a0147f28497099cef7bfa756306b","type":"TRIAL","name":"A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.","canonical_id":"clinicaltrials.gov:NCT07228390","description":"Hidradenitis Suppurativa","metadata":null},{"id":"68650d334c6744c0bf70ce558a2702a9","type":"TRIAL","name":"A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis","canonical_id":"clinicaltrials.gov:NCT07013201","description":"Palmoplantar Pustulosis","metadata":null},{"id":"01f267dbcc264dc1a52dbe5b66dad28a","type":"TRIAL","name":"A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT02688647","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"08f46583aa73451ab018395aead7ab9a","type":"TRIAL","name":"A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants","canonical_id":"clinicaltrials.gov:NCT04211272","description":"Healthy","metadata":null},{"id":"0abdf009944b4a0d951512b32652e17e","type":"TRIAL","name":"A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design","canonical_id":"clinicaltrials.gov:NCT01821274","description":"Skin Irritation","metadata":null},{"id":"3af8b59f41c34eb1a0901081c72c41bb","type":"TRIAL","name":"A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT05259722","description":"Chronic Hand Eczema","metadata":null},{"id":"da400a0f2e174c76be7840b27a2a3f37","type":"TRIAL","name":"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01399125","description":"Alzheimer's Disease","metadata":null},{"id":"77ff9cd8a33142f69c501f4c8e483643","type":"TRIAL","name":"A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT04005287","description":"Peripheral Neuropathy; Painful Diabetic Neuropathy; Diabetic Neuropathies, Painful","metadata":null},{"id":"c6faffd6a2434916a9fe9887d7b60037","type":"TRIAL","name":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","canonical_id":"clinicaltrials.gov:NCT04677959","description":"Asthma","metadata":null},{"id":"78be4ae737444292a29a5bb12372cd27","type":"TRIAL","name":"A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD","canonical_id":"clinicaltrials.gov:NCT01336608","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"58f6efa6ecf6492c88945ff64a8e99f5","type":"TRIAL","name":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT03034915","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"bad1829e312f427e82b683ad2bfa6375","type":"TRIAL","name":"A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)","canonical_id":"clinicaltrials.gov:NCT02394561","description":"Plaque Type Psorisis","metadata":null},{"id":"e65fdfa06a634e34aac681dcf7c63fe4","type":"TRIAL","name":"A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder","canonical_id":"clinicaltrials.gov:NCT01103362","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"77a0427b2b4449af88567d9cfd1b9ea0","type":"TRIAL","name":"A 2\u00d72 Factorial Randomized Controlled Trial for ERCP","canonical_id":"clinicaltrials.gov:NCT07584902","description":"Biliary and Pancreatic Diseases; Endoscopic Retrograde Cholangiopancreatography (ERCP)","metadata":null},{"id":"f12f7e2d204349e1a9905ba81ea7499c","type":"TRIAL","name":"A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya\u00ae","canonical_id":"clinicaltrials.gov:NCT01705236","description":"Relapsing Remitting Multiple Sclerosis RRMS","metadata":null},{"id":"7e05b6377c9f4834982c84be22ee648d","type":"TRIAL","name":"A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT05958407","description":"Atopic Dermatitis; Atopic Hand Eczema","metadata":null},{"id":"deddd846918a492d86f091489070b58a","type":"TRIAL","name":"A 36-Week Extension to Protocol ISA04-03","canonical_id":"clinicaltrials.gov:NCT00258713","description":"Psoriasis","metadata":null},{"id":"b2ce09f1041148e280694eb3734ebdde","type":"TRIAL","name":"A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT00698022","description":"Healthy","metadata":null},{"id":"b4872a3e434a427ab5e78a340e068513","type":"TRIAL","name":"A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses","canonical_id":"clinicaltrials.gov:NCT06136403","description":"Epidermolysis Bullosa Simplex; Ichthyosis; Genodermatosis; Inflammatory Congenital Ichthyoses","metadata":null},{"id":"27abf330c6cb4017b7f399428e4bf40b","type":"TRIAL","name":"A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo","canonical_id":"clinicaltrials.gov:NCT05583526","description":"Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo","metadata":null},{"id":"34256b48c9a548d4a1ad2eeec14833ba","type":"TRIAL","name":"A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo","canonical_id":"clinicaltrials.gov:NCT06163326","description":"Vitiligo","metadata":null},{"id":"7cd191015c2843acb815c849bd74157b","type":"TRIAL","name":"A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus","canonical_id":"clinicaltrials.gov:NCT07335588","description":"Lichen Sclerosus","metadata":null},{"id":"0362baa9094c4de6943794ab102111de","type":"TRIAL","name":"A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","canonical_id":"clinicaltrials.gov:NCT00953147","description":"Allergic Rhinitis; Perennial Allergic Rhinitis","metadata":null},{"id":"1214c68fded847a593b0d630ed3568ae","type":"TRIAL","name":"A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients","canonical_id":"clinicaltrials.gov:NCT00106639","description":"Kidney Transplantation","metadata":null},{"id":"3a1bf592194d437cb229c9aa54587791","type":"TRIAL","name":"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01216072","description":"Relapsing Forms of Multiple Sclerosis","metadata":null},{"id":"c56496ed3b1449e3a1271122e9a8fe6b","type":"TRIAL","name":"A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03465787","description":"Schizophrenia","metadata":null},{"id":"3eb23afbc2c34056ad044c7a9e750adf","type":"TRIAL","name":"A Bioavailability Study of LY2452473 and Tadalafil","canonical_id":"clinicaltrials.gov:NCT01401543","description":"Erectile Dysfunction","metadata":null},{"id":"aa4bbf648ded435caf4568698964ff9d","type":"TRIAL","name":"A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.","canonical_id":"clinicaltrials.gov:NCT07138378","description":"Cancer","metadata":null},{"id":"06557b02202e49ef9a7ce2f8c112d522","type":"TRIAL","name":"A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence","canonical_id":"clinicaltrials.gov:NCT00768482","description":"Opioid Dependence","metadata":null},{"id":"e06077c3bc99421b912a576791d115c1","type":"TRIAL","name":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS\u00ae in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03751202","description":"Bioequivalence","metadata":null},{"id":"aba585c5777d4d7b846544da538acab5","type":"TRIAL","name":"A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms","canonical_id":"clinicaltrials.gov:NCT03213353","description":"Bioequivalence; Healthy Volunteers","metadata":null},{"id":"06466258af95403e8113a1def91990f4","type":"TRIAL","name":"A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04672460","description":"Advanced Solid Tumors; Solid Tumors; Ovarian Cancer; Breast Cancer; Prostate Cancer; NSCLC; Pancreatic Cancer; Colorectal Cancer","metadata":null},{"id":"3761c49557a74583b43a190d087b4c3d","type":"TRIAL","name":"A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin","canonical_id":"clinicaltrials.gov:NCT01447797","description":"Healthy","metadata":null},{"id":"261ec3d67f314ff3b2e343388be301e4","type":"TRIAL","name":"A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab","canonical_id":"clinicaltrials.gov:NCT02173392","description":"Psoriasis","metadata":null},{"id":"4eadb42f724b406da9a6b9db648bf711","type":"TRIAL","name":"A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02196805","description":"Chinese Healthy Volunteers","metadata":null},{"id":"c6e06d8857384809a277ac74e7b7bb8d","type":"TRIAL","name":"A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT03776227","description":"Type 2 Diabetes Mellitus; Healthy Subjects","metadata":null},{"id":"229c9000dbd54255848ab671b0b579cf","type":"TRIAL","name":"A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo\u2122 (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01501799","description":"Acne Vulgaris","metadata":null},{"id":"7bc43fce5668419d9326538951806364","type":"TRIAL","name":"A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan","canonical_id":"clinicaltrials.gov:NCT01197001","description":"Healthy","metadata":null},{"id":"e59cd693d8f941848c0bf02079a4c4ec","type":"TRIAL","name":"A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants","canonical_id":"clinicaltrials.gov:NCT05292131","description":"Healthy Study Participants","metadata":null},{"id":"d40ee141bc5040edb3cc8a394c41546a","type":"TRIAL","name":"A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05363384","description":"Healthy","metadata":null},{"id":"38ebaad87f85461fae0931cf320ac5ad","type":"TRIAL","name":"A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06475729","description":"Healthy","metadata":null},{"id":"2e810b699651464abb83d3cb027b61cf","type":"TRIAL","name":"A Bioequivalence Study of Corplex\u2122 Donepezil Transdermal Delivery System Compared to Aricept\u00ae","canonical_id":"clinicaltrials.gov:NCT03259958","description":"Alzheimer's Disease","metadata":null},{"id":"cc4b281b045c4e9696aabe42609e2b75","type":"TRIAL","name":"A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01928316","description":"Healthy","metadata":null},{"id":"adf2998b69fd4a5eb7a9852ba4901cfa","type":"TRIAL","name":"A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers","canonical_id":"clinicaltrials.gov:NCT04400123","description":"Healthy Adult Subjects","metadata":null},{"id":"18ddb3469d244805b063db4a0220be1f","type":"TRIAL","name":"A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05644353","description":"Healthy","metadata":null},{"id":"bc8e6dc22caf424984dfadcbff3f897e","type":"TRIAL","name":"A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05515601","description":"Healthy","metadata":null},{"id":"4a12e12100e44b059a87e60052c61189","type":"TRIAL","name":"A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components","canonical_id":"clinicaltrials.gov:NCT02073227","description":"Healthy Volunteers","metadata":null},{"id":"92ec222f464a42d1b399a65a7aaeade2","type":"TRIAL","name":"A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants","canonical_id":"clinicaltrials.gov:NCT02077803","description":"Healthy","metadata":null},{"id":"c8a56b7e82894f1d82290702ad8e3661","type":"TRIAL","name":"A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration","canonical_id":"clinicaltrials.gov:NCT01755494","description":"Type 2 Diabetes Mellitus(T2DM)","metadata":null},{"id":"86b40589618b46f0baaf23a08e1d8794","type":"TRIAL","name":"A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations","canonical_id":"clinicaltrials.gov:NCT02596100","description":"Healthy","metadata":null},{"id":"11136b312ef54e8f8f0ec321de5a7707","type":"TRIAL","name":"A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients","canonical_id":"clinicaltrials.gov:NCT01426789","description":"Rheumatoid Arthritis","metadata":null},{"id":"c57bf93bb86b44c19a8324412a78c1c8","type":"TRIAL","name":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01297244","description":"Renal Cell Carcinoma","metadata":null},{"id":"7268701fdef449c1b1527b6269fc40b5","type":"TRIAL","name":"A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)","canonical_id":"clinicaltrials.gov:NCT02714036","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"637ea84e050c41ac9de5377498f37230","type":"TRIAL","name":"A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT02807558","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"254f80cdf2cc4d869bcd86622043fe89","type":"TRIAL","name":"A Blood Stem Cell Transplant for Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT03249831","description":"Sickle Cell Disease; Sickle Cell Disorder; Hemoglobinopathies; Thalassemia; Anemia, Sickle Cell","metadata":null},{"id":"6ea16d1677654702aa396d2da08c36cb","type":"TRIAL","name":"A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06424522","description":"Low Anterior Resection Syndrome; Rectal Carcinoma","metadata":null},{"id":"1239eccb410f4f5d91637aa60f3fbb7a","type":"TRIAL","name":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02602860","description":"Healthy Volunteers","metadata":null},{"id":"c286d2768f18430bbdf3fb1d0b31c982","type":"TRIAL","name":"A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population","canonical_id":"clinicaltrials.gov:NCT05527288","description":"Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders","metadata":null},{"id":"2c0fe20f99014140b55e5458e03a11d5","type":"TRIAL","name":"A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque","canonical_id":"clinicaltrials.gov:NCT06305559","description":"Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic","metadata":null},{"id":"afa12fbb23b740e0902a7e47fd02e307","type":"TRIAL","name":"A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.","canonical_id":"clinicaltrials.gov:NCT06018116","description":"Metastatic Urothelial Carcinoma","metadata":null},{"id":"8cc3f0577669426ba091df62936d7eab","type":"TRIAL","name":"A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01210846","description":"Advanced Solid Tumors","metadata":null},{"id":"9e5dc2d425404f76959fbb6e53e6c617","type":"TRIAL","name":"A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans","canonical_id":"clinicaltrials.gov:NCT06998368","description":"Mediation of 5G Effects on Sleep","metadata":null},{"id":"7dc66d94b1e549bfb0de80a1d85b6ad0","type":"TRIAL","name":"A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation","canonical_id":"clinicaltrials.gov:NCT04176393","description":"Relapsed or Refractory Acute Myeloid Leukemia","metadata":null},{"id":"96f9560e17584c1d9744cb47f3ee7b0f","type":"TRIAL","name":"A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone","canonical_id":"clinicaltrials.gov:NCT04008186","description":"Healthy Adult Subjects","metadata":null},{"id":"d05b3e1f01654eca810f3dbc1a858e97","type":"TRIAL","name":"A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China","canonical_id":"clinicaltrials.gov:NCT07040306","description":"Graves\u00b4 Disease","metadata":null},{"id":"f4236d849cd2490ab76654096a1b1ef7","type":"TRIAL","name":"A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate","canonical_id":"clinicaltrials.gov:NCT07357324","description":"Benign Prostatic Hyperplasia; Nocturia Associated With Nocturnal Polyuria","metadata":null},{"id":"7f7890025e6d4235999bd70d98759000","type":"TRIAL","name":"A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","canonical_id":"clinicaltrials.gov:NCT00525265","description":"Cardiac Edema","metadata":null},{"id":"d763e88e847642a789749a95329d32a2","type":"TRIAL","name":"A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)","canonical_id":"clinicaltrials.gov:NCT00225862","description":"Restless Legs Syndrome","metadata":null},{"id":"3dfaabbdfb0e4a9e944535664251dfc8","type":"TRIAL","name":"A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00363857","description":"Restless Legs Syndrome (RLS); Restless Legs Syndrome","metadata":null},{"id":"6e64b28021cf4303a1258bac98f1112c","type":"TRIAL","name":"A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT06212245","description":"Neuromyelitis Optica Spectrum Disorders","metadata":null},{"id":"722ba0f176d047aa8386919c10f8714b","type":"TRIAL","name":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","canonical_id":"clinicaltrials.gov:NCT04455750","description":"Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"108f7a0b96604b05a65fca9d14f74250","type":"TRIAL","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","canonical_id":"clinicaltrials.gov:NCT05335993","description":"Recurrent Ovarian Cancer; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Ovarian Cancer; Recurrent Fallopian Tube Cancer; Peritoneal Cancer; Recurrent Carcinoma of Ovary; Adenocarcinoma of Ovary","metadata":null},{"id":"fffb25c560ba491ca7025b46c1f16962","type":"TRIAL","name":"A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV","canonical_id":"clinicaltrials.gov:NCT07635992","description":"HIV (Human Immunodeficiency Virus)","metadata":null},{"id":"5fa7ec5b103e43aeb6864cb130598107","type":"TRIAL","name":"A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT01649024","description":"Malignant Mesothelioma","metadata":null},{"id":"0c64c85010024b788e197d290839e0b4","type":"TRIAL","name":"A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)","canonical_id":"clinicaltrials.gov:NCT01306318","description":"Healthy Volunteers","metadata":null},{"id":"8661305f8c054e0aa935344fe13244d6","type":"TRIAL","name":"A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06283134","description":"Colorectal Cancer Metastatic","metadata":null},{"id":"6499b7c7bf3c4bdc88ca5a887d5c45dd","type":"TRIAL","name":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","canonical_id":"clinicaltrials.gov:NCT06829199","description":"Early Triple Negative Breast Cancer","metadata":null},{"id":"b30e9d32750445c1b34424cc7409fef5","type":"TRIAL","name":"A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT03695380","description":"OVARIAN CANCER","metadata":null},{"id":"ee1e302c0aca427f9da262820af5bcdb","type":"TRIAL","name":"A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC","canonical_id":"clinicaltrials.gov:NCT06235931","description":"Breast Neoplasms","metadata":null},{"id":"c510f7d8e66c47ef9c9f7815fab486ae","type":"TRIAL","name":"A Clinical Study of Hyperthyroidism in Children","canonical_id":"clinicaltrials.gov:NCT06570967","description":"Hyperthyroidism","metadata":null},{"id":"941594c8ef824e80a84ed19d758991cc","type":"TRIAL","name":"A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC","canonical_id":"clinicaltrials.gov:NCT05360979","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"daa348cce5164abdaae4312bfd2547e2","type":"TRIAL","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","canonical_id":"clinicaltrials.gov:NCT06305767","description":"Bladder Cancer","metadata":null},{"id":"29d720d990cd410f928f4676953da602","type":"TRIAL","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07502014","description":"Metastatic Colorectal Cancer (CRC); mCRC","metadata":null},{"id":"1778c3f03db94e17a7441c74422cb86d","type":"TRIAL","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07585279","description":"Metastatic Colorectal Cancer (CRC); Liposomal Irinotecan; Second-Line","metadata":null},{"id":"584a70ac1eca4a808eff3b18b6912102","type":"TRIAL","name":"A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)","canonical_id":"clinicaltrials.gov:NCT06692647","description":"Healthy; Pain","metadata":null},{"id":"89d2ec2352f548e9bf7e61af6abc5d52","type":"TRIAL","name":"A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)","canonical_id":"clinicaltrials.gov:NCT07661108","description":"Healthy","metadata":null},{"id":"663a7f7e3c0a44c0bf8bb5df7a48acf0","type":"TRIAL","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07407283","description":"Prostate Cancer","metadata":null},{"id":"c4e93222c0ec435393ce2f9aa2bf3d66","type":"TRIAL","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT07714668","description":"Ovarian Cancer; Recurrent Ovarian Cancer","metadata":null},{"id":"f016fadf04014273a7e4065154a1f33c","type":"TRIAL","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","canonical_id":"clinicaltrials.gov:NCT06966700","description":"Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms","metadata":null},{"id":"564bb490dcc94f31bd7ef671d9a17509","type":"TRIAL","name":"A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient","canonical_id":"clinicaltrials.gov:NCT01757262","description":"Coronary Heart Disease","metadata":null},{"id":"25c4613c04164bd8a6b78f6c12ab8577","type":"TRIAL","name":"A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression","canonical_id":"clinicaltrials.gov:NCT01524497","description":"Depression","metadata":null},{"id":"30467a61fbf3455f93203a84c2bd9704","type":"TRIAL","name":"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)","canonical_id":"clinicaltrials.gov:NCT01050426","description":"Pancreatic Cancer","metadata":null},{"id":"e713125c9bc441b8b6fb0980ffe398c0","type":"TRIAL","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","canonical_id":"clinicaltrials.gov:NCT06890884","description":"Lymphoma, Large B-Cell, Diffuse","metadata":null},{"id":"2d4cdbd888e243a4b0dce872d98d993f","type":"TRIAL","name":"A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT00523978","description":"Paroxysmal Atrial Fibrillation","metadata":null},{"id":"5e0cd9a551784e2b889b03a267836479","type":"TRIAL","name":"A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT07085195","description":"Parkinson Disease (PD); Gene Therapy; Safety and Efficacy; Clozapine","metadata":null},{"id":"13b817e5469542198ead39fd47fa2e40","type":"TRIAL","name":"A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT06890858","description":"Ovarian Cancer","metadata":null},{"id":"9b6060427ec54161ab846bd8c78c0d51","type":"TRIAL","name":"A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus","canonical_id":"clinicaltrials.gov:NCT06741982","description":"HNSCC; Lysogenic HSV Virus; Neoadjuvant Therapy; Immunotherapy; Targeted Therapy","metadata":null},{"id":"bcfd36ec4386408f973e2c748562bd46","type":"TRIAL","name":"A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","canonical_id":"clinicaltrials.gov:NCT06864130","description":"Osteoporosis in Post-menopausal Women","metadata":null},{"id":"6077db2301954d0db7cd8520cb866607","type":"TRIAL","name":"A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07250542","description":"Prostate Cancer","metadata":null},{"id":"6819952582064709a02d653716d66f20","type":"TRIAL","name":"A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00260156","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"3e13a8791671417aa2afd0e960e298f5","type":"TRIAL","name":"A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00238498","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"10b3ea641cda4097a19ba73c59ff59c7","type":"TRIAL","name":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","canonical_id":"clinicaltrials.gov:NCT00219115","description":"Hypertension","metadata":null},{"id":"5ad4f99770c043179bbad8be45086d9e","type":"TRIAL","name":"A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine","canonical_id":"clinicaltrials.gov:NCT00294710","description":"Hypertension","metadata":null},{"id":"4e23d8d0b51c4b5aabcea8d90e1389fc","type":"TRIAL","name":"A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00276094","description":"Atrophy; Vaginal Diseases","metadata":null},{"id":"bb417b33634643ffbc9958e07c864a76","type":"TRIAL","name":"A Clinical Study to Evaluate PK, PD, and PG of Rosuvastatin in the Elderly","canonical_id":"clinicaltrials.gov:NCT03715101","description":"Elderly","metadata":null},{"id":"69357a69457f49fcaf693b32f580fcf3","type":"TRIAL","name":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","canonical_id":"clinicaltrials.gov:NCT02224157","description":"Asthma","metadata":null},{"id":"e10b903507e446479c961c2bec84e5fe","type":"TRIAL","name":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","canonical_id":"clinicaltrials.gov:NCT02149199","description":"Asthma","metadata":null},{"id":"c2c707852f14477091e051bd7d47b40e","type":"TRIAL","name":"A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT01252056","description":"Diabetic Nephropathy","metadata":null},{"id":"8681577c50db43d3b211e3c89b0b351c","type":"TRIAL","name":"A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00630539","description":"Atrophy; Vaginal Diseases","metadata":null},{"id":"7b518ac6113b45c59f0ecacd88774bfb","type":"TRIAL","name":"A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA","canonical_id":"clinicaltrials.gov:NCT05223166","description":"Excessive Daytime Sleepiness","metadata":null},{"id":"af72ba4825c64deb9fbcbc83d62a64b1","type":"TRIAL","name":"A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies","canonical_id":"clinicaltrials.gov:NCT06616415","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"a44920d22f8e4bed80613d876a4adc90","type":"TRIAL","name":"A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.","canonical_id":"clinicaltrials.gov:NCT00219089","description":"Hypertension, Diabetes Mellitus","metadata":null},{"id":"5ee827ad250c45ee9dc5a5d041fc11a3","type":"TRIAL","name":"A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain","canonical_id":"clinicaltrials.gov:NCT03213457","description":"Endometriosis","metadata":null},{"id":"2faaa2e2ead54178bc408398d263e922","type":"TRIAL","name":"A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","canonical_id":"clinicaltrials.gov:NCT01620528","description":"Endometriosis","metadata":null},{"id":"e6a28813f0c84b2fac231022bc2493b5","type":"TRIAL","name":"A Clinical Study to Evaluate the Safety of Ospemifene","canonical_id":"clinicaltrials.gov:NCT00566982","description":"Atrophy; Vaginal Diseases","metadata":null},{"id":"8dbd9ddfd58549cf8a671313715aa890","type":"TRIAL","name":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT07267130","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"23556186dc80492e8c0e228ffdc7c611","type":"TRIAL","name":"A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).","canonical_id":"clinicaltrials.gov:NCT03809650","description":"Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","metadata":null},{"id":"a7096949e0ef44ad9d127b7a1bb211bb","type":"TRIAL","name":"A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02770222","description":"Healthy Subjects","metadata":null},{"id":"7d9e0d259c5b41199443efd82fbf72a1","type":"TRIAL","name":"A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures","canonical_id":"clinicaltrials.gov:NCT01964560","description":"Epilepsy","metadata":null},{"id":"e344bcacf9564dbc87792f05e4b376e3","type":"TRIAL","name":"A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.","canonical_id":"clinicaltrials.gov:NCT03422328","description":"Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension","metadata":null},{"id":"fb562469d9914677870a56e674c45675","type":"TRIAL","name":"A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994","canonical_id":"clinicaltrials.gov:NCT02582866","description":"Epilepsy","metadata":null},{"id":"5844904fd14948b39806025110db3c65","type":"TRIAL","name":"A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)","canonical_id":"clinicaltrials.gov:NCT01156571","description":"Atherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome","metadata":null},{"id":"bd55128fe99d4641b1b49c3b9eb20b0d","type":"TRIAL","name":"A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.","canonical_id":"clinicaltrials.gov:NCT07040956","description":"Head and Neck Squamous Cell Carcinoma; Low-dose Radiotherapy; Immunotherapy; Targeted Therapy","metadata":null},{"id":"a6c93ceed03f43adb8b70fcbf668bbf9","type":"TRIAL","name":"A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06767800","description":"Gastroesophageal Adenocarcinoma","metadata":null},{"id":"8a7cfaf0700a4142b2556a433c605f26","type":"TRIAL","name":"A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT00675649","description":"Asthma","metadata":null},{"id":"cf8f5950b758475faab7c92aae2737fd","type":"TRIAL","name":"A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.","canonical_id":"clinicaltrials.gov:NCT04134845","description":"Ventricular Tachycardia","metadata":null},{"id":"129aef5b66ce422794e5e0cd745c334b","type":"TRIAL","name":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS\u00ae 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","canonical_id":"clinicaltrials.gov:NCT03676413","description":"Asthma","metadata":null},{"id":"d6cdeecc3e264cd49472dd3d64843c23","type":"TRIAL","name":"A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT01042158","description":"Pulmonary Arterial Hypertension; Systemic Sclerosis; Scleroderma Spectrum of Diseases; Connective Tissue Disease; Pulmonary Hypertension","metadata":null},{"id":"ee72cf25519a4dbebde773c3e79c89fa","type":"TRIAL","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","canonical_id":"clinicaltrials.gov:NCT07554339","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"cbfb0eaf40c64ba3927c8b2086d95c66","type":"TRIAL","name":"A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome","canonical_id":"clinicaltrials.gov:NCT02829268","description":"Wolfram Syndrome; Diabetes Mellitus; Optic Nerve Atrophy; Ataxia","metadata":null},{"id":"b94127acc87340009e3334b3035735dc","type":"TRIAL","name":"A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread","canonical_id":"clinicaltrials.gov:NCT07256223","description":"Clear Cell Renal Cell Cancer (ccRCC); Liver Metastasis","metadata":null},{"id":"a85c00f0f4c9416487aeb98a10943ecf","type":"TRIAL","name":"A Clinical Trial of Fluvoxamine for Melancholia","canonical_id":"clinicaltrials.gov:NCT04160377","description":"Depressive Disorder; Endogenous Depression; Melancholia","metadata":null},{"id":"548e62c8a42347ca8dcc7e0976c851cf","type":"TRIAL","name":"A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT07709897","description":"Prevention of Postoperative Nausea and Vomiting","metadata":null},{"id":"beebada1aa2544ea82d58c5f02d4ce5d","type":"TRIAL","name":"A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)","canonical_id":"clinicaltrials.gov:NCT05708950","description":"Cancer; Solid Tumor; Melanoma; Carcinoma; Sarcoma; Lung Cancer; Prostate Cancer; Breast Cancer; Colo-rectal Cancer; Uterine Cancer; Pancreatic Cancer; Gastric Cancer; Esophageal Cancer; Thyroid Cancer; Ovarian Cancer; Kidney Cancer; Head and Neck Cancer","metadata":null},{"id":"7ccf4c8cb2f04d749d291c57c688d753","type":"TRIAL","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","canonical_id":"clinicaltrials.gov:NCT07791758","description":"Metastatic Colorectal Carcinoma","metadata":null},{"id":"92310e7586864d0fa2af707c0d239f1a","type":"TRIAL","name":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","canonical_id":"clinicaltrials.gov:NCT06157827","description":"Advanced Neuroendocrine Carcinoma","metadata":null},{"id":"8cfab5c3e8f04d6ea791249732656c99","type":"TRIAL","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","canonical_id":"clinicaltrials.gov:NCT07570173","description":"B-cell Acute Lymphoblastic Leukemia","metadata":null},{"id":"4ce240bf7b0c4642beb565337e801192","type":"TRIAL","name":"A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)","canonical_id":"clinicaltrials.gov:NCT07709000","description":"Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies","metadata":null},{"id":"fda12198b2464a22a30b1e725120c297","type":"TRIAL","name":"A Clinical Trial of Patients With Melanoma","canonical_id":"clinicaltrials.gov:NCT02915666","description":"Melanoma","metadata":null},{"id":"ef87fcf95fdf457fa0baf41ba8cd373e","type":"TRIAL","name":"A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)","canonical_id":"clinicaltrials.gov:NCT03272503","description":"ALS; Amyotrophic Lateral Sclerosis","metadata":null},{"id":"396f332e072a4fe8887195c73af6f5a1","type":"TRIAL","name":"A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)","canonical_id":"clinicaltrials.gov:NCT01935518","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"e30d8411a04f4cc7a9f3ab457afa5ef8","type":"TRIAL","name":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","canonical_id":"clinicaltrials.gov:NCT06496490","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"8944d924bc6f4961a88e9bbcda17798d","type":"TRIAL","name":"A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT07406035","description":"Psoriatic Arthritis","metadata":null},{"id":"7c5d4bfb90c34263bcfb5a12db94dcc8","type":"TRIAL","name":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT04657991","description":"Melanoma","metadata":null},{"id":"d0bf9c865b7e4dd3b0a94456d3f8bfb3","type":"TRIAL","name":"A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT05624528","description":"Obsessive-Compulsive Disorder; OCD","metadata":null},{"id":"3b13e5907cc0455ab919e52ea6bdf77b","type":"TRIAL","name":"A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001","canonical_id":"clinicaltrials.gov:NCT04945226","description":"Androgenetic Alopecia","metadata":null},{"id":"314141e075e74dbfa063131ae9ef79a0","type":"TRIAL","name":"A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment","canonical_id":"clinicaltrials.gov:NCT04112589","description":"Acute Myeloid Leukemia","metadata":null},{"id":"a33260fe24da4a08abb9a715eed3a49b","type":"TRIAL","name":"A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin","canonical_id":"clinicaltrials.gov:NCT02392130","description":"Skin Tissue Diseases; Connective Tissue Diseases","metadata":null},{"id":"ac6ba809e1e142ba9d13c2cbfd2e72d0","type":"TRIAL","name":"A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting","canonical_id":"clinicaltrials.gov:NCT02413008","description":"Vaginal Atrophy","metadata":null},{"id":"7e46e6dda6e64fedaf22726715123498","type":"TRIAL","name":"A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337","canonical_id":"clinicaltrials.gov:NCT03346187","description":"Dyslipidemias","metadata":null},{"id":"3e4fa792a4c749e780ffe523d46adf38","type":"TRIAL","name":"A Clinical Trial to Demonstrate the Efficacy of Cangrelor","canonical_id":"clinicaltrials.gov:NCT00305162","description":"Myocardial Infarction (MI); Acute Coronary Syndromes (ACS)","metadata":null},{"id":"4c2026ba47114976b2d7801b9bfd4ad8","type":"TRIAL","name":"A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea","canonical_id":"clinicaltrials.gov:NCT00126399","description":"Rosacea","metadata":null},{"id":"f227230088f44715b242165b5796e7ab","type":"TRIAL","name":"A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain","canonical_id":"clinicaltrials.gov:NCT06076486","description":"Endometriosis","metadata":null},{"id":"bf8bab7afe0b486b90cefaa805649874","type":"TRIAL","name":"A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.","canonical_id":"clinicaltrials.gov:NCT06732895","description":"Achondroplasia","metadata":null},{"id":"8b9d881555014a269859b640526e6b4b","type":"TRIAL","name":"A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia","canonical_id":"clinicaltrials.gov:NCT05598320","description":"Achondroplasia","metadata":null},{"id":"63a2fcff5ba948edbbbc04e87edc3d00","type":"TRIAL","name":"A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia","canonical_id":"clinicaltrials.gov:NCT06079398","description":"Achondroplasia","metadata":null},{"id":"e4dffb3c08604de1ae9cd86c3b77fbbf","type":"TRIAL","name":"A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT03009487","description":"Hypertension; Hyperlipidemias","metadata":null},{"id":"0ee1e7a8500d4a92bdb528c7b9dc873e","type":"TRIAL","name":"A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379","canonical_id":"clinicaltrials.gov:NCT06204107","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d4fb5a2af87b4e88ab599839d7d10203","type":"TRIAL","name":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03609294","description":"Hypertension; Diabetes","metadata":null},{"id":"689c3c84ee8f43dc9baf531f2be0f866","type":"TRIAL","name":"A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT01539616","description":"Hypertriglyceridemia; Dyslipidemia","metadata":null},{"id":"9d259cd39c3b4381b3f26c53469a26ba","type":"TRIAL","name":"A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.","canonical_id":"clinicaltrials.gov:NCT00321997","description":"Age-Related Macular Degeneration","metadata":null},{"id":"cd5756a8c55e42b6a585b06158ca144d","type":"TRIAL","name":"A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD","canonical_id":"clinicaltrials.gov:NCT00354445","description":"Age-Related Macular Degeneration (AMD)","metadata":null},{"id":"9a0a5054329c4a639aa5d4931969a5b7","type":"TRIAL","name":"A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00312351","description":"Macular Degeneration","metadata":null},{"id":"859e7a47bad94a629fa4e1d0a45060ca","type":"TRIAL","name":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03530683","description":"Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"b7c3317ca96d4d21bc646c543f1be9e1","type":"TRIAL","name":"A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00196339","description":"Prostate Cancer","metadata":null},{"id":"39fc52a03f6849f0866dfb7d2d2e5321","type":"TRIAL","name":"A Cohort Study Comparing IFX to CS for Moderate to Severe UC","canonical_id":"clinicaltrials.gov:NCT04879966","description":"Moderate to Severe Ulcerative Colitis","metadata":null},{"id":"58119e1c00be4f1ea76d8f175569381f","type":"TRIAL","name":"A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT06801353","description":"Chronic Rhinosinusitis with Nasal Polyps (CRSwNP); Biological Therapy; Biomarkers","metadata":null},{"id":"38a37dfbfd2a402884616b2f7b57a636","type":"TRIAL","name":"A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data","canonical_id":"clinicaltrials.gov:NCT01381523","description":"Migraine Disorders","metadata":null},{"id":"99d0034dd0ca4496ba116d3aab27c9f1","type":"TRIAL","name":"A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients","canonical_id":"clinicaltrials.gov:NCT02367456","description":"Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"1bebeda54d584c0da35fa223d9364fc9","type":"TRIAL","name":"A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03101280","description":"Gynecologic Neoplasms","metadata":null},{"id":"52892a8a19854aa6ac2a08ddb955fe7a","type":"TRIAL","name":"A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis","canonical_id":"clinicaltrials.gov:NCT05359406","description":"Advanced Rectal Cancer; Distal Metastasis","metadata":null},{"id":"eeee05a254c44ff8a06af10eba742621","type":"TRIAL","name":"A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)","canonical_id":"clinicaltrials.gov:NCT00451204","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"8495695bf31642ba87059531a7d53216","type":"TRIAL","name":"A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT03571308","description":"Non Hodgkin Lymphoma","metadata":null},{"id":"a4f585cdb6834aa5ba4c7ef9a11b70f9","type":"TRIAL","name":"A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS","canonical_id":"clinicaltrials.gov:NCT06657079","description":"ARDS; Prevention and Control","metadata":null},{"id":"ffe807134131493ba87ab5b7143cbd1b","type":"TRIAL","name":"A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%","canonical_id":"clinicaltrials.gov:NCT01426867","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"fc6ac3d0515941699ed0c781dee52838","type":"TRIAL","name":"A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs","canonical_id":"clinicaltrials.gov:NCT00823043","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"21e1866f64de46ff84148d059eed9301","type":"TRIAL","name":"A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib","canonical_id":"clinicaltrials.gov:NCT03050398","description":"Breast Cancer","metadata":null},{"id":"ad81c677c92e4c2cb694516d304b680c","type":"TRIAL","name":"A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study","canonical_id":"clinicaltrials.gov:NCT01380431","description":"To Determine Bioequivalence Under Fed Conditions","metadata":null},{"id":"b256b8bd9b4f42a997a03236cb4821e3","type":"TRIAL","name":"A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)","canonical_id":"clinicaltrials.gov:NCT00751166","description":"Urticaria","metadata":null},{"id":"a08e6896b206407db949616c8cbc795d","type":"TRIAL","name":"A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued","canonical_id":"clinicaltrials.gov:NCT00633672","description":"NSAID Associated Gastric Ulcers","metadata":null},{"id":"cdd684ec618c45eab001c57df780df41","type":"TRIAL","name":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT03474081","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"1c51583b72f7484ea6a5e0beec5f7ece","type":"TRIAL","name":"A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen","canonical_id":"clinicaltrials.gov:NCT00319332","description":"Lymphoma, Small Cleaved-Cell, Follicular; Lymphoma, Large-Cell, Follicular; Lymphoma, Follicular; Lymphoma, Non-Hodgkin","metadata":null},{"id":"29fff3099ee14710ac42b559b8753340","type":"TRIAL","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","canonical_id":"clinicaltrials.gov:NCT04711252","description":"ER-Positive HER2-Negative Breast Cancer","metadata":null},{"id":"fb58a2db61324e3db6852c5143e5a057","type":"TRIAL","name":"A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging","canonical_id":"clinicaltrials.gov:NCT01406080","description":"Photoaging; Photodamage","metadata":null},{"id":"9078ab88f98c4181b7610934373033e1","type":"TRIAL","name":"A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children","canonical_id":"clinicaltrials.gov:NCT06918418","description":"Asthma Exacerbation; Children","metadata":null},{"id":"1bca5eb637e64b35af83757cf418ab78","type":"TRIAL","name":"A Comparative Study of KES524 in Patients With Obesity Disease","canonical_id":"clinicaltrials.gov:NCT00165685","description":"Obesity","metadata":null},{"id":"5ba8e2fdb52e4c5a8c82bb42320066c6","type":"TRIAL","name":"A Comparative Study of KSO-0400 in BPH Patients With LUTS","canonical_id":"clinicaltrials.gov:NCT01222650","description":"Benign Prostatic Hyperplasia (BPH)","metadata":null},{"id":"6eea789337864eec92b5f8ab50335ed3","type":"TRIAL","name":"A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)","canonical_id":"clinicaltrials.gov:NCT00783224","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"f9dcd07313a94a16b25d420df0fd1cd0","type":"TRIAL","name":"A Comparative Study of Rupatadine 10 mg Tablets and Clarinex\u00ae 5 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT05356143","description":"Healthy","metadata":null},{"id":"1de29194735a47a09a871b6736f823f2","type":"TRIAL","name":"A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne","canonical_id":"clinicaltrials.gov:NCT00887484","description":"Acne Vulgaris","metadata":null},{"id":"00ac0071f7dc4cac8d46a5e5b20415d1","type":"TRIAL","name":"A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment","canonical_id":"clinicaltrials.gov:NCT05145270","description":"Major Depressive Disorder","metadata":null},{"id":"de0a5d587c4b46018bf5acf5bcbae03c","type":"TRIAL","name":"A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma","canonical_id":"clinicaltrials.gov:NCT04953741","description":"Asthma in Children","metadata":null},{"id":"041f88c8b86142f29ab334cd1d55fb70","type":"TRIAL","name":"A Comparative Sudy Comparing Argatroban\u00ae IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome","canonical_id":"clinicaltrials.gov:NCT00787332","description":"Suspected Heparin-Induced Thrombocytopenia","metadata":null},{"id":"a693cb945d4c46aca029e0aae813be80","type":"TRIAL","name":"A Comparison Between Clobetasol Propionate 0.05% (Clobex\u00ae) Spray and Clobetasol Propionate 0.05% (Olux\u00ae) Foam","canonical_id":"clinicaltrials.gov:NCT00436540","description":"Psoriasis","metadata":null},{"id":"dbc075b11d4642119a7f4cb2e5fdab54","type":"TRIAL","name":"A Comparison Of Local Anesthetic Agents And Steroid On Tracheal Tube Cuff","canonical_id":"clinicaltrials.gov:NCT04085744","description":"Anesthesia Intubation Complication; Intubation Complication; Sore Throat","metadata":null},{"id":"8bd527594cf34fb1991bad5e7a9f09fb","type":"TRIAL","name":"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines","canonical_id":"clinicaltrials.gov:NCT00232180","description":"Heart Failure","metadata":null},{"id":"6f2ff0e6964342e7aaae97dbc9b01e6b","type":"TRIAL","name":"A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat","canonical_id":"clinicaltrials.gov:NCT00647829","description":"Pharyngitis","metadata":null},{"id":"78e295bff3c9429797c4f76651fb2f5f","type":"TRIAL","name":"A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00666302","description":"Dermatitis, Atopic","metadata":null},{"id":"d87b190907f14506841b5d3724ef2c65","type":"TRIAL","name":"A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)","canonical_id":"clinicaltrials.gov:NCT00389740","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"4d0aecbb8ab14f94addfaef974a30f46","type":"TRIAL","name":"A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity","canonical_id":"clinicaltrials.gov:NCT01477736","description":"Spinal Cord Injury","metadata":null},{"id":"75876d664bfd45799e1639ae5c10578d","type":"TRIAL","name":"A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room","canonical_id":"clinicaltrials.gov:NCT00457366","description":"Agitation","metadata":null},{"id":"b5f4696d8e11485c8bd37f75621a267d","type":"TRIAL","name":"A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair","canonical_id":"clinicaltrials.gov:NCT02056301","description":"Pectus Excavatum","metadata":null},{"id":"fed26ab5e93d4fa1a0b3489fe6b9d339","type":"TRIAL","name":"A Comparison of Analgesic \u0130mpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT02253446","description":"Primary Dysmenorrhea","metadata":null},{"id":"15a00ed418984adfb29b3db82416dea3","type":"TRIAL","name":"A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT00540787","description":"Paroxysmal Atrial Fibrillation","metadata":null},{"id":"72fb8f4bc8d24f6aa0faac557feda67c","type":"TRIAL","name":"A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin","canonical_id":"clinicaltrials.gov:NCT00759941","description":"Glaucoma","metadata":null},{"id":"705682c055f341be91e952100d1de919","type":"TRIAL","name":"A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT02636946","description":"Glaucoma; Open-Angle Ocular Hypertension","metadata":null},{"id":"41a5bbedc7be4a11b56045679007cf72","type":"TRIAL","name":"A Comparison of Bupropion SR and Placebo for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT00176449","description":"Tobacco Use Disorder","metadata":null},{"id":"511591e57a594cf4b75af1fb35e0d37b","type":"TRIAL","name":"A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery","canonical_id":"clinicaltrials.gov:NCT00260988","description":"Thromboembolism; Hemodialysis","metadata":null},{"id":"a8d7e502bb2148b4a1c53b4ae324ae3e","type":"TRIAL","name":"A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00122850","description":"Anxiety Disorders","metadata":null},{"id":"cb5b8e6991f543f3800edf39c53c4c0b","type":"TRIAL","name":"A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain","canonical_id":"clinicaltrials.gov:NCT02197143","description":"Dyspepsia","metadata":null},{"id":"28791bd2fc9b44719dce77cb2e049c2a","type":"TRIAL","name":"A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients","canonical_id":"clinicaltrials.gov:NCT00690521","description":"Congestive Heart Failure","metadata":null},{"id":"fb09ca29e66848cc92f7d11af887b5e1","type":"TRIAL","name":"A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache","canonical_id":"clinicaltrials.gov:NCT06473597","description":"Migraine","metadata":null},{"id":"1346c03252c2473facbd0b35262d8f7e","type":"TRIAL","name":"A Comparison of PF708 and Forteo in Osteoporosis Patients","canonical_id":"clinicaltrials.gov:NCT03002428","description":"Osteoporosis","metadata":null},{"id":"914239bf58e84457b1fd779257da2d6e","type":"TRIAL","name":"A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification","canonical_id":"clinicaltrials.gov:NCT01001806","description":"Cataracts","metadata":null},{"id":"13bf49ee42a04773ab9eb298c578a010","type":"TRIAL","name":"A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)","canonical_id":"clinicaltrials.gov:NCT01023724","description":"Post Operative Anterior Chamber Inflammation (Flare)","metadata":null},{"id":"9884374b2a0140b18c1057e992018ac0","type":"TRIAL","name":"A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification","canonical_id":"clinicaltrials.gov:NCT01021761","description":"Cataracts","metadata":null},{"id":"55c0d3a316b540b2acae71fb7dde0aa6","type":"TRIAL","name":"A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis","canonical_id":"clinicaltrials.gov:NCT01813643","description":"Methamphetamine Dependence","metadata":null},{"id":"3a8f523221d84980933c3334d1c50fed","type":"TRIAL","name":"A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's","canonical_id":"clinicaltrials.gov:NCT00331149","description":"Parkinson Disease","metadata":null},{"id":"02be4dbeea894157afd23909670d04fc","type":"TRIAL","name":"A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block","canonical_id":"clinicaltrials.gov:NCT02151487","description":"Upper Extremity Surgery","metadata":null},{"id":"736d6d937d6d41a3b210d793a7be6e70","type":"TRIAL","name":"A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression","canonical_id":"clinicaltrials.gov:NCT00644982","description":"Depressive Disorder, Major","metadata":null},{"id":"7944fffe114d443886b72400fb9c9d31","type":"TRIAL","name":"A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.","canonical_id":"clinicaltrials.gov:NCT00636246","description":"Depressive Disorder, Major","metadata":null},{"id":"ab9f05b5748247829cb4a3d2bbbaa7a9","type":"TRIAL","name":"A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00044044","description":"Schizophrenia","metadata":null},{"id":"878cefad18bc4d24945ce32729cf9fb0","type":"TRIAL","name":"A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis","canonical_id":"clinicaltrials.gov:NCT03432533","description":"Post-Menopausal Osteoporosis","metadata":null},{"id":"73f10f705b184b4a9528d4576fd0c696","type":"TRIAL","name":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04115631","description":"Liver Lymphoma; Mantle Cell Lymphoma","metadata":null},{"id":"df8b0e26a62049cda87812568f7e907c","type":"TRIAL","name":"A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo","canonical_id":"clinicaltrials.gov:NCT00350636","description":"Overactive Bladder","metadata":null},{"id":"85b5ccdcc9a3427d97ab5feced144adc","type":"TRIAL","name":"A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine","canonical_id":"clinicaltrials.gov:NCT00314340","description":"Chronic Pain","metadata":null},{"id":"f94a2a1cbdaa4221ade22054afed550b","type":"TRIAL","name":"A Comparison of the Control of Asthma Provided by Symbicort\u00ae Turbuhaler\u00ae Versus Symbicort\u00ae Turbuhaler\u00ae Plus Pulmicort\u00ae Turbuhaler\u00ae Plus Terbutaline Turbuhaler\u00ae","canonical_id":"clinicaltrials.gov:NCT00244608","description":"Asthma","metadata":null},{"id":"055650bc97104d38bc9791525065ac36","type":"TRIAL","name":"A Comparison of the Drug Therapy Versus Re-Ablation","canonical_id":"clinicaltrials.gov:NCT01709682","description":"Paroxysmal Atrial Fibrillation; Failed First Radiofrequency Ablation Procedure","metadata":null},{"id":"40e574fcaf05486d9a9ff038d758e269","type":"TRIAL","name":"A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma","canonical_id":"clinicaltrials.gov:NCT00991822","description":"Glaucoma, Open-Angle","metadata":null},{"id":"7ba1c1eb243d4f40bdb954bb15775915","type":"TRIAL","name":"A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00249223","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"e8ceb07b4d884c36b60389325a45a058","type":"TRIAL","name":"A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study","canonical_id":"clinicaltrials.gov:NCT01254721","description":"Acute Bipolar Mania","metadata":null},{"id":"4505f6a77a4247ef9714e2b4a9bcce8a","type":"TRIAL","name":"A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement","canonical_id":"clinicaltrials.gov:NCT00756236","description":"Myocardial Ischemia","metadata":null},{"id":"a873d71145944c05ab66624fe7393e10","type":"TRIAL","name":"A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.","canonical_id":"clinicaltrials.gov:NCT05822713","description":"PONV","metadata":null},{"id":"98674e12365e4cc3a6bb0703d29c553b","type":"TRIAL","name":"A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol in Intracranial Surgery","canonical_id":"clinicaltrials.gov:NCT01628562","description":"Tachycardia; Hypertension; Myocardial Ischemia","metadata":null},{"id":"0fe24d6ad4a04671a04c5b6f4fd20fd5","type":"TRIAL","name":"A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study","canonical_id":"clinicaltrials.gov:NCT04273776","description":"Performance Enhancing Product Use","metadata":null},{"id":"28aaf40094ca42a6bc60600f8408184b","type":"TRIAL","name":"A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump","canonical_id":"clinicaltrials.gov:NCT00266539","description":"Pain, Postoperative","metadata":null},{"id":"be85a8245b6c47f0b0ba83a924a58d6b","type":"TRIAL","name":"A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (\u2265 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy","canonical_id":"clinicaltrials.gov:NCT00639691","description":"Asthma","metadata":null},{"id":"2e98c901b4b1430a92653b13740873bd","type":"TRIAL","name":"A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","canonical_id":"clinicaltrials.gov:NCT07408063","description":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"e5e940daf5174c6f92cb451a155f54b4","type":"TRIAL","name":"A Confirmation Study of Eribulin in Combination With Capecitabine","canonical_id":"clinicaltrials.gov:NCT01323530","description":"Metastatic Breast Cancer","metadata":null},{"id":"877866908b4d4843b8e2465c6e4b8319","type":"TRIAL","name":"A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01840605","description":"Dermatitis; Atopic","metadata":null},{"id":"467dcb8466aa47518742e08edfd8b94c","type":"TRIAL","name":"A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy","canonical_id":"clinicaltrials.gov:NCT04776993","description":"Graves' Orbitopathy","metadata":null},{"id":"9e8062ae98b34468b9c0b9376af3abb7","type":"TRIAL","name":"A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057","canonical_id":"clinicaltrials.gov:NCT00712933","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"a03a276fbd084fc8b78872877961bd73","type":"TRIAL","name":"A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02","canonical_id":"clinicaltrials.gov:NCT00583362","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"368ce4a7bec5472890b7227fe761106b","type":"TRIAL","name":"A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma","canonical_id":"clinicaltrials.gov:NCT00109200","description":"Asthma","metadata":null},{"id":"e641191b6bdb4189ba506c059b491168","type":"TRIAL","name":"A Controlled Trial of Erenumab in Migraine Prevention","canonical_id":"clinicaltrials.gov:NCT03812224","description":"Migraine","metadata":null},{"id":"0c318824b1594e9688b904347d7f3cfe","type":"TRIAL","name":"A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine","canonical_id":"clinicaltrials.gov:NCT00475514","description":"Migraine","metadata":null},{"id":"e831896acaab4d748b2e537760499ede","type":"TRIAL","name":"A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease","canonical_id":"clinicaltrials.gov:NCT00134173","description":"Coronary Disease; Coronary Arteriosclerosis; Hyperlipidemia","metadata":null},{"id":"4f15e5f4d975440ab1825e4c96dd8c47","type":"TRIAL","name":"A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.","canonical_id":"clinicaltrials.gov:NCT02295280","description":"Headache","metadata":null},{"id":"6e3effc849c041748a8b77210fcefb17","type":"TRIAL","name":"A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine","canonical_id":"clinicaltrials.gov:NCT01103050","description":"Allergic Rhinitis","metadata":null},{"id":"e8e05cbee2ef431089584d58943d5c54","type":"TRIAL","name":"A Crossover Pilot Study of the Effect of Amiloride on Proteinuria","canonical_id":"clinicaltrials.gov:NCT02522650","description":"Proteinuria","metadata":null},{"id":"9f33fc1f81354358a6c7f0e6c6fc837b","type":"TRIAL","name":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","canonical_id":"clinicaltrials.gov:NCT00615459","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"ac76d819aca149178263218bd3a3c1f2","type":"TRIAL","name":"A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02390609","description":"Healthy","metadata":null},{"id":"5ae1cee9d64e410788c2f3774d5c1e3e","type":"TRIAL","name":"A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression","canonical_id":"clinicaltrials.gov:NCT05932407","description":"Major Depressive Disorder","metadata":null},{"id":"888b5a9fa8f547eca1ba5a62ad4a4fae","type":"TRIAL","name":"A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)","canonical_id":"clinicaltrials.gov:NCT00445094","description":"Infection; Pneumonia","metadata":null},{"id":"e9b701d9822e479da6c28d0b028e4b1f","type":"TRIAL","name":"A Degarelix Trial in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01242748","description":"Prostate Cancer","metadata":null},{"id":"9399c957f08041ce8f8daf70ed66dd51","type":"TRIAL","name":"A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT05872256","description":"Scalp Psoriasis","metadata":null},{"id":"a5f2b7a7d6e545d296300d725d17bec1","type":"TRIAL","name":"A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial","canonical_id":"clinicaltrials.gov:NCT07074756","description":"Glioma; Recurrent Glioma; Recurrent Glioblastoma","metadata":null},{"id":"4ea4297d2c264308ac63ad771c22db1d","type":"TRIAL","name":"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01296555","description":"Solid Cancers; Non-Hodgkin's Lymphoma","metadata":null},{"id":"d08ac6ae9d234226a235bf7129803f76","type":"TRIAL","name":"A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01521299","description":"Advanced Solid Tumors","metadata":null},{"id":"2a2e32a97da64a4e8d800c743f2ff336","type":"TRIAL","name":"A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures","canonical_id":"clinicaltrials.gov:NCT05610085","description":"Neonatal Seizure; Neonatal Encephalopathy; Hypoxic-Ischemic Encephalopathy; Seizure Newborn","metadata":null},{"id":"6b493862c2844a5d836d204358ab9cc4","type":"TRIAL","name":"A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT05343637","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"8bd0a6e344514c8e946dcb48014152a6","type":"TRIAL","name":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03266159","description":"Solid Tumours","metadata":null},{"id":"90d8cb7bbff54a0b895d8b5e403f3074","type":"TRIAL","name":"A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03251924","description":"Cancer; Tumors; Neoplasm; Malignancy","metadata":null},{"id":"553a54b05dd64534b2b519a5614eb733","type":"TRIAL","name":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)","canonical_id":"clinicaltrials.gov:NCT04333706","description":"Breast; Metastatic; Triple Negative; Cancer; Disseminated Tumor Cell","metadata":null},{"id":"4abf6a7abe334a65b10b3b1a9010e57b","type":"TRIAL","name":"A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01755390","description":"Advanced Solid Tumor","metadata":null},{"id":"af6d59a978794ffd8a871338fc565327","type":"TRIAL","name":"A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas","canonical_id":"clinicaltrials.gov:NCT04464798","description":"Lymphoma","metadata":null},{"id":"ea2196ac9e91470981a881b89325faa7","type":"TRIAL","name":"A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07512076","description":"Prostate Cancer Patients; Elderly Patients; Pharmacokinetic Study","metadata":null},{"id":"faedaf7a3ece4afc963a9d0133ae6045","type":"TRIAL","name":"A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02390050","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"181bbb147e39455ab5dc2f0d0c27605b","type":"TRIAL","name":"A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03809663","description":"Atopic Dermatitis","metadata":null},{"id":"b5fd938748494c5c961e0b8e9aca6cc4","type":"TRIAL","name":"A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)","canonical_id":"clinicaltrials.gov:NCT03086460","description":"Asthma","metadata":null},{"id":"24f2c876850a4e96892c8afe835326a6","type":"TRIAL","name":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT01212471","description":"Dry Eye Syndrome","metadata":null},{"id":"d95746e62ec84b6796777ff7721d0e59","type":"TRIAL","name":"A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI","canonical_id":"clinicaltrials.gov:NCT03236311","description":"Microvascular Coronary Artery Disease","metadata":null},{"id":"ce22f27696fb4fe7b3e2d6cbf05b8e2e","type":"TRIAL","name":"A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02236000","description":"Breast Cancer","metadata":null},{"id":"a1dd9412bda84ccb929aea28ac86f232","type":"TRIAL","name":"A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)","canonical_id":"clinicaltrials.gov:NCT00851734","description":"Keratoconjunctivitis Sicca","metadata":null},{"id":"7cc64fdd9724405e98e7207a3f42a008","type":"TRIAL","name":"A Dose-Finding Study of Folotyn\u00ae (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT02594267","description":"Peripheral T-Cell Lymphoma (PTCL)","metadata":null},{"id":"cab07deb51984646b4df9c0d9d4a4b53","type":"TRIAL","name":"A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)","canonical_id":"clinicaltrials.gov:NCT00246337","description":"Migraine","metadata":null},{"id":"08236755d84d433fadf8c496e5aea9f3","type":"TRIAL","name":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","canonical_id":"clinicaltrials.gov:NCT01217073","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c42d8ce177b64a28bd9fe39f482e8315","type":"TRIAL","name":"A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD","canonical_id":"clinicaltrials.gov:NCT02038829","description":"COPD","metadata":null},{"id":"909005f55a1c48099935027ee9400170","type":"TRIAL","name":"A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)","canonical_id":"clinicaltrials.gov:NCT00650624","description":"Osteoarthritis, Knee","metadata":null},{"id":"7730c4d24d0b4758a91450f0db7c4e67","type":"TRIAL","name":"A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)","canonical_id":"clinicaltrials.gov:NCT00234104","description":"Heart Failure, Congestive; Edema","metadata":null},{"id":"f72d49fb55da4f3b8b98e9a368d9681f","type":"TRIAL","name":"A Dose-finding Study of Silodosin in Patients With Urinary Calculi","canonical_id":"clinicaltrials.gov:NCT01539265","description":"Urinary Calculus","metadata":null},{"id":"19f98a854f3049fab9d26329a61f6e4c","type":"TRIAL","name":"A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.","canonical_id":"clinicaltrials.gov:NCT00175825","description":"Epilepsy","metadata":null},{"id":"345eeff67b3a4be1ab2f1eca20f0d8ad","type":"TRIAL","name":"A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)","canonical_id":"clinicaltrials.gov:NCT03192176","description":"Menopause; Hot Flashes","metadata":null},{"id":"80ee6c7d33444e668769b4453e41e7be","type":"TRIAL","name":"A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy","canonical_id":"clinicaltrials.gov:NCT01497652","description":"Parkinson's Disease","metadata":null},{"id":"e789ad6899774dc587b30a91cb4007bc","type":"TRIAL","name":"A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT00821483","description":"Migraine","metadata":null},{"id":"e0de1e308f914fad973866ed449a00e6","type":"TRIAL","name":"A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT00649415","description":"Dysmenorrhea","metadata":null},{"id":"c300e18faf5a469cbe5c59226b21650b","type":"TRIAL","name":"A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00181571","description":"ADHD","metadata":null},{"id":"c542a32da30d4cd698a1f3e43013ae3f","type":"TRIAL","name":"A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide","canonical_id":"clinicaltrials.gov:NCT00820885","description":"Pharmacokinetics and Safety of Elevated Doses","metadata":null},{"id":"b2587e5fbe3541498fcdf40d108681a1","type":"TRIAL","name":"A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches","canonical_id":"clinicaltrials.gov:NCT00391755","description":"Migraine Headache","metadata":null},{"id":"ee2fb70a028d425ca6cc5eaff65dc9f8","type":"TRIAL","name":"A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT00737256","description":"Schizophrenia; Cocaine Dependence","metadata":null},{"id":"70769b20bd7c44ce91b2a42522c24e82","type":"TRIAL","name":"A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan","canonical_id":"clinicaltrials.gov:NCT00648258","description":"Osteoarthritis","metadata":null},{"id":"4fa7a4a7b0d24448a5c3346cd6d9e0f7","type":"TRIAL","name":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","canonical_id":"clinicaltrials.gov:NCT00683852","description":"Major Depressive Disorder","metadata":null},{"id":"9df9de3fb6854d698feff723e63095a5","type":"TRIAL","name":"A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT00624663","description":"Rivastigmine Toxicity","metadata":null},{"id":"1d6fc536110f404da85eea10b8f9c45c","type":"TRIAL","name":"A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients","canonical_id":"clinicaltrials.gov:NCT00336310","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"aaa332a0232644f297d19b5938dc8138","type":"TRIAL","name":"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients","canonical_id":"clinicaltrials.gov:NCT00002408","description":"Diarrhea; HIV Infections","metadata":null},{"id":"c143ba6edab343e291f1c9a9c9658081","type":"TRIAL","name":"A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness","canonical_id":"clinicaltrials.gov:NCT06444529","description":"Ocular Redness","metadata":null},{"id":"b222ef6ee9ac49098200cd1af5940459","type":"TRIAL","name":"A Double-blind \"Preferred\" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00661700","description":"Erectile Dysfunction","metadata":null},{"id":"53a68b9daa124a0086f4116f9f5f280f","type":"TRIAL","name":"A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food","canonical_id":"clinicaltrials.gov:NCT01468038","description":"Sleep Disorder","metadata":null},{"id":"384759d6d77f46fb8d1b68d64a69668a","type":"TRIAL","name":"A Double-blind RCT to Investigate the Effect of a Novel Herbal Patch for the Treatment of PF","canonical_id":"clinicaltrials.gov:NCT05584046","description":"Plantar Fasciitis","metadata":null},{"id":"edb9f0a9d7ac4f5f9cd539edf71b78ab","type":"TRIAL","name":"A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara\u00ae in Patients With Moderate-to-Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04595409","description":"Plaque Psoriasis","metadata":null},{"id":"bb8277ec85434184a53a1882c9f1d709","type":"TRIAL","name":"A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain","canonical_id":"clinicaltrials.gov:NCT00657449","description":"Acute Pain","metadata":null},{"id":"42d3d09e9f234165993976f8f9a1b0a8","type":"TRIAL","name":"A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients","canonical_id":"clinicaltrials.gov:NCT00374777","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"0980f533b5624651968e372506bf9768","type":"TRIAL","name":"A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia","canonical_id":"clinicaltrials.gov:NCT00283946","description":"Sleep Initiation and Maintenance Disorders; Sleep Disorders","metadata":null},{"id":"fe7da9a698be4dac86ebe6ab9e83bf2e","type":"TRIAL","name":"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04342663","description":"COVID 19; Coronavirus","metadata":null},{"id":"73dd6a1d62d040eaa96d1ac189d1de7b","type":"TRIAL","name":"A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine","canonical_id":"clinicaltrials.gov:NCT04589143","description":"Major Depressive Disorder","metadata":null},{"id":"ffae79f1d3af498fbe574f8c73c1878b","type":"TRIAL","name":"A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 \u03bcg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02153489","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"75517f5ae28840b9a04f7b752ee21d39","type":"TRIAL","name":"A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (\u2265 16 to 75 Years Old) With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT00698581","description":"Epilepsy","metadata":null},{"id":"e61167cbd08f444ea7c18430005c42fb","type":"TRIAL","name":"A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (\u2265 16 to 75 Years Old) With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT00699283","description":"Epilepsy","metadata":null},{"id":"8e25ffeab9714ae383a45e94c069e6bb","type":"TRIAL","name":"A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06194214","description":"Healthy","metadata":null},{"id":"07617c27bade46ca9fa31298836b02df","type":"TRIAL","name":"A Drug Interaction Study of LY3871801 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05602675","description":"Healthy","metadata":null},{"id":"982e0fe00c3a4d86b12d27a2807b813f","type":"TRIAL","name":"A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma","canonical_id":"clinicaltrials.gov:NCT01185548","description":"Lymphoma; Advanced Cancer","metadata":null},{"id":"8ba052ff88e345d7aa638700642c55d2","type":"TRIAL","name":"A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.","canonical_id":"clinicaltrials.gov:NCT00842400","description":"Obesity","metadata":null},{"id":"58af6e7f891a450f92262732590a2743","type":"TRIAL","name":"A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine","canonical_id":"clinicaltrials.gov:NCT01358968","description":"Cancer","metadata":null},{"id":"d4fa1a6fb6464e9b9a10cc1123a13ba1","type":"TRIAL","name":"A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment","canonical_id":"clinicaltrials.gov:NCT01802515","description":"Cocaine Dependence; Opiate Dependence","metadata":null},{"id":"8704233042b54ab9a61fd270ec5c41bd","type":"TRIAL","name":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","canonical_id":"clinicaltrials.gov:NCT03333018","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"0223b3c331eb4f01972fc4d00ac7a1ed","type":"TRIAL","name":"A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide","canonical_id":"clinicaltrials.gov:NCT03387657","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7ed5d33224f9483dbae8420cd70164bc","type":"TRIAL","name":"A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol","canonical_id":"clinicaltrials.gov:NCT02940379","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d24d7b3c68d4447e965659090d319c2d","type":"TRIAL","name":"A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants","canonical_id":"clinicaltrials.gov:NCT05445232","description":"Obesity","metadata":null},{"id":"e56204c675734d82843b348504afe744","type":"TRIAL","name":"A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin\u00ae)","canonical_id":"clinicaltrials.gov:NCT07181343","description":"Psoriasis (PsO)","metadata":null},{"id":"e3ce64cfbd3e4605b3e64de59bc3fa9b","type":"TRIAL","name":"A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril","canonical_id":"clinicaltrials.gov:NCT03414723","description":"Diabetes Mellitus; Healthy Subjects","metadata":null},{"id":"078058d5a728441b876337301b0d5bd3","type":"TRIAL","name":"A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06092931","description":"Healthy Participants","metadata":null},{"id":"d55350d9ffd44d0a95719d3a764fe766","type":"TRIAL","name":"A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib","canonical_id":"clinicaltrials.gov:NCT03723395","description":"Drug-drug Interaction","metadata":null},{"id":"6951d0d82bae4dabaf3c22bcb11d6743","type":"TRIAL","name":"A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin","canonical_id":"clinicaltrials.gov:NCT03826602","description":"Drug-drug Interaction","metadata":null},{"id":"13a50a1bad7a40b0b583dcf4f8ff814c","type":"TRIAL","name":"A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01017939","description":"Prostate Neoplasms","metadata":null},{"id":"4896d7ea0b504309b7a83f965e4e7910","type":"TRIAL","name":"A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)","canonical_id":"clinicaltrials.gov:NCT06703463","description":"Healthy","metadata":null},{"id":"cb0419aec62a4fa7a756aa84f7ac9de2","type":"TRIAL","name":"A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)","canonical_id":"clinicaltrials.gov:NCT06554639","description":"Prostatic Neoplasms","metadata":null},{"id":"fa70e1a57fc74a93931cad3e890916bb","type":"TRIAL","name":"A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)","canonical_id":"clinicaltrials.gov:NCT07548606","description":"Healthy","metadata":null},{"id":"f105680f55f14d27b7cccd3e88f04afd","type":"TRIAL","name":"A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06111521","description":"Healthy","metadata":null},{"id":"399633c9ddf2440b946f869ef2868820","type":"TRIAL","name":"A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib","canonical_id":"clinicaltrials.gov:NCT01772290","description":"Healthy Volunteer","metadata":null},{"id":"6ead530e169f42328ed913d7950c875c","type":"TRIAL","name":"A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01100619","description":"Papillary Thyroid Cancer; Follicular Thyroid Cancer; Huerthle Cell Thyroid Cancer; Renal Cell Carcinoma","metadata":null},{"id":"5431e818dc1a4de79bd013a0b2e624fb","type":"TRIAL","name":"A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)","canonical_id":"clinicaltrials.gov:NCT05532358","description":"Healthy Volunteers","metadata":null},{"id":"3f406ed780554dc98d9f015eb11a1e08","type":"TRIAL","name":"A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02705963","description":"Solid Tumors","metadata":null},{"id":"5a4e76409f9743f09c29b0d0ddfe95e9","type":"TRIAL","name":"A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast","canonical_id":"clinicaltrials.gov:NCT01561963","description":"Healthy Subjects","metadata":null},{"id":"2e80b619fb3b4c988dc83b86eb223d46","type":"TRIAL","name":"A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST","canonical_id":"clinicaltrials.gov:NCT04530981","description":"GIST - Gastrointestinal Stromal Tumor","metadata":null},{"id":"012cc8c4844b420998e95ae31106a53f","type":"TRIAL","name":"A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin","canonical_id":"clinicaltrials.gov:NCT01606748","description":"Malignant Solid Tumor","metadata":null},{"id":"ac7cbd1055d741d482488d9849910cbb","type":"TRIAL","name":"A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin","canonical_id":"clinicaltrials.gov:NCT06081166","description":"Healthy Volunteers","metadata":null},{"id":"58e4e0894c764324b7c8a092a731800c","type":"TRIAL","name":"A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06503679","description":"Healthy","metadata":null},{"id":"19d26046ab584b869f822a74d8f04509","type":"TRIAL","name":"A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects","canonical_id":"clinicaltrials.gov:NCT06837142","description":"Healthy Male Subjects","metadata":null},{"id":"cf46d42b87d04277ad2f22965d01b6c3","type":"TRIAL","name":"A Drug-drug Interaction Study of DP-R213","canonical_id":"clinicaltrials.gov:NCT02654093","description":"Healthy","metadata":null},{"id":"9e69b4e4b69e4c689ff2fb3ceaf6b0e4","type":"TRIAL","name":"A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants","canonical_id":"clinicaltrials.gov:NCT06979973","description":"Healthy","metadata":null},{"id":"d57d6da4e0bd4164834c79ba44dee62d","type":"TRIAL","name":"A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib","canonical_id":"clinicaltrials.gov:NCT04494659","description":"Healthy Adult Subjects","metadata":null},{"id":"aabea9514a2d42f1967deddf6725254d","type":"TRIAL","name":"A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.","canonical_id":"clinicaltrials.gov:NCT06823752","description":"Insomnia","metadata":null},{"id":"45bf61f81b3d4af2ac1a506ace0c153a","type":"TRIAL","name":"A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00960986","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"f7d7ca27ca76488a816703133995ced6","type":"TRIAL","name":"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet\u00ae in Parkinson's Disease Subjects","canonical_id":"clinicaltrials.gov:NCT01171313","description":"Parkinson's Disease","metadata":null},{"id":"16c94b7d37d54b878d2d940013df5a6e","type":"TRIAL","name":"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea","canonical_id":"clinicaltrials.gov:NCT01381900","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"472fad54bea54241832a5befb0b02528","type":"TRIAL","name":"A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide","canonical_id":"clinicaltrials.gov:NCT07585747","description":"Follicular Lymphoma","metadata":null},{"id":"11294937cb5041b99783f3a7e4ebf606","type":"TRIAL","name":"A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants","canonical_id":"clinicaltrials.gov:NCT02039323","description":"Healthy Adult Females","metadata":null},{"id":"ea571ac2ccaf4c6e963b5163b122eb95","type":"TRIAL","name":"A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT05934838","description":"Follicular Lymphoma; B-Cell Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma","metadata":null},{"id":"69c282645d5e46cca8a6b7b789effde5","type":"TRIAL","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body","canonical_id":"clinicaltrials.gov:NCT06413680","description":"Melanoma; Clear-Cell Renal-Cell Carcinoma (ccRCC); Advanced Solid Tumors","metadata":null},{"id":"b6c21b597f3444eaaaeced151e4f7066","type":"TRIAL","name":"A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03471663","description":"Breast Cancer","metadata":null},{"id":"b2d3bda68c9d48b2a49f89feef7613a1","type":"TRIAL","name":"A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT05835986","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"6c85ba19a6a84949b4617650cc7f8cbb","type":"TRIAL","name":"A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT01059435","description":"Osteopenia","metadata":null},{"id":"ae246afe94bb4f71a90192e82738026b","type":"TRIAL","name":"A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study","canonical_id":"clinicaltrials.gov:NCT01822639","description":"Hypertension","metadata":null},{"id":"499d28dfad7142b59ff0d73de5cb7123","type":"TRIAL","name":"A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01494532","description":"Parkinson Disease","metadata":null},{"id":"2b7c8b561bca4fee93a490e39e1cae79","type":"TRIAL","name":"A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT00235443","description":"Diabetic Neuropathy","metadata":null},{"id":"e2fbb34891624b10967e0d73ad1765b9","type":"TRIAL","name":"A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)","canonical_id":"clinicaltrials.gov:NCT03820726","description":"Lung Diseases, Interstitial","metadata":null},{"id":"9dd3d38c8252424eba1d03b9ff06e886","type":"TRIAL","name":"A Food Effect Study of Pitolisant Delayed-Release in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT07860736","description":"Healthy Participants","metadata":null},{"id":"ef098db0b01a4d7b96279e87d34aaaf0","type":"TRIAL","name":"A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01363999","description":"Healthy Volunteer","metadata":null},{"id":"a28fd0a3c3e14a359e192a9ecd882cbd","type":"TRIAL","name":"A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT00568295","description":"Osteoarthritis of the Knee","metadata":null},{"id":"9cf5b8293f1c41e5a2b91bedae6d5d82","type":"TRIAL","name":"A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03978403","description":"Migraine","metadata":null},{"id":"30b25f23521c4f4d8c4b930c48e4090b","type":"TRIAL","name":"A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT05683977","description":"Small Cell Lung Carcinoma","metadata":null},{"id":"864bfb1201ad4ca988f54014e36c5a9b","type":"TRIAL","name":"A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01712490","description":"Hodgkin Lymphoma","metadata":null},{"id":"ef68dcdb58bb4490b837ed555ffa4cf1","type":"TRIAL","name":"A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)","canonical_id":"clinicaltrials.gov:NCT00914212","description":"Obesity","metadata":null},{"id":"93b1f09fe6604985bf13ccaf86153a2a","type":"TRIAL","name":"A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease","canonical_id":"clinicaltrials.gov:NCT01944436","description":"Lewy Body Disease","metadata":null},{"id":"bf117cd263204873bfedcc14507ba8e7","type":"TRIAL","name":"A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","canonical_id":"clinicaltrials.gov:NCT01931670","description":"Endometriosis","metadata":null},{"id":"9540e5f624e14ae2905e510cbdb80d48","type":"TRIAL","name":"A Global Prospective Observational Registry of Patients With Pompe Disease","canonical_id":"clinicaltrials.gov:NCT06121011","description":"Pompe Disease","metadata":null},{"id":"129e5edaa744476198ccd569bc4ac511","type":"TRIAL","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","canonical_id":"clinicaltrials.gov:NCT03591510","description":"FLT3-mutated Acute Myeloid Leukemia","metadata":null},{"id":"edda066e88854736bde960ded7ea748f","type":"TRIAL","name":"A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT03512197","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"65c5534d666549e0b7ce816cc18da385","type":"TRIAL","name":"A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing","canonical_id":"clinicaltrials.gov:NCT03330457","description":"Bleeding","metadata":null},{"id":"1467c0acf0204765ace019a4851d43d2","type":"TRIAL","name":"A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234","canonical_id":"clinicaltrials.gov:NCT05567367","description":"Healthy Volunteer","metadata":null},{"id":"032c1959755b4a61843d370eb181b168","type":"TRIAL","name":"A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01765868","description":"Healthy Subjects","metadata":null},{"id":"d17166178d0645a1bc54cf0c5a66e6ea","type":"TRIAL","name":"A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma","canonical_id":"clinicaltrials.gov:NCT07014540","description":"Neuroendocrine Carcinomas (NEC)","metadata":null},{"id":"2961b3ad7e00481aba210bd241cfa9a6","type":"TRIAL","name":"A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT01456039","description":"Lymphoma, T-cell, Peripheral","metadata":null},{"id":"4411202f50ed49f0b693ad112ad67cd8","type":"TRIAL","name":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","canonical_id":"clinicaltrials.gov:NCT01636947","description":"Nausea; Vomiting","metadata":null},{"id":"1ce54385ad3f47f78fe7601dd0f0628e","type":"TRIAL","name":"A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically","canonical_id":"clinicaltrials.gov:NCT02220348","description":"Breast Feeding; Constipation; Irritable Bowel Syndrome","metadata":null},{"id":"55df55c431df40d587f7f7f6574835c8","type":"TRIAL","name":"A Lifestyle and Combination Medication Therapy Diabetes Prevention Study","canonical_id":"clinicaltrials.gov:NCT00116922","description":"Impaired Glucose Tolerance; Diabetes","metadata":null},{"id":"2b2b80e34eef4482be8e98a273d198bd","type":"TRIAL","name":"A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT00367432","description":"Epilepsies; Partial","metadata":null},{"id":"9be0d730d5694bc89fe83c3edaa1065c","type":"TRIAL","name":"A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants","canonical_id":"clinicaltrials.gov:NCT01933880","description":"Attention Deficit Hyperactivity Disorder (ADHD)","metadata":null},{"id":"dff75be8911a43399ee7a28e3ce4eced","type":"TRIAL","name":"A Long Term Safety Study With Atrasentan","canonical_id":"clinicaltrials.gov:NCT00127478","description":"Prostate Cancer; Adenocarcinoma","metadata":null},{"id":"9315ced798fb42939adab7eba7b8fe9c","type":"TRIAL","name":"A Long Term Safety Study of Degarelix in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00967018","description":"Prostate Cancer","metadata":null},{"id":"7d354316d2f345618b0c1c10b6d0a076","type":"TRIAL","name":"A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00667719","description":"Essential Hypertension","metadata":null},{"id":"3a8c0e6a873f46f9ba4d5171826e5046","type":"TRIAL","name":"A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)","canonical_id":"clinicaltrials.gov:NCT00578786","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"e6ebaf4f6aa44aaeb9e3e46900300795","type":"TRIAL","name":"A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients","canonical_id":"clinicaltrials.gov:NCT00234832","description":"Obesity","metadata":null},{"id":"21f8efb481a54ad7aa5bdec2a6904077","type":"TRIAL","name":"A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","canonical_id":"clinicaltrials.gov:NCT03714815","description":"Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","metadata":null},{"id":"b46b31e103f249cf91e26f3e08cf4f5a","type":"TRIAL","name":"A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT02584855","description":"Psoriatic Arthritis","metadata":null},{"id":"3fc06ba7cbba49ec9d3da01c61fdef44","type":"TRIAL","name":"A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01665430","description":"Rheumatoid Arthritis","metadata":null},{"id":"b31bce307a5c466d87a548ae7d6264d1","type":"TRIAL","name":"A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","canonical_id":"clinicaltrials.gov:NCT04702568","description":"Paroxysmal Nocturnal Hemoglobinuria; PNH","metadata":null},{"id":"616d27107106497bb088a0134ece431b","type":"TRIAL","name":"A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)","canonical_id":"clinicaltrials.gov:NCT00561574","description":"Sleep Initiation and Maintenance Disorder; Elderly; Mental Disorder; Dyssomnias; Sleep Disorders; Sleep Disorder, Intrinsic","metadata":null},{"id":"8d84782ad54846d4936769040fd78191","type":"TRIAL","name":"A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia","canonical_id":"clinicaltrials.gov:NCT05458128","description":"Idiopathic Hypersomnia; Excessive Daytime Sleepiness","metadata":null},{"id":"c423e88c19e64432b8f259fc82646c82","type":"TRIAL","name":"A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00170755","description":"Overactive Bladder Syndrome","metadata":null},{"id":"97c47514906f4684906d2d5e74265efb","type":"TRIAL","name":"A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00095745","description":"Major Depressive Disorder","metadata":null},{"id":"323e2b4077eb40579242e63749346c49","type":"TRIAL","name":"A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.","canonical_id":"clinicaltrials.gov:NCT07029828","description":"Severe Alopecia Areata","metadata":null},{"id":"1a31f017e3294d1dba2c4c909c5e2ac0","type":"TRIAL","name":"A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00811018","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"45b286283970485883225ed6a1c254cf","type":"TRIAL","name":"A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT02382276","description":"Alcohol Dependence","metadata":null},{"id":"43b25cabdc8340978ba672550d930c5b","type":"TRIAL","name":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT04232553","description":"Crohn's Disease","metadata":null},{"id":"6b80ddc3619449068b00579a4aaf9be2","type":"TRIAL","name":"A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00721123","description":"Rheumatoid Arthritis","metadata":null},{"id":"718e0fd6434c48e6980d5d8c5160b920","type":"TRIAL","name":"A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)","canonical_id":"clinicaltrials.gov:NCT01063868","description":"Diabetic Neuropathy, Painful; Diabetic Polyneuropathy","metadata":null},{"id":"f825fd9439f44dc9a008b41932575700","type":"TRIAL","name":"A Long-term Study for the Treatment of Painful Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT00641719","description":"Diabetic Neuropathies","metadata":null},{"id":"41b63e32896f4957ad40a82cdd790f50","type":"TRIAL","name":"A Long-term Study of AK102 in Patients With Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT04173403","description":"Hypercholesterolemia","metadata":null},{"id":"1ae21e231de14e56a5f81bd943ce2f25","type":"TRIAL","name":"A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable","canonical_id":"clinicaltrials.gov:NCT03428100","description":"Atopic Dermatitis","metadata":null},{"id":"f2b9374d67a248379714a07f13518b28","type":"TRIAL","name":"A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","canonical_id":"clinicaltrials.gov:NCT04204616","description":"Prurigo Nodularis","metadata":null},{"id":"ac55ad34516a4e47b7e82d2b67c7ad69","type":"TRIAL","name":"A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)","canonical_id":"clinicaltrials.gov:NCT03556202","description":"Psoriasis","metadata":null},{"id":"a34934827b8f4eeb905863df79ab1f57","type":"TRIAL","name":"A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)","canonical_id":"clinicaltrials.gov:NCT02711852","description":"Hematologic Malignancy","metadata":null},{"id":"d87acdc851234434b1ed16b03a84e1e4","type":"TRIAL","name":"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT01777139","description":"Epilepsy","metadata":null},{"id":"ca1e68afa14f4996948e850c4f1c1dd0","type":"TRIAL","name":"A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss","canonical_id":"clinicaltrials.gov:NCT00108524","description":"Diabetes Mellitus; Obesity","metadata":null},{"id":"9f1884da171047fe94471b9c56aa2105","type":"TRIAL","name":"A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03524092","description":"Ulcerative Colitis","metadata":null},{"id":"ed28790f711b4d76bf20167ed0afe7ea","type":"TRIAL","name":"A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433","canonical_id":"clinicaltrials.gov:NCT03345823","description":"Crohn's Disease","metadata":null},{"id":"a6287f4742514152aeb8ccceacb7904e","type":"TRIAL","name":"A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT03517943","description":"Clinical Pharmacology","metadata":null},{"id":"2c00b027c02544299d14c592614bfafc","type":"TRIAL","name":"A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)","canonical_id":"clinicaltrials.gov:NCT04844606","description":"Ulcerative Colitis; Ulcerative Colitis Chronic; Inflammatory Bowel Diseases; Crohn's Disease","metadata":null},{"id":"5b1ccb48cb694eafb11bd69ad14b77a2","type":"TRIAL","name":"A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07483073","description":"Colitis, Ulcerative; Crohn Disease","metadata":null},{"id":"32313c81158a4e0daa8ea38c66eebeda","type":"TRIAL","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","canonical_id":"clinicaltrials.gov:NCT05999994","description":"Neoplasms; Child; Adolescent","metadata":null},{"id":"92549cf56b04487eb8ba92656030e1e3","type":"TRIAL","name":"A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT07787169","description":"Alzheimer Disease; Amyloid; Plaque, Amyloid; Healthy Volunteers","metadata":null},{"id":"0360f5fadbd94859922570473c1bc2a8","type":"TRIAL","name":"A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01088594","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"836404fd180544b1a967d7d78b1a5120","type":"TRIAL","name":"A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US","canonical_id":"clinicaltrials.gov:NCT06952426","description":"Immunoglobulin A Nephropathy","metadata":null},{"id":"70519cb03a2049f6ad7f531fbfb89594","type":"TRIAL","name":"A Model About the Response of Belimumab in SLE","canonical_id":"clinicaltrials.gov:NCT04893161","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"642fa95918d94c01a269012ca59730de","type":"TRIAL","name":"A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)","canonical_id":"clinicaltrials.gov:NCT03767075","description":"Advanced Solid Tumor","metadata":null},{"id":"fd12c311353249e1b0388b70abc71a28","type":"TRIAL","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT07681596","description":"Relapsed or Refractory Multiple Myeloma","metadata":null},{"id":"4a7ef9aa780046699336c334d0036ba0","type":"TRIAL","name":"A MolEcularly Guided Anti-Cancer Drug Off-Label Trial","canonical_id":"clinicaltrials.gov:NCT04185831","description":"Solid Tumor","metadata":null},{"id":"7e357e08398b4a6b8bc654eda71f8c71","type":"TRIAL","name":"A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT01709656","description":"Ankylosing Spondylitis","metadata":null},{"id":"626e54b916d64cb5b6f4cd3224e1426e","type":"TRIAL","name":"A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00773630","description":"Intermittent Claudication","metadata":null},{"id":"1da7abea83b44f16a8e266185cb4adfe","type":"TRIAL","name":"A Multi-Arm, Platform Trial For Relapsed Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT07334301","description":"Relapsed Neuroblastoma","metadata":null},{"id":"ddbb15a884f34f10bba658892d553e25","type":"TRIAL","name":"A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene","canonical_id":"clinicaltrials.gov:NCT02651688","description":"Acquired Hypogonadotropic Hypogonadism; Obesity","metadata":null},{"id":"11fff92cd8b84e4c97e47b17eeed7898","type":"TRIAL","name":"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","canonical_id":"clinicaltrials.gov:NCT00915551","description":"Actinic Keratosis","metadata":null},{"id":"04c97450208a4ae599d2a66393596c55","type":"TRIAL","name":"A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID","canonical_id":"clinicaltrials.gov:NCT06974084","description":"Long COVID","metadata":null},{"id":"f39ab463d4b9456190a338ff4d6b68aa","type":"TRIAL","name":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","canonical_id":"clinicaltrials.gov:NCT03251378","description":"Advanced Solid Tumors; Metastatic Colon Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Rectal Cancer","metadata":null},{"id":"656789e6c24847ce8ee804f08fbfd4fd","type":"TRIAL","name":"A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle","canonical_id":"clinicaltrials.gov:NCT00671320","description":"Pain; Sprains and Strains; Sprain","metadata":null},{"id":"33d34f23e4a9407b85340959d444cd3f","type":"TRIAL","name":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02681094","description":"Type 2 Diabetes Mellitus; Inadequate Glycaemic Control","metadata":null},{"id":"584cb3f006f746ab918d47132ee4a338","type":"TRIAL","name":"A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02103725","description":"Atopic Dermatitis","metadata":null},{"id":"654606e394614670bb60a1e5a66994b2","type":"TRIAL","name":"A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider","canonical_id":"clinicaltrials.gov:NCT01244061","description":"Smoking Cessation","metadata":null},{"id":"27e41f49c89b4f81bb926be453c1b4c9","type":"TRIAL","name":"A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib","canonical_id":"clinicaltrials.gov:NCT06284486","description":"Acute Myeloid Leukemia","metadata":null},{"id":"51d668e2279740df86cb6ee38ad55768","type":"TRIAL","name":"A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.\"","canonical_id":"clinicaltrials.gov:NCT04998786","description":"Multiple Myeloma at First Relapse","metadata":null},{"id":"db35f745bbe04489ba22bf61d021e063","type":"TRIAL","name":"A Multi-center Study of Apixaban(APPROACH)","canonical_id":"clinicaltrials.gov:NCT04550637","description":"Evaluate the Safety and Efficacy of Apixaban","metadata":null},{"id":"8ff8b3625e084110b413e3b63feb8056","type":"TRIAL","name":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04229004","description":"Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma","metadata":null},{"id":"8272f924b855454aba4a07258b73c64a","type":"TRIAL","name":"A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622","canonical_id":"clinicaltrials.gov:NCT03306043","description":"Hypereosinophilic Syndrome","metadata":null},{"id":"a78ca73cf96a498f9296b2324d8ef787","type":"TRIAL","name":"A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04087174","description":"Prostate Cancer","metadata":null},{"id":"6cec8b7cd75e4f79a938a1b61552fa88","type":"TRIAL","name":"A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome","canonical_id":"clinicaltrials.gov:NCT00578825","description":"Severe Acute Respiratory Syndrome","metadata":null},{"id":"8d53fd5129ae4065817a2047df9d7f59","type":"TRIAL","name":"A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period","canonical_id":"clinicaltrials.gov:NCT01656720","description":"Faecal Incontinence","metadata":null},{"id":"702d0eef8c7a4e04acb8b6dfe9ebc5b2","type":"TRIAL","name":"A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise","canonical_id":"clinicaltrials.gov:NCT02407704","description":"Depression; Depressive Disorder, Major; Depressive Disorder; Unipolar Depression; Major Depressive Disorder","metadata":null},{"id":"30840770dc6c433da59c5017161f1b14","type":"TRIAL","name":"A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT07595133","description":"Sepsis","metadata":null},{"id":"677900dc01df47bd9e2248a2fd37d15f","type":"TRIAL","name":"A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression","canonical_id":"clinicaltrials.gov:NCT05361330","description":"Outpatients / Inpatients With Depression","metadata":null},{"id":"78fc93766de7420b918cfcae53bae90c","type":"TRIAL","name":"A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00348062","description":"Glaucoma","metadata":null},{"id":"cf7e6f7b9f8a4e5fa77e3eba02807e2a","type":"TRIAL","name":"A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05183139","description":"Multiple Myeloma","metadata":null},{"id":"414848613b824448879f05c38f9432fa","type":"TRIAL","name":"A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders","canonical_id":"clinicaltrials.gov:NCT07417813","description":"Insomnia; Psychiatric Disorders","metadata":null},{"id":"d38eeebd345647ccbfc01dad1567bdcd","type":"TRIAL","name":"A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07418931","description":"Advanced Squamous Non-Small Cell Lung Cancer","metadata":null},{"id":"df52285b71e84626a23e0b36b40e87a6","type":"TRIAL","name":"A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)","canonical_id":"clinicaltrials.gov:NCT03847272","description":"Patients With Newly Diagnosed Active NISU","metadata":null},{"id":"90a9d9aaf6064bc3bca221f1a97e1afb","type":"TRIAL","name":"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT02130557","description":"Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive","metadata":null},{"id":"e4b7efbf37c742a693b14ea74a7414a2","type":"TRIAL","name":"A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD","canonical_id":"clinicaltrials.gov:NCT07762872","description":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","metadata":null},{"id":"cea595d4c0884066abd4f34fdedc7748","type":"TRIAL","name":"A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection","canonical_id":"clinicaltrials.gov:NCT05514314","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"fdd5089b01454924bc3fe91cdde1000d","type":"TRIAL","name":"A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin","canonical_id":"clinicaltrials.gov:NCT06440824","description":"CTIT-Chemotherapy Induced Thrombocytopenia","metadata":null},{"id":"484d7acf7aef427799a55949b851a93f","type":"TRIAL","name":"A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction","canonical_id":"clinicaltrials.gov:NCT07822113","description":"Voiding Dysfunction; Female LUTS","metadata":null},{"id":"c08e03d7e8194c2787c4924d8d7e1196","type":"TRIAL","name":"A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients","canonical_id":"clinicaltrials.gov:NCT02671942","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"f7d7a167115c41e5adf1bb60dde5aa61","type":"TRIAL","name":"A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00965315","description":"Diabetes; CVD","metadata":null},{"id":"4ee5aee5a1924f89931259e7a76f1111","type":"TRIAL","name":"A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00269802","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"dbba4fdaf6974b0995b2600ea619a723","type":"TRIAL","name":"A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT01693718","description":"Head and Neck","metadata":null},{"id":"049db0dd378143f3a4ad2ce01ede95ec","type":"TRIAL","name":"A Multicenter Study of the Efficacy and Safety of Esketamine for Analgesia During Cesarean Section","canonical_id":"clinicaltrials.gov:NCT04548973","description":"Fetal or Neonatal Effect of Damage to Placenta From Caesarean Section","metadata":null},{"id":"215ac9b0b71b4326bfefcae061c58774","type":"TRIAL","name":"A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor","canonical_id":"clinicaltrials.gov:NCT06664970","description":"MDS","metadata":null},{"id":"54ec8a2533964e9ab7ef1258393e706f","type":"TRIAL","name":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","canonical_id":"clinicaltrials.gov:NCT02065336","description":"Hepatitis B, Chronic","metadata":null},{"id":"8c7d11f8335b4170a784f044fee882d6","type":"TRIAL","name":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","canonical_id":"clinicaltrials.gov:NCT00942604","description":"Actinic Keratoses","metadata":null},{"id":"a3354730496b4c8a9da8cb0c52d61654","type":"TRIAL","name":"A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT01479504","description":"Nasopharyngeal Carcinoma","metadata":null},{"id":"47fb1d93282342b7bb33d50d9542df71","type":"TRIAL","name":"A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)","canonical_id":"clinicaltrials.gov:NCT00004845","description":"Alzheimer Disease","metadata":null},{"id":"9bffb2ad05584e6f86eb6f192f367865","type":"TRIAL","name":"A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00645268","description":"Erectile Dysfunction; Diabetes Mellitus, Type 2","metadata":null},{"id":"3315dcefb058423ea8f091dbc49e267f","type":"TRIAL","name":"A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults","canonical_id":"clinicaltrials.gov:NCT01987427","description":"Chronic Weight Management","metadata":null},{"id":"36f87c8de26b44d28e9475edf9fa6340","type":"TRIAL","name":"A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain","canonical_id":"clinicaltrials.gov:NCT00660855","description":"Pain, Post Surgical","metadata":null},{"id":"3b7faca0b51e4954a54cef304536dbbc","type":"TRIAL","name":"A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures","canonical_id":"clinicaltrials.gov:NCT00938431","description":"Epilepsy","metadata":null},{"id":"f7e1e0df21aa45e881080fb234775ebb","type":"TRIAL","name":"A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery","canonical_id":"clinicaltrials.gov:NCT06583330","description":"Colorectal Surgery; VTE (Venous Thromboembolism)","metadata":null},{"id":"d145d45e1c614d2688d571d25b8d500b","type":"TRIAL","name":"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01761266","description":"Hepatocellular Carcinoma (HCC)","metadata":null},{"id":"6e3489fa99a94de58530474d21043fd2","type":"TRIAL","name":"A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT00936988","description":"Hyperparathyroidism, Primary","metadata":null},{"id":"4828e12cec2043af96851ada8bda79a2","type":"TRIAL","name":"A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07684261","description":"Solid Tumor","metadata":null},{"id":"a1316b981b61403280cf429b0a26cda0","type":"TRIAL","name":"A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia\u00ae in Mature Breast Milk of Lactating Mothers","canonical_id":"clinicaltrials.gov:NCT02154425","description":"Axial Spondyloarthritis (AxSpA); Non-radiographic Evidence-AxSpA; Ankylosing Spondylitis; Crohn's Disease; Psoriatic Arthritis; Rheumatoid Arthritis","metadata":null},{"id":"924d8375f22d447b86db08b5aec0ed90","type":"TRIAL","name":"A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence","canonical_id":"clinicaltrials.gov:NCT07009470","description":"HCC","metadata":null},{"id":"2a4662f50c644cb6afb9fe9788b0ded0","type":"TRIAL","name":"A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07778368","description":"Oral Squamous Cell Carcinoma (OSCC)","metadata":null},{"id":"6ddad6b30cb0402d9fb88f5901c2acaa","type":"TRIAL","name":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","canonical_id":"clinicaltrials.gov:NCT04503551","description":"Diabetic Retinopathy","metadata":null},{"id":"5e4f75601d1a4b6889d05da653346de7","type":"TRIAL","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)","canonical_id":"clinicaltrials.gov:NCT00628342","description":"Gastroesophageal Reflux Disease (GERD)","metadata":null},{"id":"7bd047bb75a4487a86fd1c8f5934ae17","type":"TRIAL","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH","canonical_id":"clinicaltrials.gov:NCT00296465","description":"InFertility","metadata":null},{"id":"832963f174e24c96ae86da3358288dca","type":"TRIAL","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)","canonical_id":"clinicaltrials.gov:NCT01321554","description":"Thyroid Cancer","metadata":null},{"id":"07fbc27798544824842dea7cf98f7dc7","type":"TRIAL","name":"A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)","canonical_id":"clinicaltrials.gov:NCT02364947","description":"Alcohol Dependence","metadata":null},{"id":"2553b9521cbf46bd87c477766a678954","type":"TRIAL","name":"A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin","canonical_id":"clinicaltrials.gov:NCT04624893","description":"Diffuse Large B-Cell Lymphoma (DLBCL)","metadata":null},{"id":"276e78bff90748d39d38106049176520","type":"TRIAL","name":"A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients","canonical_id":"clinicaltrials.gov:NCT07694973","description":"Pancreatic Ductal Adenocarcinoma (PDAC)","metadata":null},{"id":"d7509e22b6c64109aeed1afe40b1e5f9","type":"TRIAL","name":"A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT07842185","description":"Acute Ischemic Stroke","metadata":null},{"id":"6b400656cbc842ddaf825d27a38c57b6","type":"TRIAL","name":"A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome","canonical_id":"clinicaltrials.gov:NCT00436033","description":"Fibromyalgia Syndrome","metadata":null},{"id":"fee8793257ef4f8483316e26248fed4f","type":"TRIAL","name":"A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction","canonical_id":"clinicaltrials.gov:NCT00650598","description":"Pain, Postoperative","metadata":null},{"id":"fc91fa2558e0499fb3f1e825910cfa51","type":"TRIAL","name":"A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00287118","description":"Candidates for Systemic Therapy for Psoriasis; Psoriasis","metadata":null},{"id":"7c4bc07e325448eaa37c91d08619532d","type":"TRIAL","name":"A Multicomponent Intervention for Prevention and Treatment of Sleep Disturbances in a Psychiatric Intensive Care Unit","canonical_id":"clinicaltrials.gov:NCT04995263","description":"Dyssomnias","metadata":null},{"id":"3dc3ecac11b443218e01b3b4679720f4","type":"TRIAL","name":"A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients","canonical_id":"clinicaltrials.gov:NCT02857244","description":"Parkinson's Disease","metadata":null},{"id":"8082518b726c4e3cadf75c0ab3aeb7a3","type":"TRIAL","name":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","canonical_id":"clinicaltrials.gov:NCT05658874","description":"Interstitial Cystitis; Levator Spasm; Bladder Pain Syndrome","metadata":null},{"id":"bb151e39ed71436ab18eaba806d1d50e","type":"TRIAL","name":"A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04045678","description":"Parkinson Disease","metadata":null},{"id":"2bc992afa2e8497ca4c57c9fed29e545","type":"TRIAL","name":"A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases","canonical_id":"clinicaltrials.gov:NCT05564221","description":"Atopic Healthy Subjects; Adult Subjects With Allergic Diseases","metadata":null},{"id":"3e887ac0f6f24276a216a1e18469bb8c","type":"TRIAL","name":"A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot","canonical_id":"clinicaltrials.gov:NCT01870999","description":"Schizophrenia","metadata":null},{"id":"56888fa792cd47ef80c41ded9fdb58f3","type":"TRIAL","name":"A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)","canonical_id":"clinicaltrials.gov:NCT01018823","description":"Healthy Volunteer","metadata":null},{"id":"058f6c678e304ec88d5a233434569fcb","type":"TRIAL","name":"A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)","canonical_id":"clinicaltrials.gov:NCT01825785","description":"Postmenopausal; Osteopenia","metadata":null},{"id":"73d585bdef7f4c5ca773f3dced571dca","type":"TRIAL","name":"A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT01343303","description":"Osteoarthritis, Knee","metadata":null},{"id":"f1c3094a73664a099d8056730a8b58b1","type":"TRIAL","name":"A Multiple-Dose Study of Sinemet\u00ae CR (Carbidopa/Levodopa) in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00460954","description":"Parkinson's Disease","metadata":null},{"id":"b1487622c8d8446da5bc61b4bea9b218","type":"TRIAL","name":"A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA","canonical_id":"clinicaltrials.gov:NCT04822350","description":"Urothelial Carcinoma","metadata":null},{"id":"a650ca903563438b8a4aa137e8056239","type":"TRIAL","name":"A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC","canonical_id":"clinicaltrials.gov:NCT07705126","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"020545fdb0da43488359486dd506ae84","type":"TRIAL","name":"A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.","canonical_id":"clinicaltrials.gov:NCT03715725","description":"Non-valvular Atrial Fibrillation","metadata":null},{"id":"9af97300856049ffaa17cad6196c7442","type":"TRIAL","name":"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02441946","description":"Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma","metadata":null},{"id":"35de632bdf6f4505be8e3491d9c46eba","type":"TRIAL","name":"A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein","canonical_id":"clinicaltrials.gov:NCT03170336","description":"Chronic Kidney Diseases","metadata":null},{"id":"181919c95709439ca49f735e8d88cf8b","type":"TRIAL","name":"A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo","canonical_id":"clinicaltrials.gov:NCT00224107","description":"Benign Prostatic Hyperplasia (BPH)","metadata":null},{"id":"71f08fbc74174fa6975e79e7f74e5ea8","type":"TRIAL","name":"A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo","canonical_id":"clinicaltrials.gov:NCT00224120","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"fa97eb35892b4bfc9dffb3ede95442fd","type":"TRIAL","name":"A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)","canonical_id":"clinicaltrials.gov:NCT01975324","description":"Non Arteritic Ischemic Optic Neuropathy","metadata":null},{"id":"f51739e5d47f473096413b458a920f26","type":"TRIAL","name":"A New More Efficient Cycloplegia Scheme","canonical_id":"clinicaltrials.gov:NCT02177539","description":"Refractive Errors","metadata":null},{"id":"d59eb28cf4bd45ca99732bb13e86e947","type":"TRIAL","name":"A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00399477","description":"Parkinson's Disease","metadata":null},{"id":"9fbea3b633834fa1bdf6e4f474628f40","type":"TRIAL","name":"A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy","canonical_id":"clinicaltrials.gov:NCT01705730","description":"Rheumatoid Arthritis","metadata":null},{"id":"d4057988d10f408d8c5f58b3eccbfbeb","type":"TRIAL","name":"A Non-drug Methods Study in Participants With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01459016","description":"Alzheimer's Disease","metadata":null},{"id":"2e03ad4620584c1da761d89c7f2e1aeb","type":"TRIAL","name":"A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery","canonical_id":"clinicaltrials.gov:NCT01352039","description":"Hip Fracture Surgery","metadata":null},{"id":"847b596d273a4e0d8e2567085f0b5de1","type":"TRIAL","name":"A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated","canonical_id":"clinicaltrials.gov:NCT05683054","description":"Psoriasis","metadata":null},{"id":"af93e437def4496b9be88041f674e510","type":"TRIAL","name":"A Non-inferiority Trial on Pain Relief During Oocyte Retrieval","canonical_id":"clinicaltrials.gov:NCT02494180","description":"Infertility","metadata":null},{"id":"00804df8207f454987719a930ae4b818","type":"TRIAL","name":"A Non-inferiority, Comparative Study Between Foraseq\u00ae, Eurofarma\u00b4s Formoterol/Budesonide and Alenia\u00ae in Asthma","canonical_id":"clinicaltrials.gov:NCT01167010","description":"Asthma","metadata":null},{"id":"566939f147cf45b7ae07aab0f92bffe7","type":"TRIAL","name":"A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT07266350","description":"Cervical Cancer Metastatic; Cervical Cancer Recurrent","metadata":null},{"id":"c776c018481f4c5ab29cb9cc0654bafa","type":"TRIAL","name":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","canonical_id":"clinicaltrials.gov:NCT04662944","description":"Neovascular Age-Related Macular Degeneration","metadata":null},{"id":"cbebee97f032400380f5fe2a0cd028ed","type":"TRIAL","name":"A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients","canonical_id":"clinicaltrials.gov:NCT06227429","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"277a4e3a799349de837d0fde4ac99580","type":"TRIAL","name":"A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning","canonical_id":"clinicaltrials.gov:NCT03806751","description":"Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging","metadata":null},{"id":"4ad0a94606bf4862968481e937b8fc09","type":"TRIAL","name":"A Novel Approach to Infantile Spasms","canonical_id":"clinicaltrials.gov:NCT03347526","description":"Infantile Spasm","metadata":null},{"id":"d8a0e8f3005244c493036634ed84e9c7","type":"TRIAL","name":"A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)","canonical_id":"clinicaltrials.gov:NCT07852091","description":"Chronic Hepatitis B","metadata":null},{"id":"835b8aeafd2e44aab0824b6f0477f287","type":"TRIAL","name":"A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT06527729","description":"Alopecia Areata","metadata":null},{"id":"c5b957a33b4042c18d53b1cd541c6060","type":"TRIAL","name":"A Novel Pharmacological Therapy for Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT03919955","description":"Sleep Apnea","metadata":null},{"id":"9dfc3361872c4bd2b1c5fc4153382c16","type":"TRIAL","name":"A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism","canonical_id":"clinicaltrials.gov:NCT02563834","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"32e79e8f269d4ff0bff23f4eb8e9efd7","type":"TRIAL","name":"A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation","canonical_id":"clinicaltrials.gov:NCT06676085","description":"ECMO","metadata":null},{"id":"668cd1a15f2c43e8919980c8a78d9ff0","type":"TRIAL","name":"A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China","canonical_id":"clinicaltrials.gov:NCT06512337","description":"Plaque Psoriasis","metadata":null},{"id":"d0117edaaa484e6cae5bb9caa53da70c","type":"TRIAL","name":"A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)","canonical_id":"clinicaltrials.gov:NCT00279747","description":"Arthritis, Juvenile Rheumatoid","metadata":null},{"id":"27e26c2ae27841fda8ca17c374f3e9b0","type":"TRIAL","name":"A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT00644358","description":"Major Depressive Disorder","metadata":null},{"id":"53b694076e3849fa98c5d1cdcc612300","type":"TRIAL","name":"A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021","canonical_id":"clinicaltrials.gov:NCT01560403","description":"Short Bowel Syndrome","metadata":null},{"id":"de75fdc256894e49852950251abe34d6","type":"TRIAL","name":"A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).","canonical_id":"clinicaltrials.gov:NCT00441558","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"6c553d70bac34423ad2916ee0c6818d8","type":"TRIAL","name":"A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01320020","description":"Epithelial Cancer Patients","metadata":null},{"id":"9bb5964e3fc04ba9893c45371392c022","type":"TRIAL","name":"A Open-label, Drug-Drug Interaction With Maraviroc (DDI)","canonical_id":"clinicaltrials.gov:NCT02480894","description":"Infection, Human Immunodeficiency Virus","metadata":null},{"id":"f8d45d5af3f549249e75306aca84ff10","type":"TRIAL","name":"A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS","canonical_id":"clinicaltrials.gov:NCT02473627","description":"Healthy","metadata":null},{"id":"ab1e34a15c7c4d51808d49d6f8808621","type":"TRIAL","name":"A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER","canonical_id":"clinicaltrials.gov:NCT07107490","description":"Extensive Stage Small Cell Lung Cancer","metadata":null},{"id":"1240d380ae434dcd8f5502b09ab22ae1","type":"TRIAL","name":"A PMS of Jakavi\u00ae in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea","canonical_id":"clinicaltrials.gov:NCT05621733","description":"Graft-versus-Host Disease","metadata":null},{"id":"3e4c2e0e945b4420a0390c38c7673678","type":"TRIAL","name":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","canonical_id":"clinicaltrials.gov:NCT07172867","description":"Diabetes Mellitus, Type 2; Obesity","metadata":null},{"id":"4aff95614d334e1a809dd5547fc70417","type":"TRIAL","name":"A Pharmacodynamic Study Comparing Zegerid\u00ae and Prilosec OTC\u00ae (Study CL2008-02)(P07814)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00765206","description":"Gastric Acid; Human Experimentation","metadata":null},{"id":"2e4ba705a1ab4bad891ae0d4a450e92f","type":"TRIAL","name":"A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure","canonical_id":"clinicaltrials.gov:NCT01005290","description":"Hypertension","metadata":null},{"id":"8c2692880df34205a0d393cfa356260d","type":"TRIAL","name":"A Pharmacogenomic Study of Candesartan in Heart Failure","canonical_id":"clinicaltrials.gov:NCT00400582","description":"Heart Failure","metadata":null},{"id":"af8ee984017f4a679c7fc749817a9cf5","type":"TRIAL","name":"A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01340677","description":"Healthy","metadata":null},{"id":"63feba8c15de40cd985cffc0b1834870","type":"TRIAL","name":"A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses","canonical_id":"clinicaltrials.gov:NCT01244620","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"d39dcfcc29ff4ba1b6a8efa697cfde50","type":"TRIAL","name":"A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects","canonical_id":"clinicaltrials.gov:NCT04457180","description":"Advanced Solid Tumor","metadata":null},{"id":"25afa5b3a5b7409a9fecfb7f6dc113c7","type":"TRIAL","name":"A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02945020","description":"Healthy","metadata":null},{"id":"360c6c4ee13e419da492adaa9be43188","type":"TRIAL","name":"A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease","canonical_id":"clinicaltrials.gov:NCT01870388","description":"Liver Diseases; Hepatic Insufficiency","metadata":null},{"id":"de7a70fcc6664e608005ca051e61f566","type":"TRIAL","name":"A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04086758","description":"Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"4b5c4ad8ba53404faa17618cd09181d5","type":"TRIAL","name":"A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT01952080","description":"Short Bowel Syndrome","metadata":null},{"id":"6f2464230f1742faa7c21e7e774dfd08","type":"TRIAL","name":"A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema","canonical_id":"clinicaltrials.gov:NCT01386658","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"b421fefe4cec461bb38a927a51a60fe7","type":"TRIAL","name":"A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT07120152","description":"IBD - Inflammatory Bowel Disease; RA - Rheumatoid Arthritis","metadata":null},{"id":"449b201ff46c4b35a10cb72acbf797f2","type":"TRIAL","name":"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01340846","description":"Cancer","metadata":null},{"id":"0e6c987dbd774c84baed1ae8c25b235f","type":"TRIAL","name":"A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)","canonical_id":"clinicaltrials.gov:NCT03921411","description":"Atopic Dermatitis","metadata":null},{"id":"fef3b384d3bd4a27a81274e461b1552e","type":"TRIAL","name":"A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01202734","description":"Healthy","metadata":null},{"id":"5e1fe49d09fb43c4b33a85b59c437047","type":"TRIAL","name":"A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT03983161","description":"Healthy Volunteers; Hepatic Impairment","metadata":null},{"id":"17f84d43536f4fc2a1a3603f60c1a720","type":"TRIAL","name":"A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00797745","description":"Hepatitis C, Chronic","metadata":null},{"id":"6e0945e6de8140008eca0cc6b835bb67","type":"TRIAL","name":"A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01168934","description":"Healthy","metadata":null},{"id":"8c840c9989df42d59565bf521e026a32","type":"TRIAL","name":"A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation","canonical_id":"clinicaltrials.gov:NCT06990711","description":"Antibody Mediated Rejection of Lung Transplant","metadata":null},{"id":"3105ea12226f4ea89fe58d81630e781d","type":"TRIAL","name":"A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT","canonical_id":"clinicaltrials.gov:NCT00460421","description":"Leukemia","metadata":null},{"id":"b889669164af4a84a685d76d302cdf3f","type":"TRIAL","name":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03420742","description":"Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors","metadata":null},{"id":"0b890c13f0c34e8a899a2c21a76a04ac","type":"TRIAL","name":"A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1","canonical_id":"clinicaltrials.gov:NCT00267657","description":"Amphetamine-Related Disorders","metadata":null},{"id":"2ddd53f5d96c4d7587fd18002451d4b0","type":"TRIAL","name":"A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects","canonical_id":"clinicaltrials.gov:NCT02927353","description":"Healthy Volunteer","metadata":null},{"id":"358cf0dd6d64439ab5f79ee5d21c0b15","type":"TRIAL","name":"A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler","canonical_id":"clinicaltrials.gov:NCT01371786","description":"Allergic Rhinitis (AR)","metadata":null},{"id":"0b6215c2463e45eeb91084492e3aff98","type":"TRIAL","name":"A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03343054","description":"Neoplasms; Breast Neoplasms","metadata":null},{"id":"7bfca7bbdef241378664522a23da0980","type":"TRIAL","name":"A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03162900","description":"Healthy Volunteers","metadata":null},{"id":"655d53cf5e2c424daa87d9d96b6455ab","type":"TRIAL","name":"A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03978689","description":"Head and Neck Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Related Carcinoma","metadata":null},{"id":"4159a9bf2785436ba366b5654cc1fa22","type":"TRIAL","name":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05536141","description":"Clear Cell Renal Cell Carcinoma; Solid Tumors","metadata":null},{"id":"f4374452bdb74aebbbca383ed3ae4d87","type":"TRIAL","name":"A Phase 1 Study of BHV-1530 in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06874335","description":"Solid Tumor","metadata":null},{"id":"c297299a2a29495eb5654936e1357b9f","type":"TRIAL","name":"A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01309412","description":"Multiple Myeloma","metadata":null},{"id":"4dee06692e7042039f2fbd63d7e8678d","type":"TRIAL","name":"A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT01476657","description":"Hematologic Malignancies","metadata":null},{"id":"e8d4ccea5a17402f91b975de3bf856bc","type":"TRIAL","name":"A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)","canonical_id":"clinicaltrials.gov:NCT02411929","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"6c234d1861474a96a8ed22429f914637","type":"TRIAL","name":"A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT00830869","description":"Advanced Non-hematologic Malignancies","metadata":null},{"id":"5b44744617de43fbb52999dde8f64f08","type":"TRIAL","name":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","canonical_id":"clinicaltrials.gov:NCT07170592","description":"Treatment-Refractory Solid Tumors","metadata":null},{"id":"bb18437208eb4738a472ae70fd74240b","type":"TRIAL","name":"A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT07425899","description":"Healthy Volunteer","metadata":null},{"id":"3265b538c7fc44ca82531aeab9d0905e","type":"TRIAL","name":"A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT00789568","description":"Phenylketonuria","metadata":null},{"id":"3945f17dfd0e4a31a29f4a72a33f3c8e","type":"TRIAL","name":"A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab","canonical_id":"clinicaltrials.gov:NCT01975831","description":"Breast Cancer; Ovarian Cancer; Colorectal Cancer; Cervical Cancer; Renal Cell Carcinoma","metadata":null},{"id":"67a7a4559d6f43449021b7b2c53b612f","type":"TRIAL","name":"A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01363778","description":"Healthy","metadata":null},{"id":"5fe8bf403ecc4330965bf5d6922cea4d","type":"TRIAL","name":"A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01363804","description":"Healthy","metadata":null},{"id":"5df674339a1f4c48b42a1f1d72ddb7af","type":"TRIAL","name":"A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT03105986","description":"Healthy","metadata":null},{"id":"f2b1fc214ba44f768f9253c3d9b49eb6","type":"TRIAL","name":"A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03302845","description":"Drug-drug Interaction","metadata":null},{"id":"750083f29fc448cca4f0bd5b8e2b8f02","type":"TRIAL","name":"A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab","canonical_id":"clinicaltrials.gov:NCT04112498","description":"Cancer","metadata":null},{"id":"36c3ef40361e4974baa2f05b63499caf","type":"TRIAL","name":"A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)","canonical_id":"clinicaltrials.gov:NCT02103283","description":"Diabetic Macular Edema","metadata":null},{"id":"d62175728f5e4c529706c90b78c876a2","type":"TRIAL","name":"A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06392659","description":"Pain","metadata":null},{"id":"27481819eb08420baaf9f8f31efa4a95","type":"TRIAL","name":"A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma","canonical_id":"clinicaltrials.gov:NCT01592396","description":"Asthma","metadata":null},{"id":"941c0351b30048ff9da616069c1a0a8d","type":"TRIAL","name":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05848739","description":"Colon Cancer; Metastatic Colon Cancer","metadata":null},{"id":"71436fcc7dc84a8194b813d98115ffd9","type":"TRIAL","name":"A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.","canonical_id":"clinicaltrials.gov:NCT00726869","description":"Multiple Myeloma","metadata":null},{"id":"f45a442d497a437581f3c7858b56167c","type":"TRIAL","name":"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT02406742","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"eadcad1cc20847b59b0d9e2874afbfe3","type":"TRIAL","name":"A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT01975519","description":"Advanced Soft Tissue Sarcoma","metadata":null},{"id":"a8858be0a5fd4cbaa429570b746cd22d","type":"TRIAL","name":"A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors","canonical_id":"clinicaltrials.gov:NCT05120960","description":"Brain Tumor","metadata":null},{"id":"8c6090af79694f5a869d585aaca21b0e","type":"TRIAL","name":"A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04075747","description":"Acute Myeloid Leukemia","metadata":null},{"id":"394866bab0a64876a44c2922c8d92a5c","type":"TRIAL","name":"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma","canonical_id":"clinicaltrials.gov:NCT01826448","description":"V600-mutated BRAF Unresectable Melanoma; V600-mutated BRAF Metastatic Melanoma; Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor","metadata":null},{"id":"3c3e1629ef8e416c9af0da20574cc435","type":"TRIAL","name":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04556773","description":"Metastatic Breast Cancer","metadata":null},{"id":"a458f010730a45d8a63df555daf74edc","type":"TRIAL","name":"A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03666143","description":"Advanced Solid Tumors","metadata":null},{"id":"3e5eca3df0bc42108ffa34677ab6e3c3","type":"TRIAL","name":"A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324","canonical_id":"clinicaltrials.gov:NCT07484074","description":"Diabetic Macular Edema (DME); Neovascular (Wet) Age-Related Macular Degeneration","metadata":null},{"id":"11ebac0ce30845aeb2bcba860ab045d8","type":"TRIAL","name":"A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients","canonical_id":"clinicaltrials.gov:NCT06540391","description":"Melanoma","metadata":null},{"id":"a9affbc85212470cba109022a5f6d90a","type":"TRIAL","name":"A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00563147","description":"Renal Cell Carcinoma","metadata":null},{"id":"13e17fc8993b42bf905d4e23b6d89fdc","type":"TRIAL","name":"A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02340975","description":"Gastric or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"10b3eb35800f4d2899d9d0c2b24d5b4c","type":"TRIAL","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04538742","description":"Metastatic Breast Cancer","metadata":null},{"id":"bfdf0d2c822b4b60b1782483807b2f27","type":"TRIAL","name":"A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression","canonical_id":"clinicaltrials.gov:NCT07431216","description":"Glioblastoma (GBM)","metadata":null},{"id":"8e3093d0db45458e9a439e594c6e76e7","type":"TRIAL","name":"A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00717340","description":"Metastatic Breast Cancer","metadata":null},{"id":"e3f2e5223f404aba8e2441ac997a17a4","type":"TRIAL","name":"A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia","canonical_id":"clinicaltrials.gov:NCT06433557","description":"Achondroplasia","metadata":null},{"id":"eeabacef606c46ddb995b0e39ca2d94b","type":"TRIAL","name":"A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases","canonical_id":"clinicaltrials.gov:NCT06570798","description":"Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis","metadata":null},{"id":"1370c45f48d84b93b37053571a6fef0a","type":"TRIAL","name":"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02096354","description":"Colorectal Neoplasms","metadata":null},{"id":"19137970ebf646d0a6e6fa6cecc06912","type":"TRIAL","name":"A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT04038359","description":"Indolent Non-Hodgkin Lymphoma","metadata":null},{"id":"d6a02bec191c41dc88083fa1081273e5","type":"TRIAL","name":"A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT07822373","description":"Muscle-invasive Bladder Urothelial Carcinoma","metadata":null},{"id":"ab3b4abcd8ba47688b606fd46c38251f","type":"TRIAL","name":"A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance","canonical_id":"clinicaltrials.gov:NCT02146937","description":"Detectable Prostate Nodules","metadata":null},{"id":"e1afc0d4584343b2a747bebf878629e2","type":"TRIAL","name":"A Phase 2 Study of CIM331 for Atopic Dermatitis Patients","canonical_id":"clinicaltrials.gov:NCT01986933","description":"Atopic Dermatitis","metadata":null},{"id":"f6b4d3748d1646539cc78076786d1640","type":"TRIAL","name":"A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03339219","description":"Advanced Renal Cell Carcinoma","metadata":null},{"id":"ca6c19b657184e5381a8dda4cd5605d5","type":"TRIAL","name":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML","canonical_id":"clinicaltrials.gov:NCT05199051","description":"AML; Leukaemia (Acute Myeloid)","metadata":null},{"id":"f9e1b6e1ae774c8aa401426c165d0609","type":"TRIAL","name":"A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation","canonical_id":"clinicaltrials.gov:NCT06081829","description":"Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic","metadata":null},{"id":"2a4c384aad594c2bb9280649c081a87d","type":"TRIAL","name":"A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01801904","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"75db43c685b941af9c9092c495a422ae","type":"TRIAL","name":"A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT01108458","description":"Pancreatic Cancer","metadata":null},{"id":"8bff884695704aaab727001af3023f71","type":"TRIAL","name":"A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia","canonical_id":"clinicaltrials.gov:NCT01124617","description":"Pain; Diabetic Neuropathies; Neuralgia; Postherpetic Neuralgia","metadata":null},{"id":"ec7356bd001f4d308f6edf713748c793","type":"TRIAL","name":"A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma","canonical_id":"clinicaltrials.gov:NCT00234429","description":"Colorectal Cancer","metadata":null},{"id":"5dc43f0c91c442cd88f0de37afad7310","type":"TRIAL","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07659795","description":"Colorectal Cancer","metadata":null},{"id":"04b0e47ec81249ffb003a46f6f40269c","type":"TRIAL","name":"A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT00445978","description":"Sickle Cell Disease","metadata":null},{"id":"ac75bd0d972d47d79e2368c471c0c6c6","type":"TRIAL","name":"A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT03897868","description":"Hypertension","metadata":null},{"id":"207183b9aa334304adb8f91b7f485386","type":"TRIAL","name":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenstr\u00f6m Macroglobulinemia","canonical_id":"clinicaltrials.gov:NCT06986174","description":"Waldenstr\u00f6m Macroglobulinemia; Lymphoplasmacytic Lymphoma; B-Cell Lymphoproliferative Disorder; Indolent Lymphoma","metadata":null},{"id":"7fcd830094814e54a834a19c46d8dbf6","type":"TRIAL","name":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension","canonical_id":"clinicaltrials.gov:NCT04257929","description":"Prader-Willi Syndrome","metadata":null},{"id":"14db6c6804344f338727c7243ee6c570","type":"TRIAL","name":"A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05900973","description":"Prostate Cancer","metadata":null},{"id":"32fe4faabdb845289bc969a36afdfe9f","type":"TRIAL","name":"A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants","canonical_id":"clinicaltrials.gov:NCT07535034","description":"Gout","metadata":null},{"id":"bcfa834b9e2641a79973a4e4a87b5815","type":"TRIAL","name":"A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.","canonical_id":"clinicaltrials.gov:NCT05833763","description":"Mantle Cell Lymphoma; Mantle Cell Lymphoma Refractory","metadata":null},{"id":"57b7d1a8bd8f4419a5613e6f36d6c301","type":"TRIAL","name":"A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)","canonical_id":"clinicaltrials.gov:NCT02657369","description":"Thyroid Carcinoma, Anaplastic","metadata":null},{"id":"374aced7c6a94a13bdb58d53245fc450","type":"TRIAL","name":"A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor","canonical_id":"clinicaltrials.gov:NCT01874665","description":"GIST","metadata":null},{"id":"c79db340bb04463f92a2321a38a3d565","type":"TRIAL","name":"A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)","canonical_id":"clinicaltrials.gov:NCT02034916","description":"Breast Neoplasms; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation","metadata":null},{"id":"960a664ff6a54cb6be1635d73e720749","type":"TRIAL","name":"A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02852967","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"88194da877b549d4845cf073deadb4b0","type":"TRIAL","name":"A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction","canonical_id":"clinicaltrials.gov:NCT00532844","description":"Endothelial Dysfunction","metadata":null},{"id":"3deecae825c4487e991cbdfdf85396bb","type":"TRIAL","name":"A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT01629667","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"bd666b495ebd4519bd5137b0552bdc25","type":"TRIAL","name":"A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab","canonical_id":"clinicaltrials.gov:NCT06535737","description":"Hepatocellular Carcinoma Non-resectable","metadata":null},{"id":"76f5ebc22fec4c1884f5fb467df85315","type":"TRIAL","name":"A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors","canonical_id":"clinicaltrials.gov:NCT02366312","description":"Keratocystic Odontogenic Tumor","metadata":null},{"id":"0b2c2cc623b94dfd946b70214e395dba","type":"TRIAL","name":"A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT05267600","description":"Bullous Pemphigoid","metadata":null},{"id":"e0cf1a530420448f906d19cfa46c5803","type":"TRIAL","name":"A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT01605825","description":"Ischemic Stroke","metadata":null},{"id":"65dcc5cfc18345148a18fbbd433757f3","type":"TRIAL","name":"A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)","canonical_id":"clinicaltrials.gov:NCT01580228","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"e168c22246964005a021c823d655be9a","type":"TRIAL","name":"A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01564537","description":"Relapsed Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"9e120be11ab843148b00a385ae15cbce","type":"TRIAL","name":"A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT01100307","description":"Macular Edema; Diabetic Mellitus; Retinal Disease","metadata":null},{"id":"e5d250da576147428ce8c8dea320a4ca","type":"TRIAL","name":"A Phase 3 Study With P2B001 in Subjects With Early Parkinson's","canonical_id":"clinicaltrials.gov:NCT03329508","description":"Parkinson Disease; Early Parkinson's Disease","metadata":null},{"id":"8e84753766054e189e0d182338e99c70","type":"TRIAL","name":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT01474512","description":"Psoriasis","metadata":null},{"id":"e2a338202b6b4302960da85aaf47d46a","type":"TRIAL","name":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)","canonical_id":"clinicaltrials.gov:NCT01597245","description":"Psoriasis","metadata":null},{"id":"258e314c41034546be9cd96a2cce8529","type":"TRIAL","name":"A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","canonical_id":"clinicaltrials.gov:NCT02722694","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"18f3a8b7311d4ef5ace3f2acf4735416","type":"TRIAL","name":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","canonical_id":"clinicaltrials.gov:NCT00327015","description":"Diabetes","metadata":null},{"id":"1df9cec42bf643b598be3c19e0e5ba98","type":"TRIAL","name":"A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)","canonical_id":"clinicaltrials.gov:NCT02004522","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"a29823147e3447a083b2119bb57696c9","type":"TRIAL","name":"A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT04176588","description":"Moderately to Severely Active Ulcerative Colitis","metadata":null},{"id":"0f5e724606254bcb9816ca0b79376b0c","type":"TRIAL","name":"A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT01933919","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"0d41295cc5a44dc8824ec4f137e2bed3","type":"TRIAL","name":"A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy","canonical_id":"clinicaltrials.gov:NCT07851220","description":"Glomerulonephritis, Membranous","metadata":null},{"id":"63102f39a4124f068954b56681e275b5","type":"TRIAL","name":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT03165734","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"1cecf6788f68434e963f8b92c4639026","type":"TRIAL","name":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT06702124","description":"Alzheimer Disease","metadata":null},{"id":"9922131fe7954226ab601e75f84228e3","type":"TRIAL","name":"A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01266811","description":"Multiple Myeloma","metadata":null},{"id":"38f55b731b754477b6695f48b227cdd4","type":"TRIAL","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.","canonical_id":"clinicaltrials.gov:NCT04680052","description":"Follicular Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"8c5cd797de0341ea95299ff35f576993","type":"TRIAL","name":"A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia","canonical_id":"clinicaltrials.gov:NCT05156047","description":"Idiopathic Hypersomnia","metadata":null},{"id":"93195cb56be14503baadf4662a34aa2b","type":"TRIAL","name":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","canonical_id":"clinicaltrials.gov:NCT04740671","description":"Age Related Macular Degeneration","metadata":null},{"id":"6ae0995cfb85442fad90fbf2de1187c7","type":"TRIAL","name":"A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment","canonical_id":"clinicaltrials.gov:NCT06400511","description":"Blepharitis","metadata":null},{"id":"093883e24fe9415d8bd18dc482165d1b","type":"TRIAL","name":"A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT02161757","description":"Uncontrolled Asthma","metadata":null},{"id":"db798b7ed5024ce8a2829974f124d576","type":"TRIAL","name":"A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT02194699","description":"Uncontrolled Asthma","metadata":null},{"id":"a5f770351ee84de19e67861dde1ace10","type":"TRIAL","name":"A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye","canonical_id":"clinicaltrials.gov:NCT01743729","description":"Dry Eye Disease","metadata":null},{"id":"85ed146e6169439aa240e17b46a66a35","type":"TRIAL","name":"A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone","canonical_id":"clinicaltrials.gov:NCT02531035","description":"Type 1 Diabetes Mellitus (T1DM); High Level of Sugar (Glucose) in the Blood","metadata":null},{"id":"46416bbb9dd04810b1e794b418089b59","type":"TRIAL","name":"A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)","canonical_id":"clinicaltrials.gov:NCT01578499","description":"Primary Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Cutaneous T-Cell Lymphoma","metadata":null},{"id":"c5541ee0ca3b4cf79743d632ffe8a373","type":"TRIAL","name":"A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis","canonical_id":"clinicaltrials.gov:NCT00747344","description":"Psoriasis","metadata":null},{"id":"189e863f03a74d1fafb6c1c2278b1a01","type":"TRIAL","name":"A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight","canonical_id":"clinicaltrials.gov:NCT05209984","description":"Overweight; Obesity","metadata":null},{"id":"24750edf7bba447abca15af14ee748d4","type":"TRIAL","name":"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT01880424","description":"Irritable Bowel Syndrome With Constipation (IBS-C)","metadata":null},{"id":"c298888941444e5e847181925aceb1fd","type":"TRIAL","name":"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01241591","description":"Psoriasis","metadata":null},{"id":"b85cdee4da3a4b1990e43915688f8969","type":"TRIAL","name":"A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)","canonical_id":"clinicaltrials.gov:NCT05681715","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"67eb4cb0c3b7419284085cebe9a19973","type":"TRIAL","name":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.","canonical_id":"clinicaltrials.gov:NCT00423202","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"a42177ce373e470fb5e0d03c0883257d","type":"TRIAL","name":"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects","canonical_id":"clinicaltrials.gov:NCT02135692","description":"Asthma","metadata":null},{"id":"1bd805045f7a4ea99e87b676cf6cdf42","type":"TRIAL","name":"A Phase 4 Clinical Study of Brodalumab","canonical_id":"clinicaltrials.gov:NCT04183881","description":"Psoriasis Vulgaris; Psoriatic Arthritis; Pustular; Psoriasis, Palmaris Et Plantaris; Psoriatic Erythroderma","metadata":null},{"id":"114287d5ea4a48c1bedf99fb2bb76535","type":"TRIAL","name":"A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment","canonical_id":"clinicaltrials.gov:NCT03226899","description":"Gout; Chronic Kidney Disease (CKD)","metadata":null},{"id":"079f167895544eec8db1048237ec9a1d","type":"TRIAL","name":"A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.","canonical_id":"clinicaltrials.gov:NCT02425826","description":"Parapsoriasis","metadata":null},{"id":"436aaaaabe9749ea99c9ee20541bd079","type":"TRIAL","name":"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","canonical_id":"clinicaltrials.gov:NCT02656173","description":"Overactive Bladder","metadata":null},{"id":"a15d49d074d24d5a8a594d716a05c894","type":"TRIAL","name":"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01016977","description":"Acne Vulgaris","metadata":null},{"id":"0b8624ce5b5a434985bf4dd7a2cb3b6e","type":"TRIAL","name":"A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT04850755","description":"Advance Solid Malignancies; Metastatic Solid Malignancies","metadata":null},{"id":"224be308f8e24c63b7970f9d9dcdaa0f","type":"TRIAL","name":"A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02252263","description":"Multiple Myeloma","metadata":null},{"id":"ba3009208413490e8f24b16b774bba00","type":"TRIAL","name":"A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT03746041","description":"Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"7ccf14cde9d14fd1b776eb68f2d655f6","type":"TRIAL","name":"A Phase I Study of Famitinib Malate in Patients With Solid Tumor","canonical_id":"clinicaltrials.gov:NCT01762280","description":"Advanced Solid Tumor","metadata":null},{"id":"11128a1a23e24b15a4db56834b22381e","type":"TRIAL","name":"A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03086291","description":"Stomach Cancer","metadata":null},{"id":"4396e2013e734d4ab311c2a9f850f6ed","type":"TRIAL","name":"A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00568022","description":"Breast Cancer","metadata":null},{"id":"b0b37ffe69bb43c5ac9e182327f37760","type":"TRIAL","name":"A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03945721","description":"Triple Negative Breast Cancer; Residual Disease","metadata":null},{"id":"4bd7099f74074cce92e9f681c1651e1f","type":"TRIAL","name":"A Phase I Study of Pazopanib in Adult Patients With Liver Cancer","canonical_id":"clinicaltrials.gov:NCT00370513","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"2e72915c2dcf4afcb31136bb42313556","type":"TRIAL","name":"A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas","canonical_id":"clinicaltrials.gov:NCT07444619","description":"Soft Tissue Sarcomas","metadata":null},{"id":"ada9a1d06cb4429f825bad15ee0e4c9b","type":"TRIAL","name":"A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects","canonical_id":"clinicaltrials.gov:NCT05325346","description":"Heparin-induced Thrombocytopenia","metadata":null},{"id":"bc62946be2314d9f84359bb52e070656","type":"TRIAL","name":"A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma","canonical_id":"clinicaltrials.gov:NCT00000681","description":"Sarcoma, Kaposi; HIV Infections","metadata":null},{"id":"0238163bc18d4f93b664c2e2aa7a4b2f","type":"TRIAL","name":"A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02653872","description":"Healthy Subjects","metadata":null},{"id":"e82e509cc91244449debb2f9a2c04f85","type":"TRIAL","name":"A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00721331","description":"Atopic Dermatitis","metadata":null},{"id":"39e0966a70fe45368f49a3a8052a53a2","type":"TRIAL","name":"A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00752843","description":"Healthy Subjects","metadata":null},{"id":"aa6e4ed5ad0949f78f2cac92c8eae30c","type":"TRIAL","name":"A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception","canonical_id":"clinicaltrials.gov:NCT02173808","description":"Contraceptive Usage","metadata":null},{"id":"574caf9619474195b7b101840120b1cd","type":"TRIAL","name":"A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability","canonical_id":"clinicaltrials.gov:NCT04735822","description":"Healthy Volunteers","metadata":null},{"id":"69602ee56c7146f982e75c36a05eaf88","type":"TRIAL","name":"A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT07343960","description":"Moderate Hepatic Impairment","metadata":null},{"id":"90780c590a164810bb3b13b004a3c999","type":"TRIAL","name":"A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03874832","description":"Migraine With Aura; Migraine Without Aura; Migraine","metadata":null},{"id":"1630c6295e4f47788a8f6abc99258f49","type":"TRIAL","name":"A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib","canonical_id":"clinicaltrials.gov:NCT00513253","description":"Healthy Subjects","metadata":null},{"id":"f3943261c0b2443ab6aed852d138640f","type":"TRIAL","name":"A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)","canonical_id":"clinicaltrials.gov:NCT06218511","description":"Hepatocellular Carcinoma","metadata":null},{"id":"5d3b9c30f9004931b72324cd654730af","type":"TRIAL","name":"A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT","canonical_id":"clinicaltrials.gov:NCT00477542","description":"Hematologic Malignancies","metadata":null},{"id":"489b05aa371a4c21b6066765ba1e42e0","type":"TRIAL","name":"A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors","canonical_id":"clinicaltrials.gov:NCT05781386","description":"Advanced Solid Tumor; Cutaneous T Cell Lymphoma","metadata":null},{"id":"3ee1f609c6b945ad8592e28407851b12","type":"TRIAL","name":"A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18","canonical_id":"clinicaltrials.gov:NCT00500058","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"6453277c4501427e8f2015eb22fd3d0d","type":"TRIAL","name":"A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors","canonical_id":"clinicaltrials.gov:NCT02422589","description":"ALK-positive Advanced Tumors","metadata":null},{"id":"47c1d9ec542e4958b61f7d7fcf5ac093","type":"TRIAL","name":"A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT00586924","description":"Hairy Cell Leukemia","metadata":null},{"id":"788989634e134237a509baf51f12661f","type":"TRIAL","name":"A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours","canonical_id":"clinicaltrials.gov:NCT01938612","description":"Advanced Solid Tumors","metadata":null},{"id":"edfc6c87862645d7b059f8c3d6b22ea9","type":"TRIAL","name":"A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT03276052","description":"Healthy Volunteers","metadata":null},{"id":"70ea4a98088144a9aafe5a10601c9b19","type":"TRIAL","name":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","canonical_id":"clinicaltrials.gov:NCT02891603","description":"Graft Vs Host Disease; GVHD","metadata":null},{"id":"2ebad92f212f488095b2ae4c481eb926","type":"TRIAL","name":"A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.","canonical_id":"clinicaltrials.gov:NCT01732640","description":"Squamous Cell Carcinoma of the Head and Neck","metadata":null},{"id":"1fe1124206d54879a470b54494d4f427","type":"TRIAL","name":"A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA\u00ae) in the Treatment of Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00238628","description":"Lung Cancer","metadata":null},{"id":"a32dc5fed5db43f483ebdae0f34fe0d4","type":"TRIAL","name":"A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT00510250","description":"Cancer of the Cervix","metadata":null},{"id":"bd41d8c4d84841c9b5a0d6711e81ea65","type":"TRIAL","name":"A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT06235801","description":"Myeloid Leukemia","metadata":null},{"id":"381438f10e4742e2a7728cb5c8a918b5","type":"TRIAL","name":"A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06207305","description":"Metastatic Appendiceal Adenocarcinoma; Intraperitoneal Paclitaxel","metadata":null},{"id":"b2d1709e09b549598746e889b917e555","type":"TRIAL","name":"A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat\u00ae Serum Proteomic Evaluation","canonical_id":"clinicaltrials.gov:NCT01728181","description":"Non-small Cell Lung Cancer; Stage IV Disease; EGFR Unknown or Wild-type","metadata":null},{"id":"f69337b882c04b579dceb35505dd8b8c","type":"TRIAL","name":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT05849662","description":"Leukemia, Juvenile Myelomonocytic; JMML; JCML; Neurofibromatosis 1; CBL Syndrome","metadata":null},{"id":"971b63cf606c41e8a66a05c15969a4b0","type":"TRIAL","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06953323","description":"Advanced Solid Tumor","metadata":null},{"id":"eb5a2d6c4ec5491fbd493e8b7ad45658","type":"TRIAL","name":"A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas","canonical_id":"clinicaltrials.gov:NCT00045708","description":"Adult Anaplastic Astrocytoma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor","metadata":null},{"id":"dff1577761c94383aa12f4516c3d6686","type":"TRIAL","name":"A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06757335","description":"Breast Cancer","metadata":null},{"id":"5ee737df1ccd4f3f8b39025dfd03a671","type":"TRIAL","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","canonical_id":"clinicaltrials.gov:NCT06247995","description":"Breast Cancer","metadata":null},{"id":"4dd7c3f5195a44d0a85499c2e544e7a1","type":"TRIAL","name":"A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL","canonical_id":"clinicaltrials.gov:NCT02268851","description":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma","metadata":null},{"id":"ffcabeac742a41759b775397465b241b","type":"TRIAL","name":"A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT01673737","description":"Neoplasm Malignant","metadata":null},{"id":"43d369aef0814113802a7d28e20b53c0","type":"TRIAL","name":"A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05984602","description":"Pancreatic Cancer","metadata":null},{"id":"5955c38ec3dc40a89ee4a3f84973b7c5","type":"TRIAL","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","canonical_id":"clinicaltrials.gov:NCT07233850","description":"Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Oesophageal Cancer","metadata":null},{"id":"b5dd22a6986949e5a12ba45939bdef4c","type":"TRIAL","name":"A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer","canonical_id":"clinicaltrials.gov:NCT05241899","description":"Gastric Cancer","metadata":null},{"id":"efa6a4cf172540e5aca6d014b2cee13f","type":"TRIAL","name":"A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT07700875","description":"Essential Hypertension","metadata":null},{"id":"817be25a0da5483f9e726189fe4ff977","type":"TRIAL","name":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases","canonical_id":"clinicaltrials.gov:NCT06218888","description":"Colo-rectal Cancer","metadata":null},{"id":"fc1d9df68daf4d9baab18afb813254ef","type":"TRIAL","name":"A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00490646","description":"Metastatic Breast Cancer","metadata":null},{"id":"f956a67c79974e38bd2ac0d9ddaeb889","type":"TRIAL","name":"A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT07197697","description":"Breast Cancer","metadata":null},{"id":"13fad18b5b4949929165ebd0c9ce12b1","type":"TRIAL","name":"A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder","canonical_id":"clinicaltrials.gov:NCT05137262","description":"Urothelial Carcinoma; Bladder Cancer","metadata":null},{"id":"85d252e4afb942f2a27be2a506418806","type":"TRIAL","name":"A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.","canonical_id":"clinicaltrials.gov:NCT01485926","description":"Breast Cancer","metadata":null},{"id":"d415aa9e1b91402a8be0df8c1bc4878b","type":"TRIAL","name":"A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06029036","description":"Prostate Cancer","metadata":null},{"id":"35159c614867446d89c3f5bf33346884","type":"TRIAL","name":"A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy","canonical_id":"clinicaltrials.gov:NCT02159690","description":"Prostate Cancer; Localized Prostate Cancer","metadata":null},{"id":"ed79feb8a74f4dec85fb5f0ced7c060e","type":"TRIAL","name":"A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT02584777","description":"Primary Myelofibrosis","metadata":null},{"id":"b8ea550b19a0441fa7e1cc8545241c61","type":"TRIAL","name":"A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT01656031","description":"Leukemia","metadata":null},{"id":"991ec347925a4091a957c05df0ee5d5e","type":"TRIAL","name":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","canonical_id":"clinicaltrials.gov:NCT03498521","description":"Cancer of Unknown Primary Site","metadata":null},{"id":"447b0b9b527440a49c55a19d9e974c72","type":"TRIAL","name":"A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy","canonical_id":"clinicaltrials.gov:NCT07604909","description":"Colorectal Cancer; Relapse","metadata":null},{"id":"a55aa2dd77eb4d48b99f09c5b2fdc7ec","type":"TRIAL","name":"A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)","canonical_id":"clinicaltrials.gov:NCT06284564","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"4574b7356939455097274429e0e7950f","type":"TRIAL","name":"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif\u00ae in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00050778","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"59c70a2779934a78b883327ffee3a264","type":"TRIAL","name":"A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas","canonical_id":"clinicaltrials.gov:NCT02389244","description":"Ewing Sarcomas; Chondrosarcomas; Osteosarcomas; Chondroma; CIC-Rearranged Sarcoma","metadata":null},{"id":"fe86455186134037b4ed3ba6efdee353","type":"TRIAL","name":"A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00612118","description":"Allergic Rhinitis; Rhinitis, Allergic, Seasonal","metadata":null},{"id":"6955760cbc6c4f7580f6255192c3e97e","type":"TRIAL","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07405801","description":"Breast Cancer","metadata":null},{"id":"3f319108ed374d97ac204267c5185d55","type":"TRIAL","name":"A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma","canonical_id":"clinicaltrials.gov:NCT04416451","description":"Marginal Zone Lymphoma","metadata":null},{"id":"6e3336af63ab45dfa7e724136003a59b","type":"TRIAL","name":"A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00500292","description":"Colorectal; Cancer","metadata":null},{"id":"b6c5181686ab43c3a8ea347b64c4c7a9","type":"TRIAL","name":"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","canonical_id":"clinicaltrials.gov:NCT05319431","description":"Unresectable, Non-metastatic Hepatocellular Carcinoma","metadata":null},{"id":"889824d522ee47b1ad8ecba7785e58cf","type":"TRIAL","name":"A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan","canonical_id":"clinicaltrials.gov:NCT00577278","description":"Graft Versus Host Disease; Leukemia; Lymphoma","metadata":null},{"id":"166e5853b8da46f9a1cc7c4300453a70","type":"TRIAL","name":"A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02059213","description":"Prostate Cancer","metadata":null},{"id":"241adb9e9e604775821d37b8815e569a","type":"TRIAL","name":"A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy","canonical_id":"clinicaltrials.gov:NCT01693822","description":"Clear-cell Metastatic Renal Cell Carcinoma","metadata":null},{"id":"80ac36a6888f4d179f0166a3d9945e8d","type":"TRIAL","name":"A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC","canonical_id":"clinicaltrials.gov:NCT07510594","description":"Large-Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Neuroendocrine Carcinoma","metadata":null},{"id":"a7516f02d9124358837ccc3aae7cbfed","type":"TRIAL","name":"A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00632541","description":"Metastatic Breast Cancer","metadata":null},{"id":"5ea48163eacf4dccb57820a7dd6259de","type":"TRIAL","name":"A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00201669","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"b76b3641231e48daaf5ba61c837f8a74","type":"TRIAL","name":"A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01545882","description":"Prostatic Neoplasms","metadata":null},{"id":"b26eab9608a64ab89168f06ca3e0895c","type":"TRIAL","name":"A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies","canonical_id":"clinicaltrials.gov:NCT03847649","description":"Cancer","metadata":null},{"id":"d9f27ac44c7e40e19a97479a69610398","type":"TRIAL","name":"A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT01783444","description":"Breast Cancer","metadata":null},{"id":"8441801af286483bad4ab552d9b3af43","type":"TRIAL","name":"A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02976116","description":"NSCLC","metadata":null},{"id":"15a5865862694585bc97fb03d054fb85","type":"TRIAL","name":"A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00108732","description":"Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer","metadata":null},{"id":"df6508a4269f4f5cb8209a6be3c2b4f9","type":"TRIAL","name":"A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT07106671","description":"CRS - Cytokine Release Syndrome; Myeloma","metadata":null},{"id":"e081cbd7bc7049a1bce42a2245225ecf","type":"TRIAL","name":"A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT06855225","description":"Combined Hepatocellular and Cholangiocarcinoma","metadata":null},{"id":"4f5a8f04880844b089126c1f829b0357","type":"TRIAL","name":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07506109","description":"BRAF V600E; Colorectal Cancer; Sintilimab; MSS (Microsatellite Stable); Cetuximab; Dabrafenib; Ipilimumab N01","metadata":null},{"id":"ae2fba71e6a44e5d826311ddbd18b4a0","type":"TRIAL","name":"A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma","canonical_id":"clinicaltrials.gov:NCT07791615","description":"Lymphoma; NK T-Cell Lymphoma","metadata":null},{"id":"70c3a9b173a744a7951581d7234704c1","type":"TRIAL","name":"A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas","canonical_id":"clinicaltrials.gov:NCT01782313","description":"Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma","metadata":null},{"id":"5d5e8af8bd764c2181182e2c6ccaf935","type":"TRIAL","name":"A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)","canonical_id":"clinicaltrials.gov:NCT05673928","description":"Metastatic Solid Tumor; Brain Metastases","metadata":null},{"id":"7442f4b7728b42d48a0213cbc11913be","type":"TRIAL","name":"A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury","canonical_id":"clinicaltrials.gov:NCT00036062","description":"Respiratory Distress Syndrome, Adult; Acute Lung Injury","metadata":null},{"id":"aad60f1470334b77bfab3f52ce0cda5b","type":"TRIAL","name":"A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges","canonical_id":"clinicaltrials.gov:NCT02336451","description":"ALK-positive Non-small Cell Lung Cancer","metadata":null},{"id":"938b2acfe20844b0a91174f3a9e3dca2","type":"TRIAL","name":"A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT00808977","description":"Ulcerative Colitis","metadata":null},{"id":"0660bba3ec374e28b57ac5d7d54d2707","type":"TRIAL","name":"A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)","canonical_id":"clinicaltrials.gov:NCT00702143","description":"Alzheimer's Disease; Mild Cognitive Impairment","metadata":null},{"id":"85b87b3ce9b64bc8b42397a3c1822609","type":"TRIAL","name":"A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1","canonical_id":"clinicaltrials.gov:NCT07034508","description":"DLBCL - Diffuse Large B Cell Lymphoma","metadata":null},{"id":"419b9ed8cd064fbea107707072889593","type":"TRIAL","name":"A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT03006848","description":"Osteosarcoma","metadata":null},{"id":"a0ffac631bde40168f977205e64d4562","type":"TRIAL","name":"A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.","canonical_id":"clinicaltrials.gov:NCT05005468","description":"NSCLC","metadata":null},{"id":"eb356a3a5fed46baa216be07c7a2f870","type":"TRIAL","name":"A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00479167","description":"Follicular Lymphoma","metadata":null},{"id":"a6cfbc85ed844f5f802ecb0b0f59d759","type":"TRIAL","name":"A Phase II Trial of Early Medical Adrenalectomy for \"D0.5\" Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00006371","description":"Prostate Cancer","metadata":null},{"id":"6b0ff16a25dd4e04954c973020ff3bf1","type":"TRIAL","name":"A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula","canonical_id":"clinicaltrials.gov:NCT03174353","description":"Pancreatic Leak; Pancreatic Fistula; Pancreaticoduodenal; Fistula; Pancreatectomy; Hyperglycemia","metadata":null},{"id":"d532b0fda490469984390090cbb62986","type":"TRIAL","name":"A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma","canonical_id":"clinicaltrials.gov:NCT04007588","description":"Melanoma Stage III; Melanoma Stage IV","metadata":null},{"id":"898737afe8f44b2b83ec0c2f806e9d88","type":"TRIAL","name":"A Phase II Trial of Regadenoson in Sickle Cell Anemia","canonical_id":"clinicaltrials.gov:NCT01788631","description":"Sickle Cell Anemia","metadata":null},{"id":"a4d24eef447d467c8096bedaed1dcba6","type":"TRIAL","name":"A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)","canonical_id":"clinicaltrials.gov:NCT01605396","description":"Breast Neoplasms","metadata":null},{"id":"cddf5da5cdd44466888a0b889e33e729","type":"TRIAL","name":"A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract","canonical_id":"clinicaltrials.gov:NCT01697800","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"03526cd0a6eb4ba5a76179859f3f3e58","type":"TRIAL","name":"A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01680887","description":"Cocaine Dependence","metadata":null},{"id":"648e20b3b2de44da89fe329772058b1c","type":"TRIAL","name":"A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC","canonical_id":"clinicaltrials.gov:NCT05837052","description":"Unresectable Lung Non-Small Cell Carcinoma","metadata":null},{"id":"0f09540d1f6d4387a391d96d4d2a13ec","type":"TRIAL","name":"A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC","canonical_id":"clinicaltrials.gov:NCT00664326","description":"Carcinoma, Renal Cell","metadata":null},{"id":"ac4d9ce221084c4db03df6d70c58675e","type":"TRIAL","name":"A Phase II, Double Blind Study of 2 Doses of ZACTIMA\u2122(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients","canonical_id":"clinicaltrials.gov:NCT00454116","description":"Colorectal Cancer","metadata":null},{"id":"5bc76098ec904c2ba0e962593aade61e","type":"TRIAL","name":"A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201","canonical_id":"clinicaltrials.gov:NCT00831649","description":"Rheumatoid Arthritis","metadata":null},{"id":"3ed6365e633544dfa65ecd85f937c2b3","type":"TRIAL","name":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC","canonical_id":"clinicaltrials.gov:NCT07245797","description":"Breast Cancer","metadata":null},{"id":"ae5c5be033074f4bacd35672da975bd1","type":"TRIAL","name":"A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases","canonical_id":"clinicaltrials.gov:NCT04460729","description":"Non-small Cell Lung Carcinoma (NSCLC)","metadata":null},{"id":"b401b1207656448d9e0f09e2fde30c87","type":"TRIAL","name":"A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes","canonical_id":"clinicaltrials.gov:NCT01620242","description":"Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer","metadata":null},{"id":"087ae79c5d864e84a122a7521fddab63","type":"TRIAL","name":"A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1\u03b2 Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT04239157","description":"Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome","metadata":null},{"id":"e90a22a8df7643e1bd54e954564adacf","type":"TRIAL","name":"A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT02150967","description":"Advanced Cholangiocarcinoma; FGFR2 Gene Mutation","metadata":null},{"id":"bd9cb0f2778141a3beaa52039a51e61d","type":"TRIAL","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","canonical_id":"clinicaltrials.gov:NCT07441512","description":"TNBC - Triple-Negative Breast Cancer; TNBC","metadata":null},{"id":"2cc7db75584a4c2d94e9912b4248a6b0","type":"TRIAL","name":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02937818","description":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","metadata":null},{"id":"0684f797eea84463a7b46c878422fd92","type":"TRIAL","name":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","canonical_id":"clinicaltrials.gov:NCT03008408","description":"Recurrent Endometrial Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Endometrial Endometrioid Adenocarcinoma; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC\u2026","metadata":null},{"id":"995bf10855754ec2a343835c69b4971c","type":"TRIAL","name":"A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection","canonical_id":"clinicaltrials.gov:NCT00000793","description":"HIV Infections; Peripheral Nervous System Disease","metadata":null},{"id":"a148f04185ef4a06a6898c1bc6866241","type":"TRIAL","name":"A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets","canonical_id":"clinicaltrials.gov:NCT07124221","description":"Hyperprolactinemia","metadata":null},{"id":"92a29f9f63dc4909a3b0bea88c99061c","type":"TRIAL","name":"A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT07146386","description":"Benign Prostatic Hyperplasia; Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","metadata":null},{"id":"455817a2fe1548e993e10499ed6adc53","type":"TRIAL","name":"A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis","canonical_id":"clinicaltrials.gov:NCT06850480","description":"Reflux Esophagitis (RE)","metadata":null},{"id":"a360f8a1875a4f259142de48b441fc02","type":"TRIAL","name":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07393321","description":"HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer","metadata":null},{"id":"5170f1be01f0448bba22735a435bf548","type":"TRIAL","name":"A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00000658","description":"Lymphoma, Non-Hodgkin; HIV Infections","metadata":null},{"id":"f413db5c66ed4c55b3c3464f42b6a480","type":"TRIAL","name":"A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","canonical_id":"clinicaltrials.gov:NCT00048568","description":"Rheumatoid Arthritis","metadata":null},{"id":"6b4edc80a6ca400a8d7f3b74b8af973e","type":"TRIAL","name":"A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00484289","description":"Rheumatoid Arthritis","metadata":null},{"id":"5bdfc87195a244c1afa8747c01eb8210","type":"TRIAL","name":"A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)","canonical_id":"clinicaltrials.gov:NCT04636957","description":"Acute Otitis Externa","metadata":null},{"id":"af7a69061b3a40c28e9013e0a187dd03","type":"TRIAL","name":"A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00481247","description":"Myeloid Leukemia, Chronic","metadata":null},{"id":"bc64a4475133433bb3918bea8de2dfdf","type":"TRIAL","name":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07446335","description":"Advanced Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"ffb9682d252348468f2ea402bac9be7e","type":"TRIAL","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","canonical_id":"clinicaltrials.gov:NCT07533123","description":"Triple Negative Breast Cancer","metadata":null},{"id":"c83ba00d37994bf0ad1ce5414330666d","type":"TRIAL","name":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","canonical_id":"clinicaltrials.gov:NCT03580369","description":"Chronic Spontaneous Urticaria","metadata":null},{"id":"bf6bfe9953cf47fc8b6fc8ca5bac43ba","type":"TRIAL","name":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07816380","description":"NSCLC (Advanced Non-small Cell Lung Cancer)","metadata":null},{"id":"7f5d4e2a9ec14060a7d7c179d24786ab","type":"TRIAL","name":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT06015737","description":"Cutaneous Lupus Erythematosus","metadata":null},{"id":"7aa42f07b7814951926cd55cb5b6b36d","type":"TRIAL","name":"A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02570893","description":"Esophageal Cancer","metadata":null},{"id":"63efcb82797245c284aaabb6ec73f7d3","type":"TRIAL","name":"A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma","canonical_id":"clinicaltrials.gov:NCT02495922","description":"Multiple Myeloma","metadata":null},{"id":"0c569e56b44b4e9ca1f63345b00385fe","type":"TRIAL","name":"A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","canonical_id":"clinicaltrials.gov:NCT01952223","description":"Adenocarcinoma of Prostate; Progression of Prostate Cancer","metadata":null},{"id":"9b87111a42f24b8a84bf4bd161e8cb54","type":"TRIAL","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT06126640","description":"HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","metadata":null},{"id":"d6fdf2a433374b0bbd8dfd968f2a2d74","type":"TRIAL","name":"A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00465803","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"ec6888798b3d41be9167a59fa2c64950","type":"TRIAL","name":"A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02287922","description":"Rheumatoid Arthritis","metadata":null},{"id":"99be4f1ca8604011b9c478345aae5b2a","type":"TRIAL","name":"A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK","canonical_id":"clinicaltrials.gov:NCT06269484","description":"Liver Cirrhosis","metadata":null},{"id":"4fa6b150f385432ba00a2e0d1805f261","type":"TRIAL","name":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00471380","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"59f13099d9864d598d01245e835240b6","type":"TRIAL","name":"A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer","canonical_id":"clinicaltrials.gov:NCT03956654","description":"Breast Cancer","metadata":null},{"id":"2fc4cb35c01f487cbf0a028806d14efa","type":"TRIAL","name":"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.","canonical_id":"clinicaltrials.gov:NCT02989402","description":"Alzheimer's Disease","metadata":null},{"id":"01fcf0e84f6b41a5a1fd5d1778c00e00","type":"TRIAL","name":"A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection","canonical_id":"clinicaltrials.gov:NCT02498015","description":"Hepatitis C, Chronic","metadata":null},{"id":"cee76f5ec2614d0c87230299d6df3aa7","type":"TRIAL","name":"A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.","canonical_id":"clinicaltrials.gov:NCT00234988","description":"Obesity","metadata":null},{"id":"ec98cec9a41a4cedba6be34c36b8615d","type":"TRIAL","name":"A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00788060","description":"Renal Cell Carcinoma","metadata":null},{"id":"6dbe16ab5d3249c795a491e484c49562","type":"TRIAL","name":"A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT05704634","description":"Lung Cancer","metadata":null},{"id":"d75e9c1cf409423ba23716ca4f5f8397","type":"TRIAL","name":"A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT03866239","description":"Colorectal Cancer","metadata":null},{"id":"08f406bb2dd74689b96a1e4a725edf85","type":"TRIAL","name":"A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT07170475","description":"Parkinson's Disease (PD)","metadata":null},{"id":"e8a9733c5f43499885591d11f353122b","type":"TRIAL","name":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06848699","description":"Solid Tumor Cancer; Non Small Cell Lung Cancer","metadata":null},{"id":"2e804879b55f442fa40471b902ef9c9c","type":"TRIAL","name":"A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT03677141","description":"B-cell Non-Hodgkin Lymphoma","metadata":null},{"id":"b33dcedee40e46bd83e34f58f24b4bdc","type":"TRIAL","name":"A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07358585","description":"Colon Cancer Adenocarcinoma","metadata":null},{"id":"3b4cedddc59748bfb73c727ef6408dc2","type":"TRIAL","name":"A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06732856","description":"Stomach Neoplasm; Gastric (Stomach) Cancer","metadata":null},{"id":"fb948e0761774c6d8e4e6517328bc99b","type":"TRIAL","name":"A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT07618390","description":"Breast Cancer","metadata":null},{"id":"bb64c0716eb941daa6420feaae6386d4","type":"TRIAL","name":"A Phase \u2161 Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery","canonical_id":"clinicaltrials.gov:NCT06680466","description":"Pain","metadata":null},{"id":"8a7ff85307334d90acfc04fcd893eaf3","type":"TRIAL","name":"A Phase \u2162 Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension","canonical_id":"clinicaltrials.gov:NCT01970059","description":"Hypertension","metadata":null},{"id":"cabc672daf44417e98964204d3eb3718","type":"TRIAL","name":"A Phase \u2162 Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis","canonical_id":"clinicaltrials.gov:NCT05108766","description":"Plaque Psoriasis","metadata":null},{"id":"caf5bc25c23c4afe973fff4c314826e4","type":"TRIAL","name":"A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT01732380","description":"Inoperable Esophageal Cancer Stage I-III","metadata":null},{"id":"e569196730494da5bf1e8461dc21b5c0","type":"TRIAL","name":"A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation","canonical_id":"clinicaltrials.gov:NCT03781219","description":"Solid Tumor","metadata":null},{"id":"a4da7689bee04720977cd32304c4550b","type":"TRIAL","name":"A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis","canonical_id":"clinicaltrials.gov:NCT05664880","description":"Chronic Pancreatitis","metadata":null},{"id":"b9e1b2464a9b4d689438c7b0706f84c9","type":"TRIAL","name":"A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT01634789","description":"Healthy","metadata":null},{"id":"6a1040ae1baa4e09a9516be263a14886","type":"TRIAL","name":"A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression","canonical_id":"clinicaltrials.gov:NCT00718770","description":"Thyroid Cancer","metadata":null},{"id":"678a67d654484cfea305a3a00c99a303","type":"TRIAL","name":"A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01255163","description":"Alzheimer's Disease; Mild Cognitive Impairment","metadata":null},{"id":"b229f53559254221ac1a4785bf50795f","type":"TRIAL","name":"A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)","canonical_id":"clinicaltrials.gov:NCT00183963","description":"Breast Carcinoma","metadata":null},{"id":"8464d68dd8594281babab03042252fcf","type":"TRIAL","name":"A Pilot Comparison Study of Vibrating Mesh Versus Standard Jet Nebuliser for Bronchodilator Delivery in COPD","canonical_id":"clinicaltrials.gov:NCT02686086","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"361efff4568f4e758d3c417ab853eadf","type":"TRIAL","name":"A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy","canonical_id":"clinicaltrials.gov:NCT00870363","description":"HIV Infections","metadata":null},{"id":"e624b3e9efc249bc973d5aa8df2ebccf","type":"TRIAL","name":"A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3","canonical_id":"clinicaltrials.gov:NCT00002106","description":"HIV Infections","metadata":null},{"id":"2c5a42d6d9324c3d8a6c8cf2483954ef","type":"TRIAL","name":"A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)","canonical_id":"clinicaltrials.gov:NCT02509793","description":"Huntington's Disease","metadata":null},{"id":"80d1e6699df5439c83cb879585f0f50c","type":"TRIAL","name":"A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00200421","description":"Hypertension","metadata":null},{"id":"05c2d599c3ea4b41a3c21b43fb45ab6a","type":"TRIAL","name":"A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients","canonical_id":"clinicaltrials.gov:NCT01567540","description":"Hepatitis C","metadata":null},{"id":"569a336eccd947be9f18dcec5f2bc244","type":"TRIAL","name":"A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults","canonical_id":"clinicaltrials.gov:NCT02633371","description":"Hyperhidrosis","metadata":null},{"id":"4a4aa8c24e534c1e9b43770205ef9b77","type":"TRIAL","name":"A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02749617","description":"Anti-Xa Activity","metadata":null},{"id":"5ac744e9cfda4739a19e5122d71b561e","type":"TRIAL","name":"A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma","canonical_id":"clinicaltrials.gov:NCT00242359","description":"Allergy Induced Asthma","metadata":null},{"id":"8b60d4b375694b2eaa6a47539ac98c0e","type":"TRIAL","name":"A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients","canonical_id":"clinicaltrials.gov:NCT00827112","description":"Human Immunodeficiency Virus-1","metadata":null},{"id":"54840194b05547ada0b12efa337294be","type":"TRIAL","name":"A Pilot Study for PK/PD Parameter of Colchicine in Chronic Kidney Disease Patient.","canonical_id":"clinicaltrials.gov:NCT01173107","description":"Chronic Kidney Disease","metadata":null},{"id":"86a548981fb347b5bb35998d92e75b64","type":"TRIAL","name":"A Pilot Study for the Treatment of Iris Neovascularization With Macugen","canonical_id":"clinicaltrials.gov:NCT00295828","description":"Iris Neovascularization; Diabetic Retinopathy","metadata":null},{"id":"c365957bb29049fc925f5b5e3279ab6d","type":"TRIAL","name":"A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris","canonical_id":"clinicaltrials.gov:NCT00815633","description":"Pityriasis Rubra Pilaris","metadata":null},{"id":"78e35465b7e946b09d62cf6d1ec6bbee","type":"TRIAL","name":"A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV","canonical_id":"clinicaltrials.gov:NCT01949168","description":"Chronic Hepatitis C","metadata":null},{"id":"4fb9532c623445e09c5a6b72210ac27b","type":"TRIAL","name":"A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02435108","description":"c-MET Positive Gastric Cancer","metadata":null},{"id":"8ab770a521dd4290876594240c8b6170","type":"TRIAL","name":"A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL","canonical_id":"clinicaltrials.gov:NCT01483690","description":"Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia","metadata":null},{"id":"924686a7b27f4dbf8331beacdcaf15af","type":"TRIAL","name":"A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia","canonical_id":"clinicaltrials.gov:NCT06285825","description":"Cytopenia","metadata":null},{"id":"d6bc3e98a0074b4098c7070d484ad989","type":"TRIAL","name":"A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes","canonical_id":"clinicaltrials.gov:NCT03412955","description":"Breast Cancer","metadata":null},{"id":"4b467765bf4d4b34925a94520ac9f9c6","type":"TRIAL","name":"A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis","canonical_id":"clinicaltrials.gov:NCT06591455","description":"Primary Biliary Cholangitis (PBC)","metadata":null},{"id":"bcdea93b6a2d4bc0b63e0486a8983392","type":"TRIAL","name":"A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT04929379","description":"Diabetic Nephropathies","metadata":null},{"id":"bbd6b3e29ae84e77a07996a512ec9166","type":"TRIAL","name":"A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study","canonical_id":"clinicaltrials.gov:NCT02013089","description":"Gastrointestinal Cancers","metadata":null},{"id":"a2658fef19214865aba398cefd8e581f","type":"TRIAL","name":"A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03587285","description":"Prostatic Neoplasms","metadata":null},{"id":"59ddf8248e7649f483a06484e5ac5284","type":"TRIAL","name":"A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients","canonical_id":"clinicaltrials.gov:NCT07533565","description":"Cirrhosis; Asthma","metadata":null},{"id":"72254e8991104f229433ad599e84f818","type":"TRIAL","name":"A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT05753657","description":"Metastatic Breast Cancer; Hyperinsulinism; Hyperglycemia Drug Induced","metadata":null},{"id":"ca68691668c34cfdab59bebe06a6cc61","type":"TRIAL","name":"A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide","canonical_id":"clinicaltrials.gov:NCT01110187","description":"Traumatic Brain Injury","metadata":null},{"id":"ff6ce7d73a95480b95c7a12350b96016","type":"TRIAL","name":"A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03519308","description":"Pancreatic Cancer","metadata":null},{"id":"0410910d61694610a51f974bf57058d5","type":"TRIAL","name":"A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension","canonical_id":"clinicaltrials.gov:NCT01658657","description":"Hypertension; Plasma Renin Activity","metadata":null},{"id":"ab27015b74214f9faf680c971835888f","type":"TRIAL","name":"A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome","canonical_id":"clinicaltrials.gov:NCT02400463","description":"Hemophagocytic Syndrome (HPS)","metadata":null},{"id":"aaf5cf19984d4592a6ccc8c9effe08c5","type":"TRIAL","name":"A Pilot Study of Sivelestat Sodium to Shorten Mechanical Ventilation in Acute Aortic Dissection","canonical_id":"clinicaltrials.gov:NCT05874700","description":"Acute Aortic Dissection","metadata":null},{"id":"f46b391de54b4c63974b5ed860acd92e","type":"TRIAL","name":"A Pilot Study of Suvorexant for Insomnia in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT02729714","description":"Insomnia","metadata":null},{"id":"f0c490043f6240a3901e624865e60a39","type":"TRIAL","name":"A Pilot Study of Terazosin for Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03905811","description":"Parkinson Disease","metadata":null},{"id":"165934119c87412187717314c13fd206","type":"TRIAL","name":"A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT02684097","description":"Alopecia Areata","metadata":null},{"id":"665239e2273e49888d4ea3b2e09221ae","type":"TRIAL","name":"A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT02068079","description":"Melanoma","metadata":null},{"id":"f2be18eb66a14f69a737ce1823168b6b","type":"TRIAL","name":"A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT00961064","description":"Myelodysplastic Syndromes; Thrombocytopenia","metadata":null},{"id":"51a0128a3f2e473ab2781bd68dbaf94c","type":"TRIAL","name":"A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis","canonical_id":"clinicaltrials.gov:NCT02787083","description":"Cystitis, Interstitial","metadata":null},{"id":"4e0ad6e7dece4361884ce2aea3b6704c","type":"TRIAL","name":"A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.","canonical_id":"clinicaltrials.gov:NCT01035333","description":"Obesity","metadata":null},{"id":"06350dc5d1134aad83b5dc199bc6abbd","type":"TRIAL","name":"A Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee","canonical_id":"clinicaltrials.gov:NCT00903994","description":"Tendonitis of the Shoulder, Elbow, or Knee","metadata":null},{"id":"2292f18bffeb4c909359980971adaa9b","type":"TRIAL","name":"A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults","canonical_id":"clinicaltrials.gov:NCT07233291","description":"Psoriasis (PsO)","metadata":null},{"id":"2ac21213a64f40f086ab0c4e9783d086","type":"TRIAL","name":"A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD","canonical_id":"clinicaltrials.gov:NCT01959022","description":"Stress Disorders, Post-Traumatic","metadata":null},{"id":"fc00c36db5b7407b80acf8893cb43a91","type":"TRIAL","name":"A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza\u00ae in Patients With Severe Hypertriglyceridemia","canonical_id":"clinicaltrials.gov:NCT01594983","description":"Non Familial Chylocmicronemia Syndrome (Non-FCS)","metadata":null},{"id":"4ee03de8a69b40f3b41145f61b5aeaf4","type":"TRIAL","name":"A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT01163799","description":"Transplant; Failure, Kidney","metadata":null},{"id":"b30acc96fb4243b7b3b7a8eb56aefb3f","type":"TRIAL","name":"A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03948581","description":"Healthy Volunteers","metadata":null},{"id":"e44a011d95824b3b942b1ddc3bbe80c1","type":"TRIAL","name":"A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial","canonical_id":"clinicaltrials.gov:NCT01696214","description":"Asthma","metadata":null},{"id":"a2785060ac0c4a1b82bb5daa8bbe8cd6","type":"TRIAL","name":"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00214214","description":"New Onset Type 1 Diabetes Mellitus","metadata":null},{"id":"1f8e6499c8fa49febf73f0009b732eac","type":"TRIAL","name":"A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population","canonical_id":"clinicaltrials.gov:NCT06585540","description":"Post Operative Nausea and Vomiting","metadata":null},{"id":"ad6fdea854d04f0da0163ee940c5d080","type":"TRIAL","name":"A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura","canonical_id":"clinicaltrials.gov:NCT01485367","description":"Senile Purpura","metadata":null},{"id":"3b9fffae278944c7aa51f91aef0ea957","type":"TRIAL","name":"A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT00607503","description":"Type 1 Diabetes","metadata":null},{"id":"63f02ad638fa434c8ef6848ccd11553e","type":"TRIAL","name":"A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00467181","description":"Cardiac Surgery With Cardiopulmonary Bypass","metadata":null},{"id":"6d0e8ed7c9f248ef9663a1bfd6679fc7","type":"TRIAL","name":"A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity","canonical_id":"clinicaltrials.gov:NCT05289869","description":"Pregnant Patients With Obesity","metadata":null},{"id":"33ee70f9da2141348b8958584a422ddd","type":"TRIAL","name":"A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation","canonical_id":"clinicaltrials.gov:NCT03422705","description":"Pacemakers, Heart Failure","metadata":null},{"id":"feb8a9a7ea4c4c66a0be57eda3a900e2","type":"TRIAL","name":"A Pilot Trial Evaluating the Effect of Tropisetron on Postoperative Cognitive Dysfunction After Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT04195204","description":"Postoperative Cognitive Dysfunction; Postoperative Delirium","metadata":null},{"id":"99e68ef9e5f6414696f82ce6a7df0742","type":"TRIAL","name":"A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)","canonical_id":"clinicaltrials.gov:NCT05284032","description":"Platelet Refractoriness; Hematologic Malignancy","metadata":null},{"id":"0bf33b4389a842c083588b16faabb8e5","type":"TRIAL","name":"A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C","canonical_id":"clinicaltrials.gov:NCT00814606","description":"Hepatitis C; Hepatitis C Virus","metadata":null},{"id":"e28a8ffa7c534231b8e5261133b67c02","type":"TRIAL","name":"A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks","canonical_id":"clinicaltrials.gov:NCT02720991","description":"Abortion, 3 Months","metadata":null},{"id":"fd09873955d84e8fa8ef37989f7be248","type":"TRIAL","name":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02021422","description":"Pancreas Cancer","metadata":null},{"id":"935584b5ea90485d823a26f2ced53389","type":"TRIAL","name":"A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00848926","description":"Disease, Hodgkin","metadata":null},{"id":"a5e6f600bc3646bb82bd79f9aa5074ad","type":"TRIAL","name":"A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet","canonical_id":"clinicaltrials.gov:NCT01900587","description":"Healthy","metadata":null},{"id":"abc8ecb5d9da46c1a68a327029d22033","type":"TRIAL","name":"A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)","canonical_id":"clinicaltrials.gov:NCT00746382","description":"Dermatitis","metadata":null},{"id":"c511ea3d346c4ef4b38499619b511b61","type":"TRIAL","name":"A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01356940","description":"Multiple Sclerosis","metadata":null},{"id":"d94aa6c25f104e4ca88f67a1a0be87a6","type":"TRIAL","name":"A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.","canonical_id":"clinicaltrials.gov:NCT00335205","description":"Bipolar Disorder; Major Depressive Disorder","metadata":null},{"id":"c8f3dd7c0c0741238e220999d07d2a46","type":"TRIAL","name":"A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain","canonical_id":"clinicaltrials.gov:NCT01288937","description":"Idiopathic Peripheral Neuropathy","metadata":null},{"id":"03ad1f10d5164a53b06e32381616ec1b","type":"TRIAL","name":"A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients","canonical_id":"clinicaltrials.gov:NCT01536041","description":"Asthma","metadata":null},{"id":"1f11e834b0e9481fa4c854052f60ee6c","type":"TRIAL","name":"A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)","canonical_id":"clinicaltrials.gov:NCT01155466","description":"Parkinson Disease","metadata":null},{"id":"1b5068353d9a4afcb0c287619f3b9eb5","type":"TRIAL","name":"A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)","canonical_id":"clinicaltrials.gov:NCT01155479","description":"Parkinson Disease","metadata":null},{"id":"7e53c36dea91409a915e685969fcd34e","type":"TRIAL","name":"A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT00463242","description":"Major Depressive Disorder","metadata":null},{"id":"110c8ace0baa40e19c13622feb94476b","type":"TRIAL","name":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT01628926","description":"Parkinson's Disease","metadata":null},{"id":"959908c129dc419ea28906bb07c6d896","type":"TRIAL","name":"A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03464097","description":"Crohn Disease","metadata":null},{"id":"060723fbe0b041f1906bd063a91a8577","type":"TRIAL","name":"A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction","canonical_id":"clinicaltrials.gov:NCT00567814","description":"Cocaine Dependence; Cocaine Addiction","metadata":null},{"id":"73df3043225a419ebf5998de48779154","type":"TRIAL","name":"A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain","canonical_id":"clinicaltrials.gov:NCT01675050","description":"Functional Abdominal Pain","metadata":null},{"id":"b7f30748092346e18e3626679b2b998b","type":"TRIAL","name":"A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT00659412","description":"Psoriatic Arthritis","metadata":null},{"id":"8fe799b0c750473c88f780bc3794e381","type":"TRIAL","name":"A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT05692154","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"2dcf4502fe654e25b1b98fe8054527ed","type":"TRIAL","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05565378","description":"Lung Cancer, Non-Small Cell","metadata":null},{"id":"f01a100bceae4e55a5bd4728c2adc1d0","type":"TRIAL","name":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","canonical_id":"clinicaltrials.gov:NCT05708235","description":"Breast Cancer","metadata":null},{"id":"0867c788fc8b4102a4536e5732a364b1","type":"TRIAL","name":"A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer","canonical_id":"clinicaltrials.gov:NCT00480246","description":"Healthy","metadata":null},{"id":"d606cd2a793f489fa08c90de2d5a7637","type":"TRIAL","name":"A Post Approval Commitment Study on Tabrecta\u00ae (Capmatinib) in South Korea","canonical_id":"clinicaltrials.gov:NCT05703516","description":"Non-Small-Cell Lung Carcinoma","metadata":null},{"id":"be1160434b424373a35ba382458f2484","type":"TRIAL","name":"A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea","canonical_id":"clinicaltrials.gov:NCT06073873","description":"Ulcerative Colitis","metadata":null},{"id":"7321758c04de4decbb60029289582f6e","type":"TRIAL","name":"A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT06073847","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"3effb329a3a24624a4690de2d2cd91af","type":"TRIAL","name":"A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients","canonical_id":"clinicaltrials.gov:NCT05744063","description":"Primary Hemophagocytic Lymphohistiocytosis","metadata":null},{"id":"2297dec2b8254452b442577b69b14d76","type":"TRIAL","name":"A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil","canonical_id":"clinicaltrials.gov:NCT04228588","description":"Eosinophilic Asthma","metadata":null},{"id":"05a4522c410a40b59f6cf4237f2551c8","type":"TRIAL","name":"A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy","canonical_id":"clinicaltrials.gov:NCT03150602","description":"Peripheral T Cell Lymphoma; Progression, Disease","metadata":null},{"id":"6e9b6630ab9d40cd98198c215404c4c3","type":"TRIAL","name":"A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression","canonical_id":"clinicaltrials.gov:NCT03623711","description":"Major Depressive Disorder; Depression, Unipolar","metadata":null},{"id":"1fa64123d3864931a64c3afe0e769799","type":"TRIAL","name":"A Preliminary Drug Drug Interaction Study With TA-8995","canonical_id":"clinicaltrials.gov:NCT02124954","description":"Pharmacokinetic Interactions","metadata":null},{"id":"5477ea3719624ddcbb001ef292b213d7","type":"TRIAL","name":"A Prevention Trial in Subjects at High Risk for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01500577","description":"Breast Cancer","metadata":null},{"id":"2eda4b089d6a47b2b70e942413e98284","type":"TRIAL","name":"A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05725343","description":"Lung Cancer","metadata":null},{"id":"586b9851eacb40a5afcfca058a898cba","type":"TRIAL","name":"A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function","canonical_id":"clinicaltrials.gov:NCT00818038","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"df6fb60e3aab448e827aa36a4059e7fc","type":"TRIAL","name":"A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT01704534","description":"Hidradenitis Suppurativa","metadata":null},{"id":"fd31542b05a94e818d2ab354dc9a676d","type":"TRIAL","name":"A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder","canonical_id":"clinicaltrials.gov:NCT03291041","description":"Jet Lag Disorder","metadata":null},{"id":"22001aaafd4b4b55a59d84ab2861b6e3","type":"TRIAL","name":"A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)","canonical_id":"clinicaltrials.gov:NCT04521751","description":"Overweight or Obesity","metadata":null},{"id":"6c2e02ddd94d4c5c8ac4a8f1f884d67f","type":"TRIAL","name":"A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo","canonical_id":"clinicaltrials.gov:NCT04145674","description":"Restless Legs Syndrome","metadata":null},{"id":"bbad70a408ee4cbb833652142efac2fa","type":"TRIAL","name":"A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)","canonical_id":"clinicaltrials.gov:NCT05755737","description":"Vasovagal Syncope (VVS); Syncope","metadata":null},{"id":"2c19e8f16aa44d0c8cb12b4f7e3203f8","type":"TRIAL","name":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT02484690","description":"Choroidal Neovascularization","metadata":null},{"id":"dd557daa21a24e2d8de962736000cf5c","type":"TRIAL","name":"A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT07399067","description":"Atopic Dermatitis","metadata":null},{"id":"a1007df365e84187ac45976733ac1618","type":"TRIAL","name":"A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT04991753","description":"Arthritis, Rheumatoid","metadata":null},{"id":"fa2184401c5049faaafeb52876d06762","type":"TRIAL","name":"A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome","canonical_id":"clinicaltrials.gov:NCT05643794","description":"Fibromyalgia","metadata":null},{"id":"6e0db99bc271496494d2938c0bffec3e","type":"TRIAL","name":"A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients","canonical_id":"clinicaltrials.gov:NCT06087419","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"20433d6d36e24f8f91db37d37fe5b71d","type":"TRIAL","name":"A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)","canonical_id":"clinicaltrials.gov:NCT07487311","description":"Inflamatory Bowel Disease","metadata":null},{"id":"f19fa4e69e314235bc864d7b232bfe5d","type":"TRIAL","name":"A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases","canonical_id":"clinicaltrials.gov:NCT07143045","description":"EGFR Mutant Advanced Non-small Cell Lung Cancer; Central Nervous System (CNS) Metastases","metadata":null},{"id":"4309187c0ca94cfaa2ebf5a15aae8374","type":"TRIAL","name":"A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome","canonical_id":"clinicaltrials.gov:NCT07695298","description":"Presumed Ocular Histoplasmosis","metadata":null},{"id":"f78d8643c1924c88babc2d7f36e275dc","type":"TRIAL","name":"A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden","canonical_id":"clinicaltrials.gov:NCT05387616","description":"Follicular Lymphoma","metadata":null},{"id":"217d3a3eef734955994e4ebd9e5dd20f","type":"TRIAL","name":"A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT07778745","description":"NSCLC","metadata":null},{"id":"f31e3fa6b9b448ac8ca034b4a961948c","type":"TRIAL","name":"A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients","canonical_id":"clinicaltrials.gov:NCT04916756","description":"Sjogren's Syndrome","metadata":null},{"id":"ce5added792749de8e9af23ddbf951b7","type":"TRIAL","name":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07189325","description":"Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy","metadata":null},{"id":"79c5ab1602514640a623d00e0d2ea304","type":"TRIAL","name":"A Prospective Real World Study of Rimegepant in the Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT05709106","description":"Migraine","metadata":null},{"id":"407dacbf794e4d2e9b70a39e98228ca8","type":"TRIAL","name":"A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT07795177","description":"Metastatic Hormone-Sensitive Prostate Cancer","metadata":null},{"id":"44272807706a4f369f5a148856a9232d","type":"TRIAL","name":"A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF","canonical_id":"clinicaltrials.gov:NCT02389218","description":"Atrial Fibrillation","metadata":null},{"id":"ae7821a9f39441e89e6af22696dfef83","type":"TRIAL","name":"A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)","canonical_id":"clinicaltrials.gov:NCT07459556","description":"SAR","metadata":null},{"id":"e91950c94baa4d7fb450dc31a8af7867","type":"TRIAL","name":"A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag","canonical_id":"clinicaltrials.gov:NCT06426043","description":"Aplastic Anemia","metadata":null},{"id":"1a0646c1d69849a08b8669f3ac940e38","type":"TRIAL","name":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","canonical_id":"clinicaltrials.gov:NCT06019728","description":"Fabry's Disease","metadata":null},{"id":"12214761f7394f6a8bf417be8a79e0e6","type":"TRIAL","name":"A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab","canonical_id":"clinicaltrials.gov:NCT05388474","description":"HIV Infections; Multi-Antiviral Resistance","metadata":null},{"id":"5ce109004f9f4f4c91eef429491fe276","type":"TRIAL","name":"A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy","canonical_id":"clinicaltrials.gov:NCT01399580","description":"Chronic Kidney Disease; Diabetic Nephropathy","metadata":null},{"id":"4c88e1452e80447f89ba5c383b263aca","type":"TRIAL","name":"A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07485920","description":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","metadata":null},{"id":"546dddae59bd4951b4f1dc802268c3a7","type":"TRIAL","name":"A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07647094","description":"NSCLC","metadata":null},{"id":"9333e1ce1c154259ab8ee1ad3b27e318","type":"TRIAL","name":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07543848","description":"Rectal Neoplasms; Rectal Adenocarcinoma","metadata":null},{"id":"c18913f4b8064192a8eeaa9456e0ca6c","type":"TRIAL","name":"A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice","canonical_id":"clinicaltrials.gov:NCT00855738","description":"Focal Epilepsy","metadata":null},{"id":"6c32a1ebeca84de1a4d78756279435db","type":"TRIAL","name":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","canonical_id":"clinicaltrials.gov:NCT02386072","description":"Urinary Bladder Overactive; Overactive Bladder; Urinary Bladder Diseases; Urologic Diseases","metadata":null},{"id":"5668ec548927489f8aaa8ad6d01ea493","type":"TRIAL","name":"A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT07667621","description":"Migraine; Migraine Disease; Migraine in Adults; Migraine Headache; Acute Migraine; Migraine Without Aura; Migraine With Aura","metadata":null},{"id":"525f8795f1b344a1bc514e947538a065","type":"TRIAL","name":"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri\u00ae) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients","canonical_id":"clinicaltrials.gov:NCT00871780","description":"Relapsing Remitting Multiple Sclerosis (RRMS)","metadata":null},{"id":"56c9971d5557487bae054bac018af52f","type":"TRIAL","name":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","canonical_id":"clinicaltrials.gov:NCT06467500","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"ce3cebc81554412fa6334c46176682a0","type":"TRIAL","name":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol","canonical_id":"clinicaltrials.gov:NCT01817452","description":"Breast Cancer","metadata":null},{"id":"1bb9433193f14b468bdcba75a39ee23c","type":"TRIAL","name":"A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC","canonical_id":"clinicaltrials.gov:NCT07422753","description":"Hepatocellular Carcinoma (HCC)","metadata":null},{"id":"be9ae54de0da44b39ccc2a258ed60d73","type":"TRIAL","name":"A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)","canonical_id":"clinicaltrials.gov:NCT00096954","description":"Asthma","metadata":null},{"id":"13fd41251b1e4985b47213d48114c8f4","type":"TRIAL","name":"A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments","canonical_id":"clinicaltrials.gov:NCT05152472","description":"Unresectable Gastrointestinal Stromal Tumor (GIST); Locally Advanced Gastrointestinal Stromal Tumor (GIST); Metastatic Gastrointestinal Stromal Tumor","metadata":null},{"id":"5fe7db3c2403468b904240ad39f9bd77","type":"TRIAL","name":"A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07349043","description":"Peritoneal Metastasis; CRC (Colorectal Cancer)","metadata":null},{"id":"de68decd396a4b459c54ea497fd01ec2","type":"TRIAL","name":"A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk","canonical_id":"clinicaltrials.gov:NCT07515469","description":"HCC - Hepatocellular Carcinoma; Iparomlimab and Tuvonralimab Injection; Neoadjuvant Immunotherapy","metadata":null},{"id":"bb78d3a1f0324eafa06ca3deeebf9d13","type":"TRIAL","name":"A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07741617","description":"Urologic Neoplasms","metadata":null},{"id":"4e094fac550f4a17bac251601a910b4b","type":"TRIAL","name":"A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion","canonical_id":"clinicaltrials.gov:NCT07790419","description":"Liver Cancer","metadata":null},{"id":"79dce0226e99493da9897b599c119582","type":"TRIAL","name":"A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)","canonical_id":"clinicaltrials.gov:NCT01817803","description":"Congestive Heart Failure","metadata":null},{"id":"6b53a71728424db393ee6692502eb46e","type":"TRIAL","name":"A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07854964","description":"Locally Advanced Rectal Cancer","metadata":null},{"id":"2d48803ae7cc40318dad8b9e21ace1bc","type":"TRIAL","name":"A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)","canonical_id":"clinicaltrials.gov:NCT02047422","description":"Congestive Heart Failure","metadata":null},{"id":"a09a8de68bea4a7ea31b003507e104a2","type":"TRIAL","name":"A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07196748","description":"Colitis, Ulcerative","metadata":null},{"id":"35d8590d83634dc5b924fdd093fe494e","type":"TRIAL","name":"A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT\u2122 in France, Italy and Spain","canonical_id":"clinicaltrials.gov:NCT02081690","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"68be661a871c48e5a25724967b2e53d1","type":"TRIAL","name":"A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00484003","description":"Atopic Eczema","metadata":null},{"id":"0a51a10f3a984aa28cdc8d92bb52c82a","type":"TRIAL","name":"A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)","canonical_id":"clinicaltrials.gov:NCT01127308","description":"Type 2 Diabetes Mellitus (T2DM)","metadata":null},{"id":"b79e61a5b637430784a3ddb6929e0386","type":"TRIAL","name":"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide","canonical_id":"clinicaltrials.gov:NCT00696657","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"6b4e9b2f8aa240c198b26149ac875a42","type":"TRIAL","name":"A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.","canonical_id":"clinicaltrials.gov:NCT00668096","description":"Erectile Dysfunction","metadata":null},{"id":"3348d6cfed0a43789fdb8262652b9ff1","type":"TRIAL","name":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06585969","description":"Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like","metadata":null},{"id":"9c875ad7d55949ac9a86ceb382235c2b","type":"TRIAL","name":"A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03258320","description":"Prostate Cancer Patients","metadata":null},{"id":"ccefa5e682594860b1793f71a0715e4b","type":"TRIAL","name":"A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 \u00b5g Once Daily and Tiotropium 2.5 \u00b5g Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT01152450","description":"Asthma","metadata":null},{"id":"3f12a115729e43bd8c8e85a03543b167","type":"TRIAL","name":"A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00144326","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"557de5d500894cd98dbca137e2df467b","type":"TRIAL","name":"A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00717951","description":"Advanced Breast Cancer","metadata":null},{"id":"a4aac1e0333e4bde92df8ab23cca712d","type":"TRIAL","name":"A Randomized Clinical Trail of The Effect of Postoperative Uric Acid Control on Stone Recurrence and Renal Function in Patients With Hyperuricemia of Urolithiasis.","canonical_id":"clinicaltrials.gov:NCT04398251","description":"Hypouricemia, Renal; Urolithiasis","metadata":null},{"id":"5a208b8fb4a24fe0be34e8ffba7936d9","type":"TRIAL","name":"A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT01524744","description":"Oral Lichen Planus","metadata":null},{"id":"633bd78c02074909b768ea5929e97e46","type":"TRIAL","name":"A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy","canonical_id":"clinicaltrials.gov:NCT04159493","description":"Vaginal Atrophy","metadata":null},{"id":"cbfea7c47097451cbc6a140672ebc940","type":"TRIAL","name":"A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT00774007","description":"Irritable Bowel Syndrome","metadata":null},{"id":"868fb7d8ba7e4f4cb1bcc0389bce2c45","type":"TRIAL","name":"A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity","canonical_id":"clinicaltrials.gov:NCT07783854","description":"Obesity & Overweight","metadata":null},{"id":"172fd4d5b8f84d2f93ffa61eecb15281","type":"TRIAL","name":"A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD","canonical_id":"clinicaltrials.gov:NCT03339258","description":"Stress Disorders, Post-Traumatic","metadata":null},{"id":"016ea13b22c94e4ea9e8fbd43e64b5b6","type":"TRIAL","name":"A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)","canonical_id":"clinicaltrials.gov:NCT01892345","description":"Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"99c8fc059c2c438dad8b8390b64729fc","type":"TRIAL","name":"A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC","canonical_id":"clinicaltrials.gov:NCT00789802","description":"Contraception; Bleeding","metadata":null},{"id":"b1e8cf52a20b485e938cd9bf366cc088","type":"TRIAL","name":"A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT01937156","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"c9b10881ad0b49e7bf13028e7150ef76","type":"TRIAL","name":"A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn","canonical_id":"clinicaltrials.gov:NCT06651476","description":"Sunburn","metadata":null},{"id":"18dc5a82f9a04f52a3d1cd47e55ac70d","type":"TRIAL","name":"A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia","canonical_id":"clinicaltrials.gov:NCT07293728","description":"Hypertension; Preeclampsia","metadata":null},{"id":"4215294023854dd2aa808954d73936ea","type":"TRIAL","name":"A Randomized Phase 2 Study of Cemiplimab \u00b1 ISA101b in HPV16-Positive OPC","canonical_id":"clinicaltrials.gov:NCT03669718","description":"Squamous Cell Carcinoma of the Oropharynx; HPV16 Positive","metadata":null},{"id":"ce752817a2dd4edbbedcbeaa95fc2bb3","type":"TRIAL","name":"A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03512756","description":"Pancreatic Cancer","metadata":null},{"id":"142fd6351fb046e89c61ed74652d10cc","type":"TRIAL","name":"A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT02016716","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"4df2cbc0cc8c43bea32e11b182b53a03","type":"TRIAL","name":"A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma","canonical_id":"clinicaltrials.gov:NCT01562197","description":"Glioblastoma Multiforme","metadata":null},{"id":"cd6658d3bdf14a0e92e22c913a7b1864","type":"TRIAL","name":"A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage","canonical_id":"clinicaltrials.gov:NCT00887159","description":"Extensive Stage Small Cell Lung Carcinoma; Recurrent Small Cell Lung Carcinoma","metadata":null},{"id":"60cd2518a178435eb59b8f09429c86ee","type":"TRIAL","name":"A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker","canonical_id":"clinicaltrials.gov:NCT06156527","description":"Lazertinib","metadata":null},{"id":"9c59360658134153990959ab3725729d","type":"TRIAL","name":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","canonical_id":"clinicaltrials.gov:NCT01743989","description":"Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","metadata":null},{"id":"b6157dbbc89444d68946d00551991d8d","type":"TRIAL","name":"A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00256204","description":"Parkinson's Disease","metadata":null},{"id":"bd0d32cb712c47d687e1be699fc02a9a","type":"TRIAL","name":"A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT03836664","description":"Migraine","metadata":null},{"id":"2dd0f326b0c949e5b1d4a9ef42f02bd0","type":"TRIAL","name":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02216786","description":"Estrogen Receptor Positive Breast Cancer","metadata":null},{"id":"10d45b216b5c4196af10962f6ba5912f","type":"TRIAL","name":"A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01526369","description":"Metastatic Breast Cancer","metadata":null},{"id":"428eab2100fa4716a5972d7b6c53e556","type":"TRIAL","name":"A Randomized Study of Three Medication Regimens for Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT01587274","description":"Acute Low Back Pain","metadata":null},{"id":"3f8433abfcc14f799fd8df5103905950","type":"TRIAL","name":"A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones","canonical_id":"clinicaltrials.gov:NCT00583258","description":"Kidney Stones","metadata":null},{"id":"2efb900c69064e78a179ba85d2b6cf61","type":"TRIAL","name":"A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients","canonical_id":"clinicaltrials.gov:NCT06707246","description":"Hidradenitis Suppurativa","metadata":null},{"id":"eeb50262a3174d80ab22f0efa44ea800","type":"TRIAL","name":"A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI","canonical_id":"clinicaltrials.gov:NCT00440778","description":"Myocardial Infarction; Ischemia","metadata":null},{"id":"8260f8d0b0784e56a648112ce993edac","type":"TRIAL","name":"A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)","canonical_id":"clinicaltrials.gov:NCT07188896","description":"Advanced Renal Cell Carcinoma (aRCC); Metastatic Renal Cell Carcinoma ( mRCC); Clear Cell Renal Cell Carcinoma (ccRCC)","metadata":null},{"id":"9ad88711ba7c4cf283549794360e0938","type":"TRIAL","name":"A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine","canonical_id":"clinicaltrials.gov:NCT00644033","description":"Menstrually Associated Migraine","metadata":null},{"id":"93378a91e7db4fe6aa09ea361bb9d25b","type":"TRIAL","name":"A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function","canonical_id":"clinicaltrials.gov:NCT02105870","description":"Myocardial Infarction; Coronary Artery Disease","metadata":null},{"id":"a8a116b6d3aa414c9d40d378cef426af","type":"TRIAL","name":"A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors","canonical_id":"clinicaltrials.gov:NCT01265550","description":"GERD","metadata":null},{"id":"42e31520abde4ad4acb4cae3b84ffd97","type":"TRIAL","name":"A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT00072969","description":"Myelodysplastic Syndromes","metadata":null},{"id":"82c5b00185b64bdf96e3ff42afb15758","type":"TRIAL","name":"A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).","canonical_id":"clinicaltrials.gov:NCT02737319","description":"Nephropathy","metadata":null},{"id":"7910891a8c9f49389daa14ce3ace154f","type":"TRIAL","name":"A Randomized Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT04324060","description":"Low/Intermediate Risk-1 MDS","metadata":null},{"id":"b5090202a24b432cbdd6a3f70877aa46","type":"TRIAL","name":"A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)","canonical_id":"clinicaltrials.gov:NCT06384547","description":"Thyroid Eye Disease","metadata":null},{"id":"cd4de564350d426eb13d62abcf6ca4ac","type":"TRIAL","name":"A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00382213","description":"Atherosclerosis","metadata":null},{"id":"26c243c2bbed47b4bc2bcb0a50595887","type":"TRIAL","name":"A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease","canonical_id":"clinicaltrials.gov:NCT00841789","description":"Mucocutaneous Lymph Node Syndrome; Kawasaki Disease","metadata":null},{"id":"7eeeb71e740842568ab229c92b66091e","type":"TRIAL","name":"A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00190775","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"d133a05ae7c44f25ad48c3cb27cc1a9f","type":"TRIAL","name":"A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain","canonical_id":"clinicaltrials.gov:NCT00661635","description":"Laparoscopic Cholecystectomy; Pain","metadata":null},{"id":"d9a219c7cc3847099495d5d3314b7c2a","type":"TRIAL","name":"A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.","canonical_id":"clinicaltrials.gov:NCT00330460","description":"Osteoporosis; Osteopenia","metadata":null},{"id":"1fa26091cbcb42908d04356c97521a8e","type":"TRIAL","name":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber","canonical_id":"clinicaltrials.gov:NCT00420082","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"390171b6da714192843d267ae66dfeae","type":"TRIAL","name":"A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT04940390","description":"Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"a2c6766538a5475bbd48dfba44ab87ff","type":"TRIAL","name":"A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT00859105","description":"Actinic Keratosis","metadata":null},{"id":"08795526e65b40a5b3f1cbeb53770443","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine","canonical_id":"clinicaltrials.gov:NCT05458011","description":"Migraine","metadata":null},{"id":"ca626403c9f446e7a5a1b181bdba6da1","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT01539512","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"bc582bb7a5b0403aa4a04fd9c5a9900b","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT03901482","description":"Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"8c6e5ad1f7c64d5da86f8ea4b876742c","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01231464","description":"Rhinitis, Allergic, Perennial; Allergic Rhinitis","metadata":null},{"id":"4b92afb69bf9417f97c78e72803c7810","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Trial of Anrikefon for Postoperative Analgesia After Percutaneous Nephrolithotomy","canonical_id":"clinicaltrials.gov:NCT07825142","description":"Postoperative Pain; Nephrolithiasis","metadata":null},{"id":"5eeac07715e44cc1a303dfde49aac097","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT00997087","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"0268cbbff3074248a37e979a8a69ba5c","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm","canonical_id":"clinicaltrials.gov:NCT00235963","description":"Subarachnoid Hemorrhage; Delayed Vasospasm","metadata":null},{"id":"362296154a654f4ebb7803c63530e558","type":"TRIAL","name":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease","canonical_id":"clinicaltrials.gov:NCT00001101","description":"Lyme Disease","metadata":null},{"id":"0331646cb95c4cc093ab65c580556228","type":"TRIAL","name":"A Randomized, Double-blind Comparison of Morphine and Sufentanil for Prehospital Traumatic Severe Acute Pain","canonical_id":"clinicaltrials.gov:NCT00656773","description":"Acute Pain","metadata":null},{"id":"2e440c3a6c0849cdae6da4ddfd80c1c6","type":"TRIAL","name":"A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01615185","description":"Schizophrenia","metadata":null},{"id":"80257a15cd9f40859415c1b29e3040b8","type":"TRIAL","name":"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid\u00ae OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.","canonical_id":"clinicaltrials.gov:NCT00775203","description":"Major Depressive Disorder","metadata":null},{"id":"c9ce7ee804a448378a4e9fd17faaa05c","type":"TRIAL","name":"A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)","canonical_id":"clinicaltrials.gov:NCT00322569","description":"Coronary Disease","metadata":null},{"id":"c9fb97989ef84dcbbb06fd93fe445a31","type":"TRIAL","name":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","canonical_id":"clinicaltrials.gov:NCT00723606","description":"Schizophrenia","metadata":null},{"id":"3e5b00d4861340ad9d059f2269397b6f","type":"TRIAL","name":"A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study","canonical_id":"clinicaltrials.gov:NCT07751497","description":"Vestibular Migraine","metadata":null},{"id":"ba3f396864d645a89e916d01cb0c73fd","type":"TRIAL","name":"A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome","canonical_id":"clinicaltrials.gov:NCT00651235","description":"Marfan Syndrome","metadata":null},{"id":"cfaff056112942cb9c491fc3c8801fbe","type":"TRIAL","name":"A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation","canonical_id":"clinicaltrials.gov:NCT02136524","description":"Healthy Volunteer","metadata":null},{"id":"b5f330c3ae9a4d9387fcb016ab397fc0","type":"TRIAL","name":"A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00561717","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"082fd0848dcd48a3b904d4b9ce285b60","type":"TRIAL","name":"A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT01640002","description":"Overactive Bladder Associated With HTLV-1","metadata":null},{"id":"59a2041808674b848e66f2682e8844a6","type":"TRIAL","name":"A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering","canonical_id":"clinicaltrials.gov:NCT01684657","description":"Stuttering","metadata":null},{"id":"231022e360ac429880331d784f36ea2e","type":"TRIAL","name":"A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects","canonical_id":"clinicaltrials.gov:NCT00549666","description":"Pharmacokinetics","metadata":null},{"id":"1de2337882894901a8df95de291f303b","type":"TRIAL","name":"A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen","canonical_id":"clinicaltrials.gov:NCT04446026","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"6de22e9b5922476ca95d9cf8ca4b975a","type":"TRIAL","name":"A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis","canonical_id":"clinicaltrials.gov:NCT03718299","description":"Psoriasis","metadata":null},{"id":"7a49ca23778847f3a0e3f9d8b0862e68","type":"TRIAL","name":"A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy","canonical_id":"clinicaltrials.gov:NCT04737837","description":"Epilepsy; Focal-Onset Seizure","metadata":null},{"id":"6024bdfdd6df42f4aef5ccc58589e8d2","type":"TRIAL","name":"A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Na\u00efve and Warfarin Na\u00efve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage","canonical_id":"clinicaltrials.gov:NCT03189069","description":"Atrial Fibrillation","metadata":null},{"id":"73a8f1d0d2264fb29d06d22c039b4877","type":"TRIAL","name":"A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients","canonical_id":"clinicaltrials.gov:NCT05293938","description":"Primary Biliary Cholangitis","metadata":null},{"id":"b2b3a7923c9244c09b6215d21f23a481","type":"TRIAL","name":"A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07543250","description":"Breast Cancer","metadata":null},{"id":"cf8b200f3d9745d88995812ccc333541","type":"TRIAL","name":"A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents","canonical_id":"clinicaltrials.gov:NCT06470178","description":"Colorectal Cancer","metadata":null},{"id":"5f550fa020b1429da8cbabc8af6fff52","type":"TRIAL","name":"A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)","canonical_id":"clinicaltrials.gov:NCT06680817","description":"Neovascular Age-related Macular Degeneration; Diabetic Macular Edema","metadata":null},{"id":"c088d3f738f74800959d534eba557d20","type":"TRIAL","name":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","canonical_id":"clinicaltrials.gov:NCT05476926","description":"Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion; Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Hemi-retinal Vein Occlusion","metadata":null},{"id":"fd59adff6aa04232ac3819e5abb03641","type":"TRIAL","name":"A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05744466","description":"Psoriasis","metadata":null},{"id":"2e7d247fd7da4e0ea9368f5bcdc4125c","type":"TRIAL","name":"A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features","canonical_id":"clinicaltrials.gov:NCT06999941","description":"Psoriasis; Eczema; JAK Inhibitor","metadata":null},{"id":"84fb533016854bc3b637449b24700048","type":"TRIAL","name":"A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC","canonical_id":"clinicaltrials.gov:NCT07418879","description":"Non-small Cell Lung Cancer; RET Fusion; Pralsetinib","metadata":null},{"id":"ef643c8bb5d747b0ae14f88075b9f2b5","type":"TRIAL","name":"A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL","canonical_id":"clinicaltrials.gov:NCT05883709","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"ffe18b897f5a439b8f0f15cf3a513ae6","type":"TRIAL","name":"A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)","canonical_id":"clinicaltrials.gov:NCT06701513","description":"Psoriasis","metadata":null},{"id":"3d139e9288074521b868974b38823ee4","type":"TRIAL","name":"A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT05942222","description":"Chronic Rhinosinusitis With Nasal Polyps; Asthma; Eosinophilic; Eosinophilia","metadata":null},{"id":"0aea4652fe7245cc8b79a8f4e8c4ff01","type":"TRIAL","name":"A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss","canonical_id":"clinicaltrials.gov:NCT06909123","description":"Lactation Suppressed","metadata":null},{"id":"86b71c178a6f4d53acfab363c169ebd8","type":"TRIAL","name":"A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT05757310","description":"Recurrent Severe Aplastic Anemia; Refractory Severe Aplastic Anemia","metadata":null},{"id":"809323def558432fb5e92c88c46fba42","type":"TRIAL","name":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","canonical_id":"clinicaltrials.gov:NCT03572231","description":"Overactive Bladder (OAB)","metadata":null},{"id":"7af65fbbd3734571b3402f37339242f1","type":"TRIAL","name":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-na\u00efve Prostate Cancer in Japan","canonical_id":"clinicaltrials.gov:NCT04034095","description":"Prostatic Neoplasms","metadata":null},{"id":"aa7f172f23524747b5dcde70f91846c8","type":"TRIAL","name":"A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization","canonical_id":"clinicaltrials.gov:NCT01157455","description":"Coronary Artery Diseases","metadata":null},{"id":"b0a5321d860749d6b77478470151288a","type":"TRIAL","name":"A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS","canonical_id":"clinicaltrials.gov:NCT02463825","description":"Amyotrophic Lateral Sclerosis (ALS)","metadata":null},{"id":"fad24f7494784329bcbdcd579d041299","type":"TRIAL","name":"A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda\u00ae(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.","canonical_id":"clinicaltrials.gov:NCT03560336","description":"Obesity; Overweight","metadata":null},{"id":"7f7cc5d73a434c82aae9b690ac6034ed","type":"TRIAL","name":"A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01893866","description":"Healthy Volunteers","metadata":null},{"id":"5983be2c06df4509a57cde86d04bde8d","type":"TRIAL","name":"A Relative Bioavailability Study With a Novel PanCytoVir\u2122 Oral Suspension (100 mg/ml)","canonical_id":"clinicaltrials.gov:NCT06025344","description":"Relative Bioavailability","metadata":null},{"id":"b441399423004a0bbd3bb6518d8260c4","type":"TRIAL","name":"A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01079065","description":"Healthy","metadata":null},{"id":"52a2333439154fbf8c13643377ca4449","type":"TRIAL","name":"A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01079052","description":"Healthy","metadata":null},{"id":"6d3963e7dbdb4bb88b1bd8a6592d20af","type":"TRIAL","name":"A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00864149","description":"Healthy","metadata":null},{"id":"3ff1d6302e3d42e68e8f76b80674a9b2","type":"TRIAL","name":"A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00870480","description":"Healthy","metadata":null},{"id":"20058d819fb741aea146bc2d64a644b7","type":"TRIAL","name":"A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00871247","description":"Healthy","metadata":null},{"id":"4c93f26a78654e8e80ad0ca22aed2001","type":"TRIAL","name":"A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00865696","description":"Healthy","metadata":null},{"id":"7f50339b35e64258a330b4e518e0f88e","type":"TRIAL","name":"A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00865384","description":"Healthy","metadata":null},{"id":"f6fa41e8484b43e0afcfd6df6128e0f1","type":"TRIAL","name":"A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00992862","description":"Healthy","metadata":null},{"id":"6e2e7315cfdd46ddbba7173e0dcf7855","type":"TRIAL","name":"A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00864344","description":"Healthy","metadata":null},{"id":"580c96a0129d45859832774d0eb01da6","type":"TRIAL","name":"A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323","canonical_id":"clinicaltrials.gov:NCT02094924","description":"Hypertension","metadata":null},{"id":"44927e458ef046ebaece8632ba005048","type":"TRIAL","name":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","canonical_id":"clinicaltrials.gov:NCT05579249","description":"Obesity","metadata":null},{"id":"dfeb0a9033b6486d9462d8172ea8da4c","type":"TRIAL","name":"A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease","canonical_id":"clinicaltrials.gov:NCT04992065","description":"Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"8634c58892e14c0dab030fa3f4df3ce4","type":"TRIAL","name":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice","canonical_id":"clinicaltrials.gov:NCT04537637","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"5630a2d1688c4fae89e1c23a09422398","type":"TRIAL","name":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice","canonical_id":"clinicaltrials.gov:NCT03457012","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"40d077bdc01d4c33bccbd7e1d1a0eb47","type":"TRIAL","name":"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice","canonical_id":"clinicaltrials.gov:NCT04067999","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"bc6f9775da4d434cba8ed1e7b49a0582","type":"TRIAL","name":"A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting","canonical_id":"clinicaltrials.gov:NCT00440232","description":"Migraine","metadata":null},{"id":"d5189113f4ad47fe85a3360300a9a8f9","type":"TRIAL","name":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT04734197","description":"Dry Eye Disease","metadata":null},{"id":"daedd0bf574148bdb990ff202acec56c","type":"TRIAL","name":"A Research Study for Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00106418","description":"Prostate Cancer; Metastases","metadata":null},{"id":"27fea233a16f424aa95af5f25817abdd","type":"TRIAL","name":"A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is","canonical_id":"clinicaltrials.gov:NCT04786873","description":"Growth Hormone Deficiency","metadata":null},{"id":"f51c66ebac614322b0d9da9d1bd71ce8","type":"TRIAL","name":"A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens","canonical_id":"clinicaltrials.gov:NCT04238962","description":"Overweight; Obesity","metadata":null},{"id":"caad32e929f54d36b53166716fc040b2","type":"TRIAL","name":"A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity","canonical_id":"clinicaltrials.gov:NCT04969939","description":"Obesity","metadata":null},{"id":"ee7ed203368d428a867e958212a22928","type":"TRIAL","name":"A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity","canonical_id":"clinicaltrials.gov:NCT06780449","description":"Obesity","metadata":null},{"id":"46a31fe14ae44a39a9713e826ff59154","type":"TRIAL","name":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","canonical_id":"clinicaltrials.gov:NCT06534411","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"29e9731547f74e19bd5a95892719b9ae","type":"TRIAL","name":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)","canonical_id":"clinicaltrials.gov:NCT05259033","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"2f23898e25394fbaa00bf55c0f747c95","type":"TRIAL","name":"A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT00108953","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"f7e17adbe4d74d9fb8ac22cd4598cacb","type":"TRIAL","name":"A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients","canonical_id":"clinicaltrials.gov:NCT01607593","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"9c136d7ba9884d56ba5f837b671b56bc","type":"TRIAL","name":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","canonical_id":"clinicaltrials.gov:NCT04115423","description":"Infection; Rheumatoid Arthritis","metadata":null},{"id":"f16866fecb3d4f74b9cae2488b4ee043","type":"TRIAL","name":"A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis","canonical_id":"clinicaltrials.gov:NCT06410040","description":"ALK-positive Non-small Cell Lung Cancer; Brain Metastases; Meningeal Metastasis","metadata":null},{"id":"e4c8957ce95f4869a885b47525108a30","type":"TRIAL","name":"A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT06195228","description":"Advanced Thyroid Cancer Patients Who Received Target Therapy","metadata":null},{"id":"9a689e2e97b8411792e61d938ec6b6e3","type":"TRIAL","name":"A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)","canonical_id":"clinicaltrials.gov:NCT05785468","description":"Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"92a0067413ce4cfbb2092718d653d6be","type":"TRIAL","name":"A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon","canonical_id":"clinicaltrials.gov:NCT00498615","description":"Raynaud; Scleroderma","metadata":null},{"id":"f1d020633e844acab8970b6058167d79","type":"TRIAL","name":"A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)","canonical_id":"clinicaltrials.gov:NCT04138875","description":"PTLD; Lymphoid Tumor; Hematopoietic/Lymphoid Cancer; Plasmacytic Hyperplasia PTLD; Infectious Mononucleosis; Florid Follicular Hyperplasia PTLD; Polymorphic PTLD; Monomorphic PTLD; Classical Hodgkin Lymphoma Type PTLD","metadata":null},{"id":"95bc38cabcfb4b99b8c9269be8e873f7","type":"TRIAL","name":"A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols","canonical_id":"clinicaltrials.gov:NCT01369433","description":"Solid Tumors","metadata":null},{"id":"e7d170d604024a669f1ac61942d8d42b","type":"TRIAL","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","canonical_id":"clinicaltrials.gov:NCT07172919","description":"Advanced Solid Tumors","metadata":null},{"id":"49c8ab8a397144e487da25d0c9b20e44","type":"TRIAL","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","canonical_id":"clinicaltrials.gov:NCT05862285","description":"Cancer","metadata":null},{"id":"306085aa8b0043a1b56df231919b344a","type":"TRIAL","name":"A Rollover Study for Patients Who Participated in Other Romidepsin Protocols","canonical_id":"clinicaltrials.gov:NCT01353664","description":"Lymphoma; Cancer","metadata":null},{"id":"e293c749822c4b95903ebe63acfb53d7","type":"TRIAL","name":"A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged \u226514 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.","canonical_id":"clinicaltrials.gov:NCT05027802","description":"Fibrodysplasia Ossificans Progressiva (FOP)","metadata":null},{"id":"2f0105e98d6348ecae00e55294293352","type":"TRIAL","name":"A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia","canonical_id":"clinicaltrials.gov:NCT07542756","description":"Insomnia; Insomnia Disorder; Chronic Insomnia; Chronic Insomnia Disorder","metadata":null},{"id":"062cb3ec0c54494f8515297bb3f7e761","type":"TRIAL","name":"A SU2C Catalyst\u00ae Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03331562","description":"Pancreatic Cancer; Pancreas Adenocarcinoma; Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma","metadata":null},{"id":"d318c026fc4b4e06ba12aafedf7a62a4","type":"TRIAL","name":"A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00923182","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"598f2f3500ac4bbdacfebc86aa946a21","type":"TRIAL","name":"A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation","canonical_id":"clinicaltrials.gov:NCT00067730","description":"Sepsis; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Infection","metadata":null},{"id":"c3f954c08a8a46e8bd92573d5607e313","type":"TRIAL","name":"A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo","canonical_id":"clinicaltrials.gov:NCT00158093","description":"Hypertension","metadata":null},{"id":"d9fcafc9f8834720b7da6288a5d181bb","type":"TRIAL","name":"A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers","canonical_id":"clinicaltrials.gov:NCT04926324","description":"Rectal Neoplasms; Rectal Neoplasm Malignant","metadata":null},{"id":"0a0dfb31a256478ba394cffd34ab64f0","type":"TRIAL","name":"A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01830140","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"fcdabae4411f45ecad0ebbbeedf85ea1","type":"TRIAL","name":"A Safety Study of Brentuximab Vedotin in Participants With HIV","canonical_id":"clinicaltrials.gov:NCT05244473","description":"Human Immunodeficiency Virus","metadata":null},{"id":"f3f579f3144a492182575e889116d4ff","type":"TRIAL","name":"A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT06862219","description":"Metastatic Urothelial Carcinoma","metadata":null},{"id":"2c3fc473d121403a82820cb23cf28580","type":"TRIAL","name":"A Safety Study of Eptifibatide in Patients With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT00834899","description":"Sickle Cell Disease","metadata":null},{"id":"7b5c743cdb404f39940048ea4c8c9c1b","type":"TRIAL","name":"A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma","canonical_id":"clinicaltrials.gov:NCT02490930","description":"Glioblastoma; Anaplastic Astrocytoma","metadata":null},{"id":"50e95b68f4db49b88a133ec208bb9e27","type":"TRIAL","name":"A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura","canonical_id":"clinicaltrials.gov:NCT02614287","description":"Migraine","metadata":null},{"id":"9c402768169a4069b8c0ee8d5d1d86f4","type":"TRIAL","name":"A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT02517021","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"34d7599b2782494fbd2248887cc5de87","type":"TRIAL","name":"A Safety Study of Mirikizumab (LY3074828)","canonical_id":"clinicaltrials.gov:NCT01947933","description":"Psoriasis","metadata":null},{"id":"3f2a0bb0e2fd491383d50ad0d8f932f1","type":"TRIAL","name":"A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease","canonical_id":"clinicaltrials.gov:NCT03575052","description":"Neuropsychiatric Symptoms Related to Neurodegenerative Disease","metadata":null},{"id":"79eb56afa85748e9a30e1d799668da93","type":"TRIAL","name":"A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects","canonical_id":"clinicaltrials.gov:NCT03722823","description":"Hepatic Impairment","metadata":null},{"id":"483d2e43cef842e0be26035fcc3a5376","type":"TRIAL","name":"A Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach","canonical_id":"clinicaltrials.gov:NCT00261586","description":"Analgesics","metadata":null},{"id":"9ed31d8e38c84c40b5f97103113f1be6","type":"TRIAL","name":"A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.","canonical_id":"clinicaltrials.gov:NCT01863771","description":"Colitis, Ulcerative","metadata":null},{"id":"3190622f757a4d089197f01556781a24","type":"TRIAL","name":"A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults","canonical_id":"clinicaltrials.gov:NCT02481947","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"63c72322a85144d2a3801e6a8820bf0e","type":"TRIAL","name":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","canonical_id":"clinicaltrials.gov:NCT00242580","description":"Macular Degeneration; Choroidal Neovascularization","metadata":null},{"id":"56a4e57825a54e47ad562188974c80bb","type":"TRIAL","name":"A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00528697","description":"Attention-Deficit/Hyperactivity Disorder","metadata":null},{"id":"e895944e93074511a8d04a7973e4e37b","type":"TRIAL","name":"A Safety and Efficacy Study of ALPHAGAN\u00ae P and LUMIGAN\u00ae in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01525173","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"5caa8da7cf694809ad6b7a51ffadbd60","type":"TRIAL","name":"A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus","canonical_id":"clinicaltrials.gov:NCT00135733","description":"Lichen Planus","metadata":null},{"id":"8f2a618ffbc7420e918a5b926debec53","type":"TRIAL","name":"A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)","canonical_id":"clinicaltrials.gov:NCT04814368","description":"Knee Osteoarthritis","metadata":null},{"id":"90fadd854712473d9dcf4c18e4899acd","type":"TRIAL","name":"A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00483964","description":"Schizophrenia","metadata":null},{"id":"6123826f551c40c8a2d85f5d4925f1c3","type":"TRIAL","name":"A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01106651","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"d6ec065095d844bf9f99c2d70cafae56","type":"TRIAL","name":"A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01464034","description":"Multiple Myeloma","metadata":null},{"id":"64a1ca1b748a488988f9be1634aec484","type":"TRIAL","name":"A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).","canonical_id":"clinicaltrials.gov:NCT01451541","description":"Perennial Allergic Rhinitis; PAR","metadata":null},{"id":"c8d50a53db0f48a28247e8a0b636bb39","type":"TRIAL","name":"A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)","canonical_id":"clinicaltrials.gov:NCT01458275","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"5ec30c5e78ab4b99ba9e3ad93074f85a","type":"TRIAL","name":"A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT04707079","description":"Follicular Lymphoma","metadata":null},{"id":"cca25a0cba16471aa8f069ee35f7e755","type":"TRIAL","name":"A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03641560","description":"Metastatic Castration Resistant Prostate Cancer","metadata":null},{"id":"f351cef91d204840ac58e9c2320af7fa","type":"TRIAL","name":"A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung","canonical_id":"clinicaltrials.gov:NCT01218516","description":"Adenocarcinoma of the Lung","metadata":null},{"id":"7a6137c02450400caf04b3badb46e076","type":"TRIAL","name":"A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01114698","description":"Depression","metadata":null},{"id":"725063a6d4104b12875dbbe4af581392","type":"TRIAL","name":"A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT02078609","description":"AML and High Risk MDS","metadata":null},{"id":"6e28c7158a9340c3a799e1c375bf7f39","type":"TRIAL","name":"A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma","canonical_id":"clinicaltrials.gov:NCT03562195","description":"Asthma","metadata":null},{"id":"530b098ac37549f7b65e031b621073a8","type":"TRIAL","name":"A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis","canonical_id":"clinicaltrials.gov:NCT01903798","description":"Alcoholic Hepatitis","metadata":null},{"id":"c223777047ad44459bbab5234ccd6b0f","type":"TRIAL","name":"A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.","canonical_id":"clinicaltrials.gov:NCT01821677","description":"Diabetic Macular Edema","metadata":null},{"id":"1adfd87812c541b99ad49b722da04bba","type":"TRIAL","name":"A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01917019","description":"Multiple Sclerosis, Remittent Progressive; Multiple Sclerosis, Primary Progressive; Relapsing-Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple Sclerosis","metadata":null},{"id":"6d0e765012764be8bdd90002156eb191","type":"TRIAL","name":"A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants","canonical_id":"clinicaltrials.gov:NCT01309386","description":"Neoplasms","metadata":null},{"id":"1a2e85cf27f04fa59fe7bf34a76f0f91","type":"TRIAL","name":"A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder","canonical_id":"clinicaltrials.gov:NCT01685151","description":"Bipolar Disorder","metadata":null},{"id":"2cd4201ebb534e86b8961f2821d7828d","type":"TRIAL","name":"A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT04180982","description":"Hyperuricemia","metadata":null},{"id":"36d5f2d6209648b18c9cddbb4eabd30c","type":"TRIAL","name":"A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males","canonical_id":"clinicaltrials.gov:NCT02781311","description":"Alopecia","metadata":null},{"id":"0fdc522ddab74255983a11a46329a7f8","type":"TRIAL","name":"A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)","canonical_id":"clinicaltrials.gov:NCT00385827","description":"Cancer, Prostate","metadata":null},{"id":"7084d59608cd4e1391567c217b0ea1e9","type":"TRIAL","name":"A Safety and Efficacy Study of Tralokinumab in Adults With Asthma","canonical_id":"clinicaltrials.gov:NCT01402986","description":"Asthma","metadata":null},{"id":"ead58d7e1fa54af09598ff2d83501e41","type":"TRIAL","name":"A Safety and Efficacy Study of Xolair in Peanut Allergy","canonical_id":"clinicaltrials.gov:NCT00086606","description":"Allergy","metadata":null},{"id":"96fa63c8ee9b42e9a70d486303b7f276","type":"TRIAL","name":"A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation","canonical_id":"clinicaltrials.gov:NCT02559817","description":"Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"bc2e6aee16cb449e83a601193455f7bf","type":"TRIAL","name":"A Safety and Efficacy Study of the Dynalink\u00ae-E Everolimus Eluting Peripheral Stent System","canonical_id":"clinicaltrials.gov:NCT00475566","description":"Atherosclerosis; Peripheral Vascular Disease","metadata":null},{"id":"580bf635fda14bae92d480e6df3c03c1","type":"TRIAL","name":"A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention","canonical_id":"clinicaltrials.gov:NCT02630459","description":"Migraine","metadata":null},{"id":"ea96076090fc4cd5b2e99ca26274d303","type":"TRIAL","name":"A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT00302445","description":"Plaque Psoriasis","metadata":null},{"id":"92b945c68641417ca588c58adeb473d1","type":"TRIAL","name":"A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT02791516","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"fa8e07eaec6d4fb4a9e3b8fae8293c1d","type":"TRIAL","name":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","canonical_id":"clinicaltrials.gov:NCT00368277","description":"Hypertension","metadata":null},{"id":"35961873430e4dfdbe36878f83bafd3c","type":"TRIAL","name":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT03310619","description":"Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular","metadata":null},{"id":"998336a2c3464f48aa895074e57ec404","type":"TRIAL","name":"A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT00386139","description":"Hypertension","metadata":null},{"id":"604fe600cd0b4cfd88d232dcf2b2cd63","type":"TRIAL","name":"A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01592110","description":"Schizophrenia","metadata":null},{"id":"01e2c6ecf3f9411ba9ce3deadc65fdd3","type":"TRIAL","name":"A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium","canonical_id":"clinicaltrials.gov:NCT01242579","description":"HIV Infections","metadata":null},{"id":"8c4829de69bd41ed833e9b1dbe5dff2f","type":"TRIAL","name":"A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)","canonical_id":"clinicaltrials.gov:NCT02924766","description":"Prostatic Neoplasms","metadata":null},{"id":"f4ef9983d70e483c9badd8fcda07cc9b","type":"TRIAL","name":"A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02220842","description":"Lymphoma","metadata":null},{"id":"78f1a6a5aae8433b9a3a05d8b093e664","type":"TRIAL","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)","canonical_id":"clinicaltrials.gov:NCT03930953","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"95671dd34c964678944f16c41c815a51","type":"TRIAL","name":"A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT02106195","description":"Psoriasis Vulgaris","metadata":null},{"id":"facdc99f5526461eb443d20875dc61eb","type":"TRIAL","name":"A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)","canonical_id":"clinicaltrials.gov:NCT00991133","description":"Lymphoblastic Leukemia, Acute, Childhood","metadata":null},{"id":"7635ef662e374375aa4e7f15ad57d3c2","type":"TRIAL","name":"A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia","canonical_id":"clinicaltrials.gov:NCT00515034","description":"Pneumonia, Ventilator-Associated; Pneumonia, Bacterial; Pneumonia; Abdominal Abscess; Bacterial Infections","metadata":null},{"id":"67b3289932dc45b5b35e82c0ef1caef1","type":"TRIAL","name":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","canonical_id":"clinicaltrials.gov:NCT01185028","description":"Hepatitis C Infection; HIV Infection","metadata":null},{"id":"dbba8b8969c543fe9b00267c522f3067","type":"TRIAL","name":"A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.","canonical_id":"clinicaltrials.gov:NCT00629876","description":"Anemia","metadata":null},{"id":"87b43d2be0d64383999192b4fd1fe0eb","type":"TRIAL","name":"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.","canonical_id":"clinicaltrials.gov:NCT00386607","description":"Hypertension","metadata":null},{"id":"0008dedb0d5b439ab596c51cbc50e594","type":"TRIAL","name":"A Safety, Efficacy and Tolerability Study of SEP-225289","canonical_id":"clinicaltrials.gov:NCT00584974","description":"Depressive Disorder, Major","metadata":null},{"id":"86fc3cae735d498daac017842c264187","type":"TRIAL","name":"A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)","canonical_id":"clinicaltrials.gov:NCT05176639","description":"Thyroid Eye Disease","metadata":null},{"id":"7cb65cf8fd3e4b2483b05c5ed75b4dda","type":"TRIAL","name":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT02096601","description":"Parkinson's Disease","metadata":null},{"id":"f22d01f8601842c8b6209af75b3c40d1","type":"TRIAL","name":"A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects","canonical_id":"clinicaltrials.gov:NCT03914755","description":"Healthy","metadata":null},{"id":"684713ba1a5740a2a342710a3c3ead7a","type":"TRIAL","name":"A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks","canonical_id":"clinicaltrials.gov:NCT00719914","description":"ST-Elevation Myocardial Infarction","metadata":null},{"id":"122b4285921d4207ae3f9a47327df69e","type":"TRIAL","name":"A Safety/Tolerability and PK Study With Azstarys\u00ae in Children With ADHD","canonical_id":"clinicaltrials.gov:NCT05721235","description":"Attention Deficit/Hyperactivity Disorder","metadata":null},{"id":"6b04791da57744a1928471708e771210","type":"TRIAL","name":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","canonical_id":"clinicaltrials.gov:NCT03311555","description":"Prostate Cancer","metadata":null},{"id":"9efcda640dbc40d5b0d2b3a12b581bc5","type":"TRIAL","name":"A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole","canonical_id":"clinicaltrials.gov:NCT07199504","description":"Restless Leg Syndrome Due to Uraemia","metadata":null},{"id":"f722637fa0ef48c8ade09e8054212cc1","type":"TRIAL","name":"A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain","canonical_id":"clinicaltrials.gov:NCT04504812","description":"Knee Osteoarthritis","metadata":null},{"id":"cc5c0d085ca542fe8ebaaa646a3193b8","type":"TRIAL","name":"A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin","canonical_id":"clinicaltrials.gov:NCT03449251","description":"Cardiovascular Diseases; Type 2 Diabetes Mellitus","metadata":null},{"id":"ac7d54fb8c894b5abf3a2074d1c73faa","type":"TRIAL","name":"A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT00150241","description":"Smoking Cessation","metadata":null},{"id":"f4f6e80f8d094608a8435ae51c75dbd1","type":"TRIAL","name":"A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01942161","description":"Schizophrenia","metadata":null},{"id":"4fcd1ae00398457fa63d91991bb408c6","type":"TRIAL","name":"A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities","canonical_id":"clinicaltrials.gov:NCT01787383","description":"Actinic Keratosis","metadata":null},{"id":"27f84eee9f8a41deb2891d50e74683b9","type":"TRIAL","name":"A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL","canonical_id":"clinicaltrials.gov:NCT03349333","description":"Refractory Peripheral T-Cell Lymphoma; Relapsed T-Cell Lymphoma","metadata":null},{"id":"af701bd1fef048bdb43e4e4d70b727b6","type":"TRIAL","name":"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04486716","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"748812cc308043bc823ee8a077ec2d8e","type":"TRIAL","name":"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)","canonical_id":"clinicaltrials.gov:NCT04520269","description":"Breast Cancer","metadata":null},{"id":"3cb061761dfa47998dea653e8f2cec8b","type":"TRIAL","name":"A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex\u00ae ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02447328","description":"Locally Advanced or; Metastatic Breast Cancer","metadata":null},{"id":"8eafbb0ba8bb4a72935a1412c031bded","type":"TRIAL","name":"A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01316848","description":"Food Effect of Tivozanib in Health Subjects","metadata":null},{"id":"79d676909c384a7c84289e39d5c19984","type":"TRIAL","name":"A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01142063","description":"Healthy","metadata":null},{"id":"9f44231c65e343739ff6c7d182f51527","type":"TRIAL","name":"A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age","canonical_id":"clinicaltrials.gov:NCT02398669","description":"Obesity","metadata":null},{"id":"f2d7979df5b34549a97688732ab98736","type":"TRIAL","name":"A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01314898","description":"Healthy Volunteers","metadata":null},{"id":"5b220965efa442a5a22d55f4cdd97a71","type":"TRIAL","name":"A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults","canonical_id":"clinicaltrials.gov:NCT05040295","description":"Healthy Participants","metadata":null},{"id":"40a5cabac17a47c182c0064aea2d4647","type":"TRIAL","name":"A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)","canonical_id":"clinicaltrials.gov:NCT01628042","description":"Overactive Bladder","metadata":null},{"id":"43b51d4c191a47919defc92af5f18bc6","type":"TRIAL","name":"A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT00673088","description":"Parkinson's Disease; Restless Leg Syndrome","metadata":null},{"id":"524d27bec5294174b4ad9d1932379a7e","type":"TRIAL","name":"A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)","canonical_id":"clinicaltrials.gov:NCT00989079","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"45e9422f91214b3dac4c933fcad424c3","type":"TRIAL","name":"A Single Patient Study of Sapropterin for Multisystem Smooth Muscle Dysfunction Syndrome","canonical_id":"clinicaltrials.gov:NCT07574034","description":"Multisystemic Smooth Muscle Dysfunction Syndrome","metadata":null},{"id":"c6f8ebf202924fb8b275f39b1502a1d9","type":"TRIAL","name":"A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT06717269","description":"Healthy Volunteer","metadata":null},{"id":"71dfe161284a41599b1cd397148ccf1b","type":"TRIAL","name":"A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05278676","description":"Healthy Volunteers","metadata":null},{"id":"aee495b41ea542edbae0a7bc9c184666","type":"TRIAL","name":"A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT04555733","description":"Healthy Volunteer","metadata":null},{"id":"bed3897fdacb4931b9e3ca0518d7df2a","type":"TRIAL","name":"A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers","canonical_id":"clinicaltrials.gov:NCT03887221","description":"Healthy","metadata":null},{"id":"d45d8a1845f2487b88d767feef77a5f7","type":"TRIAL","name":"A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT06981858","description":"LOCALLY ADVANCED CERVICAL CANCERS","metadata":null},{"id":"27ad3644a32343e39c810b2d7195d39c","type":"TRIAL","name":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","canonical_id":"clinicaltrials.gov:NCT05593497","description":"High-Risk Prostate Cancer","metadata":null},{"id":"7017e78d5bab4090a9c0dd0f2e05d251","type":"TRIAL","name":"A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07828873","description":"Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"ee393be575864f21807d20ebc2f9e5be","type":"TRIAL","name":"A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00796211","description":"Plaque Psoriasis","metadata":null},{"id":"5ffeb1efc73c400f8ca22e24004a7aff","type":"TRIAL","name":"A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)","canonical_id":"clinicaltrials.gov:NCT06681623","description":"Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis","metadata":null},{"id":"b57f5dc3937240ce9059c725cf9b8157","type":"TRIAL","name":"A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema","canonical_id":"clinicaltrials.gov:NCT01487044","description":"Diabetic Macular Edema","metadata":null},{"id":"14ccc6b3bc06499686d4758ab1bf42a3","type":"TRIAL","name":"A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT01487070","description":"PDR","metadata":null},{"id":"82d55e8cbc254946b9ac96f685ede02e","type":"TRIAL","name":"A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia","canonical_id":"clinicaltrials.gov:NCT03201562","description":"Presbyopia","metadata":null},{"id":"f4ae1bbaaf9c45d78a5f6687402a8421","type":"TRIAL","name":"A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms","canonical_id":"clinicaltrials.gov:NCT00637884","description":"Cat Induced Allergic Rhinitis","metadata":null},{"id":"b568a8d1cbdc44088d3801e48c94ac47","type":"TRIAL","name":"A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00902161","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e7d6decac8374e88aaea9781a73a4a44","type":"TRIAL","name":"A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function","canonical_id":"clinicaltrials.gov:NCT01631097","description":"Hepatic Impairment","metadata":null},{"id":"efd6b26fd61e427aa5956f9325823b86","type":"TRIAL","name":"A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)","canonical_id":"clinicaltrials.gov:NCT01737684","description":"Overactive Bladder","metadata":null},{"id":"3beb27ca1063488eb858abede8bfcd16","type":"TRIAL","name":"A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function","canonical_id":"clinicaltrials.gov:NCT01761773","description":"Healthy; Renal Impairment","metadata":null},{"id":"10b5d9f7e8b14831bcbf92453e066e6b","type":"TRIAL","name":"A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)","canonical_id":"clinicaltrials.gov:NCT01275170","description":"Infectious Disease","metadata":null},{"id":"52bbfd6fae1a4947ab54c87c9f05885b","type":"TRIAL","name":"A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00674310","description":"Parkinson's Disease; Restless Leg Syndrome","metadata":null},{"id":"a6088e9c64e34780ba9fbcb517dc4623","type":"TRIAL","name":"A Single-arm Exploratory Study of Neoadjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT05527808","description":"Lung Adenocarcinoma","metadata":null},{"id":"ab765b243f5240d8b7742072d14d5113","type":"TRIAL","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy","canonical_id":"clinicaltrials.gov:NCT07728955","description":"Small Cell Lung Cancer ( SCLC )","metadata":null},{"id":"3b942bc0bca249ea9c1663aaa677bec0","type":"TRIAL","name":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT06553781","description":"Malignant Melanoma","metadata":null},{"id":"bfb93f7a9cf14a4ba21d1f55f713ec67","type":"TRIAL","name":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance","canonical_id":"clinicaltrials.gov:NCT07622550","description":"Metastatic Colorectal Cancer (CRC)","metadata":null},{"id":"925039e767ed482b9c5c26cd1933888d","type":"TRIAL","name":"A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT07619235","description":"Biliary Tract Cancer (BTC)","metadata":null},{"id":"3f5c0d3742e2452e83744df74dab7cb2","type":"TRIAL","name":"A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.","canonical_id":"clinicaltrials.gov:NCT05747729","description":"Neuroendocrine Carcinoma","metadata":null},{"id":"13e98c731cc9451388e59a006df63a1c","type":"TRIAL","name":"A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT05941325","description":"Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma","metadata":null},{"id":"f9b39c49e553483fbef07a94e28b55b6","type":"TRIAL","name":"A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects","canonical_id":"clinicaltrials.gov:NCT02679469","description":"Alcohol Dependence","metadata":null},{"id":"0ace2f54f4e04579896f82ab73007b20","type":"TRIAL","name":"A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT07108816","description":"Resectable Stage II-IIIB NSCLC","metadata":null},{"id":"26bc40b8fa7a4f6d8fd17a2c78709dab","type":"TRIAL","name":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07347951","description":"Locally Advanced Rectal Cancer (LARC)","metadata":null},{"id":"d99c969a535d48f3b362d900929607cb","type":"TRIAL","name":"A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women","canonical_id":"clinicaltrials.gov:NCT01101061","description":"Osteopenia","metadata":null},{"id":"bf84acfb876b4545b5290a9bebed0a2d","type":"TRIAL","name":"A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)","canonical_id":"clinicaltrials.gov:NCT00506389","description":"Insomnia","metadata":null},{"id":"b31f3f02743848239ce817f843498451","type":"TRIAL","name":"A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression","canonical_id":"clinicaltrials.gov:NCT00141271","description":"Bipolar Disorder","metadata":null},{"id":"d9beff27161346199e8a576560bf188a","type":"TRIAL","name":"A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis","canonical_id":"clinicaltrials.gov:NCT01537042","description":"Restless Legs Syndrome; End-Stage Renal Disease","metadata":null},{"id":"216566117e7949b9b2eea1397518b58d","type":"TRIAL","name":"A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05544812","description":"Colorectal Cancer","metadata":null},{"id":"4adf155b851b4e1f9af88bfc0a97a32d","type":"TRIAL","name":"A Smoking Cessation Intervention for Yale Dining Employees","canonical_id":"clinicaltrials.gov:NCT02562521","description":"Smoking Cessation","metadata":null},{"id":"22e63414d0a144718d49b6d9d0914ffc","type":"TRIAL","name":"A Stepwise Strategy Utilizing Buprenorphine and Methadone","canonical_id":"clinicaltrials.gov:NCT00310934","description":"Heroin Dependence","metadata":null},{"id":"1d3bacaf067e46ddabd89cb07cdf8c1c","type":"TRIAL","name":"A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period","canonical_id":"clinicaltrials.gov:NCT06108544","description":"Plaque Psoriasis","metadata":null},{"id":"e7eb51793c9f47c6b62a4c6492f3f0a4","type":"TRIAL","name":"A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients","canonical_id":"clinicaltrials.gov:NCT01007630","description":"Parkinson's Disease","metadata":null},{"id":"fe528d6089584cbf9b6e38a7f606fb0f","type":"TRIAL","name":"A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)","canonical_id":"clinicaltrials.gov:NCT00160667","description":"Neuralgia, Postherpetic","metadata":null},{"id":"ac7cdc7ea03f49d6ad20405b32983871","type":"TRIAL","name":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","canonical_id":"clinicaltrials.gov:NCT00374907","description":"Type 2 Diabetes","metadata":null},{"id":"95e60ecd835843c599f2bad591b0ae44","type":"TRIAL","name":"A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne","canonical_id":"clinicaltrials.gov:NCT06336629","description":"Acne Vulgaris","metadata":null},{"id":"d666ef8a8f7948e6b75972fb920699bf","type":"TRIAL","name":"A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)","canonical_id":"clinicaltrials.gov:NCT02293902","description":"Rheumatoid Arthritis","metadata":null},{"id":"dea7ace562094d4aa82e883fb36573a4","type":"TRIAL","name":"A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne","canonical_id":"clinicaltrials.gov:NCT06336603","description":"Acne Vulgaris","metadata":null},{"id":"1bf2faba217e4bccb3f0ad1f3fd3e05c","type":"TRIAL","name":"A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT","canonical_id":"clinicaltrials.gov:NCT01654484","description":"Glaucoma and Ocular Hypertension","metadata":null},{"id":"3e181eda1a5d4195aa71950e53e76e18","type":"TRIAL","name":"A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)","canonical_id":"clinicaltrials.gov:NCT02373202","description":"Rheumatoid Arthritis","metadata":null},{"id":"86ffa1b4b427449c8f154c8f592c0e76","type":"TRIAL","name":"A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone","canonical_id":"clinicaltrials.gov:NCT03633591","description":"Healthy Volunteers","metadata":null},{"id":"bb9da2c942b04de2bcc2de51acb6cba8","type":"TRIAL","name":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","canonical_id":"clinicaltrials.gov:NCT04295005","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"2f403ff374b244aaa2b3bae2031bc58a","type":"TRIAL","name":"A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT03979807","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"fcdce4cf342b4f5fac5ddf6f7937b4c1","type":"TRIAL","name":"A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib","canonical_id":"clinicaltrials.gov:NCT06200714","description":"Idiopathic Pulmonary Fibrosis; Diarrhoea","metadata":null},{"id":"33b0adbe7bd748c397356a26431d5f51","type":"TRIAL","name":"A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide","canonical_id":"clinicaltrials.gov:NCT05526248","description":"Biochemically Recurrent Prostate Cancer","metadata":null},{"id":"8af5b526909942a78dc6e5dd86969ee7","type":"TRIAL","name":"A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy","canonical_id":"clinicaltrials.gov:NCT01478594","description":"Colorectal Cancer","metadata":null},{"id":"0dc4c1ac599248bd8bc1ff88e5a2744c","type":"TRIAL","name":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT05926960","description":"Melanoma","metadata":null},{"id":"6fdec51c1d6f44bdbea9119768eac0c7","type":"TRIAL","name":"A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients","canonical_id":"clinicaltrials.gov:NCT04237584","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"98e68d3fd054429f857168e8e5505d2d","type":"TRIAL","name":"A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease","canonical_id":"clinicaltrials.gov:NCT03729362","description":"Pompe Disease (Late-onset)","metadata":null},{"id":"7e7583046b0e4010a2004784fd71fda3","type":"TRIAL","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","canonical_id":"clinicaltrials.gov:NCT07391657","description":"Relapsed Refractory Multiple Myeloma","metadata":null},{"id":"84de08e281574ef0ba7dfec3a96db675","type":"TRIAL","name":"A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE","canonical_id":"clinicaltrials.gov:NCT05171075","description":"Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism","metadata":null},{"id":"673c114370904819b8cc55b2580be771","type":"TRIAL","name":"A Study Comparing Aczone\u00ae Plus Differin\u00ae Versus Duac\u00ae Plus Differin\u00ae in Patients With Severe Facial Acne","canonical_id":"clinicaltrials.gov:NCT01231334","description":"Acne Vulgaris","metadata":null},{"id":"9d6073d9811343c2b176009793dbd30f","type":"TRIAL","name":"A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT04797793","description":"Acne Vulgaris","metadata":null},{"id":"b43b603041504568b3260d73e46391f7","type":"TRIAL","name":"A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants","canonical_id":"clinicaltrials.gov:NCT02075840","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"e4ba9132e0a94f8fa1d1df1083d22bfe","type":"TRIAL","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06413498","description":"Multiple Myeloma","metadata":null},{"id":"89ee87bc5b904a739985d0ce1a34c021","type":"TRIAL","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)","canonical_id":"clinicaltrials.gov:NCT06382142","description":"Triple-Negative Breast Cancer","metadata":null},{"id":"115dff01046c4ea5b391c8077ee4914a","type":"TRIAL","name":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT03737708","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"91d912000dd7441f8b64462fbee8f8ed","type":"TRIAL","name":"A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02513550","description":"Plaque Psoriasis","metadata":null},{"id":"1f5a94ccff2f41eb847437c73ca323ff","type":"TRIAL","name":"A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression","canonical_id":"clinicaltrials.gov:NCT00666757","description":"Depression","metadata":null},{"id":"97c0a85525fc41a28e43a868b7518558","type":"TRIAL","name":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","canonical_id":"clinicaltrials.gov:NCT04320342","description":"COPD; COPD Exacerbation","metadata":null},{"id":"59de2c6ab1f84d11ae7fdbbd1c8a8eed","type":"TRIAL","name":"A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain","canonical_id":"clinicaltrials.gov:NCT01190722","description":"Hallux Valgus; Postoperative Pain","metadata":null},{"id":"16d0edadafe34f848cb5ffe642edec0f","type":"TRIAL","name":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii\u00ae Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","canonical_id":"clinicaltrials.gov:NCT05282771","description":"Plaque Psoriasis","metadata":null},{"id":"7e3a5ef25b884c9faf7b4a79a73438dd","type":"TRIAL","name":"A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)","canonical_id":"clinicaltrials.gov:NCT06964165","description":"Ovarian Neoplasms","metadata":null},{"id":"af86a2a08322476ea6abbea40ebca827","type":"TRIAL","name":"A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)","canonical_id":"clinicaltrials.gov:NCT05429970","description":"Ovarian Cancer; Ovarian Carcinoma; Stage II Ovary Cancer; Stage II Ovarian Cancer; Stage III Ovary Cancer; Stage III Ovarian Cancer; Stage IV Ovary Cancer; Stage IV Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Stage II Fallopian Tube Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Primary Peritoneal Carcinoma","metadata":null},{"id":"121d494d2cce4fa4acf00002ad8cf72d","type":"TRIAL","name":"A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02627677","description":"Chronic Phase Chronic Myeloid Leukemia","metadata":null},{"id":"85bb646091234c1595d2bfffac6866f6","type":"TRIAL","name":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy","canonical_id":"clinicaltrials.gov:NCT03675308","description":"Psoriatic Arthritis","metadata":null},{"id":"79cf74a35f0846c286929fdabbe7a966","type":"TRIAL","name":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)","canonical_id":"clinicaltrials.gov:NCT03671148","description":"Psoriatic Arthritis (PsA)","metadata":null},{"id":"36de84bdcb0d45ecbe809c812b813b1b","type":"TRIAL","name":"A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT01513317","description":"Myelodysplastic Syndrome","metadata":null},{"id":"ee916cd948674ad38e75e98e6851625a","type":"TRIAL","name":"A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06333678","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"c539698f5e6c4e84bf30818c9660f146","type":"TRIAL","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","canonical_id":"clinicaltrials.gov:NCT06208150","description":"Multiple Myeloma","metadata":null},{"id":"365e8fd5694c4187835a44d66363b677","type":"TRIAL","name":"A Study Comparing Tapinarof Cream 1% and Vtama\u00ae Cream 1% in the Treatment of Plaque Psoriasis.","canonical_id":"clinicaltrials.gov:NCT07546214","description":"Plaque Psoriasis","metadata":null},{"id":"9f472b8ad7ff414dbc2da5367e95690f","type":"TRIAL","name":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC\u00ae (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02886702","description":"Plaque Psoriasis","metadata":null},{"id":"fc87ef438e814adab3358ee15375afc6","type":"TRIAL","name":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC\u00ae (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02886715","description":"Acne Vulgaris","metadata":null},{"id":"cb45b234074b434d913260060d5ba8e3","type":"TRIAL","name":"A Study Comparing Tazarotene Cream 0.1% to Tazorac\u00ae and Both to a Placebo Control in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02411955","description":"Acne Vulgaris","metadata":null},{"id":"4cfe9cfd92d3441aad71f66aa60002e0","type":"TRIAL","name":"A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris\u2122 Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02273817","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"4e89d063527646b791f721b1861a9f1f","type":"TRIAL","name":"A Study Comparing Tretinoin Cream 0.025% and RETIN-A\u00ae Cream 0.025% in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT04724473","description":"Acne Vulgaris","metadata":null},{"id":"690c35a929a0445b9a297820e8b425ac","type":"TRIAL","name":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF\u00ae CREAM (US REFERENCE LISTED DRUG), AKLIEF\u2122 CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT06733402","description":"Acne Vulgaris","metadata":null},{"id":"63cfe9e41c68427d94855beec8ded76e","type":"TRIAL","name":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF\u00ae Cream in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT06063473","description":"Acne Vulgaris","metadata":null},{"id":"afe18ce5fe404037b6607ccf328350b7","type":"TRIAL","name":"A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma","canonical_id":"clinicaltrials.gov:NCT02455245","description":"Low Grade Glioma","metadata":null},{"id":"e62a18b167174eec96ca334d9c7b21e1","type":"TRIAL","name":"A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment","canonical_id":"clinicaltrials.gov:NCT07179315","description":"Head and Neck Cancer","metadata":null},{"id":"9e6d2cf836af46ff9c07e4b7a5fac6a1","type":"TRIAL","name":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","canonical_id":"clinicaltrials.gov:NCT02675426","description":"Rheumatoid Arthritis","metadata":null},{"id":"3d0e51713d034798a416d953c2c9584c","type":"TRIAL","name":"A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01689519","description":"Malignant Melanoma","metadata":null},{"id":"c490249a5d854809abc4da866ecc61e2","type":"TRIAL","name":"A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06973291","description":"Plaque Psoriasis","metadata":null},{"id":"210b8f2529b24ed287115b440d37039d","type":"TRIAL","name":"A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista\u2122 Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02279563","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"fc6ed64a8eac414999f28c87a7013083","type":"TRIAL","name":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT07223502","description":"Hypertension (HTN)","metadata":null},{"id":"389dfcb5043046c595f45aea4589af3e","type":"TRIAL","name":"A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01038427","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"a8871ac902304f4f80eda39f05a46bac","type":"TRIAL","name":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02731846","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"b8cea65a84d44ea9be4af4725a641b4e","type":"TRIAL","name":"A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00883337","description":"Multiple Sclerosis","metadata":null},{"id":"f8ee7475eb3249f3b12709a25fc70da1","type":"TRIAL","name":"A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.","canonical_id":"clinicaltrials.gov:NCT00269880","description":"Angioplasty, Transluminal, Percutaneous Coronary","metadata":null},{"id":"f0858e44b0114ba6b9c0aea069481d37","type":"TRIAL","name":"A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)","canonical_id":"clinicaltrials.gov:NCT02964338","description":"Chronic Cluster Headache","metadata":null},{"id":"bb4e850cc3ac4b1aa965591fc8606551","type":"TRIAL","name":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","canonical_id":"clinicaltrials.gov:NCT06516978","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"74a2d6c3d9e548de8dd915de804c4311","type":"TRIAL","name":"A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT00636064","description":"Pain","metadata":null},{"id":"6cf4514eed3743ce80bce4010ebfe9c3","type":"TRIAL","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06435429","description":"Metastatic HER2-positive Breast Cancer","metadata":null},{"id":"5506911237d247a39435c353c1db676d","type":"TRIAL","name":"A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs","canonical_id":"clinicaltrials.gov:NCT00649844","description":"Schizophrenia","metadata":null},{"id":"40e89c019a8a4b70935618ecc7207947","type":"TRIAL","name":"A Study Comparing the Efficacy of Pataday\u00ae Once Daily Relief Extra Strength to Flonase\u00ae Allergy Relief in Subjects With Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT05314621","description":"Allergic Conjunctivitis","metadata":null},{"id":"bd886c87cbe047e9b15497d9cd254dee","type":"TRIAL","name":"A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00699049","description":"Urinary Bladder, Overactive","metadata":null},{"id":"564cacf8d2a4477b88b28ba57a80d610","type":"TRIAL","name":"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02164513","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"93b4a8a4292a43d6a1d277f234143292","type":"TRIAL","name":"A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)","canonical_id":"clinicaltrials.gov:NCT02491437","description":"Female Infertility","metadata":null},{"id":"dc9f7caf3615493ca93b5d099312a399","type":"TRIAL","name":"A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.","canonical_id":"clinicaltrials.gov:NCT00171366","description":"Hypertension","metadata":null},{"id":"bfe5fd4a4a36485c93a9e4a107feb2ef","type":"TRIAL","name":"A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy","canonical_id":"clinicaltrials.gov:NCT01169090","description":"Type 2 Diabetes","metadata":null},{"id":"77df67a8162c4b56a549efaaafc5b37f","type":"TRIAL","name":"A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT06411249","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"f135a6e0e6c5411897351f0bf3890c7a","type":"TRIAL","name":"A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis","canonical_id":"clinicaltrials.gov:NCT00440518","description":"Migraine","metadata":null},{"id":"8e25aaf4b0a44ec499aa95ec9a828afe","type":"TRIAL","name":"A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC\u00ae) Model.","canonical_id":"clinicaltrials.gov:NCT03479307","description":"Allergic Conjunctivitis","metadata":null},{"id":"04a6ee7f71694e2eaf7f9a1a5c5951d4","type":"TRIAL","name":"A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05644379","description":"Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy","metadata":null},{"id":"9134327a68324038b9b9997d455e8408","type":"TRIAL","name":"A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants","canonical_id":"clinicaltrials.gov:NCT06476834","description":"Healthy Volunteers","metadata":null},{"id":"f1634b2f164d465894ea63efa250d9be","type":"TRIAL","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT05645692","description":"Urothelial Cancer","metadata":null},{"id":"8594c13201194a7294bd52e3682fa632","type":"TRIAL","name":"A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04388501","description":"Healthy","metadata":null},{"id":"72163f16c60849e1baf0c58bb85474a2","type":"TRIAL","name":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT05171647","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"f08c0e5011994a80bb0fa7031d5f46fc","type":"TRIAL","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03416179","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"6d0dab6b51d64d5ab4df419f8a0beb32","type":"TRIAL","name":"A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)","canonical_id":"clinicaltrials.gov:NCT02288377","description":"Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours","metadata":null},{"id":"41eee22f38424f38b95bb7b43e754fd2","type":"TRIAL","name":"A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents","canonical_id":"clinicaltrials.gov:NCT01143077","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"fd14c4638df042899efa9c28c95508df","type":"TRIAL","name":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02132949","description":"Breast Cancer","metadata":null},{"id":"9bf892530f574e93a91def53a77eb0d7","type":"TRIAL","name":"A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.","canonical_id":"clinicaltrials.gov:NCT04903093","description":"Healthy Volunteers","metadata":null},{"id":"63f396eb1d94435ebb3d58f9db8c1749","type":"TRIAL","name":"A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT02729896","description":"Lymphoma","metadata":null},{"id":"592c498a46704f13ba920ca351f06800","type":"TRIAL","name":"A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT04809467","description":"Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma","metadata":null},{"id":"3dedd729e8dd41ddbfe65d6471535a2b","type":"TRIAL","name":"A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers","canonical_id":"clinicaltrials.gov:NCT06496568","description":"PIK3CA-Mutated Cancers","metadata":null},{"id":"e953a71954484352a07d927e5589f20b","type":"TRIAL","name":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","canonical_id":"clinicaltrials.gov:NCT04632992","description":"Advanced Unresectable or Metastatic Solid Malignancy","metadata":null},{"id":"bffd36a1d93a4df78e82fbc297fd818f","type":"TRIAL","name":"A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin","canonical_id":"clinicaltrials.gov:NCT00774605","description":"Smoking Cessation","metadata":null},{"id":"b94bedee64de45cea5b790918f16bbc6","type":"TRIAL","name":"A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT03222609","description":"Myelofibrosis (MF)","metadata":null},{"id":"56306145f789466ebd0f1f3f0d2909e1","type":"TRIAL","name":"A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT00379756","description":"Erectile Dysfunction","metadata":null},{"id":"a6fe53a2d3c74951a49633f32898f6ee","type":"TRIAL","name":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","canonical_id":"clinicaltrials.gov:NCT05004350","description":"BRAF V600E; Metastatic Colorectal Cancer","metadata":null},{"id":"05789be0218046d78c90fef8201d532e","type":"TRIAL","name":"A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types","canonical_id":"clinicaltrials.gov:NCT04311710","description":"Tumor","metadata":null},{"id":"e24b3dbdcbdd42a9a857debc68b2ba97","type":"TRIAL","name":"A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission","canonical_id":"clinicaltrials.gov:NCT05479058","description":"Ulcerative Colitis","metadata":null},{"id":"391b0ea1eae0488e9607bdcff81fb2ea","type":"TRIAL","name":"A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT05785611","description":"Axial Spondyloarthritis","metadata":null},{"id":"2bca0e98c2834787b1fefd4f78f2886f","type":"TRIAL","name":"A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT06865417","description":"Ulcerative Colitis","metadata":null},{"id":"5c57b54086c348f39a5ca6382f28ccfd","type":"TRIAL","name":"A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01219010","description":"Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cell Neoplasm","metadata":null},{"id":"139040d5c1df471f964c6da509a0551a","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH","canonical_id":"clinicaltrials.gov:NCT03818607","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"df9699b9d4034383b388f6d50df2d454","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty","canonical_id":"clinicaltrials.gov:NCT00269906","description":"Angina, Unstable; Angioplasty, Transluminal, Percutaneous Coronary","metadata":null},{"id":"e4f77a4c867b43d99f2bd3d75688ca65","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty","canonical_id":"clinicaltrials.gov:NCT00269893","description":"Angina, Unstable; Angioplasty, Transluminal, Percutaneous Coronary","metadata":null},{"id":"0521e2edf11245b8967021c142255ea4","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT02576327","description":"Vomiting","metadata":null},{"id":"7ab1bdc3f2fb4c1dbe91e591a8de9591","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","canonical_id":"clinicaltrials.gov:NCT04931342","description":"Ovarian Cancer","metadata":null},{"id":"7dc47f100c404740af10dcc3bbba72c3","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04623021","description":"COVID-19","metadata":null},{"id":"453635f560ba4540b054ae81d493999e","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04628143","description":"COVID-19","metadata":null},{"id":"2f19e52a3ae44fe1b2e88a1e1b669350","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne","canonical_id":"clinicaltrials.gov:NCT06415305","description":"Acne Vulgaris","metadata":null},{"id":"992380db59ea419683f13a9e7f6f9042","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","canonical_id":"clinicaltrials.gov:NCT05306340","description":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","metadata":null},{"id":"82eb5ff04db248eca32a153a23106da5","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04191499","description":"Breast Cancer","metadata":null},{"id":"6d9cb8ded24c489ea9ed7130d293eece","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06790693","description":"Breast Cancer","metadata":null},{"id":"fa0a294da103430087007294744e992f","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","canonical_id":"clinicaltrials.gov:NCT05646862","description":"Breast Cancer","metadata":null},{"id":"07b16916ef214f809d90f76032889854","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome","canonical_id":"clinicaltrials.gov:NCT07569081","description":"VEXAS Syndrome","metadata":null},{"id":"9e8bf306418940cd892f5016a74565d9","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","canonical_id":"clinicaltrials.gov:NCT03555149","description":"Colorectal Cancer","metadata":null},{"id":"9b3b4b46808a4aaa841d428aa6acea4d","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04802759","description":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","metadata":null},{"id":"f5abc4f8a46649f4888ac75c9d6c6be1","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03424005","description":"Metastatic Breast Cancer","metadata":null},{"id":"e63977dee44b43a6b83a32f41dce9f14","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT04173273","description":"Crohn's Disease","metadata":null},{"id":"325278c2ee8b4a84ae349c3928e16363","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00654082","description":"Spinal Cord Injury; Erectile Dysfunction; Spinal Cord Trauma; Injuries, Spinal Cord; Impotence","metadata":null},{"id":"a044a076aef34869badd55e054900e63","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)","canonical_id":"clinicaltrials.gov:NCT00491738","description":"Renal Cell Carcinoma","metadata":null},{"id":"e01584bf840c4817b8a71ab1ef5d0027","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01201915","description":"Basal Cell Carcinoma","metadata":null},{"id":"fb0d0e929d644f4ba0e0bec129170028","type":"TRIAL","name":"A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00833417","description":"Basal Cell Carcinoma","metadata":null},{"id":"fc980c1293944d12986f6a35fbe2d6cf","type":"TRIAL","name":"A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis","canonical_id":"clinicaltrials.gov:NCT03022617","description":"Psoriatic Nail; Psoriasis Vulgaris; Psoriasis","metadata":null},{"id":"03e57916e8834b82a033f9b0c6df4480","type":"TRIAL","name":"A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01049243","description":"Atopic Dermatitis","metadata":null},{"id":"1e72d1d837e149a290f8459aab72799d","type":"TRIAL","name":"A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status","canonical_id":"clinicaltrials.gov:NCT07034391","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"734f78530db1427db55d73d031ce82c2","type":"TRIAL","name":"A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)","canonical_id":"clinicaltrials.gov:NCT00926185","description":"Dry Eye","metadata":null},{"id":"d7107142ceeb403b9c0c77398011acb4","type":"TRIAL","name":"A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT05303285","description":"Ankylosing Spondylitis (AS)","metadata":null},{"id":"c22146d170ae4bd3b3abe9fcaaba8ef9","type":"TRIAL","name":"A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00631917","description":"Hypertension","metadata":null},{"id":"d07a4b24437940869150e6deb1dc4187","type":"TRIAL","name":"A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","canonical_id":"clinicaltrials.gov:NCT01083615","description":"Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer","metadata":null},{"id":"56210c1e1d414c9087c4222666ec4487","type":"TRIAL","name":"A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00740792","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"afe49b98cae84cbfae4c2507b59d5623","type":"TRIAL","name":"A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases","canonical_id":"clinicaltrials.gov:NCT03625141","description":"Metastatic Melanoma","metadata":null},{"id":"537635d6519c4decb53b6a7a8b69bbbe","type":"TRIAL","name":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","canonical_id":"clinicaltrials.gov:NCT04929223","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"efabb43c9c504abaa2268b32a6c683b5","type":"TRIAL","name":"A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT05188417","description":"Acute Ischemic Stroke","metadata":null},{"id":"0c1b8150ab544a8ebe862316baebff3a","type":"TRIAL","name":"A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT07128628","description":"Dry Eye Disease","metadata":null},{"id":"7167c5aebde8486fa10332f739aa55f2","type":"TRIAL","name":"A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT07748208","description":"Breast Cancer; Diabetes Type II","metadata":null},{"id":"b531e47d3dc14ab4b5de7b4a8d4e70d1","type":"TRIAL","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT05091424","description":"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","metadata":null},{"id":"e58047ae0a3c461b9b6219622f261a05","type":"TRIAL","name":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02099058","description":"Advanced Solid Tumors Cancer","metadata":null},{"id":"8d62b3b51381409bb3c76558b3abd89f","type":"TRIAL","name":"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT03840200","description":"Breast Cancer; Prostate Cancer; Ovarian Cancer","metadata":null},{"id":"055b8849d44e459f8cbc57d27165b5e1","type":"TRIAL","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","canonical_id":"clinicaltrials.gov:NCT04774718","description":"ALK Fusion-positive Solid or CNS Tumors","metadata":null},{"id":"b851046490a04cef9eb163d34d4e1799","type":"TRIAL","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors","canonical_id":"clinicaltrials.gov:NCT04432584","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"eaa59ade2f81489393383d36026e7284","type":"TRIAL","name":"A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01562275","description":"Neoplasms","metadata":null},{"id":"00a73688a88149ddbbfa1319e6fc4275","type":"TRIAL","name":"A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT06641388","description":"Healthy Subjects (HS)","metadata":null},{"id":"46a29c9d8e144ef8a2d33a5d641bb20e","type":"TRIAL","name":"A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT07043283","description":"Healthy Subjects","metadata":null},{"id":"bfe1470b54af42a88dd3f6bb1ded16f2","type":"TRIAL","name":"A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis","canonical_id":"clinicaltrials.gov:NCT03827200","description":"Cirrhosis; Portal Hypertension; Ascites","metadata":null},{"id":"07e9140b15e14bacae30927203967dd4","type":"TRIAL","name":"A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function","canonical_id":"clinicaltrials.gov:NCT01522950","description":"Hypertension","metadata":null},{"id":"6783a42f093f4b3a900c25f5e73bd3ba","type":"TRIAL","name":"A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity","canonical_id":"clinicaltrials.gov:NCT00203268","description":"Migraine","metadata":null},{"id":"73f5768ee15645c0bc7105a67622f561","type":"TRIAL","name":"A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","canonical_id":"clinicaltrials.gov:NCT01729871","description":"Atrial Fibrillation","metadata":null},{"id":"bf659ba1571448c8ac93c04246186061","type":"TRIAL","name":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","canonical_id":"clinicaltrials.gov:NCT06049797","description":"Hot Flashes","metadata":null},{"id":"d676fbb888114e60b08edde471f92358","type":"TRIAL","name":"A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention","canonical_id":"clinicaltrials.gov:NCT05269667","description":"Neuromyelitis Optica Spectrum Disorder; NMOSD","metadata":null},{"id":"47310dd4589f42e8a502d0385788cdf2","type":"TRIAL","name":"A Study In Patients With Advanced Solid Tumor","canonical_id":"clinicaltrials.gov:NCT00726752","description":"Neoplasms","metadata":null},{"id":"caffcdcb505545e5971d794a86a46683","type":"TRIAL","name":"A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03884491","description":"Healthy","metadata":null},{"id":"9b6e3570e0c34fb39a2638a7bb552951","type":"TRIAL","name":"A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05076175","description":"Colitis, Ulcerative","metadata":null},{"id":"90e8f4bf791548c29609ea7c2c4f6a55","type":"TRIAL","name":"A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081","canonical_id":"clinicaltrials.gov:NCT06809608","description":"Healthy Participants","metadata":null},{"id":"9c3542a91b6142ea8471306df5066c54","type":"TRIAL","name":"A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT02023125","description":"Healthy Volunteer","metadata":null},{"id":"f9be6762c77849368a36d35e348dd824","type":"TRIAL","name":"A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00960141","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"bc46cd4847884470ab723a59e5ee3a0a","type":"TRIAL","name":"A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07546383","description":"Squamous Cell Carcinoma of Head and Neck","metadata":null},{"id":"2cc6da91545c43edbb25f7908bc7a06c","type":"TRIAL","name":"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia\u00ae)","canonical_id":"clinicaltrials.gov:NCT05335031","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"a646b30b3349440184c4716dd4751106","type":"TRIAL","name":"A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects","canonical_id":"clinicaltrials.gov:NCT00134199","description":"Obesity","metadata":null},{"id":"fb17460b15b947e093ffa7b4dffbce66","type":"TRIAL","name":"A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT00600821","description":"Non-Small-Cell Lung Carcinoma; Adenocarcinoma","metadata":null},{"id":"46a2211fc1e24e2b8305627159301602","type":"TRIAL","name":"A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01639001","description":"NSCLC (Non-small Cell Lung Cancer)","metadata":null},{"id":"3d0d4107c54e4a419733df70a35f058c","type":"TRIAL","name":"A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07285863","description":"Exocrine Pancreatic Insufficiency; Chronic Pancreatitis","metadata":null},{"id":"e54e3d0967754f5ba57d12c6a4742d6a","type":"TRIAL","name":"A Study Of Galcanezumab In Participants With Episodic Cluster Headache","canonical_id":"clinicaltrials.gov:NCT02397473","description":"Episodic Cluster Headache","metadata":null},{"id":"9aeab258d3004d1a93cf674459afe357","type":"TRIAL","name":"A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation","canonical_id":"clinicaltrials.gov:NCT03130556","description":"Healthy Volunteers","metadata":null},{"id":"350ab859017a4a5d8b1c1f93640f2f15","type":"TRIAL","name":"A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01232556","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"ea474cfc53394c37a932c03a29521f11","type":"TRIAL","name":"A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT01564784","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"7835cdc21aa343bf8eaa032db7df292a","type":"TRIAL","name":"A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT03052608","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"693fa077334341f8b6202df9cbbcc398","type":"TRIAL","name":"A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B","canonical_id":"clinicaltrials.gov:NCT01327547","description":"HIV Coinfection","metadata":null},{"id":"b870044064484f5fae0863a66855d66d","type":"TRIAL","name":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","canonical_id":"clinicaltrials.gov:NCT03337698","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"9e111f0c59624d4a87730f9a08a9d50d","type":"TRIAL","name":"A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT06438614","description":"Refractory Neuroblastoma; Soft Tissue Cancer","metadata":null},{"id":"0abed6402a2b4fe3939f1e298f26bb3c","type":"TRIAL","name":"A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor","canonical_id":"clinicaltrials.gov:NCT01128842","description":"Advanced Malignant Solid Tumors","metadata":null},{"id":"3ced2996866a478981afa2a827b3845a","type":"TRIAL","name":"A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01684215","description":"Neoplasms; Breast Neoplasms","metadata":null},{"id":"a0f23759be0b4843ba0d1ffd1427ea21","type":"TRIAL","name":"A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)","canonical_id":"clinicaltrials.gov:NCT01920061","description":"Neoplasm","metadata":null},{"id":"e8813813a2654a2d8455bef02f896adf","type":"TRIAL","name":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira\u00ae) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).","canonical_id":"clinicaltrials.gov:NCT02480153","description":"Rheumatoid Arthritis","metadata":null},{"id":"ae7626092c434bd2badc587c0ca552e9","type":"TRIAL","name":"A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients","canonical_id":"clinicaltrials.gov:NCT00349427","description":"Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2","metadata":null},{"id":"7e09dc332fe44e138cff222117a55039","type":"TRIAL","name":"A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00113516","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"a705acaa045a47a4b2c185d47ff95b19","type":"TRIAL","name":"A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain","canonical_id":"clinicaltrials.gov:NCT00418782","description":"Osteoarthritis","metadata":null},{"id":"c91094129a5049f69d7af93e7c272615","type":"TRIAL","name":"A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol","canonical_id":"clinicaltrials.gov:NCT00644670","description":"Dyslipidemias","metadata":null},{"id":"023c14995cfe4c97a34c8c2e58893089","type":"TRIAL","name":"A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00375596","description":"Allergic Conjunctivitis","metadata":null},{"id":"b7ae21d23a274b4796652b254ae5b0b4","type":"TRIAL","name":"A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.","canonical_id":"clinicaltrials.gov:NCT00343200","description":"Impotence","metadata":null},{"id":"313d5e7213b8422b9fe837134b195060","type":"TRIAL","name":"A Study Of The Selective PKC-\u03b2 Inhibitor MS- 553","canonical_id":"clinicaltrials.gov:NCT03492125","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Aggressive Lymphoma","metadata":null},{"id":"704aa3ec40334f94a59ebce17a9d7e62","type":"TRIAL","name":"A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World","canonical_id":"clinicaltrials.gov:NCT04337138","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"0c7bf134d6f043768659b074d5b97f14","type":"TRIAL","name":"A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients","canonical_id":"clinicaltrials.gov:NCT03677596","description":"Leukemia; Precursor b-Cell Lymphoblastic Leukemia-Lymphoma; ACUTE LYMPHOBLASTIC LEUKEMIA","metadata":null},{"id":"2fbaebba125a428faddeb65740633942","type":"TRIAL","name":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","canonical_id":"clinicaltrials.gov:NCT05179876","description":"Hypertension, Pulmonary","metadata":null},{"id":"217a274528264675aa23b78484272847","type":"TRIAL","name":"A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers","canonical_id":"clinicaltrials.gov:NCT00404274","description":"Nausea and Vomiting, Chemotherapy-Induced","metadata":null},{"id":"0f300c66b033480a90159efea19a1f42","type":"TRIAL","name":"A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products","canonical_id":"clinicaltrials.gov:NCT01313728","description":"Acne Vulgaris","metadata":null},{"id":"eca21402cc64499d9e15aa00edc19142","type":"TRIAL","name":"A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture","canonical_id":"clinicaltrials.gov:NCT00887354","description":"Osteoporosis","metadata":null},{"id":"37cae08317344b31bb5619a2bf9376a6","type":"TRIAL","name":"A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo","canonical_id":"clinicaltrials.gov:NCT06118411","description":"Vitiligo","metadata":null},{"id":"834e7ed4066b4190a4155359d02794af","type":"TRIAL","name":"A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02684032","description":"Breast Cancer","metadata":null},{"id":"68a138bdd21d4deea55ffa39de147115","type":"TRIAL","name":"A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide","canonical_id":"clinicaltrials.gov:NCT00671424","description":"Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2","metadata":null},{"id":"0b964e78f888433a833bc5124a135352","type":"TRIAL","name":"A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly","canonical_id":"clinicaltrials.gov:NCT00068042","description":"Acromegaly","metadata":null},{"id":"b0bbc99985a340b09a821602af52bc1c","type":"TRIAL","name":"A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands","canonical_id":"clinicaltrials.gov:NCT02546375","description":"Chronic Myeloid Leukaemia","metadata":null},{"id":"371c86f6be844d1fb84c913083fe4581","type":"TRIAL","name":"A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers","canonical_id":"clinicaltrials.gov:NCT01364519","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"ea6ffdf222414ed7a6083d738e08812a","type":"TRIAL","name":"A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection","canonical_id":"clinicaltrials.gov:NCT01721408","description":"Intra-abdominal Infection","metadata":null},{"id":"50738ec589fc41b290e8622eff1d5d45","type":"TRIAL","name":"A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI","canonical_id":"clinicaltrials.gov:NCT01848106","description":"Coronary Artery Disease","metadata":null},{"id":"e7343a8ce7654bdbaf9bea77875a9a93","type":"TRIAL","name":"A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00666705","description":"Healthy","metadata":null},{"id":"7409d99b3e3a4f008008219401c03e50","type":"TRIAL","name":"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT01458951","description":"Ulcerative Colitis","metadata":null},{"id":"b7474416c242473cb8b98ebd42e9bedf","type":"TRIAL","name":"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT04963270","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"ac6ada5db00b4e819aa2ffb9b239b08e","type":"TRIAL","name":"A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01114841","description":"Acne Vulgaris","metadata":null},{"id":"164eaedea5c04eee9d674f0a0aeefb5b","type":"TRIAL","name":"A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension","canonical_id":"clinicaltrials.gov:NCT00635232","description":"Hypertension","metadata":null},{"id":"7484093b41844cbb92dd5244baa60ba6","type":"TRIAL","name":"A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers","canonical_id":"clinicaltrials.gov:NCT02084875","description":"Healthy","metadata":null},{"id":"15cfbb1c2c2b4aab9930a6637695742d","type":"TRIAL","name":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","canonical_id":"clinicaltrials.gov:NCT02033889","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"9e8d9453fa72438fb1e54c19fc7750b3","type":"TRIAL","name":"A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.","canonical_id":"clinicaltrials.gov:NCT02486302","description":"Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Plaque Psoriasis","metadata":null},{"id":"a97478a094de41c598654c9c16c277f0","type":"TRIAL","name":"A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00649311","description":"Hypertension","metadata":null},{"id":"86871f403a7b485a9df6e6e82999b107","type":"TRIAL","name":"A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02267746","description":"Acne Vulgaris","metadata":null},{"id":"fc99caab5c8548aea75e424064355bdf","type":"TRIAL","name":"A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition","canonical_id":"clinicaltrials.gov:NCT01557244","description":"Urinary Bladder, Neurogenic","metadata":null},{"id":"6f3a184308334437af8968ea61adeffd","type":"TRIAL","name":"A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.","canonical_id":"clinicaltrials.gov:NCT00405119","description":"Gastroesophageal Reflux Disease; Reflux, Gastroesophageal","metadata":null},{"id":"e315a1230fd44a0aaeb8ec8bfe1eeea0","type":"TRIAL","name":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03972306","description":"Multiple Sclerosis (MS)","metadata":null},{"id":"272b752c7c9a4043ad50136bef575442","type":"TRIAL","name":"A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00501267","description":"Overactive Bladder","metadata":null},{"id":"b9a5558896124e3bb53ed17721adcfab","type":"TRIAL","name":"A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes","canonical_id":"clinicaltrials.gov:NCT03375138","description":"Healthy Volunteers","metadata":null},{"id":"1659d202c95e4d608f4e1d36fff6e331","type":"TRIAL","name":"A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017","canonical_id":"clinicaltrials.gov:NCT04927858","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c07076d2239743bcb8aca2464a9886dd","type":"TRIAL","name":"A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT00512902","description":"Alveolitis; Systemic Sclerosis","metadata":null},{"id":"a3472bdd7359484684b55dec7567d391","type":"TRIAL","name":"A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)","canonical_id":"clinicaltrials.gov:NCT05925049","description":"Multiple Sclerosis","metadata":null},{"id":"ba185594fc5543ac861af3c6ec7320fe","type":"TRIAL","name":"A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH","canonical_id":"clinicaltrials.gov:NCT00510406","description":"Lower Urinary Tract Symptoms; Prostatic Hyperplasia","metadata":null},{"id":"8daaa32fad0e4c118e786a03ba6cd404","type":"TRIAL","name":"A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT04965675","description":"Chronic Migraine in Children","metadata":null},{"id":"4c26c764039c4c9d8d3657650dc04c93","type":"TRIAL","name":"A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT05164172","description":"Migraine","metadata":null},{"id":"4cc1b64aac534f75acb45e9dadc34398","type":"TRIAL","name":"A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT04393883","description":"Non-small-lung-cell Cancer, NSCLC; Pembrolizumab","metadata":null},{"id":"e6245efd589449f193770800d44f0e6c","type":"TRIAL","name":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","canonical_id":"clinicaltrials.gov:NCT02955212","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"50149887cefd4aaa8596a8fed0719c6e","type":"TRIAL","name":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03410992","description":"Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis; Psoriatic Arthritis","metadata":null},{"id":"5a1e50d614a14c3cac5e4cca4ad5ee2d","type":"TRIAL","name":"A Study for Adult Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00965081","description":"Fibromyalgia, Primary; Fibromyalgia, Secondary","metadata":null},{"id":"74414761eb85410c87408ce838019959","type":"TRIAL","name":"A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT00844857","description":"Bipolar Depression","metadata":null},{"id":"9ea95b4cb3e0434c94b93c0ad0d84831","type":"TRIAL","name":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","canonical_id":"clinicaltrials.gov:NCT03492580","description":"Diabetes Mellitus, Type 2; Cardiovascular Diseases","metadata":null},{"id":"13116358ea67415796ce796aa6afa96a","type":"TRIAL","name":"A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody","canonical_id":"clinicaltrials.gov:NCT02069899","description":"Hemophagocytic Lymphohistiocytosis","metadata":null},{"id":"e98444ae4de04b96b4d9c7d1df98ff62","type":"TRIAL","name":"A Study for Participants With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00709995","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"62c2ccbf99e0426fb243cd6f31e1e982","type":"TRIAL","name":"A Study for Participants With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00520923","description":"Schizophrenia","metadata":null},{"id":"48efaf0e1e86457ba63e3236a3e6d5a1","type":"TRIAL","name":"A Study for Patients With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00414973","description":"Osteoporosis","metadata":null},{"id":"96c6324f815545128ab31518dfe0860f","type":"TRIAL","name":"A Study for Post-Marketing Surveillance of Nesina\u00ae Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea","canonical_id":"clinicaltrials.gov:NCT04980040","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"511d16a6e9764117afef79f41a3d7bcc","type":"TRIAL","name":"A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs","canonical_id":"clinicaltrials.gov:NCT00831129","description":"Pre-diabetes","metadata":null},{"id":"1ab19f4851974ddbb481c0a26a3abba8","type":"TRIAL","name":"A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)","canonical_id":"clinicaltrials.gov:NCT00235014","description":"Hypertension; Diabetes","metadata":null},{"id":"805d9404cd6a42bdaaa44980c847b02e","type":"TRIAL","name":"A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00728949","description":"Metastatic Breast Cancer","metadata":null},{"id":"3c2307fb409342b9b9438dbdd6e37e49","type":"TRIAL","name":"A Study for Tysabri Participant Preference","canonical_id":"clinicaltrials.gov:NCT05304520","description":"Relapsing-Remitting Multiple Sclerosis (RRMS)","metadata":null},{"id":"2ab3463cba77403eb2e3046839da113b","type":"TRIAL","name":"A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide","canonical_id":"clinicaltrials.gov:NCT05901649","description":"Metastatic Hormone-sensitive Prostate Cancer","metadata":null},{"id":"2ec64b2611644ba283d0d085b520dde4","type":"TRIAL","name":"A Study for the Treatment of Diabetic Peripheral Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT00552175","description":"Diabetic Neuropathies","metadata":null},{"id":"c68099e9339041eb938cbf69aa836510","type":"TRIAL","name":"A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function","canonical_id":"clinicaltrials.gov:NCT01287065","description":"Asthma","metadata":null},{"id":"46b4b368eac145d0accfa3dafa836d10","type":"TRIAL","name":"A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT01127646","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"88ad165269c245f09118eb3ace354848","type":"TRIAL","name":"A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice","canonical_id":"clinicaltrials.gov:NCT07602530","description":"Hot Flashes","metadata":null},{"id":"ef5bc3488f8d4aae92f20b54ddaf903f","type":"TRIAL","name":"A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib","canonical_id":"clinicaltrials.gov:NCT00996762","description":"Neoplasms, Breast","metadata":null},{"id":"570e8b116f2d46d1900bc3214408d010","type":"TRIAL","name":"A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab","canonical_id":"clinicaltrials.gov:NCT04537429","description":"Migraine in Children; Migraine","metadata":null},{"id":"b5f28be8d14b4d7e8d283556e7d7b77f","type":"TRIAL","name":"A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause","canonical_id":"clinicaltrials.gov:NCT07455812","description":"Hot Flashes","metadata":null},{"id":"d140940a20b84e40856a910f8953c78e","type":"TRIAL","name":"A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines","canonical_id":"clinicaltrials.gov:NCT05074459","description":"Healthy Participants","metadata":null},{"id":"5df96f4aee4d4138a00950dba6a01760","type":"TRIAL","name":"A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood","canonical_id":"clinicaltrials.gov:NCT06367153","description":"Healthy","metadata":null},{"id":"f3e2b56ff00245f49ac8a084890bb445","type":"TRIAL","name":"A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood","canonical_id":"clinicaltrials.gov:NCT07081932","description":"Healthy","metadata":null},{"id":"d53a1b42d1864a0baa64b8542790e192","type":"TRIAL","name":"A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood","canonical_id":"clinicaltrials.gov:NCT07649941","description":"Healthy","metadata":null},{"id":"2c9675aa342f4e4a84c7fe50bfab8f00","type":"TRIAL","name":"A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood","canonical_id":"clinicaltrials.gov:NCT05723874","description":"Healthy","metadata":null},{"id":"e0c2a7ad84724a8ea42c3efa44905c7f","type":"TRIAL","name":"A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule","canonical_id":"clinicaltrials.gov:NCT04938453","description":"Healthy","metadata":null},{"id":"e3ea74c8b90c47b4852102a9d29b5ea5","type":"TRIAL","name":"A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body","canonical_id":"clinicaltrials.gov:NCT06494761","description":"Healthy","metadata":null},{"id":"928c330d00c54dcc9daea414a3d44d0f","type":"TRIAL","name":"A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood","canonical_id":"clinicaltrials.gov:NCT06193811","description":"Healthy","metadata":null},{"id":"796ea659139a448f84d2bbb29b714603","type":"TRIAL","name":"A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood","canonical_id":"clinicaltrials.gov:NCT06647810","description":"Healthy","metadata":null},{"id":"71885a81d49f4245a80b4084da12bce9","type":"TRIAL","name":"A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure","canonical_id":"clinicaltrials.gov:NCT03979820","description":"Healthy","metadata":null},{"id":"5fad44b467d24119bcae7da0275d8afe","type":"TRIAL","name":"A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol","canonical_id":"clinicaltrials.gov:NCT04550234","description":"Chronic Kidney Disease","metadata":null},{"id":"eac97e726e76462896ff18d43d8a1fe1","type":"TRIAL","name":"A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation","canonical_id":"clinicaltrials.gov:NCT01406158","description":"Pharmacokinetics of Solifenacin Succinate; Healthy Volunteers","metadata":null},{"id":"f5dab32e5b5f40538e0c4879a79f071b","type":"TRIAL","name":"A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab","canonical_id":"clinicaltrials.gov:NCT01495000","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"77276f90f2b24cb082e80ae959805657","type":"TRIAL","name":"A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302","canonical_id":"clinicaltrials.gov:NCT03268811","description":"Short Bowel Syndrome","metadata":null},{"id":"9ff256a4489b41c6aab50e7533930845","type":"TRIAL","name":"A Study in Japanese Participants With Moderate-to-Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT01624233","description":"Psoriasis","metadata":null},{"id":"710ceee476a842ddb93de20d4eebe66a","type":"TRIAL","name":"A Study in Moderate to Severe Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01710358","description":"Rheumatoid Arthritis","metadata":null},{"id":"f8f7d927751648389ee30da9944b18dd","type":"TRIAL","name":"A Study in Moderate to Severe Rheumatoid Arthritis Participants","canonical_id":"clinicaltrials.gov:NCT01721057","description":"Rheumatoid Arthritis","metadata":null},{"id":"163675df817a4757858571f0d44fc2f3","type":"TRIAL","name":"A Study in Non Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01139775","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"d25eb4b21a66484ba2ac46c5a97e3ec3","type":"TRIAL","name":"A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03522246","description":"Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response","metadata":null},{"id":"1af3f66e7b064bff801b5e4efec540d1","type":"TRIAL","name":"A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil","canonical_id":"clinicaltrials.gov:NCT03695094","description":"Epilepsy","metadata":null},{"id":"2c579f27a36a499d90e6673ac801e51c","type":"TRIAL","name":"A Study in Participants With Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT01107457","description":"Psoriasis","metadata":null},{"id":"c1d5d2f60578432fa066b86c8eca71f9","type":"TRIAL","name":"A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)","canonical_id":"clinicaltrials.gov:NCT01646177","description":"Psoriasis","metadata":null},{"id":"d041d3cc71b54c30ba56583c5df84839","type":"TRIAL","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","canonical_id":"clinicaltrials.gov:NCT03768063","description":"Cancer","metadata":null},{"id":"65d379f210204b818ffd4e974652a4fc","type":"TRIAL","name":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","canonical_id":"clinicaltrials.gov:NCT04412291","description":"Covid-19","metadata":null},{"id":"26ca4b671f7a4b92817ee089ad2d658c","type":"TRIAL","name":"A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001","canonical_id":"clinicaltrials.gov:NCT06588738","description":"Plaque Psoriasis","metadata":null},{"id":"5e7ae32852264ecba4f6d65f7f51c962","type":"TRIAL","name":"A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe","canonical_id":"clinicaltrials.gov:NCT05569148","description":"Neovascular Age-related Macular Degeneration; Diabetic Macular Edema","metadata":null},{"id":"5c61e05f928742b8b6f3d36ff1b1e8ff","type":"TRIAL","name":"A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)","canonical_id":"clinicaltrials.gov:NCT04163016","description":"Rheumatoid Arthritis; Psoriatic Arthritis; Crohn's Disease; Axial Spondyloarthritis; Plaque Psoriasis","metadata":null},{"id":"9ce70822d7e748179a615111946b41d8","type":"TRIAL","name":"A Study in Second Line Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01183780","description":"Colorectal Cancer","metadata":null},{"id":"497bd86251c54273aee8619b0568a808","type":"TRIAL","name":"A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment","canonical_id":"clinicaltrials.gov:NCT04011475","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"9ba692f5a6214d4398e7321c8f52c30d","type":"TRIAL","name":"A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described","canonical_id":"clinicaltrials.gov:NCT04122976","description":"Prostate Cancer","metadata":null},{"id":"98f7a43bd809471c9510cfb760fa364c","type":"TRIAL","name":"A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07733765","description":"Alopecia Areata","metadata":null},{"id":"c4dcd684c7e344ba81bfd2a4e635de5a","type":"TRIAL","name":"A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00855582","description":"Erectile Dysfunction; Benign Prostatic Hyperplasia","metadata":null},{"id":"e94eb1a9561c4a66ae27a8f4266fcb1a","type":"TRIAL","name":"A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung","canonical_id":"clinicaltrials.gov:NCT04552535","description":"Squamous Non-small Cell Lung Cancer","metadata":null},{"id":"e0840508d16d4b90abe3c734fe14834b","type":"TRIAL","name":"A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01565343","description":"Alzheimer's Disease","metadata":null},{"id":"70af933e95544469b040657350eb0afb","type":"TRIAL","name":"A Study of 18F-AV-45 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01564706","description":"Alzheimer Disease","metadata":null},{"id":"5548ea572d39448b8be963221181964f","type":"TRIAL","name":"A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT06873945","description":"Alopecia Areata","metadata":null},{"id":"df195a56e9794f5296f88febacc8f24d","type":"TRIAL","name":"A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01173549","description":"Healthy","metadata":null},{"id":"d4984a091add423ca488cc9054e6c989","type":"TRIAL","name":"A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)","canonical_id":"clinicaltrials.gov:NCT04171791","description":"CTCL","metadata":null},{"id":"e4c8d8aff66b4ad2af5cb27ebcac0abe","type":"TRIAL","name":"A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function","canonical_id":"clinicaltrials.gov:NCT03282513","description":"Hepatic Impairment","metadata":null},{"id":"a0b238953cd84ea4abb0ecc4d72b1d38","type":"TRIAL","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05859750","description":"Pancreatic Cancer","metadata":null},{"id":"8ad0e908e2e6448dbcd641c9235a7a61","type":"TRIAL","name":"A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06341335","description":"Gastric and Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"c7b930ce7cb94dad9f91208e0ebf36fa","type":"TRIAL","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT06530251","description":"Hepatocellular Carcinoma","metadata":null},{"id":"289c7db9c11f43f5933cbc3249b334af","type":"TRIAL","name":"A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers","canonical_id":"clinicaltrials.gov:NCT07811232","description":"Endometrial Neoplasms; Soft Tissue Sarcoma (STS); Breast Neoplasms","metadata":null},{"id":"89bd0b509f664b758a5c85d1d3c5d890","type":"TRIAL","name":"A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma","canonical_id":"clinicaltrials.gov:NCT00002439","description":"Sarcoma, Kaposi; HIV Infections","metadata":null},{"id":"8342c72c430e45de98def39ba82b976c","type":"TRIAL","name":"A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma","canonical_id":"clinicaltrials.gov:NCT00002188","description":"Sarcoma, Kaposi; HIV Infections","metadata":null},{"id":"3a365467069b4b5f9ccc24b83bd404b9","type":"TRIAL","name":"A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation","canonical_id":"clinicaltrials.gov:NCT01028222","description":"Melanoma","metadata":null},{"id":"914340cbcfb3496fa97a5725241ddb3e","type":"TRIAL","name":"A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction","canonical_id":"clinicaltrials.gov:NCT00663767","description":"Dental Pain","metadata":null},{"id":"5432b3f97a464310a275c1c2fd8fc662","type":"TRIAL","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","canonical_id":"clinicaltrials.gov:NCT05867420","description":"Advanced Solid Tumors","metadata":null},{"id":"064fe67a9340414794bdbbb47e312eaf","type":"TRIAL","name":"A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02897219","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"b6a0eb90d4714ac3be3f8f42273059d3","type":"TRIAL","name":"A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00621868","description":"Diabetes Mellitus","metadata":null},{"id":"52c7aacfcf2b4c4b990075fa223cc3f7","type":"TRIAL","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","canonical_id":"clinicaltrials.gov:NCT06564038","description":"Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Mantle-cell Lymphoma; Large B-cell Lymphoma; B-cell Non-Hodgkin Lymphoma","metadata":null},{"id":"0dfda9e49fec4e249ddbeec7f8b0641f","type":"TRIAL","name":"A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate","canonical_id":"clinicaltrials.gov:NCT00345748","description":"Rheumatoid Arthritis","metadata":null},{"id":"bbb48a60af4b455d895f3e040d164ae8","type":"TRIAL","name":"A Study of Abatacept in Patients With Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00406653","description":"Crohn's Disease","metadata":null},{"id":"3a922763704544a4bbad1f276e95e221","type":"TRIAL","name":"A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)","canonical_id":"clinicaltrials.gov:NCT00046228","description":"Myocardial Infarction","metadata":null},{"id":"9d26db6e6fd347c0a16cc483cd6ab1e8","type":"TRIAL","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02747004","description":"Metastatic Breast Cancer","metadata":null},{"id":"c5e40258fd34467db3251e6099f4cc90","type":"TRIAL","name":"A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02079636","description":"Carcinoma, Non-small Cell Lung","metadata":null},{"id":"9ae24f4fe35848ada96ff7fefbcc49d9","type":"TRIAL","name":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT04238819","description":"Relapsed Solid Tumor; Refractory Solid Tumor","metadata":null},{"id":"b50c633b18dd43de93c068cd74c3e500","type":"TRIAL","name":"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02675231","description":"Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer","metadata":null},{"id":"dee3368596a54d9fa45a148ec3244068","type":"TRIAL","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05951959","description":"Mantle Cell Lymphoma (MCL)","metadata":null},{"id":"a965a251cb0b4a3bb2b172be2d5ea390","type":"TRIAL","name":"A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04435483","description":"Pharmacokinetics; Bioavailability","metadata":null},{"id":"56d1cb688efc4f4c96e30e9bd8b3d80c","type":"TRIAL","name":"A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT03205046","description":"DLBCL; Richter Syndrome","metadata":null},{"id":"ebd94c6f28fb49eba100a5ec731b27a5","type":"TRIAL","name":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","canonical_id":"clinicaltrials.gov:NCT02717624","description":"Mantle Cell Lymphoma (MCL)","metadata":null},{"id":"73713e1ec43444a585ceb938d098146e","type":"TRIAL","name":"A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02735876","description":"Mantle Cell Lymphoma","metadata":null},{"id":"4a1a0eddbbf34f87b64fdeac182c8dce","type":"TRIAL","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","canonical_id":"clinicaltrials.gov:NCT02970318","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"f56b1e7be5314ae6a38c3c0844e2b9db","type":"TRIAL","name":"A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease","canonical_id":"clinicaltrials.gov:NCT05590416","description":"Vogt-Koyanagi-Harada Disease; Adalimumab","metadata":null},{"id":"8a1a516699484db2a02d1a7f85ab3f7f","type":"TRIAL","name":"A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.","canonical_id":"clinicaltrials.gov:NCT06306560","description":"Extensive-stage Small-cell Lung Cancer","metadata":null},{"id":"7cb8bc9c95ed4541bf5da9bd7c025443","type":"TRIAL","name":"A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03167112","description":"Pancreatic Cancer","metadata":null},{"id":"d7b437a4ea724285b8e02b68d46e29c2","type":"TRIAL","name":"A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities","canonical_id":"clinicaltrials.gov:NCT03639987","description":"Cognitive Dysfunction; Alzheimer's Disease","metadata":null},{"id":"cd9d55ff58814cf48ae8e52ce6ad8f05","type":"TRIAL","name":"A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic\u00ae) During the French Early Access Program (Temporary Authorization for Use [TAU])","canonical_id":"clinicaltrials.gov:NCT03139513","description":"Melanoma","metadata":null},{"id":"1051dd731b5b4bd5b9f74598f0a419c9","type":"TRIAL","name":"A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT01871805","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"5feb25ec29fd4ff68381811f3ecf0da3","type":"TRIAL","name":"A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment","canonical_id":"clinicaltrials.gov:NCT01801111","description":"Non-Small-Cell Lung Carcinoma","metadata":null},{"id":"89d371c13c3744a7a3a42fb399ace9c2","type":"TRIAL","name":"A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)","canonical_id":"clinicaltrials.gov:NCT07001384","description":"Anaplastic Lymphoma Kinase; Anaplastic Large Cell Lymphoma","metadata":null},{"id":"afd4ec9a610f400ca5a49e9856adae35","type":"TRIAL","name":"A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT03131206","description":"ALK-positive Non-small Cell Lung Cancer (NSCLC); RET-positive Non-small Cell Lung Cancer (NSCLC); RET-positive Thyroid Cancer","metadata":null},{"id":"04699c7613b643a4b3d2510723e39036","type":"TRIAL","name":"A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020","canonical_id":"clinicaltrials.gov:NCT05385705","description":"Breast Neoplasms","metadata":null},{"id":"edbcdf338d9c4ddea43cf78f653c4efd","type":"TRIAL","name":"A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy","canonical_id":"clinicaltrials.gov:NCT00708201","description":"Postoperative Ileus","metadata":null},{"id":"6326504b2abf4913896ef3285b9323c3","type":"TRIAL","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT06385080","description":"Squamous Cell Carcinoma of Head and Neck","metadata":null},{"id":"43cb740c44754fa48e085c7a10056a93","type":"TRIAL","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05379595","description":"Advanced or Metastatic Colorectal Cancer","metadata":null},{"id":"8416fdbc8b6649c987697e3fd1873a49","type":"TRIAL","name":"A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05653427","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"04dd05751b1242acb09bda2189b161c7","type":"TRIAL","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05488314","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"410a8e47b5344f2ab6f0f0c5fba59673","type":"TRIAL","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","canonical_id":"clinicaltrials.gov:NCT06750094","description":"Colorectal Neoplasms","metadata":null},{"id":"0ed1ee41522d4d668fde8338270305a1","type":"TRIAL","name":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04487080","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"13b4a058308c412caf4b96020a62ec6a","type":"TRIAL","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","canonical_id":"clinicaltrials.gov:NCT04988295","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"c725acf58533421eb8be17335be7570a","type":"TRIAL","name":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT04965090","description":"Metastatic Non Small Cell Lung Cancer; Recurrent Non Small Cell Lung Cancer","metadata":null},{"id":"75e191973804492bbc88406d83156cf2","type":"TRIAL","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07227025","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"f600e42f8a9d49289a7c0cd480bb2870","type":"TRIAL","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06662786","description":"Colorectal Neoplasms","metadata":null},{"id":"c358b9f8517b4b09b36d4dffc6a90d74","type":"TRIAL","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT07276399","description":"Squamous Cell Carcinoma of Head and Neck","metadata":null},{"id":"4d133a5019094bca98f8660bbc4d1f0e","type":"TRIAL","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06667076","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"4ca3f4b8beb7463783ff4244858f171c","type":"TRIAL","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05498428","description":"Carcinoma, Non-small-Cell Lung","metadata":null},{"id":"0250ff8eb8c145799928ab4f0fa20b0e","type":"TRIAL","name":"A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT04945733","description":"Stomach Neoplasms; Esophageal Neoplasms","metadata":null},{"id":"977a18044b824f6c88022c6395ba8808","type":"TRIAL","name":"A Study of Amivantamab in People With Esophagogastric Cancer","canonical_id":"clinicaltrials.gov:NCT05117931","description":"Esophagogastric Cancer","metadata":null},{"id":"25a75115de8c4f3592a94d8a81e5b2d3","type":"TRIAL","name":"A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders","canonical_id":"clinicaltrials.gov:NCT02125318","description":"Thrombocytosis; Myeloproliferative Neoplasms","metadata":null},{"id":"91f72c2a1ad4436ca5eb64b6d08ac8cf","type":"TRIAL","name":"A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients","canonical_id":"clinicaltrials.gov:NCT00202644","description":"Thrombocythemia, Hemorrhagic","metadata":null},{"id":"86e5fbf303b944729f7aa69eb3869585","type":"TRIAL","name":"A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy","canonical_id":"clinicaltrials.gov:NCT04148430","description":"B Cell ALL; B-Cell Lymphoma; B-cell Non Hodgkin Lymphoma","metadata":null},{"id":"c490f7023a554f72aca397eaf0c62178","type":"TRIAL","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","canonical_id":"clinicaltrials.gov:NCT02489318","description":"Prostate Cancer","metadata":null},{"id":"075fe0845fde4912865c34654a76b87c","type":"TRIAL","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","canonical_id":"clinicaltrials.gov:NCT04325828","description":"Salivary Gland Neoplasms","metadata":null},{"id":"cf3bc423f17341d2b4a0ccdd9b8637fa","type":"TRIAL","name":"A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03344614","description":"Colorectal Cancer","metadata":null},{"id":"366397e6d9774daba0340c183c70cb2d","type":"TRIAL","name":"A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart","canonical_id":"clinicaltrials.gov:NCT02415400","description":"Acute Coronary Syndromes","metadata":null},{"id":"5c28d15c480f470ab99a95a7de3b54cd","type":"TRIAL","name":"A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06088199","description":"Plaque Psoriasis","metadata":null},{"id":"4c5f61e7fecc470f932a40b8ec4cc4c2","type":"TRIAL","name":"A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects","canonical_id":"clinicaltrials.gov:NCT02275481","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"fa44edd78a59449d8761a95c3d78e506","type":"TRIAL","name":"A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01375842","description":"Tumors; Hematologic Malignancies","metadata":null},{"id":"549421395f4146e38cf492599d479a02","type":"TRIAL","name":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT02908672","description":"Melanoma","metadata":null},{"id":"e4daf29c64074b79a0377e10aebc4438","type":"TRIAL","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05009069","description":"Rectal Neoplasms; Rectal Cancer","metadata":null},{"id":"4baa9859f98f436ca60685ee6b465e69","type":"TRIAL","name":"A Study of Atezolizumab in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02458638","description":"Tumors","metadata":null},{"id":"3cfa833260ec4c2c8d331d4374f84f8c","type":"TRIAL","name":"A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03693573","description":"Renal Cell Carcinoma","metadata":null},{"id":"770d9cbdfa4d4cd0aeed2c38ef85f7db","type":"TRIAL","name":"A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00036543","description":"Prostate Cancer","metadata":null},{"id":"3402ffeef93245f484108688f5e5a8e3","type":"TRIAL","name":"A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors","canonical_id":"clinicaltrials.gov:NCT00920764","description":"Chronic Kidney Disease; Diabetic Nephropathy","metadata":null},{"id":"b8f426152e514fc58f55cfde5089e324","type":"TRIAL","name":"A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT05568407","description":"Bladder Cancer","metadata":null},{"id":"0485f4d5e57b481b90edf9227c15a84f","type":"TRIAL","name":"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03637491","description":"Pancreatic Cancer","metadata":null},{"id":"59d86b1f5d3f47b0890f733c26fdfcb1","type":"TRIAL","name":"A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT05198804","description":"Ovarian Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer","metadata":null},{"id":"6f03fd2017094c3cb6dcdea834e3b8c6","type":"TRIAL","name":"A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT07676175","description":"Previously Untreated Peripheral T-Cell Lymphoma","metadata":null},{"id":"eb071c7e6b514eb1878fcb00ee13049c","type":"TRIAL","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","canonical_id":"clinicaltrials.gov:NCT06970743","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"c44f138a072e4dd7ae6b59185ccb069c","type":"TRIAL","name":"A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia","canonical_id":"clinicaltrials.gov:NCT07064486","description":"Type 2 Diabetes (T2DM)","metadata":null},{"id":"6bb15d077f0740999154546d240ff07b","type":"TRIAL","name":"A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02283320","description":"KRAS Positive Patients With Non-small Cell Lung Cancer; Squamous Cell Non-small Cell Lung Cancer","metadata":null},{"id":"e8e1cfa79d884a9aa7fda663fd1b5723","type":"TRIAL","name":"A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT06986785","description":"Advanced Hepatocellular Carcinoma","metadata":null},{"id":"df32f75696b545849392472ce96ac824","type":"TRIAL","name":"A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT07797881","description":"Nasopharyngeal Carcinoma (NPC)","metadata":null},{"id":"d4b5a72ed4234abc9990992dadcc382b","type":"TRIAL","name":"A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids","canonical_id":"clinicaltrials.gov:NCT00402168","description":"Renal Transplant","metadata":null},{"id":"455a194a90f34aef8a4f595b8f5cdbcc","type":"TRIAL","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06697197","description":"Advanced Solid Tumors","metadata":null},{"id":"d5730b7c04ab4b7bae4a5e3ca9c2e098","type":"TRIAL","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","canonical_id":"clinicaltrials.gov:NCT07492680","description":"Solid Tumors","metadata":null},{"id":"c792eb8f258d498e830ec276651d831e","type":"TRIAL","name":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07335796","description":"Prostate Cancer","metadata":null},{"id":"7d7864627b5a4bbcb24680090ddbc1a0","type":"TRIAL","name":"A Study of BNC105P Combined With Ibrutinib","canonical_id":"clinicaltrials.gov:NCT03454165","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"2489f03ec67d4aca95ed43ce75d9b1d0","type":"TRIAL","name":"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05433480","description":"Breast Cancer","metadata":null},{"id":"24eda24de36f432089657d0e71d3d1ea","type":"TRIAL","name":"A Study of Baclofen ER","canonical_id":"clinicaltrials.gov:NCT02003664","description":"Cocaine Dependence","metadata":null},{"id":"007ff44f358b4c0b82a7f303307be00e","type":"TRIAL","name":"A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03952559","description":"Atopic Dermatitis","metadata":null},{"id":"2c750fdd7a4c467d9f88d3fdb94b71da","type":"TRIAL","name":"A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis","canonical_id":"clinicaltrials.gov:NCT04088409","description":"Uveitis","metadata":null},{"id":"1d8f405b3db84312a6e5b2c906e7c0ea","type":"TRIAL","name":"A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02576938","description":"Atopic Dermatitis","metadata":null},{"id":"2614d976ce7b4a138493568793315910","type":"TRIAL","name":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03915964","description":"Rheumatoid Arthritis","metadata":null},{"id":"71e81fbc074442fd9eb33f61a6733a0c","type":"TRIAL","name":"A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03334396","description":"Atopic Dermatitis","metadata":null},{"id":"b7f01142115543a09fa70abf62541f81","type":"TRIAL","name":"A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)","canonical_id":"clinicaltrials.gov:NCT07222332","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"5572a16b37ca4df985edcdfbc595846a","type":"TRIAL","name":"A Study of Baricitinib and Ciclosporin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01968057","description":"Healthy Volunteers","metadata":null},{"id":"41d7708fbe5d4741ae8c24e55d4153d9","type":"TRIAL","name":"A Study of Baricitinib and Simvastatin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01960140","description":"Healthy Volunteers","metadata":null},{"id":"c1cfc5ac526b4f32a6f0c4c567d2646d","type":"TRIAL","name":"A Study of Baricitinib in Healthy Japanese Participants","canonical_id":"clinicaltrials.gov:NCT02263911","description":"Healthy Participants","metadata":null},{"id":"ab32b8698d784f4baa523a0fd10a0d8d","type":"TRIAL","name":"A Study of Baricitinib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03212638","description":"Healthy","metadata":null},{"id":"c69bc729fe4a454793e2f6c4da8fd767","type":"TRIAL","name":"A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis","canonical_id":"clinicaltrials.gov:NCT03773978","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"b3aa2d52790e42cabf610376cef867f5","type":"TRIAL","name":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT04086745","description":"Rheumatoid Arthritis","metadata":null},{"id":"5936fab9b4954d0b83463731d6326b3c","type":"TRIAL","name":"A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT01484496","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"b6cd49425a2a4ff58723db5a2290628b","type":"TRIAL","name":"A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy","canonical_id":"clinicaltrials.gov:NCT01610492","description":"Glomerulonephritis, Membranous","metadata":null},{"id":"20feaaa36c5045868c831ad5c0ece0ad","type":"TRIAL","name":"A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT00424476","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"43bc42186e20465eb00632a1ffa1dbab","type":"TRIAL","name":"A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia","canonical_id":"clinicaltrials.gov:NCT01142011","description":"Symptomatic Waldenstroms Macroglobulinaemia","metadata":null},{"id":"fe8eff20dba14849a9046a3cbafcafad","type":"TRIAL","name":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06472076","description":"Lung Cancer, Non-Small Cell","metadata":null},{"id":"fd7ec176b00c4af59b9330f141e38477","type":"TRIAL","name":"A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)","canonical_id":"clinicaltrials.gov:NCT07116031","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"c5243a7b50ac45229315c0eeb675ee7e","type":"TRIAL","name":"A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT07006506","description":"Graft Versus Host Disease; Graft Vs Host Disease; Hematologic Malignancy","metadata":null},{"id":"ddf6949e282341c3afeaef9c857c486b","type":"TRIAL","name":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)","canonical_id":"clinicaltrials.gov:NCT05468697","description":"Renal Cell Carcinoma","metadata":null},{"id":"1fa826ac3a73400fa80c93fee1be3ba3","type":"TRIAL","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07538271","description":"SCLC, Extensive Stage","metadata":null},{"id":"c8395f6bb1a24c8eb4ea48eb96e01a36","type":"TRIAL","name":"A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04791319","description":"Dermatitis, Atopic","metadata":null},{"id":"57a86287dd6b42519ca9ed0cd1a2649b","type":"TRIAL","name":"A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01364012","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"f279231c52f441918115f8f12444afa5","type":"TRIAL","name":"A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT05296304","description":"Cutaneous T-cell Lymphoma","metadata":null},{"id":"b2933d33687144c9901f45e97ace205c","type":"TRIAL","name":"A Study of Bezafibrate in Mitochondrial Myopathy","canonical_id":"clinicaltrials.gov:NCT02398201","description":"Mitochondrial Diseases","metadata":null},{"id":"1c57f0d20f67468cb3e9330671533136","type":"TRIAL","name":"A Study of Bimatoprost 0.01% in the Clinical Setting","canonical_id":"clinicaltrials.gov:NCT01814761","description":"Glaucoma, Primary Open Angle; Ocular Hypertension","metadata":null},{"id":"4fe9f5d0bcb149d9b3cd3fead3d552db","type":"TRIAL","name":"A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers","canonical_id":"clinicaltrials.gov:NCT03843775","description":"Advanced BRAF Mutant Cancers","metadata":null},{"id":"78eaf2245c56428c8cba97442947a97f","type":"TRIAL","name":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","canonical_id":"clinicaltrials.gov:NCT02291289","description":"Colorectal Cancer","metadata":null},{"id":"1a37c45fbd83469fad2597d442133fc1","type":"TRIAL","name":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT06852222","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"b3fc968a1359471b807833d5e8cb5b5b","type":"TRIAL","name":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","canonical_id":"clinicaltrials.gov:NCT06079879","description":"Essential Thrombocythemia","metadata":null},{"id":"df8a6e1dd6f041dbab463edb450c74d6","type":"TRIAL","name":"A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)","canonical_id":"clinicaltrials.gov:NCT02842827","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"705f86bd0288440e92e92a0892a8011f","type":"TRIAL","name":"A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment","canonical_id":"clinicaltrials.gov:NCT05673603","description":"Renal Impairment","metadata":null},{"id":"8b23a96bd3ef47fbbde46edf42e8dd9d","type":"TRIAL","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02979522","description":"Hodgkin Disease","metadata":null},{"id":"413348e0e3c349ca8dfd188913d61de8","type":"TRIAL","name":"A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02572167","description":"Hodgkin Lymphoma","metadata":null},{"id":"e31d152da08e4ac788481c16f15f02b9","type":"TRIAL","name":"A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression","canonical_id":"clinicaltrials.gov:NCT04569032","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"e612355fb5a94e0cb9b7c00fbf8e8de0","type":"TRIAL","name":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03596866","description":"ALK+ Advanced NSCLC","metadata":null},{"id":"20b60c67bf204d50a1d9d7e07df0ebee","type":"TRIAL","name":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","canonical_id":"clinicaltrials.gov:NCT03535740","description":"ALK-positive Advanced NSCLC","metadata":null},{"id":"12add7d9a72846758dae8986698ec220","type":"TRIAL","name":"A Study of Brivaracetam in Subjects With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT00175929","description":"Epilepsy, Focal","metadata":null},{"id":"513bb11eac5a4058af71af6cc05e6a6b","type":"TRIAL","name":"A Study of Brodalumab (SILIQ\u00ae) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen","canonical_id":"clinicaltrials.gov:NCT04149587","description":"Psoriasis","metadata":null},{"id":"24067a16df5e47d5b8d10470e7286b42","type":"TRIAL","name":"A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)","canonical_id":"clinicaltrials.gov:NCT02985983","description":"Axial Spondyloarthritis","metadata":null},{"id":"290182fb3a7e47bcbbedefda63e51909","type":"TRIAL","name":"A Study of Bumetanide for the Treatment of Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT03156153","description":"Autism Spectrum Disorder","metadata":null},{"id":"eab2f5878f0648288998a75ec66c155c","type":"TRIAL","name":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","canonical_id":"clinicaltrials.gov:NCT01625351","description":"Ewing Sarcoma; Gastrointestinal Tumor; Germ Cell Tumor; Hepatic Tumor; Lymphoma; Wilms Tumor; Rhabdoid Tumor; Clear Cell Carcinoma; Renal Cell Carcinoma; Melanoma; Neuroblastoma; Rhabdomyosarcoma; Non-rhabdomyosarcoma","metadata":null},{"id":"c3239c64b86f4d8080ff2636af404755","type":"TRIAL","name":"A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT05937152","description":"Diabetic Polyneuropathy","metadata":null},{"id":"b0aba8bc6a3642d4a8c3b225b44c4738","type":"TRIAL","name":"A Study of CPX-351 (Vyxeos\u2122) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04209725","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"720db2184d4246d495eb4ca5741bf8f4","type":"TRIAL","name":"A Study of CS060380 Tablets in Patients With MASH and Obesity","canonical_id":"clinicaltrials.gov:NCT07466017","description":"Metabolic Dysfunction-associated Steatohepatitis (MASH); Obesity","metadata":null},{"id":"2dbe13c8ca204bb29fd110ee4cb340ac","type":"TRIAL","name":"A Study of Cabergoline for the Treatment of Cocaine Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00033111","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"23f594178bbb4fec9ace68eae886a6ba","type":"TRIAL","name":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","canonical_id":"clinicaltrials.gov:NCT05999149","description":"TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"4c9f5528e11545e69b774317d7bb33eb","type":"TRIAL","name":"A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01508182","description":"Healthy","metadata":null},{"id":"87da12e26241448c9d6253fe473829fa","type":"TRIAL","name":"A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01508195","description":"Healthy","metadata":null},{"id":"c6b4bd0dbec6407e8a1913e810abdae3","type":"TRIAL","name":"A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies","canonical_id":"clinicaltrials.gov:NCT02334748","description":"Systemic Juvenile Idiopathic Arthritis; Hereditary Periodic Fevers","metadata":null},{"id":"c2d7d363095541fa90eb10a32714f300","type":"TRIAL","name":"A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor","canonical_id":"clinicaltrials.gov:NCT02750215","description":"Malignant Non-small Cell Neoplasm of Lung Stage IV","metadata":null},{"id":"27c6f37fda1947d5bba0aa0a118bdffd","type":"TRIAL","name":"A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02151851","description":"Rheumatoid Arthritis","metadata":null},{"id":"80f2b81992f644acbe08dc2cd7b22655","type":"TRIAL","name":"A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04241731","description":"Colorectal Cancer","metadata":null},{"id":"4be2579f7f3c4a8aa282e9721fd3ec21","type":"TRIAL","name":"A Study of Cetuximab\u03b2 Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07000305","description":"Advanced Colorectal Cancer","metadata":null},{"id":"149625cdaca84e788f4f39a79d7e64b5","type":"TRIAL","name":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04709276","description":"Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Cancer","metadata":null},{"id":"18a84d2acfbd4b5a8f48d591631c8809","type":"TRIAL","name":"A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)","canonical_id":"clinicaltrials.gov:NCT06260748","description":"Cerebrotendinous Xanthomatoses","metadata":null},{"id":"91f53bfdf7434759b7e1a544db84e619","type":"TRIAL","name":"A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)","canonical_id":"clinicaltrials.gov:NCT00384475","description":"Rhinitis, Allergic, Seasonal; Hay Fever","metadata":null},{"id":"1c9fcfe537fd44df8119ed5a6eb07533","type":"TRIAL","name":"A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease","canonical_id":"clinicaltrials.gov:NCT00000881","description":"Cytomegalovirus Infections; Cytomegalovirus Retinitis; HIV Infections","metadata":null},{"id":"1e94ac1a535e425fb3a64da67edfb3a6","type":"TRIAL","name":"A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease","canonical_id":"clinicaltrials.gov:NCT01281553","description":"Gastroesophageal Reflux","metadata":null},{"id":"486fbf5470704105b613939c3dc8c3a6","type":"TRIAL","name":"A Study of Cisapride in Premature Infants With Feeding Problems","canonical_id":"clinicaltrials.gov:NCT01281566","description":"Infant, Premature; Infant, Newborn","metadata":null},{"id":"10a2afed84024ebc888efba5f27c300e","type":"TRIAL","name":"A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.","canonical_id":"clinicaltrials.gov:NCT01969877","description":"Locally Advanced Head and Neck Cancer","metadata":null},{"id":"e0e0f4e434e145b78eb1790ef1f5b288","type":"TRIAL","name":"A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders","canonical_id":"clinicaltrials.gov:NCT04739423","description":"Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia","metadata":null},{"id":"3f6c15f23251412c9a97eeaa371811cc","type":"TRIAL","name":"A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)","canonical_id":"clinicaltrials.gov:NCT00317642","description":"Acute Myelogenous Leukemia","metadata":null},{"id":"d45d5b93782a4faa96f737bf904c2cd6","type":"TRIAL","name":"A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.","canonical_id":"clinicaltrials.gov:NCT00315705","description":"Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Relapsed Leukemia","metadata":null},{"id":"13f5815c7fa0423e9ae8c209b18f0993","type":"TRIAL","name":"A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03312530","description":"Multiple Myeloma","metadata":null},{"id":"555e632792054eaeaf122996074b4000","type":"TRIAL","name":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","canonical_id":"clinicaltrials.gov:NCT06521567","description":"Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinsic Pontine Glioma (DIPG); Ependymoma; Osteosarcoma; Hepatic Tumors; Hepatoblastoma; Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Rhabdomyosarcoma","metadata":null},{"id":"cecf9e9db23c46f9b2a5113be096669e","type":"TRIAL","name":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","canonical_id":"clinicaltrials.gov:NCT05508867","description":"Hodgkin Lymphoma","metadata":null},{"id":"8753ea51b545446ca1e24c1f14a46c9f","type":"TRIAL","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","canonical_id":"clinicaltrials.gov:NCT04538664","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"5ef5d825a31f4f048f4ceee0d2e30973","type":"TRIAL","name":"A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)","canonical_id":"clinicaltrials.gov:NCT00383162","description":"Migraine Disorders","metadata":null},{"id":"46261ffd9aa7468aad4afa2536931549","type":"TRIAL","name":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04028245","description":"Carcinoma, Renal Cell","metadata":null},{"id":"b6c96acdf5a440a9a7a4b7a57e98dd00","type":"TRIAL","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05908734","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"d447d609474649bd9c615cfb5102d9bc","type":"TRIAL","name":"A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06532032","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"d510e96a35914bd09be9ad6963006cc2","type":"TRIAL","name":"A Study of Combination Therapy in Children With ADHD","canonical_id":"clinicaltrials.gov:NCT01940978","description":"ADHD; Attention Deficit Hyperactivity Disorder; Attention Deficit Disorder With Hyperactivity; Mental Disorders Diagnosed in Childhood; Attention Deficit and Disruptive Behavior Disorders","metadata":null},{"id":"bb616f870d1b45299d6bfb55f531920b","type":"TRIAL","name":"A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05028348","description":"Multiple Myeloma","metadata":null},{"id":"3785bf355e764a7292afee7a4d7b516a","type":"TRIAL","name":"A Study of Continuous Oral Contraceptives and Doxycycline","canonical_id":"clinicaltrials.gov:NCT00480532","description":"Contraceptives, Oral","metadata":null},{"id":"07c7d0c028514d6eba99664a01a34f6b","type":"TRIAL","name":"A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension","canonical_id":"clinicaltrials.gov:NCT00444834","description":"Hypertension","metadata":null},{"id":"d0b1726926ce4fd3a22edcee7cdb4c88","type":"TRIAL","name":"A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04253262","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"f04188e81cf9490290b03c03e6821a59","type":"TRIAL","name":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged \u2265 2 Years, With Mild-moderate AD","canonical_id":"clinicaltrials.gov:NCT03539601","description":"Atopic Dermatitis","metadata":null},{"id":"d2ff8daed3ee4b69ad63622750c844c4","type":"TRIAL","name":"A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT00101725","description":"Irritable Bowel Syndrome; Colonic Diseases; Diarrhea; Gastrointestinal Disease","metadata":null},{"id":"e0fe36eb49c44b1b9825e2689a704827","type":"TRIAL","name":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT03822559","description":"Open-angle Glaucoma, Ocular Hypertension","metadata":null},{"id":"9790e4ee4a904ea094dd11ddea3ec7ff","type":"TRIAL","name":"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT01181167","description":"Prevention; Venous Thromboembolism","metadata":null},{"id":"1928a3d9eb614dfc877d7df4f937b5bc","type":"TRIAL","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","canonical_id":"clinicaltrials.gov:NCT07139873","description":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","metadata":null},{"id":"b46abc8645764e7695c2df2a73231cdb","type":"TRIAL","name":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06978400","description":"Neoplasms","metadata":null},{"id":"872af725923f4b7e9d55fc5be8e59084","type":"TRIAL","name":"A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India","canonical_id":"clinicaltrials.gov:NCT07806591","description":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","metadata":null},{"id":"360b4ba8dead40b9befcf1b7b3d75792","type":"TRIAL","name":"A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy","canonical_id":"clinicaltrials.gov:NCT00362466","description":"Leukemia","metadata":null},{"id":"282f5929b1e44726ae842381a50fabbd","type":"TRIAL","name":"A Study of Decreased Mental Function Associated With HIV","canonical_id":"clinicaltrials.gov:NCT00027040","description":"Cognitive Disorders; HIV Infections","metadata":null},{"id":"936449fa73d749a09c427871692dd621","type":"TRIAL","name":"A Study of Definitive Therapy to Treat Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02716974","description":"Prostate Cancer","metadata":null},{"id":"a007cfc890f945a2842c5c41c5d6a213","type":"TRIAL","name":"A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT02833610","description":"Multiple Myeloma","metadata":null},{"id":"b2e75568d3da4e20bbdae17c7c5b6f13","type":"TRIAL","name":"A Study of Depemokimab in Participants of 6 to 11 Years of Age","canonical_id":"clinicaltrials.gov:NCT07671001","description":"Asthma","metadata":null},{"id":"b6b2f92c3f3343d98fdb8cfe52e1eee1","type":"TRIAL","name":"A Study of Different Use Regimens Using Two Acne Treatments","canonical_id":"clinicaltrials.gov:NCT00907257","description":"Acne Vulgaris","metadata":null},{"id":"9c56cc532576446093c2f1cc0303222b","type":"TRIAL","name":"A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease","canonical_id":"clinicaltrials.gov:NCT07117851","description":"Extramammary Paget Disease; Scrotum Disease","metadata":null},{"id":"eeaf0f7e3dda4885b0738b05d7b25b16","type":"TRIAL","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","canonical_id":"clinicaltrials.gov:NCT04879329","description":"Urothelial Carcinoma","metadata":null},{"id":"00da04ef09114737be8cc063d807e1bc","type":"TRIAL","name":"A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06944496","description":"Gastric Carcinoma","metadata":null},{"id":"50f32b584aed4143bac9460d27c813c5","type":"TRIAL","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","canonical_id":"clinicaltrials.gov:NCT07315750","description":"Gastric Carcinoma","metadata":null},{"id":"0d777fb6c5b744379c5e2ec2b128c036","type":"TRIAL","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06157892","description":"Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Metastatic Breast Cancer; Metastatic Gastric Cancer; Advanced Breast Cancer; Advanced Gastric Cancer","metadata":null},{"id":"dd96998f242b42aa999231f4b39534db","type":"TRIAL","name":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","canonical_id":"clinicaltrials.gov:NCT06003231","description":"Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms","metadata":null},{"id":"1cc877b458ef4d389685467165e82c7b","type":"TRIAL","name":"A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01703091","description":"Non-small Cell Lung Cancer Metastatic","metadata":null},{"id":"8c2e4474830a4605a2fd291891f0ac0a","type":"TRIAL","name":"A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)","canonical_id":"clinicaltrials.gov:NCT05108922","description":"Mild Cognitive Impairment (MCI); Alzheimer Disease","metadata":null},{"id":"579431a116564fd389525f6fe811941b","type":"TRIAL","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT06317311","description":"Carcinoma","metadata":null},{"id":"4a84a71b24c14e15a19e88a13ced8953","type":"TRIAL","name":"A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05723562","description":"Neoplasms, Rectal","metadata":null},{"id":"e112d7bc885141bfa75a002c852d456f","type":"TRIAL","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06256588","description":"Neoplasms, Head and Neck","metadata":null},{"id":"07de7a3f7c754391be735f9f379ba1f5","type":"TRIAL","name":"A Study of Dotinurad Versus Allopurinol in Participants With Gout","canonical_id":"clinicaltrials.gov:NCT07089875","description":"Gout","metadata":null},{"id":"94544d37af9a4a5790e1b230ae277184","type":"TRIAL","name":"A Study of Dotinurad Versus Allopurinol in Tophaceous Gout","canonical_id":"clinicaltrials.gov:NCT07089888","description":"Tophaceous Gout","metadata":null},{"id":"2bda37d4272b4d7da16183ba1b24faf2","type":"TRIAL","name":"A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT02451943","description":"Soft Tissue Sarcoma","metadata":null},{"id":"3a09f02df1ce412a9fc00a6ee8e78411","type":"TRIAL","name":"A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT01855919","description":"Back Pain Lower Back Chronic","metadata":null},{"id":"0ce1b2129abe4b86ab2b3795efb38952","type":"TRIAL","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT02519348","description":"Hepatocellular Carcinoma","metadata":null},{"id":"d4467278625e4e7f9bac1c76b2a544fd","type":"TRIAL","name":"A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05508659","description":"Advanced Solid Tumors","metadata":null},{"id":"aba94389fcd943cc96e6d82cafbaf6a2","type":"TRIAL","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","canonical_id":"clinicaltrials.gov:NCT06522737","description":"Lymphoma","metadata":null},{"id":"b86b7e3fb0154dea98b44ba7773add28","type":"TRIAL","name":"A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor","canonical_id":"clinicaltrials.gov:NCT02640833","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Non-Hodgkin Lymphoma","metadata":null},{"id":"4de616f10ef44226afa01d4542e822bf","type":"TRIAL","name":"A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT04193293","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"3a989ee2a03144e08e66bdaa98670c8c","type":"TRIAL","name":"A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)","canonical_id":"clinicaltrials.gov:NCT02576275","description":"Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"31baee4a9b204fb5932849d825fd54bb","type":"TRIAL","name":"A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)","canonical_id":"clinicaltrials.gov:NCT02391545","description":"CD20+ Follicular Lymphoma","metadata":null},{"id":"f9024eb0c2854556800471685e44a8f2","type":"TRIAL","name":"A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01882803","description":"Indolent Non-Hodgkin Lymphoma","metadata":null},{"id":"1868693c0fd843a89d0a9692e136a102","type":"TRIAL","name":"A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT03372057","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"d6d4305a0dec418ebbfc9a5cc79423e8","type":"TRIAL","name":"A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment","canonical_id":"clinicaltrials.gov:NCT01136733","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"88688d24c0c244eb9518831e50d835d8","type":"TRIAL","name":"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors","canonical_id":"clinicaltrials.gov:NCT03775850","description":"Colorectal Cancer Metastatic; Triple Negative Breast Cancer; Non Small Cell Lung Cancer; Bladder Cancer; GastroEsophageal Cancer; Renal Cell Carcinoma; MSI-H","metadata":null},{"id":"6e4ce6d8827a4b1098ec746c72bb80ba","type":"TRIAL","name":"A Study of ELIGARD\u00ae in Hormone-dependent Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03035032","description":"Prostate Cancer","metadata":null},{"id":"13919515390447969575f707a0e1ad06","type":"TRIAL","name":"A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies","canonical_id":"clinicaltrials.gov:NCT00249808","description":"Psoriasis","metadata":null},{"id":"85c48a0a60254850ad298604e2e43198","type":"TRIAL","name":"A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)","canonical_id":"clinicaltrials.gov:NCT00073372","description":"Cerebrovascular Accident; Brain Ischemia; Acute Disease","metadata":null},{"id":"84333bdf8f7b4c6e9dede6a317c14ca7","type":"TRIAL","name":"A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)","canonical_id":"clinicaltrials.gov:NCT02139943","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"4df0ec1fcc024540a8b4c87a1131c5e7","type":"TRIAL","name":"A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05469113","description":"Healthy","metadata":null},{"id":"202a45a33b3b432f81aa2402d755188b","type":"TRIAL","name":"A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma","canonical_id":"clinicaltrials.gov:NCT07456033","description":"Asthma","metadata":null},{"id":"5126e645f28f4eba8ee1c3aa05d7404d","type":"TRIAL","name":"A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids","canonical_id":"clinicaltrials.gov:NCT05653219","description":"Primary Immune Thrombocytopenia","metadata":null},{"id":"635ce76ac5ff40e6882ebf49866328cb","type":"TRIAL","name":"A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections","canonical_id":"clinicaltrials.gov:NCT02321800","description":"Urinary Tract Infections","metadata":null},{"id":"fa8f289e4caa4d5aad825047358eebbd","type":"TRIAL","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","canonical_id":"clinicaltrials.gov:NCT06483334","description":"Metastatic Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma","metadata":null},{"id":"151a3f66a99847bc95a9fa0c76a41e57","type":"TRIAL","name":"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02718833","description":"Multiple Myeloma","metadata":null},{"id":"3b812ce1964d4704b814f088e62a9cf4","type":"TRIAL","name":"A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT07637578","description":"Multiple Myeloma (MM); Multiple Myeloma Refractory; Multiple Myeloma in Relapse; Multiple Myeloma","metadata":null},{"id":"fda70ffec78541ab9cb04504fbca6582","type":"TRIAL","name":"A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT06598943","description":"Ulcerative Colitis; Ulcerative Colitis Chronic","metadata":null},{"id":"6427282f94b84c87b6d32e4133cf7c94","type":"TRIAL","name":"A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02323191","description":"Solid Cancers","metadata":null},{"id":"d5267d4285c442c7982c4f34b0c7061a","type":"TRIAL","name":"A Study of Emapalumab for Pediatric Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT06430788","description":"Aplastic Anemia; Cytopenia; Hypocellular Marrow","metadata":null},{"id":"718680d6d24f4bb896d51d93cf1fb66c","type":"TRIAL","name":"A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT02082210","description":"Advanced Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Cancer; Renal Cell Carcinoma; Non-Small Cell Lung Cancer","metadata":null},{"id":"1378ec2e24374d0c9ab23b655eaee4d2","type":"TRIAL","name":"A Study of Enalapril in Treatment of Venous Malformations","canonical_id":"clinicaltrials.gov:NCT06788314","description":"Venous Malformation; Pain; Quality of Life; Vascular Malformation","metadata":null},{"id":"525e1adbe81a4b35806073d9969698df","type":"TRIAL","name":"A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT03219333","description":"Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms; Renal Pelvis Neoplasms; Urothelial Cancer; Ureteral Neoplasms; Urethral Neoplasms","metadata":null},{"id":"2a2339edaf2a4636bf21f1bc3d518de7","type":"TRIAL","name":"A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract","canonical_id":"clinicaltrials.gov:NCT05868265","description":"Urothelial Carcinoma","metadata":null},{"id":"e27bbe5fc45d4c05b854c7932ccdcb4d","type":"TRIAL","name":"A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)","canonical_id":"clinicaltrials.gov:NCT06772779","description":"Healthy","metadata":null},{"id":"703dfb1f3a9848d7be173d206f8fa979","type":"TRIAL","name":"A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05414630","description":"Non-small Cell Lung Cancer Stage III","metadata":null},{"id":"f27408d02a64456faf198affc02ed654","type":"TRIAL","name":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05726292","description":"Prostate Cancer; Prostate Adenocarcinoma","metadata":null},{"id":"2ed3dc82cbfd490787928fb14b36dda4","type":"TRIAL","name":"A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07030699","description":"Lymphoma","metadata":null},{"id":"46ea64d3228b49a5b0a212d6b4c9a492","type":"TRIAL","name":"A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)","canonical_id":"clinicaltrials.gov:NCT07082868","description":"Primary Central Nervous System Lymphoma (PCNSL); Primary Central Nervous System Lymphoma; Relapsed Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma; Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma (SCNSL)","metadata":null},{"id":"7a7db0eb595949c39dbda9d4ea0a4e1c","type":"TRIAL","name":"A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00407927","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"3896e15460d54ff4b2e316820195006b","type":"TRIAL","name":"A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache","canonical_id":"clinicaltrials.gov:NCT05452239","description":"Migraine; Medication Overuse Headache","metadata":null},{"id":"4a6d31246d874203b85df4012a9c62c6","type":"TRIAL","name":"A Study of Eptinezumab in Pediatric Participants With Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT05897320","description":"Episodic Migraine","metadata":null},{"id":"a94fc63f44ac46b0aa3aaad7716b18fa","type":"TRIAL","name":"A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02654769","description":"Actinic Keratosis","metadata":null},{"id":"e31738d3d4c44c92818cbc36432997dc","type":"TRIAL","name":"A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","canonical_id":"clinicaltrials.gov:NCT02091999","description":"Metastatic Urothelial Cancer and Other Malignant Solid Tumors","metadata":null},{"id":"bc644c61bb114b129e76871e582e71a6","type":"TRIAL","name":"A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma","canonical_id":"clinicaltrials.gov:NCT01290549","description":"Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia","metadata":null},{"id":"799f6545de064c008e423ae949699639","type":"TRIAL","name":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","canonical_id":"clinicaltrials.gov:NCT03852160","description":"Depressive Disorder, Treatment-Resistant","metadata":null},{"id":"ad38cedbcdaa4081a5b79fffd7350d29","type":"TRIAL","name":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","canonical_id":"clinicaltrials.gov:NCT02915744","description":"Metastasis; Breast Cancer","metadata":null},{"id":"42aed2686cfc45b7bb9ef5265fa841d7","type":"TRIAL","name":"A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)","canonical_id":"clinicaltrials.gov:NCT01429168","description":"Osteoarthritis","metadata":null},{"id":"4832f06ce9a34e23aed69bed5000b653","type":"TRIAL","name":"A Study of Evacetrapib and Digoxin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01897493","description":"Healthy Volunteers","metadata":null},{"id":"710500fa709147e6aa26e901e6e8d39a","type":"TRIAL","name":"A Study of Evacetrapib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01736254","description":"Healthy Volunteers","metadata":null},{"id":"eecf021f782e47efa20cc506b26df9ef","type":"TRIAL","name":"A Study of Evacetrapib in Japanese and Non-Japanese Participants","canonical_id":"clinicaltrials.gov:NCT01958489","description":"Healthy Volunteers","metadata":null},{"id":"c1cb8a1f21f94d5fbd674bd294459cfc","type":"TRIAL","name":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04425070","description":"Peripheral T-cell Lymphoma; NK/T-cell Lymphoma","metadata":null},{"id":"71bb272fb3a545c799ad23e57d5ee898","type":"TRIAL","name":"A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis","canonical_id":"clinicaltrials.gov:NCT01954693","description":"Tuberous Sclerosis","metadata":null},{"id":"5ab179686c114f67a8dafd0cad2286e6","type":"TRIAL","name":"A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy","canonical_id":"clinicaltrials.gov:NCT04539223","description":"Carotid Artery Stenosis; Asymptomatic Carotid Artery Stenosis","metadata":null},{"id":"74d81b02e55848e29fc21db05fdf97d3","type":"TRIAL","name":"A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)","canonical_id":"clinicaltrials.gov:NCT05524545","description":"Bladder Cancer; Urothelial Carcinoma","metadata":null},{"id":"e2caeefb93fc4fd286c84a26c95e3d1d","type":"TRIAL","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","canonical_id":"clinicaltrials.gov:NCT05002127","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma","metadata":null},{"id":"4d649e1d6256429991f4ab5e9b3f5478","type":"TRIAL","name":"A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)","canonical_id":"clinicaltrials.gov:NCT03013218","description":"Metastatic Cancer; Solid Tumor; Advanced Cancer; NonHodgkin Lymphoma","metadata":null},{"id":"dca5c89374a44d9ea477e89438a40492","type":"TRIAL","name":"A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00500318","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"33a3221d88f241a8b73663368406938a","type":"TRIAL","name":"A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)","canonical_id":"clinicaltrials.gov:NCT00783263","description":"Hypercholesterolemia","metadata":null},{"id":"f37ebf385a9446cd821f250bb57e0341","type":"TRIAL","name":"A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01653574","description":"Breast Neoplasms","metadata":null},{"id":"88cc2b9aef264f808fbf09a22b2de44b","type":"TRIAL","name":"A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02364362","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"24b89e595b5f4feaaa49bb40ded723f6","type":"TRIAL","name":"A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC","canonical_id":"clinicaltrials.gov:NCT03904823","description":"EGFR-mutant Non-Small Cell Lung Cancer","metadata":null},{"id":"2981426c5ad5402f845dfe71f9546675","type":"TRIAL","name":"A Study of Famitinib in Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01762293","description":"Colorectal Cancer; Colorectal Cancer Metastatic; Colorectal Cancer Recurrent","metadata":null},{"id":"cfa13cfaeae148afa6a31b39adb143dc","type":"TRIAL","name":"A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer","canonical_id":"clinicaltrials.gov:NCT01829841","description":"Renal Cell Cancer; Metastatic Renal Cell Cancer","metadata":null},{"id":"d6a4b6434f094377a2eb7498eb1c5c94","type":"TRIAL","name":"A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02356991","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"41641892af8a4600bafaed4c394d8c68","type":"TRIAL","name":"A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor","canonical_id":"clinicaltrials.gov:NCT01994213","description":"Gastroenteropancreatic Neuroendocrine Tumor","metadata":null},{"id":"91d0d25adf02499a8726c51b76864fdd","type":"TRIAL","name":"A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT02699450","description":"Diabetic Macular Edema","metadata":null},{"id":"135e23ca44534374bfdafdafe976aeed","type":"TRIAL","name":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT04955938","description":"IDH Mutation; IDH1 Mutation; IDH2 Gene Mutation; Blood Cancer; Myeloproliferative Neoplasm","metadata":null},{"id":"07259c9a841641f88ae7f6d2c2df9b7a","type":"TRIAL","name":"A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","canonical_id":"clinicaltrials.gov:NCT04446650","description":"Primary Myelofibrosis","metadata":null},{"id":"b6899c56af1744d1bcc914d77f7478fb","type":"TRIAL","name":"A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT05033886","description":"Vasomotor Symptoms","metadata":null},{"id":"ba38b2099031438590bea5b9e4cd0f44","type":"TRIAL","name":"A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice","canonical_id":"clinicaltrials.gov:NCT06964113","description":"Ulcerative Colitis","metadata":null},{"id":"f60c2d384c2c448e923619c0687c0751","type":"TRIAL","name":"A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT06625242","description":"Rheumatoid Arthritis","metadata":null},{"id":"3f95033738be4c829393b59145164b89","type":"TRIAL","name":"A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT01178073","description":"Hypertension, Pulmonary","metadata":null},{"id":"b50a418a16ab4fd0862523a192d58952","type":"TRIAL","name":"A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors","canonical_id":"clinicaltrials.gov:NCT03707340","description":"Breast Cancer; Hyposexual Desire Disorder","metadata":null},{"id":"612effbc5d854604893be47f2c4bd78b","type":"TRIAL","name":"A Study of Florbetapir (18F) in Japanese Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01660815","description":"Alzheimer's Disease","metadata":null},{"id":"f73d2d8e4b794d32968be0084ed5b85c","type":"TRIAL","name":"A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis","canonical_id":"clinicaltrials.gov:NCT01048866","description":"Pharyngitis","metadata":null},{"id":"e124692c68764aeb83775b8dbe4b7414","type":"TRIAL","name":"A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients","canonical_id":"clinicaltrials.gov:NCT06169202","description":"Fruquintinib; Irinotecan; Capecitabine; Gastrointestinal Tumours","metadata":null},{"id":"2571d013b1f5445e8be5c56c6c62a5b1","type":"TRIAL","name":"A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04577963","description":"Triple Negative Breast Cancer; Endometrial Cancer; Solid Tumor, Unspecified, Adult; Colorectal Cancer","metadata":null},{"id":"1d0f7b0f6c2e497fbc96c026a9af4a56","type":"TRIAL","name":"A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT06857214","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"55bf905ee56242ca959c0ed7e32f8267","type":"TRIAL","name":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","canonical_id":"clinicaltrials.gov:NCT04718389","description":"Asthma","metadata":null},{"id":"066d5025f9f640d0b1c0a1629a16ccc5","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT05127486","description":"Migraine; Episodic Migraine","metadata":null},{"id":"d0ccadd10413404bbc62286c1868fbda","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine","canonical_id":"clinicaltrials.gov:NCT03559257","description":"Migraine","metadata":null},{"id":"5e432af78ada47a3934deb40f42b8708","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT04085289","description":"Healthy","metadata":null},{"id":"02aaf860c336438b9277fe560fab4c0d","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT04616326","description":"Chronic Migraine","metadata":null},{"id":"00d48dc1ca974562990d48870c7d2022","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT03432286","description":"Episodic Migraine","metadata":null},{"id":"3a00d5e568e1462a83882f96be095a3d","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT03963232","description":"Episodic Migraine","metadata":null},{"id":"9852d940c86b4a4ca21bb90d1717d8a2","type":"TRIAL","name":"A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache","canonical_id":"clinicaltrials.gov:NCT02163993","description":"Migraine Headache","metadata":null},{"id":"714068d559804f5e86cabecc30794420","type":"TRIAL","name":"A Study of Galcanezumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02576951","description":"Healthy","metadata":null},{"id":"d6d8ebd90ba54e4582f0dc46b0c023b3","type":"TRIAL","name":"A Study of Galcanezumab in Healthy Participants.","canonical_id":"clinicaltrials.gov:NCT02836613","description":"Healthy","metadata":null},{"id":"5d064cc2e2224c42a45d6be7801cccfb","type":"TRIAL","name":"A Study of Galcanezumab in Participants With Chronic Cluster Headache","canonical_id":"clinicaltrials.gov:NCT02438826","description":"Chronic Cluster Headache","metadata":null},{"id":"fb9a7cff42b1489797153debb4973295","type":"TRIAL","name":"A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist","canonical_id":"clinicaltrials.gov:NCT04294147","description":"Migraine","metadata":null},{"id":"af9f371e587947fea9ef8d31d84437e6","type":"TRIAL","name":"A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Na\u00efve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02941601","description":"Locally Advanced Squamous Non-Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Cancer","metadata":null},{"id":"5ccea753d65542e8be3324867c3dcc3a","type":"TRIAL","name":"A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01788566","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"94d113cea55d4156ad7cf63152001ef1","type":"TRIAL","name":"A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy","canonical_id":"clinicaltrials.gov:NCT04027309","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2","metadata":null},{"id":"29592fb050e34f41a34959eee85b753a","type":"TRIAL","name":"A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT05756777","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"c92bcb0c814543ae829e4403a1d479ef","type":"TRIAL","name":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","canonical_id":"clinicaltrials.gov:NCT03467373","description":"B-Cell Lymphoma; Non-Hodgkin Lymphoma","metadata":null},{"id":"0d071aede1604b7b80b8ed7791227303","type":"TRIAL","name":"A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06765317","description":"Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma","metadata":null},{"id":"1cfac6669d3140eca368ad2eb93f7f4e","type":"TRIAL","name":"A Study of Golimumab in Participants With Active Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT02186873","description":"Ankylosing Spondylitis","metadata":null},{"id":"5ace90a1951a40e38bd44c6781d81945","type":"TRIAL","name":"A Study of Golimumab in Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT02181673","description":"Arthritis, Psoriatic","metadata":null},{"id":"3e8f14c1e9ba45d498f1c938e6cb13b5","type":"TRIAL","name":"A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03733925","description":"Spondylitis, Ankylosing; Arthritis, Psoriatic","metadata":null},{"id":"e880f5b9e5ba4cb9a1f70bbfc7f2af15","type":"TRIAL","name":"A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT05083078","description":"Arthritis, Psoriatic; Healthy","metadata":null},{"id":"3654a480af034c108dd33ce4bf55b9d8","type":"TRIAL","name":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04288089","description":"Receptors, Estrogen; Genes, Erbb-2; Breast Neoplasms","metadata":null},{"id":"9aeafa4d08ba4df6b58ae92b5a590c44","type":"TRIAL","name":"A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone","canonical_id":"clinicaltrials.gov:NCT04158947","description":"HER2-positive Breast Cancer; Brain Metastases","metadata":null},{"id":"1fe9874e11f141d38b8a8c514888c5c4","type":"TRIAL","name":"A Study of HRS-9057 in Patients With Heart Failure and Volume Overload","canonical_id":"clinicaltrials.gov:NCT06506994","description":"Heart Failure With Volume Overload","metadata":null},{"id":"ed4e84d1f4914edb948ea7e48d334c68","type":"TRIAL","name":"A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)","canonical_id":"clinicaltrials.gov:NCT02951598","description":"Alzheimer Disease; Mild Cognitive Impairment","metadata":null},{"id":"863bfb3dfd7a4e84816ad3b68a9ebad2","type":"TRIAL","name":"A Study of How the Medicine Called \"Etrasimod\" Works in Children With the Gut Disease Called Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07470879","description":"Colitis, Ulcerative","metadata":null},{"id":"c9cae5c537d04706bd85b20dd7fe81d1","type":"TRIAL","name":"A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT03528629","description":"Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer","metadata":null},{"id":"a3c32bf2f2d840c2927cfcbcc80db6e1","type":"TRIAL","name":"A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma","canonical_id":"clinicaltrials.gov:NCT00533702","description":"Metastatic Malignant Melanoma","metadata":null},{"id":"7e1d7e06db3a4acda0e592d00326e721","type":"TRIAL","name":"A Study of IXAZOMIB in Adult Patients With Lymphoma","canonical_id":"clinicaltrials.gov:NCT00893464","description":"Lymphoma","metadata":null},{"id":"cd3cbeac872249c8bad75df9bc027cbe","type":"TRIAL","name":"A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05560399","description":"Multiple Myeloma","metadata":null},{"id":"4c7892fcb0e0447bad44f74a6d54116a","type":"TRIAL","name":"A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT02537613","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"690a7ec7c67e4622b66d984ee59e9457","type":"TRIAL","name":"A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT01611090","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"3801d20a5e0c45b9bc230e9af5f63a6e","type":"TRIAL","name":"A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants","canonical_id":"clinicaltrials.gov:NCT03888755","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"95e266c93f88452c9d2525fa80ef5f37","type":"TRIAL","name":"A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)","canonical_id":"clinicaltrials.gov:NCT00912093","description":"Hereditary Angioedema","metadata":null},{"id":"e8cae1bae29e48759f219119276f0eac","type":"TRIAL","name":"A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05104788","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"a20598f6eaeb40bbaf6fdc44fd9d4e6f","type":"TRIAL","name":"A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07196722","description":"Crohn Disease","metadata":null},{"id":"e75ae3183930450da39d1aca2e581d51","type":"TRIAL","name":"A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL","canonical_id":"clinicaltrials.gov:NCT01203930","description":"Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)","metadata":null},{"id":"c5822c73eeba4d7bbe08709b11dd71fa","type":"TRIAL","name":"A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","canonical_id":"clinicaltrials.gov:NCT00471497","description":"Myelogenous Leukemia, Chronic","metadata":null},{"id":"9eaf05ca47aa44ab90a37311b6c6c203","type":"TRIAL","name":"A Study of Imlunestrant (LY3484356) in Female Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05444556","description":"Healthy","metadata":null},{"id":"060087dafed640bb8bf79d678b2bf9c9","type":"TRIAL","name":"A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease","canonical_id":"clinicaltrials.gov:NCT04540497","description":"IgG4 Related Disease","metadata":null},{"id":"03138086bc42405a824a4e801870378a","type":"TRIAL","name":"A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag","canonical_id":"clinicaltrials.gov:NCT07759804","description":"Pulmonary Arterial Hypertension (PAH)","metadata":null},{"id":"babc70badf1540b8997a276a61746282","type":"TRIAL","name":"A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT05687032","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"1622eab77e0f41d291babce39efa0d07","type":"TRIAL","name":"A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs","canonical_id":"clinicaltrials.gov:NCT02712112","description":"Gastrointestinal Stromal Tumors (GISTs)","metadata":null},{"id":"4d037fdb3c5e499eab573d70b0702734","type":"TRIAL","name":"A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China","canonical_id":"clinicaltrials.gov:NCT05268068","description":"Healthy Volunteers","metadata":null},{"id":"9b41a89afd8344548aa9cb00cfa4c7a1","type":"TRIAL","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06827613","description":"Triple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancer","metadata":null},{"id":"020647e19ff941b0b2cec005e91e116b","type":"TRIAL","name":"A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04060862","description":"Breast Cancer","metadata":null},{"id":"7b4abc22f9b24d179b2a64ebdb39431c","type":"TRIAL","name":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06967155","description":"Neoplasms","metadata":null},{"id":"f9d5e760af5b4cd380c88cc744f97f0a","type":"TRIAL","name":"A Study of Isatuximab-based Therapy in Participants With Lymphoma","canonical_id":"clinicaltrials.gov:NCT03769181","description":"Lymphoma","metadata":null},{"id":"19cd619e4b07485e91a57175017ef417","type":"TRIAL","name":"A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)","canonical_id":"clinicaltrials.gov:NCT05263999","description":"Graft Versus Host Disease; GVHD; Acute-graft-versus-host Disease; Acute GVHD; aGVHD","metadata":null},{"id":"22470120e2f14bdba56e29a19082d464","type":"TRIAL","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT07815665","description":"Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC)","metadata":null},{"id":"f0abd0590dea42c5aec5b24f8721c451","type":"TRIAL","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT00883116","description":"Endometrial Cancer","metadata":null},{"id":"e5210d03960a4c768340a4afcafffca8","type":"TRIAL","name":"A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01217957","description":"Multiple Myeloma","metadata":null},{"id":"194ab6188fc048ef957d459c4e552cda","type":"TRIAL","name":"A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03323151","description":"Mantle-Cell Lymphoma","metadata":null},{"id":"f19979ba322c4d678c3f07207849ba08","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03573323","description":"Plaque Psoriasis","metadata":null},{"id":"b48eec28ba4044f09649c11af8355bbf","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03151551","description":"Psoriatic Arthritis","metadata":null},{"id":"208e33cb74084d1592d67038ebc7ac70","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT04527380","description":"Juvenile Psoriatic Arthritis; Enthesitis Related Arthritis","metadata":null},{"id":"9733425e23d4464caecf0b03350b00fd","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT04285229","description":"Spondyloarthritis","metadata":null},{"id":"5831e901ca954425b0710c0c29ebb26a","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT02349295","description":"Psoriatic Arthritis","metadata":null},{"id":"22ca94cca2b048789c918068eacae734","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis","canonical_id":"clinicaltrials.gov:NCT02718898","description":"Genital Psoriasis; Psoriasis","metadata":null},{"id":"b2ae2fd047bd43fbb5d32cb0b3a05cc9","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02561806","description":"Plaque Psoriasis","metadata":null},{"id":"8c1eceb62ece4b169c648b72fa4a764a","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","canonical_id":"clinicaltrials.gov:NCT02634801","description":"Plaque Psoriasis","metadata":null},{"id":"b26ce3c97e874ad48b0e93140abd016a","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT02757352","description":"Axial Spondyloarthritis","metadata":null},{"id":"a845b52b487b426b866d3c0f06d1f1f4","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis","canonical_id":"clinicaltrials.gov:NCT03942042","description":"Generalized Pustular Psoriasis; Erythrodermic Psoriasis","metadata":null},{"id":"45ffb99c32064f77920bf84fcd7683f2","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT02696798","description":"Spondyloarthritis","metadata":null},{"id":"ef98aad710c047c39fdeee2ab0e6aba0","type":"TRIAL","name":"A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT02696785","description":"Spondyloarthritis","metadata":null},{"id":"0739f32021cd40d0991a55187b67730e","type":"TRIAL","name":"A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT03073213","description":"Psoriasis","metadata":null},{"id":"f9fcd6e34cec4b008efb672de0cf9117","type":"TRIAL","name":"A Study of Ixekizumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03848416","description":"Healthy","metadata":null},{"id":"7a12d781494a4483b7f156ffb7f5cf38","type":"TRIAL","name":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT01695239","description":"Psoriasis, Arthritic","metadata":null},{"id":"77b8d2fa173a46ce9c62df723911534b","type":"TRIAL","name":"A Study of Ixekizumab in Participants With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02993471","description":"Psoriasis","metadata":null},{"id":"e45fce750eba4cb2bd60df718e0e72e7","type":"TRIAL","name":"A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02497378","description":"Multiple Myeloma","metadata":null},{"id":"81c9d6a02f004f27a069a04df067792f","type":"TRIAL","name":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01998971","description":"Multiple Myeloma","metadata":null},{"id":"9180e43000d44e79964f900f8d85ea69","type":"TRIAL","name":"A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)","canonical_id":"clinicaltrials.gov:NCT06220604","description":"Plaque Psoriasis","metadata":null},{"id":"e1f7fabe0b0f495c82953a17e544c1da","type":"TRIAL","name":"A Study of JNJ-77474462 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04544813","description":"Healthy","metadata":null},{"id":"96c9d8ac1bb24716a28800c6ed777016","type":"TRIAL","name":"A Study of JNJ-80202135 in Healthy Chinese Adult Participants","canonical_id":"clinicaltrials.gov:NCT05151692","description":"Healthy","metadata":null},{"id":"6b8d5cc7877c4433a8bff980e348f627","type":"TRIAL","name":"A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06095089","description":"Prostatic Neoplasms","metadata":null},{"id":"5296cd8db3fd406186ca9043c10e8e50","type":"TRIAL","name":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT06150157","description":"Neoplasms","metadata":null},{"id":"7657a4f46cf3464385092545c56d2429","type":"TRIAL","name":"A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07107230","description":"Advanced Stage Solid Tumors","metadata":null},{"id":"27735fa462614df185c8dd992aa54ba5","type":"TRIAL","name":"A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT07332533","description":"HER2-positive Gastric Cancer","metadata":null},{"id":"7732f6ebc639491aa67e0d2000dcad49","type":"TRIAL","name":"A Study of Ketamine in Patients With Treatment-resistant Depression","canonical_id":"clinicaltrials.gov:NCT01627782","description":"Major Depressive Disorder","metadata":null},{"id":"42d3e4700a824a13814ea7f3702715c8","type":"TRIAL","name":"A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy","canonical_id":"clinicaltrials.gov:NCT00231478","description":"Post-Operative Nausea and Vomiting","metadata":null},{"id":"27ac9ee3fd1149b081a34b154c93f648","type":"TRIAL","name":"A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement","canonical_id":"clinicaltrials.gov:NCT03399487","description":"Non-small Cell Lung Cancer Harboring ROS1 Rearrangement","metadata":null},{"id":"92f666e7de064e848bf891e9ae61ac99","type":"TRIAL","name":"A Study of LY2157299 in Participants With Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01246986","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"d6a8e01cb0e14382b48561dfc05db042","type":"TRIAL","name":"A Study of LY2228820 in Participants With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT01393990","description":"Advanced Cancer","metadata":null},{"id":"85b877c3e067458c8e4720186ff267cd","type":"TRIAL","name":"A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01391130","description":"Metastatic Clear Cell Renal Cell Carcinoma","metadata":null},{"id":"22d89c69a89c45a59ea07f69d94c3a96","type":"TRIAL","name":"A Study of LY2623091 in Male and Females With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT01427972","description":"Chronic Kidney Disease","metadata":null},{"id":"4edca0b145e34f6bb4f5243fd08fb09c","type":"TRIAL","name":"A Study of LY2624803 in Participants With Transient Insomnia","canonical_id":"clinicaltrials.gov:NCT01779830","description":"Transient Insomnia","metadata":null},{"id":"1b99aac36fdf425a9dc4dff9054bc97b","type":"TRIAL","name":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","canonical_id":"clinicaltrials.gov:NCT02057133","description":"Breast Neoplasms","metadata":null},{"id":"1408f232ceaa4d99b5b1d6accf519ef2","type":"TRIAL","name":"A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT02959177","description":"Migraine","metadata":null},{"id":"4ce3304875af40888419e56dcaf8d702","type":"TRIAL","name":"A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine","canonical_id":"clinicaltrials.gov:NCT02959190","description":"Migraine","metadata":null},{"id":"b946ccf741ea46cf86fc54e547bdb64b","type":"TRIAL","name":"A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache","canonical_id":"clinicaltrials.gov:NCT02797951","description":"Episodic Cluster Headache; Chronic Cluster Headache","metadata":null},{"id":"be5f74bf9d3c4c7fa6fcd38922939084","type":"TRIAL","name":"A Study of LY3023414 and Necitumumab in Squamous Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02443337","description":"Non-small Cell Lung Cancer Metastatic","metadata":null},{"id":"7b564cc018f744adaf13f5aab392671d","type":"TRIAL","name":"A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT04276428","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"aaadb7aa8d984f618e60b5494abf7f89","type":"TRIAL","name":"A Study of LY3537021 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05444569","description":"Healthy","metadata":null},{"id":"216a37a2b9b94a92b93f8dc3ceb36486","type":"TRIAL","name":"A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07483099","description":"Crohn Disease","metadata":null},{"id":"b180985c4a3b41178b8ba0b6f174c484","type":"TRIAL","name":"A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT07787182","description":"Healthy Volunteers; Alzheimer Disease; Amyloid; Plaque, Amyloid","metadata":null},{"id":"7b8176d729524190b9a64f652bdf0631","type":"TRIAL","name":"A Study of LY4515100 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07339722","description":"Healthy","metadata":null},{"id":"80018833a9094cef8aa5509218227acd","type":"TRIAL","name":"A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)","canonical_id":"clinicaltrials.gov:NCT07843459","description":"Healthy Volunteers; Alzheimer Disease; Amyloid; Plaque, Amyloid; Plasma","metadata":null},{"id":"bfed6701c52c41f091ef6180101942b3","type":"TRIAL","name":"A Study of LY900010 in Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT01160289","description":"Erectile Dysfunction","metadata":null},{"id":"b4f42ec52b0d4f09b95d03fd097dcc65","type":"TRIAL","name":"A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)","canonical_id":"clinicaltrials.gov:NCT05460325","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"debce9e1c9474a049fd4bc06b5c5d40e","type":"TRIAL","name":"A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)","canonical_id":"clinicaltrials.gov:NCT04206605","description":"Angioedema","metadata":null},{"id":"fc54e641add641e283e9dec207a4dcec","type":"TRIAL","name":"A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children","canonical_id":"clinicaltrials.gov:NCT04070326","description":"Hereditary Angioedema","metadata":null},{"id":"cdde46788476425b894b951357cc4fb6","type":"TRIAL","name":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05388669","description":"Advanced or Metastatic Non-small Cell Lung Cancer","metadata":null},{"id":"8ed6424582d74eb899f06db4db31a8e8","type":"TRIAL","name":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04077463","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"9924e333872c4cd6b38ce9ed945e614b","type":"TRIAL","name":"A Study of Lemborexant in Chinese Participants With Insomnia Disorder","canonical_id":"clinicaltrials.gov:NCT04549168","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"a9fe5c52dd5f4b338f8ce9000c3c75e9","type":"TRIAL","name":"A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00913835","description":"Ovarian Neoplasms","metadata":null},{"id":"e10a6549734a426e8eed9cdcd3d8a593","type":"TRIAL","name":"A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor","canonical_id":"clinicaltrials.gov:NCT04444895","description":"Angioedema","metadata":null},{"id":"13930b85d9d94cb0b54ca3dfc4e91bda","type":"TRIAL","name":"A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome","canonical_id":"clinicaltrials.gov:NCT04572243","description":"Epilepsies, Myoclonic","metadata":null},{"id":"7adf77219c7f4e32bee6ff317102260e","type":"TRIAL","name":"A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China","canonical_id":"clinicaltrials.gov:NCT03909971","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"dad84ce6c0444216bab503fd1a806433","type":"TRIAL","name":"A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients","canonical_id":"clinicaltrials.gov:NCT04255602","description":"Acute Coronary Syndrome; Coronary Stent Implantation","metadata":null},{"id":"a59e07e05bc74798a0929284cd251891","type":"TRIAL","name":"A Study of Lumigan\u00ae 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","canonical_id":"clinicaltrials.gov:NCT01589510","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"a902930f299f4596aaf3bb622576a7b9","type":"TRIAL","name":"A Study of Lumigan\u00ae in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","canonical_id":"clinicaltrials.gov:NCT01632423","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"a1df55b94b9d4c5aa6ec680ad5b89e7f","type":"TRIAL","name":"A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression","canonical_id":"clinicaltrials.gov:NCT04383691","description":"Bipolar I Depression","metadata":null},{"id":"c19e1746fab1448d801b049dabbe6273","type":"TRIAL","name":"A Study of Lurasidone HCl in Subjects With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03393026","description":"Schizophrenia","metadata":null},{"id":"16c5bd76b7c44ae5a1599973923edd4c","type":"TRIAL","name":"A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03708744","description":"Migraine","metadata":null},{"id":"1a75ae7a84c149cf91f2e29fa06129b7","type":"TRIAL","name":"A Study of MD-120 in Patients With Depression","canonical_id":"clinicaltrials.gov:NCT04345471","description":"Major Depressive Disorder","metadata":null},{"id":"282c05ebf4134b8da1211a5fe0dbd63a","type":"TRIAL","name":"A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)","canonical_id":"clinicaltrials.gov:NCT03158103","description":"Gastrointestinal Stromal Tumor (GIST)","metadata":null},{"id":"0c5d93e2745f4be3bf6d5bb8b390675b","type":"TRIAL","name":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","canonical_id":"clinicaltrials.gov:NCT03219268","description":"Advanced Solid Tumors; Hematologic Neoplasms; Ovarian Cancer; HER2-positive Advanced Solid Tumors; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Cervical Cancer; TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"c0e93a18040c46a6b85330669b8080f4","type":"TRIAL","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","canonical_id":"clinicaltrials.gov:NCT06979596","description":"Malignant Neoplasm","metadata":null},{"id":"078f6a01894e4f058a581f4cd0343513","type":"TRIAL","name":"A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)","canonical_id":"clinicaltrials.gov:NCT00700661","description":"Asthma","metadata":null},{"id":"a242ab5f185d405ebf0d1013d2417c67","type":"TRIAL","name":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092768","description":"Osteoarthritis","metadata":null},{"id":"2bfb4741aa824e0bb346464c484fc444","type":"TRIAL","name":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092781","description":"Osteoarthritis","metadata":null},{"id":"a1c6fe8c8f764565b548fbf8e0104fa5","type":"TRIAL","name":"A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00788710","description":"Acute Pain Following a Total Abdominal Hysterectomy","metadata":null},{"id":"481fd830a49342f09f27887c3eeb1efb","type":"TRIAL","name":"A Study of MT-0551 in Patients With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT05198557","description":"Systemic Sclerosis","metadata":null},{"id":"911d08da75e14142b0798fe5c8ece9d9","type":"TRIAL","name":"A Study of Macitentan in Children Below 2 Years of Age","canonical_id":"clinicaltrials.gov:NCT05731492","description":"Arterial Hypertension, Pulmonary","metadata":null},{"id":"5eec30145c4c4687a4e436ed0ca2d092","type":"TRIAL","name":"A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil","canonical_id":"clinicaltrials.gov:NCT04540744","description":"Healthy","metadata":null},{"id":"7a6507dd28e44b6db1c0a6667f586d42","type":"TRIAL","name":"A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma","canonical_id":"clinicaltrials.gov:NCT04200066","description":"Glioblastoma; Brain Tumor","metadata":null},{"id":"e075e36f00644b709588fa0d5c6a87ea","type":"TRIAL","name":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","canonical_id":"clinicaltrials.gov:NCT04274738","description":"Waldenstrom's Macroglobulinemia","metadata":null},{"id":"71c7b783640d49ada0be7635d3fe1b3f","type":"TRIAL","name":"A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders","canonical_id":"clinicaltrials.gov:NCT04154488","description":"Neutropenia","metadata":null},{"id":"496734864e374fbeba6e4ec1d43a9cfe","type":"TRIAL","name":"A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections","canonical_id":"clinicaltrials.gov:NCT06056297","description":"Neutropenia","metadata":null},{"id":"945099b5369e4692b4777684cf37d1c4","type":"TRIAL","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT06679829","description":"Multiple Myeloma","metadata":null},{"id":"ea63173b4e0c40c989ec55b445008149","type":"TRIAL","name":"A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04083651","description":"Pancreatic Cancer","metadata":null},{"id":"9499270b4ef045f8afc0b52e2f72455f","type":"TRIAL","name":"A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)","canonical_id":"clinicaltrials.gov:NCT02630368","description":"Solid Tumors; Soft-tissue Sarcoma; Breast Cancer","metadata":null},{"id":"b29624cbbd4e4b789a90ebe246c909f0","type":"TRIAL","name":"A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems","canonical_id":"clinicaltrials.gov:NCT05599126","description":"Depression","metadata":null},{"id":"347e5e0040654e7880df14c7fce7e914","type":"TRIAL","name":"A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19","canonical_id":"clinicaltrials.gov:NCT04771000","description":"Covid19; Hypoxemia","metadata":null},{"id":"5a2e97bae29d49ed8e984e9d7f3a4853","type":"TRIAL","name":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","canonical_id":"clinicaltrials.gov:NCT03280030","description":"Acute Myeloid Leukemia","metadata":null},{"id":"7d1e7462b6e0444680329ae18a4bc78d","type":"TRIAL","name":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","canonical_id":"clinicaltrials.gov:NCT06843967","description":"Well Differentiated Liposarcoma; Dedifferentiated Liposarcoma; Liposarcoma; Myxoid Liposarcoma; Round Cell Liposarcoma; Myxoid Pleomorphic Liposarcoma; Pleomorphic Liposarcoma; Unresectable Liposarcoma; Unresectable Dedifferentiated Liposarcoma","metadata":null},{"id":"36b86b1cb4c042c1935917297cee8bb8","type":"TRIAL","name":"A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","canonical_id":"clinicaltrials.gov:NCT07850635","description":"Neurofibromatosis Type 1-Associated Plexiform Neurofibromas","metadata":null},{"id":"0fcd2a765c174cdc88dd7d70a69305e5","type":"TRIAL","name":"A Study of Mirdametinib in People With Central Nervous System Tumors","canonical_id":"clinicaltrials.gov:NCT07539441","description":"Central Nervous System Tumors; Glioma","metadata":null},{"id":"205c18129ae84f1795013284816c5d2c","type":"TRIAL","name":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","canonical_id":"clinicaltrials.gov:NCT05054374","description":"Breast Cancer; Breast Cancer Stage IV; HER2-negative Breast Cancer; Solid Carcinoma; MEK1 Gene Mutation; MEK2 Gene Mutation; Metastatic Breast Cancer","metadata":null},{"id":"96b615768c314850a65917c8f239fc08","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) Injection in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03053622","description":"Healthy","metadata":null},{"id":"efeded4cc8ba4a9fa928b38b916a8fa1","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)","canonical_id":"clinicaltrials.gov:NCT04004611","description":"Ulcerative Colitis","metadata":null},{"id":"56d62dac65d944959a609694d54adc16","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02568423","description":"Healthy","metadata":null},{"id":"13edfb3d3ea64753a230658a74b4a2c5","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT02891226","description":"Crohn's Disease","metadata":null},{"id":"1ef0f2b3622e4b73b22c673713f7a8c3","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03926130","description":"Crohn's Disease","metadata":null},{"id":"fd1527dfc63a4099a1469338c4f87d54","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02899988","description":"Plaque Psoriasis","metadata":null},{"id":"d49aefdbc4074a04ac60dc0b91da2971","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02589665","description":"Ulcerative Colitis","metadata":null},{"id":"99e9a7918b28476aa7c155abb0465438","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05767021","description":"Ulcerative Colitis; Ulcerative Colitis Chronic","metadata":null},{"id":"792b544b3c434a50805315ee51e9a627","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT04469062","description":"Ulcerative Colitis","metadata":null},{"id":"85eb4bc68a614f7ba202d554a355a0db","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT05509777","description":"Crohn's Disease","metadata":null},{"id":"4938d574f06841b9acfe6b1cfaab0999","type":"TRIAL","name":"A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05784246","description":"Ulcerative Colitis","metadata":null},{"id":"ae26dfcb6a2b41d2822141f90edfc15a","type":"TRIAL","name":"A Study of Mirikizumab Solution (LY3074828) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07446101","description":"Healthy","metadata":null},{"id":"65ce6ce1bd4e4b7bae6725e15495a42f","type":"TRIAL","name":"A Study of Mirikizumab in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT04137380","description":"Healthy","metadata":null},{"id":"80084b776e0549dfad6ecd8d4588a046","type":"TRIAL","name":"A Study of Mirikizumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04607733","description":"Healthy","metadata":null},{"id":"7244eac0176d4852b0b3716bdda7fa08","type":"TRIAL","name":"A Study of Mirikizumab in Participants With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03718884","description":"Psoriasis","metadata":null},{"id":"30d46d3b49d940a0a342bd04fcab1ce4","type":"TRIAL","name":"A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1","canonical_id":"clinicaltrials.gov:NCT06698003","description":"T-Cell Leukemia/Lymphoma, Adult; T-cell Leukemia/Lymphoma; T-cell Leukemia; Lymphoma","metadata":null},{"id":"ddffd78da66442ecab1c0b2f88a5ddf7","type":"TRIAL","name":"A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)","canonical_id":"clinicaltrials.gov:NCT04173494","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"05bb1e6f04dc4fcca7d34c1f3288b4f1","type":"TRIAL","name":"A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT06847867","description":"Myelodysplastic Syndromes","metadata":null},{"id":"10edf22948ab43e58379e486bc430899","type":"TRIAL","name":"A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia","canonical_id":"clinicaltrials.gov:NCT00435591","description":"Hyponatremia; Euvolemia; Hypervolemia","metadata":null},{"id":"5aaf4ef26f01434d997ef2ac9f43d33e","type":"TRIAL","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT04302025","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"241393f43d5346aaa7ffdb81dd7202d5","type":"TRIAL","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT03635983","description":"Melanoma","metadata":null},{"id":"abf80b5f80fb4266a4e72d9be4adce87","type":"TRIAL","name":"A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT02392507","description":"Carcinoma, Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"f569de325afb493aa450f49dbe3494c7","type":"TRIAL","name":"A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03086369","description":"Metastatic Pancreatic Cancer","metadata":null},{"id":"18d97aae66264211972bf789ee51db63","type":"TRIAL","name":"A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy","canonical_id":"clinicaltrials.gov:NCT01443403","description":"Opioid-induced Constipation","metadata":null},{"id":"4da045340d2c4d1ba9618c434d0a8551","type":"TRIAL","name":"A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection","canonical_id":"clinicaltrials.gov:NCT04355169","description":"Postoperative Gastrointestinal Dysfunction","metadata":null},{"id":"26cb9bd68a1841ebae95985ed657df4a","type":"TRIAL","name":"A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects","canonical_id":"clinicaltrials.gov:NCT00537420","description":"Obesity","metadata":null},{"id":"bfc29be17e304ae2b1901485df2743ca","type":"TRIAL","name":"A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)","canonical_id":"clinicaltrials.gov:NCT06855771","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"5f39651b3cfe42368d50208a4f9cc153","type":"TRIAL","name":"A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01624467","description":"Solid Tumors","metadata":null},{"id":"cb2300a585434980851883015409e2b0","type":"TRIAL","name":"A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02411591","description":"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis","metadata":null},{"id":"49bd2dabc20144f5af12fb7d8a75cb14","type":"TRIAL","name":"A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01769391","description":"Squamous Non Small Cell Lung Cancer","metadata":null},{"id":"053e479cbf2b497089bb2d0d3821992d","type":"TRIAL","name":"A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT01763788","description":"Squamous Non-small Cell Lung Cancer","metadata":null},{"id":"965bac7912894ec1ae7c85b011386336","type":"TRIAL","name":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","canonical_id":"clinicaltrials.gov:NCT05384626","description":"Locally Advanced Solid Tumor; Metastatic Solid Tumor","metadata":null},{"id":"f4dcde8cf9554d2dae6f988b98415f6e","type":"TRIAL","name":"A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT07047690","description":"Systemic Sclerosis","metadata":null},{"id":"eed0fa80096a4c9d9bd43566ec56adaa","type":"TRIAL","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","canonical_id":"clinicaltrials.gov:NCT07586202","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"7c52655b4f31453eb81be5944b92b837","type":"TRIAL","name":"A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02030860","description":"Adenocarcinoma of the Pancreas","metadata":null},{"id":"a09b6d7d5c7b45cc969aa9a2f9d26a7c","type":"TRIAL","name":"A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors","canonical_id":"clinicaltrials.gov:NCT01158950","description":"Impulsive Behavior","metadata":null},{"id":"3718ceb57b30472aa5526378c4ba85aa","type":"TRIAL","name":"A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT04951622","description":"Myasthenia Gravis","metadata":null},{"id":"03c25f5f2e814b2199d55e9747f03b24","type":"TRIAL","name":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04973566","description":"Healthy","metadata":null},{"id":"0d6d971744d741568048deba3e98c831","type":"TRIAL","name":"A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT04883619","description":"Lupus Nephritis","metadata":null},{"id":"41c97564e55c44eca9ac56ad13c31e47","type":"TRIAL","name":"A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT04882878","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"ee3580b82fbd4b6da08d2a894fcf8756","type":"TRIAL","name":"A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT07438496","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"45440b0fd7d84b14ac476a4290c6cc25","type":"TRIAL","name":"A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)","canonical_id":"clinicaltrials.gov:NCT04968912","description":"Sjogren's Syndrome","metadata":null},{"id":"20fa9cbabb504a00824e11ab88c1f270","type":"TRIAL","name":"A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT05265273","description":"Myasthenia Gravis","metadata":null},{"id":"b76024a7da78424a896ccd43ce4d8649","type":"TRIAL","name":"A Study of Nipocalimab in Healthy Male and Female Participants","canonical_id":"clinicaltrials.gov:NCT04848558","description":"Healthy","metadata":null},{"id":"2ca7b9ccbb1d41fea50f49d4fb0dbd29","type":"TRIAL","name":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","canonical_id":"clinicaltrials.gov:NCT05379634","description":"Myositis","metadata":null},{"id":"8d5597afdccb4bd49f66462a2a9543e2","type":"TRIAL","name":"A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","canonical_id":"clinicaltrials.gov:NCT05912517","description":"Hemolytic Disease of the Fetus and Newborn","metadata":null},{"id":"000b252c477f42d8b62c03f8a50e7071","type":"TRIAL","name":"A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)","canonical_id":"clinicaltrials.gov:NCT06449651","description":"Thrombocytopenia, Neonatal Alloimmune","metadata":null},{"id":"b2efaad8f8834d06910b98f544c9fdd6","type":"TRIAL","name":"A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)","canonical_id":"clinicaltrials.gov:NCT06533098","description":"Thrombocytopenia, Neonatal Alloimmune","metadata":null},{"id":"153c4239a1564d11b46072f15d7ac57a","type":"TRIAL","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03431350","description":"Prostatic Neoplasms, Castration-Resistant","metadata":null},{"id":"35055a8c57c842ae8497e26f91c3f61a","type":"TRIAL","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","canonical_id":"clinicaltrials.gov:NCT04497844","description":"Prostatic Neoplasms","metadata":null},{"id":"0bc66a03f3f44bb5b692bdafa215cc29","type":"TRIAL","name":"A Study of Niraparib in Patients With Relapsed Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04392102","description":"Ovarian Cancer","metadata":null},{"id":"83e64362d32540a7b87445be2062fe23","type":"TRIAL","name":"A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread","canonical_id":"clinicaltrials.gov:NCT02060188","description":"Microsatellite Unstable Colorectal Cancer; Microsatellite Stable Colorectal Cancer; Mismatch Repair Proficient Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer","metadata":null},{"id":"fffa4713f34c46b6bb38aa361d4e6e44","type":"TRIAL","name":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","canonical_id":"clinicaltrials.gov:NCT02927769","description":"Hodgkin Disease","metadata":null},{"id":"33b863d6f8b94518839cb00601fd29ab","type":"TRIAL","name":"A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.","canonical_id":"clinicaltrials.gov:NCT02960854","description":"Severe Sepsis","metadata":null},{"id":"05793845955e4835b91179086c7805a4","type":"TRIAL","name":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT04464759","description":"Melanoma","metadata":null},{"id":"a97c37c9e201411fa92f164c63b55647","type":"TRIAL","name":"A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01928394","description":"Advanced or Metastatic Solid Tumors","metadata":null},{"id":"e49eb4cadfb94049ae92bd8b8e8ac645","type":"TRIAL","name":"A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03195478","description":"Solid Tumor","metadata":null},{"id":"f3d312d8b76f45ae8d37fd61dc55a8da","type":"TRIAL","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03742102","description":"Triple Negative Breast Neoplasms","metadata":null},{"id":"3ce4af71c98f4ac68a2664b716ee0d7e","type":"TRIAL","name":"A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)","canonical_id":"clinicaltrials.gov:NCT00544869","description":"Cardiac Edema","metadata":null},{"id":"203ac404d0ba4baeabdc89b743fcd846","type":"TRIAL","name":"A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00825149","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"7951c84dbdfb43719525bc50309f8e61","type":"TRIAL","name":"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT02600897","description":"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"5c9381009e2d4d09a46111177efccd02","type":"TRIAL","name":"A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT02611323","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"34a4e49e2cfc481f87a3f6f0ff04e8e5","type":"TRIAL","name":"A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)","canonical_id":"clinicaltrials.gov:NCT00485589","description":"Rheumatoid Arthritis","metadata":null},{"id":"aaa1a491ca5b40948f5cc61fe21a705f","type":"TRIAL","name":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01412333","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"27b61de1fc124822a3c6cd8fd6425858","type":"TRIAL","name":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01247324","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"50e793564c9a4742a10d50481acda6d6","type":"TRIAL","name":"A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT02723071","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"33226b6f58894925af0527fbf464666d","type":"TRIAL","name":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","canonical_id":"clinicaltrials.gov:NCT02861014","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"c1828db42be84c8ab86c66c9f7b70b0e","type":"TRIAL","name":"A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT06649214","description":"Schizophrenia","metadata":null},{"id":"db5cb6e9816f404f9f9c22779ae11b9d","type":"TRIAL","name":"A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors","canonical_id":"clinicaltrials.gov:NCT01316263","description":"Gastrointestinal Stromal Tumor (GIST)","metadata":null},{"id":"b246419173cc4cf3acd7909d69b794a3","type":"TRIAL","name":"A Study of Olaratumab (IMC-3G3) in Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01204710","description":"Prostate Cancer","metadata":null},{"id":"22d2bbb5ce184088b19366d3c4b6050d","type":"TRIAL","name":"A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT03126591","description":"Soft Tissue Sarcoma","metadata":null},{"id":"c222152a33134bb2be3e74451cd85bcf","type":"TRIAL","name":"A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT02659020","description":"Soft Tissue Sarcoma","metadata":null},{"id":"702cd88132ce462db653a2416d6a0bf6","type":"TRIAL","name":"A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT02783599","description":"Soft Tissue Sarcoma","metadata":null},{"id":"67d8fbace33e47c6a8d494d24f65a842","type":"TRIAL","name":"A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT03283696","description":"Soft Tissue Sarcoma","metadata":null},{"id":"824141996d984fa2bf50fc4746d215cb","type":"TRIAL","name":"A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer","canonical_id":"clinicaltrials.gov:NCT02677116","description":"Neoplasm Metastasis","metadata":null},{"id":"6ad6801c81a14e5b8fb582a250e8c50c","type":"TRIAL","name":"A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT02326025","description":"Sarcoma, Soft Tissue","metadata":null},{"id":"68425a7439e243ce8ceb45d54c66c393","type":"TRIAL","name":"A Study of Olaratumab in Japanese Participants With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT02377752","description":"Neoplasm","metadata":null},{"id":"0208a44b4c434a62b184bde31731ed80","type":"TRIAL","name":"A Study of Olaratumab in Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT01185964","description":"Sarcoma, Soft Tissue","metadata":null},{"id":"98ebb132bbd743b4ab130da543528df3","type":"TRIAL","name":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","canonical_id":"clinicaltrials.gov:NCT00314574","description":"Asthma","metadata":null},{"id":"5864747d62f3472ab759a74de18fb65b","type":"TRIAL","name":"A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)","canonical_id":"clinicaltrials.gov:NCT01456325","description":"Non-Squamous Non-Small Cell Lung Cancer","metadata":null},{"id":"96073cbbc93347618936f17bb33a7e3c","type":"TRIAL","name":"A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)","canonical_id":"clinicaltrials.gov:NCT01469234","description":"Rhinitis","metadata":null},{"id":"be8687d66c8b489996085f078a003926","type":"TRIAL","name":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom","canonical_id":"clinicaltrials.gov:NCT00751049","description":"Ocular Hypertension; Open Angle Glaucoma","metadata":null},{"id":"4e3353345f8041ab937243a36cc3cf6b","type":"TRIAL","name":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","canonical_id":"clinicaltrials.gov:NCT06104449","description":"Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer","metadata":null},{"id":"2fa4ec9620b34cf09daca4bb1737c10f","type":"TRIAL","name":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","canonical_id":"clinicaltrials.gov:NCT06136650","description":"Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms","metadata":null},{"id":"009306c6958e4c2fb98a350e4abd9840","type":"TRIAL","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","canonical_id":"clinicaltrials.gov:NCT04971226","description":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","metadata":null},{"id":"73df3f12e9684ebbb8eb69dffc2766b7","type":"TRIAL","name":"A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT02809105","description":"Chronic Constipation","metadata":null},{"id":"29b6c028f85a4da7bc24ec5cc44baf87","type":"TRIAL","name":"A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT02181413","description":"Multiple Myeloma; Autologous Stem Cell Transplant","metadata":null},{"id":"eff48ae8f9334e75826a216ff6192e0c","type":"TRIAL","name":"A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma","canonical_id":"clinicaltrials.gov:NCT03505554","description":"Anaplastic Large Cell Lymphoma, ALK-Positive","metadata":null},{"id":"a7f181a18f2e4b1fa5715aa9081a75ad","type":"TRIAL","name":"A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain","canonical_id":"clinicaltrials.gov:NCT01186770","description":"Opioid-Induced Constipation","metadata":null},{"id":"a16180a9484c43c585dd5c8abbee5490","type":"TRIAL","name":"A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT04176198","description":"Myelofibrosis","metadata":null},{"id":"ff35c86fe2c1428a8340b11843f1784e","type":"TRIAL","name":"A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01292187","description":"Osteopenia","metadata":null},{"id":"56703035595840b1841ba69048f396b5","type":"TRIAL","name":"A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)","canonical_id":"clinicaltrials.gov:NCT01482715","description":"Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Advanced Solid Tumor With Evidence of Germline or Somatic BRCA","metadata":null},{"id":"6e98822187c64da9853f2aaaa709e83b","type":"TRIAL","name":"A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","canonical_id":"clinicaltrials.gov:NCT06059846","description":"Urinary Tract Infection; Acute Pyelonephritis","metadata":null},{"id":"eb75cbb816ce483f9444949bf5cba3ee","type":"TRIAL","name":"A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT07751848","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"4d8f885159484acb88190d0cfb866e2f","type":"TRIAL","name":"A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04092595","description":"Healthy Volunteers","metadata":null},{"id":"571dc1ed7d96491ea07c1d6f363b8c91","type":"TRIAL","name":"A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00960960","description":"Breast Cancer","metadata":null},{"id":"3100c8f6b9184b7da5c8ff00e3c74ed3","type":"TRIAL","name":"A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT01170663","description":"Gastric Cancer","metadata":null},{"id":"f968bf5e23b4412db945d280879cf27c","type":"TRIAL","name":"A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00153842","description":"Carcinoma, Non-small-cell Lung","metadata":null},{"id":"0232cad7e4a649b5ba96e521f14761fb","type":"TRIAL","name":"A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT00918203","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"f13285f3c174455196eb51c45751ea24","type":"TRIAL","name":"A Study of Pain Relief in Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT00298974","description":"Osteoarthritis","metadata":null},{"id":"e989286a764e48899bfbf6bbbd6ea76e","type":"TRIAL","name":"A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02448771","description":"Breast Cancer Stage IV; Unresectable Locally Advanced Invasive Breast Cancer; Metastatic Invasive Breast Cancer","metadata":null},{"id":"295a0e0fc66045d083ca6f04d3029e81","type":"TRIAL","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00626639","description":"Mucositis; Head and Neck Cancer","metadata":null},{"id":"b73fd631e8ad4f0ab2c08b0e2ac14a58","type":"TRIAL","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00131638","description":"Head and Neck Cancer","metadata":null},{"id":"6004f6f5591a496ab330f6684f3e1aba","type":"TRIAL","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy","canonical_id":"clinicaltrials.gov:NCT00540332","description":"Head and Neck Cancer","metadata":null},{"id":"02f38fc5448548cb9bdf26c487f695bc","type":"TRIAL","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00434161","description":"Multiple Myeloma","metadata":null},{"id":"bc321c4345a54b12827a9da4669104c0","type":"TRIAL","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer","canonical_id":"clinicaltrials.gov:NCT00393822","description":"Colon Cancer","metadata":null},{"id":"b41ae826c2f94b2a968766b15213a6d1","type":"TRIAL","name":"A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a","canonical_id":"clinicaltrials.gov:NCT01724021","description":"Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma","metadata":null},{"id":"d25b799bd40e4d728b0835c95d29a9d5","type":"TRIAL","name":"A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization","canonical_id":"clinicaltrials.gov:NCT06503250","description":"Unresectable Hepatocellular Carcinoma","metadata":null},{"id":"e874d39df8c6452b8345607ba79af075","type":"TRIAL","name":"A Study of Pasireotide in People With Prolactinoma","canonical_id":"clinicaltrials.gov:NCT06295952","description":"Prolactin-Producing Pituitary Tumor","metadata":null},{"id":"b2bbd0746e5b4281a8274ac726831e9a","type":"TRIAL","name":"A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study","canonical_id":"clinicaltrials.gov:NCT00360087","description":"Pulmonary Hypertension; Sickle Cell Anemia","metadata":null},{"id":"7aba4371dd75480ca49af6d3709cf2d7","type":"TRIAL","name":"A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment","canonical_id":"clinicaltrials.gov:NCT05597085","description":"Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia","metadata":null},{"id":"71db6ecbb2324984b67ae3ce90d6b0dc","type":"TRIAL","name":"A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan\u00ae UD Monotherapy for Medical Reasons","canonical_id":"clinicaltrials.gov:NCT01853085","description":"Glaucoma, Primary Open Angle; Ocular Hypertension","metadata":null},{"id":"c09f151efbdb4ba6baab9e85398ee576","type":"TRIAL","name":"A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment","canonical_id":"clinicaltrials.gov:NCT02864199","description":"Hepatitis C, Chronic","metadata":null},{"id":"4a5cff1a7c0c4c02a17cf042eec82b1d","type":"TRIAL","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","canonical_id":"clinicaltrials.gov:NCT05652686","description":"Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC); Neuroendocrine Carcinomas (NEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","metadata":null},{"id":"887d21ecd88640f4bbc1be84b1621512","type":"TRIAL","name":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","canonical_id":"clinicaltrials.gov:NCT04199104","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"7fabe0b11cba4a6e92842c37161f8284","type":"TRIAL","name":"A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)","canonical_id":"clinicaltrials.gov:NCT02036502","description":"Multiple Myeloma","metadata":null},{"id":"077d356a5fd948f6803a992242e5b147","type":"TRIAL","name":"A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02755272","description":"Carcinoma Breast Stage IV","metadata":null},{"id":"d2cb3d4df63c4c7a9a87ca037260c7e3","type":"TRIAL","name":"A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma","canonical_id":"clinicaltrials.gov:NCT00192088","description":"Advanced Gastric Carcinoma","metadata":null},{"id":"573f6f4012de4551af1910ce34f8c33a","type":"TRIAL","name":"A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01491737","description":"Breast Cancer","metadata":null},{"id":"c4e4655ae3684385ac0de86baf45ac4c","type":"TRIAL","name":"A Study of Pertuzumab in Participants With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02480010","description":"Prostate Cancer","metadata":null},{"id":"ae955f5d91f44bd6bbe07a3855b0dea2","type":"TRIAL","name":"A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan","canonical_id":"clinicaltrials.gov:NCT04703322","description":"Tenosynovial Giant Cell Tumor","metadata":null},{"id":"f22cc7cf68814663bd8b0f0aca8b5c5f","type":"TRIAL","name":"A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00653822","description":"Pharmacokinetics of Alefacept","metadata":null},{"id":"b6a596ff72bc4bc7925d135ee488730e","type":"TRIAL","name":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07181694","description":"Healthy Adult Male","metadata":null},{"id":"8f2af96c77fc42db92b14621e4a8a9bc","type":"TRIAL","name":"A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT03118947","description":"Agitation and Aggression in Alzheimer's Disease","metadata":null},{"id":"bc0bac538093452fb16a887fb75870c7","type":"TRIAL","name":"A Study of Pitolisant in Participants With Prader-Willi Syndrome","canonical_id":"clinicaltrials.gov:NCT07219485","description":"Prader-Willi Syndrome","metadata":null},{"id":"c734d4e5682340dd8223e233cc3fd3c8","type":"TRIAL","name":"A Study of Pitolisant in Patients With Prader-Willi Syndrome","canonical_id":"clinicaltrials.gov:NCT06366464","description":"Prader-Willi Syndrome","metadata":null},{"id":"1cd851a4dc224dd89a9afd4212408a79","type":"TRIAL","name":"A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP","canonical_id":"clinicaltrials.gov:NCT07702851","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"1190445c76bf4d2b9fba5009b1b6d200","type":"TRIAL","name":"A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT01992653","description":"Lymphoma, Non Hodgkin","metadata":null},{"id":"3809762763c1485d942dc9f10252de5d","type":"TRIAL","name":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03589326","description":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","metadata":null},{"id":"1d81969dbc8849c7bcf3785b24596e5d","type":"TRIAL","name":"A Study of Ponesimod in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05552196","description":"Healthy","metadata":null},{"id":"8d8da62c314c4218a10c3a3e9d731026","type":"TRIAL","name":"A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State","canonical_id":"clinicaltrials.gov:NCT03882255","description":"Healthy","metadata":null},{"id":"0bec3c3e28af467a9e313eface1f2a62","type":"TRIAL","name":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT04172597","description":"Breast Cancer; Colorectal Cancer; Solid Tumor; Glioblastome Multiforme","metadata":null},{"id":"9565831ff612480892dc63e0a54ba789","type":"TRIAL","name":"A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","canonical_id":"clinicaltrials.gov:NCT04760288","description":"Medullary Thyroid Cancer","metadata":null},{"id":"d1452bfd0dd44823894c5ccbe34350e4","type":"TRIAL","name":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT04222972","description":"RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue","metadata":null},{"id":"d24ec1c777bb459bbf75a77f2bc38093","type":"TRIAL","name":"A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer","canonical_id":"clinicaltrials.gov:NCT00277160","description":"Neutropenia; Breast Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer","metadata":null},{"id":"74607e0c42804898991c810577fd677c","type":"TRIAL","name":"A Study of Propranolol to Treat Kaposi Sarcoma","canonical_id":"clinicaltrials.gov:NCT05797662","description":"Kaposi Sarcoma","metadata":null},{"id":"76773d667e3c4cfebf12a0df668613bc","type":"TRIAL","name":"A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT06406205","description":"Lupus Nephritis","metadata":null},{"id":"571fefc6d34c4832a3020f99d34516c6","type":"TRIAL","name":"A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT04473664","description":"Hepatic Impairment; Moderate Impaired Hepatic Function","metadata":null},{"id":"30c9b4d224984a55aa2d16cbf9326dcc","type":"TRIAL","name":"A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum","canonical_id":"clinicaltrials.gov:NCT06791070","description":"Paget Disease, Extramammary; Scrotum Disease","metadata":null},{"id":"87388757445344b99693338c3b19b766","type":"TRIAL","name":"A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)","canonical_id":"clinicaltrials.gov:NCT04578847","description":"Chronic Myeloid Leukemia; Chronic Myeloid Leukemia in Remission; BCR-ABL Positive Chronic Myelogenous Leukemia","metadata":null},{"id":"d71a18c6e2734492be2d3ea98378f35b","type":"TRIAL","name":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","canonical_id":"clinicaltrials.gov:NCT01677754","description":"Alzheimer's Disease","metadata":null},{"id":"dabe519751444527b3e9e86d5ed0b5dc","type":"TRIAL","name":"A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01326000","description":"Colorectal Cancer","metadata":null},{"id":"650fa90d7dda4206b85a34547fda5895","type":"TRIAL","name":"A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00735696","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"ee9b6023d0cf436fbc9ccbd83b60ad2d","type":"TRIAL","name":"A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","canonical_id":"clinicaltrials.gov:NCT02314117","description":"Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"eae4e86bad92425598087c3d17feba7f","type":"TRIAL","name":"A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer","canonical_id":"clinicaltrials.gov:NCT02069041","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"eced70fadd3a4c6798d37bb078a8ed36","type":"TRIAL","name":"A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02789345","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"58b69b582b254b2e8beb5a349f28bc88","type":"TRIAL","name":"A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","canonical_id":"clinicaltrials.gov:NCT02359058","description":"Stomach Neoplasms","metadata":null},{"id":"0f9bbbe9012f46d291636f922e48178c","type":"TRIAL","name":"A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02539225","description":"Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"0e2b06420ca7441c995040dd03212c9c","type":"TRIAL","name":"A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT01983878","description":"Gastric Cancer","metadata":null},{"id":"36c59a1148f1427db5209b1c696847c7","type":"TRIAL","name":"A Study of Ramucirumab or Icrucumab in Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01111604","description":"Colon Cancer; Rectal Cancer","metadata":null},{"id":"1b2cdbd494ac4762b65be6b14e7099ec","type":"TRIAL","name":"A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria","canonical_id":"clinicaltrials.gov:NCT03406507","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"6be9120905b948b8bd3dd4e767eb4c89","type":"TRIAL","name":"A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)","canonical_id":"clinicaltrials.gov:NCT01334918","description":"Coronary Artery Disease (CAD)","metadata":null},{"id":"a1e4a8727d6247e8a89f4ce22c06803e","type":"TRIAL","name":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT04623775","description":"Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer","metadata":null},{"id":"aa1021daa2434d8d92b754f3a92fab2a","type":"TRIAL","name":"A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT03052725","description":"Eosinophils, Asthma","metadata":null},{"id":"5d2b8f3e2c1d4b50b13f122d5f417929","type":"TRIAL","name":"A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06075758","description":"Breast Cancer","metadata":null},{"id":"40a40a8819214fee896c2e5410a3694d","type":"TRIAL","name":"A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)","canonical_id":"clinicaltrials.gov:NCT01234857","description":"Breast Cancer","metadata":null},{"id":"d49dde8fb1b34738a3ec68b60ebe9f72","type":"TRIAL","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","canonical_id":"clinicaltrials.gov:NCT07221253","description":"Biliary Tract Cancer","metadata":null},{"id":"dbc54546f3d3490181282ee30c065951","type":"TRIAL","name":"A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT00249171","description":"Schizophrenia; Psychotic Disorders; Emergency Treatment","metadata":null},{"id":"50ca382b75c744789446ab4dba39040b","type":"TRIAL","name":"A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00078598","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"39d1d6be1709437dbe497631767e95b8","type":"TRIAL","name":"A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine","canonical_id":"clinicaltrials.gov:NCT00300924","description":"Migraine","metadata":null},{"id":"494168551a8948038db2a0a9ab2f1e82","type":"TRIAL","name":"A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","canonical_id":"clinicaltrials.gov:NCT00812006","description":"Migraine","metadata":null},{"id":"e4ac70c29097404ebb742a5aa7910dd6","type":"TRIAL","name":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)","canonical_id":"clinicaltrials.gov:NCT00642460","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"33a56cf051934aca9a171d6bab4d5278","type":"TRIAL","name":"A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)","canonical_id":"clinicaltrials.gov:NCT00960063","description":"Neoplasms; Solid Tumors; Bone Cancer; Kidney Tumor; Neuroblastoma","metadata":null},{"id":"8d6071748eac499bbb7490ad12e99b9e","type":"TRIAL","name":"A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)","canonical_id":"clinicaltrials.gov:NCT00157872","description":"Rheumatoid Arthritis","metadata":null},{"id":"df6c3b3b6451488dba2c8eb0cde1f2a7","type":"TRIAL","name":"A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)","canonical_id":"clinicaltrials.gov:NCT00140894","description":"Adenomatous Polyposis Coli","metadata":null},{"id":"0c233d0dd3e74269ac0b1ed28dc52e79","type":"TRIAL","name":"A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)","canonical_id":"clinicaltrials.gov:NCT00140920","description":"Pain","metadata":null},{"id":"5c77c14bec2047649d0ca0b37b64aa5c","type":"TRIAL","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","canonical_id":"clinicaltrials.gov:NCT06879717","description":"Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC","metadata":null},{"id":"d8ddabf17576430f9a5580618203a302","type":"TRIAL","name":"A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00379639","description":"Pancreatic Cancer","metadata":null},{"id":"76b81dcdd8a948e6a2607c0b650c4232","type":"TRIAL","name":"A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP","canonical_id":"clinicaltrials.gov:NCT06658834","description":"Primary Immune Thrombocytopenia","metadata":null},{"id":"177dac5618be4753affe53154d4bbed2","type":"TRIAL","name":"A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04671901","description":"Solid Tumor; Solid Tumor, Childhood; Solid Carcinoma","metadata":null},{"id":"933b781d1f0841bc9597ae6112b3f0a0","type":"TRIAL","name":"A Study of Romosozumab (EVENITY\u00ae) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.","canonical_id":"clinicaltrials.gov:NCT06079476","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"1389ae7e487c4f47af93710e736906a9","type":"TRIAL","name":"A Study of Romosozumab in People With Breast Cancer and Osteoporosis","canonical_id":"clinicaltrials.gov:NCT07776613","description":"Breast Cancer; Metastatic Breast Cancer (MBC)","metadata":null},{"id":"64f94bbb89e94676897d73b7aff39262","type":"TRIAL","name":"A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis","canonical_id":"clinicaltrials.gov:NCT05775094","description":"Osteoporosis; Multiple Myeloma","metadata":null},{"id":"cb0d8872c6924f7b998e61553a158cd7","type":"TRIAL","name":"A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause","canonical_id":"clinicaltrials.gov:NCT03728933","description":"Restless Legs Syndrome","metadata":null},{"id":"3ee5f9bef0b74f9291f2bbb170b21a5a","type":"TRIAL","name":"A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02819999","description":"Small Cell Lung Cancer","metadata":null},{"id":"6c1745a49649429ba9edd386adc425b6","type":"TRIAL","name":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT06149559","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"09c238d288b94d369fd1fdb3c6e12395","type":"TRIAL","name":"A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03542175","description":"Breast Cancer","metadata":null},{"id":"3917533b58164d03876def0d0075a331","type":"TRIAL","name":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","canonical_id":"clinicaltrials.gov:NCT02975934","description":"Metastatic Castration Resistant Prostate Cancer","metadata":null},{"id":"5d25985ded2e4813bab0814f22d02c8a","type":"TRIAL","name":"A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma","canonical_id":"clinicaltrials.gov:NCT04624178","description":"Leiomyosarcoma","metadata":null},{"id":"136e22bfbcef485dbb576d8166214b1e","type":"TRIAL","name":"A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor","canonical_id":"clinicaltrials.gov:NCT03499444","description":"Advanced Solid Tumor","metadata":null},{"id":"fa2066f0bcad430cba747be111d501a5","type":"TRIAL","name":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","canonical_id":"clinicaltrials.gov:NCT02952534","description":"Metastatic Castration Resistant Prostate Cancer","metadata":null},{"id":"d1cfc43b67ba4b0ea3d3ed6aba84e938","type":"TRIAL","name":"A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation","canonical_id":"clinicaltrials.gov:NCT02042378","description":"Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"1407edc9deb04f2cbd6f6e9a38216206","type":"TRIAL","name":"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)","canonical_id":"clinicaltrials.gov:NCT01891344","description":"Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"2c0af181537b49b4ab03347d7c7ae3ac","type":"TRIAL","name":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","canonical_id":"clinicaltrials.gov:NCT05010005","description":"T-cell Lymphomas; NK-Cell Lymphomas; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocyte Leukemia","metadata":null},{"id":"4fed48e27d084b83b3cefb081cdee0c1","type":"TRIAL","name":"A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT05714072","description":"Myelofibrosis Due to and Following Polycythemia Vera","metadata":null},{"id":"61f69303aafa448181934366acc96f94","type":"TRIAL","name":"A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT06773195","description":"Myelofibrosis","metadata":null},{"id":"d92b838dd9f9451ebd1ae10712e7e0fe","type":"TRIAL","name":"A Study of Ruxolitinib in Pancreatic Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02119663","description":"Pancreatic Cancer","metadata":null},{"id":"c998b1322acb41ac97e06d45fef8a022","type":"TRIAL","name":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","canonical_id":"clinicaltrials.gov:NCT03112603","description":"Graft-versus-host Disease (GVHD)","metadata":null},{"id":"75fe9e4234a5485b8a2ac1cc4965552c","type":"TRIAL","name":"A Study of SHR-1802 in Patients With Advanced Solid Tumor","canonical_id":"clinicaltrials.gov:NCT05208177","description":"Advanced Solid Tumor","metadata":null},{"id":"8b57d6f57487445f8b107af8f46da15e","type":"TRIAL","name":"A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03520478","description":"Prostate Cancer; Hormone-Dependent Prostate Cancer","metadata":null},{"id":"962d941d0597491289bcb200fa53e387","type":"TRIAL","name":"A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05103826","description":"ER+ / HER2- Advanced Breast Cancer","metadata":null},{"id":"cf152af4ddab4429988a12ce83ef496f","type":"TRIAL","name":"A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT04733417","description":"Advanced Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"3877156cc8074738a10a61f05b1ffaa2","type":"TRIAL","name":"A Study of SHR6508 in Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT05663411","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"e3ab676a169943bc92869baebe07114a","type":"TRIAL","name":"A Study of SKB315 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05367635","description":"Advanced Solid Tumors","metadata":null},{"id":"014165e4f0654799a8a1b113b3cc3a0e","type":"TRIAL","name":"A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)","canonical_id":"clinicaltrials.gov:NCT07766005","description":"Hidradenitis Suppurativa (HS)","metadata":null},{"id":"82ef2aea95714f499b9936ba371b91c5","type":"TRIAL","name":"A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.","canonical_id":"clinicaltrials.gov:NCT06270225","description":"Gout Arthritis","metadata":null},{"id":"6cc3b3714a1a45a7a1dbd448c96b93bf","type":"TRIAL","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT07672223","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"a433faeac8d84a908eaf080059250f16","type":"TRIAL","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","canonical_id":"clinicaltrials.gov:NCT07040644","description":"Triple Negative Breast Neoplasms","metadata":null},{"id":"51dc2598722749ad9ff0842e25d50770","type":"TRIAL","name":"A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","canonical_id":"clinicaltrials.gov:NCT07063212","description":"Squamous Cell Carcinoma of Head and Neck; Sinus Cancer; Nasal Cavity Cancer; Oral Cavity Cancer; Oropharynx Cancer; Hypopharynx Cancer; Larynx Cancer; Oral Squamous Cell Carcinoma; Oropharynx Squamous Cell Carcinoma; Hypopharynx Squamous Cell Carcinoma; Larynx Squamous Cell Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma","metadata":null},{"id":"a250b12ec3c24aa89573a33b0e46671e","type":"TRIAL","name":"A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","canonical_id":"clinicaltrials.gov:NCT00361335","description":"Rheumatoid Arthritis","metadata":null},{"id":"6da2065681da4a7b821e49ab1f96ef8a","type":"TRIAL","name":"A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis","canonical_id":"clinicaltrials.gov:NCT00267969","description":"Psoriasis","metadata":null},{"id":"d3393f7090b742ad89882d8c71ca9401","type":"TRIAL","name":"A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT00658567","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"71d842e91e634088abef642d64bcea77","type":"TRIAL","name":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","canonical_id":"clinicaltrials.gov:NCT00313313","description":"Diabetes","metadata":null},{"id":"b3c0725364434706b97557ab884805f3","type":"TRIAL","name":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04294160","description":"BRAF V600 Colorectal Cancer","metadata":null},{"id":"3295a6e892a04fa2b56e1014e7f75ca4","type":"TRIAL","name":"A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05980806","description":"Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia","metadata":null},{"id":"57d9c7703760419cbd5d9dcdda815cf8","type":"TRIAL","name":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT04211337","description":"Medullary Thyroid Cancer","metadata":null},{"id":"1fd043bdfe86469994dc988ad03b8c87","type":"TRIAL","name":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","canonical_id":"clinicaltrials.gov:NCT04590235","description":"Neurofibromatosis 1; Neurofibroma Plexiform","metadata":null},{"id":"21e328f53e5843499d432d60fc5e43a3","type":"TRIAL","name":"A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01134848","description":"Sphincter of Oddi Dysfunction","metadata":null},{"id":"ba83aad7a4a840b7a6cadfd3198610e4","type":"TRIAL","name":"A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.","canonical_id":"clinicaltrials.gov:NCT00261911","description":"Obesity","metadata":null},{"id":"e1cc8146d5a54ee6a733b390a80ddf19","type":"TRIAL","name":"A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00793819","description":"Nocturia; Prostatic Hyperplasia","metadata":null},{"id":"ac10812be0034cb28792408ab2644ad2","type":"TRIAL","name":"A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01484275","description":"High-risk Smoldering Multiple Myeloma","metadata":null},{"id":"9d2e292e87db45cd9f3baa64faff5fda","type":"TRIAL","name":"A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes","canonical_id":"clinicaltrials.gov:NCT02806960","description":"Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2","metadata":null},{"id":"b5f479fb95e2462182f62b83c7bba31b","type":"TRIAL","name":"A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)","canonical_id":"clinicaltrials.gov:NCT04675983","description":"Gastric Adenocarcinoma","metadata":null},{"id":"ce5784e549694f94b92ce21c0c67cbb6","type":"TRIAL","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06856200","description":"Advanced HR - Positive, HER2 - Negative Breast Cancer; Resistant to (Neo)Adjuvant Endocrine Therapy","metadata":null},{"id":"d04cd8e4716347f091a7076585ca5e72","type":"TRIAL","name":"A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00411554","description":"Diabetes Mellitus, Non-Insulin-Dependent","metadata":null},{"id":"6a38e4ffb7ae41d49e01281ca65daec8","type":"TRIAL","name":"A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)","canonical_id":"clinicaltrials.gov:NCT00337558","description":"Overactive Bladder; Urinary Incontinence; Urge Incontinence","metadata":null},{"id":"870749bc40ab46bf8a5fb112db51bcf4","type":"TRIAL","name":"A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT07770698","description":"Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia; Pediatric Cancer; Pediatric ALL, Relapsed; Pediatric ALL; Pediatric ALL, B Cell; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Pediatric AML; R/R AML; R/R B-cell ALL","metadata":null},{"id":"bb41cb053323416f99b7e995cd951fb9","type":"TRIAL","name":"A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT05064449","description":"Healthy Volunteers","metadata":null},{"id":"411a398be16b47fea819ea1551724aab","type":"TRIAL","name":"A Study of Staccato Loxapine (ADASUVE\u00ae) for Inhalation","canonical_id":"clinicaltrials.gov:NCT04148963","description":"Psychomotor Agitation; Schizophrenia; Bipolar Disorder","metadata":null},{"id":"884e227b6f334381a1adb47343d22eea","type":"TRIAL","name":"A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)","canonical_id":"clinicaltrials.gov:NCT07544862","description":"Atopic Dermatitis (AD)","metadata":null},{"id":"1939d9ed4f48428786acd0171df3c9bf","type":"TRIAL","name":"A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","canonical_id":"clinicaltrials.gov:NCT07483268","description":"CRSWNP","metadata":null},{"id":"8a31681b88e343088dd389f092adfca5","type":"TRIAL","name":"A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT02684786","description":"Pulmonary Artery Hypertension","metadata":null},{"id":"a3dac70e21fb466aadf9f2d55506a7cc","type":"TRIAL","name":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01941095","description":"Rheumatoid Arthritis","metadata":null},{"id":"428ca03d33264a4f8ecff6fbfc1def9f","type":"TRIAL","name":"A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT01143090","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"33a8e2bd4e6e48668468481b1e129730","type":"TRIAL","name":"A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT01718327","description":"Unresectable and Advanced Cholangiocarcinoma","metadata":null},{"id":"4f844c5659704954bdef0750212d1f18","type":"TRIAL","name":"A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma","canonical_id":"clinicaltrials.gov:NCT02623127","description":"Thymic Carcinoma","metadata":null},{"id":"b6fba898e0e341c0b8ffcfddf2337c56","type":"TRIAL","name":"A Study of Surgical Techniques During Cystectomy","canonical_id":"clinicaltrials.gov:NCT06703476","description":"Bladder Cancer","metadata":null},{"id":"0caa743ded44440aa80c44aa3cd634d1","type":"TRIAL","name":"A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy","canonical_id":"clinicaltrials.gov:NCT06156332","description":"Advanced Solid Tumors With Neuroendocrine Differentiation","metadata":null},{"id":"0cc7d66efc564bd7bdfb3c142a99a43e","type":"TRIAL","name":"A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01977378","description":"Major Depressive Disorder","metadata":null},{"id":"5b3dc75218c04b619ca906cf083aa3f8","type":"TRIAL","name":"A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)","canonical_id":"clinicaltrials.gov:NCT06655883","description":"Insomnia","metadata":null},{"id":"632b2fc6f4f94874b0083752badfaf41","type":"TRIAL","name":"A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy","canonical_id":"clinicaltrials.gov:NCT06945107","description":"Plaque Psoriasis","metadata":null},{"id":"ac9d620f57074a339c959a6990a3cdd3","type":"TRIAL","name":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","canonical_id":"clinicaltrials.gov:NCT04639219","description":"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast","metadata":null},{"id":"b06ecd961d8847d8b50dfe5bdc32740f","type":"TRIAL","name":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02954406","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"1dbc17c518df487bb20f547fdc86b340","type":"TRIAL","name":"A Study of TEPEZZA\u00ae Treatment in Participants With Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT06389578","description":"Thyroid Eye Disease","metadata":null},{"id":"1088a5c11faa474da67b9ad82650f7d2","type":"TRIAL","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06038578","description":"Gastric Adenocarcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"2b4ceed6398c4a21a1df4b8215d1fddf","type":"TRIAL","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","canonical_id":"clinicaltrials.gov:NCT06846671","description":"CLL; Chronic Lymphocytic Leukemia","metadata":null},{"id":"46f38a5aed6d4e11aaf843b9d9cea9cf","type":"TRIAL","name":"A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms","canonical_id":"clinicaltrials.gov:NCT01139762","description":"Benign Prostatic Hyperplasia; Enlarged Prostate","metadata":null},{"id":"70862a38db294d7aac3fa83a09bb690f","type":"TRIAL","name":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00970632","description":"Benign Prostatic Hyperplasia (BPH)","metadata":null},{"id":"e7065918766f4f1f924220c27725fb9d","type":"TRIAL","name":"A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05788289","description":"Mantle Cell Lymphoma; MCL","metadata":null},{"id":"d5fd7c37cbc2448d8f8983c531c3583f","type":"TRIAL","name":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03148795","description":"Prostate Cancer","metadata":null},{"id":"597530c1554c462d9bc94a18660c1989","type":"TRIAL","name":"A Study of Talazoparib in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03070548","description":"Advanced Solid Tumors","metadata":null},{"id":"953d0eb1153c4e76ac9e5d18ddba7586","type":"TRIAL","name":"A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy","canonical_id":"clinicaltrials.gov:NCT01516008","description":"Hallux Valgus","metadata":null},{"id":"2ab9e417f076456e8f943036f038f77b","type":"TRIAL","name":"A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT00531960","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"23bbd4a0685f48779c5a4fccbed109c7","type":"TRIAL","name":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT04486352","description":"Endometrial Cancer","metadata":null},{"id":"8a6bbdf470184a22b4089e6eaf8a8f9d","type":"TRIAL","name":"A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma","canonical_id":"clinicaltrials.gov:NCT00002212","description":"Sarcoma, Kaposi; HIV Infections","metadata":null},{"id":"19b9eb15376e47169a9cfdb828c316a6","type":"TRIAL","name":"A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.","canonical_id":"clinicaltrials.gov:NCT00754988","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"e324cc9ff6e24854866944ced1fb86f9","type":"TRIAL","name":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04179864","description":"Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"9600aaed4ea54ca1990b102b2023ea9e","type":"TRIAL","name":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05551936","description":"Follicular Lymphoma","metadata":null},{"id":"63fedd077bf6474189d32eb8ba19111d","type":"TRIAL","name":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT02601950","description":"Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of Ovary; Renal Medullary Carcinoma; Epithelioid Sarcoma; Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval); Any Solid Tumor With an EZH2 GOF Mutation","metadata":null},{"id":"743c6257c3114ee098ed28994a1a85c0","type":"TRIAL","name":"A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma","canonical_id":"clinicaltrials.gov:NCT05713110","description":"Relapsed/Refractory Lymphoma","metadata":null},{"id":"6a2104527f1a4a00a6eb56744e73a59c","type":"TRIAL","name":"A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.","canonical_id":"clinicaltrials.gov:NCT05205252","description":"Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy","metadata":null},{"id":"f56c5394fadb4b43aa1568cbe00dc135","type":"TRIAL","name":"A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT03009344","description":"Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","metadata":null},{"id":"ed70907bad944cc2934ef31e96f96715","type":"TRIAL","name":"A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan","canonical_id":"clinicaltrials.gov:NCT05228158","description":"Lymphoma, Follicular","metadata":null},{"id":"3b2104d9c44243a4908b8e669273843d","type":"TRIAL","name":"A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT06973304","description":"Short Bowel Syndrome","metadata":null},{"id":"6a6ed7df464e4d7f8882a24e3713653d","type":"TRIAL","name":"A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older","canonical_id":"clinicaltrials.gov:NCT05027308","description":"Short Bowel Syndrome","metadata":null},{"id":"9bbbf74e92f54912a1d6261d3e93484b","type":"TRIAL","name":"A Study of Teduglutide in Japanese People With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT05023382","description":"Short Bowel Syndrome","metadata":null},{"id":"0df840116c4a4c77bb1a266dbd00126d","type":"TRIAL","name":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","canonical_id":"clinicaltrials.gov:NCT03940703","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"cb925373c3c0460b862473252ef033ff","type":"TRIAL","name":"A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07619339","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"bad62c0c02ff44809d4d3826b8f1c35c","type":"TRIAL","name":"A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT07265258","description":"Thyroid Eye Disease","metadata":null},{"id":"783f215a4d67455bae7fc0765887248b","type":"TRIAL","name":"A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users","canonical_id":"clinicaltrials.gov:NCT01438749","description":"Healthy Volunteer","metadata":null},{"id":"002275f434ab42728653aec5fc0621b0","type":"TRIAL","name":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","canonical_id":"clinicaltrials.gov:NCT01878318","description":"Rheumatoid Arthritis","metadata":null},{"id":"e8ef730bf40148fcb8d63398a5b93268","type":"TRIAL","name":"A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants","canonical_id":"clinicaltrials.gov:NCT01767623","description":"Neoplasms","metadata":null},{"id":"3ea95a52dd5f43a08a2352a0fd13bea2","type":"TRIAL","name":"A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia","canonical_id":"clinicaltrials.gov:NCT00002154","description":"Cognitive Disorders; HIV Infections","metadata":null},{"id":"99b5e39156d745259109cb4a5d0531bf","type":"TRIAL","name":"A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03997786","description":"Moderate-to-severe Chronic Plaque Psoriasis","metadata":null},{"id":"d59bf88151d24a688f2bed9624b2bc73","type":"TRIAL","name":"A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)","canonical_id":"clinicaltrials.gov:NCT06029257","description":"Genital Psoriasis","metadata":null},{"id":"5161dadae1fb494eafe9d5463a15c09a","type":"TRIAL","name":"A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03987919","description":"Type 2 Diabetes","metadata":null},{"id":"0fb7be5d916748d5b22a7bd1a8e0b10b","type":"TRIAL","name":"A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities","canonical_id":"clinicaltrials.gov:NCT05822830","description":"Obesity; Overweight","metadata":null},{"id":"7adb626d7b914ae4a43a72edf13cb152","type":"TRIAL","name":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03783442","description":"Esophageal Squamous Cell Carcinoma (ESCC)","metadata":null},{"id":"a0be4c4380364027818216cf040976ac","type":"TRIAL","name":"A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00502307","description":"Carcinoma, Renal Cell","metadata":null},{"id":"2c7480b4c63e4ea594193e4b886d2bae","type":"TRIAL","name":"A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT03970616","description":"Hepatocellular Carcinoma","metadata":null},{"id":"8026c77bf1724b64babd51cb89418f6e","type":"TRIAL","name":"A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy","canonical_id":"clinicaltrials.gov:NCT01209689","description":"Spondylitis, Ankylosing","metadata":null},{"id":"5a6cd3dbd14245d5b0d311a471ce5e10","type":"TRIAL","name":"A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease","canonical_id":"clinicaltrials.gov:NCT00744276","description":"Fibrocystic Disease of Breast","metadata":null},{"id":"ecc3799aaf794d78895d8b787ba7a6a5","type":"TRIAL","name":"A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT07714187","description":"Mycosis Fungoides; Cutaneous T-cell Lymphoma","metadata":null},{"id":"e3ec9ae04bc54eebbfd694961f55408a","type":"TRIAL","name":"A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol","canonical_id":"clinicaltrials.gov:NCT00138762","description":"Hyperlipidemia","metadata":null},{"id":"80df90de5661415bbad74ec3e8a5a2d5","type":"TRIAL","name":"A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02085473","description":"Asthma; Healthy Subjects or Volunteers","metadata":null},{"id":"2770359aee9f462d9589e6190fb46349","type":"TRIAL","name":"A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab","canonical_id":"clinicaltrials.gov:NCT00875979","description":"Metastatic Breast Cancer","metadata":null},{"id":"665f14199be242aaaad7ef0b03ae15cb","type":"TRIAL","name":"A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function","canonical_id":"clinicaltrials.gov:NCT01513083","description":"Breast Cancer","metadata":null},{"id":"63e5383bf571439fbd1ad1c217d2387f","type":"TRIAL","name":"A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition","canonical_id":"clinicaltrials.gov:NCT05787574","description":"Primary Immune Regulatory Disorder; Autoimmune Lymphoproliferative; Immune System Diseases","metadata":null},{"id":"0f191f76feb0471ca36a0ff43c403b05","type":"TRIAL","name":"A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)","canonical_id":"clinicaltrials.gov:NCT02588131","description":"Pleural Mesothelioma; Peritoneal Mesothelioma","metadata":null},{"id":"f0d98c2cc79b48d08c4643a3c6ac3811","type":"TRIAL","name":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","canonical_id":"clinicaltrials.gov:NCT04721977","description":"Breast Cancer","metadata":null},{"id":"8a83207727144c13a49ef4290be347a8","type":"TRIAL","name":"A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01983501","description":"HER2 Positive Breast Cancers","metadata":null},{"id":"0c8033859a7c4911bb28ba273e166f7e","type":"TRIAL","name":"A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02025192","description":"HER2 Positive Metastatic Breast Cancers","metadata":null},{"id":"a0603755f6ba437ba42ab54fdfaa27ab","type":"TRIAL","name":"A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain","canonical_id":"clinicaltrials.gov:NCT05892068","description":"Metastatic Breast Cancer","metadata":null},{"id":"5f9881f561c3405a96e9f232f156de7e","type":"TRIAL","name":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04539938","description":"HER2 Positive Breast Cancer","metadata":null},{"id":"938023b7051b42b2bfed1b5bffff4160","type":"TRIAL","name":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05253651","description":"Colorectal Neoplasms","metadata":null},{"id":"ad497a75e78b44b1b8f82e9a538474d9","type":"TRIAL","name":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05672524","description":"Adenocarcinoma of the Rectum; Locally Advanced Rectal Adenocarcinoma; Rectal Adenocarcinoma; HER2 Positive Rectal Adenocarcinoma; Rectal Cancer","metadata":null},{"id":"73c38d15557c4922a62f465703d45240","type":"TRIAL","name":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05132582","description":"HER2 Positive Breast Cancer","metadata":null},{"id":"cfeee3eb2c8f4bbd973667b8e4decf61","type":"TRIAL","name":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03975647","description":"HER2-positive Breast Cancer","metadata":null},{"id":"02d6c83f8ab7432bb5471f33f5274c91","type":"TRIAL","name":"A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)","canonical_id":"clinicaltrials.gov:NCT00092352","description":"Osteoarthritis","metadata":null},{"id":"6f1ae2842c0e47dfa49053f2a8aa5f35","type":"TRIAL","name":"A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092365","description":"Osteoarthritis","metadata":null},{"id":"2081ffcbff63463187aa7f91d8363191","type":"TRIAL","name":"A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092378","description":"Postoperative Pain","metadata":null},{"id":"2ac5adfbd0304fa49be3cd8c98e7a8ff","type":"TRIAL","name":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092300","description":"Postoperative Pain","metadata":null},{"id":"2ef6e6877ed7462cb605b54a9a9a9a1b","type":"TRIAL","name":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)","canonical_id":"clinicaltrials.gov:NCT00092313","description":"Postoperative Pain","metadata":null},{"id":"1e0140efe4a24a36b9e3745ed2a2b046","type":"TRIAL","name":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)","canonical_id":"clinicaltrials.gov:NCT00092326","description":"Postoperative Pain","metadata":null},{"id":"e5944699db9149db843f8afa1961346d","type":"TRIAL","name":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092339","description":"Postoperative Pain","metadata":null},{"id":"020ea5df86d44abcb9e1b5ec2580feb9","type":"TRIAL","name":"A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01896479","description":"Medullary Thyroid Cancer","metadata":null},{"id":"b152702c68ea43c0a147534bccd42e9d","type":"TRIAL","name":"A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05392530","description":"Healthy","metadata":null},{"id":"9f188f3a4fbe41c9ad72a9329e50e20d","type":"TRIAL","name":"A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01565330","description":"Alzheimer Disease","metadata":null},{"id":"f604e218ce764f9b911bb3a12f760c7d","type":"TRIAL","name":"A Study of Two Formulations of Ixekizumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04259346","description":"Healthy","metadata":null},{"id":"75c3f6fffb554dac87bffcb87579e83d","type":"TRIAL","name":"A Study of Two Macitentan Formulations in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05433675","description":"Healthy","metadata":null},{"id":"f943f642fb8a45ed808e622c65e84733","type":"TRIAL","name":"A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas","canonical_id":"clinicaltrials.gov:NCT01815840","description":"Basal Cell Carcinoma","metadata":null},{"id":"16e54afbd5d04ec2ad84405e29a44c8d","type":"TRIAL","name":"A Study of Ultra High Dose Diuretics to Treat Heart Failure","canonical_id":"clinicaltrials.gov:NCT06036914","description":"Heart Failure; With Decompensation","metadata":null},{"id":"d028b3ab318141b5b6b4aa05ba730965","type":"TRIAL","name":"A Study of Use of Ella\u00ae, an Emergency Contraceptive, Under Simulated OTC Conditions","canonical_id":"clinicaltrials.gov:NCT03208985","description":"Emergency Contraception","metadata":null},{"id":"42f14f4f91a74b7a86e179f6ef6d0d5b","type":"TRIAL","name":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT05029921","description":"Crohn Disease","metadata":null},{"id":"1fe5e39a004e404db8bb9df3b8c3b1d4","type":"TRIAL","name":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","canonical_id":"clinicaltrials.gov:NCT04882072","description":"Takayasu Arteritis","metadata":null},{"id":"c4a7e310f7074538b52f48cc486313c9","type":"TRIAL","name":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)","canonical_id":"clinicaltrials.gov:NCT04630028","description":"Colitis, Ulcerative","metadata":null},{"id":"7f95c891c1f948f9bdb8d3fce7532192","type":"TRIAL","name":"A Study of Ustekinumab to Evaluate a \"Subject-tailored\" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01550744","description":"Psoriasis","metadata":null},{"id":"f66d899309d64574bbb4cc7aeeee9ca2","type":"TRIAL","name":"A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT05444530","description":"Myeloproliferative Neoplasms","metadata":null},{"id":"e78590e1070442c4ad9f22f8323f8aed","type":"TRIAL","name":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","canonical_id":"clinicaltrials.gov:NCT03217812","description":"Multiple Myeloma","metadata":null},{"id":"035af1b9c13047438098e38fed130760","type":"TRIAL","name":"A Study of VG712 in Patients With Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT07529405","description":"Mycosis Fungoides","metadata":null},{"id":"c35483925a5645e3b9d2dcf9e86f7c47","type":"TRIAL","name":"A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02386111","description":"Carcinoma, Renal Cell; Kidney Diseases; Kidney Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms; Neoplasms; Neoplasms by Histologic Type; Clear-cell Metastatic Renal Cell Carcinoma","metadata":null},{"id":"420c281216ef4543affc91ead2b51b82","type":"TRIAL","name":"A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT06227910","description":"Crohn's Disease","metadata":null},{"id":"14a9e20d66464614a44fe1f4119ac7f4","type":"TRIAL","name":"A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)","canonical_id":"clinicaltrials.gov:NCT05442567","description":"Ulcerative Colitis; Crohn's Disease","metadata":null},{"id":"1a14f564ecb9410ea0fd10ebc987b5ad","type":"TRIAL","name":"A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma","canonical_id":"clinicaltrials.gov:NCT01667419","description":"Melanoma","metadata":null},{"id":"19f4b6907c9a41ac97234a6f2b635000","type":"TRIAL","name":"A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01271803","description":"Malignant Melanoma","metadata":null},{"id":"cd0d02159e484d419c2c770ed227a092","type":"TRIAL","name":"A Study of Vemurafenib in Participants With Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01307397","description":"Malignant Melanoma","metadata":null},{"id":"1a0b64c1f2004b37a977b79a31b8ef32","type":"TRIAL","name":"A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01685892","description":"Lymphocytic Leukemia, Chronic","metadata":null},{"id":"51947d987afc4d45928ee7c3263e84c7","type":"TRIAL","name":"A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT02436239","description":"Major Depressive Disorder","metadata":null},{"id":"8d5c00111e1544368899316946a2fa2e","type":"TRIAL","name":"A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study","canonical_id":"clinicaltrials.gov:NCT00959647","description":"Ovarian Cancer; Basal Cell Carcinoma; Metastatic Colorectal Cancer","metadata":null},{"id":"be4174fd2381460791aed37ce5ac433d","type":"TRIAL","name":"A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01160250","description":"Basal Cell Carcinoma","metadata":null},{"id":"aa98f341e945407fa4b5656ece2efa3a","type":"TRIAL","name":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission","canonical_id":"clinicaltrials.gov:NCT00739661","description":"Ovarian Cancer","metadata":null},{"id":"789f805e82f8470cac1cece7efdadb37","type":"TRIAL","name":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00636610","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"94f86483878041b68532897a88ec94db","type":"TRIAL","name":"A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy","canonical_id":"clinicaltrials.gov:NCT02115828","description":"Prostate Cancer","metadata":null},{"id":"0e3fe66a672449e5bafe03a9def95834","type":"TRIAL","name":"A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT01880437","description":"Myelodysplastic Syndromes, Myelogenous Leukemia, Acute","metadata":null},{"id":"69f226bfb71a447d96542b2cf43fd197","type":"TRIAL","name":"A Study of Vonoprazan in Adults With Helicobacter Pylori","canonical_id":"clinicaltrials.gov:NCT04753437","description":"Helicobacter Pylori","metadata":null},{"id":"5f12b2a8407d48f49ca7750dc8d0c25f","type":"TRIAL","name":"A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication","canonical_id":"clinicaltrials.gov:NCT01488071","description":"Major Depressive Disorder","metadata":null},{"id":"b4bc5d367e9649fd8c855a38721e213b","type":"TRIAL","name":"A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT07204314","description":"Major Depressive Disorder","metadata":null},{"id":"6cf5dbd0114c4c8ca13abe6ecd581a18","type":"TRIAL","name":"A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)","canonical_id":"clinicaltrials.gov:NCT03657043","description":"Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"810905d319154ebf94fe98c0bdde237c","type":"TRIAL","name":"A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT00210613","description":"Sexual Dysfunction; Ejaculation","metadata":null},{"id":"50d1e0c00de342dd9212481762bd724b","type":"TRIAL","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07213674","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"5c4c443cb66947b78a7ef3e115dd75fe","type":"TRIAL","name":"A Study of Xenical (Orlistat) in Overweight and Obese Adolescents","canonical_id":"clinicaltrials.gov:NCT00940628","description":"Obesity","metadata":null},{"id":"47bb99a7578747de82a11005602dc45c","type":"TRIAL","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-na\u00efve Extensive-stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07739758","description":"SCLC, Extensive Stage","metadata":null},{"id":"90c3583e38994601996094142c351b80","type":"TRIAL","name":"A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment","canonical_id":"clinicaltrials.gov:NCT01007292","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"9abee599e8be48949f5eb69d5761b53f","type":"TRIAL","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","canonical_id":"clinicaltrials.gov:NCT05100862","description":"Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"5bcdf74356fa4a5292965b79551813f1","type":"TRIAL","name":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","canonical_id":"clinicaltrials.gov:NCT03653507","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"48370b9993b244c4b959a4194b325c55","type":"TRIAL","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT03505320","description":"Pharmacokinetics of Zolbetuximab; Gastric Cancer; Gastro-esophageal Junction (GEJ) Cancer; Pharmacokinetics of Oxaliplatin; Pharmacokinetics of Fluorouracil Bolus (5-FU)","metadata":null},{"id":"a1c1e5db68da462582029278d3af755f","type":"TRIAL","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03816163","description":"Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma","metadata":null},{"id":"97f84ec9f2014683bdee157021d7c75e","type":"TRIAL","name":"A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT07829757","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"43f5d76499774fbbbee5d947294f5467","type":"TRIAL","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06901531","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"f4af5fb906dc4b47b1d8c20701196655","type":"TRIAL","name":"A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT06396091","description":"Metastatic Pancreatic Adenocarcinoma","metadata":null},{"id":"8f5a1bce3d25466bbe6d237f32f85e93","type":"TRIAL","name":"A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss","canonical_id":"clinicaltrials.gov:NCT00333229","description":"Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women","metadata":null},{"id":"3f63dc8275a84e2492e97cb2f47bafe9","type":"TRIAL","name":"A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia","canonical_id":"clinicaltrials.gov:NCT00380081","description":"Insomnia","metadata":null},{"id":"1bf228ca7173420a9e4da2b73303b299","type":"TRIAL","name":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00314171","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"335f214b3c3a434f88c33e8c2c24daf1","type":"TRIAL","name":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00314158","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"f0e9da93cdad4e849e600380272d1aba","type":"TRIAL","name":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00326092","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"b642a5dd05864da084e547b3c25cced1","type":"TRIAL","name":"A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT05203510","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"24d30238efe94a4aa07a7f276871dfd3","type":"TRIAL","name":"A Study of a Melatonin Receptor Agonist to Prevent Migraine","canonical_id":"clinicaltrials.gov:NCT00739024","description":"Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"e2d07d98064547a18611410013f19983","type":"TRIAL","name":"A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise","canonical_id":"clinicaltrials.gov:NCT01435902","description":"Asthma","metadata":null},{"id":"b4c4566aa97e43ac88aee1f927c873ae","type":"TRIAL","name":"A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00148122","description":"Head and Neck Cancer","metadata":null},{"id":"ae554c15de664b918d0fad2117a7737f","type":"TRIAL","name":"A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy","canonical_id":"clinicaltrials.gov:NCT02623465","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"5613dbff89cd493588c59528375b52fc","type":"TRIAL","name":"A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT00952614","description":"Central Retinal Vein Occlusion","metadata":null},{"id":"148e8f0e8a0a4f5eb70431daef7af269","type":"TRIAL","name":"A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment","canonical_id":"clinicaltrials.gov:NCT07006688","description":"IDH1-Mutated Malignancies","metadata":null},{"id":"fcd9c2d947874629bd223afc477dbf2e","type":"TRIAL","name":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","canonical_id":"clinicaltrials.gov:NCT05884398","description":"Metastatic Castrate-sensitive Prostate Cancer","metadata":null},{"id":"6f587568a2634a5d926d64396d1701bc","type":"TRIAL","name":"A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","canonical_id":"clinicaltrials.gov:NCT03391882","description":"Motor OFF Episodes Associated With Parkinson's Disease","metadata":null},{"id":"f5d63385e6e24c5da18e826c7cf05c96","type":"TRIAL","name":"A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)","canonical_id":"clinicaltrials.gov:NCT00127179","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"57a313378215439b8c60ce57fc8cf39c","type":"TRIAL","name":"A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)","canonical_id":"clinicaltrials.gov:NCT06566989","description":"Metastatic Prostate Cancer","metadata":null},{"id":"ef85994758fc407abccd92fc9d768e27","type":"TRIAL","name":"A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03758339","description":"Healthy","metadata":null},{"id":"3aecf88326d74dbea1514379a9712474","type":"TRIAL","name":"A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants","canonical_id":"clinicaltrials.gov:NCT05652257","description":"Healthy Volunteers","metadata":null},{"id":"dbc0fcf654b1449e9fe9636685d16b55","type":"TRIAL","name":"A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant","canonical_id":"clinicaltrials.gov:NCT01403389","description":"Delayed Function of Renal Transplant","metadata":null},{"id":"e34b1e494f3643c7a95b6144a81848db","type":"TRIAL","name":"A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT00426348","description":"Glomerulonephritis; IGA Nephropathy","metadata":null},{"id":"572876e90ebb4a37ba332eca3bc24839","type":"TRIAL","name":"A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT02215330","description":"Central Serous Chorioretinopathy","metadata":null},{"id":"bd22b01c95c74f2aba055f68131a4fae","type":"TRIAL","name":"A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose","canonical_id":"clinicaltrials.gov:NCT06908954","description":"Hepatic Impairment; Healthy","metadata":null},{"id":"e6ef94a0d2874e30a672a4eb6e5a475b","type":"TRIAL","name":"A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02906605","description":"Prostatic Neoplasms, Castration-Resistant","metadata":null},{"id":"271b52562a90433b8fa5c0bd7c1c3568","type":"TRIAL","name":"A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT07392242","description":"Acute Myeloid Leukemia","metadata":null},{"id":"f5c184e5001f48e8bd9099d3fa80f54d","type":"TRIAL","name":"A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC","canonical_id":"clinicaltrials.gov:NCT02451930","description":"Stage IV Non-Small Cell Lung Cancer","metadata":null},{"id":"3dc8795954fb47bab35eac5ad53b7b7a","type":"TRIAL","name":"A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)","canonical_id":"clinicaltrials.gov:NCT06382987","description":"Plaque Psoriasis","metadata":null},{"id":"11b1cb997ea9499a9f3a8d9d04913898","type":"TRIAL","name":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT04030962","description":"Dry Eye Disease; Dry Eye Syndrome","metadata":null},{"id":"94b95717cf8947d288321838df264b88","type":"TRIAL","name":"A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT03871257","description":"Low Grade Glioma; Neurofibromatosis Type 1; Visual Pathway Glioma","metadata":null},{"id":"a3f0544fcc8e4166a930c24c81b6d0d5","type":"TRIAL","name":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT04166409","description":"Low Grade Astrocytoma; Low Grade Glioma; Metastatic Low Grade Astrocytoma; Metastatic Low Grade Glioma; WHO Grade 1 Glioma; WHO Grade 2 Glioma","metadata":null},{"id":"a6b9630b34ee41188e402a03c6dcc71f","type":"TRIAL","name":"A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07740720","description":"Neoplasms, Rectal","metadata":null},{"id":"33c5d575cfb34c649fd184feb9113fd6","type":"TRIAL","name":"A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT02387801","description":"Psoriasis","metadata":null},{"id":"77b96c3ca28046b292bab9321c70e3ab","type":"TRIAL","name":"A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT06635772","description":"Immunoglobulin a Nephropathy","metadata":null},{"id":"c64232825deb4e9c86c52dfcb5218cd9","type":"TRIAL","name":"A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT03762850","description":"Immunoglobulin A Nephropathy","metadata":null},{"id":"a14e690b27c648b6afe9fbd4d375a386","type":"TRIAL","name":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","canonical_id":"clinicaltrials.gov:NCT07101939","description":"Obesity; Muscle Loss","metadata":null},{"id":"6228f8d11b5b4f559daf08fd3a7d9f35","type":"TRIAL","name":"A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification","canonical_id":"clinicaltrials.gov:NCT05649111","description":"Uveitis, Anterior","metadata":null},{"id":"c7f49dfb962b4048927c403266927c61","type":"TRIAL","name":"A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)","canonical_id":"clinicaltrials.gov:NCT07232589","description":"Healthy","metadata":null},{"id":"53b83688010f48c6abeb712660847a93","type":"TRIAL","name":"A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01436201","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1c335b2e15e24ec1b172932989a0e315","type":"TRIAL","name":"A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02085252","description":"Prostate Cancer","metadata":null},{"id":"f09debff777d4319b8733f070228e327","type":"TRIAL","name":"A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01665404","description":"Healthy Volunteer","metadata":null},{"id":"b3020c9a926e43d89f91c418975118ce","type":"TRIAL","name":"A Study of the Effect of LY2189265 on Two Blood Pressure Drugs","canonical_id":"clinicaltrials.gov:NCT01324388","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"14e5c5f83af741c49bdad4c5505d0bb6","type":"TRIAL","name":"A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT02837783","description":"Irritable Bowel Syndrome Characterized by Constipation","metadata":null},{"id":"59d23613142d407ba64c1fce8159ff8d","type":"TRIAL","name":"A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04459585","description":"Healthy Subjects; Drug-drug Interaction; Pharmacokinetics; Quizartinib","metadata":null},{"id":"36a9f091dd4c47778fdd78881c838104","type":"TRIAL","name":"A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy","canonical_id":"clinicaltrials.gov:NCT01849666","description":"Malignant Melanoma, Neoplasms","metadata":null},{"id":"40d3c326ab3a428fa5355e24ad6f5fbc","type":"TRIAL","name":"A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04459598","description":"Healthy Subjects; Drug-drug Interaction; Pharmacokinetics; Quizartinib","metadata":null},{"id":"e92d70918fa94d5bba2d7533b7a7fa82","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT00210704","description":"Erectile Dysfunction","metadata":null},{"id":"3f67f08fce0f4f46bdcaa08b8a10ece9","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT00229073","description":"Erectile Dysfunction","metadata":null},{"id":"85600458f68945f580d3cc88e34f5d33","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT00211094","description":"Ejaculation","metadata":null},{"id":"7b204e2e1a6541aebf16d1baeea495b8","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.","canonical_id":"clinicaltrials.gov:NCT00211107","description":"Ejaculation","metadata":null},{"id":"e5d562c5d3c8452996b54a5fbf0be894","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00287742","description":"Alzheimer's Disease; Dementia","metadata":null},{"id":"0bbddbd88e28487ea957c6be66bd8326","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia","canonical_id":"clinicaltrials.gov:NCT00249145","description":"Dementia; Alzheimer Disease; Dementia, Vascular","metadata":null},{"id":"63c898ee912a4ba7a9012a567027d495","type":"TRIAL","name":"A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01969357","description":"Type 2 Diabetes","metadata":null},{"id":"c8f50dc6fcc54ab2a7cce3714bfa640a","type":"TRIAL","name":"A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome","canonical_id":"clinicaltrials.gov:NCT01133353","description":"Tourette's Syndrome","metadata":null},{"id":"897ea491dbbf4aa197cec98f52eecd3a","type":"TRIAL","name":"A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA\u00ae (Leflunomide) in Saudi Arabia","canonical_id":"clinicaltrials.gov:NCT06714461","description":"Rheumatoid Arthritis; Psoriatic Arthritis","metadata":null},{"id":"b4d1f8e7aab34d9b978b2cc7cb4073ff","type":"TRIAL","name":"A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation","canonical_id":"clinicaltrials.gov:NCT00408200","description":"Atrial Fibrillation","metadata":null},{"id":"c2ca01d7bfcd48038617a355eb74e991","type":"TRIAL","name":"A Study of the Effectiveness of Xultophy\u00ae (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02754817","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"0b8799d5010d468dbf805a53f6116562","type":"TRIAL","name":"A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01483781","description":"Diabetes Mellitus, Type 2; Plasma Volume","metadata":null},{"id":"bc9590c658a944e4a447e0d12095dc31","type":"TRIAL","name":"A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)","canonical_id":"clinicaltrials.gov:NCT00311844","description":"Conjunctivitis, Allergic","metadata":null},{"id":"cd8235bbf458418897eb10d6886e4730","type":"TRIAL","name":"A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives","canonical_id":"clinicaltrials.gov:NCT00825188","description":"Obesity; Hypertension","metadata":null},{"id":"6062ba7f22284b489ca3a94d6441aa91","type":"TRIAL","name":"A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome","canonical_id":"clinicaltrials.gov:NCT00017927","description":"McCune Albright Syndrome; Polyostotic Fibrous Dysplasia","metadata":null},{"id":"061fd80579ec4a938906acdd1d92edbd","type":"TRIAL","name":"A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01984229","description":"Healthy Volunteer","metadata":null},{"id":"1be27dd3da1f41dbbc73e242f2b56e88","type":"TRIAL","name":"A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs","canonical_id":"clinicaltrials.gov:NCT00649064","description":"Schizoaffective Disorder; Schizophrenia","metadata":null},{"id":"621db32ec1694c479f2d22532ae790ed","type":"TRIAL","name":"A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT00476151","description":"Diabetic Peripheral Neuropathy; Neuralgia","metadata":null},{"id":"2ef3cb8daccb4186914182b3d0b1d024","type":"TRIAL","name":"A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp","canonical_id":"clinicaltrials.gov:NCT03123471","description":"Psoriasis","metadata":null},{"id":"1cffac8555dc4436aea1345b8ddbf201","type":"TRIAL","name":"A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)","canonical_id":"clinicaltrials.gov:NCT01617187","description":"Schizophrenia","metadata":null},{"id":"e98d85e76bae451eabdb0e7a14bb6fe9","type":"TRIAL","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","canonical_id":"clinicaltrials.gov:NCT07742215","description":"Myeloma Multiple","metadata":null},{"id":"500c9897be844d54a41658d6bc8ca030","type":"TRIAL","name":"A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07321093","description":"Relapsing-remitting Multiple Sclerosis (RRMS)","metadata":null},{"id":"7c6749791ab944778e075732abd2867d","type":"TRIAL","name":"A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease","canonical_id":"clinicaltrials.gov:NCT06572384","description":"Lung Diseases, Interstitial","metadata":null},{"id":"8fab6294ed024ffa9b1ea36f9ba3ca62","type":"TRIAL","name":"A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT05878717","description":"Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic","metadata":null},{"id":"931aecab82994a188d653f6f898708ca","type":"TRIAL","name":"A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)","canonical_id":"clinicaltrials.gov:NCT06685835","description":"Hidradenitis Suppurativa","metadata":null},{"id":"a82515604f964e3983e6703327a58cc1","type":"TRIAL","name":"A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)","canonical_id":"clinicaltrials.gov:NCT06013241","description":"Chronic Rhinosinusitis Without Nasal Polyps","metadata":null},{"id":"b94b3c18ba374f438b60c69a559fa236","type":"TRIAL","name":"A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT03481660","description":"Diabetic Macular Edema","metadata":null},{"id":"67a821edacbb4001b72603cabfd25b24","type":"TRIAL","name":"A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)","canonical_id":"clinicaltrials.gov:NCT01918033","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"bd1cd603714c48dbb081c7ca10aa434d","type":"TRIAL","name":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","canonical_id":"clinicaltrials.gov:NCT01958671","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f80da8a262444f4b8f4bd03eb18dce99","type":"TRIAL","name":"A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)","canonical_id":"clinicaltrials.gov:NCT01986855","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"2cf4c086cf2a40fe93ed75790e1f067c","type":"TRIAL","name":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03466411","description":"Crohn's Disease","metadata":null},{"id":"b035732ef7934fbd869240739a98d999","type":"TRIAL","name":"A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00240708","description":"Schizophrenia","metadata":null},{"id":"4aefc6c5c26b4af697630c274543bc84","type":"TRIAL","name":"A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT01438489","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"09a11733faa1405b942b3735557daecd","type":"TRIAL","name":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00676715","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"696ffee606cc4befbcff474a64aef3fd","type":"TRIAL","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","canonical_id":"clinicaltrials.gov:NCT04488822","description":"Tenosynovial Giant Cell Tumor","metadata":null},{"id":"798d51165502407b838fa18048f10d72","type":"TRIAL","name":"A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03105102","description":"Crohn's Disease","metadata":null},{"id":"b4f56759e46e4ee187529183ad20de66","type":"TRIAL","name":"A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament","canonical_id":"clinicaltrials.gov:NCT00236535","description":"Sprains and Strains; Pain","metadata":null},{"id":"92fd6d3dd1fe4e55a69c494be615d886","type":"TRIAL","name":"A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine","canonical_id":"clinicaltrials.gov:NCT00236561","description":"Migraine; Common Migraine; Classic Migraine; Headache","metadata":null},{"id":"ca10032ce4804e5eb926ea0accca6cb3","type":"TRIAL","name":"A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas","canonical_id":"clinicaltrials.gov:NCT02147158","description":"Leiomyoma; Uterine Hemorrhage","metadata":null},{"id":"d8b13f0692a545238ef7e98c53a3b273","type":"TRIAL","name":"A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)","canonical_id":"clinicaltrials.gov:NCT01314872","description":"Urinary Bladder, Overactive","metadata":null},{"id":"7e71f44baa7b476eb833d69580bafe02","type":"TRIAL","name":"A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT07850752","description":"IgA Nephropathy (IgAN)","metadata":null},{"id":"c4d6dd807abc49ccaf1f09a8499b87dd","type":"TRIAL","name":"A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas","canonical_id":"clinicaltrials.gov:NCT02147197","description":"Leiomyoma; Uterine Hemorrhage","metadata":null},{"id":"17e8efaf396644128aebb74234bd95f7","type":"TRIAL","name":"A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)","canonical_id":"clinicaltrials.gov:NCT00819585","description":"Gout","metadata":null},{"id":"61eab390228c4477b4d9801ac0a60f8a","type":"TRIAL","name":"A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis","canonical_id":"clinicaltrials.gov:NCT00789399","description":"Deep Vein Thrombosis; Coronary Artery Bypass Surgery; Venous Thromboembolism","metadata":null},{"id":"106d2620ab5a4c8e9d6116c2ac5017b7","type":"TRIAL","name":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta\u00ae in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07386938","description":"Locally Advanced Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"0170e9f557d8423283193c358644f89f","type":"TRIAL","name":"A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)","canonical_id":"clinicaltrials.gov:NCT00521599","description":"Asthma","metadata":null},{"id":"7dceab88b89243cdb9b7ab5ba105c09c","type":"TRIAL","name":"A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV","canonical_id":"clinicaltrials.gov:NCT02431325","description":"HIV","metadata":null},{"id":"b0b398fb8ab84fd0bf86aa765d53b1cc","type":"TRIAL","name":"A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02543918","description":"Healthy","metadata":null},{"id":"36e4f61d2921451b80f7a0c2cb68005e","type":"TRIAL","name":"A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life","canonical_id":"clinicaltrials.gov:NCT03774875","description":"Psoriasis","metadata":null},{"id":"c4fef67957774c9cb445369b3f7e6abf","type":"TRIAL","name":"A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06290050","description":"Healthy Volunteers","metadata":null},{"id":"0e6da5ce8c5a480aa654e0481ab65abd","type":"TRIAL","name":"A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT05995249","description":"Healthy Volunteers","metadata":null},{"id":"17b561d3a2e94eccb4f78cfc5b420dc5","type":"TRIAL","name":"A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05337254","description":"Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"a9c1bfecccf6460db785f3df6b464138","type":"TRIAL","name":"A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06178783","description":"Healthy Volunteers","metadata":null},{"id":"93bd926a198d4eac86a4a0f3a452b8b3","type":"TRIAL","name":"A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems","canonical_id":"clinicaltrials.gov:NCT03098680","description":"Drug-Related Side Effects and Adverse Reactions; Cardiovascular System Disease","metadata":null},{"id":"86e2e3282dd9495395b70ae30d415285","type":"TRIAL","name":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","canonical_id":"clinicaltrials.gov:NCT01500382","description":"Overactive Bladder; Overactive Urinary Bladder","metadata":null},{"id":"d0dde865d7574b12913ba418c4dd4dc2","type":"TRIAL","name":"A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)","canonical_id":"clinicaltrials.gov:NCT01390441","description":"Rheumatoid Arthritis","metadata":null},{"id":"b7739d08e4784ceda3eab374372b6e29","type":"TRIAL","name":"A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects","canonical_id":"clinicaltrials.gov:NCT01288157","description":"Healthy Adult Chinese Males","metadata":null},{"id":"a755211e1ea445ccad0df0595e3f56e3","type":"TRIAL","name":"A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.","canonical_id":"clinicaltrials.gov:NCT03496870","description":"Parkinson Disease","metadata":null},{"id":"25f590d4c5e249d1910ade4ab7dc19fb","type":"TRIAL","name":"A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder","canonical_id":"clinicaltrials.gov:NCT02905227","description":"Migraine","metadata":null},{"id":"48a7e4f01fc343eb9335c3d5af0047f2","type":"TRIAL","name":"A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery","canonical_id":"clinicaltrials.gov:NCT00651300","description":"Pain","metadata":null},{"id":"28289d6382c142a4aaf664aa84e354ad","type":"TRIAL","name":"A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy","canonical_id":"clinicaltrials.gov:NCT04663204","description":"Immunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA; Glomerulonephritis; Autoimmune Diseases; Immune System Diseases","metadata":null},{"id":"85a82ffca7224991904bc0f6786caa47","type":"TRIAL","name":"A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation","canonical_id":"clinicaltrials.gov:NCT00250354","description":"Conduct Disorder; Oppositional Defiant Disorder; Disruptive Behavior Disorder","metadata":null},{"id":"4d9d22a329b743c494dd0584a72b7311","type":"TRIAL","name":"A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.","canonical_id":"clinicaltrials.gov:NCT01013753","description":"Asthma","metadata":null},{"id":"24f570c065d545d984429d084fdd898d","type":"TRIAL","name":"A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00538304","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"c83f2d21bf44425e8ef5e29223a0638e","type":"TRIAL","name":"A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)","canonical_id":"clinicaltrials.gov:NCT01230827","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"da4a2a87c7c14e648ec65bb1cc55156b","type":"TRIAL","name":"A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00401843","description":"Multiple Myeloma","metadata":null},{"id":"a90cf3eaa6374422885e9c37d1944839","type":"TRIAL","name":"A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks","canonical_id":"clinicaltrials.gov:NCT03292640","description":"Acne Vulgaris","metadata":null},{"id":"570aa48d612e4335821e01404fb3c649","type":"TRIAL","name":"A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases","canonical_id":"clinicaltrials.gov:NCT06901817","description":"Leptomeningeal Metastasis","metadata":null},{"id":"041957ae2b5b4e56875ae60308474f89","type":"TRIAL","name":"A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT00477672","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"10dd1321bfaa4752a7efa14cc470f731","type":"TRIAL","name":"A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT02035553","description":"Alzheimer's Disease Psychosis","metadata":null},{"id":"f3602d73ae534bf2b78844fa25720ccf","type":"TRIAL","name":"A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT01174004","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"af7d6cb83dc74fda9d84e3d32fb25fa3","type":"TRIAL","name":"A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT06068465","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"14eafab338964de4abf845947e8eef15","type":"TRIAL","name":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT00307437","description":"Psoriasis","metadata":null},{"id":"7766167ca3b04fdcbb035a504945734c","type":"TRIAL","name":"A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma","canonical_id":"clinicaltrials.gov:NCT02633007","description":"Asthma","metadata":null},{"id":"af5ce9ed082440a8ac6b40b868fc16e4","type":"TRIAL","name":"A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia","canonical_id":"clinicaltrials.gov:NCT00866281","description":"Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia","metadata":null},{"id":"2497a45643d4457d95f5991883abf3c3","type":"TRIAL","name":"A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT06596681","description":"Pain, Intractable","metadata":null},{"id":"dfc34a25dab145f48ad18a65d1d74d87","type":"TRIAL","name":"A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT00550238","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"e11f1f2a36eb4471a7a4e345f0f0ad35","type":"TRIAL","name":"A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00862641","description":"Asthma; Coronary Artery Disease; Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"71ef96979043403c87dc7c08dbe2d1c4","type":"TRIAL","name":"A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State","canonical_id":"clinicaltrials.gov:NCT04451772","description":"Systemic Lupus Erythematosus (SLE)","metadata":null},{"id":"e9489a02e78b4206b06433079f6cd2a4","type":"TRIAL","name":"A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone","canonical_id":"clinicaltrials.gov:NCT02019329","description":"Schizophrenia","metadata":null},{"id":"6b3af62c44b54b9d9821f8e3f7feda72","type":"TRIAL","name":"A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01981499","description":"Migraine","metadata":null},{"id":"451a87747e5c4d3495cc3027f7ebead4","type":"TRIAL","name":"A Study of the Treatment of Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00543023","description":"Osteoporosis, Post-Menopausal","metadata":null},{"id":"5d248b267b7640d39d5fde2658cde214","type":"TRIAL","name":"A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study","canonical_id":"clinicaltrials.gov:NCT00516854","description":"Chest Pain","metadata":null},{"id":"2f998697cd7941288f64ecc16f4368fc","type":"TRIAL","name":"A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria","canonical_id":"clinicaltrials.gov:NCT00189878","description":"Urticaria","metadata":null},{"id":"f16049de4a9d409ea36ba5be64a5e142","type":"TRIAL","name":"A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure","canonical_id":"clinicaltrials.gov:NCT04252287","description":"Heart Failure","metadata":null},{"id":"f813ccef65fd4fb59d46f16d60ac4cdd","type":"TRIAL","name":"A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme","canonical_id":"clinicaltrials.gov:NCT00191828","description":"Weight Gain","metadata":null},{"id":"385e36d6c94b413aa57f71d9accf9b68","type":"TRIAL","name":"A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males","canonical_id":"clinicaltrials.gov:NCT04802967","description":"No Condition","metadata":null},{"id":"b71479f1aedc417dbb48acfdc33d528d","type":"TRIAL","name":"A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL","canonical_id":"clinicaltrials.gov:NCT04722172","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"991c4c314f7840148e401b82711d846a","type":"TRIAL","name":"A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy","canonical_id":"clinicaltrials.gov:NCT06713135","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"097a675c36ad4c8898acbf9f1a74ba45","type":"TRIAL","name":"A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas","canonical_id":"clinicaltrials.gov:NCT03058406","description":"Sarcoma, Soft Tissue","metadata":null},{"id":"5af8af65fe334d52a8d99599eb92d742","type":"TRIAL","name":"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)","canonical_id":"clinicaltrials.gov:NCT02803918","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c2bf962a1d0b4f0599ab29724242606b","type":"TRIAL","name":"A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking","canonical_id":"clinicaltrials.gov:NCT01076283","description":"Alcoholism","metadata":null},{"id":"f213a666dbdb45c0a07a2258f310c195","type":"TRIAL","name":"A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis","canonical_id":"clinicaltrials.gov:NCT06564298","description":"Stomach Neoplasms","metadata":null},{"id":"8143e83300dc4e2bb620675a97213b5e","type":"TRIAL","name":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","canonical_id":"clinicaltrials.gov:NCT06927375","description":"Thyroid-Associated Ophthalmopathy","metadata":null},{"id":"c2d5bb3aeb8846c2b98e9238b51cccf3","type":"TRIAL","name":"A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness","canonical_id":"clinicaltrials.gov:NCT03204487","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"44352013c653449cbe556c0ac28f44ab","type":"TRIAL","name":"A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT03739320","description":"Severe Eosinophilic Asthma","metadata":null},{"id":"d1a45c669e0c4a048abb4f9ee4830c92","type":"TRIAL","name":"A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05827874","description":"Healthy","metadata":null},{"id":"4dbe6f32f85b4837bbc8c00be8b61493","type":"TRIAL","name":"A Study on the Effects of Repeat Doses of Intraject\u00ae Sumatriptan on Local Site Signs","canonical_id":"clinicaltrials.gov:NCT00620425","description":"Healthy","metadata":null},{"id":"d56b26dc05b24876bdaef8e2416a65ce","type":"TRIAL","name":"A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT07741188","description":"Gallbladder Stones; Gallbladder Polyps","metadata":null},{"id":"345337cd6ead4829ae7ea357ed7eccda","type":"TRIAL","name":"A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas","canonical_id":"clinicaltrials.gov:NCT00219778","description":"Leiomyoma","metadata":null},{"id":"69ea047c661a4f69bb5635b7439d56cf","type":"TRIAL","name":"A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT05646264","description":"Schizophrenia; Negative Symptoms in Schizophrenia","metadata":null},{"id":"d626c74925124fba8e3aa989a7b66034","type":"TRIAL","name":"A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy","canonical_id":"clinicaltrials.gov:NCT07069270","description":"Vunakizumab; Adebrelimab; Small Cell Lung Cancer","metadata":null},{"id":"25e9e96fbe364c7a88f08d2fd476e720","type":"TRIAL","name":"A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11","canonical_id":"clinicaltrials.gov:NCT06759636","description":"CTIT: Cancer Therapy Induced Thrombocytopenia","metadata":null},{"id":"094cce7848a34fe9987af337fb0551aa","type":"TRIAL","name":"A Study on the Usability of the Needle-free Intraject\u00ae System in Adult Patients During Acute Migraine Attack","canonical_id":"clinicaltrials.gov:NCT00530517","description":"Migraine Headache","metadata":null},{"id":"f92091c929194189a4aeb000d55030f0","type":"TRIAL","name":"A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01954238","description":"Healthy Volunteers","metadata":null},{"id":"ef69faf80c684db2af976f9496a5d085","type":"TRIAL","name":"A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)","canonical_id":"clinicaltrials.gov:NCT00694369","description":"Postoperative Dental Pain","metadata":null},{"id":"23641a1338b541b89cedfd8964f5434a","type":"TRIAL","name":"A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04924140","description":"Healthy Volunteers","metadata":null},{"id":"1bced16919bd4029a47990caac6e4daa","type":"TRIAL","name":"A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03698513","description":"Healthy Volunteers","metadata":null},{"id":"fcacd003631a4a14a6969ef8e7521b57","type":"TRIAL","name":"A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT06461897","description":"Atopic Dermatitis","metadata":null},{"id":"c28018e82d9144439c2bbd6e9db5db8d","type":"TRIAL","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT07581002","description":"Acute Myeloid Leukemia","metadata":null},{"id":"0a2a89630b9d4052a92775617c2bb4cf","type":"TRIAL","name":"A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide","canonical_id":"clinicaltrials.gov:NCT05760313","description":"Functional Constipation","metadata":null},{"id":"fdf1073db7aa4fbaa7cbe19a7d934870","type":"TRIAL","name":"A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation","canonical_id":"clinicaltrials.gov:NCT05652205","description":"Functional Constipation (FC); Chronic Idiopathic Constipation (CIC)","metadata":null},{"id":"db94e0fe389e498c81e83e527f7e87c2","type":"TRIAL","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06568939","description":"Non-Small Cell Lung Cancer; c-MET","metadata":null},{"id":"b831b6230df54405a985a00bd87e8110","type":"TRIAL","name":"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT05995353","description":"Crohn's Disease","metadata":null},{"id":"9a10db25c1d1489e811e990eb29d2239","type":"TRIAL","name":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","canonical_id":"clinicaltrials.gov:NCT06100744","description":"Juvenile Psoriatic Arthritis","metadata":null},{"id":"a5dd57028ae4460c960f067996e6a57d","type":"TRIAL","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT06090539","description":"Relapsed/Refractory Non-Hodgkin Lymphoma","metadata":null},{"id":"3d0510152d4c4eb8be6004aa124623f8","type":"TRIAL","name":"A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants","canonical_id":"clinicaltrials.gov:NCT04277624","description":"Healthy Volunteers","metadata":null},{"id":"0ef1f60d687f4ee29407c6c3be6600cb","type":"TRIAL","name":"A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01981278","description":"Healthy","metadata":null},{"id":"796a48719e3d4d8cbef6b7e2011bc3c8","type":"TRIAL","name":"A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02019485","description":"Healthy","metadata":null},{"id":"c184795f59354f289e19cb6d61f67ed2","type":"TRIAL","name":"A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms","canonical_id":"clinicaltrials.gov:NCT03421496","description":"Infantile Spasm","metadata":null},{"id":"9360a73a46d945c0b2cee950866386df","type":"TRIAL","name":"A Study to Assess Capecitabine (Xeloda\u00ae) in Patients With Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00077857","description":"Breast Cancer","metadata":null},{"id":"a148528250a74aeebc55fc4527ae1f42","type":"TRIAL","name":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT04928846","description":"Non Small Cell Lung Cancer; c-MET","metadata":null},{"id":"47914ad1108546e2889d50e86808f9c5","type":"TRIAL","name":"A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT05513703","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"a31e4cb787804066a899e1a856258fe0","type":"TRIAL","name":"A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets","canonical_id":"clinicaltrials.gov:NCT03225352","description":"Moderate Pain","metadata":null},{"id":"56e9012b1a7046bd8c80876b315c9e29","type":"TRIAL","name":"A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol","canonical_id":"clinicaltrials.gov:NCT01099839","description":"Healthy Volunteers; Pharmacokinetics of ASP1941","metadata":null},{"id":"debc776b41104f4a9b3fb7d9f99051e8","type":"TRIAL","name":"A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates","canonical_id":"clinicaltrials.gov:NCT02211079","description":"Healthy","metadata":null},{"id":"d25e00ce0a8e463eb433444fc4c107fe","type":"TRIAL","name":"A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT01371994","description":"Urinary Incontinence","metadata":null},{"id":"dcaa45500eed4de9846b8f613f123f11","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis","canonical_id":"clinicaltrials.gov:NCT04751188","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"f4fc203577944c1a833479b77e5075bb","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP","canonical_id":"clinicaltrials.gov:NCT04346654","description":"Immune Thrombocytopenia (ITP)","metadata":null},{"id":"6c8b6b3ddccb4a98afc61da42feb9446","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03101670","description":"Psoriatic Arthritis","metadata":null},{"id":"085eb0d71ff14bea87216301a7d8f431","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT03117270","description":"Ankylosing Spondylitis","metadata":null},{"id":"4f8d0ab9942d479db4dc74ea41225e7c","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation","canonical_id":"clinicaltrials.gov:NCT06068881","description":"Follicular Lymphoma; Refractory Follicular Lymphoma","metadata":null},{"id":"01ecce8f9eba418ea8f4c9dad2372c6b","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","canonical_id":"clinicaltrials.gov:NCT03022045","description":"Psoriasis","metadata":null},{"id":"d16f215b7a1f47a4862294a4063e8160","type":"TRIAL","name":"A Study to Assess Efficacy and Safety of the Ketoprofen vs Diclofenac","canonical_id":"clinicaltrials.gov:NCT04421911","description":"Osteoarthritis","metadata":null},{"id":"bff0e80a5d3a4a7aa4203d6bddd8d906","type":"TRIAL","name":"A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)","canonical_id":"clinicaltrials.gov:NCT04907539","description":"Colorectal Cancer","metadata":null},{"id":"ee986b83de6a47748ddcaf6c586f2c7a","type":"TRIAL","name":"A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00140972","description":"Osteoarthritis","metadata":null},{"id":"bdb458f48c7a4634b507639dd8e89768","type":"TRIAL","name":"A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT07466550","description":"Healthy Volunteer","metadata":null},{"id":"7b452e05c058439fba9843857a14662a","type":"TRIAL","name":"A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body","canonical_id":"clinicaltrials.gov:NCT04712396","description":"Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)","metadata":null},{"id":"2c12ebc3593d4ab3a3d1a1f263d584ef","type":"TRIAL","name":"A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab","canonical_id":"clinicaltrials.gov:NCT04365387","description":"Dermatitis, Atopic","metadata":null},{"id":"28d8421a47134ff59bfba3ec03138371","type":"TRIAL","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07821684","description":"Non-Squamous Non-Small Cell Lung Cancer","metadata":null},{"id":"7282614f60174fb1964792f115f25bf2","type":"TRIAL","name":"A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT06206421","description":"Hot Flashes","metadata":null},{"id":"6926e755bce74de98d22a678f2a93e61","type":"TRIAL","name":"A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study","canonical_id":"clinicaltrials.gov:NCT02875548","description":"Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Synovial Sarcoma; Epitheliod Sarcoma (ES); Mesothelioma; Advanced Solid Tumors; Renal Medullary Carcinoma; Non-Hodgkin Lymphoma (NHL)","metadata":null},{"id":"c201a804810546199e81b7cf78fc64a7","type":"TRIAL","name":"A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","canonical_id":"clinicaltrials.gov:NCT04051944","description":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","metadata":null},{"id":"42de8ecb878745c29d07d44df345aca6","type":"TRIAL","name":"A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women","canonical_id":"clinicaltrials.gov:NCT07669077","description":"Healthy","metadata":null},{"id":"93190e8893c04d09bf37305afaff23da","type":"TRIAL","name":"A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study","canonical_id":"clinicaltrials.gov:NCT04215146","description":"Breast Cancer Metastatic","metadata":null},{"id":"140c715aa89640ebbe3aa2e5abe9d70f","type":"TRIAL","name":"A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting","canonical_id":"clinicaltrials.gov:NCT06488170","description":"Plaque Psoriasis","metadata":null},{"id":"13eccb42c37547739603938a0f467351","type":"TRIAL","name":"A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06487572","description":"Healthy Volunteers","metadata":null},{"id":"f60b03cff3384e4f9ba4fa6a0f93c9c7","type":"TRIAL","name":"A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05826574","description":"Healthy Volunteers","metadata":null},{"id":"01339a4440af4bfbafb19ccfe3bba326","type":"TRIAL","name":"A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","canonical_id":"clinicaltrials.gov:NCT01618669","description":"Coronary Artery Disease (CAD)","metadata":null},{"id":"71457e9e7a654bd8b12d0b5099bddbc4","type":"TRIAL","name":"A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily","canonical_id":"clinicaltrials.gov:NCT04983589","description":"Presbyopia","metadata":null},{"id":"960b722a921e42878751c8227dd870c4","type":"TRIAL","name":"A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01316107","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"5be784e671fa49ae95316a28092d629d","type":"TRIAL","name":"A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment","canonical_id":"clinicaltrials.gov:NCT03978611","description":"Melanoma","metadata":null},{"id":"1f0379b9c69b41809f726d13dbdf0971","type":"TRIAL","name":"A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients","canonical_id":"clinicaltrials.gov:NCT06425900","description":"Acne Vulgaris","metadata":null},{"id":"96fc048e442c4167b12eea1ccec952d8","type":"TRIAL","name":"A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05852340","description":"Healthy Volunteers; Adult; Pharmacokinetics","metadata":null},{"id":"e2ef3f8245e24b29a6b498c6268eeb9b","type":"TRIAL","name":"A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)","canonical_id":"clinicaltrials.gov:NCT05166109","description":"Becker Muscular Dystrophy","metadata":null},{"id":"6b173b6077d9422f985d40c2794c3e54","type":"TRIAL","name":"A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)","canonical_id":"clinicaltrials.gov:NCT05185622","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"618c61e63cdc4e6d83ac9003e7c4f562","type":"TRIAL","name":"A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)","canonical_id":"clinicaltrials.gov:NCT02760264","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"ffd964987bb1408ba6123501cc9b9d1b","type":"TRIAL","name":"A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT02932410","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"0a3a7fe0fa2a433284d04b01bcda6fa7","type":"TRIAL","name":"A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack","canonical_id":"clinicaltrials.gov:NCT00510419","description":"Migraine","metadata":null},{"id":"d593cab4615f4054a5a439dd302ab8dc","type":"TRIAL","name":"A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia","canonical_id":"clinicaltrials.gov:NCT01355068","description":"Healthy","metadata":null},{"id":"ea3b40b562614d61b5ea48194cea8bbf","type":"TRIAL","name":"A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)","canonical_id":"clinicaltrials.gov:NCT03535194","description":"Psoriasis","metadata":null},{"id":"de41a135cd4c491eb027950dcbc75970","type":"TRIAL","name":"A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP","canonical_id":"clinicaltrials.gov:NCT03524612","description":"Immune Thrombocytopenic Purpura (ITP)","metadata":null},{"id":"91d0c3783fe84e158ecafdf62707ad59","type":"TRIAL","name":"A Study to Assess the Analgesia and Sedation Using Intranasal Dexmedetomidine in Third Molar Surgery Under Local Anaesthesia","canonical_id":"clinicaltrials.gov:NCT01132794","description":"Pain; Sedation","metadata":null},{"id":"54179a6146c649e8a80e162a25ef82c8","type":"TRIAL","name":"A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal Female Participants","canonical_id":"clinicaltrials.gov:NCT07851649","description":"Healthy Female Participants; Postmenopause","metadata":null},{"id":"93086e2c9fb54e96adf83c6f96c2614b","type":"TRIAL","name":"A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07571824","description":"Healthy Adult Participants","metadata":null},{"id":"f64703598240478792745daafe2edb63","type":"TRIAL","name":"A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants","canonical_id":"clinicaltrials.gov:NCT06312566","description":"Healthy Study Participants","metadata":null},{"id":"540de876b57749f39412b2f1357b049b","type":"TRIAL","name":"A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants","canonical_id":"clinicaltrials.gov:NCT05315947","description":"Healthy Study Participants","metadata":null},{"id":"77bc95a9f307432888b08197bf525c80","type":"TRIAL","name":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01463774","description":"Healthy","metadata":null},{"id":"90252391610e47afa91c2c419c40dab7","type":"TRIAL","name":"A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT00846196","description":"Osteoporosis","metadata":null},{"id":"2e4a69b7164a4e73b4a90ee74b99666b","type":"TRIAL","name":"A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)","canonical_id":"clinicaltrials.gov:NCT00945750","description":"Heartburn","metadata":null},{"id":"6eb9b6b6ae734f3890ce890e849d4762","type":"TRIAL","name":"A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00944671","description":"Heartburn","metadata":null},{"id":"0a4ba48d25ab491692add3b6466e2bfa","type":"TRIAL","name":"A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets","canonical_id":"clinicaltrials.gov:NCT03196531","description":"Healthy","metadata":null},{"id":"a6705d3b2b25432bb9bd7842f4f220fe","type":"TRIAL","name":"A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants","canonical_id":"clinicaltrials.gov:NCT02851095","description":"Healthy","metadata":null},{"id":"5e44282e1f0d43719e34a08f96863518","type":"TRIAL","name":"A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants","canonical_id":"clinicaltrials.gov:NCT02846506","description":"Healthy","metadata":null},{"id":"c1cc57297e2241b19de5d76c0bf57a20","type":"TRIAL","name":"A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants","canonical_id":"clinicaltrials.gov:NCT02865668","description":"Healthy","metadata":null},{"id":"c4b1f89e58d64accaf32b5bfc57b4f04","type":"TRIAL","name":"A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx\u00ae (Bimekizumab)","canonical_id":"clinicaltrials.gov:NCT06888193","description":"Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Axial Spondyloarthritis; Hidradenitis Suppurativa","metadata":null},{"id":"8c2143739b014122b4c296e2651d4932","type":"TRIAL","name":"A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women","canonical_id":"clinicaltrials.gov:NCT06720714","description":"Healthy Participants","metadata":null},{"id":"804867f4f1fb41ad96d5ffa81083f3b0","type":"TRIAL","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT06109272","description":"Hepatocellular Carcinoma","metadata":null},{"id":"4f9d2efb820b4ddfbc6501b61a56fb39","type":"TRIAL","name":"A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01402076","description":"Healthy Volunteers","metadata":null},{"id":"9990f2c5177d4855acca4375af123bcb","type":"TRIAL","name":"A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01115985","description":"Healthy; Pharmacokinetics of Atorvastatin","metadata":null},{"id":"0b03bf1239c24a1b93fd84ad1c87d293","type":"TRIAL","name":"A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01115972","description":"Healthy; Pharmacokinetics of Valsartan","metadata":null},{"id":"d912d07a270949f28acb42553dedad75","type":"TRIAL","name":"A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.","canonical_id":"clinicaltrials.gov:NCT05644600","description":"Healthy Subjects","metadata":null},{"id":"221ca9117c4e4df8b476b33b7040007d","type":"TRIAL","name":"A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants","canonical_id":"clinicaltrials.gov:NCT01873001","description":"Healthy Volunteers","metadata":null},{"id":"0142f5d7ba974484839f207f48f2ef02","type":"TRIAL","name":"A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05932277","description":"Healthy Volunteers","metadata":null},{"id":"5a662b0389f44b7489e86075527179ff","type":"TRIAL","name":"A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT05168202","description":"Leukemia, Myeloid, Acute; Myelodysplastic Syndromes","metadata":null},{"id":"22096426035e4cfc91aaff6ec14196ef","type":"TRIAL","name":"A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours","canonical_id":"clinicaltrials.gov:NCT04958226","description":"Solid Tumour","metadata":null},{"id":"8af5cee93d0149c5b25bd95a1ea7f203","type":"TRIAL","name":"A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone","canonical_id":"clinicaltrials.gov:NCT00000788","description":"Candidiasis; HIV Infections","metadata":null},{"id":"3d54e623c0c04032b3766d4c4050c6ca","type":"TRIAL","name":"A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants","canonical_id":"clinicaltrials.gov:NCT04641260","description":"Healthy Subjects","metadata":null},{"id":"998edd0ebb25483486708233a7346ac1","type":"TRIAL","name":"A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT01027169","description":"Hepatic Impairment","metadata":null},{"id":"769700204bd244379d0d7d922c404d2e","type":"TRIAL","name":"A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04956627","description":"Healthy Participants","metadata":null},{"id":"7bc4bc22bbb348b29ace178f28264703","type":"TRIAL","name":"A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07018635","description":"Healthy Participants","metadata":null},{"id":"f3ac75ec35e64ef9a10d159b2ad59124","type":"TRIAL","name":"A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01626651","description":"Healthy","metadata":null},{"id":"8ad061dc55b044148af225d68bfcaebe","type":"TRIAL","name":"A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01797198","description":"Drug-Drug Interaction (DDI); Healthy Subjects","metadata":null},{"id":"8fc19e6b7b4f44c8a236df51a80a0486","type":"TRIAL","name":"A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05932303","description":"Healthy Participants","metadata":null},{"id":"b20c617991414dfba2069c6548a3ddbf","type":"TRIAL","name":"A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT05806567","description":"Immune System Disorder; Healthy Volunteers","metadata":null},{"id":"05f83cae957842adb908de90bb877dd3","type":"TRIAL","name":"A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam","canonical_id":"clinicaltrials.gov:NCT05901714","description":"Healthy Participants","metadata":null},{"id":"f70ce2c38c424944a6b45322d02d4afd","type":"TRIAL","name":"A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)","canonical_id":"clinicaltrials.gov:NCT00697203","description":"Dyslipidemia","metadata":null},{"id":"c2b8ed20de7c40f7a89207e07ef24b16","type":"TRIAL","name":"A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT01026428","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"401bf7f3d3c046028715076b2e2cef8e","type":"TRIAL","name":"A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan","canonical_id":"clinicaltrials.gov:NCT01370148","description":"Liver Disease","metadata":null},{"id":"0026e92b0eaf42afbfe7665e37d09276","type":"TRIAL","name":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00106548","description":"Rheumatoid Arthritis","metadata":null},{"id":"4a050e65974840f78bd26f4af7791f58","type":"TRIAL","name":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy","canonical_id":"clinicaltrials.gov:NCT00106522","description":"Rheumatoid Arthritis","metadata":null},{"id":"7b97d50d5fc44b1b80dae61c50148b0e","type":"TRIAL","name":"A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT06390722","description":"Atopic Dermatitis; Sleep Disturbance","metadata":null},{"id":"e0ae43df35284f18818f85fa58bc5774","type":"TRIAL","name":"A Study to Assess the Effect of Ustekinumab (Stelara\u00ae) and Etanercept (Enbrel\u00ae) in Participants With Moderate to Severe Psoriasis (MK-0000-206)","canonical_id":"clinicaltrials.gov:NCT01276847","description":"Psoriasis","metadata":null},{"id":"f2c0a88df26f4d2c8238640885ee54d1","type":"TRIAL","name":"A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","canonical_id":"clinicaltrials.gov:NCT06782373","description":"VEXAS; VEXAS Syndrome","metadata":null},{"id":"27f309fbba464758af3f2c56ad6cc95b","type":"TRIAL","name":"A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge\u00ae) in Participants With Advanced Basal Cell Carcinoma (BCC)","canonical_id":"clinicaltrials.gov:NCT02371967","description":"Basal Cell Carcinoma","metadata":null},{"id":"91a86c35f4b643f8a1a733c99749ef68","type":"TRIAL","name":"A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT04239027","description":"Neovascular Age Related Macular Degeneration","metadata":null},{"id":"d4451d9a633b4c36bd6f3ef0c2d7e43e","type":"TRIAL","name":"A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01733108","description":"Healthy","metadata":null},{"id":"b024ba2fb1a442c580aec235812189d1","type":"TRIAL","name":"A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD","canonical_id":"clinicaltrials.gov:NCT06533553","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"4e3b229d611a433c92ba9e125b45e162","type":"TRIAL","name":"A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT05888207","description":"Healthy Male Subjects","metadata":null},{"id":"4858749fc16e48d8ad22ea1a2885d329","type":"TRIAL","name":"A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01577680","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"b817662d2bd845afae794b06047112a9","type":"TRIAL","name":"A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01428284","description":"Healthy","metadata":null},{"id":"52d5df6e4e5e4c0e98ee557006191bbe","type":"TRIAL","name":"A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04562116","description":"Atopic Dermatitis","metadata":null},{"id":"6346d7f0c925453b8fb8208cb31543f4","type":"TRIAL","name":"A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07840612","description":"Healthy","metadata":null},{"id":"bf81a0d9edf94147ba29796bdd9a9dd9","type":"TRIAL","name":"A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06030076","description":"Plaque Psoriasis","metadata":null},{"id":"4bc8b175d4dc41729c07019425558ce8","type":"TRIAL","name":"A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00351507","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"5dd0b968336a4f1da9913a342fb42850","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01135433","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"30fe72cf35e542238560d2f2266a10aa","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01225081","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a403d55f1a754aaeb33d1d7afd3e7dbe","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01242215","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"42bda8f11bc24188a2aa8bd75ccbb849","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients","canonical_id":"clinicaltrials.gov:NCT01057628","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"4eff6ae2ff1f4dd2b1218d38a31d5f94","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy","canonical_id":"clinicaltrials.gov:NCT05059223","description":"Narcolepsy; Cataplexy; Excessive Daytime Sleepiness","metadata":null},{"id":"34581c8412bc44f4aff0ad846f853041","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00617604","description":"De Novo Kidney Transplantation","metadata":null},{"id":"45f39b10b2c644d18794cceeefe0ed79","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate","canonical_id":"clinicaltrials.gov:NCT00673556","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"2a3c457727c440fa8859b63570d755eb","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05565560","description":"Plaque Psoriasis","metadata":null},{"id":"5349d8204c304267b3442abbefaae1e9","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion","canonical_id":"clinicaltrials.gov:NCT03347422","description":"Cold Agglutinin Disease","metadata":null},{"id":"907a2f9a70c24ca887026912c50498e5","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting","canonical_id":"clinicaltrials.gov:NCT03021018","description":"Epilepsy","metadata":null},{"id":"0783b039b122456e84d5007e24145b0b","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","canonical_id":"clinicaltrials.gov:NCT02755649","description":"Atopic Dermatitis","metadata":null},{"id":"da331377a3fd4c4aa47feec8b7d93f6f","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02175784","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"274e8a6d12854950b08144c9dbb07319","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin","canonical_id":"clinicaltrials.gov:NCT02794792","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7e7c58c3d9094753927d0a3fe6e60a17","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","canonical_id":"clinicaltrials.gov:NCT04501679","description":"Prurigo Nodularis","metadata":null},{"id":"7ac4e86c435e4a6c8e7a381eae128ed3","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)","canonical_id":"clinicaltrials.gov:NCT06450639","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"0f0db6ed1d484cf7aec781b735b1b4bf","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00674063","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"0027c01351284055a77ae465d0eb2650","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)","canonical_id":"clinicaltrials.gov:NCT03439670","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"0aef1990efb3461f91cfe3590e13e8b1","type":"TRIAL","name":"A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00654914","description":"Erectile Dysfunction","metadata":null},{"id":"434829c94ad34a4ca079684cb48fb906","type":"TRIAL","name":"A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma","canonical_id":"clinicaltrials.gov:NCT04234464","description":"Exercise Induced Bronchospasm","metadata":null},{"id":"e0e319a472d7433e8e8e05a3fc9a00fb","type":"TRIAL","name":"A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease","canonical_id":"clinicaltrials.gov:NCT00099203","description":"Pain; Bone Neoplasm; Neoplasm Metastasis","metadata":null},{"id":"f0c37900649e4c7d810922d009e4f0fd","type":"TRIAL","name":"A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00122499","description":"Prostate Cancer; Erectile Dysfunction","metadata":null},{"id":"aa6ee93e8a8c495797c7fcea92dd0938","type":"TRIAL","name":"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol\u00ae) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia","canonical_id":"clinicaltrials.gov:NCT01451411","description":"Hyponatremia","metadata":null},{"id":"da8d383b4ca94d47aa9c9dca39423d0c","type":"TRIAL","name":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01202188","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"39b989a43a5a49b48c0207e8e249a591","type":"TRIAL","name":"A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","canonical_id":"clinicaltrials.gov:NCT03861481","description":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","metadata":null},{"id":"86432d701ee54588a579572cda7107f4","type":"TRIAL","name":"A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis","canonical_id":"clinicaltrials.gov:NCT04594369","description":"Non-Cystic Fibrosis Bronchiectasis","metadata":null},{"id":"4689c08ebe5c4088b8c09fc845a1cd24","type":"TRIAL","name":"A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT04224688","description":"Primary Immune Thrombocytopenia","metadata":null},{"id":"e2014fc6baf64912a90a693f63be8374","type":"TRIAL","name":"A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06568458","description":"Healthy Participants","metadata":null},{"id":"b1de5bcb58a2475aa7dbe3bf73e99b73","type":"TRIAL","name":"A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02616965","description":"Cutaneous T-cell Lymphoma (CTCL)","metadata":null},{"id":"489e5d01643f41ab921eada03e395daf","type":"TRIAL","name":"A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02561923","description":"Healthy","metadata":null},{"id":"a996e0a382e94835928fb946ad9d6c51","type":"TRIAL","name":"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity","canonical_id":"clinicaltrials.gov:NCT01565694","description":"Neurogenic Detrusor Overactivity","metadata":null},{"id":"7d601f53050548779682693d2b8c93e9","type":"TRIAL","name":"A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT07111013","description":"Dry Eye Disease","metadata":null},{"id":"c346e552957b4712a2760a426adcdd52","type":"TRIAL","name":"A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)","canonical_id":"clinicaltrials.gov:NCT05113745","description":"Narcolepsy; Cataplexy; Excessive Daytime Sleepiness","metadata":null},{"id":"4e484cc3e7e44143848e8eba926d5067","type":"TRIAL","name":"A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01054092","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"5487d281137646a4997e69ba7b732cdd","type":"TRIAL","name":"A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT04009499","description":"Psoriatic Arthritis","metadata":null},{"id":"8d2c07f03d6647d5a4afb4a940970a55","type":"TRIAL","name":"A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02532998","description":"Pharmacodynamics; Healthy Subjects","metadata":null},{"id":"8b9a90a061ef426a9083f1d016fb6647","type":"TRIAL","name":"A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder","canonical_id":"clinicaltrials.gov:NCT05594589","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"addd8e6515c942acbf5b23c9952e40f7","type":"TRIAL","name":"A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05216887","description":"Healthy Volunteer","metadata":null},{"id":"252e84f1ef4145afbf19e223f0362f09","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers","canonical_id":"clinicaltrials.gov:NCT01748526","description":"Healthy","metadata":null},{"id":"bf80ecfab8ff4b5d8481e5aa4aa61d22","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT06921850","description":"Hidradenitis Suppurativa","metadata":null},{"id":"0386fc4a73d34673ad895849da14dfb2","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02601625","description":"Safety; Pharmacokinetics; Healthy Subjects","metadata":null},{"id":"6d12c4671e0f444ba25e98d5d0388160","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI","canonical_id":"clinicaltrials.gov:NCT01634555","description":"Solid Tumors","metadata":null},{"id":"dbaeb708cb91493385e6f3d74a479dfc","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04718896","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"4f07c7869c1641e1a75d2fa9c9dfa4ea","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01780259","description":"Healthy","metadata":null},{"id":"624d64d47496400e831c8c65fc1cbe83","type":"TRIAL","name":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline","canonical_id":"clinicaltrials.gov:NCT01879748","description":"Parkinson's Disease","metadata":null},{"id":"a827260b964541ac8606d670eb665839","type":"TRIAL","name":"A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07859007","description":"Healthy Volunteers","metadata":null},{"id":"e363956855fd4724b1b4aa3f1678b7e4","type":"TRIAL","name":"A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept","canonical_id":"clinicaltrials.gov:NCT01339481","description":"Rheumatoid Arthritis","metadata":null},{"id":"a13d4e91acfe40e69fc0acdc2cc95cb2","type":"TRIAL","name":"A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06344728","description":"Healthy Participants","metadata":null},{"id":"2fcde711c3ad48dfbc8bf0ae8f7fd943","type":"TRIAL","name":"A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02322749","description":"Healthy Volunteers Bioequivalence or Bioavailability Study","metadata":null},{"id":"1579a20caeb84e4f8ce27f6fdae75963","type":"TRIAL","name":"A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT06937619","description":"Healthy Volunteer","metadata":null},{"id":"c63cf2bfc07449dbb39a11391098d83a","type":"TRIAL","name":"A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets","canonical_id":"clinicaltrials.gov:NCT03151720","description":"Healthy","metadata":null},{"id":"63004e5eb77943898757e96324273828","type":"TRIAL","name":"A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation","canonical_id":"clinicaltrials.gov:NCT05514119","description":"Liver Transplant","metadata":null},{"id":"862f96a7bc1c4959b8c54f029c7e0060","type":"TRIAL","name":"A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients","canonical_id":"clinicaltrials.gov:NCT00592475","description":"Liver Cirrhosis","metadata":null},{"id":"db19f7e4e4cd4fcfb73def20a17b0139","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01242228","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7123fc7b896a42809febd8ab21991e03","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With \u03b1-glucosidase Inhibitor in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01242202","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"46edbcde468341d0bb17b90651dcee21","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00543569","description":"Kidney Transplantation","metadata":null},{"id":"b714dbe1536d4b7cba592992071bcdb9","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT02148133","description":"Cytopaenia","metadata":null},{"id":"93b12a8cdf924ca5b35d887da6267763","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04162769","description":"Atopic Dermatitis","metadata":null},{"id":"25e132f42072412baaed1ef6488c0b14","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications","canonical_id":"clinicaltrials.gov:NCT02408523","description":"Epilepsy","metadata":null},{"id":"599f669eb20c4a3cb67db476965bedc4","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT04682639","description":"Eosinophilic Esophagitis","metadata":null},{"id":"652d34fb92124fbc82f2abee9f99d7f5","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )","canonical_id":"clinicaltrials.gov:NCT03047395","description":"Psoriasis","metadata":null},{"id":"010ee505f73247afba6370a6e471a286","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00269191","description":"Osteoarthritis","metadata":null},{"id":"43f8d9b9d62a4b829c259e287ecab85a","type":"TRIAL","name":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","canonical_id":"clinicaltrials.gov:NCT02605434","description":"Parkinson's Disease","metadata":null},{"id":"fb6cacc27b96441a8b16a4b0c1f08b9b","type":"TRIAL","name":"A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNF\u03b1 Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT01900574","description":"Colitis, Ulcerative","metadata":null},{"id":"e2c6d39923a54da68bddc0220474c272","type":"TRIAL","name":"A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients","canonical_id":"clinicaltrials.gov:NCT03102398","description":"Erectile Dysfunction","metadata":null},{"id":"f5b74cc026294b79baa5018f6dc28e99","type":"TRIAL","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","canonical_id":"clinicaltrials.gov:NCT04817007","description":"Myelofibrosis","metadata":null},{"id":"311a26b263cb4a7c9da79b9ebcbc0731","type":"TRIAL","name":"A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause","canonical_id":"clinicaltrials.gov:NCT04451226","description":"Hot Flashes","metadata":null},{"id":"7d1b9b222ff744b9a76ea0dbb70ff19e","type":"TRIAL","name":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03403712","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"af53bc41702b4f7dbb9b5f659ab5e9e2","type":"TRIAL","name":"A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02571140","description":"Drug Safety and Bioavailability","metadata":null},{"id":"5667b6e210b6466c8663dac0deaf235f","type":"TRIAL","name":"A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours","canonical_id":"clinicaltrials.gov:NCT02586987","description":"Lung Cancer; Melanoma; Head and Neck Carcinoma; Gastroesophageal Cancer; Breast Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Biliary Tract Cancer","metadata":null},{"id":"4a63d0ee859e41a691ef0e5841691690","type":"TRIAL","name":"A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT03653247","description":"Sickle Cell Disease","metadata":null},{"id":"2974141f34dc4af2ba704aa3be522896","type":"TRIAL","name":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT05090904","description":"Cystic Fibrosis","metadata":null},{"id":"e98c36d4f6aa43c4ba639be45d72657f","type":"TRIAL","name":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults","canonical_id":"clinicaltrials.gov:NCT05351086","description":"Healthy","metadata":null},{"id":"2432abf5a9c948318b28d12dbafd168d","type":"TRIAL","name":"A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS","canonical_id":"clinicaltrials.gov:NCT06249867","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"fe10921e6f3d470c98080f274bf555cd","type":"TRIAL","name":"A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India","canonical_id":"clinicaltrials.gov:NCT07459543","description":"Unresectable Melanoma; Metastatic Melanoma","metadata":null},{"id":"196999ad6ea24256929b090f5376c519","type":"TRIAL","name":"A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07452692","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"9863c9ddaa584f638f5077eb3579de58","type":"TRIAL","name":"A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment","canonical_id":"clinicaltrials.gov:NCT01990261","description":"Non-Squamous Non-Small Cell Lung Cancer","metadata":null},{"id":"70cd82b8f5b34119a997af1e9e102ccb","type":"TRIAL","name":"A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT04499235","description":"Pemphigoid, Bullous","metadata":null},{"id":"4d16e56f9ef94105843c66bd8c647b2a","type":"TRIAL","name":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","canonical_id":"clinicaltrials.gov:NCT04940039","description":"Schizophrenia","metadata":null},{"id":"138f4b4a681249f9aed50ee22e1e8902","type":"TRIAL","name":"A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects","canonical_id":"clinicaltrials.gov:NCT01597609","description":"Obesity","metadata":null},{"id":"bf5e564e8fd44e3eb17a6f9b4e4667bf","type":"TRIAL","name":"A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib","canonical_id":"clinicaltrials.gov:NCT04366713","description":"HER2 Amplified Breast Cancer","metadata":null},{"id":"e5f61682299b458896dd78bfe310362a","type":"TRIAL","name":"A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.","canonical_id":"clinicaltrials.gov:NCT01703845","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"ba390eaba38c49378185cefe71d5364d","type":"TRIAL","name":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02583594","description":"Progressive Multiple Sclerosis","metadata":null},{"id":"a7e080306aa240309ab1d2ed21244330","type":"TRIAL","name":"A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations","canonical_id":"clinicaltrials.gov:NCT02962960","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"dfa5d240a98c44aeafcb54401dc9fc27","type":"TRIAL","name":"A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT00911859","description":"Multiple Myeloma","metadata":null},{"id":"7292ed18c15840898968f2d0836af642","type":"TRIAL","name":"A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03234972","description":"Multiple Myeloma","metadata":null},{"id":"d967ac6fe5744e85ba4856a07e781e03","type":"TRIAL","name":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","canonical_id":"clinicaltrials.gov:NCT02431702","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"2a94ae90c0684901a4d803eb664449ef","type":"TRIAL","name":"A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)","canonical_id":"clinicaltrials.gov:NCT04451330","description":"Acne Vulgaris","metadata":null},{"id":"57bd82f25f474fdf883a584bb2057bde","type":"TRIAL","name":"A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients","canonical_id":"clinicaltrials.gov:NCT01181232","description":"Sleep Initiation and Maintenance Disorders; Primary Insomnia","metadata":null},{"id":"f94e878031cf4e6f8334f800904252ce","type":"TRIAL","name":"A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils","canonical_id":"clinicaltrials.gov:NCT02693769","description":"ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)","metadata":null},{"id":"bb227e96c42342d0863d44e9e86a6bfc","type":"TRIAL","name":"A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels","canonical_id":"clinicaltrials.gov:NCT02010944","description":"Phase 1; Bioavailability; Healthy Subjects","metadata":null},{"id":"274a71d41a6848cc81460f0221c51886","type":"TRIAL","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","canonical_id":"clinicaltrials.gov:NCT07393282","description":"High Risk Smoldering Multiple Myeloma (HR-SMM)","metadata":null},{"id":"17739b903ed748929c26a411448daf46","type":"TRIAL","name":"A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00239382","description":"Arthritis, Rheumatoid","metadata":null},{"id":"510f57b1758d4d08994149f79495dfc0","type":"TRIAL","name":"A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis","canonical_id":"clinicaltrials.gov:NCT01328015","description":"Hyperhidrosis","metadata":null},{"id":"356b0c2c4604407f92a9b60db490caaa","type":"TRIAL","name":"A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole","canonical_id":"clinicaltrials.gov:NCT03980756","description":"Gastritis","metadata":null},{"id":"ce1b3e4955ad4fd19e9a650f1c5772ef","type":"TRIAL","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","canonical_id":"clinicaltrials.gov:NCT06459180","description":"Cervical Cancer","metadata":null},{"id":"b8b5e3c473404d29a94f56e13ed941ef","type":"TRIAL","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","canonical_id":"clinicaltrials.gov:NCT04293562","description":"Acute Myeloid Leukemia","metadata":null},{"id":"d7cff9959dd3446fa870ff8d7c5c9227","type":"TRIAL","name":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","canonical_id":"clinicaltrials.gov:NCT05675410","description":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","metadata":null},{"id":"4171c2a64de84823880009623f1c4ccc","type":"TRIAL","name":"A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01030783","description":"Advanced Renal Cell Carcinoma","metadata":null},{"id":"2d52ccb28d2642c2a0cd3354faf99547","type":"TRIAL","name":"A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)","canonical_id":"clinicaltrials.gov:NCT02627963","description":"Carcinoma, Renal Cell","metadata":null},{"id":"6e6cca9e3a06451f9cd78770b4842ef9","type":"TRIAL","name":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT04576117","description":"Recurrent Low Grade Astrocytoma; Recurrent WHO Grade 2 Glioma; Refractory Low Grade Astrocytoma; Refractory Low Grade Glioma; Refractory WHO Grade 1 Glioma","metadata":null},{"id":"efcc8ab5647a4e5897c9dad20672c4b3","type":"TRIAL","name":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","canonical_id":"clinicaltrials.gov:NCT03595124","description":"Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; TFE3-Rearranged Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma","metadata":null},{"id":"24b89a0b7ee24311a6d0fe1b1e00cbfc","type":"TRIAL","name":"A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04548219","description":"Healthy","metadata":null},{"id":"22e2859ed4f54283a7cec4ed7fc1aefc","type":"TRIAL","name":"A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05069896","description":"Healthy","metadata":null},{"id":"867e498d8b34450b983a27539c4125df","type":"TRIAL","name":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","canonical_id":"clinicaltrials.gov:NCT02706873","description":"Rheumatoid Arthritis","metadata":null},{"id":"034e1c4e06b84c98a9db5cfd3a4e2c07","type":"TRIAL","name":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","canonical_id":"clinicaltrials.gov:NCT03504397","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"8e31cfe81af74a1989aa36d1d017968c","type":"TRIAL","name":"A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02230904","description":"Parkinson's Disease","metadata":null},{"id":"24c904c676754e6296cb2df85a3d4d72","type":"TRIAL","name":"A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases","canonical_id":"clinicaltrials.gov:NCT04511013","description":"Acral Lentiginous Melanoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Metastatic Mucosal Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8","metadata":null},{"id":"fcdefab046d74bfbaab8976fe48bd8dd","type":"TRIAL","name":"A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin","canonical_id":"clinicaltrials.gov:NCT01953887","description":"EC905; Pharmacokinetics; Healthy Subjects","metadata":null},{"id":"c89fe1a624ca4b9da8cf919d14f8814b","type":"TRIAL","name":"A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State","canonical_id":"clinicaltrials.gov:NCT01121926","description":"Healthy Subjects; Bioavailability; Pharmacokinetics","metadata":null},{"id":"bbf7cd5206c54d16b623cb6f376b47b7","type":"TRIAL","name":"A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06054425","description":"Healthy Volunteers","metadata":null},{"id":"4b775d448764485ab65356499a5ea86c","type":"TRIAL","name":"A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet","canonical_id":"clinicaltrials.gov:NCT01273506","description":"Healthy Volunteer","metadata":null},{"id":"7de137923cc0475c9485ea1bff3b18c4","type":"TRIAL","name":"A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet","canonical_id":"clinicaltrials.gov:NCT01273532","description":"Healthy Volunteer","metadata":null},{"id":"65573d29dd44434bb0620238a7e8a69a","type":"TRIAL","name":"A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants","canonical_id":"clinicaltrials.gov:NCT03707717","description":"Healthy Volunteers","metadata":null},{"id":"1e3107fdda254e0f8693d2f05b1d501f","type":"TRIAL","name":"A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function","canonical_id":"clinicaltrials.gov:NCT04241835","description":"Hepatic Impairment; Advanced Malignant Solid Tumor","metadata":null},{"id":"1b1fabd46e434255b75b50259ec55f17","type":"TRIAL","name":"A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01309425","description":"Healthy Volunteer","metadata":null},{"id":"a8540169bd3b43ca929d4c684907aecb","type":"TRIAL","name":"A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01964170","description":"Prostate Cancer","metadata":null},{"id":"bac004dd245d44bf8c77de4e6b2d0bb1","type":"TRIAL","name":"A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible","canonical_id":"clinicaltrials.gov:NCT00000939","description":"HIV Infections","metadata":null},{"id":"798749e994ff4af88bcc1171f609ec18","type":"TRIAL","name":"A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat\u00ae Inhaler in Patients With Moderate to Severe Asthma","canonical_id":"clinicaltrials.gov:NCT01311661","description":"Asthma","metadata":null},{"id":"c81976050a134933ac9ab714f84a642e","type":"TRIAL","name":"A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects","canonical_id":"clinicaltrials.gov:NCT02094937","description":"Asthma","metadata":null},{"id":"6d55d62b78714fdea62cbd702cb9c849","type":"TRIAL","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT06045806","description":"Multiple Myeloma","metadata":null},{"id":"638fae34867a4d948e7582e723623523","type":"TRIAL","name":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","canonical_id":"clinicaltrials.gov:NCT06205290","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"74dd3fa3396d43bc8445f46e0dd9e904","type":"TRIAL","name":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","canonical_id":"clinicaltrials.gov:NCT04285567","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"185549b4429f48e6b4d2891f32c3265d","type":"TRIAL","name":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT02446418","description":"Asthma","metadata":null},{"id":"af8f53aaee1f43a4a65bef9a87b407ef","type":"TRIAL","name":"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","canonical_id":"clinicaltrials.gov:NCT00291642","description":"Rhinitis; Allergic; Seasonal","metadata":null},{"id":"cf4f4bc2cced400daa26c1e326991cf5","type":"TRIAL","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression \u2265 1%","canonical_id":"clinicaltrials.gov:NCT06561386","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"be70433bdfa3452dae759139a9414b26","type":"TRIAL","name":"A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT07186413","description":"Acne Vulgaris","metadata":null},{"id":"343709a3496f4bfea7a339f8fdb4196b","type":"TRIAL","name":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00900731","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"94c41aad2be84f2580bd122feb1ec0ba","type":"TRIAL","name":"A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03215966","description":"Healthy Subjects","metadata":null},{"id":"aaf8235cbcf54ef68016577c82513179","type":"TRIAL","name":"A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01877889","description":"Healthy","metadata":null},{"id":"6f9cd49e86a04bc181a902f6a8ced17c","type":"TRIAL","name":"A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05602025","description":"Asthma","metadata":null},{"id":"f7d01d37a9b8412b8cc91d93d18cec72","type":"TRIAL","name":"A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03961308","description":"Healthy Volunteers","metadata":null},{"id":"30574fc1513346f497e6855aac8f96ce","type":"TRIAL","name":"A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C","canonical_id":"clinicaltrials.gov:NCT02564497","description":"Renal Transplantation","metadata":null},{"id":"9bc2ce21fab9403a9574b60a557f8f01","type":"TRIAL","name":"A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug","canonical_id":"clinicaltrials.gov:NCT03014674","description":"Asthma","metadata":null},{"id":"9cf1d58922fc482ca6c176814ef641bb","type":"TRIAL","name":"A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07789964","description":"Healthy","metadata":null},{"id":"257dcdd78bd44e04b3b20dad2e387c55","type":"TRIAL","name":"A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06132867","description":"Healthy Volunteers","metadata":null},{"id":"7943a6d5073e4144b9cfd2aee371aa45","type":"TRIAL","name":"A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00990301","description":"Healthy","metadata":null},{"id":"b6c5be3b71c2453b9f34999326e98f05","type":"TRIAL","name":"A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT02186171","description":"Osteoporosis in Men","metadata":null},{"id":"0ba08037579a4c1bb2e6008730607eda","type":"TRIAL","name":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT06812754","description":"Hot Flashes","metadata":null},{"id":"0f490012910f42ebadfb5b381d2c1872","type":"TRIAL","name":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT06206408","description":"Hot Flashes","metadata":null},{"id":"601009531aee4442b758427a72944078","type":"TRIAL","name":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT06440967","description":"Hot Flashes","metadata":null},{"id":"c194a0496d104b94a8dced03c758924f","type":"TRIAL","name":"A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT07829653","description":"Hot Flashes","metadata":null},{"id":"d807f46b0dad48a8b81d9de208a830ad","type":"TRIAL","name":"A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)","canonical_id":"clinicaltrials.gov:NCT02395133","description":"Atopic Dermatitis","metadata":null},{"id":"3a09b34d55364475b0661fed7eb80e71","type":"TRIAL","name":"A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03627936","description":"Healthy Participants","metadata":null},{"id":"5200bafec9c64fbfa2399b651f4185df","type":"TRIAL","name":"A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects","canonical_id":"clinicaltrials.gov:NCT02972125","description":"Healthy Volunteers","metadata":null},{"id":"8d5e8339aa5648d083a531fd54880d51","type":"TRIAL","name":"A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth","canonical_id":"clinicaltrials.gov:NCT05181839","description":"X-Linked Hypophosphatemia","metadata":null},{"id":"d235ed60c7094c5682676584479c5eef","type":"TRIAL","name":"A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea","canonical_id":"clinicaltrials.gov:NCT00650637","description":"Diarrhea","metadata":null},{"id":"2c202bf37fa44cc79747ca9295918b9a","type":"TRIAL","name":"A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects","canonical_id":"clinicaltrials.gov:NCT01842607","description":"Asthma","metadata":null},{"id":"b0201f2f1d09462ca3d09eeb11cc2197","type":"TRIAL","name":"A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors","canonical_id":"clinicaltrials.gov:NCT03546894","description":"Anaplastic Lymphoma Kinase-positive; Carcinoma Non-small-cell Lung","metadata":null},{"id":"50b214acdf53486eb69d99fc9ecf300d","type":"TRIAL","name":"A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01421043","description":"Healthy","metadata":null},{"id":"f070f57a7363499682ff3286c637163d","type":"TRIAL","name":"A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.","canonical_id":"clinicaltrials.gov:NCT00156689","description":"Chronic Idiopathic Axonal Polyneuropathy","metadata":null},{"id":"dcb0a9a04c20411e9b53866ace55dd3e","type":"TRIAL","name":"A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04796831","description":"Healthy Subjects","metadata":null},{"id":"f0d38d71c8ea4f9d8c5fa6120737c1c8","type":"TRIAL","name":"A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem","canonical_id":"clinicaltrials.gov:NCT05106153","description":"Healthy Non-dependent, Recreational Sedative Users; Abuse Potential","metadata":null},{"id":"ae6fbd2e88af4e20bbbe8ebd88bd5dd9","type":"TRIAL","name":"A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users","canonical_id":"clinicaltrials.gov:NCT03158025","description":"Insomnia Disorders","metadata":null},{"id":"463227f8d92141baa717f01804dd2891","type":"TRIAL","name":"A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants","canonical_id":"clinicaltrials.gov:NCT03501277","description":"Healthy Volunteers","metadata":null},{"id":"0051f783673c457bb9161ea233dfc7f7","type":"TRIAL","name":"A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06268301","description":"Healthy Volunteers","metadata":null},{"id":"0b5f7534ab1046c5a58e58e9d1be6368","type":"TRIAL","name":"A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects","canonical_id":"clinicaltrials.gov:NCT05918614","description":"Immune System Disorder (Healthy Volunteer)","metadata":null},{"id":"2335dcbf857241b1a8b78bee3c443ee2","type":"TRIAL","name":"A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04941755","description":"Healthy Participants","metadata":null},{"id":"965239b29fa14e65b40cb4d4d494f612","type":"TRIAL","name":"A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects","canonical_id":"clinicaltrials.gov:NCT05918588","description":"Immune System Disorder (Healthy Volunteer)","metadata":null},{"id":"900c66aa25b14aa0a5e09b2dfd05dc1c","type":"TRIAL","name":"A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT05918627","description":"Immune System Disorder (Healthy Volunteer)","metadata":null},{"id":"3839c2fa74a548b7beb1cd405a7f9e4a","type":"TRIAL","name":"A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period","canonical_id":"clinicaltrials.gov:NCT00792636","description":"Migraine Disorders","metadata":null},{"id":"5710469bece94baaa0c76070f8ff1075","type":"TRIAL","name":"A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD","canonical_id":"clinicaltrials.gov:NCT01525615","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"6dddd1764be9488fa5c4d2275e11f5b3","type":"TRIAL","name":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease-modifying Anti-rheumatic Drugs","canonical_id":"clinicaltrials.gov:NCT04908202","description":"Psoriatic Arthritis","metadata":null},{"id":"2ef70976f3fb4ff8ac448d4b0cc02e86","type":"TRIAL","name":"A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT06795048","description":"Neovascular Age-related Macular Degeneration (nAMD)","metadata":null},{"id":"df9b0d90bb784fe08743bda088b633a3","type":"TRIAL","name":"A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy","canonical_id":"clinicaltrials.gov:NCT04058704","description":"Non Small Cell Lung Cancer; Brain Metastases","metadata":null},{"id":"5c9eb67845144aae9ef0354230f8a4a3","type":"TRIAL","name":"A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)","canonical_id":"clinicaltrials.gov:NCT01225731","description":"Psoriasis","metadata":null},{"id":"b84cc9d2dd334e4faace02df63772f9d","type":"TRIAL","name":"A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment","canonical_id":"clinicaltrials.gov:NCT00999336","description":"Renal Impairment","metadata":null},{"id":"dc5aea451bed4dc7baa6ffa695005dff","type":"TRIAL","name":"A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05530655","description":"Prostate Cancer; Radiation Toxicity; Urinary Complication","metadata":null},{"id":"a160c9d50897405eb7e8907afa2c2936","type":"TRIAL","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)","canonical_id":"clinicaltrials.gov:NCT03989414","description":"Multiple Myeloma","metadata":null},{"id":"e1ff87c7e5ac47f2b62c72072249586a","type":"TRIAL","name":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00839527","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"7cc569cde39840348d3b0ae5fa3f799e","type":"TRIAL","name":"A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants","canonical_id":"clinicaltrials.gov:NCT04503603","description":"Healthy Volunteers","metadata":null},{"id":"f6733bf2de3045a88f7006712aa3136d","type":"TRIAL","name":"A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00632216","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"caa77ff1a2db4a09907937111f3e893a","type":"TRIAL","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","canonical_id":"clinicaltrials.gov:NCT05944224","description":"Advanced Solid Tumors","metadata":null},{"id":"7b57027423b641bc9ab5a708e1afc3f4","type":"TRIAL","name":"A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT00044512","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"b72bb1e898484ebf836ef9b4c1a7349f","type":"TRIAL","name":"A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain","canonical_id":"clinicaltrials.gov:NCT00364546","description":"Osteoarthritis; Pain Intensity Assessment; Arthralgia; Sciatica; Low Back Pain","metadata":null},{"id":"bf472022374b4788bc9c5e7faab44e72","type":"TRIAL","name":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","canonical_id":"clinicaltrials.gov:NCT02302079","description":"Diabetes Mellitus; Diabetic Macular Edema","metadata":null},{"id":"8fa711e943d74e0c8084da50f5ad915b","type":"TRIAL","name":"A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks","canonical_id":"clinicaltrials.gov:NCT00884104","description":"Overactive Bladder","metadata":null},{"id":"9b0e580d305b4599b0629cef505f6b93","type":"TRIAL","name":"A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05601882","description":"Atopic Dermatitis","metadata":null},{"id":"3ea7275410054a489a1c30d6a641514b","type":"TRIAL","name":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","canonical_id":"clinicaltrials.gov:NCT01732458","description":"Post-operative Nausea; Post-operative Vomiting","metadata":null},{"id":"f6b8f387ca884fe59da1196da6cb896b","type":"TRIAL","name":"A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT06481306","description":"Anemia, Sickle Cell; Healthy Volunteers","metadata":null},{"id":"248472e6d52d4dd7851b5b7ff8e9b815","type":"TRIAL","name":"A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07768189","description":"Oropharyngeal Carcinoma (OPC)","metadata":null},{"id":"30caf42db9644e058b6afbfb32859f34","type":"TRIAL","name":"A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT05106335","description":"Advanced NSCLC","metadata":null},{"id":"8a7d66cc3e5e4aaebcf013b909f224a6","type":"TRIAL","name":"A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide","canonical_id":"clinicaltrials.gov:NCT03004534","description":"Breast Cancer Female","metadata":null},{"id":"840d4401935542d8856b5aff388b690e","type":"TRIAL","name":"A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure","canonical_id":"clinicaltrials.gov:NCT03443843","description":"Rhinitis, Allergic","metadata":null},{"id":"4459b44b404f4639b90d86f456c07e44","type":"TRIAL","name":"A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies","canonical_id":"clinicaltrials.gov:NCT04162795","description":"Allergic Rhinitis","metadata":null},{"id":"3d9af62ef0b2442a9312e91118c6a773","type":"TRIAL","name":"A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 Years","canonical_id":"clinicaltrials.gov:NCT07835074","description":"Persistent Allergic Rhinitis","metadata":null},{"id":"4cca05c3b0f74e09b6070713e397732b","type":"TRIAL","name":"A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT00459745","description":"Combined Hyperlipidemia","metadata":null},{"id":"f9e8f0d8e41b44398f2169aac17f4127","type":"TRIAL","name":"A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02951819","description":"Multiple Myeloma","metadata":null},{"id":"0f7cf42c12d54731aab555875befc90b","type":"TRIAL","name":"A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT03981796","description":"Neoplasms","metadata":null},{"id":"88bf5ce596b445bb84f0032fd44e361a","type":"TRIAL","name":"A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00729768","description":"Kidney Transplantation","metadata":null},{"id":"69788f8b82ff47aea435a9e71b44e275","type":"TRIAL","name":"A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies","canonical_id":"clinicaltrials.gov:NCT00338143","description":"Psoriasis","metadata":null},{"id":"9ee9e4d76c4a454699e3704b6b7038d5","type":"TRIAL","name":"A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT05620407","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"85feed88f91f42b5b6bfac489ddb65cd","type":"TRIAL","name":"A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis","canonical_id":"clinicaltrials.gov:NCT06042920","description":"Palmoplantar Psoriasis; Genital Psoriasis","metadata":null},{"id":"146d1e93250a4492aabe33367344b5ae","type":"TRIAL","name":"A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00189241","description":"Basal Cell Carcinoma","metadata":null},{"id":"d171cd69fe01426b8a1935971be8b114","type":"TRIAL","name":"A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)","canonical_id":"clinicaltrials.gov:NCT05644665","description":"Ulcerative Colitis","metadata":null},{"id":"32e089f17d854d72885ab0525f32788d","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms","canonical_id":"clinicaltrials.gov:NCT06693648","description":"Osteoarthritis of Knee; Osteoarthritis, Knee","metadata":null},{"id":"5d7d9308c4654e8a9cf91b4cacdfa617","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","canonical_id":"clinicaltrials.gov:NCT06232707","description":"Multiple Myeloma","metadata":null},{"id":"7904fa5ee9d04a7ca79087d31b9842dc","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)","canonical_id":"clinicaltrials.gov:NCT03265132","description":"Still's Disease, Adult-Onset; Still's Disease, Juvenile-Onset","metadata":null},{"id":"6bf8aa26d5b44daab042ffc3277491c1","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)","canonical_id":"clinicaltrials.gov:NCT04857034","description":"Lupus Erythematosus, Discoid; Lupus Erythematosus, Subacute Cutaneous","metadata":null},{"id":"25957999621e45b7ba6ca00ea3038eb9","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT05556265","description":"Alopecia Areata","metadata":null},{"id":"a9e1970e03c24ee58fa89c1c41f3ec77","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","canonical_id":"clinicaltrials.gov:NCT01294683","description":"Primary Hypercholesterolemia; Dyslipidemia","metadata":null},{"id":"8221a8c42e784969877a6aae2d07d411","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)","canonical_id":"clinicaltrials.gov:NCT02284516","description":"Dry Eye Disease","metadata":null},{"id":"a044dafffe7749d78f5f1fa48707e4a2","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT04271475","description":"Chronic Thromboembolic Pulmonary Hypertension","metadata":null},{"id":"f65566d6a37445aa949395da559e31aa","type":"TRIAL","name":"A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT04169373","description":"Spondyloarthritis","metadata":null},{"id":"012b18898e5e485c95ee1dbe07f06cc5","type":"TRIAL","name":"A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout","canonical_id":"clinicaltrials.gov:NCT05007392","description":"Gout","metadata":null},{"id":"14a68f44e0e14e6488b0b7591eba89b2","type":"TRIAL","name":"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT05265728","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"f38a0bd75208466d9f561b81ec809742","type":"TRIAL","name":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","canonical_id":"clinicaltrials.gov:NCT03368664","description":"Multiple Sclerosis","metadata":null},{"id":"61cde0c546b2433caff5fb9fac8a2924","type":"TRIAL","name":"A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study","canonical_id":"clinicaltrials.gov:NCT02646683","description":"Crohn Disease","metadata":null},{"id":"609609b5e9cf4ef79abeb868df4706ca","type":"TRIAL","name":"A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy","canonical_id":"clinicaltrials.gov:NCT04995419","description":"Metastatic Urothelial Cancer","metadata":null},{"id":"89f948d8dc1b4890b10c97f135876441","type":"TRIAL","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","canonical_id":"clinicaltrials.gov:NCT04225117","description":"Locally Advanced or Metastatic Malignant Solid Tumors","metadata":null},{"id":"699cbe19f3ad4d6d8b792757ccbd8df1","type":"TRIAL","name":"A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05287126","description":"Ulcerative Colitis","metadata":null},{"id":"0a4fe49a6f5f4956b7e56edafdd10b61","type":"TRIAL","name":"A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa","canonical_id":"clinicaltrials.gov:NCT00134966","description":"Parkinson's Disease","metadata":null},{"id":"0161b9a8e4ff44f7bfda2bb45a865d08","type":"TRIAL","name":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","canonical_id":"clinicaltrials.gov:NCT05133531","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"c598722e5e0c4deda03f750985fbfd8c","type":"TRIAL","name":"A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04913285","description":"Solid Tumor, Adult; Non-small Cell Lung Cancer; Melanoma","metadata":null},{"id":"f90a10cefdd34de3ad6ce507df997673","type":"TRIAL","name":"A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women","canonical_id":"clinicaltrials.gov:NCT04890561","description":"Healthy Volunteers","metadata":null},{"id":"026f810a140f41d1913449c290b2acb6","type":"TRIAL","name":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","canonical_id":"clinicaltrials.gov:NCT03695237","description":"Central Precocious Puberty (CPP)","metadata":null},{"id":"822f5f85fb964db48c608d84d639d299","type":"TRIAL","name":"A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain","canonical_id":"clinicaltrials.gov:NCT00361504","description":"Osteoarthritis, Hip; Osteoarthritis, Knee; Lower Back Pain; Pain","metadata":null},{"id":"c732b817334445fabb149ebcc09f800d","type":"TRIAL","name":"A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients","canonical_id":"clinicaltrials.gov:NCT01672762","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c07e0be1fd7f4dc6b1d580275d710d64","type":"TRIAL","name":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","canonical_id":"clinicaltrials.gov:NCT04641975","description":"Overactive Bladder (OAB); Pharmacokinetics of Mirabegron","metadata":null},{"id":"2e51f632ff044e2da68b1f62edc8c988","type":"TRIAL","name":"A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03534947","description":"Basal Cell Carcinoma; Basal Cell Carcinoma of Skin, Site Unspecified; Skin Cancer; Invasive Carcinoma","metadata":null},{"id":"f2dfc6a2022a420e81b9e45c3a52d69b","type":"TRIAL","name":"A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","canonical_id":"clinicaltrials.gov:NCT00673920","description":"Rheumatoid Arthritis","metadata":null},{"id":"11532110c0ad4bc9bd6a03e59a81df4d","type":"TRIAL","name":"A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03674112","description":"HER2-Positive Early Breast Cancer","metadata":null},{"id":"dd9e924cb40f469eb01bcb81cf6488f9","type":"TRIAL","name":"A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)","canonical_id":"clinicaltrials.gov:NCT01235962","description":"Renal Cell Carcinoma (RCC); Cancer","metadata":null},{"id":"fa9c5ce1ef66412ab187bc0ca9779363","type":"TRIAL","name":"A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)","canonical_id":"clinicaltrials.gov:NCT07503873","description":"Multiple Sclerosis","metadata":null},{"id":"1275283e9a6e493f858f03b93fa63df2","type":"TRIAL","name":"A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT02102750","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"d4601070bfac406298d9c691ab3ae694","type":"TRIAL","name":"A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)","canonical_id":"clinicaltrials.gov:NCT05199688","description":"Neuromyelitis Optica Spectrum Disorder; NMOSD","metadata":null},{"id":"09f61f519b244f42b26b0e36ac5e59b5","type":"TRIAL","name":"A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)","canonical_id":"clinicaltrials.gov:NCT07503340","description":"Relapsing-remitting Multiple Sclerosis","metadata":null},{"id":"a1f3c2a826734b249f5e2ce724ce7d85","type":"TRIAL","name":"A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT07142642","description":"Healthy Volunteers","metadata":null},{"id":"6d2dce31b2f545ea993be84d88d66c7f","type":"TRIAL","name":"A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate","canonical_id":"clinicaltrials.gov:NCT06772246","description":"Healthy Subjects","metadata":null},{"id":"55ee8eaa3de441b1afc188d70acb2eac","type":"TRIAL","name":"A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics","canonical_id":"clinicaltrials.gov:NCT02087098","description":"Urinary Bladder, Overactive","metadata":null},{"id":"d0e648e632514fb584881bcdfef3dd0f","type":"TRIAL","name":"A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT00109317","description":"Psoriasis","metadata":null},{"id":"1808c6eefe244f91be1302abb09c5a3e","type":"TRIAL","name":"A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g","canonical_id":"clinicaltrials.gov:NCT00109252","description":"Psoriasis","metadata":null},{"id":"636254b17c2645c2b00db532c1a085b1","type":"TRIAL","name":"A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies","canonical_id":"clinicaltrials.gov:NCT00096980","description":"Psoriasis","metadata":null},{"id":"7b5068a972f54bd286f5fa97a69d3e39","type":"TRIAL","name":"A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent","canonical_id":"clinicaltrials.gov:NCT00336973","description":"Psoriasis","metadata":null},{"id":"346d3cca9ee344efb5f60a6280b56130","type":"TRIAL","name":"A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment","canonical_id":"clinicaltrials.gov:NCT01318837","description":"Over Active Bladder","metadata":null},{"id":"a6c83dd3bdbd403d9969d0407b73ed04","type":"TRIAL","name":"A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03706040","description":"Dermatitis","metadata":null},{"id":"e83d4214f05348a19b094f212a623be8","type":"TRIAL","name":"A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome","canonical_id":"clinicaltrials.gov:NCT00140933","description":"Pain","metadata":null},{"id":"8a71e36cdc6c4020845a70bdfeba9e89","type":"TRIAL","name":"A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT04650854","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"f340365d65204ff3b3303b78ea5b12ef","type":"TRIAL","name":"A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)","canonical_id":"clinicaltrials.gov:NCT03824704","description":"Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; High Grade Serous Carcinoma; Endometrioid Adenocarcinoma","metadata":null},{"id":"d6bdbb492c174421bb70144438300c9c","type":"TRIAL","name":"A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)","canonical_id":"clinicaltrials.gov:NCT03992131","description":"Ovarian Cancer; Triple-negative Breast Cancer; Urothelial Carcinoma; Solid Tumor","metadata":null},{"id":"ab5308c35ba540eda1a49788713ab11f","type":"TRIAL","name":"A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes","canonical_id":"clinicaltrials.gov:NCT04171700","description":"Solid Tumor","metadata":null},{"id":"e648cc62873a43659856d0c8dea369b1","type":"TRIAL","name":"A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC","canonical_id":"clinicaltrials.gov:NCT03764293","description":"Locally Advanced or Metastatic and Unresectable HCC","metadata":null},{"id":"800e19817fd14e18aacf279d51d03380","type":"TRIAL","name":"A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.","canonical_id":"clinicaltrials.gov:NCT04619433","description":"Non-squamous Non-small-cell Lung Cancer","metadata":null},{"id":"639ed2a03eaa4360a318ad18c238b28f","type":"TRIAL","name":"A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT06909136","description":"Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly","metadata":null},{"id":"99d8c4ff85fa434ca3da0b82268fd98c","type":"TRIAL","name":"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control","canonical_id":"clinicaltrials.gov:NCT03242018","description":"Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 4","metadata":null},{"id":"8043f24a4d6d4b71b1c155a38eb1ebeb","type":"TRIAL","name":"A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms","canonical_id":"clinicaltrials.gov:NCT05128344","description":"Spasms, Infantile","metadata":null},{"id":"ee6195751db04d9c88853f18f8dc94f9","type":"TRIAL","name":"A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain","canonical_id":"clinicaltrials.gov:NCT03343067","description":"Endometriosis","metadata":null},{"id":"97e9542d724f4825b09777082ca73887","type":"TRIAL","name":"A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain","canonical_id":"clinicaltrials.gov:NCT05648669","description":"Endometriosis","metadata":null},{"id":"2b3c37965f4c4507b45ed5e872966ce1","type":"TRIAL","name":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)","canonical_id":"clinicaltrials.gov:NCT05123703","description":"Relapsing-remitting Multiple Sclerosis","metadata":null},{"id":"4afb97db826642d2bceee43870df4932","type":"TRIAL","name":"A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout","canonical_id":"clinicaltrials.gov:NCT01736514","description":"Gout","metadata":null},{"id":"9b525cd7aabe4075b66fd96ca2887c49","type":"TRIAL","name":"A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF","canonical_id":"clinicaltrials.gov:NCT03925194","description":"Cystic Fibrosis, 10011762","metadata":null},{"id":"fb2ef11542ee4908979bf7de8ec374ec","type":"TRIAL","name":"A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205","canonical_id":"clinicaltrials.gov:NCT04241068","description":"Alzheimer's Disease","metadata":null},{"id":"07852e5d24e4486f9b17e3478add333f","type":"TRIAL","name":"A Study to Evaluate Safety and Tolerability of QLS-101 in NTG","canonical_id":"clinicaltrials.gov:NCT04857827","description":"Normal Tension Glaucoma (NTG)","metadata":null},{"id":"a19b1084154c493aa54d19281850f79e","type":"TRIAL","name":"A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants","canonical_id":"clinicaltrials.gov:NCT03859219","description":"Healthy-volunteers","metadata":null},{"id":"551577bfd3b54402939698ab85bcd5a3","type":"TRIAL","name":"A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03661138","description":"Atopic Dermatitis","metadata":null},{"id":"a1f7ece3ec9745cd80cf45ec2ec13830","type":"TRIAL","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05372354","description":"Multiple Myeloma","metadata":null},{"id":"a9adb9b02cc54580bac5d1e41fc70ff8","type":"TRIAL","name":"A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05129280","description":"Solid Tumors","metadata":null},{"id":"a02545213ac14d89b7b0c4ae67f47e9e","type":"TRIAL","name":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT07344558","description":"Idiopathic Pulmonary Fibrosis (IPF)","metadata":null},{"id":"89e1fcd0073a4d1fb69729033068e590","type":"TRIAL","name":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)","canonical_id":"clinicaltrials.gov:NCT07768592","description":"Alzheimers Disease","metadata":null},{"id":"1597ce5f171d45a090d142925b37ad45","type":"TRIAL","name":"A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging","canonical_id":"clinicaltrials.gov:NCT01264861","description":"Parkinson Disease","metadata":null},{"id":"dbd87211fe5f4029b0649693faebbc88","type":"TRIAL","name":"A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)","canonical_id":"clinicaltrials.gov:NCT03551522","description":"NASH - Nonalcoholic Steatohepatitis","metadata":null},{"id":"f6fa5be3a7d44da784cde19d1c2babd0","type":"TRIAL","name":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","canonical_id":"clinicaltrials.gov:NCT03412565","description":"Multiple Myeloma","metadata":null},{"id":"93274f95c0724544a90f15942e318cfc","type":"TRIAL","name":"A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04690855","description":"Breast Cancer; Triple Negative Breast Cancer","metadata":null},{"id":"51e1eee8a5b84d9cb5557ae3af1e264b","type":"TRIAL","name":"A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine","canonical_id":"clinicaltrials.gov:NCT00472303","description":"Tumor; Pain","metadata":null},{"id":"9e27e53d88574330929522659ce99000","type":"TRIAL","name":"A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT07465289","description":"Ocular Myasthenia Gravis","metadata":null},{"id":"201cb95732af476f9644db9dd324a337","type":"TRIAL","name":"A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects","canonical_id":"clinicaltrials.gov:NCT01652703","description":"Hypercholesterolemia and High Risk for Cardiovascular Events","metadata":null},{"id":"e9474ed302d34b38bd0239bab9ec2f6f","type":"TRIAL","name":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","canonical_id":"clinicaltrials.gov:NCT02138747","description":"Overactive Bladder (OAB)","metadata":null},{"id":"ff9031fe4033461f84d37c28cc909b8e","type":"TRIAL","name":"A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine","canonical_id":"clinicaltrials.gov:NCT04825678","description":"Migraine","metadata":null},{"id":"24e6a7bed5bb4388a5fce9369f8bc542","type":"TRIAL","name":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03568318","description":"Atopic Dermatitis","metadata":null},{"id":"1f643da65cb849c1a0e389cd81461187","type":"TRIAL","name":"A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT07066722","description":"HIV Infections","metadata":null},{"id":"475fcb9222984ef2b8994398716ad6ab","type":"TRIAL","name":"A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","canonical_id":"clinicaltrials.gov:NCT03153111","description":"Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"420538d6a1a84de2aa55f52dedc2fcba","type":"TRIAL","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","canonical_id":"clinicaltrials.gov:NCT06101134","description":"Melanoma","metadata":null},{"id":"21bb624c51ca46e5b6736e9eacdb6645","type":"TRIAL","name":"A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet","canonical_id":"clinicaltrials.gov:NCT01943487","description":"Drug-Drug Interaction (DDI); Healthy Subjects","metadata":null},{"id":"62fc0f611a214bb6b60825b237375a69","type":"TRIAL","name":"A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy","canonical_id":"clinicaltrials.gov:NCT05868122","description":"Pain","metadata":null},{"id":"cc934b4d10654aefab0b7dd9cd70e914","type":"TRIAL","name":"A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02838420","description":"Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer","metadata":null},{"id":"a124a886be7e42878c01becf74a04db3","type":"TRIAL","name":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","canonical_id":"clinicaltrials.gov:NCT01342913","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"da295cf5106c45189bfda52ae7593569","type":"TRIAL","name":"A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02343289","description":"Healthy","metadata":null},{"id":"d2cdc36a3bfe454d9c26688ffbdd9763","type":"TRIAL","name":"A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users","canonical_id":"clinicaltrials.gov:NCT02144415","description":"Healthy Volunteers; Drug Users","metadata":null},{"id":"5e5ee0fcb0de481c8ea2f2abf1c28528","type":"TRIAL","name":"A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03895385","description":"Healthy Volunteers","metadata":null},{"id":"2ad2483276c24b8fb4f8826f66b41cd7","type":"TRIAL","name":"A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications","canonical_id":"clinicaltrials.gov:NCT04877288","description":"Renal Allograft Recipients","metadata":null},{"id":"48ddcb26898a48f49c88bc5bcaed8d12","type":"TRIAL","name":"A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05051553","description":"Healthy Volunteers","metadata":null},{"id":"58f121f74f0348898c43f9164938fe83","type":"TRIAL","name":"A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05283681","description":"Healthy Volunteers","metadata":null},{"id":"f17069ebbc7443f0a73d680812500600","type":"TRIAL","name":"A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01019603","description":"Acne Vulgaris","metadata":null},{"id":"22c1b2805c444d4984f71210f72e189f","type":"TRIAL","name":"A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT04465396","description":"Healthy Volunteers","metadata":null},{"id":"3fe34f48a3574446ab4362845d310e5f","type":"TRIAL","name":"A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06851871","description":"Healthy Participants","metadata":null},{"id":"16bbd784106b4735a7229167beebbb7e","type":"TRIAL","name":"A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants","canonical_id":"clinicaltrials.gov:NCT04255862","description":"Healthy Study Participants","metadata":null},{"id":"4ea72a0c682b44eea48e39ddc08c317f","type":"TRIAL","name":"A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab\u2122 in Patients Undergoing an Elective Abdominal Liposuction Procedure","canonical_id":"clinicaltrials.gov:NCT00894699","description":"Sedation; Anxiety; Pain","metadata":null},{"id":"b5bdb077539d493dabbc96ac62df48a6","type":"TRIAL","name":"A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib","canonical_id":"clinicaltrials.gov:NCT06378892","description":"Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation","metadata":null},{"id":"059daf46c34f43659c6fbd81fccd11f0","type":"TRIAL","name":"A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy","canonical_id":"clinicaltrials.gov:NCT00327145","description":"Hypertension","metadata":null},{"id":"8018d87588314dd0a7f116a14e4a5609","type":"TRIAL","name":"A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis","canonical_id":"clinicaltrials.gov:NCT03090100","description":"Psoriasis","metadata":null},{"id":"b42baf042d9142ddbd52ba2d35eef2fa","type":"TRIAL","name":"A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis","canonical_id":"clinicaltrials.gov:NCT02969525","description":"Psoriatic Arthritis","metadata":null},{"id":"6db78bccb91d4faa822a4f52b7d09804","type":"TRIAL","name":"A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04949269","description":"Healthy Participants","metadata":null},{"id":"3aad9d8913bd4ce0b7cfbb9f5c7ac5b5","type":"TRIAL","name":"A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04772079","description":"Plaque Psoriasis","metadata":null},{"id":"b73e335c7dc94e8987fe00b5e9ad8d14","type":"TRIAL","name":"A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05045313","description":"Healthy Subjects","metadata":null},{"id":"448ce50e2d254a30b7b429c74fe73a46","type":"TRIAL","name":"A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis","canonical_id":"clinicaltrials.gov:NCT05052983","description":"Prurigo Nodularis","metadata":null},{"id":"66945d589fb64f93b93e810ff213dded","type":"TRIAL","name":"A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT01714843","description":"Constipation-predominant Irritable Bowel Syndrome (IBS-C)","metadata":null},{"id":"178542ca08ce4824a00265309a5d7a46","type":"TRIAL","name":"A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01071850","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"91570c70797f49fb8c63eb5068b9c49b","type":"TRIAL","name":"A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01117584","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"9ff086d51ff64aec8e68e8a26f00d8ba","type":"TRIAL","name":"A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT01597492","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"2d8326fac11d440bbf3a82321f25aa84","type":"TRIAL","name":"A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02061878","description":"Alzheimer's Disease","metadata":null},{"id":"ef9e834af272447faf04760e51b55253","type":"TRIAL","name":"A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06506916","description":"Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis","metadata":null},{"id":"86421fd215424e1b95ba79e1b840793a","type":"TRIAL","name":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","canonical_id":"clinicaltrials.gov:NCT02547935","description":"Type 2 Diabetes Mellitus, CKD and Albuminuria","metadata":null},{"id":"63e1eb0cf9e24788a5901c0e2b7dcb27","type":"TRIAL","name":"A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting","canonical_id":"clinicaltrials.gov:NCT05701995","description":"Psoriasis","metadata":null},{"id":"8f0899d3a85648189425a2a289979eef","type":"TRIAL","name":"A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma","canonical_id":"clinicaltrials.gov:NCT04203797","description":"Asthma","metadata":null},{"id":"041320cf470b42d3baa35323eb5e08d4","type":"TRIAL","name":"A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235","canonical_id":"clinicaltrials.gov:NCT04464577","description":"Healthy Participants","metadata":null},{"id":"62a9204ddb5d4a029fae55b4a3b4dc7c","type":"TRIAL","name":"A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03174548","description":"Diabetes Mellitus","metadata":null},{"id":"67c7aee377fb41f9af4371ca16b26b47","type":"TRIAL","name":"A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib","canonical_id":"clinicaltrials.gov:NCT03627754","description":"Hepatic Impairment","metadata":null},{"id":"d211bb62028a4784bdc602cdbfdd4da5","type":"TRIAL","name":"A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT04254783","description":"Ulcerative Colitis (UC); Crohn's Disease","metadata":null},{"id":"e1eac7d9c70d420fae06a3eba10df67b","type":"TRIAL","name":"A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors","canonical_id":"clinicaltrials.gov:NCT02019264","description":"Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes","metadata":null},{"id":"8b17375b02db47e1ab13f8be47595c78","type":"TRIAL","name":"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT02044874","description":"Smoking Cessation","metadata":null},{"id":"5c643392643b412e97e26dd96ed37418","type":"TRIAL","name":"A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)","canonical_id":"clinicaltrials.gov:NCT06814132","description":"Kidney Failure, Chronic; End-Stage Kidney Disease; Renal Failure, Chronic; Renal Failure, End-Stage; Healthy Participants","metadata":null},{"id":"c6403a60cee34c9f980102e3607ad034","type":"TRIAL","name":"A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)","canonical_id":"clinicaltrials.gov:NCT00282386","description":"Colorectal Adenoma","metadata":null},{"id":"5cd4f360807043f7b9463dc050406c6a","type":"TRIAL","name":"A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib","canonical_id":"clinicaltrials.gov:NCT07144111","description":"Hepatic Impairment","metadata":null},{"id":"7358c51ddd6345869b7aa89995573296","type":"TRIAL","name":"A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04094519","description":"Prostate Cancer","metadata":null},{"id":"e96abe5ca38048058fa4d0807f425c23","type":"TRIAL","name":"A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine","canonical_id":"clinicaltrials.gov:NCT02128321","description":"Pharmacokinetics of Repaglinide; Pharmacokinetics of Caffeine; Healthy Subjects","metadata":null},{"id":"8f054e3c64cc4c89a379496185b4ccb0","type":"TRIAL","name":"A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss","canonical_id":"clinicaltrials.gov:NCT00000854","description":"HIV Infections; HIV Wasting Syndrome","metadata":null},{"id":"1faa010877a24d6ea1f235e3ad859605","type":"TRIAL","name":"A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT07219602","description":"Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)","metadata":null},{"id":"e3b302b901c74e918423adb757587c4c","type":"TRIAL","name":"A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass","canonical_id":"clinicaltrials.gov:NCT00950950","description":"Osteopenia","metadata":null},{"id":"c71aae92d3814934b141a081cd8e2818","type":"TRIAL","name":"A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT02111317","description":"Healthy Subjects; Pharmacokinetics of ASP015K","metadata":null},{"id":"1cf4ebe2838e41b2bf00c399da6c2b0f","type":"TRIAL","name":"A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00351585","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"5c27f4491885464da74461ce78017728","type":"TRIAL","name":"A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT04898101","description":"Healthy Volunteers","metadata":null},{"id":"2f5d3d98354e4f2e9dfbe65f577593a5","type":"TRIAL","name":"A Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women","canonical_id":"clinicaltrials.gov:NCT02451826","description":"Ovulation Inhibition","metadata":null},{"id":"4b689b870f4348d38cbf32410182e791","type":"TRIAL","name":"A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT04702464","description":"Healthy Volunteers","metadata":null},{"id":"7018369d627f49c0ae93442ac2642060","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine","canonical_id":"clinicaltrials.gov:NCT00505414","description":"Pain; Neoplasm; Cancer","metadata":null},{"id":"9dd8123b14284eee8d2557790c342625","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07347600","description":"Locally Advanced Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"919853c3d9264d7cb93d842f56baa37e","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD","canonical_id":"clinicaltrials.gov:NCT04571164","description":"Parkinson Disease","metadata":null},{"id":"8c7337a68acf4530a1fca7f5a24d4297","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05954910","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"e2d41cc4c0234a0e8fbbd767ed4c3ac1","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT00449176","description":"Low Back Pain","metadata":null},{"id":"7d3d019d76724974a0ac377c71630e74","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo","canonical_id":"clinicaltrials.gov:NCT01813890","description":"Hallux Valgus","metadata":null},{"id":"023bc8c851bd4dd3b33ab0c6ee674e04","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.","canonical_id":"clinicaltrials.gov:NCT00613938","description":"Arthralgia; Bunion; Hallux Valgus; Pain","metadata":null},{"id":"12433047e0e446d2aff87afb827f8855","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety","canonical_id":"clinicaltrials.gov:NCT00364533","description":"Arthroplasty","metadata":null},{"id":"a4fb0d0d7cdb4bbeb6f57f0ccae5d1bf","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.","canonical_id":"clinicaltrials.gov:NCT00364247","description":"Arthralgia; Bunion; Hallux Valgus; Pain Assessment; Tapentadol","metadata":null},{"id":"f7bb0982c79841e5904c8330e8968ff0","type":"TRIAL","name":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","canonical_id":"clinicaltrials.gov:NCT01456169","description":"Essential Hypertension","metadata":null},{"id":"a9bf04dea5a54c7ca5e8b3399e4482fe","type":"TRIAL","name":"A Study to Evaluate the Effectiveness of STELARA \u2122 (USTEKINUMAB) in the Treatment of Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT01558310","description":"Scalp Psoriasis; Plaque Psoriasis","metadata":null},{"id":"c69a66f9486a432f9bb09e966f4017a3","type":"TRIAL","name":"A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor","canonical_id":"clinicaltrials.gov:NCT07105111","description":"Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Tardive Dyskinesia","metadata":null},{"id":"696c877748754c75a62e795579588f35","type":"TRIAL","name":"A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer","canonical_id":"clinicaltrials.gov:NCT00925743","description":"Solid Cancer","metadata":null},{"id":"8514517f1cf341f69fb37146de235634","type":"TRIAL","name":"A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01261156","description":"Healthy Subjects","metadata":null},{"id":"d84b29cbb6174e338165cf80dda68790","type":"TRIAL","name":"A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01643889","description":"Healthy","metadata":null},{"id":"1a08b32030b04316a2c365911a1d8690","type":"TRIAL","name":"A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00382512","description":"Plaque Psoriasis","metadata":null},{"id":"f3da36c2178c446bbb0da481212e67f4","type":"TRIAL","name":"A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin","canonical_id":"clinicaltrials.gov:NCT07118215","description":"Healthy Volunteers","metadata":null},{"id":"8273b1ffb64c4a9d9b89b18724b42795","type":"TRIAL","name":"A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.","canonical_id":"clinicaltrials.gov:NCT00203125","description":"Parkinson's Disease","metadata":null},{"id":"3acfb06649ab462b930f05ccdcaac84d","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","canonical_id":"clinicaltrials.gov:NCT06571045","description":"Diabetic Macular Edema (DME)","metadata":null},{"id":"78e4a9803a9149c18838ad00a7927e73","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT03615768","description":"Acne Vulgaris","metadata":null},{"id":"1c5bf0af62a348798d56a0978401e824","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT05930028","description":"Essential Hypertension; Primary Hypercholesterolemia","metadata":null},{"id":"16d50967aaff4335b7f6601f6e43dfbd","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03370133","description":"Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis; Psoriatic Arthritis","metadata":null},{"id":"c5de1038caff456c961b0b686e1b74ce","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06425549","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"a08db7c037b748ecadfe0615eba0a7e6","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03536884","description":"Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis","metadata":null},{"id":"ce7b60f6efb64437b01fa223421814d6","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05020249","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"c96c8dda57294f79b47406c3d58e524f","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT06624228","description":"Psoriatic Arthritis","metadata":null},{"id":"b1ba79f6819341eca9e6e8d9b53689e7","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03598790","description":"Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis","metadata":null},{"id":"0475c97e772b48fa80eb8210247d33cd","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03412747","description":"Chronic Plaque Psoriasis; Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"0c33044fad704d6782ad13375c8e3b77","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06011733","description":"Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis","metadata":null},{"id":"47c25ae1bf5b45ce9ebbb3ae9b9ee173","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT04242446","description":"Hidradenitis Suppurativa","metadata":null},{"id":"3dc13edb05fe4a7791f229289dca7dc6","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT04242498","description":"Hidradenitis Suppurativa","metadata":null},{"id":"f9862ce93ea24c7aa1fb2e373f300c61","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis","canonical_id":"clinicaltrials.gov:NCT07219420","description":"Palmoplantar Pustulosis","metadata":null},{"id":"78b16043d36442a0b1a46ccec7f17345","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT03928743","description":"Ankylosing Spondylitis","metadata":null},{"id":"16826a0b07f642488f410435036900d1","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT03928704","description":"Nonradiographic Axial Spondyloarthritis","metadata":null},{"id":"e5dfd88ac4f447dbb367f287409237e6","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03896581","description":"Psoriatic Arthritis","metadata":null},{"id":"a2ac2a36df954470b5d001b3f91522ad","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","canonical_id":"clinicaltrials.gov:NCT03083665","description":"Partial Seizures With or Without Secondary Generalization; Epilepsy","metadata":null},{"id":"79317e295df74d1fa4597fcc986c26b4","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease","canonical_id":"clinicaltrials.gov:NCT01024036","description":"Multicentric Castleman's Disease","metadata":null},{"id":"591bc8194a194d09960734c5a6a59731","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss","canonical_id":"clinicaltrials.gov:NCT05910450","description":"Alopecia, Androgenetic","metadata":null},{"id":"49b86094050f4e968989984f17d8eda4","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)","canonical_id":"clinicaltrials.gov:NCT05914805","description":"Alopecia, Androgenetic","metadata":null},{"id":"736a6bc4404b4e8aa51ca6fa7e822951","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT05282069","description":"Overactive Bladder","metadata":null},{"id":"4a96c83fbb8d4d7aa6666f388fcd1f95","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sj\u00f6gren's Syndrome","canonical_id":"clinicaltrials.gov:NCT05946941","description":"Sj\u00f6gren's Syndrome","metadata":null},{"id":"df4680e94db14c16b8783688b9930fa9","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT02963506","description":"Ankylosing Spondylitis","metadata":null},{"id":"3c5ba78ce41a46a69836a6efce62cd03","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","canonical_id":"clinicaltrials.gov:NCT04417894","description":"Moderate to Severe Atopic Hand and Foot Dermatitis","metadata":null},{"id":"c0fdda9b38f048dba2972073353335d2","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06586112","description":"Plaque Psoriasis","metadata":null},{"id":"31bb85ac71704d7c9858dd273be3586f","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients","canonical_id":"clinicaltrials.gov:NCT06212973","description":"Seasonal Allergic Conjunctivitis","metadata":null},{"id":"5fa075694c6144f68e8017015ac3006d","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine","canonical_id":"clinicaltrials.gov:NCT04152083","description":"Migraine","metadata":null},{"id":"8e78fcee849c47e9bcb69244594088b1","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments","canonical_id":"clinicaltrials.gov:NCT04418765","description":"Migraine","metadata":null},{"id":"b3068fc345054254a7ea64c333dc7f12","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache","canonical_id":"clinicaltrials.gov:NCT03971071","description":"Migraine Headache","metadata":null},{"id":"04d64eeaa2294c8bb805b00e3beb9aa2","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","canonical_id":"clinicaltrials.gov:NCT02630706","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"56b1cc04dec54157bcece921ab0b14d9","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT03622593","description":"Diabetic Macular Edema","metadata":null},{"id":"aa592444b7e2479dbdb0b3540ed7dddd","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)","canonical_id":"clinicaltrials.gov:NCT03622580","description":"Diabetic Macular Edema","metadata":null},{"id":"83fa6b8c10ce41cfac68d2d830aa9e3c","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT04740905","description":"Macular Edema; Branch Retinal Vein Occlusion","metadata":null},{"id":"7517d85c8bf244f6893e64a0673c08bc","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT04740931","description":"Macular Edema; Central Retinal Vein Occlusion; Hemiretinal Vein Occlusion","metadata":null},{"id":"85b637a4bb644f0b867577e6534e8d97","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)","canonical_id":"clinicaltrials.gov:NCT03823300","description":"Wet Macular Degeneration","metadata":null},{"id":"1ca53478085247ddb457fd330891679b","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)","canonical_id":"clinicaltrials.gov:NCT03823287","description":"Wet Macular Degeneration","metadata":null},{"id":"0406c1ec0c154115bb186d5728717cf2","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","canonical_id":"clinicaltrials.gov:NCT06176352","description":"Choroidal Neovascularization Secondary to Pathologic Myopia","metadata":null},{"id":"7a75a8aa8a324007af186c79a076cc15","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT04041284","description":"Migraine; Major Depressive Disorder","metadata":null},{"id":"cd464061a4d549469274de055587a69a","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","canonical_id":"clinicaltrials.gov:NCT05296798","description":"Locally Advanced or Metastatic Breast Cancer","metadata":null},{"id":"f2644bc0039f4183ac1f04ca11b815c5","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression","canonical_id":"clinicaltrials.gov:NCT05215925","description":"HLX07, nsqNSCLC, High EGFR Expression","metadata":null},{"id":"e4aa8796144a447bb6e606a368ebfec8","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations","canonical_id":"clinicaltrials.gov:NCT06596876","description":"Parkinson's Disease","metadata":null},{"id":"72e167be431e4115aab7f9cd1307d5ac","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD","canonical_id":"clinicaltrials.gov:NCT05972473","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"e959844076c54bfc9ab4304f436a5be1","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema\uff08DME\uff09","canonical_id":"clinicaltrials.gov:NCT06908876","description":"Diabetic Macular Oedema","metadata":null},{"id":"311056f316b041e085e8612052d5e960","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT06807424","description":"Arthritis, Psoriatic","metadata":null},{"id":"a5e959c89e8a4705bd98eca01363dbe7","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07323576","description":"Colorectal Cancer","metadata":null},{"id":"3aafc4252c214ef093ecbf292d39ec89","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05894239","description":"Metastatic Breast Cancer","metadata":null},{"id":"4776bebc27d24c53900ec5f953e7c21f","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia","canonical_id":"clinicaltrials.gov:NCT06164951","description":"Achondroplasia","metadata":null},{"id":"eb4c3f44a0d244ef82e6ec04726c3224","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-na\u00efve Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT06878404","description":"Arthritis, Psoriatic","metadata":null},{"id":"e83943e5c99a40ee9e078fb17df8c784","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).","canonical_id":"clinicaltrials.gov:NCT05325203","description":"Heterozygous Familial Hypercholesterolemia","metadata":null},{"id":"28d636d3bb7649dba5e59269de638713","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or S\u00e9zary Syndrome Previously Treated With Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT06285370","description":"Cutaneous T-Cell Lymphoma","metadata":null},{"id":"099d60b929774583a6d66eaa8d087eab","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension","canonical_id":"clinicaltrials.gov:NCT00817635","description":"Hypertension","metadata":null},{"id":"b6c6d1d9b6da4fef8a62d4e945887f6c","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03235050","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"bd976600f023478fba148f46cc52c96b","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)","canonical_id":"clinicaltrials.gov:NCT07673744","description":"Myasthenia Gravis","metadata":null},{"id":"99ff5f6693c44bd9afdde75342fedc97","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC","canonical_id":"clinicaltrials.gov:NCT04262804","description":"Breast Cancer Metastatic","metadata":null},{"id":"63a59cb25451467fba3ef4e937c779c9","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03482011","description":"Psoriasis","metadata":null},{"id":"fc3276aa5a8c4a9f91c1558b60c2225f","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT03178552","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"dd25e139fb3d479d8d0758d1b761b2a7","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)","canonical_id":"clinicaltrials.gov:NCT05335122","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"9f0f1d29eb9046e3a3087bb0abf2dc2f","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma","canonical_id":"clinicaltrials.gov:NCT05562466","description":"Asthma","metadata":null},{"id":"cb08d44f936e41f88bb889bc1e241db9","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT01270464","description":"Eosinophilic Asthma","metadata":null},{"id":"d029ab09e78e449486e1444615bb0bfe","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT01287039","description":"Eosinophilic Asthma","metadata":null},{"id":"9907eb85ac3d4148a59e61c719aa8571","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT01285323","description":"Eosinophilic Asthma","metadata":null},{"id":"df6795c3f2324329bb69bf214a0b0adf","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)","canonical_id":"clinicaltrials.gov:NCT05063162","description":"Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)","metadata":null},{"id":"30b63cca38ce42c19484620bd8e6d741","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT07463521","description":"Ocular Myasthenia Gravis","metadata":null},{"id":"93c6e7950beb48ab8c89e71a73db7b06","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis \uff08EGPA\uff09","canonical_id":"clinicaltrials.gov:NCT05979051","description":"Eosinophilic Granulomatosis With Polyangiitis","metadata":null},{"id":"8347996a591e40e6a631015fdc654780","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","canonical_id":"clinicaltrials.gov:NCT06220123","description":"Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","metadata":null},{"id":"b2ae83bdc00c4ec8976443c0dfa02d1b","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea","canonical_id":"clinicaltrials.gov:NCT05312632","description":"Parkinson Disease","metadata":null},{"id":"b4938e778a4f4f88aa5620dc5792949b","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa","canonical_id":"clinicaltrials.gov:NCT03881371","description":"Parkinson Disease","metadata":null},{"id":"1f01187bf57d465f962b10be3e3e531c","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer","canonical_id":"clinicaltrials.gov:NCT05216237","description":"Gastric Cancer; Chemotherapy; Immunotherapy","metadata":null},{"id":"92bbb0c029934c0ab28b89de8aeb4fa0","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00541450","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"cfcfe0e795a34b12a8d6df4a3cccd4d4","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT06481891","description":"Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy","metadata":null},{"id":"03f102022a6f455ba628fd43735411da","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","canonical_id":"clinicaltrials.gov:NCT06241118","description":"Dermatitis Atopic","metadata":null},{"id":"4c1372f742c340029cb6184181335a41","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)","canonical_id":"clinicaltrials.gov:NCT01722331","description":"Plaque Psoriasis","metadata":null},{"id":"accb7a81bbed4d3fa3f68270a0331a92","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.","canonical_id":"clinicaltrials.gov:NCT06611163","description":"Moderate to Severe Genital Psoriasis","metadata":null},{"id":"f8261d6b731642528cb90b4518b7c687","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)","canonical_id":"clinicaltrials.gov:NCT02945046","description":"Episodic Cluster Headache","metadata":null},{"id":"0e170a8fc8fc4a8cb2558d48e6afffe0","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF\u03b1 Naive Participants With Active Radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT02437162","description":"Axial Spondyloarthritis","metadata":null},{"id":"394fcb2cce38492ab5dc1c4cc5570c24","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis","canonical_id":"clinicaltrials.gov:NCT02790138","description":"Pouchitis","metadata":null},{"id":"f155be3b87d54b6e9dbee9cc4d157efc","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation","canonical_id":"clinicaltrials.gov:NCT00048165","description":"Heart Transplantation","metadata":null},{"id":"5f07f96bf1b24c2f9cc555b83c4afa17","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","canonical_id":"clinicaltrials.gov:NCT01729754","description":"Plaque Psoriasis","metadata":null},{"id":"3123774fdd3d450fa7cba9179874b867","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","canonical_id":"clinicaltrials.gov:NCT00894556","description":"Acute Migraine","metadata":null},{"id":"197aa40cbb084a43be81b6522961dba1","type":"TRIAL","name":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)","canonical_id":"clinicaltrials.gov:NCT01001234","description":"Migraine, Acute","metadata":null},{"id":"f31d816a1ddd469798e6cd6d5976d00b","type":"TRIAL","name":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","canonical_id":"clinicaltrials.gov:NCT04669041","description":"Hypercholesterolemia","metadata":null},{"id":"9cdacc03d46b45b49e5e8d65f99521d6","type":"TRIAL","name":"A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.","canonical_id":"clinicaltrials.gov:NCT01929317","description":"Parkinson Disease","metadata":null},{"id":"4f148fc856754e508aa8eb93fa26413d","type":"TRIAL","name":"A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms","canonical_id":"clinicaltrials.gov:NCT06223880","description":"Major Depressive Disorder","metadata":null},{"id":"7985007212ba4f9a82b6ba12f4a03389","type":"TRIAL","name":"A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","canonical_id":"clinicaltrials.gov:NCT02094573","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"c462b5f05608413a938e50e79cec0df0","type":"TRIAL","name":"A Study to Evaluate the Efficacy of PanCytoVir\u2122 for the Treatment of Non-Hospitalized Patients With COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT05442983","description":"COVID-19","metadata":null},{"id":"f884f1c3ca8042acb17eab8462a94a3c","type":"TRIAL","name":"A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).","canonical_id":"clinicaltrials.gov:NCT00725361","description":"n Ulcer; Scleroderma, Systemic","metadata":null},{"id":"d46d2aa004894266a1709f093c252571","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","canonical_id":"clinicaltrials.gov:NCT03434041","description":"Depressive Disorder, Treatment-Resistant","metadata":null},{"id":"717f192d2c384484b956fe873d018ee8","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","canonical_id":"clinicaltrials.gov:NCT04544436","description":"Multiple Sclerosis","metadata":null},{"id":"b6661e51cf7d41879925606dfe2515a2","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH","canonical_id":"clinicaltrials.gov:NCT03985423","description":"Hemophagocytic Lymphohistiocytoses","metadata":null},{"id":"6a1788f670444c11946b77c9f88f4ffd","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00779220","description":"Rheumatoid Arthritis","metadata":null},{"id":"3c20528844af4511a307a53429a20fa2","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","canonical_id":"clinicaltrials.gov:NCT05503264","description":"NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis","metadata":null},{"id":"c69fbb38c3ba48058b1058797ec4a86b","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","canonical_id":"clinicaltrials.gov:NCT05271409","description":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","metadata":null},{"id":"52bc1a394b6c4cec9dbb4ab00ba1c768","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT06106828","description":"Thyroid Eye Disease","metadata":null},{"id":"30e7eac33842409d8f8cf26d7e2e7a5a","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy","canonical_id":"clinicaltrials.gov:NCT05470985","description":"Crohn Disease","metadata":null},{"id":"2618032ce8b143568aca5a28d7b73f7c","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures","canonical_id":"clinicaltrials.gov:NCT04519645","description":"Electroencephalographic Neonatal Seizures; Epilepsy","metadata":null},{"id":"0a9a40efd4b04a8c9e86360a3f2e7f2e","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","canonical_id":"clinicaltrials.gov:NCT04666610","description":"Childhood Absence Epilepsy; Juvenile Absence Epilepsy","metadata":null},{"id":"d1db49c5856840379743ec9839a28808","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","canonical_id":"clinicaltrials.gov:NCT02418585","description":"Treatment-resistant Depression","metadata":null},{"id":"df181921917a47688236f511af779161","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","canonical_id":"clinicaltrials.gov:NCT02757768","description":"Benign Prostatic Hyperplasia; Overactive Bladder","metadata":null},{"id":"afa16eb366f24e57be6b473169f9eded","type":"TRIAL","name":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT04200456","description":"Primary Immune Thrombocytopenia","metadata":null},{"id":"0ad1690af947489bbfd6bf9acb10885a","type":"TRIAL","name":"A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT06238817","description":"Atopic Dermatitis","metadata":null},{"id":"5f51079f5cc94b5f9caa24b9bdfddd6c","type":"TRIAL","name":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","canonical_id":"clinicaltrials.gov:NCT03169959","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"93ab8ecd916a4ba2a644b4313a27d3bc","type":"TRIAL","name":"A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05599828","description":"Healthy Participants","metadata":null},{"id":"b3d0bf95aba54a69972010344ab12f5e","type":"TRIAL","name":"A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03783026","description":"Psoriatic Arthritis","metadata":null},{"id":"7b8db2b4fe574758ab688689c631042e","type":"TRIAL","name":"A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients","canonical_id":"clinicaltrials.gov:NCT06415292","description":"Acne Vulgaris","metadata":null},{"id":"ed1e831c1b89494db0ba21407bdaca43","type":"TRIAL","name":"A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis","canonical_id":"clinicaltrials.gov:NCT05517928","description":"Healthy","metadata":null},{"id":"c933c4881e6a4dd3a5de4d27de39dffc","type":"TRIAL","name":"A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT06454188","description":"Psoriatic Arthritis; Spondyloarthritis, Axial","metadata":null},{"id":"e5a6c5c054a54c7c84c27a3eb3b5aa36","type":"TRIAL","name":"A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01112787","description":"Acne Vulgaris","metadata":null},{"id":"7501ca092261497c863248012f586897","type":"TRIAL","name":"A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT03355573","description":"Ankylosing Spondylitis","metadata":null},{"id":"7d1820712e864a23a11570847e69b3e1","type":"TRIAL","name":"A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)","canonical_id":"clinicaltrials.gov:NCT03519945","description":"Ulcerative Colitis","metadata":null},{"id":"af740b47fe934e0ca0823e0a2e821bd4","type":"TRIAL","name":"A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03347110","description":"Psoriatic Arthritis","metadata":null},{"id":"8d5e2c2802cc45bb93e02153cf4b9054","type":"TRIAL","name":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT04432831","description":"Diabetic Macular Edema","metadata":null},{"id":"192942c3ec3f4bd48a21ad06232c7dd6","type":"TRIAL","name":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT04777201","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"57e809a2403b4521a0967b41ab15b3e9","type":"TRIAL","name":"A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT04877990","description":"Crohn Disease; Ulcerative Colitis","metadata":null},{"id":"10b620da2dee462faf46927cb9f09703","type":"TRIAL","name":"A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03230292","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"64a19640ec3641919710724235c39bd6","type":"TRIAL","name":"A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03010527","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"2e4b87591fda468ebc73c9443a6f6567","type":"TRIAL","name":"A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT04436640","description":"Axial Spondyloarthritis; Ankylosing Spondylitis; r-axSpa; Nr-axSpa","metadata":null},{"id":"f91deb30ba774f50892885c53634274a","type":"TRIAL","name":"A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT06028438","description":"Arthritis, Rheumatoid","metadata":null},{"id":"e3d009ca150e4f0c8ff18b0dc815f527","type":"TRIAL","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07155174","description":"Small Cell Lung Cancer","metadata":null},{"id":"33e9badd51664454ba4df3479b27ce46","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers","canonical_id":"clinicaltrials.gov:NCT02046629","description":"Multiple Sclerosis","metadata":null},{"id":"a96f5840751d41ecb50eb8575fa84c56","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT05517525","description":"Hepatic Impairment","metadata":null},{"id":"abf6e9c04b7e442ba50890a4eae3bb41","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03025542","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"65a699c63e14466d8b0f3e5f7be61d90","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT04882540","description":"Healthy Participants","metadata":null},{"id":"7806c11844da4ea1a16e32ed79cc5988","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage","canonical_id":"clinicaltrials.gov:NCT02300025","description":"Healthy Volunteer","metadata":null},{"id":"cfb37a4157504d649bb12913301efce6","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects","canonical_id":"clinicaltrials.gov:NCT04793204","description":"Healthy Volunteers","metadata":null},{"id":"054ec6ca3aee47f48e3ee6ba4fc3ca52","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes","canonical_id":"clinicaltrials.gov:NCT03714022","description":"Rheumatoid Arthritis","metadata":null},{"id":"3ca7c1a3ea1547dd83b99190cd66fb50","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC","canonical_id":"clinicaltrials.gov:NCT04398108","description":"HER2 Positive Metastatic Breast Cancer","metadata":null},{"id":"dcb84b587e59431e811be6d2672a68b3","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT00852137","description":"Actinic Keratosis","metadata":null},{"id":"ff6b0bd2c2524ddc9afe7f3669bf08d3","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT04211558","description":"Healthy Volunteer","metadata":null},{"id":"581db291726c43a9be2a32ece34b2370","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT03989544","description":"Asthma","metadata":null},{"id":"4e2e4feacbd04c26a580b5dae976c7bf","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)","canonical_id":"clinicaltrials.gov:NCT06987539","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"1913216c52fc4e4ab93c3dfd1fa8a39e","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)","canonical_id":"clinicaltrials.gov:NCT07211633","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"551d83d9b9e34a4e811e27b4dd987e73","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)","canonical_id":"clinicaltrials.gov:NCT01206517","description":"Schizophrenia; Bipolar I Disorder","metadata":null},{"id":"6102ff51b3f5423d9d0a3223f98ab853","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy","canonical_id":"clinicaltrials.gov:NCT03405714","description":"Epilepsy","metadata":null},{"id":"dfc264b2aecb4098b05496bcd900bdef","type":"TRIAL","name":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis","canonical_id":"clinicaltrials.gov:NCT03725007","description":"Juvenile Idiopathic Arthritis (JIA)","metadata":null},{"id":"b639f078a4404d9784fd036bf5125de4","type":"TRIAL","name":"A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00850681","description":"Actinic Keratosis","metadata":null},{"id":"d5ea1db4caa24be7a5cd9523047e2868","type":"TRIAL","name":"A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00850811","description":"Actinic Keratosis","metadata":null},{"id":"fdef0574fba24296b361d4abba9de5f7","type":"TRIAL","name":"A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01115322","description":"Acne Vulgaris","metadata":null},{"id":"09092833624f4c838871648bda904d38","type":"TRIAL","name":"A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT01119651","description":"Acne Vulgaris","metadata":null},{"id":"a582ec439714444db768aef766ee05c6","type":"TRIAL","name":"A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07827716","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"64ab7709b77040e79c2a963ac8f623ee","type":"TRIAL","name":"A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients","canonical_id":"clinicaltrials.gov:NCT06415279","description":"Acne Vulgaris","metadata":null},{"id":"3a26ce0cdf6a492c99c49fe07a6e1374","type":"TRIAL","name":"A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05028127","description":"Healthy Volunteers","metadata":null},{"id":"181eb4c67f8044efbe441792345e9fe1","type":"TRIAL","name":"A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT04528290","description":"Healthy Volunteers","metadata":null},{"id":"901d3d05a9634929b99f809c7504cc5b","type":"TRIAL","name":"A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria","canonical_id":"clinicaltrials.gov:NCT03118713","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"4598ff6f4533440080243d7a883b3ec1","type":"TRIAL","name":"A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT04647383","description":"Sleep Apnea, Obstructive; Pulmonary Disease, Chronic Obstructive; Respiration Disorders","metadata":null},{"id":"80955cb4278441f69a92a87302db7f06","type":"TRIAL","name":"A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT04109976","description":"Psoriatic Arthritis","metadata":null},{"id":"3f109a24203048279b231d4829233523","type":"TRIAL","name":"A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)","canonical_id":"clinicaltrials.gov:NCT03766685","description":"Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis","metadata":null},{"id":"820aa59c79a54813a28e8f7907d82e36","type":"TRIAL","name":"A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00719862","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"575e29caf532487faed54ba7349de152","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07023302","description":"Alopecia Areata","metadata":null},{"id":"c721f3dd63b74dd18e5f592f22fd65d1","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT06051786","description":"Allergic Rhinitis","metadata":null},{"id":"afd516512a7c410291375ef29fc13c70","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00660829","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"868053afd0b945e9a025572472490fe7","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00651118","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"61a85593c97d4448aa5cef5d9659ca70","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00883168","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"569f3784994a40639a33d910d76a5a19","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00824473","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"8fbac81cbec8477a8f473ccb4a2d0f52","type":"TRIAL","name":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00660517","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"4b39b31b8ca247eb8a5d44db4a51abdf","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)","canonical_id":"clinicaltrials.gov:NCT00442611","description":"Scleroderma, Diffuse; Scleroderma, Systemic","metadata":null},{"id":"2729e5fa465643daa4badc0a82d7caeb","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01028963","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"0546ba277dd8453caa5c55b68ed611b9","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00250575","description":"Schizophrenia","metadata":null},{"id":"5d479118e84b4d46ab48062a9bea2763","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT00918463","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"372c86a3f96b4996aebf1653cf484611","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","canonical_id":"clinicaltrials.gov:NCT05342623","description":"Chronic Kidney Diseases; Pruritus","metadata":null},{"id":"63f3ba4245304a849bfebf82e0a1a489","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp","canonical_id":"clinicaltrials.gov:NCT00669214","description":"Psoriasis","metadata":null},{"id":"eeb0f227fa314888898ff4c7c1f76e70","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet","canonical_id":"clinicaltrials.gov:NCT00312026","description":"Psoriasis","metadata":null},{"id":"f067c4e0e3334d6d9f6f46377275630d","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","canonical_id":"clinicaltrials.gov:NCT03886220","description":"Uterine Fibroids","metadata":null},{"id":"3990177a4cb244d08721b7206c40b83b","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema","canonical_id":"clinicaltrials.gov:NCT07290855","description":"Bradykinin-mediated Angioedema; Hereditary Angioedema (HAE)","metadata":null},{"id":"736fe273abe54e948018c9f5a2aade65","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","canonical_id":"clinicaltrials.gov:NCT05795699","description":"Fuchs Endothelial Corneal Dystrophy","metadata":null},{"id":"242eb8a0d003498587997cf178c67ea5","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT03671018","description":"B-cell Non-Hodgkin Lymphoma","metadata":null},{"id":"de59ba22e9a04b13a77fc37df741b107","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","canonical_id":"clinicaltrials.gov:NCT06663137","description":"Non Muscle Invasive Bladder Cancer","metadata":null},{"id":"418d3154be9d4b9a9481f2c2cdbb7f8a","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","canonical_id":"clinicaltrials.gov:NCT02292719","description":"Chronic Hepatitis C Virus Infection","metadata":null},{"id":"9f34fe3c665e4e3b9aa0e902bed14c04","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis","canonical_id":"clinicaltrials.gov:NCT00646035","description":"End Stage Renal Disease","metadata":null},{"id":"6dc5043304f6445ea36130afdf4b1212","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04182204","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"41e69becd43743458b2862d687bc43d8","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","canonical_id":"clinicaltrials.gov:NCT04660539","description":"Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"e6668f3fcf0744ed9d711aa4b7426a38","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne","canonical_id":"clinicaltrials.gov:NCT01017120","description":"Acne Vulgaris","metadata":null},{"id":"43470a7837994a7bbfd43eabba537f66","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301","canonical_id":"clinicaltrials.gov:NCT01017146","description":"Acne Vulgaris","metadata":null},{"id":"76139ab112e147fd85031484713e6c5f","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT00741884","description":"Smoking Cessation","metadata":null},{"id":"ba61c995b5bc47c9ae8f9f940f409c2a","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT00720278","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"20d544e78b9341dc834a56eca7bb7d26","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304","canonical_id":"clinicaltrials.gov:NCT02656303","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"366af3d4f4084d6694099b7791e13880","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)","canonical_id":"clinicaltrials.gov:NCT02819635","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"c128c15442934b8c9b0250e0da7f8a66","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","canonical_id":"clinicaltrials.gov:NCT01369355","description":"Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease","metadata":null},{"id":"8f91ad070d8a42a3a59ad58dfa91b12b","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01018862","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"4dcb7cfb665c4fd3980bc6e3eeae3210","type":"TRIAL","name":"A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies","canonical_id":"clinicaltrials.gov:NCT01368445","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"9a22f29acfc94717bbef65f1508d96dc","type":"TRIAL","name":"A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT07843693","description":"Healthy Volunteers","metadata":null},{"id":"e924e37eaafb4fe98a5533de444ffee0","type":"TRIAL","name":"A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT04604782","description":"Myocardial Ischemia; Coronary Artery Disease","metadata":null},{"id":"0aa3c84dd7b4410c9f010edb5e2832e6","type":"TRIAL","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","canonical_id":"clinicaltrials.gov:NCT05824975","description":"Advanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian Cancer (PROC); Hepatocellular Carcinoma (HCC); Colorectal Cancer (CRC); HER2 Negative Breast Cancer; Cutaneous Melanoma; Renal Cell Carcinoma (RCC)","metadata":null},{"id":"ebafe9b3879a44b49d2d7089c74878c0","type":"TRIAL","name":"A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","canonical_id":"clinicaltrials.gov:NCT03685630","description":"Partial Seizures With or Without Secondary Generalization; Epilepsy","metadata":null},{"id":"d1394cd8bf894c3ca53dc7891bf43fc4","type":"TRIAL","name":"A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)","canonical_id":"clinicaltrials.gov:NCT00092027","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"554b482c21e84797b2f1ac2adb99d401","type":"TRIAL","name":"A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)","canonical_id":"clinicaltrials.gov:NCT01004263","description":"Acute Migraine With or Without Aura in Adolescents","metadata":null},{"id":"8b0d8ce4f46e41ab9fcd7bd4d9caf059","type":"TRIAL","name":"A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT05176951","description":"Pulmonary Hypertension","metadata":null},{"id":"82e59e84fe274527b25c01a0280dfb7f","type":"TRIAL","name":"A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00720382","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"971f58b551644aef875299f6e6bdf5bd","type":"TRIAL","name":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","canonical_id":"clinicaltrials.gov:NCT04982549","description":"Unresectable Stage III NSCLC","metadata":null},{"id":"54ba2dd7d31e4e0d9b610ab1a1ac0d93","type":"TRIAL","name":"A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.","canonical_id":"clinicaltrials.gov:NCT04573556","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"1db2c4687231453abd6c8011db24d6a1","type":"TRIAL","name":"A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT07652515","description":"Neoplasms, Endometrial","metadata":null},{"id":"13ead0868ebe4d389d5145dda7b773ac","type":"TRIAL","name":"A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)","canonical_id":"clinicaltrials.gov:NCT06897527","description":"Neoplasms, Endometrial","metadata":null},{"id":"de0df3cd8d294fe1866b52a3a68e4fb8","type":"TRIAL","name":"A Study to Evaluate the Safety of Empliciti\u00ae (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan","canonical_id":"clinicaltrials.gov:NCT06163040","description":"Relapsed or Refractory Multiple Myeloma","metadata":null},{"id":"5c9b0edcd6d7434d9a1b88087ad82d05","type":"TRIAL","name":"A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease","canonical_id":"clinicaltrials.gov:NCT01400503","description":"Multicentric Castleman's Disease","metadata":null},{"id":"7ce2a4b4737949d19ed3a864415437f3","type":"TRIAL","name":"A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants","canonical_id":"clinicaltrials.gov:NCT06133049","description":"Multiple Sclerosis","metadata":null},{"id":"63173481445b4cb29d1dbeca1f2024ed","type":"TRIAL","name":"A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants","canonical_id":"clinicaltrials.gov:NCT06126835","description":"Ulcerative Colitis","metadata":null},{"id":"b46bff5c50de4104ac74a2fd5034f800","type":"TRIAL","name":"A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g","canonical_id":"clinicaltrials.gov:NCT00096603","description":"Psoriasis","metadata":null},{"id":"90be9d22959340b7a21aea27b9958b92","type":"TRIAL","name":"A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT04406649","description":"Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"84d8427aa4724677a584e5787aeaf330","type":"TRIAL","name":"A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT02902809","description":"Inadequately Controlled Asthma","metadata":null},{"id":"0434f6df01f14f0fb5b1831326dda49f","type":"TRIAL","name":"A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18","canonical_id":"clinicaltrials.gov:NCT04808505","description":"Glycogen Storage Disease Type II Infantile Onset","metadata":null},{"id":"ef6b9e17697c4342abe67f7a564d267b","type":"TRIAL","name":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir","canonical_id":"clinicaltrials.gov:NCT02569710","description":"Chronic Hepatitis C","metadata":null},{"id":"948af88ebb2246cd9db70eb8d1df8646","type":"TRIAL","name":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","canonical_id":"clinicaltrials.gov:NCT04449874","description":"Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors","metadata":null},{"id":"d30bbbe350b24b46bf726f1e907d5d59","type":"TRIAL","name":"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02514668","description":"Plasma Cell Myeloma","metadata":null},{"id":"4887b0c8d6e1417a8c87fe86c712f6f8","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","canonical_id":"clinicaltrials.gov:NCT04392648","description":"Relapsed and/or Refractory Multiple Myeloma","metadata":null},{"id":"9be2a3b7a14243488ff9be9263d9e4f8","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients","canonical_id":"clinicaltrials.gov:NCT05729074","description":"Mild to Moderate Atopic Dermatitis","metadata":null},{"id":"8a53103974484fbb88f88f6b20bac94c","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04154800","description":"Health Participants","metadata":null},{"id":"dd41d32755a34926a460aa0658cfae21","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06144697","description":"Healthy Participants","metadata":null},{"id":"259b687065734d9c85718eaad0943be2","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT05255601","description":"Lymphoma, Non-Hodgkin; Hodgkin Disease","metadata":null},{"id":"69ada241ddc441a5a7c0f660b584f1ab","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)","canonical_id":"clinicaltrials.gov:NCT07425522","description":"Diabetic Macular Edema","metadata":null},{"id":"feb9e3be3431439aa88a3fe2b6da1fa4","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)","canonical_id":"clinicaltrials.gov:NCT01449461","description":"Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"35655d7816b54dbdbd9311e207314658","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT06850922","description":"Diabetic Macular Edema","metadata":null},{"id":"38d5daf67ef047aa89a7d19a6f1191d0","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04828343","description":"Healthy Study Participants","metadata":null},{"id":"f7cb6724a4134d1d814421d7479d7003","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT02841995","description":"Graft vs Host Disease","metadata":null},{"id":"a3287b5f6e7942d784f6419bcd43ce9e","type":"TRIAL","name":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant","canonical_id":"clinicaltrials.gov:NCT06213818","description":"Healthy Participants","metadata":null},{"id":"77e7bc18fda246ce8029ef87568802da","type":"TRIAL","name":"A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC","canonical_id":"clinicaltrials.gov:NCT04024813","description":"Primary Sclerosing Cholangitis","metadata":null},{"id":"31df9b58ca5e401592675a717b41ebdf","type":"TRIAL","name":"A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age","canonical_id":"clinicaltrials.gov:NCT00834041","description":"Hypertension","metadata":null},{"id":"79b7497fe2a54550a2b10b2a70b87c23","type":"TRIAL","name":"A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05956002","description":"Healthy Participants","metadata":null},{"id":"9f69fa8f8250426da67aca9e535388e6","type":"TRIAL","name":"A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-na\u00efve and Biologic-na\u00efve Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT07430306","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"6048b1f45506421b80da584e23c0966f","type":"TRIAL","name":"A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease","canonical_id":"clinicaltrials.gov:NCT00864201","description":"Hypertension, Pulmonary; Connective Tissue Disease","metadata":null},{"id":"b740748481f6468d9f2aece7594f9382","type":"TRIAL","name":"A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients","canonical_id":"clinicaltrials.gov:NCT00000945","description":"HIV Infections; Leukoencephalopathy, Progressive Multifocal","metadata":null},{"id":"24f77cd3425c418cadcd10fdafd8c0b0","type":"TRIAL","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","canonical_id":"clinicaltrials.gov:NCT06746116","description":"Advanced or Recurrent Endometrial Cancer","metadata":null},{"id":"99f4974b5c124364b82b678f77380714","type":"TRIAL","name":"A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05382715","description":"Colitis, Ulcerative","metadata":null},{"id":"ef9758235c2f40a98c7449c200966eaa","type":"TRIAL","name":"A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT02922933","description":"Volunteers; Healthy Volunteers; Human Volunteers; Normal Volunteers","metadata":null},{"id":"f8cea5e0d5054f5da7285caee1207537","type":"TRIAL","name":"A Study to Examine the Efficacy and Safety of Meridia\u00ae (Sibutramine Hydrochloride) in Binge-Eating Disorder","canonical_id":"clinicaltrials.gov:NCT00402584","description":"Binge Eating Disorder; Obesity","metadata":null},{"id":"c9febafebe4846b08ff405dd7a78e57a","type":"TRIAL","name":"A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)","canonical_id":"clinicaltrials.gov:NCT03492281","description":"Overactive Bladder","metadata":null},{"id":"406a26ff9ace4679bca46e59b8b09f87","type":"TRIAL","name":"A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects","canonical_id":"clinicaltrials.gov:NCT00402077","description":"Overweight; Obesity","metadata":null},{"id":"d40da8da5a80491f924f97bf4cb25cbc","type":"TRIAL","name":"A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects","canonical_id":"clinicaltrials.gov:NCT00053378","description":"Hypocalcemia","metadata":null},{"id":"5293b88651f3442492e23fdbc9ff602d","type":"TRIAL","name":"A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02001584","description":"Healthy Volunteers;; Obese, Otherwise Healthy Volunteers","metadata":null},{"id":"4955c06289894b338cc20c03484953f5","type":"TRIAL","name":"A Study to Explore the Effect of Acid-reducing Agents","canonical_id":"clinicaltrials.gov:NCT04935112","description":"Healthy Adults","metadata":null},{"id":"e15da2f4197143f781225b8c25802821","type":"TRIAL","name":"A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache","canonical_id":"clinicaltrials.gov:NCT03107052","description":"Cluster Headache","metadata":null},{"id":"d42ccbd5a9ec406985051209825d99d3","type":"TRIAL","name":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study","canonical_id":"clinicaltrials.gov:NCT05954429","description":"Colorectal Cancer","metadata":null},{"id":"ab1df9d1577d4245b4af39c7cf114323","type":"TRIAL","name":"A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT04003389","description":"Hot Flashes","metadata":null},{"id":"2a77277154024060bac83ba9f3813b5e","type":"TRIAL","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab","canonical_id":"clinicaltrials.gov:NCT04590326","description":"Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancer","metadata":null},{"id":"626ed662102f489cb86e890b0b1bfe50","type":"TRIAL","name":"A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT04003155","description":"Hot Flashes","metadata":null},{"id":"9cf9689e7a134298bab5843063f74656","type":"TRIAL","name":"A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2","canonical_id":"clinicaltrials.gov:NCT04003142","description":"Hot Flashes","metadata":null},{"id":"0a2fad6411b9429c9daad5ff6aa45732","type":"TRIAL","name":"A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT04234204","description":"Hot Flashes","metadata":null},{"id":"0b832009a4384e5ea1a0507659e545aa","type":"TRIAL","name":"A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India","canonical_id":"clinicaltrials.gov:NCT07685769","description":"Acute Treatment of Migraine","metadata":null},{"id":"67f2608961c1404581cdab759f0c6368","type":"TRIAL","name":"A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause","canonical_id":"clinicaltrials.gov:NCT05034042","description":"Hot Flashes","metadata":null},{"id":"cb300c4f9ae54a35bf04956dc97dffe5","type":"TRIAL","name":"A Study to Improve the Collaboration Between Primary and Secondary Health Care on the Treatment of Osteoporosis After a Hip Fracture.","canonical_id":"clinicaltrials.gov:NCT05904353","description":"Hip Fractures; Osteoporosis; Zoledronic Acid; Ambulant Nurse; Case Manager","metadata":null},{"id":"fad6a16c0f8343f48b169b5c1cf5ac71","type":"TRIAL","name":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07312851","description":"Healthy Participants","metadata":null},{"id":"beea6585a01949ddbc431c6a4bedf859","type":"TRIAL","name":"A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Na\u00efve Participants With Diabetic Macular Edema Treated With Faricimab","canonical_id":"clinicaltrials.gov:NCT04597918","description":"Diabetic Macular Edema","metadata":null},{"id":"5e8af748a57a4a478b3513c71cfc3de2","type":"TRIAL","name":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03914625","description":"B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome","metadata":null},{"id":"04b7a5728c574039bfe3b96d4f00553e","type":"TRIAL","name":"A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab","canonical_id":"clinicaltrials.gov:NCT06706817","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"76168070741b4850873330a4670d1da2","type":"TRIAL","name":"A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05965570","description":"Healthy Volunteers","metadata":null},{"id":"04b132dd78e64e0da0aa145986dfe90a","type":"TRIAL","name":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","canonical_id":"clinicaltrials.gov:NCT06263231","description":"Sarcoma,Soft Tissue","metadata":null},{"id":"96192e3ddb89408c96df94275fcdb94b","type":"TRIAL","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged \u2265 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","canonical_id":"clinicaltrials.gov:NCT05941897","description":"Advanced or Metastatic NSCLC","metadata":null},{"id":"b6b41933b8cb435c994db5400f7cd2ee","type":"TRIAL","name":"A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)","canonical_id":"clinicaltrials.gov:NCT02788279","description":"Colorectal Cancer","metadata":null},{"id":"9b76121abaa843a5a9057bd68bf0c3ff","type":"TRIAL","name":"A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05680740","description":"Psoriasis","metadata":null},{"id":"1713050392fb4a0c9304ddbd182af8bb","type":"TRIAL","name":"A Study to Investigate Efficacy and Safety of VTAMA\u00ae (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region","canonical_id":"clinicaltrials.gov:NCT05789576","description":"Psoriasis","metadata":null},{"id":"4dff3dcf6fa44ad991378e9a55d4ab40","type":"TRIAL","name":"A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT05224102","description":"Diabetic Macular Edema","metadata":null},{"id":"1c1dfcec6a5c4d9f8bfa3d290e89a2b1","type":"TRIAL","name":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","canonical_id":"clinicaltrials.gov:NCT07433569","description":"Asthma","metadata":null},{"id":"64efd044006d43ff9f27a4aef0c005cb","type":"TRIAL","name":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","canonical_id":"clinicaltrials.gov:NCT01655069","description":"Urinary Bladder, Overactive","metadata":null},{"id":"a9be4cb0921744a3b52a5186d2edefeb","type":"TRIAL","name":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)","canonical_id":"clinicaltrials.gov:NCT06687967","description":"Lichen Simplex Chronicus","metadata":null},{"id":"1d5244fb9ba149948817927449da1e86","type":"TRIAL","name":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","canonical_id":"clinicaltrials.gov:NCT06207123","description":"Acute Leukemia; Lymphoblastic Leukemia; Lymphoblastic Lymphoma","metadata":null},{"id":"f86668f820e74906a17c9089c623b969","type":"TRIAL","name":"A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)","canonical_id":"clinicaltrials.gov:NCT07684599","description":"Neoplasms, Endometrial","metadata":null},{"id":"6f557d1d29bb42eb97da072bfb1b0481","type":"TRIAL","name":"A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab","canonical_id":"clinicaltrials.gov:NCT07520162","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"7354891a8f1e4edf8f3b3e7a6b0df24c","type":"TRIAL","name":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","canonical_id":"clinicaltrials.gov:NCT07221838","description":"Generalized Myasthenia Gravis; gMG","metadata":null},{"id":"9f959b5fb92b45eaaa4b73e4606ef3b0","type":"TRIAL","name":"A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function","canonical_id":"clinicaltrials.gov:NCT06858696","description":"Hepatic Insufficiency","metadata":null},{"id":"6f0fa720eeb74f90916aaa9e79a2068c","type":"TRIAL","name":"A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT07630714","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"0078d5ea25fd4c1e8c10c8e9808713be","type":"TRIAL","name":"A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)","canonical_id":"clinicaltrials.gov:NCT02986373","description":"Psoriatic Arthritis","metadata":null},{"id":"c99cd5a5e8834f799b65b1c24409e1ed","type":"TRIAL","name":"A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN","canonical_id":"clinicaltrials.gov:NCT05856760","description":"Immunoglobulin A Nephropathy","metadata":null},{"id":"67a79ce16b1f4444961845b36eeb17fa","type":"TRIAL","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","canonical_id":"clinicaltrials.gov:NCT05801029","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"dfd053523fdd4f099aebc33f5ebaddea","type":"TRIAL","name":"A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT07265479","description":"Atopic Dermatitis","metadata":null},{"id":"a86c42ac3d254e1eaefbb8d08c4b12d4","type":"TRIAL","name":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT06716424","description":"Type 2 Diabetes","metadata":null},{"id":"6ae57e0435ba4439a9073f62e98d78de","type":"TRIAL","name":"A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)","canonical_id":"clinicaltrials.gov:NCT07135973","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"dd04529c30a44c998d71cd914df978d2","type":"TRIAL","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05704049","description":"Relapsed/Refractory Multiple Myeloma","metadata":null},{"id":"cd564e00a6554312a2ebbb0a960a9e92","type":"TRIAL","name":"A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients","canonical_id":"clinicaltrials.gov:NCT06199557","description":"Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes, Adult","metadata":null},{"id":"960779064d334d70bfae28714e629c81","type":"TRIAL","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT07154290","description":"Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Carcinoma Non Small Cell Lung","metadata":null},{"id":"3079b789469943d2a81dd6a3827f36df","type":"TRIAL","name":"A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)","canonical_id":"clinicaltrials.gov:NCT05419401","description":"Healthy Volunteer","metadata":null},{"id":"72c3adf29e3b4e68a1b9ef7c7c473a09","type":"TRIAL","name":"A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects","canonical_id":"clinicaltrials.gov:NCT03204474","description":"Healthy Male Chinese Volunteers","metadata":null},{"id":"babd8fc234b2412a8c303a0a1bc23b70","type":"TRIAL","name":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","canonical_id":"clinicaltrials.gov:NCT03319667","description":"Plasma Cell Myeloma","metadata":null},{"id":"1ef505fb77f74ec9ac7fa366ee17ef48","type":"TRIAL","name":"A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT01710670","description":"Healthy Volunteers","metadata":null},{"id":"dd8f4d76143c43e5bd0319c7effeab6b","type":"TRIAL","name":"A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05069870","description":"Healthy Subjects","metadata":null},{"id":"ce3ffd7e809c4dca92a6255f85d8b4e1","type":"TRIAL","name":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06948747","description":"Healthy Participants","metadata":null},{"id":"4b5a572546284290973b088c0fdd8aed","type":"TRIAL","name":"A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07088913","description":"Healthy Participants","metadata":null},{"id":"e9fa225dd6cc4f21b8b314380f72cff5","type":"TRIAL","name":"A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT04501640","description":"Pharmacokinetics of Mirabegron; Food Effect; Healthy Chinese Subjects","metadata":null},{"id":"95f6187e235c481a8e7f821092647a75","type":"TRIAL","name":"A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State","canonical_id":"clinicaltrials.gov:NCT02608034","description":"Metastatic Melanoma, BRAF V600 Mutation Positive","metadata":null},{"id":"71a5ecd1c65c4d1d90fb8e27adf055a5","type":"TRIAL","name":"A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function","canonical_id":"clinicaltrials.gov:NCT04482270","description":"Hepatic Impairment; Healthy Volunteers","metadata":null},{"id":"94a06f1f86b54588b1968895a5824422","type":"TRIAL","name":"A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02447315","description":"Healthy Subjects","metadata":null},{"id":"0743491c5f1d4a049f4563a8ceca17fc","type":"TRIAL","name":"A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function","canonical_id":"clinicaltrials.gov:NCT04476849","description":"Healthy Volunteers; Renal Impairment","metadata":null},{"id":"141bd77a31bd4278931ff24a127f5629","type":"TRIAL","name":"A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin","canonical_id":"clinicaltrials.gov:NCT01519128","description":"Healthy","metadata":null},{"id":"faf522cbd9894164aac4f39d60f13121","type":"TRIAL","name":"A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril","canonical_id":"clinicaltrials.gov:NCT06292091","description":"Hypertension","metadata":null},{"id":"dcb58cdb98b748968257c5981cf11471","type":"TRIAL","name":"A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants","canonical_id":"clinicaltrials.gov:NCT05985590","description":"Healthy Volunteers","metadata":null},{"id":"08f6a71ce1a64908abab111cb9bc3690","type":"TRIAL","name":"A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05355935","description":"Healthy Volunteer","metadata":null},{"id":"a92c49093488480c9cae5629abd718d4","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)","canonical_id":"clinicaltrials.gov:NCT06455449","description":"Polymyositis, Dermatomyositis","metadata":null},{"id":"792d472a8d6c404184cb039557d19972","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma","canonical_id":"clinicaltrials.gov:NCT04321330","description":"Carcinoma, Thymic","metadata":null},{"id":"6a474a3f964d4a1794d81efe65edafa8","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease","canonical_id":"clinicaltrials.gov:NCT07771439","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"c38ed44d793b495cb08010c19f7cc88e","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT03170518","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"502acf33927c48888de10f5050c00f66","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03264066","description":"Solid Tumors","metadata":null},{"id":"79d70d1b81134ae7872c1d6a510d0f7e","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged \u226518 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))","canonical_id":"clinicaltrials.gov:NCT05731128","description":"Colitis Ulcerative","metadata":null},{"id":"93d853c2eb3548cd9bd9c547cc245b27","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT07412470","description":"Kidney Transplant Rejection","metadata":null},{"id":"05d50c5b0a7d40e7bb65f39b7811656f","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC","canonical_id":"clinicaltrials.gov:NCT06478043","description":"Small-cell Lung Cancer","metadata":null},{"id":"737522450ab4478eb8cbe8aac52d1c04","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT01054443","description":"Immune Thrombocytopenia (ITP)","metadata":null},{"id":"8be1e26e00634e1aab7357d5dc5d0546","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma","canonical_id":"clinicaltrials.gov:NCT06023589","description":"Asthma","metadata":null},{"id":"83f96f535b034f608106e24da36ce814","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","canonical_id":"clinicaltrials.gov:NCT06883305","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"77f4c8966e794e7b9268e3464e13acbc","type":"TRIAL","name":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)","canonical_id":"clinicaltrials.gov:NCT06878261","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"8a9ff0665bdf4003b524e7d2da1b123a","type":"TRIAL","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","canonical_id":"clinicaltrials.gov:NCT06008093","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"4a3af0aa1cff425a9c3a036c3214d364","type":"TRIAL","name":"A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)","canonical_id":"clinicaltrials.gov:NCT06716606","description":"Connective Tissue Diseases","metadata":null},{"id":"b494e5b6b2d74758b88b2e2bcb99b23e","type":"TRIAL","name":"A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]","canonical_id":"clinicaltrials.gov:NCT01280721","description":"Autosomal Dominant Polycystic Kidney Disease \uff08ADPKD)","metadata":null},{"id":"701cbc5c34a54bdb827010faf8ea27df","type":"TRIAL","name":"A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT04124965","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"5fb66a1be5e143008434f84517b6e58d","type":"TRIAL","name":"A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT04596995","description":"Primary Immune Thrombocytopenia","metadata":null},{"id":"fbab89afb4be4cb29d179e4a4c1b9a51","type":"TRIAL","name":"A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT01125514","description":"Heart Failure","metadata":null},{"id":"287ec9bb2d3f4ad78127f8bce3d13c77","type":"TRIAL","name":"A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07198087","description":"Primary Central Nervous System Lymphoma (PCNSL)","metadata":null},{"id":"730118836ad24e67a969e716540785f5","type":"TRIAL","name":"A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.","canonical_id":"clinicaltrials.gov:NCT02040597","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"70499f3dc5254e11bc880d2731922275","type":"TRIAL","name":"A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00687700","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"22942f5e957640a78ba83dc30941d463","type":"TRIAL","name":"A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03103568","description":"Drug Drug Interaction","metadata":null},{"id":"f9356f8f49434d82935e621ebed4065a","type":"TRIAL","name":"A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03922997","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"77f4fb48850c49a2b4fd0e8326f58d2e","type":"TRIAL","name":"A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)","canonical_id":"clinicaltrials.gov:NCT03311854","description":"Macrophage Activation Syndrome; Lymphohistiocytosis, Hemophagocytic; Arthritis, Juvenile; Adult Onset Still Disease","metadata":null},{"id":"8623ee45ddae4f9492737f2fb1b37769","type":"TRIAL","name":"A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","canonical_id":"clinicaltrials.gov:NCT05826353","description":"Fuchs Endothelial Corneal Dystrophy","metadata":null},{"id":"fcc6e8603e9b459595d06bac8269aaba","type":"TRIAL","name":"A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT06507306","description":"Solid Tumor, Adult","metadata":null},{"id":"153c80054f5f4232afddda5b702fb4a1","type":"TRIAL","name":"A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT05528172","description":"Corneal Edema After Cataract Surgery","metadata":null},{"id":"4cc364cb6149477b87ff3f7be6ba755d","type":"TRIAL","name":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","canonical_id":"clinicaltrials.gov:NCT05735184","description":"Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML; AML With Mutated NPM1; Acute Myeloid Leukemia Recurrent; Acute Myeloid Leukemia, in Relapse; NPM1 Mutation; KMT2Ar; Myeloid Sarcoma; Nucleophosmin 1-mutated Acute Myeloid Leukemia","metadata":null},{"id":"a19a84f9132b4d6e89b5c06baa6a6889","type":"TRIAL","name":"A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive","canonical_id":"clinicaltrials.gov:NCT02993250","description":"Hepatitis C, Chronic","metadata":null},{"id":"7ee39ac64a774c07b142b0185d381ac7","type":"TRIAL","name":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07667322","description":"Multiple Sclerosis","metadata":null},{"id":"d838e121a99643419cc7a6bffb341a11","type":"TRIAL","name":"A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT06839872","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"72136c026acf48f69ca4e54d0d5e4694","type":"TRIAL","name":"A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT05721950","description":"Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"89b9f731b47a43c1b93e4d9b9f44e5bb","type":"TRIAL","name":"A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food","canonical_id":"clinicaltrials.gov:NCT06369454","description":"Healthy Volunteers","metadata":null},{"id":"80dc13a0eaa84a9a80cad711a28de16d","type":"TRIAL","name":"A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.","canonical_id":"clinicaltrials.gov:NCT06678555","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"9a1ca9e859b94ea2b1c9b2af6506dd03","type":"TRIAL","name":"A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled","canonical_id":"clinicaltrials.gov:NCT06282991","description":"Non-Small Cell Lung Carcinoma","metadata":null},{"id":"1e735ce28d894ab5b43ee85f8f08c159","type":"TRIAL","name":"A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07029711","description":"Severe Alopecia Areata","metadata":null},{"id":"07e6d1e4b3df4600b3037a1da2e242bd","type":"TRIAL","name":"A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment","canonical_id":"clinicaltrials.gov:NCT07567352","description":"Non-Small-Cell Lung; ALK-positive Advanced NSCLC; ALK-positive Non-small-cell Lung Cancer; ALK-positive NSCLC","metadata":null},{"id":"d144c3b19d42451d9e487df33e620ac8","type":"TRIAL","name":"A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics","canonical_id":"clinicaltrials.gov:NCT07406282","description":"Prostatic Neoplasms; Metastatic Hormone-Sensitive Prostate Cancer","metadata":null},{"id":"73455330d1954efaaadd7eb149136d57","type":"TRIAL","name":"A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.","canonical_id":"clinicaltrials.gov:NCT07219615","description":"Chronic Spontaneous Urticaria","metadata":null},{"id":"ed811f3248d34741b6ed272df0991e07","type":"TRIAL","name":"A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC","canonical_id":"clinicaltrials.gov:NCT07556549","description":"Non-Small Cell Lung Cancer ALK-positive","metadata":null},{"id":"63bc6f1ab6494918b4cebd63e64be462","type":"TRIAL","name":"A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06172348","description":"Healthy Volunteers","metadata":null},{"id":"294eeb2153b54ebb88a961773deb63a1","type":"TRIAL","name":"A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database","canonical_id":"clinicaltrials.gov:NCT04923139","description":"Treatment of Venous Thromboembolism","metadata":null},{"id":"cffcd29205c94f2f8e50550718e1a2d0","type":"TRIAL","name":"A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe","canonical_id":"clinicaltrials.gov:NCT04925180","description":"Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea; Hypersexuality in Men; Sexual Deviations in Men; Prostate Cancer","metadata":null},{"id":"2431f4dc11c8475b9e8198bfe7047db9","type":"TRIAL","name":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","canonical_id":"clinicaltrials.gov:NCT05834348","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"c4a8ac8e91744c70aa3b02657385b8f3","type":"TRIAL","name":"A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT06294925","description":"Colitis, Ulcerative","metadata":null},{"id":"142e99db7d064f8da33b21bb12fb6c60","type":"TRIAL","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","canonical_id":"clinicaltrials.gov:NCT07723248","description":"Metastatic Castration Resistant Prostate Cancer","metadata":null},{"id":"7c911f69013a4cb0b1012ec5a5b8946b","type":"TRIAL","name":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","canonical_id":"clinicaltrials.gov:NCT06551324","description":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","metadata":null},{"id":"8274279a84fd446a97afe359fe1b6fb2","type":"TRIAL","name":"A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment","canonical_id":"clinicaltrials.gov:NCT06848088","description":"Melanoma","metadata":null},{"id":"32d44275997242baa2dc5d1c19d0e9b8","type":"TRIAL","name":"A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants","canonical_id":"clinicaltrials.gov:NCT05371652","description":"Acute Migraine","metadata":null},{"id":"6aa7183de8bf484c84bdc4a3b6556420","type":"TRIAL","name":"A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings","canonical_id":"clinicaltrials.gov:NCT07200128","description":"Severe Alopecia Areata","metadata":null},{"id":"fac92f7114c340fa9d11ff7de9bdbf75","type":"TRIAL","name":"A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.","canonical_id":"clinicaltrials.gov:NCT05810038","description":"Migraine","metadata":null},{"id":"43ccf199209043afac19797aacd9207a","type":"TRIAL","name":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","canonical_id":"clinicaltrials.gov:NCT07483632","description":"Relapsing Forms of Multiple Sclerosis","metadata":null},{"id":"7a34e909758b44b38a119a2fef3b2e17","type":"TRIAL","name":"A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine","canonical_id":"clinicaltrials.gov:NCT07609914","description":"Acute Treatment of Migraine","metadata":null},{"id":"01ee622483d34dbe964de4da98e9d079","type":"TRIAL","name":"A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction","canonical_id":"clinicaltrials.gov:NCT05224609","description":"Moderate Hepatic Impairment; Severe Hepatic Impairment; Healthy Volunteers","metadata":null},{"id":"3a96ea070c9446849b77316ef906f758","type":"TRIAL","name":"A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age","canonical_id":"clinicaltrials.gov:NCT05650333","description":"Alopecia Areata","metadata":null},{"id":"6c441c7507c644c095039547791f0221","type":"TRIAL","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","canonical_id":"clinicaltrials.gov:NCT07062965","description":"Breast Cancer","metadata":null},{"id":"00e8ab820f1a42f9a47adcadacc38dff","type":"TRIAL","name":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","canonical_id":"clinicaltrials.gov:NCT05355701","description":"Melanoma; Non-Small-Cell Lung Cancer; Thyroid Cancer; Glioma; Advanced Colorectal Cancer (Part 1)","metadata":null},{"id":"54403fed5e5b444baf011f77528f22fd","type":"TRIAL","name":"A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine","canonical_id":"clinicaltrials.gov:NCT06616194","description":"Migraine","metadata":null},{"id":"a4a7409a2efd4192b181374321a6d75d","type":"TRIAL","name":"A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT07729462","description":"Preventive Treatment of Migraine","metadata":null},{"id":"4379e9e972bb4ce8955b2d51815b15fb","type":"TRIAL","name":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","canonical_id":"clinicaltrials.gov:NCT06641466","description":"Menstrual Migraine","metadata":null},{"id":"c126f36cfd3448e79b23b2c8eda8b968","type":"TRIAL","name":"A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema","canonical_id":"clinicaltrials.gov:NCT07783425","description":"Atopic Dermatitis","metadata":null},{"id":"3d6abf0324784b0f86fddf6f392cd751","type":"TRIAL","name":"A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection","canonical_id":"clinicaltrials.gov:NCT05732454","description":"Atopic Dermatitis; Atopic Dermatitis, Unspecified; Eczema; Eczema, Atopic","metadata":null},{"id":"38846581a6ab4a199a2c76265a898aab","type":"TRIAL","name":"A Study to Learn About the Study Medicine NURTEC\u00ae ODT 75 mg After it is Released Into the Markets in Korea","canonical_id":"clinicaltrials.gov:NCT07497854","description":"Migraine With or Without Aura","metadata":null},{"id":"5b0dd734358242cf817a9ad2d471dba3","type":"TRIAL","name":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","canonical_id":"clinicaltrials.gov:NCT06704724","description":"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"2fd69ca8ea5c4535b0821e9b232768df","type":"TRIAL","name":"A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT06279234","description":"Type 2 Diabetes Mellitus (T2DM); Obesity","metadata":null},{"id":"d762558958dc4240af5a217e06abb631","type":"TRIAL","name":"A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07783282","description":"Prostate Cancer","metadata":null},{"id":"660ff8a42f344635af2b2c24109a9755","type":"TRIAL","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT07450599","description":"High-risk Localized Prostate Cancer","metadata":null},{"id":"bf59324cb32845f1bfb46d3f4e147ecb","type":"TRIAL","name":"A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women","canonical_id":"clinicaltrials.gov:NCT07153159","description":"Healthy Participant","metadata":null},{"id":"71c15c1055ec4d728c5e7908df6d244b","type":"TRIAL","name":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY\u00ae) in Participants Who Took it During Pregnancy And About the Health of Their Babies","canonical_id":"clinicaltrials.gov:NCT05688436","description":"Multiple Sclerosis","metadata":null},{"id":"41f6337bc6ef4ee6ac01c21ebc4cce29","type":"TRIAL","name":"A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy","canonical_id":"clinicaltrials.gov:NCT07029139","description":"Primary Membranous Nephropathy","metadata":null},{"id":"27660f39feae4f718a3355821d79398e","type":"TRIAL","name":"A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults","canonical_id":"clinicaltrials.gov:NCT07290036","description":"Psoriatic Arthritis; Axial Spondyloarthritis","metadata":null},{"id":"dcfbcd27626949c9a0fadc9cf529f8ba","type":"TRIAL","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT05785767","description":"Advanced Non-Small Cell Lung Cancer","metadata":null},{"id":"ef1c0648427843359e4a78037aea85b6","type":"TRIAL","name":"A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium","canonical_id":"clinicaltrials.gov:NCT01691482","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"e8b98794007a48dc84ec7b8386135700","type":"TRIAL","name":"A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication","canonical_id":"clinicaltrials.gov:NCT07612267","description":"Lactation; Inflammatory Bowel Disease","metadata":null},{"id":"256139ddb130452d96ceffb2ab85d477","type":"TRIAL","name":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","canonical_id":"clinicaltrials.gov:NCT06902545","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"f5675a8f7f1b4ef3a488a0c8c5f3fa88","type":"TRIAL","name":"A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin","canonical_id":"clinicaltrials.gov:NCT06603285","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"45a9cbccd261442a9e06a8475ca63ffe","type":"TRIAL","name":"A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet","canonical_id":"clinicaltrials.gov:NCT07184086","description":"Obesity","metadata":null},{"id":"74e9d2f2e83b407fa538181a034c0131","type":"TRIAL","name":"A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT07477704","description":"Hypercholesterolemia","metadata":null},{"id":"cf7909e37b724cff95512c9d435ef3bb","type":"TRIAL","name":"A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06624059","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"48778c9e1861488a99babf6c3682c845","type":"TRIAL","name":"A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)","canonical_id":"clinicaltrials.gov:NCT04786574","description":"Autosomal Recessive Polycystic Kidney Disease (ARPKD)","metadata":null},{"id":"2c4802adab6f4e07858df929ffbe875a","type":"TRIAL","name":"A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection","canonical_id":"clinicaltrials.gov:NCT06011954","description":"Urothelial Cancer","metadata":null},{"id":"f0c29e7d95b6438b928c583f5cb3ef03","type":"TRIAL","name":"A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)","canonical_id":"clinicaltrials.gov:NCT03435601","description":"Rheumatoid Arthritis","metadata":null},{"id":"2d81f862759e40e9a5384465024d939d","type":"TRIAL","name":"A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B","canonical_id":"clinicaltrials.gov:NCT05845645","description":"Healthy Study Participants","metadata":null},{"id":"76528887130e464e921424a596ee3f78","type":"TRIAL","name":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","canonical_id":"clinicaltrials.gov:NCT07235293","description":"Colorectal Cancer","metadata":null},{"id":"cff181dca14e4a83896e4edef14b00a1","type":"TRIAL","name":"A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT03971422","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"d72974b10ddf4888bd2e1b349d4e79d3","type":"TRIAL","name":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT04643483","description":"Crohn's Disease","metadata":null},{"id":"96c5b84619904d408ffa4216ff1ffe9a","type":"TRIAL","name":"A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","canonical_id":"clinicaltrials.gov:NCT06082037","description":"Lung Transplant Rejection","metadata":null},{"id":"207d340ff5cd4b7c9050320be14015bf","type":"TRIAL","name":"A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin","canonical_id":"clinicaltrials.gov:NCT04233801","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"f71f611c0cb540f5812b45deb5049fbc","type":"TRIAL","name":"A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis","canonical_id":"clinicaltrials.gov:NCT05065190","description":"Lung Diseases, Interstitial","metadata":null},{"id":"4394f9014be34279a70628e99a0c599c","type":"TRIAL","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07287150","description":"Metastatic Castration-Resistant Prostate Cancer","metadata":null},{"id":"f7af07b98e804f37b1f2b51930649631","type":"TRIAL","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07054190","description":"Breast Cancer","metadata":null},{"id":"1bcf1ff63427440e911100f734aea56b","type":"TRIAL","name":"A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT01683409","description":"Diabetic Kidney Disease","metadata":null},{"id":"543a0aa62d6a4f51b17e34c4dd4f74eb","type":"TRIAL","name":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT04978493","description":"Crohn Disease","metadata":null},{"id":"868abfa0609848b6a52164bd48073543","type":"TRIAL","name":"A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT04153929","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"649f569823744b12b9d92077274e40ff","type":"TRIAL","name":"A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06926660","description":"Chronic Kidney Disease","metadata":null},{"id":"210a705c2e094cba90eeab5348e5d57a","type":"TRIAL","name":"A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure","canonical_id":"clinicaltrials.gov:NCT06424288","description":"Heart Failure","metadata":null},{"id":"1062f6ddedec4108be37f1ad75982e77","type":"TRIAL","name":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","canonical_id":"clinicaltrials.gov:NCT06143891","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"b0bca77499594ff39ba54f6b1fda03c9","type":"TRIAL","name":"A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)","canonical_id":"clinicaltrials.gov:NCT03347188","description":"Post-Traumatic Headache","metadata":null},{"id":"7c182bc82a4b462ea595430f126d2891","type":"TRIAL","name":"A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome","canonical_id":"clinicaltrials.gov:NCT04447729","description":"Interstitial Cystitis","metadata":null},{"id":"66a7e15d9f3047e4a03ca5d1915bea91","type":"TRIAL","name":"A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age","canonical_id":"clinicaltrials.gov:NCT04464707","description":"Migraine","metadata":null},{"id":"6e1beffbf67a4d61acc9a92cffd07842","type":"TRIAL","name":"A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age","canonical_id":"clinicaltrials.gov:NCT04458857","description":"Migraine","metadata":null},{"id":"351138689c7e4b43bf60a36fe72eb99d","type":"TRIAL","name":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT05691478","description":"High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma","metadata":null},{"id":"13a3bf440ecf4225a8758e155e97e8dc","type":"TRIAL","name":"A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat\u00ae Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale","canonical_id":"clinicaltrials.gov:NCT04223843","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"782faba6bc834844823703055b99a2d9","type":"TRIAL","name":"A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)","canonical_id":"clinicaltrials.gov:NCT00152490","description":"Crohn's Disease","metadata":null},{"id":"0b8058722ed94887ad0c1fe17d378966","type":"TRIAL","name":"A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT03965091","description":"Fibromyalgia","metadata":null},{"id":"1d90905248ed4f389c59d32acb0cbf97","type":"TRIAL","name":"A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00088634","description":"Schizophrenia","metadata":null},{"id":"c5c0858d39f44a78953942e8e7d48f4a","type":"TRIAL","name":"A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT03215277","description":"Ankylosing Spondylitis","metadata":null},{"id":"2d630c74e668456491b1042dad6f8214","type":"TRIAL","name":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03895203","description":"Psoriatic Arthritis","metadata":null},{"id":"d854e06b442e44ffb9978bd7584e1a3a","type":"TRIAL","name":"A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.","canonical_id":"clinicaltrials.gov:NCT03248531","description":"Hidradenitis Suppurativa","metadata":null},{"id":"fc187c19893c486dabdaf4ca5c0f2e80","type":"TRIAL","name":"A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT05067335","description":"Osteoporosis","metadata":null},{"id":"e84639a850d74ea48b05a29c12db61c5","type":"TRIAL","name":"A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis","canonical_id":"clinicaltrials.gov:NCT04875975","description":"Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis","metadata":null},{"id":"ae754cacd35441aab04c4b13b0965cc2","type":"TRIAL","name":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","canonical_id":"clinicaltrials.gov:NCT06315322","description":"Childhood Absence Epilepsy; Juvenile Absence Epilepsy","metadata":null},{"id":"8ff0b507258847f69a1fb7650633ab2e","type":"TRIAL","name":"A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","canonical_id":"clinicaltrials.gov:NCT05109234","description":"Childhood Absence Epilepsy; Juvenile Absence Epilepsy","metadata":null},{"id":"cb0c8180627b474bbd26e5aaf38ddb62","type":"TRIAL","name":"A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT04901195","description":"Hidradenitis Suppurativa","metadata":null},{"id":"134ae704856f4d6ab3714084ad971d67","type":"TRIAL","name":"A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment","canonical_id":"clinicaltrials.gov:NCT04627285","description":"Epilepsy","metadata":null},{"id":"e7860b8457dd4b9b9cc715e296bb00bf","type":"TRIAL","name":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","canonical_id":"clinicaltrials.gov:NCT03325439","description":"Electroencephalographic Neonatal Seizures","metadata":null},{"id":"5892e26954394377b47c45f2b7a19f9f","type":"TRIAL","name":"A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)","canonical_id":"clinicaltrials.gov:NCT00813995","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"696e27e631874ee9944cae39b8e9d898","type":"TRIAL","name":"A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)","canonical_id":"clinicaltrials.gov:NCT00827918","description":"Schizophrenia","metadata":null},{"id":"f8543023d3e14a07bc5d37abc674ee27","type":"TRIAL","name":"A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures","canonical_id":"clinicaltrials.gov:NCT04715646","description":"Epilepsy","metadata":null},{"id":"da493ba056f04c59aa86fec488821077","type":"TRIAL","name":"A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00088621","description":"Schizophrenia","metadata":null},{"id":"af6bbaea27ce407f9cc8648329442268","type":"TRIAL","name":"A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude","canonical_id":"clinicaltrials.gov:NCT01794078","description":"Acute Mountain Sickness and Fatigue","metadata":null},{"id":"f2f01c346a624ecaa03c0aa2a01a7a4d","type":"TRIAL","name":"A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","canonical_id":"clinicaltrials.gov:NCT03250377","description":"Partial Seizures With or Without Secondary Generalization; Epilepsy","metadata":null},{"id":"258478c544b141f08acd80af9309a391","type":"TRIAL","name":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT06418529","description":"Rheumatoid Arthritis","metadata":null},{"id":"b027d2eaa1814a0e90a0efbc1fd4bafc","type":"TRIAL","name":"A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT05310071","description":"Alzheimer's Disease","metadata":null},{"id":"5e9b8eecf60046078d7591c5d03d090b","type":"TRIAL","name":"A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients","canonical_id":"clinicaltrials.gov:NCT01118572","description":"Post Operative Pain","metadata":null},{"id":"cf3bc2fd7d8e451caf8c654e0cc0b9c8","type":"TRIAL","name":"A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.","canonical_id":"clinicaltrials.gov:NCT06673654","description":"Atopic Dermatitis","metadata":null},{"id":"6902251b0fc34ba090029d3f6abf0dc7","type":"TRIAL","name":"A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT06140290","description":"Healthy Participants","metadata":null},{"id":"b8bcd25c66a3444dbf65d4d317452d1f","type":"TRIAL","name":"A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-na\u00efve Patients.","canonical_id":"clinicaltrials.gov:NCT00145171","description":"Parkinson Disease","metadata":null},{"id":"ec43d175820147279564de0537960038","type":"TRIAL","name":"A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC","canonical_id":"clinicaltrials.gov:NCT01673386","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"45437f67a5db46c9a4e54f63bcd702b6","type":"TRIAL","name":"A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema","canonical_id":"clinicaltrials.gov:NCT05509569","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"d8bbc4e75d484dbcad56d0e1a23f59b4","type":"TRIAL","name":"A Survey of Lanadelumab in Participants With Hereditary Angioedema","canonical_id":"clinicaltrials.gov:NCT05397431","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"ed5fe8f1880345c380effa02b332267c","type":"TRIAL","name":"A Survey on Efficacy and Safety in Patients With Endometriosis","canonical_id":"clinicaltrials.gov:NCT02921763","description":"Endometriosis","metadata":null},{"id":"1c08df1ce5c24892acedbe130644b6a1","type":"TRIAL","name":"A Target Occupancy Study With Ritlecitinib.","canonical_id":"clinicaltrials.gov:NCT05128058","description":"Healthy","metadata":null},{"id":"698d857a0a2d42ed9c2f7c3fa84f359b","type":"TRIAL","name":"A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)","canonical_id":"clinicaltrials.gov:NCT00923247","description":"Medullary Thyroid Carcinoma","metadata":null},{"id":"19778ddea634459fa7fa05d6639b5168","type":"TRIAL","name":"A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina","canonical_id":"clinicaltrials.gov:NCT02087007","description":"Vasospastic Angina","metadata":null},{"id":"a8edf72fabee427bbbcd9f31e7f6bca1","type":"TRIAL","name":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT05022004","description":"Primary Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"3f29a36a1db44ad0a4e5c30c6bce5222","type":"TRIAL","name":"A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT03566134","description":"Overactive Bladder","metadata":null},{"id":"4627c82340a44a95b329391d8fbfd630","type":"TRIAL","name":"A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657\u2022K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00922441","description":"Essential Hypertension","metadata":null},{"id":"849ab783413143549d603076be0027b4","type":"TRIAL","name":"A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02202603","description":"Drug Safety","metadata":null},{"id":"ec636c8183f44917b05d3fd35138d51a","type":"TRIAL","name":"A Translational Approach to Gitelman Syndrome","canonical_id":"clinicaltrials.gov:NCT00822107","description":"Gitelman Syndrome","metadata":null},{"id":"820208e62765480abf99faca47a427db","type":"TRIAL","name":"A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer","canonical_id":"clinicaltrials.gov:NCT03829345","description":"Oesophageal Cancer; Gastro-Oesophageal Junction Cancer; Gastric Cancer","metadata":null},{"id":"09fb350036cb45b0b7e1e01c6ae36268","type":"TRIAL","name":"A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02249104","description":"Acne Vulgaris","metadata":null},{"id":"65f44e7632fc4ec8bc15ddb49c2bd9ee","type":"TRIAL","name":"A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound","canonical_id":"clinicaltrials.gov:NCT07304024","description":"Central Auditory Processing Disorder; Hearing Impaired (Partially); Hearing; Hearing Abnormality; Hearing Disability; Hearing Disorder; Hearing Disorders; Hearing Impairment, Sensorineural; Hearing Handicap; Hearing Impaired; Hearing Impairment; Hearing Loss; Central Auditory Disease; Noise Exposure; Noise Induced Hearing Loss; Noise-Induced Hearing Loss; Sound Perception; Myelin Degeneration; Myelinopathy; Myelin Integrity; Remyelination; Hidden Hearing Loss; Cocktail Party Skill; Cocktail Par\u2026","metadata":null},{"id":"94c977692ee8455b8e59d78ba334e40d","type":"TRIAL","name":"A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET","canonical_id":"clinicaltrials.gov:NCT04427787","description":"Metastatic Well Differentiated Neuroendocrine Neoplasm; Neuroendocrine Tumors","metadata":null},{"id":"0d78076c048a4c7f95ed3dd37c33706b","type":"TRIAL","name":"A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics","canonical_id":"clinicaltrials.gov:NCT00964964","description":"Diabetes; Diabetes Mellitus, Type 1","metadata":null},{"id":"fb7228bc9e054e3688b1755585dde0db","type":"TRIAL","name":"A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00363896","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"297d023a109842fe8c2a955e5e85a4a3","type":"TRIAL","name":"A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00357825","description":"Pain","metadata":null},{"id":"6ee80b0bbcfe4518b72607f34bb97f02","type":"TRIAL","name":"A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.","canonical_id":"clinicaltrials.gov:NCT00353808","description":"Pain","metadata":null},{"id":"7c669bfe05434a6e91fafa95980b9a38","type":"TRIAL","name":"A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery","canonical_id":"clinicaltrials.gov:NCT00245375","description":"Laparoscopic Cholecystectomy; Inguinal Hernia; Abdominal Hernia; Umbilical Hernia","metadata":null},{"id":"55ace3f579524fb9a9ae4dc4d96d3c5b","type":"TRIAL","name":"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","canonical_id":"clinicaltrials.gov:NCT03172494","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"67428b20aa454ae6b1fac3b12dc99bfe","type":"TRIAL","name":"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","canonical_id":"clinicaltrials.gov:NCT02100475","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"068699eea85440e1bdecf1b70a144450","type":"TRIAL","name":"A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy","canonical_id":"clinicaltrials.gov:NCT00953017","description":"Colonoscopy","metadata":null},{"id":"c54ee1b5181d41a6832695ecb55fc5b9","type":"TRIAL","name":"A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03331835","description":"Psoriasis Vulgaris","metadata":null},{"id":"cdf0a93761214e22b9ad4bde2ff23a86","type":"TRIAL","name":"A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury","canonical_id":"clinicaltrials.gov:NCT03273062","description":"Brain Injuries; Brain Injuries, Traumatic; Brain Injury, Chronic","metadata":null},{"id":"fd645d078b7e477ca3fdd7eb64a9d96f","type":"TRIAL","name":"A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment","canonical_id":"clinicaltrials.gov:NCT02800083","description":"Alcohol Abuse, Nervous System","metadata":null},{"id":"a4cefc0c353d45b3bdee314ceef70e1e","type":"TRIAL","name":"A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)","canonical_id":"clinicaltrials.gov:NCT04893785","description":"Lung Neuroendocrine Neoplasm; GEP Neuroendocrine Tumor","metadata":null},{"id":"392185e9bc654dc28fe436c1d920d5c2","type":"TRIAL","name":"A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01154881","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"2bd1fdded9874dc5bccb339bd188cee3","type":"TRIAL","name":"A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years","canonical_id":"clinicaltrials.gov:NCT00909961","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"482f984c311d4c12873e0cc81b1fc1f2","type":"TRIAL","name":"A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.","canonical_id":"clinicaltrials.gov:NCT05670925","description":"Triple-Negative Breast Cancer","metadata":null},{"id":"e0d1a1fe3b62441aa0e8bb9dff1f7613","type":"TRIAL","name":"A Trial Investigating Lu AF28996 in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT06277609","description":"Healthy Participants","metadata":null},{"id":"bf4270825d774ce0a4f917959be4c819","type":"TRIAL","name":"A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03466567","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"9201ae26700944009e42ea1aaa226715","type":"TRIAL","name":"A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02070510","description":"Diabetes; Healthy","metadata":null},{"id":"f611e1d9337e446cb2cd7abba136ef1a","type":"TRIAL","name":"A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment","canonical_id":"clinicaltrials.gov:NCT01678430","description":"Chronic Lymphocytic Leukaemia","metadata":null},{"id":"293ffc2c90ac48d6842d42454bf726a1","type":"TRIAL","name":"A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)","canonical_id":"clinicaltrials.gov:NCT04455815","description":"COVID-19 Infection","metadata":null},{"id":"27a3cf0751704be18faaf049b24d4935","type":"TRIAL","name":"A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.","canonical_id":"clinicaltrials.gov:NCT00625833","description":"Diabetic Neuropathies","metadata":null},{"id":"31d4c629e39f44da8f4150a97f4f0a15","type":"TRIAL","name":"A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.","canonical_id":"clinicaltrials.gov:NCT02733874","description":"Psoriasis","metadata":null},{"id":"1325228efc4044d1865a27017ffc5b35","type":"TRIAL","name":"A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00242008","description":"Parkinson's Disease","metadata":null},{"id":"486b354700f14192b2d948c875bc737c","type":"TRIAL","name":"A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC","canonical_id":"clinicaltrials.gov:NCT02852083","description":"Squamous Cell Lung Cancer; Non-Squamous Cell Lung Cancer; Non-Small Cell Lung Cancer","metadata":null},{"id":"7f837a77d1bd4f57893ff0ab42f19bcf","type":"TRIAL","name":"A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function","canonical_id":"clinicaltrials.gov:NCT02665039","description":"Urothelial Carcinoma; Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer; Urethra Cancer","metadata":null},{"id":"0885ae9d242440968b11d1ed77bd9472","type":"TRIAL","name":"A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03392428","description":"Cancer of the Prostate; Metastatic Cancer","metadata":null},{"id":"5d7e3634e593457c95adf035645ba780","type":"TRIAL","name":"A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent","canonical_id":"clinicaltrials.gov:NCT01418157","description":"Acute Mountain Sickness","metadata":null},{"id":"e7a5893405ff4af1ae765ace64251127","type":"TRIAL","name":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","canonical_id":"clinicaltrials.gov:NCT03899337","description":"Richter Syndrome","metadata":null},{"id":"dae2ddcd298b49ec9a82bdbe0c120822","type":"TRIAL","name":"A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3","canonical_id":"clinicaltrials.gov:NCT04524208","description":"Neuroendocrine Tumors; Neuroendocrine Carcinoma","metadata":null},{"id":"31c891e07f334b78a3fcb496eeaaa960","type":"TRIAL","name":"A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT06367075","description":"Advanced Soft-tissue Sarcoma","metadata":null},{"id":"8cbe7e63000e44568df6bfdcc2b9ba43","type":"TRIAL","name":"A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Na\u00efve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05042375","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"96df7fb816f94b42b3d4c11a70e6436e","type":"TRIAL","name":"A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients","canonical_id":"clinicaltrials.gov:NCT05214976","description":"Advanced Solid Tumors","metadata":null},{"id":"b8dfd186c9a549c8ae7680a7d479955c","type":"TRIAL","name":"A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)","canonical_id":"clinicaltrials.gov:NCT04129996","description":"Triple-Negative Breast Cancer","metadata":null},{"id":"f00233b0a01f45d2a0b029daa85945fb","type":"TRIAL","name":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","canonical_id":"clinicaltrials.gov:NCT04074187","description":"Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"a9c87ff4ad7c45a19280970f0980d9c8","type":"TRIAL","name":"A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19","canonical_id":"clinicaltrials.gov:NCT04330586","description":"COVID-19","metadata":null},{"id":"d8fcd6d424734c89b50c72edac6a10f7","type":"TRIAL","name":"A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)","canonical_id":"clinicaltrials.gov:NCT02491268","description":"Mild Cognitive Impairment","metadata":null},{"id":"b8dca52b99df4744924c819f265b56de","type":"TRIAL","name":"A Trial of Digoxin Before Second-Trimester Abortion","canonical_id":"clinicaltrials.gov:NCT01047748","description":"Induced Abortion","metadata":null},{"id":"181f1a8bcad54f8797ddca00f2e070d5","type":"TRIAL","name":"A Trial of EVL\\GVS Alone vs. EVL\\GVS Combined Propranolol","canonical_id":"clinicaltrials.gov:NCT01298284","description":"Liver Cirrhosis; Hepatoma","metadata":null},{"id":"14094cba26f242418e2b8cac2073b321","type":"TRIAL","name":"A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications","canonical_id":"clinicaltrials.gov:NCT06701526","description":"Migraine","metadata":null},{"id":"7f65aa251e9348b492aa68d20fff7e7a","type":"TRIAL","name":"A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies","canonical_id":"clinicaltrials.gov:NCT00402714","description":"Hematologic Malignancies","metadata":null},{"id":"5c79088ee90845cc9aeae5b2fc7e0ad0","type":"TRIAL","name":"A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT04479904","description":"Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"e8eac851aeb844659ccc98914d759bf2","type":"TRIAL","name":"A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","canonical_id":"clinicaltrials.gov:NCT03755518","description":"Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"0f6802ae3c164d83b0134da352d29bef","type":"TRIAL","name":"A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00233909","description":"Leukemia, Myeloid","metadata":null},{"id":"dee27b9e394e4f13bf12ca57bc9f7e70","type":"TRIAL","name":"A Trial of Guanfacine-er for Cannabis Use Disorder","canonical_id":"clinicaltrials.gov:NCT05273567","description":"Cannabis Use","metadata":null},{"id":"36e3e68615a74d07bf8ee60ed2a50755","type":"TRIAL","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","canonical_id":"clinicaltrials.gov:NCT07601048","description":"KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","metadata":null},{"id":"15304b23d145492bb9e24bb0aa1f9154","type":"TRIAL","name":"A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis","canonical_id":"clinicaltrials.gov:NCT06569056","description":"Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)","metadata":null},{"id":"d4ddf83c4ed747e7b5d06b0c95003c48","type":"TRIAL","name":"A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)","canonical_id":"clinicaltrials.gov:NCT00049777","description":"Sepsis","metadata":null},{"id":"808afe5e62074a1596e6d19bc28097e9","type":"TRIAL","name":"A Trial of Hydroxyurea in Spinal Muscular Atrophy","canonical_id":"clinicaltrials.gov:NCT00485511","description":"Spinal Muscular Atrophy","metadata":null},{"id":"251c8d503d7a44bbbdc588c9056d74f4","type":"TRIAL","name":"A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)","canonical_id":"clinicaltrials.gov:NCT02495519","description":"Fibromatosis","metadata":null},{"id":"169bc45955fa43a0adc9df55a3191d0e","type":"TRIAL","name":"A Trial of Inebilizumab in Participants With Autoimmune Hepatitis","canonical_id":"clinicaltrials.gov:NCT07598825","description":"Autoimmune Hepatitis; AIH","metadata":null},{"id":"fe5b8c26247442ee85c21c42c0294372","type":"TRIAL","name":"A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement","canonical_id":"clinicaltrials.gov:NCT07455591","description":"Osteo Arthritis of the Knee","metadata":null},{"id":"e3b9d73d005348b6a9ce851aa25d1a27","type":"TRIAL","name":"A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis","canonical_id":"clinicaltrials.gov:NCT06144060","description":"Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)","metadata":null},{"id":"4bee05818a0e4da2940f3bf0b97a719a","type":"TRIAL","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","canonical_id":"clinicaltrials.gov:NCT06624644","description":"Melanoma (Skin Cancer); Melanoma Stage IIIB-IV; Cutaneous Melanoma; Unresectable Melanoma","metadata":null},{"id":"587c70530f504fa188aa2441af56ecb5","type":"TRIAL","name":"A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis","canonical_id":"clinicaltrials.gov:NCT00921349","description":"Variceal Bleeding; Cirrhosis","metadata":null},{"id":"66d9e3d1669e469499df532cb0a7cff5","type":"TRIAL","name":"A Trial of Linaclotide 290 \u03bcg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT03573908","description":"Irritable Bowel Syndrome Characterized by Constipation","metadata":null},{"id":"24dd7d0328fb49f6b99dab1b15a9d05b","type":"TRIAL","name":"A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck","canonical_id":"clinicaltrials.gov:NCT07346196","description":"Squamous Cell Carcinoma","metadata":null},{"id":"15040a5f26d44ddd8365ef55bc3f6f20","type":"TRIAL","name":"A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)","canonical_id":"clinicaltrials.gov:NCT01245816","description":"Familial Adenomatous Polyposis","metadata":null},{"id":"d131e34cd6e8489ea839746bbf7f608b","type":"TRIAL","name":"A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding","canonical_id":"clinicaltrials.gov:NCT01103154","description":"Variceal Rebleeding","metadata":null},{"id":"4d7b03ec32524ad69ed4e72cbc22a60f","type":"TRIAL","name":"A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects","canonical_id":"clinicaltrials.gov:NCT04985721","description":"Cancer","metadata":null},{"id":"ace52721b0314995a2ab645bf05b5099","type":"TRIAL","name":"A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC","canonical_id":"clinicaltrials.gov:NCT07062328","description":"Biliary Tract Carcinoma","metadata":null},{"id":"39d7d50372c14ca0a65ae72bc6db4301","type":"TRIAL","name":"A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00426764","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"9e09233a395548858abaffd1b40cfa01","type":"TRIAL","name":"A Trial of Rosiglitazone for Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT00065065","description":"Ulcerative Colitis; Inflammatory Bowel Disease","metadata":null},{"id":"50b04c3f27e840dbaa4bf546ee4f51ec","type":"TRIAL","name":"A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC","canonical_id":"clinicaltrials.gov:NCT04699968","description":"Non-Small-Cell Lung Cancer","metadata":null},{"id":"d78364a91804468f967147fa609b03cd","type":"TRIAL","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06417554","description":"Advanced Solid Tumors","metadata":null},{"id":"ff49f97008e54111abe63a76b5fca7c0","type":"TRIAL","name":"A Trial of Sertraline in Young Children With Autism Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT02385799","description":"Autism Spectrum Disorder","metadata":null},{"id":"6ceeb84b590c49628e845f1146f85ced","type":"TRIAL","name":"A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations","canonical_id":"clinicaltrials.gov:NCT05983159","description":"Slow-Flow Vascular Malformation; Fast-Flow Vascular Malformation; Vascular Malformations; Venous Malformation; Lymphatic Malformation, Low Flow; Lymphatic Malformation; Lymphangioma; Arteriovenous Malformations; Venous Malformation, Low Flow; Cystic Hygroma; Vascular Anomaly; Vascular Anomalies; PI3K Gene Mutation; MAP2K1 Gene Mutation; PIK3CA-related Overgrowth Spectrum; Arteriovenous Malformation (AVM); KRAS G12C; KRAS G12D","metadata":null},{"id":"97ec1ee20e224dbf9edf46f3d6bc2189","type":"TRIAL","name":"A Trial of Telmisartan Prevention of Cardiovascular Disease","canonical_id":"clinicaltrials.gov:NCT01075698","description":"Hypertension","metadata":null},{"id":"f1478d948426406f8d3c9839851690bb","type":"TRIAL","name":"A Trial of Tisotumab Vedotin in Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT03438396","description":"Cervical Cancer","metadata":null},{"id":"9cfb99cc8d4844e58c12ff4195344df6","type":"TRIAL","name":"A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT03913741","description":"Solid Tumor","metadata":null},{"id":"f080af5c57c043b98e79d4b32719eb5b","type":"TRIAL","name":"A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda\u00ae) in Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01306630","description":"Advanced Solid Tumors; Locally Advanced or Metastatic Breast or Colorectal Cancer","metadata":null},{"id":"a624508a00b846b4885dad6ff6b4ba55","type":"TRIAL","name":"A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02399943","description":"Colorectal Cancer; KRAS Wildtype; NRAS Wildtype; BRAF Wildtype","metadata":null},{"id":"a732bf7a32734298b52a8b853d6356a8","type":"TRIAL","name":"A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT07588568","description":"EoE; Eosinophilic Esophagitis; Eosinophilic Esophagitis (EoE)","metadata":null},{"id":"0d24f3153048410a809814ccf20dc9e5","type":"TRIAL","name":"A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery","canonical_id":"clinicaltrials.gov:NCT01183559","description":"Cancer of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Cancer of the Stomach","metadata":null},{"id":"5db47f6275154aa4b1bb84ef873ebf07","type":"TRIAL","name":"A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)","canonical_id":"clinicaltrials.gov:NCT07568236","description":"Vasomotor Symptoms; Prostate Cancer","metadata":null},{"id":"c0e60186352b4053986f1a76aca7a62e","type":"TRIAL","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","canonical_id":"clinicaltrials.gov:NCT05050942","description":"Gastro-enteropancreatic Neuroendocrine Tumor","metadata":null},{"id":"c26ab5d70ef7405d9a00498a8adb65c9","type":"TRIAL","name":"A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)","canonical_id":"clinicaltrials.gov:NCT06326671","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"ca493f0428164263aa26e2d6c0db28a0","type":"TRIAL","name":"A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia","canonical_id":"clinicaltrials.gov:NCT05332366","description":"Frontal Fibrosing Alopecia","metadata":null},{"id":"68597a6215a549109aedd31a7e02188c","type":"TRIAL","name":"A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.","canonical_id":"clinicaltrials.gov:NCT02717858","description":"Metabolism and Nutrition Disorder; Obesity","metadata":null},{"id":"aeef16e9775248b980a2062f11e83fed","type":"TRIAL","name":"A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)","canonical_id":"clinicaltrials.gov:NCT07710157","description":"Minimal Change Disease (MCD)","metadata":null},{"id":"caa4e8ae165143c98c354d18f60485b8","type":"TRIAL","name":"A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT00220337","description":"Painful Diabetic Neuropathy","metadata":null},{"id":"c79ae7e666c04e34953f75f6071f3c13","type":"TRIAL","name":"A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)","canonical_id":"clinicaltrials.gov:NCT04320316","description":"Epidermal Nevus Syndrome","metadata":null},{"id":"50b218ecf94c4ddd8e97f3dd619046ee","type":"TRIAL","name":"A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04674826","description":"Healthy","metadata":null},{"id":"e3a99aff1683403c8082decdee7dc30f","type":"TRIAL","name":"A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects","canonical_id":"clinicaltrials.gov:NCT03378635","description":"Hypoglycemia; Diabetes Mellitus, Type 1","metadata":null},{"id":"8a7143c46e114d219c8282cc40218cca","type":"TRIAL","name":"A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)","canonical_id":"clinicaltrials.gov:NCT01101464","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"91ac43b8058a4e43be60811630be7fd2","type":"TRIAL","name":"A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT06004050","description":"Chronic Hand Eczema","metadata":null},{"id":"55104154b0654e8d98d2f0de3355fc85","type":"TRIAL","name":"A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People","canonical_id":"clinicaltrials.gov:NCT05050279","description":"Healthy","metadata":null},{"id":"9e3d1622c3794c42a335f0c7e3d5a073","type":"TRIAL","name":"A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT06366243","description":"Healthy Participants","metadata":null},{"id":"c92fb261eac14717bf53d9d21df8e2f6","type":"TRIAL","name":"A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD","canonical_id":"clinicaltrials.gov:NCT00280371","description":"COPD","metadata":null},{"id":"d5bafc6da4554e4ab088387b4e843820","type":"TRIAL","name":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT02763319","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"455ba56d0572461692427b2a78296b0d","type":"TRIAL","name":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT06311682","description":"Atopic Dermatitis","metadata":null},{"id":"1a0d0b3285664e10aa4511a4809fa6e7","type":"TRIAL","name":"A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis","canonical_id":"clinicaltrials.gov:NCT00816556","description":"Atrophic Vaginitis","metadata":null},{"id":"9c406a388c464fb88a220e50b7953467","type":"TRIAL","name":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","canonical_id":"clinicaltrials.gov:NCT03568500","description":"Schizophrenia; Schizoaffective Disorder; First Episode Psychosis","metadata":null},{"id":"a1cbf7d749c14c8d8c6abae8b69294d8","type":"TRIAL","name":"A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject","canonical_id":"clinicaltrials.gov:NCT01737931","description":"Healthy","metadata":null},{"id":"fa10be42d168455bbd97ebb2af6c388c","type":"TRIAL","name":"A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01211587","description":"Parkinson's Disease With Cognitive Impairments","metadata":null},{"id":"717ef5fa6d8d4bf7a44ddafe26d3ddbe","type":"TRIAL","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","canonical_id":"clinicaltrials.gov:NCT04626635","description":"Advanced Solid Tumors","metadata":null},{"id":"d287a3443b6e4552a8931be207f1c77f","type":"TRIAL","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","canonical_id":"clinicaltrials.gov:NCT03972657","description":"Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC)","metadata":null},{"id":"5bc8ac6196684eadb4e889b2fe9f1eed","type":"TRIAL","name":"A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT00861445","description":"Painful Diabetic Neuropathy","metadata":null},{"id":"478ddaedcae84c998097240396141186","type":"TRIAL","name":"A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants","canonical_id":"clinicaltrials.gov:NCT06674941","description":"Healthy Volunteers","metadata":null},{"id":"4a91fb6deda54ec8af2291c84cccd1ae","type":"TRIAL","name":"A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT06248619","description":"Thyroid Eye Disease","metadata":null},{"id":"8cf51f812df94689ac85365205ffa679","type":"TRIAL","name":"A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT06845124","description":"Alcohol Addiction; Alcoholism","metadata":null},{"id":"5b916b9fe43a45f59c02daf2e64f6ff7","type":"TRIAL","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05730036","description":"Relapsed Refractory Multiple Myeloma (RRMM)","metadata":null},{"id":"8860ba30fb2b426aaa3d9426be787f92","type":"TRIAL","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","canonical_id":"clinicaltrials.gov:NCT06190951","description":"Melanoma","metadata":null},{"id":"ac82a45197ea4374a90fdc94cfa6875a","type":"TRIAL","name":"A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine","canonical_id":"clinicaltrials.gov:NCT00174395","description":"Migraine","metadata":null},{"id":"97ce89023d5d43ed862a381c1c8e8149","type":"TRIAL","name":"A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT04530110","description":"Migraine","metadata":null},{"id":"843338088c794ebf8f50ae6d65795ec9","type":"TRIAL","name":"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01566162","description":"Schizophrenia","metadata":null},{"id":"5836082390d1451fa6191caf0112102d","type":"TRIAL","name":"A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)","canonical_id":"clinicaltrials.gov:NCT01208207","description":"Spondylitis, Ankylosing","metadata":null},{"id":"826a0bc3f81543fea2ed7dda4e5f198c","type":"TRIAL","name":"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","canonical_id":"clinicaltrials.gov:NCT01208181","description":"Arthritis, Rheumatoid","metadata":null},{"id":"e98181c9b8a64301869ea3ee38c21043","type":"TRIAL","name":"A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain","canonical_id":"clinicaltrials.gov:NCT00455442","description":"Weight-Gain Prevention","metadata":null},{"id":"bc239166943b4a28a3cc75f48edee1e7","type":"TRIAL","name":"A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity","canonical_id":"clinicaltrials.gov:NCT00712322","description":"Neurogenic Detrusor Overactivity","metadata":null},{"id":"6eebaa634b004b51adeb60c86f309ebc","type":"TRIAL","name":"A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression","canonical_id":"clinicaltrials.gov:NCT00208156","description":"Depressive Disorder, Major","metadata":null},{"id":"153e83bda21f4f4b9c1b5a91fdad1beb","type":"TRIAL","name":"A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression","canonical_id":"clinicaltrials.gov:NCT00130676","description":"Major Depressive Disorder; Psychotic Disorders","metadata":null},{"id":"df57bf435e89472bb0832d6c8bd9d51b","type":"TRIAL","name":"A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT01878201","description":"Essential Hypertension","metadata":null},{"id":"caf1939755c244b4b0860af801708f49","type":"TRIAL","name":"A Weight Loss Study in Overweight Men and Women","canonical_id":"clinicaltrials.gov:NCT00993421","description":"Obesity","metadata":null},{"id":"8e2a2c4c2bbb4375bff8fb169a851464","type":"TRIAL","name":"A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.","canonical_id":"clinicaltrials.gov:NCT05361564","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"f70ddc07734849c0b272b3cf7a1ec0b7","type":"TRIAL","name":"A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT01480141","description":"Lung Cancer","metadata":null},{"id":"2e59148a3a9a4e9dabf4d584de4788ac","type":"TRIAL","name":"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]","canonical_id":"clinicaltrials.gov:NCT06693284","description":"Primary Malignant Peripheral Nerve Sheath Tumors","metadata":null},{"id":"74270b8a3545472b934d1b8c24ac6abd","type":"TRIAL","name":"A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients","canonical_id":"clinicaltrials.gov:NCT00401362","description":"Advanced Illness Patients With Opioid Induced Constipation","metadata":null},{"id":"abbb06ae625b4f21a7a1fda4e5062bfb","type":"GO_TERM","name":"A axonemal microtubule","canonical_id":"go:GO:0097649","description":"\"A complete microtubule with 13 protofilaments that fuses with an incomplete microtubule called B tubule (containing 10 protofilaments only) to form an axonemal outer doublet. Inner and outer dynein arms, as well as the radial spoke, are attached to the A tubule.\" [GOC:cilia, ISBN:0716731363]","metadata":null},{"id":"2cb59532fa264483900ff0239d8c9c59","type":"GO_TERM","name":"A band","canonical_id":"go:GO:0031672","description":"\"The dark-staining region of a sarcomere, in which myosin thick filaments are present; the center is traversed by the paler H zone, which in turn contains the M line.\" [ISBN:0321204131]","metadata":null},{"id":"edf1427954cb47d4a0509f2ef6b27494","type":"TRIAL","name":"A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]","canonical_id":"clinicaltrials.gov:NCT00160524","description":"Crohn's Disease","metadata":null},{"id":"edd24043814d48cca0e688cfec847b3d","type":"TRIAL","name":"A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy","canonical_id":"clinicaltrials.gov:NCT02177071","description":"Crohn's Disease","metadata":null},{"id":"c1a2fe7c85bf49548fb8443a9cc5c35a","type":"TRIAL","name":"A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 \u03bcg of Ulipristal Acetate (UPA)","canonical_id":"clinicaltrials.gov:NCT03230539","description":"Contraception","metadata":null},{"id":"6b40913462304782bc8c37548eb7cb8c","type":"TRIAL","name":"A+C in Metastatic Lung Adenocarcinoma Cancer","canonical_id":"clinicaltrials.gov:NCT02946359","description":"Lung Adenocarcinoma Metastatic","metadata":null},{"id":"98ed94cc72e44270b7b2d62d9682b2f1","type":"GO_TERM","name":"A-type (transient outward) potassium channel activity","canonical_id":"go:GO:0005250","description":"\"Enables the transmembrane transfer of a potassium ion by an outwardly-rectifying voltage-gated channel that produces a transient outward current upon a step change in membrane potential.\" [GOC:mah, PMID:5575340]","metadata":null},{"id":"0cd3b8f2393b49678ed7305755f7313a","type":"GO_TERM","name":"A1 adenosine receptor binding","canonical_id":"go:GO:0031686","description":"\"Binding to an A1 adenosine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ab808347069f40d58e46b3f1ecefd37e","type":"GO_TERM","name":"A1-type glycerophospholipase activity","canonical_id":"go:GO:0140322","description":"\"A glycerophospholipase activity that cleaves the fatty acid attached to the sn-1 position of the glycerol group of a glycerophospholipid.\" [PMID:30109646]","metadata":null},{"id":"b7d334fa080247558c06db84a23938e7","type":"GENE","name":"A1BG","canonical_id":"hgnc:HGNC:5","description":"alpha-1-B glycoprotein","metadata":null},{"id":"ff28f2c0fd594e28971298d9e35615d5","type":"GENE","name":"A1BG-AS1","canonical_id":"hgnc:HGNC:37133","description":"A1BG antisense RNA 1","metadata":{"aliases":["FLJ23569","NCRNA00181","A1BGAS","A1BG-AS"]}},{"id":"17118942d1be4ea580cda553204ea21e","type":"GENE","name":"A1CF","canonical_id":"hgnc:HGNC:24086","description":"APOBEC1 complementation factor","metadata":{"aliases":["ACF","ASP","ACF64","ACF65","APOBEC1CF"]}},{"id":"2a5f968c2157498f8fb119165d8dd41c","type":"GO_TERM","name":"A2-type glycerophospholipase activity","canonical_id":"go:GO:0004623","description":"\"A glycerophospholipase activity that cleaves the fatty acid attached to the sn-2 position of the glycerol group of a glycerophospholipid. Substrates include phosphatidylcholine, phosphatidylethanolamine, choline plasmalogen and phosphatides.\" [PMID:30109646]","metadata":null},{"id":"d48706fe86cb431183ef80f21851df79","type":"GO_TERM","name":"A2A adenosine receptor binding","canonical_id":"go:GO:0031687","description":"\"Binding to an A2A adenosine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"276dc1d0c24841f78417d82a843601e2","type":"GO_TERM","name":"A2B adenosine receptor binding","canonical_id":"go:GO:0031688","description":"\"Binding to an A2B adenosine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cbdd21079fdd43d797cf461a97671f4b","type":"GENE","name":"A2M","canonical_id":"hgnc:HGNC:7","description":null,"metadata":null},{"id":"d0a828bb2b1c4c59893e53f04917bbbf","type":"GENE","name":"A2M-AS1","canonical_id":"hgnc:HGNC:27057","description":"A2M antisense RNA 1","metadata":{"aliases":["lncA2M-AS1"]}},{"id":"ca600c902fb744f4b51a8a2be497c784","type":"GENE","name":"A2ML1","canonical_id":"hgnc:HGNC:23336","description":"alpha-2-macroglobulin like 1","metadata":{"aliases":["FLJ25179","p170","CPAMD9"]}},{"id":"38534adf3db4465dbe0cd82240039f7a","type":"GENE","name":"A2ML1-AS1","canonical_id":"hgnc:HGNC:41022","description":"A2ML1 antisense RNA 1","metadata":null},{"id":"85ad37a7ea3b44e5adfe3dbf835bff1b","type":"GENE","name":"A2ML1-AS2","canonical_id":"hgnc:HGNC:41523","description":"A2ML1 antisense RNA 2","metadata":null},{"id":"7d275d90e4ac43a996d0ef65b4a72780","type":"GO_TERM","name":"A3 adenosine receptor binding","canonical_id":"go:GO:0031689","description":"\"Binding to an A3 adenosine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"bbb1f214d6bf4479b3a92260087e9207","type":"GENE","name":"A3GALT2","canonical_id":"hgnc:HGNC:30005","description":"alpha 1,3-galactosyltransferase 2","metadata":{"aliases":["IGBS3S","IGB3S","A3GALT2P"]}},{"id":"f4eafbe02bd34c5aa8cda04e6ebe35da","type":"GENE","name":"A4GALT","canonical_id":"hgnc:HGNC:18149","description":"alpha 1,4-galactosyltransferase (P1PK blood group)","metadata":{"aliases":["A14GALT","Gb3S","P(k)","P1"]}},{"id":"a8f402d4782d4863b28b604e1a6e6d7e","type":"GENE","name":"A4GNT","canonical_id":"hgnc:HGNC:17968","description":"alpha-1,4-N-acetylglucosaminyltransferase","metadata":{"aliases":["alpha4GnT"]}},{"id":"ae0eeb1b49594dd788d9a637296ae073","type":"GO_TERM","name":"AAA codon-amino acid adaptor activity","canonical_id":"go:GO:0033443","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AAA codon.\" [GOC:mah]","metadata":null},{"id":"b64e6e836c1c40f281f5b5cadfab8f11","type":"GENE","name":"AAAS","canonical_id":"hgnc:HGNC:13666","description":"aladin WD repeat nucleoporin","metadata":null},{"id":"a263f2ad6fa24938aa5473205fb4fbf1","type":"GO_TERM","name":"AAC codon-amino acid adaptor activity","canonical_id":"go:GO:0033442","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AAC codon.\" [GOC:mah]","metadata":null},{"id":"f54d6a014f074d099e4f3307aceec1ac","type":"TRIAL","name":"AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas","canonical_id":"clinicaltrials.gov:NCT07290985","description":"Gastroesophageal Adenocarcinoma","metadata":null},{"id":"b6a7e50e5cf14cda95a2dfd2c38a0eb0","type":"GENE","name":"AACS","canonical_id":"hgnc:HGNC:21298","description":"acetoacetyl-CoA synthetase","metadata":{"aliases":["FLJ12389","SUR-5","ACSF1"]}},{"id":"238962b9757645288e936bf0bf44a021","type":"GENE","name":"AACSP1","canonical_id":"hgnc:HGNC:18226","description":"acetoacetyl-CoA synthetase pseudogene 1","metadata":{"aliases":["AACSL"]}},{"id":"793d0312d5e3415f829e0a4494dc7dc3","type":"GENE","name":"AADAC","canonical_id":"hgnc:HGNC:17","description":"arylacetamide deacetylase","metadata":{"aliases":["DAC","CES5A1"]}},{"id":"76126b53326a491087eb343afefc6487","type":"GENE","name":"AADACL2","canonical_id":"hgnc:HGNC:24427","description":"arylacetamide deacetylase like 2","metadata":{"aliases":["MGC72001"]}},{"id":"3a455a15ef2e40d4b518a55a9d37fdae","type":"GENE","name":"AADACL2-AS1","canonical_id":"hgnc:HGNC:50301","description":"AADACL2 antisense RNA 1","metadata":null},{"id":"ee660a6270b845c08325119bbb1c1483","type":"GENE","name":"AADACL3","canonical_id":"hgnc:HGNC:32037","description":"arylacetamide deacetylase like 3","metadata":{"aliases":["OTTHUMG00000001887"]}},{"id":"05b029f7024f4d8384ae90c1c947ac91","type":"GENE","name":"AADACL4","canonical_id":"hgnc:HGNC:32038","description":"arylacetamide deacetylase like 4","metadata":{"aliases":["OTTHUMG00000001889"]}},{"id":"84080ee1803f42a280c4c7d0682612c4","type":"GENE","name":"AADACP1","canonical_id":"hgnc:HGNC:50305","description":"arylacetamide deacetylase pseudogene 1","metadata":null},{"id":"fdb4c18c50fc4b8183dd9080108b475b","type":"GENE","name":"AADAT","canonical_id":"hgnc:HGNC:17929","description":"aminoadipate aminotransferase","metadata":{"aliases":["KATII","KAT2","KYAT2"]}},{"id":"6c1fa76be7fc401fb16f7df191488029","type":"GO_TERM","name":"AAG codon-amino acid adaptor activity","canonical_id":"go:GO:0033444","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AAG codon.\" [GOC:mah]","metadata":null},{"id":"226af3f1ddb14fd28385ebdbac1a30a4","type":"GENE","name":"AAGAB","canonical_id":"hgnc:HGNC:25662","description":"alpha and gamma adaptin binding protein","metadata":{"aliases":["FLJ11506","p34"]}},{"id":"9d9c0eb9e99d47f9a1d0016eaeac5634","type":"GENE","name":"AAK1","canonical_id":"hgnc:HGNC:19679","description":"AP2 associated kinase 1","metadata":{"aliases":["KIAA1048","DKFZp686K16132"]}},{"id":"40d8299cf010462d86fc5b32136a0003","type":"GENE","name":"AAMDC","canonical_id":"hgnc:HGNC:30205","description":"adipogenesis associated Mth938 domain containing","metadata":{"aliases":["PTD015","FLJ21035","CK067","C11orf67"]}},{"id":"c7c36654c93e424c93af82f83daff73b","type":"GENE","name":"AAMP","canonical_id":"hgnc:HGNC:18","description":"angio associated migratory cell protein","metadata":null},{"id":"2a3dc04630da4d83b47fa271708ac124","type":"GENE","name":"AANAT","canonical_id":"hgnc:HGNC:19","description":"aralkylamine N-acetyltransferase","metadata":{"aliases":["SNAT"]}},{"id":"d44bac47580b4e57aee6f9c1a269000a","type":"GENE","name":"AAR2","canonical_id":"hgnc:HGNC:15886","description":"AAR2 splicing factor","metadata":{"aliases":["bA234K24.2","C20orf4"]}},{"id":"9761b1f0e77d49f59230d701b401b74b","type":"GENE","name":"AARD","canonical_id":"hgnc:HGNC:33842","description":"alanine and arginine rich domain containing protein","metadata":{"aliases":["LOC441376","C8orf85"]}},{"id":"c068acf69a87435a84dab836d0f18842","type":"TRIAL","name":"AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)","canonical_id":"clinicaltrials.gov:NCT01118520","description":"Abdominal Aortic Aneurysm","metadata":null},{"id":"3a29ad01733c423ca6f5f159a0fc329d","type":"GENE","name":"AARS1","canonical_id":"hgnc:HGNC:20","description":"alanyl-tRNA synthetase 1","metadata":{"aliases":["CMT2N","AlaRS","AARS"]}},{"id":"ae0b43eb86ea49bdad38fce277b96ca8","type":"GENE","name":"AARS1P1","canonical_id":"hgnc:HGNC:49894","description":"alanyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["AARSP1"]}},{"id":"9bdd72eb0f7249b488207dce6a334128","type":"GENE","name":"AARS2","canonical_id":"hgnc:HGNC:21022","description":"alanyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["KIAA1270","bA444E17.1","AARSL"]}},{"id":"3b902c5a6de24999ae07628addbaca8a","type":"GENE","name":"AARSD1","canonical_id":"hgnc:HGNC:28417","description":"alanyl-tRNA synthetase domain containing 1","metadata":{"aliases":["MGC2744","AlaXp"]}},{"id":"f782f6d25a7b4764824b415852a89f0d","type":"GENE","name":"AARSD1P1","canonical_id":"hgnc:HGNC:54994","description":"AARSD1 pseudogene 1","metadata":null},{"id":"463cac65817b43f39bc5fa3de228922b","type":"GENE","name":"AASDH","canonical_id":"hgnc:HGNC:23993","description":"aminoadipate-semialdehyde dehydrogenase","metadata":{"aliases":["NRPS998","LYS2","ACSF4"]}},{"id":"bf04cce1cb8248f792fd17c9f9b5e140","type":"GENE","name":"AASDH-DT","canonical_id":"hgnc:HGNC:58795","description":"AASDH divergent transcript","metadata":null},{"id":"b9d0bc9b654642038508f82eaadb53f5","type":"GENE","name":"AASDHPPT","canonical_id":"hgnc:HGNC:14235","description":"aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase","metadata":{"aliases":["LYS5","CGI-80","AASD-PPT","ACPS"]}},{"id":"3b38fdcd97b64e9d8a5d4524027266c6","type":"GENE","name":"AASDHPPT-AS1","canonical_id":"hgnc:HGNC:58262","description":"AASDHPPT antisense RNA 1","metadata":null},{"id":"5bbb4319eba44fec835fec4067605c02","type":"GENE","name":"AASS","canonical_id":"hgnc:HGNC:17366","description":"aminoadipate-semialdehyde synthase","metadata":{"aliases":["LORSDH","LKRSDH","LKR/SDH"]}},{"id":"ad99aa5bb16b4010a2ce527fd5572cae","type":"GENE","name":"AATBC","canonical_id":"hgnc:HGNC:51526","description":"apoptosis associated transcript in bladder cancer","metadata":null},{"id":"65b8eeccae4c435da4fbfb41c5d7cf3b","type":"GENE","name":"AATF","canonical_id":"hgnc:HGNC:19235","description":null,"metadata":null},{"id":"b0dc29e735cb473284573ea5866edb33","type":"GO_TERM","name":"AAU codon-amino acid adaptor activity","canonical_id":"go:GO:0033441","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AAU codon.\" [GOC:mah]","metadata":null},{"id":"e55dbb64a1cf41ff8ce32c654c09ca12","type":"GENE","name":"AAVS1","canonical_id":"hgnc:HGNC:22","description":"adeno-associated virus integration site 1","metadata":{"aliases":["AAV"]}},{"id":"f330cb84bad541e5b77c8913912d9007","type":"GENE","name":"ABAT","canonical_id":"hgnc:HGNC:23","description":"4-aminobutyrate aminotransferase","metadata":{"aliases":["GABAT","GABA-T"]}},{"id":"07e1408829a84686ae42232fb04027ce","type":"PROTEIN","name":"ABAT","canonical_id":"uniprot:P80404","description":null,"metadata":null},{"id":"9b77ff63a2ad4188a23be406f331afdb","type":"GO_TERM","name":"ABC-type 3',5'-cyclic GMP transmembrane transporter activity","canonical_id":"go:GO:1905948","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + 3',5'-cyclic GMP(in) = ADP + phosphate + 3',5'-cyclic GMP(out).\" [GO_REF:0000070, GOC:TermGenie, PMID:18310115]","metadata":null},{"id":"67ab2d4c26884c69bceb05edb4c43b7c","type":"GO_TERM","name":"ABC-type D-allose transporter activity","canonical_id":"go:GO:0015615","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + D-allose(out) = ADP + phosphate + D-allose(in).\" [PMID:9401019, RHEA:29799]","metadata":null},{"id":"2dedcdeca5c842f48f68a81c3d6e485b","type":"GO_TERM","name":"ABC-type D-galactofuranose transporter","canonical_id":"go:GO:0103116","description":"\"Catalysis of the reaction: alpha-D-galactofuranose + ATP + H2O = alpha-D-galactofuranose + hydrogenphosphate + ADP + H+.\" [GOC:pz, PMID:19744923, RHEA:61716]","metadata":null},{"id":"7af1a51629a44b53954187619356eeb5","type":"GO_TERM","name":"ABC-type D-methionine transporter activity","canonical_id":"go:GO:0033232","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + D-methionine(out/in) = ADP + phosphate + D-methionine(in/out).\" [GOC:mlg, PMID:12169620, PMID:12819857, PMID:18621668, RHEA:29767]","metadata":null},{"id":"f9d2f96ae8ae4e23b6fa0b3fd6134d34","type":"GO_TERM","name":"ABC-type D-ribose transporter activity","canonical_id":"go:GO:0015611","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + D-ribose(out) = ADP + phosphate + D-ribose(in).\" [RHEA:29903]","metadata":null},{"id":"a29089a0e69f4376858efb24ebb2d376","type":"GO_TERM","name":"ABC-type D-xylose transporter activity","canonical_id":"go:GO:0015614","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + D-xylose(out) = ADP + phosphate + D-xylose(in).\" [RHEA:29899]","metadata":null},{"id":"ca3f9a2fb3664a97b6315c722be7b5db","type":"GO_TERM","name":"ABC-type L-arabinose transporter activity","canonical_id":"go:GO:0015612","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + L-arabinose(out) = ADP + phosphate + L-arabinose(in).\" [RHEA:30007]","metadata":null},{"id":"4c779379a32843edbefb98b5a68d04c1","type":"GO_TERM","name":"ABC-type L-cysteine transporter activity","canonical_id":"go:GO:0033230","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + L-cysteine(in) = ADP + H+ + L-cysteine(out) + phosphate.\" [PMID:25837721, PMID:32144203, RHEA:29783]","metadata":null},{"id":"1b3431e9ba6641d98a5db0da6b7499bb","type":"GO_TERM","name":"ABC-type alkanesulfonate transporter transporter activity","canonical_id":"go:GO:0042959","description":"\"Enables the transfer of an alkanesulfonate from one side of a membrane to the other according to the reaction: ATP + H2O + alkanesulfonate(out) = ADP + phosphate + alkanesulfonate(in).\" [PMID:10506196]","metadata":null},{"id":"264a8dee586444f3945e482608a7b0c0","type":"GO_TERM","name":"ABC-type amino acid transporter activity","canonical_id":"go:GO:0015424","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + amino acid(out/in) = ADP + phosphate + amino acid(in/out).\" [GOC:ai, GOC:mah]","metadata":null},{"id":"46abe5293c564a51afa1c25fbfe03411","type":"GO_TERM","name":"ABC-type azole transporter activity","canonical_id":"go:GO:0140394","description":"\"Enables the transfer of azoles, heterocyclic compound found in many biologically important substances, from one side of a membrane to the other according to the reaction: ATP + H2O + azole(in) = ADP + phosphate + azole(out).\" [PMID:31501141, RHEA:33503]","metadata":null},{"id":"5b7cacfc0fcc418fb5f746eebdd4f736","type":"GO_TERM","name":"ABC-type bacteriocin transporter activity","canonical_id":"go:GO:0043214","description":"\"Enables the transfer of a bacteriocin from one side of a membrane to the other according to the reaction: ATP + H2O = ADP + phosphate.\" [GOC:mlg, PMID:33040342]","metadata":null},{"id":"9d97c8b66e5e43f0a234b335d3425b32","type":"GO_TERM","name":"ABC-type beta-glucan transporter activity","canonical_id":"go:GO:0015441","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + beta-glucan(in) = ADP + phosphate + beta-glucan(out).\" [RHEA:18453]","metadata":null},{"id":"a039dcfeaad6445c91e8fad7cf2585aa","type":"GO_TERM","name":"ABC-type betaine transporter activity","canonical_id":"go:GO:0031458","description":"\"Catalysis of the reaction: ATP + H2O + a betaine(out) = ADP + phosphate + a betaine(in).\" [GOC:mlg]","metadata":null},{"id":"535de183e872471e81092e006fbfbc21","type":"GO_TERM","name":"ABC-type bile acid transporter activity","canonical_id":"go:GO:0015432","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: cholate(in) + ATP + H2O = cholate(out) + ADP + phosphate + H+.\" [RHEA:50048]","metadata":null},{"id":"4eccacb540864d0295fb2de5b0181da1","type":"GO_TERM","name":"ABC-type cadmium transporter activity","canonical_id":"go:GO:0015434","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Cd (cytosol) = ADP + phosphate + Cd (vacuole).\" [PMID:12455987]","metadata":null},{"id":"2877b226ca70443285c9d2e9e40932ef","type":"GO_TERM","name":"ABC-type capsular-polysaccharide transporter activity","canonical_id":"go:GO:0015436","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + capsular polysaccharide(in) = ADP + phosphate + capsular polysaccharide(out).\" [EC:7.6.2.12]","metadata":null},{"id":"091c1cb378674114a5a54457966a476c","type":"GO_TERM","name":"ABC-type carbohydrate transporter activity","canonical_id":"go:GO:0043211","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O = ADP + phosphate, to directly drive the transport of carbohydrates and their derivatives across a membrane.\" [EC:7.5.2.-, GOC:mlg]","metadata":null},{"id":"3595699a51fe40dab8b7ddcbb5bdd78c","type":"GO_TERM","name":"ABC-type choline transporter activity","canonical_id":"go:GO:0033266","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate, to directly drive the transport of choline across a membrane.\" [GOC:mlg]","metadata":null},{"id":"3c32c3dfb2a347df90c5762ad36ddc27","type":"GO_TERM","name":"ABC-type doxorubicin transporter activity","canonical_id":"go:GO:1901242","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + doxorubicin(in) = ADP + phosphate + doxorubicin(out).\" [GOC:TermGenie, PMID:12057006, PMID:15090538]","metadata":null},{"id":"38dce3544d8444d4bdf06b3663630ec5","type":"GO_TERM","name":"ABC-type fatty-acyl-CoA transporter activity","canonical_id":"go:GO:0015607","description":"\"Catalysis of the reaction ATP + H2O + fatty acyl CoA(Side 1) = ADP + phosphate + fatty acyl CoA(Side 2). A fatty acyl CoA group is any acyl group derived from a fatty acid with a coenzyme A group attached to it.\" [RHEA:15181]","metadata":null},{"id":"81c7a627468644c3b53f2d4a5f58a9c6","type":"GO_TERM","name":"ABC-type ferric hydroxamate transporter activity","canonical_id":"go:GO:0015625","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + ferric-hydroxamate(out) = ADP + phosphate + ferric-hydroxamate(in).\" [PMID:1551849]","metadata":null},{"id":"338c04522b814db3a8ffc2c7bac61691","type":"GO_TERM","name":"ABC-type ferric iron transporter activity","canonical_id":"go:GO:0015408","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Fe3+(out) = ADP + phosphate + Fe3+(in).\" [RHEA:12332]","metadata":null},{"id":"18dceedecfcc43e9aa52ed3bd8b715d4","type":"GO_TERM","name":"ABC-type ferric-enterobactin transporter activity","canonical_id":"go:GO:0015624","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + ferric-enterobactin(out) = ADP + phosphate + ferric-enterobactin(in).\" [RHEA:58492]","metadata":null},{"id":"079df572d0114820b06c6130b85e4007","type":"GO_TERM","name":"ABC-type glutathione S-conjugate transporter activity","canonical_id":"go:GO:0015431","description":"\"Catalysis of the reaction: an S-substituted glutathione(in) + ATP + H2O = an S-substituted glutathione(out) + ADP + phosphate + H+.\" [PMID:1455517, RHEA:19121]","metadata":null},{"id":"2f980e81aa904abc97d537531307fb6b","type":"GO_TERM","name":"ABC-type glycerol-3-phosphate transporter activity","canonical_id":"go:GO:0015430","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + glycerol-3-phosphate(out) = ADP + phosphate + glycerol-3-phosphate(in).\" [RHEA:21668]","metadata":null},{"id":"f350f725f7844697a7da50f8380a2168","type":"GO_TERM","name":"ABC-type glycine betaine transporter activity","canonical_id":"go:GO:0031459","description":"\"Catalysis of the reaction: ATP + H2O + glycine betaine(out) = ADP + phosphate + glycine betaine(in).\" [GOC:mlg, RHEA:32783]","metadata":null},{"id":"3c28238abeb943d7bc4fa9d7c12d286a","type":"GO_TERM","name":"ABC-type guanine transporter activity","canonical_id":"go:GO:0008558","description":"\"Catalyses the reaction: ATP + H2O + guanine(out) = ADP + phosphate + guanine(in).\" [RHEA:20832]","metadata":null},{"id":"4ed7b1ef9345463ab26f981bc8932856","type":"GO_TERM","name":"ABC-type heme transporter activity","canonical_id":"go:GO:0015439","description":"\"Catalysis of the reaction: ATP + H2O + heme(in) = ADP + phosphate + heme(out).\" [RHEA:19261]","metadata":null},{"id":"6ab3e8a26d0d4ae0be0033bcd2b9b9d4","type":"GO_TERM","name":"ABC-type indole transporter activity","canonical_id":"go:GO:0160080","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + indole(in) = ADP + phosphate + indole(out).\" [PMID:37146609]","metadata":null},{"id":"ecf5be63edc8496fa955cb49f130efac","type":"GO_TERM","name":"ABC-type iron-sulfur cluster transporter activity","canonical_id":"go:GO:0140481","description":"\"Catalysis of the reaction: ATP + H2O + iron-sulfur cluster(in) = ADP + phosphate + iron-sulfur cluster(out).\" [PMID:31040179]","metadata":null},{"id":"543ef2351cee40e1a99aca72946ce18f","type":"GO_TERM","name":"ABC-type maltose transporter activity","canonical_id":"go:GO:0015423","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + maltose(out) = ADP + phosphate + maltose(in).\" [RHEA:22132]","metadata":null},{"id":"e02bf633e6864fd287eabded686a26fa","type":"GO_TERM","name":"ABC-type manganese transporter activity","canonical_id":"go:GO:0015410","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Mn2+(out) = ADP + phosphate + Mn2+(in).\" [RHEA:17365]","metadata":null},{"id":"7beb9979347e4a909f59c41001c45baa","type":"GO_TERM","name":"ABC-type molybdate transporter activity","canonical_id":"go:GO:0015412","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + molybdate(out) = ADP + phosphate + molybdate(in).\" [RHEA:22020]","metadata":null},{"id":"311f476dcf0947a48a7bf34192360b79","type":"GO_TERM","name":"ABC-type monosaccharide transporter activity","canonical_id":"go:GO:0015407","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + monosaccharide(out) = ADP + phosphate + monosaccharide(in). Ribose, xylose, arabinose, galactose and methylgalactoside are imported.\" [MetaCyc:3.6.3.17-RXN]","metadata":null},{"id":"181f4366655e49d499b9b76f0e918be6","type":"GO_TERM","name":"ABC-type nickel transporter activity","canonical_id":"go:GO:0015413","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Ni2+(out) = ADP + phosphate + Ni2+(in).\" [RHEA:15557]","metadata":null},{"id":"0e8a3a9656e040eb8b8c7b6250053db0","type":"GO_TERM","name":"ABC-type nitrate transporter activity","canonical_id":"go:GO:0015414","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + nitrate(out) = ADP + phosphate + nitrate(in).\" [RHEA:13181]","metadata":null},{"id":"ae43c273f2e541cbabf3aae5c10078ca","type":"GO_TERM","name":"ABC-type oligogalacturonide transporter activity","canonical_id":"go:GO:0033154","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + oligogalacturonide(out) = ADP + phosphate + oligogalacturonide(in).\" [GOC:mlg, PMID:11555291, PMID:17451747]","metadata":null},{"id":"183e59b3b9e542ac825c82370f762c22","type":"GO_TERM","name":"ABC-type oligopeptide transporter activity","canonical_id":"go:GO:0015421","description":"\"Catalysis of the reaction: ATP + H2O + oligopeptide(out) = ADP + phosphate + oligopeptide(in).\" [RHEA:14429]","metadata":null},{"id":"81c6b82a8a62475cb9294256fda2095d","type":"GO_TERM","name":"ABC-type oligosaccharide transporter activity","canonical_id":"go:GO:0015422","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + oligosaccharide(out) = ADP + phosphate + oligosaccharide(in).\" [EC:7.5.2.2]","metadata":null},{"id":"1b405460e9bf424a9ab906d0baab0e2d","type":"GO_TERM","name":"ABC-type peptide antigen transporter activity","canonical_id":"go:GO:0015433","description":"\"Catalysis of the reaction: peptide antigen(in) + ATP = peptide antigen(out) + ADP + phosphate.\" [TC:3.A.1.209.1]","metadata":null},{"id":"34e5f4ad08784fcbad5f3f79fd977b05","type":"GO_TERM","name":"ABC-type peptide transporter activity","canonical_id":"go:GO:0015440","description":"\"Catalysis of the reaction: ATP + H2O + peptide(in) = ADP + phosphate + peptide(out). Peptides exported include alpha-hemolysin, cyclolysin, colicin V and siderophores from Gram-negative bacteria, and bacteriocin, subtilin, competence factor and pediocin from Gram-positive bacteria.\" [EC:7.4.2.5]","metadata":null},{"id":"9132a83cd5d1407794848a99f180f8e1","type":"GO_TERM","name":"ABC-type phosphonate transporter activity","canonical_id":"go:GO:0015416","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + phosphonate(out) = ADP + phosphate + phosphonate(in). A phosphonate is any salt, anion, or ester of phosphonic acid (HPO(OH)2).\" [RHEA:18065]","metadata":null},{"id":"4b7ad1e934384f939c8f58722dbe872e","type":"GO_TERM","name":"ABC-type phytochelatin transporter activity","canonical_id":"go:GO:0044604","description":"\"Enables the directed movement of a phytochelatin from one side of a membrane to the other. Phytochelatins are a group of peptides that bind metals (Cd, Zn, Cu, Pb, Hg) in thiolate coordination complexes.\" [GOC:mah, PMID:1396551]","metadata":null},{"id":"aa88aa1cdc574b16bafdb5e6c0a3536f","type":"GO_TERM","name":"ABC-type polyamine transporter activity","canonical_id":"go:GO:0015417","description":"\"Catalysis of the reaction: ATP + H2O + polyamine(out) = ADP + phosphate + polyamine(in).\" [RHEA:29999]","metadata":null},{"id":"6aea9697878946ac83bef4f858e0008e","type":"GO_TERM","name":"ABC-type protein transporter activity","canonical_id":"go:GO:0015462","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + protein(out) = ADP + phosphate + protein(in).\" [GOC:jl]","metadata":null},{"id":"a93a50798f554986aabf7fa805960992","type":"GO_TERM","name":"ABC-type putrescine transporter activity","canonical_id":"go:GO:0015594","description":"\"Catalysis of the reaction: putrescine(out) + ATP + H2O = putrescine(in) + ADP + phosphate + H+.\" [RHEA:29995]","metadata":null},{"id":"be4b5fbcbe61404a891913d09311caa3","type":"GO_TERM","name":"ABC-type quaternary ammonium compound transporting activity","canonical_id":"go:GO:0015418","description":"\"Catalysis of the reaction: ATP + H2O + quaternary ammonium(out) = ADP + H+ + phosphate + quaternary ammonium(in).\" [GOC:pz, RHEA:11036]","metadata":null},{"id":"acda7293ca154c3989a28b3d035c4027","type":"GO_TERM","name":"ABC-type sodium transporter activity","canonical_id":"go:GO:0140679","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Na(in) = ADP + phosphate + Na(out).\" [PMID:9106203]","metadata":null},{"id":"02481960c2ed4a6e8eaedcdad276bc51","type":"GO_TERM","name":"ABC-type sterol transporter activity","canonical_id":"go:GO:0034041","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + sterol(in) = ADP + phosphate + sterol(out).\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"0528972c9dc847488c0880869a0f16d0","type":"GO_TERM","name":"ABC-type sulfate transporter activity","canonical_id":"go:GO:0015419","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + sulfate(out) = ADP + phosphate + sulfate(in).\" [RHEA:10192]","metadata":null},{"id":"c2956e23d5e24b169326029a9425885d","type":"GO_TERM","name":"ABC-type taurine transporter transporter activity","canonical_id":"go:GO:0015411","description":"\"Enables the transfer of taurine from one side of a membrane to the other according to the reaction: ATP + H2O + taurine(out) = ADP + phosphate + taurine(in).\" [RHEA:14613]","metadata":null},{"id":"0dc2a307298d471fb24dbc1651572738","type":"GO_TERM","name":"ABC-type teichoic acid transporter activity","canonical_id":"go:GO:0015438","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + teichoic acid(in) = ADP + phosphate + teichoic acid(out).\" [PMID:7565096]","metadata":null},{"id":"41935943f1dc4fe0bd8a9b85ea278e58","type":"GO_TERM","name":"ABC-type thiamine transporter activity","canonical_id":"go:GO:0048502","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + thiamine(out) = ADP + H+ + phosphate + thiamine(in).\" [PMID:12175925, PMID:9535878, RHEA:29811]","metadata":null},{"id":"62ee9786c195476cb7c5cc1e7dedebb3","type":"GO_TERM","name":"ABC-type thiosulfate transporter activity","canonical_id":"go:GO:0102025","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + thiosulfate(out) = ADP + phosphate + thiosulfate(in).\" [GOC:mlg, GOC:pz]","metadata":null},{"id":"71db40893cf54649b37cabb7e702eb2a","type":"GO_TERM","name":"ABC-type transporter activity","canonical_id":"go:GO:0140359","description":"\"Primary active transporter characterized by two nucleotide-binding domains and two transmembrane domains. Uses the energy generated from ATP hydrolysis to drive the transport of a substance across a membrane.\" [PMID:26517899]","metadata":null},{"id":"4a9dbeb1ff984f8cbfddb4acaa41773a","type":"GO_TERM","name":"ABC-type tungstate transporter activity","canonical_id":"go:GO:1901238","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + tungstate(in) = ADP + phosphate + tungstate(out).\" [GOC:TermGenie, PMID:16952940, PMID:21784948, RHEA:35027]","metadata":null},{"id":"bbfb24a339a54cd0b77a8f4440cb7662","type":"GO_TERM","name":"ABC-type vitamin B12 transporter activity","canonical_id":"go:GO:0015420","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: vitamin B12(out) + ATP + H2O = ADP + an vitamin B12(in) + H+ + phosphate. Vitamin B12 is alkylcob(III)alamin.\" [GOC:pz, RHEA:17873]","metadata":null},{"id":"e350c367277e438495df4d287ab44c6e","type":"GO_TERM","name":"ABC-type xenobiotic transporter activity","canonical_id":"go:GO:0008559","description":"\"Catalysis of the reaction: ATP + H2O + xenobiotic(in) = ADP + phosphate + xenobiotic(out).\" [EC:7.6.2.2]","metadata":null},{"id":"d0e67742a8f648ad87c2389ba7409ba8","type":"GO_TERM","name":"ABC-type zinc transporter activity","canonical_id":"go:GO:0015633","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Zn2+(out) = ADP + phosphate + Zn2+(in).\" [RHEA:29795]","metadata":null},{"id":"1b0dd4de3a6a4d86b0dd28b49f1693df","type":"GENE","name":"ABCA1","canonical_id":"hgnc:HGNC:29","description":null,"metadata":null},{"id":"50aaa1637a0f474eaeace873141944e5","type":"PROTEIN","name":"ABCA1","canonical_id":"uniprot:O95477","description":null,"metadata":null},{"id":"7ce2d0e93c4348a897d4bc68b6eaf8bf","type":"GENE","name":"ABCA10","canonical_id":"hgnc:HGNC:30","description":"ATP binding cassette subfamily A member 10","metadata":{"aliases":["EST698739"]}},{"id":"efaab1d2b493470ab2d3a276bf6c6323","type":"GENE","name":"ABCA11P","canonical_id":"hgnc:HGNC:31","description":"ATP binding cassette subfamily A member 11, pseudogene","metadata":{"aliases":["ABCA10P","EST1133530","FLJ14297","ABCA11"]}},{"id":"e90dc2cdb7ad459e9fa477b9c5811b7e","type":"GENE","name":"ABCA12","canonical_id":"hgnc:HGNC:14637","description":"ATP binding cassette subfamily A member 12","metadata":{"aliases":["DKFZP434G232","LI2","ICR2B"]}},{"id":"b27b24e117544e939d12677faa057d52","type":"GENE","name":"ABCA13","canonical_id":"hgnc:HGNC:14638","description":"ATP binding cassette subfamily A member 13","metadata":{"aliases":["FLJ33876","FLJ33951"]}},{"id":"7da7846b016c4d16a89c833a37d71241","type":"GENE","name":"ABCA15P","canonical_id":"hgnc:HGNC:34405","description":"ATP binding cassette subfamily A member 15, pseudogene","metadata":{"aliases":["ABCA15P1","FLJ41766","NCRNA00169","CRYM-AS1"]}},{"id":"08486322d73642e59a1b8885939ea374","type":"GENE","name":"ABCA16P","canonical_id":"hgnc:HGNC:55707","description":"ATP binding cassette subfamily A member 16, pseudogene","metadata":{"aliases":["ABCA15P2","ABCA3P1"]}},{"id":"dca21c64d0fd4267befb83d9f505d9da","type":"GENE","name":"ABCA17P","canonical_id":"hgnc:HGNC:32972","description":"ATP binding cassette subfamily A member 17, pseudogene","metadata":null},{"id":"ee2daafdb72f41a8966096b33c5b3999","type":"GENE","name":"ABCA2","canonical_id":"hgnc:HGNC:32","description":"ATP binding cassette subfamily A member 2","metadata":{"aliases":["ABC2"]}},{"id":"de910882531c4ca59872d081aa037b2c","type":"GENE","name":"ABCA3","canonical_id":"hgnc:HGNC:33","description":null,"metadata":null},{"id":"8e7e2cb5cdda489ea0a5f5868423a9bf","type":"GENE","name":"ABCA4","canonical_id":"hgnc:HGNC:34","description":"ATP binding cassette subfamily A member 4","metadata":{"aliases":["FFM","ARMD2","CORD3","STGD1","ABCR","RP19","STGD"]}},{"id":"834b895da31f46619ea4a173b523a479","type":"GENE","name":"ABCA5","canonical_id":"hgnc:HGNC:35","description":"ATP binding cassette subfamily A member 5","metadata":{"aliases":["EST90625"]}},{"id":"bdf0417f14554d89999a7d649efdac8c","type":"GENE","name":"ABCA6","canonical_id":"hgnc:HGNC:36","description":"ATP binding cassette subfamily A member 6","metadata":{"aliases":["EST155051"]}},{"id":"53e89e9bafb84584ad430bff4322b592","type":"GENE","name":"ABCA7","canonical_id":"hgnc:HGNC:37","description":"ATP binding cassette subfamily A member 7","metadata":{"aliases":["ABCX"]}},{"id":"35ca3fd3a88b4d169ef635c3334959ea","type":"GENE","name":"ABCA8","canonical_id":"hgnc:HGNC:38","description":"ATP binding cassette subfamily A member 8","metadata":{"aliases":["KIAA0822"]}},{"id":"7552f0dcbf23461d88babdb9d9666f46","type":"GENE","name":"ABCA9","canonical_id":"hgnc:HGNC:39","description":"ATP binding cassette subfamily A member 9","metadata":{"aliases":["EST640918"]}},{"id":"d77f5b5cdd904b48bc3d240be4d60558","type":"GENE","name":"ABCA9-AS1","canonical_id":"hgnc:HGNC:39983","description":"ABCA9 antisense RNA 1","metadata":null},{"id":"8782c8edb2624ca991d31fa12d6986f2","type":"GENE","name":"ABCB1","canonical_id":"hgnc:HGNC:40","description":null,"metadata":null},{"id":"ad87e2bae6c64fcfb67dceb622e5af24","type":"GENE","name":"ABCB10","canonical_id":"hgnc:HGNC:41","description":"ATP binding cassette subfamily B member 10","metadata":{"aliases":["EST20237","M-ABC2","MTABC2"]}},{"id":"bdded9d7244644e68925f42f606e19dd","type":"GENE","name":"ABCB10P1","canonical_id":"hgnc:HGNC:14114","description":"ABCB10 pseudogene 1","metadata":{"aliases":["M-ABC2","MABC2","ABCB10P","ABCB10P2"]}},{"id":"a0451dd5f38243c095906be5fa1f0161","type":"GENE","name":"ABCB10P3","canonical_id":"hgnc:HGNC:31129","description":"ABCB10 pseudogene 3","metadata":null},{"id":"2775de063a674fb18ebf8dbf6ba92cf6","type":"GENE","name":"ABCB10P4","canonical_id":"hgnc:HGNC:31130","description":"ABCB10 pseudogene 4","metadata":null},{"id":"50dc663a713c4e99b8f15eb759073aa0","type":"GENE","name":"ABCB11","canonical_id":"hgnc:HGNC:42","description":null,"metadata":null},{"id":"64b587fb491a46c3a77a3ba2c310b9bc","type":"GENE","name":"ABCB4","canonical_id":"hgnc:HGNC:45","description":null,"metadata":null},{"id":"cd0c56c498ac49858d6cf856a3fb38fa","type":"GENE","name":"ABCB4P1","canonical_id":"hgnc:HGNC:59206","description":"ABCB4 pseudogene 1","metadata":null},{"id":"ec90ba78f91a46a39db4e3f491d632fb","type":"GENE","name":"ABCB5","canonical_id":"hgnc:HGNC:46","description":"ATP binding cassette subfamily B member 5","metadata":{"aliases":["EST422562","ABCB5beta","ABCB5alpha"]}},{"id":"3f5a6119244b4b3685d562a46aa9fe02","type":"GENE","name":"ABCB6","canonical_id":"hgnc:HGNC:47","description":"ATP binding cassette subfamily B member 6 (LAN blood group)","metadata":{"aliases":["EST45597","umat","MTABC3"]}},{"id":"03f89d3e3fec4ffea8f9d4a37f2418ba","type":"GENE","name":"ABCB7","canonical_id":"hgnc:HGNC:48","description":"ATP binding cassette subfamily B member 7","metadata":{"aliases":["EST140535","Atm1p","ASAT","ABC7"]}},{"id":"9e7200100cd540c58909cd0f706c9fb2","type":"GENE","name":"ABCB8","canonical_id":"hgnc:HGNC:49","description":null,"metadata":null},{"id":"5cdde1638c3248299ba2529cab888613","type":"GENE","name":"ABCB9","canonical_id":"hgnc:HGNC:50","description":"ATP binding cassette subfamily B member 9","metadata":{"aliases":["EST122234"]}},{"id":"114cbe43c05445c2bac8f7c7e22892ee","type":"GENE","name":"ABCC1","canonical_id":"hgnc:HGNC:51","description":null,"metadata":null},{"id":"bfa2d17a8ef34d7cae99ae5837f90b0d","type":"GENE","name":"ABCC10","canonical_id":"hgnc:HGNC:52","description":"ATP binding cassette subfamily C member 10","metadata":{"aliases":["EST182763","MRP7","SIMRP7"]}},{"id":"716bc4d9836b456dbb8ee79e5ce7490b","type":"GENE","name":"ABCC11","canonical_id":"hgnc:HGNC:14639","description":"ATP binding cassette subfamily C member 11","metadata":{"aliases":["MRP8"]}},{"id":"d5d5548076fb496b9081d48e05427714","type":"GENE","name":"ABCC12","canonical_id":"hgnc:HGNC:14640","description":"ATP binding cassette subfamily C member 12","metadata":{"aliases":["MRP9"]}},{"id":"e8828829ae9a452483df1a229b211574","type":"GENE","name":"ABCC13","canonical_id":"hgnc:HGNC:16022","description":"ATP binding cassette subfamily C member 13 (pseudogene)","metadata":{"aliases":["PRED6","C21orf73","ABCC13P"]}},{"id":"7c0081d490a0457d895bffe5e42f74de","type":"GENE","name":"ABCC2","canonical_id":"hgnc:HGNC:53","description":null,"metadata":null},{"id":"12e1b2e543404819bf0337df059c6812","type":"GENE","name":"ABCC3","canonical_id":"hgnc:HGNC:54","description":null,"metadata":null},{"id":"7b792596fb414869bff6bcf8df8d8f94","type":"GENE","name":"ABCC4","canonical_id":"hgnc:HGNC:55","description":null,"metadata":null},{"id":"7c1fe68bae7c47299f234b9efa01cc69","type":"GENE","name":"ABCC5","canonical_id":"hgnc:HGNC:56","description":"ATP binding cassette subfamily C member 5","metadata":{"aliases":["MRP5","SMRP","EST277145","MOAT-C"]}},{"id":"062172f9b56240b9aca61724bd14606b","type":"GENE","name":"ABCC5-AS1","canonical_id":"hgnc:HGNC:40055","description":"ABCC5 antisense RNA 1","metadata":null},{"id":"ae1a5f4fffcb433a95ce7330ecd19479","type":"GENE","name":"ABCC6","canonical_id":"hgnc:HGNC:57","description":null,"metadata":null},{"id":"f90df7fab4ee49599c270ba28066d522","type":"GENE","name":"ABCC6P1","canonical_id":"hgnc:HGNC:33352","description":"ATP binding cassette subfamily C member 6 pseudogene 1","metadata":null},{"id":"5bc58e2aadc84410adfe2cf21d693094","type":"GENE","name":"ABCC6P2","canonical_id":"hgnc:HGNC:33353","description":"ATP binding cassette subfamily C member 6 pseudogene 2","metadata":null},{"id":"bac2b2d5efb547d7af27fde72659e5bb","type":"GENE","name":"ABCC8","canonical_id":"hgnc:HGNC:59","description":"ATP binding cassette subfamily C member 8","metadata":{"aliases":["HI","PHHI","SUR1","MRP8","ABC36","HHF1","TNDM2","SUR","HRINS"]}},{"id":"32db4c520c354696b52fc31830b1ef0e","type":"GENE","name":"ABCC9","canonical_id":"hgnc:HGNC:60","description":"ATP binding cassette subfamily C member 9","metadata":{"aliases":["SUR2","CMD1O"]}},{"id":"dd055971f59a42ecbf26312e649fcd50","type":"DISEASE","name":"ABCD syndrome","canonical_id":"mondo:0010895","description":null,"metadata":null},{"id":"435773b95e5440dc98ed9862ac555466","type":"GENE","name":"ABCD1","canonical_id":"hgnc:HGNC:61","description":"ATP binding cassette subfamily D member 1","metadata":{"aliases":["AMN","ALDP","adrenoleukodystrophy","ALD"]}},{"id":"a6517ff4c8aa4f3bbc57e6325b056247","type":"GENE","name":"ABCD1P1","canonical_id":"hgnc:HGNC:62","description":"ATP binding cassette subfamily D member 1 pseudogene 1","metadata":null},{"id":"801509dbce4a453da1e95985f38297b9","type":"GENE","name":"ABCD1P2","canonical_id":"hgnc:HGNC:63","description":"ATP binding cassette subfamily D member 1 pseudogene 2","metadata":{"aliases":["bA453N3.6"]}},{"id":"af6dadcb02774e5198d4921118f91c62","type":"GENE","name":"ABCD1P3","canonical_id":"hgnc:HGNC:64","description":"ATP binding cassette subfamily D member 1 pseudogene 3","metadata":null},{"id":"cbf6f38e53c54f1096f6adfa3a411ace","type":"GENE","name":"ABCD1P4","canonical_id":"hgnc:HGNC:65","description":"ATP binding cassette subfamily D member 1 pseudogene 4","metadata":null},{"id":"1986952a9062490d93b34dfafca5edfa","type":"GENE","name":"ABCD1P5","canonical_id":"hgnc:HGNC:42662","description":"ATP binding cassette subfamily D member 1 pseudogene 5","metadata":null},{"id":"35e824cc17b9448a9fe9dc2b9c1c83ee","type":"GENE","name":"ABCD2","canonical_id":"hgnc:HGNC:66","description":"ATP binding cassette subfamily D member 2","metadata":{"aliases":["ALDR","ALDRP","ALDL1"]}},{"id":"58e8fc1429ca405bb3bfdc26531ef3cd","type":"GENE","name":"ABCD3","canonical_id":"hgnc:HGNC:67","description":"ATP binding cassette subfamily D member 3","metadata":{"aliases":["PMP70","ZWS2","PXMP1"]}},{"id":"1f11df0c4797478c8fdc99b3aa966209","type":"GENE","name":"ABCD4","canonical_id":"hgnc:HGNC:68","description":"ATP binding cassette subfamily D member 4","metadata":{"aliases":["PMP69","P70R","EST352188","PXMP1L"]}},{"id":"e3f7c95c153b4e9bba1c3fb6bc8875e2","type":"GENE","name":"ABCE1","canonical_id":"hgnc:HGNC:69","description":"ATP binding cassette subfamily E member 1","metadata":{"aliases":["RLI","OABP","RLI1","RNASEL1","RNASELI","RNS4I"]}},{"id":"28e8b3162b524cf68e733c909276ecc9","type":"GENE","name":"ABCE1P1","canonical_id":"hgnc:HGNC:58656","description":"ABCE1 pseudogene 1","metadata":{"aliases":["ABCE1P2"]}},{"id":"1e4fe80ece4e4d4fbbb13bf8b0faf2b9","type":"GENE","name":"ABCE1P2","canonical_id":"hgnc:HGNC:58657","description":"ABCE1 pseudogene 2","metadata":null},{"id":"d057abc391094e25b80d1e408153ee70","type":"GENE","name":"ABCE1P3","canonical_id":"hgnc:HGNC:58658","description":"ABCE1 pseudogene 3","metadata":null},{"id":"9ba0bf351c3c41fa8310b3d0fe4fb307","type":"GENE","name":"ABCF1","canonical_id":"hgnc:HGNC:70","description":"ATP binding cassette subfamily F member 1","metadata":{"aliases":["EST123147","ABC50"]}},{"id":"09297b5103054987a2b3087c19f156ad","type":"GENE","name":"ABCF1-DT","canonical_id":"hgnc:HGNC:53628","description":"ABCF1 divergent transcript","metadata":null},{"id":"f3adb7c7de474b50af551a95f61b9412","type":"GENE","name":"ABCF2","canonical_id":"hgnc:HGNC:71","description":"ATP binding cassette subfamily F member 2","metadata":{"aliases":["EST133090","ABC28","M-ABC1","HUSSY-18"]}},{"id":"a0524be146a2415aac1115c551bdbe59","type":"GENE","name":"ABCF2-H2BK1","canonical_id":"hgnc:HGNC:54751","description":"ABCF2-H2BK1 readthrough","metadata":{"aliases":["ABCF2-H2BE1"]}},{"id":"c6490dc1fd3f4c3d8fb229181b0adfb6","type":"GENE","name":"ABCF2P1","canonical_id":"hgnc:HGNC:48841","description":"ATP binding cassette subfamily F member 2 pseudogene 1","metadata":null},{"id":"8b36cb22057a42398cf7841d1effb197","type":"GENE","name":"ABCF2P2","canonical_id":"hgnc:HGNC:48842","description":"ATP binding cassette subfamily F member 2 pseudogene 2","metadata":null},{"id":"bf12279991eb4902b156c80f199174ca","type":"GENE","name":"ABCF3","canonical_id":"hgnc:HGNC:72","description":"ATP binding cassette subfamily F member 3","metadata":{"aliases":["EST201864"]}},{"id":"7393dfffd108421f83fa7255297f4b07","type":"GENE","name":"ABCG1","canonical_id":"hgnc:HGNC:73","description":null,"metadata":null},{"id":"1fb36810518b4573940aa25d8161f6a8","type":"GENE","name":"ABCG2","canonical_id":"hgnc:HGNC:74","description":null,"metadata":null},{"id":"26b667630f6a47419f60ab1ca1cb1722","type":"GENE","name":"ABCG4","canonical_id":"hgnc:HGNC:13884","description":null,"metadata":null},{"id":"c95b776af51445d5a10dfe3cb6303556","type":"GENE","name":"ABCG5","canonical_id":"hgnc:HGNC:13886","description":null,"metadata":null},{"id":"48a28a1cdec84be3bbdc0d85c1f1a976","type":"GENE","name":"ABCG8","canonical_id":"hgnc:HGNC:13887","description":null,"metadata":null},{"id":"9fd9c544413b4d92a52b419fead1c918","type":"TRIAL","name":"ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.","canonical_id":"clinicaltrials.gov:NCT00291759","description":"Breast Cancer","metadata":null},{"id":"611e12c279d740168245d16fe5883a26","type":"GENE","name":"ABHD1","canonical_id":"hgnc:HGNC:17553","description":"abhydrolase domain containing 1","metadata":{"aliases":["LABH1","FLJ36128"]}},{"id":"6ff610dd08b04cfaaf430a9bc79146f3","type":"GENE","name":"ABHD10","canonical_id":"hgnc:HGNC:25656","description":"abhydrolase domain containing 10, depalmitoylase","metadata":{"aliases":["FLJ11342"]}},{"id":"18082a1564b746a4b5ea1c40412dbc50","type":"GENE","name":"ABHD11","canonical_id":"hgnc:HGNC:16407","description":"abhydrolase domain containing 11","metadata":{"aliases":["PP1226","WBSCR21"]}},{"id":"0a8ccbf87ec645769a3b53552733941a","type":"GENE","name":"ABHD12","canonical_id":"hgnc:HGNC:15868","description":"abhydrolase domain containing 12, lysophospholipase","metadata":{"aliases":["DKFZP434P106","dJ965G21.2","BEM46L2","ABHD12A","C20orf22"]}},{"id":"c9f383d150c942249a933d90d9012168","type":"GENE","name":"ABHD12B","canonical_id":"hgnc:HGNC:19837","description":"abhydrolase domain containing 12B","metadata":{"aliases":["BEM46L3","C14orf29"]}},{"id":"52a0a472f9f740e7aefc58a8704a3d29","type":"GENE","name":"ABHD13","canonical_id":"hgnc:HGNC:20293","description":"abhydrolase domain containing 13","metadata":{"aliases":["bA153I24.2","FLJ14906","BEM46L1","C13orf6"]}},{"id":"12741705716e4d30bd451e6c70056aa5","type":"GENE","name":"ABHD14A","canonical_id":"hgnc:HGNC:24538","description":"abhydrolase domain containing 14A","metadata":{"aliases":["DKFZP564O243","DORZ1"]}},{"id":"66e43c8096c743c299eefffaee12066f","type":"GENE","name":"ABHD14A-ACY1","canonical_id":"hgnc:HGNC:38856","description":"ABHD14A-ACY1 readthrough","metadata":null},{"id":"b588bed440e44a16883f1e8f9cb5a60f","type":"GENE","name":"ABHD14B","canonical_id":"hgnc:HGNC:28235","description":"abhydrolase domain containing 14B","metadata":{"aliases":["MGC15429","CIB"]}},{"id":"7aba85cc1f62427abb152ee2f838ef0f","type":"GENE","name":"ABHD15","canonical_id":"hgnc:HGNC:26971","description":"abhydrolase domain containing 15","metadata":null},{"id":"51db4a7811774ccc8deeb4b23d8cc37d","type":"GENE","name":"ABHD15-AS1","canonical_id":"hgnc:HGNC:49685","description":"ABHD15 antisense RNA 1","metadata":{"aliases":["linc-TP53I13","lnc-TP53I13"]}},{"id":"5ce98a33d04c493c8537f6eb30cd6332","type":"GENE","name":"ABHD16A","canonical_id":"hgnc:HGNC:13921","description":"abhydrolase domain containing 16A, phospholipase","metadata":{"aliases":["NG26","D6S82E","BAT5"]}},{"id":"cf5ad22e8ff848b09d45e566dd2a94ab","type":"GENE","name":"ABHD16A-AS1","canonical_id":"hgnc:HGNC:59161","description":"ABHD16A antisense RNA 1","metadata":null},{"id":"60f2701667fd4968b4e7833121056b73","type":"GENE","name":"ABHD16B","canonical_id":"hgnc:HGNC:16128","description":"abhydrolase domain containing 16B","metadata":{"aliases":["dJ591C20.1","C20orf135"]}},{"id":"b05d59ab84a94cb8b0dda1e55c0d8623","type":"GENE","name":"ABHD16B-AS1","canonical_id":"hgnc:HGNC:58392","description":"ABHD16B antisense RNA 1","metadata":null},{"id":"0e7de206945b4dee867bf521b64de046","type":"GENE","name":"ABHD17A","canonical_id":"hgnc:HGNC:28756","description":"abhydrolase domain containing 17A, depalmitoylase","metadata":{"aliases":["MGC5244","C19orf27","FAM108A1"]}},{"id":"ef261ac8db044e2eae43d2954d2201df","type":"GENE","name":"ABHD17AP1","canonical_id":"hgnc:HGNC:28394","description":"ABHD17A pseudogene 1","metadata":{"aliases":["C1orf47","FAM108A2","ABHD17AP2","FAM108A3","FAM108A11P","FAM108A3P"]}},{"id":"1ed23011e3704d7ca20c8f40f97f7577","type":"GENE","name":"ABHD17AP3","canonical_id":"hgnc:HGNC:34041","description":"ABHD17A pseudogene 3","metadata":{"aliases":["FAM108A4","FAM108A4P"]}},{"id":"a7728c843d2443dca4b8bf0335bc6502","type":"GENE","name":"ABHD17AP4","canonical_id":"hgnc:HGNC:34042","description":"ABHD17A pseudogene 4","metadata":{"aliases":["FAM108A5","FAM108A5P"]}},{"id":"6073f770e41b4674a453b9bc3a20a3bc","type":"GENE","name":"ABHD17AP5","canonical_id":"hgnc:HGNC:34043","description":"ABHD17A pseudogene 5","metadata":{"aliases":["FAM108A6","FAM108A6P"]}},{"id":"80020b6945844e0cad3752910155a641","type":"GENE","name":"ABHD17AP6","canonical_id":"hgnc:HGNC:34044","description":"ABHD17A pseudogene 6","metadata":{"aliases":["FAM108A7P"]}},{"id":"fa4921505a5c4c60ade057594b72d6ba","type":"GENE","name":"ABHD17AP7","canonical_id":"hgnc:HGNC:38508","description":"ABHD17A pseudogene 7","metadata":{"aliases":["FAM108A8P"]}},{"id":"87587aa8a1a948258e073c769c0a6c0c","type":"GENE","name":"ABHD17AP8","canonical_id":"hgnc:HGNC:38509","description":"ABHD17A pseudogene 8","metadata":{"aliases":["FAM108A9P"]}},{"id":"85d513900f684a9bae26dfc82691168c","type":"GENE","name":"ABHD17AP9","canonical_id":"hgnc:HGNC:38510","description":"ABHD17A pseudogene 9","metadata":{"aliases":["FAM108A10P"]}},{"id":"6ce9804435e44374848ecac835b09c83","type":"GENE","name":"ABHD17B","canonical_id":"hgnc:HGNC:24278","description":"abhydrolase domain containing 17B, depalmitoylase","metadata":{"aliases":["CGI-67","C9orf77","FAM108B1"]}},{"id":"7729a3a171284c64a0005477b1873d16","type":"GENE","name":"ABHD17C","canonical_id":"hgnc:HGNC:26925","description":"abhydrolase domain containing 17C, depalmitoylase","metadata":{"aliases":["FAM108C1"]}},{"id":"f8b100194dbb49e9b2dab0664ddd5ab7","type":"GENE","name":"ABHD18","canonical_id":"hgnc:HGNC:26111","description":"abhydrolase domain containing 18","metadata":{"aliases":["FLJ21106","C4orf29"]}},{"id":"7b0a390a51fe44079ed5e3aa80b0fa74","type":"GENE","name":"ABHD2","canonical_id":"hgnc:HGNC:18717","description":"abhydrolase domain containing 2, acylglycerol lipase","metadata":{"aliases":["LABH2"]}},{"id":"7a5ba6cc59c4479689bbe480c9b4b88b","type":"GENE","name":"ABHD3","canonical_id":"hgnc:HGNC:18718","description":"abhydrolase domain containing 3, phospholipase","metadata":{"aliases":["LABH3"]}},{"id":"a385f68a65354615b732fcf24bb00387","type":"GENE","name":"ABHD4","canonical_id":"hgnc:HGNC:20154","description":"abhydrolase domain containing 4, N-acyl phospholipase B","metadata":{"aliases":["FLJ12816"]}},{"id":"c147d5e73d5d4eab9dacfac3e6de7d3f","type":"GENE","name":"ABHD5","canonical_id":"hgnc:HGNC:21396","description":"abhydrolase domain containing 5, lysophosphatidic acid acyltransferase","metadata":{"aliases":["CGI-58","NCIE2"]}},{"id":"09d00e85494245578fe86a46d7d48e6b","type":"GENE","name":"ABHD6","canonical_id":"hgnc:HGNC:21398","description":"abhydrolase domain containing 6, acylglycerol lipase","metadata":null},{"id":"f2ad733e76434a098060a873c647bbf8","type":"GENE","name":"ABHD8","canonical_id":"hgnc:HGNC:23759","description":"abhydrolase domain containing 8","metadata":{"aliases":["FLJ11743","MGC14280","MGC2512"]}},{"id":"85680123c0da4d38957f74ebd65a9622","type":"TRIAL","name":"ABI-008 Trial in Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00531271","description":"Metastatic Breast Cancer","metadata":null},{"id":"8674d5587a6d4c93bf43e734dc2153bb","type":"GENE","name":"ABI1","canonical_id":"hgnc:HGNC:11320","description":"abl interactor 1","metadata":{"aliases":["E3B1","ABI-1","SSH3BP1"]}},{"id":"cc22b3580c4e4b0f891b755e0c91c04c","type":"GENE","name":"ABI1P1","canonical_id":"hgnc:HGNC:20035","description":"abl interactor 1 pseudogene 1","metadata":{"aliases":["SSH3BP1P","ABI1P"]}},{"id":"17e443028add4bd58f29dbacc6643138","type":"GENE","name":"ABI2","canonical_id":"hgnc:HGNC:24011","description":"abl interactor 2","metadata":{"aliases":["ABI-2","AIP-1","ABI2B","AblBP3","argBPIA","SSH3BP2"]}},{"id":"26988163d1d344018df7d7a20823cebe","type":"GENE","name":"ABI3","canonical_id":"hgnc:HGNC:29859","description":"ABI family member 3","metadata":{"aliases":["NESH","SSH3BP3"]}},{"id":"bfe21c713dd64597a6ced54fcda66f88","type":"GENE","name":"ABI3BP","canonical_id":"hgnc:HGNC:17265","description":"ABI family member 3 binding protein","metadata":{"aliases":["NESHBP","DKFZP586L2024","TARSH"]}},{"id":"fc15fc273be840ccae463585f40bc70f","type":"GO_TERM","name":"ABIN2-NFKB1-MAP3K8 complex","canonical_id":"go:GO:0034977","description":"\"A protein complex that contains the precursor form of NF-kappaB (p105), the NF-kappaB inhibitor ABIN-2, and the kinase TPL-2 (MAP3K8); the complex stabilizes TPL-2 and is involved in signaling in lipopolysaccharide (LPS)-stimulated macrophages.\" [PMID:15169888]","metadata":null},{"id":"4e3e74bfda1147deb7c7281d319293d4","type":"GENE","name":"ABITRAM","canonical_id":"hgnc:HGNC:1364","description":"actin binding transcription modulator","metadata":{"aliases":["CG-8","FLJ20457","Simiate","C9orf6","FAM206A"]}},{"id":"ceaa6309f1ec4340a602450e94b53af9","type":"GENE","name":"ABITRAMP1","canonical_id":"hgnc:HGNC:39851","description":"ABITRAM pseudogene 1","metadata":{"aliases":["FAM206BP"]}},{"id":"57d7c3a13c464dfaa08c7d2d672ec568","type":"GENE","name":"ABL1","canonical_id":"hgnc:HGNC:76","description":null,"metadata":null},{"id":"7a54213edb0e4cc28eae6a9e68fc0176","type":"PROTEIN","name":"ABL1","canonical_id":"uniprot:P00519","description":null,"metadata":null},{"id":"87e791e59fb346c29cb19cbaf5681276","type":"GENE","name":"ABL1","canonical_id":"ensembl:ENSG00000097007","description":null,"metadata":null},{"id":"9556176cddf044b4a5e6b88e2f46cbca","type":"GENE","name":"ABL2","canonical_id":"hgnc:HGNC:77","description":null,"metadata":null},{"id":"7bb29ed934a3418096473b310f4c633f","type":"TRIAL","name":"ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness","canonical_id":"clinicaltrials.gov:NCT00484471","description":"Bipolar Disorder","metadata":null},{"id":"22cd25943103425094045f1a8be56779","type":"GENE","name":"ABLIM1","canonical_id":"hgnc:HGNC:78","description":"actin binding LIM protein 1","metadata":{"aliases":["abLIM","limatin","LIMAB1","ABLIM"]}},{"id":"055dd92dcccd4035be90244d3dba8750","type":"GENE","name":"ABLIM2","canonical_id":"hgnc:HGNC:19195","description":"actin binding LIM protein family member 2","metadata":{"aliases":["KIAA1808"]}},{"id":"2c3ffcde9d0a4ae9b0ff945237819c95","type":"GENE","name":"ABLIM2-DT","canonical_id":"hgnc:HGNC:58727","description":"ABLIM2 divergent transcript","metadata":null},{"id":"85b7edd53e61448c94ad01f4ebf4b498","type":"GENE","name":"ABLIM3","canonical_id":"hgnc:HGNC:29132","description":"actin binding LIM protein family member 3","metadata":{"aliases":["KIAA0843"]}},{"id":"623042a23d014b799812c23dbd62f7b4","type":"GENE","name":"ABO","canonical_id":"hgnc:HGNC:79","description":"ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase","metadata":{"aliases":["A3GALNT","A3GALT1"]}},{"id":"f881fd0b093c4e8f9c3752a3601c7c81","type":"GENE","name":"ABR","canonical_id":"hgnc:HGNC:81","description":"ABR activator of RhoGEF and GTPase","metadata":{"aliases":["MDB"]}},{"id":"534eeb22a6494db5afd2563591343947","type":"GENE","name":"ABR-AS1","canonical_id":"hgnc:HGNC:55674","description":"ABR antisense RNA 1","metadata":null},{"id":"0ae2e47e614b443ab5893400af171f1a","type":"GENE","name":"ABRA","canonical_id":"hgnc:HGNC:30655","description":"actin binding Rho activating protein","metadata":{"aliases":["STARS"]}},{"id":"15678461f8284bbe94bee55b586631d1","type":"GENE","name":"ABRACL","canonical_id":"hgnc:HGNC:21230","description":"ABRA C-terminal like","metadata":{"aliases":["PRO2013","HSPC280","Costars","C6orf115"]}},{"id":"29fea438c6a5474f93103be7f83a7834","type":"GENE","name":"ABRAXAS1","canonical_id":"hgnc:HGNC:25829","description":"abraxas 1, BRCA1 A complex subunit","metadata":{"aliases":["FLJ13614","ABRA1","ABRAXAS","CCDC98","FAM175A"]}},{"id":"e3e251ab27f444b4b00ec02688306032","type":"GENE","name":"ABRAXAS1P1","canonical_id":"hgnc:HGNC:56461","description":"ABRAXAS1 pseudogene 1","metadata":null},{"id":"ed2bcb3f0aa84b21820cd17a3b884640","type":"GENE","name":"ABRAXAS1P2","canonical_id":"hgnc:HGNC:56462","description":"ABRAXAS1 pseudogene 2","metadata":null},{"id":"590f459598c545ccad387fcc6fa1607d","type":"GENE","name":"ABRAXAS2","canonical_id":"hgnc:HGNC:28975","description":"abraxas 2, BRISC complex subunit","metadata":{"aliases":["Em:AC068896.4","ABRO1","KIAA0157","FAM175B"]}},{"id":"8680b759ac224ac584db1aa5104329d6","type":"TRIAL","name":"ABSORB II Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT01425281","description":"Coronary Artery Disease","metadata":null},{"id":"82e67cbf12924620a3a0ef733260e54a","type":"TRIAL","name":"ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)","canonical_id":"clinicaltrials.gov:NCT02471391","description":"Mantle Cell Lymphoma","metadata":null},{"id":"754536b1840b4ce190ec8d7c7adc689b","type":"DRUG","name":"ABT-267","canonical_id":"mesh:C586094","description":null,"metadata":null},{"id":"7e20c2e8e6994668837c9e6fcca5a4a0","type":"TRIAL","name":"ABT-751 With Chemotherapy for Relapsed Pediatric ALL","canonical_id":"clinicaltrials.gov:NCT00439296","description":"Recurrent Pediatric ALL; Relapsed Pediatric ALL; Acute Lymphoblastic Leukemia; Refractory Pediatric ALL","metadata":null},{"id":"647fd8aa56cf4b918e76f1a8d0e89b9d","type":"GENE","name":"ABT1","canonical_id":"hgnc:HGNC:17369","description":"activator of basal transcription 1","metadata":{"aliases":["Esf2"]}},{"id":"4642653c235942e8884bc883df96e3af","type":"GENE","name":"ABT1P1","canonical_id":"hgnc:HGNC:39557","description":"activator of basal transcription 1 pseudogene 1","metadata":null},{"id":"f186493f579d4f9eb2c58c5dc936d915","type":"GENE","name":"ABTB1","canonical_id":"hgnc:HGNC:18275","description":"ankyrin repeat and BTB domain containing 1","metadata":{"aliases":["BPOZ","EF1ABP","Btb3","BTBD21","BPOZ-2"]}},{"id":"46361ebd632444bea098ec713e7837cb","type":"GENE","name":"ABTB2","canonical_id":"hgnc:HGNC:23842","description":"ankyrin repeat and BTB domain containing 2","metadata":{"aliases":["DKFZP586C1619","BTBD22","ABTB2A"]}},{"id":"512d450a0d86485889d1288cec00eebb","type":"GENE","name":"ABTB3","canonical_id":"hgnc:HGNC:23844","description":"ankyrin repeat and BTB domain containing 3","metadata":{"aliases":["FLJ33957","ABTB2B","BTBD11"]}},{"id":"0a27e66c4dd94020a01e31b508522770","type":"GO_TERM","name":"ACA codon-amino acid adaptor activity","canonical_id":"go:GO:0033439","description":"\"A triplet codon-amino acid adaptor activity that recognizes an ACA codon.\" [GOC:mah]","metadata":null},{"id":"f94e9a73290c48d2aabf4aa2071ebbac","type":"GENE","name":"ACAA1","canonical_id":"hgnc:HGNC:82","description":"acetyl-CoA acyltransferase 1","metadata":{"aliases":["Lnc-Myd88"]}},{"id":"57d33f62261a4e3cacb78fc9734eafde","type":"GENE","name":"ACAA2","canonical_id":"hgnc:HGNC:83","description":"acetyl-CoA acyltransferase 2","metadata":{"aliases":["DSAEC"]}},{"id":"644b9fcad912405db9dcdfd53243c86b","type":"GENE","name":"ACAA2P1","canonical_id":"hgnc:HGNC:55880","description":"ACAA2 pseudogene 1","metadata":null},{"id":"65babc64797644eba109bb585258140c","type":"GENE","name":"ACACA","canonical_id":"hgnc:HGNC:84","description":null,"metadata":null},{"id":"1d30d8238bf24a3fa001f84e6c495d7d","type":"GENE","name":"ACACB","canonical_id":"hgnc:HGNC:85","description":null,"metadata":null},{"id":"09b8b9e595414beea77d089b213ce1c9","type":"GENE","name":"ACAD10","canonical_id":"hgnc:HGNC:21597","description":"acyl-CoA dehydrogenase family member 10","metadata":{"aliases":["MGC5601"]}},{"id":"db3c754cda304a1e89a22017a3fec3c6","type":"GENE","name":"ACAD11","canonical_id":"hgnc:HGNC:30211","description":"acyl-CoA dehydrogenase family member 11","metadata":{"aliases":["FLJ12592"]}},{"id":"16ce0fe649c84672a3a7af0067495dee","type":"GENE","name":"ACAD8","canonical_id":"hgnc:HGNC:87","description":"acyl-CoA dehydrogenase family member 8","metadata":null},{"id":"ce3c28cb11a94af696c1e5eb8e4c59e6","type":"GENE","name":"ACAD9","canonical_id":"hgnc:HGNC:21497","description":"acyl-CoA dehydrogenase family member 9","metadata":{"aliases":["NPD002","MGC14452"]}},{"id":"e5427ce3004d4a25acaa472970eb164a","type":"GENE","name":"ACAD9-DT","canonical_id":"hgnc:HGNC:56086","description":"ACAD9 divergent transcript","metadata":null},{"id":"7ad0d04527a14a8e832663814c0dd8b3","type":"GENE","name":"ACADL","canonical_id":"hgnc:HGNC:88","description":null,"metadata":null},{"id":"774ada6052b94c5e849466608f7c4a7f","type":"GENE","name":"ACADM","canonical_id":"hgnc:HGNC:89","description":"acyl-CoA dehydrogenase medium chain","metadata":{"aliases":["MCAD","MCADH","ACAD1"]}},{"id":"97f2d44bbf0047e29d8406c7681cd7c2","type":"GENE","name":"ACADS","canonical_id":"hgnc:HGNC:90","description":"acyl-CoA dehydrogenase short chain","metadata":{"aliases":["SCAD","ACAD3"]}},{"id":"65caf8f181af4332b1127e8f596508e7","type":"GENE","name":"ACADSB","canonical_id":"hgnc:HGNC:91","description":"acyl-CoA dehydrogenase short/branched chain","metadata":{"aliases":["SBCAD","ACAD7"]}},{"id":"27dd125cba144184ae12a5f8c5308daf","type":"GENE","name":"ACADVL","canonical_id":"hgnc:HGNC:92","description":"acyl-CoA dehydrogenase very long chain","metadata":{"aliases":["VLCAD","LCACD","ACAD6"]}},{"id":"5da3003e30124a32a9dd4115c1510983","type":"GENE","name":"ACAN","canonical_id":"hgnc:HGNC:319","description":null,"metadata":null},{"id":"e5c35efe8694491bb87066c114b4df64","type":"GENE","name":"ACAP1","canonical_id":"hgnc:HGNC:16467","description":"ArfGAP with coiled-coil, ankyrin repeat and PH domains 1","metadata":{"aliases":["KIAA0050","CENTB1"]}},{"id":"fe1a525210e74493b212e4b9f056efac","type":"GENE","name":"ACAP2","canonical_id":"hgnc:HGNC:16469","description":"ArfGAP with coiled-coil, ankyrin repeat and PH domains 2","metadata":{"aliases":["KIAA0041","CNT-B2","CENTB2"]}},{"id":"a6f1048f6abf4741a618a12a986d1493","type":"GENE","name":"ACAP2-IT1","canonical_id":"hgnc:HGNC:41426","description":"ACAP2 intronic transcript 1","metadata":null},{"id":"e7ba070288d7408ba9589443719403ad","type":"GENE","name":"ACAP3","canonical_id":"hgnc:HGNC:16754","description":"ArfGAP with coiled-coil, ankyrin repeat and PH domains 3","metadata":{"aliases":["KIAA1716","CENTB5"]}},{"id":"3172d9e12a6343f58641766b1ed8930a","type":"GENE","name":"ACAT1","canonical_id":"hgnc:HGNC:93","description":null,"metadata":null},{"id":"27efc5026d37414d8c364a08de5b2513","type":"GENE","name":"ACAT2","canonical_id":"hgnc:HGNC:94","description":null,"metadata":null},{"id":"1170ab4b80ea47b0aed18f4fab27c851","type":"GENE","name":"ACBD3","canonical_id":"hgnc:HGNC:15453","description":null,"metadata":null},{"id":"5a4c817f0ce04a7ca6dac9ec0eccdb8e","type":"GENE","name":"ACBD3-AS1","canonical_id":"hgnc:HGNC:40701","description":"ACBD3 antisense RNA 1","metadata":{"aliases":["RP11-275I14.4"]}},{"id":"46c4b577c911403f8467aa6322792f3c","type":"GENE","name":"ACBD4","canonical_id":"hgnc:HGNC:23337","description":"acyl-CoA binding domain containing 4","metadata":{"aliases":["FLJ13322"]}},{"id":"8b37d4614a76450283592375f73a94e9","type":"GENE","name":"ACBD5","canonical_id":"hgnc:HGNC:23338","description":"acyl-CoA binding domain containing 5","metadata":{"aliases":["DKFZp434A2417","KIAA1996"]}},{"id":"ae50140d19ec42a2bf290d0920aba178","type":"GENE","name":"ACBD6","canonical_id":"hgnc:HGNC:23339","description":"acyl-CoA binding domain containing 6","metadata":{"aliases":["MGC2404"]}},{"id":"9052f31e3f324f269dc8725e0330a92e","type":"GENE","name":"ACBD7","canonical_id":"hgnc:HGNC:17715","description":"acyl-CoA binding domain containing 7","metadata":{"aliases":["FLJ38219","bA455B2.2"]}},{"id":"05eb7d9151054bf9b93e9cddb42d788b","type":"GENE","name":"ACBD7P1","canonical_id":"hgnc:HGNC:58659","description":"ACBD7 pseudogene 1","metadata":null},{"id":"dbf0b4e688c344feb84c8ba406be9874","type":"GO_TERM","name":"ACC codon-amino acid adaptor activity","canonical_id":"go:GO:0033438","description":"\"A triplet codon-amino acid adaptor activity that recognizes an ACC codon.\" [GOC:mah]","metadata":null},{"id":"bb62b6321aa94752bb7c4e371be6d8fb","type":"GENE","name":"ACCS","canonical_id":"hgnc:HGNC:23989","description":"1-aminocyclopropane-1-carboxylate synthase homolog (inactive)","metadata":{"aliases":["PHACS","ACS"]}},{"id":"3f3a0036103b4d9b84774a51723c9ffe","type":"GENE","name":"ACCSL","canonical_id":"hgnc:HGNC:34391","description":"1-aminocyclopropane-1-carboxylate synthase homolog (inactive) like","metadata":null},{"id":"905e2a0485d14d53b0afa0bf4db26fcc","type":"GENE","name":"ACCSLP1","canonical_id":"hgnc:HGNC:56899","description":"ACCSL pseudogene 1","metadata":null},{"id":"bf3eca578569401eb0bb88fdd56706ae","type":"GENE","name":"ACD","canonical_id":"hgnc:HGNC:25070","description":"ACD shelterin complex subunit and telomerase recruitment factor","metadata":{"aliases":["Ptop","Pip1","Tpp1","Tint1"]}},{"id":"e0452c52661743b5bec378013b55ff0a","type":"GENE","name":"ACE","canonical_id":"hgnc:HGNC:2707","description":null,"metadata":null},{"id":"f2455560e0214077aa8891d9eb8285ac","type":"PROTEIN","name":"ACE","canonical_id":"uniprot:P12821","description":null,"metadata":null},{"id":"c1bd5103c1864c29bd08758074515b79","type":"TRIAL","name":"ACE Inhibition and Novel Cardiovascular Risk Factors","canonical_id":"clinicaltrials.gov:NCT00051389","description":"Cardiovascular Diseases; Heart Diseases; Hypertension","metadata":null},{"id":"fcb62d4c96b54145b5a27013ea3fff46","type":"TRIAL","name":"ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01535235","description":"HIV","metadata":null},{"id":"72403d3f88ba4cc483354648e8b18b8c","type":"TRIAL","name":"ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression","canonical_id":"clinicaltrials.gov:NCT06408246","description":"Depression","metadata":null},{"id":"765a9162f518451ebdc1586693106f14","type":"GENE","name":"ACE2","canonical_id":"hgnc:HGNC:13557","description":null,"metadata":null},{"id":"ff85ea7533a64d10a3684aef77ccb431","type":"GENE","name":"ACE2-DT","canonical_id":"hgnc:HGNC:56255","description":"ACE2 divergent transcript","metadata":{"aliases":["GS1-594A7.3"]}},{"id":"1669cdd4de4c47719ca473b8e7275759","type":"GENE","name":"ACE3P","canonical_id":"hgnc:HGNC:44365","description":"angiotensin I converting enzyme 3, pseudogene","metadata":null},{"id":"daceb920897d4fc39e04eb6acffbc9af","type":"GENE","name":"ACER1","canonical_id":"hgnc:HGNC:18356","description":"alkaline ceramidase 1","metadata":{"aliases":["ASAH3"]}},{"id":"19c00ad20a3549b58212f0c2edeba977","type":"GENE","name":"ACER2","canonical_id":"hgnc:HGNC:23675","description":"alkaline ceramidase 2","metadata":{"aliases":["FLJ41587","ALKCDase2","ASAH3L"]}},{"id":"7e7dccbd6e3340b7aca6ed91b73837ec","type":"GENE","name":"ACER2P1","canonical_id":"hgnc:HGNC:54674","description":"ACER2 pseudogene 1","metadata":null},{"id":"6e599ee7a1494a1696cd1d7f23d3ea7d","type":"GENE","name":"ACER3","canonical_id":"hgnc:HGNC:16066","description":"alkaline ceramidase 3","metadata":{"aliases":["FLJ11238","APHC","PHCA"]}},{"id":"1b1415af4a174c10975db311b5f03e2a","type":"GENE","name":"ACER3-AS1","canonical_id":"hgnc:HGNC:58067","description":"ACER antisense RNA 1","metadata":null},{"id":"a78a6a9a5a384a5eb9f632130fbfbb37","type":"TRIAL","name":"ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension","canonical_id":"clinicaltrials.gov:NCT03295734","description":"Hypertension; Aging; Sedentary Lifestyle","metadata":null},{"id":"86a27942828a4b0fae293242ee9d1e9e","type":"GO_TERM","name":"ACF complex","canonical_id":"go:GO:0016590","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (SNF2H in mammals, Isw2 in S. cerevisiae), an ACF1 homolog, and generally no other subunits, though Xenopus is an exception with a third non-conserved subunit. ACF plays roles in regulation of RNA polymerase II transcription and in DNA replication and repair.\" [GOC:bf, GOC:krc, PMID:12192034, PMID:15284901, PMID:16568949, PMID:21810179]","metadata":null},{"id":"fc2199a2557044bfa979d2bd6f21a1bd","type":"GO_TERM","name":"ACG codon-amino acid adaptor activity","canonical_id":"go:GO:0033440","description":"\"A triplet codon-amino acid adaptor activity that recognizes an ACG codon.\" [GOC:mah]","metadata":null},{"id":"37136a7ef7d24673ac0ef7618ed031b2","type":"GENE","name":"ACHE","canonical_id":"hgnc:HGNC:108","description":null,"metadata":null},{"id":"9abfe8ff250a4fbe8ab4b8a5b591b597","type":"GENE","name":"ACIN1","canonical_id":"hgnc:HGNC:17066","description":"apoptotic chromatin condensation inducer 1","metadata":{"aliases":["KIAA0670","fSAP152","ACINUS"]}},{"id":"a6e1081b68ef4bb6b3f06d7846dca74f","type":"GENE","name":"ACKR1","canonical_id":"hgnc:HGNC:4035","description":null,"metadata":null},{"id":"be64318c773a4c168e2876d729b0e342","type":"GENE","name":"ACKR2","canonical_id":"hgnc:HGNC:1565","description":"atypical chemokine receptor 2","metadata":{"aliases":["CCR10","D6","CCR9","CMKBR9","CCBP2"]}},{"id":"950413af27ed4447a4555e9a9001c9bb","type":"GENE","name":"ACKR3","canonical_id":"hgnc:HGNC:23692","description":null,"metadata":null},{"id":"4318d983e5b24ddda84d5c9ae7a69647","type":"GENE","name":"ACKR4","canonical_id":"hgnc:HGNC:1611","description":"atypical chemokine receptor 4","metadata":{"aliases":["CCR11","CCBP2","VSHK1","CCX-CKR","PPR1","CCRL1"]}},{"id":"a6498ff9f4c140d4af2a288ef694b142","type":"GENE","name":"ACKR4P1","canonical_id":"hgnc:HGNC:21142","description":"ACKR4 pseudogene 1","metadata":{"aliases":["dJ509I19.4","CCRL1P","CCRL1P1"]}},{"id":"0a55b3ad7ef54757935e0af95010f2be","type":"GENE","name":"ACKR5","canonical_id":"hgnc:HGNC:13708","description":"atypical chemokine receptor 5","metadata":{"aliases":["hrhAMR","G10D","AM-R","ADMR","GPR182"]}},{"id":"21965af0253849dead461216a5e5da8d","type":"TRIAL","name":"ACL Repair and Multimodal Analgesia","canonical_id":"clinicaltrials.gov:NCT01868425","description":"Pain","metadata":null},{"id":"abb631442c204846b1f3d4f6d7b3b2b6","type":"GENE","name":"ACLY","canonical_id":"hgnc:HGNC:115","description":null,"metadata":null},{"id":"a1ba69ec1ea84cf78974390be15d3a95","type":"GENE","name":"ACMSD","canonical_id":"hgnc:HGNC:19288","description":"aminocarboxymuconate semialdehyde decarboxylase","metadata":null},{"id":"0730ff5219e54e3eac9a86fc61b82096","type":"GENE","name":"ACNATP","canonical_id":"hgnc:HGNC:34504","description":"acyl-CoA:amino acid N-acyltransferase, pseudogene","metadata":{"aliases":["BAATP1"]}},{"id":"76594b38933c4a7883baa8ab6319f26c","type":"GENE","name":"ACO1","canonical_id":"hgnc:HGNC:117","description":null,"metadata":null},{"id":"9573fcf7bb21470baaa3f2b3c9f0508b","type":"GENE","name":"ACO2","canonical_id":"hgnc:HGNC:118","description":"aconitase 2","metadata":{"aliases":["ACONM"]}},{"id":"80e8788effb64123a8d986fbe84d2c13","type":"GENE","name":"ACO2P1","canonical_id":"hgnc:HGNC:56989","description":"ACO2 pseudogene 1","metadata":null},{"id":"a817d053bb4b463c87fe0448fe4d933b","type":"GENE","name":"ACO2P2","canonical_id":"hgnc:HGNC:56990","description":"ACO2 pseudogene 2","metadata":null},{"id":"e49ab2f3e7364e9ab39583d222f1244e","type":"GENE","name":"ACOD1","canonical_id":"hgnc:HGNC:33904","description":"aconitate decarboxylase 1","metadata":{"aliases":["CAD","IRG1"]}},{"id":"22ddd815f1a046829a572fb4e62d5676","type":"GENE","name":"ACOT1","canonical_id":"hgnc:HGNC:33128","description":"acyl-CoA thioesterase 1","metadata":{"aliases":["ACH2","CTE-1","LACH2"]}},{"id":"6036657e1ad543f2826028e6d14a571b","type":"GENE","name":"ACOT11","canonical_id":"hgnc:HGNC:18156","description":"acyl-CoA thioesterase 11","metadata":{"aliases":["STARD14","BFIT","KIAA0707","BFIT1","THEM1","THEA"]}},{"id":"30ab2ca570734dc09e1362752339313e","type":"GENE","name":"ACOT12","canonical_id":"hgnc:HGNC:24436","description":"acyl-CoA thioesterase 12","metadata":{"aliases":["Cach","THEAL","STARD15"]}},{"id":"6cbcf0bb23534fd7aae917fb34122777","type":"GENE","name":"ACOT12-DT","canonical_id":"hgnc:HGNC:59089","description":"ACOT12 divergent transcript","metadata":null},{"id":"8863d439a3ff48de89bd5664357da189","type":"GENE","name":"ACOT13","canonical_id":"hgnc:HGNC:20999","description":"acyl-CoA thioesterase 13","metadata":{"aliases":["HT012","THEM2"]}},{"id":"c55daebdd112433fbe51714103394cf6","type":"GENE","name":"ACOT2","canonical_id":"hgnc:HGNC:18431","description":"acyl-CoA thioesterase 2","metadata":{"aliases":["Mte1","ZAP128"]}},{"id":"b7622702a9624d788b3672881ab11698","type":"GENE","name":"ACOT4","canonical_id":"hgnc:HGNC:19748","description":"acyl-CoA thioesterase 4","metadata":{"aliases":["FLJ31235","PTE-Ib","PTE2B"]}},{"id":"833120c750394b3490df9a437b7767e4","type":"GENE","name":"ACOT4P1","canonical_id":"hgnc:HGNC:58578","description":"ACOT4 pseudogene 1","metadata":null},{"id":"80ffe5bc6eb343c59371901368510969","type":"GENE","name":"ACOT6","canonical_id":"hgnc:HGNC:33159","description":"acyl-CoA thioesterase 6","metadata":{"aliases":["C14orf42"]}},{"id":"89ebe20a75ab4e2eaeba179d73cb4d08","type":"GENE","name":"ACOT7","canonical_id":"hgnc:HGNC:24157","description":null,"metadata":null},{"id":"0d08a7910ac64f719245b768c11c21b9","type":"GENE","name":"ACOT8","canonical_id":"hgnc:HGNC:15919","description":"acyl-CoA thioesterase 8","metadata":{"aliases":["hACTE-III","hTE","PTE-2","NAP1","PTE1"]}},{"id":"388cb512254a41a282f6439b29a612c7","type":"GENE","name":"ACOT9","canonical_id":"hgnc:HGNC:17152","description":"acyl-CoA thioesterase 9","metadata":{"aliases":["CGI-16","MT-ACT48","ACATE2"]}},{"id":"7be732ada58847a09b36e3912981e7c5","type":"GENE","name":"ACOX1","canonical_id":"hgnc:HGNC:119","description":null,"metadata":null},{"id":"a2fdc3018a4940339cd327bc7bf3952b","type":"GENE","name":"ACOX2","canonical_id":"hgnc:HGNC:120","description":"acyl-CoA oxidase 2","metadata":{"aliases":["BRCACOX","BRCOX","THCCox"]}},{"id":"7ac6eef076fb4772b034959e39ac9254","type":"GENE","name":"ACOX3","canonical_id":"hgnc:HGNC:121","description":"acyl-CoA oxidase 3, pristanoyl","metadata":null},{"id":"61077f0da6334755a9c532a727be2e93","type":"GENE","name":"ACOXL","canonical_id":"hgnc:HGNC:25621","description":"acyl-CoA oxidase like","metadata":{"aliases":["FLJ11042","ACOX4"]}},{"id":"018ae4e7edc14dd39b75e8cf30333cbb","type":"GENE","name":"ACOXL-AS1","canonical_id":"hgnc:HGNC:41112","description":"ACOXL antisense RNA 1","metadata":null},{"id":"e23577a2af964bf19e7abd18ea6d4c7f","type":"GO_TERM","name":"ACP phosphopantetheine attachment site binding","canonical_id":"go:GO:0044620","description":"\"Binding to the attachment site of the phosphopantetheine prosthetic group of an acyl carrier protein (ACP).\" [GOC:jl, GOC:vw]","metadata":null},{"id":"0d2178ce457d4e6186984d3583694955","type":"GO_TERM","name":"ACP-dependent peptidyl-lysine N6-myristoyltransferase activity","canonical_id":"go:GO:0140769","description":"\"Catalysis of the reaction: L-lysyl-[protein] + tetradecanoyl-[ACP] = H+ + holo-[ACP] + N(6)-tetradecanoyl-L-lysyl-[protein].\" [PMID:32461253, RHEA:70611]","metadata":null},{"id":"f5815d2d36b44878851650082cae71dc","type":"GO_TERM","name":"ACP-dependent peptidyl-lysine N6-palmitoyltransferase activity","canonical_id":"go:GO:0140771","description":"\"Catalysis of the reaction: hexadecanoyl-[ACP] + L-lysyl-[protein] = H+ + holo-[ACP] + N(6)-hexadecanoyl-L-lysyl-[protein].\" [PMID:32461253, RHEA:70615]","metadata":null},{"id":"4ee81876acb14ded96f529cbbfc62a6d","type":"GENE","name":"ACP1","canonical_id":"hgnc:HGNC:122","description":"acid phosphatase 1","metadata":{"aliases":["HAAP","LMW-PTP","LMWPTP"]}},{"id":"8dde537ea5084a1c8b3860e53d752f74","type":"GENE","name":"ACP2","canonical_id":"hgnc:HGNC:123","description":"acid phosphatase 2, lysosomal","metadata":{"aliases":["LAP"]}},{"id":"5bb9e0f3cc89464888b50aa65ed8f135","type":"GENE","name":"ACP3","canonical_id":"hgnc:HGNC:125","description":"acid phosphatase 3","metadata":{"aliases":["ACP-3","PAP","TM-PAP","ACPP"]}},{"id":"74587c94f8284d47bd03c2fb0d6c6e90","type":"GENE","name":"ACP4","canonical_id":"hgnc:HGNC:14376","description":"acid phosphatase 4","metadata":{"aliases":["ACPT"]}},{"id":"95d3331fb3354d4d8a2d6edffdf2719f","type":"GENE","name":"ACP5","canonical_id":"hgnc:HGNC:124","description":null,"metadata":null},{"id":"9b0657e474674182b4de09077817456a","type":"GENE","name":"ACP6","canonical_id":"hgnc:HGNC:29609","description":"acid phosphatase 6, lysophosphatidic","metadata":{"aliases":["LPAP","ACPL1"]}},{"id":"a79b316ca76f4540ad9ddaadcc10023e","type":"GENE","name":"ACP7","canonical_id":"hgnc:HGNC:33781","description":"acid phosphatase 7, tartrate resistant (putative)","metadata":{"aliases":["FLJ16165","PAPL1","PAPL"]}},{"id":"e0d3279b77e243029c4aa29b7c511191","type":"DISEASE","name":"ACPA-positive rheumatoid arthritis","canonical_id":"efo:0009459","description":null,"metadata":null},{"id":"5e88c63d8d2948859733d72331412aea","type":"GENE","name":"ACR","canonical_id":"hgnc:HGNC:126","description":null,"metadata":null},{"id":"6ad3351a947f4cba80e89dc847cb7865","type":"GENE","name":"ACRBP","canonical_id":"hgnc:HGNC:17195","description":"acrosin binding protein","metadata":{"aliases":["SP32","OY-TES-1","CT23"]}},{"id":"a8b2554ce2eb41e48aaa31e8583fa4a8","type":"TRIAL","name":"ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding","canonical_id":"clinicaltrials.gov:NCT00616460","description":"Hematologic Diseases","metadata":null},{"id":"bc21ede4580d45db8f03170a84374a8e","type":"GENE","name":"ACRP1","canonical_id":"hgnc:HGNC:54745","description":"ACR pseudogene 1","metadata":null},{"id":"f7e5c827b05d43628a16157f49c15877","type":"GENE","name":"ACRV1","canonical_id":"hgnc:HGNC:127","description":null,"metadata":null},{"id":"fbf5683a2340483e96e83ecd9fe7f679","type":"GENE","name":"ACSBG1","canonical_id":"hgnc:HGNC:29567","description":"acyl-CoA synthetase bubblegum family member 1","metadata":{"aliases":["BGM","FLJ30320","MGC14352","BG1","KIAA0631","hBG1","hsBG"]}},{"id":"cbce0113cdef4cb0ba52f46f2c845ea8","type":"GENE","name":"ACSBG2","canonical_id":"hgnc:HGNC:24174","description":"acyl-CoA synthetase bubblegum family member 2","metadata":{"aliases":["BGR","PRTD-NY3","DKFZp434K1635"]}},{"id":"0d7ce472250b4f71b92758f93da493ad","type":"GENE","name":"ACSBG3P","canonical_id":"hgnc:HGNC:59199","description":"acyl-CoA synthetase bubblegum family member 3, pseudogene","metadata":null},{"id":"c838f4ac393849ba8c7fcf18def40240","type":"GENE","name":"ACSF2","canonical_id":"hgnc:HGNC:26101","description":"acyl-CoA synthetase family member 2","metadata":{"aliases":["FLJ20920","ACSMW"]}},{"id":"e97e892957a74fe38e1391706aaa4491","type":"GENE","name":"ACSF3","canonical_id":"hgnc:HGNC:27288","description":"acyl-CoA synthetase family member 3","metadata":null},{"id":"6bf5e2169a3f41f69af321d530f0e238","type":"GENE","name":"ACSL1","canonical_id":"hgnc:HGNC:3569","description":null,"metadata":null},{"id":"a56decfd2fbf48f2b2ef35ad25a47fbc","type":"GENE","name":"ACSL1-DT","canonical_id":"hgnc:HGNC:58916","description":"ACSL1 divergent transcript","metadata":null},{"id":"1ab1688e027e463687f3b1da4d66d728","type":"GENE","name":"ACSL3","canonical_id":"hgnc:HGNC:3570","description":"acyl-CoA synthetase long chain family member 3","metadata":{"aliases":["ACS3","PRO2194","FACL3"]}},{"id":"9bdb699d606f4bbc938c9f5cf93f3aee","type":"GENE","name":"ACSL3-AS1","canonical_id":"hgnc:HGNC:40227","description":"ACSL3 antisense RNA 1","metadata":null},{"id":"a248016b9fd54cd584ac755f6ffb2408","type":"GENE","name":"ACSL3P1","canonical_id":"hgnc:HGNC:56529","description":"ACSL3 pseudogene 1","metadata":null},{"id":"48a3218eba09452ab843f3917f5ca715","type":"GENE","name":"ACSL4","canonical_id":"hgnc:HGNC:3571","description":"acyl-CoA synthetase long chain family member 4","metadata":{"aliases":["ACS4","LACS4","FACL4","MRX63","MRX68"]}},{"id":"54a3e5b2b4554c23a098b36708aaa92b","type":"GENE","name":"ACSL5","canonical_id":"hgnc:HGNC:16526","description":"acyl-CoA synthetase long chain family member 5","metadata":{"aliases":["ACS5","ACS2","FACL5"]}},{"id":"b488ded87641425f84f2a04d7d646b5e","type":"GENE","name":"ACSL6","canonical_id":"hgnc:HGNC:16496","description":"acyl-CoA synthetase long chain family member 6","metadata":{"aliases":["KIAA0837","ACS2","LACS5","LACS2","FACL6"]}},{"id":"45e921b59a3247088ccf1221376484ef","type":"GENE","name":"ACSL6-AS1","canonical_id":"hgnc:HGNC:40772","description":"ACSL6 antisense RNA 1","metadata":null},{"id":"7c15e267b688450a96c91fd9722ce8b6","type":"GENE","name":"ACSL6-AS2","canonical_id":"hgnc:HGNC:40773","description":"ACSL6 antisense RNA 2","metadata":null},{"id":"8c1e6cdea28f433d89b3960a435058f4","type":"GENE","name":"ACSM1","canonical_id":"hgnc:HGNC:18049","description":"acyl-CoA synthetase medium chain family member 1","metadata":{"aliases":["MACS1","BUCS1"]}},{"id":"f9c5f0014e324859ac52ec7cc3a272ec","type":"GENE","name":"ACSM2A","canonical_id":"hgnc:HGNC:32017","description":"acyl-CoA synthetase medium chain family member 2A","metadata":{"aliases":["A-923A4.1","MGC150530","ACSM2"]}},{"id":"e555523807ab4bffab4567389f531a0f","type":"GENE","name":"ACSM2B","canonical_id":"hgnc:HGNC:30931","description":"acyl-CoA synthetase medium chain family member 2B","metadata":{"aliases":["HXMA","HYST1046","ACSM2"]}},{"id":"dd9ee8aecefa4771867f72a9801d82fb","type":"GENE","name":"ACSM3","canonical_id":"hgnc:HGNC:10522","description":"acyl-CoA synthetase medium chain family member 3","metadata":{"aliases":["SA","SAH"]}},{"id":"8885a71a85d743e99b482f4f5f9f2fce","type":"GENE","name":"ACSM4","canonical_id":"hgnc:HGNC:32016","description":"acyl-CoA synthetase medium chain family member 4","metadata":null},{"id":"030c4551dcd14fe28dd8c48402cc745d","type":"GENE","name":"ACSM5","canonical_id":"hgnc:HGNC:26060","description":"acyl-CoA synthetase medium chain family member 5","metadata":{"aliases":["FLJ20581"]}},{"id":"b6d7dd7d31ff44cb90605594b3af5cc1","type":"GENE","name":"ACSM5P1","canonical_id":"hgnc:HGNC:51295","description":"acyl-CoA synthetase medium chain family member 5 pseudogene 1","metadata":null},{"id":"cacde078d7fd41b5b3ce1a9609affe3f","type":"GENE","name":"ACSM6","canonical_id":"hgnc:HGNC:31665","description":"acyl-CoA synthetase medium chain family member 6","metadata":{"aliases":["bA310E22.3","C10orf129"]}},{"id":"5665bac6ae2c4e7fbdc5f207c37df350","type":"GENE","name":"ACSS1","canonical_id":"hgnc:HGNC:16091","description":"acyl-CoA synthetase short chain family member 1","metadata":{"aliases":["dJ568C11.3","AceCS2L","MGC33843","ACAS2L"]}},{"id":"3119918edac74c0b8687b1de2eb54dd5","type":"GENE","name":"ACSS2","canonical_id":"hgnc:HGNC:15814","description":"acyl-CoA synthetase short chain family member 2","metadata":{"aliases":["ACS","ACSA","AceCS","dJ1161H23.1","ACAS2"]}},{"id":"b303655a8d53473c81172ffacb321d4f","type":"GENE","name":"ACSS3","canonical_id":"hgnc:HGNC:24723","description":"acyl-CoA synthetase short chain family member 3","metadata":{"aliases":["FLJ21963"]}},{"id":"e4bcda535af54106b0ba134bcb103b97","type":"GENE","name":"ACSS3-AS1","canonical_id":"hgnc:HGNC:58286","description":"ACSS3 antisense RNA 1","metadata":null},{"id":"462423c0562849a2989db7a34b0c6439","type":"TRIAL","name":"ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.","canonical_id":"clinicaltrials.gov:NCT04061798","description":"Abdominal Aortic Aneurysm; Surgery; Arterial Disease","metadata":null},{"id":"32280804e2f64a53aeb73c45928fda95","type":"GENE","name":"ACTA1","canonical_id":"hgnc:HGNC:129","description":null,"metadata":null},{"id":"2f32f6181d0540b9b1ecb38e9984d4c7","type":"GENE","name":"ACTA2","canonical_id":"hgnc:HGNC:130","description":null,"metadata":null},{"id":"fbddde34c92048b6abfd9a53720903ab","type":"GENE","name":"ACTA2-AS1","canonical_id":"hgnc:HGNC:45169","description":"ACTA2 antisense RNA 1","metadata":{"aliases":["uc001kfo.1","ZXF1","UC001kfo"]}},{"id":"7d4bffcfaf9545e0b0863c0bb583a880","type":"GENE","name":"ACTB","canonical_id":"hgnc:HGNC:132","description":"actin beta","metadata":null},{"id":"bf7e1a2327934169bd642e675f158690","type":"GENE","name":"ACTBL2","canonical_id":"hgnc:HGNC:17780","description":"actin beta like 2","metadata":{"aliases":["DKFZp686D0972"]}},{"id":"75711cd5af654e58b89dc6a0acb15a0a","type":"GENE","name":"ACTBP1","canonical_id":"hgnc:HGNC:134","description":"ACTB pseudogene 1","metadata":null},{"id":"7976ca1bc6ab4ab5b750b7e51b14f3e9","type":"GENE","name":"ACTBP10","canonical_id":"hgnc:HGNC:31819","description":"ACTB pseudogene 10","metadata":null},{"id":"d8e2e0375eb047aba9e967c63f26533e","type":"GENE","name":"ACTBP11","canonical_id":"hgnc:HGNC:33971","description":"ACTB pseudogene 11","metadata":null},{"id":"f96bd458d866442393be47fc646a35b5","type":"GENE","name":"ACTBP12","canonical_id":"hgnc:HGNC:150","description":"ACTB pseudogene 12","metadata":{"aliases":["ACTGP5"]}},{"id":"aa5fbb1445bc48708d7836fd2314fb5a","type":"GENE","name":"ACTBP14","canonical_id":"hgnc:HGNC:45086","description":"ACTB pseudogene 14","metadata":null},{"id":"6285d0668f5b4b00be0c40bea167d3f1","type":"GENE","name":"ACTBP15","canonical_id":"hgnc:HGNC:55065","description":"ACTB pseudogene 15","metadata":null},{"id":"ba245fca436d4918a41285d983716c6e","type":"GENE","name":"ACTBP16","canonical_id":"hgnc:HGNC:56590","description":"ACTB pseudogene 16","metadata":null},{"id":"017fbf91c81e44d987165a9c3071f63c","type":"GENE","name":"ACTBP2","canonical_id":"hgnc:HGNC:135","description":"ACTB pseudogene 2","metadata":null},{"id":"e65e7235cccf4c9b83ab991f0cf6b4a6","type":"GENE","name":"ACTBP3","canonical_id":"hgnc:HGNC:136","description":"ACTB pseudogene 3","metadata":null},{"id":"48430ea84d1349f8940282e4fd18a506","type":"GENE","name":"ACTBP4","canonical_id":"hgnc:HGNC:137","description":"ACTB pseudogene 4","metadata":null},{"id":"110df73084ce49a89c87df78a0dbbc49","type":"GENE","name":"ACTBP6","canonical_id":"hgnc:HGNC:139","description":"ACTB pseudogene 6","metadata":null},{"id":"a6f5f1b934d4443cab4c2eea2ac49117","type":"GENE","name":"ACTBP7","canonical_id":"hgnc:HGNC:140","description":"ACTB pseudogene 7","metadata":null},{"id":"e312a99ff4f44e32b63e111fb07c84fb","type":"GENE","name":"ACTBP8","canonical_id":"hgnc:HGNC:141","description":"ACTB pseudogene 8","metadata":{"aliases":["ACTBP2"]}},{"id":"2050a8af08e84f2a8291ec756a718880","type":"GENE","name":"ACTBP9","canonical_id":"hgnc:HGNC:142","description":"ACTB pseudogene 9","metadata":null},{"id":"220e194a2edc4179b44b6cf99f5886ea","type":"GENE","name":"ACTC1","canonical_id":"hgnc:HGNC:143","description":null,"metadata":null},{"id":"d8254d05b5a34012a550899873fec096","type":"GENE","name":"ACTE1P","canonical_id":"hgnc:HGNC:51491","description":"actin epsilon 1, pseudogene","metadata":null},{"id":"8927a34143b74fdd886d329de0a55c6a","type":"GENE","name":"ACTG1","canonical_id":"hgnc:HGNC:144","description":"actin gamma 1","metadata":{"aliases":["ACTG","DFNA20","DFNA26"]}},{"id":"34ba90eef4fd4b818e4be61d97166d60","type":"GENE","name":"ACTG1P1","canonical_id":"hgnc:HGNC:146","description":"actin gamma 1 pseudogene 1","metadata":{"aliases":["ACTGP1","ACT1GP1"]}},{"id":"cdf5c2a3421b421ebe87f145e188d6d4","type":"GENE","name":"ACTG1P10","canonical_id":"hgnc:HGNC:155","description":"actin gamma 1 pseudogene 10","metadata":{"aliases":["ACTL1","ACTGP10"]}},{"id":"da76d59549ab43da8d610f8794f90f80","type":"GENE","name":"ACTG1P11","canonical_id":"hgnc:HGNC:37651","description":"actin gamma 1 pseudogene 11","metadata":null},{"id":"9ac7e7375f7747ab81162a24333cdae3","type":"GENE","name":"ACTG1P12","canonical_id":"hgnc:HGNC:44496","description":"actin gamma 1 pseudogene 12","metadata":null},{"id":"f639b982d52f428080387a8801c4cff6","type":"GENE","name":"ACTG1P13","canonical_id":"hgnc:HGNC:49058","description":"actin gamma 1 pseudogene 13","metadata":null},{"id":"d0a4700cab7f468bb7c37d300e5c7799","type":"GENE","name":"ACTG1P14","canonical_id":"hgnc:HGNC:49751","description":"actin gamma 1 pseudogene 14","metadata":null},{"id":"5af1aed015f9421b87c2c0717d4cc309","type":"GENE","name":"ACTG1P15","canonical_id":"hgnc:HGNC:51495","description":"actin gamma 1 pseudogene 15","metadata":null},{"id":"726c376c7cef413e8f2eac3fce2a6520","type":"GENE","name":"ACTG1P16","canonical_id":"hgnc:HGNC:51496","description":"actin gamma 1 pseudogene 16","metadata":null},{"id":"fc509f0b7b9645ac8147884bcaa11eb9","type":"GENE","name":"ACTG1P17","canonical_id":"hgnc:HGNC:51497","description":"actin gamma 1 pseudogene 17","metadata":null},{"id":"2b7a0be38c2c4d1f8990ec784104f3ea","type":"GENE","name":"ACTG1P18","canonical_id":"hgnc:HGNC:51498","description":"actin gamma 1 pseudogene 18","metadata":null},{"id":"3798e973b7be411e8a9c3c6eb2bbb5aa","type":"GENE","name":"ACTG1P19","canonical_id":"hgnc:HGNC:51499","description":"actin gamma 1 pseudogene 19","metadata":null},{"id":"d0c276bae5244782a278da086cd76b51","type":"GENE","name":"ACTG1P2","canonical_id":"hgnc:HGNC:147","description":"actin gamma 1 pseudogene 2","metadata":{"aliases":["ACTL2","ACTGP2"]}},{"id":"97a789b49f9146cfa7ab552b0c8b5965","type":"GENE","name":"ACTG1P20","canonical_id":"hgnc:HGNC:51500","description":"actin gamma 1 pseudogene 20","metadata":null},{"id":"44e29b82318747c48ddc5500db78af40","type":"GENE","name":"ACTG1P21","canonical_id":"hgnc:HGNC:51501","description":"actin gamma 1 pseudogene 21","metadata":null},{"id":"40d79d5004344d3da8ffb8eadbe76a0a","type":"GENE","name":"ACTG1P22","canonical_id":"hgnc:HGNC:51502","description":"actin gamma 1 pseudogene 22","metadata":null},{"id":"4c33850a24b7425e9eab68e23467afbe","type":"GENE","name":"ACTG1P23","canonical_id":"hgnc:HGNC:51503","description":"actin gamma 1 pseudogene 23","metadata":null},{"id":"aedd6d9abe2b4cc9a4dacbc1c55bb08b","type":"GENE","name":"ACTG1P24","canonical_id":"hgnc:HGNC:49661","description":"actin gamma 1 pseudogene 24","metadata":{"aliases":["POTENP"]}},{"id":"629c7afa77414a198357781aee991ce2","type":"GENE","name":"ACTG1P25","canonical_id":"hgnc:HGNC:54872","description":"actin gamma 1 pseudogene 25","metadata":{"aliases":["AGPG"]}},{"id":"614ff5299c4d4576871878a36e69dd72","type":"GENE","name":"ACTG1P3","canonical_id":"hgnc:HGNC:148","description":"actin gamma 1 pseudogene 3","metadata":{"aliases":["ACTGP3"]}},{"id":"e1ce51bea4b148edb6400b073de3ad35","type":"GENE","name":"ACTG1P4","canonical_id":"hgnc:HGNC:149","description":"actin gamma 1 pseudogene 4","metadata":{"aliases":["ACTGP4"]}},{"id":"bce513809c934ae893557fc9fef9b217","type":"GENE","name":"ACTG1P6","canonical_id":"hgnc:HGNC:151","description":"actin gamma 1 pseudogene 6","metadata":{"aliases":["ACTGP6"]}},{"id":"17bcc5507b9b40809f64eade4d062234","type":"GENE","name":"ACTG1P7","canonical_id":"hgnc:HGNC:152","description":"actin gamma 1 pseudogene 7","metadata":{"aliases":["ACTGP7"]}},{"id":"3f75737f7b0249a2a36d773509f00133","type":"GENE","name":"ACTG1P8","canonical_id":"hgnc:HGNC:153","description":"actin gamma 1 pseudogene 8","metadata":{"aliases":["ACTGP8"]}},{"id":"b32e3676d3fa44bfb34ed0ecf0b76bfb","type":"GENE","name":"ACTG1P9","canonical_id":"hgnc:HGNC:154","description":"actin gamma 1 pseudogene 9","metadata":{"aliases":["ACTGP9"]}},{"id":"f5075f737ee34deeb3b8c2431356c791","type":"GENE","name":"ACTG2","canonical_id":"hgnc:HGNC:145","description":null,"metadata":null},{"id":"face0db282c2449781d1d2c3f26c1392","type":"DISEASE","name":"ACTH-dependent Cushing syndrome","canonical_id":"mondo:0020528","description":null,"metadata":null},{"id":"39be09ab3c8844e09a479433c0f9370a","type":"TRIAL","name":"ACTIV-2: A Study for Outpatients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04518410","description":"Coronavirus; Covid19","metadata":null},{"id":"5e3efc32dc0848a8bb1dd794be469c9a","type":"TRIAL","name":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)","canonical_id":"clinicaltrials.gov:NCT05890586","description":"Covid19","metadata":null},{"id":"34da609e442b46179638e44609aed4fa","type":"TRIAL","name":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)","canonical_id":"clinicaltrials.gov:NCT05736874","description":"Covid19","metadata":null},{"id":"4a61c5b89c6a4d8cbdcf7c364fd1312d","type":"TRIAL","name":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)","canonical_id":"clinicaltrials.gov:NCT05894564","description":"Covid19","metadata":null},{"id":"92d1d3d547834420ac74435318162087","type":"TRIAL","name":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)","canonical_id":"clinicaltrials.gov:NCT05894577","description":"Covid19","metadata":null},{"id":"a4a42490ead34f8d9ef03fc1b5e04072","type":"GENE","name":"ACTL10","canonical_id":"hgnc:HGNC:16127","description":"actin like 10","metadata":{"aliases":["C20orf134"]}},{"id":"d073226d97f24f63a5551e7efb62f7e4","type":"GENE","name":"ACTL11P","canonical_id":"hgnc:HGNC:44626","description":"actin like 11, pseudogene","metadata":{"aliases":["ACTBP13"]}},{"id":"6916e31fa3734e25934f45dad7a37f94","type":"GENE","name":"ACTL6A","canonical_id":"hgnc:HGNC:24124","description":"actin like 6A","metadata":{"aliases":["Actl6","BAF53A","Arp4","Baf53a","INO80K","SMARCN1"]}},{"id":"ce403e9298a74d8da75049718d1fc44f","type":"GENE","name":"ACTL6A-AS1","canonical_id":"hgnc:HGNC:58683","description":"ACTL6A antisense RNA 1","metadata":null},{"id":"8bb60dd29fcc406e8bbf36a480c6ece7","type":"GENE","name":"ACTL6B","canonical_id":"hgnc:HGNC:160","description":"actin like 6B","metadata":{"aliases":["BAF53B","SMARCN2","ACTL6"]}},{"id":"84b28295b2aa41cab1196ee71ccf125b","type":"GENE","name":"ACTL7A","canonical_id":"hgnc:HGNC:161","description":"actin like 7A","metadata":null},{"id":"c7010df9ee714b8ca67f94eedf4f861d","type":"GENE","name":"ACTL7B","canonical_id":"hgnc:HGNC:162","description":"actin like 7B","metadata":{"aliases":["Tact1"]}},{"id":"983a5a96a61540dc870a8ea9ca1c436b","type":"GENE","name":"ACTL8","canonical_id":"hgnc:HGNC:24018","description":"actin like 8","metadata":{"aliases":["CT57"]}},{"id":"d6d1a4166f4e400f916bfae5ea8d710c","type":"GENE","name":"ACTL9","canonical_id":"hgnc:HGNC:28494","description":"actin like 9","metadata":{"aliases":["MGC33407"]}},{"id":"f8c4baeeb30c4482806781760fec55d0","type":"GENE","name":"ACTMAP","canonical_id":"hgnc:HGNC:24758","description":"actin maturation protease","metadata":{"aliases":["FLJ41131","C19orf54"]}},{"id":"fe90aa869420428f8e8cec715e87fc04","type":"GENE","name":"ACTN1","canonical_id":"hgnc:HGNC:163","description":"actinin alpha 1","metadata":null},{"id":"180aa5579cb44c4d93dd35a7660e87d9","type":"GENE","name":"ACTN1-DT","canonical_id":"hgnc:HGNC:20131","description":"ACTN1 divergent transcript","metadata":{"aliases":["C14orf84","ACTN1-AS1"]}},{"id":"2c07fea9489f40a3b78a75d502132520","type":"GENE","name":"ACTN2","canonical_id":"hgnc:HGNC:164","description":"actinin alpha 2","metadata":null},{"id":"9c04c908773643e1bc8751c4b421da80","type":"GENE","name":"ACTN3","canonical_id":"hgnc:HGNC:165","description":"actinin alpha 3","metadata":null},{"id":"bffd750357474bf4aaa460dd136e849e","type":"GENE","name":"ACTN3-AS1","canonical_id":"hgnc:HGNC:58248","description":"ACTN3 antisense RNA 1","metadata":null},{"id":"cbd9275a52284bc48c599e1f34045eb8","type":"GENE","name":"ACTN4","canonical_id":"hgnc:HGNC:166","description":null,"metadata":null},{"id":"5b473ee46f3c4ac2967873175881807c","type":"GENE","name":"ACTN4-AS1","canonical_id":"hgnc:HGNC:58572","description":"ACTN4 antisense RNA 1","metadata":null},{"id":"75157cc82df94f2f9970f36daaf85db6","type":"GENE","name":"ACTN4P1","canonical_id":"hgnc:HGNC:44028","description":"actinin alpha 4 pseudogene 1","metadata":null},{"id":"102e573c3aa34b1590844eeba57d3b92","type":"GENE","name":"ACTN4P2","canonical_id":"hgnc:HGNC:44032","description":"actinin alpha 4 pseudogene 2","metadata":null},{"id":"a822cf3e60df4aa28fc526c63bbc65b2","type":"GENE","name":"ACTP1","canonical_id":"hgnc:HGNC:51621","description":"actin family pseudogene 1","metadata":null},{"id":"933815b35d374657821c0bb1b8be55f9","type":"GENE","name":"ACTR10","canonical_id":"hgnc:HGNC:17372","description":"actin related protein 10","metadata":{"aliases":["HARP11","ACTR11","Arp11","Arp10"]}},{"id":"eefaaf9af0ba47819024d1ba20d147d5","type":"GENE","name":"ACTR1A","canonical_id":"hgnc:HGNC:167","description":"actin related protein 1A","metadata":{"aliases":["ARP1","Arp1A"]}},{"id":"e4bc9d4544924e1ba783023508e8e9cb","type":"GENE","name":"ACTR1AP1","canonical_id":"hgnc:HGNC:54703","description":"ACTR1A pseudogene 1","metadata":null},{"id":"42c4911d0adc4f6b941610a02431d3b8","type":"GENE","name":"ACTR1B","canonical_id":"hgnc:HGNC:168","description":"actin related protein 1B","metadata":{"aliases":["Arp1B","CTRN2"]}},{"id":"28c39db7a15d4e8b8de42c8c0dec9e92","type":"GENE","name":"ACTR2","canonical_id":"hgnc:HGNC:169","description":"actin related protein 2","metadata":{"aliases":["ARP2"]}},{"id":"ec2b2facab3047ce8c155a942d486f6e","type":"GENE","name":"ACTR2P1","canonical_id":"hgnc:HGNC:56978","description":"ACTR2 pseudogene 1","metadata":null},{"id":"743a5dfa87394dc58a373548483f819c","type":"GENE","name":"ACTR2P2","canonical_id":"hgnc:HGNC:57006","description":"ACTR2 pseudogene 2","metadata":null},{"id":"967309b3e8eb4f23a32487f26c3efc5b","type":"GENE","name":"ACTR3","canonical_id":"hgnc:HGNC:170","description":"actin related protein 3","metadata":{"aliases":["ARP3"]}},{"id":"b39c9bb5a59242f189096fe8f0a27bbb","type":"GENE","name":"ACTR3-AS1","canonical_id":"hgnc:HGNC:53965","description":"ACTR3 antisense RNA 1","metadata":{"aliases":["AC104653.1"]}},{"id":"5b1f1c4046e241e6b10f37b5b0c0a9d5","type":"GENE","name":"ACTR3B","canonical_id":"hgnc:HGNC:17256","description":"actin related protein 3B","metadata":{"aliases":["ARP11","ARP3beta"]}},{"id":"f6e89af1c80d4a4cb51d9fb182cbb2c4","type":"GENE","name":"ACTR3BP1","canonical_id":"hgnc:HGNC:37724","description":"ACTR3B pseudogene 1","metadata":null},{"id":"fdf0ee5c079e422f84d21dfecc827281","type":"GENE","name":"ACTR3BP2","canonical_id":"hgnc:HGNC:38677","description":"ACTR3B pseudogene 2","metadata":{"aliases":["FKSG73"]}},{"id":"2911c6490ae44927b21a618f3af4541d","type":"GENE","name":"ACTR3BP3","canonical_id":"hgnc:HGNC:38678","description":"ACTR3B pseudogene 3","metadata":null},{"id":"00c055ea397a4a8cba16a88d39c90aeb","type":"GENE","name":"ACTR3BP4","canonical_id":"hgnc:HGNC:38681","description":"ACTR3B pseudogene 4","metadata":null},{"id":"901e5009aacc436c83b539d467965927","type":"GENE","name":"ACTR3BP5","canonical_id":"hgnc:HGNC:38682","description":"ACTR3B pseudogene 5","metadata":null},{"id":"ffc69b8ac8d14345811831eb55532537","type":"GENE","name":"ACTR3BP6","canonical_id":"hgnc:HGNC:38683","description":"ACTR3B pseudogene 6","metadata":null},{"id":"9984f03ea83a43b5aec4e23fee009db4","type":"GENE","name":"ACTR3BP7","canonical_id":"hgnc:HGNC:54971","description":"ACTR3B pseudogene 7","metadata":null},{"id":"269a6a6b95574bf7b0816cb36be92f25","type":"GENE","name":"ACTR3C","canonical_id":"hgnc:HGNC:37282","description":"actin related protein 3C","metadata":{"aliases":["ARP11"]}},{"id":"5ce472fa5ff040bbb31d120a0711d519","type":"GENE","name":"ACTR3P1","canonical_id":"hgnc:HGNC:31820","description":"ACTR3 pseudogene 1","metadata":null},{"id":"799e658bfe8c406e8aeabe816fee885b","type":"GENE","name":"ACTR3P2","canonical_id":"hgnc:HGNC:38676","description":"ACTR3 pseudogene 2","metadata":null},{"id":"48cb557babe740e297f5aaa86b0c096a","type":"GENE","name":"ACTR3P3","canonical_id":"hgnc:HGNC:38679","description":"ACTR3 pseudogene 3","metadata":null},{"id":"85dc726ba03a4956b79fdd89711e46be","type":"GENE","name":"ACTR5","canonical_id":"hgnc:HGNC:14671","description":"actin related protein 5","metadata":{"aliases":["FLJ12785","Arp5","INO80M"]}},{"id":"e8b194a1d90f4affb829d2e04d2efa90","type":"GENE","name":"ACTR6","canonical_id":"hgnc:HGNC:24025","description":"actin related protein 6","metadata":{"aliases":["ARP6","FLJ13433"]}},{"id":"ccaf1b4c23014c9db0936ef440ac1e8e","type":"GENE","name":"ACTR6P1","canonical_id":"hgnc:HGNC:44210","description":"ACTR6 pseudogene 1","metadata":null},{"id":"d93701a3861e4d97a0060fcb40d4080b","type":"GENE","name":"ACTR8","canonical_id":"hgnc:HGNC:14672","description":"actin related protein 8","metadata":{"aliases":["INO80N","ARP8"]}},{"id":"4f2aee886a2e4d96bc083ab91ae1df83","type":"GENE","name":"ACTRT1","canonical_id":"hgnc:HGNC:24027","description":"actin related protein T1","metadata":{"aliases":["AIP1","KIAA0705","ARIP1","Arp-T1"]}},{"id":"bd372575806d4b8988b39e2aaeb72b8a","type":"GENE","name":"ACTRT1P1","canonical_id":"hgnc:HGNC:55127","description":"ACTRT1 pseudogene 1","metadata":null},{"id":"13ad220e52a846319bc17ddfa3b40df7","type":"GENE","name":"ACTRT2","canonical_id":"hgnc:HGNC:24026","description":"actin related protein T2","metadata":{"aliases":["Arp-T2","ARPM2","FLJ25424"]}},{"id":"468b0b2f8117403da5114051bc3ca98f","type":"GENE","name":"ACTRT3","canonical_id":"hgnc:HGNC:24022","description":"actin related protein T3","metadata":{"aliases":["ARPM1"]}},{"id":"f950fbcd720848aeb6f77824a7ac10c6","type":"TRIAL","name":"ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination","canonical_id":"clinicaltrials.gov:NCT00708344","description":"Hypertension","metadata":null},{"id":"21601113106344b9bce51547b1fb925c","type":"GO_TERM","name":"ACU codon-amino acid adaptor activity","canonical_id":"go:GO:0033437","description":"\"A triplet codon-amino acid adaptor activity that recognizes an ACU codon.\" [GOC:mah]","metadata":null},{"id":"d80fe4a6051f4f8f9451b9bbfc26cc39","type":"GENE","name":"ACVR1","canonical_id":"hgnc:HGNC:171","description":"activin A receptor type 1","metadata":{"aliases":["SKR1","ALK2","ACVR1A","ACVRLK2"]}},{"id":"d57ca1098e984a0cb53fece9b2401919","type":"GENE","name":"ACVR1B","canonical_id":"hgnc:HGNC:172","description":"activin A receptor type 1B","metadata":{"aliases":["ALK4","SKR2","ActRIB","ACVRLK4"]}},{"id":"d01000ce2e3c42198200ae62d40353e1","type":"GENE","name":"ACVR1C","canonical_id":"hgnc:HGNC:18123","description":"activin A receptor type 1C","metadata":{"aliases":["ALK7","ACVRLK7"]}},{"id":"63d6adbaf43443d2929ef71ce178d6fa","type":"GENE","name":"ACVR2A","canonical_id":"hgnc:HGNC:173","description":"activin A receptor type 2A","metadata":{"aliases":["ACTRII","ACVR2"]}},{"id":"5513ec824e844dd6ad2e96d671bc59af","type":"GENE","name":"ACVR2B","canonical_id":"hgnc:HGNC:174","description":"activin A receptor type 2B","metadata":{"aliases":["ActR-IIB"]}},{"id":"d49de1a9a96d465c92dfcd2db10d7813","type":"GENE","name":"ACVR2B-AS1","canonical_id":"hgnc:HGNC:44161","description":"ACVR2B antisense RNA 1","metadata":null},{"id":"2d0f01de9c824b96858f70fbef87a416","type":"GENE","name":"ACVRL1","canonical_id":"hgnc:HGNC:175","description":null,"metadata":null},{"id":"6d65aa72a54746cfa9df480cc3212099","type":"TRIAL","name":"ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL","canonical_id":"clinicaltrials.gov:NCT02787369","description":"Recurrent Chronic Lymphoid Leukemia","metadata":null},{"id":"7ad8eb1106184eeca7ecc3f5533d4ac7","type":"GENE","name":"ACY1","canonical_id":"hgnc:HGNC:177","description":"aminoacylase 1","metadata":null},{"id":"0b38bcbae26049a2b8e7b682ef676a4c","type":"GENE","name":"ACY3","canonical_id":"hgnc:HGNC:24104","description":"aminoacylase 3","metadata":{"aliases":["HCBP1","MGC9740","ACY-3","ASPA2"]}},{"id":"cc5a517e66554929993338e318a7cab6","type":"GENE","name":"ACYP1","canonical_id":"hgnc:HGNC:179","description":"acylphosphatase 1","metadata":null},{"id":"aefe3d45885c4976a2b15298b6ac0eba","type":"GENE","name":"ACYP2","canonical_id":"hgnc:HGNC:180","description":"acylphosphatase 2","metadata":null},{"id":"2cc27114f1534254a918406decdf373f","type":"TRIAL","name":"ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.","canonical_id":"clinicaltrials.gov:NCT04961528","description":"Hemoptysis","metadata":null},{"id":"b2efa87f44b14cebb9076ce38c8b46c2","type":"TRIAL","name":"ACute and Chronic Effects of Saxagliptin","canonical_id":"clinicaltrials.gov:NCT01521312","description":"Impaired Glucose Tolerance","metadata":null},{"id":"022a5b8fd7b7416f9e602ff0802022bb","type":"TRIAL","name":"AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05669339","description":"Hepatocellular Carcinoma","metadata":null},{"id":"f0918d16bc97478498709b13a0ff9655","type":"GENE","name":"ADA","canonical_id":"hgnc:HGNC:186","description":null,"metadata":null},{"id":"f9d27f8cdafc4af596b0b33a9be67aa8","type":"PROTEIN","name":"ADA","canonical_id":"uniprot:P00813","description":null,"metadata":null},{"id":"9db542b1017a4007a66635799349e3f8","type":"GO_TERM","name":"ADA complex","canonical_id":"go:GO:0140671","description":"\"A chromatin remodeling complex that regulates transcription via acetylation primarily of nucleosomal histones H3 and H2B. In budding yeast shares the histone acetylation (HAT) module of ADA2-GCN5-NGG1-SGF29 with the related SAGA complex.\" [GOC:bhm, PMID:21734642, PMID:28966424]","metadata":null},{"id":"1d82328ab2294237a2667886526d8156","type":"GENE","name":"ADA2","canonical_id":"hgnc:HGNC:1839","description":"adenosine deaminase 2","metadata":{"aliases":["ADGF","IDGFL","CECR1"]}},{"id":"14e8268e69c3451da53794d5a2a8d307","type":"GENE","name":"ADAD1","canonical_id":"hgnc:HGNC:30713","description":"adenosine deaminase domain containing 1","metadata":{"aliases":["Tenr"]}},{"id":"d36f407ed14b43978083dccfb2785773","type":"GENE","name":"ADAD1-AS1","canonical_id":"hgnc:HGNC:58882","description":"ADAD1 and BLTP1 antisense RNA 1","metadata":null},{"id":"1dc5b2ebd10a41d9852ebfe66e62a2b8","type":"GENE","name":"ADAD1P1","canonical_id":"hgnc:HGNC:44550","description":"adenosine deaminase domain containing 1 pseudogene 1","metadata":null},{"id":"b7372095a54f417baa0430cbf23fb109","type":"GENE","name":"ADAD1P2","canonical_id":"hgnc:HGNC:44552","description":"adenosine deaminase domain containing 1 pseudogene 2","metadata":null},{"id":"8d135000c1a648b391425255f7bf3c75","type":"GENE","name":"ADAD2","canonical_id":"hgnc:HGNC:30714","description":"adenosine deaminase domain containing 2","metadata":{"aliases":["TENRL","FLJ00337"]}},{"id":"c0b6bc8ef66f40d88828e48e1083bf35","type":"GENE","name":"ADAD2-AS1","canonical_id":"hgnc:HGNC:58422","description":"ADAD2 antisense RNA 1","metadata":null},{"id":"535ac73cde8745b8b8eb40c977d11d61","type":"TRIAL","name":"ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects","canonical_id":"clinicaltrials.gov:NCT00936676","description":"Parkinson's Disease","metadata":null},{"id":"f0adf88c6e3b4feea4285154de7b6c1b","type":"GENE","name":"ADAM10","canonical_id":"hgnc:HGNC:188","description":null,"metadata":null},{"id":"c266ddc2abc4426f9b2e31b011865fd1","type":"GENE","name":"ADAM11","canonical_id":"hgnc:HGNC:189","description":"ADAM metallopeptidase domain 11","metadata":{"aliases":["MDC"]}},{"id":"8e1e37d8d00e4016b3fc220a7f3e847f","type":"GENE","name":"ADAM12","canonical_id":"hgnc:HGNC:190","description":null,"metadata":null},{"id":"87a678b4c33847a2aa666cd2ca8c8277","type":"GENE","name":"ADAM15","canonical_id":"hgnc:HGNC:193","description":"ADAM metallopeptidase domain 15","metadata":{"aliases":["MDC15"]}},{"id":"c8a7a0ab3440498eb7ce859d58e639c3","type":"GENE","name":"ADAM17","canonical_id":"hgnc:HGNC:195","description":null,"metadata":null},{"id":"897d8d288ea34f34bdc127a1ff8dfd0d","type":"GENE","name":"ADAM18","canonical_id":"hgnc:HGNC:196","description":"ADAM metallopeptidase domain 18","metadata":{"aliases":["tMDCIII","ADAM27"]}},{"id":"908c598641e044e78bf3242984223ef0","type":"GENE","name":"ADAM19","canonical_id":"hgnc:HGNC:197","description":"ADAM metallopeptidase domain 19","metadata":{"aliases":["MLTNB"]}},{"id":"af29683dcce1421db118834b4082c3f6","type":"GENE","name":"ADAM19-AS1","canonical_id":"hgnc:HGNC:40061","description":"ADAM19 antisense RNA 1","metadata":null},{"id":"5dc8d3928463457783259146b5d48421","type":"GENE","name":"ADAM1A","canonical_id":"hgnc:HGNC:187","description":"ADAM metallopeptidase domain 1A (pseudogene)","metadata":{"aliases":["ADAM1AP","FTNAP","PH-30a","Ftna","ADAM1P","ADAM1"]}},{"id":"0f358e43899041df8ff08e82ac073981","type":"GENE","name":"ADAM1B","canonical_id":"hgnc:HGNC:44366","description":"ADAM metallopeptidase domain 1B (pseudogene)","metadata":{"aliases":["ADAM1BP"]}},{"id":"a8696f8a60584dc3b6e2ed42062ed819","type":"GENE","name":"ADAM2","canonical_id":"hgnc:HGNC:198","description":"ADAM metallopeptidase domain 2","metadata":{"aliases":["PH-30b","PH30","CT15","FTNB"]}},{"id":"2626f9ffe42e48c4b59b83d4f63f1de8","type":"GENE","name":"ADAM20","canonical_id":"hgnc:HGNC:199","description":"ADAM metallopeptidase domain 20","metadata":null},{"id":"4a398194302b4e12b1551369e1791341","type":"GENE","name":"ADAM20P1","canonical_id":"hgnc:HGNC:20102","description":"ADAM metallopeptidase domain 20 pseudogene 1","metadata":{"aliases":["C14orf55"]}},{"id":"11da4c50a8c84c478cf16c24425514e9","type":"GENE","name":"ADAM20P2","canonical_id":"hgnc:HGNC:43901","description":"ADAM metallopeptidase domain 20 pseudogene 2","metadata":null},{"id":"7a789277a92c4681a88dc16d934dfa87","type":"GENE","name":"ADAM20P3","canonical_id":"hgnc:HGNC:43902","description":"ADAM metallopeptidase domain 20 pseudogene 3","metadata":null},{"id":"b594dddc682a434a85d0f07fa52e15f2","type":"GENE","name":"ADAM21","canonical_id":"hgnc:HGNC:200","description":"ADAM metallopeptidase domain 21","metadata":{"aliases":["ADAM31"]}},{"id":"ca8a74099958441da303d64ef2081ad8","type":"GENE","name":"ADAM21P1","canonical_id":"hgnc:HGNC:19822","description":"ADAM metallopeptidase domain 21 pseudogene 1","metadata":{"aliases":["ADAM21P"]}},{"id":"96050cc01640494a9b04f74475c831b3","type":"GENE","name":"ADAM22","canonical_id":"hgnc:HGNC:201","description":"ADAM metallopeptidase domain 22","metadata":{"aliases":["MDC2"]}},{"id":"9b9e5db4110848d0b106ade35dcef0f5","type":"GENE","name":"ADAM23","canonical_id":"hgnc:HGNC:202","description":null,"metadata":null},{"id":"fac4994804414bcdadfcb20c3cb14abb","type":"GENE","name":"ADAM24P","canonical_id":"hgnc:HGNC:203","description":"ADAM metallopeptidase domain 24, pseudogene","metadata":null},{"id":"bc1eaccb2abf4d8cb2db9952f024277d","type":"GENE","name":"ADAM28","canonical_id":"hgnc:HGNC:206","description":"ADAM metallopeptidase domain 28","metadata":{"aliases":["eMDCII","MDC-Lm","MDC-Ls","ADAM23"]}},{"id":"aa4dc1334dfa4570873068ec85907c79","type":"GENE","name":"ADAM29","canonical_id":"hgnc:HGNC:207","description":"ADAM metallopeptidase domain 29","metadata":{"aliases":["svph1","CT73"]}},{"id":"dae6eb284f4a478c9718bd66ab46cd03","type":"GENE","name":"ADAM30","canonical_id":"hgnc:HGNC:208","description":"ADAM metallopeptidase domain 30","metadata":{"aliases":["svph4"]}},{"id":"e528124b2cfd492a876857e849a55265","type":"GENE","name":"ADAM32","canonical_id":"hgnc:HGNC:15479","description":"ADAM metallopeptidase domain 32","metadata":null},{"id":"3250733a54a142f7b4aa6d99981a57af","type":"GENE","name":"ADAM33","canonical_id":"hgnc:HGNC:15478","description":"ADAM metallopeptidase domain 33","metadata":{"aliases":["DKFZp434K0521","dJ964F7.1","C20orf153"]}},{"id":"4416e0efb9de4ad9bef8b4654bec9095","type":"GENE","name":"ADAM3A","canonical_id":"hgnc:HGNC:209","description":"ADAM metallopeptidase domain 3A (pseudogene)","metadata":{"aliases":["ADAM3AP","ADAM3","tMDCI","CYRN1"]}},{"id":"ada841ba8f234c318d471dd50ccb4198","type":"GENE","name":"ADAM3B","canonical_id":"hgnc:HGNC:210","description":"ADAM metallopeptidase domain 3B (pseudogene)","metadata":{"aliases":["CYRN2"]}},{"id":"1ce33002df9d457b952ce0cab75150c3","type":"GENE","name":"ADAM5","canonical_id":"hgnc:HGNC:212","description":"ADAM metallopeptidase domain 5 (pseudogene)","metadata":{"aliases":["tMDCII","ADAM5P"]}},{"id":"2d6d59618f5347aab8f4f6d86a4e7b91","type":"GENE","name":"ADAM6","canonical_id":"hgnc:HGNC:213","description":"ADAM metallopeptidase domain 6 (pseudogene)","metadata":{"aliases":["ADAM6P","tMDCIV","C14orf96"]}},{"id":"cb5867b86dff4f91a1e42acd66323ed6","type":"GENE","name":"ADAM7","canonical_id":"hgnc:HGNC:214","description":"ADAM metallopeptidase domain 7","metadata":{"aliases":["GP-83","EAPI"]}},{"id":"97f28a668f9049558c78611f247b2cd9","type":"GENE","name":"ADAM7-AS1","canonical_id":"hgnc:HGNC:56152","description":"ADAM7, ADAMDEC1 and ADAM28 antisense RNA 1","metadata":null},{"id":"414c23081b7043afaa20a4000798e10a","type":"GENE","name":"ADAM7-AS2","canonical_id":"hgnc:HGNC:56153","description":"ADAM7 antisense RNA 2","metadata":null},{"id":"6c90f2bfa58f4d929ef0c7f852cd1977","type":"GENE","name":"ADAM8","canonical_id":"hgnc:HGNC:215","description":"ADAM metallopeptidase domain 8","metadata":{"aliases":["CD156","MS2","CD156A"]}},{"id":"55d1cf6709fa431d8cf14d238fe7b44f","type":"GENE","name":"ADAM9","canonical_id":"hgnc:HGNC:216","description":"ADAM metallopeptidase domain 9","metadata":{"aliases":["MDC9","KIAA0021","MCMP","Mltng","CORD9"]}},{"id":"250405e16e174e6ab06ea3e1319ff5bf","type":"GENE","name":"ADAMDEC1","canonical_id":"hgnc:HGNC:16299","description":"ADAM like decysin 1","metadata":{"aliases":["M12.219"]}},{"id":"ffa22b7a1f284852873cba2fabe3fe9c","type":"GENE","name":"ADAMTS1","canonical_id":"hgnc:HGNC:217","description":null,"metadata":null},{"id":"c0c3378bd45f495ea34095568ea490d9","type":"GENE","name":"ADAMTS10","canonical_id":"hgnc:HGNC:13201","description":"ADAM metallopeptidase with thrombospondin type 1 motif 10","metadata":{"aliases":["ADAM-TS10"]}},{"id":"9722c18f37084830a67c1db453d0194b","type":"GENE","name":"ADAMTS10-AS1","canonical_id":"hgnc:HGNC:58599","description":"ADAMTS10 antisense RNA 1","metadata":null},{"id":"30cfe509158e4b009de83a6db090fbd2","type":"GENE","name":"ADAMTS12","canonical_id":"hgnc:HGNC:14605","description":"ADAM metallopeptidase with thrombospondin type 1 motif 12","metadata":null},{"id":"91862fa1ea1e467a9983f190b006c6b8","type":"GENE","name":"ADAMTS13","canonical_id":"hgnc:HGNC:1366","description":"ADAM metallopeptidase with thrombospondin type 1 motif 13","metadata":{"aliases":["VWFCP","TTP","vWF-CP","FLJ42993","MGC118899","MGC118900","DKFZp434C2322","C9orf8"]}},{"id":"9804367276e74870b28b6e79e96857c9","type":"GENE","name":"ADAMTS14","canonical_id":"hgnc:HGNC:14899","description":"ADAM metallopeptidase with thrombospondin type 1 motif 14","metadata":null},{"id":"334986210db24afe8b54d3886b3e5749","type":"GENE","name":"ADAMTS15","canonical_id":"hgnc:HGNC:16305","description":"ADAM metallopeptidase with thrombospondin type 1 motif 15","metadata":null},{"id":"bfd50a183dab467bb6e0ec4860ea5dae","type":"GENE","name":"ADAMTS16","canonical_id":"hgnc:HGNC:17108","description":"ADAM metallopeptidase with thrombospondin type 1 motif 16","metadata":{"aliases":["ADAMTS16s"]}},{"id":"da71ecf1f07d4313ad2fcc59b9b46b23","type":"GENE","name":"ADAMTS16-AS1","canonical_id":"hgnc:HGNC:58093","description":"ADAMTS16 antisense RNA 1","metadata":{"aliases":["AC022424.2"]}},{"id":"11a4b53d9a5a479e8ab0c75c2f974f63","type":"GENE","name":"ADAMTS16-DT","canonical_id":"hgnc:HGNC:55548","description":"ADAMTS16 divergent transcript","metadata":null},{"id":"c4882440ec014d6cadaa0273c2625807","type":"GENE","name":"ADAMTS17","canonical_id":"hgnc:HGNC:17109","description":"ADAM metallopeptidase with thrombospondin type 1 motif 17","metadata":{"aliases":["FLJ32769","FLJ16363"]}},{"id":"b032c755588d4e6e9a55f4b361198f2d","type":"GENE","name":"ADAMTS17-AS1","canonical_id":"hgnc:HGNC:58617","description":"ADAMTS17 antisense RNA 1","metadata":null},{"id":"e31feba8f61e47eab7f8b0baeb09a7de","type":"GENE","name":"ADAMTS18","canonical_id":"hgnc:HGNC:17110","description":"ADAM metallopeptidase with thrombospondin type 1 motif 18","metadata":{"aliases":["ADAMTS21"]}},{"id":"89ac81619f8d450c917d1c6b5d546b8d","type":"GENE","name":"ADAMTS19","canonical_id":"hgnc:HGNC:17111","description":"ADAM metallopeptidase with thrombospondin type 1 motif 19","metadata":null},{"id":"57463814393148098d1d599714006427","type":"GENE","name":"ADAMTS19-AS1","canonical_id":"hgnc:HGNC:40797","description":"ADAMTS19 antisense RNA 1","metadata":{"aliases":["RP11-346A9.1"]}},{"id":"fd684fbfe5394f75927495b38fec858e","type":"GENE","name":"ADAMTS2","canonical_id":"hgnc:HGNC:218","description":"ADAM metallopeptidase with thrombospondin type 1 motif 2","metadata":{"aliases":["ADAMTS-3","hPCPNI","PCINP","ADAM-TS2","NPI"]}},{"id":"09615576e7a9487d9e222e372a2ab15d","type":"GENE","name":"ADAMTS20","canonical_id":"hgnc:HGNC:17178","description":"ADAM metallopeptidase with thrombospondin type 1 motif 20","metadata":{"aliases":["GON-1"]}},{"id":"9e60a1d2731346c79dadf8beae5e47e0","type":"GENE","name":"ADAMTS3","canonical_id":"hgnc:HGNC:219","description":"ADAM metallopeptidase with thrombospondin type 1 motif 3","metadata":{"aliases":["KIAA0366","ADAMTS-4"]}},{"id":"6b60621fdfb34738a2166dee56d961b0","type":"GENE","name":"ADAMTS3-AS1","canonical_id":"hgnc:HGNC:40063","description":"ADAMTS3 antisense RNA 1","metadata":null},{"id":"ddf4998f0c1f4d6488ca2e37491f875f","type":"GENE","name":"ADAMTS3-AS2","canonical_id":"hgnc:HGNC:58811","description":"ADAMTS3 antisense RNA 2","metadata":null},{"id":"9149bdb6632645b4937b97ed2e3ad919","type":"GENE","name":"ADAMTS3-AS3","canonical_id":"hgnc:HGNC:58812","description":"ADAMTS3 antisense RNA 3","metadata":null},{"id":"3095adc85989499a90063d195177eac9","type":"GENE","name":"ADAMTS4","canonical_id":"hgnc:HGNC:220","description":"ADAM metallopeptidase with thrombospondin type 1 motif 4","metadata":{"aliases":["KIAA0688","ADAMTS-2","ADMP-1"]}},{"id":"97ba25a654284948bbc5cce74d60e4d5","type":"GENE","name":"ADAMTS5","canonical_id":"hgnc:HGNC:221","description":null,"metadata":null},{"id":"bb811d99a37944649055eb7a9a6c6134","type":"GENE","name":"ADAMTS6","canonical_id":"hgnc:HGNC:222","description":"ADAM metallopeptidase with thrombospondin type 1 motif 6","metadata":{"aliases":["ADAM-TS6"]}},{"id":"5dca453f613c4787a757bd54259b0358","type":"GENE","name":"ADAMTS6-DT","canonical_id":"hgnc:HGNC:59062","description":"ADAMTS6 divergent transcript","metadata":null},{"id":"d196e3795516405ea7c0aa6d63fe701e","type":"GENE","name":"ADAMTS7","canonical_id":"hgnc:HGNC:223","description":"ADAM metallopeptidase with thrombospondin type 1 motif 7","metadata":{"aliases":["ADAM-TS7","DKFZp434H204"]}},{"id":"7272b6c479bc483ebe1d4e9d57024f90","type":"GENE","name":"ADAMTS7P1","canonical_id":"hgnc:HGNC:49407","description":"ADAMTS7 pseudogene 1","metadata":{"aliases":["ADAMTS7P2"]}},{"id":"f98d0653ac6b4c34b6b4ee87ac4cbf02","type":"GENE","name":"ADAMTS7P3","canonical_id":"hgnc:HGNC:49409","description":"ADAMTS7 pseudogene 3","metadata":null},{"id":"6c7b0e8e81cb420ab4297aca830696b9","type":"GENE","name":"ADAMTS7P4","canonical_id":"hgnc:HGNC:49410","description":"ADAMTS7 pseudogene 4","metadata":null},{"id":"77833b44856649a3a98e7f7e7e1296ee","type":"GENE","name":"ADAMTS7P5","canonical_id":"hgnc:HGNC:56992","description":"ADAMTS7 pseudogene 5","metadata":null},{"id":"cc8a490d367e40c8a05deba9db1f0c9a","type":"GENE","name":"ADAMTS8","canonical_id":"hgnc:HGNC:224","description":"ADAM metallopeptidase with thrombospondin type 1 motif 8","metadata":{"aliases":["METH2","FLJ41712","ADAM-TS8"]}},{"id":"83235c086c9d4fe8a6415ce16cd3166e","type":"GENE","name":"ADAMTS9","canonical_id":"hgnc:HGNC:13202","description":"ADAM metallopeptidase with thrombospondin type 1 motif 9","metadata":{"aliases":["KIAA1312"]}},{"id":"3b2f8d3572f443d1a0f30928626a4008","type":"GENE","name":"ADAMTS9-AS1","canonical_id":"hgnc:HGNC:40625","description":"ADAMTS9 antisense RNA 1","metadata":null},{"id":"633a62884dc240e286ba65be5e6defed","type":"GENE","name":"ADAMTS9-AS2","canonical_id":"hgnc:HGNC:42435","description":"ADAMTS9 antisense RNA 2","metadata":null},{"id":"d436c4f95e4646fb9555d580a08bb0f4","type":"GENE","name":"ADAMTSL1","canonical_id":"hgnc:HGNC:14632","description":"ADAMTS like 1","metadata":{"aliases":["ADAMTSR1","FLJ35283","C9orf94"]}},{"id":"649410ce5871476eb54d1b4f12884de6","type":"GENE","name":"ADAMTSL2","canonical_id":"hgnc:HGNC:14631","description":"ADAMTS like 2","metadata":{"aliases":["KIAA0605"]}},{"id":"a5a27b1a47aa423ca2260f91868e4f44","type":"GENE","name":"ADAMTSL3","canonical_id":"hgnc:HGNC:14633","description":"ADAMTS like 3","metadata":{"aliases":["KIAA1233","punctin-2"]}},{"id":"be07a5d467bc4bbdb540a2105b6b26c5","type":"GENE","name":"ADAMTSL4","canonical_id":"hgnc:HGNC:19706","description":"ADAMTS like 4","metadata":{"aliases":["DKFZP434K1772","TSRC1"]}},{"id":"878286c00bd14420898486da7204c386","type":"GENE","name":"ADAMTSL4-AS1","canonical_id":"hgnc:HGNC:32041","description":"ADAMTSL4 antisense RNA 1","metadata":{"aliases":["FLJ45786","C1orf138"]}},{"id":"078f9037974941b29dec7ee461163912","type":"GENE","name":"ADAMTSL4-AS2","canonical_id":"hgnc:HGNC:40895","description":"ADAMTSL4 antisense RNA 2","metadata":null},{"id":"5a9cd39dca1d43abb4205b70aa0b3726","type":"GENE","name":"ADAMTSL5","canonical_id":"hgnc:HGNC:27912","description":"ADAMTS like 5","metadata":{"aliases":["THSD6"]}},{"id":"c23af0c2520d4d81a45961cae808a426","type":"GENE","name":"ADAP1","canonical_id":"hgnc:HGNC:16486","description":"ArfGAP with dual PH domains 1","metadata":{"aliases":["GCS1L","CENTA1"]}},{"id":"7cf63f8aedbc41249fd3ac4a5d4d6fc8","type":"GENE","name":"ADAP2","canonical_id":"hgnc:HGNC:16487","description":"ArfGAP with dual PH domains 2","metadata":{"aliases":["CENTA2"]}},{"id":"650a6e73c6a449a8bbdf595ec0c60273","type":"GENE","name":"ADAR","canonical_id":"hgnc:HGNC:225","description":"adenosine deaminase RNA specific","metadata":{"aliases":["ADAR1","DRADA","IFI4","G1P1"]}},{"id":"665755093ae34963bedf07fa30efd3a6","type":"GENE","name":"ADARB1","canonical_id":"hgnc:HGNC:226","description":"adenosine deaminase RNA specific B1","metadata":{"aliases":["ADAR2","DRADA2","ADAR2g","DRABA2","RED1","hRED1","ADAR2a-L1","ADAR2a-L2","ADAR2a-L3","ADAR2a","ADAR2b","ADAR2c","ADAR2d"]}},{"id":"5204943df61847dc83ee4b190d6a7b7a","type":"GENE","name":"ADARB2","canonical_id":"hgnc:HGNC:227","description":null,"metadata":null},{"id":"3268a140c0594e0e9e7899e7e92b3252","type":"GENE","name":"ADARB2-AS1","canonical_id":"hgnc:HGNC:23299","description":"ADARB2 antisense RNA 1","metadata":{"aliases":["bA466B20.1","C10orf109","NCRNA00168"]}},{"id":"d0b2c2f77ba44000b3021c26dc888652","type":"TRIAL","name":"ADASUVE-Lorazepam Drug-Drug Interaction","canonical_id":"clinicaltrials.gov:NCT01877642","description":"Healthy Volunteers","metadata":null},{"id":"016f8407e65142d582a639a1c6cae7ff","type":"GENE","name":"ADAT1","canonical_id":"hgnc:HGNC:228","description":"adenosine deaminase tRNA specific 1","metadata":null},{"id":"f0232069db7642cbadd3794645a14e37","type":"GENE","name":"ADAT2","canonical_id":"hgnc:HGNC:21172","description":"adenosine deaminase tRNA specific 2","metadata":{"aliases":["dJ20N2.1","TAD2","DEADC1"]}},{"id":"57d3f87c54824086a719fe0f16401294","type":"GENE","name":"ADAT3","canonical_id":"hgnc:HGNC:25151","description":"adenosine deaminase tRNA specific 3","metadata":{"aliases":["TAD3"]}},{"id":"3ab60602c8c04cf1b5e24dcc9004872f","type":"GENE","name":"ADCK1","canonical_id":"hgnc:HGNC:19038","description":"aarF domain containing kinase 1","metadata":{"aliases":["FLJ39600"]}},{"id":"1e84460b501044a9840b3bb5b239310b","type":"GENE","name":"ADCK2","canonical_id":"hgnc:HGNC:19039","description":"aarF domain containing kinase 2","metadata":{"aliases":["MGC20727"]}},{"id":"3a351f3e499146cf8d05ae953d1b1db3","type":"GENE","name":"ADCK5","canonical_id":"hgnc:HGNC:21738","description":"aarF domain containing kinase 5","metadata":{"aliases":["FLJ35454"]}},{"id":"0d13bfb4fb4845819bd15e80c33d5c7c","type":"GENE","name":"ADCP1","canonical_id":"hgnc:HGNC:229","description":"adenosine deaminase complexing protein 1","metadata":null},{"id":"ea826e55f92e4bbeaf51341cc649e3b8","type":"GENE","name":"ADCY1","canonical_id":"hgnc:HGNC:232","description":"adenylate cyclase 1","metadata":{"aliases":["AC1","DFNB44"]}},{"id":"aa1536f8d4b34d8692414a5d691c5e53","type":"GENE","name":"ADCY10","canonical_id":"hgnc:HGNC:21285","description":"adenylate cyclase 10","metadata":{"aliases":["SAC","Sacy","SACI","HCA2","RP1-313L4.2"]}},{"id":"0aca15711caf4453b7513164626c6c6f","type":"GENE","name":"ADCY10P1","canonical_id":"hgnc:HGNC:44143","description":"ADCY10 pseudogene 1","metadata":null},{"id":"75885561fb7643b7b304b5872c05e2cd","type":"GENE","name":"ADCY2","canonical_id":"hgnc:HGNC:233","description":"adenylate cyclase 2","metadata":{"aliases":["HBAC2","KIAA1060","AC2"]}},{"id":"e80889860b4c4e05b726542358427649","type":"GENE","name":"ADCY2-AS1","canonical_id":"hgnc:HGNC:40064","description":"ADCY2 antisense RNA 1","metadata":null},{"id":"380e541daf71431a8d0caa8252f3bd47","type":"GENE","name":"ADCY2-AS2","canonical_id":"hgnc:HGNC:58999","description":"ADCY2 antisense RNA 2","metadata":null},{"id":"6902ee28ff7a42039b4b1ccf40c3b50d","type":"GENE","name":"ADCY3","canonical_id":"hgnc:HGNC:234","description":"adenylate cyclase 3","metadata":{"aliases":["AC3"]}},{"id":"a2f0a7c97279466385098bcdd41d61c8","type":"GENE","name":"ADCY4","canonical_id":"hgnc:HGNC:235","description":"adenylate cyclase 4","metadata":{"aliases":["AC4"]}},{"id":"0b764fee513d40d3905a1accb176be75","type":"GENE","name":"ADCY5","canonical_id":"hgnc:HGNC:236","description":"adenylate cyclase 5","metadata":{"aliases":["AC5"]}},{"id":"8672ab12d2864c5597947ffd1647dbf9","type":"GENE","name":"ADCY6","canonical_id":"hgnc:HGNC:237","description":"adenylate cyclase 6","metadata":{"aliases":["AC6"]}},{"id":"7a1b69e18c194184a68a5a8fff846532","type":"GENE","name":"ADCY6-DT","canonical_id":"hgnc:HGNC:53332","description":"ADCY6 divergent transcript","metadata":null},{"id":"ef728def0d31412ea40682f8224d1bab","type":"GENE","name":"ADCY7","canonical_id":"hgnc:HGNC:238","description":"adenylate cyclase 7","metadata":{"aliases":["KIAA0037","AC7"]}},{"id":"106c2d88f9a2461abe79adc557b48448","type":"GENE","name":"ADCY8","canonical_id":"hgnc:HGNC:239","description":"adenylate cyclase 8","metadata":{"aliases":["HBAC1","AC8","ADCY3"]}},{"id":"d0e50fd4c41e44f281561b5939096fa0","type":"GENE","name":"ADCY9","canonical_id":"hgnc:HGNC:240","description":"adenylate cyclase 9","metadata":{"aliases":["AC9"]}},{"id":"13d861f56f6f45a887bc36c27cd2d6ab","type":"GENE","name":"ADCYAP1","canonical_id":"hgnc:HGNC:241","description":"adenylate cyclase activating polypeptide 1","metadata":{"aliases":["PACAP"]}},{"id":"09a7d77d20aa4d0fadbc19823d014f1b","type":"GENE","name":"ADCYAP1R1","canonical_id":"hgnc:HGNC:242","description":"ADCYAP receptor type I","metadata":{"aliases":["PAC1","PACAPR","PAC1R"]}},{"id":"3da1b43b40904b69a7a56dfc2aee3290","type":"GENE","name":"ADD1","canonical_id":"hgnc:HGNC:243","description":"adducin 1","metadata":null},{"id":"fc891abbc3d34815b4d5ac1933ce0579","type":"GENE","name":"ADD1-DT","canonical_id":"hgnc:HGNC:58714","description":"ADD1 divergent transcript","metadata":null},{"id":"5899e046551f4439920e36f137b7cac5","type":"GENE","name":"ADD2","canonical_id":"hgnc:HGNC:244","description":"adducin 2","metadata":{"aliases":["ADDB"]}},{"id":"f388f6f062cc4b31ade116eeea78ee66","type":"GENE","name":"ADD2-AS1","canonical_id":"hgnc:HGNC:40065","description":"ADD2 antisense RNA 1","metadata":null},{"id":"4920fbcb41554b82b8bdf686115bd9e4","type":"GENE","name":"ADD3","canonical_id":"hgnc:HGNC:245","description":"adducin 3","metadata":{"aliases":["ADDL"]}},{"id":"8d52097e33af4ceeb7d816867d988415","type":"GENE","name":"ADD3-AS1","canonical_id":"hgnc:HGNC:48682","description":"ADD3 antisense RNA 1","metadata":null},{"id":"472f191b90024173a7cd31f1ae757333","type":"TRIAL","name":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT01375322","description":"Hypertension; Diabetes Mellitus, Type 2; Albuminuria","metadata":null},{"id":"8b96622616a043ecbffe231d37b6958a","type":"GENE","name":"ADGB","canonical_id":"hgnc:HGNC:21212","description":"androglobin","metadata":{"aliases":["FLJ23121","dJ408K24.1","CAPN16","C6orf103"]}},{"id":"3ea5107836514e91a6c857b5f3f67d9a","type":"GENE","name":"ADGB-DT","canonical_id":"hgnc:HGNC:55654","description":"ADGB divergent transcript","metadata":null},{"id":"8fc1da4155ed446288b41da491ed4dbe","type":"GENE","name":"ADGRA1","canonical_id":"hgnc:HGNC:13838","description":"adhesion G protein-coupled receptor A1","metadata":{"aliases":["KIAA1828","GPR123"]}},{"id":"94ee8738da65466580a54dced59f785a","type":"GENE","name":"ADGRA1-AS1","canonical_id":"hgnc:HGNC:49543","description":"ADGRA1 antisense RNA 1","metadata":{"aliases":["GPR123-AS1"]}},{"id":"5c67c6cb1b214957909e4a6acea2cb66","type":"GENE","name":"ADGRA2","canonical_id":"hgnc:HGNC:17849","description":"adhesion G protein-coupled receptor A2","metadata":{"aliases":["TEM5","DKFZp434C211","DKFZp434J0911","KIAA1531","FLJ14390","GPR124"]}},{"id":"30e492d9c0944abb8080796c73de7e04","type":"GENE","name":"ADGRA3","canonical_id":"hgnc:HGNC:13839","description":"adhesion G protein-coupled receptor A3","metadata":{"aliases":["FLJ38547","PGR21","GPR125"]}},{"id":"870bc98525b94d20a6602d434abc915b","type":"GENE","name":"ADGRA3P1","canonical_id":"hgnc:HGNC:55918","description":"ADGRA3 pseudogene 1","metadata":null},{"id":"7c70fa8925bc486b8fcc7a9d24da89b6","type":"GENE","name":"ADGRB1","canonical_id":"hgnc:HGNC:943","description":null,"metadata":null},{"id":"f470ba47dad946b28f4b804e82a0f8f0","type":"GENE","name":"ADGRB2","canonical_id":"hgnc:HGNC:944","description":"adhesion G protein-coupled receptor B2","metadata":{"aliases":["BAI2"]}},{"id":"dfe5cf6cbf044907aad6ad981aa3da53","type":"GENE","name":"ADGRB3","canonical_id":"hgnc:HGNC:945","description":"adhesion G protein-coupled receptor B3","metadata":{"aliases":["KIAA0550","BAI3"]}},{"id":"93b08b63b3fe426f8b7fe6fdd6519ea1","type":"GENE","name":"ADGRB3-DT","canonical_id":"hgnc:HGNC:55774","description":"ADGRB3 divergent transcript","metadata":{"aliases":["AL391807.1","RP3-525N10.2"]}},{"id":"bf59a02662384f42839fe3c2ea55bb0d","type":"GENE","name":"ADGRD1","canonical_id":"hgnc:HGNC:19893","description":"adhesion G protein-coupled receptor D1","metadata":{"aliases":["DKFZp434B1272","PGR25","GPR133"]}},{"id":"945f77a168224d5dac0d823e26a08b04","type":"GENE","name":"ADGRD1-AS1","canonical_id":"hgnc:HGNC:53314","description":"ADGRD1 antisense RNA 1","metadata":{"aliases":["LACAT8"]}},{"id":"4a827405f5b544e2b58f39184a7fc1d0","type":"GENE","name":"ADGRD1-AS2","canonical_id":"hgnc:HGNC:58275","description":"ADGRD1 antisense RNA 2","metadata":null},{"id":"080dc7c84a184aec95b598f6e2a10417","type":"GENE","name":"ADGRD2","canonical_id":"hgnc:HGNC:18651","description":"adhesion G protein-coupled receptor D2","metadata":{"aliases":["PGR24","GPR144"]}},{"id":"79e4c7bf72fd4431a36d95bb701fb54d","type":"GENE","name":"ADGRE1","canonical_id":"hgnc:HGNC:3336","description":"adhesion G protein-coupled receptor E1","metadata":{"aliases":["TM7LN3","EMR1"]}},{"id":"5edef1ebff1b494dac07295605da9503","type":"GENE","name":"ADGRE2","canonical_id":"hgnc:HGNC:3337","description":"adhesion G protein-coupled receptor E2","metadata":{"aliases":["CD312","EMR2"]}},{"id":"48f6dc5ff3b64fbc9ae31b6135000da6","type":"GENE","name":"ADGRE3","canonical_id":"hgnc:HGNC:23647","description":"adhesion G protein-coupled receptor E3","metadata":{"aliases":["EMR3"]}},{"id":"0811bcd9c92c43d8adc5609c48878aec","type":"GENE","name":"ADGRE4P","canonical_id":"hgnc:HGNC:19240","description":"adhesion G protein-coupled receptor E4, pseudogene","metadata":{"aliases":["PGR16","GPR127","EMR4","EMR4P"]}},{"id":"e7761a3420fd4853805d623f729dc897","type":"GENE","name":"ADGRE5","canonical_id":"hgnc:HGNC:1711","description":null,"metadata":null},{"id":"c2b6d017e17248de99d5f7e54ffc09c4","type":"GENE","name":"ADGRF1","canonical_id":"hgnc:HGNC:18990","description":"adhesion G protein-coupled receptor F1","metadata":{"aliases":["hGPCR36","PGR19","GPR110"]}},{"id":"98419668bf334f769904ffd840754823","type":"GENE","name":"ADGRF2P","canonical_id":"hgnc:HGNC:18991","description":"adhesion G protein-coupled receptor F2, pseudogene","metadata":{"aliases":["hGPCR35","PGR20","GPR111","ADGRF2"]}},{"id":"706ef104848441e998e5148c74cfceab","type":"GENE","name":"ADGRF3","canonical_id":"hgnc:HGNC:18989","description":"adhesion G protein-coupled receptor F3","metadata":{"aliases":["hGPCR37","PGR23","GPR113"]}},{"id":"73fb288fd8a74adfa3bdccbd94bc96ac","type":"GENE","name":"ADGRF4","canonical_id":"hgnc:HGNC:19011","description":"adhesion G protein-coupled receptor F4","metadata":{"aliases":["FLJ38076","PGR18","GPR115"]}},{"id":"a106d13e41be4653b82edd581156b200","type":"GENE","name":"ADGRF5","canonical_id":"hgnc:HGNC:19030","description":"adhesion G protein-coupled receptor F5","metadata":{"aliases":["DKFZp564O1923","KIAA0758","GPR116"]}},{"id":"48d3a916c7134878b98c38f53a798f5d","type":"GENE","name":"ADGRF5-AS1","canonical_id":"hgnc:HGNC:40864","description":"ADGRF5 antisense RNA 1","metadata":null},{"id":"128319fc112240a68daa17b5556ac659","type":"GENE","name":"ADGRF5P1","canonical_id":"hgnc:HGNC:32922","description":"adhesion G protein-coupled receptor F5 pseudogene 1","metadata":{"aliases":["GPR116P1"]}},{"id":"10510ba84cc34f12961328e6aef09c0c","type":"GENE","name":"ADGRF5P2","canonical_id":"hgnc:HGNC:32921","description":"adhesion G protein-coupled receptor F5 pseudogene 2","metadata":{"aliases":["GPR116P2"]}},{"id":"ef04a2493b1345f196dcededbb8ae751","type":"GENE","name":"ADGRG1","canonical_id":"hgnc:HGNC:4512","description":"adhesion G protein-coupled receptor G1","metadata":{"aliases":["TM7LN4","TM7XN1","GPR56"]}},{"id":"1a28dbe708904a76b770985af8ef1999","type":"GENE","name":"ADGRG2","canonical_id":"hgnc:HGNC:4516","description":"adhesion G protein-coupled receptor G2","metadata":{"aliases":["HE6","TM7LN2","EDDM6","GPR64"]}},{"id":"301e68816c6d4cc0b65f17192139e8e6","type":"GENE","name":"ADGRG3","canonical_id":"hgnc:HGNC:13728","description":"adhesion G protein-coupled receptor G3","metadata":{"aliases":["Pb99","PGR26","GPR97"]}},{"id":"24b61e58d4074dd3b4c4bdd78eef9040","type":"GENE","name":"ADGRG4","canonical_id":"hgnc:HGNC:18992","description":"adhesion G protein-coupled receptor G4","metadata":{"aliases":["RP1-299I16","PGR17","GPR112"]}},{"id":"5d996411b1b54669b54a426c8ba207f9","type":"GENE","name":"ADGRG5","canonical_id":"hgnc:HGNC:19010","description":"adhesion G protein-coupled receptor G5","metadata":{"aliases":["PGR27","GPR114"]}},{"id":"e1c6aad989584f1088887318c2982cbf","type":"GENE","name":"ADGRG6","canonical_id":"hgnc:HGNC:13841","description":"adhesion G protein-coupled receptor G6","metadata":{"aliases":["FLJ14937","GPR126"]}},{"id":"52d500aa06dc43a1a1876e16043bafa6","type":"GENE","name":"ADGRG7","canonical_id":"hgnc:HGNC:19241","description":"adhesion G protein-coupled receptor G7","metadata":{"aliases":["FLJ14454","GPR128"]}},{"id":"725c7a1ec1b84f67861f21dab7e7ce14","type":"GENE","name":"ADGRL1","canonical_id":"hgnc:HGNC:20973","description":"adhesion G protein-coupled receptor L1","metadata":{"aliases":["KIAA0821","CIRL1","LEC2","LPHN1"]}},{"id":"0dc0f27b70bb476187627c8ab0e3f613","type":"GENE","name":"ADGRL1-AS1","canonical_id":"hgnc:HGNC:55309","description":"ADGRL1 antisense RNA 1","metadata":null},{"id":"1c6d176df007429a80a15102ae9baa38","type":"GENE","name":"ADGRL2","canonical_id":"hgnc:HGNC:18582","description":"adhesion G protein-coupled receptor L2","metadata":{"aliases":["KIAA0786","LEC1","CIRL2","LPHH1","LPHN2"]}},{"id":"1daa3f6b3a6f49198238b2d3e4ab1653","type":"GENE","name":"ADGRL3","canonical_id":"hgnc:HGNC:20974","description":"adhesion G protein-coupled receptor L3","metadata":{"aliases":["KIAA0768","LEC3","LPHN3"]}},{"id":"4e23c643beba4d10aee522a83171348a","type":"GENE","name":"ADGRL3-AS1","canonical_id":"hgnc:HGNC:50604","description":"ADGRL3 antisense RNA 1","metadata":{"aliases":["LPHN3-AS1"]}},{"id":"c6d22f7ae48340c49c20762683cfe81d","type":"GENE","name":"ADGRL3-AS2","canonical_id":"hgnc:HGNC:58798","description":"ADGRL3 antisense RNA 2","metadata":null},{"id":"6cbd861930fd452dbf9381b996a1adbc","type":"GENE","name":"ADGRL3-AS3","canonical_id":"hgnc:HGNC:58799","description":"ADGRL3 antisense RNA 3","metadata":null},{"id":"32170ceff055416c8173b01fa0922f08","type":"GENE","name":"ADGRL4","canonical_id":"hgnc:HGNC:20822","description":"adhesion G protein-coupled receptor L4","metadata":{"aliases":["ETL","ELTD1"]}},{"id":"74d18d02149c4b21bc159cefb3ac3b21","type":"GENE","name":"ADGRV1","canonical_id":"hgnc:HGNC:17416","description":"adhesion G protein-coupled receptor V1","metadata":{"aliases":["DKFZp761P0710","KIAA0686","FEB4","VLGR1","USH2C","MASS1","GPR98"]}},{"id":"46f4f52ff1b44598a53a01597d825f82","type":"GENE","name":"ADGRV1-AS1","canonical_id":"hgnc:HGNC:59094","description":"ADGRV1 antisense RNA 1","metadata":null},{"id":"9945b041251344d0934645634b9dd8d9","type":"GENE","name":"ADH1A","canonical_id":"hgnc:HGNC:249","description":null,"metadata":null},{"id":"d5340b2b35964e299c372203c9fd8745","type":"GENE","name":"ADH1B","canonical_id":"hgnc:HGNC:250","description":"alcohol dehydrogenase 1B (class I), beta polypeptide","metadata":{"aliases":["ADH2"]}},{"id":"599e14a2adb14ea6b8ae695355f9ca2f","type":"GENE","name":"ADH1C","canonical_id":"hgnc:HGNC:251","description":"alcohol dehydrogenase 1C (class I), gamma polypeptide","metadata":{"aliases":["ADH3"]}},{"id":"f5035a4e54b14e00a1a090441dd72ed0","type":"GENE","name":"ADH4","canonical_id":"hgnc:HGNC:252","description":"alcohol dehydrogenase 4 (class II), pi polypeptide","metadata":{"aliases":["ADH-2"]}},{"id":"bf3cb0f38e684146a19a07e069e5555c","type":"GENE","name":"ADH5","canonical_id":"hgnc:HGNC:253","description":null,"metadata":null},{"id":"6ba7f617941d4c86b35298bf4565d1bf","type":"GENE","name":"ADH5P2","canonical_id":"hgnc:HGNC:22976","description":"ADH5 pseudogene 2","metadata":null},{"id":"9b39e0397c5440e99a7400554c0b0518","type":"GENE","name":"ADH5P3","canonical_id":"hgnc:HGNC:22991","description":"ADH5 pseudogene 3","metadata":null},{"id":"3ca6974d55c94fcf8b9194d7ca50f76f","type":"GENE","name":"ADH5P4","canonical_id":"hgnc:HGNC:21377","description":"ADH5 pseudogene 4","metadata":{"aliases":["bA707M13.2","ADH5B"]}},{"id":"eec4e10168a8425e8a1d61ff4818b56f","type":"GENE","name":"ADH5P5","canonical_id":"hgnc:HGNC:54523","description":"ADH5 pseudogene 5","metadata":null},{"id":"7cf8baf717c74211ba596dbbaec13be6","type":"GENE","name":"ADH6","canonical_id":"hgnc:HGNC:255","description":null,"metadata":null},{"id":"c720f4e7c2f842db9cabf734401bd3e5","type":"GENE","name":"ADH7","canonical_id":"hgnc:HGNC:256","description":"alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide","metadata":{"aliases":["ADH-4"]}},{"id":"74b8edc018e14068a4e2d4c61e49f534","type":"TRIAL","name":"ADHD Medication and Predictors of Treatment Outcome","canonical_id":"clinicaltrials.gov:NCT02136147","description":"Attention Deficit Disorder With Hyperactivity (ADHD)","metadata":null},{"id":"5cced00bebd24e1b94ae2b0489eb5a8b","type":"GENE","name":"ADHFE1","canonical_id":"hgnc:HGNC:16354","description":"alcohol dehydrogenase iron containing 1","metadata":{"aliases":["FLJ32430"]}},{"id":"cc65647ac6a04768b19a5e9404b0d3b9","type":"GENE","name":"ADI1","canonical_id":"hgnc:HGNC:30576","description":"acireductone dioxygenase 1","metadata":{"aliases":["SIPL","MTCBP-1","ARD","APL1","FLJ10913","HMFT1638","mtnD"]}},{"id":"3a2ce7b5e77d4c569dac24e0080f1fd0","type":"GENE","name":"ADI1P1","canonical_id":"hgnc:HGNC:52339","description":"acireductone dioxygenase 1 pseudogene 1","metadata":null},{"id":"aefcf6de029342a7a2b6d407e3216f7f","type":"GENE","name":"ADI1P2","canonical_id":"hgnc:HGNC:52340","description":"acireductone dioxygenase 1 pseudogene 2","metadata":null},{"id":"b967e4e9e13e4e04970968e2cabaf6c2","type":"GENE","name":"ADI1P3","canonical_id":"hgnc:HGNC:52341","description":"acireductone dioxygenase 1 pseudogene 3","metadata":null},{"id":"4db21a4b3b0e449a92ba85ce5191bb09","type":"GENE","name":"ADIG","canonical_id":"hgnc:HGNC:28606","description":"adipogenin","metadata":{"aliases":["MGC39724","SMAF1","RP5-1100H13.2"]}},{"id":"3826ec433d49441e916e0eda88922472","type":"GENE","name":"ADIPINT","canonical_id":"hgnc:HGNC:56273","description":"adipocyte associated pyruvate carboxylase interacting lncRNA","metadata":null},{"id":"85f0be0762f649f2869489b284e9c445","type":"GENE","name":"ADIPOQ","canonical_id":"hgnc:HGNC:13633","description":null,"metadata":null},{"id":"0d5f759f4ac940069646bed8248b7f90","type":"GENE","name":"ADIPOQ-AS1","canonical_id":"hgnc:HGNC:40648","description":"ADIPOQ antisense RNA 1","metadata":null},{"id":"af744d46b0984cef812fdee956ec24eb","type":"GENE","name":"ADIPOR1","canonical_id":"hgnc:HGNC:24040","description":null,"metadata":null},{"id":"863acffe0487460481f1c88f94966429","type":"GENE","name":"ADIPOR1P1","canonical_id":"hgnc:HGNC:44910","description":"adiponectin receptor 1 pseudogene 1","metadata":null},{"id":"b5dbdaa344194b71a988eb4f7621b9c4","type":"GENE","name":"ADIPOR1P2","canonical_id":"hgnc:HGNC:44911","description":"adiponectin receptor 1 pseudogene 2","metadata":null},{"id":"f4f88c95d24e4f18a2b7f683ca30851b","type":"GENE","name":"ADIPOR2","canonical_id":"hgnc:HGNC:24041","description":null,"metadata":null},{"id":"7c632de334c64f539c54635aa3397191","type":"GENE","name":"ADIRF","canonical_id":"hgnc:HGNC:24043","description":"adipogenesis regulatory factor","metadata":{"aliases":["APM2","AFRO","C10orf116"]}},{"id":"0111311f4af140e3bbfa16b624dd7bf6","type":"GENE","name":"ADIRF-AS1","canonical_id":"hgnc:HGNC:45127","description":"ADIRF antisense RNA 1","metadata":null},{"id":"f30cbf3193834d3097a0dc01ddd4c498","type":"GENE","name":"ADISSP","canonical_id":"hgnc:HGNC:15873","description":"adipose secreted signaling protein","metadata":{"aliases":["FLJ20550","C20orf27"]}},{"id":"a4b62acb7e894dfba268dc29bae3f2d6","type":"GENE","name":"ADISSPP1","canonical_id":"hgnc:HGNC:58498","description":"ADISSP pseudogene 1","metadata":null},{"id":"ce01be128e614d68b482fa1a00a6c425","type":"GENE","name":"ADISSPP2","canonical_id":"hgnc:HGNC:58499","description":"ADISSP pseudogene 2","metadata":null},{"id":"9d71b38d863249c1a4c5d25acc1897f0","type":"GENE","name":"ADK","canonical_id":"hgnc:HGNC:257","description":"adenosine kinase","metadata":{"aliases":["AK"]}},{"id":"90c095e18fe94f7eb12aad3f1a819a78","type":"GENE","name":"ADK-AS1","canonical_id":"hgnc:HGNC:58381","description":"ADK antisense RNA 1","metadata":null},{"id":"8a372339dd604be5994cb6c727dc4874","type":"GENE","name":"ADM","canonical_id":"hgnc:HGNC:259","description":null,"metadata":null},{"id":"40ea3610c9094641b97062f51638430e","type":"GENE","name":"ADM-DT","canonical_id":"hgnc:HGNC:55516","description":"ADM divergent transcript","metadata":null},{"id":"a814b1a24e0b49ae8635e0510cf2cbca","type":"GENE","name":"ADM2","canonical_id":"hgnc:HGNC:28898","description":"adrenomedullin 2","metadata":{"aliases":["AM2","FLJ21135"]}},{"id":"4da63e79013d4bae9554211d74b383c3","type":"GENE","name":"ADM5","canonical_id":"hgnc:HGNC:27293","description":"adrenomedullin 5 (putative)","metadata":{"aliases":["AM5","C19orf76"]}},{"id":"15188d6cf9854e46b836a631401edf6b","type":"GENE","name":"ADNP","canonical_id":"hgnc:HGNC:15766","description":"activity dependent neuroprotector homeobox","metadata":{"aliases":["KIAA0784","ADNP1"]}},{"id":"b6fe88aa47804cfd8b941d958197b534","type":"GENE","name":"ADNP-AS1","canonical_id":"hgnc:HGNC:51227","description":"ADNP antisense RNA 1","metadata":null},{"id":"9f7e80ac013442caa714ce4e73fba846","type":"GENE","name":"ADNP2","canonical_id":"hgnc:HGNC:23803","description":"ADNP homeobox 2","metadata":{"aliases":["KIAA0863","ZNF508"]}},{"id":"15b8da1285924a4fbd0691c292f00ea6","type":"GENE","name":"ADO","canonical_id":"hgnc:HGNC:23506","description":"2-aminoethanethiol dioxygenase","metadata":{"aliases":["FLJ14547","C10orf22"]}},{"id":"1477d50a22d64728b6a14b940f1a4d0b","type":"GENE","name":"ADORA1","canonical_id":"hgnc:HGNC:262","description":null,"metadata":null},{"id":"72a72aa8dc3f49a381297204f0eda139","type":"PROTEIN","name":"ADORA1","canonical_id":"uniprot:P30542","description":null,"metadata":null},{"id":"6d4a7f05b83442fbb7e4c70abe2b01f1","type":"GENE","name":"ADORA1-AS1","canonical_id":"hgnc:HGNC:40067","description":"ADORA1 antisense RNA 1","metadata":null},{"id":"11240461a552474284f7ecefc39a3cb3","type":"GENE","name":"ADORA1-AS2","canonical_id":"hgnc:HGNC:40066","description":"ADORA1 antisense RNA 2","metadata":null},{"id":"51e5a7987d524fcd9eaedc003751ba99","type":"GENE","name":"ADORA2A","canonical_id":"hgnc:HGNC:263","description":null,"metadata":null},{"id":"12417768776a4fbfa2c447c242e6cefa","type":"PROTEIN","name":"ADORA2A","canonical_id":"uniprot:P29274","description":null,"metadata":null},{"id":"d0527f635fba4580bcd911da830800dc","type":"GENE","name":"ADORA2A-AS1","canonical_id":"hgnc:HGNC:37122","description":"ADORA2A antisense RNA 1","metadata":{"aliases":["FLJ34651","hLinfRNA1","C22orf45"]}},{"id":"15ae0b9d5a6343288dcc9100b0ee570b","type":"GENE","name":"ADORA2B","canonical_id":"hgnc:HGNC:264","description":"adenosine A2b receptor","metadata":null},{"id":"3625d356040043ddace80d639be67055","type":"GENE","name":"ADORA2BP1","canonical_id":"hgnc:HGNC:265","description":"adenosine A2b receptor pseudogene 1","metadata":{"aliases":["ADORA2BP"]}},{"id":"ba126aae2c2a466e9f170db8c29c6fd4","type":"GENE","name":"ADORA3","canonical_id":"hgnc:HGNC:268","description":null,"metadata":null},{"id":"e0fecb1a46b94a689d2098787f669e41","type":"GO_TERM","name":"ADP binding","canonical_id":"go:GO:0043531","description":"\"Binding to ADP, adenosine 5'-diphosphate.\" [GOC:jl]","metadata":null},{"id":"6c057ec6bdd94673bdf3f041839e6760","type":"GO_TERM","name":"ADP biosynthetic process","canonical_id":"go:GO:0006172","description":"\"The chemical reactions and pathways resulting in the formation of ADP, adenosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"791b8335b07740698e75a6b4b6966d21","type":"GO_TERM","name":"ADP catabolic process","canonical_id":"go:GO:0046032","description":"\"The chemical reactions and pathways resulting in the breakdown of ADP, adenosine 5'-diphosphate.\" [GOC:curators]","metadata":null},{"id":"b4992aa837334ef1a77fbb30fb936534","type":"GO_TERM","name":"ADP deaminase activity","canonical_id":"go:GO:0047629","description":"\"Catalysis of the reaction: ADP + H2O + H+ = IDP + NH4+.\" [RHEA:12741]","metadata":null},{"id":"a2f4935058dd47fa99a2271e5a464fca","type":"GO_TERM","name":"ADP metabolic process","canonical_id":"go:GO:0046031","description":"\"The chemical reactions and pathways involving ADP, adenosine 5'-diphosphate.\" [GOC:curators]","metadata":null},{"id":"4c24fce9507a4864b1b683eeea6a2df0","type":"GO_TERM","name":"ADP phosphatase activity","canonical_id":"go:GO:0043262","description":"\"Catalysis of the reaction: ADP + H2O = AMP + phosphate + H+.\" [PMID:1470606, RHEA:61436]","metadata":null},{"id":"36559e5704b9443abce96222a9b4cf22","type":"GO_TERM","name":"ADP reductase activity","canonical_id":"go:GO:0051061","description":"\"Catalysis of the reaction: dADP + thioredoxin disulfide + H2O = ADP + thioredoxin.\" [MetaCyc:ADPREDUCT-RXN]","metadata":null},{"id":"7a914aab9d0a48f691fab694cccb0029","type":"GO_TERM","name":"ADP transmembrane transporter activity","canonical_id":"go:GO:0015217","description":"\"Enables the transfer of ADP, adenosine diphosphate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"6bf98f8285e242368058f4c2e2c656a5","type":"GO_TERM","name":"ADP transport","canonical_id":"go:GO:0015866","description":"\"The directed movement of ADP, adenosine diphosphate, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"eed95ffba2f94105943a532a77f626c8","type":"GO_TERM","name":"ADP-D-ribose binding","canonical_id":"go:GO:0072570","description":"\"Binding to ADP-D-ribose, an ADP-aldose having ribose as the aldose fragment.\" [GOC:mah, GOC:sart, PMID:20088964]","metadata":null},{"id":"627d2c44caf1426d8a27944f0a726652","type":"GO_TERM","name":"ADP-D-ribose modification-dependent protein binding","canonical_id":"go:GO:0160002","description":"\"Binding to a protein upon ADP-ribosylation of the target protein.\" [PMID:26673700]","metadata":null},{"id":"feb35e0931f545b39988dd3c38f750f3","type":"GO_TERM","name":"ADP-L-glycero-beta-D-manno-heptose biosynthetic process","canonical_id":"go:GO:0097171","description":"\"The chemical reactions and pathways resulting in the formation of ADP-L-glycero-beta-D-manno-heptose, an ADP-L-glycero-D-manno-heptose having beta-configuration at the anomeric centre of the heptose. ADP-L-glycero-beta-D-manno-heptose (also called ADP-L-beta-D-heptose or ADP-L-glycero-D-manno-heptose) is a nucleotide-sugar precursor of the inner core lipopolysaccharide (LPS) from D-glycero-beta-D-manno-heptose 7-phosphate.\" [GOC:yaf, PMID:11751812]","metadata":null},{"id":"83d03993a7944302849c9cd637553ccc","type":"GO_TERM","name":"ADP-dependent NAD(P)H-hydrate dehydratase activity","canonical_id":"go:GO:0052855","description":"\"Catalysis of the reaction: (6S)-6beta-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide + ADP = AMP + H+ + NAD(P)H + phosphate.\" [EC:4.2.1.136, PMID:21994945]","metadata":null},{"id":"2767c799a99c4ad0b1eb03905ee4784f","type":"GO_TERM","name":"ADP-glucose pyrophosphatase activity","canonical_id":"go:GO:0080042","description":"\"Catalysis of the reaction: ADP-glucose + H2O = AMP + glucose-1-phosphate.\" [GOC:tb]","metadata":null},{"id":"1099ee18b7234e2692238402b7f5a3f8","type":"GO_TERM","name":"ADP-glyceromanno-heptose 6-epimerase activity","canonical_id":"go:GO:0008712","description":"\"Catalysis of the reaction: ADP-D-glycero-D-manno-heptose = ADP-L-glycero-D-manno-heptose.\" [EC:5.1.3.20, RHEA:17577]","metadata":null},{"id":"76a3b9f617a14810b3c07210ef4c9aec","type":"GO_TERM","name":"ADP-heptose-lipopolysaccharide heptosyltransferase activity","canonical_id":"go:GO:0008713","description":"\"Catalysis of the reaction: heptosyl-KDO2-lipid A + ADP-L-glycero-beta-D-manno-heptose = heptosyl2-KDO2-lipid A + ADP + H+.\" [RHEA:74071]","metadata":null},{"id":"4ef49d1df7a842b091ee39a16e19b9ab","type":"GO_TERM","name":"ADP-phosphoglycerate phosphatase activity","canonical_id":"go:GO:0047630","description":"\"Catalysis of the reaction: 3-ADP-2-phosphoglycerate + H2O = 3-ADP-glycerate + phosphate.\" [RHEA:15861]","metadata":null},{"id":"3eed1016aca64aa6a8ff8b46e1dd1f4f","type":"GO_TERM","name":"ADP-ribose diphosphatase activity","canonical_id":"go:GO:0047631","description":"\"Catalysis of the reaction: ADP-ribose + H2O = AMP + D-ribose 5-phosphate.\" [EC:3.6.1.13]","metadata":null},{"id":"66cb373161b4451b8e62e28f0e978e4a","type":"GO_TERM","name":"ADP-ribose pyrophosphatase activity","canonical_id":"go:GO:0080041","description":"\"Catalysis of the reaction: ADP-ribose + H2O = AMP + ribose-1-phosphate.\" [GOC:tb]","metadata":null},{"id":"6e266edfb3124697b74c2e1cfcf12577","type":"GO_TERM","name":"ADP-ribosylarginine-[protein] hydrolase activity","canonical_id":"go:GO:0003875","description":"\"Catalysis of the reactions: H2O + N(omega)-(ADP-D-ribosyl)-L-arginyl-[protein] = ADP-D-ribose + L-arginyl-[protein], and H2O + N(omega)-(ADP-D-ribosyl)-L-arginine = ADP-D-ribose + L-arginine.\" [EC:3.2.2.19]","metadata":null},{"id":"7e396eac03ad48e7bc429ce026b7be00","type":"GO_TERM","name":"ADP-ribosylglutamate-[protein] hydrolase activity","canonical_id":"go:GO:0140293","description":"\"Catalysis of the reaction: 5-O-(ADP-D-ribosyl)-L-glutamyl-[protein] + H2O = L-glutamyl-[protein] + ADP-D-ribose + H+.\" [PMID:23481255, RHEA:58248]","metadata":null},{"id":"789a589d76534ee9b4fcb9c8878e9e24","type":"GO_TERM","name":"ADP-ribosylserine-[protein] hydrolase activity","canonical_id":"go:GO:0140292","description":"\"Catalysis of the reaction: O-(ADP-D-ribosyl)-L-seryl-[protein] + H2O = ADP-D-ribose + L-seryl-[protein].\" [PMID:28650317, PMID:29234005, RHEA:58256]","metadata":null},{"id":"fab5bc6768364a1f8f05a0a6ece91faa","type":"GO_TERM","name":"ADP-riboxanase-[protein] activity","canonical_id":"go:GO:0140740","description":"\"Catalysis of the reaction: L-arginyl-[protein] + NAD+ = ADP-riboxanated L-argininyl-[protein] + H+ + NH4+ + nicotinamide.\" [PMID:34671164, RHEA:69500]","metadata":null},{"id":"42eff84539eb476e899c095777648982","type":"GO_TERM","name":"ADP-specific glucokinase activity","canonical_id":"go:GO:0043843","description":"\"Catalysis of the reaction: ADP + D-glucose = AMP + D-glucose 6-phosphate.\" [EC:2.7.1.147]","metadata":null},{"id":"45e7d8f3b6f046ed8fde993c9f37aa30","type":"GO_TERM","name":"ADP-specific phosphofructokinase activity","canonical_id":"go:GO:0043844","description":"\"Catalysis of the reaction: ADP + D-fructose 6-phosphate = AMP + D-fructose 1,6-bisphosphate.\" [EC:2.7.1.146]","metadata":null},{"id":"50d8e031c0054c87a229114c83f7961b","type":"GO_TERM","name":"ADP-sugar pyrophosphatase activity","canonical_id":"go:GO:0019144","description":"\"Catalysis of the reaction: ADP-sugar + H2O = AMP + alpha-D-aldose 1-phosphate.\" [EC:3.6.1.21]","metadata":null},{"id":"fab7c9f599bc43cbb223696cf9a8cb54","type":"GO_TERM","name":"ADP-thymidine kinase activity","canonical_id":"go:GO:0047628","description":"\"Catalysis of the reaction: ADP + thymidine = AMP + thymidine 5'-phosphate.\" [EC:2.7.1.118, MetaCyc:ADP--THYMIDINE-KINASE-RXN]","metadata":null},{"id":"05bb6a94ac62479eb0cc5f32e42ea8b9","type":"GO_TERM","name":"ADP:phosphate antiporter activity","canonical_id":"go:GO:0140988","description":"\"Enables the transfer of ADP from one side of a membrane to the other according to the reaction: ADP(out) + phosphate(in) = ADP(in) + phosphate(out).\" [PMID:15123600]","metadata":null},{"id":"3b9e9932d77a4b60b6eb69bd5a8d9ab8","type":"GO_TERM","name":"ADPG pyrophosphorylase complex","canonical_id":"go:GO:0030929","description":"\"Complex that possesses ADPG pyrophosphorylase activity. In all organisms where it has been found, the complex is a tetramer. In bacteria, it is a homotetramer. In plants, the complex is a heterotetramer composed small and large subunits.\" [GOC:tb, PMID:9680965]","metadata":null},{"id":"ceae8622d02f44dc8af759d7ccdaa29a","type":"GENE","name":"ADPGK","canonical_id":"hgnc:HGNC:25250","description":"ADP dependent glucokinase","metadata":{"aliases":["DKFZp434B195","ADP-GK"]}},{"id":"b0d1225355b64a8d9b05862524575185","type":"GENE","name":"ADPGK-AS1","canonical_id":"hgnc:HGNC:44144","description":"ADPGK antisense RNA 1","metadata":null},{"id":"f78ec471dd1d4a5393daeb158d5dbc16","type":"GENE","name":"ADPRH","canonical_id":"hgnc:HGNC:269","description":"ADP-ribosylarginine hydrolase","metadata":{"aliases":["ARH1"]}},{"id":"3dbcea704685473388a672d6a384c5a8","type":"GENE","name":"ADPRH-AS1","canonical_id":"hgnc:HGNC:58775","description":"ADPRH antisense RNA 1","metadata":{"aliases":["AC073352.1"]}},{"id":"6c9f1ab06edf481494ba63c1665f98f9","type":"GENE","name":"ADPRHL1","canonical_id":"hgnc:HGNC:21303","description":"ADP-ribosylhydrolase like 1","metadata":{"aliases":["ARH2"]}},{"id":"77f8010053fc4d62856da9a201d60187","type":"GENE","name":"ADPRM","canonical_id":"hgnc:HGNC:30925","description":"ADP-ribose/CDP-alcohol diphosphatase, manganese dependent","metadata":{"aliases":["MDS006","C17orf48"]}},{"id":"620dd0745cdd42668130610510685b67","type":"GENE","name":"ADPRS","canonical_id":"hgnc:HGNC:21304","description":"ADP-ribosylserine hydrolase","metadata":{"aliases":["ARH3","FLJ20446","ADPRHL2"]}},{"id":"386a564ef1844b11b71c599b6a9fa16d","type":"GENE","name":"ADRA1A","canonical_id":"hgnc:HGNC:277","description":null,"metadata":null},{"id":"26ad73b590d7408bbf0d0b5597109d5a","type":"PROTEIN","name":"ADRA1A","canonical_id":"uniprot:P35348","description":null,"metadata":null},{"id":"f164dc09c06e4ccdb0086475455fc1b2","type":"GENE","name":"ADRA1B","canonical_id":"hgnc:HGNC:278","description":"adrenoceptor alpha 1B","metadata":null},{"id":"2bb0736f5da7471e8e6066ba120f483d","type":"GENE","name":"ADRA1D","canonical_id":"hgnc:HGNC:280","description":"adrenoceptor alpha 1D","metadata":{"aliases":["ADRA1R","ADRA1A","ADRA1"]}},{"id":"7da041f5af8f4b7b8b65baa58aa3c1c6","type":"GENE","name":"ADRA2A","canonical_id":"hgnc:HGNC:281","description":"adrenoceptor alpha 2A","metadata":{"aliases":["ADRAR","ADRA2","ADRA2R"]}},{"id":"d59063ad5e364532b155a2eee85863dd","type":"PROTEIN","name":"ADRA2A","canonical_id":"uniprot:P08913","description":null,"metadata":null},{"id":"fa5bedabdd6c4f119b586d9f43e47356","type":"GENE","name":"ADRA2B","canonical_id":"hgnc:HGNC:282","description":null,"metadata":null},{"id":"a536169acb65408dbec20236051b33f9","type":"GENE","name":"ADRA2C","canonical_id":"hgnc:HGNC:283","description":"adrenoceptor alpha 2C","metadata":{"aliases":["ADRARL2","ADRA2L2","ADRA2RL2"]}},{"id":"f9083ad19cea4b7da977faa339d2b750","type":"GENE","name":"ADRB1","canonical_id":"hgnc:HGNC:285","description":"adrenoceptor beta 1","metadata":{"aliases":["ADRB1R"]}},{"id":"5fb7b3568c944bfab9a744e50b8c58c2","type":"PROTEIN","name":"ADRB1","canonical_id":"uniprot:P08588","description":null,"metadata":null},{"id":"8e8c7a7caa2c4a5e9d1d0234ac3dacea","type":"GENE","name":"ADRB2","canonical_id":"hgnc:HGNC:286","description":null,"metadata":null},{"id":"02854d3a81284a69823f7c0c5a5f3a42","type":"PROTEIN","name":"ADRB2","canonical_id":"uniprot:P07550","description":null,"metadata":null},{"id":"84ed2cc36a5748f59ee3be2525291338","type":"GENE","name":"ADRB2-OT1","canonical_id":"hgnc:HGNC:59277","description":"ADRB2 overlapping transcript 1","metadata":null},{"id":"46c17fb4c7f44e4ebf0f7f31c7fb0ea8","type":"GENE","name":"ADRB3","canonical_id":"hgnc:HGNC:288","description":null,"metadata":null},{"id":"cbc5a002271e4878b77165ab334f6d7a","type":"PROTEIN","name":"ADRB3","canonical_id":"uniprot:P13945","description":null,"metadata":null},{"id":"6b546de9c42048159d8b13280f187c7d","type":"TRIAL","name":"ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS","canonical_id":"clinicaltrials.gov:NCT02859584","description":"Acute Hepatitis","metadata":null},{"id":"bf74a6c1edb346ce97c9575e72d3b93b","type":"GENE","name":"ADRM1","canonical_id":"hgnc:HGNC:15759","description":"ADRM1 26S proteasome ubiquitin receptor","metadata":{"aliases":["GP110","Rpn13","ARM1","PSMD16"]}},{"id":"3e79429ac7404fa3b01caaf9d7cb5485","type":"GENE","name":"ADSL","canonical_id":"hgnc:HGNC:291","description":"adenylosuccinate lyase","metadata":null},{"id":"6a15e9b6cdce45c79fa7c43f843bf4d6","type":"GENE","name":"ADSS1","canonical_id":"hgnc:HGNC:20093","description":"adenylosuccinate synthase 1","metadata":{"aliases":["FLJ38602","ADSSL1"]}},{"id":"a87be30e5ec24873ac80466f5199ad1c","type":"GENE","name":"ADSS2","canonical_id":"hgnc:HGNC:292","description":"adenylosuccinate synthase 2","metadata":{"aliases":["ADSS"]}},{"id":"1917db4a04c6432d8e5b2a5b41481bbb","type":"TRIAL","name":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","canonical_id":"clinicaltrials.gov:NCT04916613","description":"Prostate Cancer Metastatic","metadata":null},{"id":"67ec61ef704b49ffbf959a0bf898b6a0","type":"GENE","name":"ADTRP","canonical_id":"hgnc:HGNC:21214","description":"androgen dependent TFPI regulating protein","metadata":{"aliases":["dJ413H6.1","AIG1L","C6orf105"]}},{"id":"32a0bc89e2cd4f68906839130b7c3f58","type":"TRIAL","name":"ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan\u00ae in Patients Undergoing Myocardial Perfusion Imaging (MPI)","canonical_id":"clinicaltrials.gov:NCT00208299","description":"Coronary Artery Disease","metadata":null},{"id":"160565075f634adaaa6ce31e0837d464","type":"TRIAL","name":"ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan\u00ae in Patients Undergoing Myocardial Perfusion Imaging (MPI)","canonical_id":"clinicaltrials.gov:NCT00208312","description":"Coronary Artery Disease","metadata":null},{"id":"992492a21e8e456dba362ae8de66eeed","type":"TRIAL","name":"ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00379899","description":"Chronic Kidney Disease; End Stage Renal Disease; Coronary Artery Calcification; Vascular Calcification; Calcification; Cardiovascular Disease; Chronic Renal Failure; Hyperparathyroidism; Kidney Disease; Nephrology; Secondary Hyperparathyroidism","metadata":null},{"id":"8fd9e294beb54ae29452909f7ccd1ab6","type":"GENE","name":"AEBP1","canonical_id":"hgnc:HGNC:303","description":"AE binding protein 1","metadata":{"aliases":["ACLP"]}},{"id":"188aa4269ad9402bb3e0afa55a815d82","type":"GENE","name":"AEBP2","canonical_id":"hgnc:HGNC:24051","description":"AE binding protein 2","metadata":{"aliases":["MGC17922"]}},{"id":"09dff172aa2d4a9aaf2d0fe41f87a362","type":"GENE","name":"AEN","canonical_id":"hgnc:HGNC:25722","description":"apoptosis enhancing nuclease","metadata":{"aliases":["FLJ12484","FLJ12562","ISG20L1"]}},{"id":"3cb1472598a4443b8855999d1bbe2a3f","type":"GENE","name":"AES","canonical_id":"hgnc:HGNC:307","description":null,"metadata":null},{"id":"e5e4051e184343dd8ba46b5dee30d941","type":"GO_TERM","name":"AF-1 domain binding","canonical_id":"go:GO:0050683","description":"\"Binding to an AF-1 protein domain, a ligand-independent transactivation domain which is required for the full transcriptional activity of the receptor.\" [PMID:9682036]","metadata":null},{"id":"95628d3ad7e6467092e9c56a42193661","type":"GO_TERM","name":"AF-2 domain binding","canonical_id":"go:GO:0050682","description":"\"Binding to an AF-2 protein domain, a highly conserved ligand-dependent transactivation domain which is essential for receptor-mediated transcriptional activation.\" [PMID:9682036]","metadata":null},{"id":"e327708559f1433fa084ce1ec4438816","type":"TRIAL","name":"AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC","canonical_id":"clinicaltrials.gov:NCT04413201","description":"Non-squamous NSCLC","metadata":null},{"id":"894ec93cbaad49f8822aaad17a4fddd4","type":"GENE","name":"AFAP1","canonical_id":"hgnc:HGNC:24017","description":"actin filament associated protein 1","metadata":{"aliases":["AFAP-110","AFAP"]}},{"id":"ca97d31c56964668bb7106302d08671b","type":"GENE","name":"AFAP1-AS1","canonical_id":"hgnc:HGNC:28141","description":"AFAP1 antisense RNA 1","metadata":{"aliases":["ATMLP","MGC10981","AFAP1AS","AFAP1-AS"]}},{"id":"e8d9fbf1ea6b4571802df84122795c4a","type":"GENE","name":"AFAP1-AS2","canonical_id":"hgnc:HGNC:58726","description":"AFAP1 antisense RNA 2","metadata":null},{"id":"543b7893a79745e1a351177cf979393f","type":"GENE","name":"AFAP1L1","canonical_id":"hgnc:HGNC:26714","description":"actin filament associated protein 1 like 1","metadata":{"aliases":["FLJ36748"]}},{"id":"a77ebc27745e4617802fe967f3610601","type":"GENE","name":"AFAP1L1-AS1","canonical_id":"hgnc:HGNC:59278","description":"AFAP1L1 and ABLIM3 antisense RNA1","metadata":null},{"id":"d011c64ea46b4cd1a2151339dac4803c","type":"GENE","name":"AFAP1L1-AS2","canonical_id":"hgnc:HGNC:59279","description":"AFAP1L1 antisense RNA 2","metadata":null},{"id":"8f4ef29dbae34411ba5af43b5a417087","type":"GENE","name":"AFAP1L2","canonical_id":"hgnc:HGNC:25901","description":"actin filament associated protein 1 like 2","metadata":{"aliases":["FLJ14564","Em:AC005383.4","XB130","KIAA1914"]}},{"id":"e80dc097d876419d93f35599ec7c6203","type":"GENE","name":"AFDN","canonical_id":"hgnc:HGNC:7137","description":"afadin, adherens junction formation factor","metadata":{"aliases":["AF-6","AF6","MLLT4"]}},{"id":"a4d6a6fc50b247139c016a5b2c42810c","type":"GENE","name":"AFDN-DT","canonical_id":"hgnc:HGNC:21236","description":"AFDN divergent transcript","metadata":{"aliases":["HGC6.4","dJ431P23.3","XBP1SBM","AFDN-AS1","C6orf124","LINC01558","MLLT4-AS1"]}},{"id":"0c19aa1405da4b368e3f77518194ca3b","type":"GENE","name":"AFF1","canonical_id":"hgnc:HGNC:7135","description":"ALF transcription elongation factor 1","metadata":{"aliases":["AF-4","AF4","FEL","PBM1","MLLT2"]}},{"id":"eba5f7cd391b4a70b0e0c508af9c4096","type":"GENE","name":"AFF1-AS1","canonical_id":"hgnc:HGNC:53447","description":"AFF1 antisense RNA 1","metadata":null},{"id":"a842ae653e00405c9be3fa9d2ae3c4f0","type":"GENE","name":"AFF2","canonical_id":"hgnc:HGNC:3776","description":"ALF transcription elongation factor 2","metadata":{"aliases":["FRAXE","FMR2"]}},{"id":"d0d730e2353042658c29e90350216d82","type":"GENE","name":"AFF2-IT1","canonical_id":"hgnc:HGNC:41334","description":"AFF2 intronic transcript 1","metadata":null},{"id":"5f7c2a6e33174ea6bcd129dbc932d7cb","type":"GENE","name":"AFF3","canonical_id":"hgnc:HGNC:6473","description":"ALF transcription elongation factor 3","metadata":{"aliases":["MLLT2-like","LAF4"]}},{"id":"4bccd993ea5946e18af3ed3f79fb1f55","type":"GENE","name":"AFF4","canonical_id":"hgnc:HGNC:17869","description":"ALF transcription elongation factor 4","metadata":{"aliases":["AF5Q31","MCEF"]}},{"id":"b4142a4d714f4f5dbe48dbf830647c09","type":"GENE","name":"AFF4-DT","canonical_id":"hgnc:HGNC:55235","description":"AFF4 divergent transcript","metadata":null},{"id":"cfa83248c6b44dac97a22ec03b237f49","type":"GENE","name":"AFF4P1","canonical_id":"hgnc:HGNC:56526","description":"AFF4 pseudogene 1","metadata":null},{"id":"076730faa07e4e51b014c5d31f30d149","type":"GENE","name":"AFG1L","canonical_id":"hgnc:HGNC:16411","description":"AFG1 like ATPase","metadata":{"aliases":["AFG1","LACE1"]}},{"id":"4a83dddcecc1497e94bb4215ab3549eb","type":"GENE","name":"AFG2A","canonical_id":"hgnc:HGNC:18119","description":"AAA ATPase AFG2A","metadata":{"aliases":["SPAF","AFG2","SPATA5"]}},{"id":"01ceeceec0cb4ea0a2afd8a5a833a9a2","type":"GENE","name":"AFG2B","canonical_id":"hgnc:HGNC:28762","description":"AAA ATPase AFG2B","metadata":{"aliases":["MGC5347","FLJ12286","SPATA5L1"]}},{"id":"63a40712a490478d94e523c634db6fc6","type":"GENE","name":"AFG3L1P","canonical_id":"hgnc:HGNC:314","description":"AFG3 like matrix AAA peptidase subunit 1, pseudogene","metadata":{"aliases":["AFG3","AFG3L1"]}},{"id":"1b83c19b93c84b4a9ac53762768236bb","type":"GENE","name":"AFG3L2","canonical_id":"hgnc:HGNC:315","description":"AFG3 like matrix AAA peptidase subunit 2","metadata":{"aliases":["SPAX5","SCA28"]}},{"id":"9e2e8c04d08a46c282482bfcd4321cad","type":"GENE","name":"AFG3L2P1","canonical_id":"hgnc:HGNC:24169","description":"AFG3L2 pseudogene 1","metadata":{"aliases":["AFG3L2P"]}},{"id":"42a910fbb5104907a41dee262a379ac0","type":"GENE","name":"AFM","canonical_id":"hgnc:HGNC:316","description":"afamin","metadata":{"aliases":["ALB2","ALBA"]}},{"id":"96b3f8fdaee94099b4a4620b5633985d","type":"GENE","name":"AFMID","canonical_id":"hgnc:HGNC:20910","description":"arylformamidase","metadata":{"aliases":["DKFZp686F03259","KF"]}},{"id":"5f5cbd2d7794412fbe3612ed4198c978","type":"GENE","name":"AFP","canonical_id":"hgnc:HGNC:317","description":null,"metadata":null},{"id":"775f0dba15334cafacac281b691537a6","type":"TRIAL","name":"AFTER: Altering Fat Through Estrogen and Raloxifene","canonical_id":"clinicaltrials.gov:NCT00149604","description":"Postmenopause","metadata":null},{"id":"edba9a7b2e3a4bca9c306bb56d7b6b25","type":"GENE","name":"AFTPH","canonical_id":"hgnc:HGNC:25951","description":"aftiphilin","metadata":{"aliases":["MGC33965","FLJ20080","FLJ23793","Nbla10388"]}},{"id":"eb4861db4e034059a9fecc3eedcf8ca2","type":"GENE","name":"AFTPH-DT","canonical_id":"hgnc:HGNC:52788","description":"AFTPH divergent transcript","metadata":null},{"id":"3842beb311204207b4a22556a5d4f08f","type":"TRIAL","name":"AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC","canonical_id":"clinicaltrials.gov:NCT06472037","description":"Locally Advanced Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"30e4d56064f542b1be4b7d38ca04651f","type":"TRIAL","name":"AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT00071006","description":"Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome","metadata":null},{"id":"176b89e0e58c49a283e6422c7f58a3a9","type":"GENE","name":"AGA","canonical_id":"hgnc:HGNC:318","description":"aspartylglucosaminidase","metadata":{"aliases":["ASRG"]}},{"id":"6c84390cbad6456dbe90cd78a60a460c","type":"GO_TERM","name":"AGA codon-amino acid adaptor activity","canonical_id":"go:GO:0033447","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AGA codon.\" [GOC:mah]","metadata":null},{"id":"b07e66ea663e43bb94688ed11dc21563","type":"GENE","name":"AGA-DT","canonical_id":"hgnc:HGNC:27730","description":"AGA divergent transcript","metadata":null},{"id":"e6af5b0377014d9bb554973538647c17","type":"GENE","name":"AGAP1","canonical_id":"hgnc:HGNC:16922","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 1","metadata":{"aliases":["KIAA1099","GGAP1","CENTG2"]}},{"id":"be17d2d14f6241e188e6f609c04e3f13","type":"GENE","name":"AGAP1-IT1","canonical_id":"hgnc:HGNC:41427","description":"AGAP1 intronic transcript 1","metadata":null},{"id":"b0dbc54a4cc34bd68f9891a16e57381e","type":"GENE","name":"AGAP10P","canonical_id":"hgnc:HGNC:23659","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 10, pseudogene","metadata":{"aliases":["bA358L16.1","bA144G6.2","AGAP10","CTGLF7","CTGLF10P"]}},{"id":"03012a861dec47968a2324e9e8d233ff","type":"GENE","name":"AGAP11","canonical_id":"hgnc:HGNC:29421","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 11","metadata":{"aliases":["KIAA1975"]}},{"id":"d9d1cacf37634139bc4dbc4a6c1240f4","type":"GENE","name":"AGAP12P","canonical_id":"hgnc:HGNC:23661","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 12, pseudogene","metadata":{"aliases":["bA164N7.2","CTGLF12P"]}},{"id":"6cf614c9d8b94a8dabc9ad91336fd8ae","type":"GENE","name":"AGAP13P","canonical_id":"hgnc:HGNC:23499","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 13, pseudogene","metadata":{"aliases":["bA548K23.1","CTGLF9P"]}},{"id":"d1c577552828439a81c7bbb2b0458bb3","type":"GENE","name":"AGAP14P","canonical_id":"hgnc:HGNC:23660","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 14, pseudogene","metadata":{"aliases":["bA145E20.1","CTGLF11P","AGAP14"]}},{"id":"3c1ae6fc6cf34c138af8e4093c4dce0c","type":"GENE","name":"AGAP2","canonical_id":"hgnc:HGNC:16921","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 2","metadata":{"aliases":["CENTG1"]}},{"id":"aee72266489c4873a2b8e5f6130b8f23","type":"GENE","name":"AGAP2-AS1","canonical_id":"hgnc:HGNC:48633","description":"AGAP2 antisense RNA 1","metadata":{"aliases":["LOC100130776","PUNISHER"]}},{"id":"a5ca71699c6640bfa54dfef2995bd98a","type":"GENE","name":"AGAP3","canonical_id":"hgnc:HGNC:16923","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 3","metadata":{"aliases":["CENTG3"]}},{"id":"e6bbdc22aedd44a5bca8a519b77e75da","type":"GENE","name":"AGAP4","canonical_id":"hgnc:HGNC:23459","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 4","metadata":{"aliases":["Em:AC012044.1","MRIP2","CTGLF1","AGAP8","CTGLF5"]}},{"id":"993e338bc2d5428d9a681cb483e81b71","type":"GENE","name":"AGAP5","canonical_id":"hgnc:HGNC:23467","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 5","metadata":{"aliases":["Em:AC073389.1","CTGLF2"]}},{"id":"9224c4a274b748ca86c4e8aff272532e","type":"GENE","name":"AGAP6","canonical_id":"hgnc:HGNC:23466","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 6","metadata":{"aliases":["bA324H6.1","CTGLF3"]}},{"id":"0d43cab7ead54d6d9fd088dcab1449ae","type":"GENE","name":"AGAP7P","canonical_id":"hgnc:HGNC:23465","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 7, pseudogene","metadata":{"aliases":["bA109G10.1","CTGLF4","AGAP7"]}},{"id":"6eaf0c2d78494768bd090b31aa3a6036","type":"GENE","name":"AGAP9","canonical_id":"hgnc:HGNC:23463","description":"ArfGAP with GTPase domain, ankyrin repeat and PH domain 9","metadata":{"aliases":["bA301J7.2","FLJ00312","CTGLF6"]}},{"id":"863500baebe64003a9eb6a8a79a3c21a","type":"GENE","name":"AGBL1","canonical_id":"hgnc:HGNC:26504","description":"AGBL carboxypeptidase 1","metadata":{"aliases":["FLJ32310","CCP4"]}},{"id":"694ea4203e7940718c056faaa7323843","type":"GENE","name":"AGBL1-AS1","canonical_id":"hgnc:HGNC:48617","description":"AGBL1 antisense RNA 1","metadata":null},{"id":"6e148b86aeeb4d0f9a7d0ea587416b31","type":"GENE","name":"AGBL2","canonical_id":"hgnc:HGNC:26296","description":"AGBL carboxypeptidase 2","metadata":{"aliases":["FLJ23598","CCP2"]}},{"id":"c970c640fb534a9bbc25384967601a6e","type":"GENE","name":"AGBL3","canonical_id":"hgnc:HGNC:27981","description":"AGBL carboxypeptidase 3","metadata":{"aliases":["MGC32955","CCP3"]}},{"id":"6ec3dc4b3a84432b91fcbe9ba8667406","type":"GENE","name":"AGBL4","canonical_id":"hgnc:HGNC:25892","description":"AGBL carboxypeptidase 4","metadata":{"aliases":["FLJ14442","CCP6"]}},{"id":"b68346143654455dab9dd552b864e76c","type":"GENE","name":"AGBL4-AS1","canonical_id":"hgnc:HGNC:41123","description":"AGBL4 antisense RNA 1","metadata":null},{"id":"aece615e05d14d65a6ba2ad243244f1f","type":"GENE","name":"AGBL4-IT1","canonical_id":"hgnc:HGNC:41482","description":"AGBL4 intronic transcript 1","metadata":null},{"id":"591d2f862eed4d46a593557ea651b2fd","type":"GENE","name":"AGBL5","canonical_id":"hgnc:HGNC:26147","description":"AGBL carboxypeptidase 5","metadata":{"aliases":["FLJ21839","CCP5"]}},{"id":"1d420963f2df4e09903b8ce2b344d5b2","type":"GENE","name":"AGBL5-AS1","canonical_id":"hgnc:HGNC:41133","description":"AGBL5 antisense RNA 1","metadata":null},{"id":"f49a6e2609e845fdaa5404b15854fb5f","type":"GENE","name":"AGBL5-IT1","canonical_id":"hgnc:HGNC:41484","description":"AGBL5 intronic transcript 1","metadata":null},{"id":"59f9142c859e434d9b6525829200ce46","type":"GO_TERM","name":"AGC codon-amino acid adaptor activity","canonical_id":"go:GO:0033446","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AGC codon.\" [GOC:mah]","metadata":null},{"id":"4e1d2a44009f4d8d95632b318d0dccaf","type":"GENE","name":"AGER","canonical_id":"hgnc:HGNC:320","description":null,"metadata":null},{"id":"e5e1d015e5484d498eb583ce5aa5d74a","type":"GENE","name":"AGFG1","canonical_id":"hgnc:HGNC:5175","description":"ArfGAP with FG repeats 1","metadata":{"aliases":["RIP","RAB","HRB"]}},{"id":"84a330a685ff42c6a34fddf4d66b3cba","type":"GENE","name":"AGFG2","canonical_id":"hgnc:HGNC:5177","description":"ArfGAP with FG repeats 2","metadata":{"aliases":["RABR","HRBL"]}},{"id":"fc75175ffc6948089799770a64f3559e","type":"GO_TERM","name":"AGG codon-amino acid adaptor activity","canonical_id":"go:GO:0033448","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AGG codon.\" [GOC:mah]","metadata":null},{"id":"d6d70b7515ee41c2846ab9fdc24f7529","type":"GENE","name":"AGGF1","canonical_id":"hgnc:HGNC:24684","description":null,"metadata":null},{"id":"e9340d7f96e14912a1ac8a3e700a5746","type":"GENE","name":"AGGF1P1","canonical_id":"hgnc:HGNC:38051","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 1","metadata":null},{"id":"682e3560b63b4f58a378525c41fff8cf","type":"GENE","name":"AGGF1P10","canonical_id":"hgnc:HGNC:51747","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 10","metadata":null},{"id":"0f3f41e60116476283da1106cfae75c0","type":"GENE","name":"AGGF1P2","canonical_id":"hgnc:HGNC:38052","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 2","metadata":null},{"id":"dc40ea12d2094476b09add1043ca4725","type":"GENE","name":"AGGF1P3","canonical_id":"hgnc:HGNC:38053","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 3","metadata":null},{"id":"613aea5896854d5f864401330b0087aa","type":"GENE","name":"AGGF1P4","canonical_id":"hgnc:HGNC:38054","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 4","metadata":null},{"id":"1e53bf42da5547c087c4c093db9c6636","type":"GENE","name":"AGGF1P5","canonical_id":"hgnc:HGNC:51741","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 5","metadata":null},{"id":"b3ac445bf8734204b8763436bce224df","type":"GENE","name":"AGGF1P6","canonical_id":"hgnc:HGNC:51744","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 6","metadata":null},{"id":"f85948965738439ca3e4176bb3caa15d","type":"GENE","name":"AGGF1P7","canonical_id":"hgnc:HGNC:51740","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 7","metadata":null},{"id":"16a8ce6e95ea47f9926b0cf7c11d1a98","type":"GENE","name":"AGGF1P8","canonical_id":"hgnc:HGNC:51745","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 8","metadata":null},{"id":"95e350a575ec49e5a2fad270cfbb7cba","type":"GENE","name":"AGGF1P9","canonical_id":"hgnc:HGNC:51746","description":"angiogenic factor with G-patch and FHA domains 1 pseudogene 9","metadata":null},{"id":"33cfd57c0dea42538341a0578abae5cf","type":"TRIAL","name":"AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine","canonical_id":"clinicaltrials.gov:NCT05324852","description":"Emergence Delirium","metadata":null},{"id":"770fd1421e05467c847307ddc242a179","type":"GENE","name":"AGK","canonical_id":"hgnc:HGNC:21869","description":"acylglycerol kinase","metadata":{"aliases":["FLJ10842","MULK"]}},{"id":"c1d1fd6890f14a4aa059b9a0670bc37e","type":"GENE","name":"AGK-DT","canonical_id":"hgnc:HGNC:55356","description":"AGK divergent transcript","metadata":null},{"id":"56ce3a7d64804dab8475a70ce7657c56","type":"GENE","name":"AGKP1","canonical_id":"hgnc:HGNC:37661","description":"AGK pseudogene 1","metadata":{"aliases":["AGKY1"]}},{"id":"e0112bd8c9ed4d41972f92f3dd459445","type":"GENE","name":"AGKP2","canonical_id":"hgnc:HGNC:55132","description":"AGK pseudogene 2","metadata":null},{"id":"0383f60d04a54f91b5cefba11173cab6","type":"GENE","name":"AGL","canonical_id":"hgnc:HGNC:321","description":"amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase","metadata":{"aliases":["GDE"]}},{"id":"6ecd52bc6a5f40acaff3ce129617af40","type":"GENE","name":"AGMAT","canonical_id":"hgnc:HGNC:18407","description":"agmatinase (putative)","metadata":{"aliases":["FLJ23384"]}},{"id":"d424468b89da450ebf9bee0296abdf10","type":"GENE","name":"AGMO","canonical_id":"hgnc:HGNC:33784","description":"alkylglycerol monooxygenase","metadata":{"aliases":["FLJ16237","TMEM195"]}},{"id":"e3473ec2de0643d0b85f0554becaed73","type":"GENE","name":"AGO1","canonical_id":"hgnc:HGNC:3262","description":null,"metadata":null},{"id":"31dea2479033487694f8153ce4ff5e73","type":"GENE","name":"AGO2","canonical_id":"hgnc:HGNC:3263","description":"argonaute RISC catalytic component 2","metadata":{"aliases":["hAGO2","Q10","LINC00980","EIF2C2","CASC7"]}},{"id":"436280d25c65415788cb79a2ed5118e2","type":"GENE","name":"AGO3","canonical_id":"hgnc:HGNC:18421","description":"argonaute RISC catalytic component 3","metadata":{"aliases":["hAGO3","FLJ12765","EIF2C3"]}},{"id":"13f2f2fb8bc24e1e8f873dbd9a3b0df0","type":"GENE","name":"AGO4","canonical_id":"hgnc:HGNC:18424","description":"argonaute RISC component 4","metadata":{"aliases":["hAGO4","KIAA1567","FLJ20033","EIF2C4"]}},{"id":"399b3e3e4f4d4467b2d3c9bfa0e21d90","type":"GENE","name":"AGPAT1","canonical_id":"hgnc:HGNC:324","description":"1-acylglycerol-3-phosphate O-acyltransferase 1","metadata":{"aliases":["LPAAT-alpha","LPLAT1"]}},{"id":"e4e406b414894161afff4d7079b42b6d","type":"GENE","name":"AGPAT2","canonical_id":"hgnc:HGNC:325","description":"1-acylglycerol-3-phosphate O-acyltransferase 2","metadata":{"aliases":["LPAAT-beta","LPLAT2","BSCL"]}},{"id":"67ad35ee074e46ab9047e4ef72977d4f","type":"GENE","name":"AGPAT3","canonical_id":"hgnc:HGNC:326","description":"1-acylglycerol-3-phosphate O-acyltransferase 3","metadata":{"aliases":["LPAAT-gamma","LPAAT3","LPLAT3"]}},{"id":"537658bdd19946a3aed177284a33d6f4","type":"GENE","name":"AGPAT4","canonical_id":"hgnc:HGNC:20885","description":"1-acylglycerol-3-phosphate O-acyltransferase 4","metadata":{"aliases":["LPAAT-delta","dJ473J16.2","LPAAT4","LPLAT4"]}},{"id":"2c9b693cf42d42bb8002b5e4698e1e64","type":"GENE","name":"AGPAT4-IT1","canonical_id":"hgnc:HGNC:20988","description":"AGPAT4 intronic transcript 1","metadata":{"aliases":["FLJ23112","C6orf59","NCRNA00241"]}},{"id":"36246839d5b44ca8bfb5e4d37d71dd67","type":"GENE","name":"AGPAT5","canonical_id":"hgnc:HGNC:20886","description":"1-acylglycerol-3-phosphate O-acyltransferase 5","metadata":{"aliases":["FLJ11210","LPAAT-e","LPAAT-epsilon","LPLAT5"]}},{"id":"cbddcd200f3a428eb69e788b5707f63c","type":"GENE","name":"AGPAT5P1","canonical_id":"hgnc:HGNC:37709","description":"1-acylglycerol-3-phosphate O-acyltransferase 5 pseudogene 1","metadata":null},{"id":"d6cdd5cb172543619e6f0a67eec8a214","type":"GENE","name":"AGPS","canonical_id":"hgnc:HGNC:327","description":"alkylglycerone phosphate synthase","metadata":{"aliases":["ADHAPS","ADAS","ALDHPSY","ADPS","ADAP-S"]}},{"id":"ecbdf7e14fd141fd85aca666e1591826","type":"GENE","name":"AGPS-DT","canonical_id":"hgnc:HGNC:49277","description":"AGPS divergent transcript","metadata":{"aliases":["AC019080.1"]}},{"id":"9251a0e87d5c461b9fec083c1fc55016","type":"GENE","name":"AGR2","canonical_id":"hgnc:HGNC:328","description":null,"metadata":null},{"id":"8097dfc77b554506adab6ec0824ed4ec","type":"GENE","name":"AGR3","canonical_id":"hgnc:HGNC:24167","description":"anterior gradient 3, protein disulphide isomerase family member","metadata":{"aliases":["HAG3","hAG-3","BCMP11","PDIA18"]}},{"id":"9a326a3d99894affb37bfcbc465ac3c7","type":"GENE","name":"AGRN","canonical_id":"hgnc:HGNC:329","description":"agrin","metadata":{"aliases":["AGRIN"]}},{"id":"aecc6fecb70f4500a6a5f4a79bec34fc","type":"GENE","name":"AGRP","canonical_id":"hgnc:HGNC:330","description":"agouti related neuropeptide","metadata":{"aliases":["Agrt","ART","ASIP2"]}},{"id":"e88a7732d513405498146f5b11e33449","type":"GENE","name":"AGT","canonical_id":"hgnc:HGNC:333","description":null,"metadata":null},{"id":"bdc0ac7a08744ea09e969dd2b6ed1d5b","type":"GENE","name":"AGTPBP1","canonical_id":"hgnc:HGNC:17258","description":"ATP/GTP binding carboxypeptidase 1","metadata":{"aliases":["KIAA1035","Nna1","CCP1"]}},{"id":"90ebc5c739784ae19ca0ce1f2aa526df","type":"GENE","name":"AGTR1","canonical_id":"hgnc:HGNC:336","description":null,"metadata":null},{"id":"0d2c718e3da946de82e2f86d68eb2efc","type":"PROTEIN","name":"AGTR1","canonical_id":"uniprot:P30556","description":null,"metadata":null},{"id":"7b2774f95dbf4a819b6228cceb5dfc62","type":"GENE","name":"AGTR2","canonical_id":"hgnc:HGNC:338","description":"angiotensin II receptor type 2","metadata":{"aliases":["AT2","MRX88"]}},{"id":"b0ab88c0957a41a386f3a31ae12911e5","type":"GENE","name":"AGTRAP","canonical_id":"hgnc:HGNC:13539","description":"angiotensin II receptor associated protein","metadata":{"aliases":["ATRAP"]}},{"id":"17bab15a032841db831343c18bbfb012","type":"GO_TERM","name":"AGU codon-amino acid adaptor activity","canonical_id":"go:GO:0033445","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AGU codon.\" [GOC:mah]","metadata":null},{"id":"5aad963892fb4038a48c6d2149dcc198","type":"GENE","name":"AGXT","canonical_id":"hgnc:HGNC:341","description":"alanine--glyoxylate aminotransferase","metadata":{"aliases":["AGXT1","PH1","AGT","SPT","AGT1","TLH6","Ser-PyrAT","SPAT"]}},{"id":"065ad64194c74af48e41ea492583660f","type":"GENE","name":"AGXT2","canonical_id":"hgnc:HGNC:14412","description":"alanine--glyoxylate aminotransferase 2","metadata":{"aliases":["AGT2"]}},{"id":"cbba306a227e4d5db29dfdf6daf15cca","type":"GENE","name":"AGXT2-AS1","canonical_id":"hgnc:HGNC:59027","description":"AGXT2 antisense RNA 1","metadata":null},{"id":"f1f459b1737d43d886624eea95fbefbf","type":"GENE","name":"AHCTF1","canonical_id":"hgnc:HGNC:24618","description":"AT-hook containing transcription factor 1","metadata":{"aliases":["ELYS"]}},{"id":"eb836aad07174b769bc6df9c840e54e4","type":"GENE","name":"AHCTF1P1","canonical_id":"hgnc:HGNC:24620","description":"AT-hook containing transcription factor 1 pseudogene 1","metadata":{"aliases":["ELYS-like","AHCTF1P"]}},{"id":"6d81b904e6bd433c848295c4376fa129","type":"GENE","name":"AHCY","canonical_id":"hgnc:HGNC:343","description":"adenosylhomocysteinase","metadata":{"aliases":["SAHH","AdoHcyase"]}},{"id":"85818c13733c4c9083e96f0a82b8896a","type":"GENE","name":"AHCYL1","canonical_id":"hgnc:HGNC:344","description":"adenosylhomocysteinase like 1","metadata":{"aliases":["XPVKONA","IRBIT","PPP1R78"]}},{"id":"29ae666cba1a428aa317782382d64a6d","type":"GENE","name":"AHCYL2","canonical_id":"hgnc:HGNC:22204","description":"adenosylhomocysteinase like 2","metadata":{"aliases":["KIAA0828","long-IRBIT","IRBIT2","ADOHCYASE3"]}},{"id":"6dbae81e025444ff84b43137bcf83087","type":"GENE","name":"AHCYP1","canonical_id":"hgnc:HGNC:44993","description":"adenosylhomocysteinase pseudogene 1","metadata":null},{"id":"9859f99f34724110a35314e73aa20257","type":"GENE","name":"AHCYP2","canonical_id":"hgnc:HGNC:44994","description":"adenosylhomocysteinase pseudogene 2","metadata":null},{"id":"c0081bde45aa42b2ad6c3cd2ec0d701b","type":"GENE","name":"AHCYP3","canonical_id":"hgnc:HGNC:44995","description":"adenosylhomocysteinase pseudogene 3","metadata":null},{"id":"d581a27244134aa297618557028294c2","type":"GENE","name":"AHCYP4","canonical_id":"hgnc:HGNC:44996","description":"adenosylhomocysteinase pseudogene 4","metadata":null},{"id":"544ecb4e1042498a9ae03cbceecdaf3d","type":"GENE","name":"AHCYP5","canonical_id":"hgnc:HGNC:44997","description":"adenosylhomocysteinase pseudogene 5","metadata":null},{"id":"bbb69e82f27c4d5287c43709f4f45349","type":"GENE","name":"AHCYP6","canonical_id":"hgnc:HGNC:44998","description":"adenosylhomocysteinase pseudogene 6","metadata":null},{"id":"003c8267290a46f58749a90a12a8783e","type":"GENE","name":"AHCYP7","canonical_id":"hgnc:HGNC:44999","description":"adenosylhomocysteinase pseudogene 7","metadata":null},{"id":"9cce827eedce4c43b6ab33bf33ae06ae","type":"GENE","name":"AHCYP8","canonical_id":"hgnc:HGNC:45000","description":"adenosylhomocysteinase pseudogene 8","metadata":null},{"id":"e80e6e72eae349089ec31516f2900108","type":"GENE","name":"AHDC1","canonical_id":"hgnc:HGNC:25230","description":"AT-hook DNA binding motif containing 1","metadata":{"aliases":["DJ159A19.3","RP1-159A19.1"]}},{"id":"9ea43a4cefc240df938bfd4fcb5710f5","type":"GENE","name":"AHI1","canonical_id":"hgnc:HGNC:21575","description":"Abelson helper integration site 1","metadata":{"aliases":["FLJ20069","ORF1","JBTS3"]}},{"id":"a092d908ce3a498f9d9b441b2d0e37dd","type":"GENE","name":"AHI1-DT","canonical_id":"hgnc:HGNC:32526","description":"AHI1 divergent transcript","metadata":{"aliases":["C6orf217","NCRNA00271","LINC00271"]}},{"id":"4a7134335a284f7eb8eef796c5a128c0","type":"GENE","name":"AHNAK","canonical_id":"hgnc:HGNC:347","description":"AHNAK nucleoprotein","metadata":{"aliases":["MGC5395","AHNAK1"]}},{"id":"988181a1600b427b9c9c7bd03ae43019","type":"GENE","name":"AHNAK2","canonical_id":"hgnc:HGNC:20125","description":"AHNAK nucleoprotein 2","metadata":{"aliases":["C14orf78"]}},{"id":"3442923eafbf4c319c580310630f17f3","type":"GENE","name":"AHR","canonical_id":"hgnc:HGNC:348","description":null,"metadata":null},{"id":"7ccb59ed4b804c6983de4f7a2f1c36dc","type":"PROTEIN","name":"AHR","canonical_id":"uniprot:P35869","description":null,"metadata":null},{"id":"089a666a956349268202027f058e3781","type":"GENE","name":"AHRR","canonical_id":"hgnc:HGNC:346","description":null,"metadata":null},{"id":"a7c2e2f5e98b488ba4cec5762e335fa5","type":"GENE","name":"AHSA1","canonical_id":"hgnc:HGNC:1189","description":"activator of HSP90 ATPase activity 1","metadata":{"aliases":["p38","Aha1","hAha1","C14orf3"]}},{"id":"7da8ccab2c2d40beb74a35e48db1084a","type":"GENE","name":"AHSA2P","canonical_id":"hgnc:HGNC:20437","description":"activator of HSP90 ATPase homolog 2, pseudogene","metadata":{"aliases":["DKFZp564C236","Hch1","AHA1","AHSA2"]}},{"id":"3c9e623d29c54578a651411b00c75313","type":"GENE","name":"AHSG","canonical_id":"hgnc:HGNC:349","description":"alpha 2-HS glycoprotein","metadata":{"aliases":["FETUA","A2HS","HSGA"]}},{"id":"4bec5acdd9874227a1e82f5059e4a4ed","type":"GENE","name":"AHSP","canonical_id":"hgnc:HGNC:18075","description":"alpha hemoglobin stabilizing protein","metadata":{"aliases":["EDRF","ERAF"]}},{"id":"7ead68ff75b14e28a18a692f18565827","type":"TRIAL","name":"AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease","canonical_id":"clinicaltrials.gov:NCT07857421","description":"Hyperthyroidism; Graves Disease; Thyrotoxicosis","metadata":null},{"id":"39c50371fe824f8ea839e75b82850ef6","type":"TRIAL","name":"AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL","canonical_id":"clinicaltrials.gov:NCT07594899","description":"Large B-Cell Lymphoma (LBCL)","metadata":null},{"id":"8a93bd5131494610b00deb46d5fcbf84","type":"GENE","name":"AICDA","canonical_id":"hgnc:HGNC:13203","description":null,"metadata":null},{"id":"051a2041848746b7bcfb7a10b8f76e00","type":"GENE","name":"AIDA","canonical_id":"hgnc:HGNC:25761","description":"axin interactor, dorsalization associated","metadata":{"aliases":["FLJ12806","C1orf80"]}},{"id":"4f4e0457b7b04ada8a4d34794c823508","type":"GENE","name":"AIDAP1","canonical_id":"hgnc:HGNC:54663","description":"AIDA pseudogene 1","metadata":null},{"id":"de1b2679d3f8459ebee0fc9243ed318c","type":"GENE","name":"AIDAP2","canonical_id":"hgnc:HGNC:54664","description":"AIDA pseudogene 2","metadata":null},{"id":"bca62f7a5dc847b3b00d1d9264e9e542","type":"GENE","name":"AIDAP3","canonical_id":"hgnc:HGNC:54665","description":"AIDA pseudogene 3","metadata":null},{"id":"3d6b3d06a1dc45849c6e74d01dbc2bae","type":"GENE","name":"AIF1","canonical_id":"hgnc:HGNC:352","description":"allograft inflammatory factor 1","metadata":{"aliases":["IRT-1","AIF-1","Em:AF129756.17","IBA1"]}},{"id":"2d86593dec67409ea89879665173b953","type":"GENE","name":"AIF1L","canonical_id":"hgnc:HGNC:28904","description":"allograft inflammatory factor 1 like","metadata":{"aliases":["IBA2","FLJ12783","C9orf58"]}},{"id":"6a2490107acf4a97bd6a669bc5cd2c29","type":"GENE","name":"AIFM1","canonical_id":"hgnc:HGNC:8768","description":"apoptosis inducing factor mitochondria associated 1","metadata":{"aliases":["AIF","CMTX4","DFNX5","PDCD8","NAMSD","AUNX1"]}},{"id":"78861352e50146038799bdcea9c6ff2e","type":"GENE","name":"AIFM1P1","canonical_id":"hgnc:HGNC:44884","description":"AIFM1 pseudogene 1","metadata":null},{"id":"b1e835353d0a4e7b96bec7a56474a478","type":"GENE","name":"AIFM2","canonical_id":"hgnc:HGNC:21411","description":"AIF family member 2, ferroptosis suppressor","metadata":{"aliases":["FLJ14497","PRG3","FSP1","AMID"]}},{"id":"c30bc9d33c334bd1ae3d979e46196ffa","type":"GENE","name":"AIFM3","canonical_id":"hgnc:HGNC:26398","description":"AIF family member 3","metadata":{"aliases":["AIFL","FLJ30473"]}},{"id":"83f6acd1937448a6a27c037ada5e16e3","type":"GENE","name":"AIG1","canonical_id":"hgnc:HGNC:21607","description":"androgen induced 1","metadata":{"aliases":["dJ95L4.1","AIG-1","FLJ10485"]}},{"id":"605f35d5420648cd825d4c709e9e1d74","type":"GENE","name":"AIG1P1","canonical_id":"hgnc:HGNC:43926","description":"androgen induced 1 pseudogene 1","metadata":null},{"id":"347a9559af3343639c9201e6237a41d3","type":"GENE","name":"AIM2","canonical_id":"hgnc:HGNC:357","description":"absent in melanoma 2","metadata":{"aliases":["PYHIN4"]}},{"id":"71d108d03934461d90446b92a24100f9","type":"GO_TERM","name":"AIM2 inflammasome complex","canonical_id":"go:GO:0097169","description":"\"An inflammasome complex that consists of AIM2, ASC, and caspase-1. AIM2 is a member of the HN-200 protein family that appears to be the sensor of cytosolic double-stranded DNA.\" [GOC:vp, PMID:20303873]","metadata":null},{"id":"9e97da34f4a945bc9c3e47532dccf509","type":"GO_TERM","name":"AIM2 inflammasome complex assembly","canonical_id":"go:GO:0140970","description":"\"The aggregation, arrangement and bonding together of a set of components to form the AIM2 inflammasome complex.\" [PMID:33467177]","metadata":null},{"id":"79ffa33cda394964b05ff177c9e33e31","type":"GENE","name":"AIMP1","canonical_id":"hgnc:HGNC:10648","description":"aminoacyl tRNA synthetase complex interacting multifunctional protein 1","metadata":{"aliases":["EMAPII","EMAP-2","p43","SCYE1"]}},{"id":"5a6f3038458141ce8c82c7a825f8d84b","type":"GENE","name":"AIMP1P1","canonical_id":"hgnc:HGNC:16543","description":"aminoacyl tRNA synthetase complex interacting multifunctional protein 1 pseudogene 1","metadata":{"aliases":["bA400P21.1","SCYE1P"]}},{"id":"0d3a03a3e1de472daa61f74b9b0a9a7f","type":"GENE","name":"AIMP1P2","canonical_id":"hgnc:HGNC:43693","description":"aminoacyl tRNA synthetase complex interacting multifunctional protein 1 pseudogene 2","metadata":null},{"id":"836b4f8e1bbf4877b85a3a58cf8a1407","type":"GENE","name":"AIMP2","canonical_id":"hgnc:HGNC:20609","description":"aminoacyl tRNA synthetase complex interacting multifunctional protein 2","metadata":{"aliases":["p38","PRO0992","JTV-1","JTV1"]}},{"id":"c7e25fee4ef94f6295b25065cb837aa1","type":"GENE","name":"AIP","canonical_id":"hgnc:HGNC:358","description":null,"metadata":null},{"id":"ae188ea8454f4e469b1fdc6a0a579ab8","type":"GO_TERM","name":"AIP1-IRE1 complex","canonical_id":"go:GO:1990597","description":"\"A protein complex consisting of IRE1 (inositol-requiring enzyme-1) bound to AIP1 (ASK1-interacting protein 1/DAB2-interacting protein).\" [GOC:bf, GOC:PARL, PMID:18281285]","metadata":null},{"id":"68fdd45106f8400f8041d53b2767e6ab","type":"GENE","name":"AIPL1","canonical_id":"hgnc:HGNC:359","description":"AIP like 1 HSP90 co-chaperone","metadata":{"aliases":["LCA4"]}},{"id":"7216cf38e6804b609871d0de20791bee","type":"GENE","name":"AIRE","canonical_id":"hgnc:HGNC:360","description":null,"metadata":null},{"id":"30d24d42561b4472978a662728e74188","type":"GENE","name":"AIRIM","canonical_id":"hgnc:HGNC:26039","description":"AFG2 interacting ribosome maturation factor","metadata":{"aliases":["FLJ20508","C1orf109"]}},{"id":"2be40d5435f74e3189f689fc8faad63c","type":"GENE","name":"AIRN","canonical_id":"hgnc:HGNC:34515","description":"antisense of IGF2R non-protein coding RNA","metadata":{"aliases":["AIR","NCRNA00088","IGF2RAS","IGF2R-AS1"]}},{"id":"77cc0b1b8ec74a3b8daa5e626cfe6ab5","type":"GENE","name":"AJAP1","canonical_id":"hgnc:HGNC:30801","description":"adherens junctions associated protein 1","metadata":{"aliases":["SHREW1","SHREW-1","MOT8"]}},{"id":"bb38073c65084680abebf8fc2eb9583d","type":"GENE","name":"AJM1","canonical_id":"hgnc:HGNC:37284","description":"apical junction component 1 homolog","metadata":{"aliases":["ajm-1","C9orf172"]}},{"id":"06d211c43d3d40debd82b4c450eb0d95","type":"GENE","name":"AJUBA","canonical_id":"hgnc:HGNC:20250","description":"ajuba LIM protein","metadata":{"aliases":["MGC15563","JUB"]}},{"id":"62fdc54ff15a45ddad5cfea9ee2e2e37","type":"GENE","name":"AJUBA-DT","canonical_id":"hgnc:HGNC:55449","description":"AJUBA divergent transcript","metadata":null},{"id":"96c65234ea334ab7bae3d7736a2eecc4","type":"TRIAL","name":"AK-R215 Pharmacokinetic Study Phase I","canonical_id":"clinicaltrials.gov:NCT03321318","description":"Healthy","metadata":null},{"id":"d20acbc768a84130921da080b11835b0","type":"GENE","name":"AK1","canonical_id":"hgnc:HGNC:361","description":"adenylate kinase 1","metadata":{"aliases":["ADK","Adk1"]}},{"id":"b06f167b86294affa5c85aeb9db28abe","type":"TRIAL","name":"AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT06494995","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"850ddb4f722848e991498722b42e7538","type":"TRIAL","name":"AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer","canonical_id":"clinicaltrials.gov:NCT06196697","description":"Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"9f7bbcc1235f4cb9866ba490e8035819","type":"TRIAL","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT06646055","description":"Metastatic Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"004df0c8273343d295fdaf3ddd54613f","type":"GENE","name":"AK2","canonical_id":"hgnc:HGNC:362","description":"adenylate kinase 2","metadata":null},{"id":"9a502bc9026a44458d8d788957e3f442","type":"GENE","name":"AK2-AS1","canonical_id":"hgnc:HGNC:58388","description":"AK2 antisense RNA 1","metadata":null},{"id":"5f7c4d73bd57483b842ece1dfa55d94c","type":"GENE","name":"AK2P1","canonical_id":"hgnc:HGNC:24037","description":"adenylate kinase 2 pseudogene 1","metadata":{"aliases":["AK2B"]}},{"id":"4c80dd4995e943c5843cc3aa5d0bf749","type":"GENE","name":"AK2P2","canonical_id":"hgnc:HGNC:33542","description":"adenylate kinase 2 pseudogene 2","metadata":null},{"id":"5e47c6331d26431886b144051be11def","type":"GENE","name":"AK3","canonical_id":"hgnc:HGNC:17376","description":"adenylate kinase 3","metadata":{"aliases":["AKL3L1","AK6","AK3L1"]}},{"id":"c757e4e5dc9349e0926fc7401a8a177f","type":"GENE","name":"AK3P2","canonical_id":"hgnc:HGNC:31099","description":"AK3 pseudogene 2","metadata":{"aliases":["HsT26053"]}},{"id":"20cd29ceb7ed4ecfbd2a5f5373204720","type":"GENE","name":"AK3P3","canonical_id":"hgnc:HGNC:39062","description":"AK3 pseudogene 3","metadata":null},{"id":"9f3a2ca3bb95451dbe769566a1744966","type":"GENE","name":"AK3P4","canonical_id":"hgnc:HGNC:39063","description":"AK3 pseudogene 4","metadata":null},{"id":"578f3d4ea0c8439b907fc132987d6165","type":"GENE","name":"AK3P5","canonical_id":"hgnc:HGNC:39064","description":"AK3 pseudogene 5","metadata":null},{"id":"a78e1560f8c342a7a3a8c1d032c2c3dc","type":"GENE","name":"AK3P6","canonical_id":"hgnc:HGNC:39065","description":"AK3 pseudogene 6","metadata":null},{"id":"1c2f9c13ab9a446eb3609cb006ff49a5","type":"GENE","name":"AK3P7","canonical_id":"hgnc:HGNC:56418","description":"AK3 pseudogene 7","metadata":null},{"id":"bf3399468a4d42abb239a5a7835be417","type":"GENE","name":"AK4","canonical_id":"hgnc:HGNC:363","description":null,"metadata":null},{"id":"25f95c8e88dd4919994c2e969cfc394b","type":"GENE","name":"AK4P1","canonical_id":"hgnc:HGNC:364","description":"adenylate kinase 4 pseudogene 1","metadata":{"aliases":["AK3P1"]}},{"id":"e56f4282bf7b46f6997c1c72c8736b25","type":"GENE","name":"AK4P2","canonical_id":"hgnc:HGNC:39066","description":"adenylate kinase 4 pseudogene 2","metadata":null},{"id":"c046211e6e5642a1a5fe972ea3c3484f","type":"GENE","name":"AK4P3","canonical_id":"hgnc:HGNC:21596","description":"adenylate kinase 4 pseudogene 3","metadata":{"aliases":["AK3L2P","AK3L2"]}},{"id":"473059720f8a449ca87a1b5989665337","type":"GENE","name":"AK4P4","canonical_id":"hgnc:HGNC:39067","description":"adenylate kinase 4 pseudogene 4","metadata":null},{"id":"1be196d86182496ebcb5275054208863","type":"GENE","name":"AK4P5","canonical_id":"hgnc:HGNC:39068","description":"adenylate kinase 4 pseudogene 5","metadata":null},{"id":"a6832d6302064e8aaa8f5936437d712d","type":"GENE","name":"AK4P6","canonical_id":"hgnc:HGNC:39069","description":"adenylate kinase 4 pseudogene 6","metadata":null},{"id":"0e69ebff7df347729bb3061deb743e6a","type":"GENE","name":"AK5","canonical_id":"hgnc:HGNC:365","description":"adenylate kinase 5","metadata":null},{"id":"8e3633d0758f40798922b0e65eab1baf","type":"GENE","name":"AK5-AS1","canonical_id":"hgnc:HGNC:40069","description":"AK5 antisense RNA 1","metadata":null},{"id":"b1c6270de7f34301a238f29db3515f72","type":"GENE","name":"AK6","canonical_id":"hgnc:HGNC:49151","description":"adenylate kinase 6","metadata":{"aliases":["CINAP"]}},{"id":"369f88eee655441e81dede946ce570ee","type":"GENE","name":"AK6P1","canonical_id":"hgnc:HGNC:51678","description":"adenylate kinase 6 pseudogene 1","metadata":null},{"id":"8cb4c3eaf3364722a6d675ab6aa920d8","type":"GENE","name":"AK6P2","canonical_id":"hgnc:HGNC:51679","description":"adenylate kinase 6 pseudogene 2","metadata":null},{"id":"8ba674ef9e5b4aa2b48172121f8cc11c","type":"GENE","name":"AK7","canonical_id":"hgnc:HGNC:20091","description":"adenylate kinase 7","metadata":{"aliases":["FLJ32864","FAP75","CFAP75"]}},{"id":"2ebbf83b9c7d4420b8aa4242ef86d39c","type":"GENE","name":"AK8","canonical_id":"hgnc:HGNC:26526","description":"adenylate kinase 8","metadata":{"aliases":["FLJ32704","C9orf98"]}},{"id":"027e251d58ad49eeb64762d404fc8532","type":"GENE","name":"AK9","canonical_id":"hgnc:HGNC:33814","description":"adenylate kinase 9","metadata":{"aliases":["FLJ42177","FLJ25791","dJ70A9.1","MGC26954","C6orf224","AKD2","C6orf199","AKD1"]}},{"id":"4a6d46a928674adcba33f32504d4609d","type":"GENE","name":"AKAIN1","canonical_id":"hgnc:HGNC:28285","description":"A-kinase anchor inhibitor 1","metadata":{"aliases":["C18orf42"]}},{"id":"9be3aa593bf54c2daf4ea07a7b60a959","type":"GENE","name":"AKAIN1-AS1","canonical_id":"hgnc:HGNC:58563","description":"AKAIN1 antisense RNA 1","metadata":null},{"id":"5063b07ca21c449b91bafd550fa5eb19","type":"GENE","name":"AKAP1","canonical_id":"hgnc:HGNC:367","description":"A-kinase anchoring protein 1","metadata":{"aliases":["AKAP121","AKAP149","SAKAP84","S-AKAP84","AKAP84","D-AKAP1","PPP1R43","TDRD17","PRKA1"]}},{"id":"739e9bce35e8487394d1cfc148446821","type":"GENE","name":"AKAP1-DT","canonical_id":"hgnc:HGNC:55339","description":"AKAP1 divergent transcript","metadata":null},{"id":"de9c80e1bad240e6b531e1ca7fb687d8","type":"GENE","name":"AKAP10","canonical_id":"hgnc:HGNC:368","description":"A-kinase anchoring protein 10","metadata":{"aliases":["D-AKAP2","PRKA10","MGC9414"]}},{"id":"065b38487f6c4d398e0b3c142f6a1fb2","type":"GENE","name":"AKAP11","canonical_id":"hgnc:HGNC:369","description":"A-kinase anchoring protein 11","metadata":{"aliases":["KIAA0629","AKAP220","PRKA11","FLJ11304","DKFZp781I12161","PPP1R44"]}},{"id":"1652b679dcb1475daa274ced2e92f443","type":"GENE","name":"AKAP12","canonical_id":"hgnc:HGNC:370","description":null,"metadata":null},{"id":"fefa083501424dbea4cc131039790882","type":"GENE","name":"AKAP13","canonical_id":"hgnc:HGNC:371","description":"A-kinase anchoring protein 13","metadata":{"aliases":["Ht31","BRX","AKAP-Lbc","c-lbc","PROTO-LB","HA-3","ARHGEF13","LBC"]}},{"id":"f340c959d6704328823abca98acc005e","type":"GENE","name":"AKAP13-AS1","canonical_id":"hgnc:HGNC:55975","description":"AKAP13 antisense RNA 1","metadata":null},{"id":"2c160984565a44ac843745b09dff29ed","type":"GENE","name":"AKAP14","canonical_id":"hgnc:HGNC:24061","description":"A-kinase anchoring protein 14","metadata":{"aliases":["AKAP28"]}},{"id":"f832e2003e194a18bca82cbc7c8ee6c4","type":"GENE","name":"AKAP17A","canonical_id":"hgnc:HGNC:18783","description":"A-kinase anchoring protein 17A","metadata":{"aliases":["XE7","XE7Y","DXYS155E","MGC39904","721P","CCDC133","CXYorf3","SFRS17A"]}},{"id":"54a02d27843e47328572a1d8bf515fc7","type":"GENE","name":"AKAP17BP","canonical_id":"hgnc:HGNC:38514","description":"A-kinase anchoring protein 17B, pseudogene","metadata":{"aliases":["AKAP16B","AKAP16BP"]}},{"id":"7824f2adee2f41669de13e70ad18436c","type":"GENE","name":"AKAP19","canonical_id":"hgnc:HGNC:28191","description":"A-kinase anchoring protein 19","metadata":{"aliases":["MGC13057","smAKAP","C2orf88"]}},{"id":"c0791cb00d34417aa1492dc947bff4c6","type":"GENE","name":"AKAP2","canonical_id":"hgnc:HGNC:372","description":"A-kinase anchoring protein 2","metadata":{"aliases":["AKAP-KL","KIAA0920","DKFZp564L0716","MISP2","PRKA2"]}},{"id":"6c49d7f967d3463f8e078481d7b3b910","type":"GENE","name":"AKAP3","canonical_id":"hgnc:HGNC:373","description":"A-kinase anchoring protein 3","metadata":{"aliases":["FSP95","SOB1","AKAP110","CT82"]}},{"id":"16aa8e980cfe40d586f437d8c9c4ba3c","type":"GENE","name":"AKAP4","canonical_id":"hgnc:HGNC:374","description":"A-kinase anchoring protein 4","metadata":{"aliases":["p82","hAKAP82","AKAP82","Fsc1","HI","CT99"]}},{"id":"be61e6434f094452a0cf84a4290957ab","type":"GENE","name":"AKAP5","canonical_id":"hgnc:HGNC:375","description":"A-kinase anchoring protein 5","metadata":{"aliases":["AKAP75","AKAP79"]}},{"id":"5606bc94388f4040bd8f650e95943ff0","type":"GENE","name":"AKAP6","canonical_id":"hgnc:HGNC:376","description":"A-kinase anchoring protein 6","metadata":{"aliases":["KIAA0311","mAKAP","AKAP100","PRKA6","ADAP6"]}},{"id":"e35766ff4e3d462d8c07d8f3921cd54d","type":"GENE","name":"AKAP7","canonical_id":"hgnc:HGNC:377","description":"A-kinase anchoring protein 7","metadata":{"aliases":["AKAP18","AKAP15"]}},{"id":"6b1dc95fed7449909ade6476359e4ea0","type":"GENE","name":"AKAP8","canonical_id":"hgnc:HGNC:378","description":"A-kinase anchoring protein 8","metadata":{"aliases":["AKAP95","DKFZp586B1222"]}},{"id":"894a36bad67642e5b30982292e61e75c","type":"GENE","name":"AKAP8L","canonical_id":"hgnc:HGNC:29857","description":"A-kinase anchoring protein 8 like","metadata":{"aliases":["NAKAP95","HAP95"]}},{"id":"4c5f9d4e6c134688a6b415073ee00701","type":"GENE","name":"AKAP8P1","canonical_id":"hgnc:HGNC:49758","description":"A-kinase anchoring protein 8 pseudogene 1","metadata":null},{"id":"3c5373cf60f9441aa2af9aed5314675b","type":"GENE","name":"AKAP9","canonical_id":"hgnc:HGNC:379","description":"A-kinase anchoring protein 9","metadata":{"aliases":["KIAA0803","AKAP350","AKAP450","CG-NAP","YOTIAO","HYPERION","PRKA9","MU-RMS-40.16A","PPP1R45","LQT11"]}},{"id":"fca515a8644c49cb85f63dd5a178e0d7","type":"GENE","name":"AKIP1","canonical_id":"hgnc:HGNC:1170","description":"A-kinase interacting protein 1","metadata":{"aliases":["BCA3","C11orf17"]}},{"id":"e39011ed599a47eab27a2c56679b5d04","type":"GENE","name":"AKIRIN1","canonical_id":"hgnc:HGNC:25744","description":"akirin 1","metadata":{"aliases":["FLJ12666","C1orf108"]}},{"id":"c6d06b3cc5384629ba3a0eba12a2ab26","type":"GENE","name":"AKIRIN1P1","canonical_id":"hgnc:HGNC:50794","description":"akirin 1 pseudogene 1","metadata":null},{"id":"2e71e748385f4dacbb40d66c48d4ed1e","type":"GENE","name":"AKIRIN1P2","canonical_id":"hgnc:HGNC:50797","description":"akirin 1 pseudogene 2","metadata":null},{"id":"fcd9b430a59c415f9dae6a46e87a3a33","type":"GENE","name":"AKIRIN2","canonical_id":"hgnc:HGNC:21407","description":"akirin 2","metadata":{"aliases":["FLJ10342","dJ486L4.2","C6orf166"]}},{"id":"db554f5fcd8544d8ac568973eb29f90b","type":"GENE","name":"AKIRIN2P1","canonical_id":"hgnc:HGNC:50796","description":"akirin 2 pseudogene 1","metadata":null},{"id":"df4bdaa2b19c435a9f1e7dacb4d7d403","type":"TRIAL","name":"AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma","canonical_id":"clinicaltrials.gov:NCT01200108","description":"Asthma","metadata":null},{"id":"de6565ea4f6841aa8f5ffbdd65a795bd","type":"GENE","name":"AKNA","canonical_id":"hgnc:HGNC:24108","description":"AT-hook transcription factor","metadata":{"aliases":["KIAA1968"]}},{"id":"95e16e8b61bb41c99365c341dfa0a900","type":"GENE","name":"AKNAD1","canonical_id":"hgnc:HGNC:28398","description":"AKNA domain containing 1","metadata":{"aliases":["MGC26989","C1orf62"]}},{"id":"e5945d494ba8427bba7bed6e57db7388","type":"GENE","name":"AKR1A1","canonical_id":"hgnc:HGNC:380","description":"aldo-keto reductase family 1 member A1","metadata":{"aliases":["ALR","DD3"]}},{"id":"2c05ffff172140b49515ada2747ab92f","type":"GENE","name":"AKR1B1","canonical_id":"hgnc:HGNC:381","description":null,"metadata":null},{"id":"78ef5b413d304de1b81877d8bc5b366e","type":"PROTEIN","name":"AKR1B1","canonical_id":"uniprot:P15121","description":null,"metadata":null},{"id":"1c4d9314546f4838ac393a6f881330f7","type":"GENE","name":"AKR1B10","canonical_id":"hgnc:HGNC:382","description":"aldo-keto reductase family 1 member B10","metadata":{"aliases":["AKR1B12","ARL-1","HIS","ARL1","HSI","ALDRLn","AKR1B11"]}},{"id":"6dae481530334e1db8557377c8301e1e","type":"GENE","name":"AKR1B10P1","canonical_id":"hgnc:HGNC:45062","description":"aldo-keto reductase family 1 member B10 pseudogene 1","metadata":null},{"id":"2d1ed2abd24745b19f8f4192d0c7fd33","type":"GENE","name":"AKR1B10P2","canonical_id":"hgnc:HGNC:45063","description":"aldo-keto reductase family 1 member B10 pseudogene 2","metadata":null},{"id":"a0d38dac9a234367a497d3d7e0c658b6","type":"GENE","name":"AKR1B15","canonical_id":"hgnc:HGNC:37281","description":"aldo-keto reductase family 1 member B15","metadata":null},{"id":"9cc9e9ee43df4a2ebc32fef4830498b5","type":"GENE","name":"AKR1B1P1","canonical_id":"hgnc:HGNC:420","description":"aldehyde reductase family 1 member B1 pseudogene 1","metadata":{"aliases":["ALDRL1"]}},{"id":"c5fa06e681164886af3f627e0db6ded8","type":"GENE","name":"AKR1B1P2","canonical_id":"hgnc:HGNC:425","description":"aldo-keto reductase family 1 member B1 pseudogene 2","metadata":{"aliases":["ALDRP"]}},{"id":"bb3f7d35d9df4436b8f5919c4ab6554d","type":"GENE","name":"AKR1B1P3","canonical_id":"hgnc:HGNC:422","description":"aldo-keto reductase family 1 member B1 pseudogene 3","metadata":{"aliases":["Coromarker","ALDRL3"]}},{"id":"8c73f3c758924f918c4fda9d6ad7ff01","type":"GENE","name":"AKR1B1P4","canonical_id":"hgnc:HGNC:423","description":"aldo-keto reductase family 1 member B1 pseudogene 4","metadata":{"aliases":["ALDRL4"]}},{"id":"7817e9770bdf43fe935cdf54e1aa59a8","type":"GENE","name":"AKR1B1P5","canonical_id":"hgnc:HGNC:20002","description":"aldo-keto reductase family 1 member B1 pseudogene 5","metadata":{"aliases":["AKR1B1P"]}},{"id":"a86786afb43b4b3d8a2866d63bf7ce71","type":"GENE","name":"AKR1B1P6","canonical_id":"hgnc:HGNC:33498","description":"aldo-keto reductase family 1 member B1 pseudogene 6","metadata":null},{"id":"dc4575be5fde4fe7b329a142e9d175e2","type":"GENE","name":"AKR1B1P7","canonical_id":"hgnc:HGNC:33497","description":"aldo-keto reductase family 1 member B1 pseudogene 7","metadata":null},{"id":"a713b4568dad46bc8a46da84bbde2e66","type":"GENE","name":"AKR1B1P8","canonical_id":"hgnc:HGNC:33496","description":"aldo-keto reductase family 1 member B1 pseudogene 8","metadata":null},{"id":"0a3876abae244e0ba034ef1ce5e6221c","type":"GENE","name":"AKR1C1","canonical_id":"hgnc:HGNC:384","description":"aldo-keto reductase family 1 member C1","metadata":{"aliases":["DDH","MBAB","DD1","HAKRC","DDH1"]}},{"id":"411583c0aada4e3cb5c8a477501d9347","type":"GENE","name":"AKR1C2","canonical_id":"hgnc:HGNC:385","description":null,"metadata":null},{"id":"c931c6cb2ba54f679fa65b8bcc992427","type":"GENE","name":"AKR1C3","canonical_id":"hgnc:HGNC:386","description":null,"metadata":null},{"id":"ae5fd04cdf844deb8fcd2b08dd07c825","type":"GENE","name":"AKR1C4","canonical_id":"hgnc:HGNC:387","description":null,"metadata":null},{"id":"e20b9f16c0334c6ca313baedc719d904","type":"GENE","name":"AKR1C5P","canonical_id":"hgnc:HGNC:44679","description":"aldo-keto reductase family 1 member C5, pseudogene","metadata":null},{"id":"41f282fc0a384c47912fd5a3edd228f7","type":"GENE","name":"AKR1C6P","canonical_id":"hgnc:HGNC:44680","description":"aldo-keto reductase family 1 member C6, pseudogene","metadata":{"aliases":["TAKR"]}},{"id":"3ddc31d170934c91928d228c004d9b68","type":"GENE","name":"AKR1C7P","canonical_id":"hgnc:HGNC:44681","description":"aldo-keto reductase family 1 member C7, pseudogene","metadata":null},{"id":"f1075f608ad7476b9502e018322e30a5","type":"GENE","name":"AKR1C8","canonical_id":"hgnc:HGNC:23469","description":"aldo-keto reductase family 1 member C8","metadata":{"aliases":["AKR1CL1","AKR1C8P"]}},{"id":"dcd980d333fa4964b0bedcd32f5555ce","type":"GENE","name":"AKR1D1","canonical_id":"hgnc:HGNC:388","description":"aldo-keto reductase family 1 member D1","metadata":{"aliases":["SRD5B1"]}},{"id":"d33de926c6114ab59609ee67985dc029","type":"GENE","name":"AKR1D1P1","canonical_id":"hgnc:HGNC:11288","description":"aldo-keto reductase family 1 member D1 pseudogene 1","metadata":{"aliases":["SRD5BP1","AKR1D1P"]}},{"id":"c3845b0a855a4a7da2fa2553841ffc8a","type":"GENE","name":"AKR1E2","canonical_id":"hgnc:HGNC:23437","description":"aldo-keto reductase family 1 member E2","metadata":{"aliases":["MGC10612","HTSP1","htAKR","AKRDC1","AKR1CL2"]}},{"id":"72ff76a065ef49cdbc915d351c49ef37","type":"GENE","name":"AKR7A2","canonical_id":"hgnc:HGNC:389","description":"aldo-keto reductase family 7 member A2","metadata":{"aliases":["AFAR"]}},{"id":"1cf1fef053b346d69b0c1207ce8c45e5","type":"GENE","name":"AKR7A2P1","canonical_id":"hgnc:HGNC:24062","description":"AKR7A2 pseudogene 1","metadata":{"aliases":["AFARP1"]}},{"id":"c5e9285715a84018bddeea8263c0d517","type":"GENE","name":"AKR7A2P2","canonical_id":"hgnc:HGNC:55059","description":"AKR7A2P pseudogene 1","metadata":null},{"id":"351ad79bc1894562ae22537153db7fe3","type":"GENE","name":"AKR7A3","canonical_id":"hgnc:HGNC:390","description":"aldo-keto reductase family 7 member A3","metadata":null},{"id":"074dc5473f3e488ab0ddabb875fde3ff","type":"GENE","name":"AKR7L","canonical_id":"hgnc:HGNC:24056","description":"aldo-keto reductase family 7 like (gene/pseudogene)","metadata":{"aliases":["AFAR3"]}},{"id":"a01e3294f917474cb507aa8bb2d2bd76","type":"GENE","name":"AKT1","canonical_id":"hgnc:HGNC:391","description":null,"metadata":null},{"id":"e351cc97e11d46f5a86738356f02bcce","type":"GENE","name":"AKT1","canonical_id":"ensembl:ENSG00000142208","description":null,"metadata":null},{"id":"f0f6fef96dbb45d3abeae4398f00abbf","type":"BIOMARKER","name":"AKT1 E17K AND BRAF V600E","canonical_id":"civic:5484","description":null,"metadata":null},{"id":"edf5a355a7094aa5bdcf3f3a71503e4d","type":"GENE","name":"AKT1S1","canonical_id":"hgnc:HGNC:28426","description":"AKT1 substrate 1","metadata":{"aliases":["PRAS40","MGC2865","Lobe"]}},{"id":"9d98c47503dc4c32981a15964d5b0d13","type":"GENE","name":"AKT2","canonical_id":"hgnc:HGNC:392","description":null,"metadata":null},{"id":"e2ebe7b8ac6344319bf906356e5405c2","type":"PROTEIN","name":"AKT2","canonical_id":"uniprot:P31751","description":null,"metadata":null},{"id":"d35431cb81eb407eb7afe9c3da68a281","type":"GENE","name":"AKT3","canonical_id":"hgnc:HGNC:393","description":"AKT serine/threonine kinase 3","metadata":{"aliases":["PKBG","RAC-gamma","PRKBG"]}},{"id":"ce115a437d6f45408cdae416779389a3","type":"GENE","name":"AKT3-IT1","canonical_id":"hgnc:HGNC:41304","description":"AKT3 intronic transcript 1","metadata":null},{"id":"1c9ed4c2634146c088e7722eb9c66409","type":"GENE","name":"AKTIP","canonical_id":"hgnc:HGNC:16710","description":"AKT interacting protein","metadata":{"aliases":["FLJ13258","FTS"]}},{"id":"4c6aeafc58b9427897e7e5e9f6d45467","type":"GENE","name":"AKTIPP1","canonical_id":"hgnc:HGNC:56419","description":"AKTIP pseudogene 1","metadata":null},{"id":"ae455b2682384e4ba024ca2330409d6b","type":"GENE","name":"AKTIPP2","canonical_id":"hgnc:HGNC:56420","description":"AKTIP pseudogene 2","metadata":null},{"id":"0b7fb90d5b4c4e73abddd67d625d258a","type":"GENE","name":"AKTIPP3","canonical_id":"hgnc:HGNC:56421","description":"AKTIP pseudogene 3","metadata":null},{"id":"03c6d8a08ec446c0beeb6b8d0a6feef7","type":"GENE","name":"ALAD","canonical_id":"hgnc:HGNC:395","description":"aminolevulinate dehydratase","metadata":{"aliases":["ALADH","PBGS"]}},{"id":"e50bdd03683849f0a27040da4cbd7eb4","type":"GENE","name":"ALAS1","canonical_id":"hgnc:HGNC:396","description":null,"metadata":null},{"id":"952e64812b804a609c4dc1661d6a9aa8","type":"GENE","name":"ALAS2","canonical_id":"hgnc:HGNC:397","description":null,"metadata":null},{"id":"1cdd171a7c8d4c32b31d100db10034ed","type":"GENE","name":"ALB","canonical_id":"hgnc:HGNC:399","description":null,"metadata":null},{"id":"2d782bb2f18145f38049e8b4588d7917","type":"TRIAL","name":"ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","canonical_id":"clinicaltrials.gov:NCT04329611","description":"COVID-19","metadata":null},{"id":"748d8d9b7a9d4498bbeefcd94c95826b","type":"GENE","name":"ALCAM","canonical_id":"hgnc:HGNC:400","description":"activated leukocyte cell adhesion molecule","metadata":{"aliases":["CD166","MEMD"]}},{"id":"621c727bbbc447d098df02b7371e235b","type":"GENE","name":"ALDH16A1","canonical_id":"hgnc:HGNC:28114","description":"aldehyde dehydrogenase 16 family member A1","metadata":{"aliases":["MGC10204"]}},{"id":"401ba3966d2949bfb6412210e73be37e","type":"GENE","name":"ALDH18A1","canonical_id":"hgnc:HGNC:9722","description":"aldehyde dehydrogenase 18 family member A1","metadata":{"aliases":["P5CS","GSAS","PYCS","SPG9"]}},{"id":"fb3600b7b5f249919138a8d4db90b520","type":"GENE","name":"ALDH1A1","canonical_id":"hgnc:HGNC:402","description":null,"metadata":null},{"id":"7db31dbdacc7460c9187529465711811","type":"GENE","name":"ALDH1A2","canonical_id":"hgnc:HGNC:15472","description":null,"metadata":null},{"id":"1d9f611d502d4017a4fc2d9f59350e4b","type":"GENE","name":"ALDH1A2-AS1","canonical_id":"hgnc:HGNC:27515","description":"ALDH1A2 antisense RNA 1","metadata":null},{"id":"0415969efbb447dd83b0bf8a2375d9c8","type":"GENE","name":"ALDH1A3","canonical_id":"hgnc:HGNC:409","description":null,"metadata":null},{"id":"a6c366111c7443cd824a0cb9ed9cd78f","type":"GENE","name":"ALDH1A3-AS1","canonical_id":"hgnc:HGNC:55416","description":"ALDH1A3 antisense RNA 1","metadata":null},{"id":"36116defe4794328a550ee97b740e85c","type":"GENE","name":"ALDH1B1","canonical_id":"hgnc:HGNC:407","description":"aldehyde dehydrogenase 1 family member B1","metadata":{"aliases":["ALDHX","ALDH5"]}},{"id":"cfaf30918eb5403a86f1522895c6cb56","type":"GENE","name":"ALDH1L1","canonical_id":"hgnc:HGNC:3978","description":"aldehyde dehydrogenase 1 family member L1","metadata":{"aliases":["10-fTHF","FDH","FTHFD"]}},{"id":"0a7636200da44530b1baaa307537d374","type":"GENE","name":"ALDH1L1-AS1","canonical_id":"hgnc:HGNC:40244","description":"ALDH1L1 antisense RNA 1","metadata":null},{"id":"8135030d91aa4d98b61ce1ef9fb5aff2","type":"GENE","name":"ALDH1L1-AS2","canonical_id":"hgnc:HGNC:42446","description":"ALDH1L1 antisense RNA 2","metadata":null},{"id":"b5b70d0b0741400f96efa7e5f46a7238","type":"GENE","name":"ALDH1L2","canonical_id":"hgnc:HGNC:26777","description":"aldehyde dehydrogenase 1 family member L2","metadata":{"aliases":["FLJ38508","mtFDH"]}},{"id":"8944b0d848154f68bf9b6e0af56c71ef","type":"GENE","name":"ALDH2","canonical_id":"hgnc:HGNC:404","description":"aldehyde dehydrogenase 2 family member","metadata":null},{"id":"d2ada39230144ad2b028da2d1a6efabc","type":"GENE","name":"ALDH3A1","canonical_id":"hgnc:HGNC:405","description":"aldehyde dehydrogenase 3 family member A1","metadata":{"aliases":["ALDH3"]}},{"id":"4db2719e94514110a66b6e39c26e7137","type":"GENE","name":"ALDH3A2","canonical_id":"hgnc:HGNC:403","description":"aldehyde dehydrogenase 3 family member A2","metadata":{"aliases":["FALDH","SLS","ALDH10"]}},{"id":"eb9b233346af406fb21ca9a69c8e6bfb","type":"GENE","name":"ALDH3B1","canonical_id":"hgnc:HGNC:410","description":"aldehyde dehydrogenase 3 family member B1","metadata":{"aliases":["ALDH7"]}},{"id":"d33391de3c404102b872a9bb587fc403","type":"GENE","name":"ALDH3B2","canonical_id":"hgnc:HGNC:411","description":"aldehyde dehydrogenase 3 family member B2","metadata":{"aliases":["ALDH8"]}},{"id":"4affc79da97f4895b4520f18c58f7ff2","type":"GENE","name":"ALDH4A1","canonical_id":"hgnc:HGNC:406","description":"aldehyde dehydrogenase 4 family member A1","metadata":{"aliases":["P5CDh","ALDH4"]}},{"id":"eca74916e68f4e1f9b9ac935b7817f7d","type":"GENE","name":"ALDH5A1","canonical_id":"hgnc:HGNC:408","description":"aldehyde dehydrogenase 5 family member A1","metadata":{"aliases":["SSADH","SSDH"]}},{"id":"bfa6804324fc44a496c7a0085d15a831","type":"GENE","name":"ALDH6A1","canonical_id":"hgnc:HGNC:7179","description":"aldehyde dehydrogenase 6 family member A1","metadata":{"aliases":["MMSDH"]}},{"id":"aeefa5e443c04a39a2cdfa8b1d586ece","type":"GENE","name":"ALDH7A1","canonical_id":"hgnc:HGNC:877","description":"aldehyde dehydrogenase 7 family member A1","metadata":{"aliases":["EPD","PDE","ATQ1"]}},{"id":"275fb3b362f54406b8a1f50873afa556","type":"GENE","name":"ALDH7A1P1","canonical_id":"hgnc:HGNC:878","description":"aldehyde dehydrogenase 7 family member A1 pseudogene 1","metadata":{"aliases":["ATQL1"]}},{"id":"69d56905794c47ceaab8daa0ec26234f","type":"GENE","name":"ALDH7A1P2","canonical_id":"hgnc:HGNC:879","description":"aldehyde dehydrogenase 7 family member A1 pseudogene 2","metadata":{"aliases":["ATQL2"]}},{"id":"0eafd51f5d9847e4b97ff16e8d1fc28d","type":"GENE","name":"ALDH7A1P3","canonical_id":"hgnc:HGNC:880","description":"aldehyde dehydrogenase 7 family member A1 pseudogene 3","metadata":{"aliases":["ATQL3"]}},{"id":"9425a198f6bb4537ad61c3e92dc3416f","type":"GENE","name":"ALDH7A1P4","canonical_id":"hgnc:HGNC:881","description":"aldehyde dehydrogenase 7 family member A1 pseudogene 4","metadata":{"aliases":["ATQL4"]}},{"id":"cb50714a69c343e4ac16234d60279ce0","type":"GENE","name":"ALDH8A1","canonical_id":"hgnc:HGNC:15471","description":"aldehyde dehydrogenase 8 family member A1","metadata":{"aliases":["ALDH12"]}},{"id":"bddb0a5966924be4a1c8fd46136e50ab","type":"GENE","name":"ALDH9A1","canonical_id":"hgnc:HGNC:412","description":"aldehyde dehydrogenase 9 family member A1","metadata":{"aliases":["E3","ALDH7","ALDH4","ALDH9"]}},{"id":"83434e40749a4c3097fb5e61c8d4eaf1","type":"GENE","name":"ALDOA","canonical_id":"hgnc:HGNC:414","description":null,"metadata":null},{"id":"436a358b509c4e1aab98ecf42f01a75c","type":"GENE","name":"ALDOAP1","canonical_id":"hgnc:HGNC:415","description":"ALDOA pseudogene 1","metadata":null},{"id":"fcb0e31b707d4368a6c5c7842e77ad63","type":"GENE","name":"ALDOAP2","canonical_id":"hgnc:HGNC:416","description":"ALDOA pseudogene 2","metadata":null},{"id":"523710b81b19427698e9624cf9d4412e","type":"GENE","name":"ALDOB","canonical_id":"hgnc:HGNC:417","description":null,"metadata":null},{"id":"68fc77ed84734dc0bab182fe06b7cb86","type":"GENE","name":"ALDOC","canonical_id":"hgnc:HGNC:418","description":"aldolase, fructose-bisphosphate C","metadata":null},{"id":"748aae6df7d14371b55c5f31f01aecae","type":"GENE","name":"ALDOC-AS1","canonical_id":"hgnc:HGNC:56941","description":"ALDOC antisense RNA 1","metadata":null},{"id":"b869972b3d664b419c452a21287f2a72","type":"TRIAL","name":"ALF-ONE : ALFuzosin ONcE Daily","canonical_id":"clinicaltrials.gov:NCT00280605","description":"Prostatic Hyperplasia","metadata":null},{"id":"2a0e88ace838441b8e4c9d916971743b","type":"TRIAL","name":"ALF-STONE: Alfuzosin in Uretheric Stones","canonical_id":"clinicaltrials.gov:NCT00454402","description":"Prostatic Hyperplasia","metadata":null},{"id":"0518b9917c114fae82142cfb9e9a3e31","type":"TRIAL","name":"ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH","canonical_id":"clinicaltrials.gov:NCT00290030","description":"Prostatic Hyperplasia; Acute Urinary Retention","metadata":null},{"id":"e67c4ce0f8ad4cca8b388c1a3e958d57","type":"GENE","name":"ALG1","canonical_id":"hgnc:HGNC:18294","description":"ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase","metadata":{"aliases":["HMT-1","HMAT1","CDG1K","Mat-1"]}},{"id":"cfb7975341554397a5ffb149e93e0b69","type":"GENE","name":"ALG10","canonical_id":"hgnc:HGNC:23162","description":"ALG10 alpha-1,2-glucosyltransferase","metadata":{"aliases":["FLJ14751","DIE2","ALG10A"]}},{"id":"9ba53364cacc41c89e0228db889c781d","type":"GENE","name":"ALG10B","canonical_id":"hgnc:HGNC:31088","description":"ALG10 alpha-1,2-glucosyltransferase B","metadata":{"aliases":["KCR1"]}},{"id":"18cb20979e7248eda0ffa6c62c76949f","type":"GENE","name":"ALG11","canonical_id":"hgnc:HGNC:32456","description":"ALG11 alpha-1,2-mannosyltransferase","metadata":{"aliases":["KIAA0266","CDG1P"]}},{"id":"886cf23d842b45c3934a0fbf14ad731f","type":"GENE","name":"ALG12","canonical_id":"hgnc:HGNC:19358","description":"ALG12 alpha-1,6-mannosyltransferase","metadata":{"aliases":["ECM39","CDG1G"]}},{"id":"c78541fae73e4b91a894916f09fb06b6","type":"GENE","name":"ALG13","canonical_id":"hgnc:HGNC:30881","description":"ALG13 UDP-N-acetylglucosaminyltransferase subunit","metadata":{"aliases":["MDS031","YGL047W","FLJ23018","TDRD13","CDG1S","GLT28D1","CXorf45"]}},{"id":"5f39cd2447a1425db6c64431937cb44f","type":"GENE","name":"ALG13-AS1","canonical_id":"hgnc:HGNC:41277","description":"ALG13 antisense RNA 1","metadata":null},{"id":"f0b4cfb7fb524d1bac5765323ca9b992","type":"GENE","name":"ALG14","canonical_id":"hgnc:HGNC:28287","description":"ALG14 UDP-N-acetylglucosaminyltransferase subunit","metadata":{"aliases":["MGC19780"]}},{"id":"e9a2b9c970ed4c92ad7be03986119f9d","type":"GENE","name":"ALG1L10P","canonical_id":"hgnc:HGNC:44379","description":"ALG1 like 10, pseudogene","metadata":null},{"id":"bc535971efe04d7da27a604ff76a5704","type":"GENE","name":"ALG1L11P","canonical_id":"hgnc:HGNC:44380","description":"ALG1 like 11, pseudogene","metadata":null},{"id":"9bbd62bf453342ce9c900f4784984f83","type":"GENE","name":"ALG1L12P","canonical_id":"hgnc:HGNC:44381","description":"ALG1 like 12, pseudogene","metadata":null},{"id":"500a810f7c404b118b7909e3ccc240c1","type":"GENE","name":"ALG1L13P","canonical_id":"hgnc:HGNC:44382","description":"ALG1 like 13, pseudogene","metadata":null},{"id":"e5c00780fafe4a00b211921a194a2196","type":"GENE","name":"ALG1L14P","canonical_id":"hgnc:HGNC:44383","description":"ALG1 like 14, pseudogene","metadata":null},{"id":"384092fa352f481b88b285614ad988ec","type":"GENE","name":"ALG1L15P","canonical_id":"hgnc:HGNC:44384","description":"ALG1 like 15, pseudogene","metadata":null},{"id":"0a5245a7ea2047d69f93b70467325bca","type":"GENE","name":"ALG1L1P","canonical_id":"hgnc:HGNC:33721","description":"ALG1 like 1, pseudogene","metadata":{"aliases":["ALG1L1","ALG1L"]}},{"id":"5f8f4d4f71734d8bb4ae07cfd841b262","type":"GENE","name":"ALG1L2","canonical_id":"hgnc:HGNC:37258","description":"ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase like 2","metadata":null},{"id":"196de75a49ed4ad59464ae7353f35ee7","type":"GENE","name":"ALG1L3P","canonical_id":"hgnc:HGNC:44372","description":"ALG1 like 3, pseudogene","metadata":null},{"id":"12cef754c7664aac8191591a09eb1259","type":"GENE","name":"ALG1L5P","canonical_id":"hgnc:HGNC:44374","description":"ALG1 like 5, pseudogene","metadata":null},{"id":"eedf3e3cb1bd4d748d4aefe6733bb67d","type":"GENE","name":"ALG1L6P","canonical_id":"hgnc:HGNC:44375","description":"ALG1 like 6, pseudogene","metadata":null},{"id":"20f314e783e64ee4866268ecc173a471","type":"GENE","name":"ALG1L7P","canonical_id":"hgnc:HGNC:44376","description":"ALG1 like 7, pseudogene","metadata":null},{"id":"3a34b5f2c6a2416b866ffec9d85bc3ec","type":"GENE","name":"ALG1L8P","canonical_id":"hgnc:HGNC:44377","description":"ALG1 like 8, pseudogene","metadata":null},{"id":"86497a279ba244d680cccc726f29d856","type":"GENE","name":"ALG1L9P","canonical_id":"hgnc:HGNC:44378","description":"ALG1 like 9, pseudogene","metadata":null},{"id":"a0754bb64a9d4a47993e4aba8812a6e8","type":"GENE","name":"ALG2","canonical_id":"hgnc:HGNC:23159","description":"ALG2 alpha-1,3/1,6-mannosyltransferase","metadata":{"aliases":["CDGIi","FLJ14511","hALPG2","NET38","CDG1I"]}},{"id":"5728a4ec78704a5c9635968a32bb4ea0","type":"GENE","name":"ALG3","canonical_id":"hgnc:HGNC:23056","description":"ALG3 alpha-1,3- mannosyltransferase","metadata":{"aliases":["NOT56L","Not56","CDGS4","D16Ertd36e"]}},{"id":"3bfee94c15af41ce9296d6a607b3d022","type":"GENE","name":"ALG3P1","canonical_id":"hgnc:HGNC:45159","description":"ALG3 pseudogene 1","metadata":null},{"id":"9cc25808f90e48078d71dbe543073837","type":"GENE","name":"ALG5","canonical_id":"hgnc:HGNC:20266","description":"ALG5 dolichyl-phosphate beta-glucosyltransferase","metadata":{"aliases":["bA421P11.2"]}},{"id":"9641048c3ec5431ca56a9d9fe7d41f4a","type":"GENE","name":"ALG6","canonical_id":"hgnc:HGNC:23157","description":"ALG6 alpha-1,3-glucosyltransferase","metadata":null},{"id":"a249c1fb300d4b1fba4a44a79ececf5c","type":"GENE","name":"ALG8","canonical_id":"hgnc:HGNC:23161","description":"ALG8 alpha-1,3-glucosyltransferase","metadata":{"aliases":["MGC2840"]}},{"id":"4bb99cb060594aa0a6271398841931ee","type":"GENE","name":"ALG9","canonical_id":"hgnc:HGNC:15672","description":"ALG9 alpha-1,2-mannosyltransferase","metadata":{"aliases":["DIBD1"]}},{"id":"a574177a217f492bb7dab816a6f00cc4","type":"GENE","name":"ALG9-IT1","canonical_id":"hgnc:HGNC:41409","description":"ALG9 intronic transcript 1","metadata":null},{"id":"dce3a564511443dc8bad74cbf01c7f15","type":"GENE","name":"ALK","canonical_id":"hgnc:HGNC:427","description":null,"metadata":null},{"id":"67d38fb2c516426fbd4562d6527ea393","type":"PROTEIN","name":"ALK","canonical_id":"uniprot:Q9UM73","description":null,"metadata":null},{"id":"843faa1e4914457d8069e04c4aa87dc3","type":"GENE","name":"ALK","canonical_id":"ensembl:ENSG00000171094","description":null,"metadata":null},{"id":"605ae16a6c964f8aa2a562f34991e618","type":"BIOMARKER","name":"ALK Alternative Transcript (ATI)","canonical_id":"civic:813","description":null,"metadata":null},{"id":"e13aa2f947474744a8f7d276e6fa3d2b","type":"BIOMARKER","name":"ALK Exon 4-11 Deletion","canonical_id":"civic:546","description":null,"metadata":null},{"id":"ce8da4db08f649a6af041e11e63c513a","type":"BIOMARKER","name":"ALK F1174L","canonical_id":"civic:8","description":null,"metadata":null},{"id":"a69d7e9be29347f59189cd3694ae2c24","type":"BIOMARKER","name":"ALK F1174L AND RANBP2::ALK Fusion","canonical_id":"civic:5969","description":null,"metadata":null},{"id":"3b9fed0aeec04cdfba69e2dc8d711356","type":"BIOMARKER","name":"ALK F1245C","canonical_id":"civic:545","description":null,"metadata":null},{"id":"9eaf6e8ba3f54f1ab488ed25576fc713","type":"BIOMARKER","name":"ALK F1245V","canonical_id":"civic:1269","description":null,"metadata":null},{"id":"7db10be3dfa1425795b0db034d1d69b9","type":"BIOMARKER","name":"ALK G1202R AND v::ALK Fusion","canonical_id":"civic:4236","description":null,"metadata":null},{"id":"c60e4f1c7b0f402489a74a32fbd3b6e5","type":"BIOMARKER","name":"ALK G1269A AND v::ALK Fusion","canonical_id":"civic:4311","description":null,"metadata":null},{"id":"31ac927ea0bb42faa62fcdcc59e720d6","type":"BIOMARKER","name":"ALK I1171","canonical_id":"civic:523","description":null,"metadata":null},{"id":"f3960d2695b846bb906aeb43f9909688","type":"BIOMARKER","name":"ALK I1171N AND HIP1::ALK Fusion","canonical_id":"civic:4332","description":null,"metadata":null},{"id":"d1fedd7ab2014d2283eefea97b58e505","type":"BIOMARKER","name":"ALK I1171T","canonical_id":"civic:3239","description":null,"metadata":null},{"id":"6cd34bcc807442fb9bab6ac3ee4cf3dc","type":"DRUG","name":"ALK Inhibitor TAE684","canonical_id":"ncit:C171615","description":null,"metadata":null},{"id":"eedf103343b24e82bb9c454c18148a42","type":"BIOMARKER","name":"ALK Mutation","canonical_id":"civic:508","description":null,"metadata":null},{"id":"85cf84dfb05d43b5bcb030b4235700d3","type":"BIOMARKER","name":"ALK R1275Q","canonical_id":"civic:9","description":null,"metadata":null},{"id":"65fdb8894f174140b62a1469ff88740f","type":"TRIAL","name":"ALK21-004: Single-dose Opiate Challenge of Medisorb\u00ae Naltrexone (VIVITROL\u00ae) in Adults Who Use Opioids","canonical_id":"clinicaltrials.gov:NCT01218984","description":"Opiate Dependence","metadata":null},{"id":"72a96fda5c3941dc81e0d200c69021f0","type":"TRIAL","name":"ALK29-002: A Study of Baclofen Formulations in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT00802035","description":"Alcohol Dependence","metadata":null},{"id":"c35c2309ef2b48cab4b138a687192f8c","type":"GENE","name":"ALKAL1","canonical_id":"hgnc:HGNC:33775","description":"ALK and LTK ligand 1","metadata":{"aliases":["UNQ9433","AUGB","FAM150A"]}},{"id":"3f85816152dc42bcb6af19094ad1292b","type":"GENE","name":"ALKAL2","canonical_id":"hgnc:HGNC:27683","description":"ALK and LTK ligand 2","metadata":{"aliases":["AUGA","FAM150B"]}},{"id":"62eb463fd8224e3caa72d5692eed096a","type":"GENE","name":"ALKBH1","canonical_id":"hgnc:HGNC:17911","description":"alkB homolog 1, histone H2A dioxygenase","metadata":{"aliases":["hABH","alkB","ABH","ALKBH"]}},{"id":"3374efb79676463ba15466dda4f049f8","type":"GENE","name":"ALKBH2","canonical_id":"hgnc:HGNC:32487","description":null,"metadata":null},{"id":"41ec51490a19429d8be7c524f7f4f8a5","type":"GENE","name":"ALKBH3","canonical_id":"hgnc:HGNC:30141","description":"alkB homolog 3, alpha-ketoglutarate dependent dioxygenase","metadata":{"aliases":["DEPC-1"]}},{"id":"fc3d1b11c0a24478be7beec2e133edb3","type":"GENE","name":"ALKBH3-AS1","canonical_id":"hgnc:HGNC:48670","description":"ALKBH3 antisense RNA 1","metadata":null},{"id":"a4d2e0c37aaf4405a65a2f31389d8790","type":"GENE","name":"ALKBH4","canonical_id":"hgnc:HGNC:21900","description":"alkB homolog 4, lysine demethylase","metadata":{"aliases":["FLJ20013"]}},{"id":"8c79fc5f7b254251bf972abbc1a8b6a4","type":"GENE","name":"ALKBH5","canonical_id":"hgnc:HGNC:25996","description":"alkB homolog 5, RNA demethylase","metadata":{"aliases":["FLJ20308","OFOXD1"]}},{"id":"77a1eca397c34aa0b4ee215a20fa2ec5","type":"GENE","name":"ALKBH6","canonical_id":"hgnc:HGNC:28243","description":"alkB homolog 6, nucleotide demethylase","metadata":{"aliases":["MGC15677"]}},{"id":"eb856599254a449583d29056ace9cafb","type":"GENE","name":"ALKBH7","canonical_id":"hgnc:HGNC:21306","description":"alkB homolog 7, RNA demethylase","metadata":{"aliases":["MGC10974","SPATA11"]}},{"id":"5852a21513ce46d9a88984b9fa0c222f","type":"GENE","name":"ALKBH8","canonical_id":"hgnc:HGNC:25189","description":"alkB homolog 8, tRNA methyltransferase","metadata":{"aliases":["MGC10235","TRM9","TRMT9A"]}},{"id":"35cef8293c3f4147bd43f3a5c52ae397","type":"GENE","name":"ALLC","canonical_id":"hgnc:HGNC:17377","description":"allantoicase","metadata":{"aliases":["ALC"]}},{"id":"4e33dff8e69542b4be4769c250fc4dd5","type":"TRIAL","name":"ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00140907","description":"High Blood Pressure","metadata":null},{"id":"c37c654d9f64433a84423736053aee42","type":"GENE","name":"ALMS1","canonical_id":"hgnc:HGNC:428","description":"ALMS1 centrosome and basal body associated protein","metadata":{"aliases":["KIAA0328"]}},{"id":"9d818f54c398432fa6bf6d084f2f16f2","type":"GENE","name":"ALMS1-IT1","canonical_id":"hgnc:HGNC:41305","description":"ALMS1 intronic transcript 1","metadata":null},{"id":"87bfff243855400d976b233962d4f08c","type":"GENE","name":"ALMS1P1","canonical_id":"hgnc:HGNC:29586","description":"ALMS1 pseudogene 1","metadata":{"aliases":["ALMS1L","ALMS1P"]}},{"id":"236e5c631f9940ebb28608eb2425707f","type":"GENE","name":"ALOX12","canonical_id":"hgnc:HGNC:429","description":null,"metadata":null},{"id":"40d6f05705994547b4086de2bd35163e","type":"GENE","name":"ALOX12B","canonical_id":"hgnc:HGNC:430","description":"arachidonate 12-lipoxygenase, 12R type","metadata":{"aliases":["12R-LOX"]}},{"id":"77b9c5992a084154bf2f6e86cccb060e","type":"GENE","name":"ALOX12P1","canonical_id":"hgnc:HGNC:431","description":"arachidonate 12-lipoxygenase pseudogene 1","metadata":{"aliases":["ALOX12P"]}},{"id":"f3226f0f3b3b462a9e247749e716c31d","type":"GENE","name":"ALOX12P2","canonical_id":"hgnc:HGNC:432","description":"arachidonate 12-lipoxygenase pseudogene 2","metadata":null},{"id":"6f0c5af967b142a4b4b3454fd6ee2fdb","type":"GENE","name":"ALOX15","canonical_id":"hgnc:HGNC:433","description":null,"metadata":null},{"id":"b41ea40f38a647b89e544aad726d694e","type":"GENE","name":"ALOX15B","canonical_id":"hgnc:HGNC:434","description":null,"metadata":null},{"id":"6fe2057008fb49e6ae7e70dfc8d06612","type":"GENE","name":"ALOX15P1","canonical_id":"hgnc:HGNC:13742","description":"arachidonate 15-lipoxygenase pseudogene 1","metadata":{"aliases":["ALOX15P"]}},{"id":"eb09a5d68ac54e1c81cc8d8930b50cc1","type":"GENE","name":"ALOX15P2","canonical_id":"hgnc:HGNC:39027","description":"arachidonate 15-lipoxygenase pseudogene 2","metadata":null},{"id":"20a5ae8a182149f18ae45978a62aa681","type":"GENE","name":"ALOX5","canonical_id":"hgnc:HGNC:435","description":null,"metadata":null},{"id":"89ac4f5e22074fa5809d00d5f6b1665a","type":"PROTEIN","name":"ALOX5","canonical_id":"uniprot:P09917","description":null,"metadata":null},{"id":"f6816acc186547579a5bb817ea8e4ee2","type":"GENE","name":"ALOX5AP","canonical_id":"hgnc:HGNC:436","description":null,"metadata":null},{"id":"03cae1145b0f4a8c978cc11f35a125fa","type":"GENE","name":"ALOXE3","canonical_id":"hgnc:HGNC:13743","description":"arachidonate epidermal lipoxygenase 3","metadata":{"aliases":["eLOX3","E-LOX"]}},{"id":"691371e2040b441fb61c4012875965fc","type":"GENE","name":"ALOXE3P1","canonical_id":"hgnc:HGNC:44238","description":"arachidonate lipoxygenase 3 pseudogene 1","metadata":null},{"id":"af708af6d3d8470692db688f1546bce0","type":"GENE","name":"ALPG","canonical_id":"hgnc:HGNC:441","description":"alkaline phosphatase, germ cell","metadata":{"aliases":["GCAP","ALPPL2"]}},{"id":"86da87f9aab94f96a3dcc9c1dde2594b","type":"GENE","name":"ALPI","canonical_id":"hgnc:HGNC:437","description":null,"metadata":null},{"id":"f334ff2906604c1985ea48ef75421d13","type":"TRIAL","name":"ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function","canonical_id":"clinicaltrials.gov:NCT00485238","description":"Glaucoma","metadata":null},{"id":"e6dc27dd6271415fb8c4d49f21e9b6c9","type":"GENE","name":"ALPK1","canonical_id":"hgnc:HGNC:20917","description":"alpha kinase 1","metadata":{"aliases":["Lak","FLJ22670","KIAA1527"]}},{"id":"aa56d1099a0a4e7098139ebba945937c","type":"GENE","name":"ALPK2","canonical_id":"hgnc:HGNC:20565","description":"alpha kinase 2","metadata":{"aliases":["HAK"]}},{"id":"93957da30f2e4b78b717ae1db9267c8a","type":"GENE","name":"ALPK2-AS1","canonical_id":"hgnc:HGNC:58575","description":"ALPK2 antisense RNA 1","metadata":null},{"id":"c9de8e6b9a1d442eafc89c2cd6281c58","type":"GENE","name":"ALPK3","canonical_id":"hgnc:HGNC:17574","description":"alpha kinase 3","metadata":{"aliases":["MAK","KIAA1330","Midori"]}},{"id":"be3c04c88fac403484e056b63f9fc6ac","type":"GENE","name":"ALPL","canonical_id":"hgnc:HGNC:438","description":null,"metadata":null},{"id":"66e9d206aa764d61993a4f8046dea555","type":"GENE","name":"ALPP","canonical_id":"hgnc:HGNC:439","description":"alkaline phosphatase, placental","metadata":{"aliases":["PALP","PLAP"]}},{"id":"9b7527bbb9454a0a9645c619c5044e3a","type":"GENE","name":"ALPPP","canonical_id":"hgnc:HGNC:14016","description":"alkaline phosphatase, pseudogene","metadata":null},{"id":"b9c2c16f0c7e4652b2ce738199be2746","type":"GENE","name":"ALS2","canonical_id":"hgnc:HGNC:443","description":"alsin Rho guanine nucleotide exchange factor ALS2","metadata":{"aliases":["ALS2CR6"]}},{"id":"8e07800812804f05b45983cae9176d17","type":"GENE","name":"ALS2CL","canonical_id":"hgnc:HGNC:20605","description":"ALS2 C-terminal like","metadata":{"aliases":["FLJ36525","RN49018","DKFZp686I0110"]}},{"id":"d212e13ed35a47c881b55a11c6259964","type":"TRIAL","name":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","canonical_id":"clinicaltrials.gov:NCT02737501","description":"Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma","metadata":null},{"id":"fe7faf48efdf415ab6eee8d8bdbb69db","type":"GENE","name":"ALX1","canonical_id":"hgnc:HGNC:1494","description":"ALX homeobox 1","metadata":{"aliases":["CART1"]}},{"id":"e1537f85207f43b7a49b8548e54ea557","type":"GENE","name":"ALX3","canonical_id":"hgnc:HGNC:449","description":"ALX homeobox 3","metadata":{"aliases":["FND"]}},{"id":"19c1aefcec544139b7e81fa5d2989b30","type":"GENE","name":"ALX4","canonical_id":"hgnc:HGNC:450","description":"ALX homeobox 4","metadata":{"aliases":["FPP","PFM","KIAA1788","PFM2"]}},{"id":"a7aabccacd7344b998656b676555aef0","type":"TRIAL","name":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Na\u00efve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","canonical_id":"clinicaltrials.gov:NCT02946463","description":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","metadata":null},{"id":"abf5f7e9406840a08f9ee49e017a19b6","type":"TRIAL","name":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","canonical_id":"clinicaltrials.gov:NCT03056040","description":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","metadata":null},{"id":"c02d7a5498db4584bdfd2268b43943ad","type":"GENE","name":"ALYREF","canonical_id":"hgnc:HGNC:19071","description":"Aly/REF export factor","metadata":{"aliases":["ALY","BEF","ALY/REF","REF","THOC4"]}},{"id":"03ceee7e776c4b7a9c583114ce0ffe32","type":"GENE","name":"AMACR","canonical_id":"hgnc:HGNC:451","description":null,"metadata":null},{"id":"eb8f6c05a66e412ca4b45e5b74638742","type":"GENE","name":"AMANZI","canonical_id":"hgnc:HGNC:55634","description":"a master non-coding RNA antagonizing inflammation","metadata":null},{"id":"5ca6a8a3ae7e4e43b9300f59c1928367","type":"GENE","name":"AMBN","canonical_id":"hgnc:HGNC:452","description":"ameloblastin","metadata":null},{"id":"e6a547d6967a4fae97a7b57a3e33d79a","type":"GENE","name":"AMBP","canonical_id":"hgnc:HGNC:453","description":"alpha-1-microglobulin/bikunin precursor","metadata":{"aliases":["UTI","HCP","EDC1","HI30","IATIL","ITILC","ITI","ITIL"]}},{"id":"8e8eb4c048f24374a666bf9189af073d","type":"GENE","name":"AMBRA1","canonical_id":"hgnc:HGNC:25990","description":"autophagy and beclin 1 regulator 1","metadata":{"aliases":["FLJ20294","KIAA1736","WDR94","DCAF3"]}},{"id":"d21dfd064f354af5bef7f00a4b99147a","type":"TRIAL","name":"AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation","canonical_id":"clinicaltrials.gov:NCT00075335","description":"Healthy","metadata":null},{"id":"f485d7ba28c940a1b5417ae7e0590e26","type":"GENE","name":"AMD1","canonical_id":"hgnc:HGNC:457","description":"adenosylmethionine decarboxylase 1","metadata":{"aliases":["SAMDC"]}},{"id":"8c9399097a204bd8848ad4ad60516d0e","type":"GENE","name":"AMD1P1","canonical_id":"hgnc:HGNC:44898","description":"adenosylmethionine decarboxylase 1 pseudogene 1","metadata":null},{"id":"97e0b739d82c437198ab912952ab8a39","type":"GENE","name":"AMD1P2","canonical_id":"hgnc:HGNC:460","description":"adenosylmethionine decarboxylase 1 pseudogene 2","metadata":{"aliases":["AMDPX","AMDPY","AMD2","AMD","AMDP1"]}},{"id":"a3d9b574639f4da9833efb47c2274ce1","type":"GENE","name":"AMD1P3","canonical_id":"hgnc:HGNC:51608","description":"adenosylmethionine decarboxylase 1 pseudogene 3","metadata":null},{"id":"f99194eaa27d4e809e811fb74b209e03","type":"GENE","name":"AMD1P4","canonical_id":"hgnc:HGNC:51609","description":"adenosylmethionine decarboxylase 1 pseudogene 4","metadata":null},{"id":"02cc38f0a7324e8fa75fae5583b0f341","type":"TRIAL","name":"AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF","canonical_id":"clinicaltrials.gov:NCT00396266","description":"Multiple Myeloma; Lymphoma, Non-Hodgkin","metadata":null},{"id":"bddca9090320446d9427e713533fae87","type":"GENE","name":"AMDHD1","canonical_id":"hgnc:HGNC:28577","description":"amidohydrolase domain containing 1","metadata":{"aliases":["MGC35366"]}},{"id":"dcb7e6eb88fd4aa9878154fffad0f918","type":"GENE","name":"AMDHD2","canonical_id":"hgnc:HGNC:24262","description":"amidohydrolase domain containing 2","metadata":{"aliases":["CGI-14"]}},{"id":"d53ab0ece3644d92aef2159a89cb7f9c","type":"GENE","name":"AMELX","canonical_id":"hgnc:HGNC:461","description":"amelogenin X-linked","metadata":{"aliases":["AMG","AIH1"]}},{"id":"7cdbcf293cc344259f4e69d3d6a4655c","type":"GENE","name":"AMELY","canonical_id":"hgnc:HGNC:462","description":"amelogenin Y-linked","metadata":{"aliases":["AMGL"]}},{"id":"c77acd907b0d4e9b95c87350b5fa42f8","type":"GENE","name":"AMER1","canonical_id":"hgnc:HGNC:26837","description":"APC membrane recruitment protein 1","metadata":{"aliases":["RP11-403E24.2","FLJ39827","WTX","FAM123B"]}},{"id":"9521d3944e79477783f4f61e2269fb57","type":"GENE","name":"AMER2","canonical_id":"hgnc:HGNC:26360","description":"APC membrane recruitment protein 2","metadata":{"aliases":["FLJ25477","FAM123A"]}},{"id":"f77dc77f26c34a96855c63e16a0f65b4","type":"GENE","name":"AMER3","canonical_id":"hgnc:HGNC:26771","description":"APC membrane recruitment protein 3","metadata":{"aliases":["FLJ38377","FAM123C"]}},{"id":"d71cc03f647e44a19e4db4ee00a788de","type":"GENE","name":"AMFR","canonical_id":"hgnc:HGNC:463","description":"autocrine motility factor receptor","metadata":{"aliases":["RNF45","gp78"]}},{"id":"3e3ac617b52844e8b9f332f66ee2f19b","type":"TRIAL","name":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00089661","description":"Breast Cancer; Low Bone Mineral Density; Osteopenia","metadata":null},{"id":"c289742caa2e4342aab844e50bf84874","type":"TRIAL","name":"AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07094113","description":"KRAS Altered Advanced or Metastatic Solid Tumors","metadata":null},{"id":"531986db9f3144c99a8d2dea9c67dd2e","type":"GENE","name":"AMH","canonical_id":"hgnc:HGNC:464","description":null,"metadata":null},{"id":"3f3c0df4c38f47bfae1bb9d79394324f","type":"GENE","name":"AMHR2","canonical_id":"hgnc:HGNC:465","description":null,"metadata":null},{"id":"311e40e1a6c142208a23a52771d9d654","type":"GENE","name":"AMIGO1","canonical_id":"hgnc:HGNC:20824","description":"adhesion molecule with Ig like domain 1","metadata":{"aliases":["AMIGO","KIAA1163"]}},{"id":"6643da2266fb489db908a1dd1357440f","type":"GENE","name":"AMIGO2","canonical_id":"hgnc:HGNC:24073","description":"adhesion molecule with Ig like domain 2","metadata":{"aliases":["ALI1","DEGA"]}},{"id":"0d27184d828d4848ac92b13c07bf7bf2","type":"GENE","name":"AMIGO3","canonical_id":"hgnc:HGNC:24075","description":"adhesion molecule with Ig like domain 3","metadata":null},{"id":"2cf7d29fda0740c1b92796f0963ea9e8","type":"TRIAL","name":"AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium","canonical_id":"clinicaltrials.gov:NCT05044611","description":"Bipolar Disorder","metadata":null},{"id":"84d42621da1747bcb31f0cec06f62eb7","type":"TRIAL","name":"AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance","canonical_id":"clinicaltrials.gov:NCT04174612","description":"Acute Myeloid Leukemia With FLT3/ITD Mutation","metadata":null},{"id":"1073cafbc47046e2b20a9a2e55c3e26e","type":"GENE","name":"AMLCR2","canonical_id":"hgnc:HGNC:466","description":"acute myeloid leukemia chromosome region 2","metadata":null},{"id":"722a3f9b88f649a087e7d4e49f242871","type":"GENE","name":"AMMECR1","canonical_id":"hgnc:HGNC:467","description":"AMMECR nuclear protein 1","metadata":null},{"id":"95e2da5a20844e5ca083548c1a2e69da","type":"GENE","name":"AMMECR1-IT1","canonical_id":"hgnc:HGNC:41306","description":"AMMECR1 intronic transcript 1","metadata":null},{"id":"2faf72c0170347519c843d9ba95c3b17","type":"GENE","name":"AMMECR1L","canonical_id":"hgnc:HGNC:28658","description":"AMMECR1 like","metadata":{"aliases":["MGC4268"]}},{"id":"746d5290e625458aa0a8d823231d4275","type":"GENE","name":"AMMECR1LP1","canonical_id":"hgnc:HGNC:39809","description":"AMMECR1 like pseudogene 1","metadata":null},{"id":"452061d259c148dfb8993a7388c3d632","type":"GENE","name":"AMN","canonical_id":"hgnc:HGNC:14604","description":"amnion associated transmembrane protein","metadata":{"aliases":["amnionless"]}},{"id":"21cfa5b4018d4325a2fd8d7598667476","type":"GENE","name":"AMN1","canonical_id":"hgnc:HGNC:27281","description":"antagonist of mitotic exit network 1 homolog","metadata":null},{"id":"6ee31cbfe8a749678800cb88e5f7a377","type":"GENE","name":"AMN1-AS1","canonical_id":"hgnc:HGNC:58137","description":"AMN1 antisense RNA 1","metadata":{"aliases":["AC023157.3"]}},{"id":"39bb4c5c50234956acee14309c7d3144","type":"GENE","name":"AMOT","canonical_id":"hgnc:HGNC:17810","description":"angiomotin","metadata":{"aliases":["KIAA1071"]}},{"id":"033a45960d654d7ea03d2a6d8ae629f9","type":"GENE","name":"AMOTL1","canonical_id":"hgnc:HGNC:17811","description":"angiomotin like 1","metadata":{"aliases":["JEAP"]}},{"id":"e1623f86dff44ea4aeb348f4520347da","type":"GENE","name":"AMOTL2","canonical_id":"hgnc:HGNC:17812","description":"angiomotin like 2","metadata":{"aliases":["LCCP"]}},{"id":"96c4a747bde14bc68b38ae769223c22d","type":"GO_TERM","name":"AMP binding","canonical_id":"go:GO:0016208","description":"\"Binding to AMP, adenosine monophosphate.\" [GOC:curators]","metadata":null},{"id":"bb7b20b30fab4b468abcd4f0e54804f4","type":"GO_TERM","name":"AMP biosynthetic process","canonical_id":"go:GO:0006167","description":"\"The chemical reactions and pathways resulting in the formation of AMP, adenosine monophosphate.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"74a8876b97914d7eb1c120be58043493","type":"GO_TERM","name":"AMP catabolic process","canonical_id":"go:GO:0006196","description":"\"The chemical reactions and pathways resulting in the breakdown of AMP, adenosine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"fe05233dcdf642b6a0851561624adaa6","type":"GO_TERM","name":"AMP deaminase activity","canonical_id":"go:GO:0003876","description":"\"Catalysis of the reaction: AMP + H2O = IMP + NH4+.\" [RHEA:14777]","metadata":null},{"id":"060f5b2cd425485eb141d670ba1e4d56","type":"GO_TERM","name":"AMP dimethylallyltransferase activity","canonical_id":"go:GO:0009824","description":"\"Catalysis of the reaction: AMP + dimethylallyl diphosphate = N(6)-(dimethylallyl)adenosine 5'-phosphate + diphosphate.\" [RHEA:15285]","metadata":null},{"id":"bfd36c182f2446ef9ba6f4109d6c38b2","type":"GO_TERM","name":"AMP kinase activity","canonical_id":"go:GO:0004017","description":"\"Catalysis of the reaction: ATP + AMP = 2 ADP.\" [RHEA:12973]","metadata":null},{"id":"846e010e1c4e47eab974f71607558d79","type":"GO_TERM","name":"AMP metabolic process","canonical_id":"go:GO:0046033","description":"\"The chemical reactions and pathways involving AMP, adenosine monophosphate.\" [GOC:curators]","metadata":null},{"id":"04c1fe7197f1446fbe79e5af364e7058","type":"GO_TERM","name":"AMP nucleosidase activity","canonical_id":"go:GO:0008714","description":"\"Catalysis of the reaction: AMP + H2O = D-ribose 5-phosphate + adenine.\" [EC:3.2.2.4, RHEA:20129]","metadata":null},{"id":"d6e71c3ddeac4838b341c8605a094237","type":"GO_TERM","name":"AMP phosphorylation","canonical_id":"go:GO:0006756","description":"\"The process of introducing a phosphate group into AMP, adenosine monophosphate, to produce ADP. Addition of two phosphate groups produces ATP.\" [GOC:ai]","metadata":null},{"id":"aee6ec2d1f7c4a21890b8fdcaf9af068","type":"GO_TERM","name":"AMP salvage","canonical_id":"go:GO:0044209","description":"\"The chemical reactions and pathways resulting in the formation of adenosine monophosphate (AMP) from derivatives of it (either adenine, ADP or adenosine 3',5'-bisphosphate) without de novo synthesis.\" [GOC:ecd, GOC:jl, PMID:8917457, PMID:9864350]","metadata":null},{"id":"3169369d149d45768e5abc0329c798fa","type":"GO_TERM","name":"AMP transmembrane transporter activity","canonical_id":"go:GO:0080122","description":"\"Enables the transfer of AMP, adenosine monophosphate, from one side of a membrane to the other.\" [PMID:18923018]","metadata":null},{"id":"585890da2a6a434d822e6808617c3343","type":"GO_TERM","name":"AMP transport","canonical_id":"go:GO:0080121","description":"\"The directed movement of AMP, adenosine monophosphate, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [PMID:18923018]","metadata":null},{"id":"4dbc47e595694c2788fb3e8b55614d11","type":"GO_TERM","name":"AMP-activated protein kinase activity","canonical_id":"go:GO:0004679","description":"\"Catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein. This reaction requires the presence of AMP.\" [GOC:mah]","metadata":null},{"id":"6faf7ddb5cdd48898f6ff5d8ef8a1557","type":"GO_TERM","name":"AMP-thymidine kinase activity","canonical_id":"go:GO:0047667","description":"\"Catalysis of the reaction: AMP + thymidine = adenosine + thymidine 5'-phosphate.\" [EC:2.7.1.114, MetaCyc:AMP--THYMIDINE-KINASE-RXN]","metadata":null},{"id":"c340125266f44c20be4d6f6e14d5bfa8","type":"GO_TERM","name":"AMPA glutamate receptor activity","canonical_id":"go:GO:0004971","description":"\"An ionotropic glutamate receptor activity that exhibits fast gating by glutamate and acts by opening a cation channel permeable to sodium, potassium, and, in the absence of a GluR2 subunit, calcium.\" [GOC:mah, PMID:10049997, PMID:8804111]","metadata":null},{"id":"7f9e0c4956a24e79bee679ddef5aba59","type":"GO_TERM","name":"AMPA glutamate receptor clustering","canonical_id":"go:GO:0097113","description":"\"The glutamate receptor clustering process in which alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors are localized to distinct domains in the cell membrane.\" [GOC:BHF, GOC:pr, GOC:sjp, PMID:12796785]","metadata":null},{"id":"3fbdd475053643c284dbe70b1c8cd3fe","type":"GO_TERM","name":"AMPA glutamate receptor complex","canonical_id":"go:GO:0032281","description":"\"An assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex. The AMPA receptors mediate fast synaptic transmission in the CNS and are composed of subunits GluR1-4, products from separate genes. These subunits have an extracellular N-terminus and an intracellular C-terminus.\" [GOC:ef]","metadata":null},{"id":"97d1a128f4714939a60b72c8452ec912","type":"GO_TERM","name":"AMPA selective glutamate receptor signaling pathway","canonical_id":"go:GO:0098990","description":"\"The series of molecular signals initiated by glutamate binding to an AMPA-selective glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dos, ISBN:9780071120005]","metadata":null},{"id":"3ce12d9d7ace4c78947c12dd68a5d6fa","type":"GENE","name":"AMPD1","canonical_id":"hgnc:HGNC:468","description":"adenosine monophosphate deaminase 1","metadata":{"aliases":["MAD","MADA"]}},{"id":"28026429f99a4f9da1f0509d07ba85e7","type":"GENE","name":"AMPD2","canonical_id":"hgnc:HGNC:469","description":"adenosine monophosphate deaminase 2","metadata":{"aliases":["SPG63"]}},{"id":"e11c5c4b7c5f422cae15e4daaa35dd6f","type":"GENE","name":"AMPD2-AS1","canonical_id":"hgnc:HGNC:40074","description":"AMPD2 antisense RNA 1","metadata":null},{"id":"525067c3c7f34080a78bcdfa2256df16","type":"GENE","name":"AMPD3","canonical_id":"hgnc:HGNC:470","description":"adenosine monophosphate deaminase 3","metadata":null},{"id":"1b40eb497eaf45d18f9c75bef4dd7ffc","type":"GENE","name":"AMPH","canonical_id":"hgnc:HGNC:471","description":"amphiphysin","metadata":null},{"id":"1cff51b0e1b34d4e8c230649f8dfd6fc","type":"TRIAL","name":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","canonical_id":"clinicaltrials.gov:NCT02796677","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"a775912477ce45d59b62c6c8a82c0aa7","type":"GO_TERM","name":"AMPylase activity","canonical_id":"go:GO:0070733","description":"\"Catalysis of the reaction: ATP + protein = diphosphate + adenylyl-protein; mediates the addition of an adenylyl (adenosine 5'-monophosphate; AMP group) to L-serine, L-threonine, and L-tyrosine residues in target proteins.\" [GOC:mah, PMID:19039103, PMID:19362538, PMID:33947243]","metadata":null},{"id":"357b09a5e4d14fc9b0cd674500dad092","type":"GENE","name":"AMT","canonical_id":"hgnc:HGNC:473","description":"aminomethyltransferase","metadata":{"aliases":["GCST","NKH"]}},{"id":"308910f083974a8e9a47ad32e2fa0917","type":"TRIAL","name":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","canonical_id":"clinicaltrials.gov:NCT03801369","description":"Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma","metadata":null},{"id":"5a4a930be94d4efdbf233fb145e04fed","type":"GENE","name":"AMTN","canonical_id":"hgnc:HGNC:33188","description":"amelotin","metadata":{"aliases":["UNQ689","RSTI689"]}},{"id":"d779a6341dab4c8299dfec8907f01f35","type":"GENE","name":"AMY1A","canonical_id":"hgnc:HGNC:474","description":"amylase alpha 1A","metadata":{"aliases":["AMY1"]}},{"id":"529d5d1c35d344fd96916f17a07df8b2","type":"GENE","name":"AMY1B","canonical_id":"hgnc:HGNC:475","description":"amylase alpha 1B","metadata":{"aliases":["AMY1"]}},{"id":"3db8350fdb7947eabc8b100cdb0a3137","type":"GENE","name":"AMY1C","canonical_id":"hgnc:HGNC:476","description":"amylase alpha 1C","metadata":{"aliases":["AMY1"]}},{"id":"21d90fec9b9040b49ee66c4b681f7a46","type":"GENE","name":"AMY2A","canonical_id":"hgnc:HGNC:477","description":"amylase alpha 2A","metadata":{"aliases":["AMY2"]}},{"id":"78e16a19f6c5404a95c833e1871471a1","type":"GENE","name":"AMY2B","canonical_id":"hgnc:HGNC:478","description":"amylase alpha 2B","metadata":{"aliases":["AMY2"]}},{"id":"98dd9da51d9e4d539adcaf70acea8c6f","type":"GENE","name":"AMYP1","canonical_id":"hgnc:HGNC:479","description":"amylase alpha pseudogene 1","metadata":{"aliases":["AMY2P"]}},{"id":"75f8917eada94963b2b3a34b6684fc25","type":"GENE","name":"AMZ1","canonical_id":"hgnc:HGNC:22231","description":"archaelysin family metallopeptidase 1","metadata":{"aliases":["KIAA1950"]}},{"id":"3f665bc9262d4a9fa0ef5fe01a776379","type":"GENE","name":"AMZ2","canonical_id":"hgnc:HGNC:28041","description":"archaelysin family metallopeptidase 2","metadata":null},{"id":"a8be5bb3eb614652bb935479a7746671","type":"GENE","name":"AMZ2P1","canonical_id":"hgnc:HGNC:26491","description":"AMZ2 pseudogene 1","metadata":{"aliases":["FLJ32065"]}},{"id":"3b2887e5fde34723a96efb4ddf1dea7e","type":"GENE","name":"AMZ2P2","canonical_id":"hgnc:HGNC:38072","description":"AMZ2 pseudogene 2","metadata":null},{"id":"145d90ad5c074b43b8447b6c5f6d2205","type":"GENE","name":"AMZ2P3","canonical_id":"hgnc:HGNC:54911","description":"AMZ2 pseudogene 3","metadata":null},{"id":"326d89472bd04863ab972371397e09d7","type":"TRIAL","name":"AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study","canonical_id":"clinicaltrials.gov:NCT01154361","description":"Angioedema","metadata":null},{"id":"599c9566483e47d9902fca4652013b84","type":"GENE","name":"ANAPC1","canonical_id":"hgnc:HGNC:19988","description":"anaphase promoting complex subunit 1","metadata":{"aliases":["MCPR","TSG24","APC1"]}},{"id":"8603170a8d3c45139a7ead5ec7943571","type":"GENE","name":"ANAPC10","canonical_id":"hgnc:HGNC:24077","description":"anaphase promoting complex subunit 10","metadata":{"aliases":["APC10","DOC1","DKFZP564L0562"]}},{"id":"1ef480a4fcdc45d58e243c8e5466c5c6","type":"GENE","name":"ANAPC10P1","canonical_id":"hgnc:HGNC:33976","description":"anaphase promoting complex subunit 10 pseudogene 1","metadata":{"aliases":["ANAPC10P"]}},{"id":"7055c51260234957ad3f416499183855","type":"GENE","name":"ANAPC11","canonical_id":"hgnc:HGNC:14452","description":"anaphase promoting complex subunit 11","metadata":{"aliases":["HSPC214","APC11","Apc11p","MGC882"]}},{"id":"51631e750b794836806c3b8e1b3c0c86","type":"GENE","name":"ANAPC13","canonical_id":"hgnc:HGNC:24540","description":"anaphase promoting complex subunit 13","metadata":{"aliases":["SWM1","APC13","DKFZP566D193"]}},{"id":"869931b13a9a4de2bd2804b7c838ed7d","type":"GENE","name":"ANAPC13P1","canonical_id":"hgnc:HGNC:56948","description":"ANAPC13 pseudogene 1","metadata":null},{"id":"d85a901b4f864f2998ff5f8c4fe623dd","type":"GENE","name":"ANAPC15","canonical_id":"hgnc:HGNC:24531","description":"anaphase promoting complex subunit 15","metadata":{"aliases":["HSPC020","DKFZP564M082","APC15","C11orf51"]}},{"id":"afb12804167c4a648a0bdd073eb94fd8","type":"GENE","name":"ANAPC15P1","canonical_id":"hgnc:HGNC:54888","description":"ANAPC15 pseudogene 1","metadata":null},{"id":"8aad6c5dc6de41b2a26adabbc07cf1b6","type":"GENE","name":"ANAPC15P2","canonical_id":"hgnc:HGNC:54889","description":"ANAPC15 pseudogene 2","metadata":null},{"id":"50bb841ccd194b97b168f9ab008e2a85","type":"GENE","name":"ANAPC16","canonical_id":"hgnc:HGNC:26976","description":"anaphase promoting complex subunit 16","metadata":{"aliases":["bA570G20.3","FLJ33728","APC16","CENP-27","C10orf104"]}},{"id":"e9f9c2744a354c4b8cd721addd10e5e1","type":"GENE","name":"ANAPC1P1","canonical_id":"hgnc:HGNC:44150","description":"ANAPC1 pseudogene 1","metadata":null},{"id":"766d12b1e6dc49678be3c040dd3e5c49","type":"GENE","name":"ANAPC1P2","canonical_id":"hgnc:HGNC:54708","description":"ANAPC1 pseudogene 2","metadata":null},{"id":"4c11cfdf08b345daba369c97348a99f5","type":"GENE","name":"ANAPC1P3","canonical_id":"hgnc:HGNC:54709","description":"ANAPC1 pseudogene 3","metadata":null},{"id":"02d81e6033ce4ad1b8ed7aad4c0c89ff","type":"GENE","name":"ANAPC1P4","canonical_id":"hgnc:HGNC:54710","description":"ANAPC1 pseudogene 4","metadata":null},{"id":"9adbf23301584f99ba54e55374b0e36d","type":"GENE","name":"ANAPC1P5","canonical_id":"hgnc:HGNC:54711","description":"ANAPC1 pseudogene 5","metadata":null},{"id":"fa88dc70d6144ff69472a9b70b052e92","type":"GENE","name":"ANAPC1P6","canonical_id":"hgnc:HGNC:54712","description":"ANAPC1 pseudogene 6","metadata":null},{"id":"df1866cbae49411e901884fb1762fc57","type":"GENE","name":"ANAPC2","canonical_id":"hgnc:HGNC:19989","description":"anaphase promoting complex subunit 2","metadata":{"aliases":["APC2","KIAA1406"]}},{"id":"1cc6e0323ea641e79f9ee3bd52c71b0d","type":"GENE","name":"ANAPC4","canonical_id":"hgnc:HGNC:19990","description":null,"metadata":null},{"id":"8404ad225e334077ab0b004f5b7c0f29","type":"GENE","name":"ANAPC4-AS1","canonical_id":"hgnc:HGNC:58748","description":"ANAPC4 antisense RNA 1","metadata":null},{"id":"326efaad3e0c430bb75c6d05201eeeb6","type":"GENE","name":"ANAPC5","canonical_id":"hgnc:HGNC:15713","description":"anaphase promoting complex subunit 5","metadata":{"aliases":["APC5"]}},{"id":"7030b851090e4bbbbf3be7ad26712103","type":"GENE","name":"ANAPC7","canonical_id":"hgnc:HGNC:17380","description":"anaphase promoting complex subunit 7","metadata":{"aliases":["APC7"]}},{"id":"529cf563bde44e039dcf6c227c7fcf77","type":"GENE","name":"ANCR","canonical_id":"hgnc:HGNC:482","description":"Angelman syndrome chromosome region","metadata":null},{"id":"b0fae83beabd4f48bdae19467b07d831","type":"GENE","name":"ANG","canonical_id":"hgnc:HGNC:483","description":null,"metadata":null},{"id":"328d103cc6e7435d937ce9c2bfb498fc","type":"GENE","name":"ANGEL1","canonical_id":"hgnc:HGNC:19961","description":"angel homolog 1","metadata":{"aliases":["Ccr4e","KIAA0759"]}},{"id":"b0c2a54b405d497aa00a6f7cfa372f8e","type":"GENE","name":"ANGEL2","canonical_id":"hgnc:HGNC:30534","description":"angel homolog 2","metadata":{"aliases":["KIAA0759L","FLJ12793","Ccr4d"]}},{"id":"be7ed9474cd24a7d80af2804fad072e3","type":"GENE","name":"ANGPT1","canonical_id":"hgnc:HGNC:484","description":null,"metadata":null},{"id":"661ce182f80b4acdb59e6b7939cf49e5","type":"GENE","name":"ANGPT2","canonical_id":"hgnc:HGNC:485","description":null,"metadata":null},{"id":"9cfb040fb64e4136a81b30df061e33fd","type":"PROTEIN","name":"ANGPT2","canonical_id":"uniprot:O15123","description":null,"metadata":null},{"id":"b01f02ffde1045abb67199956c2ebdb0","type":"GENE","name":"ANGPT4","canonical_id":"hgnc:HGNC:487","description":"angiopoietin 4","metadata":null},{"id":"93e550036a584bf7ad8347150aef60c4","type":"GENE","name":"ANGPTL1","canonical_id":"hgnc:HGNC:489","description":"angiopoietin like 1","metadata":{"aliases":["ANG3","AngY","ARP1","ANGPT3"]}},{"id":"475d5a5ac1ed4b90885b5ed04bdebffd","type":"GENE","name":"ANGPTL2","canonical_id":"hgnc:HGNC:490","description":"angiopoietin like 2","metadata":{"aliases":["ARP2","HARP"]}},{"id":"dbfe93f595aa40729e19ddf9a2d6e60d","type":"GENE","name":"ANGPTL3","canonical_id":"hgnc:HGNC:491","description":"angiopoietin like 3","metadata":{"aliases":["ANGPT5"]}},{"id":"33a29814b52948e1be0fb1cb46bd40c8","type":"PROTEIN","name":"ANGPTL3","canonical_id":"uniprot:Q9Y5C1","description":null,"metadata":null},{"id":"b4d0c18b335b4a3e9de4ace508ac733e","type":"GENE","name":"ANGPTL4","canonical_id":"hgnc:HGNC:16039","description":null,"metadata":null},{"id":"b17a62b698544f67a9d310af75e09689","type":"GENE","name":"ANGPTL5","canonical_id":"hgnc:HGNC:19705","description":"angiopoietin like 5","metadata":null},{"id":"f42a5b56c55645829e3258961c54bec0","type":"GENE","name":"ANGPTL6","canonical_id":"hgnc:HGNC:23140","description":"angiopoietin like 6","metadata":{"aliases":["ARP5","AGF"]}},{"id":"6d346c2c52cc4e86affceae98cec1230","type":"GENE","name":"ANGPTL7","canonical_id":"hgnc:HGNC:24078","description":"angiopoietin like 7","metadata":{"aliases":["CDT6","AngX"]}},{"id":"1d2b994a2c2f43d881ce89ed445eda4b","type":"GENE","name":"ANGPTL8","canonical_id":"hgnc:HGNC:24933","description":"angiopoietin like 8","metadata":{"aliases":["TD26","RIFL","C19orf80"]}},{"id":"c4e2655ed0ff44d6955dfb739bfe9b47","type":"GENE","name":"ANHX","canonical_id":"hgnc:HGNC:40024","description":"anomalous homeobox","metadata":null},{"id":"1a558493008d4d4fa93f7f019dd3bc79","type":"GENE","name":"ANK1","canonical_id":"hgnc:HGNC:492","description":"ankyrin 1","metadata":{"aliases":["SPH1","ANK"]}},{"id":"9649b512002b44b4bd90f0bae3d85cc7","type":"GENE","name":"ANK2","canonical_id":"hgnc:HGNC:493","description":"ankyrin 2","metadata":{"aliases":["FAP87","CFAP87","LQT4"]}},{"id":"be05e11782bf4d8f8431638419025503","type":"GENE","name":"ANK2-AS1","canonical_id":"hgnc:HGNC:40076","description":"ANK2 antisense RNA 1","metadata":null},{"id":"3ef695d3e64c40ffbe48f664eb5a9ba2","type":"GENE","name":"ANK2-AS2","canonical_id":"hgnc:HGNC:58871","description":"ANK2 antisense RNA 2","metadata":null},{"id":"c8a3331aa3994e3aa69e69c5b0891298","type":"GENE","name":"ANK3","canonical_id":"hgnc:HGNC:494","description":"ankyrin 3","metadata":null},{"id":"498e6544c50646a0b062c392a602a835","type":"GENE","name":"ANK3-DT","canonical_id":"hgnc:HGNC:54102","description":"ANK3 divergent transcript","metadata":null},{"id":"1495abd31482487d919d6da39882e40b","type":"GENE","name":"ANKAR","canonical_id":"hgnc:HGNC:26350","description":"ankyrin and armadillo repeat containing","metadata":{"aliases":["FLJ25415"]}},{"id":"5711f7da2e7848e0b981d92dcc65de9c","type":"GENE","name":"ANKDD1A","canonical_id":"hgnc:HGNC:28002","description":"ankyrin repeat and death domain containing 1A","metadata":{"aliases":["FLJ25870"]}},{"id":"eb4f8c7f570046e7bfafe09e3da38bb5","type":"GENE","name":"ANKDD1B","canonical_id":"hgnc:HGNC:32525","description":"ankyrin repeat and death domain containing 1B","metadata":null},{"id":"891dfee61be042e99a946bbe340a4db9","type":"GENE","name":"ANKEF1","canonical_id":"hgnc:HGNC:15803","description":"ankyrin repeat and EF-hand domain containing 1","metadata":{"aliases":["FLJ21669","dJ839B4.6","ANKRD5"]}},{"id":"e7ed14c79eb648849f3d77f95fd8a65d","type":"GENE","name":"ANKFN1","canonical_id":"hgnc:HGNC:26766","description":"ankyrin repeat and fibronectin type III domain containing 1","metadata":{"aliases":["FLJ38335"]}},{"id":"0b98a4c53606479292041a8e0d29b8a6","type":"GENE","name":"ANKFY1","canonical_id":"hgnc:HGNC:20763","description":"ankyrin repeat and FYVE domain containing 1","metadata":{"aliases":["ANKHZN","KIAA1255","ZFYVE14","BTBD23","RANK-5"]}},{"id":"101ed1dd73534e3798464d9bef6b5c5e","type":"GENE","name":"ANKH","canonical_id":"hgnc:HGNC:15492","description":"ANKH inorganic pyrophosphate transport regulator","metadata":{"aliases":["HANK","ANK","CPPDD","SLC62A1","CCAL2","CMDJ"]}},{"id":"588e5a13a2d0405e99b6d9f449068653","type":"GENE","name":"ANKH-AS1","canonical_id":"hgnc:HGNC:59005","description":"ANKH antisense RNA 1","metadata":null},{"id":"331e3b48e3974914881106a78dc62a5f","type":"GENE","name":"ANKH-DT","canonical_id":"hgnc:HGNC:55234","description":"ANKH divergent transcript","metadata":null},{"id":"ba74d63c4a97474798103ada65c828ac","type":"GENE","name":"ANKHD1","canonical_id":"hgnc:HGNC:24714","description":"ankyrin repeat and KH domain containing 1","metadata":{"aliases":["MASK","FLJ20288","FLJ11979","FLJ10042","FLJ14127","KIAA1085","MASK1"]}},{"id":"651377e91e174e80a2e8ca25fdde35aa","type":"GENE","name":"ANKHD1-DT","canonical_id":"hgnc:HGNC:55564","description":"ANKHD1 divergent transcript","metadata":null},{"id":"da27184254cc42bf8e0ba52d29d87655","type":"GENE","name":"ANKHD1-EIF4EBP3","canonical_id":"hgnc:HGNC:33530","description":"ANKHD1-EIF4EBP3 readthrough","metadata":{"aliases":["MASK-BP3"]}},{"id":"a606ee89208d42d59d6777682ac4ec84","type":"GENE","name":"ANKIB1","canonical_id":"hgnc:HGNC:22215","description":"ankyrin repeat and IBR domain containing 1","metadata":{"aliases":["DKFZP434A0225","KIAA1386"]}},{"id":"eaab5d9cd83848269a183934389d5eb2","type":"GENE","name":"ANKK1","canonical_id":"hgnc:HGNC:21027","description":"ankyrin repeat and kinase domain containing 1","metadata":{"aliases":["X-kinase"]}},{"id":"17b4e02368fb42e8bc6669e04ed66ac7","type":"GENE","name":"ANKLE1","canonical_id":"hgnc:HGNC:26812","description":"ankyrin repeat and LEM domain containing 1","metadata":{"aliases":["FLJ39369","LEMD6","ANKRD41"]}},{"id":"0a7b6661e3a24c19b2f3aa44443e6ff7","type":"GENE","name":"ANKLE2","canonical_id":"hgnc:HGNC:29101","description":"ankyrin repeat and LEM domain containing 2","metadata":{"aliases":["LEMD7","Lem4","KIAA0692"]}},{"id":"234da82e6a4b404681bcd6210662bb47","type":"GENE","name":"ANKMY1","canonical_id":"hgnc:HGNC:20987","description":"ankyrin repeat and MYND domain containing 1","metadata":{"aliases":["FLJ20499","ZMYND13"]}},{"id":"103dae1a3def491fb5df904449e8bc29","type":"GENE","name":"ANKMY2","canonical_id":"hgnc:HGNC:25370","description":"ankyrin repeat and MYND domain containing 2","metadata":{"aliases":["DKFZP564O043","ZMYND20"]}},{"id":"c601939d4d304a97ba257b88c37468c6","type":"GENE","name":"ANKRA2","canonical_id":"hgnc:HGNC:13208","description":"ankyrin repeat family A member 2","metadata":null},{"id":"434fc4e8076a4b98b4bd89e770eb90e5","type":"GENE","name":"ANKRD1","canonical_id":"hgnc:HGNC:15819","description":null,"metadata":null},{"id":"9ba56b0ee54b44fa932d455c3939b2c2","type":"GENE","name":"ANKRD10","canonical_id":"hgnc:HGNC:20265","description":"ankyrin repeat domain 10","metadata":{"aliases":["FLJ20093"]}},{"id":"2f3f9fae00264c78b0c938e1178a89c8","type":"GENE","name":"ANKRD10-IT1","canonical_id":"hgnc:HGNC:39891","description":"ANKRD10 intronic transcript 1","metadata":null},{"id":"12f349116211462aa98d7aa6fe89189d","type":"GENE","name":"ANKRD11","canonical_id":"hgnc:HGNC:21316","description":"ankyrin repeat domain 11","metadata":{"aliases":["LZ16","T13","ANCO1","ANCO-1"]}},{"id":"27166247db77484fa2ca907f6d56bc55","type":"GENE","name":"ANKRD11-AS1","canonical_id":"hgnc:HGNC:59262","description":"ANKRD11 antisense RNA 1","metadata":null},{"id":"672109cea90d4e14a875fdec27722d4e","type":"GENE","name":"ANKRD11-AS2","canonical_id":"hgnc:HGNC:59263","description":"ANKRD11 antisense RNA 2","metadata":{"aliases":["AC137932.2"]}},{"id":"2cc88a2d537e42199bd464bc0bff0afc","type":"GENE","name":"ANKRD11-AS3","canonical_id":"hgnc:HGNC:59264","description":"ANKRD11 antisense RNA 3","metadata":null},{"id":"46ceb9b454164883acea47a8d3e4a9e9","type":"GENE","name":"ANKRD11-DT","canonical_id":"hgnc:HGNC:59261","description":"ANKRD11 divergent transcript","metadata":null},{"id":"a7016df4169b4e3381a85ceedc66f3c5","type":"GENE","name":"ANKRD11P1","canonical_id":"hgnc:HGNC:54737","description":"ANKRD11 pseudogene 1","metadata":null},{"id":"11b91ba079ce4e2fb0f91712951b66a5","type":"GENE","name":"ANKRD11P2","canonical_id":"hgnc:HGNC:54738","description":"ANKRD11 pseudogene 2","metadata":null},{"id":"7f6c114d8a454b43817cc3d4af5e9951","type":"GENE","name":"ANKRD12","canonical_id":"hgnc:HGNC:29135","description":"ankyrin repeat domain 12","metadata":{"aliases":["KIAA0874","FLJ20053","GAC-1","ANCO-2"]}},{"id":"95bb2b698d824f02a71d978610a23377","type":"GENE","name":"ANKRD13A","canonical_id":"hgnc:HGNC:21268","description":"ankyrin repeat domain 13A","metadata":{"aliases":["NY-REN-25","ANKRD13"]}},{"id":"dd79afaf8ba041d6b5d2d8cc02f9f570","type":"GENE","name":"ANKRD13B","canonical_id":"hgnc:HGNC:26363","description":"ankyrin repeat domain 13B","metadata":{"aliases":["FLJ25555"]}},{"id":"67518f9de7564571b4e24f3352f035ee","type":"GENE","name":"ANKRD13C","canonical_id":"hgnc:HGNC:25374","description":"ankyrin repeat domain 13C","metadata":{"aliases":["DKFZP566D1346","dJ677H15.3"]}},{"id":"8336ba17533f4055950860eb15f7ba5c","type":"GENE","name":"ANKRD13C-DT","canonical_id":"hgnc:HGNC:4906","description":"ANKRD13C divergent transcript","metadata":{"aliases":["HHLA3"]}},{"id":"f648df103d3f4d9d8b82b2fabda9aa31","type":"GENE","name":"ANKRD13D","canonical_id":"hgnc:HGNC:27880","description":"ankyrin repeat domain 13D","metadata":null},{"id":"9b7eb2dfcae14e61b080f4b70a7a251b","type":"GENE","name":"ANKRD16","canonical_id":"hgnc:HGNC:23471","description":"ankyrin repeat domain 16","metadata":{"aliases":["DKFZP434N1511"]}},{"id":"c5cf9b5fa50c4259bbaeb18d97c59977","type":"GENE","name":"ANKRD17","canonical_id":"hgnc:HGNC:23575","description":"ankyrin repeat domain 17","metadata":{"aliases":["GTAR","KIAA0697","FLJ22206","NY-BR-16","MASK2"]}},{"id":"d495077586b845e79a927588eed18ec9","type":"GENE","name":"ANKRD17-AS1","canonical_id":"hgnc:HGNC:58814","description":"ANKRD17 antisense RNA1","metadata":null},{"id":"d9789ea740aa45e0815baab23d056ac7","type":"GENE","name":"ANKRD17-DT","canonical_id":"hgnc:HGNC:55556","description":"ANKRD17 divergent transcript","metadata":null},{"id":"f520c0d8147c4a1c82df048b9ab94145","type":"GENE","name":"ANKRD18A","canonical_id":"hgnc:HGNC:23643","description":"ankyrin repeat domain 18A","metadata":{"aliases":["KIAA2015","FLJ35740"]}},{"id":"7866159975e644f9a5031ccf2075b9be","type":"GENE","name":"ANKRD18B","canonical_id":"hgnc:HGNC:23644","description":"ankyrin repeat domain 18B","metadata":{"aliases":["bA255A11.3"]}},{"id":"d5c09d2dc94c48569c4f68e6df8b642f","type":"GENE","name":"ANKRD18CP","canonical_id":"hgnc:HGNC:43601","description":"ankyrin repeat domain 18C, pseudogene","metadata":null},{"id":"439f4fbed7ba45b0a4fa7648f183c494","type":"GENE","name":"ANKRD18DP","canonical_id":"hgnc:HGNC:28016","description":"ankyrin repeat domain 18D, pseudogene","metadata":null},{"id":"02b0a5fce504436582a28410cf83253e","type":"GENE","name":"ANKRD18EP","canonical_id":"hgnc:HGNC:43609","description":"ankyrin repeat domain 18E, pseudogene","metadata":null},{"id":"ae12156a123a493e8825466fd9178300","type":"GENE","name":"ANKRD18FP","canonical_id":"hgnc:HGNC:56404","description":"ankyrin repeat domain 18F, pseudogene","metadata":null},{"id":"b6819b4420f144e29ef1aa61cf3cc5bd","type":"GENE","name":"ANKRD19P","canonical_id":"hgnc:HGNC:22567","description":"ankyrin repeat domain 19, pseudogene","metadata":{"aliases":["FLJ36178","ANKRD19"]}},{"id":"93f5d7ac5547498aba7392551f997243","type":"GENE","name":"ANKRD2","canonical_id":"hgnc:HGNC:495","description":"ankyrin repeat domain 2","metadata":{"aliases":["ARPP"]}},{"id":"77c282f4012c4021a55b57465ec1bcbb","type":"GENE","name":"ANKRD20A1","canonical_id":"hgnc:HGNC:23665","description":"ankyrin repeat domain 20 family member A1","metadata":{"aliases":["DKFZp434A171","ANKRD20A"]}},{"id":"d5a53e2faace4d059428704f40c4c8d8","type":"GENE","name":"ANKRD20A10P","canonical_id":"hgnc:HGNC:39707","description":"ankyrin repeat domain 20 family member A10, pseudogene","metadata":{"aliases":["ANKRD20A4P1"]}},{"id":"48d57d38683e4e6cb958416dc6349ac1","type":"GENE","name":"ANKRD20A11P","canonical_id":"hgnc:HGNC:42024","description":"ankyrin repeat domain 20 family member A11, pseudogene","metadata":{"aliases":["C21orf81"]}},{"id":"9000f9fa5c024f95ac9e9f5772333248","type":"GENE","name":"ANKRD20A12P","canonical_id":"hgnc:HGNC:43603","description":"ankyrin repeat domain 20 family member A12, pseudogene","metadata":null},{"id":"c371140430e84e7a86ef5f73d3208d2f","type":"GENE","name":"ANKRD20A13P","canonical_id":"hgnc:HGNC:43604","description":"ankyrin repeat domain 20 family member A13, pseudogene","metadata":null},{"id":"6733520439034ad59ba4abe5d113d82a","type":"GENE","name":"ANKRD20A14P","canonical_id":"hgnc:HGNC:43605","description":"ankyrin repeat domain 20 family member A14, pseudogene","metadata":null},{"id":"0e2c44c34a2241379da666b41c36c55e","type":"GENE","name":"ANKRD20A15P","canonical_id":"hgnc:HGNC:43606","description":"ankyrin repeat domain 20 family member A15, pseudogene","metadata":null},{"id":"dba8f82048274bc9a978e9e721c67478","type":"GENE","name":"ANKRD20A16P","canonical_id":"hgnc:HGNC:43607","description":"ankyrin repeat domain 20 family member A16, pseudogene","metadata":null},{"id":"a9475e123fce431cad9a6b628baca2ce","type":"GENE","name":"ANKRD20A17P","canonical_id":"hgnc:HGNC:43608","description":"ankyrin repeat domain 20 family member A17, pseudogene","metadata":null},{"id":"b7eb707011a74f9cbcecb4c39b82e7ad","type":"GENE","name":"ANKRD20A18P","canonical_id":"hgnc:HGNC:23756","description":"ankyrin repeat domain 20 family member A18, pseudogene","metadata":{"aliases":["C21orf126"]}},{"id":"95b717323c4c4a348d1c9a7e9271212d","type":"GENE","name":"ANKRD20A19P","canonical_id":"hgnc:HGNC:42737","description":"ankyrin repeat domain 20 family member A19, pseudogene","metadata":null},{"id":"7234bf4d24ac4e65beb09346d6ddc149","type":"GENE","name":"ANKRD20A20P","canonical_id":"hgnc:HGNC:32319","description":"ankyrin repeat domain 20 family member A20, pseudogene","metadata":{"aliases":["CCDC29"]}},{"id":"b4115bc254454f14a5f853f0597508fe","type":"GENE","name":"ANKRD20A21P","canonical_id":"hgnc:HGNC:52329","description":"ankyrin repeat domain 20 family member A21, pseudogene","metadata":null},{"id":"25b98b599325408b95e66e28cd62c606","type":"GENE","name":"ANKRD20A2P","canonical_id":"hgnc:HGNC:31979","description":"ankyrin repeat domain 20 family member A2, pseudogene","metadata":{"aliases":["ANKRD20A2"]}},{"id":"4d46081d93a142cc98ac6e4e2763f614","type":"GENE","name":"ANKRD20A3P","canonical_id":"hgnc:HGNC:31981","description":"ankyrin repeat domain 20 family member A3, pseudogene","metadata":{"aliases":["ANKRD20A3"]}},{"id":"88da6d37aefc48c99e061a5a2244998b","type":"GENE","name":"ANKRD20A4P","canonical_id":"hgnc:HGNC:31982","description":"ankyrin repeat domain 20 family member A4, pseudogene","metadata":{"aliases":["OTTHUMG00000066855","ANKRD20A4"]}},{"id":"f7361d8210ea4929b0f451b35cf560d3","type":"GENE","name":"ANKRD20A5P","canonical_id":"hgnc:HGNC:33833","description":"ankyrin repeat domain 20 family member A5, pseudogene","metadata":{"aliases":["MGC26718","ANKRD20A5"]}},{"id":"83a8db6a61384a7993f4e9c98ddfb673","type":"GENE","name":"ANKRD20A6P","canonical_id":"hgnc:HGNC:37714","description":"ankyrin repeat domain 20 family member A6, pseudogene","metadata":null},{"id":"41240a8fb16f4889827844e8683a6035","type":"GENE","name":"ANKRD20A7P","canonical_id":"hgnc:HGNC:31980","description":"ankyrin repeat domain 20 family member A7, pseudogene","metadata":null},{"id":"2e6c99be8d4f41d78e8b38eb2bc7c2ca","type":"GENE","name":"ANKRD20A8P","canonical_id":"hgnc:HGNC:23666","description":"ankyrin repeat domain 20 family member A8, pseudogene","metadata":{"aliases":["ANKRD20B"]}},{"id":"46545dcd624e499e9060449df0edd4ac","type":"GENE","name":"ANKRD20A9P","canonical_id":"hgnc:HGNC:42023","description":"ankyrin repeat domain 20 family member A9, pseudogene","metadata":null},{"id":"81ec241784bd499cb44fe69ff0aeeadb","type":"GENE","name":"ANKRD22","canonical_id":"hgnc:HGNC:28321","description":"ankyrin repeat domain 22","metadata":{"aliases":["MGC22805"]}},{"id":"f78d018fabc14533a256957473ddfa0c","type":"GENE","name":"ANKRD23","canonical_id":"hgnc:HGNC:24470","description":"ankyrin repeat domain 23","metadata":{"aliases":["DARP","FLJ32449","MARP3"]}},{"id":"b9228252ee584221a7e3405b672b0a01","type":"GENE","name":"ANKRD24","canonical_id":"hgnc:HGNC:29424","description":"ankyrin repeat domain 24","metadata":{"aliases":["KIAA1981"]}},{"id":"3dfd52273e984af298fe2750602ad42a","type":"GENE","name":"ANKRD26","canonical_id":"hgnc:HGNC:29186","description":"ankyrin repeat domain 26","metadata":{"aliases":["KIAA1074","THC2"]}},{"id":"9f9442e7621e4e35b94adf772df60ba8","type":"GENE","name":"ANKRD26P1","canonical_id":"hgnc:HGNC:32955","description":"ankyrin repeat domain 26 pseudogene 1","metadata":{"aliases":["FLJ43980"]}},{"id":"68964f3ba8424639acab7f9fdc58d9d1","type":"GENE","name":"ANKRD26P2","canonical_id":"hgnc:HGNC:39687","description":"ankyrin repeat domain 26 pseudogene 2","metadata":null},{"id":"2d24ca570ed042d5bd2161913ff15ef1","type":"GENE","name":"ANKRD26P3","canonical_id":"hgnc:HGNC:39689","description":"ankyrin repeat domain 26 pseudogene 3","metadata":{"aliases":["LINC00414"]}},{"id":"c3c9c4fc75d94c0faff3e1a1047155f7","type":"GENE","name":"ANKRD26P4","canonical_id":"hgnc:HGNC:39690","description":"ankyrin repeat domain 26 pseudogene 4","metadata":null},{"id":"cc66c12c180f4ba98e448ca6bcbd143f","type":"GENE","name":"ANKRD27","canonical_id":"hgnc:HGNC:25310","description":"ankyrin repeat domain 27","metadata":{"aliases":["FLJ00040","DKFZp434L0718","VARP"]}},{"id":"95927069e99f49038e92006557b3a45b","type":"GENE","name":"ANKRD27-AS1","canonical_id":"hgnc:HGNC:58574","description":"ANKRD27 antisense RNA 1","metadata":null},{"id":"a64d2f94ade44c6eaa974c8f270247c9","type":"GENE","name":"ANKRD28","canonical_id":"hgnc:HGNC:29024","description":"ankyrin repeat domain 28","metadata":{"aliases":["KIAA0379","PITK","PP6-ARS-A","PPP1R65","FAP79","CFAP79"]}},{"id":"2f23a530d7cc4f20bbdce0bb39337fc7","type":"GENE","name":"ANKRD29","canonical_id":"hgnc:HGNC:27110","description":"ankyrin repeat domain 29","metadata":{"aliases":["FLJ25053"]}},{"id":"b70930c81f384f8bb682c77ee6b637c3","type":"GENE","name":"ANKRD30A","canonical_id":"hgnc:HGNC:17234","description":"ankyrin repeat domain 30A","metadata":{"aliases":["NY-BR-1"]}},{"id":"7842e9f4d2c041cc95c895cff77f4b09","type":"GENE","name":"ANKRD30B","canonical_id":"hgnc:HGNC:24165","description":"ankyrin repeat domain 30B","metadata":{"aliases":["NY-BR-1.1"]}},{"id":"1f334683d48447beabf0c7393323527a","type":"GENE","name":"ANKRD30BL","canonical_id":"hgnc:HGNC:35167","description":"ankyrin repeat domain 30B like","metadata":{"aliases":["NCRNA00164","ANKRD30BP3"]}},{"id":"8a929d8a08e8424d9ebe2733e97e1a3b","type":"GENE","name":"ANKRD30BP1","canonical_id":"hgnc:HGNC:19722","description":"ANKRD30B pseudogene 1","metadata":{"aliases":["PRED4","C21orf110","ANKRD30BP"]}},{"id":"80f29852b52140898ca81f6ddfe5b506","type":"GENE","name":"ANKRD30BP2","canonical_id":"hgnc:HGNC:16620","description":"ANKRD30B pseudogene 2","metadata":{"aliases":["CT85","CTSP-1","C21orf99"]}},{"id":"336e969898e241e288536d6438fa979b","type":"GENE","name":"ANKRD30BP3","canonical_id":"hgnc:HGNC:27873","description":"ANKRD30B pseudogene 3","metadata":null},{"id":"88431ef10c474b769bc4473fa5479d92","type":"GENE","name":"ANKRD30BP4","canonical_id":"hgnc:HGNC:59075","description":"ANKRD30B pseudogene 4","metadata":null},{"id":"116532c161984bc78c8042618a40cbda","type":"GENE","name":"ANKRD30BP5","canonical_id":"hgnc:HGNC:59076","description":"ANKRD30B pseudogene 5","metadata":null},{"id":"9660a390042d42e683cbc5024e8f1fb4","type":"GENE","name":"ANKRD30BP6","canonical_id":"hgnc:HGNC:59077","description":"ANKRD30B pseudogene 6","metadata":null},{"id":"4e6a0101fc0541a3bf8271820a19184a","type":"GENE","name":"ANKRD31","canonical_id":"hgnc:HGNC:26853","description":"ankyrin repeat domain 31","metadata":{"aliases":["FLJ40191"]}},{"id":"e4ac7eec2a8942ffb2482608fa140ec2","type":"GENE","name":"ANKRD31-DT","canonical_id":"hgnc:HGNC:59070","description":"ANKRD31 divergent transcript","metadata":null},{"id":"d564535c09aa444ab679beab8b378206","type":"GENE","name":"ANKRD33","canonical_id":"hgnc:HGNC:13788","description":"ankyrin repeat domain 33","metadata":{"aliases":["DKFZp686O1689","PANKY","C12orf7"]}},{"id":"7f28deaed2d54e11bee99d524eca27c2","type":"GENE","name":"ANKRD33B","canonical_id":"hgnc:HGNC:35240","description":"ankyrin repeat domain 33B","metadata":null},{"id":"235ec7ddd7ea4d9f87fb5a5603d8c875","type":"GENE","name":"ANKRD33B-AS1","canonical_id":"hgnc:HGNC:41298","description":"ANKRD33B antisense RNA 1","metadata":null},{"id":"d8d718a95c0749068c900ea51aafea3c","type":"GENE","name":"ANKRD33BP1","canonical_id":"hgnc:HGNC:56293","description":"ANKRD33B pseudogene 1","metadata":null},{"id":"810fac33b40e4fdf938f9dcaa2dfce20","type":"GENE","name":"ANKRD33BP10","canonical_id":"hgnc:HGNC:56302","description":"ANKRD33B pseudogene 10","metadata":null},{"id":"1d5a1c652f8b4efe8ec8bf1189e34a9d","type":"GENE","name":"ANKRD33BP2","canonical_id":"hgnc:HGNC:56294","description":"ANKRD33B pseudogene 2","metadata":null},{"id":"8e3f74f5ba664c60b65462e5617cd802","type":"GENE","name":"ANKRD33BP3","canonical_id":"hgnc:HGNC:56295","description":"ANKRD33B pseudogene 3","metadata":null},{"id":"f13ca53956ec4026814e2ceb4a86ff1e","type":"GENE","name":"ANKRD33BP4","canonical_id":"hgnc:HGNC:56296","description":"ANKRD33B pseudogene 4","metadata":null},{"id":"7b68da4b3d4d49a6973ec4b753922124","type":"GENE","name":"ANKRD33BP5","canonical_id":"hgnc:HGNC:56297","description":"ANKRD33B pseudogene 5","metadata":null},{"id":"144e453ed54c4cb8b9839e75099cae32","type":"GENE","name":"ANKRD33BP6","canonical_id":"hgnc:HGNC:56298","description":"ANKRD33B pseudogene 6","metadata":null},{"id":"97b7b0457688478f960fa2a65ba8e066","type":"GENE","name":"ANKRD33BP7","canonical_id":"hgnc:HGNC:56299","description":"ANKRD33B pseudogene 7","metadata":null},{"id":"ab01a24c3a1248edbb122629a757fad5","type":"GENE","name":"ANKRD33BP8","canonical_id":"hgnc:HGNC:56300","description":"ANKRD33B pseudogene 8","metadata":null},{"id":"ba3c163f7b5c4e01ae1c0f47051010b1","type":"GENE","name":"ANKRD33BP9","canonical_id":"hgnc:HGNC:56301","description":"ANKRD33B pseudogene 9","metadata":null},{"id":"da77e05ab5cd4aa79db87f03eb707207","type":"GENE","name":"ANKRD34A","canonical_id":"hgnc:HGNC:27639","description":"ankyrin repeat domain 34A","metadata":{"aliases":["ANKRD34"]}},{"id":"1b33fc7520304f5dadd34ceecb63b35e","type":"GENE","name":"ANKRD34B","canonical_id":"hgnc:HGNC:33736","description":"ankyrin repeat domain 34B","metadata":{"aliases":["DP58"]}},{"id":"4e5843c7752844cb9d36934f6df18c54","type":"GENE","name":"ANKRD34C","canonical_id":"hgnc:HGNC:33888","description":"ankyrin repeat domain 34C","metadata":null},{"id":"93018877289b490aa4ac6b07a05e421a","type":"GENE","name":"ANKRD34C-AS1","canonical_id":"hgnc:HGNC:48618","description":"ANKRD34C antisense RNA 1","metadata":null},{"id":"0e9af600d93e4b7abd6faf17f72c7b75","type":"GENE","name":"ANKRD35","canonical_id":"hgnc:HGNC:26323","description":"ankyrin repeat domain 35","metadata":{"aliases":["FLJ25124"]}},{"id":"620e14a5e3a84c62aa6a3e44ebdde54d","type":"GENE","name":"ANKRD35-DT","canonical_id":"hgnc:HGNC:58407","description":"ANKRD35 divergent transcript","metadata":null},{"id":"a53fe47132af45ba9078f0107b2928e9","type":"GENE","name":"ANKRD36","canonical_id":"hgnc:HGNC:24079","description":"ankyrin repeat domain 36","metadata":{"aliases":["UNQ2430"]}},{"id":"721841db19684d12b2949047cccf42c8","type":"GENE","name":"ANKRD36B","canonical_id":"hgnc:HGNC:29333","description":"ankyrin repeat domain 36B","metadata":{"aliases":["FLJ21281","KIAA1641"]}},{"id":"5f51023f042143ab8922c3a5deb1cfa6","type":"GENE","name":"ANKRD36BP1","canonical_id":"hgnc:HGNC:28169","description":"ankyrin repeat domain 36B pseudogene 1","metadata":{"aliases":["MGC12538","ANKRD26L1","ANKRD36BL1"]}},{"id":"1b4e8846bade4581a4e784fb440cf7ec","type":"GENE","name":"ANKRD36BP2","canonical_id":"hgnc:HGNC:33607","description":"ankyrin repeat domain 36B pseudogene 2","metadata":null},{"id":"362f59a830b9419191173ecf682c1c35","type":"GENE","name":"ANKRD36C","canonical_id":"hgnc:HGNC:32946","description":"ankyrin repeat domain 36C","metadata":{"aliases":["DKFZp667P0924"]}},{"id":"861d34c2d3284dadaf0c41266c971a9a","type":"GENE","name":"ANKRD36P1","canonical_id":"hgnc:HGNC:37759","description":"ankyrin repeat domain 36 pseudogene 1","metadata":null},{"id":"16b0aa024a56440f8ec840d967efecca","type":"GENE","name":"ANKRD36P2","canonical_id":"hgnc:HGNC:56921","description":"ANKRD36 pseudogene 2","metadata":null},{"id":"309888a9553d45e08b5257b6bbfe08c6","type":"GENE","name":"ANKRD37","canonical_id":"hgnc:HGNC:29593","description":"ankyrin repeat domain 37","metadata":{"aliases":["Lrp2bp"]}},{"id":"95ba386263a4414ab7975dbe79a5dfc1","type":"GENE","name":"ANKRD39","canonical_id":"hgnc:HGNC:28640","description":"ankyrin repeat domain 39","metadata":{"aliases":["MGC41816"]}},{"id":"a2855619ac5443c28ede648906a06601","type":"GENE","name":"ANKRD39P1","canonical_id":"hgnc:HGNC:56783","description":"ANKRD39 pseudogene 1","metadata":null},{"id":"e8760fd0354f4ba29ec2f7fc12c1612d","type":"GENE","name":"ANKRD40","canonical_id":"hgnc:HGNC:28233","description":"ankyrin repeat domain 40","metadata":{"aliases":["MGC15396"]}},{"id":"6269c4cc06514cb0ac1389d865cde5da","type":"GENE","name":"ANKRD40CL","canonical_id":"hgnc:HGNC:26080","description":"ANKRD40 C-terminal like","metadata":{"aliases":["FLJ20694","C17orf73","LINC00483"]}},{"id":"36451526a8ed465fa951f1fc9f8d22cc","type":"GENE","name":"ANKRD42","canonical_id":"hgnc:HGNC:26752","description":"ankyrin repeat domain 42","metadata":{"aliases":["FLJ37874","SARP","PPP1R79"]}},{"id":"3604d64281704ea48d44925b44e0f101","type":"GENE","name":"ANKRD42-DT","canonical_id":"hgnc:HGNC:55590","description":"ANKRD42 divergent transcript","metadata":null},{"id":"92213d77fc04485caf869d97e30bbaa7","type":"GENE","name":"ANKRD44","canonical_id":"hgnc:HGNC:25259","description":"ankyrin repeat domain 44","metadata":{"aliases":["PP6-ARS-B"]}},{"id":"562c8ec951cc4d06af22be8fe8deaf7c","type":"GENE","name":"ANKRD44-AS1","canonical_id":"hgnc:HGNC:41090","description":"ANKRD44 antisense RNA 1","metadata":null},{"id":"3685922fc6f84a8399954d16c0968d15","type":"GENE","name":"ANKRD44-DT","canonical_id":"hgnc:HGNC:55840","description":"ANKRD44 divergent transcript","metadata":null},{"id":"8237228ee43b4740b5d4f60546d19d4f","type":"GENE","name":"ANKRD44-IT1","canonical_id":"hgnc:HGNC:41477","description":"ANKRD44 intronic transcript 1","metadata":null},{"id":"88b419822d9b40a5a89f973c7c070606","type":"GENE","name":"ANKRD45","canonical_id":"hgnc:HGNC:24786","description":"ankyrin repeat domain 45","metadata":{"aliases":["FLJ45235","CT117"]}},{"id":"1bfeff7e72aa4d00a68cfa9827a92f6f","type":"GENE","name":"ANKRD46","canonical_id":"hgnc:HGNC:27229","description":"ankyrin repeat domain 46","metadata":null},{"id":"bce3ee6c8e9d4f4f9ff6e57f3e290d90","type":"GENE","name":"ANKRD49","canonical_id":"hgnc:HGNC:25970","description":"ankyrin repeat domain 49","metadata":{"aliases":["FLJ20189","FGIF","GBIF"]}},{"id":"24ed499544c843339639d298e096eb4c","type":"GENE","name":"ANKRD49P1","canonical_id":"hgnc:HGNC:54619","description":"ANKRD49 pseudogene 1","metadata":null},{"id":"fb8ec23901b14d098317a8894d156301","type":"GENE","name":"ANKRD49P2","canonical_id":"hgnc:HGNC:54620","description":"ANKRD49 pseudogene 2","metadata":null},{"id":"c107214beb5b41f3b58a35cfda208fc1","type":"GENE","name":"ANKRD49P3","canonical_id":"hgnc:HGNC:54621","description":"ANKRD49 pseudogene 3","metadata":null},{"id":"ffd7e6bf1e9343299be96eb1c05d1375","type":"GENE","name":"ANKRD49P4","canonical_id":"hgnc:HGNC:54622","description":"ANKRD49 pseudogene 4","metadata":null},{"id":"8ab7d2039fd045879192ac1c4c3de90b","type":"GENE","name":"ANKRD50","canonical_id":"hgnc:HGNC:29223","description":"ankyrin repeat domain 50","metadata":{"aliases":["KIAA1223"]}},{"id":"74a130baf4ca4fe987398feb0a18fb2d","type":"GENE","name":"ANKRD52","canonical_id":"hgnc:HGNC:26614","description":"ankyrin repeat domain 52","metadata":{"aliases":["FLJ34236","PP6-ARS-C"]}},{"id":"3781843c72314798ad5ac4bee86fef20","type":"GENE","name":"ANKRD53","canonical_id":"hgnc:HGNC:25691","description":"ankyrin repeat domain 53","metadata":{"aliases":["FLJ12056","FLJ36160"]}},{"id":"648e9f7947e149668a7a390433f395c0","type":"GENE","name":"ANKRD54","canonical_id":"hgnc:HGNC:25185","description":"ankyrin repeat domain 54","metadata":{"aliases":["LIAR"]}},{"id":"1c57679de7694c53ab3bde02ea910eaa","type":"GENE","name":"ANKRD54P1","canonical_id":"hgnc:HGNC:39214","description":"ankyrin repeat domain 54 pseudogene 1","metadata":null},{"id":"8fe30e82952c4a3a9097167cebe4943d","type":"GENE","name":"ANKRD55","canonical_id":"hgnc:HGNC:25681","description":"ankyrin repeat domain 55","metadata":{"aliases":["FLJ11795"]}},{"id":"b903da47720d4cb2809f79c05e50f683","type":"GENE","name":"ANKRD55-AS1","canonical_id":"hgnc:HGNC:59048","description":"ANKRD55 antisense RNA 1","metadata":null},{"id":"6211827511eb46fd86cf0be0af01ae64","type":"GENE","name":"ANKRD6","canonical_id":"hgnc:HGNC:17280","description":"ankyrin repeat domain 6","metadata":{"aliases":["KIAA0957"]}},{"id":"b7d79d3cf43444e585ea7e33bb486010","type":"GENE","name":"ANKRD6-AS1","canonical_id":"hgnc:HGNC:40804","description":"ANKRD6 antisense RNA 1","metadata":null},{"id":"19506c2c19704f2c94d78ccbd62aed5f","type":"GENE","name":"ANKRD60","canonical_id":"hgnc:HGNC:16217","description":"ankyrin repeat domain 60","metadata":{"aliases":["bA196N14.3","C20orf86"]}},{"id":"1988d026896d4a4fa5a3a27dffbbefd4","type":"GENE","name":"ANKRD61","canonical_id":"hgnc:HGNC:22467","description":"ankyrin repeat domain 61","metadata":null},{"id":"9b4ab450c38c4a36bbe26d9e526bebe1","type":"GENE","name":"ANKRD62","canonical_id":"hgnc:HGNC:35241","description":"ankyrin repeat domain 62","metadata":{"aliases":["DKFZp779B1634"]}},{"id":"0b072ba212d640258d9d441feeef673d","type":"GENE","name":"ANKRD62P1","canonical_id":"hgnc:HGNC:42363","description":"ankyrin repeat domain 62 pseudogene 1","metadata":null},{"id":"592fd85b60b2496289f51256da5546ea","type":"GENE","name":"ANKRD62P1-PARP4P3","canonical_id":"hgnc:HGNC:42393","description":"ANKRD62P1-PARP4P3 readthrough, transcribed pseudogene","metadata":{"aliases":["VWFP1-ANKRD62P1-PARP4P3"]}},{"id":"813850a37780496b8388e747532aba5f","type":"GENE","name":"ANKRD63","canonical_id":"hgnc:HGNC:40027","description":"ankyrin repeat domain 63","metadata":null},{"id":"0b7c0c9396ba42fc829c42b4c5c3f73c","type":"GENE","name":"ANKRD65","canonical_id":"hgnc:HGNC:42950","description":"ankyrin repeat domain 65","metadata":null},{"id":"03940736b60b437a8c670951ddcf4ecf","type":"GENE","name":"ANKRD65-AS1","canonical_id":"hgnc:HGNC:55844","description":"ANKRD65 antisense RNA 1","metadata":null},{"id":"b58e8774d48b415b9fddc1fb48df357e","type":"GENE","name":"ANKRD66","canonical_id":"hgnc:HGNC:44669","description":"ankyrin repeat domain 66","metadata":null},{"id":"2aac8768a28d426cb053ebe47c2ae876","type":"GENE","name":"ANKRD66-AS1","canonical_id":"hgnc:HGNC:59419","description":"ANKRD66 antisense RNA 1","metadata":null},{"id":"a9d537de979b4e04920981cefc4de6b7","type":"GENE","name":"ANKRD7","canonical_id":"hgnc:HGNC:18588","description":"ankyrin repeat domain 7","metadata":{"aliases":["TSA806"]}},{"id":"c1f9622ae97a4e79b8e076a5356000a8","type":"GENE","name":"ANKRD9","canonical_id":"hgnc:HGNC:20096","description":"ankyrin repeat domain 9","metadata":null},{"id":"25a7332f6af04e6398ee4420a31650bb","type":"GENE","name":"ANKS1A","canonical_id":"hgnc:HGNC:20961","description":"ankyrin repeat and sterile alpha motif domain containing 1A","metadata":{"aliases":["KIAA0229","ANKS1"]}},{"id":"6b9cfb5799d346f8a937f078315c2834","type":"GENE","name":"ANKS1A-AS1","canonical_id":"hgnc:HGNC:59385","description":"ANKS1A antisense RNA 1","metadata":null},{"id":"f5a97d7462474bc19fb4e68dc023b3cc","type":"GENE","name":"ANKS1B","canonical_id":"hgnc:HGNC:24600","description":"ankyrin repeat and sterile alpha motif domain containing 1B","metadata":{"aliases":["EB-1","AIDA-1","cajalin-2","ANKS2"]}},{"id":"72d95be19d6b481a9f2d40101dccd5e2","type":"GENE","name":"ANKS3","canonical_id":"hgnc:HGNC:29422","description":"ankyrin repeat and sterile alpha motif domain containing 3","metadata":{"aliases":["KIAA1977","FLJ32345","FLJ32767"]}},{"id":"bd790a7ca4034d7b89e6b82065cb18ea","type":"GENE","name":"ANKS4B","canonical_id":"hgnc:HGNC:26795","description":"ankyrin repeat and sterile alpha motif domain containing 4B","metadata":{"aliases":["FLJ38819","HARP"]}},{"id":"1ff310d6821649b689c371bb5a317396","type":"GENE","name":"ANKS6","canonical_id":"hgnc:HGNC:26724","description":"ankyrin repeat and sterile alpha motif domain containing 6","metadata":{"aliases":["FLJ36928","NPHP16","SAMD6","ANKRD14"]}},{"id":"4a4ec8ae3d544488ade0f63e3239bd7d","type":"GENE","name":"ANKUB1","canonical_id":"hgnc:HGNC:29642","description":"ankyrin repeat and ubiquitin domain containing 1","metadata":{"aliases":["C3orf16"]}},{"id":"89471656f9794ed4b98cb0c9b92df4ff","type":"GENE","name":"ANKZF1","canonical_id":"hgnc:HGNC:25527","description":"ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1","metadata":{"aliases":["FLJ10415","ZNF744","Vms1"]}},{"id":"665c282e4ffe40ae9970b96060d68182","type":"GENE","name":"ANLN","canonical_id":"hgnc:HGNC:14082","description":"anillin, actin binding protein","metadata":{"aliases":["ANILLIN","Scraps","scra"]}},{"id":"0eab5167057548dbad76cf53fc0e8ad3","type":"GENE","name":"ANO1","canonical_id":"hgnc:HGNC:21625","description":"anoctamin 1","metadata":{"aliases":["TAOS2","FLJ10261","DOG1","ORAOV2","TMEM16A"]}},{"id":"8cba46f5c1394d5b8c52fc3dcb300ecd","type":"PROTEIN","name":"ANO1","canonical_id":"uniprot:Q5XXA6","description":null,"metadata":null},{"id":"eb1569bf1a5c4215884cc46f7e928e2c","type":"GENE","name":"ANO1-AS1","canonical_id":"hgnc:HGNC:40016","description":"ANO1 antisense RNA 1","metadata":null},{"id":"cfc25e89aa004e74869aa79d4df68e97","type":"GENE","name":"ANO10","canonical_id":"hgnc:HGNC:25519","description":"anoctamin 10","metadata":{"aliases":["FLJ10375","MGC47890","SCAR10","TMEM16K"]}},{"id":"b8710cf7aaf14a7a962969928be91f88","type":"GENE","name":"ANO2","canonical_id":"hgnc:HGNC:1183","description":"anoctamin 2","metadata":{"aliases":["C12orf3","TMEM16B"]}},{"id":"a56529c277fb40bf884cdfa8bf5bff2c","type":"GENE","name":"ANO3","canonical_id":"hgnc:HGNC:14004","description":"anoctamin 3","metadata":{"aliases":["GENX-3947","DYT23","C11orf25","TMEM16C"]}},{"id":"60ae03583076424086f3d99d9b797816","type":"GENE","name":"ANO3-AS1","canonical_id":"hgnc:HGNC:54190","description":"ANO3 antisense RNA 1","metadata":null},{"id":"969f579379984113bbd9c3852712474e","type":"GENE","name":"ANO4","canonical_id":"hgnc:HGNC:23837","description":"anoctamin 4","metadata":{"aliases":["FLJ34221","FLJ34272","FLJ35277","TMEM16D"]}},{"id":"607095fabe244b38af5f128878078855","type":"GENE","name":"ANO5","canonical_id":"hgnc:HGNC:27337","description":"anoctamin 5","metadata":{"aliases":["GDD1","TMEM16E","LGMD2L"]}},{"id":"5199616417444021a5075f5dc1165350","type":"GENE","name":"ANO6","canonical_id":"hgnc:HGNC:25240","description":"anoctamin 6","metadata":{"aliases":["DKFZp313M0720","TMEM16F"]}},{"id":"cfeb421f2ca741bfb6012f402a9ce9ad","type":"GENE","name":"ANO7","canonical_id":"hgnc:HGNC:31677","description":"anoctamin 7","metadata":{"aliases":["NGEP","PCANAP5L","IPCA-5","PCANAP5","TMEM16G"]}},{"id":"ef7aff06643d4de09cd183a6f21c03b4","type":"GENE","name":"ANO7L1","canonical_id":"hgnc:HGNC:32248","description":"anoctamin 7 like 1 (pseudogene)","metadata":{"aliases":["TMEM16M","C1orf224","ANO7P1"]}},{"id":"0933eeccb43c4b0299c6cf3ab55070cb","type":"GENE","name":"ANO8","canonical_id":"hgnc:HGNC:29329","description":"anoctamin 8","metadata":{"aliases":["KIAA1623","TMEM16H"]}},{"id":"b0e61ea624384d46aa5ed397c7ef7c4c","type":"GENE","name":"ANO9","canonical_id":"hgnc:HGNC:20679","description":"anoctamin 9","metadata":{"aliases":["PIG5","TP53I5","TMEM16J"]}},{"id":"1222025efde94a13bdfc16f5340c7097","type":"GENE","name":"ANOS1","canonical_id":"hgnc:HGNC:6211","description":"anosmin 1","metadata":{"aliases":["KALIG-1","WFDC19","KAL","ADMLX","KAL1"]}},{"id":"2fb0881ecb7945eca4db834a9adedd01","type":"GENE","name":"ANOS2P","canonical_id":"hgnc:HGNC:6214","description":"anosmin 2, pseudogene","metadata":{"aliases":["KAL-Y","ADMLY","KALP"]}},{"id":"35cf0852656c4aa8884eb582479fbd80","type":"GENE","name":"ANP32A","canonical_id":"hgnc:HGNC:13233","description":"acidic nuclear phosphoprotein 32 family member A","metadata":{"aliases":["LANP","PP32","I1PP2A","PHAPI","MAPM","mapmodulin","C15orf1"]}},{"id":"e1a307e39fd444adb63fe3051d764e8f","type":"GENE","name":"ANP32A-IT1","canonical_id":"hgnc:HGNC:25672","description":"ANP32A intronic transcript 1","metadata":{"aliases":["FLJ11722","HsT18971","C15orf28","NCRNA00321"]}},{"id":"3492ab6dc02e4eb59da993aa2637efb6","type":"GENE","name":"ANP32AP1","canonical_id":"hgnc:HGNC:42949","description":"acidic nuclear phosphoprotein 32 family member A pseudogene 1","metadata":null},{"id":"c140acee31c84660b68147ee2ce69e12","type":"GENE","name":"ANP32B","canonical_id":"hgnc:HGNC:16677","description":"acidic nuclear phosphoprotein 32 family member B","metadata":{"aliases":["SSP29","PHAPI2","APRIL"]}},{"id":"99a1917b8d5644eda731e4aa1aefae7d","type":"GENE","name":"ANP32BP1","canonical_id":"hgnc:HGNC:24267","description":"acidic nuclear phosphoprotein 32 family member B pseudogene 1","metadata":null},{"id":"551ca316de214ed7abec778d65779d49","type":"GENE","name":"ANP32BP2","canonical_id":"hgnc:HGNC:38552","description":"acidic nuclear phosphoprotein 32 family member B pseudogene 2","metadata":null},{"id":"789ece2600c046cd82371be138c15e19","type":"GENE","name":"ANP32BP3","canonical_id":"hgnc:HGNC:44089","description":"acidic nuclear phosphoprotein 32 family member B pseudogene 3","metadata":null},{"id":"ebd69fe7efe142a4800e3e45e6699f33","type":"GENE","name":"ANP32CP","canonical_id":"hgnc:HGNC:16675","description":"acidic nuclear phosphoprotein 32 family member C, pseudogene","metadata":{"aliases":["PP32R1","ANP32C"]}},{"id":"44886548916f43bb963793b268cf8f18","type":"GENE","name":"ANP32D","canonical_id":"hgnc:HGNC:16676","description":"acidic nuclear phosphoprotein 32 family member D","metadata":{"aliases":["PP32R2"]}},{"id":"ec994c937a4a4dedaee47cd6b1b54380","type":"GENE","name":"ANP32E","canonical_id":"hgnc:HGNC:16673","description":"acidic nuclear phosphoprotein 32 family member E","metadata":{"aliases":["LANPL","MGC5350","LANP-L"]}},{"id":"5bf5f06c7d76499daa13a24322c17790","type":"GENE","name":"ANPEP","canonical_id":"hgnc:HGNC:500","description":null,"metadata":null},{"id":"e55129174af04ecba89e76392adff88b","type":"GO_TERM","name":"ANPR-A receptor complex","canonical_id":"go:GO:1990620","description":"\"A receptor complex composed of two ANPR-A molecules and expressed in the heart atrium in mammals; it plays a major role in the regulation of blood pressure and salt-fluid volume homeostasis. Binding of the ligand AMP in response to atrial distension (high blood volume) leads to guanylate cyclase activity of the ANPR-A receptor complex, thereby elevating intracellular cGMP levels. The end result is a reduction in blood volume and, therefore, a reduction in cardiac output and systemic blood pressure.\" [GOC:ame, PMID:15117952]","metadata":null},{"id":"bf4f26ffe15e40f1921db1ad0f2f8998","type":"TRIAL","name":"ANTI-TAC THERAPY FOR UVEITIS","canonical_id":"clinicaltrials.gov:NCT00001526","description":"Uveitis","metadata":null},{"id":"c0bd6d3ec4cf44d292436a33edf5574f","type":"GENE","name":"ANTKMT","canonical_id":"hgnc:HGNC:14152","description":"adenine nucleotide translocase lysine methyltransferase","metadata":{"aliases":["MGC2494","C16orf24","FAM173A"]}},{"id":"bf3fbf1a881741239deb7fb0d6bf8a99","type":"GENE","name":"ANTXR1","canonical_id":"hgnc:HGNC:21014","description":null,"metadata":null},{"id":"802aeeca5d2f4d37a27dc94d42aa147f","type":"GENE","name":"ANTXR2","canonical_id":"hgnc:HGNC:21732","description":"ANTXR cell adhesion molecule 2","metadata":{"aliases":["CMG2","CMG-2","FLJ31074"]}},{"id":"b9d512266db046e8a2f479dbd097d9dd","type":"GENE","name":"ANTXRL","canonical_id":"hgnc:HGNC:27277","description":"ANTXR like","metadata":null},{"id":"257bfc4189fa4d7e95d97e9694c5f9db","type":"GENE","name":"ANTXRLP1","canonical_id":"hgnc:HGNC:45004","description":"ANTXR like pseudogene 1","metadata":null},{"id":"6cea2d85530f45b393dd34f8da3204c6","type":"GENE","name":"ANXA1","canonical_id":"hgnc:HGNC:533","description":"annexin A1","metadata":{"aliases":["ANX1","LPC1"]}},{"id":"90d9d6d8f4aa4c7fa31e58215bad0dd2","type":"GENE","name":"ANXA10","canonical_id":"hgnc:HGNC:534","description":"annexin A10","metadata":{"aliases":["ANX14"]}},{"id":"46e1c6f00c164078b0d43739c4ba3c70","type":"GENE","name":"ANXA10-AS1","canonical_id":"hgnc:HGNC:58907","description":"ANXA10 antisense RNA 1","metadata":null},{"id":"d4915de2829940b0900e4bac61785655","type":"GENE","name":"ANXA11","canonical_id":"hgnc:HGNC:535","description":"annexin A11","metadata":{"aliases":["ANX11"]}},{"id":"9f8fe6325ca449ee8bb71f75cd1e3948","type":"GENE","name":"ANXA13","canonical_id":"hgnc:HGNC:536","description":"annexin A13","metadata":{"aliases":["ANX13"]}},{"id":"2ac8f274ceaf4aa499f4778f03dffe88","type":"GENE","name":"ANXA2","canonical_id":"hgnc:HGNC:537","description":"annexin A2","metadata":{"aliases":["LIP2","ANX2","ANX2L4","CAL1H","LPC2D"]}},{"id":"4462e16fc4d04dec93e6be6cf4392dfd","type":"GENE","name":"ANXA2P1","canonical_id":"hgnc:HGNC:538","description":"annexin A2 pseudogene 1","metadata":{"aliases":["LPC2A","ANX2P1","ANX2L1"]}},{"id":"eeacf5ccd5ca4a678374650cd9cc2e62","type":"GENE","name":"ANXA2P2","canonical_id":"hgnc:HGNC:539","description":"annexin A2 pseudogene 2","metadata":{"aliases":["ANX2P2","ANX2L2","LPC2B"]}},{"id":"71c4569ddd004e6b9ae44173f8c8fe64","type":"GENE","name":"ANXA2P3","canonical_id":"hgnc:HGNC:540","description":"annexin A2 pseudogene 3","metadata":{"aliases":["LIP2","ANX2P3","ANX2L3","LPC2C"]}},{"id":"4e1a44e307df4683b69b10bc2c49ae09","type":"GENE","name":"ANXA2R","canonical_id":"hgnc:HGNC:33463","description":"annexin A2 receptor","metadata":{"aliases":["AXIIR","C5orf39"]}},{"id":"1b6757e033f941e185f7f706aae9f769","type":"GENE","name":"ANXA2R-AS1","canonical_id":"hgnc:HGNC:27208","description":"ANXA2R antisense RNA 1","metadata":null},{"id":"7712c56c626c43c4b8d36946e2e9b2ba","type":"GENE","name":"ANXA2R-OT1","canonical_id":"hgnc:HGNC:48996","description":"ANXA2R overlapping transcript 1","metadata":null},{"id":"31dddbc9f24442b0942db55a2ae2471a","type":"GENE","name":"ANXA3","canonical_id":"hgnc:HGNC:541","description":"annexin A3","metadata":{"aliases":["ANX3"]}},{"id":"5d5a41a347934deba7acba477e19fe8b","type":"GENE","name":"ANXA4","canonical_id":"hgnc:HGNC:542","description":"annexin A4","metadata":{"aliases":["ANX4"]}},{"id":"c337f59c08754c44bb1b8a8579ab990d","type":"GENE","name":"ANXA5","canonical_id":"hgnc:HGNC:543","description":"annexin A5","metadata":{"aliases":["CPB-I","PAP-I","VAC-alph","RPRGL3","ENX2","ANX5"]}},{"id":"9f2bf206c13c4383a5b65e29ff15a7c1","type":"GENE","name":"ANXA6","canonical_id":"hgnc:HGNC:544","description":"annexin A6","metadata":{"aliases":["ANX6"]}},{"id":"5778ece1d6da4a878d099faa1f88b2b4","type":"GENE","name":"ANXA7","canonical_id":"hgnc:HGNC:545","description":"annexin A7","metadata":{"aliases":["ANX7"]}},{"id":"475789e0001c41b6974dac1ca848ca5a","type":"GENE","name":"ANXA8","canonical_id":"hgnc:HGNC:546","description":null,"metadata":null},{"id":"30dc6f02ba8440adaa2bc516ae816926","type":"GENE","name":"ANXA8L1","canonical_id":"hgnc:HGNC:23334","description":"annexin A8 like 1","metadata":{"aliases":["bA301J7.3","bA145E20.2","ANXA8L2"]}},{"id":"c1e58a1515f94b0db5ef51d2c0f1a396","type":"GENE","name":"ANXA9","canonical_id":"hgnc:HGNC:547","description":"annexin A9","metadata":{"aliases":["ANX31"]}},{"id":"2470eb1f16cd48159909d0eedbd072fb","type":"GENE","name":"AOAH","canonical_id":"hgnc:HGNC:548","description":"acyloxyacyl hydrolase","metadata":null},{"id":"714e06e70a0842e3826d4a5865b34751","type":"GENE","name":"AOAH-IT1","canonical_id":"hgnc:HGNC:41307","description":"AOAH intronic transcript 1","metadata":null},{"id":"1df06b73f3524eab8f9d4009ec375bda","type":"GENE","name":"AOC1","canonical_id":"hgnc:HGNC:80","description":"amine oxidase copper containing 1","metadata":{"aliases":["DAO","ABP1","ABP"]}},{"id":"c31999ffffb04317b7cb8890ea02f628","type":"GENE","name":"AOC2","canonical_id":"hgnc:HGNC:549","description":"amine oxidase copper containing 2","metadata":{"aliases":["RAO","DAO2"]}},{"id":"ca4d0ae3f74c4719949808849a16b84d","type":"GENE","name":"AOC3","canonical_id":"hgnc:HGNC:550","description":"amine oxidase copper containing 3","metadata":{"aliases":["VAP1","HPAO","VAP-1"]}},{"id":"fa2c14fbe74c4311b811c8b9aa15080c","type":"GENE","name":"AOC4P","canonical_id":"hgnc:HGNC:48869","description":"amine oxidase copper containing 4, pseudogene","metadata":{"aliases":["UPAT"]}},{"id":"0574c3c3f89346f0b6527f14f9688a49","type":"GENE","name":"AOPEP","canonical_id":"hgnc:HGNC:1361","description":"aminopeptidase O (putative)","metadata":{"aliases":["C90RF3","FLJ14675","APO","AP-O","C9orf3"]}},{"id":"1f8734d7be714d76aec645a65d86dd68","type":"GENE","name":"AOPEP-AS1","canonical_id":"hgnc:HGNC:58217","description":"AOPEP antisense RNA 1","metadata":null},{"id":"7dc2a1ea53564e968f3536a0d56c12c7","type":"GENE","name":"AOX1","canonical_id":"hgnc:HGNC:553","description":"aldehyde oxidase 1","metadata":{"aliases":["AO","AOH1"]}},{"id":"4e6f43b696c0484494f05c099c55b5aa","type":"GENE","name":"AOX2P","canonical_id":"hgnc:HGNC:18450","description":"aldehyde oxidase 2, pseudogene","metadata":{"aliases":["AOH2","AOX2"]}},{"id":"c85cdd76a5854ffc8fe623e3c0b404d5","type":"GENE","name":"AOX3P","canonical_id":"hgnc:HGNC:19049","description":"aldehyde oxidase 3, pseudogene","metadata":{"aliases":["AOH1"]}},{"id":"dfca897956f545d59eaae8f8fe544926","type":"GENE","name":"AOX3P-AOX2P","canonical_id":"hgnc:HGNC:53766","description":"AOX3P-AOX2P readthrough, transcribed pseudogene","metadata":null},{"id":"d6c7e71dc92a418682155887676ddf1f","type":"GO_TERM","name":"AP-1 adaptor complex","canonical_id":"go:GO:0030121","description":"\"A heterotetrameric AP-type membrane coat adaptor complex that consists of beta1, gamma, mu1 and sigma1 subunits and links clathrin to the membrane surface of a vesicle; vesicles with AP-1-containing coats are normally found primarily in the trans-Golgi network. In at least humans, the AP-1 complex can be heterogeneric due to the existence of multiple subunit isoforms encoded by different genes (gamma1 and gamma2, mu1A and mu1B, and sigma1A, sigma1B and sigma1C).\" [GOC:mah, PMID:10611976, PMID:21097499]","metadata":null},{"id":"67031654f5564ca78acd63c93edf58f2","type":"GO_TERM","name":"AP-1 adaptor complex binding","canonical_id":"go:GO:0035650","description":"\"Binding to an AP-1 adaptor complex. The AP-1 adaptor complex is a heterotetrameric AP-type membrane coat adaptor complex that consists of beta1, gamma, mu1 and sigma1 subunits and links clathrin to the membrane surface of a vesicle. In at least humans, the AP-1 complex can be heterogeneric due to the existence of multiple subunit isoforms encoded by different genes (gamma1 and gamma2, mu1A and mu1B, and sigma1A, sigma1B and sigma1C).\" [PMID:21097499]","metadata":null},{"id":"e137337ed7d745038974a8bde5088bcc","type":"GO_TERM","name":"AP-2 adaptor complex","canonical_id":"go:GO:0030122","description":"\"A heterotetrameric AP-type membrane coat adaptor complex that consists of alpha, beta2, mu2 and sigma2 subunits, and links clathrin to the membrane surface of a vesicle, and the cargo receptors during receptor/clathrin mediated endocytosis. Vesicles with AP-2-containing coats are normally found primarily near the plasma membrane, on endocytic vesicles. In at least humans, the AP-2 complex can be heterogeneric due to the existence of multiple subunit isoforms encoded by different alpha genes (alphaA and alphaC).\" [GOC:mah, PMID:10611976, PMID:21097499, PMID:22022230, PMID:24322426]","metadata":null},{"id":"a48cc1774bfc4e9ea056e6d262e87b30","type":"GO_TERM","name":"AP-2 adaptor complex binding","canonical_id":"go:GO:0035612","description":"\"Binding to an AP-2 adaptor complex. The AP-2 adaptor complex is a heterotetrameric AP-type membrane coat adaptor complex that consists of alpha, beta2, mu2 and sigma2 subunits and links clathrin to the membrane surface of a vesicle. In at least humans, the AP-2 complex can be heterogeneric due to the existence of multiple subunit isoforms encoded by different alpha genes (alphaA and alphaC).\" [GOC:BHF, PMID:12221107, PMID:15728179, PMID:21097499]","metadata":null},{"id":"56dfc6d12ece44758c15b84c8bf5f153","type":"GO_TERM","name":"AP-3 adaptor complex","canonical_id":"go:GO:0030123","description":"\"A heterotetrameric AP-type membrane coat adaptor complex that consists of beta3, delta, mu3 and sigma3 subunits and is found associated with endosomal membranes. AP-3 does not appear to associate with clathrin in all organisms. In at least humans, the AP-3 complex can be heterogeneric due to the existence of multiple subunit isoforms encoded by different genes (beta3A and beta3B, mu3A and mu3B, and sigma3A and sigma3B).\" [GOC:mah, PMID:10611976, PMID:21097499]","metadata":null},{"id":"b4412e764bf14c1d98be0db80f829d79","type":"GO_TERM","name":"AP-3 adaptor complex binding","canonical_id":"go:GO:0035651","description":"\"Binding to an AP-3 adaptor complex. The AP-3 adaptor complex is a heterotetrameric AP-type membrane coat adaptor complex that consists of beta3, delta, mu3 and sigma3 subunits and is found associated with endosomal membranes. In at least humans, the AP-3 complex can be heterogeneric due to the existence of multiple subunit isoforms encoded by different genes (beta3A and beta3B, mu3A and mu3B, and sigma3A and sigma3B).\" [PMID:21097499]","metadata":null},{"id":"310e4723936b4c2f8fc639344d83b1fa","type":"GO_TERM","name":"AP-4 adaptor complex","canonical_id":"go:GO:0030124","description":"\"An AP-type membrane coat adaptor complex that consists of beta4, epsilon, mu4 and sigma4 subunits and is found associated with membranes in the trans-Golgi network; it is not clear whether AP-4 forms clathrin coats in vivo.\" [GOC:mah, PMID:10611976]","metadata":null},{"id":"4b0b7564a2f240e39ec55e02d66f45ef","type":"GO_TERM","name":"AP-5 adaptor complex","canonical_id":"go:GO:0044599","description":"\"An AP-type membrane coat adaptor complex that in humans consists of beta5, zeta, mu5 and sigma5 subunits and is found associated with membranes in the endosomes; it is not clear whether AP-5 forms clathrin coats in vivo.\" [PMID:22022230]","metadata":null},{"id":"043853dd4d454e0b9c700fdbfeac2b13","type":"GO_TERM","name":"AP-type membrane coat adaptor complex","canonical_id":"go:GO:0030119","description":"\"Any of several heterotetrameric complexes that link clathrin (or another coat-forming molecule, as hypothesized for AP-3 and AP-4) to a membrane surface; they are found on coated pits and coated vesicles, and mediate sorting of cargo proteins into vesicles. Each AP complex contains two large (a beta and one of either an alpha, gamma, delta, or epsilon) subunits (110-130 kDa), a medium (mu) subunit (approximately 50 kDa), and a small (sigma) subunit (15-20 kDa).\" [GOC:mah, PMID:10611976, PMID:15473838]","metadata":null},{"id":"8e7aeaf071fe4173865444120f289116","type":"GENE","name":"AP1AR","canonical_id":"hgnc:HGNC:28808","description":"adaptor related protein complex 1 associated regulatory protein","metadata":{"aliases":["PRO0971","2C18","gamma-BAR","C4orf16"]}},{"id":"6b1c4598be2c45b8bf810a2eed13e0fa","type":"GENE","name":"AP1AR-DT","canonical_id":"hgnc:HGNC:55391","description":"AP1AR divergent transcript","metadata":null},{"id":"e382ad587924472298ad3c0fc9b44063","type":"GENE","name":"AP1B1","canonical_id":"hgnc:HGNC:554","description":"adaptor related protein complex 1 subunit beta 1","metadata":{"aliases":["BAM22","AP105A","ADTB1","CLAPB2"]}},{"id":"5f290392a05b477f9b4b7ed92e327e28","type":"GENE","name":"AP1B1P1","canonical_id":"hgnc:HGNC:297","description":"AP1B1 pseudogene 1","metadata":{"aliases":["dJ127L4.2","ADTB1L1"]}},{"id":"7808419524c74c69915355a4c2d541f1","type":"GENE","name":"AP1B1P2","canonical_id":"hgnc:HGNC:298","description":"AP1B1 pseudogene 2","metadata":{"aliases":["dJ127L4.3","ADTB1L2"]}},{"id":"639d1fa7bae24fc0bb58504e3a4d0176","type":"GENE","name":"AP1G1","canonical_id":"hgnc:HGNC:555","description":"adaptor related protein complex 1 subunit gamma 1","metadata":{"aliases":["CLAPG1","ADTG"]}},{"id":"b4c6ac76dfc84a5cb78b0f2802eb3bae","type":"GENE","name":"AP1G2","canonical_id":"hgnc:HGNC:556","description":"adaptor related protein complex 1 subunit gamma 2","metadata":{"aliases":["G2AD"]}},{"id":"918fbb7a0ed94aca84d348702ec787e5","type":"GENE","name":"AP1G2-AS1","canonical_id":"hgnc:HGNC:55442","description":"AP1G2 antisense RNA 1","metadata":null},{"id":"ff9c396781824f8f9844ff0c83163901","type":"GENE","name":"AP1M1","canonical_id":"hgnc:HGNC:13667","description":"adaptor related protein complex 1 subunit mu 1","metadata":{"aliases":["AP47","CLAPM2","mu1A"]}},{"id":"8f27e156e7f44291b8a297df6f4ba727","type":"GENE","name":"AP1M2","canonical_id":"hgnc:HGNC:558","description":"adaptor related protein complex 1 subunit mu 2","metadata":{"aliases":["HSMU1B","mu2","AP1-mu2"]}},{"id":"675e69b136d444b4b55cacb1a3cd5617","type":"GENE","name":"AP1M2P1","canonical_id":"hgnc:HGNC:54978","description":"AP1M2 pseudogene 1","metadata":null},{"id":"555591e5e019471c8c9ad857eedbc6b0","type":"GENE","name":"AP1S1","canonical_id":"hgnc:HGNC:559","description":"adaptor related protein complex 1 subunit sigma 1","metadata":{"aliases":["AP19","SIGMA1A","WUGSC:H_DJ0747G18.2","CLAPS1","EKV3"]}},{"id":"91db2603a97f412b9c93b9ac1d0e8d5c","type":"GENE","name":"AP1S2","canonical_id":"hgnc:HGNC:560","description":"adaptor related protein complex 1 subunit sigma 2","metadata":{"aliases":["SIGMA1B","MRX59","MRXS5","PGS"]}},{"id":"f58d0f25e9384ae4a547550740df243c","type":"GENE","name":"AP1S2P1","canonical_id":"hgnc:HGNC:50752","description":"AP1S2 pseudogene 1","metadata":null},{"id":"38b234ba3abf48f68a131896810b19b9","type":"GENE","name":"AP1S2P2","canonical_id":"hgnc:HGNC:59189","description":"AP1S2 pseudogene 2","metadata":null},{"id":"6e9d0b52efee4ced8568d93982c3dcc7","type":"GENE","name":"AP1S3","canonical_id":"hgnc:HGNC:18971","description":"adaptor related protein complex 1 subunit sigma 3","metadata":{"aliases":["sigma1C"]}},{"id":"2f9d4c5c42be4291a6948344ab26f6ac","type":"GENE","name":"AP2A1","canonical_id":"hgnc:HGNC:561","description":"adaptor related protein complex 2 subunit alpha 1","metadata":{"aliases":["CLAPA1","ADTAA"]}},{"id":"5f2901bf8f3d4d659fb0423d86b1b57a","type":"GENE","name":"AP2A2","canonical_id":"hgnc:HGNC:562","description":"adaptor related protein complex 2 subunit alpha 2","metadata":{"aliases":["DKFZP564D1864","HYPJ","KIAA0899","HIP9","CLAPA2","ADTAB"]}},{"id":"6430ee0db62a4e85afc59d88cd83e8f1","type":"GENE","name":"AP2B1","canonical_id":"hgnc:HGNC:563","description":"adaptor related protein complex 2 subunit beta 1","metadata":{"aliases":["ADTB2","CLAPB1"]}},{"id":"06915a9ec89848888e32b6f2a4b04db2","type":"GENE","name":"AP2B1P1","canonical_id":"hgnc:HGNC:55017","description":"AP2B1 pseudogene 1","metadata":null},{"id":"476a4248c9f0473cb3bf93a39539606c","type":"GENE","name":"AP2M1","canonical_id":"hgnc:HGNC:564","description":"adaptor related protein complex 2 subunit mu 1","metadata":{"aliases":["AP50","mu2","CLAPM1"]}},{"id":"e22f4f43d19f49e0bc78054877693386","type":"GENE","name":"AP2S1","canonical_id":"hgnc:HGNC:565","description":"adaptor related protein complex 2 subunit sigma 1","metadata":{"aliases":["FBHOk","FBH3","CLAPS2","HHC3"]}},{"id":"6ce5b825e7ac4f6ab00378bb9057952f","type":"GENE","name":"AP3B1","canonical_id":"hgnc:HGNC:566","description":"adaptor related protein complex 3 subunit beta 1","metadata":{"aliases":["ADTB3A","HPS2"]}},{"id":"cd239d6a76b04f17a8ba6ef713342efa","type":"GENE","name":"AP3B2","canonical_id":"hgnc:HGNC:567","description":"adaptor related protein complex 3 subunit beta 2","metadata":{"aliases":["NAPTB"]}},{"id":"5bdc35ceb5c1473eb20e643d411f83de","type":"GENE","name":"AP3D1","canonical_id":"hgnc:HGNC:568","description":"adaptor related protein complex 3 subunit delta 1","metadata":{"aliases":["ADTD"]}},{"id":"d9d2150f59414fe2b3b78fb85934c737","type":"GENE","name":"AP3M1","canonical_id":"hgnc:HGNC:569","description":"adaptor related protein complex 3 subunit mu 1","metadata":null},{"id":"5bf4d8d44f984fb9913fdf266205eef8","type":"GENE","name":"AP3M2","canonical_id":"hgnc:HGNC:570","description":"adaptor related protein complex 3 subunit mu 2","metadata":{"aliases":["CLA20","AP47B"]}},{"id":"5091570d17cc4705859f4532b2b27cdd","type":"GENE","name":"AP3S1","canonical_id":"hgnc:HGNC:2013","description":"adaptor related protein complex 3 subunit sigma 1","metadata":{"aliases":["CLAPS3"]}},{"id":"6654bd613a044aa990fda777f2c9d85b","type":"GENE","name":"AP3S1P1","canonical_id":"hgnc:HGNC:56914","description":"AP3S1 pseudogene 1","metadata":null},{"id":"8864b4d583394bfc8da98aa54910a732","type":"GENE","name":"AP3S1P2","canonical_id":"hgnc:HGNC:58492","description":"AP3S1 pseudogene 2","metadata":null},{"id":"9d69ede56e4a4d9cb4a34e42bcbf8778","type":"GENE","name":"AP3S1P3","canonical_id":"hgnc:HGNC:58493","description":"AP3S1 pseudogene 3","metadata":null},{"id":"9d549e9a2c0d4878ad46fe932050c72b","type":"GENE","name":"AP3S2","canonical_id":"hgnc:HGNC:571","description":"adaptor related protein complex 3 subunit sigma 2","metadata":{"aliases":["sigma3b"]}},{"id":"27d81c34a82345f8b8fdbbf9cb2ccd43","type":"GENE","name":"AP4B1","canonical_id":"hgnc:HGNC:572","description":"adaptor related protein complex 4 subunit beta 1","metadata":{"aliases":["BETA-4","SPG47"]}},{"id":"ccb23d38a8f1484791af88d9c0f430a3","type":"GENE","name":"AP4B1-AS1","canonical_id":"hgnc:HGNC:44114","description":"AP4B1 antisense RNA 1","metadata":null},{"id":"3ca92bb764404eb9be6ec666022a37e8","type":"GENE","name":"AP4E1","canonical_id":"hgnc:HGNC:573","description":"adaptor related protein complex 4 subunit epsilon 1","metadata":{"aliases":["AP-4-EPSILON","SPG51"]}},{"id":"6ef845b6baf342869cd6ccb1d92b86bb","type":"GENE","name":"AP4M1","canonical_id":"hgnc:HGNC:574","description":"adaptor related protein complex 4 subunit mu 1","metadata":{"aliases":["MU-ARP2","MU-4","SPG50"]}},{"id":"288e2ad9f32443a1b1e2602a2ddd9370","type":"GENE","name":"AP4S1","canonical_id":"hgnc:HGNC:575","description":"adaptor related protein complex 4 subunit sigma 1","metadata":{"aliases":["CLA20","AP47B","SPG52"]}},{"id":"5c009e08672b4a7f87b9902236c5012a","type":"GENE","name":"AP5B1","canonical_id":"hgnc:HGNC:25104","description":"adaptor related protein complex 5 subunit beta 1","metadata":{"aliases":["PP1030","AP-5","DKFZp761E198"]}},{"id":"2bdf3092abc04d95b458149db0ef661a","type":"GENE","name":"AP5M1","canonical_id":"hgnc:HGNC:20192","description":"adaptor related protein complex 5 subunit mu 1","metadata":{"aliases":["FLJ10813","MuD","mu5","C14orf108","MUDENG"]}},{"id":"32392d1dd38d4b40874e13bc46e3a5a5","type":"GENE","name":"AP5S1","canonical_id":"hgnc:HGNC:15875","description":"adaptor related protein complex 5 subunit sigma 1","metadata":{"aliases":["FLJ11168","C20orf29"]}},{"id":"8ef85f51a95d46ae908154384a558d5d","type":"GENE","name":"AP5Z1","canonical_id":"hgnc:HGNC:22197","description":"adaptor related protein complex 5 subunit zeta 1","metadata":{"aliases":["SPG48","zeta","KIAA0415"]}},{"id":"8c046cae08dd48fb8b01a477ef85bf9f","type":"GENE","name":"APAF1","canonical_id":"hgnc:HGNC:576","description":null,"metadata":null},{"id":"062485fccd2f4d0b92609cef0df9c788","type":"GENE","name":"APBA1","canonical_id":"hgnc:HGNC:578","description":"amyloid beta precursor protein binding family A member 1","metadata":{"aliases":["D9S411E","X11","MINT1"]}},{"id":"81eeb388563f48669bf560cd5c19c789","type":"GENE","name":"APBA2","canonical_id":"hgnc:HGNC:579","description":"amyloid beta precursor protein binding family A member 2","metadata":{"aliases":["D15S1518E","LIN-10","MGC:14091","HsT16821","X11L","MINT2"]}},{"id":"08bdfe5f9a0547aaa8bbe8ea777cc528","type":"GENE","name":"APBA3","canonical_id":"hgnc:HGNC:580","description":"amyloid beta precursor protein binding family A member 3","metadata":{"aliases":["X11L2","mint3"]}},{"id":"15239d8fc4cd40889b45181dcfe33438","type":"GENE","name":"APBB1","canonical_id":"hgnc:HGNC:581","description":null,"metadata":null},{"id":"e76007c1dd7948b3bd310f9b8e07bbf7","type":"GENE","name":"APBB1IP","canonical_id":"hgnc:HGNC:17379","description":"amyloid beta precursor protein binding family B member 1 interacting protein","metadata":{"aliases":["RARP1","PREL1","INAG1","RIAM"]}},{"id":"58233ef97ca4446099983aee7442286f","type":"GENE","name":"APBB2","canonical_id":"hgnc:HGNC:582","description":"amyloid beta precursor protein binding family B member 2","metadata":{"aliases":["FE65L","FE65L1","MGC35575"]}},{"id":"a23ce5df348c46a194a494a279add40e","type":"GENE","name":"APBB2-AS1","canonical_id":"hgnc:HGNC:58763","description":"APBB2 antisense RNA 1","metadata":null},{"id":"d8b9c35031014f8d810d56e038c9c8f0","type":"GENE","name":"APBB3","canonical_id":"hgnc:HGNC:20708","description":"amyloid beta precursor protein binding family B member 3","metadata":{"aliases":["FE65L2"]}},{"id":"07f3737990fd43a7b476e739fc04273a","type":"GENE","name":"APC","canonical_id":"hgnc:HGNC:583","description":null,"metadata":null},{"id":"db332c8d88c8447cb63074f77183698a","type":"GENE","name":"APC","canonical_id":"ensembl:ENSG00000134982","description":null,"metadata":null},{"id":"72415d0a16594ffc90e21850e965a792","type":"GO_TERM","name":"APC-IQGAP complex","canonical_id":"go:GO:0034743","description":"\"A protein complex that contains the tumor suppressor protein adenomatous polyposis coli (APC) and the Rac1 and Cdc42 effector IQGAP1; may play a role in cytoskeleton organization and cell migration.\" [PMID:15572129]","metadata":null},{"id":"6410bbb4fb6d48869b4220322a4cc0fa","type":"GO_TERM","name":"APC-IQGAP1-CLIP-170 complex","canonical_id":"go:GO:0034746","description":"\"A protein complex that contains the tumor suppressor protein adenomatous polyposis coli (APC), the small GTPase Cdc42, and CLIP-170; may play a role in cytoskeleton organization and cell migration.\" [PMID:15572129]","metadata":null},{"id":"6e45cfbc0f1e447299fbcb19e935949a","type":"GO_TERM","name":"APC-IQGAP1-Cdc42 complex","canonical_id":"go:GO:0034744","description":"\"A protein complex that contains the tumor suppressor protein adenomatous polyposis coli (APC), the small GTPase Cdc42, and the Rac1 and Cdc42 effector IQGAP1; may play a role in cytoskeleton organization and cell migration.\" [PMID:15572129]","metadata":null},{"id":"671ae965212446a093ba9ad5b0aa17ad","type":"GO_TERM","name":"APC-IQGAP1-Rac1 complex","canonical_id":"go:GO:0034745","description":"\"A protein complex that contains the tumor suppressor protein adenomatous polyposis coli (APC), the small GTPase Rac1, and the Rac1 and Cdc42 effector IQGAP1; may play a role in cytoskeleton organization and cell migration.\" [PMID:15572129]","metadata":null},{"id":"e0001b1340254830a296ed5b24e2274f","type":"GO_TERM","name":"APC-tubulin-IQGAP1 complex","canonical_id":"go:GO:0034741","description":"\"A protein complex that contains the tumor suppressor protein adenomatous polyposis coli (APC), alpha-tubulin, gamma-tubulin, and the Rac1 and Cdc42 effector IQGAP1; may play a role in cytoskeleton organization.\" [PMID:17126424]","metadata":null},{"id":"767379e2295d47f280654ab28c62db32","type":"GENE","name":"APC2","canonical_id":"hgnc:HGNC:24036","description":"APC regulator of Wnt signaling pathway 2","metadata":{"aliases":["APCL"]}},{"id":"493952768b984313ac5e6dd1da02e1c1","type":"GENE","name":"APC2-AS1","canonical_id":"hgnc:HGNC:58571","description":"APC2 antisense RNA 1","metadata":null},{"id":"3c79f966e5b843fcb496abb534553237","type":"GENE","name":"APCDD1","canonical_id":"hgnc:HGNC:15718","description":"APC down-regulated 1","metadata":{"aliases":["B7323"]}},{"id":"fcfff832f44e4eb3975e7446eb0917b1","type":"GENE","name":"APCDD1L","canonical_id":"hgnc:HGNC:26892","description":"APC down-regulated 1 like","metadata":{"aliases":["FLJ90166"]}},{"id":"4dca5d8584e44acab3c230161524d314","type":"GENE","name":"APCDD1L-DT","canonical_id":"hgnc:HGNC:27152","description":"APCDD1L divergent transcript","metadata":{"aliases":["APCDD1L-AS1"]}},{"id":"d136b5e90c7840b7a5eb88dae3f78130","type":"GENE","name":"APCS","canonical_id":"hgnc:HGNC:584","description":null,"metadata":null},{"id":"6e14e049999549169f5bb202d5ed0975","type":"GENE","name":"APEH","canonical_id":"hgnc:HGNC:586","description":"acylaminoacyl-peptide hydrolase","metadata":{"aliases":["D3F15S2","DNF15S2","D3S48E"]}},{"id":"20b7b4e7e16f4441acb8bb3dec9415c4","type":"GENE","name":"APELA","canonical_id":"hgnc:HGNC:48925","description":"apelin receptor early endogenous ligand","metadata":{"aliases":["Ende","ELA","tdl"]}},{"id":"1bd1e032f1e24cc1b9fe43e809c88095","type":"GENE","name":"APEX1","canonical_id":"hgnc:HGNC:587","description":null,"metadata":null},{"id":"a96fe5e97f7e4dacafae336323298fe3","type":"GENE","name":"APEX2","canonical_id":"hgnc:HGNC:17889","description":"apurinic/apyrimidinic endodeoxyribonuclease 2","metadata":{"aliases":["APEXL2","APE2","XTH2","ZGRF2"]}},{"id":"ca01f5bcc3334b7da0c48446be5babdc","type":"TRIAL","name":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","canonical_id":"clinicaltrials.gov:NCT00343460","description":"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"93bc4508b54e446d97302b45f98b7e5a","type":"GENE","name":"APH1A","canonical_id":"hgnc:HGNC:29509","description":null,"metadata":null},{"id":"6dc8e1dc61a049179bad17da5485741d","type":"GENE","name":"APH1B","canonical_id":"hgnc:HGNC:24080","description":"aph-1B gamma-secretase subunit","metadata":{"aliases":["PSFL","APH-1B","DKFZp564D0372"]}},{"id":"adef31b29b0f4db38b10feac01e19b83","type":"GENE","name":"API5","canonical_id":"hgnc:HGNC:594","description":"apoptosis inhibitor 5","metadata":{"aliases":["AAC-11","API5L1","AAC11"]}},{"id":"d18b847d737a43108c1c166dbc31b874","type":"GENE","name":"API5P1","canonical_id":"hgnc:HGNC:595","description":"apoptosis inhibitor 5 pseudogene 1","metadata":{"aliases":["API5L1"]}},{"id":"23800fd381314eed927ce939c09b050c","type":"GENE","name":"API5P2","canonical_id":"hgnc:HGNC:39070","description":"apoptosis inhibitor 5 pseudogene 2","metadata":null},{"id":"de36be9667824c2289da69e99596fbee","type":"GENE","name":"APIP","canonical_id":"hgnc:HGNC:17581","description":"APAF1 interacting protein","metadata":{"aliases":["CGI-29","Mmrp19","APIP2"]}},{"id":"8a21a4aec5024b069c30ca94d22b57c6","type":"GENE","name":"APLF","canonical_id":"hgnc:HGNC:28724","description":null,"metadata":null},{"id":"7e68502004a04de89fddff3dfe10f941","type":"GENE","name":"APLN","canonical_id":"hgnc:HGNC:16665","description":"apelin","metadata":{"aliases":["apelin","XNPEP2"]}},{"id":"3d5945d280a943539e1021876497937d","type":"GENE","name":"APLNR","canonical_id":"hgnc:HGNC:339","description":null,"metadata":null},{"id":"a94b678b167441adadea050d384b137e","type":"GENE","name":"APLP1","canonical_id":"hgnc:HGNC:597","description":"amyloid beta precursor like protein 1","metadata":{"aliases":["APLP"]}},{"id":"6c2f8097c4b34fee86b00a3df17334b9","type":"GENE","name":"APLP2","canonical_id":"hgnc:HGNC:598","description":"amyloid beta precursor like protein 2","metadata":{"aliases":["APPH","APPL2"]}},{"id":"06f04e8f70a74e829ab24db1b658751e","type":"GENE","name":"APMAP","canonical_id":"hgnc:HGNC:13238","description":"adipocyte plasma membrane associated protein","metadata":{"aliases":["BSCv","C20orf3"]}},{"id":"121d2fbc04414bdf9ec1cac4d9081f43","type":"GENE","name":"APOA1","canonical_id":"hgnc:HGNC:600","description":null,"metadata":null},{"id":"81a7f677deed4185ae3875029b1cd689","type":"GENE","name":"APOA1-AS","canonical_id":"hgnc:HGNC:40079","description":"APOA1 antisense RNA","metadata":null},{"id":"4a3283f405694bc4a684877be3e94b67","type":"GENE","name":"APOA2","canonical_id":"hgnc:HGNC:601","description":null,"metadata":null},{"id":"bf0b1581fdfa4800b6c4b756431d3740","type":"GENE","name":"APOA4","canonical_id":"hgnc:HGNC:602","description":null,"metadata":null},{"id":"8c3a12fbe52a447ea28be2287e8f9ee5","type":"GENE","name":"APOA5","canonical_id":"hgnc:HGNC:17288","description":null,"metadata":null},{"id":"84545a6cfcc9419ba5bc527860438a4e","type":"GENE","name":"APOB","canonical_id":"hgnc:HGNC:603","description":null,"metadata":null},{"id":"d986a7f5ff8044b7abd7179298e0e162","type":"GENE","name":"APOBEC1","canonical_id":"hgnc:HGNC:604","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 1","metadata":{"aliases":["BEDP","CDAR1","APOBEC-1","HEPR"]}},{"id":"a21c77524b104d41a07cbca15f8def1c","type":"GENE","name":"APOBEC2","canonical_id":"hgnc:HGNC:605","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 2","metadata":{"aliases":["ARCD1","ARP1"]}},{"id":"701549ccb3994de8a1942ff7a8715d6c","type":"GENE","name":"APOBEC3A","canonical_id":"hgnc:HGNC:17343","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3A","metadata":{"aliases":["ARP3","PHRBN"]}},{"id":"fdee251810ac4f0283f45139862fee4e","type":"GENE","name":"APOBEC3AP1","canonical_id":"hgnc:HGNC:43835","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3A pseudogene 1","metadata":null},{"id":"78fbc406c92a4a0cbd573734e9c73e16","type":"GENE","name":"APOBEC3A_B","canonical_id":"hgnc:HGNC:44196","description":"APOBEC3A and APOBEC3B deletion hybrid","metadata":null},{"id":"3dcb57b4cb4741d69380e436d8c2c742","type":"GENE","name":"APOBEC3B","canonical_id":"hgnc:HGNC:17352","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3B","metadata":{"aliases":["PHRBNL","FLJ21201"]}},{"id":"69fa50ca6c044c7bbb537594d0b5ae15","type":"GENE","name":"APOBEC3B-AS1","canonical_id":"hgnc:HGNC:43836","description":"APOBEC3B antisense RNA 1","metadata":null},{"id":"a273c1443552433cb3ae299743f39575","type":"GENE","name":"APOBEC3C","canonical_id":"hgnc:HGNC:17353","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3C","metadata":{"aliases":["APOBEC1L","PBI","bK150C2.3","ARDC2","ARDC4","ARP5"]}},{"id":"b7f6fdf08a2942adbbb376736cf21d59","type":"GENE","name":"APOBEC3D","canonical_id":"hgnc:HGNC:17354","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3D","metadata":{"aliases":["ARP6","APOBEC3DE","APOBEC3E"]}},{"id":"88d8972e5a274d9ca64e780b3e617177","type":"GENE","name":"APOBEC3F","canonical_id":"hgnc:HGNC:17356","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3F","metadata":{"aliases":["ARP8","BK150C2.4.MRNA","KA6"]}},{"id":"0dbeac02dd2645ecb08375dd0cd74b76","type":"GENE","name":"APOBEC3G","canonical_id":"hgnc:HGNC:17357","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3G","metadata":{"aliases":["CEM15","MDS019","dJ494G10.1","FLJ12740","bK150C2.7"]}},{"id":"38af8f6419774f0c9e7c132af1d1a546","type":"GENE","name":"APOBEC3H","canonical_id":"hgnc:HGNC:24100","description":"apolipoprotein B mRNA editing enzyme catalytic subunit 3H","metadata":{"aliases":["ARP10"]}},{"id":"7760fa84c024492994a520f77b2a95dc","type":"GENE","name":"APOBEC4","canonical_id":"hgnc:HGNC:32152","description":"apolipoprotein B mRNA editing enzyme catalytic polypeptide like 4","metadata":{"aliases":["MGC26594","FLJ25691","RP1-127C7.4","C1orf169"]}},{"id":"ecc99eacde40403b950024da8d329b38","type":"GENE","name":"APOBR","canonical_id":"hgnc:HGNC:24087","description":null,"metadata":null},{"id":"d7e87793402a464bac97568a20bb143c","type":"GENE","name":"APOC1","canonical_id":"hgnc:HGNC:607","description":"apolipoprotein C1","metadata":{"aliases":["Apo-CI","ApoC-I","apo-CIB","apoC-IB","APOC1B"]}},{"id":"28536c2882af4e159eec8e5dbeb5c268","type":"GENE","name":"APOC1P1","canonical_id":"hgnc:HGNC:608","description":"apolipoprotein C1 pseudogene 1","metadata":{"aliases":["lincRNA-APOC1P1-3","ApoC-IA","APOC1P"]}},{"id":"b4474d3b82344babbcf5a005543e59ea","type":"GENE","name":"APOC2","canonical_id":"hgnc:HGNC:609","description":"apolipoprotein C2","metadata":null},{"id":"a73be51898a34aafb83b5649dedae2d9","type":"GENE","name":"APOC3","canonical_id":"hgnc:HGNC:610","description":null,"metadata":null},{"id":"4ba428c45f374d259e1770b97c17465e","type":"GENE","name":"APOC4","canonical_id":"hgnc:HGNC:611","description":"apolipoprotein C4","metadata":null},{"id":"83a7aa1b1cb04b0f960ae1d9ec8fccf8","type":"GENE","name":"APOC4-APOC2","canonical_id":"hgnc:HGNC:44426","description":"APOC4-APOC2 readthrough (NMD candidate)","metadata":null},{"id":"9fc0a17105ad444bb46741b5ccfdfd4f","type":"GENE","name":"APOD","canonical_id":"hgnc:HGNC:612","description":null,"metadata":null},{"id":"b2bb674feed9471a9b9d6d34e025a841","type":"GENE","name":"APOE","canonical_id":"hgnc:HGNC:613","description":null,"metadata":null},{"id":"fb3a2a09fcf5423a9e0df7befe553792","type":"GENE","name":"APOF","canonical_id":"hgnc:HGNC:615","description":"apolipoprotein F","metadata":null},{"id":"ccd5bc69b1cb4fd3ab1a4a0f63482036","type":"GENE","name":"APOH","canonical_id":"hgnc:HGNC:616","description":"apolipoprotein H","metadata":{"aliases":["BG","B2G1"]}},{"id":"ff200dc5321e4b95b2d20348564ea013","type":"GENE","name":"APOL1","canonical_id":"hgnc:HGNC:618","description":"apolipoprotein L1","metadata":{"aliases":["APOL"]}},{"id":"118fc86a1b4d4da5bdc7ae7e2391c562","type":"GENE","name":"APOL2","canonical_id":"hgnc:HGNC:619","description":"apolipoprotein L2","metadata":{"aliases":["APOL-II"]}},{"id":"3621bc14f4844929888be3db6dc26dbd","type":"GENE","name":"APOL3","canonical_id":"hgnc:HGNC:14868","description":"apolipoprotein L3","metadata":{"aliases":["CG12-1","APOLIII"]}},{"id":"10f24fe3601e4e35ba307a85373c62d6","type":"GENE","name":"APOL4","canonical_id":"hgnc:HGNC:14867","description":"apolipoprotein L4","metadata":{"aliases":["APOLIV"]}},{"id":"53bd1c42380f43d2868ab5463ebc4637","type":"GENE","name":"APOL5","canonical_id":"hgnc:HGNC:14869","description":"apolipoprotein L5","metadata":{"aliases":["APOLV"]}},{"id":"4e9a1097202d4257b205f99b0c5bc476","type":"GENE","name":"APOL6","canonical_id":"hgnc:HGNC:14870","description":"apolipoprotein L6","metadata":{"aliases":["APOL-VI","APOLVI"]}},{"id":"5e9712605f9d49bca938517c75ffe8aa","type":"GENE","name":"APOLD1","canonical_id":"hgnc:HGNC:25268","description":"apolipoprotein L domain containing 1","metadata":{"aliases":["FLJ25138","DKFZP434F0318"]}},{"id":"ea6b6b81748e43e299dc1838c4580432","type":"GENE","name":"APOLTP","canonical_id":"hgnc:HGNC:53879","description":"apolipoprotein lipid transfer particle homolog","metadata":null},{"id":"2e3c6e9aa7944455b31c356debe19be6","type":"GENE","name":"APOM","canonical_id":"hgnc:HGNC:13916","description":null,"metadata":null},{"id":"a35d2c817dd243d28ce34aca2ccecff4","type":"GENE","name":"APONP","canonical_id":"hgnc:HGNC:53942","description":"apolipoprotein N, pseudogene","metadata":null},{"id":"6af9f10f124348d9afa25c8867cc082c","type":"GENE","name":"APOO","canonical_id":"hgnc:HGNC:28727","description":"apolipoprotein O","metadata":{"aliases":["MGC4825","My025","Mic23","MIC26","MICOS26","FAM121B"]}},{"id":"0244b44a582143e7a9725de2de8c1488","type":"GENE","name":"APOOL","canonical_id":"hgnc:HGNC:24009","description":"apolipoprotein O like","metadata":{"aliases":["UNQ8193","AAIR8193","Mic27","MICOS27","CXorf33","FAM121A"]}},{"id":"b255755f09504926b6192aa4e931b7c4","type":"GENE","name":"APOOP1","canonical_id":"hgnc:HGNC:48739","description":"apolipoprotein O pseudogene 1","metadata":null},{"id":"c618450702304978b214a27971041a60","type":"GENE","name":"APOOP2","canonical_id":"hgnc:HGNC:48740","description":"apolipoprotein O pseudogene 2","metadata":null},{"id":"52a868405c4447c18533d37a48a02d99","type":"GENE","name":"APOOP3","canonical_id":"hgnc:HGNC:48741","description":"apolipoprotein O pseudogene 3","metadata":null},{"id":"3d0957a649a74dc1b935066644d6b6f5","type":"GENE","name":"APOOP4","canonical_id":"hgnc:HGNC:48742","description":"apolipoprotein O pseudogene 4","metadata":null},{"id":"fbcabf05b5034378928c81d739db435b","type":"GENE","name":"APOOP5","canonical_id":"hgnc:HGNC:48743","description":"apolipoprotein O pseudogene 5","metadata":null},{"id":"f05feb1a6851447cb23734902f9c30e2","type":"GENE","name":"APP","canonical_id":"hgnc:HGNC:620","description":null,"metadata":null},{"id":"6b41753e7f974ca8baa5acba7c6b3412","type":"PROTEIN","name":"APP","canonical_id":"uniprot:P05067","description":null,"metadata":null},{"id":"6cfc5cb309b6410db9ff973ca1503a36","type":"GENE","name":"APP-DT","canonical_id":"hgnc:HGNC:55075","description":"APP divergent transcript","metadata":null},{"id":"34ded32731ee412ca5dcae3c48edda81","type":"BIOMARKER","name":"APP::NRG1 Fusion AND KRAS Wildtype","canonical_id":"civic:5415","description":null,"metadata":null},{"id":"d2f6963d1b504708a8556c5c01c67d07","type":"GENE","name":"APPAT","canonical_id":"hgnc:HGNC:56009","description":"atherosclerotic plaque pathogenesis associated transcript","metadata":{"aliases":["AC092683.1","LINC02969"]}},{"id":"c0927b3628c94b96b865fadac8e1d016","type":"GENE","name":"APPBP2","canonical_id":"hgnc:HGNC:622","description":"amyloid beta precursor protein binding protein 2","metadata":{"aliases":["KIAA0228","Hs.84084","PAT1"]}},{"id":"99627cf405e64abcbe3b803a29412d06","type":"GENE","name":"APPBP2-DT","canonical_id":"hgnc:HGNC:55423","description":"APPBP2 divergent transcript","metadata":null},{"id":"4253ba6d1daf4ddc92d65b487e39b059","type":"GENE","name":"APPL1","canonical_id":"hgnc:HGNC:24035","description":"adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1","metadata":{"aliases":["APPL"]}},{"id":"8a12b9727c4d46f69c7d8e6f0b9d0824","type":"GENE","name":"APPL2","canonical_id":"hgnc:HGNC:18242","description":"adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2","metadata":{"aliases":["FLJ10659","DIP13B"]}},{"id":"ff65f8d5b29642be8d6baed1a659c3d1","type":"TRIAL","name":"APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin","canonical_id":"clinicaltrials.gov:NCT02850289","description":"Hepatitis C, Chronic","metadata":null},{"id":"2bfa3cf0b2c54298826ad0bbbec29b3e","type":"GENE","name":"APRG1","canonical_id":"hgnc:HGNC:24082","description":"APRG1 tumor suppressor candidate","metadata":{"aliases":["C3orf35"]}},{"id":"f43713b55f59402bb168d525b3a83c22","type":"TRIAL","name":"APROVE : Irbesartan in Hypertension","canonical_id":"clinicaltrials.gov:NCT00283036","description":"Hypertension","metadata":null},{"id":"4c6931b3e552452991bc4516c0450537","type":"GENE","name":"APRT","canonical_id":"hgnc:HGNC:626","description":"adenine phosphoribosyltransferase","metadata":null},{"id":"5582869925164db59422ddc62b03e4c3","type":"TRIAL","name":"APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)","canonical_id":"clinicaltrials.gov:NCT00657137","description":"Breast Cancer","metadata":null},{"id":"ab86389931fb4e5599a3bd9043d025d5","type":"GENE","name":"APTR","canonical_id":"hgnc:HGNC:44173","description":"Alu-mediated CDKN1A/p21 transcriptional regulator","metadata":{"aliases":["RSBN1L-AS1"]}},{"id":"818848d0d8914bb98f4a8664d934e4a1","type":"GENE","name":"APTX","canonical_id":"hgnc:HGNC:15984","description":"aprataxin","metadata":{"aliases":["FLJ20157","AOA","AOA1","EAOH","EOAHA","AXA1"]}},{"id":"c230a14fdcfd4db0abebeeab9b9223e9","type":"TRIAL","name":"APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT03164694","description":"Lung Cancer","metadata":null},{"id":"d0fa44d91a9441a2b1c574dce47b5c67","type":"TRIAL","name":"APremilast After FumaRic Acid Ester Treatment","canonical_id":"clinicaltrials.gov:NCT02954081","description":"Psoriasis","metadata":null},{"id":"fbcd3a6d882e4f7aa0ab5e02cf3366c8","type":"GENE","name":"AQP1","canonical_id":"hgnc:HGNC:633","description":"aquaporin 1 (Colton blood group)","metadata":{"aliases":["CHIP28","CO"]}},{"id":"65c96bc335294915ab2fb74f68f777b5","type":"GENE","name":"AQP10","canonical_id":"hgnc:HGNC:16029","description":"aquaporin 10","metadata":null},{"id":"2ad1026b33704d0fb39750416f354f62","type":"GENE","name":"AQP11","canonical_id":"hgnc:HGNC:19940","description":"aquaporin 11","metadata":{"aliases":["AQPX1"]}},{"id":"962221d46486424b83f244251b1bfe3e","type":"GENE","name":"AQP12A","canonical_id":"hgnc:HGNC:19941","description":"aquaporin 12A","metadata":{"aliases":["AQP12"]}},{"id":"fa8a698d2cf045408cbc300b0a15d001","type":"GENE","name":"AQP12B","canonical_id":"hgnc:HGNC:6096","description":"aquaporin 12B","metadata":{"aliases":["INSSA3"]}},{"id":"67aa93158b0c4028897e21c2d808c693","type":"GENE","name":"AQP2","canonical_id":"hgnc:HGNC:634","description":"aquaporin 2","metadata":null},{"id":"8f5365606f0e422b97ef3826bea08ce3","type":"GENE","name":"AQP3","canonical_id":"hgnc:HGNC:636","description":null,"metadata":null},{"id":"27fbde539ab84011a5c28729fc347007","type":"GENE","name":"AQP4","canonical_id":"hgnc:HGNC:637","description":"aquaporin 4","metadata":{"aliases":["MIWC","AQP-4","hAQP4"]}},{"id":"0fcf58eaca2d4bf88112ee21e5d9f88f","type":"GENE","name":"AQP4-AS1","canonical_id":"hgnc:HGNC:26399","description":"AQP4 antisense RNA 1","metadata":{"aliases":["FLJ30507","C18orf16","CHST9-AS1"]}},{"id":"f51968bc93c94f0ba95aaeef78150861","type":"GENE","name":"AQP5","canonical_id":"hgnc:HGNC:638","description":"aquaporin 5","metadata":null},{"id":"7b89f03365b543e9afe57d4dad396738","type":"GENE","name":"AQP5-AS1","canonical_id":"hgnc:HGNC:55474","description":"AQP5 and AQP2 antisense RNA 2","metadata":{"aliases":["AC025154.2","MIAC"]}},{"id":"f2f820ac50584d1089a2b54a45f360b0","type":"GENE","name":"AQP6","canonical_id":"hgnc:HGNC:639","description":"aquaporin 6","metadata":{"aliases":["AQP2L"]}},{"id":"b5fad8c893f346c780dcc066ab39630c","type":"GENE","name":"AQP7","canonical_id":"hgnc:HGNC:640","description":"aquaporin 7","metadata":{"aliases":["AQP9","AQPap","AQP7L"]}},{"id":"9cb18b4ecbc0424aa3d3f44200e34db9","type":"GENE","name":"AQP7B","canonical_id":"hgnc:HGNC:53895","description":"aquaporin 7B","metadata":null},{"id":"d006358dd2d44d4f8529b24ab66643e5","type":"GENE","name":"AQP7P1","canonical_id":"hgnc:HGNC:32048","description":"aquaporin 7 pseudogene 1","metadata":null},{"id":"33a9c505ac6a4941a790135d5a2d0972","type":"GENE","name":"AQP7P2","canonical_id":"hgnc:HGNC:32049","description":"aquaporin 7 pseudogene 2","metadata":null},{"id":"d01477749f414f7c9fb3cf1e150f1dce","type":"GENE","name":"AQP7P3","canonical_id":"hgnc:HGNC:31976","description":"aquaporin 7 pseudogene 3","metadata":{"aliases":["AQPap-3"]}},{"id":"f4576b02b6b24669834c8c18aa9771fa","type":"GENE","name":"AQP7P4","canonical_id":"hgnc:HGNC:32056","description":"aquaporin 7 pseudogene 4","metadata":null},{"id":"fc2871079c61438397febfe926311fba","type":"GENE","name":"AQP7P5","canonical_id":"hgnc:HGNC:51836","description":"aquaporin 7 pseudogene 5","metadata":null},{"id":"acbd2d36487342bf8292d13880f5c9f9","type":"GENE","name":"AQP8","canonical_id":"hgnc:HGNC:642","description":"aquaporin 8","metadata":null},{"id":"8fc22c459aac4beb889932978309a4a2","type":"GENE","name":"AQP9","canonical_id":"hgnc:HGNC:643","description":"aquaporin 9","metadata":{"aliases":["SSC1","HsT17287"]}},{"id":"84ff276b402c447581b1aed7ce2d2b76","type":"GENE","name":"AQR","canonical_id":"hgnc:HGNC:29513","description":"aquarius intron-binding spliceosomal factor","metadata":{"aliases":["KIAA0560","fSAP164","IBP160"]}},{"id":"ea6e98b3741542efaa4eda803a1f851f","type":"TRIAL","name":"AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07617337","description":"ALK Positive Non-small Cell Lung Cancer","metadata":null},{"id":"09986db9e4884f118c901d702e8ce1d3","type":"GENE","name":"AR","canonical_id":"hgnc:HGNC:644","description":null,"metadata":null},{"id":"c0c2ad329feb489fada2a5099231b48e","type":"PROTEIN","name":"AR","canonical_id":"uniprot:P10275","description":null,"metadata":null},{"id":"8869897f2fc8476691e717101e45a956","type":"GENE","name":"AR","canonical_id":"ensembl:ENSG00000169083","description":null,"metadata":null},{"id":"07da2becf2a94cb0817bc3f7f20f6eca","type":"GENE","name":"ARAF","canonical_id":"hgnc:HGNC:646","description":"A-Raf proto-oncogene, serine/threonine kinase","metadata":{"aliases":["A-Raf","ARAF1"]}},{"id":"b0b758d009f4441a9feb2e5fdee11c2c","type":"GENE","name":"ARAFP1","canonical_id":"hgnc:HGNC:50824","description":"ARAF pseudogene 1","metadata":null},{"id":"92355ff38e4a45ca9d0a79f643782f88","type":"GENE","name":"ARAFP2","canonical_id":"hgnc:HGNC:647","description":"ARAF pseudogene 2","metadata":{"aliases":["PKS1","ARAF2","ARAFPS","ARAF2P"]}},{"id":"ba1b296f821048c1b64acb5e1ee32001","type":"GENE","name":"ARAFP3","canonical_id":"hgnc:HGNC:35474","description":"ARAF pseudogene 3","metadata":{"aliases":["ARAF3P"]}},{"id":"b87f7d0f7c6a4e32ae495f0bdf448423","type":"GENE","name":"ARAP1","canonical_id":"hgnc:HGNC:16925","description":"ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1","metadata":{"aliases":["CENTD2"]}},{"id":"8c58fac7151049c3871ead7ad93c0739","type":"GENE","name":"ARAP1-AS1","canonical_id":"hgnc:HGNC:39993","description":"ARAP1 antisense RNA 1","metadata":null},{"id":"bb934d6fe7ad4839b7ae54d7261145ea","type":"GENE","name":"ARAP1-AS2","canonical_id":"hgnc:HGNC:39994","description":"ARAP1 antisense RNA 2","metadata":null},{"id":"3191434decd24126b4a80525758e3911","type":"GENE","name":"ARAP2","canonical_id":"hgnc:HGNC:16924","description":"ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2","metadata":{"aliases":["PARX","CENTD1"]}},{"id":"80d71fd6af80418e809c3e4d09025623","type":"GENE","name":"ARAP2-AS1","canonical_id":"hgnc:HGNC:58751","description":"ARAP2 antisense RNA 1","metadata":null},{"id":"d1241a197b6948b0a5be50c32a709219","type":"GENE","name":"ARAP3","canonical_id":"hgnc:HGNC:24097","description":"ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3","metadata":{"aliases":["FLJ21065","DRAG1","CENTD3"]}},{"id":"02a427844b944913b7ee79229b6948f4","type":"GENE","name":"ARAP3-DT","canonical_id":"hgnc:HGNC:59174","description":"ARAP3 divergent transcript","metadata":null},{"id":"d2a03802333045328d8f2f3e07dbedc4","type":"GENE","name":"ARB2A","canonical_id":"hgnc:HGNC:25365","description":"ARB2 cotranscriptional regulator A","metadata":{"aliases":["DKFZP564D172","Toupee","C5orf21","FAM172A"]}},{"id":"01b065e401244a8a9107b8e375890070","type":"GENE","name":"ARB2A-AS1","canonical_id":"hgnc:HGNC:59095","description":"ARB2A antisense RNA 1","metadata":null},{"id":"c0716fd7b9f54406af652ad975b49699","type":"GENE","name":"ARB2A-AS2","canonical_id":"hgnc:HGNC:59096","description":"ARB2A antisense RNA 2","metadata":null},{"id":"af5cbdfa0d7145b5a7835a6b07050050","type":"GENE","name":"ARB2A-DT","canonical_id":"hgnc:HGNC:59097","description":"ARB2A divergent transcript","metadata":null},{"id":"92c3f685a5f84aff93afda694c646fc1","type":"GENE","name":"ARB2BP","canonical_id":"hgnc:HGNC:34336","description":"ARB2 family member B, pseudogene","metadata":{"aliases":["LOC131909","FLJ45679","FAM172B","FAM172BP"]}},{"id":"c85aa27f77844f8d8fb00db42e0c0a93","type":"GENE","name":"ARC","canonical_id":"hgnc:HGNC:648","description":"activity regulated cytoskeleton associated protein","metadata":{"aliases":["KIAA0278","Arg3.1"]}},{"id":"24822e574ba0445688df1b5b47917e81","type":"GO_TERM","name":"ARC complex","canonical_id":"go:GO:0033167","description":"\"A ribonucleoprotein complex that contains members of the Argonaute family of proteins, additional protein subunits, and duplex siRNA; required for heterochromatin assembly and siRNA generation. Possibly involved in the conversion of ds siRNA to ss siRNA.\" [GOC:vw, PMID:17310250]","metadata":null},{"id":"e957a837761b491ab0efc874ac3bea08","type":"GENE","name":"ARCN1","canonical_id":"hgnc:HGNC:649","description":"archain 1 coat protein complex I subunit delta","metadata":{"aliases":["delta-COP","COPD"]}},{"id":"a10d7480d44a4ec4824985bb6b167a2e","type":"GENE","name":"AREG","canonical_id":"hgnc:HGNC:651","description":null,"metadata":null},{"id":"92ac0ca6134640fab9e5aa6e2d572b71","type":"GENE","name":"AREL1","canonical_id":"hgnc:HGNC:20363","description":"apoptosis resistant E3 ubiquitin protein ligase 1","metadata":{"aliases":["FIEL1","KIAA0317"]}},{"id":"bccd8d5eb48b423399eacc06142b2652","type":"GO_TERM","name":"ARF protein signal transduction","canonical_id":"go:GO:0032011","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the ARF subfamily relays a signal.\" [GOC:mah]","metadata":null},{"id":"94137768ff144adfbd9a0f7b2d978091","type":"GENE","name":"ARF1","canonical_id":"hgnc:HGNC:652","description":null,"metadata":null},{"id":"4a78a7340fb24eb4b3fc8f575acff4a1","type":"GENE","name":"ARF1P1","canonical_id":"hgnc:HGNC:22500","description":"ARF GTPase 1 pseudogene 1","metadata":null},{"id":"7ff52307a6db4a48931d1b61b58f9ccc","type":"GENE","name":"ARF1P2","canonical_id":"hgnc:HGNC:39883","description":"ARF GTPase 1 pseudogene 2","metadata":null},{"id":"8faa6eba976e49509ac8542d9623ffe1","type":"GENE","name":"ARF1P3","canonical_id":"hgnc:HGNC:39884","description":"ARF GTPase 1 pseudogene 3","metadata":null},{"id":"b9a0894eb73d4bbebfe070a02dc32567","type":"GENE","name":"ARF2P","canonical_id":"hgnc:HGNC:44341","description":"ARF GTPase 2, pseudogene","metadata":{"aliases":["MGC57346"]}},{"id":"b5549de98a8f475f8a3d6dbff5f011ca","type":"GENE","name":"ARF3","canonical_id":"hgnc:HGNC:654","description":"ARF GTPase 3","metadata":null},{"id":"35f15965656e47eab30ad951a84f30de","type":"GENE","name":"ARF4","canonical_id":"hgnc:HGNC:655","description":"ARF GTPase 4","metadata":{"aliases":["ARF2"]}},{"id":"204daf0f298441ac8b5fe664cc3f82dc","type":"GENE","name":"ARF4-AS1","canonical_id":"hgnc:HGNC:51593","description":"ARF4 antisense RNA 1","metadata":null},{"id":"79816f4a3e9042aa9aedbefcb344e6fc","type":"GENE","name":"ARF4P1","canonical_id":"hgnc:HGNC:657","description":"ARF GTPase 4 pseudogene 1","metadata":{"aliases":["ARF4P"]}},{"id":"956e96d2d54d4063b4f067882c3bfb49","type":"GENE","name":"ARF4P2","canonical_id":"hgnc:HGNC:16599","description":"ARF GTPase 4 pseudogene 2","metadata":{"aliases":["dJ885L7.7"]}},{"id":"b2775f494a2b4c63b34948791e5eb954","type":"GENE","name":"ARF4P3","canonical_id":"hgnc:HGNC:32380","description":"ARF GTPase 4 pseudogene 3","metadata":null},{"id":"8327fe472d9543978b722d82178bddad","type":"GENE","name":"ARF4P4","canonical_id":"hgnc:HGNC:37628","description":"ARF GTPase 4 pseudogene 4","metadata":null},{"id":"32733b09c4e745f489b5868fc61da193","type":"GENE","name":"ARF4P5","canonical_id":"hgnc:HGNC:37629","description":"ARF GTPase 4 pseudogene 5","metadata":null},{"id":"c21e4a29c1454f01b52fc45957b7cdc0","type":"GENE","name":"ARF5","canonical_id":"hgnc:HGNC:658","description":"ARF GTPase 5","metadata":null},{"id":"60ccdfa2b988427f887536d051cebe85","type":"GENE","name":"ARF6","canonical_id":"hgnc:HGNC:659","description":null,"metadata":null},{"id":"9baabf9cfefc471ea4cb7030abd03850","type":"GENE","name":"ARFGAP1","canonical_id":"hgnc:HGNC:15852","description":"ARF GTPase activating protein 1","metadata":{"aliases":["FLJ10767","bA261N11.3","ARF1GAP"]}},{"id":"a1efea4dded843cbba02ef9a182a5d43","type":"GENE","name":"ARFGAP2","canonical_id":"hgnc:HGNC:13504","description":"ARF GTPase activating protein 2","metadata":{"aliases":["IRZ","Zfp289","FLJ14576","ZNF289"]}},{"id":"6f2e4966138248189ecdf839ae864aba","type":"GENE","name":"ARFGAP3","canonical_id":"hgnc:HGNC:661","description":"ARF GTPase activating protein 3","metadata":{"aliases":["ARFGAP1"]}},{"id":"d3cc325f37f84ac499e9019d484158e5","type":"GENE","name":"ARFGEF1","canonical_id":"hgnc:HGNC:15772","description":"ARF guanine nucleotide exchange factor 1","metadata":{"aliases":["DKFZP434L057","BIG1","ARFGEP1","p200"]}},{"id":"2c225b24b0a74589816e304bfceb8c41","type":"GENE","name":"ARFGEF1-DT","canonical_id":"hgnc:HGNC:55237","description":"ARFGEF1 divergent transcript","metadata":{"aliases":["lncDDR","AC021321.1"]}},{"id":"00f3c82845bb480fb89085f3d9554d4a","type":"GENE","name":"ARFGEF2","canonical_id":"hgnc:HGNC:15853","description":"ARF guanine nucleotide exchange factor 2","metadata":{"aliases":["BIG2"]}},{"id":"c659d371301744e8b16dff5f8820a35e","type":"GENE","name":"ARFGEF3","canonical_id":"hgnc:HGNC:21213","description":"ARFGEF family member 3","metadata":{"aliases":["dJ171N11.1","BIG3","PPP1R33","C6orf92","KIAA1244"]}},{"id":"fa9637fbdb174376ab14c930ade3d972","type":"GENE","name":"ARFIP1","canonical_id":"hgnc:HGNC:21496","description":"ARF interacting protein 1","metadata":{"aliases":["HSU52521"]}},{"id":"f7251af745aa43d083e38eae4f8158de","type":"GENE","name":"ARFIP2","canonical_id":"hgnc:HGNC:17160","description":"ARF interacting protein 2","metadata":{"aliases":["POR1"]}},{"id":"432adbf843fb4291abf3c16007883fc2","type":"GENE","name":"ARFRP1","canonical_id":"hgnc:HGNC:662","description":"ARF related protein 1","metadata":{"aliases":["ARP","Arp1","ARL18"]}},{"id":"8def7a088766429ebaec5bd3b22b3b17","type":"GENE","name":"ARG1","canonical_id":"hgnc:HGNC:663","description":null,"metadata":null},{"id":"b4d853b4628640a4a8020a861efbb44e","type":"GENE","name":"ARG2","canonical_id":"hgnc:HGNC:664","description":null,"metadata":null},{"id":"a3ad311b19e3423795d7c4a03b3c94a8","type":"GENE","name":"ARG2P1","canonical_id":"hgnc:HGNC:58660","description":"ARG2 pseudogene 1","metadata":null},{"id":"ee63db68e2434e98ba31326cfa830f15","type":"GENE","name":"ARGFX","canonical_id":"hgnc:HGNC:30146","description":"arginine-fifty homeobox","metadata":null},{"id":"4490b2cab9004ecabe5c415eaa5e4c0e","type":"GENE","name":"ARGFXP1","canonical_id":"hgnc:HGNC:17252","description":"arginine-fifty homeobox pseudogene 1","metadata":null},{"id":"a80341f89120446aaff0e639dd942ca8","type":"GENE","name":"ARGFXP2","canonical_id":"hgnc:HGNC:23977","description":"arginine-fifty homeobox pseudogene 2","metadata":null},{"id":"ad00f55cda0642b7803593090d00d03e","type":"GENE","name":"ARGLU1","canonical_id":"hgnc:HGNC:25482","description":"arginine and glutamate rich 1","metadata":{"aliases":["FLJ10154"]}},{"id":"fb09999b8d174207bdd1f9d45905f6c5","type":"GENE","name":"ARGLU1-DT","canonical_id":"hgnc:HGNC:43691","description":"ARGLU1 divergent transcript","metadata":{"aliases":["LINC00443","LINC00551"]}},{"id":"4602fb2046c0432ea7190f617f922a35","type":"GENE","name":"ARHGAP1","canonical_id":"hgnc:HGNC:673","description":"Rho GTPase activating protein 1","metadata":{"aliases":["RhoGAP","p50rhoGAP","CDC42GAP","Cdc42GAP"]}},{"id":"b702204b62694a54a6b1c30a3fa5ced0","type":"GENE","name":"ARHGAP10","canonical_id":"hgnc:HGNC:26099","description":"Rho GTPase activating protein 10","metadata":{"aliases":["FLJ20896","FLJ41791","GRAF2"]}},{"id":"f0c9544a35ed4b9c8bed270ab88aa0be","type":"GENE","name":"ARHGAP11A","canonical_id":"hgnc:HGNC:15783","description":"Rho GTPase activating protein 11A","metadata":{"aliases":["KIAA0013"]}},{"id":"2de65c5ccec440d596baa76cdf2d0673","type":"GENE","name":"ARHGAP11A-DT","canonical_id":"hgnc:HGNC:56188","description":"ARHGAP11A divergent transcript","metadata":null},{"id":"fcc70b7521d347eab19a72c8a39d5fa7","type":"GENE","name":"ARHGAP11A-SCG5","canonical_id":"hgnc:HGNC:56310","description":"ARHGAP11A-SCG5 readthrough","metadata":null},{"id":"ac726737a41847d8918e22b139b3e503","type":"GENE","name":"ARHGAP11B","canonical_id":"hgnc:HGNC:15782","description":"Rho GTPase activating protein 11B","metadata":{"aliases":["B'-T","FAM7B1"]}},{"id":"654b1512d5ab4909881dd9c33ac14b84","type":"GENE","name":"ARHGAP11B-DT","canonical_id":"hgnc:HGNC:55586","description":"ARHGAP11B divergent transcript","metadata":null},{"id":"2b1d5a62f05049a6bcc53709d5092e51","type":"GENE","name":"ARHGAP12","canonical_id":"hgnc:HGNC:16348","description":"Rho GTPase activating protein 12","metadata":{"aliases":["FLJ20737","FLJ10971","FLJ21785"]}},{"id":"7fcbf2ab77cc4f26b3e58dad32765692","type":"GENE","name":"ARHGAP15","canonical_id":"hgnc:HGNC:21030","description":"Rho GTPase activating protein 15","metadata":{"aliases":["BM046"]}},{"id":"cb74ca60dc8b45f3b18a47846d5983ac","type":"GENE","name":"ARHGAP15-AS1","canonical_id":"hgnc:HGNC:40949","description":"ARHGAP15 antisense RNA 1","metadata":null},{"id":"266dd953e54c4cd7b9d329ead2ab2666","type":"GENE","name":"ARHGAP16P","canonical_id":"hgnc:HGNC:19921","description":"Rho GTPase activating protein 16, pseudogene","metadata":{"aliases":["ARHGAP15P"]}},{"id":"25acbf9fe16c42dbba90ce7d45f7f06f","type":"GENE","name":"ARHGAP17","canonical_id":"hgnc:HGNC:18239","description":"Rho GTPase activating protein 17","metadata":{"aliases":["RICH1","FLJ10308","NADRIN","FLJ13219","WBP15"]}},{"id":"84488ad4b92442aeb3312956021080bc","type":"GENE","name":"ARHGAP18","canonical_id":"hgnc:HGNC:21035","description":"Rho GTPase activating protein 18","metadata":{"aliases":["MacGAP","bA307O14.2","SENEX"]}},{"id":"e6d2ebd9a6d9446a9e657ef3553a1e64","type":"GENE","name":"ARHGAP19","canonical_id":"hgnc:HGNC:23724","description":"Rho GTPase activating protein 19","metadata":{"aliases":["FLJ00194","MGC14258"]}},{"id":"022ccea9102e4327a8cf8ad76bf98470","type":"GENE","name":"ARHGAP19-SLIT1","canonical_id":"hgnc:HGNC:48348","description":"ARHGAP19-SLIT1 readthrough (NMD candidate)","metadata":null},{"id":"1ace207c48c144adbcfcfa811b0353fa","type":"GENE","name":"ARHGAP20","canonical_id":"hgnc:HGNC:18357","description":"Rho GTPase activating protein 20","metadata":{"aliases":["KIAA1391"]}},{"id":"85118ae67c8848a2993d2dca9b9633de","type":"GENE","name":"ARHGAP21","canonical_id":"hgnc:HGNC:23725","description":"Rho GTPase activating protein 21","metadata":{"aliases":["KIAA1424","ARHGAP10"]}},{"id":"b4abf58da14a41c8858b56d7c36efb55","type":"GENE","name":"ARHGAP22","canonical_id":"hgnc:HGNC:30320","description":"Rho GTPase activating protein 22","metadata":{"aliases":["RhoGAP2"]}},{"id":"331144fbd0d042c2acf5d33241c4a4dd","type":"GENE","name":"ARHGAP22-IT1","canonical_id":"hgnc:HGNC:42944","description":"ARHGAP22 intronic transcript 1","metadata":{"aliases":["FLJ35752"]}},{"id":"3e0538518a5e47799769070730e542fb","type":"GENE","name":"ARHGAP23","canonical_id":"hgnc:HGNC:29293","description":"Rho GTPase activating protein 23","metadata":{"aliases":["KIAA1501"]}},{"id":"700dbd739e144dec8048f2f8f651f993","type":"GENE","name":"ARHGAP23P1","canonical_id":"hgnc:HGNC:45039","description":"ARHGAP23 pseudogene 1","metadata":null},{"id":"c8820078cc9e4b91bff4da9d91ab6c6e","type":"GENE","name":"ARHGAP23P2","canonical_id":"hgnc:HGNC:59243","description":"ARHGAP23 pseudogene 2","metadata":null},{"id":"5b67385e14094c56b8efc843daa25f80","type":"GENE","name":"ARHGAP24","canonical_id":"hgnc:HGNC:25361","description":"Rho GTPase activating protein 24","metadata":{"aliases":["DKFZP564B1162","FLJ33877","FilGAP"]}},{"id":"deff1528b181437f9dcca40def9b1963","type":"GENE","name":"ARHGAP24-AS1","canonical_id":"hgnc:HGNC:58841","description":"ARHGAP24 antisense RNA 1","metadata":null},{"id":"a5adb4e25dcc42d98949a42d1c2a5589","type":"GENE","name":"ARHGAP25","canonical_id":"hgnc:HGNC:28951","description":"Rho GTPase activating protein 25","metadata":{"aliases":["KIAA0053"]}},{"id":"c366daaad957403096cfd7cc5812dfc3","type":"GENE","name":"ARHGAP26","canonical_id":"hgnc:HGNC:17073","description":"Rho GTPase activating protein 26","metadata":{"aliases":["GRAF","KIAA0621","OPHN1L","OPHN1L1"]}},{"id":"34ea53c936af41f1a5329266f8bd5acb","type":"GENE","name":"ARHGAP26-AS1","canonical_id":"hgnc:HGNC:40792","description":"ARHGAP26 antisense RNA 1","metadata":null},{"id":"3b8b51384c054a80b653eb66b26132f0","type":"GENE","name":"ARHGAP26-IT1","canonical_id":"hgnc:HGNC:41429","description":"ARHGAP26 intronic transcript 1","metadata":null},{"id":"5574824fbaef4578a5a261204c1fbceb","type":"GENE","name":"ARHGAP27","canonical_id":"hgnc:HGNC:31813","description":"Rho GTPase activating protein 27","metadata":{"aliases":["CAMGAP1","FLJ43547","SH3P20","SH3D20"]}},{"id":"e31939d387784c61a8bffb4d11c994fe","type":"GENE","name":"ARHGAP27P1","canonical_id":"hgnc:HGNC:28630","description":"Rho GTPase activating protein 27 pseudogene 1","metadata":{"aliases":["loc146880"]}},{"id":"f93d4bdeec68453981e58f4610372cfd","type":"GENE","name":"ARHGAP27P1-BPTFP1-KPNA2P3","canonical_id":"hgnc:HGNC:52873","description":"ARHGAP27P1-BPTFP1-KPNA2P3 readthrough, transcribed pseudogene","metadata":null},{"id":"208e5ab6e29d4452ab1421d172717477","type":"GENE","name":"ARHGAP27P2","canonical_id":"hgnc:HGNC:53771","description":"Rho GTPase activating protein 27 pseudogene 2","metadata":null},{"id":"9f537815efbb4c039abdf4fbbb61da1d","type":"GENE","name":"ARHGAP28","canonical_id":"hgnc:HGNC:25509","description":"Rho GTPase activating protein 28","metadata":{"aliases":["KIAA1314","FLJ10312"]}},{"id":"3002f884896d4272966ce9600d74b1b6","type":"GENE","name":"ARHGAP28-AS1","canonical_id":"hgnc:HGNC:55320","description":"ARHGAP28 antisense RNA 1","metadata":null},{"id":"1730572ce5ca47e18f6802c57f8ce6b5","type":"GENE","name":"ARHGAP29","canonical_id":"hgnc:HGNC:30207","description":"Rho GTPase activating protein 29","metadata":{"aliases":["PARG1"]}},{"id":"95cd2fbdda0a41079314beae5f801460","type":"GENE","name":"ARHGAP29-AS1","canonical_id":"hgnc:HGNC:54311","description":"ARHGAP29 antisense RNA 1","metadata":null},{"id":"ce407d75f3e04f0aa303b8313e1a5c54","type":"GENE","name":"ARHGAP30","canonical_id":"hgnc:HGNC:27414","description":"Rho GTPase activating protein 30","metadata":{"aliases":["FLJ00267"]}},{"id":"fc26fbc929714caca3502088b145d891","type":"GENE","name":"ARHGAP31","canonical_id":"hgnc:HGNC:29216","description":"Rho GTPase activating protein 31","metadata":{"aliases":["CDGAP"]}},{"id":"5b807418fe10421e9827b9fe36927812","type":"GENE","name":"ARHGAP31-AS1","canonical_id":"hgnc:HGNC:41235","description":"ARHGAP31 antisense RNA 1","metadata":null},{"id":"a1c06df77ec846d2a419862e17af66bd","type":"GENE","name":"ARHGAP32","canonical_id":"hgnc:HGNC:17399","description":"Rho GTPase activating protein 32","metadata":{"aliases":["GRIT","KIAA0712","MGC1892","RICS","GC-GAP"]}},{"id":"88783cbfaa114941a49f2c4d62f1434a","type":"GENE","name":"ARHGAP33","canonical_id":"hgnc:HGNC:23085","description":"Rho GTPase activating protein 33","metadata":{"aliases":["FLJ39019","TCGAP","SNX26"]}},{"id":"e2dd7a19ace74d349e8fd3946a7a8045","type":"GENE","name":"ARHGAP35","canonical_id":"hgnc:HGNC:4591","description":"Rho GTPase activating protein 35","metadata":{"aliases":["GRF-1","p190ARhoGAP","P190A","KIAA1722","p190RhoGAP","GRLF1"]}},{"id":"416cfab0f48e448da6e542577ef61252","type":"GENE","name":"ARHGAP36","canonical_id":"hgnc:HGNC:26388","description":"Rho GTPase activating protein 36","metadata":{"aliases":["FLJ30058"]}},{"id":"ea303453a5a04c7587f261d99bdf061d","type":"GENE","name":"ARHGAP39","canonical_id":"hgnc:HGNC:29351","description":"Rho GTPase activating protein 39","metadata":{"aliases":["KIAA1688","Vilse","CrGAP"]}},{"id":"eb4623e1ed9341c49502893d0c3926aa","type":"GENE","name":"ARHGAP4","canonical_id":"hgnc:HGNC:674","description":"Rho GTPase activating protein 4","metadata":{"aliases":["KIAA0131","C1","p115","RhoGAP4","SrGAP4"]}},{"id":"4b1a8ba9f64642b19f22eb907374ae1c","type":"GENE","name":"ARHGAP40","canonical_id":"hgnc:HGNC:16226","description":"Rho GTPase activating protein 40","metadata":{"aliases":["dJ1100H13.4","C20orf95"]}},{"id":"f8d595a1abe04eb281c39d0ef925a4d0","type":"GENE","name":"ARHGAP42","canonical_id":"hgnc:HGNC:26545","description":"Rho GTPase activating protein 42","metadata":{"aliases":["FLJ32810","GRAF3","AD031","TMEM133"]}},{"id":"094df0407f694d51a7a1ac966ea7eb50","type":"GENE","name":"ARHGAP42-AS1","canonical_id":"hgnc:HGNC:54801","description":"ARHGAP42 antisense RNA 1","metadata":{"aliases":["AK124326"]}},{"id":"893168f222934503ac845bb6cf44e62f","type":"GENE","name":"ARHGAP42P1","canonical_id":"hgnc:HGNC:43940","description":"ARHGAP42 pseudogene 1","metadata":null},{"id":"38eb7902de6f4679b4d3ff88e40221db","type":"GENE","name":"ARHGAP42P2","canonical_id":"hgnc:HGNC:43939","description":"ARHGAP42 pseudogene 2","metadata":null},{"id":"25a8da10ead548d89c93bbd6029f98a4","type":"GENE","name":"ARHGAP42P3","canonical_id":"hgnc:HGNC:19327","description":"ARHGAP42 pseudogene 3","metadata":{"aliases":["OPHN1P1"]}},{"id":"573ff409c955402fab7e9872db628ea3","type":"GENE","name":"ARHGAP42P4","canonical_id":"hgnc:HGNC:43941","description":"ARHGAP42 pseudogene 4","metadata":null},{"id":"bf5313660b40444695924880f298454d","type":"GENE","name":"ARHGAP42P5","canonical_id":"hgnc:HGNC:43942","description":"ARHGAP42 pseudogene 5","metadata":null},{"id":"5638e1b2dc874fd6a01eaccb6555005b","type":"GENE","name":"ARHGAP44","canonical_id":"hgnc:HGNC:29096","description":"Rho GTPase activating protein 44","metadata":{"aliases":["KIAA0672","RICH-2","RICH2"]}},{"id":"450089d549f048b689b195c8764c481a","type":"GENE","name":"ARHGAP44-AS1","canonical_id":"hgnc:HGNC:55326","description":"ARHGAP44 and MYOCD antisense RNA 1","metadata":null},{"id":"e0f257c5aa56466895ad8a5278f33bc1","type":"GENE","name":"ARHGAP45","canonical_id":"hgnc:HGNC:17102","description":"Rho GTPase activating protein 45","metadata":{"aliases":["KIAA0223","HA-1","HMHA1"]}},{"id":"3a31ea03231b4c3e978de078fb310c44","type":"GENE","name":"ARHGAP5","canonical_id":"hgnc:HGNC:675","description":"Rho GTPase activating protein 5","metadata":{"aliases":["RhoGAP5","p190-B","p190BRhoGAP","GFI2"]}},{"id":"65ac8fcdd55d4c188ca1ed669d7e1ef7","type":"GENE","name":"ARHGAP5-AS1","canonical_id":"hgnc:HGNC:20279","description":"ARHGAP5 antisense RNA 1 (head to head)","metadata":{"aliases":["MGC15504","C14orf128"]}},{"id":"40f7689a993b40058274d6adafbb7749","type":"GENE","name":"ARHGAP6","canonical_id":"hgnc:HGNC:676","description":"Rho GTPase activating protein 6","metadata":{"aliases":["rhoGAPX-1"]}},{"id":"149cfa832aaa476e9f7f9c348bdba3d9","type":"GENE","name":"ARHGAP8","canonical_id":"hgnc:HGNC:677","description":"Rho GTPase activating protein 8","metadata":{"aliases":["FLJ20185","BPGAP1"]}},{"id":"fd0ea1d535354d079d2a340850f3a4d8","type":"GENE","name":"ARHGAP9","canonical_id":"hgnc:HGNC:14130","description":"Rho GTPase activating protein 9","metadata":{"aliases":["MGC1295","10C"]}},{"id":"b37caf03ebd144d682571db76c0f1d91","type":"GENE","name":"ARHGDIA","canonical_id":"hgnc:HGNC:678","description":"Rho GDP dissociation inhibitor alpha","metadata":{"aliases":["RHOGDI","GDIA1"]}},{"id":"db78dc84042546e0992b1b97728343cc","type":"GENE","name":"ARHGDIB","canonical_id":"hgnc:HGNC:679","description":"Rho GDP dissociation inhibitor beta","metadata":{"aliases":["Ly-GDI","RhoGDI2","RAP1GN1","GDIA2","GDID4"]}},{"id":"33677c34dd6a4cf8ada7881dc45b7bf8","type":"GENE","name":"ARHGDIG","canonical_id":"hgnc:HGNC:680","description":"Rho GDP dissociation inhibitor gamma","metadata":{"aliases":["RHOGDI-3"]}},{"id":"38e31a3b0d5d41f0afb8a859559245c1","type":"GENE","name":"ARHGEF1","canonical_id":"hgnc:HGNC:681","description":null,"metadata":null},{"id":"4074fd19579f4c98a8d480c77cacd0f4","type":"GENE","name":"ARHGEF10","canonical_id":"hgnc:HGNC:14103","description":"Rho guanine nucleotide exchange factor 10","metadata":{"aliases":["KIAA0294","Gef10"]}},{"id":"26944126d53b4fa6aa88092c3d1d3bfa","type":"GENE","name":"ARHGEF10L","canonical_id":"hgnc:HGNC:25540","description":"Rho guanine nucleotide exchange factor 10 like","metadata":{"aliases":["FLJ10521","KIAA1626"]}},{"id":"59789a491f1246c2954fe4287f3f7202","type":"GENE","name":"ARHGEF11","canonical_id":"hgnc:HGNC:14580","description":"Rho guanine nucleotide exchange factor 11","metadata":{"aliases":["KIAA0380","GTRAP48","PDZ-RHOGEF"]}},{"id":"9505c2efb249430d905998c402a7f025","type":"GENE","name":"ARHGEF12","canonical_id":"hgnc:HGNC:14193","description":"Rho guanine nucleotide exchange factor 12","metadata":{"aliases":["KIAA0382","LARG"]}},{"id":"035d1b79a1384956b08290db29e2d7fc","type":"GENE","name":"ARHGEF15","canonical_id":"hgnc:HGNC:15590","description":"Rho guanine nucleotide exchange factor 15","metadata":{"aliases":["KIAA0915","Vsm-RhoGEF","ARGEF15","FLJ13791","MGC44868"]}},{"id":"de89005eada64315a25384d716c90f5c","type":"GENE","name":"ARHGEF16","canonical_id":"hgnc:HGNC:15515","description":"Rho guanine nucleotide exchange factor 16","metadata":{"aliases":["NBR","GEF16"]}},{"id":"f7726fe9fcde42469f80cead69d9c606","type":"GENE","name":"ARHGEF17","canonical_id":"hgnc:HGNC:21726","description":"Rho guanine nucleotide exchange factor 17","metadata":{"aliases":["TEM4","KIAA0337","p164-RhoGEF"]}},{"id":"95ea688690a6427391caf044d9f09dd7","type":"GENE","name":"ARHGEF17-AS1","canonical_id":"hgnc:HGNC:55485","description":"ARHGEF17 antisense RNA 1","metadata":{"aliases":["MSEP"]}},{"id":"eae1211510074adca48bced2c942a09e","type":"GENE","name":"ARHGEF18","canonical_id":"hgnc:HGNC:17090","description":"Rho/Rac guanine nucleotide exchange factor 18","metadata":{"aliases":["P114-RhoGEF","KIAA0521","MGC15913","p114RhoGEF"]}},{"id":"d2874ec5b7e5426795c4726f8883fc56","type":"GENE","name":"ARHGEF18-AS1","canonical_id":"hgnc:HGNC:55284","description":"ARHGEF18 antisense RNA 1","metadata":null},{"id":"97ada70f389a46059736151dff4a2220","type":"GENE","name":"ARHGEF19","canonical_id":"hgnc:HGNC:26604","description":"Rho guanine nucleotide exchange factor 19","metadata":{"aliases":["FLJ33962","WGEF"]}},{"id":"784ce4c02ed0495492c80efe0364217d","type":"GENE","name":"ARHGEF2","canonical_id":"hgnc:HGNC:682","description":"Rho/Rac guanine nucleotide exchange factor 2","metadata":{"aliases":["LFP40","GEF-H1","KIAA0651","P40","Lfc","GEFH1"]}},{"id":"1e450f74defc42a2bcd781139fb1a51c","type":"GENE","name":"ARHGEF2-AS1","canonical_id":"hgnc:HGNC:40082","description":"ARHGEF2 antisense RNA 1","metadata":null},{"id":"80b9d0bf686d403b834168bb0008243d","type":"GENE","name":"ARHGEF2-AS2","canonical_id":"hgnc:HGNC:55175","description":"ARHGEF2 antisense RNA 2","metadata":null},{"id":"6941686511664662808395e0f8c3404b","type":"GENE","name":"ARHGEF25","canonical_id":"hgnc:HGNC:30275","description":"Rho guanine nucleotide exchange factor 25","metadata":{"aliases":["GEFT","p63RhoGEF"]}},{"id":"32e6613ec27941b98e1ea38f0b170acf","type":"GENE","name":"ARHGEF25-AS1","canonical_id":"hgnc:HGNC:41260","description":"ARHGEF25 antisense RNA 1","metadata":null},{"id":"9b5a9538761e40a387315fb9c228eaa8","type":"GENE","name":"ARHGEF26","canonical_id":"hgnc:HGNC:24490","description":"Rho guanine nucleotide exchange factor 26","metadata":{"aliases":["DKFZP434D146","SGEF"]}},{"id":"98fe983899094e4d8f01fa9a6c805728","type":"GENE","name":"ARHGEF26-AS1","canonical_id":"hgnc:HGNC:41048","description":"ARHGEF26 antisense RNA 1","metadata":null},{"id":"c61fa184ac03489cbe78b5c1ab3902fd","type":"GENE","name":"ARHGEF28","canonical_id":"hgnc:HGNC:30322","description":"Rho guanine nucleotide exchange factor 28","metadata":{"aliases":["RGNEF","p190RhoGEF","RIP2"]}},{"id":"46a92e63c3cc436bba459ccc3180b95c","type":"GENE","name":"ARHGEF28-AS1","canonical_id":"hgnc:HGNC:59066","description":"ARHGEF28 antisense RNA 1","metadata":null},{"id":"ac64e565340d4fa0871ffc7f9f37f5ae","type":"GENE","name":"ARHGEF28-AS2","canonical_id":"hgnc:HGNC:59067","description":"ARHGEF28 antisense RNA 2","metadata":null},{"id":"ae8d38bd2a684ad8be6ae4f9bed6f2e2","type":"GENE","name":"ARHGEF28-AS3","canonical_id":"hgnc:HGNC:59068","description":"ARHGEF28 antisense RNA 3","metadata":null},{"id":"6140c2a8fd6d45c2abd0445992a14d08","type":"GENE","name":"ARHGEF28P1","canonical_id":"hgnc:HGNC:56460","description":"ARHGEF28 pseudogene 1","metadata":null},{"id":"d7f691ef17f94b429007fb857a0e47b3","type":"GENE","name":"ARHGEF3","canonical_id":"hgnc:HGNC:683","description":"Rho guanine nucleotide exchange factor 3","metadata":{"aliases":["STA3","XPLN","GEF3","DKFZP434F2429"]}},{"id":"8375046045474a9189f1929f761b384a","type":"GENE","name":"ARHGEF3-AS1","canonical_id":"hgnc:HGNC:40083","description":"ARHGEF3 antisense RNA 1","metadata":null},{"id":"ce7be17700a14be88c519cb215fdcf35","type":"GENE","name":"ARHGEF33","canonical_id":"hgnc:HGNC:37252","description":"Rho guanine nucleotide exchange factor 33","metadata":null},{"id":"26fd1fa6a05f433eb1f3b4c6f7be3f84","type":"GENE","name":"ARHGEF34P","canonical_id":"hgnc:HGNC:38086","description":"Rho guanine nucleotide exchange factor 34, pseudogene","metadata":null},{"id":"831af9d15a2a4327b32a6ea9777ef0e2","type":"GENE","name":"ARHGEF35","canonical_id":"hgnc:HGNC:33846","description":"Rho guanine nucleotide exchange factor 35","metadata":{"aliases":["FLJ43692","CTAGE4","ARHGEF5L"]}},{"id":"15e09b6bc39e45af9ee0cbfb740a7d80","type":"GENE","name":"ARHGEF35-AS1","canonical_id":"hgnc:HGNC:41292","description":"ARHGEF35 antisense RNA 1","metadata":{"aliases":["DDGC"]}},{"id":"b7aecb2dbe144bb4b6ae52aeef8c66be","type":"GENE","name":"ARHGEF37","canonical_id":"hgnc:HGNC:34430","description":"Rho guanine nucleotide exchange factor 37","metadata":{"aliases":["FLJ41603"]}},{"id":"9aa5c50eab5d402c80e60d02549125be","type":"GENE","name":"ARHGEF37-AS1","canonical_id":"hgnc:HGNC:59280","description":"ARHGEF37 antisense RNA 1","metadata":null},{"id":"76555db79633466086c1bf8aa02bc3d9","type":"GENE","name":"ARHGEF38","canonical_id":"hgnc:HGNC:25968","description":"Rho guanine nucleotide exchange factor 38","metadata":{"aliases":["FLJ20184"]}},{"id":"6d47ee04a6114f4791fb635a34c7863c","type":"GENE","name":"ARHGEF38-DT","canonical_id":"hgnc:HGNC:58862","description":"ARHGEF38 divergent transcript","metadata":null},{"id":"db78d439a3c246718c9d0bef7200b400","type":"GENE","name":"ARHGEF38-IT1","canonical_id":"hgnc:HGNC:41483","description":"ARHGEF38 intronic transcript 1","metadata":null},{"id":"f705974695cc470dbd7a600356626e55","type":"GENE","name":"ARHGEF39","canonical_id":"hgnc:HGNC:25909","description":"Rho guanine nucleotide exchange factor 39","metadata":{"aliases":["FLJ14642","C9orf100"]}},{"id":"b2dbb5bb6c784261862858fb592e4e95","type":"GENE","name":"ARHGEF4","canonical_id":"hgnc:HGNC:684","description":"Rho guanine nucleotide exchange factor 4","metadata":{"aliases":["STM6","KIAA1112","ASEF","ASEF1"]}},{"id":"ece3b62371d640a9838ce75af624cba0","type":"GENE","name":"ARHGEF4-AS1","canonical_id":"hgnc:HGNC:55716","description":"ARHGEF4 antisense RNA 1","metadata":null},{"id":"333385af3c554b3c864acc5cdf779ff1","type":"GENE","name":"ARHGEF40","canonical_id":"hgnc:HGNC:25516","description":"Rho guanine nucleotide exchange factor 40","metadata":{"aliases":["solo","FLJ10357"]}},{"id":"def34f0103664528a5832cd07e338ff2","type":"GENE","name":"ARHGEF5","canonical_id":"hgnc:HGNC:13209","description":"Rho guanine nucleotide exchange factor 5","metadata":{"aliases":["TIM","TIM1","GEF5","P60"]}},{"id":"7e3d958842df47adba797e2464596bed","type":"GENE","name":"ARHGEF6","canonical_id":"hgnc:HGNC:685","description":"Rac/Cdc42 guanine nucleotide exchange factor 6","metadata":{"aliases":["alphaPIX","Cool-2","KIAA0006","alpha-PIX","Cool2","\u03b1Pix","MRX46"]}},{"id":"8f2f32fca3414324af903313f1a9a16a","type":"GENE","name":"ARHGEF7","canonical_id":"hgnc:HGNC:15607","description":"Rho guanine nucleotide exchange factor 7","metadata":{"aliases":["KIAA0142","PIXB","DKFZp761K1021","Nbla10314","DKFZp686C12170","BETA-PIX","COOL1","P85SPR","P85","P85COOL1","P50BP","PAK3","P50"]}},{"id":"92db4feb39fd45ffb05cbf31a4010890","type":"GENE","name":"ARHGEF7-AS1","canonical_id":"hgnc:HGNC:39816","description":"ARHGEF7 antisense RNA 1","metadata":null},{"id":"8742d8da943041c188477833c4e7aa4e","type":"GENE","name":"ARHGEF7-AS2","canonical_id":"hgnc:HGNC:40717","description":"ARHGEF7 antisense RNA 2","metadata":null},{"id":"b05d470c3c4f43bf9d3d08fb5acc89cd","type":"GENE","name":"ARHGEF7-IT1","canonical_id":"hgnc:HGNC:41408","description":"ARHGEF7 intronic transcript 1","metadata":null},{"id":"a75bc535e2304d4bbb05d934c69c4894","type":"GENE","name":"ARHGEF9","canonical_id":"hgnc:HGNC:14561","description":"Cdc42 guanine nucleotide exchange factor 9","metadata":{"aliases":["KIAA0424","PEM-2"]}},{"id":"d10bc2ad980941e382f3d23cffa5eed5","type":"GENE","name":"ARHGEF9-IT1","canonical_id":"hgnc:HGNC:41401","description":"ARHGEF9 intronic transcript 1","metadata":null},{"id":"53be39a2b4b14d8dbe158b961d8a452a","type":"GENE","name":"ARID1A","canonical_id":"hgnc:HGNC:11110","description":null,"metadata":null},{"id":"6062e3b8b1e345b3ba729e474f5e0ebb","type":"TRIAL","name":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","canonical_id":"clinicaltrials.gov:NCT04953104","description":"Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Ur\u2026","metadata":null},{"id":"6bda0a7aad9a4c4daa8a29ceb02a036b","type":"GENE","name":"ARID1B","canonical_id":"hgnc:HGNC:18040","description":null,"metadata":null},{"id":"8d56c1135dfa41b0a81e1ed7ac0bd665","type":"GENE","name":"ARID1B-AS1","canonical_id":"hgnc:HGNC:40826","description":"ARID1B antisense RNA 1","metadata":null},{"id":"68573315273d408593f39807a0399117","type":"GENE","name":"ARID2","canonical_id":"hgnc:HGNC:18037","description":"AT-rich interaction domain 2","metadata":{"aliases":["KIAA1557","DKFZp686G052","FLJ30619","BAF200","SMARCF3","ZIPZAP","p200"]}},{"id":"63fe2e0ba5674532a5a20917d2482e55","type":"GENE","name":"ARID3A","canonical_id":"hgnc:HGNC:3031","description":null,"metadata":null},{"id":"3189ea67dcc741afa84a45142161ec60","type":"GENE","name":"ARID3B","canonical_id":"hgnc:HGNC:14350","description":"AT-rich interaction domain 3B","metadata":{"aliases":["BDP","DRIL2"]}},{"id":"529155a02f0243f48eb279d99ba00e21","type":"GENE","name":"ARID3BP1","canonical_id":"hgnc:HGNC:54553","description":"ARID3B pseudogene 1","metadata":null},{"id":"a8f39f9657064555bc445ede55d11875","type":"GENE","name":"ARID3C","canonical_id":"hgnc:HGNC:21209","description":"AT-rich interaction domain 3C","metadata":null},{"id":"bce2edcaea3a44f08c54992b3a0a710f","type":"GENE","name":"ARID4A","canonical_id":"hgnc:HGNC:9885","description":"AT-rich interaction domain 4A","metadata":{"aliases":["RBP1","RBP-1","RBBP1"]}},{"id":"f19b516bfc514803adbcb35bd7b36e91","type":"GENE","name":"ARID4B","canonical_id":"hgnc:HGNC:15550","description":"AT-rich interaction domain 4B","metadata":{"aliases":["BCAA","BRCAA1","SAP180","RBP1L1"]}},{"id":"cbf4401515a74225ae904463652ffd75","type":"GENE","name":"ARID5A","canonical_id":"hgnc:HGNC:17361","description":"AT-rich interaction domain 5A","metadata":{"aliases":["MRF-1","RP11-363D14"]}},{"id":"dca446cd5eb741798a8b3f04e7b23308","type":"GENE","name":"ARID5B","canonical_id":"hgnc:HGNC:17362","description":"AT-rich interaction domain 5B","metadata":{"aliases":["FLJ21150","MRF2"]}},{"id":"ff05aeb6ebdd4c81abfc3283e953f210","type":"TRIAL","name":"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02855944","description":"Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"c43ab1ff951147768e0319423657d9e9","type":"GENE","name":"ARIH1","canonical_id":"hgnc:HGNC:689","description":"ariadne RBR E3 ubiquitin protein ligase 1","metadata":{"aliases":["HARI","HHARI","UBCH7BP","ARI"]}},{"id":"fb1f614df4f74ef9a75c68e0591cc4c1","type":"GENE","name":"ARIH2","canonical_id":"hgnc:HGNC:690","description":"ariadne RBR E3 ubiquitin protein ligase 2","metadata":{"aliases":["TRIAD1"]}},{"id":"0a9c43aeb2c1496f87d8af36bd1d76d7","type":"GENE","name":"ARIH2OS","canonical_id":"hgnc:HGNC:34425","description":"ARIH2 opposite strand lncRNA","metadata":{"aliases":["C3orf71"]}},{"id":"764ec7bebfbc42f3ae7d49e0ae533c26","type":"GENE","name":"ARIH2P1","canonical_id":"hgnc:HGNC:31732","description":"ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1","metadata":{"aliases":["ARIH2P"]}},{"id":"8d46b1f1d24f49d9947d9c5bc8705697","type":"TRIAL","name":"ARIXTRA\u00ae Adherence in SVT Patients.","canonical_id":"clinicaltrials.gov:NCT01691495","description":"Thrombosis, Venous","metadata":null},{"id":"33eb96070e7347778d393f04d5e3f19d","type":"GENE","name":"ARK2C","canonical_id":"hgnc:HGNC:31696","description":"arkadia (RNF111) C-terminal like ring finger ubiquitin ligase 2C","metadata":{"aliases":["ARKL2","RNF111L2","Ark2C","lncAMPC","RNF165"]}},{"id":"5eccbb4f7ed544399a61236471170f52","type":"GENE","name":"ARK2N","canonical_id":"hgnc:HGNC:28172","description":"arkadia (RNF111) N-terminal like PKA signaling regulator 2N","metadata":{"aliases":["MGC12909","ARKL1","RNF111L1","Ark2N","C18orf25"]}},{"id":"6f9c0cb409eb445d894e31b161efd1c8","type":"GENE","name":"ARL1","canonical_id":"hgnc:HGNC:692","description":"ARF like GTPase 1","metadata":{"aliases":["ARFL1"]}},{"id":"11b3447cb06a4e449642c7f212c9b6b9","type":"GENE","name":"ARL10","canonical_id":"hgnc:HGNC:22042","description":"ARF like GTPase 10","metadata":{"aliases":["ARL10A"]}},{"id":"5181ed601ead4236aae3ec338023acd4","type":"GENE","name":"ARL11","canonical_id":"hgnc:HGNC:24046","description":"ARF like GTPase 11","metadata":{"aliases":["ARLTS1","FLJ33930"]}},{"id":"f0c2007a859f402abc67885a31d29718","type":"GENE","name":"ARL13A","canonical_id":"hgnc:HGNC:31709","description":"ARF like GTPase 13A","metadata":{"aliases":["ARL13"]}},{"id":"35276c5e95db41b780f3f130e431676a","type":"GENE","name":"ARL13B","canonical_id":"hgnc:HGNC:25419","description":"ARF like GTPase 13B","metadata":{"aliases":["DKFZp761H079","JBTS8","ARL2L1"]}},{"id":"c87bfe8f68094e8c91b4e3d4486993e9","type":"GENE","name":"ARL14","canonical_id":"hgnc:HGNC:22974","description":"ARF like GTPase 14","metadata":{"aliases":["FLJ22595","ARF7"]}},{"id":"3e4b897a1bbf489795f0858570356ec6","type":"GENE","name":"ARL14EP","canonical_id":"hgnc:HGNC:26798","description":"ARF like GTPase 14 effector protein","metadata":{"aliases":["FLJ38968","ARF7EP","C11orf46"]}},{"id":"64033772304e4d48935d10a94a514d22","type":"GENE","name":"ARL14EP-DT","canonical_id":"hgnc:HGNC:55517","description":"ARL14EP divergent transcript","metadata":null},{"id":"588829c28bb84901b87b6e599a879d52","type":"GENE","name":"ARL14EPL","canonical_id":"hgnc:HGNC:44201","description":"ARF like GTPase 14 effector protein like","metadata":null},{"id":"9033b31f2a1f409ea291f4fe20c64cd8","type":"GENE","name":"ARL14EPP1","canonical_id":"hgnc:HGNC:54676","description":"ARL14EP pseudogene 1","metadata":null},{"id":"cf3f78a4735c4f32b4fbbc0a877fc0a0","type":"GENE","name":"ARL15","canonical_id":"hgnc:HGNC:25945","description":"ARF like GTPase 15","metadata":{"aliases":["FLJ20051","ARFRP2"]}},{"id":"424b82d87e7a42019bccf299f61e2ebd","type":"GENE","name":"ARL16","canonical_id":"hgnc:HGNC:27902","description":"ARF like GTPase 16","metadata":null},{"id":"51e157869cf44a728b5a04928a1a62eb","type":"GENE","name":"ARL17A","canonical_id":"hgnc:HGNC:24096","description":"ARF like GTPase 17A","metadata":{"aliases":["ARF1P2","ARL17P1"]}},{"id":"44c6cde6bcea4a8782487df8466b6c14","type":"GENE","name":"ARL17B","canonical_id":"hgnc:HGNC:32387","description":"ARF like GTPase 17B","metadata":{"aliases":["ARL17"]}},{"id":"625e01ae53724759a0a54ba9d5bc725c","type":"GENE","name":"ARL2","canonical_id":"hgnc:HGNC:693","description":"ARF like GTPase 2","metadata":{"aliases":["ARFL2"]}},{"id":"f6a640f9577747e39be99c76db2a0d19","type":"GENE","name":"ARL2-SNX15","canonical_id":"hgnc:HGNC:49197","description":"ARL2-SNX15 readthrough (NMD candidate)","metadata":null},{"id":"a99d837dcced4f99b3e124a1c1258a33","type":"GENE","name":"ARL2BP","canonical_id":"hgnc:HGNC:17146","description":"ARF like GTPase 2 binding protein","metadata":{"aliases":["BART1","BART","RP66"]}},{"id":"dc577e05ebc04cdb8c5cc16bd2cb18b3","type":"GENE","name":"ARL2BPP1","canonical_id":"hgnc:HGNC:17742","description":"ARF like GTPase 2 binding protein pseudogene 1","metadata":{"aliases":["HsT2883"]}},{"id":"f72ef84d6ab04205bd56b287f59b121b","type":"GENE","name":"ARL2BPP10","canonical_id":"hgnc:HGNC:39454","description":"ARF like GTPase 2 binding protein pseudogene 10","metadata":null},{"id":"86b920cf3d854ba9b76e5c766bdd81f6","type":"GENE","name":"ARL2BPP2","canonical_id":"hgnc:HGNC:31036","description":"ARF like GTPase 2 binding protein pseudogene 2","metadata":{"aliases":["bcm1040","ARL2BPL"]}},{"id":"c9f3cf704311417e9af78c7275c9cd2b","type":"GENE","name":"ARL2BPP3","canonical_id":"hgnc:HGNC:39447","description":"ARF like GTPase 2 binding protein pseudogene 3","metadata":null},{"id":"438ca3a796b746d28f97456180ad5858","type":"GENE","name":"ARL2BPP4","canonical_id":"hgnc:HGNC:39448","description":"ARF like GTPase 2 binding protein pseudogene 4","metadata":null},{"id":"2943c0a7977d40deba301b65a10c13ea","type":"GENE","name":"ARL2BPP5","canonical_id":"hgnc:HGNC:39449","description":"ARF like GTPase 2 binding protein pseudogene 5","metadata":null},{"id":"166011db83be4c7b8bbde5659fabde00","type":"GENE","name":"ARL2BPP6","canonical_id":"hgnc:HGNC:39450","description":"ARF like GTPase 2 binding protein pseudogene 6","metadata":null},{"id":"c72afd9855194fa89b9e0bf777135ae4","type":"GENE","name":"ARL2BPP7","canonical_id":"hgnc:HGNC:39451","description":"ARF like GTPase 2 binding protein pseudogene 7","metadata":null},{"id":"bd37f8d956dc4c549afe0eedbbec3e68","type":"GENE","name":"ARL2BPP8","canonical_id":"hgnc:HGNC:39452","description":"ARF like GTPase 2 binding protein pseudogene 8","metadata":null},{"id":"edef3762b8f54e03ae7099765bdbe168","type":"GENE","name":"ARL2BPP9","canonical_id":"hgnc:HGNC:39453","description":"ARF like GTPase 2 binding protein pseudogene 9","metadata":null},{"id":"6efda0d7cd9b4d19b1178d092dfc9a13","type":"GENE","name":"ARL3","canonical_id":"hgnc:HGNC:694","description":"ARF like GTPase 3","metadata":{"aliases":["ARFL3"]}},{"id":"1e7f6e46da7a4b98933c26b23e51e413","type":"GENE","name":"ARL4A","canonical_id":"hgnc:HGNC:695","description":"ARF like GTPase 4A","metadata":{"aliases":["ARL4"]}},{"id":"1aacaee717af46d9b5573259c2a21553","type":"GENE","name":"ARL4AP1","canonical_id":"hgnc:HGNC:17741","description":"ARF like GTPase 4A pseudogene 1","metadata":{"aliases":["Em:AC022390.2","ARL4B","ARL4P"]}},{"id":"abcc3d446a4e414ea1d507f2b2d98d4e","type":"GENE","name":"ARL4AP2","canonical_id":"hgnc:HGNC:32379","description":"ARF like GTPase 4A pseudogene 2","metadata":{"aliases":["ARL4P2"]}},{"id":"d08d8b7262e540c29f2c4d4ccc95567d","type":"GENE","name":"ARL4AP3","canonical_id":"hgnc:HGNC:52372","description":"ARF like GTPase 4A pseudogene 3","metadata":null},{"id":"e669fc3f1f6c42b4a75fe0b9b61871c8","type":"GENE","name":"ARL4AP4","canonical_id":"hgnc:HGNC:52373","description":"ARF like GTPase 4A pseudogene 4","metadata":null},{"id":"ecf5d662b8d741acaef4791b272339d0","type":"GENE","name":"ARL4AP5","canonical_id":"hgnc:HGNC:52374","description":"ARF like GTPase 4A pseudogene 5","metadata":null},{"id":"8d54a89bba2e47fd924d892e38e90160","type":"GENE","name":"ARL4C","canonical_id":"hgnc:HGNC:698","description":"ARF like GTPase 4C","metadata":{"aliases":["LAK","ARL7"]}},{"id":"9c5be88c3db54989be06d179bbebf16c","type":"GENE","name":"ARL4D","canonical_id":"hgnc:HGNC:656","description":"ARF like GTPase 4D","metadata":{"aliases":["ARF4L"]}},{"id":"cef63ddc59414207b3055f96f332b327","type":"GENE","name":"ARL5A","canonical_id":"hgnc:HGNC:696","description":"ARF like GTPase 5A","metadata":{"aliases":["ARL5"]}},{"id":"9fe3f337f8bf46d18156f5aaa72db3a5","type":"GENE","name":"ARL5AP1","canonical_id":"hgnc:HGNC:43933","description":"ARL5A pseudogene 1","metadata":null},{"id":"d407d1b0798444bfab753aecff0720f3","type":"GENE","name":"ARL5AP2","canonical_id":"hgnc:HGNC:43937","description":"ARL5A pseudogene 2","metadata":null},{"id":"8b6c62236481458e80d463ea9045edc2","type":"GENE","name":"ARL5AP3","canonical_id":"hgnc:HGNC:43935","description":"ARL5A pseudogene 3","metadata":null},{"id":"6faab41b2eea4014982037d005b72bb4","type":"GENE","name":"ARL5AP4","canonical_id":"hgnc:HGNC:43936","description":"ARL5A pseudogene 4","metadata":null},{"id":"4ce73115598e42ba9364e98d8437d04d","type":"GENE","name":"ARL5AP5","canonical_id":"hgnc:HGNC:55001","description":"ARL5A pseudogene 5","metadata":null},{"id":"53d9c7b167734632bb829b680c7e9f0c","type":"GENE","name":"ARL5B","canonical_id":"hgnc:HGNC:23052","description":"ARF like GTPase 5B","metadata":{"aliases":["ARL8"]}},{"id":"6e648e472e064749b83e607d15c6d1b2","type":"GENE","name":"ARL5C","canonical_id":"hgnc:HGNC:31111","description":"ARF like GTPase 5C","metadata":{"aliases":["ARL12"]}},{"id":"4f4c7a85b45b4491b8d7ea443b47d6f2","type":"GENE","name":"ARL6","canonical_id":"hgnc:HGNC:13210","description":"ARF like GTPase 6","metadata":{"aliases":["RP55","BBS3"]}},{"id":"26f51c57ea064dbdb99335f73f7b6082","type":"GENE","name":"ARL6IP1","canonical_id":"hgnc:HGNC:697","description":"ARL6 interacting reticulophagy regulator 1","metadata":{"aliases":["AIP1","ARMER","KIAA0069","SPG61","ARL6IP"]}},{"id":"ea696ea6e4004aa4af12c5bc8d615f64","type":"GENE","name":"ARL6IP1P1","canonical_id":"hgnc:HGNC:23178","description":"ARF like GTPase 6 interacting protein 1 pseudogene 1","metadata":{"aliases":["ARL6IPP1"]}},{"id":"68da8d39e8354a678f754462ef10d8e8","type":"GENE","name":"ARL6IP1P2","canonical_id":"hgnc:HGNC:44971","description":"ARF like GTPase 6 interacting protein 1 pseudogene 2","metadata":null},{"id":"dd54e5fc79314cc0a176172b1afa193e","type":"GENE","name":"ARL6IP1P3","canonical_id":"hgnc:HGNC:44972","description":"ARF like GTPase 6 interacting protein 1 pseudogene 3","metadata":null},{"id":"1b9b3e0f923c459f98901242b2fe1df9","type":"GENE","name":"ARL6IP4","canonical_id":"hgnc:HGNC:18076","description":"ARF like GTPase 6 interacting protein 4","metadata":{"aliases":["SR-25","SRp25","SFRS20","SRrp37"]}},{"id":"05743082ae6540708cfe58d85e695285","type":"GENE","name":"ARL6IP5","canonical_id":"hgnc:HGNC:16937","description":null,"metadata":null},{"id":"c1b5ceaf62fc46c1b93e71b4e9555c10","type":"GENE","name":"ARL6IP6","canonical_id":"hgnc:HGNC:24048","description":"ARF like GTPase 6 interacting protein 6","metadata":{"aliases":["MGC33864"]}},{"id":"3f469493c6c140ed8bbdde8b1e591698","type":"GENE","name":"ARL8A","canonical_id":"hgnc:HGNC:25192","description":"ARF like GTPase 8A","metadata":{"aliases":["FLJ45195","Gie2","ARL10B"]}},{"id":"5503c7f6e9554049aea88f69d3b4d7ba","type":"GENE","name":"ARL8B","canonical_id":"hgnc:HGNC:25564","description":"ARF like GTPase 8B","metadata":{"aliases":["FLJ10702","Gie1","ARL10C"]}},{"id":"f4b7ed51c9f848338db3136a0eefdc24","type":"GENE","name":"ARL8BP1","canonical_id":"hgnc:HGNC:56628","description":"ARL8B pseudogene 1","metadata":null},{"id":"78eefeb3c2df452698393799910769b7","type":"GENE","name":"ARL8BP2","canonical_id":"hgnc:HGNC:56629","description":"ARL8B pseudogene 2","metadata":null},{"id":"3c0b306dd02249d6a83fffc3cd655568","type":"GENE","name":"ARL9","canonical_id":"hgnc:HGNC:23592","description":"ARF like GTPase 9","metadata":null},{"id":"4de60ee6ed2240e296b9760ad5e54044","type":"GENE","name":"ARLN","canonical_id":"hgnc:HGNC:19225","description":"allregulin","metadata":{"aliases":["HCVFTP1","ALN","C4orf3"]}},{"id":"3488f1818df84964bac5201ed1714367","type":"GENE","name":"ARLNC1","canonical_id":"hgnc:HGNC:53032","description":"androgen receptor regulated long noncoding RNA 1","metadata":{"aliases":["PRCAT47","LINC02170"]}},{"id":"86e306b0c59c4ee396889d3eb0e19997","type":"GENE","name":"ARMC1","canonical_id":"hgnc:HGNC:17684","description":"armadillo repeat containing 1","metadata":{"aliases":["FLJ10511","Arcp"]}},{"id":"be21210f2d9a426993eb334a447e8e8b","type":"GENE","name":"ARMC10","canonical_id":"hgnc:HGNC:21706","description":"armadillo repeat containing 10","metadata":{"aliases":["MGC3195","SVH"]}},{"id":"2e953050fdf9459c9a2fd34cbf6d3d7a","type":"GENE","name":"ARMC10P1","canonical_id":"hgnc:HGNC:43646","description":"armadillo repeat containing 10 pseudogene 1","metadata":null},{"id":"cdccc39c37f94aa4925440e9fe546eef","type":"GENE","name":"ARMC12","canonical_id":"hgnc:HGNC:21099","description":"armadillo repeat containing 12","metadata":{"aliases":["FLJ25390","C6orf81"]}},{"id":"34a160109e35465abb5b20b908820bc9","type":"GENE","name":"ARMC12-AS1","canonical_id":"hgnc:HGNC:27782","description":"ARMC12 antisense RNA 1","metadata":null},{"id":"e761a8e9f8144d49a0fa9ed70f466c53","type":"GENE","name":"ARMC2","canonical_id":"hgnc:HGNC:23045","description":"armadillo repeat containing 2","metadata":{"aliases":["DKFZp434P0714","bA787I22.1"]}},{"id":"30fce43bc65743f5ad281f02459a8c56","type":"GENE","name":"ARMC2-AS1","canonical_id":"hgnc:HGNC:41008","description":"ARMC2 antisense RNA 1","metadata":null},{"id":"a459701eb43a4b64b99cddba167c25a3","type":"GENE","name":"ARMC3","canonical_id":"hgnc:HGNC:30964","description":"armadillo repeat containing 3","metadata":{"aliases":["FLJ32827","CT81","VAC8"]}},{"id":"985c4c06a5f5486cba92b85b5d85d175","type":"GENE","name":"ARMC5","canonical_id":"hgnc:HGNC:25781","description":"armadillo repeat containing 5","metadata":{"aliases":["FLJ13063"]}},{"id":"380b7fdbc8424e37a09f1ee5a6cf0434","type":"GENE","name":"ARMC6","canonical_id":"hgnc:HGNC:25049","description":"armadillo repeat containing 6","metadata":{"aliases":["MGC19595"]}},{"id":"6cdeacb155dc48918929991b13327bc5","type":"GENE","name":"ARMC7","canonical_id":"hgnc:HGNC:26168","description":"armadillo repeat containing 7","metadata":{"aliases":["FLJ22160"]}},{"id":"94bbd5c36c2340e5be036e4462909386","type":"GENE","name":"ARMC8","canonical_id":"hgnc:HGNC:24999","description":"armadillo repeat containing 8","metadata":{"aliases":["HSPC056","DKFZP434A043","GID5","VID28"]}},{"id":"37fa6e38fb0546d680eeca346278055b","type":"GENE","name":"ARMC8P1","canonical_id":"hgnc:HGNC:49918","description":"armadillo repeat containing 8 pseudogene 1","metadata":null},{"id":"c05810d00b194210bf04a68236dca308","type":"GENE","name":"ARMC9","canonical_id":"hgnc:HGNC:20730","description":"armadillo repeat containing 9","metadata":{"aliases":["FLJ12584","KIAA1868","ARM","KU-MEL-1"]}},{"id":"7f3239060d2c4f12bda4cda100eabfaa","type":"GENE","name":"ARMCX1","canonical_id":"hgnc:HGNC:18073","description":"armadillo repeat containing X-linked 1","metadata":{"aliases":["ALEX1","GASP7"]}},{"id":"4db3e42a774349528558f033dd6d6da6","type":"GENE","name":"ARMCX2","canonical_id":"hgnc:HGNC:16869","description":"armadillo repeat containing X-linked 2","metadata":{"aliases":["ALEX2","KIAA0512","GASP9"]}},{"id":"09df3fe743e64136aac152ba2b0fff59","type":"GENE","name":"ARMCX3","canonical_id":"hgnc:HGNC:24065","description":"armadillo repeat containing X-linked 3","metadata":{"aliases":["ALEX3","GASP6"]}},{"id":"5843e36b9b884479abbcb98994350d38","type":"GENE","name":"ARMCX3-AS1","canonical_id":"hgnc:HGNC:41038","description":"ARMCX3 antisense RNA 1","metadata":null},{"id":"ae0f0d2c0d58415aac5591ceddbd7e87","type":"GENE","name":"ARMCX4","canonical_id":"hgnc:HGNC:28615","description":"armadillo repeat containing X-linked 4","metadata":{"aliases":["MGC40053","GASP4","CXorf35"]}},{"id":"f893df18434445ed8793af78b20bcb3f","type":"GENE","name":"ARMCX5","canonical_id":"hgnc:HGNC:25772","description":"armadillo repeat containing X-linked 5","metadata":{"aliases":["FLJ12969","GASP5"]}},{"id":"a409bd49540742fe8310096ab8fea028","type":"GENE","name":"ARMCX5-GPRASP2","canonical_id":"hgnc:HGNC:42000","description":"ARMCX5-GPRASP2 readthrough","metadata":null},{"id":"87e927e5881f406a9a4cdf0b7e87ba55","type":"GENE","name":"ARMCX6","canonical_id":"hgnc:HGNC:26094","description":"armadillo repeat containing X-linked 6","metadata":{"aliases":["FLJ20811","GASP10"]}},{"id":"19deecf760b04d6f93fed77c86e61b12","type":"GENE","name":"ARMCX7P","canonical_id":"hgnc:HGNC:49917","description":"armadillo repeat containing X-linked 7, pseudogene","metadata":{"aliases":["ARMCX6-ps","GASP10ps"]}},{"id":"d5dcfde4ae314989bfc5bb632d48007b","type":"GENE","name":"ARMH1","canonical_id":"hgnc:HGNC:34345","description":"armadillo like helical domain containing 1","metadata":{"aliases":["MGC33556","p40","NCRNA00082","C1orf228"]}},{"id":"25577555b09849a68329e06251aea8a8","type":"GENE","name":"ARMH2","canonical_id":"hgnc:HGNC:49394","description":"armadillo like helical domain containing 2","metadata":{"aliases":["C6orf229"]}},{"id":"bc9aa809f04d410e956d144190d4e6c0","type":"GENE","name":"ARMH2-AS1","canonical_id":"hgnc:HGNC:59373","description":"ARMH2 antisense RNA 1","metadata":null},{"id":"617fd6ee44194922b95bb7fa283dc7e8","type":"GENE","name":"ARMH3","canonical_id":"hgnc:HGNC:25788","description":"armadillo like helical domain containing 3","metadata":{"aliases":["FLJ13114","DGARM","C10orf76"]}},{"id":"d725143d667d4136b427ed818fee725b","type":"GENE","name":"ARMH4","canonical_id":"hgnc:HGNC:19846","description":"armadillo like helical domain containing 4","metadata":{"aliases":["UT2","C14orf37"]}},{"id":"d33c8b317ea343a790edc6ce54d0e885","type":"GENE","name":"ARMS2","canonical_id":"hgnc:HGNC:32685","description":"age-related maculopathy susceptibility 2","metadata":{"aliases":["LOC387715","ARMD8"]}},{"id":"96aecde7668e41dabc26b1461f8e5d06","type":"GENE","name":"ARNILA","canonical_id":"hgnc:HGNC:54484","description":"androgen receptor negatively regulated lncRNA","metadata":null},{"id":"c1f1b2392787405d973de507aa6762b0","type":"GENE","name":"ARNT","canonical_id":"hgnc:HGNC:700","description":null,"metadata":null},{"id":"a2f1e69ace164a55b2dc02dfad6a2b5e","type":"GENE","name":"ARNT2","canonical_id":"hgnc:HGNC:16876","description":null,"metadata":null},{"id":"687e828f3a2b4177bcae38a2c8b920df","type":"GENE","name":"ARNT2-AS1","canonical_id":"hgnc:HGNC:58338","description":"ARNT2 antisense RNA 1","metadata":null},{"id":"0274e675938846fa8f3403ade1a98bf0","type":"GENE","name":"ARNT2-AS2","canonical_id":"hgnc:HGNC:58450","description":"ARNT2 antisense RNA 2","metadata":null},{"id":"3e8b4a69600c4120aefee4203266e6e0","type":"GENE","name":"ARNT2-AS3","canonical_id":"hgnc:HGNC:58467","description":"ARNT2 antisense RNA 3","metadata":null},{"id":"769ac70261374da59e0cf5464522501b","type":"GENE","name":"ARNT2-DT","canonical_id":"hgnc:HGNC:56077","description":"ARNT2 divergent transcript","metadata":null},{"id":"c22cd86c6f5c4e018c5068e00409b6af","type":"GENE","name":"ARNTL","canonical_id":"hgnc:HGNC:701","description":null,"metadata":null},{"id":"60a9ffb97d99449a8e555bc60e7b5bac","type":"GENE","name":"ARNTL2","canonical_id":"hgnc:HGNC:18984","description":null,"metadata":null},{"id":"f30aa17f0eb44d1d857d9a3b626245bf","type":"GENE","name":"ARPC1A","canonical_id":"hgnc:HGNC:703","description":"actin related protein 2/3 complex subunit 1A","metadata":{"aliases":["SOP2Hs","SOP2L","Arc40"]}},{"id":"97ddb4200f614144b9d9e857593cb58c","type":"GENE","name":"ARPC1AP1","canonical_id":"hgnc:HGNC:56494","description":"ARPC1A pseudogene 1","metadata":null},{"id":"8fcfcfa966e445c9a96effa32e6125fc","type":"GENE","name":"ARPC1AP2","canonical_id":"hgnc:HGNC:56495","description":"ARPC1A pseudogene 2","metadata":null},{"id":"72a8b58643794cf3b0e46c44207cf05f","type":"GENE","name":"ARPC1AP3","canonical_id":"hgnc:HGNC:56496","description":"ARPC1A pseudogene 3","metadata":null},{"id":"f2d6f220bd914f9cabf5cb0b750b5017","type":"GENE","name":"ARPC1AP4","canonical_id":"hgnc:HGNC:56497","description":"ARPC1A pseudogene 4","metadata":null},{"id":"8e0e2f79612b4b8aa1eafcc0258a50de","type":"GENE","name":"ARPC1B","canonical_id":"hgnc:HGNC:704","description":"actin related protein 2/3 complex subunit 1B","metadata":{"aliases":["ARC41","p40-ARC","p41-ARC"]}},{"id":"b33761006be3429890c260bbd9f57bb6","type":"GENE","name":"ARPC1BP1","canonical_id":"hgnc:HGNC:54638","description":"ARPC1B pseudogene 1","metadata":null},{"id":"ddeca1727f764fc3a5a2328d76b726b8","type":"GENE","name":"ARPC2","canonical_id":"hgnc:HGNC:705","description":"actin related protein 2/3 complex subunit 2","metadata":{"aliases":["p34-Arc","ARC34"]}},{"id":"bcc5c47a0cf848ccb73584371f610f8e","type":"GENE","name":"ARPC3","canonical_id":"hgnc:HGNC:706","description":"actin related protein 2/3 complex subunit 3","metadata":{"aliases":["p21-Arc","ARC21"]}},{"id":"281cc150956446cfb9302ccf455645ca","type":"GENE","name":"ARPC3P1","canonical_id":"hgnc:HGNC:16092","description":"actin related protein 2/3 complex subunit 3 pseudogene 1","metadata":{"aliases":["dJ470L14.3","ARPC3B"]}},{"id":"9c1d7e0da9454c3599fe97bb3b16352b","type":"GENE","name":"ARPC3P2","canonical_id":"hgnc:HGNC:39431","description":"actin related protein 2/3 complex subunit 3 pseudogene 2","metadata":null},{"id":"8f5ac643ae794807bf240f4059305cf4","type":"GENE","name":"ARPC3P3","canonical_id":"hgnc:HGNC:39432","description":"actin related protein 2/3 complex subunit 3 pseudogene 3","metadata":null},{"id":"55ba4eeef1bb43efa36d57f7775c091c","type":"GENE","name":"ARPC3P4","canonical_id":"hgnc:HGNC:39434","description":"actin related protein 2/3 complex subunit 3 pseudogene 4","metadata":null},{"id":"a01f2891ce15440fac611f18bb16f49e","type":"GENE","name":"ARPC3P5","canonical_id":"hgnc:HGNC:39435","description":"actin related protein 2/3 complex subunit 3 pseudogene 5","metadata":null},{"id":"190e6197dd1a436eaa0cc4ef2bbef21b","type":"GENE","name":"ARPC4","canonical_id":"hgnc:HGNC:707","description":"actin related protein 2/3 complex subunit 4","metadata":{"aliases":["p20-Arc","ARC20"]}},{"id":"0a79191d631948d58f19721765ffede2","type":"GENE","name":"ARPC4-TTLL3","canonical_id":"hgnc:HGNC:38830","description":"ARPC4-TTLL3 readthrough","metadata":null},{"id":"507695618df04caf94add4701d61dc3a","type":"GENE","name":"ARPC5","canonical_id":"hgnc:HGNC:708","description":"actin related protein 2/3 complex subunit 5","metadata":{"aliases":["p16-Arc","ARC16","dJ127C7.3"]}},{"id":"3d1d54af196d42cbaaa4e0b7ee4a8732","type":"GENE","name":"ARPC5L","canonical_id":"hgnc:HGNC:23366","description":"actin related protein 2/3 complex subunit 5 like","metadata":{"aliases":["MGC3038","ARC16-2"]}},{"id":"1c83cddcf8324f51a72e74170a44158d","type":"GENE","name":"ARPIN","canonical_id":"hgnc:HGNC:28782","description":"actin related protein 2/3 complex inhibitor","metadata":{"aliases":["MGC61550","C15orf38"]}},{"id":"bd88d45a105c4801af3794251820e617","type":"GENE","name":"ARPIN-AP3S2","canonical_id":"hgnc:HGNC:38824","description":"ARPIN-AP3S2 readthrough","metadata":{"aliases":["C15orf38-AP3S2"]}},{"id":"28c271516a4149b8add6df79f0bbe741","type":"GENE","name":"ARPP19","canonical_id":"hgnc:HGNC:16967","description":"cAMP regulated phosphoprotein 19","metadata":{"aliases":["ARPP-19","ARPP-16","ARPP16","ENSAL"]}},{"id":"467b284e1bb14d3cb11093ec8c67e965","type":"GENE","name":"ARPP19P1","canonical_id":"hgnc:HGNC:54698","description":"ARPP19 pseudogene 1","metadata":null},{"id":"23d01dc128704147a4846324fee17e70","type":"GENE","name":"ARPP19P2","canonical_id":"hgnc:HGNC:54699","description":"ARPP19 pseudogene 2","metadata":null},{"id":"2214bcd604b945bf9fc917afad5a54d1","type":"GENE","name":"ARPP21","canonical_id":"hgnc:HGNC:16968","description":"cAMP regulated phosphoprotein 21","metadata":{"aliases":["ARPP-21","TARPP","R3HDM3"]}},{"id":"8e0af5f1284f4ab9b5e09e617b660d95","type":"GENE","name":"ARPP21-AS1","canonical_id":"hgnc:HGNC:40785","description":"ARPP21 antisense RNA 1","metadata":null},{"id":"82d89f20f9c24f929da10aafd4663552","type":"TRIAL","name":"ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01075048","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"31b7663bc13d49f9941592d0180192cf","type":"GENE","name":"ARR3","canonical_id":"hgnc:HGNC:710","description":"arrestin 3","metadata":{"aliases":["ARRX"]}},{"id":"040b104896d7492da9bae5d8ac004dc7","type":"GENE","name":"ARRB1","canonical_id":"hgnc:HGNC:711","description":"arrestin beta 1","metadata":{"aliases":["ARR1"]}},{"id":"71f9998808ea4efc886e19155a91882e","type":"GENE","name":"ARRB2","canonical_id":"hgnc:HGNC:712","description":"arrestin beta 2","metadata":{"aliases":["BARR2","DKFZp686L0365","ARR2"]}},{"id":"ac2da0d8087d45da9b0487599e74417c","type":"GENE","name":"ARRDC1","canonical_id":"hgnc:HGNC:28633","description":"arrestin domain containing 1","metadata":{"aliases":["MGC40555"]}},{"id":"88874e5a8a2d42828ba4a07afd77baa7","type":"GENE","name":"ARRDC1-AS1","canonical_id":"hgnc:HGNC:23395","description":"ARRDC1 antisense RNA 1","metadata":{"aliases":["C9orf37"]}},{"id":"d1ed979e315c473f87ffcd9f4a81c99c","type":"GENE","name":"ARRDC2","canonical_id":"hgnc:HGNC:25225","description":"arrestin domain containing 2","metadata":{"aliases":["CLONE24945","PP2703"]}},{"id":"04a4203979ef4d339e62e9afc3e03cb6","type":"GENE","name":"ARRDC3","canonical_id":"hgnc:HGNC:29263","description":"arrestin domain containing 3","metadata":{"aliases":["KIAA1376","TLIMP"]}},{"id":"9ce3eb2882b74966a8f0caa51aae5f15","type":"GENE","name":"ARRDC3-AS1","canonical_id":"hgnc:HGNC:44145","description":"ARRDC3 antisense RNA 1","metadata":{"aliases":["uc.168"]}},{"id":"6673002ff7444ea2acb9fb8d327738ff","type":"GENE","name":"ARRDC4","canonical_id":"hgnc:HGNC:28087","description":"arrestin domain containing 4","metadata":{"aliases":["FLJ36045"]}},{"id":"20db26c8dc87415098d299a674e2ecee","type":"GENE","name":"ARRDC5","canonical_id":"hgnc:HGNC:31407","description":"arrestin domain containing 5","metadata":null},{"id":"d3d6bd17e5b4441f963e0bc938e470f6","type":"TRIAL","name":"ARREST PAD (Peripheral Arterial Disease)","canonical_id":"clinicaltrials.gov:NCT00153166","description":"Arterial Occlusive Disease; Intermittent Claudication; Insulin Resistance","metadata":null},{"id":"1e56c218dc0c418ca65141f1f7556d74","type":"GENE","name":"ARSA","canonical_id":"hgnc:HGNC:713","description":"arylsulfatase A","metadata":{"aliases":["ASA"]}},{"id":"468df3feb6214e9e89efd206e89d3794","type":"GENE","name":"ARSB","canonical_id":"hgnc:HGNC:714","description":"arylsulfatase B","metadata":{"aliases":["ASB"]}},{"id":"7febd31980c44e0eb86b8dedd0f291c8","type":"GENE","name":"ARSC2","canonical_id":"hgnc:HGNC:716","description":"arylsulfatase C, isozyme F","metadata":{"aliases":["ARSC"]}},{"id":"407aac87f9e24fff8164f25b936f8797","type":"GENE","name":"ARSD","canonical_id":"hgnc:HGNC:717","description":"arylsulfatase D","metadata":{"aliases":["ASD"]}},{"id":"2877cfeb52214b4b8b6f1bbcab99cb2b","type":"GENE","name":"ARSD-AS1","canonical_id":"hgnc:HGNC:40085","description":"ARSD antisense RNA 1","metadata":null},{"id":"f2e495e52d244e81b6e6ad4fe5bb1113","type":"GENE","name":"ARSDP1","canonical_id":"hgnc:HGNC:718","description":"arylsulfatase D pseudogene 1","metadata":{"aliases":["ARSDY1","ARSDP"]}},{"id":"2b1213072098411280c9a1a01ba24a8a","type":"GENE","name":"ARSF","canonical_id":"hgnc:HGNC:721","description":"arylsulfatase F","metadata":{"aliases":["ASF"]}},{"id":"758ff04d2506413a8dbaad8e0e406016","type":"GENE","name":"ARSFP1","canonical_id":"hgnc:HGNC:722","description":"arylsulfatase F pseudogene 1","metadata":{"aliases":["ARSFP"]}},{"id":"76de151f5db640dcbd8e30474115da7b","type":"GENE","name":"ARSG","canonical_id":"hgnc:HGNC:24102","description":"arylsulfatase G","metadata":{"aliases":["KIAA1001"]}},{"id":"973ddf3013f2484687fdd5f3e2856002","type":"GENE","name":"ARSH","canonical_id":"hgnc:HGNC:32488","description":"arylsulfatase family member H","metadata":null},{"id":"6255c5d29b834786a4d368789e3ae803","type":"GENE","name":"ARSI","canonical_id":"hgnc:HGNC:32521","description":"arylsulfatase family member I","metadata":{"aliases":["FLJ16069","SPG66"]}},{"id":"41572a4683044a188335ff0a18e035ed","type":"GENE","name":"ARSJ","canonical_id":"hgnc:HGNC:26286","description":"arylsulfatase family member J","metadata":{"aliases":["FLJ23548"]}},{"id":"ea500bb2b40b4133b13cf5259da88c2c","type":"GENE","name":"ARSJ-DT","canonical_id":"hgnc:HGNC:58874","description":"ARSJ divergent transcript","metadata":null},{"id":"0cf4eda8ea0e4453830daa7303adcf82","type":"GENE","name":"ARSK","canonical_id":"hgnc:HGNC:25239","description":"arylsulfatase family member K","metadata":{"aliases":["DKFZp313G1735","TSULF"]}},{"id":"9d21cd78ef194896b2cfbaee2517a4c3","type":"GENE","name":"ARSL","canonical_id":"hgnc:HGNC:719","description":"arylsulfatase L","metadata":{"aliases":["CDPX","CDPX1","ARSE"]}},{"id":"a4c79bb1f20647ba8606278e7fcd5791","type":"GENE","name":"ARSLP1","canonical_id":"hgnc:HGNC:720","description":"arylsulfatase L pseudogene 1","metadata":{"aliases":["ARSEP","ARSEP1"]}},{"id":"a67bdc595c3649c59a9b9dca96c389c3","type":"GENE","name":"ART1","canonical_id":"hgnc:HGNC:723","description":"ADP-ribosyltransferase 1","metadata":{"aliases":["ART2","CD296","ARTC1"]}},{"id":"13bfb8d983a144e8b6b00e93ffeb58eb","type":"GENE","name":"ART2BP","canonical_id":"hgnc:HGNC:51489","description":"ADP-ribosyltransferase 2B, pseudogene","metadata":{"aliases":["ARTC2BP"]}},{"id":"5e298b61a367433191c0bacea48fc6b4","type":"GENE","name":"ART2P","canonical_id":"hgnc:HGNC:724","description":"ADP-ribosyltransferase 2, pseudogene","metadata":{"aliases":["ART1P","ARTC2AP","RT6"]}},{"id":"a919f308a6d64fae9ea7bb17d6ffdd41","type":"GENE","name":"ART3","canonical_id":"hgnc:HGNC:725","description":"ADP-ribosyltransferase 3 (inactive)","metadata":{"aliases":["ARTC3"]}},{"id":"70c22c9218794934ba9b2ad91ab49c82","type":"GENE","name":"ART4","canonical_id":"hgnc:HGNC:726","description":"ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)","metadata":{"aliases":["DOK1","CD297","ARTC4","DO"]}},{"id":"3290723352694956befb8770759e5d55","type":"GENE","name":"ART5","canonical_id":"hgnc:HGNC:24049","description":"ADP-ribosyltransferase 5","metadata":{"aliases":["ARTC5"]}},{"id":"34ef9565b5be43ca8c076b8d7bd5e90c","type":"TRIAL","name":"ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT00879229","description":"Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension","metadata":null},{"id":"7872e900ee9b4182b90381d47a737fa8","type":"TRIAL","name":"ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE","canonical_id":"clinicaltrials.gov:NCT05746559","description":"Chronic Kidney Disease; CKD; Cardiac Disease; Cardiopulmonary Bypass","metadata":null},{"id":"36d44a95ec2c4946a5ff00205c3d9f0b","type":"GENE","name":"ARTN","canonical_id":"hgnc:HGNC:727","description":"artemin","metadata":{"aliases":["NBN","EVN","ENOVIN"]}},{"id":"0528559060434a10913dca6c1a5f6c77","type":"GENE","name":"ARV1","canonical_id":"hgnc:HGNC:29561","description":"ARV1 fatty acid homeostasis modulator","metadata":null},{"id":"e9c37474b1de4345911e5d3566c50237","type":"GENE","name":"ARVCF","canonical_id":"hgnc:HGNC:728","description":"ARVCF delta catenin family member","metadata":null},{"id":"35088c8f38e04d399409507d6a9ea92f","type":"GENE","name":"ARX","canonical_id":"hgnc:HGNC:18060","description":null,"metadata":null},{"id":"80775efd14b1442d95a37f24256119f6","type":"TRIAL","name":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04662580","description":"Metastatic Prostate Cancer","metadata":null},{"id":"8d020eb39ae64f3c89cb9c19aad7c6cb","type":"TRIAL","name":"ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06224673","description":"HER2 Low Breast Carcinoma; Triple Negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma","metadata":null},{"id":"55e9db3e02d644f694924544146c6643","type":"GENE","name":"AS3MT","canonical_id":"hgnc:HGNC:17452","description":"arsenite methyltransferase","metadata":{"aliases":["CYT19"]}},{"id":"b93adf4e7cf849779ccd016f028acf63","type":"GENE","name":"ASAH1","canonical_id":"hgnc:HGNC:735","description":null,"metadata":null},{"id":"2a4ff1a9d736421e938dc6f34aef4ea4","type":"GENE","name":"ASAH1-AS1","canonical_id":"hgnc:HGNC:55603","description":"ASAH1 antisense RNA 1","metadata":null},{"id":"39d63801958e4287bcc6901cf92bf515","type":"GENE","name":"ASAH2","canonical_id":"hgnc:HGNC:18860","description":"N-acylsphingosine amidohydrolase 2","metadata":null},{"id":"03a269d30e2245b6b9e1088e30a78f0a","type":"GENE","name":"ASAH2B","canonical_id":"hgnc:HGNC:23456","description":"N-acylsphingosine amidohydrolase 2B","metadata":{"aliases":["bA449O16.3","ASAH2L","bA98I6.3","ASAH2C"]}},{"id":"b4f8faf4394d4416b0ce9287d5d5164d","type":"GO_TERM","name":"ASAP complex","canonical_id":"go:GO:0061574","description":"\"A protein complex involved in regulation of mRNA processing and apoptosis. It binds to RNA in a sequence-independent manner and is recruited to the EJC prior to or during the splicing process. In humans the core proteins are RNPS1, SAP18 and ACIN1.\" [GOC:dph, PMID:12665594, PMID:16314458, PMID:22388736]","metadata":null},{"id":"65c590eb3dbb4f71936919d672aac8d4","type":"GENE","name":"ASAP1","canonical_id":"hgnc:HGNC:2720","description":"ArfGAP with SH3 domain, ankyrin repeat and PH domain 1","metadata":{"aliases":["PAP","KIAA1249","ZG14P","CENTB4","DDEF1"]}},{"id":"7c62bbfe0a19429082a58be1309adc50","type":"GENE","name":"ASAP1-IT1","canonical_id":"hgnc:HGNC:24998","description":"ASAP1 intronic transcript 1","metadata":{"aliases":["HSPC054","NCRNA00050","ASAP1IT","ASAP1-IT","DDEF1IT1"]}},{"id":"877b2a7e310046d3a788f3d4e676cd8c","type":"GENE","name":"ASAP1-IT2","canonical_id":"hgnc:HGNC:48917","description":"ASAP1 intronic transcript 2","metadata":null},{"id":"a0e99806e3324b72af804c80e0d904f5","type":"GENE","name":"ASAP2","canonical_id":"hgnc:HGNC:2721","description":null,"metadata":null},{"id":"3d8ed8fdaa80434caa4bc2a011af98f0","type":"GENE","name":"ASAP3","canonical_id":"hgnc:HGNC:14987","description":"ArfGAP with SH3 domain, ankyrin repeat and PH domain 3","metadata":{"aliases":["FLJ20199","UPLC1","CENTB6","DDEFL1"]}},{"id":"fa384f69d39242ab95f10985bd80fee3","type":"GENE","name":"ASAR1-1","canonical_id":"hgnc:HGNC:57016","description":"asynchronous replication autosomal RNA 1-1","metadata":{"aliases":["ASAR1-187"]}},{"id":"a1775417f5894c9c8b774f93de10b029","type":"GENE","name":"ASAR15-1","canonical_id":"hgnc:HGNC:54861","description":"asynchronous replication autosomal RNA 15-1","metadata":{"aliases":["ASAR15"]}},{"id":"101e797fc3fc432192d6a2b27c802d7f","type":"GENE","name":"ASAR6-1","canonical_id":"hgnc:HGNC:38875","description":"asynchronous replication autosomal RNA 6-1","metadata":{"aliases":["ASAR6"]}},{"id":"fa2fe5d7c30849b5bace854ad17a63a6","type":"GENE","name":"ASAR6-2","canonical_id":"hgnc:HGNC:57017","description":"asynchronous replication autosomal RNA 6-2","metadata":{"aliases":["ASAR6-141"]}},{"id":"5b9d31e0d5494b1b8a1e9539e5c4903b","type":"GENE","name":"ASAR8-1","canonical_id":"hgnc:HGNC:57018","description":"asynchronous replication autosomal RNA 8-1","metadata":{"aliases":["ASAR8-2.7"]}},{"id":"d29c5f2703584f1a96417262c63f9ac3","type":"GENE","name":"ASAR9-1","canonical_id":"hgnc:HGNC:57019","description":"asynchronous replication autosomal RNA 9-1","metadata":{"aliases":["ASAR9-23"]}},{"id":"3c698f43f3504badb1b0368de0e92918","type":"GENE","name":"ASAR9-2","canonical_id":"hgnc:HGNC:57020","description":"asynchronous replication autosomal RNA 9-2","metadata":{"aliases":["ASAR9-24"]}},{"id":"d118df742e654a719b870cd9d39ff1f5","type":"GENE","name":"ASAR9-3","canonical_id":"hgnc:HGNC:57021","description":"asynchronous replication autosomal RNA 9-3","metadata":{"aliases":["ASAR9-30"]}},{"id":"72eda6864a1449ffb347cffe2c439762","type":"GENE","name":"ASB1","canonical_id":"hgnc:HGNC:16011","description":"ankyrin repeat and SOCS box containing 1","metadata":{"aliases":["ASB-1"]}},{"id":"98d944398fc74fd792db958b66beda30","type":"GENE","name":"ASB10","canonical_id":"hgnc:HGNC:17185","description":"ankyrin repeat and SOCS box containing 10","metadata":{"aliases":["GLC1F"]}},{"id":"4d59d6279e8b4fe780716722c3570ba1","type":"GENE","name":"ASB11","canonical_id":"hgnc:HGNC:17186","description":"ankyrin repeat and SOCS box containing 11","metadata":{"aliases":["DKFZp779E2460"]}},{"id":"667ad965f19a4d578d2b049c9eae9da7","type":"GENE","name":"ASB12","canonical_id":"hgnc:HGNC:19763","description":"ankyrin repeat and SOCS box containing 12","metadata":{"aliases":["FLJ39577"]}},{"id":"b5cd1ea0b7094079826b1f90222f9e08","type":"GENE","name":"ASB13","canonical_id":"hgnc:HGNC:19765","description":"ankyrin repeat and SOCS box containing 13","metadata":{"aliases":["FLJ13134","MGC19879"]}},{"id":"9e33e1132f1b4bbba64ea43d393a12cf","type":"GENE","name":"ASB14","canonical_id":"hgnc:HGNC:19766","description":"ankyrin repeat and SOCS box containing 14","metadata":{"aliases":["DKFZp313L0121"]}},{"id":"2d95176c36434647ab1498c5bb8a9aa1","type":"GENE","name":"ASB15","canonical_id":"hgnc:HGNC:19767","description":"ankyrin repeat and SOCS box containing 15","metadata":{"aliases":["FLJ43370"]}},{"id":"cf537e42bbdf40ea8f5cb8323afdba65","type":"GENE","name":"ASB15-AS1","canonical_id":"hgnc:HGNC:40904","description":"ASB15 antisense RNA 1","metadata":null},{"id":"bfebaffe8b104c4c994a944bcad2549d","type":"GENE","name":"ASB16","canonical_id":"hgnc:HGNC:19768","description":"ankyrin repeat and SOCS box containing 16","metadata":{"aliases":["FLJ30165"]}},{"id":"7312dfe3d8504f6d94e2d61460dd75b0","type":"GENE","name":"ASB16-AS1","canonical_id":"hgnc:HGNC:25442","description":"ASB16 antisense RNA 1","metadata":{"aliases":["DKFZp762C2414","C17orf65"]}},{"id":"44ae6f03425b44cfa4894f277b21b778","type":"GENE","name":"ASB17","canonical_id":"hgnc:HGNC:19769","description":"ankyrin repeat and SOCS box containing 17","metadata":null},{"id":"a80fde52b61044ca840d6e00f834d952","type":"GENE","name":"ASB18","canonical_id":"hgnc:HGNC:19770","description":"ankyrin repeat and SOCS box containing 18","metadata":null},{"id":"806f0d3be51e4cfb9eed1dbc67b2cc7f","type":"GENE","name":"ASB2","canonical_id":"hgnc:HGNC:16012","description":"ankyrin repeat and SOCS box containing 2","metadata":{"aliases":["ASB-2"]}},{"id":"9a2fdec029604e17bb506481266218e3","type":"GENE","name":"ASB3","canonical_id":"hgnc:HGNC:16013","description":"ankyrin repeat and SOCS box containing 3","metadata":{"aliases":["ASB-3"]}},{"id":"cf978596f3184178a6a8b439b1fad801","type":"GENE","name":"ASB4","canonical_id":"hgnc:HGNC:16009","description":"ankyrin repeat and SOCS box containing 4","metadata":{"aliases":["ASB-4"]}},{"id":"ede8eceaeac64f1484ada074f28ad0a4","type":"GENE","name":"ASB5","canonical_id":"hgnc:HGNC:17180","description":"ankyrin repeat and SOCS box containing 5","metadata":null},{"id":"85146d6978f74d0db7a74092a22245ad","type":"GENE","name":"ASB6","canonical_id":"hgnc:HGNC:17181","description":"ankyrin repeat and SOCS box containing 6","metadata":null},{"id":"1c8388f887ca42b1a174d760fc9a204a","type":"GENE","name":"ASB6-AS1","canonical_id":"hgnc:HGNC:58232","description":"ASB6 antisense RNA 1","metadata":null},{"id":"060cb2f673324f339b525b7772351b09","type":"GENE","name":"ASB7","canonical_id":"hgnc:HGNC:17182","description":"ankyrin repeat and SOCS box containing 7","metadata":null},{"id":"53abe9f9844d4fd680b3a8eb2ef5652e","type":"GENE","name":"ASB8","canonical_id":"hgnc:HGNC:17183","description":"ankyrin repeat and SOCS box containing 8","metadata":{"aliases":["MGC5540","FLJ21255"]}},{"id":"8a50e38c0c6d4f64a791e9676a8f03d5","type":"GENE","name":"ASB9","canonical_id":"hgnc:HGNC:17184","description":"ankyrin repeat and SOCS box containing 9","metadata":{"aliases":["DKFZP564L0862","MGC4954","FLJ20636"]}},{"id":"fbe03758dfd74188b916f6e2f14c586e","type":"GENE","name":"ASB9P1","canonical_id":"hgnc:HGNC:20972","description":"ankyrin repeat and SOCS box containing 9 pseudogene 1","metadata":null},{"id":"dc4d9020615e42a79ff2e54068281a6a","type":"GENE","name":"ASCC1","canonical_id":"hgnc:HGNC:24268","description":"activating signal cointegrator 1 complex subunit 1","metadata":{"aliases":["CGI-18","ASC1p50","Em:AC022392.3","p50"]}},{"id":"3150aad2cab342258f25a1efe0106d38","type":"GENE","name":"ASCC2","canonical_id":"hgnc:HGNC:24103","description":"activating signal cointegrator 1 complex subunit 2","metadata":{"aliases":["ASC1p100","FLJ21588","DKFZp586O0223"]}},{"id":"4dafd050af854a3c81aa8a8c08525c3e","type":"GENE","name":"ASCC3","canonical_id":"hgnc:HGNC:18697","description":"activating signal cointegrator 1 complex subunit 3","metadata":{"aliases":["RNAH","ASC1p200","dJ121G13.4","dJ467N11.1","HELIC1"]}},{"id":"c62a351fbb3a4af18eb51caf76cf4c99","type":"TRIAL","name":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07318389","description":"Dynamic Tumor Resistance; Metastatic Colorectal Cancer","metadata":null},{"id":"67aef514abf144c4b72648ab8eef993e","type":"GENE","name":"ASCL1","canonical_id":"hgnc:HGNC:738","description":null,"metadata":null},{"id":"2e8bf775d35c42bbbbc0ed7aaae7d2b4","type":"GENE","name":"ASCL2","canonical_id":"hgnc:HGNC:739","description":null,"metadata":null},{"id":"174ea1746a4f48388a031986ad09ede9","type":"GENE","name":"ASCL3","canonical_id":"hgnc:HGNC:740","description":"achaete-scute family bHLH transcription factor 3","metadata":{"aliases":["bHLHa42","HASH3","Sgn1"]}},{"id":"b6077a8197294e3390e92e89a900c317","type":"GENE","name":"ASCL4","canonical_id":"hgnc:HGNC:24311","description":"achaete-scute family bHLH transcription factor 4","metadata":{"aliases":["HASH4","bHLHa44"]}},{"id":"5a922ee0c1144c6bb397f7cced3dd5b9","type":"GENE","name":"ASCL5","canonical_id":"hgnc:HGNC:33169","description":"achaete-scute family bHLH transcription factor 5","metadata":{"aliases":["bHLHa47","ASH-5","AmeloD"]}},{"id":"6cf053cc27c3463bbc01d9fb08b81a2a","type":"GENE","name":"ASDURF","canonical_id":"hgnc:HGNC:53619","description":"ASNSD1 upstream open reading frame","metadata":{"aliases":["ASNSD1-uORF","ASNSD1-SEP"]}},{"id":"fd44c69270ab45a89bba358c709f3d20","type":"GENE","name":"ASF1A","canonical_id":"hgnc:HGNC:20995","description":"anti-silencing function 1A histone chaperone","metadata":{"aliases":["DKFZP547E2110","CIA"]}},{"id":"8623b545b67a48759725a526a6b27b17","type":"GENE","name":"ASF1B","canonical_id":"hgnc:HGNC:20996","description":null,"metadata":null},{"id":"8e6234e8f63e4eafbddfcee46cdf123d","type":"GENE","name":"ASGR1","canonical_id":"hgnc:HGNC:742","description":"asialoglycoprotein receptor 1","metadata":{"aliases":["CLEC4H1"]}},{"id":"067d381cf13b40f4855e0ef9caae85d1","type":"GENE","name":"ASGR2","canonical_id":"hgnc:HGNC:743","description":"asialoglycoprotein receptor 2","metadata":{"aliases":["CLEC4H2"]}},{"id":"dfb3ca255f4c403a9e51b6fcad38c4aa","type":"GENE","name":"ASH1L","canonical_id":"hgnc:HGNC:19088","description":null,"metadata":null},{"id":"5fdd4e88e3bb4c36b8650504878db268","type":"GENE","name":"ASH1L-AS1","canonical_id":"hgnc:HGNC:44146","description":"ASH1L antisense RNA 1","metadata":{"aliases":["APPLE"]}},{"id":"437b5bcb077549c3bf317267f60d9c71","type":"GENE","name":"ASH1L-IT1","canonical_id":"hgnc:HGNC:41449","description":"ASH1L intronic transcript 1","metadata":null},{"id":"4a7fa28694e644e38b592dcbcfe578b7","type":"GENE","name":"ASH2L","canonical_id":"hgnc:HGNC:744","description":"ASH2 like, histone lysine methyltransferase complex subunit","metadata":{"aliases":["ASH2L2","ASH2","Bre2","ASH2L1"]}},{"id":"9dbfd35c727b419797136f3a9132e811","type":"GENE","name":"ASH2LP1","canonical_id":"hgnc:HGNC:19332","description":"ASH2L pseudogene 1","metadata":null},{"id":"6ae31540ac9a44b9b8cb70d21c119cb6","type":"GENE","name":"ASH2LP2","canonical_id":"hgnc:HGNC:53059","description":"ASH2L pseudogene 2","metadata":null},{"id":"d42af1b60edf48aaa1a82682e46c5f4c","type":"GENE","name":"ASH2LP3","canonical_id":"hgnc:HGNC:53060","description":"ASH2L pseudogene 3","metadata":null},{"id":"fe58183e63d447f0bf1e7b52b8198492","type":"GENE","name":"ASH2LP4","canonical_id":"hgnc:HGNC:56973","description":"ASH2L pseudogene 4","metadata":null},{"id":"e5418e310fec4ba8bdfd3c95daa3c815","type":"GENE","name":"ASIC1","canonical_id":"hgnc:HGNC:100","description":"acid sensing ion channel subunit 1","metadata":{"aliases":["BNaC2","hBNaC2","ACCN2"]}},{"id":"f0bda6ddd9b74208a944b9010e62ced4","type":"GENE","name":"ASIC2","canonical_id":"hgnc:HGNC:99","description":"acid sensing ion channel subunit 2","metadata":{"aliases":["ASIC2a","BNC1","BNaC1","hBNaC1","MDEG","ACCN","ACCN1"]}},{"id":"39ac9a43688d464085c646811336eb33","type":"GENE","name":"ASIC2-AS1","canonical_id":"hgnc:HGNC:27103","description":"ASIC2 antisense RNA 1","metadata":null},{"id":"70236b2454b44a16b08cd606f05f20a6","type":"GENE","name":"ASIC2-AS2","canonical_id":"hgnc:HGNC:58564","description":"ASIC2 antisense RNA 2","metadata":null},{"id":"f787946f90db4f8ebbc50ab1528b8993","type":"GENE","name":"ASIC2-AS3","canonical_id":"hgnc:HGNC:58620","description":"ASIC2 antisense RNA 3","metadata":null},{"id":"cb07044b891246439517af845455ad86","type":"GENE","name":"ASIC3","canonical_id":"hgnc:HGNC:101","description":"acid sensing ion channel subunit 3","metadata":{"aliases":["TNaC1","DRASIC","ACCN3"]}},{"id":"c9d537e6623d4519a51f62fd4ad6f07f","type":"GENE","name":"ASIC4","canonical_id":"hgnc:HGNC:21263","description":"acid sensing ion channel subunit family member 4","metadata":{"aliases":["BNAC4","ACCN4"]}},{"id":"3af94b18601a46e391293b0199fd8a76","type":"GENE","name":"ASIC4-AS1","canonical_id":"hgnc:HGNC:40960","description":"ASIC4 antisense RNA 1","metadata":null},{"id":"a83a4012ff5042c6a5171ba239f54857","type":"GENE","name":"ASIC5","canonical_id":"hgnc:HGNC:17537","description":"acid sensing ion channel subunit family member 5","metadata":{"aliases":["INAC","HINAC","ACCN5"]}},{"id":"4de4bb2cfc37476c9e33743019f299ce","type":"GENE","name":"ASIP","canonical_id":"hgnc:HGNC:745","description":"agouti signaling protein","metadata":{"aliases":["ASP","AGTIL"]}},{"id":"4be67ad8d5c548e49cf825594f970583","type":"TRIAL","name":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","canonical_id":"clinicaltrials.gov:NCT04143607","description":"Locally Advanced or Metastatic NSCLC","metadata":null},{"id":"f4b61ef2abe8426caf649146305b4e63","type":"GENE","name":"ASL","canonical_id":"hgnc:HGNC:746","description":"argininosuccinate lyase","metadata":{"aliases":["ASAL"]}},{"id":"7e256b5540504c98ac2449a0232a5141","type":"GENE","name":"ASLP1","canonical_id":"hgnc:HGNC:747","description":"argininosuccinate lyase pseudogene 1","metadata":{"aliases":["ASLL"]}},{"id":"c5791184da9e433783cddfdcd6adc436","type":"GENE","name":"ASMER1","canonical_id":"hgnc:HGNC:53135","description":"adipocyte associated metabolic related lncRNA 1","metadata":{"aliases":["ENST00000418954","ASMER-1","LINC02246"]}},{"id":"be270dd653944d12a2b6e1debcecd0b2","type":"GENE","name":"ASMER2","canonical_id":"hgnc:HGNC:56702","description":"adipocyte associated metabolic related lncRNA 2","metadata":{"aliases":["ASMER-2","CATG00000111229.1"]}},{"id":"31752f0dd0a045b79cd24e4ab6d772d0","type":"GENE","name":"ASMT","canonical_id":"hgnc:HGNC:750","description":"acetylserotonin O-methyltransferase","metadata":{"aliases":["HIOMT","ASMTY","HIOMTY"]}},{"id":"ffa9c0f7b5444816834e082114e7b57c","type":"GENE","name":"ASMTL","canonical_id":"hgnc:HGNC:751","description":"acetylserotonin O-methyltransferase like","metadata":null},{"id":"c1f4c5e5ba7341e99e24c5a3b5e49326","type":"GENE","name":"ASMTL-AS1","canonical_id":"hgnc:HGNC:25811","description":"ASMTL antisense RNA 1","metadata":{"aliases":["FLJ13330","CXYorf2","NCRNA00105","ASMTLAS","ASMTL-AS"]}},{"id":"c052036d082c4434a212b8b6b747105a","type":"GENE","name":"ASNS","canonical_id":"hgnc:HGNC:753","description":null,"metadata":null},{"id":"550af6cdd283453baf04750d1b7d8f21","type":"GENE","name":"ASNSD1","canonical_id":"hgnc:HGNC:24910","description":"asparagine synthetase domain containing 1","metadata":{"aliases":["NS3TP1","FLJ20752","NBLA00058"]}},{"id":"4dd878346e4b4165ab2cdcbdfa39a9dc","type":"GENE","name":"ASNSP1","canonical_id":"hgnc:HGNC:754","description":"ASNS pseudogene 1","metadata":{"aliases":["ASNSL1"]}},{"id":"3aef266a3d5d491083a58f06f4e813fa","type":"GENE","name":"ASNSP2","canonical_id":"hgnc:HGNC:755","description":"ASNS pseudogene 2","metadata":{"aliases":["ASNSL2"]}},{"id":"f63a3a6993a0426b96c295ef5bab1cd9","type":"GENE","name":"ASNSP3","canonical_id":"hgnc:HGNC:39399","description":"ASNS pseudogene 3","metadata":null},{"id":"3292b9860feb4d4e9b38e96f4f727fd6","type":"GENE","name":"ASNSP4","canonical_id":"hgnc:HGNC:39400","description":"ASNS pseudogene 4","metadata":null},{"id":"9890707e71dc44588a1a0db7ea2bb35a","type":"GENE","name":"ASNSP5","canonical_id":"hgnc:HGNC:39401","description":"ASNS pseudogene 5","metadata":null},{"id":"ffee9cf1419b40139de49fc0515942b1","type":"GENE","name":"ASNSP6","canonical_id":"hgnc:HGNC:49876","description":"ASNS pseudogene 6","metadata":null},{"id":"f2613303a0154372915dbf51a69aa7dc","type":"TRIAL","name":"ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA","canonical_id":"clinicaltrials.gov:NCT01408186","description":"Upper Gastrointestinal Bleeding","metadata":null},{"id":"6d913083218b482ca98781a8a7c329db","type":"GENE","name":"ASPA","canonical_id":"hgnc:HGNC:756","description":"aspartoacylase","metadata":{"aliases":["ASP","ACY2"]}},{"id":"6ba4dcdadd50447880312dc480f4c472","type":"GENE","name":"ASPDH","canonical_id":"hgnc:HGNC:33856","description":"aspartate dehydrogenase domain containing","metadata":null},{"id":"907ea75d8dab458a8274cf5a2c59b323","type":"GENE","name":"ASPG","canonical_id":"hgnc:HGNC:20123","description":"asparaginase","metadata":{"aliases":["LysoLP","hASNase1","C14orf76"]}},{"id":"cac85239396f45fb9d2d6178c94e88e3","type":"GENE","name":"ASPH","canonical_id":"hgnc:HGNC:757","description":null,"metadata":null},{"id":"9a872a815599435eaeb1b931c699dd66","type":"GENE","name":"ASPHD1","canonical_id":"hgnc:HGNC:27380","description":"aspartate beta-hydroxylase domain containing 1","metadata":null},{"id":"f320ae5a3da847f6b643ab7dbb307598","type":"GENE","name":"ASPHD2","canonical_id":"hgnc:HGNC:30437","description":"aspartate beta-hydroxylase domain containing 2","metadata":{"aliases":["FLJ39838"]}},{"id":"9b86dd86387e4e739b7d4da896493767","type":"GENE","name":"ASPM","canonical_id":"hgnc:HGNC:19048","description":null,"metadata":null},{"id":"1c3bd5ad01004853b01ddfe8124ad81d","type":"GENE","name":"ASPN","canonical_id":"hgnc:HGNC:14872","description":null,"metadata":null},{"id":"b6741653fcb04a58b3c6baa99b52068b","type":"GENE","name":"ASPNAT","canonical_id":"hgnc:HGNC:26742","description":"aspartate N-acetyltransferase","metadata":{"aliases":["FLJ37478","Hcml3","Shati","NAT8L"]}},{"id":"7fcd39a771cc4a9fb8aa42697a9f0fd5","type":"GENE","name":"ASPRV1","canonical_id":"hgnc:HGNC:26321","description":"aspartic peptidase retroviral like 1","metadata":{"aliases":["Taps","SASPase","FLJ25084"]}},{"id":"ef5e3373be5546b9a654b2e38ce6465a","type":"GENE","name":"ASPSCR1","canonical_id":"hgnc:HGNC:13825","description":"ASPSCR1 tether for SLC2A4, UBX domain containing","metadata":{"aliases":["ASPS","ASPL","UBXD9","UBXN9","TUG"]}},{"id":"90f10df85f854f1385b853ead7a5bd8a","type":"GENE","name":"ASRGL1","canonical_id":"hgnc:HGNC:16448","description":"asparaginase and isoaspartyl peptidase 1","metadata":{"aliases":["FLJ22316","ALP1","ALP"]}},{"id":"5a73f480b83a44cd8c6939d7aff6b226","type":"GENE","name":"ASS1","canonical_id":"hgnc:HGNC:758","description":null,"metadata":null},{"id":"6b6015528d644a788e5cedd0f579e100","type":"GENE","name":"ASS1P1","canonical_id":"hgnc:HGNC:759","description":"argininosuccinate synthetase 1 pseudogene 1","metadata":{"aliases":["ASSP1"]}},{"id":"a542cf7ef31c461aaa354400b0a99131","type":"GENE","name":"ASS1P10","canonical_id":"hgnc:HGNC:760","description":"argininosuccinate synthetase 1 pseudogene 10","metadata":{"aliases":["ASSP10"]}},{"id":"27be7769cacb446c8de48814eedcd7b5","type":"GENE","name":"ASS1P11","canonical_id":"hgnc:HGNC:761","description":"argininosuccinate synthetase 1 pseudogene 11","metadata":{"aliases":["TCAG_1641141","ASSP11"]}},{"id":"7a1ba12b198a4f1482347615c31015ce","type":"GENE","name":"ASS1P12","canonical_id":"hgnc:HGNC:762","description":"argininosuccinate synthetase 1 pseudogene 12","metadata":{"aliases":["ASSP12"]}},{"id":"ecd8a8e0b72e48cd88df69cae1fe65b0","type":"GENE","name":"ASS1P13","canonical_id":"hgnc:HGNC:763","description":"argininosuccinate synthetase 1 pseudogene 13","metadata":{"aliases":["ASSP13"]}},{"id":"985c42b6ad9547c5a95928c3d4d25dc0","type":"GENE","name":"ASS1P14","canonical_id":"hgnc:HGNC:764","description":"argininosuccinate synthetase 1 pseudogene 14","metadata":{"aliases":["ASSP14"]}},{"id":"9b223d7d48084c5f97282cacf229ec85","type":"GENE","name":"ASS1P2","canonical_id":"hgnc:HGNC:765","description":"argininosuccinate synthetase 1 pseudogene 2","metadata":{"aliases":["ASSP2"]}},{"id":"21f254180b0e4ff58ece398a10077a4c","type":"GENE","name":"ASS1P3","canonical_id":"hgnc:HGNC:766","description":"argininosuccinate synthetase 1 pseudogene 3","metadata":{"aliases":["ASSP3"]}},{"id":"31ba5cf9c1ff499c9065952e40e3d558","type":"GENE","name":"ASS1P4","canonical_id":"hgnc:HGNC:767","description":"argininosuccinate synthetase 1 pseudogene 4","metadata":{"aliases":["ASSP4"]}},{"id":"b9a0a0745f05496c92e0e94f77e6342c","type":"GENE","name":"ASS1P5","canonical_id":"hgnc:HGNC:768","description":"argininosuccinate synthetase 1 pseudogene 5","metadata":{"aliases":["ASSP5"]}},{"id":"17fdd00fd0e241dc9ce7e6d1ae367e88","type":"GENE","name":"ASS1P6","canonical_id":"hgnc:HGNC:769","description":"argininosuccinate synthetase 1 pseudogene 6","metadata":{"aliases":["ASSP6"]}},{"id":"776a2288d2774c389d96828c26b47359","type":"GENE","name":"ASS1P7","canonical_id":"hgnc:HGNC:770","description":"argininosuccinate synthetase 1 pseudogene 7","metadata":{"aliases":["ASSP7"]}},{"id":"3a6baf5d4642486fbdc0c6201926b3ef","type":"GENE","name":"ASS1P8","canonical_id":"hgnc:HGNC:771","description":"argininosuccinate synthetase 1 pseudogene 8","metadata":{"aliases":["ASSP8"]}},{"id":"ad357df525334bb1a354b5bbd0dc656a","type":"GENE","name":"ASS1P9","canonical_id":"hgnc:HGNC:772","description":"argininosuccinate synthetase 1 pseudogene 9","metadata":{"aliases":["ASSP9"]}},{"id":"4b52dc30e3ce44dca01ba819d229ae69","type":"GENE","name":"ASTE1","canonical_id":"hgnc:HGNC:25021","description":"asteroid structure-specific endonuclease 1","metadata":{"aliases":["HT001"]}},{"id":"4e8b2f8ff416448c96ce2a933bee8d91","type":"GENE","name":"ASTILCS","canonical_id":"hgnc:HGNC:56718","description":"antisense transcript of PTP4A3, liver carcinoma survival associated","metadata":null},{"id":"b402d0f37d7048a3b0e7304739ff2073","type":"GENE","name":"ASTL","canonical_id":"hgnc:HGNC:31704","description":"astacin like metalloendopeptidase","metadata":{"aliases":["ovastacin","SAS1B"]}},{"id":"a4b5f9e2cefb480a8ea4431e134a0048","type":"GENE","name":"ASTN1","canonical_id":"hgnc:HGNC:773","description":"astrotactin 1","metadata":{"aliases":["ASTN"]}},{"id":"73364da7114848b5a121ee9173922915","type":"GENE","name":"ASTN2","canonical_id":"hgnc:HGNC:17021","description":"astrotactin 2","metadata":{"aliases":["KIAA0634"]}},{"id":"e4924bdc96954bac89efe5f7ebb4d06b","type":"GENE","name":"ASTN2-AS1","canonical_id":"hgnc:HGNC:51175","description":"ASTN2 antisense RNA 1","metadata":null},{"id":"3a08c34354a94afda1a6fb898bff6e7b","type":"GENE","name":"ASXL1","canonical_id":"hgnc:HGNC:18318","description":null,"metadata":null},{"id":"81bab887337749c0a51c0e1a5a49f933","type":"GENE","name":"ASXL2","canonical_id":"hgnc:HGNC:23805","description":"ASXL transcriptional regulator 2","metadata":{"aliases":["ASXH2","FLJ10898","KIAA1685"]}},{"id":"0b1743d0d6d241738fe38a5ffa9146e1","type":"GENE","name":"ASXL3","canonical_id":"hgnc:HGNC:29357","description":"ASXL transcriptional regulator 3","metadata":{"aliases":["KIAA1713"]}},{"id":"2e97672bb5c54991a3d007462f66e2be","type":"GENE","name":"ASXL3-DT","canonical_id":"hgnc:HGNC:55290","description":"ASXL3 divergent transcript","metadata":null},{"id":"3c6810565fc948479f8cda3fc6933964","type":"GENE","name":"ASZ1","canonical_id":"hgnc:HGNC:1350","description":"ankyrin repeat, SAM and basic leucine zipper domain containing 1","metadata":{"aliases":["Orf3","GASZ","ALP1","CT1.19","C7orf7","ANKL1"]}},{"id":"3e42052a37a84532bea65cf03ca242c8","type":"TRIAL","name":"AScVS and/ or Prazosin for Scorpion Envenomation","canonical_id":"clinicaltrials.gov:NCT00753064","description":"Scorpion Envenomation","metadata":null},{"id":"0cb6cdfd74d74db483b573a80d26a7ac","type":"TRIAL","name":"ATAC - Quality of Life Sub-Protocol","canonical_id":"clinicaltrials.gov:NCT00784680","description":"Quality of Life","metadata":null},{"id":"00bf129aab414b8fb39b8a3589de0de2","type":"GO_TERM","name":"ATAC complex","canonical_id":"go:GO:0140672","description":"\"A chromatin remodeling complex that regulates transcription via acetylation primarily of nucleosomal histones H3 and possibly H4. Shares the histone acetylation (HAT) module of GCN5/PCAF-ADA2-ADA3-SGF29 (or orthologs) with the related SAGA complex (GO:0000124). Contains HAT subunits GCN5 or PCAF in a mutually exclusive manner. In addition to the HAT module contains DR1/NC2B, KAT14, MBIP, WDR5, YEATS2 and ZZZ3 or orthologs. Also regulates the activity of non-histone targets and orchestrates mitotic progression by regulating Cyclin A degradation through acetylation.\" [GOC:bhm, PMID:19936620, PMID:20562830, PMID:28966424]","metadata":null},{"id":"60837587ee194278948b718a5ba4f5d1","type":"GENE","name":"ATAD1","canonical_id":"hgnc:HGNC:25903","description":"ATPase family AAA domain containing 1","metadata":{"aliases":["FLJ14600","Msp1"]}},{"id":"75d45eb57a424adcae1a65cdd6f90748","type":"GENE","name":"ATAD2","canonical_id":"hgnc:HGNC:30123","description":null,"metadata":null},{"id":"19ec06016865482290c6f96da7451731","type":"GENE","name":"ATAD2B","canonical_id":"hgnc:HGNC:29230","description":"ATPase family AAA domain containing 2B","metadata":{"aliases":["KIAA1240"]}},{"id":"3860fb2aae0f4fc9bbb74df3709065c4","type":"GENE","name":"ATAD3A","canonical_id":"hgnc:HGNC:25567","description":"ATPase family AAA domain containing 3A","metadata":{"aliases":["FLJ10709"]}},{"id":"ea7b3a4da5614bc68fe0053962810707","type":"GENE","name":"ATAD3B","canonical_id":"hgnc:HGNC:24007","description":"ATPase family AAA domain containing 3B","metadata":{"aliases":["TOB3","KIAA1273"]}},{"id":"c286f9507de54671b1a1c104933d9d26","type":"GENE","name":"ATAD3C","canonical_id":"hgnc:HGNC:32151","description":"ATPase family AAA domain containing 3C","metadata":{"aliases":["FLJ34599"]}},{"id":"870ae3a42e3346d590747e8123ca383a","type":"GENE","name":"ATAD5","canonical_id":"hgnc:HGNC:25752","description":"ATPase family AAA domain containing 5","metadata":{"aliases":["FLJ12735","FRAG1","ELG1","C17orf41"]}},{"id":"75923ca4df4f4633b379398bfada6f09","type":"GENE","name":"ATAT1","canonical_id":"hgnc:HGNC:21186","description":"alpha tubulin acetyltransferase 1","metadata":{"aliases":["FLJ13158","Em:AB023049.7","MEC17","C6orf134"]}},{"id":"fde88c594c284eb3ae11fee6d04a69c4","type":"GENE","name":"ATCAY","canonical_id":"hgnc:HGNC:779","description":"ATCAY kinesin light chain interacting caytaxin","metadata":{"aliases":["BNIP-H"]}},{"id":"da49f8fa6f1942429678296c1c6febc1","type":"GENE","name":"ATE1","canonical_id":"hgnc:HGNC:782","description":"arginyltransferase 1","metadata":null},{"id":"7c05f467f6104de2b0401737e89b6ce5","type":"GENE","name":"ATE1OSP","canonical_id":"hgnc:HGNC:49496","description":"ATE1 opposite strand, pseudogene","metadata":{"aliases":["ENST00000437593","ATE1-AS1"]}},{"id":"ea2075f99aa0466c8ef1c006c091ad5f","type":"GENE","name":"ATF1","canonical_id":"hgnc:HGNC:783","description":null,"metadata":null},{"id":"5033fb8566ea4928a30ffb6699587c5c","type":"GENE","name":"ATF1-AS1","canonical_id":"hgnc:HGNC:58960","description":"ATF1 and DIP2B antisense RNA 1","metadata":null},{"id":"49668ad6979847a4965c3ca7178f743b","type":"GO_TERM","name":"ATF1-ATF4 transcription factor complex","canonical_id":"go:GO:1990590","description":"\"Transcription factor complex consisting of ATF1 and ATF4 subunits that is capable of binding to cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3') of the GRP78 (HSPA5) promoter. Involved in the ER stress response pathway.\" [GOC:bhm, PMID:12871976]","metadata":null},{"id":"f570303df748443e84bb490bb65c7426","type":"GENE","name":"ATF1P1","canonical_id":"hgnc:HGNC:37691","description":"activating transcription factor 1 pseudogene 1","metadata":null},{"id":"3003dfd7d1674fedaa73ed2b68523041","type":"GENE","name":"ATF2","canonical_id":"hgnc:HGNC:784","description":null,"metadata":null},{"id":"268f43afacdf42ebbe4904d0e7ea4a8e","type":"GENE","name":"ATF3","canonical_id":"hgnc:HGNC:785","description":null,"metadata":null},{"id":"6c68ba13dfad46b0b2122639f6cf1661","type":"GENE","name":"ATF4","canonical_id":"hgnc:HGNC:786","description":null,"metadata":null},{"id":"0548b00c7b0048f1b84008a7cb48ac7c","type":"GO_TERM","name":"ATF4-CREB1 transcription factor complex","canonical_id":"go:GO:1990589","description":"\"Transcription factor complex consisting of ATF4 and CREB1 subunits that is capable of binding to cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3') as part of the positive regulation of transcription. Regulatory targets include the GRP78 (HSPA5) promoter in humans, whose activation by this complex is part of the ER stress response pathway.\" [GOC:bhm, PMID:12871976]","metadata":null},{"id":"77a7876f05894cb79886fbf815090463","type":"GENE","name":"ATF4P1","canonical_id":"hgnc:HGNC:789","description":"activating transcription factor 4 pseudogene 1","metadata":{"aliases":["TAXREB67P","TXREBP","ATF4P"]}},{"id":"9b1bd085f28f4493aa191671857e2b84","type":"GENE","name":"ATF4P2","canonical_id":"hgnc:HGNC:34025","description":"activating transcription factor 4 pseudogene 2","metadata":null},{"id":"2e36cf30d6004d029f9c6e6f940c0164","type":"GENE","name":"ATF4P3","canonical_id":"hgnc:HGNC:788","description":"activating transcription factor 4 pseudogene 3","metadata":{"aliases":["ATF4C"]}},{"id":"7e32e4b44fc046ee8528ef3e54e5f061","type":"GENE","name":"ATF4P4","canonical_id":"hgnc:HGNC:787","description":"activating transcription factor 4 pseudogene 4","metadata":{"aliases":["ATF4B"]}},{"id":"3aa69eb0d73640a1ad3bf0118677922d","type":"GENE","name":"ATF5","canonical_id":"hgnc:HGNC:790","description":null,"metadata":null},{"id":"4c93cc3a3a0a4826988dcaa53695e2a3","type":"GENE","name":"ATF6","canonical_id":"hgnc:HGNC:791","description":null,"metadata":null},{"id":"c786848c84734079bdccc51daa5b9d6b","type":"GENE","name":"ATF6-DT","canonical_id":"hgnc:HGNC:55826","description":"ATF6 divergent transcript","metadata":null},{"id":"dc46520f0a8e45018ff88d54278de094","type":"GO_TERM","name":"ATF6-mediated unfolded protein response","canonical_id":"go:GO:0036500","description":"\"The series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor ATF6 (activating transcription factor 6). Begins with activation of ATF6 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. Under conditions of endoplasmic reticulum stress, ATF6 translocates to the Golgi where it is processed by proteases to release a cytoplasmic domain (ATF6f), which operates as a transcriptional activator of many genes required to restore folding capacity.\" [GOC:bf, GOC:PARL, PMID:22013210]","metadata":null},{"id":"65eae60afc784e84bc05d3f9bcf3cd13","type":"GENE","name":"ATF6B","canonical_id":"hgnc:HGNC:2349","description":"activating transcription factor 6 beta","metadata":{"aliases":["G13","ATF6beta","CREBL1"]}},{"id":"ad74330252cb400dacc1830eafd02876","type":"GENE","name":"ATF7","canonical_id":"hgnc:HGNC:792","description":null,"metadata":null},{"id":"941687751f46477db1cc97dde295420f","type":"GENE","name":"ATF7-AS1","canonical_id":"hgnc:HGNC:58279","description":"ATF7 antisense RNA 1","metadata":null},{"id":"c7e6fd7f1de5424ba22adf9ba1a31c7f","type":"GENE","name":"ATF7-AS2","canonical_id":"hgnc:HGNC:59212","description":"ATF7 antisense RNA 2","metadata":null},{"id":"15eae0301211488587040e94f674b8f1","type":"GENE","name":"ATF7-NPFF","canonical_id":"hgnc:HGNC:55073","description":"ATF7-NPFF readthrough","metadata":null},{"id":"fbe5c81115a94f4aad1ad1d9d8c0b954","type":"GENE","name":"ATF7IP","canonical_id":"hgnc:HGNC:20092","description":"activating transcription factor 7 interacting protein","metadata":{"aliases":["FLJ10688","p621","ATF7IP1","MCAF1","MCAF","AM"]}},{"id":"4e3fe628e31d45879b2d2f370cfe54ec","type":"GENE","name":"ATF7IP2","canonical_id":"hgnc:HGNC:20397","description":"activating transcription factor 7 interacting protein 2","metadata":{"aliases":["FLJ12668","MCAF2"]}},{"id":"ac599546b13941ec82486eaa6fbd1c26","type":"GENE","name":"ATG10","canonical_id":"hgnc:HGNC:20315","description":"autophagy related 10","metadata":{"aliases":["DKFZP586I0418","FLJ13954","APG10L"]}},{"id":"9efabc69851c48968aa97df5a7fdf5d7","type":"GENE","name":"ATG10-AS1","canonical_id":"hgnc:HGNC:40914","description":"ATG10 antisense RNA 1","metadata":null},{"id":"edb74f657bc54b81906b9ae3f555d166","type":"GENE","name":"ATG10-IT1","canonical_id":"hgnc:HGNC:41455","description":"ATG10 intronic transcript 1","metadata":null},{"id":"ec54a7e3ac4e4e9aa35a4e2647589112","type":"GENE","name":"ATG101","canonical_id":"hgnc:HGNC:25679","description":"autophagy related 101","metadata":{"aliases":["FLJ11773","C12orf44"]}},{"id":"0b5a94d4389149e495e077c9ea3e5b92","type":"GENE","name":"ATG12","canonical_id":"hgnc:HGNC:588","description":"autophagy related 12","metadata":{"aliases":["APG12","APG12L"]}},{"id":"583b6edc39574ed8ad1fc2d17b4862d6","type":"GENE","name":"ATG12-AS1","canonical_id":"hgnc:HGNC:59117","description":"ATG12 antisense RNA 1","metadata":null},{"id":"33bf663ddb8744bbaabc589ac5a765da","type":"GENE","name":"ATG12P1","canonical_id":"hgnc:HGNC:21466","description":"autophagy related 12 pseudogene 1","metadata":{"aliases":["ATG12P"]}},{"id":"450ac2a5d8c5415cbccd834862baa04c","type":"GENE","name":"ATG12P2","canonical_id":"hgnc:HGNC:38605","description":"autophagy related 12 pseudogene 2","metadata":null},{"id":"c5befdcfa8774b8d9bab63a0c2c73bb5","type":"GENE","name":"ATG13","canonical_id":"hgnc:HGNC:29091","description":"autophagy related 13","metadata":{"aliases":["KIAA0652"]}},{"id":"e117e2b5ff1f483da45c84e2dcacdca8","type":"GENE","name":"ATG14","canonical_id":"hgnc:HGNC:19962","description":"autophagy related 14","metadata":{"aliases":["ATG14L","KIAA0831"]}},{"id":"832a92ade8564ea586947e3698aa46f1","type":"GENE","name":"ATG16L1","canonical_id":"hgnc:HGNC:21498","description":"autophagy related 16 like 1","metadata":{"aliases":["WDR30","FLJ10035","ATG16A","APG16L","ATG16L"]}},{"id":"2610366fe5904184a6777ff5241cd836","type":"GENE","name":"ATG16L2","canonical_id":"hgnc:HGNC:25464","description":"autophagy related 16 like 2","metadata":{"aliases":["FLJ00012","WDR80","ATG16B"]}},{"id":"19a06b494d0f41a3a5721056a1af1b57","type":"GO_TERM","name":"ATG2-ATG18 complex","canonical_id":"go:GO:0062079","description":"\"A protein complex essential for autophagy during nutrient deprivation, a catabolic process that sequesters undesired cellular material into autophagosomes for delivery to lysosomes for degradation. Contributes to nutrition homeostasis and damage control in eukaryotic cells. Functions at a late step of autophagosome formation for efficient completion of sequestration, probably through facilitating recruitment of ATG8-phosphatidylethanolamine (PE) to the preautophagosomal structure (PAS) and/or its protection from deconjugation by ATG4. Composed of ATG2 and ATG18 in Saccharomyces cerevisiae.\" [GOC:bhm, PMID:23230146]","metadata":null},{"id":"856a297405d8436aaf8bd49ab71ff252","type":"GENE","name":"ATG2A","canonical_id":"hgnc:HGNC:29028","description":"autophagy related 2A","metadata":{"aliases":["KIAA0404","BLTP4A"]}},{"id":"b15f6c9cff6f46468fdae04f0c5ebba6","type":"GENE","name":"ATG2B","canonical_id":"hgnc:HGNC:20187","description":"autophagy related 2B","metadata":{"aliases":["FLJ10242","BLTP4B","C14orf103"]}},{"id":"e6332e8f6d324062bca7062eb475ff28","type":"GENE","name":"ATG3","canonical_id":"hgnc:HGNC:20962","description":"autophagy related 3","metadata":{"aliases":["PC3-96","FLJ22125","MGC15201","DKFZp564M1178","APG3L"]}},{"id":"f49fb26c341945aea2237cf14c2b2430","type":"GENE","name":"ATG3P1","canonical_id":"hgnc:HGNC:31123","description":"autophagy related 3 pseudogene 1","metadata":{"aliases":["dJ54G6.1","ATG3P"]}},{"id":"8145d71b23c54d81904d9fc4120022fa","type":"GENE","name":"ATG4A","canonical_id":"hgnc:HGNC:16489","description":"autophagy related 4A cysteine peptidase","metadata":{"aliases":["AUTL2","APG4A"]}},{"id":"619b3e4412794c0db0ec76af6472725f","type":"GENE","name":"ATG4AP1","canonical_id":"hgnc:HGNC:44081","description":"autophagy related 4A cysteine peptidase pseudogene 1","metadata":null},{"id":"947acd3c6daa4932ad3891f07c7081fb","type":"GENE","name":"ATG4B","canonical_id":"hgnc:HGNC:20790","description":"autophagy related 4B cysteine peptidase","metadata":{"aliases":["Apg4B","KIAA0943","DKFZp586D1822","AUTL1","APG4B"]}},{"id":"68835a5dba934cd1aec3cfd667e67a58","type":"GENE","name":"ATG4C","canonical_id":"hgnc:HGNC:16040","description":"autophagy related 4C cysteine peptidase","metadata":{"aliases":["FLJ14867","AUTL3","AUTL1","APG4C"]}},{"id":"9105f1faacac41fe8c05151fac92394e","type":"GENE","name":"ATG4C-AS1","canonical_id":"hgnc:HGNC:58931","description":"ATG4C antisense RNA 1","metadata":{"aliases":["uc.27","uc.26"]}},{"id":"6c04621a1bde4df386bce019441089fd","type":"GENE","name":"ATG4D","canonical_id":"hgnc:HGNC:20789","description":"autophagy related 4D cysteine peptidase","metadata":{"aliases":["APG4-D","AUTL4","APG4D"]}},{"id":"374c7547ba6b472ca3887ee454c9f3cb","type":"GENE","name":"ATG5","canonical_id":"hgnc:HGNC:589","description":null,"metadata":null},{"id":"4e7182775be240e5bccddb1b8f29fff4","type":"GENE","name":"ATG7","canonical_id":"hgnc:HGNC:16935","description":null,"metadata":null},{"id":"884ebfe0800346c7a30abcfa400312be","type":"GENE","name":"ATG9A","canonical_id":"hgnc:HGNC:22408","description":"autophagy related 9A","metadata":{"aliases":["FLJ22169","APG9L1"]}},{"id":"8bede58dacb545c7a08586afd246d00c","type":"GENE","name":"ATG9B","canonical_id":"hgnc:HGNC:21899","description":"autophagy related 9B","metadata":{"aliases":["FLJ14885","APG9L2","SONE","NOS3AS"]}},{"id":"59c5ffcefbe54a7780c4c6685e1a26d5","type":"TRIAL","name":"ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT05279417","description":"Rheumatoid Arthritis","metadata":null},{"id":"502c94b8b2aa4826a074e8011116f741","type":"GENE","name":"ATIC","canonical_id":"hgnc:HGNC:794","description":"5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase","metadata":{"aliases":["PURH","AICARFT","IMPCHASE"]}},{"id":"0743d3fb793b4ebbbeaa4aed9cf642f4","type":"GENE","name":"ATL1","canonical_id":"hgnc:HGNC:11231","description":"atlastin GTPase 1","metadata":{"aliases":["FSP1","AD-FSP","SPG3","SPG3A"]}},{"id":"880e23f5a8da43ce9a15e2c3eed199b1","type":"GENE","name":"ATL2","canonical_id":"hgnc:HGNC:24047","description":"atlastin GTPase 2","metadata":{"aliases":["atlastin2","ARL6IP2"]}},{"id":"eb5916b76a09468fbfb793e4fbca290d","type":"GENE","name":"ATL3","canonical_id":"hgnc:HGNC:24526","description":"atlastin GTPase 3","metadata":{"aliases":["DKFZP564J0863"]}},{"id":"b83632c3f8644dc89b74cf66108991ed","type":"GENE","name":"ATM","canonical_id":"hgnc:HGNC:795","description":null,"metadata":null},{"id":"90149593c57c45a0943841caa514ffa4","type":"GENE","name":"ATM","canonical_id":"ensembl:ENSG00000149311","description":null,"metadata":null},{"id":"386ccd2ba1064f74a319f068aafe6c5d","type":"GENE","name":"ATMIN","canonical_id":"hgnc:HGNC:29034","description":"ATM interactor","metadata":{"aliases":["ASCIZ","KIAA0431","ZNF822"]}},{"id":"c2067207bc71436e9f2781ba2cfb5a9c","type":"GENE","name":"ATMINP1","canonical_id":"hgnc:HGNC:58530","description":"ATMIN pseudogene 1","metadata":null},{"id":"5024e94e2b4942c79d8ade49f22e74ad","type":"GENE","name":"ATMINP2","canonical_id":"hgnc:HGNC:58531","description":"ATMIN pseudogene 2","metadata":null},{"id":"508fb64922464815b7fee8848d81d256","type":"GENE","name":"ATN1","canonical_id":"hgnc:HGNC:3033","description":"atrophin 1","metadata":{"aliases":["B37","D12S755E","DRPLA"]}},{"id":"76e535c78b7446d2b8ab71e1834de9c2","type":"GENE","name":"ATOH1","canonical_id":"hgnc:HGNC:797","description":null,"metadata":null},{"id":"bf4b1e42f0da4fc3a8e10851cfd87227","type":"GENE","name":"ATOH7","canonical_id":"hgnc:HGNC:13907","description":"atonal bHLH transcription factor 7","metadata":{"aliases":["Math5","bHLHa13"]}},{"id":"2f7b9c851753440f882b25f6c12500a7","type":"GENE","name":"ATOH8","canonical_id":"hgnc:HGNC:24126","description":"atonal bHLH transcription factor 8","metadata":{"aliases":["HATH6","FLJ14708","bHLHa21"]}},{"id":"628c5e5b4a69490eac65e77d906638b1","type":"GENE","name":"ATOSA","canonical_id":"hgnc:HGNC:25609","description":"atos homolog A","metadata":{"aliases":["FLJ10980","KIAA1370","FAM214A"]}},{"id":"4058367aaaee4c4b82f77febf44d518c","type":"GENE","name":"ATOSB","canonical_id":"hgnc:HGNC:25666","description":"atos homolog B","metadata":{"aliases":["FLJ11560","bA182N22.6","KIAA1539","FAM214B"]}},{"id":"88a4406ec0f14c5ab967175162072f01","type":"GENE","name":"ATOSBP1","canonical_id":"hgnc:HGNC:54597","description":"ATOSB pseudogene 1","metadata":{"aliases":["FAM214BP1"]}},{"id":"7c30db435be94783941967f23e901b30","type":"GENE","name":"ATOX1","canonical_id":"hgnc:HGNC:798","description":"antioxidant 1 copper chaperone","metadata":{"aliases":["HAH1"]}},{"id":"bed7ea7e6ee44cce991d6abe38f0a665","type":"GENE","name":"ATOX1-AS1","canonical_id":"hgnc:HGNC:55528","description":"ATOX1 antisense RNA 1","metadata":null},{"id":"0540c67f427c4b28a61c74e98cc23f78","type":"GO_TERM","name":"ATP binding","canonical_id":"go:GO:0005524","description":"\"Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.\" [ISBN:0198506732]","metadata":null},{"id":"91a50076f62c499ca774f4e4620c098a","type":"GO_TERM","name":"ATP biosynthetic process","canonical_id":"go:GO:0006754","description":"\"The chemical reactions and pathways resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5a6000ebf2dc4ad1902ba535884d4582","type":"GO_TERM","name":"ATP citrate synthase activity","canonical_id":"go:GO:0003878","description":"\"Catalysis of the reaction: acetyl-CoA + ADP + H+ + oxaloacetate + phosphate = ATP + citrate + CoA.\" [RHEA:21160]","metadata":null},{"id":"9c0941c4ca084923a49922bdc0a7eaf5","type":"GO_TERM","name":"ATP deaminase activity","canonical_id":"go:GO:0047692","description":"\"Catalysis of the reaction: ATP + H2O + H+ = ITP + NH4+.\" [RHEA:13037]","metadata":null},{"id":"bbc9aefdaf4f43f68bd92f093ad87b65","type":"GO_TERM","name":"ATP diphosphatase activity","canonical_id":"go:GO:0047693","description":"\"Catalysis of the reaction: ATP + H2O = AMP + H+ + diphosphate.\" [RHEA:14245]","metadata":null},{"id":"3091cdb4ca89460584fa13f20d58f4a1","type":"GO_TERM","name":"ATP export","canonical_id":"go:GO:1904669","description":"\"The directed movement of ATP out of a cell or organelle.\" [GO_REF:0000074, GOC:TermGenie, PMID:24286344]","metadata":null},{"id":"b2f4cb45915e487eb2ec885e4a58d78d","type":"GO_TERM","name":"ATP generation from poly-ADP-D-ribose","canonical_id":"go:GO:1990966","description":"\"The process of generating ATP in the nucleus from poly-ADP-D-ribose. Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming.\" [PMID:27257257]","metadata":null},{"id":"906aabce94da49cd956a17fd84b08838","type":"GO_TERM","name":"ATP hydrolysis activity","canonical_id":"go:GO:0016887","description":"\"Catalysis of the reaction: ATP + H2O = ADP + H+ phosphate. ATP hydrolysis is used in some reactions as an energy source, for example to catalyze a reaction or drive transport against a concentration gradient.\" [RHEA:13065]","metadata":null},{"id":"55866c04774d4002942ebe35cee96842","type":"GO_TERM","name":"ATP metabolic process","canonical_id":"go:GO:0046034","description":"\"The chemical reactions and pathways involving ATP, adenosine triphosphate, a universally important coenzyme and enzyme regulator.\" [GOC:curators]","metadata":null},{"id":"59778c2c5e964c44b371f3d7e421a963","type":"GO_TERM","name":"ATP phosphoribosyltransferase activity","canonical_id":"go:GO:0003879","description":"\"Catalysis of the reaction: 1-(5-phospho-D-ribosyl)-ATP + diphosphate = ATP + 5-phospho-alpha-D-ribose 1-diphosphate.\" [EC:2.4.2.17]","metadata":null},{"id":"d36f43fc7bac487f874121d49d41fda8","type":"PROTEIN","name":"ATP synthase subunit c (Mycobacterium tuberculosis)","canonical_id":"uniprot:P9WPS1","description":null,"metadata":null},{"id":"8d5dfe4de42844d68524f69652572226","type":"GO_TERM","name":"ATP synthesis coupled electron transport","canonical_id":"go:GO:0042773","description":"\"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP.\" [ISBN:0716731363]","metadata":null},{"id":"9cbb5b7c128c460b84bb0e056b19f4be","type":"GO_TERM","name":"ATP transmembrane transporter activity","canonical_id":"go:GO:0005347","description":"\"Enables the transfer of ATP, adenosine triphosphate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"73b73b6eb13f4ee2a5d0d81072d80c6e","type":"GO_TERM","name":"ATP transport","canonical_id":"go:GO:0015867","description":"\"The directed movement of ATP, adenosine triphosphate, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f2c7083872934b63bfbdfe93b87ffe09","type":"GO_TERM","name":"ATP-activated inward rectifier potassium channel activity","canonical_id":"go:GO:0015272","description":"\"Enables the transmembrane transfer of a potassium ion by an inwardly-rectifying voltage-gated channel, where the inward rectification is due to a voltage-dependent block of the channel pore by ATP. An inwardly rectifying current-voltage relation is one where at any given driving force the inward flow of K+ ions exceeds the outward flow for the opposite driving force.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"14e07d6780c14fdc9d15148968c8af8d","type":"GO_TERM","name":"ATP-binding cassette (ABC) transporter complex","canonical_id":"go:GO:0043190","description":"\"A complex for the transport of metabolites into and out of the cell, typically comprised of four domains; two membrane-associated domains and two ATP-binding domains at the intracellular face of the membrane, that form a central pore through the plasma membrane. Each of the four core domains may be encoded as a separate polypeptide or the domains can be fused in any one of a number of ways into multidomain polypeptides. In Bacteria and Archaebacteria, ABC transporters also include substrate binding proteins to bind substrate external to the cytoplasm and deliver it to the transporter.\" [GOC:jl, GOC:mtg_sensu, PMID:11421269, PMID:15111107]","metadata":null},{"id":"1b74a9142d8f4ca384af57602a3a51ac","type":"GO_TERM","name":"ATP-binding cassette (ABC) transporter complex, integrated substrate binding","canonical_id":"go:GO:0055051","description":"\"A complex for the transport of metabolites out of the cell, consisting of 4 domains: two ATP-binding domains and two membrane spanning domains. In some cases, all 4 domains are contained on 1 polypeptide, while in others one ATP-binding domain and one membrane spanning domain are together on one polypeptide in what is called a half transporter. Two half-transporters come together to form a functional transporter. Transport of the substrate across the membrane is driven by the hydrolysis of ATP.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"84266e4a715a48c487da733242040727","type":"GO_TERM","name":"ATP-binding cassette (ABC) transporter complex, substrate-binding subunit-containing","canonical_id":"go:GO:0055052","description":"\"A complex for the transport of metabolites into the cell, consisting of 5 subunits: two ATP-binding subunits, two membrane spanning subunits, and one substrate-binding subunit. In organisms with two membranes, the substrate-binding protein moves freely in the periplasmic space and joins the other subunits only when bound with substrate. In organisms with only one membrane the substrate-binding protein is tethered to the cytoplasmic membrane and associated with the other subunits. Transport of the substrate across the membrane is driven by the hydrolysis of ATP.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"8a5a0d64cd604df48773b19c87202854","type":"GO_TERM","name":"ATP-binding cassette (ABC) transporter complex, transmembrane substrate-binding subunit-containing","canonical_id":"go:GO:0035796","description":"\"A complex for the transport of metabolites into the cell, consisting of 4 subunits: a transmembrane substrate-binding protein (known as the S component), and an energy-coupling module that comprises two ATP-binding proteins (known as the A and A' components) and a transmembrane protein (known as the T component). Transport of the substrate across the membrane is driven by the hydrolysis of ATP.\" [PMID:18931129, PMID:20972419, PMID:21135102]","metadata":null},{"id":"49b4b293b83f40afa1ae581733113aa2","type":"PROTEIN","name":"ATP-binding cassette sub-family C member 8","canonical_id":"uniprot:Q09428","description":null,"metadata":null},{"id":"d0fd5e51f0a64cdabc9b1ecdbd13899a","type":"PROTEIN","name":"ATP-binding cassette sub-family C member 9","canonical_id":"uniprot:O60706","description":null,"metadata":null},{"id":"342f21f08c684c77ad22545f31be9c16","type":"GO_TERM","name":"ATP-dependent DNA (cytosine-5-)-methyltransferase activity","canonical_id":"go:GO:0120328","description":"\"Catalytic activity that acts to transfer a methyl group to a DNA molecule, driven by ATP hydrolysis.\" [GOC:krc, PMID:31955845, PMID:32437639, RHEA:68984]","metadata":null},{"id":"4966e3111ca1429681c02ff465f06004","type":"GO_TERM","name":"ATP-dependent DNA damage sensor activity","canonical_id":"go:GO:0140664","description":"\"A molecule that recognises toxic DNA structures, and initiates a signaling response, driven by ATP hydrolysis.\" [PMID:33302090, PMID:33510387]","metadata":null},{"id":"2a102af8bfea4615a90d6b69d65691ee","type":"GO_TERM","name":"ATP-dependent DNA/DNA annealing activity","canonical_id":"go:GO:0036310","description":"\"An ATP-dependent activity that facilitates the formation of a complementary double-stranded DNA molecule.\" [PMID:21078962, PMID:22704558, PMID:22705370, PMID:22759634, PMID:22888405]","metadata":null},{"id":"5969affed8a94cf58cde934fbf114ab5","type":"GO_TERM","name":"ATP-dependent FeS chaperone activity","canonical_id":"go:GO:0140663","description":"\"Binding to and delivering metal ions to a target protein, driven by ATP hydrolysis.\" [PMID:16843540]","metadata":null},{"id":"6e49178960304a619ad00c1638f5e7e0","type":"GO_TERM","name":"ATP-dependent H2AZ histone chaperone activity","canonical_id":"go:GO:0140849","description":"\"A histone chaperone that mediates the exchange of histone H2A-H2B dimer and histone H2AZ-H2B dimers in a nucleosome, driven by ATP hydrolysis. Some chaperones insert H2AZ-H2B dimers and remove H2A-H2B, while others do the opposite.\" [PMID:21241891, PMID:23580526, PMID:30309918]","metadata":null},{"id":"250f3c24c11243e7b4faab93622b3449","type":"GO_TERM","name":"ATP-dependent H3-H4 histone complex chaperone activity","canonical_id":"go:GO:0140665","description":"\"A histone chaperone that carries a H3-H4 histone complex, driven by ATP hydrolysis.\" [PMID:31848341, PMID:33658433]","metadata":null},{"id":"a870052fdeda4c588f2d958a43d3c4d7","type":"GO_TERM","name":"ATP-dependent NAD(P)H-hydrate dehydratase activity","canonical_id":"go:GO:0047453","description":"\"Catalysis of the reaction: (6S)-6beta-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide + ATP = ADP + H+ + NAD(P)H + phosphate.\" [EC:4.2.1.93, PMID:3061454]","metadata":null},{"id":"b3205e0dc9ef42afb00d88d3fab07205","type":"GO_TERM","name":"ATP-dependent activity","canonical_id":"go:GO:0140657","description":"\"A molecular function characterized by the coupling of ATP hydrolysis to other steps of a reaction mechanism to make the reaction energetically favorable, for example to catalyze a reaction or drive transport against a concentration gradient.\" [PMID:24878343, PMID:25750732, PMID:32933017, PMID:33818025, PMID:33873056, PMID:33988324]","metadata":null},{"id":"fef76c04a820468bb4027a31efb97ce4","type":"GO_TERM","name":"ATP-dependent activity, acting on DNA","canonical_id":"go:GO:0008094","description":"\"Catalytic activity that acts to modify DNA, driven by ATP hydrolysis.\" [GOC:pdt]","metadata":null},{"id":"44e51c3fd725489db306d9e082263776","type":"GO_TERM","name":"ATP-dependent activity, acting on RNA","canonical_id":"go:GO:0008186","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate; this reaction requires the presence of RNA, and it drives another reaction.\" [GOC:jl]","metadata":null},{"id":"df94af8846de455d9ce80aa1a0cc9a47","type":"GO_TERM","name":"ATP-dependent chromatin remodeler activity","canonical_id":"go:GO:0140658","description":"\"An activity, driven by ATP hydrolysis, that modulates the contacts between histones and DNA, resulting in a change in chromosome architecture within the nucleosomal array, leading to chromatin remodeling.\" [PMID:14729263, PMID:19165147, PMID:21862382, PMID:30867599, PMID:34313222]","metadata":null},{"id":"170bbea28a0b461f85444a7ccbcbd177","type":"GO_TERM","name":"ATP-dependent citrate lyase complex","canonical_id":"go:GO:0140615","description":"\"A protein complex that catalyzes the cleavage of citrate into oxaloacetate and acetyl-CoA.\" [PMID:12376641]","metadata":null},{"id":"a00700ca5d7648f087bffe657cb19cd5","type":"GO_TERM","name":"ATP-dependent diacylglycerol kinase activity","canonical_id":"go:GO:0004143","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycerol + ATP = a 1,2-diacyl-sn-glycero-3-phosphate + ADP + H+.\" [GOC:elh, RHEA:10272]","metadata":null},{"id":"7f0da30c461f41a08acc203c3d4a3f77","type":"GO_TERM","name":"ATP-dependent histone chaperone activity","canonical_id":"go:GO:0140674","description":"\"Binding to and carrying a histone or a histone complex to unload or deposit it as a nucleosome, driven by ATP hydrolysis.\" [PMID:26459557]","metadata":null},{"id":"6c93f3a415b447d88f63154962dd80c7","type":"GO_TERM","name":"ATP-dependent peptidase activity","canonical_id":"go:GO:0004176","description":"\"Catalysis of the hydrolysis of peptide bonds, driven by ATP hydrolysis.\" [GOC:mah]","metadata":null},{"id":"f2506a5e5dfc413c8eed55965dada352","type":"GO_TERM","name":"ATP-dependent polydeoxyribonucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0046404","description":"\"Catalysis of the reaction: ATP + 5'-dephospho-DNA = ADP + 5'-phospho-DNA.\" [RHEA:15669]","metadata":null},{"id":"a4e8ff4cca0644feb9401e3bec73a7b6","type":"GO_TERM","name":"ATP-dependent polynucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0051734","description":"\"Catalysis of the reaction: ATP + 5'-dephosphopolynucleotide = ADP + 5'-phosphopolynucleotide. The polynucleotide may be DNA or RNA.\" [EC:2.7.1.78]","metadata":null},{"id":"af4b91a188e648b8a7a11421bfcbfbd5","type":"GO_TERM","name":"ATP-dependent polyribonucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0051736","description":"\"Catalysis of the reaction: ATP + 5'-dephospho-RNA = ADP + 5'-phospho-RNA.\" [RHEA:54580]","metadata":null},{"id":"fce720f1b4ad4e6c96264ae7c12c56b8","type":"GO_TERM","name":"ATP-dependent protein binding","canonical_id":"go:GO:0043008","description":"\"Binding to a protein or protein complex using energy from ATP hydrolysis.\" [GOC:jl]","metadata":null},{"id":"1536f9fc81b44877b741b489b56e2287","type":"GO_TERM","name":"ATP-dependent protein disaggregase activity","canonical_id":"go:GO:0140545","description":"\"An ATP-dependent molecular chaperone activity that mediates the solubilization of ordered protein aggregates.\" [PMID:26312418]","metadata":null},{"id":"88b3e94e58d94b6cbab410da9e1935c2","type":"GO_TERM","name":"ATP-dependent protein folding chaperone","canonical_id":"go:GO:0140662","description":"\"Binding to a protein or a protein-containing complex to assist the protein folding process, driven by ATP hydrolysis.\" [PMID:27365453]","metadata":null},{"id":"40fa2ef89ef24033b8471dbff41fc9c0","type":"GO_TERM","name":"ATP-dependent protein-DNA complex displacement activity","canonical_id":"go:GO:0061995","description":"\"An activity that displaces proteins or protein complexes from DNA, sometimes in a 'wire stripping' fashion, driven by ATP hydrolysis.\" [PMID:18593879]","metadata":null},{"id":"ab88740385df4302a712c72dd8af936c","type":"GO_TERM","name":"ATP-dependent protein-DNA unloader activity","canonical_id":"go:GO:0140083","description":"\"Facilitating the removal of a protein or protein complex from a DNA molecule driven by ATP hydrolysis. This can be achieved for example by introducing non-canonical DNA structures or generating torque to directly inhibit a protein-DNA binding interaction.\" [PMID:28552615]","metadata":null},{"id":"2ce47ff7697c478fbf77c4d7efb22245","type":"GO_TERM","name":"ATP-dependent topological DNA co-entrapment activity","canonical_id":"go:GO:0061776","description":"\"A DNA binding activity in which a protein complex interacts with at least one DNA duplex to encircle the DNA molecules with a loose fitting ring.\" [GOC:dph, GOC:vw, PMID:16179255, PMID:26687354, PMID:27797071, PMID:29358048, PMID:37820734]","metadata":null},{"id":"af7e99379e7642378edd82ef5465fe50","type":"PROTEIN","name":"ATP-dependent translocase ABCB1","canonical_id":"uniprot:P08183","description":null,"metadata":null},{"id":"320dadb7a33e4d84ad53cf1c452e199a","type":"GO_TERM","name":"ATP-gated ion channel activity","canonical_id":"go:GO:0035381","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when ATP has been bound by the channel complex or one of its constituent parts.\" [GOC:bf]","metadata":null},{"id":"742b6b5810de4910a7e9a86d24dc7394","type":"GO_TERM","name":"ATP-independent citrate lyase complex","canonical_id":"go:GO:0009346","description":"\"Citrate lyase is a multienzyme complex with three constituents: the alpha subunit, citrate-ACP transferase; the beta subunit, citryl-ACP lyase; and the gamma subunit, an acyl-carrier protein which also carries the prosthetic group components. All three subunits are required for citrate lyase enzyme activity. This enzyme has only been found in bacteria.\" [PMID:32302313]","metadata":null},{"id":"15cb5bd93aab48708422de1035a7d238","type":"PROTEIN","name":"ATP-sensitive inward rectifier potassium channel 1","canonical_id":"uniprot:P48048","description":null,"metadata":null},{"id":"ce84680c8b144963b11ddafe8bd5c9fc","type":"PROTEIN","name":"ATP-sensitive inward rectifier potassium channel 8","canonical_id":"uniprot:Q15842","description":null,"metadata":null},{"id":"2f7c14655367420db18af9f4f2b4b3a7","type":"GO_TERM","name":"ATP/ADP dimethylallyltransferase activity","canonical_id":"go:GO:0052622","description":"\"Catalysis of the reaction: delta(2)-isopentenyl diphosphate + ATP = diphosphate + N6-(delta(2)-isopentenyl)adenosine 5'-triphosphate.\" [EC:2.5.1.112]","metadata":null},{"id":"31b7193394554d51b2e078a69dadf5a6","type":"GENE","name":"ATP10A","canonical_id":"hgnc:HGNC:13542","description":"ATPase phospholipid transporting 10A (putative)","metadata":{"aliases":["ATPVA","ATPVC","KIAA0566","ATP10C"]}},{"id":"ae5cc8b28d7245f4b95a02472b6ffcd6","type":"GENE","name":"ATP10A-DT","canonical_id":"hgnc:HGNC:55434","description":"ATP10A divergent transcript","metadata":null},{"id":"c0f027e8665d4e5aac4d37697afbf7b2","type":"GENE","name":"ATP10B","canonical_id":"hgnc:HGNC:13543","description":"ATPase phospholipid transporting 10B (putative)","metadata":{"aliases":["ATPVB","KIAA0715","FLJ21477"]}},{"id":"e68d515aacc54515800f2b174feef52d","type":"GENE","name":"ATP10D","canonical_id":"hgnc:HGNC:13549","description":"ATPase phospholipid transporting 10D (putative)","metadata":{"aliases":["ATPVD","KIAA1487"]}},{"id":"d8aefcad3c6b473e9666324d6c3b682d","type":"GENE","name":"ATP10D-DT","canonical_id":"hgnc:HGNC:58781","description":"ATP10D divergent transcript","metadata":null},{"id":"6086c366589642e58ff3b289631a6cab","type":"GENE","name":"ATP11A","canonical_id":"hgnc:HGNC:13552","description":"ATPase phospholipid transporting 11A","metadata":{"aliases":["ATPIH","ATPIS","KIAA1021"]}},{"id":"6bba6114ec50497d9cb949212013db10","type":"GENE","name":"ATP11A-AS1","canonical_id":"hgnc:HGNC:40645","description":"ATP11A antisense RNA 1","metadata":null},{"id":"ff21f38e85a64255965b15e91a279783","type":"GENE","name":"ATP11AUN","canonical_id":"hgnc:HGNC:33793","description":"ATP11A upstream neighbor lncRNA","metadata":{"aliases":["FLJ26443","SMABLO1","C13orf35"]}},{"id":"a866ad319b9c4db0939c1dcaa14acfa2","type":"GENE","name":"ATP11B","canonical_id":"hgnc:HGNC:13553","description":"ATPase phospholipid transporting 11B (putative)","metadata":{"aliases":["ATPIF","ATPIR","KIAA0956"]}},{"id":"95a0c42bd52c4dd98466256c23c00fd8","type":"GENE","name":"ATP11B-DT","canonical_id":"hgnc:HGNC:55642","description":"ATP11B divergent transcript","metadata":null},{"id":"3ab86116071d4af9b7cb52fcdf4f5ba9","type":"GENE","name":"ATP11C","canonical_id":"hgnc:HGNC:13554","description":"ATPase phospholipid transporting 11C (ATP11C blood group)","metadata":{"aliases":["ATPIG","ATPIQ"]}},{"id":"874f29283768479da99432829409e7b6","type":"GENE","name":"ATP12A","canonical_id":"hgnc:HGNC:13816","description":"ATPase H+/K+ transporting non-gastric alpha2 subunit","metadata":{"aliases":["HK","H-K-ATPase","ATP1AL1"]}},{"id":"4d4e9ec7a59f4ef3832b97c844f0df30","type":"GENE","name":"ATP13A1","canonical_id":"hgnc:HGNC:24215","description":"ATPase 13A1","metadata":{"aliases":["KIAA1825","FLJ31858","CGI-152","ATP13A"]}},{"id":"a88c10f817884a0db20add3d6c03224e","type":"GENE","name":"ATP13A2","canonical_id":"hgnc:HGNC:30213","description":"ATPase cation transporting 13A2","metadata":{"aliases":["HSA9947","CLN12","PARK9"]}},{"id":"d6d024be95e94b37be9d71409f768f0f","type":"GENE","name":"ATP13A3","canonical_id":"hgnc:HGNC:24113","description":"ATPase 13A3","metadata":{"aliases":["AFURS1"]}},{"id":"0380ef64c007409abd9db4fd919d2072","type":"GENE","name":"ATP13A3-DT","canonical_id":"hgnc:HGNC:48570","description":"ATP13A3 divergent transcript","metadata":{"aliases":["LINC00884"]}},{"id":"83928330ee64497dbd5d4e3f3739b41d","type":"GENE","name":"ATP13A4","canonical_id":"hgnc:HGNC:25422","description":"ATPase 13A4","metadata":{"aliases":["DKFZp761I1011","FLJ37958"]}},{"id":"e656d739c9fd46e2b3a350f8622aa3f7","type":"GENE","name":"ATP13A4-AS1","canonical_id":"hgnc:HGNC:41095","description":"ATP13A4 antisense RNA 1","metadata":null},{"id":"bf9b7a1e71574d30ac68e8a25a4157a3","type":"GENE","name":"ATP13A5","canonical_id":"hgnc:HGNC:31789","description":"ATPase 13A5","metadata":{"aliases":["FLJ16025"]}},{"id":"56c7098e1bd241b090eac9b467938f7c","type":"GENE","name":"ATP13A5-AS1","canonical_id":"hgnc:HGNC:41281","description":"ATP13A5 antisense RNA 1","metadata":null},{"id":"56ab86e2b5ae4d868b6606182d7bfe17","type":"GENE","name":"ATP1A1","canonical_id":"hgnc:HGNC:799","description":"ATPase Na+/K+ transporting subunit alpha 1","metadata":null},{"id":"314ae9c5431546398ec2b17f20fd894d","type":"PROTEIN","name":"ATP1A1","canonical_id":"uniprot:P05023","description":null,"metadata":null},{"id":"6bef0119b0c14318b2fd15fd570cc70b","type":"GENE","name":"ATP1A1-AS1","canonical_id":"hgnc:HGNC:28262","description":"ATP1A1 antisense RNA 1","metadata":{"aliases":["MGC16179","C1orf203","ATP1A1OS"]}},{"id":"69d1c07311a141268e4672e070549414","type":"GENE","name":"ATP1A2","canonical_id":"hgnc:HGNC:800","description":"ATPase Na+/K+ transporting subunit alpha 2","metadata":{"aliases":["FHM2","MHP2"]}},{"id":"d8666aebde7d42a5bd4477b3d6e9fa5b","type":"GENE","name":"ATP1A3","canonical_id":"hgnc:HGNC:801","description":"ATPase Na+/K+ transporting subunit alpha 3","metadata":{"aliases":["DYT12"]}},{"id":"0672822b575945be9bd6bff9a9985150","type":"GENE","name":"ATP1A4","canonical_id":"hgnc:HGNC:14073","description":"ATPase Na+/K+ transporting subunit alpha 4","metadata":{"aliases":["ATP1AL2"]}},{"id":"483854810ef0438b8ab055c4241c87a4","type":"GENE","name":"ATP1B1","canonical_id":"hgnc:HGNC:804","description":null,"metadata":null},{"id":"e8a5a1e7ab2d48ab8de7454313801746","type":"BIOMARKER","name":"ATP1B1::NRG1 Fusion AND KRAS Wildtype","canonical_id":"civic:5414","description":null,"metadata":null},{"id":"7047a1ebfc7d4cc5bf7b0a906252369b","type":"GENE","name":"ATP1B1P1","canonical_id":"hgnc:HGNC:809","description":"ATPase Na+/K+ transporting subunit beta 1 pseudogene 1","metadata":{"aliases":["ATP1BL1"]}},{"id":"9634fb5c2c3d4ee2bf6fe42eb0cdebde","type":"GENE","name":"ATP1B2","canonical_id":"hgnc:HGNC:805","description":"ATPase Na+/K+ transporting subunit beta 2","metadata":{"aliases":["AMOG"]}},{"id":"05f60fa2e163496488fa2d5ddd297108","type":"GENE","name":"ATP1B3","canonical_id":"hgnc:HGNC:806","description":"ATPase Na+/K+ transporting subunit beta 3","metadata":{"aliases":["FLJ29027","CD298"]}},{"id":"ca814aae804640b39e19a2ab121671df","type":"GENE","name":"ATP1B3-AS1","canonical_id":"hgnc:HGNC:40088","description":"ATP1B3 antisense RNA 1","metadata":null},{"id":"030a6f25b7c8443cb1227f14fca139bd","type":"GENE","name":"ATP1B3P1","canonical_id":"hgnc:HGNC:807","description":"ATPase Na+/K+ transporting subunit beta 3 pseudogene 1","metadata":null},{"id":"ac442631931d47de95cccb521fea3694","type":"GENE","name":"ATP1B4","canonical_id":"hgnc:HGNC:808","description":"ATPase Na+/K+ transporting family member beta 4","metadata":null},{"id":"fedb9b03cf9a44549bf7bec4621d034e","type":"GENE","name":"ATP23","canonical_id":"hgnc:HGNC:29452","description":"ATP23 metallopeptidase and ATP synthase assembly factor homolog","metadata":{"aliases":["KUB3","XRCC6BP1"]}},{"id":"f2653de9200c4bc39bbb35e4b41817e0","type":"GENE","name":"ATP2A1","canonical_id":"hgnc:HGNC:811","description":"ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1","metadata":{"aliases":["SERCA1","ATP2A"]}},{"id":"2262b408691c4807990718651cf283ae","type":"GENE","name":"ATP2A1-AS1","canonical_id":"hgnc:HGNC:51370","description":"ATP2A1 antisense RNA 1","metadata":null},{"id":"83295deda4fb4af3a884ecfee9c0afbf","type":"GENE","name":"ATP2A2","canonical_id":"hgnc:HGNC:812","description":null,"metadata":null},{"id":"525c226dbf9f48e4afc56d49d2df99f5","type":"GENE","name":"ATP2A3","canonical_id":"hgnc:HGNC:813","description":null,"metadata":null},{"id":"64f19e4c07954924a8d5b8966717b4a0","type":"GENE","name":"ATP2B1","canonical_id":"hgnc:HGNC:814","description":"ATPase plasma membrane Ca2+ transporting 1","metadata":{"aliases":["PMCA1"]}},{"id":"6d5301d07b634edca8180c83afedede9","type":"GENE","name":"ATP2B1-AS1","canonical_id":"hgnc:HGNC:27883","description":"ATP2B1 antisense RNA 1","metadata":{"aliases":["LINC00936"]}},{"id":"a69291ef532c4c9994265f8baf9d1783","type":"GENE","name":"ATP2B2","canonical_id":"hgnc:HGNC:815","description":"ATPase plasma membrane Ca2+ transporting 2","metadata":{"aliases":["PMCA2"]}},{"id":"ca43332dd3ce4b698aa61b70bf8a0c94","type":"GENE","name":"ATP2B2-IT1","canonical_id":"hgnc:HGNC:41309","description":"ATP2B2 intronic transcript 1","metadata":null},{"id":"23d764452b5a46b2b978e490fa2c84f0","type":"GENE","name":"ATP2B2-IT2","canonical_id":"hgnc:HGNC:41310","description":"ATP2B2 intronic transcript 2","metadata":null},{"id":"3ed9eb6037db4965a3709bd36e7f61a5","type":"GENE","name":"ATP2B3","canonical_id":"hgnc:HGNC:816","description":"ATPase plasma membrane Ca2+ transporting 3","metadata":{"aliases":["PMCA3","CFAP39","SCAX1","CLA2"]}},{"id":"dd0157b1b12d41468cc3cde8422d4058","type":"GENE","name":"ATP2B4","canonical_id":"hgnc:HGNC:817","description":"ATPase plasma membrane Ca2+ transporting 4","metadata":{"aliases":["PMCA4","ATP2B2","MXRA1"]}},{"id":"199e9d9e20ff41b39ec8800a6b5690df","type":"GENE","name":"ATP2C1","canonical_id":"hgnc:HGNC:13211","description":null,"metadata":null},{"id":"94587d00c9e748a0a2ba3ce56aa0e054","type":"GENE","name":"ATP2C1-AS1","canonical_id":"hgnc:HGNC:58082","description":"ATP2C1 antisense RNA 1","metadata":{"aliases":["REIR-8"]}},{"id":"c42ff8d5fbb84ba4b1b1429ed63d7d0b","type":"GENE","name":"ATP2C2","canonical_id":"hgnc:HGNC:29103","description":"ATPase secretory pathway Ca2+ transporting 2","metadata":{"aliases":["KIAA0703","SPCA2"]}},{"id":"8afad31e9f6b424ebf1a1e2d1e78442a","type":"GENE","name":"ATP2C2-AS1","canonical_id":"hgnc:HGNC:53167","description":"ATP2C2 antisense RNA 1","metadata":{"aliases":["RP11-517C16.2-001","RP11-517C16.2"]}},{"id":"fffa9b120bed45f6abd2381461986d42","type":"GENE","name":"ATP4A","canonical_id":"hgnc:HGNC:819","description":"ATPase H+/K+ transporting subunit alpha","metadata":{"aliases":["ATP6A"]}},{"id":"ffbf8fa017014eda85515f602cd3b900","type":"PROTEIN","name":"ATP4A","canonical_id":"uniprot:P20648","description":null,"metadata":null},{"id":"b9a200210b5940c4b52b37d4101f87b3","type":"GENE","name":"ATP4B","canonical_id":"hgnc:HGNC:820","description":"ATPase H+/K+ transporting subunit beta","metadata":{"aliases":["ATP6B"]}},{"id":"d3cff61143c34bdaaf3913e86fdd2864","type":"GENE","name":"ATP5F1A","canonical_id":"hgnc:HGNC:823","description":null,"metadata":null},{"id":"0706239b2a8a45948e4951588950b9cc","type":"GENE","name":"ATP5F1AP1","canonical_id":"hgnc:HGNC:827","description":"ATP synthase F1 subunit alpha pseudogene 1","metadata":{"aliases":["ATP5AP1","ATP5A1P5","ATP5AL1","ATP5A1P6","ATP5A1P1"]}},{"id":"f4b1fd8e3ad54b1aa19a67ecdf36dbee","type":"GENE","name":"ATP5F1AP10","canonical_id":"hgnc:HGNC:37668","description":"ATP synthase F1 subunit alpha pseudogene 10","metadata":{"aliases":["ATP5A1P10"]}},{"id":"0d55fefb41894f8582e9e79d1dd210c8","type":"GENE","name":"ATP5F1AP2","canonical_id":"hgnc:HGNC:828","description":"ATP synthase F1 subunit alpha pseudogene 2","metadata":{"aliases":["ATP5AP2","ATP5A1P2"]}},{"id":"e25c86ea2178431183d516edfc02fcc2","type":"GENE","name":"ATP5F1AP3","canonical_id":"hgnc:HGNC:829","description":"ATP synthase F1 subunit alpha pseudogene 3","metadata":{"aliases":["ATP5AP3","ATP5A1P3"]}},{"id":"128803d4b6894c9bb0954efc4dc2b4ea","type":"GENE","name":"ATP5F1AP4","canonical_id":"hgnc:HGNC:23563","description":"ATP synthase F1 subunit alpha pseudogene 4","metadata":{"aliases":["ATP5AP4","ATP5A1P4"]}},{"id":"d6074de5f1634cc797728b65ce02f4d3","type":"GENE","name":"ATP5F1AP7","canonical_id":"hgnc:HGNC:37665","description":"ATP synthase F1 subunit alpha pseudogene 7","metadata":{"aliases":["ATP5A1P9","ATP5A1P7"]}},{"id":"43cb761d2bf74c8db882a1600c107127","type":"GENE","name":"ATP5F1AP8","canonical_id":"hgnc:HGNC:37666","description":"ATP synthase F1 subunit alpha pseudogene 8","metadata":{"aliases":["ATP5A1P8"]}},{"id":"b8a5bc9861ee4671bca092d6be4e9c10","type":"GENE","name":"ATP5F1B","canonical_id":"hgnc:HGNC:830","description":"ATP synthase F1 subunit beta","metadata":{"aliases":["ATPSB","ATP5B"]}},{"id":"8f50a22518e84088945983f1b687456d","type":"GENE","name":"ATP5F1BP1","canonical_id":"hgnc:HGNC:831","description":"ATP synthase F1 subunit beta pseudogene 1","metadata":{"aliases":["ATPMBL1","ATPSBL1","ATP5BL1","ATP5BP1"]}},{"id":"eeb15a8b1a4346be9f97898751399154","type":"GENE","name":"ATP5F1C","canonical_id":"hgnc:HGNC:833","description":"ATP synthase F1 subunit gamma","metadata":{"aliases":["ATP5CL1","ATP5C","ATP5C1"]}},{"id":"2dbc9b1ce74d4efaaff959cf02dc6a35","type":"GENE","name":"ATP5F1CP1","canonical_id":"hgnc:HGNC:834","description":"ATP synthase F1 subunit gamma pseudogene 1","metadata":{"aliases":["ATP5CL2","ATP5C2","ATP5C1P1"]}},{"id":"295c2fc6fcd24553a4e5da4fd3b7aaef","type":"GENE","name":"ATP5F1D","canonical_id":"hgnc:HGNC:837","description":"ATP synthase F1 subunit delta","metadata":{"aliases":["ATP5D"]}},{"id":"d9b049d4052a4e69bfecb4f6d3f0dbfb","type":"GENE","name":"ATP5F1E","canonical_id":"hgnc:HGNC:838","description":"ATP synthase F1 subunit epsilon","metadata":{"aliases":["ATP5E"]}},{"id":"4f01f77788db4ba0bf3776536b8125bb","type":"GENE","name":"ATP5F1EP1","canonical_id":"hgnc:HGNC:839","description":"ATP synthase F1 subunit epsilon pseudogene 1","metadata":{"aliases":["ATP5EP1"]}},{"id":"86f03895ef51437cbd2354022436f2b5","type":"GENE","name":"ATP5F1EP2","canonical_id":"hgnc:HGNC:34026","description":"ATP synthase F1 subunit epsilon pseudogene 2","metadata":{"aliases":["ATP5EP2"]}},{"id":"0ddd1ffec91b45d2875bbf3f004aa65f","type":"GENE","name":"ATP5IF1","canonical_id":"hgnc:HGNC:871","description":"ATP synthase inhibitory factor subunit 1","metadata":{"aliases":["ATPI","IP","ATPIP","MGC1167","MGC8898","ATPIF1"]}},{"id":"35e46d5fff5345c1909051743db32bfa","type":"GENE","name":"ATP5IF1-AS1","canonical_id":"hgnc:HGNC:58609","description":"ATP5IF1 antisense RNA 1","metadata":null},{"id":"fc98e4a5d1304e2f8c900530b3b685fa","type":"GENE","name":"ATP5MC1","canonical_id":"hgnc:HGNC:841","description":"ATP synthase membrane subunit c locus 1","metadata":{"aliases":["ATP5G","ATP5G1"]}},{"id":"588389cd41494860a671014464c5557d","type":"GENE","name":"ATP5MC1P1","canonical_id":"hgnc:HGNC:19815","description":"ATP synthase membrane subunit c locus 1 pseudogene 1","metadata":{"aliases":["ATP5GP3","ATP5G1P1"]}},{"id":"49739b678a9e4e55bb0c95b8cdb593c8","type":"GENE","name":"ATP5MC1P2","canonical_id":"hgnc:HGNC:19817","description":"ATP synthase membrane subunit c locus 1 pseudogene 2","metadata":{"aliases":["ATP5GP4","ATP5G1P2"]}},{"id":"16bb2efcc6f843358aa7f695a38fcb25","type":"GENE","name":"ATP5MC1P3","canonical_id":"hgnc:HGNC:39506","description":"ATP synthase membrane subunit c locus 1 pseudogene 3","metadata":{"aliases":["ATP5G1P3"]}},{"id":"2f75c089b06249788c31b266117f6d0f","type":"GENE","name":"ATP5MC1P4","canonical_id":"hgnc:HGNC:39507","description":"ATP synthase membrane subunit c locus 1 pseudogene 4","metadata":{"aliases":["ATP5G1P4"]}},{"id":"6f6ec2a18bb645d49753e068c9825d47","type":"GENE","name":"ATP5MC1P5","canonical_id":"hgnc:HGNC:39508","description":"ATP synthase membrane subunit c locus 1 pseudogene 5","metadata":{"aliases":["ATP5G1P5"]}},{"id":"3c29401a19a84d38a9b00b05aa67abe2","type":"GENE","name":"ATP5MC1P6","canonical_id":"hgnc:HGNC:39509","description":"ATP synthase membrane subunit c locus 1 pseudogene 6","metadata":{"aliases":["ATP5G1P6"]}},{"id":"315ec186cf804f10a681041c126a78ff","type":"GENE","name":"ATP5MC1P7","canonical_id":"hgnc:HGNC:39510","description":"ATP synthase membrane subunit c locus 1 pseudogene 7","metadata":{"aliases":["ATP5G1P7"]}},{"id":"014b4f5d1647463eb30c1c0bc9354413","type":"GENE","name":"ATP5MC1P8","canonical_id":"hgnc:HGNC:39511","description":"ATP synthase membrane subunit c locus 1 pseudogene 8","metadata":{"aliases":["ATP5G1P8"]}},{"id":"a500a6f55fa64ee8aabd408b7281ed3c","type":"GENE","name":"ATP5MC2","canonical_id":"hgnc:HGNC:842","description":"ATP synthase membrane subunit c locus 2","metadata":{"aliases":["ATP5G2"]}},{"id":"56a684930b99435587620f29edc89104","type":"GENE","name":"ATP5MC2P1","canonical_id":"hgnc:HGNC:844","description":"ATP5MC2 pseudogene 1","metadata":{"aliases":["ATP5GP1","ATP5G2P1"]}},{"id":"b738414a35bc4978af178fac611f7a86","type":"GENE","name":"ATP5MC2P2","canonical_id":"hgnc:HGNC:19672","description":"ATP5MC2 pseudogene 2","metadata":{"aliases":["ATP5GP2","ATP5G2P2"]}},{"id":"edea7d03e2794bc08af9d926eb40b53f","type":"GENE","name":"ATP5MC2P3","canonical_id":"hgnc:HGNC:42187","description":"ATP5MC2 pseudogene 3","metadata":{"aliases":["ATP5G2P3"]}},{"id":"241bf04a11e34fdf8b90220cddec727e","type":"GENE","name":"ATP5MC2P4","canonical_id":"hgnc:HGNC:42188","description":"ATP5MC2 pseudogene 4","metadata":{"aliases":["ATP5G2P4"]}},{"id":"ba955d50cc234a66bba31ea5f635173f","type":"GENE","name":"ATP5MC2P5","canonical_id":"hgnc:HGNC:56523","description":"ATP5MC2 pseudogene 5","metadata":null},{"id":"ca7860e37ed84004814eebbca9219e12","type":"GENE","name":"ATP5MC3","canonical_id":"hgnc:HGNC:843","description":"ATP synthase membrane subunit c locus 3","metadata":{"aliases":["ATP5G3"]}},{"id":"7d217436121a4959a4fd94eab1bb8177","type":"GENE","name":"ATP5ME","canonical_id":"hgnc:HGNC:846","description":"ATP synthase membrane subunit e","metadata":{"aliases":["ATP5I"]}},{"id":"d17dcc1dd751467bbf82b1ed01bb10f5","type":"GENE","name":"ATP5MF","canonical_id":"hgnc:HGNC:848","description":"ATP synthase membrane subunit f","metadata":{"aliases":["ATP5JL","ATP5J2"]}},{"id":"ca3b75b50c33408da65fb0b50c200996","type":"GENE","name":"ATP5MF-PTCD1","canonical_id":"hgnc:HGNC:38844","description":"ATP5MF-PTCD1 readthrough","metadata":{"aliases":["ATP5J2-PTCD1"]}},{"id":"b176ecc4e89b4975aef05a406c3e83c8","type":"GENE","name":"ATP5MFP1","canonical_id":"hgnc:HGNC:849","description":"ATP synthase membrane subunit f pseudogene 1","metadata":{"aliases":["ATP5J2LP"]}},{"id":"7623af86b64d4722863b326b01c1810b","type":"GENE","name":"ATP5MFP2","canonical_id":"hgnc:HGNC:21540","description":"ATP synthase membrane subunit f pseudogene 2","metadata":{"aliases":["bA249L21.4","ATP5J2P2"]}},{"id":"117fcb8f64fa4a44bd5402bac23115be","type":"GENE","name":"ATP5MFP3","canonical_id":"hgnc:HGNC:21286","description":"ATP synthase membrane subunit f pseudogene 3","metadata":{"aliases":["bA159H20.5","ATP5J2P3"]}},{"id":"a70ac12b7c6c449aada618902aec34f5","type":"GENE","name":"ATP5MFP4","canonical_id":"hgnc:HGNC:32451","description":"ATP synthase membrane subunit f pseudogene 4","metadata":{"aliases":["ATP5J2P4"]}},{"id":"7a7b687e20e044eca8a270a798c858ad","type":"GENE","name":"ATP5MFP5","canonical_id":"hgnc:HGNC:33611","description":"ATP synthase membrane subunit f pseudogene 5","metadata":{"aliases":["ATP5J2P5"]}},{"id":"5a6549925d714785897a57dc645ee8d8","type":"GENE","name":"ATP5MFP6","canonical_id":"hgnc:HGNC:33612","description":"ATP synthase membrane subunit f pseudogene 6","metadata":{"aliases":["ATP5J2P6"]}},{"id":"bf5878242b0c4c69a2422aa8e61eb29c","type":"GENE","name":"ATP5MFP7","canonical_id":"hgnc:HGNC:56954","description":"ATP synthase membrane subunit f pseudogene 7","metadata":null},{"id":"fc9fc1c294cc425c8c94d2b8549cd4ea","type":"GENE","name":"ATP5MG","canonical_id":"hgnc:HGNC:14247","description":"ATP synthase membrane subunit g","metadata":{"aliases":["ATP5JG","ATP5L"]}},{"id":"b5be66c4bd414e92ad440900659cb3b2","type":"GENE","name":"ATP5MGL","canonical_id":"hgnc:HGNC:13213","description":"ATP synthase membrane subunit g like","metadata":{"aliases":["dJ222E13.5","ATP5K2","ATP5L2"]}},{"id":"632091f731e64e6baf33f1820ac13a55","type":"GENE","name":"ATP5MGP1","canonical_id":"hgnc:HGNC:13214","description":"ATP synthase membrane subunit g pseudogene 1","metadata":{"aliases":["ATPE5KP1","ATP5KP1","ATP5LP1"]}},{"id":"516c3162c4c74c96b73bec1ea8d1a43f","type":"GENE","name":"ATP5MGP2","canonical_id":"hgnc:HGNC:13215","description":"ATP synthase membrane subunit g pseudogene 2","metadata":{"aliases":["ATP5KP2","ATP5LP2"]}},{"id":"c8c42f8e6fc84444804be791257fadd8","type":"GENE","name":"ATP5MGP3","canonical_id":"hgnc:HGNC:13216","description":"ATP synthase membrane subunit g pseudogene 3","metadata":{"aliases":["ATP5KP3","ATP5LP3"]}},{"id":"ed7f50fe52434ddca597b839a34a7c82","type":"GENE","name":"ATP5MGP4","canonical_id":"hgnc:HGNC:38165","description":"ATP synthase membrane subunit g pseudogene 4","metadata":{"aliases":["ATP5LP4"]}},{"id":"dfd5072b538b41f8870c2a5fd45d47e4","type":"GENE","name":"ATP5MGP5","canonical_id":"hgnc:HGNC:38167","description":"ATP synthase membrane subunit g pseudogene 5","metadata":{"aliases":["ATP5LP5"]}},{"id":"74e454804d7a4253a5767ef909799a07","type":"GENE","name":"ATP5MGP6","canonical_id":"hgnc:HGNC:38168","description":"ATP synthase membrane subunit g pseudogene 6","metadata":{"aliases":["ATP5LP6"]}},{"id":"4d2fe7a921594fc8838a453b889abe9a","type":"GENE","name":"ATP5MGP7","canonical_id":"hgnc:HGNC:38169","description":"ATP synthase membrane subunit g pseudogene 7","metadata":{"aliases":["ATP5LP7"]}},{"id":"1b96ae9e48684a76bf9b6a559af560f5","type":"GENE","name":"ATP5MGP8","canonical_id":"hgnc:HGNC:38170","description":"ATP synthase membrane subunit g pseudogene 8","metadata":{"aliases":["ATP5LP8"]}},{"id":"ea2178581e1140c18510d03984ff3566","type":"GENE","name":"ATP5MJ","canonical_id":"hgnc:HGNC:1188","description":"ATP synthase membrane subunit j","metadata":{"aliases":["MP68","MLQ","6.8PL","C14orf2","ATP5MPL"]}},{"id":"278cf3aabb96466295cc5b9efde50fee","type":"GENE","name":"ATP5MK","canonical_id":"hgnc:HGNC:30889","description":"ATP synthase membrane subunit k","metadata":{"aliases":["MGC14697","bA792D24.4","DAPIT","AGP","USMG5","ATP5MD"]}},{"id":"383ba26f7db04518b4ef1f1e02f68c80","type":"GENE","name":"ATP5MKP1","canonical_id":"hgnc:HGNC:31716","description":"ATP5MK pseudogene 1","metadata":{"aliases":["USMG5P1","ATP5MDP1"]}},{"id":"7f5a432ae7864705bfb7ca0395ac640a","type":"GENE","name":"ATP5PB","canonical_id":"hgnc:HGNC:840","description":"ATP synthase peripheral stalk-membrane subunit b","metadata":{"aliases":["ATP5F1"]}},{"id":"72c0408f771c479bba0acb52e73782ab","type":"GENE","name":"ATP5PBP1","canonical_id":"hgnc:HGNC:39742","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 1","metadata":{"aliases":["ATP5F1P1"]}},{"id":"983c70757602496ba36846bb8791a678","type":"GENE","name":"ATP5PBP2","canonical_id":"hgnc:HGNC:39743","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 2","metadata":{"aliases":["ATP5F1P2"]}},{"id":"13329cee16b4478e830af340780f1e80","type":"GENE","name":"ATP5PBP3","canonical_id":"hgnc:HGNC:39744","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 3","metadata":{"aliases":["ATP5F1P3"]}},{"id":"15a1e304a51a4a9287c54a7a9e04c00d","type":"GENE","name":"ATP5PBP4","canonical_id":"hgnc:HGNC:39745","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 4","metadata":{"aliases":["ATP5F1P4"]}},{"id":"390c1b94c19f45af98afa03a44cb0fc3","type":"GENE","name":"ATP5PBP5","canonical_id":"hgnc:HGNC:39746","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 5","metadata":{"aliases":["ATP5F1P5"]}},{"id":"2b9d714134d340e4bae84e402e952522","type":"GENE","name":"ATP5PBP6","canonical_id":"hgnc:HGNC:39747","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 6","metadata":{"aliases":["ATP5F1P6"]}},{"id":"cec2050b9ffb4cfeaa1b14407c14990a","type":"GENE","name":"ATP5PBP7","canonical_id":"hgnc:HGNC:39748","description":"ATP synthase peripheral stalk-membrane subunit b pseudogene 7","metadata":{"aliases":["ATP5F1P7"]}},{"id":"d65b94014ec04682ada3f5030d0dea1d","type":"GENE","name":"ATP5PBP8","canonical_id":"hgnc:HGNC:56483","description":"ATP5PB pseudogene 8","metadata":null},{"id":"c0eedd1f7fe74ee3a46e0b1582f7df01","type":"GENE","name":"ATP5PD","canonical_id":"hgnc:HGNC:845","description":"ATP synthase peripheral stalk subunit d","metadata":{"aliases":["ATPQ","ATP5JD","ATP5H"]}},{"id":"b81725e813d54347b79faefdc22333be","type":"GENE","name":"ATP5PDP1","canonical_id":"hgnc:HGNC:31021","description":"ATP synthase peripheral stalk subunit d pseudogene 1","metadata":{"aliases":["HsT18164","ATP5HP1"]}},{"id":"5faa75f272134ce8ac565f61641af3de","type":"GENE","name":"ATP5PDP2","canonical_id":"hgnc:HGNC:49624","description":"ATP synthase peripheral stalk subunit d pseudogene 2","metadata":{"aliases":["ATP5HP2"]}},{"id":"40a44cf1abd34469a32789697986c899","type":"GENE","name":"ATP5PDP3","canonical_id":"hgnc:HGNC:49625","description":"ATP synthase peripheral stalk subunit d pseudogene 3","metadata":{"aliases":["ATP5HP3"]}},{"id":"351aeb738fd04e5798e9a57f7862e214","type":"GENE","name":"ATP5PDP4","canonical_id":"hgnc:HGNC:49626","description":"ATP synthase peripheral stalk subunit d pseudogene 4","metadata":{"aliases":["ATP5HP4"]}},{"id":"0ed5b91533984b99ab30534c27adbaba","type":"GENE","name":"ATP5PF","canonical_id":"hgnc:HGNC:847","description":"ATP synthase peripheral stalk subunit F6","metadata":{"aliases":["CF6","ATP5A","ATP5","ATPM","ATP5J"]}},{"id":"e88484a5f6134608be034df7e2c193ed","type":"GENE","name":"ATP5PFP1","canonical_id":"hgnc:HGNC:23933","description":"ATP synthase peripheral stalk subunit F6 pseudogene 1","metadata":{"aliases":["ATP5JP1"]}},{"id":"541f15abb3b5428d92f8e383dc4422f9","type":"GENE","name":"ATP5PFP2","canonical_id":"hgnc:HGNC:56974","description":"ATP5PF pseudogene 2","metadata":null},{"id":"6aec44db1f7c4d5ea609a812bb71d8af","type":"GENE","name":"ATP5PFP3","canonical_id":"hgnc:HGNC:56975","description":"ATP5PF pseudogene 3","metadata":null},{"id":"4ccea47ae1604d7fa000a33f66642056","type":"GENE","name":"ATP5PFP4","canonical_id":"hgnc:HGNC:56976","description":"ATP5PF pseudogene 4","metadata":null},{"id":"eb1fc745e2944a9aab5c94754fdf2871","type":"GENE","name":"ATP5PO","canonical_id":"hgnc:HGNC:850","description":"ATP synthase peripheral stalk subunit OSCP","metadata":{"aliases":["OSCP","ATPO","ATP5O"]}},{"id":"7a4bb8aafa724f8bb87e56495aaa050b","type":"GENE","name":"ATP5POP1","canonical_id":"hgnc:HGNC:54673","description":"ATP5PO pseudogene 1","metadata":null},{"id":"ee6306a1f9f44953b446103a27eac074","type":"GENE","name":"ATP6AP1","canonical_id":"hgnc:HGNC:868","description":"ATPase H+ transporting accessory protein 1","metadata":{"aliases":["ORF","XAP-3","VATPS1","16A","Ac45","XAP3","CF2","ATP6S1","ATP6IP1"]}},{"id":"13bbc834f8594654bb5e0ba60d6ce1f9","type":"GENE","name":"ATP6AP1-DT","canonical_id":"hgnc:HGNC:25138","description":"ATP6AP1 divergent transcript","metadata":null},{"id":"a39c0a5ff0ee4ed9b0e3a44f4881b536","type":"GENE","name":"ATP6AP1L","canonical_id":"hgnc:HGNC:28091","description":"ATPase H+ transporting accessory protein 1 like (pseudogene)","metadata":{"aliases":["ATP6AP1LP"]}},{"id":"7b937c65c5244f808a4dfae3a7b551b8","type":"GENE","name":"ATP6AP2","canonical_id":"hgnc:HGNC:18305","description":"ATPase H+ transporting accessory protein 2","metadata":{"aliases":["PRR","M8-9","RENR","(P)RR","APT6M8-9","ATP6M8-9","ATP6IP2"]}},{"id":"a5972e8f05e24851a097b61adc0c004b","type":"GENE","name":"ATP6V0A1","canonical_id":"hgnc:HGNC:865","description":"ATPase H+ transporting V0 subunit a1","metadata":{"aliases":["a1","Vph1","Stv1","VPP1","ATP6N1","ATP6N1A"]}},{"id":"4ba74ddb69464ad28a1e7a13370c185b","type":"GENE","name":"ATP6V0A2","canonical_id":"hgnc:HGNC:18481","description":null,"metadata":null},{"id":"ad4bee34f7564c42ad2a81d6d9b7eae4","type":"GENE","name":"ATP6V0A4","canonical_id":"hgnc:HGNC:866","description":"ATPase H+ transporting V0 subunit a4","metadata":{"aliases":["RDRTA2","VPP2","RTADR","a4","Vph1","Stv1","ATP6N1B","ATP6N2","RTA1C"]}},{"id":"f086eabe69a04225910dba9112f8c75e","type":"GENE","name":"ATP6V0B","canonical_id":"hgnc:HGNC:861","description":"ATPase H+ transporting V0 subunit b","metadata":{"aliases":["VMA16","HATPL","ATP6F"]}},{"id":"c593103f1b624d85a8202c55c1c27c0a","type":"GENE","name":"ATP6V0C","canonical_id":"hgnc:HGNC:855","description":"ATPase H+ transporting V0 subunit c","metadata":{"aliases":["VATL","Vma3","ATPL","ATP6C","ATP6L"]}},{"id":"224d29be5f0141bdb3742db06922d17b","type":"GENE","name":"ATP6V0CP1","canonical_id":"hgnc:HGNC:31323","description":"ATPase H+ transporting V0 subunit c pseudogene 1","metadata":{"aliases":["ATCD1"]}},{"id":"0af1e1ed998344b6bcd260581fd0754c","type":"GENE","name":"ATP6V0CP2","canonical_id":"hgnc:HGNC:40000","description":"ATPase H+ transporting V0 subunit c pseudogene 2","metadata":null},{"id":"331dbec0364c4b6086d48752a4eff2b6","type":"GENE","name":"ATP6V0CP3","canonical_id":"hgnc:HGNC:40001","description":"ATPase H+ transporting V0 subunit c pseudogene 3","metadata":null},{"id":"8da3d524c9a1466697d1c61488c6e99a","type":"GENE","name":"ATP6V0CP4","canonical_id":"hgnc:HGNC:40002","description":"ATPase H+ transporting V0 subunit c pseudogene 4","metadata":null},{"id":"ffdf7e8c6912473c951176c7183ca7d9","type":"GENE","name":"ATP6V0D1","canonical_id":"hgnc:HGNC:13724","description":"ATPase H+ transporting V0 subunit d1","metadata":{"aliases":["ATP6DV","VATX","VPATPD","P39","Vma6","ATP6D"]}},{"id":"81e5f67bf9c045318fb4e2dd0ffd2601","type":"GENE","name":"ATP6V0D1-DT","canonical_id":"hgnc:HGNC:55268","description":"ATP6V0D1 divergent transcript","metadata":null},{"id":"b518bc0ce67947c7835d8829abcdd0d4","type":"GENE","name":"ATP6V0D2","canonical_id":"hgnc:HGNC:18266","description":"ATPase H+ transporting V0 subunit d2","metadata":{"aliases":["FLJ38708","VMA6","ATP6D2"]}},{"id":"c1b883f7444748f5ab77af2b97a77de6","type":"GENE","name":"ATP6V0E1","canonical_id":"hgnc:HGNC:863","description":null,"metadata":null},{"id":"7eedf93557404417be46da0238870704","type":"GENE","name":"ATP6V0E1-DT","canonical_id":"hgnc:HGNC:59307","description":"ATP6V0E1 divergent transcript","metadata":null},{"id":"1a1692f326a7487fbfecaf6d455d1b1e","type":"GENE","name":"ATP6V0E1P1","canonical_id":"hgnc:HGNC:41935","description":"ATPase H+ transporting V0 subunit e1 pseudogene 1","metadata":null},{"id":"b48071ae5d5549d095999a5ab7478dd7","type":"GENE","name":"ATP6V0E1P2","canonical_id":"hgnc:HGNC:41936","description":"ATPase H+ transporting V0 subunit e1 pseudogene 2","metadata":null},{"id":"04c0e49111e244c5938dec61418761d3","type":"GENE","name":"ATP6V0E1P3","canonical_id":"hgnc:HGNC:41937","description":"ATPase H+ transporting V0 subunit e1 pseudogene 3","metadata":null},{"id":"2c32063a53b042679bffa2e7474d06a0","type":"GENE","name":"ATP6V0E1P4","canonical_id":"hgnc:HGNC:41938","description":"ATPase H+ transporting V0 subunit e1 pseudogene 4","metadata":null},{"id":"3772750f7eea46b0a0dca3d423ca0f05","type":"GENE","name":"ATP6V0E2","canonical_id":"hgnc:HGNC:21723","description":"ATPase H+ transporting V0 subunit e2","metadata":{"aliases":["C7orf32","ATP6V0E2L"]}},{"id":"016dff3023e44ea5870f64997ccd0d98","type":"GENE","name":"ATP6V0E2-AS1","canonical_id":"hgnc:HGNC:44180","description":"ATP6V0E2 antisense RNA 1","metadata":null},{"id":"1ec89be4bb6743d796ca6b784fc59680","type":"GENE","name":"ATP6V1A","canonical_id":"hgnc:HGNC:851","description":"ATPase H+ transporting V1 subunit A","metadata":{"aliases":["Vma1","VA68","VPP2","ATP6A1","ATP6V1A1"]}},{"id":"42c3c757435f46beaaa89e1c28b41329","type":"GENE","name":"ATP6V1B1","canonical_id":"hgnc:HGNC:853","description":"ATPase H+ transporting V1 subunit B1","metadata":{"aliases":["VATB","RTA1B","Vma2","VPP3","ATP6B1"]}},{"id":"6fd25584dc87450e95215cd2ff1ac8df","type":"GENE","name":"ATP6V1B1-AS1","canonical_id":"hgnc:HGNC:51118","description":"ATP6V1B1 antisense RNA 1","metadata":null},{"id":"c2c42d97410b45598f05e52fd0ec4369","type":"GENE","name":"ATP6V1B2","canonical_id":"hgnc:HGNC:854","description":"ATPase H+ transporting V1 subunit B2","metadata":{"aliases":["VATB","Vma2","HO57","VPP3","ATP6B2"]}},{"id":"0952957f416c482a8502c2b81be116f6","type":"GENE","name":"ATP6V1C1","canonical_id":"hgnc:HGNC:856","description":"ATPase H+ transporting V1 subunit C1","metadata":{"aliases":["VATC","Vma5","ATP6D","ATP6C"]}},{"id":"aeace703ea7945f286f29f59a8253078","type":"GENE","name":"ATP6V1C2","canonical_id":"hgnc:HGNC:18264","description":"ATPase H+ transporting V1 subunit C2","metadata":{"aliases":["VMA5","ATP6C2"]}},{"id":"3527ecf4b65046ee86bc6fec0a98fa6b","type":"GENE","name":"ATP6V1D","canonical_id":"hgnc:HGNC:13527","description":"ATPase H+ transporting V1 subunit D","metadata":{"aliases":["VATD","VMA8","ATP6M"]}},{"id":"a5ec5e1b5fdd42e5a0744a7ad032a36d","type":"GENE","name":"ATP6V1E1","canonical_id":"hgnc:HGNC:857","description":"ATPase H+ transporting V1 subunit E1","metadata":{"aliases":["P31","Vma4","ATP6E2","ATP6E","ATP6V1E"]}},{"id":"5515eb98d16141c598743f3ade188d2b","type":"GENE","name":"ATP6V1E1P1","canonical_id":"hgnc:HGNC:859","description":"ATPase H+ transporting V1 subunit E1 pseudogene 1","metadata":{"aliases":["ATP6EP1","ATP6V1EP1"]}},{"id":"35790e5a5001433c99ad38b665b68b31","type":"GENE","name":"ATP6V1E1P2","canonical_id":"hgnc:HGNC:860","description":"ATPase H+ transporting V1 subunit E1 pseudogene 2","metadata":{"aliases":["ATP6EP2","ATP6V1EP2"]}},{"id":"583b5dcbe81340f0b045beafb43fe4cb","type":"GENE","name":"ATP6V1E1P3","canonical_id":"hgnc:HGNC:858","description":"ATPase H+ transporting V1 subunit E1 pseudogene 3","metadata":{"aliases":["ATP6EL1","ATP6V1EL1"]}},{"id":"e85c92c22e144059bfd8cc3af032c960","type":"GENE","name":"ATP6V1E2","canonical_id":"hgnc:HGNC:18125","description":"ATPase H+ transporting V1 subunit E2","metadata":{"aliases":["MGC9341","VMA4","ATP6E1","ATP6EL2","ATP6V1EL2"]}},{"id":"a454cb80e3a443ab800946962e5193ff","type":"GENE","name":"ATP6V1F","canonical_id":"hgnc:HGNC:16832","description":"ATPase H+ transporting V1 subunit F","metadata":{"aliases":["ATP6S14","VATF","Vma7"]}},{"id":"1f1f4d666d9e4e7fa2dbaf3083f68646","type":"GENE","name":"ATP6V1FP1","canonical_id":"hgnc:HGNC:56922","description":"ATP6V1F pseudogene 1","metadata":null},{"id":"a9a942dff2a04da99d4a5ad926de1542","type":"GENE","name":"ATP6V1FP2","canonical_id":"hgnc:HGNC:56923","description":"ATP6V1F pseudogene 2","metadata":null},{"id":"6918fd022ead4f9c9819a197ba355f64","type":"GENE","name":"ATP6V1G1","canonical_id":"hgnc:HGNC:864","description":"ATPase H+ transporting V1 subunit G1","metadata":{"aliases":["ATP6GL","Vma10","ATP6G","DKFZp547P234","ATP6J","ATP6G1"]}},{"id":"946a70741123495bb9280fcbac00c6fa","type":"GENE","name":"ATP6V1G1P1","canonical_id":"hgnc:HGNC:19816","description":"ATPase H+ transporting V1 subunit G1 pseudogene 1","metadata":{"aliases":["ATP6V1GP1"]}},{"id":"4bbe25c18a974450991168aa4a92b7f6","type":"GENE","name":"ATP6V1G1P2","canonical_id":"hgnc:HGNC:29359","description":"ATPase H+ transporting V1 subunit G1 pseudogene 2","metadata":{"aliases":["ATP6V1GP2"]}},{"id":"1c670398fbe8480badca883f2fa3ae9c","type":"GENE","name":"ATP6V1G1P3","canonical_id":"hgnc:HGNC:37670","description":"ATPase H+ transporting V1 subunit G1 pseudogene 3","metadata":null},{"id":"7a64a26aa0514e26bc87c8c229c09e64","type":"GENE","name":"ATP6V1G1P4","canonical_id":"hgnc:HGNC:37671","description":"ATPase H+ transporting V1 subunit G1 pseudogene 4","metadata":null},{"id":"f52e8d25586b411197b40ec52f3261d4","type":"GENE","name":"ATP6V1G1P5","canonical_id":"hgnc:HGNC:37672","description":"ATPase H+ transporting V1 subunit G1 pseudogene 5","metadata":null},{"id":"3581280a7fba4928af03f2b42e30850a","type":"GENE","name":"ATP6V1G1P6","canonical_id":"hgnc:HGNC:37673","description":"ATPase H+ transporting V1 subunit G1 pseudogene 6","metadata":null},{"id":"5e079cd8e1ae411990f07ec24d352015","type":"GENE","name":"ATP6V1G1P7","canonical_id":"hgnc:HGNC:39852","description":"ATPase H+ transporting V1 subunit G1 pseudogene 7","metadata":null},{"id":"eeb363f7bdf94489acef1cf74b47c599","type":"GENE","name":"ATP6V1G2","canonical_id":"hgnc:HGNC:862","description":"ATPase H+ transporting V1 subunit G2","metadata":{"aliases":["Vma10","NG38","Em:AC004181.3","ATP6G","ATP6G2"]}},{"id":"dbd9a2ba21b54b71bb1baae1bc4b704f","type":"GENE","name":"ATP6V1G2-DDX39B","canonical_id":"hgnc:HGNC:41999","description":"ATP6V1G2-DDX39B readthrough (NMD candidate)","metadata":null},{"id":"4a7ed374fe004b47b104f2246a7ea569","type":"GENE","name":"ATP6V1G3","canonical_id":"hgnc:HGNC:18265","description":"ATPase H+ transporting V1 subunit G3","metadata":{"aliases":["ATP6G3","Vma10"]}},{"id":"94a6b5e9026e4f55a79e0a359fd4a63d","type":"GENE","name":"ATP6V1H","canonical_id":"hgnc:HGNC:18303","description":"ATPase H+ transporting V1 subunit H","metadata":{"aliases":["CGI-11","SFD","VMA13","SFDalpha","SFDbeta"]}},{"id":"d66acc1d2eda431daa90a495e6c3f7c9","type":"GENE","name":"ATP7A","canonical_id":"hgnc:HGNC:869","description":"ATPase copper transporting alpha","metadata":{"aliases":["MNK"]}},{"id":"6700894ca4b54b1c91f069e77b9ae2da","type":"GENE","name":"ATP7B","canonical_id":"hgnc:HGNC:870","description":"ATPase copper transporting beta","metadata":{"aliases":["WND"]}},{"id":"7cecb4de97514628b6f8b69a488eb231","type":"GENE","name":"ATP7BP1","canonical_id":"hgnc:HGNC:31014","description":"ATPase copper transporting beta pseudogene 1","metadata":null},{"id":"4fb510f766be49258f20fcf1c7731b6d","type":"GENE","name":"ATP8A1","canonical_id":"hgnc:HGNC:13531","description":"ATPase phospholipid transporting 8A1","metadata":{"aliases":["ATPIA"]}},{"id":"ca5fd258c8894cbb8421cd973b682ea7","type":"GENE","name":"ATP8A1-DT","canonical_id":"hgnc:HGNC:55392","description":"ATP8A1 divergent transcript","metadata":null},{"id":"46067ff47c77499b9f1f2bfcdb59631c","type":"GENE","name":"ATP8A2","canonical_id":"hgnc:HGNC:13533","description":"ATPase phospholipid transporting 8A2","metadata":{"aliases":["ATPIB","ML-1"]}},{"id":"ad7e5e9ffea24418920624b4db60fbbf","type":"GENE","name":"ATP8A2P1","canonical_id":"hgnc:HGNC:39662","description":"ATPase phospholipid transporting 8A2 pseudogene 1","metadata":null},{"id":"c467d14004194966b0776ad6250404ac","type":"GENE","name":"ATP8A2P2","canonical_id":"hgnc:HGNC:39663","description":"ATPase phospholipid transporting 8A2 pseudogene 2","metadata":null},{"id":"fa7707f1352f480e9f7e215e2a9e42d2","type":"GENE","name":"ATP8A2P3","canonical_id":"hgnc:HGNC:42641","description":"ATPase phospholipid transporting 8A2 pseudogene 3","metadata":null},{"id":"363775e741254f919a146a5a2a0dd052","type":"GENE","name":"ATP8B1","canonical_id":"hgnc:HGNC:3706","description":"ATPase phospholipid transporting 8B1","metadata":{"aliases":["ATPIC","PFIC","FIC1","BRIC","PFIC1"]}},{"id":"7fcb289576564bda8058997b59bc6aae","type":"GENE","name":"ATP8B1-AS1","canonical_id":"hgnc:HGNC:56042","description":"ATP8B1 antisense RNA 1","metadata":{"aliases":["RP11-35G9.3"]}},{"id":"11f3b8fde8dd4d9eb825ca556d244b36","type":"GENE","name":"ATP8B2","canonical_id":"hgnc:HGNC:13534","description":"ATPase phospholipid transporting 8B2","metadata":{"aliases":["ATPID","KIAA1137"]}},{"id":"d2e47b93ac12410789633c2c587f8054","type":"GENE","name":"ATP8B3","canonical_id":"hgnc:HGNC:13535","description":"ATPase phospholipid transporting 8B3","metadata":{"aliases":["ATPIK"]}},{"id":"c3c9bdfba6c745f68bed4e77edc297e7","type":"GENE","name":"ATP8B4","canonical_id":"hgnc:HGNC:13536","description":"ATPase phospholipid transporting 8B4 (putative)","metadata":{"aliases":["ATPIM","KIAA1939"]}},{"id":"2b81c45d4cce44ae85aa0e2547269c73","type":"GENE","name":"ATP8B5P","canonical_id":"hgnc:HGNC:27245","description":"ATPase phospholipid transporting 8B5, pseudogene","metadata":{"aliases":["FetA"]}},{"id":"84e861430a034ede941b1abd6726ead9","type":"GENE","name":"ATP9A","canonical_id":"hgnc:HGNC:13540","description":"ATPase phospholipid transporting 9A","metadata":{"aliases":["KIAA0611","ATPIIA"]}},{"id":"7ffddbdb0a894b278582fdd27599cfd0","type":"GENE","name":"ATP9B","canonical_id":"hgnc:HGNC:13541","description":"ATPase phospholipid transporting 9B","metadata":{"aliases":["ATPIIB"]}},{"id":"bab0c4e35cfd40c7b7052cbb2ac6e6ac","type":"GENE","name":"ATP9B-AS1","canonical_id":"hgnc:HGNC:58587","description":"ATP9B antisense RNA 1","metadata":null},{"id":"caef13ad737840d1a2b7ea2bd2949592","type":"GO_TERM","name":"ATP:2-methylpropanoate phosphotransferase activity","canonical_id":"go:GO:0047758","description":"\"Catalysis of the reaction: 2-methylpropanoate + ATP = 2-methylpropanoyl phosphate + ADP + H+.\" [EC:2.7.2.14, RHEA:24156]","metadata":null},{"id":"8d3a56c21bfb41c7b01a8f1474f514f8","type":"GO_TERM","name":"ATP:3'-cytidine-cytidine-tRNA adenylyltransferase activity","canonical_id":"go:GO:0052929","description":"\"Catalysis of the reaction: a tRNA with a 3' CC end + ATP = a tRNA with a 3' CCA end + diphosphate.\" [PMID:31936900, PMID:33095240, RHEA:60012]","metadata":null},{"id":"3d179d23e07847659d42f3805e49b2e4","type":"GO_TERM","name":"ATP:ADP adenylyltransferase activity","canonical_id":"go:GO:0003877","description":"\"Catalysis of the reaction: ADP + ATP = phosphate + P(1),P(4)-bis(5'-adenosyl)tetraphosphate.\" [EC:2.7.7.53]","metadata":null},{"id":"2da47040ff894f60a1bf3f09cc967f20","type":"GO_TERM","name":"ATP:ADP antiporter activity","canonical_id":"go:GO:0005471","description":"\"Catalysis of the reaction: ATP(out) + ADP(in) = ATP(in) + ADP(out).\" [TC:2.A.29.1.1]","metadata":null},{"id":"b242e42f8cb0424691cdce2f6530ea6f","type":"GO_TERM","name":"ATP:ATP adenylyltransferase activity","canonical_id":"go:GO:0141192","description":"\"Catalysis of the reaction: 2 ATP + H+ = diphosphate + P(1),P(4)-bis(5'-adenosyl)tetraphosphate.\" [PMID:16884494, PMID:19710017, PMID:27398309, RHEA:34935]","metadata":null},{"id":"d1da2f7cbf584753a24e92cc72d030a9","type":"GO_TERM","name":"ATP:coenzyme F420 adenylyltransferase activity","canonical_id":"go:GO:0043910","description":"\"Catalysis of the reaction: ATP + factor gamma-F420-2 + H+ = coenzyme F390-A + diphosphate.\" [GOC:jl, MetaCyc:RXN-9385, PMID:7957247, PMID:8550473]","metadata":null},{"id":"47646a72fdaf4772a3eb925eea629cee","type":"GO_TERM","name":"ATP:phosphate antiporter activity","canonical_id":"go:GO:0140987","description":"\"Enables the transfer of ATP from one side of a membrane to the other according to the reaction: ATP(out) + phosphate(in) = ATP(in) + phosphate(out).\" [PMID:15123600]","metadata":null},{"id":"4982b58ab2f949839ff2b994cee37b7d","type":"GENE","name":"ATPAF1","canonical_id":"hgnc:HGNC:18803","description":"ATP synthase mitochondrial F1 complex assembly factor 1","metadata":{"aliases":["FLJ22351","Atp11p","ATP11"]}},{"id":"1fe9651f1d5f44e5bc06458630b337ca","type":"GENE","name":"ATPAF2","canonical_id":"hgnc:HGNC:18802","description":"ATP synthase mitochondrial F1 complex assembly factor 2","metadata":{"aliases":["Atp12p","ATP12","LP3663","MGC29736"]}},{"id":"0961e58967ed4913a515edb4fd3b3d90","type":"GENE","name":"ATPSCKMT","canonical_id":"hgnc:HGNC:27029","description":"ATP synthase c subunit lysine N-methyltransferase","metadata":{"aliases":["JS-2","FAM173B"]}},{"id":"c1ee57d77cec4961824e2dfc40ba027c","type":"GO_TERM","name":"ATPase activator activity","canonical_id":"go:GO:0001671","description":"\"Binds to and increases the activity of an ATP hydrolysis activity.\" [GOC:ajp]","metadata":null},{"id":"1275c44c14114db1a09ab7dd6c31c804","type":"GO_TERM","name":"ATPase activity, coupled to transmembrane movement of ions, rotational mechanism","canonical_id":"go:GO:0044769","description":"\"Enables the transfer of ions from one side of a membrane to the other according to the reaction: ATP + H2O + ion(in) = ADP + phosphate + ion(out), by a rotational mechanism.\" [GOC:jl]","metadata":null},{"id":"e44d12b2598a47ae8e547182a07d271e","type":"GO_TERM","name":"ATPase binding","canonical_id":"go:GO:0051117","description":"\"Binding to an ATPase, any enzyme that catalyzes the hydrolysis of ATP.\" [GOC:ai]","metadata":null},{"id":"e180bf6de9bd4381af5fcab196e056ef","type":"GO_TERM","name":"ATPase complex","canonical_id":"go:GO:1904949","description":"\"A protein complex which is capable of ATPase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:9606181]","metadata":null},{"id":"1058d021560648aea9b680015f192ed9","type":"GO_TERM","name":"ATPase dependent transmembrane transport complex","canonical_id":"go:GO:0098533","description":"\"A transmembrane protein complex that functions in ATPase dependent active transport across a membrane.\" [GOC:dos]","metadata":null},{"id":"6c5c95bcb14c47be873e253be0a229c3","type":"GO_TERM","name":"ATPase inhibitor activity","canonical_id":"go:GO:0042030","description":"\"Binds to and stops, prevents or reduces an ATP hydrolysis activity.\" [GOC:jl]","metadata":null},{"id":"d8d87c21bfbf4742811bb4f3cc27e5b3","type":"GO_TERM","name":"ATPase inhibitor complex","canonical_id":"go:GO:1903503","description":"\"A protein complex which is capable of ATPase inhibitor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16170325]","metadata":null},{"id":"a5d624d571494c359afc0dd7ea2ad39a","type":"GO_TERM","name":"ATPase regulator activity","canonical_id":"go:GO:0060590","description":"\"Binds to and modulates the activity of an ATP hydrolysis activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"68e5d32a2c3e42b1859e580e7b51592f","type":"GO_TERM","name":"ATPase-coupled 2-aminoethylphosphonate transporter activity","canonical_id":"go:GO:0033225","description":"\"Enables the directed movement of 2-aminoethylphosphonate from one side of a membrane to the other by catalysis of the reaction: ATP + H2O + 2-aminoethylphosphonate(out) = ADP + phosphate + 2-aminoethylphosphonate(in).\" [GOC:mlg]","metadata":null},{"id":"7fd762e9d7134fff8373ea3cd5f0331c","type":"GO_TERM","name":"ATPase-coupled L-glutamate tranmembrane transporter activity","canonical_id":"go:GO:0102013","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-glutamate(out) + ATP + H2O = L-glutamate(in) + ADP + phosphate + H+.\" [RHEA:29035]","metadata":null},{"id":"4b273464fccc4c33b1a064f7823fb379","type":"GO_TERM","name":"ATPase-coupled L-glutamine transmembrane transporter activity","canonical_id":"go:GO:0015599","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-glutamine(out) + ATP + H2O = L-glutamine(in) + ADP + phosphate + H+.\" [RHEA:29895]","metadata":null},{"id":"4ea60efaf31a4aacb3b2570bb205fb06","type":"GO_TERM","name":"ATPase-coupled antimonite transmembrane transporter activity","canonical_id":"go:GO:0042961","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + antimonite(in) = ADP + phosphate + antimonite(out).\" [EC:7.3.2.7]","metadata":null},{"id":"0ef090d370944674b9d3590b5830ce2b","type":"GO_TERM","name":"ATPase-coupled arsenite transmembrane transporter activity","canonical_id":"go:GO:0015446","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + arsenite(in) = ADP + phosphate + arsenite(out).\" [PMID:10970874, RHEA:11348]","metadata":null},{"id":"6b8ce61a7b53413aa9a8daf67d3a4250","type":"GO_TERM","name":"ATPase-coupled carboxylic acid transmembrane transporter activity","canonical_id":"go:GO:0033284","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + carboxylic acid(out/in) = ADP + phosphate + carboxylic acid(in/out).\" [GOC:mlg]","metadata":null},{"id":"f72bb7b72e4145d1b74a3c57cec8a817","type":"GO_TERM","name":"ATPase-coupled ectoine transmembrane transporter activity","canonical_id":"go:GO:0033286","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + ectoine(out/in) = ADP + phosphate + ectoine(in/out).\" [GOC:mlg, RHEA:32787]","metadata":null},{"id":"1545a70c443d4599bd765ffc61a91963","type":"GO_TERM","name":"ATPase-coupled hydroxyectoine transmembrane transporter activity","canonical_id":"go:GO:0033288","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + hydroxyectoine(out/in) = ADP + phosphate + hydroxyectoine(in/out).\" [GOC:mlg]","metadata":null},{"id":"93298091a46742d696533deb7ef8afdb","type":"GO_TERM","name":"ATPase-coupled intramembrane lipid carrier activity","canonical_id":"go:GO:0140326","description":"\"Catalysis of the movement of lipids from one membrane leaflet to the other, driven by ATP hydrolysis. This includes flippases and floppases.\" [PMID:16828084]","metadata":null},{"id":"432ebeeafa3a4e4fb933a425d3732f53","type":"GO_TERM","name":"ATPase-coupled ion transmembrane transporter activity","canonical_id":"go:GO:0042625","description":"\"Enables the transfer of an ion from one side of a membrane to the other, driven by the reaction: ATP + H2O = ADP + phosphate.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"24d052dc2f414af59f9cf31d58538b6a","type":"GO_TERM","name":"ATPase-coupled lipid transmembrane transporter activity","canonical_id":"go:GO:0034040","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + lipid(in) = ADP + phosphate + lipid(out).\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"8e848f859da64028a8f054860cbaf07b","type":"GO_TERM","name":"ATPase-coupled lipo-chitin oligosaccharide transmembrane transporter activity","canonical_id":"go:GO:1901514","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + lipo-chitin oligosaccharide(in) = ADP + phosphate + lipo-chitin oligosaccharide(out).\" [GOC:TermGenie]","metadata":null},{"id":"0e605d1afe5f40ef807162fa0bcffec4","type":"GO_TERM","name":"ATPase-coupled monoatomic cation transmembrane transporter activity","canonical_id":"go:GO:0019829","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + cation(out) = ADP + phosphate + cation(in).\" [GOC:ai]","metadata":null},{"id":"ad32ef516e924c6999a4525699c73b63","type":"GO_TERM","name":"ATPase-coupled monocarboxylic acid transmembrane transporter activity","canonical_id":"go:GO:0033285","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + monocarboxylic acid(out/in) = ADP + phosphate + monocarboxylic acid(in/out).\" [GOC:mlg]","metadata":null},{"id":"f54cbffce81a4b228e4238418487deaf","type":"GO_TERM","name":"ATPase-coupled nonpolar-amino acid transporter activity","canonical_id":"go:GO:0015425","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + nonpolar amino acid(out) = ADP + phosphate + nonpolar amino acid(in).\" [EC:7.4.2.2]","metadata":null},{"id":"23126f24218840e68917f132b6212041","type":"GO_TERM","name":"ATPase-coupled phosphate ion transmembrane transporter activity","canonical_id":"go:GO:0015415","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + phosphate(out) = ADP + phosphate + phosphate(in).\" [EC:7.3.2.1]","metadata":null},{"id":"47250700b36143d1acdc6f8840bdbf08","type":"GO_TERM","name":"ATPase-coupled polar amino acid-transporter activity","canonical_id":"go:GO:0015426","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + polar amino acid(out) = ADP + phosphate + polar amino acid(in).\" [EC:7.4.2.1]","metadata":null},{"id":"018b8d367b1f405bbd75c2daee0d3712","type":"GO_TERM","name":"ATPase-coupled transmembrane transporter activity","canonical_id":"go:GO:0042626","description":"\"Primary active transporter of a solute across a membrane, via the reaction: ATP + H2O = ADP + phosphate, to directly drive the transport of a substance across a membrane. The transport protein may be transiently phosphorylated (P-type transporters), or not (ABC-type transporters and other families of transporters). Primary active transport occurs up the solute's concentration gradient and is driven by a primary energy source.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"8e23472ef93342579836b6fe2ba94980","type":"GO_TERM","name":"ATPase-coupled urea transmembrane transporter activity","canonical_id":"go:GO:0033221","description":"\"Catalysis of the reaction: ATP + H2O + urea(out) = ADP + phosphate + urea(in).\" [GOC:mlg]","metadata":null},{"id":"71d9bed0285243e0a2046ac9a87e37af","type":"GENE","name":"ATR","canonical_id":"hgnc:HGNC:882","description":"ATR checkpoint kinase","metadata":{"aliases":["FRP1","SCKL","SCKL1","MEC1"]}},{"id":"b91030077b474487b277bd4ef47a7d4a","type":"GO_TERM","name":"ATR-ATRIP complex","canonical_id":"go:GO:0070310","description":"\"A protein complex that contains the protein kinase ATR and ATR-interacting protein (ATRIP) and binds single-stranded DNA; ssDNA binding affinity is increased in the presence of replication protein A.\" [GOC:mah, PMID:14724280]","metadata":null},{"id":"e7f1b8ee975b4c47a5a2b479de22833a","type":"GENE","name":"ATRAID","canonical_id":"hgnc:HGNC:24090","description":"all-trans retinoic acid induced differentiation factor","metadata":{"aliases":["HSPC013","p18","APR3","C2orf28"]}},{"id":"3b5fb493134540dabbc4cf773cfb38c6","type":"GENE","name":"ATRIP","canonical_id":"hgnc:HGNC:33499","description":"ATR interacting protein","metadata":{"aliases":["FLJ12343","MGC20625","MGC21482","MGC26740"]}},{"id":"b5fc4d2e89c34d01b043ace1bd7dc80d","type":"GENE","name":"ATRN","canonical_id":"hgnc:HGNC:885","description":"attractin","metadata":{"aliases":["DPPT-L","MGCA"]}},{"id":"f2a9613795ca435e9327ac2a72adbf73","type":"GENE","name":"ATRNL1","canonical_id":"hgnc:HGNC:29063","description":"attractin like 1","metadata":{"aliases":["KIAA0534","FLJ45344","ALP"]}},{"id":"d0fcd90a72694a2ba1f0d03e413f1e5e","type":"GENE","name":"ATRX","canonical_id":"hgnc:HGNC:886","description":null,"metadata":null},{"id":"77310c75f436494e93d953bfe8d3d311","type":"GENE","name":"ATXN1","canonical_id":"hgnc:HGNC:10548","description":"ataxin 1","metadata":{"aliases":["D6S504E","ATX1","SCA1"]}},{"id":"da78d030566d4689b7028d384f3ab8aa","type":"GENE","name":"ATXN1-AS1","canonical_id":"hgnc:HGNC:40515","description":"ATXN1 antisense RNA 1","metadata":{"aliases":["AL137003.1"]}},{"id":"02fa8793836d4e8aad3e370d79df04b0","type":"GENE","name":"ATXN10","canonical_id":"hgnc:HGNC:10549","description":"ataxin 10","metadata":{"aliases":["E46L","FLJ37990","ATX10","SCA10"]}},{"id":"753237cff17a457cab4daf9457a421cf","type":"GENE","name":"ATXN1L","canonical_id":"hgnc:HGNC:33279","description":"ataxin 1 like","metadata":{"aliases":["BOAT1"]}},{"id":"692e4d7d04ac4ae189dd78f6d45d3c85","type":"GENE","name":"ATXN2","canonical_id":"hgnc:HGNC:10555","description":null,"metadata":null},{"id":"8eeea687678f403785024eb28c6a7499","type":"GENE","name":"ATXN2-AS","canonical_id":"hgnc:HGNC:51838","description":"ATXN2 antisense RNA","metadata":null},{"id":"faa3a40cd5e34aff860a6ecbd6c30089","type":"GENE","name":"ATXN2L","canonical_id":"hgnc:HGNC:31326","description":"ataxin 2 like","metadata":{"aliases":["A2lp","A2D"]}},{"id":"f3c65517b38840eaac729bfa4e764045","type":"GENE","name":"ATXN3","canonical_id":"hgnc:HGNC:7106","description":"ataxin 3","metadata":{"aliases":["ATX3","JOS","SCA3","MJD"]}},{"id":"da5ce3bdb7ce4e23a05eb92006d96387","type":"GENE","name":"ATXN3L","canonical_id":"hgnc:HGNC:24173","description":"ataxin 3 like","metadata":{"aliases":["ATXN3L1","MJDL"]}},{"id":"e1db1eeb21d94c70a9af8dc2cd095928","type":"GENE","name":"ATXN3L2","canonical_id":"hgnc:HGNC:59195","description":"ataxin 3 like 2 (pseudogene)","metadata":null},{"id":"2429db599e914d7e8e3a116fe86c6fe7","type":"GENE","name":"ATXN7","canonical_id":"hgnc:HGNC:10560","description":null,"metadata":null},{"id":"b093067083834e0a8e38714aa3ad2f24","type":"GENE","name":"ATXN7L1","canonical_id":"hgnc:HGNC:22210","description":"ataxin 7 like 1","metadata":{"aliases":["KIAA1218","MGC33190","ATXN7L4"]}},{"id":"c7e35a83c8ec4667a89f32393e159c72","type":"GENE","name":"ATXN7L2","canonical_id":"hgnc:HGNC:28713","description":"ataxin 7 like 2","metadata":{"aliases":["MGC46534","FLJ00381"]}},{"id":"004a5fde4ab2452c917039ca7a499b6f","type":"GENE","name":"ATXN7L3","canonical_id":"hgnc:HGNC:25416","description":"ataxin 7 like 3","metadata":{"aliases":["DKFZp761G2113"]}},{"id":"7c9e2ecb7e604f788c98c2673ba0a616","type":"GENE","name":"ATXN7L3-AS1","canonical_id":"hgnc:HGNC:55298","description":"ATXN7L3 antisense RNA 1","metadata":null},{"id":"b2a4cc2dfbaa4f56aed036288cc800a9","type":"GENE","name":"ATXN7L3B","canonical_id":"hgnc:HGNC:37931","description":"ataxin 7 like 3B","metadata":{"aliases":["lnc-SCA7"]}},{"id":"d2a4451f287d4304b89e7153f3658a92","type":"GENE","name":"ATXN7L3P1","canonical_id":"hgnc:HGNC:54980","description":"ATXN7L3 pseudogene 1","metadata":null},{"id":"5bfaf3af36954252893d843c470504ef","type":"GENE","name":"ATXN8","canonical_id":"hgnc:HGNC:32925","description":"ataxin 8","metadata":null},{"id":"f1460cf9b1e149ce92cf86057203714a","type":"GENE","name":"ATXN8OS","canonical_id":"hgnc:HGNC:10561","description":"ATXN8 opposite strand lncRNA","metadata":{"aliases":["NCRNA00003","SCA8","KLHL1AS"]}},{"id":"eeeb6848c7924277982e22d3f7d33c9b","type":"GO_TERM","name":"AUA codon-amino acid adaptor activity","canonical_id":"go:GO:0033435","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AUA codon.\" [GOC:mah]","metadata":null},{"id":"36d7582b2008474b9602c03e04c8aecf","type":"GO_TERM","name":"AUC codon-amino acid adaptor activity","canonical_id":"go:GO:0033434","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AUC codon.\" [GOC:mah]","metadata":null},{"id":"2d8b5c604bf14da2b671ef6b61852585","type":"GO_TERM","name":"AUG codon-amino acid adaptor activity","canonical_id":"go:GO:0033436","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AUG codon.\" [GOC:mah]","metadata":null},{"id":"e1e2f6a562ff4615ad874b03db977905","type":"GENE","name":"AUH","canonical_id":"hgnc:HGNC:890","description":"AU RNA binding methylglutaconyl-CoA hydratase","metadata":null},{"id":"1eb316245ddd4362850779e18117b9d7","type":"GENE","name":"AUNIP","canonical_id":"hgnc:HGNC:28363","description":"aurora kinase A and ninein interacting protein","metadata":{"aliases":["MGC2603","AIBp","C1orf135"]}},{"id":"63caf1996a254183a162dad5b9e81f6a","type":"GENE","name":"AUP1","canonical_id":"hgnc:HGNC:891","description":"AUP1 lipid droplet regulating VLDL assembly factor","metadata":null},{"id":"d70b88a46ba042c49e1a5a15f7993730","type":"TRIAL","name":"AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)","canonical_id":"clinicaltrials.gov:NCT02141672","description":"Lupus Nephritis","metadata":null},{"id":"e67c29830d5641329bd299c242311f38","type":"GENE","name":"AURKA","canonical_id":"hgnc:HGNC:11393","description":null,"metadata":null},{"id":"c3616f58d92846279c396fa090e64b31","type":"GENE","name":"AURKAIP1","canonical_id":"hgnc:HGNC:24114","description":"aurora kinase A interacting protein 1","metadata":{"aliases":["Cox24","AKIP","AIP","FLJ20608","mS38"]}},{"id":"ba56bdd4b6bf4eedae4f4c5f3da4ede2","type":"GENE","name":"AURKAP1","canonical_id":"hgnc:HGNC:18611","description":"aurora kinase A pseudogene 1","metadata":{"aliases":["AurAps1","STK6P","AURKAPS1"]}},{"id":"ddc074909070471da847e7e0f89e087e","type":"GENE","name":"AURKAP2","canonical_id":"hgnc:HGNC:18612","description":"aurora kinase A pseudogene 2","metadata":{"aliases":["STK6LP","AURKAPS2"]}},{"id":"269516e35b7047dca17b02b47d244d35","type":"GENE","name":"AURKB","canonical_id":"hgnc:HGNC:11390","description":null,"metadata":null},{"id":"6ba93c1f6474421f8c868fd30525a604","type":"GENE","name":"AURKBP1","canonical_id":"hgnc:HGNC:18613","description":"aurora kinase B pseudogene 1","metadata":{"aliases":["AurBps1","AURKBPS1"]}},{"id":"c0cc9b27fb6e4ee188c91562c7f1cf32","type":"GENE","name":"AURKC","canonical_id":"hgnc:HGNC:11391","description":"aurora kinase C","metadata":{"aliases":["AurC","ARK3","STK13"]}},{"id":"b0cdb3f5e3314eb79d95bd14bddd6e5a","type":"GENE","name":"AUTS2","canonical_id":"hgnc:HGNC:14262","description":"activator of transcription and developmental regulator AUTS2","metadata":{"aliases":["KIAA0442","FBRSL2"]}},{"id":"b809e49a908648c981711ee35a057526","type":"GO_TERM","name":"AUU codon-amino acid adaptor activity","canonical_id":"go:GO:0033433","description":"\"A triplet codon-amino acid adaptor activity that recognizes an AUU codon.\" [GOC:mah]","metadata":null},{"id":"1271494bb07c4d03acfcce57434bb21c","type":"GO_TERM","name":"AV node cell action potential","canonical_id":"go:GO:0086016","description":"\"An action potential that occurs in an atrioventricular node cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"dbcbfc7bcdc44c48b3f12e58398cee11","type":"GO_TERM","name":"AV node cell to bundle of His cell communication","canonical_id":"go:GO:0086067","description":"\"The process that mediates interactions between an AV node cell and its surroundings that contributes to the process of the AV node cell communicating with a bundle of His cell in cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"e013c3adc86c4c7bbc2e5acb66f61fa3","type":"GO_TERM","name":"AV node cell to bundle of His cell communication by electrical coupling","canonical_id":"go:GO:0086053","description":"\"The process that mediates signaling interactions between an AV node cardiomyocyte and a bundle of His cardiac muscle cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"5734620f7d874214a723452d726ad15a","type":"GO_TERM","name":"AV node cell to bundle of His cell signaling","canonical_id":"go:GO:0086027","description":"\"Any process that mediates the transfer of information from an AV node cardiac muscle cell to a bundle of His cardiomyocyte.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"fbe1c42c941d43a687675b57f2c05fa0","type":"GO_TERM","name":"AV node cell-bundle of His cell adhesion involved in cell communication","canonical_id":"go:GO:0086072","description":"\"The attachment of an AV node cell to an bundle of His cell via adhesion molecules that results in the cells being juxtaposed so that they can communicate.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"a7a50907f73e4e9892d2c8aa8c0dec0e","type":"TRIAL","name":"AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00241605","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"23ca567e33f2468ba59c31336efc85b0","type":"TRIAL","name":"AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone","canonical_id":"clinicaltrials.gov:NCT00333723","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"9537f9555fad419680d90bc35b0ce1f9","type":"TRIAL","name":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","canonical_id":"clinicaltrials.gov:NCT04513951","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"c8cd7f1f80d94f77986471f935a7afbb","type":"GENE","name":"AVEN","canonical_id":"hgnc:HGNC:13509","description":"apoptosis and caspase activation inhibitor","metadata":{"aliases":["PDCD12"]}},{"id":"7702706ab35741b59d09c8216333ed05","type":"GENE","name":"AVIL","canonical_id":"hgnc:HGNC:14188","description":"advillin","metadata":{"aliases":["p92","FLJ12386","ADVIL","DOC6"]}},{"id":"0299435384894c009d3104d006d65029","type":"GENE","name":"AVL9","canonical_id":"hgnc:HGNC:28994","description":"AVL9 cell migration associated","metadata":{"aliases":["KIAA0241"]}},{"id":"29ecb56034294f18ba4453d5be93413d","type":"GENE","name":"AVP","canonical_id":"hgnc:HGNC:894","description":null,"metadata":null},{"id":"4c921f1e7fda441195e6dce62344d3d5","type":"GENE","name":"AVPI1","canonical_id":"hgnc:HGNC:30898","description":"arginine vasopressin induced 1","metadata":{"aliases":["VIP32","PP5395","VIT32"]}},{"id":"86446543240847c19e4af3bf32fde79d","type":"GENE","name":"AVPR1A","canonical_id":"hgnc:HGNC:895","description":"arginine vasopressin receptor 1A","metadata":{"aliases":["AVPR1"]}},{"id":"66998284f6e846bb8d8d837affd0f493","type":"PROTEIN","name":"AVPR1A","canonical_id":"uniprot:P37288","description":null,"metadata":null},{"id":"13c5752899834ba78238eeaa4677179c","type":"GENE","name":"AVPR1B","canonical_id":"hgnc:HGNC:896","description":"arginine vasopressin receptor 1B","metadata":{"aliases":["V1bR","VPR3","AVPR3"]}},{"id":"aa3e8aa8870948019cf536d8ecd08ed7","type":"PROTEIN","name":"AVPR1B","canonical_id":"uniprot:P47901","description":null,"metadata":null},{"id":"9bd4020f34d2445f9890413619d4e123","type":"GENE","name":"AVPR1B-DT","canonical_id":"hgnc:HGNC:55832","description":"AVPR1B divergent transcript","metadata":null},{"id":"3d2ba09fc32544ffb0ce8069a6243c8e","type":"GENE","name":"AVPR2","canonical_id":"hgnc:HGNC:897","description":"arginine vasopressin receptor 2","metadata":{"aliases":["V2R","DIR3","DIR"]}},{"id":"cd04c76825cb4d4bafc58c21ae85b8ab","type":"PROTEIN","name":"AVPR2","canonical_id":"uniprot:P30518","description":null,"metadata":null},{"id":"b4f96b2db8e2427f8f42faa0a35818bf","type":"GENE","name":"AWAT1","canonical_id":"hgnc:HGNC:23252","description":"acyl-CoA wax alcohol acyltransferase 1","metadata":{"aliases":["DGAT2L3"]}},{"id":"c646425d76b34a12a2f900d4eb30925c","type":"GENE","name":"AWAT2","canonical_id":"hgnc:HGNC:23251","description":"acyl-CoA wax alcohol acyltransferase 2","metadata":{"aliases":["MFAT","DGAT2L4"]}},{"id":"322f762bfa8845169e9c01965aba734b","type":"GENE","name":"AXDND1","canonical_id":"hgnc:HGNC:26564","description":"axonemal dynein light chain domain containing 1","metadata":{"aliases":["FLJ32940","C1orf125"]}},{"id":"a319ee74bf8d41f28b6a535fdccabaf5","type":"GENE","name":"AXIN1","canonical_id":"hgnc:HGNC:903","description":"axin 1","metadata":{"aliases":["PPP1R49"]}},{"id":"0ee26a761ea24af7906a8aef5dc9fd4e","type":"GENE","name":"AXIN2","canonical_id":"hgnc:HGNC:904","description":null,"metadata":null},{"id":"74ad49a677dd42518d61bb7798a2381c","type":"GENE","name":"AXL","canonical_id":"hgnc:HGNC:905","description":null,"metadata":null},{"id":"2a791917b83f4a2c84b66ad243f6d957","type":"TRIAL","name":"AZ, MZ, and the Pulmonary System Response to Hypoxia","canonical_id":"clinicaltrials.gov:NCT02760121","description":"Altitude Sickness; Hypertension, Pulmonary","metadata":null},{"id":"541acef45f45407585f814b5fac2dec0","type":"TRIAL","name":"AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure","canonical_id":"clinicaltrials.gov:NCT01484951","description":"Glaucoma","metadata":null},{"id":"b54d5156474d492fb8504270c9bc837f","type":"TRIAL","name":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","canonical_id":"clinicaltrials.gov:NCT06346392","description":"Gastric Cancer; Gastroesophageal Junction Cancer","metadata":null},{"id":"19d5e331eac74cd7b4799ae38129f526","type":"TRIAL","name":"AZD2066 Cocktail Study","canonical_id":"clinicaltrials.gov:NCT00930306","description":"Chronic Pain","metadata":null},{"id":"16e5a7f2526d49339f6efbcbba99ffef","type":"TRIAL","name":"AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies","canonical_id":"clinicaltrials.gov:NCT01065662","description":"Endometrial Cancer; Ovarian Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"6e7595f482424802944cddd7ace191f6","type":"TRIAL","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","canonical_id":"clinicaltrials.gov:NCT07611110","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"bb1403d663af4b05ab91172f063fa4a1","type":"TRIAL","name":"AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00535353","description":"Colorectal Cancer","metadata":null},{"id":"bdbc6542df7e424eb1d2f0beab5d3ca4","type":"TRIAL","name":"AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01085214","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"458b733d9e414f479f4b523281f5fb58","type":"TRIAL","name":"AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)","canonical_id":"clinicaltrials.gov:NCT02238353","description":"Allergic Rhinitis; House Dust Mite Allergy","metadata":null},{"id":"59a1ce7ce21c47fab436d005e4a73bb5","type":"GENE","name":"AZGP1","canonical_id":"hgnc:HGNC:910","description":"alpha-2-glycoprotein 1, zinc-binding","metadata":{"aliases":["ZA2G","ZAG"]}},{"id":"6be6604f740048aab9a67685d07ecdba","type":"GENE","name":"AZGP1P1","canonical_id":"hgnc:HGNC:911","description":"AZGP1 pseudogene 1","metadata":null},{"id":"e337bccacd914217abe671dd47aee540","type":"GENE","name":"AZGP1P2","canonical_id":"hgnc:HGNC:912","description":"AZGP1 pseudogene 2","metadata":null},{"id":"41eb208e613e44e8819818cece9a788f","type":"GENE","name":"AZI2","canonical_id":"hgnc:HGNC:24002","description":"5-azacytidine induced 2","metadata":{"aliases":["NAP1","FLJ21939","AZ2"]}},{"id":"59b5b8af0ca24a07a1a66a6c2f1be2e4","type":"GENE","name":"AZIN1","canonical_id":"hgnc:HGNC:16432","description":"antizyme inhibitor 1","metadata":{"aliases":["OAZI","ODC1L","OAZIN"]}},{"id":"2c11651a51914454920a2ec89f1ab285","type":"GENE","name":"AZIN1-AS2","canonical_id":"hgnc:HGNC:58328","description":"AZIN1 antisense RNA 2","metadata":null},{"id":"c2918ceec5bb486da8232b8e3b88e0f6","type":"GENE","name":"AZIN2","canonical_id":"hgnc:HGNC:29957","description":"antizyme inhibitor 2","metadata":{"aliases":["ODC-p","ODC1L","KIAA1945","ODCp","ADC"]}},{"id":"37b3a90d90d14d1ca18e7885a8dd82a4","type":"GENE","name":"AZU1","canonical_id":"hgnc:HGNC:913","description":"azurocidin 1","metadata":{"aliases":["AZU","CAP37","AZAMP","HBP","NAZC","HUMAZUR"]}},{"id":"857135d666ca4e09b7a2c8099bf84d95","type":"GENE","name":"AZU1P1","canonical_id":"hgnc:HGNC:49098","description":"azurocidin 1 pseudogene 1","metadata":null},{"id":"88272ec8880b486793ac0162baf2cb10","type":"TRIAL","name":"Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone","canonical_id":"clinicaltrials.gov:NCT04467983","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"41d9bb55e60e462a9ad1dc030938b5a6","type":"TRIAL","name":"Abaloparatide Before Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT04167163","description":"Osteoporosis; Arthroplasties, Knee Replacement","metadata":null},{"id":"cb1f1dec56164bc1a5023a5960e21047","type":"TRIAL","name":"Abaloparatide and Pelvic Fracture Healing","canonical_id":"clinicaltrials.gov:NCT04249232","description":"Fracture of Pelvis (Disorder)","metadata":null},{"id":"a50cf8a3357646b88680725491b14c93","type":"TRIAL","name":"Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery","canonical_id":"clinicaltrials.gov:NCT03841058","description":"Spinal Fusion","metadata":null},{"id":"336eb973ba65426d9224888eda6c3d8d","type":"TRIAL","name":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00841113","description":"Prostate Cancer","metadata":null},{"id":"3ff20d04945145908695943c8adfb23b","type":"DRUG","name":"Abatacept","canonical_id":"mesh:D000069594","description":null,"metadata":null},{"id":"84232ce2c05a4bdd854a51590f5933f2","type":"TRIAL","name":"Abatacept Conversion in Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT04955366","description":"Renal Transplant Recipient","metadata":null},{"id":"ce96ac41ce5d4e989f4dd3d4fabab0ab","type":"TRIAL","name":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT02867800","description":"Sickle Cell Disease; Graft Versus Host Disease","metadata":null},{"id":"01238e43c8914ffc89640b0f98ebb9fd","type":"TRIAL","name":"Abatacept in Juvenile Dermatomyositis","canonical_id":"clinicaltrials.gov:NCT02594735","description":"Dermatomyositis","metadata":null},{"id":"cd1adb3bec5140ec9d67a3ae6c280e92","type":"TRIAL","name":"Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)","canonical_id":"clinicaltrials.gov:NCT01954979","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"a863563c97ef4d608eea19e2c45e4e9b","type":"TRIAL","name":"Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders","canonical_id":"clinicaltrials.gov:NCT03227419","description":"Arthritis, Rheumatoid","metadata":null},{"id":"19c32c2f8c0045afad3e29114834e846","type":"TRIAL","name":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03457142","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"e99717b08ff841a6850b87da2e7cbb87","type":"TRIAL","name":"Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis","canonical_id":"clinicaltrials.gov:NCT01932554","description":"Sickle Cell Disease; Hb-SS Disease With Vasoocclusive Pain; Hemoglobin SS Disease With Vasoocclusive Crisis; Other Sickle Cell Disease With Vaso-Occlusive Pain; Hemoglobin SS Disease With Crisis","metadata":null},{"id":"de5c7543d0594d08858da6b625e24655","type":"TRIAL","name":"Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis","canonical_id":"clinicaltrials.gov:NCT00126139","description":"Stroke; Stenosis","metadata":null},{"id":"51913c26df6540ea9e2d35893671a010","type":"TRIAL","name":"Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI","canonical_id":"clinicaltrials.gov:NCT00299377","description":"Myocardial Infarction","metadata":null},{"id":"69ea190043464ff5a725c94881f80836","type":"TRIAL","name":"Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00712101","description":"ST-elevation Myocardial Infarction","metadata":null},{"id":"eea37ae9d40a45b0bdeb9b57dd818639","type":"TRIAL","name":"Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock","canonical_id":"clinicaltrials.gov:NCT00420030","description":"Shock, Cardiogenic","metadata":null},{"id":"e5204676a7e146118b5c1981e48c39ce","type":"TRIAL","name":"Abciximab in Wake-up Stroke","canonical_id":"clinicaltrials.gov:NCT00167765","description":"Stroke","metadata":null},{"id":"f8ba2125e0ff4a17aad3508a9bbb26a0","type":"TRIAL","name":"Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)","canonical_id":"clinicaltrials.gov:NCT00133003","description":"Coronary Disease; Angina, Unstable","metadata":null},{"id":"9dcc0e9851934967b72e3886e26c2869","type":"TRIAL","name":"Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue","canonical_id":"clinicaltrials.gov:NCT01632592","description":"Abdominal Obesity","metadata":null},{"id":"20b12661c75a4b858b7c5074a4953507","type":"DISEASE","name":"Abdominal abscess","canonical_id":"mesh:D018784","description":null,"metadata":null},{"id":"99fa9c99927a4ec68c0555545b3bbb85","type":"DISEASE","name":"Abdominal pain","canonical_id":"hp:0002027","description":null,"metadata":null},{"id":"90a1fce7cb1a49b0af77f607947651f6","type":"DRUG","name":"Abemaciclib","canonical_id":"ncit:C97660","description":null,"metadata":null},{"id":"d0b5b00c1b6c46a08c48be440103a059","type":"TRIAL","name":"Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness","canonical_id":"clinicaltrials.gov:NCT00545142","description":"Bipolar Disorder","metadata":null},{"id":"2a3e2449002e4816a0c767c94694a543","type":"TRIAL","name":"Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals","canonical_id":"clinicaltrials.gov:NCT00855868","description":"Alzheimer's Disease","metadata":null},{"id":"b89235cab4db42c9b0ae4d6c32650fd1","type":"TRIAL","name":"Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block","canonical_id":"clinicaltrials.gov:NCT02308748","description":"Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics","metadata":null},{"id":"f23163bf0c6d47a28d10e129381519d7","type":"TRIAL","name":"Abiraterone Acetate in Combination With Tildrakizumab","canonical_id":"clinicaltrials.gov:NCT04458311","description":"Metastatic Castration Resistant Prostate Cancer","metadata":null},{"id":"449ab7ca80fb40f08106861e81a4219f","type":"TRIAL","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT05422911","description":"Metastatic Cancer; Neoplasm, Prostate; Castrate-sensitive; Castrate-sensitive Prostate Cancer","metadata":null},{"id":"f8df8379519c4d4393866d6c33e29f79","type":"DISEASE","name":"Abnormal circulating lipid concentration","canonical_id":"hp:0003119","description":null,"metadata":null},{"id":"1993a5fe44294d069a6fb8e0d0b25d43","type":"DISEASE","name":"Abnormal glucose homeostasis","canonical_id":"hp:0011014","description":null,"metadata":null},{"id":"1293b891272b411dbd1feb1101753b04","type":"DISEASE","name":"Abnormal thrombosis","canonical_id":"hp:0001977","description":null,"metadata":null},{"id":"c8bfcc84f5074670a0dce0521510beb5","type":"DISEASE","name":"Abnormality of coagulation","canonical_id":"hp:0001928","description":null,"metadata":null},{"id":"edfe2739e3404cdb90cf5f3500a0ab71","type":"DISEASE","name":"Abnormality of limbs","canonical_id":"hp:0040064","description":null,"metadata":null},{"id":"4d07686d665845a78a5faaf09e0cf2b0","type":"DISEASE","name":"Abnormality of the cardiovascular system","canonical_id":"hp:0001626","description":null,"metadata":null},{"id":"163ca549eef94aa0a9242609f9b2a9ca","type":"DISEASE","name":"Abnormality of the musculature","canonical_id":"hp:0003011","description":null,"metadata":null},{"id":"02a81cef70574241823813ed88888509","type":"DISEASE","name":"Abnormality of the skeletal system","canonical_id":"hp:0000924","description":null,"metadata":null},{"id":"f63bb3297c2440488601cac63cfe8d11","type":"DISEASE","name":"Abnormality of the thyroid gland","canonical_id":"hp:0000820","description":null,"metadata":null},{"id":"ed7d7ecdc48d483f8774bdb0f9c22dce","type":"TRIAL","name":"Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02802098","description":"Metastatic Breast Cancer; Bevacizumab-alone Maintenance Treatment Progression","metadata":null},{"id":"17ba444d16f34ec1a3a3a9948824add2","type":"DISEASE","name":"Absence seizure","canonical_id":"mesh:D004832","description":null,"metadata":null},{"id":"aa5a77cb8a0840c4b5b1a0addb355bc9","type":"TRIAL","name":"Absolute Bioavailability Of Bosutinib","canonical_id":"clinicaltrials.gov:NCT02192294","description":"Healthy","metadata":null},{"id":"442ad86e57544845bf4988c8be5c4e5d","type":"TRIAL","name":"Absolute Bioavailability Study With Bexagliflozin","canonical_id":"clinicaltrials.gov:NCT03417076","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"6d2f1ce063dc4567a789aa8862854b12","type":"TRIAL","name":"Absolute Bioavailability Study With Ipragliflozin","canonical_id":"clinicaltrials.gov:NCT01611428","description":"Bioavailability of Ipragliflozin; Healthy Subjects","metadata":null},{"id":"bc560ac63a004b06bd1a8f51a56b13f3","type":"TRIAL","name":"Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine","canonical_id":"clinicaltrials.gov:NCT00520169","description":"Healthy","metadata":null},{"id":"bd870db825d647a19f2701a7598b808f","type":"TRIAL","name":"Absolute Bioavailability of Reslizumab in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01990443","description":"Absolute Bioavailability","metadata":null},{"id":"00897799b43043358235d9222b71b842","type":"TRIAL","name":"Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02782975","description":"Alzheimer's Disease","metadata":null},{"id":"3b817f7816c2499baf4c971e07810688","type":"TRIAL","name":"Absorption and Safety of Topical Timolol to Treat Chronic Wounds","canonical_id":"clinicaltrials.gov:NCT04903366","description":"Glaucoma, Open-Angle; Chronic Wounds","metadata":null},{"id":"ea6f1e39e2434cc7a5b9756ae6b3fb18","type":"TRIAL","name":"Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler","canonical_id":"clinicaltrials.gov:NCT04856098","description":"Healthy Volunteers","metadata":null},{"id":"41f2e6e796394575967adf9f7b7c8184","type":"TRIAL","name":"Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib","canonical_id":"clinicaltrials.gov:NCT02986100","description":"Solid Tumor","metadata":null},{"id":"a0c9c20b8ba049448d90bf8c4b8359e2","type":"TRIAL","name":"Abuse Potential of Buprenorphine/Naloxone","canonical_id":"clinicaltrials.gov:NCT00149539","description":"Opioid-Related Disorders","metadata":null},{"id":"19c44a3d515a480dba2a846723cddbbb","type":"TRIAL","name":"Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users","canonical_id":"clinicaltrials.gov:NCT00828659","description":"Drug Abuse; Healthy","metadata":null},{"id":"a9379a207630479da86d7858c4baf8f7","type":"GO_TERM","name":"Ac-Asp-Glu binding","canonical_id":"go:GO:1904492","description":"\"Binding to Ac-Asp-Glu.\" [GO_REF:0000067, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:24863754]","metadata":null},{"id":"6711336f1bf84368bb0278def847f9ec","type":"TRIAL","name":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT05583149","description":"Refractory Aggressive B-cell Lymphomas; Refractory B-Cell Non-Hodgkin Lymphoma; Aggressive B-cell NHL; Diffuse Large B-cell Lymphoma (DLBCL); De Novo or Transformed Indolent B-cell Lymphoma; DLBCL, Nos Genetic Subtypes; T Cell/Histiocyte-rich Large B-cell Lymphoma; EBV-Positive DLBCL, Nos; Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL); High-Grade B-Cell Lymphoma, Nos; C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma; Grade 3b Follicular Lymphoma; C-MYC/BCL2 Double-Hit High-Grade B-\u2026","metadata":null},{"id":"058379ffc86041078805ea9c591433d2","type":"TRIAL","name":"Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06846489","description":"Mantle Cell Lymphoma (MCL)","metadata":null},{"id":"7242fa88b89449e8a081670c38a2770b","type":"TRIAL","name":"Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04566887","description":"Mantle Cell Lymphoma","metadata":null},{"id":"3016f764de5c46a7b0f50c0d1569b3b4","type":"TRIAL","name":"Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT04836832","description":"Recurrent Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Refractory Follicular Lymphoma; Refractory Indolent Non-Hodgkin Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Nodal Marginal Zone Lymphoma; Refractory Splenic Marginal Zone Lymphoma","metadata":null},{"id":"eb37005afeba49379d3004493a7111d3","type":"TRIAL","name":"Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT03788291","description":"Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)","metadata":null},{"id":"1fc34403edef4c45a1353d944d9ca984","type":"TRIAL","name":"Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT04883437","description":"Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Indolent Non-Hodgkin Lymphoma; Lymphoplasmacytic Lymphoma; Lymphoproliferative Disorder; Mantle Cell Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"db01687faa4345d69a29ff1cba121302","type":"TRIAL","name":"Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04765111","description":"Mantle Cell Lymphoma","metadata":null},{"id":"13adf93302da4e95b370987e5d9dd5c9","type":"TRIAL","name":"Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT04198922","description":"Recurrent Moderate-Severe Chronic Graft Versus Host Disease; Hematopoietic and Lymphoid Cell Neoplasm","metadata":null},{"id":"60b5ab25f9ae4d22bae36fc6fcb0ca55","type":"TRIAL","name":"Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04189757","description":"Mantle Cell Lymphoma","metadata":null},{"id":"6d75eeae70cc4a6ab0cf6406682bbeb8","type":"TRIAL","name":"Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT04657094","description":"Autoimmune Hemolytic Anemia; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Warm Antibody Autoimmune Hemolytic Anemia","metadata":null},{"id":"4bd4f3483a7f48c3b833d78935d41df2","type":"TRIAL","name":"Acalabrutinib in CNSL","canonical_id":"clinicaltrials.gov:NCT04906902","description":"Central Nervous System Lymphoma; Refractory Central Nervous System Lymphoma; Recurrent Central Nervous System Lymphoma","metadata":null},{"id":"e03ccb34fed2450bbfbc864b45b9f6c5","type":"TRIAL","name":"Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT05336812","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"1c2f55281d3444e5884336cac4245f32","type":"TRIAL","name":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","canonical_id":"clinicaltrials.gov:NCT04624633","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia","metadata":null},{"id":"e2688a2b6b0a4f44b3164c018adce8b1","type":"TRIAL","name":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04783415","description":"Mantle Cell Lymphoma","metadata":null},{"id":"589296e3217249e2bfbeb450f1394d9a","type":"TRIAL","name":"Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL","canonical_id":"clinicaltrials.gov:NCT03863184","description":"Mantle Cell Lymphoma","metadata":null},{"id":"27afbc1f54d6486aad14b9a808b28102","type":"TRIAL","name":"Acamprosate and Methazolamide for Essential Tremor","canonical_id":"clinicaltrials.gov:NCT06312800","description":"Essential Tremor","metadata":null},{"id":"77b308b8f28c44bfb1504b77ebcca478","type":"DISEASE","name":"Acanthamoeba keratitis","canonical_id":"mesh:D015823","description":null,"metadata":null},{"id":"87f12fb84eea45048a9a3c8a7f4caecd","type":"TRIAL","name":"Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT04510168","description":"Alzheimer Disease; Dementia","metadata":null},{"id":"0303d168ba8d4d71a4b8eddf39f9992b","type":"TRIAL","name":"Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin","canonical_id":"clinicaltrials.gov:NCT02675335","description":"Diabetic Foot","metadata":null},{"id":"80dcc84ff2cb42e590868c21d0b03abf","type":"TRIAL","name":"Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis","canonical_id":"clinicaltrials.gov:NCT05520944","description":"COVID-19; COVID-19 Pandemic; COVID-19 Respiratory Infection; SARS CoV 2 Infection; SARS-CoV-2 Acute Respiratory Disease","metadata":null},{"id":"a38a1467b67b45af9b3320f95d78c979","type":"TRIAL","name":"Accelerating Gastrointestinal Recovery","canonical_id":"clinicaltrials.gov:NCT01704651","description":"Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"ff44ab1b4b0249f5a387a889740a9219","type":"TRIAL","name":"Accelerating TMS for Cervical Dystonia","canonical_id":"clinicaltrials.gov:NCT06328114","description":"Isolated Cervical Dystonia","metadata":null},{"id":"a363aae2ef2b4cefb331a166e08534ae","type":"TRIAL","name":"Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy","canonical_id":"clinicaltrials.gov:NCT02220114","description":"Infantile Spasms","metadata":null},{"id":"256fa82469684c398a569b6f45eebce6","type":"TRIAL","name":"Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)","canonical_id":"clinicaltrials.gov:NCT00725608","description":"Opioid-Related Disorders; Opiate Dependence; Drug Abuse","metadata":null},{"id":"2d187daea4ad4d5ebfc540de874ee03e","type":"TRIAL","name":"Acceptability of a Fixed Combination of Fenofibrate and Metformin","canonical_id":"clinicaltrials.gov:NCT00348725","description":"Dyslipidemia/Glucose Metabolism Disorder","metadata":null},{"id":"64f1b19c52ac4fad8c3a2bc8903da99e","type":"TRIAL","name":"Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation","canonical_id":"clinicaltrials.gov:NCT01856985","description":"Medical Abortion","metadata":null},{"id":"9190d4d97b6d482d8a13648498c1a5f9","type":"TRIAL","name":"Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT02955654","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"7417b52d5262465bb2390c941d5a46b5","type":"TRIAL","name":"Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma","canonical_id":"clinicaltrials.gov:NCT02416232","description":"Melanoma","metadata":null},{"id":"65b65e4ed469465c8902b6568b5e049f","type":"TRIAL","name":"Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab","canonical_id":"clinicaltrials.gov:NCT05339100","description":"Healthy Participants Study","metadata":null},{"id":"f3c12ba088d1410ba3c93b00a8b1a36f","type":"TRIAL","name":"Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient","canonical_id":"clinicaltrials.gov:NCT03522207","description":"TMD; Sleep Bruxism; TMJ Pain; Chronic Pain; Sleep Disorder","metadata":null},{"id":"905db963dfe0434cb2364a3071046ae3","type":"TRIAL","name":"Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking","canonical_id":"clinicaltrials.gov:NCT02130453","description":"Ischemia","metadata":null},{"id":"cb0b451afae34e428ef2298f94c33eab","type":"TRIAL","name":"Accurate Diagnosis of Multiple Sclerosis Using PET/MR","canonical_id":"clinicaltrials.gov:NCT04521439","description":"Multiple Sclerosis","metadata":null},{"id":"36b0a7aaec4a49f9b572ab80e0ffd3dd","type":"DRUG","name":"Acebutolol","canonical_id":"mesh:D000070","description":null,"metadata":null},{"id":"04957fbf080245c799f44bb62bc635d8","type":"DRUG","name":"Acetaminophen","canonical_id":"mesh:D000082","description":null,"metadata":null},{"id":"aa594ef492a2461ca145c598c6829239","type":"TRIAL","name":"Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass","canonical_id":"clinicaltrials.gov:NCT00489424","description":"Osteoporosis","metadata":null},{"id":"4aee02dadf034c068b43f728d181f841","type":"DRUG","name":"Acetazolamide","canonical_id":"mesh:D000086","description":null,"metadata":null},{"id":"9a44e5dd15c945908728e5e6313c629a","type":"TRIAL","name":"Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome","canonical_id":"clinicaltrials.gov:NCT03847571","description":"Bartter Syndrome","metadata":null},{"id":"dae093613ece42289059f11d512ab3f3","type":"TRIAL","name":"Acetazolamide Efficacy in Ataxia in PMM2-CDG","canonical_id":"clinicaltrials.gov:NCT04679389","description":"Pmm2-CDG; CDG1A","metadata":null},{"id":"9d6729d245ad4cbab4bb058462cf14cf","type":"TRIAL","name":"Acetazolamide Trial in Normal Pressure Hydrocephalus","canonical_id":"clinicaltrials.gov:NCT04975269","description":"Idiopathic Normal Pressure Hydrocephalus (INPH)","metadata":null},{"id":"a10ac7f8f97a4353a17e8ef38aa0672d","type":"TRIAL","name":"Acetazolamide and Exercise Performance at Altitude","canonical_id":"clinicaltrials.gov:NCT03525561","description":"Hypoxia; Exercise Performance; Cognitive Function; Dexterity","metadata":null},{"id":"a52d16cab0404bcaa4e36507ef109b2f","type":"TRIAL","name":"Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure","canonical_id":"clinicaltrials.gov:NCT01973335","description":"Heart Failure","metadata":null},{"id":"2a8035b15f6d40b3b3d2338c06ff5389","type":"TRIAL","name":"Acetazolamide on REM OSA","canonical_id":"clinicaltrials.gov:NCT05589792","description":"Obstructive Sleep Apnea","metadata":null},{"id":"802837f04e8948449f660a241850208a","type":"TRIAL","name":"Acetazolamide or Metolazone in Acute Heart Failure","canonical_id":"clinicaltrials.gov:NCT06273397","description":"Heart Failure Acute; Decompensated Heart Failure","metadata":null},{"id":"9e4ea9dcd3044a01906c7ebbfb472670","type":"TRIAL","name":"Acetazolamide to Prevent Post Operative CSF Leak","canonical_id":"clinicaltrials.gov:NCT02902133","description":"Cerebrospinal Fluid Leak","metadata":null},{"id":"b57de1780a33481faea4a71dd241bf37","type":"DRUG","name":"Acetic Acid","canonical_id":"mesh:D019342","description":null,"metadata":null},{"id":"0251a7d840064264ab15091bfea5c82e","type":"DRUG","name":"Acetohexamide","canonical_id":"mesh:D000092","description":null,"metadata":null},{"id":"d9e9959e2d4744f0bf3cf0825d69d68f","type":"DRUG","name":"Acetophenazine","canonical_id":"mesh:C100162","description":null,"metadata":null},{"id":"302615c21d7546dbb596fab9d64e7874","type":"DRUG","name":"Acetylcarnitine","canonical_id":"mesh:D000108","description":null,"metadata":null},{"id":"505827ab1b3844d6a3fcc13ac2956f13","type":"PROTEIN","name":"Acetylcholine receptor subunit alpha-type unc-38","canonical_id":"uniprot:F1L348","description":null,"metadata":null},{"id":"32a542c6ce1e412681c3ab771ae81433","type":"TRIAL","name":"Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors","canonical_id":"clinicaltrials.gov:NCT02008292","description":"Smoking; Schizophrenia","metadata":null},{"id":"a0bd5a9c8f834be195c5e4e1c1f49d79","type":"PROTEIN","name":"Acetylcholinesterase","canonical_id":"uniprot:P22303","description":null,"metadata":null},{"id":"81571ee5c1494f428313ae49084c8c82","type":"TRIAL","name":"Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke","canonical_id":"clinicaltrials.gov:NCT00227994","description":"Cerebrovascular Accident","metadata":null},{"id":"dd909f60241d4cc3a6d31d998f3ec6ed","type":"DRUG","name":"Acetylcysteine","canonical_id":"mesh:D000111","description":null,"metadata":null},{"id":"fb7a7f18f927430e84de5a1995a5c1cf","type":"TRIAL","name":"Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00983580","description":"Adenomatous Polyp","metadata":null},{"id":"4dd5e4e1346343c9a8d1daa084a8b195","type":"TRIAL","name":"Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.","canonical_id":"clinicaltrials.gov:NCT07330245","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"ddf7b1802297455d94251fd422692d26","type":"PROTEIN","name":"Acid ceramidase","canonical_id":"uniprot:Q13510","description":null,"metadata":null},{"id":"81d9788f4ed64c2fa606aeb01ab414d4","type":"TRIAL","name":"Acid-Associated Heartburn Symptoms and Dose of Esomeprazole","canonical_id":"clinicaltrials.gov:NCT00206024","description":"Heartburn","metadata":null},{"id":"6f48bf336e1e4abe9b057ece77e4ae6a","type":"TRIAL","name":"Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura","canonical_id":"clinicaltrials.gov:NCT04063540","description":"Migraine With Aura","metadata":null},{"id":"64a1e8081aa541db9575d45c36d7db53","type":"TRIAL","name":"Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis","canonical_id":"clinicaltrials.gov:NCT01094717","description":"Psoriasis","metadata":null},{"id":"64360befeafa4d23987b7a65c0618272","type":"TRIAL","name":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","canonical_id":"clinicaltrials.gov:NCT03290287","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"d8c1b02f9d8643079e67f37bbbd50907","type":"DRUG","name":"Aclidinium bromide","canonical_id":"mesh:C542859","description":null,"metadata":null},{"id":"f9e41b5046434fb29551f979b0324547","type":"TRIAL","name":"Aclidinium/Formoterol Fixed Combination Dose Finding Study","canonical_id":"clinicaltrials.gov:NCT00626522","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"34628752b24e491c9512755f4dc64b44","type":"DISEASE","name":"Acquired factor VIII deficiency disease","canonical_id":"mesh:C536392","description":null,"metadata":null},{"id":"3f8a7a6bfe8b45c7bedbaa936addc6b1","type":"DISEASE","name":"Acquired partial lipodystrophy","canonical_id":"mesh:C562448","description":null,"metadata":null},{"id":"7782cb9f00594b239175c876e79bff2a","type":"DISEASE","name":"Acromegaly","canonical_id":"mesh:D000172","description":null,"metadata":null},{"id":"8a46f6c76ae0491885e3ea0deacff821","type":"TRIAL","name":"Acromegaly Combination Treatment Study","canonical_id":"clinicaltrials.gov:NCT01538966","description":"Acromegaly","metadata":null},{"id":"a6b04a89a4bd495390130bbbf22ee70e","type":"TRIAL","name":"Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands","canonical_id":"clinicaltrials.gov:NCT06607666","description":"Acromegaly","metadata":null},{"id":"7909a87c8c0f46eea390fc0abacc7c31","type":"DISEASE","name":"Actinic keratosis","canonical_id":"mesh:D055623","description":null,"metadata":null},{"id":"cd7406c93e3c4770b5dad096aecaf618","type":"GO_TERM","name":"Actinobacterium-type cell wall biogenesis","canonical_id":"go:GO:0071766","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cell wall of the type found in Actinobacteria. The cell wall is the rigid or semi-rigid envelope lying outside the cell membrane. Actinobacterial cell walls contain characteristic mycolic acids, of which some are covalently linked to the cell wall peptidoglycan and others accumulate at the cell surface.\" [GOC:mah, PMID:15653820, PMID:3149973]","metadata":null},{"id":"37c5af9cb08e48e083ce2edaca3e15a2","type":"DISEASE","name":"Actinomycosis","canonical_id":"mesh:D000196","description":null,"metadata":null},{"id":"d36aaad752e14b0c8ee086ef940e622d","type":"DISEASE","name":"Actinomycosis, Cervicofacial","canonical_id":"mesh:D000197","description":null,"metadata":null},{"id":"c9a1346b06304c9481c7e4de6b557074","type":"TRIAL","name":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","canonical_id":"clinicaltrials.gov:NCT00000620","description":"Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease","metadata":null},{"id":"f76b26a7c5544bcf8dbfb161462425d5","type":"TRIAL","name":"Activated Protein C and Corticosteroids for Human Septic Shock","canonical_id":"clinicaltrials.gov:NCT00625209","description":"Septic Shock","metadata":null},{"id":"dbf90498a2ac432a837993d59f82fdf4","type":"TRIAL","name":"Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)","canonical_id":"clinicaltrials.gov:NCT05553184","description":"Type 2 Diabetes; Obesity","metadata":null},{"id":"d55f04fb1f684056bdb0faad8cf46b26","type":"TRIAL","name":"Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03088124","description":"Low Risk Prostate Cancer","metadata":null},{"id":"e73d165f2e434e1d91adee17e2458312","type":"TRIAL","name":"Activity Study of Bevacizumab With Temozolomide \u00b1 Irinotecan for Neuroblastoma in Children","canonical_id":"clinicaltrials.gov:NCT02308527","description":"Neuroblastoma","metadata":null},{"id":"6686a0e7234c43b9898cf50d1f0ef998","type":"TRIAL","name":"Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib","canonical_id":"clinicaltrials.gov:NCT02398825","description":"Chronic Myeloid Leukemia; Chronic Phase; Adults","metadata":null},{"id":"a1c67174ade046a487c6d2c28bff20b7","type":"TRIAL","name":"Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT04127110","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"e175518c591343b3b43762b6d225991b","type":"TRIAL","name":"Actual Use Study of Tamsulosin in Men","canonical_id":"clinicaltrials.gov:NCT02573311","description":"Urological Manifestations","metadata":null},{"id":"13e058dbaedc4d5cbef0e95121c544d2","type":"TRIAL","name":"Actual Use Trial of Tadalafil 5 mg","canonical_id":"clinicaltrials.gov:NCT06805513","description":"Erectile Dysfunction","metadata":null},{"id":"3057e3c12dc144b7895cdcaf4ebdf326","type":"TRIAL","name":"Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE","canonical_id":"clinicaltrials.gov:NCT01895010","description":"Nausea; Vomiting; Metastatic Liver Cancer","metadata":null},{"id":"bc339ab5e13548c7b34e0e41f7058bec","type":"TRIAL","name":"Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00003817","description":"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"8fd35df952c44b0490f54c5a60c982f8","type":"TRIAL","name":"Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean","canonical_id":"clinicaltrials.gov:NCT02959840","description":"Nausea; Vomiting; Satisfaction","metadata":null},{"id":"0b81b130bab64b52b605869bb549b4a6","type":"TRIAL","name":"Acupuncture Therapy for COVID-Related Olfactory Loss","canonical_id":"clinicaltrials.gov:NCT04952389","description":"Olfactory Dysfunction; COVID-19","metadata":null},{"id":"93ca4f61682c4499afa8d02d383df4fb","type":"TRIAL","name":"Acupuncture Versus Clonazepam in Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT02382029","description":"Burning Mouth Syndrome","metadata":null},{"id":"2597b26f9b86440a92b480f94a3b0aa9","type":"TRIAL","name":"Acupuncture for Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00610584","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"6bf53be1f46c43fdb07ac147d0d6b9f4","type":"TRIAL","name":"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00656513","description":"Head and Neck Cancer; Xerostomia","metadata":null},{"id":"5905a450a8d04ff7be1adbeb239e80d6","type":"TRIAL","name":"Acute Application of Pegvisomant and Octreotide in Acromegaly","canonical_id":"clinicaltrials.gov:NCT00595140","description":"Acromegaly","metadata":null},{"id":"4a53bca75ee94d6d98bfb2ea02c2aad7","type":"TRIAL","name":"Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD","canonical_id":"clinicaltrials.gov:NCT04446637","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"b4d42e716c3146b5b225ac70f4623318","type":"TRIAL","name":"Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva","canonical_id":"clinicaltrials.gov:NCT00274066","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"8b62af98cfe346d7aea7e226d1767d0c","type":"TRIAL","name":"Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)","canonical_id":"clinicaltrials.gov:NCT00108706","description":"Cerebrovascular Accident; Acute Stroke","metadata":null},{"id":"11ef0eb136ca4424b2e54fe5cb3073ed","type":"TRIAL","name":"Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals","canonical_id":"clinicaltrials.gov:NCT05167084","description":"Glucocorticoid Effect","metadata":null},{"id":"88b7d30b360349ac82810d36de2c5f8f","type":"TRIAL","name":"Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake","canonical_id":"clinicaltrials.gov:NCT06556277","description":"Glucocorticoids; Overweight and Obesity; Overeating","metadata":null},{"id":"6bea49621a81417bb917df9bbacb2051","type":"DISEASE","name":"Acute Coronary Syndrome","canonical_id":"mesh:D054058","description":null,"metadata":null},{"id":"b2e6a3da03f34941840998030c11df39","type":"TRIAL","name":"Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients","canonical_id":"clinicaltrials.gov:NCT02181023","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"f5b30f85b5894b6c9e87e682ebcac4a0","type":"TRIAL","name":"Acute Effect of Capsimax on Resistance Exercise Performance, Muscle Oxygenation, Nitric Oxide Release, Resting Energy Expenditure and Reaction Time","canonical_id":"clinicaltrials.gov:NCT06612658","description":"None Volunteer","metadata":null},{"id":"cf0d2c9f63c24df78aff0d8b9d28deb4","type":"TRIAL","name":"Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau","canonical_id":"clinicaltrials.gov:NCT05728736","description":"Alzheimer Disease","metadata":null},{"id":"6eb3349672ab463d9e373e15ceb5973e","type":"TRIAL","name":"Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test","canonical_id":"clinicaltrials.gov:NCT00972985","description":"Healthy","metadata":null},{"id":"16ec0b0a4d4444ca90febf1c14baccdf","type":"TRIAL","name":"Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02404870","description":"Healthy Volunteers","metadata":null},{"id":"19b4044755b542b88f4b41167eff66c0","type":"TRIAL","name":"Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT01250405","description":"Chronic Kidney Disease","metadata":null},{"id":"38691c25c8584619a45c797b872ac778","type":"TRIAL","name":"Acute Effects of Inhaled Treprostinil in Fontan Patients","canonical_id":"clinicaltrials.gov:NCT02769624","description":"Congenital Heart Disease","metadata":null},{"id":"ade182223f2544488d537e82d048be13","type":"TRIAL","name":"Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES","canonical_id":"clinicaltrials.gov:NCT04052776","description":"Spinal Cord Injuries; Drug Effect","metadata":null},{"id":"77affb1a4ed94f7293864152c317eddd","type":"TRIAL","name":"Acute Effects of Sildenafil on Endothelial Function in People With Diabetes","canonical_id":"clinicaltrials.gov:NCT00527995","description":"Type 2 Diabetes Mellitus; Endothelial Dysfunction","metadata":null},{"id":"b1afa78f9fe64a41a2b3d4a5ec6b1edb","type":"TRIAL","name":"Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis","canonical_id":"clinicaltrials.gov:NCT00252317","description":"Aortic Stenosis","metadata":null},{"id":"9df196aae5364bce8cb49c7ac746d2f9","type":"TRIAL","name":"Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics","canonical_id":"clinicaltrials.gov:NCT01411930","description":"Diabetes","metadata":null},{"id":"6ee970aceca345bfacc155afaa164b8f","type":"TRIAL","name":"Acute Labetalol Use in Preeclampsia","canonical_id":"clinicaltrials.gov:NCT03872336","description":"Preeclampsia With Severe Features","metadata":null},{"id":"5eed18197b7a402a8e03087f96dc169e","type":"DISEASE","name":"Acute Leukemia","canonical_id":"doid:12603","description":null,"metadata":null},{"id":"99e3c0672cae4087a786ab2417c47e2c","type":"TRIAL","name":"Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)","canonical_id":"clinicaltrials.gov:NCT01583218","description":"Venous Thromboembolism (VTE)","metadata":null},{"id":"c7a0bd086374467698c7e0392e3215ea","type":"TRIAL","name":"Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies","canonical_id":"clinicaltrials.gov:NCT03483207","description":"Mesenteric Vein Thrombosis","metadata":null},{"id":"ae7260668b6748f1be3877dde84191cf","type":"TRIAL","name":"Acute Migraine Treatment in the ED With Gepants","canonical_id":"clinicaltrials.gov:NCT06985342","description":"Migraine Headaches","metadata":null},{"id":"f729a8afc3344b37901be847d740f6f2","type":"TRIAL","name":"Acute Montelukast in Asthma","canonical_id":"clinicaltrials.gov:NCT01011452","description":"Acute Asthma Exacerbation","metadata":null},{"id":"8c97fb71a02e4157a41f72534f343bcc","type":"TRIAL","name":"Acute Myeloid Leukemia Real World Treatment Patterns","canonical_id":"clinicaltrials.gov:NCT04230564","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"af73846c18b7485dba6ad438e50d34c8","type":"TRIAL","name":"Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium","canonical_id":"clinicaltrials.gov:NCT05188131","description":"Hypopituitarism","metadata":null},{"id":"5a8b6ca99cce4d29a37550a2c8d7e88a","type":"TRIAL","name":"Acute Olanzapine and Lipid Response","canonical_id":"clinicaltrials.gov:NCT04181385","description":"Healthy","metadata":null},{"id":"a1fded9c4be74aa2a91b3424c98b7a55","type":"TRIAL","name":"Acute Pain Study Following Bunionectomy","canonical_id":"clinicaltrials.gov:NCT01333722","description":"Pain","metadata":null},{"id":"2a31cbe13f2747a08a5e4ce23180440c","type":"TRIAL","name":"Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide","canonical_id":"clinicaltrials.gov:NCT02294656","description":"CYSTOID MACULAR EDEMA","metadata":null},{"id":"27b16b21340f4ae2a249c32b88e2e214","type":"TRIAL","name":"Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)","canonical_id":"clinicaltrials.gov:NCT00304655","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"eb5eb01971b54f2491c36a1bf4c5aea4","type":"TRIAL","name":"Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT03365479","description":"Pulmonary Hypertension; Pulmonary Arterial Hypertension","metadata":null},{"id":"e08cb230e13a4cc5b5f96d390a9453e4","type":"TRIAL","name":"Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy","canonical_id":"clinicaltrials.gov:NCT05422664","description":"Autoimmune Encephalitis; Epilepsy; Seizures","metadata":null},{"id":"31266c314bd743ff85715f517dca7efd","type":"TRIAL","name":"Acute Tocolysis With Terbutaline for Suspected Fetal Distress","canonical_id":"clinicaltrials.gov:NCT05326269","description":"Nonreassuring Fetal Status","metadata":null},{"id":"ceae89d27bfa45d68ebd7cb5882c3487","type":"DISEASE","name":"Acute intermittent porphyria","canonical_id":"mesh:D017118","description":null,"metadata":null},{"id":"5a1f545c7556413eb50a29374deebf3e","type":"DISEASE","name":"Acute lung injury","canonical_id":"mesh:D055371","description":null,"metadata":null},{"id":"c53984a66221482eb144b351ac2ef9fa","type":"DISEASE","name":"Acute lymphoblastic leukemia","canonical_id":"mesh:D054198","description":null,"metadata":null},{"id":"51c04017530647838acb233d8530eec9","type":"DISEASE","name":"Acute maxillary sinusitis","canonical_id":"mesh:D015523","description":null,"metadata":null},{"id":"2e90a897a138420f8188b641d09af569","type":"DISEASE","name":"Acute monocytic/monoblastic leukemia","canonical_id":"mesh:D007948","description":null,"metadata":null},{"id":"608fd7bb4bb84853919a273f733b66eb","type":"DISEASE","name":"Acute myelomonocytic leukemia, FAB M4","canonical_id":"mesh:D015479","description":null,"metadata":null},{"id":"8be8c78cb18d4e238b8c49daf2612dd2","type":"DISEASE","name":"Acute pain","canonical_id":"mesh:D059787","description":null,"metadata":null},{"id":"cd6b566d9b364931a984033d4d8a6248","type":"DISEASE","name":"Acute promyelocytic leukemia","canonical_id":"mesh:D015473","description":null,"metadata":null},{"id":"33e7b47fd42b487ab094194287c0faff","type":"DRUG","name":"Adagrasib","canonical_id":"ncit:C157493","description":null,"metadata":null},{"id":"ea1860a2d8614df5bd919ae9efe756af","type":"TRIAL","name":"Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00077779","description":"Crohn's Disease","metadata":null},{"id":"f70849dad2234c93a8bc5d5048a1c5bd","type":"TRIAL","name":"Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","canonical_id":"clinicaltrials.gov:NCT00574249","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"e9f8d66935584ec28cdf38a2f83d7aee","type":"DRUG","name":"Adapalene","canonical_id":"mesh:D000068816","description":null,"metadata":null},{"id":"e20a02605d85412d8ce958ae9b11fe50","type":"TRIAL","name":"Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage","canonical_id":"clinicaltrials.gov:NCT00647556","description":"Photoaging","metadata":null},{"id":"48c41782d2ed42f2bc671db944fea773","type":"TRIAL","name":"Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00688064","description":"Severe Acne Vulgaris","metadata":null},{"id":"fc3b5478e3344d36955804e749e75f4f","type":"TRIAL","name":"Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)","canonical_id":"clinicaltrials.gov:NCT03931369","description":"Healthy Volunteers","metadata":null},{"id":"360a2d233a6d421f9e82f81ef3412ff8","type":"TRIAL","name":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","canonical_id":"clinicaltrials.gov:NCT04640168","description":"COVID-19","metadata":null},{"id":"f8d68a0881974717926f3514d3a55f31","type":"TRIAL","name":"Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis","canonical_id":"clinicaltrials.gov:NCT07826988","description":"Sickle Cell Disease; Vaso-occlusive Crisis","metadata":null},{"id":"1d2dcfc58d144621acd6ee6d80be0799","type":"TRIAL","name":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","canonical_id":"clinicaltrials.gov:NCT06381661","description":"Sepsis","metadata":null},{"id":"ba8271a2336e4ef0b8c0fa05c40076ea","type":"TRIAL","name":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","canonical_id":"clinicaltrials.gov:NCT05403723","description":"Extensive-stage Small-cell Lung Cancer","metadata":null},{"id":"9a1ef330719f4cf2968c9b8fce664865","type":"TRIAL","name":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01920932","description":"Stage II Childhood Hodgkin Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage IV Childhood Hodgkin Lymphoma","metadata":null},{"id":"7ea8624251d54daa8a8877c76ad0d12b","type":"TRIAL","name":"Add-on Cangrelor in STEMI-triggered Cardiac Arrest","canonical_id":"clinicaltrials.gov:NCT03273075","description":"Cardiopulmonary Arrest With Successful Resuscitation; ACS - Acute Coronary Syndrome; Hypothermia, Induced","metadata":null},{"id":"c57f617acfd848988d225a9e76217fe2","type":"TRIAL","name":"Add-on Diuretics in Acute Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT07372040","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"fd8fa77ceee047c0a409f1f38b834ae2","type":"TRIAL","name":"Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older","canonical_id":"clinicaltrials.gov:NCT07838974","description":"Melanoma","metadata":null},{"id":"27c2e5c842544471aedee9b9803d946b","type":"TRIAL","name":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT07383441","description":"Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8","metadata":null},{"id":"24fe500a03fe42fc881b339a87c0c1aa","type":"TRIAL","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","canonical_id":"clinicaltrials.gov:NCT07802626","description":"HR Positive/HER-2 Negative Breast Cancer","metadata":null},{"id":"75f95c36727d460689d1ddaf63d436b0","type":"TRIAL","name":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","canonical_id":"clinicaltrials.gov:NCT06390319","description":"T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoma; Mixed Phenotype Acute Leukemia","metadata":null},{"id":"bdb4ff393f514257b4bbf6dce38529a8","type":"TRIAL","name":"Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis","canonical_id":"clinicaltrials.gov:NCT07388420","description":"Hypertriglyceridemia Induced Acute Pancreatitis","metadata":null},{"id":"c548b63931fd482581040a9391dad21c","type":"TRIAL","name":"Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder","canonical_id":"clinicaltrials.gov:NCT00601354","description":"Overweight; Eating Disorders","metadata":null},{"id":"a175b940bc7a48568b7005eb191c2866","type":"TRIAL","name":"Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT03630341","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"b585e13f521e44af9a5492c8fd5fe79c","type":"TRIAL","name":"Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT06574698","description":"Neuroblastoma; GD2 Antibody (Naxitamab)","metadata":null},{"id":"9c599fdf98b64208824fc924f6cb5190","type":"TRIAL","name":"Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS","canonical_id":"clinicaltrials.gov:NCT02344888","description":"Infertility; Polycystic Ovarian Syndrome","metadata":null},{"id":"0243ce7a935f4a65b4c1e0dc01133b1a","type":"TRIAL","name":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","canonical_id":"clinicaltrials.gov:NCT02494882","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"f090866c716e4e669cd6f0cf73c3d686","type":"TRIAL","name":"Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis","canonical_id":"clinicaltrials.gov:NCT07578116","description":"Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma","metadata":null},{"id":"23e686a094bd4053869b83d83abb395f","type":"TRIAL","name":"Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)","canonical_id":"clinicaltrials.gov:NCT06210750","description":"T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma","metadata":null},{"id":"6f138dfd1af14de3a87227ee35027d2e","type":"TRIAL","name":"Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT06337331","description":"Acute Myeloid Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"d30be2294ed94fdbb4791f4cd4c2818d","type":"DISEASE","name":"Addison disease","canonical_id":"mesh:D000224","description":null,"metadata":null},{"id":"c0c8a3fe259e4e44a42a646b721d007d","type":"TRIAL","name":"Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04767698","description":"Multiple Sclerosis","metadata":null},{"id":"97c1088fa0574d38aadf83275974b0f7","type":"TRIAL","name":"Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00149734","description":"Schizophrenia","metadata":null},{"id":"9f3628f9c1fe4d10ae7dbc0471d8c2fa","type":"TRIAL","name":"Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation","canonical_id":"clinicaltrials.gov:NCT01192724","description":"Coronary Artery Disease","metadata":null},{"id":"9009a5ae72cf428faa3dadae51ee90f0","type":"TRIAL","name":"Additive Effects of Pravastatin and Valsartan","canonical_id":"clinicaltrials.gov:NCT01004237","description":"Hypertension; High Cholesterol","metadata":null},{"id":"826e3d550eb448d6abbd6a904cb26aa6","type":"TRIAL","name":"Addressing Post Cessation Weight Gain","canonical_id":"clinicaltrials.gov:NCT02412631","description":"Obesity; Smoking Cessation","metadata":null},{"id":"5f2b57f32cf44cb88f989200cf7c8252","type":"TRIAL","name":"Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy","canonical_id":"clinicaltrials.gov:NCT07309185","description":"Stomach Neoplasms","metadata":null},{"id":"26ff39f342d049419d61a970f9ee8c4d","type":"TRIAL","name":"Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC","canonical_id":"clinicaltrials.gov:NCT06467617","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"9673f7ea3e8e48fbb4a3373ae889793f","type":"TRIAL","name":"Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed","canonical_id":"clinicaltrials.gov:NCT06102759","description":"Gastric Cancer","metadata":null},{"id":"b4dc488ed4964de8aaa19113f7939710","type":"TRIAL","name":"Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC","canonical_id":"clinicaltrials.gov:NCT07567326","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"c9dc9ef77ea04c0ba91765a23306f469","type":"DISEASE","name":"Adenocarcinoma, Follicular","canonical_id":"mesh:D018263","description":null,"metadata":null},{"id":"843766b9befc4985b97a4149a70bcb5c","type":"TRIAL","name":"Adenosine Versus Verapamil for Management of Supraventricular Tachycardia Post- Coronary Artery Bypass Grafting","canonical_id":"clinicaltrials.gov:NCT04203368","description":"Supraventricular Tachycardia","metadata":null},{"id":"eff9bcf814ca482c83fce3fc6c1ff7fd","type":"TRIAL","name":"Adenosine as an Adjunct to Blood Cardioplegia","canonical_id":"clinicaltrials.gov:NCT02681913","description":"Pathological Processes; Cardiomyopathies","metadata":null},{"id":"4dfc2e233f964a68a5df230eba265dd0","type":"DISEASE","name":"Adenosine deaminase deficiency","canonical_id":"mesh:C531816","description":null,"metadata":null},{"id":"3403e7976a6445d28b7cf2c3b89a2fe0","type":"TRIAL","name":"Adenosine vs. Diltiazem","canonical_id":"clinicaltrials.gov:NCT07456423","description":"Supraventricular Tachycardia (SVT); Atrioventricular Nodal Re Entrant Tachycardia","metadata":null},{"id":"61fd72beca2445929a5872fc68942f49","type":"TRIAL","name":"Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00704522","description":"Hepatitis C, Chronic; Hepacivirus","metadata":null},{"id":"19dfd7e23ef04ef49b05ee2b891fa34a","type":"TRIAL","name":"Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)","canonical_id":"clinicaltrials.gov:NCT00723879","description":"Hepatitis C, Chronic; Hepacivirus","metadata":null},{"id":"031ba2fcac744779b518e620e08b668d","type":"TRIAL","name":"Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT04133194","description":"Ulcerative Colitis","metadata":null},{"id":"f1b07fad57794bb4a0764d6fafde9d3c","type":"TRIAL","name":"Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study","canonical_id":"clinicaltrials.gov:NCT05612594","description":"Sleep Apnea","metadata":null},{"id":"6e854dc397be488582db920089f601f8","type":"TISSUE","name":"Adipose Subcutaneous","canonical_id":"uberon:UBERON:0002190","description":null,"metadata":null},{"id":"474faed12c0f48fca6faf7fa7d48b066","type":"TISSUE","name":"Adipose Visceral Omentum","canonical_id":"uberon:UBERON:0010414","description":null,"metadata":null},{"id":"1547c9b1576d4cfd9411b3a6103347bf","type":"TRIAL","name":"Adjunctive Fludrocortisone in Septic Shock","canonical_id":"clinicaltrials.gov:NCT07451886","description":"Sepsis; Septic Shock; Sepsis - to Reduce Mortality in the Intensive Care Unit; Sepsis and Septic Shock; Sepsis at Intensive Care Unit","metadata":null},{"id":"9d199513b86e496da41625c9c8ddb912","type":"TRIAL","name":"Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","canonical_id":"clinicaltrials.gov:NCT03968159","description":"Adjunctive Treatment of Major Depressive Disorder","metadata":null},{"id":"2b252382f13b4ca685a36f3a56f591b9","type":"TRIAL","name":"Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients","canonical_id":"clinicaltrials.gov:NCT04898270","description":"Schizophrenia; Psychosis; Metabolic Syndrome; Flupentixol; Antipsychotic Agents; Central Nervous System Diseases; Clinical Therapy; Olanzapine; Quetiapine","metadata":null},{"id":"4501bc48446e47cb89e1a1911de60a0b","type":"TRIAL","name":"Adjunctive Vortioxetine in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02357797","description":"Schizophrenia; Negative Symptoms","metadata":null},{"id":"3c504b787ac94154832e887f7d22a854","type":"TRIAL","name":"Adjunctive Ziprasidone in the Treatment of Bipolar I Depression","canonical_id":"clinicaltrials.gov:NCT00483548","description":"Bipolar Disorder; Depression, Bipolar","metadata":null},{"id":"b6394b4e10364510b94c9feb51238d41","type":"TRIAL","name":"Adjunctive iTBS for First-Episode Schizophrenia","canonical_id":"clinicaltrials.gov:NCT07116850","description":"Schizophrenia Disorder","metadata":null},{"id":"59499b1d6822408aa31aa2f987381887","type":"TRIAL","name":"Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and \u2265120 kg Body Weight","canonical_id":"clinicaltrials.gov:NCT04306315","description":"Psoriasis Vulgaris","metadata":null},{"id":"3b29f30eaec74adc853509e82b68ed4a","type":"TRIAL","name":"Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children","canonical_id":"clinicaltrials.gov:NCT07012512","description":"Pupillary Constriction; Accomodation","metadata":null},{"id":"c6b181deec444ef6916373f0090dbf33","type":"TRIAL","name":"Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial","canonical_id":"clinicaltrials.gov:NCT03289260","description":"Anogenital Human Papillomavirus Infection; Condyloma Anal","metadata":null},{"id":"7f89ec919cc945058818aadbe8f67f8c","type":"TRIAL","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","canonical_id":"clinicaltrials.gov:NCT06041776","description":"Non-Small Cell Lung Cancer; EGFR Sensitive Mutation; Adjuvant Therapy","metadata":null},{"id":"af14826e5439448586667831c7efb26e","type":"TRIAL","name":"Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06528847","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"07618b214fc24489aaa77f1c29b541ac","type":"DRUG","name":"Adjuvant Chemotherapy","canonical_id":"ncit:C15360","description":null,"metadata":null},{"id":"284b9432f1de44fb823f78195b7c2ba6","type":"TRIAL","name":"Adjuvant Chemotherapy With or Without Intercalated Icotinib","canonical_id":"clinicaltrials.gov:NCT03983811","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"c5d42ad4dad645fab4cc1d138d5ffa79","type":"TRIAL","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","canonical_id":"clinicaltrials.gov:NCT05270044","description":"Melanoma","metadata":null},{"id":"221e432c61f64b258dc6a1b46cf8f95c","type":"TRIAL","name":"Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection","canonical_id":"clinicaltrials.gov:NCT03392103","description":"Gastric Cancer","metadata":null},{"id":"33aa76723747433fae91e2b4fd5d3a99","type":"TRIAL","name":"Adjuvant Intensification for LAR","canonical_id":"clinicaltrials.gov:NCT07407517","description":"Breast Cancer Females; Triple Negative Breast Cancer (TNBC)","metadata":null},{"id":"d25a4d117f1c43ca861871d2924e0980","type":"TRIAL","name":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00542451","description":"Breast Cancer; Carcinoma of the Breast","metadata":null},{"id":"5849a4e91a554a32b8b623e974fa9b2b","type":"TRIAL","name":"Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00023829","description":"Prostate Cancer","metadata":null},{"id":"9ff08e0da1d946a1ab1f2a6f4da6872c","type":"TRIAL","name":"Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence","canonical_id":"clinicaltrials.gov:NCT06682728","description":"Urothelial Carcinoma; Muscle-invasive Bladder Cancer","metadata":null},{"id":"e53b57bdc37649dfbe578b22e39aac97","type":"TRIAL","name":"Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT05201859","description":"Nasopharyngeal Carcinoma","metadata":null},{"id":"32dff91411804439ac4040a58359460f","type":"TRIAL","name":"Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma","canonical_id":"clinicaltrials.gov:NCT04741997","description":"Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation","metadata":null},{"id":"b1945ef4715f46a6a7a9a35c2e09890d","type":"TRIAL","name":"Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06693024","description":"HER2-positive Breast Cancer","metadata":null},{"id":"ab2fa492675d45b8b4aa70549a8c8d17","type":"TRIAL","name":"Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07772557","description":"Gastric or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"8e0b584ecac64f64a123d0c7d3750f52","type":"TRIAL","name":"Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction","canonical_id":"clinicaltrials.gov:NCT05480384","description":"Esophageal Adenocarcinoma; Esophageal Cancer; HER-2 Protein Overexpression; Gastroesophageal-junction Cancer","metadata":null},{"id":"ec42ba59fc124782a33e3c03e583fdbb","type":"TRIAL","name":"Adjuvant Treatment of Graves\u00b4 Ophthalmopathy With NSAID (aGO Study)","canonical_id":"clinicaltrials.gov:NCT01458600","description":"Graves\u00b4 Disease","metadata":null},{"id":"6f558c28b90a428b8bc6e384af76bd9f","type":"TRIAL","name":"Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab","canonical_id":"clinicaltrials.gov:NCT06498622","description":"Hepatocellular Carcinoma","metadata":null},{"id":"dae1534598554a9287234040e32b453b","type":"TRIAL","name":"Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study","canonical_id":"clinicaltrials.gov:NCT00191724","description":"Submassive Pulmonary Embolism","metadata":null},{"id":"5972d6f2a85c44f48ea388514a332085","type":"TRIAL","name":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","canonical_id":"clinicaltrials.gov:NCT04585477","description":"Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III","metadata":null},{"id":"edbba28b3f2b4129ac968bd06d62ce09","type":"TRIAL","name":"Administering Atropine Through Autoinjectors Within Ambulance Services for Poisoning Patients in Sri Lanka's North Central Province","canonical_id":"clinicaltrials.gov:NCT07581301","description":"Pesticide Poisoning","metadata":null},{"id":"be91a5b1e12448debd3af1c3113dfd22","type":"TRIAL","name":"Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study","canonical_id":"clinicaltrials.gov:NCT00526214","description":"Intracerebral Hemorrhage","metadata":null},{"id":"87d2571295d9441c852d5616cafd2aae","type":"TRIAL","name":"Administration of Chlorpromazine as a Treatment for COVID-19","canonical_id":"clinicaltrials.gov:NCT04354805","description":"COVID-19","metadata":null},{"id":"90a01306d7614400a99d4e21517ebfb9","type":"TRIAL","name":"Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy","canonical_id":"clinicaltrials.gov:NCT00164866","description":"Peptic Ulcer","metadata":null},{"id":"1e03fe54f74041509507b2be3fe0c6e9","type":"TRIAL","name":"Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05119140","description":"Ulcerative Colitis (Disorder)","metadata":null},{"id":"6ab4f676713b4966891e089e541b18b9","type":"TRIAL","name":"Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01374217","description":"Multiple Myeloma","metadata":null},{"id":"2b8a05e504c742548cd684e6d13523d7","type":"TRIAL","name":"Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use","canonical_id":"clinicaltrials.gov:NCT03287180","description":"Opioid-Related Disorders; Behavior, Addictive","metadata":null},{"id":"b770fe19d3194a418b5223ab25958747","type":"TRIAL","name":"Adolescent Weight Management Study","canonical_id":"clinicaltrials.gov:NCT00212173","description":"Protocol #1:Behavioral Therapy + Placebo or Sibutramine; Protocol #2: Behavioral Therapy + Meal Replacement or Conventional Food","metadata":null},{"id":"610a8b29fb0a4ade94d8c8808f9f41ef","type":"TRIAL","name":"Adoptive Therapy Using Antigen-Specific CD4 T-Cells","canonical_id":"clinicaltrials.gov:NCT02210104","description":"Melanoma; Sarcoma","metadata":null},{"id":"0c50a39d988648eda08d0f73fc823c9b","type":"TISSUE","name":"Adrenal Gland","canonical_id":"uberon:UBERON:0002369","description":null,"metadata":null},{"id":"ddacfff8fd0e4b5cae7f9bfee5a8eca7","type":"TRIAL","name":"Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01839812","description":"Adrenal Cortex Diseases; Infant Morbidity","metadata":null},{"id":"956bd5ed0a854c96832f23297bd5b7a6","type":"TRIAL","name":"Adrenal Suppression and Pharmacokinetics of Topicort\u00ae Spray, 0.25% in Pediatric Patients With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02340169","description":"Plaque Psoriasis","metadata":null},{"id":"de6ded01311f4ceba017548471e77699","type":"DISEASE","name":"Adrenal cortical hypofunction","canonical_id":"mesh:D000309","description":null,"metadata":null},{"id":"ab6b96fc9c9e45d993e83e1669b0647a","type":"TRIAL","name":"Adrenergic System in Islet Transplantation","canonical_id":"clinicaltrials.gov:NCT03079921","description":"Type1diabetes; Hypoglycemia; Hypoglycemia Unawareness; Islet Cell Transplantation","metadata":null},{"id":"469fbb4d64794f0ead22033406bc18e0","type":"DISEASE","name":"Adrenocortical Hyperfunction","canonical_id":"mesh:D000308","description":null,"metadata":null},{"id":"620d4a32108f4daf8f672752f4d5b861","type":"TRIAL","name":"Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)","canonical_id":"clinicaltrials.gov:NCT01764711","description":"Postural Tachycardia Syndrome","metadata":null},{"id":"bd1cbc0e06f54a9b966c11e38be0d90c","type":"TRIAL","name":"Adult Study Oxytocin - fMRI","canonical_id":"clinicaltrials.gov:NCT02566356","description":"Schizophrenia; Oxytocin; Social Cognition; Functional Magnetic Resonance Imaging (fMRI)","metadata":null},{"id":"42450db32d6c4e3c8b5160d37182aee0","type":"TRIAL","name":"Adults With Moderate to Severe Asthma","canonical_id":"clinicaltrials.gov:NCT00642122","description":"Asthma","metadata":null},{"id":"c24f79e36ddf4a249f3b56d5b7b27002","type":"TRIAL","name":"Advance Provision of Medication Abortion","canonical_id":"clinicaltrials.gov:NCT03829696","description":"Early Abortion","metadata":null},{"id":"9bec5409c9b74066b0a9872fe09838f7","type":"TRIAL","name":"Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy","canonical_id":"clinicaltrials.gov:NCT05285605","description":"Contraception; Contraceptive Usage; Reproductive Issues","metadata":null},{"id":"3a7ba76abe004db8aac4ee1bf0cb5298","type":"TRIAL","name":"Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients","canonical_id":"clinicaltrials.gov:NCT01736033","description":"Benign Prostate Hyperplasia","metadata":null},{"id":"cb286ac2ca9a4520b296ff610fd7a0ca","type":"TRIAL","name":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","canonical_id":"clinicaltrials.gov:NCT04318938","description":"NSCLC","metadata":null},{"id":"5eced72dd2034fa3b28fdcaaf48ddff0","type":"TRIAL","name":"Advancing Postmenopausal Preventive Therapy","canonical_id":"clinicaltrials.gov:NCT04103476","description":"Atherosclerosis; Cognitive Decline","metadata":null},{"id":"b12833233b324b9c874aab02ba682ece","type":"TRIAL","name":"Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)","canonical_id":"clinicaltrials.gov:NCT06134622","description":"Acute Ischemic Stroke","metadata":null},{"id":"d569242b47e94978b4692035ffe21c58","type":"TRIAL","name":"Advancing Transplantation Outcomes in Children","canonical_id":"clinicaltrials.gov:NCT06055608","description":"Kidney Transplant","metadata":null},{"id":"e10a89fdbf4a4ee7a46c2186800fdbb3","type":"TRIAL","name":"Adverse Events Related to Low Dose Atropine","canonical_id":"clinicaltrials.gov:NCT05683535","description":"Myopia, Progressive","metadata":null},{"id":"1ac230c1ed8f4ce884d55a24a2a7ff4d","type":"TRIAL","name":"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT00414687","description":"Hypertension, Pulmonary","metadata":null},{"id":"db3b8cbfa2a0406c879ddf4d75c29e79","type":"DRUG","name":"Afamelanotide","canonical_id":"mesh:C534526","description":null,"metadata":null},{"id":"ae2c2eec504949a5946e4492b744cb6c","type":"DRUG","name":"Afatinib","canonical_id":"ncit:C66940","description":null,"metadata":null},{"id":"f363f8a6b9114d168a0c2e2b0ff0d20a","type":"TRIAL","name":"Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT01953913","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"3eac845dd34f4d2f974da242b88d467d","type":"TRIAL","name":"Afatinib (GILOTRIF\u00ae) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)","canonical_id":"clinicaltrials.gov:NCT05107193","description":"Solid Tumors","metadata":null},{"id":"9d8f1a3762a0428b9091211ac0cfd5d7","type":"TRIAL","name":"Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification","canonical_id":"clinicaltrials.gov:NCT04880811","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"bd32048501c94a24bb7452aac158f6be","type":"TRIAL","name":"Afatinib With CT and RT for EGFR-Mutant NSCLC","canonical_id":"clinicaltrials.gov:NCT01553942","description":"Lung Cancer","metadata":null},{"id":"ecf40025a5704bd69c0256b1848e735a","type":"TRIAL","name":"Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02975141","description":"Metastatic Pancreatic Cancer","metadata":null},{"id":"a1b9a95c6ac34838b85246216f9a6815","type":"TRIAL","name":"Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03054038","description":"Non-Small Cell Lung Carcinoma","metadata":null},{"id":"995f6c613a1a4710aed899161f4cedcf","type":"TRIAL","name":"Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer","canonical_id":"clinicaltrials.gov:NCT01522768","description":"Esophageal Cancer; Gastric Cancer","metadata":null},{"id":"6a9c70fe4db8497ab201fc1a57acbc10","type":"TRIAL","name":"Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours","canonical_id":"clinicaltrials.gov:NCT01728818","description":"Focus of Study Instead","metadata":null},{"id":"38e9b988cffb43a480818574169e3b81","type":"TRIAL","name":"Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)","canonical_id":"clinicaltrials.gov:NCT02695290","description":"Carcinoma, Non-Small-Cell Lung; ErbB Receptors","metadata":null},{"id":"c24da9d915d44de1baab88e3bbd27fd1","type":"TRIAL","name":"Afatinib in NSCLC With HER2 Mutation","canonical_id":"clinicaltrials.gov:NCT02597946","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"d2c43121eb7a427ca789d97c92f500d7","type":"TRIAL","name":"Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","canonical_id":"clinicaltrials.gov:NCT06648096","description":"Fanconi Anemia; Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"09102059b0eb4befae0a336b739d7f39","type":"TRIAL","name":"Affect of Melatonin on Sleep and Cognition in Cirrhosis","canonical_id":"clinicaltrials.gov:NCT07046429","description":"Hepatic Encephalopathy; Covert Hepatic Encephalopathy; Cirrhosis; Sleep Disturbances and Insomnia","metadata":null},{"id":"d59030f3c6224a4b88ce497c548721c3","type":"TRIAL","name":"Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin","canonical_id":"clinicaltrials.gov:NCT04016207","description":"Affective Dysregulation","metadata":null},{"id":"1a0605cc4a94487a9e1711351ae3d977","type":"TRIAL","name":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT02157077","description":"Macular Degeneration; Wet Macular Degeneration; Retinal Degeneration; Retinal Diseases; Eye Diseases","metadata":null},{"id":"1a259e0824114763aa73ddf94497a5c6","type":"TRIAL","name":"Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03530267","description":"Colorectal Cancer","metadata":null},{"id":"ff19ff31edee4e11b210bbaace8c9022","type":"TRIAL","name":"African American Study of Kidney Disease and Hypertension","canonical_id":"clinicaltrials.gov:NCT04364139","description":"Hypertensive Nephrosclerosis; Chronic Renal Insufficiency","metadata":null},{"id":"d852b1c4939f4854bf46ecda1426f272","type":"TRIAL","name":"African Glaucoma Laser Trial","canonical_id":"clinicaltrials.gov:NCT03648229","description":"Open-angle Glaucoma","metadata":null},{"id":"e5dee1b4c3354f30ad7892ff54d835a4","type":"DISEASE","name":"African trypanosomiasis","canonical_id":"mesh:D014353","description":null,"metadata":null},{"id":"2a8101e2e3e44a5186c6e71c1d5e3c82","type":"DRUG","name":"Agalsidase beta","canonical_id":"mesh:C459420","description":null,"metadata":null},{"id":"66417c618069417d89676912d3bfee8b","type":"TRIAL","name":"Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion","canonical_id":"clinicaltrials.gov:NCT04181606","description":"Aging","metadata":null},{"id":"6ff9f7f991754c8dbd2fa335561c95d0","type":"DISEASE","name":"Age related macular degeneration","canonical_id":"mesh:D008268","description":null,"metadata":null},{"id":"855e877b20024cd495a02cc60afd57d9","type":"TRIAL","name":"Agents Intervening Against Delirium in Intensive Care Unit","canonical_id":"clinicaltrials.gov:NCT03392376","description":"Delirium","metadata":null},{"id":"e0529a4f39704f44a42aee91e8db5d1d","type":"TRIAL","name":"Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)","canonical_id":"clinicaltrials.gov:NCT00251576","description":"Acute Coronary Syndrome","metadata":null},{"id":"b104e025b94342c1b9ce60acb21779a0","type":"TRIAL","name":"Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma","canonical_id":"clinicaltrials.gov:NCT07704918","description":"Melanoma","metadata":null},{"id":"d40c3e7aa44d43bfa9a44abc16c0a998","type":"TRIAL","name":"Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant","canonical_id":"clinicaltrials.gov:NCT03289299","description":"Smoldering Multiple Myeloma","metadata":null},{"id":"a48dbe86fea9453190c7fa208b4f56e5","type":"TRIAL","name":"Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00794963","description":"Metabolic Syndrome","metadata":null},{"id":"7220b3ba60084573a0d56521fca3c895","type":"DISEASE","name":"Agitation","canonical_id":"hp:0000713","description":null,"metadata":null},{"id":"da6f208760e347e5937785b9478c88c4","type":"TRIAL","name":"Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)","canonical_id":"clinicaltrials.gov:NCT01822418","description":"Schizophrenia; Schizoaffective Disorder; Delusional Disorder","metadata":null},{"id":"862a80a3b57d4ca792c03b7b409e903f","type":"TRIAL","name":"Agomelatine in Depressed Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01731899","description":"Major Depression; Fibromyalgia","metadata":null},{"id":"b3f131c9a4a54cdaa48f90d17b0dab09","type":"TRIAL","name":"AiDing Diuresis wIth Tolvaptan (ADD-IT)","canonical_id":"clinicaltrials.gov:NCT02646540","description":"Cardiomyopathy; Congestive Heart Failure","metadata":null},{"id":"d45e5bed3bda4f44bc6dbb8db0eca92e","type":"GO_TERM","name":"Aim21-Tda2 complex","canonical_id":"go:GO:0110131","description":"\"A complex that localizes to actin cortical patches at sites of endocytosis and negatively regulates barbed end F-actin assembly, resulting in the generation of free actin pools. The Aim21-Tda2 complex is necessary for efficient endocytosis and balancing the distribution of actin between patches and cables.\" [GOC:rn, PMID:28706108, PMID:29467252]","metadata":null},{"id":"336fb1cf451d464fa568f769200dad1c","type":"TRIAL","name":"Aimovig Pregnancy Exposure Registry","canonical_id":"clinicaltrials.gov:NCT06150781","description":"Migraine","metadata":null},{"id":"15a007c3e9464251ba2a938fdd420657","type":"TRIAL","name":"Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China","canonical_id":"clinicaltrials.gov:NCT04762472","description":"Atherosclerosis, Coronary","metadata":null},{"id":"2021352199c54e84999e85aa048d647f","type":"TRIAL","name":"Airway Clearance Study","canonical_id":"clinicaltrials.gov:NCT00379028","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"6744b77ab0c540bd8c934bcd8efe965d","type":"TRIAL","name":"Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab","canonical_id":"clinicaltrials.gov:NCT07749001","description":"COPD (Chronic Obstructive Pulmonary Disease)","metadata":null},{"id":"5e746327292d44349fd7a25d083e2826","type":"DISEASE","name":"Airway obstruction","canonical_id":"hp:0006536","description":null,"metadata":null},{"id":"8a541b1799b1489ebe267bb2b84a3981","type":"TRIAL","name":"AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation","canonical_id":"clinicaltrials.gov:NCT05089708","description":"Acne Vulgaris","metadata":null},{"id":"01d79c3033554bc6b315ed64b7af7548","type":"TRIAL","name":"Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07415473","description":"Crohn's Diseases","metadata":null},{"id":"26b306cfad054e4a8e3c6beef5d520e8","type":"TRIAL","name":"Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01776008","description":"Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer","metadata":null},{"id":"91b988e341684c6aad5c7a046833cbfc","type":"DRUG","name":"Akt Inhibitor MK2206","canonical_id":"ncit:C90581","description":null,"metadata":null},{"id":"004d31edf4b9426c9cdd71828545bead","type":"TRIAL","name":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT01480154","description":"Advanced Malignant Solid Neoplasm; Stage III Cutaneous Melanoma AJCC v7; Stage III Prostate Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IV Prostate Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7","metadata":null},{"id":"cf57f71792f34a7c9da1cd09444b68b9","type":"TRIAL","name":"Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01245205","description":"HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"db4dc3c665554e2784bb0f98fbe8017e","type":"GO_TERM","name":"Ala-tRNA(Pro) deacylase activity","canonical_id":"go:GO:0043906","description":"\"Catalysis of the hydrolysis of misacylated Ala-tRNA(Pro).\" [GOC:jl, PMID:14663147]","metadata":null},{"id":"b8fb8120a9bf4fefa78e08892d3b6fb3","type":"GO_TERM","name":"Ala-tRNA(Thr) deacylase activity","canonical_id":"go:GO:0106105","description":"\"Catalysis of the reaction: L-alanyl-tRNA(Thr) + H2O = tRNA(Thr) + L-alanine + H+.\" [PMID:29410408, RHEA:17793]","metadata":null},{"id":"e3e73291129a4833aa7902fe3122997a","type":"DISEASE","name":"Alagille syndrome","canonical_id":"mondo:0007318","description":null,"metadata":null},{"id":"9e59812e7fe041e88ecebf86843b11e6","type":"DRUG","name":"Albiglutide","canonical_id":"mesh:C534611","description":null,"metadata":null},{"id":"b53618647b754addb61b61d133fa327e","type":"TRIAL","name":"Albumin and Furosemide for Preventing Ovarian Hyperstimulation Syndrome in ICSI Patients","canonical_id":"clinicaltrials.gov:NCT07568886","description":"Ovarian Hyper Stimulation Syndrome (OHSS)","metadata":null},{"id":"b738ca861e00449ba7474608af15ac2c","type":"DRUG","name":"Alclofenac","canonical_id":"mesh:C084615","description":null,"metadata":null},{"id":"2097a6ccea4e4cadaf2c4de4ad7cb80b","type":"TRIAL","name":"Alcohol Dependency Study: Combining Medication Treatment for Alcoholism","canonical_id":"clinicaltrials.gov:NCT00006205","description":"Alcoholism","metadata":null},{"id":"8d851f0c4dde4d84b2b1dc593604fcd4","type":"PROTEIN","name":"Alcohol dehydrogenase 1A","canonical_id":"uniprot:P07327","description":null,"metadata":null},{"id":"9498f22480d34a7aaf5b5cb63674fa9a","type":"DISEASE","name":"Alcohol withdrawal delirium","canonical_id":"mesh:D000430","description":null,"metadata":null},{"id":"ef83d840135b4cadbf9225c8074652b7","type":"DISEASE","name":"Alcoholism","canonical_id":"mesh:D000437","description":null,"metadata":null},{"id":"3a77357ea7a24aac87eb394b06c1f594","type":"PROTEIN","name":"Aldehyde dehydrogenase, mitochondrial","canonical_id":"uniprot:P05091","description":null,"metadata":null},{"id":"4a39ebda9ec54f999f0da6498d84e697","type":"DRUG","name":"Aldesleukin","canonical_id":"mesh:C082598","description":null,"metadata":null},{"id":"a1b8afc4651c42f49163416426733fb2","type":"TRIAL","name":"Aldosterone Blockade Early After Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT01059136","description":"Myocardial Infarction","metadata":null},{"id":"9768d624392d4e0aae8d42a38fb96fdc","type":"TRIAL","name":"Aldosterone and Vascular Disease in Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00214825","description":"Diabetes Mellitus; Endothelial Dysfunction; Albuminuria","metadata":null},{"id":"b5efb6ff91d94400b217c054c771b88f","type":"DISEASE","name":"Aldosteronism","canonical_id":"mesh:D006929","description":null,"metadata":null},{"id":"39b298d755664de19033c2aef6253efb","type":"DRUG","name":"Alectinib","canonical_id":"mesh:C582670","description":null,"metadata":null},{"id":"a9626b4bb6e14f93aec446f4bef849d6","type":"DRUG","name":"Alectinib","canonical_id":"ncit:C101790","description":null,"metadata":null},{"id":"5af2ad58e34149a9bb86c1d2bf7b2a72","type":"TRIAL","name":"Alectinib Pharmacokinetic in Patients With NSCLC","canonical_id":"clinicaltrials.gov:NCT05713006","description":"Non-small Cell Lung Cancer Stage IIIB; ALK Gene Mutation","metadata":null},{"id":"01c3fabb0d304e1d8582234f6784fdba","type":"TRIAL","name":"Alectinib in Combination With Bevacizumab in ALK Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT03779191","description":"ALK Gene Rearrangement Positive; Non-Squamous Non-Small Cell Neoplasm of Lung","metadata":null},{"id":"b19f367f16ed4b1ab655a356cabf490b","type":"TRIAL","name":"Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1","canonical_id":"clinicaltrials.gov:NCT06354387","description":"Hepatocellular Carcinoma","metadata":null},{"id":"21be62bbe04e4a06bd41eee1bbaa73a2","type":"TRIAL","name":"Alectinib in Neo-adjuvant Treatment of Stage III NSCLC","canonical_id":"clinicaltrials.gov:NCT05015010","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"d0ecea36436a4cfb88cb13097730ab86","type":"TRIAL","name":"Alectinib-induced Endocrine Toxicity","canonical_id":"clinicaltrials.gov:NCT06339554","description":"NSCLC Stage IV","metadata":null},{"id":"a16ee4bed4e545c481e3881ee109f506","type":"TRIAL","name":"Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.","canonical_id":"clinicaltrials.gov:NCT00407342","description":"Psoriasis","metadata":null},{"id":"f5e1a1797b454a58a122e3f7cbaa629e","type":"TRIAL","name":"Alefacept Mechanism of Action in Psoriasis","canonical_id":"clinicaltrials.gov:NCT00150982","description":"Psoriasis","metadata":null},{"id":"f9ab89dc3ae54ec88f07c5ce590257d0","type":"TRIAL","name":"Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT01319851","description":"Thalassemia; Sickle Cell Disease; Glanzmann Thrombasthenia; Wiskott-Aldrich Syndrome; Chronic-granulomatous Disease; Severe Congenital Neutropenia; Leukocyte Adhesion Deficiency; Schwachman-Diamond Syndrome; Diamond-Blackfan Anemia; Fanconi Anemia; Dyskeratosis-congenita; Chediak-Higashi Syndrome; Severe Aplastic Anemia","metadata":null},{"id":"abe71e13572d4f02a0c437da574f7606","type":"TRIAL","name":"Alefacept for Chronic Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT00397332","description":"Resistant Chronic GVHD","metadata":null},{"id":"75c656782e32418986856ce40f41cc76","type":"TRIAL","name":"Alefacept for Prevention of Graft Versus Host Disease (GVHD)","canonical_id":"clinicaltrials.gov:NCT00361413","description":"Graft Versus Host Disease","metadata":null},{"id":"7883b9f8ee4443649a330209784623b6","type":"TRIAL","name":"Alefacept in Patients With Relapsed/Refractory Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT01267643","description":"Aplastic Anemia","metadata":null},{"id":"7f634882dc2345ef81b87bb402b5a034","type":"TRIAL","name":"Alefacept in Patients With Severe Scalp Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT00167102","description":"Alopecia Areata","metadata":null},{"id":"d1410792945648c1b3acc73ac09a6096","type":"TRIAL","name":"Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy","canonical_id":"clinicaltrials.gov:NCT00953329","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"df72a384f9b34b02b5900fb63a6dd234","type":"TRIAL","name":"Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT01226420","description":"Chronic Graft-versus-host Disease","metadata":null},{"id":"ad53d02c0f7d40c2817bf4078875c058","type":"TRIAL","name":"Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00438802","description":"Lymphoma","metadata":null},{"id":"604e9f6319bd418fb40cf5700144d732","type":"TRIAL","name":"Alemtuzumab and CHOP in T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00646854","description":"Lymphoma, T-Cell, Peripheral","metadata":null},{"id":"1aa9dbd43aa64f0bb1fb421350d40902","type":"TRIAL","name":"Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00061945","description":"Acute Undifferentiated Leukemia; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; L1 Adult Acute Lymphoblastic Leukemia; L1 Childhood Acute Lymphoblastic Leukemia; L2 Adult Acute Lymphoblastic Leukemia; L2 Childhood Acute Lymphoblastic Leukemia; Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Childhood Precursor A\u2026","metadata":null},{"id":"960b4e6f4eeb410eafaef8bf4a3a32d3","type":"TRIAL","name":"Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants","canonical_id":"clinicaltrials.gov:NCT00775632","description":"Graft Versus Host Disease; Bone Marrow Transplantation","metadata":null},{"id":"a97f64b2aff74758b57a0a0dda6cee21","type":"TRIAL","name":"Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure","canonical_id":"clinicaltrials.gov:NCT00895739","description":"Nonmalignant Neoplasm","metadata":null},{"id":"d9125abbafa54c7695f0515a3e9249ce","type":"TRIAL","name":"Alemtuzumab and Pentostatin In T-cell Neoplasms","canonical_id":"clinicaltrials.gov:NCT00453193","description":"Lymphoma; Leukemia","metadata":null},{"id":"55e272fc7acd444286b11b7041b0df96","type":"TRIAL","name":"Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)","canonical_id":"clinicaltrials.gov:NCT01757574","description":"Chronic Inflammatory Demyelinating Neuropathy","metadata":null},{"id":"33370a05737a48da87546ca49c55903e","type":"TRIAL","name":"Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00634881","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"ec652e89109b4c3ab0d834501613677d","type":"TRIAL","name":"Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01361711","description":"Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia","metadata":null},{"id":"a0aa79551a824aa09450d5c1c04b52c8","type":"TRIAL","name":"Alendronate Compared to Metformin in Chronic Periodontitis","canonical_id":"clinicaltrials.gov:NCT02461667","description":"Chronic Periodontitis","metadata":null},{"id":"c96717a6dd01443cbac80a77aad87317","type":"TRIAL","name":"Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?","canonical_id":"clinicaltrials.gov:NCT00299572","description":"Peritoneal Dialysis","metadata":null},{"id":"923455bc100242ceb2be2a6633629370","type":"TRIAL","name":"Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation","canonical_id":"clinicaltrials.gov:NCT07245381","description":"Cervix Cancer","metadata":null},{"id":"f6e378060f5a4bbd9f2e6bf8019e1622","type":"TRIAL","name":"Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome","canonical_id":"clinicaltrials.gov:NCT00001728","description":"Polyostotic Fibrous Dysplasia","metadata":null},{"id":"ffeda8fefdcf49ab8882a10060cb6d60","type":"DRUG","name":"Alfuzosin","canonical_id":"mesh:C047638","description":null,"metadata":null},{"id":"56c535ad54574cf3adea775307a51af5","type":"TRIAL","name":"Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi","canonical_id":"clinicaltrials.gov:NCT00177086","description":"Kidney Calculi; Ureteral Calculi; Colic","metadata":null},{"id":"ec2cb3196c634932b6d4e510162f8434","type":"TRIAL","name":"Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort","canonical_id":"clinicaltrials.gov:NCT00467467","description":"Ureteral Stent Discomfort","metadata":null},{"id":"4b2d02a8439b4fc5a973cbb9a253ea51","type":"TRIAL","name":"Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","canonical_id":"clinicaltrials.gov:NCT00576823","description":"Hydronephrosis; Neurogenic Bladder","metadata":null},{"id":"40e8544a9b58429d821f10fd3ace4194","type":"TRIAL","name":"Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","canonical_id":"clinicaltrials.gov:NCT00549939","description":"Neurogenic Urinary Bladder","metadata":null},{"id":"72abde5536e94798ba0bb44c2a786ab3","type":"TRIAL","name":"Alfuzosin Versus Placebo in Acute Urinary Retention","canonical_id":"clinicaltrials.gov:NCT00453908","description":"Urinary Retention","metadata":null},{"id":"9ef9ac4d827c46b88964057b415b5081","type":"TRIAL","name":"Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study","canonical_id":"clinicaltrials.gov:NCT00575913","description":"Prostatic Diseases","metadata":null},{"id":"641246ac1fe94842b5ee2614fb44a94e","type":"TRIAL","name":"Alfuzosin for Medical Expulsion Therapy of Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT00713739","description":"Kidney Stones","metadata":null},{"id":"afe31c39c0144d89b1a60d36af4c3ae2","type":"TRIAL","name":"Alfuzosin for Treating Acute Urinary Retention","canonical_id":"clinicaltrials.gov:NCT00336921","description":"Acute Urinary Retention","metadata":null},{"id":"2d24a9131e7a4e6f9bff7925030b433c","type":"TRIAL","name":"Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)","canonical_id":"clinicaltrials.gov:NCT00688948","description":"Multiple Sclerosis; Bladder Dysfunction","metadata":null},{"id":"dcd7ce5e5c584ca4a90e4ed6c59eeb01","type":"DRUG","name":"Alglucerase","canonical_id":"mesh:C070292","description":null,"metadata":null},{"id":"1e69f910e7764d328c38cb34b07d8eb7","type":"TRIAL","name":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01764867","description":"Major Depressive Disorder","metadata":null},{"id":"06d9dcea2e874197bc5451fdd43cc3d2","type":"TRIAL","name":"Algorithm-informed Decision-making to Advance Pain Treatment","canonical_id":"clinicaltrials.gov:NCT07731750","description":"Chronic Low-back Pain","metadata":null},{"id":"d96f0f498d2744ff8f2664e99f8bde01","type":"TRIAL","name":"Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)","canonical_id":"clinicaltrials.gov:NCT07615179","description":"Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events","metadata":null},{"id":"507e982a3439418799f8b5e1479bcfaa","type":"TRIAL","name":"Alirocumab in Patients With Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT02938949","description":"Myocardial Infarction; Hypercholesterolemia","metadata":null},{"id":"43e1a0e17a6449e48da308bfbfe24a36","type":"TRIAL","name":"Alirocumab in Patients with Sepsis","canonical_id":"clinicaltrials.gov:NCT05469347","description":"Sepsis","metadata":null},{"id":"752f9ce44ea54f5883b68006f3273bb0","type":"TRIAL","name":"Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01482962","description":"Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma","metadata":null},{"id":"060546cde6dc422281116181dff03ca5","type":"DRUG","name":"Aliskiren","canonical_id":"mesh:C446481","description":null,"metadata":null},{"id":"b9fe2c1d891a40d3ba5f6dd2f2da9a18","type":"TRIAL","name":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","canonical_id":"clinicaltrials.gov:NCT01922141","description":"Hypertension","metadata":null},{"id":"e0c579eff0204aaa858ad2b280e6ed35","type":"TRIAL","name":"Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","canonical_id":"clinicaltrials.gov:NCT00797862","description":"Hypertension","metadata":null},{"id":"8151108cdc0f4d00a1cc8a329d3d9d26","type":"TRIAL","name":"Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","canonical_id":"clinicaltrials.gov:NCT00942994","description":"Hypertension","metadata":null},{"id":"473b4b0f00c94a38b4cc1a5d29a8ef8a","type":"TRIAL","name":"Alitretinoin in the Treatment of Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT00519675","description":"Eczema","metadata":null},{"id":"21b8739c9197419d8fb2eb6ee09dd388","type":"TRIAL","name":"Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT03026907","description":"Hand Eczema","metadata":null},{"id":"83fd9da589224caab96fba0563f577cf","type":"TRIAL","name":"Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema","canonical_id":"clinicaltrials.gov:NCT03026946","description":"Hand Eczema","metadata":null},{"id":"94a4aaa6535144e59bb5d7a1b6d00805","type":"TRIAL","name":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","canonical_id":"clinicaltrials.gov:NCT00413166","description":"Acute Promyelocytic Leukemia","metadata":null},{"id":"d2420269434e4e778a7cafa12554bd1f","type":"DISEASE","name":"Allergic Rhinitis","canonical_id":"mesh:D065631","description":null,"metadata":null},{"id":"ceace04121664120b10e66815ac3165e","type":"TRIAL","name":"Allergic Rhinitis Combination Pharmacotherapy Efficacy Study","canonical_id":"clinicaltrials.gov:NCT04601324","description":"Allergic Rhinitis","metadata":null},{"id":"2d40c4d51f4b44a69fc68d94cea778de","type":"DISEASE","name":"Allergy","canonical_id":"hp:0012393","description":null,"metadata":null},{"id":"9b9f3bd1c498421b857ef4c3a11ec1d9","type":"TRIAL","name":"Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease","canonical_id":"clinicaltrials.gov:NCT00385788","description":"Hodgkin's Disease","metadata":null},{"id":"1b7f0c77d2594e4e89c0bd34d3327c1c","type":"TRIAL","name":"Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT05993611","description":"Chronic Graft Versus Host Disease; Hematologic and Lymphocytic Disorder; Steroid Refractory Graft Versus Host Disease","metadata":null},{"id":"eb52f351e59e496785843cc4e39ab736","type":"TRIAL","name":"Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT05400603","description":"Neuroblastoma; Refractory Neuroblastoma; Relapsed Neuroblastoma; Relapsed Osteosarcoma; Refractory Osteosarcoma","metadata":null},{"id":"c35bdec49dea400c8eb30029475884df","type":"TRIAL","name":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","canonical_id":"clinicaltrials.gov:NCT03663933","description":"Lymphoproliferative Disorders; Autoimmune Lymphoproliferative; Primary T-cell Immunodeficiency Disorders; Immune System Diseases; Common Variable Immunodeficiency","metadata":null},{"id":"d1c5f9d7c9d9450b9925ca2590f5797c","type":"TRIAL","name":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT02441803","description":"Leukemia","metadata":null},{"id":"3dc16016382f4d0eab44030c2744afa3","type":"TRIAL","name":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","canonical_id":"clinicaltrials.gov:NCT05463133","description":"Chronic Granulomatous Disease","metadata":null},{"id":"f58431885f5148deb097b6b757ef0c9b","type":"TRIAL","name":"Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)","canonical_id":"clinicaltrials.gov:NCT00881556","description":"Epidermolysis Bullosa","metadata":null},{"id":"e8841e026d1641cfb3122fbd7121f774","type":"TRIAL","name":"Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT03303950","description":"Anemia; ASXL1 Gene Mutation; EZH2 Gene Mutation; IDH1 Gene Mutation; IDH2 Gene Mutation; Plasma Cell Myeloma; Primary Myelofibrosis; Recurrent Plasma Cell Myeloma; Secondary Myelofibrosis; Thrombocytopenia","metadata":null},{"id":"c4724c994cb74c679d7255550c55c79b","type":"TRIAL","name":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","canonical_id":"clinicaltrials.gov:NCT05675319","description":"Multiple Myeloma","metadata":null},{"id":"3b4d716f46e44d82a0f5458457d12cc1","type":"TRIAL","name":"Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02057770","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"51b7c00fbee24b17bce1cfbc215bce19","type":"TRIAL","name":"Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT00644371","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"1e4cde53478e41ddad769232e6db28b1","type":"TRIAL","name":"Allopurinol Add-on Treatment for Refractory Mania","canonical_id":"clinicaltrials.gov:NCT00643123","description":"Bipolar Disorder; Mixed Mania; Treatment-Resistant Mania","metadata":null},{"id":"9f580b0fa5f94274b85762d081328407","type":"TRIAL","name":"Allopurinol Maintenance Study for Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00732251","description":"Bipolar Disorder; Mania; Mixed Mania","metadata":null},{"id":"49949fd31c04400d9dd5fdd250f7282c","type":"TRIAL","name":"Allopurinol Outcome Study","canonical_id":"clinicaltrials.gov:NCT01391325","description":"Gout","metadata":null},{"id":"b5f5942cfc78409f902305f57ce3d7a6","type":"TRIAL","name":"Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis","canonical_id":"clinicaltrials.gov:NCT05511766","description":"Cirrhosis; Hepatic Encephalopathy; Ascites; Varices; SBP - Spontaneous Bacterial Peritonitis","metadata":null},{"id":"c954a3b1aa724aecad1904ce338be25f","type":"TRIAL","name":"Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010","canonical_id":"clinicaltrials.gov:NCT00175019","description":"Gout","metadata":null},{"id":"aefaf61bcfe34fccb29ca74c77408c19","type":"TRIAL","name":"Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients","canonical_id":"clinicaltrials.gov:NCT05540184","description":"AKI - Acute Kidney Injury","metadata":null},{"id":"c1eb59487afd431088179cb4317fe20d","type":"TRIAL","name":"Allopurinol in Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT03745729","description":"Acute Coronary Syndrome","metadata":null},{"id":"7c578f3e3c8a423086e92176d25b6a72","type":"TRIAL","name":"Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT03700645","description":"Diabetes Mellitus; Ischemic Heart Disease; Multi Vessel Coronary Artery Disease","metadata":null},{"id":"42be8cafa83648599ae91555692a5b48","type":"TRIAL","name":"Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'","canonical_id":"clinicaltrials.gov:NCT01550107","description":"Sarcopenia","metadata":null},{"id":"fa5fce7a2f984f0591a537060d0b4a75","type":"TRIAL","name":"Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04592666","description":"Lung Cancer, Non-small Cell; EGFR T790M; EGFR Gene Mutation","metadata":null},{"id":"6a4e555f9f1c48ff9ba9043a7fdbbae6","type":"DRUG","name":"Almotriptan","canonical_id":"mesh:C409045","description":null,"metadata":null},{"id":"2eaa1fe947fa4772b2882664adc20ec9","type":"TRIAL","name":"Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones\"","canonical_id":"clinicaltrials.gov:NCT01945242","description":"Type 2 Diabetes Melitus","metadata":null},{"id":"4c08e7c84f2842e3a6a85e8fdeec1086","type":"TRIAL","name":"Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With \u03b1-GI\"","canonical_id":"clinicaltrials.gov:NCT01945216","description":"Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution","metadata":null},{"id":"c3945333b36149529e3392cdc7d4815c","type":"TRIAL","name":"Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01964963","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a39ccf4ff8064612b4595902470fb4c5","type":"TRIAL","name":"Alogliptin Tablets Specified Drug-use Survey \"Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)\"","canonical_id":"clinicaltrials.gov:NCT02221284","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"4ded1f4f6bfa47cc881906e823862ae4","type":"TRIAL","name":"Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01990300","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d24197768a024176bd8b8c0a5a82ea75","type":"DISEASE","name":"Alopecia Areata","canonical_id":"mesh:D000506","description":null,"metadata":null},{"id":"97c37c31fcfb4eb39f7b78e14bc9b1fc","type":"TRIAL","name":"Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab","canonical_id":"clinicaltrials.gov:NCT00636805","description":"Brain Cancer","metadata":null},{"id":"d55f104129434d5e800d878b581982b0","type":"DRUG","name":"Alpelisib","canonical_id":"ncit:C94214","description":null,"metadata":null},{"id":"1d92509705bb43e78dc926947acc08ea","type":"TRIAL","name":"Alpelisib Challenge Test (ACT)","canonical_id":"clinicaltrials.gov:NCT07778524","description":"Insulin Resistance; Type 2 Diabetes; Obesity & Overweight; Healthy Adult Participants","metadata":null},{"id":"40ba70c4a36b490eb8467a5dd6d156fb","type":"TRIAL","name":"Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients","canonical_id":"clinicaltrials.gov:NCT04753203","description":"Metastatic Colorectal Cancer; PIK3CA Gene Mutation","metadata":null},{"id":"ec3f1f55982440c683f0ce571de7b165","type":"TRIAL","name":"Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03207529","description":"Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Androgen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Progn\u2026","metadata":null},{"id":"8a847a8418c24c4ab591937ad471aa25","type":"TRIAL","name":"Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT04526470","description":"Solid Tumor; Stomach Cancer","metadata":null},{"id":"09481f44c7314033b62229d7b3a349b9","type":"TRIAL","name":"Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT05472220","description":"Solid Tumors, Adult; PIK3CA Mutation-Related Tumors; PIK3CA Mutation; Human Papillomavirus-Related Carcinoma; HPV-Related Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm","metadata":null},{"id":"b6c0fb7fcd564260ae0c4eb161d0edbc","type":"TRIAL","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","canonical_id":"clinicaltrials.gov:NCT05948943","description":"Lymphatic Malformations","metadata":null},{"id":"c13fc47f54724f4b89f92fed5f022185","type":"TRIAL","name":"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05025735","description":"Metastatic Breast Cancer; HER2-negative Breast Cancer","metadata":null},{"id":"77568007ea514b7aa6c3c5d22e42484f","type":"TRIAL","name":"Alpha-1 Blockade for Alcohol Use Disorder (AUD)","canonical_id":"clinicaltrials.gov:NCT04135846","description":"Alcohol Use Disorder (AUD)","metadata":null},{"id":"96d98fd4fd44411f8cb7e1d5e643887f","type":"TRIAL","name":"Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)","canonical_id":"clinicaltrials.gov:NCT00263887","description":"Alpha 1-Antitrypsin Deficiency","metadata":null},{"id":"2071364db5ad4072b3970db1f3a318a3","type":"PROTEIN","name":"Alpha-1B adrenergic receptor","canonical_id":"uniprot:P35368","description":null,"metadata":null},{"id":"9699a13ad6e14e05ba0f24b0bf731144","type":"PROTEIN","name":"Alpha-1D adrenergic receptor","canonical_id":"uniprot:P25100","description":null,"metadata":null},{"id":"96d15c5a7fa444869fe3ea386e9e39fe","type":"PROTEIN","name":"Alpha-2B adrenergic receptor","canonical_id":"uniprot:P18089","description":null,"metadata":null},{"id":"977aadbd708c44039ae2f7613f88b057","type":"TRIAL","name":"Alpha-Blockers in Allergic Rhinitis (MAN 01)","canonical_id":"clinicaltrials.gov:NCT01946035","description":"Allergic Rhinitis","metadata":null},{"id":"72656f993f624cda8f22a2233712780f","type":"TRIAL","name":"Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men","canonical_id":"clinicaltrials.gov:NCT00700583","description":"Nocturia","metadata":null},{"id":"9e8cacf9430746c79d8117e359343d61","type":"PROTEIN","name":"Alpha-galactosidase A","canonical_id":"uniprot:P06280","description":null,"metadata":null},{"id":"7596626663894b6f8104b1e600a3f312","type":"TRIAL","name":"Alpha-lipoic Acid in Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT06253429","description":"Type 1 Diabetes","metadata":null},{"id":"6187e907775f4919aaf9bc5fcc1dcbb6","type":"TRIAL","name":"Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06625190","description":"Neuroblastoma; Rhabdomyosarcoma; Synovial Sarcoma; Peripheral Nerve Sheath Tumors; Clear Cell Sarcoma; Alveolar Soft Part Sarcoma; Desmoplastic Small Round Cell Tumor; Chordoma; Rhabdoid Tumor; Epithelioid Sarcoma; Myoepithelial Tumor; Osteosarcoma; Ewing Sarcoma; Wilms Tumor","metadata":null},{"id":"9fe25b632f344413bffc02d64f4c21f6","type":"DRUG","name":"Alprazolam","canonical_id":"mesh:D000525","description":null,"metadata":null},{"id":"73fde2792a5b4aaaa95e218d0d4c2d74","type":"DRUG","name":"Alprostadil","canonical_id":"mesh:D000527","description":null,"metadata":null},{"id":"4e9cb25036374afd912e61808fe91471","type":"DRUG","name":"Alteplase","canonical_id":"mesh:D010959","description":null,"metadata":null},{"id":"268e2becea884f579d3bbfb86dac1494","type":"TRIAL","name":"Altering Activation Patterns Post-stroke","canonical_id":"clinicaltrials.gov:NCT02418949","description":"Stroke; Muscle Spasticity; Hemiparesis","metadata":null},{"id":"ba7bf5bdaa42498888b4a15e95101199","type":"TRIAL","name":"Alternate Day Buprenorphine Administration, Phase IX - 14","canonical_id":"clinicaltrials.gov:NCT00000232","description":"Opioid-Related Disorders","metadata":null},{"id":"151372c8e1054c3f9513613362682019","type":"TRIAL","name":"Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project","canonical_id":"clinicaltrials.gov:NCT07472413","description":"Multiple Sclerosis","metadata":null},{"id":"6f9b4bb2ac304f30a565286a3bcd30ce","type":"TRIAL","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT07780838","description":"Locally Advanced Ampulla of Vater Carcinoma; Locally Advanced Biliary Tract Carcinoma; Locally Advanced Extrahepatic Cholangiocarcinoma; Locally Advanced Gallbladder Carcinoma; Locally Advanced Intrahepatic Cholangiocarcinoma; Metastatic Ampulla of Vater Carcinoma; Metastatic Biliary Tract Carcinoma; Metastatic Extrahepatic Cholangiocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Ampulla of Vater Cancer AJCC v8; Stage III Distal Bile Duct Cance\u2026","metadata":null},{"id":"ef2d2dc42bd147199e5137292ff3ba94","type":"TRIAL","name":"Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05659290","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"d1150661faa147eda9ec035aaad868f3","type":"TRIAL","name":"Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT05961124","description":"Ovarian Cancer; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; High Grade Ovarian Serous Adenocarcinoma","metadata":null},{"id":"2f9b37ebfc824fdda00889e480455578","type":"TRIAL","name":"Altreno for Chest Rejuvenation","canonical_id":"clinicaltrials.gov:NCT04096742","description":"Photodamaged Skin; Photoaging","metadata":null},{"id":"a028c196b7fc416ca703c39d0c60af14","type":"DRUG","name":"Altretamine","canonical_id":"mesh:D006585","description":null,"metadata":null},{"id":"98076eebcaab4e42b62e4f4625f05158","type":"DRUG","name":"Aluminum Hydroxide","canonical_id":"mesh:D000536","description":null,"metadata":null},{"id":"3de6ff951cc348f2b9d75f6258f87fb1","type":"DISEASE","name":"Alveolitis, Extrinsic Allergic","canonical_id":"mesh:D000542","description":null,"metadata":null},{"id":"5e4a5b983c0d4df19a28740b7b934fb1","type":"TRIAL","name":"Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain","canonical_id":"clinicaltrials.gov:NCT00259922","description":"Bowel Dysfunction; Constipation","metadata":null},{"id":"78b7f79f8f20461fbb68a193be778475","type":"TRIAL","name":"Alvimopan Use in Polytraumatized Patients","canonical_id":"clinicaltrials.gov:NCT03068975","description":"Post Operative Ileus","metadata":null},{"id":"b3bca81a0c92477c9f28d29a53cf2a71","type":"TRIAL","name":"Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol","canonical_id":"clinicaltrials.gov:NCT03216525","description":"Bladder Cancer","metadata":null},{"id":"0c4c08051dc246d99390366415540054","type":"TRIAL","name":"Alvimopan and Ileus in PSF","canonical_id":"clinicaltrials.gov:NCT02218190","description":"Ileus; Spinal Fusion","metadata":null},{"id":"20d52dadf21941ccaf2eef5b6eff2f46","type":"TRIAL","name":"Alvimopan as Rescue in Post op Ileus","canonical_id":"clinicaltrials.gov:NCT02742181","description":"Colorectal Surgery; Ileus","metadata":null},{"id":"af5bca7b659348e6b2cfe254bfe143c7","type":"TRIAL","name":"Alvimopan as a Rescue Treatment of Postoperative Ileus","canonical_id":"clinicaltrials.gov:NCT04405037","description":"Ileus; Gastrointestinal Dysfunction","metadata":null},{"id":"cfdcc0d315b84863abeeb80794d52d00","type":"DISEASE","name":"Alzheimer Disease","canonical_id":"mesh:D000544","description":null,"metadata":null},{"id":"1116618f27f945c5bf78fa4cc36439c9","type":"DISEASE","name":"Alzheimer disease","canonical_id":"mondo:0004975","description":null,"metadata":null},{"id":"ad5cbb365765493da4498bb6364e97af","type":"TRIAL","name":"Alzheimer's Disease Long-term Follow-up Study (ALF Study)","canonical_id":"clinicaltrials.gov:NCT00165724","description":"Alzheimer's Disease","metadata":null},{"id":"959b7fd552be4ae1a8d91c2070024da3","type":"TRIAL","name":"Alzheimer's Disease Neuroimaging Initiative 2","canonical_id":"clinicaltrials.gov:NCT01231971","description":"Mild Cognitive Impairment (MCI); Alzheimer's Disease (AD); Significant Memory Concern (SMC); Early Mild Cognitive Impairment (EMCI); Late Mild Cognitive Impairment (LMCI)","metadata":null},{"id":"b711a8f09e9048a2bb63c3c5bf908585","type":"TRIAL","name":"Alzheimer's Disease Research Center (ADRC) PET Component Study","canonical_id":"clinicaltrials.gov:NCT07758660","description":"Alzheimer Disease; Mild Cognitive Impairment (MCI); Dementia","metadata":null},{"id":"589b39c20a2e487a9e7fcfa9e1c62e50","type":"TRIAL","name":"Alzheimer's Disease: Therapeutic Potential of Estrogen","canonical_id":"clinicaltrials.gov:NCT00066157","description":"Alzheimer Disease","metadata":null},{"id":"55ddfcb079324719a050f4fdc6a73fde","type":"TRIAL","name":"Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults","canonical_id":"clinicaltrials.gov:NCT03706261","description":"Alzheimer Disease","metadata":null},{"id":"caab14aaa0424635bd90ffd83c6ad932","type":"TRIAL","name":"Alzheimer's in Long-Term Care--Treatment for Agitation","canonical_id":"clinicaltrials.gov:NCT00161473","description":"Alzheimer Disease; Psychomotor Agitation","metadata":null},{"id":"473f03f78a144598bbb16dda0726646b","type":"DRUG","name":"Amantadine","canonical_id":"mesh:D000547","description":null,"metadata":null},{"id":"017151567e6a4c11bd5c2b6c97fe1e47","type":"TRIAL","name":"Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness","canonical_id":"clinicaltrials.gov:NCT02025439","description":"Traumatic Brain Injury","metadata":null},{"id":"5cb320d8bca7434cbb49022c53430a6c","type":"TRIAL","name":"Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients","canonical_id":"clinicaltrials.gov:NCT03178708","description":"Spinal Curvatures","metadata":null},{"id":"9774bf43ff7a4db6a8d6f92c6fee3e1c","type":"TRIAL","name":"Amantadine for COVID-19","canonical_id":"clinicaltrials.gov:NCT04894617","description":"Covid19","metadata":null},{"id":"5f69fd4119ff4471881ae22554efd213","type":"TRIAL","name":"Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)","canonical_id":"clinicaltrials.gov:NCT00127114","description":"Dementia","metadata":null},{"id":"5be1b7e810434dca8b9b1485eede39da","type":"TRIAL","name":"Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT00851929","description":"Sarcoidosis; Pulmonary Hypertension","metadata":null},{"id":"f53e62ccf6674e15a92ff30ab031fbb7","type":"TRIAL","name":"Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT06987097","description":"Pulmonary Arterial Hypertension (PAH)","metadata":null},{"id":"40c3d16930ee4968aadf87c7b369e0ae","type":"TRIAL","name":"Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.","canonical_id":"clinicaltrials.gov:NCT01884675","description":"Hypertension","metadata":null},{"id":"8c9e9e2c20154c1f92a988d09d07f115","type":"TRIAL","name":"Ambrisentan for Treatment of Portopulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT01733095","description":"Portopulmonary Hypertension","metadata":null},{"id":"051bf8ccf74f443b94642cc96926d542","type":"TRIAL","name":"Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT02169752","description":"Pre-Pulmonary Atrial Hypertension","metadata":null},{"id":"1d2348a5b14f4df6b5b548b8721009ed","type":"TRIAL","name":"Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial","canonical_id":"clinicaltrials.gov:NCT01224210","description":"Portopulmonary Hypertension","metadata":null},{"id":"31c624330fc941bc8bdbc5aff07981d6","type":"TRIAL","name":"Ambrisentan in Single Ventricle","canonical_id":"clinicaltrials.gov:NCT02080637","description":"Hypoplastic Left Heart Syndrome; Hypoplastic Right-sided Heart Complex","metadata":null},{"id":"db46be77e94e421dbba9de11325b6961","type":"TRIAL","name":"Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","canonical_id":"clinicaltrials.gov:NCT00295542","description":"Hypertension","metadata":null},{"id":"b5ccac4192a9471fba488c515dcb2b2f","type":"TRIAL","name":"Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT02121041","description":"Hypertension","metadata":null},{"id":"f61178c11f6a403db43c1bae878453cb","type":"DRUG","name":"Amcinonide","canonical_id":"mesh:C012716","description":null,"metadata":null},{"id":"87618e8110cb4d51a6b1a68e98f102ee","type":"DISEASE","name":"Amebiasis","canonical_id":"mesh:D000562","description":null,"metadata":null},{"id":"404927681f4f4120a5d8bea8460056d5","type":"DISEASE","name":"Amebic liver abscess","canonical_id":"mesh:D008101","description":null,"metadata":null},{"id":"710b095bc6f344c98b32a89ddca21750","type":"DISEASE","name":"Amenorrhea","canonical_id":"mesh:D000568","description":null,"metadata":null},{"id":"c08f10f72c144778b4ba6c7d32d5376d","type":"DISEASE","name":"American mucocutaneous leishmaniasis","canonical_id":"mesh:D007897","description":null,"metadata":null},{"id":"17625e5d8a4a489e82e57ee4483eacaa","type":"TRIAL","name":"Amiloride Clinical Trial In Optic Neuritis","canonical_id":"clinicaltrials.gov:NCT01802489","description":"Optic Neuritis; Multiple Sclerosis","metadata":null},{"id":"dea2ddedbbcb472e9e6ea250c97c30ab","type":"TRIAL","name":"Amiloride Hydrochloride as an Effective Treatment for ADHD","canonical_id":"clinicaltrials.gov:NCT01733680","description":"ADHD","metadata":null},{"id":"ce017610d87c4ebc8705e3d2b55021d6","type":"TRIAL","name":"Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve","canonical_id":"clinicaltrials.gov:NCT01879527","description":"Optic; Neuritis, With Demyelination","metadata":null},{"id":"1d538cf806cc4ecd9f967fec5262c802","type":"TRIAL","name":"Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00547053","description":"Cystic Fibrosis","metadata":null},{"id":"b6b4c0b0918e47168099dffe9d68b504","type":"TRIAL","name":"Amiloride for Resistant Hypertension","canonical_id":"clinicaltrials.gov:NCT02122731","description":"Hypertension; Type 2 Diabetes Mellitus; Microalbuminuria","metadata":null},{"id":"ebaaecd599024f50a5390264232da070","type":"TRIAL","name":"Amiloride in Nephrotic Syndrome","canonical_id":"clinicaltrials.gov:NCT05079789","description":"Nephrotic Syndrome; Edema; Sodium Retention","metadata":null},{"id":"7b3a2af522534d64bcc1e18c613561c9","type":"PROTEIN","name":"Amiloride-sensitive sodium channel subunit gamma","canonical_id":"uniprot:P51170","description":null,"metadata":null},{"id":"4b7cecb8aaf84d128a39c51a5104b13c","type":"DRUG","name":"Amineptine","canonical_id":"mesh:C011597","description":null,"metadata":null},{"id":"8b7433b4ec6c4cdba5c0de7282307e69","type":"DRUG","name":"Aminolevulinic acid","canonical_id":"mesh:D000622","description":null,"metadata":null},{"id":"b5996e88a23f4f8fa6769215632445cd","type":"PROTEIN","name":"Aminolevulinic acid synthase","canonical_id":"uniprot:P13196","description":null,"metadata":null},{"id":"420f28cdfb724e428b1b416e1957fc68","type":"DRUG","name":"Aminosalicylic acid","canonical_id":"mesh:D010131","description":null,"metadata":null},{"id":"ee60b43d419f41a787859c55592300d5","type":"TRIAL","name":"Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","canonical_id":"clinicaltrials.gov:NCT04351763","description":"COVID-19","metadata":null},{"id":"a5a4163a132c434d8f4904e1977cfae4","type":"TRIAL","name":"Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01246232","description":"Schizophrenia","metadata":null},{"id":"0a6bc15191f3426d8c4b16e4fe92afe5","type":"TRIAL","name":"Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT07554040","description":"PONV","metadata":null},{"id":"d76d0ad4939249af839e42288e70fd76","type":"TRIAL","name":"Amisulpride in Schizophrenic Acute Phase Patients","canonical_id":"clinicaltrials.gov:NCT00436371","description":"Schizophrenia","metadata":null},{"id":"4170602e7e5b493d9f3f261349e11033","type":"TRIAL","name":"Amisulpride in Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT00331981","description":"Schizophrenia","metadata":null},{"id":"9e1d56bd902844bd9022cd01f944b168","type":"TRIAL","name":"Amitiza in Constipation Associated With PD (Parkinson's Disease)","canonical_id":"clinicaltrials.gov:NCT00908076","description":"Parkinson's Disease","metadata":null},{"id":"9097bed3bded41158ab6f772cb992bbf","type":"TRIAL","name":"Amitiza\u00ae Plus GoLYTELY\u00ae (PEG) Versus Placebo Plus GoLYTELY\u00ae for Outpatient Colonoscopy Preparation","canonical_id":"clinicaltrials.gov:NCT00645801","description":"Colonoscopy","metadata":null},{"id":"fe3445f9661546fbbaae7f7a09fd5a7a","type":"DRUG","name":"Amitriptyline","canonical_id":"mesh:D000639","description":null,"metadata":null},{"id":"14d8a35f94a74f21ab0235969ec5b356","type":"TRIAL","name":"Amitriptyline Regarding Nimesulide in Acute Idiopathic Adhesive Capsulitis","canonical_id":"clinicaltrials.gov:NCT01306708","description":"Adhesive Capsulitis","metadata":null},{"id":"a1d5694974034293bcdb0f1f81fb9a7a","type":"TRIAL","name":"Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT04725383","description":"Autism Spectrum Disorder; Repetitive Compulsive Behavior","metadata":null},{"id":"b941af10b94240899f89fb6bd6d82160","type":"TRIAL","name":"Amitriptyline vs GON and SON Blocks in Migraine","canonical_id":"clinicaltrials.gov:NCT04750967","description":"Migraine; Headache","metadata":null},{"id":"9ee28c772eb64ebb95e34d33f34064f9","type":"DRUG","name":"Amivantamab","canonical_id":"ncit:C124993","description":null,"metadata":null},{"id":"1fe1ac1df66a49c382ec4088475d66de","type":"TRIAL","name":"Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07744529","description":"Leptomeningeal Metastasis From Lung Cancer","metadata":null},{"id":"08fc3b0363e146f3b74bf2dc27d27a21","type":"TRIAL","name":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","canonical_id":"clinicaltrials.gov:NCT05845671","description":"Lung Cancer; Non Small Cell Lung Cancer","metadata":null},{"id":"c9eccb906b1349258e030f69cca2c66c","type":"TRIAL","name":"Amivantamab in Adenoid Cystic Carcinoma","canonical_id":"clinicaltrials.gov:NCT05074940","description":"Salivary Gland Cancer","metadata":null},{"id":"ec98546736e741efbb71e11fcbca213f","type":"TRIAL","name":"Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07808359","description":"Penile Squamous Cell Carcinoma; Metastatic Penile Squamous Cell Carcinoma","metadata":null},{"id":"bc42959593624bd3bca52d8755da50e3","type":"TRIAL","name":"Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI","canonical_id":"clinicaltrials.gov:NCT05601973","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"76a0abfe654d446ba86df00b225089e0","type":"TRIAL","name":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","canonical_id":"clinicaltrials.gov:NCT05299125","description":"Metastatic Non-small Cell Lung Cancers","metadata":null},{"id":"defc8a32314046f891fe0a8a302f86f7","type":"DRUG","name":"Amlodipine","canonical_id":"mesh:D017311","description":null,"metadata":null},{"id":"7aa923a129a0410a8c9f61d0f17fea56","type":"TRIAL","name":"Amlodipine as add-on to Olmesartan in Hypertension","canonical_id":"clinicaltrials.gov:NCT00220220","description":"Essential Hypertension","metadata":null},{"id":"d4f34d48f84e4159943bf9030ea0ff18","type":"TRIAL","name":"Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00834977","description":"Healthy","metadata":null},{"id":"3e1b0e868c6546f89af8cda267cf0911","type":"TRIAL","name":"Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00835367","description":"Healthy","metadata":null},{"id":"c6aad69d7c3c4e2bb84044e6cbe5c19b","type":"DRUG","name":"Amphetamine","canonical_id":"mesh:D000661","description":null,"metadata":null},{"id":"41346e57827e41b799e02fb1e660febb","type":"TRIAL","name":"Amping up With PemJAK","canonical_id":"clinicaltrials.gov:NCT07283822","description":"Non-Hodgkin Lymphoma; Hodgkin Disease Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Hodgkin Disease Recurrent; Gray Zone Lymphoma; Peripheral T-cell Lymphoma; Cutaneous T-Cell Lymphomas; Primary Mediastinal B Cell Lymphoma","metadata":null},{"id":"65079795632f4083833cb426d13b6f6e","type":"TRIAL","name":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07130903","description":"Metastatic Colorectal Adenocarcinoma","metadata":null},{"id":"1fe9c8b6750146738311757402aef176","type":"DRUG","name":"Amprenavir","canonical_id":"mesh:C095108","description":null,"metadata":null},{"id":"a9976228b9634b639bf7878a6b5b39a3","type":"TRIAL","name":"Ampyra for Optic Neuritis in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01337986","description":"Multiple Sclerosis; Optic Neuritis","metadata":null},{"id":"a5048353d4804f9d9200ce868cf05138","type":"TRIAL","name":"Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment","canonical_id":"clinicaltrials.gov:NCT02317783","description":"Breast Cancer","metadata":null},{"id":"e2765e8435a6482693719d7d0e0cfa2f","type":"DISEASE","name":"Amyloidosis","canonical_id":"mesh:D000686","description":null,"metadata":null},{"id":"9f35c939ae804c3c891b7a3afeb28e6d","type":"DISEASE","name":"Amyotrophic lateral sclerosis","canonical_id":"mesh:D000690","description":null,"metadata":null},{"id":"598c6095448c4cb5b4ab5b923afc80e6","type":"TRIAL","name":"An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00960076","description":"Type 2 Diabetes","metadata":null},{"id":"f944a2dd7f59435f9c06f58b561d47b3","type":"TRIAL","name":"An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence","canonical_id":"clinicaltrials.gov:NCT01062451","description":"Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse","metadata":null},{"id":"fc8366aafc7e461797d5b67603901bb5","type":"TRIAL","name":"An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00878462","description":"Psychosis","metadata":null},{"id":"925a5b9fccb945cd830a1ab13e62e78e","type":"TRIAL","name":"An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)","canonical_id":"clinicaltrials.gov:NCT01215227","description":"Parkinson Disease; Idiopathic Parkinson Disease","metadata":null},{"id":"c2c8c441ff3d4692b8356e0aeee742fe","type":"TRIAL","name":"An Acute Migraine Factorial Study","canonical_id":"clinicaltrials.gov:NCT06245902","description":"Migraine With or Without Aura","metadata":null},{"id":"cc942397ce844901af02ddb49c457842","type":"TRIAL","name":"An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment","canonical_id":"clinicaltrials.gov:NCT03335540","description":"Advanced Cancer","metadata":null},{"id":"f9ce77a344454571ab646ce96cb41fcb","type":"TRIAL","name":"An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab","canonical_id":"clinicaltrials.gov:NCT04249713","description":"Hidradenitis Suppurativa","metadata":null},{"id":"db23bd88ae9e45faaffcd67c521f06c2","type":"TRIAL","name":"An Analysis of the Relationship Between the Genetic Polymorphisms of Plasminogen Activator Inhibitor-1 and Ulcerative Colitis in Chinese Patients","canonical_id":"clinicaltrials.gov:NCT06961435","description":"Colitis, Ulcerative","metadata":null},{"id":"a78b1392194340e2abd9464a45b6d913","type":"TRIAL","name":"An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)","canonical_id":"clinicaltrials.gov:NCT00127647","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"684c8f13ffa74d6bb074fb70090dce0c","type":"TRIAL","name":"An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure","canonical_id":"clinicaltrials.gov:NCT00402103","description":"Hypertension","metadata":null},{"id":"29db22b915e14a3882fb24418f469316","type":"TRIAL","name":"An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL\u00ae","canonical_id":"clinicaltrials.gov:NCT06145217","description":"Drug-drug Interaction Study","metadata":null},{"id":"67c212941ba7407d99c1da22cd5a3545","type":"TRIAL","name":"An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT03501615","description":"Relapsed/Refractory Hairy Cell Leukemia","metadata":null},{"id":"5d4b44a4b58241b28f57a38640367e3d","type":"TRIAL","name":"An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03505528","description":"Metastatic Breast Cancer","metadata":null},{"id":"e81d375523834e2bb33e11ce30eb7943","type":"TRIAL","name":"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma","canonical_id":"clinicaltrials.gov:NCT01706198","description":"Asthma","metadata":null},{"id":"67b9d3dbec274445b08ba992d5485095","type":"TRIAL","name":"An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00269776","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"ea2a88c9676b4de4b7fe2ae6a6171ef3","type":"TRIAL","name":"An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)","canonical_id":"clinicaltrials.gov:NCT00399048","description":"Osteoarthritis, Knee; Osteoarthritis, Hip","metadata":null},{"id":"5302ae4bafaf4a168336e2a0570aa1a3","type":"TRIAL","name":"An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate","canonical_id":"clinicaltrials.gov:NCT02187055","description":"Rhematoid Arthritis","metadata":null},{"id":"e4d5cdb0709040b7b15a7e552a728cd3","type":"TRIAL","name":"An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT00410761","description":"Thyroid Cancer","metadata":null},{"id":"df4162127bde4cf4b765debf0f852584","type":"TRIAL","name":"An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00784875","description":"Primary Insomnia; Secondary Insomnia","metadata":null},{"id":"91f43be67588498a976b21f6ba884938","type":"TRIAL","name":"An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00751881","description":"Multiple Sclerosis","metadata":null},{"id":"085901069830408e851302a9ed732cd2","type":"TRIAL","name":"An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms","canonical_id":"clinicaltrials.gov:NCT00893113","description":"Erectile Dysfunction; Lower Urinary Tract Symptoms","metadata":null},{"id":"61e253b645114483a94f79216abb8e80","type":"TRIAL","name":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","canonical_id":"clinicaltrials.gov:NCT02235909","description":"Hypertension","metadata":null},{"id":"4af8d475dc734c6fad7ffeea1e68edc6","type":"TRIAL","name":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT03510884","description":"Hypercholesterolaemia","metadata":null},{"id":"a850cd006d0b435188e9ba2d04204791","type":"TRIAL","name":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT03510715","description":"Hypercholesterolemia","metadata":null},{"id":"da44008d183c43f699450e2f2db192b7","type":"TRIAL","name":"An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00269841","description":"Crohn Disease","metadata":null},{"id":"c5d67ccef48547dd8642e35f3fe9b359","type":"TRIAL","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","canonical_id":"clinicaltrials.gov:NCT02257736","description":"Prostatic Neoplasms","metadata":null},{"id":"f0039b242a85440595970e329b3cc6bd","type":"TRIAL","name":"An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01286090","description":"Gastroparesis; Diabetes Mellitus","metadata":null},{"id":"062824c3e6754c65922766deb49a46d7","type":"TRIAL","name":"An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options","canonical_id":"clinicaltrials.gov:NCT01281540","description":"Gastroparesis","metadata":null},{"id":"9cac4a365b0b4252931783258465050c","type":"TRIAL","name":"An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)","canonical_id":"clinicaltrials.gov:NCT01599494","description":"Infertility","metadata":null},{"id":"6f506ff2a2014727bc20256461419505","type":"TRIAL","name":"An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","canonical_id":"clinicaltrials.gov:NCT01916967","description":"Urticaria","metadata":null},{"id":"2fccaf51b7b54d85a9d93c4a6ca00f33","type":"TRIAL","name":"An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis","canonical_id":"clinicaltrials.gov:NCT00619866","description":"Endometriosis, Pain","metadata":null},{"id":"263a0fe976054ec1b5258714dc6fb9c7","type":"TRIAL","name":"An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01009047","description":"Schizophrenia","metadata":null},{"id":"bc94cc502d8d416a82026f3986be87d9","type":"TRIAL","name":"An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","canonical_id":"clinicaltrials.gov:NCT03952039","description":"Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis","metadata":null},{"id":"18f6f22582fe4ca3be43c6197e1738e0","type":"TRIAL","name":"An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients","canonical_id":"clinicaltrials.gov:NCT01453049","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1da132bc3f6a49148e5ea31d17eaf6d3","type":"TRIAL","name":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.","canonical_id":"clinicaltrials.gov:NCT01686633","description":"Asthma","metadata":null},{"id":"5c49478bc17d4bff9dc2a98320f5f6b7","type":"TRIAL","name":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT02301975","description":"Asthma","metadata":null},{"id":"2dacb6a859ab4a9c9866c49daa7eb472","type":"TRIAL","name":"An Efficacy and Safety Study of Fremanezumab in Adults With Migraine","canonical_id":"clinicaltrials.gov:NCT03308968","description":"Migraine Prophylaxis","metadata":null},{"id":"694ef636c3374e9999643650e374ed59","type":"TRIAL","name":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT00488631","description":"Colitis, Ulcerative","metadata":null},{"id":"31125b6b61b0448bb47ab226c1cbdc23","type":"TRIAL","name":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT00487539","description":"Colitis, Ulcerative","metadata":null},{"id":"a99eccd899d24372ad67130ffbf9e227","type":"TRIAL","name":"An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer","canonical_id":"clinicaltrials.gov:NCT01006356","description":"Cancer; Pain","metadata":null},{"id":"312b33a14e60464fa7eb5d48c54d36f4","type":"TRIAL","name":"An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants","canonical_id":"clinicaltrials.gov:NCT05835310","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"2441adf6c4864a4fa76d02aead59fde5","type":"TRIAL","name":"An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies","canonical_id":"clinicaltrials.gov:NCT02854436","description":"Prostatic Neoplasms","metadata":null},{"id":"5941a01e59fc43149336ef3d804671fa","type":"TRIAL","name":"An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT01339260","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"3dfdba6aa0504301bec818d46e228585","type":"TRIAL","name":"An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00666783","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"24fa1e71b05c449ba858bc68d68b9cd5","type":"TRIAL","name":"An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.","canonical_id":"clinicaltrials.gov:NCT03312634","description":"Fibrodysplasia Ossificans Progressiva","metadata":null},{"id":"7909dd5db14b4f3ebdecfd2a4de33789","type":"TRIAL","name":"An Efficacy and Safety Study of Palovarotene for the Treatment of MO","canonical_id":"clinicaltrials.gov:NCT03442985","description":"Exostoses, Multiple Hereditary","metadata":null},{"id":"bfcc597421fc4eeeb4ff6b73ed54e165","type":"TRIAL","name":"An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects","canonical_id":"clinicaltrials.gov:NCT02190747","description":"Fibrodysplasia Ossificans Progressiva","metadata":null},{"id":"725460a81c184c01a23124d21ec3197f","type":"TRIAL","name":"An Efficacy and Safety Study of Ravulizumab in ALS Participants","canonical_id":"clinicaltrials.gov:NCT04248465","description":"Amyotrophic Lateral Sclerosis; ALS","metadata":null},{"id":"528dc83747b348eda8aec156239007a9","type":"TRIAL","name":"An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD","canonical_id":"clinicaltrials.gov:NCT04201262","description":"Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"5ee9e221ab73490aaa7a653ca232dbc7","type":"TRIAL","name":"An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils","canonical_id":"clinicaltrials.gov:NCT02501629","description":"Asthma; Elevated Blood Eosinophils; Oral Corticosteroid Dependence","metadata":null},{"id":"87b4d85337a24520b080a66dc9e84601","type":"TRIAL","name":"An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00402181","description":"Multiple Myeloma","metadata":null},{"id":"0bc060b07a6b4d518c2ccaeb0dcef1f9","type":"TRIAL","name":"An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome","canonical_id":"clinicaltrials.gov:NCT00774930","description":"Carcinoid Syndrome","metadata":null},{"id":"5112dffe67664276b7daf558775565dd","type":"TRIAL","name":"An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)","canonical_id":"clinicaltrials.gov:NCT07706868","description":"Systemic Juvenile Idiopathic Arthritis (sJIA); Adult Onset Still's Disease (AOSD)","metadata":null},{"id":"091fcccc788f48b0b4dbc846c4fdd649","type":"TRIAL","name":"An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00723528","description":"Psoriasis","metadata":null},{"id":"8a1453210d3f47ff972dd238827c1327","type":"TRIAL","name":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02497469","description":"Colitis, Ulcerative","metadata":null},{"id":"22fa08debfbf4c5e8230cb2798303caf","type":"TRIAL","name":"An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00734071","description":"Generalized Anxiety Disorder","metadata":null},{"id":"c1b58169b43743e4affd4fc80a8956f3","type":"TRIAL","name":"An Efficacy and Safety Study w/ Azstarys\u00ae in Children 4-12 Years of Age With ADHD","canonical_id":"clinicaltrials.gov:NCT05685732","description":"Attention Deficit/Hyperactivity Disorder","metadata":null},{"id":"28942ef468714cd1b18fc33751fed841","type":"TRIAL","name":"An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache","canonical_id":"clinicaltrials.gov:NCT04860713","description":"Pain","metadata":null},{"id":"032191e3cae44033837f63a9b742a7c8","type":"TRIAL","name":"An Efficacy and Tolerability Study of TRAVATAN\u00ae Versus LUMIGAN\u00ae","canonical_id":"clinicaltrials.gov:NCT01664039","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"4be148ac657146a49d3cf98dd4e320af","type":"TRIAL","name":"An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00642278","description":"Diabetes Mellitus, Type II; Diabetes Mellitus, Non Insulin Dependent","metadata":null},{"id":"26ff0720b42d4acfb1dcc468a6765248","type":"TRIAL","name":"An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)","canonical_id":"clinicaltrials.gov:NCT06021054","description":"Thyroid Eye Disease","metadata":null},{"id":"a3d899b551f14143a76fe1b64ae6722d","type":"TRIAL","name":"An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT00822744","description":"Major Depressive Disorder","metadata":null},{"id":"71ade84485d9497fadba5a6db28b3173","type":"TRIAL","name":"An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00629551","description":"Depressive Disorder, Major","metadata":null},{"id":"ffb52cf9cff34c71852fb377339a5709","type":"TRIAL","name":"An End to the Yom Kippur (and Ramadan) Headache","canonical_id":"clinicaltrials.gov:NCT00263094","description":"Headache","metadata":null},{"id":"b42702b028534ae288377b0cc2507f1a","type":"TRIAL","name":"An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT03200912","description":"ACTINIC KERATOSIS","metadata":null},{"id":"e989df5c5c584e5db62d8edd5cebca25","type":"TRIAL","name":"An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients","canonical_id":"clinicaltrials.gov:NCT00274703","description":"Oesophagitis, Eosinophilic","metadata":null},{"id":"b1e9ac42dde34f1ba5088b063f830ecc","type":"TRIAL","name":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","canonical_id":"clinicaltrials.gov:NCT01764997","description":"Rheumatoid Arthritis","metadata":null},{"id":"7259936d217748d2bf800736457b6c79","type":"TRIAL","name":"An Evaluation of The Absolute Bioavailability of TH104","canonical_id":"clinicaltrials.gov:NCT06198686","description":"Healthy","metadata":null},{"id":"ff6667e098794adfa2a7bda265014a13","type":"TRIAL","name":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT00412932","description":"Hypertension","metadata":null},{"id":"2d0e5686432b45ec934698f3d21b683f","type":"TRIAL","name":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT00403481","description":"Hypertension","metadata":null},{"id":"0ba6a9b1943d4bc39f30c0e655edf243","type":"TRIAL","name":"An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT02211222","description":"Differentiated Thyroid Cancer","metadata":null},{"id":"3148c0f41b744d4b805477c0f76263ba","type":"TRIAL","name":"An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02784158","description":"Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma","metadata":null},{"id":"4e7f0d400ed44159a5a7164ae7377fee","type":"TRIAL","name":"An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis","canonical_id":"clinicaltrials.gov:NCT05344508","description":"Non-Cystic Fibrosis Bronchiectasis","metadata":null},{"id":"4355f18bd0e74b54a1e7dfa6de9ada6a","type":"TRIAL","name":"An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","canonical_id":"clinicaltrials.gov:NCT06939647","description":"Pulmonary Arterial Hypertension; Pulmonary Hypertension, Interstitial Lung Disease","metadata":null},{"id":"e7443cc43e1142fcb652817b578d8d74","type":"TRIAL","name":"An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT04136808","description":"Locally Advanced or Metastatic Urothelial Carcinoma (UC)","metadata":null},{"id":"2dcca133e12145e1b953867aa5bb08b7","type":"TRIAL","name":"An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT03114228","description":"FLT3-mutated Acute Myeloid Leukemia","metadata":null},{"id":"da9c5021608e4210a94786e683433335","type":"TRIAL","name":"An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation","canonical_id":"clinicaltrials.gov:NCT03810872","description":"Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation","metadata":null},{"id":"11a8cd2876744ee6b57fbfbe62708f52","type":"TRIAL","name":"An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07849712","description":"Non-small Cell Lung Cancer (NSCLC) Stage IV; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer","metadata":null},{"id":"9e38dec1080b454faef29c5b615f84d5","type":"TRIAL","name":"An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC","canonical_id":"clinicaltrials.gov:NCT06332300","description":"NSCLC","metadata":null},{"id":"03448b2510344199b9607759556bab5b","type":"TRIAL","name":"An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber","canonical_id":"clinicaltrials.gov:NCT05102409","description":"Dry Eye","metadata":null},{"id":"5fcc056fc48d4396a767f1df19df4c95","type":"TRIAL","name":"An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet\u00ae Gel Vehicle in Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT01837576","description":"Psoriasis Vulgaris","metadata":null},{"id":"b2363191a87d42a8896313b687b58b29","type":"TRIAL","name":"An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT01466478","description":"Psoriasis Vulgaris","metadata":null},{"id":"3940da685bee4ca59f6586ffa7590c24","type":"TRIAL","name":"An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma","canonical_id":"clinicaltrials.gov:NCT00599027","description":"Allergic Rhinitis; Asthma","metadata":null},{"id":"dbfdb3103010449792dcf35584c5f54a","type":"TRIAL","name":"An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07299890","description":"Breast Cancer","metadata":null},{"id":"1e66a3dc06c24405aafec9f5abd9aeeb","type":"TRIAL","name":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-na\u00efve Unresectable Advanced or Recurrent Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02394834","description":"Colorectal Cancer","metadata":null},{"id":"43958a3fbf964dbfb437b7a235ac0b27","type":"TRIAL","name":"An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02771093","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d57e55eefc374aa6862228a0640173f3","type":"TRIAL","name":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","canonical_id":"clinicaltrials.gov:NCT07482891","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"05ff85cf7eb24915b4eb7539826fe5db","type":"TRIAL","name":"An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.","canonical_id":"clinicaltrials.gov:NCT07776821","description":"Uterine Cervical Neoplasms","metadata":null},{"id":"34efc461f88045b5ac7bb9907d9e0732","type":"TRIAL","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","canonical_id":"clinicaltrials.gov:NCT07282262","description":"Biliary Tract Cancer","metadata":null},{"id":"4b8c828fbf6e4215937bef79bb5811fa","type":"TRIAL","name":"An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03227432","description":"Multiple Myeloma","metadata":null},{"id":"d1cb074ecac34284be9db62937935cb4","type":"TRIAL","name":"An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 \u03bcg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)","canonical_id":"clinicaltrials.gov:NCT00636961","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"c323db608bfc46e6a8781e08014fae69","type":"TRIAL","name":"An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD","canonical_id":"clinicaltrials.gov:NCT06987851","description":"Multiple Sclerosis","metadata":null},{"id":"b8a5d51795264325971416168707a1e9","type":"TRIAL","name":"An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab","canonical_id":"clinicaltrials.gov:NCT00930553","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"f1eeb67cad6c43a697030aab9e79dc0e","type":"TRIAL","name":"An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","canonical_id":"clinicaltrials.gov:NCT04597632","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"ef943a32267c4d91aa64cf62706d0175","type":"TRIAL","name":"An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT06540144","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"0b81371ea7404086ba8d8ff9e19c0657","type":"TRIAL","name":"An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits","canonical_id":"clinicaltrials.gov:NCT00219245","description":"Traumatic Brain Injury With Persistent Cognitive Deficits","metadata":null},{"id":"faed374656fb48fe982a0d73a1e165de","type":"TRIAL","name":"An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00215683","description":"Prostate Cancer","metadata":null},{"id":"5f0701ecfb2e4337801fe21c5b524e91","type":"TRIAL","name":"An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03950232","description":"Ulcerative Colitis","metadata":null},{"id":"e2f2d2cf59bc4024817073170a7276f5","type":"TRIAL","name":"An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)","canonical_id":"clinicaltrials.gov:NCT02335346","description":"Osteoarthritis of the Knee","metadata":null},{"id":"8138563aa48047dca327897b601e7ad1","type":"TRIAL","name":"An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04151719","description":"Pancreatic Cancer","metadata":null},{"id":"95d0e929342145e78dfda3c3f949c6a6","type":"TRIAL","name":"An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03467958","description":"Crohn Disease","metadata":null},{"id":"4f6ac9e9b1984a6181a2b14a4f72a0de","type":"TRIAL","name":"An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004","canonical_id":"clinicaltrials.gov:NCT03596164","description":"Short Bowel Syndrome","metadata":null},{"id":"5dc78d49dfd24f4285254c4c06683562","type":"TRIAL","name":"An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04130997","description":"Relapsing Multiple Sclerosis (RMS)","metadata":null},{"id":"4e3066d1c356425bb9d31935c4529a1d","type":"TRIAL","name":"An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00670449","description":"Multiple Sclerosis","metadata":null},{"id":"15960dc0da04484db325d4ca8e9512e1","type":"TRIAL","name":"An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)","canonical_id":"clinicaltrials.gov:NCT02760277","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"8dcc2a304244491b93ddadef835db65c","type":"TRIAL","name":"An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","canonical_id":"clinicaltrials.gov:NCT02925494","description":"Uterine Fibroids; Heavy Menstrual Bleeding","metadata":null},{"id":"7a113fbf22bd498ab5f867c1f7b47b98","type":"TRIAL","name":"An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).","canonical_id":"clinicaltrials.gov:NCT03583372","description":"Overactive Bladder","metadata":null},{"id":"2a35d6a629c7438dac879bab3be8b1dd","type":"TRIAL","name":"An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).","canonical_id":"clinicaltrials.gov:NCT01076010","description":"Advanced Renal Cell Carcinoma","metadata":null},{"id":"00c7e652f2374444aacfdac29c81d898","type":"TRIAL","name":"An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00263068","description":"Restless Legs Syndrome","metadata":null},{"id":"0b06162219b24ec0bd423f55cf0c431e","type":"TRIAL","name":"An Extension of the TG1101-RMS201 Trial","canonical_id":"clinicaltrials.gov:NCT03381170","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"64c6658074434ff7844c7de24b1b52c2","type":"TRIAL","name":"An Extension to Study MD7108240","canonical_id":"clinicaltrials.gov:NCT00733304","description":"Macular Degeneration","metadata":null},{"id":"3c830b810b074d1d88e8bc811ecf0d44","type":"TRIAL","name":"An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes","canonical_id":"clinicaltrials.gov:NCT02911857","description":"Periodic Fevers Syndrome","metadata":null},{"id":"89135722df884302b2296891990a73f7","type":"TRIAL","name":"An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation","canonical_id":"clinicaltrials.gov:NCT02937168","description":"Asthma","metadata":null},{"id":"a2b1efca86124a25b99d923cd8dcec2f","type":"TRIAL","name":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer","canonical_id":"clinicaltrials.gov:NCT01658878","description":"Hepatocellular Carcinoma","metadata":null},{"id":"2f2aefc94fbb40d8b9d039c71bbd8dc2","type":"TRIAL","name":"An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)","canonical_id":"clinicaltrials.gov:NCT03518086","description":"Ulcerative Colitis","metadata":null},{"id":"2ad6701e951b402196db27300e62595b","type":"TRIAL","name":"An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03243331","description":"Triple Negative Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"d1ba2181ff1043e5a5e2a11fdc161d22","type":"TRIAL","name":"An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT03514641","description":"Essential Hypertension","metadata":null},{"id":"226837b0bac7470c90e91b60da083d73","type":"TRIAL","name":"An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT03606577","description":"Multiple Myeloma","metadata":null},{"id":"e8bc8c1533104e9495b124a011583d4b","type":"TRIAL","name":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT00764465","description":"Healthy","metadata":null},{"id":"fbc0f34e31df49e48ee27ef2759b90b9","type":"TRIAL","name":"An Intermediate Expanded Use Trial of DFMO","canonical_id":"clinicaltrials.gov:NCT03581240","description":"Neuroblastoma; Medulloblastoma; Typical Teratoid Rhabdoid Tumor; Embryonal Tumor With Abundant Neuropil and True Rosettes; Ependymoblastoma; Medulloepithelioma","metadata":null},{"id":"6183edd812094d80b6a4c7ab44a977d2","type":"TRIAL","name":"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT05385744","description":"Multiple Sclerosis","metadata":null},{"id":"b26b72d261c843d69a2094f55391aae9","type":"TRIAL","name":"An Interventional Study of Infigratinib in Children With Hypochondroplasia","canonical_id":"clinicaltrials.gov:NCT06873035","description":"Hypochondroplasia","metadata":null},{"id":"9950615e617547a1803776f825167556","type":"TRIAL","name":"An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation","canonical_id":"clinicaltrials.gov:NCT00731562","description":"Pharmacokinetics; Bioavailability; Smoking Cessation","metadata":null},{"id":"62070d35f73d4753a8b4ca697b8e2930","type":"TRIAL","name":"An Investigation of Early Life Stress and Depression","canonical_id":"clinicaltrials.gov:NCT01701258","description":"Major Depressive Disorder (MDD); History of Childhood Sexual Abuse (CSA)","metadata":null},{"id":"1ea794e62e5542fdb176b4b6e26dbb88","type":"TRIAL","name":"An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults","canonical_id":"clinicaltrials.gov:NCT07578363","description":"Ocular Hyperemia","metadata":null},{"id":"74c429d66ad64a49a5e1f7dcd88849b6","type":"TRIAL","name":"An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00122018","description":"Kidney Failure, Acute; Kidney Failure, Chronic; Cardiac Surgical Procedures","metadata":null},{"id":"b4bd4618eba74da59ac5a50076c1b88b","type":"TRIAL","name":"An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation","canonical_id":"clinicaltrials.gov:NCT07674966","description":"Myopia","metadata":null},{"id":"51210dd9efbd46e594ff68625daa86bc","type":"TRIAL","name":"An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092638","description":"Hypercholesterolemia; Coronary Disease","metadata":null},{"id":"c7841c2579d84e81bde3d13a07ba63cc","type":"TRIAL","name":"An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092677","description":"Aortic Stenosis","metadata":null},{"id":"c0f04c54e79c4c90b6b7f941285ae55e","type":"TRIAL","name":"An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT02581631","description":"Non-Hodgkin's Disease","metadata":null},{"id":"123e7519806a4c32b733917385dd3195","type":"TRIAL","name":"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors","canonical_id":"clinicaltrials.gov:NCT02488759","description":"Various Advanced Cancer","metadata":null},{"id":"111bbd4b2c444f7f970201e58ef3ce17","type":"TRIAL","name":"An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02750514","description":"Advanced Cancer","metadata":null},{"id":"308765103b19404cb6f45ec7ab3fefae","type":"TRIAL","name":"An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02477826","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"d8db3214c45246c0ada1236001d323fd","type":"TRIAL","name":"An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)","canonical_id":"clinicaltrials.gov:NCT02654132","description":"Multiple Myeloma","metadata":null},{"id":"13429f95455c44a887c199bebe68ff15","type":"TRIAL","name":"An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers","canonical_id":"clinicaltrials.gov:NCT03994601","description":"Advanced Cancer","metadata":null},{"id":"2ba3701c21604044a85ef24f870c0580","type":"TRIAL","name":"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03338790","description":"Prostate Cancer","metadata":null},{"id":"1a7c4f4404e047d996e1e819303ddf9a","type":"TRIAL","name":"An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT05376878","description":"Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain","metadata":null},{"id":"ebcc7803c7144a549597e04ecffdf338","type":"TRIAL","name":"An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread","canonical_id":"clinicaltrials.gov:NCT03459222","description":"Advanced Cancer","metadata":null},{"id":"1360521d0a5e4a78ace08b503df9dfb3","type":"TRIAL","name":"An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)","canonical_id":"clinicaltrials.gov:NCT00127101","description":"Lymphoma","metadata":null},{"id":"66927f2d4f9948b6acd4dd02df8ca950","type":"TRIAL","name":"An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis","canonical_id":"clinicaltrials.gov:NCT05124080","description":"Nail Psoriasis","metadata":null},{"id":"0498818a957844d388d5e85563712bc9","type":"TRIAL","name":"An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01105234","description":"Irritation","metadata":null},{"id":"c11e5fa99a1341e5bab166bffc907fe1","type":"TRIAL","name":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","canonical_id":"clinicaltrials.gov:NCT06013475","description":"Non-metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"e884b9eda86044a2ac1238bee77efc4a","type":"TRIAL","name":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","canonical_id":"clinicaltrials.gov:NCT01498770","description":"Bipolar Disorder","metadata":null},{"id":"ea2d7a6c09904ae497a201a7c27ac6af","type":"TRIAL","name":"An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm\u00ae in Treatment of Type 2 Diabetes in Routine Clinical Practice","canonical_id":"clinicaltrials.gov:NCT01498900","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"0afb5e210bda45c6bc457c982b392b8c","type":"TRIAL","name":"An Observational Study For Ambrisentan","canonical_id":"clinicaltrials.gov:NCT00679224","description":"Hypertension, Pulmonary","metadata":null},{"id":"064515a37c4a4951aa33101837bf43d1","type":"TRIAL","name":"An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients","canonical_id":"clinicaltrials.gov:NCT01077570","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"9ca5b8e908634a06b0c2f98f8393930f","type":"TRIAL","name":"An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders","canonical_id":"clinicaltrials.gov:NCT04616807","description":"Myotonic Dystrophy","metadata":null},{"id":"227e3d2bd25e424cb3be810466260d5a","type":"TRIAL","name":"An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2","canonical_id":"clinicaltrials.gov:NCT02756832","description":"Diabetes Mellitus","metadata":null},{"id":"c2d5b2cee7a44ff7b6bee0dfc2237fe0","type":"TRIAL","name":"An Observational Study of Cetrotide\u00ae Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f\u00ae in Assisted Reproductive Technologies (ART)","canonical_id":"clinicaltrials.gov:NCT01109654","description":"Infertility","metadata":null},{"id":"af0820eb5fef4116969fb069e905a158","type":"TRIAL","name":"An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT06398626","description":"Colitis, Ulcerative","metadata":null},{"id":"fbb220caa6cc4dea96547bbf621f640f","type":"TRIAL","name":"An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride","canonical_id":"clinicaltrials.gov:NCT01021670","description":"Sexual Dysfunction, Physiological; Ejaculation","metadata":null},{"id":"8d4f842fdbaf42f78a55b3d17eb3644b","type":"TRIAL","name":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","canonical_id":"clinicaltrials.gov:NCT01447446","description":"Hepatitis C, Chronic","metadata":null},{"id":"345b650d49284353aaefffa8e07d2e58","type":"TRIAL","name":"An Observational Study on Sarilumab-exposed Pregnancies","canonical_id":"clinicaltrials.gov:NCT03378219","description":"Rheumatoid Arthritis -Exposure During Pregnancy","metadata":null},{"id":"5d2f38e7d3c34d9f8f46a35885f0c91f","type":"TRIAL","name":"An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe","canonical_id":"clinicaltrials.gov:NCT05363319","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"7d2d3b29bc474e46893532d1993a4a3d","type":"TRIAL","name":"An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP","canonical_id":"clinicaltrials.gov:NCT02338414","description":"Immune Thrombocytopenia","metadata":null},{"id":"1a71b4d31b02453bba13676b6a71edd0","type":"TRIAL","name":"An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas\u00ae (NIS ENEAS ISH)","canonical_id":"clinicaltrials.gov:NCT01074281","description":"Hypertension","metadata":null},{"id":"4349c8ab8fce45bea84f689f0a223d6d","type":"TRIAL","name":"An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States","canonical_id":"clinicaltrials.gov:NCT06029010","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"de4149b364444bfd998586eda526094d","type":"TRIAL","name":"An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT01914666","description":"Back Pain Lower Back Chronic","metadata":null},{"id":"e66be9c0bd9c482e8d75ae64180b06ac","type":"TRIAL","name":"An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT01064973","description":"Autism Spectrum Disorders","metadata":null},{"id":"33918a77201e48ba80e8b7e7706cf36e","type":"TRIAL","name":"An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients","canonical_id":"clinicaltrials.gov:NCT02003144","description":"Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"c7756ca78e9a4caab4bbdf4f47fe36b0","type":"TRIAL","name":"An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children","canonical_id":"clinicaltrials.gov:NCT00791700","description":"Human Immunodeficiency Virus","metadata":null},{"id":"a9cc3035298f4cd4a2742abdb80a603a","type":"TRIAL","name":"An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced \" Cold \" Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03864575","description":"Metastatic Cancer","metadata":null},{"id":"28ae26e8cc07411aa35cf2aaf74aaa7d","type":"TRIAL","name":"An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06015321","description":"Prostatic Adenocarcinoma","metadata":null},{"id":"73458a3d04e743c799f8161eedf4b8e9","type":"TRIAL","name":"An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT01587118","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"317452dcd33a4299bbe463c94f77c213","type":"TRIAL","name":"An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03237260","description":"Ulcerative Colitis","metadata":null},{"id":"5681fb6824404897b9d26fc929d9e5e7","type":"TRIAL","name":"An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy","canonical_id":"clinicaltrials.gov:NCT05055024","description":"Narcolepsy With Cataplexy; Narcolepsy; Narcolepsy Without Cataplexy","metadata":null},{"id":"c7cb66d6c2854736813a276bee5ec893","type":"TRIAL","name":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","canonical_id":"clinicaltrials.gov:NCT00508820","description":"Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura","metadata":null},{"id":"e689853b34d848aeb70aecfe9935f16b","type":"TRIAL","name":"An Open Label Study of Severe Sepsis in Adults","canonical_id":"clinicaltrials.gov:NCT00568893","description":"Severe Sepsis","metadata":null},{"id":"81bc0b2be507495381c085887f44dad0","type":"TRIAL","name":"An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT01607346","description":"Epilepsy","metadata":null},{"id":"a6083f42c1b841488ea3995dbd12045e","type":"TRIAL","name":"An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT02985398","description":"Migraine Disorder","metadata":null},{"id":"307c56d6740d4ea8bfc60fe16a7700c4","type":"TRIAL","name":"An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD","canonical_id":"clinicaltrials.gov:NCT00327470","description":"Age Related Macular Degeneration (AMD); Macular Degeneration; Choroidal Neovascularization (CNV)","metadata":null},{"id":"d0dac98feea545c8a7320b359720d483","type":"TRIAL","name":"An Open Label, Balanced, Randomized, 3\u00d73 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.","canonical_id":"clinicaltrials.gov:NCT05622370","description":"Partial Seizure","metadata":null},{"id":"5bdf84f39c154729ab283779655632c3","type":"TRIAL","name":"An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)","canonical_id":"clinicaltrials.gov:NCT01742793","description":"Hodgkin's Lymphoma; Mature T-cell Lymphoma; Multiple Myeloma","metadata":null},{"id":"dd4260e0fed2425c95a902f58860e3f9","type":"TRIAL","name":"An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)","canonical_id":"clinicaltrials.gov:NCT01535664","description":"Multiple Sclerosis","metadata":null},{"id":"d9ba85981dc147208e051255768bb16f","type":"TRIAL","name":"An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients","canonical_id":"clinicaltrials.gov:NCT05569577","description":"Luteal Phase Deficiency; Luteal Phase Support; Idiopathic Hypogonadotropic Hypogonadism","metadata":null},{"id":"19a657c8d02f4fda8047da02fcb6ce6e","type":"TRIAL","name":"An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19","canonical_id":"clinicaltrials.gov:NCT04527133","description":"COVID-19","metadata":null},{"id":"bbc470f486bf46d1b6436d32f541d683","type":"TRIAL","name":"An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa","canonical_id":"clinicaltrials.gov:NCT06518941","description":"Anorexia Nervosa","metadata":null},{"id":"7ba615c2d84b4854a68ff63559e3132c","type":"TRIAL","name":"An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.","canonical_id":"clinicaltrials.gov:NCT04183634","description":"Parkinson Disease","metadata":null},{"id":"25744e8359d847d99905d5e89f3c156d","type":"TRIAL","name":"An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02157558","description":"Drug Interactions","metadata":null},{"id":"49755d8f55f6417a8bcd66c5eec38f39","type":"TRIAL","name":"An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg","canonical_id":"clinicaltrials.gov:NCT00399295","description":"Analgesia","metadata":null},{"id":"80327f20b84244aa826dc43f890082d9","type":"TRIAL","name":"An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)","canonical_id":"clinicaltrials.gov:NCT05243680","description":"Asthma","metadata":null},{"id":"d25cffecbd674080b4786d8eefa4f99e","type":"TRIAL","name":"An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)","canonical_id":"clinicaltrials.gov:NCT02279095","description":"Fibrodysplasia Ossificans Progressiva","metadata":null},{"id":"67784657c652465a972e81a879eaf8d1","type":"TRIAL","name":"An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.","canonical_id":"clinicaltrials.gov:NCT06549400","description":"Myotonic Dystrophy","metadata":null},{"id":"bc1faa2c83174ad996a5fc1dcc8b0381","type":"TRIAL","name":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00594386","description":"Parkinson's Disease","metadata":null},{"id":"8e5f05cd283a4e2ca8b7fdae7eb99fee","type":"TRIAL","name":"An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)","canonical_id":"clinicaltrials.gov:NCT00200447","description":"Parkinson's Disease","metadata":null},{"id":"e13e96cd8e8b4171becd1f19d36704c6","type":"TRIAL","name":"An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01462318","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"b5d7f9b8acf245fb9d66ae122c71902a","type":"TRIAL","name":"An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.","canonical_id":"clinicaltrials.gov:NCT00426673","description":"Epilepsy","metadata":null},{"id":"9e9daae7bbff4ca981d8effc6ece9c90","type":"TRIAL","name":"An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder","canonical_id":"clinicaltrials.gov:NCT07812181","description":"Down Syndrome Regression Disorder (DSRD); Down Syndrome (Trisomy 21); Neuroinflammatory / Neuropsychiatric Disorder","metadata":null},{"id":"6aaf3cebb1e64130ad5b9ced13d351c8","type":"TRIAL","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT03533283","description":"Non-Hodgkins Lymphoma","metadata":null},{"id":"a5922167b043421e81bb4016be6a257c","type":"TRIAL","name":"An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)","canonical_id":"clinicaltrials.gov:NCT04950764","description":"Primary Biliary Cholangitis; Compensated Cirrhosis; Hepatic Impairment","metadata":null},{"id":"3f81ffc04a35432fa9a64b78df20d5f1","type":"TRIAL","name":"An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00191516","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"b07c23e67b88450d87db731cf10e7ba7","type":"TRIAL","name":"An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)","canonical_id":"clinicaltrials.gov:NCT00242736","description":"GERD","metadata":null},{"id":"cd0f8f61ab284245aa65e95f53fe068d","type":"TRIAL","name":"An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT00826878","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"a6d6c351fbe24442b83c6666ec18f9b5","type":"TRIAL","name":"An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01822756","description":"Solid Tumors; Pancreatic Cancer","metadata":null},{"id":"a1e5e1d57f104cecb9d5c7d91c63a01f","type":"TRIAL","name":"An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia","canonical_id":"clinicaltrials.gov:NCT00379847","description":"Hyponatremia","metadata":null},{"id":"0b3988497026477197b3fb78ea7ed8a8","type":"TRIAL","name":"An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)","canonical_id":"clinicaltrials.gov:NCT00795522","description":"Urticaria","metadata":null},{"id":"aa020a72e6084a56b134a2c38756fbd1","type":"TRIAL","name":"An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation","canonical_id":"clinicaltrials.gov:NCT01230762","description":"Ejaculation; Erectile Dysfunction; Sexual Dysfunction","metadata":null},{"id":"de8e82868a114fe18c5e752da77eee2a","type":"TRIAL","name":"An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS","canonical_id":"clinicaltrials.gov:NCT00002142","description":"Cytomegalovirus Retinitis; HIV Infections","metadata":null},{"id":"c325cb3eb2134179ae26860f908fd152","type":"TRIAL","name":"An Open-Label Study to Assess the Rate of Failure of an Enbrel\u00ae (Etanercept) SureClick\u2122 Auto-injector in Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00346294","description":"Rheumatoid Arthritis","metadata":null},{"id":"509fab14347c4a4aabb68dea266bb4bf","type":"TRIAL","name":"An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS","canonical_id":"clinicaltrials.gov:NCT06249997","description":"APDS Gene Mutation","metadata":null},{"id":"4d4332bc1bd24d0a956f72b07ceb7473","type":"TRIAL","name":"An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT01850355","description":"Autism Spectrum Disorders; Anxiety","metadata":null},{"id":"3651818b879b4217b7b26ccfd8c5a541","type":"TRIAL","name":"An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT01338636","description":"Exercise-induced Pulmonary Arterial Hypertension","metadata":null},{"id":"f807e3af89a1435d987f50a9bb72c5c3","type":"TRIAL","name":"An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses","canonical_id":"clinicaltrials.gov:NCT04549792","description":"Ichthyosis","metadata":null},{"id":"1eec059ee140427bab39e9abfc8a84a8","type":"TRIAL","name":"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","canonical_id":"clinicaltrials.gov:NCT00765999","description":"Chronic Constipation; Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"eeb512e5983c4101903bb99e680bcca9","type":"TRIAL","name":"An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS\u00ae (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT02590432","description":"Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation","metadata":null},{"id":"b59c742fdc7a458fa76b4b4b80e23d52","type":"TRIAL","name":"An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory","canonical_id":"clinicaltrials.gov:NCT01240421","description":"Metastatic Breast Cancer","metadata":null},{"id":"ce5db5f29a634528b1a2525a26246eae","type":"TRIAL","name":"An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia","canonical_id":"clinicaltrials.gov:NCT01105793","description":"Moderate to Severe Cyclic Mastalgia","metadata":null},{"id":"66dfde07cd984b23988d6cc90e1dd490","type":"TRIAL","name":"An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT00421980","description":"Ankylosing Spondylitis","metadata":null},{"id":"daf0ea45c1bf4abb82775d2cd300bf31","type":"TRIAL","name":"An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02211014","description":"Multiple Myeloma (MM)","metadata":null},{"id":"9db52458e688456d80cabd3959cb38fa","type":"TRIAL","name":"An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)","canonical_id":"clinicaltrials.gov:NCT01498445","description":"Leukemia","metadata":null},{"id":"dfbcc96188eb4b4d9feb73ba6958b4fb","type":"TRIAL","name":"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT02657343","description":"Breast Cancer","metadata":null},{"id":"b10b02ecbec747679f388ebc1d454062","type":"TRIAL","name":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","canonical_id":"clinicaltrials.gov:NCT03167437","description":"Crohn's Disease","metadata":null},{"id":"3cf5f01918204c66a5e1070be1d41771","type":"TRIAL","name":"An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum","canonical_id":"clinicaltrials.gov:NCT03137160","description":"Pyoderma Gangrenosum","metadata":null},{"id":"11eb27ed8c864d0daca37025ee6c040c","type":"TRIAL","name":"An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR","canonical_id":"clinicaltrials.gov:NCT07097701","description":"Myotonia","metadata":null},{"id":"3a73dacd69f74717acae104bdc6f3c80","type":"TRIAL","name":"An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT03911869","description":"Brain Metastases","metadata":null},{"id":"8171490dd9334be49fd7144120d87c8c","type":"TRIAL","name":"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.","canonical_id":"clinicaltrials.gov:NCT02316847","description":"Epilepsy","metadata":null},{"id":"af016c2d76ae42b4bd0cb01f82a6c5f7","type":"TRIAL","name":"An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT03817853","description":"Advanced Follicular Lymphoma","metadata":null},{"id":"2fbdd0720b9344f899eced5562204888","type":"TRIAL","name":"An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms","canonical_id":"clinicaltrials.gov:NCT01413711","description":"Infantile Spasms","metadata":null},{"id":"eae0e51645dd4246b5c1fb17b918a6f2","type":"TRIAL","name":"An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms","canonical_id":"clinicaltrials.gov:NCT05956600","description":"Schizophrenia, Treatment-Resistant","metadata":null},{"id":"274c374594ea4ce7886d94a77487b695","type":"TRIAL","name":"An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT01765855","description":"Health Volunteers","metadata":null},{"id":"1b7e8af78e324eaa82606befc00cd426","type":"TRIAL","name":"An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria","canonical_id":"clinicaltrials.gov:NCT01620268","description":"Viruria; Viremia","metadata":null},{"id":"4ff59dab4d734ca6bac524198123ba66","type":"TRIAL","name":"An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease","canonical_id":"clinicaltrials.gov:NCT00632736","description":"Parkinson Disease; Parkinson's Disease","metadata":null},{"id":"187b4aeea53e4e62bed0b7d612858683","type":"TRIAL","name":"An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02049138","description":"Rheumatoid Arthritis","metadata":null},{"id":"afd97cfc72864672b30ae77af10e24d2","type":"TRIAL","name":"An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain","canonical_id":"clinicaltrials.gov:NCT00487435","description":"Pain; Osteoarthritis; Low Back Pain","metadata":null},{"id":"3a199a3edb0a47258dcdc9a83bbe451b","type":"TRIAL","name":"An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044","canonical_id":"clinicaltrials.gov:NCT02319642","description":"Rheumatoid Arthritis","metadata":null},{"id":"a6788443cb684bac92be19157a61f458","type":"TRIAL","name":"An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin","canonical_id":"clinicaltrials.gov:NCT00678743","description":"Dyslipidemias","metadata":null},{"id":"86011372ee3d4da2bff08b90b62a26fa","type":"TRIAL","name":"An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT01129024","description":"Immune Thrombocytopenia","metadata":null},{"id":"0702ba06a3bd40a09b27eda4ae8fcf46","type":"TRIAL","name":"An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT01518309","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"a5c2c28d7f784a5da24a11871d18f036","type":"TRIAL","name":"An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease","canonical_id":"clinicaltrials.gov:NCT05174039","description":"Batten Disease","metadata":null},{"id":"d024b5bf82ae4219bd88cbb6a5de5b4c","type":"TRIAL","name":"An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301","canonical_id":"clinicaltrials.gov:NCT06179875","description":"Thyroid Eye Disease","metadata":null},{"id":"c9acc56958fb4090b5cf1246c53f8ac9","type":"TRIAL","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04305795","description":"Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Locally Advanced Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma","metadata":null},{"id":"abd54238cc81447aa022b0d593f65332","type":"TRIAL","name":"An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03915951","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"735641f4ec0844fc80e0b375b63f27d8","type":"TRIAL","name":"An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00337285","description":"Attention Deficit Hyperactivity Disorder; Attention Deficit Disorders With Hyperactivity; Attention Deficit Hyperactivity Disorders","metadata":null},{"id":"9a342cd0df4e4104b92a8c46b134d434","type":"TRIAL","name":"An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice","canonical_id":"clinicaltrials.gov:NCT05369832","description":"Colitis, Ulcerative","metadata":null},{"id":"bc260c184e094c3f8a87ece2b1cdc067","type":"TRIAL","name":"An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females","canonical_id":"clinicaltrials.gov:NCT01403038","description":"Folliculogenesis","metadata":null},{"id":"f3bb3f76da7f4bdfb6683744ca99afe5","type":"TRIAL","name":"An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia","canonical_id":"clinicaltrials.gov:NCT04173260","description":"Dystonia, Primary","metadata":null},{"id":"4994f8869d3e4567bfeb2405a6bc6179","type":"TRIAL","name":"An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT01796301","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"d826de5629984d25a0407fe3e60c6007","type":"TRIAL","name":"An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults","canonical_id":"clinicaltrials.gov:NCT01753193","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"8b54dc4b1bbf47318f04d162428c61a6","type":"TRIAL","name":"An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT06668181","description":"Enthesitis-related Arthritis; Juvenile Psoriatic Arthritis","metadata":null},{"id":"3bcca81ddd21417ab2e76195ca106b50","type":"TRIAL","name":"An Open-label Study to Identify Molecular Markers of Steroid Resistance","canonical_id":"clinicaltrials.gov:NCT01616160","description":"Nasal Polyps","metadata":null},{"id":"628e8b2c05bb475f861f51b5883694ee","type":"TRIAL","name":"An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","canonical_id":"clinicaltrials.gov:NCT02776735","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"50c19c09db864627afad1a338a423d84","type":"TRIAL","name":"An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates","canonical_id":"clinicaltrials.gov:NCT06686628","description":"Dermatitis Atopic","metadata":null},{"id":"7f213c9d836647f9ba5e0ad5ab7abd03","type":"TRIAL","name":"An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium","canonical_id":"clinicaltrials.gov:NCT00428701","description":"Gastric Ulcer","metadata":null},{"id":"2b50e8efb61f4c3b890af767a4726748","type":"TRIAL","name":"An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT03934086","description":"Migraine","metadata":null},{"id":"a6a050237f2f445dae58fcb3e1bb8c1b","type":"TRIAL","name":"An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.","canonical_id":"clinicaltrials.gov:NCT03320876","description":"Psoriatic Arthritis","metadata":null},{"id":"0e58b3cae0704e648a82eff7954da615","type":"TRIAL","name":"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","canonical_id":"clinicaltrials.gov:NCT00730171","description":"Irritable Bowel Syndrome With Constipation; Chronic Constipation","metadata":null},{"id":"8c9146764bea4064b5cc923b56e21086","type":"TRIAL","name":"An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination","canonical_id":"clinicaltrials.gov:NCT00618774","description":"Hypertension","metadata":null},{"id":"1203a410919c4cfe9ec38868b942b5d1","type":"TRIAL","name":"An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","canonical_id":"clinicaltrials.gov:NCT01676948","description":"Systemic Juvenile Idiopathic Arthritis","metadata":null},{"id":"26962ff9edd94449953fcc7d7e985839","type":"TRIAL","name":"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.","canonical_id":"clinicaltrials.gov:NCT01582061","description":"Cushing's Disease","metadata":null},{"id":"eb6eaca212e64193a339f033318726f1","type":"TRIAL","name":"An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly","canonical_id":"clinicaltrials.gov:NCT01995734","description":"Acromegaly","metadata":null},{"id":"f5c4986b6a4a4f048d2236f0b8849ebf","type":"TRIAL","name":"An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia","canonical_id":"clinicaltrials.gov:NCT04742699","description":"Insomnia","metadata":null},{"id":"7f713153eac84a90baa0322ec996aa1f","type":"TRIAL","name":"An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01945710","description":"Solid Tumors","metadata":null},{"id":"da293c94acf0410687d0d5618c4ba0ff","type":"TRIAL","name":"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam","canonical_id":"clinicaltrials.gov:NCT00761774","description":"Epilepsy","metadata":null},{"id":"f8accbef3fb04e6a92b861d6071ea4ad","type":"TRIAL","name":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02213926","description":"Mantle Cell Lymphoma (MCL)","metadata":null},{"id":"6f7a6054bda443829ea9934251788d14","type":"TRIAL","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenstr\u00f6m Macroglobulinemia","canonical_id":"clinicaltrials.gov:NCT02180724","description":"Waldenstr\u00f6m Macroglobulinemia (WM)","metadata":null},{"id":"e081cdc949da4c7a8789e92e0d00cbea","type":"TRIAL","name":"An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT05214794","description":"Systemic Sclerosis","metadata":null},{"id":"8c5af27c91d542b1b27373290228c02f","type":"TRIAL","name":"An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1\uff08Programmed Cell Death Protein 1\uff09 Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients","canonical_id":"clinicaltrials.gov:NCT04885413","description":"Recurrent/ Advanced Stage Endometrial Cancer Patients","metadata":null},{"id":"04a2f8621d9746f6b67836dd0821af35","type":"TRIAL","name":"An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors","canonical_id":"clinicaltrials.gov:NCT07639840","description":"Immune-related Dermatitis","metadata":null},{"id":"487a388945fc4cb59088f3c61eb4f14d","type":"TRIAL","name":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.","canonical_id":"clinicaltrials.gov:NCT06855849","description":"RAS/BRAF Wild-type Advanced Colorectal Cancer Patients","metadata":null},{"id":"967e6a5759ed4316877843d4760c8d41","type":"TRIAL","name":"An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed","canonical_id":"clinicaltrials.gov:NCT01583036","description":"Epilepsy","metadata":null},{"id":"d3241a0a2a4b4deeb7cd6c5afcd7bed7","type":"TRIAL","name":"An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects","canonical_id":"clinicaltrials.gov:NCT03240809","description":"Psoriasis","metadata":null},{"id":"51c827224d404a96941f7a76ce35335c","type":"TRIAL","name":"An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers","canonical_id":"clinicaltrials.gov:NCT01514019","description":"Healthy","metadata":null},{"id":"dd8666f575354593884658426b807799","type":"TRIAL","name":"An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT05038878","description":"Mild Autonomous Cortisol Excess","metadata":null},{"id":"b80a9e73e84742e4919a2646b89df093","type":"TRIAL","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07371663","description":"Solid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer; Endometrial Cancer; Malignant Melanoma","metadata":null},{"id":"9f91f8806d3c48838aed6e637875894a","type":"TRIAL","name":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","canonical_id":"clinicaltrials.gov:NCT07141771","description":"SCLC, Extensive Stage","metadata":null},{"id":"a1e8790792ba444dabfeb1e3a3a68fff","type":"TRIAL","name":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","canonical_id":"clinicaltrials.gov:NCT04395989","description":"TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"9e1ad2e385a4465c8e741e02df15df8c","type":"TRIAL","name":"An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.","canonical_id":"clinicaltrials.gov:NCT03775421","description":"Congenital Heart Disease With Fontan Circulation","metadata":null},{"id":"53035142d7cd4cf88c7c64f9fe796441","type":"TRIAL","name":"An fMRI Study of Opioid-related Changes in Neural Activity","canonical_id":"clinicaltrials.gov:NCT02818036","description":"Social Acceptance","metadata":null},{"id":"1c329e7cd67e4f71b4152caf36d49ef6","type":"TRIAL","name":"An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism","canonical_id":"clinicaltrials.gov:NCT00263796","description":"Autism","metadata":null},{"id":"34bbe318d21a4cd7919ac914caa21d97","type":"TRIAL","name":"Anabolic Steroid and Propranolol in Paediatric Burn","canonical_id":"clinicaltrials.gov:NCT05805553","description":"Arrest; Bone; Development; Growth","metadata":null},{"id":"ab880f5b0e7a49f0a8a200c4fef4e288","type":"TRIAL","name":"Anabolic Steroids and Exercise in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT00250536","description":"End-Stage Renal Disease; Muscle Weakness","metadata":null},{"id":"a16395c8fe884a7a943cda2a34df79ab","type":"TRIAL","name":"Anabolic Steroids for Nutritional Rehabilitation of Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT00242463","description":"Malnutrition; Critical Illness","metadata":null},{"id":"f90a2b65c3494def8fab8033b009b5ca","type":"TRIAL","name":"Anabolic Therapy in Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT05010590","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"31584930b38b4c82b9aa24f67096c2fa","type":"DRUG","name":"Anagrelid","canonical_id":"mesh:C021139","description":null,"metadata":null},{"id":"20acd0d4c3e6492e9aa76a05c663a773","type":"TRIAL","name":"Anagrelide Retard in Essential Thrombocythemia","canonical_id":"clinicaltrials.gov:NCT02076815","description":"Essential Thrombocythemia","metadata":null},{"id":"6375d37f561b42128959266a51cea3a0","type":"TRIAL","name":"Anagrelide Retard vs. Placebo: Efficacy and Safety in \"At-risk\" Patients With Essential Thrombocythaemia","canonical_id":"clinicaltrials.gov:NCT01230775","description":"Essential Thrombocythaemia","metadata":null},{"id":"6d577725aaf64f569152d948e3cdb891","type":"TRIAL","name":"Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia","canonical_id":"clinicaltrials.gov:NCT01065038","description":"Essential Thrombocythaemia","metadata":null},{"id":"36ffdca6b5ea40649ceda6fe2906fdbf","type":"DRUG","name":"Anakinra","canonical_id":"mesh:D053590","description":null,"metadata":null},{"id":"a06ca88903314a1d819f220fea936b7a","type":"TRIAL","name":"Anakinra and Kawasaki Disease","canonical_id":"clinicaltrials.gov:NCT02390596","description":"Kawasaki Disease; Children","metadata":null},{"id":"bb88e21c8c9345c58db431a099afa5a4","type":"TRIAL","name":"Anakinra as a Treatment for Hydradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT01516749","description":"Hidradenitis Suppurativa","metadata":null},{"id":"ceaedffe755c4f92a9ef3ac7e0876223","type":"TRIAL","name":"Anakinra for Inflammatory Pustular Skin Diseases","canonical_id":"clinicaltrials.gov:NCT01794117","description":"Sneddon-Wilkinson; Acrodermatitis Continua of Hallopeau; Pustular Psoriasis; Palmoplantar Pustulosis","metadata":null},{"id":"ecdc4392b9fd4f96ba37653d4e0598c6","type":"TRIAL","name":"Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease","canonical_id":"clinicaltrials.gov:NCT07580079","description":"Postprandial Hypoglycemia; End-stage Renal Disease (ESRD); Gastrectomy; Glucose Metabolism Disorders; Inflammation; Gastric Bypass Surgery","metadata":null},{"id":"a67f9b13c66c44d99fc71a4abd444e69","type":"TRIAL","name":"Anakinra in Dengue With Hyperinflammation ( AnaDen )","canonical_id":"clinicaltrials.gov:NCT05611710","description":"Dengue; Dengue With Warning Signs; Severe Dengue; Anakinra; Immuno-modulation; Anti-inflammatory Agents; Macrophage Activation Syndrome; Hyperinflammatory Syndrome; Cytokine Storm","metadata":null},{"id":"caf56bd9159240a1a906589f16145bfe","type":"TRIAL","name":"Anakinra in the Management of COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04643678","description":"Covid19; Pneumonia; Cytokine Release Syndrome; Corona Virus Infection; Viral Infection","metadata":null},{"id":"36d7f56d9425405895880725eed072f4","type":"TRIAL","name":"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT04844814","description":"Gout; Chronic Kidney Disease; Renal Transplantation","metadata":null},{"id":"1141b3831bec4455a9efa572391c87c4","type":"TRIAL","name":"Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection","canonical_id":"clinicaltrials.gov:NCT02527460","description":"HIV Infections; Neurologic Disorders","metadata":null},{"id":"412ac74bf337414983c4718ed2fdfecd","type":"TRIAL","name":"Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy","canonical_id":"clinicaltrials.gov:NCT03288428","description":"Postoperative Pain","metadata":null},{"id":"9e8071cc1f8642b98fedb0f64b627f47","type":"TRIAL","name":"Analgesia Effects of Nalbuphine vs Sulfentanil","canonical_id":"clinicaltrials.gov:NCT02604797","description":"C.Delivery; Surgery (Previous), Gynecological","metadata":null},{"id":"236265d624c545ec9dbcd5a35503c030","type":"TRIAL","name":"Analgesic Additives to Epidural Bupivacaine in Normal Labor","canonical_id":"clinicaltrials.gov:NCT05746351","description":"Labor Pain","metadata":null},{"id":"2006d9cbf5584c82867b88b37e0169ee","type":"TRIAL","name":"Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT02534610","description":"Postoperative Pain","metadata":null},{"id":"fb4cf5461c7d4fdba289fd2cd74b3af6","type":"TRIAL","name":"Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT01582646","description":"Postthoracotomy Pain; Postthoracoscopy Neuropathic Pain","metadata":null},{"id":"0e632fa038db44dfafc81b29579aef35","type":"TRIAL","name":"Analgesic Effect of Etoricoxib (ARCOXIA\u00ae) 120MG During Retinal Laser Photocoagulation","canonical_id":"clinicaltrials.gov:NCT00529594","description":"Proliferative Diabetic Retinopathy","metadata":null},{"id":"355e9554cce74bb9b4556f7dc406e7c0","type":"TRIAL","name":"Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery","canonical_id":"clinicaltrials.gov:NCT00683137","description":"Pain; Hallux Valgus","metadata":null},{"id":"43810a5b77374f8194913be7b5cb6bbd","type":"TRIAL","name":"Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery","canonical_id":"clinicaltrials.gov:NCT00653354","description":"Pain, Post-surgical","metadata":null},{"id":"e17f965907e84f7a931e710a9133f722","type":"TRIAL","name":"Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA\u00ae) in Coccygodygnia","canonical_id":"clinicaltrials.gov:NCT05983263","description":"Coccyx Disorder","metadata":null},{"id":"ec3d0a39fc9645ce9d032cf60a937a98","type":"TRIAL","name":"Analgesic Efficacy of Duloxetine in Patients Undergoing Lumbar Discectomy","canonical_id":"clinicaltrials.gov:NCT03549026","description":"Acute Pain","metadata":null},{"id":"febdaacf00544dc6bd7a22d5004010ba","type":"TRIAL","name":"Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia","canonical_id":"clinicaltrials.gov:NCT03715413","description":"Breast Fibroadenoma","metadata":null},{"id":"a465dc563602444ea9cced29136db47a","type":"TRIAL","name":"Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine","canonical_id":"clinicaltrials.gov:NCT01296334","description":"Pain","metadata":null},{"id":"06398ea2c7e947649b9d9cb16a5b3c74","type":"TRIAL","name":"Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT03128528","description":"Chronic Heart Failure","metadata":null},{"id":"c301b8e23b4a4f9fa27de7982a9c8011","type":"TRIAL","name":"Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00696449","description":"Acne Vulgaris","metadata":null},{"id":"9ad8bb613e2746cab96844344139a44a","type":"TRIAL","name":"Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion","canonical_id":"clinicaltrials.gov:NCT05657158","description":"Intraocular Inflammation; Retinal Vascular Occlusion","metadata":null},{"id":"0499b8f7bfe8475ca8833cbab96590c8","type":"TRIAL","name":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","canonical_id":"clinicaltrials.gov:NCT04852081","description":"Breast Cancer Stage IV","metadata":null},{"id":"a78d13449c2745cdb0843b356aff0878","type":"TRIAL","name":"Analysis of Two Therapeutic With Cetrotide\u00ae in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)","canonical_id":"clinicaltrials.gov:NCT01185704","description":"Polycystic Ovarian Syndrome","metadata":null},{"id":"ee0d58bac4c7473fa524d8304e1155b0","type":"TRIAL","name":"Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study","canonical_id":"clinicaltrials.gov:NCT04539327","description":"Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer","metadata":null},{"id":"6567d121672245fbb52b6b6bffaa8cd4","type":"TRIAL","name":"Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context","canonical_id":"clinicaltrials.gov:NCT06487078","description":"ALK+ Non-Small-Cell Lung Carcinoma","metadata":null},{"id":"a211ee0072fc465e809b76014da44efc","type":"TRIAL","name":"Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders","canonical_id":"clinicaltrials.gov:NCT02974166","description":"Temporomandibular Disorder","metadata":null},{"id":"a750e04511144931807532c1dd6410cb","type":"DISEASE","name":"Anaphylaxis","canonical_id":"mesh:D000707","description":null,"metadata":null},{"id":"b28b3d75c87b41e7a94195b351afc157","type":"DISEASE","name":"Anaplastic Thyroid Carcinoma","canonical_id":"doid:0080522","description":null,"metadata":null},{"id":"2e47ca24e90543dc91568270e9d372e7","type":"TRIAL","name":"Anastrozole 1 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01182181","description":"Healthy","metadata":null},{"id":"6797e5f0e8c646409d1f2a8996aa8f0e","type":"TRIAL","name":"Anastrozole 1 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01183390","description":"Healthy","metadata":null},{"id":"06553cd3399c4adcb2e7bbb6d9d29720","type":"TRIAL","name":"Anastrozole Administration in Elderly Hypogonadal Men","canonical_id":"clinicaltrials.gov:NCT00136695","description":"Hypogonadism","metadata":null},{"id":"affd40d564a34ddea8555d2f8ebe75ea","type":"TRIAL","name":"Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04294225","description":"Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Invasive Breast Carcinoma; Prognostic Stage I Breas\u2026","metadata":null},{"id":"c909e4458c9d45fe80332cddbb673785","type":"DISEASE","name":"Ancylostomiasis","canonical_id":"mesh:D000724","description":null,"metadata":null},{"id":"bebdc7241580474eb8a27d18d7e41a7b","type":"TRIAL","name":"Androcur Effects on Quality of Life","canonical_id":"clinicaltrials.gov:NCT00908674","description":"Prostate Cancer","metadata":null},{"id":"cbc6c0662ecc4b4a9401d77ed1669dbe","type":"TRIAL","name":"Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate","canonical_id":"clinicaltrials.gov:NCT00919022","description":"Prostate Cancer","metadata":null},{"id":"5df23003706c4e5da6e47ae740e50eb9","type":"TRIAL","name":"Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion","canonical_id":"clinicaltrials.gov:NCT04597099","description":"PCOS; Polycystic Ovary Syndrome","metadata":null},{"id":"f3860f417e194fdfa3b078bf8664205e","type":"TRIAL","name":"Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases","canonical_id":"clinicaltrials.gov:NCT02582749","description":"Prostate Cancer; Bone Metastases; Prostate Neoplasms","metadata":null},{"id":"aca5a92769c8490a98f6d077ee208eea","type":"TRIAL","name":"Androgen Deprivation Therapy Study","canonical_id":"clinicaltrials.gov:NCT00743327","description":"Hypogonadism; Metabolic Syndrome; Diabetes; Inflammation","metadata":null},{"id":"36217577541f436bbba89108b26b3572","type":"TRIAL","name":"Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study","canonical_id":"clinicaltrials.gov:NCT04585932","description":"Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"a941b6b18dcd44e9b4455f9c6391ba58","type":"TRIAL","name":"Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00589472","description":"Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer","metadata":null},{"id":"2f1adfa429754fe48669b4e23a43abfe","type":"TRIAL","name":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT04248621","description":"Prostatic Neoplasms","metadata":null},{"id":"652269c358984502832b9bbe87a12cab","type":"TRIAL","name":"Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)","canonical_id":"clinicaltrials.gov:NCT02742675","description":"Prostate Cancer","metadata":null},{"id":"e1401a9954e7476a818860a0e154ed96","type":"TRIAL","name":"Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women","canonical_id":"clinicaltrials.gov:NCT01889199","description":"Polycystic Ovary Syndrome (PCOS)","metadata":null},{"id":"ba4dfa76d55c45139d7230d794115d0e","type":"TRIAL","name":"Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide","canonical_id":"clinicaltrials.gov:NCT04335682","description":"Metastatic Prostate Cancer; Prostate Cancer Metastatic; Prostate Cancer; Castrate Resistant Prostate Cancer; Hormone Sensitive Prostate Cancer; Non-metastatic Prostate Cancer","metadata":null},{"id":"416d4b2a3e144eeaa403a39fde0ab651","type":"TRIAL","name":"Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00303615","description":"Metastatic Breast Cancer","metadata":null},{"id":"0597bb6396a041838cdc5ccb22f29030","type":"TRIAL","name":"Androgen-responsive POSLUMA-guided Intra-prostatic Boost","canonical_id":"clinicaltrials.gov:NCT07393867","description":"Intermediate Risk Prostate Cancer; High Risk Prostate Cancer; Prostate Cancer","metadata":null},{"id":"6f92cf1ca0f34b59839ba27267ffb3a4","type":"DISEASE","name":"Anemia","canonical_id":"mesh:D000740","description":null,"metadata":null},{"id":"37b17a847e1b44ca9af94166ebc86933","type":"DISEASE","name":"Anemia, Hemolytic, Autoimmune","canonical_id":"mesh:D000744","description":null,"metadata":null},{"id":"1cedbf3e53834a2ebc1027770c20966f","type":"DISEASE","name":"Anemia, Sickle Cell","canonical_id":"mesh:D000755","description":null,"metadata":null},{"id":"a61d4657885f4921b564d12f4459371a","type":"TRIAL","name":"Anesthesia Induction Schemes of Electroconvulsive Convulsions in Patients With Depression Based on EEG Monitoring","canonical_id":"clinicaltrials.gov:NCT05900245","description":"Depression; Electroconvulsive Therapy; Electroencephalography","metadata":null},{"id":"7eca2b5847324ef69e08b3293677b2ec","type":"DISEASE","name":"Angina pectoris","canonical_id":"mesh:D000787","description":null,"metadata":null},{"id":"5933549146b441799f3adf06515763a4","type":"DISEASE","name":"Angioedema","canonical_id":"mesh:D000799","description":null,"metadata":null},{"id":"63d8e291db5c4d1385b5756a5e2079af","type":"DISEASE","name":"Angiofibroma","canonical_id":"efo:1001761","description":null,"metadata":null},{"id":"91db5ab64cd84f22a8470dee3b549208","type":"DISEASE","name":"Angiofibromas","canonical_id":"hp:0010615","description":null,"metadata":null},{"id":"1b2127fcafeb491fb978e7d76b2e7c3a","type":"DISEASE","name":"Angiofollicular lymph node hyperplasia","canonical_id":"mesh:D005871","description":null,"metadata":null},{"id":"ae6821b66092438abee62632991b707b","type":"TRIAL","name":"Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)","canonical_id":"clinicaltrials.gov:NCT00073580","description":"Thrombocytopenia; Thrombosis; Cardiac Disease; Coronary Artery Bypass Surgery","metadata":null},{"id":"97f5bb5f8a7d45d681f59ebd49353593","type":"TRIAL","name":"Angiomax\u00ae or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT01464671","description":"Coronary Artery Disease","metadata":null},{"id":"3b35241475094c68bff60bd640a6b171","type":"TRIAL","name":"Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome","canonical_id":"clinicaltrials.gov:NCT00485368","description":"Marfan Syndrome","metadata":null},{"id":"13d03743dc2d45c2a865835ff4d2d0cf","type":"TRIAL","name":"Angiotensin II Blockade and Inflammation in Obesity","canonical_id":"clinicaltrials.gov:NCT01684748","description":"Overweight; Obese; Prehypertension; Hypertension","metadata":null},{"id":"45eafdd4204143f7a14b49d1a706537a","type":"TRIAL","name":"Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT03526042","description":"Atherosclerosis; Lupus Nephritis","metadata":null},{"id":"ebb7d202d6df480489e6b39e5a66aa91","type":"TRIAL","name":"Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01014338","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"3c5b470637f94147b70dc0ca6c8cb899","type":"DISEASE","name":"Angle-closure glaucoma","canonical_id":"mesh:D015812","description":null,"metadata":null},{"id":"d574b9b1b4ae430486be2bb642627ba8","type":"TRIAL","name":"Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT04931563","description":"Active Systemic Lupus Erythematosus","metadata":null},{"id":"ce1b9e6bac444a429616e1f351efbe8a","type":"TRIAL","name":"Anifrolumab Early Access Program","canonical_id":"clinicaltrials.gov:NCT04750057","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"848a951c23244ff5b31e8ba87aa2b46f","type":"TRIAL","name":"Anifrolumab Malignancy and Serious Infections Study","canonical_id":"clinicaltrials.gov:NCT07000110","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"a1944f0d7c4d4d1cbcc37a6243008098","type":"TRIAL","name":"Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT05001698","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"729cf44a81b943b38736f2fa9259ee92","type":"TRIAL","name":"Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT06673043","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"ea534b1966f64f4792416f7f3dfde8ec","type":"TRIAL","name":"Anifrolumab Treatment for 24 Weeks in Patients With Primary Sj\u00f6gren's Syndrome","canonical_id":"clinicaltrials.gov:NCT05383677","description":"Sjogren's Syndrome","metadata":null},{"id":"3178e4f957994333a376320760ee6942","type":"TRIAL","name":"Anifrolumab for Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT06374212","description":"Hidradenitis Suppurativa; Acne Inversa; Hidradenitis","metadata":null},{"id":"e8ce7bfd81164da1a361dce8a83b6caa","type":"TRIAL","name":"Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)","canonical_id":"clinicaltrials.gov:NCT07584083","description":"Antiphospholipid Syndrome (APS)","metadata":null},{"id":"b2da9829f6ca48bfaeb53363a538bfa1","type":"DISEASE","name":"Ankylosing spondylitis","canonical_id":"mesh:D013167","description":null,"metadata":null},{"id":"624f2b5f8cf645fda96eab9b9693587a","type":"TRIAL","name":"Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study","canonical_id":"clinicaltrials.gov:NCT07806292","description":"Unresectable Hepatocellular Carcinoma","metadata":null},{"id":"b28c5d6675cd4a1fa5a1feed000f4949","type":"TRIAL","name":"Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy","canonical_id":"clinicaltrials.gov:NCT07627464","description":"Renal Cell Carcinoma (RCC)","metadata":null},{"id":"dc1bc882a4294673bbc861fa1f7e3c77","type":"TRIAL","name":"Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma","canonical_id":"clinicaltrials.gov:NCT06429397","description":"Pheochromocytoma","metadata":null},{"id":"acd4c1013e30453b9ee0e6e3f82e2ffa","type":"TRIAL","name":"Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03750916","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"1449e6ac09ef4961aece398b47efce54","type":"TRIAL","name":"Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.","canonical_id":"clinicaltrials.gov:NCT05130515","description":"Platinum-resistant Recurrent Clear Cell Ovarian Cancer","metadata":null},{"id":"254cccea08ee4c3ea7469800d0f7b0cd","type":"TRIAL","name":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","canonical_id":"clinicaltrials.gov:NCT06621095","description":"Pancreatic Cancer; First-line; Metastatic Pancreatic Cancer","metadata":null},{"id":"06bc215fff6a4b2880c2b5a7f7a0c8a5","type":"TRIAL","name":"Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT07385079","description":"Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer","metadata":null},{"id":"b8786fe36f3a4ebd896e0670019e31fb","type":"TRIAL","name":"Anlotinib and Benmelstobart in DTC","canonical_id":"clinicaltrials.gov:NCT07193186","description":"Thyroid Cancer","metadata":null},{"id":"ebe7641586e7419da8865d08ac4e569f","type":"TRIAL","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT07635290","description":"Previously Treated, Advanced; Biliary Tract Cancers","metadata":null},{"id":"587dc5eb85634d83b72d872935533b40","type":"TRIAL","name":"Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA","canonical_id":"clinicaltrials.gov:NCT06222944","description":"Gastric Cancer; Adenocarcinoma of Esophagogastric Junction","metadata":null},{"id":"79505941d10f46cea1f50695991a37c1","type":"TRIAL","name":"Anorectal Manometery in Pediatric Chronic Refractory Constipation","canonical_id":"clinicaltrials.gov:NCT06543979","description":"Chronic Constipation","metadata":null},{"id":"3d2b742c8df74f329def8e3b8e02b397","type":"DISEASE","name":"Anorexia","canonical_id":"hp:0002039","description":null,"metadata":null},{"id":"fb04f5a3e2d542cfb2e043db194c5e35","type":"DISEASE","name":"Anorexia nervosa","canonical_id":"mesh:D000856","description":null,"metadata":null},{"id":"40bf546bb58443aa90fbde10d604d714","type":"DISEASE","name":"Anoxia due to high altitude","canonical_id":"mesh:D000532","description":null,"metadata":null},{"id":"d0d673283c9d4c0285bb0cfbc840a6e2","type":"TRIAL","name":"Anrikefon Injection for Postoperative Analgesia in Thoracoscopic Lung Surgery: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Center Clinical Study","canonical_id":"clinicaltrials.gov:NCT07810413","description":"Postoperative Pain","metadata":null},{"id":"4864298c7963410a9f900829187287b7","type":"TRIAL","name":"Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP","canonical_id":"clinicaltrials.gov:NCT07380113","description":"Pruritus Chronic; Kidney Diseases, Chronic; Renal Insufficiency, Chronic; Uremia; Chronic; Pruritus Due to Systemic Disorder (Disorder); Pruritus Due to Hemodialysis","metadata":null},{"id":"54bf095df96341f9b654015e11c7afe3","type":"TRIAL","name":"Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT07246785","description":"Laparoscopic Surgery; Visceral Pain, Postoperative; Anrikefon; Patient-controlled Intravenous Analgesia","metadata":null},{"id":"1f7243dc158e4308862d309e4a4b4b92","type":"TRIAL","name":"Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT07525986","description":"Laparoscopic Surgery; Visceral Pain, Postoperative; Anrikefon; Patient-controlled Intravenous Analgesia","metadata":null},{"id":"eefa9e3b90904c05ab91f9268bce7354","type":"TRIAL","name":"Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.","canonical_id":"clinicaltrials.gov:NCT05720572","description":"Atrial Fibrillation","metadata":null},{"id":"9614b7487b3d45fd8eb8dac2a6d0432a","type":"TRIAL","name":"Antenatal Allopurinol in Intrauterine Growth Restriction","canonical_id":"clinicaltrials.gov:NCT00346463","description":"Fetal Growth Retardation","metadata":null},{"id":"5418c0e12a6f41eaad359f597888d5aa","type":"TRIAL","name":"Antenatal Betamethasone and the Risk of Neonatal Hypoglycemia","canonical_id":"clinicaltrials.gov:NCT03702959","description":"Hypoglycemia","metadata":null},{"id":"eccfcfc796834fb8818facec7c071e62","type":"TRIAL","name":"Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study","canonical_id":"clinicaltrials.gov:NCT02865473","description":"Glaucoma","metadata":null},{"id":"6d90eb09a2d441718031011829959832","type":"DISEASE","name":"Anterior uveitis","canonical_id":"mesh:D014606","description":null,"metadata":null},{"id":"62d06960a8ab40f1be6b296e08d7b4c5","type":"DISEASE","name":"Anthrax","canonical_id":"mesh:D000881","description":null,"metadata":null},{"id":"dc1efd6e5f7b46ccb0aa0b05ce001f52","type":"TRIAL","name":"Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD","canonical_id":"clinicaltrials.gov:NCT00574470","description":"Graft vs Host Disease","metadata":null},{"id":"4e95e395542f4c1d82faad1359cff32c","type":"TRIAL","name":"Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients","canonical_id":"clinicaltrials.gov:NCT00379418","description":"Coronary Artery Disease","metadata":null},{"id":"10153df6ca184d9a8584ab4d687a193d","type":"TRIAL","name":"Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04128072","description":"Stage IB-IIB Cutaneous T-Cell Lymphoma","metadata":null},{"id":"fd17148edc7a4ec59c26a0223cfbdc46","type":"TRIAL","name":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03696784","description":"Lymphoma; Lymphoma, B-Cell; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases","metadata":null},{"id":"e2c9ea5a870d46438bdf7f19bc7bca02","type":"TRIAL","name":"Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT07171827","description":"Anti-CD30; Brentuximab; Doxorubicin; Vinblastine; Dacarbazine; Frontline; Advanced Classical Hodgkin Lymphoma","metadata":null},{"id":"cd8e24ffe6f2494a98d3718474e23395","type":"TRIAL","name":"Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06015724","description":"Pancreatic Ductal Adenocarcinoma; Refractory Non-Small Cell Lung Cancer","metadata":null},{"id":"abf99f91711e4275b63e927922713f75","type":"TRIAL","name":"Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT07362199","description":"Immune Thrombocytopenia; Treatment","metadata":null},{"id":"69e7c2c50aff4deeaccc6525df57deae","type":"TRIAL","name":"Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT04158752","description":"Trigeminal Neuralgia; Glossopharyngeal Neuralgia","metadata":null},{"id":"b1d676845b3841dcb4a0ec24400c8a90","type":"TRIAL","name":"Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC","canonical_id":"clinicaltrials.gov:NCT03527251","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"5bac731684fa4a1e8e5b9f803c86d6b0","type":"TRIAL","name":"Anti-Cytokine Therapy for Vasculitis","canonical_id":"clinicaltrials.gov:NCT00753103","description":"Wegener's Granulomatosis; Renal Limited Vasculitis; Microscopic Polyangiitis","metadata":null},{"id":"9ee44e8cf95249fd8bd467cf536de79e","type":"DRUG","name":"Anti-EGFR Monoclonal Antibody","canonical_id":"ncit:C133878","description":null,"metadata":null},{"id":"89fb2875c5894f28b9b0d40f59261e66","type":"TRIAL","name":"Anti-FGF23 (Burosumab) in Adult Patients With XLH","canonical_id":"clinicaltrials.gov:NCT04695860","description":"X-linked Hypophosphatemia","metadata":null},{"id":"28e2b3952f174a699a1c8bfbac07a3fa","type":"TRIAL","name":"Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT00921115","description":"Invasive Breast Cancer","metadata":null},{"id":"2791c92529584a3989ca43e7b58b6214","type":"TRIAL","name":"Anti-Inflammatory Drug and Endothelial Function","canonical_id":"clinicaltrials.gov:NCT04161339","description":"Cardiovascular Diseases; Endothelial Dysfunction; Sleep Apnea; Atherosclerosis; Coronary Artery Disease","metadata":null},{"id":"4523a3eca8b940a1bd32161c9e0ad26c","type":"TRIAL","name":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","canonical_id":"clinicaltrials.gov:NCT06042647","description":"Psoriasis Vulgaris","metadata":null},{"id":"645d3ec951b74a27bd46238959111d26","type":"TRIAL","name":"Anti-Interleukin-1 in Diabetes Action","canonical_id":"clinicaltrials.gov:NCT00711503","description":"Type 1 Diabetes","metadata":null},{"id":"de182c35b38b44d886f67f1385e3cf3a","type":"TRIAL","name":"Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT02559791","description":"Severe Persistent Asthma; Eosinophilic Bronchitis","metadata":null},{"id":"5673428be08d477bbf389076f03115fe","type":"DRUG","name":"Anti-PD-L1 Monoclonal Antibody","canonical_id":"ncit:C128057","description":null,"metadata":null},{"id":"f66390675f2d411fb6b34a1a575fe5ad","type":"DRUG","name":"Anti-PD1 Monoclonal Antibody","canonical_id":"ncit:C128037","description":null,"metadata":null},{"id":"6cb22172553e49e08ab5a893fd34c667","type":"TRIAL","name":"Anti-TNF\u03b1 to Delay or Prevent Progression to Stage 3 T1D","canonical_id":"clinicaltrials.gov:NCT04729296","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"65b206b6e0f243bcad153ff02a1833f1","type":"TRIAL","name":"Anti-Tac for Treatment of Leukemia","canonical_id":"clinicaltrials.gov:NCT00001941","description":"HTLV-I Infection; T Cell Leukemia","metadata":null},{"id":"1ab532e7b4534ad680a3f34114364f31","type":"TRIAL","name":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT04701528","description":"Covid19; Kidney Transplant Infection","metadata":null},{"id":"c78e7b2e21264312b005a0ede2291598","type":"TRIAL","name":"Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","canonical_id":"clinicaltrials.gov:NCT07254572","description":"Coronary Artery Disease; PreDiabetes","metadata":null},{"id":"8e87a54f79084dc2b9e4c6c7d766797a","type":"TRIAL","name":"Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease","canonical_id":"clinicaltrials.gov:NCT03618108","description":"Coronary Heart Disease; Chlamydophila Pneumoniae Infections","metadata":null},{"id":"4fc0d08e5ee940d687ae067734e555c7","type":"TRIAL","name":"Anti-emetic Prophylaxis With or Without Dexamethasone","canonical_id":"clinicaltrials.gov:NCT05242874","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"04991dae589f480c8b7145a148f79f83","type":"TRIAL","name":"Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging","canonical_id":"clinicaltrials.gov:NCT02628002","description":"Coronary Artery Disease","metadata":null},{"id":"7847c8c9d10343dc9a1cfeac8f29d62c","type":"TRIAL","name":"Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research","canonical_id":"clinicaltrials.gov:NCT03805035","description":"Pain","metadata":null},{"id":"cedcd1be99a64ca88b54b870c9ebccc6","type":"TRIAL","name":"Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","canonical_id":"clinicaltrials.gov:NCT07668505","description":"Myositis","metadata":null},{"id":"84086e7480154f41a6f50dfa8da29db8","type":"TRIAL","name":"Anti-inflammatory Effects of Colchicine in PCI","canonical_id":"clinicaltrials.gov:NCT01709981","description":"Coronary Artery Disease","metadata":null},{"id":"5950fc1ab6bb438b8ad9c271d44b3678","type":"TRIAL","name":"Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT01757457","description":"Myocardial Infarction","metadata":null},{"id":"0a39984d561a47b3b6de32f14c9eaecc","type":"TRIAL","name":"Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran","canonical_id":"clinicaltrials.gov:NCT02331602","description":"Atrial Fibrillation","metadata":null},{"id":"7b89026f40ac48d5a6b98774c2bb6fc0","type":"TRIAL","name":"Anti-inflammatory H1 Antihistamines Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02507635","description":"Allergic Rhinitis","metadata":null},{"id":"90777cfdb21940ac8f44e6507ebacaf4","type":"TRIAL","name":"Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo","canonical_id":"clinicaltrials.gov:NCT01309178","description":"Cystic Fibrosis; Pneumonia","metadata":null},{"id":"a1cb2e820a264ca9ac7a3d3b7aebffd7","type":"TRIAL","name":"Anti-inflammatory Status in DM2 Treated Patients","canonical_id":"clinicaltrials.gov:NCT04392557","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"b8cb61d55a41445ba187a749ff837067","type":"TRIAL","name":"Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.","canonical_id":"clinicaltrials.gov:NCT04796324","description":"Metastatic Breast Cancer","metadata":null},{"id":"2bfeac66f6f4456686fdfe36d152feab","type":"TRIAL","name":"Antialbuminuric Effects of Valsartan and Lisinopril","canonical_id":"clinicaltrials.gov:NCT00171600","description":"Hypertension; Early Diabetic Nephropathy","metadata":null},{"id":"e50807949bed475b9e13e33b43e79a2d","type":"TRIAL","name":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT03070886","description":"Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7","metadata":null},{"id":"b3fffaa28b4048f782aaeb8c3af4b5a0","type":"TRIAL","name":"Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02145546","description":"Atrial Fibrillation","metadata":null},{"id":"76bf0ba09f2b4610aa70415137e7b8f1","type":"TRIAL","name":"Antiarrhythmics Versus Implantable Defibrillators (AVID)","canonical_id":"clinicaltrials.gov:NCT00000531","description":"Arrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases; Tachycardia, Ventricular; Ventricular Fibrillation","metadata":null},{"id":"8d6b2ddb528745aba69c24a30eb4c72f","type":"TRIAL","name":"Antibiotic Prophylaxis in High-Risk Arthroplasty Patients","canonical_id":"clinicaltrials.gov:NCT04297592","description":"Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization; MRSA; Chronic Kidney Diseases; Diabetes; Autoimmune Diseases; Inflammatory Disease; Tobacco Use","metadata":null},{"id":"c24a60af590140a5b46c78ecf9b97ccf","type":"TRIAL","name":"Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach","canonical_id":"clinicaltrials.gov:NCT00002682","description":"Lymphoma","metadata":null},{"id":"3f3246b63254425f928ad21994a3eb22","type":"TRIAL","name":"Antibiotics and Vaccine Immune Responses Study","canonical_id":"clinicaltrials.gov:NCT06148025","description":"Vaccine Response Impaired","metadata":null},{"id":"371015cf8f4840828fc018671278806f","type":"TRIAL","name":"Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00892450","description":"Parkinson's Disease; Overactive Bladder","metadata":null},{"id":"877a6106dbcb41b282607c0fa6728a05","type":"TRIAL","name":"Anticholinergic vs. Botox Comparison Study","canonical_id":"clinicaltrials.gov:NCT01166438","description":"Urge Urinary Incontinence; Overactive Bladder","metadata":null},{"id":"ce7a83a421114169a30abbc84e98c3c1","type":"TRIAL","name":"Anticholium\u00ae Per Se","canonical_id":"clinicaltrials.gov:NCT03013322","description":"Shock, Septic; Sepsis; Perioperative Period","metadata":null},{"id":"6231eee6cce64ceab68c8bd9bc33da0c","type":"TRIAL","name":"Anticoagulant Therapy During Pacemaker Implantation","canonical_id":"clinicaltrials.gov:NCT00479362","description":"Hemorrhage; Thrombosis; Embolism","metadata":null},{"id":"03bb7c035c624f0e874ab85be3598d92","type":"TRIAL","name":"Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)","canonical_id":"clinicaltrials.gov:NCT00043940","description":"Heparin-Induced Thrombocytopenia; Thrombosis","metadata":null},{"id":"69439faa84d74c338c5f3ee020a12884","type":"TRIAL","name":"Anticoagulant Treatments and Percutaneous Coronary Angioplasty","canonical_id":"clinicaltrials.gov:NCT00669149","description":"Coronary Artery Disease","metadata":null},{"id":"5e106884b7524fc09a04b8aa602e51de","type":"TRIAL","name":"Anticoagulation Preference by AF Patients Study","canonical_id":"clinicaltrials.gov:NCT02607371","description":"Atrial Fibrillation","metadata":null},{"id":"d6105bd9b6964c7b859003f09ffdc810","type":"TRIAL","name":"Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis","canonical_id":"clinicaltrials.gov:NCT02240953","description":"Thrombosis","metadata":null},{"id":"1a182b40680d4b9aa1e86ff92b2bf98c","type":"TRIAL","name":"Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","canonical_id":"clinicaltrials.gov:NCT04406389","description":"COVID-19","metadata":null},{"id":"265110c526ca4e019749b0b4ec3b2289","type":"TRIAL","name":"Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection","canonical_id":"clinicaltrials.gov:NCT00180674","description":"Liver Fibrosis","metadata":null},{"id":"1a89de06a428404fa3ee0179bcd6718e","type":"TRIAL","name":"Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial","canonical_id":"clinicaltrials.gov:NCT04445935","description":"Anticoagulation in COVID-19 ARDS","metadata":null},{"id":"be5c82392de34ff48c4f13b55444f50e","type":"TRIAL","name":"Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression","canonical_id":"clinicaltrials.gov:NCT05063604","description":"Breast Cancer; Major Depressive Episode","metadata":null},{"id":"c2f94d5bb7e2443999f8dca4adbea48d","type":"TRIAL","name":"Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy","canonical_id":"clinicaltrials.gov:NCT00338767","description":"HIV Infections; Depression","metadata":null},{"id":"534c9cc9aac04956a618c52cc4cd0c81","type":"TRIAL","name":"Antidepressant Medication Plus Donepezil for Treating Late-life Depression","canonical_id":"clinicaltrials.gov:NCT00177671","description":"Depression; Dementia","metadata":null},{"id":"9119538b91ff48cd93f05ca894bca430","type":"TRIAL","name":"Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression","canonical_id":"clinicaltrials.gov:NCT01670019","description":"Major Depressive Disorder Without Psychotic Features","metadata":null},{"id":"20b86c13f9b04b4dbf707aedd8a740fc","type":"TRIAL","name":"Antidepressant Treatment of AIDS Related Depression.","canonical_id":"clinicaltrials.gov:NCT00000390","description":"Depression","metadata":null},{"id":"4d198f3dce6c498a847e16796817db75","type":"TRIAL","name":"Antidepressant Treatment of Melancholia in Late Life","canonical_id":"clinicaltrials.gov:NCT00000378","description":"Depression; Melancholia","metadata":null},{"id":"a594eb8ac49e49ddab23722f11cf9f98","type":"TRIAL","name":"Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group","canonical_id":"clinicaltrials.gov:NCT00265291","description":"Major Depressive Disorder; Major Depression; Unipolar Depression","metadata":null},{"id":"713a2e909fbd4a21a9a8edb8a0447020","type":"TRIAL","name":"Antidepressants Trial in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03652870","description":"Depression; Parkinson Disease","metadata":null},{"id":"1a3b51d6a4984ef3811317b8af2df327","type":"TRIAL","name":"Antidepressants and Bone Mineral Density","canonical_id":"clinicaltrials.gov:NCT02179268","description":"Bone Mineral Density Quantitative Trait Locus 7","metadata":null},{"id":"82ec0b3c5f76495e8a34f07637e2eb04","type":"TRIAL","name":"Antidiabetic Drugs for Steatotic Liver Disease","canonical_id":"clinicaltrials.gov:NCT03646292","description":"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes; Digestive System Disease; Liver Diseases; Fatty Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-Alcoholic Fatty Liver Disease; Hypoglycemic Agents; Physiological Effects of Drugs; Sodium-Glucose Cotransporter 2 Inhibitors; Pioglitazone; Molecular Mechanisms of Pharmacological Action; Empagliflozin; Thiazolidinediones","metadata":null},{"id":"97cdb8c50b574f209512242ebbf9865a","type":"TRIAL","name":"Antidiabetic Effects on Intrahepatic Fat","canonical_id":"clinicaltrials.gov:NCT03068065","description":"Non-Alcoholic Fatty Liver Disease; Type2 Diabetes","metadata":null},{"id":"8d3e321fbc8e41eb916e68c566bdaa66","type":"TRIAL","name":"Antiemetic Effect of the Addition of Ondansetron to the Morphine Solution in Patient-Controlled Analgesia (PCA)","canonical_id":"clinicaltrials.gov:NCT00199329","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"ee270b4ebb3044219680a49cd8c75c46","type":"TRIAL","name":"Antiepileptic Drugs and Vascular Risk Markers","canonical_id":"clinicaltrials.gov:NCT00774306","description":"Subarachnoid Hemorrhage","metadata":null},{"id":"95e4f00e86044d139d7ddcdc941fa566","type":"TRIAL","name":"Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat","canonical_id":"clinicaltrials.gov:NCT02920190","description":"Monoclonal Gammopathies; Overweight; Obesity","metadata":null},{"id":"51097353b3d54dc08a9f2f4feafc56dc","type":"TRIAL","name":"Antiglucocorticoid Augmentation of antiDepressants in Depression","canonical_id":"clinicaltrials.gov:NCT01375920","description":"Depression","metadata":null},{"id":"14c632827e3e4c6eafae2b44d5611bfb","type":"TRIAL","name":"Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders","canonical_id":"clinicaltrials.gov:NCT01333098","description":"Anxiety Disorders","metadata":null},{"id":"77e97511a58f404a885bb2e322b113a3","type":"TRIAL","name":"Antihistamines in Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT04248712","description":"Eosinophilic Esophagitis","metadata":null},{"id":"ff5980608f99498aa837c22f2223c691","type":"TRIAL","name":"Antihypertensive Effectiveness of the Associations of Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril","canonical_id":"clinicaltrials.gov:NCT00394394","description":"Hypertension","metadata":null},{"id":"a766f5ebaea3461ca545813e82648509","type":"DRUG","name":"Antimony Sodium Gluconate","canonical_id":"mesh:D000967","description":null,"metadata":null},{"id":"15431cd49667402db17a52d1989d85d7","type":"TRIAL","name":"Antimuscarinics as the First-line Treatment for Male With IPSS-V/S\u22641","canonical_id":"clinicaltrials.gov:NCT01661621","description":"Bladder Outlet Obstruction","metadata":null},{"id":"b4f9706bf98e4dddbdd7d07a28a7ea54","type":"TRIAL","name":"Antineoplastic Drugs in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT05467189","description":"Cancer","metadata":null},{"id":"29cc668c834844ba8156581de42a17d7","type":"TRIAL","name":"Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00003517","description":"Adenocarcinoma of the Prostate; Stage III Prostate Cancer; Stage IV Prostate Cancer; Recurrent Prostate Cancer","metadata":null},{"id":"fc4da03a1d3f44bbb6adc4622284476f","type":"TRIAL","name":"Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT03048019","description":"Non-ST Elevation Myocardial Infarction (NSTEMI)","metadata":null},{"id":"3619b2ef21314753a1c414ff2bb58b16","type":"TRIAL","name":"Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT02931045","description":"Myocardial Infarction","metadata":null},{"id":"bfebd1bd0009415c90734d8097ae8858","type":"TRIAL","name":"Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","canonical_id":"clinicaltrials.gov:NCT06715007","description":"Stroke, Ischemic; Small Vessel Cerebrovascular Disease; White Matter Hyperintensity","metadata":null},{"id":"db9097d3de194055b09d0a3ca9e76433","type":"TRIAL","name":"Antiplatelet Therapy in Chronic Urticaria","canonical_id":"clinicaltrials.gov:NCT06268470","description":"Chronic Urticaria","metadata":null},{"id":"0652c9ffa5de43bc9ec4130c9dc696c9","type":"TRIAL","name":"Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe","canonical_id":"clinicaltrials.gov:NCT00474123","description":"Stable Angina","metadata":null},{"id":"f898d057f630429ba22019ec42615c58","type":"TRIAL","name":"Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT01230034","description":"Hypertension; Type 2 Diabetes Mellitus; Microalbuminuria","metadata":null},{"id":"89d14fd35c54439caa4c818ab1f505ae","type":"TRIAL","name":"Antiproteinuric Effect of Valsartan and Lisinopril","canonical_id":"clinicaltrials.gov:NCT00171574","description":"Hypertension; Diabetic Nephropathy","metadata":null},{"id":"ee46b43f82c04a4b8313eeb914399a54","type":"TRIAL","name":"Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine","canonical_id":"clinicaltrials.gov:NCT03096444","description":"Pruritus","metadata":null},{"id":"01ff2aaa3ebf421caa8105edc3de764f","type":"TRIAL","name":"Antipsychotic Effects of Oxytocin","canonical_id":"clinicaltrials.gov:NCT01621737","description":"Schizophrenia","metadata":null},{"id":"de4f7c74827545179452c0d4ebcd7663","type":"TRIAL","name":"Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02240173","description":"Schizophrenia and Disorders With Psychotic Features","metadata":null},{"id":"b6c2ed620ebe4e03ab5ecfc796673e9b","type":"TRIAL","name":"Antipsychotic Polypharmacy in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00493233","description":"Schizophrenia","metadata":null},{"id":"ccc0e7b2a4024d4182399e297aa06c71","type":"TRIAL","name":"Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients","canonical_id":"clinicaltrials.gov:NCT05346419","description":"Postmenopausal Osteoporosis; Hypovitaminosis D; Hyperparathyroidism","metadata":null},{"id":"42d433a971234cfaa78ca4f5c267c7e1","type":"TRIAL","name":"Antithrombotic Activities of Sotagliflozin vs. Empagliflozin","canonical_id":"clinicaltrials.gov:NCT06618976","description":"Thrombosis","metadata":null},{"id":"838a07c769054b889e41bbc82be934ca","type":"TRIAL","name":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","canonical_id":"clinicaltrials.gov:NCT04372589","description":"COVID-19; Pneumonia","metadata":null},{"id":"a7b2887eb5414c3caba3dca37c4b2816","type":"TRIAL","name":"Antithrombotic Triple Therapy in Humans","canonical_id":"clinicaltrials.gov:NCT01812200","description":"Atrial Fibrillation; Acute Coronary Syndrome","metadata":null},{"id":"0be630d5dcdd453bbfcc9198925a68d1","type":"TRIAL","name":"Antithyroid Drug Treatment of Thyrotoxicosis in Young People","canonical_id":"clinicaltrials.gov:NCT01436994","description":"Paediatric Thyrotoxicosis","metadata":null},{"id":"011f21f60aa4498784ab9ceae1b3d221","type":"TRIAL","name":"Antithyroid Drugs During Radioiodine Therapy","canonical_id":"clinicaltrials.gov:NCT00150137","description":"Toxic Nodular Goitre; Graves Disease","metadata":null},{"id":"4b1c32f970794e06a3a1262b439f0dce","type":"DISEASE","name":"Antley-Bixler syndrome","canonical_id":"mondo:0008803","description":null,"metadata":null},{"id":"b00c3bd400e346c299fde05642ca377e","type":"DISEASE","name":"Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis","canonical_id":"mondo:0020667","description":null,"metadata":null},{"id":"e48730ee07ea4e5b95dc0a0a56251f8d","type":"TRIAL","name":"Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).","canonical_id":"clinicaltrials.gov:NCT06333951","description":"Thoracic Tumors; Non-small Cell Lung Cancer","metadata":null},{"id":"40edecac54674f11855ae9bdcbaf578c","type":"GO_TERM","name":"AnxA2-p11 complex","canonical_id":"go:GO:1990665","description":"\"A heterotetrameric protein complex comprising two Annexin A2 (AnxA2) monomers and two copies of its binding partner, S100 protein p11 (S100A10).\" [GOC:bf, GOC:BHF, GOC:nc, PMID:18799458, PMID:23483454]","metadata":null},{"id":"2a4cba0ea0ae4f4b8fcb363c5e7984a1","type":"DISEASE","name":"Anxiety","canonical_id":"mesh:D001007","description":null,"metadata":null},{"id":"b7fbb2dd93b74f3797abe719230e6a17","type":"DISEASE","name":"Anxiety disorders","canonical_id":"mesh:D001008","description":null,"metadata":null},{"id":"1ce262cd94e84fc4881a04291e7e2728","type":"TRIAL","name":"Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment","canonical_id":"clinicaltrials.gov:NCT02365870","description":"Anxiety Disorders; Parkinson Disease","metadata":null},{"id":"2b5a63883d9d433ba07752c86fa99640","type":"TRIAL","name":"Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT03412396","description":"Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8","metadata":null},{"id":"7cd78868c3d44db79953d2d1bdb0877f","type":"TRIAL","name":"Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance","canonical_id":"clinicaltrials.gov:NCT02721979","description":"Prostate Adenocarcinoma","metadata":null},{"id":"563e90ce0fda41dbae74522278930e02","type":"TRIAL","name":"Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT04781686","description":"Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"1b7e146042de4fc4a8965b2a6ff00a70","type":"DISEASE","name":"Apert syndrome","canonical_id":"mondo:0007041","description":null,"metadata":null},{"id":"9b8e4645005b46dd9078ea1fa7f4fb39","type":"DRUG","name":"Apitolisib","canonical_id":"ncit:C91731","description":null,"metadata":null},{"id":"17d42a8839fa4682931ed4b3a2d866c2","type":"TRIAL","name":"Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02565693","description":"Cerebral Hemorrhage; Atrial Fibrillation","metadata":null},{"id":"e6d608d21bd9487c98dfe06d34115f69","type":"TRIAL","name":"Apixaban Versus Warfarin for Left Ventricular Thrombus","canonical_id":"clinicaltrials.gov:NCT07709780","description":"Left Ventricular Thrombus","metadata":null},{"id":"a935852698b1425b9c15c568e4916c72","type":"TRIAL","name":"Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19","canonical_id":"clinicaltrials.gov:NCT04746339","description":"Covid19; Thrombosis","metadata":null},{"id":"12d145c557904bad8ab9d90a3118b90e","type":"TRIAL","name":"Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access","canonical_id":"clinicaltrials.gov:NCT04489849","description":"Hemodialysis Access Failure","metadata":null},{"id":"2a4f88f6cade452bb41e53653cfe4f96","type":"DISEASE","name":"Aplastic anemia","canonical_id":"mesh:D000741","description":null,"metadata":null},{"id":"4aa32165a73b412f856f1637e142a4dd","type":"DISEASE","name":"Apnea","canonical_id":"hp:0002104","description":null,"metadata":null},{"id":"1588835b6c24487c92c8e79826e950f0","type":"DRUG","name":"Apomorphine","canonical_id":"mesh:D001058","description":null,"metadata":null},{"id":"238389ef7d0b4d20b3acdea0c42605d5","type":"TRIAL","name":"Apomorphine Effects on Experimental Pain","canonical_id":"clinicaltrials.gov:NCT01744964","description":"Healthy","metadata":null},{"id":"d50b85bc343a4b1d99c5fa521cfeedd2","type":"TRIAL","name":"Apomorphine Effects on Pain in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04879134","description":"Parkinson Disease","metadata":null},{"id":"50f9aa9e615b46e5a9718603b55ad87f","type":"TRIAL","name":"Apomorphine Nasal Powder in the Treatment of Parkinson's Disease \"Off\" Periods.","canonical_id":"clinicaltrials.gov:NCT00346827","description":"Parkinson's Disease","metadata":null},{"id":"261b0f1b4da248238d14b00b5343c788","type":"TRIAL","name":"Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)","canonical_id":"clinicaltrials.gov:NCT02864004","description":"Parkinson's Disease","metadata":null},{"id":"f212eb11ad95406f8e9ef6cc0c01715e","type":"TRIAL","name":"Apomorphine in Parkinson's Disease Patients With Visual Hallucinations","canonical_id":"clinicaltrials.gov:NCT02702076","description":"Parkinson's Disease; Hallucinations, Visual","metadata":null},{"id":"483a1156bdd4401d910a3eec7de6acad","type":"TRIAL","name":"Apomorphine in Severe Brain-injured Patients","canonical_id":"clinicaltrials.gov:NCT05213169","description":"Disorder of Consciousness","metadata":null},{"id":"86e47d89cfd84aa38854c82037c2ea71","type":"TRIAL","name":"Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia","canonical_id":"clinicaltrials.gov:NCT02872818","description":"Apoptotic Signal Pathways in Endometrial Hyperplasia","metadata":null},{"id":"7f0dacd197434caea4debb6af32d1730","type":"DISEASE","name":"Appendicitis","canonical_id":"mesh:D001064","description":null,"metadata":null},{"id":"eaabcdd636fa4baf87661e6179b29280","type":"TRIAL","name":"Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT05701436","description":"Liver, Cancer of, Primary Resectable","metadata":null},{"id":"f6a0f6049b7246858526d40a7e836361","type":"TRIAL","name":"Application of Esketamine in Anesthesia of Autism Children","canonical_id":"clinicaltrials.gov:NCT05960942","description":"Autism Spectrum Disorder","metadata":null},{"id":"0fc6df47b26b42b4b7ba201a4391466e","type":"TRIAL","name":"Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy","canonical_id":"clinicaltrials.gov:NCT05291325","description":"Bowel Preparation for Colonoscopy","metadata":null},{"id":"5108e78d294740f7a856fa070142a0e6","type":"TRIAL","name":"Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation","canonical_id":"clinicaltrials.gov:NCT05379491","description":"Colonoscopy","metadata":null},{"id":"1800747f2b924e6b8c4d662f2fc571b9","type":"TRIAL","name":"Application of Miglustat in Patients With Niemann-Pick Type C","canonical_id":"clinicaltrials.gov:NCT01760564","description":"Niemann-Pick Disease Type C","metadata":null},{"id":"e11ae648c49b453284e1a03850541d8e","type":"TRIAL","name":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT06016517","description":"Arthritis, Rheumatoid","metadata":null},{"id":"466875f4960949029413e5106e2a84c5","type":"TRIAL","name":"Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients","canonical_id":"clinicaltrials.gov:NCT01610141","description":"Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism; Heart Valve Disease","metadata":null},{"id":"ef42b4a16cb045ee9600715312efccfe","type":"DRUG","name":"Apremilast","canonical_id":"mesh:C505730","description":null,"metadata":null},{"id":"344ee285183e423bb5be37718136b7c5","type":"TRIAL","name":"Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab","canonical_id":"clinicaltrials.gov:NCT04306965","description":"Atopic Dermatitis","metadata":null},{"id":"1288207f558f464b96110a0c68cd8801","type":"TRIAL","name":"Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00521339","description":"Psoriasis-Type Psoriasis; Plaque-Type Psoriasis","metadata":null},{"id":"7a8a6884e9bd4b8ea1419251756c2581","type":"TRIAL","name":"Apremilast Therapy for Acute Gouty Arthritis","canonical_id":"clinicaltrials.gov:NCT00997581","description":"Acute Gout","metadata":null},{"id":"e893b50728c9400cb615a4b044a42775","type":"TRIAL","name":"Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT03553433","description":"Psoriasis of Scalp; Psoriasis Vulgaris","metadata":null},{"id":"3d234c759e60481c9f2b9cee47529086","type":"TRIAL","name":"Apremilast and Adalimumab in Psoriatic Arthritis Patients","canonical_id":"clinicaltrials.gov:NCT07398651","description":"Psoriatic Arthritis; Ultrasound Assessment; TNF","metadata":null},{"id":"2e6014f4ee1b4791aecdbbca6b05d212","type":"TRIAL","name":"Apremilast and Moderate to Severe Chronic Hand Dermatitis","canonical_id":"clinicaltrials.gov:NCT03741933","description":"Chronic Hand Dermatitis","metadata":null},{"id":"b7437d24d03040ada8364a2e8335930e","type":"TRIAL","name":"Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis","canonical_id":"clinicaltrials.gov:NCT03576287","description":"Prurigo Nodularis","metadata":null},{"id":"39374de59f424983b2c278e37cb14df5","type":"TRIAL","name":"Apremilast for Atopic Dermatitis - A Pilot Study in Adults","canonical_id":"clinicaltrials.gov:NCT01393158","description":"Atopic Dermatitis","metadata":null},{"id":"ed569902269346a995b2db6df2a7f894","type":"TRIAL","name":"Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy","canonical_id":"clinicaltrials.gov:NCT01200264","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"97adf00e50ed42f7a815b0c47b65819c","type":"TRIAL","name":"Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03453190","description":"Psoriasis","metadata":null},{"id":"1c199dfd005c4f8d95f7c3882295b1a7","type":"TRIAL","name":"Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)","canonical_id":"clinicaltrials.gov:NCT04572997","description":"Palmoplantar Pustulosis","metadata":null},{"id":"57225a641fa349ad96e0ce1cfc98fbd7","type":"TRIAL","name":"Apremilast in the Treatment of Moderate to Severe Acne","canonical_id":"clinicaltrials.gov:NCT01074502","description":"Acne","metadata":null},{"id":"28df101696a24b819d30ec4847d570fe","type":"TRIAL","name":"Aprepitant Effects in Intravenous Heroin Dependence","canonical_id":"clinicaltrials.gov:NCT01527994","description":"Opioid Dependence","metadata":null},{"id":"a73e0778fa1545bebb29837a5461abb1","type":"TRIAL","name":"Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries","canonical_id":"clinicaltrials.gov:NCT02525848","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"13aec946220842d5aaf75352472821a3","type":"TRIAL","name":"Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT03808805","description":"Myeloproliferative Disorder; Aquagenic Pruritus","metadata":null},{"id":"d8e33fdfd0d8441f97216fc6c0024249","type":"TRIAL","name":"Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02909478","description":"Chemotherapy-induced Nausea and Vomiting; Colorectal Cancer","metadata":null},{"id":"73dcb840d4c843c48010367d12d94d8c","type":"TRIAL","name":"Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)","canonical_id":"clinicaltrials.gov:NCT01111851","description":"Chemotherapy-Induced Nausea and Vomiting (CINV)","metadata":null},{"id":"3d1a598a2dbf43d0a89c55984435914c","type":"TRIAL","name":"Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01183481","description":"Nausea; Vomiting","metadata":null},{"id":"8a3b33bdefb84065b87742548e7194b0","type":"TRIAL","name":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00337727","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"38b6ae912e564d81a3d0e886dfdacb84","type":"TRIAL","name":"Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT02933099","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"3f830a6de4204234b1174f7e427ec702","type":"TRIAL","name":"Aprepitant for the Treatment of CLIFAHDD","canonical_id":"clinicaltrials.gov:NCT07845825","description":"CLIFAHDD; Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay; NALCN Channelopathy; Ataxia - Other; Neurodevelopmental Disorder (Diagnosis)","metadata":null},{"id":"83648d90ca194914a394f7b56c90a977","type":"TRIAL","name":"Aprepitant in the Management of Biological Therapies-related Severe Pruritus","canonical_id":"clinicaltrials.gov:NCT01683552","description":"ITCH","metadata":null},{"id":"2959ae962893400db04fd2ea0da65b09","type":"TRIAL","name":"Aprepitant to Improve Same Day Discharge for TKA","canonical_id":"clinicaltrials.gov:NCT07639723","description":"PONV","metadata":null},{"id":"cd30727ecd2b4816a9d6d2f93e305a24","type":"TRIAL","name":"Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients","canonical_id":"clinicaltrials.gov:NCT00651755","description":"Lymphoma","metadata":null},{"id":"b5b0f11add434d45a2e02058443a57ff","type":"DRUG","name":"Aprotinin","canonical_id":"mesh:D007611","description":null,"metadata":null},{"id":"95a087cf192e42449ad0ee6d36194344","type":"TRIAL","name":"Aprotinin US Special Access Protocol","canonical_id":"clinicaltrials.gov:NCT00611845","description":"Postoperative Hemorrhage","metadata":null},{"id":"a9a054f5a9da4aac97ee02c47b50ac70","type":"DISEASE","name":"Aptyalism","canonical_id":"mesh:D014987","description":null,"metadata":null},{"id":"51b7bb33a1d345f89baca99699fff14a","type":"TRIAL","name":"Aquaresis Utility for Hyponatremic Acute Heart Failure Study","canonical_id":"clinicaltrials.gov:NCT02183792","description":"Heart Failure","metadata":null},{"id":"8cb702089c124a85a0afd793875ea747","type":"TRIAL","name":"Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients","canonical_id":"clinicaltrials.gov:NCT00347503","description":"Cataract","metadata":null},{"id":"c452a1781f8340ddb05c7e5724f6dcd9","type":"TRIAL","name":"Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04675086","description":"Covid19; Pneumonia, Viral","metadata":null},{"id":"32b262b1642f4f9b997ff80539e85ec3","type":"TRIAL","name":"Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT04996550","description":"Chronic Heart Failure","metadata":null},{"id":"2f5d9a8847e945e4b814b6a10d33d688","type":"TRIAL","name":"Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT03552354","description":"Stroke, Ischemic","metadata":null},{"id":"8340c997166b491d897440342feaaf0d","type":"TRIAL","name":"Argatroban Plus R-tPA for Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT03740958","description":"Stroke","metadata":null},{"id":"00b99cef6d204cfca4e5ad08136c47b6","type":"TRIAL","name":"Argatroban Plus r-tPA for Posterior Circulation Infarction\uff08AR-PCI\uff09","canonical_id":"clinicaltrials.gov:NCT03506009","description":"Argatroban, Rt-PA","metadata":null},{"id":"92436c01f2a146afb827f3dac3aced45","type":"TRIAL","name":"Argatroban Stroke Treatment - A Pilot Safety Study","canonical_id":"clinicaltrials.gov:NCT00268762","description":"Ischemic Stroke","metadata":null},{"id":"9e3ce1fa013f4c05982e966251e78919","type":"TRIAL","name":"Argatroban Versus Lepirudin in Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT00798525","description":"Heparin Induced Thrombocytopenia (HIT)","metadata":null},{"id":"2a68ade2e7704cec84d23c13160d9b6c","type":"TRIAL","name":"Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting","canonical_id":"clinicaltrials.gov:NCT01980316","description":"CVD","metadata":null},{"id":"0d0bb048e4714479b58154c11fcbb57e","type":"TRIAL","name":"Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting","canonical_id":"clinicaltrials.gov:NCT01163604","description":"CVD","metadata":null},{"id":"ac6cdaf099534ce18c40f57d26f34562","type":"TRIAL","name":"Argatroban in Critically Ill Patients With Heparin Resistance","canonical_id":"clinicaltrials.gov:NCT01734252","description":"Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance","metadata":null},{"id":"f5c6e1cc42654dca924c75a69f360a76","type":"TRIAL","name":"Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment","canonical_id":"clinicaltrials.gov:NCT00605267","description":"Breast Cancer","metadata":null},{"id":"b0f8cb71e3a149718c275334749f4fd6","type":"DRUG","name":"Aripiprazole","canonical_id":"mesh:D000068180","description":null,"metadata":null},{"id":"208f9233c1f7444da36f41b3ee2530f0","type":"TRIAL","name":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01488266","description":"Major Depressive Disorder","metadata":null},{"id":"1e4444ca2b224446ae5d53b49be7bb24","type":"TRIAL","name":"Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression","canonical_id":"clinicaltrials.gov:NCT00608543","description":"Major Depressive Disorder","metadata":null},{"id":"f6e6af5513304e4c877610bea9da87ac","type":"TRIAL","name":"Aripiprazole IM Depot for Chinese Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03287505","description":"Schizophrenia","metadata":null},{"id":"00e3377fb5da46b7a4dfc926aa0f6388","type":"TRIAL","name":"Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00102479","description":"Schizophrenia; Mania","metadata":null},{"id":"738892755b5d4217801995c2045d7b5a","type":"TRIAL","name":"Aripiprazole and Effexor XR Drug Interaction Study","canonical_id":"clinicaltrials.gov:NCT00362271","description":"Healthy","metadata":null},{"id":"5ea75b2bc8f24901b919575694304ab6","type":"TRIAL","name":"Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial","canonical_id":"clinicaltrials.gov:NCT00728312","description":"Methamphetamine Dependence","metadata":null},{"id":"0244dbf88daa4799862ec6450a228b25","type":"TRIAL","name":"Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia","canonical_id":"clinicaltrials.gov:NCT00837707","description":"Dyskinesia, Drug-Induced","metadata":null},{"id":"3cee82d09d404836a0bddd1545b928f1","type":"TRIAL","name":"Aripiprazole in Late Life Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00194038","description":"Bipolar Disorder","metadata":null},{"id":"23d3f88bac014dc5b99b992e5c3fbd34","type":"TRIAL","name":"Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome","canonical_id":"clinicaltrials.gov:NCT03449888","description":"Veterans Referred to the St. Louis VAMC Stress Tes","metadata":null},{"id":"aa100d66d00b456295382bc31a995ce8","type":"DRUG","name":"Armodafinil","canonical_id":"mesh:C579652","description":null,"metadata":null},{"id":"0e3641a84a5141fe836fdfcd98c441b8","type":"TRIAL","name":"Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure","canonical_id":"clinicaltrials.gov:NCT00555477","description":"Breast Cancer","metadata":null},{"id":"11d880cc97d046ac8ec75c0ece99efca","type":"GO_TERM","name":"Arp2/3 complex binding","canonical_id":"go:GO:0071933","description":"\"Binding to an Arp2/3 complex, a protein complex that contains two actin-related proteins, Arp2 and Arp3, and five novel proteins (ARPC1-5).\" [GOC:mah]","metadata":null},{"id":"821ae8ef55404b75ba9330d0b05f254c","type":"GO_TERM","name":"Arp2/3 complex-mediated actin nucleation","canonical_id":"go:GO:0034314","description":"\"The actin nucleation process in which actin monomers combine to form a new branch on the side of an existing actin filament; mediated by the Arp2/3 protein complex and its interaction with other proteins.\" [GOC:mah, PMID:16959963, PMID:18640983]","metadata":null},{"id":"5276b2fca4d34fb6969efe3382c83c16","type":"GO_TERM","name":"Arp2/3 protein complex","canonical_id":"go:GO:0005885","description":"\"A stable protein complex that contains two actin-related proteins, Arp2 and Arp3, and five novel proteins (ARPC1-5), and functions in the nucleation of branched actin filaments.\" [GOC:jl, GOC:vw, PMID:12479800]","metadata":null},{"id":"3886f3c4361c4c0cb84e5de907570842","type":"TRIAL","name":"Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy","canonical_id":"clinicaltrials.gov:NCT00006220","description":"Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes","metadata":null},{"id":"8a1926c1b6ae4d8a94245c6eee7de70f","type":"TRIAL","name":"Arterial Disease Multifactorial Intervention Trial (ADMIT)","canonical_id":"clinicaltrials.gov:NCT00000539","description":"Arterial Occlusive Diseases; Cardiovascular Diseases; Heart Diseases; Vascular Diseases; Diabetes Mellitus","metadata":null},{"id":"287ce12d5d594599bb14eaba2a1160d2","type":"TRIAL","name":"Arterial Hypertension Related to PARP Inhibitors (ArteRIB)","canonical_id":"clinicaltrials.gov:NCT04774406","description":"Cancer","metadata":null},{"id":"987230bf247140df876f8fc59046d747","type":"TRIAL","name":"Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.","canonical_id":"clinicaltrials.gov:NCT02785224","description":"Cardiac Arrest","metadata":null},{"id":"f16a30100d8f4eaf9672d44ef50fc4f0","type":"TRIAL","name":"Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive Pill","canonical_id":"clinicaltrials.gov:NCT07536763","description":"Contraception","metadata":null},{"id":"73a362a4373b446ba7b7d376179f6081","type":"DISEASE","name":"Arteriosclerosis","canonical_id":"mesh:D001161","description":null,"metadata":null},{"id":"4ea3abe35396451291a1f6b2f8031658","type":"TISSUE","name":"Artery Aorta","canonical_id":"uberon:UBERON:0001496","description":null,"metadata":null},{"id":"672de0f2d2f14a6e8212b2af9fa9fdc6","type":"TISSUE","name":"Artery Coronary","canonical_id":"uberon:UBERON:0001621","description":null,"metadata":null},{"id":"641c2e6adc9f4e3eb2bbeab38786a7ed","type":"TISSUE","name":"Artery Tibial","canonical_id":"uberon:UBERON:0007610","description":null,"metadata":null},{"id":"63d0fc77c67d4b5eb6021ffd6476a1c7","type":"DRUG","name":"Artesunate","canonical_id":"mesh:D000077332","description":null,"metadata":null},{"id":"b948a79881a94180a6809112ba6f9ef7","type":"DISEASE","name":"Arthralgia","canonical_id":"hp:0002829","description":null,"metadata":null},{"id":"6578fc7826484d6993d346dc2f4ddb21","type":"DISEASE","name":"Arthritis","canonical_id":"mesh:D001168","description":null,"metadata":null},{"id":"7c4b088fa298461ea5a9812b3595c52e","type":"DISEASE","name":"Arthritis, Infectious","canonical_id":"mesh:D001170","description":null,"metadata":null},{"id":"de9280d2c9e248a584740ce5e820ae7a","type":"TRIAL","name":"Arthroscopic Rotator Cuff Repair Performed With Intraarticular Tranexamic Acid Could it Provide Improved Visual Clarity and Less Post-operative Pain? A Prospective, Double Blind, Randomized Study of 64 Patients.","canonical_id":"clinicaltrials.gov:NCT05453266","description":"Rotator Cuff Tears; Rotator Cuff Rupture; Tranexamic Acid; Shoulder Arthroscopy; Visual Clarity","metadata":null},{"id":"36706b1e2ae64ff48bd7451a2572cdfe","type":"DISEASE","name":"Articular gout","canonical_id":"mesh:D015210","description":null,"metadata":null},{"id":"1085b35b0b284709a8b2fdc60071c84a","type":"DISEASE","name":"Ascariasis","canonical_id":"mesh:D001196","description":null,"metadata":null},{"id":"6c8a59b3e4c0433b9a1e855ecb2b6225","type":"TRIAL","name":"Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)","canonical_id":"clinicaltrials.gov:NCT06721871","description":"Microvillus Inclusion Disease; Congenital Disorders; Rare Diseases","metadata":null},{"id":"78e79716b5f645d1b8e1f4aea2b00e2f","type":"TRIAL","name":"Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers","canonical_id":"clinicaltrials.gov:NCT00798252","description":"Advanced Cancer","metadata":null},{"id":"80e3ed4aad284d32a8c583e91c11d842","type":"DISEASE","name":"Ascending tubular aorta aneurysm","canonical_id":"hp:0004970","description":null,"metadata":null},{"id":"e48c4a66036d487080e44be27a90eb56","type":"TRIAL","name":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","canonical_id":"clinicaltrials.gov:NCT07493408","description":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL); Blastic Transformation of Chronic Myeloid Leukemia; Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL); Haematopoietic Stem Cell Transplant, Allogeneic","metadata":null},{"id":"46ca5c581d7a4ff4a8b955a74dbd7b5a","type":"DISEASE","name":"Ascites","canonical_id":"hp:0001541","description":null,"metadata":null},{"id":"c7c16758f58249e8bb15d150ba940b93","type":"DISEASE","name":"Ascites","canonical_id":"mesh:D001201","description":null,"metadata":null},{"id":"d14672ed15ce420aa313c536693acbfa","type":"DISEASE","name":"Ascorbic acid deficiency","canonical_id":"mesh:D001206","description":null,"metadata":null},{"id":"59b9ae85068242f5b31a243b8cf867eb","type":"DRUG","name":"Asenapine","canonical_id":"mesh:C522667","description":null,"metadata":null},{"id":"ac05368771914286899a2e9422a75657","type":"TRIAL","name":"Asenapine for Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT01807741","description":"Bipolar Depression","metadata":null},{"id":"c45280a83d764104875487df40a64b09","type":"TRIAL","name":"Asenapine in the Treatment of Older Adults With Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT01460290","description":"Bipolar Disorder","metadata":null},{"id":"76dd15d6d85e4fd5a1def85276fb3c6c","type":"GO_TERM","name":"Asi complex","canonical_id":"go:GO:0097658","description":"\"A nuclear ubiquitin ligase multiprotein complex located in the inner nuclear membrane (INM) that recognizes and ubiquitinates misfolded INM proteins and also some proteins involved in sterol biosynthesis, during ER-associated protein degradation (ERAD). In S. cerevisiae, this complex contains the ubiquitin ligases Asi1p and Asi3p.\" [GOC:mcc, PMID:25236469]","metadata":null},{"id":"9b5a38bd7ae34a6f85be8b0c4e43ed44","type":"TRIAL","name":"Asian Investigation of Lanreotide Autogel\u00ae in the Management of GEP-NETs","canonical_id":"clinicaltrials.gov:NCT04696042","description":"Neuroendocrine Tumors","metadata":null},{"id":"3ff1a54efd304785ba531b0d5c52bccc","type":"TRIAL","name":"Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines","canonical_id":"clinicaltrials.gov:NCT01076478","description":"Polyneuropathy","metadata":null},{"id":"03062f03adb345b38a659731af39b35c","type":"DRUG","name":"Aspartic Acid, Potassium Salt","canonical_id":"mesh:D001224","description":null,"metadata":null},{"id":"527e4b2d94204613848d1f1e61d8d0d2","type":"DISEASE","name":"Aspergillosis","canonical_id":"mesh:D001228","description":null,"metadata":null},{"id":"375ee11d5b1f43459eb78940486c68f9","type":"DISEASE","name":"Aspergillosis, Allergic Bronchopulmonary","canonical_id":"mesh:D001229","description":null,"metadata":null},{"id":"fd050c5211fc4a5984697976e6d15b5b","type":"TRIAL","name":"Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.","canonical_id":"clinicaltrials.gov:NCT05914077","description":"Intraductal Papillary Mucinous Neoplasm of Pancreas","metadata":null},{"id":"43694b0529bd4fcbabeec0c8145e061b","type":"DISEASE","name":"Aspiration pneumonia","canonical_id":"mesh:D011015","description":null,"metadata":null},{"id":"2d27e97d6ac749b6904eeefe3689890b","type":"DRUG","name":"Aspirin","canonical_id":"mesh:D001241","description":null,"metadata":null},{"id":"a955730773f94c6b84966e4fd01f7bcc","type":"DRUG","name":"Aspirin","canonical_id":"ncit:C287","description":null,"metadata":null},{"id":"4b2c14a12309452e90991bfd498f453f","type":"TRIAL","name":"Aspirin Or Warfarin To Prevent Stroke","canonical_id":"clinicaltrials.gov:NCT00004728","description":"Stroke; Cerebral Infarction; Atherosclerosis; Constriction, Pathologic","metadata":null},{"id":"1e1652e8f9324d04a53e69f71d993d0d","type":"TRIAL","name":"Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers","canonical_id":"clinicaltrials.gov:NCT02348203","description":"Tobacco Use Disorder","metadata":null},{"id":"61235577fb684da1ac1a654d1feea3dc","type":"TRIAL","name":"Aspirin in Patients With Myocardial Infarction and Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT00501345","description":"Thrombocytopenia; Myocardial Infarction","metadata":null},{"id":"c50324bc99b6468b84609cb5cda2b637","type":"TRIAL","name":"Aspirin vs Clopidogrel After TAVR","canonical_id":"clinicaltrials.gov:NCT05493657","description":"Severe Aortic Stenosis","metadata":null},{"id":"05842f2b102f489ba6aa764ad59e4d9d","type":"TRIAL","name":"Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00699777","description":"Osteoporosis","metadata":null},{"id":"7a5d3e1b32dc48c2a3fd338a8033743e","type":"TRIAL","name":"Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.","canonical_id":"clinicaltrials.gov:NCT01750281","description":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","metadata":null},{"id":"ebb71ac5f3474bc0935cca84fd306798","type":"TRIAL","name":"Assess Efficacy and Safety of TachoComb H vs. Standard Surgical Treatment (i.e. Suturing) in Patients Undergoing Prostatectomy (TC-017-AU)","canonical_id":"clinicaltrials.gov:NCT00290836","description":"Control of Local Bleeding in Patients Undergoing Prostatectomy.","metadata":null},{"id":"7ab016b8944e4052b0b807d634a08b74","type":"TRIAL","name":"Assess Efficacy in Subjects With Traumatic Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00667966","description":"Erectile Dysfunction; Spinal Cord Injury","metadata":null},{"id":"dbcd10e74d644c66a10e177b5bb0b1e4","type":"TRIAL","name":"Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours","canonical_id":"clinicaltrials.gov:NCT00668018","description":"Erectile Dysfunction","metadata":null},{"id":"58c0ea9e8100439cb00616105376ef86","type":"TRIAL","name":"Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon","canonical_id":"clinicaltrials.gov:NCT02583789","description":"Raynaud's Phenomenon","metadata":null},{"id":"f31e8cedd5b14b71a770afa685d298e4","type":"TRIAL","name":"Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability","canonical_id":"clinicaltrials.gov:NCT01682408","description":"Pharmacokinetics","metadata":null},{"id":"f63f1c3405a1449c993079596a2919a2","type":"TRIAL","name":"Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin","canonical_id":"clinicaltrials.gov:NCT00770302","description":"Type 2 Diabetes","metadata":null},{"id":"fcc25e3e166e42698f28c8dad0c9423c","type":"TRIAL","name":"Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine","canonical_id":"clinicaltrials.gov:NCT01184560","description":"Obesity","metadata":null},{"id":"0a2401c241e748bf842170865add9b89","type":"TRIAL","name":"Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00699504","description":"Healthy","metadata":null},{"id":"4de8f11cdd984a2fb1279c8bb0397bbb","type":"TRIAL","name":"Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function","canonical_id":"clinicaltrials.gov:NCT00655590","description":"Erectile Dysfunction","metadata":null},{"id":"b6bf2b27c72a4bf4be371f821780a97d","type":"TRIAL","name":"Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects","canonical_id":"clinicaltrials.gov:NCT00658606","description":"Plaque Psoriasis","metadata":null},{"id":"5611363b0b8042ac8c48341b22907088","type":"TRIAL","name":"Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate","canonical_id":"clinicaltrials.gov:NCT00755872","description":"Bioavailability","metadata":null},{"id":"ee5abda0888243fbb554ebc7e832031a","type":"TRIAL","name":"Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo","canonical_id":"clinicaltrials.gov:NCT04530344","description":"Vitiligo","metadata":null},{"id":"62a9e35c4cf94d33b5b44379b7946adf","type":"TRIAL","name":"Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01028053","description":"Mild Cognitive Impairment; Alzheimer's Disease","metadata":null},{"id":"478eb7351599459abb83eaefd2cf7135","type":"TRIAL","name":"Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01457339","description":"Schizophrenia","metadata":null},{"id":"41ea0693286046b683823a109c2e7081","type":"TRIAL","name":"Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.","canonical_id":"clinicaltrials.gov:NCT01204177","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"eb82aca7633b4058b01ff0ea6c816973","type":"TRIAL","name":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","canonical_id":"clinicaltrials.gov:NCT05359653","description":"Multiple Sclerosis (MS); Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis Relapse; Multiple Sclerosis Brain Lesion; Multiple Sclerosis Benign","metadata":null},{"id":"272860565d594cc8890ab2b8d4ae13c4","type":"TRIAL","name":"Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy","canonical_id":"clinicaltrials.gov:NCT06065670","description":"Demyelinating Diseases; Demyelination; Corpus Callosum; Multiple Sclerosis Brain Lesion; Multiple Sclerosis Acute and Progressive; Clinically Isolated Syndrome, CNS Demyelinating","metadata":null},{"id":"ec772aa909f84e21a2a9b96db3960609","type":"TRIAL","name":"Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill","canonical_id":"clinicaltrials.gov:NCT05243186","description":"Attention Deficit Disorder","metadata":null},{"id":"a0defb74ff8840dbbdc60d81f079f5a2","type":"TRIAL","name":"Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT00663845","description":"Erectile Dysfunction","metadata":null},{"id":"b9ad6a82419e4d528348484c690468ef","type":"TRIAL","name":"Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT00978796","description":"Type 1 Diabetes","metadata":null},{"id":"9603c7b9615140cf980f849df9971563","type":"TRIAL","name":"Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach","canonical_id":"clinicaltrials.gov:NCT03772262","description":"Interaction Drug Food","metadata":null},{"id":"ca315e86f6ae48319b3670ed9deb459f","type":"TRIAL","name":"Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression","canonical_id":"clinicaltrials.gov:NCT03507608","description":"Prostate Cancer","metadata":null},{"id":"ce880b6498b846ddb45defb015133353","type":"TRIAL","name":"Assessing Medical Menstrual Regulation in the United States","canonical_id":"clinicaltrials.gov:NCT03972358","description":"Menstrual Regulation","metadata":null},{"id":"943534040914444e9c2065f167be0d83","type":"TRIAL","name":"Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal","canonical_id":"clinicaltrials.gov:NCT05046041","description":"Abortion in Second Trimester","metadata":null},{"id":"fefa1c6ce9d5467cabd063807de8c367","type":"TRIAL","name":"Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone","canonical_id":"clinicaltrials.gov:NCT07760480","description":"Lupus Nephritis; Systemic Lupus Erythematosus (SLE)","metadata":null},{"id":"a61c1b3ad041493dae6143a0740a5b66","type":"TRIAL","name":"Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.","canonical_id":"clinicaltrials.gov:NCT06785675","description":"Hidradenitis Suppurativa","metadata":null},{"id":"33b406784f5d41a9b685c3ba61a262f4","type":"TRIAL","name":"Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity","canonical_id":"clinicaltrials.gov:NCT05006638","description":"Pesticide Poisoning","metadata":null},{"id":"31ecc94be29b4874a2d59874f8193437","type":"TRIAL","name":"Assessing Trauma-related Links Between Affective and Metabolic Systems","canonical_id":"clinicaltrials.gov:NCT07862712","description":"Posttraumatic Stress Disorder; Metabolic Syndrome; Insulin Resistance","metadata":null},{"id":"36e5c43c56b748449264808fb2ccda10","type":"TRIAL","name":"Assessing Use Of Mifepristone After Progestin Priming For Use As \"Missed Period Pills\"","canonical_id":"clinicaltrials.gov:NCT04676776","description":"Missed Menstrual Period","metadata":null},{"id":"b6043f8254ef402d820aff16a21f7d5a","type":"TRIAL","name":"Assessing of Tooth Sensitivity Using Ibuprofen Before in Office-tooth Bleaching","canonical_id":"clinicaltrials.gov:NCT01530217","description":"Inflammation; Pulpitis","metadata":null},{"id":"b8bd3c8c7ac0473fb2b3b2a5e8b1cbf1","type":"TRIAL","name":"Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS","canonical_id":"clinicaltrials.gov:NCT06334094","description":"Multiple Sclerosis","metadata":null},{"id":"7466d10d34de4297b48213725faacb29","type":"TRIAL","name":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT03802630","description":"Branch Retinal Vein Occlusion","metadata":null},{"id":"80ec1ec76aad4ba9ae992fe17ef6f6c1","type":"TRIAL","name":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT03810313","description":"Central Retinal Vein Occlusion","metadata":null},{"id":"5bc028b9c9fe4669b387347a6db6a729","type":"TRIAL","name":"Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis","canonical_id":"clinicaltrials.gov:NCT02644954","description":"Psoriasis","metadata":null},{"id":"d5e8d8248acc4d00994bbf11d21bcfd0","type":"TRIAL","name":"Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver","canonical_id":"clinicaltrials.gov:NCT00274495","description":"Chronic Hepatitis C Infection; Fatty Liver","metadata":null},{"id":"9294e86601424b82a26a850d65d0c4ba","type":"TRIAL","name":"Assessing the Efficacy and Tolerability of AZARGA\u00ae (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN\u00ae) in Latin America","canonical_id":"clinicaltrials.gov:NCT01518244","description":"Glaucoma","metadata":null},{"id":"a586799d6acd427f8d3d7fbbdf4b110d","type":"TRIAL","name":"Assessing the Efficacy and Tolerability of AZARGA\u00ae (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN\u00ae (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","canonical_id":"clinicaltrials.gov:NCT01514734","description":"Glaucoma","metadata":null},{"id":"1e015b8d67af4b2eb37737f2a77ba3cc","type":"TRIAL","name":"Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism","canonical_id":"clinicaltrials.gov:NCT02137265","description":"Non Obstructive Azoospermia; Hypogonadism","metadata":null},{"id":"d68d4bdb4ee14704a58716fa2687743f","type":"TRIAL","name":"Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients","canonical_id":"clinicaltrials.gov:NCT01695707","description":"Atopic Dermatitis","metadata":null},{"id":"1dbc44acf35345cb860e023d9db35955","type":"TRIAL","name":"Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire","canonical_id":"clinicaltrials.gov:NCT00147628","description":"Impotence","metadata":null},{"id":"35d4ea1893c84573b56f991b2e8c87b8","type":"TRIAL","name":"Assessment and Tracking of Long-term Alefacept Safety","canonical_id":"clinicaltrials.gov:NCT00454701","description":"Psoriasis","metadata":null},{"id":"03192119b53a46ce8fb90659dbe413a8","type":"TRIAL","name":"Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab","canonical_id":"clinicaltrials.gov:NCT02992301","description":"Atherosclerosis; Hyperlipidemia","metadata":null},{"id":"37063e604ef642c2b3fbe4b8a2020fe0","type":"TRIAL","name":"Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma","canonical_id":"clinicaltrials.gov:NCT00469183","description":"Melasma","metadata":null},{"id":"f074dd8aa8c04ec9a6fddf9f32fd6e3a","type":"TRIAL","name":"Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD","canonical_id":"clinicaltrials.gov:NCT03028701","description":"Copd","metadata":null},{"id":"eda95a70072a4113a34d0d0b7c872825","type":"TRIAL","name":"Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.","canonical_id":"clinicaltrials.gov:NCT03232632","description":"Cardiac Amyloidosis","metadata":null},{"id":"f799f9e14970463c9e1947fb5aa5b486","type":"TRIAL","name":"Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI","canonical_id":"clinicaltrials.gov:NCT01379001","description":"Cholinergic Function","metadata":null},{"id":"5fea58d67913455fb3990eee3fffb81a","type":"TRIAL","name":"Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)","canonical_id":"clinicaltrials.gov:NCT02521311","description":"Optic Neuritis","metadata":null},{"id":"921a3f2f1b04468daade4b14e187688e","type":"TRIAL","name":"Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02040298","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"277c33eede9449e0859471e402decef5","type":"TRIAL","name":"Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics","canonical_id":"clinicaltrials.gov:NCT01457053","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"98f4ed42d801427f9260529343f232bd","type":"TRIAL","name":"Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women","canonical_id":"clinicaltrials.gov:NCT04590417","description":"Drug Interaction","metadata":null},{"id":"e7fa9f4b535e466eaaef8f98a907853a","type":"TRIAL","name":"Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne\u00ae or Placebo.","canonical_id":"clinicaltrials.gov:NCT01569113","description":"Emergency Contraception","metadata":null},{"id":"b61b63546eab41dab2b772321c7b226a","type":"TRIAL","name":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","canonical_id":"clinicaltrials.gov:NCT06884670","description":"Rectal Cancer","metadata":null},{"id":"4f55efb3a15743129ebf5d6e814c7923","type":"TRIAL","name":"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","canonical_id":"clinicaltrials.gov:NCT04361032","description":"COVID19; Intensive Care Unit","metadata":null},{"id":"f8e4547996d24a56b62462fb9e9b650d","type":"TRIAL","name":"Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT00668109","description":"Erectile Dysfunction","metadata":null},{"id":"f62b3becf52c4fa084cbf1e347c3d9e5","type":"TRIAL","name":"Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00657839","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"9658fd2ed02e44f8bc4316ab5c35697c","type":"TRIAL","name":"Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis","canonical_id":"clinicaltrials.gov:NCT03218917","description":"Non-Cystic Fibrosis Bronchiectasis","metadata":null},{"id":"4f367e15422b46b88c90b6e25718a4be","type":"TRIAL","name":"Assessment of Inflammatory Mediators (AIM)","canonical_id":"clinicaltrials.gov:NCT00219895","description":"Cystic Fibrosis","metadata":null},{"id":"1b4e64567ca643e5902b67d918c844c3","type":"TRIAL","name":"Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride","canonical_id":"clinicaltrials.gov:NCT02943213","description":"Anti-Psychotic; Management of Manifestations of Psychotic Disorders; Treatment of Schizophrenia; Control Nausea and Vomiting; Relief of Restlessness and Apprehension Before Surgery; Acute Intermittent Porphyria; Adjunct in the Treatment of Tetanus; Control Manifestations of the Manic Type of Mani-depressive Illness; Relief of Intractable Hiccups","metadata":null},{"id":"a6ab681ab33246e6a98362325e9972ab","type":"TRIAL","name":"Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN\u00ae Z) or Bimatoprost 0.01% (LUMIGAN\u00ae)","canonical_id":"clinicaltrials.gov:NCT01464424","description":"Glaucoma; Ocular Hypertension; Open-Angle Glaucoma","metadata":null},{"id":"56f6437cea0342328b89c845cd6a482b","type":"TRIAL","name":"Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches","canonical_id":"clinicaltrials.gov:NCT04022525","description":"Rheumatoid Arthritis","metadata":null},{"id":"7d50be3799574e1bbc2e1f35d4b67a57","type":"TRIAL","name":"Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients","canonical_id":"clinicaltrials.gov:NCT00534625","description":"Asthma","metadata":null},{"id":"eb5476f3e2704f9f87e5713c859ea0b0","type":"TRIAL","name":"Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases","canonical_id":"clinicaltrials.gov:NCT00434317","description":"Neoplasm Metastasis","metadata":null},{"id":"c0b01a5b531741e389ce85a4b829e78d","type":"TRIAL","name":"Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT05662189","description":"Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism","metadata":null},{"id":"520688478c664860b5a329d4782323a9","type":"TRIAL","name":"Assessment of Potential Interactions Between Cocaine and Tolcapone - 1","canonical_id":"clinicaltrials.gov:NCT00033059","description":"Cocaine-Related Disorders","metadata":null},{"id":"e06a30fb803045709b1df24b04a4a80d","type":"TRIAL","name":"Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1","canonical_id":"clinicaltrials.gov:NCT00033072","description":"Amphetamine-Related Disorders","metadata":null},{"id":"62493510605a4da29483950c82380a79","type":"TRIAL","name":"Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study","canonical_id":"clinicaltrials.gov:NCT04084314","description":"Migraine; Migraine Disorders; Migraine Headache","metadata":null},{"id":"209846c9571d4fd0acdd5f53e95a5a4c","type":"TRIAL","name":"Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old","canonical_id":"clinicaltrials.gov:NCT00510003","description":"Atopic Dermatitis","metadata":null},{"id":"9d8998b2c7a24cd7b6062c5bf1382ce1","type":"TRIAL","name":"Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT06740799","description":"Hepatic Impairment","metadata":null},{"id":"6e99619c30ff42559ecef3dd733e01c8","type":"TRIAL","name":"Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine","canonical_id":"clinicaltrials.gov:NCT00401973","description":"Schizophrenia; Schizoaffective Disorders","metadata":null},{"id":"75379bd905554890aec4095962ef57ae","type":"TRIAL","name":"Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy","canonical_id":"clinicaltrials.gov:NCT01053559","description":"Crohn's Disease","metadata":null},{"id":"f3214321c51445bb8610683a59fda398","type":"TRIAL","name":"Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element\u2122 Stent Implantation","canonical_id":"clinicaltrials.gov:NCT01581515","description":"Coronary Artery Disease","metadata":null},{"id":"3fa1709e5e764cda848c5cc8125d4a54","type":"TRIAL","name":"Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients","canonical_id":"clinicaltrials.gov:NCT02212535","description":"Major Sickle Cell Syndrome of Type SS or S\u03b2 Thalassemia","metadata":null},{"id":"4968df1cf25246e9b64aec9a1e4b5d2e","type":"TRIAL","name":"Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks","canonical_id":"clinicaltrials.gov:NCT02090465","description":"Actinic Keratosis","metadata":null},{"id":"16e13bd01c854bf193c11ecc4804c1c4","type":"TRIAL","name":"Assessment of a New \"Boosting\" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03202511","description":"Pre-Exposure Prophylaxis","metadata":null},{"id":"2d037d09f0594287957dbf71cf58d8c9","type":"TRIAL","name":"Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women","canonical_id":"clinicaltrials.gov:NCT01839643","description":"Contraception; Bleeding Pattern","metadata":null},{"id":"e02d324ef4dc4b59a6261c1ffac007a9","type":"TRIAL","name":"Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel","canonical_id":"clinicaltrials.gov:NCT00447499","description":"Acromegaly","metadata":null},{"id":"f76a9baf70c0408fad6aea66a33ec3e0","type":"TRIAL","name":"Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03191539","description":"Arthritis; Psoriasis (Etiology)","metadata":null},{"id":"8325f8d5bc21440eaf5ea249562cff4a","type":"TRIAL","name":"Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05651074","description":"Healthy Subjects","metadata":null},{"id":"2b2fde71f33a418a9a81c8b53e59e5b7","type":"TRIAL","name":"Assessment of the Effectiveness of OLMETEC\u00ae and OLMETEC PLUS\u00ae for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00811226","description":"Hypertension","metadata":null},{"id":"32d543a6027f4ecc8cfc433cc25ff2a5","type":"TRIAL","name":"Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery","canonical_id":"clinicaltrials.gov:NCT01418118","description":"Oral Cancer; Head and Neck Cancer; Free Flap; Hypotension","metadata":null},{"id":"ea99223fd9ed42e495919a1af618305b","type":"TRIAL","name":"Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures","canonical_id":"clinicaltrials.gov:NCT01648101","description":"Epilepsy","metadata":null},{"id":"d9bdc9965f854774b4b402adfcfc1b89","type":"TRIAL","name":"Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin","canonical_id":"clinicaltrials.gov:NCT01632163","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"9da0ce0c564d4eb78acfe097476ad853","type":"TRIAL","name":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","canonical_id":"clinicaltrials.gov:NCT02000622","description":"Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation","metadata":null},{"id":"19c571604c5e40f18e2b1542a7d4e80a","type":"TRIAL","name":"Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril","canonical_id":"clinicaltrials.gov:NCT03730116","description":"Arterial Hypertension; CHD - Coronary Heart Disease","metadata":null},{"id":"433c3052068d4e79bf069842be035ef0","type":"TRIAL","name":"Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients","canonical_id":"clinicaltrials.gov:NCT05744635","description":"Liver Failure","metadata":null},{"id":"cd5467df32bd46b0a94e519951628e11","type":"TRIAL","name":"Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to \u22652 NSAIDs","canonical_id":"clinicaltrials.gov:NCT01091675","description":"Ankylosing Spondylitis","metadata":null},{"id":"aeeba08b8eae4c9bb7890084e12daa03","type":"TRIAL","name":"Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02951312","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"a69b896c8d7a48ec8537bee3cb39169a","type":"TRIAL","name":"Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00633997","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"cdb9f128075f41c19e7187d219280b73","type":"TRIAL","name":"Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT01339286","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"82f318e22a06400c9b68221f6f6bf4a5","type":"TRIAL","name":"Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk","canonical_id":"clinicaltrials.gov:NCT03841383","description":"Hypertension,Essential","metadata":null},{"id":"fef6b60eff5e4dd192c3b673d1530e4d","type":"TRIAL","name":"Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa","canonical_id":"clinicaltrials.gov:NCT06626165","description":"Ulcerative Colitis","metadata":null},{"id":"d2cca8ddc73641528961675590a88b19","type":"TRIAL","name":"Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline","canonical_id":"clinicaltrials.gov:NCT03015090","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"560110394e5d475c98ae5fa7acfeaf79","type":"TRIAL","name":"Association of Amisulpride Response in Schizophrenia With Brain Image","canonical_id":"clinicaltrials.gov:NCT02095938","description":"Schizophrenia; Schizophreniform Disorder","metadata":null},{"id":"cc340133e8274eb29c36ad9baac638e2","type":"TRIAL","name":"Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00283985","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"2fc76962e69f4528b6a57ec8557e7313","type":"TRIAL","name":"Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia","canonical_id":"clinicaltrials.gov:NCT01052870","description":"Androgenetic Alopecia","metadata":null},{"id":"d095e0229f744610981a5eab572c5e5b","type":"TRIAL","name":"Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy","canonical_id":"clinicaltrials.gov:NCT04258163","description":"Metastatic Breast Cancer","metadata":null},{"id":"889b1748ad2146209de4b085773b2254","type":"DRUG","name":"Astemizole","canonical_id":"mesh:D016589","description":null,"metadata":null},{"id":"a2d631fb8e48422a9f803021cdaff5a4","type":"DISEASE","name":"Asthma","canonical_id":"mesh:D001249","description":null,"metadata":null},{"id":"7a29831a9c1e443b8ee0dcf124c8ce62","type":"TRIAL","name":"Asthma Care With Alvesco\u00ae (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)","canonical_id":"clinicaltrials.gov:NCT00404547","description":"Asthma","metadata":null},{"id":"51f301335e7044bf92f05b1d8b39f0c4","type":"TRIAL","name":"Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00635882","description":"Asthma; Airway Inflammation","metadata":null},{"id":"100e0e3b7dd340b18d08b29aaad11af9","type":"DISEASE","name":"Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome","canonical_id":"mesh:D000080445","description":null,"metadata":null},{"id":"398fee81f4c840a6a67d4777a6aeecae","type":"DISEASE","name":"Astrocytoma, anaplastic","canonical_id":"mesh:D001254","description":null,"metadata":null},{"id":"111cf3bf35574c8296a5ae0c69a002a0","type":"TRIAL","name":"Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age","canonical_id":"clinicaltrials.gov:NCT00244621","description":"Hypertension","metadata":null},{"id":"e0428f8ce90c4eada3fbbdf655cef9d9","type":"DRUG","name":"Atenolol","canonical_id":"mesh:D001262","description":null,"metadata":null},{"id":"d140d4b802d140c5a72b55bffad07a6e","type":"DRUG","name":"Atezolizumab","canonical_id":"mesh:C000594389","description":null,"metadata":null},{"id":"895851f49fd54265a95019e5c4ab13b9","type":"DRUG","name":"Atezolizumab","canonical_id":"ncit:C106250","description":null,"metadata":null},{"id":"a63d9c6459034f279d48fef306222924","type":"TRIAL","name":"Atezolizumab Plus Bevacizumab in First Line NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT03836066","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"529c9a454e6a4e1986e6398106b73381","type":"TRIAL","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","canonical_id":"clinicaltrials.gov:NCT05000294","description":"Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer","metadata":null},{"id":"bec90916544a4927ba6e61d1cb2d2108","type":"TRIAL","name":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT03181100","description":"Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Carcinoma","metadata":null},{"id":"3d0e7961175f4f91945ccef43df04402","type":"TRIAL","name":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT03237780","description":"Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Ure\u2026","metadata":null},{"id":"156174713f7b4fc59403a3ac53f1e1a4","type":"TRIAL","name":"Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study","canonical_id":"clinicaltrials.gov:NCT05019703","description":"Locally Advanced Osteosarcoma; Metastatic Osteosarcoma; Recurrent Osteosarcoma; Refractory Osteosarcoma; Unresectable Osteosarcoma","metadata":null},{"id":"c03963c94db24648ab99268a53498d1c","type":"TRIAL","name":"Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03600701","description":"Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"c4f03b29f30345f29c626f5e2e7a69cb","type":"TRIAL","name":"Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02994576","description":"Nonsmall Cell Lung Cancer","metadata":null},{"id":"b051e5b188114cb4917292afb8c06971","type":"TRIAL","name":"Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03024437","description":"Metastatic Cancer; Renal Cancer","metadata":null},{"id":"3237958a8be245739329c2113cf57376","type":"GO_TERM","name":"Atg1/ULK1 kinase complex","canonical_id":"go:GO:1990316","description":"\"A protein complex consisting of Atg1 (or Atg1 homologs e.g. ULK1, ULK2 in mammals) and Atg13 along with other proteins that regulate its function (e.g. Atg17 in yeast or RB1CC1(FIP200) in mammals). This complex has serine/threonine protein kinase activity and is involved in autophagosome formation.\" [GOC:bhm, GOC:DOS, GOC:rb, PMID:15743910, PMID:19211835, PMID:19258318, PMID:19597335, PMID:22885598]","metadata":null},{"id":"724683c752cb4a3b857a6bef7f477e8d","type":"GO_TERM","name":"Atg1/ULK1 kinase complex assembly","canonical_id":"go:GO:1904745","description":"\"The aggregation, arrangement and bonding together of a set of components to form an Atg1/UKL1 kinase complex.\" [GO_REF:0000079, GOC:dph, GOC:TermGenie, PMID:25139988]","metadata":null},{"id":"5070800937084242965b062d51b09e28","type":"GO_TERM","name":"Atg12 activating enzyme activity","canonical_id":"go:GO:0019778","description":"\"Catalysis of the activation of the small ubiquitin-related modifier APG12, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:mah]","metadata":null},{"id":"de970a61e3d441f5825d39553ea58354","type":"GO_TERM","name":"Atg12 conjugating enzyme activity","canonical_id":"go:GO:0061651","description":"\"Isoenergetic transfer of Atg12 from one protein to another via the reaction X-Atg12 + Y = Y-Atg12 + X, where both the X-Atg12 and Y-Atg12 linkages are thioester bonds between the C-terminal amino acid of Atg12 and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"5378bf5ab70044478413559a63f2e27a","type":"GO_TERM","name":"Atg12 ligase activity","canonical_id":"go:GO:0061660","description":"\"Catalysis of the transfer of Atg12 to a substrate protein via the reaction X-Atg12 + S = X + S-Atg12, where X is either an E2 or E3 enzyme, the X-Atg12 linkage is a thioester bond, and the S-Atg12 linkage is an isopeptide bond between the C-terminal amino acid of Atg12 and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"bef2a6c8840141a1b4fe408def284b21","type":"GO_TERM","name":"Atg12 transferase activity","canonical_id":"go:GO:0019777","description":"\"Catalysis of the transfer of ATG12 from one protein to another via the reaction X-ATG12 + Y = Y-ATG12 + X, where both X-ATG12 and Y-ATG12 are covalent linkages.\" [GOC:mah, PMID:12826404]","metadata":null},{"id":"501c7c97da6442e3ac83007319544f68","type":"GO_TERM","name":"Atg12-Atg5-Atg16 complex","canonical_id":"go:GO:0034274","description":"\"A protein complex required for the expansion of the autophagosomal membrane. In budding yeast, this complex consists of Atg12p, Atg5p and Atg16p.\" [GOC:rb, PMID:17986448]","metadata":null},{"id":"cf15247bcb754f5f89a20176cd7f5356","type":"GO_TERM","name":"Atg8 activating enzyme activity","canonical_id":"go:GO:0019779","description":"\"Catalysis of the activation of the small ubiquitin-related modifier APG8, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:mah]","metadata":null},{"id":"eed299f2444b45959038e5a2565f24a9","type":"GO_TERM","name":"Atg8-family conjugating enzyme activity","canonical_id":"go:GO:0141046","description":"\"Isoenergetic transfer of an Atg8 family modifier from one protein to a phosphatidylethanolamine or phosphatidylserine on a membrane, via the reaction X-Atg8 + Y = Y-Atg8 + X.\" [PMID:11100732, PMID:17986448, PMID:18704115, PMID:28234446, PMID:33909989]","metadata":null},{"id":"ad626f610f904243b73971939a3e48c8","type":"GO_TERM","name":"Atg8-family ligase activity","canonical_id":"go:GO:0019776","description":"\"Catalysis of the covalent attachment of the ubiquitin-like protein Atg8 family modifier to phosphatidylethanolamine or phosphatidylserine on a membrane.\" [PMID:12826404]","metadata":null},{"id":"287d724040a741a0b9d79ea14d33709d","type":"TRIAL","name":"Atherogenic Index of Plasma and Tadalafil Response in Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT07479901","description":"Erectile Dysfunction","metadata":null},{"id":"87ee166f48574d3ab40d6ee7745ae33d","type":"DISEASE","name":"Atherosclerosis","canonical_id":"mesh:D050197","description":null,"metadata":null},{"id":"3a9a7ad81a824cd3979e97d220da9b3a","type":"DRUG","name":"Atomoxetine","canonical_id":"mesh:D000069445","description":null,"metadata":null},{"id":"a2f012973f9e4320b21e0451ece2b83d","type":"TRIAL","name":"Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00191295","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"ebe998616351445998f51e3bfd671e35","type":"TRIAL","name":"Atomoxetine and Oxybutynin in Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT02908529","description":"Obstructive Sleep Apnea (OSA)","metadata":null},{"id":"3b30cd548a7d413896c3fbce6316fe1f","type":"TRIAL","name":"Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia","canonical_id":"clinicaltrials.gov:NCT01863251","description":"Opiate Dependence; Stimulant Dependence","metadata":null},{"id":"c648b869eeab4cacb482c9232788ee3a","type":"TRIAL","name":"Atomoxetine in Veterans With Comorbid ADHD/PTSD","canonical_id":"clinicaltrials.gov:NCT02287038","description":"Post Traumatic Stress Disorder; Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"76030882f6cd4927be3ad221fceddada","type":"TRIAL","name":"Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00191542","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"8ef330960b794f6a81c28743ee4b9229","type":"TRIAL","name":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","canonical_id":"clinicaltrials.gov:NCT07448363","description":"Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema); Atopic Dermatitis Patients; Atopic Dermatitis / Eczema; Atopic Dermatitis, Unspecified","metadata":null},{"id":"5b02837823db466496a65b6f3caf4d85","type":"DISEASE","name":"Atopic dermatitis","canonical_id":"mesh:D003876","description":null,"metadata":null},{"id":"e13fba3a69224e1180c6299bc6750ec9","type":"TRIAL","name":"Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)","canonical_id":"clinicaltrials.gov:NCT02764736","description":"Complication of Renal Dialysis","metadata":null},{"id":"a0a5329c6e4f415aa4fa9c8ec0dbe9c5","type":"TRIAL","name":"Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis.","canonical_id":"clinicaltrials.gov:NCT04056039","description":"Cardiovascular Diseases; Arthritis, Rheumatoid","metadata":null},{"id":"ae10da6e84ee414cb251ee05006ec155","type":"DRUG","name":"Atovaquone","canonical_id":"mesh:D053626","description":null,"metadata":null},{"id":"8c72d7cf42964234aeddf0a0732c3b90","type":"TRIAL","name":"Atovaquone (Mepron\u00ae) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT03568994","description":"Acute Myeloid Leukemia","metadata":null},{"id":"e66168047ba94beca3ffb52c5b465853","type":"TRIAL","name":"Atrasentan Spermatogenesis and Testicular Function","canonical_id":"clinicaltrials.gov:NCT02118714","description":"Nephropathy; Diabetes","metadata":null},{"id":"3f464414aed741f2ad631a1778e87d07","type":"TRIAL","name":"Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone","canonical_id":"clinicaltrials.gov:NCT00181558","description":"Prostate Cancer; Adenocarcinoma of the Prostate","metadata":null},{"id":"789cfc7d66e5471c858848c04ee400ae","type":"TRIAL","name":"Atrasentan in Patients With IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT04573478","description":"IgA Nephropathy; Immunoglobulin A Nephropathy","metadata":null},{"id":"7fba99c7df0d43fe99d08adb117a70b2","type":"TRIAL","name":"Atrasentan in Patients With Proteinuric Glomerular Diseases","canonical_id":"clinicaltrials.gov:NCT04573920","description":"IgA Nephropathy; Focal Segmental Glomerulosclerosis; Alport Syndrome; Diabetic Kidney Disease; Diabetic Nephropathy Type 2; Immunoglobulin A Nephropathy","metadata":null},{"id":"b0e170f2a4474488aca91c4e5279c2cc","type":"TRIAL","name":"Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00039429","description":"Kidney Cancer","metadata":null},{"id":"dd885f1e138c44bd83d189866bc3a2aa","type":"TRIAL","name":"Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT00017264","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"5814a4223e6a46f29ab0e384de51b6e0","type":"TRIAL","name":"Atrasentan in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00046943","description":"Prostate Cancer","metadata":null},{"id":"3c14dacfd7cb46aea76932365b684c3e","type":"DISEASE","name":"Atrial Fibrillation","canonical_id":"mesh:D001281","description":null,"metadata":null},{"id":"5e6e586e7e314513818d68f7d2fdea3c","type":"TRIAL","name":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","canonical_id":"clinicaltrials.gov:NCT00249795","description":"Atrial Fibrillation; Cardiovascular Disease","metadata":null},{"id":"3e335e234d8947c2944124025fb01578","type":"TRIAL","name":"Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)","canonical_id":"clinicaltrials.gov:NCT00000556","description":"Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases","metadata":null},{"id":"8bde92ecc0b24e7788a1abcc2e53c3b5","type":"TRIAL","name":"Atrial Fibrillation Patient Preference Study","canonical_id":"clinicaltrials.gov:NCT02611635","description":"Atrial Fibrillation","metadata":null},{"id":"1af822b088ef496186d1e1f69aabdc1e","type":"DISEASE","name":"Atrioventricular block","canonical_id":"mesh:D054537","description":null,"metadata":null},{"id":"9245b5d1f80e4dd78d8f93b39ba49887","type":"DISEASE","name":"Atrophic Vaginitis","canonical_id":"efo:1001271","description":null,"metadata":null},{"id":"d14d039a79aa4eabbbebc587837aa4fe","type":"DISEASE","name":"Atrophic vaginitis","canonical_id":"mesh:D059268","description":null,"metadata":null},{"id":"7cea91cbd1894f03b07b8c90f1482351","type":"DISEASE","name":"Atrophy","canonical_id":"efo:1000096","description":null,"metadata":null},{"id":"2004ca5e79bc44d6aafca9b728bf9b4c","type":"TRIAL","name":"Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)","canonical_id":"clinicaltrials.gov:NCT07028827","description":"Myopia","metadata":null},{"id":"cb54cd7787704a439dcaeb0ddc928956","type":"TRIAL","name":"Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation","canonical_id":"clinicaltrials.gov:NCT01595399","description":"Bradycardia; Hypoxemia","metadata":null},{"id":"7b2ee0a8c6ce450ba98bef05909ee327","type":"TRIAL","name":"Atropine vs Isoprenaline in the Invasive Diagnosis of Arrhythmias","canonical_id":"clinicaltrials.gov:NCT06082388","description":"Cardiac Arrhythmia; Supraventricular Arrhythmia","metadata":null},{"id":"445a5cc191d6408d849a97670415efeb","type":"TRIAL","name":"Atropine-effect During Propofol/Remifentanil Induction","canonical_id":"clinicaltrials.gov:NCT01871922","description":"Anesthesia-induced Negative Hemodynamic Effects","metadata":null},{"id":"e26a422d646d459f8867a71663c22084","type":"DISEASE","name":"Attention Deficit Disorder with Hyperactivity","canonical_id":"mesh:D001289","description":null,"metadata":null},{"id":"cc592389aac849a2be606cd23872cb4e","type":"TRIAL","name":"Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults","canonical_id":"clinicaltrials.gov:NCT00048360","description":"Attention Deficit Disorder","metadata":null},{"id":"0bd6bf8803614351b4fd79853131a5fb","type":"TRIAL","name":"Attentional Mechanisms in SCD","canonical_id":"clinicaltrials.gov:NCT06002477","description":"Subjective Cognitive Decline","metadata":null},{"id":"4aa962106de4467c8a2c86392675e739","type":"TRIAL","name":"Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints","canonical_id":"clinicaltrials.gov:NCT02394730","description":"HIV","metadata":null},{"id":"d055f9ec399c4ad190ead277da3d4e52","type":"TRIAL","name":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","canonical_id":"clinicaltrials.gov:NCT04446234","description":"Schizophrenia","metadata":null},{"id":"99cfc2366c2f4a909c7d64683487e9bc","type":"TRIAL","name":"Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT00299611","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"98fd99976d8b473d9f35e6bdfa645548","type":"TRIAL","name":"Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.","canonical_id":"clinicaltrials.gov:NCT00421369","description":"Major Depressive Disorder","metadata":null},{"id":"ce60827c46944d7497648b4e43c6df0f","type":"TRIAL","name":"Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00866749","description":"Lymphoblastic Leukemia; Lymphoblastic Lymphoma","metadata":null},{"id":"f47803d53848499cbf8c771a34c21e8d","type":"TRIAL","name":"Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT02419469","description":"Leukemia; Precursor-B Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Lymphoma","metadata":null},{"id":"99a3f89284584104a0d121e1f739b71b","type":"TRIAL","name":"Augmenting Effects of L-DOPS With Carbidopa and Entacapone","canonical_id":"clinicaltrials.gov:NCT00547911","description":"Parkinson Disease; Multiple System Atrophy; Autonomic Nervous System Diseases","metadata":null},{"id":"8dc97692be924fd99ec8209f00235664","type":"TRIAL","name":"Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects","canonical_id":"clinicaltrials.gov:NCT00567034","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"498735f1e6f74b70b65b47247dce6540","type":"DRUG","name":"Auranofin","canonical_id":"mesh:D001310","description":null,"metadata":null},{"id":"c3be908584434184b60b0463e9a3009b","type":"TRIAL","name":"Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT07348978","description":"Acne Vulgaris","metadata":null},{"id":"7cbef4c47c4b4898a70a6fc775265950","type":"TRIAL","name":"Aurinia Early Urinary Protein Reduction Predicts Response","canonical_id":"clinicaltrials.gov:NCT02949973","description":"Lupus Nephritis","metadata":null},{"id":"37862650272146aaae837e46e5a669f5","type":"TRIAL","name":"Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin","canonical_id":"clinicaltrials.gov:NCT03597464","description":"Lupus Nephritis","metadata":null},{"id":"2810559de69849cebacdb442944f91b1","type":"TRIAL","name":"Aurinia Renal Response in Active Lupus With Voclosporin","canonical_id":"clinicaltrials.gov:NCT03021499","description":"Lupus Nephritis","metadata":null},{"id":"f634dd6d8ae84589900572238e4cedf4","type":"DRUG","name":"Aurothioglucose","canonical_id":"mesh:D006051","description":null,"metadata":null},{"id":"dedd0914cae349e299adcd1c12727d01","type":"TRIAL","name":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","canonical_id":"clinicaltrials.gov:NCT04483960","description":"SARS-CoV-2 Infection (COVID-19)","metadata":null},{"id":"b20e33354ff34309a1fd32ea864b2a6d","type":"TRIAL","name":"Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT01969409","description":"Ambulatory IPF","metadata":null},{"id":"c8addcbfe2714353ae076f6c8023bcb4","type":"TRIAL","name":"Autoimmune Cytopenia and BcR Inhibitors","canonical_id":"clinicaltrials.gov:NCT03469895","description":"Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia","metadata":null},{"id":"cc34f06890f9416390dc137f0932c31f","type":"DISEASE","name":"Autoimmune Diseases","canonical_id":"mesh:D001327","description":null,"metadata":null},{"id":"5d01542f4fd64c35bdb2363d21a0f25d","type":"TRIAL","name":"Autologous Dendritic Cell Vaccine in Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT05127824","description":"Carcinoma, Renal Cell","metadata":null},{"id":"3c2abe21424c43f5941cd0b016ecf36e","type":"TRIAL","name":"Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01008462","description":"B-Cell Prolymphocytic Leukemia; Hypodiploidy; Loss of Chromosome 17p; Plasma Cell Leukemia; Progression of Multiple Myeloma or Plasma Cell Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Childhood Hodgkin Lymphoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractor\u2026","metadata":null},{"id":"869b260aa4664ec59c9a28d798aa6a57","type":"TRIAL","name":"Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers","canonical_id":"clinicaltrials.gov:NCT05912712","description":"Ulcerative Colitis Chronic Moderate; Ulcerative Colitis Chronic Severe; Rectal Ulcer","metadata":null},{"id":"64cde69cd6a24acaa5bb8f8f87b127fd","type":"TRIAL","name":"Autologous Platelet-rich Plasma for Clomiphene Citrate-induced Thin Endometrium","canonical_id":"clinicaltrials.gov:NCT03770026","description":"Infertility, Female, Associated With Anovulation","metadata":null},{"id":"583698d37b114d1a8013c7a866e11a54","type":"TRIAL","name":"Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT04491370","description":"B-cell Lymphoma; Burkitt Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Transformed Non-Hodgkin Lymphoma; Richter Syndrome; Hodgkin Lymphoma","metadata":null},{"id":"c8a7bc23fbfa44238540c25e00d6709d","type":"TRIAL","name":"Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01786707","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"0b2857aa61e14e91bc5a383d694e663b","type":"TRIAL","name":"Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.","canonical_id":"clinicaltrials.gov:NCT07486583","description":"Chronic Idiopathic Urticaria","metadata":null},{"id":"101c71841ad44a3ba78d706b68572f8a","type":"PROTEIN","name":"Autolysin","canonical_id":"uniprot:P06653","description":null,"metadata":null},{"id":"00b47f333edb491e9874c8bfe9f382d7","type":"PROTEIN","name":"Autolysin","canonical_id":"uniprot:J7M8X7","description":null,"metadata":null},{"id":"20e573e27b8b43c6b363b81234db09cc","type":"TRIAL","name":"Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00856063","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"8be81f6d92af41cd9fd6c4a4c3a12a6b","type":"TRIAL","name":"Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT02025608","description":"Restless Legs Syndrome","metadata":null},{"id":"f5afe398f5db423786b2f0746389cdd1","type":"TRIAL","name":"Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial","canonical_id":"clinicaltrials.gov:NCT04190433","description":"Breast Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Lymphoma; Sarcoma","metadata":null},{"id":"d040936712ed4bed9f6bedd226148d5e","type":"TRIAL","name":"Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07","canonical_id":"clinicaltrials.gov:NCT01447719","description":"Alzheimer's Disease","metadata":null},{"id":"cd083aa35e7545bcb826ce3ea61294bd","type":"TRIAL","name":"Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy","canonical_id":"clinicaltrials.gov:NCT00335413","description":"Hypertension","metadata":null},{"id":"8f4cdd2f09d54ab18ccfa79f31e5decb","type":"TRIAL","name":"Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT03169582","description":"Erectile Dysfunction","metadata":null},{"id":"d9f7198beabb4cf388a852871d90a4d5","type":"TRIAL","name":"Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma","canonical_id":"clinicaltrials.gov:NCT04150562","description":"Clear-Cell Renal Carcinoma","metadata":null},{"id":"aafb3d4745324912bac2880bb0be1cb8","type":"TRIAL","name":"Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT03966118","description":"Gastroesophageal Junction Adenocarcinoma; Adenocarcinoma of the Stomach","metadata":null},{"id":"9678aea142744077a18bc8c9471280a4","type":"TRIAL","name":"Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer","canonical_id":"clinicaltrials.gov:NCT03608046","description":"Colorectal Neoplasms, Malignant","metadata":null},{"id":"ef28253ec254464796b94cf2ce2891a8","type":"TRIAL","name":"Avelumab Program Rollover Study","canonical_id":"clinicaltrials.gov:NCT03815643","description":"Solid Tumors","metadata":null},{"id":"e89e313e92b846eebd5003447a89a488","type":"TRIAL","name":"Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04052204","description":"Squamous Cell Carcinoma of the Head and Neck (SCCHN); Metastatic Castration Resistant Prostate Cancer (mCRPC)","metadata":null},{"id":"0c97f036be1c48a7ad8a6e3f4cdf2df6","type":"TRIAL","name":"Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer","canonical_id":"clinicaltrials.gov:NCT03490292","description":"Resectable Esophageal Cancer; GastroEsophageal Cancer","metadata":null},{"id":"a33fb03d52b94ce28e7465ddddc0a68d","type":"TRIAL","name":"Avelumab With Chemoradiation in Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT03299660","description":"Rectal Cancer","metadata":null},{"id":"fe38943500e7482d98db26b4f01dab11","type":"TRIAL","name":"Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02953561","description":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"25fe71b51520467ca0f2456523236866","type":"TRIAL","name":"Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.","canonical_id":"clinicaltrials.gov:NCT03174405","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"3c7969a139014faaaeb1d8e8dd2b12f7","type":"TRIAL","name":"Avelumab and M1774 in ARID1A-mutated Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT06518564","description":"Endometrial Cancer; ARID1A Gene Mutation; Recurrent Endometrial Carcinoma","metadata":null},{"id":"70c7cc4d4bb743c89128cf822cd779b5","type":"TRIAL","name":"Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study","canonical_id":"clinicaltrials.gov:NCT03891238","description":"Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer","metadata":null},{"id":"423481bc469047de83747ff12033c553","type":"TRIAL","name":"Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias","canonical_id":"clinicaltrials.gov:NCT03135769","description":"Gestational Trophoblastic Neoplasias (GTN)","metadata":null},{"id":"ee48d22dc0ee4e79850a4163ea9534ae","type":"TRIAL","name":"Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03910439","description":"Myeloma, Multiple; Myeloma-Multiple","metadata":null},{"id":"a2922bbe51e341b8a83cb3bffb417916","type":"TRIAL","name":"Avelumab in First-line NSCLC (JAVELIN Lung 100)","canonical_id":"clinicaltrials.gov:NCT02576574","description":"First Line Non-Small Cell Lung Cancer","metadata":null},{"id":"5cd9d599d6d9441c8f0ad41732d9fe7a","type":"TRIAL","name":"Avelumab in G3 NEC","canonical_id":"clinicaltrials.gov:NCT03278405","description":"Neuroendocrine Carcinoma","metadata":null},{"id":"b33fe7df898e4fe588cdfa264b634f61","type":"TRIAL","name":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)","canonical_id":"clinicaltrials.gov:NCT01943461","description":"Solid Tumors","metadata":null},{"id":"b4ac3c17d99649e7966672e25bd79263","type":"TRIAL","name":"Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT03047473","description":"Glioblastoma Multiforme of Brain","metadata":null},{"id":"5b1fd614b42344d281f25941d8f3eae9","type":"TRIAL","name":"Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03046953","description":"T-Cell Lymphoma Relapsed; T-Cell Lymphoma Refractory","metadata":null},{"id":"f41b65d2d1bb44b4bdd2e4f0ef039e0d","type":"TRIAL","name":"Avelumab, Palbociclib and Axitinib in Advanced RCC","canonical_id":"clinicaltrials.gov:NCT05176288","description":"Advanced Clear Cell Renal Cell Carcinoma","metadata":null},{"id":"8b326fc2e8c04b04b2ef4a1a9e159d81","type":"TRIAL","name":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT03217747","description":"Advanced Malignant Solid Neoplasm; Castration-Resistant Prostate Carcinoma; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Refractory Malignant Solid Neoplasm; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"a679c4e57a034ee090961550b69c197c","type":"TRIAL","name":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03440567","description":"Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"1386896015454947b40176f04f62b073","type":"TRIAL","name":"Avelumab/Gemcitabine in Sarcomatoid RCC","canonical_id":"clinicaltrials.gov:NCT03483883","description":"Metastatic sRCC","metadata":null},{"id":"1914576bc15f4ece881a2af3d0fabfff","type":"TRIAL","name":"Avo In R/R And Previously Untreated MCL","canonical_id":"clinicaltrials.gov:NCT04855695","description":"Mantle Cell Lymphoma; Refractory Lymphoma","metadata":null},{"id":"6754afa7c3a4482ba1886c73761aee2f","type":"TRIAL","name":"Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","canonical_id":"clinicaltrials.gov:NCT00170950","description":"Hypertension","metadata":null},{"id":"a50f7e011a524cdc97415e7c41f5ea21","type":"DRUG","name":"Axitinib","canonical_id":"mesh:D000077784","description":null,"metadata":null},{"id":"0adf933401184dc2a0d8138cc297014d","type":"TRIAL","name":"Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer","canonical_id":"clinicaltrials.gov:NCT00678392","description":"Kidney Neoplasms","metadata":null},{"id":"323b6b37919e46cca3600e001332b747","type":"TRIAL","name":"Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00835978","description":"Carcinoma, Renal Cell","metadata":null},{"id":"943d1a94c594465083362de1f713fc95","type":"TRIAL","name":"Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma","canonical_id":"clinicaltrials.gov:NCT01558661","description":"Adenoid Cystic Carcinoma","metadata":null},{"id":"3226bb0148834da68406ddbd6b14f5b3","type":"TRIAL","name":"Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors","canonical_id":"clinicaltrials.gov:NCT04010071","description":"Hepatobiliary Neoplasm; Liver Neoplasm; Biliary Tract Neoplasms","metadata":null},{"id":"49f43c827f6d43ecb136fb9614936575","type":"TRIAL","name":"Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT01533948","description":"Extraocular Extension Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIA Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIB Melanoma; Stage IIIC Intraocular Melanoma; Stage IIIC Melanoma; Stage IV Intraocular Melanoma; Stage IV Melanoma","metadata":null},{"id":"932a0872a2c142678269e08495552a2e","type":"TRIAL","name":"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT03092674","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome/Acute Myeloid Leukemia","metadata":null},{"id":"7076613ab34a4b7e84d04f6ed2fd241a","type":"TRIAL","name":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","canonical_id":"clinicaltrials.gov:NCT02828358","description":"Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia","metadata":null},{"id":"47e23d1c92154729b34399a40d43383a","type":"TRIAL","name":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00658814","description":"Acute Myeloid Leukemia; Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A; Adult Acute Myeloid Leukemia Without Maturation; Adult\u2026","metadata":null},{"id":"fa255bca55f74f278f0ce741e9ad4214","type":"TRIAL","name":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","canonical_id":"clinicaltrials.gov:NCT04493138","description":"Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Myeloproliferative Neoplasm","metadata":null},{"id":"61f930faf12a4f71bc96098fcce3730a","type":"TRIAL","name":"Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies","canonical_id":"clinicaltrials.gov:NCT02129101","description":"Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Polycythemia Vera; Previously Treated Myelodysplastic Syndrome; Primary Myelofibrosis; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia","metadata":null},{"id":"29145a902bd14ade981faf2961e9db81","type":"TRIAL","name":"Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)","canonical_id":"clinicaltrials.gov:NCT07478991","description":"Acute Myeloid Leukemia, Adult","metadata":null},{"id":"6f4adf4448e547deb9095d42d6875a45","type":"DRUG","name":"Azapropazone","canonical_id":"mesh:D001032","description":null,"metadata":null},{"id":"2b2a3c33c32444b7955fc7d08c6fe121","type":"DRUG","name":"Azathioprine","canonical_id":"mesh:D001379","description":null,"metadata":null},{"id":"955d31ceae2e48a59ce05465075dbc4f","type":"TRIAL","name":"Azelastine Allergen Chamber - Onset of Action Study","canonical_id":"clinicaltrials.gov:NCT06126952","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"21997ce666ab4052b691b855ca952e6b","type":"TRIAL","name":"Azelastine Fluticasone Combination vs. Fluticasone","canonical_id":"clinicaltrials.gov:NCT00845598","description":"Allergic Rhinitis","metadata":null},{"id":"7a9ba61aa07347b1b76d7db2f344c00c","type":"TRIAL","name":"Azilect + Antidepressant Chart Review","canonical_id":"clinicaltrials.gov:NCT00955604","description":"Serotonin Syndrome","metadata":null},{"id":"ef3bae2757db4974822648f6176d9f3b","type":"TRIAL","name":"Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection","canonical_id":"clinicaltrials.gov:NCT03532464","description":"Chlamydia Trachomatis Infection; Vaginal Infection; Anal Infection","metadata":null},{"id":"b618306ff1ab42ad9a6f32a08b51a7e8","type":"TRIAL","name":"Azithromycin Plus Hydroxychloroquine for COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT05026801","description":"Respiratory Tract Infection Viral","metadata":null},{"id":"7c505e947f8a475599fe463a3e7fbfd8","type":"DRUG","name":"Azlocillin","canonical_id":"mesh:D001390","description":null,"metadata":null},{"id":"cb0a51187dbc49828c30ad4c799aa9a3","type":"TRIAL","name":"Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)","canonical_id":"clinicaltrials.gov:NCT00758342","description":"Intraocular Pressure","metadata":null},{"id":"bd553250c2034dc4957f836e6f0e0af4","type":"DRUG","name":"Aztreonam","canonical_id":"mesh:D001398","description":null,"metadata":null},{"id":"83eb09a2f3014e41be17173393ea390a","type":"GO_TERM","name":"B axonemal microtubule","canonical_id":"go:GO:0097650","description":"\"An incomplete microtubule containing 10 protofilaments that fuses with a complete microtubule called A tubule (containing 13 protofilaments) to form an axonemal outer doublet.\" [GOC:cilia, ISBN:0716731363]","metadata":null},{"id":"c7768432171d42a1a6721a1d78c57d33","type":"GO_TERM","name":"B cell activation","canonical_id":"go:GO:0042113","description":"\"The change in morphology and behavior of a mature or immature B cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"4043837846a84363b2291ad5b9e36b2a","type":"GO_TERM","name":"B cell activation involved in immune response","canonical_id":"go:GO:0002312","description":"\"The change in morphology and behavior of a mature or immature B cell during an immune response, resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [GOC:jal]","metadata":null},{"id":"e905f02ba4de43ef98c8e65749efd5ad","type":"GO_TERM","name":"B cell adhesion","canonical_id":"go:GO:0097323","description":"\"The attachment of a B cell to another cell via adhesion molecules.\" [GOC:jc]","metadata":null},{"id":"c402c7621c2f4af08df5c6c68c8641a1","type":"GO_TERM","name":"B cell affinity maturation","canonical_id":"go:GO:0002344","description":"\"The process in which B cells produce antibodies with increased antigen affinity. This is accomplished by somatic hypermutation and selection for B cells which produce higher affinity antibodies to antigen.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"1789f6bf1ec2438e809c992a44dbe302","type":"GO_TERM","name":"B cell anergy","canonical_id":"go:GO:0002515","description":"\"Any process contributing to anergy in B cells, a state of functional inactivation which is part of B cell tolerance induction.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"0acee2327cb24a56b7f0a5acb15d43f7","type":"GO_TERM","name":"B cell antigen processing and presentation","canonical_id":"go:GO:0002450","description":"\"The process in which a B cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"3ef6fbdd2082450f959a567669170118","type":"GO_TERM","name":"B cell antigen processing and presentation following pinocytosis","canonical_id":"go:GO:0002421","description":"\"B cell antigen processing and presentation which is initiated by uptake of antigen via pinocytosis.\" [GOC:add, PMID:7543530]","metadata":null},{"id":"fa4b855557354706adc4539a0fdfe83d","type":"GO_TERM","name":"B cell antigen processing and presentation mediated by B cell receptor uptake of antigen","canonical_id":"go:GO:0002417","description":"\"B cell antigen processing and presentation which is initiated by uptake of antigen bound to the B cell receptor.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"2582515b9a6a4f19b44ece9185e96aa5","type":"GO_TERM","name":"B cell apoptotic process","canonical_id":"go:GO:0001783","description":"\"Any apoptotic process in a B cell, a lymphocyte of B lineage with the phenotype CD19-positive and capable of B cell mediated immunity.\" [CL:0000236, GOC:add, GOC:mtg_apoptosis, ISBN:0781735149]","metadata":null},{"id":"268b0df680f74d68962697a380d3b489","type":"GO_TERM","name":"B cell chemotaxis","canonical_id":"go:GO:0035754","description":"\"The directed movement of a B cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [CL:0000236, GOC:BHF]","metadata":null},{"id":"ae57b08689bf46168cb50619630f4c5d","type":"GO_TERM","name":"B cell chemotaxis across high endothelial venule","canonical_id":"go:GO:0035769","description":"\"The movement of a B cell to cross a high endothelial venule in response to an external stimulus.\" [CL:0000236, GOC:BHF]","metadata":null},{"id":"ddfcb33d29cd48eb817534d7a11cf7d6","type":"GO_TERM","name":"B cell costimulation","canonical_id":"go:GO:0031296","description":"\"The process of providing, via surface-bound receptor-ligand pairs, a second, antigen-independent, signal in addition to that provided by the B cell receptor to augment B cell activation.\" [ISBN:0781735149]","metadata":null},{"id":"0728e1760de342ab92db0b9eca8143cf","type":"GO_TERM","name":"B cell cytokine production","canonical_id":"go:GO:0002368","description":"\"Any process that contributes to cytokine production by a B cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f4da7a63592a4c85a0b0e6a5e9ad41e4","type":"GO_TERM","name":"B cell deletion","canonical_id":"go:GO:0002516","description":"\"The apoptotic death of B cells which is part of B cell tolerance induction.\" [GOC:add, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"9ad67c2b36874e3cb28d7992aa780221","type":"GO_TERM","name":"B cell differentiation","canonical_id":"go:GO:0030183","description":"\"The process in which a precursor cell type acquires the specialized features of a B cell. A B cell is a lymphocyte of B lineage with the phenotype CD19-positive and capable of B cell mediated immunity.\" [GO_REF:0000022, GOC:mah]","metadata":null},{"id":"61bd594309fa4c51a1d5be6fef451b60","type":"GO_TERM","name":"B cell homeostasis","canonical_id":"go:GO:0001782","description":"\"The process of regulating the proliferation and elimination of B cells such that the total number of B cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:add, ISBN:0781735149, PMID:12956429]","metadata":null},{"id":"839b2eca8746448da34a1258b0c014ce","type":"GO_TERM","name":"B cell homeostatic proliferation","canonical_id":"go:GO:0002358","description":"\"The non-specific expansion of B cell populations within a whole or part of an organism to reach to a total number of B cells which will then remain stable over time in the absence of an external stimulus.\" [GOC:jal]","metadata":null},{"id":"b1dd79dfb9e84319b96cd92208eae23e","type":"GO_TERM","name":"B cell inhibitory signaling pathway","canonical_id":"go:GO:0002773","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of a B cell capable of inhibiting an immune effector process contributing to an immune response.\" [GOC:add, PMID:16413920]","metadata":null},{"id":"e1cc6a8ab6ab463a97ff2da1cbd1c866","type":"GO_TERM","name":"B cell lineage commitment","canonical_id":"go:GO:0002326","description":"\"The process in which a lymphoid progenitor cell becomes committed to become any type of B cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ebb188b6f68c4813af1cb5d5c1946bc6","type":"GO_TERM","name":"B cell mediated immunity","canonical_id":"go:GO:0019724","description":"\"Any process involved with the carrying out of an immune response by a B cell, through, for instance, the production of antibodies or cytokines, or antigen presentation to T cells.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"83a7418150454be4bc1c1acbe0a247c4","type":"GO_TERM","name":"B cell negative selection","canonical_id":"go:GO:0002352","description":"\"Any process leading to negative selection in B cells. Mechanisms of negative selection include anergy and deletion.\" [GOC:jal]","metadata":null},{"id":"45cec6ad739d4fefbfb807ccad98fcae","type":"GO_TERM","name":"B cell positive selection","canonical_id":"go:GO:0002346","description":"\"Any process in which B cells are selected to survive based on signaling through the B cell antigen receptor.\" [GOC:jal]","metadata":null},{"id":"51ffac66a1d9446fbb9303711741d168","type":"GO_TERM","name":"B cell proliferation","canonical_id":"go:GO:0042100","description":"\"The expansion of a B cell population by cell division. Follows B cell activation.\" [GOC:jl]","metadata":null},{"id":"4097f151794848b6943b87360968dcc2","type":"GO_TERM","name":"B cell proliferation involved in immune response","canonical_id":"go:GO:0002322","description":"\"The expansion of a B cell population by cell division following B cell activation during an immune response.\" [GOC:jal]","metadata":null},{"id":"c228e3ad866e4c99a9d143671325b62c","type":"GO_TERM","name":"B cell receptor apoptotic signaling pathway","canonical_id":"go:GO:1990117","description":"\"An extrinsic apoptotic signaling pathway initiated by the cross-linking of an antigen receptor on a B cell.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, PMID:15214043]","metadata":null},{"id":"17906e22581b4f4ab052ad2884ac5c31","type":"GO_TERM","name":"B cell receptor complex","canonical_id":"go:GO:0019815","description":"\"An immunoglobulin complex that is present in the plasma membrane of B cells and that in its canonical form is composed of two identical immunoglobulin heavy chains and two identical immunoglobulin light chains and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"cf6535efb6f44449922bed7022a9c765","type":"GO_TERM","name":"B cell receptor editing","canonical_id":"go:GO:0002452","description":"\"The process of replacing receptors on B cells, in which RAG gene expression allows continued light-chain gene rearrangement and expression of a new light change which combines with the previous heavy chain to form a new receptor.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"482d9bf2305b45f4885142e509e6b851","type":"GO_TERM","name":"B cell receptor internalization","canonical_id":"go:GO:0036300","description":"\"A receptor-mediated endocytosis process that results in the movement of a B cell receptor from the plasma membrane to the inside of the cell.\" [GOC:add, GOC:amm]","metadata":null},{"id":"674a4997abe54dfea98a64196045ecfa","type":"GO_TERM","name":"B cell receptor signaling pathway","canonical_id":"go:GO:0050853","description":"\"The series of molecular signals initiated by the cross-linking of an antigen receptor on a B cell.\" [GOC:add]","metadata":null},{"id":"a4e619f36834491d86b9e31ad518d809","type":"GO_TERM","name":"B cell receptor transport into immunological synapse","canonical_id":"go:GO:0032598","description":"\"The directed movement of a B cell receptor into an immunological synapse.\" [GOC:mah]","metadata":null},{"id":"c5006537fccb46b4b7b8ce2ac045d258","type":"GO_TERM","name":"B cell receptor transport into membrane raft","canonical_id":"go:GO:0032597","description":"\"The directed movement of a B cell receptor into a membrane raft.\" [GOC:mah]","metadata":null},{"id":"09524c2fa1794cc5bf5e9de5cc49af01","type":"GO_TERM","name":"B cell receptor transport within lipid bilayer","canonical_id":"go:GO:0032595","description":"\"The directed movement of a B cell receptor within a lipid bilayer.\" [GOC:mah]","metadata":null},{"id":"ea4c21e92e724ee09ee63d7e660f4047","type":"GO_TERM","name":"B cell selection","canonical_id":"go:GO:0002339","description":"\"The process dependent upon B cell antigen receptor signaling in response to self or foreign antigen through which B cells are selected for survival.\" [GOC:jal]","metadata":null},{"id":"daec82101fdd4ff59efb7d38ec7382f0","type":"GO_TERM","name":"B cell tolerance induction","canonical_id":"go:GO:0002514","description":"\"A process involving any mechanism for tolerance induction in B cells.\" [GOC:jal, ISBN:0781735149, PMID:16460922]","metadata":null},{"id":"c1a1f94d8bd944f6985fcb17afd68a17","type":"GO_TERM","name":"B cell tolerance induction in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002402","description":"\"Tolerance induction taking place in the mucosal-associated lymphoid tissue (MALT) mediated by B cells.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"2d3ad10e895e458c8fdc2c28c9e7a00b","type":"GO_TERM","name":"B-1 B cell differentiation","canonical_id":"go:GO:0001923","description":"\"The process in which a hemopoietic stem cell acquires the specialized features of a B-1 B cell. B-1 B cells are a distinct subset of B cells characterized as being CD5 positive, found predominantly in the peritoneum, pleural cavities, and spleen, and enriched for self-reactivity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"49e9ac3d76c549568b860eb510cbe2a8","type":"GO_TERM","name":"B-1 B cell homeostasis","canonical_id":"go:GO:0001922","description":"\"The process of regulating the proliferation and elimination of B cells of the B-1 subset such that the total number of B-1 B cells within a whole or part of an organism is stable over time in the absence of an outside stimulus. B-1 B cells are a distinct subset of B cells characterized as being CD5 positive, found predominantly in the peritoneum, pleural cavities, and spleen, and enriched for self-reactivity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0dfa55ff67b44e339dba1c1f7a9b1081","type":"GO_TERM","name":"B-1 B cell lineage commitment","canonical_id":"go:GO:0002336","description":"\"The process in which an immature B cell becomes committed to become a B-1 B cell.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"e4c85e758b5341b2a89e8cd433cbce6a","type":"GO_TERM","name":"B-1 B cell proliferation","canonical_id":"go:GO:0002359","description":"\"The expansion of a B-1 B cell by cell division. Follows B cell activation.\" [GOC:jal]","metadata":null},{"id":"d5d941865141424a9774beede6a1dc08","type":"GO_TERM","name":"B-1a B cell differentiation","canonical_id":"go:GO:0002337","description":"\"The process in which B cells acquire the specialized features of B-1a B cells. B-1a B cells are B-1 cells that express CD5 and arise from fetal liver precursors.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"0baee99164184274b31f42878d923a7b","type":"GO_TERM","name":"B-1b B cell differentiation","canonical_id":"go:GO:0002338","description":"\"The process in which B cells acquire the specialized features of B-1b B cells. B-1b B cells are B-1 cells that do not express CD5.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"4066f24aa58c4a0bb4de29cf0cef302c","type":"TRIAL","name":"B-Lymphocyte Immunotherapy in Islet Transplantation","canonical_id":"clinicaltrials.gov:NCT00468442","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"a5fc07a609814953bc0863a3c5d2bdba","type":"DRUG","name":"B-Raf/VEGFR-2 Inhibitor RAF265","canonical_id":"ncit:C61311","description":null,"metadata":null},{"id":"a868e971311944269dc04192d94e612c","type":"GO_TERM","name":"B-WICH complex","canonical_id":"go:GO:0110016","description":"\"A chromatin remodeling complex that positively regulates histone H3 acetylation, in particular H3K9, by recruiting histone acetyltransferases to rDNA gene regions. Located in the nucleolus where it assembles on RNA Polymerase I (Pol I) and possibly on RNA Polymerase III (Pol III) promoter and coding regions during early G1 phase and activates the post-initiation phases of Pol I transcription. May also activate RNA Polymerase II (Pol II) gene transcription. In mammals, B-WICH contains the WICH complex core of BAZ1B and SMARCA5, additional protein subunits and possibly rRNAs. Although it contains several catalytic subunits it is not clear which functions are carried out by the complex itself.\" [GOC:bhm, PMID:16603771, PMID:21559432, PMID:23555303, PMID:26044184]","metadata":null},{"id":"872ea58fbedb45dc8a18fba7096eb410","type":"DISEASE","name":"B-cell acute lymphoblastic leukemia","canonical_id":"mondo:0004947","description":null,"metadata":null},{"id":"e3e1bcf376c34e6b8b3b0e88919d8bd3","type":"DISEASE","name":"B-cell chronic lymphocytic leukemia","canonical_id":"mondo:0004948","description":null,"metadata":null},{"id":"9f56d43be22e46d8b4b0eab9b74e5d77","type":"DISEASE","name":"B-cell non-Hodgkin lymphoma","canonical_id":"mondo:0015759","description":null,"metadata":null},{"id":"3095d35b3be64698a7813c4e31724892","type":"TRIAL","name":"B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading","canonical_id":"clinicaltrials.gov:NCT01584518","description":"Fluid Over-load","metadata":null},{"id":"21e290fef3594d23ab4e05fe6c5a3e30","type":"GO_TERM","name":"B-type glycerophospholipase activity","canonical_id":"go:GO:0102545","description":"\"A glycerophospholipase activity that cleaves both fatty acisd attached to the sn-1 and the sn-2 position of the glycerol group of a glycerophospholipid. Substrates include phosphatidylcholine and phosphatidylethanolamine.\" [PMID:30109646]","metadata":null},{"id":"18ac74681a964ba2b83264df32cf5875","type":"GO_TERM","name":"B1 bradykinin receptor binding","canonical_id":"go:GO:0031712","description":"\"Binding to a B1 bradykinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"af360b43b7b14b77b167231ad8f26e1e","type":"PROTEIN","name":"B2 bradykinin receptor","canonical_id":"uniprot:P30411","description":null,"metadata":null},{"id":"465a4d205c184872a8a80ee42b07d6c4","type":"GO_TERM","name":"B2 bradykinin receptor binding","canonical_id":"go:GO:0031713","description":"\"Binding to a B2 bradykinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9823b47a6ae34574b873773f692ba2cd","type":"GENE","name":"B2M","canonical_id":"hgnc:HGNC:914","description":null,"metadata":null},{"id":"a513c6c6bfb8463284eba3121b926729","type":"GENE","name":"B2MR","canonical_id":"hgnc:HGNC:915","description":"beta-2-microglobulin regulator","metadata":null},{"id":"26892f36e1864cbbb48afd26332d2a8f","type":"GENE","name":"B3GALNT1","canonical_id":"hgnc:HGNC:918","description":"beta-1,3-N-acetylgalactosaminyltransferase 1 (Globoside blood group)","metadata":{"aliases":["beta3Gal-T3","galT3","GLOB","B3GALANT1","B3GALT3"]}},{"id":"632ca42cdc184eeb95ef515dd468c5b3","type":"GENE","name":"B3GALNT1P1","canonical_id":"hgnc:HGNC:51302","description":"beta-1,3-N-acetylgalactosaminyltransferase 1 pseudogene 1","metadata":null},{"id":"ff761504788e4dd2a2af0848e1b4d68b","type":"GENE","name":"B3GALNT2","canonical_id":"hgnc:HGNC:28596","description":"beta-1,3-N-acetylgalactosaminyltransferase 2","metadata":{"aliases":["MGC39558"]}},{"id":"9ec0e0339d994ca0b7def417d091bb3c","type":"GENE","name":"B3GALNT2P1","canonical_id":"hgnc:HGNC:51315","description":"beta-1,3-N-acetylgalactosaminyltransferase 2 pseudogene 1","metadata":null},{"id":"72064366b1dc4eb98866635c37876f52","type":"GENE","name":"B3GALT1","canonical_id":"hgnc:HGNC:916","description":"beta-1,3-galactosyltransferase 1","metadata":{"aliases":["beta3Gal-T1"]}},{"id":"c8b9e7e21afa40738668d774af7b3a2e","type":"GENE","name":"B3GALT1-AS1","canonical_id":"hgnc:HGNC:40089","description":"B3GALT1 antisense RNA 1","metadata":null},{"id":"33609c1939884e6ea8c2a9bef8056c46","type":"GENE","name":"B3GALT2","canonical_id":"hgnc:HGNC:917","description":"beta-1,3-galactosyltransferase 2","metadata":{"aliases":["beta3Gal-T2"]}},{"id":"7428f0fd0fbc4ee4a24c3aa26bd46744","type":"GENE","name":"B3GALT4","canonical_id":"hgnc:HGNC:919","description":"beta-1,3-galactosyltransferase 4","metadata":{"aliases":["beta3Gal-T4","GalT4"]}},{"id":"04e5f9aed8c14861b324f8516b61bf51","type":"GENE","name":"B3GALT5","canonical_id":"hgnc:HGNC:920","description":"beta-1,3-galactosyltransferase 5","metadata":{"aliases":["beta3Gal-T5","B3GalT-V","GLCT5","B3T5"]}},{"id":"2cf2354e9f4e47c2adb724118774644e","type":"GENE","name":"B3GALT5-AS1","canonical_id":"hgnc:HGNC:16424","description":"B3GALT5 antisense RNA 1","metadata":{"aliases":["C21orf88"]}},{"id":"8e7bf80b38ca4d7483ec0f3f2bcf808c","type":"GENE","name":"B3GALT6","canonical_id":"hgnc:HGNC:17978","description":"beta-1,3-galactosyltransferase 6","metadata":{"aliases":["beta3GalT6"]}},{"id":"ff50d0405d8c41e8b709ca9642eeec64","type":"GENE","name":"B3GALT9","canonical_id":"hgnc:HGNC:53652","description":"beta-1,3-galactosyltransferase 9","metadata":{"aliases":["B3GNT10"]}},{"id":"9cd6794230e1450dbde9a9fac237f1cd","type":"GENE","name":"B3GAT1","canonical_id":"hgnc:HGNC:921","description":"beta-1,3-glucuronyltransferase 1","metadata":{"aliases":["GlcAT-P","CD57","LEU7"]}},{"id":"3205011135984f798ea99f73ef16d7ef","type":"GENE","name":"B3GAT1-DT","canonical_id":"hgnc:HGNC:27449","description":"B3GAT1 divergent transcript","metadata":{"aliases":["LOC283177","AP004608.1"]}},{"id":"9e66fc731a7742c6bc7c8959b04f14bd","type":"GENE","name":"B3GAT2","canonical_id":"hgnc:HGNC:922","description":"beta-1,3-glucuronyltransferase 2","metadata":{"aliases":["GlcAT-S"]}},{"id":"4443d450da314e64b1f5a32e9e223ad2","type":"GENE","name":"B3GAT3","canonical_id":"hgnc:HGNC:923","description":"beta-1,3-glucuronyltransferase 3","metadata":{"aliases":["GlcAT-I"]}},{"id":"fb1dff69d3424c23a62a8a436595a960","type":"GENE","name":"B3GAT3P1","canonical_id":"hgnc:HGNC:35243","description":"beta-1,3-glucuronyltransferase 3 pseudogene 1","metadata":{"aliases":["PSIGLCAT-I","B3GAT3P"]}},{"id":"dd9ca14f0378499c934b8bc974f9d2fe","type":"GENE","name":"B3GLCT","canonical_id":"hgnc:HGNC:20207","description":"beta 3-glucosyltransferase","metadata":{"aliases":["B3GTL","B3Glc-T","B3GALTL"]}},{"id":"d12b30a72bc14da7a89be5c89a141b6d","type":"GENE","name":"B3GNT2","canonical_id":"hgnc:HGNC:15629","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2","metadata":{"aliases":["B3GNT-2","BETA3GNT","B3GN-T2","B3GN-T1","B3GNT1"]}},{"id":"384d5b7d74124026ad07617d175a5f99","type":"GENE","name":"B3GNT2P1","canonical_id":"hgnc:HGNC:51316","description":"B3GNT2 pseudogene 1","metadata":null},{"id":"5f4d26f71a024b1292818a7dbe13d24c","type":"GENE","name":"B3GNT3","canonical_id":"hgnc:HGNC:13528","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3","metadata":{"aliases":["B3GN-T3","beta3Gn-T3","HP10328","B3GNT-3","TMEM3"]}},{"id":"ef36b09eacb145ceb26e703109e83ead","type":"GENE","name":"B3GNT4","canonical_id":"hgnc:HGNC:15683","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4","metadata":{"aliases":["B3GN-T4","beta3Gn-T4"]}},{"id":"632a3b1e46db43ab81dfb6dc138ba749","type":"GENE","name":"B3GNT5","canonical_id":"hgnc:HGNC:15684","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5","metadata":{"aliases":["B3GN-T5","beta3Gn-T5"]}},{"id":"4bd7b967896044f1882b58937e01dccf","type":"GENE","name":"B3GNT6","canonical_id":"hgnc:HGNC:24141","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6","metadata":{"aliases":["B3Gn-T6"]}},{"id":"3032ca0906164a709804832fa60f619c","type":"GENE","name":"B3GNT7","canonical_id":"hgnc:HGNC:18811","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7","metadata":{"aliases":["beta3GnT7"]}},{"id":"baf86ab7d7f74bfd820c0570eb3f2ffa","type":"GENE","name":"B3GNT8","canonical_id":"hgnc:HGNC:24139","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8","metadata":{"aliases":["BGALT15","beta3Gn-T8","B3GALT7"]}},{"id":"82610c02df994b10a21e41c3a924319c","type":"GENE","name":"B3GNT9","canonical_id":"hgnc:HGNC:28714","description":"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9","metadata":{"aliases":["MGC4655"]}},{"id":"18dd648151b741c4b746e2e29348b624","type":"GENE","name":"B3GNTL1P1","canonical_id":"hgnc:HGNC:51317","description":"B3GNTL1 pseudogene 1","metadata":null},{"id":"039258f4fbe34ee3ac2e590b16c163ad","type":"GENE","name":"B3GNTL1P2","canonical_id":"hgnc:HGNC:51318","description":"B3GNTL1 pseudogene 2","metadata":null},{"id":"c888e84b7b454ed2957ee88f4c0d87e9","type":"GENE","name":"B4GALNT1","canonical_id":"hgnc:HGNC:4117","description":"beta-1,4-N-acetyl-galactosaminyltransferase 1","metadata":{"aliases":["beta1-4GalNAc-T","GALGT","SPG26"]}},{"id":"6e40af95f523475e999c92dfd13a6426","type":"GENE","name":"B4GALNT2","canonical_id":"hgnc:HGNC:24136","description":"beta-1,4-N-acetyl-galactosaminyltransferase 2 (SID blood group)","metadata":{"aliases":["Sda","Cad","GALGT2"]}},{"id":"827e1d39d43243b1847c159382bbf464","type":"GENE","name":"B4GALNT2P1","canonical_id":"hgnc:HGNC:51319","description":"B4GALNT2 pseudogene 1","metadata":null},{"id":"2e2a3c0c487d4f51af447c8c4c5eba23","type":"GENE","name":"B4GALNT3","canonical_id":"hgnc:HGNC:24137","description":"beta-1,4-N-acetyl-galactosaminyltransferase 3","metadata":{"aliases":["B4GalNac-T3","FLJ16224","FLJ40362"]}},{"id":"1bdade3914ed494c918963fec9b26988","type":"GENE","name":"B4GALNT4","canonical_id":"hgnc:HGNC:26315","description":"beta-1,4-N-acetyl-galactosaminyltransferase 4","metadata":{"aliases":["FLJ25045","NGalNAc-T1"]}},{"id":"0047ba348d264d17bc12f653b4a5eaf5","type":"GENE","name":"B4GALT1","canonical_id":"hgnc:HGNC:924","description":null,"metadata":null},{"id":"254534f6dc01430f868c18559c3a13c8","type":"GENE","name":"B4GALT1-AS1","canonical_id":"hgnc:HGNC:49910","description":"B4GALT1 antisense RNA 1","metadata":null},{"id":"185eb152bb9240e2b1d0bc87c3667715","type":"GENE","name":"B4GALT2","canonical_id":"hgnc:HGNC:925","description":"beta-1,4-galactosyltransferase 2","metadata":{"aliases":["beta4Gal-T2"]}},{"id":"9a29ddd7d57e4e269584b145e17f8754","type":"GENE","name":"B4GALT3","canonical_id":"hgnc:HGNC:926","description":"beta-1,4-galactosyltransferase 3","metadata":{"aliases":["beta4Gal-T3"]}},{"id":"7827541492804384a26c9bcf5483c447","type":"GENE","name":"B4GALT4","canonical_id":"hgnc:HGNC:927","description":"beta-1,4-galactosyltransferase 4","metadata":{"aliases":["beta4Gal-T4"]}},{"id":"2563f6769285495d991d5d9116f516d9","type":"GENE","name":"B4GALT4-AS1","canonical_id":"hgnc:HGNC:40090","description":"B4GALT4 antisense RNA 1","metadata":null},{"id":"8b18b785756749f6bf217bf96c468af3","type":"GENE","name":"B4GALT5","canonical_id":"hgnc:HGNC:928","description":null,"metadata":null},{"id":"776b46ac77ad41ad894b7cb4df26a30d","type":"GENE","name":"B4GALT6","canonical_id":"hgnc:HGNC:929","description":"beta-1,4-galactosyltransferase 6","metadata":{"aliases":["beta4GalT-VI"]}},{"id":"596a96e271024a00848fbd826a59ec10","type":"GENE","name":"B4GALT7","canonical_id":"hgnc:HGNC:930","description":"beta-1,4-galactosyltransferase 7","metadata":{"aliases":["XGALT-1","beta4Gal-T7"]}},{"id":"632813abe7264018b2be34b873dd815d","type":"GENE","name":"B4GAT1","canonical_id":"hgnc:HGNC:15685","description":"beta-1,4-glucuronyltransferase 1","metadata":{"aliases":["IGnT","iGAT","BETA3GNTI","B3GN-T1","B3GNT6","B3GNT1"]}},{"id":"5c94ca263bd3495aacbd7bb4197afd19","type":"GENE","name":"B4GAT1-DT","canonical_id":"hgnc:HGNC:56070","description":"B4GAT1 divergent transcript","metadata":null},{"id":"4fd07c9c9a59424791ac9c8141575933","type":"GO_TERM","name":"B800-820 antenna complex","canonical_id":"go:GO:0030081","description":"\"Protein-pigment complex that absorbs light at 800 and 820 nm; is peripherally associated to the bacterial reaction center; transfers excitation energy to the B875 antenna complex.\" [GOC:kd, GOC:lr]","metadata":null},{"id":"827e73f63433468abfd516c92e9b8f31","type":"GO_TERM","name":"B800-850 antenna complex","canonical_id":"go:GO:0030082","description":"\"Protein-pigment complex that absorbs light at 800 and 850 nm; is peripherally associated to the bacterial reaction center; transfers excitation energy to the B875 antenna complex.\" [GOC:kd, GOC:lr]","metadata":null},{"id":"87813a0278ca4070a3d7717f74ae305d","type":"GO_TERM","name":"B875 antenna complex","canonical_id":"go:GO:0030080","description":"\"Protein complex that surrounds and transfers excitation energy directly to the bacterial reaction center; binds bacteriochlorophyll a and has a single absorption band between 870 and 890 nm.\" [GOC:kd]","metadata":null},{"id":"f6003f6040434380be5f66e96a62f594","type":"GENE","name":"B9D1","canonical_id":"hgnc:HGNC:24123","description":"B9 domain containing 1","metadata":{"aliases":["B9","EPPB9","MKS9","MKSR-1"]}},{"id":"ef981f499559434892017c4f8d5e2728","type":"GENE","name":"B9D2","canonical_id":"hgnc:HGNC:28636","description":"B9 domain containing 2","metadata":{"aliases":["MGC4093","MKS10","MKSR-2"]}},{"id":"c54da9020d5a451a81e13f691f247363","type":"GENE","name":"BAALC","canonical_id":"hgnc:HGNC:14333","description":null,"metadata":null},{"id":"2fbe5bf3fd5246fb821381efa1149cab","type":"GENE","name":"BAALC-AS1","canonical_id":"hgnc:HGNC:50461","description":"BAALC antisense RNA 1","metadata":{"aliases":["lncFZD6","FZD6-DT"]}},{"id":"70fe0927ae314b49acc05c36ff3b2f70","type":"GENE","name":"BAALC-AS2","canonical_id":"hgnc:HGNC:28595","description":"BAALC antisense RNA 2","metadata":{"aliases":["MGC39526","C8orf56","BAALCOS"]}},{"id":"1594fad5a559483c8e03b7c940dd7558","type":"GENE","name":"BAAT","canonical_id":"hgnc:HGNC:932","description":"bile acid-CoA:amino acid N-acyltransferase","metadata":{"aliases":["BAT","BACAT"]}},{"id":"dd31200928e24533b52f330e3082b7e3","type":"GENE","name":"BABAM1","canonical_id":"hgnc:HGNC:25008","description":"BRISC and BRCA1 A complex member 1","metadata":{"aliases":["FLJ20571","HSPC142","NBA1","MERIT40","C19orf62"]}},{"id":"aa23ae83ae5f4c968acabc3fcdb43d82","type":"GENE","name":"BABAM2","canonical_id":"hgnc:HGNC:1106","description":null,"metadata":null},{"id":"5dd212cc825d446f93d0c007c9c93f92","type":"GENE","name":"BABAM2-AS1","canonical_id":"hgnc:HGNC:44171","description":"BABAM2 antisense RNA 1","metadata":{"aliases":["BRE-AS1"]}},{"id":"2661e8a32fef46de897dcc0185aa6937","type":"GENE","name":"BABAM2-AS2","canonical_id":"hgnc:HGNC:40101","description":"BABAM2 antisense RNA 2","metadata":null},{"id":"ac061807715d498bb10e55f451d3baae","type":"GENE","name":"BACC1","canonical_id":"hgnc:HGNC:28737","description":"BPTF associated chromatin complex component 1","metadata":{"aliases":["MGC49942","BAP18","HEPIS","C17orf49"]}},{"id":"20aedfbb991641b58685a82e29fe1856","type":"GENE","name":"BACE1","canonical_id":"hgnc:HGNC:933","description":null,"metadata":null},{"id":"8590c96458a84fa6816720663e42cd32","type":"GENE","name":"BACE1-AS","canonical_id":"hgnc:HGNC:37125","description":"BACE1 antisense RNA","metadata":{"aliases":["FJ573250","NCRNA00177","BACE1-AS1","BACE1AS"]}},{"id":"3ee7182f2b2b41b6983ace0efabc0212","type":"GENE","name":"BACE2","canonical_id":"hgnc:HGNC:934","description":null,"metadata":null},{"id":"004752725fc14e71b8dfe154e6ec6ee4","type":"GENE","name":"BACE2-IT1","canonical_id":"hgnc:HGNC:16024","description":"BACE2 intronic transcript 1","metadata":{"aliases":["PRED43","C21orf75","NCRNA00228"]}},{"id":"58f2b966a02e43b3be6554c9f5ddcecb","type":"GENE","name":"BACH1","canonical_id":"hgnc:HGNC:935","description":null,"metadata":null},{"id":"2091e47aa98e4b94ad3f8a688715b419","type":"GENE","name":"BACH1-AS1","canonical_id":"hgnc:HGNC:40008","description":"BACH1 antisense RNA 1","metadata":null},{"id":"506f0de448254c71b62be532ea74385d","type":"GENE","name":"BACH1-IT1","canonical_id":"hgnc:HGNC:40006","description":"BACH1 intronic transcript 1","metadata":null},{"id":"86857a2233b74129b8c8e521872fd6f4","type":"GENE","name":"BACH1-IT2","canonical_id":"hgnc:HGNC:40007","description":"BACH1 intronic transcript 2","metadata":null},{"id":"d714f9d0343742cc9768dbfe82064513","type":"GENE","name":"BACH1-IT3","canonical_id":"hgnc:HGNC:16455","description":"BACH1 intronic transcript 3","metadata":{"aliases":["C21orf8"]}},{"id":"4141135c68ef46849dac0b4efbdd3d2d","type":"GENE","name":"BACH2","canonical_id":"hgnc:HGNC:14078","description":null,"metadata":null},{"id":"d7deba9e8779448f9b185593171738d5","type":"GENE","name":"BAD","canonical_id":"hgnc:HGNC:936","description":null,"metadata":null},{"id":"2f20a92d8ef341039933ec6639f4a074","type":"GO_TERM","name":"BAD-BCL-2 complex","canonical_id":"go:GO:0097138","description":"\"A heterodimeric protein complex consisting of BAD and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"d72afd4518fc407fb4abbfabbdb4e5e8","type":"GO_TERM","name":"BAD-BCL-xl complex","canonical_id":"go:GO:0097137","description":"\"A heterodimeric protein complex consisting of BAD and BCL-xl, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"f84159b934714cdfb0302b23dac55954","type":"TRIAL","name":"BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT05659407","description":"Systemic Lupus Erythematosus; Rheumatoid Arthritis; BLyS Polymorphism","metadata":null},{"id":"c46e041f110c4d4d81cdeb7b85c3e941","type":"GENE","name":"BAG1","canonical_id":"hgnc:HGNC:937","description":null,"metadata":null},{"id":"8d2c35ce39f74fe681332f0d796a6b26","type":"GENE","name":"BAG1P1","canonical_id":"hgnc:HGNC:54932","description":"BAG1 pseudogene 1","metadata":null},{"id":"aa34e9bf3f9343ff8a54fe88da53643d","type":"GENE","name":"BAG2","canonical_id":"hgnc:HGNC:938","description":null,"metadata":null},{"id":"46a9c2c6cfe245fd8f82f565213d5c95","type":"GENE","name":"BAG3","canonical_id":"hgnc:HGNC:939","description":null,"metadata":null},{"id":"806cd28d4bb343eb8765cb3db0a980d1","type":"GENE","name":"BAG4","canonical_id":"hgnc:HGNC:940","description":"BAG cochaperone 4","metadata":{"aliases":["SODD"]}},{"id":"62fc1f91701f4603a8e1d387723b2183","type":"GENE","name":"BAG5","canonical_id":"hgnc:HGNC:941","description":"BAG cochaperone 5","metadata":null},{"id":"4dae1d8a185e430abac7abf8b53e4cb7","type":"GENE","name":"BAG5-AS1","canonical_id":"hgnc:HGNC:58460","description":"BAG5 antisense RNA 1","metadata":null},{"id":"7aece5bc9bb548b5b40dbda7ddcc1bbf","type":"GENE","name":"BAG6","canonical_id":"hgnc:HGNC:13919","description":"BAG cochaperone 6","metadata":{"aliases":["G3","D6S52E","Scythe","BAT3"]}},{"id":"a9fb56ef1a644334a17543160468bd60","type":"GENE","name":"BAGE","canonical_id":"hgnc:HGNC:942","description":"B melanoma antigen","metadata":{"aliases":["CT2.1","BAGE1"]}},{"id":"69e156d9e56e467c99d0c70e4765ac7f","type":"GENE","name":"BAGE2","canonical_id":"hgnc:HGNC:15723","description":"BAGE family member 2 (pseudogene)","metadata":{"aliases":["CT2.2"]}},{"id":"5640c3c97ff24034aeab414cd88496a2","type":"GENE","name":"BAGE3","canonical_id":"hgnc:HGNC:15728","description":"BAGE family member 3","metadata":{"aliases":["CT2.3"]}},{"id":"f2988acf51654138be3fd8889b2ff033","type":"GENE","name":"BAGE4","canonical_id":"hgnc:HGNC:15730","description":"BAGE family member 4","metadata":{"aliases":["CT2.4","MLL3P"]}},{"id":"040b0467cf18488abb440ede25f3b628","type":"GENE","name":"BAGE5","canonical_id":"hgnc:HGNC:15732","description":"BAGE family member 5","metadata":{"aliases":["CT2.5"]}},{"id":"3a8aef924f044956a4e4da3a6c28abce","type":"GENE","name":"BAHCC1","canonical_id":"hgnc:HGNC:29279","description":"BAH domain and coiled-coil containing 1","metadata":{"aliases":["KIAA1447","BAHD2"]}},{"id":"4bb276794b434b15b36b50bde916340e","type":"GENE","name":"BAHD1","canonical_id":"hgnc:HGNC:29153","description":"bromo adjacent homology domain containing 1","metadata":{"aliases":["KIAA0945"]}},{"id":"32b15da244fc49d99341c40c0a9478ca","type":"GENE","name":"BAIAP2","canonical_id":"hgnc:HGNC:947","description":"BAR/IMD domain containing adaptor protein 2","metadata":{"aliases":["BAP2","IRSp53","WAML"]}},{"id":"86c5ea4ec32b49b9acb4ce8653b3b4bd","type":"GENE","name":"BAIAP2-DT","canonical_id":"hgnc:HGNC:44342","description":"BAIAP2 divergent transcript","metadata":{"aliases":["lnc-BAIAP2","BAIAP2-AS1"]}},{"id":"585003b258584d39956e09510fd82a3f","type":"GENE","name":"BAIAP2L1","canonical_id":"hgnc:HGNC:21649","description":"BAR/IMD domain containing adaptor protein 2 like 1","metadata":{"aliases":["IRTKS"]}},{"id":"ddd095c88f754ed6b318e59bc04228ec","type":"GENE","name":"BAIAP2L2","canonical_id":"hgnc:HGNC:26203","description":"BAR/IMD domain containing adaptor protein 2 like 2","metadata":{"aliases":["FLJ22582","pinkbar"]}},{"id":"abfd26bd7a33485388528e7159a4162d","type":"GENE","name":"BAIAP3","canonical_id":"hgnc:HGNC:948","description":"BAI1 associated protein 3","metadata":{"aliases":["BAP3","KIAA0734"]}},{"id":"49896a36d8aa444ca80574c1b51b0e54","type":"GO_TERM","name":"BAK complex","canonical_id":"go:GO:0097145","description":"\"An oligomeric protein complex consisting of BAK, a member of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"8f09210d1c4c49ea92e69b3cfa4dab79","type":"GENE","name":"BAK1","canonical_id":"hgnc:HGNC:949","description":null,"metadata":null},{"id":"d2dd67c435c440cf8852b99d72668ea4","type":"GENE","name":"BAK1P1","canonical_id":"hgnc:HGNC:996","description":"BCL2 antagonist/killer 1 pseudogene 1","metadata":{"aliases":["BAK2","BCL2L7P1"]}},{"id":"bcb068c308ee417d8dabbba7c8cddc16","type":"GENE","name":"BAK1P2","canonical_id":"hgnc:HGNC:997","description":"BCL2 antagonist/killer 1 pseudogene 2","metadata":{"aliases":["BAK3","BAK3P","BCL2L7P2"]}},{"id":"f9df28b818514d8d87b1d28ab7f28156","type":"GENE","name":"BALR6","canonical_id":"hgnc:HGNC:27946","description":"B-cell acute lymphoblastic leukemia associated long RNA 6","metadata":{"aliases":["BALR-6"]}},{"id":"17a126c6c254443d8ddbed1b7f2ab138","type":"GENE","name":"BAMBI","canonical_id":"hgnc:HGNC:30251","description":null,"metadata":null},{"id":"e0ae62bf1ee34fa1aa9d35706284f0df","type":"GENE","name":"BANCR","canonical_id":"hgnc:HGNC:43877","description":"BRAF-activated non-protein coding RNA","metadata":{"aliases":["LINC00586"]}},{"id":"28f152b6b51844429d785e6affdd83d6","type":"GENE","name":"BANF1","canonical_id":"hgnc:HGNC:17397","description":"barrier to autointegration nuclear assembly factor 1","metadata":{"aliases":["BAF"]}},{"id":"d61a11882cad486d84868db7508719fb","type":"GENE","name":"BANF1P1","canonical_id":"hgnc:HGNC:20252","description":"BANF1 pseudogene 1","metadata":{"aliases":["BCRP1","D14S1460","D14S1460E","BCRG1"]}},{"id":"1600f7b8eee34cfa8c42a3a2afeed6b2","type":"GENE","name":"BANF1P2","canonical_id":"hgnc:HGNC:23426","description":"BANF1 pseudogene 2","metadata":{"aliases":["bA122K13.8","BANF1L1"]}},{"id":"05ae5e7ad60f477a818eab2f21b99625","type":"GENE","name":"BANF1P3","canonical_id":"hgnc:HGNC:43883","description":"BANF1 pseudogene 3","metadata":null},{"id":"3816dd9d76c5468db96d05290bca4bc5","type":"GENE","name":"BANF1P4","canonical_id":"hgnc:HGNC:43884","description":"BANF1 pseudogene 4","metadata":null},{"id":"a2c11599a51543f5b03be1ac2ca61798","type":"GENE","name":"BANF1P5","canonical_id":"hgnc:HGNC:43885","description":"BANF1 pseudogene 5","metadata":null},{"id":"f24b5213e2d24348807c7f384d7eb089","type":"GENE","name":"BANF2","canonical_id":"hgnc:HGNC:16172","description":"BANF family member 2","metadata":{"aliases":["dJ803K15.1","BAF-L","BAFL","BAF2","C20orf179"]}},{"id":"aaf5c4bc46cc4a17ba780d0bd1b0aaff","type":"GENE","name":"BANK1","canonical_id":"hgnc:HGNC:18233","description":"B cell scaffold protein with ankyrin repeats 1","metadata":{"aliases":["BANK","FLJ20706"]}},{"id":"be9ed34ef4f747e8909624243e5c3b0d","type":"GENE","name":"BANK1-AS1","canonical_id":"hgnc:HGNC:58860","description":"BANK1 antisense RNA 1","metadata":null},{"id":"0bbc5b9000b8443da69e858cce3829b3","type":"GENE","name":"BANP","canonical_id":"hgnc:HGNC:13450","description":"BTG3 associated nuclear protein","metadata":{"aliases":["SMARBP1","SMAR1","FLJ20538","DKFZp761H172","FLJ10177","BEND1"]}},{"id":"ef2e70d31de7428bb9e16caba3eed7d4","type":"GENE","name":"BAP1","canonical_id":"hgnc:HGNC:950","description":"BRCA1 associated deubiquitinase 1","metadata":{"aliases":["hucep-6","KIAA0272","UCHL2"]}},{"id":"9fcfb4c4b56e4ca1834ec3c50cba8c34","type":"GENE","name":"BARD1","canonical_id":"hgnc:HGNC:952","description":null,"metadata":null},{"id":"ebaf9236628f4bf8bfa99d6a38da3171","type":"GENE","name":"BARHL1","canonical_id":"hgnc:HGNC:953","description":"BarH like homeobox 1","metadata":null},{"id":"921f5d45afe444309ad4c369403be119","type":"GENE","name":"BARHL2","canonical_id":"hgnc:HGNC:954","description":"BarH like homeobox 2","metadata":null},{"id":"2fe77299b95047efb0c12912ab5bc366","type":"GENE","name":"BARX1","canonical_id":"hgnc:HGNC:955","description":"BARX homeobox 1","metadata":null},{"id":"d523ab1eae834e18a679934d36274b19","type":"GENE","name":"BARX1-DT","canonical_id":"hgnc:HGNC:50673","description":"BARX1 divergent transcript","metadata":{"aliases":["BARX1-AS1"]}},{"id":"0b11aace311542d391e6119cf9570ad7","type":"GENE","name":"BARX2","canonical_id":"hgnc:HGNC:956","description":null,"metadata":null},{"id":"b3dba75355984fea8552502488d606b9","type":"GENE","name":"BASP1","canonical_id":"hgnc:HGNC:957","description":"brain abundant membrane attached signal protein 1","metadata":{"aliases":["NAP-22","NAP22","CAP23","CAP-23"]}},{"id":"332ec48b0fd24ca4b3ed27ea8acde681","type":"GENE","name":"BASP1-AS1","canonical_id":"hgnc:HGNC:26609","description":"BASP1 antisense RNA 1","metadata":{"aliases":["LOC285696"]}},{"id":"bea3c16af81548d9a6e5ff9ef63a76de","type":"GENE","name":"BASP1P1","canonical_id":"hgnc:HGNC:39418","description":"BASP1 pseudogene 1","metadata":null},{"id":"d8a2e59ae3d846d1b24b01b73fa783b6","type":"GO_TERM","name":"BAT3 complex","canonical_id":"go:GO:0071818","description":"\"A protein complex found in mammals that transfers tail-anchored (TA) proteins from SGTA to GET3 (ASNA1/TRC4) for targeting to the endoplasmic reticulum membrane. Also chaperones polypeptides from the endoplasmic reticulum retrotranslocation machinery to the proteasome, maintaining the solubility of substrates to improve ER-associated protein degradation (ERAD). Consists of BAG6 (BAT3) and its cofactors GET4 (TRC35) and UBL4A.\" [GOC:bm, PMID:20676083, PMID:21636303]","metadata":null},{"id":"5977b4854d0e445f87bcd15a5ebb713b","type":"GO_TERM","name":"BAT3 complex binding","canonical_id":"go:GO:1904288","description":"\"Binding to a BAT3 complex.\" [GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23246001]","metadata":null},{"id":"9b00771c9b2649b88176670801420c26","type":"GENE","name":"BATF","canonical_id":"hgnc:HGNC:958","description":null,"metadata":null},{"id":"f3cebf3d0068447b9fd5bab5b34d5d4e","type":"GENE","name":"BATF2","canonical_id":"hgnc:HGNC:25163","description":"basic leucine zipper ATF-like transcription factor 2","metadata":{"aliases":["MGC20410","SARI"]}},{"id":"84c8015f751644a0a94102b94f6335e5","type":"GENE","name":"BATF3","canonical_id":"hgnc:HGNC:28915","description":null,"metadata":null},{"id":"cdcf1e1c118746829537d1935e9473aa","type":"TRIAL","name":"BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT00411632","description":"Lung Cancer","metadata":null},{"id":"1981207592d8435fbc770ae8c25a702a","type":"GENE","name":"BAX","canonical_id":"hgnc:HGNC:959","description":null,"metadata":null},{"id":"74ddd582307442bfb7a0f68611a3b08f","type":"GO_TERM","name":"BAX complex","canonical_id":"go:GO:0097144","description":"\"An oligomeric protein complex consisting of BAX, a member of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"e0c73fae277842f69a1a423d3f3b0baf","type":"TRIAL","name":"BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00098254","description":"Non-Small-Cell Lung Carcinoma","metadata":null},{"id":"bdc3d903cac446ff8d979206effe1892","type":"TRIAL","name":"BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies","canonical_id":"clinicaltrials.gov:NCT02090543","description":"Atrial Fibrillation","metadata":null},{"id":"3aa90580713b41d6b861b686792adf0b","type":"TRIAL","name":"BAY38-9456 - Supportive Trial for Spinal Injury","canonical_id":"clinicaltrials.gov:NCT00652262","description":"Erectile Dysfunction; Sexual Dysfunction; Spinal Cord Injury","metadata":null},{"id":"da4d3bc49684476ca4045eb61ba8575a","type":"TRIAL","name":"BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00665054","description":"Erectile Dysfunction","metadata":null},{"id":"12bc9cc8a2be4599baa137526901752e","type":"TRIAL","name":"BAY73-4506 Probe Substrate Study","canonical_id":"clinicaltrials.gov:NCT01287598","description":"Neoplasms","metadata":null},{"id":"ae19a0e52bde4759b460181fa5ff7271","type":"TRIAL","name":"BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT01345656","description":"Heart Failure","metadata":null},{"id":"29902b7fdcce49549af6048c870f2f77","type":"GENE","name":"BAZ1A","canonical_id":"hgnc:HGNC:960","description":"bromodomain adjacent to zinc finger domain 1A","metadata":{"aliases":["hACF1","ACF1","WALp1","WCRF180"]}},{"id":"ae4f866f731f497cadc29012ce0b3fdb","type":"GENE","name":"BAZ1A-AS1","canonical_id":"hgnc:HGNC:55440","description":"BAZ1A antisense RNA 1","metadata":null},{"id":"f7129602e5ab4017bc0b6cab12d40a14","type":"GENE","name":"BAZ1B","canonical_id":"hgnc:HGNC:961","description":"bromodomain adjacent to zinc finger domain 1B","metadata":{"aliases":["WSTF","WBSCR9","WBSCR10"]}},{"id":"e8e170a8a5b547a2bb603929515c3f8d","type":"GENE","name":"BAZ2A","canonical_id":"hgnc:HGNC:962","description":"bromodomain adjacent to zinc finger domain 2A","metadata":{"aliases":["KIAA0314","TIP5","WALp3"]}},{"id":"9a4d09caa22d4cc49cc0df3b90b513d1","type":"GENE","name":"BAZ2B","canonical_id":"hgnc:HGNC:963","description":"bromodomain adjacent to zinc finger domain 2B","metadata":{"aliases":["WALp4"]}},{"id":"1b89b6bccd624387ba9d0594421c2eb2","type":"GENE","name":"BAZ2B-AS1","canonical_id":"hgnc:HGNC:55862","description":"BAZ2B antisense RNA 1","metadata":{"aliases":["lnc-BAZ2B"]}},{"id":"7ed1e6a9231d4067a12f113d09b704d2","type":"GENE","name":"BBC3","canonical_id":"hgnc:HGNC:17868","description":null,"metadata":null},{"id":"b12d4de7c4de4c7a86296b416feb8f81","type":"GENE","name":"BBIP1","canonical_id":"hgnc:HGNC:28093","description":"BBSome interacting protein 1","metadata":{"aliases":["bA348N5.3","BBIP10","BBS18","NCRNA00081"]}},{"id":"3ae8eb7020b0483387b9d7074b6f6a96","type":"GENE","name":"BBIP1P1","canonical_id":"hgnc:HGNC:52781","description":"BBSome interacting protein 1 pseudogene 1","metadata":null},{"id":"2a0e6d7e77a84f4fbed0db4f47209704","type":"GENE","name":"BBLN","canonical_id":"hgnc:HGNC:17823","description":"bublin coiled coil protein","metadata":{"aliases":["Hero9","MGC4639","EST00098","FLJ12823","C9orf16"]}},{"id":"f6aaf2bda288422887e8678fc62884ba","type":"GENE","name":"BBLNP1","canonical_id":"hgnc:HGNC:56950","description":"BBLN pseudogene 1","metadata":null},{"id":"91190a4f0dd541418916726d2af0f1f3","type":"GENE","name":"BBLNP2","canonical_id":"hgnc:HGNC:56979","description":"BBLN pseudogene 2","metadata":null},{"id":"5ad5e54a76df424ba9fc9e61e797421d","type":"GENE","name":"BBOF1","canonical_id":"hgnc:HGNC:19855","description":"basal body orientation factor 1","metadata":{"aliases":["FBB10","C14orf45","CCDC176"]}},{"id":"2c084e2833324758bf32ff58a668f468","type":"GENE","name":"BBOX1","canonical_id":"hgnc:HGNC:964","description":"gamma-butyrobetaine hydroxylase 1","metadata":{"aliases":["gamma-BBH","G-BBH","BBH","BBOX"]}},{"id":"8ae8573ca1f74445ad0bf4fbabd4c9bc","type":"GENE","name":"BBOX1-AS1","canonical_id":"hgnc:HGNC:50700","description":"BBOX1 antisense RNA 1","metadata":null},{"id":"035c5467771a4bf89d5506ba56ba2233","type":"GENE","name":"BBS1","canonical_id":"hgnc:HGNC:966","description":"Bardet-Biedl syndrome 1","metadata":{"aliases":["FLJ23590"]}},{"id":"fe838e8fb0e545f4af8dc2cdaab8a2fd","type":"GENE","name":"BBS10","canonical_id":"hgnc:HGNC:26291","description":"Bardet-Biedl syndrome 10","metadata":{"aliases":["FLJ23560","C12orf58"]}},{"id":"e0a3e047fe854720b9d844135bbda222","type":"GENE","name":"BBS12","canonical_id":"hgnc:HGNC:26648","description":"Bardet-Biedl syndrome 12","metadata":{"aliases":["FLJ35630","FLJ41559","C4orf24"]}},{"id":"16f430e61a0b4d598f4b363ef4b19273","type":"GENE","name":"BBS2","canonical_id":"hgnc:HGNC:967","description":"Bardet-Biedl syndrome 2","metadata":{"aliases":["BBS"]}},{"id":"df6cd6e3028544658cea86fbca7542a4","type":"GENE","name":"BBS4","canonical_id":"hgnc:HGNC:969","description":"Bardet-Biedl syndrome 4","metadata":null},{"id":"7123d56f842a4995b63389343b224c99","type":"GENE","name":"BBS5","canonical_id":"hgnc:HGNC:970","description":"Bardet-Biedl syndrome 5","metadata":{"aliases":["DKFZp762I194"]}},{"id":"33a4d88c49f844fea9abe2cd04dcf055","type":"GENE","name":"BBS7","canonical_id":"hgnc:HGNC:18758","description":"Bardet-Biedl syndrome 7","metadata":{"aliases":["FLJ10715","BBS2L1"]}},{"id":"8a6fde0900774108b8fa31f50c750d1a","type":"GENE","name":"BBS7-DT","canonical_id":"hgnc:HGNC:55360","description":"BBS7 divergent transcript","metadata":null},{"id":"d52452c9e42b46c7a515d3b321176b5d","type":"GENE","name":"BBS9","canonical_id":"hgnc:HGNC:30000","description":"Bardet-Biedl syndrome 9","metadata":{"aliases":["B1","PTHB1"]}},{"id":"24d4f1e6ade54e99a839e2b561d53deb","type":"GO_TERM","name":"BBSome","canonical_id":"go:GO:0034464","description":"\"A ciliary protein complex involved in cilium biogenesis. It consists of at least seven Bardet-Biedl syndrome (BBS) proteins and BBIP10. It moves in association with IFT trains through cilia (likely as an IFT-A/B adaptor or cargo), and is required for the integrity of IFT-A and IFT-B.\" [GOC:BHF, GOC:cilia, PMID:15231740, PMID:17574030, PMID:26498262]","metadata":null},{"id":"2e64ac2c326a4a0a9ddb068b574f109c","type":"GO_TERM","name":"BBSome binding","canonical_id":"go:GO:0062063","description":"\"Binding to a BBSome complex.\" [PMID:20603001]","metadata":null},{"id":"05961b94d69e400084d605f7fc074509","type":"GENE","name":"BBX","canonical_id":"hgnc:HGNC:14422","description":"BBX high mobility group box domain containing","metadata":{"aliases":["MDS001","HSPC339","HBP2"]}},{"id":"55bf34dc45414e1a90d8cd12b5905524","type":"GENE","name":"BCAM","canonical_id":"hgnc:HGNC:6722","description":"basal cell adhesion molecule (Lutheran blood group)","metadata":{"aliases":["CD239","B-CAM","F8/G253","LU"]}},{"id":"7550b60425da4923aff3c0cbbe40f203","type":"GENE","name":"BCAN","canonical_id":"hgnc:HGNC:23059","description":"brevican","metadata":{"aliases":["BEHAB","MGC13038","CSPG7"]}},{"id":"24ff94522c2a4c41b9ce60da3629c175","type":"GENE","name":"BCAN-AS1","canonical_id":"hgnc:HGNC:55233","description":"BCAN antisense RNA 1","metadata":{"aliases":["RP11-284F21.9"]}},{"id":"26ff1e90c32640a782709781f93eae4e","type":"GENE","name":"BCAN-AS2","canonical_id":"hgnc:HGNC:56267","description":"BCAN antisense RNA 2","metadata":{"aliases":["ENST869","AL590666.2"]}},{"id":"d3972348017d402ea888b38d9eb5743c","type":"GENE","name":"BCAP29","canonical_id":"hgnc:HGNC:24131","description":"B cell receptor associated protein 29","metadata":{"aliases":["BAP29","DKFZp686M2086"]}},{"id":"de303ccec7464b4ea951d045dd9e8ef5","type":"GENE","name":"BCAP31","canonical_id":"hgnc:HGNC:16695","description":"B cell receptor associated protein 31","metadata":{"aliases":["DXS1357E","BAP31","6C6-Ag","CDM"]}},{"id":"92eb2d16f4ba4c419821a1b4b2a4eea0","type":"GENE","name":"BCAP31P1","canonical_id":"hgnc:HGNC:51323","description":"B cell receptor associated protein 31 pseudogene 1","metadata":{"aliases":["TCONS_l2_00010135"]}},{"id":"b8d8894728674d7abc51659defc1f7ef","type":"GENE","name":"BCAP31P2","canonical_id":"hgnc:HGNC:51324","description":"B cell receptor associated protein 31 pseudogene 2","metadata":{"aliases":["TCONS_l2_00009689"]}},{"id":"d232b9adc50544789f3e3590b6fa8680","type":"GENE","name":"BCAR1","canonical_id":"hgnc:HGNC:971","description":null,"metadata":null},{"id":"b74452afc7584ec2bafe463c221a6d97","type":"GENE","name":"BCAR1P1","canonical_id":"hgnc:HGNC:51325","description":"BCAR1 pseudogene 1","metadata":null},{"id":"6635e0e39f114398a5cb7a1b25785730","type":"GENE","name":"BCAR1P2","canonical_id":"hgnc:HGNC:51326","description":"BCAR1 pseudogene 2","metadata":null},{"id":"1e93699343804973bdc0793dc07c1c1a","type":"GENE","name":"BCAR3","canonical_id":"hgnc:HGNC:973","description":"BCAR3 adaptor protein, NSP family member","metadata":{"aliases":["NSP2","SH2D3B","AND-34","MIG7"]}},{"id":"e3dced0cc6074f11b20e43d629dd20d7","type":"GENE","name":"BCAR3-AS1","canonical_id":"hgnc:HGNC:40093","description":"BCAR3 antisense RNA 1","metadata":{"aliases":["TP53LC19"]}},{"id":"74477b33ffa546aa8be8ffa54838e010","type":"GENE","name":"BCAR4","canonical_id":"hgnc:HGNC:22170","description":"breast cancer anti-estrogen resistance 4","metadata":null},{"id":"4bd86f8e4127442bb6e1047d7bcff2a9","type":"GENE","name":"BCAS1","canonical_id":"hgnc:HGNC:974","description":"brain enriched myelin associated protein 1","metadata":{"aliases":["NABC1","AIBC1","PMES-2"]}},{"id":"9f8d8b12d38d4a93afe1ee5678b3c0b3","type":"GENE","name":"BCAS1-AS1","canonical_id":"hgnc:HGNC:40094","description":"BCAS1 antisense RNA 1","metadata":null},{"id":"2319c7e835664e9a876699b2c54e9114","type":"GENE","name":"BCAS2","canonical_id":"hgnc:HGNC:975","description":null,"metadata":null},{"id":"3fee90239ecd458e99fe8e553f6a3bf1","type":"GENE","name":"BCAS2P1","canonical_id":"hgnc:HGNC:39594","description":"BCAS2 pseudogene 1","metadata":null},{"id":"a5bb2b8b752f4bcd93f73c2a1052e9a5","type":"GENE","name":"BCAS2P2","canonical_id":"hgnc:HGNC:39595","description":"BCAS2 pseudogene 2","metadata":null},{"id":"fb4e47473f7a4c0f953bf57035437faa","type":"GENE","name":"BCAS2P3","canonical_id":"hgnc:HGNC:39596","description":"BCAS2 pseudogene 3","metadata":null},{"id":"cc2a4c1bf70941ad971ab64c4173af75","type":"GENE","name":"BCAS3","canonical_id":"hgnc:HGNC:14347","description":null,"metadata":null},{"id":"b8ee19dd262b4926b9bd77eaaf3fa263","type":"GENE","name":"BCAS3-AS1","canonical_id":"hgnc:HGNC:56376","description":"BCAS3 antisense RNA 1","metadata":{"aliases":["AC005884.1"]}},{"id":"b689875796a64a98a6575f93fa0746ae","type":"GENE","name":"BCAS4","canonical_id":"hgnc:HGNC:14367","description":"breast carcinoma amplified sequence 4","metadata":{"aliases":["FLJ20495","CNOL"]}},{"id":"ebb369080f5947618045f533fbbc230d","type":"GENE","name":"BCAT1","canonical_id":"hgnc:HGNC:976","description":"branched chain amino acid transaminase 1","metadata":{"aliases":["BCATc","BCT1"]}},{"id":"23a39ec2c75e4cd39731ac2b904731eb","type":"GENE","name":"BCAT1-AS1","canonical_id":"hgnc:HGNC:58192","description":"BCAT1 antisense RNA 1","metadata":null},{"id":"4df74808e2ce49308d8a7950dd34bbe8","type":"GENE","name":"BCAT1-DT","canonical_id":"hgnc:HGNC:54396","description":"BCAT1 divergent transcript","metadata":{"aliases":["lnc-BCAT1"]}},{"id":"df5e6fa828f64095a6f6198f687a0e06","type":"GENE","name":"BCAT2","canonical_id":"hgnc:HGNC:977","description":"branched chain amino acid transaminase 2","metadata":{"aliases":["BCAM","BCATm","BCT2"]}},{"id":"051e19dc4aad4b619e75ad107077f924","type":"GENE","name":"BCCIP","canonical_id":"hgnc:HGNC:978","description":"BRCA2 and CDKN1A interacting protein","metadata":{"aliases":["BCCIPalpha","TOK-1"]}},{"id":"ef759b640efb474d9629e228f7c4dcc5","type":"GENE","name":"BCDIN3D","canonical_id":"hgnc:HGNC:27050","description":"BCDIN3 domain containing RNA methyltransferase","metadata":null},{"id":"8dd1b844d87d413aab9749cd4e1fd0c6","type":"GENE","name":"BCDIN3D-AS1","canonical_id":"hgnc:HGNC:44113","description":"BCDIN3D antisense RNA 1","metadata":null},{"id":"38092b59b32b4ce8a0a254a682d28a18","type":"GENE","name":"BCHE","canonical_id":"hgnc:HGNC:983","description":"butyrylcholinesterase","metadata":{"aliases":["E1","CHE1","CHE2"]}},{"id":"cfe77693e0c14f1e80f644bac512434d","type":"PROTEIN","name":"BCHE","canonical_id":"uniprot:P06276","description":null,"metadata":null},{"id":"436652dd19c14b4892bfdf33322bbcaa","type":"GENE","name":"BCKDHA","canonical_id":"hgnc:HGNC:986","description":"branched chain keto acid dehydrogenase E1 subunit alpha","metadata":{"aliases":["MSU","OVD1A"]}},{"id":"9b200ddc880a4ab68b08e5a1d086e391","type":"GENE","name":"BCKDHB","canonical_id":"hgnc:HGNC:987","description":"branched chain keto acid dehydrogenase E1 subunit beta","metadata":{"aliases":["OVD1B"]}},{"id":"0bb80478f17f497790bfda8aefa581bb","type":"GENE","name":"BCKDK","canonical_id":"hgnc:HGNC:16902","description":"branched chain keto acid dehydrogenase kinase","metadata":null},{"id":"de9c8b94448d473d8a887c9d74238d08","type":"GO_TERM","name":"BCL-2 complex","canonical_id":"go:GO:0097148","description":"\"A homodimeric protein complex consisting of BCL-2, a member of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:bhm, GOC:so, PMID:14634621]","metadata":null},{"id":"87298e35c02040a389ffe518624c89bb","type":"GENE","name":"BCL10","canonical_id":"hgnc:HGNC:989","description":"BCL10 immune signaling adaptor","metadata":{"aliases":["CARMEN","CIPER","mE10","c-E10","CLAP"]}},{"id":"e8baa89f809343fd84bc142907c2bffb","type":"GENE","name":"BCL10-AS1","canonical_id":"hgnc:HGNC:55868","description":"BCL10 antisense RNA 1","metadata":null},{"id":"dc6adeebd3f34d75860ef9f697e73917","type":"GENE","name":"BCL11A","canonical_id":"hgnc:HGNC:13221","description":null,"metadata":null},{"id":"d10644ad2c164ca5afca5388868062ed","type":"GENE","name":"BCL11B","canonical_id":"hgnc:HGNC:13222","description":"BCL11 transcription factor B","metadata":{"aliases":["CTIP-2","CTIP2","hRIT1-alpha","SMARCM2","ZNF856B"]}},{"id":"d36858684b0941a0b4a2490adc3680e2","type":"GENE","name":"BCL11B-AS1","canonical_id":"hgnc:HGNC:40627","description":"BCL11B antisense RNA 1","metadata":null},{"id":"5b331a2d54294c719a3b45d23a8b69d6","type":"GENE","name":"BCL2","canonical_id":"hgnc:HGNC:990","description":null,"metadata":null},{"id":"f1f1e8c1c7834d32ae9ed5d8f8558067","type":"PROTEIN","name":"BCL2","canonical_id":"uniprot:P10415","description":null,"metadata":null},{"id":"eaba21e4711642299e364efb303257e9","type":"GENE","name":"BCL2","canonical_id":"ensembl:ENSG00000171791","description":null,"metadata":null},{"id":"a148f077863e411faedc0320ae2c00ac","type":"GENE","name":"BCL2A1","canonical_id":"hgnc:HGNC:991","description":null,"metadata":null},{"id":"badd6a93b2db476bb8c94cb72275974a","type":"GENE","name":"BCL2L1","canonical_id":"hgnc:HGNC:992","description":null,"metadata":null},{"id":"d670d993950141e3920393dd66a9870e","type":"GENE","name":"BCL2L1-AS1","canonical_id":"hgnc:HGNC:40095","description":"BCL2L1 antisense RNA 1","metadata":null},{"id":"96ade92d24e844c8b36ed557fec8eab4","type":"GENE","name":"BCL2L10","canonical_id":"hgnc:HGNC:993","description":"BCL2 like 10","metadata":{"aliases":["Diva","Boo","BCL-B"]}},{"id":"9426f864da4e49ba8fe8b9558de5255c","type":"GENE","name":"BCL2L11","canonical_id":"hgnc:HGNC:994","description":null,"metadata":null},{"id":"2c869ad5585e4913a095be1dfc75858c","type":"GENE","name":"BCL2L12","canonical_id":"hgnc:HGNC:13787","description":"BCL2 like 12","metadata":null},{"id":"f08b597c75584af78be98584b303dbf3","type":"GENE","name":"BCL2L12P1","canonical_id":"hgnc:HGNC:51327","description":"BCL2 like 12 pseudogene 1","metadata":null},{"id":"99259170f03843ffb669dc30b7211023","type":"GENE","name":"BCL2L13","canonical_id":"hgnc:HGNC:17164","description":null,"metadata":null},{"id":"75a53804db114362b9710f07b448af1b","type":"GENE","name":"BCL2L14","canonical_id":"hgnc:HGNC:16657","description":"BCL2 like 14","metadata":{"aliases":["BCLG","BCL-G"]}},{"id":"916aaa64477141f4b627e68b2b4fac2c","type":"GENE","name":"BCL2L15","canonical_id":"hgnc:HGNC:33624","description":"BCL2 like 15","metadata":{"aliases":["Bfk","FLJ22588","C1orf178"]}},{"id":"0bdd978a685048bd8c9b066871f7d9c3","type":"GENE","name":"BCL2L2","canonical_id":"hgnc:HGNC:995","description":"BCL2 like 2","metadata":{"aliases":["KIAA0271","BCL-W","PPP1R51"]}},{"id":"8ac08eadd477427a98bacbe10ff56e33","type":"GENE","name":"BCL2L2-PABPN1","canonical_id":"hgnc:HGNC:42959","description":"BCL2L2-PABPN1 readthrough","metadata":null},{"id":"6c622e9179d84635816e7532246838e5","type":"GENE","name":"BCL3","canonical_id":"hgnc:HGNC:998","description":null,"metadata":null},{"id":"61af9388e5d5402c9254f2bf0b64c07c","type":"GENE","name":"BCL6","canonical_id":"hgnc:HGNC:1001","description":null,"metadata":null},{"id":"c30b48ce5ccb4639970a31b4f6bdb24f","type":"GENE","name":"BCL6-AS1","canonical_id":"hgnc:HGNC:51843","description":"BCL6 antisense RNA 1","metadata":{"aliases":["lnc-RP11-211G3.3.1-1"]}},{"id":"b0b8f436e2294bfebd36573310490c40","type":"GENE","name":"BCL6B","canonical_id":"hgnc:HGNC:1002","description":"BCL6B transcription repressor","metadata":{"aliases":["ZBTB28","BAZF","ZNF62"]}},{"id":"7ab1ce8597fd4d46b4a0595c51683a7b","type":"GENE","name":"BCL7A","canonical_id":"hgnc:HGNC:1004","description":"BAF chromatin remodeling complex subunit BCL7A","metadata":{"aliases":["SMARCJ1","BCL7"]}},{"id":"e399eaf61608496fb63379458656c2c4","type":"GENE","name":"BCL7B","canonical_id":"hgnc:HGNC:1005","description":"BAF chromatin remodeling complex subunit BCL7B","metadata":{"aliases":["SMARCJ2"]}},{"id":"fcf79191302a499190c6819e933362c9","type":"GENE","name":"BCL7C","canonical_id":"hgnc:HGNC:1006","description":"BAF chromatin remodeling complex subunit BCL7C","metadata":{"aliases":["SMARCJ3"]}},{"id":"b4ad14c7b2184935835ef3874eea5574","type":"GENE","name":"BCL9","canonical_id":"hgnc:HGNC:1008","description":"BCL9 transcription coactivator","metadata":null},{"id":"6d7cddee70964842b4caae0c6f4537d3","type":"GENE","name":"BCL9L","canonical_id":"hgnc:HGNC:23688","description":"BCL9 like","metadata":{"aliases":["DLNB11","B9L","Bcl9-2"]}},{"id":"5487ca9dcd454a56ac1109287c4533b3","type":"GENE","name":"BCL9P1","canonical_id":"hgnc:HGNC:51328","description":"BCL9 pseudogene 1","metadata":null},{"id":"21a82f495535463ea13a8d176b2b1360","type":"GENE","name":"BCLAF1","canonical_id":"hgnc:HGNC:16863","description":"BCL2 associated transcription factor 1","metadata":{"aliases":["KIAA0164","BTF"]}},{"id":"4b867fb9cd0a4096a2ac06c251a16b73","type":"GENE","name":"BCLAF1P1","canonical_id":"hgnc:HGNC:51329","description":"BCL2 associated transcription factor 1 pseudogene 1","metadata":null},{"id":"c130f10755b744869ac319047351f483","type":"GENE","name":"BCLAF1P2","canonical_id":"hgnc:HGNC:51807","description":"BCL2 associated transcription factor 1 pseudogene 2","metadata":null},{"id":"5b0bb634666c43cb8713f3dd83174d8a","type":"GENE","name":"BCLAF3","canonical_id":"hgnc:HGNC:27413","description":"BCLAF1 and THRAP3 family member 3","metadata":{"aliases":["CXorf23"]}},{"id":"847fac4cefc94ac9abc34281e48c8a77","type":"GENE","name":"BCO1","canonical_id":"hgnc:HGNC:13815","description":"beta-carotene oxygenase 1","metadata":{"aliases":["FLJ10730","BCMO","BCDO","BCDO1","BCMO1"]}},{"id":"b93d2d74550f4c2db5a578b3e02e338f","type":"GENE","name":"BCO2","canonical_id":"hgnc:HGNC:18503","description":"beta-carotene oxygenase 2","metadata":{"aliases":["FLJ34464","B-DIOX-II","BCDO2"]}},{"id":"924afd440c5a4f64b06b28066741c630","type":"GENE","name":"BCOR","canonical_id":"hgnc:HGNC:20893","description":"BCL6 corepressor","metadata":{"aliases":["FLJ20285","KIAA1575"]}},{"id":"37aad60b95824738a8bda9a05830a967","type":"GO_TERM","name":"BCOR complex","canonical_id":"go:GO:0140261","description":"\"A protein-containing complex that monoubiquitinates histone H2A on K119, thus it facilitates the maintenance of the transcriptionally repressive state of some genes, such as BCL6. It consists of the corepressor BCOR or BCORL1, a Polycomb group (PcG) and a SCF ubiquitin ligase subcomplexes. In mammals, the core subunits of the complex include the PcG and PcG-associated proteins NSPC1, RING1, RNF2, and RYBP and the components of the SCF ubiquitin ligase, SKP1, and FBXL10.\" [PMID:16943429, PMID:22325352, PMID:24515802]","metadata":null},{"id":"7ea69986171144fba0ff275453878cf0","type":"GENE","name":"BCORL1","canonical_id":"hgnc:HGNC:25657","description":"BCL6 corepressor like 1","metadata":{"aliases":["FLJ11362","BCoR-L1","CXorf10"]}},{"id":"63752bac39974330a9a9c1b42d288aef","type":"GENE","name":"BCORP1","canonical_id":"hgnc:HGNC:23953","description":"BCL6 corepressor pseudogene 1","metadata":{"aliases":["FLJ39821","BCORL2"]}},{"id":"2b79508339bc4e5489c3d4ad0f8291cd","type":"GENE","name":"BCR","canonical_id":"hgnc:HGNC:1014","description":"BCR activator of RhoGEF and GTPase","metadata":{"aliases":["D22S662","CML","PHL","ALL","D22S11","BCR1"]}},{"id":"c45c84fa7dc148ee9cd9e9327144c7df","type":"PROTEIN","name":"BCR/ABL protein-tyrosine kinase","canonical_id":"uniprot:A9UF02","description":null,"metadata":null},{"id":"c47e918ca42a4993be6daf689cf8c900","type":"GENE","name":"BCRP1","canonical_id":"hgnc:HGNC:39073","description":"BCR pseudogene 1","metadata":{"aliases":["BCR-1"]}},{"id":"0d2280acfa4a485c8b7d9fa5e324ae3e","type":"GENE","name":"BCRP2","canonical_id":"hgnc:HGNC:1015","description":"BCR pseudogene 2","metadata":{"aliases":["BCR-2","BCR2","BCRL2"]}},{"id":"b04950389b2245be9279aed132efbb50","type":"GENE","name":"BCRP3","canonical_id":"hgnc:HGNC:1016","description":"BCR pseudogene 3","metadata":{"aliases":["BCR3","BCRL6","BCRL3"]}},{"id":"b3f792ec79074e0e8107bfed914fa0ce","type":"GENE","name":"BCRP4","canonical_id":"hgnc:HGNC:1017","description":"BCR pseudogene 4","metadata":{"aliases":["BCR-4","BCR4","BCRL4"]}},{"id":"f5f0e57248db4cf49db0f421b0da2377","type":"GENE","name":"BCRP5","canonical_id":"hgnc:HGNC:1018","description":"BCR pseudogene 5","metadata":{"aliases":["BCRL5"]}},{"id":"8b1aff75c18d4909b05fbc95503b52a3","type":"GENE","name":"BCRP6","canonical_id":"hgnc:HGNC:39074","description":"BCR pseudogene 6","metadata":null},{"id":"052e47397fdc455a97824c6050804185","type":"GENE","name":"BCRP7","canonical_id":"hgnc:HGNC:39075","description":"BCR pseudogene 7","metadata":null},{"id":"a6d803f7ce1d48e79495696c12486bc9","type":"GENE","name":"BCRP8","canonical_id":"hgnc:HGNC:39076","description":"BCR pseudogene 8","metadata":null},{"id":"ee13f968fa9a43fbae7dff5e267f2a77","type":"GENE","name":"BCRP9","canonical_id":"hgnc:HGNC:49113","description":"BCR pseudogene 9","metadata":null},{"id":"b362dc2f588d46c9a4ef2520ef66d705","type":"GENE","name":"BCS1L","canonical_id":"hgnc:HGNC:1020","description":"BCS1 ubiquinol-cytochrome c reductase complex chaperone","metadata":{"aliases":["Hs.6719","BCS","h-BCS","BJS"]}},{"id":"0c25d7d6a876446a9debc8181c6fdfcc","type":"TRIAL","name":"BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy","canonical_id":"clinicaltrials.gov:NCT05116774","description":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","metadata":null},{"id":"3f850b1f0e254929b233ccd172ce9b63","type":"GENE","name":"BCYRN1","canonical_id":"hgnc:HGNC:1022","description":"brain cytoplasmic RNA 1","metadata":{"aliases":["BC200","BC200a","NCRNA00004","LINC00004"]}},{"id":"117d0ed82e8f4478ae6f5478bef164e5","type":"GENE","name":"BCYRN1P1","canonical_id":"hgnc:HGNC:1023","description":"brain cytoplasmic RNA 1, pseudogene 1","metadata":{"aliases":["BC200b"]}},{"id":"feabe292372242139787a849b17aeb05","type":"GENE","name":"BCYRN1P2","canonical_id":"hgnc:HGNC:1024","description":"brain cytoplasmic RNA 1, pseudogene 2","metadata":{"aliases":["BC200g"]}},{"id":"9ae0843a229b48d19009659824076010","type":"GENE","name":"BCYRN1P3","canonical_id":"hgnc:HGNC:39833","description":"brain cytoplasmic RNA 1, pseudogene 3","metadata":null},{"id":"2a1977504516478c83206ff402c28e93","type":"GENE","name":"BDH1","canonical_id":"hgnc:HGNC:1027","description":"3-hydroxybutyrate dehydrogenase 1","metadata":{"aliases":["SDR9C1","BDH"]}},{"id":"79a1cb5083a74a77bbf7552dc97412da","type":"GENE","name":"BDH2","canonical_id":"hgnc:HGNC:32389","description":"3-hydroxybutyrate dehydrogenase 2","metadata":{"aliases":["UCPA-OR","FLJ13261","UNQ6308","PRO20933","SDR15C1","DHRS6"]}},{"id":"29be9814eb1048c8bf07c738bef8c17f","type":"GENE","name":"BDH2P1","canonical_id":"hgnc:HGNC:21476","description":"3-hydroxybutyrate dehydrogenase 2, pseudogene 1","metadata":{"aliases":["bA758C21.1","DHRS6P1"]}},{"id":"99beb57125d54d1a8aea5772ce52b842","type":"GENE","name":"BDKRB1","canonical_id":"hgnc:HGNC:1029","description":null,"metadata":null},{"id":"4e16ef8086ec451a8f937402ec7c6c14","type":"GENE","name":"BDKRB1-AS1","canonical_id":"hgnc:HGNC:58458","description":"BDKRB1 antisense RNA 1","metadata":null},{"id":"58d58bae5130404084058d4a8d4c0303","type":"GENE","name":"BDKRB2","canonical_id":"hgnc:HGNC:1030","description":null,"metadata":null},{"id":"ec97931cc19a4e9cb97a9e0f576fbe38","type":"GENE","name":"BDNF","canonical_id":"hgnc:HGNC:1033","description":null,"metadata":null},{"id":"999c297904364e5dbfb49ccda4ad31e8","type":"GENE","name":"BDNF-AS","canonical_id":"hgnc:HGNC:20608","description":"BDNF antisense RNA","metadata":{"aliases":["BT2A","BT2B","BT2C","BT2D","NCRNA00049","BDNF-AS1","BDNFAS","BDNFOS"]}},{"id":"559128841cc64133b52f81dd2cf26cdc","type":"GENE","name":"BDP1","canonical_id":"hgnc:HGNC:13652","description":null,"metadata":null},{"id":"757feab05db74aaa93f09e5d287f2ea1","type":"GENE","name":"BDP1P","canonical_id":"hgnc:HGNC:31044","description":"B double prime 1 pseudogene","metadata":null},{"id":"4df21af6fab84cc68dd0dec9e6a2fa29","type":"TRIAL","name":"BE Study Budesonide 80 \u03bcg and Formoterol Fumarate Dihydrate 4.5 \u03bcg Inhalation Product in Asthma Patient","canonical_id":"clinicaltrials.gov:NCT05322707","description":"Asthma","metadata":null},{"id":"551e4364c0bc4511b51f82174ead6226","type":"TRIAL","name":"BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza\u2122) Tablet and a 500 mg Metformin HCl XR (Glifage\u00ae XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States","canonical_id":"clinicaltrials.gov:NCT01305551","description":"Type 2 Diabetes","metadata":null},{"id":"d11d5a03ed2e4c0aafa4ce4b1f52a1ed","type":"TRIAL","name":"BE of Torrent's Esomeprazole Mg DR Capsules","canonical_id":"clinicaltrials.gov:NCT02680119","description":"Healthy","metadata":null},{"id":"974e04eb92ea40f58c80df5afe8c07fe","type":"TRIAL","name":"BEACON - ABC in Recurrent Platinum Resistant HGSOC","canonical_id":"clinicaltrials.gov:NCT03363867","description":"Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma","metadata":null},{"id":"48bab92de1224b4baca4042d3e0b7719","type":"TRIAL","name":"BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin\u00ae)/BEAM With ASCT for Relapsed DLBCL","canonical_id":"clinicaltrials.gov:NCT02366663","description":"Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"54c078318fae4bb1bd2c8f4787a00e57","type":"GENE","name":"BEAN1","canonical_id":"hgnc:HGNC:24160","description":"brain expressed associated with NEDD4 1","metadata":{"aliases":["SCA31"]}},{"id":"27109fee601347c7b11fd4cf66d9a464","type":"GENE","name":"BEAN1-AS1","canonical_id":"hgnc:HGNC:51114","description":"BEAN1 antisense RNA 1","metadata":null},{"id":"8ea2e26a810846b88f7c4131be411b7f","type":"TRIAL","name":"BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT07854652","description":"B-cell Precursor Acute Lymphoblastic Leukemia (ALL)","metadata":null},{"id":"18e8d19dcd5f455abf2f1dfa80cacb68","type":"GENE","name":"BECN1","canonical_id":"hgnc:HGNC:1034","description":null,"metadata":null},{"id":"49f383726bf841e4ac747bbafe1318c4","type":"GENE","name":"BECN1P2","canonical_id":"hgnc:HGNC:51330","description":"beclin 1 pseudogene 2","metadata":null},{"id":"a04ef84ffc9047a9bb7ae40885fccc3f","type":"GENE","name":"BECN2","canonical_id":"hgnc:HGNC:38606","description":"beclin 2","metadata":{"aliases":["BECN1P1"]}},{"id":"d4281bc2697e487b8f0cf67d23eba3af","type":"GENE","name":"BEGAIN","canonical_id":"hgnc:HGNC:24163","description":"brain enriched guanylate kinase associated","metadata":{"aliases":["KIAA1446"]}},{"id":"2f9f8f4264fc47beae80318029e9f5df","type":"GENE","name":"BEGAIN-AS1","canonical_id":"hgnc:HGNC:58465","description":"BEGAIN antisense RNA 1","metadata":null},{"id":"94bb995501a04c448a27aab6a3687ce5","type":"TRIAL","name":"BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115","canonical_id":"clinicaltrials.gov:NCT01597622","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"d6baa5508ea84dceaec81692fc079244","type":"GENE","name":"BEND2","canonical_id":"hgnc:HGNC:28509","description":"BEN domain containing 2","metadata":{"aliases":["MGC33653","CXorf20"]}},{"id":"5a7f5ac632bc47ceba93092f5681a33e","type":"GENE","name":"BEND3","canonical_id":"hgnc:HGNC:23040","description":"BEN domain containing 3","metadata":{"aliases":["KIAA1553"]}},{"id":"c5d2e19ee7c4435994fc8d363ed52dd6","type":"GENE","name":"BEND3P1","canonical_id":"hgnc:HGNC:45014","description":"BEN domain containing 3 pseudogene 1","metadata":null},{"id":"e41b55990a7140ad950367b250d6d5bc","type":"GENE","name":"BEND3P2","canonical_id":"hgnc:HGNC:45015","description":"BEN domain containing 3 pseudogene 2","metadata":null},{"id":"3da63532938b4658aac791a9c100200d","type":"GENE","name":"BEND3P3","canonical_id":"hgnc:HGNC:45016","description":"BEN domain containing 3 pseudogene 3","metadata":null},{"id":"392e949c14cf44919cbc4a042e841ca4","type":"GENE","name":"BEND4","canonical_id":"hgnc:HGNC:23815","description":"BEN domain containing 4","metadata":{"aliases":["FLJ35632","FLJ43965","CCDC4"]}},{"id":"b8f1b5e6d5744c65bf9b9a0f8ccb4b1f","type":"GENE","name":"BEND4-AS1","canonical_id":"hgnc:HGNC:58764","description":"BEND4 antisense RNA 1","metadata":null},{"id":"97ffeabbf7ae478cb3ff0689dfba6fa5","type":"GENE","name":"BEND5","canonical_id":"hgnc:HGNC:25668","description":"BEN domain containing 5","metadata":{"aliases":["FLJ11588","C1orf165"]}},{"id":"d532259fe167459a8103c055cd565099","type":"GENE","name":"BEND6","canonical_id":"hgnc:HGNC:20871","description":"BEN domain containing 6","metadata":{"aliases":["FLJ30162","bA203B9.1","C6orf65"]}},{"id":"135e7976bb8d421aa286e254e307b9c8","type":"GENE","name":"BEND7","canonical_id":"hgnc:HGNC:23514","description":"BEN domain containing 7","metadata":{"aliases":["FLJ40283","C10orf30"]}},{"id":"095b489ed5af4250b0dead7e698967fe","type":"GENE","name":"BEND7-DT","canonical_id":"hgnc:HGNC:55819","description":"BEND7 divergent transcript","metadata":null},{"id":"b7b32c30ab0e41d3909a96baa39325c2","type":"GENE","name":"BEND7P1","canonical_id":"hgnc:HGNC:51362","description":"BEN domain containing 7 pseudogene 1","metadata":null},{"id":"04500a75bc824e6fb63e5f994e9d5be3","type":"TRIAL","name":"BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH","canonical_id":"clinicaltrials.gov:NCT02375724","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"dca0882ea471458db3c32e2447b854d0","type":"TRIAL","name":"BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration","canonical_id":"clinicaltrials.gov:NCT04690062","description":"Dystrophy, Retinal","metadata":null},{"id":"77e74976f0e14b728fbff663a326fe93","type":"GENE","name":"BEST1","canonical_id":"hgnc:HGNC:12703","description":null,"metadata":null},{"id":"a5de171604324f3e8583d48cf8f3c293","type":"GENE","name":"BEST2","canonical_id":"hgnc:HGNC:17107","description":"bestrophin 2","metadata":{"aliases":["FLJ20132","VMD2L1"]}},{"id":"00974d2cd7104686a8231f633af74a37","type":"GENE","name":"BEST3","canonical_id":"hgnc:HGNC:17105","description":"bestrophin 3","metadata":{"aliases":["MGC40411","MGC13168","VMD2L3"]}},{"id":"5d639af109b544b2862a3b3a34942e85","type":"GENE","name":"BEST4","canonical_id":"hgnc:HGNC:17106","description":"bestrophin 4","metadata":{"aliases":["VMD2L2"]}},{"id":"11644bf97db444bbb1c0a4c2587694a9","type":"GENE","name":"BET1","canonical_id":"hgnc:HGNC:14562","description":"Bet1 golgi vesicular membrane trafficking protein","metadata":{"aliases":["hbet1"]}},{"id":"1654f514f9004e5791ee012c4598b62a","type":"GENE","name":"BET1-AS1","canonical_id":"hgnc:HGNC:40690","description":"BET1 antisense RNA 1","metadata":null},{"id":"3aed9b2f3be64cd0858f7732f0d5debb","type":"GENE","name":"BET1L","canonical_id":"hgnc:HGNC:19348","description":"Bet1 golgi vesicular membrane trafficking protein like","metadata":{"aliases":["GS15","GOLIM3"]}},{"id":"29e560de3e9d4754ae0b878638405d5f","type":"GENE","name":"BET1P1","canonical_id":"hgnc:HGNC:51363","description":"Bet1 golgi vesicular membrane trafficking protein pseudogene 1","metadata":null},{"id":"0ffe7ae36a6e4427baa5be70f9c228c2","type":"GENE","name":"BETALINC1","canonical_id":"hgnc:HGNC:51391","description":"Beta cell long intergenic noncoding RNA 1","metadata":{"aliases":["HI-LNC15"]}},{"id":"aa6e8056fb414589bccbcedb0820aa75","type":"TRIAL","name":"BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 \u03bcg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 \u03bcg])","canonical_id":"clinicaltrials.gov:NCT07666490","description":"Asthma","metadata":null},{"id":"d453fbdf6f9e4872bca6902fbaec55cb","type":"GENE","name":"BEX1","canonical_id":"hgnc:HGNC:1036","description":"brain expressed X-linked 1","metadata":null},{"id":"c2f2c9869c8b489a85ca2d5d0dcdb59c","type":"GENE","name":"BEX2","canonical_id":"hgnc:HGNC:30933","description":null,"metadata":null},{"id":"9a56429a79ac4bd489e5b3eab3ee4d61","type":"GENE","name":"BEX3","canonical_id":"hgnc:HGNC:13388","description":"brain expressed X-linked 3","metadata":{"aliases":["Bex","NADE","HGR74","Hero20","DXS6984E","NGFRAP1"]}},{"id":"10c81ffe82f64babbece782bd6dfefb3","type":"GENE","name":"BEX4","canonical_id":"hgnc:HGNC:25475","description":"brain expressed X-linked 4","metadata":{"aliases":["FLJ10097","BEXL1"]}},{"id":"eed963f498ff4a5883cd7b747d90019c","type":"GENE","name":"BEX5","canonical_id":"hgnc:HGNC:27990","description":"brain expressed X-linked 5","metadata":{"aliases":["NGFRAP1L1"]}},{"id":"fcec669b565d41baa8f990985452a10f","type":"TRIAL","name":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","canonical_id":"clinicaltrials.gov:NCT05922761","description":"Bronchiolitis Obliterans Syndrome; Bronchiolitis Obliterans; Lung Diseases; Chronic Graft Versus Host Disease","metadata":null},{"id":"abc33caa9c7240d690dd0e0200922aec","type":"GENE","name":"BFAR","canonical_id":"hgnc:HGNC:17613","description":"bifunctional apoptosis regulator","metadata":{"aliases":["BAR","RNF47"]}},{"id":"fb2c3ecc2895499992f03897a37c3848","type":"GENE","name":"BFSP1","canonical_id":"hgnc:HGNC:1040","description":"beaded filament structural protein 1","metadata":{"aliases":["CP94","CP115","LIFL-H","filensin"]}},{"id":"70bb89f6816d4022b11429bfe938f5f5","type":"GENE","name":"BFSP2","canonical_id":"hgnc:HGNC:1041","description":"beaded filament structural protein 2","metadata":{"aliases":["CP47","CP49","LIFL-L","phakinin"]}},{"id":"e90a83643f204e56ad43733d33a82464","type":"GENE","name":"BFSP2-AS1","canonical_id":"hgnc:HGNC:28425","description":"BFSP2 antisense RNA 1","metadata":{"aliases":["MGC2848"]}},{"id":"12a1ee40c1344ef18299f4edbc5e10d4","type":"TRIAL","name":"BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT02872259","description":"Melanoma","metadata":null},{"id":"1428466bbbdd4e2c95f9cdd9ccdb85d9","type":"GENE","name":"BGLAP","canonical_id":"hgnc:HGNC:1043","description":null,"metadata":null},{"id":"1e3bccfd35ac40e2985af51e1a1244a5","type":"GENE","name":"BGLT3","canonical_id":"hgnc:HGNC:49033","description":"beta globin locus transcript 3","metadata":{"aliases":["LINC01083","BGL3","lncRNA-BGL3"]}},{"id":"2dcd77ccb66e49e695dc0379c3c5a4e1","type":"GENE","name":"BGN","canonical_id":"hgnc:HGNC:1044","description":null,"metadata":null},{"id":"e6719f2f3f244098bedfe67884213867","type":"GO_TERM","name":"BH domain binding","canonical_id":"go:GO:0051400","description":"\"Binding to a Bcl-2 homology (BH) protein domain. Bcl-2-related proteins share homology in one to four conserved regions designated the Bcl-2 homology (BH) domains BH1, BH2, BH3 and BH4. These domains contribute at multiple levels to the function of these proteins in cell death and survival. Anti-apoptotic members of the Bcl-2 family have four BH domains (BH1-BH4). Pro-apoptotic members have fewer BH domains.\" [PMID:11048732, PMID:12133724, PMID:9020082, PMID:9704409]","metadata":null},{"id":"39329f55c8fb4d9fafd3524aae6bccd7","type":"GO_TERM","name":"BH1 domain binding","canonical_id":"go:GO:0051432","description":"\"Binding to a BH1 protein domain, present in Bcl-2 family members. Proteins that act as inhibitors of apoptosis harbour at least three BH domains: BH1, BH2 and BH3; the BH1 and BH2 domains are found in all death antagonists of the Bcl-2 family but only in one class of death agonists.\" [PMID:11048732, PMID:12133724, PMID:9020082, PMID:9704409, Prosite:PS01080]","metadata":null},{"id":"2d0d3471f33a4271a64acd7655f8791e","type":"GO_TERM","name":"BH2 domain binding","canonical_id":"go:GO:0051433","description":"\"Binding to a BH2 protein domain, present in Bcl-2 family members. Proteins that act as inhibitors of apoptosis harbour at least three BH domains: BH1, BH2 and BH3; the BH1 and BH2 domains are found in all death antagonists of the Bcl-2 family but only in one class of death agonists.\" [PMID:11048732, PMID:12133724, PMID:9020082, PMID:9704409, Prosite:PS01258]","metadata":null},{"id":"bd092af42fb940cda01f485367014afa","type":"GO_TERM","name":"BH3 domain binding","canonical_id":"go:GO:0051434","description":"\"Binding to a BH3 protein domain, present in Bcl-2 family members. The BH3 domain is a potent death domain and has an important role in protein-protein interactions and in cell death.\" [PMID:11048732, PMID:12133724, PMID:9020082, PMID:9704409, Prosite:PS01259]","metadata":null},{"id":"86922df899f84f29ba4a393cb856a984","type":"GO_TERM","name":"BH4 domain binding","canonical_id":"go:GO:0051435","description":"\"Binding to a BH4 protein domain, present in Bcl-2 family members. All anti-apoptotic proteins contain BH1 and BH2 domains; some also contain an additional N-terminal BH4 domain, which is almost never seen in pro-apoptotic proteins. Loss of the BH4 domain can diminish or abrogate anti-apoptotic function or even impart outright death-promoting properties to the protein.\" [InterPro:IPR003093, PMID:11048732, PMID:12133724, PMID:9020082, PMID:9704409, Prosite:PS01260, Prosite:PS50063]","metadata":null},{"id":"51f8c0dc72ce477083dc79d8ffd94fd4","type":"TRIAL","name":"BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)","canonical_id":"clinicaltrials.gov:NCT05299203","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"68866defd4ee4d118fd3d43764abebb0","type":"DISEASE","name":"BH4-deficient hyperphenylalaninemia A","canonical_id":"mondo:0009863","description":null,"metadata":null},{"id":"93df9d2b94884beca0d67f53ac94e33f","type":"GENE","name":"BHLHA15","canonical_id":"hgnc:HGNC:22265","description":"basic helix-loop-helix family member a15","metadata":{"aliases":["MIST1","BHLHB8"]}},{"id":"e5f9b9f896094a0f82408c8efb0f81b2","type":"GENE","name":"BHLHA9","canonical_id":"hgnc:HGNC:35126","description":"basic helix-loop-helix family member a9","metadata":{"aliases":["BHLHF42"]}},{"id":"8e68b9e97ab144569446ff5da5ed5987","type":"GENE","name":"BHLHE22","canonical_id":"hgnc:HGNC:11963","description":null,"metadata":null},{"id":"39d28efd334246f4b62f9937dfbd5bba","type":"GENE","name":"BHLHE22-AS1","canonical_id":"hgnc:HGNC:56147","description":"BHLHE22 antisense RNA 1","metadata":{"aliases":["uc.240"]}},{"id":"48ecb00614dc4fcfadef5eaa37cdc674","type":"GENE","name":"BHLHE23","canonical_id":"hgnc:HGNC:16093","description":"basic helix-loop-helix family member e23","metadata":{"aliases":["bA305P22.3","Beta4","BHLHB4"]}},{"id":"01e64434ed6d438f91fa92d237942142","type":"GENE","name":"BHLHE40","canonical_id":"hgnc:HGNC:1046","description":null,"metadata":null},{"id":"b5db4614d7434cdbace3094dc3955f46","type":"GENE","name":"BHLHE40-AS1","canonical_id":"hgnc:HGNC:44471","description":"BHLHE40 antisense RNA 1","metadata":null},{"id":"ded5930446ec4e6a97da7bc7e9f4c966","type":"GENE","name":"BHLHE41","canonical_id":"hgnc:HGNC:16617","description":null,"metadata":null},{"id":"aa39a81bc0b845b1bc744f441871414c","type":"GENE","name":"BHMT","canonical_id":"hgnc:HGNC:1047","description":null,"metadata":null},{"id":"db5ed122befb491f85db525a7f1ab4af","type":"GENE","name":"BHMT2","canonical_id":"hgnc:HGNC:1048","description":"betaine--homocysteine S-methyltransferase 2","metadata":null},{"id":"3853cab25d7149dcba8c80f0bb2d90b3","type":"TRIAL","name":"BI 44370 TA in Acute Migraine Attack","canonical_id":"clinicaltrials.gov:NCT00751803","description":"Migraine Disorders","metadata":null},{"id":"48f48b14426544bbaeb34f8b59640b6c","type":"TRIAL","name":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02684370","description":"Psoriasis","metadata":null},{"id":"12c29e5de0904a67a11d081bdc6df38a","type":"TRIAL","name":"BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03000075","description":"Psoriasis","metadata":null},{"id":"1991e63ba0ab4d51b0e04e532318ec94","type":"TRIAL","name":"BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment","canonical_id":"clinicaltrials.gov:NCT02672852","description":"Psoriasis","metadata":null},{"id":"0447f9ccd0d04e7aa149729f95f559d0","type":"TRIAL","name":"BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab","canonical_id":"clinicaltrials.gov:NCT02054481","description":"Psoriasis","metadata":null},{"id":"b12f02e22f8249eca7fe9e0e5b063f85","type":"TRIAL","name":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02684357","description":"Psoriasis","metadata":null},{"id":"df8d45a4eccf4b039cef3ccca7f3980d","type":"TRIAL","name":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02694523","description":"Psoriasis","metadata":null},{"id":"b53d110e67ca4d59a4c56bc2f8dfc2d8","type":"TRIAL","name":"BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT02719171","description":"Arthritis, Psoriatic","metadata":null},{"id":"dcbc6fe3d9c9410f8851df42d25610bb","type":"TRIAL","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA\u00ae ) in Treatment of Advanced Malignancies(Keynote-D20)","canonical_id":"clinicaltrials.gov:NCT04752826","description":"Advanced Malignancies; Ovarian Cancer; T-cell Lymphoma; Melanoma","metadata":null},{"id":"bdc757e4939048f6a7e1413e4b9eb94f","type":"TRIAL","name":"BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)","canonical_id":"clinicaltrials.gov:NCT04839471","description":"Esophageal Squamous Cell Carcinoma (ESCC)","metadata":null},{"id":"0179e67d4abf4be6bc39b7fca851c7e7","type":"TRIAL","name":"BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT01225822","description":"Venous Thromboembolism","metadata":null},{"id":"3481dd3f1c5547a992563761ad53b1c3","type":"TRIAL","name":"BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01320280","description":"Refractory Cancer","metadata":null},{"id":"6db8f497c61a43b5a6273ecb19857f77","type":"GENE","name":"BICC1","canonical_id":"hgnc:HGNC:19351","description":"BicC family RNA binding protein 1","metadata":null},{"id":"565cb5b286c6413883235d66cc2a880f","type":"GENE","name":"BICD1","canonical_id":"hgnc:HGNC:1049","description":"BICD cargo adaptor 1","metadata":null},{"id":"f9da394f3c0744aaa0998762223ab991","type":"GENE","name":"BICD1-AS1","canonical_id":"hgnc:HGNC:55475","description":"BICD1 antisense RNA 1","metadata":null},{"id":"eb0a1be1006c4393969c219b22d9fafd","type":"GENE","name":"BICD1P1","canonical_id":"hgnc:HGNC:51374","description":"BICD cargo adaptor 1 pseudogene 1","metadata":null},{"id":"8c7f629ae3f94fe99c63fd4cbf10abc4","type":"GENE","name":"BICD2","canonical_id":"hgnc:HGNC:17208","description":"BICD cargo adaptor 2","metadata":{"aliases":["KIAA0699"]}},{"id":"0420488132f441fa812023999c5698d5","type":"GENE","name":"BICDL1","canonical_id":"hgnc:HGNC:28095","description":"BICD family like cargo adaptor 1","metadata":{"aliases":["FLJ26450","BICDR-1","CCDC64"]}},{"id":"813cb6d225e847e4bd16379aeed34f32","type":"GENE","name":"BICDL2","canonical_id":"hgnc:HGNC:33584","description":"BICD family like cargo adaptor 2","metadata":{"aliases":["CCDC64B"]}},{"id":"77cb4383e98f48b9a81138b8455a58a0","type":"GENE","name":"BICDL3P","canonical_id":"hgnc:HGNC:18289","description":"BICD family like 3, pseudogene","metadata":{"aliases":["NCRNA00035","WBSCR26","LINC00035","ABHD11-AS1"]}},{"id":"b2d4288f37564a65bda640fa06682bd7","type":"GENE","name":"BICRA","canonical_id":"hgnc:HGNC:4332","description":"BRD4 interacting chromatin remodeling complex associated protein","metadata":{"aliases":["SMARCK1","GLTSCR1"]}},{"id":"aa8f0b77c30f4d9b9f84cdb48d84aad3","type":"GENE","name":"BICRA-AS1","canonical_id":"hgnc:HGNC:51588","description":"BICRA antisense RNA 1","metadata":{"aliases":["GLTSCR1-AS1"]}},{"id":"27a4bce268dd4467a47069bbda423c09","type":"GENE","name":"BICRA-AS2","canonical_id":"hgnc:HGNC:56742","description":"BICRA antisense RNA 2","metadata":{"aliases":["AC010331.1"]}},{"id":"8550dbd1cdff48ebbd7536248061b4ce","type":"GENE","name":"BICRAL","canonical_id":"hgnc:HGNC:21111","description":"BICRA like chromatin remodeling complex associated protein","metadata":{"aliases":["SMARCK2","KIAA0240","GLTSCR1L"]}},{"id":"4fe11404dcf74665af2c400a54dcbd26","type":"GENE","name":"BID","canonical_id":"hgnc:HGNC:1050","description":null,"metadata":null},{"id":"9b43dd922ada4ffcb07215ee91277fba","type":"GO_TERM","name":"BID-BCL-2 complex","canonical_id":"go:GO:0097139","description":"\"A heterodimeric protein complex consisting of BID and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"9f2b7c6a982c49b39a1e4e59e10f39ae","type":"GO_TERM","name":"BID-BCL-xl complex","canonical_id":"go:GO:1990346","description":"\"A heterodimeric protein complex consisting of BID and BCL-xl, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:bhm, PMID:14634621]","metadata":null},{"id":"d8c0d67906a34ca288eb2deba9c5d619","type":"TRIAL","name":"BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT01930890","description":"Lupus Nephritis","metadata":null},{"id":"4505e92474634bf9889726bc066dd747","type":"GENE","name":"BIK","canonical_id":"hgnc:HGNC:1051","description":"BCL2 interacting killer","metadata":{"aliases":["NBK"]}},{"id":"7afb285a7fb6431e95282357be7f94d0","type":"GO_TERM","name":"BIM-BCL-2 complex","canonical_id":"go:GO:0097141","description":"\"A heterodimeric protein complex consisting of BIM and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"d6c418564e2b47bdacbdfd8f4d6ab335","type":"GO_TERM","name":"BIM-BCL-xl complex","canonical_id":"go:GO:0097140","description":"\"A heterodimeric protein complex consisting of BIM and BCL-xl, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"cc20e8766b8a44ebbd9c857363e2a201","type":"GENE","name":"BIN1","canonical_id":"hgnc:HGNC:1052","description":null,"metadata":null},{"id":"fd1ca60a85fb46d0917912ca2d7dc97e","type":"GENE","name":"BIN2","canonical_id":"hgnc:HGNC:1053","description":"bridging integrator 2","metadata":{"aliases":["BRAP-1"]}},{"id":"b66068186fc24d2d9acdebbc5e00607d","type":"GENE","name":"BIN2P1","canonical_id":"hgnc:HGNC:43660","description":"bridging integrator 2 pseudogene 1","metadata":null},{"id":"5416efea813f44c4859a9d32253517f2","type":"GENE","name":"BIN2P2","canonical_id":"hgnc:HGNC:43661","description":"bridging integrator 2 pseudogene 2","metadata":null},{"id":"5f304493923145338a22ecb19a2d3333","type":"GENE","name":"BIN3","canonical_id":"hgnc:HGNC:1054","description":"bridging integrator 3","metadata":null},{"id":"b35c5cf9bbce4a8aaa178adf288bc849","type":"GENE","name":"BIN3-IT1","canonical_id":"hgnc:HGNC:25868","description":"BIN3 intronic transcript 1","metadata":{"aliases":["FLJ14107"]}},{"id":"c0935f15fa384ce083355a984285ee65","type":"TRIAL","name":"BIOlogics in Severe Nasal POlyposis SurvEy","canonical_id":"clinicaltrials.gov:NCT05228041","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"7ad7e38ed5334733ad11f0d68e49e89c","type":"GO_TERM","name":"BIR domain binding","canonical_id":"go:GO:1990525","description":"\"Binding to a Baculovirus Inhibitor of apoptosis protein Repeat (BIR) domain.\" [GOC:ha, InterPro:IPR001370]","metadata":null},{"id":"125c3621104c4326947f1d67f03e735a","type":"GENE","name":"BIRC2","canonical_id":"hgnc:HGNC:590","description":null,"metadata":null},{"id":"6d4dccaaf6b34794b6be9920f206a672","type":"GENE","name":"BIRC3","canonical_id":"hgnc:HGNC:591","description":null,"metadata":null},{"id":"809db930a7e4496abaf202b190a3498f","type":"GENE","name":"BIRC5","canonical_id":"hgnc:HGNC:593","description":null,"metadata":null},{"id":"f2f9b6d930c14878a16d63d0dd2bd19d","type":"GENE","name":"BIRC6","canonical_id":"hgnc:HGNC:13516","description":"baculoviral IAP repeat containing 6","metadata":{"aliases":["BRUCE"]}},{"id":"56df00d18d0f43429e986c2fe084222d","type":"GENE","name":"BIRC6-AS1","canonical_id":"hgnc:HGNC:40641","description":"BIRC6 antisense RNA 1","metadata":null},{"id":"3f05ad167b774ad1b392ecb57497dc3d","type":"GENE","name":"BIRC6-AS2","canonical_id":"hgnc:HGNC:50490","description":"BIRC6 antisense RNA 2","metadata":{"aliases":["megamind"]}},{"id":"9f8b5820fdb54dfc833b28372383ac49","type":"GENE","name":"BIRC7","canonical_id":"hgnc:HGNC:13702","description":null,"metadata":null},{"id":"9c44723c9e0047a8afc40d086ea7425d","type":"GENE","name":"BIRC8","canonical_id":"hgnc:HGNC:14878","description":"baculoviral IAP repeat containing 8","metadata":{"aliases":["ILP-2","hILP2","RNF136"]}},{"id":"b3cfe806572d42cc914c5b12ab2e8396","type":"GENE","name":"BISPR","canonical_id":"hgnc:HGNC:51290","description":"BST2 interferon stimulated positive regulator","metadata":{"aliases":["lncBST2"]}},{"id":"ac9cfe458d9141af86f50729db6fb063","type":"GENE","name":"BIVM","canonical_id":"hgnc:HGNC:16034","description":"basic, immunoglobulin-like variable motif containing","metadata":{"aliases":["FLJ20159"]}},{"id":"b9d03f03a9bf417ab8174443bbbb313d","type":"GENE","name":"BIVM-ERCC5","canonical_id":"hgnc:HGNC:43690","description":"BIVM-ERCC5 readthrough","metadata":null},{"id":"db665d1f306d41fa9255b264603194bf","type":"GENE","name":"BKGD","canonical_id":"hgnc:HGNC:30204","description":"beta-keto-L-gulonate decarboxylase","metadata":{"aliases":["PTD012","MEEP","C11orf54"]}},{"id":"7f2f5f50006945a8bbb100f5b462fb04","type":"GENE","name":"BLACAT1","canonical_id":"hgnc:HGNC:48597","description":"BLACAT1 overlapping LEMD1 locus","metadata":{"aliases":["linc-UBC1","LINC00912","onco-lncRNA-30"]}},{"id":"5984032df62942e2927e6508626cb451","type":"GENE","name":"BLACE","canonical_id":"hgnc:HGNC:20484","description":"B cell acute lymphoblastic leukemia expressed","metadata":null},{"id":"ab9183a5a6094161b229bc41ffda1ecb","type":"GENE","name":"BLCAP","canonical_id":"hgnc:HGNC:1055","description":"BLCAP apoptosis inducing factor","metadata":{"aliases":["BC10"]}},{"id":"59bf0c67106a478b825f786085ac21c3","type":"GENE","name":"BLID","canonical_id":"hgnc:HGNC:33495","description":"BH3-like motif containing, cell death inducer","metadata":{"aliases":["BRCC2"]}},{"id":"001013d9cdef44df8617552dfba16baf","type":"TRIAL","name":"BLIS - Breastfeeding Levonorgestrel IUD Study","canonical_id":"clinicaltrials.gov:NCT01990703","description":"Contraception","metadata":null},{"id":"d890ef2dcb2f4e9785627a4508bd414f","type":"GENE","name":"BLK","canonical_id":"hgnc:HGNC:1057","description":null,"metadata":null},{"id":"fe99b51d09d14d18951120ae304597f9","type":"GENE","name":"BLK-AS1","canonical_id":"hgnc:HGNC:58190","description":"BLK antisense RNA 1","metadata":null},{"id":"a6b09c7146db45ad9eccc59f61e15b80","type":"GENE","name":"BLM","canonical_id":"hgnc:HGNC:1058","description":null,"metadata":null},{"id":"5383558d6e54428798780a250c0ab889","type":"GENE","name":"BLMH","canonical_id":"hgnc:HGNC:1059","description":null,"metadata":null},{"id":"10c79e27f30b47ada597257bb428a8a4","type":"GENE","name":"BLNK","canonical_id":"hgnc:HGNC:14211","description":"B cell linker","metadata":{"aliases":["SLP65","Ly57","SLP-65","BLNK-s","BASH","bca"]}},{"id":"49cbfcdc95c94a69ad152809454443c3","type":"GO_TERM","name":"BLOC complex","canonical_id":"go:GO:0031082","description":"\"Any of several protein complexes required for the biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes, platelet dense granules, and other related organelles; acronym for biogenesis of lysosomal-related organelles complex.\" [PMID:15102850, PMID:15261680]","metadata":null},{"id":"84e780acdd244ffb9a3ed4b001f8af96","type":"GO_TERM","name":"BLOC-1 complex","canonical_id":"go:GO:0031083","description":"\"A protein complex required for the biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes and platelet dense granules. Many of the protein subunits are conserved between mouse and human; the mouse complex contains the Pallidin, Muted, Cappuccino, Dysbindin, Snapin, BLOS1, BLOS2, AND BLOS3 proteins.\" [PMID:15102850]","metadata":null},{"id":"df842eda886e48cbaa7d66763e5b8f45","type":"GO_TERM","name":"BLOC-2 complex","canonical_id":"go:GO:0031084","description":"\"A protein complex required for the biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes and platelet dense granules. The human complex contains the Hps3, Hps5, and Hps6 proteins; the mouse complex contains ru2 and ru.\" [PMID:12548288, PMID:14718540, PMID:15031569]","metadata":null},{"id":"8bdd8c90113f4b328a5c99a7979c762f","type":"GO_TERM","name":"BLOC-2 complex binding","canonical_id":"go:GO:0036461","description":"\"Binding to a BLOC-2 complex, a protein complex required for the biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes and platelet dense granules.\" [GOC:bf, GOC:PARL, PMID:22511774]","metadata":null},{"id":"7e52193b390a4f769bc13013b73c159a","type":"GO_TERM","name":"BLOC-3 complex","canonical_id":"go:GO:0031085","description":"\"A protein complex required for the biogenesis of specialized organelles of the endosomal-lysosomal system, such as melanosomes and platelet dense granules. The human complex contains the Hps1 and Hps4 proteins.\" [PMID:12756248]","metadata":null},{"id":"52b98a80ddd442cd835558106cfdb7a0","type":"GENE","name":"BLOC1S1","canonical_id":"hgnc:HGNC:4200","description":"biogenesis of lysosomal organelles complex 1 subunit 1","metadata":{"aliases":["BLOS1","BORCS1","GCN5L1"]}},{"id":"67c6cd562e0e4f8b83125e88258c1184","type":"GENE","name":"BLOC1S2","canonical_id":"hgnc:HGNC:20984","description":"biogenesis of lysosomal organelles complex 1 subunit 2","metadata":{"aliases":["MGC10120","FLJ30135","BLOS2","BORCS2"]}},{"id":"1d9053676cbd4c8a85fd016621008063","type":"GENE","name":"BLOC1S2P1","canonical_id":"hgnc:HGNC:51427","description":"BLOC1S2 pseudogene 1","metadata":null},{"id":"741553e4921448188f59f98caff01e18","type":"GENE","name":"BLOC1S3","canonical_id":"hgnc:HGNC:20914","description":"biogenesis of lysosomal organelles complex 1 subunit 3","metadata":{"aliases":["BLOS3","HPS8"]}},{"id":"f02b6019e9c644e4a1310509005ffb91","type":"GENE","name":"BLOC1S4","canonical_id":"hgnc:HGNC:24206","description":"biogenesis of lysosomal organelles complex 1 subunit 4","metadata":{"aliases":["FLJ11230","BCAS4L","CNO"]}},{"id":"63b8f8656b3c4500b28165cf923e5a81","type":"GENE","name":"BLOC1S5","canonical_id":"hgnc:HGNC:18561","description":"biogenesis of lysosomal organelles complex 1 subunit 5","metadata":{"aliases":["MU","dJ303A1.3","MUTED"]}},{"id":"f2211750a2e948bba976c8786890417a","type":"GENE","name":"BLOC1S5-TXNDC5","canonical_id":"hgnc:HGNC:42001","description":"BLOC1S5-TXNDC5 readthrough (NMD candidate)","metadata":{"aliases":["MUTED-TXNDC5"]}},{"id":"008294794a234b85819a9d390c447614","type":"GENE","name":"BLOC1S6","canonical_id":"hgnc:HGNC:8549","description":"biogenesis of lysosomal organelles complex 1 subunit 6","metadata":{"aliases":["HPS9","PA","PLDN"]}},{"id":"e7a258f2506749f7b400b5bcaec93d23","type":"GENE","name":"BLOC1S6P1","canonical_id":"hgnc:HGNC:54899","description":"BLOC1S6 pseudogene 1","metadata":null},{"id":"61cd04815417417e80dd0d0aa796cfc2","type":"TRIAL","name":"BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.","canonical_id":"clinicaltrials.gov:NCT07474961","description":"Waldenstrom Macroglobulinaemia; Multiple Myeloma","metadata":null},{"id":"1451ff1ed31e4843a6425106b5918841","type":"TRIAL","name":"BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00603291","description":"Obesity","metadata":null},{"id":"f5ccb73edf024aa9a10a1238d5ff8bd1","type":"TRIAL","name":"BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","canonical_id":"clinicaltrials.gov:NCT00395135","description":"Obesity","metadata":null},{"id":"4903450634d44559a7fbdf4378dbe85a","type":"TRIAL","name":"BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management","canonical_id":"clinicaltrials.gov:NCT00603902","description":"Obesity","metadata":null},{"id":"ddce7a88cacc456aab83b1b7cf839ae6","type":"GENE","name":"BLTP1","canonical_id":"hgnc:HGNC:26953","description":"bridge-like lipid transfer protein family member 1","metadata":{"aliases":["FLJ21404","FSA","KIAA1371","Tweek","KIAA1109"]}},{"id":"4b15141f01534415a7e496e476662bca","type":"GENE","name":"BLTP2","canonical_id":"hgnc:HGNC:28960","description":"bridge-like lipid transfer protein family member 2","metadata":{"aliases":["DKFZp686M0843","MGC111488","BCOX1","CT101","BCOX","FMP27","Hob","KIAA0100"]}},{"id":"2ed9fd5751d74fd895c6e214d5308a15","type":"GENE","name":"BLTP3B","canonical_id":"hgnc:HGNC:29102","description":"bridge-like lipid transfer protein family member 3B","metadata":{"aliases":["KIAA0701","SHIP164","UHRF1BP1L"]}},{"id":"3f01e10b30204bbbb2bc5df2ffc0a52b","type":"GENE","name":"BLTP3B-DT","canonical_id":"hgnc:HGNC:55473","description":"BLTP3B divergent transcript","metadata":{"aliases":["UHRF1BP1L-DT"]}},{"id":"8f0e09958dc04827bb14d63916e3d80d","type":"GENE","name":"BLVRA","canonical_id":"hgnc:HGNC:1062","description":"biliverdin reductase A","metadata":{"aliases":["BVRA","BVRalpha","BLVR"]}},{"id":"6e877fccd8704218a9712c976e800901","type":"GENE","name":"BLVRB","canonical_id":"hgnc:HGNC:1063","description":"biliverdin reductase B","metadata":{"aliases":["SDR43U1","FLR"]}},{"id":"fea7124d6fc7492688af007112da9c99","type":"GENE","name":"BLVRBP1","canonical_id":"hgnc:HGNC:56414","description":"BLVRB pseudogene 1","metadata":null},{"id":"68e4d10eba4c4041831dfa0f5a2a3eef","type":"GENE","name":"BLZF1","canonical_id":"hgnc:HGNC:1065","description":"basic leucine zipper nuclear factor 1","metadata":{"aliases":["JEM-1"]}},{"id":"a1576d1ef36948b69941f2a42b803ec3","type":"GENE","name":"BLZF2P","canonical_id":"hgnc:HGNC:20049","description":"basic leucine zipper nuclear factor 2, pseudogene","metadata":null},{"id":"feb714c8dd1e44b682811cdaeba4cfd9","type":"GENE","name":"BMAL2-AS1","canonical_id":"hgnc:HGNC:49892","description":"BMAL2 antisense RNA 1","metadata":{"aliases":["ARNTL2-AS1"]}},{"id":"c8f36d39fa8f47d7868d3636877780cc","type":"GENE","name":"BMERB1","canonical_id":"hgnc:HGNC:19213","description":"bMERB domain containing 1","metadata":{"aliases":["FLJ32618","C16orf45"]}},{"id":"4faa0d01454c4bd8a9664da795275ebd","type":"GENE","name":"BMF","canonical_id":"hgnc:HGNC:24132","description":"Bcl2 modifying factor","metadata":{"aliases":["FLJ00065"]}},{"id":"f6bb00522e0140348127c1b0c3906047","type":"GENE","name":"BMF-AS1","canonical_id":"hgnc:HGNC:53612","description":"BMF antisense RNA 1","metadata":null},{"id":"52df80e7d67d4b91b63f1cd7e3e36c29","type":"GENE","name":"BMI1","canonical_id":"hgnc:HGNC:1066","description":null,"metadata":null},{"id":"b89e524ef9b94d5384df78aec096827f","type":"GENE","name":"BMI1P1","canonical_id":"hgnc:HGNC:51428","description":"BMI1 proto-oncogene, polycomb ring finger pseudogene 1","metadata":{"aliases":["lnc-OPHN1-5"]}},{"id":"a7e3297f95bd4d2a993aff9250cc8253","type":"GENE","name":"BMNCR","canonical_id":"hgnc:HGNC:54188","description":"bone marrow associated non-coding RNA","metadata":null},{"id":"2898c650949842d694d43bb29eed8252","type":"GO_TERM","name":"BMP binding","canonical_id":"go:GO:0036122","description":"\"Binding to a member of the bone morphogenetic protein (BMP) family.\" [GOC:BHF, PMID:9660951]","metadata":null},{"id":"e600f45522884d7f9e1787c03a03cb7a","type":"GO_TERM","name":"BMP receptor activity","canonical_id":"go:GO:0098821","description":"\"Combining with a member of the bone morphogenetic protein (BMP) family, and transmitting a signal across the plasma membrane to initiate a change in cell activity.\" [GOC:BHF, GOC:dos]","metadata":null},{"id":"238982d0046a44b1be8a074b323f04a0","type":"GO_TERM","name":"BMP receptor binding","canonical_id":"go:GO:0070700","description":"\"Binding to a BMP receptor.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"521b638cd543431e84317c522c6970fb","type":"GO_TERM","name":"BMP receptor complex","canonical_id":"go:GO:0070724","description":"\"A protein complex that acts as a receptor for bone morphogenetic proteins (BMPs); a homo- or heterodimer of type I and/or type II BMP receptor subunits.\" [GOC:mah, GOC:mh, PMID:19377468]","metadata":null},{"id":"7d454a05c9d54407b390792e028805fe","type":"GO_TERM","name":"BMP secretion","canonical_id":"go:GO:0038055","description":"\"The controlled release of a member of the BMP family of proteins from a cell.\" [GOC:sart]","metadata":null},{"id":"33ce5ccaf11f4039bdc045d2fca283e3","type":"GO_TERM","name":"BMP signaling pathway","canonical_id":"go:GO:0030509","description":"\"The series of molecular signals initiated by the binding of a member of the BMP (bone morphogenetic protein) family to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, ISBN:0878932437, PMID:17428827]","metadata":null},{"id":"ca4b2383206c4b648207bb12b0b84821","type":"GENE","name":"BMP1","canonical_id":"hgnc:HGNC:1067","description":"bone morphogenetic protein 1","metadata":{"aliases":["BMP-1","PCOLC"]}},{"id":"185431722aba494bb022f906af1f585c","type":"GENE","name":"BMP10","canonical_id":"hgnc:HGNC:20869","description":"bone morphogenetic protein 10","metadata":null},{"id":"450a0488583f455380037a942cea6a47","type":"GENE","name":"BMP15","canonical_id":"hgnc:HGNC:1068","description":"bone morphogenetic protein 15","metadata":{"aliases":["GDF9B"]}},{"id":"27f215b06aac46a2b7970fbca2aee01f","type":"GENE","name":"BMP2","canonical_id":"hgnc:HGNC:1069","description":null,"metadata":null},{"id":"76228c025b3d4c648007336b01e39e54","type":"GENE","name":"BMP2K","canonical_id":"hgnc:HGNC:18041","description":"BMP2 inducible kinase","metadata":{"aliases":["DKFZp434K0614","BIKe"]}},{"id":"68e0cd3ab07f44ba920f1f4c93cab73f","type":"GENE","name":"BMP2K-AS1","canonical_id":"hgnc:HGNC:58834","description":"BMP2K antisense RNA 1","metadata":null},{"id":"1f76ff4956c848eb9a356ba9bf91daa5","type":"GENE","name":"BMP2K-DT","canonical_id":"hgnc:HGNC:55396","description":"BMP2K divergent transcript","metadata":null},{"id":"4eb557da9d4c412196ff42b8b589e76b","type":"GENE","name":"BMP2KL","canonical_id":"hgnc:HGNC:17080","description":"BMP2 inducible kinase like (pseudogene)","metadata":null},{"id":"8d1e243016aa4d949f24c6df635c9ed7","type":"GENE","name":"BMP3","canonical_id":"hgnc:HGNC:1070","description":"bone morphogenetic protein 3","metadata":null},{"id":"f7f79a28c99c4ab284766a8de847c573","type":"GENE","name":"BMP4","canonical_id":"hgnc:HGNC:1071","description":null,"metadata":null},{"id":"0f829e2f1aca41ffa91c0684e9ae8dc8","type":"GENE","name":"BMP5","canonical_id":"hgnc:HGNC:1072","description":"bone morphogenetic protein 5","metadata":null},{"id":"d440144c14d6411b8f29003e6dfad461","type":"GENE","name":"BMP6","canonical_id":"hgnc:HGNC:1073","description":"bone morphogenetic protein 6","metadata":{"aliases":["VGR1","VGR"]}},{"id":"8d678ecbda4c40f6bf21001d82bf3d3f","type":"GENE","name":"BMP6P1","canonical_id":"hgnc:HGNC:19329","description":"bone morphogenetic protein 6 pseudogene 1","metadata":null},{"id":"19396fdbc492485a8ed666c0e3a47c0c","type":"GENE","name":"BMP7","canonical_id":"hgnc:HGNC:1074","description":null,"metadata":null},{"id":"2bda1314b55948339cbb1b6e4230824c","type":"GENE","name":"BMP7-AS1","canonical_id":"hgnc:HGNC:40096","description":"BMP7 antisense RNA 1","metadata":null},{"id":"1121c88521d14201bc4d68421ac0f456","type":"GENE","name":"BMP8A","canonical_id":"hgnc:HGNC:21650","description":"bone morphogenetic protein 8a","metadata":{"aliases":["OP-2","Op2"]}},{"id":"7b0d396e81b54b089577f4d0ed51f744","type":"GENE","name":"BMP8B","canonical_id":"hgnc:HGNC:1075","description":"bone morphogenetic protein 8b","metadata":{"aliases":["OP-2","BMP8"]}},{"id":"8db4a5c41883465dabb89aad17410989","type":"GENE","name":"BMP8B-AS1","canonical_id":"hgnc:HGNC:54364","description":"BMP8B antisense RNA 1","metadata":null},{"id":"f15f2eaeac594473909deac9dc6ff7b3","type":"GENE","name":"BMPER","canonical_id":"hgnc:HGNC:24154","description":"BMP binding endothelial regulator","metadata":{"aliases":["Cv2","CRIM3"]}},{"id":"00241a43493b41569850a0db76cee166","type":"GENE","name":"BMPR1A","canonical_id":"hgnc:HGNC:1076","description":"bone morphogenetic protein receptor type 1A","metadata":{"aliases":["ALK3","CD292","ACVRLK3"]}},{"id":"a245f377d4d64b88a3b196457508f80f","type":"GENE","name":"BMPR1AP1","canonical_id":"hgnc:HGNC:21742","description":"bone morphogenetic protein receptor type 1A pseudogene 1","metadata":{"aliases":["BMPR1APS1"]}},{"id":"23595232fa7548278a8c8ac16586d7e2","type":"GENE","name":"BMPR1AP2","canonical_id":"hgnc:HGNC:21743","description":"bone morphogenetic protein receptor type 1A pseudogene 2","metadata":{"aliases":["BMPR1APS2"]}},{"id":"8bea7c0a6f414b4f8fa5ea896936ce52","type":"GENE","name":"BMPR1B","canonical_id":"hgnc:HGNC:1077","description":"bone morphogenetic protein receptor type 1B","metadata":{"aliases":["ALK6","CDw293"]}},{"id":"ad853a51da3f47a19d55774bbd3c4ef0","type":"GENE","name":"BMPR1B-DT","canonical_id":"hgnc:HGNC:50864","description":"BMPR1B divergent transcript","metadata":{"aliases":["TCONS_00007797","BMPR1B-AS1"]}},{"id":"ef4281ae564246f784c080ccfd950079","type":"GENE","name":"BMPR2","canonical_id":"hgnc:HGNC:1078","description":"bone morphogenetic protein receptor type 2","metadata":{"aliases":["BRK-3","T-ALK","BMPR3","BMPR-II","PPH1"]}},{"id":"995058cd0fa04f9cba09de9ccfdac140","type":"TRIAL","name":"BMS 247550 to Treat Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00030992","description":"Renal Cell Carcinoma","metadata":null},{"id":"5863856e77104994a7b307c564f967c3","type":"TRIAL","name":"BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00022529","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"c6f7e2e5769545b6bf3735c5488e54c3","type":"TRIAL","name":"BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00057850","description":"Head and Neck Cancer","metadata":null},{"id":"b9f2430feca64b14a476cf827a38d7e4","type":"TRIAL","name":"BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00043095","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"8904085af31d460d9d75b981ffff09cc","type":"TRIAL","name":"BMS-247550 in Treating Patients With Advanced Cancers","canonical_id":"clinicaltrials.gov:NCT00006221","description":"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"b12a24b16c8546b893c1a43d2bc15d87","type":"TRIAL","name":"BMS-247550 in Treating Patients With Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00016965","description":"Pancreatic Cancer","metadata":null},{"id":"18af30cf450d439995399b14ce87969f","type":"TRIAL","name":"BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT00022542","description":"Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma","metadata":null},{"id":"cfbfc9665f494e9da6e4d59272d1ec64","type":"TRIAL","name":"BMS-247550 in Treating Patients With Liver or Gallbladder Cancer","canonical_id":"clinicaltrials.gov:NCT00023946","description":"Adult Primary Cholangiocellular Carcinoma; Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Extrahepatic Bile Duct Cancer; Localized Gallbladder Cancer; Localized Resectable Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Unresectab\u2026","metadata":null},{"id":"345d6e99f49d40158c1856880af16f1e","type":"TRIAL","name":"BMS-247550 in Treating Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00033306","description":"Colorectal Cancer","metadata":null},{"id":"cab3e783dbba44faa5b2cd94abd6b8ce","type":"TRIAL","name":"BMS-247550 in Treating Patients With Stage IV Melanoma","canonical_id":"clinicaltrials.gov:NCT00036764","description":"Recurrent Melanoma; Stage IV Melanoma","metadata":null},{"id":"09194abd8d1548e08c6b66c846571b11","type":"TRIAL","name":"BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate","canonical_id":"clinicaltrials.gov:NCT00064233","description":"Leukemia","metadata":null},{"id":"30f234d23569407ea62b32ae444d37f7","type":"GENE","name":"BMS1","canonical_id":"hgnc:HGNC:23505","description":"BMS1 ribosome biogenesis factor","metadata":{"aliases":["KIAA0187","BMS1L"]}},{"id":"01f1230863c64a988a3e8b9509eff324","type":"GENE","name":"BMS1P1","canonical_id":"hgnc:HGNC:23649","description":"BMS1 pseudogene 1","metadata":{"aliases":["BMS1LP1","BMS1P5","BMS1LP5"]}},{"id":"22db518266714b66a20c27e45a505e84","type":"GENE","name":"BMS1P10","canonical_id":"hgnc:HGNC:49154","description":"BMS1 pseudogene 10","metadata":null},{"id":"e3bce487ecf54586a534d34427eea919","type":"GENE","name":"BMS1P11","canonical_id":"hgnc:HGNC:49156","description":"BMS1 pseudogene 11","metadata":null},{"id":"c6af12b6ba8846558b1d9fdeceda5abe","type":"GENE","name":"BMS1P12","canonical_id":"hgnc:HGNC:49157","description":"BMS1 pseudogene 12","metadata":null},{"id":"f31e2488e77b4d639785c1b52927037c","type":"GENE","name":"BMS1P13","canonical_id":"hgnc:HGNC:49158","description":"BMS1 pseudogene 13","metadata":null},{"id":"5ea54a63e0cc4c608e26c346e28bb09e","type":"GENE","name":"BMS1P14","canonical_id":"hgnc:HGNC:49159","description":"BMS1 pseudogene 14","metadata":null},{"id":"57cc79731f454e4183c3d7b29dacb98c","type":"GENE","name":"BMS1P15","canonical_id":"hgnc:HGNC:49160","description":"BMS1 pseudogene 15","metadata":null},{"id":"c82147b8985b49d68b0bafd8fea25852","type":"GENE","name":"BMS1P16","canonical_id":"hgnc:HGNC:49161","description":"BMS1 pseudogene 16","metadata":null},{"id":"cdfb38e9ae6b4a049f7367e88a1c4b00","type":"GENE","name":"BMS1P17","canonical_id":"hgnc:HGNC:49162","description":"BMS1 pseudogene 17","metadata":null},{"id":"751156fd383e44299637ed3ec44bcbc3","type":"GENE","name":"BMS1P18","canonical_id":"hgnc:HGNC:19436","description":"BMS1 pseudogene 18","metadata":{"aliases":["C14orf17","LINC00516"]}},{"id":"628d8ac011604a01a69cf766f5116992","type":"GENE","name":"BMS1P19","canonical_id":"hgnc:HGNC:49163","description":"BMS1 pseudogene 19","metadata":null},{"id":"2c96787e407649eea802d2ffbce11bc8","type":"GENE","name":"BMS1P2","canonical_id":"hgnc:HGNC:23650","description":"BMS1 pseudogene 2","metadata":{"aliases":["bA144G6.1","OTTHUMG00000018113","bA302K17.2","OTTHUMG00000018142","BMS1LP2","BMS1P6","BMS1LP6"]}},{"id":"c16bde2dcdc84379b23ea02b50843152","type":"GENE","name":"BMS1P20","canonical_id":"hgnc:HGNC:49153","description":"BMS1 pseudogene 20","metadata":null},{"id":"4931c410daa846b2a2af6fd45cfef0b3","type":"GENE","name":"BMS1P21","canonical_id":"hgnc:HGNC:51604","description":"BMS1 pseudogene 21","metadata":null},{"id":"889f43ec64b049efbfd237f0897a0119","type":"GENE","name":"BMS1P22","canonical_id":"hgnc:HGNC:51603","description":"BMS1 pseudogene 22","metadata":null},{"id":"fcd5190227974fa5881a7fd751fbcdb8","type":"GENE","name":"BMS1P23","canonical_id":"hgnc:HGNC:55088","description":"BMS1 pseudogene 23","metadata":null},{"id":"59f3c5b8486e4ba5be0b42e82bdeb793","type":"GENE","name":"BMS1P3","canonical_id":"hgnc:HGNC:23651","description":"BMS1 pseudogene 3","metadata":{"aliases":["bA96C23.1","OTTHUMG00000018662","BMS1LP3"]}},{"id":"d7376f73563d47bf8b9abfd07c482119","type":"GENE","name":"BMS1P4","canonical_id":"hgnc:HGNC:23652","description":"BMS1 pseudogene 4","metadata":{"aliases":["OTTHUMG00000018478","BMS1LP4"]}},{"id":"61b2a12523f24ca18da9c66710e762ce","type":"GENE","name":"BMS1P4-AGAP5","canonical_id":"hgnc:HGNC:55636","description":"BMS1P4-AGAP5 readthrough","metadata":null},{"id":"5040536f5c014433ac384ed4e524d134","type":"GENE","name":"BMS1P7","canonical_id":"hgnc:HGNC:23655","description":"BMS1 pseudogene 7","metadata":{"aliases":["bA164N7.1","OTTHUMG00000018163","BMS1LP7"]}},{"id":"a9b148d497394fc8bae2c9459a33c29e","type":"GENE","name":"BMS1P8","canonical_id":"hgnc:HGNC:49152","description":"BMS1 pseudogene 8","metadata":null},{"id":"b41049ee1cc4434d9795b70a17cae604","type":"GENE","name":"BMS1P9","canonical_id":"hgnc:HGNC:49155","description":"BMS1 pseudogene 9","metadata":null},{"id":"fa1e1c112fac43e3b51310bf2ec661be","type":"TRIAL","name":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","canonical_id":"clinicaltrials.gov:NCT02029638","description":"Kidney Transplantation","metadata":null},{"id":"a28ab04b8ea6411aa2f9104c92f82353","type":"TRIAL","name":"BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron","canonical_id":"clinicaltrials.gov:NCT04150614","description":"Nausea With Vomiting Chemotherapy-Induced","metadata":null},{"id":"dc42606f90b84a0bbdbc16dbcb5bbd7e","type":"GENE","name":"BMX","canonical_id":"hgnc:HGNC:1079","description":"BMX non-receptor tyrosine kinase","metadata":{"aliases":["ETK","PSCTK3"]}},{"id":"f7ff889fa80340868454bf8286a7fc5a","type":"GENE","name":"BNAT1","canonical_id":"hgnc:HGNC:56666","description":"breast cancer associated ESR1 regulating natural antisense transcript 1","metadata":{"aliases":["LL21NC02-21A1.1"]}},{"id":"ad6b19f180cb449d897a2ee6937051e9","type":"GENE","name":"BNC1","canonical_id":"hgnc:HGNC:1081","description":"basonuclin zinc finger protein 1","metadata":{"aliases":["HsT19447","bn1","BSN1","BNC"]}},{"id":"091d41a629554c9395cfe661e9b01bd2","type":"GENE","name":"BNC1-AS1","canonical_id":"hgnc:HGNC:58479","description":"BNC1 antisense RNA 1","metadata":null},{"id":"8dec37f9b7b84939a329d7a4466e1a4c","type":"GENE","name":"BNC2","canonical_id":"hgnc:HGNC:30988","description":"basonuclin zinc finger protein 2","metadata":{"aliases":["BSN2","FLJ20043","bn2"]}},{"id":"4198f214e58f488e9e02095375d64a7f","type":"GENE","name":"BNC2-AS1","canonical_id":"hgnc:HGNC:53727","description":"BNC2 antisense RNA 1","metadata":{"aliases":["RP11-62F24.2"]}},{"id":"bbcd4104167541a2b65e32fe1235643b","type":"GENE","name":"BNIP1","canonical_id":"hgnc:HGNC:1082","description":"BCL2 interacting protein 1","metadata":{"aliases":["Nip1","SEC20"]}},{"id":"c26f994be3a24a68af0c4b76b96ce8e7","type":"GENE","name":"BNIP1-AS1","canonical_id":"hgnc:HGNC:40097","description":"BNIP1 antisense RNA 1","metadata":null},{"id":"6eaefa131b0247a7916b78dc72fd34b6","type":"GENE","name":"BNIP2","canonical_id":"hgnc:HGNC:1083","description":"BCL2 interacting protein 2","metadata":{"aliases":["Nip2","BNIP-2"]}},{"id":"7eca20e4376c4da9abd251d8026b9e55","type":"GENE","name":"BNIP3","canonical_id":"hgnc:HGNC:1084","description":null,"metadata":null},{"id":"8ecdb78fefa641f7bd1225c79ab61648","type":"GENE","name":"BNIP3L","canonical_id":"hgnc:HGNC:1085","description":"BCL2 interacting protein 3 like","metadata":{"aliases":["Nix","BNIP3a"]}},{"id":"d7a5315d7356498b97fb00a8c7c6b092","type":"GENE","name":"BNIP3P1","canonical_id":"hgnc:HGNC:19922","description":"BCL2 interacting protein 3 pseudogene 1","metadata":{"aliases":["BNIP3P"]}},{"id":"78e183272c7a42f383f59a695c7eba8e","type":"GENE","name":"BNIP3P10","canonical_id":"hgnc:HGNC:49690","description":"BCL2 interacting protein 3 pseudogene 10","metadata":null},{"id":"105188da208445f4bb7d30e5703201f1","type":"GENE","name":"BNIP3P11","canonical_id":"hgnc:HGNC:49724","description":"BCL2 interacting protein 3 pseudogene 11","metadata":null},{"id":"657b6cb9cc804a75b22f2a82c84b8805","type":"GENE","name":"BNIP3P12","canonical_id":"hgnc:HGNC:49692","description":"BCL2 interacting protein 3 pseudogene 12","metadata":null},{"id":"28d6fa50c816449b95ec5b68ec48953b","type":"GENE","name":"BNIP3P13","canonical_id":"hgnc:HGNC:49693","description":"BCL2 interacting protein 3 pseudogene 13","metadata":null},{"id":"e66f353705ac436c9a11aa7f7a0f18cd","type":"GENE","name":"BNIP3P14","canonical_id":"hgnc:HGNC:49694","description":"BCL2 interacting protein 3 pseudogene 14","metadata":null},{"id":"6e6dafdf19df4dc6acb0762cef6a39e1","type":"GENE","name":"BNIP3P15","canonical_id":"hgnc:HGNC:49695","description":"BCL2 interacting protein 3 pseudogene 15","metadata":null},{"id":"ff578fbd572b41ca993853b031993e05","type":"GENE","name":"BNIP3P16","canonical_id":"hgnc:HGNC:49696","description":"BCL2 interacting protein 3 pseudogene 16","metadata":null},{"id":"4e6ebd024c69464cb764daa85d71e165","type":"GENE","name":"BNIP3P17","canonical_id":"hgnc:HGNC:49697","description":"BCL2 interacting protein 3 pseudogene 17","metadata":null},{"id":"970c11d77af04a7b904556f2d7094f01","type":"GENE","name":"BNIP3P18","canonical_id":"hgnc:HGNC:49698","description":"BCL2 interacting protein 3 pseudogene 18","metadata":null},{"id":"1f0aafc8aeb840b1836f33542b048829","type":"GENE","name":"BNIP3P19","canonical_id":"hgnc:HGNC:49699","description":"BCL2 interacting protein 3 pseudogene 19","metadata":null},{"id":"3fd641d72c894794bc532ea9a6eed2b2","type":"GENE","name":"BNIP3P2","canonical_id":"hgnc:HGNC:39655","description":"BCL2 interacting protein 3 pseudogene 2","metadata":null},{"id":"7de2c6965f174b98a20e52fd926fa539","type":"GENE","name":"BNIP3P20","canonical_id":"hgnc:HGNC:49700","description":"BCL2 interacting protein 3 pseudogene 20","metadata":null},{"id":"58457ad6f0d248daabd07b095a6b5989","type":"GENE","name":"BNIP3P21","canonical_id":"hgnc:HGNC:49701","description":"BCL2 interacting protein 3 pseudogene 21","metadata":null},{"id":"83a9977ee3ea4f9f9aeefc4c200a1caa","type":"GENE","name":"BNIP3P22","canonical_id":"hgnc:HGNC:49702","description":"BCL2 interacting protein 3 pseudogene 22","metadata":null},{"id":"045a44ae842c44468a7c992d3206981b","type":"GENE","name":"BNIP3P23","canonical_id":"hgnc:HGNC:49703","description":"BCL2 interacting protein 3 pseudogene 23","metadata":null},{"id":"b6120cbb4acc4f68be145a37a926db9e","type":"GENE","name":"BNIP3P24","canonical_id":"hgnc:HGNC:49704","description":"BCL2 interacting protein 3 pseudogene 24","metadata":null},{"id":"cde7e96b49ad4305a491bfb60bd329b3","type":"GENE","name":"BNIP3P25","canonical_id":"hgnc:HGNC:49705","description":"BCL2 interacting protein 3 pseudogene 25","metadata":null},{"id":"1913dc870954468ba3533e45624831fe","type":"GENE","name":"BNIP3P26","canonical_id":"hgnc:HGNC:49706","description":"BCL2 interacting protein 3 pseudogene 26","metadata":null},{"id":"65e60cb6dc554ad59b1a0dd60d64937a","type":"GENE","name":"BNIP3P27","canonical_id":"hgnc:HGNC:49707","description":"BCL2 interacting protein 3 pseudogene 27","metadata":null},{"id":"38c80fd244cd46c5b7345d2d9722098d","type":"GENE","name":"BNIP3P28","canonical_id":"hgnc:HGNC:49708","description":"BCL2 interacting protein 3 pseudogene 28","metadata":null},{"id":"e370401df48c4d57b59698efb941f093","type":"GENE","name":"BNIP3P29","canonical_id":"hgnc:HGNC:49709","description":"BCL2 interacting protein 3 pseudogene 29","metadata":null},{"id":"24cbd90a316444e4a0cdfd8724e46485","type":"GENE","name":"BNIP3P3","canonical_id":"hgnc:HGNC:39656","description":"BCL2 interacting protein 3 pseudogene 3","metadata":null},{"id":"54e9b8f77c894ccbb8c5ea51173108ba","type":"GENE","name":"BNIP3P30","canonical_id":"hgnc:HGNC:49710","description":"BCL2 interacting protein 3 pseudogene 30","metadata":null},{"id":"6c663a902bcc43bda0cab76083ce4677","type":"GENE","name":"BNIP3P31","canonical_id":"hgnc:HGNC:49711","description":"BCL2 interacting protein 3 pseudogene 31","metadata":null},{"id":"9c491f93972746c2929ee01523c6a937","type":"GENE","name":"BNIP3P32","canonical_id":"hgnc:HGNC:49712","description":"BCL2 interacting protein 3 pseudogene 32","metadata":null},{"id":"f7ceea8541014c51b5b9b596a1e25be6","type":"GENE","name":"BNIP3P33","canonical_id":"hgnc:HGNC:49713","description":"BCL2 interacting protein 3 pseudogene 33","metadata":null},{"id":"b1c4b1bd4b844fba82713541c333676c","type":"GENE","name":"BNIP3P34","canonical_id":"hgnc:HGNC:49714","description":"BCL2 interacting protein 3 pseudogene 34","metadata":null},{"id":"1cf554f7ad7c464689d6214232ce0009","type":"GENE","name":"BNIP3P35","canonical_id":"hgnc:HGNC:49715","description":"BCL2 interacting protein 3 pseudogene 35","metadata":null},{"id":"2ed48417f54a4f64b485782b3747202c","type":"GENE","name":"BNIP3P36","canonical_id":"hgnc:HGNC:49716","description":"BCL2 interacting protein 3 pseudogene 36","metadata":null},{"id":"851a797fd9ff4a3c8d52c7520f8bba9f","type":"GENE","name":"BNIP3P37","canonical_id":"hgnc:HGNC:49717","description":"BCL2 interacting protein 3 pseudogene 37","metadata":null},{"id":"659a8adc872245f2a4d6aebe709836f2","type":"GENE","name":"BNIP3P38","canonical_id":"hgnc:HGNC:49718","description":"BCL2 interacting protein 3 pseudogene 38","metadata":null},{"id":"4327a3df743943dabe4e0928b6ba05f6","type":"GENE","name":"BNIP3P39","canonical_id":"hgnc:HGNC:49719","description":"BCL2 interacting protein 3 pseudogene 39","metadata":null},{"id":"e6bb372f15d443e1967a0d383a2f85c2","type":"GENE","name":"BNIP3P4","canonical_id":"hgnc:HGNC:39657","description":"BCL2 interacting protein 3 pseudogene 4","metadata":null},{"id":"1e71578719134c85972d58fb0304a577","type":"GENE","name":"BNIP3P40","canonical_id":"hgnc:HGNC:49720","description":"BCL2 interacting protein 3 pseudogene 40","metadata":null},{"id":"7cb49d78a00f4f319841a70197e1dc48","type":"GENE","name":"BNIP3P41","canonical_id":"hgnc:HGNC:49721","description":"BCL2 interacting protein 3 pseudogene 41","metadata":null},{"id":"a41f7e9c92c64cd592f396854d05368d","type":"GENE","name":"BNIP3P42","canonical_id":"hgnc:HGNC:49722","description":"BCL2 interacting protein 3 pseudogene 42","metadata":null},{"id":"a2f5800fe2574a7d8941a04f424fb691","type":"GENE","name":"BNIP3P43","canonical_id":"hgnc:HGNC:56379","description":"BNIP3 pseudogene 43","metadata":null},{"id":"bb94bbabd82e46a181614e03ad1228f0","type":"GENE","name":"BNIP3P44","canonical_id":"hgnc:HGNC:56383","description":"BNIP3 pseudogene 44","metadata":null},{"id":"6f2592f7297242568af57c787c76c72b","type":"GENE","name":"BNIP3P45","canonical_id":"hgnc:HGNC:56386","description":"BNIP3 pseudogene 45","metadata":null},{"id":"3cbab722dcc0499ea0947b7e022dd469","type":"GENE","name":"BNIP3P46","canonical_id":"hgnc:HGNC:56387","description":"BNIP3 pseudogene 46","metadata":null},{"id":"721d0dc6abb74e9fbc10a102bfff26cb","type":"GENE","name":"BNIP3P47","canonical_id":"hgnc:HGNC:56390","description":"BNIP3 pseudogene 47","metadata":null},{"id":"242835c6f1eb40bbaf4689b672c27f59","type":"GENE","name":"BNIP3P5","canonical_id":"hgnc:HGNC:39658","description":"BCL2 interacting protein 3 pseudogene 5","metadata":null},{"id":"557817dfce55409fbc5d58c02cb0c50a","type":"GENE","name":"BNIP3P6","canonical_id":"hgnc:HGNC:39659","description":"BCL2 interacting protein 3 pseudogene 6","metadata":null},{"id":"9c81c3c81d85419d90505b68f398985b","type":"GENE","name":"BNIP3P7","canonical_id":"hgnc:HGNC:49101","description":"BCL2 interacting protein 3 pseudogene 7","metadata":null},{"id":"52d76078691d42e6b3beabe30789dc38","type":"GENE","name":"BNIP3P8","canonical_id":"hgnc:HGNC:49675","description":"BCL2 interacting protein 3 pseudogene 8","metadata":null},{"id":"1a3e3b2a95af481dab7fd39994678292","type":"GENE","name":"BNIP3P9","canonical_id":"hgnc:HGNC:49689","description":"BCL2 interacting protein 3 pseudogene 9","metadata":null},{"id":"688d81ddc4b44e538db5bc67023a996a","type":"GENE","name":"BNIP5","canonical_id":"hgnc:HGNC:33769","description":"BCL2 interacting protein 5","metadata":{"aliases":["DKFZp779B1540","C6orf222"]}},{"id":"bfd4e5b9965f44b2b5b8c6e72115d220","type":"GENE","name":"BNIP5-AS1","canonical_id":"hgnc:HGNC:59390","description":"BNIP5 antisense RNA 1","metadata":null},{"id":"f43d019fbfb7491091b3cd824862588a","type":"GENE","name":"BNIPL","canonical_id":"hgnc:HGNC:16976","description":"BCL2 interacting protein like","metadata":{"aliases":["BNIPl-1","BNIPL-2","PP753","BNIP-S","BNIP-Salpha","BNIP-Sbeta"]}},{"id":"4ec35ae44aa64fc79011f87b10853c79","type":"GENE","name":"BOC","canonical_id":"hgnc:HGNC:17173","description":"BOC cell adhesion associated, oncogene regulated","metadata":{"aliases":["CDON2","Boi"]}},{"id":"94b0216454de49bcb5305058c2b5ec07","type":"GENE","name":"BOD1","canonical_id":"hgnc:HGNC:25114","description":"biorientation of chromosomes in cell division 1","metadata":{"aliases":["FAM44B"]}},{"id":"aa7a9bf30a6247ccb71ed6212c3348bb","type":"GENE","name":"BOD1L1","canonical_id":"hgnc:HGNC:31792","description":"biorientation of chromosomes in cell division 1 like 1","metadata":{"aliases":["FLJ33215","KIAA1327","FAM44A","BOD1L"]}},{"id":"f1afb0f0d2254dc5915b12618c232e24","type":"GENE","name":"BOD1L2","canonical_id":"hgnc:HGNC:28505","description":"biorientation of chromosomes in cell division 1 like 2","metadata":{"aliases":["MGC33608","FAM44C","BOD1P"]}},{"id":"3661b0e8456441328116cfcff88a174e","type":"GENE","name":"BOD1P1","canonical_id":"hgnc:HGNC:51435","description":"biorientation of chromosomes in cell division 1 pseudogene 1","metadata":null},{"id":"06f9421609c341418278472832077eff","type":"GENE","name":"BOD1P2","canonical_id":"hgnc:HGNC:51436","description":"biorientation of chromosomes in cell division 1 pseudogene 2","metadata":null},{"id":"25a3b6d8f2ab482990bbcb5ebfcea84d","type":"GENE","name":"BOK","canonical_id":"hgnc:HGNC:1087","description":"BCL2 family apoptosis regulator BOK","metadata":{"aliases":["BCL2L9","BOKL","MGC4631"]}},{"id":"57ee14194a834c50a0f7c80f3c373c66","type":"GENE","name":"BOK-AS1","canonical_id":"hgnc:HGNC:35125","description":"BOK antisense RNA 1","metadata":{"aliases":["NCRNA00151","NAToB","BOKAS"]}},{"id":"03b4e8237244447c9e90d21fce263b99","type":"GENE","name":"BOLA1","canonical_id":"hgnc:HGNC:24263","description":"bolA family member 1","metadata":{"aliases":["CGI-143"]}},{"id":"df1d9fa290cc436c9bd5bb6715342e55","type":"GENE","name":"BOLA2","canonical_id":"hgnc:HGNC:29488","description":"bolA family member 2","metadata":{"aliases":["My016","BOLA2A"]}},{"id":"03cb9ecc8a6446c88c8ce7fdb0fbf460","type":"GENE","name":"BOLA2-SMG1P6","canonical_id":"hgnc:HGNC:53563","description":"BOLA2-SMG1P6 readthrough","metadata":null},{"id":"a45ba098df49450e9b373eaa1d222d9f","type":"GENE","name":"BOLA2B","canonical_id":"hgnc:HGNC:32479","description":"bolA family member 2B","metadata":null},{"id":"ce86843493ae4a5c8e4e50be2ddafd11","type":"GENE","name":"BOLA2P1","canonical_id":"hgnc:HGNC:51437","description":"bolA family member 2 pseudogene 1","metadata":null},{"id":"d1b130fa706d40ffa89efcddebd8cb62","type":"GENE","name":"BOLA2P2","canonical_id":"hgnc:HGNC:51438","description":"bolA family member 2 pseudogene 2","metadata":null},{"id":"01e6200b9ea446d5b064c6d3ca486504","type":"GENE","name":"BOLA2P3","canonical_id":"hgnc:HGNC:51439","description":"bolA family member 2 pseudogene 3","metadata":null},{"id":"719e97de51764729a69df5456014faa1","type":"GENE","name":"BOLA3","canonical_id":"hgnc:HGNC:24415","description":"bolA family member 3","metadata":null},{"id":"5d6c1d722b774ed2872a85cc47c4cdfb","type":"GENE","name":"BOLA3-DT","canonical_id":"hgnc:HGNC:42922","description":"BOLA3 divergent transcript","metadata":{"aliases":["BOLA3-AS1"]}},{"id":"b6662a02286f471c9971b37b68d43e00","type":"GENE","name":"BOLA3P1","canonical_id":"hgnc:HGNC:51440","description":"bolA family member 3 pseudogene 1","metadata":null},{"id":"66aca41556304d329ba60597f2196040","type":"GENE","name":"BOLA3P2","canonical_id":"hgnc:HGNC:51441","description":"bolA family member 3 pseudogene 2","metadata":null},{"id":"f130fc00a8b346d3ab68330aa8744ca1","type":"GENE","name":"BOLA3P3","canonical_id":"hgnc:HGNC:51442","description":"bolA family member 3 pseudogene 3","metadata":null},{"id":"21775404d9d34b5f89f519ca24462c81","type":"GENE","name":"BOLA3P4","canonical_id":"hgnc:HGNC:51443","description":"bolA family member 3 pseudogene 4","metadata":null},{"id":"06f2e2615cfa4423afe6a8afd1546208","type":"TRIAL","name":"BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)","canonical_id":"clinicaltrials.gov:NCT00887601","description":"Dementia","metadata":null},{"id":"9970768c8b144a769fc502ecd68cab15","type":"GENE","name":"BOLL","canonical_id":"hgnc:HGNC:14273","description":"boule RNA binding protein","metadata":{"aliases":["BOULE"]}},{"id":"75258de6a45d4c8e89e3bf27e0bdcd7b","type":"GENE","name":"BOP1","canonical_id":"hgnc:HGNC:15519","description":"BOP1 ribosomal biogenesis factor","metadata":{"aliases":["KIAA0124"]}},{"id":"4e6aeff524b84976b485b981f51dca95","type":"GENE","name":"BORA","canonical_id":"hgnc:HGNC:24724","description":"BORA aurora kinase A activator","metadata":{"aliases":["FLJ22624","C13orf34"]}},{"id":"d6e84bde108a4e2c832b95a4f262cbdd","type":"GO_TERM","name":"BORC complex","canonical_id":"go:GO:0099078","description":"\"A protein complex that is involved in positioning of the lysosome within the cytoplasm and which is composed of BLOC1S1, BLOC1S2, BORCS5, BORCS6, BORCS7, BORCS8, KXD1 and SNAPIN. The BORC complex recruits ARL8 at the cytosolic face of lysosomes and couples them to microtubule plus-end-directed kinesin motors.\" [GOC:dos, GOC:li, PMID:25898167]","metadata":null},{"id":"e5689afa0cd9431b94b370d738eda848","type":"GENE","name":"BORCS5","canonical_id":"hgnc:HGNC:17950","description":"BLOC-1 related complex subunit 5","metadata":{"aliases":["LOH1CR12","LOH12CR1"]}},{"id":"ff1c56b93a954cb1a5943e018a741f6d","type":"GENE","name":"BORCS6","canonical_id":"hgnc:HGNC:25939","description":"BLOC-1 related complex subunit 6","metadata":{"aliases":["FLJ20014","C17orf59"]}},{"id":"71c7dcf378774fa59ac1cfae1de1414c","type":"GENE","name":"BORCS7","canonical_id":"hgnc:HGNC:23516","description":"BLOC-1 related complex subunit 7","metadata":{"aliases":["FLJ40752","C10orf32"]}},{"id":"5a84a978240743979547c42d560f3c9a","type":"GENE","name":"BORCS7-ASMT","canonical_id":"hgnc:HGNC:49183","description":"BORCS7-ASMT readthrough (NMD candidate)","metadata":{"aliases":["C10orf32-ASMT"]}},{"id":"a5ba5a13e1a54c79a1505a71ea01baa6","type":"GENE","name":"BORCS8","canonical_id":"hgnc:HGNC:37247","description":"BLOC-1 related complex subunit 8","metadata":{"aliases":["MEF2BNB"]}},{"id":"14e8760ba2df4289b29aff2d3611105c","type":"GENE","name":"BORCS8-MEF2B","canonical_id":"hgnc:HGNC:39979","description":"BORCS8-MEF2B readthrough","metadata":{"aliases":["MEF2BNB-MEF2B"]}},{"id":"2c4bea39175a4e8fbf28500accafc224","type":"GENE","name":"BORCS8P1","canonical_id":"hgnc:HGNC:49883","description":"BORCS8 pseudogene 1","metadata":{"aliases":["MEF2BNBP1"]}},{"id":"03c1b428e0f543928162fd8261a5f097","type":"GENE","name":"BPESC1","canonical_id":"hgnc:HGNC:13228","description":"blepharophimosis, epicanthus inversus and ptosis candidate 1","metadata":{"aliases":["NCRNA00187"]}},{"id":"ff612f13ba1541bbaa693ffd7561b5b1","type":"GENE","name":"BPGM","canonical_id":"hgnc:HGNC:1093","description":"bisphosphoglycerate mutase","metadata":null},{"id":"8376ba74076446e2a47316680bb04637","type":"GENE","name":"BPHL","canonical_id":"hgnc:HGNC:1094","description":"biphenyl hydrolase like","metadata":{"aliases":["Bph-rp","VACVase","MCNAA"]}},{"id":"8492029eb7ee42d1a0631a374f8846f0","type":"GENE","name":"BPI","canonical_id":"hgnc:HGNC:1095","description":null,"metadata":null},{"id":"a95fd63c11a744b2a152bf422556090c","type":"GENE","name":"BPIFA1","canonical_id":"hgnc:HGNC:15749","description":"BPI fold containing family A member 1","metadata":{"aliases":["LUNX","bA49G10.5","SPLUNC1","PLUNC"]}},{"id":"92ce0c119d854c479794cbd960f778a2","type":"GENE","name":"BPIFA2","canonical_id":"hgnc:HGNC:16203","description":"BPI fold containing family A member 2","metadata":{"aliases":["bA49G10.1","SPLUNC2","PSP","C20orf70"]}},{"id":"681fae13f267490d8f25dc5e11fcb2ac","type":"GENE","name":"BPIFA3","canonical_id":"hgnc:HGNC:16204","description":"BPI fold containing family A member 3","metadata":{"aliases":["bA49G10.4","SPLUNC3","C20orf71"]}},{"id":"0009c4a96f6c4bcc8a869aad069ee849","type":"GENE","name":"BPIFA4P","canonical_id":"hgnc:HGNC:20469","description":"BPI fold containing family A member 4, pseudogene","metadata":{"aliases":["LATH","BASE"]}},{"id":"4e6f40081b8f4e91a38b222d6e98ef4d","type":"GENE","name":"BPIFA6P","canonical_id":"hgnc:HGNC:59197","description":"BPI fold containing family A member 6, pseudogene","metadata":null},{"id":"45487d37310e4996aa01bff5181c56c0","type":"GENE","name":"BPIFB1","canonical_id":"hgnc:HGNC:16108","description":"BPI fold containing family B member 1","metadata":{"aliases":["dJ1187J4.1","MGC14597","bA49G10.6","LPLUNC1","VEMSGP","C20orf114"]}},{"id":"d28e89529d25436da62295306ac0194f","type":"GENE","name":"BPIFB2","canonical_id":"hgnc:HGNC:16177","description":"BPI fold containing family B member 2","metadata":{"aliases":["dJ726C3.2","LPLUNC2","C20orf184","BPIL1"]}},{"id":"7960f1bf4d71410ebe6e3fa5f80bb9fe","type":"GENE","name":"BPIFB3","canonical_id":"hgnc:HGNC:16178","description":"BPI fold containing family B member 3","metadata":{"aliases":["dJ726C3.4","LPLUNC3","RYA3","C20orf185"]}},{"id":"a94cba77470f43b2bdcda9a3a93a3c31","type":"GENE","name":"BPIFB4","canonical_id":"hgnc:HGNC:16179","description":"BPI fold containing family B member 4","metadata":{"aliases":["dJ726C3.5","LPLUNC4","C20orf186"]}},{"id":"995c8b8d94d64faf950b1bf70b68a6ff","type":"GENE","name":"BPIFB5P","canonical_id":"hgnc:HGNC:42177","description":"BPI fold containing family B member 5, pseudogene","metadata":null},{"id":"cfe2ced5f86e4a6592bcb996cd76ad1a","type":"GENE","name":"BPIFB6","canonical_id":"hgnc:HGNC:16504","description":"BPI fold containing family B member 6","metadata":{"aliases":["LPLUNC6","BPIL3"]}},{"id":"3a2b57cc7fda48daa16ba8a47f2b3c31","type":"GENE","name":"BPIFB9P","canonical_id":"hgnc:HGNC:16109","description":"BPI fold containing family B member 9, pseudogene","metadata":{"aliases":["dJ1187J4.2","C20orf115"]}},{"id":"3085a59e22e74204980038eb8003b014","type":"GENE","name":"BPIFC","canonical_id":"hgnc:HGNC:16503","description":"BPI fold containing family C","metadata":{"aliases":["dJ149A16.7","BPIL2"]}},{"id":"a21989180071401ab999719cf9d3dd72","type":"GENE","name":"BPNT1","canonical_id":"hgnc:HGNC:1096","description":"3'(2'), 5'-bisphosphate nucleotidase 1","metadata":null},{"id":"e8a9020424bb4945ad92d3899a40b991","type":"GENE","name":"BPNT2","canonical_id":"hgnc:HGNC:26019","description":"3'(2'), 5'-bisphosphate nucleotidase 2","metadata":{"aliases":["FLJ20421","IMPA3","gPAPP","IMPAD1"]}},{"id":"16e798a4abdd4e31999197e00b3aeae8","type":"GENE","name":"BPNT2P1","canonical_id":"hgnc:HGNC:54752","description":"BPNT2 pseudogene 1","metadata":{"aliases":["BPNT2P"]}},{"id":"c89e63d3389942e9b3d44ca573c8ea6e","type":"GENE","name":"BPTF","canonical_id":"hgnc:HGNC:3581","description":null,"metadata":null},{"id":"6b081dcf438a48d9b74855ee93dfaeb4","type":"GENE","name":"BPTFP1","canonical_id":"hgnc:HGNC:52869","description":"bromodomain PHD finger transcription factor pseudogene 1","metadata":null},{"id":"c8d05820bc6a43a5a6b39dd4b7bf2ead","type":"GENE","name":"BPY2","canonical_id":"hgnc:HGNC:13508","description":"basic charge Y-linked 2","metadata":{"aliases":["BPY2A","VCY2A","VCY2"]}},{"id":"793b4e93fd5c4d5d8c3e215035e693dd","type":"GENE","name":"BPY2B","canonical_id":"hgnc:HGNC:25449","description":"basic charge Y-linked 2B","metadata":{"aliases":["VCY2B"]}},{"id":"5fc1eb8227f7439fbfa9173db7834323","type":"GENE","name":"BPY2C","canonical_id":"hgnc:HGNC:18225","description":"basic charge Y-linked 2C","metadata":{"aliases":["VCY2C"]}},{"id":"297d5c69eaf14b4dbff2973efb1d94b2","type":"GENE","name":"BPY2DP","canonical_id":"hgnc:HGNC:38794","description":"basic charge Y-linked 2D, pseudogene","metadata":null},{"id":"24bb9b8ab8454452922eccd380492f96","type":"GENE","name":"BRAF","canonical_id":"hgnc:HGNC:1097","description":"B-Raf proto-oncogene, serine/threonine kinase","metadata":{"aliases":["BRAF1","BRAF-1"]}},{"id":"97eff572d193488b81cf5339ca2bf104","type":"GENE","name":"BRAF","canonical_id":"ensembl:ENSG00000157764","description":null,"metadata":null},{"id":"d953b2554af54d6794cfc32a0abd3f9f","type":"PROTEIN","name":"BRAF","canonical_id":"uniprot:P15056","description":null,"metadata":null},{"id":"8adb3c8e6042418d8e38e7b330a73f0c","type":"BIOMARKER","name":"BRAF A598V","canonical_id":"civic:2695","description":null,"metadata":null},{"id":"8b432a92c3fa4476992100f478ebee6d","type":"BIOMARKER","name":"BRAF A728V","canonical_id":"civic:1172","description":null,"metadata":null},{"id":"3f8f773b67834f10980a0fd60eb85fdb","type":"BIOMARKER","name":"BRAF Amplification","canonical_id":"civic:1243","description":null,"metadata":null},{"id":"ba6b50aa80c74104979f82d3fca8b8c9","type":"BIOMARKER","name":"BRAF Amplification AND ( BRAF V600E OR BRAF V600K )","canonical_id":"civic:4174","description":null,"metadata":null},{"id":"d69a4fb6ed974b15b19d23128cc86ca5","type":"BIOMARKER","name":"BRAF D594A","canonical_id":"civic:575","description":null,"metadata":null},{"id":"4c75a26f6d874faa9fe4b4131602ba76","type":"BIOMARKER","name":"BRAF D594G","canonical_id":"civic:607","description":null,"metadata":null},{"id":"263a238338bb4e86ad0ebd8146e6df1d","type":"BIOMARKER","name":"BRAF D594K","canonical_id":"civic:2271","description":null,"metadata":null},{"id":"3f402bde5ec94eb58402af534d84d3a0","type":"BIOMARKER","name":"BRAF D594V","canonical_id":"civic:576","description":null,"metadata":null},{"id":"572dea62187c469ea9dcf83380ca2dcf","type":"BIOMARKER","name":"BRAF Exon 15 Mutation","canonical_id":"civic:2519","description":null,"metadata":null},{"id":"c052800ca99c441cb0a85445fd2ec7cd","type":"BIOMARKER","name":"BRAF G463E","canonical_id":"civic:3300","description":null,"metadata":null},{"id":"14d2ca7a5bac4f5282bd4cd5974d066a","type":"BIOMARKER","name":"BRAF G464V","canonical_id":"civic:1080","description":null,"metadata":null},{"id":"347a272f421f421687d3c0fdcb3b7e31","type":"BIOMARKER","name":"BRAF G466V","canonical_id":"civic:2098","description":null,"metadata":null},{"id":"163cfea177de4452ad3e3ce3a2e92759","type":"BIOMARKER","name":"BRAF G469","canonical_id":"civic:2691","description":null,"metadata":null},{"id":"521c8779cb3a4d30b028c27a1add76d1","type":"BIOMARKER","name":"BRAF G469A","canonical_id":"civic:966","description":null,"metadata":null},{"id":"4403ce08cc4440b0b2488b2b758a776c","type":"BIOMARKER","name":"BRAF G469E","canonical_id":"civic:967","description":null,"metadata":null},{"id":"275ccf8c355d45e995c76adf69ff3756","type":"BIOMARKER","name":"BRAF G496A","canonical_id":"civic:2097","description":null,"metadata":null},{"id":"17ff00f491e04c829bd31f2a7b29b099","type":"BIOMARKER","name":"BRAF G596C","canonical_id":"civic:675","description":null,"metadata":null},{"id":"6270a04fa5294857996191d7ced7499f","type":"BIOMARKER","name":"BRAF G596R","canonical_id":"civic:1535","description":null,"metadata":null},{"id":"bd8ae9c7384a43efa99e5a1296e57efa","type":"BIOMARKER","name":"BRAF G606E","canonical_id":"civic:2099","description":null,"metadata":null},{"id":"b8886d5f8cbb43ad9aec80c72aa265c8","type":"DRUG","name":"BRAF Inhibitor","canonical_id":"ncit:C155322","description":null,"metadata":null},{"id":"0eae4ace026049489687d00b7a598e2c","type":"BIOMARKER","name":"BRAF K483M","canonical_id":"civic:577","description":null,"metadata":null},{"id":"81b6c368a0a64663a9b9cde89ec70286","type":"BIOMARKER","name":"BRAF K601E","canonical_id":"civic:580","description":null,"metadata":null},{"id":"b76bcf30f73e41c880ceca18a6d18f50","type":"BIOMARKER","name":"BRAF L485_P490del","canonical_id":"civic:518","description":null,"metadata":null},{"id":"c7f04fc297ad4b919ffa46d6501a402d","type":"BIOMARKER","name":"BRAF L505H","canonical_id":"civic:654","description":null,"metadata":null},{"id":"0024d3cb244249d6b679b5655b89565a","type":"BIOMARKER","name":"BRAF L525R","canonical_id":"civic:2662","description":null,"metadata":null},{"id":"3a38997791a2498e885b4d74de541f7f","type":"BIOMARKER","name":"BRAF L597Q","canonical_id":"civic:579","description":null,"metadata":null},{"id":"f54e9c0360a14e49a0d50ab17105226e","type":"BIOMARKER","name":"BRAF L597R","canonical_id":"civic:284","description":null,"metadata":null},{"id":"5522bf18d5f64c948a1a125e3a096fcc","type":"BIOMARKER","name":"BRAF L597S","canonical_id":"civic:578","description":null,"metadata":null},{"id":"806e61f8140549bcaf0f762b9fe8c889","type":"BIOMARKER","name":"BRAF L597V","canonical_id":"civic:581","description":null,"metadata":null},{"id":"587eb620341f4161876fff52042138b3","type":"BIOMARKER","name":"BRAF Mutation","canonical_id":"civic:395","description":null,"metadata":null},{"id":"34eb35d42a7f4672a77db3b22e619b74","type":"BIOMARKER","name":"BRAF N486_P490del","canonical_id":"civic:2663","description":null,"metadata":null},{"id":"8549ee80b7ec4432abb281a7cbcd1d59","type":"BIOMARKER","name":"BRAF N581S","canonical_id":"civic:1160","description":null,"metadata":null},{"id":"02b5ba4fa92249f995aa6b4059ed4b7d","type":"BIOMARKER","name":"BRAF Non-V600","canonical_id":"civic:2281","description":null,"metadata":null},{"id":"d04eb5ca92224862a4166eb59a90c429","type":"BIOMARKER","name":"BRAF P731T","canonical_id":"civic:2100","description":null,"metadata":null},{"id":"d50a048acdfa4de98694e7aecf7aa669","type":"BIOMARKER","name":"BRAF T599dup","canonical_id":"civic:1272","description":null,"metadata":null},{"id":"8c15b9c657054734add89d6037b021e1","type":"BIOMARKER","name":"BRAF V600","canonical_id":"civic:17","description":null,"metadata":null},{"id":"3cc692fdcd8f4ef4894bc9a0ac2e1a9e","type":"BIOMARKER","name":"BRAF V600 AND BRAF Amplification","canonical_id":"civic:5411","description":null,"metadata":null},{"id":"b1313eace9874d32b4197c04c636b912","type":"BIOMARKER","name":"BRAF V600 AND PTEN Underexpression","canonical_id":"civic:5816","description":null,"metadata":null},{"id":"724a0a9a9442462589009b8417ed88b3","type":"BIOMARKER","name":"BRAF V600 OR v::BRAF Fusion","canonical_id":"civic:5077","description":null,"metadata":null},{"id":"f0b6d51328e443c59b290e13b08e4649","type":"BIOMARKER","name":"BRAF V600D","canonical_id":"civic:11","description":null,"metadata":null},{"id":"ffb6be0ae9bd4915900713f6e818dbf8","type":"BIOMARKER","name":"BRAF V600E","canonical_id":"civic:12","description":null,"metadata":null},{"id":"34b657fbf15c4f27883a071bc0ce4f1f","type":"BIOMARKER","name":"BRAF V600E AND ARAF S490T","canonical_id":"civic:5492","description":null,"metadata":null},{"id":"0d15b4513cbd44559e57cbb4f74dbbd7","type":"BIOMARKER","name":"BRAF V600E AND BRAF Amplification","canonical_id":"civic:4173","description":null,"metadata":null},{"id":"2a13993014784f90b0a57615697629c1","type":"BIOMARKER","name":"BRAF V600E AND BRAF V600M","canonical_id":"civic:4170","description":null,"metadata":null},{"id":"ae1199535d634258b3cb358bf6bc34c8","type":"BIOMARKER","name":"BRAF V600E AND EZH2 Y646F","canonical_id":"civic:4241","description":null,"metadata":null},{"id":"adafee639f6f4feb843d2956bbd03e42","type":"BIOMARKER","name":"BRAF V600E AND GNAS R201C","canonical_id":"civic:5491","description":null,"metadata":null},{"id":"c01cd67e50db489fb6a27052dd527aff","type":"BIOMARKER","name":"BRAF V600E AND KRAS G12D","canonical_id":"civic:5806","description":null,"metadata":null},{"id":"b58c6d6f9b3d409bad0f0f3cd724fc18","type":"BIOMARKER","name":"BRAF V600E AND KRAS Mutation","canonical_id":"civic:5837","description":null,"metadata":null},{"id":"e63f908b6ff840a4a464953b11d2cf59","type":"BIOMARKER","name":"BRAF V600E AND MSI High","canonical_id":"civic:5739","description":null,"metadata":null},{"id":"266ab0aa818e495297b2f2b49a2f1ec8","type":"BIOMARKER","name":"BRAF V600E AND MSI Low","canonical_id":"civic:5175","description":null,"metadata":null},{"id":"2cdda698abbf4130b093ada5a5468d18","type":"BIOMARKER","name":"BRAF V600E AND NF1 Loss","canonical_id":"civic:5379","description":null,"metadata":null},{"id":"3cab46743ee44994a08cf336ce713472","type":"BIOMARKER","name":"BRAF V600E AND NRAS Mutation","canonical_id":"civic:5703","description":null,"metadata":null},{"id":"e4a1172863944dfca6f69ce35e7e86e3","type":"BIOMARKER","name":"BRAF V600E AND PIK3CA Overexpression","canonical_id":"civic:5804","description":null,"metadata":null},{"id":"81948d410fe34515911072c196e06297","type":"BIOMARKER","name":"BRAF V600E AND PIK3R2 N561D","canonical_id":"civic:5702","description":null,"metadata":null},{"id":"e762d9c528d943e29ae37023d6bf6520","type":"BIOMARKER","name":"BRAF V600E AND PTEN Loss","canonical_id":"civic:5704","description":null,"metadata":null},{"id":"f637e1a0575c4825bdb384a7c03da3a9","type":"BIOMARKER","name":"BRAF V600E OR BRAF K601E","canonical_id":"civic:4707","description":null,"metadata":null},{"id":"5e6840fcce7b4e8aaf1173dce10707e5","type":"BIOMARKER","name":"BRAF V600E OR BRAF V600K","canonical_id":"civic:5666","description":null,"metadata":null},{"id":"c2a6944015c242179b22a2b22c039264","type":"BIOMARKER","name":"BRAF V600E OR KIAA1549::BRAF Fusion","canonical_id":"civic:4453","description":null,"metadata":null},{"id":"66756cc4229149d7b3febc573a2d9120","type":"BIOMARKER","name":"BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation","canonical_id":"civic:4748","description":null,"metadata":null},{"id":"78fb7b6523df43489f97c9ce7badb171","type":"BIOMARKER","name":"BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Mutation","canonical_id":"civic:4715","description":null,"metadata":null},{"id":"ed5f67fd95454a379743b5f0e42d3ea1","type":"GENE","name":"BRAFP1","canonical_id":"hgnc:HGNC:18615","description":"BRAF pseudogene 1","metadata":{"aliases":["BRAF2","BRAFPS2"]}},{"id":"9e4f2a9d8cd2454285b71da0c332a638","type":"GENE","name":"BRAP","canonical_id":"hgnc:HGNC:1099","description":"BRCA1 associated protein","metadata":{"aliases":["BRAP2","RNF52","IMP"]}},{"id":"98f3931c47d84b0293a7146ffb674b51","type":"GENE","name":"BRAT1","canonical_id":"hgnc:HGNC:21701","description":"BRCA1 associated ATM activator 1","metadata":{"aliases":["MGC22916","C7orf27","BAAT1"]}},{"id":"6c47b926b5f1483aba96ee16a468f0ce","type":"GENE","name":"BRCA1","canonical_id":"hgnc:HGNC:1100","description":null,"metadata":null},{"id":"6e68d7dc367b467e8500bb1de813b722","type":"GENE","name":"BRCA1","canonical_id":"ensembl:ENSG00000012048","description":null,"metadata":null},{"id":"da5e3b512c9e4d88acd8b6b485808966","type":"BIOMARKER","name":"BRCA1 Alu insertion","canonical_id":"civic:690","description":null,"metadata":null},{"id":"880802480aaf4788bf2b14455fb7caea","type":"BIOMARKER","name":"BRCA1 Expression","canonical_id":"civic:393","description":null,"metadata":null},{"id":"7dd42b0f5c3d4da08d62b29c24e54ec3","type":"BIOMARKER","name":"BRCA1 Loss-of-function","canonical_id":"civic:131","description":null,"metadata":null},{"id":"568a591d14474dff9fa197b8e121b9fb","type":"BIOMARKER","name":"BRCA1 Loss-of-function OR BAP1 Loss-of-function","canonical_id":"civic:5390","description":null,"metadata":null},{"id":"06422623b55c457b88f51dcf17f9bebf","type":"BIOMARKER","name":"BRCA1 Mutation","canonical_id":"civic:185","description":null,"metadata":null},{"id":"6c24defa3b674108971475aaeb55c005","type":"BIOMARKER","name":"BRCA1 Mutation OR BRCA2 Mutation","canonical_id":"civic:4409","description":null,"metadata":null},{"id":"dad7a8791dee400f8d923a5526a4355d","type":"BIOMARKER","name":"BRCA1 P968FS","canonical_id":"civic:473","description":null,"metadata":null},{"id":"3848d2961b9a4b7288481c4a9e725a58","type":"BIOMARKER","name":"BRCA1 Q1467*","canonical_id":"civic:1220","description":null,"metadata":null},{"id":"a1c0ec0893334809987477c2a5c481da","type":"BIOMARKER","name":"BRCA1 Underexpression","canonical_id":"civic:399","description":null,"metadata":null},{"id":"916922d94c284f6aa2f7af3dea1231ab","type":"BIOMARKER","name":"BRCA1 W1815X","canonical_id":"civic:1463","description":null,"metadata":null},{"id":"e5d92e54dad14934a89914ddbb38f90a","type":"GO_TERM","name":"BRCA1-A complex","canonical_id":"go:GO:0070531","description":"\"A protein complex that contains the BRCA1-BARD1 heterodimer, RAP80/UIMC1, BRCC3/BRCC36, BRE/BRCC45, FAM175A/CCDC98/Abraxas and MERIT40/NBA1, and specifically recognizes and binds K63-linked polyubiquitin chains present on histone H2A and H2AX at DNA damage sites.\" [GOC:mah, PMID:19261749]","metadata":null},{"id":"c1e10b76a6e442739625793042aa2732","type":"GO_TERM","name":"BRCA1-B complex","canonical_id":"go:GO:0070532","description":"\"A protein complex that contains the BRCA1-BARD1 heterodimer, BACH1 and TopBP1, and binds to DNA during S phase at DNA damage sites.\" [GOC:mah, PMID:16391231]","metadata":null},{"id":"7bff2af55d374df4bf80521ba22f5017","type":"GO_TERM","name":"BRCA1-BARD1 complex","canonical_id":"go:GO:0031436","description":"\"A heterodimeric complex comprising BRCA1 and BARD1, which possesses ubiquitin ligase activity and is involved in genome maintenance, possibly by functioning in surveillance for DNA damage.\" [PMID:12787778]","metadata":null},{"id":"e6ff8de2200d4f0da978c12266e1e161","type":"GO_TERM","name":"BRCA1-C complex","canonical_id":"go:GO:0070533","description":"\"A protein complex that contains the BRCA1-BARD1 heterodimer, CtIP and Mre11/Rad50/NBS1 (M/R/N) complex, and binds to DNA at DNA damage sites. BRCA1-C binding ta damaged DNA is required for DNA damage-induced Chk1 phosphorylation and the G2/M transition checkpoint.\" [GOC:mah, PMID:15485915, PMID:16391231]","metadata":null},{"id":"486e27e127fb45cf9178874e9ecf65a5","type":"GENE","name":"BRCA1-OT1","canonical_id":"hgnc:HGNC:58363","description":"BRCA1 overlapping transcript 1","metadata":{"aliases":["AC060780.1","lncRP11-242D8.1"]}},{"id":"478104041b2b401cabf3e2aaf85b4878","type":"GO_TERM","name":"BRCA1-Rad51 complex","canonical_id":"go:GO:0070767","description":"\"A protein complex that contains BRCA1 and Rad 51, and is involved in the control of recombination and of genome integrity.\" [GOC:mah, PMID:9008167]","metadata":null},{"id":"86094c818846438aa94f959f5cc615f2","type":"GENE","name":"BRCA1P1","canonical_id":"hgnc:HGNC:28470","description":"BRCA1 pseudogene 1","metadata":{"aliases":["LBRCA1","PsiBRCA1","pseudo-BRCA1"]}},{"id":"187e571ff3ab4ab7804a4cf8336ec88b","type":"GENE","name":"BRCA2","canonical_id":"hgnc:HGNC:1101","description":null,"metadata":null},{"id":"8274e43d762548a580ec1b16e843b598","type":"GENE","name":"BRCA2","canonical_id":"ensembl:ENSG00000139618","description":null,"metadata":null},{"id":"fa504dba48be4e28a82b3ea2d73c0fe9","type":"BIOMARKER","name":"BRCA2 D3095E","canonical_id":"civic:657","description":null,"metadata":null},{"id":"186317fa483045ff90c0931690143a7d","type":"BIOMARKER","name":"BRCA2 K3326*","canonical_id":"civic:2740","description":null,"metadata":null},{"id":"f79f5e6fa30449a7afdf3529882aaf82","type":"BIOMARKER","name":"BRCA2 Loss-of-function","canonical_id":"civic:132","description":null,"metadata":null},{"id":"f22ff315887c42b0beb8c8b537a62a53","type":"BIOMARKER","name":"BRCA2 M1?","canonical_id":"civic:1222","description":null,"metadata":null},{"id":"64f8ad6fa2af4ec0af559b6eb491a7d6","type":"BIOMARKER","name":"BRCA2 M1R","canonical_id":"civic:1221","description":null,"metadata":null},{"id":"a9862944cfaf4c5f8edd0c194490c5cb","type":"BIOMARKER","name":"BRCA2 Mutation","canonical_id":"civic:186","description":null,"metadata":null},{"id":"f33afb217ce44fd28ea90ffd14cbc1aa","type":"BIOMARKER","name":"BRCA2 R2336P","canonical_id":"civic:1226","description":null,"metadata":null},{"id":"651c9356fc5841f28d472e16494bcf7b","type":"BIOMARKER","name":"BRCA2 TRUNCATING MUTATION","canonical_id":"civic:689","description":null,"metadata":null},{"id":"17ed8283ffa644b0a69bef99c994df5c","type":"BIOMARKER","name":"BRCA2 V159M","canonical_id":"civic:1223","description":null,"metadata":null},{"id":"3d5750e790e4417ebb232c94af37d024","type":"BIOMARKER","name":"BRCA2 V211I","canonical_id":"civic:1225","description":null,"metadata":null},{"id":"fb819da8194442ebb0abf1ffd083dd9e","type":"BIOMARKER","name":"BRCA2 V211L","canonical_id":"civic:1224","description":null,"metadata":null},{"id":"06ec9578ecea477f8b262eb5c2091937","type":"GO_TERM","name":"BRCA2-BRAF35 complex","canonical_id":"go:GO:0002111","description":"\"A heterodimeric complex of BRCA2 and BRAF35 (BRCA2-associated factor 35). The BRCA2-BRAF35 complex is often associated with condensed chromatin during mitosis.\" [GOC:hjd, PMID:11207365]","metadata":null},{"id":"6280fadcaa2946f7b9d43d6b0be42630","type":"GO_TERM","name":"BRCA2-MAGE-D1 complex","canonical_id":"go:GO:0033593","description":"\"A heterodimeric protein complex formed of BRCA2 and MAGE-D1; may mediate the synergistic activities of the two proteins in regulating cell growth.\" [PMID:15930293]","metadata":null},{"id":"d6af2336ffed4da3996c941809412d01","type":"GENE","name":"BRCC3","canonical_id":"hgnc:HGNC:24185","description":"BRCA1/BRCA2-containing complex subunit 3","metadata":{"aliases":["C6.1A","BRCC36","CXorf53"]}},{"id":"ce18800fc35846928d13f0606a5a191c","type":"GENE","name":"BRCC3P1","canonical_id":"hgnc:HGNC:51444","description":"BRCA1/BRCA2-containing complex subunit 3 pseudogene 1","metadata":null},{"id":"79baf48ab09e47ea8fd6bdc7fda4f1c4","type":"GENE","name":"BRD1","canonical_id":"hgnc:HGNC:1102","description":"bromodomain containing 1","metadata":{"aliases":["BRL","BRPF2"]}},{"id":"ff54e62cb3dd450f8a4ff8c117962f2d","type":"GENE","name":"BRD10","canonical_id":"hgnc:HGNC:23378","description":"bromodomain containing 10","metadata":{"aliases":["FLJ20375","KIAA2026"]}},{"id":"182c244b9c82497e8d4f0cc935bf9eb2","type":"GENE","name":"BRD2","canonical_id":"hgnc:HGNC:1103","description":null,"metadata":null},{"id":"fdff264dbd254f07a4310d9e60bc92ce","type":"GENE","name":"BRD3","canonical_id":"hgnc:HGNC:1104","description":null,"metadata":null},{"id":"fdb32d06107c49d08ea806b823461154","type":"GENE","name":"BRD3OS","canonical_id":"hgnc:HGNC:24742","description":"BRD3 opposite strand","metadata":{"aliases":["FLJ35348","bA374P20.3","SERLOC","NCRNA00094","LINC00094"]}},{"id":"c9c7f5715ea845e19bbf725889e7d04f","type":"GENE","name":"BRD4","canonical_id":"hgnc:HGNC:13575","description":null,"metadata":null},{"id":"c629e8fa845748f4a0feab3329f4699c","type":"GENE","name":"BRD7","canonical_id":"hgnc:HGNC:14310","description":null,"metadata":null},{"id":"1059d0854c16420287e5d8c9381c82bf","type":"GENE","name":"BRD7P1","canonical_id":"hgnc:HGNC:19923","description":"bromodomain containing 7 pseudogene 1","metadata":{"aliases":["BRD7P"]}},{"id":"accd1f4daf534017b6e7816513348c11","type":"GENE","name":"BRD7P2","canonical_id":"hgnc:HGNC:33541","description":"bromodomain containing 7 pseudogene 2","metadata":null},{"id":"4a51ac337e2f4ec58678e59c8c12f5be","type":"GENE","name":"BRD7P3","canonical_id":"hgnc:HGNC:24171","description":"bromodomain containing 7 pseudogene 3","metadata":null},{"id":"82581b3d09c94875a5c8783edea2f4fd","type":"GENE","name":"BRD7P4","canonical_id":"hgnc:HGNC:37630","description":"bromodomain containing 7 pseudogene 4","metadata":null},{"id":"3d73320f96694b5ba4a29a0bf9f91780","type":"GENE","name":"BRD7P5","canonical_id":"hgnc:HGNC:37631","description":"bromodomain containing 7 pseudogene 5","metadata":null},{"id":"23b435bc5fb1460799db4d888a955312","type":"GENE","name":"BRD7P6","canonical_id":"hgnc:HGNC:37632","description":"bromodomain containing 7 pseudogene 6","metadata":null},{"id":"28a4a1759f2c47f29ad65ba11391f70f","type":"GENE","name":"BRD7P7","canonical_id":"hgnc:HGNC:56471","description":"BRD7 pseudogene 7","metadata":null},{"id":"c93678863d6d4b5c9b5bba44043ea46b","type":"GENE","name":"BRD8","canonical_id":"hgnc:HGNC:19874","description":"bromodomain containing 8","metadata":{"aliases":["SMAP","p120"]}},{"id":"0bb141567595422f92c256409fdbd894","type":"GENE","name":"BRD9","canonical_id":"hgnc:HGNC:25818","description":"bromodomain containing 9","metadata":{"aliases":["FLJ13441","SMARCI2"]}},{"id":"3504e183a41845d2b5047d0ef79ca19f","type":"GENE","name":"BRD9P1","canonical_id":"hgnc:HGNC:51445","description":"bromodomain containing 9 pseudogene 1","metadata":null},{"id":"29793c5f99bc4ae6b9b31511cc63ca64","type":"GENE","name":"BRD9P2","canonical_id":"hgnc:HGNC:51446","description":"bromodomain containing 9 pseudogene 2","metadata":null},{"id":"fd52b20d52f542f4ab45c1e88c66cbaa","type":"GENE","name":"BRDT","canonical_id":"hgnc:HGNC:1105","description":"bromodomain testis associated","metadata":{"aliases":["BRD6","CT9","BRDt"]}},{"id":"1df187aa29904f25ab31914ed932dd8c","type":"GENE","name":"BRDTP1","canonical_id":"hgnc:HGNC:51447","description":"bromodomain testis associated pseudogene 1","metadata":null},{"id":"5a0be91c98ea4861a1a274ca1c799a48","type":"GO_TERM","name":"BRE binding","canonical_id":"go:GO:0042835","description":"\"Binding to a BRE RNA element (Bruno response element).\" [PMID:10893231]","metadata":null},{"id":"fcccbb766f8e4a548c996e16254191e3","type":"GO_TERM","name":"BRE1 E3 ubiquitin ligase complex","canonical_id":"go:GO:1990352","description":"\"A homodimeric protein complex composed of the E3 ubiquitin-protein ligase BRE1. Plays a role in regulating association of RNA polymerase II with active genes.\" [GOC:bhm, PMID:19531475]","metadata":null},{"id":"60024af94350411c80e2fd65d79391d3","type":"GENE","name":"BRF1","canonical_id":"hgnc:HGNC:11551","description":"BRF1 general transcription factor IIIB subunit","metadata":{"aliases":["TFIIIB90","BRF","hBRF","TAF3B2","TAF3C","GTF3B"]}},{"id":"4b86476d17d24362a47424d56b4fa45d","type":"GENE","name":"BRF2","canonical_id":"hgnc:HGNC:17298","description":"BRF2 general transcription factor IIIB subunit","metadata":{"aliases":["FLJ11052","BRFU","TFIIIB50"]}},{"id":"19bccc4e04cc4a33ba9d645b8875aa79","type":"GENE","name":"BRI3","canonical_id":"hgnc:HGNC:1109","description":"brain protein I3","metadata":null},{"id":"cea53fb29761494e9311ce407c8050a7","type":"GENE","name":"BRI3BP","canonical_id":"hgnc:HGNC:14251","description":"BRI3 binding protein","metadata":{"aliases":["BNAS1","KG19","HCCR-2","HCCRBP-3"]}},{"id":"5c8980831630420da6a51954144ada81","type":"GENE","name":"BRI3BPP1","canonical_id":"hgnc:HGNC:51482","description":"BRI3 binding protein pseudogene 1","metadata":null},{"id":"be487c2d93404700844cfd3c02b175bd","type":"GENE","name":"BRI3P1","canonical_id":"hgnc:HGNC:33533","description":"brain protein I3 pseudogene 1","metadata":null},{"id":"5c1b2e95e54c4f2d9e5d1c63de37bc4c","type":"GENE","name":"BRI3P2","canonical_id":"hgnc:HGNC:32543","description":"brain protein I3 pseudogene 2","metadata":null},{"id":"b18d902365bd4cdbb3ed05f3247c6844","type":"GENE","name":"BRI3P3","canonical_id":"hgnc:HGNC:32544","description":"brain protein I3 pseudogene 3","metadata":null},{"id":"e1a7e7958477408f925bb2e14f77f5c1","type":"GENE","name":"BRICD5","canonical_id":"hgnc:HGNC:28309","description":"BRICHOS domain containing 5","metadata":{"aliases":["MGC21830","C16orf79"]}},{"id":"65e23b83eff54e74a15b20d8945a063b","type":"TRIAL","name":"BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression","canonical_id":"clinicaltrials.gov:NCT07618624","description":"Recurrent Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer","metadata":null},{"id":"6af8bcfd94fe4d749d735c4bf41e2e73","type":"TRIAL","name":"BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT00111566","description":"Coronary Artery Disease; Myocardial Infarction","metadata":null},{"id":"ed1c64bafb294851969a7eec3ff9b625","type":"GENE","name":"BRINP1","canonical_id":"hgnc:HGNC:2687","description":"BMP/retinoic acid inducible neural specific 1","metadata":{"aliases":["FAM5A","DBCCR1","DBC1"]}},{"id":"f32227126202455fbff040b77464ff19","type":"GENE","name":"BRINP2","canonical_id":"hgnc:HGNC:13746","description":"BMP/retinoic acid inducible neural specific 2","metadata":{"aliases":["DBCCR1L2","FAM5B"]}},{"id":"454cf636dcdb4d6eb1c2be3ed1758ba3","type":"GENE","name":"BRINP3","canonical_id":"hgnc:HGNC:22393","description":"BMP/retinoic acid inducible neural specific 3","metadata":{"aliases":["DBCCR1L","DBCCR1L1","FAM5C"]}},{"id":"becc3130cb5a43139c8f3a9c7ba0befa","type":"GENE","name":"BRINP3-DT","canonical_id":"hgnc:HGNC:50577","description":"BRINP3 divergent transcript","metadata":{"aliases":["LINC01351"]}},{"id":"b4b03dcbc3c0473e8f2a55723f4007da","type":"GENE","name":"BRIP1","canonical_id":"hgnc:HGNC:20473","description":null,"metadata":null},{"id":"1ed8e5f9da2c4922b06917ee3ff3d4e8","type":"GO_TERM","name":"BRISC complex","canonical_id":"go:GO:0070552","description":"\"A protein complex that contains the FAM175B/ABRO1, BRCC3/BRCC36, BRE/BRCC45 and MERIT40/NBA1 proteins, and specifically cleaves K63-linked polyubiquitin chains.\" [GOC:mah, PMID:19214193]","metadata":null},{"id":"ad20a0dfffbf4d1e987ccce8b5350cf8","type":"GENE","name":"BRIX1","canonical_id":"hgnc:HGNC:24170","description":"biogenesis of ribosomes BRX1","metadata":{"aliases":["BRIX","FLJ11100","BXDC2"]}},{"id":"4e6e07e44b234096b01628db5e6ae560","type":"GENE","name":"BRIX1P1","canonical_id":"hgnc:HGNC:51527","description":"BRIX1 pseudogene 1","metadata":null},{"id":"2007707d50974d458869c4b9ea480da9","type":"GENE","name":"BRK1","canonical_id":"hgnc:HGNC:23057","description":"BRICK1 subunit of SCAR/WAVE actin nucleating complex","metadata":{"aliases":["MDS027","HSPC300","C3orf10"]}},{"id":"d3ecb5e78b4446a0b251a466efcbe5ab","type":"GENE","name":"BRK1P1","canonical_id":"hgnc:HGNC:42020","description":"BRICK1 pseudogene 1","metadata":null},{"id":"445dee0401794a6896d66eafad1c8bb9","type":"GENE","name":"BRK1P2","canonical_id":"hgnc:HGNC:42021","description":"BRK1 pseudogene 2","metadata":null},{"id":"596bb3a897f44537ba2b97939fd883c7","type":"GENE","name":"BRME1","canonical_id":"hgnc:HGNC:28153","description":"break repair meiotic recombinase recruitment factor 1","metadata":{"aliases":["MGC11271","MEIOK21","C19orf57"]}},{"id":"699a9abf59ac44d292ee0f334794ee46","type":"GENE","name":"BRMS1","canonical_id":"hgnc:HGNC:17262","description":"BRMS1 transcriptional repressor and anoikis regulator","metadata":{"aliases":["DKFZP564A063"]}},{"id":"29261b25857a42b0a62c2c7455b1f986","type":"GENE","name":"BRMS1L","canonical_id":"hgnc:HGNC:20512","description":"BRMS1 like transcriptional repressor","metadata":{"aliases":["MGC11296","FLJ39177","p40","BRMS1"]}},{"id":"5e9e9fdf1d434b0aa7ca52c28ba93188","type":"GENE","name":"BROX","canonical_id":"hgnc:HGNC:26512","description":"BRO1 domain and CAAX motif containing","metadata":{"aliases":["FLJ32421","C1orf58"]}},{"id":"7561ebf438224ccf96cfd933060cdca8","type":"GENE","name":"BRPF1","canonical_id":"hgnc:HGNC:14255","description":null,"metadata":null},{"id":"5a3f8d9e305c4a30b6aa6193162a496e","type":"GENE","name":"BRPF3","canonical_id":"hgnc:HGNC:14256","description":"bromodomain and PHD finger containing 3","metadata":{"aliases":["KIAA1286"]}},{"id":"1d909a84f44f4f8686f814753a6f53bd","type":"GENE","name":"BRPF3-AS1","canonical_id":"hgnc:HGNC:55591","description":"BRPF3 antisense RNA 1","metadata":null},{"id":"53855db8066e40928b2d9968748b9e2f","type":"GENE","name":"BRRIAR","canonical_id":"hgnc:HGNC:59155","description":"BHLHE40 and RIG-I regulating ITPR1 antisense RNA","metadata":null},{"id":"8910a4d156364b4986dd636b0093f809","type":"GENE","name":"BRS3","canonical_id":"hgnc:HGNC:1113","description":null,"metadata":null},{"id":"bf438b4ae9cf45ba8d9100d78a49b795","type":"GENE","name":"BRSK1","canonical_id":"hgnc:HGNC:18994","description":"BR serine/threonine kinase 1","metadata":{"aliases":["KIAA1811","SAD-B"]}},{"id":"a3100d8485144c0e8baec21eaa57ccad","type":"GENE","name":"BRSK1-AS1","canonical_id":"hgnc:HGNC:58329","description":"BRSK1 antisense RNA 1","metadata":null},{"id":"134e097eb5b845d08275c4ce83c2247f","type":"GENE","name":"BRSK2","canonical_id":"hgnc:HGNC:11405","description":"BR serine/threonine kinase 2","metadata":{"aliases":["PEN11B","SAD-A","C11orf7","STK29"]}},{"id":"3b25cb57b2d44f858c69d4cba6189211","type":"GENE","name":"BRWD1","canonical_id":"hgnc:HGNC:12760","description":"bromodomain and WD repeat domain containing 1","metadata":{"aliases":["FLJ11315","N143","DCAF19","C21orf107","WDR9"]}},{"id":"181f2ad61e3e4f1c985a7c9ac9fba201","type":"GENE","name":"BRWD1-AS1","canonical_id":"hgnc:HGNC:40614","description":"BRWD1 antisense RNA 1","metadata":{"aliases":["C21orf87","BRWD1-AS2","BRWD1-IT2","NCRNA00257"]}},{"id":"7c097dd5353646e69ef560936f1f73a5","type":"GENE","name":"BRWD1-IT1","canonical_id":"hgnc:HGNC:41920","description":"BRWD1 intronic transcript 1","metadata":null},{"id":"88b28b64f3544b2dad57f4436dad248a","type":"GENE","name":"BRWD1P1","canonical_id":"hgnc:HGNC:51528","description":"bromodomain and WD repeat domain containing 1 pseudogene 1","metadata":null},{"id":"648258617ea14bca96382b134d81a855","type":"GENE","name":"BRWD1P2","canonical_id":"hgnc:HGNC:51529","description":"bromodomain and WD repeat domain containing 1 pseudogene 2","metadata":null},{"id":"7f700e68d3d94dd1a838e3d5e69bfcdb","type":"GENE","name":"BRWD1P3","canonical_id":"hgnc:HGNC:51530","description":"bromodomain and WD repeat domain containing 1 pseudogene 3","metadata":null},{"id":"8f7deb8c6c0d41688b71a096e232f5b3","type":"GENE","name":"BRWD3","canonical_id":"hgnc:HGNC:17342","description":"bromodomain and WD repeat domain containing 3","metadata":{"aliases":["BRODL","MRX93","FLJ38568"]}},{"id":"077f7826554e4cc69a28ce7e5654d6b2","type":"GENE","name":"BSCL2","canonical_id":"hgnc:HGNC:15832","description":"BSCL2 lipid droplet biogenesis associated, seipin","metadata":{"aliases":["seipin","GNG3LG","SPG17"]}},{"id":"d792c5e4b60549449e16e49469fb6231","type":"GENE","name":"BSDC1","canonical_id":"hgnc:HGNC:25501","description":"BSD domain containing 1","metadata":{"aliases":["FLJ10276","RP4-811H24.7"]}},{"id":"efd9404b5762434fa41f419268d1e02c","type":"GENE","name":"BSG","canonical_id":"hgnc:HGNC:1116","description":null,"metadata":null},{"id":"f68319ba15764b37a1d402ce7e7605c5","type":"GENE","name":"BSG-AS1","canonical_id":"hgnc:HGNC:55286","description":"BSG antisense RNA 1","metadata":null},{"id":"8d17fc9b60774065a437623693770ac0","type":"GENE","name":"BSN","canonical_id":"hgnc:HGNC:1117","description":"bassoon presynaptic cytomatrix protein","metadata":{"aliases":["ZNF231"]}},{"id":"4b3dd2e8ac5d456b834adfddc213e893","type":"GENE","name":"BSN-AS1","canonical_id":"hgnc:HGNC:40102","description":"BSN antisense RNA 1","metadata":null},{"id":"194c7239269445c8997282a3c0c677f7","type":"GENE","name":"BSN-DT","canonical_id":"hgnc:HGNC:42445","description":"BSN divergent transcript","metadata":{"aliases":["BSN-AS2"]}},{"id":"eea9d0949e03417a9fcf968e4f1d6130","type":"GENE","name":"BSND","canonical_id":"hgnc:HGNC:16512","description":"barttin CLCNK type accessory subunit beta","metadata":{"aliases":["BART","DFNB73"]}},{"id":"246db2efe884407c81b54a7d8464732b","type":"GENE","name":"BSNDP1","canonical_id":"hgnc:HGNC:51536","description":"BSND pseudogene 1","metadata":null},{"id":"c702692e9c424d9eacc1cf0c638a9e39","type":"GENE","name":"BSNDP2","canonical_id":"hgnc:HGNC:51537","description":"BSND pseudogene 2","metadata":null},{"id":"ac5154a60eb54380a4dc7d1c3a28fab7","type":"GENE","name":"BSNDP3","canonical_id":"hgnc:HGNC:51538","description":"BSND pseudogene 3","metadata":null},{"id":"8a41edede6bb4526ae7a3078d342efac","type":"GENE","name":"BSNDP4","canonical_id":"hgnc:HGNC:51539","description":"BSND pseudogene 4","metadata":null},{"id":"7a907a71a8b647f98ecb8fa33ebb0592","type":"GENE","name":"BSPH1","canonical_id":"hgnc:HGNC:33906","description":"binder of sperm protein homolog 1","metadata":{"aliases":["ELSPBP2","BSP1"]}},{"id":"12779dcc25cb4805bd4a872e16d087ba","type":"GENE","name":"BSPRY","canonical_id":"hgnc:HGNC:18232","description":"B-box and SPRY domain containing","metadata":{"aliases":["FLJ20150"]}},{"id":"e32b40fed89648cb9fe41bd3e0d1a5d3","type":"GENE","name":"BST1","canonical_id":"hgnc:HGNC:1118","description":null,"metadata":null},{"id":"d504f03109044600b91cb7371358a886","type":"GENE","name":"BST1-AS1","canonical_id":"hgnc:HGNC:58739","description":"BST1 antisense RNA 1","metadata":null},{"id":"49b2ab5b9d1c4be693d996acaa672261","type":"GENE","name":"BST2","canonical_id":"hgnc:HGNC:1119","description":null,"metadata":null},{"id":"550924b129844d24a0f57bfbb752c482","type":"GENE","name":"BSX","canonical_id":"hgnc:HGNC:20450","description":"brain specific homeobox","metadata":{"aliases":["BSX1"]}},{"id":"e4d80690d17c49538762ed7e66c0a75e","type":"TRIAL","name":"BTA vs Baclofen for Pelvic Myofascial Pain Syndrome","canonical_id":"clinicaltrials.gov:NCT05617118","description":"Chronic Pain; Chronic Pelvic Pain Syndrome; Myofascial Pain Syndrome; Myofascial Trigger Point Pain; Pelvic Floor Disorders","metadata":null},{"id":"db2e7be36f0e41219142085971c33ff0","type":"GENE","name":"BTAF1","canonical_id":"hgnc:HGNC:17307","description":null,"metadata":null},{"id":"8b792144679d46d8be01ee7dea1fc844","type":"GENE","name":"BTBD1","canonical_id":"hgnc:HGNC:1120","description":"BTB domain containing 1","metadata":null},{"id":"666388ab63e7407bb114dc3541235ac4","type":"GENE","name":"BTBD10","canonical_id":"hgnc:HGNC:21445","description":"BTB domain containing 10","metadata":{"aliases":["GMRP1","GMRP-1","MGC13007"]}},{"id":"cea6f26978a245eaae98844ca0c3476b","type":"GENE","name":"BTBD10P1","canonical_id":"hgnc:HGNC:51540","description":"BTB domain containing 10 pseudogene 1","metadata":null},{"id":"4b07c6abc99d4c3d8c3bf223abb19743","type":"GENE","name":"BTBD10P2","canonical_id":"hgnc:HGNC:51541","description":"BTB domain containing 10 pseudogene 2","metadata":null},{"id":"b6370b91a539411fa94e46a35338685f","type":"GENE","name":"BTBD16","canonical_id":"hgnc:HGNC:26340","description":"BTB domain containing 16","metadata":{"aliases":["FLJ25359","Em:AC061711.1","C10orf87"]}},{"id":"f672137e0b4a48c1afc267b4afb5603c","type":"GENE","name":"BTBD17","canonical_id":"hgnc:HGNC:33758","description":"BTB domain containing 17","metadata":{"aliases":["LGALS3BPL","BTBD17A","TANGO10A"]}},{"id":"5da4ad95ea91425a8d1ce4e6cce71a55","type":"GENE","name":"BTBD18","canonical_id":"hgnc:HGNC:37214","description":"BTB domain containing 18","metadata":null},{"id":"3a0ef6cbbc82401294539b17741a3e3b","type":"GENE","name":"BTBD19","canonical_id":"hgnc:HGNC:27145","description":"BTB domain containing 19","metadata":null},{"id":"f02162d22fb24df68fec3dc87fe42b06","type":"GENE","name":"BTBD2","canonical_id":"hgnc:HGNC:15504","description":"BTB domain containing 2","metadata":null},{"id":"6880d768553449409180e11782423747","type":"GENE","name":"BTBD3","canonical_id":"hgnc:HGNC:15854","description":"BTB domain containing 3","metadata":{"aliases":["KIAA0952","dJ742J24.1"]}},{"id":"888a0bcaac5c4898b88c4db660ee95ad","type":"GENE","name":"BTBD3-AS1","canonical_id":"hgnc:HGNC:40728","description":"BTBD3 antisense RNA 1","metadata":null},{"id":"e3e656fbf0114fffb901f218f6b7ecbd","type":"GENE","name":"BTBD6","canonical_id":"hgnc:HGNC:19897","description":"BTB domain containing 6","metadata":{"aliases":["BDPL"]}},{"id":"17b678143d5744248765b296604c3ead","type":"GENE","name":"BTBD6P1","canonical_id":"hgnc:HGNC:51542","description":"BTB domain containing 6 pseudogene 1","metadata":null},{"id":"ed7a58d4989e44df8c5bae5af21c981d","type":"GENE","name":"BTBD7","canonical_id":"hgnc:HGNC:18269","description":"BTB domain containing 7","metadata":{"aliases":["FLJ10648","FUP1"]}},{"id":"1ee9a5b5a7204103ac22bca359afe4a7","type":"GENE","name":"BTBD7P1","canonical_id":"hgnc:HGNC:44875","description":"BTB domain containing 7 pseudogene 1","metadata":null},{"id":"d80dd997e56945e287107c74b48b1a59","type":"GENE","name":"BTBD7P2","canonical_id":"hgnc:HGNC:44876","description":"BTB domain containing 7 pseudogene 2","metadata":null},{"id":"5289e17418d8400693addfffbad21d02","type":"GENE","name":"BTBD8","canonical_id":"hgnc:HGNC:21019","description":"BTB domain containing 8","metadata":{"aliases":["APache","KIAA1107"]}},{"id":"5710d8fcd4e14d07b8663aeca2324a3c","type":"GENE","name":"BTBD9","canonical_id":"hgnc:HGNC:21228","description":"BTB domain containing 9","metadata":{"aliases":["KIAA1880","dJ322I12.1"]}},{"id":"6f42582e0cac4a339d54f220d6195cd7","type":"GENE","name":"BTBD9-AS1","canonical_id":"hgnc:HGNC:40959","description":"BTBD9 antisense RNA 1","metadata":null},{"id":"c9e1efab7e584632af67194f5420a233","type":"GENE","name":"BTBD9-DT","canonical_id":"hgnc:HGNC:59396","description":"BTBD9 divergent transcript","metadata":null},{"id":"f89ce1a829e84b98b345e018608325bc","type":"GENE","name":"BTC","canonical_id":"hgnc:HGNC:1121","description":"betacellulin","metadata":null},{"id":"fa7e670220bf417db982533588f0c117","type":"GENE","name":"BTD","canonical_id":"hgnc:HGNC:1122","description":"biotinidase","metadata":null},{"id":"3409f67a99f04e92b5328c1b80ac78b5","type":"GENE","name":"BTF3","canonical_id":"hgnc:HGNC:1125","description":null,"metadata":null},{"id":"617e1b1fb87c491e995d2e01e23ee838","type":"GENE","name":"BTF3-DT","canonical_id":"hgnc:HGNC:55211","description":"BTF3 divergent transcript","metadata":null},{"id":"2393d1ac1e3b4055bf9a8fedc013f85a","type":"GENE","name":"BTF3L4","canonical_id":"hgnc:HGNC:30547","description":"basic transcription factor 3 like 4","metadata":{"aliases":["MGC23908"]}},{"id":"bb4ef8ea33b343e78c965b491648f247","type":"GENE","name":"BTF3L4P1","canonical_id":"hgnc:HGNC:39645","description":"basic transcription factor 3 like 4 pseudogene 1","metadata":null},{"id":"f52be3401dd44c6f82fdc9e3d9fb40d4","type":"GENE","name":"BTF3L4P2","canonical_id":"hgnc:HGNC:39646","description":"basic transcription factor 3 like 4 pseudogene 2","metadata":null},{"id":"9e4598bdb9f046de8dd34f7f28c8d0cb","type":"GENE","name":"BTF3L4P3","canonical_id":"hgnc:HGNC:39647","description":"basic transcription factor 3 like 4 pseudogene 3","metadata":null},{"id":"c61a415fe7d8479e93e654dcd80c5c16","type":"GENE","name":"BTF3L4P4","canonical_id":"hgnc:HGNC:39648","description":"basic transcription factor 3 like 4 pseudogene 4","metadata":null},{"id":"459687a49a40430386ba349698ab7192","type":"GENE","name":"BTF3P1","canonical_id":"hgnc:HGNC:1129","description":"BTF3 pseudogene 1","metadata":{"aliases":["HUMBTFA"]}},{"id":"3fcefb0563ba44c7aa2f7ea70ec76f53","type":"GENE","name":"BTF3P10","canonical_id":"hgnc:HGNC:38570","description":"basic transcription factor 3 pseudogene 10","metadata":{"aliases":["RAET1J"]}},{"id":"a74a0d7708dd45658178fcadf694974a","type":"GENE","name":"BTF3P11","canonical_id":"hgnc:HGNC:1126","description":"basic transcription factor 3 pseudogene 11","metadata":{"aliases":["HUMBTFB","TNFRSF11B","OPG","OCIF","BTF3L1"]}},{"id":"906b29005dce4c06804fc17ec51671ca","type":"GENE","name":"BTF3P12","canonical_id":"hgnc:HGNC:1127","description":"basic transcription factor 3 pseudogene 12","metadata":{"aliases":["HUMBTFC","BTF3L2"]}},{"id":"afab3cea5de6433dad6407321cdbb237","type":"GENE","name":"BTF3P13","canonical_id":"hgnc:HGNC:1128","description":"basic transcription factor 3 pseudogene 13","metadata":{"aliases":["HUMBTFD","BTF3L3"]}},{"id":"b750c28b3b064fd2abb60eae1ad35ac5","type":"GENE","name":"BTF3P14","canonical_id":"hgnc:HGNC:38571","description":"basic transcription factor 3 pseudogene 14","metadata":null},{"id":"4dc64c30c0cb402dbb7b9cebefc4a9c6","type":"GENE","name":"BTF3P15","canonical_id":"hgnc:HGNC:38567","description":"basic transcription factor 3 pseudogene 15","metadata":null},{"id":"6c03430661b04c029b108c56c94ef24f","type":"GENE","name":"BTF3P16","canonical_id":"hgnc:HGNC:38568","description":"basic transcription factor 3 pseudogene 16","metadata":null},{"id":"91438b1f4e6b4fa8a42b7db0bcdb9f97","type":"GENE","name":"BTF3P2","canonical_id":"hgnc:HGNC:19924","description":"BTF3 pseudogene 2","metadata":null},{"id":"f61d2720660442bf8da883a8ecfc07b7","type":"GENE","name":"BTF3P3","canonical_id":"hgnc:HGNC:31100","description":"BTF3 pseudogene 3","metadata":null},{"id":"f5386eb4f5e44169b2c6359b25045347","type":"GENE","name":"BTF3P4","canonical_id":"hgnc:HGNC:38566","description":"basic transcription factor 3 pseudogene 4","metadata":null},{"id":"1f8177fdd1384fb3bdf4651d0efb0caa","type":"GENE","name":"BTF3P5","canonical_id":"hgnc:HGNC:38565","description":"basic transcription factor 3 pseudogene 5","metadata":null},{"id":"26b17add7feb4aa88ef209e2eb39c0de","type":"GENE","name":"BTF3P6","canonical_id":"hgnc:HGNC:23765","description":"basic transcription factor 3 pseudogene 6","metadata":null},{"id":"0a37d5a4cf07479490f7d079cf02d9b7","type":"GENE","name":"BTF3P7","canonical_id":"hgnc:HGNC:38569","description":"basic transcription factor 3 pseudogene 7","metadata":null},{"id":"760ff77790dc494a9e5deddbdaf9cd28","type":"GENE","name":"BTF3P8","canonical_id":"hgnc:HGNC:38572","description":"basic transcription factor 3 pseudogene 8","metadata":null},{"id":"8750fc3b83ff4e9f889ea43d10b73f57","type":"GENE","name":"BTF3P9","canonical_id":"hgnc:HGNC:38573","description":"basic transcription factor 3 pseudogene 9","metadata":null},{"id":"033ab132b2944155be21eb37760c5cc9","type":"GENE","name":"BTG1","canonical_id":"hgnc:HGNC:1130","description":null,"metadata":null},{"id":"967a65b771734321abafeb3eace9f9b7","type":"GENE","name":"BTG1-DT","canonical_id":"hgnc:HGNC:55600","description":"BTG1 divergent transcript","metadata":null},{"id":"2b97d21aad3a49b99af68e3f41dddbf9","type":"GENE","name":"BTG1P1","canonical_id":"hgnc:HGNC:37692","description":"BTG anti-proliferation factor 1 pseudogene 1","metadata":null},{"id":"db037ee5e65d4a039f6cbf8039a6007c","type":"GENE","name":"BTG2","canonical_id":"hgnc:HGNC:1131","description":null,"metadata":null},{"id":"5e002899e2c0421d9c7b548888625c1f","type":"GENE","name":"BTG2-DT","canonical_id":"hgnc:HGNC:49452","description":"BTG2 divergent transcript","metadata":{"aliases":["LINC01136"]}},{"id":"7098a16aa240438ab1c2c9250c78dac8","type":"GENE","name":"BTG3","canonical_id":"hgnc:HGNC:1132","description":null,"metadata":null},{"id":"11b42543f9de46e0b0267ca4a616f7fc","type":"GENE","name":"BTG3-AS1","canonical_id":"hgnc:HGNC:53145","description":"BTG3 antisense RNA 1","metadata":{"aliases":["ASBEL"]}},{"id":"057d3c294ef34630a706200bff81e732","type":"GENE","name":"BTG3P1","canonical_id":"hgnc:HGNC:51543","description":"BTG anti-proliferation factor 3 pseudogene 1","metadata":null},{"id":"cfe9bd63d4874695a01e9ac1d4a9cfd4","type":"GENE","name":"BTG4","canonical_id":"hgnc:HGNC:13862","description":"BTG anti-proliferation factor 4","metadata":{"aliases":["PC3B","APRO3"]}},{"id":"3a89e5f339ca4af6b119b78c373729b4","type":"GENE","name":"BTG4P1","canonical_id":"hgnc:HGNC:51544","description":"BTG anti-proliferation factor 4 pseudogene 1","metadata":null},{"id":"46a0c19715374673ad49c97eb1c4eb3c","type":"GENE","name":"BTK","canonical_id":"hgnc:HGNC:1133","description":null,"metadata":null},{"id":"93c84bd263d24c5295193e79c7c8aa17","type":"PROTEIN","name":"BTK","canonical_id":"uniprot:Q06187","description":null,"metadata":null},{"id":"7c3f098da46d447d90e230e37d099e53","type":"GENE","name":"BTK","canonical_id":"ensembl:ENSG00000010671","description":null,"metadata":null},{"id":"6610ae675817439abaddab9d63d5ffac","type":"GENE","name":"BTLA","canonical_id":"hgnc:HGNC:21087","description":"B and T lymphocyte associated","metadata":{"aliases":["BTLA1","CD272"]}},{"id":"9ead0df62ae04041a401b004b062ae3e","type":"GENE","name":"BTN1A1","canonical_id":"hgnc:HGNC:1135","description":"butyrophilin subfamily 1 member A1","metadata":{"aliases":["BT","BTN1","BTN"]}},{"id":"755df44d11294c4798282016daf41706","type":"GENE","name":"BTN1A1P1","canonical_id":"hgnc:HGNC:51545","description":"butyrophilin subfamily 1 member A1 pseudogene 1","metadata":null},{"id":"e681f7b5193043eabefb896bc0eef59a","type":"GENE","name":"BTN2A1","canonical_id":"hgnc:HGNC:1136","description":"butyrophilin subfamily 2 member A1","metadata":{"aliases":["BT2.1","BTF1","BTN2.1"]}},{"id":"5609aae09db747e89b61dd1defcd941e","type":"GENE","name":"BTN2A2","canonical_id":"hgnc:HGNC:1137","description":"butyrophilin subfamily 2 member A2","metadata":{"aliases":["BTF2","BT2.2","BTN2.2"]}},{"id":"90cd9e8219254c04afbaf52525fdbe54","type":"GENE","name":"BTN2A3P","canonical_id":"hgnc:HGNC:13229","description":"butyrophilin subfamily 2 member A3, pseudogene","metadata":{"aliases":["BTN2.3","BTN2A3"]}},{"id":"d4e3a32f64294a8d8f8809a034fe7de1","type":"GENE","name":"BTN3A1","canonical_id":"hgnc:HGNC:1138","description":"butyrophilin subfamily 3 member A1","metadata":{"aliases":["BT3.1","BTF5","CD277","BTN3.1"]}},{"id":"c115a11f9b1e4da4b8396c3618f61bd3","type":"GENE","name":"BTN3A2","canonical_id":"hgnc:HGNC:1139","description":"butyrophilin subfamily 3 member A2","metadata":{"aliases":["BTN3.2"]}},{"id":"3b71ab7112d5483586c37cafef9cd460","type":"GENE","name":"BTN3A3","canonical_id":"hgnc:HGNC:1140","description":"butyrophilin subfamily 3 member A3","metadata":{"aliases":["BTF3","BTN3.3"]}},{"id":"092907e716eb43eea0e328a93d4d4a61","type":"GENE","name":"BTNL10P","canonical_id":"hgnc:HGNC:42540","description":"butyrophilin like 10, pseudogene","metadata":{"aliases":["BUTR1","BTN4","BTNL10"]}},{"id":"44bc06fb17f5473ea0abce7d639e3deb","type":"GENE","name":"BTNL12P","canonical_id":"hgnc:HGNC:52935","description":"butyrophilin like 12, pseudogene","metadata":{"aliases":["LRRC58-DT"]}},{"id":"36a1122055984fdaa18dbb29f63fad5f","type":"GENE","name":"BTNL2","canonical_id":"hgnc:HGNC:1142","description":"butyrophilin like 2","metadata":{"aliases":["HSBLMHC1","BTL-II","BTN7"]}},{"id":"d13c6a5d8cf347d8aa7a08419b282e50","type":"GENE","name":"BTNL3","canonical_id":"hgnc:HGNC:1143","description":"butyrophilin like 3","metadata":{"aliases":["BTNLR","BTN9.1"]}},{"id":"29df2de17bf54f63a6ce8aa2f3116ee6","type":"GENE","name":"BTNL8","canonical_id":"hgnc:HGNC:26131","description":"butyrophilin like 8","metadata":{"aliases":["FLJ21458","BTN9.2"]}},{"id":"8531fada7d224599bc5ede578f069a8b","type":"GENE","name":"BTNL9","canonical_id":"hgnc:HGNC:24176","description":"butyrophilin like 9","metadata":{"aliases":["FLJ32535","BTN8"]}},{"id":"48aabcd3bf864409ab78fb143a7e015e","type":"GENE","name":"BTRC","canonical_id":"hgnc:HGNC:1144","description":null,"metadata":null},{"id":"09a769f8eb6b4f95b23bb7953cced154","type":"GENE","name":"BTRCP1","canonical_id":"hgnc:HGNC:51546","description":"beta-transducin repeat containing E3 ubiquitin protein ligase pseudogene 1","metadata":null},{"id":"8812fe10019f4126ba0626b2dc48034c","type":"GENE","name":"BUB1","canonical_id":"hgnc:HGNC:1148","description":"BUB1 mitotic checkpoint serine/threonine kinase","metadata":{"aliases":["hBUB1","BUB1A","BUB1L"]}},{"id":"dc9e6bc997f5489d8e792233e11bf911","type":"GENE","name":"BUB1B","canonical_id":"hgnc:HGNC:1149","description":null,"metadata":null},{"id":"57c2417985f741c181eafe61f8d635c6","type":"GENE","name":"BUB1B-PAK6","canonical_id":"hgnc:HGNC:52276","description":"BUB1B-PAK6 readthrough","metadata":null},{"id":"49df1e13c7f04828b37883b8409846f5","type":"GENE","name":"BUB1P1","canonical_id":"hgnc:HGNC:49529","description":"BUB1 mitotic checkpoint serine/threonine kinase pseudogene 1","metadata":null},{"id":"515c542d02854b2ebf494c676dea41b7","type":"GENE","name":"BUB3","canonical_id":"hgnc:HGNC:1151","description":"BUB3 mitotic checkpoint protein","metadata":{"aliases":["BUB3L"]}},{"id":"cc92a4fdd2a04ff88867d155d4f01d0e","type":"GENE","name":"BUB3P1","canonical_id":"hgnc:HGNC:51559","description":"BUB3 mitotic checkpoint protein pseudogene 1","metadata":null},{"id":"93e33edf1aaa4849ae7b68f2fc538ab3","type":"GENE","name":"BUD13","canonical_id":"hgnc:HGNC:28199","description":"BUD13 spliceosome associated protein","metadata":{"aliases":["MGC13125","fSAP71","Cwc26"]}},{"id":"c1624f47e4db452f8d5a3d98cbe3ac6b","type":"GENE","name":"BUD13-DT","canonical_id":"hgnc:HGNC:55834","description":"BUD13 divergent transcript","metadata":null},{"id":"cad7ccb0587b4298979149d06add1876","type":"GENE","name":"BUD13P1","canonical_id":"hgnc:HGNC:51560","description":"BUD13 homolog pseudogene 1","metadata":null},{"id":"ec3acf32632c430ca8b1a357631db984","type":"GENE","name":"BUD23","canonical_id":"hgnc:HGNC:16405","description":"BUD23 rRNA methyltransferase and ribosome maturation factor","metadata":{"aliases":["MGC19709","MGC2022","MGC5140","PP3381","WBMT","MERM1","WBSCR22"]}},{"id":"592488139b8043ec96ce0c90fd81d416","type":"GENE","name":"BUD31","canonical_id":"hgnc:HGNC:29629","description":"BUD31 spliceosome associated protein","metadata":{"aliases":["YCR063W","EDG-2","EDG2","fSAP17","Cwc14","G10"]}},{"id":"0ecf0971cb3f4cc5bc945184616a8dd4","type":"GENE","name":"BUD31P1","canonical_id":"hgnc:HGNC:51561","description":"BUD31 homolog pseudogene 1","metadata":null},{"id":"3b5274d1957f494793c534f90ae3b4bb","type":"GENE","name":"BUD31P2","canonical_id":"hgnc:HGNC:51562","description":"BUD31 homolog pseudogene 2","metadata":null},{"id":"ea9f88b44e534e18ae1a929fd1b9fec1","type":"TRIAL","name":"BUILD 3: Bosentan Use in Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT00391443","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"f4984582e4bb4b30bde0c470f52b9f2e","type":"TRIAL","name":"BUSCLAB - Buscopan to Prevent Slow Progress in Labor","canonical_id":"clinicaltrials.gov:NCT03961165","description":"Labor (Obstetrics)--Complications; Labor; Prolonged, First Stage","metadata":null},{"id":"fc8c1be5bd09483ab45f4cc52ec48738","type":"TRIAL","name":"BV After Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT03540849","description":"Hodgkin Lymphoma","metadata":null},{"id":"7e4b9be3917045509f55dbbbce22eb06","type":"GENE","name":"BVR1","canonical_id":"hgnc:HGNC:1153","description":"Burkitt lymphoma variant rearranging region 1","metadata":null},{"id":"716fb5d5b79d4b3daaf63c498eee91ac","type":"TRIAL","name":"BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01870505","description":"Metastatic or Locally-advanced Unresectable Breast Cancer","metadata":null},{"id":"f6a893f51fa74a2da71a35e5fc5efe20","type":"TRIAL","name":"BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02379247","description":"Breast Cancer","metadata":null},{"id":"a79ad49f20d34f22a9320590d046b649","type":"GENE","name":"BYSL","canonical_id":"hgnc:HGNC:1157","description":"bystin like","metadata":{"aliases":["Enp1"]}},{"id":"5066979342d447a2910d0c98ba61e846","type":"GENE","name":"BZW1","canonical_id":"hgnc:HGNC:18380","description":"basic leucine zipper and W2 domains 1","metadata":{"aliases":["BZAP45","KIAA0005","5MP2"]}},{"id":"a1d5d5ea1af2424e99124afc4eef7c62","type":"GENE","name":"BZW1-AS1","canonical_id":"hgnc:HGNC:40839","description":"BZW1 antisense RNA 1","metadata":null},{"id":"80fbb8c6b0e14ecf9546ca23dd9f25a5","type":"GENE","name":"BZW1P1","canonical_id":"hgnc:HGNC:31378","description":"basic leucine zipper and W2 domains 1 pseudogene 1","metadata":null},{"id":"e5bc3dc097de4a80ad3459b049ee5ccc","type":"GENE","name":"BZW1P2","canonical_id":"hgnc:HGNC:33954","description":"basic leucine zipper and W2 domains 1 pseudogene 2","metadata":{"aliases":["BZW1L1"]}},{"id":"f6acd3de3cec408783d827c9c5c42755","type":"GENE","name":"BZW2","canonical_id":"hgnc:HGNC:18808","description":"basic leucine zipper and W2 domains 2","metadata":{"aliases":["HSPC028","MST017","MSTP017","5MP1"]}},{"id":"2bf3dfb07b70467c9de27a9e28b63b07","type":"DRUG","name":"Bacampicillin","canonical_id":"mesh:C011674","description":null,"metadata":null},{"id":"ba193165152b43e1832c3f8e71c1a4b5","type":"TRIAL","name":"Back Pain in Patients With Severe Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00761332","description":"Osteoporosis","metadata":null},{"id":"9817c16f49854cdf81f34481773ad311","type":"DISEASE","name":"Back pain","canonical_id":"hp:0003418","description":null,"metadata":null},{"id":"59fb72826d4f4384acc83c6c15cb20fc","type":"DISEASE","name":"Backache","canonical_id":"mesh:D001416","description":null,"metadata":null},{"id":"549c409a02ea43128c65932916f4c19d","type":"TRIAL","name":"Baclocur\u00ae Post-Authorisation Safety Study in Real-life Settings in France","canonical_id":"clinicaltrials.gov:NCT04679142","description":"Alcohol Use Disorder","metadata":null},{"id":"bfd939f3bbe042e2a84e83c6ef4d850c","type":"TRIAL","name":"Baclofen Effects on Smoking Urge and Withdrawal","canonical_id":"clinicaltrials.gov:NCT00257894","description":"Nicotine Use Disorder; Nicotine Dependence; Smoking; Tobacco Use Disorder","metadata":null},{"id":"7af2779b731741beaad21813ee4b389e","type":"TRIAL","name":"Baclofen Treatment of Ataxia Telangiectasia","canonical_id":"clinicaltrials.gov:NCT00640003","description":"Ataxia Telangiectasia","metadata":null},{"id":"cf44bd7c32f44c5f97d6a9e2dc9cab9f","type":"TRIAL","name":"Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence","canonical_id":"clinicaltrials.gov:NCT05935553","description":"Benzodiazepine Dependence","metadata":null},{"id":"3445aaed95614c0ba07e4eebbd9089a2","type":"TRIAL","name":"Baclofen for Rumination","canonical_id":"clinicaltrials.gov:NCT03113396","description":"Rumination; Supra-gastric Belching","metadata":null},{"id":"a9edb50c19a74b0490293dac5f08207a","type":"TRIAL","name":"Baclofen for Smoking Cessation in a Non-Psychiatric Population","canonical_id":"clinicaltrials.gov:NCT01228994","description":"Nicotine Dependence","metadata":null},{"id":"27b1cf24eaab415885859493cf6c3cb6","type":"TRIAL","name":"Baclofen for Treating Anxiety and Alcoholism","canonical_id":"clinicaltrials.gov:NCT01751386","description":"Alcoholism; Alcohol Dependence; Alcohol Drinking Related Problems; Alcohol Drinking; Anxiety Disorder","metadata":null},{"id":"0a3ac3fe8a5849fab4d799a6c9dbe129","type":"TRIAL","name":"Baclofen for the Treatment of Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT01266655","description":"Alcohol Dependence","metadata":null},{"id":"5909dcb4348342ed8852f4993b0946b3","type":"TRIAL","name":"Baclofen for the Treatment of Alcohol Drinkers","canonical_id":"clinicaltrials.gov:NCT01604330","description":"Alcoholism","metadata":null},{"id":"39bb199452f14e04bc5cc7d8afb7d283","type":"TRIAL","name":"Baclofen for the Treatment of Cocaine Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00082485","description":"Cocaine-Related Disorders","metadata":null},{"id":"a5be59a20cbb4e60b3f36b7ddb3fc0d3","type":"TRIAL","name":"Baclofen in Managing Acute Alcohol Withdrawal","canonical_id":"clinicaltrials.gov:NCT03293017","description":"Alcohol Use Disorder; Alcohol Withdrawal","metadata":null},{"id":"0444d875d15f44c49159c5940925c2a1","type":"TRIAL","name":"Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease","canonical_id":"clinicaltrials.gov:NCT01711125","description":"Alcoholic Liver Disease; Alcohol Dependence","metadata":null},{"id":"d59c1f80754e45ad9c06c05908a613c2","type":"TRIAL","name":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT00516503","description":"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"df9d1e3e4b3d4054affc0f8dacd27f0f","type":"DISEASE","name":"Bacterial Skin Diseases","canonical_id":"mesh:D017192","description":null,"metadata":null},{"id":"05141c7c758545be8571ed67c0e4aa30","type":"DISEASE","name":"Bacterial infection due to Serratia","canonical_id":"mesh:D016868","description":null,"metadata":null},{"id":"e1dc4c3f03b9439dba9b0eda727cf1e3","type":"DISEASE","name":"Bacterial meningitis","canonical_id":"mesh:D016920","description":null,"metadata":null},{"id":"139c9868a81848fc8e6677732b504750","type":"DISEASE","name":"Bacterial pneumonia","canonical_id":"mesh:D018410","description":null,"metadata":null},{"id":"69cafc49071a4ff8ba6e4a7ee86e0f82","type":"DISEASE","name":"Bacterial septicemia","canonical_id":"mesh:D018805","description":null,"metadata":null},{"id":"b2df3c73286c40e9becb25ac9d0b7e1a","type":"DISEASE","name":"Bacterial urinary infection","canonical_id":"mesh:D014552","description":null,"metadata":null},{"id":"6948a160d73e435bb91b1b282ba00276","type":"DISEASE","name":"Bacterial vaginosis","canonical_id":"mesh:D016585","description":null,"metadata":null},{"id":"a932b9573a4a4d268fc45d5d8fdb6dd1","type":"TRIAL","name":"Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial","canonical_id":"clinicaltrials.gov:NCT02433041","description":"Postoperative Delirium","metadata":null},{"id":"55d2f911ee464a2f8c18c9173ace04ba","type":"TRIAL","name":"Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine","canonical_id":"clinicaltrials.gov:NCT06736938","description":"Sedation During Bronchoscopy","metadata":null},{"id":"b1b7cba5948a4c248a8ec824603312a5","type":"GO_TERM","name":"Bam protein complex","canonical_id":"go:GO:1990063","description":"\"Protein complex which is involved in assembly and insertion of beta-barrel proteins into the outer membrane. In E. coli it is composed of BamABCDE, of the outer membrane protein BamA, and four lipoproteins BamB, BamC, BamD and BamE. BamA interacts directly with BamB and the BamCDE subcomplex.\" [GOC:bhm, PMID:20378773]","metadata":null},{"id":"742a300d8db148ac8a4f2b8d04ae0ad3","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Apixaban","canonical_id":"clinicaltrials.gov:NCT03448783","description":"Obesity, Morbid","metadata":null},{"id":"658b48d073f74f9ab1652b157b9e37de","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Atomoxetine","canonical_id":"clinicaltrials.gov:NCT03460210","description":"Obesity, Morbid","metadata":null},{"id":"d11c195fba734a2eb3431dfd9b601229","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Enalapril","canonical_id":"clinicaltrials.gov:NCT03460366","description":"Obesity, Morbid","metadata":null},{"id":"14c2658378ad446fb0b3399fabf7daf2","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Fluoxetine","canonical_id":"clinicaltrials.gov:NCT03476525","description":"Obesity, Morbid","metadata":null},{"id":"d94954f810e84bf6badaf14cdaf4e0e1","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Losartan","canonical_id":"clinicaltrials.gov:NCT03519893","description":"Obesity, Morbid","metadata":null},{"id":"508590ffc3024e98816d138f713f8689","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Methylphenidate","canonical_id":"clinicaltrials.gov:NCT03440190","description":"Obesity, Morbid","metadata":null},{"id":"9d274ffdb3b4452caa8b425bda725640","type":"TRIAL","name":"Bariatric Surgery and Pharmacokinetics of Venlafaxine","canonical_id":"clinicaltrials.gov:NCT03532477","description":"Obesity, Morbid","metadata":null},{"id":"87bb398cb12d4cbdb702b77a63915020","type":"TRIAL","name":"Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus","canonical_id":"clinicaltrials.gov:NCT05188521","description":"Cutaneous Lichen Planus","metadata":null},{"id":"31cf7caec8644f159f7cc7bbfc23425b","type":"TRIAL","name":"Baricitinib Curative Repression of HIV-1","canonical_id":"clinicaltrials.gov:NCT07209267","description":"HIV Infection; HIV","metadata":null},{"id":"5cba7d61ba5e4f458f38718a2dd0c147","type":"TRIAL","name":"Baricitinib for Post-HSCT Persistent Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT07535645","description":"Persistent Thrombocytopenia; Allogeneic Hematopoietic Stem Cell Transplantation","metadata":null},{"id":"922005da8c434b409fb26e4c39c95f32","type":"TRIAL","name":"Baricitinib for Refractory Takayasu Arteritis","canonical_id":"clinicaltrials.gov:NCT06662721","description":"Takayasu Arteritis","metadata":null},{"id":"7f3e916940664a609d96332af30bd345","type":"TRIAL","name":"Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT04131738","description":"Graft-versus-host-disease; Graft Vs Host Disease","metadata":null},{"id":"04080ce17ecd4305badf6b6bdab46558","type":"TRIAL","name":"Baricitinib in New-onset Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT04774224","description":"Type 1 Diabetes","metadata":null},{"id":"a0618c9f10c3488981d02eaee9b485e3","type":"TRIAL","name":"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","canonical_id":"clinicaltrials.gov:NCT04320277","description":"Pharmacological Action","metadata":null},{"id":"aac6258e455443b39f43acf745ebbf0e","type":"TRIAL","name":"Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial","canonical_id":"clinicaltrials.gov:NCT05827497","description":"Rheumatoid Arthritis","metadata":null},{"id":"45584f0a00fc44539b835e25fb653634","type":"GO_TERM","name":"Barr body","canonical_id":"go:GO:0001740","description":"\"A structure found in a female mammalian cell containing an unpaired X chromosome that has become densely heterochromatic, silenced and localized at the nuclear periphery.\" [GOC:hjd, GOC:mr, NIF_Subcellular:sao1571698684]","metadata":null},{"id":"3a065077a21e4c8184231713d9f71759","type":"DISEASE","name":"Barrett's Adenocarcinoma","canonical_id":"doid:7941","description":null,"metadata":null},{"id":"42ae21ebfa3c43849ac53e281f3501bd","type":"TRIAL","name":"Barrett's Esophagus - 315 - 3 Way Cross Over","canonical_id":"clinicaltrials.gov:NCT00637988","description":"Barrett's Esophagus","metadata":null},{"id":"3893fa3a13b34022876518f9688a73b0","type":"DISEASE","name":"Bartonella Infections","canonical_id":"mesh:D001474","description":null,"metadata":null},{"id":"1c42ff3f294a43f1b17703df219f3722","type":"DISEASE","name":"Bartter disease type 1","canonical_id":"mondo:0100344","description":null,"metadata":null},{"id":"48a417d928d04fc4b56d8fe0cd6adf00","type":"DISEASE","name":"Bartter syndrome","canonical_id":"mondo:0015231","description":null,"metadata":null},{"id":"591829a1e2494e219ef0ee0855f48f62","type":"DISEASE","name":"Bartter syndrome with hypocalcemia","canonical_id":"mondo:0016983","description":null,"metadata":null},{"id":"6a2fd95a0bdd473daa2f076f675b22b6","type":"TRIAL","name":"Basal Cell Carcinoma Chemoprevention Trial","canonical_id":"clinicaltrials.gov:NCT05212246","description":"Basal Cell Carcinoma","metadata":null},{"id":"ee79711035904ff1b696d3eb732d3963","type":"TRIAL","name":"Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate","canonical_id":"clinicaltrials.gov:NCT03569345","description":"Carcinoma, Basal Cell","metadata":null},{"id":"c657ed4b0ee54d6ba83025130078f464","type":"DISEASE","name":"Basal Ganglia Diseases","canonical_id":"mesh:D001480","description":null,"metadata":null},{"id":"91e0d5ce10904a198bcfba59fa568086","type":"TRIAL","name":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","canonical_id":"clinicaltrials.gov:NCT06959771","description":"CD40L-HyperIgM Syndrome","metadata":null},{"id":"023e3870f5f446adbc5c356bbc5c65db","type":"TRIAL","name":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","canonical_id":"clinicaltrials.gov:NCT06325709","description":"Chronic Granulomatous Disease (CGD); X-Linked Chronic Granulomatous Disease","metadata":null},{"id":"8ef1fa89f18c4b188096c844771fc119","type":"TRIAL","name":"Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM","canonical_id":"clinicaltrials.gov:NCT07775313","description":"WHIM; Warts; Hypogammaglobulinemia; Immunodeficiency; Myelokathexis","metadata":null},{"id":"7a7ec16b51a747e3aeb6070bd6f93ba4","type":"TRIAL","name":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","canonical_id":"clinicaltrials.gov:NCT06851767","description":"X-linked Severe Combined Immunodeficiency; X-SCID; XSCID","metadata":null},{"id":"b14cf27ea9ea47118b56b8ed4e3d9914","type":"TRIAL","name":"Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders","canonical_id":"clinicaltrials.gov:NCT01571609","description":"Hyperlipidemia; Diabetes Mellitus; Metabolic Syndrome; Arterial Hypertension; Obesity","metadata":null},{"id":"821b66682adb4171bdba387e0f89a5f6","type":"TRIAL","name":"Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00663442","description":"ADHD","metadata":null},{"id":"7bcbf95ede2445db9542f5720d13f7f6","type":"TRIAL","name":"Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT06236230","description":"Parkinson Disease","metadata":null},{"id":"53e51495e8cf4b6aa2df0d01961edf13","type":"TRIAL","name":"Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD","canonical_id":"clinicaltrials.gov:NCT05021276","description":"Safety and Efficacy","metadata":null},{"id":"5d85fcf1ed644fb5b655608938c65498","type":"TRIAL","name":"Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","canonical_id":"clinicaltrials.gov:NCT01953926","description":"Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","metadata":null},{"id":"9323327383c54f8483978d9ffea74f98","type":"TRIAL","name":"Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT04480359","description":"Ankylosing Spondylitis","metadata":null},{"id":"4793bf2df4b2487fb97a208c57e48b80","type":"TRIAL","name":"Bazedoxifene -Treatment for Women With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT04113993","description":"Schizophrenia; Schizophreniform Disorders; Schizo Affective Disorder","metadata":null},{"id":"8c489a9f92da46a5973300dd1fe064a4","type":"TRIAL","name":"Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04002934","description":"Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"93bda55f4d60435594419739f600f573","type":"TRIAL","name":"Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)","canonical_id":"clinicaltrials.gov:NCT01416194","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"828a11ccd2984446b01a0cde9685838d","type":"TRIAL","name":"Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04812808","description":"Pancreas Cancer","metadata":null},{"id":"641eb4261c7b42fa9a9c92fd35b618be","type":"TRIAL","name":"Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)","canonical_id":"clinicaltrials.gov:NCT02237079","description":"Obesity; Glucose Homeostasis; Postmenopausal Symptoms","metadata":null},{"id":"29fbe7e4438744f1b6431da01171e82b","type":"GO_TERM","name":"Bcl-2 family protein complex","canonical_id":"go:GO:0097136","description":"\"A protein complex that consists of members of the Bcl-2 family of anti- and proapoptotic regulators. Bcl-2 proteins respond to cues from various forms of intracellular stress, such as DNA damage or cytokine deprivation, and interact with opposing family members to determine whether or not the caspase proteolytic cascade should be unleashed.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"cb3940c7b5c8400c873351b6ed7ea7be","type":"GO_TERM","name":"Bcl3-Bcl10 complex","canonical_id":"go:GO:0032996","description":"\"A protein complex containing Bcl3 and Bcl10, which forms when Akt1 is activated by TNF-alpha to phosphorylate Bcl10; the Bcl3-Bcl10 complex is translocated to the nucleus.\" [PMID:16280327]","metadata":null},{"id":"4f951bdc5e61422ab49c98b12de2f3ea","type":"GO_TERM","name":"Bcl3/NF-kappaB2 complex","canonical_id":"go:GO:0033257","description":"\"A protein complex containing one Bcl protein and one or more copies of NF-kappaB2; formation of complexes of different stoichiometry depends on the Bcl3:NF-kappaB2 ratio, and allow Bcl3 to exert different regulatory effects on NF-kappaB2-dependent transcription.\" [GOC:mah, PMID:9407099]","metadata":null},{"id":"c8aaa1450eb24610bf5da98adc724d91","type":"DISEASE","name":"Beare-Stevenson cutis gyrata syndrome","canonical_id":"mondo:0007412","description":null,"metadata":null},{"id":"69308164509044d3b2c40712848cddd9","type":"TRIAL","name":"Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II","canonical_id":"clinicaltrials.gov:NCT07686926","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"763e0e2dc3ae43e899a4876ad62f9715","type":"DISEASE","name":"Bedaquiline","canonical_id":"mesh:C493870","description":null,"metadata":null},{"id":"039fd1f8d4654e49a3b29519a17ed32e","type":"TRIAL","name":"Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05007938","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"5945f2ba5c754c33a06f232f975684ce","type":"DRUG","name":"Befunolol","canonical_id":"mesh:C006034","description":null,"metadata":null},{"id":"47aa5c9d08a5411c9d98c7f5bbca9875","type":"TRIAL","name":"Behavioral Therapy Plus Naltrexone for Alcoholism","canonical_id":"clinicaltrials.gov:NCT00000456","description":"Alcoholism; Alcohol Dependence","metadata":null},{"id":"f47e9ff0c6ae471683ed79dfa43478fa","type":"TRIAL","name":"Behavioral and Pharmacological Treatment for Insomnia","canonical_id":"clinicaltrials.gov:NCT00042146","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"163fd3c69a854f04893e9fd2ccafd9e8","type":"TRIAL","name":"Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse","canonical_id":"clinicaltrials.gov:NCT00671632","description":"Drug Abuse","metadata":null},{"id":"808bc1b90d0f45fb85c4687a02347583","type":"TRIAL","name":"Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT03149809","description":"Overactive Bladder; Parkinson Disease","metadata":null},{"id":"1996541b473a4daebbc15f17d17412da","type":"DISEASE","name":"Behcet disease","canonical_id":"mondo:0007191","description":null,"metadata":null},{"id":"3c94db98248e49459eb59c1f019188d5","type":"TRIAL","name":"Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study","canonical_id":"clinicaltrials.gov:NCT03401619","description":"Osteoporosis\uff0cNeurological Disorders","metadata":null},{"id":"19f3834ec4cb4840bcb59a3a96abb302","type":"TRIAL","name":"Bela 8 Week Dosing","canonical_id":"clinicaltrials.gov:NCT02560558","description":"Kidney Transplantation","metadata":null},{"id":"34144f9261094147a73ecf0699913d62","type":"TRIAL","name":"Belatacept 3 Month Post Transplant Conversion Study","canonical_id":"clinicaltrials.gov:NCT02213068","description":"Transplant; Failure, Kidney; EBV","metadata":null},{"id":"74505e055782467fbecd27f8e9603890","type":"TRIAL","name":"Belatacept Early Steroid Withdrawal Trial","canonical_id":"clinicaltrials.gov:NCT01729494","description":"Renal Transplantation","metadata":null},{"id":"f524871ff8c44bc481ee21b2924929ab","type":"TRIAL","name":"Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)","canonical_id":"clinicaltrials.gov:NCT00256750","description":"Kidney Transplantation; Chronic Kidney Failure","metadata":null},{"id":"68b9f2712a2d454d92a22392746e4638","type":"TRIAL","name":"Belatacept Pharmacokinetic Trial in Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00578448","description":"Renal Transplantation","metadata":null},{"id":"ba4355d23fca4eafaa2124aa486998e5","type":"TRIAL","name":"Belatacept Post Depletional Repopulation to Facilitate Tolerance","canonical_id":"clinicaltrials.gov:NCT00565773","description":"Organ Transplantation","metadata":null},{"id":"957791632c5b4d098c236c253d730fde","type":"TRIAL","name":"Belatacept Therapy for the Failing Renal Allograft","canonical_id":"clinicaltrials.gov:NCT01921218","description":"Failing Renal Allograft","metadata":null},{"id":"b440bdd2803d4bcd9c6b755bf7e20745","type":"TRIAL","name":"Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction","canonical_id":"clinicaltrials.gov:NCT05562869","description":"Chronic Kidney Failure","metadata":null},{"id":"bcccff951cec4e05a8b21b0c6a46f791","type":"TRIAL","name":"Belatacept in De Novo Heart Transplantation","canonical_id":"clinicaltrials.gov:NCT04477629","description":"Heart Transplantation","metadata":null},{"id":"0d8d5526bda54005940ce3f8dc56e2e3","type":"TRIAL","name":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","canonical_id":"clinicaltrials.gov:NCT02130817","description":"End Stage Renal Disease; Antibody Mediated Rejection","metadata":null},{"id":"7303e55850864e4caab13f825a221dd9","type":"TRIAL","name":"Belatacept in Liver Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00555321","description":"Immunosuppression in Solid Organ Transplant","metadata":null},{"id":"f5a4ce2ee7f64a53831348176b164874","type":"TRIAL","name":"Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores","canonical_id":"clinicaltrials.gov:NCT01496417","description":"End-Stage Renal Disease","metadata":null},{"id":"441a39ef49b74cbfb621741bd7b163ee","type":"TRIAL","name":"Belatacept to Prevent Organ Rejection in Kidney Transplant Patients","canonical_id":"clinicaltrials.gov:NCT00346151","description":"Renal Transplant","metadata":null},{"id":"e6ae54209af74fd58cf94c54cd7bb2c2","type":"TRIAL","name":"Belgian Drug-utilization Study to Evaluate the Use of VIMPAT\u00ae as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older","canonical_id":"clinicaltrials.gov:NCT01236001","description":"Seizures","metadata":null},{"id":"22ee2371403d4d79869d0f1cc56d73bd","type":"TRIAL","name":"Belimumab (BENLYSTA\u00ae) Pregnancy Registry","canonical_id":"clinicaltrials.gov:NCT01532310","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"4c50127b19264a8080b9270f07b2a4be","type":"TRIAL","name":"Belimumab After Rituximab in Resistant Primary Juvenile SS","canonical_id":"clinicaltrials.gov:NCT06410833","description":"Sjogren's Syndrome; Pediatric ALL","metadata":null},{"id":"82492de9ed5848ffab5ab0b0b7a8d623","type":"TRIAL","name":"Belimumab Assessment of Safety in SLE","canonical_id":"clinicaltrials.gov:NCT01705977","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"35795260df774097bb54f23e1bf58d47","type":"TRIAL","name":"Belimumab In Early Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT04956484","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"6ef8e7412f3b40419a0d5bef715bc5d3","type":"TRIAL","name":"Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT02880852","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"a5757658c3974b89a799a4ebe78a89b4","type":"TRIAL","name":"Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients","canonical_id":"clinicaltrials.gov:NCT02119156","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"1a376c2d35e644719f13c48c205aca53","type":"TRIAL","name":"Belimumab Treatment for IgG4-related Disease","canonical_id":"clinicaltrials.gov:NCT04660565","description":"IgG4-related Disease","metadata":null},{"id":"49eb536b43fe457ea94676e36096ffdb","type":"TRIAL","name":"Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies","canonical_id":"clinicaltrials.gov:NCT03244059","description":"Chronic Obstructive Pulmonary Disease; Emphysema","metadata":null},{"id":"6c00e6a03ca84f6a9b5903d9c141359b","type":"TRIAL","name":"Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT03207958","description":"Graft Vs Host Disease; Graft-versus-host-disease","metadata":null},{"id":"2d8581c0bfc54a07aab1c3b40d9d9973","type":"TRIAL","name":"Belimumab in Patients with Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT05069051","description":"Chronic Lymphoid Leukemia in Relapse","metadata":null},{"id":"05f71e9d3d6c44e59c95e36b4d890272","type":"TRIAL","name":"Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized","canonical_id":"clinicaltrials.gov:NCT07539857","description":"Kidney Transplant Rejection","metadata":null},{"id":"deb36a4f206f4eacaa31ee533dd2087a","type":"TRIAL","name":"Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL","canonical_id":"clinicaltrials.gov:NCT01686165","description":"Anaplastic Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma","metadata":null},{"id":"f84a92d66ca044fc8d7d27bc83235a93","type":"TRIAL","name":"Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07691450","description":"Recurrent Anaplastic Large Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type; Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymph\u2026","metadata":null},{"id":"ccde1d56e38c4ce5b0d0226897ef4dfb","type":"TRIAL","name":"Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee","canonical_id":"clinicaltrials.gov:NCT00163254","description":"Patients Above 18 Years","metadata":null},{"id":"694307d5e7b74dbaa22401735cdf012f","type":"TRIAL","name":"Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD","canonical_id":"clinicaltrials.gov:NCT07794514","description":"Hematopoietic Stem Cell Transplantation (HSCT); cGVHD; Hepatic cGVHD; Belumosudil; Ruxolitinib","metadata":null},{"id":"e39334de34144022aec8351d8e681502","type":"TRIAL","name":"Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)","canonical_id":"clinicaltrials.gov:NCT07643025","description":"cGVHD","metadata":null},{"id":"7479c0c8ad9b481b8126b3e0fa7d7bd6","type":"TRIAL","name":"Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","canonical_id":"clinicaltrials.gov:NCT06046248","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"3adc4d1ceade4fb18ddb131799daa0b5","type":"TRIAL","name":"Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT06751602","description":"Rejection Chronic Renal","metadata":null},{"id":"60034536a8b143e8819d3aa3bb3adde1","type":"TRIAL","name":"Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT05996627","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"204df1e9a62f41c1b9e4728f37e9ee54","type":"TRIAL","name":"Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT06476132","description":"Lung Transplant","metadata":null},{"id":"f64185e398c340eaac49be429580280d","type":"TRIAL","name":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","canonical_id":"clinicaltrials.gov:NCT05111626","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"eeec3b1f1fb24717a7e0341802658d24","type":"TRIAL","name":"Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy","canonical_id":"clinicaltrials.gov:NCT06680622","description":"Metastatic Gastro-esophageal Adenocarcinoma","metadata":null},{"id":"e1dddd9fa9ef4994a69906f645b74631","type":"DRUG","name":"Bemiparin","canonical_id":"mesh:C411345","description":null,"metadata":null},{"id":"bcee32fa51164452b2cb0ec07589b688","type":"TRIAL","name":"Benazepril HCl 40 mg Tablets, Fasting","canonical_id":"clinicaltrials.gov:NCT00836576","description":"Healthy","metadata":null},{"id":"1cc1e257b6d94fb8bd571f5b9029856c","type":"TRIAL","name":"Benazepril HCl 40 mg Tablets, Fed","canonical_id":"clinicaltrials.gov:NCT00836537","description":"Healthy","metadata":null},{"id":"21cf5749d3884d9ba978935b5f868846","type":"TRIAL","name":"Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01234922","description":"Hypertension; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"cc6d74dd9e424b34bdd686d383a239d9","type":"TRIAL","name":"Benazepril for Advanced Chronic Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT00270426","description":"Chronic Kidney Failure","metadata":null},{"id":"03738184ca324f7cb5f1f536fb72018e","type":"TRIAL","name":"Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01234467","description":"Diffuse Large B-Cell Lymphoma; Lymphoma, Diffuse Large-Cell; Diffuse Large-Cell Lymphoma; Lymphoma","metadata":null},{"id":"b7033f8bc19540b9acca10031fa993aa","type":"TRIAL","name":"Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02224729","description":"Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma","metadata":null},{"id":"cac0efd8478a42ad8279f389d52ca7d0","type":"TRIAL","name":"Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting","canonical_id":"clinicaltrials.gov:NCT02499627","description":"Lymphatic Diseases","metadata":null},{"id":"ca3d61de8daf49148143a80a077bedf2","type":"DRUG","name":"Bendroflumethiazide","canonical_id":"mesh:D001539","description":null,"metadata":null},{"id":"451a315d06bc4a05a631c4438bd0144e","type":"TRIAL","name":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","canonical_id":"clinicaltrials.gov:NCT02286414","description":"Atrial Fibrillation","metadata":null},{"id":"effee0bacf874b66b9696e8dc1dcd986","type":"TRIAL","name":"Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT06299540","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"c309063bcc5a41a79a17032994f97b99","type":"TRIAL","name":"Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT02646397","description":"Chronic Kidney Disease","metadata":null},{"id":"7d39bcd80e3a41f095a3c25ca96480f3","type":"TRIAL","name":"Benign Prostatic Hyperplasia in Taiwan","canonical_id":"clinicaltrials.gov:NCT00941343","description":"Prostatic Diseases","metadata":null},{"id":"eafbe6ea6c1448c19d5b4fa87208a6ef","type":"DISEASE","name":"Benign intracranial hypertension","canonical_id":"mesh:D011559","description":null,"metadata":null},{"id":"3218fef1bdbe4eb3b1da05a9a727f022","type":"DISEASE","name":"Benign prostatic hyperplasia","canonical_id":"mesh:D011470","description":null,"metadata":null},{"id":"f48255abe1ba41ec86e93cabd40ddff2","type":"TRIAL","name":"Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC","canonical_id":"clinicaltrials.gov:NCT06637163","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"2978c723e62a4ff59b68b1531218cff7","type":"TRIAL","name":"Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy","canonical_id":"clinicaltrials.gov:NCT07537777","description":"Hepatocellular Carcinoma (HCC); First-line Targeted Therapy Failure; Oligometastatic Hepatocellular Carcinoma; Benmelstobart; Anlotinib; SBRT","metadata":null},{"id":"9fffce330837452da7cbf55f29b0a8c2","type":"TRIAL","name":"Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07538258","description":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","metadata":null},{"id":"67ef6f2a857b4d3d8cbf57943d8960df","type":"TRIAL","name":"Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT07489300","description":"Ovarian Cancer; Fallopian Tube Cancers; Primary Peritoneal Cancer","metadata":null},{"id":"92086f72b2c6430aae38c9ff0d5285e1","type":"TRIAL","name":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06931145","description":"Extensive-stage Small Cell Lung Cancer","metadata":null},{"id":"af16dd683b3c45138ab56f61472ba187","type":"TRIAL","name":"Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer","canonical_id":"clinicaltrials.gov:NCT06848439","description":"Mouth Neoplasms; Neoadjuvant Therapy; Immunotherapy; Molecular Targeted Therapy","metadata":null},{"id":"0b4d7ff30e7645e984e281fa066ec675","type":"TRIAL","name":"Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation","canonical_id":"clinicaltrials.gov:NCT00534573","description":"Clozapine-induced Hypersalivation","metadata":null},{"id":"8cc28b0eed2e47efb75915e9859fa764","type":"DRUG","name":"Benzatropine","canonical_id":"mesh:D001590","description":null,"metadata":null},{"id":"febfa7ee8eac4c4fb33edffae2376413","type":"DRUG","name":"Benznidazole","canonical_id":"mesh:C009999","description":null,"metadata":null},{"id":"929ce394e4b84ae3b5f3f5a4c7bfbfcc","type":"TRIAL","name":"Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center","canonical_id":"clinicaltrials.gov:NCT06056349","description":"Cluster Seizure","metadata":null},{"id":"4081521dcfbc4693b7cb2a2f0487096b","type":"DRUG","name":"Benzoic Acid","canonical_id":"mesh:D019817","description":null,"metadata":null},{"id":"8525542d755645c0b9a9c55bea58657b","type":"DRUG","name":"Benzonatate","canonical_id":"mesh:C029755","description":null,"metadata":null},{"id":"23ff3f16f9ad4cb1a18388474bf73d7a","type":"DRUG","name":"Benzoyl peroxide","canonical_id":"mesh:D001585","description":null,"metadata":null},{"id":"2db51e5b4a9545c9bb412fac1e2f15d7","type":"DRUG","name":"Benzphetamine","canonical_id":"mesh:D001589","description":null,"metadata":null},{"id":"f675519a95f64ceab8201cd49d43058a","type":"DRUG","name":"Benzyl alcohol","canonical_id":"mesh:D019905","description":null,"metadata":null},{"id":"0d00503bc75b43498fe8b581586668a8","type":"TRIAL","name":"Beovu Experience UZ Leuven","canonical_id":"clinicaltrials.gov:NCT05220085","description":"Age-Related Macular Degeneration","metadata":null},{"id":"231e40e86bc44477b4bc7fff6fb60d7b","type":"GO_TERM","name":"Bergmann glial cell differentiation","canonical_id":"go:GO:0060020","description":"\"The process in which neuroepithelial cells of the neural tube give rise to Brgmann glial cells, specialized bipotential progenitors cells of the cerebellum. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GOC:dph, PMID:10375501]","metadata":null},{"id":"b7aa6755a3ed4023b0b9c1e0b6e6462a","type":"DISEASE","name":"Berylliosis","canonical_id":"mesh:D001607","description":null,"metadata":null},{"id":"5c9b39ce5c6848d8a45f8125295a09df","type":"TRIAL","name":"Besponsa Post Marketing Surveillance Study","canonical_id":"clinicaltrials.gov:NCT04307134","description":"Hematologic Malignancy","metadata":null},{"id":"e4035ec63d864b5eb22b6939c5bf7675","type":"TRIAL","name":"Beta 2 Adrenergic Stimulation vs Cold Exposure to Activate Human Brown Adipose Tissue","canonical_id":"clinicaltrials.gov:NCT05294965","description":"Thermogenesis","metadata":null},{"id":"46820a3ab0c547e4ad49e77074c05f7d","type":"TRIAL","name":"Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate","canonical_id":"clinicaltrials.gov:NCT02944201","description":"Prostate Cancer","metadata":null},{"id":"68c6aaadc1c54799bb7d0d67a4542ce9","type":"TRIAL","name":"Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children","canonical_id":"clinicaltrials.gov:NCT01723371","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"4ffcd059aa0f4284b2328fc65ffecd18","type":"TRIAL","name":"Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab","canonical_id":"clinicaltrials.gov:NCT00737763","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"62bfad56b875448e930e8bef1ef008e1","type":"TRIAL","name":"Beta-2 Polymorphisms and Beta Receptor Selectivity","canonical_id":"clinicaltrials.gov:NCT00214318","description":"Heart Failure","metadata":null},{"id":"7649da2b4752468cb3d1ed5a7ad61e2c","type":"TRIAL","name":"Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT04909255","description":"Sjogren's Syndrome; Overactive Bladder Syndrome","metadata":null},{"id":"2d304a5c05e54988a386f6f553d0b808","type":"TRIAL","name":"Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence","canonical_id":"clinicaltrials.gov:NCT05806164","description":"Urgency Urinary Incontinence","metadata":null},{"id":"53d218e36dd04213bacd92ef301fc533","type":"TRIAL","name":"Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)","canonical_id":"clinicaltrials.gov:NCT02051413","description":"Major Depressive Disorder; Major Depressive Episode","metadata":null},{"id":"0f5248a6455b4736996be5816d52e626","type":"TRIAL","name":"Beta-blocker vs. Ic Antiarrhythmic Drug for PVC","canonical_id":"clinicaltrials.gov:NCT03561935","description":"Premature Ventricular Complex","metadata":null},{"id":"8e7a79cb97a24ecebcde020ba1dee587","type":"TRIAL","name":"Beta-blockers for Oesophageal Varices","canonical_id":"clinicaltrials.gov:NCT03776955","description":"Cirrhoses, Liver; Oesophageal Varices","metadata":null},{"id":"7246c495f53d43c39de1e178f2f4041d","type":"PROTEIN","name":"Beta-lactamase","canonical_id":"uniprot:P05364","description":null,"metadata":null},{"id":"376d578ec29a4d4dbb351886e9c01d25","type":"PROTEIN","name":"Beta-lactamase","canonical_id":"uniprot:P00807","description":null,"metadata":null},{"id":"4bc439d31e854da38dd10a994e8ea0ce","type":"PROTEIN","name":"Beta-lactamase SHV-1","canonical_id":"uniprot:P0AD63","description":null,"metadata":null},{"id":"f2fe14014e404a3e8713344a8b00df63","type":"PROTEIN","name":"Beta-lactamase SHV-1","canonical_id":"uniprot:P0AD64","description":null,"metadata":null},{"id":"b0dee7257097435a9bfa1f4632e077e3","type":"PROTEIN","name":"Beta-lactamase SHV-2","canonical_id":"uniprot:P0A9Z7","description":null,"metadata":null},{"id":"bb637fbe1d1e4c63ba7a891616c2fe91","type":"PROTEIN","name":"Beta-lactamase TEM","canonical_id":"uniprot:P62594","description":null,"metadata":null},{"id":"513397acd09f4549860decaa23d6a618","type":"TRIAL","name":"Beta2-adrenergic Agonism and Muscle Remodelling","canonical_id":"clinicaltrials.gov:NCT03565302","description":"Hypertrophy; Physiologic Hypertrophy; Physical Activity","metadata":null},{"id":"72d90fab06d04d4ab9d67f66abb1e4eb","type":"TRIAL","name":"Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure","canonical_id":"clinicaltrials.gov:NCT02775539","description":"Pulmonary Hypertension; Mirabegron; Heart Failure; Pulmonary Vascular Resistance Abnormality","metadata":null},{"id":"96e7ae5169a147d4964385d684f37f18","type":"TRIAL","name":"Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study","canonical_id":"clinicaltrials.gov:NCT03901690","description":"Genital Wart Virus Infection","metadata":null},{"id":"5b690617b10c461c8e0a3fccbc078f26","type":"DRUG","name":"Betahistine","canonical_id":"mesh:D001621","description":null,"metadata":null},{"id":"b64064db9ee24660a6a0507ad93b24a0","type":"DRUG","name":"Betaine","canonical_id":"mesh:D001622","description":null,"metadata":null},{"id":"5dd13c7842b24e979edfe4bb616a5fea","type":"TRIAL","name":"Betamethasone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis","canonical_id":"clinicaltrials.gov:NCT02604537","description":"DeQuervain Tendinopathy","metadata":null},{"id":"6c04bb24248c433aabda57b62ae75adc","type":"DRUG","name":"Bethanechol","canonical_id":"mesh:D018723","description":null,"metadata":null},{"id":"4b85b1990d404ad7b48db548529b9cdc","type":"TRIAL","name":"Bethanechol Prior to Pancreatic Surgery","canonical_id":"clinicaltrials.gov:NCT03572283","description":"Pancreas Cancer","metadata":null},{"id":"cadde0251ff54ac99c1f588f62252a12","type":"TRIAL","name":"Bethanechol for Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT02058537","description":"Eosinophilic Esophagitis (EoE)","metadata":null},{"id":"b7d0ad9e0d7d433889234cf04476e6cb","type":"TRIAL","name":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","canonical_id":"clinicaltrials.gov:NCT04985435","description":"Rheumatoid Arthritis","metadata":null},{"id":"2359c82344d04f28a3b6076486507ad9","type":"DRUG","name":"Bevacizumab","canonical_id":"mesh:D000068258","description":null,"metadata":null},{"id":"98c7cf84ad9643ac9ce42a8f31c508d9","type":"DRUG","name":"Bevacizumab","canonical_id":"ncit:C2039","description":null,"metadata":null},{"id":"4e989e0da8d145889da598bd3a4e74c3","type":"TRIAL","name":"Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation","canonical_id":"clinicaltrials.gov:NCT05263947","description":"Carcinoma, Non-Small-Cell Lung; Bevacizumab; Tyrosine Kinase Inhibitor; EGFR L858R","metadata":null},{"id":"4d2aa6ceae584bd6a81108124f6efa7a","type":"TRIAL","name":"Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00923130","description":"Renal Cell Carcinoma","metadata":null},{"id":"06d01116a0c449adb6cc96889c9b671c","type":"TRIAL","name":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01989780","description":"Metastatic Breast Cancer","metadata":null},{"id":"ab54869892ec4884b89494662622141e","type":"TRIAL","name":"Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial","canonical_id":"clinicaltrials.gov:NCT00370422","description":"Diabetic Macular Edema","metadata":null},{"id":"eac609f9fc1d494db19f12e4ba5b41c5","type":"TRIAL","name":"Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT01481545","description":"Rectal Cancer","metadata":null},{"id":"78758795dc0b439b85cec3901714945e","type":"TRIAL","name":"Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT00795665","description":"Glioma","metadata":null},{"id":"ea715176e792406599f964d4530890a7","type":"TRIAL","name":"Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00467142","description":"Colorectal Cancer","metadata":null},{"id":"9eaf197333544f42be3c0177fca9c8e3","type":"TRIAL","name":"Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma","canonical_id":"clinicaltrials.gov:NCT00883688","description":"Brain Cancer; Pediatric Cancers","metadata":null},{"id":"ee3cb0c4e0d5413faa68f990bcb4c91e","type":"TRIAL","name":"Bevacizumab in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00416637","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"da7aef9847f241a790996eccb30a86e0","type":"TRIAL","name":"Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02942043","description":"Malignant Pleural Effusion","metadata":null},{"id":"6b50e60285994c69808fa84e81492f38","type":"TRIAL","name":"Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00112528","description":"Pancreatic Cancer","metadata":null},{"id":"f4c5bca76b77498ca44e3cd932c00ba7","type":"TRIAL","name":"Bexagliflozin Drug/Drug Interaction Study With Digoxin","canonical_id":"clinicaltrials.gov:NCT03197324","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"48b77419e6b249de946ea8c6f2e482ec","type":"TRIAL","name":"Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection","canonical_id":"clinicaltrials.gov:NCT03167411","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"590cca2e44fe4aebbe6dac8cfc58d70e","type":"TRIAL","name":"Bexagliflozin Efficacy and Safety Trial","canonical_id":"clinicaltrials.gov:NCT02558296","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"b6917b18d2374448b23a51a09784cf75","type":"DRUG","name":"Bexarotene","canonical_id":"mesh:C095105","description":null,"metadata":null},{"id":"3858157053544228b790253480e27c10","type":"TRIAL","name":"Bexarotene Amyloid Treatment for Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01782742","description":"Alzheimer's Disease","metadata":null},{"id":"ed935e5dcb1c4afe881bda7091537e4e","type":"TRIAL","name":"Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00535574","description":"Schizophrenia","metadata":null},{"id":"a4602925eaa748ceb0fe177a659f603c","type":"TRIAL","name":"Bexarotene Treatment in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00141947","description":"Schizophrenia","metadata":null},{"id":"2c2820bb231647ff84efeafb52d72848","type":"TRIAL","name":"Bexarotene With Narrow-Band UVB for Psoriasis","canonical_id":"clinicaltrials.gov:NCT00151008","description":"Psoriasis","metadata":null},{"id":"55dafcf2ffe849f6a100c046f40fa468","type":"TRIAL","name":"Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients","canonical_id":"clinicaltrials.gov:NCT00534898","description":"Schizophrenia; Schizoaffective Disorder; Cognition","metadata":null},{"id":"288bb804f0e847c2b4e5381dbe9690f4","type":"TRIAL","name":"Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00425477","description":"Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases","metadata":null},{"id":"d375c1d88af04c48bedd94d5b648cb4c","type":"TRIAL","name":"Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00030849","description":"Lymphoma","metadata":null},{"id":"1d6bff3880364b889fbb6f01f9afeb5d","type":"TRIAL","name":"Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03323658","description":"Breast Atypical Ductal Hyperplasia; Breast Atypical Lobular Hyperplasia; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ; Invasive Breast Carcinoma","metadata":null},{"id":"a20f5bfe4db84c088afd85b41180a972","type":"TRIAL","name":"Bexarotene in Preventing Breast Cancer in Women at Genetic Risk","canonical_id":"clinicaltrials.gov:NCT00055991","description":"Breast Cancer","metadata":null},{"id":"71e4df73493347e6aa954ce4cc4cb9b9","type":"TRIAL","name":"Bexarotene in Treating Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00003752","description":"Breast Cancer","metadata":null},{"id":"98cb0ddda0704fe7b97ac2a8935cf99e","type":"TRIAL","name":"Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00514293","description":"Lung Cancer","metadata":null},{"id":"80482f68d4be4a9da59308481a27b872","type":"TRIAL","name":"Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA","canonical_id":"clinicaltrials.gov:NCT07343661","description":"EGPA - Eosinophilic Granulomatosis With Polyangiitis; Severe Asthma; Eosinophilic Asthma","metadata":null},{"id":"2c7ecb8d65e54b439913e3c0b9d69714","type":"TRIAL","name":"Bezafibrate Plus Berberine in Mixed Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT02548832","description":"Mixed Dyslipidemia","metadata":null},{"id":"0d210f78b25b4d5eb7a6eb7834b14f9d","type":"TRIAL","name":"Bezafibrate Trial in CPT2 Deficiency","canonical_id":"clinicaltrials.gov:NCT00336167","description":"Carnitine Palmitoyl Transferase 2 Deficiency","metadata":null},{"id":"ce5ed196ffd34c5284a17b054845c85d","type":"TRIAL","name":"Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT02291796","description":"Acute Myocardial Infarction","metadata":null},{"id":"3379cddda4b847c0adab7ffd2a415dbc","type":"TRIAL","name":"BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study","canonical_id":"clinicaltrials.gov:NCT02481245","description":"Bipolar Disorder; Depressive Episode","metadata":null},{"id":"3941707a5a2d4a90be35ee2abdd32992","type":"DRUG","name":"Bezlotoxumab","canonical_id":"mesh:C000613978","description":null,"metadata":null},{"id":"16a5889afb164fe4a4d715c833a456b7","type":"TRIAL","name":"Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00551044","description":"Prostatic Neoplasms","metadata":null},{"id":"dec71652795949358a7181714c268f31","type":"TRIAL","name":"Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00814788","description":"Prostate Cancer","metadata":null},{"id":"743c133503ca4f6bb298ff572d58c181","type":"TRIAL","name":"Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery","canonical_id":"clinicaltrials.gov:NCT03147196","description":"Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma","metadata":null},{"id":"34b028dcb39a4664adb3835d82425313","type":"TRIAL","name":"Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04509999","description":"COVID-19","metadata":null},{"id":"4bd1a57916bf4714a784b2ee80794574","type":"PROTEIN","name":"Bifunctional autolysin","canonical_id":"uniprot:P0C5Z8","description":null,"metadata":null},{"id":"0e1d067ab8524315928a307217f1aae6","type":"PROTEIN","name":"Bifunctional dihydrofolate reductase-thymidylate synthase","canonical_id":"uniprot:P13922","description":null,"metadata":null},{"id":"7f4c0e038ed7484fbdea8cb1617624c8","type":"TRIAL","name":"Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01202149","description":"Eczema; Atopic Dermatitis","metadata":null},{"id":"6ea08d5b23b149d294a7a6d853c73aa2","type":"DISEASE","name":"Bilateral tonic-clonic seizure","canonical_id":"hp:0002069","description":null,"metadata":null},{"id":"5b26ff4c5001418f8a9bd1c6064252c8","type":"DISEASE","name":"Biliary Tract Cancer","canonical_id":"doid:4607","description":null,"metadata":null},{"id":"6b142df106544a909f765f79af36be63","type":"DRUG","name":"Bimatoprost","canonical_id":"mesh:D000069580","description":null,"metadata":null},{"id":"bcec63fac1394928953de21a76c4efcc","type":"TRIAL","name":"Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo","canonical_id":"clinicaltrials.gov:NCT03487042","description":"Generalized Vitiligo","metadata":null},{"id":"ef0362f234584d108e116d95c06324c7","type":"TRIAL","name":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","canonical_id":"clinicaltrials.gov:NCT00440011","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"ca71b96cb530424d9a3d2ef29b8548f5","type":"TRIAL","name":"Bimatoprost as a Treatment for Graves' Orbitopathy","canonical_id":"clinicaltrials.gov:NCT03708627","description":"Graves Ophthalmopathy","metadata":null},{"id":"88875ae0cd3b4c1fbcec01e89acc006c","type":"TRIAL","name":"Bimatoprost in the Treatment of Eyelash Hypotrichosis","canonical_id":"clinicaltrials.gov:NCT01698554","description":"Idiopathic Eyelash Hypotrichosis","metadata":null},{"id":"f1a3d6cabce64a86a26fb7732cb296f3","type":"TRIAL","name":"Bimekizumab in Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06336343","description":"Plaque Psoriasis","metadata":null},{"id":"3583f87d957c4321a884b7da670be7e7","type":"TRIAL","name":"Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)","canonical_id":"clinicaltrials.gov:NCT07497620","description":"Pityriasis Rubra Pilaris","metadata":null},{"id":"fdaa03a6de50409293065e5c35635d25","type":"DRUG","name":"Binimetinib","canonical_id":"ncit:C84865","description":null,"metadata":null},{"id":"9c9294bc94df4ef881607a746bedfc3b","type":"TRIAL","name":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","canonical_id":"clinicaltrials.gov:NCT03839342","description":"Solid Tumor","metadata":null},{"id":"3fa0d9872e7e4d70b394704c938472fb","type":"TRIAL","name":"Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases","canonical_id":"clinicaltrials.gov:NCT05026983","description":"Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8","metadata":null},{"id":"e78dc07021e0406db94f472561e9d5a5","type":"TRIAL","name":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04735068","description":"Non-Small Cell Lung Cancer; KRAS Mutation-Related Tumors","metadata":null},{"id":"2a29e9ea56b7403b86b0c004fc87952e","type":"TRIAL","name":"Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04870034","description":"Colorectal Carcinoma; Lung Adenocarcinoma; Malignant Solid Neoplasm; Pancreatic Carcinoma","metadata":null},{"id":"0a04ae98c3dd4df3a65168076822f622","type":"TRIAL","name":"Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03981614","description":"Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma","metadata":null},{"id":"94b34a864520438bb675e84331464320","type":"TRIAL","name":"Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04971187","description":"Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Squamous Non-Small Cell Carcinoma","metadata":null},{"id":"47674f8b157f41119e8dd0a48690b2d3","type":"TRIAL","name":"Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine","canonical_id":"clinicaltrials.gov:NCT04113772","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"42db1fbae13741dbb3fa4013a061c685","type":"TRIAL","name":"Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00813774","description":"Bioavailability Study on Healthy Volunteers","metadata":null},{"id":"564c61ee5bd6423a97e39e0a689ff17e","type":"TRIAL","name":"Bio-equivalence Study Between SAPHRIS and Asenapine","canonical_id":"clinicaltrials.gov:NCT01948024","description":"Schizophrenia; Bipolar Disorder","metadata":null},{"id":"602b699422d14636812afdc63343cbc9","type":"TRIAL","name":"Bio-significance of LPC16:0 in Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT04832100","description":"Fibromyalgia, Primary; Pain; Soreness, Muscle; Oxidative Stress; Metabolomics; Lipidomics","metadata":null},{"id":"155564c3215945a89ff802ee5b4defdc","type":"TRIAL","name":"BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers","canonical_id":"clinicaltrials.gov:NCT05457998","description":"Alzheimer Disease; Mild Cognitive Impairment; Dementia","metadata":null},{"id":"0cddbb72d3cb46e89cd8ad4f9479ec96","type":"TRIAL","name":"Bioavailability Comparison Study of Two Types of Nimodipine Injections in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03794843","description":"Bioavailability; Safety Issues; Ischemic Cerebrovascular Disease","metadata":null},{"id":"db045724501f4b679add615db1f884c5","type":"TRIAL","name":"Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)","canonical_id":"clinicaltrials.gov:NCT02750332","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"0cade4ffe40f4d40b3dd9d3e235b989a","type":"TRIAL","name":"Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact","canonical_id":"clinicaltrials.gov:NCT01261481","description":"Healthy","metadata":null},{"id":"eac3bf6da81742d0b83e5752cca6edbe","type":"TRIAL","name":"Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00653419","description":"To Determine Bioequivalence Under Fasting Conditions","metadata":null},{"id":"e0a1ca8e4f1f4c62b6f145fba9535402","type":"TRIAL","name":"Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00652730","description":"To Determine Bioequivalence Under Fed Conditions","metadata":null},{"id":"099abfd9be31436fbc2252f3ca5ddfac","type":"TRIAL","name":"Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01155960","description":"Healthy","metadata":null},{"id":"d3be39945e304a6ea5b6970b4534131c","type":"TRIAL","name":"Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT02006602","description":"Hypertension","metadata":null},{"id":"dca9c1e54f4446f8a77865921a0011e9","type":"TRIAL","name":"Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT02006589","description":"Hypertension","metadata":null},{"id":"ff309ad46f7c4af58dc1f33285fa5535","type":"TRIAL","name":"Bioavailability Study of Clonazepam ODT Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00652912","description":"To Determine Bioequivalence Under Fasting Conditions","metadata":null},{"id":"7363a4d26cc84261868447aee488ea4b","type":"TRIAL","name":"Bioavailability Study of Clonazepam Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00652639","description":"To Determine Bioequivalence Under Fasting Conditions","metadata":null},{"id":"4571c8f53bea4e81811177492da33f0a","type":"TRIAL","name":"Bioavailability Study of Colcrys\u00ae in Apple Juice","canonical_id":"clinicaltrials.gov:NCT01123395","description":"Healthy","metadata":null},{"id":"b79694c4bf4240e490bcce03673ffdc9","type":"TRIAL","name":"Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01314352","description":"Fed","metadata":null},{"id":"8834c90a4fa14d00a0e76f486f6d4113","type":"TRIAL","name":"Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.","canonical_id":"clinicaltrials.gov:NCT01314339","description":"Fasting","metadata":null},{"id":"764cf8cd2387493197b7bb97815a2203","type":"TRIAL","name":"Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT02291341","description":"Healthy","metadata":null},{"id":"cb5592e9aa0f48c3be2c3583f38cc286","type":"TRIAL","name":"Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01511731","description":"Healthy","metadata":null},{"id":"a8e139efac644a00b21df250b3b55c32","type":"TRIAL","name":"Bioavailability Study of Fexofenadine HCl New Formulation Tablet","canonical_id":"clinicaltrials.gov:NCT06284902","description":"Healthy Volunteers","metadata":null},{"id":"a3983303f3ab47ad8e173ee1544eea46","type":"TRIAL","name":"Bioavailability Study of Leflunomide Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00652665","description":"To Determine the Bioequivalence Study Under Fasting","metadata":null},{"id":"216a93600ad04416a27c1146c32a8c6e","type":"TRIAL","name":"Bioavailability Study of Propranolol Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00653120","description":"To Determine Bioequivalence Under Fasting Conditions","metadata":null},{"id":"52e415b119c442128126b9f72e239ad7","type":"TRIAL","name":"Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150\u00ae) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02195804","description":"Healthy","metadata":null},{"id":"cd980c1285084f2f9506b46b6193fe28","type":"TRIAL","name":"Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.","canonical_id":"clinicaltrials.gov:NCT02165046","description":"Asthma; Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"b8898fd8ece54f9293fa324f6f50aadb","type":"TRIAL","name":"Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00653393","description":"To Determine the Bioavailability of Tranylcypromine","metadata":null},{"id":"69d44dc0b74144bc9967514941ef30d7","type":"TRIAL","name":"Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX\u00ae in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01507610","description":"Migraine","metadata":null},{"id":"955cc2bbb01a43148756716da19bfaad","type":"TRIAL","name":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07015671","description":"Bioequivalence Study in Healthy Subjects; PK/PD","metadata":null},{"id":"b5f06802fbca426fa3071b8dd0163fc3","type":"TRIAL","name":"Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone","canonical_id":"clinicaltrials.gov:NCT03116295","description":"Parkinson Disease","metadata":null},{"id":"4419ca05e0af407aae223dcc2152af5d","type":"TRIAL","name":"Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05681247","description":"Hyperlipidemias","metadata":null},{"id":"97c98e7943ee4baa820e65191901e6ea","type":"TRIAL","name":"Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%","canonical_id":"clinicaltrials.gov:NCT05461456","description":"Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Rash; Rash; Pruritus; Urticaria; Urticaria Chronic; Psoriasis; Psoriasis Vulgaris; Skin Rash; Skin Inflammation; Eczema","metadata":null},{"id":"582e018f688d49dcb1bcd4ea42cab2b0","type":"TRIAL","name":"Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.","canonical_id":"clinicaltrials.gov:NCT00416468","description":"Healthy","metadata":null},{"id":"1b0afb91056c4951a1951f4aad9dcdd3","type":"TRIAL","name":"Bioavailability of Belumosudil (KD025) in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02557139","description":"Bioavailability","metadata":null},{"id":"3fd94beea5424dcf90cb59f2e4cfeb0f","type":"TRIAL","name":"Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT04916769","description":"Healthy Participants","metadata":null},{"id":"8ebf1f10107c4e00ac25bf0b42557d25","type":"TRIAL","name":"Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT03401346","description":"Migraine Headache","metadata":null},{"id":"2ff3281a19fb49599b770ccfe8b2c0f1","type":"TRIAL","name":"Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02261090","description":"Healthy","metadata":null},{"id":"11573681f02a483480509c14876f95a7","type":"TRIAL","name":"Bioavailability of Prochlorperazine Suppositories, 25 mg","canonical_id":"clinicaltrials.gov:NCT00992472","description":"Healthy","metadata":null},{"id":"827d0bd50efc4dbf8393bf62eaeeb4de","type":"TRIAL","name":"Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 \u03bcg/ 5 \u03bcg) in Chinese COPD Patients","canonical_id":"clinicaltrials.gov:NCT02969317","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"7e9dc3078b024d8f9f972ce9d68c3104","type":"TRIAL","name":"Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid\u00ae at Steady-state.","canonical_id":"clinicaltrials.gov:NCT06773767","description":"Bioavailability Heathy Volunteers; Bioavailability Study; Bioequivalance","metadata":null},{"id":"6ad4dc0b118940a19e9b41aa01a43827","type":"TRIAL","name":"Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs","canonical_id":"clinicaltrials.gov:NCT05857384","description":"Obstructive Sleep Apnea","metadata":null},{"id":"bba2b03456d54eb7aedef1e8fee7c3fe","type":"TRIAL","name":"Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects","canonical_id":"clinicaltrials.gov:NCT01986608","description":"Healthy Volunteers","metadata":null},{"id":"338581a850c2461d8686673a873240a3","type":"TRIAL","name":"Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid","canonical_id":"clinicaltrials.gov:NCT05611905","description":"Renal Excretion; Bacterial Infections; Inflammatory Disease; Oncologic Disease","metadata":null},{"id":"c2d2e5ce289a45629f84162865c79fa0","type":"TRIAL","name":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","canonical_id":"clinicaltrials.gov:NCT06062810","description":"Breast Cancer","metadata":null},{"id":"d2b293becf5442ca96968de45ce5c553","type":"TRIAL","name":"Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01154218","description":"Healthy","metadata":null},{"id":"3cd83f7b1f00445998b4f122e2b777dd","type":"TRIAL","name":"Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01374139","description":"Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)","metadata":null},{"id":"cb35acd5095445889e73897c4f9a7b46","type":"TRIAL","name":"Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations","canonical_id":"clinicaltrials.gov:NCT05810740","description":"Melanoma; BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma","metadata":null},{"id":"eee5aa39962844f4b12f2bb515b38a81","type":"TRIAL","name":"Bioequivalence Fasting Study in Patients","canonical_id":"clinicaltrials.gov:NCT02072954","description":"Schizophrenia","metadata":null},{"id":"5239c0b7bb0c4c93bf765d1f63f61f37","type":"TRIAL","name":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A","canonical_id":"clinicaltrials.gov:NCT02801526","description":"Hypertension","metadata":null},{"id":"a3cff92f9c7a4b63a3e21e9a549c9cc5","type":"TRIAL","name":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B","canonical_id":"clinicaltrials.gov:NCT02811731","description":"Hypertension","metadata":null},{"id":"ff6bd3b36bb74347afa73009747f4a04","type":"TRIAL","name":"Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05572281","description":"Healthy","metadata":null},{"id":"50bb7ff6e4474e35b72630830dfb7bd2","type":"TRIAL","name":"Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets","canonical_id":"clinicaltrials.gov:NCT00800475","description":"Bioavailability","metadata":null},{"id":"15fcb0efb73d44789386b50d10426ef3","type":"TRIAL","name":"Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT01568281","description":"Safety; Pharmacokinetics","metadata":null},{"id":"126d5c0b375949188569521991855e39","type":"TRIAL","name":"Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine","canonical_id":"clinicaltrials.gov:NCT00975325","description":"Erectile Dysfunction","metadata":null},{"id":"75c4a6669af64404a6f73a834cec1bd1","type":"TRIAL","name":"Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00396799","description":"Menopause","metadata":null},{"id":"01083469022546c3a2bb1487bd031182","type":"TRIAL","name":"Bioequivalence Study Of Pediatric Appropriate Formulation","canonical_id":"clinicaltrials.gov:NCT00758004","description":"Hypercholesterolemia","metadata":null},{"id":"93c39414e29644ba8572b429f61a5259","type":"TRIAL","name":"Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt\u00ae 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","canonical_id":"clinicaltrials.gov:NCT02512042","description":"Glaucoma","metadata":null},{"id":"2ebc47c34b2742f89e2a81f9fe716723","type":"TRIAL","name":"Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01506050","description":"Healthy","metadata":null},{"id":"ddde3688a0aa4298984694e1d885be4b","type":"TRIAL","name":"Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05697003","description":"Bioequivalence","metadata":null},{"id":"a88fd3d0f7034d6bb0fcb75c82cffb6a","type":"TRIAL","name":"Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT06025214","description":"Bioequivalence","metadata":null},{"id":"7ac5ea1e21a0459096d584968e078530","type":"TRIAL","name":"Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites","canonical_id":"clinicaltrials.gov:NCT05075876","description":"Healthy Volunteers","metadata":null},{"id":"d11b660ed8ad4912a5f3496c5485e650","type":"TRIAL","name":"Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit\u00ae)","canonical_id":"clinicaltrials.gov:NCT02179931","description":"Healthy Men and Women","metadata":null},{"id":"69b8894b597f4932b67fc36e02bfe5af","type":"TRIAL","name":"Bioequivalence Study in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00844324","description":"Hypertension","metadata":null},{"id":"384e69ac51814263a532890583a9b3de","type":"TRIAL","name":"Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets","canonical_id":"clinicaltrials.gov:NCT06154434","description":"Healthy Subject","metadata":null},{"id":"853ac84523f0420b9cbbabf04c150d4f","type":"TRIAL","name":"Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01155895","description":"Healthy","metadata":null},{"id":"c43df93638604771aa553106ca93fa77","type":"TRIAL","name":"Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions","canonical_id":"clinicaltrials.gov:NCT01155908","description":"Healthy","metadata":null},{"id":"67eb713fa408446dad190f7a04dc5195","type":"TRIAL","name":"Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets","canonical_id":"clinicaltrials.gov:NCT03422575","description":"Healthy","metadata":null},{"id":"f597b3946d1744df9f26f3f2a6049a14","type":"TRIAL","name":"Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05464745","description":"Bioequivalence; Healthy Subjects","metadata":null},{"id":"b6eb261177c045dab9fca67293e293dd","type":"TRIAL","name":"Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01133496","description":"Healthy","metadata":null},{"id":"0339877dc9364cebbe2862d59ad99fa2","type":"TRIAL","name":"Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01506011","description":"Fasting","metadata":null},{"id":"afef8881832b4016b22e281e062f36ab","type":"TRIAL","name":"Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01505998","description":"Fed","metadata":null},{"id":"a1177a230e104429b677ca7f68a141cf","type":"TRIAL","name":"Bioequivalence Study of Anastrozole 1 mg Tablet","canonical_id":"clinicaltrials.gov:NCT01105299","description":"Healthy","metadata":null},{"id":"475e78416e2542dd8ed5097b6a466625","type":"TRIAL","name":"Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray","canonical_id":"clinicaltrials.gov:NCT06180083","description":"Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis","metadata":null},{"id":"83f606585a3041bca894737abfe54eb3","type":"TRIAL","name":"Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00778726","description":"Healthy","metadata":null},{"id":"da08492d01ba4aa3af7f5b48d4b96b28","type":"TRIAL","name":"Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00778674","description":"Healthy","metadata":null},{"id":"d3c8559fdf274541b497b8c551064ffa","type":"TRIAL","name":"Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer\u00ae 125 mg Tablets IR In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04101370","description":"Bioequivalence","metadata":null},{"id":"6dfb56200ec54fa4b2e0238b2b787efe","type":"TRIAL","name":"Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT04549480","description":"Healthy Participants","metadata":null},{"id":"273dbcf589154122ae6d5cf984816d0b","type":"TRIAL","name":"Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00653055","description":"To Determine Bioequivalence Under Fasting Conditions","metadata":null},{"id":"5513642ca97f409cbe59a332b2ca6149","type":"TRIAL","name":"Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00415844","description":"Healthy","metadata":null},{"id":"0e9786f2a6254ac6a6877cd1fd3f121b","type":"TRIAL","name":"Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00415922","description":"Healthy","metadata":null},{"id":"cc9edf2ceb864402a624d135c33f42f9","type":"TRIAL","name":"Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00415740","description":"Healthy","metadata":null},{"id":"49a3033f19064d7794bc31514805c23b","type":"TRIAL","name":"Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00775619","description":"Healthy","metadata":null},{"id":"3e2aa29924614883bbd7eb35587bc637","type":"TRIAL","name":"Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01577914","description":"Fasting State","metadata":null},{"id":"e4d41ad44a1f4f568774f4d7c8cb24a6","type":"TRIAL","name":"Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00776022","description":"Healthy","metadata":null},{"id":"a73770676c3c4be6bab4d26f27ee77ac","type":"TRIAL","name":"Bioequivalence Study of Clonazepam 2 Mg Tablets","canonical_id":"clinicaltrials.gov:NCT06834503","description":"Healthy; Healthy Donors","metadata":null},{"id":"6da5f4d77c7e4815b021c3fdea74e5a7","type":"TRIAL","name":"Bioequivalence Study of Colchicine Tablets","canonical_id":"clinicaltrials.gov:NCT01021020","description":"Healthy","metadata":null},{"id":"ef2bbaaa25b04da0ad8f8768bd5154c1","type":"TRIAL","name":"Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product","canonical_id":"clinicaltrials.gov:NCT02053753","description":"Healthy Volunteer","metadata":null},{"id":"f66d9f86204045f993964c6f0d1bb053","type":"TRIAL","name":"Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01506791","description":"Healthy","metadata":null},{"id":"6222199e7f38491a8cc929f37257db61","type":"TRIAL","name":"Bioequivalence Study of Digoxin Tablet in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06546215","description":"Heart Failure","metadata":null},{"id":"46fa5decbba945fb859f51401d78575e","type":"TRIAL","name":"Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition","canonical_id":"clinicaltrials.gov:NCT01389609","description":"Hypertension","metadata":null},{"id":"ba4ec7d725144e6ca21ffb2d6c3ab3d3","type":"TRIAL","name":"Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01133444","description":"Healthy","metadata":null},{"id":"a4cb4092826c45359767170e8d245a35","type":"TRIAL","name":"Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01066754","description":"Healthy","metadata":null},{"id":"cf9e6ac2ae7849bbabc6b996321f9588","type":"TRIAL","name":"Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01133457","description":"Healthy","metadata":null},{"id":"180c927707c249458108d46be674d49c","type":"TRIAL","name":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT05976737","description":"Healthy","metadata":null},{"id":"3f6468af6c684d1c99163b1e2dc19f58","type":"TRIAL","name":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT06180720","description":"Healthy","metadata":null},{"id":"9261516c41d64c24ac5c99280efe0382","type":"TRIAL","name":"Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01746719","description":"Fasting","metadata":null},{"id":"cf04689e937c4f5184974bbf3fc3e5b5","type":"TRIAL","name":"Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01749228","description":"Healthy","metadata":null},{"id":"aaf92e9752174b99a736bf95c0205195","type":"TRIAL","name":"Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01827865","description":"Fasting","metadata":null},{"id":"a4e7b3a6efb144e8836cebb1373c4658","type":"TRIAL","name":"Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01831687","description":"Fasting","metadata":null},{"id":"093d6d854a6843bb9532cda089717170","type":"TRIAL","name":"Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01735370","description":"Fasting","metadata":null},{"id":"f3eaf221ecac46fbad2ac20c0cfa5081","type":"TRIAL","name":"Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01735383","description":"Fed","metadata":null},{"id":"9e298f3187d84a959d1db3cbc8fac28d","type":"TRIAL","name":"Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01910090","description":"Healthy","metadata":null},{"id":"1d59382a848f49aa922620f759a069c7","type":"TRIAL","name":"Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT05336279","description":"Solid Tumor","metadata":null},{"id":"bb49095e3dff48878508d1be77ac8e4b","type":"TRIAL","name":"Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00775359","description":"Healthy","metadata":null},{"id":"c3dfb4b80cb54556806a9b16bbed1c29","type":"TRIAL","name":"Bioequivalence Study of Fenofibric Acid Versus Tricor\u00ae (Fenofibrate)","canonical_id":"clinicaltrials.gov:NCT00961116","description":"Healthy","metadata":null},{"id":"04347780975a4272b70b439d22bb2168","type":"TRIAL","name":"Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01133470","description":"Healthy","metadata":null},{"id":"4d1e1f371cbd414fbdc2d0a2646b9d15","type":"TRIAL","name":"Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01888718","description":"Healthy","metadata":null},{"id":"a6acb4a6dd8c4a3494ec9d4076f83031","type":"TRIAL","name":"Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil","canonical_id":"clinicaltrials.gov:NCT01365091","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7ee2f2c5f0134c468ea89361d202ae13","type":"TRIAL","name":"Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)","canonical_id":"clinicaltrials.gov:NCT04494191","description":"Healthy","metadata":null},{"id":"092588335ff9452a88f3956c2c2a2b3c","type":"TRIAL","name":"Bioequivalence Study of Fluoxetine in Healthy Adult Subjects Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT05532332","description":"Healthy Subjects","metadata":null},{"id":"ce32291c43164ba7afa98a8a816239bb","type":"TRIAL","name":"Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00776334","description":"Healthy","metadata":null},{"id":"b3807b7a52214d098cefedbd31c448e7","type":"TRIAL","name":"Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00776672","description":"Healthy","metadata":null},{"id":"c4b56f2f38ad4596a60631aefbfb5f4b","type":"TRIAL","name":"Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00778713","description":"Healthy","metadata":null},{"id":"7d629f21825a45efb97ca60f6e8c6d2f","type":"TRIAL","name":"Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00777972","description":"Healthy","metadata":null},{"id":"4c86243677bd4b0b89baa7a2cafc4fac","type":"TRIAL","name":"Bioequivalence Study of Generic Leflunomide 20 mg Film-coated Tablets and Reference Product Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT06228443","description":"Healthy Volunteer","metadata":null},{"id":"0a33290548724a02a2b6d77bc70108ad","type":"TRIAL","name":"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro\u00ae and Placebo","canonical_id":"clinicaltrials.gov:NCT01135069","description":"Acne","metadata":null},{"id":"127bfb114d314872aeceadc15d3a3155","type":"TRIAL","name":"Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects","canonical_id":"clinicaltrials.gov:NCT07393022","description":"Pharmacokinetic Analysis; Bioequivalence; Health Adult Subjects","metadata":null},{"id":"6f02dfed416e4369801ac4bc9cade37a","type":"TRIAL","name":"Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01735344","description":"Fed","metadata":null},{"id":"24180824b2624739b24970ceb329d398","type":"TRIAL","name":"Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00778115","description":"Healthy","metadata":null},{"id":"f19b0445411249ba97b298db755e9c40","type":"TRIAL","name":"Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00776282","description":"Healthy","metadata":null},{"id":"d0374e9f44f0444eba95d86257b85293","type":"TRIAL","name":"Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi\u00ae' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg","canonical_id":"clinicaltrials.gov:NCT06553937","description":"PAH","metadata":null},{"id":"d46f624434b048a8be8eda6983b6ead5","type":"TRIAL","name":"Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic\u00ae Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic\u00ae Tablets 15 mg) in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT02183181","description":"Healthy","metadata":null},{"id":"212ccd9eb7404d98affd64483984c665","type":"TRIAL","name":"Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01161147","description":"Healthy","metadata":null},{"id":"a3243690040943dc81d5723e116167f7","type":"TRIAL","name":"Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants","canonical_id":"clinicaltrials.gov:NCT02220218","description":"Healthy","metadata":null},{"id":"6b64c641e9e645d690f53fed599b6186","type":"TRIAL","name":"Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01884896","description":"Fasting","metadata":null},{"id":"409e013c1a0d4f38ad0bd22f670d9a3b","type":"TRIAL","name":"Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01691469","description":"Healthy","metadata":null},{"id":"1c6faed389d444d9877cf800ab6d1355","type":"TRIAL","name":"Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05531994","description":"Healthy Volunteers","metadata":null},{"id":"622c730d544a423fac86db8aa037e88c","type":"TRIAL","name":"Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01671722","description":"Healthy","metadata":null},{"id":"64025781fe29410190dbde08013f16a9","type":"TRIAL","name":"Bioequivalence Study of Nimesulide 100 mg Tablets","canonical_id":"clinicaltrials.gov:NCT01745614","description":"Pain","metadata":null},{"id":"5f1294f613184eb39ed9f1d411eb07fa","type":"TRIAL","name":"Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01503437","description":"Fasting","metadata":null},{"id":"809b1ce17b4249849699fac9661ba2b0","type":"TRIAL","name":"Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01523093","description":"Healthy","metadata":null},{"id":"23e6808592cc4719ac0f54c8b7c5ef61","type":"TRIAL","name":"Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT02322632","description":"Healthy","metadata":null},{"id":"566d0be7daea4264b47e9c9af2590e6f","type":"TRIAL","name":"Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT06213610","description":"Bioequivalence","metadata":null},{"id":"e164d38cfcb8499db76f0b28f8d7c8fe","type":"TRIAL","name":"Bioequivalence Study of Pimavanserin 34 mg Capsule","canonical_id":"clinicaltrials.gov:NCT06450184","description":"Parkinson Disease Psychosis","metadata":null},{"id":"12747d9e55ba4c87a9bb6b071239ab0f","type":"TRIAL","name":"Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel\u00ae Cream, 1% in Mild to Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03107611","description":"Atopic Dermatitis","metadata":null},{"id":"0871d6dacbb24cf8b16ca50be09c83f1","type":"TRIAL","name":"Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01146106","description":"Healthy","metadata":null},{"id":"f6f784fc826e40d7a010dea899430302","type":"TRIAL","name":"Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01146093","description":"Healthy","metadata":null},{"id":"c78a847b23454643a8af957a71ec3518","type":"TRIAL","name":"Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01566487","description":"Healthy","metadata":null},{"id":"e0c96cf956cb4e0998bffcc538ebedb4","type":"TRIAL","name":"Bioequivalence Study of Ramipril 10 mg Capsules Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00879476","description":"Healthy","metadata":null},{"id":"8de58cd48dce4b87b69b607cf50d4bc5","type":"TRIAL","name":"Bioequivalence Study of Revolade\u00ae Eltrombopag 50 mg","canonical_id":"clinicaltrials.gov:NCT06834451","description":"Healthy; Healthy Donors","metadata":null},{"id":"6f3258b73d594d7992456dc7cc94c259","type":"TRIAL","name":"Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01222923","description":"Healthy","metadata":null},{"id":"a73e27a972cd4bc9be3ee5613e06e16d","type":"TRIAL","name":"Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01722201","description":"Fasting","metadata":null},{"id":"b4ae452694b94b938717a77bb87d2774","type":"TRIAL","name":"Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01146067","description":"Healthy","metadata":null},{"id":"e43156860dab4995a395b814d01a06a3","type":"TRIAL","name":"Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01146041","description":"Healthy","metadata":null},{"id":"8187bf9f228241b684f25c60414f7592","type":"TRIAL","name":"Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00946036","description":"Healthy","metadata":null},{"id":"6dc13b2c07d14017af0208032121e4a3","type":"TRIAL","name":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","canonical_id":"clinicaltrials.gov:NCT06124495","description":"Bioequivalence; Diabetes Mellitus, Type 2","metadata":null},{"id":"fa09d61752904bd2963fa7ff50f9c8c7","type":"TRIAL","name":"Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)","canonical_id":"clinicaltrials.gov:NCT05767632","description":"Healthy","metadata":null},{"id":"f197193ebfb0439fa6778a23651babff","type":"TRIAL","name":"Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex \u00ae, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT03799536","description":"Bioequivalence","metadata":null},{"id":"d2f8a592bebf4fe893b65ec5bfc05a44","type":"TRIAL","name":"Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.","canonical_id":"clinicaltrials.gov:NCT07266779","description":"Type 2 Diabetes","metadata":null},{"id":"5a1b6bf165c440de93b1a09eb17ed36d","type":"TRIAL","name":"Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05663398","description":"Bioequivalence; Healthy Subjects","metadata":null},{"id":"f3a063e1362c497e819ab88b8b44cf88","type":"TRIAL","name":"Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT03696329","description":"Healthy","metadata":null},{"id":"0c6c2d85de1e4381bf2c220eaa384df5","type":"TRIAL","name":"Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT03702855","description":"Healthy","metadata":null},{"id":"2b148c3bfb70400e904dca63dab55847","type":"TRIAL","name":"Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01996475","description":"Healthy","metadata":null},{"id":"9b732bd5f4d1411ebeb5499e623ddcf7","type":"TRIAL","name":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT01418586","description":"Healthy","metadata":null},{"id":"aa9df8dd2e794f559fd59be471d08f1b","type":"TRIAL","name":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01418599","description":"Healthy","metadata":null},{"id":"d9f769bee3454a3b9740d26e508305e8","type":"TRIAL","name":"Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT02965261","description":"Healthy Subjects","metadata":null},{"id":"5d031efa913c4084aaa8128f06808f86","type":"TRIAL","name":"Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.","canonical_id":"clinicaltrials.gov:NCT02962336","description":"Healthy Subjects","metadata":null},{"id":"3502399f5d5444488764d2fa9779a698","type":"TRIAL","name":"Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01164787","description":"Healthy","metadata":null},{"id":"3770de2ca4b645e6a155eaad00f53bc7","type":"TRIAL","name":"Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01164800","description":"Healthy","metadata":null},{"id":"ab46bfd96b02462a982dedc1bc1b8482","type":"TRIAL","name":"Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions","canonical_id":"clinicaltrials.gov:NCT06762743","description":"Epilepsy (treatment Refractory)","metadata":null},{"id":"49fb77f4a66a427a9b4c87e46e88ee89","type":"TRIAL","name":"Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01264302","description":"Healthy","metadata":null},{"id":"b6ef1392cfcc46baadd058164273c5a7","type":"TRIAL","name":"Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT05061901","description":"Bioequivalence","metadata":null},{"id":"b09aa103b6df4018adb6de2763c74ea6","type":"TRIAL","name":"Bioequivalence Study of Two Formulations of Propafenone 300 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT03915340","description":"Bioequivalence","metadata":null},{"id":"1a07b58ce03d4829ae32624bc2573025","type":"TRIAL","name":"Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT05685277","description":"Bioequivalence","metadata":null},{"id":"76972d38035548c7a16c3e3d262e1a0a","type":"TRIAL","name":"Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT05786339","description":"Therapeutic Equivalency","metadata":null},{"id":"0893df75ba56473a8df1ccbc5beba13b","type":"TRIAL","name":"Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin","canonical_id":"clinicaltrials.gov:NCT02750709","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"76623a0af892455bbbc35cebda97fe1c","type":"TRIAL","name":"Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)","canonical_id":"clinicaltrials.gov:NCT02750345","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"bcaf9782e82f4b3db5eebc4c02b7bf1d","type":"TRIAL","name":"Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects","canonical_id":"clinicaltrials.gov:NCT06043297","description":"Antithrombic Drug","metadata":null},{"id":"baebd073e7c148eca4150db22c7c6d7d","type":"TRIAL","name":"Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01283061","description":"Healthy","metadata":null},{"id":"af9ef7514ec645d6a219cc38a2a7c96b","type":"TRIAL","name":"Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01581879","description":"Healthy","metadata":null},{"id":"869b3a8d8f1a4686b5f50fcc15e1e87d","type":"TRIAL","name":"Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00779441","description":"Healthy","metadata":null},{"id":"cd1f605cf0404e2eafd2cb606348c66e","type":"TRIAL","name":"Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 \u00d7 500 mg Glucophage XR","canonical_id":"clinicaltrials.gov:NCT01192152","description":"Diabetes Mellitus","metadata":null},{"id":"f347c001270b4c21b024ae584c981773","type":"TRIAL","name":"Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State","canonical_id":"clinicaltrials.gov:NCT02052713","description":"Urologic Diseases","metadata":null},{"id":"9c5d9d399556493091c718baac10ec61","type":"TRIAL","name":"Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00776217","description":"Healthy","metadata":null},{"id":"7b9b0ca127a042d397ee152619e74915","type":"TRIAL","name":"Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)","canonical_id":"clinicaltrials.gov:NCT06180057","description":"Cerebrotendinous Xanthomatoses","metadata":null},{"id":"4d02668e94ef4611ad0e3600aaa17a94","type":"TRIAL","name":"Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam\u00ae 50 Coated Tablet","canonical_id":"clinicaltrials.gov:NCT05082662","description":"Non-steroidal Anti-inflammatory (NSAID); Analgesic; Antipyretic","metadata":null},{"id":"ccd2943696c34dc4a81e7c78e3678404","type":"TRIAL","name":"Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination","canonical_id":"clinicaltrials.gov:NCT01485445","description":"Asthma","metadata":null},{"id":"f8957349a5614029859b18c5a3703a74","type":"TRIAL","name":"Bioequivalence Study to Compare Ibuprofen/ Paracetamol Tablets (200mg Ibuprofen/ 500mg Paracetamol) Versus Nuromol\u00ae Tablets (200mg Ibuprofen/ 500mg Paracetamol)","canonical_id":"clinicaltrials.gov:NCT06180070","description":"Migraine; Headache; Backache","metadata":null},{"id":"89f46a614ebe45cab108a0074b776d2d","type":"TRIAL","name":"Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet\u00ae","canonical_id":"clinicaltrials.gov:NCT06073600","description":"Fed Conditions","metadata":null},{"id":"58ae3490e85b4e90a03517c618c358b4","type":"TRIAL","name":"Bioequivalence Study to Compare Two Formulations of Deanxit\u00ae","canonical_id":"clinicaltrials.gov:NCT03472651","description":"Healthy","metadata":null},{"id":"0c047b9928994fd4be65063e913e300b","type":"TRIAL","name":"Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07769359","description":"Bioequivalence; Adhesion; Adverse Effects","metadata":null},{"id":"dd8da23b58a44cbabecb37e4025df13f","type":"TRIAL","name":"Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib","canonical_id":"clinicaltrials.gov:NCT04204902","description":"Healthy","metadata":null},{"id":"7bafdf62ad6f4e7b93d2807da1ea893a","type":"TRIAL","name":"Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01182636","description":"Acne Vulgaris","metadata":null},{"id":"11bd1d23e57347b39703786a4e783551","type":"TRIAL","name":"Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145","canonical_id":"clinicaltrials.gov:NCT02307461","description":"Healthy","metadata":null},{"id":"c211b9d5c0e5484b910640a267966804","type":"TRIAL","name":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara\u2122 (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT00948428","description":"Actinic Keratoses","metadata":null},{"id":"88759e7f2e324a49bba0eff2032ead90","type":"TRIAL","name":"Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.","canonical_id":"clinicaltrials.gov:NCT02189733","description":"Healthy Volunteers","metadata":null},{"id":"caa472596e384bfe9dda06b016dfef40","type":"TRIAL","name":"Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.","canonical_id":"clinicaltrials.gov:NCT01857362","description":"Healthy","metadata":null},{"id":"18ebcc8bfecb49b6b1839be3220116b0","type":"TRIAL","name":"Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension","canonical_id":"clinicaltrials.gov:NCT01682538","description":"Healthy Volunteers","metadata":null},{"id":"9c7f460659904f53b6b2d77da78a1b3e","type":"TRIAL","name":"Bioequivalence of RYTHMOL SR\u00ae Manufactured at Two Different Sites","canonical_id":"clinicaltrials.gov:NCT01956487","description":"Arrhythmia, Cardiac","metadata":null},{"id":"3c7d5eb7e2414da4b5aadb7a89111426","type":"TRIAL","name":"Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets","canonical_id":"clinicaltrials.gov:NCT03056703","description":"Pain","metadata":null},{"id":"e5b363c6e8494179b41fd47419b1752b","type":"TRIAL","name":"Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib","canonical_id":"clinicaltrials.gov:NCT03629223","description":"Healthy","metadata":null},{"id":"caf9eb29f9734d489bf5055865ecd007","type":"TRIAL","name":"Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02262598","description":"Healthy","metadata":null},{"id":"77fedfe0b51042dab26fa406b57f501a","type":"TRIAL","name":"Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02214992","description":"Healthy","metadata":null},{"id":"59d4d1de05c745dd8a211915ba7ce879","type":"TRIAL","name":"Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)","canonical_id":"clinicaltrials.gov:NCT00972595","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"30457d415f104ea3976b7aa7f51a9b64","type":"TRIAL","name":"Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00414947","description":"Healthy","metadata":null},{"id":"a3ee4c4fcac54c2a99adcb9714664204","type":"TRIAL","name":"Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02221414","description":"Healthy","metadata":null},{"id":"7177873e7a9a4f6cad65493ad6732bd5","type":"TRIAL","name":"Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02221401","description":"Healthy","metadata":null},{"id":"d7c47577da784d37b1292239aba447a9","type":"TRIAL","name":"Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)","canonical_id":"clinicaltrials.gov:NCT02060201","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"bbae11f0c3c449a997df12f5066fa5f9","type":"TRIAL","name":"Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00601874","description":"Dry Mouth","metadata":null},{"id":"3cba6193402d4c1fbac7fcdd44a5e29e","type":"TRIAL","name":"Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00602407","description":"Intermittent Claudication","metadata":null},{"id":"5da7b7e4f3bf4403a8d9ae403addf3f9","type":"TRIAL","name":"Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00602524","description":"Dry Mouth","metadata":null},{"id":"08d7a81b021940e88ce28969b57becd9","type":"TRIAL","name":"Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00618059","description":"Dry Mouth","metadata":null},{"id":"79038d52ea014372b02dbd75fe54e65a","type":"TRIAL","name":"Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01331434","description":"Breast Cancer","metadata":null},{"id":"0bb0ed45da414afc94be3e2fad465039","type":"TRIAL","name":"Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00775827","description":"Healthy","metadata":null},{"id":"cab1da6d173d421e890aa9227b4f78cb","type":"TRIAL","name":"Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT01107353","description":"Depression","metadata":null},{"id":"094f08bf59504fd3bb40136e22a9541d","type":"TRIAL","name":"Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01367626","description":"Breast Cancer","metadata":null},{"id":"1963b6a9dbd743aca3043036d793d5f3","type":"TRIAL","name":"Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01216878","description":"Hypertension","metadata":null},{"id":"3ed58be90f3a46018db74fc74966cdc1","type":"TRIAL","name":"Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00618163","description":"Inflammation","metadata":null},{"id":"a3846f56ed274551a4178dae34156713","type":"TRIAL","name":"Bioequivalency Study of Meloxicam Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00601887","description":"Inflammation","metadata":null},{"id":"b2d22771848245268fca8c5b5cc9661a","type":"TRIAL","name":"Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT01161667","description":"Migraine","metadata":null},{"id":"9faad39ee9ef4a45bda9e357e8b8ecd6","type":"TRIAL","name":"Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01161654","description":"Migraine","metadata":null},{"id":"573f8fae4be34e2fbfec5378e571ad0f","type":"TRIAL","name":"Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01013155","description":"Essential Hypertension","metadata":null},{"id":"a0f4ffad2d95458c8057668f0fd9002d","type":"TRIAL","name":"Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT00754962","description":"Depression","metadata":null},{"id":"fb3dc2bb5dbf4b03ab66c66ceb40f43c","type":"TRIAL","name":"Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01131702","description":"Healthy","metadata":null},{"id":"eeaa6680f2af4a628f4a070e7a0da1b0","type":"TRIAL","name":"Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00601666","description":"Insomnia","metadata":null},{"id":"4b7b70581c984b9caf030e4aec341e30","type":"TRIAL","name":"Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00602719","description":"Insomnia","metadata":null},{"id":"9fd31315d9c740119e5373e8e3b3863d","type":"TRIAL","name":"Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00837915","description":"Healthy","metadata":null},{"id":"046c3dae4dd645a8a1700c244ffe08fd","type":"TRIAL","name":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","canonical_id":"clinicaltrials.gov:NCT07491913","description":"Takayasu Arteritis","metadata":null},{"id":"0933ed3820b0410cb2523fdbe0c9a730","type":"TRIAL","name":"Biological Aspects of Depression and Antidepressant Drugs","canonical_id":"clinicaltrials.gov:NCT00018733","description":"Depression","metadata":null},{"id":"2e92fe0e7a5641148029554e128434b5","type":"TRIAL","name":"Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection","canonical_id":"clinicaltrials.gov:NCT07144865","description":"Proliferative Diabetic Retinopathy","metadata":null},{"id":"a3f5f95e49f0454c8dab5314f09635b8","type":"TRIAL","name":"Biological Effect of Warfarin on Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03536208","description":"Pancreatic Cancer","metadata":null},{"id":"22a7f565ac4b4af6b29580f246690078","type":"TRIAL","name":"Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine","canonical_id":"clinicaltrials.gov:NCT07832032","description":"Migraine","metadata":null},{"id":"8392ec4b029843d2938a466c079d11ee","type":"TRIAL","name":"Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma","canonical_id":"clinicaltrials.gov:NCT00004024","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"c17c88cd3147470da0ac3f41f073d944","type":"TRIAL","name":"Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer","canonical_id":"clinicaltrials.gov:NCT00004061","description":"Leukemia; Lymphoma; Oral Complications","metadata":null},{"id":"f24a48f5b81f4b7bbccc8525d80a8ca7","type":"TRIAL","name":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","canonical_id":"clinicaltrials.gov:NCT05168475","description":"Giant Cell Arteritis; Takayasu Arteritis; Cogan Syndrome; Relapsing Polychondritis; Cryoglobulinemic Vasculitis; IgA Vasculitis; Polyarteritis Nodosa; Cutaneous Polyarteritis Nodosa; Primary Angiitis of Central Nervous System","metadata":null},{"id":"39d93744dc9846ba967252df98eaa72f","type":"TRIAL","name":"Biomarker Guided Therapies in Stage A/B Heart Failure","canonical_id":"clinicaltrials.gov:NCT02230891","description":"Hypertension; Diabetes; Cardiovascular Disease","metadata":null},{"id":"6cff011fcb0145bca2fe63684665cf99","type":"TRIAL","name":"Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF","canonical_id":"clinicaltrials.gov:NCT06331624","description":"Idiopathic Pulmonary Fibrosis; IPF","metadata":null},{"id":"054413e001b84470b0ec14de9694dd31","type":"TRIAL","name":"Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)","canonical_id":"clinicaltrials.gov:NCT02595840","description":"Non-small-cell Lung Cancer With Somatic EGFR Mutations","metadata":null},{"id":"731bc279ee064c07b82cf89f110b96e3","type":"TRIAL","name":"Biomarker Study in Participants With Migraine","canonical_id":"clinicaltrials.gov:NCT02766517","description":"Migraine Disorders","metadata":null},{"id":"4384c1b685154883ab3fd825e7ecbca6","type":"TRIAL","name":"Biomarker and Genetic Predictors of Erenumab Treatment Response","canonical_id":"clinicaltrials.gov:NCT04265755","description":"Migraine","metadata":null},{"id":"145475e9173a4a31a11342809256827b","type":"TRIAL","name":"Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)","canonical_id":"clinicaltrials.gov:NCT02404155","description":"Schizophrenia","metadata":null},{"id":"b507c3a87070497a8860583de71845cb","type":"TRIAL","name":"Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab","canonical_id":"clinicaltrials.gov:NCT03960268","description":"Hidradenitis Suppurativa","metadata":null},{"id":"475ccb62697a42488b7cc4c240a6e795","type":"TRIAL","name":"Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.","canonical_id":"clinicaltrials.gov:NCT05888350","description":"Cough","metadata":null},{"id":"1cc6537249fa490b9117bb1e8cdb3abd","type":"TRIAL","name":"Biomarkers for Prediction of Analgesic Efficacy in Knee OA.","canonical_id":"clinicaltrials.gov:NCT05256342","description":"Knee, Osteoarthritis (OA); Biomarkers for Prediction of OA Treatment Efficacy","metadata":null},{"id":"7f06a005bb1044bb8dbe8a730a982c74","type":"TRIAL","name":"Biomarkers in Clozapine-responding Schizophrenia","canonical_id":"clinicaltrials.gov:NCT05316883","description":"Schizophrenia; Psychosis","metadata":null},{"id":"0156f6de142b4dff8026a43a4c149ce8","type":"TRIAL","name":"Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab","canonical_id":"clinicaltrials.gov:NCT07520045","description":"Diabetic Retinopathy (DR); Diabetic Macular Edema (DME)","metadata":null},{"id":"39240ff19f9240f4bd020ffff521d76b","type":"TRIAL","name":"Biomarkers of Fast Acting Therapies in Major Depression","canonical_id":"clinicaltrials.gov:NCT02165449","description":"Major Depressive Disorder","metadata":null},{"id":"7ef7f9a0220d461ca00528739c6cad10","type":"TRIAL","name":"Biomarkers of Injectable Extended Release Naltrexone Treatment","canonical_id":"clinicaltrials.gov:NCT02324725","description":"Heroin Dependence; Opioid Dependence","metadata":null},{"id":"a5b6e55376e74e5683519baea0946a7c","type":"TRIAL","name":"Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use","canonical_id":"clinicaltrials.gov:NCT07217678","description":"Glaucoma; Open-Angle Glaucoma; Ocular Hypertension; Glaucoma Suspect","metadata":null},{"id":"40e0e14926c24309a90d12f15f0cb535","type":"TRIAL","name":"Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma","canonical_id":"clinicaltrials.gov:NCT05708300","description":"Chronic Rhinosinusitis With Nasal Polyps; Asthma","metadata":null},{"id":"7fa8bf95b957484aa11fd94425f2ae55","type":"TRIAL","name":"Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01176851","description":"Healthy","metadata":null},{"id":"6bb5fe33f04a46dd93c52036d975ee0f","type":"TRIAL","name":"Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor","canonical_id":"clinicaltrials.gov:NCT01598025","description":"Acute Leukemia; Chronic Leukemia; Myelodysplastic Syndrome; Non-Hodgkins Lymphoma","metadata":null},{"id":"eb9595e716804a718f8e0c1e3c3640b4","type":"TRIAL","name":"Biperiden Trial for Epilepsy Prevention","canonical_id":"clinicaltrials.gov:NCT04945213","description":"Brain Injury Traumatic Moderate; Brain Injury Traumatic Severe; Post Traumatic Epilepsy","metadata":null},{"id":"c125448c3c44449593f8baad957fd997","type":"TRIAL","name":"Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex","canonical_id":"clinicaltrials.gov:NCT01358357","description":"Bipolar I Disorder","metadata":null},{"id":"d75ad6f514694525b4d5b9222acd49b3","type":"TRIAL","name":"Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride","canonical_id":"clinicaltrials.gov:NCT00893841","description":"Bipolar Depression","metadata":null},{"id":"a66ed43b05fc43c499a6f729103c5b84","type":"DISEASE","name":"Bipolar disorder","canonical_id":"mesh:D001714","description":null,"metadata":null},{"id":"240a52d406464ca9bf2387f4a32bceb3","type":"DISEASE","name":"Birk-Barel syndrome","canonical_id":"mondo:0012856","description":null,"metadata":null},{"id":"d3894e22384746a691edb4c6c1161113","type":"TRIAL","name":"Birth Ball Versus Meperidine and Haloperidol Injection for Pain Relief During First Stage of Labour","canonical_id":"clinicaltrials.gov:NCT02493192","description":"Parturition; Humanizing Deliver; Labor Pain; Natural Childbirth; Labor Onset; First Labor Stage","metadata":null},{"id":"66689854a1d0479b81dfa19ff3ef09f4","type":"DRUG","name":"Bisacodyl","canonical_id":"mesh:D001726","description":null,"metadata":null},{"id":"2c79ea35a31a40ae8af455369b67790c","type":"TRIAL","name":"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects","canonical_id":"clinicaltrials.gov:NCT00666627","description":"Post-menopausal Osteoporosis","metadata":null},{"id":"b4285bcd9e3547b2b0ae9e7e945b4d79","type":"TRIAL","name":"Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery","canonical_id":"clinicaltrials.gov:NCT04922333","description":"Bone Loss","metadata":null},{"id":"90cde111bbe44d71879ad68a04477c0d","type":"TRIAL","name":"Bivalirudin Infusion for Ventricular Infarction Limitation","canonical_id":"clinicaltrials.gov:NCT02565147","description":"Acute Myocardial Infarction","metadata":null},{"id":"3d37192674504a6f98bf923f588e82ac","type":"TRIAL","name":"Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients","canonical_id":"clinicaltrials.gov:NCT00759083","description":"Heparin-Induced Thrombocytopenia; Heparin-induced Thrombocytopenia and Thrombosis Syndrome","metadata":null},{"id":"86af27fce36d4f42944ee791bdf7e1ad","type":"TRIAL","name":"Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI","canonical_id":"clinicaltrials.gov:NCT03822975","description":"ST Elevation Myocardial Infarction","metadata":null},{"id":"7e101c7855ba4479af2c42966eeb00f6","type":"TRIAL","name":"Bivalirudin as a Procedural Anticoagulant in Pediatrics","canonical_id":"clinicaltrials.gov:NCT00503126","description":"Cardiology","metadata":null},{"id":"e44c418c39e64b42bd2902e6de4484ac","type":"TRIAL","name":"Bivalirudin in Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT02897037","description":"Acute Myocardial Infarction","metadata":null},{"id":"24f346438c1b4d41ada51fbeed0b149a","type":"TRIAL","name":"Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.","canonical_id":"clinicaltrials.gov:NCT04046029","description":"Acute Coronary Syndrome; Percutaneous Coronary Intervention; Aging; Anticoagulants and Bleeding Disorders","metadata":null},{"id":"cb83b1c3fc1049bcadbff1cdca21efe1","type":"TRIAL","name":"Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT03882775","description":"STEMI; Percutaneous Coronary Intervention; Aged","metadata":null},{"id":"437ccb6c9a24402899d8dd2976723f2b","type":"TRIAL","name":"Bivalirudin in Late PCI for Oatients With STEMI","canonical_id":"clinicaltrials.gov:NCT04185077","description":"STEMI - ST Elevation Myocardial Infarction","metadata":null},{"id":"93b193ad168544f388b78a7f2a7d973e","type":"TRIAL","name":"Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI","canonical_id":"clinicaltrials.gov:NCT00093184","description":"Myocardial Infarction","metadata":null},{"id":"1fc9cc811592444f8ff98d39d94b70e5","type":"TRIAL","name":"Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI","canonical_id":"clinicaltrials.gov:NCT02787317","description":"Coronary Disease","metadata":null},{"id":"9bbd0aba62da46ddb5fc824d2389c7ff","type":"TRIAL","name":"Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART","canonical_id":"clinicaltrials.gov:NCT02311231","description":"ST-segment Elevation Myocardial Infarction; Non ST-segment Elevation Myocardial Infarction","metadata":null},{"id":"2d801665007a43d5bc6652d399f80955","type":"TRIAL","name":"Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy","canonical_id":"clinicaltrials.gov:NCT06861374","description":"ST-segment Elevation Myocardial Infarction (STEMI)","metadata":null},{"id":"be4045d5dcbd4dcfa499ffcdf12f3ab5","type":"TRIAL","name":"Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI","canonical_id":"clinicaltrials.gov:NCT01158846","description":"ST-Elevation Myocardial Infarction; Primary Percutaneous Coronary Intervention","metadata":null},{"id":"85d3dcb99fb4456f9e80f4b2fef7e43b","type":"TRIAL","name":"Black Education and Treatment of Hypertension (BEAT HTN)","canonical_id":"clinicaltrials.gov:NCT00661895","description":"Hypertension","metadata":null},{"id":"edbc4da16b894893a5c7de47a39e5402","type":"TISSUE","name":"Bladder","canonical_id":"uberon:UBERON:0001255","description":null,"metadata":null},{"id":"e5123d7354554f028beef16b00f4813e","type":"DISEASE","name":"Bladder Carcinoma","canonical_id":"doid:4007","description":null,"metadata":null},{"id":"6b5f590c6e374dbdb99d287063bf2dfc","type":"DISEASE","name":"Blastic phase of chronic myeloid leukemia","canonical_id":"mesh:D001752","description":null,"metadata":null},{"id":"2091c5e7b12e4ea9a9d3cc6c1b74cf85","type":"DISEASE","name":"Blastomycosis","canonical_id":"mesh:D001759","description":null,"metadata":null},{"id":"826baf60551f4868b10f7f2446462f5b","type":"TRIAL","name":"Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA\u00ae in Contraception and Treatment of Menorrhagia","canonical_id":"clinicaltrials.gov:NCT00393198","description":"Contraception; Menorrhagia","metadata":null},{"id":"af2d114015264908beb25c0e8bd4d871","type":"TRIAL","name":"Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions","canonical_id":"clinicaltrials.gov:NCT00002872","description":"Metastatic Cancer","metadata":null},{"id":"8c3b82ed22ad47cf951b414cdae3f1d6","type":"TRIAL","name":"Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL","canonical_id":"clinicaltrials.gov:NCT06554626","description":"Precursor B-Cell Lymphoblastic Leukemia","metadata":null},{"id":"95d8815fa32b4d8aadb3f0148ccf827e","type":"TRIAL","name":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT04329325","description":"Acute Lymphoblastic Leukemia; Philadelphia Chromosome-Positive","metadata":null},{"id":"fa8e95476e8f49e4865ffb269bcff173","type":"TRIAL","name":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT02877303","description":"B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma","metadata":null},{"id":"5f3f8fbd0a484a6bbb6ba07774504911","type":"TRIAL","name":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03263572","description":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia; t(9;22)","metadata":null},{"id":"1bbaaeff064e458797b010c1545067f7","type":"TRIAL","name":"Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema","canonical_id":"clinicaltrials.gov:NCT01919801","description":"Angiotensin Converting Enzyme Inhibitor Induced Angioedema","metadata":null},{"id":"95f83d3c03cc4c32b79ea641c2c60978","type":"TRIAL","name":"Blinking and Yawning in Epilepsy: The Role of Dopamine","canonical_id":"clinicaltrials.gov:NCT01432821","description":"Idiopathic Generalized Epilepsy","metadata":null},{"id":"d36c1883b7864fc3aa523538da0c227e","type":"TRIAL","name":"Block-replacement Therapy During Radioiodine Therapy","canonical_id":"clinicaltrials.gov:NCT00150124","description":"Toxic Nodular Goitre; Graves' Disease","metadata":null},{"id":"8f1165447cbe4092932354f50b854513","type":"TRIAL","name":"Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence","canonical_id":"clinicaltrials.gov:NCT00134888","description":"Opioid-Related Disorders","metadata":null},{"id":"54e6abef4b4241bcab8a665ff97c45b1","type":"TRIAL","name":"Blockade of Vascular Potassium Channels During Human Endotoxemia","canonical_id":"clinicaltrials.gov:NCT00185003","description":"Endotoxemia","metadata":null},{"id":"6c1565450d304fd0ba2036d1b6b9a46d","type":"TRIAL","name":"Blood Pressure After Endovascular Stroke Therapy-II","canonical_id":"clinicaltrials.gov:NCT04116112","description":"Acute Stroke; Endovascular Thrombectomy","metadata":null},{"id":"d1e86691a9e5485a956705b3e36e4ab3","type":"TRIAL","name":"Blood Pressure Lowering in Acute Stroke Trial","canonical_id":"clinicaltrials.gov:NCT01400256","description":"Stroke, Acute","metadata":null},{"id":"4e93f2bc4add40ff940b766327c6af28","type":"TRIAL","name":"Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population","canonical_id":"clinicaltrials.gov:NCT00760266","description":"Hypertension","metadata":null},{"id":"50fa6964faae446e87c7707be9e93cd4","type":"TRIAL","name":"Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans","canonical_id":"clinicaltrials.gov:NCT00739596","description":"Hypertension","metadata":null},{"id":"7b34488e40ca4e3db296f368629fe414","type":"TRIAL","name":"Blood Pressure Management in Stroke Following Endovascular Treatment","canonical_id":"clinicaltrials.gov:NCT04484350","description":"Stroke, Acute; Vessels; Occlusion; Blood Pressure; Endovascular Thrombectomy; Mechanical Thrombectomy","metadata":null},{"id":"938b3f1a8462477fa7e567cb8ad10363","type":"TRIAL","name":"Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives","canonical_id":"clinicaltrials.gov:NCT00679653","description":"Obesity; Hypertension","metadata":null},{"id":"b043f85e38e94888958ccc8aec9dc34b","type":"TRIAL","name":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","canonical_id":"clinicaltrials.gov:NCT01978015","description":"Uveitis, Anterior; Cystoid Macular Edema","metadata":null},{"id":"24142eca82e1460f8416730ca5cc2d1a","type":"TRIAL","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","canonical_id":"clinicaltrials.gov:NCT05317858","description":"Brain Tumor; Non Small Cell Lung Cancer","metadata":null},{"id":"c0aa7bac58c0462fa41f5eb8e6dc3d6b","type":"TRIAL","name":"Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye","canonical_id":"clinicaltrials.gov:NCT01661946","description":"Diabetic Macular Edema","metadata":null},{"id":"bc9b25048b624454a1804e132eb96440","type":"TRIAL","name":"Body Composition and Adipose Tissue in HIV","canonical_id":"clinicaltrials.gov:NCT03226821","description":"HIV Lipodystrophy Syndrome; Growth Hormone Deficiency; Body Composition","metadata":null},{"id":"6fe817f16e9549e3809d1037d295eb2b","type":"TRIAL","name":"Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure","canonical_id":"clinicaltrials.gov:NCT00811486","description":"Right Heart Failure; Pulmonary Hypertension","metadata":null},{"id":"26b6d75727b74ee6ace12ac8bf6837bd","type":"TRIAL","name":"Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT07834112","description":"Bipolar Disorder (BD)","metadata":null},{"id":"ad8ef7304a0e4fc5b02319c2d95286a9","type":"GO_TERM","name":"Bolwig's organ development","canonical_id":"go:GO:0055034","description":"\"The process whose specific outcome is the progression of the Bolwig's organ over time, from its formation to the mature structure. The larval eye in Drosophila is a relatively simple sensory system composed of Bolwig's organs: two clusters, each composed of 12 photoreceptor cells from which axons extend in a single fascicle to the brain.\" [GOC:mtg_sensu]","metadata":null},{"id":"353ee51afc374c35898c1de0af15a664","type":"GO_TERM","name":"Bolwig's organ morphogenesis","canonical_id":"go:GO:0001746","description":"\"The morphogenetic process in which the anatomical structures of the larval eye in Drosophila are generated and organized. The larval eye in Drosophila is a relatively simple sensory system composed of Bolwig's organs: two clusters, each composed of 12 photoreceptor cells from which axons extend in a single fascicle to the brain.\" [PMID:6185380]","metadata":null},{"id":"d1090fb0a2d645b8b54cdce91a9e728e","type":"TRIAL","name":"Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial","canonical_id":"clinicaltrials.gov:NCT01968850","description":"HIV","metadata":null},{"id":"09575e9de64a4e9984fa3fbbb0ff783b","type":"TRIAL","name":"Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease","canonical_id":"clinicaltrials.gov:NCT00261950","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"06d62b83a94a43d0a30e500830ec18a3","type":"TRIAL","name":"Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole","canonical_id":"clinicaltrials.gov:NCT00421447","description":"Breast Cancer","metadata":null},{"id":"be0f9e96f1d7448688472abfa5f8807f","type":"TRIAL","name":"Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00532545","description":"Osteoporosis, Post-Menopausal","metadata":null},{"id":"f85d78f369644a49a4173be43219d1dd","type":"TRIAL","name":"Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment","canonical_id":"clinicaltrials.gov:NCT04637360","description":"Hyperparathyroidism; Secondary, Renal","metadata":null},{"id":"e9d46db4d8f84274aea9b62f453acf8a","type":"TRIAL","name":"Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT04990128","description":"Hip Osteoarthritis","metadata":null},{"id":"4802ac027da942c39973c808f9c8ca4f","type":"TRIAL","name":"Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium","canonical_id":"clinicaltrials.gov:NCT05343572","description":"Asherman Syndrome; Atrophic Endometrium; Recurrent Implantation Failure","metadata":null},{"id":"5bf2adfa69ee4b48a3c1c85905b732ce","type":"TRIAL","name":"Bone Marrow Transplant With Abatacept for Non-Malignant Diseases","canonical_id":"clinicaltrials.gov:NCT01917708","description":"Hurler Syndrome; Fanconi Anemia; Glanzmann Thrombasthenia; Wiskott-Aldrich Syndrome; Chronic Granulomatous Disease; Severe Congenital Neutropenia; Leukocyte Adhesion Deficiency; Shwachman-Diamond Syndrome; Diamond-Blackfan Anemia; Dyskeratosis-congenita; Chediak-Higashi Syndrome; Severe Aplastic Anemia; Thalassemia Major; Hemophagocytic Lymphohistiocytosis; Sickle Cell Disease","metadata":null},{"id":"82a2e473e45d490aaca0f70b36541e6d","type":"TRIAL","name":"Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003187","description":"Leukemia; Lymphoma; Myelodysplastic Syndromes","metadata":null},{"id":"2f4fabefbd1e438497924c09f936725a","type":"TRIAL","name":"Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","canonical_id":"clinicaltrials.gov:NCT01350245","description":"Acute Myeloid Leukemia; Myelodysplastic Syndromes; Biphenotypic Leukemia; Acute Lymphocytic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Plasma Cell Neoplasms; Lymphoma; Hodgkin's Disease; Aplastic Anemia","metadata":null},{"id":"ee9baff316054c859344ead542a17fa0","type":"TRIAL","name":"Bone MicroArchitecture in Acromegaly","canonical_id":"clinicaltrials.gov:NCT03225040","description":"Acromegaly; Osteoporosis Risk","metadata":null},{"id":"16f89bdff25f46d4904961d673491f59","type":"TRIAL","name":"Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00372099","description":"Postmenopause","metadata":null},{"id":"3bdf5da2985f4eb39391e735769133d8","type":"TRIAL","name":"Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy","canonical_id":"clinicaltrials.gov:NCT01541397","description":"Hyperphenylalaninemia; Phenylketonuria","metadata":null},{"id":"8110c39b2e4545a68dc82fd7eac59940","type":"TRIAL","name":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","canonical_id":"clinicaltrials.gov:NCT00354302","description":"Breast Cancer; Osteoporosis","metadata":null},{"id":"5f4e1961295642b4be6ffe2a594850c9","type":"TRIAL","name":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","canonical_id":"clinicaltrials.gov:NCT01400412","description":"HIV-1 Infection","metadata":null},{"id":"23d74cfc3982424299277a321ab570e7","type":"TRIAL","name":"Boosting Osimertinib Blood Brain Barrier Penetration","canonical_id":"clinicaltrials.gov:NCT07485452","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"7d933a61cf164d92b567da2a0009cdb2","type":"DRUG","name":"Bortezomib","canonical_id":"mesh:D000069286","description":null,"metadata":null},{"id":"5d355747f43b42e385a4391ec8ed7e47","type":"TRIAL","name":"Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma","canonical_id":"clinicaltrials.gov:NCT00504634","description":"Multiple Myeloma","metadata":null},{"id":"76eccfd6c7c744559c91cf5b4e6c2e2e","type":"TRIAL","name":"Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML","canonical_id":"clinicaltrials.gov:NCT05982756","description":"Bortezomib; Acute Myeloid Leukemia","metadata":null},{"id":"323651aedeb7412b9afd7515a7341322","type":"TRIAL","name":"Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02808091","description":"Extranodal NK-T-CELL LYMPHOMA","metadata":null},{"id":"acdfc03158324f528b1c455eba2ff7f6","type":"TRIAL","name":"Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00622674","description":"Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Pancreatic Cancer; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"05268caf6ccf4289b0fce3d261124528","type":"TRIAL","name":"Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT01998503","description":"Amyloidosis","metadata":null},{"id":"d89deca5633446409ce1f64105e5894f","type":"TRIAL","name":"Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis","canonical_id":"clinicaltrials.gov:NCT01083316","description":"Amyloidosis","metadata":null},{"id":"9bdd1b8dec8946419f8a85c83e80614b","type":"TRIAL","name":"Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00541359","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"fac59e4d970d4d5c89a4da6f205ae50d","type":"TRIAL","name":"Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00818649","description":"Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"17ac651525b04107adab31c7c23d8ef8","type":"TRIAL","name":"Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT00839956","description":"DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma","metadata":null},{"id":"d8ed376ffc5d4c4393140cfe04834b98","type":"TRIAL","name":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00598169","description":"Lymphoma","metadata":null},{"id":"3bf3a077d3034fa991cfb1585da64a09","type":"TRIAL","name":"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT04240054","description":"Multiple Myeloma","metadata":null},{"id":"5d9cfed117c2406584cbceaa6ef47ac5","type":"TRIAL","name":"Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00378209","description":"Multiple Myeloma","metadata":null},{"id":"0cd20a1261f5410788d527073999de32","type":"TRIAL","name":"Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease","canonical_id":"clinicaltrials.gov:NCT00520767","description":"Primary Systemic Amyloidosis; Light Chain Deposition Disease","metadata":null},{"id":"13155c7556fe473cb2ab9403dd32a698","type":"DRUG","name":"Bosentan","canonical_id":"mesh:C086232","description":null,"metadata":null},{"id":"9d5aca073a114f81a009954fc02588e8","type":"TRIAL","name":"Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery","canonical_id":"clinicaltrials.gov:NCT01184404","description":"Congenital Heart Disease","metadata":null},{"id":"d0109046cebe4bc5a84650b77e738047","type":"TRIAL","name":"Bosentan and Pulmonary Endothelial Function","canonical_id":"clinicaltrials.gov:NCT01721564","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"93874cfd399f4b60ba7709787d88125f","type":"TRIAL","name":"Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.","canonical_id":"clinicaltrials.gov:NCT01218607","description":"Heart Septal Defects, Atrial","metadata":null},{"id":"8737dfbe92b347bdaec2b1c3b606e092","type":"TRIAL","name":"Bosentan for Severe Mitral Valve Dysfunction","canonical_id":"clinicaltrials.gov:NCT01270750","description":"SECONDARY PULMONARY HYPERTENSION; MITRAL STENOSIS; CHILDHOOD RHEUMATOID FEVER; CONGESTIVE HEART FAILURE","metadata":null},{"id":"7f222df06c2c4968ad15e88764a9addd","type":"TRIAL","name":"Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis","canonical_id":"clinicaltrials.gov:NCT01518595","description":"Hepatopulmonary Syndrome; Liver Cirrhosis","metadata":null},{"id":"f8d6b32ccbf34fe08b03f40afae559b3","type":"TRIAL","name":"Bosentan in Children With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00319267","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"484d082914904d369bc9ee0e2e10df09","type":"TRIAL","name":"Bosentan in Children With Pulmonary Arterial Hypertension Extension Study","canonical_id":"clinicaltrials.gov:NCT00319020","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"4f99f72d7f4745188ccb689d9ee2b534","type":"TRIAL","name":"Bosentan in Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT01395732","description":"Systemic Sclerosis; Digital Ulcers","metadata":null},{"id":"5c005b22e69e4dde8a213465c6a7e0f2","type":"TRIAL","name":"Bosentan in Treatment of Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00266162","description":"Eisenmenger Syndrome","metadata":null},{"id":"fa1d77eabebc450ea09ea0de2ad3e564","type":"TRIAL","name":"Bosentan in the Treatment of Giant Cell Arteritis","canonical_id":"clinicaltrials.gov:NCT06957002","description":"Giant Cell Arteritis (GCA)","metadata":null},{"id":"8991411fc1a34c8b946f2fb9ef5aeb71","type":"DRUG","name":"Bosutinib","canonical_id":"mesh:C471992","description":null,"metadata":null},{"id":"54b9fba0709841aa82ab223ce04d1911","type":"TRIAL","name":"Bosutinib For Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT01233869","description":"Polycystic Kidney, Autosomal Dominant","metadata":null},{"id":"e526803839ff43f6a77d4c075f125374","type":"TRIAL","name":"Bosutinib In Subjects With Renal Impairment","canonical_id":"clinicaltrials.gov:NCT01233882","description":"Renal Disease, End-Stage; Renal Insufficiency, Chronic; Renal Insufficiency, Acute","metadata":null},{"id":"efff4d143dff4004b202bde5ced404d1","type":"TRIAL","name":"Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008","canonical_id":"clinicaltrials.gov:NCT01903733","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"7dabad5be6c14eb9be1ac4de8b149d0f","type":"TRIAL","name":"Bosutinib in Adult Patients With Recurrent Glioblastoma","canonical_id":"clinicaltrials.gov:NCT01331291","description":"Glioblastoma","metadata":null},{"id":"0a80e2a59d424fa5a0b42a87d1937298","type":"TRIAL","name":"Bosutinib in Elderly Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02810990","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"7001cc1f91f14810b74f9c6bda337a86","type":"TRIAL","name":"Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04258943","description":"Philadelphia Chromosome Positive CML; Accelerated Phase Chronic Myelogenous Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia","metadata":null},{"id":"bfa175067b7640c4b355f06445165c42","type":"TRIAL","name":"Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure","canonical_id":"clinicaltrials.gov:NCT02906696","description":"Blasts Under 15 Percent of Bone Marrow Nucleated Cells; Blasts Under 15 Percent of Peripheral Blood White Cells; Blasts Under 30 Percent of Bone Marrow Nucleated Cells; Blasts Under 30 Percent of Peripheral Blood White Cells; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","metadata":null},{"id":"475ab61d20404a4992e13b52ee80c0c5","type":"TRIAL","name":"Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy","canonical_id":"clinicaltrials.gov:NCT05672316","description":"Advanced Colorectal Adenocarcinoma; Advanced Microsatellite Stable Colorectal Carcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8","metadata":null},{"id":"f93146d4e7c9481c8e8468c94d378734","type":"TRIAL","name":"Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06575725","description":"Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma; Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8","metadata":null},{"id":"ee23e92c3f154073b37c516d9a75f362","type":"TRIAL","name":"Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder","canonical_id":"clinicaltrials.gov:NCT01716624","description":"Neurogenic Bladder","metadata":null},{"id":"fc24f4d632854a09afcd6e6fd231b76c","type":"DISEASE","name":"Botulism","canonical_id":"mesh:D001906","description":null,"metadata":null},{"id":"384c70c8ac2f4066b4040edbcecec1ff","type":"DISEASE","name":"Boutonneuse fever","canonical_id":"mesh:D001907","description":null,"metadata":null},{"id":"752217f240314f019a144226c2de5000","type":"TRIAL","name":"BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT07258680","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"c12099b0f6224e6db808309e0477ad4c","type":"TRIAL","name":"BrUOG 390: Neoadjuvant Treatment With Talazoparib","canonical_id":"clinicaltrials.gov:NCT04598321","description":"BRCA1 Mutation; BRCA2 Mutation; Ovarian Cancer; Fallopian Tube Cancer; High Grade Serous Carcinoma","metadata":null},{"id":"46c1d50ce5d346168ab668325888dadf","type":"TRIAL","name":"BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer","canonical_id":"clinicaltrials.gov:NCT00447122","description":"Metastatic Pancreatic Cancer","metadata":null},{"id":"a9b6448692ad4ef9867a0fa623227766","type":"TRIAL","name":"Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07645118","description":"Locally Advanced Rectal Cancer","metadata":null},{"id":"4c881047ac5646ad83f554aa473045b9","type":"TRIAL","name":"Brad Arrhythmia Induced by Repeated Succinylcholine During Gynecological Laparoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT02676011","description":"Bradycardia","metadata":null},{"id":"e1e804dda29c45dc9c5a513fd60cb697","type":"DISEASE","name":"Brain Abscess","canonical_id":"mesh:D001922","description":null,"metadata":null},{"id":"856aedee59fb49439c92f4a5352fd830","type":"TRIAL","name":"Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication","canonical_id":"clinicaltrials.gov:NCT00375843","description":"Depression","metadata":null},{"id":"d08922e58e674dc7a2e84cd9fcef4fce","type":"TISSUE","name":"Brain Amygdala","canonical_id":"uberon:UBERON:0001876","description":null,"metadata":null},{"id":"8f653f35ed004746ab22a9ae7887a2a9","type":"TRIAL","name":"Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People","canonical_id":"clinicaltrials.gov:NCT02669225","description":"Normal Physiology","metadata":null},{"id":"ac4c7caa4be04756b5ae1213e3901104","type":"TISSUE","name":"Brain Anterior cingulate cortex BA24","canonical_id":"uberon:UBERON:0009835","description":null,"metadata":null},{"id":"f40d53ed2e6a4f4db103b8a6d32ef771","type":"TRIAL","name":"Brain Blood Vessel Responses to Changes in Blood Flow","canonical_id":"clinicaltrials.gov:NCT06629077","description":"Magnetic Resonance Imaging; Cerebrovascular Circulation","metadata":null},{"id":"60b070a06b3843f7bd11dafa2be89d07","type":"TRIAL","name":"Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort","canonical_id":"clinicaltrials.gov:NCT06629090","description":"Magnetic Resonance Imaging; Cerebrovascular Circulation","metadata":null},{"id":"535b5733b8c24afca0fe433789234d19","type":"TISSUE","name":"Brain Caudate basal ganglia","canonical_id":"uberon:UBERON:0001873","description":null,"metadata":null},{"id":"4a9156b90bac4e4299e9267072837080","type":"TISSUE","name":"Brain Cerebellar Hemisphere","canonical_id":"uberon:UBERON:0002037","description":null,"metadata":null},{"id":"3651a207602d4da3b62caba0a9eb0f8a","type":"TRIAL","name":"Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles","canonical_id":"clinicaltrials.gov:NCT02063269","description":"Alzheimer's Disease","metadata":null},{"id":"8a434dd536bb4d778528b86f45977e1e","type":"TRIAL","name":"Brain Changes in Psoriasis After Secukinumab Treatment","canonical_id":"clinicaltrials.gov:NCT04717466","description":"Psoriasis; Healthy","metadata":null},{"id":"a516772886754d9b8f1fb2508e6f9793","type":"TRIAL","name":"Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants","canonical_id":"clinicaltrials.gov:NCT02685969","description":"Alzheimer's Disease","metadata":null},{"id":"34841a5e0f2a4cc3a750a57c59e7d844","type":"TRIAL","name":"Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia","canonical_id":"clinicaltrials.gov:NCT04134416","description":"Aphasia; Stroke","metadata":null},{"id":"3262c67037c8463eb2825e014b035ab7","type":"TISSUE","name":"Brain Cortex","canonical_id":"uberon:UBERON:0001870","description":null,"metadata":null},{"id":"fb3cd39e421844fa8865d6224e7197e9","type":"TRIAL","name":"Brain Dopamine Function in Adults With ADHD","canonical_id":"clinicaltrials.gov:NCT00580814","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"da74d5ea82b44d1981ab93905a22209f","type":"TISSUE","name":"Brain Frontal Cortex BA9","canonical_id":"uberon:UBERON:0009834","description":null,"metadata":null},{"id":"eb906b36dd3f43ad9344bce0967af9ef","type":"TRIAL","name":"Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02","canonical_id":"clinicaltrials.gov:NCT00659373","description":"Breast Cancer; Fatigue; Sleep Disorders","metadata":null},{"id":"06a28b4faa304a2c98e66a35306fabc5","type":"TISSUE","name":"Brain Hippocampus","canonical_id":"uberon:UBERON:0001954","description":null,"metadata":null},{"id":"f40ca8a5739245b092fb4d3d0b464cd2","type":"TISSUE","name":"Brain Hypothalamus","canonical_id":"uberon:UBERON:0001898","description":null,"metadata":null},{"id":"67bdd5d02eb44364a2e4087764032819","type":"TRIAL","name":"Brain Imaging Study of Adults With Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT01093768","description":"Autism Spectrum Disorders","metadata":null},{"id":"75b7a494837c40e9905c091a097d1de9","type":"TRIAL","name":"Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.","canonical_id":"clinicaltrials.gov:NCT07758270","description":"Multiple Sclerosis (MS) - Relapsing-remitting","metadata":null},{"id":"fff869cc100d47239100f1155e378686","type":"TRIAL","name":"Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration","canonical_id":"clinicaltrials.gov:NCT02389738","description":"Blood Brain Barrier Defect","metadata":null},{"id":"d3cf31f670d742bb8e4602b2d306aecb","type":"TRIAL","name":"Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT01160588","description":"Social Phobia; Generalized Anxiety Disorder; Separation Anxiety Disorder","metadata":null},{"id":"6556872dcb234b5287196cde8fec17bf","type":"TRIAL","name":"Brain Metastases In ErbB2-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00437073","description":"Neoplasms, Breast","metadata":null},{"id":"fedf9c0a689540e9a3fcb2cb21c558d4","type":"TRIAL","name":"Brain Metastasis in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01077648","description":"Cancer","metadata":null},{"id":"62f7909cface46baaf82d4f6c8d6f41f","type":"TRIAL","name":"Brain Networks Implicated in Lifelong Premature Ejaculation Patients","canonical_id":"clinicaltrials.gov:NCT04850703","description":"Premature Ejaculation; Sexual Dysfunction","metadata":null},{"id":"ed26e228e7724349a420a2a4d2bdeaf9","type":"TRIAL","name":"Brain Networks and Addiction Susceptibility","canonical_id":"clinicaltrials.gov:NCT01924468","description":"Nicotine Dependence","metadata":null},{"id":"fc2cfff511cb41fba2aa2a1fc00151a2","type":"TISSUE","name":"Brain Nucleus accumbens basal ganglia","canonical_id":"uberon:UBERON:0001882","description":null,"metadata":null},{"id":"31e9a55f079940359929ab9612beac28","type":"TISSUE","name":"Brain Putamen basal ganglia","canonical_id":"uberon:UBERON:0001874","description":null,"metadata":null},{"id":"ee673ffbc9da45189d2b0941f96e0ffa","type":"TRIAL","name":"Brain Receptors in Sympathetic Nervous System Regulation","canonical_id":"clinicaltrials.gov:NCT00029627","description":"Healthy","metadata":null},{"id":"a8ad48ffaec447b197d0439c3025ebe2","type":"TISSUE","name":"Brain Spinal cord cervical c-1","canonical_id":"uberon:UBERON:0006469","description":null,"metadata":null},{"id":"cf021b69738f4e87b25c983f1035a029","type":"TISSUE","name":"Brain Substantia nigra","canonical_id":"uberon:UBERON:0002038","description":null,"metadata":null},{"id":"5fef0d2386624fb3b4530d35359dc821","type":"TRIAL","name":"Brain Vascular Disease in Aging and Dementia","canonical_id":"clinicaltrials.gov:NCT03075007","description":"Alzheimer Disease; White Matter Hyperintensities; Dementia; Aging","metadata":null},{"id":"7be522a273e4470e81306211997b1e44","type":"TRIAL","name":"Brazilian Lung Immunotherapy Study","canonical_id":"clinicaltrials.gov:NCT05081674","description":"Lung Neoplasm","metadata":null},{"id":"c601a912d0e04a67822dad1d329ff2c2","type":"GO_TERM","name":"Bre1-Rad6 ubiquitin ligase complex","canonical_id":"go:GO:1990302","description":"\"A ubiquitin ligase complex consisting of Bre1 and Rad6 that mediates monoubiquitination of histone H2B to form H2BK123ub1. H2BK123ub1 gives a specific tag for epigenetic transcriptional activation, elongation by RNA polymerase II, telomeric silencing, and is also a prerequisite for H3K4me and H3K79me formation. It thereby plays a central role in histone code and gene regulation. It also modulates the formation of double-strand breaks during meiosis.\" [GOC:bhm, PMID:19531475]","metadata":null},{"id":"31eead2be05645918b51eed8a8147152","type":"DISEASE","name":"Breast Cancer","canonical_id":"doid:1612","description":null,"metadata":null},{"id":"03f0c2813a5c44baaac0dba90a3f7b78","type":"TRIAL","name":"Breast Cancer - Anti-Progestin Prevention Study 1","canonical_id":"clinicaltrials.gov:NCT02408770","description":"Breast Cancer","metadata":null},{"id":"bc4b0024f8104d0c91783219c2121d8c","type":"TRIAL","name":"Breast Cancer BRCA1 Carriers: a Pilot Study","canonical_id":"clinicaltrials.gov:NCT05062174","description":"BRCA1 Mutation; High-grade Serous Ovarian Cancer; TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"eb80572593084fa18382571da1185c8e","type":"TRIAL","name":"Breast Cancer Treatment Based on Organ-like Culture","canonical_id":"clinicaltrials.gov:NCT03925233","description":"Breast Cancer Organoids","metadata":null},{"id":"220f6c3f5c0e4286bd8349807ce2bfb1","type":"TRIAL","name":"Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial","canonical_id":"clinicaltrials.gov:NCT02950480","description":"Breast Cancer","metadata":null},{"id":"9faf3e63109044ed8baeca88f91da84f","type":"DISEASE","name":"Breast Carcinoma","canonical_id":"doid:3459","description":null,"metadata":null},{"id":"8c481ca30c9b4afebe270675dae47b51","type":"TISSUE","name":"Breast Mammary Tissue","canonical_id":"uberon:UBERON:0008367","description":null,"metadata":null},{"id":"a5ee5d88d9a64b5387059a81836f2de2","type":"TRIAL","name":"Breast Stimulation Versus Pitocin for Induction of Labor","canonical_id":"clinicaltrials.gov:NCT00984347","description":"Labor Induction","metadata":null},{"id":"db7bf0cfeefe4e7b984b99310af88878","type":"DISEASE","name":"Breast Tubular Carcinoma","canonical_id":"doid:6587","description":null,"metadata":null},{"id":"81bfde5755e54d5b9b5f31b4c74ad0e5","type":"DISEASE","name":"Breast hypertrophy","canonical_id":"hp:0010313","description":null,"metadata":null},{"id":"dc4c286d0adb44ad97f127939aa6e761","type":"TRIAL","name":"Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.","canonical_id":"clinicaltrials.gov:NCT02292979","description":"Hodgkin Lymphoma","metadata":null},{"id":"a9a835f86a884bd0933375bae0c02b86","type":"TRIAL","name":"Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01393717","description":"Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma","metadata":null},{"id":"bfbeaa25edd142b2ab38ae00e07b15f9","type":"TRIAL","name":"Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01868451","description":"Hodgkin Lymphoma","metadata":null},{"id":"e09a60117e8740a893f4349c7e7ef0a2","type":"TRIAL","name":"Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02275598","description":"Hodgkin Lymphoma","metadata":null},{"id":"64951683595e46539f8ecfb09750ea4d","type":"TRIAL","name":"Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01534078","description":"Hodgkin Lymphoma","metadata":null},{"id":"5855c87c988b47c694e4ef85324edd7f","type":"TRIAL","name":"Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas","canonical_id":"clinicaltrials.gov:NCT03187210","description":"Lymphoma","metadata":null},{"id":"4784c73556364f298b2f41240848e43e","type":"TRIAL","name":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02166463","description":"Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Childhood Hodgkin Lymphoma; Classic Hodgkin Lymphoma","metadata":null},{"id":"0520232838134a39aec7313a418172ac","type":"TRIAL","name":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03113500","description":"Adult T-Cell Leukemia/Lymphoma; Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Angioimmunoblastic T-Cell Lymphoma; Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma; Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma; Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Hepatosplenic T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Peripheral T-Cell Lymphoma,\u2026","metadata":null},{"id":"ffb1cfa3f2ba4ca381d623ebdebca149","type":"TRIAL","name":"Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT03373305","description":"CD30-Positive Neoplastic Cells Present; Folliculotropic Mycosis Fungoides; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome","metadata":null},{"id":"5b2a6213fed6441fb329c460f0a288b3","type":"TRIAL","name":"Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT02280785","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"6b98d9d6d6b2460c93c734bdd43ca341","type":"TRIAL","name":"Brentuximab Vedotin for Steroid Refractory GvHD","canonical_id":"clinicaltrials.gov:NCT01596218","description":"Graft vs. Host Disease","metadata":null},{"id":"32558cabe532426eb3c4e7be98ad2a99","type":"TRIAL","name":"Brentuximab Vedotin for Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT03222492","description":"Diffuse Cutaneous Systemic Sclerosis; Scleroderma; dcSSc","metadata":null},{"id":"b09c3cab466b4a4d8eaa52368abb6d3c","type":"TRIAL","name":"Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly","canonical_id":"clinicaltrials.gov:NCT01671813","description":"Lymphoma","metadata":null},{"id":"c316b4b8f9214b7aae91096bf58f69bf","type":"TRIAL","name":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT04685616","description":"Hodgkin Lymphoma","metadata":null},{"id":"3ad192009bc34d578ce4d08efcde3a70","type":"TRIAL","name":"Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas","canonical_id":"clinicaltrials.gov:NCT02388490","description":"Relapsed or Refractory EBV-and CD30-positive Lymphomas","metadata":null},{"id":"ab6c999cfae348a9b127bde1959d95de","type":"TRIAL","name":"Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors","canonical_id":"clinicaltrials.gov:NCT02689219","description":"Germ Cell Tumors; Testis Cancer; Testicular Cancer; Embryonal Carcinoma; Nonseminomatous Germ Cell Tumor","metadata":null},{"id":"f6149ccb7fb444fc9814eeffb0f44bc3","type":"TRIAL","name":"Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT01807598","description":"Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic Mastocytosis","metadata":null},{"id":"eca9b80fa5274e18855632fc405f4230","type":"TRIAL","name":"Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02191930","description":"Hodgkin Lymphoma","metadata":null},{"id":"9a3bac2e0307485a911aa5c77a37efc7","type":"TRIAL","name":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01979536","description":"Anaplastic Large Cell Lymphoma, ALK-Positive; Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma; Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma; Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma","metadata":null},{"id":"41f76501e2a04378a4b4faaa10835540","type":"DRUG","name":"Brexpiprazole","canonical_id":"mesh:C000591922","description":null,"metadata":null},{"id":"89fbd65d7dc34d72bdc7f5bf63a60592","type":"TRIAL","name":"Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT04174170","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"63dbe9bb6caf46c381641e0149953e9c","type":"TRIAL","name":"Bridging Intestinal Failure With Teduglutide - a Case Report","canonical_id":"clinicaltrials.gov:NCT04916665","description":"Short Bowel Syndrome","metadata":null},{"id":"130b1f0e753a49ab82d02d8d4a52c6f8","type":"TRIAL","name":"Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT","canonical_id":"clinicaltrials.gov:NCT02349178","description":"Leukemia, Acute Lymphoblastic; Acute Myeloid Leukemia","metadata":null},{"id":"b2f864b8e97c48639d20ed913a32201d","type":"DRUG","name":"Brigatinib","canonical_id":"ncit:C98831","description":null,"metadata":null},{"id":"effeb56236054db9a6f9df74a94e008a","type":"TRIAL","name":"Brigatinib Before Brain Irradiation Trial (B3i Trial)","canonical_id":"clinicaltrials.gov:NCT04634110","description":"Brain Metastases; Lung Cancer","metadata":null},{"id":"275c1ed2c21e417e9c0e1753988f25e6","type":"TRIAL","name":"Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)","canonical_id":"clinicaltrials.gov:NCT06522360","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"efcd62ca327d49a8bfaada03ff134964","type":"TRIAL","name":"Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05718297","description":"NSCLC, Stage III; ALK-rearrangement","metadata":null},{"id":"da6df8622016419b91d4ce21d5c6ac77","type":"TRIAL","name":"Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC","canonical_id":"clinicaltrials.gov:NCT04227028","description":"Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"2b1788f3c52040179f9f591db9cb1e68","type":"TRIAL","name":"Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04005144","description":"ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Progressive Disease; ROS1 Gene Rearrangement; Stage IIIB Lung Cancer; Stage IIIC Lung Cancer; Stage IV Lung Cancer; Stage IVA Lung Cancer; Stage IVB Lung Cancer","metadata":null},{"id":"d26608a596514b30bb4568a4f882dc4f","type":"TRIAL","name":"Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays","canonical_id":"clinicaltrials.gov:NCT04074993","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"2e96050c152f41e489b790eecbd53b4d","type":"TRIAL","name":"Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04925609","description":"Anaplastic Large Cell Lymphoma, ALK-Positive; Inflammatory Myofibroblastic Tumor; Other Solid Tumor","metadata":null},{"id":"d59e42835a8a4c5fa3c16806017dd8c0","type":"TRIAL","name":"Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03719898","description":"Anaplastic Large Cell Lymphoma, ALK-Positive","metadata":null},{"id":"4eabf96f71e94cb7bffd9626d3807b92","type":"TRIAL","name":"Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers","canonical_id":"clinicaltrials.gov:NCT03868423","description":"Advanced Malignant Neoplasm; ALK Fusion Protein Expression; ALK Gene Amplification; ALK Gene Mutation; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Malignant Solid Neoplasm; ROS1 Fusion Positive; ROS1 Gene Amplification; ROS1 Gene Mutation","metadata":null},{"id":"b96fd50dcd0f40e19052e3d3bcd27adc","type":"TRIAL","name":"Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%","canonical_id":"clinicaltrials.gov:NCT00440141","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"2883c2689ac84299b05dbf8e756c428b","type":"TRIAL","name":"Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT03542006","description":"Central Serous Chorioretinopathy","metadata":null},{"id":"87643094b29c4b97b470db921b0110ed","type":"TRIAL","name":"Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections","canonical_id":"clinicaltrials.gov:NCT04523844","description":"Eye Diseases; Injection Complication; Intraocular Pressure","metadata":null},{"id":"ae89bf4d3bc74b43b700631d444797b8","type":"TRIAL","name":"Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy","canonical_id":"clinicaltrials.gov:NCT03192826","description":"Posterior Capsule Opacification; Ocular Hypertension","metadata":null},{"id":"c81a1ffed8484c0cb3877680f8115a67","type":"TRIAL","name":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01310777","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"17ffc773536044d19c660cae9bd58254","type":"TRIAL","name":"Bristol Bladder Trial","canonical_id":"clinicaltrials.gov:NCT01616875","description":"Infiltrating Bladder Urothelial Carcinoma","metadata":null},{"id":"1ed552bf44054e1fa8d60ded2252fea6","type":"DRUG","name":"Brivaracetam","canonical_id":"mesh:C482793","description":null,"metadata":null},{"id":"e61b4b1f2d764680b43bd1869f5a1780","type":"TRIAL","name":"Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT01261325","description":"Epilepsy","metadata":null},{"id":"0b6e1533d52c4c4b9db55ab73b439a15","type":"TRIAL","name":"Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT01339559","description":"Epilepsy","metadata":null},{"id":"52ce8415c6174a9f98ad2c92d7acf14b","type":"TRIAL","name":"Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy","canonical_id":"clinicaltrials.gov:NCT00504881","description":"Epilepsy","metadata":null},{"id":"44ac2dfb5d0a40adbcbb05e6ebec32c1","type":"TRIAL","name":"Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults","canonical_id":"clinicaltrials.gov:NCT00357669","description":"Unverricht-Lundborg Disease","metadata":null},{"id":"7d6b808dbcf54b23879731d2e0c94420","type":"TRIAL","name":"Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","canonical_id":"clinicaltrials.gov:NCT05639946","description":"Spinal Cord Injuries; Neuropathic Pain","metadata":null},{"id":"6a70a6f8032d4abdb235e7e6853b6f66","type":"TRIAL","name":"Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT04379011","description":"Spinal Cord Injuries","metadata":null},{"id":"211720b1231d4432868a8bf1ca71306d","type":"TRIAL","name":"Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study","canonical_id":"clinicaltrials.gov:NCT03517423","description":"Epilepsy","metadata":null},{"id":"1e15a72a25f44f16aada49449ad82d98","type":"TRIAL","name":"Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","canonical_id":"clinicaltrials.gov:NCT06740812","description":"Nausea and Vomiting; Nausea; Vomiting","metadata":null},{"id":"e28a19f7e6094be89ee00404f4ba5a8f","type":"TRIAL","name":"Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT01150890","description":"Crohn's Disease","metadata":null},{"id":"e31bc6a0ebb3447f8c7b9116488019bb","type":"TRIAL","name":"Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate","canonical_id":"clinicaltrials.gov:NCT00950989","description":"Rheumatoid Arthritis","metadata":null},{"id":"23343fc8b59a49cd98ca09fe76c85b78","type":"TRIAL","name":"Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects","canonical_id":"clinicaltrials.gov:NCT01937260","description":"Psoriasis","metadata":null},{"id":"dc6bcb2dcb9648ad8d281e8ab17cf4d3","type":"TRIAL","name":"Brodalumab in Palmoplantar Psoriasis","canonical_id":"clinicaltrials.gov:NCT04622033","description":"Palmoplantar Psoriasis","metadata":null},{"id":"edb98c62791944f5b6ae942b3f443af5","type":"TRIAL","name":"Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies","canonical_id":"clinicaltrials.gov:NCT03403036","description":"Psoriasis","metadata":null},{"id":"8040792489674d63a7cb4668fcf62edf","type":"TRIAL","name":"Brodalumab in the Treatment of Immune-Related Adverse Events","canonical_id":"clinicaltrials.gov:NCT06673329","description":"Breast Cancer; Esophageal Cancer; Kidney Cancer; Lung Cancer; Thyroid Cancer; Gynecologic Cancer; Pancreatic Cancer; Stomach Cancer; Brain Tumor; Colon Cancer; Rectal Cancer; Head and Neck Cancer; Oral Cancer; Liver Cancer; Skin Cancer; Prostate Cancer; Testicular Cancer; Solid Tumor","metadata":null},{"id":"88f5f9e59bd64d1c83fa4898364796e8","type":"TRIAL","name":"Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT06498050","description":"Diabetic Macular Edema","metadata":null},{"id":"b062651333764ada9aa244bd58e8d8e4","type":"TRIAL","name":"Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice","canonical_id":"clinicaltrials.gov:NCT05112835","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"555bb7cb30564ef39eb3e90d34db2f49","type":"TRIAL","name":"Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT07096713","description":"Anti-VEGF Therapy","metadata":null},{"id":"e2d432286fe045a8851a8ab86945a50a","type":"TRIAL","name":"Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation","canonical_id":"clinicaltrials.gov:NCT04698850","description":"Wet Macular Degeneration","metadata":null},{"id":"da0cea7886b04840846e65af80a43eba","type":"TRIAL","name":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","canonical_id":"clinicaltrials.gov:NCT01475877","description":"Myopia","metadata":null},{"id":"7d36f1943d394b0aa2d7f8699803cd13","type":"TRIAL","name":"Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase","canonical_id":"clinicaltrials.gov:NCT00520260","description":"Dry Eye Disease; Ocular Comfort","metadata":null},{"id":"a814213f7a6145cea794d5f3a1bfd7bb","type":"TRIAL","name":"Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening","canonical_id":"clinicaltrials.gov:NCT00469781","description":"Cystoid Macular Edema,; Retinal Thickening","metadata":null},{"id":"cb286fd56a6749e897c37699fc59d8da","type":"TRIAL","name":"Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy","canonical_id":"clinicaltrials.gov:NCT05107921","description":"Familial Exudative Vitreoretinopathies","metadata":null},{"id":"efacf3f9ac7f4379bbc6dbde1986b940","type":"TRIAL","name":"Bromfenac Versus Dexamethasone After Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT03317847","description":"Inflammation Eye","metadata":null},{"id":"5437775115e4464fb66d46a57341e700","type":"TRIAL","name":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT02137161","description":"Cataract; Pseudoexfoliation Syndrome","metadata":null},{"id":"be93944916544783ad251c66bf113b64","type":"TRIAL","name":"Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02544321","description":"Type 1 Diabetes","metadata":null},{"id":"bf44d8c0c4c540068075c45c21ad247e","type":"TRIAL","name":"Bromocriptine and Insulin Sensitivity","canonical_id":"clinicaltrials.gov:NCT02428946","description":"Insulin Sensitivity","metadata":null},{"id":"3a2b1a360916459f994a295a05432c9f","type":"TRIAL","name":"Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment","canonical_id":"clinicaltrials.gov:NCT01893450","description":"Graves Ophthalmopathy","metadata":null},{"id":"b8a92c5fd6064cf19e912a4d363527bf","type":"TRIAL","name":"Bromocriptine for Patients With Schizophrenia and Prediabetes","canonical_id":"clinicaltrials.gov:NCT03575000","description":"Schizophrenia; PreDiabetes","metadata":null},{"id":"5653bfb355374e4e97ce8da1aae42dbd","type":"TRIAL","name":"Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age","canonical_id":"clinicaltrials.gov:NCT06250257","description":"Dilated Cardiomyopathy","metadata":null},{"id":"d3518039aaaf4b8b872f498612e38353","type":"TRIAL","name":"Bromocriptine in the Treatment of Peripartum Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT02590601","description":"Peripartum Cardiomyopathy","metadata":null},{"id":"066f6dd2cf544e2885f8fe41a47929bf","type":"DRUG","name":"Brompheniramine","canonical_id":"mesh:D001977","description":null,"metadata":null},{"id":"69e6d6642598418ba31a6646552878da","type":"TRIAL","name":"Bronchial Hyper-responsiveness in Reflux Cough","canonical_id":"clinicaltrials.gov:NCT00668317","description":"Cough","metadata":null},{"id":"bc8d2796402a453ead7925cb22f78130","type":"DISEASE","name":"Bronchiectasis","canonical_id":"mesh:D001987","description":null,"metadata":null},{"id":"9874bd95ecc442e58a026e1fe994df3d","type":"DISEASE","name":"Bronchiolo-alveolar Adenocarcinoma","canonical_id":"doid:4926","description":null,"metadata":null},{"id":"76a3df83e5bc479e9ce46648e6d8c716","type":"DISEASE","name":"Bronchitis","canonical_id":"mesh:D001991","description":null,"metadata":null},{"id":"729ee6f7cc914682acd1234006a5cece","type":"DISEASE","name":"Bronchitis, Chronic","canonical_id":"mesh:D029481","description":null,"metadata":null},{"id":"d371c7d27988401790d9941e778959cc","type":"TRIAL","name":"Bronchodilators on the Exercise Capacity of Bronchiectasis Patients","canonical_id":"clinicaltrials.gov:NCT05183841","description":"Bronchiectasis Adult","metadata":null},{"id":"e42bdb5a1ecf4c60854bbfee23daf63e","type":"DISEASE","name":"Bronchospasm","canonical_id":"mesh:D001986","description":null,"metadata":null},{"id":"8fc6aa28c2ed42d3b96638bed66d624f","type":"DISEASE","name":"Brucellosis","canonical_id":"mesh:D002006","description":null,"metadata":null},{"id":"d090ff9fdb4c48308c70b3b49659eca3","type":"DISEASE","name":"Brugada syndrome","canonical_id":"mondo:0015263","description":null,"metadata":null},{"id":"a1224c1aa9964459830897c81bb6523d","type":"DISEASE","name":"Brugada syndrome 1","canonical_id":"mondo:0011001","description":null,"metadata":null},{"id":"956fa9b6cc43442fae52889ff9efaf40","type":"DISEASE","name":"Brugada syndrome 3","canonical_id":"mondo:0012742","description":null,"metadata":null},{"id":"58c2abeeda2d4d23a84fa9590838331d","type":"DISEASE","name":"Brunner syndrome","canonical_id":"mondo:0010379","description":null,"metadata":null},{"id":"deb5876986a34ac78c373431bc509930","type":"DISEASE","name":"Bruton-type agammaglobulinemia","canonical_id":"mondo:0010421","description":null,"metadata":null},{"id":"5d1d81efc9e74b54885bce8932133d81","type":"DISEASE","name":"Bruxism","canonical_id":"mesh:D002012","description":null,"metadata":null},{"id":"70242887b7074b7ca6a26577514f21b3","type":"GO_TERM","name":"BtuCD complex","canonical_id":"go:GO:1990193","description":"\"Protein complex involved in cobalamin (vitamin B12) transport through the plasma membrane. In E. coli, the complex is a tetramer and consists of the cytoplasmic ATPase BtuD homodimer together with the transmembrane BtuC homodimer.\" [GOC:bhm, PMID:22569249]","metadata":null},{"id":"e4cecc27abb24f81bdb8dd4705943d98","type":"GO_TERM","name":"Bub1-Bub3 complex localization to kinetochore","canonical_id":"go:GO:1990299","description":"\"A cellular protein complex localization that acts on a Bub1-Bub3 complex; as a result, the complex is transported to, or maintained in, a specific location at the kinetochore.\" [PMID:22521786]","metadata":null},{"id":"b210f42e3675494398372889590a033b","type":"TRIAL","name":"Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT04592198","description":"Nausea With Vomiting Chemotherapy-Induced","metadata":null},{"id":"6f996d75edb64218b08c48a6bd53caaa","type":"TRIAL","name":"Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC","canonical_id":"clinicaltrials.gov:NCT05199818","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"0310475c0305422594d0c179888a3be9","type":"TRIAL","name":"Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT","canonical_id":"clinicaltrials.gov:NCT02779959","description":"Migraine Disorders","metadata":null},{"id":"56c333703f5c4c7d90de2dec142e079a","type":"DRUG","name":"Buclizine","canonical_id":"mesh:C046894","description":null,"metadata":null},{"id":"ec711021a93d40cf89df7f0a28b74017","type":"DRUG","name":"Budesonide","canonical_id":"mesh:D019819","description":null,"metadata":null},{"id":"e8c68e3a40f845348717cb874f9411e6","type":"TRIAL","name":"Budesonide / Formoterol in Treatment of Exacerbations of COPD","canonical_id":"clinicaltrials.gov:NCT00239278","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"68013c5863a342f0b8f4099639a9f962","type":"TRIAL","name":"Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)","canonical_id":"clinicaltrials.gov:NCT00747110","description":"Colitis, Ulcerative","metadata":null},{"id":"28ed00591c54470d9f49726d8286a813","type":"TRIAL","name":"Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis","canonical_id":"clinicaltrials.gov:NCT00450086","description":"Collagenous Colitis","metadata":null},{"id":"fb4237e54fe144cfa037d9bb51fd2bbb","type":"TRIAL","name":"Budesonide Following Endoscopic Dilatation of Esophageal Strictures in Children.","canonical_id":"clinicaltrials.gov:NCT07560462","description":"Esophageal Stricture","metadata":null},{"id":"b619440f66f14c378b07d2532d8683d8","type":"TRIAL","name":"Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05341401","description":"Ulcerative Colitis Chronic","metadata":null},{"id":"3e6cdba6526f44bd9212f087a291c16a","type":"TRIAL","name":"Budesonide With Intratracheal Surfactants in Extremely Preterm Infants","canonical_id":"clinicaltrials.gov:NCT04019106","description":"Bronchopulmonary Dysplasia; Respiratory Distress Syndrome in Premature Infant","metadata":null},{"id":"8461aa67579443dcad19ab84a4b6e1b0","type":"TRIAL","name":"Budesonide/Formoterol Turbuhaler\u00ae Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","canonical_id":"clinicaltrials.gov:NCT04705727","description":"Asthma in Children","metadata":null},{"id":"ad00c368d8b24b1d9ea80a8f6d54f236","type":"DISEASE","name":"Bulimia nervosa","canonical_id":"mesh:D052018","description":null,"metadata":null},{"id":"2e566cee1c104901a723dc40274ad574","type":"TRIAL","name":"Bumetanide Versus Furosemide in Heart Failure","canonical_id":"clinicaltrials.gov:NCT00372762","description":"Heart Failure","metadata":null},{"id":"bd8b5b3cc91742bb8a833ac2454b1383","type":"TRIAL","name":"Bumetanide in Hypokalaemic Periodic Paralysis","canonical_id":"clinicaltrials.gov:NCT02582476","description":"Hypokalemic Periodic Paralysis","metadata":null},{"id":"f50314d6866a47a098694d8c97a020d0","type":"TRIAL","name":"Bumetanide in Patients With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT06052163","description":"Alzheimer Disease","metadata":null},{"id":"ace5ae6e30e242b68ecb6aadb876182e","type":"TRIAL","name":"Bumetanide vs. Furosemide in Cirrhosis","canonical_id":"clinicaltrials.gov:NCT06941415","description":"Cirrhosis","metadata":null},{"id":"fb6759c76af249c785a9da7c046b869c","type":"DRUG","name":"Bunazosin","canonical_id":"mesh:C018176","description":null,"metadata":null},{"id":"e3cf122bf9fc4a66b8a019d4b78aa7de","type":"GO_TERM","name":"Bunina body","canonical_id":"go:GO:0097407","description":"\"Small granular inclusions (about 1-3 microns in diameter) found in the anterior horn cells, and appearing either singly or in a group. Sometimes they are arranged in small beaded chains. Bunina bodies express cystatin C and consist of electron-dense amorphous material that contains tubules or vesicular structures. The amorphous material frequently includes a cytoplasmic island containing neurofilaments and other micro-organelles.\" [NIF_Subcellular:nlx_subcell_20090101, PMID:18026741]","metadata":null},{"id":"6f0f8bf388aa41f3897ef8c4bf41a8c0","type":"TRIAL","name":"Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT02614508","description":"Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma","metadata":null},{"id":"f5ac7eabfebc475ab61810e4bbe13972","type":"DRUG","name":"Buprenorphine","canonical_id":"mesh:D002047","description":null,"metadata":null},{"id":"0010b1fd31a247e39dd57478446c6f18","type":"TRIAL","name":"Buprenorphine Disposition and Cyclosporine","canonical_id":"clinicaltrials.gov:NCT01648270","description":"Healthy","metadata":null},{"id":"d7e4ce95a2b6460e982547d2d1152396","type":"TRIAL","name":"Buprenorphine Dosing Interval - 5","canonical_id":"clinicaltrials.gov:NCT00000209","description":"Opioid-Related Disorders","metadata":null},{"id":"ecad69a17a6a4a4f91c7b030eefd9f17","type":"TRIAL","name":"Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines","canonical_id":"clinicaltrials.gov:NCT01671410","description":"Neonatal Abstinence Syndrome","metadata":null},{"id":"78b65bbdeee94498a7eedbd6490d3ef9","type":"TRIAL","name":"Buprenorphine in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT03174067","description":"Opioid Withdrawal; Opioid-use Disorder","metadata":null},{"id":"173be6e7f3d9426c8ee17a244c7bc93a","type":"TRIAL","name":"Buprenorphine's Dose Response Curve","canonical_id":"clinicaltrials.gov:NCT00460239","description":"Opioid-related Disorders","metadata":null},{"id":"597982c846d74abf980aa617102c40b8","type":"TRIAL","name":"Bupropion Treatment for Youth Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT00344695","description":"Nicotine Dependence","metadata":null},{"id":"73d34d15100a46f78425e2d011267c96","type":"TRIAL","name":"Bupropion as a Smoking Cessation Aid in Alcoholics","canonical_id":"clinicaltrials.gov:NCT00044434","description":"Alcoholism; Smoking","metadata":null},{"id":"77ff83d88e714d8ebda0ddd90847f7fe","type":"TRIAL","name":"Bupropion in the Treatment of Pathological Gambling","canonical_id":"clinicaltrials.gov:NCT00055393","description":"Pathological Gambling","metadata":null},{"id":"542d49bb0bdd4b84a5e78beb14cd810d","type":"TRIAL","name":"Buproprion for Binge Drinking","canonical_id":"clinicaltrials.gov:NCT03169244","description":"Alcohol Abuse","metadata":null},{"id":"ea5c31594f3348af9b20760391902dba","type":"TRIAL","name":"Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study","canonical_id":"clinicaltrials.gov:NCT07711808","description":"Overactive Bladder (OAB)","metadata":null},{"id":"a305cca2148d44c69c53bb3ecde064c4","type":"TRIAL","name":"Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients","canonical_id":"clinicaltrials.gov:NCT05870956","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"fd794d8afe7b454b8ca6a76b980febc2","type":"DISEASE","name":"Burkitt's lymphoma","canonical_id":"mesh:D002051","description":null,"metadata":null},{"id":"0a6b3163942f4a0c8825c8dabafa1992","type":"TRIAL","name":"Burning Mouth Syndrome - New Diagnostic Criteria and Treatment","canonical_id":"clinicaltrials.gov:NCT05059418","description":"Burning Mouth Syndrome","metadata":null},{"id":"1f51bec96dee4de3a54b65513f039b12","type":"TRIAL","name":"Burosumab for CSHS","canonical_id":"clinicaltrials.gov:NCT03993821","description":"Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS); Epidermal Nevus Syndrome","metadata":null},{"id":"57e53496fff24cca8fa9f8949970c774","type":"TRIAL","name":"Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia","canonical_id":"clinicaltrials.gov:NCT05509595","description":"Fibrous Dysplasia Of Bone","metadata":null},{"id":"883f35bc3894486f8bedc29150c0c243","type":"TRIAL","name":"Burosumab in Children and Adolescents With X-linked Hypophosphatemia","canonical_id":"clinicaltrials.gov:NCT04419363","description":"Rare Diseases; X-linked Hypophosphatemia","metadata":null},{"id":"2cf75e6d239d44eb85f2f7cd8bccfcb0","type":"DISEASE","name":"Bursitis","canonical_id":"mesh:D002062","description":null,"metadata":null},{"id":"2f0f89f8b57b4cd0b45543b58c84032e","type":"TRIAL","name":"Buspirone Hydrochloride 30mg Tablets, Fasting","canonical_id":"clinicaltrials.gov:NCT00840606","description":"Healthy","metadata":null},{"id":"36d39b314a164288aae8e1ae8b278540","type":"TRIAL","name":"Buspirone Hydrochloride 30mg Tablets, Non-Fasting","canonical_id":"clinicaltrials.gov:NCT00840398","description":"Healthy","metadata":null},{"id":"08e8b47c395b41b5b659f40afcc88a3b","type":"TRIAL","name":"Buspirone Therapy for Localized Epilepsy","canonical_id":"clinicaltrials.gov:NCT01496612","description":"Anxiety Disorder; Seizures; Epilepsy; Partial Epilepsy; Depression","metadata":null},{"id":"51186ca309d24b66bdaf66b6d71e9b1c","type":"TRIAL","name":"Buspirone Treatment for Marijuana Dependence","canonical_id":"clinicaltrials.gov:NCT00875836","description":"Marijuana Dependence","metadata":null},{"id":"4f867cc4c20242f7b1a1d29b1c3380c2","type":"TRIAL","name":"Buspirone Treatment of Anxiety in Williams Syndrome","canonical_id":"clinicaltrials.gov:NCT04807517","description":"Williams Syndrome; Anxiety","metadata":null},{"id":"8d81b6d600fe4e16917ffb74ac681422","type":"TRIAL","name":"Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease","canonical_id":"clinicaltrials.gov:NCT02617017","description":"Parkinson","metadata":null},{"id":"88aacf4aa8f94d7385560133dc581549","type":"TRIAL","name":"Buspirone and Melatonin for Depression Following Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT04400266","description":"Depression; Brain Injuries, Traumatic","metadata":null},{"id":"7285250f11ec4f3580c0ad0aa673b06d","type":"TRIAL","name":"Buspirone as a Potential Treatment for Recurrent Central Apnea","canonical_id":"clinicaltrials.gov:NCT00746954","description":"Central Apnea; Heart Failure","metadata":null},{"id":"08489368556a474083261f4a3afda882","type":"TRIAL","name":"Buspirone for Anxiety in Autistic Youth","canonical_id":"clinicaltrials.gov:NCT07439042","description":"Anxiety; Autism Spectrum Disorder","metadata":null},{"id":"8abde8a3bc674d85810787b6ba981d7b","type":"TRIAL","name":"Buspirone for Functional Dysphagia","canonical_id":"clinicaltrials.gov:NCT02674412","description":"Functional Dysphagia; Ineffective Esophageal Motility","metadata":null},{"id":"f0e1a4d283564bdeb5ebb3deaa86afae","type":"TRIAL","name":"Buspirone for Opioid Tapering","canonical_id":"clinicaltrials.gov:NCT03521960","description":"Opioid-Related Disorders; Dependency (Psychology); Pain, Chronic; Opiate Withdrawal Syndrome","metadata":null},{"id":"7d3761fb986540a18742ff8eb59bd04e","type":"TRIAL","name":"Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression","canonical_id":"clinicaltrials.gov:NCT01821690","description":"Traumatic Brain Injury","metadata":null},{"id":"8c4a02ff189c4113883b8adc1430d840","type":"TRIAL","name":"Buspirone in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02803749","description":"Parkinson Disease; Anxiety","metadata":null},{"id":"77f263ca27d3458999d09f2de15e0ede","type":"TRIAL","name":"Buspirone in Reducing Shortness of Breath in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT00053846","description":"Dyspnea; Pulmonary Complications; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"d1f5ddd075ec4e9ead1351f723828bd0","type":"TRIAL","name":"Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder","canonical_id":"clinicaltrials.gov:NCT00873509","description":"Autistic Disorder","metadata":null},{"id":"f6f556e622ac443dba9da6e4498f6fe0","type":"TRIAL","name":"Buspirone, Stress, and Attentional Bias to Marijuana Cues","canonical_id":"clinicaltrials.gov:NCT02132832","description":"Cannabis Use Disorder","metadata":null},{"id":"39034b07d6b94270b094565fa99137b9","type":"TRIAL","name":"Busulfan and Cyclophosphamide Followed By ALLO BMT","canonical_id":"clinicaltrials.gov:NCT01685411","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"eae6b021e6db4576b5634d296f35dcef","type":"TRIAL","name":"Busulfan and Fludarabine in Patients With AML and MDS","canonical_id":"clinicaltrials.gov:NCT00502905","description":"Leukemia","metadata":null},{"id":"4965fa5a7a7142e98e12a86dabae67c8","type":"TRIAL","name":"Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00469014","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia","metadata":null},{"id":"92a062998cf1495799c6a0d46946d4c1","type":"TRIAL","name":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","canonical_id":"clinicaltrials.gov:NCT00245037","description":"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition","metadata":null},{"id":"3ca0d8604b3c4d7da8024ea7a4e11a70","type":"TRIAL","name":"Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT00629798","description":"Acute Myeloid Leukemia; Advanced Myelodysplastic Syndromes","metadata":null},{"id":"014f89449e3e4154b6455e3723bc2a17","type":"TRIAL","name":"Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT01643668","description":"Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"fdd27c5e2df241d5ab8ed6058368dc46","type":"DRUG","name":"Butalbital","canonical_id":"mesh:C004470","description":null,"metadata":null},{"id":"77de7d367dbf40acbabfd6e2e4e63c86","type":"DRUG","name":"Butoconazole","canonical_id":"mesh:C017125","description":null,"metadata":null},{"id":"3487dc7ad9ea4f39aa1db0582ddf309d","type":"TRIAL","name":"Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT03398759","description":"Agitation","metadata":null},{"id":"682e79f88c5f456488f047554030db4c","type":"TRIAL","name":"Butorphanol in Pain Following Ablation for Hepatic Tumor","canonical_id":"clinicaltrials.gov:NCT06031129","description":"Visceral Pain; Microwave Ablation; Hepatic Tumor","metadata":null},{"id":"b0d3be4bbbc8480d854972303b08abc8","type":"GO_TERM","name":"C bouton","canonical_id":"go:GO:1990024","description":"\"Synaptic bouton found in spinal cord on the soma and proximal dendrites of motor neurons.\" [NIF_Subcellular:nlx_subcell_100208]","metadata":null},{"id":"610065d4a3f445f8941eb9ebe3a963e8","type":"GO_TERM","name":"C zone","canonical_id":"go:GO:0014705","description":"\"A region of the A band in which myosin-binding protein C is located and that can be seen by electron microscopy. This is a functional zone that also includes myosin.\" [GOC:mtg_muscle]","metadata":null},{"id":"d1b36cdb586d49b7936eaa137c80d6af","type":"GO_TERM","name":"C-22 sterol desaturase (NADPH) activity","canonical_id":"go:GO:0000249","description":"\"Catalysis of the reaction: 5-dehydroepisterol + H+ + NADPH + O2 = ergosta-5,7,22,24(28)-tetraen-3beta-ol + 2 H2O + NADP+. This reaction is the introduction of a double bond between the C-22 and C-23 carbons of certain sterols. Also converts sitosterol and 24-epi-campesterol to stigmasterol and brassicasterol, respectively.\" [EC:1.14.19.41]","metadata":null},{"id":"68a898930e864f0cbba2cf9f120ca64c","type":"GO_TERM","name":"C-4 methylsterol oxidase activity","canonical_id":"go:GO:0000254","description":"\"Catalysis of the reaction: 4,4-dimethyl-5alpha-cholest-7-en-3beta-ol + 6 Fe(II)-[cytochrome b5] + 5 H+ + 3 O2 = 4alpha-carboxy-4beta-methyl-5alpha-cholest-7-ene-3beta-ol + 6 Fe(III)-[cytochrome b5] + 4 H2O.\" [PMID:9811880, RHEA:55220]","metadata":null},{"id":"2e2c69483e1a44c5ad140b4a81095e75","type":"GO_TERM","name":"C-5 sterol desaturase activity","canonical_id":"go:GO:0000248","description":"\"Catalysis of the reaction: 5,7,24(28)-ergostatrienol + O2 + NADPH = 5,7,22,24(28)-ergostatetraenol + 2 H2O + NADP+.\" [GOC:curators]","metadata":null},{"id":"b7b338bf26994022b16dc87f809f151e","type":"GO_TERM","name":"C-8 sterol isomerase activity","canonical_id":"go:GO:0000247","description":"\"Catalysis of the reaction: fecosterol = episterol.\" [PMID:8988026, RHEA:33435]","metadata":null},{"id":"b73816533b274c3089709ef47f354270","type":"GO_TERM","name":"C-C chemokine binding","canonical_id":"go:GO:0019957","description":"\"Binding to a C-C chemokine; C-C chemokines do not have an amino acid between the first two cysteines of the characteristic four-cysteine motif.\" [GOC:ai]","metadata":null},{"id":"a07db5c4738b4fe6aee7e7ae1e9031c2","type":"GO_TERM","name":"C-C chemokine receptor CCR2 signaling pathway","canonical_id":"go:GO:0038150","description":"\"The series of molecular signals initiated by a the C-C chemokine type 2 receptor (CCR2) on the surface of a cell binding to one of it's physiological ligands, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"d579b04dec3646ceb2923b803541c766","type":"GO_TERM","name":"C-C chemokine receptor CCR4 signaling pathway","canonical_id":"go:GO:0038152","description":"\"The series of molecular signals initiated by a the C-C chemokine type 2 receptor (CCR4) on the surface of a cell binding to one of it's physiological ligands, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"4c84caebc51c401284f01783f2a4058b","type":"GO_TERM","name":"C-C chemokine receptor CCR7 signaling pathway","canonical_id":"go:GO:0038118","description":"\"The series of molecular signals initiated by a the C-C chemokine type 7 receptor on the surface of a cell binding to one of it's physiological ligands, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:15059845, PMID:15778365]","metadata":null},{"id":"7e2d79721c8341679fabc1c78e178b87","type":"GO_TERM","name":"C-C chemokine receptor activity","canonical_id":"go:GO:0016493","description":"\"Combining with a C-C chemokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. C-C chemokines do not have an amino acid between the first two cysteines of the characteristic four-cysteine motif.\" [GOC:signaling, PMID:8662823]","metadata":null},{"id":"f9da9fab311a425da31e26b06f1fdeec","type":"GO_TERM","name":"C-C motif chemokine 19 receptor activity","canonical_id":"go:GO:0038117","description":"\"Combining with the C-C motif chemokine 19 (CCL19) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:signaling, PMID:15059845]","metadata":null},{"id":"9502b689068e4896beff794d77cb091a","type":"GO_TERM","name":"C-C motif chemokine 2 receptor activity","canonical_id":"go:GO:0038149","description":"\"Combining with the C-C motif chemokine 2 (CCL2) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:signaling]","metadata":null},{"id":"e97f2cd0e7204b5fb2bd3c3e9e29760b","type":"GO_TERM","name":"C-C motif chemokine 21 receptor activity","canonical_id":"go:GO:0038121","description":"\"Combining with the C-C motif chemokine 21 (CCL21) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:signaling, PMID:15059845]","metadata":null},{"id":"c80029f6244745a08d56e98e8b66158a","type":"GO_TERM","name":"C-C motif chemokine 5 receptor activity","canonical_id":"go:GO:0038122","description":"\"Combining with the C-C motif chemokine 5 (CCL5) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:signaling]","metadata":null},{"id":"68669065dd9e4c74b2bbb3a992d74788","type":"GO_TERM","name":"C-X-C chemokine binding","canonical_id":"go:GO:0019958","description":"\"Binding to a C-X-C chemokine; C-X-C chemokines have a single amino acid between the first two cysteines of the characteristic four cysteine motif.\" [GOC:ai]","metadata":null},{"id":"f9091e85434a41b193af574c46cc33d8","type":"GO_TERM","name":"C-X-C chemokine receptor CXCR4 signaling pathway","canonical_id":"go:GO:0038159","description":"\"The series of molecular signals initiated by a the C-X-C chemokine type 4 receptor on the surface of a cell binding to one of it's physiological ligands, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"c491c793ffc44147ae05eefa0cd40a98","type":"GO_TERM","name":"C-X-C chemokine receptor activity","canonical_id":"go:GO:0016494","description":"\"Combining with a C-X-C chemokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. A C-X-C chemokine has a single amino acid between the first two cysteines of the characteristic four cysteine motif.\" [GOC:signaling, PMID:8662823]","metadata":null},{"id":"60dcf2610c974529a5d7d8d778c32ea2","type":"PROTEIN","name":"C-X-C chemokine receptor type 1","canonical_id":"uniprot:P25024","description":null,"metadata":null},{"id":"5ea09d736e9b48d9bff7dd2a5aec9170","type":"GO_TERM","name":"C-X-C motif chemokine 12 receptor activity","canonical_id":"go:GO:0038147","description":"\"Combining with the C-X-C motif chemokine 12 (CXCL12) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, PMID:22204316]","metadata":null},{"id":"63d9a079820341b3bed66b3674faeae9","type":"GO_TERM","name":"C-X3-C chemokine binding","canonical_id":"go:GO:0019960","description":"\"Binding to a C-X3-C chemokine; C-X3-C chemokines have three amino acids between the first two cysteines of the characteristic four-cysteine motif.\" [GOC:ai]","metadata":null},{"id":"b7d2eb7787bc478991f1c7fc317b11ca","type":"GO_TERM","name":"C-X3-C chemokine receptor activity","canonical_id":"go:GO:0016495","description":"\"Combining with a C-X3-C chemokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. A C-X3-C chemokine has three amino acids between the first two cysteines of the characteristic four-cysteine motif.\" [GOC:dph, GOC:signaling]","metadata":null},{"id":"dfcb257ee33d4fbda13e35c9e1532c2e","type":"GO_TERM","name":"C-acetyltransferase activity","canonical_id":"go:GO:0016453","description":"\"Catalysis of the transfer of an acetyl group to a carbon atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"4011c2eeae044671a71148021428fec3","type":"GO_TERM","name":"C-fiber","canonical_id":"go:GO:0044299","description":"\"The axon of a dorsal root ganglion cell that are responsive to pain and temperature. C-fibers are small in diameter (0.2-1.5 um) and unmyelinated.\" [NIF_Subcellular:nlx_subcell_20090210]","metadata":null},{"id":"795ae932fc8347e39a958c89717c1671","type":"GO_TERM","name":"C-methyltransferase activity","canonical_id":"go:GO:0008169","description":"\"Catalysis of the transfer of a methyl group to the carbon atom of an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"8942cf0105d84ab88f0e699b56ccb0c2","type":"GO_TERM","name":"C-palmitoyltransferase activity","canonical_id":"go:GO:0016454","description":"\"Catalysis of the transfer of a palmitoyl group to a carbon atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"5dae066bf3cc43e0b5f1b72c0c29f423","type":"GO_TERM","name":"C-rich single-stranded DNA binding","canonical_id":"go:GO:1990829","description":"\"Binding to C-rich, single-stranded DNA.\" [PMID:8127654]","metadata":null},{"id":"98f68f5cb0f14f6d8165742ad8d9fb9b","type":"GO_TERM","name":"C-rich strand telomeric DNA binding","canonical_id":"go:GO:0061730","description":"\"Binding to C-rich, single-stranded, telomere-associated DNA.\" [GOC:dph, GOC:kmv, PMID:18329362]","metadata":null},{"id":"55aa0803e362433b8a9b403dd4a2b2e8","type":"GO_TERM","name":"C-terminal protein amino acid modification","canonical_id":"go:GO:0018410","description":"\"The alteration of the C-terminal amino acid residue in a protein.\" [GOC:mah]","metadata":null},{"id":"432876d6d3a6414e8c5f1c770869eb04","type":"GO_TERM","name":"C-terminal protein deglutamylation","canonical_id":"go:GO:0035609","description":"\"The removal of a C-terminal, gene-encoded glutamate residue from a protein.\" [GOC:sp, PMID:21074048]","metadata":null},{"id":"ba5d62713fb84414bc244b1d5ec048fe","type":"GO_TERM","name":"C-terminal protein demethylation","canonical_id":"go:GO:1990577","description":"\"The removal of a methyl group from the C-terminal amino acid of a protein.\" [PMID:11060018]","metadata":null},{"id":"5ec7eb0a4acd47338613a9461a0d612a","type":"GO_TERM","name":"C-terminal protein lipidation","canonical_id":"go:GO:0006501","description":"\"The covalent attachment of a lipid group to the carboxy-terminus of a protein.\" [GOC:jl]","metadata":null},{"id":"334ba2b028a24cf1aaf3d1fc6d7f5b34","type":"GO_TERM","name":"C-terminal protein methylation","canonical_id":"go:GO:0006481","description":"\"The methylation of the C-terminal amino acid of a protein.\" [GOC:ai]","metadata":null},{"id":"9be5d6ae126a467f870702a355231877","type":"GO_TERM","name":"C-type glycerophospholipase activity","canonical_id":"go:GO:0004629","description":"\"A glycerophospholipase activity that cleaves the first phosphodiester bond between the phosphate and glycerol, producing a mono- or a diacylglycerol, depending on whether the substrate is a lysoglycerophospholipid or a glycerophospholipid.\" [PMID:30109646]","metadata":null},{"id":"f3261d7194e24181888f7a4f44812d94","type":"GO_TERM","name":"C/EBP complex","canonical_id":"go:GO:1990647","description":"\"A dimeric, sequence specific DNA-binding transcription factor complex regulating the expression of genes involved in immune and inflammatory responses. Exists at least as alpha and beta homodimeric forms. Binds to regulatory regions of several acute-phase and cytokines genes and probably plays a role in the regulation of acute-phase reaction, inflammation and hemopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Transcription factor activity is inhibited by binding of CHOP forming heterodimers with alternative transcription factor activities.\" [GOC:bhm, GOC:pad, GOC:PARL, PMID:8657121]","metadata":null},{"id":"4b01b737149b471f895ab195d61025ce","type":"GO_TERM","name":"C1 axonemal microtubule","canonical_id":"go:GO:1990719","description":"\"One of two microtubules present in the axonemal central pair. It is distinguishable from the C2 axonemal microtubule (also called C2 tubule) by the presence of differing protein components of the projections.\" [GOC:cilia, PMID:21586547, PMID:9295136]","metadata":null},{"id":"9f892ed25e434f6cb1f35a9a07cfc7b5","type":"GENE","name":"C10orf105","canonical_id":"hgnc:HGNC:20304","description":"chromosome 10 open reading frame 105","metadata":{"aliases":["FLJ00245"]}},{"id":"b4b25c8f70854dfba10bb1ccd6298a74","type":"GENE","name":"C10orf120","canonical_id":"hgnc:HGNC:25707","description":"chromosome 10 open reading frame 120","metadata":{"aliases":["bA318C4.1"]}},{"id":"e4ded4d6d967472dbe188223b71e4dda","type":"GENE","name":"C10orf126","canonical_id":"hgnc:HGNC:28693","description":"chromosome 10 open reading frame 126","metadata":{"aliases":["MGC45541","bA492M23.1"]}},{"id":"7615b03aa0b2433ba8e89e0ea49fa908","type":"GENE","name":"C10orf143","canonical_id":"hgnc:HGNC:48677","description":"chromosome 10 open reading frame 143","metadata":{"aliases":["LINC00959"]}},{"id":"d3f8d5927a5142ff88d609b11d382b2f","type":"GENE","name":"C10orf53","canonical_id":"hgnc:HGNC:27421","description":"chromosome 10 open reading frame 53","metadata":{"aliases":["Em:AC069546.1"]}},{"id":"b1caf19e29d14db3bdc13c842b20a44d","type":"GENE","name":"C10orf55","canonical_id":"hgnc:HGNC:31008","description":"chromosome 10 putative open reading frame 55","metadata":{"aliases":["bA417O11.3"]}},{"id":"4f3c4347d1c0461caee029856c6b129d","type":"GENE","name":"C10orf62","canonical_id":"hgnc:HGNC:23294","description":"chromosome 10 open reading frame 62","metadata":{"aliases":["bA548K23.1"]}},{"id":"206a0e4bb00c4d638275227b4d66ed8c","type":"GENE","name":"C10orf67","canonical_id":"hgnc:HGNC:28716","description":"chromosome 10 open reading frame 67","metadata":{"aliases":["MGC46732","bA215C7.4","LINC01552","C10orf115"]}},{"id":"4e114027295b4a4c947321e4944b80cf","type":"GENE","name":"C10orf67-AS1","canonical_id":"hgnc:HGNC:55861","description":"C10orf67 antisense RNA 1","metadata":null},{"id":"58e270e301b4463ebb2f6a1c1b48934b","type":"GENE","name":"C10orf71","canonical_id":"hgnc:HGNC:26973","description":"chromosome 10 open reading frame 71","metadata":{"aliases":["FLJ45913","CEFIP"]}},{"id":"c99cd243e00e41a89095fccbcc09ffa6","type":"GENE","name":"C10orf71-AS1","canonical_id":"hgnc:HGNC:45007","description":"C10orf71 antisense RNA 1","metadata":null},{"id":"d5661f5c36f542e4acd8f171a5803463","type":"GENE","name":"C10orf88","canonical_id":"hgnc:HGNC:25822","description":"chromosome 10 open reading frame 88","metadata":{"aliases":["FLJ13490","Em:AC073585.5","PAAT"]}},{"id":"4273de57ec8844a09fd263ada3efa3c9","type":"GENE","name":"C10orf88B","canonical_id":"hgnc:HGNC:44080","description":"C10orf88B (pseudogene)","metadata":{"aliases":["C10orf88BP"]}},{"id":"1e9829895d5c45bca8722fc8b433ab8b","type":"GENE","name":"C10orf90","canonical_id":"hgnc:HGNC:26563","description":"chromosome 10 open reading frame 90","metadata":{"aliases":["FLJ32938","bA422P15.2","FATS"]}},{"id":"647a8e243a0646f9b272a36bc87bc186","type":"GENE","name":"C10orf95","canonical_id":"hgnc:HGNC:25880","description":"chromosome 10 open reading frame 95","metadata":{"aliases":["FLJ14280"]}},{"id":"4230f0350c80449faa4a5cf97aa18f50","type":"GENE","name":"C10orf95-AS1","canonical_id":"hgnc:HGNC:45238","description":"C10orf95 antisense RNA 1","metadata":{"aliases":["RPARP-AS1"]}},{"id":"06d3636dfc594d1ea421701583132ecc","type":"GENE","name":"C11orf16","canonical_id":"hgnc:HGNC:1169","description":"chromosome 11 open reading frame 16","metadata":null},{"id":"f351b05cea46491890f6513a0e5a7e8c","type":"GENE","name":"C11orf21","canonical_id":"hgnc:HGNC:13231","description":"chromosome 11 open reading frame 21","metadata":null},{"id":"12e7ca8240e04547adbb69c458a9dbf5","type":"GENE","name":"C11orf24","canonical_id":"hgnc:HGNC:1174","description":"chromosome 11 open reading frame 24","metadata":{"aliases":["DM4E3"]}},{"id":"f0661b4992474d5ba87f58a437711bb6","type":"GENE","name":"C11orf40","canonical_id":"hgnc:HGNC:23986","description":"chromosome 11 putative open reading frame 40","metadata":{"aliases":["NOV1"]}},{"id":"106dffb211a048b6a149e5ddab42f651","type":"GENE","name":"C11orf42","canonical_id":"hgnc:HGNC:28541","description":"chromosome 11 open reading frame 42","metadata":{"aliases":["MGC34805"]}},{"id":"72b62ddf88f24c38986e14f7a109289b","type":"GENE","name":"C11orf52","canonical_id":"hgnc:HGNC:30531","description":"chromosome 11 open reading frame 52","metadata":{"aliases":["MGC14839","FLJ25219"]}},{"id":"90af41eb5a8643f5a234e45e3ba1e42d","type":"GENE","name":"C11orf58","canonical_id":"hgnc:HGNC:16990","description":"chromosome 11 open reading frame 58","metadata":{"aliases":["SMAP","Hero20"]}},{"id":"5800e22f96594f57986f9d491093dfb2","type":"GENE","name":"C11orf58P1","canonical_id":"hgnc:HGNC:58580","description":"C11orf58 pseudogene 1","metadata":null},{"id":"8cdbf88ade314d40acec8ceca8d18a95","type":"GENE","name":"C11orf65","canonical_id":"hgnc:HGNC:28519","description":"chromosome 11 open reading frame 65","metadata":{"aliases":["MGC33948","MFI"]}},{"id":"646d1dac576d4e81aa6bcdc46fdee2b2","type":"GENE","name":"C11orf68","canonical_id":"hgnc:HGNC:28801","description":"chromosome 11 open reading frame 68","metadata":{"aliases":["P5326","BLES03"]}},{"id":"2c3e73deb5ea451bac48f7cdb835eb99","type":"GENE","name":"C11orf71","canonical_id":"hgnc:HGNC:25937","description":"chromosome 11 open reading frame 71","metadata":{"aliases":["FLJ20010"]}},{"id":"60643b6210284b30acd4738b04d25ce7","type":"GENE","name":"C11orf86","canonical_id":"hgnc:HGNC:34442","description":"chromosome 11 open reading frame 86","metadata":{"aliases":["FLJ22675","FACI"]}},{"id":"be90f76275cf49868607875c4fb85523","type":"GENE","name":"C11orf87","canonical_id":"hgnc:HGNC:33788","description":"chromosome 11 open reading frame 87","metadata":{"aliases":["LOH11CR1A","LOC399947","NEURIM1"]}},{"id":"df2a4476a2284ee2b817e28b969630e8","type":"GENE","name":"C11orf91","canonical_id":"hgnc:HGNC:34444","description":"chromosome 11 open reading frame 91","metadata":null},{"id":"ae41206f78c943aa8797cc5620f7a319","type":"GENE","name":"C11orf96","canonical_id":"hgnc:HGNC:38675","description":"chromosome 11 open reading frame 96","metadata":{"aliases":["AG2"]}},{"id":"433bbdd7778f4770af5290aff83a1a01","type":"GENE","name":"C11orf97","canonical_id":"hgnc:HGNC:49544","description":"chromosome 11 open reading frame 97","metadata":{"aliases":["LINC01171"]}},{"id":"6795fc4b946e4fa1930cd4f50fa63398","type":"GENE","name":"C11orf98","canonical_id":"hgnc:HGNC:51238","description":"chromosome 11 open reading frame 98","metadata":{"aliases":["C11orf48"]}},{"id":"3d0985879d584a41af6a5b3edfb2ec77","type":"GENE","name":"C11orf98P1","canonical_id":"hgnc:HGNC:49784","description":"C11orf98 pseudogene 1","metadata":null},{"id":"d13ff1c9a667420ba18b74255fed8636","type":"GENE","name":"C11orf98P2","canonical_id":"hgnc:HGNC:56319","description":"C11orf98 pseudogene 2","metadata":null},{"id":"32217260096d46d897b9e991ac5c0830","type":"GENE","name":"C11orf98P3","canonical_id":"hgnc:HGNC:56320","description":"C11orf98 pseudogene 3","metadata":null},{"id":"4a6d02f464e94331958f7bb4fb6a239f","type":"GENE","name":"C12orf42","canonical_id":"hgnc:HGNC:24729","description":"chromosome 12 open reading frame 42","metadata":{"aliases":["FLJ25323"]}},{"id":"190cb435be7040dd9885d6505624ac60","type":"GENE","name":"C12orf42-AS1","canonical_id":"hgnc:HGNC:56185","description":"C12orf42 antisense RNA 1","metadata":null},{"id":"9e32866d57f246a7bba6bfd04fe3c6ec","type":"GENE","name":"C12orf43","canonical_id":"hgnc:HGNC:25719","description":"chromosome 12 open reading frame 43","metadata":{"aliases":["FLJ12448","Custos"]}},{"id":"740a672ff6074a2a9e9edc473ec027b2","type":"GENE","name":"C12orf56","canonical_id":"hgnc:HGNC:26967","description":"chromosome 12 open reading frame 56","metadata":null},{"id":"a7e68a78624b4f74b937397778e44362","type":"GENE","name":"C12orf57","canonical_id":"hgnc:HGNC:29521","description":"chromosome 12 open reading frame 57","metadata":{"aliases":["GRCC10","C10"]}},{"id":"76b003bba57847bca14879a0ff4e684a","type":"GENE","name":"C12orf60","canonical_id":"hgnc:HGNC:28726","description":"chromosome 12 open reading frame 60","metadata":{"aliases":["MGC47869"]}},{"id":"c6e9e6e793dc48a8b66dcf903c755833","type":"GENE","name":"C12orf71","canonical_id":"hgnc:HGNC:34452","description":"chromosome 12 open reading frame 71","metadata":{"aliases":["LOC728858"]}},{"id":"c16dcebe9344402a92122d30db2c6492","type":"GENE","name":"C12orf71BP","canonical_id":"hgnc:HGNC:56323","description":"chromosome 12 open reading frame 71B, pseudogene","metadata":null},{"id":"bc7b33b69dcf40dca404e66d2aa77479","type":"GENE","name":"C12orf75","canonical_id":"hgnc:HGNC:35164","description":"chromosome 12 open reading frame 75","metadata":{"aliases":["OCC-1","OCC1","AGD3"]}},{"id":"33f9518008d149b7abe1ceda2f1b03b6","type":"GENE","name":"C12orf75-AS1","canonical_id":"hgnc:HGNC:55936","description":"C12orf75 antisense RNA 1","metadata":{"aliases":["KCCAT198"]}},{"id":"726c43c648174ed199efcbd38f9d8831","type":"GENE","name":"C12orf76","canonical_id":"hgnc:HGNC:33790","description":"chromosome 12 open reading frame 76","metadata":{"aliases":["FLJ40142"]}},{"id":"75bee83e38244184b01b108c6cde26c9","type":"GENE","name":"C13orf42","canonical_id":"hgnc:HGNC:42693","description":"chromosome 13 open reading frame 42","metadata":{"aliases":["LINC00371"]}},{"id":"ec12390884894dfab7490dde0c089035","type":"GENE","name":"C13orf46","canonical_id":"hgnc:HGNC:53786","description":"chromosome 13 open reading frame 46","metadata":null},{"id":"74b2213dc2aa4658866ac89da8f75e95","type":"GENE","name":"C14orf119","canonical_id":"hgnc:HGNC:20270","description":"chromosome 14 open reading frame 119","metadata":{"aliases":["FLJ20671"]}},{"id":"e6e13ca6ddfd47deb1554de66eede9f0","type":"GENE","name":"C14orf119P1","canonical_id":"hgnc:HGNC:57043","description":"C14orf119 pseudogene 1","metadata":null},{"id":"37693d0568d349d89618189579ce06c7","type":"GENE","name":"C14orf132","canonical_id":"hgnc:HGNC:20346","description":"chromosome 14 open reading frame 132","metadata":{"aliases":["C14orf88"]}},{"id":"651edac6d89b4801a1a890b79e0f24a3","type":"GENE","name":"C14orf180","canonical_id":"hgnc:HGNC:33795","description":"chromosome 14 open reading frame 180","metadata":{"aliases":["NRAC","C14orf77"]}},{"id":"9b82492ce4964546ab58a8a6f1c151a7","type":"GENE","name":"C14orf39","canonical_id":"hgnc:HGNC:19849","description":"chromosome 14 open reading frame 39","metadata":{"aliases":["SIX6OS1"]}},{"id":"14e1a5cbc31e40edb8116aa42935fe0a","type":"GENE","name":"C14orf93","canonical_id":"hgnc:HGNC:20162","description":"chromosome 14 open reading frame 93","metadata":{"aliases":["FLJ12154","RTFC"]}},{"id":"89fb15ad0fe04a4d83997dace9816059","type":"GENE","name":"C15orf32","canonical_id":"hgnc:HGNC:26549","description":"chromosome 15 putative open reading frame 32","metadata":{"aliases":["FLJ32831"]}},{"id":"69a4b4b91b2849eda06ec99e49317852","type":"GENE","name":"C15orf40","canonical_id":"hgnc:HGNC:28443","description":"chromosome 15 open reading frame 40","metadata":{"aliases":["MGC29937"]}},{"id":"7ea9b331338e4313bea86026a951bfc8","type":"GENE","name":"C15orf61","canonical_id":"hgnc:HGNC:34453","description":"chromosome 15 open reading frame 61","metadata":{"aliases":["LOC145853"]}},{"id":"0ef245b476e54b68a0aa19e3fce0f8f7","type":"GENE","name":"C15orf62","canonical_id":"hgnc:HGNC:34489","description":"chromosome 15 open reading frame 62","metadata":{"aliases":["LOC643338"]}},{"id":"02073ab6fa3946fbb555df96e9779231","type":"GENE","name":"C16orf46","canonical_id":"hgnc:HGNC:26525","description":"chromosome 16 open reading frame 46","metadata":{"aliases":["FLJ32702"]}},{"id":"ac08af2030194703b56b43bf4d716044","type":"GENE","name":"C16orf46-AS1","canonical_id":"hgnc:HGNC:58545","description":"C16orf46 antisense RNA 1","metadata":null},{"id":"d55ce828d4584096a2036dff7e505913","type":"GENE","name":"C16orf46-DT","canonical_id":"hgnc:HGNC:56680","description":"C16orf46 divergent transcript","metadata":{"aliases":["lnc-ATMIN-4:2"]}},{"id":"4281dd9dfaa34fa3a3ae74ee33253367","type":"GENE","name":"C16orf54","canonical_id":"hgnc:HGNC:26649","description":"chromosome 16 open reading frame 54","metadata":{"aliases":["FLJ35681","SAIL"]}},{"id":"260fe5650755404d94ee89cc83e13fe6","type":"GENE","name":"C16orf78","canonical_id":"hgnc:HGNC:28479","description":"chromosome 16 open reading frame 78","metadata":{"aliases":["MGC33367"]}},{"id":"8e4061db91a14b9aa1959f35fa3dfd2e","type":"GENE","name":"C16orf82","canonical_id":"hgnc:HGNC:30755","description":"chromosome 16 open reading frame 82","metadata":{"aliases":["TNT"]}},{"id":"d0a8c932a55940f7a75af51cf43617f3","type":"GENE","name":"C16orf86","canonical_id":"hgnc:HGNC:33755","description":"chromosome 16 open reading frame 86","metadata":{"aliases":["FLJ41802"]}},{"id":"b821a393733f49c9b60c2fb6c169ea3f","type":"GENE","name":"C16orf89","canonical_id":"hgnc:HGNC:28687","description":"chromosome 16 open reading frame 89","metadata":{"aliases":["MGC45438"]}},{"id":"bf90c62d95f741219fc546d1a2c88460","type":"GENE","name":"C16orf90","canonical_id":"hgnc:HGNC:34455","description":"chromosome 16 open reading frame 90","metadata":{"aliases":["LOC646174"]}},{"id":"b80ff4732dd64a99bff5b04f25738938","type":"GENE","name":"C16orf95","canonical_id":"hgnc:HGNC:40033","description":"chromosome 16 open reading frame 95","metadata":null},{"id":"e9e98ecbe3a44e088b6235bc0ce90293","type":"GENE","name":"C16orf95-DT","canonical_id":"hgnc:HGNC:55269","description":"C16orf95 divergent transcript","metadata":null},{"id":"b4b8d8ec1aee4b30a733eda556f995d0","type":"GENE","name":"C16orf96","canonical_id":"hgnc:HGNC:40031","description":"chromosome 16 open reading frame 96","metadata":null},{"id":"78256499b8244f5799f56c88742ecc6b","type":"GENE","name":"C17orf100","canonical_id":"hgnc:HGNC:34494","description":"chromosome 17 open reading frame 100","metadata":{"aliases":["LOC388327"]}},{"id":"321458b9b11c4eff96c8957ba6f2b2a9","type":"GENE","name":"C17orf107","canonical_id":"hgnc:HGNC:37238","description":"chromosome 17 open reading frame 107","metadata":null},{"id":"546eb793fa624ee89357c0b302558f8f","type":"GENE","name":"C17orf113","canonical_id":"hgnc:HGNC:53437","description":"chromosome 17 open reading frame 113","metadata":null},{"id":"db7a67c744964ff79b51c79dbefa3fbc","type":"GENE","name":"C17orf114","canonical_id":"hgnc:HGNC:55343","description":"chromosome 17 open reading frame 114","metadata":null},{"id":"f61bc508b8a243b5b8ad9749fd56a21d","type":"GENE","name":"C17orf58","canonical_id":"hgnc:HGNC:27568","description":"chromosome 17 open reading frame 58","metadata":null},{"id":"50b94b687f3c42c3ab34af84f1b36e3f","type":"GENE","name":"C17orf67","canonical_id":"hgnc:HGNC:27900","description":"chromosome 17 open reading frame 67","metadata":null},{"id":"610ddfad37374241812beb9b6fa59117","type":"GENE","name":"C17orf75","canonical_id":"hgnc:HGNC:30173","description":"chromosome 17 open reading frame 75","metadata":{"aliases":["NJMU-R1","SRI2"]}},{"id":"4d75180b2ca64d37aa7e8d63ac130004","type":"GENE","name":"C17orf78","canonical_id":"hgnc:HGNC:26831","description":"chromosome 17 open reading frame 78","metadata":{"aliases":["FLJ39647"]}},{"id":"5786e526c0cf405ab99dd336b4a74d30","type":"GENE","name":"C18orf15","canonical_id":"hgnc:HGNC:26447","description":"chromosome 18 putative open reading frame 15","metadata":{"aliases":["FLJ31338","HsT3231"]}},{"id":"8b7502d8abb34563bfeeb64a7d2bd523","type":"GENE","name":"C18orf32","canonical_id":"hgnc:HGNC:31690","description":"chromosome 18 open reading frame 32","metadata":{"aliases":["FLJ23458"]}},{"id":"c877eea47db844e99333e978705ae21f","type":"GENE","name":"C18orf32P1","canonical_id":"hgnc:HGNC:58494","description":"C18orf32 pseudogene 1","metadata":null},{"id":"7f6aa66dd32b47908ca07752bab32d20","type":"GENE","name":"C18orf32P2","canonical_id":"hgnc:HGNC:58495","description":"C18orf32 pseudogene 2","metadata":null},{"id":"3dbeb19755ab4f97a08baca5fe5063e5","type":"GENE","name":"C18orf32P3","canonical_id":"hgnc:HGNC:58496","description":"C18orf32 pseudogene 3","metadata":null},{"id":"66595c85fff248ef8b316baabc502117","type":"GENE","name":"C18orf32P4","canonical_id":"hgnc:HGNC:58497","description":"C18orf32 pseudogene 4","metadata":null},{"id":"5403b29078514589950cad4208722a06","type":"GENE","name":"C18orf54","canonical_id":"hgnc:HGNC:13796","description":"chromosome 18 open reading frame 54","metadata":{"aliases":["MGC33382","LAS2"]}},{"id":"48358484c7094045ba30733b19154e3b","type":"GENE","name":"C18orf63","canonical_id":"hgnc:HGNC:40037","description":"chromosome 18 open reading frame 63","metadata":{"aliases":["DKFZP781G0119"]}},{"id":"f7666c828dcd499caf3aa5bd95ad8140","type":"GENE","name":"C19orf12","canonical_id":"hgnc:HGNC:25443","description":"chromosome 19 open reading frame 12","metadata":{"aliases":["MGC10922","DKFZP762D096","NBIA4","MPAN","SPG43"]}},{"id":"f89b4a0474354a3a96e158a5632b5395","type":"GENE","name":"C19orf18","canonical_id":"hgnc:HGNC:28642","description":"chromosome 19 open reading frame 18","metadata":{"aliases":["MGC41906"]}},{"id":"98b86a8962944879b57533e4b46007ae","type":"GENE","name":"C19orf25","canonical_id":"hgnc:HGNC:26711","description":"chromosome 19 open reading frame 25","metadata":{"aliases":["FLJ36666"]}},{"id":"9b31d88f30f84cd28791f5f8de1ffcfd","type":"GENE","name":"C19orf33","canonical_id":"hgnc:HGNC:16668","description":"chromosome 19 open reading frame 33","metadata":{"aliases":["IMUP-1","IMUP-2","H2RSP","IMUP"]}},{"id":"937f3085f5444651928a00660f43886b","type":"GENE","name":"C19orf38","canonical_id":"hgnc:HGNC:34073","description":"chromosome 19 open reading frame 38","metadata":{"aliases":["HIDE1"]}},{"id":"fe0fc606ee6b49c193fc26855f610d3a","type":"GENE","name":"C19orf44","canonical_id":"hgnc:HGNC:26141","description":"chromosome 19 open reading frame 44","metadata":{"aliases":["FLJ21742","FCAP71"]}},{"id":"56767a75215e4915be6a41b5673c883a","type":"GENE","name":"C19orf47","canonical_id":"hgnc:HGNC:26723","description":"chromosome 19 open reading frame 47","metadata":{"aliases":["FLJ36888"]}},{"id":"99e835e8697445cb889d281a64cc536f","type":"GENE","name":"C19orf48P","canonical_id":"hgnc:HGNC:29667","description":"chromosome 19 open reading frame 48, pseudogene","metadata":{"aliases":["MGC13170","BC006151","C19orf48"]}},{"id":"bfb986be757049639855b6d67015a2be","type":"GENE","name":"C19orf53","canonical_id":"hgnc:HGNC:24991","description":"chromosome 19 open reading frame 53","metadata":{"aliases":["L10K","Hero11","LYDG10","HSPC023"]}},{"id":"d9cc58de9cb846c182213970d2b6ab3d","type":"GENE","name":"C19orf67","canonical_id":"hgnc:HGNC:34354","description":"chromosome 19 open reading frame 67","metadata":null},{"id":"8bd589e718d34271841b5c8610ee22f8","type":"GENE","name":"C19orf73","canonical_id":"hgnc:HGNC:25534","description":"chromosome 19 open reading frame 73","metadata":{"aliases":["FLJ10490"]}},{"id":"527ed0679b164a508c1b858107512214","type":"GENE","name":"C19orf81","canonical_id":"hgnc:HGNC:40041","description":"chromosome 19 open reading frame 81","metadata":null},{"id":"c3a51e54067a4f1f970fd9b088cb7184","type":"GENE","name":"C19orf84","canonical_id":"hgnc:HGNC:27112","description":"chromosome 19 open reading frame 84","metadata":null},{"id":"56a73d7f77944b9fad79eb9b975452a9","type":"GENE","name":"C19orf85","canonical_id":"hgnc:HGNC:53653","description":"chromosome 19 open reading frame 85","metadata":null},{"id":"7ec38af3d7c54319a5f145f786af15b7","type":"GENE","name":"C1D","canonical_id":"hgnc:HGNC:29911","description":"C1D nuclear receptor corepressor","metadata":{"aliases":["SUNCOR","SUN-CoR","LRP1","Rrp47"]}},{"id":"e6a82ffea1c04d9a947bdf0aad766ec4","type":"GENE","name":"C1DP1","canonical_id":"hgnc:HGNC:31465","description":"C1D nuclear receptor corepressor pseudogene 1","metadata":{"aliases":["bA195O1.1"]}},{"id":"584750a5bae941eab8967bb30382934c","type":"GENE","name":"C1DP2","canonical_id":"hgnc:HGNC:31660","description":"C1D nuclear receptor corepressor pseudogene 2","metadata":{"aliases":["bA369J21.3"]}},{"id":"fd7ab69cfb2e47eba3107cce336e3875","type":"GENE","name":"C1DP3","canonical_id":"hgnc:HGNC:31661","description":"C1D nuclear receptor corepressor pseudogene 3","metadata":{"aliases":["bA369J21.2"]}},{"id":"bb932277e60547099d38970e7c69dfda","type":"GENE","name":"C1DP4","canonical_id":"hgnc:HGNC:38028","description":"C1D nuclear receptor corepressor pseudogene 4","metadata":null},{"id":"c4ac319117b74b49bd336d34d305aba4","type":"GENE","name":"C1DP5","canonical_id":"hgnc:HGNC:51613","description":"C1D nuclear receptor corepressor pseudogene 5","metadata":null},{"id":"f3aa07906d8d4a1d97da20954b9866a3","type":"GENE","name":"C1GALT1","canonical_id":"hgnc:HGNC:24337","description":"core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1","metadata":{"aliases":["C1GALT","T-synthase"]}},{"id":"4ebc3e8e1c4e40889b3923f04949316c","type":"GENE","name":"C1GALT1C1","canonical_id":"hgnc:HGNC:24338","description":"C1GALT1 specific chaperone 1","metadata":{"aliases":["COSMC","C1GALT2"]}},{"id":"5cf61ed554b442f1bb234eb51d2c09d3","type":"GENE","name":"C1GALT1C1L","canonical_id":"hgnc:HGNC:51617","description":"C1GALT1 specific chaperone 1 like","metadata":null},{"id":"a3f14ca5afb1477d94d1f5650dddb8d5","type":"GENE","name":"C1GALT1P1","canonical_id":"hgnc:HGNC:51614","description":"C1GALT1 pseudogene 1","metadata":null},{"id":"bc82593857734924b471fbf409019c8e","type":"GENE","name":"C1GALT1P2","canonical_id":"hgnc:HGNC:51615","description":"C1GALT1 pseudogene 2","metadata":null},{"id":"99fe5730cecc430a8680eee5bc642c03","type":"GENE","name":"C1GALT1P3","canonical_id":"hgnc:HGNC:51616","description":"C1GALT1 pseudogene 3","metadata":null},{"id":"2c3e8129ae7f451ab9e9d4bd3c98703c","type":"GENE","name":"C1QA","canonical_id":"hgnc:HGNC:1241","description":"complement C1q A chain","metadata":null},{"id":"b1ebc28ad0044c23b30ba7760e151c28","type":"GENE","name":"C1QB","canonical_id":"hgnc:HGNC:1242","description":"complement C1q B chain","metadata":null},{"id":"31fbd161a0b649189e973815a56488c3","type":"GENE","name":"C1QBP","canonical_id":"hgnc:HGNC:1243","description":null,"metadata":null},{"id":"97f588749bd34902928d415de19ca087","type":"GENE","name":"C1QBPP1","canonical_id":"hgnc:HGNC:1244","description":"complement C1q binding protein pseudogene 1","metadata":{"aliases":["C1QBPP"]}},{"id":"c9fd60ffa4c945e092116ab58fc7532f","type":"GENE","name":"C1QBPP2","canonical_id":"hgnc:HGNC:51618","description":"complement C1q binding protein pseudogene 2","metadata":null},{"id":"b1c6a6a874ec4a6dbd969890ea181fcc","type":"GENE","name":"C1QBPP3","canonical_id":"hgnc:HGNC:51619","description":"complement C1q binding protein pseudogene 3","metadata":null},{"id":"7e610e69b8da4eee8b30f30a10e45d93","type":"GENE","name":"C1QC","canonical_id":"hgnc:HGNC:1245","description":"complement C1q C chain","metadata":{"aliases":["C1QG"]}},{"id":"839def0c23784bf6b746c3b134547a22","type":"GENE","name":"C1QL1","canonical_id":"hgnc:HGNC:24182","description":"complement C1q like 1","metadata":{"aliases":["CRF","C1QRF","C1QTNF14","CTRP14"]}},{"id":"517990625e314898ab7e3182f84d4fe8","type":"GENE","name":"C1QL1P1","canonical_id":"hgnc:HGNC:51809","description":"complement C1q like 1 pseudogene 1","metadata":null},{"id":"f7c4ca96f220414ab2be9fa2e879aa80","type":"GENE","name":"C1QL2","canonical_id":"hgnc:HGNC:24181","description":"complement C1q like 2","metadata":{"aliases":["CTRP10","C1QTNF10"]}},{"id":"14b9cb4626da4778bfa019c7533f0685","type":"GENE","name":"C1QL3","canonical_id":"hgnc:HGNC:19359","description":"complement C1q like 3","metadata":{"aliases":["K100","C1ql","C1QTNF13","CTRP13"]}},{"id":"6c59ed23e8d54541aefd1694c36f8ab2","type":"GENE","name":"C1QL4","canonical_id":"hgnc:HGNC:31416","description":"complement C1q like 4","metadata":{"aliases":["C1QTNF11","CTRP11"]}},{"id":"03bc18045b534354b2fd289586d63015","type":"GENE","name":"C1QTNF1","canonical_id":"hgnc:HGNC:14324","description":"C1q and TNF related 1","metadata":{"aliases":["CTRP1","ZSIG37","GIP","FLJ90694"]}},{"id":"a068250e2cf9408f9d3e3231206c3c8d","type":"GENE","name":"C1QTNF1-AS1","canonical_id":"hgnc:HGNC:44351","description":"C1QTNF1 antisense RNA 1","metadata":null},{"id":"1ba1258b5fe94005902b8dc44996ffca","type":"GENE","name":"C1QTNF12","canonical_id":"hgnc:HGNC:32308","description":"C1q and TNF related 12","metadata":{"aliases":["MGC105127","CTRP12","ADIPOLIN","C1QDC2","FAM132A"]}},{"id":"c9ff3b067eaa4d1891352bd22ce65d67","type":"GENE","name":"C1QTNF2","canonical_id":"hgnc:HGNC:14325","description":"C1q and TNF related 2","metadata":{"aliases":["CTRP2"]}},{"id":"1e90c33a49934b619a6a5bc3a5673140","type":"GENE","name":"C1QTNF3","canonical_id":"hgnc:HGNC:14326","description":"C1q and TNF related 3","metadata":{"aliases":["CTRP3","Cors","Corcs","2310005P21Rik","Cors-26"]}},{"id":"77e0827a20ac4899a5ab99471835408f","type":"GENE","name":"C1QTNF3-AMACR","canonical_id":"hgnc:HGNC:49198","description":"C1QTNF3-AMACR readthrough (NMD candidate)","metadata":null},{"id":"2211bc80cc924f80a5bcf4d161555215","type":"GENE","name":"C1QTNF3-DT","canonical_id":"hgnc:HGNC:59025","description":"C1QTNF3 divergent transcript","metadata":null},{"id":"575049be97584f52961b27b44f72cfa6","type":"GENE","name":"C1QTNF4","canonical_id":"hgnc:HGNC:14346","description":"C1q and TNF related 4","metadata":{"aliases":["CTRP4","ZACRP4"]}},{"id":"8dbed430917440e5bd44586c4aa9ce02","type":"GENE","name":"C1QTNF5","canonical_id":"hgnc:HGNC:14344","description":null,"metadata":null},{"id":"a7ab5d8c74874d06aba203cfcc18687b","type":"GENE","name":"C1QTNF6","canonical_id":"hgnc:HGNC:14343","description":"C1q and TNF related 6","metadata":{"aliases":["CTRP6","ZACRP6"]}},{"id":"02ec8187e9f046408f46b60d252be8ee","type":"GENE","name":"C1QTNF7","canonical_id":"hgnc:HGNC:14342","description":"C1q and TNF related 7","metadata":{"aliases":["CTRP7"]}},{"id":"8ee34ccde4704fd3b3aa1e802866920e","type":"GENE","name":"C1QTNF7-AS1","canonical_id":"hgnc:HGNC:40683","description":"C1QTNF7 antisense RNA 1","metadata":null},{"id":"6aef9290de30413ba65900d634ce1028","type":"GENE","name":"C1QTNF8","canonical_id":"hgnc:HGNC:31374","description":"C1q and TNF related 8","metadata":{"aliases":["UNQ5829","CTRP8"]}},{"id":"a29f9638f2d14a308a4adafabda6c28c","type":"GENE","name":"C1QTNF9","canonical_id":"hgnc:HGNC:28732","description":"C1q and TNF related 9","metadata":{"aliases":["MGC48915","CTRP9","C1QTNF9A","AQL1"]}},{"id":"1adbcd16ee064aa98bb5664a9a756b42","type":"GENE","name":"C1QTNF9-AS1","canonical_id":"hgnc:HGNC:39906","description":"C1QTNF9 antisense RNA 1","metadata":null},{"id":"da2fbd1e21cc419d889a83b4e4521e94","type":"GENE","name":"C1QTNF9B","canonical_id":"hgnc:HGNC:34072","description":"C1q and TNF related 9B","metadata":{"aliases":["CTRP9B"]}},{"id":"4d83e0ebf60d4432828a6769d98284bf","type":"GENE","name":"C1R","canonical_id":"hgnc:HGNC:1246","description":"complement C1r","metadata":null},{"id":"b569a2bc01ef4d5a8f5885593bad441b","type":"GENE","name":"C1RL","canonical_id":"hgnc:HGNC:21265","description":"complement C1r subcomponent like","metadata":{"aliases":["C1r-LP","C1RL1"]}},{"id":"9ec8930dcb6c49bba052bafb485a3fdd","type":"GENE","name":"C1RL-AS1","canonical_id":"hgnc:HGNC:27461","description":"C1RL antisense RNA 1","metadata":{"aliases":["MATL2963"]}},{"id":"9a649511a26246f4bdd6db4b1027c6f2","type":"GENE","name":"C1S","canonical_id":"hgnc:HGNC:1247","description":"complement C1s","metadata":null},{"id":"3caf3fd82c0b49dfb4892461b4a79f23","type":"PROTEIN","name":"C1S","canonical_id":"uniprot:P09871","description":null,"metadata":null},{"id":"70bd552758fc4c02ab9268bf8521f86b","type":"GENE","name":"C1orf105","canonical_id":"hgnc:HGNC:29591","description":"chromosome 1 open reading frame 105","metadata":null},{"id":"8b5d607c1f58478995ebf016e1b5b4b6","type":"GENE","name":"C1orf115","canonical_id":"hgnc:HGNC:25873","description":"chromosome 1 open reading frame 115","metadata":{"aliases":["FLJ14146","RDD1"]}},{"id":"51e1e17788d74b1d9ebd945c24a57d89","type":"GENE","name":"C1orf116","canonical_id":"hgnc:HGNC:28667","description":"chromosome 1 open reading frame 116","metadata":{"aliases":["SARG","FLJ36507","MGC2742","MGC4309"]}},{"id":"fc48791d582c44669d05e60cd8615b97","type":"GENE","name":"C1orf122","canonical_id":"hgnc:HGNC:24789","description":"chromosome 1 open reading frame 122","metadata":{"aliases":["FLJ45459"]}},{"id":"87e71a7a80c14a70a7cf6b4ffcd35ae0","type":"GENE","name":"C1orf141","canonical_id":"hgnc:HGNC:32044","description":"chromosome 1 open reading frame 141","metadata":null},{"id":"77131de6b2234e85a5b789f82e0bfac2","type":"GENE","name":"C1orf146","canonical_id":"hgnc:HGNC:24032","description":"chromosome 1 open reading frame 146","metadata":{"aliases":["SPO16","SCRE"]}},{"id":"11d76da7de584e249b99ecfb143da1f4","type":"GENE","name":"C1orf159","canonical_id":"hgnc:HGNC:26062","description":"chromosome 1 open reading frame 159","metadata":{"aliases":["FLJ20584"]}},{"id":"6f976ebdbe25454a97a30b4ae5693efd","type":"GENE","name":"C1orf162","canonical_id":"hgnc:HGNC:28344","description":"chromosome 1 open reading frame 162","metadata":{"aliases":["MGC24133"]}},{"id":"2b3291763fc64f6499cb50adbe83962e","type":"GENE","name":"C1orf167","canonical_id":"hgnc:HGNC:25262","description":"chromosome 1 open reading frame 167","metadata":{"aliases":["DKFZp434E1410","RP11-56N19.2"]}},{"id":"17f0cf09bd4e4f58bd92347fde0d3856","type":"GENE","name":"C1orf167-AS1","canonical_id":"hgnc:HGNC:41091","description":"C1orf167 antisense RNA 1","metadata":null},{"id":"8571c68882cb40ada388cb93e94cef27","type":"GENE","name":"C1orf174","canonical_id":"hgnc:HGNC:27915","description":"chromosome 1 open reading frame 174","metadata":{"aliases":["RP13-531C17.2"]}},{"id":"61b3086eefe040f99bc307057ad8294d","type":"GENE","name":"C1orf185","canonical_id":"hgnc:HGNC:28096","description":"chromosome 1 open reading frame 185","metadata":{"aliases":["FLJ27485"]}},{"id":"cf35d8757772422789b9f177fc5bac29","type":"GENE","name":"C1orf198","canonical_id":"hgnc:HGNC:25900","description":"chromosome 1 open reading frame 198","metadata":{"aliases":["FLJ14525","MGC10710","FLJ16283","DKFZp667D152","FLJ38847"]}},{"id":"a68af065a67b4987b7bed1a2acead380","type":"GENE","name":"C1orf202","canonical_id":"hgnc:HGNC:56760","description":"chromosome 1 open reading frame 202","metadata":null},{"id":"5815b08adc5b4277befce41a4a1c5bb1","type":"GENE","name":"C1orf21","canonical_id":"hgnc:HGNC:15494","description":"chromosome 1 open reading frame 21","metadata":{"aliases":["PIG13"]}},{"id":"d4871c32dafa4829ac47b628cb417f4f","type":"GENE","name":"C1orf21-DT","canonical_id":"hgnc:HGNC:55249","description":"C1orf21 divergent transcript","metadata":null},{"id":"a433f10ef11340c88a209f78cab5a723","type":"GENE","name":"C1orf210","canonical_id":"hgnc:HGNC:28755","description":"chromosome 1 open reading frame 210","metadata":{"aliases":["MGC52423","TEMP"]}},{"id":"5a58f6e276d5490a95ea74d3b808dd4d","type":"GENE","name":"C1orf216","canonical_id":"hgnc:HGNC:26800","description":"chromosome 1 open reading frame 216","metadata":{"aliases":["FLJ38984"]}},{"id":"782720c01f4c4263abef36636e5d4bfd","type":"GENE","name":"C1orf220","canonical_id":"hgnc:HGNC:33805","description":"chromosome 1 putative open reading frame 220","metadata":{"aliases":["FLJ35530"]}},{"id":"6be4e729b1b54e9eab40caf9dcd479f8","type":"GENE","name":"C1orf226","canonical_id":"hgnc:HGNC:34351","description":"chromosome 1 open reading frame 226","metadata":{"aliases":["FLJ13137"]}},{"id":"8fa4c7d13ce0482a891bb20d40cb4567","type":"GENE","name":"C1orf232","canonical_id":"hgnc:HGNC:53426","description":"chromosome 1 open reading frame 230","metadata":null},{"id":"0d5bfea29f074c5f969c0e92e48d27b8","type":"GENE","name":"C1orf35","canonical_id":"hgnc:HGNC:19032","description":"chromosome 1 open reading frame 35","metadata":{"aliases":["MGC4174","MMTAG2"]}},{"id":"0da5a667184a4d909da613f827817613","type":"GENE","name":"C1orf50","canonical_id":"hgnc:HGNC:28795","description":"chromosome 1 open reading frame 50","metadata":{"aliases":["MGC955"]}},{"id":"c6270570c6404e9ab2a3cba3a79cc575","type":"GENE","name":"C1orf52","canonical_id":"hgnc:HGNC:24871","description":"chromosome 1 open reading frame 52","metadata":{"aliases":["gm117","FLJ44982"]}},{"id":"66da49d8b665481f84ed793deb3c339a","type":"GENE","name":"C1orf53","canonical_id":"hgnc:HGNC:30003","description":"chromosome 1 open reading frame 53","metadata":null},{"id":"abfda1c0370f434eb4b09e3a324cb12e","type":"GENE","name":"C1orf54","canonical_id":"hgnc:HGNC:26258","description":"chromosome 1 open reading frame 54","metadata":{"aliases":["FLJ23221"]}},{"id":"0cc384aa349d4829b8a07b23e21c82b3","type":"GENE","name":"C1orf56","canonical_id":"hgnc:HGNC:26045","description":"chromosome 1 open reading frame 56","metadata":{"aliases":["FLJ20519","MENT"]}},{"id":"487b28d03ac644b8b19782083417f4a4","type":"GENE","name":"C1orf74","canonical_id":"hgnc:HGNC:26319","description":"chromosome 1 open reading frame 74","metadata":{"aliases":["FLJ25078","URLC4"]}},{"id":"19f85ff6e74b40fb8b230b36802b6223","type":"GENE","name":"C1orf87","canonical_id":"hgnc:HGNC:28547","description":"chromosome 1 open reading frame 87","metadata":{"aliases":["MGC34837","CREF"]}},{"id":"2dd32ff9a55f41429372f3d4569b5011","type":"GENE","name":"C1orf94","canonical_id":"hgnc:HGNC:28250","description":"chromosome 1 open reading frame 94","metadata":{"aliases":["MGC15882"]}},{"id":"18ce134df44742479eb4dc55f0979a8d","type":"GENE","name":"C2","canonical_id":"hgnc:HGNC:1248","description":"complement C2","metadata":null},{"id":"1f8077d6fe6240aea2363d78ab05bce9","type":"GO_TERM","name":"C2 axonemal microtubule","canonical_id":"go:GO:1990720","description":"\"One of two microtubules present in the axonemal central pair. It is distinguishable from the C1 axonemal microtubule (also called C1 tubule) by the presence of differing protein components of the projections.\" [GOC:cilia, PMID:21586547, PMID:9295136]","metadata":null},{"id":"b12c55993c2a440f8223ce5a4f48478a","type":"GO_TERM","name":"C2 domain binding","canonical_id":"go:GO:0110036","description":"\"Binding to the C2 domain of a protein, a protein structural domain involved in targeting proteins to cell membranes.\" [GOC:sl, PMID:24882364]","metadata":null},{"id":"0f513b7bfbbc468dad65bcede1fa34a1","type":"GENE","name":"C2-AS1","canonical_id":"hgnc:HGNC:49464","description":"C2 antisense RNA 1","metadata":null},{"id":"df8f3d38bd814c71a4fb07a4ae280493","type":"GENE","name":"C20orf141","canonical_id":"hgnc:HGNC:16134","description":"chromosome 20 open reading frame 141","metadata":{"aliases":["dJ860F19.4"]}},{"id":"b74ae521469d48008081316a65858977","type":"GENE","name":"C20orf144","canonical_id":"hgnc:HGNC:16137","description":"chromosome 20 open reading frame 144","metadata":{"aliases":["dJ63M2.6","bclt"]}},{"id":"050f8d0e1f9b43428363a469a8c85dcd","type":"GENE","name":"C20orf173","canonical_id":"hgnc:HGNC:16166","description":"chromosome 20 open reading frame 173","metadata":{"aliases":["dJ477O4.4"]}},{"id":"01402926409e4e49a6a1832347894d07","type":"GENE","name":"C20orf181","canonical_id":"hgnc:HGNC:16174","description":"chromosome 20 putative open reading frame 181","metadata":{"aliases":["dJ824A14.1"]}},{"id":"e824acce2936481c9883111b979bcf0a","type":"GENE","name":"C20orf202","canonical_id":"hgnc:HGNC:37254","description":"chromosome 20 open reading frame 202","metadata":null},{"id":"ff11aa4166514ddfb1522dbc49225d19","type":"GENE","name":"C20orf203","canonical_id":"hgnc:HGNC:26592","description":"chromosome 20 open reading frame 203","metadata":{"aliases":["FLJ33706"]}},{"id":"5cd9ac91ce8349a1a1545d737085de62","type":"GENE","name":"C20orf204","canonical_id":"hgnc:HGNC:27655","description":"chromosome 20 open reading frame 204","metadata":{"aliases":["DKFZp434G015","FLJ27267","PRR17","NCRNA00176","LINC00176"]}},{"id":"b4311e975c624bad872e4443a2b3b51d","type":"GENE","name":"C20orf96","canonical_id":"hgnc:HGNC:16227","description":"chromosome 20 open reading frame 96","metadata":{"aliases":["dJ1103G7.2"]}},{"id":"1835f4e92ca64bbbb4cd6d6ed805d85b","type":"GO_TERM","name":"C21-steroid hormone biosynthetic process","canonical_id":"go:GO:0006700","description":"\"The chemical reactions and pathways resulting in the formation of C21-steroid hormones, steroid compounds containing 21 carbons which function as hormones.\" [GOC:ai]","metadata":null},{"id":"9996b0e0d11649e99985bcca0350c4ed","type":"GO_TERM","name":"C21-steroid hormone catabolic process","canonical_id":"go:GO:0008208","description":"\"The chemical reactions and pathways resulting in the breakdown of C21-steroid hormones, steroid compounds containing 21 carbons which function as hormones.\" [GOC:ai]","metadata":null},{"id":"7cd0f949f8d041dbbb4b39225a0b6b6d","type":"GO_TERM","name":"C21-steroid hormone metabolic process","canonical_id":"go:GO:0008207","description":"\"The chemical reactions and pathways involving C21-steroid hormones, steroid compounds containing 21 carbons which function as hormones.\" [GOC:ai]","metadata":null},{"id":"e3435ce0fe7c44bbb983d013e60972a2","type":"GENE","name":"C21orf140","canonical_id":"hgnc:HGNC:39602","description":"chromosome 21 open reading frame 140","metadata":{"aliases":["FAM243A"]}},{"id":"df73112d1d0d4c9582502536dfa513b4","type":"GENE","name":"C21orf58","canonical_id":"hgnc:HGNC:1300","description":"chromosome 21 open reading frame 58","metadata":null},{"id":"50b243978fae4417a9463d857dd88759","type":"GENE","name":"C21orf91","canonical_id":"hgnc:HGNC:16459","description":"chromosome 21 open reading frame 91","metadata":{"aliases":["YG81","EURL","CSSG1","BTG3-7:1","C21orf38","C21orf14"]}},{"id":"31f7b686ecb245b4b0e70a534142c2cb","type":"GENE","name":"C21orf91-OT1","canonical_id":"hgnc:HGNC:16729","description":"C21orf91 overlapping transcript 1","metadata":{"aliases":["D21S2089E","NCRNA00285"]}},{"id":"08cb784d309a47859c159c3d6924ada4","type":"GENE","name":"C22orf15","canonical_id":"hgnc:HGNC:15558","description":"chromosome 22 open reading frame 15","metadata":{"aliases":["FLJ36561","N27C7-3"]}},{"id":"2887b3fe50404df2a2114b18301498ad","type":"GENE","name":"C22orf23","canonical_id":"hgnc:HGNC:18589","description":"chromosome 22 open reading frame 23","metadata":{"aliases":["FLJ32787","EVG1","LOC84645"]}},{"id":"e8f82aa4ada64cd59e533e768075a51b","type":"GENE","name":"C22orf31","canonical_id":"hgnc:HGNC:26931","description":"chromosome 22 open reading frame 31","metadata":{"aliases":["HS747E2A","bK747E2.1"]}},{"id":"3fd89b1cd1fb448b9a7f1c1783283255","type":"GENE","name":"C22orf39","canonical_id":"hgnc:HGNC:27012","description":"chromosome 22 open reading frame 39","metadata":{"aliases":["MGC74441","Pants"]}},{"id":"0c4646a689f64c8b85427cd5df1aa9d5","type":"GENE","name":"C22orf42","canonical_id":"hgnc:HGNC:27160","description":"chromosome 22 open reading frame 42","metadata":null},{"id":"fc33f82cabc74c78977d152d09fe6b3f","type":"GENE","name":"C22orf46P","canonical_id":"hgnc:HGNC:26294","description":"chromosome 22 open reading frame 46, pseudogene","metadata":{"aliases":["TAAP1","FLJ23584","CTA-216E10.6","C22orf46"]}},{"id":"20ce7f6e868548adbb6fcf885c447bf0","type":"GENE","name":"C2CD2","canonical_id":"hgnc:HGNC:1266","description":"C2 calcium dependent domain containing 2","metadata":{"aliases":["TMEM24L","DKFZP586F0422","C21orf258","C21orf25"]}},{"id":"dd7fd9f68da24a069153d90c5f100bb0","type":"GENE","name":"C2CD2L","canonical_id":"hgnc:HGNC:29000","description":"C2CD2 like","metadata":{"aliases":["KIAA0285","TMEM24"]}},{"id":"149329b5c9bc4bb99ef64c05b08fb8f6","type":"GENE","name":"C2CD3","canonical_id":"hgnc:HGNC:24564","description":"C2 domain containing 3 centriole elongation regulator","metadata":{"aliases":["DKFZP586P0123"]}},{"id":"bd85f1a0211648d6a03e6adcb2f187ff","type":"GENE","name":"C2CD4A","canonical_id":"hgnc:HGNC:33627","description":"C2 calcium dependent domain containing 4A","metadata":{"aliases":["NLF1","FAM148A"]}},{"id":"34c81b81420d4aab833951c3a7a948de","type":"GENE","name":"C2CD4B","canonical_id":"hgnc:HGNC:33628","description":"C2 calcium dependent domain containing 4B","metadata":{"aliases":["NLF2","FAM148B"]}},{"id":"9aa89aae5628475aa2dc49d2ba68a781","type":"GENE","name":"C2CD4C","canonical_id":"hgnc:HGNC:29417","description":"C2 calcium dependent domain containing 4C","metadata":{"aliases":["NLF3","KIAA1957","FAM148C"]}},{"id":"f39d19fcbead4a37aa0ed62d63c9f7d8","type":"GENE","name":"C2CD4D","canonical_id":"hgnc:HGNC:37210","description":"C2 calcium dependent domain containing 4D","metadata":{"aliases":["FAM148D"]}},{"id":"9e9a02ff9cc34eb799fa093250a7260a","type":"GENE","name":"C2CD4D-AS1","canonical_id":"hgnc:HGNC:54045","description":"C2CD4D and THEM5 antisense RNA 1","metadata":null},{"id":"e46cdf61541c4437b44ef7c49443dbf6","type":"GENE","name":"C2CD5","canonical_id":"hgnc:HGNC:29062","description":"C2 calcium dependent domain containing 5","metadata":{"aliases":["CDP138","KIAA0528"]}},{"id":"e6523a71f18c42c98d4abdcec1b8bb1e","type":"GENE","name":"C2CD5-AS1","canonical_id":"hgnc:HGNC:55961","description":"C2CD5 antisense RNA 1","metadata":null},{"id":"610445e11b9b41bfb4f511bf1778dd4a","type":"GO_TERM","name":"C2H2 zinc finger domain binding","canonical_id":"go:GO:0070742","description":"\"Binding to a C2H2-type zinc finger domain of a protein. The C2H2 zinc finger is the classical zinc finger domain, in which two conserved cysteines and histidines co-ordinate a zinc ion.\" [GOC:BHF, GOC:mah, Pfam:PF00096]","metadata":null},{"id":"1f9b50cf721647cca4eb7729fc490795","type":"GENE","name":"C2orf15","canonical_id":"hgnc:HGNC:28436","description":"chromosome 2 open reading frame 15","metadata":{"aliases":["MGC29762"]}},{"id":"3234934bea064b8499551308c662c8f4","type":"GENE","name":"C2orf42","canonical_id":"hgnc:HGNC:26056","description":"chromosome 2 open reading frame 42","metadata":{"aliases":["FLJ20558"]}},{"id":"c224c0f880bb4fd0bd1c356e7d16f8fc","type":"GENE","name":"C2orf49-DT","canonical_id":"hgnc:HGNC:55178","description":"C2orf49 divergent transcript","metadata":null},{"id":"6495e7d6b8f24be783d12edb7cd9f598","type":"GENE","name":"C2orf66","canonical_id":"hgnc:HGNC:33809","description":"chromosome 2 open reading frame 66","metadata":{"aliases":["UNQ6411"]}},{"id":"dbc6bd4abbca494bbd34f2749c0caddf","type":"GENE","name":"C2orf68","canonical_id":"hgnc:HGNC:34353","description":"chromosome 2 open reading frame 68","metadata":null},{"id":"78b322284bf74a10a886df2b405ef0f0","type":"GENE","name":"C2orf69","canonical_id":"hgnc:HGNC:26799","description":"chromosome 2 open reading frame 69","metadata":{"aliases":["FLJ38973"]}},{"id":"469ddbc3751d4a7eb484d336c39b26b9","type":"GENE","name":"C2orf69P1","canonical_id":"hgnc:HGNC:51800","description":"chromosome 2 open reading frame 69 pseudogene 1","metadata":null},{"id":"541b8a446cda48018a473a8bf2374e41","type":"GENE","name":"C2orf69P2","canonical_id":"hgnc:HGNC:51801","description":"chromosome 2 open reading frame 69 pseudogene 2","metadata":null},{"id":"fb6f4318cd534104bc629f27e2c4f6b3","type":"GENE","name":"C2orf69P3","canonical_id":"hgnc:HGNC:51802","description":"chromosome 2 open reading frame 69 pseudogene 3","metadata":null},{"id":"28d002df499e4dab8086e86484ffc1c1","type":"GENE","name":"C2orf69P4","canonical_id":"hgnc:HGNC:51803","description":"chromosome 2 open reading frame 69 pseudogene 4","metadata":null},{"id":"829e95a668134648a6878cab3c2213e4","type":"GENE","name":"C2orf69P5","canonical_id":"hgnc:HGNC:51804","description":"chromosome 2 open reading frame 69 pseudogene 5","metadata":null},{"id":"36bd3277611d4218b8493dc9f6221b54","type":"GENE","name":"C2orf72","canonical_id":"hgnc:HGNC:27418","description":" chromosome 2 open reading frame 72 ","metadata":{"aliases":["LOC257407"]}},{"id":"dcd12b3c1efe4afd8d7a2188600c9a52","type":"GENE","name":"C2orf74-AS1","canonical_id":"hgnc:HGNC:56377","description":"C2orf74 antisense RNA 1","metadata":{"aliases":["AC016747.2","C2orf74-DT"]}},{"id":"ad40a76f5cc74828944fdee2e6b59eed","type":"GENE","name":"C2orf76","canonical_id":"hgnc:HGNC:27017","description":"chromosome 2 open reading frame 76","metadata":{"aliases":["MGC104437","LOC130355","AIM29"]}},{"id":"1c59455cabb34c13b64aeb9cf4d84f41","type":"GENE","name":"C2orf78","canonical_id":"hgnc:HGNC:34349","description":"chromosome 2 open reading frame 78","metadata":{"aliases":["FLJ43987","hCG1989538","COG5373"]}},{"id":"ad5a76d4038b4d8890ee9d6d945344ef","type":"GENE","name":"C2orf80","canonical_id":"hgnc:HGNC:34352","description":"chromosome 2 open reading frame 80","metadata":{"aliases":["LOC389073","GONDA1"]}},{"id":"37d00cf57b6d4453bb5b0ae166739b57","type":"GENE","name":"C2orf81","canonical_id":"hgnc:HGNC:34350","description":"chromosome 2 open reading frame 81","metadata":{"aliases":["LOC388963","hCG40743"]}},{"id":"687ccc18f7c04d7b949983783cb4b6bb","type":"GENE","name":"C2orf92","canonical_id":"hgnc:HGNC:49272","description":"chromosome 2 open reading frame 92","metadata":{"aliases":["LINC01125"]}},{"id":"58602af702ea4416a590b43e72919d35","type":"GENE","name":"C3","canonical_id":"hgnc:HGNC:1318","description":null,"metadata":null},{"id":"05ec186c0a2d4707b1c3bd6df422361f","type":"GENE","name":"C3AR1","canonical_id":"hgnc:HGNC:1319","description":"complement C3a receptor 1","metadata":{"aliases":["C3AR","AZ3B"]}},{"id":"206f987bcbb142009030f5f4e9332d65","type":"GENE","name":"C3CER1","canonical_id":"hgnc:HGNC:1320","description":"chromosome 3 common eliminated region 1","metadata":{"aliases":["CER1"]}},{"id":"c0b5096729bb4f3696e503cde1050c27","type":"GO_TERM","name":"C3HC4-type RING finger domain binding","canonical_id":"go:GO:0055131","description":"\"Binding to a C3HC4-type zinc finger domain of a protein. The C3HC4-type zinc finger is a variant of RING finger, is a cysteine-rich domain of 40 to 60 residues that coordinates two zinc ions, and has the consensus sequence: C-X2-C-X(9-39)-C-X(1-3)-H-X(2-3)-C-X2-C-X(4-48)-C-X2-C, where X is any amino acid. Many proteins containing a C3HC4-type RING finger play a key role in the ubiquitination pathway.\" [GOC:amm, InterPro:IPR001841, InterPro:IPR018957]","metadata":null},{"id":"c88a0bd1a3f3402d99b4ab8e1286e63f","type":"GENE","name":"C3P1","canonical_id":"hgnc:HGNC:34414","description":"complement 3 precursor pseudogene","metadata":{"aliases":["CPLP"]}},{"id":"d0878116868a4e8bb580cad295da714f","type":"GENE","name":"C3orf18","canonical_id":"hgnc:HGNC:24837","description":"chromosome 3 open reading frame 18","metadata":{"aliases":["G20"]}},{"id":"3012a18579bd4bccb4885f0bf03aa181","type":"GENE","name":"C3orf22","canonical_id":"hgnc:HGNC:28534","description":"chromosome 3 open reading frame 22","metadata":{"aliases":["MGC34728"]}},{"id":"ac5c3473a23642699132084462560598","type":"GENE","name":"C3orf36","canonical_id":"hgnc:HGNC:26170","description":"chromosome 3 putative open reading frame 36","metadata":{"aliases":["FLJ22173"]}},{"id":"cdc99c5f0698427bb8d5ea72a86a08b0","type":"GENE","name":"C3orf38","canonical_id":"hgnc:HGNC:28384","description":"chromosome 3 open reading frame 38","metadata":{"aliases":["MGC26717"]}},{"id":"ab8b27b1cbbb42ce886c6549ee914b86","type":"GENE","name":"C3orf49","canonical_id":"hgnc:HGNC:25190","description":"chromosome 3 open reading frame 49","metadata":null},{"id":"955d884fcfd4495fbde86b48b84e6e6e","type":"GENE","name":"C3orf49P1","canonical_id":"hgnc:HGNC:55036","description":"C3orf49 pseudogene 1","metadata":null},{"id":"74471297b2c04a44aee479c011ba7023","type":"GENE","name":"C3orf52","canonical_id":"hgnc:HGNC:26255","description":"chromosome 3 open reading frame 52","metadata":{"aliases":["FLJ23186","TTMP"]}},{"id":"0962145b29d441d1ac42cb1ac4b1bb4f","type":"GENE","name":"C3orf62","canonical_id":"hgnc:HGNC:24771","description":"chromosome 3 open reading frame 62","metadata":{"aliases":["FLJ43654","MAPS"]}},{"id":"c3890b76584444fc8529d675c4006e7f","type":"GENE","name":"C3orf70","canonical_id":"hgnc:HGNC:33731","description":"chromosome 3 open reading frame 70","metadata":null},{"id":"0314259d1fac4df394f8b12a9d87a8db","type":"GENE","name":"C3orf80","canonical_id":"hgnc:HGNC:40048","description":"chromosome 3 open reading frame 80","metadata":null},{"id":"3c9363cc7b4241399091e52880317c2c","type":"GENE","name":"C3orf85","canonical_id":"hgnc:HGNC:53432","description":"chromosome 3 open reading frame 85","metadata":{"aliases":["FLJ22763"]}},{"id":"c0b212be2ca8471c8fd6fe69485a72eb","type":"GENE","name":"C3orf86P","canonical_id":"hgnc:HGNC:44570","description":"chromosome 3 open reading frame 86, pseudogene","metadata":{"aliases":["LINC00694","C3orf86"]}},{"id":"87ac5225e3224a3b96a63a339f3cb7c8","type":"GO_TERM","name":"C4 photosynthesis","canonical_id":"go:GO:0009760","description":"\"The combination of atmospheric CO2 with a 3-carbon molecule phosphoenol pyruvate (PEP) in the mesophyll cells to make a 4-carbon acid which is immediately converted to malic acid. The malic acid is then passed across to the bundle sheath cells where it is broken down again to pyruvic acid and CO2. The acid is passed back to the mesophyll cells to be used again, while the CO2 is fed into the reductive pentose-phosphate cycle (Calvin cycle) and converted into sugar and starch.\" [ISBN:0816017360]","metadata":null},{"id":"ba5d1dd33e93467582dad5fa7b5ceeca","type":"GO_TERM","name":"C4-dicarboxylate transmembrane transporter activity","canonical_id":"go:GO:0015556","description":"\"Enables the transfer of C4-dicarboxylate from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"303ac8d7fe05404ab93f9755f1d25d63","type":"GO_TERM","name":"C4-dicarboxylate transport","canonical_id":"go:GO:0015740","description":"\"The directed movement of a C4-dicarboxylate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A C4-dicarboxylate is the anion of a dicarboxylic acid that contains four carbon atoms.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"806aa2d13b8f46659295c053b3edfabd","type":"GENE","name":"C4A","canonical_id":"hgnc:HGNC:1323","description":null,"metadata":null},{"id":"b1a53d6ed35449dbbbb9132f27ec3332","type":"GENE","name":"C4A-AS1","canonical_id":"hgnc:HGNC:39753","description":"C4A antisense RNA 1","metadata":null},{"id":"2c5972daf9c943618144672f135c6988","type":"GENE","name":"C4A_2","canonical_id":"hgnc:HGNC:58753","description":"complement component 4A (Chido/Rodgers blood group), copy 2","metadata":null},{"id":"30d6e04a72b044d0bafaff1844e8b8dc","type":"GENE","name":"C4B","canonical_id":"hgnc:HGNC:1324","description":null,"metadata":null},{"id":"86c8015b63a54214902cfd9f5c2290ae","type":"GENE","name":"C4B-AS1","canonical_id":"hgnc:HGNC:39752","description":"C4B antisense RNA 1","metadata":null},{"id":"ad13760f223b4422af2b0771e9e34996","type":"GENE","name":"C4BPA","canonical_id":"hgnc:HGNC:1325","description":"complement component 4 binding protein alpha","metadata":{"aliases":["C4BP"]}},{"id":"a7fc3b9e78ad49e38dcb0231f5619a4a","type":"GENE","name":"C4BPAP2","canonical_id":"hgnc:HGNC:1327","description":"C4BPA pseudogene 2","metadata":{"aliases":["C4BPAL2"]}},{"id":"dfd67960cb054b2486914aebd2879972","type":"GENE","name":"C4BPAP3","canonical_id":"hgnc:HGNC:51640","description":"C4BPA pseudogene 3","metadata":null},{"id":"cf739b8d82684251904ddc78dccc73e9","type":"GENE","name":"C4BPB","canonical_id":"hgnc:HGNC:1328","description":null,"metadata":null},{"id":"182fbe33dcc24967ac178ba00f618517","type":"GENE","name":"C4B_2","canonical_id":"hgnc:HGNC:42398","description":"complement component 4B (Chido/Rodgers blood group), copy 2","metadata":null},{"id":"950c8f1928ec4f8b9d57a87478a47e8b","type":"GENE","name":"C4orf17","canonical_id":"hgnc:HGNC:25274","description":"chromosome 4 open reading frame 17","metadata":{"aliases":["DKFZP434G072"]}},{"id":"5916f6781c744ad6950fd15a06c76a07","type":"GENE","name":"C4orf33","canonical_id":"hgnc:HGNC:27025","description":"chromosome 4 open reading frame 33","metadata":{"aliases":["FLJ33703"]}},{"id":"6794ea8797fb49e1adfda42b725b1c6b","type":"GENE","name":"C4orf36","canonical_id":"hgnc:HGNC:28386","description":"chromosome 4 open reading frame 36","metadata":{"aliases":["MGC26744"]}},{"id":"f10ad9b7fec745369667386783489230","type":"GENE","name":"C4orf46","canonical_id":"hgnc:HGNC:27320","description":"chromosome 4 open reading frame 46","metadata":{"aliases":["LOC201725","RCDG1"]}},{"id":"d20918649cc24d2fbad9c872ca56e9e3","type":"GENE","name":"C4orf46P1","canonical_id":"hgnc:HGNC:55882","description":"C4orf46 pseudogene 1","metadata":null},{"id":"1978b1089a8f443f9e28dffcdd17f564","type":"GENE","name":"C4orf46P2","canonical_id":"hgnc:HGNC:55883","description":"C4orf46 pseudogene 2","metadata":null},{"id":"e806668ed9ac47b69eca0e0a96a1e7cc","type":"GENE","name":"C4orf46P3","canonical_id":"hgnc:HGNC:55884","description":"C4orf46 pseudogene 3","metadata":null},{"id":"f1211c3be88b426895e59f3d20ab4392","type":"GENE","name":"C4orf46P4","canonical_id":"hgnc:HGNC:55885","description":"C4orf46 pseudogene 4","metadata":null},{"id":"1dda105c5bc1447a876fca8f63c30a53","type":"GENE","name":"C4orf50","canonical_id":"hgnc:HGNC:33766","description":"chromosome 4 open reading frame 50","metadata":{"aliases":["FLJ46481"]}},{"id":"e3578e37a5a24003937998fab8081a10","type":"GENE","name":"C4orf51","canonical_id":"hgnc:HGNC:37264","description":"chromosome 4 open reading frame 51","metadata":null},{"id":"be11a8224530404b900f46d92b4a7fd3","type":"GENE","name":"C4orf54","canonical_id":"hgnc:HGNC:27741","description":"chromosome 4 open reading frame 54","metadata":{"aliases":["FOPV","LOC285556"]}},{"id":"d4b4bd0cf32a44f0abd5f400261b4575","type":"GENE","name":"C5","canonical_id":"hgnc:HGNC:1331","description":"complement C5","metadata":{"aliases":["CPAMD4","C5a","C5b"]}},{"id":"9ed68215333643c7aa19b59ebbbba576","type":"PROTEIN","name":"C5","canonical_id":"uniprot:P01031","description":null,"metadata":null},{"id":"3ac35aad02f3488f8dd0dccc51cafa02","type":"GENE","name":"C5-OT1","canonical_id":"hgnc:HGNC:53618","description":"C5 3' UTR overlapping transcript 1","metadata":{"aliases":["C5T1lncRNA"]}},{"id":"9da84dfca5d54946bf74d26ad1bd7f31","type":"GO_TERM","name":"C5-methylcytidine-containing RNA reader activity","canonical_id":"go:GO:0062153","description":"\"A protein adaptor that recognizes and binds an RNA molecule modified by C5-methylcytidine.\" [PMID:28418038]","metadata":null},{"id":"079b8529299248978069cb13f2b5c687","type":"GENE","name":"C5AR1","canonical_id":"hgnc:HGNC:1338","description":"complement C5a receptor 1","metadata":{"aliases":["C5A","C5AR","CD88","C5R1"]}},{"id":"6aa3d12a4ad34a018802d7c35537d838","type":"GENE","name":"C5AR2","canonical_id":"hgnc:HGNC:4527","description":"complement C5a receptor 2","metadata":{"aliases":["C5L2","GPR77"]}},{"id":"3a2843e835a14621928334ef35dd9744","type":"GO_TERM","name":"C5L2 anaphylatoxin chemotactic receptor binding","canonical_id":"go:GO:0031715","description":"\"Binding to a C5L2 anaphylatoxin chemotactic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"35386c29abe44bffac19124188ffb048","type":"GO_TERM","name":"C5a anaphylatoxin chemotactic receptor binding","canonical_id":"go:GO:0031714","description":"\"Binding to a C5a anaphylatoxin chemotactic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"bffdb662e5c644b89df5504c531f7a93","type":"GENE","name":"C5orf15","canonical_id":"hgnc:HGNC:20656","description":"chromosome 5 open reading frame 15","metadata":{"aliases":["KCT2","HTGN29"]}},{"id":"971265099e0241b9a3443b4d0cb36407","type":"GENE","name":"C5orf15-DT","canonical_id":"hgnc:HGNC:59135","description":"C5orf15 divergent transcript","metadata":null},{"id":"38cebdbdacc94ce9b5b5a9be11584564","type":"GENE","name":"C5orf15P1","canonical_id":"hgnc:HGNC:58661","description":"C5orf15 pseudogene 1","metadata":null},{"id":"214ba181e226448c88bdb043bc2a40ba","type":"GENE","name":"C5orf22","canonical_id":"hgnc:HGNC:25639","description":"chromosome 5 open reading frame 22","metadata":{"aliases":["FLJ11193"]}},{"id":"b98e88cf133e47f7b1f275f48218ad0d","type":"GENE","name":"C5orf24","canonical_id":"hgnc:HGNC:26746","description":"chromosome 5 open reading frame 24","metadata":{"aliases":["FLJ37562"]}},{"id":"371cd9536c854f099c22ac1ed24df172","type":"GENE","name":"C5orf34","canonical_id":"hgnc:HGNC:24738","description":"chromosome 5 open reading frame 34","metadata":{"aliases":["FLJ32363"]}},{"id":"40e08aa4382642589875091e15a50e03","type":"GENE","name":"C5orf34-AS1","canonical_id":"hgnc:HGNC:41061","description":"C5orf34 antisense RNA 1","metadata":null},{"id":"bd52d70bc8264676998024c9475bfb1b","type":"GENE","name":"C5orf46","canonical_id":"hgnc:HGNC:33768","description":"chromosome 5 open reading frame 46","metadata":{"aliases":["MGC23985","SSSP1","AP-64"]}},{"id":"e61b62d3661f41b582d3208ac18c121d","type":"GENE","name":"C5orf47","canonical_id":"hgnc:HGNC:27026","description":"chromosome 5 open reading frame 47","metadata":{"aliases":["LOC133491"]}},{"id":"9e28d997e57346938997c4b3f5c9f5dd","type":"GENE","name":"C5orf52","canonical_id":"hgnc:HGNC:35121","description":"chromosome 5 open reading frame 52","metadata":null},{"id":"f51337126d844a748d45eea060050ff1","type":"GENE","name":"C5orf58","canonical_id":"hgnc:HGNC:37272","description":"chromosome 5 open reading frame 58","metadata":null},{"id":"b8cbdc4250af4b5b9212989b67fcb5f4","type":"GENE","name":"C5orf63","canonical_id":"hgnc:HGNC:40051","description":"chromosome 5 open reading frame 63","metadata":{"aliases":["YDR286C","FLJ44606"]}},{"id":"2fe2db8f8cd04b3ea58be3cad35c9f84","type":"GENE","name":"C5orf67","canonical_id":"hgnc:HGNC:51252","description":"chromosome 5 putative open reading frame 67","metadata":null},{"id":"d5671510dbe6461383e14823d97c976f","type":"GENE","name":"C6","canonical_id":"hgnc:HGNC:1339","description":"complement C6","metadata":null},{"id":"17954eb73b18441cb2bc85739579df06","type":"GENE","name":"C6orf118","canonical_id":"hgnc:HGNC:21233","description":"chromosome 6 open reading frame 118","metadata":{"aliases":["MGC23884","bA85G2.1"]}},{"id":"16e3bcb623b846a1b5745e12a8a7841e","type":"GENE","name":"C6orf120","canonical_id":"hgnc:HGNC:21247","description":"chromosome 6 open reading frame 120","metadata":{"aliases":["bA160E12.4"]}},{"id":"a074d55f92d0435088f7d207231daae8","type":"GENE","name":"C6orf132","canonical_id":"hgnc:HGNC:21288","description":"chromosome 6 open reading frame 132","metadata":{"aliases":["bA7K24.2","LncCCLM"]}},{"id":"0b4e9c3b8bae4691885a524aec72f798","type":"GENE","name":"C6orf136","canonical_id":"hgnc:HGNC:21301","description":"chromosome 6 open reading frame 136","metadata":{"aliases":["Em:AB023049.8"]}},{"id":"5a3ed4c7fa314688aa246a57545501a5","type":"GENE","name":"C6orf141","canonical_id":"hgnc:HGNC:21351","description":"chromosome 6 open reading frame 141","metadata":{"aliases":["MGC46457"]}},{"id":"b9bcdc7845384938855a96cdf612ad73","type":"GENE","name":"C6orf15","canonical_id":"hgnc:HGNC:13927","description":"chromosome 6 open reading frame 15","metadata":{"aliases":["STG"]}},{"id":"cf22220590064ab2b24c4de5d3e0a564","type":"GENE","name":"C6orf163","canonical_id":"hgnc:HGNC:21403","description":"chromosome 6 open reading frame 163","metadata":null},{"id":"4f6c9303b044443fa244ec6e28692312","type":"GENE","name":"C6orf47","canonical_id":"hgnc:HGNC:19076","description":"chromosome 6 open reading frame 47","metadata":{"aliases":["D6S53E","G4"]}},{"id":"4fac9464e8074439bdb212a1ba5166db","type":"GENE","name":"C6orf47-AS1","canonical_id":"hgnc:HGNC:39767","description":"C6orf47 antisense RNA 1","metadata":null},{"id":"36662929a61144a5b3b1140621ac7a54","type":"GENE","name":"C6orf52","canonical_id":"hgnc:HGNC:20881","description":"chromosome 6 open reading frame 52","metadata":null},{"id":"ccf20838bd9644ddba2c2421267c013c","type":"GENE","name":"C6orf58","canonical_id":"hgnc:HGNC:20960","description":"chromosome 6 open reading frame 58","metadata":{"aliases":["LEG1"]}},{"id":"8a540b198fa94ab694899c00a098e478","type":"GENE","name":"C6orf62","canonical_id":"hgnc:HGNC:20998","description":"chromosome 6 open reading frame 62","metadata":{"aliases":["FLJ12619","DKFZP564G182","XTP12"]}},{"id":"82f19dd475d3488bbac5e6fd6278d3a7","type":"GENE","name":"C6orf89","canonical_id":"hgnc:HGNC:21114","description":"chromosome 6 open reading frame 89","metadata":{"aliases":["FLJ25357","BRAP"]}},{"id":"0b69758ae9744da4b72136b8337daa65","type":"GENE","name":"C6orf89-AS1","canonical_id":"hgnc:HGNC:59392","description":"C6orf89 antisense RNA 1","metadata":null},{"id":"8ef98e803c724548aa34cae6125a424c","type":"GENE","name":"C7","canonical_id":"hgnc:HGNC:1346","description":"complement C7","metadata":null},{"id":"2c3fc7b2aea94bb0abbd00ff3fffb8a0","type":"GENE","name":"C7orf25","canonical_id":"hgnc:HGNC:21703","description":"chromosome 7 open reading frame 25","metadata":{"aliases":["PANAD","MGC2821"]}},{"id":"dad2c8f84e91428187cd1cc7ac052f1e","type":"GENE","name":"C7orf33","canonical_id":"hgnc:HGNC:21724","description":"chromosome 7 open reading frame 33","metadata":null},{"id":"77101e8a145f49609710e0008c356890","type":"GENE","name":"C7orf57","canonical_id":"hgnc:HGNC:22247","description":"chromosome 7 open reading frame 57","metadata":{"aliases":["FCAP33"]}},{"id":"c7a93e2189e840d4ba38e79ee767b12a","type":"GENE","name":"C7orf78","canonical_id":"hgnc:HGNC:55185","description":"chromosome 7 open reading frame 78","metadata":null},{"id":"1c3a762175db4385b98cffd8c3570c80","type":"GENE","name":"C8A","canonical_id":"hgnc:HGNC:1352","description":"complement C8 alpha chain","metadata":null},{"id":"3df5df0d4fa9452ab397f34d02648a91","type":"GENE","name":"C8B","canonical_id":"hgnc:HGNC:1353","description":"complement C8 beta chain","metadata":null},{"id":"3886feba668943188e69ae813254d14f","type":"GENE","name":"C8G","canonical_id":"hgnc:HGNC:1354","description":"complement C8 gamma chain","metadata":null},{"id":"fbe7f0503a5e41f3b877ef3817a51d0c","type":"GENE","name":"C8orf17","canonical_id":"hgnc:HGNC:17737","description":"chromosome 8 putative open reading frame 17","metadata":{"aliases":["MOST-1"]}},{"id":"b700b08715624835ae1556ce04b5283c","type":"GENE","name":"C8orf33","canonical_id":"hgnc:HGNC:26104","description":"chromosome 8 open reading frame 33","metadata":{"aliases":["FLJ20989"]}},{"id":"d637fa5bb2e64c05be41f276013e625e","type":"GENE","name":"C8orf34","canonical_id":"hgnc:HGNC:30905","description":"chromosome 8 open reading frame 34","metadata":{"aliases":["vest-1","VEST1"]}},{"id":"d225270e0fa7457c97fdef754003d7f1","type":"GENE","name":"C8orf34-AS1","canonical_id":"hgnc:HGNC:27840","description":"C8orf34 antisense RNA 1","metadata":null},{"id":"a9f885b94d294016b62600be50f13566","type":"GENE","name":"C8orf44","canonical_id":"hgnc:HGNC:25646","description":"chromosome 8 putative open reading frame 44","metadata":{"aliases":["FLJ11267"]}},{"id":"701611a422b24e75ba9e3d5773c86ea5","type":"GENE","name":"C8orf44-SGK3","canonical_id":"hgnc:HGNC:48354","description":"C8orf44-SGK3 readthrough","metadata":null},{"id":"08c17acb3cf948b3b5cada9031312902","type":"GENE","name":"C8orf48","canonical_id":"hgnc:HGNC:26345","description":"chromosome 8 open reading frame 48","metadata":{"aliases":["FLJ25402"]}},{"id":"80ece99da1694783939051f500b3aa1b","type":"GENE","name":"C8orf58","canonical_id":"hgnc:HGNC:32233","description":"chromosome 8 open reading frame 58","metadata":{"aliases":["FLJ34715"]}},{"id":"e4cce9e3e15042d2ab812dec352e0466","type":"GENE","name":"C8orf74","canonical_id":"hgnc:HGNC:32296","description":"chromosome 8 open reading frame 74","metadata":null},{"id":"2e017bfa542d4f0aa8819dac82fd16ff","type":"GENE","name":"C8orf76","canonical_id":"hgnc:HGNC:25924","description":"chromosome 8 open reading frame 76","metadata":{"aliases":["FLJ14825"]}},{"id":"9858e65d87fa4d54b16d3e6f5d617561","type":"GENE","name":"C8orf82","canonical_id":"hgnc:HGNC:33826","description":"chromosome 8 open reading frame 82","metadata":{"aliases":["MGC70857"]}},{"id":"344f26ca56db47dbbcab11b9062d870a","type":"GENE","name":"C8orf88","canonical_id":"hgnc:HGNC:44672","description":"chromosome 8 open reading frame 88","metadata":null},{"id":"c011ded086d348be9b8ce0792662c6f8","type":"GENE","name":"C8orf89","canonical_id":"hgnc:HGNC:51258","description":"chromosome 8 open reading frame 89","metadata":null},{"id":"ae1973ad9374422eb617de62f1049b5c","type":"GENE","name":"C8orf90","canonical_id":"hgnc:HGNC:56305","description":"chromosome 8 open reading frame 90","metadata":null},{"id":"a8df292ca785409a8a4973325a877299","type":"GENE","name":"C9","canonical_id":"hgnc:HGNC:1358","description":"complement C9","metadata":null},{"id":"5b80ada2e29d44dd8a6a4303b4be77e1","type":"GENE","name":"C9orf152","canonical_id":"hgnc:HGNC:31455","description":"chromosome 9 open reading frame 152","metadata":{"aliases":["bA470J20.2"]}},{"id":"d4b09755f25e4fd28c16a7c268c147e8","type":"GENE","name":"C9orf153","canonical_id":"hgnc:HGNC:31456","description":"chromosome 9 open reading frame 153","metadata":{"aliases":["bA507D14.1"]}},{"id":"069157af87c64c49a48ead376d3a8c50","type":"GENE","name":"C9orf163","canonical_id":"hgnc:HGNC:26718","description":"chromosome 9 putative open reading frame 163","metadata":{"aliases":["FLJ36779"]}},{"id":"7a29e84e593748e79024fd72ab33f204","type":"GENE","name":"C9orf40","canonical_id":"hgnc:HGNC:23433","description":"chromosome 9 open reading frame 40","metadata":{"aliases":["FLJ10110"]}},{"id":"bfe6b58a24e14efe98c8c793a12b2240","type":"GENE","name":"C9orf43","canonical_id":"hgnc:HGNC:23570","description":"chromosome 9 open reading frame 43","metadata":{"aliases":["MGC17358"]}},{"id":"1f5079b861e94833b3877470bc81aa8a","type":"GENE","name":"C9orf50","canonical_id":"hgnc:HGNC:23677","description":"chromosome 9 open reading frame 50","metadata":{"aliases":["FLJ35803"]}},{"id":"a6d44f6e41f94bafbc8582899e620ed0","type":"GENE","name":"C9orf57","canonical_id":"hgnc:HGNC:27037","description":"chromosome 9 open reading frame 57","metadata":null},{"id":"e1c6366a05e746a7a4fae5665617b071","type":"GENE","name":"C9orf72","canonical_id":"hgnc:HGNC:28337","description":"C9orf72-SMCR8 complex subunit","metadata":{"aliases":["MGC23980","DENNL72","DENND9"]}},{"id":"2bbfe76105f842be854c6bfcc284f271","type":"GENE","name":"C9orf78","canonical_id":"hgnc:HGNC:24932","description":"chromosome 9 open reading frame 78","metadata":{"aliases":["HSPC220","HCA59","CSU2"]}},{"id":"dd467ac6c58041b0a7fd27cec31e5851","type":"GENE","name":"C9orf78P1","canonical_id":"hgnc:HGNC:56567","description":"C9orf78 pseudogene 1","metadata":null},{"id":"c1e4701e70c2451abb1fd95ea78772c1","type":"GENE","name":"C9orf78P2","canonical_id":"hgnc:HGNC:56568","description":"C9orf78 pseudogene 2","metadata":null},{"id":"4521223de85d440384331608399d2b0e","type":"GENE","name":"C9orf85","canonical_id":"hgnc:HGNC:28784","description":"chromosome 9 open reading frame 85","metadata":{"aliases":["MGC61599"]}},{"id":"852c082651ee4f4e9c8911ee42ed7a24","type":"GENE","name":"C9orf85P1","canonical_id":"hgnc:HGNC:56317","description":"C9orf85 pseudogene 1","metadata":null},{"id":"3b40591e43f14412a206b81487ce5850","type":"GENE","name":"C9orf85P2","canonical_id":"hgnc:HGNC:56318","description":"C9orf85 pseudogene 2","metadata":null},{"id":"a6952a18b9294051911ca40508209000","type":"TRIAL","name":"CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen","canonical_id":"clinicaltrials.gov:NCT00305838","description":"Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer","metadata":null},{"id":"e20fa95f4fd04d5b8bf4f0060f2b7aa4","type":"TRIAL","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","canonical_id":"clinicaltrials.gov:NCT03328078","description":"Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma","metadata":null},{"id":"ce758b15b60947f681ec2d51b33a5dbf","type":"GENE","name":"CA1","canonical_id":"hgnc:HGNC:1368","description":"carbonic anhydrase 1","metadata":{"aliases":["Car1"]}},{"id":"2c4f0c1ac50d47e8b41e3f1d173fc849","type":"PROTEIN","name":"CA1","canonical_id":"uniprot:P00915","description":null,"metadata":null},{"id":"c62b52b97e5a4fbfb3fbd7d7c7288a1b","type":"GENE","name":"CA10","canonical_id":"hgnc:HGNC:1369","description":"carbonic anhydrase 10 (inactive)","metadata":{"aliases":["CARPX","CA-RPX","HUCEP-15"]}},{"id":"4b1c08f17e8f4d678a69e7b7a229775b","type":"GENE","name":"CA11","canonical_id":"hgnc:HGNC:1370","description":"carbonic anhydrase 11 (inactive)","metadata":{"aliases":["CARP2","CARPX1"]}},{"id":"339694c8321842218c111101e10e8556","type":"GENE","name":"CA12","canonical_id":"hgnc:HGNC:1371","description":null,"metadata":null},{"id":"707bcaf9346643fb84e7e3c7c87d464b","type":"PROTEIN","name":"CA12","canonical_id":"uniprot:O43570","description":null,"metadata":null},{"id":"8d2d037269674015a0560c1f3e838425","type":"GENE","name":"CA13","canonical_id":"hgnc:HGNC:14914","description":"carbonic anhydrase 13","metadata":{"aliases":["CAXIII","FLJ37995","MGC59868"]}},{"id":"8c273bc4462043e3b0dbb614ab08ed7c","type":"GENE","name":"CA14","canonical_id":"hgnc:HGNC:1372","description":"carbonic anhydrase 14","metadata":null},{"id":"a57dc8da35d74e46ae544fd6ef56b332","type":"GENE","name":"CA14P1","canonical_id":"hgnc:HGNC:58646","description":"CA14 pseudogene 1","metadata":null},{"id":"f4a60e24df45499a9a5903bdf3b332fd","type":"GENE","name":"CA15P1","canonical_id":"hgnc:HGNC:44364","description":"CA15 pseudogene 1","metadata":null},{"id":"66f296339e72403694e99e4cf88638fa","type":"GENE","name":"CA15P2","canonical_id":"hgnc:HGNC:14916","description":"CA15 pseudogene 2","metadata":null},{"id":"2b69c080d0394d8689698bf0f5ac354e","type":"GENE","name":"CA15P3","canonical_id":"hgnc:HGNC:44363","description":"CA15 pseudogene 3","metadata":null},{"id":"eba0e1bf44004681bd50537bc7b2dad4","type":"GENE","name":"CA2","canonical_id":"hgnc:HGNC:1373","description":null,"metadata":null},{"id":"b762bd3f4fc341b1b502b39469164cce","type":"PROTEIN","name":"CA2","canonical_id":"uniprot:P00918","description":null,"metadata":null},{"id":"b418ff47e33c4ef5a2d1cf0a0a6d5fa0","type":"GENE","name":"CA3","canonical_id":"hgnc:HGNC:1374","description":"carbonic anhydrase 3","metadata":{"aliases":["Car3","CAIII"]}},{"id":"bc38ecb6d90d4c8aa0fbf0fee7ceeb97","type":"GO_TERM","name":"CA3 pyramidal cell dendrite","canonical_id":"go:GO:0097442","description":"\"A dendrite of a hippocampal CA3 pyramidal cell.\" [NIF_Subcellular:nlx_subcell_1005001]","metadata":null},{"id":"df46ffcf35fe4c5b8d22f8e552ff5ba0","type":"GENE","name":"CA3-AS1","canonical_id":"hgnc:HGNC:51657","description":"CA3 antisense RNA 1","metadata":null},{"id":"5360f1bb08e74117bed3e4f964ec0715","type":"GENE","name":"CA4","canonical_id":"hgnc:HGNC:1375","description":"carbonic anhydrase 4","metadata":{"aliases":["CAIV","Car4","RP17"]}},{"id":"9aa5ed42138a4c9fa62a33e203492332","type":"PROTEIN","name":"CA4","canonical_id":"uniprot:P22748","description":null,"metadata":null},{"id":"72e6d2bffb7e4a31b2795d30884fa5fd","type":"GENE","name":"CA5A","canonical_id":"hgnc:HGNC:1377","description":"carbonic anhydrase 5A","metadata":{"aliases":["CA5","CAV","CAVA","CA5"]}},{"id":"06ef020e4db64182b685bae30bfde5be","type":"GENE","name":"CA5AP1","canonical_id":"hgnc:HGNC:1379","description":"carbonic anhydrase 5A pseudogene 1","metadata":{"aliases":["CA5P"]}},{"id":"a55597a8611d44c8a3e34fa5efe59261","type":"GENE","name":"CA5B","canonical_id":"hgnc:HGNC:1378","description":"carbonic anhydrase 5B","metadata":null},{"id":"83966e0a79b940a39cd1d966cb179964","type":"GENE","name":"CA5BP1","canonical_id":"hgnc:HGNC:29544","description":"carbonic anhydrase 5B pseudogene 1","metadata":{"aliases":["PRO2325","CA5BL","CA5BP"]}},{"id":"15176957fe98401b8d69025d94202db0","type":"GENE","name":"CA6","canonical_id":"hgnc:HGNC:1380","description":"carbonic anhydrase 6","metadata":null},{"id":"33227ad20c7844c6895f8038422e5ced","type":"GENE","name":"CA7","canonical_id":"hgnc:HGNC:1381","description":"carbonic anhydrase 7","metadata":null},{"id":"26b3fa0a0e2d4ec1abd723584e7fc342","type":"PROTEIN","name":"CA7","canonical_id":"uniprot:P43166","description":null,"metadata":null},{"id":"07dc8b67380b4ea8a7000dbe86aa607d","type":"GENE","name":"CA8","canonical_id":"hgnc:HGNC:1382","description":"carbonic anhydrase 8 (inactive)","metadata":{"aliases":["CARP","CA-RP","CA-VIII","CALS"]}},{"id":"ec573d5f6faa4a77b54092e8f72af402","type":"GENE","name":"CA9","canonical_id":"hgnc:HGNC:1383","description":null,"metadata":null},{"id":"00dade8fa0b244ca8d0c943dd7a8ac82","type":"GO_TERM","name":"CAA codon-amino acid adaptor activity","canonical_id":"go:GO:0033427","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CAA codon.\" [GOC:mah]","metadata":null},{"id":"b1f0d0aad0c942bdab5876452b5fa960","type":"GENE","name":"CAAP1","canonical_id":"hgnc:HGNC:25834","description":"caspase activity and apoptosis inhibitor 1","metadata":{"aliases":["FLJ13657","CAAP","C9orf82"]}},{"id":"91f392fabce94cd59be08e84acd84f87","type":"GO_TERM","name":"CAAX-box protein maturation","canonical_id":"go:GO:0080120","description":"\"A series of specific posttranslational modifications to the CAAX box region of CAAX box proteins. CAAX box proteins are eukaryotic proteins that contain a CAAX motif where the C is a cysteine, the two A residues are aliphatic amino acids and the X can be one of several amino acids. The CAAX-box proteins undergo three sequential, enzymatic, post-translational modifications essential to their targeting: First, the proteins are prenylated by one of two prenyltransferases called farnesyltransferase and geranylgeranyltransferase-I. Prenylation results in the covalent attachment of either farnesyl or geranylgeranyl isoprenoid groups to the cysteine in the CAAX box motif. Prenylation is followed by proteolytic removal of the last three amino acids of the protein (AAX). Finally, the newly exposed carboxylate group of the isoprenylcysteine is methylated by an ER-associated prenyl-dependent carboxylmethyltransferase.\" [PMID:12039957, PMID:17114793, PMID:18641086]","metadata":null},{"id":"3bf267d6dc144f4d950c20c80f54eedb","type":"GO_TERM","name":"CAAX-box protein processing","canonical_id":"go:GO:0071586","description":"\"The second process in a series of specific posttranslational modifications to the CAAX box region of CAAX box proteins, in which the last three amino acids of the protein (AAX) are removed by proteolysis.\" [GOC:mah]","metadata":null},{"id":"fd5446df17284835a92a90bab4123364","type":"GO_TERM","name":"CAAX-protein geranylgeranyltransferase activity","canonical_id":"go:GO:0004662","description":"\"Catalysis of the reaction: geranylgeranyl diphosphate + protein-cysteine = S-geranylgeranyl-protein + diphosphate. This reaction is the formation of a thioether linkage between the C-1 atom of the geranylgeranyl group and a cysteine residue fourth from the C-terminus of the protein. The protein substrates have the C-terminal sequence CA1A2X, where the terminal residue, X, is preferably leucine and A2 should not be aromatic. Known substrates include most g-subunits of heterotrimeric G proteins and Ras-related GTPases such as members of the Ras and Rac/Rho families.\" [EC:2.5.1.59, PMID:8621375]","metadata":null},{"id":"2b37320a6c7a469fb15ad07be761c66b","type":"GO_TERM","name":"CAAX-protein geranylgeranyltransferase complex","canonical_id":"go:GO:0005953","description":"\"A heterodimeric enzyme, composed of an alpha and a beta subunit. Participates in the post-translational C-terminal modification of several small GTPases, allowing their targeting to the membrane.\" [PMID:9781874]","metadata":null},{"id":"74f1835bd4db43eba2f4eee9179a1d8c","type":"GENE","name":"CAB39","canonical_id":"hgnc:HGNC:20292","description":"calcium binding protein 39","metadata":{"aliases":["CGI-66","MO25"]}},{"id":"367c5c91e32b47e4b7f1496a5063ff2e","type":"GENE","name":"CAB39L","canonical_id":"hgnc:HGNC:20290","description":"calcium binding protein 39 like","metadata":{"aliases":["bA103J18.3","FLJ12577","MO2L","MLAA-34"]}},{"id":"ec43397e17ed429da0fd872c345e9a65","type":"GENE","name":"CAB39P1","canonical_id":"hgnc:HGNC:51641","description":"calcium binding protein 39 pseudogene 1","metadata":null},{"id":"272523e273a146b78835c79a53bba1b7","type":"GENE","name":"CABCOCO1","canonical_id":"hgnc:HGNC:28678","description":"ciliary associated calcium binding coiled-coil 1","metadata":{"aliases":["bA63A2.1","Em:AC022398.2","MGC44593","ARIEL","C10orf107"]}},{"id":"5e74ee5e9e6e444ea26f8f4e26e94c6c","type":"GENE","name":"CABIN1","canonical_id":"hgnc:HGNC:24187","description":null,"metadata":null},{"id":"7fccee33d17a45db96aaff9f4fe075a3","type":"GENE","name":"CABLES1","canonical_id":"hgnc:HGNC:25097","description":null,"metadata":null},{"id":"ea5360e42417474faeb8570f47555cfe","type":"GENE","name":"CABLES2","canonical_id":"hgnc:HGNC:16143","description":"Cdk5 and Abl enzyme substrate 2","metadata":{"aliases":["dJ908M14.2","ik3-2","C20orf150"]}},{"id":"b0dad630d96a44bca9969b2cdcb20c0f","type":"GENE","name":"CABP1","canonical_id":"hgnc:HGNC:1384","description":"calcium binding protein 1","metadata":null},{"id":"6637f8ab3f8046af98cff42519b48e6f","type":"GENE","name":"CABP1-DT","canonical_id":"hgnc:HGNC:55491","description":"CABP1 divergent transcript","metadata":{"aliases":["AC125616.1"]}},{"id":"6c3b31f2f5af42978fc2efb0d533ac40","type":"GENE","name":"CABP2","canonical_id":"hgnc:HGNC:1385","description":"calcium binding protein 2","metadata":{"aliases":["DFNB93"]}},{"id":"41149a97900644eea707dcd14439b8fc","type":"GENE","name":"CABP4","canonical_id":"hgnc:HGNC:1386","description":"calcium binding protein 4","metadata":{"aliases":["CSNB2B"]}},{"id":"1c5169778ded46c1a1389904bef9652b","type":"GENE","name":"CABP5","canonical_id":"hgnc:HGNC:13714","description":"calcium binding protein 5","metadata":{"aliases":["CaBP3","CABP3"]}},{"id":"1471f6347b324b05926f367609dba69a","type":"GENE","name":"CABP7","canonical_id":"hgnc:HGNC:20834","description":"calcium binding protein 7","metadata":{"aliases":["MGC57793"]}},{"id":"868347f302dd4bbc92ee124623330387","type":"GENE","name":"CABP7-DT","canonical_id":"hgnc:HGNC:55758","description":"CABP7 divergent transcript","metadata":null},{"id":"a4bcba76bb754b66bac70552cf7734cf","type":"GENE","name":"CABS1","canonical_id":"hgnc:HGNC:30710","description":"calcium binding protein, spermatid associated 1","metadata":{"aliases":["NYD-SP26","FLJ32897","CLPH","C4orf35"]}},{"id":"95ae99b754db43c18b3800a9d5f45c97","type":"GENE","name":"CABYR","canonical_id":"hgnc:HGNC:15569","description":"calcium binding tyrosine phosphorylation regulated","metadata":{"aliases":["FSP-2","CBP86","CT88"]}},{"id":"c5cb5ea955d04beeb1b3962ec087d5d9","type":"GENE","name":"CABYR-AS1","canonical_id":"hgnc:HGNC:58561","description":"CABYR antisense RNA 1","metadata":null},{"id":"8656231e3eb746f1a8d433831be21d70","type":"GENE","name":"CABYRP1","canonical_id":"hgnc:HGNC:31902","description":"calcium binding tyrosine phosphorylation regulated pseudogene 1","metadata":{"aliases":["CABYRP"]}},{"id":"90a29d34c574485298d751b3c79c3749","type":"GO_TERM","name":"CAC codon-amino acid adaptor activity","canonical_id":"go:GO:0033426","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CAC codon.\" [GOC:mah]","metadata":null},{"id":"4d87eee471904557a1b0c065b988e7b3","type":"GENE","name":"CACFD1","canonical_id":"hgnc:HGNC:1365","description":"calcium channel flower domain containing 1","metadata":{"aliases":["D9S2135","flower","C9orf7"]}},{"id":"59943879cc2a4f37a8843d2d495d05dc","type":"GENE","name":"CACHD1","canonical_id":"hgnc:HGNC:29314","description":"cache domain containing 1","metadata":{"aliases":["KIAA1573","VWCD1"]}},{"id":"12e8c364b50640b7bad4f1cbf00e337c","type":"GENE","name":"CACNA1A","canonical_id":"hgnc:HGNC:1388","description":"calcium voltage-gated channel subunit alpha1 A","metadata":{"aliases":["Cav2.1","EA2","APCA","HPCA","FHM","CACNL1A4","SCA6","MHP1","MHP"]}},{"id":"8d17d2a0e40041778d5475ec72f10fd9","type":"GENE","name":"CACNA1B","canonical_id":"hgnc:HGNC:1389","description":"calcium voltage-gated channel subunit alpha1 B","metadata":{"aliases":["Cav2.2","CACNN","CACNL1A5"]}},{"id":"bc239e9ac1af42d9af33a2afaef1b07f","type":"PROTEIN","name":"CACNA1B","canonical_id":"uniprot:Q00975","description":null,"metadata":null},{"id":"f6dd2f44802942a28e20be42acf284c2","type":"GENE","name":"CACNA1B-AS1","canonical_id":"hgnc:HGNC:56165","description":"CACNA1B antisense RNA 1","metadata":null},{"id":"c895d81f54034df38f17a2571ab96a73","type":"GENE","name":"CACNA1B-AS2","canonical_id":"hgnc:HGNC:58213","description":"CACNA1B antisense RNA 2","metadata":null},{"id":"1b7ac0a7dacc4e839dc203bb7aef8807","type":"GENE","name":"CACNA1C","canonical_id":"hgnc:HGNC:1390","description":"calcium voltage-gated channel subunit alpha1 C","metadata":{"aliases":["Cav1.2","CACH2","CACN2","TS","LQT8","CCHL1A1","CACNL1A1","CACNA1C-IT2"]}},{"id":"8fc5b56fb698488cac4c84bfb6562b48","type":"PROTEIN","name":"CACNA1C","canonical_id":"uniprot:Q13936","description":null,"metadata":null},{"id":"11c53524c18842d4b0d9063b6cc2af62","type":"GENE","name":"CACNA1C-AS3","canonical_id":"hgnc:HGNC:40117","description":"CACNA1C antisense RNA 3","metadata":null},{"id":"22d2b95c94324942960012d7046b70ec","type":"GENE","name":"CACNA1C-AS4","canonical_id":"hgnc:HGNC:40116","description":"CACNA1C antisense RNA 4","metadata":null},{"id":"9117c93e5b1c4dfd8282f5136d43c12e","type":"GENE","name":"CACNA1C-IT1","canonical_id":"hgnc:HGNC:41312","description":"CACNA1C intronic transcript 1","metadata":null},{"id":"5f1b799ca8ea41fa9c75ba4df1d52ca5","type":"GENE","name":"CACNA1C-IT3","canonical_id":"hgnc:HGNC:41314","description":"CACNA1C intronic transcript 3","metadata":null},{"id":"f40680d3c44f4db59fc3329a0831e93d","type":"DISEASE","name":"CACNA1C-related disorder","canonical_id":"mondo:0700321","description":null,"metadata":null},{"id":"2db2399c7eac498dbea043e7da40c15f","type":"GENE","name":"CACNA1D","canonical_id":"hgnc:HGNC:1391","description":"calcium voltage-gated channel subunit alpha1 D","metadata":{"aliases":["Cav1.3","CACH3","CACN4","CCHL1A2","CACNL1A2"]}},{"id":"b37405ff1bd543a48943d0d476f83b6e","type":"GENE","name":"CACNA1E","canonical_id":"hgnc:HGNC:1392","description":"calcium voltage-gated channel subunit alpha1 E","metadata":{"aliases":["Cav2.3","BII","CACH6","CACNL1A6"]}},{"id":"381b94789ce644d6839ca4c79766adc9","type":"GENE","name":"CACNA1F","canonical_id":"hgnc:HGNC:1393","description":"calcium voltage-gated channel subunit alpha1 F","metadata":{"aliases":["Cav1.4","JM8","JMC8","CSNBX2","CORDX3","CSNB2A","OA2","CSNB2","AIED"]}},{"id":"37980f4892c8487582487cc840424912","type":"GENE","name":"CACNA1G","canonical_id":"hgnc:HGNC:1394","description":"calcium voltage-gated channel subunit alpha1 G","metadata":{"aliases":["Cav3.1","NBR13"]}},{"id":"02cd99f921ad496ba051de0143bd36bf","type":"GENE","name":"CACNA1G-AS1","canonical_id":"hgnc:HGNC:27377","description":"CACNA1G antisense RNA 1","metadata":{"aliases":["CAS1"]}},{"id":"5d24c8e6ea66492281ce479e5b554fa7","type":"GENE","name":"CACNA1H","canonical_id":"hgnc:HGNC:1395","description":null,"metadata":null},{"id":"9c878a4f19bf4be48a85862fca28ab49","type":"GENE","name":"CACNA1I","canonical_id":"hgnc:HGNC:1396","description":"calcium voltage-gated channel subunit alpha1 I","metadata":{"aliases":["Cav3.3"]}},{"id":"188f34543f604b719d97473e3b5aec06","type":"GENE","name":"CACNA1S","canonical_id":"hgnc:HGNC:1397","description":"calcium voltage-gated channel subunit alpha1 S","metadata":{"aliases":["Cav1.1","hypoPP","HOKPP","MHS5","CACNL1A3"]}},{"id":"9334dd9caf614095a34b6b7bf48f33cc","type":"GENE","name":"CACNA2D1","canonical_id":"hgnc:HGNC:1399","description":"calcium voltage-gated channel auxiliary subunit alpha2delta 1","metadata":{"aliases":["lncRNA-N3","alpha2delta-1","CACNL2A","CACNA2","MHS3","LINC01112"]}},{"id":"3c0205e52a1a4493a54d1356c2c3ab35","type":"GENE","name":"CACNA2D1-AS1","canonical_id":"hgnc:HGNC:40120","description":"CACNA2D1 antisense RNA 1","metadata":null},{"id":"c86cf12b53664e6c9e5ebf058d6c7be1","type":"GENE","name":"CACNA2D2","canonical_id":"hgnc:HGNC:1400","description":"calcium voltage-gated channel auxiliary subunit alpha2delta 2","metadata":{"aliases":["KIAA0558","alpha2delta-2"]}},{"id":"4c78e8b744bc4283939d94aa3effe134","type":"GENE","name":"CACNA2D3","canonical_id":"hgnc:HGNC:15460","description":"calcium voltage-gated channel auxiliary subunit alpha2delta 3","metadata":{"aliases":["HSA272268","alpha2delta-3"]}},{"id":"c285b7e0078a4694a01da19693d6b8ea","type":"GENE","name":"CACNA2D3-AS1","canonical_id":"hgnc:HGNC:40702","description":"CACNA2D3 antisense RNA 1","metadata":null},{"id":"1c09d104664f46299f6d8a73ed389ffc","type":"GENE","name":"CACNA2D4","canonical_id":"hgnc:HGNC:20202","description":"calcium voltage-gated channel auxiliary subunit alpha2delta 4","metadata":{"aliases":["alpha2delta-4"]}},{"id":"687f72ad0a61419c9638344d3685ccca","type":"GENE","name":"CACNB1","canonical_id":"hgnc:HGNC:1401","description":"calcium voltage-gated channel auxiliary subunit beta 1","metadata":{"aliases":["CACNLB1"]}},{"id":"de6451ecdc8d40b4b126f066a79db024","type":"GENE","name":"CACNB1-AS1","canonical_id":"hgnc:HGNC:58562","description":"CACNB1 antisense RNA 1","metadata":null},{"id":"5686179afc574df380eaf742929669f6","type":"GENE","name":"CACNB2","canonical_id":"hgnc:HGNC:1402","description":"calcium voltage-gated channel auxiliary subunit beta 2","metadata":{"aliases":["MYSB","CACNLB2"]}},{"id":"2c2c4c50c802445e931addb0bb3915c6","type":"GENE","name":"CACNB2-AS1","canonical_id":"hgnc:HGNC:58168","description":"CACNB2 antisense RNA 1","metadata":null},{"id":"c196b569584144a989f919f2991cfadd","type":"GENE","name":"CACNB2-AS2","canonical_id":"hgnc:HGNC:58169","description":"CACNB2 antisense RNA 2","metadata":null},{"id":"340f82e1a6a545ed9610467687195dbc","type":"GENE","name":"CACNB3","canonical_id":"hgnc:HGNC:1403","description":"calcium voltage-gated channel auxiliary subunit beta 3","metadata":{"aliases":["CACNLB3"]}},{"id":"0cb185b4c9164d9ab3b32204ece41e75","type":"GENE","name":"CACNB4","canonical_id":"hgnc:HGNC:1404","description":"calcium voltage-gated channel auxiliary subunit beta 4","metadata":{"aliases":["EJM4"]}},{"id":"dcf5d4e49c044fbea79971b9a9cb4c47","type":"GENE","name":"CACNG1","canonical_id":"hgnc:HGNC:1405","description":"calcium voltage-gated channel auxiliary subunit gamma 1","metadata":{"aliases":["CACNLG"]}},{"id":"70030ae1904b4abe8758678d89b6a62b","type":"GENE","name":"CACNG2","canonical_id":"hgnc:HGNC:1406","description":"calcium voltage-gated channel auxiliary subunit gamma 2","metadata":{"aliases":["stargazin","MGC138502","MGC138504"]}},{"id":"5d839cb5a1d74dab9323e9309aa72e71","type":"GENE","name":"CACNG2-DT","canonical_id":"hgnc:HGNC:55682","description":"CACNG2 divergent transcript","metadata":null},{"id":"f1a35164a37a4a2d8ddc0bc43c896e0d","type":"GENE","name":"CACNG3","canonical_id":"hgnc:HGNC:1407","description":"calcium voltage-gated channel auxiliary subunit gamma 3","metadata":null},{"id":"eab84487ac1840a5a18852a049e0c716","type":"GENE","name":"CACNG4","canonical_id":"hgnc:HGNC:1408","description":"calcium voltage-gated channel auxiliary subunit gamma 4","metadata":{"aliases":["MGC11138","MGC24983"]}},{"id":"b3fa84fb49a849e69c2590f63293d3d9","type":"GENE","name":"CACNG5","canonical_id":"hgnc:HGNC:1409","description":"calcium voltage-gated channel auxiliary subunit gamma 5","metadata":null},{"id":"1027c47668fe453dbae7079f6b517d05","type":"GENE","name":"CACNG6","canonical_id":"hgnc:HGNC:13625","description":"calcium voltage-gated channel auxiliary subunit gamma 6","metadata":null},{"id":"d07d9750a68d4c3497879469570f85ad","type":"GENE","name":"CACNG7","canonical_id":"hgnc:HGNC:13626","description":"calcium voltage-gated channel auxiliary subunit gamma 7","metadata":null},{"id":"39a2e549b07e46fba9c8e83c541e05f7","type":"GENE","name":"CACNG8","canonical_id":"hgnc:HGNC:13628","description":"calcium voltage-gated channel auxiliary subunit gamma 8","metadata":null},{"id":"6b75a7483d884b9bbe70594cce487274","type":"GENE","name":"CACSTL1","canonical_id":"hgnc:HGNC:56690","description":"chromosomal aberration CCDC6::RET stimulating lncRNA 1","metadata":{"aliases":["CASTL1"]}},{"id":"6fc2b67aeab24211b8e62bdb39470c08","type":"GENE","name":"CACTIN","canonical_id":"hgnc:HGNC:29938","description":"cactin, spliceosome C complex subunit","metadata":{"aliases":["NY-REN-24","fSAPc","C19orf29"]}},{"id":"283f0cb9e5af4e5c88ad6c9c1f5d2054","type":"GENE","name":"CACTIN-AS1","canonical_id":"hgnc:HGNC:31391","description":"CACTIN antisense RNA 1","metadata":{"aliases":["C19orf29OS","C19orf29-AS1"]}},{"id":"0626936fddfb40a4a93ccf3787e08513","type":"GENE","name":"CACUL1","canonical_id":"hgnc:HGNC:23727","description":"CDK2 associated cullin domain 1","metadata":{"aliases":["FLJ40409","MGC33215","CAC1","C10orf46"]}},{"id":"b25c30f717714753b55ebfd0760e1ad2","type":"GENE","name":"CACYBP","canonical_id":"hgnc:HGNC:30423","description":"calcyclin binding protein","metadata":{"aliases":["SIP","S100A6BP"]}},{"id":"8b2de299c5fd43d9bc5edbf6a3e234a5","type":"GENE","name":"CACYBPP1","canonical_id":"hgnc:HGNC:45122","description":"calcyclin binding protein pseudogene 1","metadata":null},{"id":"eddd892caf124ee699085aa8df4657f7","type":"GENE","name":"CACYBPP2","canonical_id":"hgnc:HGNC:45123","description":"calcyclin binding protein pseudogene 2","metadata":null},{"id":"b005b40e05b7468f92bd3993a8d406a8","type":"GENE","name":"CACYBPP3","canonical_id":"hgnc:HGNC:45124","description":"calcyclin binding protein pseudogene 3","metadata":null},{"id":"2ee9b605deda49af88aa7ad633126f77","type":"GENE","name":"CAD","canonical_id":"hgnc:HGNC:1424","description":null,"metadata":null},{"id":"1bbf99ea5b104028970cfe3757f0e2e2","type":"GENE","name":"CADM1","canonical_id":"hgnc:HGNC:5951","description":"cell adhesion molecule 1","metadata":{"aliases":["NECL2","ST17","BL2","SYNCAM","IGSF4A","Necl-2","SYNCAM1","RA175","TSLC1","IGSF4"]}},{"id":"724ed609b1d843dba42d1c09bd6625b4","type":"GENE","name":"CADM1-AS1","canonical_id":"hgnc:HGNC:56177","description":"CADM1 antisense RNA 1","metadata":null},{"id":"dbe095396a5745bb9606f24ef2ed5784","type":"GENE","name":"CADM2","canonical_id":"hgnc:HGNC:29849","description":"cell adhesion molecule 2","metadata":{"aliases":["NECL3","Necl-3","SynCAM2","SynCAM-2","IGSF4D"]}},{"id":"0c3ffbb8618a4adb97e7ce45055fe21d","type":"GENE","name":"CADM2-AS1","canonical_id":"hgnc:HGNC:41248","description":"CADM2 antisense RNA 1","metadata":null},{"id":"3aa18a5defa84231857135b94c921278","type":"GENE","name":"CADM2-AS2","canonical_id":"hgnc:HGNC:41247","description":"CADM2 antisense RNA 2","metadata":null},{"id":"dcfed60c97d944ec93e9e16d9a52b35a","type":"GENE","name":"CADM3","canonical_id":"hgnc:HGNC:17601","description":"cell adhesion molecule 3","metadata":{"aliases":["BIgR","FLJ10698","TSLL1","NECL1","SynCAM3","Necl-1","IGSF4B"]}},{"id":"3bf402ecb7a6423fa385475e7dad3e99","type":"GENE","name":"CADM3-AS1","canonical_id":"hgnc:HGNC:40812","description":"CADM3 antisense RNA 1","metadata":{"aliases":["CTA-134P22.2"]}},{"id":"4c87440ff3dd42bcba3e317587e5ab7f","type":"GENE","name":"CADM4","canonical_id":"hgnc:HGNC:30825","description":"cell adhesion molecule 4","metadata":{"aliases":["TSLL2","Necl-4","SynCAM4","IGSF4C"]}},{"id":"9f63ffa8b8144534ac3b9e1994a690c1","type":"GENE","name":"CADPS","canonical_id":"hgnc:HGNC:1426","description":"calcium dependent secretion activator","metadata":{"aliases":["CAPS","KIAA1121","CAPS1","UNC-31","CADPS1"]}},{"id":"e814aaf530754afa8eb32cf33836ff94","type":"GENE","name":"CADPS2","canonical_id":"hgnc:HGNC:16018","description":"calcium dependent secretion activator 2","metadata":{"aliases":["CAPS2"]}},{"id":"d361ae7819764eaea58eabfcf1b776c9","type":"GO_TERM","name":"CAF-1 complex","canonical_id":"go:GO:0033186","description":"\"A conserved heterotrimeric protein complex that promotes histone H3 and H4 deposition onto newly synthesized DNA during replication or DNA repair; specifically facilitates replication-dependent nucleosome assembly with the major histone H3 (H3.1). In many species the CAF-1 subunits are designated p150, p60, and p48.\" [PMID:17065558, PMID:17083276]","metadata":null},{"id":"c27a19062cf74221a0ad52659bc12973","type":"GO_TERM","name":"CAG codon-amino acid adaptor activity","canonical_id":"go:GO:0033428","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CAG codon.\" [GOC:mah]","metadata":null},{"id":"2073e1ba0c9544e0be095f109f1c63dd","type":"GENE","name":"CAGE1","canonical_id":"hgnc:HGNC:21622","description":"cancer antigen 1","metadata":{"aliases":["bA69L16.7","CT95","CTAG3"]}},{"id":"24d284661f79485b9644492f43e5ff5a","type":"GENE","name":"CAGE1-AS1","canonical_id":"hgnc:HGNC:59342","description":"CAGE1 antisense RNA 1","metadata":null},{"id":"4bf53494b4624183b94fd92f5864c757","type":"GENE","name":"CAHM","canonical_id":"hgnc:HGNC:42860","description":"colon adenocarcinoma hypermethylated","metadata":{"aliases":["LINC00468"]}},{"id":"54d2b43f866a499f8bad48c4603455cb","type":"GO_TERM","name":"CAK-ERCC2 complex","canonical_id":"go:GO:0070516","description":"\"A protein complex formed by the association of the cyclin-dependent protein kinase activating kinase (CAK) holoenzyme complex with ERCC2.\" [PMID:8692841, PMID:8692842]","metadata":null},{"id":"38c233bed5f24f5e86e42833cd8373e7","type":"GENE","name":"CALB1","canonical_id":"hgnc:HGNC:1434","description":null,"metadata":null},{"id":"9fb42008496f43e197ed78831a5afc50","type":"GENE","name":"CALB2","canonical_id":"hgnc:HGNC:1435","description":"calbindin 2","metadata":{"aliases":["CAL2"]}},{"id":"beab9ff10c6349db838b309a0c46eeba","type":"GENE","name":"CALCA","canonical_id":"hgnc:HGNC:1437","description":"calcitonin related polypeptide alpha","metadata":{"aliases":["CGRP","CGRP-alpha","CALC1"]}},{"id":"94acf1df74a84dad87dac5f04400c194","type":"PROTEIN","name":"CALCA","canonical_id":"uniprot:P06881","description":null,"metadata":null},{"id":"a3a0e9f6949a4329ab246af2f024fdbe","type":"GENE","name":"CALCB","canonical_id":"hgnc:HGNC:1438","description":"calcitonin related polypeptide beta","metadata":{"aliases":["FLJ30166","CGRP-II","CALC2"]}},{"id":"7895218893984f82a28058e4af0b0b01","type":"GENE","name":"CALCOCO1","canonical_id":"hgnc:HGNC:29306","description":"calcium binding and coiled-coil domain 1","metadata":{"aliases":["KIAA1536","calphoglin","Cocoa"]}},{"id":"e237f5015c114429bdf2ef9682107952","type":"GENE","name":"CALCOCO1-AS1","canonical_id":"hgnc:HGNC:59213","description":"CALCOCO1 antisense RNA 1","metadata":null},{"id":"f9af021b80df433fa43600e5616fb303","type":"GENE","name":"CALCOCO2","canonical_id":"hgnc:HGNC:29912","description":"calcium binding and coiled-coil domain 2","metadata":{"aliases":["MGC17318","NDP52"]}},{"id":"89c5a28ce7af4b589e2ef78c16cc3852","type":"GENE","name":"CALCP","canonical_id":"hgnc:HGNC:1439","description":"calcitonin pseudogene","metadata":{"aliases":["CALC3"]}},{"id":"3712498e80cf42fa8cec6ca4b09552d7","type":"GENE","name":"CALCR","canonical_id":"hgnc:HGNC:1440","description":"calcitonin receptor","metadata":{"aliases":["CTR","CT-R"]}},{"id":"cda973fe73434d2083af74607fd76ba8","type":"PROTEIN","name":"CALCR","canonical_id":"uniprot:P30988","description":null,"metadata":null},{"id":"1204cb25f3bc4353b6507d09a9757dbf","type":"GENE","name":"CALCRL","canonical_id":"hgnc:HGNC:16709","description":"calcitonin receptor like receptor","metadata":{"aliases":["CGRPR","CRLR"]}},{"id":"cf7b4089be524ca992b247adcb9c2207","type":"PROTEIN","name":"CALCRL","canonical_id":"uniprot:Q16602","description":null,"metadata":null},{"id":"b903911209284c2daec2271c9b31a791","type":"GENE","name":"CALCRL-AS1","canonical_id":"hgnc:HGNC:55863","description":"CALCRL and TFPI antisense RNA 1","metadata":null},{"id":"dd3da7a09f0549afbfefe1d050ab38e3","type":"GENE","name":"CALD1","canonical_id":"hgnc:HGNC:1441","description":null,"metadata":null},{"id":"8241a4de1d974e68a7b315d2a7b31775","type":"GENE","name":"CALHM1","canonical_id":"hgnc:HGNC:23494","description":"calcium homeostasis modulator 1","metadata":{"aliases":["FAM26C"]}},{"id":"85bd7e8b4c5a4bc4a1a8ff847c25d204","type":"GENE","name":"CALHM2","canonical_id":"hgnc:HGNC:23493","description":"calcium homeostasis modulator family member 2","metadata":{"aliases":["FAM26B"]}},{"id":"76fb7bf940894e42a0c9232860e57825","type":"GENE","name":"CALHM2-AS1","canonical_id":"hgnc:HGNC:58612","description":"CALHM2 antisense RNA 1","metadata":null},{"id":"337a1e3cbb7743149b22d539e9a22c36","type":"GENE","name":"CALHM3","canonical_id":"hgnc:HGNC:23458","description":"calcium homeostasis modulator 3","metadata":{"aliases":["bA225H22.7","FAM26A"]}},{"id":"6f304a5d94ef4920b12745f48a22abb6","type":"GENE","name":"CALHM4","canonical_id":"hgnc:HGNC:21094","description":"calcium homeostasis modulator family member 4","metadata":{"aliases":["FLJ32239","C6orf78","FAM26D"]}},{"id":"d8795fdf108d473f8bcc21548b484bf8","type":"GENE","name":"CALHM5","canonical_id":"hgnc:HGNC:21568","description":"calcium homeostasis modulator family member 5","metadata":{"aliases":["dJ493F7.3","MGC45451","C6orf188","FAM26E"]}},{"id":"7d897a4e6d6746f3af7d731a05d840cb","type":"GENE","name":"CALHM6","canonical_id":"hgnc:HGNC:33391","description":"calcium homeostasis modulator family member 6","metadata":{"aliases":["RP1-93H18.5","OTTHUMP00000017061","OTTHUMP00000017062","dJ93H18.5","INAM","C6orf187","FAM26F"]}},{"id":"8e74851c9e7a4d84b33b81375ea192ae","type":"GENE","name":"CALHM6-AS1","canonical_id":"hgnc:HGNC:40971","description":"CALHM6 antisense RNA 1","metadata":{"aliases":["RP1-93H18.6"]}},{"id":"c75e0afec2234f07963617dcdfe1d72c","type":"GENE","name":"CALM1","canonical_id":"hgnc:HGNC:1442","description":"calmodulin 1","metadata":{"aliases":["CAMI","PHKD","DD132","PHKD1","CALML2"]}},{"id":"eb3672fc01124a97b60310bd62da7402","type":"GENE","name":"CALM1P1","canonical_id":"hgnc:HGNC:1443","description":"calmodulin 1 pseudogene 1","metadata":{"aliases":["CALML1"]}},{"id":"0cd289c15ee64c37bf4597b61302127f","type":"GENE","name":"CALM1P2","canonical_id":"hgnc:HGNC:1444","description":"calmodulin 1 pseudogene 2","metadata":{"aliases":["TCAG_1643085"]}},{"id":"6661728e822241b5b77c8e842d6090b4","type":"GENE","name":"CALM2","canonical_id":"hgnc:HGNC:1445","description":"calmodulin 2","metadata":{"aliases":["PHKD","PHKD2","CAMII"]}},{"id":"9f5b8b013d7a44c3a981dc21431b400c","type":"GENE","name":"CALM2P1","canonical_id":"hgnc:HGNC:1446","description":"calmodulin 2 pseudogene 1","metadata":null},{"id":"8fbe2a99aa4b4bd18ad6e01edec2b34c","type":"GENE","name":"CALM2P2","canonical_id":"hgnc:HGNC:1447","description":"calmodulin 2 pseudogene 2","metadata":null},{"id":"75f967412dd94eda83ab78af679d1fa9","type":"GENE","name":"CALM2P3","canonical_id":"hgnc:HGNC:1448","description":"calmodulin 2 pseudogene 3","metadata":null},{"id":"d464058e88f24f1d8591140af08e86ce","type":"GENE","name":"CALM2P4","canonical_id":"hgnc:HGNC:39661","description":"calmodulin 2 pseudogene 4","metadata":null},{"id":"efb2e58f9f9e430ba32e28340b8d0f14","type":"GENE","name":"CALM3","canonical_id":"hgnc:HGNC:1449","description":"calmodulin 3","metadata":{"aliases":["PHKD","PHKD3"]}},{"id":"f93f71fb19004c96b95598b762ff93c1","type":"GENE","name":"CALML3","canonical_id":"hgnc:HGNC:1452","description":"calmodulin like 3","metadata":{"aliases":["CLP"]}},{"id":"251b57ed8e6047dfb13fd598d147085f","type":"GENE","name":"CALML3-AS1","canonical_id":"hgnc:HGNC:44682","description":"CALML3 antisense RNA 1","metadata":null},{"id":"75189f94a0e94ba788066b3de3c0c314","type":"GENE","name":"CALML4","canonical_id":"hgnc:HGNC:18445","description":"calmodulin like 4","metadata":{"aliases":["MGC4809","NY-BR-20"]}},{"id":"c7e12a246a0b45d0918287f28ef67fd3","type":"GENE","name":"CALML5","canonical_id":"hgnc:HGNC:18180","description":"calmodulin like 5","metadata":{"aliases":["CLSP"]}},{"id":"97f21ffcab774bd0b5efb53e1b8410ad","type":"GENE","name":"CALML6","canonical_id":"hgnc:HGNC:24193","description":"calmodulin like 6","metadata":{"aliases":["CAGLP"]}},{"id":"b473203ee10547c49dbdad76328197c2","type":"GENE","name":"CALN1","canonical_id":"hgnc:HGNC:13248","description":"calneuron 1","metadata":{"aliases":["CABP8"]}},{"id":"3d98950630ce45d1a9f598695bd15b1a","type":"GENE","name":"CALR","canonical_id":"hgnc:HGNC:1455","description":"calreticulin","metadata":{"aliases":["RO","SSA","cC1qR","CRT","FLJ26680","CALR1"]}},{"id":"e6e1f8b675674e04adf3a15edc9e8dbe","type":"GENE","name":"CALR3","canonical_id":"hgnc:HGNC:20407","description":"calreticulin 3","metadata":{"aliases":["CRT2","FLJ25355","MGC26577","CT93"]}},{"id":"b5bdf1076c244640ad9a9575c09cf7d4","type":"GENE","name":"CALR4P","canonical_id":"hgnc:HGNC:35456","description":"calreticulin 4, pseudogene","metadata":null},{"id":"80f29d7baa0145c786c01abb17250f63","type":"GENE","name":"CALU","canonical_id":"hgnc:HGNC:1458","description":"calumenin","metadata":null},{"id":"cc88bd151357449b885f4bedb6096b47","type":"GENE","name":"CALY","canonical_id":"hgnc:HGNC:17938","description":"calcyon neuron specific vesicular protein","metadata":{"aliases":["CALCYON","NSG3","DRD1IP"]}},{"id":"cf7d41640dea4327b3077f160dd72409","type":"GENE","name":"CALYD2-AS2","canonical_id":"hgnc:HGNC:41073","description":"CALYD2 antisense RNA 2","metadata":null},{"id":"9b3ef209304c4cb5888c3625b41e2e8f","type":"GO_TERM","name":"CAM photosynthesis","canonical_id":"go:GO:0009761","description":"\"The combination of atmospheric CO2 with a 3-carbon molecule phosphoenol pyruvate (PEP) to make malic acid. The malic acid is then passed into the vacuole where it is stored until daylight, when it is shuttled back out to be used as a substrate in the light reaction of photosynthesis.\" [ISBN:0582015952]","metadata":null},{"id":"c9c84e1a6a6a41288ddb77ece7e615c7","type":"GENE","name":"CAMK1","canonical_id":"hgnc:HGNC:1459","description":"calcium/calmodulin dependent protein kinase I","metadata":{"aliases":["CaMKI","CaMKI-alpha"]}},{"id":"7d78942987c14074a9c1cdb77accb63e","type":"GENE","name":"CAMK1D","canonical_id":"hgnc:HGNC:19341","description":"calcium/calmodulin dependent protein kinase ID","metadata":{"aliases":["CKLiK"]}},{"id":"3f547bbc793e43269720f4fa38f0d21b","type":"GENE","name":"CAMK1G","canonical_id":"hgnc:HGNC:14585","description":"calcium/calmodulin dependent protein kinase IG","metadata":{"aliases":["VWS1","CLICKIII","dJ272L16.1"]}},{"id":"4639f86a0dcd4b36ba5fd216cdb0f654","type":"GENE","name":"CAMK2A","canonical_id":"hgnc:HGNC:1460","description":"calcium/calmodulin dependent protein kinase II alpha","metadata":{"aliases":["KIAA0968","CaMKIINalpha","CaMKII\u03b1","CAMKA"]}},{"id":"83ca5779595c4ebb9818e8f912e2389f","type":"GENE","name":"CAMK2B","canonical_id":"hgnc:HGNC:1461","description":"calcium/calmodulin dependent protein kinase II beta","metadata":{"aliases":["CAM2","CAMK2","CaMKII\u03b2","CAMKB"]}},{"id":"92a15fe793f64b0382cf20d5c7d00114","type":"GENE","name":"CAMK2D","canonical_id":"hgnc:HGNC:1462","description":"calcium/calmodulin dependent protein kinase II delta","metadata":{"aliases":["CAMKD"]}},{"id":"517fe0752a314df0b3fdf4e868f5ff1f","type":"GENE","name":"CAMK2D-AS1","canonical_id":"hgnc:HGNC:58873","description":"CAMK2D antisense RNA 1","metadata":null},{"id":"2f10c0a3426d43bb9d4d702505d0321d","type":"GENE","name":"CAMK2G","canonical_id":"hgnc:HGNC:1463","description":"calcium/calmodulin dependent protein kinase II gamma","metadata":{"aliases":["CAMKG"]}},{"id":"59870eaa7aa948f48243640c8a2771f7","type":"GENE","name":"CAMK2G-AS1","canonical_id":"hgnc:HGNC:56057","description":"CAMK2G antisense RNA 1","metadata":null},{"id":"6d120ea9efe74be0b5bd4cd6d10d3432","type":"GENE","name":"CAMK2N1","canonical_id":"hgnc:HGNC:24190","description":"calcium/calmodulin dependent protein kinase II inhibitor 1","metadata":{"aliases":["CaMKIINalpha"]}},{"id":"70655ecea39d4efb8aff924d894d9784","type":"GENE","name":"CAMK2N2","canonical_id":"hgnc:HGNC:24197","description":"calcium/calmodulin dependent protein kinase II inhibitor 2","metadata":{"aliases":["CaM-KIIN"]}},{"id":"574c64a4529d46339e723315fd5f3e5f","type":"GENE","name":"CAMK4","canonical_id":"hgnc:HGNC:1464","description":"calcium/calmodulin dependent protein kinase IV","metadata":{"aliases":["CaMK-GR","CaMKIV"]}},{"id":"914149c43f164115b4626240a8e05a9e","type":"GENE","name":"CAMK4-AS1","canonical_id":"hgnc:HGNC:40124","description":"CAMK4 antisense RNA 1","metadata":null},{"id":"2dd4bd68d18344cd894d5545a674a897","type":"GO_TERM","name":"CAMKK-AMPK signaling cascade","canonical_id":"go:GO:0061762","description":"\"The series of molecular signals in which calmodulin-dependent protein kinase activity enabled by a CAMKK directly activates an AMPK. The cascade begins with calmodulin binding calcium which in turn binds CAMKK enabling its calmodulin-dependent protein kinase activity. The cascade ends with AMP-activated protein kinase activity.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:23010169, PMID:24709372]","metadata":null},{"id":"3affad07186843ae8c9f61887c0967ea","type":"GENE","name":"CAMKK1","canonical_id":"hgnc:HGNC:1469","description":"calcium/calmodulin dependent protein kinase kinase 1","metadata":{"aliases":["DKFZp761M0423","CAMKKA","MGC34095"]}},{"id":"5f50e453e7d5477abf79a6cc301601d8","type":"GENE","name":"CAMKK2","canonical_id":"hgnc:HGNC:1470","description":"calcium/calmodulin dependent protein kinase kinase 2","metadata":{"aliases":["CAMKK","KIAA0787","CAMKKB","MGC15254"]}},{"id":"2f6e5f440d9c40a2b1824ac6012531eb","type":"GENE","name":"CAMKMT","canonical_id":"hgnc:HGNC:26276","description":"calmodulin-lysine N-methyltransferase","metadata":{"aliases":["CLNMT","C2orf34"]}},{"id":"14fad714146d42f69f9924fb090ce6ac","type":"GENE","name":"CAMKV","canonical_id":"hgnc:HGNC:28788","description":"CaM kinase like vesicle associated","metadata":{"aliases":["MGC8407","VACAMKL"]}},{"id":"c78b6513761b447cb7bec75d9c8ab624","type":"GENE","name":"CAMLG","canonical_id":"hgnc:HGNC:1471","description":"calcium modulating ligand","metadata":{"aliases":["CAML","GET2"]}},{"id":"9042bb264ef941b8a927078699f0e011","type":"TRIAL","name":"CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients","canonical_id":"clinicaltrials.gov:NCT04608266","description":"Covid19","metadata":null},{"id":"4a54ab1782874a9da0f2087317018da5","type":"GENE","name":"CAMP","canonical_id":"hgnc:HGNC:1472","description":null,"metadata":null},{"id":"6eb8688ee87b47daa18b1f3c8e152259","type":"TRIAL","name":"CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT03591380","description":"Kidney Transplantation","metadata":null},{"id":"9a9b76e6a7d64e069ecf44179c3814c2","type":"GENE","name":"CAMSAP1","canonical_id":"hgnc:HGNC:19946","description":"calmodulin regulated spectrin associated protein 1","metadata":{"aliases":["FLJ31228","DKFZp434F195"]}},{"id":"bfa67b183d5b410b918a85ee09c7a738","type":"GENE","name":"CAMSAP1-DT","canonical_id":"hgnc:HGNC:55648","description":"CAMSAP1 divergent transcript","metadata":null},{"id":"f26b98439181419ebbcbb468f5063bf7","type":"GENE","name":"CAMSAP2","canonical_id":"hgnc:HGNC:29188","description":"calmodulin regulated spectrin associated protein family member 2","metadata":{"aliases":["KIAA1078","CAMSAP1L1"]}},{"id":"4b0eed53a1864b9d81ff4d98b245fa82","type":"GENE","name":"CAMSAP3","canonical_id":"hgnc:HGNC:29307","description":"calmodulin regulated spectrin associated protein family member 3","metadata":{"aliases":["Nezha","PPP1R80","KIAA1543"]}},{"id":"a0da08d14946440f834fc6cff9191fd0","type":"GENE","name":"CAMTA1","canonical_id":"hgnc:HGNC:18806","description":"calmodulin binding transcription activator 1","metadata":{"aliases":["KIAA0833"]}},{"id":"66eb52011b654db2a5163bf139fdfd16","type":"GENE","name":"CAMTA1-AS1","canonical_id":"hgnc:HGNC:40856","description":"CAMTA1 antisense RNA 1","metadata":null},{"id":"868df832f9dc45e0ac2b7a24e1d58160","type":"GENE","name":"CAMTA1-AS2","canonical_id":"hgnc:HGNC:40855","description":"CAMTA1 antisense RNA 2","metadata":null},{"id":"4626ef374d2846b7a93ad8858282076f","type":"GENE","name":"CAMTA1-AS3","canonical_id":"hgnc:HGNC:40854","description":"CAMTA1 antisense RNA 3","metadata":{"aliases":["AL512330.1"]}},{"id":"9be4ff2ca53641c384b8c3dac6e81b19","type":"GENE","name":"CAMTA1-AS4","canonical_id":"hgnc:HGNC:58083","description":"CAMTA1 antisense RNA 4","metadata":{"aliases":["REIR-9"]}},{"id":"6161547364fc4414a646f646eac138d5","type":"GENE","name":"CAMTA1-DT","canonical_id":"hgnc:HGNC:53020","description":"CAMTA1 divergent transcript","metadata":{"aliases":["lncCAMTA1"]}},{"id":"744d40945e4d4ad7a142541f7dcee3d6","type":"GENE","name":"CAMTA1-IT1","canonical_id":"hgnc:HGNC:41446","description":"CAMTA1 intronic transcript 1","metadata":null},{"id":"4a46cfec467d4e86a149c51e2973fc94","type":"GENE","name":"CAMTA2","canonical_id":"hgnc:HGNC:18807","description":"calmodulin binding transcription activator 2","metadata":{"aliases":["KIAA0909"]}},{"id":"4cd68dfd8d014f0a9a08367d3c6f206d","type":"GENE","name":"CAMTA2-AS1","canonical_id":"hgnc:HGNC:55342","description":"CAMTA2 antisense RNA 1","metadata":null},{"id":"81cff3b935ec48859046d694b3c1c224","type":"GENE","name":"CAND1","canonical_id":"hgnc:HGNC:30688","description":"cullin associated and neddylation dissociated 1","metadata":{"aliases":["TIP120A","DKFZp434M1414","KIAA0829","TIP120"]}},{"id":"23398ea3fa374d5fb76635c2f7fb25c6","type":"GENE","name":"CAND2","canonical_id":"hgnc:HGNC:30689","description":"cullin associated and neddylation dissociated 2 (putative)","metadata":{"aliases":["TIP120B","KIAA0667","Tp120b"]}},{"id":"a810d4c23e1d436e9c388bc09c034c5b","type":"GENE","name":"CANT1","canonical_id":"hgnc:HGNC:19721","description":"calcium activated nucleotidase 1","metadata":{"aliases":["SHAPY","SCAN-1"]}},{"id":"f03e5ecf37fd48fbae37be355862c459","type":"GENE","name":"CANT1P1","canonical_id":"hgnc:HGNC:56915","description":"CANT1 pseudogene 1","metadata":null},{"id":"a860b9b318d44e1f9767d0134ff251ad","type":"GENE","name":"CANX","canonical_id":"hgnc:HGNC:1473","description":"calnexin","metadata":{"aliases":["CNX","IP90","P90"]}},{"id":"6a319a7dad604d9388c6ca7d5c4273a9","type":"GO_TERM","name":"CAP-Gly domain binding","canonical_id":"go:GO:0071794","description":"\"Binding to a CAP-Gly domain of a protein. The CAP_Gly domain is a conserved, glycine-rich domain of about 42 residues found in some cytoskeleton-associated proteins, and features a novel protein fold containing three beta-sheets.\" [GOC:mah, InterPro:IPR000938]","metadata":null},{"id":"cbb7da33411b4aa0b86cf9f9cf98a883","type":"GENE","name":"CAP1","canonical_id":"hgnc:HGNC:20040","description":"cyclase associated actin cytoskeleton regulatory protein 1","metadata":{"aliases":["CAP"]}},{"id":"3251884c963b44e7b7e391155a7c1322","type":"GENE","name":"CAP1P1","canonical_id":"hgnc:HGNC:31134","description":"CAP1 pseudogene 1","metadata":null},{"id":"a96d49edb37f47d0b43012372fe18fbf","type":"GENE","name":"CAP1P2","canonical_id":"hgnc:HGNC:31970","description":"CAP1 pseudogene 2","metadata":null},{"id":"ebf1e3c672cf42dfbb8e45d37d74eafc","type":"GENE","name":"CAP2","canonical_id":"hgnc:HGNC:20039","description":"cyclase associated actin cytoskeleton regulatory protein 2","metadata":null},{"id":"65a08ff66ad048afb356e8c8a50c21b6","type":"GENE","name":"CAP2-AS1","canonical_id":"hgnc:HGNC:59363","description":"CAP2 antisense RNA 1","metadata":null},{"id":"ecf3be8e63444542909b509760c4692c","type":"GENE","name":"CAP2P1","canonical_id":"hgnc:HGNC:20142","description":"cyclase associated actin cytoskeleton regulatory protein 2 pseudogene 1","metadata":null},{"id":"3a95dc14d7974c7da0ed3635de384cea","type":"TRIAL","name":"CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders","canonical_id":"clinicaltrials.gov:NCT02500602","description":"Posttraumatic Stress Disorder; Alcohol Use Disorders","metadata":null},{"id":"3cf324218d274396b24104b55d2cc8bb","type":"GENE","name":"CAPG","canonical_id":"hgnc:HGNC:1474","description":"capping actin protein, gelsolin like","metadata":{"aliases":["MCP","AFCP"]}},{"id":"8833eba1dcd049bf8c2d7306884c9e51","type":"TRIAL","name":"CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock","canonical_id":"clinicaltrials.gov:NCT05267886","description":"Shock, Cardiogenic","metadata":null},{"id":"4a7197773e21406e93e78fec6ed3acac","type":"GENE","name":"CAPN1","canonical_id":"hgnc:HGNC:1476","description":"calpain 1","metadata":{"aliases":["muCANP","muCL","CANP","CANPL1"]}},{"id":"b76bebb27db24b1cabcd2f9e5a39efd2","type":"GENE","name":"CAPN1-AS1","canonical_id":"hgnc:HGNC:56068","description":"CAPN1 antisense RNA 1","metadata":null},{"id":"15e8ab2e229247f8ad2312b2d1a70c6c","type":"GENE","name":"CAPN10","canonical_id":"hgnc:HGNC:1477","description":null,"metadata":null},{"id":"e4feb9b69c9742d29a88facf0f2d7c75","type":"GENE","name":"CAPN10-DT","canonical_id":"hgnc:HGNC:48839","description":"CAPN10 divergent transcript","metadata":{"aliases":["locus959","CAPN10-AS1"]}},{"id":"3fa81cb23d024c92b0f325de4b902b22","type":"GENE","name":"CAPN11","canonical_id":"hgnc:HGNC:1478","description":"calpain 11","metadata":null},{"id":"d4a473ce70cf4b5e8f43abeb6efe2f53","type":"GENE","name":"CAPN12","canonical_id":"hgnc:HGNC:13249","description":"calpain 12","metadata":null},{"id":"a570ff6d16e949fca101fa5161327dfc","type":"GENE","name":"CAPN13","canonical_id":"hgnc:HGNC:16663","description":"calpain 13","metadata":{"aliases":["FLJ23523"]}},{"id":"0abc478983a048ebb12a626096f51dd8","type":"GENE","name":"CAPN14","canonical_id":"hgnc:HGNC:16664","description":"calpain 14","metadata":null},{"id":"9ce5988fa7eb4b5b87c4d48142421ca9","type":"GENE","name":"CAPN15","canonical_id":"hgnc:HGNC:11182","description":"calpain 15","metadata":{"aliases":["SOLH"]}},{"id":"769d2d8c42ce4713b00a309beb58b4d7","type":"GENE","name":"CAPN15-AS1","canonical_id":"hgnc:HGNC:58544","description":"CAPN15 antisense RNA 1","metadata":null},{"id":"10b86b53ff7d49deb9228fcc9cf2b069","type":"GENE","name":"CAPN2","canonical_id":"hgnc:HGNC:1479","description":"calpain 2","metadata":{"aliases":["mCANP","CANPml","CANPL2"]}},{"id":"8a59196e04214ddaa8f41a772d439231","type":"GENE","name":"CAPN3","canonical_id":"hgnc:HGNC:1480","description":"calpain 3","metadata":{"aliases":["CANP3","p94","nCL-1","LGMD2","LGMD2A"]}},{"id":"6f3327e7f5874c4c9818bfa10784ec11","type":"GENE","name":"CAPN5","canonical_id":"hgnc:HGNC:1482","description":"calpain 5","metadata":{"aliases":["nCL-3","HTRA3","ADNIV","VRNI"]}},{"id":"3a0a4810f01d44cabb16d255e88d244a","type":"GENE","name":"CAPN6","canonical_id":"hgnc:HGNC:1483","description":null,"metadata":null},{"id":"22cb14dd62c74a17b4fc7fc895f5f5df","type":"GENE","name":"CAPN7","canonical_id":"hgnc:HGNC:1484","description":"calpain 7","metadata":{"aliases":["PalBH"]}},{"id":"24d9c8157d08401da208cb7dbb05edb4","type":"GENE","name":"CAPN8","canonical_id":"hgnc:HGNC:1485","description":"calpain 8","metadata":{"aliases":["nCL-2"]}},{"id":"cb70f7d5d8d744f6879853c1ee548be4","type":"GENE","name":"CAPN9","canonical_id":"hgnc:HGNC:1486","description":"calpain 9","metadata":{"aliases":["nCL-4","GC36"]}},{"id":"a1cfccc2d62244dfb1b2340bf1c22575","type":"GENE","name":"CAPN9-AS1","canonical_id":"hgnc:HGNC:58238","description":"CAPN9 antisense RNA 1","metadata":null},{"id":"d450dcb2c2ca44bfa5b7571efff1c1f6","type":"GENE","name":"CAPNS1","canonical_id":"hgnc:HGNC:1481","description":null,"metadata":null},{"id":"ef2e1b2e310a452cb82f7add625305a8","type":"GENE","name":"CAPNS1P1","canonical_id":"hgnc:HGNC:39562","description":"calpain small subunit 1 pseudogene 1","metadata":null},{"id":"f3b41fb53e574ab89599f39835939090","type":"GENE","name":"CAPNS2","canonical_id":"hgnc:HGNC:16371","description":"calpain small subunit 2","metadata":{"aliases":["MGC12536","MGC14804"]}},{"id":"f2a26d7aeb9a4826ac30f70f125c469d","type":"TRIAL","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07383285","description":"Rectal Neoplasms Malignant","metadata":null},{"id":"391da1b1f6604b2f87e5723a33141377","type":"TRIAL","name":"CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT06281405","description":"Locally Advanced Rectal Cancer; Neoadjuvant Therapy","metadata":null},{"id":"5c1c7b1d85644334b6ceb2172d6e0b78","type":"TRIAL","name":"CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater","canonical_id":"clinicaltrials.gov:NCT01202409","description":"Gastrointestinal Cancer","metadata":null},{"id":"2bcb09c18ff04e2f8ed558f520202af7","type":"TRIAL","name":"CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS","canonical_id":"clinicaltrials.gov:NCT07612774","description":"Coronary; Coronary Artery Disease","metadata":null},{"id":"065446b4bd5146a99614bcf4649e4b43","type":"GENE","name":"CAPRIN1","canonical_id":"hgnc:HGNC:6743","description":"cell cycle associated protein 1","metadata":{"aliases":["caprin-1","RNG105","M11S1","GPIAP1"]}},{"id":"ddb572b4e925415f8485583d2a921275","type":"GENE","name":"CAPRIN2","canonical_id":"hgnc:HGNC:21259","description":"caprin family member 2","metadata":{"aliases":["EEG1","FLJ22569","FLJ11391","caprin-2","RNG140","C1QDC1"]}},{"id":"9d8c678e7f574e8499b4b393d7ca2738","type":"GENE","name":"CAPS","canonical_id":"hgnc:HGNC:1487","description":"calcyphosine","metadata":{"aliases":["CAPS1","MGC126562"]}},{"id":"b15001cba8d24e8aafca0c810a622cc2","type":"GENE","name":"CAPS2","canonical_id":"hgnc:HGNC:16471","description":"calcyphosine 2","metadata":null},{"id":"6cb054467f104dc7953748f710f261dc","type":"GENE","name":"CAPS2-AS1","canonical_id":"hgnc:HGNC:40769","description":"CAPS2 antisense RNA 1","metadata":null},{"id":"bd3c158e1f484b23bca7692864ee7f99","type":"TRIAL","name":"CAPSAICIN Trial: Assessing Capsaicin as a Chemopreventive Agent for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02037464","description":"Prostate Cancer","metadata":null},{"id":"2b1801caaec14d6a91471b386cd7833b","type":"GENE","name":"CAPSL","canonical_id":"hgnc:HGNC:28375","description":"calcyphosine like","metadata":{"aliases":["MGC26610"]}},{"id":"12a6f32f60ac4cd5b3d069130d011fd0","type":"GENE","name":"CAPSL-DT","canonical_id":"hgnc:HGNC:56266","description":"CAPSL divergent transcript","metadata":{"aliases":["lnc-IL7R-1"]}},{"id":"4013b184cb3146919bc0f33b7ec4a9b6","type":"GENE","name":"CAPZA1","canonical_id":"hgnc:HGNC:1488","description":"capping actin protein of muscle Z-line subunit alpha 1","metadata":{"aliases":["CAPPA1"]}},{"id":"d6f8e3f29a38411db2256e17d52bb020","type":"GENE","name":"CAPZA1P1","canonical_id":"hgnc:HGNC:1489","description":"CAPZA1 pseudogene 1","metadata":{"aliases":["CAPZA1P"]}},{"id":"f0fe5dbecc3747679009c439ad9cde8c","type":"GENE","name":"CAPZA1P2","canonical_id":"hgnc:HGNC:54563","description":"CAPZA1 pseudogene 2","metadata":null},{"id":"cf5470b46696417da018b437367c5b8a","type":"GENE","name":"CAPZA1P3","canonical_id":"hgnc:HGNC:54564","description":"CAPZA1 pseudogene 3","metadata":null},{"id":"ada92784a82848f5b0986246445cccc4","type":"GENE","name":"CAPZA1P4","canonical_id":"hgnc:HGNC:54565","description":"CAPZA1 pseudogene 4","metadata":null},{"id":"8fc2237387fe4c638f72b43d7464e484","type":"GENE","name":"CAPZA1P5","canonical_id":"hgnc:HGNC:54566","description":"CAPZA1 pseudogene 5","metadata":null},{"id":"975f2cf38b8b410f9f5a234fb6a6a450","type":"GENE","name":"CAPZA2","canonical_id":"hgnc:HGNC:1490","description":"capping actin protein of muscle Z-line subunit alpha 2","metadata":{"aliases":["CAPZ","CAPPA2"]}},{"id":"59611d2746f9439fa0ba409739d551f8","type":"GENE","name":"CAPZA3","canonical_id":"hgnc:HGNC:24205","description":"capping actin protein of muscle Z-line subunit alpha 3","metadata":{"aliases":["Gsg3","CAPPA3"]}},{"id":"a6a365909fb549f48092426b94a9e828","type":"GENE","name":"CAPZB","canonical_id":"hgnc:HGNC:1491","description":"capping actin protein of muscle Z-line subunit beta","metadata":null},{"id":"75f9a22e027e4ef1b03187e6fa875cd5","type":"GENE","name":"CAPZBP1","canonical_id":"hgnc:HGNC:54734","description":"CAPZB pseudogene 1","metadata":null},{"id":"e17ead3ab049411bbf27634efd431aac","type":"TRIAL","name":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","canonical_id":"clinicaltrials.gov:NCT04603872","description":"Multiple Myeloma in Relapse; Multiple Myeloma, Refractory; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphocytic Leukaemia Refractory; Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory","metadata":null},{"id":"14cf4a1c69904958b4e4b256b08420db","type":"TRIAL","name":"CAR-T Cells in Treating Patients With Relapsed or Refractory NHL","canonical_id":"clinicaltrials.gov:NCT04626739","description":"Refractory Indolent Adult Non-Hodgkin Lymphoma","metadata":null},{"id":"c82d8fa4614149cc962bd60a3a664694","type":"TRIAL","name":"CAR-T Followed by Bispecific Antibodies","canonical_id":"clinicaltrials.gov:NCT04889716","description":"Large B-cell Lymphoma; DLBCL - Diffuse Large B Cell Lymphoma","metadata":null},{"id":"a61e8a6bc1aa4ec681af6997ff00c444","type":"GO_TERM","name":"CARD domain binding","canonical_id":"go:GO:0050700","description":"\"Binding to a CARD (N-terminal caspase recruitment) domain, a protein-protein interaction domain that belongs to the death domain-fold superfamily. These protein molecule families are similar in structure with each consisting of six or seven anti-parallel alpha-helices that form highly specific homophilic interactions between signaling partners. CARD exists in the N-terminal prodomains of several caspases and in apoptosis-regulatory proteins and mediates the assembly of CARD-containing proteins that participate in activation or suppression of CARD carrying members of the caspase family.\" [PMID:12054670]","metadata":null},{"id":"fe3edecca7034c02a8c8ca9ccc725026","type":"GENE","name":"CARD10","canonical_id":"hgnc:HGNC:16422","description":"caspase recruitment domain family member 10","metadata":{"aliases":["CARMA3","BIMP1"]}},{"id":"1565edb7b1b8405997e6df2bcb9489c1","type":"GENE","name":"CARD11","canonical_id":"hgnc:HGNC:16393","description":"caspase recruitment domain family member 11","metadata":{"aliases":["CARMA1","BIMP3"]}},{"id":"85159738da0f4c39b6b549d1e52e9b1d","type":"GENE","name":"CARD11-AS1","canonical_id":"hgnc:HGNC:40766","description":"CARD11 antisense RNA 1","metadata":null},{"id":"48b6c851c8bd4a0dbca5d01aa22eaea1","type":"GENE","name":"CARD14","canonical_id":"hgnc:HGNC:16446","description":"caspase recruitment domain family member 14","metadata":{"aliases":["CARMA2","BIMP2","PSORS2"]}},{"id":"bda4e271da8c4ababdea816a13168d96","type":"GENE","name":"CARD16","canonical_id":"hgnc:HGNC:33701","description":"caspase recruitment domain family member 16","metadata":{"aliases":["COP1","COP","PSEUDO-ICE","LLID-114769"]}},{"id":"ab608268b4074035833bb221f2452f46","type":"GENE","name":"CARD17P","canonical_id":"hgnc:HGNC:33827","description":"caspase recruitment domain family member 17, pseudogene","metadata":{"aliases":["INCA","CARD17"]}},{"id":"a11a69cf82c54de481a483da3c7df52f","type":"GENE","name":"CARD18","canonical_id":"hgnc:HGNC:28861","description":"caspase recruitment domain family member 18","metadata":{"aliases":["UNQ5804","ICEBERG","pseudo-ICE"]}},{"id":"d4aaaffd388c45a08891d8fd75367bf9","type":"GENE","name":"CARD19","canonical_id":"hgnc:HGNC:28148","description":"caspase recruitment domain family member 19","metadata":{"aliases":["MGC11115","bA370F5.1","BinCARD","C9orf89"]}},{"id":"23424b2122364435aba39cf920f22cdc","type":"GENE","name":"CARD6","canonical_id":"hgnc:HGNC:16394","description":"caspase recruitment domain family member 6","metadata":{"aliases":["CINCIN1"]}},{"id":"d2554a1d4a844dcda6977bf57d28ab0c","type":"GENE","name":"CARD8","canonical_id":"hgnc:HGNC:17057","description":null,"metadata":null},{"id":"b55319b47d3c4092bb6acfea0d61e613","type":"GO_TERM","name":"CARD8 inflammasome complex","canonical_id":"go:GO:0140634","description":"\"An inflammasome complex that consists of CARD8 and CASP1.\" [PMID:33420028, PMID:33420033, PMID:33542150]","metadata":null},{"id":"a2691c79a1894763aaaf1aa9481ae3a4","type":"GO_TERM","name":"CARD8 inflammasome complex assembly","canonical_id":"go:GO:0140633","description":"\"The aggregation, arrangement and bonding together of a set of components to form a CARD8 inflammasome complex.\" [PMID:33420028, PMID:33420033, PMID:33542150]","metadata":null},{"id":"8aaaf85d43e341949c793b4e5f854b52","type":"GENE","name":"CARD8-AS1","canonical_id":"hgnc:HGNC:51408","description":"CARD8 antisense RNA 1","metadata":{"aliases":["LOC100505812","AC008392.1"]}},{"id":"5b19d0f0e43343e98452729bb32b04de","type":"GENE","name":"CARD9","canonical_id":"hgnc:HGNC:16391","description":"caspase recruitment domain family member 9","metadata":null},{"id":"f604a030aa544e4a814453dadaf46aff","type":"GENE","name":"CARF","canonical_id":"hgnc:HGNC:14435","description":"calcium responsive transcription factor","metadata":{"aliases":["FLJ21579","NYD-SP24","ALS2CR8"]}},{"id":"5c5d8ce4add64c369e7391ea5fdfac9e","type":"GENE","name":"CARHSP1","canonical_id":"hgnc:HGNC:17150","description":"calcium regulated heat stable protein 1","metadata":{"aliases":["CRHSP-24","CSDC1"]}},{"id":"ee6f3d3aac2243fba6b016c4202b5716","type":"GENE","name":"CARHSP1-DT","canonical_id":"hgnc:HGNC:55361","description":"CARHSP1 divergent transcript","metadata":null},{"id":"24dbb1eac2f4485aa8454d6706f97ac2","type":"GENE","name":"CARINH","canonical_id":"hgnc:HGNC:33838","description":"colitis associated IRF1 antisense regulator of intestinal homeostasis","metadata":{"aliases":["C5orf56","IRF1-AS1"]}},{"id":"d5e2c1a999ac43c4bea130bda673734a","type":"GENE","name":"CARM1","canonical_id":"hgnc:HGNC:23393","description":null,"metadata":null},{"id":"986f47f286e2469bb7a1e14a3b10fd04","type":"GENE","name":"CARM1LP","canonical_id":"hgnc:HGNC:23392","description":"coactivator associated arginine methyltransferase 1 like, pseudogene","metadata":{"aliases":["CARM1L","CARM1P1"]}},{"id":"f8b8dd5da64e46f0a743f49979fd59d3","type":"GENE","name":"CARMAL","canonical_id":"hgnc:HGNC:55102","description":"coronary artery disease region linked MFGE8 regulatory lncRNA","metadata":{"aliases":["RP11-326A19.4"]}},{"id":"a29604010fc3486d8ce2340ef2057d8f","type":"GENE","name":"CARMIL1","canonical_id":"hgnc:HGNC:21581","description":"capping protein regulator and myosin 1 linker 1","metadata":{"aliases":["dJ501N12.1","FLJ20048","CARMIL","LRRC16","LRRC16A"]}},{"id":"691455181fc34ae5a015659686067f14","type":"GENE","name":"CARMIL1-AS1","canonical_id":"hgnc:HGNC:59375","description":"CARMIL1 antisense RNA 1","metadata":null},{"id":"9ad0f61206544854a56617c4a3b231b1","type":"GENE","name":"CARMIL2","canonical_id":"hgnc:HGNC:27089","description":"capping protein regulator and myosin 1 linker 2","metadata":{"aliases":["LRRC16C","RLTPR"]}},{"id":"f427e5947f4748bb9b704112e12a42da","type":"GENE","name":"CARMIL2P1","canonical_id":"hgnc:HGNC:56522","description":"CARMIL2 pseudogene 1","metadata":null},{"id":"a1a9ef8433624b82810a49858566b6ba","type":"GENE","name":"CARMIL3","canonical_id":"hgnc:HGNC:20272","description":"capping protein regulator and myosin 1 linker 3","metadata":{"aliases":["BC008134","crml-1","C14orf121","LRRC16B"]}},{"id":"a1cbd3c6b4d34890ba5b42ab91aeaa89","type":"GENE","name":"CARMN","canonical_id":"hgnc:HGNC:42872","description":"cardiac mesoderm enhancer-associated non-coding RNA","metadata":{"aliases":["CARMEN","MIR143HG"]}},{"id":"a2aaeaddbcbe48dca384f8f107aee456","type":"GENE","name":"CARNMT1","canonical_id":"hgnc:HGNC:23435","description":"carnosine N-methyltransferase 1","metadata":{"aliases":["FLJ25795","C9orf41"]}},{"id":"4bfc25d79ecd455388c5d96b3ed045f1","type":"GENE","name":"CARNMT1-AS1","canonical_id":"hgnc:HGNC:51188","description":"CARNMT1 antisense RNA 1","metadata":{"aliases":["C9orf41-AS1"]}},{"id":"911aa823773d4a40b3b6bfb778834690","type":"GENE","name":"CARNS1","canonical_id":"hgnc:HGNC:29268","description":"carnosine synthase 1","metadata":{"aliases":["KIAA1394","ATPGD1"]}},{"id":"205a9ab7d3bf4c57ab99bf4fbd3d025e","type":"TRIAL","name":"CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound","canonical_id":"clinicaltrials.gov:NCT06861075","description":"Cirrhosis; Portal Hypertension Related to Cirrhosis","metadata":null},{"id":"d221c666bf994f148758078a6bf40762","type":"GENE","name":"CARS1","canonical_id":"hgnc:HGNC:1493","description":"cysteinyl-tRNA synthetase 1","metadata":{"aliases":["CARS"]}},{"id":"3dd32fcbf05941b5b825c159a973337a","type":"GENE","name":"CARS1-AS1","canonical_id":"hgnc:HGNC:40125","description":"CARS1 antisense RNA 1","metadata":{"aliases":["CARS-AS1"]}},{"id":"991f38b6867c498caa7749ac9dbfd204","type":"GENE","name":"CARS1P1","canonical_id":"hgnc:HGNC:50477","description":"cysteinyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["CARSP1"]}},{"id":"d52fe3fd4dd24130a91ca0409ac619db","type":"GENE","name":"CARS1P2","canonical_id":"hgnc:HGNC:50478","description":"cysteinyl-tRNA synthetase 1 pseudogene 2","metadata":{"aliases":["CARSP2"]}},{"id":"7f55f3d2be724211ac5e3effbda21424","type":"GENE","name":"CARS2","canonical_id":"hgnc:HGNC:25695","description":"cysteinyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["FLJ12118"]}},{"id":"64832418f5594b06919e0e1d9fc4462a","type":"GENE","name":"CARTPT","canonical_id":"hgnc:HGNC:24323","description":null,"metadata":null},{"id":"1baa477243d64af1894fe19862fe1637","type":"GENE","name":"CASC11","canonical_id":"hgnc:HGNC:48939","description":"cancer susceptibility 11","metadata":{"aliases":["TCONS_00014535","LINC00990","CARLo-7","ENST00000518376","MYMLR"]}},{"id":"f0fd78b7977d43f79c8af308c165c863","type":"GENE","name":"CASC15","canonical_id":"hgnc:HGNC:28245","description":"cancer susceptibility 15","metadata":{"aliases":["lnc-SOX4-1","LINC00340"]}},{"id":"4d02716ae54f49feb8c388bebf5755d1","type":"GENE","name":"CASC16","canonical_id":"hgnc:HGNC:48608","description":"cancer susceptibility 16","metadata":{"aliases":["LOC643714","LINC00918"]}},{"id":"a4b412818131447ba44868c64033bf64","type":"GENE","name":"CASC17","canonical_id":"hgnc:HGNC:43911","description":"cancer susceptibility 17","metadata":{"aliases":["LINC00600"]}},{"id":"80256f4a17994a3cb5da696bce90c824","type":"GENE","name":"CASC18","canonical_id":"hgnc:HGNC:49463","description":"cancer susceptibility 18","metadata":{"aliases":["LOC101929110"]}},{"id":"6e6df89666c44f0b9e037785b604ff34","type":"GENE","name":"CASC19","canonical_id":"hgnc:HGNC:49476","description":"cancer susceptibility 19","metadata":{"aliases":["CARLo-6","LINC01245"]}},{"id":"61357091e02b41bb8547c5f1914f4bf7","type":"GENE","name":"CASC2","canonical_id":"hgnc:HGNC:22933","description":"cancer susceptibility 2","metadata":{"aliases":["C10orf5"]}},{"id":"c7a819e032974fc7a71d6275cd42e6ec","type":"GENE","name":"CASC20","canonical_id":"hgnc:HGNC:49477","description":"cancer susceptibility 20","metadata":null},{"id":"b350b9d34bed40e7a7e074213b11aeb7","type":"GENE","name":"CASC21","canonical_id":"hgnc:HGNC:49836","description":"cancer susceptibility 21","metadata":{"aliases":["CARLo-2","LINC01244"]}},{"id":"9bce31cc01644d5a8e7e88fb573b49e0","type":"GENE","name":"CASC22","canonical_id":"hgnc:HGNC:50627","description":"cancer susceptibility 22","metadata":{"aliases":["TCONS_00024290","LincRNA-ENST00000515084","LINC01373"]}},{"id":"f7a1cb839dae40caa4c30842cba80778","type":"GENE","name":"CASC23","canonical_id":"hgnc:HGNC:50865","description":"cancer susceptibility 23","metadata":{"aliases":["LINC01464"]}},{"id":"a51c30d710e3422580158872009652ab","type":"GENE","name":"CASC3","canonical_id":"hgnc:HGNC:17040","description":"CASC3 exon junction complex subunit","metadata":{"aliases":["MLN51","BTZ"]}},{"id":"baa3965e135a44aebc75b7fee7895376","type":"GENE","name":"CASC6","canonical_id":"hgnc:HGNC:49076","description":"cancer susceptibility 6","metadata":null},{"id":"e93880cf46e34ac88d6149b21c01d45f","type":"GENE","name":"CASC8","canonical_id":"hgnc:HGNC:45129","description":"cancer susceptibility 8","metadata":{"aliases":["LINC00860","CARLo-1"]}},{"id":"3e355e64ec954f87b9ebbc1c27bb094e","type":"GENE","name":"CASC9","canonical_id":"hgnc:HGNC:48906","description":"cancer susceptibility 9","metadata":{"aliases":["LINC00981","ESCCAL-1","linc-JPH1"]}},{"id":"749ca685b9614e7e96380be817cd8cbe","type":"GENE","name":"CASD1","canonical_id":"hgnc:HGNC:16014","description":"CAS1 domain sialic acid O acetyltransferase 1","metadata":{"aliases":["FLJ21213","FLJ21879","C7orf12","Cas1"]}},{"id":"69a51f0b274043f28e096d1a317b9a72","type":"TRIAL","name":"CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers","canonical_id":"clinicaltrials.gov:NCT00822809","description":"Cancer; Neoplasms; Carcinoma; Malignant Ascites","metadata":null},{"id":"176092e6241744c0a11ef39d2f6f0c59","type":"GENE","name":"CASK","canonical_id":"hgnc:HGNC:1497","description":"calcium/calmodulin dependent serine protein kinase","metadata":{"aliases":["LIN2","CAGH39","FGS4","TNRC8"]}},{"id":"8837ac2229a44819a98ba83242928ed3","type":"GENE","name":"CASK-AS1","canonical_id":"hgnc:HGNC:40126","description":"CASK antisense RNA 1","metadata":null},{"id":"7b42faac8ba54a6ebab0dfde18e400f3","type":"GENE","name":"CASKIN1","canonical_id":"hgnc:HGNC:20879","description":"CASK interacting protein 1","metadata":{"aliases":["KIAA1306","ANKS5A"]}},{"id":"b373529022b447909d7deaf2c30d2062","type":"GENE","name":"CASKIN2","canonical_id":"hgnc:HGNC:18200","description":"CASK interacting protein 2","metadata":{"aliases":["KIAA1139","FLJ21609","ANKS5B"]}},{"id":"5e845f25e01a423fa9a1e68b40f81265","type":"GENE","name":"CASKP1","canonical_id":"hgnc:HGNC:1498","description":"calcium/calmodulin dependent serine protein kinase pseudogene 1","metadata":{"aliases":["CASKP"]}},{"id":"2791ad67881c41429f22dcb3a7d2269d","type":"GENE","name":"CASP1","canonical_id":"hgnc:HGNC:1499","description":null,"metadata":null},{"id":"0c1105da7526412eb464a3ff0e5edc38","type":"GENE","name":"CASP10","canonical_id":"hgnc:HGNC:1500","description":"caspase 10","metadata":{"aliases":["MCH4","FLICE-2"]}},{"id":"55dae07dda0e4cb29e91ffef72148d08","type":"GENE","name":"CASP12","canonical_id":"hgnc:HGNC:19004","description":"caspase 12 (gene/pseudogene)","metadata":{"aliases":["CASP12P1"]}},{"id":"ac74aabb0a3e4d1fbcf58119262f5543","type":"GENE","name":"CASP14","canonical_id":"hgnc:HGNC:1502","description":"caspase 14","metadata":{"aliases":["MICE","MGC119078","MGC119079","caspase-14"]}},{"id":"23cd0ee77a3044cbbecb8ac5c90a2dc6","type":"GENE","name":"CASP16P","canonical_id":"hgnc:HGNC:27290","description":"caspase 16, pseudogene","metadata":{"aliases":["CASP16"]}},{"id":"77c44c72404f43bfbf952aa2b5622013","type":"GENE","name":"CASP1P1","canonical_id":"hgnc:HGNC:43775","description":"caspase 1 pseudogene 1","metadata":null},{"id":"d0c4d6ad10db4fbea07a4d754071c70b","type":"GENE","name":"CASP1P2","canonical_id":"hgnc:HGNC:43776","description":"caspase 1 pseudogene 2","metadata":null},{"id":"0f16721d005c454aa832ab6058b7a994","type":"GENE","name":"CASP1P3","canonical_id":"hgnc:HGNC:43777","description":"caspase 1 pseudogene 3","metadata":null},{"id":"ad21a8f11bfa4d6391357013136e22b8","type":"GENE","name":"CASP2","canonical_id":"hgnc:HGNC:1503","description":null,"metadata":null},{"id":"35cd339c811f4d1486cecaa37ff1160f","type":"GENE","name":"CASP3","canonical_id":"hgnc:HGNC:1504","description":null,"metadata":null},{"id":"94a7bfde45814b068fa80d3566fd0056","type":"GENE","name":"CASP3P1","canonical_id":"hgnc:HGNC:43596","description":"caspase 3 pseudogene 1","metadata":null},{"id":"4b79c0e729034bc8a43ce20d3134974f","type":"GENE","name":"CASP4","canonical_id":"hgnc:HGNC:1505","description":"caspase 4","metadata":{"aliases":["ICE(rel)II","ICH-2","TX"]}},{"id":"d7997cfd3df5444688756c1d59b4afb3","type":"GENE","name":"CASP4LP","canonical_id":"hgnc:HGNC:53657","description":"caspase 4 like, pseudogene","metadata":{"aliases":["CASP17P"]}},{"id":"967f428689c44c7d89dd3528baac5c97","type":"GENE","name":"CASP5","canonical_id":"hgnc:HGNC:1506","description":"caspase 5","metadata":{"aliases":["ICE(rel)III"]}},{"id":"76bcf04b8eb9412c853c1552474fb785","type":"GENE","name":"CASP6","canonical_id":"hgnc:HGNC:1507","description":"caspase 6","metadata":{"aliases":["MCH2","caspase-6","CSP-6"]}},{"id":"95a97ba932824601a16da9489f1bb038","type":"GENE","name":"CASP7","canonical_id":"hgnc:HGNC:1508","description":null,"metadata":null},{"id":"dca6ca82aea64f258f6a4eeb55047965","type":"GENE","name":"CASP8","canonical_id":"hgnc:HGNC:1509","description":null,"metadata":null},{"id":"16b244f3666646e582b9e4fdea768bb2","type":"GENE","name":"CASP8AP2","canonical_id":"hgnc:HGNC:1510","description":"caspase 8 associated protein 2","metadata":{"aliases":["FLASH","CED-4","RIP25","FLJ11208","KIAA1315"]}},{"id":"5b383aab1fda46c98f0a71b95bf4d09b","type":"GENE","name":"CASP9","canonical_id":"hgnc:HGNC:1511","description":null,"metadata":null},{"id":"7a939ac590c947ac8837a9501bfe8efd","type":"GENE","name":"CASQ1","canonical_id":"hgnc:HGNC:1512","description":"calsequestrin 1","metadata":{"aliases":["PDIB1","CSQ1","CASQ"]}},{"id":"38e14251fee2432ead5cb28fce4c26a2","type":"GENE","name":"CASQ2","canonical_id":"hgnc:HGNC:1513","description":"calsequestrin 2","metadata":{"aliases":["PDIB2"]}},{"id":"7f7fa226b27f4804a3bd2ba9cf10f67f","type":"GENE","name":"CASR","canonical_id":"hgnc:HGNC:1514","description":null,"metadata":null},{"id":"613069786ca44fa782f11f5a859876d8","type":"PROTEIN","name":"CASR","canonical_id":"uniprot:P41180","description":null,"metadata":null},{"id":"eece316d3dcb45068242988272922546","type":"GENE","name":"CASS4","canonical_id":"hgnc:HGNC:15878","description":"Cas scaffold protein family member 4","metadata":{"aliases":["HEFL","HEPL","C20orf32"]}},{"id":"0d1f903712e24414ae679036e4a65016","type":"GENE","name":"CAST","canonical_id":"hgnc:HGNC:1515","description":"calpastatin","metadata":{"aliases":["MIR583HG"]}},{"id":"e436ff28a82245ddb126ba926036647e","type":"GENE","name":"CASTOR1","canonical_id":"hgnc:HGNC:34423","description":"cytosolic arginine sensor for mTORC1 subunit 1","metadata":{"aliases":["GATSL3"]}},{"id":"5f4bd025a7c44cf7854fcbe0a8bc955c","type":"GENE","name":"CASTOR2","canonical_id":"hgnc:HGNC:37073","description":"cytosolic arginine sensor for mTORC1 subunit 2","metadata":{"aliases":["GATSL1","GATSL2"]}},{"id":"886a5de11a2e412ebea79f3a96edd775","type":"GENE","name":"CASTOR3P","canonical_id":"hgnc:HGNC:29954","description":"CASTOR family member 3, pseudogene","metadata":{"aliases":["DKFZp686B07267","STAG3OS","GATS","CASTOR3"]}},{"id":"ce1e79b476644118ac7c8065ab670990","type":"GENE","name":"CASZ1","canonical_id":"hgnc:HGNC:26002","description":"castor zinc finger 1","metadata":{"aliases":["FLJ20321","ZNF693","castor","cst","SRG"]}},{"id":"6a55715018ca438f8062fa229e6c1d1d","type":"GENE","name":"CASZ1-AS1","canonical_id":"hgnc:HGNC:58339","description":"CASZ1 antisense RNA 1","metadata":null},{"id":"e64b3134e81e480a92658210ad27a975","type":"GENE","name":"CAT","canonical_id":"hgnc:HGNC:1516","description":null,"metadata":null},{"id":"45c57894b6894db98af06e7c56ca294f","type":"GO_TERM","name":"CAT tailing","canonical_id":"go:GO:0140708","description":"\"The C-terminal elongation of 60S-anchored stalled nascent polypeptide chains with untemplated alanine and threonine tails (CAT tails). CAT tails participate in the recognition of stalled nascent chains by the ribosome quality control system.\" [PMID:25554787, PMID:32934225]","metadata":null},{"id":"389a2f17554a42ceb76a747fccae5ff0","type":"TRIAL","name":"CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00659425","description":"Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma","metadata":null},{"id":"40664781dfb94fd4875afcf815194115","type":"TRIAL","name":"CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib","canonical_id":"clinicaltrials.gov:NCT04676334","description":"Metastatic Castration-Resistant Prostate Cancer; Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Other Solid Tumor","metadata":null},{"id":"1d5b9ea7891e4c41a8f57e0596243555","type":"GENE","name":"CATED","canonical_id":"hgnc:HGNC:58685","description":"CATED platinum resistance associated lncRNA regulator of DHX36","metadata":null},{"id":"1c35fdd4abba4171abd99aecd3afff69","type":"TRIAL","name":"CATIE- Schizophrenia Trial","canonical_id":"clinicaltrials.gov:NCT00014001","description":"Schizophrenia","metadata":null},{"id":"5471ad56fa8448ec80223c4d97fd5c59","type":"GENE","name":"CATIP","canonical_id":"hgnc:HGNC:25062","description":"ciliogenesis associated TTC17 interacting protein","metadata":{"aliases":["MGC50811","C2orf62"]}},{"id":"6235cb42f5934558b58892d1408957a6","type":"GENE","name":"CATIP-AS1","canonical_id":"hgnc:HGNC:41080","description":"CATIP antisense RNA 1","metadata":null},{"id":"8e8806959632467986aef856cbe21d30","type":"GENE","name":"CATIP-AS2","canonical_id":"hgnc:HGNC:41079","description":"CATIP antisense RNA 2","metadata":null},{"id":"c68da079f6a643229389588ba7bf8807","type":"GENE","name":"CATR1","canonical_id":"hgnc:HGNC:1525","description":"CATR tumorigenicity conversion 1","metadata":null},{"id":"543c9cabc34e4ae38759c13a75d93249","type":"GENE","name":"CATSPER1","canonical_id":"hgnc:HGNC:17116","description":"cation channel sperm associated 1","metadata":{"aliases":["CATSPER"]}},{"id":"71c93331dee64b90ae235856b13317ed","type":"GENE","name":"CATSPER2","canonical_id":"hgnc:HGNC:18810","description":"cation channel sperm associated 2","metadata":null},{"id":"0ae727518eb946269de2301a4df4637d","type":"GENE","name":"CATSPER2P1","canonical_id":"hgnc:HGNC:31054","description":"CATSPER2 pseudogene 1","metadata":{"aliases":["CATSPER2B"]}},{"id":"6697938831d9444f9112a4b8b28ead4e","type":"GENE","name":"CATSPER2P2","canonical_id":"hgnc:HGNC:56816","description":"CATSPER2 pseudogene 2","metadata":null},{"id":"7c4ffb3f3f884f10a4ff25621b6c018c","type":"GENE","name":"CATSPER3","canonical_id":"hgnc:HGNC:20819","description":"cation channel sperm associated 3","metadata":{"aliases":["CACRC"]}},{"id":"1f23c213b9034ec28bab53ba6081dca9","type":"GENE","name":"CATSPER4","canonical_id":"hgnc:HGNC:23220","description":"cation channel sperm associated 4","metadata":null},{"id":"dda9b2f37d834b458538a5483585f3bf","type":"GENE","name":"CATSPERB","canonical_id":"hgnc:HGNC:20500","description":"catsper channel auxiliary subunit beta","metadata":{"aliases":["FLJ14298","C14orf161"]}},{"id":"c5ebdb8a21f24c8299cc40f7a7ef5eff","type":"GENE","name":"CATSPERD","canonical_id":"hgnc:HGNC:28598","description":"catsper channel auxiliary subunit delta","metadata":{"aliases":["MGC39581","TMEM146"]}},{"id":"b4a0ea6850fa4fb68be916e3f08bdfa3","type":"GENE","name":"CATSPERE","canonical_id":"hgnc:HGNC:28491","description":"catsper channel auxiliary subunit epsilon","metadata":{"aliases":["MGC33370","C1orf101"]}},{"id":"aa7bbc5c77eb48c18df3ec84236e31bc","type":"GENE","name":"CATSPERG","canonical_id":"hgnc:HGNC:25243","description":"catsper channel auxiliary subunit gamma","metadata":{"aliases":["DKFZp434A1022","FLJ46353","C19orf15"]}},{"id":"d2dedafc646f44d2b777b2925e96c898","type":"GENE","name":"CATSPERH","canonical_id":"hgnc:HGNC:49389","description":"catsper channel auxiliary subunit eta","metadata":{"aliases":["TMEM262"]}},{"id":"85a7555284834aa7859386a3d516e585","type":"GENE","name":"CATSPERQ","canonical_id":"hgnc:HGNC:44155","description":"catsper channel auxiliary subunit theta","metadata":{"aliases":["C8orfK29","TMEM249"]}},{"id":"a5876313e9224299bf35e6cf4acc6f2f","type":"GENE","name":"CATSPERT","canonical_id":"hgnc:HGNC:14438","description":"catsper channel auxiliary subunit tau","metadata":{"aliases":["FLJ25351","ALS2CR11","C2CD6"]}},{"id":"bf237c943a25453794cb30917d35eb62","type":"GENE","name":"CATSPERZ","canonical_id":"hgnc:HGNC:19231","description":"catsper channel auxiliary subunit zeta","metadata":{"aliases":["DKFZP566E164","C11orf20","TEX40"]}},{"id":"6b43aee19caa4f09a863717d704ce374","type":"GO_TERM","name":"CAU codon-amino acid adaptor activity","canonical_id":"go:GO:0033425","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CAU codon.\" [GOC:mah]","metadata":null},{"id":"cc35c500df464b20a7b01a211746fa1e","type":"GENE","name":"CAV1","canonical_id":"hgnc:HGNC:1527","description":null,"metadata":null},{"id":"def2c876d2fb4e7bb85c9a1533adba22","type":"GENE","name":"CAV2","canonical_id":"hgnc:HGNC:1528","description":"caveolin 2","metadata":{"aliases":["CAV"]}},{"id":"5c0bfc4603454b138198074c5573c316","type":"GENE","name":"CAV2-DT","canonical_id":"hgnc:HGNC:40129","description":"CAV2 divergent transcript","metadata":{"aliases":["AC002066.1"]}},{"id":"b5e0616011474b628915713f22d6b507","type":"GENE","name":"CAV3","canonical_id":"hgnc:HGNC:1529","description":"caveolin 3","metadata":{"aliases":["VIP-21","LGMD1C","VIP21","LQT9"]}},{"id":"ce4668a87d6e418e8cf9d2bf933f53e6","type":"GENE","name":"CAVIN1","canonical_id":"hgnc:HGNC:9688","description":"caveolae associated protein 1","metadata":{"aliases":["cavin-1","CGL4","PTRF"]}},{"id":"122766f6ee794f3cb521752e37d24900","type":"GENE","name":"CAVIN2","canonical_id":"hgnc:HGNC:10690","description":"caveolae associated protein 2","metadata":{"aliases":["SDR","PS-p68","cavin-2","SDPR"]}},{"id":"e2bbb3bc070d432f94a2a8fcbd3f5609","type":"GENE","name":"CAVIN2-AS1","canonical_id":"hgnc:HGNC:40517","description":"CAVIN2 and TMEFF2 antisense RNA 1","metadata":{"aliases":["LOC105373813"]}},{"id":"94b653c0c1bf41208fb3ba50b871a688","type":"GENE","name":"CAVIN3","canonical_id":"hgnc:HGNC:9400","description":"caveolae associated protein 3","metadata":{"aliases":["SRBC","HSRBC","MGC20400","cavin-3","PRKCDBP"]}},{"id":"dadb3087cf044320bddbf25b26e56442","type":"GENE","name":"CAVIN4","canonical_id":"hgnc:HGNC:33742","description":"caveolae associated protein 4","metadata":{"aliases":["cavin-4","MURC"]}},{"id":"b586057db21f49e7b949e7b5a7151cdf","type":"TRIAL","name":"CAndesartan vs LIsinopril Effects on the BRain","canonical_id":"clinicaltrials.gov:NCT01984164","description":"Hypertension; Mild Cognitive Impairment","metadata":null},{"id":"d1b2197dd67c4d6b9fe6a3679fcd2c64","type":"TRIAL","name":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","canonical_id":"clinicaltrials.gov:NCT07294677","description":"Leukemia; Lymphoma","metadata":null},{"id":"7dca9fc0bba6497a99d35becf5aa1d93","type":"GENE","name":"CBARP","canonical_id":"hgnc:HGNC:28617","description":"CACN subunit beta associated regulatory protein","metadata":{"aliases":["MGC40084","DOS","BARP","C19orf26"]}},{"id":"f4508e0a30394e9c8624a224e66d0ce4","type":"GENE","name":"CBARP-DT","canonical_id":"hgnc:HGNC:55285","description":"CBARP divergent transcript","metadata":null},{"id":"2fdf0d01d6894cf18922ff485c0b9797","type":"GO_TERM","name":"CBF3 complex","canonical_id":"go:GO:0031518","description":"\"A multisubunit protein complex that binds to centromeric DNA and initiates kinetochore assembly. In yeast, this complex consists of four subunits, namely Ctf13p, Skp1p, Cep3p and Cbf2p.\" [PMID:13679521, PMID:9407032]","metadata":null},{"id":"e4af36d28c7648e5837e71b02bf25751","type":"GENE","name":"CBFA2T2","canonical_id":"hgnc:HGNC:1536","description":"CBFA2/RUNX1 partner transcriptional co-repressor 2","metadata":{"aliases":["MTGR1","ZMYND3"]}},{"id":"fcf7d6097f164fb1afa276371bffbc5e","type":"GENE","name":"CBFA2T3","canonical_id":"hgnc:HGNC:1537","description":null,"metadata":null},{"id":"e249b2544dcf44c29a74d31ab90f6ddb","type":"GENE","name":"CBFB","canonical_id":"hgnc:HGNC:1539","description":null,"metadata":null},{"id":"6cd9b7e58f4f4e4d8c91c99fe66adaea","type":"GENE","name":"CBL","canonical_id":"hgnc:HGNC:1541","description":"Cbl proto-oncogene","metadata":{"aliases":["RNF55","c-Cbl","CBL2"]}},{"id":"b94d348c7d4a48c08cc4733f4c0e4946","type":"GENE","name":"CBLB","canonical_id":"hgnc:HGNC:1542","description":"Cbl proto-oncogene B","metadata":{"aliases":["RNF56","Cbl-b"]}},{"id":"f8a41856dc3a480b9b413b216429caae","type":"GENE","name":"CBLC","canonical_id":"hgnc:HGNC:15961","description":"Cbl proto-oncogene C","metadata":{"aliases":["CBL-3","CBL-SL","RNF57"]}},{"id":"b83b3dbc144f4b26a2c036cc5d37f053","type":"GENE","name":"CBLIF","canonical_id":"hgnc:HGNC:4268","description":"cobalamin binding intrinsic factor","metadata":{"aliases":["TCN3","IF","IFMH","INF","GIF"]}},{"id":"d2a12fbbdfc146f3a3060b9176b7dfb6","type":"GENE","name":"CBLL1","canonical_id":"hgnc:HGNC:21225","description":"Cbl proto-oncogene like 1","metadata":{"aliases":["HAKAI","FLJ23109","RNF188"]}},{"id":"a67befe2363e486b88c762c5ba1dbd30","type":"GENE","name":"CBLL1-AS1","canonical_id":"hgnc:HGNC:55571","description":"CBLL1 antisense RNA 1","metadata":null},{"id":"6380219ed5924f47882305dd7a0b1bc0","type":"GENE","name":"CBLL1P1","canonical_id":"hgnc:HGNC:55074","description":"CBLL1 pseudogene 1","metadata":null},{"id":"8f92b28f5eaf4bf695c0e4dbdd6a1bc8","type":"GENE","name":"CBLL2","canonical_id":"hgnc:HGNC:26371","description":"Cbl proto-oncogene like 2","metadata":{"aliases":["FLJ25735","HAKAIL","CT138","ZNF645"]}},{"id":"e68f58ec42b944d99ae025a0daaab034","type":"GENE","name":"CBLN1","canonical_id":"hgnc:HGNC:1543","description":"cerebellin 1 precursor","metadata":null},{"id":"76d68e9dcce14f14b00375f82374024f","type":"GENE","name":"CBLN2","canonical_id":"hgnc:HGNC:1544","description":"cerebellin 2 precursor","metadata":null},{"id":"551c00e895484159972c734a8ec90c5e","type":"GENE","name":"CBLN3","canonical_id":"hgnc:HGNC:20146","description":"cerebellin 3 precursor","metadata":null},{"id":"673f6aad342740b0a92c44815a51b50b","type":"GENE","name":"CBLN4","canonical_id":"hgnc:HGNC:16231","description":"cerebellin 4 precursor","metadata":{"aliases":["dJ885A10.1","CBLNL1"]}},{"id":"469a03c4bef24b88a6759b3d12b39783","type":"GO_TERM","name":"CBM complex","canonical_id":"go:GO:0032449","description":"\"A protein complex comprising Bcl10, MALT1 and a CARD domain-containing protein (CARD9, CARD10 or CARD11); plays a role in signal transduction during NF-kappaB activation.\" [PMID:12909454, PMID:30467369]","metadata":null},{"id":"f6337f0a0c5d42e1a42181009c48df97","type":"GENE","name":"CBR1","canonical_id":"hgnc:HGNC:1548","description":"carbonyl reductase 1","metadata":{"aliases":["SDR21C1","CBR"]}},{"id":"6e512579dd7c49adaa643220ad12b724","type":"GENE","name":"CBR1-AS1","canonical_id":"hgnc:HGNC:55777","description":"CBR1 antisense RNA 1","metadata":null},{"id":"c203b56004e043d0b86459044f342cd6","type":"GENE","name":"CBR3","canonical_id":"hgnc:HGNC:1549","description":"carbonyl reductase 3","metadata":{"aliases":["SDR21C2"]}},{"id":"60692de9eca24fc891f0710a2cbab374","type":"GENE","name":"CBR3-AS1","canonical_id":"hgnc:HGNC:43664","description":"CBR3 antisense RNA 1","metadata":{"aliases":["PlncRNA-1"]}},{"id":"991a203c8a6d487982c88ecdae8aa27c","type":"GENE","name":"CBR4","canonical_id":"hgnc:HGNC:25891","description":"carbonyl reductase 4","metadata":{"aliases":["FLJ14431","SDR45C1"]}},{"id":"24858bc6ee8245ca9b52daf64c0edb93","type":"GENE","name":"CBR4-DT","canonical_id":"hgnc:HGNC:55540","description":"CBR4 divergent transcript","metadata":null},{"id":"619f5979dfa349f19c76d53e5186ebb3","type":"GENE","name":"CBS","canonical_id":"hgnc:HGNC:1550","description":null,"metadata":null},{"id":"f6d045de73564d85aa53257bfbb56bd4","type":"GENE","name":"CBSLR","canonical_id":"hgnc:HGNC:55459","description":"CBS mRNA stabilizing lncRNA","metadata":{"aliases":["TCONS_00001221"]}},{"id":"ecc23ffc62f541db8d2e3abed0471252","type":"GENE","name":"CBX1","canonical_id":"hgnc:HGNC:1551","description":"chromobox 1","metadata":{"aliases":["HP1Hs-beta","M31","MOD1","CBX","HP1-BETA","Hp1beta"]}},{"id":"cad44bfff8b747f5a6a73823995f6f91","type":"GENE","name":"CBX1P1","canonical_id":"hgnc:HGNC:38655","description":"chromobox 1 pseudogene 1","metadata":null},{"id":"6fc0ad8786d7449aaf16dd2befe98bfc","type":"GENE","name":"CBX1P2","canonical_id":"hgnc:HGNC:38656","description":"chromobox 1 pseudogene 2","metadata":null},{"id":"11280d650e884c5eb4744e0406a5f07c","type":"GENE","name":"CBX1P3","canonical_id":"hgnc:HGNC:38657","description":"chromobox 1 pseudogene 3","metadata":null},{"id":"8e7437f1b9184b5f8f31726fffbfb406","type":"GENE","name":"CBX1P4","canonical_id":"hgnc:HGNC:38658","description":"chromobox 1 pseudogene 4","metadata":null},{"id":"8d96ea36455a41b093a00900def82452","type":"GENE","name":"CBX1P5","canonical_id":"hgnc:HGNC:21006","description":"chromobox 1 pseudogene 5","metadata":{"aliases":["CBX9"]}},{"id":"abbe6149528648b8b5835d3b010267da","type":"GENE","name":"CBX2","canonical_id":"hgnc:HGNC:1552","description":"chromobox 2","metadata":{"aliases":["MGC10561","M33","CDCA6"]}},{"id":"57729fc55c714c6480eb7b9619767792","type":"GENE","name":"CBX3","canonical_id":"hgnc:HGNC:1553","description":"chromobox 3","metadata":{"aliases":["HP1Hs-gamma","HP1gamma"]}},{"id":"e23ac8c4846d4dcd9708ea2190e38ce3","type":"GENE","name":"CBX3P1","canonical_id":"hgnc:HGNC:33950","description":"CBX3 pseudogene 1","metadata":null},{"id":"5879c2a3d70649d691d5392ccfcb4def","type":"GENE","name":"CBX3P10","canonical_id":"hgnc:HGNC:56409","description":"CBX3 pseudogene 10","metadata":null},{"id":"0b7c861573b440b6a1a4ef6a467e53cf","type":"GENE","name":"CBX3P2","canonical_id":"hgnc:HGNC:42874","description":"CBX3 pseudogene 2","metadata":null},{"id":"7f7d742eea79407ab4baafc3b0d1c373","type":"GENE","name":"CBX3P3","canonical_id":"hgnc:HGNC:42875","description":"CBX3 pseudogene 3","metadata":null},{"id":"d9939b2225194342b54b69d936b0b58f","type":"GENE","name":"CBX3P4","canonical_id":"hgnc:HGNC:42876","description":"CBX3 pseudogene 4","metadata":null},{"id":"bed55eeb4ae348e08222ce7e3eb9b80a","type":"GENE","name":"CBX3P5","canonical_id":"hgnc:HGNC:42877","description":"CBX3 pseudogene 5","metadata":null},{"id":"9f860f412104495ca4791114141641a7","type":"GENE","name":"CBX3P6","canonical_id":"hgnc:HGNC:42878","description":"CBX3 pseudogene 6","metadata":null},{"id":"788f39435edb46f389a1f8f0e0a11e98","type":"GENE","name":"CBX3P7","canonical_id":"hgnc:HGNC:42879","description":"CBX3 pseudogene 7","metadata":null},{"id":"9f83444b54b144cd9e4f149d02037700","type":"GENE","name":"CBX3P8","canonical_id":"hgnc:HGNC:42880","description":"CBX3 pseudogene 8","metadata":null},{"id":"dbc8f66fc32944feb19c6c146c98cb2a","type":"GENE","name":"CBX3P9","canonical_id":"hgnc:HGNC:42881","description":"CBX3 pseudogene 9","metadata":null},{"id":"7abb370daf1c4c129fc004481192ea60","type":"GENE","name":"CBX4","canonical_id":"hgnc:HGNC:1554","description":"chromobox 4","metadata":{"aliases":["hPC2","PC2","NBP16"]}},{"id":"d95e01bb708f4a118c2acdb120238c6f","type":"GENE","name":"CBX5","canonical_id":"hgnc:HGNC:1555","description":null,"metadata":null},{"id":"3456e82e96b84341a849f26edc2c4888","type":"GENE","name":"CBX5P1","canonical_id":"hgnc:HGNC:38659","description":"chromobox 5 pseudogene 1","metadata":null},{"id":"9f23407e42e843b199ca386ceea7190f","type":"GENE","name":"CBX6","canonical_id":"hgnc:HGNC:1556","description":"chromobox 6","metadata":null},{"id":"0136d4019e564e2d9a7e198bd85cb0d8","type":"GENE","name":"CBX7","canonical_id":"hgnc:HGNC:1557","description":null,"metadata":null},{"id":"cd38c4e7cb384055a873aa696b1711a0","type":"GENE","name":"CBX7-AS1","canonical_id":"hgnc:HGNC:58395","description":"CBX7 antisense RNA 1","metadata":null},{"id":"3db01a5e7a264f06a03d0768ce601f3c","type":"GENE","name":"CBX8","canonical_id":"hgnc:HGNC:15962","description":null,"metadata":null},{"id":"d783d03bc77b4c4bb51110b6e752fdf9","type":"GENE","name":"CBY1","canonical_id":"hgnc:HGNC:1307","description":"chibby 1, beta catenin antagonist","metadata":{"aliases":["PIGEA14","PIGEA-14","Chibby","Cby","Chibby1","C22orf2","PGEA1"]}},{"id":"d1d2d9f3a60b4add8ae16c2b89c81d6b","type":"GENE","name":"CBY1P1","canonical_id":"hgnc:HGNC:54769","description":"CBY1 pseudogene 1","metadata":null},{"id":"1b1302455f534794b84309ed7c543c0e","type":"GENE","name":"CBY2","canonical_id":"hgnc:HGNC:30720","description":"chibby family member 2","metadata":{"aliases":["NURIT","SPERT"]}},{"id":"cd686f7c38ac4168bd1c07bc0b49ca55","type":"GENE","name":"CBY3","canonical_id":"hgnc:HGNC:33278","description":"chibby family member 3","metadata":null},{"id":"4f75f0a83a81472f9c0b673287b6603a","type":"GO_TERM","name":"CC tRNA cytidylyltransferase activity","canonical_id":"go:GO:0052927","description":"\"Catalysis of the reaction: a tRNA precursor + CTP = a tRNA with a 3' CC end + 2 diphosphate.\" [PMID:31936900, PMID:33095240, RHEA:60008]","metadata":null},{"id":"ba90500a911744158ea5f6c8d9f09445","type":"GO_TERM","name":"CC-preferring endodeoxyribonuclease activity","canonical_id":"go:GO:0033891","description":"\"Catalysis of the endonucleolytic cleavage to give 5'-phosphooligonucleotide end-products, with a preference for cleavage within the sequence CC.\" [EC:3.1.21.6]","metadata":null},{"id":"0c80173bbc39432e9d12c74323bd95af","type":"GENE","name":"CC2D1A","canonical_id":"hgnc:HGNC:30237","description":"coiled-coil and C2 domain containing 1A","metadata":{"aliases":["FLJ20241","MRT3","Freud-1","Lgd2","TAPE","Aki-1"]}},{"id":"4d508e28d71345cf9f8f014865aa2900","type":"GENE","name":"CC2D1B","canonical_id":"hgnc:HGNC:29386","description":"coiled-coil and C2 domain containing 1B","metadata":{"aliases":["KIAA1836","Freud-2","Lgd1"]}},{"id":"68c4eb355c3c45909f03278dd25873bb","type":"GENE","name":"CC2D2A","canonical_id":"hgnc:HGNC:29253","description":"coiled-coil and C2 domain containing 2A","metadata":{"aliases":["KIAA1345","MKS6","JBTS9"]}},{"id":"c0114a54c0834c0eab5eba3b7fc2a035","type":"GENE","name":"CC2D2B","canonical_id":"hgnc:HGNC:31666","description":"coiled-coil and C2 domain containing 2B","metadata":{"aliases":["bA248J23.4","bA690P14.3","C10orf130","C10orf131"]}},{"id":"99e14d1ed7894d8db0cdd6fcf16388d4","type":"GO_TERM","name":"CCA codon-amino acid adaptor activity","canonical_id":"go:GO:0033423","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CCA codon.\" [GOC:mah]","metadata":null},{"id":"0a30dd0c5fc74235998ccf8b2676d9e1","type":"GO_TERM","name":"CCA tRNA nucleotidyltransferase activity","canonical_id":"go:GO:0004810","description":"\"Catalysis of the reaction: a tRNA precursor + ATP + 2 CTP = a tRNA with a 3' CCA end + 3 diphosphate.\" [PMID:2247609, RHEA:14433]","metadata":null},{"id":"eb66441713f241e08ffbed368ae69202","type":"GO_TERM","name":"CCAAT-binding factor complex","canonical_id":"go:GO:0016602","description":"\"A heteromeric transcription factor complex that binds to the CCAAT-box upstream of promoters; functions as both an activator and a repressor, depending on its interacting cofactors. Typically trimeric consisting of NFYA, NFYB and NFYC subunits. In Saccharomyces, it activates the transcription of genes in response to growth in a nonfermentable carbon source and consists of four known subunits: HAP2, HAP3, HAP4 and HAP5.\" [GOC:bhm, PMID:7828851]","metadata":null},{"id":"afb521ad9f0b4390a2594e776179962d","type":"GO_TERM","name":"CCACCA tRNA nucleotidyltransferase activity","canonical_id":"go:GO:0160016","description":"\"Catalysis of the reaction: a tRNA with a 3' CCA end + 2 CTP + ATP = a tRNA with a 3' CCACCA end + 3 diphosphate.\" [PMID:22076379, RHEA:76235]","metadata":null},{"id":"577b564d59054ae691e6fa64f28c13b1","type":"GENE","name":"CCAR1","canonical_id":"hgnc:HGNC:24236","description":"cell division cycle and apoptosis regulator 1","metadata":{"aliases":["CARP1","CARP-1","uc.285+","FLJ10590"]}},{"id":"4ee72b7af7af430a8d2a0a881c8fe14a","type":"GENE","name":"CCAR2","canonical_id":"hgnc:HGNC:23360","description":null,"metadata":null},{"id":"a08db5bdabc240af9d4bba8d7b52346f","type":"GENE","name":"CCAT1","canonical_id":"hgnc:HGNC:45128","description":"colon cancer associated transcript 1","metadata":{"aliases":["CARLo-5","onco-lncRNA-40"]}},{"id":"40154e72bb1446e2b4e1856aefa7ead4","type":"GENE","name":"CCAT2","canonical_id":"hgnc:HGNC:47044","description":"colon cancer associated transcript 2","metadata":{"aliases":["NCCP1","LINC00873"]}},{"id":"055bfeff6de64ab199abe7cbdf84fea2","type":"GENE","name":"CCBE1","canonical_id":"hgnc:HGNC:29426","description":"collagen and calcium binding EGF domains 1","metadata":{"aliases":["FLJ30681","KIAA1983"]}},{"id":"6ddbd9b3115e4586aec1ddd571c37462","type":"GENE","name":"CCBE1-AS1","canonical_id":"hgnc:HGNC:58570","description":"CCBE1 antisense RNA 1","metadata":null},{"id":"dd55b9d3b9284969969d97c92f72f454","type":"GO_TERM","name":"CCC codon-amino acid adaptor activity","canonical_id":"go:GO:0033422","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CCC codon.\" [GOC:mah]","metadata":null},{"id":"0142cf308fb14f46a28ee90a46527f5f","type":"GENE","name":"CCDC102A","canonical_id":"hgnc:HGNC:28097","description":"coiled-coil domain containing 102A","metadata":{"aliases":["MGC10992"]}},{"id":"5a1e409a9d9a436ab0d17e3cee7eed37","type":"GENE","name":"CCDC102B","canonical_id":"hgnc:HGNC:26295","description":"coiled-coil domain containing 102B","metadata":{"aliases":["FLJ23594","HsT1731","AN","C18orf14","ACY1L"]}},{"id":"dc6c40b376204ec38b734a3bbaf24162","type":"GENE","name":"CCDC106","canonical_id":"hgnc:HGNC:30181","description":"coiled-coil domain containing 106","metadata":{"aliases":["HSU79303"]}},{"id":"ad15949b67eb4d7183ca2f93088a3bfe","type":"GENE","name":"CCDC107","canonical_id":"hgnc:HGNC:28465","description":"coiled-coil domain containing 107","metadata":{"aliases":["MGC31967"]}},{"id":"31d1fd795c3e4bbd8f8d9166246c2f9e","type":"GENE","name":"CCDC110","canonical_id":"hgnc:HGNC:28504","description":"coiled-coil domain containing 110","metadata":{"aliases":["KM-HN-1","MGC33607","CT52"]}},{"id":"a3ae6e2b318e4ac195ed4316405d6980","type":"GENE","name":"CCDC110-AS1","canonical_id":"hgnc:HGNC:58917","description":"CCDC110 antisense RNA 1","metadata":null},{"id":"3106a562ab33427298d741a2345fef8f","type":"GENE","name":"CCDC112","canonical_id":"hgnc:HGNC:28599","description":"coiled-coil domain containing 112","metadata":{"aliases":["MGC39633"]}},{"id":"7dc917a1b6ed418691eb828dac736c92","type":"GENE","name":"CCDC112-DT","canonical_id":"hgnc:HGNC:59116","description":"CCDC112 divergent transcript","metadata":null},{"id":"4dd6ad0e22404854aa66546a36254ee0","type":"GENE","name":"CCDC116","canonical_id":"hgnc:HGNC:26688","description":"coiled-coil domain containing 116","metadata":{"aliases":["FLJ36046"]}},{"id":"ad259a7ae3e8491b8b94b0238dcdeb9d","type":"GENE","name":"CCDC117","canonical_id":"hgnc:HGNC:26599","description":"coiled-coil domain containing 117","metadata":{"aliases":["FLJ33814"]}},{"id":"8ea8640af9024ad9901a106d6d8636af","type":"GENE","name":"CCDC12","canonical_id":"hgnc:HGNC:28332","description":"coiled-coil domain containing 12","metadata":{"aliases":["MGC23918"]}},{"id":"ab582a4086044998b3e1f115a4c2ae29","type":"GENE","name":"CCDC120","canonical_id":"hgnc:HGNC:28910","description":"coiled-coil domain containing 120","metadata":{"aliases":["JM11"]}},{"id":"daccd0ecd4ff4c6b90f734eab0611767","type":"GENE","name":"CCDC121","canonical_id":"hgnc:HGNC:25833","description":"coiled-coil domain containing 121","metadata":{"aliases":["FLJ43364","FLJ13646"]}},{"id":"6c0d680b65d749d7887986b629284ad3","type":"GENE","name":"CCDC121P1","canonical_id":"hgnc:HGNC:55052","description":"CCDC121 pseudogene 1","metadata":null},{"id":"a61f009968cd4d82a89f850a8e437865","type":"GENE","name":"CCDC122","canonical_id":"hgnc:HGNC:26478","description":"coiled-coil domain containing 122","metadata":{"aliases":["FLJ31846"]}},{"id":"9ec56c73d0e24f70ac7f00535874ee6b","type":"GENE","name":"CCDC124","canonical_id":"hgnc:HGNC:25171","description":"coiled-coil domain containing 124","metadata":{"aliases":["Lso2","oxs1"]}},{"id":"0814f1eaff7846b1bac3833ba4d719e5","type":"GENE","name":"CCDC125","canonical_id":"hgnc:HGNC:28924","description":"coiled-coil domain containing 125","metadata":{"aliases":["KENAE"]}},{"id":"43f920b7a0a64b5d9fbb56ae2c972c0b","type":"GENE","name":"CCDC126","canonical_id":"hgnc:HGNC:22398","description":"coiled-coil domain containing 126","metadata":{"aliases":["FLJ23031"]}},{"id":"e3ed3ff534514246a6760ff833f588a3","type":"GENE","name":"CCDC127","canonical_id":"hgnc:HGNC:30520","description":"coiled-coil domain containing 127","metadata":{"aliases":["FLJ25701"]}},{"id":"e8f48487efe143d1a8664e0b00b03a63","type":"GENE","name":"CCDC12P1","canonical_id":"hgnc:HGNC:54595","description":"CCDC12 pseudogene 1","metadata":null},{"id":"e251b6611c2d4ef59f82a51eab2c2c5d","type":"GENE","name":"CCDC13","canonical_id":"hgnc:HGNC:26358","description":"coiled-coil domain containing 13","metadata":{"aliases":["FLJ25467"]}},{"id":"0e88eac2fc2143449b4f47ff88f9f585","type":"GENE","name":"CCDC13-AS1","canonical_id":"hgnc:HGNC:41142","description":"CCDC13 antisense RNA 1","metadata":null},{"id":"873470bec98c4e6d900404ddb59cc6c5","type":"GENE","name":"CCDC13-AS2","canonical_id":"hgnc:HGNC:53019","description":"CCDC13 antisense RNA 2","metadata":{"aliases":["LINC02158"]}},{"id":"464edef99a4249d1afe7e5ed98f7a665","type":"GENE","name":"CCDC134","canonical_id":"hgnc:HGNC:26185","description":"coiled-coil domain containing 134","metadata":{"aliases":["FLJ22349"]}},{"id":"8564d02f31c74e118d75595118e78a51","type":"GENE","name":"CCDC136","canonical_id":"hgnc:HGNC:22225","description":"coiled-coil domain containing 136","metadata":{"aliases":["KIAA1793","NAG6","DKFZP434G156"]}},{"id":"8b82f06c4dc34c2a9f6d063e466d69fa","type":"GENE","name":"CCDC137","canonical_id":"hgnc:HGNC:33451","description":"coiled-coil domain containing 137","metadata":{"aliases":["MGC16597"]}},{"id":"548f7e138acd4beca0f0397ec2537413","type":"GENE","name":"CCDC137P1","canonical_id":"hgnc:HGNC:33459","description":"CCDC137 pseudogene 1","metadata":{"aliases":["CCDC137P"]}},{"id":"734b921dc483446aa9b3a0f30e3c4b40","type":"GENE","name":"CCDC137P2","canonical_id":"hgnc:HGNC:56429","description":"CCDC137 pseudogene 2","metadata":null},{"id":"d31d95a1785d4f6798a79becfe7084e8","type":"GENE","name":"CCDC138","canonical_id":"hgnc:HGNC:26531","description":"coiled-coil domain containing 138","metadata":{"aliases":["FLJ32745"]}},{"id":"9f4d099fcdc146fe91716abf7ad465d4","type":"GENE","name":"CCDC14","canonical_id":"hgnc:HGNC:25766","description":"coiled-coil domain containing 14","metadata":{"aliases":["FLJ12892","DKFZp434L1050"]}},{"id":"52e04c26db3b400783a4e96f7c22ce8b","type":"GENE","name":"CCDC140","canonical_id":"hgnc:HGNC:26514","description":"CCDC140 long non-coding RNA","metadata":{"aliases":["FLJ32447"]}},{"id":"f66c6a61151c468899c61b9fd86299e4","type":"GENE","name":"CCDC141","canonical_id":"hgnc:HGNC:26821","description":"coiled-coil domain containing 141","metadata":{"aliases":["FLJ39502","CAMDI"]}},{"id":"56d87b5b9a8b4feb8867d95fdb253844","type":"GENE","name":"CCDC142","canonical_id":"hgnc:HGNC:25889","description":"coiled-coil domain containing 142","metadata":{"aliases":["FLJ14397"]}},{"id":"bbc59e19974148dbad0819d97e325503","type":"GENE","name":"CCDC144A","canonical_id":"hgnc:HGNC:29072","description":"coiled-coil domain containing 144A","metadata":{"aliases":["KIAA0565","FLJ43983"]}},{"id":"f5f1b0a631254e2aa065e5466ae97257","type":"GENE","name":"CCDC144BP","canonical_id":"hgnc:HGNC:26704","description":"coiled-coil domain containing 144B, pseudogene","metadata":{"aliases":["FLJ36492","CCDC144B"]}},{"id":"8976278cb445412f9663c1b6afcfad5a","type":"GENE","name":"CCDC144CP","canonical_id":"hgnc:HGNC:29073","description":"coiled-coil domain containing 144C, pseudogene","metadata":{"aliases":["CCDC144C"]}},{"id":"fac8c109655b4beca7a7e52ed0125790","type":"GENE","name":"CCDC144NL","canonical_id":"hgnc:HGNC:33735","description":"CCDC144A N-terminal like (pseudogene)","metadata":{"aliases":["MGC87631"]}},{"id":"ae89e84f5bb34e368b8bfd066a6b08e2","type":"GENE","name":"CCDC144NL-AS1","canonical_id":"hgnc:HGNC:51340","description":"CCDC144NL antisense RNA 1","metadata":null},{"id":"e0ddcf81bb424b79be7057f5492bafe6","type":"GENE","name":"CCDC146","canonical_id":"hgnc:HGNC:29296","description":"coiled-coil domain containing 146","metadata":{"aliases":["KIAA1505","MBO2"]}},{"id":"4f00f7df5fd84084b649ef3efdf8a78b","type":"GENE","name":"CCDC146-AS1","canonical_id":"hgnc:HGNC:58425","description":"CCDC146 antisense RNA 1","metadata":null},{"id":"745b8814af7046a48de5d80f5cca37b6","type":"GENE","name":"CCDC148","canonical_id":"hgnc:HGNC:25191","description":"coiled-coil domain containing 148","metadata":{"aliases":["MGC125588"]}},{"id":"99f06e58d8c9418f86e4b694746a0e41","type":"GENE","name":"CCDC148-AS1","canonical_id":"hgnc:HGNC:44134","description":"CCDC148 antisense RNA 1","metadata":null},{"id":"2305e9f7742a4535bc2add3c4fe0ca42","type":"GENE","name":"CCDC149","canonical_id":"hgnc:HGNC:25405","description":"coiled-coil domain containing 149","metadata":{"aliases":["DKFZp761B107"]}},{"id":"30a7dbb2aba04a41bb28cd99779630b8","type":"GENE","name":"CCDC149-AS1","canonical_id":"hgnc:HGNC:58745","description":"CCDC149 and LGI2 antisense RNA 1","metadata":null},{"id":"ec52a4c3ccc0466da607c04bd6ec0b56","type":"GENE","name":"CCDC15","canonical_id":"hgnc:HGNC:25798","description":"coiled-coil domain containing 15","metadata":{"aliases":["FLJ13215"]}},{"id":"fa62a697fa6a481cabd6562e77cbcdc8","type":"GENE","name":"CCDC15-DT","canonical_id":"hgnc:HGNC:54193","description":"CCDC15 divergent transcript","metadata":null},{"id":"a90261cbc63f4ade8510604ff019d287","type":"GENE","name":"CCDC150","canonical_id":"hgnc:HGNC:26834","description":"coiled-coil domain containing 150","metadata":{"aliases":["FLJ39660"]}},{"id":"c80759680f994dc7848441fdf35e970e","type":"GENE","name":"CCDC150P1","canonical_id":"hgnc:HGNC:50280","description":"coiled-coil domain containing 150 pseudogene 1","metadata":null},{"id":"34f06af8e2a7426f9587d30c6f978f06","type":"GENE","name":"CCDC152","canonical_id":"hgnc:HGNC:34438","description":"coiled-coil domain containing 152","metadata":{"aliases":["LOC100129792"]}},{"id":"51e0b090bb2641ae87ed5776fd120ce2","type":"GENE","name":"CCDC154","canonical_id":"hgnc:HGNC:34454","description":"coiled-coil domain containing 154","metadata":{"aliases":["LOC645811","C16orf29"]}},{"id":"360fda4ed3d546b4aff6c6982e81441b","type":"GENE","name":"CCDC157","canonical_id":"hgnc:HGNC:33854","description":"coiled-coil domain containing 157","metadata":null},{"id":"330c5ffa925b4cae8c46c44f98329c6e","type":"GENE","name":"CCDC158","canonical_id":"hgnc:HGNC:26374","description":"coiled-coil domain containing 158","metadata":{"aliases":["FLJ25770"]}},{"id":"06d76f7e9fdc4fe0b8b5bd75c63eb391","type":"GENE","name":"CCDC159","canonical_id":"hgnc:HGNC:26996","description":"coiled-coil domain containing 159","metadata":null},{"id":"de696a8215c8441d85a0dbb3d702a7d9","type":"GENE","name":"CCDC160","canonical_id":"hgnc:HGNC:37286","description":"coiled-coil domain containing 160","metadata":null},{"id":"58fa03f03ee24ef88a1dec9f561ec458","type":"GENE","name":"CCDC162P","canonical_id":"hgnc:HGNC:21565","description":"coiled-coil domain containing 162, pseudogene","metadata":{"aliases":["bA425D10.7","bA425D10.3","bA487F23.3","C6orf184","C6orf185","CCDC162","C6orf183"]}},{"id":"daa215d119654d50add41e2943aa8d03","type":"GENE","name":"CCDC163","canonical_id":"hgnc:HGNC:27003","description":"CCDC163 homolog","metadata":{"aliases":["LOC126661","C1orf231","CCDC163P"]}},{"id":"6f34b88eb9fe46918f5a836c1890583d","type":"GENE","name":"CCDC166","canonical_id":"hgnc:HGNC:41910","description":"coiled-coil domain containing 166","metadata":null},{"id":"7f9479a2bdac44a9984ac43790266ea5","type":"GENE","name":"CCDC167","canonical_id":"hgnc:HGNC:21239","description":"coiled-coil domain containing 167","metadata":{"aliases":["dJ153P14.2","C6orf129"]}},{"id":"6d3cad44532445e49595f2dca6f74351","type":"GENE","name":"CCDC169","canonical_id":"hgnc:HGNC:34361","description":"coiled-coil domain containing 169","metadata":{"aliases":["RP11-251J8.1","LOC728591","C13orf38"]}},{"id":"86b1dab3ecdd469780ce35570f743215","type":"GENE","name":"CCDC169-SOHLH2","canonical_id":"hgnc:HGNC:38866","description":"CCDC169-SOHLH2 readthrough","metadata":{"aliases":["C13orf38-SOHLH2"]}},{"id":"c6b4d1df9e8142bc9fadee5ae6899425","type":"GENE","name":"CCDC17","canonical_id":"hgnc:HGNC:26574","description":"coiled-coil domain containing 17","metadata":{"aliases":["FLJ33084"]}},{"id":"8a628b35399944e28b9e07fc6a70464c","type":"GENE","name":"CCDC170","canonical_id":"hgnc:HGNC:21177","description":"coiled-coil domain containing 170","metadata":{"aliases":["FLJ23305","bA282P11.1","C6orf97"]}},{"id":"d880b7f906e94f839cdd0e9c03da4b1a","type":"GENE","name":"CCDC171","canonical_id":"hgnc:HGNC:29828","description":"coiled-coil domain containing 171","metadata":{"aliases":["FLJ39267","FLJ46740","Em:AL513423.1","bA778P13.1","bA536D16.1","C9orf93"]}},{"id":"b9384b0e9754416d9bc7a34ec755e501","type":"GENE","name":"CCDC172","canonical_id":"hgnc:HGNC:30524","description":"coiled-coil domain containing 172","metadata":{"aliases":["MGC35062","C10orf96"]}},{"id":"11d32ce1ef50477486bdd7f31ab9cee7","type":"GENE","name":"CCDC174","canonical_id":"hgnc:HGNC:28033","description":"coiled-coil domain containing 174","metadata":{"aliases":["FLJ33839","ctr1","C3orf19"]}},{"id":"2b56e2568bf542559f90bff195180f30","type":"GENE","name":"CCDC175","canonical_id":"hgnc:HGNC:19847","description":"coiled-coil domain containing 175","metadata":{"aliases":["C14orf38"]}},{"id":"4cea5d54085349d0ae891433674296b5","type":"GENE","name":"CCDC177","canonical_id":"hgnc:HGNC:23243","description":"coiled-coil domain containing 177","metadata":{"aliases":["PLPL","C14orf162"]}},{"id":"432d89b60eab430f9c0587e8b6009b47","type":"GENE","name":"CCDC178","canonical_id":"hgnc:HGNC:29588","description":"coiled-coil domain containing 178","metadata":{"aliases":["FLJ44050","C18orf34"]}},{"id":"357b69a1b9684ec69df18f6f0eff5b80","type":"GENE","name":"CCDC179","canonical_id":"hgnc:HGNC:44653","description":"coiled-coil domain containing 179","metadata":null},{"id":"16eb974a158b46558ca2111f4c106a9a","type":"GENE","name":"CCDC18","canonical_id":"hgnc:HGNC:30370","description":"coiled-coil domain containing 18","metadata":{"aliases":["NY-SAR-41"]}},{"id":"97b4178344eb43d781d029ef22eef186","type":"GENE","name":"CCDC18-AS1","canonical_id":"hgnc:HGNC:52262","description":"CCDC18 antisense RNA 1","metadata":{"aliases":["ENST00000440778.1"]}},{"id":"3477bb9b37524e3ab1b14e78021e7b92","type":"GENE","name":"CCDC180","canonical_id":"hgnc:HGNC:29303","description":"coiled-coil domain containing 180","metadata":{"aliases":["DKFZp434I2420","BDAG1","FAP76","CFAP76","KIAA1529","C9orf174"]}},{"id":"bc91e26f11b446328703863089064d56","type":"GENE","name":"CCDC181","canonical_id":"hgnc:HGNC:28051","description":"coiled-coil domain containing 181","metadata":{"aliases":["FLJ25846","C1orf114"]}},{"id":"ceb876f50b964d56a98ecd7c05df5970","type":"GENE","name":"CCDC182","canonical_id":"hgnc:HGNC:49392","description":"coiled-coil domain containing 182","metadata":null},{"id":"415ff1df8af94d6789d3548689a75896","type":"GENE","name":"CCDC183","canonical_id":"hgnc:HGNC:28236","description":"coiled-coil domain containing 183","metadata":{"aliases":["MGC15438","bA216L13.7","KIAA1984"]}},{"id":"7a21d835ff51426a9fd10cc04044fcf5","type":"GENE","name":"CCDC183-AS1","canonical_id":"hgnc:HGNC:44105","description":"CCDC183 antisense RNA 1","metadata":{"aliases":["KIAA1984-AS1"]}},{"id":"ade04a8064bb4533b724dac1069852f4","type":"GENE","name":"CCDC184","canonical_id":"hgnc:HGNC:33749","description":"coiled-coil domain containing 184","metadata":{"aliases":["LOC387856","C12orf68"]}},{"id":"7be0d7b25f4f4b029040def6a94aa175","type":"GENE","name":"CCDC185","canonical_id":"hgnc:HGNC:26654","description":"coiled-coil domain containing 185","metadata":{"aliases":["FLJ35728","C1orf65"]}},{"id":"6239dd332dcb49ef9a791d271256a7b4","type":"GENE","name":"CCDC186","canonical_id":"hgnc:HGNC:24349","description":"coiled-coil domain containing 186","metadata":{"aliases":["FLJ10188","FLJ35301","CCCP-1","golgin104","C10orf118"]}},{"id":"56a7db41cc3e4ca4be0e2f7919a93eef","type":"GENE","name":"CCDC187","canonical_id":"hgnc:HGNC:30942","description":"coiled-coil domain containing 187","metadata":{"aliases":["MGC50722"]}},{"id":"f324c1d4b9e34b0a9550de78b673be69","type":"GENE","name":"CCDC188","canonical_id":"hgnc:HGNC:51899","description":"coiled-coil domain containing 188","metadata":null},{"id":"0b9f38e2d766452a9c097413be6fb716","type":"GENE","name":"CCDC188BP","canonical_id":"hgnc:HGNC:56303","description":"coiled-coil domain containing 188B, pseudogene","metadata":null},{"id":"080af690b7c34b8098a635d2398ab3ee","type":"GENE","name":"CCDC190","canonical_id":"hgnc:HGNC:28736","description":"coiled-coil domain containing 190","metadata":{"aliases":["MGC48998","C1orf110"]}},{"id":"cc6cf3ec9072427bbd7a273b7cda8047","type":"GENE","name":"CCDC191","canonical_id":"hgnc:HGNC:29272","description":"coiled-coil domain containing 191","metadata":{"aliases":["KIAA1407"]}},{"id":"3ac3605c1f5649d4834b8158fb7e0740","type":"GENE","name":"CCDC192","canonical_id":"hgnc:HGNC:49566","description":"coiled-coil domain containing 192","metadata":{"aliases":["LINC01183"]}},{"id":"9d756ba4f8cc47b0916d295b0b4a583c","type":"GENE","name":"CCDC192-AS1","canonical_id":"hgnc:HGNC:59128","description":"CCDC192 antisense RNA 1","metadata":null},{"id":"d320b952e10648a6b433ca00355f3282","type":"GENE","name":"CCDC194","canonical_id":"hgnc:HGNC:53438","description":"coiled-coil domain containing 194","metadata":null},{"id":"84db2b46937e4bc9bc58f8be36cf3bb6","type":"GENE","name":"CCDC195","canonical_id":"hgnc:HGNC:53441","description":"coiled-coil domain containing 195","metadata":null},{"id":"802b815fc0c74bef8b685b5859f954f5","type":"GENE","name":"CCDC196","canonical_id":"hgnc:HGNC:20100","description":"coiled-coil domain containing 196","metadata":{"aliases":["C14orf53","NCRNA00238","LINC00238"]}},{"id":"02230e17eaa940ff8a624021fffc7747","type":"GENE","name":"CCDC197","canonical_id":"hgnc:HGNC:19860","description":"coiled-coil domain containing 197","metadata":{"aliases":["LINC00521","C14orf48"]}},{"id":"33b4334311d84fef85b6709264c13a36","type":"GENE","name":"CCDC198","canonical_id":"hgnc:HGNC:20189","description":"coiled-coil domain containing 198","metadata":{"aliases":["FLJ10650","FAME","C14orf105"]}},{"id":"d058bac708b949d58cba36ec3eaeadf0","type":"GENE","name":"CCDC200","canonical_id":"hgnc:HGNC:43658","description":"coiled-coil domain containing 200","metadata":{"aliases":["TMEM106A-AS1","LINC00854"]}},{"id":"092f80b5ef48491fbfbacde8a478957a","type":"GENE","name":"CCDC201","canonical_id":"hgnc:HGNC:54081","description":"coiled-coil domain containing 201","metadata":null},{"id":"0542d2ca572945fb8079816435642378","type":"GENE","name":"CCDC22","canonical_id":"hgnc:HGNC:28909","description":"CCC complex scaffolding subunit CCDC22","metadata":{"aliases":["JM1","CXorf37"]}},{"id":"5057454bc0d7409e970eece2aa3d9383","type":"GENE","name":"CCDC24","canonical_id":"hgnc:HGNC:28688","description":"coiled-coil domain containing 24","metadata":{"aliases":["MGC45441"]}},{"id":"2f1c330c5fcf44a5a91136b4daf18218","type":"GENE","name":"CCDC25","canonical_id":"hgnc:HGNC:25591","description":"coiled-coil domain containing 25","metadata":{"aliases":["FLJ10853"]}},{"id":"0cd2eaf3f89842aba6041f24f2e9d219","type":"GENE","name":"CCDC25P1","canonical_id":"hgnc:HGNC:58662","description":"CCDC25 pseudogene 1","metadata":null},{"id":"57ffdb70268c4a95ae197bd432c9e9f7","type":"GENE","name":"CCDC25P2","canonical_id":"hgnc:HGNC:58663","description":"CCDC25 pseudogene 2","metadata":null},{"id":"8ebe6b2d116942b28aae20ab66c8e7f4","type":"GENE","name":"CCDC26","canonical_id":"hgnc:HGNC:28416","description":"CCDC26 long non-coding RNA","metadata":{"aliases":["MGC27434","RAM"]}},{"id":"1928aaf2e4c546aeac6c3d0b0c511f5d","type":"GENE","name":"CCDC27","canonical_id":"hgnc:HGNC:26546","description":"coiled-coil domain containing 27","metadata":{"aliases":["FLJ32825"]}},{"id":"a3f2632221894e3ba07d7c971986c4fe","type":"GENE","name":"CCDC28A","canonical_id":"hgnc:HGNC:21098","description":"coiled-coil domain containing 28A","metadata":{"aliases":["CCRL1AP","DKFZp586D0623","LTAP2A","C6orf80"]}},{"id":"8efdcc7820cb4b0dacb8552ab7727c16","type":"GENE","name":"CCDC28A-AS1","canonical_id":"hgnc:HGNC:51715","description":"CCDC28A antisense RNA 1","metadata":{"aliases":["GVQW2"]}},{"id":"3138488f4e0a41a79c45d60dee5a72a2","type":"GENE","name":"CCDC28B","canonical_id":"hgnc:HGNC:28163","description":"coiled-coil domain containing 28B","metadata":{"aliases":["MGC1203","RP4-622L5.5","LTAP2B"]}},{"id":"4fcfea1e922749b485605f79aa14711c","type":"GENE","name":"CCDC3","canonical_id":"hgnc:HGNC:23813","description":"coiled-coil domain containing 3","metadata":{"aliases":["DKFZp761F241"]}},{"id":"09ab066030d54d45973f4259c9d1168f","type":"GENE","name":"CCDC30","canonical_id":"hgnc:HGNC:26103","description":"coiled-coil domain containing 30","metadata":{"aliases":["FLJ20972","PFD6L","LOC728621"]}},{"id":"81c2e3e4a8b342ce8fc88b4065ea8c3c","type":"GENE","name":"CCDC32","canonical_id":"hgnc:HGNC:28295","description":"coiled-coil domain containing 32","metadata":{"aliases":["MGC20481","C15orf57"]}},{"id":"1431c3a24064443da9239d2bfa47f1e2","type":"GENE","name":"CCDC33","canonical_id":"hgnc:HGNC:26552","description":"coiled-coil domain containing 33","metadata":{"aliases":["FLJ32855","CT61","CC2D3"]}},{"id":"e4c7b0d86c8a4fa9bde66204b9e1ceaf","type":"GENE","name":"CCDC33-AS1","canonical_id":"hgnc:HGNC:58163","description":"CCDC33 antisense RNA 1","metadata":{"aliases":["lnc-CYP11A1-1"]}},{"id":"d97ca8eef60e45c8813559aa96a88867","type":"GENE","name":"CCDC34","canonical_id":"hgnc:HGNC:25079","description":"coiled-coil domain containing 34","metadata":{"aliases":["NY-REN-41","L15","RAMA3"]}},{"id":"4d6d7ab9b80747259b97e5a89de64be8","type":"GENE","name":"CCDC34P1","canonical_id":"hgnc:HGNC:44008","description":"coiled-coil domain containing 34 pseudogene 1","metadata":null},{"id":"d978f45b7569482b8e05ff8b325a7613","type":"GENE","name":"CCDC38","canonical_id":"hgnc:HGNC:26843","description":"coiled-coil domain containing 38","metadata":{"aliases":["FLJ40089"]}},{"id":"39e8ee7b9a274fd29c5c7dbc33573cc7","type":"GENE","name":"CCDC39","canonical_id":"hgnc:HGNC:25244","description":"coiled-coil domain 39 molecular ruler complex subunit","metadata":{"aliases":["DKFZp434A128","CILD14","FAP59","CFAP59"]}},{"id":"abd5202c9b2b4c19b042e788882a9f5b","type":"GENE","name":"CCDC39-AS1","canonical_id":"hgnc:HGNC:41089","description":"CCDC39 antisense RNA 1","metadata":null},{"id":"8ff2695106324ecf8cbff1b5f8d24665","type":"GENE","name":"CCDC40","canonical_id":"hgnc:HGNC:26090","description":"coiled-coil domain 40 molecular ruler complex subunit","metadata":{"aliases":["FLJ20753","KIAA1640","FLJ32021","CILD15","FAP172","CFAP172"]}},{"id":"63e54e459d1841d59282bdf2765b1b82","type":"GENE","name":"CCDC42","canonical_id":"hgnc:HGNC:26528","description":"coiled-coil domain containing 42","metadata":{"aliases":["FLJ32734","CCDC42A"]}},{"id":"09a5a97d4c4a437a8ebd8089654f7777","type":"GENE","name":"CCDC43","canonical_id":"hgnc:HGNC:26472","description":"coiled-coil domain containing 43","metadata":{"aliases":["FLJ31795"]}},{"id":"d0331ac6f2fa423babd5780f6eea8934","type":"GENE","name":"CCDC47","canonical_id":"hgnc:HGNC:24856","description":"coiled-coil domain containing 47","metadata":{"aliases":["GK001"]}},{"id":"6f5633cd2eae4b348d616c6e8407fd5c","type":"GENE","name":"CCDC50","canonical_id":"hgnc:HGNC:18111","description":"coiled-coil domain containing 50","metadata":{"aliases":["Ymer","C3orf6","DFNA44"]}},{"id":"d593345fbc824cfbaff251474eb1276f","type":"GENE","name":"CCDC51","canonical_id":"hgnc:HGNC:25714","description":"coiled-coil domain containing 51","metadata":{"aliases":["FLJ12436","MITOK"]}},{"id":"3aad724a375249c58d1d91f3a69a0383","type":"GENE","name":"CCDC54","canonical_id":"hgnc:HGNC:30703","description":"coiled-coil domain containing 54","metadata":{"aliases":["NYD-SP17","FLJ25362","SP17"]}},{"id":"7bc272abde3d4775b8b608f56604a5ab","type":"GENE","name":"CCDC54-AS1","canonical_id":"hgnc:HGNC:56107","description":"CCDC54 antisense RNA 1","metadata":null},{"id":"a2c2ce338bbf458daca77e2b1c299053","type":"GENE","name":"CCDC57","canonical_id":"hgnc:HGNC:27564","description":"coiled-coil domain containing 57","metadata":{"aliases":["FLJ00130","FLJ23754"]}},{"id":"e3f4b5d08cbf47c0acdedc8936289fe3","type":"GENE","name":"CCDC59","canonical_id":"hgnc:HGNC:25005","description":"coiled-coil domain containing 59","metadata":{"aliases":["HSPC128","TAP26","BR22"]}},{"id":"fb66e563375144f299031f92686a1e9a","type":"GENE","name":"CCDC59P1","canonical_id":"hgnc:HGNC:58666","description":"CCDC59 pseudogene 1","metadata":null},{"id":"911b73cc30174c8fb556b5d143376813","type":"GENE","name":"CCDC59P2","canonical_id":"hgnc:HGNC:58667","description":"CCDC59 pseudogene 2","metadata":null},{"id":"e5776a464c264f45aa698271350bc19e","type":"GENE","name":"CCDC6","canonical_id":"hgnc:HGNC:18782","description":"coiled-coil domain containing 6","metadata":{"aliases":["PTC","TPC","H4","PTC1","TST1","D10S170"]}},{"id":"09e44306ce6e4af98fbd62888d7ab385","type":"GENE","name":"CCDC60","canonical_id":"hgnc:HGNC:28610","description":"coiled-coil domain containing 60","metadata":{"aliases":["MGC39827"]}},{"id":"86066a669e584a84b8f46597613978d3","type":"GENE","name":"CCDC61","canonical_id":"hgnc:HGNC:33629","description":"coiled-coil domain containing 61","metadata":{"aliases":["VFL3","hVFL3"]}},{"id":"bab9b50bceec4320bc0985d8c0ce46e1","type":"GENE","name":"CCDC62","canonical_id":"hgnc:HGNC:30723","description":"coiled-coil domain containing 62","metadata":{"aliases":["TSP-NY","FLJ40344","CT109","ERAP75"]}},{"id":"262a991b55b647c1ac0674544f48f5df","type":"GENE","name":"CCDC63","canonical_id":"hgnc:HGNC:26669","description":"coiled-coil domain containing 63","metadata":{"aliases":["ODA5","FLJ35843"]}},{"id":"a05ddf3bb713480fa04f8444422573a6","type":"GENE","name":"CCDC66","canonical_id":"hgnc:HGNC:27709","description":"coiled-coil domain containing 66","metadata":{"aliases":["DKFZp686C0433"]}},{"id":"11877c2f4a8b4a44a39f75f761874708","type":"GENE","name":"CCDC68","canonical_id":"hgnc:HGNC:24350","description":"coiled-coil domain containing 68","metadata":{"aliases":["SE57-1"]}},{"id":"681a8af913c34dbfb88d2afe38a4978a","type":"GENE","name":"CCDC69","canonical_id":"hgnc:HGNC:24487","description":"coiled-coil domain containing 69","metadata":{"aliases":["FLJ13705","DKFZP434C171"]}},{"id":"5cf3bac8a2704fe38cf33dac157f4a72","type":"GENE","name":"CCDC7","canonical_id":"hgnc:HGNC:26533","description":"coiled-coil domain containing 7","metadata":{"aliases":["FLJ32762","FLJ13031","BIOT2","C10orf68"]}},{"id":"1b065b5ccbef452cbe991a39103b6fca","type":"GENE","name":"CCDC70","canonical_id":"hgnc:HGNC:25303","description":"coiled-coil domain containing 70","metadata":{"aliases":["DKFZP434K1172","FLJ25853"]}},{"id":"627157c05e50444b8b373dca7be0bbc7","type":"GENE","name":"CCDC71","canonical_id":"hgnc:HGNC:25760","description":"coiled-coil domain containing 71","metadata":{"aliases":["FLJ12800"]}},{"id":"20207d9c36404c71a6e2ef49684418af","type":"GENE","name":"CCDC71L","canonical_id":"hgnc:HGNC:26685","description":"coiled-coil domain containing 71 like","metadata":{"aliases":["FLJ36031","C7orf74"]}},{"id":"e0f4d201494e4df8ad359300e56d4b43","type":"GENE","name":"CCDC73","canonical_id":"hgnc:HGNC:23261","description":"coiled-coil domain containing 73","metadata":{"aliases":["NY-SAR-79"]}},{"id":"c1f78e42b9cd4f9f9dc396a125c60ca2","type":"GENE","name":"CCDC74A","canonical_id":"hgnc:HGNC:25197","description":"coiled-coil domain containing 74A","metadata":{"aliases":["FLJ40345"]}},{"id":"deb3efde13894296bdf3101313c70f81","type":"GENE","name":"CCDC74B","canonical_id":"hgnc:HGNC:25267","description":"coiled-coil domain containing 74B","metadata":{"aliases":["DKFZp434E2321"]}},{"id":"0daf2208481240afb094b6173510154d","type":"GENE","name":"CCDC74BP1","canonical_id":"hgnc:HGNC:51917","description":"coiled-coil domain containing 74B pseudogene 1","metadata":null},{"id":"72bce39241904afa8e4b70e347b0bb37","type":"GENE","name":"CCDC77","canonical_id":"hgnc:HGNC:28203","description":"coiled-coil domain containing 77","metadata":{"aliases":["MGC13183"]}},{"id":"e8a8bd4508194eab8d6bec84f0c1524f","type":"GENE","name":"CCDC78","canonical_id":"hgnc:HGNC:14153","description":"coiled-coil domain containing 78","metadata":{"aliases":["FLJ34512","C16orf25"]}},{"id":"4a41c3cd45514f92b77e5bad2fb1bd4f","type":"GENE","name":"CCDC8","canonical_id":"hgnc:HGNC:25367","description":"coiled-coil domain containing 8 subunit of 3M complex","metadata":{"aliases":["DKFZp564K0322","3M3","PPP1R20","p90"]}},{"id":"4ad573fceb4d4a5db43b5679fbdad526","type":"GENE","name":"CCDC80","canonical_id":"hgnc:HGNC:30649","description":"coiled-coil domain containing 80","metadata":{"aliases":["URB","SSG1","DRO1","CL2","TCONS_00006930","LINC01279"]}},{"id":"32171290f9cf429ea41cb435b56402da","type":"GENE","name":"CCDC81","canonical_id":"hgnc:HGNC:26281","description":"coiled-coil domain containing 81","metadata":{"aliases":["FLJ16339","FLJ23514"]}},{"id":"4e841d8c8b0f4df280e4ae23eae286bd","type":"GENE","name":"CCDC82","canonical_id":"hgnc:HGNC:26282","description":"coiled-coil domain containing 82","metadata":{"aliases":["FLJ23518"]}},{"id":"652398be52bf4aaab73064997bbaa9f8","type":"GENE","name":"CCDC83","canonical_id":"hgnc:HGNC:28535","description":"coiled-coil domain containing 83","metadata":{"aliases":["MGC34732","FLJ42119","CT148","KP-CoT-23"]}},{"id":"abc058cedd184f2fa4c8b375d2e1c7a3","type":"GENE","name":"CCDC85A","canonical_id":"hgnc:HGNC:29400","description":"coiled-coil domain containing 85A","metadata":{"aliases":["KIAA1912"]}},{"id":"04841a126aec4e4e969b3666a1295dab","type":"GENE","name":"CCDC85B","canonical_id":"hgnc:HGNC:24926","description":"coiled-coil domain containing 85B","metadata":{"aliases":["DIPA"]}},{"id":"814f727de4ea45528380ae682265bf08","type":"GENE","name":"CCDC85C","canonical_id":"hgnc:HGNC:35459","description":"coiled-coil domain containing 85C","metadata":null},{"id":"b959375b9a774394a63fdb63e6681087","type":"GENE","name":"CCDC86","canonical_id":"hgnc:HGNC:28359","description":"coiled-coil domain containing 86","metadata":{"aliases":["MGC2574","cyclon","Cgr1"]}},{"id":"f78bea1b7bf948ccb3a19b2791448b38","type":"GENE","name":"CCDC86-AS1","canonical_id":"hgnc:HGNC:56314","description":"CCDC86 antisense RNA 1","metadata":{"aliases":["RP5-1148A21.3","lncRP5"]}},{"id":"d8d9320774e0493893aacd7dd394a999","type":"GENE","name":"CCDC86P1","canonical_id":"hgnc:HGNC:58668","description":"CCDC86 pseudogene 1","metadata":null},{"id":"94cf2bb32c854d1e91949267451d81f8","type":"GENE","name":"CCDC86P2","canonical_id":"hgnc:HGNC:58669","description":"CCDC86 pseudogene 2","metadata":null},{"id":"6b096b99ee1c450a98c695fa3fedb8da","type":"GENE","name":"CCDC87","canonical_id":"hgnc:HGNC:25579","description":"coiled-coil domain containing 87","metadata":{"aliases":["FLJ10786"]}},{"id":"84dde9178efd4096a9416bab2c33a7a4","type":"GENE","name":"CCDC88A","canonical_id":"hgnc:HGNC:25523","description":"coiled-coil and HOOK domain protein 88A","metadata":{"aliases":["FLJ10392","APE","GIV","HkRP1","GRDN","KIAA1212"]}},{"id":"d75ad92cdb7b444b9cdebed6a9d5ef08","type":"GENE","name":"CCDC88B","canonical_id":"hgnc:HGNC:26757","description":"coiled-coil and HOOK domain protein 88B","metadata":{"aliases":["FLJ37970","BRLZ","HkRP3","FLJ00354","GIPIE","CCDC88"]}},{"id":"e6fefb61076b41e0b07fe84f28d8c0f3","type":"GENE","name":"CCDC88C","canonical_id":"hgnc:HGNC:19967","description":"coiled-coil and HOOK domain protein 88C","metadata":{"aliases":["DAPLE","HkRP2","SCA40","KIAA1509"]}},{"id":"746de033ddd9479183697377f4ff5690","type":"GENE","name":"CCDC88C-DT","canonical_id":"hgnc:HGNC:55438","description":"CCDC88C divergent transcript","metadata":null},{"id":"133d3b9cc2b24c7b8e092c092f3a69d4","type":"GENE","name":"CCDC89","canonical_id":"hgnc:HGNC:26762","description":"coiled-coil domain containing 89","metadata":{"aliases":["FLJ38159"]}},{"id":"bd14857d546b40e8b798b7948ac614a3","type":"GENE","name":"CCDC9","canonical_id":"hgnc:HGNC:24560","description":"coiled-coil domain containing 9","metadata":{"aliases":["DKFZP586M1019"]}},{"id":"11a0a193598b47ff947155c7eee6474b","type":"GENE","name":"CCDC90B","canonical_id":"hgnc:HGNC:28108","description":"coiled-coil domain containing 90B","metadata":{"aliases":["MDS025","MDS011"]}},{"id":"c8984a77f2e449ad90f628847ef25922","type":"GENE","name":"CCDC90B-AS1","canonical_id":"hgnc:HGNC:55505","description":"CCDC90B antisense RNA 1","metadata":null},{"id":"d1091c3e62074e26b61f7f465ef21c9a","type":"GENE","name":"CCDC91","canonical_id":"hgnc:HGNC:24855","description":"coiled-coil domain containing 91","metadata":{"aliases":["p56","FLJ11088","DKFZp779L1558"]}},{"id":"4374a8c2a6fe44e9b8b6cb2fb4786b2a","type":"GENE","name":"CCDC92","canonical_id":"hgnc:HGNC:29563","description":"coiled-coil domain containing 92","metadata":{"aliases":["FLJ22471"]}},{"id":"d128ece233f24404a81459572e930f71","type":"GENE","name":"CCDC92B","canonical_id":"hgnc:HGNC:52279","description":"coiled-coil domain containing 92B","metadata":null},{"id":"3c2a657a15a64a45861b91203fec041a","type":"GENE","name":"CCDC93","canonical_id":"hgnc:HGNC:25611","description":"CCC complex scaffolding subunit CCDC93","metadata":{"aliases":["FLJ10996"]}},{"id":"54ee65018887445da74d429e605a5925","type":"GENE","name":"CCDC97","canonical_id":"hgnc:HGNC:28289","description":"coiled-coil domain containing 97","metadata":{"aliases":["FLJ40267","MGC20255"]}},{"id":"fb36ee933a314f8ab69ef54ad35cf4d6","type":"GENE","name":"CCDC9B","canonical_id":"hgnc:HGNC:33488","description":"coiled-coil domain containing 9B","metadata":{"aliases":["FLJ43339","C15orf52"]}},{"id":"e0cc2099c3da4cf89c9131e43f6e643f","type":"GENE","name":"CCDST","canonical_id":"hgnc:HGNC:55988","description":"cervical cancer associated DHX9 suppressive transcript","metadata":{"aliases":["AL589986.2","lnc-CCDST","LINC02962","FLG-AS1"]}},{"id":"64381c76d76546538710d7fabe31db39","type":"GENE","name":"CCEPR","canonical_id":"hgnc:HGNC:51693","description":"cervical carcinoma expressed PCNA regulatory lncRNA","metadata":{"aliases":["CCHE1"]}},{"id":"d9dbb3be45f54662a71a16072e244efa","type":"GENE","name":"CCER1","canonical_id":"hgnc:HGNC:28373","description":"coiled-coil glutamate rich protein 1","metadata":{"aliases":["MGC26598","C12orf12"]}},{"id":"d7080bb533aa4627a0b5e60234342298","type":"GENE","name":"CCER2","canonical_id":"hgnc:HGNC:44662","description":"coiled-coil glutamate rich protein 2","metadata":null},{"id":"12f6c9532d1548a08841252e9ae3d9cb","type":"GO_TERM","name":"CCG codon-amino acid adaptor activity","canonical_id":"go:GO:0033424","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CCG codon.\" [GOC:mah]","metadata":null},{"id":"bb096f7557224fb28f26e4ad965d5925","type":"GENE","name":"CCHCR1","canonical_id":"hgnc:HGNC:13930","description":"coiled-coil alpha-helical rod protein 1","metadata":{"aliases":["HCR","C6orf18"]}},{"id":"1148a1d10c6a4a7d999d788529b45af8","type":"TRIAL","name":"CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00079235","description":"Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer","metadata":null},{"id":"04637c15861444cc95a094620b20c20b","type":"GENE","name":"CCIN","canonical_id":"hgnc:HGNC:1568","description":"calicin","metadata":{"aliases":["KBTBD14","BTBD20"]}},{"id":"8f0619623b7046149183f20a4c2d2e43","type":"GENE","name":"CCK","canonical_id":"hgnc:HGNC:1569","description":null,"metadata":null},{"id":"4d27e4cc914b4cc2a9e44ac81c11a56a","type":"GENE","name":"CCKAR","canonical_id":"hgnc:HGNC:1570","description":"cholecystokinin A receptor","metadata":{"aliases":["CCK1R","CCK-AR","CCK-1R"]}},{"id":"022735cef41c4d9bb9ca1dac924ed2bf","type":"GENE","name":"CCKBR","canonical_id":"hgnc:HGNC:1571","description":"cholecystokinin B receptor","metadata":{"aliases":["CCK2R","GASR","CCK-BR","CCK-2R"]}},{"id":"ea2f1cec23b1415a8414ea5333252d5a","type":"GENE","name":"CCL1","canonical_id":"hgnc:HGNC:10609","description":"C-C motif chemokine ligand 1","metadata":{"aliases":["I-309","TCA3","P500","SISe","SCYA1"]}},{"id":"95ec384d94a54bb6b705c2b93b808219","type":"GENE","name":"CCL11","canonical_id":"hgnc:HGNC:10610","description":null,"metadata":null},{"id":"8274dfc7a9cf4699b756bffdbab69bd8","type":"GENE","name":"CCL13","canonical_id":"hgnc:HGNC:10611","description":null,"metadata":null},{"id":"5310c8165f864ac580a2d0374fd68d98","type":"GENE","name":"CCL14","canonical_id":"hgnc:HGNC:10612","description":"C-C motif chemokine ligand 14","metadata":{"aliases":["HCC-1","HCC-3","NCC-2","SCYL2","CKb1","MCIF","SCYA14"]}},{"id":"6fa16e4883874d99810aec0f07ae09b4","type":"GENE","name":"CCL15","canonical_id":"hgnc:HGNC:10613","description":"C-C motif chemokine ligand 15","metadata":{"aliases":["HCC-2","NCC-3","SCYL3","MIP-5","Lkn-1","MIP-1d","HMRP-2B","SCYA15"]}},{"id":"26e24a35e5f94158a7ddbd35b5a884e3","type":"GENE","name":"CCL15-CCL14","canonical_id":"hgnc:HGNC:44436","description":"CCL15-CCL14 readthrough (NMD candidate)","metadata":null},{"id":"ef3870ec764e4873a90ece663e4f7c01","type":"GENE","name":"CCL16","canonical_id":"hgnc:HGNC:10614","description":"C-C motif chemokine ligand 16","metadata":{"aliases":["NCC-4","SCYL4","LEC","HCC-4","LMC","LCC-1","CKb12","Mtn-1","SCYA16"]}},{"id":"fc338ecb42b04389a2ac744dce222da5","type":"GENE","name":"CCL17","canonical_id":"hgnc:HGNC:10615","description":null,"metadata":null},{"id":"2dcff78c24f5480a81eef826ab86eece","type":"GENE","name":"CCL18","canonical_id":"hgnc:HGNC:10616","description":"C-C motif chemokine ligand 18","metadata":{"aliases":["DC-CK1","PARC","AMAC-1","DCCK1","MIP-4","CKb7","SCYA18"]}},{"id":"f608caf9d31e4512b9bc825a6318d47a","type":"GENE","name":"CCL19","canonical_id":"hgnc:HGNC:10617","description":null,"metadata":null},{"id":"42f613a14b8b4035aa575297eb6481ca","type":"GO_TERM","name":"CCL19-activated CCR7 signaling pathway","canonical_id":"go:GO:0038119","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL19 to a C-C chemokine type 7 receptor (CCR7) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:15059845]","metadata":null},{"id":"ef4022eb11d7419dba1120258fabe49f","type":"GENE","name":"CCL2","canonical_id":"hgnc:HGNC:10618","description":null,"metadata":null},{"id":"939055b5d6e4456ead76a39cd540bffd","type":"GO_TERM","name":"CCL2-activated CCR2 signaling pathway","canonical_id":"go:GO:0038151","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL2 to a C-C chemokine type 2 receptor (CCR2) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"d722a56dd59b4a5aaa4e9facb4ca64ff","type":"GO_TERM","name":"CCL2-activated CCR4 signaling pathway","canonical_id":"go:GO:0038153","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL2 to a C-C chemokine type 4 receptor (CCR4) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"92d88477c46b4b00aa21e4c6c236f3b5","type":"GENE","name":"CCL20","canonical_id":"hgnc:HGNC:10619","description":null,"metadata":null},{"id":"d18037ff05e6423c8cb97a8296efe27b","type":"GENE","name":"CCL21","canonical_id":"hgnc:HGNC:10620","description":null,"metadata":null},{"id":"9a42151646ee4b92b192fa2dd8f7786c","type":"GO_TERM","name":"CCL21-activated CCR7 signaling pathway","canonical_id":"go:GO:0038120","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL21 to a C-C chemokine type 7 receptor (CCR7) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:15059845]","metadata":null},{"id":"0de6a2361e9649f2b72c82e48b67c246","type":"GENE","name":"CCL22","canonical_id":"hgnc:HGNC:10621","description":null,"metadata":null},{"id":"efa25c67dbbe41358552468ba3ad278e","type":"GENE","name":"CCL23","canonical_id":"hgnc:HGNC:10622","description":"C-C motif chemokine ligand 23","metadata":{"aliases":["Ckb-8","MPIF-1","MIP-3","CKb8","SCYA23"]}},{"id":"7482cdd52b664e8fb21e08ebda0a70ea","type":"GENE","name":"CCL24","canonical_id":"hgnc:HGNC:10623","description":"C-C motif chemokine ligand 24","metadata":{"aliases":["Ckb-6","MPIF-2","eotaxin-2","MPIF2","SCYA24"]}},{"id":"c148b680d90e4862856bbc38d0b476b0","type":"GENE","name":"CCL25","canonical_id":"hgnc:HGNC:10624","description":"C-C motif chemokine ligand 25","metadata":{"aliases":["TECK","Ckb15","SCYA25"]}},{"id":"e0de3c17069240a399b26f684671ee07","type":"GENE","name":"CCL26","canonical_id":"hgnc:HGNC:10625","description":null,"metadata":null},{"id":"122c2d80946146c8a24a622ee5547f87","type":"GENE","name":"CCL27","canonical_id":"hgnc:HGNC:10626","description":"C-C motif chemokine ligand 27","metadata":{"aliases":["ALP","ILC","CTACK","skinkine","ESkine","PESKY","CTAK","SCYA27"]}},{"id":"2e02c50dcddc4110bea7de244d55f7b7","type":"GENE","name":"CCL28","canonical_id":"hgnc:HGNC:17700","description":"C-C motif chemokine ligand 28","metadata":{"aliases":["SCYA28","MEC","CCK1"]}},{"id":"474d23daec894299b9b61ef0db50fbca","type":"GENE","name":"CCL3","canonical_id":"hgnc:HGNC:10627","description":null,"metadata":null},{"id":"3cd7eb8c122441f4a9d5e8a4394ed51e","type":"GENE","name":"CCL3-AS1","canonical_id":"hgnc:HGNC:55229","description":"CCL3 antisense RNA 1","metadata":null},{"id":"4d362ce1d5194a24a925f95b07fc9c10","type":"GENE","name":"CCL3L1","canonical_id":"hgnc:HGNC:10628","description":"C-C motif chemokine ligand 3 like 1","metadata":{"aliases":["G0S19-2","LD78BETA","D17S1718","SCYA3L","SCYA3L1"]}},{"id":"254593e34f0549408fd984f5b7097c9a","type":"GENE","name":"CCL3L3","canonical_id":"hgnc:HGNC:30554","description":"C-C motif chemokine ligand 3 like 3","metadata":{"aliases":["MGC12815"]}},{"id":"a19074fa83064e83b21d60b53f963e80","type":"GENE","name":"CCL3P1","canonical_id":"hgnc:HGNC:10629","description":"C-C motif chemokine ligand 3 pseudogene 1","metadata":{"aliases":["LD78gamma","SCYA3L2","CCL3L2"]}},{"id":"164da902a29d4067916a0306b94877fb","type":"GENE","name":"CCL4","canonical_id":"hgnc:HGNC:10630","description":null,"metadata":null},{"id":"32363bc7ac054c2283c40d3c128cb31f","type":"GENE","name":"CCL4L1","canonical_id":"hgnc:HGNC:10631","description":"C-C motif chemokine ligand 4 like 1","metadata":{"aliases":["AT744.2","LAG-1","SCYA4L","CCL4L"]}},{"id":"8c01b866e26b4132b82fcb5b34659985","type":"GENE","name":"CCL4L2","canonical_id":"hgnc:HGNC:24066","description":"C-C motif chemokine ligand 4 like 2","metadata":null},{"id":"013fb6b1067548dfa02c037165cbcf90","type":"GENE","name":"CCL5","canonical_id":"hgnc:HGNC:10632","description":null,"metadata":null},{"id":"94b794745b004952a8cf1e9f2babc3da","type":"GENE","name":"CCL5-AS1","canonical_id":"hgnc:HGNC:58767","description":"CCL5 regulatory antisense RNA 1","metadata":{"aliases":["lncTAF15:1-1"]}},{"id":"53d3e7cdbac047e79c7e0f807de7b767","type":"GENE","name":"CCL7","canonical_id":"hgnc:HGNC:10634","description":null,"metadata":null},{"id":"a81d2009be404922ab7a55e34e8f9bbc","type":"GENE","name":"CCL8","canonical_id":"hgnc:HGNC:10635","description":"C-C motif chemokine ligand 8","metadata":{"aliases":["MCP-2","HC14","SCYA8"]}},{"id":"c568093eb21a40c29ee40e1143b42aa5","type":"GENE","name":"CCM2","canonical_id":"hgnc:HGNC:21708","description":"CCM2 scaffold protein","metadata":{"aliases":["MGC4607","OSM","C7orf22"]}},{"id":"207a33c58f1f48179d5572ab859868bb","type":"GENE","name":"CCM2L","canonical_id":"hgnc:HGNC:16153","description":"CCM2 like scaffold protein","metadata":{"aliases":["dJ310O13.5","C20orf160"]}},{"id":"c3cf7492e9fb4d5a95e9b54199fbb57e","type":"GENE","name":"CCM2L-AS1","canonical_id":"hgnc:HGNC:58356","description":"CCM2L antisense RNA 1","metadata":null},{"id":"8ae2d2100c06404bb0907ab91df40c68","type":"TRIAL","name":"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy","canonical_id":"clinicaltrials.gov:NCT05131828","description":"Multiple Sclerosis","metadata":null},{"id":"f46eebb9556f44abafa0820aff12d9de","type":"GENE","name":"CCN2-AS1","canonical_id":"hgnc:HGNC:40164","description":"CCN2 antisense RNA 1","metadata":{"aliases":["AL133346.1"]}},{"id":"cfd0d6a271724a7a8472eef5812bd136","type":"GENE","name":"CCN3","canonical_id":"hgnc:HGNC:7885","description":"cellular communication network factor 3","metadata":{"aliases":["IGFBP9","NOV"]}},{"id":"d00f1f1ee4d040cdaa2e301788058ef3","type":"GENE","name":"CCN4","canonical_id":"hgnc:HGNC:12769","description":"cellular communication network factor 4","metadata":{"aliases":["WISP-1","WISP1-OT1","WISP1-UT1","WISP1"]}},{"id":"41fc84c7fdf94f3aa47e84e52ea89bc6","type":"GENE","name":"CCN6","canonical_id":"hgnc:HGNC:12771","description":"cellular communication network factor 6","metadata":{"aliases":["WISP-3","WISP3"]}},{"id":"ba1a7be5f3a84c0e9939d6b1fdd1a324","type":"GENE","name":"CCNA1","canonical_id":"hgnc:HGNC:1577","description":null,"metadata":null},{"id":"ba02d2b2e7c0424b8ece2c9cb36ead2b","type":"GENE","name":"CCNA2","canonical_id":"hgnc:HGNC:1578","description":null,"metadata":null},{"id":"b52c6fb27dea4dae967074c110fb5324","type":"GENE","name":"CCNB1","canonical_id":"hgnc:HGNC:1579","description":null,"metadata":null},{"id":"50bd4d0d960a4ff9b245a124d99447e1","type":"GENE","name":"CCNB1IP1","canonical_id":"hgnc:HGNC:19437","description":"cyclin B1 interacting protein 1","metadata":{"aliases":["HEI10","C14orf18"]}},{"id":"490a30f33a3e47a18d19adde2eeddf48","type":"GENE","name":"CCNB1IP1P1","canonical_id":"hgnc:HGNC:37693","description":"cyclin B1 interacting protein 1 pseudogene 1","metadata":null},{"id":"8d8d5a163cbd4b9cae3d2c7293a3fdb7","type":"GENE","name":"CCNB1IP1P2","canonical_id":"hgnc:HGNC:37694","description":"cyclin B1 interacting protein 1 pseudogene 2","metadata":null},{"id":"4e21e36823d84a98b2043304288f9adc","type":"GENE","name":"CCNB1IP1P3","canonical_id":"hgnc:HGNC:37695","description":"cyclin B1 interacting protein 1 pseudogene 3","metadata":null},{"id":"0437f2c1ee1b46639af8c0a5fb5d1222","type":"GENE","name":"CCNB2","canonical_id":"hgnc:HGNC:1580","description":null,"metadata":null},{"id":"691759fafab6481a8e9b870fe18879f9","type":"GENE","name":"CCNB2P1","canonical_id":"hgnc:HGNC:50850","description":"cyclin B2 pseudogene 1","metadata":null},{"id":"d58dfd6e479f498baa1b90bd779ecddd","type":"GENE","name":"CCNB3","canonical_id":"hgnc:HGNC:18709","description":"cyclin B3","metadata":{"aliases":["CYCB3"]}},{"id":"225d4437d8014185ab94ae15d0777208","type":"GENE","name":"CCNB3P1","canonical_id":"hgnc:HGNC:50851","description":"cyclin B3 pseudogene 1","metadata":null},{"id":"6d14790546e9494e9a101b0cde373370","type":"GENE","name":"CCNC","canonical_id":"hgnc:HGNC:1581","description":null,"metadata":null},{"id":"9bfc039ad85040b88f02072e7d1589a8","type":"GENE","name":"CCND1","canonical_id":"hgnc:HGNC:1582","description":null,"metadata":null},{"id":"24556ea9c3ce4d62ba1146270dda3124","type":"GENE","name":"CCND1","canonical_id":"ensembl:ENSG00000110092","description":null,"metadata":null},{"id":"14aa61f212e6422d81ad9643c145ec0f","type":"PROTEIN","name":"CCND1","canonical_id":"uniprot:P24385","description":null,"metadata":null},{"id":"585e6b71803849488f7dc383ffee97fc","type":"GENE","name":"CCND2","canonical_id":"hgnc:HGNC:1583","description":null,"metadata":null},{"id":"2ba11c071dfd4cf1b6546f63fd0676c3","type":"GENE","name":"CCND2-AS1","canonical_id":"hgnc:HGNC:49398","description":"CCND2 antisense RNA 1","metadata":{"aliases":["CCND2-AS2"]}},{"id":"7f4d884b859544c8b799cd083e2c46ba","type":"GENE","name":"CCND2P1","canonical_id":"hgnc:HGNC:1584","description":"cyclin D2 pseudogene 1","metadata":{"aliases":["CCND2P"]}},{"id":"4ae5f78ce2a84da585985d609210f167","type":"GENE","name":"CCND3","canonical_id":"hgnc:HGNC:1585","description":null,"metadata":null},{"id":"3767dd4a782342e793605d7ca5c6b810","type":"GENE","name":"CCND3-AS1","canonical_id":"hgnc:HGNC:59403","description":"CCND3 antisense RNA 1","metadata":null},{"id":"f1d39b029ce34af897dc846ad38b931e","type":"GENE","name":"CCND3-AS2","canonical_id":"hgnc:HGNC:59404","description":"CCND3 antisense RNA 2","metadata":null},{"id":"371ed47fba2149f4af11ac5fd7b4a560","type":"GENE","name":"CCND3P1","canonical_id":"hgnc:HGNC:1586","description":"cyclin D3 pseudogene 1","metadata":{"aliases":["CCND3P"]}},{"id":"c602729edb3b4c5a8223f0bb08b4ec2a","type":"GENE","name":"CCND3P2","canonical_id":"hgnc:HGNC:50852","description":"cyclin D3 pseudogene 2","metadata":null},{"id":"276bb4ed148b4e37b7f408d1a43c52b0","type":"GENE","name":"CCNDBP1","canonical_id":"hgnc:HGNC:1587","description":"cyclin D1 binding protein 1","metadata":{"aliases":["DIP1","GCIP","HHM"]}},{"id":"59b67a98e0954064b4639ce73ed6b522","type":"GENE","name":"CCNE1","canonical_id":"hgnc:HGNC:1589","description":null,"metadata":null},{"id":"8ea45046ddaf4e89b9b52142f846c868","type":"GENE","name":"CCNE2","canonical_id":"hgnc:HGNC:1590","description":null,"metadata":null},{"id":"5a8b4393441e4e90b075448685aa743b","type":"GENE","name":"CCNF","canonical_id":"hgnc:HGNC:1591","description":"cyclin F","metadata":{"aliases":["FBX1","FBXO1"]}},{"id":"956a914dc074498eb4bd0be50b00197c","type":"GENE","name":"CCNG1","canonical_id":"hgnc:HGNC:1592","description":"cyclin G1","metadata":{"aliases":["CCNG"]}},{"id":"9ecaad48d10a4542ab040e2645d704e6","type":"GENE","name":"CCNG1P1","canonical_id":"hgnc:HGNC:39177","description":"cyclin G1 pseudogene 1","metadata":null},{"id":"1c457109dcab4f54981777328a9aaa57","type":"GENE","name":"CCNG2","canonical_id":"hgnc:HGNC:1593","description":null,"metadata":null},{"id":"fa591a45ce004c7d85d951bbe6755e12","type":"GENE","name":"CCNG2-AS1","canonical_id":"hgnc:HGNC:58829","description":"CCNG2 antisense RNA 1","metadata":null},{"id":"b9b98ab39f8b4fb2b28e9f84b72c4c04","type":"GENE","name":"CCNG2P1","canonical_id":"hgnc:HGNC:50853","description":"cyclin G2 pseudogene 1","metadata":null},{"id":"96e5dc89a08a44e09d9f6a27af186640","type":"GENE","name":"CCNH","canonical_id":"hgnc:HGNC:1594","description":"cyclin H","metadata":{"aliases":["p34","p37","CycH"]}},{"id":"2639c0b09a3a45deb52e6a850f7d8fc6","type":"GENE","name":"CCNH-AS1","canonical_id":"hgnc:HGNC:59091","description":"CCNH antisense RNA 1","metadata":null},{"id":"ee09bb0006de414f97f5cb023c797e1d","type":"GENE","name":"CCNHP1","canonical_id":"hgnc:HGNC:50854","description":"cyclin H pseudogene 1","metadata":null},{"id":"21bf0c30758449088ecb63cf7d1d6324","type":"GENE","name":"CCNI","canonical_id":"hgnc:HGNC:1595","description":"cyclin I","metadata":{"aliases":["CCNI1"]}},{"id":"dd642251663e4a029b3b9d5090206da3","type":"GENE","name":"CCNI-AS1","canonical_id":"hgnc:HGNC:58826","description":"CCNI antisense RNA 1","metadata":null},{"id":"fae469bbcdb74aa9b22b2f65d15c1057","type":"GENE","name":"CCNI-AS2","canonical_id":"hgnc:HGNC:58827","description":"CCNI antisense RNA 2","metadata":null},{"id":"4884adbe9e6f4c388362f8dc66c0ca05","type":"GENE","name":"CCNI-DT","canonical_id":"hgnc:HGNC:58828","description":"CCNI divergent transcript","metadata":null},{"id":"805decfb19a744ce9842588a7a5332c9","type":"GENE","name":"CCNI2","canonical_id":"hgnc:HGNC:33869","description":"cyclin I family member 2","metadata":{"aliases":["FLJ16793"]}},{"id":"87e189d5f4a245bd9c183223bc26aa63","type":"GENE","name":"CCNJ","canonical_id":"hgnc:HGNC:23434","description":"cyclin J","metadata":{"aliases":["FLJ10895","bA690P14.1"]}},{"id":"48913d2268434f1180a64d398b8e3279","type":"GENE","name":"CCNJL","canonical_id":"hgnc:HGNC:25876","description":"cyclin J like","metadata":{"aliases":["FLJ14166"]}},{"id":"86779295b65f4202b559a449e1f8fdf7","type":"GENE","name":"CCNJP1","canonical_id":"hgnc:HGNC:22512","description":"cyclin J pseudogene 1","metadata":{"aliases":["CCNJP"]}},{"id":"271f9123c1d049ba8c043472437e4c4e","type":"GENE","name":"CCNJP2","canonical_id":"hgnc:HGNC:37997","description":"cyclin J pseudogene 2","metadata":null},{"id":"69ef76925ce848119f7fad4824b1103e","type":"GENE","name":"CCNK","canonical_id":"hgnc:HGNC:1596","description":"cyclin K","metadata":{"aliases":["CPR4"]}},{"id":"88e418f9426d4812bf727a704b30fe46","type":"GENE","name":"CCNL1","canonical_id":"hgnc:HGNC:20569","description":"cyclin L1","metadata":{"aliases":["ania-6a"]}},{"id":"4f300e5129ab4a64aee81a6a3bfff825","type":"GENE","name":"CCNL2","canonical_id":"hgnc:HGNC:20570","description":"cyclin L2","metadata":{"aliases":["ania-6b","PCEE","SB138","HLA-ISO","CCNS","CCNM"]}},{"id":"565beb5ef67d41a588704a0583a5b747","type":"GENE","name":"CCNL2P1","canonical_id":"hgnc:HGNC:50855","description":"cyclin L2 pseudogene 1","metadata":null},{"id":"1fb2a5ad62614b0ba5178efe0333d0c1","type":"GENE","name":"CCNO","canonical_id":"hgnc:HGNC:18576","description":"cyclin O","metadata":{"aliases":["UDG2","FLJ22422","UNG2","CCNU"]}},{"id":"2b877d42b19441bba4b11382a5d781a7","type":"GENE","name":"CCNO-DT","canonical_id":"hgnc:HGNC:55543","description":"CCNO divergent transcript","metadata":null},{"id":"6d93d2fa42954ea782db80c38dc39433","type":"GENE","name":"CCNP","canonical_id":"hgnc:HGNC:25805","description":"cyclin P","metadata":{"aliases":["FLJ13265","CNTD2"]}},{"id":"469692e6f4264be581265b84ccd38224","type":"GENE","name":"CCNQ","canonical_id":"hgnc:HGNC:28434","description":"cyclin Q","metadata":{"aliases":["CycM","FAM58A"]}},{"id":"a749abf204a94479a841bb2dafbb3a0d","type":"GENE","name":"CCNQP1","canonical_id":"hgnc:HGNC:27373","description":"CCNQ pseudogene 1","metadata":{"aliases":["FAM58B","FAM58BP"]}},{"id":"a28d3529c9134a77b6cc406ae7e1bd19","type":"GENE","name":"CCNQP2","canonical_id":"hgnc:HGNC:38436","description":"CCNQ pseudogene 2","metadata":{"aliases":["FAM58Y","FAM58AP1","FAM58CP"]}},{"id":"b6d96b809f2d4b098cfee7db8d4f0e00","type":"GENE","name":"CCNQP3","canonical_id":"hgnc:HGNC:42022","description":"CCNQ pseudogene 3","metadata":{"aliases":["FAM58DP"]}},{"id":"2c5274fa114c4cd1adaf8c1ea197e917","type":"GENE","name":"CCNT1","canonical_id":"hgnc:HGNC:1599","description":null,"metadata":null},{"id":"b08b3bbc7f3e4c20badbd5ae496bad09","type":"GENE","name":"CCNT2","canonical_id":"hgnc:HGNC:1600","description":"cyclin T2","metadata":null},{"id":"fb013f4625af4648893c44a01c662961","type":"GENE","name":"CCNT2-AS1","canonical_id":"hgnc:HGNC:40130","description":"CCNT2 antisense RNA 1","metadata":null},{"id":"340342f5eb7041c2817c5763a384254d","type":"GENE","name":"CCNT2P1","canonical_id":"hgnc:HGNC:39178","description":"cyclin T2 pseudogene 1","metadata":null},{"id":"de509463d3e14f198d2c2cc30c1d823c","type":"GENE","name":"CCNY","canonical_id":"hgnc:HGNC:23354","description":"cyclin Y","metadata":{"aliases":["CFP1","CBCP1","C10orf9"]}},{"id":"81711bde27084d6f9d772ec924cbc223","type":"GENE","name":"CCNY-AS1","canonical_id":"hgnc:HGNC:55252","description":"CCNY antisense RNA 1","metadata":{"aliases":["AL117336.3","LINC02634"]}},{"id":"d8a2bb4b85cb48f1bb358ad7fd90774a","type":"GENE","name":"CCNYL1","canonical_id":"hgnc:HGNC:26868","description":"cyclin Y like 1","metadata":{"aliases":["FLJ40432"]}},{"id":"6d097ffbdacc4943a92a1e0fbbeee2fc","type":"GENE","name":"CCNYL1B","canonical_id":"hgnc:HGNC:56313","description":"cyclin Y like 1B","metadata":null},{"id":"d3249795cc51413fb36f49237102158d","type":"GENE","name":"CCNYL2","canonical_id":"hgnc:HGNC:23495","description":"cyclin Y like 2 (pseudogene)","metadata":{"aliases":["bA178A10.2","CCNYL2P","C10orf21"]}},{"id":"eed0f16517ef42c0bcd7f7bde2ca6a15","type":"GENE","name":"CCNYL3","canonical_id":"hgnc:HGNC:33206","description":"cyclin Y like 3 (pseudogene)","metadata":null},{"id":"baec642837d74cf8be4448611d3035be","type":"GENE","name":"CCNYL4","canonical_id":"hgnc:HGNC:54655","description":"cyclin Y like 4 (pseudogene)","metadata":null},{"id":"011633ed25ce4ab3b0fd5e1bf9465ff2","type":"GENE","name":"CCNYL5","canonical_id":"hgnc:HGNC:54656","description":"cyclin Y like 5 (pseudogene)","metadata":null},{"id":"b646d21a7e22428da832f9df37b6c24c","type":"GENE","name":"CCNYL6","canonical_id":"hgnc:HGNC:54657","description":"cyclin Y like 6 (pseudogene)","metadata":null},{"id":"827ffbeb3fe748748927fa1807b42627","type":"GENE","name":"CCNYL7","canonical_id":"hgnc:HGNC:54659","description":"cyclin Y like 7 (pseudogene)","metadata":null},{"id":"94882e144abf47ea9e9abe89c9ee5bfd","type":"GENE","name":"CCP110","canonical_id":"hgnc:HGNC:24342","description":"centriolar coiled-coil protein 110","metadata":{"aliases":["KIAA0419","CP110"]}},{"id":"786054aaebdb46b9980b8b83d1df1114","type":"GENE","name":"CCPG1","canonical_id":"hgnc:HGNC:24227","description":"cell cycle progression 1","metadata":{"aliases":["KIAA1254","CPR8"]}},{"id":"dcc5bf87785d46008ff16a924c0d92f1","type":"GO_TERM","name":"CCR chemokine receptor binding","canonical_id":"go:GO:0048020","description":"\"Binding to a CCR chemokine receptor.\" [GOC:ai]","metadata":null},{"id":"9d210e7821044137b4f48cb2933de27a","type":"GENE","name":"CCR1","canonical_id":"hgnc:HGNC:1602","description":null,"metadata":null},{"id":"0e67ae36da684fdb9290909978ca0d79","type":"GO_TERM","name":"CCR1 chemokine receptor binding","canonical_id":"go:GO:0031726","description":"\"Binding to a CCR1 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"8782887806fb47aa84c082f38463fc18","type":"GENE","name":"CCR10","canonical_id":"hgnc:HGNC:4474","description":"C-C motif chemokine receptor 10","metadata":{"aliases":["GPR2"]}},{"id":"a0a44a2711ce47afaa4617c8525c4bee","type":"GO_TERM","name":"CCR10 chemokine receptor binding","canonical_id":"go:GO:0031735","description":"\"Binding to a CCR10 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"525c8e2878674098b12146b59927df55","type":"GO_TERM","name":"CCR11 chemokine receptor binding","canonical_id":"go:GO:0031736","description":"\"Binding to a CCR11 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a4e4d4cce57043d8bc6e528c49c94d8a","type":"GENE","name":"CCR12P","canonical_id":"hgnc:HGNC:39812","description":"C-C motif chemokine receptor 12, pseudogene","metadata":{"aliases":["GPR183P1"]}},{"id":"44792c83c67444d99a4eeb32183528ab","type":"GENE","name":"CCR2","canonical_id":"hgnc:HGNC:1603","description":null,"metadata":null},{"id":"2d1a5edd6b99472bb29a78bd19ddcdac","type":"GO_TERM","name":"CCR2 chemokine receptor binding","canonical_id":"go:GO:0031727","description":"\"Binding to a CCR2 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"5c74be0342904ab5ae47740feff4e6a7","type":"GENE","name":"CCR3","canonical_id":"hgnc:HGNC:1604","description":null,"metadata":null},{"id":"b1c7a2ae5b044494b723017dc808fff3","type":"GO_TERM","name":"CCR3 chemokine receptor binding","canonical_id":"go:GO:0031728","description":"\"Binding to a CCR3 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6582ae16b0954b269e89e39f5fc4538d","type":"GENE","name":"CCR4","canonical_id":"hgnc:HGNC:1605","description":null,"metadata":null},{"id":"c472d012df3f4affbeb50674d5a97398","type":"PROTEIN","name":"CCR4","canonical_id":"uniprot:P51679","description":null,"metadata":null},{"id":"77234740759a44318d051196d9e81f41","type":"GO_TERM","name":"CCR4 chemokine receptor binding","canonical_id":"go:GO:0031729","description":"\"Binding to a CCR4 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ed17c5b7840540caba9da825108b2e2e","type":"GO_TERM","name":"CCR4-NOT complex","canonical_id":"go:GO:0030014","description":"\"The Ccr4-Not complex is an eukaryotically conserved deadenylase that can initiate cytoplasmic mRNA decay, and reduce translation by releasing poly(A)-binding protein (Pab1/PABPC1). Ccr4-Not contains seven core subunits, including two poly(A)-specific exonucleases, Ccr4/CNOT6/CNOT6L and Caf1/Pop2/CNOT7/CNOT8.\" [GOC:sart, PMID:11113136, PMID:11239395, PMID:22785621, PMID:30601114]","metadata":null},{"id":"823cded9b0544c88a59ceb08f82ce746","type":"GO_TERM","name":"CCR4-NOT complex binding","canonical_id":"go:GO:1905762","description":"\"Binding to a CCR4-NOT complex.\" [GOC:TermGenie, PMID:26942678]","metadata":null},{"id":"84bd6e8224e448e48b0d1819b65238aa","type":"GO_TERM","name":"CCR4-NOT core complex","canonical_id":"go:GO:0030015","description":"\"The core of the CCR4-NOT complex. In Saccharomyces the CCR4-NOT core complex comprises Ccr4p, Caf1p, Caf40p, Caf130p, Not1p, Not2p, Not3p, Not4p, and Not5p.\" [GOC:sart, PMID:11113136]","metadata":null},{"id":"6e702ff55e92409790631b0750f0615c","type":"GENE","name":"CCR5","canonical_id":"hgnc:HGNC:1606","description":null,"metadata":null},{"id":"fee8da2758664abb987bea57393a5977","type":"PROTEIN","name":"CCR5","canonical_id":"uniprot:P51681","description":null,"metadata":null},{"id":"11ccb84b235344d0b5989bf765ee25a3","type":"GO_TERM","name":"CCR5 chemokine receptor binding","canonical_id":"go:GO:0031730","description":"\"Binding to a CCR5 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"62cac1b0fac6410084cddb435290e156","type":"GENE","name":"CCR5AS","canonical_id":"hgnc:HGNC:54398","description":"CCR5 antisense RNA","metadata":null},{"id":"2b470bea81554e1ebd1cad3c94e41543","type":"GENE","name":"CCR6","canonical_id":"hgnc:HGNC:1607","description":null,"metadata":null},{"id":"3bc20d37126a41ca8dc46f0866bb30a8","type":"GO_TERM","name":"CCR6 chemokine receptor binding","canonical_id":"go:GO:0031731","description":"\"Binding to a CCR6 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"468818f1cec7476fa76ef6fe3b256d42","type":"GENE","name":"CCR7","canonical_id":"hgnc:HGNC:1608","description":null,"metadata":null},{"id":"0c8df9fa6b984022b38f9d2f7f793459","type":"GO_TERM","name":"CCR7 chemokine receptor binding","canonical_id":"go:GO:0031732","description":"\"Binding to a CCR7 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e053dd3eba6b4fc6904e88f52285494e","type":"GENE","name":"CCR8","canonical_id":"hgnc:HGNC:1609","description":"C-C motif chemokine receptor 8","metadata":{"aliases":["CY6","TER1","CKR-L1","GPR-CY6","CDw198","CMKBRL2","CMKBR8"]}},{"id":"62cc0d6b23d6486fb64b7f20330fa7f3","type":"GO_TERM","name":"CCR8 chemokine receptor binding","canonical_id":"go:GO:0031733","description":"\"Binding to a CCR8 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d7a8100370194f81a20fdbd5b7eed98b","type":"GENE","name":"CCR9","canonical_id":"hgnc:HGNC:1610","description":"C-C motif chemokine receptor 9","metadata":{"aliases":["GPR-9-6","CDw199","GPR28"]}},{"id":"aba37654e55949658ecfc7e1a863fd50","type":"GO_TERM","name":"CCR9 chemokine receptor binding","canonical_id":"go:GO:0031734","description":"\"Binding to a CCR9 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cb3ada1bf60b441686e7804e9d31b0ce","type":"GENE","name":"CCRL2","canonical_id":"hgnc:HGNC:1612","description":"C-C motif chemokine receptor like 2","metadata":{"aliases":["HCR","CRAM-B","CKRX","CRAM-A","ACKR5"]}},{"id":"4df602e37c484a4e8ef444d0a1ef237f","type":"GENE","name":"CCS","canonical_id":"hgnc:HGNC:1613","description":"copper chaperone for superoxide dismutase","metadata":null},{"id":"378b1fbb9e5849278bc271cc0721aee6","type":"GENE","name":"CCSAP","canonical_id":"hgnc:HGNC:29578","description":"centriole, cilia and spindle associated protein","metadata":{"aliases":["FLJ41471","CSAP","C1orf96"]}},{"id":"c927f0c19c8e42d68039739a44972150","type":"GENE","name":"CCSER1","canonical_id":"hgnc:HGNC:29349","description":"coiled-coil serine rich protein 1","metadata":{"aliases":["KIAA1680","FAM190A"]}},{"id":"15a1aed3bd3f43ea88dc45560fa4d1ac","type":"GENE","name":"CCSER1-AS1","canonical_id":"hgnc:HGNC:58853","description":"CCSER1 antisense RNA 1","metadata":null},{"id":"cac21a2d8733486f895571a3f72ea018","type":"GENE","name":"CCSER2","canonical_id":"hgnc:HGNC:29197","description":"coiled-coil serine rich protein 2","metadata":{"aliases":["KIAA1128","FAM190B"]}},{"id":"515d66a94dff4efb8271725e6fe548a6","type":"GENE","name":"CCSER2P1","canonical_id":"hgnc:HGNC:56795","description":"CCSER2 pseudogene 1","metadata":null},{"id":"c8f48a83d1b140b2982a963b291d7c79","type":"GENE","name":"CCT2","canonical_id":"hgnc:HGNC:1615","description":"chaperonin containing TCP1 subunit 2","metadata":{"aliases":["Cctb"]}},{"id":"21e3733df8ce47a2939a5866f8dedc7d","type":"GENE","name":"CCT3","canonical_id":"hgnc:HGNC:1616","description":"chaperonin containing TCP1 subunit 3","metadata":{"aliases":["Cctg","TRIC5"]}},{"id":"8893e3e0055b4d4ba1c8f5b6145a2df6","type":"GENE","name":"CCT3P1","canonical_id":"hgnc:HGNC:35129","description":"chaperonin containing TCP1 subunit 3 pseudogene 1","metadata":null},{"id":"feba816f901f495fbf6642221ce4c2d2","type":"GENE","name":"CCT4","canonical_id":"hgnc:HGNC:1617","description":"chaperonin containing TCP1 subunit 4","metadata":{"aliases":["Cctd"]}},{"id":"c8836f534f2342799f665a9449da0308","type":"GENE","name":"CCT4P1","canonical_id":"hgnc:HGNC:35151","description":"chaperonin containing TCP1 subunit 4 pseudogene 1","metadata":null},{"id":"99c241b736f040f4a5df29d942034490","type":"GENE","name":"CCT4P2","canonical_id":"hgnc:HGNC:35141","description":"chaperonin containing TCP1 subunit 4 pseudogene 2","metadata":null},{"id":"eda025498ce2425399e7a7b1e4537356","type":"GENE","name":"CCT5","canonical_id":"hgnc:HGNC:1618","description":"chaperonin containing TCP1 subunit 5","metadata":{"aliases":["KIAA0098","CCTE"]}},{"id":"ffe386cc403d4604bb98d66e5e4861b7","type":"GENE","name":"CCT5-AS1","canonical_id":"hgnc:HGNC:58210","description":"CCT5 antisense RNA 1","metadata":null},{"id":"e4fca80731224674a8e92ac539ed6dbc","type":"GENE","name":"CCT5P1","canonical_id":"hgnc:HGNC:35135","description":"chaperonin containing TCP1 subunit 5 pseudogene 1","metadata":null},{"id":"dbe50d5bc1aa41dea08b41d568ffa89e","type":"GENE","name":"CCT5P2","canonical_id":"hgnc:HGNC:35139","description":"chaperonin containing TCP1 subunit 5 pseudogene 2","metadata":null},{"id":"3dc68b309f594e019defa0694d3214d1","type":"GENE","name":"CCT6A","canonical_id":"hgnc:HGNC:1620","description":"chaperonin containing TCP1 subunit 6A","metadata":{"aliases":["TTCP20","TCPZ","Cctz","HTR3","TCP20","CCT6"]}},{"id":"887f4de18cf64e1b9bb7267f12f74447","type":"GENE","name":"CCT6A2P","canonical_id":"hgnc:HGNC:33094","description":"chaperonin containing TCP1 family member 6A2, pseudogene","metadata":{"aliases":["CCT6AP1","CCT6P1"]}},{"id":"9d985c6055fb46febe8dddc185eaa863","type":"GENE","name":"CCT6A3P","canonical_id":"hgnc:HGNC:35137","description":"chaperonin containing TCP1 family member 6A3, pseudogene","metadata":{"aliases":["CCT6P3"]}},{"id":"87997a7ad25e46618c9a7c2431ad9a9f","type":"GENE","name":"CCT6B","canonical_id":"hgnc:HGNC:1621","description":"chaperonin containing TCP1 subunit 6B","metadata":{"aliases":["Cctz2","TSA303"]}},{"id":"a1e7b4beac5a45eda78653cd1bce06d4","type":"GENE","name":"CCT6P2","canonical_id":"hgnc:HGNC:35150","description":"chaperonin containing TCP1 subunit 6 pseudogene 2","metadata":null},{"id":"38de2a5b5de34e89a3999bfdb2b1ab24","type":"GENE","name":"CCT6P4","canonical_id":"hgnc:HGNC:35148","description":"chaperonin containing TCP1 subunit 6 pseudogene 4","metadata":null},{"id":"cf808f091df44521a614e4c553ab789f","type":"GENE","name":"CCT6P5","canonical_id":"hgnc:HGNC:38608","description":"chaperonin containing TCP1 subunit 6 pseudogene 5","metadata":{"aliases":["CCT6-2P"]}},{"id":"f3d4d483c77c43a8b41bc9b0c22b59ed","type":"GENE","name":"CCT7","canonical_id":"hgnc:HGNC:1622","description":"chaperonin containing TCP1 subunit 7","metadata":{"aliases":["Ccth","Nip7-1"]}},{"id":"10fa0e82068d4ec6b1577e710a0a5ff3","type":"GENE","name":"CCT7P1","canonical_id":"hgnc:HGNC:35149","description":"chaperonin containing TCP1 subunit 7 pseudogene 1","metadata":null},{"id":"131ea80ae51447dbb53dac34fc74fe45","type":"GENE","name":"CCT7P2","canonical_id":"hgnc:HGNC:35134","description":"chaperonin containing TCP1 subunit 7 pseudogene 2","metadata":null},{"id":"58c5c6165e184aa0931bd0d0a923e99f","type":"GENE","name":"CCT8","canonical_id":"hgnc:HGNC:1623","description":"chaperonin containing TCP1 subunit 8","metadata":{"aliases":["Cctq","PRED71","C21orf112"]}},{"id":"45736848bcef4174962f868f91c54ecb","type":"GENE","name":"CCT8L1P","canonical_id":"hgnc:HGNC:32153","description":"chaperonin containing TCP1 subunit 8 like 1, pseudogene","metadata":{"aliases":["CCT8L1"]}},{"id":"abf226d8ce0949babef64376f1bd3cd0","type":"GENE","name":"CCT8L2","canonical_id":"hgnc:HGNC:15553","description":"chaperonin containing TCP1 subunit 8 like 2","metadata":{"aliases":["CESK1"]}},{"id":"648020c43de248ef9f1f224d2878653e","type":"GENE","name":"CCT8P1","canonical_id":"hgnc:HGNC:35144","description":"chaperonin containing TCP1 subunit 8 pseudogene 1","metadata":null},{"id":"99d60ec637db43aab4809a4ad26325fa","type":"GO_TERM","name":"CCU codon-amino acid adaptor activity","canonical_id":"go:GO:0033421","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CCU codon.\" [GOC:mah]","metadata":null},{"id":"a74f65c16bd94326af5945764c7b085f","type":"GENE","name":"CCZ1","canonical_id":"hgnc:HGNC:21691","description":"CCZ1 vacuolar protein trafficking and biogenesis associated","metadata":{"aliases":["CGI-43","CCZ1A","C7orf28A"]}},{"id":"a6e4239df1304e24b4a8655f13e55788","type":"GENE","name":"CCZ1B","canonical_id":"hgnc:HGNC:21717","description":"CCZ1B vacuolar protein trafficking and biogenesis associated","metadata":{"aliases":["DKFZP586I1023","H_NH0577018.2","MGC19819","C7orf28B"]}},{"id":"dba76154bb904dc3a9de04218102b31a","type":"GENE","name":"CCZ1P1","canonical_id":"hgnc:HGNC:55746","description":"CCZ1 pseudogene 1","metadata":null},{"id":"d25a808ca4124f41a8ee64cc41c8a40d","type":"GENE","name":"CD101","canonical_id":"hgnc:HGNC:5949","description":"CD101 molecule","metadata":{"aliases":["V7","IGSF2"]}},{"id":"1c91e671f59544b282caa5931481ea43","type":"GENE","name":"CD101-AS1","canonical_id":"hgnc:HGNC:55665","description":"CD101 antisense RNA 1","metadata":null},{"id":"005e9d977b0c40beb90e50197fd11637","type":"GENE","name":"CD109","canonical_id":"hgnc:HGNC:21685","description":"CD109 molecule","metadata":{"aliases":["HPA-15","FLJ38569","DKFZp762L1111","CPAMD7"]}},{"id":"0446e3dcf7b74577ab163a4822a43877","type":"GENE","name":"CD109-AS1","canonical_id":"hgnc:HGNC:55765","description":"CD109 antisense RNA 1","metadata":null},{"id":"5aced5d96b78454a8ab076bfb52ec18a","type":"GENE","name":"CD14","canonical_id":"hgnc:HGNC:1628","description":null,"metadata":null},{"id":"1f29d483a0e241f28ce478e59654e582","type":"GENE","name":"CD151","canonical_id":"hgnc:HGNC:1630","description":null,"metadata":null},{"id":"26c3b00452f741c8b274f32c5c363196","type":"GO_TERM","name":"CD154 receptor binding","canonical_id":"go:GO:0042615","description":"\"Binding to CD154, a receptor found on the surface of some activated lymphocytes.\" [GOC:jl, ISBN:0120781859]","metadata":null},{"id":"63d19ef621544852bafcadf09add1d93","type":"GENE","name":"CD160","canonical_id":"hgnc:HGNC:17013","description":"CD160 molecule","metadata":{"aliases":["BY55","NK1","NK28"]}},{"id":"89509d3081184c63a13b71898cd19b4a","type":"GENE","name":"CD163","canonical_id":"hgnc:HGNC:1631","description":null,"metadata":null},{"id":"20cb4407fb794c90b978a21c15363198","type":"GENE","name":"CD163L1","canonical_id":"hgnc:HGNC:30375","description":"CD163 molecule like 1","metadata":{"aliases":["M160","CD163B","SCARI2","WC1"]}},{"id":"aaedb606aa85410cbd4e9c9122b5d971","type":"GENE","name":"CD164","canonical_id":"hgnc:HGNC:1632","description":"CD164 molecule","metadata":{"aliases":["MUC-24","MGC-24","DFNA66","MGC-24v"]}},{"id":"fd4c4b74eecb41e59c84005be5ab847c","type":"GENE","name":"CD164L2","canonical_id":"hgnc:HGNC:32043","description":"CD164 molecule like 2","metadata":null},{"id":"77698149f46547b19f0a92bc5a4b7222","type":"GENE","name":"CD177","canonical_id":"hgnc:HGNC:30072","description":"CD177 molecule","metadata":{"aliases":["HNA-2","PRV1","HNA2A","NB1"]}},{"id":"39e80da104d1487fb3001d471ab5ce83","type":"GENE","name":"CD177P1","canonical_id":"hgnc:HGNC:34508","description":"CD177 molecule pseudogene 1","metadata":{"aliases":["CD177P"]}},{"id":"331a72ffb39042d2bcb63295b3458832","type":"GENE","name":"CD180","canonical_id":"hgnc:HGNC:6726","description":"CD180 molecule","metadata":{"aliases":["RP105","Ly78","LY64"]}},{"id":"d0a5fb26af7f489fb4dc7233f8e7f87c","type":"GENE","name":"CD19","canonical_id":"hgnc:HGNC:1633","description":null,"metadata":null},{"id":"cdcfa2e298934823acd4b63b0df6d649","type":"PROTEIN","name":"CD19","canonical_id":"uniprot:P15391","description":null,"metadata":null},{"id":"60cc265c84aa4cd795901814ec0856c0","type":"TRIAL","name":"CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL","canonical_id":"clinicaltrials.gov:NCT00586391","description":"B Cell Lymphoma; Chronic Lymphocytic Leukemia; Acute Lymphocytic Leukemia","metadata":null},{"id":"ec1952052f7d4a92b2f7c78567121450","type":"TRIAL","name":"CD19-B Cell Depletion in PAIS-ME/CFS Patients","canonical_id":"clinicaltrials.gov:NCT07724834","description":"Post-acute Infectious Syndrome (PAIS); Post-COVID 19 Condition (PCC or Long COVID); Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)","metadata":null},{"id":"4d0c425c41164ce9864e50f7e8cc5eb7","type":"GO_TERM","name":"CD19-Vav-PIK3R1 complex","canonical_id":"go:GO:0070024","description":"\"A protein complex that contains the cell surface signaling molecule CD19, the Ras guanine nucleotide exchange factor Vav, and the regulatory subunit alpha of phosphatidylinositol 3-kinase (PI3K).\" [PMID:7528218]","metadata":null},{"id":"c9bf9d122e1241ffa13766a5a5779d38","type":"GENE","name":"CD1A","canonical_id":"hgnc:HGNC:1634","description":"CD1a molecule","metadata":{"aliases":["CD1"]}},{"id":"c4cd2d850d094067998f9d8fb08813d2","type":"GENE","name":"CD1B","canonical_id":"hgnc:HGNC:1635","description":"CD1b molecule","metadata":{"aliases":["CD1"]}},{"id":"383cd2d0eab74129bee070d32839742c","type":"GENE","name":"CD1C","canonical_id":"hgnc:HGNC:1636","description":"CD1c molecule","metadata":{"aliases":["CD1"]}},{"id":"de0d3c306fa94a84bd0b364cdb345e38","type":"GENE","name":"CD1D","canonical_id":"hgnc:HGNC:1637","description":null,"metadata":null},{"id":"d75dd39c235f4a86b0b2584f5a4691af","type":"GENE","name":"CD1E","canonical_id":"hgnc:HGNC:1638","description":"CD1e molecule","metadata":null},{"id":"21e9f354b3f04cffba2190a0f30f2bce","type":"GENE","name":"CD2","canonical_id":"hgnc:HGNC:1639","description":null,"metadata":null},{"id":"5bb166529ef64036aeaf0d8bfded6f61","type":"PROTEIN","name":"CD2","canonical_id":"uniprot:P06729","description":null,"metadata":null},{"id":"400cc7cd59f5469aa5bfb3820acf05d4","type":"GO_TERM","name":"CD20-Lck-Fyn complex","canonical_id":"go:GO:0070331","description":"\"A protein complex that contains the cell-surface protein CD20 and the Src family tyrosine kinases Lck and Fyn.\" [GOC:mah, PMID:7545683]","metadata":null},{"id":"068132c8af8143439d9c7f26ef561805","type":"GO_TERM","name":"CD20-Lck-Lyn-Fyn complex","canonical_id":"go:GO:0070332","description":"\"A protein complex that contains the cell-surface protein CD20 and the Src family tyrosine kinases Lck, Lyn and Fyn.\" [GOC:mah, PMID:7545683]","metadata":null},{"id":"6143d351b398413aaca1810b060957e4","type":"GENE","name":"CD200","canonical_id":"hgnc:HGNC:7203","description":"CD200 molecule","metadata":{"aliases":["MRC","OX-2","MOX1","MOX2"]}},{"id":"66249013c756491a8932cebaf8f06bad","type":"GENE","name":"CD200LP","canonical_id":"hgnc:HGNC:55196","description":"CD200 like, pseudogene","metadata":null},{"id":"57ea9e6ca245421daeda75869d7b7ee2","type":"GENE","name":"CD200R1","canonical_id":"hgnc:HGNC:24235","description":"CD200 receptor 1","metadata":{"aliases":["OX2R","HCRTR2","CD200R","MOX2R"]}},{"id":"869bc2f76f1344e3b676c459f57bd777","type":"GENE","name":"CD200R1L","canonical_id":"hgnc:HGNC:24665","description":"CD200 receptor 1 like","metadata":{"aliases":["CD200RLa","CD200R2"]}},{"id":"d5b7c9e6794643b08b37eb02e0994cad","type":"GENE","name":"CD200R1L-AS1","canonical_id":"hgnc:HGNC:54071","description":"CD200R1L antisense RNA 1","metadata":null},{"id":"dcd6e2e410984d49aa6f43fc94641027","type":"GENE","name":"CD200R1P1","canonical_id":"hgnc:HGNC:56477","description":"CD200R1 pseudogene 1","metadata":null},{"id":"c976bb694db5412aa818a8c29c0a8dab","type":"GENE","name":"CD207","canonical_id":"hgnc:HGNC:17935","description":"CD207 molecule","metadata":{"aliases":["Langerin","CLEC4K"]}},{"id":"a8f7e10153d04b7788e024c4ff4f1ba4","type":"GENE","name":"CD209","canonical_id":"hgnc:HGNC:1641","description":"CD209 molecule","metadata":{"aliases":["DC-SIGN","hDC-SIGN","CDSIGN","DC-SIGN1","CLEC4L"]}},{"id":"2655a9e11a0a4ef7a39634d5c001cea0","type":"GENE","name":"CD22","canonical_id":"hgnc:HGNC:1643","description":null,"metadata":null},{"id":"4c54162470dc4e769419f6b1c9c92803","type":"PROTEIN","name":"CD22","canonical_id":"uniprot:P20273","description":null,"metadata":null},{"id":"da8a304ce3414756aa20ba5f50f3ba78","type":"GENE","name":"CD226","canonical_id":"hgnc:HGNC:16961","description":"CD226 molecule","metadata":{"aliases":["DNAM-1","DNAM1","PTA1","TLiSA1"]}},{"id":"437ee4a96b784a049b9ff3913e2255b2","type":"GENE","name":"CD24","canonical_id":"hgnc:HGNC:1645","description":null,"metadata":null},{"id":"38212847e44949bfa304cfd09db5bae9","type":"GENE","name":"CD244","canonical_id":"hgnc:HGNC:18171","description":"CD244 molecule","metadata":{"aliases":["2B4","NAIL","NKR2B4","Nmrk","SLAMF4"]}},{"id":"9b626a319f2a4a84aab03a36eb319db2","type":"GENE","name":"CD247","canonical_id":"hgnc:HGNC:1677","description":null,"metadata":null},{"id":"96d881244263493babe0fcbda9781628","type":"GENE","name":"CD248","canonical_id":"hgnc:HGNC:18219","description":"CD248 molecule","metadata":{"aliases":["TEM1","CD164L1"]}},{"id":"052ba6afa7c84112b66ca94d069b9f8a","type":"GENE","name":"CD24P1","canonical_id":"hgnc:HGNC:1646","description":"CD24 molecule pseudogene 1","metadata":{"aliases":["CD24L1"]}},{"id":"613a48afdebe494e95c6b8fcfe9ef526","type":"GENE","name":"CD24P2","canonical_id":"hgnc:HGNC:1647","description":"CD24 molecule pseudogene 2","metadata":{"aliases":["CD24L2"]}},{"id":"420fda8b55af4077982e9d4b3da9a3ec","type":"GENE","name":"CD24P3","canonical_id":"hgnc:HGNC:1648","description":"CD24 molecule pseudogene 3","metadata":{"aliases":["CD24L3"]}},{"id":"e940a4d7ec29458884f7a2f6f93ad3cb","type":"GENE","name":"CD24P4","canonical_id":"hgnc:HGNC:1649","description":"CD24 molecule pseudogene 4","metadata":{"aliases":["lnc-HSFY2-10:1","CD24L4"]}},{"id":"ecf7a04430654adeaba079443476be56","type":"GENE","name":"CD24P5","canonical_id":"hgnc:HGNC:56381","description":"CD24 pseudogene 5","metadata":null},{"id":"8d3dcba6db154ed5b1e551d9cfc71753","type":"GENE","name":"CD27","canonical_id":"hgnc:HGNC:11922","description":"CD27 molecule","metadata":{"aliases":["S152","Tp55","TNFRSF7"]}},{"id":"0cadca82b30944e2bbd9c94d42d45d5f","type":"GO_TERM","name":"CD27 receptor binding","canonical_id":"go:GO:0005175","description":"\"Binding to a CD27, a receptor found on the surface of T cells and some B cells and NK cells.\" [GOC:jl, ISBN:0120781859]","metadata":null},{"id":"e9ee8260dcab4898a509a14103645554","type":"GO_TERM","name":"CD27 signaling pathway","canonical_id":"go:GO:0160162","description":"\"The series of molecular signals initiated by the binding of the cell surface receptor CD27 to its physiological ligand CD70, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:26359318, PMID:8387892]","metadata":null},{"id":"d21e583272e941f5b88f6e65f92bed34","type":"GENE","name":"CD27-AS1","canonical_id":"hgnc:HGNC:43896","description":"CD27 antisense RNA 1","metadata":null},{"id":"3f3998887dda4d33a22a387213e9be79","type":"GENE","name":"CD274","canonical_id":"hgnc:HGNC:17635","description":"CD274 molecule","metadata":{"aliases":["B7-H","B7H1","PD-L1","PDL1","B7-H1","PDCD1LG1"]}},{"id":"a5c1522bb4f042eb947c39ca0bc0930c","type":"PROTEIN","name":"CD274","canonical_id":"uniprot:Q9NZQ7","description":null,"metadata":null},{"id":"021d9ce6e011461d8a25b2ad33f2f793","type":"GENE","name":"CD276","canonical_id":"hgnc:HGNC:19137","description":"CD276 molecule","metadata":{"aliases":["B7-H3","B7H3","B7RP-2"]}},{"id":"f4676fdbd94e41ffb6aa49eb7e4b2871","type":"GENE","name":"CD28","canonical_id":"hgnc:HGNC:1653","description":null,"metadata":null},{"id":"21fb1d0af18747edabe3566df2ddf431","type":"GENE","name":"CD2AP","canonical_id":"hgnc:HGNC:14258","description":null,"metadata":null},{"id":"80c2e32577e241359d1a7adc214f5309","type":"GENE","name":"CD2AP-DT","canonical_id":"hgnc:HGNC:55263","description":"CD2AP divergent transcript","metadata":null},{"id":"3d1d7c4f69fc43d9916737edf4a72700","type":"GENE","name":"CD2BP2","canonical_id":"hgnc:HGNC:1656","description":"CD2 cytoplasmic tail binding protein 2","metadata":{"aliases":["LIN1","Snu40","PPP1R59","U5-52K"]}},{"id":"e3beeed8705949ec84760b8d3379543b","type":"GENE","name":"CD2BP2-DT","canonical_id":"hgnc:HGNC:53029","description":"CD2BP2 divergent transcript","metadata":null},{"id":"a37653e599474543bb1a5161f024f08b","type":"GENE","name":"CD300A","canonical_id":"hgnc:HGNC:19319","description":"CD300a molecule","metadata":{"aliases":["Irp60","CMRF35H","CMRF-35-H9","IRC1","IRC2","IGSF12"]}},{"id":"18677765dd784844bbc7c6e8808d9d6b","type":"GENE","name":"CD300C","canonical_id":"hgnc:HGNC:19320","description":"CD300c molecule","metadata":{"aliases":["CMRF35","LIR","CMRF-35A","CMRF35A","IGSF16"]}},{"id":"a262f05666dd453e994f581cc6e86f07","type":"GENE","name":"CD300E","canonical_id":"hgnc:HGNC:28874","description":"CD300e molecule","metadata":{"aliases":["IREM2","CLM2","CD300LE"]}},{"id":"5a561214a2f84167b63a88cda3da7316","type":"GENE","name":"CD300H","canonical_id":"hgnc:HGNC:52292","description":"CD300H molecule (gene/pseudogene)","metadata":null},{"id":"c484e14b068f458382149c89dbb5e974","type":"GENE","name":"CD300LB","canonical_id":"hgnc:HGNC:30811","description":"CD300 molecule like family member b","metadata":{"aliases":["TREM5","CLM7"]}},{"id":"8a83116e6ab54a75b5a8b97747dbc259","type":"GENE","name":"CD300LD","canonical_id":"hgnc:HGNC:16848","description":"CD300 molecule like family member d","metadata":{"aliases":["CMRF35A4","CD300D"]}},{"id":"51facad51c72479fa753a5711d7e2f03","type":"GENE","name":"CD300LD-AS1","canonical_id":"hgnc:HGNC:26480","description":"CD300LD antisense RNA 1","metadata":{"aliases":["FLJ31882","C17orf77"]}},{"id":"d902067776a7493ab23f75de29c8168f","type":"GENE","name":"CD300LF","canonical_id":"hgnc:HGNC:29883","description":"CD300 molecule like family member f","metadata":{"aliases":["IREM1","NKIR","IGSF13","CD300f","CLM1"]}},{"id":"a9399191f2944178a027f9e35bc1d742","type":"GENE","name":"CD300LG","canonical_id":"hgnc:HGNC:30455","description":"CD300 molecule like family member g","metadata":{"aliases":["Trem4","CLM9"]}},{"id":"63da6aec38474141b6217519c4d30588","type":"GENE","name":"CD302","canonical_id":"hgnc:HGNC:30843","description":"CD302 molecule","metadata":{"aliases":["DCL-1","KIAA0022","BIMLEC","CLEC13A"]}},{"id":"5aa838ec80344277a2409a46c63345de","type":"GENE","name":"CD320","canonical_id":"hgnc:HGNC:16692","description":"CD320 molecule","metadata":{"aliases":["8D6","8D6A","TCblR","TCN2R","sCD320","TCII-R"]}},{"id":"4ab6afc3221b464cb1989586a28d6825","type":"GENE","name":"CD33","canonical_id":"hgnc:HGNC:1659","description":null,"metadata":null},{"id":"9da0792b08c74861bd7e83098906ce9b","type":"PROTEIN","name":"CD33","canonical_id":"uniprot:P20138","description":null,"metadata":null},{"id":"5cb5f80dca45448bbcae78ba447e997a","type":"GENE","name":"CD34","canonical_id":"hgnc:HGNC:1662","description":null,"metadata":null},{"id":"67b3c0dbeac84f0d8e85abb7c0ee8f77","type":"GENE","name":"CD36","canonical_id":"hgnc:HGNC:1663","description":null,"metadata":null},{"id":"908982ec05174c0ca7342bc6badce595","type":"GENE","name":"CD37","canonical_id":"hgnc:HGNC:1666","description":"CD37 molecule","metadata":{"aliases":["TSPAN26"]}},{"id":"d143737450fa4a07b33e7f6a749cd392","type":"GENE","name":"CD38","canonical_id":"hgnc:HGNC:1667","description":null,"metadata":null},{"id":"356e0ba068984755b191e58cef6465a1","type":"PROTEIN","name":"CD38","canonical_id":"uniprot:P28907","description":null,"metadata":null},{"id":"5f820151d4294b7cb8120c760a509cb9","type":"GENE","name":"CD38-AS1","canonical_id":"hgnc:HGNC:58740","description":"CD38 antisense RNA 1","metadata":null},{"id":"3ef3e06938d94faaaba197dfb09c6ecb","type":"GENE","name":"CD3D","canonical_id":"hgnc:HGNC:1673","description":"CD3 delta subunit of T-cell receptor complex","metadata":{"aliases":["CD3DELTA","CD3-DELTA","T3D"]}},{"id":"0e916a02b6244a628081b72634583394","type":"GENE","name":"CD3E","canonical_id":"hgnc:HGNC:1674","description":"CD3 epsilon subunit of T-cell receptor complex","metadata":{"aliases":["CD3epsilon","CD3-epsilon"]}},{"id":"ded6290be4e3463b80d9d046b3da7310","type":"PROTEIN","name":"CD3E","canonical_id":"uniprot:P07766","description":null,"metadata":null},{"id":"67ea29f7a3bf401fa0abe144e1e2e555","type":"GENE","name":"CD3G","canonical_id":"hgnc:HGNC:1675","description":null,"metadata":null},{"id":"297db5a08fa74d0781ad88a562175add","type":"GENE","name":"CD4","canonical_id":"hgnc:HGNC:1678","description":null,"metadata":null},{"id":"cc38ac4ff48a4b3382cb3e0c2929c8c8","type":"PROTEIN","name":"CD4","canonical_id":"uniprot:P01730","description":null,"metadata":null},{"id":"e5e4059e4f3f4d1da1bad9d350472351","type":"GO_TERM","name":"CD4 receptor binding","canonical_id":"go:GO:0042609","description":"\"Binding to a CD4, a receptor found on the surface of T cells, monocytes and macrophages.\" [GOC:jl, MSH:D015704]","metadata":null},{"id":"60bb5470519f48658b9e161546a823a5","type":"GO_TERM","name":"CD4-positive gamma-delta intraepithelial T cell differentiation","canonical_id":"go:GO:0002306","description":"\"The process in which a precursor cell type acquires the specialized features of a CD4-positive, gamma-delta intraepithelial T cell. Intraepithelial T cells are found among epithelial cells in mucosal areas and have distinct phenotypes and developmental pathways.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"63e1b8cf388c4826b07ddc21b29151d2","type":"GO_TERM","name":"CD4-positive or CD8-positive, alpha-beta T cell lineage commitment","canonical_id":"go:GO:0043369","description":"\"The process in which an immature T cell commits to CD4-positive T cell lineage or the CD8-positive lineage of alpha-beta T cells.\" [ISBN:0781735149]","metadata":null},{"id":"0cb926ec98e14c73996ab1bec9af4eda","type":"GO_TERM","name":"CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation","canonical_id":"go:GO:0002361","description":"\"The process in which a precursor cell type acquires the specialized features of a CD4-positive, CD25-positive, alpha-beta regulatory T cell.\" [GOC:add, PMID:15207821]","metadata":null},{"id":"2e66411bf3cc4f6db145dfe4e23b0a7a","type":"GO_TERM","name":"CD4-positive, CD25-positive, alpha-beta regulatory T cell lineage commitment","canonical_id":"go:GO:0002362","description":"\"The process in which a CD4-positive, alpha-beta T cell becomes committed to becoming a CD4-positive, CD25-positive, alpha-beta regulatory T cell.\" [GOC:add, PMID:15207821]","metadata":null},{"id":"9997a94e2c444530a3a25e1a930644e6","type":"GO_TERM","name":"CD4-positive, alpha-beta T cell activation","canonical_id":"go:GO:0035710","description":"\"The change in morphology and behavior of a CD4-positive, alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [CL:0000624, GOC:BHF]","metadata":null},{"id":"8fb241bc11e741eaaabaf426c4d13948","type":"GO_TERM","name":"CD4-positive, alpha-beta T cell costimulation","canonical_id":"go:GO:0035783","description":"\"The process of providing, via surface-bound receptor-ligand pairs, a second, antigen-independent, signal in addition to that provided by the T cell receptor to augment CD4-positive, alpha-beta T cell activation.\" [CL:0000624, GOC:BHF, GOC:pr]","metadata":null},{"id":"e30e4ac26dce40febe248e26927fe216","type":"GO_TERM","name":"CD4-positive, alpha-beta T cell cytokine production","canonical_id":"go:GO:0035743","description":"\"Any process that contributes to cytokine production by a CD4-positive, alpha-beta T cell.\" [CL:0000624, GOC:BHF]","metadata":null},{"id":"f089f8614011458eaaa21d648908ab82","type":"GO_TERM","name":"CD4-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043367","description":"\"The process in which a relatively unspecialized T cell acquires specialized features of a mature CD4-positive, alpha-beta T cell.\" [CL:0000624, ISBN:0781735149]","metadata":null},{"id":"686f8ec5f0b94ead9b70b924b27c9b99","type":"GO_TERM","name":"CD4-positive, alpha-beta T cell lineage commitment","canonical_id":"go:GO:0043373","description":"\"The process in which an immature T cell becomes committed to becoming a CD4-positive, alpha-beta T cell.\" [ISBN:0781735149]","metadata":null},{"id":"ddfba970a8e84c97809e78ed75b3eac7","type":"GO_TERM","name":"CD4-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:0035739","description":"\"The expansion of a CD4-positive, alpha-beta T cell population by cell division.\" [CL:0000624, GOC:BHF]","metadata":null},{"id":"a0a6ba7d0ea342f18191529dc9ec315f","type":"GO_TERM","name":"CD4-positive, alpha-beta intraepithelial T cell differentiation","canonical_id":"go:GO:0002301","description":"\"The process in which a precursor cell type acquires the specialized features of a CD4-positive, alpha-beta intraepithelial T cell. Intraepithelial T cells are found among epithelial cells in mucosal areas and have distinct phenotypes and developmental pathways.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"4526b800d23945a4a545ab49b82b54d4","type":"GENE","name":"CD40","canonical_id":"hgnc:HGNC:11919","description":null,"metadata":null},{"id":"8f18a228afd7437a8af392cf0d3bbcf2","type":"GO_TERM","name":"CD40 receptor binding","canonical_id":"go:GO:0005174","description":"\"Binding to CD40, a receptor found on the surface of all B-lymphocytes.\" [GOC:jl, ISBN:0120781859]","metadata":null},{"id":"fdc83098b6df4c3084749bba3d4e1f04","type":"GO_TERM","name":"CD40 receptor complex","canonical_id":"go:GO:0035631","description":"\"A protein complex that contains at least CD40 (a cell surface receptor of the tumour necrosis factor receptor (TNFR) superfamily), and other signaling molecules.\" [GOC:BHF, PMID:20614026, PMID:9221764]","metadata":null},{"id":"be6e6d83cf1f4cd08fe7249413f1ea06","type":"GO_TERM","name":"CD40 signaling pathway","canonical_id":"go:GO:0023035","description":"\"The series of molecular signals initiated by the binding of the cell surface receptor CD40 to one of its physiological ligands, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mtg_signal, GOC:signaling, PMID:11348017]","metadata":null},{"id":"60dc412d2c4d479cb468f72dd2af8873","type":"GENE","name":"CD40LG","canonical_id":"hgnc:HGNC:11935","description":null,"metadata":null},{"id":"10f5d525798f4b3889ac321ab29b4a60","type":"GENE","name":"CD44","canonical_id":"hgnc:HGNC:1681","description":null,"metadata":null},{"id":"38fa3db0e8b44ff4be20e2d7856ae049","type":"GENE","name":"CD44-AS1","canonical_id":"hgnc:HGNC:40133","description":"CD44 antisense RNA 1","metadata":{"aliases":["RP1-68D18.4","hLinfRNA5"]}},{"id":"1c3d562d50354361a5754e0b5b48f6d6","type":"GENE","name":"CD44-DT","canonical_id":"hgnc:HGNC:56175","description":"CD44 divergent transcript","metadata":null},{"id":"848ba95058fc41789a4f04081826d98b","type":"GENE","name":"CD46","canonical_id":"hgnc:HGNC:6953","description":null,"metadata":null},{"id":"ac9123a0c48b4cb5a40ce12bfa34eff1","type":"GENE","name":"CD46P1","canonical_id":"hgnc:HGNC:6959","description":"CD46 molecule pseudogene 1","metadata":{"aliases":["MCPL","CD46P"]}},{"id":"b4602736340b48089b8303ead14a95f4","type":"GENE","name":"CD47","canonical_id":"hgnc:HGNC:1682","description":"CD47 molecule","metadata":{"aliases":["IAP","OA3","MER6"]}},{"id":"05cd32473d0a4d4cb10e1d217c15e9f9","type":"GENE","name":"CD48","canonical_id":"hgnc:HGNC:1683","description":"CD48 molecule","metadata":{"aliases":["BLAST","mCD48","hCD48","SLAMF2","BCM1"]}},{"id":"badc491603c040918d31a3155a7f3fcc","type":"GENE","name":"CD5","canonical_id":"hgnc:HGNC:1685","description":"CD5 molecule","metadata":{"aliases":["T1","LEU1"]}},{"id":"be4827940c14427ca7dd677c1b2cf78f","type":"GENE","name":"CD52","canonical_id":"hgnc:HGNC:1804","description":"CD52 molecule","metadata":{"aliases":["HE5","EDDM5","CDW52"]}},{"id":"ace4db1a18ed424c854d5f095e373536","type":"PROTEIN","name":"CD52","canonical_id":"uniprot:P31358","description":null,"metadata":null},{"id":"071addd7bd114cdc952315d4fe005a87","type":"GENE","name":"CD53","canonical_id":"hgnc:HGNC:1686","description":"CD53 molecule","metadata":{"aliases":["TSPAN25","MOX44"]}},{"id":"6056f5a773234ca486a4c9cc83ff0a8d","type":"GENE","name":"CD55","canonical_id":"hgnc:HGNC:2665","description":"CD55 molecule (Cromer blood group)","metadata":{"aliases":["CR","TC","CROM","DAF"]}},{"id":"853bb102aedf4016ba3f0161b7de5817","type":"TRIAL","name":"CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02189629","description":"Acne Vulgaris","metadata":null},{"id":"5c21a95c3bf74ef8b0f81401d05ef010","type":"GENE","name":"CD58","canonical_id":"hgnc:HGNC:1688","description":null,"metadata":null},{"id":"dafdb9ae5f4342eab8cc4684c3b9e390","type":"GENE","name":"CD59","canonical_id":"hgnc:HGNC:1689","description":null,"metadata":null},{"id":"ecc8f2109d7d42e9aba7566944378151","type":"GENE","name":"CD5L","canonical_id":"hgnc:HGNC:1690","description":"CD5 molecule like","metadata":{"aliases":["Spalpha","API6"]}},{"id":"a4aaf361aec24da196b785679f3b0f1d","type":"GENE","name":"CD6","canonical_id":"hgnc:HGNC:1691","description":null,"metadata":null},{"id":"4d716f74b6154060a527c878b952e8a6","type":"PROTEIN","name":"CD6","canonical_id":"uniprot:P30203","description":null,"metadata":null},{"id":"3c10d3ffc3364c4583c88bb446db035e","type":"GENE","name":"CD63","canonical_id":"hgnc:HGNC:1692","description":"CD63 molecule","metadata":{"aliases":["ME491","TSPAN30","HOP-26","Pltgp40","AD1","MLA1"]}},{"id":"3ff08396b0924c6e9db647d6a45a217d","type":"GENE","name":"CD63-AS1","canonical_id":"hgnc:HGNC:55455","description":"CD63 antisense RNA 1","metadata":{"aliases":["CEAM"]}},{"id":"6454862d0b8e418e96c06fbef904b586","type":"GENE","name":"CD68","canonical_id":"hgnc:HGNC:1693","description":null,"metadata":null},{"id":"b1918b06657a4e33927e3629173096a9","type":"GENE","name":"CD69","canonical_id":"hgnc:HGNC:1694","description":null,"metadata":null},{"id":"44aa67b475d14769af9e19061ae5d2f3","type":"GENE","name":"CD7","canonical_id":"hgnc:HGNC:1695","description":"CD7 molecule","metadata":{"aliases":["GP40","LEU-9","TP41","Tp40"]}},{"id":"a508b0f8cd0b4235824ee4bfb22b96c3","type":"GENE","name":"CD70","canonical_id":"hgnc:HGNC:11937","description":null,"metadata":null},{"id":"2383a04ec7634d7185f31fd93a04c737","type":"GO_TERM","name":"CD70 receptor binding","canonical_id":"go:GO:0042614","description":"\"Binding to a CD70, a receptor found on the surface of most activated B cells and some activated T cells.\" [GOC:jl, ISBN:0120781859]","metadata":null},{"id":"33ffbe1fa9e940509a2296b6651ffc44","type":"GENE","name":"CD72","canonical_id":"hgnc:HGNC:1696","description":"CD72 molecule","metadata":{"aliases":["LYB2","CD72b"]}},{"id":"528efda4993b4e26973caf3feeae0e09","type":"GENE","name":"CD74","canonical_id":"hgnc:HGNC:1697","description":null,"metadata":null},{"id":"aca6095cef38477bb828b00bc9c6d2e3","type":"GENE","name":"CD79A","canonical_id":"hgnc:HGNC:1698","description":null,"metadata":null},{"id":"0a203fd90fc84c7d9b45d44c55744484","type":"GENE","name":"CD79B","canonical_id":"hgnc:HGNC:1699","description":"CD79b molecule","metadata":{"aliases":["B29","Ig-beta","Igbeta","IGB"]}},{"id":"64a50c066b184d24b8ebdadfccc7cc32","type":"PROTEIN","name":"CD79B","canonical_id":"uniprot:P40259","description":null,"metadata":null},{"id":"06be569be450438e924692f2a0e79fba","type":"GO_TERM","name":"CD8 receptor binding","canonical_id":"go:GO:0042610","description":"\"Binding to a CD8, a receptor found on the surface of thymocytes and cytotoxic and suppressor T-lymphocytes.\" [GOC:jl, MSH:D016827]","metadata":null},{"id":"8c8a52c2d916490b9bb67288263fdb85","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell activation","canonical_id":"go:GO:0036037","description":"\"The change in morphology and behavior of a CD8-positive, alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [CL:0000625, GOC:yaf]","metadata":null},{"id":"4acd6718890348b7a3b17f847019e0a7","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043374","description":"\"The process in which a relatively unspecialized T cell acquires specialized features of a mature CD8-positive, alpha-beta T cell.\" [ISBN:0781735149]","metadata":null},{"id":"277e36b2e74e470494c4cbe7c354bcae","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell differentiation involved in immune response","canonical_id":"go:GO:0002302","description":"\"The process in which an antigenically naive CD8-positive, alpha-beta T cell acquires the specialized features of an effector, regulatory, or memory T cell as part of an immune response. Effector T cells include cells which provide T cell help or exhibit cytotoxicity towards other cells.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0c0b1173926b4c60aeab2a0de9ef9936","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell extravasation","canonical_id":"go:GO:0035697","description":"\"The migration of a CD8-positive, alpha-beta T cell from the blood vessels into the surrounding tissue.\" [CL:0000625, GOC:BHF]","metadata":null},{"id":"622b68f3b78d4d23969214d8a1758092","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell homeostasis","canonical_id":"go:GO:0160165","description":"\"The process of regulating the proliferation and elimination of CD8-positive alpha-beta T cells such that the total number of CD8-positive alpha-beta T cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [PMID:30650357, PMID:33815406]","metadata":null},{"id":"56fbba6ede4c4cf7b9623af65492c623","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell lineage commitment","canonical_id":"go:GO:0043375","description":"\"The process in which an immature T cell becomes committed to becoming a CD8-positive, alpha-beta T cell.\" [ISBN:0781735149]","metadata":null},{"id":"a4629d9ba136410a93da3a86fd7636e2","type":"GO_TERM","name":"CD8-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:0035740","description":"\"The expansion of a CD8-positive, alpha-beta T cell population by cell division.\" [CL:0000625, GOC:BHF]","metadata":null},{"id":"c7f4da80e2b548e89482858f29594a3a","type":"GO_TERM","name":"CD8-positive, alpha-beta cytotoxic T cell differentiation","canonical_id":"go:GO:0002308","description":"\"The process in which a precursor cell type acquires the specialized features of a CD8-positive, alpha-beta cytotoxic T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c358f95a738842598df19c8e6c039c76","type":"GO_TERM","name":"CD8-positive, alpha-beta cytotoxic T cell extravasation","canonical_id":"go:GO:0035698","description":"\"The migration of a CD8-positive, alpha-beta cytotoxic T cell from the blood vessels into the surrounding tissue.\" [CL:0000794, GOC:BHF]","metadata":null},{"id":"1405c405fec040ddab9b1dbb4e20d080","type":"GO_TERM","name":"CD8-positive, alpha-beta intraepithelial T cell differentiation","canonical_id":"go:GO:0002300","description":"\"The process in which a precursor cell type acquires the specialized features of a CD8-positive, alpha-beta intraepithelial T cell. Intraepithelial T cells are found among epithelial cells in mucosal areas and have distinct phenotypes and developmental pathways.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a74f069038ad4b11ba028f7bf4136a26","type":"GO_TERM","name":"CD8-positive, alpha-beta regulatory T cell differentiation","canonical_id":"go:GO:0002307","description":"\"The process in which a precursor cell type acquires the specialized features of a CD8-positive, alpha-beta regulatory T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f3d545440b92428fabc9512cf8120fb2","type":"GO_TERM","name":"CD8-positive, gamma-delta intraepithelial T cell differentiation","canonical_id":"go:GO:0002305","description":"\"The process in which a precursor cell type acquires the specialized features of a CD8-positive, gamma-delta intraepithelial T cell. Intraepithelial T cells are found among epithelial cells in mucosal areas and have distinct phenotypes and developmental pathways.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a80c3b853df74a099ee56738237df3db","type":"GENE","name":"CD80","canonical_id":"hgnc:HGNC:1700","description":null,"metadata":null},{"id":"267537afbaa04b76a482af227829c19b","type":"PROTEIN","name":"CD80","canonical_id":"uniprot:P33681","description":null,"metadata":null},{"id":"ec239515c2b643a99787fc0f2c7deac2","type":"GENE","name":"CD81","canonical_id":"hgnc:HGNC:1701","description":"CD81 molecule","metadata":{"aliases":["TAPA-1","TSPAN28","S5.7","TAPA1"]}},{"id":"f9e3a60307bd4a459663638d7b6387bd","type":"GENE","name":"CD81-AS1","canonical_id":"hgnc:HGNC:49384","description":"CD81 antisense RNA 1","metadata":null},{"id":"0e19fb329b48416b9148087ce7bd7e04","type":"GENE","name":"CD82","canonical_id":"hgnc:HGNC:6210","description":null,"metadata":null},{"id":"2438859888764342964c06301f591c1e","type":"GENE","name":"CD82-AS1","canonical_id":"hgnc:HGNC:56287","description":"CD82 antisense RNA 1","metadata":null},{"id":"1316979885db436fad6f75b360a7951a","type":"GENE","name":"CD83","canonical_id":"hgnc:HGNC:1703","description":null,"metadata":null},{"id":"31b3ab7dbe44440db2d7f5179267de6f","type":"GENE","name":"CD83-AS1","canonical_id":"hgnc:HGNC:59359","description":"CD83 antisense RNA 1","metadata":null},{"id":"45f77d58fe1b481baf53bd9612d89b22","type":"GENE","name":"CD83P1","canonical_id":"hgnc:HGNC:13946","description":"CD83 molecule pseudogene 1","metadata":{"aliases":["HB15p","b34I8.3","CD83P"]}},{"id":"5c5f0058eb5840de93735ee0ad426cb4","type":"GENE","name":"CD84","canonical_id":"hgnc:HGNC:1704","description":"CD84 molecule","metadata":{"aliases":["SLAMF5","hCD84","mCD84"]}},{"id":"501ca487ecd04e71b76545bac7eaa31d","type":"GENE","name":"CD84-AS1","canonical_id":"hgnc:HGNC:58385","description":"CD84 antisense RNA 1","metadata":null},{"id":"2c25512b237b4b879f5f8a994797717f","type":"GENE","name":"CD84P1","canonical_id":"hgnc:HGNC:55159","description":"CD84 pseudogene 1","metadata":null},{"id":"4e5426ce26a84d0c9dbfe1e1c3419988","type":"GENE","name":"CD86","canonical_id":"hgnc:HGNC:1705","description":null,"metadata":null},{"id":"039c5391b9104b548c7cf66371cd4c3d","type":"PROTEIN","name":"CD86","canonical_id":"uniprot:P42081","description":null,"metadata":null},{"id":"50b5123db446418cba9d7751243d5442","type":"GENE","name":"CD8A","canonical_id":"hgnc:HGNC:1706","description":null,"metadata":null},{"id":"50c9d7ee4a914aadbe15f5c8bd1b4034","type":"GENE","name":"CD8B","canonical_id":"hgnc:HGNC:1707","description":null,"metadata":null},{"id":"44df396675144dfcabc90b6f2d067fd1","type":"GENE","name":"CD8B2","canonical_id":"hgnc:HGNC:1708","description":"CD8B family member 2","metadata":{"aliases":["CD8BP"]}},{"id":"6a7d6ce5695e4fee9f7e3d118569acd3","type":"GENE","name":"CD9","canonical_id":"hgnc:HGNC:1709","description":"CD9 molecule","metadata":{"aliases":["BA2","P24","TSPAN29","MRP-1","MIC3"]}},{"id":"bf7d739d2b7e403c8ec5ff3a1d1ccc5b","type":"GENE","name":"CD93","canonical_id":"hgnc:HGNC:15855","description":"CD93 molecule","metadata":{"aliases":["C1qRP","C1qR(P)","dJ737E23.1","CDw93","ECSM3","MXRA4","C1QR1"]}},{"id":"07c977de3ced40e18cd348ac7e4db835","type":"GO_TERM","name":"CD95 death-inducing signaling complex","canonical_id":"go:GO:0031265","description":"\"A protein complex formed upon binding of Fas/CD95/APO-1 to its ligand. The complex includes FADD/Mort1, procaspase-8/10 and c-FLIP in addition to the ligand-bound receptor.\" [PMID:12628743, PMID:12655293]","metadata":null},{"id":"c8cceebbf4a245b988f14c5ec10268d2","type":"GENE","name":"CD96","canonical_id":"hgnc:HGNC:16892","description":"CD96 molecule","metadata":{"aliases":["TACTILE"]}},{"id":"b57c12e765464b0da3be548cc7cf3d98","type":"GENE","name":"CD99","canonical_id":"hgnc:HGNC:7082","description":null,"metadata":null},{"id":"4e0bbb82755e4acc883b418190636fab","type":"GENE","name":"CD99L2","canonical_id":"hgnc:HGNC:18237","description":"CD99 molecule like 2","metadata":{"aliases":["CD99B","MIC2L1"]}},{"id":"fe9006e38c154e5aad58d7e1baa0f388","type":"GENE","name":"CD99P1","canonical_id":"hgnc:HGNC:7083","description":"CD99 molecule pseudogene 1","metadata":{"aliases":["MIC2R","NCRNA00103","CXYorf12","CD99L1"]}},{"id":"32b187101b604655a2452d572ffd65c7","type":"GENE","name":"CDA","canonical_id":"hgnc:HGNC:1712","description":null,"metadata":null},{"id":"b7a627517b7d455195db84f87512b491","type":"GENE","name":"CDADC1","canonical_id":"hgnc:HGNC:20299","description":"cytidine and dCMP deaminase domain containing 1","metadata":{"aliases":["NYD-SP15"]}},{"id":"dfdd9ac0f8dd4b90bca25da8270f3046","type":"GENE","name":"CDAN1","canonical_id":"hgnc:HGNC:1713","description":null,"metadata":null},{"id":"4dd1996993404bc2869aefcec36c977d","type":"GENE","name":"CDC123","canonical_id":"hgnc:HGNC:16827","description":"cell division cycle 123","metadata":{"aliases":["D123","C10orf7"]}},{"id":"cb1b83332f6c4609a4fe63f98a2638e9","type":"GENE","name":"CDC14A","canonical_id":"hgnc:HGNC:1718","description":"cell division cycle 14A","metadata":{"aliases":["Cdc14A1","Cdc14A2","cdc14","DFNB105","DFNB32"]}},{"id":"b3c538f2445247cba5a4f44cd8063580","type":"GENE","name":"CDC14B","canonical_id":"hgnc:HGNC:1719","description":"cell division cycle 14B","metadata":{"aliases":["Cdc14B1","Cdc14B2","CDC14B3","hCDC14B"]}},{"id":"3110b1cc9f894e98afeb5b50b084adc9","type":"GENE","name":"CDC14C","canonical_id":"hgnc:HGNC:22427","description":"cell division cycle 14C","metadata":{"aliases":["MGC26484","CDC14B2","CDC14Bretro","CDC14CP"]}},{"id":"6aa8db418c32434389a52fcc46520d27","type":"GENE","name":"CDC16","canonical_id":"hgnc:HGNC:1720","description":"cell division cycle 16","metadata":{"aliases":["APC6","ANAPC6","CUT9"]}},{"id":"b2a7bdb9c1b9411591e9579626c9b148","type":"GENE","name":"CDC20","canonical_id":"hgnc:HGNC:1723","description":null,"metadata":null},{"id":"50672a132ce94e3fa55eabddf0a78356","type":"GENE","name":"CDC20-DT","canonical_id":"hgnc:HGNC:55681","description":"CDC20 divergent transcript","metadata":null},{"id":"d4aad11142054d1983d6cd90ea41eca8","type":"GENE","name":"CDC20B","canonical_id":"hgnc:HGNC:24222","description":"cell division cycle 20B","metadata":{"aliases":["FLJ37927"]}},{"id":"36063474505a4b6eb994c3b58de08eb3","type":"GENE","name":"CDC20P1","canonical_id":"hgnc:HGNC:29487","description":"cell division cycle 20 pseudogene 1","metadata":{"aliases":["OTTHUMG00000020142","CDC20P"]}},{"id":"2212b7cb47b1439aada53f850804aa3a","type":"GENE","name":"CDC23","canonical_id":"hgnc:HGNC:1724","description":"cell division cycle 23","metadata":{"aliases":["APC8","ANAPC8","CUT23"]}},{"id":"dbdf6dc4c0cd42e99edad38e74ab4d27","type":"GENE","name":"CDC25A","canonical_id":"hgnc:HGNC:1725","description":null,"metadata":null},{"id":"97340418007443df96049d1bf774c7b3","type":"GENE","name":"CDC25B","canonical_id":"hgnc:HGNC:1726","description":null,"metadata":null},{"id":"c236b3915fa64d08b7a3fd81f5492180","type":"GENE","name":"CDC25C","canonical_id":"hgnc:HGNC:1727","description":null,"metadata":null},{"id":"46d522f4df814ae3bd106d23fc3b4ace","type":"GENE","name":"CDC26","canonical_id":"hgnc:HGNC:17839","description":"cell division cycle 26","metadata":{"aliases":["APC12","ANAPC12","C9orf17"]}},{"id":"75dcb3d0bfa2458482c909e19d6f98a3","type":"GENE","name":"CDC26P1","canonical_id":"hgnc:HGNC:22770","description":"cell division cycle 26 pseudogene 1","metadata":{"aliases":["TCAG_1970866","CDC26P"]}},{"id":"19af1f2869864304b036c5f2b2880114","type":"GENE","name":"CDC27","canonical_id":"hgnc:HGNC:1728","description":"cell division cycle 27","metadata":{"aliases":["APC3","ANAPC3","NUC2","D0S1430E","D17S978E"]}},{"id":"b0d5f0bb4bac4d27977303b482245eb2","type":"GENE","name":"CDC27P1","canonical_id":"hgnc:HGNC:38091","description":"cell division cycle 27 pseudogene 1","metadata":null},{"id":"a0ce25b51ced43e688cdf2e09023744d","type":"GENE","name":"CDC27P10","canonical_id":"hgnc:HGNC:51760","description":"cell division cycle 27 pseudogene 10","metadata":null},{"id":"6091b83d5b844774b7e80209fbf0b966","type":"GENE","name":"CDC27P11","canonical_id":"hgnc:HGNC:51761","description":"cell division cycle 27 pseudogene 11","metadata":null},{"id":"f7855a0fd06a41cb94e54c69932e5921","type":"GENE","name":"CDC27P2","canonical_id":"hgnc:HGNC:38092","description":"cell division cycle 27 pseudogene 2","metadata":null},{"id":"b5dd6a1dacfa479190503d44ec077da1","type":"GENE","name":"CDC27P3","canonical_id":"hgnc:HGNC:51754","description":"cell division cycle 27 pseudogene 3","metadata":null},{"id":"0d37ef38688e4d31be2a54a876622246","type":"GENE","name":"CDC27P4","canonical_id":"hgnc:HGNC:51753","description":"cell division cycle 27 pseudogene 4","metadata":null},{"id":"12ce64267f7a4d868cb3f27171019003","type":"GENE","name":"CDC27P5","canonical_id":"hgnc:HGNC:51755","description":"cell division cycle 27 pseudogene 5","metadata":null},{"id":"f525c77e0cd045ae9bfc01c871580cb4","type":"GENE","name":"CDC27P6","canonical_id":"hgnc:HGNC:51756","description":"cell division cycle 27 pseudogene 6","metadata":null},{"id":"4b6fcea67da74dc58bdf8aa1d997c883","type":"GENE","name":"CDC27P7","canonical_id":"hgnc:HGNC:51757","description":"cell division cycle 27 pseudogene 7","metadata":null},{"id":"c90e04358d6146d2be2c386a1a3de8e2","type":"GENE","name":"CDC27P8","canonical_id":"hgnc:HGNC:51758","description":"cell division cycle 27 pseudogene 8","metadata":null},{"id":"ecd228d801ef4aa99bc6ebc29de6781f","type":"GENE","name":"CDC27P9","canonical_id":"hgnc:HGNC:51759","description":"cell division cycle 27 pseudogene 9","metadata":null},{"id":"36c0c9c236d749d9a0abe622fb77cac7","type":"GENE","name":"CDC34","canonical_id":"hgnc:HGNC:1734","description":null,"metadata":null},{"id":"858f843c54424f30bebcd547aa9b44b5","type":"GENE","name":"CDC37","canonical_id":"hgnc:HGNC:1735","description":"cell division cycle 37, HSP90 cochaperone","metadata":{"aliases":["P50CDC37"]}},{"id":"c3e4bdf2b7ea4875b43069835ba221cf","type":"GENE","name":"CDC37L1","canonical_id":"hgnc:HGNC:17179","description":"cell division cycle 37 like 1, HSP90 cochaperone","metadata":{"aliases":["HARC","FLJ20639","CDC37B"]}},{"id":"92f0daa0a3b04eaab6a6d0b2643dc613","type":"GENE","name":"CDC37L1-DT","canonical_id":"hgnc:HGNC:49735","description":"CDC37L1 divergent transcript","metadata":{"aliases":["CDC37L1-AS1"]}},{"id":"1435fe39ac78400d9bee176d8f434fc2","type":"GENE","name":"CDC37P1","canonical_id":"hgnc:HGNC:34406","description":"cell division cycle 37 pseudogene 1","metadata":{"aliases":["A-761H5.2"]}},{"id":"76a77862c6214a7ba903a99f2ad7bed5","type":"GENE","name":"CDC37P2","canonical_id":"hgnc:HGNC:35453","description":"cell division cycle 37 pseudogene 2","metadata":null},{"id":"ccd2593ad61941b58cbdcfc9ec213ce2","type":"GENE","name":"CDC40","canonical_id":"hgnc:HGNC:17350","description":"cell division cycle 40","metadata":{"aliases":["PRP17","EHB3","PRPF17","FLJ10564"]}},{"id":"52bc2fed6c344e31a0bfdc276a8493f6","type":"GENE","name":"CDC42","canonical_id":"hgnc:HGNC:1736","description":null,"metadata":null},{"id":"9ecc519ce85245cd9c4b07f3cd20d629","type":"GENE","name":"CDC42-AS1","canonical_id":"hgnc:HGNC:54314","description":"CDC42 antisense RNA 1","metadata":null},{"id":"20227559352f4901a58612066efdd341","type":"GENE","name":"CDC42-IT1","canonical_id":"hgnc:HGNC:41317","description":"CDC42 intronic transcript 1","metadata":null},{"id":"1491070b1a184cab8bce1350de5fbbf5","type":"GENE","name":"CDC42BPA","canonical_id":"hgnc:HGNC:1737","description":"CDC42 binding protein kinase alpha","metadata":{"aliases":["MRCKA","PK428","FLJ23347","KIAA0451","MRCKalpha"]}},{"id":"5bbbaab1fe0449ed8847e88dedf1d495","type":"GENE","name":"CDC42BPB","canonical_id":"hgnc:HGNC:1738","description":"CDC42 binding protein kinase beta","metadata":{"aliases":["MRCKB","KIAA1124"]}},{"id":"097850c6e7b449dc996d9c9e8cabedd5","type":"GENE","name":"CDC42BPB-AS1","canonical_id":"hgnc:HGNC:58618","description":"CDC42BPB antisense RNA 1","metadata":null},{"id":"c02b1463adae4f8e837fe582abb26492","type":"GENE","name":"CDC42BPG","canonical_id":"hgnc:HGNC:29829","description":null,"metadata":null},{"id":"0effe816a10841b8936f927ec4e01b10","type":"GENE","name":"CDC42EP1","canonical_id":"hgnc:HGNC:17014","description":"CDC42 effector protein 1","metadata":{"aliases":["MSE55","CEP1","Borg5"]}},{"id":"57618b863cfb495da364368ea41e9e5d","type":"GENE","name":"CDC42EP2","canonical_id":"hgnc:HGNC:16263","description":"CDC42 effector protein 2","metadata":{"aliases":["CEP2","BORG1"]}},{"id":"759efb79bc7849409de0f6cec37c728e","type":"GENE","name":"CDC42EP3","canonical_id":"hgnc:HGNC:16943","description":"CDC42 effector protein 3","metadata":{"aliases":["CEP3","UB1","BORG2"]}},{"id":"9b290b7f4ce54d738724c28252ba90a4","type":"GENE","name":"CDC42EP3-AS1","canonical_id":"hgnc:HGNC:56370","description":"CDC42EP3 antisense RNA 1","metadata":{"aliases":["AC006369.1","LINC03063"]}},{"id":"f6e850d9a1804bf8bec41f5e0a9b115d","type":"GENE","name":"CDC42EP3P1","canonical_id":"hgnc:HGNC:49673","description":"CDC42 effector protein 3 pseudogene 1","metadata":null},{"id":"f66aa98b688d4ed1a9eac2c9d0edbb36","type":"GENE","name":"CDC42EP4","canonical_id":"hgnc:HGNC:17147","description":"CDC42 effector protein 4","metadata":{"aliases":["CEP4","KAIA1777","BORG4","MGC3740","MGC17125"]}},{"id":"cc7f563afc444f8b9182067f8823bf5c","type":"GENE","name":"CDC42EP5","canonical_id":"hgnc:HGNC:17408","description":"CDC42 effector protein 5","metadata":{"aliases":["CEP5","Borg3"]}},{"id":"49032f43b5fe44efa44af510b663ab4d","type":"GENE","name":"CDC42P1","canonical_id":"hgnc:HGNC:16339","description":"CDC42 pseudogene 1","metadata":{"aliases":["bK3216D2.3"]}},{"id":"3ee4ab74b92e4696b3b72dff0c4d5fa3","type":"GENE","name":"CDC42P2","canonical_id":"hgnc:HGNC:33952","description":"CDC42 pseudogene 2","metadata":null},{"id":"f731b814194746aeb0aafb98ca59e8c6","type":"GENE","name":"CDC42P3","canonical_id":"hgnc:HGNC:44427","description":"CDC42 pseudogene 3","metadata":null},{"id":"394a17a791ed484aa1bb7468a4f6adb4","type":"GENE","name":"CDC42P4","canonical_id":"hgnc:HGNC:44428","description":"CDC42 pseudogene 4","metadata":null},{"id":"929fb01725084491baac4274696f2763","type":"GENE","name":"CDC42P5","canonical_id":"hgnc:HGNC:44429","description":"CDC42 pseudogene 5","metadata":null},{"id":"3a69e7d6c0b64c4eb75186a08eea5c6c","type":"GENE","name":"CDC42P6","canonical_id":"hgnc:HGNC:44430","description":"CDC42 pseudogene 6","metadata":null},{"id":"c82074c1cad142fda01bffe47883375c","type":"GENE","name":"CDC42P7","canonical_id":"hgnc:HGNC:56410","description":"CDC42 pseudogene 7","metadata":null},{"id":"5f3aa7a496504d149fa4921ea990b232","type":"GENE","name":"CDC42P8","canonical_id":"hgnc:HGNC:59181","description":"CDC42 pseudogene 8","metadata":null},{"id":"1471b90c1f704e6d957af690e8f23026","type":"GENE","name":"CDC42P9","canonical_id":"hgnc:HGNC:59182","description":"CDC42 pseudogene 9","metadata":null},{"id":"aac4f484449f44d291a95553f0af8bcb","type":"GENE","name":"CDC42SE1","canonical_id":"hgnc:HGNC:17719","description":"CDC42 small effector 1","metadata":{"aliases":["SCIP1","SPEC1"]}},{"id":"8980f816e3664ff2a1b53fbb1c7a5962","type":"GENE","name":"CDC42SE2","canonical_id":"hgnc:HGNC:18547","description":"CDC42 small effector 2","metadata":{"aliases":["FLJ21967","SPEC2"]}},{"id":"b6f81cef85274a5e82c00cb9b543c1c5","type":"GENE","name":"CDC45","canonical_id":"hgnc:HGNC:1739","description":"cell division cycle 45","metadata":{"aliases":["CDC45L2","CDC45L"]}},{"id":"8bae1be3444e4b1a8a4f489c1d30d5d1","type":"GENE","name":"CDC50A","canonical_id":"hgnc:HGNC:16667","description":"cell division cycle 50 P4-ATPase accessory subunit A","metadata":{"aliases":["FLJ10856","C6orf67","TMEM30A"]}},{"id":"a6ca6d5a2dc8463f8e1c3d1dbb53bd08","type":"GENE","name":"CDC50B","canonical_id":"hgnc:HGNC:27254","description":"cell division cycle 50 P4-ATPase accessory subunit B","metadata":{"aliases":["TMEM30B"]}},{"id":"acb5ffc6cfd14e118378796f6f8f63e9","type":"GENE","name":"CDC50CP","canonical_id":"hgnc:HGNC:30443","description":"CDC50 family member C, pseudogene","metadata":{"aliases":["CDC50C","TMEM30C","TMEM30CP"]}},{"id":"5b5addad5ac14ba890aa261734818fbb","type":"GENE","name":"CDC5L","canonical_id":"hgnc:HGNC:1743","description":null,"metadata":null},{"id":"7345f68fbdcf4cf0b034e30afdfd8881","type":"GENE","name":"CDC5L-AS1","canonical_id":"hgnc:HGNC:59416","description":"CDC5L antisense RNA 1","metadata":null},{"id":"075f9d685f0a4fd688ba46d2b3aecac4","type":"GENE","name":"CDC6","canonical_id":"hgnc:HGNC:1744","description":null,"metadata":null},{"id":"f11ff87a4a78488497b844ba8ee0d103","type":"GENE","name":"CDC7","canonical_id":"hgnc:HGNC:1745","description":"cell division cycle 7","metadata":{"aliases":["Hsk1","huCdc7","HsCdc7","CDC7L1"]}},{"id":"aa1e1d1af11e41cdb5028246e45f550c","type":"GENE","name":"CDC73","canonical_id":"hgnc:HGNC:16783","description":null,"metadata":null},{"id":"b700df1ecca14602b536128309be4688","type":"GENE","name":"CDCA2","canonical_id":"hgnc:HGNC:14623","description":"cell division cycle associated 2","metadata":{"aliases":["Repo-Man","PPP1R81"]}},{"id":"a83e22ec35f84620a7daced776902a33","type":"GENE","name":"CDCA3","canonical_id":"hgnc:HGNC:14624","description":"cell division cycle associated 3","metadata":{"aliases":["TOME-1","GRCC8"]}},{"id":"811030f33548468ca4c083d3cc570584","type":"GENE","name":"CDCA3P1","canonical_id":"hgnc:HGNC:56264","description":"CDCA3 pseudogene 1","metadata":{"aliases":["lncCDCA3L"]}},{"id":"50f87ce826df4974ae0fed8786c3200e","type":"GENE","name":"CDCA4","canonical_id":"hgnc:HGNC:14625","description":"cell division cycle associated 4","metadata":{"aliases":["SEI-3","TRIP-Br3","FLJ20764","Hepp"]}},{"id":"4230d5ff8a184e64a75446f9bb31171e","type":"GENE","name":"CDCA4P1","canonical_id":"hgnc:HGNC:49770","description":"cell division cycle associated 4 pseudogene 1","metadata":null},{"id":"741dda57b4de4d2da7c35d8571e380c5","type":"GENE","name":"CDCA4P2","canonical_id":"hgnc:HGNC:49771","description":"cell division cycle associated 4 pseudogene 2","metadata":null},{"id":"e7d053d3be82475a995d6aeaebb071dd","type":"GENE","name":"CDCA4P3","canonical_id":"hgnc:HGNC:49772","description":"cell division cycle associated 4 pseudogene 3","metadata":null},{"id":"123b60a57fc1408fbb8e4692c34ee058","type":"GENE","name":"CDCA4P4","canonical_id":"hgnc:HGNC:49773","description":"cell division cycle associated 4 pseudogene 4","metadata":null},{"id":"2a437fdb2de2466bb1d221b37beaab1c","type":"GENE","name":"CDCA5","canonical_id":"hgnc:HGNC:14626","description":"cell division cycle associated 5","metadata":null},{"id":"5305e89c4f00489998e2fac5e535e288","type":"GENE","name":"CDCA7","canonical_id":"hgnc:HGNC:14628","description":null,"metadata":null},{"id":"682218e2ba5645e380d809e264313c02","type":"GENE","name":"CDCA7L","canonical_id":"hgnc:HGNC:30777","description":null,"metadata":null},{"id":"829e66bb067a47f8a71149a7487c4295","type":"GENE","name":"CDCA7P1","canonical_id":"hgnc:HGNC:56918","description":"CDCA7 pseudogene 1","metadata":null},{"id":"2b967663a7fd45858fc85a1e6b560e3c","type":"GENE","name":"CDCA7P2","canonical_id":"hgnc:HGNC:56919","description":"CDCA7 pseudogene 2","metadata":null},{"id":"d1f816b850cd4b26861f34d4ea34a7b3","type":"GENE","name":"CDCA8","canonical_id":"hgnc:HGNC:14629","description":"cell division cycle associated 8","metadata":{"aliases":["FLJ12042","MESRGP","BOR","DasraB"]}},{"id":"f5bb2414e5114522baebb20cac5dcee0","type":"GENE","name":"CDCP1","canonical_id":"hgnc:HGNC:24357","description":"CUB domain containing protein 1","metadata":{"aliases":["CD318","SIMA135"]}},{"id":"12c8e966e7274ea4a071ad8e7834d4ab","type":"GENE","name":"CDCP2","canonical_id":"hgnc:HGNC:27297","description":"CUB domain containing protein 2","metadata":null},{"id":"63305d8609e949bf848f56a65e104664","type":"GENE","name":"CDH1","canonical_id":"hgnc:HGNC:1748","description":null,"metadata":null},{"id":"bbfb76a2c91845e48b0b2a5ee1ddc82d","type":"GENE","name":"CDH10","canonical_id":"hgnc:HGNC:1749","description":"cadherin 10","metadata":null},{"id":"7bb67d2ce8e34d25bbe27bd3ef17d86b","type":"GENE","name":"CDH10-AS2","canonical_id":"hgnc:HGNC:59018","description":"CDH10 antisense RNA 2","metadata":null},{"id":"950c5ecebf074b5592b31e1ddb8a46ef","type":"GENE","name":"CDH11","canonical_id":"hgnc:HGNC:1750","description":null,"metadata":null},{"id":"dcc7041b311642daa35ca6f300c0dadb","type":"GENE","name":"CDH12","canonical_id":"hgnc:HGNC:1751","description":"cadherin 12","metadata":{"aliases":["Br-cadherin","CDHB"]}},{"id":"6674422bb1f34cfa96336661e78a962c","type":"GENE","name":"CDH12-AS1","canonical_id":"hgnc:HGNC:59011","description":"CDH12 antisense RNA 1","metadata":null},{"id":"2679318b00e84a1e80c87b741f1cf7c0","type":"GENE","name":"CDH12-AS2","canonical_id":"hgnc:HGNC:59012","description":"CDH12 antisense RNA 2","metadata":null},{"id":"55d10d3a5e974b8180e93f6b66524ed2","type":"GENE","name":"CDH12-AS3","canonical_id":"hgnc:HGNC:59013","description":"CDH12 antisense RNA 3","metadata":null},{"id":"bed48056a7f7429ba6f6381315fc679e","type":"GENE","name":"CDH12-AS4","canonical_id":"hgnc:HGNC:59014","description":"CDH12 antisense RNA 4","metadata":null},{"id":"6e89ede0690547098f3fa13bd918e45b","type":"GENE","name":"CDH12-AS5","canonical_id":"hgnc:HGNC:59015","description":"CDH12 antisense RNA 5","metadata":null},{"id":"ab40e1e0660a4650b14ef5f4c95c2978","type":"GENE","name":"CDH12P1","canonical_id":"hgnc:HGNC:37698","description":"cadherin 12 pseudogene 1","metadata":null},{"id":"9cbb6e5c38884262b7974abcae677b74","type":"GENE","name":"CDH12P2","canonical_id":"hgnc:HGNC:1752","description":"cadherin 12 pseudogene 2","metadata":{"aliases":["C41-CAD","CDH12P"]}},{"id":"3829342817b744c5bf8ed1e6b137f16f","type":"GENE","name":"CDH12P3","canonical_id":"hgnc:HGNC:37699","description":"cadherin 12 pseudogene 3","metadata":null},{"id":"d78615b3f4f8410495cbabe6afa3881f","type":"GENE","name":"CDH12P4","canonical_id":"hgnc:HGNC:37700","description":"cadherin 12 pseudogene 4","metadata":null},{"id":"ef5ab56f7d9549dc82439154911c8533","type":"GENE","name":"CDH13","canonical_id":"hgnc:HGNC:1753","description":null,"metadata":null},{"id":"096d7a02a45f42e3800f774ea92fa465","type":"GENE","name":"CDH13-AS1","canonical_id":"hgnc:HGNC:55989","description":"CDH13 antisense RNA 1","metadata":{"aliases":["RP11-543N12.1"]}},{"id":"34424b0a7cbe47a399b99c8b6ebb94ee","type":"GENE","name":"CDH13-AS2","canonical_id":"hgnc:HGNC:56243","description":"CDH13 antisense RNA 2","metadata":null},{"id":"a16a44fd41394530a5ec3af84d857238","type":"GENE","name":"CDH15","canonical_id":"hgnc:HGNC:1754","description":"cadherin 15","metadata":{"aliases":["CDH3","CDH14"]}},{"id":"a5a80efb8b804139bb60b2fe1991177c","type":"GENE","name":"CDH16","canonical_id":"hgnc:HGNC:1755","description":"cadherin 16","metadata":null},{"id":"c5a6b9c57c6c461e94f51546f7599d4d","type":"GENE","name":"CDH17","canonical_id":"hgnc:HGNC:1756","description":null,"metadata":null},{"id":"38aafe0621bf4a398126698fb42b252d","type":"GENE","name":"CDH18","canonical_id":"hgnc:HGNC:1757","description":"cadherin 18","metadata":{"aliases":["CDH14","EY-CADHERIN"]}},{"id":"426686f8df704f07b22f788bb31d46c5","type":"GENE","name":"CDH18-AS1","canonical_id":"hgnc:HGNC:53088","description":"CDH18 antisense RNA 1","metadata":null},{"id":"f32ac739901d463489110ee30d23edbc","type":"GENE","name":"CDH18-AS2","canonical_id":"hgnc:HGNC:59009","description":"CDH18 antisense RNA 2","metadata":null},{"id":"76bbc82906b94c2d8a67f1b67c86716e","type":"GENE","name":"CDH18-AS3","canonical_id":"hgnc:HGNC:59010","description":"CDH18 antisense RNA 3","metadata":null},{"id":"9bd962954573429d81032b386ee46e59","type":"GENE","name":"CDH19","canonical_id":"hgnc:HGNC:1758","description":"cadherin 19","metadata":{"aliases":["CDH7"]}},{"id":"bfd2e7ac0d1f4486acc2fabc41d70625","type":"GENE","name":"CDH2","canonical_id":"hgnc:HGNC:1759","description":null,"metadata":null},{"id":"07f310d16ed54cb3831745a85a6182fb","type":"GENE","name":"CDH2-AS1","canonical_id":"hgnc:HGNC:40138","description":"CDH2 antisense RNA 1","metadata":null},{"id":"6c481e9d43904b44942352f1cfbc71ea","type":"GENE","name":"CDH20","canonical_id":"hgnc:HGNC:1760","description":"cadherin 20","metadata":{"aliases":["CDH7L3","Cdh7"]}},{"id":"c3661ee24109473081bbaac9d7e94316","type":"GENE","name":"CDH22","canonical_id":"hgnc:HGNC:13251","description":"cadherin 22","metadata":{"aliases":["dJ998H6.1","C20orf25"]}},{"id":"d43df356dd00446ab9702e1d9fa75c93","type":"GENE","name":"CDH23","canonical_id":"hgnc:HGNC:13733","description":"cadherin related 23","metadata":{"aliases":["CDHR23","DFNB12","USH1D"]}},{"id":"41ea48b7dc564944a7871cf9a4c3ef39","type":"GENE","name":"CDH23-AS1","canonical_id":"hgnc:HGNC:31433","description":"CDH23 antisense RNA 1","metadata":{"aliases":["bA327E2.3","C10orf106","NCRNA00223"]}},{"id":"975d84f6f91d4619b702069942941e2c","type":"GENE","name":"CDH24","canonical_id":"hgnc:HGNC:14265","description":"cadherin 24","metadata":{"aliases":["CDH11L"]}},{"id":"3c03631114a5421598f6af518ac1a0f5","type":"GENE","name":"CDH26","canonical_id":"hgnc:HGNC:15902","description":"cadherin 26","metadata":{"aliases":["VR20"]}},{"id":"4f85695595be42749fe9eb984a34f096","type":"GENE","name":"CDH3","canonical_id":"hgnc:HGNC:1762","description":null,"metadata":null},{"id":"323ca393cdc1483fbe249d6684b1ff9b","type":"GENE","name":"CDH3-AS1","canonical_id":"hgnc:HGNC:56084","description":"CDH3 antisense RNA 1","metadata":null},{"id":"2fb4edc7c782455d98cdde3e38c7b457","type":"GENE","name":"CDH4","canonical_id":"hgnc:HGNC:1763","description":"cadherin 4","metadata":{"aliases":["R-CAD"]}},{"id":"3df3e851960b42c1aef356edfde7b0a8","type":"GENE","name":"CDH4-AS1","canonical_id":"hgnc:HGNC:40139","description":"CDH4 antisense RNA 1","metadata":null},{"id":"bb96ad61e6bc4ae0a51a22bbeed3511e","type":"GENE","name":"CDH4-AS2","canonical_id":"hgnc:HGNC:58218","description":"CDH4 antisense RNA 2","metadata":null},{"id":"155e1694a5014c60bceb19884450a5e2","type":"GENE","name":"CDH5","canonical_id":"hgnc:HGNC:1764","description":null,"metadata":null},{"id":"f6a277c9cd7c46fe865e4f3ee74a2f63","type":"GENE","name":"CDH6","canonical_id":"hgnc:HGNC:1765","description":null,"metadata":null},{"id":"0cb5720d493647f196603aefd829cc74","type":"GENE","name":"CDH7","canonical_id":"hgnc:HGNC:1766","description":"cadherin 7","metadata":null},{"id":"0bcf5c35c77441beadf41389311e3f11","type":"GENE","name":"CDH8","canonical_id":"hgnc:HGNC:1767","description":"cadherin 8","metadata":null},{"id":"dc617f63695b4f408f4a87f6f2b6c46f","type":"GENE","name":"CDH8-AS1","canonical_id":"hgnc:HGNC:55399","description":"CDH8 antisense RNA 1","metadata":null},{"id":"63576377ca45429584a37e4a462082bd","type":"GENE","name":"CDH9","canonical_id":"hgnc:HGNC:1768","description":"cadherin 9","metadata":null},{"id":"24e7fb152cbb4308a3ae64c07e286622","type":"GENE","name":"CDHR1","canonical_id":"hgnc:HGNC:14550","description":"cadherin related family member 1","metadata":{"aliases":["KIAA1775","CORD15","RP65","PCDH21"]}},{"id":"b56def867ac14427a0ab4b030d3c6ea1","type":"GENE","name":"CDHR17P","canonical_id":"hgnc:HGNC:53741","description":"cadherin related family member 17, pseudogene","metadata":null},{"id":"6b112632975641f0b8a8bdc90cc9f35f","type":"GENE","name":"CDHR18P","canonical_id":"hgnc:HGNC:53742","description":"cadherin related family member 18, pseudogene","metadata":null},{"id":"70755ca5381944d787f2f5bf0452ea70","type":"GENE","name":"CDHR2","canonical_id":"hgnc:HGNC:18231","description":"cadherin related family member 2","metadata":{"aliases":["PC-LKC","FLJ20124","FLJ20383","PCLKC","PCDH24"]}},{"id":"16c7a04d51114155bf06c04473998681","type":"GENE","name":"CDHR3","canonical_id":"hgnc:HGNC:26308","description":"cadherin related family member 3","metadata":{"aliases":["FLJ44366","FLJ23834","CDH28"]}},{"id":"569aa11aa9614d84bc94201dc7b766fe","type":"GENE","name":"CDHR4","canonical_id":"hgnc:HGNC:34527","description":"cadherin related family member 4","metadata":{"aliases":["VLLR9392","CDH29"]}},{"id":"327a2b7a1c3540f3a46c7febe6404613","type":"GENE","name":"CDHR5","canonical_id":"hgnc:HGNC:7521","description":"cadherin related family member 5","metadata":{"aliases":["FLJ20219","MU-PCDH","MUCDHL","MUPCDH"]}},{"id":"9c452834c442474ca2a33266c59940a0","type":"GENE","name":"CDIN1","canonical_id":"hgnc:HGNC:26929","description":"CDAN1 interacting nuclease 1","metadata":{"aliases":["HH114","MGC11326","FLJ22851","C15orf41"]}},{"id":"d0cc99e4ce80424298a210f1e4135bc4","type":"GENE","name":"CDIP1","canonical_id":"hgnc:HGNC:13234","description":"cell death inducing p53 target 1","metadata":{"aliases":["CDIP","LITAFL","C16orf5"]}},{"id":"4be0544246ea48cba36f3d2d17b4958b","type":"GENE","name":"CDIPT","canonical_id":"hgnc:HGNC:1769","description":"CDP-diacylglycerol--inositol 3-phosphatidyltransferase","metadata":{"aliases":["PIS1","PIS"]}},{"id":"acc606907bb4409f917f477b72ec9141","type":"GENE","name":"CDIPTOSP","canonical_id":"hgnc:HGNC:48609","description":"CDIP transferase opposite strand, pseudogene","metadata":{"aliases":["lnc-CTHCC","CDIPT-AS1"]}},{"id":"058dd868a06540b6a418315be57c418f","type":"GENE","name":"CDK1","canonical_id":"hgnc:HGNC:1722","description":null,"metadata":null},{"id":"6b2e884adf1b470ba72d9c8d2e9e190e","type":"GENE","name":"CDK10","canonical_id":"hgnc:HGNC:1770","description":"cyclin dependent kinase 10","metadata":{"aliases":["PISSLRE"]}},{"id":"a756f5c94d6e474086d8911c31d9d9a8","type":"GENE","name":"CDK11A","canonical_id":"hgnc:HGNC:1730","description":"cyclin dependent kinase 11A","metadata":{"aliases":["PITSLRE","CDK11-p110","CDK11-p58","CDK11-p46","p58GTA","CDC2L3","CDC2L2"]}},{"id":"def706264bd1471ebf3722b3f5baaa59","type":"GENE","name":"CDK11B","canonical_id":"hgnc:HGNC:1729","description":null,"metadata":null},{"id":"333bba42d18f4defa0e44d92db008131","type":"GENE","name":"CDK12","canonical_id":"hgnc:HGNC:24224","description":"cyclin dependent kinase 12","metadata":{"aliases":["CRK7","CRKR","KIAA0904","CRKRS"]}},{"id":"33dd0bfbc9074528bcb7ca3d82c27a20","type":"GENE","name":"CDK13","canonical_id":"hgnc:HGNC:1733","description":"cyclin dependent kinase 13","metadata":{"aliases":["CHED","CDC2L","KIAA1791","CDC2L5"]}},{"id":"634b700612c946459865ab05f067291e","type":"GENE","name":"CDK13-DT","canonical_id":"hgnc:HGNC:55407","description":"CDK13 divergent transcript","metadata":{"aliases":["AC072061.1"]}},{"id":"f0e4d2187fe44e04b054868a20c87604","type":"GENE","name":"CDK14","canonical_id":"hgnc:HGNC:8883","description":"cyclin dependent kinase 14","metadata":{"aliases":["PFTAIRE1","PFTK1"]}},{"id":"3330b17d4cb94063aec8f96cf07b1aca","type":"GENE","name":"CDK15","canonical_id":"hgnc:HGNC:14434","description":"cyclin dependent kinase 15","metadata":{"aliases":["PFTAIRE2","ALS2CR7","PFTK2"]}},{"id":"2a4d9e5b390144049bd4e8b6e536deb0","type":"GENE","name":"CDK16","canonical_id":"hgnc:HGNC:8749","description":"cyclin dependent kinase 16","metadata":{"aliases":["PCTAIRE","PCTAIRE1","PCTGAIRE","FLJ16665","PCTK1"]}},{"id":"ceb75ce6f8c54fc5908854eefc128368","type":"GENE","name":"CDK17","canonical_id":"hgnc:HGNC:8750","description":"cyclin dependent kinase 17","metadata":{"aliases":["PCTAIRE2","PCTK2"]}},{"id":"40f14098e9cd4aa6bff21b22a5d1910e","type":"GENE","name":"CDK18","canonical_id":"hgnc:HGNC:8751","description":"cyclin dependent kinase 18","metadata":{"aliases":["PCTAIRE3","PCTK3"]}},{"id":"9eb63717a19044b491e71b8bd76911e5","type":"GENE","name":"CDK19","canonical_id":"hgnc:HGNC:19338","description":"cyclin dependent kinase 19","metadata":{"aliases":["KIAA1028","bA346C16.3","CDK11","CDC2L6"]}},{"id":"1e152b1c92314062989bcf4a108180e5","type":"GENE","name":"CDK2","canonical_id":"hgnc:HGNC:1771","description":null,"metadata":null},{"id":"0389c71466304749adb398ee1a672625","type":"GENE","name":"CDK20","canonical_id":"hgnc:HGNC:21420","description":null,"metadata":null},{"id":"9eca8a68111d454380503fcda5fc44ff","type":"GENE","name":"CDK20-AS1","canonical_id":"hgnc:HGNC:58688","description":"CDK20 antisense RNA 1","metadata":null},{"id":"41a9522be0fe4b6aa346e6c8686b48d8","type":"GENE","name":"CDK2AP1","canonical_id":"hgnc:HGNC:14002","description":"cyclin dependent kinase 2 associated protein 1","metadata":{"aliases":["DORC1","doc-1","DOC1","ST19","p12DOC-1"]}},{"id":"05da089537344bb1ad040f156cb8e675","type":"GENE","name":"CDK2AP1P1","canonical_id":"hgnc:HGNC:56493","description":"CDK2AP1 pseudogene 1","metadata":null},{"id":"52ddc32aea374268ac52579f7211ebe3","type":"GENE","name":"CDK2AP2","canonical_id":"hgnc:HGNC:30833","description":"cyclin dependent kinase 2 associated protein 2","metadata":{"aliases":["DOC-1R","p14"]}},{"id":"f51e08d68da949b3ae44df75b26658e8","type":"GENE","name":"CDK2AP2P1","canonical_id":"hgnc:HGNC:38492","description":"cyclin dependent kinase 2 associated protein 2 pseudogene 1","metadata":null},{"id":"2600cf2782bb4aa989dadd0fcde0ce2e","type":"GENE","name":"CDK2AP2P2","canonical_id":"hgnc:HGNC:38493","description":"cyclin dependent kinase 2 associated protein 2 pseudogene 2","metadata":null},{"id":"2129d88bc53643b19eddd153ae1c6ae0","type":"GENE","name":"CDK2AP2P3","canonical_id":"hgnc:HGNC:38494","description":"cyclin dependent kinase 2 associated protein 2 pseudogene 3","metadata":null},{"id":"d621a83077144768aab9bbc332bcfaa7","type":"GENE","name":"CDK3","canonical_id":"hgnc:HGNC:1772","description":"cyclin dependent kinase 3","metadata":null},{"id":"f882f7426cfa4674b06bf4fbfbb8e85e","type":"GENE","name":"CDK4","canonical_id":"hgnc:HGNC:1773","description":null,"metadata":null},{"id":"6ec88b7cd42445bf87edf8b5eea59a5b","type":"GENE","name":"CDK4","canonical_id":"ensembl:ENSG00000135446","description":null,"metadata":null},{"id":"c35f41bffa8b43428fa7622fce893ae0","type":"PROTEIN","name":"CDK4","canonical_id":"uniprot:P11802","description":null,"metadata":null},{"id":"98b2c86556f744d4ae7e90d989155ff2","type":"GENE","name":"CDK4P1","canonical_id":"hgnc:HGNC:19040","description":"cyclin dependent kinase 4 pseudogene 1","metadata":{"aliases":["CDK4PS"]}},{"id":"d476b52034504c099fdc75b59f43e643","type":"GENE","name":"CDK5","canonical_id":"hgnc:HGNC:1774","description":"cyclin dependent kinase 5","metadata":{"aliases":["PSSALRE"]}},{"id":"8c9fdfa1d7f449ce93706bb594b4c4a1","type":"GENE","name":"CDK5P1","canonical_id":"hgnc:HGNC:21261","description":"cyclin dependent kinase 5 pseudogene 1","metadata":{"aliases":["CDK5PS"]}},{"id":"08cf0ad1202c4efc99ff2a43478647ee","type":"GENE","name":"CDK5R1","canonical_id":"hgnc:HGNC:1775","description":null,"metadata":null},{"id":"f52797e07a2946848214fc903b378cee","type":"GENE","name":"CDK5R2","canonical_id":"hgnc:HGNC:1776","description":"cyclin dependent kinase 5 regulatory subunit 2","metadata":{"aliases":["p39nck5ai","P39","NCK5AI"]}},{"id":"0684b108fe1b4800bb957e8c66ae0d89","type":"GENE","name":"CDK5R2-AS1","canonical_id":"hgnc:HGNC:55677","description":"CDK5R2 antisense RNA 1","metadata":{"aliases":["LINC01494"]}},{"id":"27f2ab7346394a9bb72a54d55b6fde53","type":"GENE","name":"CDK5RAP1","canonical_id":"hgnc:HGNC:15880","description":"CDK5RAP1 mitochondrial tRNA methylthiotransferase","metadata":{"aliases":["CGI-05","HSPC167","C42","C20orf34"]}},{"id":"c6702bf11a384f75a2eb388a57408983","type":"GENE","name":"CDK5RAP2","canonical_id":"hgnc:HGNC:18672","description":"CDK5 regulatory subunit associated protein 2","metadata":{"aliases":["C48","FLJ10867","CEP215","MCPH3"]}},{"id":"5e65b2fd9c2d45998cee98d779ea6510","type":"GENE","name":"CDK5RAP3","canonical_id":"hgnc:HGNC:18673","description":"CDK5 regulatory subunit associated protein 3","metadata":{"aliases":["MST016","FLJ13660","C53","IC53","HSF-27","OK/SW-cl.114","LZAP"]}},{"id":"940aa84b983c49fc9f7fd68a6c56ff09","type":"GENE","name":"CDK5RAP3P1","canonical_id":"hgnc:HGNC:56953","description":"CDK5RAP3 pseudogene 1","metadata":null},{"id":"74ffea492e2e4c699deeee0455ebcb6b","type":"GENE","name":"CDK6","canonical_id":"hgnc:HGNC:1777","description":null,"metadata":null},{"id":"3f3a98d760ab48f1bc6767cfe7a658d0","type":"GENE","name":"CDK6","canonical_id":"ensembl:ENSG00000105810","description":null,"metadata":null},{"id":"6e19a7a7b9e44653b375c57a7d0c1492","type":"PROTEIN","name":"CDK6","canonical_id":"uniprot:Q00534","description":null,"metadata":null},{"id":"377e348259fc40fc998f32ade83ef40b","type":"GENE","name":"CDK6-AS1","canonical_id":"hgnc:HGNC:40141","description":"CDK6 antisense RNA 1","metadata":{"aliases":["BALR-2","AC002454.1"]}},{"id":"c5b5b2fe8d88498d8038d06ad0beb57a","type":"GENE","name":"CDK7","canonical_id":"hgnc:HGNC:1778","description":"cyclin dependent kinase 7","metadata":{"aliases":["CAK1","CDKN7","MO15","STK1","CAK"]}},{"id":"8d20ae8ba0254ccf9797a01d1a12a860","type":"GENE","name":"CDK7P1","canonical_id":"hgnc:HGNC:18614","description":"cyclin dependent kinase 7 pseudogene 1","metadata":{"aliases":["CDK7PS"]}},{"id":"4b8a803e39a7468eaef2685ae7da6481","type":"GENE","name":"CDK8","canonical_id":"hgnc:HGNC:1779","description":"cyclin dependent kinase 8","metadata":{"aliases":["K35"]}},{"id":"52778bb4b1c6424ca507eaaac0946874","type":"GENE","name":"CDK8P1","canonical_id":"hgnc:HGNC:18995","description":"cyclin dependent kinase 8 pseudogene 1","metadata":{"aliases":["CDK8PS"]}},{"id":"eda4ac5c36704cca956c226302d341fa","type":"GENE","name":"CDK8P2","canonical_id":"hgnc:HGNC:52296","description":"cyclin dependent kinase 8 pseudogene 2","metadata":null},{"id":"d3dc27ced21d43f19165fdb403821e78","type":"GENE","name":"CDK9","canonical_id":"hgnc:HGNC:1780","description":"cyclin dependent kinase 9","metadata":{"aliases":["PITALRE","C-2k","TAK","CDC2L4"]}},{"id":"34b697b4b6cc40fda22cf5ad7c8de654","type":"GENE","name":"CDKAL1","canonical_id":"hgnc:HGNC:21050","description":"CDKAL1 threonylcarbamoyladenosine tRNA methylthiotransferase","metadata":{"aliases":["FLJ20342"]}},{"id":"b45759ddcebc4119b7613850dbada113","type":"GENE","name":"CDKAL1-AS1","canonical_id":"hgnc:HGNC:40951","description":"CDKAL1 antisense RNA 1","metadata":null},{"id":"16dd4548aa9d47c0a8289c355899db16","type":"GENE","name":"CDKAL1-AS2","canonical_id":"hgnc:HGNC:59371","description":"CDKAL1 antisense RNA 2","metadata":null},{"id":"8f4928c4493c48efb908f642de7a6ec3","type":"GENE","name":"CDKAL1-AS3","canonical_id":"hgnc:HGNC:59372","description":"CDKAL1 antisense RNA 3","metadata":null},{"id":"a95007da1afb4addafd072a7ff82f978","type":"GENE","name":"CDKL1","canonical_id":"hgnc:HGNC:1781","description":"cyclin dependent kinase like 1","metadata":{"aliases":["KKIALRE"]}},{"id":"49d161e7bc534bbfb99a112dce701b8b","type":"GENE","name":"CDKL2","canonical_id":"hgnc:HGNC:1782","description":"cyclin dependent kinase like 2","metadata":{"aliases":["P56","KKIAMRE"]}},{"id":"7237bda67b9048c7859a3c69b61ac06a","type":"GENE","name":"CDKL3","canonical_id":"hgnc:HGNC:15483","description":"cyclin dependent kinase like 3","metadata":{"aliases":["NKIAMRE"]}},{"id":"4ea8ed9ed727441e9ca966220e635771","type":"GENE","name":"CDKL4","canonical_id":"hgnc:HGNC:19287","description":"cyclin dependent kinase like 4","metadata":null},{"id":"acf05e65511c4d6eae02c0bf57b1f14c","type":"GENE","name":"CDKL5","canonical_id":"hgnc:HGNC:11411","description":null,"metadata":null},{"id":"c648816b9be04c46afedbdc11b11039d","type":"GENE","name":"CDKN1A","canonical_id":"hgnc:HGNC:1784","description":null,"metadata":null},{"id":"ebd42e7ada09472fbcc04960b0825b97","type":"GENE","name":"CDKN1A-AS1","canonical_id":"hgnc:HGNC:42399","description":"CDKN1A antisense RNA 1","metadata":{"aliases":["p21NAT"]}},{"id":"68497f31625c4c4f820090441b5f9713","type":"GENE","name":"CDKN1B","canonical_id":"hgnc:HGNC:1785","description":null,"metadata":null},{"id":"8f5c99ea18d84d2f8bc74124b5dfb8dd","type":"GENE","name":"CDKN1C","canonical_id":"hgnc:HGNC:1786","description":null,"metadata":null},{"id":"7de69bab348e48d5b01de60b5cc1f40e","type":"GENE","name":"CDKN2A","canonical_id":"hgnc:HGNC:1787","description":null,"metadata":null},{"id":"6e2871c2780d422f910ae722f77ff179","type":"GENE","name":"CDKN2A-AS1","canonical_id":"hgnc:HGNC:23831","description":"CDKN2A antisense RNA 1","metadata":{"aliases":["bA149I2.3","C9orf53","CDKN2A-DT"]}},{"id":"98c89085bdd94f4ca8866c5deea37384","type":"GENE","name":"CDKN2AIP","canonical_id":"hgnc:HGNC:24325","description":"CDKN2A interacting protein","metadata":{"aliases":["XTBD2","FLJ20036","CARF"]}},{"id":"fed9b6d58a554a9281251a3982487b3b","type":"GENE","name":"CDKN2B","canonical_id":"hgnc:HGNC:1788","description":null,"metadata":null},{"id":"8e9b8c7182e144d29507fdf94b05c0ed","type":"GENE","name":"CDKN2B-AS1","canonical_id":"hgnc:HGNC:34341","description":"CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1","metadata":{"aliases":["ANRIL","RP11-145E5.4","NCRNA00089","p15AS","CDKN2B-AS","PCAT12","66CTG","CDKN2BAS"]}},{"id":"ae08aadbaada4d1599e064d8ba83c6e4","type":"GENE","name":"CDKN2C","canonical_id":"hgnc:HGNC:1789","description":null,"metadata":null},{"id":"de3371daa9644af1bbe306b298b5f7b1","type":"GENE","name":"CDKN2D","canonical_id":"hgnc:HGNC:1790","description":"cyclin dependent kinase inhibitor 2D","metadata":{"aliases":["INK4D","p19"]}},{"id":"e62ece9802d94d569b7fb816d934bbf0","type":"GENE","name":"CDKN3","canonical_id":"hgnc:HGNC:1791","description":null,"metadata":null},{"id":"76b50711e3aa4c7d8a414abb3b891e69","type":"GENE","name":"CDNF","canonical_id":"hgnc:HGNC:24913","description":"cerebral dopamine neurotrophic factor","metadata":{"aliases":["ARMETL1"]}},{"id":"7f8254f1e5cf46e88ce21084cb95a3cf","type":"GENE","name":"CDO1","canonical_id":"hgnc:HGNC:1795","description":null,"metadata":null},{"id":"3cfa9fd437964f0d8dcf7097b7b8979f","type":"GENE","name":"CDON","canonical_id":"hgnc:HGNC:17104","description":"cell adhesion associated, oncogene regulated","metadata":{"aliases":["ORCAM","CDO","CDON1","Ihog"]}},{"id":"50bfb2f3a9ce48349618cec5224affed","type":"GENE","name":"CDONP1","canonical_id":"hgnc:HGNC:58647","description":"CDON pseudogene 1","metadata":null},{"id":"43406c6201c04b93911ae9bb7b6c0c2f","type":"GENE","name":"CDONP2","canonical_id":"hgnc:HGNC:58648","description":"CDON pseudogene 2","metadata":null},{"id":"5853f18aadd44b58816caf6073416f70","type":"GENE","name":"CDONP3","canonical_id":"hgnc:HGNC:58649","description":"CDON pseudogene 3","metadata":null},{"id":"12417480091e4ac9a7c9b059ff386382","type":"GENE","name":"CDONP4","canonical_id":"hgnc:HGNC:58650","description":"CDON pseudogene 4","metadata":null},{"id":"d6dfae0236bc4a4f999a244090e86a58","type":"GO_TERM","name":"CDP biosynthetic process","canonical_id":"go:GO:0046705","description":"\"The chemical reactions and pathways resulting in the formation of CDP, cytidine (5'-)diphosphate.\" [GOC:ai]","metadata":null},{"id":"dbf0b88b9c0a48bba0526f35fb955308","type":"GO_TERM","name":"CDP catabolic process","canonical_id":"go:GO:0046706","description":"\"The chemical reactions and pathways resulting in the breakdown of CDP, cytidine (5'-)diphosphate.\" [GOC:ai]","metadata":null},{"id":"3f9efe6b0f604a63b71f610086424e1c","type":"GO_TERM","name":"CDP metabolic process","canonical_id":"go:GO:0046704","description":"\"The chemical reactions and pathways involving CDP, cytidine (5'-)diphosphate.\" [GOC:ai]","metadata":null},{"id":"88540e0caad64337aa5f30ab563967bb","type":"GO_TERM","name":"CDP phosphatase activity","canonical_id":"go:GO:0036384","description":"\"Catalysis of the reaction: CDP + H2O = CMP + phosphate.\" [GOC:al, RHEA:64880]","metadata":null},{"id":"82d762c912de4ecf93847657d37f034d","type":"GO_TERM","name":"CDP reductase activity","canonical_id":"go:GO:0051063","description":"\"Catalysis of the reaction: dCDP + thioredoxin disulfide + H2O = CDP + thioredoxin.\" [MetaCyc:CDPREDUCT-RXN]","metadata":null},{"id":"4c2e2fcb856e4205be2cbcea89df73c2","type":"GO_TERM","name":"CDP-2,3-bis-(O-geranylgeranyl)-sn-glycerol synthase activity","canonical_id":"go:GO:0043338","description":"\"Catalysis of the reaction: 2,3-bis-O-(geranylgeranyl)-sn-glycerol 1-phosphate + CTP + H+ = CDP-2,3-bis-O-(geranylgeranyl)-sn-glycerol + diphosphate.\" [GOC:jl, PMID:10960477, RHEA:25690]","metadata":null},{"id":"2bc2ea3996f1496b9b6cb6ec1a8a7360","type":"GO_TERM","name":"CDP-4-dehydro-6-deoxyglucose reductase activity","canonical_id":"go:GO:0047099","description":"\"Catalysis of the reaction: H2O + NAD(P)+ + CDP-4-dehydro-3,6-dideoxy-D-glucose = NAD(P)H + CDP-4-dehydro-6-deoxy-D-glucose.\" [EC:1.17.1.1, MetaCyc:1.17.1.1-RXN]","metadata":null},{"id":"21bea7e940f548549205953b8d785f09","type":"GO_TERM","name":"CDP-abequose epimerase activity","canonical_id":"go:GO:0047732","description":"\"Catalysis of the reaction: CDP-3,6-dideoxy-D-glucose = CDP-3,6-dideoxy-D-mannose.\" [EC:5.1.3.10, RHEA:21656]","metadata":null},{"id":"5e3f66b981724a6c94a164e4e1c95cb7","type":"GO_TERM","name":"CDP-alcohol phosphatidyltransferase activity","canonical_id":"go:GO:0017169","description":"\"Catalysis of the reaction: CDP + alcohol = CMP + phosphatidyl alcohol.\" [GOC:ai]","metadata":null},{"id":"a3fabf592e224f1c8b66b0ac099099b1","type":"GO_TERM","name":"CDP-choline pathway","canonical_id":"go:GO:0006657","description":"\"The phosphatidylcholine biosynthetic process that begins with the phosphorylation of choline and ends with the combination of CDP-choline with diacylglycerol to form phosphatidylcholine.\" [ISBN:0471331309, MetaCyc:PWY3O-450]","metadata":null},{"id":"a3d7eb52d80247d5b8b8e810b4b543aa","type":"GO_TERM","name":"CDP-diacylglycerol biosynthetic process","canonical_id":"go:GO:0016024","description":"\"The chemical reactions and pathways resulting in the formation of CDP-diacylglycerol, CDP-1,2-diacylglycerol, a substance composed of diacylglycerol in glycosidic linkage with cytidine diphosphate.\" [PMID:24533860]","metadata":null},{"id":"d8985f5a51d448218f2b0c2c2f48cd76","type":"GO_TERM","name":"CDP-diacylglycerol catabolic process","canonical_id":"go:GO:0046342","description":"\"The chemical reactions and pathways resulting in the breakdown of CDP-diacylglycerol, CDP-1,2-diacylglycerol, a substance composed of diacylglycerol in glycosidic linkage with cytidine diphosphate.\" [PMID:6147353]","metadata":null},{"id":"75b74e8855494ad39ef40106c3e3534f","type":"GO_TERM","name":"CDP-diacylglycerol diphosphatase activity","canonical_id":"go:GO:0008715","description":"\"Catalysis of the reaction: CDP-diacylglycerol + H2O = a phosphatidate + CMP + 2 H+.\" [EC:3.6.1.26, RHEA:15221]","metadata":null},{"id":"2f54be04b7af4129b4c62ae2b728fbd6","type":"GO_TERM","name":"CDP-diacylglycerol metabolic process","canonical_id":"go:GO:0046341","description":"\"The chemical reactions and pathways involving CDP-diacylglycerol, CDP-1,2-diacylglycerol, a substance composed of diacylglycerol in glycosidic linkage with cytidine diphosphate. It is a common intermediate in phospholipid biosynthesis.\" [PMID:24533860]","metadata":null},{"id":"e306947308e9490cbd9075b0c48049cc","type":"GO_TERM","name":"CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase activity","canonical_id":"go:GO:0008444","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + CDP-diacylglycerol = 3-(3-sn-phosphatidyl)-sn-glycerol 1-phosphate + CMP + H+.\" [EC:2.7.8.5, RHEA:12593]","metadata":null},{"id":"237092cdf4c54f058600b223fe07cb05","type":"GO_TERM","name":"CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity","canonical_id":"go:GO:0003881","description":"\"Catalysis of the reaction: myo-inositol + CDP-diacylglycerol = 1-phosphatidyl-1D-myo-inositol + CMP + H+.\" [EC:2.7.8.11, RHEA:11580]","metadata":null},{"id":"fb5f878765fd49c99d154e7eac525d9e","type":"GO_TERM","name":"CDP-diacylglycerol-serine O-phosphatidyltransferase activity","canonical_id":"go:GO:0003882","description":"\"Catalysis of the reaction: CDP-diacylglycerol + L-serine = CMP + O-sn-phosphatidyl-L-serine.\" [EC:2.7.8.8]","metadata":null},{"id":"91f1e0c5a6f24146a1be77b4dd5b00a7","type":"GO_TERM","name":"CDP-glucose 4,6-dehydratase activity","canonical_id":"go:GO:0047733","description":"\"Catalysis of the reaction: CDP-D-glucose = CDP-4-dehydro-6-deoxy-D-glucose + H2O.\" [EC:4.2.1.45, RHEA:17153]","metadata":null},{"id":"a42c4e6341424846861e41896048c93a","type":"GO_TERM","name":"CDP-glycerol diphosphatase activity","canonical_id":"go:GO:0047734","description":"\"Catalysis of the reaction: CDP-glycerol + H2O = sn-glycerol 3-phosphate + CMP + 2 H+.\" [EC:3.6.1.16, RHEA:21692]","metadata":null},{"id":"c3ca1fd051b24efe98cad644e411f17a","type":"GO_TERM","name":"CDP-glycerol glycerophosphotransferase activity","canonical_id":"go:GO:0047355","description":"\"Catalysis of the reaction: glycerophosphate(n) + CDP-glycerol = glycerophosphate(n+1) + CMP.\" [EC:2.7.8.12]","metadata":null},{"id":"bf4bb477e05b4eed83842cf36358aa7c","type":"GO_TERM","name":"CDP-ribitol ribitolphosphotransferase activity","canonical_id":"go:GO:0047356","description":"\"Catalysis of the reaction: ribitol phosphate(n) + CDP-ribitol = ribitol phosphate(n+1) + CMP.\" [EC:2.7.8.14]","metadata":null},{"id":"f4e747ef08b249ae890137961bfbd83f","type":"GENE","name":"CDPF1","canonical_id":"hgnc:HGNC:33710","description":"cysteine rich DPF motif domain containing 1","metadata":{"aliases":["CDKN1A","C22orf40"]}},{"id":"0408cb24ac8e4f1a99bcd06dad97c188","type":"GENE","name":"CDPF1P1","canonical_id":"hgnc:HGNC:54763","description":"CDPF1 pseudogene 1","metadata":null},{"id":"91b79452522b4e78acfac5337fc40edb","type":"GENE","name":"CDR1","canonical_id":"hgnc:HGNC:1798","description":"cerebellar degeneration related 1","metadata":{"aliases":["CDR62A","CDR34","CDR"]}},{"id":"779aecfe9c3745afb763ac6a70342813","type":"GENE","name":"CDR2","canonical_id":"hgnc:HGNC:1799","description":"cerebellar degeneration related protein 2","metadata":{"aliases":["CDR62","Yo"]}},{"id":"93ae2ecdab22429e8d0b07143f7e9147","type":"GENE","name":"CDR2-DT","canonical_id":"hgnc:HGNC:55381","description":"CDR2 divergent transcript","metadata":null},{"id":"8ca701d7a253426783c71ce709de9c7b","type":"GENE","name":"CDR2L","canonical_id":"hgnc:HGNC:29999","description":"cerebellar degeneration related protein 2 like","metadata":{"aliases":["HUMPPA"]}},{"id":"424a5f5f99bf4982a71c99809b788c08","type":"GENE","name":"CDRT10","canonical_id":"hgnc:HGNC:14390","description":"CMT1A duplicated region transcript 10","metadata":null},{"id":"5838429fde424fcbae57ffdb6d5471e6","type":"GENE","name":"CDRT11","canonical_id":"hgnc:HGNC:14391","description":"CMT1A duplicated region transcript 11","metadata":null},{"id":"15eae837eb254567a627b730d6c50a67","type":"GENE","name":"CDRT12","canonical_id":"hgnc:HGNC:14392","description":"CMT1A duplicated region transcript 12","metadata":null},{"id":"11f5664331464ab0a5ba291779dff503","type":"GENE","name":"CDRT13","canonical_id":"hgnc:HGNC:14393","description":"CMT1A duplicated region transcript 13","metadata":null},{"id":"c7860293b58046faa1dcfa872617047e","type":"GENE","name":"CDRT15","canonical_id":"hgnc:HGNC:14395","description":"CMT1A duplicated region transcript 15","metadata":null},{"id":"50357dfb66434fe29f6cfd1ff96694e5","type":"GENE","name":"CDRT15L2","canonical_id":"hgnc:HGNC:34075","description":"CMT1A duplicated region transcript 15 like 2","metadata":null},{"id":"3cabe08d4a3b4e48a8c17c4895b5c344","type":"GENE","name":"CDRT15P1","canonical_id":"hgnc:HGNC:33168","description":"CDRT15 pseudogene 1","metadata":{"aliases":["CDRT15P"]}},{"id":"db7bd765e91c4d18a2a0e557e2c4d9df","type":"GENE","name":"CDRT15P10","canonical_id":"hgnc:HGNC:38413","description":"CDRT15 pseudogene 10","metadata":{"aliases":["C2orf27AP1"]}},{"id":"314e341a0e2c4520a771319b3f7c5800","type":"GENE","name":"CDRT15P11","canonical_id":"hgnc:HGNC:54918","description":"CDRT15 pseudogene 11","metadata":null},{"id":"6f4cc41a5b6f4580803f4a24480fb4de","type":"GENE","name":"CDRT15P12","canonical_id":"hgnc:HGNC:54919","description":"CDRT15 pseudogene 12","metadata":null},{"id":"b926b30ec2764377959a36e7618d277e","type":"GENE","name":"CDRT15P13","canonical_id":"hgnc:HGNC:54920","description":"CDRT15 pseudogene 13","metadata":null},{"id":"ddc71a9d24c245308a3697ffce8d45f5","type":"GENE","name":"CDRT15P14","canonical_id":"hgnc:HGNC:50418","description":"CDRT15 pseudogene 14","metadata":{"aliases":["C2orf27AP3"]}},{"id":"dcb7b07063eb4dfdab6a364634ef09fd","type":"GENE","name":"CDRT15P2","canonical_id":"hgnc:HGNC:34074","description":"CDRT15 pseudogene 2","metadata":{"aliases":["CDRT15L1"]}},{"id":"b75fc3d9d25e46ae9ecf6906a39aa488","type":"GENE","name":"CDRT15P3","canonical_id":"hgnc:HGNC:33824","description":"CDRT15 pseudogene 3","metadata":{"aliases":["MGC50273","C2orf27B"]}},{"id":"51844721f24e4073ba70fa773e062f67","type":"GENE","name":"CDRT15P4","canonical_id":"hgnc:HGNC:54913","description":"CDRT15 pseudogene 4","metadata":null},{"id":"1ad5d851051545cbb5f35533714d221c","type":"GENE","name":"CDRT15P5","canonical_id":"hgnc:HGNC:49813","description":"CDRT15 pseudogene 5","metadata":{"aliases":["C2orf27AP2"]}},{"id":"9289afd0fc5645fda0338799115d2d12","type":"GENE","name":"CDRT15P6","canonical_id":"hgnc:HGNC:54914","description":"CDRT15 pseudogene 6","metadata":null},{"id":"f73cab494c6b49bca6bec3c5cc466102","type":"GENE","name":"CDRT15P7","canonical_id":"hgnc:HGNC:54915","description":"CDRT15 pseudogene 7","metadata":null},{"id":"1967d7a70e6743ba86c72ab43a0304ae","type":"GENE","name":"CDRT15P8","canonical_id":"hgnc:HGNC:54916","description":"CDRT15 pseudogene 8","metadata":null},{"id":"8375db6616984f3d887a39c66dd6d9b0","type":"GENE","name":"CDRT15P9","canonical_id":"hgnc:HGNC:54917","description":"CDRT15 pseudogene 9","metadata":null},{"id":"651801f5bb6e4c16a9ac455f7867d5f5","type":"GENE","name":"CDRT2","canonical_id":"hgnc:HGNC:14381","description":"CMT1A duplicated region transcript 2","metadata":null},{"id":"468ad8943b3f44769b6b9fe598df95ee","type":"GENE","name":"CDRT3","canonical_id":"hgnc:HGNC:14382","description":"CMT1A duplicated region transcript 3","metadata":null},{"id":"dc836922e8bb4ccda4a1d59b44d8340d","type":"GENE","name":"CDRT4","canonical_id":"hgnc:HGNC:14383","description":"CMT1A duplicated region transcript 4","metadata":{"aliases":["FLJ36674"]}},{"id":"5a49814569b841429192ebfcfe52805f","type":"GENE","name":"CDRT5","canonical_id":"hgnc:HGNC:14384","description":"CMT1A duplicated region transcript 5","metadata":null},{"id":"c24ea53c94314f45afee3298822d4ef4","type":"GENE","name":"CDRT7","canonical_id":"hgnc:HGNC:14386","description":"CMT1A duplicated region transcript 7","metadata":{"aliases":["NCRNA00025","LINC00025"]}},{"id":"19f20b8df177437e93b7196d4fbc16b4","type":"GENE","name":"CDRT8","canonical_id":"hgnc:HGNC:14387","description":"CMT1A duplicated region transcript 8","metadata":null},{"id":"1f648c40f408452f9b1ae93297a30a73","type":"GENE","name":"CDS1","canonical_id":"hgnc:HGNC:1800","description":"CDP-diacylglycerol synthase 1","metadata":null},{"id":"64e7a2f164424b328bb96b85dcaa6a70","type":"GENE","name":"CDS1-AS1","canonical_id":"hgnc:HGNC:58840","description":"CDS1 antisense RNA 1","metadata":null},{"id":"bb0f37ed4a794418b1f38231a26c2fe7","type":"GENE","name":"CDS2","canonical_id":"hgnc:HGNC:1801","description":"CDP-diacylglycerol synthase 2","metadata":null},{"id":"cfa14e1668b04d829034811ad12195b8","type":"GENE","name":"CDSN","canonical_id":"hgnc:HGNC:1802","description":"corneodesmosin","metadata":{"aliases":["D6S586E"]}},{"id":"3e09becd42ac4ec981b57c04c48799ea","type":"GENE","name":"CDT1","canonical_id":"hgnc:HGNC:24576","description":"chromatin licensing and DNA replication factor 1","metadata":{"aliases":["DUP","RIS2"]}},{"id":"a9038ce1da044ec2b313a337232e241c","type":"GENE","name":"CDV3","canonical_id":"hgnc:HGNC:26928","description":"CDV3 homolog","metadata":{"aliases":["H41"]}},{"id":"090e179792904643bd1604a12b8bec0d","type":"GENE","name":"CDV3P1","canonical_id":"hgnc:HGNC:42387","description":"CDV3 pseudogene 1","metadata":null},{"id":"fb48783e496d44c380e9f7696086573f","type":"GENE","name":"CDX1","canonical_id":"hgnc:HGNC:1805","description":null,"metadata":null},{"id":"19dd10434ef44941a0883b8fcae2822c","type":"GENE","name":"CDX2","canonical_id":"hgnc:HGNC:1806","description":null,"metadata":null},{"id":"13c4452da8d54e2daa13d9395eaeda19","type":"GENE","name":"CDX4","canonical_id":"hgnc:HGNC:1808","description":"caudal type homeobox 4","metadata":null},{"id":"333339a57c12450f965ad5b30db21f88","type":"GENE","name":"CDY1","canonical_id":"hgnc:HGNC:1809","description":"chromodomain Y-linked 1","metadata":{"aliases":["CDY1A"]}},{"id":"983786b7a72c4e97bbee3d44f96839b6","type":"GENE","name":"CDY10P","canonical_id":"hgnc:HGNC:23848","description":"chromodomain Y-linked 10 pseudogene","metadata":null},{"id":"d4395895f9514b479bff068f911b7407","type":"GENE","name":"CDY11P","canonical_id":"hgnc:HGNC:23852","description":"chromodomain Y-linked 11 pseudogene","metadata":null},{"id":"057b7edb351a4dc09a419d2d256e6d5d","type":"GENE","name":"CDY12P","canonical_id":"hgnc:HGNC:23856","description":"chromodomain Y-linked 12 pseudogene","metadata":null},{"id":"d30b94ddbbe840c0a6423c2dac2e60cc","type":"GENE","name":"CDY13P","canonical_id":"hgnc:HGNC:23857","description":"chromodomain Y-linked 13 pseudogene","metadata":null},{"id":"7459bdcbc78848e3a49fba834fb09267","type":"GENE","name":"CDY14P","canonical_id":"hgnc:HGNC:23858","description":"chromodomain Y-linked 14 pseudogene","metadata":null},{"id":"a83067911c0a423c93026cb8aa51b30d","type":"GENE","name":"CDY15P","canonical_id":"hgnc:HGNC:23859","description":"chromodomain Y-linked 15 pseudogene","metadata":null},{"id":"9e9c5a41ad6049268c8aa20d3f150489","type":"GENE","name":"CDY16P","canonical_id":"hgnc:HGNC:23860","description":"chromodomain Y-linked 16 pseudogene","metadata":null},{"id":"55c3eb314c7a42c1a8f047c103543208","type":"GENE","name":"CDY17P","canonical_id":"hgnc:HGNC:23861","description":"chromodomain Y-linked 17 pseudogene","metadata":null},{"id":"6ae9bb9049ff4d34bf19536c08e058fc","type":"GENE","name":"CDY18P","canonical_id":"hgnc:HGNC:23862","description":"chromodomain Y-linked 18 pseudogene","metadata":null},{"id":"f7a51d1554d14053965251ec4f2635ef","type":"GENE","name":"CDY19P","canonical_id":"hgnc:HGNC:23863","description":"chromodomain Y-linked 19 pseudogene","metadata":null},{"id":"bd0b4f25f9d44b20add86c10bad3f7fd","type":"GENE","name":"CDY1B","canonical_id":"hgnc:HGNC:23920","description":"chromodomain Y-linked 1B","metadata":null},{"id":"ec60fcdcfcbd42a79452840d6af20976","type":"GENE","name":"CDY20P","canonical_id":"hgnc:HGNC:23864","description":"chromodomain Y-linked 20 pseudogene","metadata":null},{"id":"ca6e3970cf4d4de1bb2cfb2aaee6eb73","type":"GENE","name":"CDY21P","canonical_id":"hgnc:HGNC:23865","description":"chromodomain Y-linked 21 pseudogene","metadata":null},{"id":"e4ad5d797b00490f8fd4e4ecf792edab","type":"GENE","name":"CDY22P","canonical_id":"hgnc:HGNC:23866","description":"chromodomain Y-linked 22 pseudogene","metadata":null},{"id":"da7024029f8c447889145f1ec162327d","type":"GENE","name":"CDY23P","canonical_id":"hgnc:HGNC:23867","description":"chromodomain Y-linked 23 pseudogene","metadata":null},{"id":"8f9de1ceda27460d88b4a71da024edaf","type":"GENE","name":"CDY2A","canonical_id":"hgnc:HGNC:1810","description":"chromodomain Y-linked 2A","metadata":{"aliases":["CDY2"]}},{"id":"8a9939d3afe44fe89c82f58e1cd9a45e","type":"GENE","name":"CDY2B","canonical_id":"hgnc:HGNC:23921","description":"chromodomain Y-linked 2B","metadata":{"aliases":["CDY"]}},{"id":"dbbab043963740c29ab6d41823ff6e6c","type":"GENE","name":"CDY3P","canonical_id":"hgnc:HGNC:23849","description":"chromodomain Y-linked 3 pseudogene","metadata":null},{"id":"4ddfd4b688b34557aa8ebc596eca759b","type":"GENE","name":"CDY4P","canonical_id":"hgnc:HGNC:23872","description":"chromodomain Y-linked 4 pseudogene","metadata":null},{"id":"aa0bfb47ea5c494d9531e9184c1bb110","type":"GENE","name":"CDY5P","canonical_id":"hgnc:HGNC:23850","description":"chromodomain Y-linked 5 pseudogene","metadata":null},{"id":"4d37ac8a21b14d75a08ee20f37f66fed","type":"GENE","name":"CDY6P","canonical_id":"hgnc:HGNC:23853","description":"chromodomain Y-linked 6 pseudogene","metadata":null},{"id":"bae5a8d55eb047378226d16361c1a219","type":"GENE","name":"CDY7P","canonical_id":"hgnc:HGNC:23854","description":"chromodomain Y-linked 7 pseudogene","metadata":null},{"id":"b48792a04db64d6eacfe61898988c22b","type":"GENE","name":"CDY8P","canonical_id":"hgnc:HGNC:23855","description":"chromodomain Y-linked 8 pseudogene","metadata":null},{"id":"d5d3181173314fc199810ccab75d061d","type":"GENE","name":"CDY9P","canonical_id":"hgnc:HGNC:23851","description":"chromodomain Y-linked 9 pseudogene","metadata":null},{"id":"9afa8d2a5f754aa1a2466a95f69294a0","type":"GENE","name":"CDYL","canonical_id":"hgnc:HGNC:1811","description":"chromodomain Y like","metadata":{"aliases":["DKFZP586C1622","CDYL1"]}},{"id":"80ef34ffbdfa4c34a8891268ccee038f","type":"GENE","name":"CDYL-AS1","canonical_id":"hgnc:HGNC:40142","description":"CDYL antisense RNA 1","metadata":null},{"id":"1a37bb3ea5a74ce997a2a48493df2619","type":"GENE","name":"CDYL2","canonical_id":"hgnc:HGNC:23030","description":"chromodomain Y like 2","metadata":{"aliases":["FLJ38866"]}},{"id":"54ef317d75564af4bb6dee34a345e272","type":"GENE","name":"CDYLP1","canonical_id":"hgnc:HGNC:52805","description":"CDYL pseudogene 1","metadata":null},{"id":"9693a14761d147b6a158090fdfaf916b","type":"GENE","name":"CEACAM1","canonical_id":"hgnc:HGNC:1814","description":null,"metadata":null},{"id":"a8064e047da44d18bfb0972b5aca9b95","type":"GENE","name":"CEACAM16","canonical_id":"hgnc:HGNC:31948","description":"CEA cell adhesion molecule 16, tectorial membrane component","metadata":{"aliases":["DFNA4B"]}},{"id":"5c75ad2345f241c4aaa5439d5d5f5f45","type":"GENE","name":"CEACAM16-AS1","canonical_id":"hgnc:HGNC:55317","description":"CEACAM16, CEACAM19 and PVR antisense RNA 1","metadata":null},{"id":"9fe592ce1ad14949a6cde8d1eb2cbf99","type":"GENE","name":"CEACAM18","canonical_id":"hgnc:HGNC:31949","description":"CEA cell adhesion molecule 18","metadata":null},{"id":"5f9e4778c027482f9c9e0128bcdfdd1a","type":"GENE","name":"CEACAM19","canonical_id":"hgnc:HGNC:31951","description":"CEA cell adhesion molecule 19","metadata":{"aliases":["CEAL1"]}},{"id":"40cdff37ff974d6aa0564a4df3a8d6bb","type":"GENE","name":"CEACAM20","canonical_id":"hgnc:HGNC:24879","description":"CEA cell adhesion molecule 20","metadata":{"aliases":["UNQ9366"]}},{"id":"bd3c0cd66b1e4158943b97fbaa19efe7","type":"GENE","name":"CEACAM21","canonical_id":"hgnc:HGNC:28834","description":"CEA cell adhesion molecule 21","metadata":{"aliases":["R29124_1","FLJ13540"]}},{"id":"a47ba4c0a2fd4eb685b39fd6fb0ff650","type":"GENE","name":"CEACAM22P","canonical_id":"hgnc:HGNC:38029","description":"CEA cell adhesion molecule 22, pseudogene","metadata":null},{"id":"ed72a5ff0b5f4f60a979724a3fc6a50d","type":"GENE","name":"CEACAM3","canonical_id":"hgnc:HGNC:1815","description":"CEA cell adhesion molecule 3","metadata":{"aliases":["CD66d","CGM1a","CGM1"]}},{"id":"71d04322d89f4266b1c28e1d641e4df3","type":"GENE","name":"CEACAM4","canonical_id":"hgnc:HGNC:1816","description":"CEA cell adhesion molecule 4","metadata":{"aliases":["CGM7"]}},{"id":"de3ddf3f85ec48fdb4a3959368bf126a","type":"GENE","name":"CEACAM5","canonical_id":"hgnc:HGNC:1817","description":null,"metadata":null},{"id":"d2f76fd9478d41f589959de6a05977cd","type":"GENE","name":"CEACAM6","canonical_id":"hgnc:HGNC:1818","description":"CEA cell adhesion molecule 6","metadata":{"aliases":["CD66c","NCA-50/90","NCA"]}},{"id":"185d79893c7e4ccf8eaf08fdde889d97","type":"GENE","name":"CEACAM7","canonical_id":"hgnc:HGNC:1819","description":"CEA cell adhesion molecule 7","metadata":{"aliases":["CEA","CGM2"]}},{"id":"e229d2c543724b16a5e874f49d3874bc","type":"GENE","name":"CEACAM8","canonical_id":"hgnc:HGNC:1820","description":"CEA cell adhesion molecule 8","metadata":{"aliases":["CD66b","CGM6"]}},{"id":"7ed76fa0d2684a45b982988c99957a9f","type":"GENE","name":"CEACAMP1","canonical_id":"hgnc:HGNC:1821","description":"CEA cell adhesion molecule pseudogene 1","metadata":{"aliases":["CGM8"]}},{"id":"5d1b291efd654eca8e5e4949383ed96c","type":"GENE","name":"CEACAMP10","canonical_id":"hgnc:HGNC:1822","description":"CEA cell adhesion molecule pseudogene 10","metadata":{"aliases":["CGM17"]}},{"id":"311d4301367e438e906c503825ce2690","type":"GENE","name":"CEACAMP11","canonical_id":"hgnc:HGNC:1823","description":"CEA cell adhesion molecule pseudogene 11","metadata":{"aliases":["CGM18"]}},{"id":"a010a4dd75214325b72409cd763beb1e","type":"GENE","name":"CEACAMP2","canonical_id":"hgnc:HGNC:1824","description":"CEA cell adhesion molecule pseudogene 2","metadata":{"aliases":["CGM9"]}},{"id":"cb4f1d61ce7f40e8a6e742e74ba4e0ce","type":"GENE","name":"CEACAMP3","canonical_id":"hgnc:HGNC:1825","description":"CEA cell adhesion molecule pseudogene 3","metadata":{"aliases":["CGM10","CEACAM24P"]}},{"id":"e86e8fa9b7ac4fa39b7c48c4e8040e35","type":"GENE","name":"CEACAMP4","canonical_id":"hgnc:HGNC:1826","description":"CEA cell adhesion molecule pseudogene 4","metadata":{"aliases":["CGM11"]}},{"id":"dcbb5015a22d452eb2bb85e9d98ec815","type":"GENE","name":"CEACAMP5","canonical_id":"hgnc:HGNC:1827","description":"CEA cell adhesion molecule pseudogene 5","metadata":{"aliases":["CGM12"]}},{"id":"c835f88f5ef64233a6ad6f7200ab5ddd","type":"GENE","name":"CEACAMP6","canonical_id":"hgnc:HGNC:1828","description":"CEA cell adhesion molecule pseudogene 6","metadata":{"aliases":["CGM13"]}},{"id":"1d278f9b656b40de9249fb005eed9e0a","type":"GENE","name":"CEACAMP7","canonical_id":"hgnc:HGNC:1829","description":"CEA cell adhesion molecule pseudogene 7","metadata":{"aliases":["CGM14"]}},{"id":"7c543b29258b4a808dbfb62824eef03f","type":"GENE","name":"CEACAMP8","canonical_id":"hgnc:HGNC:1830","description":"CEA cell adhesion molecule pseudogene 8","metadata":{"aliases":["CGM15"]}},{"id":"530b6d4fcceb4071a515efde997468d6","type":"GENE","name":"CEACAMP9","canonical_id":"hgnc:HGNC:1831","description":"CEA cell adhesion molecule pseudogene 9","metadata":{"aliases":["CGM16"]}},{"id":"8b51d7cfa8bd4995b33ecfc30e3afe65","type":"DISEASE","name":"CEBALID syndrome","canonical_id":"mondo:0032908","description":null,"metadata":null},{"id":"f80156efcc5841eba63d09b036d48f2b","type":"GENE","name":"CEBPA","canonical_id":"hgnc:HGNC:1833","description":null,"metadata":null},{"id":"ebb6e9020a004543a2adbe6d992428a7","type":"GENE","name":"CEBPA-DT","canonical_id":"hgnc:HGNC:25710","description":"CEBPA divergent transcript","metadata":{"aliases":["ADINR","CEBPA-AS1"]}},{"id":"c44e293629e84923a8a6789692472bb0","type":"GENE","name":"CEBPB","canonical_id":"hgnc:HGNC:1834","description":null,"metadata":null},{"id":"7a3a2163fe924d50bebf71404a00d090","type":"GENE","name":"CEBPB-AS1","canonical_id":"hgnc:HGNC:51226","description":"CEBPB antisense RNA 1","metadata":null},{"id":"590995db140b4a4f88bf3713a662d43a","type":"GENE","name":"CEBPD","canonical_id":"hgnc:HGNC:1835","description":null,"metadata":null},{"id":"1e811079ebbc46db8e1fa94abd005d99","type":"GENE","name":"CEBPE","canonical_id":"hgnc:HGNC:1836","description":null,"metadata":null},{"id":"e471637c0145451cb3c7e0854ef9e50f","type":"GENE","name":"CEBPG","canonical_id":"hgnc:HGNC:1837","description":null,"metadata":null},{"id":"1ffa4d6faae3463bba5df68d273db841","type":"GENE","name":"CEBPZ","canonical_id":"hgnc:HGNC:24218","description":null,"metadata":null},{"id":"95a8e21df7c64892a7201fbfbb738e65","type":"GENE","name":"CEBPZOS","canonical_id":"hgnc:HGNC:49288","description":"CEBPZ opposite strand","metadata":{"aliases":["CEBPZ-AS1"]}},{"id":"edfb619dc81c4204be5c8bdb12714ffa","type":"GENE","name":"CECR","canonical_id":"hgnc:HGNC:1838","description":"cat eye syndrome chromosome region","metadata":null},{"id":"6e12a5acc5654c52bfe64e2188cc1d69","type":"GENE","name":"CECR2","canonical_id":"hgnc:HGNC:1840","description":"CECR2 histone acetyl-lysine reader","metadata":{"aliases":["KIAA1740"]}},{"id":"fe2b5871d99d449e9b5e9e397817846f","type":"GENE","name":"CECR3","canonical_id":"hgnc:HGNC:1841","description":"cat eye syndrome chromosome region, candidate 3","metadata":null},{"id":"63bd96b32915454989e84c11cd0f08df","type":"GENE","name":"CECR7","canonical_id":"hgnc:HGNC:1845","description":"cat eye syndrome chromosome region, candidate 7","metadata":{"aliases":["SAHL1"]}},{"id":"01be6a2696254f2f8c36e85df6ce1dad","type":"GENE","name":"CECR9","canonical_id":"hgnc:HGNC:1847","description":"cat eye syndrome chromosome region, candidate 9","metadata":null},{"id":"eb4facc765a04111935c47b208f8e19e","type":"GENE","name":"CEDORA","canonical_id":"hgnc:HGNC:56653","description":"CDH13 antisense oligodendrocyte and neuron associated lncRNA","metadata":{"aliases":["RP11-298D21.1","FEDORA"]}},{"id":"058159548789481fa9f16c288425cab8","type":"GENE","name":"CEL","canonical_id":"hgnc:HGNC:1848","description":null,"metadata":null},{"id":"3727d1094a354ed3ac6295a7621efd23","type":"GENE","name":"CELA1","canonical_id":"hgnc:HGNC:3308","description":"chymotrypsin like elastase 1","metadata":{"aliases":["ELA1"]}},{"id":"1a254bb5eafb42dcb0a3efbe418d99e5","type":"GENE","name":"CELA2A","canonical_id":"hgnc:HGNC:24609","description":"chymotrypsin like elastase 2A","metadata":{"aliases":["ELA2A"]}},{"id":"b495f2a8a3ac491db6ef60a92a14cf01","type":"GENE","name":"CELA2B","canonical_id":"hgnc:HGNC:29995","description":"chymotrypsin like elastase 2B","metadata":{"aliases":["RP11-265F14.2","ELA2B"]}},{"id":"d109890c2a274099a5ed9ec28ae3fbb6","type":"GENE","name":"CELA3A","canonical_id":"hgnc:HGNC:15944","description":"chymotrypsin like elastase 3A","metadata":{"aliases":["ELA3","ELA3A"]}},{"id":"c75221f6363a4200be2eaf71ad02f68f","type":"GENE","name":"CELA3B","canonical_id":"hgnc:HGNC:15945","description":"chymotrypsin like elastase 3B","metadata":{"aliases":["CBPP","ELA3B"]}},{"id":"cfb5fafe917f4048bb9b59c0fd12ae27","type":"GENE","name":"CELF1","canonical_id":"hgnc:HGNC:2549","description":"CUGBP Elav-like family member 1","metadata":{"aliases":["CUG-BP","hNab50","BRUNOL2","NAB50","CUGBP","NAPOR","EDEN-BP","CUGBP1"]}},{"id":"dd37006827a44485b2f5fa5a7bac7c05","type":"GENE","name":"CELF2","canonical_id":"hgnc:HGNC:2550","description":"CUGBP Elav-like family member 2","metadata":{"aliases":["Etr-3","NAPOR-2","BRUNOL3","CUGBP2"]}},{"id":"3deb07322a374850950e6041089bc1a6","type":"GENE","name":"CELF2-AS1","canonical_id":"hgnc:HGNC:23515","description":"CELF2 antisense RNA 1","metadata":{"aliases":["FLJ40494","Em:AC026887.2","C10orf31"]}},{"id":"763f71edf321424ba5f7547dabd0d832","type":"GENE","name":"CELF2-AS2","canonical_id":"hgnc:HGNC:44703","description":"CELF2 antisense RNA 2","metadata":null},{"id":"116cd9df9784441abe35d391cc1f4a2d","type":"GENE","name":"CELF2-AS3","canonical_id":"hgnc:HGNC:58224","description":"CELF2 antisense RNA 3","metadata":null},{"id":"263d48a08fd84de6932ddb538c45f4f9","type":"GENE","name":"CELF2-AS4","canonical_id":"hgnc:HGNC:58359","description":"CELF2 antisense RNA 4","metadata":null},{"id":"01630b542d67426b8e9d0f181d60d19e","type":"GENE","name":"CELF2-DT","canonical_id":"hgnc:HGNC:54157","description":"CELF2 divergent transript","metadata":null},{"id":"bc5dde01bf784c5b9d7a5fd36b710ff2","type":"GENE","name":"CELF3","canonical_id":"hgnc:HGNC:11967","description":"CUGBP Elav-like family member 3","metadata":{"aliases":["CAGH4","BRUNOL1","ERDA4","MGC57297","TNRC4"]}},{"id":"017b885608d3495480ad327899528c7d","type":"GENE","name":"CELF4","canonical_id":"hgnc:HGNC:14015","description":"CUGBP Elav-like family member 4","metadata":{"aliases":["BRUNOL4"]}},{"id":"aa4a92d7cfad4b518db69c2c98717d04","type":"GENE","name":"CELF5","canonical_id":"hgnc:HGNC:14058","description":"CUGBP Elav-like family member 5","metadata":{"aliases":["BRUNOL5"]}},{"id":"2ec56da322a14665bb02c26854ea58a3","type":"GENE","name":"CELF6","canonical_id":"hgnc:HGNC:14059","description":"CUGBP Elav-like family member 6","metadata":{"aliases":["BRUNOL6"]}},{"id":"b0f3676dd7ce4b1dafee9919c0dd616a","type":"GENE","name":"CELF6-AS1","canonical_id":"hgnc:HGNC:58304","description":"CELF6 antisense RNA 1","metadata":null},{"id":"91c01425e2ec4d4ab74b96d487168c46","type":"GENE","name":"CELP","canonical_id":"hgnc:HGNC:1849","description":"carboxyl ester lipase pseudogene","metadata":{"aliases":["CELL"]}},{"id":"6decdcb259464e6b8b268af32b96c116","type":"GENE","name":"CELSR1","canonical_id":"hgnc:HGNC:1850","description":"cadherin EGF LAG seven-pass G-type receptor 1","metadata":{"aliases":["ME2","HFMI2","FMI2","CDHF9","ADGRC1"]}},{"id":"c6196a471bed4d92b42bf7fc76d37356","type":"GENE","name":"CELSR1P1","canonical_id":"hgnc:HGNC:55984","description":"CELSR1 pseudogene 1","metadata":null},{"id":"68d6ef4310aa48088712dcce59b353a3","type":"GENE","name":"CELSR2","canonical_id":"hgnc:HGNC:3231","description":"cadherin EGF LAG seven-pass G-type receptor 2","metadata":{"aliases":["KIAA0279","MEGF3","Flamingo1","CDHF10","ADGRC2","EGFL2"]}},{"id":"2249237f878d4c22bc6ab87fb094d1bd","type":"GENE","name":"CELSR3","canonical_id":"hgnc:HGNC:3230","description":null,"metadata":null},{"id":"a382972316de44d7be0f5fcea0cc1cf5","type":"GENE","name":"CEMIP","canonical_id":"hgnc:HGNC:29213","description":"cell migration inducing hyaluronidase 1","metadata":{"aliases":["IR2155535","TMEM2L","HYBID","CEMIP1","KIAA1199"]}},{"id":"d61414a6c3ea424fa4499bf34e881af4","type":"GENE","name":"CEMIP2","canonical_id":"hgnc:HGNC:11869","description":"cell migration inducing hyaluronidase 2","metadata":{"aliases":["TMEM2"]}},{"id":"b827e1e6371540aa810f743477035d07","type":"GENE","name":"CEMP1","canonical_id":"hgnc:HGNC:32553","description":"cementum protein 1","metadata":{"aliases":["CP-23"]}},{"id":"5b33291cf02e4f18a7376dc1a490b7dc","type":"GENE","name":"CENATAC","canonical_id":"hgnc:HGNC:30460","description":"centrosomal AT-AC splicing factor","metadata":{"aliases":["DLNB14","CCDC84"]}},{"id":"1c2f76f15c4a42659aca141e843ea683","type":"GENE","name":"CENATAC-AS1","canonical_id":"hgnc:HGNC:58699","description":"CENATAC antisense RNA 1","metadata":{"aliases":["AP003392.1"]}},{"id":"9b37254848654eb692e992d66d365ee2","type":"GENE","name":"CENATAC-DT","canonical_id":"hgnc:HGNC:54215","description":"CENATAC divergent transcript","metadata":{"aliases":["CCDC84-DT"]}},{"id":"a5ab19156ed54ef58e6cd197adeb119d","type":"GENE","name":"CENATACP1","canonical_id":"hgnc:HGNC:56949","description":"CENATAC pseudogene 1","metadata":null},{"id":"2e20e41742674dfa968e1d938eddefc1","type":"TRIAL","name":"CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab","canonical_id":"clinicaltrials.gov:NCT05121038","description":"Colon Cancer; Pancreas Cancer; Digestive Cancer","metadata":null},{"id":"0ecea5e3c2fc4f5397a335d3ceb9a3e8","type":"GENE","name":"CEND1","canonical_id":"hgnc:HGNC:24153","description":"cell cycle exit and neuronal differentiation 1","metadata":{"aliases":["FLJ90066","BM88"]}},{"id":"8d61b008063344298dd22c64f4d7124b","type":"GENE","name":"CEND1P1","canonical_id":"hgnc:HGNC:43674","description":"cell cycle exit and neuronal differentiation 1 pseudogene 1","metadata":null},{"id":"f4f013c7aec64675b3c6cae5f63defae","type":"GENE","name":"CEND1P2","canonical_id":"hgnc:HGNC:43675","description":"cell cycle exit and neuronal differentiation 1 pseudogene 2","metadata":null},{"id":"d8c3c2d109ab4ae68e5ceeb09984c3c8","type":"GO_TERM","name":"CENP-A containing chromatin","canonical_id":"go:GO:0061638","description":"\"The specialized chromatin located in the centromeric core region or the entire centromeric region in organisms with point centromeres, which is enriched for CENP-A-containing nucleosomes. This chromatin forms a 3-dimensional structure which provides a platform for kinetochore assembly and microtubule attachment.\" [GOC:vw, PMID:20206496, PMID:22729156, PMID:24710126]","metadata":null},{"id":"9ea62cd643d64baab3be29e18dbbe314","type":"GO_TERM","name":"CENP-A containing chromatin assembly","canonical_id":"go:GO:0034080","description":"\"The formation of chromatin containing the histone H3 variant CENP-A to form centromeric chromatin. This specialised chromatin occurs at centromeric region in point centromeres, and the central core in modular centromeres.\" [GOC:mah, GOC:vw, PMID:18158900, PMID:19217403, PMID:35422390]","metadata":null},{"id":"ceab8367a1ec474799d83f50839b5ec1","type":"GO_TERM","name":"CENP-A containing nucleosome","canonical_id":"go:GO:0043505","description":"\"A form of nucleosome located only at the centromere, in which the histone H3 is replaced by the variant form CENP-A (sometimes known as CenH3).\" [GOC:curators, PMID:15175412, PMID:16183641]","metadata":null},{"id":"98ae58164a494d56a3e5645e490cf353","type":"GO_TERM","name":"CENP-A containing nucleosome binding","canonical_id":"go:GO:0097030","description":"\"Binding to a centromere-specific nucleosome, a form of nucleosome located only at the centromere, in which the histone H3 is replaced by the variant form CENP-A (sometimes known as CenH3).\" [GOC:jp, PMID:21412236]","metadata":null},{"id":"d536a6bca5e444f1872e5e8faf09bd44","type":"GO_TERM","name":"CENP-A eviction from euchromatin","canonical_id":"go:GO:0140898","description":"\"A chromatin remodeling process in which CENP-A is removed from euchromatin regions to prevent neocentromere formation.\" [PMID:27666591]","metadata":null},{"id":"6fa4de8011224144bd8b986ceceb25c8","type":"GO_TERM","name":"CENP-A recruiting complex","canonical_id":"go:GO:0098654","description":"\"A protein complex that includes Mis16(Yippee family) and/or Mis18 (WD repeat) subunits that is involved in the deposition of centromere specific (CENP-A containing) nucleosomes at the centromere.\" [PMID:24774534]","metadata":null},{"id":"cc238f0cd50c47f2899a6cc96cb7f363","type":"GO_TERM","name":"CENP-T-W-S-X complex","canonical_id":"go:GO:0061838","description":"\"A histone-variant containing protein complex which forms a centromere specific nucleosome-like structure, involved in centromeric chromatin organization.\" [PMID:22304909, PMID:22304917]","metadata":null},{"id":"bee8c5d4e98a4eebb588065adfb78489","type":"GENE","name":"CENPA","canonical_id":"hgnc:HGNC:1851","description":"centromere protein A","metadata":{"aliases":["CENP-A","CenH3"]}},{"id":"fd4b7d62511c450190a5feb200090f23","type":"GENE","name":"CENPB","canonical_id":"hgnc:HGNC:1852","description":"centromere protein B","metadata":null},{"id":"fc069c7acdb94c17beee4432c861655e","type":"GENE","name":"CENPBD1P","canonical_id":"hgnc:HGNC:28272","description":"CENPB DNA-binding domain containing 1, pseudogene","metadata":{"aliases":["MGC16385","CENPBD1"]}},{"id":"c566bcf537c949ec90b17ead4627c71b","type":"GENE","name":"CENPBD2P","canonical_id":"hgnc:HGNC:28421","description":"CENPB DNA-binding domains containing 2, pseudogene","metadata":{"aliases":["CENPBD1P1"]}},{"id":"d87b92676cd94b1faaa52b292736c06d","type":"GENE","name":"CENPC","canonical_id":"hgnc:HGNC:1854","description":"centromere protein C","metadata":{"aliases":["CENP-C","hcp-4","MIF2","CENPC1"]}},{"id":"7ba973730fda4a919f1557ecd03c1114","type":"GENE","name":"CENPCP1","canonical_id":"hgnc:HGNC:1855","description":"centromere protein C pseudogene 1","metadata":{"aliases":["CENPC","CENPC2","CENPC1P1"]}},{"id":"1a76cd14c5d5489fb0e303cf9368e152","type":"GENE","name":"CENPE","canonical_id":"hgnc:HGNC:1856","description":"centromere protein E","metadata":{"aliases":["KIF10","PPP1R61"]}},{"id":"b6e70829d11640f993486d7d9dbe6fab","type":"GENE","name":"CENPF","canonical_id":"hgnc:HGNC:1857","description":"centromere protein F","metadata":{"aliases":["hcp-1"]}},{"id":"3215dc00ae564de5a9bca7133bef6eb5","type":"GENE","name":"CENPH","canonical_id":"hgnc:HGNC:17268","description":null,"metadata":null},{"id":"a68a413aceab4db0b363d8fc489d9033","type":"GENE","name":"CENPH-DT","canonical_id":"hgnc:HGNC:59063","description":"CENPH divergent transcript","metadata":null},{"id":"2879fa65fd124254942e8a88e3b08993","type":"GENE","name":"CENPI","canonical_id":"hgnc:HGNC:3968","description":"centromere protein I","metadata":{"aliases":["LRPR1","CENP-I","Mis6","FSHPRH1"]}},{"id":"f39f9619799248b7b9ee89ac49d42155","type":"GENE","name":"CENPIP1","canonical_id":"hgnc:HGNC:39575","description":"centromere protein I pseudogene 1","metadata":null},{"id":"155c905cc80c4f48a5a6fc1632954dab","type":"GENE","name":"CENPK","canonical_id":"hgnc:HGNC:29479","description":"centromere protein K","metadata":{"aliases":["FKSG14","SOLT","CENP-K"]}},{"id":"6f02e180c05549ebaab0be01fc2e2cc0","type":"GENE","name":"CENPL","canonical_id":"hgnc:HGNC:17879","description":"centromere protein L","metadata":{"aliases":["dJ383J4.3","FLJ31044","C1orf155"]}},{"id":"42caf0c00c0049689bc07ae719e16d3e","type":"GENE","name":"CENPM","canonical_id":"hgnc:HGNC:18352","description":"centromere protein M","metadata":{"aliases":["Pane1","CENP-M","MGC861","C22orf18"]}},{"id":"6cdb4ac08f404e9ab94909032ba08bcb","type":"GENE","name":"CENPN","canonical_id":"hgnc:HGNC:30873","description":"centromere protein N","metadata":{"aliases":["FLJ13607","FLJ22660","BM039","C16orf60"]}},{"id":"3a7e5620d46b40dc909ab0f1fd766fec","type":"GENE","name":"CENPN-AS1","canonical_id":"hgnc:HGNC:55106","description":"CENPN antisense RNA 1","metadata":null},{"id":"fa6dccd401714c998f3351e25836c1a5","type":"GENE","name":"CENPNP1","canonical_id":"hgnc:HGNC:54592","description":"CENPN pseudogene 1","metadata":null},{"id":"f8f8a92844ac443aad97e04fb2d2b71d","type":"GENE","name":"CENPNP2","canonical_id":"hgnc:HGNC:54593","description":"CENPN pseudogene 2","metadata":null},{"id":"a067f3ee691d473888b3caf5d8f2494f","type":"GENE","name":"CENPO","canonical_id":"hgnc:HGNC:28152","description":"centromere protein O","metadata":{"aliases":["MGC11266","CENP-O"]}},{"id":"3c92f84f3c07401a80cb8643eb72aa98","type":"GENE","name":"CENPP","canonical_id":"hgnc:HGNC:32933","description":"centromere protein P","metadata":{"aliases":["RP11-19J3.3","CENP-P"]}},{"id":"cb80d62894c145e3b83e8d1fe76cd004","type":"GENE","name":"CENPPP1","canonical_id":"hgnc:HGNC:56411","description":"CENPP pseudogene 1","metadata":null},{"id":"b43bdc6c74d2460fbfada9128f0d2368","type":"GENE","name":"CENPQ","canonical_id":"hgnc:HGNC:21347","description":"centromere protein Q","metadata":{"aliases":["FLJ10545","CENP-Q","C6orf139"]}},{"id":"39bcfd8273014e1e89e7a80cf9bef461","type":"GENE","name":"CENPS","canonical_id":"hgnc:HGNC:23163","description":"centromere protein S","metadata":{"aliases":["CENP-S","FAAP16","APITD1","MHF1"]}},{"id":"8a8222167157441498592dbdc6950f05","type":"GENE","name":"CENPS-CORT","canonical_id":"hgnc:HGNC:38843","description":"CENPS-CORT readthrough","metadata":{"aliases":["APITD1-CORT"]}},{"id":"851d3f35cfec4080ba8bc7cc3a05e516","type":"GENE","name":"CENPT","canonical_id":"hgnc:HGNC:25787","description":"centromere protein T","metadata":{"aliases":["FLJ13111","CENP-T","C16orf56"]}},{"id":"13a7e623893f44929730e77a8153ed23","type":"GENE","name":"CENPU","canonical_id":"hgnc:HGNC:21348","description":"centromere protein U","metadata":{"aliases":["CENP-U","KLIP1","CENP-50","PBIP1","MLF1IP"]}},{"id":"244b3ed7f4d64c03a9ca4426e43fa708","type":"GENE","name":"CENPUP1","canonical_id":"hgnc:HGNC:49889","description":"centromere protein U pseudogene 1","metadata":null},{"id":"08d10600cb1144f18fe78827588be0c4","type":"GENE","name":"CENPUP2","canonical_id":"hgnc:HGNC:49890","description":"centromere protein U pseudogene 2","metadata":null},{"id":"f753d2072f7e478c9a53b552db9040f9","type":"GENE","name":"CENPV","canonical_id":"hgnc:HGNC:29920","description":"centromere protein V","metadata":{"aliases":["p30","CENP-V","PRR6"]}},{"id":"6457933491364107816d3306dd04aebe","type":"GENE","name":"CENPVL1","canonical_id":"hgnc:HGNC:31851","description":"centromere protein V like 1","metadata":{"aliases":["PRR6L1","CENPVP1"]}},{"id":"29bc45ec0fd746f5997ced9cd36d8dfc","type":"GENE","name":"CENPVL2","canonical_id":"hgnc:HGNC:43879","description":"centromere protein V like 2","metadata":{"aliases":["CENPVP2"]}},{"id":"7a5ac525dc6248abbecf0451552d1270","type":"GENE","name":"CENPVL3","canonical_id":"hgnc:HGNC:43880","description":"centromere protein V like 3","metadata":{"aliases":["CENPVP3"]}},{"id":"09a2b9953e794e76a3d01d78c4c2f5c0","type":"GENE","name":"CENPW","canonical_id":"hgnc:HGNC:21488","description":null,"metadata":null},{"id":"22cf39c668cd4442a1467bdbc2a07d85","type":"GENE","name":"CENPX","canonical_id":"hgnc:HGNC:11422","description":"centromere protein X","metadata":{"aliases":["MGC14480","FAAP10","CENP-X","STRA13","MHF2"]}},{"id":"923afd4a2a2042659e54ca44f8b646c5","type":"GENE","name":"CEP104","canonical_id":"hgnc:HGNC:24866","description":"centrosomal protein 104","metadata":{"aliases":["GlyBP","RP1-286D6.4","CFAP256","ROC22","JBTS25","KIAA0562"]}},{"id":"6718dce683ac4a8bbb6b4f8d55118ad3","type":"GENE","name":"CEP112","canonical_id":"hgnc:HGNC:28514","description":"centrosomal protein 112","metadata":{"aliases":["MGC33887","CCDC46"]}},{"id":"520284b633724fbe9d590b66d1cd354b","type":"GENE","name":"CEP120","canonical_id":"hgnc:HGNC:26690","description":"centrosomal protein 120","metadata":{"aliases":["FLJ36090","CCDC100"]}},{"id":"d160d88ce65c46358632b622869f5beb","type":"GENE","name":"CEP126","canonical_id":"hgnc:HGNC:29264","description":"centrosomal protein 126","metadata":{"aliases":["KIAA1377"]}},{"id":"4368f38eb55946f9a0495551278b2639","type":"GENE","name":"CEP128","canonical_id":"hgnc:HGNC:20359","description":"centrosomal protein 128","metadata":{"aliases":["C14orf61","C14orf145"]}},{"id":"766d0dd5edc04d13b50d0f0066827e5a","type":"GENE","name":"CEP131","canonical_id":"hgnc:HGNC:29511","description":"centrosomal protein 131","metadata":{"aliases":["AZ1","KIAA1118","AZI1"]}},{"id":"de104ee6a2f142dc92830c7bb7f91ef7","type":"GENE","name":"CEP135","canonical_id":"hgnc:HGNC:29086","description":"centrosomal protein 135","metadata":{"aliases":["FLJ13621","KIAA0635","CEP4"]}},{"id":"60a96d33f9554037babbd8d739f88949","type":"GENE","name":"CEP135-AS1","canonical_id":"hgnc:HGNC:58793","description":"CEP135 antisense RNA 1","metadata":null},{"id":"b7ee1a0574ae4a6fb728ad3cd0697746","type":"GENE","name":"CEP15","canonical_id":"hgnc:HGNC:25024","description":"centrosomal protein 15","metadata":{"aliases":["HT021","C3orf14"]}},{"id":"78deb8293c4741fa9a45f4ba97cadcea","type":"GENE","name":"CEP152","canonical_id":"hgnc:HGNC:29298","description":"centrosomal protein 152","metadata":{"aliases":["KIAA0912","SCKL5","MCPH9"]}},{"id":"ff8d4f83535a41b1813846dd9189f88d","type":"GENE","name":"CEP152-AS1","canonical_id":"hgnc:HGNC:58297","description":"CEP152 antisense RNA 1","metadata":null},{"id":"91c37da9dc2944c784c44ee7c5c498d6","type":"GENE","name":"CEP162","canonical_id":"hgnc:HGNC:21107","description":"centrosomal protein 162","metadata":{"aliases":["QN1","C6orf84","KIAA1009"]}},{"id":"0a2e24fe442b43b9a118d04cfd4af972","type":"GENE","name":"CEP164","canonical_id":"hgnc:HGNC:29182","description":"centrosomal protein 164","metadata":{"aliases":["KIAA1052","NPHP15"]}},{"id":"83c7439cf3f6427e82367b96324ee3da","type":"GENE","name":"CEP164P1","canonical_id":"hgnc:HGNC:44988","description":"centrosomal protein 164 pseudogene 1","metadata":null},{"id":"92286bb414d040bf97599f985edcb53a","type":"GENE","name":"CEP170","canonical_id":"hgnc:HGNC:28920","description":"centrosomal protein 170","metadata":{"aliases":["KAB","FAM68A","KIAA0470"]}},{"id":"4dc78d0be70a4cc88e51dc7decfd455b","type":"GENE","name":"CEP170B","canonical_id":"hgnc:HGNC:20362","description":"centrosomal protein 170B","metadata":{"aliases":["FAM68C","Cep170R","KIAA0284"]}},{"id":"7f4ffa28f0b84350bb2e56eed73b25c9","type":"GENE","name":"CEP170P1","canonical_id":"hgnc:HGNC:28364","description":"centrosomal protein 170 pseudogene 1","metadata":{"aliases":["MGC26143","FAM68B","KIAA0470L","CEP170L"]}},{"id":"3ee894827ee049119a492bee59546a7b","type":"GENE","name":"CEP19","canonical_id":"hgnc:HGNC:28209","description":"centrosomal protein 19","metadata":{"aliases":["MGC14126","C3orf34"]}},{"id":"f5d5ddd404fa49708f201eba91f8d6e4","type":"GENE","name":"CEP192","canonical_id":"hgnc:HGNC:25515","description":"centrosomal protein 192","metadata":{"aliases":["KIAA1569","FLJ10352","PPP1R62"]}},{"id":"2683ca38b5334076b8ec70b1865ca23b","type":"GENE","name":"CEP192-DT","canonical_id":"hgnc:HGNC:55313","description":"CEP192 divergent transcript","metadata":{"aliases":["RP11-773H22.4"]}},{"id":"3221a0669d3d4cb39ed2126f4c3b7414","type":"GENE","name":"CEP192P1","canonical_id":"hgnc:HGNC:55779","description":"CEP192 pseudogene 1","metadata":null},{"id":"e978bd9bde8349acbd47b3307fa6e05b","type":"GENE","name":"CEP19P1","canonical_id":"hgnc:HGNC:54796","description":"CEP19 pseudogene 1","metadata":null},{"id":"926baab85fdf45ec94aee2d5c5fc0d63","type":"GENE","name":"CEP20","canonical_id":"hgnc:HGNC:26435","description":"centrosomal protein 20","metadata":{"aliases":["DKFZp686N1651","FLJ31153","PHSECRG2","FOR20","C16orf63","FOPNL"]}},{"id":"42d07aa2e477473087eaed1994753adf","type":"GENE","name":"CEP250","canonical_id":"hgnc:HGNC:1859","description":"centrosomal protein 250","metadata":{"aliases":["C-NAP1","CEP2"]}},{"id":"296537ac2abb48e9be63b706e1d3a4a6","type":"GENE","name":"CEP250-AS1","canonical_id":"hgnc:HGNC:40143","description":"CEP250 antisense RNA 1","metadata":null},{"id":"6af2e895311f4a8fb3fe6ad349b9d52c","type":"GENE","name":"CEP290","canonical_id":"hgnc:HGNC:29021","description":"centrosomal protein 290","metadata":{"aliases":["KIAA0373","FLJ13615","3H11Ag","rd16","NPHP6","JBTS5","SLSN6","LCA10","MKS4","BBS14","CT87","POC3"]}},{"id":"fd185968ab64419fa85ff15c884bd25e","type":"GENE","name":"CEP295","canonical_id":"hgnc:HGNC:29366","description":"centrosomal protein 295","metadata":{"aliases":["KIAA1731"]}},{"id":"0764f6cbf9f34b6ab97349d62208726e","type":"GENE","name":"CEP295NL","canonical_id":"hgnc:HGNC:44659","description":"CEP295 N-terminal like","metadata":{"aliases":["DDC8","KIAA1731NL"]}},{"id":"54f84e8780d04a8f86e057c040170e7d","type":"GENE","name":"CEP350","canonical_id":"hgnc:HGNC:24238","description":"centrosomal protein 350","metadata":{"aliases":["KIAA0480","CAP350"]}},{"id":"20ad4836f5994be5a15fc351e8dacbeb","type":"GENE","name":"CEP41","canonical_id":"hgnc:HGNC:12370","description":"centrosomal protein 41","metadata":{"aliases":["DKFZp762H1311","FLJ22445","JBTS15","TSGA14"]}},{"id":"f7b01e1d66044585bff38f1712fad21f","type":"GENE","name":"CEP43","canonical_id":"hgnc:HGNC:17012","description":"centrosomal protein 43","metadata":{"aliases":["FOP","FGFR1OP"]}},{"id":"179011fa0434443e8adaa2594177abe9","type":"GENE","name":"CEP44","canonical_id":"hgnc:HGNC:29356","description":"centrosomal protein 44","metadata":{"aliases":["KIAA1712"]}},{"id":"b6374df5cc88401aa2e7f1997bc92a0e","type":"GENE","name":"CEP55","canonical_id":"hgnc:HGNC:1161","description":null,"metadata":null},{"id":"b6a7e8dd79a34c61977cc179f1adb820","type":"GENE","name":"CEP57","canonical_id":"hgnc:HGNC:30794","description":"centrosomal protein 57","metadata":{"aliases":["Translokin","TSP57","KIAA0092"]}},{"id":"392a32c6ac274e189e480dc47eee5cbe","type":"GENE","name":"CEP57L1","canonical_id":"hgnc:HGNC:21561","description":"centrosomal protein 57 like 1","metadata":{"aliases":["bA487F23.2","MGC21731","C6orf182"]}},{"id":"fce21c4fac8743fe94787d69d1a47c34","type":"GENE","name":"CEP57L1P1","canonical_id":"hgnc:HGNC:23521","description":"centrosomal protein 57 like 1 pseudogene 1","metadata":{"aliases":["C10orf37","C6orf182P"]}},{"id":"fc95406c5d2a4efcbcc4eba8a46f35bc","type":"GENE","name":"CEP63","canonical_id":"hgnc:HGNC:25815","description":"centrosomal protein 63","metadata":{"aliases":["FLJ13386"]}},{"id":"2aa5a4f2ba664a3c8abcae26b32c61c9","type":"GENE","name":"CEP63-AS1","canonical_id":"hgnc:HGNC:58371","description":"CEP63 antisense RNA 1","metadata":null},{"id":"bb70ae2545aa4c179a3fdf6bf01bb993","type":"GENE","name":"CEP68","canonical_id":"hgnc:HGNC:29076","description":"centrosomal protein 68","metadata":{"aliases":["KIAA0582"]}},{"id":"d360720dcefb4c81a3561fda45824595","type":"GENE","name":"CEP70","canonical_id":"hgnc:HGNC:29972","description":"centrosomal protein 70","metadata":{"aliases":["BITE","FLJ13036"]}},{"id":"d364566304f44e2da0f9db7e96910587","type":"GENE","name":"CEP72","canonical_id":"hgnc:HGNC:25547","description":"centrosomal protein 72","metadata":{"aliases":["KIAA1519","FLJ10565"]}},{"id":"067571fe495940c59e50dbd2fb30ded4","type":"GENE","name":"CEP72-DT","canonical_id":"hgnc:HGNC:55563","description":"CEP72 divergent transcript","metadata":null},{"id":"29756df327554d9aaaa2ff1da3c8cc68","type":"GENE","name":"CEP76","canonical_id":"hgnc:HGNC:25727","description":"centrosomal protein 76","metadata":{"aliases":["HsT1705","FLJ12542","C18orf9"]}},{"id":"34750cf857354ec8a8f83ccafa5cb83a","type":"GENE","name":"CEP78","canonical_id":"hgnc:HGNC:25740","description":"centrosomal protein 78","metadata":{"aliases":["FLJ12643","C9orf81"]}},{"id":"37c0204494b245938d0673192dd1a261","type":"GENE","name":"CEP83","canonical_id":"hgnc:HGNC:17966","description":"centrosomal protein 83","metadata":{"aliases":["NY-REN-58","NPHP18","CCDC41"]}},{"id":"a8f944c74f584ed9bcc6d008dea79d68","type":"GENE","name":"CEP83-DT","canonical_id":"hgnc:HGNC:27055","description":"CEP83 divergent transcript","metadata":{"aliases":["CCDC41-AS1","CEP83-AS1"]}},{"id":"ea8d1f954fdc49549be150bc1accf0df","type":"GENE","name":"CEP85","canonical_id":"hgnc:HGNC:25309","description":"centrosomal protein 85","metadata":{"aliases":["DKFZP434L0117","CCDC21"]}},{"id":"c8e5cb37934c4bda9d06c00b5132149e","type":"GENE","name":"CEP85L","canonical_id":"hgnc:HGNC:21638","description":"centrosomal protein 85L","metadata":{"aliases":["NY-BR-15","bA57K17.2","C6orf204"]}},{"id":"5fc0dfcaca604e4d944d574a195606a3","type":"GENE","name":"CEP89","canonical_id":"hgnc:HGNC:25907","description":"centrosomal protein 89","metadata":{"aliases":["FLJ14640","CCDC123"]}},{"id":"0c764fa6e8b44ad798a572692c6142a9","type":"GENE","name":"CEP95","canonical_id":"hgnc:HGNC:25141","description":"centrosomal protein 95","metadata":{"aliases":["DKFZp667E1824","CCDC45"]}},{"id":"50186575793d4d718fe5e261db7b4f13","type":"GENE","name":"CEP97","canonical_id":"hgnc:HGNC:26244","description":"centrosomal protein 97","metadata":{"aliases":["FLJ23047","LRRIQ2"]}},{"id":"c65efb2212d34e559807483d1d61cb0b","type":"GENE","name":"CEPT1","canonical_id":"hgnc:HGNC:24289","description":"choline/ethanolamine phosphotransferase 1","metadata":null},{"id":"7bf8714cb1cc4237b066cb7dbb9cb3f5","type":"GENE","name":"CER1","canonical_id":"hgnc:HGNC:1862","description":"cerberus 1, DAN family BMP antagonist","metadata":{"aliases":["DAND4"]}},{"id":"fed7cc3105104a35981e20c28c031306","type":"GENE","name":"CERCAM","canonical_id":"hgnc:HGNC:23723","description":"cerebral endothelial cell adhesion molecule","metadata":{"aliases":["GLT25D3","CEECAM1"]}},{"id":"8ce6d66a9575488bacee0c6151a3aab4","type":"GO_TERM","name":"CERF complex","canonical_id":"go:GO:0090537","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (specifically SNF2L in mammals, which contain two ISWI homologs) and a CECR2 homolog. In mammals, CERF is involved in regulation of transcription from RNA polymerase II promoters.\" [GOC:krc]","metadata":null},{"id":"68ffbe730fbe497a8d7e768461ed1da5","type":"GENE","name":"CERK","canonical_id":"hgnc:HGNC:19256","description":"ceramide kinase","metadata":{"aliases":["hCERK","FLJ23239","dA59H18.3","DKFZp434E0211","FLJ21430","KIAA1646","LK4","dA59H18.2"]}},{"id":"002a7cb8c07b44b98fd601b852b3b862","type":"GENE","name":"CERKL","canonical_id":"hgnc:HGNC:21699","description":"CERK like autophagy regulator","metadata":{"aliases":["RP26"]}},{"id":"d49c845502ce4fb69552e936fffa5659","type":"GENE","name":"CERNA1","canonical_id":"hgnc:HGNC:52664","description":"competing endogenous lncRNA 1 for miR-4707-5p and miR-4767","metadata":{"aliases":["LOC100129973"]}},{"id":"e0732f74b41042dcb60931765a7dbe0c","type":"GENE","name":"CERNA2","canonical_id":"hgnc:HGNC:51354","description":"competing endogenous lncRNA 2 for microRNA let-7b","metadata":{"aliases":["HOST2"]}},{"id":"1fb17b4bcdd343e8ba84c793fcea033d","type":"GENE","name":"CERNA3","canonical_id":"hgnc:HGNC:53469","description":"competing endogenous lncRNA 3 for miR-645","metadata":{"aliases":["CTA"]}},{"id":"fe30473ea7f1442ea1de16e665097a94","type":"GENE","name":"CEROX1","canonical_id":"hgnc:HGNC:53928","description":"cytoplasmic endogenous regulator of oxidative phosphorylation 1","metadata":null},{"id":"32cdaa9f2cc04420a0d9de35e762fbf0","type":"GENE","name":"CERS1","canonical_id":"hgnc:HGNC:14253","description":"ceramide synthase 1","metadata":{"aliases":["LAG1","UOG1","LASS1"]}},{"id":"26b5ac6512ff4beb82f0dd80411ab251","type":"GENE","name":"CERS2","canonical_id":"hgnc:HGNC:14076","description":null,"metadata":null},{"id":"a66c4e8d56ce454699513ed076de23ee","type":"GENE","name":"CERS2-AS1","canonical_id":"hgnc:HGNC:58295","description":"CERS2 antisense RNA 1","metadata":null},{"id":"4fbd47fec3304cf5a93d760ffca3323d","type":"GENE","name":"CERS3","canonical_id":"hgnc:HGNC:23752","description":"ceramide synthase 3","metadata":{"aliases":["MGC27091","LASS3"]}},{"id":"974bff68215c4634a7eabd6c9ff94873","type":"GENE","name":"CERS3-AS1","canonical_id":"hgnc:HGNC:51431","description":"CERS3 antisense RNA 1","metadata":null},{"id":"4079985f50c044fb86787f03d6903bc9","type":"GENE","name":"CERS4","canonical_id":"hgnc:HGNC:23747","description":"ceramide synthase 4","metadata":{"aliases":["FLJ12089","Trh1","LASS4"]}},{"id":"0c367ac0623849f5b40a0d0c7fe56e20","type":"GENE","name":"CERS5","canonical_id":"hgnc:HGNC:23749","description":"ceramide synthase 5","metadata":{"aliases":["Trh4","MGC45411","FLJ25304","LASS5"]}},{"id":"1ad3f64b554d4f8aaf62463042903cd2","type":"GENE","name":"CERS6","canonical_id":"hgnc:HGNC:23826","description":"ceramide synthase 6","metadata":{"aliases":["LASS6"]}},{"id":"5a1edfe5dfd74342a179ab2b47ebbac2","type":"GENE","name":"CERS6-AS1","canonical_id":"hgnc:HGNC:44485","description":"CERS6 antisense RNA 1","metadata":null},{"id":"88035a6dd5a740f0aaa9aa195a2a56bf","type":"GENE","name":"CERT1","canonical_id":"hgnc:HGNC:2205","description":"ceramide transporter 1","metadata":{"aliases":["GPBP","STARD11","CERT","COL4A3BP"]}},{"id":"b1a31b37e40c4160868ee77604f5e563","type":"GENE","name":"CES1","canonical_id":"hgnc:HGNC:1863","description":null,"metadata":null},{"id":"15d6915f10a04ccb892b7ca9996fbc03","type":"GENE","name":"CES1P1","canonical_id":"hgnc:HGNC:18546","description":"carboxylesterase 1 pseudogene 1","metadata":{"aliases":["PCE-3","CESR","CES1A3","CES4"]}},{"id":"079527928b6e45f5ba3680396bff20bc","type":"GENE","name":"CES1P2","canonical_id":"hgnc:HGNC:48928","description":"carboxylesterase 1 pseudogene 2","metadata":null},{"id":"9775b0332e844d779525c9dc3125977e","type":"GENE","name":"CES2","canonical_id":"hgnc:HGNC:1864","description":"carboxylesterase 2","metadata":{"aliases":["CE-2","iCE","CES2A1"]}},{"id":"bac43e1bcfa64961895af8313bde7b7c","type":"GENE","name":"CES3","canonical_id":"hgnc:HGNC:1865","description":"carboxylesterase 3","metadata":{"aliases":["FLJ21736","ES31"]}},{"id":"803328267d4e4fcf8b0cfb3a57720fb3","type":"GENE","name":"CES4A","canonical_id":"hgnc:HGNC:26741","description":"carboxylesterase 4A","metadata":{"aliases":["FLJ37464","CES8"]}},{"id":"31def5c7caa940f58e0e193b086c5c8b","type":"GENE","name":"CES5A","canonical_id":"hgnc:HGNC:26459","description":"carboxylesterase 5A","metadata":{"aliases":["FLJ31547","CES4C1","CES5","CAUXIN","CES7"]}},{"id":"183276f77f9149a58386c46487fa554e","type":"GENE","name":"CES5AP1","canonical_id":"hgnc:HGNC:38516","description":"carboxylesterase 5A pseudogene 1","metadata":null},{"id":"503b8ce7d71b4e9c887205da25bdfbfa","type":"GENE","name":"CETN1","canonical_id":"hgnc:HGNC:1866","description":"centrin 1","metadata":{"aliases":["CEN1","CETN"]}},{"id":"98a0e161633a4a6b9ee257161a2bdb11","type":"GENE","name":"CETN2","canonical_id":"hgnc:HGNC:1867","description":"centrin 2","metadata":{"aliases":["CEN2","CALT"]}},{"id":"f660f3f7bdf94064b6b648c8f2ddc438","type":"GENE","name":"CETN3","canonical_id":"hgnc:HGNC:1868","description":"centrin 3","metadata":{"aliases":["CEN3"]}},{"id":"d4dd2ba6db9345e78ed5670646fc8497","type":"GENE","name":"CETN3-AS1","canonical_id":"hgnc:HGNC:59093","description":"CETN3 antisense RNA 1","metadata":null},{"id":"bceb54d8ed2748b982d2442e4108240c","type":"GENE","name":"CETN4P","canonical_id":"hgnc:HGNC:35450","description":"centrin 4, pseudogene","metadata":null},{"id":"9a678b35a71c4e149f1f53479fef4170","type":"GENE","name":"CETP","canonical_id":"hgnc:HGNC:1869","description":null,"metadata":null},{"id":"a1957f84cbe7441d99059588d8e3879d","type":"GENE","name":"CFAP100","canonical_id":"hgnc:HGNC:26842","description":"cilia and flagella associated protein 100","metadata":{"aliases":["FLJ40083","MIA1","CCDC37"]}},{"id":"8429ee76c2ca485dbdf26a52f79b7013","type":"GENE","name":"CFAP100-DT","canonical_id":"hgnc:HGNC:49641","description":"CFAP100 divergent transcript","metadata":{"aliases":["CCDC37-AS1","CCDC37-DT"]}},{"id":"d7e121ec5bd5418ba6be078c618fc7d2","type":"GENE","name":"CFAP107","canonical_id":"hgnc:HGNC:28567","description":"cilia and flagella associated protein 107","metadata":{"aliases":["MGC35194","C1orf158"]}},{"id":"5190beb7be864124a6fbd016451b80a3","type":"GENE","name":"CFAP119","canonical_id":"hgnc:HGNC:28078","description":"cilia and flagella associated protein 119","metadata":{"aliases":["MGC104706","C16orf93","CCDC189"]}},{"id":"460e8dc7b9244e7db63c9bff9edf087b","type":"GENE","name":"CFAP126","canonical_id":"hgnc:HGNC:32325","description":"cilia and flagella associated protein 126","metadata":{"aliases":["Flattop","Fltp","C1orf192"]}},{"id":"3830368ab4fe42f387322e9c301feb6d","type":"GENE","name":"CFAP141","canonical_id":"hgnc:HGNC:32305","description":"cilia and flagella associated protein 141","metadata":{"aliases":["C1orf189"]}},{"id":"9f7f6cd8990b4aa1bbb86979268eab19","type":"GENE","name":"CFAP144","canonical_id":"hgnc:HGNC:34347","description":"cilia and flagella associated protein 144","metadata":{"aliases":["LOC440585","hCG23177","FAM183A"]}},{"id":"5c315de2d07842f2b277c894a65c0151","type":"GENE","name":"CFAP144P1","canonical_id":"hgnc:HGNC:34511","description":"CFAP144 pseudogene 1","metadata":{"aliases":["LOC340286","THEG6","FAM183B","FAM183BP"]}},{"id":"704ce1805b784b2585a3a8c357a1a8b5","type":"GENE","name":"CFAP144P2","canonical_id":"hgnc:HGNC:51331","description":"CFAP144 pseudogene 2","metadata":{"aliases":["FAM183DP"]}},{"id":"0b7e308146464875b90bff617ce526d1","type":"GENE","name":"CFAP144P3","canonical_id":"hgnc:HGNC:51332","description":"CFAP144 pseudogene 3","metadata":{"aliases":["FAM183EP"]}},{"id":"383829cd813e4ebcbfc6699ceb4cfe9c","type":"GENE","name":"CFAP157","canonical_id":"hgnc:HGNC:27843","description":"cilia and flagella associated protein 157","metadata":{"aliases":["C9orf117"]}},{"id":"f9a05078757a4e1d9b47e19e817ef729","type":"GENE","name":"CFAP161","canonical_id":"hgnc:HGNC:26782","description":"cilia and flagella associated protein 161","metadata":{"aliases":["FLJ38615","C15orf26"]}},{"id":"49988b80f2cd4947887c98a208a77d6d","type":"GENE","name":"CFAP184","canonical_id":"hgnc:HGNC:26900","description":"cilia and flagella associated protein 184","metadata":{"aliases":["FLJ90575","CCDC96"]}},{"id":"99e4906758d64cf487a707604c2a030a","type":"GENE","name":"CFAP184-OT1","canonical_id":"hgnc:HGNC:58725","description":"CFAP184 overlapping transcript 1","metadata":null},{"id":"e45fbaecde514572a9a2dc383733ce80","type":"GENE","name":"CFAP20","canonical_id":"hgnc:HGNC:29523","description":"cilia and flagella associated protein 20","metadata":{"aliases":["GTL3","fSAP23","C16orf80"]}},{"id":"46f79f211e7c447cb6a5e0afbc334b4b","type":"GENE","name":"CFAP20-AS1","canonical_id":"hgnc:HGNC:58532","description":"CFAP20 antisense RNA 1","metadata":null},{"id":"23a908b3ac7d431189d7c1f0180bbf47","type":"GENE","name":"CFAP206","canonical_id":"hgnc:HGNC:21405","description":"cilia and flagella associated protein 206","metadata":{"aliases":["FLJ25974","dJ382I10.1","C6orf165"]}},{"id":"3677fcfc7bf24527ace745ce65d6872e","type":"GENE","name":"CFAP20DC","canonical_id":"hgnc:HGNC:24763","description":"CFAP20 domain containing","metadata":{"aliases":["FLJ42117","FLJ42930","C3orf67"]}},{"id":"f1c585347b334da8bdbc72260a7c97f3","type":"GENE","name":"CFAP20DC-AS1","canonical_id":"hgnc:HGNC:41063","description":"CFAP20DC antisense RNA 1","metadata":{"aliases":["C3orf67-AS1"]}},{"id":"5e70a6ac132e4a408c12e4a7ae54e780","type":"GENE","name":"CFAP20DC-DT","canonical_id":"hgnc:HGNC:55618","description":"CFAP20DC divergent transcript","metadata":null},{"id":"7707b1f833d940e48d914593abcc2138","type":"GENE","name":"CFAP210","canonical_id":"hgnc:HGNC:25064","description":"cilia and flagella associated protein 210","metadata":{"aliases":["LOC129881","C2orf77","CCDC173"]}},{"id":"ec0bbe7a60a447199fa166c35ec91e9a","type":"GENE","name":"CFAP221","canonical_id":"hgnc:HGNC:33720","description":"cilia and flagella associated protein 221","metadata":{"aliases":["FAP221","PCDP1"]}},{"id":"e778391bd01d4c95b8b0ccf7281f1e74","type":"GENE","name":"CFAP251","canonical_id":"hgnc:HGNC:28506","description":"cilia and flagella associated protein 251","metadata":{"aliases":["MGC33630","CaM-IP4","WDR66"]}},{"id":"2e6481d29ce94d33b6cb6bf0b07b5643","type":"GENE","name":"CFAP263","canonical_id":"hgnc:HGNC:25002","description":"cilia and flagella associated protein 263","metadata":{"aliases":["HSPC065","DKFZp434N1418","CCDC113"]}},{"id":"dc9ea3d92bbd4ae0b5285b10bacd29f4","type":"GENE","name":"CFAP276","canonical_id":"hgnc:HGNC:32331","description":"cilia and flagella associated protein 276","metadata":{"aliases":["C1orf194"]}},{"id":"6fcda464650b4c7c9a890e66f25db50d","type":"GENE","name":"CFAP298","canonical_id":"hgnc:HGNC:1301","description":"cilia and flagella associated protein 298","metadata":{"aliases":["FLJ20467","FBB18","CILD26","Kur","DNAAF16","C21orf48","C21orf59"]}},{"id":"073116f4cd5c40f6b7b7cf1ad8d3e514","type":"GENE","name":"CFAP298-TCP10L","canonical_id":"hgnc:HGNC:54636","description":"CFAP298-TCP10L readthrough","metadata":{"aliases":["FLJ10932","LINC00846","C21orf77"]}},{"id":"ce7938c5c498472eb64a72005907fe4a","type":"GENE","name":"CFAP299","canonical_id":"hgnc:HGNC:28554","description":"cilia and flagella associated protein 299","metadata":{"aliases":["C4orf22"]}},{"id":"896bc3c84f8e4893b00fcf513c6ea961","type":"GENE","name":"CFAP299-AS1","canonical_id":"hgnc:HGNC:58835","description":"CFAP299 antisense RNA 1","metadata":null},{"id":"1e29b88d734f4b349de17f44423997cc","type":"GENE","name":"CFAP300","canonical_id":"hgnc:HGNC:28188","description":"cilia and flagella associated protein 300","metadata":{"aliases":["MGC13040","FBB5","DNAAF17","C11orf70"]}},{"id":"2aff439a1f514d91a15ac4c45ac31cb7","type":"GENE","name":"CFAP36","canonical_id":"hgnc:HGNC:30540","description":"cilia and flagella associated protein 36","metadata":{"aliases":["MGC15407","BARTL1","CCDC104"]}},{"id":"da832af74a4042eba547b5ca67844a93","type":"GENE","name":"CFAP410","canonical_id":"hgnc:HGNC:1260","description":"cilia and flagella associated protein 410","metadata":{"aliases":["YF5","A2","LRRC76","C21orf2"]}},{"id":"302978b1883744028d2842707f7e12c4","type":"GENE","name":"CFAP418","canonical_id":"hgnc:HGNC:27232","description":"cilia and flagella associated protein 418","metadata":{"aliases":["MOT25","FLJ30600","CORD16","RP64","BBS21","FAP418","SMALLTALK","C8orf37"]}},{"id":"3d8e0b4fdfd446ff82d6bc8e3d4ae0f0","type":"GENE","name":"CFAP418-AS1","canonical_id":"hgnc:HGNC:50444","description":"CFAP418 antisense RNA 1","metadata":{"aliases":["tospeak","C8orf37-AS1"]}},{"id":"3c198183626f494b93976be1b1d10572","type":"GENE","name":"CFAP43","canonical_id":"hgnc:HGNC:26684","description":"cilia and flagella associated protein 43","metadata":{"aliases":["FLJ36006","bA373N18.2","FLJ22944","C10orf79","WDR96"]}},{"id":"b1cbb35f0c6b4da99c4f56f4917d96e4","type":"GENE","name":"CFAP44","canonical_id":"hgnc:HGNC:25631","description":"cilia and flagella associated protein 44","metadata":{"aliases":["FLJ11142","WDR52"]}},{"id":"3b0aeaba6cff4f45858898e92cea4e64","type":"GENE","name":"CFAP44-AS1","canonical_id":"hgnc:HGNC:41113","description":"CFAP44 antisense RNA 1","metadata":{"aliases":["WDR52-AS1"]}},{"id":"47a5293a26b5434d8eafd7875e85f604","type":"GENE","name":"CFAP45","canonical_id":"hgnc:HGNC:17229","description":"cilia and flagella associated protein 45","metadata":{"aliases":["NESG1","CCDC19"]}},{"id":"b6ce1807043749b186047e5729529d36","type":"GENE","name":"CFAP46","canonical_id":"hgnc:HGNC:25247","description":"cilia and flagella associated protein 46","metadata":{"aliases":["DKFZp434A1721","bA288G11.4","bA288G11.5","bB137A17.2","FLJ25954","bB137A17.3","C10orf123","C10orf124","C10orf93","C10orf92","TTC40"]}},{"id":"118b311498ed40c883b6dee99b81cb8a","type":"GENE","name":"CFAP47","canonical_id":"hgnc:HGNC:26708","description":"cilia and flagella associated protein 47","metadata":{"aliases":["FLJ36601","RP13-11B7.1","MGC34831","CXorf59","CXorf22","CXorf30","CHDC2"]}},{"id":"ab0e4205c4ba462b8a885678a47855f5","type":"GENE","name":"CFAP52","canonical_id":"hgnc:HGNC:16053","description":"cilia and flagella associated protein 52","metadata":{"aliases":["WDRPUH","FLJ37528","WDR16"]}},{"id":"f557505b30294159ad9a3b26bc42db33","type":"GENE","name":"CFAP53","canonical_id":"hgnc:HGNC:26530","description":"cilia and flagella associated protein 53","metadata":{"aliases":["FLJ32743","CCDC11"]}},{"id":"e295a29308f24aaf94155bd370565995","type":"GENE","name":"CFAP53P1","canonical_id":"hgnc:HGNC:43919","description":"CFAP53 pseudogene 1","metadata":{"aliases":["CCDC11P1"]}},{"id":"2e04727755ad4df5b3635799224f7f02","type":"GENE","name":"CFAP54","canonical_id":"hgnc:HGNC:26456","description":"cilia and flagella associated protein 54","metadata":{"aliases":["FLJ31514","FLJ44112","C12orf63","C12orf55"]}},{"id":"8175458354274546aa44b17c63f57f23","type":"GENE","name":"CFAP57","canonical_id":"hgnc:HGNC:26485","description":"cilia and flagella associated protein 57","metadata":{"aliases":["FLJ32000","WDR65"]}},{"id":"1207ebbc51984314aa14f404feed429b","type":"GENE","name":"CFAP58","canonical_id":"hgnc:HGNC:26676","description":"cilia and flagella associated protein 58","metadata":{"aliases":["FLJ35908","bA554P13.1","C10orf80","CCDC147"]}},{"id":"aabab364798d450b855e85af1ac574c3","type":"GENE","name":"CFAP58-DT","canonical_id":"hgnc:HGNC:45243","description":"CFAP58 divergent transcript","metadata":{"aliases":["lncITPRIP-1","CCDC147-AS1","CFAP58-AS1"]}},{"id":"7a5f2b3166f247d48b4599b242a9ac13","type":"GENE","name":"CFAP61","canonical_id":"hgnc:HGNC:15872","description":"cilia and flagella associated protein 61","metadata":{"aliases":["DKFZP434K156","dJ1002M8.3","CaM-IP3","C20orf26"]}},{"id":"c3ea75b8f4ef4e44bf4e5f38eec3c04d","type":"GENE","name":"CFAP61-AS1","canonical_id":"hgnc:HGNC:40731","description":"CFAP61 antisense RNA 1","metadata":null},{"id":"639f26d5ab1a401baf384e503805a400","type":"GENE","name":"CFAP65","canonical_id":"hgnc:HGNC:25325","description":"cilia and flagella associated protein 65","metadata":{"aliases":["DKFZp434O0527","MGC35338","CCDC108"]}},{"id":"ecac8df7d12a4971992e66dd4228636d","type":"GENE","name":"CFAP65-AS1","canonical_id":"hgnc:HGNC:58353","description":"CFAP65 antisense RNA 1","metadata":null},{"id":"61a591c3bd16471ea4662cc0d9c106a4","type":"GENE","name":"CFAP68","canonical_id":"hgnc:HGNC:1163","description":"cilia and flagella associated protein 68","metadata":{"aliases":["FLJ23499","C11orf1"]}},{"id":"f30aa0fa72bf4fed9a7b36e6890189e8","type":"GENE","name":"CFAP69","canonical_id":"hgnc:HGNC:26107","description":"cilia and flagella associated protein 69","metadata":{"aliases":["FLJ21062","FAP69","C7orf63"]}},{"id":"40c83887f9694971bd47a808af53fb98","type":"GENE","name":"CFAP69P1","canonical_id":"hgnc:HGNC:50809","description":"CFAP69 pseudogene 1","metadata":null},{"id":"cadfc9abe6e7496994db8839ccc278d3","type":"GENE","name":"CFAP70","canonical_id":"hgnc:HGNC:30726","description":"cilia and flagella associated protein 70","metadata":{"aliases":["FLJ25765","TTC18"]}},{"id":"33c587885afe410797908e7b6faf448e","type":"GENE","name":"CFAP73","canonical_id":"hgnc:HGNC:37100","description":"cilia and flagella associated protein 73","metadata":{"aliases":["MIA2","CCDC42B"]}},{"id":"5e42da91c0994a5c9e528773adbecb92","type":"GENE","name":"CFAP74","canonical_id":"hgnc:HGNC:29368","description":"cilia and flagella associated protein 74","metadata":{"aliases":["FLJ45476","C1orf222","KIAA1751"]}},{"id":"53fa83c444044453b6764b4702965886","type":"GENE","name":"CFAP77","canonical_id":"hgnc:HGNC:33776","description":"cilia and flagella associated protein 77","metadata":{"aliases":["FLJ46082","C9orf171"]}},{"id":"c05833db3e694379b78aac4e08c95c16","type":"GENE","name":"CFAP90","canonical_id":"hgnc:HGNC:27028","description":"cilia and flagella associated protein 90","metadata":{"aliases":["LOC134121","C5orf49"]}},{"id":"13610e32ae474ebf8a7ddf406bf02dc2","type":"GENE","name":"CFAP91","canonical_id":"hgnc:HGNC:24010","description":"cilia and flagella associated protein 91","metadata":{"aliases":["AAT1","AAT1alpha","SPATA26","CaM-IP2","AAT-1","C3orf15","MAATS1"]}},{"id":"e2d4dd36550647238169458114c59fac","type":"GENE","name":"CFAP92","canonical_id":"hgnc:HGNC:29231","description":"cilia and flagella associated protein 92 (putative)","metadata":{"aliases":["FLJ43738","FAP92","KIAA1257"]}},{"id":"187c7d2cd0df4ea6809d86e501fed682","type":"GENE","name":"CFAP95","canonical_id":"hgnc:HGNC:31422","description":"cilia and flagella associated protein 95","metadata":{"aliases":["C9orf135"]}},{"id":"d693f422cdc549d9ac1232eff862d6f6","type":"GENE","name":"CFAP95-DT","canonical_id":"hgnc:HGNC:48713","description":"CFAP95 divergent transcript","metadata":{"aliases":["C9orf135-AS1","C9orf135-DT"]}},{"id":"52dd3079299f4115b3ea97d5a80a7435","type":"GENE","name":"CFAP96","canonical_id":"hgnc:HGNC:34346","description":"cilia and flagella associated protein 96","metadata":{"aliases":["LOC441054","C4orf47"]}},{"id":"dd1b7784e2a44018aa1b95f4850d0c79","type":"GENE","name":"CFAP97","canonical_id":"hgnc:HGNC:29276","description":"cilia and flagella associated protein 97","metadata":{"aliases":["DKFZp434F1728","hmw","KIAA1430"]}},{"id":"48d2153437814a998f149e4a25b95ef2","type":"GENE","name":"CFAP97D1","canonical_id":"hgnc:HGNC:37241","description":"CFAP97 domain containing 1","metadata":{"aliases":["C17orf105"]}},{"id":"a3d4b83a09814b078c2dd3ac4279ef5d","type":"GENE","name":"CFAP97D1-AS1","canonical_id":"hgnc:HGNC:58321","description":"CFAP97D1 antisense RNA 1","metadata":null},{"id":"5296a6aa11624d93ac4a0c40e33350b1","type":"GENE","name":"CFAP97D2","canonical_id":"hgnc:HGNC:53789","description":"CFAP97 domain containing 2","metadata":null},{"id":"df310ca846a24d3198f3f14c8d798d16","type":"GENE","name":"CFAP97P1","canonical_id":"hgnc:HGNC:54528","description":"CFAP97 pseudogene 1","metadata":null},{"id":"a342314208cd4f81a520513004241900","type":"GENE","name":"CFAP99","canonical_id":"hgnc:HGNC:51180","description":"cilia and flagella associated protein 99","metadata":null},{"id":"7f0bdc57943d445aa6e56d9134b6d2c8","type":"GENE","name":"CFB","canonical_id":"hgnc:HGNC:1037","description":null,"metadata":null},{"id":"36b142ab86214719ac60aa8ee5d24151","type":"GENE","name":"CFC1","canonical_id":"hgnc:HGNC:18292","description":"cryptic, EGF-CFC family member 1","metadata":{"aliases":["CRYPTIC","HTX2"]}},{"id":"ae09530f6f32484fa42de0dde4185a65","type":"GENE","name":"CFC1B","canonical_id":"hgnc:HGNC:33983","description":"cryptic, EGF-CFC family member 1B","metadata":null},{"id":"8a9693523a494332b13bf06684d98471","type":"GENE","name":"CFD","canonical_id":"hgnc:HGNC:2771","description":"complement factor D","metadata":{"aliases":["ADN","DF","PFD"]}},{"id":"5272a04a1f5f41e39e5ec28b2a2ea25b","type":"GENE","name":"CFDP1","canonical_id":"hgnc:HGNC:1873","description":"chromatin remodeling protein CFDP1","metadata":{"aliases":["BCNT","p97","CP27","SWC5","Yeti","CENP-29"]}},{"id":"1776d4108c064d89a0551a3d9798d4bb","type":"GENE","name":"CFH","canonical_id":"hgnc:HGNC:4883","description":null,"metadata":null},{"id":"68fe293f2cb14a2f839db148a1f1b9c9","type":"GENE","name":"CFHR1","canonical_id":"hgnc:HGNC:4888","description":"complement factor H related 1","metadata":{"aliases":["H36-1","FHR1","CFHL","H36-2","HFL1","CFHL1","CFHR1P","HFL2","CFHL1P"]}},{"id":"9fdbb853675d47649a6064a9c6387d12","type":"GENE","name":"CFHR2","canonical_id":"hgnc:HGNC:4890","description":"complement factor H related 2","metadata":{"aliases":["FHR2","HFL3","CFHL2"]}},{"id":"30183b75e20d4446b6df6e4be108cf97","type":"GENE","name":"CFHR3","canonical_id":"hgnc:HGNC:16980","description":"complement factor H related 3","metadata":{"aliases":["FHR-3","HLF4","FHR3","DOWN16","CFHL3"]}},{"id":"179987117ff142059a881e4c7bd795a1","type":"GENE","name":"CFHR4","canonical_id":"hgnc:HGNC:16979","description":"complement factor H related 4","metadata":{"aliases":["FHR-4","FHR4","CFHL4"]}},{"id":"271eabdb12704cab84e20cb14cf43eb5","type":"GENE","name":"CFHR5","canonical_id":"hgnc:HGNC:24668","description":"complement factor H related 5","metadata":{"aliases":["FHR5","FHR-5","CFHL5"]}},{"id":"0e1ab639efda4837b6ada86151753926","type":"GENE","name":"CFI","canonical_id":"hgnc:HGNC:5394","description":null,"metadata":null},{"id":"3fc65510640b4ab8997d643955961d1f","type":"GENE","name":"CFL1","canonical_id":"hgnc:HGNC:1874","description":"cofilin 1","metadata":{"aliases":["CFL"]}},{"id":"670523af3c5c441a892f717a419b9e71","type":"GENE","name":"CFL1P1","canonical_id":"hgnc:HGNC:28560","description":"cofilin 1 pseudogene 1","metadata":{"aliases":["MGC35136","CFLP1"]}},{"id":"b8bad4c88d9f42ccbea8048c8f579d1e","type":"GENE","name":"CFL1P2","canonical_id":"hgnc:HGNC:1878","description":"cofilin 1 pseudogene 2","metadata":{"aliases":["CFLL2","CFLP2"]}},{"id":"926008399a494a8fa2ad85bab1c3fab5","type":"GENE","name":"CFL1P3","canonical_id":"hgnc:HGNC:1879","description":"cofilin 1 pseudogene 3","metadata":{"aliases":["CFLL3","CFLP3"]}},{"id":"e0f798224a3e4c8cb2188826dde18d42","type":"GENE","name":"CFL1P4","canonical_id":"hgnc:HGNC:1880","description":"cofilin 1 pseudogene 4","metadata":{"aliases":["CFLL4","CFLP4"]}},{"id":"b92d88dee37a44289046f36cf2e296ef","type":"GENE","name":"CFL1P5","canonical_id":"hgnc:HGNC:1877","description":"cofilin 1 pseudogene 5","metadata":{"aliases":["CFLL1","CFLP5"]}},{"id":"e474756e8ea1430c8f062cbf0d73dac2","type":"GENE","name":"CFL1P6","canonical_id":"hgnc:HGNC:34545","description":"cofilin 1 pseudogene 6","metadata":{"aliases":["CFLP6"]}},{"id":"4d07e6be6a08436eb6d48372e148e1b2","type":"GENE","name":"CFL1P7","canonical_id":"hgnc:HGNC:39959","description":"cofilin 1 pseudogene 7","metadata":null},{"id":"cc625ec1c8e24a688b41427b7d6ddb07","type":"GENE","name":"CFL1P8","canonical_id":"hgnc:HGNC:39960","description":"cofilin 1 pseudogene 8","metadata":null},{"id":"740733d3370a496a89f7f08268f9bce3","type":"GENE","name":"CFL2","canonical_id":"hgnc:HGNC:1875","description":"cofilin 2","metadata":{"aliases":["NEM7"]}},{"id":"0df0575bf3fb4d6aa50f00563ae89ffa","type":"GENE","name":"CFLAR","canonical_id":"hgnc:HGNC:1876","description":null,"metadata":null},{"id":"90e4630a84c94eda9f7bf433c725ec6b","type":"GENE","name":"CFLAR-AS1","canonical_id":"hgnc:HGNC:14437","description":"CFLAR antisense RNA 1","metadata":{"aliases":["ALS2CR10"]}},{"id":"c5cd28dcfb1f410abe12f934079726b3","type":"GENE","name":"CFP","canonical_id":"hgnc:HGNC:8864","description":"complement factor properdin","metadata":{"aliases":["PFC"]}},{"id":"005b0543d3484ded9775a865de981f40","type":"GENE","name":"CFTR","canonical_id":"hgnc:HGNC:1884","description":null,"metadata":null},{"id":"7643bd27b5bf4943a50ea67454930669","type":"PROTEIN","name":"CFTR","canonical_id":"uniprot:P13569","description":null,"metadata":null},{"id":"56d7791f794b46e59c003a7667747a3c","type":"GENE","name":"CFTR-AS1","canonical_id":"hgnc:HGNC:40144","description":"CFTR antisense RNA 1","metadata":{"aliases":["ANCF1","BGas"]}},{"id":"e33af454bf614b54bee7ffd892806f32","type":"GENE","name":"CFTR-AS2","canonical_id":"hgnc:HGNC:40145","description":"CFTR antisense RNA 2","metadata":{"aliases":["lnc-CTTNBP2-1:1"]}},{"id":"fc3009fbe1434ec195de72db3b0efa1b","type":"GO_TERM","name":"CFTR-NHERF-ezrin complex","canonical_id":"go:GO:0034662","description":"\"A protein complex that contains ezrin, Na+/H+ exchanger regulatory factor (NHERF, also called EBP50), and two copies of the cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR molecules interact with NHERF via their cytoplasmic tail domains; the complex is thought to link the CFTR channel to the actin cytoskeleton and contribute to the regulation of channel activity.\" [PMID:16129695, PMID:16798722, PMID:16926444]","metadata":null},{"id":"c2000ea756c54aafac559bd92bddfecd","type":"DISEASE","name":"CFTR-related disorder","canonical_id":"mondo:7770004","description":null,"metadata":null},{"id":"dd275724f1f546108859307e98e8a8d9","type":"GENE","name":"CFTRP1","canonical_id":"hgnc:HGNC:16182","description":"CFTR pseudogene 1","metadata":{"aliases":["dJ760C5.1","C20orf189"]}},{"id":"54a94a36961b482b92b850fb2148c7d7","type":"GENE","name":"CFTRP2","canonical_id":"hgnc:HGNC:51351","description":"CFTR pseudogene 2","metadata":null},{"id":"7c1a27910347453fa39153ffd6030bd1","type":"GENE","name":"CFTRP3","canonical_id":"hgnc:HGNC:51352","description":"CFTR pseudogene 3","metadata":null},{"id":"cefc96f2f5af42d28674029124bbb5bc","type":"GENE","name":"CGA","canonical_id":"hgnc:HGNC:1885","description":null,"metadata":null},{"id":"ec1d6e8766184281bab15d86e6eeb3a1","type":"TRIAL","name":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","canonical_id":"clinicaltrials.gov:NCT06665087","description":"Colon Cancer; Rectal Cancer","metadata":null},{"id":"18c974863dc7433994e8dee56a6ce272","type":"GO_TERM","name":"CGA codon-amino acid adaptor activity","canonical_id":"go:GO:0033431","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CGA codon.\" [GOC:mah]","metadata":null},{"id":"e59efe3e93014fa6afee46462056495f","type":"GENE","name":"CGAS","canonical_id":"hgnc:HGNC:21367","description":"cyclic GMP-AMP synthase","metadata":{"aliases":["h-cGAS","D4","C6orf150","MB21D1"]}},{"id":"733ef43a9a954e3d9d33d47ffaac5c02","type":"GENE","name":"CGB1","canonical_id":"hgnc:HGNC:16721","description":"chorionic gonadotropin subunit beta 1","metadata":null},{"id":"cd433093b29d4c278b71e3a782fdd548","type":"GENE","name":"CGB2","canonical_id":"hgnc:HGNC:16722","description":"chorionic gonadotropin subunit beta 2","metadata":null},{"id":"7fbff2180cde4314838c130948010b42","type":"GENE","name":"CGB3","canonical_id":"hgnc:HGNC:1886","description":null,"metadata":null},{"id":"d1969b89de7f49d383ed4c3b362ae476","type":"GENE","name":"CGB5","canonical_id":"hgnc:HGNC:16452","description":null,"metadata":null},{"id":"3f8b65105e3b4d9f94d30ad29fe23c9b","type":"GENE","name":"CGB7","canonical_id":"hgnc:HGNC:16451","description":"chorionic gonadotropin subunit beta 7","metadata":{"aliases":["CG-beta-a"]}},{"id":"7124a25717b248f48a7fc2e3c5eb9415","type":"GENE","name":"CGB8","canonical_id":"hgnc:HGNC:16453","description":"chorionic gonadotropin subunit beta 8","metadata":null},{"id":"23dcc2b9282a4897b8a601cd70e1bf12","type":"GO_TERM","name":"CGC codon-amino acid adaptor activity","canonical_id":"go:GO:0033430","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CGC codon.\" [GOC:mah]","metadata":null},{"id":"6d16a49ea0bd4e3685c9007c58d8cdea","type":"GO_TERM","name":"CGG codon-amino acid adaptor activity","canonical_id":"go:GO:0033432","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CGG codon.\" [GOC:mah]","metadata":null},{"id":"dc58a8a2a05f4c01bffbc7ba6119566a","type":"GENE","name":"CGGBP1","canonical_id":"hgnc:HGNC:1888","description":"CGG triplet repeat binding protein 1","metadata":{"aliases":["p20-CGGBP","CGGBP"]}},{"id":"f3eb00a918e84dd3b5ae317d2fa1524d","type":"GENE","name":"CGN","canonical_id":"hgnc:HGNC:17429","description":"cingulin","metadata":{"aliases":["KIAA1319"]}},{"id":"9afa6367438d4604b48cf58906d36432","type":"GENE","name":"CGNL1","canonical_id":"hgnc:HGNC:25931","description":"cingulin like 1","metadata":{"aliases":["FLJ14957","JACOP","KIAA1749","PCING"]}},{"id":"9033f794d43747a38eb49aaa63aa9e74","type":"GENE","name":"CGREF1","canonical_id":"hgnc:HGNC:16962","description":"cell growth regulator with EF-hand domain 1","metadata":{"aliases":["CGR11"]}},{"id":"5f4304a5ee1e4b00a28f54091798109e","type":"TRIAL","name":"CGRP Inhibition, Autonomic Function, and Migraine","canonical_id":"clinicaltrials.gov:NCT04628429","description":"Episodic Migraine; Chronic Migraine","metadata":null},{"id":"492c089496e046ca991e888054e9efb0","type":"GO_TERM","name":"CGRP receptor complex","canonical_id":"go:GO:1990406","description":"\"A transmembrane, G protein-coupled signaling receptor complex recognized by calcitonin gene-related peptides (CGRP).\" [GOC:bhm, PMID:20826335]","metadata":null},{"id":"dde711b5e10348898a969f36abd8a3a7","type":"TRIAL","name":"CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients","canonical_id":"clinicaltrials.gov:NCT02466334","description":"Cluster Headache","metadata":null},{"id":"1f5a4a7da9934edeb4c21429911342e9","type":"GENE","name":"CGRRF1","canonical_id":"hgnc:HGNC:15528","description":"cell growth regulator with ring finger domain 1","metadata":{"aliases":["CGR19","RNF197"]}},{"id":"3a224b32e22b4645bd5eb8b8f8c95eb0","type":"TRIAL","name":"CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02401815","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"1eeac16fe2cb4fc08e62458d8c203734","type":"GO_TERM","name":"CGU codon-amino acid adaptor activity","canonical_id":"go:GO:0033429","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CGU codon.\" [GOC:mah]","metadata":null},{"id":"8b2ea3c791454fedb5f30aef21754a45","type":"GO_TERM","name":"CH domain binding","canonical_id":"go:GO:0051401","description":"\"Binding to a calponin homology protein domain, a domain of 100 residues that occurs in signaling and cytoskeletal proteins.\" [PMID:11911887, Prosite:PDOC50021]","metadata":null},{"id":"81c76b747de749f3af3c95f7fa7c0a4e","type":"GENE","name":"CH25H","canonical_id":"hgnc:HGNC:1907","description":"cholesterol 25-hydroxylase","metadata":null},{"id":"9007f9682e5e4a1b8aeb11bd1452d7d4","type":"GENE","name":"CHAC1","canonical_id":"hgnc:HGNC:28680","description":null,"metadata":null},{"id":"5281801b1b894343a25ab62a5376626b","type":"GENE","name":"CHAC2","canonical_id":"hgnc:HGNC:32363","description":"ChaC glutathione specific gamma-glutamylcyclotransferase 2","metadata":{"aliases":["GCG1"]}},{"id":"322466f2ebbb41c2aade05c6d316af86","type":"GENE","name":"CHAD","canonical_id":"hgnc:HGNC:1909","description":"chondroadherin","metadata":{"aliases":["SLRR4A"]}},{"id":"d7192e8367fb4218b4e2d6b367c561b4","type":"GENE","name":"CHADL","canonical_id":"hgnc:HGNC:25165","description":"chondroadherin like","metadata":{"aliases":["SLRR4B"]}},{"id":"0c2a86f011e5406488b2a09663026601","type":"GENE","name":"CHAER1","canonical_id":"hgnc:HGNC:53620","description":"cardiac hypertrophy associated epigenetic regulator 1","metadata":{"aliases":["Chaer"]}},{"id":"5a8dcbb1e90342a3917747873b77eb73","type":"GENE","name":"CHAF1A","canonical_id":"hgnc:HGNC:1910","description":"chromatin assembly factor 1 subunit A","metadata":{"aliases":["CAF1P150","CAF1B","CAF-1","CAF1","P150","MGC71229"]}},{"id":"5e40b6dfb4684c9f88f4af0ad1645ae8","type":"GENE","name":"CHAF1B","canonical_id":"hgnc:HGNC:1911","description":"chromatin assembly factor 1 subunit B","metadata":{"aliases":["CAF1P60","CAF-1","CAF1","CAF1A","MPP7","MPHOSPH7"]}},{"id":"5ba4edd1056c41feb0b2d7d1e11d398c","type":"GENE","name":"CHAMP1","canonical_id":"hgnc:HGNC:20311","description":"chromosome alignment maintaining phosphoprotein 1","metadata":{"aliases":["CAMP","CHAMP","C13orf8","ZNF828"]}},{"id":"79fecf48ab5643548f23bafca6afcb05","type":"GENE","name":"CHASERR","canonical_id":"hgnc:HGNC:48626","description":"CHD2 adjacent suppressive regulatory RNA","metadata":{"aliases":["LINC01578"]}},{"id":"e675ec923aa94e87ae0374b9eac4be81","type":"GENE","name":"CHAT","canonical_id":"hgnc:HGNC:1912","description":null,"metadata":null},{"id":"9506549089284d64a8dcd238a83d6ae0","type":"GENE","name":"CHCHD1","canonical_id":"hgnc:HGNC:23518","description":"coiled-coil-helix-coiled-coil-helix domain containing 1","metadata":{"aliases":["FLJ25854","mS37","C10orf34"]}},{"id":"62420ab6443c4e79be3e417ff7227bbd","type":"GENE","name":"CHCHD10","canonical_id":"hgnc:HGNC:15559","description":"coiled-coil-helix-coiled-coil-helix domain containing 10","metadata":{"aliases":["N27C7-4","MIX17A","C22orf16"]}},{"id":"0ccc174b9dd34d22b635a5e19412f566","type":"GENE","name":"CHCHD2","canonical_id":"hgnc:HGNC:21645","description":"coiled-coil-helix-coiled-coil-helix domain containing 2","metadata":{"aliases":["MIX17B","MNRR1","C7orf17"]}},{"id":"eb7635aa28744551957af09a105a6f93","type":"GENE","name":"CHCHD2P1","canonical_id":"hgnc:HGNC:39585","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 1","metadata":null},{"id":"57387c1ae4e44758acdb3689418a99c0","type":"GENE","name":"CHCHD2P10","canonical_id":"hgnc:HGNC:39593","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 10","metadata":null},{"id":"6c712475cba449439f5035ba7513b7e1","type":"GENE","name":"CHCHD2P11","canonical_id":"hgnc:HGNC:49029","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 11","metadata":null},{"id":"fff5b209a1c94f139a3a658dd7e281c2","type":"GENE","name":"CHCHD2P2","canonical_id":"hgnc:HGNC:39586","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 2","metadata":null},{"id":"c6de31b3f8d34c72a97ba7ba1a9f380b","type":"GENE","name":"CHCHD2P3","canonical_id":"hgnc:HGNC:39587","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 3","metadata":null},{"id":"a45bba910b984f1e9a3f634a5823267b","type":"GENE","name":"CHCHD2P4","canonical_id":"hgnc:HGNC:39588","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 4","metadata":null},{"id":"0211943f88ed4e439fa244237c374697","type":"GENE","name":"CHCHD2P5","canonical_id":"hgnc:HGNC:39589","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 5","metadata":null},{"id":"e185fd02692c49f5bfff6677a2a99a4d","type":"GENE","name":"CHCHD2P6","canonical_id":"hgnc:HGNC:39590","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 6","metadata":null},{"id":"4130607b09164b80ad0ae4bfbbf4a4a4","type":"GENE","name":"CHCHD2P7","canonical_id":"hgnc:HGNC:39591","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 7","metadata":null},{"id":"570c4580092441a9aed18a6bc7348dc5","type":"GENE","name":"CHCHD2P8","canonical_id":"hgnc:HGNC:39592","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 8","metadata":null},{"id":"507ba5bb8f2e43afa6b3eb8fcc40b4ce","type":"GENE","name":"CHCHD2P9","canonical_id":"hgnc:HGNC:23676","description":"coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 9","metadata":{"aliases":["C9orf49","CHCHD9"]}},{"id":"6d5d2c7ba71746279e8f3df9c27533fe","type":"GENE","name":"CHCHD3","canonical_id":"hgnc:HGNC:21906","description":"coiled-coil-helix-coiled-coil-helix domain containing 3","metadata":{"aliases":["FLJ20420","MINOS3","PPP1R22","Mic19","MICOS19"]}},{"id":"b9371256c6b94647b2a7ca79fd4cc72f","type":"GENE","name":"CHCHD3P1","canonical_id":"hgnc:HGNC:44697","description":"coiled-coil-helix-coiled-coil-helix domain containing 3 pseudogene 1","metadata":null},{"id":"6b84b1b5ca6d488495434da575781738","type":"GENE","name":"CHCHD3P2","canonical_id":"hgnc:HGNC:44698","description":"coiled-coil-helix-coiled-coil-helix domain containing 3 pseudogene 2","metadata":null},{"id":"ed96d40ee2e24009a0f6696afef1f2c7","type":"GENE","name":"CHCHD3P3","canonical_id":"hgnc:HGNC:44699","description":"coiled-coil-helix-coiled-coil-helix domain containing 3 pseudogene 3","metadata":null},{"id":"1feb773b26ba422a9a019f1c6e0fe928","type":"GENE","name":"CHCHD4","canonical_id":"hgnc:HGNC:26467","description":"coiled-coil-helix-coiled-coil-helix domain containing 4","metadata":{"aliases":["FLJ31709","TIMM40","MIA40"]}},{"id":"1fbe80c00bbf4cddb5575b44c16de41d","type":"GENE","name":"CHCHD4P1","canonical_id":"hgnc:HGNC:44489","description":"coiled-coil-helix-coiled-coil-helix domain containing 4 pseudogene 1","metadata":null},{"id":"add148d2e2924c8e9929f3453a8d6fb6","type":"GENE","name":"CHCHD4P2","canonical_id":"hgnc:HGNC:44490","description":"coiled-coil-helix-coiled-coil-helix domain containing 4 pseudogene 2","metadata":null},{"id":"cc53c605b704403eae1e6df90a8dc0ba","type":"GENE","name":"CHCHD4P3","canonical_id":"hgnc:HGNC:44491","description":"coiled-coil-helix-coiled-coil-helix domain containing 4 pseudogene 3","metadata":null},{"id":"e19055e0413f40f5994e583e38f8045f","type":"GENE","name":"CHCHD4P4","canonical_id":"hgnc:HGNC:44492","description":"coiled-coil-helix-coiled-coil-helix domain containing 4 pseudogene 4","metadata":null},{"id":"720426210a054f09a03481ef06f0df21","type":"GENE","name":"CHCHD4P5","canonical_id":"hgnc:HGNC:44493","description":"coiled-coil-helix-coiled-coil-helix domain containing 4 pseudogene 5","metadata":null},{"id":"808ebd90a0f14d7da4c4722c25f8d4dc","type":"GENE","name":"CHCHD5","canonical_id":"hgnc:HGNC:17840","description":"coiled-coil-helix-coiled-coil-helix domain containing 5","metadata":{"aliases":["MGC11104","MIC14","MIX14","C2orf9"]}},{"id":"942ef78c61924f76b291dc346745f69a","type":"GENE","name":"CHCHD6","canonical_id":"hgnc:HGNC:28184","description":"coiled-coil-helix-coiled-coil-helix domain containing 6","metadata":{"aliases":["MGC13016","PPP1R23","CHCM1","Mic25","MICOS25"]}},{"id":"0d894f10ba6e484abe1f1bf8c9400bf0","type":"GENE","name":"CHCHD7","canonical_id":"hgnc:HGNC:28314","description":"coiled-coil-helix-coiled-coil-helix domain containing 7","metadata":{"aliases":["MGC2217","COX23"]}},{"id":"faeaaf4322f64ab39099286fd2221318","type":"GENE","name":"CHCT1","canonical_id":"hgnc:HGNC:26990","description":"CHD1 helical C-terminal domain containing 1","metadata":{"aliases":["C17orf64"]}},{"id":"967ea48982134cd0b1e6b9995e37d938","type":"GO_TERM","name":"CHD-type complex","canonical_id":"go:GO:0090545","description":"\"A SWI/SNF-type complex that contains a subunit from the CHD(Chromodomain helicase DNA-binding) family. The CHD family is characterized by two signature sequence motifs: tandem chromodomains located in the N-terminal region, and the SNF2-like ATPase domain located in the central region of the protein structure.\" [GOC:krc, GOC:tb, PMID:17350655]","metadata":null},{"id":"54c0534c7f054894a70e2da87c528dba","type":"GENE","name":"CHD1","canonical_id":"hgnc:HGNC:1915","description":"chromodomain helicase DNA binding protein 1","metadata":null},{"id":"e9f8bad087ad417095d5f532b74a9c8b","type":"GENE","name":"CHD1-DT","canonical_id":"hgnc:HGNC:52907","description":"CHD1 divergent transcript","metadata":{"aliases":["LINC02062"]}},{"id":"c5b4bb229a1a4c82996ac9d53f2eb9da","type":"GENE","name":"CHD1L","canonical_id":"hgnc:HGNC:1916","description":"chromodomain helicase DNA binding protein 1 like","metadata":{"aliases":["ALC1"]}},{"id":"c908a7d176da4ec8a1c51da24770d8d8","type":"GENE","name":"CHD2","canonical_id":"hgnc:HGNC:1917","description":"chromodomain helicase DNA binding protein 2","metadata":{"aliases":["FLJ38614","DKFZp547I1315","DKFZp781D1727","DKFZp686E01200"]}},{"id":"9619f479b69a4995a26ae68d4e815ed3","type":"GENE","name":"CHD3","canonical_id":"hgnc:HGNC:1918","description":"chromodomain helicase DNA binding protein 3","metadata":{"aliases":["Mi-2a","ZFH","Mi2-ALPHA"]}},{"id":"c251f1b79ce14fa4aba52eed89c60c87","type":"GENE","name":"CHD4","canonical_id":"hgnc:HGNC:1919","description":null,"metadata":null},{"id":"9cca4f1e1dbd494088d5c41ec67dd083","type":"GENE","name":"CHD4-AS1","canonical_id":"hgnc:HGNC:58242","description":"CHD4 antisense RNA 1","metadata":null},{"id":"19e704beef0a4e36982eb39df7c59c9c","type":"GENE","name":"CHD5","canonical_id":"hgnc:HGNC:16816","description":"chromodomain helicase DNA binding protein 5","metadata":null},{"id":"169f7014b0f646d38b45fefe801aa40f","type":"GENE","name":"CHD6","canonical_id":"hgnc:HGNC:19057","description":"chromodomain helicase DNA binding protein 6","metadata":{"aliases":["KIAA1335","FLJ22369","dJ620E11.1","CHD5","RIGB"]}},{"id":"1a5c6bb318de43f2bffa84c3e1b95e6e","type":"GENE","name":"CHD7","canonical_id":"hgnc:HGNC:20626","description":"chromodomain helicase DNA binding protein 7","metadata":{"aliases":["KIAA1416","FLJ20357","FLJ20361","CRG"]}},{"id":"436b49782c664d4ab67caa8573390339","type":"GENE","name":"CHD8","canonical_id":"hgnc:HGNC:20153","description":null,"metadata":null},{"id":"056c1d2500df4871b5664fbd47fdd172","type":"GENE","name":"CHD9","canonical_id":"hgnc:HGNC:25701","description":"chromodomain helicase DNA binding protein 9","metadata":{"aliases":["FLJ12178","KIAA0308","BC022889"]}},{"id":"cf2efa7e4fff4781a48c8045446b6b48","type":"GENE","name":"CHD9NB","canonical_id":"hgnc:HGNC:53436","description":"CHD9 neighbor","metadata":{"aliases":["PR-lncRNA-1"]}},{"id":"8d47038f903844f8976bea1e64286aed","type":"GENE","name":"CHDH","canonical_id":"hgnc:HGNC:24288","description":"choline dehydrogenase","metadata":null},{"id":"bb567214a0ca4241bef20dff4ff5d1c3","type":"GENE","name":"CHEK1","canonical_id":"hgnc:HGNC:1925","description":null,"metadata":null},{"id":"acf943e4857c494a93571127c810827d","type":"GENE","name":"CHEK2","canonical_id":"hgnc:HGNC:16627","description":null,"metadata":null},{"id":"655826e511c04ed883202aab309ab93b","type":"GENE","name":"CHEK2","canonical_id":"ensembl:ENSG00000183765","description":null,"metadata":null},{"id":"8836a9f773974e9594dc8292ff5501ab","type":"GENE","name":"CHEK2P1","canonical_id":"hgnc:HGNC:37999","description":"CHEK2 pseudogene 1","metadata":{"aliases":["CHEK2L1"]}},{"id":"05664b4470ce4de7b0d15727b22c9029","type":"GENE","name":"CHEK2P2","canonical_id":"hgnc:HGNC:43578","description":"CHEK2 pseudogene 2","metadata":null},{"id":"d3a44ebe50f44186ab2df06bf84394c3","type":"GENE","name":"CHEK2P3","canonical_id":"hgnc:HGNC:43579","description":"CHEK2 pseudogene 3","metadata":null},{"id":"af93461f67e64f85bc1acb5d43104fb1","type":"GENE","name":"CHEK2P4","canonical_id":"hgnc:HGNC:43580","description":"CHEK2 pseudogene 4","metadata":null},{"id":"1e97b324e1064db69f6493c71fc89056","type":"GENE","name":"CHEK2P5","canonical_id":"hgnc:HGNC:43581","description":"CHEK2 pseudogene 5","metadata":null},{"id":"a1a01eb3d048495bb19e4f53c989c7ee","type":"GENE","name":"CHEK2P6","canonical_id":"hgnc:HGNC:55703","description":"CHEK2 pseudogene 6","metadata":null},{"id":"2227c6dffcc24b8a9d35b17fd897f827","type":"GENE","name":"CHEK2P7","canonical_id":"hgnc:HGNC:55704","description":"CHEK2 pseudogene 7","metadata":null},{"id":"3121d15ad2f445478a7ba42c8dfca8a9","type":"GENE","name":"CHERP","canonical_id":"hgnc:HGNC:16930","description":"calcium homeostasis endoplasmic reticulum protein","metadata":{"aliases":["ERPROT213-21","DAN16"]}},{"id":"7578c6e2191345fdb37fecb9b9f87a4d","type":"GENE","name":"CHFR","canonical_id":"hgnc:HGNC:20455","description":"checkpoint with forkhead and ring finger domains","metadata":{"aliases":["FLJ10796","RNF196"]}},{"id":"1bb7cc68ebbe4703882c8e88301b3838","type":"GENE","name":"CHFR-DT","canonical_id":"hgnc:HGNC:55658","description":"CHFR divergent transcript","metadata":null},{"id":"8cf9194f279b4f31afa581ba8d7e9824","type":"GENE","name":"CHGA","canonical_id":"hgnc:HGNC:1929","description":null,"metadata":null},{"id":"9d84c6c96b534dcfbc64bc292cec8df0","type":"GENE","name":"CHGB","canonical_id":"hgnc:HGNC:1930","description":null,"metadata":null},{"id":"0a1cb3c12bf84f17a67ea7e3a4dbf92d","type":"GENE","name":"CHI3L1","canonical_id":"hgnc:HGNC:1932","description":null,"metadata":null},{"id":"6405db875253445eb45cbfecb8ebdaff","type":"GENE","name":"CHI3L2","canonical_id":"hgnc:HGNC:1933","description":"chitinase 3 like 2","metadata":{"aliases":["YKL-39","YKL39"]}},{"id":"38f015eb6b3a4bafb25c2417feca7619","type":"GENE","name":"CHIA","canonical_id":"hgnc:HGNC:17432","description":"chitinase acidic","metadata":{"aliases":["AMCase","TSA1902","CHIT2"]}},{"id":"f5fd2a9512814c0c8f273908868c69a8","type":"GENE","name":"CHIAP1","canonical_id":"hgnc:HGNC:44462","description":"chitinase, acidic pseudogene 1","metadata":null},{"id":"cb8ccd06ba7541328a2be925fa7b63b1","type":"GENE","name":"CHIAP2","canonical_id":"hgnc:HGNC:44463","description":"chitinase, acidic pseudogene 2","metadata":null},{"id":"633ed6a89cad4d519231503996f98a9a","type":"GENE","name":"CHIAP3","canonical_id":"hgnc:HGNC:44464","description":"chitinase, acidic pseudogene 3","metadata":null},{"id":"add82f75651a418a992f6291c8e7ad9d","type":"GENE","name":"CHIC1","canonical_id":"hgnc:HGNC:1934","description":"cysteine rich hydrophobic domain 1","metadata":{"aliases":["BRX"]}},{"id":"7757b2547ab64c56aaed6f79626b5364","type":"GENE","name":"CHIC2","canonical_id":"hgnc:HGNC:1935","description":"cysteine rich hydrophobic domain 2","metadata":{"aliases":["BTL"]}},{"id":"4f97194b10004a3db7d39ef7c8295d79","type":"GENE","name":"CHIC2-DT","canonical_id":"hgnc:HGNC:58788","description":"CHIC2 divergent transcript","metadata":null},{"id":"28ff52073e7c4b87878f9223d2abbe5c","type":"GENE","name":"CHID1","canonical_id":"hgnc:HGNC:28474","description":"chitinase domain containing 1","metadata":{"aliases":["MGC3234","FLJ42707","SI-CLP"]}},{"id":"eac685818cfe4bef981a3d4186662933","type":"GENE","name":"CHILL1","canonical_id":"hgnc:HGNC:55933","description":"cancer hallmarks in lung lncRNA 1","metadata":null},{"id":"636fc5ec8853464a8c2561aaf12ba4f8","type":"TRIAL","name":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","canonical_id":"clinicaltrials.gov:NCT06262438","description":"Acute Myeloid Leukemia in Children","metadata":null},{"id":"96a10d39c292430b9f1f8a881c4d1d61","type":"GENE","name":"CHIT1","canonical_id":"hgnc:HGNC:1936","description":"chitinase 1","metadata":{"aliases":["CHIT","CHI3"]}},{"id":"19bbacbe65584b56b43369d49769006c","type":"GENE","name":"CHKA","canonical_id":"hgnc:HGNC:1937","description":"choline kinase alpha","metadata":{"aliases":["CKI","CHK"]}},{"id":"852cd98d3bca465aa16d37d69caad2b5","type":"GENE","name":"CHKA-DT","canonical_id":"hgnc:HGNC:55504","description":"CHKA divergent transcript","metadata":null},{"id":"25f07436f1624e5cba4110196c5c0489","type":"GENE","name":"CHKB","canonical_id":"hgnc:HGNC:1938","description":"choline kinase beta","metadata":{"aliases":["CHETK","CHKL"]}},{"id":"de79ae82987540c39f59000406389356","type":"GENE","name":"CHKB-CPT1B","canonical_id":"hgnc:HGNC:41998","description":"CHKB-CPT1B readthrough (NMD candidate)","metadata":null},{"id":"77ec8c96f8964d13b2ccdb65e63a3d44","type":"GENE","name":"CHKB-DT","canonical_id":"hgnc:HGNC:40146","description":"CHKB divergent transcript","metadata":{"aliases":["TCONS_00029632","HRAT","CHKB-AS1"]}},{"id":"f8425529fe97436086f9467a42722796","type":"GENE","name":"CHL1","canonical_id":"hgnc:HGNC:1939","description":"cell adhesion molecule L1 like","metadata":{"aliases":["CALL","L1CAM2","FLJ44930","MGC132578"]}},{"id":"ac5b6c9da3044bf8b64d0a36313a40ac","type":"GENE","name":"CHL1-AS1","canonical_id":"hgnc:HGNC:40148","description":"CHL1 antisense RNA 1","metadata":null},{"id":"3f7364f634a448a0ab3b37a0a7a3c9eb","type":"GENE","name":"CHL1-AS2","canonical_id":"hgnc:HGNC:40147","description":"CHL1 antisense RNA 2","metadata":null},{"id":"31fe4e7efa124901a958f53aeabd999a","type":"GENE","name":"CHLSN","canonical_id":"hgnc:HGNC:22421","description":"cholesin","metadata":{"aliases":["MGC11257","YCR016W","C7orf50"]}},{"id":"299a59dfecee46388d99d3e340fcbe4e","type":"GENE","name":"CHLSN-AS1","canonical_id":"hgnc:HGNC:58147","description":"CHLSN antisense RNA 1","metadata":{"aliases":["AC091729.7"]}},{"id":"0774ee09c45445fab2079afc0f52a004","type":"GENE","name":"CHM","canonical_id":"hgnc:HGNC:1940","description":"CHM Rab escort protein","metadata":{"aliases":["REP-1","TCD","DXS540"]}},{"id":"40917f96945d4705911dc53b64ac7a11","type":"GENE","name":"CHML","canonical_id":"hgnc:HGNC:1941","description":"CHM like Rab escort protein","metadata":{"aliases":["REP-2"]}},{"id":"749ab65c4a1443d387aacd1f245026fe","type":"GENE","name":"CHMP1A","canonical_id":"hgnc:HGNC:8740","description":"charged multivesicular body protein 1A","metadata":{"aliases":["KIAA0047","CHMP1","Vps46A","PRSM1","PCOLN3"]}},{"id":"481955ece1964ae89ea592349ba2d579","type":"GENE","name":"CHMP1AP1","canonical_id":"hgnc:HGNC:39514","description":"charged multivesicular body protein 1A pseudogene 1","metadata":null},{"id":"9d1d08858b02455cb6c14f59c8360d02","type":"GENE","name":"CHMP1B","canonical_id":"hgnc:HGNC:24287","description":"charged multivesicular body protein 1B","metadata":{"aliases":["CHMP1.5","C18orf2","Vps46B"]}},{"id":"34c5b5b8cbc14eb281fe7398467ec778","type":"GENE","name":"CHMP1B-AS1","canonical_id":"hgnc:HGNC:52778","description":"CHMP1B antisense RNA 1","metadata":null},{"id":"518f16fe26d04291be548e19cc795bf9","type":"GENE","name":"CHMP1B2P","canonical_id":"hgnc:HGNC:49380","description":"charged multivesicular body protein 1B2, pseudogene","metadata":null},{"id":"28f1e2b7cc4f4d409adfd0c10144d540","type":"GENE","name":"CHMP2A","canonical_id":"hgnc:HGNC:30216","description":"charged multivesicular body protein 2A","metadata":{"aliases":["BC-2","CHMP2","VPS2","VPS2A"]}},{"id":"340ff24c0aca4e0c9cb0e0f6525d24ac","type":"GENE","name":"CHMP2B","canonical_id":"hgnc:HGNC:24537","description":"charged multivesicular body protein 2B","metadata":{"aliases":["DKFZP564O123","CHMP2.5","VPS2B"]}},{"id":"558d809403984d998fb3ff69ca5be00d","type":"GENE","name":"CHMP3","canonical_id":"hgnc:HGNC:29865","description":"charged multivesicular body protein 3","metadata":{"aliases":["NEDF","CGI-149","VPS24"]}},{"id":"fff12f1acd49410bb0f2473f3f4805f7","type":"GENE","name":"CHMP3-AS1","canonical_id":"hgnc:HGNC:55795","description":"CHMP3 and RNF103 antisense RNA 1","metadata":null},{"id":"99a15cbfbf514dda96bcc6fd7c530688","type":"GENE","name":"CHMP4A","canonical_id":"hgnc:HGNC:20274","description":"charged multivesicular body protein 4A","metadata":{"aliases":["HSPC134","VPS32A","hSnf7-1","Snf7-1","C14orf123"]}},{"id":"b5c15b1f2ac0480d9871646f9dbf948c","type":"GENE","name":"CHMP4AP1","canonical_id":"hgnc:HGNC:54739","description":"CHMP4A pseudogene 1","metadata":null},{"id":"36f2858e981b44fcb1ab5561ec3a08a7","type":"GENE","name":"CHMP4B","canonical_id":"hgnc:HGNC:16171","description":"charged multivesicular body protein 4B","metadata":{"aliases":["dJ553F4.4","Shax1","SNF7-2","VPS32B","C20orf178"]}},{"id":"7641173586634d068d5a91d8967678a5","type":"GENE","name":"CHMP4BP1","canonical_id":"hgnc:HGNC:43616","description":"charged multivesicular body protein 4B pseudogene 1","metadata":null},{"id":"1e614162aef24aa288383a731146ab77","type":"GENE","name":"CHMP4C","canonical_id":"hgnc:HGNC:30599","description":"charged multivesicular body protein 4C","metadata":{"aliases":["MGC22825","Shax3","VPS32C"]}},{"id":"77b7f4da3b7940f89b9054ae03e36908","type":"GENE","name":"CHMP5","canonical_id":"hgnc:HGNC:26942","description":"charged multivesicular body protein 5","metadata":{"aliases":["Spike","Vps60","CGI-34","HSPC177","C9orf83","SNF7DC2"]}},{"id":"86c9bf1602e54bc2982e0e387d57bc8f","type":"GENE","name":"CHMP5P1","canonical_id":"hgnc:HGNC:54950","description":"CHMP5 pseudogene 1","metadata":null},{"id":"7543c10bf84447cf9bc8e8793ec44dac","type":"GENE","name":"CHMP6","canonical_id":"hgnc:HGNC:25675","description":"charged multivesicular body protein 6","metadata":{"aliases":["FLJ11749","VPS20"]}},{"id":"aecb82f7486a4c06b8290dde44401303","type":"GENE","name":"CHMP7","canonical_id":"hgnc:HGNC:28439","description":"charged multivesicular body protein 7","metadata":{"aliases":["MGC29816"]}},{"id":"8ff82ac01809496d80a8c296af06114e","type":"GENE","name":"CHN1","canonical_id":"hgnc:HGNC:1943","description":"chimerin 1","metadata":{"aliases":["RhoGAP2","ARHGAP2","n-chimerin","CHN","DURS2"]}},{"id":"2ed5e678769b49af8b2676b467def5b2","type":"GENE","name":"CHN2","canonical_id":"hgnc:HGNC:1944","description":"chimerin 2","metadata":{"aliases":["ARHGAP3","RhoGAP3"]}},{"id":"56fc6a6a415e4ab3a3945a9d124685f9","type":"GENE","name":"CHN2-AS1","canonical_id":"hgnc:HGNC:40149","description":"CHN2 antisense RNA 1","metadata":null},{"id":"cb6fa3e899cc4c1c93536dbbeee6e525","type":"TRIAL","name":"CHOCOlate MeLatonin for AdolescenT MigrainE","canonical_id":"clinicaltrials.gov:NCT03597529","description":"Migraine","metadata":null},{"id":"97b50feb2dc34046a80c0317872771ce","type":"GENE","name":"CHODL","canonical_id":"hgnc:HGNC:17807","description":"chondrolectin","metadata":{"aliases":["FLJ12627","PRED12","MT75","C21orf68"]}},{"id":"30c59dc3fb5d4b01a2e9017a7ffd083c","type":"GENE","name":"CHODL-AS2","canonical_id":"hgnc:HGNC:58357","description":"CHODL antisense RNA 2","metadata":null},{"id":"95fae995fc284f6f87d2f49595a895e6","type":"TRIAL","name":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01746173","description":"T-cell Non-Hodgkin Lymphoma","metadata":null},{"id":"4e568532a385442e9668c3eabd301756","type":"GO_TERM","name":"CHOP-ATF3 complex","canonical_id":"go:GO:1990622","description":"\"A heterodimeric protein complex that is composed of CHOP (C/EBP homology protein, GADD153) and ATF3 (activating transcription factor 3) subunits.\" [GOC:bf, GOC:PARL, PMID:8622660]","metadata":null},{"id":"de04a2d75ace41129f29cf930acfd99a","type":"GO_TERM","name":"CHOP-ATF4 complex","canonical_id":"go:GO:1990617","description":"\"A heterodimeric transcription factor complex that is composed of CHOP (C/EBP homology protein, GADD153) and ATF4 (activating transcription factor 4, also known as cAMP response element binding protein-2/CREB-2) subunits.\" [GOC:bf, GOC:PARL, PMID:18940792]","metadata":null},{"id":"14347b075d15443ab1477d1d28811457","type":"GO_TERM","name":"CHOP-C/EBP complex","canonical_id":"go:GO:0036488","description":"\"A heterodimeric protein complex that is composed of the transcription factor CHOP (GADD153) and a member of the C/EBP family of transcription factors.\" [GOC:bf, GOC:PARL, PMID:1547942]","metadata":null},{"id":"9c8e64bf002a487f8f4e06ebf798977f","type":"GENE","name":"CHORDC1","canonical_id":"hgnc:HGNC:14525","description":"cysteine and histidine rich domain containing 1","metadata":{"aliases":["CHP1","CHP-1"]}},{"id":"b418952145664e878d0f642a7af33fcc","type":"GENE","name":"CHORDC1P1","canonical_id":"hgnc:HGNC:54687","description":"CHORDC1 pseudogene 1","metadata":null},{"id":"b4bc7768a9fe453fb726ea849e5bc84e","type":"GENE","name":"CHORDC1P3","canonical_id":"hgnc:HGNC:54689","description":"CHORDC1 pseudogene 3","metadata":null},{"id":"e5804254f058467badd4652d65006861","type":"GENE","name":"CHORDC1P4","canonical_id":"hgnc:HGNC:54688","description":"CHORDC1 pseudogene 4","metadata":null},{"id":"e437a6b93dfa4a668d77de02c964cf80","type":"GENE","name":"CHORDC1P5","canonical_id":"hgnc:HGNC:54690","description":"CHORDC1 pseudogene 5","metadata":null},{"id":"8b12c771a9684c0aa166d240d21ad8a0","type":"GENE","name":"CHORDC2P","canonical_id":"hgnc:HGNC:20050","description":"cysteine and histidine rich domain containing 2, pseudogene","metadata":null},{"id":"95263b999399495095c0c8b9a9892bab","type":"GENE","name":"CHP1","canonical_id":"hgnc:HGNC:17433","description":"calcineurin like EF-hand protein 1","metadata":{"aliases":["Sid470p","CHP","SLC9A1BP","p22","p24"]}},{"id":"981386b0e805468ca6610d0122b2d134","type":"GENE","name":"CHP1P1","canonical_id":"hgnc:HGNC:54895","description":"CHP1 pseudogene 1","metadata":null},{"id":"dbb097bfd99e4d54a237af69732f613d","type":"GENE","name":"CHP1P2","canonical_id":"hgnc:HGNC:54896","description":"CHP1 pseudogene 2","metadata":null},{"id":"366d7cfd116a4c7fa5a6023a40104ae2","type":"GENE","name":"CHP1P3","canonical_id":"hgnc:HGNC:54897","description":"CHP1 pseudogene 3","metadata":null},{"id":"e81a37cc12d74fff8094748c4ceb29ce","type":"GENE","name":"CHP2","canonical_id":"hgnc:HGNC:24927","description":"calcineurin like EF-hand protein 2","metadata":null},{"id":"54d87aa4668b4467958f4d2ae011de4c","type":"GENE","name":"CHPF","canonical_id":"hgnc:HGNC:24291","description":"chondroitin polymerizing factor","metadata":{"aliases":["CSS2","CHSY2","CHPF1"]}},{"id":"fd6ae47fd6b346638b4fef33d3f42f41","type":"GENE","name":"CHPF2","canonical_id":"hgnc:HGNC:29270","description":"chondroitin polymerizing factor 2","metadata":{"aliases":["KIAA1402","ChSy-3","CSGlcA-T"]}},{"id":"967bba3a5940498c86595c9d4b9bb636","type":"GENE","name":"CHPT1","canonical_id":"hgnc:HGNC:17852","description":"choline phosphotransferase 1","metadata":{"aliases":["CPT1"]}},{"id":"b9dd3880e1f140f88e29f1bd6afd6857","type":"GO_TERM","name":"CHRAC","canonical_id":"go:GO:0008623","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (SNF2H in mammals, Isw2 in S. cerevisiae), an ACF1 homolog, and additional small histone fold subunits (generally two of these, but Xenopus has only one and some additional non-conserved subunits). CHRAC plays roles in the regulation of RNA polymerase II transcription and in DNA replication and repair.\" [GOC:bf, GOC:krc, PMID:15284901, PMID:16568949, PMID:21810179, PMID:9252192]","metadata":null},{"id":"58bc832e224c4f23ab1bf66953f24ddb","type":"GENE","name":"CHRAC1","canonical_id":"hgnc:HGNC:13544","description":"chromatin accessibility complex subunit 1","metadata":{"aliases":["CHRAC15","YCL1"]}},{"id":"edf6bfdf9c984cac9156fde5b16096a8","type":"GENE","name":"CHRD","canonical_id":"hgnc:HGNC:1949","description":"chordin","metadata":null},{"id":"91297c957b60497d8f7cb51f4ebb4880","type":"GENE","name":"CHRDL1","canonical_id":"hgnc:HGNC:29861","description":"chordin like 1","metadata":{"aliases":["NRLN1","CHL","MGC1"]}},{"id":"f4e82b5ac7da4c489eef47c26c767c9b","type":"GENE","name":"CHRDL2","canonical_id":"hgnc:HGNC:24168","description":"chordin like 2","metadata":{"aliases":["BNF1"]}},{"id":"ad4032bcc4954792a6d35644b826ab5d","type":"GENE","name":"CHRFAM7A","canonical_id":"hgnc:HGNC:15781","description":"CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion","metadata":{"aliases":["D-10","CHRNA7-DR1"]}},{"id":"3469935e1daa45efa390d09484918dad","type":"GENE","name":"CHRFAM7AP1","canonical_id":"hgnc:HGNC:37766","description":"CHRFAM7A pseudogene 1","metadata":null},{"id":"4fe0b655e93c452e8ca3ed06ec5e0ee5","type":"GENE","name":"CHRFAM7AP2","canonical_id":"hgnc:HGNC:23937","description":"CHRFAM7A pseudogene 2","metadata":null},{"id":"d2e24baf0efe4e6c814f80b769a3e876","type":"GENE","name":"CHRM1","canonical_id":"hgnc:HGNC:1950","description":"cholinergic receptor muscarinic 1","metadata":null},{"id":"4ddfecce1f0947c0a0148f2ea80bc119","type":"PROTEIN","name":"CHRM1","canonical_id":"uniprot:P11229","description":null,"metadata":null},{"id":"5cfea7b2c28146b1a0748d6d3e5ef864","type":"GENE","name":"CHRM1-AS1","canonical_id":"hgnc:HGNC:58194","description":"CHRM1 antisense RNA 1","metadata":null},{"id":"a993e80b2bb942c6a413e5135e7201d3","type":"GENE","name":"CHRM2","canonical_id":"hgnc:HGNC:1951","description":"cholinergic receptor muscarinic 2","metadata":null},{"id":"dc7c69793951474393f772666687871f","type":"PROTEIN","name":"CHRM2","canonical_id":"uniprot:P08172","description":null,"metadata":null},{"id":"67de039a8722429c9ec3840552d33dcf","type":"GENE","name":"CHRM3","canonical_id":"hgnc:HGNC:1952","description":"cholinergic receptor muscarinic 3","metadata":{"aliases":["m3AChR"]}},{"id":"8d230327922544ac9a86b1dfdd1f74d0","type":"PROTEIN","name":"CHRM3","canonical_id":"uniprot:P20309","description":null,"metadata":null},{"id":"a917c9a5b2964ce38ea6382dc98fec4f","type":"GENE","name":"CHRM3-AS1","canonical_id":"hgnc:HGNC:40150","description":"CHRM3 antisense RNA 1","metadata":null},{"id":"573569c1026c4e6eaf41dbd4dd7184eb","type":"GENE","name":"CHRM3-AS2","canonical_id":"hgnc:HGNC:43725","description":"CHRM3 antisense RNA 2","metadata":null},{"id":"910aa70e211846889cc04631ac4d8112","type":"GENE","name":"CHRM4","canonical_id":"hgnc:HGNC:1953","description":"cholinergic receptor muscarinic 4","metadata":null},{"id":"ba990694f10c4bc7a628d3e75375dc43","type":"GENE","name":"CHRM5","canonical_id":"hgnc:HGNC:1954","description":"cholinergic receptor muscarinic 5","metadata":null},{"id":"b3ac3830ca704223bc676d5aa7f0f01f","type":"GENE","name":"CHRNA1","canonical_id":"hgnc:HGNC:1955","description":null,"metadata":null},{"id":"978a6e964f384a2c842fabce25274d44","type":"GENE","name":"CHRNA10","canonical_id":"hgnc:HGNC:13800","description":"cholinergic receptor nicotinic alpha 10 subunit","metadata":null},{"id":"95a804fa921449dcb7c5c9ea2d3972d9","type":"GENE","name":"CHRNA2","canonical_id":"hgnc:HGNC:1956","description":"cholinergic receptor nicotinic alpha 2 subunit","metadata":null},{"id":"c89da78ecb1e4faf935f78eb954b7047","type":"GENE","name":"CHRNA3","canonical_id":"hgnc:HGNC:1957","description":null,"metadata":null},{"id":"934ab6ad004f42c49f220bdc81df556e","type":"GENE","name":"CHRNA4","canonical_id":"hgnc:HGNC:1958","description":"cholinergic receptor nicotinic alpha 4 subunit","metadata":{"aliases":["BFNC","EBN","EBN1"]}},{"id":"4ed64009bfe14cf2bd9a8705c81b7319","type":"GENE","name":"CHRNA5","canonical_id":"hgnc:HGNC:1959","description":null,"metadata":null},{"id":"7d68beb72e1643199c0eca08b0500842","type":"GENE","name":"CHRNA6","canonical_id":"hgnc:HGNC:15963","description":"cholinergic receptor nicotinic alpha 6 subunit","metadata":null},{"id":"fc3948a4bac44f0a80755a3d889a4c3d","type":"GENE","name":"CHRNA7","canonical_id":"hgnc:HGNC:1960","description":"cholinergic receptor nicotinic alpha 7 subunit","metadata":{"aliases":["a7nAChR"]}},{"id":"9102ed7966af4a379588cfbf999ad4c2","type":"GENE","name":"CHRNA9","canonical_id":"hgnc:HGNC:14079","description":"cholinergic receptor nicotinic alpha 9 subunit","metadata":{"aliases":["NACHRA9"]}},{"id":"858595eb2e0f40e5b0aec0743f821a0f","type":"GENE","name":"CHRNB1","canonical_id":"hgnc:HGNC:1961","description":"cholinergic receptor nicotinic beta 1 subunit","metadata":{"aliases":["CHRNB"]}},{"id":"c3bd442463404c51aa35d081775cbc0d","type":"GENE","name":"CHRNB2","canonical_id":"hgnc:HGNC:1962","description":"cholinergic receptor nicotinic beta 2 subunit","metadata":null},{"id":"50d701fc3ca045e58575f1ba96d6ef09","type":"PROTEIN","name":"CHRNB2","canonical_id":"uniprot:P17787","description":null,"metadata":null},{"id":"0fc767e3cf9c47eeb3c68632c22d3880","type":"GENE","name":"CHRNB3","canonical_id":"hgnc:HGNC:1963","description":"cholinergic receptor nicotinic beta 3 subunit","metadata":null},{"id":"d6266208ecf14099bdca2c3c00e9c618","type":"GENE","name":"CHRNB4","canonical_id":"hgnc:HGNC:1964","description":null,"metadata":null},{"id":"269ed4b471da4a3b9164fca83fc00627","type":"GENE","name":"CHRND","canonical_id":"hgnc:HGNC:1965","description":"cholinergic receptor nicotinic delta subunit","metadata":{"aliases":["ACHRD"]}},{"id":"60026dde33f9447e816158cae0edc57c","type":"GENE","name":"CHRNE","canonical_id":"hgnc:HGNC:1966","description":null,"metadata":null},{"id":"1809de08c62249dc9ed05d5ab1d7be2a","type":"GENE","name":"CHRNG","canonical_id":"hgnc:HGNC:1967","description":"cholinergic receptor nicotinic gamma subunit","metadata":{"aliases":["ACHRG"]}},{"id":"747d5aef6a2c4ba2a657bf16013c298d","type":"GENE","name":"CHROMR","canonical_id":"hgnc:HGNC:54059","description":"cholesterol induced regulator of metabolism RNA","metadata":{"aliases":["CHROME","PRKRA-AS1"]}},{"id":"80c136a08d1c429db157834b34aa129f","type":"GENE","name":"CHST1","canonical_id":"hgnc:HGNC:1969","description":"carbohydrate sulfotransferase 1","metadata":{"aliases":["C6ST","KSGal6ST"]}},{"id":"89f79fb5700e457ca3570c083ceaca51","type":"GENE","name":"CHST10","canonical_id":"hgnc:HGNC:19650","description":"carbohydrate sulfotransferase 10","metadata":{"aliases":["HNK-1ST"]}},{"id":"c8dd3e75f76f4af7963f5b750d174ca6","type":"GENE","name":"CHST11","canonical_id":"hgnc:HGNC:17422","description":"carbohydrate sulfotransferase 11","metadata":{"aliases":["C4ST1","C4St-1","C4ST","HSA269537"]}},{"id":"44e4a13e09044d9bac3c79e5cf32d4df","type":"GENE","name":"CHST12","canonical_id":"hgnc:HGNC:17423","description":"carbohydrate sulfotransferase 12","metadata":{"aliases":["C4S-2","C4ST2"]}},{"id":"33fc135832ce4558969dd9c846e71f21","type":"GENE","name":"CHST13","canonical_id":"hgnc:HGNC:21755","description":"carbohydrate sulfotransferase 13","metadata":{"aliases":["C4ST3"]}},{"id":"c520eaa3cae448eb9ee1501aafe80657","type":"GENE","name":"CHST14","canonical_id":"hgnc:HGNC:24464","description":"carbohydrate sulfotransferase 14","metadata":{"aliases":["HD4ST","D4ST-1","D4ST1"]}},{"id":"9c7e519a3d324d7282bcb4aba2033004","type":"GENE","name":"CHST15","canonical_id":"hgnc:HGNC:18137","description":"carbohydrate sulfotransferase 15","metadata":{"aliases":["GALNAC4S-6ST","BRAG","KIAA0598"]}},{"id":"cd8e4c46e8b14919a8ae1ed20af4f172","type":"GENE","name":"CHST2","canonical_id":"hgnc:HGNC:1970","description":"carbohydrate sulfotransferase 2","metadata":{"aliases":["C6ST"]}},{"id":"83b99fa5f2ae4754b0a5584a86f665b1","type":"GENE","name":"CHST3","canonical_id":"hgnc:HGNC:1971","description":"carbohydrate sulfotransferase 3","metadata":{"aliases":["C6ST","C6ST1"]}},{"id":"8162de0cb34a480ab7254216390cd8d4","type":"GENE","name":"CHST4","canonical_id":"hgnc:HGNC:1972","description":null,"metadata":null},{"id":"aa3e2f8b6a77405198b98558305e94c1","type":"GENE","name":"CHST5","canonical_id":"hgnc:HGNC:1973","description":"carbohydrate sulfotransferase 5","metadata":{"aliases":["I-GLCNAC-6-ST","FLJ22167"]}},{"id":"72166049ca394baaaf7981bedf939cd3","type":"GENE","name":"CHST6","canonical_id":"hgnc:HGNC:6938","description":"carbohydrate sulfotransferase 6","metadata":{"aliases":["MCDC1"]}},{"id":"12c5fa32064645eba3d517fbe2b04424","type":"GENE","name":"CHST7","canonical_id":"hgnc:HGNC:13817","description":"carbohydrate sulfotransferase 7","metadata":{"aliases":["C6ST-2","C6ST2"]}},{"id":"6ce9e543b27e4e5796dfa712f68b528d","type":"GENE","name":"CHST8","canonical_id":"hgnc:HGNC:15993","description":"carbohydrate sulfotransferase 8","metadata":{"aliases":["GALNAC4ST-1"]}},{"id":"e8ef37ee6c3140bd9e0b30e271129191","type":"GENE","name":"CHST9","canonical_id":"hgnc:HGNC:19898","description":"carbohydrate sulfotransferase 9","metadata":{"aliases":["GALNAC4ST-2","GALNAC-4-ST2"]}},{"id":"7e2829dc38814a90bea0b89c37fd0dd6","type":"GENE","name":"CHSY1","canonical_id":"hgnc:HGNC:17198","description":"chondroitin sulfate synthase 1","metadata":{"aliases":["KIAA0990","CSS1"]}},{"id":"03a945b38938497182ba936f8c71c16f","type":"GENE","name":"CHSY3","canonical_id":"hgnc:HGNC:24293","description":"chondroitin sulfate synthase 3","metadata":{"aliases":["CSS3","CHSY-2"]}},{"id":"3ed1062ce79c4a89b7f35315299a7591","type":"GENE","name":"CHSY3-AS1","canonical_id":"hgnc:HGNC:58253","description":"CHSY3 antisense RNA 1","metadata":null},{"id":"0f9eae0be3fc462c8f0e4fa52b23a93a","type":"GENE","name":"CHTF18","canonical_id":"hgnc:HGNC:18435","description":"chromosome transmission fidelity factor 18","metadata":{"aliases":["CHL12","C321D2.4","Ctf18","C16orf41"]}},{"id":"32816524bced4b5d826c7de1b58c7e99","type":"GENE","name":"CHTF8","canonical_id":"hgnc:HGNC:24353","description":"chromosome transmission fidelity factor 8","metadata":{"aliases":["FLJ20400","CTF8"]}},{"id":"dfce35c3f23c4c39ae9d1421a1ec4728","type":"GENE","name":"CHTF8P1","canonical_id":"hgnc:HGNC:35443","description":"chromosome transmission fidelity factor 8 pseudogene 1","metadata":{"aliases":["CHTF8P"]}},{"id":"639b09fd0caf46d2acfe416a59a80556","type":"GENE","name":"CHTOP","canonical_id":"hgnc:HGNC:24511","description":"chromatin target of PRMT1","metadata":{"aliases":["DKFZP547E1010","SRAG","FOP","C1orf77"]}},{"id":"4c3e17bf0284440797fb9d22ab629968","type":"GENE","name":"CHUK","canonical_id":"hgnc:HGNC:1974","description":null,"metadata":null},{"id":"da856759b839427b85491ebe1b90315b","type":"GENE","name":"CHUK-DT","canonical_id":"hgnc:HGNC:55813","description":"CHUK divergent transcript","metadata":null},{"id":"1042e34c66854c3f9d8f2731ec0ce4a4","type":"GENE","name":"CHURC1","canonical_id":"hgnc:HGNC:20099","description":"churchill domain containing 1","metadata":{"aliases":["My015","FLJ33064","C14orf52"]}},{"id":"a86687c1c0b44b1296b60b3b71f5328b","type":"GENE","name":"CHURC1-FNTB","canonical_id":"hgnc:HGNC:42960","description":"CHURC1-FNTB readthrough","metadata":null},{"id":"e412a534a3f54c6384309b6ed74c7c43","type":"TRIAL","name":"CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen","canonical_id":"clinicaltrials.gov:NCT01762891","description":"Antiphospholipid Antibody Syndrome","metadata":null},{"id":"cfd4b919919142669e97a8d8f31cfc81","type":"GENE","name":"CIAO1","canonical_id":"hgnc:HGNC:14280","description":null,"metadata":null},{"id":"f9fa16cc1bca4bfdb793c57e02671abf","type":"GENE","name":"CIAO2A","canonical_id":"hgnc:HGNC:26235","description":"cytosolic iron-sulfur assembly component 2A","metadata":{"aliases":["FLJ22875","CIA2A","FAM96A"]}},{"id":"777cdfc291ed449b8ee4b0bca083daa2","type":"GENE","name":"CIAO2AP1","canonical_id":"hgnc:HGNC:43861","description":"CIAO2A pseudogene 1","metadata":{"aliases":["FAM96AP1"]}},{"id":"e5951d08e1944ded935fd4b4b38de2fa","type":"GENE","name":"CIAO2AP2","canonical_id":"hgnc:HGNC:43862","description":"CIAO2A pseudogene 2","metadata":{"aliases":["FAM96AP2"]}},{"id":"47016133c6504c499a7b74e4632cebdd","type":"GENE","name":"CIAO2B","canonical_id":"hgnc:HGNC:24261","description":"cytosolic iron-sulfur assembly component 2B","metadata":{"aliases":["CGI-128","MIP18","CIA2B","FAM96B"]}},{"id":"0315215cbf0d4c6297f889a67467dc64","type":"GENE","name":"CIAO3","canonical_id":"hgnc:HGNC:14179","description":"cytosolic iron-sulfur assembly component 3","metadata":{"aliases":["FLJ21988","PRN","HPRN","IOP1","NAR1","NARFL"]}},{"id":"e921567b45eb4f2da7b6469ab6ac40d5","type":"GENE","name":"CIAPIN1","canonical_id":"hgnc:HGNC:28050","description":"cytokine induced apoptosis inhibitor 1","metadata":{"aliases":["CIAE2"]}},{"id":"6c30b8bdc3b146e4b61ac0e15ed9225a","type":"GENE","name":"CIAPIN1P","canonical_id":"hgnc:HGNC:31087","description":"cytokine induced apoptosis inhibitor 1 pseudogene","metadata":{"aliases":["HsT2384"]}},{"id":"9ca22ea840634c0a835d71df4d2b8453","type":"GENE","name":"CIART","canonical_id":"hgnc:HGNC:25200","description":"circadian associated repressor of transcription","metadata":{"aliases":["BC017397","CHRONO","C1orf51"]}},{"id":"573e47218b214b37814bd2da49bf09cb","type":"GENE","name":"CIB1","canonical_id":"hgnc:HGNC:16920","description":"calcium and integrin binding 1","metadata":{"aliases":["SIP2-28","CIB","KIP"]}},{"id":"e860794a8f2747f8bc23e3ac3fe3ae77","type":"GENE","name":"CIB2","canonical_id":"hgnc:HGNC:24579","description":"calcium and integrin binding family member 2","metadata":{"aliases":["KIP2","DFNB48","USH1J"]}},{"id":"716ec0345bd94ef78776175fc5e603cd","type":"GENE","name":"CIB3","canonical_id":"hgnc:HGNC:24580","description":"calcium and integrin binding family member 3","metadata":{"aliases":["KIP3"]}},{"id":"d8be7f823dfb432fa6fe28d036a3f891","type":"GENE","name":"CIB4","canonical_id":"hgnc:HGNC:33703","description":"calcium and integrin binding family member 4","metadata":null},{"id":"b88119cca7cb4981969aed1684003fc6","type":"GENE","name":"CIBAR1","canonical_id":"hgnc:HGNC:30452","description":"CBY1 interacting BAR domain containing 1","metadata":{"aliases":["FLJ38979","BARMR1","FAM92A1","FAM92A"]}},{"id":"b6ac400b2b39445dae736e73d72379ae","type":"GENE","name":"CIBAR1-DT","canonical_id":"hgnc:HGNC:43644","description":"CIBAR1 divergent transcript","metadata":{"aliases":["LINC00535"]}},{"id":"2f4770e5a056468b8894b1ee6372ed50","type":"GENE","name":"CIBAR1P1","canonical_id":"hgnc:HGNC:32278","description":"CIBAR1 pseudogene 1","metadata":{"aliases":["FAM92A2","FAM92A1P1"]}},{"id":"ba6f98dcffb14f07a04979152ed0523a","type":"GENE","name":"CIBAR1P2","canonical_id":"hgnc:HGNC:32287","description":"CIBAR1 pseudogene 2","metadata":{"aliases":["MGC71735","MGC102964","FAM92A3","FAM92A1P2"]}},{"id":"ee9bec5ce3694839abcf0fed61bbc674","type":"GENE","name":"CIBAR2","canonical_id":"hgnc:HGNC:24781","description":"CBY1 interacting BAR domain containing 2","metadata":{"aliases":["FLJ44299","FAM92B"]}},{"id":"c92ad67febbc47c5b63bbf039b18d697","type":"GENE","name":"CIC","canonical_id":"hgnc:HGNC:14214","description":null,"metadata":null},{"id":"ca6f4ae02b124f14bb5e77e23f3b2377","type":"GENE","name":"CICP1","canonical_id":"hgnc:HGNC:23936","description":"capicua transcriptional repressor pseudogene 1","metadata":null},{"id":"8478faa795ae4ecab2208a371b9ee6fc","type":"GENE","name":"CICP10","canonical_id":"hgnc:HGNC:37901","description":"capicua transcriptional repressor pseudogene 10","metadata":null},{"id":"5e3023e14dfa40a9a3d2f7626a68c8d3","type":"GENE","name":"CICP11","canonical_id":"hgnc:HGNC:37903","description":"capicua transcriptional repressor pseudogene 11","metadata":null},{"id":"559644559be84b71b4cd891786c866f4","type":"GENE","name":"CICP12","canonical_id":"hgnc:HGNC:37905","description":"capicua transcriptional repressor pseudogene 12","metadata":null},{"id":"ed3ef33e440e44459248e271924fcdb7","type":"GENE","name":"CICP13","canonical_id":"hgnc:HGNC:37907","description":"capicua transcriptional repressor pseudogene 13","metadata":null},{"id":"f549d8bc9ef94c008c56937247eb3902","type":"GENE","name":"CICP14","canonical_id":"hgnc:HGNC:38542","description":"capicua transcriptional repressor pseudogene 14","metadata":null},{"id":"362bc49d72f74004a7d9579e56957289","type":"GENE","name":"CICP15","canonical_id":"hgnc:HGNC:38549","description":"capicua transcriptional repressor pseudogene 15","metadata":null},{"id":"a3cd72eabb8c47eb854ff8bebfa7469e","type":"GENE","name":"CICP16","canonical_id":"hgnc:HGNC:38550","description":"capicua transcriptional repressor pseudogene 16","metadata":null},{"id":"db22e64084f04464ba9ef77f6a39cc88","type":"GENE","name":"CICP17","canonical_id":"hgnc:HGNC:48827","description":"capicua transcriptional repressor pseudogene 17","metadata":null},{"id":"d1c5e57329c0476d8a59aadaeaefe1d8","type":"GENE","name":"CICP18","canonical_id":"hgnc:HGNC:48828","description":"capicua transcriptional repressor pseudogene 18","metadata":null},{"id":"22d8cb3bd6e64e368d3c20ea3c67915e","type":"GENE","name":"CICP19","canonical_id":"hgnc:HGNC:48829","description":"capicua transcriptional repressor pseudogene 19","metadata":null},{"id":"84dec6b9d8e842c591ba441a81070bcc","type":"GENE","name":"CICP2","canonical_id":"hgnc:HGNC:23935","description":"capicua transcriptional repressor pseudogene 2","metadata":null},{"id":"7e16f2f04c374df59422ebe56f58ad5c","type":"GENE","name":"CICP20","canonical_id":"hgnc:HGNC:48830","description":"capicua transcriptional repressor pseudogene 20","metadata":null},{"id":"2743849e617648f09a8d76e503c6bdcd","type":"GENE","name":"CICP21","canonical_id":"hgnc:HGNC:48836","description":"capicua transcriptional repressor pseudogene 21","metadata":null},{"id":"397b4d18e9b344a2ada9bbd9c9ea5150","type":"GENE","name":"CICP22","canonical_id":"hgnc:HGNC:48838","description":"capicua transcriptional repressor pseudogene 22","metadata":null},{"id":"526e6854e54f42579f4b588f7b88fbf2","type":"GENE","name":"CICP23","canonical_id":"hgnc:HGNC:48833","description":"capicua transcriptional repressor pseudogene 23","metadata":null},{"id":"7db026ef78784f6eafb01c90275bdc85","type":"GENE","name":"CICP24","canonical_id":"hgnc:HGNC:48831","description":"capicua transcriptional repressor pseudogene 24","metadata":null},{"id":"0bd981d7714049a68baa0098abafb019","type":"GENE","name":"CICP25","canonical_id":"hgnc:HGNC:48837","description":"capicua transcriptional repressor pseudogene 25","metadata":null},{"id":"f4bac996c48246f08dd625ed7698f7b5","type":"GENE","name":"CICP26","canonical_id":"hgnc:HGNC:48834","description":"capicua transcriptional repressor pseudogene 26","metadata":null},{"id":"e6b54f35f6db4b3394a5414cdd67eba0","type":"GENE","name":"CICP27","canonical_id":"hgnc:HGNC:48835","description":"capicua transcriptional repressor pseudogene 27","metadata":null},{"id":"5372137c4f1c4e7f9f0dab506eedafef","type":"GENE","name":"CICP28","canonical_id":"hgnc:HGNC:48832","description":"capicua transcriptional repressor pseudogene 28","metadata":null},{"id":"a5af1382cffd4dda8ab32a54b2264a2f","type":"GENE","name":"CICP3","canonical_id":"hgnc:HGNC:37742","description":"capicua transcriptional repressor pseudogene 3","metadata":null},{"id":"ce74b62d0fb441b5990343a32dcb5bab","type":"GENE","name":"CICP4","canonical_id":"hgnc:HGNC:37753","description":"capicua transcriptional repressor pseudogene 4","metadata":null},{"id":"d5fd2e32d1224fd7823f77678c8b2b4e","type":"GENE","name":"CICP5","canonical_id":"hgnc:HGNC:37754","description":"capicua transcriptional repressor pseudogene 5","metadata":null},{"id":"49bc5e2453b84a4eadc902cd057c1975","type":"GENE","name":"CICP6","canonical_id":"hgnc:HGNC:37755","description":"capicua transcriptional repressor pseudogene 6","metadata":null},{"id":"3520590b0c7f463188118c991c20466c","type":"GENE","name":"CICP7","canonical_id":"hgnc:HGNC:37756","description":"capicua transcriptional repressor pseudogene 7","metadata":null},{"id":"c1f7ba54a3c040048b142d1a532b5fbc","type":"GENE","name":"CICP8","canonical_id":"hgnc:HGNC:37757","description":"capicua transcriptional repressor pseudogene 8","metadata":null},{"id":"6c990f953e8c47dbad2c4e6fab89cb6d","type":"GENE","name":"CICP9","canonical_id":"hgnc:HGNC:37758","description":"capicua transcriptional repressor pseudogene 9","metadata":null},{"id":"c46ee6db5dd343148d6bd1a7aca301b0","type":"GENE","name":"CIDEA","canonical_id":"hgnc:HGNC:1976","description":"cell death inducing DFFA like effector a","metadata":{"aliases":["CIDE-A"]}},{"id":"731800df5fc2447fb92fa4d72a29e5f7","type":"GENE","name":"CIDEB","canonical_id":"hgnc:HGNC:1977","description":"cell death inducing DFFA like effector b","metadata":null},{"id":"9ee91d62ba6d4a26b9930c6a51b46b21","type":"GENE","name":"CIDEC","canonical_id":"hgnc:HGNC:24229","description":"cell death inducing DFFA like effector c","metadata":{"aliases":["CIDE-3","FLJ20871","Fsp27"]}},{"id":"9cfaf1d337c1476eb66484d6554e80f5","type":"GENE","name":"CIDEC-AS1","canonical_id":"hgnc:HGNC:59244","description":"CIDEC antisense RNA 1","metadata":null},{"id":"c4696895f20b4e6ca988301a4bbfe0bd","type":"GENE","name":"CIDECP1","canonical_id":"hgnc:HGNC:24230","description":"CIDEC pseudogene 1","metadata":{"aliases":["CICE","CIDECP"]}},{"id":"92310b07035c4c13ab284de53c16f95a","type":"GENE","name":"CIDECP2","canonical_id":"hgnc:HGNC:56519","description":"CIDEC pseudogene 2","metadata":null},{"id":"68c3f462c21645b2b1b4c9f8455e6cfc","type":"TRIAL","name":"CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)","canonical_id":"clinicaltrials.gov:NCT05014724","description":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","metadata":null},{"id":"798be503c4f34908b699e118b72d4cab","type":"GENE","name":"CIITA","canonical_id":"hgnc:HGNC:7067","description":null,"metadata":null},{"id":"42aa865031a943ffa5d4a4a2caf0c1e4","type":"GENE","name":"CILK1","canonical_id":"hgnc:HGNC:21219","description":"ciliogenesis associated kinase 1","metadata":{"aliases":["MRK","LCK2","KIAA0936","MGC46090","ICK"]}},{"id":"afca7ac05650419999e20024ba5cdc52","type":"GENE","name":"CILP","canonical_id":"hgnc:HGNC:1980","description":"cartilage intermediate layer protein","metadata":{"aliases":["HsT18872","CILP1"]}},{"id":"8504bfa1922b46bab00d74f8c9d4fc75","type":"GENE","name":"CILP2","canonical_id":"hgnc:HGNC:24213","description":"cartilage intermediate layer protein 2","metadata":{"aliases":["MGC45771"]}},{"id":"93ba24a2b2b540d59305e3ba721e257c","type":"GENE","name":"CIMAP1A","canonical_id":"hgnc:HGNC:19905","description":"ciliary microtubule associated protein 1A","metadata":{"aliases":["SHIPPO1","hSHIPPO","CT135","ODF3"]}},{"id":"4ded6c02bf004a74b39a25fc44d58810","type":"GENE","name":"CIMAP1B","canonical_id":"hgnc:HGNC:34388","description":"ciliary microtubule associated protein 1B","metadata":{"aliases":["FAP123","ODF3B"]}},{"id":"52290f661bcc43ddba8b460d486fa20f","type":"GENE","name":"CIMAP1C","canonical_id":"hgnc:HGNC:28735","description":"ciliary microtubule associated protein 1C","metadata":{"aliases":["MGC48986","ODF3L1"]}},{"id":"579bfba34a9b4babbfb2f1d015cb5f5f","type":"GENE","name":"CIMAP1D","canonical_id":"hgnc:HGNC:26841","description":"CIMAP1 family member D","metadata":{"aliases":["FLJ40059","C19orf19","ODF3L2"]}},{"id":"68fcf8ffe4de4763a95aa57b152095eb","type":"GENE","name":"CIMAP2","canonical_id":"hgnc:HGNC:26854","description":"ciliary microtubule associated protein 2","metadata":{"aliases":["FLJ40201","LEM","C1orf177","LEXM"]}},{"id":"6971a5179fc6481182aa0c47d0417e72","type":"GENE","name":"CIMAP3","canonical_id":"hgnc:HGNC:27009","description":"ciliary microtubule associated protein 3","metadata":{"aliases":["FLJ23853","pitchfork","C1orf88","PIFO"]}},{"id":"d4e17628de2b458a971282098e51e9ba","type":"TRIAL","name":"CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04220476","description":"Breast Cancer","metadata":null},{"id":"0b8cbb0e8ddd45ca939e75fcd66a336e","type":"GENE","name":"CIMIP1","canonical_id":"hgnc:HGNC:16216","description":"ciliary microtubule inner protein 1","metadata":{"aliases":["bA196N14.1","LLC1","C20orf85"]}},{"id":"5f54171452fe41f9b6ab585b376d708a","type":"GENE","name":"CIMIP2A","canonical_id":"hgnc:HGNC:33818","description":"ciliary microtubule inner protein 2A","metadata":{"aliases":["FAM166A"]}},{"id":"f3ae4dcefe854e598c8d93a9360031c7","type":"GENE","name":"CIMIP2B","canonical_id":"hgnc:HGNC:34242","description":"ciliary microtubule inner protein 2B","metadata":{"aliases":["FAM166B"]}},{"id":"e6c252c241384466963a993a01e424ae","type":"GENE","name":"CIMIP2C","canonical_id":"hgnc:HGNC:27938","description":"ciliary microtubule inner protein 2C","metadata":{"aliases":["LOC339778","C2orf70","FAM166C"]}},{"id":"f00d9c30229440a699493218049324b9","type":"GENE","name":"CIMIP3","canonical_id":"hgnc:HGNC:55126","description":"ciliary microtubule inner protein 3","metadata":{"aliases":["GUCA1ANB"]}},{"id":"a0359912128c40918fd728fc632903e8","type":"GENE","name":"CIMIP4","canonical_id":"hgnc:HGNC:28568","description":"ciliary microtubule inner protein 4","metadata":{"aliases":["MGC35206","EAN57","C22orf33","TEX33"]}},{"id":"2cd8daca76fd44b38379af6523b3d350","type":"GENE","name":"CIMIP5","canonical_id":"hgnc:HGNC:26324","description":"ciliary microtubule inner protein 5","metadata":{"aliases":["FLJ25143","C2orf50"]}},{"id":"385fac9cc101492ca487b523cae9a536","type":"GENE","name":"CIMIP6","canonical_id":"hgnc:HGNC:26861","description":"ciliary microtubule inner protein 6","metadata":{"aliases":["FLJ40298","C2orf73"]}},{"id":"df8c42ec792b4de4ba1e3125ee381385","type":"GENE","name":"CIMIP7","canonical_id":"hgnc:HGNC:44666","description":"ciliary microtubule inner protein 7","metadata":{"aliases":["C3orf84"]}},{"id":"e88ecd07c1bb4fc8bde47e06fa9f7465","type":"DISEASE","name":"CINCA syndrome","canonical_id":"mondo:0011776","description":null,"metadata":null},{"id":"e7d5f3fa0274481da2938ca7bdcbbca5","type":"GENE","name":"CINP","canonical_id":"hgnc:HGNC:23789","description":"cyclin dependent kinase 2 interacting protein","metadata":{"aliases":["MGC849"]}},{"id":"66b3e5e2756c4757a2278b9eb89d823c","type":"GENE","name":"CIP2A","canonical_id":"hgnc:HGNC:29302","description":null,"metadata":null},{"id":"d6c61847b2114517b90becec8f7f0cea","type":"GENE","name":"CIPC","canonical_id":"hgnc:HGNC:20365","description":"CLOCK interacting pacemaker","metadata":{"aliases":["KIAA1737"]}},{"id":"5a7a47a071a3457390419d745ecc540b","type":"GENE","name":"CIR1P1","canonical_id":"hgnc:HGNC:44011","description":"CIR1 pseudogene 1","metadata":null},{"id":"093e638dd27642c591719dac7aaa49d6","type":"GENE","name":"CIR1P2","canonical_id":"hgnc:HGNC:44012","description":"CIR1 pseudogene 2","metadata":null},{"id":"f860a20c558c46a98691f5526d1289f9","type":"GENE","name":"CIR1P3","canonical_id":"hgnc:HGNC:44013","description":"CIR1 pseudogene 3","metadata":null},{"id":"1120c7e160414582a78e6c3ded783587","type":"GENE","name":"CIRBP","canonical_id":"hgnc:HGNC:1982","description":"cold inducible RNA binding protein","metadata":{"aliases":["CIRP"]}},{"id":"7fac1174c92a4fc59263bc7eb31f8740","type":"GENE","name":"CIRBP-AS1","canonical_id":"hgnc:HGNC:28588","description":"CIRBP antisense RNA 1","metadata":{"aliases":["MGC39338","C19orf23"]}},{"id":"dd19b46eafab43a9a888a5db4edc4377","type":"GENE","name":"CIROP","canonical_id":"hgnc:HGNC:53647","description":"ciliated left-right organizer metallopeptidase","metadata":{"aliases":["LMLN2"]}},{"id":"6ff5b9c592b340bd811ea6f0bf32a147","type":"GENE","name":"CIROZ","canonical_id":"hgnc:HGNC:26730","description":"ciliated left-right organizer protein containing ZP-N domains","metadata":{"aliases":["FLJ37118","C1orf127"]}},{"id":"0bf81189e3b0496ca7a6b7e0a47ab1ae","type":"GENE","name":"CIRSR","canonical_id":"hgnc:HGNC:24217","description":"corepressor of RBPJ and splicing regulator","metadata":{"aliases":["CIR","CIR1"]}},{"id":"2d63420a01fa4a5a9c47b6e4c165386a","type":"GENE","name":"CISAT","canonical_id":"hgnc:HGNC:59202","description":"cobalt protoporphyrin induced and SFPQ associated RNA transcript","metadata":null},{"id":"79e7e9dc321441a6b025a8edf05915de","type":"GENE","name":"CISD1","canonical_id":"hgnc:HGNC:30880","description":"CDGSH iron sulfur domain 1","metadata":{"aliases":["MDS029","mitoNEET","C10orf70","ZCD1"]}},{"id":"1c4bd645138b4bf292910d4046e19757","type":"GENE","name":"CISD1P1","canonical_id":"hgnc:HGNC:29611","description":"CDGSH iron sulfur domain 1 pseudogene 1","metadata":{"aliases":["ZCD1B","CISD1B"]}},{"id":"808a02cbf81345abb57b16d3e29c6c01","type":"GENE","name":"CISD2","canonical_id":"hgnc:HGNC:24212","description":"CDGSH iron sulfur domain 2","metadata":{"aliases":["Miner1","ERIS","NAF-1","ZCD2","WFS2"]}},{"id":"901e74473e0145198f540d730ac6dbd8","type":"GENE","name":"CISD3","canonical_id":"hgnc:HGNC:27578","description":"CDGSH iron sulfur domain 3","metadata":{"aliases":["Miner2","MiNT"]}},{"id":"3c98d29133094d65ac70ee99ff04a062","type":"GENE","name":"CISH","canonical_id":"hgnc:HGNC:1984","description":null,"metadata":null},{"id":"a50ed5c08e044a4f8c84091c16d89fc0","type":"GENE","name":"CIST1","canonical_id":"hgnc:HGNC:55823","description":"colon, intestine and stomach enriched 1","metadata":null},{"id":"0fd9e964d016492698c99a747c249845","type":"GENE","name":"CISTR","canonical_id":"hgnc:HGNC:49426","description":"chondrogenesis-associated transcript","metadata":{"aliases":["CISTR-ACT","CISTRACT","re52431"]}},{"id":"b951b1cea8314b81912c4a2a5e152443","type":"GENE","name":"CIT","canonical_id":"hgnc:HGNC:1985","description":"citron rho-interacting serine/threonine kinase","metadata":{"aliases":["KIAA0949","STK21","CRIK","CITK"]}},{"id":"84b795e230ba402cafac3a4f8d9f4432","type":"GENE","name":"CITED1","canonical_id":"hgnc:HGNC:1986","description":"Cbp/p300 interacting transactivator with ED-rich tail 1","metadata":{"aliases":["MSG1"]}},{"id":"f41e399666ae47eeb51947ea7b9e6225","type":"GENE","name":"CITED2","canonical_id":"hgnc:HGNC:1987","description":null,"metadata":null},{"id":"83b28fde863047bd8e33d2fdb3e84b01","type":"GENE","name":"CITED4","canonical_id":"hgnc:HGNC:18696","description":"Cbp/p300 interacting transactivator with ED-rich tail 4","metadata":null},{"id":"a35a3945e9a54f7f8a39e2acc05ac203","type":"GENE","name":"CIZ1","canonical_id":"hgnc:HGNC:16744","description":"CDKN1A interacting zinc finger protein 1","metadata":{"aliases":["LSFR1","ZNF356"]}},{"id":"93aa400a6c9d42f8a2c24f049f9a4a38","type":"TRIAL","name":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","canonical_id":"clinicaltrials.gov:NCT05689021","description":"Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"33cb49726ba44f9a943d575391443478","type":"GENE","name":"CKAP2","canonical_id":"hgnc:HGNC:1990","description":"cytoskeleton associated protein 2","metadata":{"aliases":["LB1","FLJ10749","se20-10","TMAP"]}},{"id":"6fcf5b80c26944cfb55a366d92f623c7","type":"GENE","name":"CKAP2-DT","canonical_id":"hgnc:HGNC:56053","description":"CKAP2 divergent transcript","metadata":null},{"id":"db17d2030b97467cbd8de00a6eda31e6","type":"GENE","name":"CKAP2L","canonical_id":"hgnc:HGNC:26877","description":"cytoskeleton associated protein 2L","metadata":{"aliases":["FLJ40629","radmis"]}},{"id":"ce906322c6264d748e18796d542a91d4","type":"GENE","name":"CKAP2LP1","canonical_id":"hgnc:HGNC:54420","description":"CKAP2L pseudogene 1","metadata":null},{"id":"0676f8577a5041e09338d6aa5aea8d0f","type":"GENE","name":"CKAP2P1","canonical_id":"hgnc:HGNC:49923","description":"cytoskeleton associated protein 2 pseudogene 1","metadata":null},{"id":"c7fa1b8c51a94860b38c87595b201dca","type":"GENE","name":"CKAP4","canonical_id":"hgnc:HGNC:16991","description":"cytoskeleton associated protein 4","metadata":{"aliases":["P63","CLIMP-63","CLIMP63","ERGIC-63"]}},{"id":"5cab5ccd03064bae888f6f9ad12e25bf","type":"GENE","name":"CKAP5","canonical_id":"hgnc:HGNC:28959","description":"cytoskeleton associated protein 5","metadata":{"aliases":["ch-TOG","KIAA0097","TOG","TOGp"]}},{"id":"a446d16222f84e39b46f49d02f117d81","type":"GENE","name":"CKB","canonical_id":"hgnc:HGNC:1991","description":"creatine kinase B","metadata":{"aliases":["CKBB"]}},{"id":"4a7902ae9459492d967b0c9ee8ddcdad","type":"GENE","name":"CKBP1","canonical_id":"hgnc:HGNC:1993","description":"creatine kinase B pseudogene 1","metadata":null},{"id":"9a48c625415b473bb62cad591108912d","type":"TRIAL","name":"CKD-330 Drug-Drug Interaction Study (Candesartan)","canonical_id":"clinicaltrials.gov:NCT02064621","description":"Hypertension","metadata":null},{"id":"e8eefae64ff74e85ad77478d56993f9f","type":"TRIAL","name":"CKD-828 Drug Interaction Study (Telmisartan)","canonical_id":"clinicaltrials.gov:NCT01356017","description":"Healthy Male Volunteers","metadata":null},{"id":"d4d513a9f6fb4c21b9afa6b96877cec2","type":"TRIAL","name":"CKD-828 Telmisartan Non-Responder Trial","canonical_id":"clinicaltrials.gov:NCT01426100","description":"Hypertension","metadata":null},{"id":"d8c6cad7ab1748c8a792cf47590352fe","type":"GENE","name":"CKLF","canonical_id":"hgnc:HGNC:13253","description":"chemokine like factor","metadata":{"aliases":["UCK-1","CKLF3","CKLF4","HSPC224","C32","CKLF1"]}},{"id":"2c129d396a954a6383b50b060eaca540","type":"GENE","name":"CKLF-CMTM1","canonical_id":"hgnc:HGNC:39977","description":"CKLF-CMTM1 readthrough","metadata":null},{"id":"1d96af45c1fb4c8faf10d934cd988f12","type":"GENE","name":"CKM","canonical_id":"hgnc:HGNC:1994","description":null,"metadata":null},{"id":"df390dc9ef024a7a91a2dc70e24f457a","type":"TRIAL","name":"CKM For Safe Use of SGLT2i in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT07211802","description":"Type 1 Diabetes (T1D)","metadata":null},{"id":"67c1575bd73c4c4a9bb92e451870739a","type":"GO_TERM","name":"CKM complex","canonical_id":"go:GO:1990508","description":"\"Cyclin-dependent kinase complex which reversibly associates with the Mediator complex. In Saccharomyces cerevisiae it consists of SSN2, SSN3, SSN8 and SRB8.\" [GOC:bhm, PMID:12200444]","metadata":null},{"id":"fd9657503a3e44999d370d1034f579b7","type":"GENE","name":"CKMT1A","canonical_id":"hgnc:HGNC:31736","description":"creatine kinase, mitochondrial 1A","metadata":{"aliases":["CKMT1"]}},{"id":"effcf4afd91a4982956e92c42e8e1262","type":"GENE","name":"CKMT1B","canonical_id":"hgnc:HGNC:1995","description":"creatine kinase, mitochondrial 1B","metadata":{"aliases":["UMTCK","CKMT","CKMT1"]}},{"id":"34e38235dcc64465810910f919880bfc","type":"GENE","name":"CKMT2","canonical_id":"hgnc:HGNC:1996","description":"creatine kinase, mitochondrial 2","metadata":{"aliases":["SMTCK"]}},{"id":"43065289cf4b4439b681e5e119d8b1d0","type":"GENE","name":"CKMT2-AS1","canonical_id":"hgnc:HGNC:48997","description":"CKMT2 antisense RNA 1","metadata":null},{"id":"fccf8e089c3f40ffb7a7697db2dbbca4","type":"GENE","name":"CKS1B","canonical_id":"hgnc:HGNC:19083","description":"CDC28 protein kinase regulatory subunit 1B","metadata":{"aliases":["ckshs1","CKS1"]}},{"id":"112f5bb54c54417e8474f1ba7dc0f78b","type":"GENE","name":"CKS1BP1","canonical_id":"hgnc:HGNC:20004","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 1","metadata":{"aliases":["CKS1BP"]}},{"id":"f18f51794a534605a369c65d5081e32a","type":"GENE","name":"CKS1BP2","canonical_id":"hgnc:HGNC:24232","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 2","metadata":{"aliases":["bA192N10.2"]}},{"id":"17f6f895eb7646fab795baad4a0556f2","type":"GENE","name":"CKS1BP3","canonical_id":"hgnc:HGNC:24233","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 3","metadata":null},{"id":"d4d6807e82b44f1a968bf017164694fe","type":"GENE","name":"CKS1BP4","canonical_id":"hgnc:HGNC:17395","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 4","metadata":null},{"id":"21cf4aca40c543b1b3fc9054c528db4a","type":"GENE","name":"CKS1BP5","canonical_id":"hgnc:HGNC:17640","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 5","metadata":null},{"id":"4bc2c502bd274f639b82dc1538edeffe","type":"GENE","name":"CKS1BP6","canonical_id":"hgnc:HGNC:24608","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 6","metadata":null},{"id":"d4353986a91b4d8aab18537365bf895a","type":"GENE","name":"CKS1BP7","canonical_id":"hgnc:HGNC:1999","description":"CDC28 protein kinase regulatory subunit 1B pseudogene 7","metadata":{"aliases":["CKS1","CKS1A"]}},{"id":"180c7edc2d7741529dea6c430d1048c1","type":"GENE","name":"CKS2","canonical_id":"hgnc:HGNC:2000","description":null,"metadata":null},{"id":"802e0b3b9d7946e6abe072f8745e3a9a","type":"TRIAL","name":"CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert\u00ae Versus Reference Treatment","canonical_id":"clinicaltrials.gov:NCT00642135","description":"Retinal Anomalies; Premature Birth","metadata":null},{"id":"29ab896279ce4ff389a961aff40142fd","type":"GENE","name":"CLASP1","canonical_id":"hgnc:HGNC:17088","description":"cytoplasmic linker associated protein 1","metadata":{"aliases":["KIAA0622","MAST1"]}},{"id":"5bf226a2add74efa8b8c190020126be5","type":"GENE","name":"CLASP1-AS1","canonical_id":"hgnc:HGNC:55328","description":"CLASP1 antisense RNA 1","metadata":null},{"id":"e439507972c34e038707a33d11ab58df","type":"GENE","name":"CLASP2","canonical_id":"hgnc:HGNC:17078","description":"cytoplasmic linker associated protein 2","metadata":{"aliases":["KIAA0627"]}},{"id":"e30603cef19446a3b3929f3ac17af1f8","type":"GENE","name":"CLASRP","canonical_id":"hgnc:HGNC:17731","description":"CLK4 associating serine/arginine rich protein","metadata":{"aliases":["SWAP2","CLASP","SFRS16"]}},{"id":"6e6b419a0283410da6740b607ccaf85e","type":"GENE","name":"CLBA1","canonical_id":"hgnc:HGNC:20126","description":"clathrin binding box of aftiphilin containing 1","metadata":{"aliases":["C14orf79"]}},{"id":"16a68da27da44d3d95abc1d0efed89d1","type":"GENE","name":"CLC","canonical_id":"hgnc:HGNC:2014","description":"Charcot-Leyden crystal galectin","metadata":{"aliases":["LGALS10","MGC149659","Gal-10"]}},{"id":"0105c792b1c84557af09f05d8056199c","type":"GENE","name":"CLCA1","canonical_id":"hgnc:HGNC:2015","description":"chloride channel accessory 1","metadata":{"aliases":["CaCC","CLCRG1"]}},{"id":"fd4dca03faf04d2c9c5ed07753a30a32","type":"GENE","name":"CLCA2","canonical_id":"hgnc:HGNC:2016","description":"chloride channel accessory 2","metadata":{"aliases":["CLCRG2"]}},{"id":"84a349f5906649ec867f9033080867d3","type":"GENE","name":"CLCA3P","canonical_id":"hgnc:HGNC:2017","description":"chloride channel accessory 3, pseudogene","metadata":{"aliases":["CLCA3"]}},{"id":"43de245ca121443780716f538918e241","type":"GENE","name":"CLCA4","canonical_id":"hgnc:HGNC:2018","description":"chloride channel accessory 4","metadata":{"aliases":["CaCC2"]}},{"id":"2e41bf97858147729d1b3bd5444431be","type":"GENE","name":"CLCA4-AS1","canonical_id":"hgnc:HGNC:54055","description":"CLCA4 antisense RNA 1","metadata":null},{"id":"c1bd52e71cf14585a3a9be5715cec364","type":"GENE","name":"CLCC1","canonical_id":"hgnc:HGNC:29675","description":"chloride channel CLIC like 1","metadata":{"aliases":["MCLC"]}},{"id":"9640d94387cb4f09b7d19e4ecf00ab41","type":"GENE","name":"CLCF1","canonical_id":"hgnc:HGNC:17412","description":"cardiotrophin like cytokine factor 1","metadata":{"aliases":["NNT1","BSF3","CLC","NR6","CISS2","BSF-3","NNT-1"]}},{"id":"46cd039672ae46be9b3d18751d00cc2a","type":"GENE","name":"CLCN1","canonical_id":"hgnc:HGNC:2019","description":"chloride voltage-gated channel 1","metadata":{"aliases":["CLC1","ClC-1"]}},{"id":"82666d645a6347c3b9d90d5b22865e33","type":"GENE","name":"CLCN2","canonical_id":"hgnc:HGNC:2020","description":"chloride voltage-gated channel 2","metadata":{"aliases":["CLC2","EJM6","ClC-2"]}},{"id":"f9a567a606ad4fce91ecef957a2dbf80","type":"PROTEIN","name":"CLCN2","canonical_id":"uniprot:P51788","description":null,"metadata":null},{"id":"47764a0d18fd4253a667fe7f98976aec","type":"GENE","name":"CLCN3","canonical_id":"hgnc:HGNC:2021","description":"Cl-/H+ antiporter 3","metadata":{"aliases":["CLC3","ClC-3"]}},{"id":"2d5072ad936e4683b53cd3c61a8d68e8","type":"GENE","name":"CLCN3P1","canonical_id":"hgnc:HGNC:49775","description":"chloride voltage-gated channel 3 pseudogene 1","metadata":null},{"id":"b5ed351591984e6987ad409841279b6c","type":"GENE","name":"CLCN4","canonical_id":"hgnc:HGNC:2022","description":"Cl-/H+ antiporter 4","metadata":{"aliases":["CLC4","ClC-4"]}},{"id":"03368518a9c642bca72f08e238e80e68","type":"GENE","name":"CLCN5","canonical_id":"hgnc:HGNC:2023","description":null,"metadata":null},{"id":"9ae89ce47c414f84b33a35802f14e7e2","type":"GENE","name":"CLCN6","canonical_id":"hgnc:HGNC:2024","description":"Cl-/H+ antiporter 6","metadata":{"aliases":["CLC-6","KIAA0046","ClC-6"]}},{"id":"6e09c7ca52e346d5bd46c77b7329284c","type":"GENE","name":"CLCN7","canonical_id":"hgnc:HGNC:2025","description":"Cl-/H+ antiporter 7","metadata":{"aliases":["CLC-7","OPTA2","CLC7","ClC-7","PPP1R63"]}},{"id":"3fbfecca27d3475d9db5427909719b0e","type":"GENE","name":"CLCN7-AS1","canonical_id":"hgnc:HGNC:58480","description":"CLCN7 antisense RNA 1","metadata":null},{"id":"a2bba86a80284bd282d9cc0eaf017c70","type":"GENE","name":"CLCNKA","canonical_id":"hgnc:HGNC:2026","description":null,"metadata":null},{"id":"eefcbed2c5124231822cfb4a57735eea","type":"GENE","name":"CLCNKB","canonical_id":"hgnc:HGNC:2027","description":"chloride voltage-gated channel Kb","metadata":{"aliases":["hClC-Kb","CLCKB","ClC-K2","ClC-Kb"]}},{"id":"3bda2a45cb284406ab49df50b6e9d225","type":"GENE","name":"CLCP1","canonical_id":"hgnc:HGNC:19257","description":"Charcot-Leyden crystal protein pseudogene 1","metadata":null},{"id":"cee5e9e09ae041e594364e1daa518578","type":"GENE","name":"CLCP2","canonical_id":"hgnc:HGNC:42536","description":"Charcot-Leyden crystal protein pseudogene 2","metadata":{"aliases":["LGALS10P1"]}},{"id":"e8bfd22e13c94d2eb10d95c88e0b0d40","type":"GENE","name":"CLDN1","canonical_id":"hgnc:HGNC:2032","description":"claudin 1","metadata":{"aliases":["SEMP1","ILVASC"]}},{"id":"2a744c6abb924ee2bca3072ac9c9ddf2","type":"GENE","name":"CLDN10","canonical_id":"hgnc:HGNC:2033","description":"claudin 10","metadata":{"aliases":["OSP-L","CPETRL3"]}},{"id":"1d1c99927c0a4360924c8a4a2d2ae63b","type":"GENE","name":"CLDN10-AS1","canonical_id":"hgnc:HGNC:39907","description":"CLDN10 antisense RNA 1","metadata":null},{"id":"fe238ba0008c445e9549830cd700f92c","type":"GENE","name":"CLDN11","canonical_id":"hgnc:HGNC:8514","description":"claudin 11","metadata":{"aliases":["OSP","OTM"]}},{"id":"d9614bc4972c4fbdacdc169b6739acd3","type":"GENE","name":"CLDN12","canonical_id":"hgnc:HGNC:2034","description":"claudin 12","metadata":null},{"id":"78914d3b702a4262b7b36432824cc4bb","type":"GENE","name":"CLDN14","canonical_id":"hgnc:HGNC:2035","description":"claudin 14","metadata":{"aliases":["DFNB29"]}},{"id":"c8df67dc83e345e1aaad595ccbdc9dd8","type":"GENE","name":"CLDN15","canonical_id":"hgnc:HGNC:2036","description":"claudin 15","metadata":null},{"id":"192a88651bd4474bbf68e8399e835531","type":"GENE","name":"CLDN16","canonical_id":"hgnc:HGNC:2037","description":"claudin 16","metadata":{"aliases":["PCLN1","HOMG3"]}},{"id":"a06020167a8b441ca70ff369baa1fdc6","type":"GENE","name":"CLDN17","canonical_id":"hgnc:HGNC:2038","description":"claudin 17","metadata":{"aliases":["MGC126552","MGC126554"]}},{"id":"a7b293c7765541f78c1259fb68a58476","type":"GENE","name":"CLDN18","canonical_id":"hgnc:HGNC:2039","description":"claudin 18","metadata":{"aliases":["SFTPJ"]}},{"id":"fc230c0d0fa848edacf05d84638442aa","type":"PROTEIN","name":"CLDN18","canonical_id":"uniprot:P56856","description":null,"metadata":null},{"id":"dea0871048f248118298846a10898718","type":"GENE","name":"CLDN19","canonical_id":"hgnc:HGNC:2040","description":"claudin 19","metadata":null},{"id":"7f0de307c07b4fc6b38295e3a8eb7210","type":"GENE","name":"CLDN2","canonical_id":"hgnc:HGNC:2041","description":null,"metadata":null},{"id":"861c232399624f8eac8a587456c0b469","type":"GENE","name":"CLDN20","canonical_id":"hgnc:HGNC:2042","description":"claudin 20","metadata":null},{"id":"b734302fc5c443f4a153f02f1e01db40","type":"GENE","name":"CLDN22","canonical_id":"hgnc:HGNC:2044","description":"claudin 22","metadata":{"aliases":["CLDN21"]}},{"id":"74e6f13cd1c548b9be20c3f375233545","type":"GENE","name":"CLDN23","canonical_id":"hgnc:HGNC:17591","description":"claudin 23","metadata":{"aliases":["CLDNL"]}},{"id":"6b39fbad00b443c9b3b4873da3fd1d1e","type":"GENE","name":"CLDN24","canonical_id":"hgnc:HGNC:37200","description":"claudin 24","metadata":{"aliases":["CLDN21"]}},{"id":"409ffaf63a7a433aaaaf831ec92e97a4","type":"GENE","name":"CLDN25","canonical_id":"hgnc:HGNC:37218","description":"claudin 25","metadata":null},{"id":"d9c695e3567448cd977718c56b2907f9","type":"GENE","name":"CLDN3","canonical_id":"hgnc:HGNC:2045","description":null,"metadata":null},{"id":"b55fa8a176a14acea41d7dd30391aedf","type":"GENE","name":"CLDN34","canonical_id":"hgnc:HGNC:51259","description":"claudin 34","metadata":null},{"id":"b0d7964218754bd1b43bca466ee1481c","type":"GENE","name":"CLDN4","canonical_id":"hgnc:HGNC:2046","description":"claudin 4","metadata":{"aliases":["CPE-R","WBSCR8","hCPE-R","CPETR","CPETR1"]}},{"id":"251ae67dd35042d2959aecaa4b7bb96f","type":"GENE","name":"CLDN5","canonical_id":"hgnc:HGNC:2047","description":"claudin 5","metadata":{"aliases":["CPETRL1","BEC1","AWAL","TMVCF"]}},{"id":"f66b36c3cd3e4c34a1c3da2df0d668cb","type":"GENE","name":"CLDN6","canonical_id":"hgnc:HGNC:2048","description":"claudin 6","metadata":null},{"id":"8c5ee00e7e2940efbf85e09f565b1987","type":"GENE","name":"CLDN7","canonical_id":"hgnc:HGNC:2049","description":null,"metadata":null},{"id":"af72772ca6e44e54bd3cf5347907d476","type":"GENE","name":"CLDN7P1","canonical_id":"hgnc:HGNC:54935","description":"CLDN7 pseudogene 1","metadata":null},{"id":"1e44f542e9e047c286aaf427fc8e4ad8","type":"GENE","name":"CLDN8","canonical_id":"hgnc:HGNC:2050","description":"claudin 8","metadata":null},{"id":"5c21b58b39eb489f8eaaf7f822caef50","type":"GENE","name":"CLDN9","canonical_id":"hgnc:HGNC:2051","description":"claudin 9","metadata":null},{"id":"abe84d73ad5c46888ed82fe0480fdf2d","type":"GENE","name":"CLDND1","canonical_id":"hgnc:HGNC:1322","description":"claudin domain containing 1","metadata":{"aliases":["Z38","C3orf4"]}},{"id":"237ea0347a484a05a9b9fbfdaaf7c3a0","type":"GENE","name":"CLDND1-AS1","canonical_id":"hgnc:HGNC:58245","description":"CLDND1 antisense RNA 1","metadata":null},{"id":"8664169eeeaa4ec1a8a8793e3a535e43","type":"GENE","name":"CLDND2","canonical_id":"hgnc:HGNC:28511","description":"claudin domain containing 2","metadata":{"aliases":["MGC33839"]}},{"id":"af34a4eae5044ade8e233ac9115c41fc","type":"GENE","name":"CLEC10A","canonical_id":"hgnc:HGNC:16916","description":"C-type lectin domain containing 10A","metadata":{"aliases":["HML2","HML","CD301","CLECSF13","CLECSF14"]}},{"id":"f00afcc8cec6483cb89259015f59f4b1","type":"GENE","name":"CLEC11A","canonical_id":"hgnc:HGNC:10576","description":"C-type lectin domain containing 11A","metadata":{"aliases":["P47","LSLCL","CLECSF3","SCGF"]}},{"id":"7cda8ce0dff049d09bca8cb719d9cd42","type":"GENE","name":"CLEC12A","canonical_id":"hgnc:HGNC:31713","description":"C-type lectin domain family 12 member A","metadata":{"aliases":["CLL-1","MICL","CD371","DCAL-2"]}},{"id":"c3aa61d6fe9541c6b441e0c107c0a7c1","type":"GENE","name":"CLEC12A-AS1","canonical_id":"hgnc:HGNC:53407","description":"CLEC12A antisense RNA 1","metadata":null},{"id":"351e18dcf7e24d11ba84fe515058c9a7","type":"GENE","name":"CLEC12B","canonical_id":"hgnc:HGNC:31966","description":"C-type lectin domain family 12 member B","metadata":null},{"id":"0de2211b295b41e08a9cea01d8c7bed1","type":"GENE","name":"CLEC14A","canonical_id":"hgnc:HGNC:19832","description":"C-type lectin domain containing 14A","metadata":{"aliases":["C14orf27"]}},{"id":"d32a136cb08f412692d1f9f296a133de","type":"GENE","name":"CLEC16A","canonical_id":"hgnc:HGNC:29013","description":"C-type lectin domain containing 16A","metadata":{"aliases":["Gop-1","KIAA0350"]}},{"id":"2d6fb90528d449e98ec37f3e57d2135e","type":"GENE","name":"CLEC17A","canonical_id":"hgnc:HGNC:34520","description":"C-type lectin domain containing 17A","metadata":{"aliases":["FLJ45910"]}},{"id":"8a1737c6a79d478890137db1a5004941","type":"GENE","name":"CLEC18A","canonical_id":"hgnc:HGNC:30388","description":"C-type lectin domain family 18 member A","metadata":{"aliases":["MRCL"]}},{"id":"1b6d063bd84042f99618e8627e2cad33","type":"GENE","name":"CLEC18B","canonical_id":"hgnc:HGNC:33849","description":"C-type lectin domain family 18 member B","metadata":{"aliases":["MRCL2"]}},{"id":"7a461382865242d1b804550b76d45431","type":"GENE","name":"CLEC18C","canonical_id":"hgnc:HGNC:28538","description":"C-type lectin domain family 18 member C","metadata":{"aliases":["MGC34761","MRCL3"]}},{"id":"801d7b2c2f9d4b57b316b38cfce9c9e9","type":"GENE","name":"CLEC19A","canonical_id":"hgnc:HGNC:34522","description":"C-type lectin domain containing 19A","metadata":null},{"id":"baceb7af2d31481fb8136e93fad9b886","type":"GENE","name":"CLEC1A","canonical_id":"hgnc:HGNC:24355","description":"C-type lectin domain family 1 member A","metadata":{"aliases":["CLEC1","CLEC-1","MGC34328"]}},{"id":"ffe88625634c428cb1fa008a88b16352","type":"GENE","name":"CLEC1B","canonical_id":"hgnc:HGNC:24356","description":"C-type lectin domain family 1 member B","metadata":{"aliases":["CLEC2","CLEC-2"]}},{"id":"4d00e97fc4b747569ea55534fd0cda58","type":"GENE","name":"CLEC20A","canonical_id":"hgnc:HGNC:34521","description":"C-type lectin domain containing 20A","metadata":{"aliases":["FLJ44005","RP4-593C16.2","NCRNA00083","LINC00083"]}},{"id":"11bef4e47b3e4889b75d106bb8694ab6","type":"GENE","name":"CLEC2A","canonical_id":"hgnc:HGNC:24191","description":"C-type lectin domain family 2 member A","metadata":{"aliases":["UNQ5792","INPE5792","KACL","PILAR"]}},{"id":"32de6b4a85014a35a9b527b83feec8fc","type":"GENE","name":"CLEC2B","canonical_id":"hgnc:HGNC:2053","description":"C-type lectin domain family 2 member B","metadata":{"aliases":["AICL","HP10085","CLECSF2"]}},{"id":"8caf18ce2ce345839fd2152b48100531","type":"GENE","name":"CLEC2D","canonical_id":"hgnc:HGNC:14351","description":"C-type lectin domain family 2 member D","metadata":{"aliases":["LLT1","CLAX","OCIL"]}},{"id":"bdcfdfad2ab04e4987c27ceb56f2647b","type":"GENE","name":"CLEC2L","canonical_id":"hgnc:HGNC:21969","description":"C-type lectin domain family 2 member L","metadata":{"aliases":["FLJ32986"]}},{"id":"e84452c0d2204bc8a63bdcf0abc19bb6","type":"GENE","name":"CLEC3A","canonical_id":"hgnc:HGNC:2052","description":"C-type lectin domain family 3 member A","metadata":{"aliases":["CLECSF1"]}},{"id":"a7c37f78c7804b1b83f342ee222001c8","type":"GENE","name":"CLEC3B","canonical_id":"hgnc:HGNC:11891","description":"C-type lectin domain family 3 member B","metadata":{"aliases":["TN","TNA"]}},{"id":"d9ad853c40414dda85ddd69f08d7a178","type":"GENE","name":"CLEC4A","canonical_id":"hgnc:HGNC:13257","description":"C-type lectin domain family 4 member A","metadata":{"aliases":["DCIR","DDB27","CD367","hDCIR","CLECSF6"]}},{"id":"aaf6fafe36064a7f838e36d5bd8fc6df","type":"GENE","name":"CLEC4C","canonical_id":"hgnc:HGNC:13258","description":null,"metadata":null},{"id":"2ad6791c484f47f7a31202a834bb7b84","type":"GENE","name":"CLEC4D","canonical_id":"hgnc:HGNC:14554","description":"C-type lectin domain family 4 member D","metadata":{"aliases":["Mpcl","CD368","MCL","Dectin-3","CLECSF8"]}},{"id":"40fb2eab3c0040588104e3e56d923f6e","type":"GENE","name":"CLEC4E","canonical_id":"hgnc:HGNC:14555","description":"C-type lectin domain family 4 member E","metadata":{"aliases":["MINCLE","CLECSF9"]}},{"id":"2137a11bb08b44f3a6118e56e827d4a0","type":"GENE","name":"CLEC4F","canonical_id":"hgnc:HGNC:25357","description":"C-type lectin domain family 4 member F","metadata":{"aliases":["FLJ39110","KCLR","CLECSF13"]}},{"id":"a3eae3ff32d448b6ae0ccf3e8094f366","type":"GENE","name":"CLEC4G","canonical_id":"hgnc:HGNC:24591","description":null,"metadata":null},{"id":"dc7ff5834ee14292a55744d945dfc688","type":"GENE","name":"CLEC4GP1","canonical_id":"hgnc:HGNC:33502","description":"C-type lectin domain family 4 member G pseudogene 1","metadata":null},{"id":"529a0a5ac6c64fb491d40cb90aeb7bcc","type":"GENE","name":"CLEC4M","canonical_id":"hgnc:HGNC:13523","description":"C-type lectin domain family 4 member M","metadata":{"aliases":["L-SIGN","CD209L1","HP10347","DC-SIGNR","LSIGN","DCSIGNR","DC-SIGN2","CD209L","CD299"]}},{"id":"91ce7ef39178410ab6d9a361757ee013","type":"GENE","name":"CLEC4OP","canonical_id":"hgnc:HGNC:52651","description":"C-type lectin domain family 4 member O, pseudogene","metadata":{"aliases":["LINC01835","CLEC4O"]}},{"id":"cab439ef81f4499e9f70b880de527ed5","type":"GENE","name":"CLEC5A","canonical_id":"hgnc:HGNC:2054","description":"C-type lectin domain containing 5A","metadata":{"aliases":["MDL-1","CLECSF5"]}},{"id":"8ed8ca7a91dc486fbcebde0f6dac8ff4","type":"GENE","name":"CLEC6A","canonical_id":"hgnc:HGNC:14556","description":"C-type lectin domain containing 6A","metadata":{"aliases":["dectin-2","hDECTIN-2","CLECSF10"]}},{"id":"3d0da7b042894d0498b79a6b18a74c65","type":"GENE","name":"CLEC7A","canonical_id":"hgnc:HGNC:14558","description":"C-type lectin domain containing 7A","metadata":{"aliases":["DECTIN-1","hDectin-1","CD369","SCARE2","CLECSF12"]}},{"id":"37a2cb5bb0fc41d5a1e097bc77dcd8dd","type":"GENE","name":"CLEC9A","canonical_id":"hgnc:HGNC:26705","description":"C-type lectin domain containing 9A","metadata":{"aliases":["DNGR1","UNQ9341","HEEE9341","CD370","DNGR-1"]}},{"id":"8f113baaa10b41e6888dfc8174a97be8","type":"GENE","name":"CLECL1","canonical_id":"hgnc:HGNC:24462","description":"C-type lectin like 1","metadata":{"aliases":["DCAL1","CLECL1P"]}},{"id":"2413fa869c0c424e8f465d3b3e13c68e","type":"GENE","name":"CLGN","canonical_id":"hgnc:HGNC:2060","description":"calmegin","metadata":null},{"id":"4171c11249cf445c9b6e63a1be29980a","type":"GENE","name":"CLHC1","canonical_id":"hgnc:HGNC:26453","description":"clathrin heavy chain linker domain containing 1","metadata":{"aliases":["FLJ31438","C2orf63"]}},{"id":"7ed53b71b5d0454091bb32460d523b91","type":"GO_TERM","name":"CLIC/GEEC-mediated endocytosis","canonical_id":"go:GO:7770084","description":"\"An endocytosis process in which clathrin-uncoated carriers (CLICs) internalize plasma membrane cargo and deliver it to GPI-enriched early endosomal compartments (GEECs).\" [PMID:19036340, PMID:22177561]","metadata":null},{"id":"1b6c305f9bb44df1b7be4cafd82986db","type":"GENE","name":"CLIC1","canonical_id":"hgnc:HGNC:2062","description":"CLIC family member 1","metadata":{"aliases":["NCC27","p64CLCP","G6","CLCNL1"]}},{"id":"8c3e09b3171b44ee9bb333037cacbb02","type":"GENE","name":"CLIC1P1","canonical_id":"hgnc:HGNC:32691","description":"CLIC1 pseudogene 1","metadata":null},{"id":"a9b2edf454f54e948e1d68fa8da95a3c","type":"GENE","name":"CLIC1P2","canonical_id":"hgnc:HGNC:58671","description":"CLIC1 pseudogene 2","metadata":null},{"id":"57fcd08e7e84468097ddae6502f011c7","type":"GENE","name":"CLIC1P3","canonical_id":"hgnc:HGNC:58672","description":"CLIC1 pseudogene 3","metadata":null},{"id":"00bbe67c43134898bae797e329911c76","type":"GENE","name":"CLIC2","canonical_id":"hgnc:HGNC:2063","description":"CLIC family member 2","metadata":{"aliases":["XAP121","CLCNL2"]}},{"id":"c17d6f6fdd04402e90c379ee3a582145","type":"GENE","name":"CLIC3","canonical_id":"hgnc:HGNC:2064","description":"CLIC family member 3","metadata":null},{"id":"e5dccb84d1ac414eb623fb288b34cf35","type":"GENE","name":"CLIC4","canonical_id":"hgnc:HGNC:13518","description":"CLIC family member 4","metadata":{"aliases":["DKFZP566G223","CLIC4L","P64H1","H1","huH1","p64H1"]}},{"id":"5cbfdbe4a72949c7b411712fb140686d","type":"GENE","name":"CLIC4P1","canonical_id":"hgnc:HGNC:49797","description":"CLIC4 pseudogene 1","metadata":null},{"id":"58ec739f00084b659b3a8b667950558c","type":"GENE","name":"CLIC4P2","canonical_id":"hgnc:HGNC:49798","description":"CLIC4 pseudogene 2","metadata":null},{"id":"5b4c054a23944fb1bf83f45bd92a8fba","type":"GENE","name":"CLIC4P3","canonical_id":"hgnc:HGNC:49799","description":"CLIC4 pseudogene 3","metadata":null},{"id":"82c678b28da9402ead39a4cba5663c09","type":"GENE","name":"CLIC5","canonical_id":"hgnc:HGNC:13517","description":"CLIC family member 5","metadata":{"aliases":["DFNB102"]}},{"id":"ae5c2578ccc94bbb869a4720bb15cc91","type":"GENE","name":"CLIC5-AS1","canonical_id":"hgnc:HGNC:59418","description":"CLIC5 antisense RNA 1","metadata":null},{"id":"4120bc6b925f40808e42de1cbdeb5392","type":"GENE","name":"CLIC6","canonical_id":"hgnc:HGNC:2065","description":"CLIC family member 6","metadata":{"aliases":["CLIC5","CLIC1L"]}},{"id":"8d243693d439408f80bf184f048133c0","type":"GENE","name":"CLINT1","canonical_id":"hgnc:HGNC:23186","description":"clathrin interactor 1","metadata":{"aliases":["ENTH","KIAA0171","EPNR","CLINT"]}},{"id":"f62925d88eae44228699b92baa2cebb4","type":"GENE","name":"CLINT1-DT","canonical_id":"hgnc:HGNC:59293","description":"CLINT1 divergent transcript","metadata":null},{"id":"dac4b3570ee74356abca2ec82117eec1","type":"GENE","name":"CLIP1","canonical_id":"hgnc:HGNC:10461","description":"CAP-Gly domain containing linker protein 1","metadata":{"aliases":["CYLN1","CLIP170","CLIP","CLIP-170","RSN"]}},{"id":"bd69c54026ca434d9e9bb886f964b184","type":"GENE","name":"CLIP1-AS1","canonical_id":"hgnc:HGNC:48586","description":"CLIP1 antisense RNA 1","metadata":null},{"id":"a9ed0bae209c4434a4960ecf8e6042a5","type":"GENE","name":"CLIP2","canonical_id":"hgnc:HGNC:2586","description":"CAP-Gly domain containing linker protein 2","metadata":{"aliases":["CLIP-115","KIAA0291","WSCR4","CLIP","WSCR3","WBSCR4","CYLN2","WBSCR3"]}},{"id":"f7d5b0b52ad74189a2b4bc2509665d7f","type":"GENE","name":"CLIP3","canonical_id":"hgnc:HGNC:24314","description":"CAP-Gly domain containing linker protein 3","metadata":{"aliases":["CLIPR-59","RSNL1"]}},{"id":"87872a0552094623b0d75023784197d7","type":"GENE","name":"CLIP4","canonical_id":"hgnc:HGNC:26108","description":"CAP-Gly domain containing linker protein family member 4","metadata":{"aliases":["FLJ21069","RSNL2"]}},{"id":"3ac56f543721428c9e731e0f9c0c58f6","type":"GENE","name":"CLK1","canonical_id":"hgnc:HGNC:2068","description":"CDC like kinase 1","metadata":null},{"id":"f8a9dfc940f844c59a6578fd357b69ad","type":"GENE","name":"CLK2","canonical_id":"hgnc:HGNC:2069","description":"CDC like kinase 2","metadata":null},{"id":"881af66c3de741dabd845829488b0cb8","type":"GENE","name":"CLK2P1","canonical_id":"hgnc:HGNC:2070","description":"CDC like kinase 2, pseudogene 1","metadata":{"aliases":["CLK2P"]}},{"id":"bd58989d17884b5aaabe5f6113c15ae3","type":"GENE","name":"CLK3","canonical_id":"hgnc:HGNC:2071","description":null,"metadata":null},{"id":"7a0df3efc0b14d81821a7142f149473c","type":"GENE","name":"CLK3-AS1","canonical_id":"hgnc:HGNC:58198","description":"CLK3 antisense RNA 1","metadata":null},{"id":"090f361dc59b4833b0187162c2ca317d","type":"GENE","name":"CLK3P1","canonical_id":"hgnc:HGNC:49785","description":"CDC like kinase 3 pseudogene 1","metadata":null},{"id":"2731cc6c9bd5411b8ed58bc41e0cc8f8","type":"GENE","name":"CLK3P2","canonical_id":"hgnc:HGNC:49786","description":"CDC like kinase 3 pseudogene 2","metadata":null},{"id":"c4fb23ec99c442e997fbdae41e9c7c93","type":"GENE","name":"CLK4","canonical_id":"hgnc:HGNC:13659","description":"CDC like kinase 4","metadata":null},{"id":"09d50688aea94209ac623a67f6a0c8c4","type":"TRIAL","name":"CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)","canonical_id":"clinicaltrials.gov:NCT01998880","description":"Lymphocytic Leukemia, Chronic","metadata":null},{"id":"4dc109817ed34bb9a0e290d4556b7986","type":"GENE","name":"CLLU1","canonical_id":"hgnc:HGNC:29841","description":"chronic lymphocytic leukemia up-regulated 1","metadata":null},{"id":"92c3192376694739a241e3378b2f6162","type":"GENE","name":"CLLU1-AS1","canonical_id":"hgnc:HGNC:24070","description":"CLLU1 antisense RNA 1","metadata":{"aliases":["CLLU1OS"]}},{"id":"0964dea23daa4ccbafc6f6ed280d6c12","type":"GENE","name":"CLMAT3","canonical_id":"hgnc:HGNC:52287","description":"colorectal liver metastasis associated transcript 3","metadata":{"aliases":["SPARC-AS1"]}},{"id":"a283b32a7a824b6384326546a7939e2e","type":"GENE","name":"CLMB","canonical_id":"hgnc:HGNC:23362","description":"calcimembrin","metadata":{"aliases":["MGC17624","MICT1","C16orf74"]}},{"id":"2dd9a16b3a114fb5bf7d2b18f9edd78a","type":"GENE","name":"CLMN","canonical_id":"hgnc:HGNC:19972","description":"calmin","metadata":{"aliases":["FLJ12383","KIAA1188","KIAA0500"]}},{"id":"4dd4ed1f30ec4f53b129aca8866cf53a","type":"GENE","name":"CLMP","canonical_id":"hgnc:HGNC:24039","description":"CXADR like cell adhesion molecule","metadata":{"aliases":["ASAM","FLJ22415","ACAM"]}},{"id":"4e2fee4916a547b5b465327b383cccb9","type":"GENE","name":"CLN3","canonical_id":"hgnc:HGNC:2074","description":"CLN3 lysosomal/endosomal transmembrane protein, battenin","metadata":{"aliases":["BTN1","JNCL","SLC29B1","BTS"]}},{"id":"3cf59f6ce5e340f194e75c93dd51268b","type":"GENE","name":"CLN5","canonical_id":"hgnc:HGNC:2076","description":"CLN5 lysosomal BMP synthase","metadata":null},{"id":"5239bb4a91e24e1cad1f3c1c6f8edcb3","type":"GENE","name":"CLN6","canonical_id":"hgnc:HGNC:2077","description":"CLN6 transmembrane ER protein","metadata":{"aliases":["FLJ20561","HsT18960","nclf"]}},{"id":"2f008fde433a44ca82bb1b9a56edc612","type":"GENE","name":"CLN8","canonical_id":"hgnc:HGNC:2079","description":"CLN8 transmembrane ER and ERGIC protein","metadata":{"aliases":["FLJ39417","TLCD6","EPMR","C8orf61"]}},{"id":"244321164b4a479d81ec5e55c259225c","type":"GENE","name":"CLN8-AS1","canonical_id":"hgnc:HGNC:55523","description":"CLN8 antisense RNA 1","metadata":null},{"id":"edafec34d3ba4e79bcc2b201c279d2e1","type":"GENE","name":"CLNK","canonical_id":"hgnc:HGNC:17438","description":"cytokine dependent hematopoietic cell linker","metadata":{"aliases":["MIST"]}},{"id":"901a883271fa46ba9dc5fae498df06da","type":"GENE","name":"CLNK-AS1","canonical_id":"hgnc:HGNC:58732","description":"CLNK antisense RNA 1","metadata":null},{"id":"7405899d22f34b90b7270aa358e2e20e","type":"GENE","name":"CLNK-AS2","canonical_id":"hgnc:HGNC:58733","description":"CLNK antisense RNA 2","metadata":null},{"id":"5ed6e87033814ccdad87ae595156922e","type":"GENE","name":"CLNK-AS3","canonical_id":"hgnc:HGNC:58734","description":"CLNK antisense RNA 3","metadata":null},{"id":"978c24f574c0407ca028d69e146d7c96","type":"GENE","name":"CLNK-DT","canonical_id":"hgnc:HGNC:58735","description":"CLNK divergent transcript","metadata":null},{"id":"4e2dd299aef748278f5e804452109eed","type":"GENE","name":"CLNS1A","canonical_id":"hgnc:HGNC:2080","description":"chloride nucleotide-sensitive channel 1A","metadata":{"aliases":["ICln","CLCI"]}},{"id":"27986570ec9e45ff905b642f82676c02","type":"GENE","name":"CLNS1AP1","canonical_id":"hgnc:HGNC:2081","description":"chloride nucleotide-sensitive channel 1A pseudogene 1","metadata":{"aliases":["ICln","CLNS1B"]}},{"id":"30ccd67cd1a544a5913b83bade5db696","type":"GENE","name":"CLOCK","canonical_id":"hgnc:HGNC:2082","description":null,"metadata":null},{"id":"aa0c4469f3b148fa805e590cf052d802","type":"GENE","name":"CLOCK-AS1","canonical_id":"hgnc:HGNC:58790","description":"CLOCK antisense RNA 1","metadata":null},{"id":"84203be7f16c4cb08cb6acdf8108756f","type":"GO_TERM","name":"CLOCK-BMAL transcription complex","canonical_id":"go:GO:1990513","description":"\"Transcription factor complex which interacts with E-box regulatory elements in target genes, including Period (Per1, Per2, Per3) and Cryptochrome (Cry1, Cry2), to activate their transcription during the daytime. The CRY-PER complexes inhibit CLOCK-BMAL1-driven transcription in a negative feedback loop to generate circadian rhythms.\" [GOC:bhm, PMID:23229515]","metadata":null},{"id":"6cee86a032414e969815947fae96af18","type":"GENE","name":"CLP1","canonical_id":"hgnc:HGNC:16999","description":"cleavage factor polyribonucleotide kinase subunit 1","metadata":{"aliases":["HEAB","hClp1"]}},{"id":"30bae638cf844e58ac8592c1e46a77bf","type":"GENE","name":"CLPB","canonical_id":"hgnc:HGNC:30664","description":"ClpB family mitochondrial disaggregase","metadata":{"aliases":["SKD3","FLJ13152","ANKCLP"]}},{"id":"c7b8fc378c224308ae28cfde11d57b7d","type":"GENE","name":"CLPP","canonical_id":"hgnc:HGNC:2084","description":"caseinolytic mitochondrial matrix peptidase proteolytic subunit","metadata":null},{"id":"96c9653a280c491c909e346c456d0e8b","type":"GENE","name":"CLPS","canonical_id":"hgnc:HGNC:2085","description":"colipase","metadata":null},{"id":"3d066149032646fb997b6f3637576f25","type":"GENE","name":"CLPSL1","canonical_id":"hgnc:HGNC:21251","description":"colipase like 1","metadata":{"aliases":["dJ510O8.6","C6orf127"]}},{"id":"3a3584e640e2427ab7eb6426e687dbd0","type":"GENE","name":"CLPSL2","canonical_id":"hgnc:HGNC:21250","description":"colipase like 2","metadata":{"aliases":["dJ510O8.5","UNQ3045","C6orf126"]}},{"id":"37ad19c613bd411994723a11de6b1a4e","type":"GENE","name":"CLPSL2-AS1","canonical_id":"hgnc:HGNC:59387","description":"CLPSL2 antisense RNA 1","metadata":null},{"id":"63ac2e35b8db4f29832352b3cf43d7a0","type":"GENE","name":"CLPTM1","canonical_id":"hgnc:HGNC:2087","description":"CLPTM1 regulator of GABA type A receptor forward trafficking","metadata":null},{"id":"8f316bb64f1d4256bdebbfdc1a0d5a5c","type":"GENE","name":"CLPTM1L","canonical_id":"hgnc:HGNC:24308","description":"CLPTM1 like","metadata":{"aliases":["FLJ14400","CRR9"]}},{"id":"0647167abc854c72a8bc2ab3fa7660f3","type":"GENE","name":"CLPTM1L-DT","canonical_id":"hgnc:HGNC:58991","description":"CLPTM1L divergent transcript","metadata":null},{"id":"a5e3ac53a9434f289f8a69ab8d140370","type":"GENE","name":"CLPTM1LP1","canonical_id":"hgnc:HGNC:49023","description":"CLPTM1L pseudogene 1","metadata":null},{"id":"8698971191fa44b7ad900f956135aacb","type":"GENE","name":"CLPX","canonical_id":"hgnc:HGNC:2088","description":"caseinolytic mitochondrial matrix peptidase chaperone subunit X","metadata":null},{"id":"9761b383b615451586fefd8efbade36e","type":"GO_TERM","name":"CLRC complex","canonical_id":"go:GO:0043494","description":"\"An cullin-dependent E3 ubiquitin ligase/histone H3-K9 methyltransferase complex essential for heterochromatin assembly by RNAi.\" [GOC:vw, PMID:16127433, PMID:20211136]","metadata":null},{"id":"a9c57fa3e5cb418690b9601d170bf496","type":"GO_TERM","name":"CLRC complex localization to heterochromatin","canonical_id":"go:GO:0044382","description":"\"The process by which a CLRC complex is transported to, or maintained in, heterochromatin. CLRC complex is an active cullin-dependent E3 ubiquitin ligase complex essential for heterochromatin assembly by RNAi and histone H3K9 methylation.\" [GOC:jl]","metadata":null},{"id":"211469049baf47cc98193db5fb8b29b0","type":"GENE","name":"CLRN1","canonical_id":"hgnc:HGNC:12605","description":"clarin 1","metadata":{"aliases":["USH3","USH3A","RP61"]}},{"id":"92e5a087f65f4b3aae2452bd85c8fb59","type":"GENE","name":"CLRN2","canonical_id":"hgnc:HGNC:33939","description":"clarin 2","metadata":{"aliases":["DFNB117"]}},{"id":"92c7917c9e91424191b9ab1aabe6d507","type":"GENE","name":"CLRN3","canonical_id":"hgnc:HGNC:20795","description":"clarin 3","metadata":{"aliases":["MGC32871","USH3AL1","TMEM12"]}},{"id":"0c38c545b00a4b0d94452334b1e27717","type":"GENE","name":"CLSPN","canonical_id":"hgnc:HGNC:19715","description":"claspin","metadata":null},{"id":"bfa7fcbe67c6461f827dbabfd6cbce2e","type":"GENE","name":"CLSPN-AS1","canonical_id":"hgnc:HGNC:40896","description":"CLSPN antisense RNA 1","metadata":null},{"id":"721a57d4daf244e88f22edcbeb8b818a","type":"GENE","name":"CLSPN-DT","canonical_id":"hgnc:HGNC:58226","description":"CLSPN divergent transcript","metadata":null},{"id":"7723964983ec46578cbb79086738ced7","type":"GENE","name":"CLSTN1","canonical_id":"hgnc:HGNC:17447","description":"calsyntenin 1","metadata":{"aliases":["CSTN1","KIAA0911","CDHR12"]}},{"id":"f8ea559989e34275aafc45d43dc628bc","type":"GENE","name":"CLSTN2","canonical_id":"hgnc:HGNC:17448","description":"calsyntenin 2","metadata":{"aliases":["CSTN2","CS2","FLJ39113","CDHR13"]}},{"id":"e6ad849f291a4396896feec8fe07f2f0","type":"GENE","name":"CLSTN2-AS1","canonical_id":"hgnc:HGNC:49095","description":"CLSTN2 antisense RNA 1","metadata":null},{"id":"e3fb9244021e4bf5b76643756babf474","type":"GENE","name":"CLSTN3","canonical_id":"hgnc:HGNC:18371","description":"calsyntenin 3","metadata":{"aliases":["CSTN3","KIAA0726","CDHR14"]}},{"id":"98d1eae1d9e749f7a7e836d1650deff8","type":"GENE","name":"CLTA","canonical_id":"hgnc:HGNC:2090","description":"clathrin light chain A","metadata":{"aliases":["Lca"]}},{"id":"5310e1990191445c8c941da3addc0bbc","type":"GENE","name":"CLTAP1","canonical_id":"hgnc:HGNC:58673","description":"CLTA pseudogene 1","metadata":null},{"id":"a649c9ba9ac64ece8f2924a21bd083e2","type":"GENE","name":"CLTAP2","canonical_id":"hgnc:HGNC:58674","description":"CLTA pseudogene 2","metadata":null},{"id":"84033139322744b1bd672cc5d3dd1095","type":"GENE","name":"CLTB","canonical_id":"hgnc:HGNC:2091","description":"clathrin light chain B","metadata":{"aliases":["Lcb"]}},{"id":"cb1b969b93724448ace839e1de87808d","type":"GENE","name":"CLTC","canonical_id":"hgnc:HGNC:2092","description":"clathrin heavy chain","metadata":{"aliases":["Hc","CLTCL2"]}},{"id":"4d6385068f304498bded87e9d74c7add","type":"GENE","name":"CLTCL1","canonical_id":"hgnc:HGNC:2093","description":"clathrin heavy chain like 1","metadata":{"aliases":["CLTD","CLH22","CHC22","CLTCL"]}},{"id":"bc6c217296df4c199e9b28b1ece5f75a","type":"GENE","name":"CLTRN","canonical_id":"hgnc:HGNC:29437","description":"collectrin, amino acid transport regulator","metadata":{"aliases":["NX17","TMEM27"]}},{"id":"2a5dd5586ef54e458c667b6e77968130","type":"GENE","name":"CLU","canonical_id":"hgnc:HGNC:2095","description":null,"metadata":null},{"id":"a56235175b184669b5eb92a27aa5586e","type":"GENE","name":"CLUH","canonical_id":"hgnc:HGNC:29094","description":"CLUH binding protein of NUMT mRNA","metadata":{"aliases":["CLU1","KIAA0664"]}},{"id":"1be54f0ec5cb4ef2833650abf7b5affc","type":"GENE","name":"CLUHP1","canonical_id":"hgnc:HGNC:38416","description":"CLUH pseudogene 1","metadata":{"aliases":["KIAA0664L1","KIAA0664P1"]}},{"id":"4fc6d3640f8a48d7b03940ca5184b8df","type":"GENE","name":"CLUHP10","canonical_id":"hgnc:HGNC:51574","description":"CLUH pseudogene 10","metadata":null},{"id":"c6453df9b53e4e51b12184eb23512375","type":"GENE","name":"CLUHP11","canonical_id":"hgnc:HGNC:51806","description":"CLUH pseudogene 11","metadata":null},{"id":"bdda6a69bffb486ca031745246b9ec41","type":"GENE","name":"CLUHP2","canonical_id":"hgnc:HGNC:38453","description":"CLUH pseudogene 2","metadata":{"aliases":["KIAA0664L2","KIAA0664P2"]}},{"id":"a2c63ab8b1c448b4a42994064d354c82","type":"GENE","name":"CLUHP3","canonical_id":"hgnc:HGNC:28447","description":"CLUH pseudogene 3","metadata":{"aliases":["MGC3020","C16orf67","KIAA0664P3","KIAA0664L3"]}},{"id":"55e428150dac43c7a49cf4a284e2641d","type":"GENE","name":"CLUHP4","canonical_id":"hgnc:HGNC:38470","description":"CLUH pseudogene 4","metadata":{"aliases":["KIAA0664L4","KIAA0664P4"]}},{"id":"44cc65dae28a48e9b7c0b4c1c8675610","type":"GENE","name":"CLUHP5","canonical_id":"hgnc:HGNC:38471","description":"CLUH pseudogene 5","metadata":{"aliases":["KIAA0664L5","KIAA0664P5"]}},{"id":"2c40d36b2259444696c2bf6778d5bcc6","type":"GENE","name":"CLUHP6","canonical_id":"hgnc:HGNC:51571","description":"CLUH pseudogene 6","metadata":null},{"id":"5791e08dc2184c21affdf18879995261","type":"GENE","name":"CLUHP7","canonical_id":"hgnc:HGNC:51570","description":"CLUH pseudogene 7","metadata":null},{"id":"3b7a1b5362b14d74965952ff174ca3e4","type":"GENE","name":"CLUHP8","canonical_id":"hgnc:HGNC:51573","description":"CLUH pseudogene 8","metadata":null},{"id":"511094be5f67430880b26423fcdae72d","type":"GENE","name":"CLUHP9","canonical_id":"hgnc:HGNC:51572","description":"CLUH pseudogene 9","metadata":null},{"id":"9cd605e0a196417cabe1c12b93b9abb0","type":"GENE","name":"CLUL1","canonical_id":"hgnc:HGNC:2096","description":"clusterin like 1","metadata":null},{"id":"5419db1ab4ee40799939feeb89f84db5","type":"GENE","name":"CLVS1","canonical_id":"hgnc:HGNC:23139","description":"clavesin 1","metadata":{"aliases":["MGC34646","CRALBPL","C6orf212L","RLBP1L1"]}},{"id":"e8867ae96bf04ac2a4d8a60a30716b4c","type":"GENE","name":"CLVS1-AS1","canonical_id":"hgnc:HGNC:58429","description":"CLVS1 antisense RNA 1","metadata":null},{"id":"328720bbd6ed49a2affaa366b5425888","type":"GENE","name":"CLVS2","canonical_id":"hgnc:HGNC:23046","description":"clavesin 2","metadata":{"aliases":["bA160A10.4","C6orf212","C6orf213","RLBP1L2"]}},{"id":"eb7c856d7a664fbb8b1e251e717b21c1","type":"GENE","name":"CLXN","canonical_id":"hgnc:HGNC:25678","description":"calaxin","metadata":{"aliases":["FLJ11767","ODAD5","EFCAB1"]}},{"id":"461c948391ff42a196b66311516372e9","type":"GENE","name":"CLYBL","canonical_id":"hgnc:HGNC:18355","description":"citramalyl-CoA lyase","metadata":{"aliases":["CLB"]}},{"id":"e0f1ce0c5ceb4c3ea00db55ed6fc80d5","type":"GENE","name":"CLYBL-AS1","canonical_id":"hgnc:HGNC:39893","description":"CLYBL antisense RNA 1","metadata":null},{"id":"55aaa2ad9d76419fabc7bd5681aa5cd1","type":"GENE","name":"CLYBL-AS2","canonical_id":"hgnc:HGNC:39894","description":"CLYBL antisense RNA 2","metadata":null},{"id":"30152b0dd54d4a6f9e37da1b6c86a47f","type":"GENE","name":"CLYBL-AS3","canonical_id":"hgnc:HGNC:56191","description":"CLYBL antisense RNA 3","metadata":null},{"id":"a00a70e776a54e48be6af14af52bc8f2","type":"TRIAL","name":"CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment","canonical_id":"clinicaltrials.gov:NCT07585760","description":"Multiple Myeloma (MM); Multiple Myeloma Light Chain Induced Renal Insufficiency","metadata":null},{"id":"ed3765edd2ed4a65a2b9f65ccdb9f0f1","type":"TRIAL","name":"CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse","canonical_id":"clinicaltrials.gov:NCT00003673","description":"Leukemia","metadata":null},{"id":"b3c2ff436bde428fa7f2b291805d31ed","type":"TRIAL","name":"CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse","canonical_id":"clinicaltrials.gov:NCT00003131","description":"Leukemia","metadata":null},{"id":"75187114880344c4ace43c37b9fbcdb2","type":"GENE","name":"CMA1","canonical_id":"hgnc:HGNC:2097","description":"chymase 1","metadata":null},{"id":"fb5bfecad0a446a6bc9d72862b6f7ceb","type":"GENE","name":"CMAHP","canonical_id":"hgnc:HGNC:2098","description":"cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene","metadata":{"aliases":["CMAH"]}},{"id":"b6a7845489f94d099f61183d37d07359","type":"GENE","name":"CMAS","canonical_id":"hgnc:HGNC:18290","description":"cytidine monophosphate N-acetylneuraminic acid synthetase","metadata":null},{"id":"7d5ebce959604f548559c3e6d3369d98","type":"GENE","name":"CMBL","canonical_id":"hgnc:HGNC:25090","description":"carboxymethylenebutenolidase homolog","metadata":{"aliases":["FLJ23617"]}},{"id":"cc42c1a0a4714c049f3fd7b48235a8fc","type":"TRIAL","name":"CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT01664910","description":"Hematopoietic and Lymphoid Cell Neoplasm","metadata":null},{"id":"0ca4d3400fb94f2bb1c9168fbe5ee207","type":"GENE","name":"CMC1","canonical_id":"hgnc:HGNC:28783","description":"C-X9-C motif containing 1","metadata":{"aliases":["MGC61571","C3orf68"]}},{"id":"d24f47c06e60491e84c9097aecfb8111","type":"GENE","name":"CMC1P1","canonical_id":"hgnc:HGNC:58675","description":"CMC1 pseudogene 1","metadata":null},{"id":"d74219fe22c2450f81da998173d4bf42","type":"GENE","name":"CMC1P2","canonical_id":"hgnc:HGNC:58676","description":"CMC1 pseudogene 2","metadata":null},{"id":"2692a72bca2d485fb009ff90b478349b","type":"GENE","name":"CMC1P3","canonical_id":"hgnc:HGNC:58677","description":"CMC1 pseudogene 3","metadata":null},{"id":"2fa0fbaefb9c4d30a29478a16622b557","type":"GENE","name":"CMC1P4","canonical_id":"hgnc:HGNC:58678","description":"CMC1 pseudogene 4","metadata":null},{"id":"da38c36d04f8437d985438ca92ae4159","type":"GENE","name":"CMC2","canonical_id":"hgnc:HGNC:24447","description":"C-X9-C motif containing 2","metadata":{"aliases":["DC13","MGC45036","C16orf61"]}},{"id":"162ff3c97c9147fda9a6b08d36f9718d","type":"GENE","name":"CMC2P1","canonical_id":"hgnc:HGNC:51479","description":"CMC2 pseudogene 1","metadata":null},{"id":"a28ba793294945f2b2e832afd454408f","type":"GENE","name":"CMC2P2","canonical_id":"hgnc:HGNC:51476","description":"CMC2 pseudogene 2","metadata":null},{"id":"7250a38106d8431ca2420024d3e27da9","type":"GENE","name":"CMC2P3","canonical_id":"hgnc:HGNC:51477","description":"CMC2 pseudogene 3","metadata":null},{"id":"21ec9ee104474efb853e03639b0ae542","type":"GENE","name":"CMC2P4","canonical_id":"hgnc:HGNC:51475","description":"CMC2 pseudogene 4","metadata":null},{"id":"1c1408473dc846a1a73b6939e8b7e67e","type":"GENE","name":"CMC4","canonical_id":"hgnc:HGNC:35428","description":"C-X9-C motif containing 4","metadata":{"aliases":["P8MTCP1","p8","MTCP1NB"]}},{"id":"159c796c715448cc806531f04d348224","type":"GO_TERM","name":"CMG complex","canonical_id":"go:GO:0071162","description":"\"A protein complex that contains the GINS complex, Cdc45p, and the heterohexameric MCM complex, and that is involved in unwinding DNA during replication.\" [GOC:rb, PMID:19228417]","metadata":null},{"id":"0294868d9f0641c7a44ebbbfeee8ed1e","type":"GO_TERM","name":"CMG complex assembly","canonical_id":"go:GO:0140529","description":"\"The aggregation, arrangement and bonding together of a set of components to form the CMG complex, a protein complex that contains the GINS complex, Cdc45p, and the heterohexameric MCM complex, and that is involved in unwinding DNA during replication. The process begins when additional proteins (e.g. Cdc45 and Sld3) join the loaded, inactive double MCM hexamer at replication origins, and ends when Mcm10 triggers the separation of the Mcm2-7 double hexamers, forming two active CMG complexes.\" [PMID:22718908, PMID:28501329]","metadata":null},{"id":"194a13d2036c4de9bb07c31c4f0506b5","type":"GENE","name":"CMIP","canonical_id":"hgnc:HGNC:24319","description":"c-Maf inducing protein","metadata":null},{"id":"323ddb47f8134136ab7a505eab0f13bb","type":"GENE","name":"CMKLR1","canonical_id":"hgnc:HGNC:2121","description":"chemerin chemokine-like receptor 1","metadata":{"aliases":["RVER1","ERV1","ChemR23"]}},{"id":"64d9108716b742159e7dc04957cae55b","type":"GENE","name":"CMKLR2","canonical_id":"hgnc:HGNC:4463","description":"chemerin chemokine-like receptor 2","metadata":{"aliases":["GPR1"]}},{"id":"b28111f366754774b37c26e32d4b7cda","type":"GENE","name":"CMKLR2-AS","canonical_id":"hgnc:HGNC:48602","description":"CMKLR2 antisense RNA","metadata":{"aliases":["GPR1AS","GPR1-AS1","GPR1-AS"]}},{"id":"7fd450cd326c483a8734cdc118fa94db","type":"DISEASE","name":"CML (ph+)","canonical_id":"mesh:D015464","description":null,"metadata":null},{"id":"60cfe3061d9148d89718af7819926a9d","type":"TRIAL","name":"CML Treated With Bosutinib After Relapse","canonical_id":"clinicaltrials.gov:NCT02445742","description":"Chronic Myeloblastic Leukaemia","metadata":null},{"id":"c2e0d1999f534744b322ebf6d787c46e","type":"GO_TERM","name":"CMP biosynthetic process","canonical_id":"go:GO:0009224","description":"\"The chemical reactions and pathways resulting in the formation of CMP, cytidine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"546ceae3fb694f8cb2f433c306984ae8","type":"GO_TERM","name":"CMP catabolic process","canonical_id":"go:GO:0006248","description":"\"The chemical reactions and pathways resulting in the breakdown of CMP, cytidine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"5e70b8e9a7744012b5833f6473053e6f","type":"GO_TERM","name":"CMP kinase activity","canonical_id":"go:GO:0036430","description":"\"Catalysis of the reaction: ATP + CMP = ADP + CDP.\" [RHEA:11600]","metadata":null},{"id":"57903b83aa424c92bfdb3f11e372232e","type":"GO_TERM","name":"CMP metabolic process","canonical_id":"go:GO:0046035","description":"\"The chemical reactions and pathways involving CMP, cytidine monophosphate.\" [GOC:curators]","metadata":null},{"id":"c91a18c5ef5c4b9c85bf010721bf2ad7","type":"GO_TERM","name":"CMP phosphorylation","canonical_id":"go:GO:0061566","description":"\"The process of introducing a phosphate group into CMP, cytidine monophosphate, to produce CDP. Addition of two phosphate groups produces CTP.\" [GOC:dph, PMID:23416111]","metadata":null},{"id":"09d2a19c20b043a9bc10a74055bb825a","type":"GO_TERM","name":"CMP salvage","canonical_id":"go:GO:0006238","description":"\"Any process that generates CMP, cytidine monophosphate, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"fded74c6cfe849438c81a3d8410a0313","type":"TRIAL","name":"CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine","canonical_id":"clinicaltrials.gov:NCT06158698","description":"Cardiomyopathies; Myocarditis; Inflammatory Cardiomyopathy; Heart Failure; Ventricular Arrythmia","metadata":null},{"id":"469d354c2d074992bdee1c51e68ca15c","type":"GO_TERM","name":"CMP-N-acetylneuraminate biosynthetic process","canonical_id":"go:GO:0006055","description":"\"The chemical reactions and pathways resulting in the formation of CMP-N-acetylneuraminate, a substance composed of 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-non-3-ulosonic acid in glycosidic linkage with cytidine monophosphate.\" [GOC:ai]","metadata":null},{"id":"55c4ebcba6544dd6b4839c458cab7dd5","type":"GO_TERM","name":"CMP-N-acetylneuraminate metabolic process","canonical_id":"go:GO:0046381","description":"\"The chemical reactions and pathways involving CMP-N-acetylneuraminate, a substance composed of 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-non-3-ulosonic acid in glycosidic linkage with cytidine monophosphate.\" [GOC:ai]","metadata":null},{"id":"82bf633314004d82af93ea3595f96b8a","type":"GO_TERM","name":"CMP-N-acetylneuraminate monooxygenase activity","canonical_id":"go:GO:0030338","description":"\"Catalysis of the reaction: CMP-N-acetyl-beta-neuraminate + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = CMP-N-glycoloyl-beta-neuraminate + 2 Fe(III)-[cytochrome b5] + H2O.\" [EC:1.14.18.2]","metadata":null},{"id":"a0f7fa4ae8d64b308e803b1d6fd29ea9","type":"GO_TERM","name":"CMP-N-acetylneuraminate transmembrane transport","canonical_id":"go:GO:0015782","description":"\"The directed movement of CMP-N-acetylneuraminate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"729d88a455584fe38046934e86c07c1f","type":"GO_TERM","name":"CMP-N-acetylneuraminate transmembrane transporter activity","canonical_id":"go:GO:0005456","description":"\"Enables the transfer of a CMP-N-acetylneuraminate from one side of a membrane to the other.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"8d783f0be2c8418e9ab6486c85cae918","type":"GO_TERM","name":"CMP-N-acylneuraminate phosphodiesterase activity","canonical_id":"go:GO:0047392","description":"\"Catalysis of the reaction: H2O + CMP-N-acylneuraminate = N-acylneuraminate + CMP.\" [EC:3.1.4.40, MetaCyc:3.1.4.40-RXN]","metadata":null},{"id":"90a3c4674f52491d874437562085825e","type":"GO_TERM","name":"CMP-keto-3-deoxy-D-manno-octulosonic acid biosynthetic process","canonical_id":"go:GO:0033468","description":"\"The chemical reactions and pathways resulting in the formation of CMP-keto-3-deoxy-D-manno-octulosonic acid, a substance composed of the acidic sugar 3-deoxy-D-manno-octulosonic acid in glycosidic linkage with cytidine monophosphate.\" [GOC:mah, MetaCyc:PWY-1269]","metadata":null},{"id":"e41938a82cd94bc683710afec171d9c8","type":"GENE","name":"CMPK1","canonical_id":"hgnc:HGNC:18170","description":"cytidine/uridine monophosphate kinase 1","metadata":{"aliases":["UMP-CMPK","CMPK"]}},{"id":"1417c9bbe72a45abafe092df6d403502","type":"GENE","name":"CMPK1P1","canonical_id":"hgnc:HGNC:56924","description":"CMPK1 pseudogene 1","metadata":null},{"id":"64695b1d332a46b7905cc53a3d225b32","type":"GENE","name":"CMPK1P2","canonical_id":"hgnc:HGNC:56925","description":"CMPK1 pseudogene 2","metadata":null},{"id":"0bbcaa5218654799a9fb608acc48c865","type":"GENE","name":"CMPK2","canonical_id":"hgnc:HGNC:27015","description":"cytidine/uridine monophosphate kinase 2","metadata":{"aliases":["TYKi","UMP-CMPK2","NDK"]}},{"id":"4ec917c78e0841a7ae96b12d0ab227a0","type":"TRIAL","name":"CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib","canonical_id":"clinicaltrials.gov:NCT01227577","description":"Chronic Myelogenous Leukemia in Chronic Phase","metadata":null},{"id":"27ce8efc1cd74277aac9d14a4b746873","type":"TRIAL","name":"CMR Right Ventricular Contractile Reserve Following Lung Resection","canonical_id":"clinicaltrials.gov:NCT06465277","description":"Lung Cancer; Surgery; Anesthesia","metadata":null},{"id":"2a7212c819ff4befa942cd874953e259","type":"GENE","name":"CMSS1","canonical_id":"hgnc:HGNC:28666","description":"cms1 ribosomal small subunit homolog","metadata":{"aliases":["MGC4308","C3orf26"]}},{"id":"bcbafcba58944dd78e6b603191ebbbe5","type":"GENE","name":"CMTM1","canonical_id":"hgnc:HGNC:19172","description":"CKLF like MARVEL transmembrane domain containing 1","metadata":{"aliases":["CKLFH1a","CKLFH","CKLFSF1"]}},{"id":"efa090cda7524285adbdafc97d783446","type":"GENE","name":"CMTM2","canonical_id":"hgnc:HGNC:19173","description":"CKLF like MARVEL transmembrane domain containing 2","metadata":{"aliases":["MGC39436","FLJ25732","CKLFSF2"]}},{"id":"8bce75c188754769a11d6a19fc31c688","type":"GENE","name":"CMTM2-AS1","canonical_id":"hgnc:HGNC:58533","description":"CMTM2 antisense RNA 1","metadata":null},{"id":"d70621785f674605afa376b2a68c37f9","type":"GENE","name":"CMTM3","canonical_id":"hgnc:HGNC:19174","description":"CKLF like MARVEL transmembrane domain containing 3","metadata":{"aliases":["FLJ31762","BNAS2","CKLFSF3"]}},{"id":"4b0015685e9245bca263af07a14ad229","type":"GENE","name":"CMTM4","canonical_id":"hgnc:HGNC:19175","description":"CKLF like MARVEL transmembrane domain containing 4","metadata":{"aliases":["CKLFSF4"]}},{"id":"0143ee5290754d3583512522d485989c","type":"GENE","name":"CMTM5","canonical_id":"hgnc:HGNC:19176","description":"CKLF like MARVEL transmembrane domain containing 5","metadata":{"aliases":["FLJ37521","CKLFSF5"]}},{"id":"23fcc2e9da7b4b39b50e4b2db49f3bb8","type":"GENE","name":"CMTM6","canonical_id":"hgnc:HGNC:19177","description":"CKLF like MARVEL transmembrane domain containing 6","metadata":{"aliases":["FLJ20396","CKLFSF6"]}},{"id":"42365437289f423e988f9131a8b9370f","type":"GENE","name":"CMTM7","canonical_id":"hgnc:HGNC:19178","description":"CKLF like MARVEL transmembrane domain containing 7","metadata":{"aliases":["FLJ30992","CKLFSF7"]}},{"id":"262ebb09c8174860a097cc894b595822","type":"GENE","name":"CMTM8","canonical_id":"hgnc:HGNC:19179","description":"CKLF like MARVEL transmembrane domain containing 8","metadata":{"aliases":["CKLFSF8"]}},{"id":"5112859879034da3aeb748fac6491ea8","type":"GENE","name":"CMTR1","canonical_id":"hgnc:HGNC:21077","description":"cap methyltransferase 1","metadata":{"aliases":["MTr1","ISG95","KIAA0082","FTSJD2"]}},{"id":"217d0fcd4b5442928a4edc35af947d53","type":"GENE","name":"CMTR1-AS1","canonical_id":"hgnc:HGNC:59395","description":"CMTR1 antisense RNA 1","metadata":null},{"id":"7c3c0e9888374e97bd795d08d2c8b642","type":"GENE","name":"CMTR2","canonical_id":"hgnc:HGNC:25635","description":"cap methyltransferase 2","metadata":{"aliases":["FLJ11171","AFT","MTr2","FTSJD1"]}},{"id":"a773d3445949430dbe5dab1f557c0bf9","type":"DISEASE","name":"CMV infection","canonical_id":"mesh:D003586","description":null,"metadata":null},{"id":"9b3e0e02c7ad4841b078e491231ac7ec","type":"GENE","name":"CMYA5","canonical_id":"hgnc:HGNC:14305","description":"cardiomyopathy associated 5","metadata":{"aliases":["SPRYD2","DKFZp451G223","TRIM76","C5orf10"]}},{"id":"d39986f2cbe94f74bfb75b0cb08638fa","type":"GENE","name":"CMYA5-AS1","canonical_id":"hgnc:HGNC:59086","description":"CMYA5 antisense RNA 1","metadata":null},{"id":"0446455770d24d17b3fe6a676a4169b5","type":"GENE","name":"CNBD1","canonical_id":"hgnc:HGNC:26663","description":"cyclic nucleotide binding domain containing 1","metadata":{"aliases":["FLJ35802"]}},{"id":"d79133d10a9a468bbbecc0176f9df4f5","type":"GENE","name":"CNBD2","canonical_id":"hgnc:HGNC:16145","description":"cyclic nucleotide binding domain containing 2","metadata":{"aliases":["dJ954P9.1","C20orf152","CNMPD1"]}},{"id":"f91b432191bd45c39a7e7dd0046c7d53","type":"GO_TERM","name":"CNBH domain intrinsic ligand binding","canonical_id":"go:GO:0106151","description":"\"Interacting selectivity and noncovalently with a cyclic nucleotide mimicking protein motif that is part of the same protein. The CNBHD is a domain on KCNH channels that creates a binding pocket on the KCNH channel that resembles the cyclic nucleotide- binding domain on other ion channels. It binds to a peptide motif that is part of the same protein rather than a cyclic nucleotide.\" [GOC:cvs, PMID:27025590, PMID:29567795]","metadata":null},{"id":"7ee68611f82a4249a61b7edae594dcf3","type":"GENE","name":"CNBP","canonical_id":"hgnc:HGNC:13164","description":null,"metadata":null},{"id":"af7839fb8c0e4f4fa22fc3bec960e7cc","type":"GENE","name":"CNDP1","canonical_id":"hgnc:HGNC:20675","description":"carnosine dipeptidase 1","metadata":{"aliases":["MGC10825","CN1","CPGL2","HsT2308"]}},{"id":"e032adddf97d484fb1e4785b000a4455","type":"GENE","name":"CNDP1-AS1","canonical_id":"hgnc:HGNC:58557","description":"CNDP1 antisense RNA 1","metadata":null},{"id":"b4f49daf77c545ce845f7eaa9caad4ea","type":"GENE","name":"CNDP2","canonical_id":"hgnc:HGNC:24437","description":"carnosine dipeptidase 2","metadata":{"aliases":["FLJ10830","CN2","HsT2298","CPGL","PEPA"]}},{"id":"6fcc24d241844900a25eba851e904c80","type":"GENE","name":"CNEP1R1","canonical_id":"hgnc:HGNC:26759","description":"CTD nuclear envelope phosphatase 1 regulatory subunit 1","metadata":{"aliases":["FLJ38101","NEP1-R1","C16orf69","TMEM188"]}},{"id":"23a2b30c8a9a41b98a2ee4c11b3cbdf0","type":"GENE","name":"CNEP1R1P1","canonical_id":"hgnc:HGNC:55037","description":"CNEP1R1 pseudogene 1","metadata":null},{"id":"870b9e31969b4f08812c9bb916547295","type":"GENE","name":"CNFN","canonical_id":"hgnc:HGNC:30183","description":"cornifelin","metadata":{"aliases":["PLAC8L2"]}},{"id":"1c07313676cd477d86a0ca4351dce5d8","type":"GENE","name":"CNGA1","canonical_id":"hgnc:HGNC:2148","description":"cyclic nucleotide gated channel subunit alpha 1","metadata":{"aliases":["RCNC1","RCNCa","CNG1","RP49","CNCG1","CNCG"]}},{"id":"e5916a05814f4e90b5bbcc2c8a60db88","type":"GENE","name":"CNGA2","canonical_id":"hgnc:HGNC:2149","description":"cyclic nucleotide gated channel subunit alpha 2","metadata":{"aliases":["CNG2","OCNC1","OCNCa","OCNCALPHA","OCNCalpha","FLJ46312","CNCA1","CNCA"]}},{"id":"c9696422da624855961929442e06311e","type":"GENE","name":"CNGA3","canonical_id":"hgnc:HGNC:2150","description":"cyclic nucleotide gated channel subunit alpha 3","metadata":{"aliases":["CCNC1","CCNCa","CNG3","CNCG3","ACHM2"]}},{"id":"7f37018a08724143a62c2b8ac4cfd7e1","type":"GENE","name":"CNGA4","canonical_id":"hgnc:HGNC:2152","description":"cyclic nucleotide gated channel subunit alpha 4","metadata":{"aliases":["OCNC2","OCNCb","CNG5","CNCA2","CNGB2"]}},{"id":"2578b86626704beaa88ab4359a7433ce","type":"GENE","name":"CNGB1","canonical_id":"hgnc:HGNC:2151","description":"cyclic nucleotide gated channel subunit beta 1","metadata":{"aliases":["RCNC2","RCNCb","GARP","GAR1","CNGB1B","RP45","CNCG2","CNCG3L"]}},{"id":"2d716064097043e9a0c95c4db4a93ecc","type":"GENE","name":"CNGB3","canonical_id":"hgnc:HGNC:2153","description":"cyclic nucleotide gated channel subunit beta 3","metadata":{"aliases":["ACHM3","ACHM1","RMCH"]}},{"id":"bea31cc298154ab882c97c10715ebd17","type":"GENE","name":"CNGB3-AS1","canonical_id":"hgnc:HGNC:58258","description":"CNGB3 antisense RNA 1","metadata":null},{"id":"4fbeff7641ad489e8b527b545079b528","type":"TRIAL","name":"CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction","canonical_id":"clinicaltrials.gov:NCT04013620","description":"Chronic Kidney Failure","metadata":null},{"id":"929123602c9241249371e86ff4f6bf9b","type":"GENE","name":"CNIH1","canonical_id":"hgnc:HGNC:19431","description":"cornichon family member 1","metadata":{"aliases":["TGAM77","CNIL","CNIH"]}},{"id":"b1a5e927573945fc82ddf0aa68fbbcd5","type":"GENE","name":"CNIH2","canonical_id":"hgnc:HGNC:28744","description":"cornichon family AMPA receptor auxiliary protein 2","metadata":{"aliases":["MGC50896","Cnil","CNIH-2"]}},{"id":"c260ad2f80e44015a4d8a5613258c73b","type":"GENE","name":"CNIH3","canonical_id":"hgnc:HGNC:26802","description":"cornichon family AMPA receptor auxiliary protein 3","metadata":{"aliases":["FLJ38993","CNIH-3"]}},{"id":"45bf3cfd36564c7e9681fa105052e8bc","type":"GENE","name":"CNIH3-AS1","canonical_id":"hgnc:HGNC:41163","description":"CNIH3 antisense RNA 1","metadata":null},{"id":"2467248c35344d41801f9c92eb1ecd4b","type":"GENE","name":"CNIH3-AS2","canonical_id":"hgnc:HGNC:41162","description":"CNIH3 antisense RNA 2","metadata":null},{"id":"cacc010de5884e89baa5057b6808fedb","type":"GENE","name":"CNIH4","canonical_id":"hgnc:HGNC:25013","description":"cornichon family member 4","metadata":{"aliases":["HSPC163"]}},{"id":"88e9e19b28834942b2885fc5c23f2739","type":"GENE","name":"CNKSR1","canonical_id":"hgnc:HGNC:19700","description":"connector enhancer of kinase suppressor of Ras 1","metadata":{"aliases":["CNK1","KSR","CNK"]}},{"id":"72a382bfe5954cc4a07f9c4ee6212219","type":"GENE","name":"CNKSR2","canonical_id":"hgnc:HGNC:19701","description":"connector enhancer of kinase suppressor of Ras 2","metadata":{"aliases":["maguin","KIAA0902","CNK2","KSR2"]}},{"id":"90387a3e5bb84ac5acb68cca96874a76","type":"GENE","name":"CNKSR3","canonical_id":"hgnc:HGNC:23034","description":"CNKSR family member 3","metadata":{"aliases":["FLJ31349","MAGI1"]}},{"id":"eec821efd08e45f9a54210967b8369da","type":"GENE","name":"CNMD","canonical_id":"hgnc:HGNC:17005","description":null,"metadata":null},{"id":"63f9cb0e81964283bfc677d5be43f4a3","type":"GENE","name":"CNN1","canonical_id":"hgnc:HGNC:2155","description":"calponin 1","metadata":{"aliases":["SMCC","Sm-Calp"]}},{"id":"92cd1e36481f4d398f1759e659e92b8f","type":"GENE","name":"CNN2","canonical_id":"hgnc:HGNC:2156","description":"calponin 2","metadata":null},{"id":"ab10603ce9734da18e060a4ee74679cd","type":"GENE","name":"CNN2P1","canonical_id":"hgnc:HGNC:39526","description":"calponin 2 pseudogene 1","metadata":null},{"id":"af9ad8e9f2fb4ed48e7ad4f099e50494","type":"GENE","name":"CNN2P10","canonical_id":"hgnc:HGNC:39535","description":"calponin 2 pseudogene 10","metadata":null},{"id":"2c9cd1757ffb47b4b535b6949d1f6d57","type":"GENE","name":"CNN2P11","canonical_id":"hgnc:HGNC:39536","description":"calponin 2 pseudogene 11","metadata":null},{"id":"6c1118534be3481d8ac2bd00b0b6c39b","type":"GENE","name":"CNN2P12","canonical_id":"hgnc:HGNC:39834","description":"calponin 2 pseudogene 12","metadata":null},{"id":"e5acef71316247f48167d027fccf4452","type":"GENE","name":"CNN2P2","canonical_id":"hgnc:HGNC:39527","description":"calponin 2 pseudogene 2","metadata":null},{"id":"3eadbeb9f3e34ccb973601435804a618","type":"GENE","name":"CNN2P3","canonical_id":"hgnc:HGNC:39528","description":"calponin 2 pseudogene 3","metadata":null},{"id":"d873b8657b48410793a201a8e9e1958e","type":"GENE","name":"CNN2P4","canonical_id":"hgnc:HGNC:39529","description":"calponin 2 pseudogene 4","metadata":{"aliases":["CNN2P5"]}},{"id":"32c8048f67b64fb2bc0d4d1c2df89028","type":"GENE","name":"CNN2P6","canonical_id":"hgnc:HGNC:39531","description":"calponin 2 pseudogene 6","metadata":null},{"id":"2a01d04fe18041ad8d3d48fc931adaf5","type":"GENE","name":"CNN2P7","canonical_id":"hgnc:HGNC:39532","description":"calponin 2 pseudogene 7","metadata":null},{"id":"d507f1e39b234b7dae03ad3814084de5","type":"GENE","name":"CNN2P8","canonical_id":"hgnc:HGNC:39533","description":"calponin 2 pseudogene 8","metadata":null},{"id":"9bec4a244b31401bafcc9f19cfd4b810","type":"GENE","name":"CNN2P9","canonical_id":"hgnc:HGNC:39534","description":"calponin 2 pseudogene 9","metadata":null},{"id":"8755d06ef30e4987acb08e61a689af75","type":"GENE","name":"CNN3","canonical_id":"hgnc:HGNC:2157","description":"calponin 3","metadata":null},{"id":"7067272bc6044d6d879a7246ce733e4f","type":"GENE","name":"CNN3-DT","canonical_id":"hgnc:HGNC:54176","description":"CNN3 divergent transcript","metadata":{"aliases":["RP4-639F20.1","ALG14-AS1"]}},{"id":"039f6e5a90d24120974d868753107716","type":"GENE","name":"CNN3P1","canonical_id":"hgnc:HGNC:38666","description":"calponin 3 pseudogene 1","metadata":null},{"id":"c1d71b6f27634589acfa364585579ac1","type":"GENE","name":"CNNM1","canonical_id":"hgnc:HGNC:102","description":"cyclin and CBS domain divalent metal cation transport mediator 1","metadata":{"aliases":["SLC70A1","ACDP1"]}},{"id":"c05118bc1de749bd8db8536a548f3e64","type":"GENE","name":"CNNM2","canonical_id":"hgnc:HGNC:103","description":"cyclin and CBS domain divalent metal cation transport mediator 2","metadata":{"aliases":["SLC70A2","ACDP2"]}},{"id":"7fa55244e3e74ae6993c4453694f1ef3","type":"GENE","name":"CNNM3","canonical_id":"hgnc:HGNC:104","description":"cyclin and CBS domain divalent metal cation transport mediator 3","metadata":{"aliases":["SLC70A3","ACDP3"]}},{"id":"0ae76324782246b390a500b999f36b77","type":"GENE","name":"CNNM3-DT","canonical_id":"hgnc:HGNC:53592","description":"CNNM3 divergent transcript","metadata":{"aliases":["LOC100506036"]}},{"id":"aa66cf2461e64c088ae1e77dc3e42e6e","type":"GENE","name":"CNNM4","canonical_id":"hgnc:HGNC:105","description":"cyclin and CBS domain divalent metal cation transport mediator 4","metadata":{"aliases":["SLC70A4","KIAA1592","ACDP4"]}},{"id":"b10215dc2faf4675b9b4095fc8287e5a","type":"GENE","name":"CNOT1","canonical_id":"hgnc:HGNC:7877","description":"CCR4-NOT transcription complex subunit 1","metadata":{"aliases":["CDC39","NOT1H","KIAA1007","AD-005","NOT1"]}},{"id":"aac6b174ac8845a8afb6dfb9f8ace110","type":"GENE","name":"CNOT10","canonical_id":"hgnc:HGNC:23817","description":"CCR4-NOT transcription complex subunit 10","metadata":{"aliases":["FLJ12890","FLJ13165"]}},{"id":"762d4e3d22764433b96aeec8778aa9dc","type":"GENE","name":"CNOT10-AS1","canonical_id":"hgnc:HGNC:41031","description":"CNOT10 antisense RNA 1","metadata":null},{"id":"3eac2163f09e42158a0797cc2dc30b2c","type":"GENE","name":"CNOT11","canonical_id":"hgnc:HGNC:25217","description":"CCR4-NOT transcription complex subunit 11","metadata":{"aliases":["C40","C2orf29"]}},{"id":"b6e3383733e14b59ad73ec6d3eb7807e","type":"GENE","name":"CNOT12","canonical_id":"hgnc:HGNC:19081","description":"CCR4-NOT transcription complex subunit 12","metadata":{"aliases":["TAB182","KIAA1741","FLJ45975","TNKS1BP1"]}},{"id":"7f3291450ccb4a3ea49da5646776da8a","type":"GENE","name":"CNOT2","canonical_id":"hgnc:HGNC:7878","description":"CCR4-NOT transcription complex subunit 2","metadata":{"aliases":["CDC36","NOT2H","NOT2"]}},{"id":"9a9f0bd853904003a74d0375653cb305","type":"GENE","name":"CNOT3","canonical_id":"hgnc:HGNC:7879","description":"CCR4-NOT transcription complex subunit 3","metadata":{"aliases":["NOT3H","KIAA0691","LENG2","NOT3"]}},{"id":"83ac1ac26088489ea71fa4a38ba93007","type":"GENE","name":"CNOT4","canonical_id":"hgnc:HGNC:7880","description":"CCR4-NOT transcription complex subunit 4","metadata":{"aliases":["CLONE243","NOT4H","NOT4"]}},{"id":"8e729f301ac8439cb046c5d3b5a9382e","type":"GENE","name":"CNOT4P1","canonical_id":"hgnc:HGNC:39272","description":"CCR4-NOT transcription complex subunit 4 pseudogene 1","metadata":null},{"id":"6313db21e66a49e7b91e557891d9ed90","type":"GENE","name":"CNOT6","canonical_id":"hgnc:HGNC:14099","description":"CCR4-NOT transcription complex subunit 6","metadata":{"aliases":["CCR4","KIAA1194","Ccr4a"]}},{"id":"96ae0f7c76e14d179f9685e5adb79466","type":"GENE","name":"CNOT6L","canonical_id":"hgnc:HGNC:18042","description":"CCR4-NOT transcription complex subunit 6 like","metadata":{"aliases":["DKFZp434K098","Ccr4b"]}},{"id":"605746794d0546d9bd53bf7cc09386e4","type":"GENE","name":"CNOT6L-DT","canonical_id":"hgnc:HGNC:58831","description":"CNOT6L divergent transcript","metadata":null},{"id":"a3bf87c179e94c8a865cacd8e60a3c8b","type":"GENE","name":"CNOT6LP1","canonical_id":"hgnc:HGNC:32355","description":"CNOT6L pseudogene 1","metadata":null},{"id":"f9d2852cc67a4e6e9d3454ab2bc648e8","type":"GENE","name":"CNOT7","canonical_id":"hgnc:HGNC:14101","description":null,"metadata":null},{"id":"52b23276833e4a5ebeb0409467364ff6","type":"GENE","name":"CNOT7P1","canonical_id":"hgnc:HGNC:44248","description":"CCR4-NOT transcription complex subunit 7 pseudogene 1","metadata":null},{"id":"1e1a8dfc290b494ea0c79d6b90069f9b","type":"GENE","name":"CNOT7P2","canonical_id":"hgnc:HGNC:44249","description":"CCR4-NOT transcription complex subunit 7 pseudogene 2","metadata":null},{"id":"7930800cf6a349e0ae86be82845f93d6","type":"GENE","name":"CNOT8","canonical_id":"hgnc:HGNC:9207","description":null,"metadata":null},{"id":"11d3cc35af8d423dbf4bf8002aa73367","type":"GENE","name":"CNOT9","canonical_id":"hgnc:HGNC:10445","description":"CCR4-NOT transcription complex subunit 9","metadata":{"aliases":["RCD1","RCD1+","CT129","CAF40","RQCD1"]}},{"id":"038e048ce2a54286b5e1ed4eeea738fa","type":"GENE","name":"CNP","canonical_id":"hgnc:HGNC:2158","description":null,"metadata":null},{"id":"36f28f7d1b254044911232b5414b123a","type":"GENE","name":"CNPPD1","canonical_id":"hgnc:HGNC:25220","description":"cyclin Pas1/PHO80 domain containing 1","metadata":{"aliases":["CGI-57","C2orf24"]}},{"id":"04123da4b86a42e9a158326a80e54c2c","type":"GENE","name":"CNPY1","canonical_id":"hgnc:HGNC:27786","description":"canopy FGF signaling regulator 1","metadata":null},{"id":"567a7ee968754ee4a9dff56b7384d60e","type":"GENE","name":"CNPY2","canonical_id":"hgnc:HGNC:13529","description":"canopy FGF signaling regulator 2","metadata":{"aliases":["HP10390","ZSIG9","TMEM4"]}},{"id":"cb861462986146a28fb0acce6ef9cdc8","type":"GENE","name":"CNPY2-AS1","canonical_id":"hgnc:HGNC:55480","description":"CNPY2 antisense RNA 1","metadata":null},{"id":"2171135c88644d23b69c76551005984e","type":"GENE","name":"CNPY3","canonical_id":"hgnc:HGNC:11968","description":"canopy FGF signaling regulator 3","metadata":{"aliases":["CAG4A","TNRC5"]}},{"id":"513def05a8984b7f910f1dd1ab66a5b7","type":"GENE","name":"CNPY3-AS1","canonical_id":"hgnc:HGNC:59408","description":"CNPY3 antisense RNA 1","metadata":null},{"id":"c35de84fb6fb4174bfe0193e97edb304","type":"GENE","name":"CNPY4","canonical_id":"hgnc:HGNC:28631","description":"canopy FGF signaling regulator 4","metadata":{"aliases":["MGC40499","PRAT4B"]}},{"id":"33359078557e4e908da17a37ca5468b8","type":"GENE","name":"CNR1","canonical_id":"hgnc:HGNC:2159","description":null,"metadata":null},{"id":"449c6a354ffd4757bf5c9b2201925be1","type":"GENE","name":"CNR2","canonical_id":"hgnc:HGNC:2160","description":"cannabinoid receptor 2","metadata":{"aliases":["CB2"]}},{"id":"fd6abc9529a540beb2b0de32a91217a4","type":"GENE","name":"CNRIP1","canonical_id":"hgnc:HGNC:24546","description":"cannabinoid receptor interacting protein 1","metadata":{"aliases":["DKFZP566K1924","CRIP1","CRIP1a","CRIP1b","C2orf32"]}},{"id":"1c5c301c5079420181e3d21acc3df9d7","type":"TRIAL","name":"CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC","canonical_id":"clinicaltrials.gov:NCT04739358","description":"Advanced Non-Small Cell Lung Cancer With MET Mutations","metadata":null},{"id":"2039ba15283640fcbac2c1ab915e8f5d","type":"GENE","name":"CNST","canonical_id":"hgnc:HGNC:26486","description":"consortin, connexin sorting protein","metadata":{"aliases":["FLJ32001","PPP1R64","C1orf71"]}},{"id":"12cbde86072748059e5a622f03286408","type":"GENE","name":"CNTD1","canonical_id":"hgnc:HGNC:26847","description":"cyclin N-terminal domain containing 1","metadata":{"aliases":["FLJ40137","CNTD"]}},{"id":"b4017fcfeea1469cb672b71e4f32a74e","type":"GENE","name":"CNTF","canonical_id":"hgnc:HGNC:2169","description":"ciliary neurotrophic factor","metadata":{"aliases":["HCNTF"]}},{"id":"773b1f5876304618aab5e84a89cf3653","type":"GENE","name":"CNTFR","canonical_id":"hgnc:HGNC:2170","description":"ciliary neurotrophic factor receptor","metadata":null},{"id":"6857248ab70d4a5b85c6009821620cd4","type":"GENE","name":"CNTFR-AS1","canonical_id":"hgnc:HGNC:48712","description":"CNTFR antisense RNA 1","metadata":null},{"id":"29f3b8f2b32a42a683d4911d3ed93452","type":"GO_TERM","name":"CNTFR-CLCF1 complex","canonical_id":"go:GO:0097059","description":"\"A protein complex that is composed of two soluble ciliary neurotrophic factor receptor alpha subunits (product of the CNTFR gene) and two molecules of cardiotrophin-like cytokine factor 1 (product of the CLCF1 gene). The complex is secreted into the extracellular space.\" [GOC:BHF, PMID:11285233]","metadata":null},{"id":"85c4d21d301342b9abe1621904600e4b","type":"GENE","name":"CNTLN","canonical_id":"hgnc:HGNC:23432","description":"centlein","metadata":{"aliases":["FLJ20276","bA340N12.1","OTTHUMG00000019597","C9orf101","C9orf39"]}},{"id":"8cf360eab1f54398803d9d45467b34bb","type":"GENE","name":"CNTN1","canonical_id":"hgnc:HGNC:2171","description":"contactin 1","metadata":{"aliases":["F3","GP135"]}},{"id":"a3911b90ac80464ab69d76df51abda48","type":"GENE","name":"CNTN2","canonical_id":"hgnc:HGNC:2172","description":"contactin 2","metadata":{"aliases":["TAG-1","TAX1","TAX","AXT"]}},{"id":"a7019ad723944d0c9d9987b773c60390","type":"GENE","name":"CNTN3","canonical_id":"hgnc:HGNC:2173","description":"contactin 3","metadata":{"aliases":["BIG-1","PANG"]}},{"id":"690044a928ea4f1ab75774bf75f1ca70","type":"GENE","name":"CNTN4","canonical_id":"hgnc:HGNC:2174","description":"contactin 4","metadata":{"aliases":["BIG-2"]}},{"id":"622184210a9e47078568f10bb342eda6","type":"GENE","name":"CNTN4-AS1","canonical_id":"hgnc:HGNC:39985","description":"CNTN4 antisense RNA 1","metadata":null},{"id":"74104ca72c1049c4892b30cd4cbf2314","type":"GENE","name":"CNTN4-AS2","canonical_id":"hgnc:HGNC:39986","description":"CNTN4 antisense RNA 2","metadata":null},{"id":"002b9f09771f486a971aee67bc47fd47","type":"GENE","name":"CNTN5","canonical_id":"hgnc:HGNC:2175","description":"contactin 5","metadata":{"aliases":["NB-2","hNB-2"]}},{"id":"0cc9dd5e6ffb4c47bd16554a7809e067","type":"GENE","name":"CNTN6","canonical_id":"hgnc:HGNC:2176","description":"contactin 6","metadata":{"aliases":["NB-3"]}},{"id":"07a12f6754734b0cbae83c9ca429c6ba","type":"GENE","name":"CNTNAP1","canonical_id":"hgnc:HGNC:8011","description":"contactin associated protein 1","metadata":{"aliases":["p190","Caspr","CNTNAP","NRXN4"]}},{"id":"00857986fedc4d3c8a9070db71f04c26","type":"GENE","name":"CNTNAP1-AS1","canonical_id":"hgnc:HGNC:58591","description":"CNTNAP1 antisense RNA 1","metadata":null},{"id":"0cce4096e58a411fbce88a66ead82f39","type":"GENE","name":"CNTNAP2","canonical_id":"hgnc:HGNC:13830","description":null,"metadata":null},{"id":"157655f6d1b142a1bd75e9a169600035","type":"GENE","name":"CNTNAP2-AS1","canonical_id":"hgnc:HGNC:40657","description":"CNTNAP2 antisense RNA 1","metadata":null},{"id":"1a0cfe749fe1459d9fc3255c80601357","type":"GENE","name":"CNTNAP3","canonical_id":"hgnc:HGNC:13834","description":"contactin associated protein family member 3","metadata":{"aliases":["CASPR3","KIAA1714","FLJ14195","CNTNAP3A"]}},{"id":"ff72793afaa74abf926c401a5cfee6d4","type":"GENE","name":"CNTNAP3B","canonical_id":"hgnc:HGNC:32035","description":"contactin associated protein family member 3B","metadata":null},{"id":"4a8c45eefe5a42b4be3c3faa0c0e93ba","type":"GENE","name":"CNTNAP3C","canonical_id":"hgnc:HGNC:53878","description":"contactin associated protein family member 3C","metadata":null},{"id":"fe273d80c83246b4a4a3748b710b66ad","type":"GENE","name":"CNTNAP3P1","canonical_id":"hgnc:HGNC:49591","description":"CNTNAP3 pseudogene 1","metadata":null},{"id":"afbe377fb4cf4a28983f60d848cc1032","type":"GENE","name":"CNTNAP3P2","canonical_id":"hgnc:HGNC:49589","description":"CNTNAP3 pseudogene 2","metadata":null},{"id":"3c5ff5a1489b40209c10e47b1b45b395","type":"GENE","name":"CNTNAP3P3","canonical_id":"hgnc:HGNC:49580","description":"CNTNAP3 pseudogene 3","metadata":null},{"id":"701d4240a7174ed8a928cb6b8350472e","type":"GENE","name":"CNTNAP3P4","canonical_id":"hgnc:HGNC:49581","description":"CNTNAP3 pseudogene 4","metadata":null},{"id":"5db2b9131c1d4f9b8cb4d55e96248b53","type":"GENE","name":"CNTNAP3P5","canonical_id":"hgnc:HGNC:49588","description":"CNTNAP3 pseudogene 5","metadata":null},{"id":"23091a14e7f8493389fd96d8d77c3cf9","type":"GENE","name":"CNTNAP3P6","canonical_id":"hgnc:HGNC:49583","description":"CNTNAP3 pseudogene 6","metadata":null},{"id":"1836659526a44976bdf5fbea7e7c80fb","type":"GENE","name":"CNTNAP3P7","canonical_id":"hgnc:HGNC:49585","description":"CNTNAP3 pseudogene 7","metadata":null},{"id":"8ea997e60de4465188fbf22d88ab2fcc","type":"GENE","name":"CNTNAP3P8","canonical_id":"hgnc:HGNC:49586","description":"CNTNAP3 pseudogene 8","metadata":null},{"id":"4590d9f7010f433785f0b7fa136649e7","type":"GENE","name":"CNTNAP3P9","canonical_id":"hgnc:HGNC:49587","description":"CNTNAP3 pseudogene 9","metadata":null},{"id":"88f272a38a6e41fab803f8e53922ddc6","type":"GENE","name":"CNTNAP4","canonical_id":"hgnc:HGNC:18747","description":"contactin associated protein family member 4","metadata":{"aliases":["CASPR4","KIAA1763"]}},{"id":"2a9081f6478b435ca78679d82f6aaa61","type":"GENE","name":"CNTNAP5","canonical_id":"hgnc:HGNC:18748","description":"contactin associated protein family member 5","metadata":{"aliases":["caspr5","FLJ31966"]}},{"id":"1cdf25988c2c46229a59c89447c8d3b3","type":"GENE","name":"CNTNAP5-DT","canonical_id":"hgnc:HGNC:55794","description":"CNTNAP5 divergent transcript","metadata":null},{"id":"27204888bdb94b5590d9f2819b457d49","type":"GENE","name":"CNTRL","canonical_id":"hgnc:HGNC:1858","description":"centriolin","metadata":{"aliases":["CEP1","CEP110"]}},{"id":"7ab9fe0ac1514d09b8fe34f88c8e5623","type":"GENE","name":"CNTROB","canonical_id":"hgnc:HGNC:29616","description":"centrobin, centriole duplication and spindle assembly protein","metadata":{"aliases":["LIP8","PP1221"]}},{"id":"36a9386d39af460eb7689c0c090ac548","type":"GO_TERM","name":"CO-methylating acetyl-CoA synthase activity","canonical_id":"go:GO:0043884","description":"\"Catalysis of the reaction: Co(I)-[corrinoid Fe-S protein] + acetyl-CoA + H+ = methyl-Co(III)-[corrinoid Fe-S protein] + CO + CoA.\" [PMID:1748656, RHEA:45212]","metadata":null},{"id":"578ce767b33f459cb96aa5249abb9d3b","type":"GENE","name":"COA1","canonical_id":"hgnc:HGNC:21868","description":"cytochrome c oxidase assembly factor 1","metadata":{"aliases":["FLJ10803","MITRAC15","C7orf44"]}},{"id":"6657bcf5855a4f7faa0b8f60f5d0f866","type":"GENE","name":"COA1P1","canonical_id":"hgnc:HGNC:56995","description":"COA1 pseudogene 1","metadata":null},{"id":"81182f50dd3f44cabe3034658fe9cbf8","type":"GENE","name":"COA3","canonical_id":"hgnc:HGNC:24990","description":"cytochrome c oxidase assembly factor 3","metadata":{"aliases":["HSPC009","MITRAC12","COX25","hCOA3","CCDC56"]}},{"id":"b047abd959b94d7b86ec9d90c46a606a","type":"GENE","name":"COA4","canonical_id":"hgnc:HGNC:24604","description":"cytochrome c oxidase assembly factor 4 homolog","metadata":{"aliases":["E2IG2","CMC3","CHCHD8"]}},{"id":"a03b025dcb7842eb85802e5ee473dbea","type":"GENE","name":"COA5","canonical_id":"hgnc:HGNC:33848","description":"cytochrome c oxidase assembly factor 5","metadata":{"aliases":["MGC52110","FLJ27524","Pet191","C2orf64"]}},{"id":"433ba4dbfd6b434daa26a40123440c2b","type":"GENE","name":"COA6","canonical_id":"hgnc:HGNC:18025","description":"cytochrome c oxidase assembly factor 6","metadata":{"aliases":["C1orf31"]}},{"id":"95324f9e378345ac8d93a1738656ea22","type":"GENE","name":"COA6-AS1","canonical_id":"hgnc:HGNC:40825","description":"COA6 antisense RNA 1","metadata":null},{"id":"4d4713f52ee8435aa9039a1fb743b032","type":"GENE","name":"COA7","canonical_id":"hgnc:HGNC:25716","description":"cytochrome c oxidase assembly factor 7","metadata":{"aliases":["FLJ12439","RESA1","C1orf163","SELRC1"]}},{"id":"6edb2f227c4c4c04b4366e85e31a5ddf","type":"GENE","name":"COA8","canonical_id":"hgnc:HGNC:20492","description":"cytochrome c oxidase assembly factor 8","metadata":{"aliases":["MGC2562","APOP-1","C14orf153","APOPT1"]}},{"id":"65c4a4978dc540e89a19b5415e72067f","type":"TRIAL","name":"COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study","canonical_id":"clinicaltrials.gov:NCT05724771","description":"Chronic Migraine, Headache","metadata":null},{"id":"607e5d36644744dbb06f78014902c091","type":"TRIAL","name":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","canonical_id":"clinicaltrials.gov:NCT06627530","description":"Prostate Cancer","metadata":null},{"id":"7b757f8a19134cf09a8d149e1e3fea59","type":"TRIAL","name":"COAST Study - Cholesterol Optimization After Stroke","canonical_id":"clinicaltrials.gov:NCT07256171","description":"Stroke (CVA) or Transient Ischemic Attack; Cerebral Hemorrhage","metadata":null},{"id":"9570ef1fcbf3408a80a163d79ec82712","type":"GENE","name":"COASY","canonical_id":"hgnc:HGNC:29932","description":"Coenzyme A synthase","metadata":{"aliases":["DPCK","NBP","PPAT"]}},{"id":"9d6420995c494914acc7a76a7b942ade","type":"GENE","name":"COBL","canonical_id":"hgnc:HGNC:22199","description":"cordon-bleu WH2 repeat protein","metadata":{"aliases":["KIAA0633"]}},{"id":"2d95a1a56a694f77b8eef554bf2e7c7b","type":"GENE","name":"COBLL1","canonical_id":"hgnc:HGNC:23571","description":"cordon-bleu WH2 repeat protein like 1","metadata":{"aliases":["KIAA0977"]}},{"id":"8fbe5b562f3b484da89ba1c91a534173","type":"GENE","name":"COBLP1","canonical_id":"hgnc:HGNC:55060","description":"COBL pseudogene 1","metadata":null},{"id":"46dd9e90d32c4f9490c08c92f075ddd3","type":"GENE","name":"COCH","canonical_id":"hgnc:HGNC:2180","description":"cochlin","metadata":{"aliases":["COCH-5B2","DFNA31","DFNA9"]}},{"id":"f2166cc21fce4490bd3f647632fba6e2","type":"GENE","name":"COCH-AS1","canonical_id":"hgnc:HGNC:58454","description":"COCH antisense RNA 1","metadata":null},{"id":"eca95440b96a42e1a8803d8fe303952e","type":"GO_TERM","name":"COG complex","canonical_id":"go:GO:0017119","description":"\"A multisubunit tethering complex of the CATCHR family (complexes associated with tethering containing helical rods) that has a role in tethering vesicles to the Golgi prior to fusion. Composed of 8 subunits COG1-8.\" [GOC:krc, PMID:11980916, PMID:20972446, PMID:9792665]","metadata":null},{"id":"336a2dc4eeb04e15978e982435d3c7a5","type":"GO_TERM","name":"COG complex binding","canonical_id":"go:GO:0140164","description":"\"Binding to a Golgi transport complex, a multisubunit tethering complex of the CATCHR family.\" [GOC:ha, PMID:28100664]","metadata":null},{"id":"ba807ce0e2d14e9ab1d52322d4878cca","type":"GENE","name":"COG1","canonical_id":"hgnc:HGNC:6545","description":"component of oligomeric golgi complex 1","metadata":{"aliases":["KIAA1381","LDLB"]}},{"id":"ed5977fd51ca4070a1e6c23a1301a36c","type":"GENE","name":"COG2","canonical_id":"hgnc:HGNC:6546","description":"component of oligomeric golgi complex 2","metadata":{"aliases":["LDLC"]}},{"id":"1ab07d9b1aba4425b343b53f725807be","type":"GENE","name":"COG3","canonical_id":"hgnc:HGNC:18619","description":"component of oligomeric golgi complex 3","metadata":{"aliases":["SEC34"]}},{"id":"267ecd785527444981aab38fead53659","type":"GENE","name":"COG4","canonical_id":"hgnc:HGNC:18620","description":"component of oligomeric golgi complex 4","metadata":{"aliases":["COD1","DKFZP586E1519"]}},{"id":"6b69b84c9bbd481c83073698fb5dba4c","type":"GENE","name":"COG5","canonical_id":"hgnc:HGNC:14857","description":"component of oligomeric golgi complex 5","metadata":{"aliases":["GTC90","GOLTC1"]}},{"id":"f10688040b234e4099ae3359921eb699","type":"GENE","name":"COG6","canonical_id":"hgnc:HGNC:18621","description":"component of oligomeric golgi complex 6","metadata":{"aliases":["COD2","KIAA1134"]}},{"id":"5ba3eee93b54499890303b8731306fdd","type":"GENE","name":"COG7","canonical_id":"hgnc:HGNC:18622","description":"component of oligomeric golgi complex 7","metadata":null},{"id":"8ec2decd032248708b0624294e5a2938","type":"GENE","name":"COG8","canonical_id":"hgnc:HGNC:18623","description":"component of oligomeric golgi complex 8","metadata":{"aliases":["FLJ22315","DOR1"]}},{"id":"17df0bf7a2844657ba932c79514b6b82","type":"GENE","name":"COIL","canonical_id":"hgnc:HGNC:2184","description":"coilin","metadata":{"aliases":["CLN80","p80-coilin"]}},{"id":"6e5b6f7d63ca4c9b97cba5abe58cf884","type":"GENE","name":"COILP1","canonical_id":"hgnc:HGNC:19927","description":"coilin pseudogene 1","metadata":{"aliases":["COILP"]}},{"id":"c385c4b7a7404de092fda03771a6b28a","type":"GENE","name":"COILP2","canonical_id":"hgnc:HGNC:25389","description":"coilin pseudogene 2","metadata":null},{"id":"9ab296008ff646699b4845fe9a469520","type":"GENE","name":"COL10A1","canonical_id":"hgnc:HGNC:2185","description":null,"metadata":null},{"id":"df56dcbf0fc5431c858404464728c4d4","type":"GENE","name":"COL11A1","canonical_id":"hgnc:HGNC:2186","description":null,"metadata":null},{"id":"8ea1fc1ca1b046ba8e9ba911ae32b9f0","type":"GENE","name":"COL11A2","canonical_id":"hgnc:HGNC:2187","description":null,"metadata":null},{"id":"7b64935b6157499f84b35a64e1762ae6","type":"GENE","name":"COL11A2-AS1","canonical_id":"hgnc:HGNC:59382","description":"COL11A2 antisense RNA 1","metadata":null},{"id":"d91ac0808ed3464f9211ee15b2693211","type":"GENE","name":"COL11A2P1","canonical_id":"hgnc:HGNC:13947","description":"collagen type XI alpha 2 pseudogene 1","metadata":{"aliases":["cD0826Q1.1","COL11A2P"]}},{"id":"0c5ce7592c074045b9ae266e4300a313","type":"GENE","name":"COL12A1","canonical_id":"hgnc:HGNC:2188","description":"collagen type XII alpha 1 chain","metadata":{"aliases":["COL12A1L"]}},{"id":"75977d62754d412e96c13da87c0f49b4","type":"GENE","name":"COL13A1","canonical_id":"hgnc:HGNC:2190","description":"collagen type XIII alpha 1 chain","metadata":null},{"id":"eb370ffc22f9435e960e767a5631b146","type":"GENE","name":"COL14A1","canonical_id":"hgnc:HGNC:2191","description":"collagen type XIV alpha 1 chain","metadata":{"aliases":["UND"]}},{"id":"173ad71017dd43d38e5aad65b9c4e63e","type":"GENE","name":"COL15A1","canonical_id":"hgnc:HGNC:2192","description":"collagen type XV alpha 1 chain","metadata":null},{"id":"99b6677f165a4b14a2e464d773a837af","type":"GENE","name":"COL15A1-AS1","canonical_id":"hgnc:HGNC:58152","description":"COL15A1 antisense RNA 1","metadata":{"aliases":["AL136084.3"]}},{"id":"4c98e0be8b4b424896f04b1b8b835c00","type":"GENE","name":"COL16A1","canonical_id":"hgnc:HGNC:2193","description":"collagen type XVI alpha 1 chain","metadata":null},{"id":"1bdd098f9c2c48468a26a6737e6c83af","type":"GENE","name":"COL17A1","canonical_id":"hgnc:HGNC:2194","description":"collagen type XVII alpha 1 chain","metadata":{"aliases":["BP180","BPAG2"]}},{"id":"56945c74541f407f87f6e695d425b7a1","type":"GENE","name":"COL18A1","canonical_id":"hgnc:HGNC:2195","description":null,"metadata":null},{"id":"c18c0f13af074bcab4070c89b9cf87a0","type":"GENE","name":"COL18A1-AS1","canonical_id":"hgnc:HGNC:23132","description":"COL18A1 antisense RNA 1","metadata":{"aliases":["PRED80","C21orf123","NCRNA00175"]}},{"id":"3074b8444af7471597a10a12b63893ea","type":"GENE","name":"COL18A1-AS2","canonical_id":"hgnc:HGNC:40155","description":"COL18A1 antisense RNA 2","metadata":null},{"id":"48431bbf7a1f47f9a25c88ddf5dc3c4c","type":"GENE","name":"COL19A1","canonical_id":"hgnc:HGNC:2196","description":"collagen type XIX alpha 1 chain","metadata":null},{"id":"69a2b65e8e4f4140af44dc3b2aa6ff63","type":"GENE","name":"COL1A1","canonical_id":"hgnc:HGNC:2197","description":null,"metadata":null},{"id":"b63fd7aec0e64cecb4ef63a9be609b26","type":"GENE","name":"COL1A2","canonical_id":"hgnc:HGNC:2198","description":null,"metadata":null},{"id":"f706af007ceb41648d56c20ddbe412ff","type":"GENE","name":"COL1A2-AS1","canonical_id":"hgnc:HGNC:53133","description":"COL1A2 antisense RNA 1","metadata":{"aliases":["TCONS_00013888","lncRNA8975-1"]}},{"id":"8dedae5702ae46719835d97aa07c9bf4","type":"GENE","name":"COL1AR","canonical_id":"hgnc:HGNC:2199","description":"collagen type I alpha receptor","metadata":null},{"id":"afe0e9b70c3d464ebce9c006dc88885b","type":"GENE","name":"COL20A1","canonical_id":"hgnc:HGNC:14670","description":"collagen type XX alpha 1 chain","metadata":{"aliases":["KIAA1510"]}},{"id":"da13e9dd483346a083abe302adf6f62d","type":"GENE","name":"COL21A1","canonical_id":"hgnc:HGNC:17025","description":"collagen type XXI alpha 1 chain","metadata":null},{"id":"49276021b26d4deaa5352ceb5ef94640","type":"GENE","name":"COL22A1","canonical_id":"hgnc:HGNC:22989","description":"collagen type XXII alpha 1 chain","metadata":null},{"id":"a065bbbc703d4bf1bb8f59b5ed9642b9","type":"GENE","name":"COL23A1","canonical_id":"hgnc:HGNC:22990","description":"collagen type XXIII alpha 1 chain","metadata":{"aliases":["DKFZp434K0621"]}},{"id":"be741fd0d4f141ab802901faee27286b","type":"GENE","name":"COL23A1-AS1","canonical_id":"hgnc:HGNC:41005","description":"COL23A1 antisense RNA 1","metadata":null},{"id":"03b448263bf64b52a3cdc6f5cfbdfb1b","type":"GENE","name":"COL23A1-AS2","canonical_id":"hgnc:HGNC:59315","description":"COL23A1 antisense RNA 2","metadata":null},{"id":"97e2779c96b445e1a48a1af6d6fff0b6","type":"GENE","name":"COL23A1-AS3","canonical_id":"hgnc:HGNC:59316","description":"COL23A1 antisense RNA 3","metadata":null},{"id":"cc6705033c3a4850a1f2c5c8af02182c","type":"GENE","name":"COL23A1-AS4","canonical_id":"hgnc:HGNC:59317","description":"COL23A1 antisense RNA 4","metadata":null},{"id":"bef1fe68628d438fb0766e3a1d1290fb","type":"GENE","name":"COL24A1","canonical_id":"hgnc:HGNC:20821","description":"collagen type XXIV alpha 1 chain","metadata":null},{"id":"2d07ef61fc714e27a1fd8547e11f896c","type":"GENE","name":"COL25A1","canonical_id":"hgnc:HGNC:18603","description":"collagen type XXV alpha 1 chain","metadata":null},{"id":"97ffdd4a0f32464a83e577063ad021bb","type":"GENE","name":"COL25A1-AS1","canonical_id":"hgnc:HGNC:58867","description":"COL25A1 antisense RNA 1","metadata":null},{"id":"b912d96ab7e5460a931e5388f05b600b","type":"GENE","name":"COL25A1-AS2","canonical_id":"hgnc:HGNC:58868","description":"COL25A1 antisense RNA 2","metadata":null},{"id":"f713d935bc974757bc0cf2232e0dad63","type":"GENE","name":"COL25A1-DT","canonical_id":"hgnc:HGNC:32963","description":"COL25A1 divergent transcript","metadata":{"aliases":["FLJ45231","ZCCHC23"]}},{"id":"5eb56bfcc8da4beabdd32696583c34de","type":"GENE","name":"COL26A1","canonical_id":"hgnc:HGNC:18038","description":"collagen type XXVI alpha 1 chain","metadata":{"aliases":["Emu2","EMI6","EMID2"]}},{"id":"0b3ab0d1e6f442ea99f685fd99d0320a","type":"GENE","name":"COL27A1","canonical_id":"hgnc:HGNC:22986","description":"collagen type XXVII alpha 1 chain","metadata":{"aliases":["KIAA1870","MGC11337","FLJ11895"]}},{"id":"9f6272221e264758b0e8a1fb06498eb8","type":"GENE","name":"COL28A1","canonical_id":"hgnc:HGNC:22442","description":"collagen type XXVIII alpha 1 chain","metadata":null},{"id":"1dd91fb3a090414fa23a479114ae41de","type":"GENE","name":"COL2A1","canonical_id":"hgnc:HGNC:2200","description":null,"metadata":null},{"id":"083f8d9457394c89942fcce557301626","type":"GENE","name":"COL3A1","canonical_id":"hgnc:HGNC:2201","description":"collagen type III alpha 1 chain","metadata":{"aliases":["EDS4A"]}},{"id":"65dc0508ca534c56a404295926c14dcf","type":"GENE","name":"COL4A1","canonical_id":"hgnc:HGNC:2202","description":null,"metadata":null},{"id":"d984a493f32d43a48aa9c221691aa99c","type":"GENE","name":"COL4A2","canonical_id":"hgnc:HGNC:2203","description":null,"metadata":null},{"id":"5a12551806bb4ebd9b4d255f1b803069","type":"GENE","name":"COL4A2-AS1","canonical_id":"hgnc:HGNC:40156","description":"COL4A2 antisense RNA 1","metadata":null},{"id":"84256852e3164f1499a5824e7be08347","type":"GENE","name":"COL4A2-AS2","canonical_id":"hgnc:HGNC:39849","description":"COL4A2 antisense RNA 2","metadata":null},{"id":"07d9424828fa428c9fdb56471957f55f","type":"GENE","name":"COL4A3","canonical_id":"hgnc:HGNC:2204","description":null,"metadata":null},{"id":"d3e74411de6c4e9b9089c6aa041565d3","type":"GENE","name":"COL4A4","canonical_id":"hgnc:HGNC:2206","description":null,"metadata":null},{"id":"fad7f9153fa84bdca508182b69dbc862","type":"GENE","name":"COL4A5","canonical_id":"hgnc:HGNC:2207","description":"collagen type IV alpha 5 chain","metadata":{"aliases":["ASLN","ATS"]}},{"id":"e9dea105fea445a3a17b710e44615b49","type":"GENE","name":"COL4A6","canonical_id":"hgnc:HGNC:2208","description":"collagen type IV alpha 6 chain","metadata":null},{"id":"4efcdd1cb10a409a9041b1e6afe6f2ff","type":"GENE","name":"COL5A1","canonical_id":"hgnc:HGNC:2209","description":"collagen type V alpha 1 chain","metadata":null},{"id":"02593c3499d74a5db406860eaf5c19cc","type":"GENE","name":"COL5A1-AS1","canonical_id":"hgnc:HGNC:31368","description":"COL5A1 antisense RNA 1","metadata":{"aliases":["bA54A22.4","C9orf104"]}},{"id":"ac8a6d10e3fe49ddb3a5461546e0a5dc","type":"GENE","name":"COL5A2","canonical_id":"hgnc:HGNC:2210","description":"collagen type V alpha 2 chain","metadata":null},{"id":"e37aa9373fa24f54b5cea9037c610494","type":"GENE","name":"COL5A3","canonical_id":"hgnc:HGNC:14864","description":"collagen type V alpha 3 chain","metadata":null},{"id":"0be2b59fb28841da862a04e946756238","type":"GENE","name":"COL6A1","canonical_id":"hgnc:HGNC:2211","description":"collagen type VI alpha 1 chain","metadata":null},{"id":"962ccb164ba34f0a86537ed8eeaedd2a","type":"GENE","name":"COL6A2","canonical_id":"hgnc:HGNC:2212","description":"collagen type VI alpha 2 chain","metadata":null},{"id":"4f909b7a6d3e415d9b71af4aebe54c73","type":"GENE","name":"COL6A2-DT","canonical_id":"hgnc:HGNC:55814","description":"COL6A2 divergent transcript","metadata":null},{"id":"9fc9c903f4aa4043b7b4627666382684","type":"GENE","name":"COL6A3","canonical_id":"hgnc:HGNC:2213","description":"collagen type VI alpha 3 chain","metadata":null},{"id":"e03880dcaa404170957c30a2b3671f64","type":"GENE","name":"COL6A4P1","canonical_id":"hgnc:HGNC:33484","description":"collagen type VI alpha 4 pseudogene 1","metadata":{"aliases":["VWA6","DIVA","COL6A4","COL6A4P","DVWA"]}},{"id":"81f5c03f41014351bee9e8a1cb2d30f3","type":"GENE","name":"COL6A4P2","canonical_id":"hgnc:HGNC:38501","description":"collagen type VI alpha 4 pseudogene 2","metadata":{"aliases":["COL6A4"]}},{"id":"f18c92083e5e479eaac6aa7045f72d7f","type":"GENE","name":"COL6A5","canonical_id":"hgnc:HGNC:26674","description":"collagen type VI alpha 5 chain","metadata":{"aliases":["FLJ35880","VWA4","COL29A1"]}},{"id":"e927e58795b44f5abc306bb2b0795429","type":"GENE","name":"COL6A6","canonical_id":"hgnc:HGNC:27023","description":"collagen type VI alpha 6 chain","metadata":null},{"id":"acde379587a94913b1996464a58bc3c3","type":"GENE","name":"COL7A1","canonical_id":"hgnc:HGNC:2214","description":null,"metadata":null},{"id":"849e80a8f02b4f1a8ddc46a7b28f298f","type":"GENE","name":"COL8A1","canonical_id":"hgnc:HGNC:2215","description":"collagen type VIII alpha 1 chain","metadata":{"aliases":["MGC9568","C3orf7"]}},{"id":"35190768e2da430c9955025cff0a0812","type":"GENE","name":"COL8A2","canonical_id":"hgnc:HGNC:2216","description":"collagen type VIII alpha 2 chain","metadata":{"aliases":["PPCD","FECD1","PPCD2","FECD"]}},{"id":"edb6bf038f6146329e4e38fb417d552a","type":"GENE","name":"COL9A1","canonical_id":"hgnc:HGNC:2217","description":"collagen type IX alpha 1 chain","metadata":null},{"id":"5db02dc7887545ec971ed38f201f0959","type":"GENE","name":"COL9A2","canonical_id":"hgnc:HGNC:2218","description":"collagen type IX alpha 2 chain","metadata":{"aliases":["MED","EDM2"]}},{"id":"1954982834364e3cac6234568be0934d","type":"GENE","name":"COL9A3","canonical_id":"hgnc:HGNC:2219","description":"collagen type IX alpha 3 chain","metadata":{"aliases":["IDD","MED","EDM3","FLJ90759","DJ885L7.4.1"]}},{"id":"066bfc060fe348aa90dda7003321bac4","type":"GENE","name":"COLCA1","canonical_id":"hgnc:HGNC:33789","description":"colorectal cancer associated 1","metadata":{"aliases":["FLJ45803","CASC12","C11orf92"]}},{"id":"b82bccbca1b7494ab789d19b5b7bc983","type":"GENE","name":"COLEC10","canonical_id":"hgnc:HGNC:2220","description":"collectin subfamily member 10","metadata":{"aliases":["CL-L1","CL-10"]}},{"id":"ad35bb18ddf94da196a9f130756995ae","type":"GENE","name":"COLEC11","canonical_id":"hgnc:HGNC:17213","description":"collectin subfamily member 11","metadata":{"aliases":["MGC3279","CL-K1","CL-11"]}},{"id":"2221c4e7bf444098851e3cf1f207087c","type":"GENE","name":"COLEC12","canonical_id":"hgnc:HGNC:16016","description":"collectin subfamily member 12","metadata":{"aliases":["SRCL","CL-P1","SCARA4"]}},{"id":"bab446ce708b45d984acbfb56ce05b40","type":"GENE","name":"COLGALT1","canonical_id":"hgnc:HGNC:26182","description":"collagen beta(1-O)galactosyltransferase 1","metadata":{"aliases":["FLJ22329","GLT25D1"]}},{"id":"5eec1e44d1854760bdde71de483945d5","type":"GENE","name":"COLGALT2","canonical_id":"hgnc:HGNC:16790","description":"collagen beta(1-O)galactosyltransferase 2","metadata":{"aliases":["KIAA0584","C1orf17","GLT25D2"]}},{"id":"bd80baf48fc4415da07ceca33e34e47e","type":"GENE","name":"COLQ","canonical_id":"hgnc:HGNC:2226","description":"collagen like tail subunit of asymmetric acetylcholinesterase","metadata":{"aliases":["EAD"]}},{"id":"5f632fa10b1240ecaf4440ffe8a49891","type":"TRIAL","name":"COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease","canonical_id":"clinicaltrials.gov:NCT05873881","description":"Heart Failure","metadata":null},{"id":"58b3dea358c246a987bb57b5a803535f","type":"GO_TERM","name":"COMA complex","canonical_id":"go:GO:0000817","description":"\"A kinetochore multiprotein complex that bridges the subunits that are in contact with centromeric DNA and the subunits bound to microtubules during kinetochore assembly. In yeast, consists of Ctf19p, Okp1p, Mcm21p, and Ame1p.\" [GOC:se, PMID:14633972]","metadata":null},{"id":"88aae48bcf57474186b57b8f8a82947b","type":"GENE","name":"COMETT","canonical_id":"hgnc:HGNC:51196","description":"cytosolic oncogenic antisense to MET transcript","metadata":{"aliases":["COMET","LINC01510"]}},{"id":"e34707bcafd549ef81cba80fbebd3bfd","type":"GENE","name":"COMMD1","canonical_id":"hgnc:HGNC:23024","description":"copper metabolism domain containing 1","metadata":{"aliases":["MURR1","MGC27155","C2orf5"]}},{"id":"214c80db73fe4c1783ab808e24b7c047","type":"GENE","name":"COMMD10","canonical_id":"hgnc:HGNC:30201","description":"COMM domain containing 10","metadata":{"aliases":["PTD002"]}},{"id":"7a5e17337e35480c8d04e9ccab33d9ad","type":"GENE","name":"COMMD10-AS1","canonical_id":"hgnc:HGNC:58400","description":"COMMD10 antisense RNA 1","metadata":null},{"id":"bd0f003e205744d2a61a588e5ea2d50a","type":"GENE","name":"COMMD10-AS2","canonical_id":"hgnc:HGNC:59118","description":"COMMD10 antisense RNA 2","metadata":null},{"id":"2cf52792eaa64f0389e6e7558a97e496","type":"GENE","name":"COMMD2","canonical_id":"hgnc:HGNC:24993","description":"COMM domain containing 2","metadata":{"aliases":["HSPC042"]}},{"id":"7259aada54eb449dba8940d3bed90c5e","type":"GENE","name":"COMMD3","canonical_id":"hgnc:HGNC:23332","description":"COMM domain containing 3","metadata":{"aliases":["BUP","C10orf8"]}},{"id":"085590efe4124c51887640877ae10b4a","type":"GENE","name":"COMMD3-BMI1","canonical_id":"hgnc:HGNC:48326","description":"COMMD3-BMI1 readthrough","metadata":null},{"id":"38f4f4fad7b641cbb47dd1d80c84e9fe","type":"GENE","name":"COMMD4","canonical_id":"hgnc:HGNC:26027","description":"COMM domain containing 4","metadata":{"aliases":["FLJ20452"]}},{"id":"90f148edca7a477f8aa1cbce464e43f6","type":"GENE","name":"COMMD4P1","canonical_id":"hgnc:HGNC:51909","description":"COMM domain containing 4 pseudogene 1","metadata":null},{"id":"a07f4276396547bf912b4023f8b8b1ea","type":"GENE","name":"COMMD4P2","canonical_id":"hgnc:HGNC:51910","description":"COMM domain containing 4 pseudogene 2","metadata":null},{"id":"f71d272bf8b24f3182b1fd5e7a2a3aaa","type":"GENE","name":"COMMD5","canonical_id":"hgnc:HGNC:17902","description":"COMM domain containing 5","metadata":{"aliases":["HT002","FLJ13008","HCaRG"]}},{"id":"969db06371584b79b5c2f556b536549e","type":"GENE","name":"COMMD5P1","canonical_id":"hgnc:HGNC:56190","description":"COMMD5 pseudogene 1","metadata":null},{"id":"eb6f50f3f9944a8d91da9893c81163f5","type":"GENE","name":"COMMD6","canonical_id":"hgnc:HGNC:24015","description":"COMM domain containing 6","metadata":{"aliases":["Acrg"]}},{"id":"1e8aeea665394713ba8410ee83d5dc47","type":"GENE","name":"COMMD6P1","canonical_id":"hgnc:HGNC:58500","description":"COMMD6 pseudogene 1","metadata":null},{"id":"2af2c21c26af452cb762b03601f03512","type":"GENE","name":"COMMD7","canonical_id":"hgnc:HGNC:16223","description":"COMM domain containing 7","metadata":{"aliases":["dJ1085F17.3","C20orf92"]}},{"id":"92260f4644e54b949fe795609186bb07","type":"GENE","name":"COMMD8","canonical_id":"hgnc:HGNC:26036","description":"COMM domain containing 8","metadata":{"aliases":["FLJ20502"]}},{"id":"f34852b385b94dafb8f64f00c11af299","type":"GENE","name":"COMMD8-DT","canonical_id":"hgnc:HGNC:58765","description":"COMMD8 divergent transcript","metadata":null},{"id":"cb41a3ed05bd4d53a1e114ef3393cc5a","type":"GENE","name":"COMMD9","canonical_id":"hgnc:HGNC:25014","description":"COMM domain containing 9","metadata":{"aliases":["HSPC166","FLJ31106"]}},{"id":"66e4ecdf4b9943fda136e278fdadcb68","type":"TRIAL","name":"COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities","canonical_id":"clinicaltrials.gov:NCT07245680","description":"Pulmonary Arterial Hypertension (PAH); Comorbidities; Cardiovascular Disease (CVD)","metadata":null},{"id":"c377da6ca8ca4606bd8a7277118ef31c","type":"GENE","name":"COMP","canonical_id":"hgnc:HGNC:2227","description":null,"metadata":null},{"id":"c53df425554a487cbd9bc7efb64928f5","type":"TRIAL","name":"COMPARISON OF EFFICACY OF DIFFERENT DRUG COMBINATIONS IN ACUTE SCIATICA","canonical_id":"clinicaltrials.gov:NCT05626140","description":"Sciatica Acute; Sciatica","metadata":null},{"id":"73c6f83a1cc746bd8b8f124bd294567f","type":"TRIAL","name":"COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI","canonical_id":"clinicaltrials.gov:NCT05790902","description":"Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi","metadata":null},{"id":"44068e99bbec4535af2e478fe4edac2c","type":"GENE","name":"COMT","canonical_id":"hgnc:HGNC:2228","description":"catechol-O-methyltransferase","metadata":null},{"id":"07803e20d5e845dcaa45390e16d42688","type":"PROTEIN","name":"COMT","canonical_id":"uniprot:P21964","description":null,"metadata":null},{"id":"581ef432359e45b49961a42c29734fe4","type":"TRIAL","name":"COMT Inhibition Among Individuals With Comorbid AUD/ADHD","canonical_id":"clinicaltrials.gov:NCT03904498","description":"Alcohol Use Disorder; Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"d843d1f8597741a0957e02088fa54f7e","type":"TRIAL","name":"COMT Polymorphism and Entacapone Efficacy","canonical_id":"clinicaltrials.gov:NCT00373087","description":"Parkinson's Disease","metadata":null},{"id":"11d5a257d6b545a8952a28a7c6cf0bb9","type":"GENE","name":"COMTD1","canonical_id":"hgnc:HGNC:26309","description":"catechol-O-methyltransferase domain containing 1","metadata":{"aliases":["FLJ23841"]}},{"id":"65cf452f6b324713911802a55a5cd4fc","type":"TRIAL","name":"COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"","canonical_id":"clinicaltrials.gov:NCT07281027","description":"New Onset Refractory Status Epilepticus; New-Onset Refractory Status Epilepticus; Febrile Infection-Related Epilepsy Syndrome (FIRES)","metadata":null},{"id":"2ab671c0fd744543beb4fa5c5efb099c","type":"GENE","name":"COP1-DT","canonical_id":"hgnc:HGNC:55666","description":"COP1 divergent transcript","metadata":null},{"id":"da31b4c6ebcf44a490c1c95094d58179","type":"GENE","name":"COP1P1","canonical_id":"hgnc:HGNC:31900","description":"COP1 pseudogene 1","metadata":{"aliases":["RFWD2P","RFWD2P1"]}},{"id":"115bd7c58f0e49fcb2d1fd19b876aaf6","type":"GO_TERM","name":"COP9 signalosome","canonical_id":"go:GO:0008180","description":"\"A protein complex that catalyzes the deneddylation of proteins, including the cullin component of SCF ubiquitin E3 ligase; deneddylation increases the activity of cullin family ubiquitin ligases. The signalosome is involved in many regulatory process, including some which control development, in many species; also regulates photomorphogenesis in plants; in many species its subunits are highly similar to those of the proteasome.\" [PMID:11019806, PMID:12186635, PMID:14570571]","metadata":null},{"id":"1b86fa4f46574075be1e141b4c0ecbf0","type":"GO_TERM","name":"COP9 signalosome assembly","canonical_id":"go:GO:0010387","description":"\"The aggregation, arrangement and bonding together of a set of components to form a COP9 signalosome.\" [PMID:17307927]","metadata":null},{"id":"6a73f13fae5c45b89031a8f0385b3fdb","type":"GENE","name":"COPA","canonical_id":"hgnc:HGNC:2230","description":"coat protein complex I subunit alpha","metadata":{"aliases":["HEP-COP","alpha-COP"]}},{"id":"a6bfa05633554417b24d67ed44a33bd8","type":"GENE","name":"COPB1","canonical_id":"hgnc:HGNC:2231","description":"coat protein complex I subunit beta 1","metadata":{"aliases":["COPB"]}},{"id":"d751951eba2e455488f943e35f1532a3","type":"GENE","name":"COPB2","canonical_id":"hgnc:HGNC:2232","description":"coat protein complex I subunit beta 2","metadata":{"aliases":["beta'-COP","betaprime-COP"]}},{"id":"a7eb47de096f4504a570a72426e67573","type":"GENE","name":"COPB2-DT","canonical_id":"hgnc:HGNC:55579","description":"COPB2 divergent transcript","metadata":{"aliases":["RP11-319G6.1"]}},{"id":"1dd9d41726474ea7962f35aa3670e509","type":"GENE","name":"COPDA1","canonical_id":"hgnc:HGNC:53171","description":"chronic obstructive pulmonary disease associated lncRNA 1","metadata":{"aliases":["RP11-731F5.2"]}},{"id":"12eb919d58b84bf686657f237a0f64b9","type":"GENE","name":"COPE","canonical_id":"hgnc:HGNC:2234","description":"coat protein complex I subunit epsilon","metadata":{"aliases":["epsilon-COP"]}},{"id":"cf8e00cb7ef4449e9aa17511b3af9d02","type":"GENE","name":"COPG1","canonical_id":"hgnc:HGNC:2236","description":"coat protein complex I subunit gamma 1","metadata":{"aliases":["COPG"]}},{"id":"7e8056783c664ad694c8eca7095d352d","type":"GENE","name":"COPG2","canonical_id":"hgnc:HGNC:2237","description":"coat protein complex I subunit gamma 2","metadata":{"aliases":["2-COP"]}},{"id":"23aa6ca492b945c5ac9cedffa96ba3a7","type":"GENE","name":"COPG2IT1","canonical_id":"hgnc:HGNC:2238","description":"COPG2 imprinted transcript 1","metadata":{"aliases":["CIT1","NCRNA00170","COPG2AS"]}},{"id":"a23133acc88a4822ab6deac135677b7d","type":"GO_TERM","name":"COPI coating of Golgi vesicle","canonical_id":"go:GO:0048205","description":"\"The addition of COPI proteins and adaptor proteins to Golgi membranes during the formation of transport vesicles, forming a vesicle coat.\" [GOC:jid, GOC:mah, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"91a1b90fe4ee48929866a192864209b1","type":"GO_TERM","name":"COPI coating of Golgi vesicle, cis-Golgi to rough ER","canonical_id":"go:GO:0010788","description":"\"The addition of COPI proteins and adaptor proteins to Golgi membranes during the formation of cis-Golgi to rough ER transport vesicles, forming a vesicle coat.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1db07c4a0d6a4726af11714f7429472a","type":"GO_TERM","name":"COPI coating of Golgi vesicle, inter-Golgi cisterna","canonical_id":"go:GO:0010787","description":"\"The addition of COPI proteins and adaptor proteins to Golgi membranes during the formation of inter-Golgi cisterna transport vesicles, forming a vesicle coat.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9716b3fed17f4535aa32cfbe3c796b40","type":"GO_TERM","name":"COPI vesicle coat","canonical_id":"go:GO:0030126","description":"\"One of two multimeric complexes that forms a membrane vesicle coat. The mammalian COPI subunits are called alpha-, beta-, beta'-, gamma-, delta-, epsilon- and zeta-COP. Vesicles with COPI coats are found associated with Golgi membranes at steady state.\" [GOC:mah, PMID:11252894]","metadata":null},{"id":"638bf1974a63472dade0ec0972e53b56","type":"GO_TERM","name":"COPI-coated Golgi to ER transport vesicle","canonical_id":"go:GO:0030142","description":"\"A vesicle that mediates transport from the Golgi to the endoplasmic reticulum.\" [GOC:mah, PMID:22160157]","metadata":null},{"id":"2f88722cd1094ff5ba51254a84b2e214","type":"GO_TERM","name":"COPI-coated inter-Golgi transport vesicle","canonical_id":"go:GO:0030143","description":"\"A vesicle that mediates transport of cargo within the Golgi complex (for example, between cisternae of the Golgi stack).\" [GOC:mah]","metadata":null},{"id":"44bb427989794807868653c11704d34b","type":"GO_TERM","name":"COPI-coated vesicle","canonical_id":"go:GO:0030137","description":"\"A vesicle with a coat formed of the COPI coat complex proteins. COPI-coated vesicles are found associated with Golgi membranes at steady state, are involved in Golgi to endoplasmic reticulum (retrograde) vesicle transport, and possibly also in intra-Golgi transport.\" [GOC:mah, PMID:11252894]","metadata":null},{"id":"8bde2be6b0004856a469d111d7b940cc","type":"GO_TERM","name":"COPI-coated vesicle budding","canonical_id":"go:GO:0035964","description":"\"The evagination of a Golgi membrane, resulting in formation of a COPI-coated vesicle.\" [GOC:br, PMID:10052452, PMID:17041781]","metadata":null},{"id":"daceeb642d354fdf9109f34a18f2cd56","type":"GO_TERM","name":"COPI-coated vesicle lumen","canonical_id":"go:GO:0106172","description":"\"The volume enclosed by the membrane of a COPI-coated endocytic vesicle.\" [GOC:pde, PMID:29535154]","metadata":null},{"id":"a5e5192aaf234fa3a42a3df6194743bd","type":"GO_TERM","name":"COPI-coated vesicle membrane","canonical_id":"go:GO:0030663","description":"\"The lipid bilayer surrounding a COPI-coated vesicle.\" [GOC:mah]","metadata":null},{"id":"2504ddb1c9274527bbdf57e87dc66267","type":"GO_TERM","name":"COPII receptor activity","canonical_id":"go:GO:0097020","description":"\"Binding specifically to a substance (cargo) to deliver it to a COPII transport vesicle. Cargo receptors span a membrane (either the plasma membrane or a vesicle membrane), binding simultaneously to cargo molecules and coat adaptors, to efficiently recruit soluble proteins to nascent vesicles.\" [GOC:rb, PMID:16957051, PMID:20236934]","metadata":null},{"id":"8fc14050ff3c4e5bb1c0bb5debf159b1","type":"GO_TERM","name":"COPII vesicle coat","canonical_id":"go:GO:0030127","description":"\"One of two multimeric complexes that forms a membrane vesicle coat. COPII is best characterized in S. cerevisiae, where the subunits are called Sar1p, Sec13p, Sec31p, Sec23p, and Sec24p. Vesicles with COPII coats are found associated with endoplasmic reticulum (ER) membranes at steady state.\" [GOC:ascb_2009, GOC:dph, GOC:mah, GOC:tb, PMID:11252894]","metadata":null},{"id":"de877e5b70b44b11bb66f9073c705dcb","type":"GO_TERM","name":"COPII vesicle coat assembly","canonical_id":"go:GO:0048208","description":"\"The addition of COPII proteins and adaptor proteins to ER membranes during the formation of transport vesicles, forming a vesicle coat.\" [GOC:ascb_2009, GOC:dph, GOC:jid, GOC:mah, GOC:tb, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"f0049ff900c4466e876f19804adb02e4","type":"GO_TERM","name":"COPII vesicle uncoating","canonical_id":"go:GO:0090112","description":"\"The process in which COPII vesicle coat proteins are disassembled, and released.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d1e6397f7f2c43359e9fb4d353fd6e8c","type":"GO_TERM","name":"COPII vesicles tethering complex","canonical_id":"go:GO:0106103","description":"\"A protein complex that resides in the cis-golgi membrane and plays a role in the tethering of COPII vesicles, through an interaction with vesicle tethering proteins (p115 in H. Sapiens and Uso1 S. cerevisiae), granting the cis-Golgi and endoplasmic reticulum to Golgi vesicle-mediated transport. It is composed by GRASP65 and GM130 protein in H. sapiens and by Bug1 and Grh1 proteins in S. cerevisiae.\" [GOC:lnp, PMID:21482742, PMID:9628863]","metadata":null},{"id":"19bf178a31c8484b8825b0d8a9dd0043","type":"GO_TERM","name":"COPII-coated ER to Golgi transport vesicle","canonical_id":"go:GO:0030134","description":"\"A vesicle with a coat formed of the COPII coat complex proteins. The COPII coat complex is formed by the Sec23p/Sec24p and the Sec13p/Sec31p heterodimers. COPII-associated vesicles transport proteins from the rough endoplasmic reticulum to the Golgi apparatus (anterograde transport).\" [PMID:11252894, PMID:17499046, PMID:22160157, PMID:8004676, Wikipedia:COPII]","metadata":null},{"id":"d815b9d9cc624487894c8700d229adbb","type":"GO_TERM","name":"COPII-coated vesicle budding","canonical_id":"go:GO:0090114","description":"\"The evagination of an endoplasmic reticulum membrane, resulting in formation of a COPII-coated vesicle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"c958e0df9dca483eafc6c92b529ae7ab","type":"GO_TERM","name":"COPII-coated vesicle cargo loading","canonical_id":"go:GO:0090110","description":"\"The formation of a macromolecular complex between the COPII coat proteins and proteins and/or lipoproteins that are going to be transported by the COPII vesicle to the Golgi.\" [GOC:ascb_2009, GOC:dph, GOC:lb, GOC:tb]","metadata":null},{"id":"a84ed9d2e96040aeaea12cad0a815d2a","type":"GO_TERM","name":"COPII-coated vesicle lumen","canonical_id":"go:GO:0106173","description":"\"The volume enclosed by the membrane of a COPII-coated endocytic vesicle.\" [GOC:pde, PMID:21172817]","metadata":null},{"id":"a3f9bb87e0fe44b5830f720baf073180","type":"GENE","name":"COPRS","canonical_id":"hgnc:HGNC:28848","description":"coordinator of PRMT5 and differentiation stimulator","metadata":{"aliases":["TTP1","HSA272196","COPR5","C17orf79"]}},{"id":"5f83e0b007c74b038e4bb9f3982e2731","type":"GENE","name":"COPRSP1","canonical_id":"hgnc:HGNC:54677","description":"COPRS pseudogene 1","metadata":null},{"id":"989295efa30e4579a224d8b7b35d2dc0","type":"GENE","name":"COPS2","canonical_id":"hgnc:HGNC:30747","description":"COP9 signalosome subunit 2","metadata":{"aliases":["TRIP15","ALIEN","CSN2"]}},{"id":"e4c445e6db92487ebdfb02411f0aaee6","type":"GENE","name":"COPS3","canonical_id":"hgnc:HGNC:2239","description":"COP9 signalosome subunit 3","metadata":{"aliases":["SGN3","CSN3"]}},{"id":"12427a69bf094aba93f80427fd298fd1","type":"GENE","name":"COPS3P1","canonical_id":"hgnc:HGNC:56728","description":"COPS3 pseudogene 1","metadata":null},{"id":"8c4905e1deda4c7fb43a803d3a811114","type":"GENE","name":"COPS4","canonical_id":"hgnc:HGNC:16702","description":"COP9 signalosome subunit 4","metadata":{"aliases":["CSN4","SGN4"]}},{"id":"81c42e5195ea4980b71d836867ea9f36","type":"GENE","name":"COPS5","canonical_id":"hgnc:HGNC:2240","description":null,"metadata":null},{"id":"8659513e980b4e4890cd3175add670ef","type":"GENE","name":"COPS5P1","canonical_id":"hgnc:HGNC:24332","description":"COP9 signalosome subunit 5 pseudogene 1","metadata":{"aliases":["COPS5P"]}},{"id":"3849fff4b0094737a94e4ca5838e053a","type":"GENE","name":"COPS5P2","canonical_id":"hgnc:HGNC:45266","description":"COP9 signalosome subunit 5 pseudogene 2","metadata":null},{"id":"4d982a5b71664a57a0a75a8cab6beeca","type":"GENE","name":"COPS6","canonical_id":"hgnc:HGNC:21749","description":"COP9 signalosome subunit 6","metadata":{"aliases":["MOV34-34KD","CSN6"]}},{"id":"84ed7f53c6d54480a898015121641b7d","type":"GENE","name":"COPS7A","canonical_id":"hgnc:HGNC:16758","description":"COP9 signalosome subunit 7A","metadata":{"aliases":["CSN7A"]}},{"id":"e3fee07624c3439da3be2e789c2b21e1","type":"GENE","name":"COPS7B","canonical_id":"hgnc:HGNC:16760","description":"COP9 signalosome subunit 7B","metadata":{"aliases":["CSN7B"]}},{"id":"b69a997ca28741a593f31c70e176dc3f","type":"GENE","name":"COPS8","canonical_id":"hgnc:HGNC:24335","description":"COP9 signalosome subunit 8","metadata":{"aliases":["COP9","CSN8","MGC1297","SGN8"]}},{"id":"9c6d3a77d88b45319e43be6cc0405f2f","type":"GENE","name":"COPS8-DT","canonical_id":"hgnc:HGNC:55816","description":"COPS8 divergent transcript","metadata":null},{"id":"fdc536a8402a46c3b838426bc3fe2065","type":"GENE","name":"COPS8P1","canonical_id":"hgnc:HGNC:45269","description":"COP9 signalosome subunit 8 pseudogene 1","metadata":null},{"id":"2bad5ac7ce5d4559b9504710e096364c","type":"GENE","name":"COPS8P2","canonical_id":"hgnc:HGNC:45270","description":"COP9 signalosome subunit 8 pseudogene 2","metadata":null},{"id":"103dde97d529429d9a0a4741ec2ffcd1","type":"GENE","name":"COPS8P3","canonical_id":"hgnc:HGNC:45271","description":"COP9 signalosome subunit 8 pseudogene 3","metadata":null},{"id":"84b63bfdf9f3458997f5ab0c0fb45658","type":"GENE","name":"COPS9","canonical_id":"hgnc:HGNC:21314","description":"COP9 signalosome subunit 9","metadata":{"aliases":["CSNAP","MYEOV2"]}},{"id":"cca8956fb8ec40a58d5c8a189a51e99d","type":"GENE","name":"COPZ1","canonical_id":"hgnc:HGNC:2243","description":"coat protein complex I subunit zeta 1","metadata":{"aliases":["CGI-120","COPZ"]}},{"id":"c300db0a5ca94bb58118d82cc44dafc8","type":"GENE","name":"COPZ2","canonical_id":"hgnc:HGNC:19356","description":"coat protein complex I subunit zeta 2","metadata":{"aliases":["MGC23008"]}},{"id":"d8c9477e122d40378a348335503a6540","type":"GENE","name":"COQ10A","canonical_id":"hgnc:HGNC:26515","description":"coenzyme Q10A","metadata":{"aliases":["FLJ32452"]}},{"id":"747937a44328401bb3a5bf4fcd5a7696","type":"GENE","name":"COQ10B","canonical_id":"hgnc:HGNC:25819","description":"coenzyme Q10B","metadata":{"aliases":["FLJ13448"]}},{"id":"056e9bf0b12347e8b8c8f642984cd94e","type":"GENE","name":"COQ10BP1","canonical_id":"hgnc:HGNC:44912","description":"coenzyme Q10B pseudogene 1","metadata":null},{"id":"ebc248234a234517a25ec6a1bfa3e806","type":"GENE","name":"COQ10BP2","canonical_id":"hgnc:HGNC:44913","description":"coenzyme Q10B pseudogene 2","metadata":null},{"id":"db1569c56e094fbf80de2ff9eace05b7","type":"GENE","name":"COQ2","canonical_id":"hgnc:HGNC:25223","description":"coenzyme Q2, polyprenyltransferase","metadata":{"aliases":["CL640","FLJ26072"]}},{"id":"e33fa6fcbaff489f8b3b5b71bd6e64ce","type":"GENE","name":"COQ3","canonical_id":"hgnc:HGNC:18175","description":"coenzyme Q3, methyltransferase","metadata":{"aliases":["bA9819.1"]}},{"id":"6667a95578d0418bb56e59991e7fb138","type":"GENE","name":"COQ4","canonical_id":"hgnc:HGNC:19693","description":"coenzyme Q4","metadata":{"aliases":["CGI-92"]}},{"id":"911c578eaf104f3c816bf14b65b9ac06","type":"GENE","name":"COQ5","canonical_id":"hgnc:HGNC:28722","description":"coenzyme Q5, methyltransferase","metadata":{"aliases":["MGC4767"]}},{"id":"788f049b409948ec98703a1a9283ca98","type":"GENE","name":"COQ6","canonical_id":"hgnc:HGNC:20233","description":"coenzyme Q6, monooxygenase","metadata":{"aliases":["CGI-10"]}},{"id":"e0ba0cf695204b819281574afcd72826","type":"GENE","name":"COQ7","canonical_id":"hgnc:HGNC:2244","description":"coenzyme Q7, hydroxylase","metadata":{"aliases":["CLK-1","CAT5"]}},{"id":"f615f708ef1645a98b9bd74b17c6610f","type":"GENE","name":"COQ7-DT","canonical_id":"hgnc:HGNC:55362","description":"COQ7 divergent transcript","metadata":null},{"id":"78de8da173e04cd9b1b8f299cee2eab6","type":"GENE","name":"COQ8A","canonical_id":"hgnc:HGNC:16812","description":"coenzyme Q8A","metadata":{"aliases":["COQ8","SCAR9","CABC1","ADCK3"]}},{"id":"67da65204945460c9f2b489532b13572","type":"GENE","name":"COQ8B","canonical_id":"hgnc:HGNC:19041","description":"coenzyme Q8B","metadata":{"aliases":["FLJ12229","COQ8","ADCK4"]}},{"id":"44a8d8bad28c44628e53d7c1e9db7896","type":"GENE","name":"COQ9","canonical_id":"hgnc:HGNC:25302","description":"coenzyme Q9","metadata":{"aliases":["DKFZP434K046","C16orf49"]}},{"id":"ec328cc917504b19a11643aadd90b598","type":"TRIAL","name":"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","canonical_id":"clinicaltrials.gov:NCT04346797","description":"SARS-CoV-2; COVID19","metadata":null},{"id":"662d5dc820d3492f8ad8cb9a514cef1c","type":"GENE","name":"CORIN","canonical_id":"hgnc:HGNC:19012","description":"corin, serine peptidase","metadata":{"aliases":["PRSC","CRN","ATC2","Lrp4","TMPRSS10"]}},{"id":"75efd80d76574800ad03e3e4a5f3bbc6","type":"GENE","name":"CORIN-AS1","canonical_id":"hgnc:HGNC:58782","description":"CORIN and NFXL1 antisense RNA 1","metadata":null},{"id":"33fbb8936087438f9e750f0807e69f7c","type":"GENE","name":"CORO1A","canonical_id":"hgnc:HGNC:2252","description":"coronin 1A","metadata":{"aliases":["HCORO1","p57","coronin-1"]}},{"id":"b270be40cb2048ecb3d6078f1badf41e","type":"GENE","name":"CORO1A-AS1","canonical_id":"hgnc:HGNC:55367","description":"CORO1A antisense RNA 1","metadata":null},{"id":"1abb7f83a5cd4841be1249b74d314430","type":"GENE","name":"CORO1B","canonical_id":"hgnc:HGNC:2253","description":"coronin 1B","metadata":{"aliases":["coronin-2"]}},{"id":"af6db0388427431db1a99bc041e93468","type":"GENE","name":"CORO1C","canonical_id":"hgnc:HGNC:2254","description":null,"metadata":null},{"id":"09700bdec41b42aab0d85a7ecf16ca7f","type":"GENE","name":"CORO1CP1","canonical_id":"hgnc:HGNC:55002","description":"CORO1C pseudogene 1","metadata":null},{"id":"53744da2b6fd4dff9f2882df1f3a5962","type":"GENE","name":"CORO2A","canonical_id":"hgnc:HGNC:2255","description":"coronin 2A","metadata":{"aliases":["IR10","WDR2"]}},{"id":"b01004620e2940829b2661c98f793e4c","type":"GENE","name":"CORO2B","canonical_id":"hgnc:HGNC:2256","description":"coronin 2B","metadata":{"aliases":["ClipinC","KIAA0925"]}},{"id":"d54a0e0440b14fefabc60fd101cc04e1","type":"GENE","name":"CORO6","canonical_id":"hgnc:HGNC:21356","description":"coronin 6","metadata":{"aliases":["FLJ14871","ClipinE"]}},{"id":"d3ea04cec3c64fd287279abe3d23eca4","type":"GENE","name":"CORO7","canonical_id":"hgnc:HGNC:26161","description":"coronin 7","metadata":{"aliases":["FLJ22021","POD1"]}},{"id":"c520bb5ddb824e08871e2c288281230f","type":"GENE","name":"CORO7-PAM16","canonical_id":"hgnc:HGNC:44424","description":"CORO7-PAM16 readthrough","metadata":null},{"id":"f264b5d04d2943d994c1e6ceb0c78bcc","type":"GENE","name":"CORT","canonical_id":"hgnc:HGNC:2257","description":"cortistatin","metadata":{"aliases":["MGC32686","SST2"]}},{"id":"803ec66dd50a48e39450a9dc09150af1","type":"TRIAL","name":"CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)","canonical_id":"clinicaltrials.gov:NCT03335956","description":"Healthy","metadata":null},{"id":"649d56e25138456b8ac761e8558e7d3e","type":"GO_TERM","name":"CORVET complex","canonical_id":"go:GO:0033263","description":"\"A multimeric protein complex that acts as an endosomal tethering complex (CORVET = class C core vacuole/endosome tethering) by cooperating with Rab GTPases to capture endosomal vesicles and trap them prior to the action of SNAREs; the complex is involved in endo-lysosomal biogenesis and required for transport between endosome and vacuole. The Saccharomyces cerevisiae complex contains Vps8p, Vps3p, Pep5p, Vps16p, Pep3p, and Vps33p.\" [PMID:17488625]","metadata":null},{"id":"f081cb4bae13423092e2dc4c65f1226d","type":"GENE","name":"COSMOC","canonical_id":"hgnc:HGNC:51610","description":"cell fate and sterol metabolism associated divergent transcript of MOCOS","metadata":null},{"id":"56717bf95e7a4448abfd40de9223f875","type":"GENE","name":"COTL1","canonical_id":"hgnc:HGNC:18304","description":"coactosin like F-actin binding protein 1","metadata":{"aliases":["CLP"]}},{"id":"55600a0301f74feeb713844e90f69bdd","type":"GENE","name":"COTL1-AS1","canonical_id":"hgnc:HGNC:58542","description":"COTL1 antisense RNA 1","metadata":null},{"id":"3e532815389744d99dd0041eff07fd74","type":"GENE","name":"COTL1P1","canonical_id":"hgnc:HGNC:2086","description":"COTL1 pseudogene 1","metadata":{"aliases":["CLPSMCR"]}},{"id":"9864bc0c7f2948c88ec809ba0f1da06e","type":"GENE","name":"COTL1P2","canonical_id":"hgnc:HGNC:24322","description":"COTL1 pseudogene 2","metadata":{"aliases":["CLPSMCR"]}},{"id":"cbaeb8413bf945cfaec1ca74b76c9377","type":"DISEASE","name":"COVID-19","canonical_id":"mondo:0100096","description":null,"metadata":null},{"id":"71338d87415d4f189d5cadbdcb64a71e","type":"TRIAL","name":"COVID-19 Antithrombotic Rivaroxaban Evaluation","canonical_id":"clinicaltrials.gov:NCT04757857","description":"COVID-19","metadata":null},{"id":"3480ac0b8e6a478d94774dc6bae7e48b","type":"TRIAL","name":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol","canonical_id":"clinicaltrials.gov:NCT04662073","description":"Covid19","metadata":null},{"id":"34dee02d31fa4e14b9cc522b7302a52f","type":"TRIAL","name":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol","canonical_id":"clinicaltrials.gov:NCT04662086","description":"Covid19","metadata":null},{"id":"cd646f601cd642f0ad4db5cbdbcfa718","type":"TRIAL","name":"COVID-19 Ozanimod Intervention Study","canonical_id":"clinicaltrials.gov:NCT04405102","description":"COVID-19","metadata":null},{"id":"1d030e5e8aaf4c15b7d204fba5a6b97c","type":"TRIAL","name":"COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","canonical_id":"clinicaltrials.gov:NCT04397328","description":"COVID-19","metadata":null},{"id":"63a5c9111214448899f4c6061faad598","type":"TRIAL","name":"COVID-19 Soliris Expanded Access Protocol","canonical_id":"clinicaltrials.gov:NCT04802083","description":"Covid19","metadata":null},{"id":"46f3df798fc9405aac613e96edbe6f88","type":"TRIAL","name":"COVID-19 VaccinE Response in Rheumatology Patients","canonical_id":"clinicaltrials.gov:NCT05080218","description":"Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis","metadata":null},{"id":"50b0e31f58d946fcb467cb53d3c54a7f","type":"TRIAL","name":"COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)","canonical_id":"clinicaltrials.gov:NCT04510194","description":"Covid19; SARS-CoV Infection","metadata":null},{"id":"6165360115c94107aa79521209fe1f0a","type":"TRIAL","name":"COX-2 Inhibition in Allergic Asthma","canonical_id":"clinicaltrials.gov:NCT01002690","description":"Asthma","metadata":null},{"id":"b9cf70057abe44a4aeaa89c9e01f2c7f","type":"TRIAL","name":"COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined","canonical_id":"clinicaltrials.gov:NCT01361789","description":"Rupture of Anterior Cruciate Ligament","metadata":null},{"id":"b6920891e23b41eaa0a7f8cfffe31aef","type":"GENE","name":"COX1","canonical_id":"hgnc:HGNC:7419","description":null,"metadata":null},{"id":"6e4cb0a0c88c46609d076b83e42c2df4","type":"GENE","name":"COX10","canonical_id":"hgnc:HGNC:2260","description":"cytochrome c oxidase assembly factor heme A:farnesyltransferase COX10","metadata":null},{"id":"c964526685514378be3de32e179f0cbd","type":"GENE","name":"COX10-DT","canonical_id":"hgnc:HGNC:38873","description":"COX10 divergent transcript","metadata":{"aliases":["COX10AS","COX10-AS","COX10-AS1"]}},{"id":"03bbf3d5e029497892a6e481c427c005","type":"GENE","name":"COX11","canonical_id":"hgnc:HGNC:2261","description":"cytochrome c oxidase copper chaperone COX11","metadata":{"aliases":["COX11P"]}},{"id":"f3a7b4170c4a47ed81d2167b581a922e","type":"GENE","name":"COX11P1","canonical_id":"hgnc:HGNC:2262","description":"COX11 pseudogene 1","metadata":{"aliases":["COX11P"]}},{"id":"ab72de52f7df4a27a5d6246d08785266","type":"GENE","name":"COX14","canonical_id":"hgnc:HGNC:28216","description":"cytochrome c oxidase assembly factor COX14","metadata":{"aliases":["MGC14288","C12orf62"]}},{"id":"c89f6dcfc8514783a2a712c42bd13691","type":"GENE","name":"COX15","canonical_id":"hgnc:HGNC:2263","description":"cytochrome c oxidase assembly factor COX15","metadata":{"aliases":["CEMCOX2"]}},{"id":"70b0ad30b13a4fd5a7e5cea22b80b8b0","type":"GENE","name":"COX16","canonical_id":"hgnc:HGNC:20213","description":"cytochrome c oxidase assembly factor COX16","metadata":{"aliases":["HSPC203","C14orf112"]}},{"id":"adbd13d5be744aee87548a158d8f5777","type":"GENE","name":"COX16P1","canonical_id":"hgnc:HGNC:57007","description":"COX16 pseudogene 1","metadata":null},{"id":"6f28ba3d62b54be0975fac9b7433bfb4","type":"GENE","name":"COX17","canonical_id":"hgnc:HGNC:2264","description":"cytochrome c oxidase copper chaperone COX17","metadata":null},{"id":"6cbc04bba3c640cda5cc13e055ca6416","type":"GENE","name":"COX17P1","canonical_id":"hgnc:HGNC:24341","description":"COX17 pseudogene 1","metadata":{"aliases":["COX17P"]}},{"id":"482e65080b1a47c99bf935e1448f6caf","type":"GENE","name":"COX18","canonical_id":"hgnc:HGNC:26801","description":"cytochrome c oxidase assembly factor COX18","metadata":{"aliases":["FLJ38991","OXA1L2"]}},{"id":"07f46f43735e47b3a62a251abee04ffc","type":"GENE","name":"COX18-DT","canonical_id":"hgnc:HGNC:58813","description":"COX18 divergent transcript","metadata":null},{"id":"6699fb8776854398947cbc42c9c2a0f8","type":"GENE","name":"COX19","canonical_id":"hgnc:HGNC:28074","description":"cytochrome c oxidase assembly factor COX19","metadata":{"aliases":["MGC104475"]}},{"id":"66ace92162b241dcb0bcd150e630fbfc","type":"GENE","name":"COX20","canonical_id":"hgnc:HGNC:26970","description":"cytochrome c oxidase assembly factor COX20","metadata":{"aliases":["FLJ43269","FAM36A"]}},{"id":"02390ae62e974c64b19d9b3bcfb73786","type":"GENE","name":"COX20P1","canonical_id":"hgnc:HGNC:31435","description":"COX20 pseudogene 1","metadata":{"aliases":["bA119F7.2","FAM36B"]}},{"id":"80d99ba25607434a9bfd3b07a1129b09","type":"GENE","name":"COX20P2","canonical_id":"hgnc:HGNC:43772","description":"COX20 pseudogene 2","metadata":null},{"id":"cd286607731c40b7b636d03a06ae8ad1","type":"GENE","name":"COX4I1","canonical_id":"hgnc:HGNC:2265","description":"cytochrome c oxidase subunit 4I1","metadata":{"aliases":["COX4-1","COXIV","COXIV-1","COX4"]}},{"id":"88a6d0f28cbb442da1cc6dc90a5785fa","type":"GENE","name":"COX4I1P1","canonical_id":"hgnc:HGNC:2266","description":"cytochrome c oxidase subunit 4I1 pseudogene 1","metadata":{"aliases":["COX4P1","COX4L1"]}},{"id":"2ab80403c946497bae4ce6428df92d8b","type":"GENE","name":"COX4I1P2","canonical_id":"hgnc:HGNC:38036","description":"cytochrome c oxidase subunit 4I1 pseudogene 2","metadata":null},{"id":"0e0163923c054dee9c02ac9a87a9ef19","type":"GENE","name":"COX4I2","canonical_id":"hgnc:HGNC:16232","description":"cytochrome c oxidase subunit 4I2","metadata":{"aliases":["COXIV-2","COX4B","dJ857M17.2","COX4-2","COX4L2"]}},{"id":"cd71f035e15b45eca6e90de216ed44fe","type":"GENE","name":"COX5A","canonical_id":"hgnc:HGNC:2267","description":"cytochrome c oxidase subunit 5A","metadata":{"aliases":["COX-VA"]}},{"id":"a6aeb6700c7948a282557c75f09f4c91","type":"GENE","name":"COX5AP1","canonical_id":"hgnc:HGNC:2268","description":"cytochrome c oxidase subunit 5A pseudogene 1","metadata":null},{"id":"cb054bdcf15f42a6b92d76c66fef248b","type":"GENE","name":"COX5AP2","canonical_id":"hgnc:HGNC:20005","description":"cytochrome c oxidase subunit 5A pseudogene 2","metadata":null},{"id":"a6fdfdcbf5294a40bd096743500ef6a2","type":"GENE","name":"COX5B","canonical_id":"hgnc:HGNC:2269","description":"cytochrome c oxidase subunit 5B","metadata":null},{"id":"b9ba8d46637741548c5028b756e2b897","type":"GENE","name":"COX5BP1","canonical_id":"hgnc:HGNC:2270","description":"cytochrome c oxidase subunit 5B pseudogene 1","metadata":{"aliases":["COX5BL1"]}},{"id":"88aacb5fe373475fbce62f8163ca8c36","type":"GENE","name":"COX5BP2","canonical_id":"hgnc:HGNC:2271","description":"cytochrome c oxidase subunit 5B pseudogene 2","metadata":{"aliases":["COX5BL2"]}},{"id":"984db231924a457dae335ee1642f5e9a","type":"GENE","name":"COX5BP3","canonical_id":"hgnc:HGNC:2272","description":"cytochrome c oxidase subunit 5B pseudogene 3","metadata":{"aliases":["COX5BL3"]}},{"id":"6fead36982f84b168f66f52a697f839b","type":"GENE","name":"COX5BP4","canonical_id":"hgnc:HGNC:2273","description":"cytochrome c oxidase subunit 5B pseudogene 4","metadata":{"aliases":["COX5BL4"]}},{"id":"91fdecd52afd4b609c2723fe4fd6a66d","type":"GENE","name":"COX5BP5","canonical_id":"hgnc:HGNC:2274","description":"cytochrome c oxidase subunit 5B pseudogene 5","metadata":{"aliases":["COX5BL5"]}},{"id":"66e798bd1e9348548441c89a51ff5b1d","type":"GENE","name":"COX5BP6","canonical_id":"hgnc:HGNC:2275","description":"cytochrome c oxidase subunit 5B pseudogene 6","metadata":{"aliases":["COX5BL6"]}},{"id":"202c8c7afc2f450ca73f78900acb7076","type":"GENE","name":"COX5BP7","canonical_id":"hgnc:HGNC:2276","description":"cytochrome c oxidase subunit 5B pseudogene 7","metadata":{"aliases":["COX5BL7"]}},{"id":"b93938dc4f1d4cb692bc03af9735cb2f","type":"GENE","name":"COX5BP8","canonical_id":"hgnc:HGNC:39083","description":"cytochrome c oxidase subunit 5B pseudogene 8","metadata":null},{"id":"f560a40e1c094bc59d90a69a724a50f5","type":"GENE","name":"COX6A1","canonical_id":"hgnc:HGNC:2277","description":null,"metadata":null},{"id":"d1e394d8d9d54aa58076d9e6a3595d0e","type":"GENE","name":"COX6A1P1","canonical_id":"hgnc:HGNC:2278","description":"COX6A1 pseudogene 1","metadata":{"aliases":["COX6A1P"]}},{"id":"d6f5c85f63744f8696eb0686d191b9ef","type":"GENE","name":"COX6A1P2","canonical_id":"hgnc:HGNC:35239","description":"COX6A1 pseudogene 2","metadata":null},{"id":"bf97bcc0106b4ff1bce655d08588f57d","type":"GENE","name":"COX6A1P3","canonical_id":"hgnc:HGNC:37633","description":"COX6A1 pseudogene 3","metadata":null},{"id":"a18252d583b944c9b26fd71cfb928ef2","type":"GENE","name":"COX6A1P4","canonical_id":"hgnc:HGNC:56621","description":"COX6A1 pseudogene 4","metadata":null},{"id":"6aee1ab0d0944d4ba75a58e223377026","type":"GENE","name":"COX6A1P5","canonical_id":"hgnc:HGNC:56622","description":"COX6A1 pseudogene 5","metadata":null},{"id":"773025f44a1a453aad13a2466627020c","type":"GENE","name":"COX6A1P6","canonical_id":"hgnc:HGNC:56623","description":"COX6A1 pseudogene 6","metadata":null},{"id":"9fee4697da3945e992a5540ae72f9d1b","type":"GENE","name":"COX6A1P7","canonical_id":"hgnc:HGNC:56624","description":"COX6A1 pseudogene 7","metadata":null},{"id":"260ea50785b04218bcb6d4190c0a443c","type":"GENE","name":"COX6A2","canonical_id":"hgnc:HGNC:2279","description":"cytochrome c oxidase subunit 6A2","metadata":{"aliases":["COX6AH","COXVIAH","COXVIa-M"]}},{"id":"246b742353fd48928c252d132e2f369d","type":"GENE","name":"COX6B1","canonical_id":"hgnc:HGNC:2280","description":"cytochrome c oxidase subunit 6B1","metadata":{"aliases":["COXG","COX6B"]}},{"id":"1557fb576d724d11a5df06ac63e374f3","type":"GENE","name":"COX6B1P1","canonical_id":"hgnc:HGNC:2281","description":"cytochrome c oxidase subunit 6B1 pseudogene 1","metadata":{"aliases":["COX6BP1"]}},{"id":"bb9283ec30384a33a9bff4b1c87e3513","type":"GENE","name":"COX6B1P2","canonical_id":"hgnc:HGNC:2282","description":"cytochrome c oxidase subunit 6B1 pseudogene 2","metadata":{"aliases":["COX6BP2"]}},{"id":"aebbc6ac57a141a882a11c56a28fac1c","type":"GENE","name":"COX6B1P3","canonical_id":"hgnc:HGNC:2283","description":"cytochrome c oxidase subunit 6B1 pseudogene 3","metadata":{"aliases":["COX6BP3"]}},{"id":"c8554a543bc74200a37f2fb131d562c6","type":"GENE","name":"COX6B1P4","canonical_id":"hgnc:HGNC:2284","description":"cytochrome c oxidase subunit 6B1 pseudogene 4","metadata":{"aliases":["COX6BP4"]}},{"id":"5fea09bbe5024e67a07f3191f40d3190","type":"GENE","name":"COX6B1P5","canonical_id":"hgnc:HGNC:37675","description":"cytochrome c oxidase subunit 6B1 pseudogene 5","metadata":null},{"id":"ed185fa49a9f476e987897a5199902fe","type":"GENE","name":"COX6B1P6","canonical_id":"hgnc:HGNC:37676","description":"cytochrome c oxidase subunit 6B1 pseudogene 6","metadata":null},{"id":"dc1cfedeeaff496eb12c6b8435034041","type":"GENE","name":"COX6B1P7","canonical_id":"hgnc:HGNC:37677","description":"cytochrome c oxidase subunit 6B1 pseudogene 7","metadata":null},{"id":"6b8838ee13d04d9d8428eecd6509c525","type":"GENE","name":"COX6B2","canonical_id":"hgnc:HGNC:24380","description":"cytochrome c oxidase subunit 6B2","metadata":{"aliases":["COXVIB2","FLJ32865","CT59"]}},{"id":"ef9aa07a2be5434ea9bc56c1e6aad297","type":"GENE","name":"COX6C","canonical_id":"hgnc:HGNC:2285","description":"cytochrome c oxidase subunit 6C","metadata":null},{"id":"e1a939375a534c53b82833acc3977345","type":"GENE","name":"COX6CP1","canonical_id":"hgnc:HGNC:2286","description":"cytochrome c oxidase subunit 6C pseudogene 1","metadata":null},{"id":"208788c21fbb415aaeb22e024469a3ba","type":"GENE","name":"COX6CP10","canonical_id":"hgnc:HGNC:49362","description":"cytochrome c oxidase subunit 6C pseudogene 10","metadata":null},{"id":"4da2f249af0e4a04b7d8b58c4a8963d8","type":"GENE","name":"COX6CP11","canonical_id":"hgnc:HGNC:49363","description":"cytochrome c oxidase subunit 6C pseudogene 11","metadata":null},{"id":"71c6a939ec414443af7f15ccdcd6d63e","type":"GENE","name":"COX6CP12","canonical_id":"hgnc:HGNC:49364","description":"cytochrome c oxidase subunit 6C pseudogene 12","metadata":null},{"id":"10162fa989c248d49ab04f3ed636bf29","type":"GENE","name":"COX6CP13","canonical_id":"hgnc:HGNC:49365","description":"cytochrome c oxidase subunit 6C pseudogene 13","metadata":null},{"id":"341fa6288dca4444b525045fd8df02bd","type":"GENE","name":"COX6CP14","canonical_id":"hgnc:HGNC:49366","description":"cytochrome c oxidase subunit 6C pseudogene 14","metadata":null},{"id":"2bc14b20b2534b8a8889eac822456e9b","type":"GENE","name":"COX6CP15","canonical_id":"hgnc:HGNC:49368","description":"cytochrome c oxidase subunit 6C pseudogene 15","metadata":null},{"id":"7d1379b506564000852bc946e0c096ee","type":"GENE","name":"COX6CP16","canonical_id":"hgnc:HGNC:49367","description":"cytochrome c oxidase subunit 6C pseudogene 16","metadata":null},{"id":"605eed3c15fd42d380593ae59d9a5f6e","type":"GENE","name":"COX6CP17","canonical_id":"hgnc:HGNC:49369","description":"cytochrome c oxidase subunit 6C pseudogene 17","metadata":null},{"id":"d0607f07c91a451d93a1bf04cca6c099","type":"GENE","name":"COX6CP18","canonical_id":"hgnc:HGNC:49370","description":"cytochrome c oxidase subunit 6C pseudogene 18","metadata":null},{"id":"c3176130146e49c790e45e74cf1570fe","type":"GENE","name":"COX6CP2","canonical_id":"hgnc:HGNC:16600","description":"cytochrome c oxidase subunit 6C pseudogene 2","metadata":{"aliases":["dJ894K16.1"]}},{"id":"da47cedbde014656bd463a79b9e05830","type":"GENE","name":"COX6CP3","canonical_id":"hgnc:HGNC:31721","description":"cytochrome c oxidase subunit 6C pseudogene 3","metadata":null},{"id":"35323cf93dbf47648f01d6689c8e9b43","type":"GENE","name":"COX6CP4","canonical_id":"hgnc:HGNC:32374","description":"cytochrome c oxidase subunit 6C pseudogene 4","metadata":null},{"id":"c30fc4e8860948e1900957c39d656f94","type":"GENE","name":"COX6CP5","canonical_id":"hgnc:HGNC:42791","description":"cytochrome c oxidase subunit 6C pseudogene 5","metadata":null},{"id":"087ab58513db4531989433f36655fbb9","type":"GENE","name":"COX6CP6","canonical_id":"hgnc:HGNC:47037","description":"cytochrome c oxidase subunit 6C pseudogene 6","metadata":null},{"id":"b3458e822bbe44e6ab798cdbc5b61299","type":"GENE","name":"COX6CP7","canonical_id":"hgnc:HGNC:49359","description":"cytochrome c oxidase subunit 6C pseudogene 7","metadata":null},{"id":"2a47f6f9cc4e4a72b4e1258c70732b45","type":"GENE","name":"COX6CP8","canonical_id":"hgnc:HGNC:49360","description":"cytochrome c oxidase subunit 6C pseudogene 8","metadata":null},{"id":"585e7b719902466a9c6caa0768b77b02","type":"GENE","name":"COX6CP9","canonical_id":"hgnc:HGNC:49361","description":"cytochrome c oxidase subunit 6C pseudogene 9","metadata":null},{"id":"7cc6195205d843448627a6e0667269b6","type":"GENE","name":"COX7A1","canonical_id":"hgnc:HGNC:2287","description":"cytochrome c oxidase subunit 7A1","metadata":{"aliases":["COX7AH","COX7A"]}},{"id":"c4923bfb93eb4bd6931d0107507ed87a","type":"GENE","name":"COX7A2","canonical_id":"hgnc:HGNC:2288","description":"cytochrome c oxidase subunit 7A2","metadata":{"aliases":["COXVIIa-L","COX7AL"]}},{"id":"c7e05525653743e2925142f96441f7dc","type":"GENE","name":"COX7A2L","canonical_id":"hgnc:HGNC:2289","description":"cytochrome c oxidase subunit 7A2 like","metadata":{"aliases":["EB1","COX7RP","COX7AR","SIG81","SCAF1","SCAFI"]}},{"id":"f446cfdab0fc42bdacd5070d553d8125","type":"GENE","name":"COX7A2P1","canonical_id":"hgnc:HGNC:20006","description":"cytochrome c oxidase subunit 7A2 pseudogene 1","metadata":{"aliases":["COX7A3P","COX7AP1"]}},{"id":"9331b38da074470582f642e41a4cae49","type":"GENE","name":"COX7A2P2","canonical_id":"hgnc:HGNC:2290","description":"cytochrome c oxidase subunit 7A2 pseudogene 2","metadata":{"aliases":["COX7AL2","COX7A3","COX7AP2"]}},{"id":"e6b518666e1a4f35a29dbee2b4cbd556","type":"GENE","name":"COX7B","canonical_id":"hgnc:HGNC:2291","description":"cytochrome c oxidase subunit 7B","metadata":null},{"id":"aa53282d7dff469d82170195fd054e85","type":"GENE","name":"COX7B2","canonical_id":"hgnc:HGNC:24381","description":"cytochrome c oxidase subunit 7B2","metadata":null},{"id":"cea39122b85c406a8bf2ab8f7f7ba8f7","type":"GENE","name":"COX7BP1","canonical_id":"hgnc:HGNC:16529","description":"COX7B pseudogene 1","metadata":{"aliases":["bK714B7.1"]}},{"id":"e20d3cca3e6c438191dd0cdcd51fe46a","type":"GENE","name":"COX7BP2","canonical_id":"hgnc:HGNC:16601","description":"COX7B pseudogene 2","metadata":{"aliases":["dJ901O8.2"]}},{"id":"c667ccecfabe4c858ce6df1c4a9d71ae","type":"GENE","name":"COX7BP3","canonical_id":"hgnc:HGNC:56507","description":"COX7B pseudogene 3","metadata":null},{"id":"0581ca0625a54114ae096549de244b36","type":"GENE","name":"COX7BP4","canonical_id":"hgnc:HGNC:56508","description":"COX7B pseudogene 4","metadata":null},{"id":"36fbc77d185f42d2bd416ab8a9440e0f","type":"GENE","name":"COX7BP6","canonical_id":"hgnc:HGNC:56585","description":"COX7B pseudogene 6","metadata":null},{"id":"1a3d4a28eff84b7db5f6b66e59174ca7","type":"GENE","name":"COX7C","canonical_id":"hgnc:HGNC:2292","description":null,"metadata":null},{"id":"5b6de2ea6e414d1ba7c2ec9015e78657","type":"GENE","name":"COX7CP1","canonical_id":"hgnc:HGNC:2293","description":"COX7C pseudogene 1","metadata":null},{"id":"39f0c85f49fe4b1e916c2d62b3d66ec8","type":"GENE","name":"COX7CP2","canonical_id":"hgnc:HGNC:56510","description":"COX7C pseudogene 2","metadata":null},{"id":"4d8684733a364f7aac3b208cea4ef284","type":"GENE","name":"COX7CP3","canonical_id":"hgnc:HGNC:56511","description":"COX7C pseudogene 3","metadata":null},{"id":"5344877d128f42cc8ba7059bf201b719","type":"GENE","name":"COX7CP4","canonical_id":"hgnc:HGNC:56512","description":"COX7C pseudogene 4","metadata":null},{"id":"9e72f0c7b2ef4e72a5bbc394a336a31a","type":"GENE","name":"COX8A","canonical_id":"hgnc:HGNC:2294","description":"cytochrome c oxidase subunit 8A","metadata":{"aliases":["COX8-2","COX8L","VIII-L","COX","VIII","COX8"]}},{"id":"c5529cc039ea40a7a09ea457730fc8a3","type":"GENE","name":"COX8BP","canonical_id":"hgnc:HGNC:31395","description":"cytochrome c oxidase subunit 8B, pseudogene","metadata":{"aliases":["COX8-1","COX8H","COX8B"]}},{"id":"4df6034cdcc84d89b76a13e1d9b23743","type":"GENE","name":"COX8C","canonical_id":"hgnc:HGNC:24382","description":"cytochrome c oxidase subunit 8C","metadata":{"aliases":["COX8-3"]}},{"id":"57337736aaf94f5aaabf23cab2391b27","type":"GENE","name":"COX8CP1","canonical_id":"hgnc:HGNC:56920","description":"COX8C pseudogene 1","metadata":null},{"id":"fede6d808aca4c19b7692ee92a5631e2","type":"GENE","name":"COXFA4","canonical_id":"hgnc:HGNC:7687","description":"cytochrome c oxidase associated subunit FA4","metadata":{"aliases":["MLRQ","CI-9k","MRCAF1","MISTR1","NDUFA4"]}},{"id":"88be1baf571b406a94db534a174dabcb","type":"GENE","name":"COXFA4L2","canonical_id":"hgnc:HGNC:29836","description":"cytochrome c oxidase hypoxia associated subunit FA4L2","metadata":{"aliases":["NUOMS","FLJ26118","MISTRH","NDUFA4L2"]}},{"id":"564dedaada844feea2dd1b6a0fdf375e","type":"GENE","name":"COXFA4L3","canonical_id":"hgnc:HGNC:29898","description":"cytochrome c oxidase associated subunit FA4L3","metadata":{"aliases":["NMES1","MIR147BHG","COXFA4L3","MOCCI","MISTRAV","C15orf48"]}},{"id":"1b4847c211b0485bb1408e31d1558eb5","type":"GENE","name":"COXFA4L3-AS1","canonical_id":"hgnc:HGNC:56076","description":"COXFA4L3 antisense RNA 1","metadata":null},{"id":"45c4fd0ac7da4aa4907fff9024f5d0c7","type":"GENE","name":"COXFA4P1","canonical_id":"hgnc:HGNC:29835","description":"COXFA4 pseudogene 1","metadata":{"aliases":["NDUFA4P1"]}},{"id":"36ea9c84b6b8469eb5ec0b82fb07c4cc","type":"GENE","name":"COXFA4P2","canonical_id":"hgnc:HGNC:31362","description":"COXFA4 pseudogene 2","metadata":{"aliases":["bcm1723","NDUFA4L","NDUFA4P2"]}},{"id":"bafd7b5c0dd443be8f1a8b8110abfc18","type":"GENE","name":"COXFA4P3","canonical_id":"hgnc:HGNC:58527","description":"COXFA4 pseudogene 3","metadata":null},{"id":"87991349b9dd4dd0a39a02b09f3e6700","type":"GENE","name":"COXFA4P4","canonical_id":"hgnc:HGNC:58528","description":"COXFA4 pseudogene 4","metadata":null},{"id":"cd5a9d243cfd4c408bfc012ee0494f5d","type":"GENE","name":"COXFA4P5","canonical_id":"hgnc:HGNC:58529","description":"COXFA4 pseudogene 5","metadata":null},{"id":"87a621b61a6b44a6b2c5294c1c0c82b9","type":"TRIAL","name":"COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients","canonical_id":"clinicaltrials.gov:NCT02095522","description":"NSTEMI","metadata":null},{"id":"f03695ddf2284a4fb249382daf44f830","type":"TRIAL","name":"COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT03156816","description":"Myocardial Infarction","metadata":null},{"id":"7a4e73a807ab4aec9e1efc1ee19b7141","type":"TRIAL","name":"COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia","canonical_id":"clinicaltrials.gov:NCT01217879","description":"Hypertension","metadata":null},{"id":"40a723599ec44f65a47cff7ed77c371e","type":"GENE","name":"CP","canonical_id":"hgnc:HGNC:2295","description":"ceruloplasmin","metadata":{"aliases":["AB073614"]}},{"id":"1a8145f89ecd489bb33099d373ff8e5e","type":"GENE","name":"CPA1","canonical_id":"hgnc:HGNC:2296","description":"carboxypeptidase A1","metadata":{"aliases":["CPA"]}},{"id":"f7fb6758d5ff455dbade00a47b7dd1ca","type":"GENE","name":"CPA2","canonical_id":"hgnc:HGNC:2297","description":"carboxypeptidase A2","metadata":null},{"id":"8129e9879a424edabdbc39ebf1d09d01","type":"GENE","name":"CPA3","canonical_id":"hgnc:HGNC:2298","description":"carboxypeptidase A3","metadata":null},{"id":"54fb4b3577aa477a9d42c227b11d5e0a","type":"GENE","name":"CPA4","canonical_id":"hgnc:HGNC:15740","description":"carboxypeptidase A4","metadata":{"aliases":["CPA3"]}},{"id":"e75695607424452f856bb0a094a9ee5c","type":"GENE","name":"CPA5","canonical_id":"hgnc:HGNC:15722","description":"carboxypeptidase A5","metadata":null},{"id":"1869e31af43d45caab1757d5d42155ab","type":"GENE","name":"CPA6","canonical_id":"hgnc:HGNC:17245","description":"carboxypeptidase A6","metadata":{"aliases":["CPAH"]}},{"id":"b7e94e2597434bd3959158b125ccdb81","type":"GENE","name":"CPAMD8","canonical_id":"hgnc:HGNC:23228","description":"C3 and PZP like alpha-2-macroglobulin domain containing 8","metadata":{"aliases":["KIAA1283","VIP","K-CAP"]}},{"id":"b78c3a83a4b942779094c4db9b53876e","type":"GENE","name":"CPAMD8P1","canonical_id":"hgnc:HGNC:58113","description":"CPAMD8 pseudogene 1","metadata":null},{"id":"cb0c527e1ada45efa866bc8d0573023a","type":"GENE","name":"CPAP","canonical_id":"hgnc:HGNC:17272","description":"centrosome assembly and centriole elongation protein","metadata":{"aliases":["LAP","LIP1","BM032","SASS4","SCKL4","Sas-4","CENPJ","MCPH6"]}},{"id":"cc2e1e4ae6804e26a8d70f3109dc1aae","type":"GENE","name":"CPB1","canonical_id":"hgnc:HGNC:2299","description":"carboxypeptidase B1","metadata":null},{"id":"40539fb3aa704d46b4787657072fa76b","type":"GENE","name":"CPB2","canonical_id":"hgnc:HGNC:2300","description":"carboxypeptidase B2","metadata":{"aliases":["CPU","PCPB","TAFI"]}},{"id":"84aa465c43744a528988b326c4ccb70e","type":"GENE","name":"CPB2-AS1","canonical_id":"hgnc:HGNC:39898","description":"CPB2 antisense RNA 1","metadata":null},{"id":"1b04ed8d2c5044b0ac89b9d5f3048305","type":"GENE","name":"CPD","canonical_id":"hgnc:HGNC:2301","description":null,"metadata":null},{"id":"1d31290985e043eda151f52016325e8f","type":"GENE","name":"CPDP1","canonical_id":"hgnc:HGNC:53102","description":"carboxypeptidase D pseudogene 1","metadata":null},{"id":"6d33acc112544e4187787582bb089b33","type":"GENE","name":"CPE","canonical_id":"hgnc:HGNC:2303","description":"carboxypeptidase E","metadata":null},{"id":"62eef0aa3bf74e88abddfaf8a281209a","type":"GENE","name":"CPEB1","canonical_id":"hgnc:HGNC:21744","description":null,"metadata":null},{"id":"68fc8030cab64c278803fa3de0ebe216","type":"GENE","name":"CPEB1-AS1","canonical_id":"hgnc:HGNC:27523","description":"CPEB1 antisense RNA 1","metadata":null},{"id":"4c023ef1ef3544fa94bbd7626009567f","type":"GENE","name":"CPEB2","canonical_id":"hgnc:HGNC:21745","description":"cytoplasmic polyadenylation element binding protein 2","metadata":null},{"id":"6893f22a2cd5432480725417e7b44ef7","type":"GENE","name":"CPEB2-DT","canonical_id":"hgnc:HGNC:49082","description":"CPEB2 divergent transcript","metadata":{"aliases":["DRAIR","CPEB2-AS1"]}},{"id":"f237fa1d45fe4c61b8d82fb229801fbe","type":"GENE","name":"CPEB3","canonical_id":"hgnc:HGNC:21746","description":"cytoplasmic polyadenylation element binding protein 3","metadata":{"aliases":["KIAA0940"]}},{"id":"f82eb6bc5e0c49d6b208833f94bd54e5","type":"GENE","name":"CPEB4","canonical_id":"hgnc:HGNC:21747","description":"cytoplasmic polyadenylation element binding protein 4","metadata":{"aliases":["KIAA1673"]}},{"id":"a7c735fac6774c99af0a383b4879ad7e","type":"GENE","name":"CPED1","canonical_id":"hgnc:HGNC:26159","description":"cadherin like and PC-esterase domain containing 1","metadata":{"aliases":["FLJ21986","C7orf58"]}},{"id":"5cbccaec182d4a0693c5ed1882fa3109","type":"GENE","name":"CPHL1P","canonical_id":"hgnc:HGNC:31714","description":"ceruloplasmin and hephaestin like 1, pseudogene","metadata":{"aliases":["CPHL1"]}},{"id":"fddc018537ce4479b0783ba3a5983356","type":"GENE","name":"CPHXL","canonical_id":"hgnc:HGNC:51815","description":"cytoplasmic polyadenylated homeobox like","metadata":null},{"id":"a732051f17904e449b1fde214c50bed7","type":"GENE","name":"CPHXL2","canonical_id":"hgnc:HGNC:55919","description":"cytoplasmic polyadenylated homeobox like 2","metadata":null},{"id":"9f55095629764a8082bb27ca0fd5a9c0","type":"TRIAL","name":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03699319","description":"Pancreatic Cancer","metadata":null},{"id":"261443a6467d49fb9c254d0c2085e752","type":"GENE","name":"CPLANE1","canonical_id":"hgnc:HGNC:25801","description":"ciliogenesis and planar polarity effector complex subunit 1","metadata":{"aliases":["FLJ13231","JBTS17","Hug","C5orf42"]}},{"id":"a242a6d6604e4d17819f9cf74cd9d8f3","type":"GENE","name":"CPLANE1-AS1","canonical_id":"hgnc:HGNC:56117","description":"CPLANE1 antisense RNA 1","metadata":null},{"id":"4704461ec89647608b3d84e5fe3db58e","type":"GENE","name":"CPLANE2","canonical_id":"hgnc:HGNC:28127","description":"ciliogenesis and planar polarity effector complex subunit 2","metadata":{"aliases":["MGC10731","C1orf89","RSG1"]}},{"id":"6dcdf8ad5d3047cebf9b5da65790dc6b","type":"GENE","name":"CPLX1","canonical_id":"hgnc:HGNC:2309","description":"complexin 1","metadata":{"aliases":["CPX-I"]}},{"id":"e36aa414d114421f823b9dcd10665875","type":"GENE","name":"CPLX1-AS1","canonical_id":"hgnc:HGNC:58706","description":"CPLX1 antisense RNA 1","metadata":null},{"id":"0941152834ab451caa848d1532c4ad0a","type":"GENE","name":"CPLX2","canonical_id":"hgnc:HGNC:2310","description":"complexin 2","metadata":{"aliases":["CPX-2","DKFZp547D155"]}},{"id":"7e9855c3e16e4c60a45a2ce005bd9caf","type":"GENE","name":"CPLX3","canonical_id":"hgnc:HGNC:27652","description":"complexin 3","metadata":{"aliases":["CPX-III"]}},{"id":"66ddc4daf82c4e88928ff0519efdfd38","type":"GENE","name":"CPLX4","canonical_id":"hgnc:HGNC:24330","description":"complexin 4","metadata":{"aliases":["CPX-IV"]}},{"id":"c264d9bc992a49c28b7a16c9129d4673","type":"GENE","name":"CPM","canonical_id":"hgnc:HGNC:2311","description":"carboxypeptidase M","metadata":null},{"id":"66028146cb344a35bebd317bfe2fcfe3","type":"GENE","name":"CPMER","canonical_id":"hgnc:HGNC:55992","description":"cytoplasmic mesoderm regulator","metadata":null},{"id":"5629807b9317413d9d44d73ae477ce80","type":"GENE","name":"CPN1","canonical_id":"hgnc:HGNC:2312","description":"carboxypeptidase N subunit 1","metadata":null},{"id":"599f991d23a043aa8af549e46d2b4188","type":"GENE","name":"CPN2","canonical_id":"hgnc:HGNC:2313","description":"carboxypeptidase N subunit 2","metadata":{"aliases":["ACBP"]}},{"id":"27ebf648ddd84eeb92137784ffd44f64","type":"GENE","name":"CPNE1","canonical_id":"hgnc:HGNC:2314","description":"copine 1","metadata":{"aliases":["CPN1"]}},{"id":"f5ab56e5902347eda767254580032695","type":"GENE","name":"CPNE2","canonical_id":"hgnc:HGNC:2315","description":"copine 2","metadata":{"aliases":["CPN2"]}},{"id":"acde1d5c32e94c6c9b26bb59cb4315d3","type":"GENE","name":"CPNE2-DT","canonical_id":"hgnc:HGNC:55398","description":"CPNE2 divergent transcript","metadata":null},{"id":"488993205e094705a2212066eeac74a0","type":"GENE","name":"CPNE3","canonical_id":"hgnc:HGNC:2316","description":"copine 3","metadata":null},{"id":"5e1f867d93df469a8a578d13a3c426d7","type":"GENE","name":"CPNE4","canonical_id":"hgnc:HGNC:2317","description":"copine 4","metadata":{"aliases":["COPN4","CPN4"]}},{"id":"54767e4b496f4ff588624acaab675d19","type":"GENE","name":"CPNE5","canonical_id":"hgnc:HGNC:2318","description":"copine 5","metadata":{"aliases":["CPN5","COPN5","KIAA1599"]}},{"id":"1cbdf001b2b742cba6833544f876c8b7","type":"GENE","name":"CPNE5-AS1","canonical_id":"hgnc:HGNC:59391","description":"CPNE5 antisense RNA 1","metadata":null},{"id":"abb272925a66467aae9f15a8ad08a423","type":"GENE","name":"CPNE6","canonical_id":"hgnc:HGNC:2319","description":"copine 6","metadata":{"aliases":["N-copine","copine-6"]}},{"id":"c2b35cc2efd94911a0f0feecb01298d4","type":"GENE","name":"CPNE7","canonical_id":"hgnc:HGNC:2320","description":"copine 7","metadata":null},{"id":"d3c5b34bcd7a48898bf1ab78be173c14","type":"GENE","name":"CPNE8","canonical_id":"hgnc:HGNC:23498","description":"copine 8","metadata":null},{"id":"b243b45e87e0447685112e673d5892c6","type":"GENE","name":"CPNE8-AS1","canonical_id":"hgnc:HGNC:53937","description":"CPNE8 antisense RNA 1","metadata":{"aliases":["RP11-396F22.1"]}},{"id":"d6a0a402c4a94afdad5a726186852e44","type":"GENE","name":"CPNE9","canonical_id":"hgnc:HGNC:24336","description":"copine family member 9","metadata":{"aliases":["KIAA4217"]}},{"id":"ea60b5ca7c244e1084dbac4a239980ec","type":"GENE","name":"CPO","canonical_id":"hgnc:HGNC:21011","description":"carboxypeptidase O","metadata":null},{"id":"e9da864b44524687a2e5f49d55e6802a","type":"GENE","name":"CPOX","canonical_id":"hgnc:HGNC:2321","description":"coproporphyrinogen oxidase","metadata":{"aliases":["CPX","HCP","CPO"]}},{"id":"b274d534958647888f6a1c8200b3aff8","type":"GENE","name":"CPP","canonical_id":"hgnc:HGNC:2322","description":"ceruloplasmin pseudogene","metadata":null},{"id":"328a0e92baf040008413758a09bd2116","type":"GENE","name":"CPPED1","canonical_id":"hgnc:HGNC:25632","description":"calcineurin like phosphoesterase domain containing 1","metadata":{"aliases":["CSTP1","FLJ11151"]}},{"id":"f848aa7fe1c846d2a23a9dc78b31217b","type":"GENE","name":"CPQ","canonical_id":"hgnc:HGNC:16910","description":"carboxypeptidase Q","metadata":{"aliases":["LDP","PGCP"]}},{"id":"c210b0ab022a4ff3bd9a16aab19e82b8","type":"GENE","name":"CPS1","canonical_id":"hgnc:HGNC:2323","description":"carbamoyl-phosphate synthase 1","metadata":{"aliases":["GATD6"]}},{"id":"ee405702ea2d481ead89bf19c2abc0a1","type":"GENE","name":"CPS1-IT1","canonical_id":"hgnc:HGNC:30102","description":"CPS1 intronic transcript 1","metadata":{"aliases":["PRO0132","CPS1-IT","CPS1IT"]}},{"id":"f52d930ff567470bae79264f088019cf","type":"GENE","name":"CPSF1","canonical_id":"hgnc:HGNC:2324","description":"cleavage and polyadenylation specific factor 1","metadata":{"aliases":["CPSF160"]}},{"id":"77199de61d8c491fa55b49e72272dc82","type":"GENE","name":"CPSF1P1","canonical_id":"hgnc:HGNC:19251","description":"CPSF1 pseudogene 1","metadata":{"aliases":["dJ90G24.5"]}},{"id":"571031e33971444296eeb5252e1353fb","type":"GENE","name":"CPSF1P2","canonical_id":"hgnc:HGNC:54959","description":"CPSF1 pseudogene 2","metadata":null},{"id":"d132a9a336c44b6bb7ba501e41441e69","type":"GENE","name":"CPSF2","canonical_id":"hgnc:HGNC:2325","description":"cleavage and polyadenylation specific factor 2","metadata":{"aliases":["KIAA1367","CPSF100"]}},{"id":"6133eaf2cfd640a5b8856ffaea317e4f","type":"GENE","name":"CPSF3","canonical_id":"hgnc:HGNC:2326","description":"cleavage and polyadenylation specific factor 3","metadata":{"aliases":["CPSF-73","CPSF73","YSH1"]}},{"id":"41a90179fe9a453b8e92e20543243878","type":"GENE","name":"CPSF4","canonical_id":"hgnc:HGNC:2327","description":"cleavage and polyadenylation specific factor 4","metadata":{"aliases":["NAR","CPSF30"]}},{"id":"f1cd3e9f3def404b9c626857a87f6315","type":"GENE","name":"CPSF4L","canonical_id":"hgnc:HGNC:33632","description":"cleavage and polyadenylation specific factor 4 like","metadata":null},{"id":"a7b09103a80d408a892936cea5c67ac2","type":"GENE","name":"CPSF6","canonical_id":"hgnc:HGNC:13871","description":"cleavage and polyadenylation specific factor 6","metadata":{"aliases":["CFIM","HPBRII-4","HPBRII-7","CFIM68","CFIM72"]}},{"id":"7940ef02ba0842fb9c44c8d5017b8969","type":"GENE","name":"CPSF6P1","canonical_id":"hgnc:HGNC:57009","description":"CPSF6 pseudogene 1","metadata":null},{"id":"b6019cdcd5ef4531af3d95970c3d8ab1","type":"GENE","name":"CPSF7","canonical_id":"hgnc:HGNC:30098","description":"cleavage and polyadenylation specific factor 7","metadata":{"aliases":["FLJ12529","CFIM59"]}},{"id":"a967e175ca384102a65edbd4c4fef2db","type":"GENE","name":"CPT1A","canonical_id":"hgnc:HGNC:2328","description":null,"metadata":null},{"id":"37ebcb6e51684ab3bdbbe646158eab1a","type":"GENE","name":"CPT1B","canonical_id":"hgnc:HGNC:2329","description":null,"metadata":null},{"id":"d66ed8f00d92422bab508e5cdfbfb8fd","type":"GENE","name":"CPT1C","canonical_id":"hgnc:HGNC:18540","description":"carnitine palmitoyltransferase 1C","metadata":{"aliases":["FLJ23809","CPTIC","CPT1P","CATL1"]}},{"id":"3ee528833842487389b16667791d0fec","type":"GENE","name":"CPT2","canonical_id":"hgnc:HGNC:2330","description":"carnitine palmitoyltransferase 2","metadata":{"aliases":["CPTASE","CPT1"]}},{"id":"c44341f01f684115a1d5c468aae991e5","type":"GENE","name":"CPT2P1","canonical_id":"hgnc:HGNC:49538","description":"carnitine palmitoyltransferase 2 pseudogene 1","metadata":null},{"id":"adf5ba59cd88465cbf79e728962f6027","type":"GENE","name":"CPTP","canonical_id":"hgnc:HGNC:28116","description":"ceramide-1-phosphate transfer protein","metadata":{"aliases":["MGC10334","GLTPD1"]}},{"id":"de51d311bc444af881be744a0b61b8a8","type":"GENE","name":"CPVL","canonical_id":"hgnc:HGNC:14399","description":"carboxypeptidase vitellogenic like","metadata":null},{"id":"af4b8c4414544905897670f54cdacb5a","type":"GENE","name":"CPVL-AS1","canonical_id":"hgnc:HGNC:40685","description":"CPVL antisense RNA 1","metadata":null},{"id":"89bc19131628437995da6f79ea06f273","type":"GENE","name":"CPVL-AS2","canonical_id":"hgnc:HGNC:56138","description":"CPVL antisense RNA 2","metadata":null},{"id":"58fb3f4077ec402ea920e50dabf69a14","type":"TRIAL","name":"CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03904251","description":"Acute Myelogenous Leukemia","metadata":null},{"id":"37475eda5d1d4789a6f93414ace499ca","type":"TRIAL","name":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04231851","description":"Acute Myelogenous Leukemia (AML) Due to Therapy; Acute Myeloid Leukemia With Myelodysplasia-Related Changes","metadata":null},{"id":"2ad64ed2c98d4138a950c0b9c84531dd","type":"GENE","name":"CPXCR1","canonical_id":"hgnc:HGNC:2332","description":"CPX chromosome region candidate 1","metadata":{"aliases":["CT77"]}},{"id":"efbed703a07c48da9d4463c2b72b5945","type":"GENE","name":"CPXM1","canonical_id":"hgnc:HGNC:15771","description":"carboxypeptidase X, M14 family member 1","metadata":{"aliases":["CPX-1","CPX1","CPXM"]}},{"id":"2d9c17f1f5f04fe1a695dca35e61a112","type":"GENE","name":"CPXM2","canonical_id":"hgnc:HGNC:26977","description":"carboxypeptidase X, M14 family member 2","metadata":{"aliases":["UNQ676","CPX2"]}},{"id":"ee74d93d950845e4b1c1c69804ae9671","type":"GENE","name":"CPXM2-AS1","canonical_id":"hgnc:HGNC:58377","description":"CPXM2 antisense RNA 1","metadata":null},{"id":"c4bfc910dfc54d35ba645efb48f338d7","type":"GENE","name":"CPZ","canonical_id":"hgnc:HGNC:2333","description":"carboxypeptidase Z","metadata":null},{"id":"6b882b4454c2437daf2fe991050f7b15","type":"GENE","name":"CR1","canonical_id":"hgnc:HGNC:2334","description":null,"metadata":null},{"id":"d67b8f87d9784a8caef30ce39c8b4b41","type":"GENE","name":"CR1-AS1","canonical_id":"hgnc:HGNC:40160","description":"CR1 antisense RNA 1","metadata":{"aliases":["AL137789.1"]}},{"id":"7dd1f30e083d43e5b3dcc44c18d15187","type":"GENE","name":"CR1L","canonical_id":"hgnc:HGNC:2335","description":"complement C3b/C4b receptor 1 like","metadata":null},{"id":"66755e593f8e4e87b645b69d680bfb9c","type":"GENE","name":"CR2","canonical_id":"hgnc:HGNC:2336","description":null,"metadata":null},{"id":"ab6e61a9ce464cca95feadc049ea8601","type":"TRIAL","name":"CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","canonical_id":"clinicaltrials.gov:NCT05356403","description":"Chronic Kidney Diseases; Pruritus","metadata":null},{"id":"4b9697edb8e34b779b994008421845c0","type":"GENE","name":"CRABP1","canonical_id":"hgnc:HGNC:2338","description":null,"metadata":null},{"id":"ff5adab6cc4741ef8ce800518b539d85","type":"GENE","name":"CRABP2","canonical_id":"hgnc:HGNC:2339","description":null,"metadata":null},{"id":"1f5c6122044b468fb29a39324959bf4e","type":"GENE","name":"CRACD","canonical_id":"hgnc:HGNC:29219","description":"capping protein inhibiting regulator of actin dynamics","metadata":{"aliases":["CRAD","KIAA1211"]}},{"id":"5cc17c80e95c43979ddefd5e8454a15f","type":"GENE","name":"CRACD-AS1","canonical_id":"hgnc:HGNC:58794","description":"CRACD antisense RNA 1","metadata":null},{"id":"c37c206eca444cefae7753a2a6a5cce1","type":"GENE","name":"CRACDL","canonical_id":"hgnc:HGNC:33454","description":"CRACD like","metadata":{"aliases":["MGC42367","C2orf55","KIAA1211L"]}},{"id":"64e3eceae5d44e2b8d3cdcfbc503af06","type":"GENE","name":"CRACR2A","canonical_id":"hgnc:HGNC:28657","description":"calcium release activated channel regulator 2A","metadata":{"aliases":["MGC4266","RAB46","EFCAB4B"]}},{"id":"77b03505037749aa86facbf0a05c73b5","type":"GENE","name":"CRACR2B","canonical_id":"hgnc:HGNC:28703","description":"calcium release activated channel regulator 2B","metadata":{"aliases":["MGC45840","EFCAB4A"]}},{"id":"c66e789cb46f4e19b5ac74e9180f00da","type":"GENE","name":"CRADD","canonical_id":"hgnc:HGNC:2340","description":"CARD and death domain containing adaptor protein","metadata":{"aliases":["RAIDD"]}},{"id":"0603a752674544eaab2dc52c47c70d61","type":"GENE","name":"CRADD-AS1","canonical_id":"hgnc:HGNC:56184","description":"CRADD antisense RNA 1","metadata":null},{"id":"c3464b380bdf49d1b2f9d16569256364","type":"GENE","name":"CRADDP1","canonical_id":"hgnc:HGNC:56563","description":"CRADD pseudogene 1","metadata":null},{"id":"e422b22c47914e79a7d5dbe0d31c2917","type":"TRIAL","name":"CRAFT: The NCT-PMO-1602 Phase II Trial","canonical_id":"clinicaltrials.gov:NCT04551521","description":"Metastatic or Locally Advanced Malignancies","metadata":null},{"id":"b570c5a7a2cb48a68a3e61411b63c84b","type":"GENE","name":"CRAMP1","canonical_id":"hgnc:HGNC:14122","description":"cramped chromatin regulator 1","metadata":{"aliases":["KIAA1426","CRAMP1L"]}},{"id":"ca638ebfd7cb4c339fd6afa558fc36cf","type":"GENE","name":"CRAT","canonical_id":"hgnc:HGNC:2342","description":"carnitine O-acetyltransferase","metadata":{"aliases":["CAT1"]}},{"id":"f59fec964ac74c99ba72c48b7e56fd74","type":"GENE","name":"CRB1","canonical_id":"hgnc:HGNC:2343","description":"crumbs cell polarity complex component 1","metadata":{"aliases":["LCA8","RP12"]}},{"id":"78321ad979674988afc1b7b70fa75096","type":"GENE","name":"CRB2","canonical_id":"hgnc:HGNC:18688","description":"crumbs cell polarity complex component 2","metadata":{"aliases":["FLJ38464","FLJ16786"]}},{"id":"77e84f48a7a049f5b57946caf55aa9bb","type":"GENE","name":"CRB3","canonical_id":"hgnc:HGNC:20237","description":"crumbs cell polarity complex component 3","metadata":{"aliases":["MGC17303"]}},{"id":"1d1907c854944fafb42ca61a65cb024b","type":"GENE","name":"CRB3P1","canonical_id":"hgnc:HGNC:49684","description":"crumbs cell polarity complex component 3 pseudogene 1","metadata":null},{"id":"eb35528b0f754bfd8aa01d3824734f38","type":"GENE","name":"CRBN","canonical_id":"hgnc:HGNC:30185","description":"cereblon","metadata":{"aliases":["MRT2","MRT2A"]}},{"id":"ea4baee6e9a34315bf04f6af88eddd3d","type":"GENE","name":"CRCP","canonical_id":"hgnc:HGNC:17888","description":"CGRP receptor component","metadata":{"aliases":["CGRP-RCP","RCP","RCP9","C17","POLR3I"]}},{"id":"30bcead637f14089b711dbbe0d183bad","type":"GENE","name":"CRCT1","canonical_id":"hgnc:HGNC:29875","description":"cysteine rich C-terminal 1","metadata":{"aliases":["NICE-1","C1orf42"]}},{"id":"d4518c148fa34be59f172ab9965e58a4","type":"GO_TERM","name":"CRD domain binding","canonical_id":"go:GO:0071906","description":"\"Binding to a CRD (context dependent regulatory) domain, a domain of about 130 residues that is the most divergent region among the LEF/TCF proteins.\" [GOC:yaf, PMID:19460168]","metadata":null},{"id":"b73871d832054f728533e64ef273d18c","type":"GO_TERM","name":"CRD-mediated mRNA stability complex","canonical_id":"go:GO:0070937","description":"\"A protein complex that binds to, and promotes stabilization of, mRNA molecules containing the coding region instability determinant (CRD). In human, it may consist of IGF2BP1, HNRNPU, SYNCRIP/HNRNPQ, YBX1, and DHX9.\" [GOC:mah, PMID:19029303]","metadata":null},{"id":"8f69c06ab2b149fe9d9eb15716812dbe","type":"GO_TERM","name":"CRD-mediated mRNA stabilization","canonical_id":"go:GO:0070934","description":"\"An mRNA stabilization process in which one or more RNA-binding proteins associate with a sequence in the open reading frame called the coding region instability determinant (CRD).\" [GOC:mah, PMID:19029303]","metadata":null},{"id":"0dd5766b66bb4a9e9d2bfd98de956033","type":"GENE","name":"CREB1","canonical_id":"hgnc:HGNC:2345","description":null,"metadata":null},{"id":"d45dd03754324b8ba73a54a6001bd4e3","type":"GENE","name":"CREB3","canonical_id":"hgnc:HGNC:2347","description":null,"metadata":null},{"id":"7d4116be5c784e479780b31fe1f2afc2","type":"GENE","name":"CREB3L1","canonical_id":"hgnc:HGNC:18856","description":null,"metadata":null},{"id":"8b29bf9ea3ca487990693216e87b3f2f","type":"GENE","name":"CREB3L2","canonical_id":"hgnc:HGNC:23720","description":"cAMP responsive element binding protein 3 like 2","metadata":{"aliases":["BBF2H7","TCAG_1951439"]}},{"id":"1a7f867304d146dd8a74303d15233c52","type":"GENE","name":"CREB3L2-AS1","canonical_id":"hgnc:HGNC:41030","description":"CREB3L2 antisense RNA 1","metadata":null},{"id":"721f06ae7fc24f64aeaacc74203c274a","type":"GENE","name":"CREB3L3","canonical_id":"hgnc:HGNC:18855","description":"cAMP responsive element binding protein 3 like 3","metadata":{"aliases":["CREB-H","CREBH"]}},{"id":"9b706cbad88f4f8e9fdc7a5930461219","type":"GENE","name":"CREB3L4","canonical_id":"hgnc:HGNC:18854","description":null,"metadata":null},{"id":"5e218b7677ae4096ac3f69847208d11f","type":"GENE","name":"CREB5","canonical_id":"hgnc:HGNC:16844","description":null,"metadata":null},{"id":"cf9664a0eab144d99f1fbfbca2ecdeb0","type":"GENE","name":"CREBBP","canonical_id":"hgnc:HGNC:2348","description":null,"metadata":null},{"id":"edfd1f6e5e744bbeaec94b3a9425a7fb","type":"GENE","name":"CREBL2","canonical_id":"hgnc:HGNC:2350","description":"cAMP responsive element binding protein like 2","metadata":null},{"id":"01f3a677d8b04ee5b08e1e9fbd1dd4cb","type":"GENE","name":"CREBRF","canonical_id":"hgnc:HGNC:24050","description":"CREB3 regulatory factor","metadata":{"aliases":["LRF","C5orf41"]}},{"id":"c4ab7efe06974a3491d06698e6f5a2a6","type":"GENE","name":"CREBZF","canonical_id":"hgnc:HGNC:24905","description":"CREB/ATF bZIP transcription factor","metadata":{"aliases":["ZF","SMILE"]}},{"id":"c53d8d3fc0724f16b4d56a61a914372a","type":"GENE","name":"CREG1","canonical_id":"hgnc:HGNC:2351","description":null,"metadata":null},{"id":"34318a87dfad4c0f81f3e4c9014215e9","type":"GENE","name":"CREG2","canonical_id":"hgnc:HGNC:14272","description":"cellular repressor of E1A stimulated genes 2","metadata":null},{"id":"0f6c782cd9f44d599a3ae17f87e3bc9e","type":"GENE","name":"CRELD1","canonical_id":"hgnc:HGNC:14630","description":"CRELD disulfide isomerase 1","metadata":{"aliases":["CIRRIN","AVSD2"]}},{"id":"8e6e8301741f4b979969e487a4caf449","type":"GENE","name":"CRELD2","canonical_id":"hgnc:HGNC:28150","description":"CRELD disulfide isomerase 2","metadata":{"aliases":["MGC11256"]}},{"id":"c13d929cb4ff4dceb03d88b5d55904cc","type":"GENE","name":"CREM","canonical_id":"hgnc:HGNC:2352","description":null,"metadata":null},{"id":"731b33ae7f3347aeb787d53532208cac","type":"GENE","name":"CRH","canonical_id":"hgnc:HGNC:2355","description":null,"metadata":null},{"id":"e8ae1218d5574640b52711772fd6781f","type":"GENE","name":"CRHBP","canonical_id":"hgnc:HGNC:2356","description":null,"metadata":null},{"id":"05bb967f3e9447ecb8a8108892f5d914","type":"GENE","name":"CRHR1","canonical_id":"hgnc:HGNC:2357","description":null,"metadata":null},{"id":"ef6e717d7f2a45e5a6b6d05a5c839e4d","type":"GENE","name":"CRHR2","canonical_id":"hgnc:HGNC:2358","description":"corticotropin releasing hormone receptor 2","metadata":{"aliases":["CRF2","CRF-RB","HM-CRF"]}},{"id":"09531779f59d474bb149e76459b086b7","type":"GENE","name":"CRIM1","canonical_id":"hgnc:HGNC:2359","description":"cysteine rich transmembrane BMP regulator 1","metadata":{"aliases":["S52"]}},{"id":"93b130048bd84bbfbc1f2530739f45d3","type":"GENE","name":"CRIM1-DT","canonical_id":"hgnc:HGNC:54057","description":"CRIM1 divergent transcript","metadata":{"aliases":["RP11-490M8.1"]}},{"id":"709c808be73346c890a5fe04f5c13e5e","type":"GENE","name":"CRIP1","canonical_id":"hgnc:HGNC:2360","description":"cysteine rich protein 1","metadata":{"aliases":["CRIP"]}},{"id":"1ce4e0f0a2c64eb98b74d11fca884aae","type":"GENE","name":"CRIP1P1","canonical_id":"hgnc:HGNC:44516","description":"cysteine rich protein 1 pseudogene 1","metadata":null},{"id":"fbf96207ff5f4ccbaacdfbc87daa48ec","type":"GENE","name":"CRIP1P2","canonical_id":"hgnc:HGNC:44517","description":"cysteine rich protein 1 pseudogene 2","metadata":null},{"id":"ede0a735a6e540fcbf3da4e3589950e6","type":"GENE","name":"CRIP1P3","canonical_id":"hgnc:HGNC:44518","description":"cysteine rich protein 1 pseudogene 3","metadata":null},{"id":"dc886c8d5f1d4491921c268886d2d0be","type":"GENE","name":"CRIP1P4","canonical_id":"hgnc:HGNC:44519","description":"cysteine rich protein 1 pseudogene 4","metadata":null},{"id":"5199ccf8b65b4c23b50c18c9413bb7a9","type":"GENE","name":"CRIP2","canonical_id":"hgnc:HGNC:2361","description":"cysteine rich protein 2","metadata":{"aliases":["CRP2","ESP1"]}},{"id":"20924a416df04d6cab1807d06899581f","type":"GENE","name":"CRIP3","canonical_id":"hgnc:HGNC:17751","description":"cysteine rich protein 3","metadata":{"aliases":["TLP-A","bA480N24.2","TLP"]}},{"id":"f227c5694aae40af91a925f62d0f259e","type":"GENE","name":"CRIPT","canonical_id":"hgnc:HGNC:14312","description":"CXXC repeat containing interactor of PDZ3 domain","metadata":{"aliases":["HSPC139"]}},{"id":"b40b1eb897fd415e9f26e9e06818c77e","type":"GENE","name":"CRIPTO3","canonical_id":"hgnc:HGNC:11703","description":"cripto, EGF-CFC family member 3","metadata":{"aliases":["TDGF2","CR-3","CRIPTO-3","TDGF3","TDGF1P3"]}},{"id":"66364a34852f48248bbcb8e9d46401b2","type":"GENE","name":"CRIPTOP1","canonical_id":"hgnc:HGNC:42350","description":"CRIPTO pseudogene 1","metadata":{"aliases":["TDGF1P1"]}},{"id":"7f67028d1c574cf3a33bf0b96c91563d","type":"GENE","name":"CRIPTOP2","canonical_id":"hgnc:HGNC:11702","description":"CRIPTO pseudogene 2","metadata":{"aliases":["CR-2","CRIPTO-2","TDGF2","TDGF1P2"]}},{"id":"1b8d078921c349ad8ec934064319d5a1","type":"GENE","name":"CRIPTOP4","canonical_id":"hgnc:HGNC:11704","description":"CRIPTO pseudogene 4","metadata":{"aliases":["CR-4","CRIPTO-4","TDGF4","TDGF1P4"]}},{"id":"4505e32737144127b759544222a0b473","type":"GENE","name":"CRIPTOP5","canonical_id":"hgnc:HGNC:11705","description":"CRIPTO pseudogene 5","metadata":{"aliases":["CR-5","CRIPTO-5","TDGF5","TDGF1P5"]}},{"id":"53477df4ab7a4abd84ec2556bc7a3337","type":"GENE","name":"CRIPTOP6","canonical_id":"hgnc:HGNC:11706","description":"CRIPTO pseudogene 6","metadata":{"aliases":["CR-6","CRIPTO-6","TDGF6","TDGF1P6"]}},{"id":"626086e865074d8b9584ca9fb387edd9","type":"GENE","name":"CRIPTOP7","canonical_id":"hgnc:HGNC:11707","description":"CRIPTO pseudogene 7","metadata":{"aliases":["CR-7","CRIPTO-7","TDGF7","TDGF1P7"]}},{"id":"bbec7285656a4e14bb50e586204ebf33","type":"GENE","name":"CRISP1","canonical_id":"hgnc:HGNC:304","description":null,"metadata":null},{"id":"399c05d32d0148bebc36d3795ed883dc","type":"GENE","name":"CRISP2","canonical_id":"hgnc:HGNC:12024","description":"cysteine rich secretory protein 2","metadata":{"aliases":["CRISP-2","CT36","GAPDL5","TPX1"]}},{"id":"71fc9b3020f3432f8e8cb7fa7ae8927b","type":"GENE","name":"CRISP3","canonical_id":"hgnc:HGNC:16904","description":null,"metadata":null},{"id":"73a09129e0a049e09d76550ee6bbe474","type":"GENE","name":"CRISPLD1","canonical_id":"hgnc:HGNC:18206","description":"cysteine rich secretory protein LCCL domain containing 1","metadata":{"aliases":["Cocoacrisp","DKFZp762F133","LCRISP1"]}},{"id":"bf3bda526af34453a44f53690f02ee7d","type":"GENE","name":"CRISPLD2","canonical_id":"hgnc:HGNC:25248","description":"cysteine rich secretory protein LCCL domain containing 2","metadata":{"aliases":["DKFZP434B044","LGL1","LCRISP2"]}},{"id":"850d9c75619a491fbbe85f4319f0c4c0","type":"GO_TERM","name":"CRISPR-cas system","canonical_id":"go:GO:0099048","description":"\"A defense response of that serves to clear host cells of foreign DNA and RNA. It has three distinct stage: acquisition of foreign DNA by integration into CRISPR loci in the host chromosome, CRISPR RNA (crRNA) biogenesis, and target interference. CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeat, which describes the nature of the loci.\" [PMID:23495939, PMID:27302758, PMID:29440578]","metadata":null},{"id":"f9126312d24445309af8db5edfd4246f","type":"GENE","name":"CRK","canonical_id":"hgnc:HGNC:2362","description":"CRK proto-oncogene, adaptor protein","metadata":null},{"id":"6c91f5b0a30e4c48b39c53768b550736","type":"GENE","name":"CRK-AS1","canonical_id":"hgnc:HGNC:58106","description":"CRK antisense RNA 1","metadata":{"aliases":["RP11-818O24.3"]}},{"id":"c59648549aa84fe49be83f230643ef5f","type":"GENE","name":"CRKL","canonical_id":"hgnc:HGNC:2363","description":"CRK like proto-oncogene, adaptor protein","metadata":null},{"id":"049993373a0d4d9bbbd1a7c49bf1ff59","type":"GO_TERM","name":"CRLF-CLCF1 complex","canonical_id":"go:GO:0097058","description":"\"A heterodimeric protein complex that is composed of cardiotrophin-like cytokine factor 1 (product of the CLCF1 gene) and cytokine receptor-like factor 1 (product of the CRLF gene) and is secreted into the extracellular space. The CRLF-CLCF1 complex is a ligand for the ciliary neurotrophic factor (CNTF) receptor complex.\" [GOC:BHF, PMID:10966616]","metadata":null},{"id":"fb5856e2763f410bad38dc80ad51d481","type":"GENE","name":"CRLF1","canonical_id":"hgnc:HGNC:2364","description":null,"metadata":null},{"id":"b4d48e6a2a964b82aa8aaac46e60ea20","type":"GENE","name":"CRLF2","canonical_id":"hgnc:HGNC:14281","description":"cytokine receptor like factor 2","metadata":{"aliases":["CRL2","TSLPR"]}},{"id":"2999a98c4aa840daacd79473cef85fa4","type":"GENE","name":"CRLF3","canonical_id":"hgnc:HGNC:17177","description":"cytokine receptor like factor 3","metadata":{"aliases":["CREME9","CYTOR4"]}},{"id":"ec60dfb0ef0641e28a1e716cf42c2858","type":"GENE","name":"CRLF3P1","canonical_id":"hgnc:HGNC:54732","description":"CRLF3 pseudogene 1","metadata":null},{"id":"aa258993241340b4bfbc1fcb86a2893d","type":"GENE","name":"CRLF3P2","canonical_id":"hgnc:HGNC:54733","description":"CRLF3 pseudogene 2","metadata":null},{"id":"303c4ef2944945d8887dfa99a650273e","type":"GENE","name":"CRLF3P3","canonical_id":"hgnc:HGNC:54742","description":"CRLF3 pseudogene 3","metadata":null},{"id":"ab570b78fb444a649417342ecc2668b6","type":"GENE","name":"CRLS1","canonical_id":"hgnc:HGNC:16148","description":"cardiolipin synthase 1","metadata":{"aliases":["dJ967N21.6","CLS1","GCD10","C20orf155"]}},{"id":"ee0642f5437b4b4ca65b90c6e3bd06aa","type":"GENE","name":"CRMA","canonical_id":"hgnc:HGNC:26393","description":"cardiomyocyte maturation associated lncRNA","metadata":{"aliases":["FLJ30313","CARMA","C20orf200","NCRNA00335","C20orf166-AS1","MIR1-1HG-AS1"]}},{"id":"49911f7001dc468fae84b6eaf6abccd7","type":"GENE","name":"CRMP1","canonical_id":"hgnc:HGNC:2365","description":null,"metadata":null},{"id":"aa74ea388e544a84ba0f7f606fc34e0d","type":"GENE","name":"CRNDE","canonical_id":"hgnc:HGNC:37078","description":"colorectal neoplasia differentially expressed","metadata":{"aliases":["LOC643911","LINC00180","CRNDEP"]}},{"id":"8fac3bb8c3234a56aedd86a6ed10a2af","type":"GENE","name":"CRNKL1","canonical_id":"hgnc:HGNC:15762","description":"crooked neck pre-mRNA splicing factor 1","metadata":{"aliases":["CRN","CLF","SYF3","Clf1"]}},{"id":"e1c4cc63ba8a4ac3bedc84503ddd02a6","type":"GENE","name":"CRNN","canonical_id":"hgnc:HGNC:1230","description":"cornulin","metadata":{"aliases":["SEP53","C1orf10"]}},{"id":"976645e17864425094c04d6e4f5b5928","type":"GENE","name":"CROCC","canonical_id":"hgnc:HGNC:21299","description":"ciliary rootlet coiled-coil, rootletin","metadata":{"aliases":["rootletin","ROLT","CROCC1"]}},{"id":"f7e81cc8c71442759a2392857b3c3422","type":"GENE","name":"CROCC2","canonical_id":"hgnc:HGNC:51677","description":"ciliary rootlet coiled-coil, rootletin family member 2","metadata":null},{"id":"cfb2a784cdfa40669105c45f6b798413","type":"GENE","name":"CROCCP1","canonical_id":"hgnc:HGNC:33602","description":"CROCC pseudogene 1","metadata":{"aliases":["CROCCP"]}},{"id":"34dbd643770140fea152b4294ed37a46","type":"GENE","name":"CROCCP2","canonical_id":"hgnc:HGNC:28170","description":"CROCC pseudogene 2","metadata":{"aliases":["MGC12760","CROCCL1"]}},{"id":"98af3db6653c408eafead9d9cf6d8739","type":"GENE","name":"CROCCP3","canonical_id":"hgnc:HGNC:29405","description":"CROCC pseudogene 3","metadata":{"aliases":["KIAA1922","CROCCL2"]}},{"id":"2d0a850f3ad84506950ff1a6d63ea204","type":"GENE","name":"CROCCP4","canonical_id":"hgnc:HGNC:43864","description":"CROCC pseudogene 4","metadata":null},{"id":"335a605a28a64673896544b3a5220cd7","type":"GENE","name":"CROCCP5","canonical_id":"hgnc:HGNC:43865","description":"CROCC pseudogene 5","metadata":null},{"id":"575122f1aa88453a96f9b4eca9758468","type":"GO_TERM","name":"CROP complex","canonical_id":"go:GO:0170071","description":"\"A complex involved in membrane fission during protein exchange in endo-lysosomal compartments. CROP joins members of two protein families: the peripheral subunits of retromer, a coat forming endosomal transport carriers, and membrane inserting PROPPINs.\" [PMID:35466426]","metadata":null},{"id":"f477dba119b34462ba6582aa3da30ac2","type":"GENE","name":"CROT","canonical_id":"hgnc:HGNC:2366","description":"carnitine O-octanoyltransferase","metadata":{"aliases":["COT"]}},{"id":"b79f468d2f5a4a3fa4ca97582e97fb2b","type":"GENE","name":"CRP","canonical_id":"hgnc:HGNC:2367","description":null,"metadata":null},{"id":"36f325c68b934c15a715f0642a24e356","type":"GENE","name":"CRPP1","canonical_id":"hgnc:HGNC:2368","description":"C-reactive protein pseudogene 1","metadata":null},{"id":"549de010181a40e18442819d84595d18","type":"GENE","name":"CRPPA","canonical_id":"hgnc:HGNC:37276","description":"CDP-L-ribitol pyrophosphorylase A","metadata":{"aliases":["hCG_1745121","IspD","Nip","ISPD"]}},{"id":"06ab662e17d4400f84effff37d172161","type":"GENE","name":"CRPPA-AS1","canonical_id":"hgnc:HGNC:48962","description":"CRPPA antisense RNA 1","metadata":{"aliases":["ISPD-AS1"]}},{"id":"6b269d37925246748648e5a6ec13867f","type":"GENE","name":"CRSP5","canonical_id":"hgnc:HGNC:2374","description":"cofactor required for Sp1 transcriptional activation subunit 5","metadata":{"aliases":["CRSP85"]}},{"id":"6db558f8a50e432fab45ac7873a3b006","type":"TRIAL","name":"CRT-Guanfacine for SPD","canonical_id":"clinicaltrials.gov:NCT02524899","description":"Schizotypal Personality Disorder; SPD","metadata":null},{"id":"39d75cc5f8cb4ad2b10f32bef828ec04","type":"GENE","name":"CRTAC1","canonical_id":"hgnc:HGNC:14882","description":"cartilage acidic protein 1","metadata":{"aliases":["FLJ10320","CEP-68","ASPIC1"]}},{"id":"da64ac54e1934b6185cc37157abd6718","type":"GENE","name":"CRTAM","canonical_id":"hgnc:HGNC:24313","description":"cytotoxic and regulatory T cell molecule","metadata":{"aliases":["CD355"]}},{"id":"d8a2fca8932749fb8a866116549fae03","type":"GENE","name":"CRTAP","canonical_id":"hgnc:HGNC:2379","description":"cartilage associated protein","metadata":{"aliases":["CASP","LEPREL3","P3H5"]}},{"id":"7254c95de5e04b6684e6ac92440eb3ff","type":"GENE","name":"CRTC1","canonical_id":"hgnc:HGNC:16062","description":null,"metadata":null},{"id":"5f79d2ca27434dd39bf8c5cf84657a39","type":"GENE","name":"CRTC1P1","canonical_id":"hgnc:HGNC:54616","description":"CRTC1 pseudogene 1","metadata":null},{"id":"e0344f4d04504d09b27927e15e379404","type":"GENE","name":"CRTC2","canonical_id":"hgnc:HGNC:27301","description":"CREB regulated transcription coactivator 2","metadata":{"aliases":["TORC2"]}},{"id":"f16a977c2928456bbcf6972578202d32","type":"GENE","name":"CRTC3","canonical_id":"hgnc:HGNC:26148","description":"CREB regulated transcription coactivator 3","metadata":{"aliases":["FLJ21868"]}},{"id":"f9511182679e40998b046d30038475ec","type":"GENE","name":"CRTC3-AS1","canonical_id":"hgnc:HGNC:51433","description":"CRTC3 antisense RNA 1","metadata":null},{"id":"672a1617380449979210cc6f6a4c364d","type":"GENE","name":"CRX","canonical_id":"hgnc:HGNC:2383","description":null,"metadata":null},{"id":"e3ae34e27d2b43578f44443081b9127b","type":"GENE","name":"CRY1","canonical_id":"hgnc:HGNC:2384","description":null,"metadata":null},{"id":"826a8f38214d4d5ba2834389e80cdaa6","type":"GENE","name":"CRY2","canonical_id":"hgnc:HGNC:2385","description":null,"metadata":null},{"id":"ddcc8f8f5c3049ffa14a8bf9518ef8d2","type":"GENE","name":"CRYAA","canonical_id":"hgnc:HGNC:2388","description":"crystallin alpha A","metadata":{"aliases":["HSPB4","CRYA1"]}},{"id":"83d5f23e10a54ec0b53064dad19efd74","type":"GENE","name":"CRYAB","canonical_id":"hgnc:HGNC:2389","description":null,"metadata":null},{"id":"69b5013fc07a404f9efb5f83a7cb800e","type":"GENE","name":"CRYBA1","canonical_id":"hgnc:HGNC:2394","description":"crystallin beta A1","metadata":{"aliases":["CRYB1"]}},{"id":"a4d5185499e747c1952385587708a68c","type":"GENE","name":"CRYBA2","canonical_id":"hgnc:HGNC:2395","description":"crystallin beta A2","metadata":null},{"id":"7a27c518476644139472610f6cc9ca85","type":"GENE","name":"CRYBA4","canonical_id":"hgnc:HGNC:2396","description":"crystallin beta A4","metadata":null},{"id":"0cb1ded60c7a4e62aa48067d4c6a1509","type":"GENE","name":"CRYBB1","canonical_id":"hgnc:HGNC:2397","description":"crystallin beta B1","metadata":null},{"id":"0cb459b4c59c41e496d3e5e1c72b86e8","type":"GENE","name":"CRYBB2","canonical_id":"hgnc:HGNC:2398","description":"crystallin beta B2","metadata":{"aliases":["CCA2","CRYB2A","CRYB2"]}},{"id":"da03fa54ebcc4146982b66aa77ada52f","type":"GENE","name":"CRYBB2P1","canonical_id":"hgnc:HGNC:2399","description":"crystallin beta B2 pseudogene 1","metadata":{"aliases":["CRYB2B"]}},{"id":"388a74e90476430c9d9bec7c7f966710","type":"GENE","name":"CRYBB3","canonical_id":"hgnc:HGNC:2400","description":"crystallin beta B3","metadata":{"aliases":["CRYB3"]}},{"id":"0a020e890c8d4a08add400f19d031b8c","type":"GENE","name":"CRYBG1","canonical_id":"hgnc:HGNC:356","description":"crystallin beta-gamma domain containing 1","metadata":{"aliases":["ST4","AIM1"]}},{"id":"a9d7f28f9bfc4dce9b299a57d06f7ed1","type":"GENE","name":"CRYBG2","canonical_id":"hgnc:HGNC:17295","description":"crystallin beta-gamma domain containing 2","metadata":{"aliases":["FLJ38020","AIM1L"]}},{"id":"5f1f2862b0dd4b1f90be3f0d7ae0748e","type":"GENE","name":"CRYBG3","canonical_id":"hgnc:HGNC:34427","description":"crystallin beta-gamma domain containing 3","metadata":{"aliases":["DKFZp667G2110"]}},{"id":"6aa6f784f1e14a62aec20c19b5418646","type":"GENE","name":"CRYGA","canonical_id":"hgnc:HGNC:2408","description":null,"metadata":null},{"id":"a6f7cabe5c1e45e2affbdda12dbbe7d6","type":"GENE","name":"CRYGB","canonical_id":"hgnc:HGNC:2409","description":null,"metadata":null},{"id":"53b3ccd419ac468bb5e2e5966fda9e6a","type":"GENE","name":"CRYGC","canonical_id":"hgnc:HGNC:2410","description":null,"metadata":null},{"id":"3ffaf286b5664db7841e2562b2d728da","type":"GENE","name":"CRYGD","canonical_id":"hgnc:HGNC:2411","description":"crystallin gamma D","metadata":{"aliases":["CRYG4"]}},{"id":"f0309b5ad07b412595070f4d87869c86","type":"GENE","name":"CRYGEP","canonical_id":"hgnc:HGNC:2412","description":"crystallin gamma E, pseudogene","metadata":{"aliases":["G2","CRYG5","CCL","CRYGEP1"]}},{"id":"334cdbeaddae4b6db49b0288aaf5887b","type":"GENE","name":"CRYGFP","canonical_id":"hgnc:HGNC:2413","description":"crystallin gamma F, pseudogene","metadata":{"aliases":["p1","CRYG6","CRYGFP1"]}},{"id":"bad97cbde68041ef9001e1f148e4cc94","type":"GENE","name":"CRYGGP","canonical_id":"hgnc:HGNC:2414","description":"crystallin gamma G, pseudogene","metadata":{"aliases":["CRYGGP1"]}},{"id":"64901f955be9494e9c03dc27482d90df","type":"GENE","name":"CRYGN","canonical_id":"hgnc:HGNC:20458","description":"crystallin gamma N","metadata":null},{"id":"cc1d32843b124dea9146d9858dfa6cd6","type":"GENE","name":"CRYGN-AS1","canonical_id":"hgnc:HGNC:58406","description":"CRYGN antisense RNA 1","metadata":null},{"id":"063d576be7b747efb37fee39636675e2","type":"GENE","name":"CRYGS","canonical_id":"hgnc:HGNC:2417","description":"crystallin gamma S","metadata":{"aliases":["CRYG8"]}},{"id":"cbc014ebcb58456fabb7a6908c0da858","type":"GENE","name":"CRYL1","canonical_id":"hgnc:HGNC:18246","description":"crystallin lambda 1","metadata":{"aliases":["GDH","lambda-CRY","MGC149525","MGC149526"]}},{"id":"8f5fe9fb599646ec983e6453fe37cdef","type":"GENE","name":"CRYM","canonical_id":"hgnc:HGNC:2418","description":"crystallin mu","metadata":{"aliases":["DFNA40"]}},{"id":"2223da315a6641a880f3b7d6626b8c06","type":"GENE","name":"CRYZ","canonical_id":"hgnc:HGNC:2419","description":"crystallin zeta","metadata":null},{"id":"74e5b307c6624f12a3d3897474bcef67","type":"GENE","name":"CRYZL1","canonical_id":"hgnc:HGNC:2420","description":"crystallin zeta like 1","metadata":{"aliases":["QOH-1","4P11","Fy-4","FERRY4"]}},{"id":"11be11fab78040a18a65ca0ba7c98afe","type":"GENE","name":"CRYZL2P","canonical_id":"hgnc:HGNC:52164","description":"crystallin zeta like 2, pseudogene","metadata":null},{"id":"b354277122b8443c87d8233cbab6f7d4","type":"GENE","name":"CRYZL2P-SEC16B","canonical_id":"hgnc:HGNC:53757","description":"CRYZL2P-SEC16B readthrough","metadata":null},{"id":"7776426f163248fdb71951b7de3bb916","type":"GENE","name":"CRYZP1","canonical_id":"hgnc:HGNC:2421","description":"crystallin zeta pseudogene 1","metadata":null},{"id":"c28ac0c0ec1a4667bf64e15784157983","type":"GENE","name":"CRYZP2","canonical_id":"hgnc:HGNC:49203","description":"crystallin zeta pseudogene 2","metadata":null},{"id":"b74a0ba66fd248f4a7f9f8a93b55e8fa","type":"GENE","name":"CS","canonical_id":"hgnc:HGNC:2422","description":"citrate synthase","metadata":null},{"id":"c4549ca965354c7e88665a3a9f7c4fc3","type":"GENE","name":"CSAD","canonical_id":"hgnc:HGNC:18966","description":"cysteine sulfinic acid decarboxylase","metadata":{"aliases":["CSADC","PCAP","CSD"]}},{"id":"acc28ef7ba0b4e218cb31500894b8d2d","type":"GENE","name":"CSAD-AS1","canonical_id":"hgnc:HGNC:58448","description":"CSAD antisense RNA 1","metadata":null},{"id":"82a630efc88e4597927fe1f13f80a54b","type":"GENE","name":"CSAG1","canonical_id":"hgnc:HGNC:24294","description":"chondrosarcoma associated gene 1","metadata":{"aliases":["CSAGE","CT24.1"]}},{"id":"884e21aec443415f80eac94c828d4289","type":"GENE","name":"CSAG2","canonical_id":"hgnc:HGNC:16847","description":"CSAG family member 2","metadata":{"aliases":["TRAG3","CT24.2","CSAG3B"]}},{"id":"9c6cf539479042b9bc3885fae540e852","type":"GENE","name":"CSAG3","canonical_id":"hgnc:HGNC:26237","description":"CSAG family member 3","metadata":{"aliases":["CSAG3A"]}},{"id":"8285133dde9c475b9ed8187916d584fb","type":"GENE","name":"CSAG4","canonical_id":"hgnc:HGNC:20923","description":"CSAG family member 4 (pseudogene)","metadata":null},{"id":"e8841bb107d846aeb715c0bd2911eaa4","type":"GENE","name":"CSDC2","canonical_id":"hgnc:HGNC:30359","description":"cold shock domain containing C2","metadata":{"aliases":["PIPPin"]}},{"id":"f55521e018a14551a2481370ffb0eaf7","type":"GENE","name":"CSDE1","canonical_id":"hgnc:HGNC:29905","description":"cold shock domain containing E1","metadata":{"aliases":["D1S155E","UNR"]}},{"id":"d7b8a61622204bc38b75759a10baf919","type":"GENE","name":"CSE1L","canonical_id":"hgnc:HGNC:2431","description":"chromosome segregation 1 like","metadata":{"aliases":["CAS","XPO2","CSE1"]}},{"id":"dfcd309fb32345ea8738de749e7a9d65","type":"GENE","name":"CSE1L-DT","canonical_id":"hgnc:HGNC:51232","description":"CSE1L divergent transcript","metadata":{"aliases":["CSE1L-AS1"]}},{"id":"715480bab3f9439a895bc7850f20fcbb","type":"GENE","name":"CSF1","canonical_id":"hgnc:HGNC:2432","description":null,"metadata":null},{"id":"736224f1fbb74a2987adc26f6531490d","type":"GO_TERM","name":"CSF1-CSF1R complex","canonical_id":"go:GO:1990682","description":"\"A protein complex consisting of a macrophage colony-stimulating factor (CSF1, also called M-CSF) dimer bound to a dimerized receptor (CSF1R, also called FMS). Receptor dimerization requires the presence of the ligand.\" [GOC:bf, GOC:BHF, GOC:nc, PMID:19017797]","metadata":null},{"id":"97f4f47e03024179a19f16da51562a07","type":"GENE","name":"CSF1R","canonical_id":"hgnc:HGNC:2433","description":null,"metadata":null},{"id":"85697e39358044ec96957083a04a38fe","type":"PROTEIN","name":"CSF1R","canonical_id":"uniprot:P07333","description":null,"metadata":null},{"id":"17bc3aac24cb4aeda1e463e035b3498b","type":"DISEASE","name":"CSF1R-related disorder","canonical_id":"mondo:0100632","description":null,"metadata":null},{"id":"462e470cb39646248d1759479bc7704d","type":"GENE","name":"CSF2","canonical_id":"hgnc:HGNC:2434","description":null,"metadata":null},{"id":"e28c991b10e34499b1ab194484458b4f","type":"GENE","name":"CSF2RA","canonical_id":"hgnc:HGNC:2435","description":null,"metadata":null},{"id":"ff1c06779ea947a6a5d1611101634fb6","type":"GENE","name":"CSF2RB","canonical_id":"hgnc:HGNC:2436","description":"colony stimulating factor 2 receptor subunit beta","metadata":{"aliases":["IL5RB","CD131","betaGMR","IL3RB"]}},{"id":"eab5032371ce4240a1bd6ed1e415d1f0","type":"GENE","name":"CSF2RBP1","canonical_id":"hgnc:HGNC:2437","description":"CSF2RB pseudogene 1","metadata":{"aliases":["CSF2RB2"]}},{"id":"42c980cd669448609c227e6e4eca68f2","type":"GENE","name":"CSF3","canonical_id":"hgnc:HGNC:2438","description":"colony stimulating factor 3","metadata":{"aliases":["MGC45931","GCSF","G-CSF","C17orf33"]}},{"id":"f082906061244a3b964b829f5ce3b6c3","type":"GENE","name":"CSF3R","canonical_id":"hgnc:HGNC:2439","description":null,"metadata":null},{"id":"5f72f19b3f9c46c6aa013cb381214bfd","type":"PROTEIN","name":"CSF3R","canonical_id":"uniprot:Q99062","description":null,"metadata":null},{"id":"becfe41fcd5a452195f145e4c5f8a95f","type":"GENE","name":"CSGALNACT1","canonical_id":"hgnc:HGNC:24290","description":"chondroitin sulfate N-acetylgalactosaminyltransferase 1","metadata":{"aliases":["CSGalNAcT-1","FLJ11264","ChGn"]}},{"id":"5b59c417a2c64b02b6ec2d2633aa5dce","type":"GENE","name":"CSGALNACT1-AS1","canonical_id":"hgnc:HGNC:58187","description":"CSGALNACT1 antisense RNA 1","metadata":null},{"id":"a75a8547287e45329699036952aff352","type":"GENE","name":"CSGALNACT2","canonical_id":"hgnc:HGNC:24292","description":"chondroitin sulfate N-acetylgalactosaminyltransferase 2","metadata":{"aliases":["GALNACT2","MGC40204","PRO0082","GALNACT-2"]}},{"id":"867a59069a3c4f65acff9e0542afb5fa","type":"GENE","name":"CSGALNACT2-DT","canonical_id":"hgnc:HGNC:55174","description":"CSGALNACT2 divergent transcript","metadata":null},{"id":"813b48a63daf4b90bf9250a5e1a6c191","type":"GENE","name":"CSGALNACT2P1","canonical_id":"hgnc:HGNC:55033","description":"CSGALNACT2 pseudogene 1","metadata":null},{"id":"d362a738a7eb457ca921ebb642e07fbb","type":"GENE","name":"CSGALNACT2P2","canonical_id":"hgnc:HGNC:55034","description":"CSGALNACT2 pseudogene 2","metadata":null},{"id":"c6cab59a6faf47298c63597a84f32ca0","type":"GENE","name":"CSH1","canonical_id":"hgnc:HGNC:2440","description":null,"metadata":null},{"id":"73c31496e6d747a891183d8de031bf2f","type":"GENE","name":"CSH2","canonical_id":"hgnc:HGNC:2441","description":null,"metadata":null},{"id":"6e6f42dda1604ae2825bbbadf6d401e5","type":"GENE","name":"CSHL1","canonical_id":"hgnc:HGNC:2442","description":"chorionic somatomammotropin hormone like 1","metadata":{"aliases":["hCS-L","CSL","CS-5","MGC149868","CSHP1"]}},{"id":"ff4b7334886749339224b928f16a8aea","type":"GENE","name":"CSK","canonical_id":"hgnc:HGNC:2444","description":"C-terminal Src kinase","metadata":null},{"id":"e081b4ca116246fc830f9f9113ffb2cf","type":"GO_TERM","name":"CSK-GAP-A.p62 complex","canonical_id":"go:GO:0070214","description":"\"A protein complex that contains the protein-tyrosine kinase CSK and the GTPase-activating protein (GAP)-associated p62 (GAP-A.p62); may mediate translocation of proteins, including GAP and CSK, to membrane or cytoskeletal regions upon c-Src activation.\" [PMID:7544435]","metadata":null},{"id":"50925339c9cf4ba789a04a45ed9cdea1","type":"GENE","name":"CSKMT","canonical_id":"hgnc:HGNC:33113","description":"citrate synthase lysine methyltransferase","metadata":{"aliases":["U99HG","CS-KMT","METTL12"]}},{"id":"0b1d605177a24bda9f59751cf61338c1","type":"GO_TERM","name":"CSL-Notch-Mastermind transcription factor complex","canonical_id":"go:GO:1990433","description":"\"A DNA-binding transcription factor complex consisting of CSL and mastermind proteins in complex with the cleaved, intracellular domain of Notch. It is required for both repression and activation of Notch target genes.\" [GOC:bhm, GOC:dos, PMID:16530045]","metadata":null},{"id":"7736cc96f35840dcb9ea94b9ebd4c4b9","type":"GENE","name":"CSMD1","canonical_id":"hgnc:HGNC:14026","description":"CUB and Sushi multiple domains 1","metadata":{"aliases":["KIAA1890","PPP1R24"]}},{"id":"3527314560744537b2619dcb47a98da2","type":"GENE","name":"CSMD2","canonical_id":"hgnc:HGNC:19290","description":"CUB and Sushi multiple domains 2","metadata":{"aliases":["KIAA1884"]}},{"id":"709252fbca6c4182a9f8a23514bce586","type":"GENE","name":"CSMD2-AS1","canonical_id":"hgnc:HGNC:40882","description":"CSMD2 antisense RNA 1","metadata":{"aliases":["ENST00000434181"]}},{"id":"f3c67afcbcb74e0dbb8b8d7d139a4842","type":"GENE","name":"CSMD3","canonical_id":"hgnc:HGNC:19291","description":"CUB and Sushi multiple domains 3","metadata":null},{"id":"807a7c153d84470f994861a9595950cf","type":"GENE","name":"CSN1S1","canonical_id":"hgnc:HGNC:2445","description":"casein alpha s1","metadata":{"aliases":["CASA","CSN1"]}},{"id":"8e654742b5eb4a07ab54b3bae7ee291f","type":"GENE","name":"CSN1S2AP","canonical_id":"hgnc:HGNC:20230","description":"casein alpha s2 like A, pseudogene","metadata":{"aliases":["CSN1S2A"]}},{"id":"99fa8fffe63b42c6ae4547885f90256d","type":"GENE","name":"CSN1S2BP","canonical_id":"hgnc:HGNC:20227","description":"casein alpha s2 like B, pseudogene","metadata":{"aliases":["CSN1S2B"]}},{"id":"544e9a5fadd14b53bd929d60663df4ca","type":"GENE","name":"CSN2","canonical_id":"hgnc:HGNC:2447","description":null,"metadata":null},{"id":"c019f68135044ae49a92755f6e5c44a6","type":"GENE","name":"CSN3","canonical_id":"hgnc:HGNC:2446","description":"casein kappa","metadata":{"aliases":["CSN10"]}},{"id":"17314800d51940968612758bbad5e0dc","type":"GENE","name":"CSNK1A1","canonical_id":"hgnc:HGNC:2451","description":null,"metadata":null},{"id":"b954b66cde1840a1bbadf571e6bcfe41","type":"GENE","name":"CSNK1A1L","canonical_id":"hgnc:HGNC:20289","description":"casein kinase 1 alpha 1 like","metadata":{"aliases":["MGC33182"]}},{"id":"ac96f818af2441fcbfa49059efe8560f","type":"GENE","name":"CSNK1A1P1","canonical_id":"hgnc:HGNC:30446","description":"casein kinase 1 alpha 1 pseudogene 1","metadata":{"aliases":["CSNK1A1P"]}},{"id":"7af2a09ba41642d19137c6a31cbf6e5d","type":"GENE","name":"CSNK1A1P2","canonical_id":"hgnc:HGNC:30445","description":"casein kinase 1 alpha 1 pseudogene 2","metadata":null},{"id":"fba673e9aed443d79c9267f869d8d28c","type":"GENE","name":"CSNK1A1P3","canonical_id":"hgnc:HGNC:38669","description":"casein kinase 1 alpha 1 pseudogene 3","metadata":null},{"id":"baceb4ed43a04bf983dab147701586c1","type":"GENE","name":"CSNK1D","canonical_id":"hgnc:HGNC:2452","description":"casein kinase 1 delta","metadata":{"aliases":["HCKID","CKID","CKIdelta"]}},{"id":"c8449feeb31a4e7c8ec390212d9b7632","type":"GENE","name":"CSNK1E","canonical_id":"hgnc:HGNC:2453","description":"casein kinase 1 epsilon","metadata":{"aliases":["HCKIE","CKIE","CKIepsilon"]}},{"id":"1c612ab947cf4eafbfae1f650226a4a2","type":"GENE","name":"CSNK1G1","canonical_id":"hgnc:HGNC:2454","description":"casein kinase 1 gamma 1","metadata":{"aliases":["CK1gamma1"]}},{"id":"df2ae339b8eb4d8b9f87df9d78b86e6f","type":"GENE","name":"CSNK1G2","canonical_id":"hgnc:HGNC:2455","description":"casein kinase 1 gamma 2","metadata":{"aliases":["CK1g2"]}},{"id":"85cf1ecdd6524554839acea3c2a9a40c","type":"GENE","name":"CSNK1G2-AS1","canonical_id":"hgnc:HGNC:28604","description":"CSNK1G2 antisense RNA 1","metadata":{"aliases":["MGC39696","C19orf34"]}},{"id":"9a538326e5ee4979b41665033fab3b4b","type":"GENE","name":"CSNK1G2P1","canonical_id":"hgnc:HGNC:49739","description":"casein kinase 1 gamma 2 pseudogene 1","metadata":null},{"id":"08f0c73c14504002b201c5d7898ec30d","type":"GENE","name":"CSNK1G3","canonical_id":"hgnc:HGNC:2456","description":"casein kinase 1 gamma 3","metadata":null},{"id":"6af8a73c30dc48fe824f563dcf38ddf4","type":"GENE","name":"CSNK1G3-AS1","canonical_id":"hgnc:HGNC:59123","description":"CSNK1G3 antisense RNA 1","metadata":null},{"id":"dba6d7d34fc04bee8932a0e1e089d3d8","type":"GENE","name":"CSNK2A1","canonical_id":"hgnc:HGNC:2457","description":null,"metadata":null},{"id":"7a6ad915f6f64667a9bac0186cebb462","type":"GENE","name":"CSNK2A2","canonical_id":"hgnc:HGNC:2459","description":"casein kinase 2 alpha 2","metadata":{"aliases":["CSNK2A1","CK2alpha'"]}},{"id":"8b45493fb2d84ad19c3838306ea85578","type":"GENE","name":"CSNK2A2IP","canonical_id":"hgnc:HGNC:53637","description":"casein kinase 2 subunit alpha' interacting protein","metadata":{"aliases":["CSNKA2IP"]}},{"id":"aac8d36615504229983759a181048dca","type":"GENE","name":"CSNK2A3","canonical_id":"hgnc:HGNC:2458","description":"casein kinase 2 alpha 3","metadata":{"aliases":["CSNK2A1P"]}},{"id":"59c1c6fd9369466db6f34908fc8f6b34","type":"GENE","name":"CSNK2B","canonical_id":"hgnc:HGNC:2460","description":null,"metadata":null},{"id":"7bf174d4f199473dac5929b6612e700c","type":"GENE","name":"CSP1","canonical_id":"hgnc:HGNC:54777","description":"CS pseudogene 1","metadata":null},{"id":"45b713c617264d1da52b80b974699af4","type":"GENE","name":"CSP2","canonical_id":"hgnc:HGNC:54779","description":"CS pseudogene 2","metadata":null},{"id":"34f1a13048364f0189da68651b1073a4","type":"GENE","name":"CSP3","canonical_id":"hgnc:HGNC:54780","description":"CS pseudogene 3","metadata":null},{"id":"0d548f11d5354c4caf1743494f5f2426","type":"GENE","name":"CSPG4","canonical_id":"hgnc:HGNC:2466","description":"chondroitin sulfate proteoglycan 4","metadata":{"aliases":["MCSPG","MEL-CSPG","MSK16","NG2","MCSP","HMW-MAA","CSPG4A"]}},{"id":"ec206c38ee4c4ecca1795126220a62c9","type":"GENE","name":"CSPG4BP","canonical_id":"hgnc:HGNC:51505","description":"chondroitin sulfate proteoglycan family member 4B, pseudogene","metadata":null},{"id":"86232bd860f64c85bc103883b1c4127b","type":"GENE","name":"CSPG4P10","canonical_id":"hgnc:HGNC:48361","description":"chondroitin sulfate proteoglycan 4 pseudogene 10","metadata":null},{"id":"dfe00a3d8d8b4554ad1a5bc8ba2a69e6","type":"GENE","name":"CSPG4P11","canonical_id":"hgnc:HGNC:48363","description":"chondroitin sulfate proteoglycan 4 pseudogene 11","metadata":null},{"id":"dcf1a6e155e54e8cb6f43cc33d3af210","type":"GENE","name":"CSPG4P12","canonical_id":"hgnc:HGNC:48362","description":"chondroitin sulfate proteoglycan 4 pseudogene 12","metadata":null},{"id":"ebb77cbf694041cb8318aef2440194a5","type":"GENE","name":"CSPG4P13","canonical_id":"hgnc:HGNC:49195","description":"chondroitin sulfate proteoglycan 4 pseudogene 13","metadata":null},{"id":"d7d9d958de1c40f1addd0642b2ed58e8","type":"GENE","name":"CSPG4P1Y","canonical_id":"hgnc:HGNC:16478","description":"CSPG4 pseudogene 1 Y-linked","metadata":{"aliases":["CSPG4LYP1","CSPG4P1"]}},{"id":"4b051289cb3a4ab1954b909d89c2f052","type":"GENE","name":"CSPG4P2Y","canonical_id":"hgnc:HGNC:32424","description":"CSPG4 pseudogene 2 Y-linked","metadata":{"aliases":["CSPG4LYP2","CSPG4P2"]}},{"id":"e049298720684b7db7bd582f77547b73","type":"GENE","name":"CSPG4P3Y","canonical_id":"hgnc:HGNC:38111","description":"CSPG4 pseudogene 3 Y-linked","metadata":{"aliases":["CSPG4P3","CSPG4P6Y"]}},{"id":"2ca2397421204d4b97f84b61fd0640f9","type":"GENE","name":"CSPG4P4Y","canonical_id":"hgnc:HGNC:38535","description":"CSPG4 pseudogene 4 Y-linked","metadata":{"aliases":["CSPG4P4","CSPG4P7Y"]}},{"id":"e207af01fb654cada58a8cb52217f029","type":"GENE","name":"CSPG4P5","canonical_id":"hgnc:HGNC:29403","description":"chondroitin sulfate proteoglycan 4 pseudogene 5","metadata":null},{"id":"140c2513219f456d8335935b8e3f9379","type":"GENE","name":"CSPG4P9","canonical_id":"hgnc:HGNC:48360","description":"chondroitin sulfate proteoglycan 4 pseudogene 9","metadata":null},{"id":"fb1677701cb0406582ca4b65ab651fa8","type":"GENE","name":"CSPG5","canonical_id":"hgnc:HGNC:2467","description":"chondroitin sulfate proteoglycan 5","metadata":{"aliases":["NGC"]}},{"id":"fe855b1dcd2141ff98c53329ad66c980","type":"GENE","name":"CSPP1","canonical_id":"hgnc:HGNC:26193","description":"centrosome and spindle pole associated protein 1","metadata":{"aliases":["FLJ22490","CSPP","JBTS21","CSPP-L"]}},{"id":"2033dbb63c3f4981bf64892ac78024d2","type":"GENE","name":"CSRNP1","canonical_id":"hgnc:HGNC:14300","description":"cysteine and serine rich nuclear protein 1","metadata":{"aliases":["URAX1","DKFZp566F164","FAM130B","TAIP-3","AXUD1"]}},{"id":"00652eeb82d540ef9305d09b7fa610da","type":"GENE","name":"CSRNP2","canonical_id":"hgnc:HGNC:16006","description":"cysteine and serine rich nuclear protein 2","metadata":{"aliases":["C12ORF2","TAIP-12","PPP1R72","C12orf22","FAM130A1"]}},{"id":"28f057edeef843ba9c38025795bc2c1e","type":"GENE","name":"CSRNP3","canonical_id":"hgnc:HGNC:30729","description":"cysteine and serine rich nuclear protein 3","metadata":{"aliases":["FLJ32093","TAIP-2","PPP1R73","FAM130A2"]}},{"id":"ac0ebbd3f22344eb8f144b87d06e5744","type":"GENE","name":"CSRP1","canonical_id":"hgnc:HGNC:2469","description":null,"metadata":null},{"id":"6ce1d7928b784703aa855c93ae4fa3eb","type":"GENE","name":"CSRP1-AS1","canonical_id":"hgnc:HGNC:55856","description":"CSRP1 antisense RNA 1","metadata":{"aliases":["AC096677.1"]}},{"id":"e3501c3bb9b144e5adad5750a5622c7f","type":"GENE","name":"CSRP2","canonical_id":"hgnc:HGNC:2470","description":"cysteine and glycine rich protein 2","metadata":{"aliases":["SmLIM","CRP2","LMO5"]}},{"id":"80db349b6c2241a29c58a051b7f5b7d7","type":"GENE","name":"CSRP2P1","canonical_id":"hgnc:HGNC:2471","description":"CSRP2 pseudogene 1","metadata":{"aliases":["CSRP2P"]}},{"id":"2d10ada1db08405c90e49ab2e2427611","type":"GENE","name":"CSRP2P2","canonical_id":"hgnc:HGNC:56524","description":"CSRP2 pseudogene 2","metadata":null},{"id":"65f0a1446be34e35b846ef2b87819f4f","type":"GENE","name":"CSRP3","canonical_id":"hgnc:HGNC:2472","description":"cysteine and glycine rich protein 3","metadata":{"aliases":["CLP","MLP","CMD1M"]}},{"id":"9d12fc9ea8554849a28a71050a02886c","type":"GENE","name":"CSRP3-AS1","canonical_id":"hgnc:HGNC:54183","description":"CSRP3 and E2F8 antisense RNA 1","metadata":null},{"id":"d2cf538522da4259b0abe31ea89df9fd","type":"GO_TERM","name":"CST complex","canonical_id":"go:GO:1990879","description":"\"A complex formed by the association of Cdc13 (CTC1 in mammals) with Stn1 in yeast (OBFC1 in mammals) and Ten1 protein (also TEN1 in mammals) with single-stranded telomeric DNA. The CST complex plays a role in telomere protection.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:19854130, PMID:22965356]","metadata":null},{"id":"d1a1e2121ac34a1e8d0f9db678730898","type":"GENE","name":"CST1","canonical_id":"hgnc:HGNC:2473","description":"cystatin SN","metadata":null},{"id":"b7b64ea0f665437d9554eab3f0926ad8","type":"GENE","name":"CST11","canonical_id":"hgnc:HGNC:15959","description":"cystatin 11","metadata":{"aliases":["dJ322G13.6","CTES2","CST8L"]}},{"id":"718fc2efad924872b51dd4b8ebe199c1","type":"GENE","name":"CST12P","canonical_id":"hgnc:HGNC:31920","description":"cystatin 12, pseudogene","metadata":{"aliases":["Cst","E2","Ctes4"]}},{"id":"d4f48f34f1064b2998a7fff6922d7601","type":"GENE","name":"CST13P","canonical_id":"hgnc:HGNC:44335","description":"cystatin 13, pseudogene","metadata":{"aliases":["CTES6","CSTT"]}},{"id":"a78bfd16050f42b69c0e4c6904a9d32d","type":"GENE","name":"CST2","canonical_id":"hgnc:HGNC:2474","description":"cystatin SA","metadata":null},{"id":"6acd39b7608d4b169a77bce3c5a05b01","type":"GENE","name":"CST2P1","canonical_id":"hgnc:HGNC:45042","description":"cystatin SA pseudogene 1","metadata":null},{"id":"6ea2b75cf19e4c45b66677a5385d0c04","type":"GENE","name":"CST3","canonical_id":"hgnc:HGNC:2475","description":"cystatin C","metadata":null},{"id":"6d067004262d475eb979a17f97502485","type":"GENE","name":"CST4","canonical_id":"hgnc:HGNC:2476","description":"cystatin S","metadata":null},{"id":"a58d2f1e60f7463a8b9e0efe5ebce079","type":"GENE","name":"CST5","canonical_id":"hgnc:HGNC:2477","description":null,"metadata":null},{"id":"7602d238894049f59b3edcc8e7f9d8ab","type":"GENE","name":"CST6","canonical_id":"hgnc:HGNC:2478","description":"cystatin E/M","metadata":null},{"id":"dc66dcca7e4542abbf91a9e81e696ec9","type":"GENE","name":"CST7","canonical_id":"hgnc:HGNC:2479","description":"cystatin F","metadata":null},{"id":"89151a8b393848fa9a1da34bc27d38d4","type":"GENE","name":"CST8","canonical_id":"hgnc:HGNC:2480","description":"cystatin 8","metadata":{"aliases":["CRES","CTES5"]}},{"id":"0cc328b1c69e483283eb714c66141249","type":"GENE","name":"CST9","canonical_id":"hgnc:HGNC:13261","description":"cystatin 9","metadata":{"aliases":["CLM","CTES7A"]}},{"id":"2b29eb05ca2f45a89e602f0781e966c5","type":"GENE","name":"CST9L","canonical_id":"hgnc:HGNC:16233","description":"cystatin 9 like","metadata":{"aliases":["bA218C14.1","CTES7B"]}},{"id":"4a3f573707d442f38ec85d076bec65ad","type":"GENE","name":"CST9LP1","canonical_id":"hgnc:HGNC:39552","description":"cystatin 9-like pseudogene 1","metadata":{"aliases":["CTES7C"]}},{"id":"5b9906cd4c5b42da99e279a9a4cbd5bb","type":"GENE","name":"CST9LP2","canonical_id":"hgnc:HGNC:44337","description":"cystatin 9-like pseudogene 2","metadata":{"aliases":["CTES7D"]}},{"id":"64fa3c465fb74efbbadb8264d7fdef67","type":"GENE","name":"CSTA","canonical_id":"hgnc:HGNC:2481","description":null,"metadata":null},{"id":"8a13fd3574404af38ecca33ba5f40a45","type":"GENE","name":"CSTB","canonical_id":"hgnc:HGNC:2482","description":"cystatin B","metadata":{"aliases":["CST6","PME","EPM1","STFB"]}},{"id":"00ec964ab0ef466fa7ac659455738852","type":"GENE","name":"CSTBP1","canonical_id":"hgnc:HGNC:56380","description":"CSTB pseudogene 1","metadata":null},{"id":"f03c15de49a9419487fb38cfd00f678c","type":"GENE","name":"CSTF1","canonical_id":"hgnc:HGNC:2483","description":"cleavage stimulation factor subunit 1","metadata":null},{"id":"16bade4d3af64ea78680202f792b0295","type":"GENE","name":"CSTF2","canonical_id":"hgnc:HGNC:2484","description":"cleavage stimulation factor subunit 2","metadata":{"aliases":["CstF-64"]}},{"id":"6c89c3aafd1e493986e31b53ed3d3231","type":"GENE","name":"CSTF2T","canonical_id":"hgnc:HGNC:17086","description":"cleavage stimulation factor subunit 2 tau variant","metadata":{"aliases":["DKFZp434C1013","KIAA0689","CstF-64T","tauCstF-64"]}},{"id":"17cec853762948b380e22f162fd414d4","type":"GENE","name":"CSTF3","canonical_id":"hgnc:HGNC:2485","description":"cleavage stimulation factor subunit 3","metadata":{"aliases":["CstF-77"]}},{"id":"5bc025e5df054ce4b054b161a22f9e20","type":"GENE","name":"CSTF3-DT","canonical_id":"hgnc:HGNC:27882","description":"CSTF3 divergent transcript","metadata":{"aliases":["CSTF3-AS1"]}},{"id":"bfd50dd4c8324201b8070b1a8f1a76c8","type":"GENE","name":"CSTL1","canonical_id":"hgnc:HGNC:15958","description":"cystatin like 1","metadata":{"aliases":["dJ322G13.4","CTES1"]}},{"id":"ecdbf1d2049f4ad590682019799d1de3","type":"GENE","name":"CSTP1","canonical_id":"hgnc:HGNC:2486","description":"cystatin pseudogene 1","metadata":{"aliases":["dJ850N15.1"]}},{"id":"636dca23b4c6439fa8475a298d9a0cc8","type":"GENE","name":"CSTP2","canonical_id":"hgnc:HGNC:2487","description":"cystatin pseudogene 2","metadata":null},{"id":"37f84c71c6b648b58a4c46916d785e00","type":"GENE","name":"CSTPP1","canonical_id":"hgnc:HGNC:28720","description":"centriolar satellite-associated tubulin polyglutamylase complex regulator 1","metadata":{"aliases":["FLJ22210","MGC4707","C11orf49"]}},{"id":"a38655fc092a495ba3890a154f6b5b9f","type":"GENE","name":"CT45A1","canonical_id":"hgnc:HGNC:33267","description":"cancer/testis antigen family 45 member A1","metadata":{"aliases":["CT45-1","CT45.1"]}},{"id":"2d641181e008459daf9072b4bd736f23","type":"GENE","name":"CT45A10","canonical_id":"hgnc:HGNC:51263","description":"cancer/testis antigen family 45 member A10","metadata":null},{"id":"206a6a64cca94477a7b2faefd52ffd27","type":"GENE","name":"CT45A11P","canonical_id":"hgnc:HGNC:51336","description":"cancer/testis antigen family 45 member A11, pseudogene","metadata":null},{"id":"903096c2ca254ad883e2b82a420a8106","type":"GENE","name":"CT45A2","canonical_id":"hgnc:HGNC:28400","description":"cancer/testis antigen family 45 member A2","metadata":{"aliases":["CT45-2","CT45.2"]}},{"id":"986550837e0c4572996fc5d07fb45619","type":"GENE","name":"CT45A3","canonical_id":"hgnc:HGNC:33268","description":"cancer/testis antigen family 45 member A3","metadata":{"aliases":["CT45-3","CT45.3","CT45-4","CT45.4","CT45A4"]}},{"id":"93e64d89d9014220886b2c3fc2a5bf8d","type":"GENE","name":"CT45A5","canonical_id":"hgnc:HGNC:33270","description":"cancer/testis antigen family 45 member A5","metadata":{"aliases":["CT45-5","CT45.5"]}},{"id":"cae218e6c33d4402a2693862a9897057","type":"GENE","name":"CT45A6","canonical_id":"hgnc:HGNC:33271","description":"cancer/testis antigen family 45 member A6","metadata":{"aliases":["CT45-6","CT45.6"]}},{"id":"51e81cf9d7b7492ea50cc318c7607c3c","type":"GENE","name":"CT45A7","canonical_id":"hgnc:HGNC:51260","description":"cancer/testis antigen family 45 member A7","metadata":null},{"id":"63203398affd41a09cdf3a9620b6ef93","type":"GENE","name":"CT45A8","canonical_id":"hgnc:HGNC:51261","description":"cancer/testis antigen family 45 member A8","metadata":null},{"id":"0ab90f7357974801bcd09723ca656491","type":"GENE","name":"CT45A9","canonical_id":"hgnc:HGNC:51262","description":"cancer/testis antigen family 45 member A9","metadata":null},{"id":"ea0e1aab7de943b68d81e806a406b5a2","type":"GENE","name":"CT45B1P","canonical_id":"hgnc:HGNC:33580","description":"cancer/testis antigen family 45 member B1, pseudogene","metadata":null},{"id":"fffc0b5a612d4c5b9f1842d72277c86a","type":"GENE","name":"CT47A1","canonical_id":"hgnc:HGNC:33282","description":"cancer/testis antigen family 47 member A1","metadata":{"aliases":["CT47.1"]}},{"id":"4bbe090347bd4dfca909a7eed275f508","type":"GENE","name":"CT47A10","canonical_id":"hgnc:HGNC:33291","description":"cancer/testis antigen family 47 member A10","metadata":{"aliases":["CT47.10"]}},{"id":"cb3c83b047b7421d889b422769e97ad3","type":"GENE","name":"CT47A11","canonical_id":"hgnc:HGNC:27397","description":"cancer/testis antigen family 47 member A11","metadata":{"aliases":["CT47.11"]}},{"id":"f14b41f5b8f04a6d8938b82a70b86a97","type":"GENE","name":"CT47A12","canonical_id":"hgnc:HGNC:33292","description":"cancer/testis antigen family 47 member A12","metadata":{"aliases":["CT47.12"]}},{"id":"8824ad10377d4f748d16f71c8cd2163e","type":"GENE","name":"CT47A2","canonical_id":"hgnc:HGNC:33283","description":"cancer/testis antigen family 47 member A2","metadata":{"aliases":["CT47.2"]}},{"id":"b55f4775b8ad4d028b935ce080eba6ad","type":"GENE","name":"CT47A3","canonical_id":"hgnc:HGNC:33284","description":"cancer/testis antigen family 47 member A3","metadata":{"aliases":["CT47.3"]}},{"id":"e877851b432240dd8902b389eb66ea3c","type":"GENE","name":"CT47A4","canonical_id":"hgnc:HGNC:33285","description":"cancer/testis antigen family 47 member A4","metadata":{"aliases":["CT47.4"]}},{"id":"49a5fe2e9a87431e8920f0148eaae48f","type":"GENE","name":"CT47A5","canonical_id":"hgnc:HGNC:33286","description":"cancer/testis antigen family 47 member A5","metadata":{"aliases":["CT47.5"]}},{"id":"1966fb50eefc483186d174a318e8a5f1","type":"GENE","name":"CT47A6","canonical_id":"hgnc:HGNC:33287","description":"cancer/testis antigen family 47 member A6","metadata":{"aliases":["CT47.6"]}},{"id":"908a023cd202489a9df526335feaf487","type":"GENE","name":"CT47A7","canonical_id":"hgnc:HGNC:33288","description":"cancer/testis antigen family 47 member A7","metadata":{"aliases":["CT47.7"]}},{"id":"99328aeac50e47c0a67e133a3b2cec35","type":"GENE","name":"CT47A8","canonical_id":"hgnc:HGNC:33289","description":"cancer/testis antigen family 47 member A8","metadata":{"aliases":["CT47.8"]}},{"id":"307b96e09288406aa0cc2df68562a4ba","type":"GENE","name":"CT47A9","canonical_id":"hgnc:HGNC:33290","description":"cancer/testis antigen family 47 member A9","metadata":{"aliases":["CT47.9"]}},{"id":"aa570ecf3d0749618921a4fcf0e41c29","type":"GENE","name":"CT47B1","canonical_id":"hgnc:HGNC:33293","description":"cancer/testis antigen family 47 member B1","metadata":{"aliases":["CT47.13"]}},{"id":"c61f445a179d4757a6d0181af7e6f8a8","type":"GENE","name":"CT47C1","canonical_id":"hgnc:HGNC:53820","description":"cancer/testis antigen family 47 member C1","metadata":null},{"id":"db893f6eadc74f43a0a9aab60fd70a38","type":"GENE","name":"CT55","canonical_id":"hgnc:HGNC:26047","description":"cancer/testis antigen 55","metadata":{"aliases":["FLJ20527","CXorf48"]}},{"id":"7a2f90fe99794beb9b6e3e2398c583a8","type":"GENE","name":"CT55P1","canonical_id":"hgnc:HGNC:59158","description":"CT55 pseudogene 1","metadata":null},{"id":"76461d7693d94fd8ae26c0162ef17beb","type":"GENE","name":"CT55P2","canonical_id":"hgnc:HGNC:59159","description":"CT55 pseudogene 2","metadata":null},{"id":"b52906d5e61f4bf191bd2ca58305a46e","type":"GENE","name":"CT62","canonical_id":"hgnc:HGNC:27286","description":"cancer/testis associated 62","metadata":null},{"id":"b73d4f607445458394edf9423c3a326f","type":"GENE","name":"CT66","canonical_id":"hgnc:HGNC:54198","description":"cancer/testis associated transcript 66","metadata":null},{"id":"6ea0a49805c24c91be081d3a4bfef790","type":"GENE","name":"CT69","canonical_id":"hgnc:HGNC:37196","description":"cancer/testis associated transcript 69","metadata":null},{"id":"28ff22c1e5e446218b15b6de788037f6","type":"GENE","name":"CT70","canonical_id":"hgnc:HGNC:37195","description":"cancer/testis associated transcript 70","metadata":{"aliases":["LeXis"]}},{"id":"b9ef1ef026c84db9846090a2b1cd0a4a","type":"GENE","name":"CT75","canonical_id":"hgnc:HGNC:37174","description":"cancer/testis associated transcript 75","metadata":null},{"id":"22168f56a7d449d2a22d4c897c9bf4b8","type":"GENE","name":"CT83","canonical_id":"hgnc:HGNC:33494","description":"cancer/testis antigen 83","metadata":{"aliases":["KK-LC-1","FLJ20611","FLJ22913","CXorf61"]}},{"id":"f05a5c4e94ed40f280608dd99e427613","type":"GENE","name":"CTAG1A","canonical_id":"hgnc:HGNC:24198","description":"cancer/testis antigen 1A","metadata":{"aliases":["LAGE2A","ESO1"]}},{"id":"4dff6e76beb147e8a3c797229e05d9a5","type":"GENE","name":"CTAG1B","canonical_id":"hgnc:HGNC:2491","description":"cancer/testis antigen 1B","metadata":{"aliases":["NY-ESO-1","LAGE2B","LAGE2A","ESO1","CT6.1","CTAG","CTAG1"]}},{"id":"895f129398104cf38dc4eb0a1acba858","type":"GENE","name":"CTAG2","canonical_id":"hgnc:HGNC:2492","description":"cancer/testis antigen 2","metadata":{"aliases":["LAGE-1","CAMEL","LAGE1","ESO2","MGC3803","MGC138724","CT6.2a","CT6.2b","LAGE-1a","LAGE-1b"]}},{"id":"cda6f43b9f714ec8ad571ae300565049","type":"GENE","name":"CTAGE1","canonical_id":"hgnc:HGNC:24346","description":"cutaneous T cell lymphoma-associated antigen 1","metadata":{"aliases":["cTAGE-1","cTAGE-2","CTAGE","CT21.1","CT21.2"]}},{"id":"8a3ac7912869421a990a62aacb3160cd","type":"GENE","name":"CTAGE10P","canonical_id":"hgnc:HGNC:37288","description":"CTAGE family member 10, pseudogene","metadata":null},{"id":"8453c78b9fcb4b1a96526fde8458b179","type":"GENE","name":"CTAGE11P","canonical_id":"hgnc:HGNC:37293","description":"CTAGE family member 11, pseudogene","metadata":null},{"id":"b40156f8665d40dea23dabf065ff3026","type":"GENE","name":"CTAGE12P","canonical_id":"hgnc:HGNC:37297","description":"CTAGE family member 12, pseudogene","metadata":null},{"id":"1c12c9ea1b4f4151a2e152a2de7be27e","type":"GENE","name":"CTAGE13P","canonical_id":"hgnc:HGNC:37298","description":"CTAGE family member 13, pseudogene","metadata":null},{"id":"6056ba8ed63e4ba9a0c33ecfb66926e4","type":"GENE","name":"CTAGE14P","canonical_id":"hgnc:HGNC:37299","description":"CTAGE family member 14, pseudogene","metadata":null},{"id":"be7f28bfcb704a4e8c9d401bb7021431","type":"GENE","name":"CTAGE15","canonical_id":"hgnc:HGNC:37295","description":"CTAGE family member 15","metadata":{"aliases":["CTAGE15P"]}},{"id":"c4fd48acb19c44d098ffc131e5f8eff7","type":"GENE","name":"CTAGE16P","canonical_id":"hgnc:HGNC:41967","description":"CTAGE family member 16, pseudogene","metadata":null},{"id":"edddee3926bd42b59ecd3d7fd1ed21ad","type":"GENE","name":"CTAGE3P","canonical_id":"hgnc:HGNC:24348","description":"CTAGE family member 3, pseudogene","metadata":{"aliases":["cTAGE-3","CTAGE3"]}},{"id":"d38f73adece04a8380eab2f8546e2fde","type":"GENE","name":"CTAGE4","canonical_id":"hgnc:HGNC:24772","description":"CTAGE family member 4","metadata":{"aliases":["FLJ43692","cTAGE-4"]}},{"id":"7372c7feed3c42d1b386c40f7a20961f","type":"GENE","name":"CTAGE6","canonical_id":"hgnc:HGNC:28644","description":"CTAGE family member 6","metadata":{"aliases":["MGC41943","CTAGE6P"]}},{"id":"49bba62d66fc460cb1c3ffb203224a23","type":"GENE","name":"CTAGE7P","canonical_id":"hgnc:HGNC:25111","description":"CTAGE family member 7, pseudogene","metadata":{"aliases":["bA500G10.2","MGC33437","rcCTAGE5","CTAGEP","CTAGE7"]}},{"id":"2f93a2eb4e624b7bac3dbb4ef59f1ba6","type":"GENE","name":"CTAGE8","canonical_id":"hgnc:HGNC:37294","description":"CTAGE family member 8","metadata":null},{"id":"f2bfb85b38354ac9bce04060e6ef5a9a","type":"GENE","name":"CTAGE9","canonical_id":"hgnc:HGNC:37275","description":"CTAGE family member 9","metadata":null},{"id":"3162eb730bb14ae8aa84d8a0d9496e7e","type":"GENE","name":"CTBP1","canonical_id":"hgnc:HGNC:2494","description":null,"metadata":null},{"id":"84f585f173884e6caf3ab8d2b2c41bf0","type":"GENE","name":"CTBP1-AS","canonical_id":"hgnc:HGNC:48337","description":"CTBP1 antisense RNA","metadata":{"aliases":["PCAT10"]}},{"id":"924f1deaddac4758bb6dfec2919baf4d","type":"GENE","name":"CTBP1-DT","canonical_id":"hgnc:HGNC:28307","description":"CTBP1 divergent transcript","metadata":{"aliases":["DDUP","MGC21675","C4orf42","CTBP1-AS1","CTBP1-AS2"]}},{"id":"430559a7b1c641fdb10e875a1d42f4e1","type":"GENE","name":"CTBP2","canonical_id":"hgnc:HGNC:2495","description":null,"metadata":null},{"id":"8da480de65f84963be9ee39bae60e12e","type":"GENE","name":"CTBP2P1","canonical_id":"hgnc:HGNC:23940","description":"CTBP2 pseudogene 1","metadata":null},{"id":"2cfe3a3a3f9e4db68dd976c842b87bb0","type":"GENE","name":"CTBP2P10","canonical_id":"hgnc:HGNC:54512","description":"CTBP2 pseudogene 10","metadata":null},{"id":"d41dc46627b7425f97c1d84d3b35e389","type":"GENE","name":"CTBP2P11","canonical_id":"hgnc:HGNC:54513","description":"CTBP2 pseudogene 11","metadata":null},{"id":"c23ae4611fa54c6d912811143c1dc613","type":"GENE","name":"CTBP2P2","canonical_id":"hgnc:HGNC:45194","description":"CTBP2 pseudogene 2","metadata":null},{"id":"5c46f829361c47e4a26927d90cd537bb","type":"GENE","name":"CTBP2P3","canonical_id":"hgnc:HGNC:45195","description":"CTBP2 pseudogene 3","metadata":null},{"id":"4983f7249a814b2c8e51dee67602cde6","type":"GENE","name":"CTBP2P4","canonical_id":"hgnc:HGNC:45196","description":"CTBP2 pseudogene 4","metadata":null},{"id":"89dce033a9124a7d867205ff435a74f3","type":"GENE","name":"CTBP2P5","canonical_id":"hgnc:HGNC:45197","description":"CTBP2 pseudogene 5","metadata":null},{"id":"ca8d61af17b64b71b93a65e29a261b2d","type":"GENE","name":"CTBP2P6","canonical_id":"hgnc:HGNC:45198","description":"CTBP2 pseudogene 6","metadata":null},{"id":"119189b2d2bc4df2b30f6e1865c0dd88","type":"GENE","name":"CTBP2P7","canonical_id":"hgnc:HGNC:45199","description":"CTBP2 pseudogene 7","metadata":null},{"id":"ee37f98decb14631a481e533b46da5c2","type":"GENE","name":"CTBP2P8","canonical_id":"hgnc:HGNC:45200","description":"CTBP2 pseudogene 8","metadata":null},{"id":"c439850d788d40598246b6d8eaf609e2","type":"GENE","name":"CTBP2P9","canonical_id":"hgnc:HGNC:54511","description":"CTBP2 pseudogene 9","metadata":null},{"id":"7f7033b31f9147a78777a1b8ddf4ca31","type":"GENE","name":"CTBS","canonical_id":"hgnc:HGNC:2496","description":"chitobiase","metadata":{"aliases":["CTB"]}},{"id":"f3a458a33ed248f7b6c0adf554dd8171","type":"GENE","name":"CTC1","canonical_id":"hgnc:HGNC:26169","description":"CST telomere replication complex component 1","metadata":{"aliases":["FLJ22170","AAF132","C17orf68"]}},{"id":"ba9ef1484a1243aaaf0b46b0d3f4a677","type":"GENE","name":"CTCF","canonical_id":"hgnc:HGNC:13723","description":null,"metadata":null},{"id":"dcd444c30bb140a698c7be2c5c2ad5fe","type":"GENE","name":"CTCF-DT","canonical_id":"hgnc:HGNC:55409","description":"CTCF divergent transcript","metadata":null},{"id":"6869f0d0dd904a4d85abaa668ee27a3b","type":"GENE","name":"CTCFL","canonical_id":"hgnc:HGNC:16234","description":null,"metadata":null},{"id":"a1af23d462f4462ea942627b6c04f254","type":"TRIAL","name":"CTCL Directed Therapy","canonical_id":"clinicaltrials.gov:NCT03116659","description":"Lymphoma, T-Cell, Cutaneous","metadata":null},{"id":"9b25f2b4e19c4b09834233cfe5aba119","type":"GO_TERM","name":"CTDK-1 complex","canonical_id":"go:GO:0070692","description":"\"A positive transcription elongation factor complex that comprises the CDK kinase CTK1 (in budding yeast), Lsk1 (in fission yeast) (corresponding to the Panther PTHR24056:SF39 family), a cyclin and an additional gamma subunit (corresponding to the InterPRO entry IPR024638).\" [GOC:mah, GOC:vw, PMID:16721054, PMID:19328067]","metadata":null},{"id":"c9041dc97ac3458c99528ce1703e9afa","type":"GENE","name":"CTDNEP1","canonical_id":"hgnc:HGNC:19085","description":"CTD nuclear envelope phosphatase 1","metadata":{"aliases":["HSA011916","NET56","DULLARD"]}},{"id":"b6e992c33bd747098f8fdb7b919875ec","type":"GENE","name":"CTDNEP1P1","canonical_id":"hgnc:HGNC:56481","description":"CTDNEP1 pseudogene 1","metadata":null},{"id":"fe8039362e8c4923993409a821cb5a02","type":"GENE","name":"CTDNEP1P2","canonical_id":"hgnc:HGNC:56482","description":"CTDNEP1 pseudogene 2","metadata":null},{"id":"782b3fc7203b4185828c3848e0680470","type":"GENE","name":"CTDP1","canonical_id":"hgnc:HGNC:2498","description":"CTD phosphatase 1","metadata":{"aliases":["FCP1"]}},{"id":"d609dc60cb6a4e09b54d78c62bf7f82e","type":"GENE","name":"CTDP1-DT","canonical_id":"hgnc:HGNC:26370","description":"CTDP1 divergent transcript","metadata":null},{"id":"a70bd008b499446fad456a731fc8cd47","type":"GENE","name":"CTDSP1","canonical_id":"hgnc:HGNC:21614","description":"CTD small phosphatase 1","metadata":{"aliases":["NLIIF","SCP1"]}},{"id":"70805e44551e4370881ff7f7d36b9d74","type":"GENE","name":"CTDSP2","canonical_id":"hgnc:HGNC:17077","description":"CTD small phosphatase 2","metadata":{"aliases":["OS4","SCP2","PSR2"]}},{"id":"5ce6e439b3fd4ce3a9a8ec9e4a9dcfbd","type":"GENE","name":"CTDSP2-AS1","canonical_id":"hgnc:HGNC:58449","description":"CTDSP2 antisense RNA 1","metadata":null},{"id":"e05f34d3c5ea420d92cf4ae913fff634","type":"GENE","name":"CTDSPL","canonical_id":"hgnc:HGNC:16890","description":"CTD small phosphatase like","metadata":{"aliases":["HYA22","SCP3","PSR1","RBSP3","C3orf8"]}},{"id":"e9b194de34734b238e7f7c86dd3a2c46","type":"GENE","name":"CTDSPL2","canonical_id":"hgnc:HGNC:26936","description":"CTD small phosphatase like 2","metadata":{"aliases":["HSPC129","FLJ10523"]}},{"id":"c60a0206aa2949d485e6b8089e3bd78c","type":"GENE","name":"CTDSPL2-DT","canonical_id":"hgnc:HGNC:55415","description":"CTDSPL2 divergent transcript","metadata":null},{"id":"f60cf32eaa214050b4df0c7591d1da68","type":"GENE","name":"CTDSPL2P1","canonical_id":"hgnc:HGNC:55031","description":"CTDSPL2 pseudogene 1","metadata":null},{"id":"6fe40530636042a9af07cce81b76154e","type":"GENE","name":"CTDSPL2P2","canonical_id":"hgnc:HGNC:55042","description":"CTDSPL2 pseudogene 2","metadata":null},{"id":"a2fadc993f244b039f00bf689d23b11d","type":"GENE","name":"CTF1","canonical_id":"hgnc:HGNC:2499","description":"cardiotrophin 1","metadata":{"aliases":["CT-1","CT1"]}},{"id":"273fab4677b44657ad6a5c54fd5adb1e","type":"GENE","name":"CTF2P","canonical_id":"hgnc:HGNC:33173","description":"cardiotrophin 2, pseudogene","metadata":{"aliases":["NP"]}},{"id":"2fe63837fe2b44dca75bde1317900964","type":"GENE","name":"CTGF","canonical_id":"hgnc:HGNC:2500","description":null,"metadata":null},{"id":"64d03fcb919c4ce59cc7d4a220cd924a","type":"GENE","name":"CTH","canonical_id":"hgnc:HGNC:2501","description":"cystathionine gamma-lyase","metadata":{"aliases":["CSE"]}},{"id":"7c4c82b16dc44290aeaaefdf65c0c9c9","type":"GENE","name":"CTHRC1","canonical_id":"hgnc:HGNC:18831","description":"collagen triple helix repeat containing 1","metadata":null},{"id":"323c40e53be14abe91f04a34a8e3ba1a","type":"GENE","name":"CTHRC1P1","canonical_id":"hgnc:HGNC:50463","description":"collagen triple helix repeat containing 1 pseudogene 1","metadata":null},{"id":"cc0d66faa6454c22b3028ed8059d73b2","type":"GENE","name":"CTIF","canonical_id":"hgnc:HGNC:23925","description":"cap binding complex dependent translation initiation factor","metadata":{"aliases":["KIAA0427"]}},{"id":"66cd9a6ebea14e128c4444b4ce96b81f","type":"GENE","name":"CTIF-AS1","canonical_id":"hgnc:HGNC:58323","description":"CTIF antisense RNA 1","metadata":null},{"id":"9609cb7d347d4916be09e1851c856469","type":"GENE","name":"CTLA4","canonical_id":"hgnc:HGNC:2505","description":null,"metadata":null},{"id":"0cc2b5f04bf749cb8e70e659de72a316","type":"PROTEIN","name":"CTLA4","canonical_id":"uniprot:P16410","description":null,"metadata":null},{"id":"758b83ab489d474785d193db9afd95cf","type":"GENE","name":"CTNNA1","canonical_id":"hgnc:HGNC:2509","description":"catenin alpha 1","metadata":{"aliases":["CAP102"]}},{"id":"f7407cb836654a3d94bfecc43e0e4241","type":"GENE","name":"CTNNA1-AS1","canonical_id":"hgnc:HGNC:55535","description":"CTNNA1 antisense RNA 1","metadata":null},{"id":"75d33be209a64fa5b260e9669cffb0ae","type":"GENE","name":"CTNNA1P1","canonical_id":"hgnc:HGNC:2513","description":"catenin alpha 1 pseudogene 1","metadata":{"aliases":["CTNNAP1"]}},{"id":"0140c4c112df4cef91feea715faba99c","type":"GENE","name":"CTNNA2","canonical_id":"hgnc:HGNC:2510","description":"catenin alpha 2","metadata":{"aliases":["CAP-R","CT114"]}},{"id":"73d2c041e7f84dbc88c6d1c74695fa55","type":"GENE","name":"CTNNA2-AS1","canonical_id":"hgnc:HGNC:40165","description":"CTNNA2 antisense RNA 1","metadata":null},{"id":"dbfa1d2f8d044c6ebc350738ba978620","type":"GENE","name":"CTNNA3","canonical_id":"hgnc:HGNC:2511","description":"catenin alpha 3","metadata":{"aliases":["VR22","MGC26194"]}},{"id":"c124bc32fbeb4a33bafad49809b3451f","type":"GENE","name":"CTNNA3-AS1","canonical_id":"hgnc:HGNC:58344","description":"CTNNA3 antisense RNA 1","metadata":null},{"id":"83846e80d55d4bf791485ccca12adb3a","type":"GENE","name":"CTNNAL1","canonical_id":"hgnc:HGNC:2512","description":"catenin alpha like 1","metadata":{"aliases":["CLLP","alpha-CATU"]}},{"id":"c9c2f1decfa94320a2b851516f17612c","type":"GENE","name":"CTNNB1","canonical_id":"hgnc:HGNC:2514","description":null,"metadata":null},{"id":"8aaeaf0d27194dd4a90df6b5ad8c828f","type":"GENE","name":"CTNNB1","canonical_id":"ensembl:ENSG00000168036","description":null,"metadata":null},{"id":"23e8594316ca49b8a8b6c304733457f1","type":"GENE","name":"CTNNBIP1","canonical_id":"hgnc:HGNC:16913","description":null,"metadata":null},{"id":"2a521c1ee06745d7bb3df69c209f9169","type":"GENE","name":"CTNNBIP1-AS1","canonical_id":"hgnc:HGNC:40782","description":"CTNNBIP1 antisense RNA 1","metadata":null},{"id":"f4d538cf9402403085c189e5db808e77","type":"GENE","name":"CTNNBL1","canonical_id":"hgnc:HGNC:15879","description":"catenin beta like 1","metadata":{"aliases":["FLJ21108","P14L","P14","NAP","NYD-SP19","C20orf33"]}},{"id":"1df99f3a14c64d7fa089d9813f264722","type":"GENE","name":"CTNNBL1P1","canonical_id":"hgnc:HGNC:54948","description":"CTNNBL1 pseudogene 1","metadata":null},{"id":"b7d8434ca7194d83b9c46390c9f32425","type":"GENE","name":"CTNND1","canonical_id":"hgnc:HGNC:2515","description":"catenin delta 1","metadata":{"aliases":["KIAA0384","p120","p120cas","p120ctn","CTNND"]}},{"id":"697f55c456274724b4880a398bb08062","type":"GENE","name":"CTNND2","canonical_id":"hgnc:HGNC:2516","description":"catenin delta 2","metadata":{"aliases":["NPRAP","GT24"]}},{"id":"1bcd44b8ac68496685e39eef9512bfca","type":"GENE","name":"CTNND2-AS1","canonical_id":"hgnc:HGNC:59002","description":"CTNND2 antisense RNA 1","metadata":null},{"id":"599a0de503df4113bbeba0b1045e6bf0","type":"GENE","name":"CTNS","canonical_id":"hgnc:HGNC:2518","description":"cystinosin, lysosomal cystine transporter","metadata":{"aliases":["CTNS-LSB","PQLC4","SLC66A4"]}},{"id":"040c0dc350964cec8a2e9ecbfbe2dbd8","type":"GENE","name":"CTNS-AS1","canonical_id":"hgnc:HGNC:56090","description":"CTNS antisense RNA 1","metadata":null},{"id":"500c266d84ef49e19e029fe2bc6051ff","type":"GO_TERM","name":"CTP binding","canonical_id":"go:GO:0002135","description":"\"Binding to CTP, cytidine 5'-triphosphate.\" [GOC:hjd, ISBN:0124020607]","metadata":null},{"id":"1874016ac9244bf5af6ec9f8b6a04235","type":"GO_TERM","name":"CTP biosynthetic process","canonical_id":"go:GO:0006241","description":"\"The chemical reactions and pathways resulting in the formation of CTP, cytidine 5'-triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"43cf8a1538b14a35aa867ea6002a5b55","type":"GO_TERM","name":"CTP catabolic process","canonical_id":"go:GO:0006254","description":"\"The chemical reactions and pathways resulting in the breakdown of CTP, cytidine 5'-triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"4b21a43b306b4f908b6f4b05b4c03600","type":"GO_TERM","name":"CTP metabolic process","canonical_id":"go:GO:0046036","description":"\"The chemical reactions and pathways involving CTP, cytidine triphosphate.\" [GOC:curators]","metadata":null},{"id":"07e78a0294ef44afa5b31f715b5482f4","type":"GO_TERM","name":"CTP salvage","canonical_id":"go:GO:0044211","description":"\"Any process which produces cytidine 5'-triphosphate (CTP) from derivatives of it, without de novo synthesis.\" [GOC:ecd, GOC:jl, PMID:10501935]","metadata":null},{"id":"592425b5f8034dfa8bc7a2ef221801de","type":"GO_TERM","name":"CTP synthase activity","canonical_id":"go:GO:0003883","description":"\"Catalysis of the reaction: ATP + UTP + glutamine + H20= ADP + phosphate + CTP + glutamate.\" [PMID:12354108, RHEA:26426]","metadata":null},{"id":"3ca66e375e8e4fbab699959783fd3d44","type":"GO_TERM","name":"CTP-dependent diacylglycerol kinase activity","canonical_id":"go:GO:0141035","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycerol + CTP = a 1,2-diacyl-sn-glycero-3-phosphate + CDP + H+.\" [RHEA:25948]","metadata":null},{"id":"87c4fdb9f3614452a369e8a3b0de1adf","type":"GENE","name":"CTPS1","canonical_id":"hgnc:HGNC:2519","description":null,"metadata":null},{"id":"27e0761731ea4223a882f1610b39d82d","type":"GENE","name":"CTPS2","canonical_id":"hgnc:HGNC:2520","description":"CTP synthase 2","metadata":{"aliases":["GATD5B"]}},{"id":"460c20bc9976422bab832a94b48d5fb2","type":"GO_TERM","name":"CTPase activity","canonical_id":"go:GO:0043273","description":"\"Catalysis of the reaction: CTP + H2O = CDP + H+ + phosphate. May or may not be coupled to another reaction.\" [RHEA:29387]","metadata":null},{"id":"0b7456a5dc684b86b8c7e1e759b57ed6","type":"GENE","name":"CTR9","canonical_id":"hgnc:HGNC:16850","description":"CTR9 component of Paf1/RNA polymerase II complex","metadata":{"aliases":["KIAA0155","TSBP","p150TSP","SH2BP1"]}},{"id":"e300b4d730d443b8a31b646c86c95678","type":"GENE","name":"CTRB1","canonical_id":"hgnc:HGNC:2521","description":"chymotrypsinogen B1","metadata":{"aliases":["CTRB"]}},{"id":"b8010676a51a436da8b064d64c0ec73a","type":"GENE","name":"CTRB2","canonical_id":"hgnc:HGNC:2522","description":"chymotrypsinogen B2","metadata":null},{"id":"91514f1da322436387d969aa0d21e8ca","type":"GENE","name":"CTRC","canonical_id":"hgnc:HGNC:2523","description":"chymotrypsin C","metadata":{"aliases":["CLCR","ELA4"]}},{"id":"d7cd9e3f6f7b445e976f706ccd07b8a5","type":"GENE","name":"CTRL","canonical_id":"hgnc:HGNC:2524","description":"chymotrypsin like","metadata":{"aliases":["CTRL1"]}},{"id":"df1432d27e43473cbea410deff9f9bdf","type":"GENE","name":"CTSA","canonical_id":"hgnc:HGNC:9251","description":"cathepsin A","metadata":{"aliases":["GSL","PPGB"]}},{"id":"4554479aa7de451889f0d5a2af9c2337","type":"GENE","name":"CTSB","canonical_id":"hgnc:HGNC:2527","description":null,"metadata":null},{"id":"e93360aeb3bc48d5a38e4734baab63a3","type":"GENE","name":"CTSBP1","canonical_id":"hgnc:HGNC:59236","description":"CTSB pseudogene 1","metadata":null},{"id":"9017b0b5da07427194552bd2358d284f","type":"GENE","name":"CTSBP2","canonical_id":"hgnc:HGNC:59237","description":"CTSB pseudogene 2","metadata":null},{"id":"73a699101e464eaca1c631b98917d609","type":"GENE","name":"CTSC","canonical_id":"hgnc:HGNC:2528","description":"cathepsin C","metadata":{"aliases":["DPP1","PLS","PALS"]}},{"id":"22cbadeae3cf4c909c911d4903fc8a54","type":"PROTEIN","name":"CTSC","canonical_id":"uniprot:P53634","description":null,"metadata":null},{"id":"c761abf7358141b2aa52bf72e1571b95","type":"DISEASE","name":"CTSC-related disorder","canonical_id":"mondo:0800465","description":null,"metadata":null},{"id":"8916125baac2437f87258018766876ac","type":"GENE","name":"CTSD","canonical_id":"hgnc:HGNC:2529","description":null,"metadata":null},{"id":"2e527933e37f4fe782fee7604358e95b","type":"GENE","name":"CTSE","canonical_id":"hgnc:HGNC:2530","description":"cathepsin E","metadata":null},{"id":"3f42a43d73dd481ab2901d2619d77b83","type":"GENE","name":"CTSF","canonical_id":"hgnc:HGNC:2531","description":"cathepsin F","metadata":{"aliases":["CATSF","CLN13"]}},{"id":"dbfda7abe3f144cb9f7d05c47f88abf0","type":"GENE","name":"CTSG","canonical_id":"hgnc:HGNC:2532","description":null,"metadata":null},{"id":"4a3f890d86384123bd4592f023b29996","type":"GENE","name":"CTSH","canonical_id":"hgnc:HGNC:2535","description":"cathepsin H","metadata":{"aliases":["ACC-4","ACC-5","ACC4","ACC5","CPSB"]}},{"id":"5909fe2506ee44aeb39ec3d0484ee477","type":"GENE","name":"CTSK","canonical_id":"hgnc:HGNC:2536","description":null,"metadata":null},{"id":"8c1891371b5146b4921a76ef9d0ec61e","type":"GENE","name":"CTSL","canonical_id":"hgnc:HGNC:2537","description":null,"metadata":null},{"id":"a78db4a57ba24d7f81d1c3dadcf2f00c","type":"GENE","name":"CTSL3P","canonical_id":"hgnc:HGNC:33132","description":"cathepsin L family member 3, pseudogene","metadata":{"aliases":["HCTSL-s","CTSL3"]}},{"id":"2c970ce78aa74fc9882cf30fc7462954","type":"GENE","name":"CTSLP1","canonical_id":"hgnc:HGNC:2539","description":"cathepsin L pseudogene 1","metadata":{"aliases":["CTSLL","CTSLL1","CTSL1P1"]}},{"id":"c5ac7497662e487990ba2ff9bc4e5e76","type":"GENE","name":"CTSLP2","canonical_id":"hgnc:HGNC:2540","description":"cathepsin L pseudogene 2","metadata":{"aliases":["bA342C24.4","bA144G6.6","CTSLL2","CTSL1P2","CTSLP5","CTSLL5","CTSL1P5","CTSLP7","CTSLL7","CTSL1P7"]}},{"id":"66b402cd285a4474bce716a55e85f5ea","type":"GENE","name":"CTSLP3","canonical_id":"hgnc:HGNC:2541","description":"cathepsin L pseudogene 3","metadata":{"aliases":["CTSLL3","CTSL1P3"]}},{"id":"dacbf6e1d656480f8459dd563d17b9b9","type":"GENE","name":"CTSLP4","canonical_id":"hgnc:HGNC:23645","description":"cathepsin L pseudogene 4","metadata":{"aliases":["bA564C4.3","OTTHUMG00000018237","CTSLL4","CTSL1P4"]}},{"id":"170286df85c34bb0a95d0b9f181c1f35","type":"GENE","name":"CTSLP6","canonical_id":"hgnc:HGNC:23611","description":"cathepsin L pseudogene 6","metadata":{"aliases":["bA479O17.1","CTSLL6","CTSL1P6"]}},{"id":"71bc09be83df49eaaeeba99036283dc2","type":"GENE","name":"CTSLP8","canonical_id":"hgnc:HGNC:39084","description":"cathepsin L pseudogene 8","metadata":{"aliases":["CTSL1P8"]}},{"id":"427da47e21e9446a911b6d933a0da125","type":"GENE","name":"CTSO","canonical_id":"hgnc:HGNC:2542","description":"cathepsin O","metadata":{"aliases":["CTSO1"]}},{"id":"293c0848182d48dd97288048efa45117","type":"GENE","name":"CTSS","canonical_id":"hgnc:HGNC:2545","description":null,"metadata":null},{"id":"dd85069f324541a090d59efdaf347ede","type":"GENE","name":"CTSV","canonical_id":"hgnc:HGNC:2538","description":null,"metadata":null},{"id":"a5b54fed7fe64bec8eaba080496c60b1","type":"GENE","name":"CTSW","canonical_id":"hgnc:HGNC:2546","description":"cathepsin W","metadata":null},{"id":"8010264494d74582812ec9df112067e9","type":"GENE","name":"CTSZ","canonical_id":"hgnc:HGNC:2547","description":"cathepsin Z","metadata":{"aliases":["CTSX"]}},{"id":"853b4b5dd38f49a9a792058073777613","type":"GENE","name":"CTTN","canonical_id":"hgnc:HGNC:3338","description":"cortactin","metadata":{"aliases":["EMS1"]}},{"id":"2a80a0ff0a6a41819c06bf5737eea955","type":"GENE","name":"CTTN-DT","canonical_id":"hgnc:HGNC:55592","description":"CTTN divergent transcript","metadata":null},{"id":"e9c3a836a7a748e2a4613613ccda18e2","type":"GENE","name":"CTTNBP2","canonical_id":"hgnc:HGNC:15679","description":"cortactin binding protein 2","metadata":{"aliases":["KIAA1758","Orf4","CORTBP2","C7orf8"]}},{"id":"86e50a20afb648a296810a4b52fe4f8b","type":"GENE","name":"CTTNBP2NL","canonical_id":"hgnc:HGNC:25330","description":"CTTNBP2 N-terminal like","metadata":{"aliases":["DKFZp547A023"]}},{"id":"535bd806948b40c1bb53a8525c2dc718","type":"GENE","name":"CTU1","canonical_id":"hgnc:HGNC:29590","description":"cytosolic thiouridylase subunit 1","metadata":{"aliases":["MGC17332","NCS6","ATPBD3"]}},{"id":"d0d22356436244f3b56c3bf065f646e9","type":"GENE","name":"CTU2","canonical_id":"hgnc:HGNC:28005","description":"cytosolic thiouridylase subunit 2","metadata":{"aliases":["NCS2","C16orf84"]}},{"id":"de5fd7a8b91a45489672b5692023039e","type":"GENE","name":"CTXN1","canonical_id":"hgnc:HGNC:31108","description":"cortexin 1","metadata":{"aliases":["FLJ25968"]}},{"id":"5ab80142b94c4b76a88b9a2b21e52c6a","type":"GENE","name":"CTXN2","canonical_id":"hgnc:HGNC:31109","description":"cortexin 2","metadata":null},{"id":"192366c9d67042c7893c8980703d779f","type":"GENE","name":"CTXN2-AS1","canonical_id":"hgnc:HGNC:55426","description":"CTXN2 antisense RNA 1","metadata":null},{"id":"ebfa2e359f4146e998f7e76df270cb38","type":"GENE","name":"CTXN3","canonical_id":"hgnc:HGNC:31110","description":"cortexin 3","metadata":null},{"id":"f4b3e88e7f5e4b83905143247664bdb3","type":"GENE","name":"CTXN3-AS1","canonical_id":"hgnc:HGNC:59127","description":"CTXN3 and CCDC192  antisense RNA 1","metadata":null},{"id":"7b06d5d5b7ff4a33bad2a93efe876847","type":"GENE","name":"CTXND1","canonical_id":"hgnc:HGNC:50507","description":"cortexin domain containing 1","metadata":{"aliases":["LINC01314"]}},{"id":"1906d2ade37a46f5a3a50bc1d26030db","type":"GENE","name":"CTXND2","canonical_id":"hgnc:HGNC:53440","description":"cortexin domain containing 2","metadata":null},{"id":"b18ab884338749d78ad7a09302a30b6a","type":"TRIAL","name":"CTx-1301 Comparative Bioavailability Study","canonical_id":"clinicaltrials.gov:NCT04138498","description":"ADHD","metadata":null},{"id":"9a76edd1b37a40558e42e3bbf50adfb7","type":"TRIAL","name":"CU Programme of Idarucizumab for Japanese Patients","canonical_id":"clinicaltrials.gov:NCT02831660","description":"Hemorrhage","metadata":null},{"id":"de63cd9c8dc849feb96d2c7ecd160b1c","type":"GO_TERM","name":"CUA codon-amino acid adaptor activity","canonical_id":"go:GO:0033419","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CUA codon.\" [GOC:mah]","metadata":null},{"id":"6822ac12395049fd9682dee3ccc35150","type":"GENE","name":"CUBN","canonical_id":"hgnc:HGNC:2548","description":"cubilin","metadata":{"aliases":["IFCR","gp280","MGA1"]}},{"id":"099726d1a66d4e66b0204d2552ade5b5","type":"GENE","name":"CUBNP1","canonical_id":"hgnc:HGNC:44983","description":"cubilin pseudogene 1","metadata":null},{"id":"c68208230f4a4d529badc3102797b1a5","type":"GENE","name":"CUBNP2","canonical_id":"hgnc:HGNC:44984","description":"cubilin pseudogene 2","metadata":null},{"id":"962ca866973947eeb4cd74035aa1ca31","type":"GENE","name":"CUBNP3","canonical_id":"hgnc:HGNC:44985","description":"cubilin pseudogene 3","metadata":null},{"id":"0d5d7672124440c8848a896e00e1520f","type":"GO_TERM","name":"CUC codon-amino acid adaptor activity","canonical_id":"go:GO:0033418","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CUC codon.\" [GOC:mah]","metadata":null},{"id":"a2e555708d9141a79b5e72052c0e88cb","type":"GO_TERM","name":"CUE1-UBC7 ubiquitin-conjugating enzyme complex","canonical_id":"go:GO:1990389","description":"\"A protein complex capable of ubiquitin-conjugating enzyme activity during ER-associated protein degradation (ERAD). In S. cerevisiae, UBC7 is the ubiquitin-conjugating enzyme (E2) and requires binding to the ER surface by CUE1.\" [GOC:bhm, PMID:23028185]","metadata":null},{"id":"ad53d030bfdd42f5b748d8793adf98db","type":"GENE","name":"CUEDC1","canonical_id":"hgnc:HGNC:31350","description":"CUE domain containing 1","metadata":null},{"id":"a4c0fb1898ec440eb2bc884cd234ca7e","type":"GENE","name":"CUEDC1-AS1","canonical_id":"hgnc:HGNC:58621","description":"CUEDC1 antisense RNA 1","metadata":null},{"id":"4fd78fd4577846f7acdec44f623a1cd5","type":"GENE","name":"CUEDC2","canonical_id":"hgnc:HGNC:28352","description":"CUE domain containing 2","metadata":{"aliases":["MGC2491","C10orf66"]}},{"id":"322e35d7243b49fba47311b4312d69d8","type":"GO_TERM","name":"CUG codon-amino acid adaptor activity","canonical_id":"go:GO:0033420","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CUG codon.\" [GOC:mah]","metadata":null},{"id":"2c28c6b99cb8420f95dfbddfa116db82","type":"GO_TERM","name":"CUGBP1-eIF2 complex","canonical_id":"go:GO:0071075","description":"\"A protein complex that contains the eukaryotic translation initiation factor 2 complex (EIF2), CUG binding protein 1, and several endoplasmic reticulum proteins; the complex is involved in the regulation of translation.\" [PMID:16931514]","metadata":null},{"id":"92dd9a5ef653465d86e0ad74a2ebec90","type":"GENE","name":"CUL1","canonical_id":"hgnc:HGNC:2551","description":"cullin 1","metadata":null},{"id":"57d9e5aabbb04f05891d356c118c074d","type":"GENE","name":"CUL1P1","canonical_id":"hgnc:HGNC:49567","description":"cullin 1 pseudogene 1","metadata":null},{"id":"7a220174302745fe85a9448e0eb815a7","type":"GENE","name":"CUL2","canonical_id":"hgnc:HGNC:2552","description":"cullin 2","metadata":null},{"id":"add87af2041f43c3aa0e4b28edac54c8","type":"GENE","name":"CUL3","canonical_id":"hgnc:HGNC:2553","description":"cullin 3","metadata":null},{"id":"99fb0ffdf0fb450585ff20605d7cd812","type":"GENE","name":"CUL4A","canonical_id":"hgnc:HGNC:2554","description":"cullin 4A","metadata":null},{"id":"c2ba4a28483a4e34ab9e511896225379","type":"GENE","name":"CUL4AP1","canonical_id":"hgnc:HGNC:44027","description":"cullin 4A pseudogene 1","metadata":null},{"id":"34264e5c56294d2c92799b1ccc36ed55","type":"GENE","name":"CUL4B","canonical_id":"hgnc:HGNC:2555","description":"cullin 4B","metadata":null},{"id":"7d8b6b14fa694e588f92949ac18fd075","type":"GENE","name":"CUL5","canonical_id":"hgnc:HGNC:2556","description":"cullin 5","metadata":{"aliases":["VACM-1"]}},{"id":"4d6586cc29694b08893ddfa6498dc030","type":"GENE","name":"CUL7","canonical_id":"hgnc:HGNC:21024","description":"cullin 7","metadata":{"aliases":["dJ20C7.5","KIAA0076"]}},{"id":"2380c7f9c6e0460499d9f4cecae10b4e","type":"GENE","name":"CUL9","canonical_id":"hgnc:HGNC:15982","description":"cullin 9","metadata":{"aliases":["H7AP1","KIAA0708","PARC"]}},{"id":"617ba14a4a78456988dccf12c5a4e3a3","type":"GENE","name":"CUL9-AS1","canonical_id":"hgnc:HGNC:58240","description":"CUL9 antisense RNA 1","metadata":null},{"id":"bca0f966595c4c59b3d85fba8afe37b6","type":"TRIAL","name":"CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)","canonical_id":"clinicaltrials.gov:NCT03559660","description":"Crohn's Disease","metadata":null},{"id":"1a2ea25e52c949f5ba3ef567962c9f35","type":"GENE","name":"CUPIN1P","canonical_id":"hgnc:HGNC:54490","description":"cupin superfamily member 1, pseudogene","metadata":null},{"id":"a8f765166d8b42b2b3fe2dc6d515eca2","type":"GO_TERM","name":"CURI complex","canonical_id":"go:GO:0032545","description":"\"A protein complex that is involved in the transcription of ribosomal genes. In Saccharomyces this complex consists of Ckb2p, Utp22p, Rrp7p and Ifh1p.\" [PMID:17452446]","metadata":null},{"id":"903c2e6cea1b4997b2321e39d3f99a7f","type":"GO_TERM","name":"CUT catabolic process","canonical_id":"go:GO:0071034","description":"\"The chemical reactions and pathways resulting in the breakdown of cryptic unstable transcripts (CUTs).\" [GOC:dgf, GOC:krc]","metadata":null},{"id":"9db83c74c8444a3a8786c815ca7c999e","type":"GENE","name":"CUTA","canonical_id":"hgnc:HGNC:21101","description":"cutA divalent cation tolerance homolog","metadata":{"aliases":["C6orf82","ACHAP"]}},{"id":"ab4e87170b13425cabf8aba56c7c9678","type":"GENE","name":"CUTALP","canonical_id":"hgnc:HGNC:27367","description":"cutA divalent cation tolerance like, pseudogene","metadata":{"aliases":["PSMD5-AS1"]}},{"id":"8cc2a8351aae4d4fbb13c42537744e8c","type":"GENE","name":"CUTC","canonical_id":"hgnc:HGNC:24271","description":"cutC copper transporter","metadata":{"aliases":["CGI-32"]}},{"id":"40a4ff85fe7a4a33acf2d782af1127f4","type":"GO_TERM","name":"CUU codon-amino acid adaptor activity","canonical_id":"go:GO:0033417","description":"\"A triplet codon-amino acid adaptor activity that recognizes a CUU codon.\" [GOC:mah]","metadata":null},{"id":"acceb9f119f143578a62bd21accd7fa4","type":"GENE","name":"CUX1","canonical_id":"hgnc:HGNC:2557","description":null,"metadata":null},{"id":"f65b705def56487bbec31051b7dec69d","type":"GENE","name":"CUX2","canonical_id":"hgnc:HGNC:19347","description":"cut like homeobox 2","metadata":{"aliases":["KIAA0293","CDP2","CUTL2"]}},{"id":"c0e44a6c3bd24e2b8e720bfa4642d50c","type":"GENE","name":"CUX2P1","canonical_id":"hgnc:HGNC:33694","description":"cut like homeobox 2 pseudogene 1","metadata":null},{"id":"f270d2ef02294b3eb416d15cdcedf9dd","type":"GENE","name":"CUX2P2","canonical_id":"hgnc:HGNC:33695","description":"cut like homeobox 2 pseudogene 2","metadata":null},{"id":"732d7d0827d64151a2e10f85d38d5f49","type":"GENE","name":"CUZD1","canonical_id":"hgnc:HGNC:17937","description":"CUB and zona pellucida like domains 1","metadata":{"aliases":["ERG-1","UO-44"]}},{"id":"385f757eb7c2493aaf2ec84f8f8718a0","type":"TRIAL","name":"CVL006 Combination Therapy in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07157956","description":"Advanced Solid Tumor","metadata":null},{"id":"9669752eb2ab47cabdc7ef2ed0d17f40","type":"GENE","name":"CWC15","canonical_id":"hgnc:HGNC:26939","description":"CWC15 spliceosome associated protein","metadata":{"aliases":["C11orf5","HSPC148","Cwf15","AD002"]}},{"id":"fbf54992de774207aad4d5174fdcc936","type":"GENE","name":"CWC22","canonical_id":"hgnc:HGNC:29322","description":"CWC22 spliceosome associated protein","metadata":{"aliases":["KIAA1604","EIF4GL","fSAPb","NCM"]}},{"id":"45dae1eb0728469a9d2eebc8882933fa","type":"GENE","name":"CWC25","canonical_id":"hgnc:HGNC:25989","description":"CWC25 spliceosome associated protein","metadata":{"aliases":["FLJ20291","CCDC49"]}},{"id":"587293ab670e4a988887a20cec142c60","type":"GENE","name":"CWC27","canonical_id":"hgnc:HGNC:10664","description":"CWC27 spliceosome associated cyclophilin","metadata":{"aliases":["NY-CO-10","SDCCAG-10","SDCCAG10"]}},{"id":"794a2de3ff0d4bf8aca66bb5384b3d63","type":"GENE","name":"CWC27-AS1","canonical_id":"hgnc:HGNC:59061","description":"CWC27 antisense RNA 1","metadata":null},{"id":"3eff30fa5b2b4124866d02e8a817a60b","type":"GENE","name":"CWF19L1","canonical_id":"hgnc:HGNC:25613","description":"CWF19 like cell cycle control factor 1","metadata":{"aliases":["FLJ10998","hDrn1"]}},{"id":"46755cd0b44a49be84e11ff8599beac2","type":"GENE","name":"CWF19L2","canonical_id":"hgnc:HGNC:26508","description":"CWF19 like cell cycle control factor 2","metadata":{"aliases":["FLJ32343"]}},{"id":"7923ced18233406ca2adf1b387a229df","type":"GENE","name":"CWH43","canonical_id":"hgnc:HGNC:26133","description":"cell wall biogenesis 43 C-terminal homolog","metadata":{"aliases":["FLJ21511","CWH43-C","PGAP2IP"]}},{"id":"dce723149ffb4a11bf969da74739ed61","type":"GO_TERM","name":"CX3C chemokine receptor binding","canonical_id":"go:GO:0031737","description":"\"Binding to a CX3C chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c760e9a7747c46458144cb65aa0d0a8c","type":"GENE","name":"CX3CL1","canonical_id":"hgnc:HGNC:10647","description":null,"metadata":null},{"id":"9f7e0fc8355944d8a10107d66769a38e","type":"GENE","name":"CX3CR1","canonical_id":"hgnc:HGNC:2558","description":"C-X3-C motif chemokine receptor 1","metadata":{"aliases":["CMKDR1","V28","CCRL1","GPR13","CMKBRL1"]}},{"id":"ec47a8acdb57423996cf7b6fa61365a5","type":"GENE","name":"CXADR","canonical_id":"hgnc:HGNC:2559","description":null,"metadata":null},{"id":"8e546189a4f7497b93c2552020c7f542","type":"GENE","name":"CXADRP1","canonical_id":"hgnc:HGNC:23770","description":"CXADR pseudogene 1","metadata":{"aliases":["CAR","CXADRP"]}},{"id":"5fbe451152df44bca640424a223dd65a","type":"GENE","name":"CXADRP2","canonical_id":"hgnc:HGNC:33973","description":"CXADR pseudogene 2","metadata":null},{"id":"8e82069dd16e4131a320710996914dcb","type":"GENE","name":"CXADRP3","canonical_id":"hgnc:HGNC:33974","description":"CXADR pseudogene 3","metadata":null},{"id":"d106a1656cac4ff8aaf59df499514dc7","type":"GENE","name":"CXCL1","canonical_id":"hgnc:HGNC:4602","description":null,"metadata":null},{"id":"35db5905734d432c8c5ba3193d688b88","type":"GENE","name":"CXCL10","canonical_id":"hgnc:HGNC:10637","description":null,"metadata":null},{"id":"0cb05196127c4fc68aeb4a6cd5ff88e8","type":"GENE","name":"CXCL11","canonical_id":"hgnc:HGNC:10638","description":"C-X-C motif chemokine ligand 11","metadata":{"aliases":["H174","b-R1","I-TAC","IP-9","SCYB9B","SCYB11"]}},{"id":"346d3496dc8e471da807b77fb913029b","type":"GENE","name":"CXCL12","canonical_id":"hgnc:HGNC:10672","description":null,"metadata":null},{"id":"180ad97bda004809a26da181da667ea7","type":"GO_TERM","name":"CXCL12-activated CXCR4 signaling pathway","canonical_id":"go:GO:0038160","description":"\"The series of molecular signals initiated by the binding of the C-X-C chemokine CXCL12 to a C-X-C chemokine type 4 receptor (CXCR4) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn]","metadata":null},{"id":"2168211559204138a9333e8130887557","type":"GENE","name":"CXCL13","canonical_id":"hgnc:HGNC:10639","description":"C-X-C motif chemokine ligand 13","metadata":{"aliases":["BLC","BCA-1","BLR1L","ANGIE","ANGIE2","SCYB13"]}},{"id":"616630e795d54cf78c6fdf2926e851f8","type":"GENE","name":"CXCL13-AS1","canonical_id":"hgnc:HGNC:58830","description":"CXCL13 antisense RNA 1","metadata":null},{"id":"0144827cb96b4f14a3ab2d2d587604a2","type":"GENE","name":"CXCL14","canonical_id":"hgnc:HGNC:10640","description":null,"metadata":null},{"id":"8191a8416a3a43159fa5a36f1521e5b5","type":"GENE","name":"CXCL16","canonical_id":"hgnc:HGNC:16642","description":"C-X-C motif chemokine ligand 16","metadata":{"aliases":["SR-PSOX","CXCLG16","SRPSOX"]}},{"id":"76ceb093999244899c6b2f9030adb663","type":"GENE","name":"CXCL17","canonical_id":"hgnc:HGNC:19232","description":"C-X-C motif chemokine ligand 17","metadata":{"aliases":["Dcip1","UNQ473","DMC","VCC1"]}},{"id":"2cc5ffbc2fe7446bb864846303a05360","type":"GENE","name":"CXCL1P1","canonical_id":"hgnc:HGNC:10641","description":"C-X-C motif chemokine ligand 1 pseudogene 1","metadata":{"aliases":["MGSAP","GROP","GRO1P","SCYB1P","CXCL1P"]}},{"id":"3ee36f255489491ca840a9a7163b16de","type":"GENE","name":"CXCL2","canonical_id":"hgnc:HGNC:4603","description":null,"metadata":null},{"id":"46186f6d44d5456d81dd5fe26c4e562c","type":"GENE","name":"CXCL3","canonical_id":"hgnc:HGNC:4604","description":"C-X-C motif chemokine ligand 3","metadata":{"aliases":["SCYB3","GROg","MIP-2b","CINC-2b","GRO3"]}},{"id":"3445dd2c85244e149368d8bd1384e80d","type":"GENE","name":"CXCL3-AS1","canonical_id":"hgnc:HGNC:58815","description":"CXCL3 antisense RNA 1","metadata":null},{"id":"0ebd00e7481f493b9904ea65dbbed0d6","type":"GENE","name":"CXCL5","canonical_id":"hgnc:HGNC:10642","description":null,"metadata":null},{"id":"0bc66837411b4e468c5954132f050d2d","type":"GENE","name":"CXCL6","canonical_id":"hgnc:HGNC:10643","description":"C-X-C motif chemokine ligand 6","metadata":{"aliases":["GCP-2","CKA-3","SCYB6"]}},{"id":"02acc3b877244e828fb6a38ea70266ac","type":"GENE","name":"CXCL8","canonical_id":"hgnc:HGNC:6025","description":null,"metadata":null},{"id":"85bd2dedf4d94239a2f40b76ab3b44d9","type":"GENE","name":"CXCL9","canonical_id":"hgnc:HGNC:7098","description":"C-X-C motif chemokine ligand 9","metadata":{"aliases":["SCYB9","Humig","crg-10","CMK","MIG"]}},{"id":"10e3fbacd42249c9a50071ab9c4021c7","type":"GO_TERM","name":"CXCR chemokine receptor binding","canonical_id":"go:GO:0045236","description":"\"Binding to a chemokine receptor in the CXCR family.\" [GOC:ceb, PMID:11910892]","metadata":null},{"id":"d61171eedf61497f931299a76f124210","type":"GENE","name":"CXCR1","canonical_id":"hgnc:HGNC:6026","description":null,"metadata":null},{"id":"6b768b1dd26d4ec8aec0d6c5aeb8b069","type":"GO_TERM","name":"CXCR1 chemokine receptor binding","canonical_id":"go:GO:0045237","description":"\"Binding to a CXCR1 chemokine receptor.\" [GOC:ceb, PMID:11910892]","metadata":null},{"id":"d413a470cddf4cd6bf0f9d601ae991ff","type":"GENE","name":"CXCR2","canonical_id":"hgnc:HGNC:6027","description":null,"metadata":null},{"id":"262be3e5d33f4e34a5a9ba965c26897c","type":"GO_TERM","name":"CXCR2 chemokine receptor binding","canonical_id":"go:GO:0045238","description":"\"Binding to a CXCR2 chemokine receptor.\" [GOC:ceb, PMID:11910892]","metadata":null},{"id":"fe729d4046e44316a1de45f3e70d1243","type":"GENE","name":"CXCR2P1","canonical_id":"hgnc:HGNC:6028","description":"C-X-C motif chemokine receptor 2 pseudogene 1","metadata":{"aliases":["IL8RBP","CXCR2P"]}},{"id":"6e713576dccc4fd1a334911e147f21ac","type":"GENE","name":"CXCR3","canonical_id":"hgnc:HGNC:4540","description":null,"metadata":null},{"id":"f470db612aca46c3af05778aed1c9aba","type":"GO_TERM","name":"CXCR3 chemokine receptor binding","canonical_id":"go:GO:0048248","description":"\"Binding to a CXCR3 chemokine receptor.\" [GOC:jid, PMID:10556837]","metadata":null},{"id":"97229ddcce3e43909f11c688d6c58161","type":"GENE","name":"CXCR4","canonical_id":"hgnc:HGNC:2561","description":null,"metadata":null},{"id":"5ff4a1699c914c72b1b43e3ae76c5112","type":"PROTEIN","name":"CXCR4","canonical_id":"uniprot:P61073","description":null,"metadata":null},{"id":"9b0f6467ae4c41cbb09a0f874068c97c","type":"GO_TERM","name":"CXCR4 chemokine receptor binding","canonical_id":"go:GO:0031723","description":"\"Binding to a CXCR4 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"85e3b6297fa74831b8f5575348ad724b","type":"GENE","name":"CXCR5","canonical_id":"hgnc:HGNC:1060","description":null,"metadata":null},{"id":"a5c8f274d2e54ee9951b67a3017be634","type":"GO_TERM","name":"CXCR5 chemokine receptor binding","canonical_id":"go:GO:0031724","description":"\"Binding to a CXCR5 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"62c8b9d9514b4af2932b23d5541863d0","type":"GENE","name":"CXCR6","canonical_id":"hgnc:HGNC:16647","description":"C-X-C motif chemokine receptor 6","metadata":{"aliases":["TYMSTR","STRL33","BONZO","CD186"]}},{"id":"9515ab4945ac4675a6fdff8abf9b4d55","type":"GO_TERM","name":"CXCR6 chemokine receptor binding","canonical_id":"go:GO:0031725","description":"\"Binding to a CXCR6 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e5dbc2b940e646529b2e9a589391f5b9","type":"GENE","name":"CXXC1","canonical_id":"hgnc:HGNC:24343","description":"CXXC finger protein 1","metadata":{"aliases":["HsT2645","PCCX1","hCGBP","PHF18","CGBP","SPP1","CFP1","ZCGPC1"]}},{"id":"022f2ee14964413f9d9be59f5905e1cd","type":"GENE","name":"CXXC1P1","canonical_id":"hgnc:HGNC:27864","description":"CXXC finger protein 1 pseudogene 1","metadata":{"aliases":["FLJ36789","CXorf25","NCRNA00236"]}},{"id":"ba74a155b0f14dbf8d5c2d18d24c7bcc","type":"GENE","name":"CXXC4","canonical_id":"hgnc:HGNC:24593","description":"CXXC finger protein 4","metadata":{"aliases":["IDAX"]}},{"id":"4c51bdac9a504737a0d08958436cdc10","type":"GENE","name":"CXXC4-AS1","canonical_id":"hgnc:HGNC:41054","description":"CXXC4 antisense RNA 1","metadata":null},{"id":"ef3bd160e220473ca95d69201a4bcd3f","type":"GENE","name":"CXXC5","canonical_id":"hgnc:HGNC:26943","description":null,"metadata":null},{"id":"9a8c8769821a4deab36649ac117b48e6","type":"GENE","name":"CXXC5-AS1","canonical_id":"hgnc:HGNC:53009","description":"CXXC5 antisense RNA 1","metadata":null},{"id":"241dd2d3433949bb95a62ee75198f0bb","type":"GENE","name":"CXorf38","canonical_id":"hgnc:HGNC:28589","description":"chromosome X open reading frame 38","metadata":{"aliases":["MGC39350"]}},{"id":"2b559396967848c9a543fa310850cfb5","type":"GENE","name":"CXorf49","canonical_id":"hgnc:HGNC:30891","description":"chromosome X open reading frame 49","metadata":null},{"id":"9eaa8c5250514cbcbf2102975bedf754","type":"GENE","name":"CXorf49B","canonical_id":"hgnc:HGNC:34229","description":"chromosome X open reading frame 49B","metadata":null},{"id":"a21ac7baf3a542e289093ccae037a3ca","type":"GENE","name":"CXorf49C","canonical_id":"hgnc:HGNC:53552","description":"chromosome X open reading frame 49C","metadata":null},{"id":"880a61e7cbcb4bc3a0abbd0900edfa27","type":"GENE","name":"CXorf51A","canonical_id":"hgnc:HGNC:30533","description":"chromosome X open reading frame 51A","metadata":{"aliases":["CXorf51"]}},{"id":"51fcfcf152754a0a92b975ef554022be","type":"GENE","name":"CXorf51B","canonical_id":"hgnc:HGNC:42787","description":"chromosome X open reading frame 51B","metadata":null},{"id":"e5fe552e54d9413bb48ffa9e060b6513","type":"GENE","name":"CXorf58","canonical_id":"hgnc:HGNC:26356","description":"chromosome X open reading frame 58","metadata":{"aliases":["FLJ25444"]}},{"id":"510a79bfda3e49b0b4a3af0b0c313976","type":"GENE","name":"CXorf65","canonical_id":"hgnc:HGNC:33713","description":"chromosome X open reading frame 65","metadata":null},{"id":"55e8df6b95c64ebcb77f9d068c014f28","type":"GENE","name":"CXorf66","canonical_id":"hgnc:HGNC:33743","description":"chromosome X open reading frame 66","metadata":{"aliases":["RP11-35F15.2","SGPX"]}},{"id":"aaf37a1c82434318a3c67c45fe41bc2c","type":"GENE","name":"CYB561","canonical_id":"hgnc:HGNC:2571","description":"cytochrome b561","metadata":{"aliases":["FRRS2","CYB561A1","CGCytb"]}},{"id":"14df1a7d42624f9bb2c91f20d98cc1db","type":"GENE","name":"CYB561A3","canonical_id":"hgnc:HGNC:23014","description":"cytochrome b561 family member A3","metadata":{"aliases":["LCYTB","CYBASC3"]}},{"id":"2067a7cf28064a29841dc7678c43aad1","type":"GENE","name":"CYB561D1","canonical_id":"hgnc:HGNC:26804","description":"cytochrome b561 family member D1","metadata":{"aliases":["FLJ39035","FLJ44753"]}},{"id":"feebdef62f674e92b8853fb1afcbeae2","type":"GENE","name":"CYB561D2","canonical_id":"hgnc:HGNC:30253","description":"cytochrome b561 family member D2","metadata":{"aliases":["101F6","TSP10","TSCytb"]}},{"id":"2fc468bc9439490695fe1f2eae2ebb94","type":"GENE","name":"CYB5A","canonical_id":"hgnc:HGNC:2570","description":"cytochrome b5 type A","metadata":{"aliases":["MCB5","CYB5"]}},{"id":"af1f47c6c7fd4cb8b86ad0593f8925ed","type":"GENE","name":"CYB5AP2","canonical_id":"hgnc:HGNC:2573","description":"cytochrome b5 type A pseudogene 2","metadata":{"aliases":["CYB5P2"]}},{"id":"7c9ada9575dc4eb3882397ef83ac829e","type":"GENE","name":"CYB5AP3","canonical_id":"hgnc:HGNC:2574","description":"cytochrome b5 type A pseudogene 3","metadata":{"aliases":["Psgb-5-1","CYB5P3"]}},{"id":"c9bde841ede34236aa3bfe48522f36e9","type":"GENE","name":"CYB5AP4","canonical_id":"hgnc:HGNC:2575","description":"cytochrome b5 type A pseudogene 4","metadata":{"aliases":["bA189G24.1","Psgb-5-2","CYB5P4"]}},{"id":"d3cb9e55919a469c856b82f5374c4c30","type":"GENE","name":"CYB5AP5","canonical_id":"hgnc:HGNC:2576","description":"cytochrome b5 type A pseudogene 5","metadata":{"aliases":["CYB5P5"]}},{"id":"52639d712297489a84089992e9e67145","type":"GENE","name":"CYB5B","canonical_id":"hgnc:HGNC:24374","description":"cytochrome b5 type B","metadata":{"aliases":["CYB5-M"]}},{"id":"b13504939d124b15ae70c93963059ec9","type":"GENE","name":"CYB5D1","canonical_id":"hgnc:HGNC:26516","description":"cytochrome b5 domain containing 1","metadata":{"aliases":["FLJ32499"]}},{"id":"3cbdee2c5c454eaebec84c60974d5796","type":"GENE","name":"CYB5D2","canonical_id":"hgnc:HGNC:28471","description":"cytochrome b5 domain containing 2","metadata":{"aliases":["MGC32124"]}},{"id":"beecda86bf6d4f32836e8249ac6a6b9d","type":"GENE","name":"CYB5R1","canonical_id":"hgnc:HGNC:13397","description":"cytochrome b5 reductase 1","metadata":{"aliases":["humb5R2","NQO3A2"]}},{"id":"9b2d0a919cec40a9b1a951799b5ce5a2","type":"GENE","name":"CYB5R2","canonical_id":"hgnc:HGNC:24376","description":"cytochrome b5 reductase 2","metadata":null},{"id":"1e34e0eebb79487e880106bff9957962","type":"GENE","name":"CYB5R3","canonical_id":"hgnc:HGNC:2873","description":"cytochrome b5 reductase 3","metadata":{"aliases":["B5R","DIA1"]}},{"id":"0bb32166e6314b9d93c2ec2a692384df","type":"GENE","name":"CYB5R4","canonical_id":"hgnc:HGNC:20147","description":"cytochrome b5 reductase 4","metadata":{"aliases":["b5+b5R","dJ676J13.1","NCB5OR"]}},{"id":"7cfa1ea4bb0e4ab2a866cfc8314e1c1d","type":"GENE","name":"CYB5RL","canonical_id":"hgnc:HGNC:32220","description":"cytochrome b5 reductase like","metadata":{"aliases":["LOC606495"]}},{"id":"1b1319e1780f405eaf6b8b7aa7306e9a","type":"GENE","name":"CYBA","canonical_id":"hgnc:HGNC:2577","description":"cytochrome b-245 alpha chain","metadata":{"aliases":["p22-PHOX","p22phox"]}},{"id":"d4e5e69c188041de99d1e0f48270945d","type":"GENE","name":"CYBB","canonical_id":"hgnc:HGNC:2578","description":null,"metadata":null},{"id":"c785f8bd236e4533a73d86a782b6ea04","type":"GENE","name":"CYBC1","canonical_id":"hgnc:HGNC:28672","description":"cytochrome b-245 chaperone 1","metadata":{"aliases":["MGC4368","FLJ90469","Eros","C17orf62"]}},{"id":"d36e8ff581374e11af57715bb2958dc6","type":"GENE","name":"CYBRD1","canonical_id":"hgnc:HGNC:20797","description":"cytochrome b reductase 1","metadata":{"aliases":["DCYTB","FLJ23462","FRRS3","CYB561A2"]}},{"id":"c09c5afa43eb4f629e5f5edefe9a4f44","type":"GENE","name":"CYC1","canonical_id":"hgnc:HGNC:2579","description":null,"metadata":null},{"id":"d09413e4463a423db940e32857aaccb2","type":"GENE","name":"CYCS","canonical_id":"hgnc:HGNC:19986","description":"cytochrome c, somatic","metadata":{"aliases":["HCS","CYC"]}},{"id":"d238355206974cfebc218b06b3cb3359","type":"GENE","name":"CYCSP1","canonical_id":"hgnc:HGNC:20095","description":"CYCS pseudogene 1","metadata":{"aliases":["HC5","HCP36"]}},{"id":"3c3841ac9bf24affbbfee0d344da75c6","type":"GENE","name":"CYCSP10","canonical_id":"hgnc:HGNC:24384","description":"CYCS pseudogene 10","metadata":{"aliases":["HCP10"]}},{"id":"ba37066261e745d59697f6bae3fffe9d","type":"GENE","name":"CYCSP11","canonical_id":"hgnc:HGNC:24385","description":"CYCS pseudogene 11","metadata":{"aliases":["HCP11"]}},{"id":"87ebe8a87b444da38be50501b358082a","type":"GENE","name":"CYCSP12","canonical_id":"hgnc:HGNC:24386","description":"CYCS pseudogene 12","metadata":{"aliases":["HCP12","HCP13","CYCSP13"]}},{"id":"8a29f685b0cd43fa81da67ea4ca53a76","type":"GENE","name":"CYCSP14","canonical_id":"hgnc:HGNC:24388","description":"CYCS pseudogene 14","metadata":{"aliases":["HCP14"]}},{"id":"71381bfbe5d84624baa8dcfb48c4bfaa","type":"GENE","name":"CYCSP16","canonical_id":"hgnc:HGNC:24389","description":"CYCS pseudogene 16","metadata":{"aliases":["HCP16"]}},{"id":"89f0b4c04a7942a98c06ba0da0f79617","type":"GENE","name":"CYCSP17","canonical_id":"hgnc:HGNC:24390","description":"CYCS pseudogene 17","metadata":{"aliases":["HCP17"]}},{"id":"bbd5509cc4344c5db293bf09bfc16b00","type":"GENE","name":"CYCSP18","canonical_id":"hgnc:HGNC:24391","description":"CYCS pseudogene 18","metadata":{"aliases":["HCP18"]}},{"id":"8abb8ca998f0429b9dcc2dedf01dd7e4","type":"GENE","name":"CYCSP19","canonical_id":"hgnc:HGNC:24392","description":"CYCS pseudogene 19","metadata":{"aliases":["HCP19"]}},{"id":"72606f4a9dcc44fca4f4440f593c8014","type":"GENE","name":"CYCSP2","canonical_id":"hgnc:HGNC:24410","description":"CYCS pseudogene 2","metadata":{"aliases":["HCP37"]}},{"id":"b82075d7fc994f979150c9c79eead7cb","type":"GENE","name":"CYCSP20","canonical_id":"hgnc:HGNC:24394","description":"CYCS pseudogene 20","metadata":{"aliases":["HCP20"]}},{"id":"91398c01029c46f6a0d067145a5e5442","type":"GENE","name":"CYCSP22","canonical_id":"hgnc:HGNC:24396","description":"CYCS pseudogene 22","metadata":{"aliases":["HCP22"]}},{"id":"70babee5a9f3453384487a64af84f049","type":"GENE","name":"CYCSP23","canonical_id":"hgnc:HGNC:24397","description":"CYCS pseudogene 23","metadata":{"aliases":["HCP23"]}},{"id":"d4c3626ea6f948369a2006424215fb0a","type":"GENE","name":"CYCSP24","canonical_id":"hgnc:HGNC:24398","description":"CYCS pseudogene 24","metadata":{"aliases":["HCP24","HC3","HCP31"]}},{"id":"1ed04a96f4384380a9fafaa4ea559623","type":"GENE","name":"CYCSP25","canonical_id":"hgnc:HGNC:24399","description":"CYCS pseudogene 25","metadata":{"aliases":["HC10","HCP25"]}},{"id":"3a85a7f8b2374d86b6d38a81e49a1eac","type":"GENE","name":"CYCSP26","canonical_id":"hgnc:HGNC:24400","description":"CYCS pseudogene 26","metadata":{"aliases":["HCP26"]}},{"id":"04980a956b77470eae167f743a1aa5b4","type":"GENE","name":"CYCSP27","canonical_id":"hgnc:HGNC:24401","description":"CYCS pseudogene 27","metadata":{"aliases":["HCP27"]}},{"id":"07876307dae448fa9e7219a1042d8733","type":"GENE","name":"CYCSP28","canonical_id":"hgnc:HGNC:24402","description":"CYCS pseudogene 28","metadata":{"aliases":["HCP28"]}},{"id":"929cd5baa0f348bfba102203c5cb4a10","type":"GENE","name":"CYCSP29","canonical_id":"hgnc:HGNC:24403","description":"CYCS pseudogene 29","metadata":{"aliases":["HCP29"]}},{"id":"32f2c4bf8232456fa9d07e32796b7df5","type":"GENE","name":"CYCSP3","canonical_id":"hgnc:HGNC:24395","description":"CYCS pseudogene 3","metadata":{"aliases":["HCP21","HS7"]}},{"id":"e03d37d54f0c4285b77540d3de76fdc6","type":"GENE","name":"CYCSP30","canonical_id":"hgnc:HGNC:24405","description":"CYCS pseudogene 30","metadata":{"aliases":["HCP30"]}},{"id":"b8cae9eab0e74d0f828d313c6d6cd3b9","type":"GENE","name":"CYCSP32","canonical_id":"hgnc:HGNC:24406","description":"CYCS pseudogene 32","metadata":{"aliases":["HCP32"]}},{"id":"3537d8446f8643ea9de2d19c4116552d","type":"GENE","name":"CYCSP33","canonical_id":"hgnc:HGNC:24407","description":"CYCS pseudogene 33","metadata":{"aliases":["HCP33"]}},{"id":"f0f8902206ce46debbd85655b8cbe20c","type":"GENE","name":"CYCSP34","canonical_id":"hgnc:HGNC:24408","description":"CYCS pseudogene 34","metadata":{"aliases":["HCP34"]}},{"id":"47e2d36110124e869b6d862649cac6ef","type":"GENE","name":"CYCSP35","canonical_id":"hgnc:HGNC:24409","description":"CYCS pseudogene 35","metadata":{"aliases":["HCP35","HC8"]}},{"id":"c099882bd36d4075aee539751a7edd29","type":"GENE","name":"CYCSP38","canonical_id":"hgnc:HGNC:24411","description":"CYCS pseudogene 38","metadata":{"aliases":["HCP38","HC2"]}},{"id":"f3034be5fd414bde91982db9d6cdd250","type":"GENE","name":"CYCSP39","canonical_id":"hgnc:HGNC:24412","description":"CYCS pseudogene 39","metadata":{"aliases":["HC1","HCP39"]}},{"id":"eb0d167c2b784d3da6a40d091dcb2647","type":"GENE","name":"CYCSP4","canonical_id":"hgnc:HGNC:24413","description":"CYCS pseudogene 4","metadata":{"aliases":["HCP4"]}},{"id":"7de6511c23cf45758814507f9b8be522","type":"GENE","name":"CYCSP40","canonical_id":"hgnc:HGNC:24414","description":"CYCS pseudogene 40","metadata":{"aliases":["HCP40","HC7"]}},{"id":"05368c298b594a968ba0a1403dbe60e1","type":"GENE","name":"CYCSP41","canonical_id":"hgnc:HGNC:2580","description":"CYCS pseudogene 41","metadata":{"aliases":["HCP41","CYC1LP4"]}},{"id":"bd62d9720fd34a3faa5a7c232f29daf7","type":"GENE","name":"CYCSP42","canonical_id":"hgnc:HGNC:2581","description":"CYCS pseudogene 42","metadata":{"aliases":["CYC1LP5"]}},{"id":"47bedad9841e41e3bdb44ead727b5c7f","type":"GENE","name":"CYCSP43","canonical_id":"hgnc:HGNC:24417","description":"CYCS pseudogene 43","metadata":{"aliases":["HCP43"]}},{"id":"5c68d3e20d7b47808b4e0c9e2d54531a","type":"GENE","name":"CYCSP44","canonical_id":"hgnc:HGNC:24418","description":"CYCS pseudogene 44","metadata":{"aliases":["HCP44"]}},{"id":"35741ddfadad4de5bede36d616eb33c5","type":"GENE","name":"CYCSP45","canonical_id":"hgnc:HGNC:24419","description":"CYCS pseudogene 45","metadata":{"aliases":["HCP45"]}},{"id":"b0877dbb7b484e199e22ec8ca9093256","type":"GENE","name":"CYCSP46","canonical_id":"hgnc:HGNC:23941","description":"CYCS pseudogene 46","metadata":{"aliases":["HCP46","HCP47"]}},{"id":"ad0cab20a61544b597ae571c0701ae08","type":"GENE","name":"CYCSP48","canonical_id":"hgnc:HGNC:23942","description":"CYCS pseudogene 48","metadata":{"aliases":["HCP48"]}},{"id":"4062ea13a8a2477aaa0be184349126b8","type":"GENE","name":"CYCSP49","canonical_id":"hgnc:HGNC:23943","description":"CYCS pseudogene 49","metadata":{"aliases":["HCP49","CYCSP54"]}},{"id":"8989544a8c2344e79adcc4ac62fb18b1","type":"GENE","name":"CYCSP5","canonical_id":"hgnc:HGNC:24416","description":"CYCS pseudogene 5","metadata":{"aliases":["HCP5"]}},{"id":"b5c399569bee48a6be5c35a099f37961","type":"GENE","name":"CYCSP51","canonical_id":"hgnc:HGNC:24383","description":"CYCS pseudogene 51","metadata":{"aliases":["HCP1"]}},{"id":"3372acc8a45a4a57a1893af25cbf39c4","type":"GENE","name":"CYCSP52","canonical_id":"hgnc:HGNC:24393","description":"CYCS pseudogene 52","metadata":{"aliases":["HCP2","HC6"]}},{"id":"1fee1d694e7b4d90a6254977d77f3a71","type":"GENE","name":"CYCSP53","canonical_id":"hgnc:HGNC:24404","description":"CYCS pseudogene 53","metadata":{"aliases":["HCP3"]}},{"id":"7e36dd71a27f42e286b237a816102a76","type":"GENE","name":"CYCSP55","canonical_id":"hgnc:HGNC:21252","description":"CYCS pseudogene 55","metadata":{"aliases":["bA513I15.3","HCP15","CYCSL1"]}},{"id":"34cdd865d89f46f58c5d0980e9960243","type":"GENE","name":"CYCSP56","canonical_id":"hgnc:HGNC:56573","description":"CYCS pseudogene 56","metadata":null},{"id":"fed6cb3a2ec6410b9d288930dadf4fdd","type":"GENE","name":"CYCSP6","canonical_id":"hgnc:HGNC:24421","description":"CYCS pseudogene 6","metadata":{"aliases":["HCP6"]}},{"id":"684af75b99e74a8a8bce0e436e9ad099","type":"GENE","name":"CYCSP7","canonical_id":"hgnc:HGNC:24422","description":"CYCS pseudogene 7","metadata":{"aliases":["HCP7"]}},{"id":"1a256d1a7f5f4681aed30b89937bcd8c","type":"GENE","name":"CYCSP8","canonical_id":"hgnc:HGNC:24423","description":"CYCS pseudogene 8","metadata":{"aliases":["HCP8"]}},{"id":"4f122f93171c43b2b860f46fa9e99f5e","type":"GENE","name":"CYCTP","canonical_id":"hgnc:HGNC:24424","description":"cytochrome c, testis, pseudogene","metadata":{"aliases":["HCP9"]}},{"id":"5976f1911ed54040844ff9c21d3d4938","type":"GENE","name":"CYDAER","canonical_id":"hgnc:HGNC:40594","description":"cytoplasmic differentiation associated epidermal RNA","metadata":{"aliases":["RP11-295G20.2","TSNAX-DT"]}},{"id":"c6dcfb537e3748089fc423522dbb0faa","type":"GENE","name":"CYFIP1","canonical_id":"hgnc:HGNC:13759","description":"cytoplasmic FMR1 interacting protein 1","metadata":{"aliases":["KIAA0068","P140SRA-1","SHYC"]}},{"id":"85f41201a01f4b5bb5a402024490319f","type":"GENE","name":"CYFIP2","canonical_id":"hgnc:HGNC:13760","description":null,"metadata":null},{"id":"11004e575e104ddbb0082e49eda57598","type":"GENE","name":"CYFIP2-AS1","canonical_id":"hgnc:HGNC:59290","description":"CYFIP2 antisense RNA 1","metadata":null},{"id":"aef7cd2704914df48f4413b9b64f419c","type":"GENE","name":"CYGB","canonical_id":"hgnc:HGNC:16505","description":"cytoglobin","metadata":{"aliases":["HGB","STAP"]}},{"id":"b8b1a3b1a87f4f28bc21a6e326850ef8","type":"GENE","name":"CYKILR","canonical_id":"hgnc:HGNC:58085","description":"cyclin dependent kinase inhibitor 2A regulated lncRNA","metadata":null},{"id":"68d4b6a950b841aca8deea70938a5f4d","type":"GENE","name":"CYLC1","canonical_id":"hgnc:HGNC:2582","description":"cylicin 1","metadata":null},{"id":"8e56b4f4e8bf4b278058854baa0d36ef","type":"GENE","name":"CYLC2","canonical_id":"hgnc:HGNC:2583","description":"cylicin 2","metadata":null},{"id":"c5324b8434ec4168ac69c7a8b9c2a492","type":"GENE","name":"CYLD","canonical_id":"hgnc:HGNC:2584","description":null,"metadata":null},{"id":"3605aedcb34945db95f100dae52852f9","type":"GENE","name":"CYLD-AS1","canonical_id":"hgnc:HGNC:55352","description":"CYLD antisense RNA 1","metadata":null},{"id":"4210aac30d894b8e8235792a03661a8d","type":"GENE","name":"CYLD-AS2","canonical_id":"hgnc:HGNC:56848","description":"CYLD antisense RNA 2","metadata":null},{"id":"7fb0e0427b9d4c7bbdd9e1beaf8eaa6e","type":"GENE","name":"CYMP","canonical_id":"hgnc:HGNC:2588","description":"chymosin, pseudogene","metadata":null},{"id":"27806b99d36e418ba6a4c5f6490dfb5a","type":"GENE","name":"CYMP-AS1","canonical_id":"hgnc:HGNC:52509","description":"CYMP antisense RNA 1","metadata":null},{"id":"f309ee911b544ada9637132e0c0ccce2","type":"GENE","name":"CYP11A1","canonical_id":"hgnc:HGNC:2590","description":null,"metadata":null},{"id":"5cc246dbd5e7434da17aaa8fea25ea47","type":"PROTEIN","name":"CYP11A1","canonical_id":"uniprot:P05108","description":null,"metadata":null},{"id":"d00f47e965c142f0860a21a155021756","type":"GENE","name":"CYP11B1","canonical_id":"hgnc:HGNC:2591","description":null,"metadata":null},{"id":"5637b45983c34dcc8b06b70ecf6d458d","type":"PROTEIN","name":"CYP11B1","canonical_id":"uniprot:P15538","description":null,"metadata":null},{"id":"8e4e2fe3ea6c466cb2c882d3c5d653f9","type":"GENE","name":"CYP11B2","canonical_id":"hgnc:HGNC:2592","description":null,"metadata":null},{"id":"6683b181ca8e417d8fe59fe6b7f89633","type":"GENE","name":"CYP17A1","canonical_id":"hgnc:HGNC:2593","description":null,"metadata":null},{"id":"ff05af1a48fc4aa9aaf5ce8fbbec8fa2","type":"GENE","name":"CYP17A1-AS1","canonical_id":"hgnc:HGNC:31671","description":"CYP17A1 antisense RNA 1","metadata":{"aliases":["bA753C18.3","CYP17A1OS"]}},{"id":"bf895dd0a7cd4aa69dabdfc485e284c8","type":"GENE","name":"CYP19A1","canonical_id":"hgnc:HGNC:2594","description":null,"metadata":null},{"id":"d32fbda3b283430f8331de6673c94068","type":"PROTEIN","name":"CYP19A1","canonical_id":"uniprot:P11511","description":null,"metadata":null},{"id":"894e790a1db844ed9a2166a6a8862dd8","type":"GENE","name":"CYP1A1","canonical_id":"hgnc:HGNC:2595","description":null,"metadata":null},{"id":"f6c3e2395532454586136a03c2244a88","type":"GENE","name":"CYP1A2","canonical_id":"hgnc:HGNC:2596","description":null,"metadata":null},{"id":"915582e2cf3446208e57e7983a61795e","type":"GENE","name":"CYP1B1","canonical_id":"hgnc:HGNC:2597","description":null,"metadata":null},{"id":"c2e2b10f18554334913ecf19707405d1","type":"GENE","name":"CYP1B1-AS1","canonical_id":"hgnc:HGNC:28543","description":"CYP1B1 antisense RNA 1","metadata":{"aliases":["MGC34824","C2orf58"]}},{"id":"3d8bd9fffb4e43688bfb8de896c4a5b8","type":"GENE","name":"CYP1D1P","canonical_id":"hgnc:HGNC:39968","description":"cytochrome P450 family 1 subfamily D member 1, pseudogene","metadata":{"aliases":["CYP1A8P"]}},{"id":"2f5c413b26304576bb7f906be324823b","type":"GENE","name":"CYP20A1","canonical_id":"hgnc:HGNC:20576","description":"cytochrome P450 family 20 subfamily A member 1","metadata":{"aliases":["CYP-M"]}},{"id":"0127e5eca17a4577bfa603f91dcb263c","type":"GENE","name":"CYP21A1P","canonical_id":"hgnc:HGNC:2599","description":"cytochrome P450 family 21 subfamily A member 1, pseudogene","metadata":{"aliases":["P450c21A","CYP21P","CYP21A"]}},{"id":"3d96c94a499e45dfa7842f18e90687d5","type":"GENE","name":"CYP21A2","canonical_id":"hgnc:HGNC:2600","description":"cytochrome P450 family 21 subfamily A member 2","metadata":{"aliases":["P450c21B","CA21H","CPS1","CAH1","CYP21","CYP21B"]}},{"id":"f1eb9b33ee8a4fd5852f3572de464566","type":"GENE","name":"CYP24A1","canonical_id":"hgnc:HGNC:2602","description":null,"metadata":null},{"id":"58b6a267eb544dcdad852ad13e0eb19e","type":"GENE","name":"CYP26A1","canonical_id":"hgnc:HGNC:2603","description":"cytochrome P450 family 26 subfamily A member 1","metadata":{"aliases":["P450RAI","CP26","CYP26","P450RAI1"]}},{"id":"9b3abf48081247f0bd40a4876f888987","type":"GENE","name":"CYP26B1","canonical_id":"hgnc:HGNC:20581","description":"cytochrome P450 family 26 subfamily B member 1","metadata":{"aliases":["P450RAI-2"]}},{"id":"aa8c2134bc23458aa6d9012008fb9a55","type":"GENE","name":"CYP26C1","canonical_id":"hgnc:HGNC:20577","description":"cytochrome P450 family 26 subfamily C member 1","metadata":null},{"id":"2e157ddbd867423dbd8ebef3fce7bee7","type":"GENE","name":"CYP26C1-DT","canonical_id":"hgnc:HGNC:55836","description":"CYP26C1 divergent transcript","metadata":null},{"id":"b9481ada6f65452b9e4725c921390a6e","type":"GENE","name":"CYP27A1","canonical_id":"hgnc:HGNC:2605","description":null,"metadata":null},{"id":"6067fcdfcb1b4ad1b160e7ad3b968613","type":"GENE","name":"CYP27B1","canonical_id":"hgnc:HGNC:2606","description":null,"metadata":null},{"id":"0701abfae17244a3aa9a05421d0c7ffd","type":"GENE","name":"CYP27C1","canonical_id":"hgnc:HGNC:33480","description":"cytochrome P450 family 27 subfamily C member 1","metadata":{"aliases":["FLJ16008"]}},{"id":"d805fe5e88b34840a44af7186554dc12","type":"GENE","name":"CYP2A13","canonical_id":"hgnc:HGNC:2608","description":"cytochrome P450 family 2 subfamily A member 13","metadata":{"aliases":["CPAD","CYP2A"]}},{"id":"68d7752aaa7649b4a97805d395485946","type":"GENE","name":"CYP2A6","canonical_id":"hgnc:HGNC:2610","description":null,"metadata":null},{"id":"e9a027c3f3ed4dd6b1e5fde41973d9d5","type":"GENE","name":"CYP2A7","canonical_id":"hgnc:HGNC:2611","description":"cytochrome P450 family 2 subfamily A member 7","metadata":{"aliases":["CYP2A"]}},{"id":"b0aa47926a9048588da4edf0f23f7fa9","type":"GENE","name":"CYP2A7P1","canonical_id":"hgnc:HGNC:2612","description":"cytochrome P450 family 2 subfamily A member 7 pseudogene 1","metadata":{"aliases":["CYP2A18PN","CYP2A7PT"]}},{"id":"541ffe7226f24e63a2fcab614e025dac","type":"GENE","name":"CYP2A7P2","canonical_id":"hgnc:HGNC:2613","description":"cytochrome P450 family 2 subfamily A member 7 pseudogene 2","metadata":{"aliases":["CYP2A18PC"]}},{"id":"9c66d0b5eda142e2984fb4cb15b8ce73","type":"GENE","name":"CYP2AB1P","canonical_id":"hgnc:HGNC:39975","description":"cytochrome P450 family 2 subfamily AB member 1, pseudogene","metadata":null},{"id":"70b2ccbcce52404e9cf6d3ab3ade186d","type":"GENE","name":"CYP2AC1P","canonical_id":"hgnc:HGNC:39976","description":"cytochrome P450 family 2 subfamily AC member 1, pseudogene","metadata":null},{"id":"cf861506dbf546958cd7a7dfa2dfd888","type":"GENE","name":"CYP2B6","canonical_id":"hgnc:HGNC:2615","description":null,"metadata":null},{"id":"bdda0f6f81454c8c9ce27bea85f558b2","type":"GENE","name":"CYP2B7P","canonical_id":"hgnc:HGNC:2616","description":"cytochrome P450 family 2 subfamily B member 7, pseudogene","metadata":{"aliases":["CYP2B","CYP2B7P1"]}},{"id":"04bb86e8e57f46b29284c4ccb776c424","type":"GENE","name":"CYP2C115P","canonical_id":"hgnc:HGNC:42405","description":"cytochrome P450 family 2 subfamily C member 115, pseudogene","metadata":{"aliases":["CYP2C9-de1b"]}},{"id":"85d6f3cf4b92474b8306d9d9329ab1bc","type":"GENE","name":"CYP2C18","canonical_id":"hgnc:HGNC:2620","description":"cytochrome P450 family 2 subfamily C member 18","metadata":{"aliases":["P450IIC17","CPCI","CYP2C","CYP2C17"]}},{"id":"80338121f7b9484fb659bba3a415e2ff","type":"GENE","name":"CYP2C19","canonical_id":"hgnc:HGNC:2621","description":null,"metadata":null},{"id":"dd99aa98f98240b4a7ccf380a56c4b90","type":"TRIAL","name":"CYP2C19 Genotype Predictor of Gastric Acid Suppression","canonical_id":"clinicaltrials.gov:NCT01824199","description":"Esophagitis","metadata":null},{"id":"95c2271f2f7f4c1d8f9fa6608b458008","type":"GENE","name":"CYP2C23P","canonical_id":"hgnc:HGNC:39970","description":"cytochrome P450 family 2 subfamily C member 23, pseudogene","metadata":{"aliases":["CYP2C62P"]}},{"id":"9ff1bf0901ba4dc69c6a0ea06a0e84e4","type":"GENE","name":"CYP2C56P","canonical_id":"hgnc:HGNC:39971","description":"cytochrome P450 family 2 subfamily C member 56, pseudogene","metadata":{"aliases":["CYP2C-se1[7]"]}},{"id":"66cbb116b40a4f83a3ab11fce7ca8e62","type":"GENE","name":"CYP2C58P","canonical_id":"hgnc:HGNC:39969","description":"cytochrome P450 family 2 subfamily C member 58, pseudogene","metadata":null},{"id":"1a714ad6b742416ca29b8f4efd1012c9","type":"GENE","name":"CYP2C59P","canonical_id":"hgnc:HGNC:42406","description":"cytochrome P450 family 2 subfamily C member 59, pseudogene","metadata":{"aliases":["CYP2C9-de2c3c"]}},{"id":"090070776b2440578d60a5d1f8a29b74","type":"GENE","name":"CYP2C60P","canonical_id":"hgnc:HGNC:42410","description":"cytochrome P450 family 2 subfamily C member 60, pseudogene","metadata":{"aliases":["CYP2C8-de6b"]}},{"id":"a83949d32bcd4965a2142b05f3d751d1","type":"GENE","name":"CYP2C61P","canonical_id":"hgnc:HGNC:39972","description":"cytochrome P450 family 2 subfamily C member 61, pseudogene","metadata":{"aliases":["CYP2C-se2[1:2]"]}},{"id":"7412bf84fbc24b1a9d8be45b365b2874","type":"GENE","name":"CYP2C63P","canonical_id":"hgnc:HGNC:42411","description":"cytochrome P450 family 2 subfamily C member 63, pseudogene","metadata":{"aliases":["CYP2C-se3[1]"]}},{"id":"22a346bd9aaf4da2b4e13c29d33cc7a1","type":"GENE","name":"CYP2C64P","canonical_id":"hgnc:HGNC:39974","description":"cytochrome P450 family 2 subfamily C member 64, pseudogene","metadata":{"aliases":["CYP2C-se4[1]"]}},{"id":"f16ce12ed2c247c5bb27956743bb4f52","type":"GENE","name":"CYP2C8","canonical_id":"hgnc:HGNC:2622","description":null,"metadata":null},{"id":"25fd573186ac465689a17f5000de139d","type":"GENE","name":"CYP2C9","canonical_id":"hgnc:HGNC:2623","description":null,"metadata":null},{"id":"740f37667b8a4e499b5b2b9eab372d65","type":"TRIAL","name":"CYP2C9 Activity Evaluated With a Simple Finger Prick","canonical_id":"clinicaltrials.gov:NCT01026714","description":"Healthy Volunteers","metadata":null},{"id":"bd1251a3672b4c8f91a54dd400068eb3","type":"GENE","name":"CYP2D6","canonical_id":"hgnc:HGNC:2625","description":null,"metadata":null},{"id":"19ee793ac24b4ff1a0a8e4e776b03d56","type":"GENE","name":"CYP2D7","canonical_id":"hgnc:HGNC:2624","description":"cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)","metadata":{"aliases":["CYP2D","CYP2D@","CYP2D7P1","CYP2D7P"]}},{"id":"2c314c5bf7854afd82431a2b522204cf","type":"GENE","name":"CYP2D8P","canonical_id":"hgnc:HGNC:2628","description":"ccytochrome P450 family 2 subfamily D member 8, pseudogene","metadata":{"aliases":["CYP2DP1","CYP2D8P1"]}},{"id":"65d6807227644a79b2a40540c565796f","type":"GENE","name":"CYP2E1","canonical_id":"hgnc:HGNC:2631","description":null,"metadata":null},{"id":"79d1c097d71841caaec17a0bba34f2c6","type":"GENE","name":"CYP2F1","canonical_id":"hgnc:HGNC:2632","description":null,"metadata":null},{"id":"5659137898714334ba53de5fba4f5226","type":"GENE","name":"CYP2F2P","canonical_id":"hgnc:HGNC:18851","description":"cytochrome P450 family 2 subfamily F member 2, pseudogene","metadata":{"aliases":["CYP2F1P"]}},{"id":"7e25caa2356349939dcab9e230d69ce4","type":"GENE","name":"CYP2G1P","canonical_id":"hgnc:HGNC:2633","description":"cytochrome P450 family 2 subfamily G member 1, pseudogene","metadata":{"aliases":["CYP2GP1","CYP2G1"]}},{"id":"d11266ec362746459361e01140fc9693","type":"GENE","name":"CYP2G2P","canonical_id":"hgnc:HGNC:15653","description":"cytochrome P450 family 2 subfamily G member 2, pseudogene","metadata":{"aliases":["CYP2GP2","CYP2G2"]}},{"id":"79a529501b1e4785a53e436b4bae6276","type":"GENE","name":"CYP2J2","canonical_id":"hgnc:HGNC:2634","description":null,"metadata":null},{"id":"547b2777f12448de91555bbfad92cf23","type":"GENE","name":"CYP2R1","canonical_id":"hgnc:HGNC:20580","description":"cytochrome P450 family 2 subfamily R member 1","metadata":null},{"id":"b320da656aa64b99bd290cf64176c128","type":"GENE","name":"CYP2S1","canonical_id":"hgnc:HGNC:15654","description":"cytochrome P450 family 2 subfamily S member 1","metadata":null},{"id":"8e289d5a71a24b9d959158b0738baead","type":"GENE","name":"CYP2T1P","canonical_id":"hgnc:HGNC:18852","description":"cytochrome P450 family 2 subfamily T member 1, pseudogene","metadata":{"aliases":["CYP2T2P"]}},{"id":"1b72baaeefd845efa4953d1d3c818c30","type":"GENE","name":"CYP2T3P","canonical_id":"hgnc:HGNC:18853","description":"cytochrome P450 family 2 subfamily T member 3, pseudogene","metadata":null},{"id":"97372ed4b2664f3b87784dbfbdbb5904","type":"GENE","name":"CYP2U1","canonical_id":"hgnc:HGNC:20582","description":"cytochrome P450 family 2 subfamily U member 1","metadata":{"aliases":["SPG49","SPG56"]}},{"id":"2b35927702724510af84964be1b4ece9","type":"GENE","name":"CYP2U1-AS1","canonical_id":"hgnc:HGNC:54817","description":"CYP2U1 and SGMS2 antisense RNA 1","metadata":null},{"id":"8c41bc40227f4674bb1dd3d184ccdc46","type":"GENE","name":"CYP2W1","canonical_id":"hgnc:HGNC:20243","description":"cytochrome P450 family 2 subfamily W member 1","metadata":{"aliases":["FLJ20359","MGC34287"]}},{"id":"d9964031fcf147c3bbfe6a2e732a0a78","type":"GENE","name":"CYP39A1","canonical_id":"hgnc:HGNC:17449","description":"cytochrome P450 family 39 subfamily A member 1","metadata":null},{"id":"f0a9b85e879c487baf5a77aaede0433a","type":"GENE","name":"CYP3A137P","canonical_id":"hgnc:HGNC:42419","description":"cytochrome P450 family 3 subfamily A member 137, pseudogene","metadata":{"aliases":["CYP3A43-de1b"]}},{"id":"b18f601a9dc8448da26d03577a329ffd","type":"GENE","name":"CYP3A4","canonical_id":"hgnc:HGNC:2637","description":null,"metadata":null},{"id":"8f09c90470624f438be24edae5f9a52d","type":"GENE","name":"CYP3A4-AS1","canonical_id":"hgnc:HGNC:58107","description":"CYP3A4 antisense RNA 1","metadata":{"aliases":["AC069294.1"]}},{"id":"a501bf6a482f4e59b731b1b7ae4c50ac","type":"GENE","name":"CYP3A43","canonical_id":"hgnc:HGNC:17450","description":"cytochrome P450 family 3 subfamily A member 43","metadata":null},{"id":"5c2784e2e90545258437e8ea54b75530","type":"GENE","name":"CYP3A5","canonical_id":"hgnc:HGNC:2638","description":null,"metadata":null},{"id":"c83771402d704c8b88cbe555a22a8c87","type":"GENE","name":"CYP3A51P","canonical_id":"hgnc:HGNC:42418","description":"cytochrome P450 family 3 subfamily A member 51, pseudogene","metadata":{"aliases":["CYP3A5-de13c","CYP3A5-de1b2b","CYP3A5P1"]}},{"id":"e3d60c867e2b46fc9f94d14147a892df","type":"GENE","name":"CYP3A52P","canonical_id":"hgnc:HGNC:42412","description":"cytochrome P450 family 3 subfamily A member 52, pseudogene","metadata":{"aliases":["CYP3A43-de4c6c"]}},{"id":"57b0082bbeef466b80088472711e3422","type":"GENE","name":"CYP3A54P","canonical_id":"hgnc:HGNC:42413","description":"cytochrome P450 family 3 subfamily A member 54, pseudogene","metadata":{"aliases":["CYP3A-se1[2]"]}},{"id":"b8672e1bdca44b72babf17d312c80179","type":"GENE","name":"CYP3A7","canonical_id":"hgnc:HGNC:2640","description":null,"metadata":null},{"id":"ca358e9d097c4f0e89036f6186279612","type":"GENE","name":"CYP3A7-CYP3A51P","canonical_id":"hgnc:HGNC:51504","description":"CYP3A7-CYP3A51P readthrough","metadata":null},{"id":"3be67f444e654fab8f2feceb048b5fee","type":"GENE","name":"CYP46A1","canonical_id":"hgnc:HGNC:2641","description":null,"metadata":null},{"id":"06b65cfdbb004c5a95bf9d89a7e6b243","type":"GENE","name":"CYP46A4P","canonical_id":"hgnc:HGNC:42349","description":"cytochrome P450 family 46 subfamily A member 4, pseudogene","metadata":{"aliases":["CYP46A-se1[12:13:14]"]}},{"id":"da98c75bda73432cb3f74f8f2667648a","type":"GENE","name":"CYP4A11","canonical_id":"hgnc:HGNC:2642","description":"cytochrome P450 family 4 subfamily A member 11","metadata":{"aliases":["CYP4AII","CYP4A2"]}},{"id":"a2050e4076ef4ffd8c8ddcbf518c24e7","type":"GENE","name":"CYP4A22","canonical_id":"hgnc:HGNC:20575","description":"cytochrome P450 family 4 subfamily A member 22","metadata":null},{"id":"bd491cf773fe4311a981dc5e6f16f98e","type":"GENE","name":"CYP4A22-AS1","canonical_id":"hgnc:HGNC:43715","description":"CYP4A22 antisense RNA 1","metadata":{"aliases":["ncRNA-a3"]}},{"id":"5628de47a6024c12944954739208c414","type":"GENE","name":"CYP4A26P","canonical_id":"hgnc:HGNC:39980","description":"cytochrome P450 family 4 subfamily A member 26, pseudogene","metadata":{"aliases":["CYP4A-se1[12]"]}},{"id":"38bfe56b082c4c9782dfe478c41f7703","type":"GENE","name":"CYP4A27P","canonical_id":"hgnc:HGNC:42414","description":"cytochrome P450 family 4 subfamily A member 27, pseudogene","metadata":{"aliases":["CYP4A-se3[12]"]}},{"id":"5f28d6271a2f4f5f820641735e6a58cd","type":"GENE","name":"CYP4A43P","canonical_id":"hgnc:HGNC:42417","description":"cytochrome P450 family 4 subfamily A member 43, pseudogene","metadata":{"aliases":["CYP4A-se2[1]"]}},{"id":"498b34b59b514578b86db1b96b2b94d4","type":"GENE","name":"CYP4A44P","canonical_id":"hgnc:HGNC:42416","description":"cytochrome P450 family 4 subfamily A member 44, pseudogene","metadata":{"aliases":["CYP4A-se4[2]"]}},{"id":"f8ae349e3fe349b2934bbab0c68b2a2e","type":"GENE","name":"CYP4B1","canonical_id":"hgnc:HGNC:2644","description":"cytochrome P450 family 4 subfamily B member 1","metadata":null},{"id":"f2040d07d32848cd833c09c76d58ffd7","type":"GENE","name":"CYP4F10P","canonical_id":"hgnc:HGNC:39943","description":"cytochrome P450 family 4 subfamily F member 10, pseudogene","metadata":null},{"id":"f6b0b09a7b5447c59a606b7440b0c094","type":"GENE","name":"CYP4F11","canonical_id":"hgnc:HGNC:13265","description":"cytochrome P450 family 4 subfamily F member 11","metadata":null},{"id":"1da9375935694d1ea4ac8e88a062452e","type":"GENE","name":"CYP4F12","canonical_id":"hgnc:HGNC:18857","description":null,"metadata":null},{"id":"3d5fa4ff17e342dfaa536e366df868c2","type":"GENE","name":"CYP4F2","canonical_id":"hgnc:HGNC:2645","description":"cytochrome P450 family 4 subfamily F member 2","metadata":null},{"id":"48b51221e4dc4037b689987c7593356a","type":"GENE","name":"CYP4F22","canonical_id":"hgnc:HGNC:26820","description":"cytochrome P450 family 4 subfamily F member 22","metadata":{"aliases":["FLJ39501"]}},{"id":"ecaf79eb419b463da7cc76faca7ab212","type":"GENE","name":"CYP4F23P","canonical_id":"hgnc:HGNC:39944","description":"cytochrome P450 family 4 subfamily F member 23, pseudogene","metadata":null},{"id":"eadfd68a1d9044729ce8b9b52bbcbb16","type":"GENE","name":"CYP4F24P","canonical_id":"hgnc:HGNC:39945","description":"cytochrome P450 family 4 subfamily F member 24, pseudogene","metadata":null},{"id":"2f6066449ae647cba55c91a5070cf53f","type":"GENE","name":"CYP4F25P","canonical_id":"hgnc:HGNC:39949","description":"cytochrome P450 family 4 subfamily F member 25, pseudogene","metadata":{"aliases":["CYP4F-se1[6:8]"]}},{"id":"a49f4ae482ab48219e90a2123232775d","type":"GENE","name":"CYP4F26P","canonical_id":"hgnc:HGNC:39948","description":"cytochrome P450 family 4 subfamily F member 26, pseudogene","metadata":{"aliases":["CYP4F-se2[6]"]}},{"id":"98625d3c70d14be0acdbf7649e29af8e","type":"GENE","name":"CYP4F27P","canonical_id":"hgnc:HGNC:39946","description":"cytochrome P450 family 4 subfamily F member 27, pseudogene","metadata":{"aliases":["CYP4F-se3[6:7:8]"]}},{"id":"14a2dae0294d402fa0f425dc93917e4d","type":"GENE","name":"CYP4F29P","canonical_id":"hgnc:HGNC:2647","description":"cytochrome P450 family 4 subfamily F member 29, pseudogene","metadata":{"aliases":["CYP4F-se4[6:7:8]","C21orf15","CYP4F3LP"]}},{"id":"13dddab1bdfd4576a148b30294594a28","type":"GENE","name":"CYP4F3","canonical_id":"hgnc:HGNC:2646","description":"cytochrome P450 family 4 subfamily F member 3","metadata":{"aliases":["CYP4F","LTB4H"]}},{"id":"9217dae69cfa4f4e8d6e984e5878e918","type":"GENE","name":"CYP4F30P","canonical_id":"hgnc:HGNC:25270","description":"cytochrome P450 family 4 subfamily F member 30, pseudogene","metadata":{"aliases":["DKFZp434F1719","4F-se9[6:7:8]","C2orf14"]}},{"id":"30072cc10cf24a4fb26673a46e7134b2","type":"GENE","name":"CYP4F31P","canonical_id":"hgnc:HGNC:39955","description":"cytochrome P450 family 4 subfamily F member 31, pseudogene","metadata":{"aliases":["CYP4F-se10[6:7:8]"]}},{"id":"9738a26cc37d422181a481335ec4aae2","type":"GENE","name":"CYP4F32P","canonical_id":"hgnc:HGNC:39951","description":"cytochrome P450 family 4 subfamily F member 32, pseudogene","metadata":{"aliases":["CYP4F-se5[6:8]"]}},{"id":"2519b7e1f0b54e60bad25d4fd1eff68a","type":"GENE","name":"CYP4F33P","canonical_id":"hgnc:HGNC:39952","description":"cytochrome P450 family 4 subfamily F member 33, pseudogene","metadata":{"aliases":["CYP4F-se6[6]"]}},{"id":"b89a92024d1a4520b30f62355629c3dc","type":"GENE","name":"CYP4F34P","canonical_id":"hgnc:HGNC:39953","description":"cytochrome P450 family 4 subfamily F member 34, pseudogene","metadata":{"aliases":["CYP4F-se7[6:7:8]"]}},{"id":"9b192bf8cd9e4c4e8c58236b86470a6b","type":"GENE","name":"CYP4F35P","canonical_id":"hgnc:HGNC:39954","description":"cytochrome P450 family 4 subfamily F member 35, pseudogene","metadata":{"aliases":["CYP4F-se8[6:7:8]"]}},{"id":"bb2292d1dd8248d0bb90e66a1fad9808","type":"GENE","name":"CYP4F36P","canonical_id":"hgnc:HGNC:42407","description":"cytochrome P450 family 4 subfamily F member 36, pseudogene","metadata":{"aliases":["CYP4F2-de12b"]}},{"id":"439c2c55e8344cc7bca56bf25b36b223","type":"GENE","name":"CYP4F44P","canonical_id":"hgnc:HGNC:39957","description":"cytochrome P450 family 4 subfamily F member 44, pseudogene","metadata":{"aliases":["CYP4F-se12[6:8]"]}},{"id":"048e0e08774d4f3c8651b7731e0e891b","type":"GENE","name":"CYP4F45P","canonical_id":"hgnc:HGNC:39950","description":"cytochrome P450 family 4 subfamily F member 45, pseudogene","metadata":{"aliases":["CYP4F-se13[6:8]"]}},{"id":"4ff6afd7afcb42dda3ea08c34d374932","type":"GENE","name":"CYP4F59P","canonical_id":"hgnc:HGNC:39947","description":"cytochrome P450 family 4 subfamily F member 59, pseudogene","metadata":{"aliases":["CYP4F-se14[6:8]"]}},{"id":"f61109b0276d4479b3bd376f02714bea","type":"GENE","name":"CYP4F60P","canonical_id":"hgnc:HGNC:42468","description":"cytochrome P450 family 4 subfamily F member 60, pseudogene","metadata":{"aliases":["CYP4F-se15[6:7:8]"]}},{"id":"23c6a31738b44636aef3571abe3d1c41","type":"GENE","name":"CYP4F61P","canonical_id":"hgnc:HGNC:42469","description":"cytochrome P450 family 4 subfamily F member 61, pseudogene","metadata":{"aliases":["CYP4F-se16[6:7:8]"]}},{"id":"061edff073e64d388af5cf9a264af475","type":"GENE","name":"CYP4F62P","canonical_id":"hgnc:HGNC:39956","description":"cytochrome P450 family 4 subfamily F member 62, pseudogene","metadata":{"aliases":["CYP4F-se11[6:7:8]","CYP4F43P"]}},{"id":"ef38d1edbc894ae086e29c14861679d8","type":"GENE","name":"CYP4F8","canonical_id":"hgnc:HGNC:2648","description":"cytochrome P450 family 4 subfamily F member 8","metadata":null},{"id":"789b7128896442a8b9d6c1801e702fab","type":"GENE","name":"CYP4F9P","canonical_id":"hgnc:HGNC:39940","description":"cytochrome P450 family 4 subfamily F member 9, pseudogene","metadata":null},{"id":"27ab7cb66f4c4afd871fd91f5baa8438","type":"GENE","name":"CYP4V2","canonical_id":"hgnc:HGNC:23198","description":"cytochrome P450 family 4 subfamily V member 2","metadata":{"aliases":["CYP4AH1"]}},{"id":"5a7bce5eea45407987f9ae663bad6fec","type":"GENE","name":"CYP4X1","canonical_id":"hgnc:HGNC:20244","description":"cytochrome P450 family 4 subfamily X member 1","metadata":{"aliases":["MGC40051"]}},{"id":"344433288fa34a0aa2604b00374f467c","type":"GENE","name":"CYP4Z1","canonical_id":"hgnc:HGNC:20583","description":"cytochrome P450 family 4 subfamily Z member 1","metadata":{"aliases":["CYP4A20"]}},{"id":"ccce6b2bf6b2401aa68bb94249e97870","type":"GENE","name":"CYP4Z2P","canonical_id":"hgnc:HGNC:24426","description":"cytochrome P450 family 4 subfamily Z member 2, pseudogene","metadata":{"aliases":["FLJ40054"]}},{"id":"0331a770114447e3ad02d3d7c6fa9975","type":"GENE","name":"CYP51A1","canonical_id":"hgnc:HGNC:2649","description":"cytochrome P450 family 51 subfamily A member 1","metadata":{"aliases":["CP51","CYPL1","P450L1","LDM","P450-14DM","CYP51"]}},{"id":"594d0f26c0ac48e2a4c4bf0298570bea","type":"GENE","name":"CYP51A1-AS1","canonical_id":"hgnc:HGNC:50694","description":"CYP51A1 antisense RNA 1","metadata":{"aliases":["ENST00000453068","LRRD1-AS1"]}},{"id":"8d2ae64b19b14784aa73c937fca685a0","type":"GENE","name":"CYP51A1P1","canonical_id":"hgnc:HGNC:20245","description":"cytochrome P450 family 51 subfamily A member 1 pseudogene 1","metadata":{"aliases":["CYP51P1"]}},{"id":"d8bcea398e5f47e9b03b6a909ddfbc29","type":"GENE","name":"CYP51A1P2","canonical_id":"hgnc:HGNC:20251","description":"cytochrome P450 family 51 subfamily A member 1 pseudogene 2","metadata":{"aliases":["CYP51P2"]}},{"id":"34e46792b1a344058450f2682f017f71","type":"GENE","name":"CYP51A1P3","canonical_id":"hgnc:HGNC:41991","description":"cytochrome P450 family 51 subfamily A member 1 pseudogene 3","metadata":{"aliases":["CYP51P3"]}},{"id":"b4b6666796db4e19b61dbbe3a5534dc7","type":"GENE","name":"CYP7A1","canonical_id":"hgnc:HGNC:2651","description":null,"metadata":null},{"id":"d77048b0029946ae8ec4981498ebd7f2","type":"GENE","name":"CYP7B1","canonical_id":"hgnc:HGNC:2652","description":null,"metadata":null},{"id":"9c8487b5632a412ca39aab40f4a9ea6a","type":"GENE","name":"CYP8B1","canonical_id":"hgnc:HGNC:2653","description":null,"metadata":null},{"id":"6e6abbd4c9f6484b97d8ad3912c09de1","type":"GENE","name":"CYR61","canonical_id":"hgnc:HGNC:2654","description":null,"metadata":null},{"id":"110319c1ae43475e866cbc1cd50dcb12","type":"GENE","name":"CYREN","canonical_id":"hgnc:HGNC:22432","description":"cell cycle regulator of NHEJ","metadata":{"aliases":["MGC5242","FLJ27285","CYREN-1","CYREN-2","FLJ22450","MRI","MRI-2","C7orf49"]}},{"id":"8ef63a92215f401eb29189802faeb0cc","type":"GENE","name":"CYRIA","canonical_id":"hgnc:HGNC:25373","description":"CYFIP related Rac1 interactor A","metadata":{"aliases":["DKFZP566A1524","FLJ11080","CYRI-A","FAM49A"]}},{"id":"3d82ecb711fb451892ca7e05cbf600b9","type":"GENE","name":"CYRIB","canonical_id":"hgnc:HGNC:25216","description":"CYFIP related Rac1 interactor B","metadata":{"aliases":["BM-009","CYRI-B","CYRI","FAM49B"]}},{"id":"b0af3ae2031d4449bf3200ffe720fb9a","type":"GENE","name":"CYRIB-AS1","canonical_id":"hgnc:HGNC:58396","description":"CYRIB antisense RNA 1","metadata":null},{"id":"af2d4ff2324743dd894e88e4f2652bf9","type":"GENE","name":"CYS1","canonical_id":"hgnc:HGNC:18525","description":"cystin 1","metadata":null},{"id":"af9bf8a930aa43678c32afc66db33c1f","type":"GENE","name":"CYSLTR1","canonical_id":"hgnc:HGNC:17451","description":null,"metadata":null},{"id":"8be5903038bf4d148a19822a43908353","type":"PROTEIN","name":"CYSLTR1","canonical_id":"uniprot:Q9Y271","description":null,"metadata":null},{"id":"30db9a6076374d0d8278a385d6129c30","type":"GENE","name":"CYSLTR2","canonical_id":"hgnc:HGNC:18274","description":"cysteinyl leukotriene receptor 2","metadata":{"aliases":["CysLT(2)","CYSLT2R"]}},{"id":"fb70cf4f646a4a89809045096d111067","type":"GENE","name":"CYSRT1","canonical_id":"hgnc:HGNC:30529","description":"cysteine rich tail 1","metadata":{"aliases":["MGC59937","C9orf169"]}},{"id":"c84bcf41d87e437c9098b53ec9f354d3","type":"GENE","name":"CYSTM1","canonical_id":"hgnc:HGNC:30239","description":"cysteine rich transmembrane module containing 1","metadata":{"aliases":["ORF1-FL49","C5orf32"]}},{"id":"f356d0f272a340a9b3137a72bf9d5e5d","type":"GENE","name":"CYTH1","canonical_id":"hgnc:HGNC:9501","description":"cytohesin 1","metadata":{"aliases":["B2-1","D17S811E","cytohesin-1","PSCD1"]}},{"id":"7e804d1ccd9d4710b84c8806ae2eb3bd","type":"GENE","name":"CYTH1P1","canonical_id":"hgnc:HGNC:54900","description":"CYTH1 pseudogene 1","metadata":null},{"id":"fdaeef87f88d44d583da4403a260ff7c","type":"GENE","name":"CYTH2","canonical_id":"hgnc:HGNC:9502","description":"cytohesin 2","metadata":{"aliases":["CTS18.1","Sec7p-L","ARNO","Sec7p-like","cytohesin-2","PSCD2L","PSCD2"]}},{"id":"43099cc13d164b51919d82493374fe7f","type":"GENE","name":"CYTH3","canonical_id":"hgnc:HGNC:9504","description":"cytohesin 3","metadata":{"aliases":["GRP1","ARNO3","cytohesin-3","PSCD3"]}},{"id":"9aad729161c74c2fa6ba99697bb11573","type":"GENE","name":"CYTH4","canonical_id":"hgnc:HGNC:9505","description":"cytohesin 4","metadata":{"aliases":["CYT4","cytohesin-4","PSCD4"]}},{"id":"7ebeaa196c024b22a6f49457ad4080ac","type":"GENE","name":"CYTIP","canonical_id":"hgnc:HGNC:9506","description":"cytohesin 1 interacting protein","metadata":{"aliases":["B3-1","HE","CYBR","CASP","CYTHIP","PSCDBP"]}},{"id":"8de0c801778d49568ae2390220b55b22","type":"GENE","name":"CYTL1","canonical_id":"hgnc:HGNC:24435","description":"cytokine like 1","metadata":{"aliases":["C17","C4orf4"]}},{"id":"0120ea9314bd41cda1391250f01941a9","type":"GENE","name":"CYTOR","canonical_id":"hgnc:HGNC:28717","description":"cytoskeleton regulator RNA","metadata":{"aliases":["MGC4677","C2orf59","NCRNA00152","LINC00152"]}},{"id":"0a4f65b87f4b465b9d782c849ece3847","type":"GENE","name":"CYYR1","canonical_id":"hgnc:HGNC:16274","description":"cysteine and tyrosine rich 1","metadata":{"aliases":["C21orf95"]}},{"id":"06559e6bb3f2461c992444ee71e3dd24","type":"GENE","name":"CYYR1-AS1","canonical_id":"hgnc:HGNC:39560","description":"CYYR1 antisense RNA 1","metadata":null},{"id":"de377aa4c0ec457cad6c84ed675a38f7","type":"GENE","name":"CZIB","canonical_id":"hgnc:HGNC:26059","description":"CXXC motif containing zinc binding protein","metadata":{"aliases":["FLJ20580","C1orf123"]}},{"id":"738d1163274f4da79143e665810aa6b4","type":"GENE","name":"CZIB-DT","canonical_id":"hgnc:HGNC:55408","description":"CZIB divergent transcript","metadata":null},{"id":"8328238c7ad5489695e2a2b8bd4a1e3d","type":"TRIAL","name":"CaOx Stone Prevention","canonical_id":"clinicaltrials.gov:NCT07225764","description":"Kidney Stones","metadata":null},{"id":"b3eb2d2ce16a4a40a28dc004cd439393","type":"TRIAL","name":"Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01500720","description":"Small Cell Lung Cancer","metadata":null},{"id":"c23e400ed27b4411b671862bba109753","type":"TRIAL","name":"Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01308567","description":"Prostate Cancer","metadata":null},{"id":"55653ae06ec04008855b790a6f9ad62b","type":"TRIAL","name":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","canonical_id":"clinicaltrials.gov:NCT02485691","description":"Prostate Cancer Metastatic","metadata":null},{"id":"772a2df9a6ac4280b3b54c2eacf46f1b","type":"TRIAL","name":"Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02844582","description":"Hormone-Resistant Prostate Cancer; Stage IV Prostate Adenocarcinoma","metadata":null},{"id":"5f3e5d18c3224f75bf9607235899cfa9","type":"TRIAL","name":"Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01497964","description":"Gastric Cancer","metadata":null},{"id":"2e0561f4fd1a44b2972717209bf96e70","type":"TRIAL","name":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05340374","description":"Metastatic Castration-resistant Prostate Cancer; mCRPC","metadata":null},{"id":"0255bd810f5a4a09a1985fb1f4432de0","type":"TRIAL","name":"Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01750866","description":"Castrate-resistant Metastatic Prostate Cancer","metadata":null},{"id":"8cd83f157348413a9d2b0ad65dd8dd50","type":"TRIAL","name":"Cabazitaxel in Platinum Refractory Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT01747239","description":"Ovarian Cancer","metadata":null},{"id":"0c590722700d49db9e87145959a8ebba","type":"TRIAL","name":"Cabazitaxel in Relapsed and Metastatic NSCLC","canonical_id":"clinicaltrials.gov:NCT01852578","description":"NSCLC","metadata":null},{"id":"18cf5bf837d24f048f23f5daefa5525c","type":"TRIAL","name":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","canonical_id":"clinicaltrials.gov:NCT03050866","description":"Circulating Tumor Cell; Metastatic Prostate Cancer","metadata":null},{"id":"bc0fcceb5b3146bc9db1d4eb86ed1d2c","type":"TRIAL","name":"Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02254785","description":"Metastatic Castration-Resistant Prostatic Cancer","metadata":null},{"id":"0d7d20dde8c8443c8add7d5bc60a852f","type":"TRIAL","name":"Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)","canonical_id":"clinicaltrials.gov:NCT01830231","description":"Urothelium Transitional Cell Carcinoma","metadata":null},{"id":"a58cff3504694e13bfd09827b0db5182","type":"DRUG","name":"Cabergoline","canonical_id":"mesh:D000077465","description":null,"metadata":null},{"id":"dcc426ecab784731be6c3282770cb260","type":"TRIAL","name":"Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS","canonical_id":"clinicaltrials.gov:NCT07255911","description":"PCOS","metadata":null},{"id":"9110b03f661f489e83e52b06fe76feea","type":"TRIAL","name":"Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility","canonical_id":"clinicaltrials.gov:NCT03549741","description":"Infertility","metadata":null},{"id":"4841ae4c1d834a94b06b1a00c4038adc","type":"TRIAL","name":"Cabergoline Before or After Oocyte Collection for Follicular Resolution","canonical_id":"clinicaltrials.gov:NCT04096027","description":"Infertility, Female","metadata":null},{"id":"fd34b510d03d4392b26ea3c087994dac","type":"TRIAL","name":"Cabergoline Effect on Blood Sugar in Type 2 Diabetics","canonical_id":"clinicaltrials.gov:NCT01459601","description":"Diabetes Type 2","metadata":null},{"id":"740dc40e678d4282841f0c34edae9cbf","type":"TRIAL","name":"Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT02875587","description":"OHSS","metadata":null},{"id":"d9f491da156b4d189aac92fa3f383890","type":"TRIAL","name":"Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention","canonical_id":"clinicaltrials.gov:NCT03473613","description":"Ovarian Hyperstimulation","metadata":null},{"id":"d22706ddfa54495a84f0553429d35738","type":"TRIAL","name":"Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT02461875","description":"OHSS","metadata":null},{"id":"30a902a59914436fa23fc224764dd163","type":"TRIAL","name":"Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention","canonical_id":"clinicaltrials.gov:NCT01530490","description":"Complications Associated With Artificial Fertilization; Disorder of Endocrine Ovary","metadata":null},{"id":"645f1dc173b04df492e86124a43971d8","type":"TRIAL","name":"Cabergoline as a Preventive Treatment for Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT05525611","description":"Migraine","metadata":null},{"id":"7003501d3581450f90f681c9938e09ae","type":"TRIAL","name":"Cabergoline for Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT07072910","description":"Migraine","metadata":null},{"id":"b9346f0d9e4d4001b6e8f3b70ef09620","type":"TRIAL","name":"Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss","canonical_id":"clinicaltrials.gov:NCT06029673","description":"Lactation Suppressed","metadata":null},{"id":"f6689997fab448328e128ec7831e307b","type":"TRIAL","name":"Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss","canonical_id":"clinicaltrials.gov:NCT04701333","description":"Lactation Suppressed","metadata":null},{"id":"4af32d5bad124df1b37a2169e26b59a4","type":"TRIAL","name":"Cabergoline for the Treatment of Chronic Pain Due to Endometriosis","canonical_id":"clinicaltrials.gov:NCT03928288","description":"Endometriosis","metadata":null},{"id":"25f13d4b99d14aeaa2dfe05bf6b95cd3","type":"TRIAL","name":"Cabergoline in Nonfunctioning Pituitary Adenomas","canonical_id":"clinicaltrials.gov:NCT03271918","description":"Pituitary Adenoma; Nonfunctioning Pituitary Adenoma","metadata":null},{"id":"73a9c367b5bf482d9f65ae112829dd7d","type":"TRIAL","name":"Cabergoline in the Management of Nonfunctioning Pituitary Adenoma","canonical_id":"clinicaltrials.gov:NCT07034859","description":"Pituitary Adenoma; MRI; RCT","metadata":null},{"id":"12981245d8ad4d5e86c199a4290c288c","type":"DRUG","name":"Cabozantinib","canonical_id":"mesh:C558660","description":null,"metadata":null},{"id":"0cd46101d1614dc1b70031e84c3eeead","type":"DRUG","name":"Cabozantinib","canonical_id":"ncit:C52200","description":null,"metadata":null},{"id":"f76d9a9d297b46028a91940febf754e6","type":"TRIAL","name":"Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT01954745","description":"Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma of the Extrahepatic Bile Duct","metadata":null},{"id":"a112ed5d89774efaa80bb8cffe1c0197","type":"TRIAL","name":"Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT03534804","description":"Metastatic Urothelial Carcinoma; Bladder Cancer","metadata":null},{"id":"8317a7f2a95d40c89ded171b2fac9c3b","type":"TRIAL","name":"Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT04230954","description":"Cervical Cancer; Recurrent Cervical Cancer; Metastatic Cervical Cancer; Persistent Cervical Cancer","metadata":null},{"id":"05e112cf13354ddf93bcee59ea5168b9","type":"TRIAL","name":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","canonical_id":"clinicaltrials.gov:NCT02496208","description":"Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoi\u2026","metadata":null},{"id":"1b9fe747332e4d45abe1752f5734b3f5","type":"TRIAL","name":"Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer","canonical_id":"clinicaltrials.gov:NCT06377722","description":"Renal Cell Carcinoma Metastatic; Renal Cell Carcinoma Stage IV; Renal Cell Carcinoma Stage III","metadata":null},{"id":"866335d34b524f58b452a08f140c7e26","type":"TRIAL","name":"Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors","canonical_id":"clinicaltrials.gov:NCT04767906","description":"Hepatocellular Carcinoma","metadata":null},{"id":"e88fb0fbfbda466f826694ec429c2f43","type":"TRIAL","name":"Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT04173338","description":"Non Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Urothelial Carcinoma; Malignant Mesothelioma","metadata":null},{"id":"b5484e55198140e3b2eaba2ef5833420","type":"TRIAL","name":"Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01630590","description":"Prostate Cancer","metadata":null},{"id":"dafe4ccf14c54385ad91fc766301670f","type":"TRIAL","name":"Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma","canonical_id":"clinicaltrials.gov:NCT05559879","description":"Gynecologic Cancer; Carcinoma; Uterine Cancer; Endometrial Cancer","metadata":null},{"id":"5849deda6e764a4181c799444f39df27","type":"TRIAL","name":"Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06934057","description":"Kidney Cancer; Renal Cell Cancer","metadata":null},{"id":"2556ef7aa8574299a9f702c7e2a034ae","type":"TRIAL","name":"Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02008383","description":"Colorectal Cancer","metadata":null},{"id":"50f3acb942a74e3ba92ad112c7dfac93","type":"TRIAL","name":"Cabozantinib and Pembrolizumab in Metastatic Pancreas","canonical_id":"clinicaltrials.gov:NCT05052723","description":"Pancreatic Cancer","metadata":null},{"id":"7e16bd86d55447d780213f706c64d3d5","type":"TRIAL","name":"Cabozantinib for Adults With Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT01755195","description":"Refractory Soft Tissue Sarcomas","metadata":null},{"id":"e0a2a976f7ce4820ae1d2502e6251fd9","type":"TRIAL","name":"Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT04878029","description":"Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma","metadata":null},{"id":"2faa30740ce8478a878437c326e6b40a","type":"TRIAL","name":"Cabozantinib in Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT04588051","description":"HCC","metadata":null},{"id":"24026d17e8d848ebb94aac0f063a9b56","type":"TRIAL","name":"Cabozantinib in High Grade Neuroendocrine Neoplasms","canonical_id":"clinicaltrials.gov:NCT04412629","description":"High Grade Neuroendocrine Neoplasms","metadata":null},{"id":"d5ee726ebd78463ebf98ac974b082f3f","type":"TRIAL","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","canonical_id":"clinicaltrials.gov:NCT01639508","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"a72a7e8ccac441a6988d1084ecb67975","type":"TRIAL","name":"Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma","canonical_id":"clinicaltrials.gov:NCT03370718","description":"Metastatic Carcinoma in the Adrenal Cortex; Stage III Adrenal Cortex Carcinoma AJCC v8; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma","metadata":null},{"id":"63523d29a4004f56bf8616c2de336d32","type":"TRIAL","name":"Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01812668","description":"Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"7c6d0d83ec3e445a80b0e852b37649fb","type":"DISEASE","name":"Cachexia","canonical_id":"hp:0004326","description":null,"metadata":null},{"id":"d112be2b6a244ec1a12524d6512688f7","type":"TRIAL","name":"Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC","canonical_id":"clinicaltrials.gov:NCT06138496","description":"Clear Cell Renal Cell Carcinoma","metadata":null},{"id":"bfa14f48fa1049028535261956878016","type":"TRIAL","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06367088","description":"Triple-negative Breast Cancer; Cadonilimab","metadata":null},{"id":"a1cada12f952412e8f3a1145f3f4191f","type":"TRIAL","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","canonical_id":"clinicaltrials.gov:NCT06551207","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"95ac06791a6047549a015f9dd440edef","type":"TRIAL","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","canonical_id":"clinicaltrials.gov:NCT06168786","description":"Colorectal Cancer","metadata":null},{"id":"2136df79f54b401893111738a9c31984","type":"TRIAL","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT06438822","description":"Cholangiocarcinoma","metadata":null},{"id":"2ccfebd424a1416192d2270a51bbad62","type":"TRIAL","name":"Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05913570","description":"Colorectal Cancer; Mismatch Repair-deficient (dMMR); Microsatellite Instability-high (MSI-H); Neoadjuvant Therapy","metadata":null},{"id":"dbe7d03b709f40b79198425802e87fed","type":"TRIAL","name":"Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06218810","description":"Metastatic Colorectal Cancer; Microsatellite Stable Colorectal Carcinoma; RAS Mutation; Cadonilimab","metadata":null},{"id":"9c5f77d2f7384dcf846a2de974e14ecc","type":"TRIAL","name":"Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05815290","description":"dMMR Colorectal Cancer","metadata":null},{"id":"fc2219c07997489fabfe11284ffbdece","type":"TRIAL","name":"Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT05816499","description":"NSCLC Stage IV; NSCLC Stage IIIB; NSCLC Stage IIIC","metadata":null},{"id":"cca9bbc8c8c54159b0a32d6b296e2658","type":"TRIAL","name":"Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT05656144","description":"Soft Tissue Sarcoma","metadata":null},{"id":"243d45ded1224a0795cd76b05d7bb374","type":"TRIAL","name":"Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT05898256","description":"Nasopharyngeal Carcinoma; Immune Checkpoint Inhibitors","metadata":null},{"id":"5a9ba3256ad64ae0996eb5e8aa8739fe","type":"TRIAL","name":"Caecal pH as a Biomarker for Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT02360384","description":"Irritable Bowel Syndrome","metadata":null},{"id":"501eb7bc91b7465aa8cbe2a57841210f","type":"TRIAL","name":"Caffeinated Chewing Gum on Special Forces Performance","canonical_id":"clinicaltrials.gov:NCT06638372","description":"Caffeine; Placebo","metadata":null},{"id":"26352c6be207494daf645a55100258d9","type":"TRIAL","name":"Caffeine Intake and Additive Effects on Cognition","canonical_id":"clinicaltrials.gov:NCT02647567","description":"Healthy","metadata":null},{"id":"bce1120dbfb14f5abea3559d35cadba4","type":"TRIAL","name":"Caffeine for Apnea of Prematurity (CAP)","canonical_id":"clinicaltrials.gov:NCT00182312","description":"Apnea of Prematurity","metadata":null},{"id":"c9860646cce44e2a87ee80d07f1c100d","type":"TRIAL","name":"Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","canonical_id":"clinicaltrials.gov:NCT00826280","description":"Coronary Artery Disease (CAD)","metadata":null},{"id":"3c8968a5b1ee42f0aa9d67b8f6afa262","type":"GO_TERM","name":"Cajal body","canonical_id":"go:GO:0015030","description":"\"A class of nuclear body, first seen after silver staining by Ramon y Cajal in 1903, enriched in small nuclear ribonucleoproteins, and certain general RNA polymerase II transcription factors; ultrastructurally, they appear as a tangle of coiled, electron-dense threads roughly 0.5 micrometers in diameter; involved in aspects of snRNP biogenesis; the protein coilin serves as a marker for Cajal bodies. Some argue that Cajal bodies are the sites for preassembly of transcriptosomes, unitary particles involved in transcription and processing of RNA.\" [NIF_Subcellular:nlx_subcell_090901, PMID:10944589, PMID:11031238, PMID:7559785]","metadata":null},{"id":"811522846076413db3f1c8c70432d26d","type":"GO_TERM","name":"Cajal body organization","canonical_id":"go:GO:0030576","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of Cajal bodies, nuclear bodies that appear ultrastructurally as a tangle of coiled, electron-dense threads roughly 0.5 micrometers in diameter and are enriched in ribonucleoproteins, and certain general RNA polymerase II transcription factors.\" [GOC:mah, PMID:11031238]","metadata":null},{"id":"3d83c88ffd2648aaaee2e4d9b0f3fb57","type":"GO_TERM","name":"Cajal-Retzius cell differentiation","canonical_id":"go:GO:0021870","description":"\"The process in which a neuroblast acquires specialized structural and/or functional features of a Cajal-Retzius cell, one of a transient population of pioneering neurons in the cerebral cortex. These cells are slender bipolar cells of the developing marginal zone. One feature of these cells in mammals is that they express the Reelin gene.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e8330cee1b4e471388349b83ca59ce58","type":"TRIAL","name":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00671034","description":"Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia","metadata":null},{"id":"cdc4b1031fa54fe6b0b8187a3d6c44fe","type":"TRIAL","name":"Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05034627","description":"Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8","metadata":null},{"id":"a5b5373765a64dccbf581e9acd09bfcd","type":"TRIAL","name":"Calcimimetics in Hypophosphatemic Rickets","canonical_id":"clinicaltrials.gov:NCT00844740","description":"Familial Hypophosphatemic Rickets","metadata":null},{"id":"db18c3d0ea2045d58de894323ba84c4f","type":"TRIAL","name":"Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01033500","description":"Islets of Langerhans Transplantation; Diabetes Mellitus, Type 1; Kidney Transplantation","metadata":null},{"id":"663a2b26fe0d42ed9930a5431d6c696f","type":"PROTEIN","name":"Calcineurin subunit B type 1","canonical_id":"uniprot:P63098","description":null,"metadata":null},{"id":"1253a762829247f8886a2d505efe06d5","type":"DRUG","name":"Calcitonin (salmon synthetic)","canonical_id":"mesh:C028815","description":null,"metadata":null},{"id":"c6d9ddb7b8a943a48c77c21bc6c10bbb","type":"TRIAL","name":"Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness","canonical_id":"clinicaltrials.gov:NCT07653516","description":"Acute Mountain Sickness","metadata":null},{"id":"2d3610c0a33140909bb5f47df7e5c9a9","type":"TRIAL","name":"Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity","canonical_id":"clinicaltrials.gov:NCT03935984","description":"Primary Hyperparathyroidism; Hypercalcemia","metadata":null},{"id":"86e5f2466ea4407aaea9274e4283044a","type":"TRIAL","name":"Calcitonin in the Treatment of Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00754884","description":"Fibromyalgia","metadata":null},{"id":"260e2417e3074b398f7bf7ad5ec4b2d9","type":"DRUG","name":"Calcium Carbonate","canonical_id":"mesh:D002119","description":null,"metadata":null},{"id":"702378d07c984956b8dc4b669550da80","type":"TRIAL","name":"Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT02271360","description":"Infertility","metadata":null},{"id":"bbee097ae0044aa289779555f7d4ffd5","type":"TRIAL","name":"Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00043069","description":"Osteoporosis; Prostate Cancer","metadata":null},{"id":"09ce21060a964955b055ceac4b30853b","type":"DRUG","name":"Calcium acetate","canonical_id":"mesh:C120662","description":null,"metadata":null},{"id":"b9fc2d6cd056427d9b92f308956d9be5","type":"TRIAL","name":"Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00998738","description":"Neuropathy; Pain; Recurrent Breast Carcinoma; Stage IV Breast Cancer","metadata":null},{"id":"9372ea179f004a2cafe9ce31ded30e97","type":"DRUG","name":"Calcium chloride","canonical_id":"mesh:D002122","description":null,"metadata":null},{"id":"276609a3f5fd4807a70e0df849c69d9e","type":"DRUG","name":"Calcium gluconate","canonical_id":"mesh:D002125","description":null,"metadata":null},{"id":"732b59b43321400496db6e2a5aa09b03","type":"DRUG","name":"Calcium pantothenate","canonical_id":"mesh:D010205","description":null,"metadata":null},{"id":"2e5c78e5297842ff8690cab84a77588b","type":"PROTEIN","name":"Calcium-activated potassium channel subunit alpha-1","canonical_id":"uniprot:Q12791","description":null,"metadata":null},{"id":"0a7c00e0cc664085ad42f4e73faa4e55","type":"PROTEIN","name":"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A","canonical_id":"uniprot:P54750","description":null,"metadata":null},{"id":"11fe4656b12a437ca16c21cfb5c4fc07","type":"PROTEIN","name":"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B","canonical_id":"uniprot:Q01064","description":null,"metadata":null},{"id":"af5a0f42dece41ff86f4753411f508ce","type":"DRUG","name":"Calfactant","canonical_id":"mesh:C117342","description":null,"metadata":null},{"id":"39ef592d5aa5402c9037ffeb04e72f44","type":"PROTEIN","name":"Calmodulin-1","canonical_id":"uniprot:P0DP23","description":null,"metadata":null},{"id":"9a199f014939450ab0a9606a391bd915","type":"TRIAL","name":"Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)","canonical_id":"clinicaltrials.gov:NCT04583592","description":"COVID-19","metadata":null},{"id":"a9a8d9a10f8545a78be24c2cd0b8f536","type":"TRIAL","name":"Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04470544","description":"Severe Acute Respiratory Syndrome","metadata":null},{"id":"1dc039a2d5784162ae1a2e03dccc7c2e","type":"TRIAL","name":"Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation","canonical_id":"clinicaltrials.gov:NCT05474664","description":"Fontan Operation; Protein-Losing Enteropathy; Camostat Mesylate","metadata":null},{"id":"4d97b4418aa94627b04906075f9c3cc2","type":"TRIAL","name":"Camostat Mesylate in COVID-19 Outpatients","canonical_id":"clinicaltrials.gov:NCT04353284","description":"COVID-19","metadata":null},{"id":"245c3030b14b4230a62971fd17f338be","type":"TRIAL","name":"Camostat With Bicalutamide for COVID-19","canonical_id":"clinicaltrials.gov:NCT04652765","description":"Covid19; SARS-CoV Infection; Coronavirus Infection","metadata":null},{"id":"917d06b12fca45728c898c1d81138b60","type":"TRIAL","name":"Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients","canonical_id":"clinicaltrials.gov:NCT04530617","description":"Covid19; Diabetes; Hypertension; Obesity","metadata":null},{"id":"c3d706f36fe44231b062cd183217732f","type":"TRIAL","name":"Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT00069238","description":"Lymphoma, T-Cell; Lymphoma, Extranodal NK-T-Cell","metadata":null},{"id":"f95d29f55fe346159cc5e10ed340988a","type":"TRIAL","name":"Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT07627620","description":"Cervical Cancer","metadata":null},{"id":"703070cf3d7d4980983ca280e4431fb0","type":"TRIAL","name":"Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma","canonical_id":"clinicaltrials.gov:NCT04888429","description":"Sarcomatoid Carcinoma of Lung","metadata":null},{"id":"9706383c4a6144958544304ba387e763","type":"TRIAL","name":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","canonical_id":"clinicaltrials.gov:NCT07471815","description":"Breast Cancer Triple Negative Breast Cancer","metadata":null},{"id":"d78a32ada5fe471e8f1ec5155d87e83d","type":"TRIAL","name":"Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies","canonical_id":"clinicaltrials.gov:NCT07662681","description":"Head and Neck Cancer","metadata":null},{"id":"487b923e87ea4b1c88e1b86762bed9f3","type":"TRIAL","name":"Can Additional Drug Therapy Accelerate Response Time to Antidepressants","canonical_id":"clinicaltrials.gov:NCT00221494","description":"Depression","metadata":null},{"id":"268dd49fbb074568b2f15fa5084cbb48","type":"TRIAL","name":"Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery","canonical_id":"clinicaltrials.gov:NCT00357851","description":"Pancreatitis","metadata":null},{"id":"bed4d69bb5b84cd8b3aa9bc8f246b0b1","type":"TRIAL","name":"Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!","canonical_id":"clinicaltrials.gov:NCT06608186","description":"PCOS (Polycystic Ovary Syndrome)","metadata":null},{"id":"0a975c5f015f440dabbcb2c2614b1112","type":"TRIAL","name":"Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria","canonical_id":"clinicaltrials.gov:NCT03331289","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"d4d25c83a30842a58114537ba9dd8604","type":"TRIAL","name":"Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?","canonical_id":"clinicaltrials.gov:NCT02286843","description":"Breast Cancer Metastases; HER2 Positive Breast","metadata":null},{"id":"a1249bee9f4b46559bb2089377e20248","type":"TRIAL","name":"Can Intrauterine Levonorgestrel Releasing Device Be a Treatment Option for Postmenstrual Spotting in Isthmocele","canonical_id":"clinicaltrials.gov:NCT04872244","description":"Isthmocele; Post-menstrual Spotting Bleeding; Pelvic Pain","metadata":null},{"id":"8fc0dd6e2da74ca59d678742a9c1ea10","type":"TRIAL","name":"Can MRI Evaluate Beta-blocker Response in Portal Hypertension?","canonical_id":"clinicaltrials.gov:NCT03114813","description":"Liver Cirrhosis; Portal Hypertension; Varix, Esophageal","metadata":null},{"id":"156512bfa5144490962259b44e27d4c5","type":"TRIAL","name":"Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?","canonical_id":"clinicaltrials.gov:NCT00949377","description":"Colonic Inertia","metadata":null},{"id":"5a7a007dab7b482ab9014ea333c82017","type":"TRIAL","name":"Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?","canonical_id":"clinicaltrials.gov:NCT01605370","description":"Hypertension","metadata":null},{"id":"da6c2f49c64d4ceabda72bcba26b3764","type":"TRIAL","name":"Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT00772395","description":"Bone Loss","metadata":null},{"id":"150a65d64a6046a9ba53447804d9c4ff","type":"TRIAL","name":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","canonical_id":"clinicaltrials.gov:NCT04684212","description":"Atrial Fibrillation; Left Atrial Appendage Thrombosis; CVA","metadata":null},{"id":"7ea2c73e0dcd401fa293a812b926eadf","type":"TRIAL","name":"Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis?","canonical_id":"clinicaltrials.gov:NCT04036929","description":"Hand Osteoarthritis","metadata":null},{"id":"ada8c4e02d884788838b2546761e63c6","type":"TRIAL","name":"Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis","canonical_id":"clinicaltrials.gov:NCT00332332","description":"Psoriasis","metadata":null},{"id":"fedc58ae223147809846474c75e1ab9d","type":"TRIAL","name":"Canadian EdoxAban(Lixiana\u00ae) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE","canonical_id":"clinicaltrials.gov:NCT03488420","description":"Atrial Fibrillation and Flutter; Valvular Heart Disease","metadata":null},{"id":"68c288827103404dbcffdf5ddcd0e89e","type":"TRIAL","name":"Canadian Pegvisomant Compassionate Study In Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT00151437","description":"Acromegaly","metadata":null},{"id":"77db2398747547558ec7064b3f65ac93","type":"TRIAL","name":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","canonical_id":"clinicaltrials.gov:NCT03297606","description":"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors","metadata":null},{"id":"d3fa8944cbe84944bb8d1a6cab7bdeff","type":"TRIAL","name":"Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity","canonical_id":"clinicaltrials.gov:NCT05132231","description":"Psoriasis","metadata":null},{"id":"d1ef0373737148429b0a3e8476fa3363","type":"TRIAL","name":"Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)","canonical_id":"clinicaltrials.gov:NCT00233532","description":"Hypertension","metadata":null},{"id":"3a712ff45efa46bbaab50c72379cffa9","type":"DRUG","name":"Canagliflozin","canonical_id":"mesh:D000068896","description":null,"metadata":null},{"id":"05d0a71ee9bd440daae3ea7618d856c4","type":"TRIAL","name":"Canagliflozin (Invokana\u2122) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","canonical_id":"clinicaltrials.gov:NCT02694263","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"513f7b4731bb4925afbc5eeae8040cc4","type":"TRIAL","name":"Canagliflozin and Myocardial Fibrosis","canonical_id":"clinicaltrials.gov:NCT05367063","description":"Type 2 Diabetes; Cardiovascular Risk","metadata":null},{"id":"12a7ae2ac47146c4ac352ec87935bbeb","type":"TRIAL","name":"Canagliflozin in Advanced Renal Disease With MRI Endpoints","canonical_id":"clinicaltrials.gov:NCT06182839","description":"ESRD, CKD Stage 4, CKD Stage 5","metadata":null},{"id":"f44d00b090fa49a986793fdee415c1ad","type":"DRUG","name":"Canakinumab","canonical_id":"mesh:C541220","description":null,"metadata":null},{"id":"fa9ea6824078436882c0683f22d366e5","type":"TRIAL","name":"Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT00947427","description":"Type 1 Diabetes; Preservation of Insulin Secretion; Newly Diagnosed Type 1 Diabetes; Canakinumab in Type 1 Diabetes","metadata":null},{"id":"c1102ce4d4b040fa89ee1114489e1b2c","type":"TRIAL","name":"Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA","canonical_id":"clinicaltrials.gov:NCT04798339","description":"Myelodysplastic Syndromes","metadata":null},{"id":"06f3487baf9d488e947517abcb65113b","type":"TRIAL","name":"Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF","canonical_id":"clinicaltrials.gov:NCT01805960","description":"Atrial Fibrillation","metadata":null},{"id":"a7efb049998c400c978e2a8c2d4ef268","type":"TRIAL","name":"Canakinumab in Covid-19 Cardiac Injury (The Three C Study)","canonical_id":"clinicaltrials.gov:NCT04365153","description":"COVID-19; SARS-CoV 2","metadata":null},{"id":"95152f3f8b8645deb37cd4aad966dd89","type":"DISEASE","name":"Cancer","canonical_id":"doid:162","description":null,"metadata":null},{"id":"307638cc838d45dd9c38cdbc4bd96c92","type":"TRIAL","name":"Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban","canonical_id":"clinicaltrials.gov:NCT02746185","description":"Neoplasm; Venous Thromboembolism","metadata":null},{"id":"e656e21ff1a34c8da06b3691d23cf11b","type":"TRIAL","name":"Cancer of the Pancreas Screening Study (CAPS 3)","canonical_id":"clinicaltrials.gov:NCT00438906","description":"Pancreatic Neoplasm; Peutz-Jeghers Syndrome","metadata":null},{"id":"19c23087ac9c483f9a60a327882f1fb9","type":"TRIAL","name":"CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study","canonical_id":"clinicaltrials.gov:NCT04138316","description":"Migraine; Head Pain","metadata":null},{"id":"9c850952c61b4af79ada3f2e8a58a831","type":"TRIAL","name":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT\u00ae\ufe0f for Systemic Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT05920005","description":"Hypertension","metadata":null},{"id":"0cfbffbc5c9e4f1ea3775e68a165cb4b","type":"TRIAL","name":"Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)","canonical_id":"clinicaltrials.gov:NCT02016183","description":"Hypertension","metadata":null},{"id":"0ff9ac65cf2442ce8e693b7773aa6e5f","type":"TRIAL","name":"Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)","canonical_id":"clinicaltrials.gov:NCT00634712","description":"Congestive Heart Failure","metadata":null},{"id":"300aa77dfcea439dacc3acd4739c3c34","type":"DRUG","name":"Candicidin","canonical_id":"mesh:D002174","description":null,"metadata":null},{"id":"8dfd03d15c0e490494b25a8d4a8864ad","type":"DISEASE","name":"Candidemia","canonical_id":"mesh:D058387","description":null,"metadata":null},{"id":"9216306f28a24f688bdd98a66e207824","type":"DISEASE","name":"Candidiasis","canonical_id":"mesh:D002177","description":null,"metadata":null},{"id":"7d8abea151834131a3cf9f3ca42babd2","type":"DISEASE","name":"Candidiasis of skin","canonical_id":"mesh:D002179","description":null,"metadata":null},{"id":"fca9cfe67125479091e6dfa0dcfb4751","type":"DISEASE","name":"Candidiasis, Oral","canonical_id":"mesh:D002180","description":null,"metadata":null},{"id":"18f50058d24a4fd78addea79b63a61fb","type":"DISEASE","name":"Candidiasis, Vulvovaginal","canonical_id":"mesh:D002181","description":null,"metadata":null},{"id":"c3d88279d2e44e0f8b6e5378b4a86e04","type":"TRIAL","name":"Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI","canonical_id":"clinicaltrials.gov:NCT02943369","description":"STEMI","metadata":null},{"id":"d97a5d4df98c42739910c178bd66620e","type":"TRIAL","name":"Cangrelor Neonatal PK/PD and Safety Study","canonical_id":"clinicaltrials.gov:NCT02765633","description":"Partial Obstruction of Systemic to Pulmonary Artery Shunt; Complete Obstruction of Systemic to Pulmonary Artery Shunt","metadata":null},{"id":"fc8764f22feb453a888c45c4281241cd","type":"TRIAL","name":"Cangrelor Prasugrel Transition Study","canonical_id":"clinicaltrials.gov:NCT01852019","description":"Coronary Artery Disease","metadata":null},{"id":"021902f65a7e43ed8b3b49437c97ab41","type":"TRIAL","name":"Cangrelor Ticagrelor Transition Study","canonical_id":"clinicaltrials.gov:NCT01766466","description":"Coronary Artery Disease","metadata":null},{"id":"abc29a9ae6ba4da9b273c2174e5685c3","type":"TRIAL","name":"Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.","canonical_id":"clinicaltrials.gov:NCT00385138","description":"Atherosclerosis; Acute Coronary Syndrome (ACS)","metadata":null},{"id":"becd37ec505844ba93dad44245d6489e","type":"TRIAL","name":"Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI","canonical_id":"clinicaltrials.gov:NCT04005729","description":"Out-Of-Hospital Cardiac Arrest; Acute Coronary Syndrome","metadata":null},{"id":"a9d51d9a12a0482c817d82bac3673a4a","type":"TRIAL","name":"Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size","canonical_id":"clinicaltrials.gov:NCT03043274","description":"STEMI - ST Elevation Myocardial Infarction","metadata":null},{"id":"f3e30097a3c54c5faeb65091d38e8732","type":"TRIAL","name":"Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO","canonical_id":"clinicaltrials.gov:NCT06792643","description":"Cardiogenic Shock; Extracorporeal Membrane Oxygenation Complication; Platelet Dysfunction","metadata":null},{"id":"01d6e1062fb0400e8dd7bb226d548ecc","type":"TRIAL","name":"Cangrelor to Clopidogrel or Prasugrel Transition Study","canonical_id":"clinicaltrials.gov:NCT01979445","description":"Coronary Artery Disease (CAD)","metadata":null},{"id":"b29f2d41e6264ab3bcca42f1bf97598e","type":"TRIAL","name":"Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI","canonical_id":"clinicaltrials.gov:NCT03182855","description":"Acute Coronary Syndrome; Myocardial Infarction; STEMI - ST Elevation Myocardial Infarction","metadata":null},{"id":"2b7be0e9b36044d48f5f58223e5358db","type":"TRIAL","name":"Cannabidiol and CES1 Interactions in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04603391","description":"Drug Interaction","metadata":null},{"id":"63049c97a7ad47b49031a2f719bb08d3","type":"PROTEIN","name":"Cannabinoid receptor 1","canonical_id":"uniprot:P21554","description":null,"metadata":null},{"id":"689ef9b08a064870b71723b7f0ab3807","type":"TRIAL","name":"Cannabinoids and Biological Reactivity to Stress","canonical_id":"clinicaltrials.gov:NCT06430580","description":"Cannabis Use Disorder","metadata":null},{"id":"eaee178f7bd4456dbe84fe8c628c85a7","type":"TRIAL","name":"Cannabis and Tobacco Co-use Study","canonical_id":"clinicaltrials.gov:NCT04228965","description":"Tobacco Use Disorder","metadata":null},{"id":"7ffc4e1f78494f71a9ebdfc3d7e3944a","type":"DRUG","name":"Capecitabine","canonical_id":"mesh:D000069287","description":null,"metadata":null},{"id":"fb32e9e3431f46b4bdfe19df7eabb4cf","type":"DRUG","name":"Capecitabine","canonical_id":"ncit:C1794","description":null,"metadata":null},{"id":"a5a393be801e4531a629ecf1d0cde85f","type":"TRIAL","name":"Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00496366","description":"Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; HER2/Neu-positive Breast Cancer","metadata":null},{"id":"e3dca38f42424e4fbe886e72b0d4b0a1","type":"TRIAL","name":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00684983","description":"HER2 Positive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7","metadata":null},{"id":"b8c2ec36795247c7ab724510bdc6a155","type":"TRIAL","name":"Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT01044433","description":"Head and Neck Cancer; Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent V\u2026","metadata":null},{"id":"ffdafb74cd0b41619a5c296dc565620e","type":"TRIAL","name":"Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02935309","description":"Rectal Cancer; Rectal Adenocarcinoma","metadata":null},{"id":"5c98a3b83c31412f9ff2e0aa7cb43a91","type":"TRIAL","name":"Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT00814619","description":"Colorectal Cancer","metadata":null},{"id":"4a5acf0a15c7490389b65ef7b387e5ac","type":"TRIAL","name":"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01873833","description":"HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"fcca9ea7f15841368494b4d1b8dc49a5","type":"TRIAL","name":"Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT00711412","description":"Esophageal Cancer","metadata":null},{"id":"a1925d8075d2423d9ef02d104f19d13f","type":"TRIAL","name":"Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease","canonical_id":"clinicaltrials.gov:NCT05800275","description":"Leptomeningeal Metastasis; Leptomeningeal Disease; HER2-positive Metastatic Breast Cancer","metadata":null},{"id":"e5cf025508e54f67944e4f72a7fe80fd","type":"TRIAL","name":"Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00983268","description":"Pancreatic Cancer; Periampullary Adenocarcinoma","metadata":null},{"id":"9f3e3e58e62948d589357791418e72c6","type":"TRIAL","name":"Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine","canonical_id":"clinicaltrials.gov:NCT00440167","description":"Pancreatic Cancer","metadata":null},{"id":"0e252f29d24b4b19b58b11b1c42f87a8","type":"TRIAL","name":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07281768","description":"Colorectal Cancer","metadata":null},{"id":"88a3f71f3a4744a4bc89701a1d025440","type":"DRUG","name":"Capivasertib","canonical_id":"ncit:C102564","description":null,"metadata":null},{"id":"9189c1d13cbd41a8b9ad4f84db374223","type":"TRIAL","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","canonical_id":"clinicaltrials.gov:NCT04862663","description":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","metadata":null},{"id":"58e877ba49fc48659cb3df5ef84c48a1","type":"TRIAL","name":"Capivasertib China PK Study","canonical_id":"clinicaltrials.gov:NCT04742036","description":"Advanced Solid Tumours","metadata":null},{"id":"6b7fa8bf9d29453f9596cb6a6027dfb4","type":"TRIAL","name":"Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06607757","description":"CCCA Assessed by Ki67 Drop Below <2.7% From Baseline","metadata":null},{"id":"5b40757fe2f344f4b474de6add014fbb","type":"TRIAL","name":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","canonical_id":"clinicaltrials.gov:NCT04493853","description":"Hormone-Sensitive Prostate Cancer","metadata":null},{"id":"cbe29cac1c974bfaa0c274db0d3bb5bb","type":"TRIAL","name":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04305496","description":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","metadata":null},{"id":"d5a1db9e96c241fdbc1fbd75f58ea87c","type":"TRIAL","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","canonical_id":"clinicaltrials.gov:NCT03997123","description":"Triple Negative Breast Neoplasms","metadata":null},{"id":"d921c1da5b1b4cceb1844348e424f0e5","type":"TRIAL","name":"Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.","canonical_id":"clinicaltrials.gov:NCT03172208","description":"Healthy Volunteers","metadata":null},{"id":"ee98e572ed83450cbf51af5cdc8d22f3","type":"TRIAL","name":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","canonical_id":"clinicaltrials.gov:NCT05468320","description":"Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"7ea24b37fe844c77859bffa1aac6f9ad","type":"TRIAL","name":"Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation","canonical_id":"clinicaltrials.gov:NCT05435846","description":"Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer","metadata":null},{"id":"c614a430e9794796a96d8c5ae1460e22","type":"TRIAL","name":"Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation","canonical_id":"clinicaltrials.gov:NCT03693339","description":"Cancer; Lung Cancer Metastatic; MET Gene Mutation","metadata":null},{"id":"cf54bc96dd71421ab5ee564a1ce4a3d9","type":"TRIAL","name":"Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma","canonical_id":"clinicaltrials.gov:NCT02587650","description":"ALK Fusion Protein Expression; BRAF wt Allele; Invasive Skin Melanoma; MET Fusion Gene Positive; NRAS wt Allele; NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive; RET Fusion Positive; ROS1 Fusion Positive; Stage III Cutaneous Melanoma; Stage IIIA Cutaneous Melanoma; Stage IIIB Cutaneous Melanoma; Stage IIIC Cutaneous Melanoma; Stage IV Cutaneous Melanoma","metadata":null},{"id":"86b74d65e77c45b0a22a41fecbd7bf52","type":"DRUG","name":"Capreomycin","canonical_id":"mesh:D002207","description":null,"metadata":null},{"id":"ff10426150f34c4c9adaef21d1a52eb2","type":"DRUG","name":"Capsaicin","canonical_id":"mesh:D002211","description":null,"metadata":null},{"id":"ccc61ab841104d488ccb703a38074f76","type":"TRIAL","name":"Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT05840562","description":"Chemotherapy-induced Peripheral Neuropathy","metadata":null},{"id":"6e12316985924ba88984e583db5075a7","type":"TRIAL","name":"Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy","canonical_id":"clinicaltrials.gov:NCT05098067","description":"Hyperemesis Gravidarum; Nausea Gravidarum; Vomiting of Pregnancy","metadata":null},{"id":"4af360a24c1041f49ed26add0bfb4aca","type":"TRIAL","name":"Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT01125215","description":"Painful Diabetic Neuropathy","metadata":null},{"id":"acc2675ca0004c04bde66049e5cd1d66","type":"TRIAL","name":"Capsaicin in Digital Osteoarthritis Versus Control","canonical_id":"clinicaltrials.gov:NCT06444919","description":"Osteoarthritis Hand; Neuropathic Pain","metadata":null},{"id":"361fa9a0451343069255adb62ee4be64","type":"TRIAL","name":"Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)","canonical_id":"clinicaltrials.gov:NCT04918069","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"56e0f63f26df4917817aeb1120dc6fab","type":"TRIAL","name":"Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2)","canonical_id":"clinicaltrials.gov:NCT02138630","description":"Metabolism; Exercise","metadata":null},{"id":"7b8470d275ee4c779b2a892d57c1f88c","type":"DRUG","name":"Captopril","canonical_id":"mesh:D002216","description":null,"metadata":null},{"id":"c747c3c4222a4ea6a14e30289aa72996","type":"TRIAL","name":"Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT04629651","description":"Bone Marrow Fibrosis; Myeloproliferative Neoplasm","metadata":null},{"id":"46933b3d18b64e00aa5bd10b2fbac7bc","type":"TRIAL","name":"Captopril Versus Atenolol to Prevent Expansion Rate of Thoracic Aortic Aneurysms","canonical_id":"clinicaltrials.gov:NCT04224675","description":"Aneurysm","metadata":null},{"id":"94006fbfde6644338479b64ac0684328","type":"TRIAL","name":"Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00004230","description":"Cancer","metadata":null},{"id":"38ff8068fced46049806b3220c346a63","type":"TRIAL","name":"Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00077064","description":"Lung Cancer; Pulmonary Complications; Radiation Fibrosis","metadata":null},{"id":"7fceaa62ffba4ee3b6125e3cdd0d4d81","type":"TRIAL","name":"Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients","canonical_id":"clinicaltrials.gov:NCT00564408","description":"Headache","metadata":null},{"id":"99d45fc35c074cc1a737ec2d559f8fd8","type":"TRIAL","name":"Carbachol\u00b4s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow","canonical_id":"clinicaltrials.gov:NCT00357864","description":"Headache","metadata":null},{"id":"f75173d6b8a04e0192a28f170b8b2ad6","type":"DRUG","name":"Carbamide","canonical_id":"mesh:D014508","description":null,"metadata":null},{"id":"192555e160764ddc9e15be48183cc13c","type":"DRUG","name":"Carbenicillin","canonical_id":"mesh:D002228","description":null,"metadata":null},{"id":"93cfc9a448e8476f9df3a19aef159bfa","type":"DRUG","name":"Carbetocin","canonical_id":"mesh:C020731","description":null,"metadata":null},{"id":"71830e1594fc41f7a41382023f7dc036","type":"TRIAL","name":"Carbidopa-Levodopa in Dry AMD With Geographic Atrophy","canonical_id":"clinicaltrials.gov:NCT03451500","description":"Age Related Macular Degeneration","metadata":null},{"id":"dd6f717905824dab8173091bbf0d6d74","type":"TRIAL","name":"Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off","canonical_id":"clinicaltrials.gov:NCT00601978","description":"Parkinson's Disease","metadata":null},{"id":"7ec81e2be6494f5a8838cc47e72dbc8c","type":"TRIAL","name":"Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off","canonical_id":"clinicaltrials.gov:NCT00642356","description":"Parkinson's Disease","metadata":null},{"id":"a59436b619fe41b09fa7ef6ab99d04b7","type":"TRIAL","name":"Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT02165644","description":"Acute Cerebrovascular Accident; Vasospasm","metadata":null},{"id":"c7fabce0c1874b84841ae6ef1a3c344f","type":"DRUG","name":"Carboplatin","canonical_id":"mesh:D016190","description":null,"metadata":null},{"id":"94af4f901ee5403e9abebe68f8bc6071","type":"DRUG","name":"Carboplatin","canonical_id":"ncit:C1282","description":null,"metadata":null},{"id":"9ea88e371e7244de80f5bf9f80087e70","type":"TRIAL","name":"Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00070486","description":"Lung Cancer","metadata":null},{"id":"87aadbfb209e460686cd77b71f4ce6af","type":"TRIAL","name":"Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT01191892","description":"Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer","metadata":null},{"id":"e2180b8707e34d30b9622fc660799bca","type":"TRIAL","name":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00616967","description":"Breast Cancer","metadata":null},{"id":"678afee1ee8a4035b7687541987d8787","type":"TRIAL","name":"Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00321633","description":"brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)","metadata":null},{"id":"a60f905a7a834506adb33c2fb4440648","type":"TRIAL","name":"Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC","canonical_id":"clinicaltrials.gov:NCT00621049","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"3c975ca575554a6ca14ed2cb248a91ba","type":"TRIAL","name":"Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00998101","description":"Lung Cancer","metadata":null},{"id":"80a784121b3847bea7632b941e976ab8","type":"TRIAL","name":"Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination","canonical_id":"clinicaltrials.gov:NCT03462212","description":"Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer","metadata":null},{"id":"81351a6ea30f45fcae68b58a8bda2b1a","type":"TRIAL","name":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06897579","description":"Extensive Stage Small Cell Lung Cancer","metadata":null},{"id":"26bb461a21fc4f40af7eb509876e3e68","type":"TRIAL","name":"Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT01188876","description":"Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"5a8ff657154946e4a64a43b3aa459be6","type":"DISEASE","name":"Carcinoid syndrome","canonical_id":"mesh:D008303","description":null,"metadata":null},{"id":"f264675668cb4b04a18df1324b8052df","type":"DISEASE","name":"Carcinoma, Renal Cell","canonical_id":"mesh:D002292","description":null,"metadata":null},{"id":"07c2363ea49f47de961f4739434a4dc6","type":"TRIAL","name":"Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling","canonical_id":"clinicaltrials.gov:NCT00384540","description":"Vasculopathy; Allograft","metadata":null},{"id":"39de779f874b4d3fba11302e8183b1ae","type":"TRIAL","name":"Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)","canonical_id":"clinicaltrials.gov:NCT00000464","description":"Arrhythmia; Cardiovascular Diseases; Heart Arrest; Heart Diseases; Myocardial Infarction; Ventricular Fibrillation","metadata":null},{"id":"d91a9de59d36426b9c19e970fe032a8d","type":"TRIAL","name":"Cardiac Arrhythmia Pilot Study (CAPS)","canonical_id":"clinicaltrials.gov:NCT00000504","description":"Arrhythmia; Cardiovascular Diseases; Heart Diseases; Ventricular Arrhythmia","metadata":null},{"id":"c439bd9e74274f2388647c652cd01040","type":"TRIAL","name":"Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00292227","description":"Parkinson's Disease","metadata":null},{"id":"0a27970a586a4449a1aa0721aefc65cb","type":"TRIAL","name":"Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.","canonical_id":"clinicaltrials.gov:NCT07828223","description":"Kidney Transplantation","metadata":null},{"id":"183fd9f6f18248618d366843d1d4f12b","type":"TRIAL","name":"Cardiac Sarcoidosis Response To Steroids Trial","canonical_id":"clinicaltrials.gov:NCT01210677","description":"Cardiac Sarcoidosis; Sarcoidosis","metadata":null},{"id":"2701affb88c44960ba77e532e9ef0537","type":"DISEASE","name":"Cardiogenic shock","canonical_id":"mesh:D012770","description":null,"metadata":null},{"id":"4c35dd7567314892a972dccc9dfa231c","type":"TRIAL","name":"Cardiometabolic Consequences of the Loss of Ovarian Function","canonical_id":"clinicaltrials.gov:NCT06264882","description":"Menopause; Estrogen Deficiency; Aging; Adiposity","metadata":null},{"id":"39c62fe958ea44f5ad47951704020ca9","type":"DISEASE","name":"Cardiomyopathy, Hypertrophic","canonical_id":"mesh:D002312","description":null,"metadata":null},{"id":"755c57779f0545c7b33ecb5601f0e793","type":"TRIAL","name":"Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone","canonical_id":"clinicaltrials.gov:NCT01849861","description":"Healthy","metadata":null},{"id":"6b3df3cafeeb4ddd8eb5556b399974f0","type":"TRIAL","name":"Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS","canonical_id":"clinicaltrials.gov:NCT03261570","description":"Postural Orthostatic Tachycardia Syndrome (POTS); POTS; Orthostatic Intolerance","metadata":null},{"id":"9f8f7f4ff48a4f1582c1925990bc5ae5","type":"TRIAL","name":"Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04709731","description":"Chronic Myeloid Leukemia (CML)","metadata":null},{"id":"10774cf148d141e2b25a3784e666864b","type":"TRIAL","name":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","canonical_id":"clinicaltrials.gov:NCT06027606","description":"Healthy","metadata":null},{"id":"f2f9e3cbfbd642aa86c2bddb8efde002","type":"TRIAL","name":"Cardiovascular Disease Risk in Women With Endometriosis","canonical_id":"clinicaltrials.gov:NCT03746535","description":"Endometriosis","metadata":null},{"id":"ec6cb565f29c4e3894c0b7d2001e5fd6","type":"TRIAL","name":"Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT01483053","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"2084c5e2681e4d1d8647ec6eb13257c2","type":"TRIAL","name":"Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT02245230","description":"Hypertension; Hypertension, Essential","metadata":null},{"id":"219563286aab487b829840a406c5cf53","type":"TRIAL","name":"Cardiovascular Events Based On Statin Initiation In The Elderly","canonical_id":"clinicaltrials.gov:NCT01304641","description":"Cardiovascular; Dyslipidemia","metadata":null},{"id":"df0734b995b54ac481789ae83cb3e275","type":"TRIAL","name":"Cardiovascular Function in COPD Patients","canonical_id":"clinicaltrials.gov:NCT03055988","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"447c5ebbdcbb42e5905c21a037e47f1e","type":"TRIAL","name":"Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study","canonical_id":"clinicaltrials.gov:NCT05030545","description":"Primary Aldosteronism; Hypertension","metadata":null},{"id":"21de4964dcb243ccaa5b021a646c2b92","type":"TRIAL","name":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","canonical_id":"clinicaltrials.gov:NCT01986881","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"0be72a1548c7475e8a8a117c0b63f4bc","type":"TRIAL","name":"Cardiovascular Protection After Preeclampsia With Enalapril","canonical_id":"clinicaltrials.gov:NCT07222852","description":"Preeclampsia; Hypertensive Disorder of Pregnancy; Hypertension; Gestational Hypertension; Gestational Hypertension After Childbirth","metadata":null},{"id":"b34cb9a6565246cd9846a7595d5a138f","type":"TRIAL","name":"Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease","canonical_id":"clinicaltrials.gov:NCT00305201","description":"Kawasaki Disease","metadata":null},{"id":"819ffba791c94e49a4ef67cd33bdd086","type":"TRIAL","name":"Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)","canonical_id":"clinicaltrials.gov:NCT01101035","description":"Cardiovascular Disease","metadata":null},{"id":"57a47ac4c69e40ea9eeef873c8db2a7d","type":"TRIAL","name":"Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines","canonical_id":"clinicaltrials.gov:NCT03155100","description":"Multiple Myeloma in Relapse","metadata":null},{"id":"047874c04a1b4adfb24930a6e1d3010e","type":"TRIAL","name":"Carfilzomib and Belatacept for Desensitization","canonical_id":"clinicaltrials.gov:NCT05017545","description":"Highly Sensitized Prospective Kidney Transplant Recipients","metadata":null},{"id":"5e0632c90cab4ded8b9ff686560e829b","type":"TRIAL","name":"Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT01812720","description":"Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma","metadata":null},{"id":"e73037fce3bb47b0bb054b2db418573e","type":"TRIAL","name":"Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma","canonical_id":"clinicaltrials.gov:NCT02114502","description":"Myeloma","metadata":null},{"id":"214cb6cbe0e1406383b3989e410963f7","type":"DRUG","name":"Carmustine","canonical_id":"mesh:D002330","description":null,"metadata":null},{"id":"1779a87b6a3e41fead595926319fe1cf","type":"TRIAL","name":"Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT00003467","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"0729e83d1d7d4dc1b55a616c92a6f690","type":"TRIAL","name":"Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT01099072","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"e6487a511de5468888e0f5ec4c08f68b","type":"TRIAL","name":"Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo","canonical_id":"clinicaltrials.gov:NCT00532246","description":"Osteoporosis, Post-Menopausal","metadata":null},{"id":"942ce2b82d1d4306a9982d1799b18a7a","type":"TRIAL","name":"Carotid Artery Stenting With Cilostazol Addition for Restenosis","canonical_id":"clinicaltrials.gov:NCT01261234","description":"In-stent Restenosis After Carotid Artery Stenting","metadata":null},{"id":"2973527d255c4595ba3bc7012ed8c9a7","type":"TRIAL","name":"Carpal Tunnel Syndrome - Randomized Clinical Trial Evaluating Effectiveness of Ultrasound in Corticosteroid Injection","canonical_id":"clinicaltrials.gov:NCT02036125","description":"Carpal Tunnel Syndrome","metadata":null},{"id":"c38a31b53e9e467baecadb5be832c429","type":"DRUG","name":"Carvedilol","canonical_id":"mesh:C043211","description":null,"metadata":null},{"id":"971b089e624a4de39dff3878f75014eb","type":"TRIAL","name":"Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.","canonical_id":"clinicaltrials.gov:NCT01196481","description":"Cirrhosis","metadata":null},{"id":"01aaa69a520e4eafb72f70b0a0315963","type":"TRIAL","name":"Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)","canonical_id":"clinicaltrials.gov:NCT01221792","description":"Post-Traumatic Stress Disorder","metadata":null},{"id":"efda12745cf843669858719c8dd4652c","type":"TRIAL","name":"Carvedilol and Alverine in Portal Hypertension","canonical_id":"clinicaltrials.gov:NCT06696248","description":"Hypertension, Portal","metadata":null},{"id":"16f7bccb9aaf463c8fff74310e3707cb","type":"TRIAL","name":"Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00638222","description":"Vascular Disease; Kidney Disease","metadata":null},{"id":"953d4f3c59d8429a96b903e0d0b3eff0","type":"TRIAL","name":"Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis","canonical_id":"clinicaltrials.gov:NCT01212250","description":"Cirrhosis","metadata":null},{"id":"fb466a0ef73b4c9883fdba9246217e5b","type":"TRIAL","name":"Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors","canonical_id":"clinicaltrials.gov:NCT02717507","description":"Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm","metadata":null},{"id":"3c60d4fe716246e8932dcadb0079ce41","type":"TRIAL","name":"Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis","canonical_id":"clinicaltrials.gov:NCT03069339","description":"Cirrhosis","metadata":null},{"id":"f03da2cc2a0c48319a61ca94da890abe","type":"TRIAL","name":"Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00636259","description":"Adenocarcinoma of the Prostate","metadata":null},{"id":"7897269781164a7989b94f8c89f9f2fc","type":"TRIAL","name":"Casodex vs Placebo in Non-Metastatic Early Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00672282","description":"Non-Metastatic Prostate Cancer","metadata":null},{"id":"604a1490a9e34ac9ad3dec8281ac31f5","type":"GO_TERM","name":"Casparian strip","canonical_id":"go:GO:0048226","description":"\"Region of plant cell wall specialised to act as a seal to prevent back leakage of secreted material (analogous to tight junction between epithelial cells). Found particularly where root parenchymal cells secrete solutes into xylem vessels. The barrier is composed of suberin; a fatty substance, containing long chain fatty acids and fatty esters, also found in the cell walls of cork cells (phellem) in higher plants.\" [GOC:jid]","metadata":null},{"id":"f55f4ce352c44380bf69de1fad198f1e","type":"GO_TERM","name":"Casparian strip assembly","canonical_id":"go:GO:0160073","description":"\"The aggregation, arrangement and bonding together of a set of components to form a Casparian strip, a region of plant cell wall specialised to act as a seal to prevent back leakage of secreted material.\" [PMID:28104889]","metadata":null},{"id":"5e6134418a9744efa87502e39c6a6fc6","type":"DRUG","name":"Caspofungin","canonical_id":"mesh:D000077336","description":null,"metadata":null},{"id":"f12bc7a13ef54d7d9aa4656495b8d738","type":"DISEASE","name":"Castration-resistant Prostate Carcinoma","canonical_id":"doid:0080909","description":null,"metadata":null},{"id":"25669a6baf8f40e3a8abcb97fa3efbaf","type":"GO_TERM","name":"CatSper complex","canonical_id":"go:GO:0036128","description":"\"A sperm-specific voltage-gated calcium channel that controls the intracellular calcium ion concentration and, thereby, the swimming behavior of sperm. Consists of a heteromeric tetramer surrounding a calcium ion- selective pore. May also contain additional auxiliary subunits.\" [GOC:sp, PMID:17478420, PMID:21224844, PMID:22354039]","metadata":null},{"id":"0550855a2e6f4b728df31e2d4e1bc2f3","type":"TRIAL","name":"Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)","canonical_id":"clinicaltrials.gov:NCT02294955","description":"Atrial Fibrillation; Quality of Life","metadata":null},{"id":"d3c5809c31d44328921e56145b30af05","type":"TRIAL","name":"Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias","canonical_id":"clinicaltrials.gov:NCT01780311","description":"Ventricular Tachycardia; Ventricular Premature Complexes","metadata":null},{"id":"3051e5798f0f4bf98b5b9fb15a7782f6","type":"PROTEIN","name":"Cation-dependent mannose-6-phosphate receptor","canonical_id":"uniprot:P20645","description":null,"metadata":null},{"id":"70518f3cf56e4094812fd7678cdf257c","type":"TRIAL","name":"Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission","canonical_id":"clinicaltrials.gov:NCT01246440","description":"Ovarian Cancer","metadata":null},{"id":"7d4de9e2a58b4707b7cb5a06fdd6f2b4","type":"TRIAL","name":"Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas","canonical_id":"clinicaltrials.gov:NCT01504256","description":"Gastric Adenocarcinoma With Peritoneal Carcinomatosis; Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis; Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis","metadata":null},{"id":"0c110165230646c28185a90b09b4238f","type":"TRIAL","name":"Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine","canonical_id":"clinicaltrials.gov:NCT04799847","description":"Bladder Cancer","metadata":null},{"id":"fb2a7d95ebd549248f7c5ed3a2170629","type":"TRIAL","name":"Caudal Epidural Catheterization in Pediatric Renal Transplant: Effect on Hemodynamics and Pain After Surgery","canonical_id":"clinicaltrials.gov:NCT02037802","description":"Renal Failure","metadata":null},{"id":"ca7cfb599a4c4c32876b54500125e9ea","type":"GO_TERM","name":"Cbf1-Met4-Met28 complex","canonical_id":"go:GO:0089713","description":"\"A heteromeric complex consisting of Cbf1 and basic leucine zipper (bZIP) containing transcriptional activators, Met4 and Met28, that forms over the sequence TCACGTG in the upstream activating sequence (UAS) of genes involved in sulfur amino acid metabolism, resulting in their transcriptional activation.\" [PMID:8665859, PMID:9171357]","metadata":null},{"id":"287d85c26c0141c8a1fba17e639b486f","type":"GO_TERM","name":"Cbp3p-Cbp6 complex","canonical_id":"go:GO:0061671","description":"\"A protein complex located at the mitochondrial ribosome tunnel exit that is involved in efficient translation and protein complex assembly.\" [GOC:dph, GOC:rb, PMID:21670217]","metadata":null},{"id":"59f0bd58baee4340a20d4429125bd9b4","type":"GO_TERM","name":"Cdc24p-Far1p-Gbetagamma complex","canonical_id":"go:GO:0120171","description":"\"A complex that forms at the cell cortex in response to pheromone treatment and is required for the polarized growth of haploid yeast cells towards a mating partner during yeast mating. In the yeast Saccharomyces cerevisiae, this complex consists of Cdc24p, Far1p, Ste4p (G-protein beta subunit) and Ste18p (G-protein gamma subunit).\" [PMID:10087263]","metadata":null},{"id":"c98031edc266413e9892d6566d2e1d80","type":"GO_TERM","name":"Cdc42 GTPase complex","canonical_id":"go:GO:0071521","description":"\"A protein complex formed by the association of the small GTPase Cdc42 with additional proteins. In Schizosaccharomyces the complex contains the Cdc42, Ras1, Scd1, Scd2, andShk1 proteins, and functions in the Ras1-Scd GTPase signaling pathway.\" [GOC:mah, GOC:vw, PMID:10567532, PMID:7923372, PMID:8943016]","metadata":null},{"id":"1cd9b68bc7984050bbe42fca7e8ccccb","type":"GO_TERM","name":"Cdc42 protein signal transduction","canonical_id":"go:GO:0032488","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Cdc42 subfamily relays a signal.\" [GOC:mah, PMID:18558478]","metadata":null},{"id":"1c77524c73f841fcbe4ee3651cedba74","type":"GO_TERM","name":"Cdc48p-Npl4p-Vms1p AAA ATPase complex","canonical_id":"go:GO:0036266","description":"\"A multiprotein ATPase complex involved in the release of polyubiquitinated proteins, including those damaged by oxidative stress, from the outer mitochondria membrane into the cytoplasm where they are presented to the proteasome for proteolysis, a process also referred to as mitochondria-associated degradation (MAD). In budding yeast, this complex includes Cdc48p, Npl4p and Vms1p.\" [GOC:rn, PMID:21070972, PMID:21936843]","metadata":null},{"id":"f3a1da76f088489eaea01a9fece48f0f","type":"GO_TERM","name":"Cdc50p-Drs2p complex","canonical_id":"go:GO:1990530","description":"\"A protein complex that functions as a phospholipid-translocating P-Type ATPase. In budding yeast, this complex consists of Cdc50p and Drs2p proteins, and is involved in the trafficking of transport vesicles between the late Golgi and the early endosome.\" [GOC:rb, PMID:15090616, PMID:22234261]","metadata":null},{"id":"922fe7ef043d48a1bc751486780dbd40","type":"GO_TERM","name":"Cdc73/Paf1 complex","canonical_id":"go:GO:0016593","description":"\"A multiprotein complex that associates with RNA polymerase II and general RNA polymerase II transcription factor complexes and may be involved in both transcriptional initiation and elongation. In Saccharomyces the complex contains Paf1p, Cdc73p, Ctr9p, Rtf1p, and Leo1p.\" [PMID:11884586]","metadata":null},{"id":"5145750630f94cd0b1da6f6621c21ead","type":"GO_TERM","name":"Cdr2 medial cortical node complex","canonical_id":"go:GO:0110115","description":"\"A megadalton-sized complex at the medial cortex organized as an oligomeric core of SAD family protein kinases involved in cell size-dependent localization and phosphorylation of Wee1 during interphase.\" [GOC:vw, PMID:29514920]","metadata":null},{"id":"027e7fa2f872495098f4331613a4af48","type":"GO_TERM","name":"Cdv-dependent cytokinesis","canonical_id":"go:GO:0061639","description":"\"A cytokinesis that involves a set of conserved proteins including the Cdv proteins, and results in the formation of two similarly sized and shaped cells.\" [GOC:dph, PMID:18987308]","metadata":null},{"id":"1270c9d732e440beb172a406d2b8ef4c","type":"DRUG","name":"Cediranib","canonical_id":"ncit:C80867","description":null,"metadata":null},{"id":"ff8b3c7a97af44f8a6c36ab81dddbbe6","type":"TRIAL","name":"Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT01364051","description":"Metastatic Melanoma; Refractory Malignant Solid Neoplasm; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm","metadata":null},{"id":"e08f3229b3a9460f93ef30d3d65c456f","type":"DRUG","name":"Cefaclor","canonical_id":"mesh:D002433","description":null,"metadata":null},{"id":"226edee675b746e3af8cdd56bb87b96d","type":"DRUG","name":"Cefadroxil","canonical_id":"mesh:D002434","description":null,"metadata":null},{"id":"62eea915a60f4fc09595eef309e07b7f","type":"TRIAL","name":"Cefalium\u00ae Compared to Tylenol\u00ae in the Treatment of Migraine Attacks","canonical_id":"clinicaltrials.gov:NCT02582996","description":"Migraine","metadata":null},{"id":"37bb9b0d2051444c9c99874ae0c3e88b","type":"DRUG","name":"Cefamandole","canonical_id":"mesh:D002435","description":null,"metadata":null},{"id":"b8c386228bae41dba152201e135aa598","type":"DRUG","name":"Cefapirin","canonical_id":"mesh:D002514","description":null,"metadata":null},{"id":"bbb83cd47d2148d4a90915a7813a3d4a","type":"DRUG","name":"Cefazolin","canonical_id":"mesh:D002437","description":null,"metadata":null},{"id":"b8e5043769c541728fac113204c5328f","type":"DRUG","name":"Cefdinir","canonical_id":"mesh:C056814","description":null,"metadata":null},{"id":"d7010b6962f843ad874183ec871cf241","type":"DRUG","name":"Cefditoren pivoxil","canonical_id":"mesh:C057710","description":null,"metadata":null},{"id":"aaca714ab312412a8ea420fa5fbdb2ce","type":"DRUG","name":"Cefepime","canonical_id":"mesh:C043266","description":null,"metadata":null},{"id":"a88a706cec2a4f6db1f9b094da98e905","type":"DRUG","name":"Cefixime","canonical_id":"mesh:D020682","description":null,"metadata":null},{"id":"765044b1843342aebeb7c0462fc434d1","type":"DRUG","name":"Cefmetazole","canonical_id":"mesh:D015311","description":null,"metadata":null},{"id":"f274413a1e244c4287dd39d292e59ee1","type":"DRUG","name":"Cefonicid","canonical_id":"mesh:D015790","description":null,"metadata":null},{"id":"60825f511fc8405d861d48b07ee1d5d4","type":"DRUG","name":"Cefradine","canonical_id":"mesh:D002515","description":null,"metadata":null},{"id":"149440cf2da847faaa6676f8fa2c01e9","type":"DRUG","name":"Ceftaroline fosamil","canonical_id":"mesh:C515501","description":null,"metadata":null},{"id":"67777f68c8ce4c009eae0a94be7978bd","type":"DRUG","name":"Ceftibuten","canonical_id":"mesh:D000077722","description":null,"metadata":null},{"id":"8183a821e4c74b228e136df557ba93e8","type":"DRUG","name":"Ceftriaxone","canonical_id":"mesh:D002443","description":null,"metadata":null},{"id":"d3e3755a417f4573bac4789d293a9c6d","type":"TRIAL","name":"Celebrex In Acute Gouty Arthritis Study","canonical_id":"clinicaltrials.gov:NCT00549549","description":"Arthritis, Gouty","metadata":null},{"id":"ec21eaea11924e4cb011bb2c0b017b74","type":"DRUG","name":"Celecoxib","canonical_id":"ncit:C1728","description":null,"metadata":null},{"id":"1e1cc2661eec45a2aa62c384ae60e246","type":"TRIAL","name":"Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis","canonical_id":"clinicaltrials.gov:NCT00033371","description":"Colorectal Cancer; Familial Adenomatous Polyposis","metadata":null},{"id":"56298de0ba5b448787c7c526104e6a92","type":"TRIAL","name":"Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder","canonical_id":"clinicaltrials.gov:NCT00084578","description":"Bladder Cancer","metadata":null},{"id":"843ddc10c4ce4fff9daa89a0cf3cb181","type":"TRIAL","name":"Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer","canonical_id":"clinicaltrials.gov:NCT00087256","description":"Colorectal Cancer","metadata":null},{"id":"50d3e48650a442b2b24a484b2a847760","type":"TRIAL","name":"Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00070057","description":"Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer","metadata":null},{"id":"67830250ec0f48dcb77cdb470204b99f","type":"TRIAL","name":"Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00045591","description":"Breast Cancer","metadata":null},{"id":"03fec0f6534449c697eb5b73f3f466f9","type":"TRIAL","name":"Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps","canonical_id":"clinicaltrials.gov:NCT00005094","description":"Colon Cancer; Rectal Cancer","metadata":null},{"id":"baa4731923414987923b51e636394553","type":"TRIAL","name":"Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer","canonical_id":"clinicaltrials.gov:NCT07174570","description":"Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8","metadata":null},{"id":"f4a610549d754ade9cca3e476e6dfa87","type":"TRIAL","name":"Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus","canonical_id":"clinicaltrials.gov:NCT00066716","description":"Esophageal Cancer","metadata":null},{"id":"b959a521f41449ca8e33013243f8a07e","type":"TRIAL","name":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","canonical_id":"clinicaltrials.gov:NCT03403634","description":"Metastatic Carcinoma in the Liver; Recurrent Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7","metadata":null},{"id":"2e764bd8ab3f45a69f0b74a7508f94c8","type":"DRUG","name":"Celiprolol","canonical_id":"mesh:D017272","description":null,"metadata":null},{"id":"701ad4eaf7b149f5bc9bc234b4ea2c7e","type":"TRIAL","name":"Celiprolol Versus Ditiazem for the Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery","canonical_id":"clinicaltrials.gov:NCT03752931","description":"Postoperative Cardiac Complication","metadata":null},{"id":"6ed2cc041d1d4f58a91f4dc3eea46b6c","type":"TRIAL","name":"Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT04863183","description":"Mesenchymal Stem Cells; Knee Osteoarthritis; Cell Therapy","metadata":null},{"id":"67d7b56135c84bccb772049d6048d3d8","type":"PROTEIN","name":"Cell division protein FtsI (Staphylococcus aureus)","canonical_id":"uniprot:Q53725","description":null,"metadata":null},{"id":"cc9bdfa2abba4cb4bd8dca8ad71248f2","type":"TISSUE","name":"Cells Cultured fibroblasts","canonical_id":"uberon:EFO:0002009","description":null,"metadata":null},{"id":"1fd38387528b4a1a9b5906afeae9c4ae","type":"TISSUE","name":"Cells EBV-transformed lymphocytes","canonical_id":"uberon:EFO:0000572","description":null,"metadata":null},{"id":"2f5fb91c425648b0abc0c62514f5c3a3","type":"TRIAL","name":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06790602","description":"Pancreatic Ductal Adenocarcinoma (mPDAC)","metadata":null},{"id":"b05a7e4ca3184ffa9a8bc8a200e41725","type":"TRIAL","name":"Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07715734","description":"Kidney Transplant Recipient; Cutaneous Squamous Cell Carcinoma (CSCC); Advanced Cutaneous Squamous Cell Carcinoma; Kidney Transplant","metadata":null},{"id":"338fd09cd6f34174a9fa88c6271fa960","type":"TRIAL","name":"Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery","canonical_id":"clinicaltrials.gov:NCT03565783","description":"Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck; Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck; Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","metadata":null},{"id":"e40bfc3a26a641439475a2b11d6baf8e","type":"TRIAL","name":"Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations","canonical_id":"clinicaltrials.gov:NCT05567055","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"80bd16095b4547c8af26e25c0985fe96","type":"TRIAL","name":"Centrally Acting ACE Inhibition in SLE","canonical_id":"clinicaltrials.gov:NCT04486118","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"3826b053c5c64eaaabddbd419af7ec35","type":"TRIAL","name":"Cerebellum-based Imaging Neural Markers for Antipsychotic Response","canonical_id":"clinicaltrials.gov:NCT07483294","description":"Psychosis; Acute","metadata":null},{"id":"b592bc76ec31437aa109a42e094c3602","type":"TRIAL","name":"Cerebral Amyloid Imaging Using Florbetapir (AV-45)","canonical_id":"clinicaltrials.gov:NCT02813434","description":"Dementia; Cognition Disorders","metadata":null},{"id":"cda9f3ec68c442528e1e2cbf4ec2e116","type":"TRIAL","name":"Cerebral Flow-metabolism Coupling During Adult Surgery","canonical_id":"clinicaltrials.gov:NCT05941494","description":"Anesthesia","metadata":null},{"id":"9a006a8f05714bef91135ee5c1dad435","type":"TRIAL","name":"Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia","canonical_id":"clinicaltrials.gov:NCT04282629","description":"Aneurysmal Subarachnoid Hemorrhage","metadata":null},{"id":"b934daec13254a72b4d5dc0cb9c0f1b4","type":"TRIAL","name":"Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration","canonical_id":"clinicaltrials.gov:NCT04649398","description":"Subarachnoid Hemorrhage, Aneurysmal; Delayed Cerebral Ischemia; Vasospasm, Cerebral","metadata":null},{"id":"69c16a6c80db4913a8aba20123ef3616","type":"TRIAL","name":"Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation","canonical_id":"clinicaltrials.gov:NCT02932488","description":"Healthy Volunteers","metadata":null},{"id":"31b63333cdf04185b141f50fd74f3547","type":"DISEASE","name":"Cerebral cysticercosis","canonical_id":"mesh:D020019","description":null,"metadata":null},{"id":"d35fe28ec16e4bb9a2c2944efb5c6e0d","type":"DISEASE","name":"Cerebral edema","canonical_id":"mesh:D001929","description":null,"metadata":null},{"id":"f00372b4cbfb4c7cb210c0ce117e6b10","type":"TRIAL","name":"Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)","canonical_id":"clinicaltrials.gov:NCT01822951","description":"Alzheimer Disease","metadata":null},{"id":"64d9822f4ba54e40918b651d76cf3dbd","type":"DISEASE","name":"Cerebrotendinous Xanthomatosis","canonical_id":"mesh:D019294","description":null,"metadata":null},{"id":"fae2d9097bc04f58856198d8ee90aa18","type":"DISEASE","name":"Cerebrovascular accident","canonical_id":"mesh:D020521","description":null,"metadata":null},{"id":"4147358ea46742e9a8b87143e3641747","type":"DISEASE","name":"Cerebrovascular disease","canonical_id":"mesh:D002561","description":null,"metadata":null},{"id":"1256fec327d74fe690f7bacd8bb48287","type":"DRUG","name":"Ceritinib","canonical_id":"ncit:C115112","description":null,"metadata":null},{"id":"177968c08de74dacb94efabc1056f7cf","type":"TRIAL","name":"Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)","canonical_id":"clinicaltrials.gov:NCT02186821","description":"Tumors With Aberrations in ALK or ROS1","metadata":null},{"id":"635ce9ea4d564f86943ae8974b5e1010","type":"TRIAL","name":"Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT03087448","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"3f91305533f040df9310cd6bb572e81c","type":"TRIAL","name":"Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT03611738","description":"Non-small Cell Lung Cancer; Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB; Stage IV Non-small Cell Lung Cancer; EGFR Negative Non-Small Cell Lung Cancer","metadata":null},{"id":"68d394efdc554b3bbcdd4542c34407f9","type":"TRIAL","name":"Ceritinib Rare Indications Study in ALK+ Tumors","canonical_id":"clinicaltrials.gov:NCT02465528","description":"Tumors With Aberrations in ALK; Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblastic Tumor; Glioblastoma","metadata":null},{"id":"30f16d0c362c406fad495e3edd16215c","type":"TRIAL","name":"Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02729961","description":"Anaplastic Large Cell Lymphoma, ALK-Positive; CD30-Positive Neoplastic Cells Present; Systemic Anaplastic Large Cell Lymphoma","metadata":null},{"id":"8f0a9885387b456e809b98ffede4f08b","type":"TRIAL","name":"Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02227940","description":"Advanced Malignant Solid Neoplasm; ALK Positive; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer","metadata":null},{"id":"7197527e418944b0a3cc95a26d8131d1","type":"TRIAL","name":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02321501","description":"ALK Positive; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; ROS1 Gene Rearrangement; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7","metadata":null},{"id":"dd812b2626024ec99d82351771f40420","type":"TRIAL","name":"Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02513667","description":"ALK-positive Non-small Cell Lung Cancer","metadata":null},{"id":"5db9176d8b48492bb4e89db62af79693","type":"TRIAL","name":"Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT02289144","description":"Metastatic Anaplastic Thyroid Cancer; Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer","metadata":null},{"id":"cccc64a8de2344aaabab1184db0fb99f","type":"DRUG","name":"Cerivastatin","canonical_id":"mesh:C086276","description":null,"metadata":null},{"id":"e5276a22c14842f4860f712042bb077c","type":"TRIAL","name":"Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab","canonical_id":"clinicaltrials.gov:NCT00307931","description":"Crohn's Disease","metadata":null},{"id":"c0706f71c1ff41dbbda8b2633e39529d","type":"DRUG","name":"Certolizumab pegol","canonical_id":"mesh:D000068582","description":null,"metadata":null},{"id":"9dcb35cf813c4ab89f5a8aedcd28915f","type":"DISEASE","name":"Cervical Cancer","canonical_id":"doid:4362","description":null,"metadata":null},{"id":"65dc0936d6a3421e9a12241a109417ba","type":"TRIAL","name":"Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies","canonical_id":"clinicaltrials.gov:NCT02623881","description":"Pregnancy","metadata":null},{"id":"80cd8283063b455d95d109a1af2b358e","type":"TRIAL","name":"Cervical Preparation Before Dilation and Evacuation","canonical_id":"clinicaltrials.gov:NCT01751087","description":"Abortion, Induced","metadata":null},{"id":"fff43fb56ce54150b5d427d378e25180","type":"TRIAL","name":"Cervical Rippening With Antiprogesterone in Midtrimester Abortions","canonical_id":"clinicaltrials.gov:NCT00410345","description":"Abortion, Missed","metadata":null},{"id":"3d38c457c03e4e9b8872e34ebf8c5956","type":"DISEASE","name":"Cervical Squamous Cell Carcinoma","canonical_id":"doid:3744","description":null,"metadata":null},{"id":"eaf3c9272df84334b953c70bb512c8b2","type":"TRIAL","name":"Cervical Traction vs. Active Management of 3rd Stage of Labor","canonical_id":"clinicaltrials.gov:NCT04747015","description":"Post Partum Hemorrhage","metadata":null},{"id":"d0924b25e5954b7382d82b4c180138c4","type":"DISEASE","name":"Cervix Carcinoma","canonical_id":"doid:2893","description":null,"metadata":null},{"id":"b2d7650b23d64cf9a977c5decc319df5","type":"TISSUE","name":"Cervix Ectocervix","canonical_id":"uberon:UBERON:0012249","description":null,"metadata":null},{"id":"19391feb3bfe4485b692af7f1d70e9e1","type":"TISSUE","name":"Cervix Endocervix","canonical_id":"uberon:UBERON:0000458","description":null,"metadata":null},{"id":"e2bca46937fc45239b629991a6837e6e","type":"TRIAL","name":"Cessation Screening Project","canonical_id":"clinicaltrials.gov:NCT04188873","description":"Nicotine Dependence","metadata":null},{"id":"fc704b6b27b342d3b777b2e0da4804b1","type":"TRIAL","name":"Cetirizine Chewable Bioequivalence and Food Effect Study","canonical_id":"clinicaltrials.gov:NCT03772158","description":"Allergy","metadata":null},{"id":"c69b593be77d4da1bf842ffa5588c9ca","type":"TRIAL","name":"Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition","canonical_id":"clinicaltrials.gov:NCT01064102","description":"Healthy","metadata":null},{"id":"43a0b20c89a74a669ab4786117b0e61c","type":"TRIAL","name":"Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition","canonical_id":"clinicaltrials.gov:NCT01064115","description":"Healthy","metadata":null},{"id":"8f3efdff56af4d5ba07f30a1c5a9b020","type":"TRIAL","name":"Cetirizine and Famotidine for COVID-19","canonical_id":"clinicaltrials.gov:NCT04836806","description":"Covid19","metadata":null},{"id":"4855609657d5437e830e695c0bd099c5","type":"DRUG","name":"Cetuximab","canonical_id":"ncit:C1723","description":null,"metadata":null},{"id":"2836e2ea0dfe45ddbbd461a5d999d0f5","type":"TRIAL","name":"Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.","canonical_id":"clinicaltrials.gov:NCT00251381","description":"Oropharyngeal Neoplasms","metadata":null},{"id":"eddde34ea8bb46c1a361435350a440c6","type":"TRIAL","name":"Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)","canonical_id":"clinicaltrials.gov:NCT03944252","description":"Squamous Cell Anal Carcinoma","metadata":null},{"id":"0098f2a213bd4f5c88f6759e58019952","type":"TRIAL","name":"Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT04161560","description":"Drug Safety ; Drug Specificity","metadata":null},{"id":"078a022130e844d8a1ae59facbb24874","type":"TRIAL","name":"Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer","canonical_id":"clinicaltrials.gov:NCT04375384","description":"Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma","metadata":null},{"id":"c7d6326e209e467fb728ceba587d8bf3","type":"TRIAL","name":"Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC","canonical_id":"clinicaltrials.gov:NCT07509099","description":"Squamous Cell Carcinoma of Head and Neck","metadata":null},{"id":"c0f11aa07f904204b37df1e9663e8d6d","type":"TRIAL","name":"Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)","canonical_id":"clinicaltrials.gov:NCT00599131","description":"Cancer of Larynx","metadata":null},{"id":"13b224b29a7c4c2492d46b5571ae3c1c","type":"TRIAL","name":"Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT02177838","description":"Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Orophary\u2026","metadata":null},{"id":"8769de521b5844b4988b4b02bad86383","type":"TRIAL","name":"Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)","canonical_id":"clinicaltrials.gov:NCT03727763","description":"Colorectal Cancer","metadata":null},{"id":"9bad2377ee8d419d8dc495f88c8c675e","type":"TRIAL","name":"Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)","canonical_id":"clinicaltrials.gov:NCT00623558","description":"Head and Neck Neoplasm","metadata":null},{"id":"61c0025e45ad480c9c218115dee0e213","type":"TRIAL","name":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT01388790","description":"Gastric Cancer","metadata":null},{"id":"c375ec4186f7400683be4a4451dc6a8b","type":"TRIAL","name":"Cetuximab in Treating Patients With M\u00e9n\u00e9trier Disease at High Risk of Developing Stomach Cancer","canonical_id":"clinicaltrials.gov:NCT00477880","description":"Gastric Cancer; Precancerous Condition","metadata":null},{"id":"e40ca44ddbb74c1b8b35abb78f002c2a","type":"TRIAL","name":"Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00301028","description":"Head and Neck Cancer","metadata":null},{"id":"8339b5c287e3470088e3dfbfdf6d3b02","type":"TRIAL","name":"Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma","canonical_id":"clinicaltrials.gov:NCT00292955","description":"Cancer of the Cervix","metadata":null},{"id":"a906c835f384461fbc919fa3c4d0fb72","type":"DRUG","name":"Cetuximab/Irinotecan Regimen","canonical_id":"ncit:C63606","description":null,"metadata":null},{"id":"a809446e4904438c9c0b12e535648866","type":"DISEASE","name":"Chancroid","canonical_id":"mesh:D002602","description":null,"metadata":null},{"id":"a4e3d2836ef64c629430e7fa5e79b009","type":"TRIAL","name":"ChangE From Any Systemic psoriasiS therapY to Raptiva","canonical_id":"clinicaltrials.gov:NCT00697593","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"6835e4a741f745f9b4edc12a8d47682f","type":"TRIAL","name":"Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT00642720","description":"Quality of Life; Acromegaly","metadata":null},{"id":"d5ab9b59c9b54e80b331539e23df5132","type":"TRIAL","name":"Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma","canonical_id":"clinicaltrials.gov:NCT01725360","description":"Asthma","metadata":null},{"id":"402173a0976045c38af8e9549e7428fd","type":"TRIAL","name":"Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT03168555","description":"Bile Acid Malabsorption; Cholelithiasis","metadata":null},{"id":"847afdffdeb34ef6b8eb200fabb75842","type":"TRIAL","name":"Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00536653","description":"Osteoporosis","metadata":null},{"id":"4a3ac0da96d14d23b708c59ae678a021","type":"TRIAL","name":"Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support.","canonical_id":"clinicaltrials.gov:NCT02408003","description":"Heart Failure, Diastolic; Aortic Valve Stenosis; Monitoring, Physiologic; Physiology","metadata":null},{"id":"6fddcce23c1a46fbad1ac364700b16b0","type":"TRIAL","name":"Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols","canonical_id":"clinicaltrials.gov:NCT02933593","description":"Hypertension","metadata":null},{"id":"a10435555ed4497eb4d60e49567e50a7","type":"TRIAL","name":"Changes in Central Arterial Pressure When Comparing Nifedipine/Labetalol for Routine Hypertension Control in Pregnancy","canonical_id":"clinicaltrials.gov:NCT02912910","description":"Hypertension","metadata":null},{"id":"4b8fd9da0ebb4584b76916322dcb08f4","type":"TRIAL","name":"Changes in Cerebral Oxygenation and Cognitive Functions","canonical_id":"clinicaltrials.gov:NCT04948957","description":"Hypotension; Controlled; Cognitive Dysfunction","metadata":null},{"id":"3e55b063226143d69e09ca60928656f9","type":"TRIAL","name":"Changes in Myocardial Biomechanics and Early Short-term Doxycycline Therapy in Patients With Primary Anterior STEMI","canonical_id":"clinicaltrials.gov:NCT02562651","description":"Vascular Diseases; Cardiovascular Diseases; Acute Myocardial Infarction","metadata":null},{"id":"e739bf6dd0454a81b7af37a03fa1faec","type":"TRIAL","name":"Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study","canonical_id":"clinicaltrials.gov:NCT04838665","description":"Retinopathy of Prematurity","metadata":null},{"id":"0a6b240195b642888670b57ee7580677","type":"TRIAL","name":"Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment","canonical_id":"clinicaltrials.gov:NCT02156999","description":"Osteoporosis","metadata":null},{"id":"cc764c66e7cd48dab4ab841595b9b403","type":"TRIAL","name":"Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant","canonical_id":"clinicaltrials.gov:NCT00552851","description":"Acromegaly; Heart Failure; Hypertrophy, Left Ventricular","metadata":null},{"id":"59e2a90d6bef4c699b02abcf434bcd5d","type":"TRIAL","name":"Chantix & Bupropion for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT00587769","description":"Smoking; Tobacco Use Disorder","metadata":null},{"id":"a7f162a141be4af7a3e731bd62488c79","type":"TRIAL","name":"Characteristics of Islet \u03b2-cell Functions in Chinese Patients With Graves' Disease","canonical_id":"clinicaltrials.gov:NCT02376088","description":"Graves Disease","metadata":null},{"id":"703b8d82b8a24c3eb6fcc7d7cba2f600","type":"TRIAL","name":"Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05650060","description":"Plaque Psoriasis","metadata":null},{"id":"3773cbe434504eb1b53d5aab3190139d","type":"TRIAL","name":"Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib","canonical_id":"clinicaltrials.gov:NCT06531109","description":"Alopecia Areata","metadata":null},{"id":"6d7f37b8b9774a388c047e792d41773a","type":"TRIAL","name":"Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration","canonical_id":"clinicaltrials.gov:NCT01352065","description":"Pulmonary Hypertension","metadata":null},{"id":"2aaa5e83baad49d5994821441595129a","type":"TRIAL","name":"Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women","canonical_id":"clinicaltrials.gov:NCT02333045","description":"HIV","metadata":null},{"id":"0238697ee72d40ee99bdc28151111e23","type":"TRIAL","name":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT01040689","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"7941c8ab31794f9a99effcbd2562ac15","type":"TRIAL","name":"Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch","canonical_id":"clinicaltrials.gov:NCT04588532","description":"Itch","metadata":null},{"id":"a472315d345447b48dc6568abc378180","type":"TRIAL","name":"Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor","canonical_id":"clinicaltrials.gov:NCT04554888","description":"Itch","metadata":null},{"id":"a6c15b40f33040ec9e2a4ea2813168bf","type":"TRIAL","name":"Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT01904487","description":"Alcoholism","metadata":null},{"id":"f0a5f94d8b72431fb55b290a247e2979","type":"TRIAL","name":"Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01576354","description":"Multiple Sclerosis","metadata":null},{"id":"0d19e285b0654f86ac90673ec08c8be2","type":"TRIAL","name":"Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive\u00ae in the Management of Short Bowel Syndrome Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT03562130","description":"Short Bowel Syndrome","metadata":null},{"id":"a3abb90f246c4b49982c3436a20313b3","type":"TRIAL","name":"Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases","canonical_id":"clinicaltrials.gov:NCT05357612","description":"Neurodegenerative Diseases; Parkinson Disease; Parkinson Disease Psychosis","metadata":null},{"id":"55ec3853cf8b45fd9dd96bdc899aed4c","type":"TRIAL","name":"Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-\u03b2) Therapies to Peginterferon Beta-1a (BIIB017)","canonical_id":"clinicaltrials.gov:NCT01939002","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"26dcdc5704c84e9fa3b79800184ff236","type":"TRIAL","name":"Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors","canonical_id":"clinicaltrials.gov:NCT00471588","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"45919cb11c6c437d820a84788f9dcf21","type":"TRIAL","name":"Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings","canonical_id":"clinicaltrials.gov:NCT07348172","description":"Drug Liking","metadata":null},{"id":"512665fb4a724a2994f6469bbdeb533e","type":"TRIAL","name":"Characterizing Response to Antipsychotics in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT06159322","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"653a2ca6f7fe448486a4a0d97182cc48","type":"DISEASE","name":"Charcot-Marie-tooth disease, axonal, type 2DD","canonical_id":"mondo:0054833","description":null,"metadata":null},{"id":"3d33d4b1e99e46d88be44f0ff6fd620f","type":"TRIAL","name":"Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC","canonical_id":"clinicaltrials.gov:NCT05200988","description":"Urothelial Carcinoma; Bladder Cancer","metadata":null},{"id":"1a3ec6a2b8474994b8aeaa8154dcf5c5","type":"TRIAL","name":"Chemo-free BRCA-targeted Neoadjuvant Strategy","canonical_id":"clinicaltrials.gov:NCT05209529","description":"TNBC - Triple-Negative Breast Cancer; BRCA1 Mutation; BRCA2 Mutation","metadata":null},{"id":"9762caade2e94c0a9c64436b57b26bbd","type":"TRIAL","name":"Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer","canonical_id":"clinicaltrials.gov:NCT05106296","description":"Ependymoma; Medulloblastoma; Glioblastoma; Primary Brain Tumor","metadata":null},{"id":"ca1b9d90c44c42b5854957b9d48109d4","type":"TRIAL","name":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","canonical_id":"clinicaltrials.gov:NCT06669013","description":"Bone Sarcoma; Embryonal Rhabdomyosarcoma; Alveolar Rhabdomyosarcoma","metadata":null},{"id":"1d986ea03db84cb08ee7414ee7287df1","type":"TRIAL","name":"Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma","canonical_id":"clinicaltrials.gov:NCT07375563","description":"Neuroblastoma (NB); Ganglioneuroblastoma","metadata":null},{"id":"171a1a4d988f4b2a9abc57f1b7f6ab64","type":"TRIAL","name":"Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00256217","description":"DCIS","metadata":null},{"id":"5a0826cdf269463ea56d7d3c8f92d0b8","type":"TRIAL","name":"Chemoprevention of Gastric Carcinogenesis","canonical_id":"clinicaltrials.gov:NCT02794428","description":"Gastric Cancer; Gastric Intestinal Metaplasia","metadata":null},{"id":"398a4904d9984cb18640e725121ea624","type":"TRIAL","name":"Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC","canonical_id":"clinicaltrials.gov:NCT04189094","description":"Small Cell Lung Cancer Limited Stage","metadata":null},{"id":"2172e422fe6e4b31b5247ad1b06aec10","type":"TRIAL","name":"Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin","canonical_id":"clinicaltrials.gov:NCT02562599","description":"Nasopharyngeal Carcinoma","metadata":null},{"id":"1c1ced2cddad4296a1539183eeb2ebe1","type":"TRIAL","name":"Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00906945","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"e42c94a99f324b629f50f4a63deaa757","type":"DRUG","name":"Chemotherapy","canonical_id":"ncit:C15632","description":null,"metadata":null},{"id":"ac426d7f509148d18d906040b961506b","type":"TRIAL","name":"Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00679029","description":"HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer","metadata":null},{"id":"b045af92476f4e54a5246be5ec46ba38","type":"TRIAL","name":"Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)","canonical_id":"clinicaltrials.gov:NCT04926467","description":"Pancreatic Adenocarcinoma","metadata":null},{"id":"be266a880fe34164849f896d91c4a440","type":"TRIAL","name":"Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01132807","description":"Lymphoma","metadata":null},{"id":"527368ee3e684a28960e0466d9c1233d","type":"TRIAL","name":"Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00003953","description":"Breast Cancer","metadata":null},{"id":"98b81e8ba41b4321a7a7087d72d8f201","type":"TRIAL","name":"Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00002552","description":"Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"e132c6f50ac947699158013dda77a144","type":"TRIAL","name":"Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00002855","description":"Prostate Cancer","metadata":null},{"id":"f2f8fd0e4c904b08ab98ee45457f7bd1","type":"TRIAL","name":"Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00002951","description":"Esophageal Cancer; Head and Neck Cancer","metadata":null},{"id":"989ca385deab448f9542a5563ab7e3db","type":"TRIAL","name":"Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003631","description":"Lymphoma","metadata":null},{"id":"b8797c70dca442278b3b4389ed6daa60","type":"TRIAL","name":"Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma","canonical_id":"clinicaltrials.gov:NCT00577629","description":"Lymphoma, B-Cell","metadata":null},{"id":"a1689023d6c6454cb9c95facb33dc2fb","type":"TRIAL","name":"Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00002828","description":"Colorectal Cancer","metadata":null},{"id":"5772ce6e7d6c4bc09d682d7afe75987e","type":"TRIAL","name":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","canonical_id":"clinicaltrials.gov:NCT07493161","description":"Ph+ ALL","metadata":null},{"id":"7b30942508ba4a3fb54390676ac6f25b","type":"TRIAL","name":"Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00052299","description":"Leukemia","metadata":null},{"id":"73a82def2c0a45179bf39fe26c86f3b5","type":"TRIAL","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00024167","description":"Prostate Cancer","metadata":null},{"id":"01977ecb710b4b6cadea9fba8361e738","type":"TRIAL","name":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","canonical_id":"clinicaltrials.gov:NCT04521946","description":"Anaplastic Ependymoma; Atypical Teratoid/Rhabdoid Tumor; Central Nervous System Germ Cell Tumor; Choroid Plexus Carcinoma; Intracranial Myeloid Sarcoma; Malignant Brain Neoplasm; Malignant Glioma; Medulloblastoma; Primitive Neuroectodermal Tumor; Recurrent Anaplastic Ependymoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Malignant Brain Neoplasm; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Primitive Neuroectodermal Tumor","metadata":null},{"id":"dd984f4b351e48159fce3dfc33ad4613","type":"TRIAL","name":"Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation","canonical_id":"clinicaltrials.gov:NCT02095782","description":"Non-small-cell Lung Cancer","metadata":null},{"id":"50af4202d68d4ff0a4d64467737fb486","type":"TRIAL","name":"Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00667251","description":"Breast Cancer","metadata":null},{"id":"e019a49467fc4947ba486e9b15f9895b","type":"TRIAL","name":"Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00012051","description":"Lymphoma","metadata":null},{"id":"3b628dceffc845fd872ee5cc0ed8bee6","type":"TRIAL","name":"Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00046852","description":"Infection; Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"9f1914f0ba744177991a0e19590c04d5","type":"TRIAL","name":"Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00030589","description":"Lymphoma","metadata":null},{"id":"f2b8bc5998b54467b34a3407f1ed9bf6","type":"TRIAL","name":"Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT05600127","description":"Urothelial Carcinoma","metadata":null},{"id":"1978a91b22174384a806a87d2b6082b3","type":"TRIAL","name":"Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas","canonical_id":"clinicaltrials.gov:NCT04617457","description":"Pancreatic Cancer; Metastasis; Surgery; Oligometastatic Disease","metadata":null},{"id":"10c3a9fb8260480e82b8272c6bbc72ba","type":"TRIAL","name":"Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00072020","description":"Breast Cancer; Metastatic Cancer","metadata":null},{"id":"84343fac58464cdf8285b147c1fb2fbe","type":"TRIAL","name":"Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)","canonical_id":"clinicaltrials.gov:NCT05049863","description":"Small-cell Lung Cancer; Small Cell Lung Carcinoma","metadata":null},{"id":"677ab0871b8b49548a53301b22184634","type":"TRIAL","name":"Chemotherapy of NSCLC With or Without Icotinib","canonical_id":"clinicaltrials.gov:NCT02430974","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"6af78c1890c84eab8ef2bffce63c4d6e","type":"TRIAL","name":"Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00626015","description":"Malignant Neoplasms of Brain","metadata":null},{"id":"fd9e87ad27af4f50a0bb5cf0b1078a7e","type":"DISEASE","name":"Chemotherapy-induced nausea and vomiting","canonical_id":"efo:0006911","description":null,"metadata":null},{"id":"d5375b86c6dd406381c6152bd854cb82","type":"DRUG","name":"Chenodiol","canonical_id":"mesh:D002635","description":null,"metadata":null},{"id":"4e6c44fdbc6047e6aadb96bee6625163","type":"TRIAL","name":"Chest Pain Pilot Study","canonical_id":"clinicaltrials.gov:NCT00251901","description":"Chest Pain; Gastroesophageal Reflux","metadata":null},{"id":"78eb6452549249aaac97edfe868fc569","type":"DISEASE","name":"Chest pain","canonical_id":"hp:0100749","description":null,"metadata":null},{"id":"1779e4a1e8fe4ea28a35dab27c14b997","type":"TRIAL","name":"Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients","canonical_id":"clinicaltrials.gov:NCT02725099","description":"Acute Coronary Syndromes; ST Elevation Myocardial Infarction","metadata":null},{"id":"098c8a7e05564552a422b43b3c6c85f4","type":"TRIAL","name":"Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients","canonical_id":"clinicaltrials.gov:NCT07074457","description":"CD30+ Peripheral T-cell Lymphoma","metadata":null},{"id":"efdc02a2fafd4f8fb4f405cc13f0d32a","type":"TRIAL","name":"Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed","canonical_id":"clinicaltrials.gov:NCT06547476","description":"Breast Cancer","metadata":null},{"id":"0a0bb4df8f67464f996120357d36c9e0","type":"TRIAL","name":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05958719","description":"Peripheral T Cell Lymphoma; Epigenetic Repression","metadata":null},{"id":"71edfe56ed414dbaa849d271fc581c27","type":"TRIAL","name":"Child and Adolescent Anxiety Disorders (CAMS)","canonical_id":"clinicaltrials.gov:NCT00052078","description":"Anxiety Disorders; Social Phobia; Generalized Anxiety Disorder","metadata":null},{"id":"f3b1f9ace7104eb594dca7fc4ad133dc","type":"TRIAL","name":"Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)","canonical_id":"clinicaltrials.gov:NCT00319488","description":"Asthma; Lung Diseases","metadata":null},{"id":"42fa4d126107452782be56b54db1f11e","type":"DISEASE","name":"Childhood Ependymoma","canonical_id":"doid:5509","description":null,"metadata":null},{"id":"6441481e9e04429abb459d41aa0caf8d","type":"TRIAL","name":"Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects","canonical_id":"clinicaltrials.gov:NCT00122044","description":"Dystonia","metadata":null},{"id":"38ba6fedf2aa43bda8cb09804f54870a","type":"DISEASE","name":"Childhood Low-grade Glioma","canonical_id":"doid:0080830","description":null,"metadata":null},{"id":"94912f506d41461593a4fb5a02609824","type":"TRIAL","name":"China HeadAche DIsorders RegiStry","canonical_id":"clinicaltrials.gov:NCT05334927","description":"Headache Disorders, Primary; Migraine; New Daily Persistent Headache; Medication Overuse Headache; Tension-Type Headache; Trigeminal Autonomic Cephalalgia","metadata":null},{"id":"426b05ee7526489e954fe6ead973df06","type":"TRIAL","name":"China Stroke Primary Prevention Trial","canonical_id":"clinicaltrials.gov:NCT00794885","description":"Primary Hypertension","metadata":null},{"id":"a725728fac7142c7b258108cfc5d631b","type":"TRIAL","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06868654","description":"Multiple Myeloma","metadata":null},{"id":"44fdb3d7842e40b89721f913db8feba6","type":"TRIAL","name":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","canonical_id":"clinicaltrials.gov:NCT05480150","description":"Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic","metadata":null},{"id":"7ee61c28f1fc4562a112ae6be5a295a6","type":"TRIAL","name":"Chinese Tuina Therapy for Treatment of Chronic Nonspecific Low Back Pain","canonical_id":"clinicaltrials.gov:NCT04976790","description":"Chronic Nonspecific Low Back Pain","metadata":null},{"id":"023ae3c15ea54c7fb73b129f5f6e1c26","type":"DISEASE","name":"Chlamydia Infections","canonical_id":"mesh:D002690","description":null,"metadata":null},{"id":"bcb4743d333a41ccbc1a29ad502ed935","type":"DISEASE","name":"Chlamydial pneumonia","canonical_id":"mesh:D061387","description":null,"metadata":null},{"id":"19e1989fd7584baa9ec88a841dcf8a1a","type":"DISEASE","name":"Chloasma","canonical_id":"mesh:D008548","description":null,"metadata":null},{"id":"3aa0d7d08e454b6e89d6d4ba254fe9ca","type":"DRUG","name":"Chlorambucil","canonical_id":"mesh:D002699","description":null,"metadata":null},{"id":"1f003db980c74d54a75704b0eab7e067","type":"DRUG","name":"Chlormezanone","canonical_id":"mesh:D002720","description":null,"metadata":null},{"id":"aeb63ba7c5f743358d3b522930b761ee","type":"DRUG","name":"Chlorphenamine","canonical_id":"mesh:D002744","description":null,"metadata":null},{"id":"31717049301e4edfaa4a1d9c155297d5","type":"TRIAL","name":"Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I","canonical_id":"clinicaltrials.gov:NCT05449405","description":"COVID-19; Symptoms and Signs; COVID-19 Pandemic; Coronavirus Disease 2019; Coronavirus Infections","metadata":null},{"id":"61e7f4fad8894154a40b59007dcbf5d2","type":"TRIAL","name":"Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III","canonical_id":"clinicaltrials.gov:NCT05886829","description":"COVID-19; Symptoms and Signs; COVID-19 Pandemic; Coronavirus Disease 2019; Coronavirus Infections","metadata":null},{"id":"eeee1fa1a8384c69b63deb1c3e0937ad","type":"TRIAL","name":"Chlorpromazine and Standard of Care in Glioblastoma","canonical_id":"clinicaltrials.gov:NCT05190315","description":"Glioblastoma Multiforme","metadata":null},{"id":"ff47bd5df03b42a486e7491b582ca727","type":"DRUG","name":"Chlorpropamide","canonical_id":"mesh:D002747","description":null,"metadata":null},{"id":"3ceb908071f84352a3ea2a8f9c63eee5","type":"DRUG","name":"Chlortalidone","canonical_id":"mesh:D002752","description":null,"metadata":null},{"id":"648442c451544eda98f56f807790f797","type":"TRIAL","name":"Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial","canonical_id":"clinicaltrials.gov:NCT03923933","description":"Renal Insufficiency, Chronic","metadata":null},{"id":"5aef5738d9b149adbdf3709f4be48a9a","type":"DRUG","name":"Chlortetracycline","canonical_id":"mesh:D002751","description":null,"metadata":null},{"id":"0c2771d36454487b8aaf984bf477cde5","type":"TRIAL","name":"Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function","canonical_id":"clinicaltrials.gov:NCT01822860","description":"Hypertension","metadata":null},{"id":"6af99b1de05442f9b6db72bb0db95d1b","type":"TRIAL","name":"Chlorthalidone and HCTZ Impacts on Platelet Activation","canonical_id":"clinicaltrials.gov:NCT02100462","description":"Hypertension","metadata":null},{"id":"2ac7215b38fe4d79bb3e15ee421b90f7","type":"TRIAL","name":"Chlorthalidone in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02841280","description":"Renal Insufficiency, Chronic; Hypertension","metadata":null},{"id":"99d15e2cad77430a8900ddb2e0cfe71b","type":"DISEASE","name":"Cholangiocarcinoma","canonical_id":"doid:4947","description":null,"metadata":null},{"id":"ee2a25a8af6a415dbbaf5f1c153fa83c","type":"DISEASE","name":"Cholangitis","canonical_id":"mesh:D002761","description":null,"metadata":null},{"id":"2dfff53bc6f344ba9b54ed0c2a854df6","type":"DISEASE","name":"Cholecystitis","canonical_id":"mesh:D002764","description":null,"metadata":null},{"id":"0eb8e6bec8234a2db2f5f4aafa434335","type":"PROTEIN","name":"Cholecystokinin","canonical_id":"uniprot:P06307","description":null,"metadata":null},{"id":"65194187522842feb771a7b8cd5592e4","type":"DISEASE","name":"Cholelithiasis","canonical_id":"mesh:D002769","description":null,"metadata":null},{"id":"9005b1c640ed4a439baf3d0b8f0a072b","type":"DISEASE","name":"Cholera","canonical_id":"mesh:D002771","description":null,"metadata":null},{"id":"2d8e26cc3e4b4ed18527ef330046282c","type":"TRIAL","name":"Cholestanol in Humans","canonical_id":"clinicaltrials.gov:NCT00018694","description":"Cerebrotendinous Xanthomatosis","metadata":null},{"id":"7760ec2229b54446b107118c8f7b02e1","type":"TRIAL","name":"Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00090168","description":"Hypercholesterolemia; Atherosclerotic Disease; Coronary Disease","metadata":null},{"id":"c565236fd46849cd8ebd7208651c5178","type":"TRIAL","name":"Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study","canonical_id":"clinicaltrials.gov:NCT05263778","description":"Cardiovascular Diseases; NSTEMI; STEMI","metadata":null},{"id":"c3ebcc2f848446ada2d5ead9f294b526","type":"PROTEIN","name":"Cholesteryl ester transfer protein","canonical_id":"uniprot:P11597","description":null,"metadata":null},{"id":"ecf589ac39314fe4ba6981f06c3b1cf2","type":"DRUG","name":"Cholestyramine Resin","canonical_id":"mesh:D002792","description":null,"metadata":null},{"id":"642b7fb21d58405f841f399953de8f5e","type":"TRIAL","name":"Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT05365425","description":"Dyslipidemia; Atherosclerosis; Diabetes Mellitus, Type 2","metadata":null},{"id":"f252c1ffd1db436894ee676ed965a9f9","type":"DRUG","name":"Choline magnesium trisalicylate","canonical_id":"mesh:C017959","description":null,"metadata":null},{"id":"100d8c172b32496ead1ad77aece70ea2","type":"TRIAL","name":"Cholinergic Mechanisms of Attention in Aging","canonical_id":"clinicaltrials.gov:NCT04756232","description":"Subjective Cognitive Decline","metadata":null},{"id":"b0421a82d40d42778f90a861a1fa4151","type":"TRIAL","name":"Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies","canonical_id":"clinicaltrials.gov:NCT00055575","description":"Mood Disorders; Healthy; Unipolar Depression; Bipolar Depression","metadata":null},{"id":"d3904ec083d34c3193b1e3bb1b602e43","type":"TRIAL","name":"Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT03840837","description":"Parkinson Disease; Parkinson Disease Dementia","metadata":null},{"id":"cb3a626d196d4677b62bae110b6418fa","type":"DISEASE","name":"Chordoma","canonical_id":"doid:3302","description":null,"metadata":null},{"id":"747740ad3be748e19c1918ba0ffa33b9","type":"DISEASE","name":"Chorioretinitis","canonical_id":"mesh:D002825","description":null,"metadata":null},{"id":"4870c5c928814b1fa15a143840bf77da","type":"TRIAL","name":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","canonical_id":"clinicaltrials.gov:NCT03966560","description":"Glaucoma, Open-Angle","metadata":null},{"id":"e4d511fcfe434c8cbf2c4485d9a412e7","type":"DISEASE","name":"Choroiditis","canonical_id":"mesh:D002833","description":null,"metadata":null},{"id":"50752704be284a5fae5d8095721df4c3","type":"DISEASE","name":"Chromoblastomycosis","canonical_id":"mesh:D002862","description":null,"metadata":null},{"id":"da4ab5727d464ef6aac26e80024239f0","type":"TRIAL","name":"Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project","canonical_id":"clinicaltrials.gov:NCT05989581","description":"Hypertension in Pregnancy","metadata":null},{"id":"d84381a1277d434f84126ca35969e726","type":"DISEASE","name":"Chronic Kidney Disease-Mineral and Bone Disorder","canonical_id":"mesh:D012080","description":null,"metadata":null},{"id":"f3b339a700a0491d98a1b1666bcee2db","type":"TRIAL","name":"Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML","canonical_id":"clinicaltrials.gov:NCT00123474","description":"Myeloid Leukemia, Chronic, Chronic-Phase","metadata":null},{"id":"f776fb604dbf45cfaa19de36a7237364","type":"TRIAL","name":"Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study","canonical_id":"clinicaltrials.gov:NCT00978731","description":"Leukemia","metadata":null},{"id":"c3843ae9bc7a4a67a70ad84aa1c7d45c","type":"DISEASE","name":"Chronic Obstructive Asthma","canonical_id":"efo:0009759","description":null,"metadata":null},{"id":"31cf1c91f4344506a3e86cd724251b1f","type":"TRIAL","name":"Chronic Pain in Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00006428","description":"Spinal Cord Injuries; Pain","metadata":null},{"id":"0c194dc06dbf4f54bd95609ad7faca15","type":"TRIAL","name":"Chronic Urticaria - Long Term Assessment of Effects of Rupatadine","canonical_id":"clinicaltrials.gov:NCT02358265","description":"Chronic Urticaria","metadata":null},{"id":"ac8e5254ffb04a4ca476b3913fbf9012","type":"TRIAL","name":"Chronic Widespread Pain and White Blood Cell Activation","canonical_id":"clinicaltrials.gov:NCT02984397","description":"Widespread Chronic Pain","metadata":null},{"id":"1d6b0929060a4dbba28623a6f2126ded","type":"DISEASE","name":"Chronic hepatitis C","canonical_id":"mesh:D019698","description":null,"metadata":null},{"id":"cc78919852094953bc12b16ef602f8ed","type":"DISEASE","name":"Chronic idiopathic urticaria","canonical_id":"mesh:D000080223","description":null,"metadata":null},{"id":"32f095b25f954f548de9c0910e6c06a7","type":"DISEASE","name":"Chronic obstructive lung disease","canonical_id":"mesh:D029424","description":null,"metadata":null},{"id":"6e2d431892334edfb658f19cdd3e9b5f","type":"DISEASE","name":"Chronic pain","canonical_id":"hp:0012532","description":null,"metadata":null},{"id":"cb98bf7785a74831a69650d8fdb1a34f","type":"DISEASE","name":"Chronic pain","canonical_id":"mesh:D059350","description":null,"metadata":null},{"id":"19c77bc03d67408f927bec14a3841509","type":"DISEASE","name":"Chronic phase chronic myeloid leukemia","canonical_id":"mesh:D015466","description":null,"metadata":null},{"id":"3943e5471fdf49dfa2b3b979c912a6d4","type":"TRIAL","name":"Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin","canonical_id":"clinicaltrials.gov:NCT01425970","description":"Hepatitis C","metadata":null},{"id":"b26b3533e8c740ed8999501ef98eea27","type":"TRIAL","name":"Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT06951776","description":"Circadian Rhythm Disorders; Osteoporosis","metadata":null},{"id":"47b82af46ff345afab4f7229493db404","type":"TRIAL","name":"Chymase Angiotensin-(1-12) Axis In Hypertensive Disease","canonical_id":"clinicaltrials.gov:NCT05644769","description":"Hypertension","metadata":null},{"id":"222ed93469c54d67bb9332b2d311f7c8","type":"TRIAL","name":"CiPA Phase 1 ECG Biomarker Validation Study","canonical_id":"clinicaltrials.gov:NCT03070470","description":"Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics","metadata":null},{"id":"3f2082b089064e3791c2859e6156e882","type":"TRIAL","name":"Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis","canonical_id":"clinicaltrials.gov:NCT02665806","description":"Chronic Rhinosinustis With Polyps","metadata":null},{"id":"ceeeba663ac74fac84eca4eb3dc82a34","type":"TRIAL","name":"Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.","canonical_id":"clinicaltrials.gov:NCT01231854","description":"Atopic Dermatitis","metadata":null},{"id":"360651e78f5d4816831a721bab97b262","type":"DRUG","name":"Cilastatin","canonical_id":"mesh:D015377","description":null,"metadata":null},{"id":"e5ad2e924b674b32bc72888a1518f6e4","type":"TRIAL","name":"Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events","canonical_id":"clinicaltrials.gov:NCT00886574","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"df133c8f1c3847aaa36b50a6c71cab6d","type":"TRIAL","name":"Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT07144956","description":"Aneurysmal Subarachnoid Hemorrhage","metadata":null},{"id":"0a31af74318a4ab1b015ae94d3aef383","type":"TRIAL","name":"Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT07719894","description":"Type 2 Diabetes Mellitus (T2DM); Atherosclerosis","metadata":null},{"id":"2c38d78beb5141d58328ee438647292f","type":"TRIAL","name":"Cilostazol and Endothelial Progenitor Cell","canonical_id":"clinicaltrials.gov:NCT04407312","description":"Myocardial Infarction, Acute","metadata":null},{"id":"69d9359965274b2db43c469e826fd380","type":"TRIAL","name":"Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)","canonical_id":"clinicaltrials.gov:NCT04148105","description":"Aneurysmal Subarachnoid Hemorrhage","metadata":null},{"id":"77d72171e6f648349178d0b5326b4d3d","type":"TRIAL","name":"Cilostazol for HFpEF","canonical_id":"clinicaltrials.gov:NCT05126836","description":"Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"931c8456800044d4bbc4aa3dcd50a490","type":"TRIAL","name":"Cilostazol for Prevention of Recurrent Stroke Trial","canonical_id":"clinicaltrials.gov:NCT07174414","description":"Stroke Recurrence; Myocardial Infarction; Vascular Death; Ischemic Stroke; TIA (Transient Ischemic Attack); Stroke (CVA) or Transient Ischemic Attack; Recurrent Stroke","metadata":null},{"id":"8bc9cddcf9db4bb1aa1c05fd832ac65e","type":"TRIAL","name":"Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes","canonical_id":"clinicaltrials.gov:NCT06989697","description":"Type 2 Diabets Mellitus; Cognitive Ability, General","metadata":null},{"id":"b6e472a5dff840969fc67d44df303477","type":"DRUG","name":"Cimetidine","canonical_id":"mesh:D002927","description":null,"metadata":null},{"id":"91d83fe993b14ad0bdc2f7fd72b5cf5f","type":"TRIAL","name":"Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis","canonical_id":"clinicaltrials.gov:NCT00094484","description":"Kidney Disease; Chronic Kidney Disease","metadata":null},{"id":"7a48df709175457b9b1e5c78b5c20ad6","type":"TRIAL","name":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01054079","description":"Adenocarcinoma of the Prostate; Recurrent Prostate Cancer","metadata":null},{"id":"be0d87b660b044dfb0f5065d39bf566a","type":"TRIAL","name":"Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients","canonical_id":"clinicaltrials.gov:NCT01447368","description":"Kidney Failure; Secondary Hyperparathyroidism; Vascular Diseases","metadata":null},{"id":"a0a2ca80f7d8499db61592803a94d9cf","type":"TRIAL","name":"Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT02338934","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"7f872a4742614d4b843aa62f77c9dd44","type":"TRIAL","name":"Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)","canonical_id":"clinicaltrials.gov:NCT01479088","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"a9e00e6b136846aaac50e474fbeb24cf","type":"TRIAL","name":"Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level","canonical_id":"clinicaltrials.gov:NCT01101113","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"59dd8c7078e14555918c3c05f77607cc","type":"TRIAL","name":"Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00415584","description":"Secondary Hyperparathyroidism; Hypercalcemia","metadata":null},{"id":"c9ebebdf0dfd4f98a8d9dbc1b20922fc","type":"TRIAL","name":"Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT01143987","description":"Hyperparathyroidism; Arterial Stiffness","metadata":null},{"id":"dbdea7eec1694a38b99f6515ec958617","type":"DRUG","name":"Cinchocaine","canonical_id":"mesh:D003992","description":null,"metadata":null},{"id":"a73993432c134d9cac08f50749e2c38d","type":"DRUG","name":"Cinnarizine","canonical_id":"mesh:D002936","description":null,"metadata":null},{"id":"c882142837b247fd814c6409b56d43dd","type":"TRIAL","name":"Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain","canonical_id":"clinicaltrials.gov:NCT00227292","description":"Low Back Pain; Depression","metadata":null},{"id":"585fed20d6434db4a7be47b227b036f8","type":"TRIAL","name":"Ciprofibrate and Pre-diabetes","canonical_id":"clinicaltrials.gov:NCT03662984","description":"Myocardial Insulin Sensitivity; Impaired Glucose Metabolism; Diastolic Dysfunction","metadata":null},{"id":"aa1ed8c97ca84e298dae2bf4377cfae1","type":"TRIAL","name":"Ciprofol Versus Propofol With Low-Dose Sufentanil for Painless Bronchoscopy","canonical_id":"clinicaltrials.gov:NCT07744061","description":"Bronchoscopy; Procedural Sedation","metadata":null},{"id":"24349c4ecb6e475daecfbad94d054d95","type":"TRIAL","name":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","canonical_id":"clinicaltrials.gov:NCT00800540","description":"Glaucoma","metadata":null},{"id":"c7ec49bf2d0342898b108e9cbca77b3f","type":"TRIAL","name":"Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03844620","description":"Refractory Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8","metadata":null},{"id":"629773a0beee4528a77033a07ee00589","type":"TRIAL","name":"Circulating Myokine Levels and Bone Metabolism","canonical_id":"clinicaltrials.gov:NCT04206618","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"f293cb698b18484791d00b83c846f539","type":"TRIAL","name":"Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04849364","description":"Breast Cancer; Triple Negative Breast Cancer","metadata":null},{"id":"8cab016ac4824c59a1bb5421fd2bd96d","type":"TRIAL","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT06992336","description":"Breast Cancer","metadata":null},{"id":"0c94b5b9eaee45fc8ba9b7e8a204dbec","type":"DRUG","name":"Cisplatin","canonical_id":"mesh:D002945","description":null,"metadata":null},{"id":"f38839055322496f963a895b4f44f3fe","type":"DRUG","name":"Cisplatin","canonical_id":"ncit:C376","description":null,"metadata":null},{"id":"666989e9b650425182a8c8f757ae07d4","type":"TRIAL","name":"Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer","canonical_id":"clinicaltrials.gov:NCT02485548","description":"Head and Neck Squamous Cell Cancer","metadata":null},{"id":"b52f935bfc0e46a1a4607c360e8a0305","type":"TRIAL","name":"Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)","canonical_id":"clinicaltrials.gov:NCT02393794","description":"Triple-Negative Breast Cancer; Breast Cancer","metadata":null},{"id":"8d59df1fa5184058a45075032b8ae3f0","type":"TRIAL","name":"Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura","canonical_id":"clinicaltrials.gov:NCT00004920","description":"Malignant Mesothelioma","metadata":null},{"id":"0a22299e389742fa9f6960a6a34f5e51","type":"TRIAL","name":"Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT02567409","description":"Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Stage IV Bladder Urothelial Carcinoma AJCC v7","metadata":null},{"id":"9ef0e140289a46d6bfca25c6c3db9e40","type":"TRIAL","name":"Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT00137852","description":"Esophageal Cancer","metadata":null},{"id":"17dc3282aa594ac2b41ab176cbfb82d6","type":"DRUG","name":"Citalopram","canonical_id":"mesh:D015283","description":null,"metadata":null},{"id":"3ce68fb724154ff28b2bba0bb247d5ad","type":"TRIAL","name":"Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00931775","description":"Major Depressive Disorder; Antidepressant Treatment Response","metadata":null},{"id":"d7e295daa9784d60af79a50913160773","type":"TRIAL","name":"Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT04497168","description":"Parkinson Disease","metadata":null},{"id":"ddab5a32e9914fb791d1f16497e2ad86","type":"TRIAL","name":"Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)","canonical_id":"clinicaltrials.gov:NCT00086645","description":"Autistic Disorder","metadata":null},{"id":"e461ed1f73c147eda69a289632a775db","type":"TRIAL","name":"Citalopram vs Clomipramine vs Placebo in Recurrent Depression","canonical_id":"clinicaltrials.gov:NCT01575158","description":"Depression","metadata":null},{"id":"3725a22178064b03bcb9cd3275ffcb6e","type":"DRUG","name":"Citric acid","canonical_id":"mesh:D019343","description":null,"metadata":null},{"id":"77f5059053904a09a51ff5393453c243","type":"TRIAL","name":"Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial","canonical_id":"clinicaltrials.gov:NCT00133822","description":"Post-Traumatic Stress Disorders","metadata":null},{"id":"41a0ab9aef864a73894a991042457bec","type":"TRIAL","name":"Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01026623","description":"Hormone-Resistant Prostate Cancer; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer","metadata":null},{"id":"8aee2acbefc24c4a975910f7190b00cc","type":"DRUG","name":"Cladribine","canonical_id":"mesh:D017338","description":null,"metadata":null},{"id":"f34a22f0cfa047d3947b94e6ece98fa9","type":"TRIAL","name":"Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML","canonical_id":"clinicaltrials.gov:NCT01161550","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"8d905b0b653c43a9803ea50ba5808351","type":"TRIAL","name":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT04047641","description":"Acute Myeloid Leukemia; Blasts 20 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic Syndrome","metadata":null},{"id":"b576baf0b9154c0e883c255034553daf","type":"TRIAL","name":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02115295","description":"Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Blasts 10 Percent or More of Peripheral Blood White Cells; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leuk\u2026","metadata":null},{"id":"27aebf2495044791b7816b853d814f9a","type":"TRIAL","name":"Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT05891795","description":"Acne Vulgaris","metadata":null},{"id":"06b1464e7da4427ba1f1a2ec3e6fd868","type":"TRIAL","name":"Class 3 Biowaivers","canonical_id":"clinicaltrials.gov:NCT01010698","description":"Healthy","metadata":null},{"id":"10798fd34f9248769bdaff949d365d25","type":"DISEASE","name":"Classical phenylketonuria","canonical_id":"mesh:D010661","description":null,"metadata":null},{"id":"3c636228617f43839dc607525fb5e447","type":"TRIAL","name":"Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00184366","description":"Plaque Psoriasis","metadata":null},{"id":"20b316caf3ba4bcd8c5f18ee9182d1b2","type":"TRIAL","name":"Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT05338450","description":"Multiple Sclerosis; Internuclear Ophthalmoplegia","metadata":null},{"id":"a718447452234b628ea4af4bdcf9c244","type":"TRIAL","name":"Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome","canonical_id":"clinicaltrials.gov:NCT06315699","description":"Williams Syndrome; Child; Neurodevelopmental Delay","metadata":null},{"id":"d1bf126cc431415ba80f585ae7325357","type":"TRIAL","name":"Clemastine Treatment in Individuals With Williams Syndrome","canonical_id":"clinicaltrials.gov:NCT06087757","description":"Williams Syndrome","metadata":null},{"id":"a3ae9d6d6fd84280a69f148fd9501ff2","type":"TRIAL","name":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","canonical_id":"clinicaltrials.gov:NCT06591091","description":"Depression","metadata":null},{"id":"833361e10d8d40fd966ea1f208c581b4","type":"TRIAL","name":"Clemastine in Cardiovascular Surgery","canonical_id":"clinicaltrials.gov:NCT03826004","description":"Efficacy and Safety","metadata":null},{"id":"a75bdaf6affb46f894b205cc330191b2","type":"TRIAL","name":"Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT06013618","description":"Neuroblastoma","metadata":null},{"id":"4f0685623ffa4bf2a736446e48dd0576","type":"TRIAL","name":"Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation","canonical_id":"clinicaltrials.gov:NCT01339572","description":"Non-Hodgkin's Lymphoma; Multiple Myeloma","metadata":null},{"id":"87fc3089d8084412b4b04ca4913cb13d","type":"TRIAL","name":"Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy","canonical_id":"clinicaltrials.gov:NCT05468671","description":"Endobronchial Metastases; Bronchoesophageal Fistula; General Anesthetic Drug Adverse Reaction","metadata":null},{"id":"ade10faf7fc04ff1a1fe0d7d3ca5ef90","type":"TRIAL","name":"Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying","canonical_id":"clinicaltrials.gov:NCT01844622","description":"Digestive System Disease","metadata":null},{"id":"00bb4102a0fe4d81a30882071d7edd33","type":"TRIAL","name":"Clinical Benefits of Seroquel XR in Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01672554","description":"Schizophrenia; Anxiety","metadata":null},{"id":"bb2b38bb1c6844cbb35df5f00d59ff76","type":"TRIAL","name":"Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies","canonical_id":"clinicaltrials.gov:NCT07564271","description":"Idiopathic Inflammatory Myopathies (IIMs)","metadata":null},{"id":"fba4319e26e941a8b695a5785025f195","type":"TRIAL","name":"Clinical Characteristics and Pathophysiology of Post-Traumatic Headache","canonical_id":"clinicaltrials.gov:NCT03791515","description":"Post-Traumatic Headache; Concussion, Mild","metadata":null},{"id":"a70e6faa791d4d3ab3ad587260a15941","type":"TRIAL","name":"Clinical Confirmation of a Pharmacodynamic Interaction Between Tropisetron and Paracetamol","canonical_id":"clinicaltrials.gov:NCT00487110","description":"Pain","metadata":null},{"id":"016c113ddb524ec2b29ce973a0b0735e","type":"TRIAL","name":"Clinical Determinants and Adverse Reactions to Tropicamide/Phenylephrine in Hospitalized Patients.","canonical_id":"clinicaltrials.gov:NCT07178600","description":"Adverse Drug Effect; Phenylephrine; Hypertension; Cardiovascular Complication; Ophthalmology; Ocular Discomfort","metadata":null},{"id":"f0a26aaff21045a98277e94baa4c576e","type":"TRIAL","name":"Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT00137020","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"30db6841636e42c48ccc335b10843e39","type":"TRIAL","name":"Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01164059","description":"Schizophrenia","metadata":null},{"id":"bfaf66d0df914c00a4451525903e2c80","type":"TRIAL","name":"Clinical Effectiveness of Tigecycline for Scrub Typhus.","canonical_id":"clinicaltrials.gov:NCT07513103","description":"Scrub Typhus","metadata":null},{"id":"968d456a72a14ee98aca5b8229de12cf","type":"TRIAL","name":"Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up","canonical_id":"clinicaltrials.gov:NCT01863134","description":"Non ST Elevation Myocardial Infarction","metadata":null},{"id":"d928fd86dbd74429bfcd5bfad149dddb","type":"TRIAL","name":"Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT06218862","description":"ARDS Due to Disease Caused by SARS Co-V-2","metadata":null},{"id":"8ff2be8f62ce41ed8338ec30d07b6c75","type":"TRIAL","name":"Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1","canonical_id":"clinicaltrials.gov:NCT01406873","description":"Myotonic Dystrophy","metadata":null},{"id":"44fca250c4f64952803f80ddd7f59bde","type":"TRIAL","name":"Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients","canonical_id":"clinicaltrials.gov:NCT05475665","description":"Essential Hypertension","metadata":null},{"id":"fbfb503f46a74890a39459297e39220f","type":"TRIAL","name":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","canonical_id":"clinicaltrials.gov:NCT05476354","description":"Essential Hypertension","metadata":null},{"id":"fb137abecf8e4c10a449274b59e4756d","type":"TRIAL","name":"Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin","canonical_id":"clinicaltrials.gov:NCT05504226","description":"Type 2 Diabetes","metadata":null},{"id":"50b6213a481f485a8fd3785149bd0caa","type":"TRIAL","name":"Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin","canonical_id":"clinicaltrials.gov:NCT05504239","description":"Type 2 Diabetes","metadata":null},{"id":"59be8aec6c50462c9c9d42e409eab22b","type":"TRIAL","name":"Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04418128","description":"Corona Virus Infection; COVID-19","metadata":null},{"id":"5f674f7f558a4759b0d104463d8db2dd","type":"TRIAL","name":"Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days","canonical_id":"clinicaltrials.gov:NCT04172961","description":"Dry Eye","metadata":null},{"id":"353b06ea36274263aa441bad6c37b56e","type":"TRIAL","name":"Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo\u00ae Forte Gel in Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02651220","description":"Acne","metadata":null},{"id":"bca8aff61b354a20b33298cc376cf0fe","type":"TRIAL","name":"Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista\u2122","canonical_id":"clinicaltrials.gov:NCT02249663","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"69c2fc0f5bfb442e841c48f140659bea","type":"TRIAL","name":"Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid","canonical_id":"clinicaltrials.gov:NCT00331045","description":"Cancer; Constipation","metadata":null},{"id":"c90b842b3156480fb56dbd8bba507453","type":"TRIAL","name":"Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma","canonical_id":"clinicaltrials.gov:NCT04185350","description":"Insulinoma","metadata":null},{"id":"4b08f3b6455344f4b461f3b5adbcc757","type":"TRIAL","name":"Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03802838","description":"Schizophrenia","metadata":null},{"id":"de0fec20849b45f893955561a8b740f4","type":"TRIAL","name":"Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)","canonical_id":"clinicaltrials.gov:NCT00828750","description":"Idiopathic Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Idiopathic","metadata":null},{"id":"c1a09ecf23da4885920af17f932d3e02","type":"TRIAL","name":"Clinical Evaluation of Etafilcon A With Ketotifen","canonical_id":"clinicaltrials.gov:NCT03388138","description":"Visual Acuity","metadata":null},{"id":"b6d3c9c82cd248148a3ade74dc410998","type":"TRIAL","name":"Clinical Evaluation of Florbetapir in Primary Progressive Aphasia","canonical_id":"clinicaltrials.gov:NCT04726527","description":"Primary Progressive Aphasia; Alzheimer Disease; Dementia","metadata":null},{"id":"3109ba8a1f9349c19757e05bd3da023b","type":"TRIAL","name":"Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy","canonical_id":"clinicaltrials.gov:NCT07560735","description":"Dry Eye","metadata":null},{"id":"d435e86e97a9474db2785ac079eae5d7","type":"TRIAL","name":"Clinical Evaluation of Patients With X-linked Retinoschisis","canonical_id":"clinicaltrials.gov:NCT02331173","description":"X-linked Retinoschisis; XLRS","metadata":null},{"id":"ae0ea50a0e0849518543fbd96fd002d8","type":"TRIAL","name":"Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00530790","description":"Restless Legs Syndrome","metadata":null},{"id":"3a9de038ff794e379cbe984e800ac2f1","type":"TRIAL","name":"Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)","canonical_id":"clinicaltrials.gov:NCT00996944","description":"Restless Legs Syndrome","metadata":null},{"id":"2fd11d49dd6b4cb6928bbe4221c3a35d","type":"TRIAL","name":"Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)","canonical_id":"clinicaltrials.gov:NCT00434304","description":"Parkinson Disease","metadata":null},{"id":"b62653e04a7a424b8403456f92a11b24","type":"TRIAL","name":"Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis","canonical_id":"clinicaltrials.gov:NCT07459972","description":"Liver Cirrhosis; Portal Hypertension Related to Cirrhosis","metadata":null},{"id":"3f2351a3412b46f7ad69c3598eeec894","type":"TRIAL","name":"Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT07555301","description":"IgA Nephropathy (IgAN)","metadata":null},{"id":"2c5b9bcb27624a6c9bc94a01e320144e","type":"TRIAL","name":"Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program","canonical_id":"clinicaltrials.gov:NCT07562347","description":"Advanced Solid Tumor","metadata":null},{"id":"d6d5978e27b647ceaf32de9ac48cd9cf","type":"TRIAL","name":"Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.","canonical_id":"clinicaltrials.gov:NCT04262024","description":"Health Education","metadata":null},{"id":"71125b351d5e4269a852de32b671eea4","type":"TRIAL","name":"Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients","canonical_id":"clinicaltrials.gov:NCT02023086","description":"Fabry Disease","metadata":null},{"id":"87e1ae811f5145ad89b8dd0635b7c4b9","type":"TRIAL","name":"Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II","canonical_id":"clinicaltrials.gov:NCT00861692","description":"Heparin-induced Thrombocytopenia Type II","metadata":null},{"id":"2c70c7ca4c774ec7a71b6f4271e7385c","type":"TRIAL","name":"Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis","canonical_id":"clinicaltrials.gov:NCT07503652","description":"Palmoplantar Pustulosis (PPP)","metadata":null},{"id":"d26500bf2b394ed39de596cc1dc52ec5","type":"TRIAL","name":"Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)","canonical_id":"clinicaltrials.gov:NCT03944785","description":"Idiopathic Parkinson Disease","metadata":null},{"id":"2f33423027ac4f3bbfeb919c74a27079","type":"TRIAL","name":"Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects","canonical_id":"clinicaltrials.gov:NCT04108104","description":"Alcohol Use Disorder","metadata":null},{"id":"13f3cfdfcd6f40bdb824c0872529cf6a","type":"TRIAL","name":"Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database","canonical_id":"clinicaltrials.gov:NCT01150760","description":"Ileus","metadata":null},{"id":"c708b8bddc1c48b4a6241ab15fc83219","type":"TRIAL","name":"Clinical Outcomes From Nalmefene","canonical_id":"clinicaltrials.gov:NCT05808881","description":"Opioid Overdose","metadata":null},{"id":"cc716cd8a9cb40b8960698e208e4db54","type":"TRIAL","name":"Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)","canonical_id":"clinicaltrials.gov:NCT03881852","description":"Narcolepsy; Cataplexy Narcolepsy; Excessive Sleepiness","metadata":null},{"id":"62f2335f06264221986058d94ac609e6","type":"TRIAL","name":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","canonical_id":"clinicaltrials.gov:NCT01310127","description":"Inflammation; Pseudophakia","metadata":null},{"id":"5ed4f797ee704d008537c2b1befba38b","type":"TRIAL","name":"Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function","canonical_id":"clinicaltrials.gov:NCT07186062","description":"Acute Decompensated Heart Failure (ADHF); Cardiorenal Syndrome (CRS)","metadata":null},{"id":"9d350c9471444e6a86c345608aeaf4ab","type":"TRIAL","name":"Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid","canonical_id":"clinicaltrials.gov:NCT04719650","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"0b8dc34963ba43dca6df06c2188ef70d","type":"TRIAL","name":"Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)","canonical_id":"clinicaltrials.gov:NCT01026415","description":"Carcinomas; Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Neoplasms","metadata":null},{"id":"5c38c8821de44e9497e7a93c8e3ea7d1","type":"TRIAL","name":"Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1","canonical_id":"clinicaltrials.gov:NCT02931071","description":"Fanconi Anemia","metadata":null},{"id":"b6a0589938ec4e958775696ecde57f6b","type":"TRIAL","name":"Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)","canonical_id":"clinicaltrials.gov:NCT03941132","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"d0db5d28c0bc402bb431b5b6e193ee68","type":"TRIAL","name":"Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors","canonical_id":"clinicaltrials.gov:NCT01168817","description":"Erectile Dysfunction","metadata":null},{"id":"114a68a82457487b90f8b90106c3090b","type":"TRIAL","name":"Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis","canonical_id":"clinicaltrials.gov:NCT07546552","description":"Female Infertility; NF-\u03baB Ligand; RANKL; Osteoporosis; Follicle Development","metadata":null},{"id":"9cb08de3d20e4dd8b3b2490391a0e780","type":"TRIAL","name":"Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder","canonical_id":"clinicaltrials.gov:NCT01912391","description":"Borderline Personality Disorder","metadata":null},{"id":"eb2cf1729c0a409382343c57df6e59d9","type":"TRIAL","name":"Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol","canonical_id":"clinicaltrials.gov:NCT03245554","description":"Gastrointestinal Cancer","metadata":null},{"id":"8ea4628449474ccf905c20e6c1990d97","type":"TRIAL","name":"Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT02977832","description":"Benign Prostatic Hypertrophy With Outflow Obstruction; Benign Prostatic Hyperplasia","metadata":null},{"id":"8600edfc685d45dd905a0118f7574066","type":"TRIAL","name":"Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","canonical_id":"clinicaltrials.gov:NCT04704947","description":"Beta Blocker Toxicity","metadata":null},{"id":"cfac3005bc67436ab710736e1c7c5e27","type":"TRIAL","name":"Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma","canonical_id":"clinicaltrials.gov:NCT01436110","description":"Asthma","metadata":null},{"id":"d6d70a28efcc468f8bef9367bb8c6aa3","type":"TRIAL","name":"Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy","canonical_id":"clinicaltrials.gov:NCT05637086","description":"Epilepsy","metadata":null},{"id":"bfde9c574a5e4ae0acfdb10d82b4f4cc","type":"TRIAL","name":"Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT06108518","description":"Rheumatoid Arthritis","metadata":null},{"id":"54458f1607f44cfdb933589ba426777e","type":"TRIAL","name":"Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)","canonical_id":"clinicaltrials.gov:NCT02968901","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"0e25f88cb316491b8ac69a66cbf3c5b2","type":"TRIAL","name":"Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy","canonical_id":"clinicaltrials.gov:NCT05553717","description":"IHD; Gastro-Intestinal Disorder; Aspirin Induced Esophageal Ulcer","metadata":null},{"id":"280727efeee746eb8890d732439276c0","type":"TRIAL","name":"Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)","canonical_id":"clinicaltrials.gov:NCT00150202","description":"Macular Degeneration","metadata":null},{"id":"dfc304d16fec41e1bdbf84611fae3bae","type":"TRIAL","name":"Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00239928","description":"Macular Degeneration","metadata":null},{"id":"82f17d4fa7974af19508b95cd4f66f90","type":"TRIAL","name":"Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT04754035","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"13e376a00cd44d5496190464eb02cd14","type":"TRIAL","name":"Clinical Study for Patients With Hypertension Associated With Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT01764295","description":"Hypertension; Dyslipidemia","metadata":null},{"id":"10806c1c4ce2427e886812da53bb3c74","type":"TRIAL","name":"Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone","canonical_id":"clinicaltrials.gov:NCT02115048","description":"Breast Neoplasms","metadata":null},{"id":"9d94da80ed6f4c5cbd34a4b623ad17f8","type":"TRIAL","name":"Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam","canonical_id":"clinicaltrials.gov:NCT00736931","description":"Epilepsy","metadata":null},{"id":"61c85c37fafb4f98abd5dab354602ebc","type":"TRIAL","name":"Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN","canonical_id":"clinicaltrials.gov:NCT05817955","description":"MDS/MPN","metadata":null},{"id":"ccdc642db2fe482d9b9332506cad0fe9","type":"TRIAL","name":"Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00291668","description":"Crohn's Disease","metadata":null},{"id":"e1f660c38e324e0089754a6a8d9799f7","type":"TRIAL","name":"Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02889692","description":"Cancer","metadata":null},{"id":"c373cf4a3f5d4fa0ac4193f1bd2cc8cd","type":"TRIAL","name":"Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.","canonical_id":"clinicaltrials.gov:NCT03992885","description":"Non-squamous Non-small Cell Lung Cancer","metadata":null},{"id":"3f5b351a090349b481ae84f87440f842","type":"TRIAL","name":"Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection","canonical_id":"clinicaltrials.gov:NCT02694848","description":"Angina","metadata":null},{"id":"e1ee9a200e6b45cfb96e2077e808f3ea","type":"TRIAL","name":"Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT06357741","description":"Knee Osteoarthritis","metadata":null},{"id":"cd07cd8f8f9c4ade9d79edb604fd9806","type":"TRIAL","name":"Clinical Study of Divozilimab in Patients With Systemic Scleroderma","canonical_id":"clinicaltrials.gov:NCT05726630","description":"Systemic Scleroderma","metadata":null},{"id":"49d1b0c85760472e93bbffddcb786e7a","type":"TRIAL","name":"Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma\uff08CSHEIN\uff09","canonical_id":"clinicaltrials.gov:NCT07278674","description":"High Risk Neuroblastoma","metadata":null},{"id":"5c61090d15dc4814a90a7de07885ce94","type":"TRIAL","name":"Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06861192","description":"Prostate CA","metadata":null},{"id":"ac13b8eeac954228b9cef045d32469b6","type":"TRIAL","name":"Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors","canonical_id":"clinicaltrials.gov:NCT05191914","description":"Breast Cancer","metadata":null},{"id":"213673b73e4e4d378899794e12c25ea6","type":"TRIAL","name":"Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05509634","description":"Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy","metadata":null},{"id":"cf8ffd81f5c746949d0b7db0a91813fb","type":"TRIAL","name":"Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant","canonical_id":"clinicaltrials.gov:NCT01019577","description":"Metastatic Breast Cancer","metadata":null},{"id":"73e26f8d89334bc7be4b7c4a3589511c","type":"TRIAL","name":"Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.","canonical_id":"clinicaltrials.gov:NCT00162136","description":"Solid Malignancies","metadata":null},{"id":"8af1ccd818b04d8c8991b69e720f4da7","type":"TRIAL","name":"Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument","canonical_id":"clinicaltrials.gov:NCT01841762","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"e6b91fd0c7cc4b5091f6a92ca10fe0ae","type":"TRIAL","name":"Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy","canonical_id":"clinicaltrials.gov:NCT01845688","description":"Idiopathic Membranous Nephropathy","metadata":null},{"id":"b68fd096f99248b78c64730aee3ab8ae","type":"TRIAL","name":"Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01544894","description":"Postmenopausal Osteoporosis; Compliance","metadata":null},{"id":"9747841bca644e1bb10b3039eb89e735","type":"TRIAL","name":"Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy","canonical_id":"clinicaltrials.gov:NCT05394740","description":"Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma","metadata":null},{"id":"e98aff829aee4c35bf03e99f6c96a640","type":"TRIAL","name":"Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00629642","description":"Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases","metadata":null},{"id":"6a7ef11c585047858a7f5c54fd0d0711","type":"TRIAL","name":"Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan","canonical_id":"clinicaltrials.gov:NCT03147677","description":"Type 2 Diabetic Nephropathy","metadata":null},{"id":"1bd6558dc08645b1b58ab2bd2fad9eec","type":"TRIAL","name":"Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor\u00ae) for Atrophic Vaginitis in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01370551","description":"Atrophic Vaginitis","metadata":null},{"id":"affd121374a049dea25b620d73a64cbf","type":"TRIAL","name":"Clinical Study of the Effect of Methylprednisolone Combined","canonical_id":"clinicaltrials.gov:NCT04810819","description":"Methylprednisolone;Dihydroxypropyltheophylline;One Lung Ventilation;Respiratory Dynamics","metadata":null},{"id":"da99538aed304f0d8dd9a09fa02fc02a","type":"TRIAL","name":"Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification","canonical_id":"clinicaltrials.gov:NCT03693989","description":"Cataract","metadata":null},{"id":"5266e126fe964728afd2c654c36f32d2","type":"TRIAL","name":"Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma","canonical_id":"clinicaltrials.gov:NCT02254954","description":"Glioblastoma","metadata":null},{"id":"d9235fa2ce0f4b9cb9acdf99952c5f39","type":"TRIAL","name":"Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy","canonical_id":"clinicaltrials.gov:NCT06748638","description":"Lactulose; Bowel Preparation","metadata":null},{"id":"d93ec7cade264f549108794beba9c628","type":"TRIAL","name":"Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT05203705","description":"Prevention of Venous Thrombosis After TKA","metadata":null},{"id":"f0ef4861a9ce469995efdaca395e9d60","type":"TRIAL","name":"Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation","canonical_id":"clinicaltrials.gov:NCT02554903","description":"Pulmonary Hypertension","metadata":null},{"id":"26c9b024d46542168915c3ef33aaefa6","type":"TRIAL","name":"Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT02021292","description":"Chronic Thromboembolic Pulmonary Hypertension","metadata":null},{"id":"0d44f56e999341ad9a2a0e49e3afbc20","type":"TRIAL","name":"Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00667823","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"805817023a344bf69bfdbd470c9e63f2","type":"TRIAL","name":"Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome","canonical_id":"clinicaltrials.gov:NCT01739400","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"1b21abdf81ac40a2a384f2ff3364ecf7","type":"TRIAL","name":"Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT02060721","description":"Chronic Thromboembolic Pulmonary Hypertension","metadata":null},{"id":"433799d5fc7f4214b5292a2e00b5a6d6","type":"TRIAL","name":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT03904693","description":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","metadata":null},{"id":"d61443099e5e435eac33c5a9f6ffbb7f","type":"TRIAL","name":"Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera\u00ae)","canonical_id":"clinicaltrials.gov:NCT02907177","description":"Multiple Sclerosis","metadata":null},{"id":"56b4fed238d5480783a4ce963774fc00","type":"TRIAL","name":"Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza \u00ae in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT05800418","description":"Gastric Cancer; Non-small Cell Lung Cancer; Colo-rectal Cancer","metadata":null},{"id":"ceddb35486b4412b944125f5fe0a59a8","type":"TRIAL","name":"Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets Under Fed Conditions.","canonical_id":"clinicaltrials.gov:NCT07633028","description":"Bioequivalence Study in Healthy Subjects","metadata":null},{"id":"3fdbf2415ae347149edc3b6b57c0026c","type":"TRIAL","name":"Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.","canonical_id":"clinicaltrials.gov:NCT07763964","description":"Bioequivalance","metadata":null},{"id":"efcba863622a4977a6d3e70090585fb5","type":"TRIAL","name":"Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT07698275","description":"Bioequivalance","metadata":null},{"id":"f92e7efc7f064b20b436140a11b524ce","type":"TRIAL","name":"Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06612203","description":"Advanced Breast Cancer","metadata":null},{"id":"eb8ac2a3ad6248f9b82477c038483ee3","type":"TRIAL","name":"Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure","canonical_id":"clinicaltrials.gov:NCT00219180","description":"Hypertension","metadata":null},{"id":"12760c5a0e7840799f2f746ac24e5231","type":"TRIAL","name":"Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT07043322","description":"Gynecologic Disease","metadata":null},{"id":"28da1507b1714a2ea9cf35eba1b0d6ac","type":"TRIAL","name":"Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome","canonical_id":"clinicaltrials.gov:NCT01743001","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"301e3973d9664ae9ab1a2e7f0cfa4faa","type":"TRIAL","name":"Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.","canonical_id":"clinicaltrials.gov:NCT00219024","description":"Hypertension","metadata":null},{"id":"0b837789e7bc44ff95ab2d23300654ba","type":"TRIAL","name":"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease","canonical_id":"clinicaltrials.gov:NCT00319046","description":"Gaucher Disease Type 1","metadata":null},{"id":"bbf76f92618e459fb47a02f04613b7d4","type":"TRIAL","name":"Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction","canonical_id":"clinicaltrials.gov:NCT02070991","description":"Pulmonary Hypertension","metadata":null},{"id":"d512dd430f164fdcb46c6e59e67f5dac","type":"TRIAL","name":"Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441","canonical_id":"clinicaltrials.gov:NCT02479204","description":"Healthy Subjects","metadata":null},{"id":"34bb49a29afa4747b30497e411556be4","type":"TRIAL","name":"Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD","canonical_id":"clinicaltrials.gov:NCT02461134","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"54013f21314849d3b2d447663f502a68","type":"TRIAL","name":"Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT03359291","description":"Healthy Subjects","metadata":null},{"id":"f1c7d057e166488d8efcb03c4411f802","type":"TRIAL","name":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","canonical_id":"clinicaltrials.gov:NCT04310579","description":"Hypercapnia; Ventilatory Depression","metadata":null},{"id":"4612466142124c63bc270baa452e0df2","type":"TRIAL","name":"Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01093326","description":"Multiple Sclerosis","metadata":null},{"id":"cc95c8b7828541f08f9cc64568ba0841","type":"TRIAL","name":"Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration","canonical_id":"clinicaltrials.gov:NCT04397445","description":"Ranitidine Adverse Reaction; Pharmacokinetics; Food-drug Interaction","metadata":null},{"id":"d58dc09624eb431bb564963f380a5f61","type":"TRIAL","name":"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%","canonical_id":"clinicaltrials.gov:NCT00598832","description":"Acne Vulgaris","metadata":null},{"id":"ab45f5cf550a4d58ab2c34fe69d34328","type":"TRIAL","name":"Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03295786","description":"Parkinson Disease; Movement Disorders; Neurodegenerative Diseases; Nervous System Diseases; Brain Diseases","metadata":null},{"id":"6457d7f5d7f44468ba0a51c1eb1bea0a","type":"TRIAL","name":"Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT06364956","description":"Bladder Cancer","metadata":null},{"id":"eca0c6eed5a84ca98d36805f5e7010d9","type":"TRIAL","name":"Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years","canonical_id":"clinicaltrials.gov:NCT03562481","description":"Anesthesia, Local; Pain","metadata":null},{"id":"22a1f672d80f450bb96dfb19d0d1a565","type":"TRIAL","name":"Clinical Trial Comparing Intravenous and Oral Diclofenac and Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT03472339","description":"Pain Management; Limb Injury","metadata":null},{"id":"7b63fbc98fd344329a9b8770e0b75b22","type":"TRIAL","name":"Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria","canonical_id":"clinicaltrials.gov:NCT02935699","description":"Acute Urticaria","metadata":null},{"id":"5f72606b7f984b45991f4a24baf2372f","type":"TRIAL","name":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","canonical_id":"clinicaltrials.gov:NCT02714634","description":"Rheumatoid Arthritis; Insufficient Response to Methotrexate or Leflunomide","metadata":null},{"id":"a6aa9080c9c1442b9e1126a69ae398df","type":"TRIAL","name":"Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.","canonical_id":"clinicaltrials.gov:NCT05937906","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"3f4a9f1688c344d29e8f3ef5b3c3680e","type":"TRIAL","name":"Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01055756","description":"Allergic Rhinitis","metadata":null},{"id":"ab8d93a505c44fe3867aec2f1c5e6bf2","type":"TRIAL","name":"Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment","canonical_id":"clinicaltrials.gov:NCT07317050","description":"Acute Respiratory Distress Syndrome (ARDS)","metadata":null},{"id":"355652c6a9eb47cb953f24c5d0e58fc3","type":"TRIAL","name":"Clinical Trial for 'Shen Qu Xiao Shi' Oral Liquid in the Treatments of Children's Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT05030116","description":"Dyspepsia","metadata":null},{"id":"d3c597cc01e14ff1b7b288518412f099","type":"TRIAL","name":"Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT04558931","description":"Multiple Myeloma","metadata":null},{"id":"2901395109ec4be9a9c421132e79ce93","type":"TRIAL","name":"Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390","canonical_id":"clinicaltrials.gov:NCT00996216","description":"Hepatitis C","metadata":null},{"id":"dd1b24abfa564008be64950e5e08486a","type":"TRIAL","name":"Clinical Trial for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00076531","description":"Prostate Cancer","metadata":null},{"id":"45fea7e0add04ae4a31b4bb76e71d074","type":"TRIAL","name":"Clinical Trial for the Prevention of Vasovagal Syncope","canonical_id":"clinicaltrials.gov:NCT00118482","description":"Syncope, Vasovagal, Neurally-Mediated","metadata":null},{"id":"e63a33085abb41f5b5bb4b93b8be0a02","type":"TRIAL","name":"Clinical Trial in Males With BPH (Enlarged Prostate)","canonical_id":"clinicaltrials.gov:NCT00029822","description":"Urinary Retention; Prostatic Hyperplasia; Benign Prostatic Hypertrophy","metadata":null},{"id":"cbe90733db9f497bb67eb09b5d925caa","type":"TRIAL","name":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy","canonical_id":"clinicaltrials.gov:NCT04554680","description":"Thyroid Cancer","metadata":null},{"id":"f53959337cfe4c27a431bf6c663cfde7","type":"TRIAL","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT05230810","description":"HER2-positive Metastatic Breast Cancer","metadata":null},{"id":"c4a55afc2d6e4dbcad885e7e4fdff45e","type":"TRIAL","name":"Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02006121","description":"Parkinson's Disease","metadata":null},{"id":"7e61e461aebc4a2ab3733321237e32d5","type":"TRIAL","name":"Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions","canonical_id":"clinicaltrials.gov:NCT03189641","description":"Coronary Artery Disease","metadata":null},{"id":"537c9a77308342778bc5c8bcb967525e","type":"TRIAL","name":"Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00135200","description":"Multiple Myeloma","metadata":null},{"id":"981d35e78ca7480381bad54cd4af698e","type":"TRIAL","name":"Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia","canonical_id":"clinicaltrials.gov:NCT01023867","description":"Alzheimer's Disease; Dementia","metadata":null},{"id":"b621df174bbe4cac83ecb35f70670d3a","type":"TRIAL","name":"Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY)","canonical_id":"clinicaltrials.gov:NCT04838717","description":"Syphilis","metadata":null},{"id":"7b892765e4fd4a39a141079817b147cb","type":"TRIAL","name":"Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02399566","description":"Lung Adenocarcinoma","metadata":null},{"id":"acb49a7ea6624e15a305a600e79bee41","type":"TRIAL","name":"Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults","canonical_id":"clinicaltrials.gov:NCT06414837","description":"Gout With Hyperuricemia in Adults","metadata":null},{"id":"199f8303683d4efcb7139a9bce87d2b2","type":"TRIAL","name":"Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02716714","description":"Actinic Keratosis","metadata":null},{"id":"e1eb3b388cd144e58bf2bd9c4bcd269f","type":"TRIAL","name":"Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy","canonical_id":"clinicaltrials.gov:NCT06862596","description":"Spinal and Bulbar Muscular Atrophy","metadata":null},{"id":"762d7969385f461fb4cfc89197d068f3","type":"TRIAL","name":"Clinical Trial of Mifepristone for Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT00043654","description":"Bipolar Disorder","metadata":null},{"id":"fe6d6e5ba1524a5d8ca8741025ca314d","type":"TRIAL","name":"Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT03203590","description":"2-year Disease-Free Survival","metadata":null},{"id":"fce940116d434b03ae18b4ed9b701363","type":"TRIAL","name":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","canonical_id":"clinicaltrials.gov:NCT07059091","description":"Chronic Obstructive Pulmonary Disease (COPD); Allergies","metadata":null},{"id":"6c5e881346264ee0a7ccd1abb09f1c57","type":"TRIAL","name":"Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma","canonical_id":"clinicaltrials.gov:NCT03026517","description":"Melanoma","metadata":null},{"id":"36f2325044c946dc8a1707df7cdbe949","type":"TRIAL","name":"Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations","canonical_id":"clinicaltrials.gov:NCT01736891","description":"Parkinson\u00b4s Disease","metadata":null},{"id":"6897e4d785444af88f4eae23ae6e6047","type":"TRIAL","name":"Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)","canonical_id":"clinicaltrials.gov:NCT00739830","description":"Endometrial Cancer","metadata":null},{"id":"6f92c7b9b3a649c4936ce51b93715566","type":"TRIAL","name":"Clinical Trial of Sarilumab in Adults With COVID-19","canonical_id":"clinicaltrials.gov:NCT04357860","description":"SARS-CoV 2; SARS","metadata":null},{"id":"064c5387b26749f29d3793b70b0cfd20","type":"TRIAL","name":"Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04586543","description":"Metastatic Castration-resistant Prostate Cancer; Adenocarcinoma of the Prostate","metadata":null},{"id":"5624086889d942398ec44b1146f34070","type":"TRIAL","name":"Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma","canonical_id":"clinicaltrials.gov:NCT04312204","description":"Primary Pulmonary Lymphoepithelioma-like Carcinoma; Lung Cancer","metadata":null},{"id":"b32eed010ee4417d91e944d452f624f4","type":"TRIAL","name":"Clinical Trial of Teriparatide in Japan","canonical_id":"clinicaltrials.gov:NCT00191867","description":"Osteoporosis","metadata":null},{"id":"93dbeef686fd40eda9c4e972549d15e5","type":"TRIAL","name":"Clinical Trial of Tolcapone for Cognition in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00044083","description":"Schizophrenia","metadata":null},{"id":"b0f12353499a432cbb9b89397f508ae7","type":"TRIAL","name":"Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)","canonical_id":"clinicaltrials.gov:NCT04692155","description":"Mantle Cell Lymphoma","metadata":null},{"id":"703f4b201e2c4ef295ed504f0ff660cf","type":"TRIAL","name":"Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia","canonical_id":"clinicaltrials.gov:NCT00442676","description":"Preeclampsia","metadata":null},{"id":"d2394ced27114adb8ad92e4f54478e99","type":"TRIAL","name":"Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn","canonical_id":"clinicaltrials.gov:NCT03332524","description":"Sunburn","metadata":null},{"id":"4e59750777f5464dae9bcb2778ea1ebc","type":"TRIAL","name":"Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma","canonical_id":"clinicaltrials.gov:NCT03291314","description":"Recurrent Glioblastoma (WHO-Grade IV Glioma)","metadata":null},{"id":"5d17b195f51340c8864680bef1d9d0be","type":"TRIAL","name":"Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02982083","description":"Rheumatoid Arthritis","metadata":null},{"id":"4aa725f988ce4bcdb51e5d012e2e58ba","type":"TRIAL","name":"Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)","canonical_id":"clinicaltrials.gov:NCT00977665","description":"Multiple System Atrophy","metadata":null},{"id":"5a3472ee476c4e81a9c949b4e2705a07","type":"TRIAL","name":"Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","canonical_id":"clinicaltrials.gov:NCT00435760","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"3991ef9041864b70b0188f0f4376d7ba","type":"TRIAL","name":"Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03669757","description":"Psoriasis Vulgaris","metadata":null},{"id":"5ceb2c26362b44c8b491f569cf95f600","type":"TRIAL","name":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00790023","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"07681735eb6741d99d78e2558127a935","type":"TRIAL","name":"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","canonical_id":"clinicaltrials.gov:NCT01010971","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"6db5a83dd28b432c845d245f34cf295a","type":"TRIAL","name":"Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT07013851","description":"MMRd/MSI-H Stage II-III Endometrial Cancer","metadata":null},{"id":"9d7c5e06000442a2be64fe9dca934ed4","type":"TRIAL","name":"Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old","canonical_id":"clinicaltrials.gov:NCT04687761","description":"Leukemia, Myeloid, Acute; De Novo; Age More 60yr","metadata":null},{"id":"08e0424efcfa4115bb6aaebf3830129e","type":"TRIAL","name":"Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","canonical_id":"clinicaltrials.gov:NCT07076706","description":"Male Pattern of Hair Loss, Androgenic Alopecia; Androgenetic Alopecia (AGA)","metadata":null},{"id":"a96cb88be7aa40eebeab45131a78de74","type":"TRIAL","name":"Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma","canonical_id":"clinicaltrials.gov:NCT04200755","description":"Localized Scleroderma","metadata":null},{"id":"b5bc8fe2093c49c68652be9c8a654654","type":"TRIAL","name":"Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream","canonical_id":"clinicaltrials.gov:NCT04361136","description":"Healthy","metadata":null},{"id":"01a6a1a954754dacbb167007447c49b9","type":"TRIAL","name":"Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT04856969","description":"Healthy Adult Volunteers","metadata":null},{"id":"e70eec8277044118acba7c520be236a2","type":"TRIAL","name":"Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream","canonical_id":"clinicaltrials.gov:NCT04807751","description":"Healthy","metadata":null},{"id":"067944dcfb6140aa85a4521884f5013a","type":"TRIAL","name":"Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04445272","description":"COVID-19","metadata":null},{"id":"f34192b6041b4f43ba53a2686dc5adff","type":"TRIAL","name":"Clinical Trial to Evaluate the Efficacy and Safety of Suvaro\u00aeOD Tablet in Patients With Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT06153433","description":"Dyslipidemia","metadata":null},{"id":"b90dd3164c954c72a7ab7f9175f788f6","type":"TRIAL","name":"Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04890626","description":"SARS-CoV-2 Infection","metadata":null},{"id":"304b4fe09cfe4fc0874fe3e6b095058f","type":"TRIAL","name":"Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin","canonical_id":"clinicaltrials.gov:NCT01775839","description":"DRUG REACTIONS","metadata":null},{"id":"c6c2e196625145b189ced1dddf954bec","type":"TRIAL","name":"Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT04818944","description":"Acute Ischemic Stroke; Ischemic Stroke","metadata":null},{"id":"11d2df5092714b4abb6f4f1d97b0acb4","type":"TRIAL","name":"Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT01102660","description":"Osteoarthritis","metadata":null},{"id":"696eea9171754084bf8def75c700dc77","type":"TRIAL","name":"Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT06247410","description":"Parkinson Disease","metadata":null},{"id":"6849cefb00f5427daa9b894c1d454551","type":"TRIAL","name":"Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)","canonical_id":"clinicaltrials.gov:NCT04730037","description":"CTEPH","metadata":null},{"id":"eb4c4674e39a423a94554d124bfaa9d0","type":"TRIAL","name":"Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine","canonical_id":"clinicaltrials.gov:NCT01928563","description":"Healthy Male Subjects","metadata":null},{"id":"994a5ff548e5492e9bef43ca3b8ca89b","type":"TRIAL","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","canonical_id":"clinicaltrials.gov:NCT07548177","description":"Alveolar Soft Part Sarcoma","metadata":null},{"id":"afc1dd4596ca4923aacaef62c2940261","type":"TRIAL","name":"Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02056743","description":"Healthy","metadata":null},{"id":"82166b303a7f4d559b56566bba20f3ad","type":"TRIAL","name":"Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients","canonical_id":"clinicaltrials.gov:NCT04223596","description":"Lung Cancer; NSCLC; NSCLC Stage IIIB; NSCLC Stage IV","metadata":null},{"id":"aa3ce7f0ef904037b6d71762eb72de03","type":"TRIAL","name":"Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction","canonical_id":"clinicaltrials.gov:NCT06800274","description":"Allergic Conjunctivitis; Dry Eye Disease (DED)","metadata":null},{"id":"dc47d19381624d0abb99b604535ecb31","type":"TRIAL","name":"Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT06665997","description":"Sickle Cell Disease (SCD); Vaso-Occlusive Pain Episode in Sickle Cell Disease","metadata":null},{"id":"04f2527515194255858572a522d9f9ba","type":"TRIAL","name":"Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants","canonical_id":"clinicaltrials.gov:NCT01037530","description":"Intermittent Claudicants","metadata":null},{"id":"fc5eb63769834d8381b8b2c3b7f3043e","type":"TRIAL","name":"Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin","canonical_id":"clinicaltrials.gov:NCT03508856","description":"Actinic Keratosis; Photo-aged Skin","metadata":null},{"id":"1e3167f15abd4340b5f41e71c27f5c39","type":"TRIAL","name":"Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT02443311","description":"Oral Lichen Planus","metadata":null},{"id":"168d13c4e3ae42e2919bef6f625f8bbb","type":"TRIAL","name":"Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.","canonical_id":"clinicaltrials.gov:NCT05755659","description":"Neoplasms","metadata":null},{"id":"350139fee04a46f19498444c797c676f","type":"TRIAL","name":"Clinician-patient Interaction During Addiction Consultation","canonical_id":"clinicaltrials.gov:NCT01769651","description":"Drug Dependency","metadata":null},{"id":"505829d2137e4bb88f6a5cfe3a252a1e","type":"TRIAL","name":"Clobazam Use in Epilepsia Partialis Continua - Pilot Study","canonical_id":"clinicaltrials.gov:NCT02134366","description":"Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy","metadata":null},{"id":"365b5ee92c0140579bdb1d69add37889","type":"DRUG","name":"Clobetasol","canonical_id":"mesh:D002990","description":null,"metadata":null},{"id":"9c60a6a751854605beb12fd43e1aed2e","type":"TRIAL","name":"Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)","canonical_id":"clinicaltrials.gov:NCT04246801","description":"Cataract","metadata":null},{"id":"21c0d8285faa4b1da7e597d7a1806a39","type":"TRIAL","name":"Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population","canonical_id":"clinicaltrials.gov:NCT05724446","description":"Cataracts Infantile","metadata":null},{"id":"d9e5740ce1b74640ad81b58fb14c96ec","type":"TRIAL","name":"Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp","canonical_id":"clinicaltrials.gov:NCT00881868","description":"Scalp Psoriasis","metadata":null},{"id":"acdd68a9497945e490ffbf2d1a10da70","type":"TRIAL","name":"Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus","canonical_id":"clinicaltrials.gov:NCT02573883","description":"Vulvar Lichen Sclerosus","metadata":null},{"id":"2f45ece2495e48829ee59bafb4328af5","type":"TRIAL","name":"Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus","canonical_id":"clinicaltrials.gov:NCT00393263","description":"Lichen Sclerosus","metadata":null},{"id":"aaf8c6dace2d4ed5b877e5736961b68c","type":"DRUG","name":"Clocortolone pivalate","canonical_id":"mesh:C007088","description":null,"metadata":null},{"id":"2aaabb7af46d47a281b2e9ded056e2a0","type":"TRIAL","name":"Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01629082","description":"Myeldysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia; Bone Marrow Diseases; Neutropenia; Acute Myeloid Leukemia (AML)","metadata":null},{"id":"379c9ac4fd76473e88ca02bb6daea8b9","type":"TRIAL","name":"Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT01295307","description":"Acute Myeloid Leukemia","metadata":null},{"id":"dd8df4b120bc4743a6b4f77f822b7537","type":"TRIAL","name":"Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia","canonical_id":"clinicaltrials.gov:NCT01158885","description":"Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute","metadata":null},{"id":"c370542c59844a13b3332b7b1682373a","type":"TRIAL","name":"Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders","canonical_id":"clinicaltrials.gov:NCT00293410","description":"Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic/Myeloproliferative Diseases","metadata":null},{"id":"09cb3d5edfdc400986a2e75e4ed493eb","type":"TRIAL","name":"Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease","canonical_id":"clinicaltrials.gov:NCT00863434","description":"Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia","metadata":null},{"id":"446717fe293048db928d59a160f3a943","type":"TRIAL","name":"Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00577694","description":"Leukemia","metadata":null},{"id":"9d6549adff664ff7931e0a1c82ecce2e","type":"TRIAL","name":"Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT00641030","description":"Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"e2b429c6825e4862bd94dee777180908","type":"TRIAL","name":"Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years","canonical_id":"clinicaltrials.gov:NCT01193400","description":"Acute Myelogenous Leukemia","metadata":null},{"id":"1a97fdc7dafc40f88cf9faf898411f95","type":"TRIAL","name":"Clofarabine for Langerhans in Pedi","canonical_id":"clinicaltrials.gov:NCT01796405","description":"Langerhans Cell Histiocytosis","metadata":null},{"id":"ee80132c58b64578a688e2e4677efa07","type":"TRIAL","name":"Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT00156013","description":"Lymphoma, B-Cell; Lymphoma, Non-Hodgkin","metadata":null},{"id":"48691eddf2004e5eb4fe768aaf3ab411","type":"TRIAL","name":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02085408","description":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute\u2026","metadata":null},{"id":"b71a022024fe44cba66a6845698202b3","type":"TRIAL","name":"Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm","canonical_id":"clinicaltrials.gov:NCT01101880","description":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia; Myeloproliferative Neoplasm With 10% Bl\u2026","metadata":null},{"id":"d469c5caa8b64477a7bde147559858bf","type":"TRIAL","name":"Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00602225","description":"Acute Myeloid Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia","metadata":null},{"id":"0a26c5c42ea24520a9bc501c97e1deeb","type":"TRIAL","name":"Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia","canonical_id":"clinicaltrials.gov:NCT00838240","description":"Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"aa5a59f0f9d940409c3a7a9132aed279","type":"TRIAL","name":"Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation","canonical_id":"clinicaltrials.gov:NCT00593645","description":"Myelodysplastic Syndromes; Acute Myeloid Leukemia","metadata":null},{"id":"4927293bf47540308286dfb1fedb44ac","type":"TRIAL","name":"Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT00943592","description":"Advanced Hematologic Malignancies; Leukemia; Preleukemia","metadata":null},{"id":"78402986d19342e19efb0cdaf7ec553c","type":"TRIAL","name":"Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults","canonical_id":"clinicaltrials.gov:NCT01462253","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"fca921465ef14ccbb65b4cc4a49684e3","type":"DRUG","name":"Clofedanol","canonical_id":"mesh:C010432","description":null,"metadata":null},{"id":"4c1a2f15ddf14d8ebf7016086e8def32","type":"DRUG","name":"Clomifene","canonical_id":"mesh:D002996","description":null,"metadata":null},{"id":"d228c08d27c64020905285fef120fad3","type":"TRIAL","name":"Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT02644304","description":"Female Reproductive Problem","metadata":null},{"id":"c2ef71fa0e2e484f969a0d98d44ba155","type":"TRIAL","name":"Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs","canonical_id":"clinicaltrials.gov:NCT02479256","description":"PCOS","metadata":null},{"id":"e27f36ce6d4c44eb93fb6164df28db83","type":"TRIAL","name":"Clomiphene Citrate for Treatment of Acromegaly","canonical_id":"clinicaltrials.gov:NCT02274311","description":"Acromegaly","metadata":null},{"id":"2ef6a4668ecf450db3b521f39e5cd7a9","type":"TRIAL","name":"Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration","canonical_id":"clinicaltrials.gov:NCT01880086","description":"Hypogonadism; Opioid-Related Disorders; Male Infertility","metadata":null},{"id":"035e0eba01f84751aa967fe293a28c55","type":"TRIAL","name":"Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03061136","description":"Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder","metadata":null},{"id":"0b99b18a8e8a4259acbb8def209e45bf","type":"TRIAL","name":"Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT00025740","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"1763565594be40468754072d9daefd7f","type":"TRIAL","name":"Clonazepam in Children Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT04287361","description":"Epilepticus Status","metadata":null},{"id":"ceaf3dcc34b744cc93a19b738830f2f3","type":"DRUG","name":"Clonidine","canonical_id":"mesh:D003000","description":null,"metadata":null},{"id":"dd174027dbaf4a8088650fd1de66b3ba","type":"TRIAL","name":"Clonidine Added Lidocaine in Intraocular Pressure and Hemodynamics Ocular in Sub-Tenon's and Peribulbar Anesthesia","canonical_id":"clinicaltrials.gov:NCT02733757","description":"Anesthesia","metadata":null},{"id":"ce8e9d062c124558b25227344af90680","type":"TRIAL","name":"Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.","canonical_id":"clinicaltrials.gov:NCT04648020","description":"Chemoradiotherapy-Induced Severe Oral Mucositis","metadata":null},{"id":"0cb5d9b27eb44c5ba8bda8d4971be2d0","type":"TRIAL","name":"Clonidine for Neonatal Abstinence Syndrome Study","canonical_id":"clinicaltrials.gov:NCT01175668","description":"Neonatal Abstinence Syndrome","metadata":null},{"id":"7cefd620c5f54509bdc24a9b24b8c5cf","type":"TRIAL","name":"Clonidine in Ultrasound-guided Rectus Sheath Block for Outpatient Umbilical Hernioplasty","canonical_id":"clinicaltrials.gov:NCT07062497","description":"Hernia, Umbilical; Clonidine; Pain, Postoperative; Ambulatory Surgical Procedures; Regional Anesthesia Block","metadata":null},{"id":"111a12d203f949d28e8ef14c0283c385","type":"TRIAL","name":"Clonidine is Better Than Zopiclone for Insomnia Treatment in Chronic Pain Patients","canonical_id":"clinicaltrials.gov:NCT05277038","description":"Insomnia Chronic; Pain, Chronic","metadata":null},{"id":"f6b2ade937804f5da948d8569d6f99ef","type":"TRIAL","name":"Clonidine to Prevent Delirium After Electroconvulsive Therapy.","canonical_id":"clinicaltrials.gov:NCT04828226","description":"Major Depressive Disorder; Catatonia; Bipolar Disorder; Delirium Postseizure","metadata":null},{"id":"3ce8a577c7674532a86884db04d7618e","type":"TRIAL","name":"Clonidine vs. Dexmedetomidine in Agitated Delirium in Intensive Care Patients","canonical_id":"clinicaltrials.gov:NCT04758936","description":"Delirium; Critical Illness","metadata":null},{"id":"b1debe695f884535b068c7edbaf10adc","type":"DRUG","name":"Clopidogrel","canonical_id":"mesh:D000077144","description":null,"metadata":null},{"id":"78a0eae8c8634d299ac2937d97a9247f","type":"TRIAL","name":"Clopidogrel Versus Cilostazol in Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT06242132","description":"Ischemic Stroke","metadata":null},{"id":"eb724e8c66d648e699318135c224a8ef","type":"TRIAL","name":"Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT06242145","description":"Ischemic Stroke","metadata":null},{"id":"bb12e8bf8e6a4843a9c670af1488d656","type":"TRIAL","name":"Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting","canonical_id":"clinicaltrials.gov:NCT01572623","description":"Carotid Stenosis","metadata":null},{"id":"55666693e53843578e56d5c101034c3e","type":"DRUG","name":"Clorazepate Dipotassium","canonical_id":"mesh:D003009","description":null,"metadata":null},{"id":"d8eb13a9053241f5ac317376184d5c1d","type":"TRIAL","name":"Closing Volume Interpretation and Bronchodilators Effect","canonical_id":"clinicaltrials.gov:NCT01437748","description":"Healthy; COPD","metadata":null},{"id":"96b2c9a41006402092367a8759146b1f","type":"DISEASE","name":"Clostridium difficile infection","canonical_id":"mesh:D003015","description":null,"metadata":null},{"id":"31ec85f36f534540a03a1a28f5ff4ec0","type":"DRUG","name":"Cloxacillin","canonical_id":"mesh:D003023","description":null,"metadata":null},{"id":"cdf47ba23e6d4695a27d3d07615fa499","type":"TRIAL","name":"Clozapine IM and Aggression in Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT00189995","description":"Schizophrenia","metadata":null},{"id":"e4f6b9591bb7439eb82af39372a8febf","type":"TRIAL","name":"Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00169039","description":"Schizophrenia","metadata":null},{"id":"317fc7d1604548df8f37bc4d95494e4d","type":"TRIAL","name":"Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database","canonical_id":"clinicaltrials.gov:NCT04074213","description":"Lymphoma; Leukemia","metadata":null},{"id":"680ae67195c04ab0920220e901300b7d","type":"TRIAL","name":"Clozapine for Treatment-Resistant Mania","canonical_id":"clinicaltrials.gov:NCT00029458","description":"Bipolar Disorder","metadata":null},{"id":"52758748eba44dffb070a237269840e6","type":"TRIAL","name":"Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00036582","description":"Bipolar Disorder","metadata":null},{"id":"7122288be1514993a535e097ccd33e93","type":"TRIAL","name":"Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial","canonical_id":"clinicaltrials.gov:NCT00224315","description":"Schizophrenia, Schizoaffective Disorder","metadata":null},{"id":"c23cabc42edb4bf9b1d1008d211be7f4","type":"TRIAL","name":"Cluster Headache Treatment With Rimegepant","canonical_id":"clinicaltrials.gov:NCT05264714","description":"Cluster Headache","metadata":null},{"id":"5c372b9d22c1480382deccea65a0dc9b","type":"DISEASE","name":"Cluster headache syndrome","canonical_id":"mesh:D003027","description":null,"metadata":null},{"id":"32c538cbf6fa4a07b699f0eee663f4d1","type":"TRIAL","name":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092612","description":"Hypercholesterolemia; Coronary Disease","metadata":null},{"id":"1fd8a6f18396416dac3d39aff3ad08ff","type":"TRIAL","name":"Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients","canonical_id":"clinicaltrials.gov:NCT03313661","description":"Diabetes","metadata":null},{"id":"4f5b0fd3c05040be873ac55cf2f2c9b2","type":"TRIAL","name":"Co-administration of Iloprost and Eptifibatide in Septic Shock Patients","canonical_id":"clinicaltrials.gov:NCT02204852","description":"Septic Shock","metadata":null},{"id":"051ac380ec33419a93901232256e2dab","type":"TRIAL","name":"Co-administration of Olodaterol Respimat\u00ae and Tiotropium Handihaler\u00ae","canonical_id":"clinicaltrials.gov:NCT01694771","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"8981e5f91ff34616bdf853bace344bb2","type":"TRIAL","name":"Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT00652379","description":"Acromegaly; Insulin Resistance; Impaired Glucose Tolerance","metadata":null},{"id":"d7bc1d0882a14b4baba8976e2034b971","type":"GO_TERM","name":"CoA carboxylase activity","canonical_id":"go:GO:0016421","description":"\"Catalysis of the joining of a carboxyl group to a molecule that is attached to CoA, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [GOC:mah]","metadata":null},{"id":"c644b517c3ce4aa7ba4970f5f8173db6","type":"GO_TERM","name":"CoA-dependent peptidyl-lysine N6-myristoyltransferase activity","canonical_id":"go:GO:0140770","description":"\"Catalysis of the reaction: L-lysyl-[protein] + tetradecanoyl-CoA = CoA + H+ + N(6)-tetradecanoyl-L-lysyl-[protein].\" [PMID:1402651, RHEA:59752]","metadata":null},{"id":"7cf4afdcbee54d5c897446e6b05f7e0e","type":"GO_TERM","name":"CoA-dependent peptidyl-lysine N6-palmitoyltransferase activity","canonical_id":"go:GO:0140772","description":"\"Catalysis of the reaction: L-lysyl-[protein] + hexadecanoyl-CoA = CoA + H+ + N(6)-hexadecanoyl-L-lysyl-[protein].\" [PMID:30061757]","metadata":null},{"id":"9bbcd58d6b9649ecb4395e147943750f","type":"GO_TERM","name":"CoA-disulfide reductase (NADPH) activity","canonical_id":"go:GO:0050451","description":"\"Catalysis of the reaction: 2 CoA + NADP+ = CoA-disulfide + NADPH + H+.\" [RHEA:14705]","metadata":null},{"id":"193a43c255fe43c0826d3ac51b1f6095","type":"GO_TERM","name":"CoA-glutathione reductase (NADPH) activity","canonical_id":"go:GO:0050452","description":"\"Catalysis of the reaction: CoA + glutathione + NADP+ = CoA-glutathione + NADPH + H+.\" [RHEA:14617]","metadata":null},{"id":"052bd7f7ef7b414da418f205c9ddf6d1","type":"GO_TERM","name":"CoA-ligase activity","canonical_id":"go:GO:0016405","description":"\"Catalysis of the reaction: substrate + ATP + CoASH = AMP + diphosphate + substrate-CoA.\" [GOC:ai]","metadata":null},{"id":"0231120c1dc64bef81560ab7a1ae9baa","type":"GO_TERM","name":"CoA-synthesizing protein complex","canonical_id":"go:GO:1990143","description":"\"A multisubunit complex likely involved in the synthesis of coenzyme A (CoA). In S. cerevisiae, the complex consists of at least Cab2, Cab3, Cab4 and Cab5 but may also include Sis2 and Vhs3. The latter subunits are shared by the GO:0071513 phosphopantothenoylcysteine decarboxylase complex that catalyses the third step of the coenzyme A (CoA) biosynthetic pathway.\" [GOC:rb, PMID:23789928]","metadata":null},{"id":"d6915da49f7444028a24782e5c7dc02a","type":"GO_TERM","name":"CoA-transferase activity","canonical_id":"go:GO:0008410","description":"\"Catalysis of the transfer of a coenzyme A (CoA) group from one compound (donor) to another (acceptor).\" [EC:2.8.3.-]","metadata":null},{"id":"7f4342a6b0af42599c4a11e89fae79e8","type":"GO_TERM","name":"CoB--CoM heterodisulfide reductase activity","canonical_id":"go:GO:0051912","description":"\"Catalysis of the reaction: coenzyme B + coenzyme M + methanophenazine = N-{7-[(2-sulfoethyl)dithio]heptanoyl}-3-O-phospho-L-threonine + dihydromethanophenazine.\" [RHEA:18085]","metadata":null},{"id":"8ebbffe0501742c098d2d5714488600e","type":"GO_TERM","name":"CoB-CoM heterodisulfide reductase complex","canonical_id":"go:GO:0044678","description":"\"A protein complex that in Methanobacterium thermoautotrophicum is composed of six subunits, and in Methanosarcina barkeri contains is composed of either two subunits or nine subunits. Catalyzes the conversion of coenzyme B, coenzyme M, and methanophenazine to form N-{7-[(2-sulfoethyl)dithio]heptanoyl}-3-O-phospho-L-threonine and dihydromethanophenazine.\" [GOC:mengo_curators, PMID:8119281, PMID:8174566, PMID:9063468]","metadata":null},{"id":"254879d44f3242b6a228a8b2b4025054","type":"TRIAL","name":"Coadministration of GA2 Sporozoites With Adjuvants","canonical_id":"clinicaltrials.gov:NCT05468606","description":"Malaria,Falciparum","metadata":null},{"id":"ee4bd8e1520845638911eb7ba3a9a5b2","type":"PROTEIN","name":"Coagulation factor IX","canonical_id":"uniprot:P00740","description":null,"metadata":null},{"id":"71b01d6988b645d89ed5a4eb896517d0","type":"PROTEIN","name":"Coagulation factor VII","canonical_id":"uniprot:P08709","description":null,"metadata":null},{"id":"87badaa29008476e88cd2a77aed22ece","type":"DISEASE","name":"Coarctation of aorta","canonical_id":"mesh:D001017","description":null,"metadata":null},{"id":"0909a5dbc9b54fae908b857ae4d15258","type":"DISEASE","name":"Cobalamin deficiency","canonical_id":"mesh:D014806","description":null,"metadata":null},{"id":"c39783acde3246b185004586568c9b62","type":"DRUG","name":"Cobimetinib","canonical_id":"ncit:C68923","description":null,"metadata":null},{"id":"65996b1ccf90489394e64658698349c2","type":"TRIAL","name":"Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)","canonical_id":"clinicaltrials.gov:NCT05125471","description":"Arteriovenous Malformations (Extracranial)","metadata":null},{"id":"cea9cfbe9efc44d7b17100c9396b4855","type":"TRIAL","name":"Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors","canonical_id":"clinicaltrials.gov:NCT03108131","description":"Skin Squamous Cell Carcinoma; Appendix Adenocarcinoma; Rare Lesion; Locally Advanced Malignant Neoplasm; Locally Advanced Skin Squamous Cell Carcinoma; Metastatic Malignant Neoplasm; Metastatic Skin Squamous Cell Carcinoma; Metastatic Small Intestinal Adenocarcinoma; Rare Neoplastic Syndrome; Refractory Malignant Neoplasm; Stage IV Small Intestinal Adenocarcinoma AJCC v8; Unresectable Malignant Neoplasm","metadata":null},{"id":"6163f0031ec54dc2bb2415db85bf1b19","type":"TRIAL","name":"Cobimetinib for BRAF-wild-type or Mutated Histiocytoses","canonical_id":"clinicaltrials.gov:NCT04007848","description":"Disease or R Group Histiocytoses","metadata":null},{"id":"744be50707944e8da25e299c39f3783a","type":"TRIAL","name":"Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations","canonical_id":"clinicaltrials.gov:NCT04409639","description":"Chronic Myelomonocytic Leukemia (CMML)","metadata":null},{"id":"7156b7a0202949d492a2633406789f66","type":"TRIAL","name":"Cocaine Use and Outcomes of General Anesthesia","canonical_id":"clinicaltrials.gov:NCT02692534","description":"Anesthesia","metadata":null},{"id":"592149268f9c442db0ced1555ead846f","type":"TRIAL","name":"Cocaine and Zolmitriptan","canonical_id":"clinicaltrials.gov:NCT05019430","description":"Cocaine Use Disorder","metadata":null},{"id":"7b0443ed15004a23a7f532f8c4d402ef","type":"TRIAL","name":"Cocaine-Metyrapone Interaction Study - 1","canonical_id":"clinicaltrials.gov:NCT00033098","description":"Cocaine-Related Disorders; Infusions, Intravenous","metadata":null},{"id":"e2f208a3d8c24c568023d7459579203b","type":"TRIAL","name":"Cocaine/Crack and Reduction of Compulsion With Biperiden","canonical_id":"clinicaltrials.gov:NCT01251393","description":"Cocaine Dependence","metadata":null},{"id":"d2dd8123ba4e4e92965ed76961663bc7","type":"DISEASE","name":"Coccidioidomycosis","canonical_id":"mesh:D003047","description":null,"metadata":null},{"id":"e26af7129922409e9b2c82453eeac565","type":"TRIAL","name":"Codeine in Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT00174538","description":"Sickle Cell Disease","metadata":null},{"id":"49b973525516454fb78ee23b5ef8422d","type":"TRIAL","name":"Codeine on Pharyngeal and Esophageal Motility","canonical_id":"clinicaltrials.gov:NCT03784105","description":"Esophageal Motility Disorders","metadata":null},{"id":"c590624a8d87406bab7f30fe10eb94d9","type":"TRIAL","name":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT07019012","description":"T2DM","metadata":null},{"id":"9b4efb5b6daf4bc88e65cdbcafa9ed3c","type":"TRIAL","name":"Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)","canonical_id":"clinicaltrials.gov:NCT04730635","description":"Alzheimer's Disease; Mild Cognitive Impairment","metadata":null},{"id":"b3faac9a6b0947b2b6aa68e8ed054452","type":"TRIAL","name":"Cognition in the Study of Tamoxifen and Raloxifene","canonical_id":"clinicaltrials.gov:NCT00687102","description":"Cognition; Aging","metadata":null},{"id":"9343d362c2564c5f95395432005e763b","type":"TRIAL","name":"Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine","canonical_id":"clinicaltrials.gov:NCT01380288","description":"Alzheimer's Disease","metadata":null},{"id":"cbb7b0e39cc248fbae2e0dd509084360","type":"TRIAL","name":"Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over","canonical_id":"clinicaltrials.gov:NCT00170768","description":"Healthy Volunteers","metadata":null},{"id":"67129cf66758405baa0068c6fad2ea50","type":"TRIAL","name":"Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients","canonical_id":"clinicaltrials.gov:NCT04658654","description":"Mild Cognitive Impairment; Mild Dementia; Amnestic Mild Cognitive Disorder","metadata":null},{"id":"76ba91a3f9ff439eacb299cd8bc47bf3","type":"TRIAL","name":"Cognitive Effects of Treatment of Interictal Discharges","canonical_id":"clinicaltrials.gov:NCT00916149","description":"Epilepsy","metadata":null},{"id":"2a3b09eef6254d708507fdf80381e4d8","type":"TRIAL","name":"Cognitive Enhancement in Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00597896","description":"Bipolar Disorder","metadata":null},{"id":"c6310879efcd4c3ca28922b9ac420543","type":"TRIAL","name":"Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment","canonical_id":"clinicaltrials.gov:NCT00993876","description":"Cognitive Performance in Major Depression","metadata":null},{"id":"618bd345a75a47a187c75d11cda6a574","type":"TRIAL","name":"Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations","canonical_id":"clinicaltrials.gov:NCT00446420","description":"Cognitive Impairment","metadata":null},{"id":"4bb26170b87b423a802c3aa8645470b5","type":"TRIAL","name":"Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia","canonical_id":"clinicaltrials.gov:NCT02761330","description":"Depression; Delirium; Seizures; Cognitive Disorders","metadata":null},{"id":"574271cf02654c62a98402589f63e9b4","type":"TRIAL","name":"Cognitive Remediation for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01393457","description":"Cocaine Dependence","metadata":null},{"id":"f3eabbacf13749bdb43e0417b199918a","type":"TRIAL","name":"Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine","canonical_id":"clinicaltrials.gov:NCT00777218","description":"Migraine","metadata":null},{"id":"056a3777541a4c6190c70c226b688de4","type":"TRIAL","name":"Cognitive and Drug Therapy for Drug-Resistant Depression","canonical_id":"clinicaltrials.gov:NCT00000376","description":"Depression; Anxiety Disorders; Personality Disorders; Drug-resistant Depression","metadata":null},{"id":"dc3e28226c4a4f13840a54a511436524","type":"TRIAL","name":"Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00065767","description":"Alzheimer Disease","metadata":null},{"id":"676061afbec644dca6ba294a238f085a","type":"TRIAL","name":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment","canonical_id":"clinicaltrials.gov:NCT03924193","description":"Binge-Eating Disorder; Obesity","metadata":null},{"id":"4827fe1c12684ce2a0d0626e4bf19def","type":"TRIAL","name":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment","canonical_id":"clinicaltrials.gov:NCT03926052","description":"Binge-Eating Disorder; Obesity","metadata":null},{"id":"0825f8d198894565a02f695417d4289a","type":"TRIAL","name":"Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT01637935","description":"Diabetes; Bladder Cancer","metadata":null},{"id":"3fe2c9555a8b46d990a3579629c3fce0","type":"TRIAL","name":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","canonical_id":"clinicaltrials.gov:NCT02081339","description":"Macular Disease","metadata":null},{"id":"b8c65489b47d4898a03f9f243984a47f","type":"TRIAL","name":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","canonical_id":"clinicaltrials.gov:NCT02321267","description":"Macular Disease","metadata":null},{"id":"23ccc39f93504b959f1adbac45142c77","type":"TRIAL","name":"Colchicine Effect on Perivascular Inflammation Index on Coronary CTA","canonical_id":"clinicaltrials.gov:NCT05347316","description":"Atherosclerosis; Inflammatory Response; Coronary Disease","metadata":null},{"id":"4436aebb0f734374b8eb4578bd5601e6","type":"TRIAL","name":"Colchicine Plus Phenolic Monoterpenes to Treat COVID-19","canonical_id":"clinicaltrials.gov:NCT04392141","description":"COVID-19","metadata":null},{"id":"db79572135944f16ab18785a229b9037","type":"TRIAL","name":"Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT07349875","description":"Coronary Artery Disease (CAD)","metadata":null},{"id":"0a1e1198b88b40278ed4c8319b26ee2a","type":"TRIAL","name":"Colchicine and Inflammation in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT05677555","description":"End Stage Renal Disease on Dialysis","metadata":null},{"id":"ce585bf12a254537ad05e6bfa159a033","type":"TRIAL","name":"Colchicine for Diabetic Nephropathy Trial","canonical_id":"clinicaltrials.gov:NCT02442921","description":"Diabetic Nephropathies","metadata":null},{"id":"5a20290b154d4f0699b0ed476eb9b299","type":"TRIAL","name":"Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage","canonical_id":"clinicaltrials.gov:NCT07026994","description":"Cerebral Amyloid Angiopathy; Intracerebral Hemorrhage Lobar","metadata":null},{"id":"8cbdcf2d8acb44ea85adefce5fc59801","type":"TRIAL","name":"Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)","canonical_id":"clinicaltrials.gov:NCT04762771","description":"Covid19","metadata":null},{"id":"2f440c3b799d48e2a11c711d3dcae047","type":"TRIAL","name":"Colchicine for the Treatment of Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT03913442","description":"Osteoarthritis; Osteo Arthritis Knee","metadata":null},{"id":"790a9fab8c244728bf201767ebcb88b5","type":"TRIAL","name":"Colchicine in Chronic Limb-Threatening Ischemia","canonical_id":"clinicaltrials.gov:NCT07536373","description":"Chronic Limb-Threatening Ischemia","metadata":null},{"id":"31f8e417ceaf4c19913b292bd67eb3a9","type":"TRIAL","name":"Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT05726019","description":"Coronary Artery Disease; Acute Coronary Syndrome; Coronary Artery Bypass; Myocardial Reperfusion; Postpericardiotomy Syndrome; Postoperative Atrial Fibrilation; Perioperative Myocardial Infarction","metadata":null},{"id":"641ef884ccc6439a85070029a04d1b81","type":"TRIAL","name":"Colchicine in Patients With Mild and Severe Coronavirus Disease","canonical_id":"clinicaltrials.gov:NCT04367168","description":"COVID","metadata":null},{"id":"c0eade327dae4912b57702c5d055a825","type":"TRIAL","name":"Colchicine in Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT02594111","description":"Coronary Artery Disease; Acute Coronary Syndrome","metadata":null},{"id":"995d138baa42499eaa46a0ab56f81924","type":"TRIAL","name":"Cold Agglutinin Disease Real World Evidence Registry","canonical_id":"clinicaltrials.gov:NCT05791708","description":"Cold Agglutinin Disease (CAD); Cold Agglutinin Syndrome (CAS)","metadata":null},{"id":"ab839cee239e4c64a1a50b4e4132e2ed","type":"TRIAL","name":"Cold Contact Urticaria Treatment With Rilonacept","canonical_id":"clinicaltrials.gov:NCT02171416","description":"Cold Contact Urticaria","metadata":null},{"id":"e1e5f3e49a0e4efea1130709151f23d4","type":"DRUG","name":"Colecalciferol","canonical_id":"mesh:D002762","description":null,"metadata":null},{"id":"3c43559a0dd24d43b7e199e8fa5c448c","type":"DRUG","name":"Colestipol","canonical_id":"mesh:D003084","description":null,"metadata":null},{"id":"b864e740a57249b2bc503319eee586da","type":"DRUG","name":"Colfosceril palmitate","canonical_id":"mesh:C081581","description":null,"metadata":null},{"id":"4d381dd888da46f4a4eb75ef27152023","type":"DRUG","name":"Colistin","canonical_id":"mesh:D003091","description":null,"metadata":null},{"id":"b6963b9a55fc47c0990b5c3e438a4c0d","type":"TRIAL","name":"Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)","canonical_id":"clinicaltrials.gov:NCT07507188","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"60e64939934d4fe78697c5c79e8923f7","type":"DISEASE","name":"Colon Adenocarcinoma","canonical_id":"doid:234","description":null,"metadata":null},{"id":"ac2a55087c154dffb5a662d52a0fba94","type":"DISEASE","name":"Colon Cancer","canonical_id":"doid:219","description":null,"metadata":null},{"id":"5e1b23d0100a4ba9ab7d02f6e5b80229","type":"DISEASE","name":"Colon Carcinoma","canonical_id":"doid:1520","description":null,"metadata":null},{"id":"f537d63c59d842fc9cb431eb24f9cd27","type":"DISEASE","name":"Colon Mucinous Adenocarcinoma","canonical_id":"doid:3029","description":null,"metadata":null},{"id":"e90aa140738245b98e7c7f15e5166eba","type":"TRIAL","name":"Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG","canonical_id":"clinicaltrials.gov:NCT04138004","description":"Indication for Modification of Patient Status (Diagnosis)","metadata":null},{"id":"0474893149b34404b80b97846162b501","type":"TISSUE","name":"Colon Sigmoid","canonical_id":"uberon:UBERON:0001159","description":null,"metadata":null},{"id":"70dd6d016fbc474aafc6607063437841","type":"TISSUE","name":"Colon Transverse","canonical_id":"uberon:UBERON:0001157","description":null,"metadata":null},{"id":"6b086b0ec0ac44a899cf35a51fd50e52","type":"DISEASE","name":"Colonic Neoplasms","canonical_id":"mesh:D003110","description":null,"metadata":null},{"id":"ba24577ce07348f7bd6afe77ffc8b699","type":"TRIAL","name":"Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00004192","description":"Lymphoma; Neutropenia","metadata":null},{"id":"2457901c8dcf4c15bf8cc3c7aa4c773e","type":"TRIAL","name":"Color Doppler Analys\u0131s Of Uterin And Intraovarian Blood Flow Before And After Treatment W\u0131th Cabergoline In Hyperprolactinemic Patients","canonical_id":"clinicaltrials.gov:NCT01957839","description":"Adverse Reaction to Other Drugs and Medicines","metadata":null},{"id":"03d82e5b8b7844af9cb51ea53b992e31","type":"DISEASE","name":"Colorectal Adenocarcinoma","canonical_id":"doid:0050861","description":null,"metadata":null},{"id":"c4588d74be0f4725b23e43ab4289d45a","type":"DISEASE","name":"Colorectal Cancer","canonical_id":"doid:9256","description":null,"metadata":null},{"id":"8d0e4f9269ba4e65bc52ff9a77d7a1e8","type":"TRIAL","name":"Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy","canonical_id":"clinicaltrials.gov:NCT01939223","description":"Colorectal Neoplasms","metadata":null},{"id":"46c5de0361f04ee89c9cfdf67c696aa3","type":"TRIAL","name":"Colorectal Metastasis Prevention International Trial 2","canonical_id":"clinicaltrials.gov:NCT03919461","description":"Colorectal Neoplasms","metadata":null},{"id":"df61310a07c14511a5d402ad91607608","type":"TRIAL","name":"Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC","canonical_id":"clinicaltrials.gov:NCT07782242","description":"Etrasimod; Mesalazine; Ulcerative Colitis (UC); Head-to-head","metadata":null},{"id":"65576c5d681941afa6e84573f5cbb368","type":"TRIAL","name":"Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1","canonical_id":"clinicaltrials.gov:NCT07554417","description":"GLP - 1; Obesity & Overweight; Muscle Loss; Exercise Intervention; Dietary Assessment","metadata":null},{"id":"fe42284b942b4e4aa367e29b9be88dab","type":"TRIAL","name":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT03462342","description":"High Grade Serous Carcinoma","metadata":null},{"id":"5552af834b89445ca961e0e8aa64f707","type":"TRIAL","name":"Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT05696366","description":"Type 1 Diabetes","metadata":null},{"id":"5d6824f806a84f5ba540162ed60c5d03","type":"TRIAL","name":"Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)","canonical_id":"clinicaltrials.gov:NCT00061373","description":"Ischemic Stroke","metadata":null},{"id":"fef70a50303e4b87891abe3dad028f02","type":"TRIAL","name":"Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients","canonical_id":"clinicaltrials.gov:NCT00738621","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"dd6dead582f44453832e3fbaf76d8130","type":"TRIAL","name":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00613457","description":"Leukemia","metadata":null},{"id":"10d6d9e3b7c948c98f3cf2160a492574","type":"TRIAL","name":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00430118","description":"Leukemia","metadata":null},{"id":"cc2ae6171fcb42c485f71a1ad4bf69d2","type":"TRIAL","name":"Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus","canonical_id":"clinicaltrials.gov:NCT00008047","description":"Esophageal Cancer","metadata":null},{"id":"74908f933d11465ead415170b4796df2","type":"TRIAL","name":"Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00017290","description":"Lymphoma","metadata":null},{"id":"7f88498f0eb24f79be2e1003e9b666b3","type":"TRIAL","name":"Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00004056","description":"Leukemia","metadata":null},{"id":"04ebffe21c9e477ea7d6313dde2836c4","type":"TRIAL","name":"Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00002941","description":"Lymphoma","metadata":null},{"id":"1c0462d3491d4222ba2cc300939af02d","type":"TRIAL","name":"Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00002638","description":"Leukemia","metadata":null},{"id":"70ef66a8e23945f2bc9daca837aec804","type":"TRIAL","name":"Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00006747","description":"Graft Versus Host Disease; Lymphoma","metadata":null},{"id":"67b3640038454373b63d82e5c65a7d63","type":"TRIAL","name":"Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00003490","description":"Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"f5ebd6e5c7d84fecac46f94fe43e8cbe","type":"TRIAL","name":"Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00003405","description":"Leukemia","metadata":null},{"id":"6792a1a064cd445ba8b8019bda1595b7","type":"TRIAL","name":"Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations","canonical_id":"clinicaltrials.gov:NCT01206049","description":"Cholangiocarcinoma","metadata":null},{"id":"07006537b7c44ef6a07b385866a067c4","type":"TRIAL","name":"Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00003996","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"d913b8b18ea741ee9de3c85aa1e831cf","type":"TRIAL","name":"Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003728","description":"Leukemia; Lymphoma","metadata":null},{"id":"26fc1fc752a3405298711c3cb8434c60","type":"TRIAL","name":"Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors","canonical_id":"clinicaltrials.gov:NCT00002566","description":"Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor","metadata":null},{"id":"59dec295486443ed817afe101ef0c07e","type":"TRIAL","name":"Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00003084","description":"Prostate Cancer","metadata":null},{"id":"43d5b1d165574c49856c9694991fd8e8","type":"TRIAL","name":"Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03628131","description":"Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor","metadata":null},{"id":"23ef1849e8444ae1854a0089dbe75950","type":"TRIAL","name":"Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01511562","description":"Lymphoma","metadata":null},{"id":"4149772a3b4549cca765187225e5f31c","type":"TRIAL","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00002798","description":"Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts\u2026","metadata":null},{"id":"56fa41586b8d400cb649e7a39a48164c","type":"TRIAL","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00002701","description":"Leukemia","metadata":null},{"id":"442cec22e5ea44f0b31b6f8dc8e4f3eb","type":"TRIAL","name":"Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00022126","description":"Leukemia","metadata":null},{"id":"8d4cb9bfa9984352a91595732fbb32c9","type":"TRIAL","name":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00792948","description":"Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Adult L1 Acute Lymphoblastic Leukemia; Adult L2 Acute Lymphoblastic Leukemia; Adult T Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia","metadata":null},{"id":"6b8b0ca9b51442a6b9dd028a3dc04c40","type":"TRIAL","name":"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00372593","description":"Leukemia","metadata":null},{"id":"8065a144fbab4f5da10c897a7f057a44","type":"TRIAL","name":"Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00025064","description":"Lymphoma","metadata":null},{"id":"9e833b8e884440d3899fbfc414722fc8","type":"TRIAL","name":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00005584","description":"Lymphoma","metadata":null},{"id":"4d4093bb39e24963b5629d7334f612df","type":"TRIAL","name":"Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00004112","description":"Lymphoma","metadata":null},{"id":"df67578f66074e2682c8cdf68abdabe2","type":"TRIAL","name":"Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT00982592","description":"Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage IIIA Gastric Cancer; Stage IIIB Gastric Cancer; Stage IIIC Gastric Cancer; Stage IV Gastric Cancer","metadata":null},{"id":"21cd99d8db33474aabf23f404d8fd959","type":"TRIAL","name":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","canonical_id":"clinicaltrials.gov:NCT03203525","description":"Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm","metadata":null},{"id":"c74fe3ecadd0480995d90b103b635347","type":"TRIAL","name":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","canonical_id":"clinicaltrials.gov:NCT00390793","description":"Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; t(9;22)","metadata":null},{"id":"f0787ecdc427483aa37dca01dff9034b","type":"TRIAL","name":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03488225","description":"Acute Lymphoblastic Leukemia in Remission; B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","metadata":null},{"id":"d72b4b0f5e0744b2ae9b9269fc6e380a","type":"TRIAL","name":"Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT00004897","description":"Esophageal Cancer","metadata":null},{"id":"a2d1f8cafcb34dd88051626d245fb30e","type":"TRIAL","name":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT00004188","description":"Neuroblastoma","metadata":null},{"id":"82ec0cdde22744e7bba70c2ee72f3ac2","type":"TRIAL","name":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00003972","description":"Breast Cancer","metadata":null},{"id":"65f57b3bcac64deab2a0b94abb60f315","type":"TRIAL","name":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT01424982","description":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Adult Acute Lymphoblastic Leukemia in Complete Remission; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Untreated Adult Acute Lymphoblastic Leukemia","metadata":null},{"id":"572c70fe0bb54eeb877a0275a090a5db","type":"TRIAL","name":"Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01336933","description":"Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma","metadata":null},{"id":"3d5db4a896d04e94a70cabd87793530c","type":"TRIAL","name":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00006012","description":"Drug/Agent Toxicity by Tissue/Organ; Lung Cancer; Radiation Toxicity","metadata":null},{"id":"ef34c6719da040f7b4eb93d603772502","type":"TRIAL","name":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer","canonical_id":"clinicaltrials.gov:NCT00002466","description":"Kidney Cancer; Sarcoma","metadata":null},{"id":"dab39412788c48c99358c903dd57b90b","type":"TRIAL","name":"Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00049413","description":"Leukemia; Lymphoma","metadata":null},{"id":"a466e475c75e44b087d16343965574a0","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00005585","description":"Leukemia","metadata":null},{"id":"900c7b7c729d4435b835e24deba08e50","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00002812","description":"Leukemia","metadata":null},{"id":"f433ec26f9fc4e1480afc7b76f8145f7","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors","canonical_id":"clinicaltrials.gov:NCT00002463","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"55c67f0115284d35b3019c74ba9a7931","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00005596","description":"Leukemia","metadata":null},{"id":"74650e76e8594487b6817af7fb946b3e","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00002744","description":"Leukemia","metadata":null},{"id":"77c9c8095b414f96ae62adf462b56a89","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00002517","description":"Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"162df47ccf0e4739a320c30a530603b3","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003423","description":"Lymphoma","metadata":null},{"id":"55d30e7d92e84f4390303174cb4a6048","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Progressive Brain Tumors","canonical_id":"clinicaltrials.gov:NCT00002944","description":"Brain Tumors; Central Nervous System Tumors","metadata":null},{"id":"10896525d6454975ba419686efcd417b","type":"TRIAL","name":"Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00002816","description":"Leukemia","metadata":null},{"id":"5cd0983697f74c9bac0e573cd504266f","type":"TRIAL","name":"Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00002471","description":"Leukemia; Lymphoma","metadata":null},{"id":"c356cece336b446bb65d148250c002f3","type":"TRIAL","name":"Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00301925","description":"Breast Cancer","metadata":null},{"id":"2f534e6c490f49aa8a0b028309781481","type":"TRIAL","name":"Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas","canonical_id":"clinicaltrials.gov:NCT00030264","description":"Neurofibromatosis Type 1; Precancerous Condition","metadata":null},{"id":"affd6487bf444d8896d1dfee401b0618","type":"TRIAL","name":"Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00003001","description":"Colorectal Cancer","metadata":null},{"id":"337e2b4b46da4edf9b70dcee1acb4ed5","type":"TRIAL","name":"Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma","canonical_id":"clinicaltrials.gov:NCT00003346","description":"Melanoma (Skin)","metadata":null},{"id":"b8ab1a92e3864a72a5f62b77f3588d76","type":"TRIAL","name":"Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00005825","description":"Lung Cancer","metadata":null},{"id":"ea3710f512a84722b817aa7962fe0c51","type":"TRIAL","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00103285","description":"Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia","metadata":null},{"id":"f6af50d5bb7340a4b7eb14da6baa8803","type":"TRIAL","name":"Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00967057","description":"Leukemia","metadata":null},{"id":"cd05b1de10164f2091b9063b81a3d46e","type":"TRIAL","name":"Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00002785","description":"Leukemia","metadata":null},{"id":"3086c775763a4b168298cbc27755017a","type":"TRIAL","name":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT00134030","description":"Localized Osteosarcoma; Metastatic Osteosarcoma","metadata":null},{"id":"f44fb7e3150947ba8bbccbd3a6be1b51","type":"TRIAL","name":"Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003541","description":"Lymphoma","metadata":null},{"id":"b7df07d9adbb49e59320bc5e6e38569e","type":"TRIAL","name":"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors","canonical_id":"clinicaltrials.gov:NCT00335556","description":"Childhood Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Clear Cell Sarcoma of the Kidney; Papillary Renal Cell Carcinoma; Rhabdoid Tumor of the Kidney; Stage I Renal Cell Cancer; Stage I Renal Wilms Tumor; Stage II Renal Cell Cancer; Stage II Renal Wilms Tumor; Stage III Renal Cell Cancer; Stage III Renal Wilms Tumor; Stage IV Renal Cell Cancer; Stage IV Renal Wilms Tumor","metadata":null},{"id":"63d21ed993b5494cbeee6980f67b3943","type":"TRIAL","name":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02481310","description":"Adult Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma; Diffuse Large B-Cell Lymphoma; MYC Gene Mutation; Plasmablastic Lymphoma","metadata":null},{"id":"73551a1249d6462a9c5b7b8b546389d7","type":"TRIAL","name":"Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00004228","description":"Lymphoma","metadata":null},{"id":"1a077a1433554dbc8956b5a8c23f456c","type":"TRIAL","name":"Combination Daclizumab/Denileukin Diftitox to Treat Uveitis","canonical_id":"clinicaltrials.gov:NCT00326508","description":"Non-infectious Intermediate and Posterior Uveitis","metadata":null},{"id":"60f7fe85b3f64255893786721451da06","type":"TRIAL","name":"Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL","canonical_id":"clinicaltrials.gov:NCT00178841","description":"Cutaneous T-cell Lymphoma; Mycosis Fungoides; Sezary Syndrome","metadata":null},{"id":"1497f7cfd3984edc90adadfb8449062e","type":"TRIAL","name":"Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT01857921","description":"Coronary Artery","metadata":null},{"id":"4c5f95f8874c4009b515e410af5e22dc","type":"TRIAL","name":"Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00003734","description":"Prostate Cancer","metadata":null},{"id":"cf4c08f27bf641e296903e37a8c0bf6d","type":"TRIAL","name":"Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma","canonical_id":"clinicaltrials.gov:NCT04958486","description":"Fossa Ependymoma","metadata":null},{"id":"3b3df9dee5664547aa6ad08fcb538dab","type":"TRIAL","name":"Combination Letrozole and Clomiphene Citrate Versus Letrozole Alone","canonical_id":"clinicaltrials.gov:NCT06507332","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"680c5f612c3340f18adaed6a66b3027e","type":"TRIAL","name":"Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT02689284","description":"Gastric Cancer; Stomach Cancer; Esophageal Cancer","metadata":null},{"id":"fdaeb1d03d3e4c45b62f40d6d2fd5d02","type":"TRIAL","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","canonical_id":"clinicaltrials.gov:NCT04082364","description":"Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer","metadata":null},{"id":"56f91bb7816f4783878ce51cc3720323","type":"TRIAL","name":"Combination Nicotine Patch / Lorcaserin for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT02906644","description":"Nicotine Dependence","metadata":null},{"id":"d5a4e9cf7ed5413c974e92b4568018f9","type":"TRIAL","name":"Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)","canonical_id":"clinicaltrials.gov:NCT02633956","description":"Nonalcoholic Steatohepatitis","metadata":null},{"id":"6019b7a8aff746ceac28e23b88ea8308","type":"TRIAL","name":"Combination Of PAXIL Tablet And Benzodiazepines","canonical_id":"clinicaltrials.gov:NCT00259883","description":"Mental Disorders","metadata":null},{"id":"e7002b45f2b74d8e851969ae08d89f44","type":"TRIAL","name":"Combination Osilodrostat and Cabergoline in Cushing's Disease","canonical_id":"clinicaltrials.gov:NCT07603466","description":"Cushing Disease Due to Increased ACTH Secretion","metadata":null},{"id":"a38df29c107f40efa8c910a983779b08","type":"TRIAL","name":"Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00805233","description":"Age-Related Macular Degeneration","metadata":null},{"id":"6a8500f6cb554bbbaed6068f1304a8b7","type":"TRIAL","name":"Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma","canonical_id":"clinicaltrials.gov:NCT03958045","description":"Small Cell Lung Cancer","metadata":null},{"id":"c8576d6325ff4d7aa985b59bb21d91de","type":"TRIAL","name":"Combination Study for High Risk Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT03104270","description":"Multiple Myeloma","metadata":null},{"id":"da3f938d6962426f8ee66ac625f94f70","type":"TRIAL","name":"Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06876142","description":"Multiple Myeloma; Relapsed and/or Refractory Multiple Myeloma (RRMM)","metadata":null},{"id":"b8de59857b484c69897494cc7f747252","type":"TRIAL","name":"Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents","canonical_id":"clinicaltrials.gov:NCT02165475","description":"Fecal Incontinence","metadata":null},{"id":"d4c4fddb3eb1497eac068346e9ea3743","type":"TRIAL","name":"Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","canonical_id":"clinicaltrials.gov:NCT04338906","description":"COVID","metadata":null},{"id":"7a446c0acd68416aa7f5315b37102aef","type":"TRIAL","name":"Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT01621113","description":"Spinal Cord Injury","metadata":null},{"id":"14786f335e4347a9ab11956eb8b80bb8","type":"TRIAL","name":"Combination Therapy With Differin\u00ae Gel 0.3% and Duac\u00ae (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00671749","description":"Acne Vulgaris","metadata":null},{"id":"5450de215ad04fe39d762b5389d35ce1","type":"TRIAL","name":"Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna","canonical_id":"clinicaltrials.gov:NCT00707174","description":"Cancer; Lentigo Maligna","metadata":null},{"id":"175cd18c3c304e46a256eef7eebea4d4","type":"TRIAL","name":"Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT01155284","description":"Type 1 Diabetes","metadata":null},{"id":"0006641e81b44902a72fff9be74d95df","type":"TRIAL","name":"Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07209163","description":"Peripheral T Cell Lymphoma","metadata":null},{"id":"5539c04082ec40e58d6825fde06ffff9","type":"TRIAL","name":"Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT06134193","description":"Carcinoma; Intrahepatic Cholangiocarcinoma; Gallbladder Cancer; Surufatinib; Angiogenesis Inhibitors; Tislelizumab; Antineoplastic Agents, Immunological; Immunotherapy","metadata":null},{"id":"ad32d18b07074ba1b8edae405afebeeb","type":"TRIAL","name":"Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients","canonical_id":"clinicaltrials.gov:NCT01440582","description":"Myeloma","metadata":null},{"id":"1ceaedf2d125400e8be7d9f8374fdfa8","type":"TRIAL","name":"Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents","canonical_id":"clinicaltrials.gov:NCT07854561","description":"Anemia Associated With Chronic Kidney Disease","metadata":null},{"id":"df94bf286a0c4609b172ac67dda4c73f","type":"TRIAL","name":"Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study","canonical_id":"clinicaltrials.gov:NCT07177326","description":"Erectile Dysfunction","metadata":null},{"id":"9db9f8afe61a49afad931620d6da23e1","type":"TRIAL","name":"Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat","canonical_id":"clinicaltrials.gov:NCT01510769","description":"Tophaceous Gout","metadata":null},{"id":"797cd55f46f44d7abe3aaec9a6b5c996","type":"TRIAL","name":"Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome","canonical_id":"clinicaltrials.gov:NCT00303004","description":"Eisenmenger Syndrome","metadata":null},{"id":"24e723d1376c4e7b95ff60ece4c87ca5","type":"TRIAL","name":"Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)","canonical_id":"clinicaltrials.gov:NCT00922506","description":"Overactive Bladder; Benign Prostatic Hyperplasia","metadata":null},{"id":"275980baf4044c7ebecccd2cc55a75a3","type":"TRIAL","name":"Combination Weekly Taxotere\u2122 With Iressa\u2122 /Placebo in Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00319618","description":"Metastatic Breast Cancer","metadata":null},{"id":"d4c7c7ec825b4714a420d3df571e4ff1","type":"TRIAL","name":"Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus","canonical_id":"clinicaltrials.gov:NCT03103022","description":"Patent Ductus Arteriosus; Neonate","metadata":null},{"id":"9de1f084417c41be8fc0d81a13666c6b","type":"TRIAL","name":"Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas","canonical_id":"clinicaltrials.gov:NCT03631953","description":"Meningioma","metadata":null},{"id":"43e569607fbd484cb1fc36c13e4137e6","type":"TRIAL","name":"Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression","canonical_id":"clinicaltrials.gov:NCT01436643","description":"Depression; Relapsing-remitting Multiple Sclerosis","metadata":null},{"id":"acc5592fddd6407aa3ee4d9bd58f97a4","type":"TRIAL","name":"Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00367094","description":"Hypertension","metadata":null},{"id":"f603e5701ac342838a6d5e658ae50a57","type":"TRIAL","name":"Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT07443956","description":"Psoriatic Arthritis (PsA); Obesity & Overweight","metadata":null},{"id":"a5cbcd7789644f4eb512e6d1cefc58c7","type":"TRIAL","name":"Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05135845","description":"Oesophageal Adenocarcinoma; Gastric Adenocarcinoma","metadata":null},{"id":"1299ec166ebe48a68bcb42448e9b2726","type":"TRIAL","name":"Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03032614","description":"Breast Cancer Stage IV; Ovarian Cancer; BRCA1 Mutation; BRCA2 Mutation","metadata":null},{"id":"3ba7ea328ae84a758fc7ad966a1ce8d1","type":"TRIAL","name":"Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock","canonical_id":"clinicaltrials.gov:NCT00320099","description":"Septic Shock","metadata":null},{"id":"d6877ca47ee645da97591ec50e1c7f5e","type":"TRIAL","name":"Combination of Danazole With Berberine in the Treatment of ITP","canonical_id":"clinicaltrials.gov:NCT03909763","description":"Corticosteroid-resistant or Relapsed ITP","metadata":null},{"id":"78870a4ece1b4ae0bbc54fe5373d0360","type":"TRIAL","name":"Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01130662","description":"Acute Myeloid Leukemia","metadata":null},{"id":"aa737334c4df42718c74304be1469aee","type":"TRIAL","name":"Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)","canonical_id":"clinicaltrials.gov:NCT05524857","description":"Myeloproliferative Neoplasm","metadata":null},{"id":"6902223c29ba4f2b815b0802a65fae24","type":"TRIAL","name":"Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03360734","description":"Solid Tumor, Adult","metadata":null},{"id":"0dd2bc3c4e854af0aca4deb59d2bf959","type":"TRIAL","name":"Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly","canonical_id":"clinicaltrials.gov:NCT06168773","description":"Delirium in Old Age","metadata":null},{"id":"4cad1bc6fa3e4a2f9abde9b617b8db10","type":"TRIAL","name":"Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02356458","description":"Mantle Cell Lymphoma","metadata":null},{"id":"d203f1a72dcf41aa8b9d3ad27459aeb5","type":"TRIAL","name":"Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02278458","description":"Pancreatic Cancer","metadata":null},{"id":"4620885941074f449991a737c921a591","type":"TRIAL","name":"Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02024633","description":"Pancreatic Cancer","metadata":null},{"id":"81c1a62f5e0f4e97b9febf41e982cafb","type":"TRIAL","name":"Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET","canonical_id":"clinicaltrials.gov:NCT02231762","description":"Gastroenteropancreatic Neuroendocrine Tumors","metadata":null},{"id":"f8328368885f406190b019b5d350611a","type":"TRIAL","name":"Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","canonical_id":"clinicaltrials.gov:NCT04385290","description":"Acute Myeloid Leukemia","metadata":null},{"id":"3fc119babe5c4e748bee0afe3f2fb072","type":"TRIAL","name":"Combination of Nalbuphine and Dexmedetomidine Versus Sufentanil and Dexmedetomidine on Patients","canonical_id":"clinicaltrials.gov:NCT05445024","description":"Laparoscopic; Gastrointestinal Surgery","metadata":null},{"id":"7e51ab3dae044c26ac2b90d9ff856f07","type":"TRIAL","name":"Combination of Netupitant and Palonosetron (Akynzeo\u00ae) in the Treatment of Refractory CINV","canonical_id":"clinicaltrials.gov:NCT03008213","description":"Chemotherapy Induced Nausea Vomiting","metadata":null},{"id":"9d1982be384d40eab04766cdc97e722f","type":"TRIAL","name":"Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma","canonical_id":"clinicaltrials.gov:NCT01352312","description":"Chronic Lymphocytic Leukemia; B-Cell Non-Hodgkin's Lymphoma","metadata":null},{"id":"5c2f5ffe2d1d46c5b52635a3b9302862","type":"TRIAL","name":"Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC","canonical_id":"clinicaltrials.gov:NCT02947113","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"5c6c11e162834f58a08589d7ffa02d55","type":"TRIAL","name":"Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD","canonical_id":"clinicaltrials.gov:NCT03135054","description":"AML; FLT3-ITD Mutation","metadata":null},{"id":"cc4f81accd874a7aab443d4b00d25dab","type":"TRIAL","name":"Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone","canonical_id":"clinicaltrials.gov:NCT01998217","description":"Pancreatic Stone Disease","metadata":null},{"id":"58e4c84f356f4ebe9a06471376c90f19","type":"TRIAL","name":"Combination of Sotyktu and Enstilar for Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06329258","description":"Psoriasis","metadata":null},{"id":"5ce3877e943345238ec73b4ffd5c9a2c","type":"TRIAL","name":"Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT02059772","description":"Diabetic Macular Edema","metadata":null},{"id":"4e6378411a1e4f60b5ef8b70577703d7","type":"TRIAL","name":"Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined","canonical_id":"clinicaltrials.gov:NCT06414681","description":"Myelofibrosis\uff0cMF","metadata":null},{"id":"986bcd36259d4971a2f9a733019fa819","type":"TRIAL","name":"Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT00316095","description":"Hypertension; Dyslipidemias","metadata":null},{"id":"2881c6eb1bac4eab8df4f92b7f3dee6c","type":"TRIAL","name":"Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01423123","description":"Breast Cancer","metadata":null},{"id":"7bd25115b6ce41a781a648aabf0ef820","type":"TRIAL","name":"Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy","canonical_id":"clinicaltrials.gov:NCT00723918","description":"HIV-associated Neuropathy; Polyneuropathy","metadata":null},{"id":"2d993472c72f4673bd8387b2bbe1fdd7","type":"TRIAL","name":"Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01799161","description":"Non-Small Cell Lung Cancer; Non-small-cell Lung Carcinoma; Lung Cancer; NSCLC","metadata":null},{"id":"5299147552a64c479d6a8b06dec7498c","type":"TRIAL","name":"Combinations of Pharmacologic Smoking Cessation Treatments","canonical_id":"clinicaltrials.gov:NCT00018187","description":"Smoking","metadata":null},{"id":"8f6406ed8800412aaa5e7db76dd52209","type":"TRIAL","name":"Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding","canonical_id":"clinicaltrials.gov:NCT01597531","description":"Type 2 Diabetes; Gastric Banding","metadata":null},{"id":"0af7b9cd2ef24c789f57194a312e09fd","type":"TRIAL","name":"Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT03644823","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"7e5f24cd04e14c85938f2413d9c3ebbf","type":"TRIAL","name":"Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01535027","description":"Osteoporosis","metadata":null},{"id":"e0eb265bd79644faaef1d0251527ab18","type":"TRIAL","name":"Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT07062354","description":"Head &Amp; Neck Cancer; Head &Amp; Neck Squamous Cell Carcinoma","metadata":null},{"id":"c8627aaca22c4e0ab653bf5e53a259cb","type":"TRIAL","name":"Combined Anabolic Therapy","canonical_id":"clinicaltrials.gov:NCT06558188","description":"Osteoporosis, Postmenopausal; Osteoporosis","metadata":null},{"id":"a6a9f46d4b3b4f21bb14cb9d0a2eb348","type":"TRIAL","name":"Combined Analgesia to Control Pain in Children Seen in Emergency Department (ED) for a Trauma of a Limb","canonical_id":"clinicaltrials.gov:NCT01189773","description":"Trauma","metadata":null},{"id":"091f1c7da16a4fbb8969494133a1d804","type":"TRIAL","name":"Combined Behavioral and Drug Treatment of Overactive Bladder in Men","canonical_id":"clinicaltrials.gov:NCT01175382","description":"Overactive Bladder; Lower Urinary Tract Symptoms","metadata":null},{"id":"dd237cb88ab64838b338edcaf06d1854","type":"TRIAL","name":"Combined Behavioral/Pharmacological Therapy for Insomnia","canonical_id":"clinicaltrials.gov:NCT00044629","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"38db24c2984e4a008c2a44cf13c29fbc","type":"TRIAL","name":"Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT00470223","description":"Sarcoma","metadata":null},{"id":"41d0815a576d4cb089e38df23f5b0ebf","type":"TRIAL","name":"Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children","canonical_id":"clinicaltrials.gov:NCT07064278","description":"Refractory Mycoplasma Pneumoniae Pneumonia","metadata":null},{"id":"23eae0dae8844437a5fa2bfa196daf75","type":"TRIAL","name":"Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior","canonical_id":"clinicaltrials.gov:NCT01495195","description":"Cocaine Use Disorders","metadata":null},{"id":"22cf4cddcaa941ad9be8937e668a64ad","type":"TRIAL","name":"Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease","canonical_id":"clinicaltrials.gov:NCT00200174","description":"Breast Cancer","metadata":null},{"id":"2b40e72337cd46fd80500d01b7f0ef47","type":"TRIAL","name":"Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT06642181","description":"Mindfulness; Guanfacine; Opioid Use Disorder","metadata":null},{"id":"7f71d9a0699c4741a56760068957630d","type":"TRIAL","name":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05713994","description":"Hepatocellular Carcinoma Non-resectable","metadata":null},{"id":"5aaf9b2a4d634cd69079966276c5060e","type":"TRIAL","name":"Combined IV and Topical TXA in Major Spine Surgery","canonical_id":"clinicaltrials.gov:NCT04797156","description":"Spine Surgery; Back Pain","metadata":null},{"id":"741a609d3cf04e20bc6a28fd776a9c17","type":"TRIAL","name":"Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)","canonical_id":"clinicaltrials.gov:NCT01186640","description":"T-cell-prolymphocytic Leukemia","metadata":null},{"id":"97b0c7c4179a4da79def0f8c75b43611","type":"TRIAL","name":"Combined Immunosuppression for Pediatric Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT05043870","description":"Crohn Disease; Infliximab; Immunosuppression; Children, Only","metadata":null},{"id":"9a120b8e342f45109dbd9bbcb1a2b294","type":"TRIAL","name":"Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT04152356","description":"HepatoCellular Carcinoma","metadata":null},{"id":"ae05b5d575cd43cbb8416ad52a8402cc","type":"TRIAL","name":"Combined Intravenous Tramadol and Paracetamol Versus Intramuscular Pethidine for Pain Relief During the First Stage of Labor. Compare the Efficacy and Adverse Effects","canonical_id":"clinicaltrials.gov:NCT07264309","description":"Pain Management; Birth","metadata":null},{"id":"cd5d55084594491eb280443b699e010e","type":"TRIAL","name":"Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT01823081","description":"Diabetic Macular Edema","metadata":null},{"id":"a7d1c4fb8f1743fda86d3565973ace1b","type":"TRIAL","name":"Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients","canonical_id":"clinicaltrials.gov:NCT03391219","description":"Retinal Vein Occlusion","metadata":null},{"id":"6deab47080c84b329d5965a8db708f73","type":"TRIAL","name":"Combined Ketamine/Propofol for Emergency Department Procedural Sedation","canonical_id":"clinicaltrials.gov:NCT01126957","description":"Procedural Sedation and Analgesia","metadata":null},{"id":"517d30f1d6cc4543b71d9a40dce11936","type":"TRIAL","name":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","canonical_id":"clinicaltrials.gov:NCT05702879","description":"Ulcerative Colitis","metadata":null},{"id":"562547d6a6f04479ae6b898f9a143822","type":"TRIAL","name":"Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial","canonical_id":"clinicaltrials.gov:NCT01178671","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"527a2e37b7d24ec9aebd7eb173367775","type":"TRIAL","name":"Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","canonical_id":"clinicaltrials.gov:NCT00324415","description":"Anal Cancer","metadata":null},{"id":"5885191f8d4b43d79251a95b2db68539","type":"TRIAL","name":"Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)","canonical_id":"clinicaltrials.gov:NCT02045667","description":"Non Dystrophic Myotonia","metadata":null},{"id":"d16855289d22446a80f885ba173e451e","type":"TRIAL","name":"Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC","canonical_id":"clinicaltrials.gov:NCT03274804","description":"Metastatic Colorectal Cancer; MSS","metadata":null},{"id":"2158be98a0de4954843730779507e816","type":"TRIAL","name":"Combined Pharmacotherapies for Alcoholism","canonical_id":"clinicaltrials.gov:NCT00768508","description":"Alcoholism","metadata":null},{"id":"c018837f272d4c799536992343f52c27","type":"TRIAL","name":"Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks","canonical_id":"clinicaltrials.gov:NCT00667472","description":"Port-Wine Stain","metadata":null},{"id":"ed274409b6764dd2ac55caa8c38d6395","type":"TRIAL","name":"Combined Renin Inhibition/Beta-blockade","canonical_id":"clinicaltrials.gov:NCT00627861","description":"Hypertension","metadata":null},{"id":"b591fd943bbb4eed97bcd11df7c3a7a8","type":"TRIAL","name":"Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo","canonical_id":"clinicaltrials.gov:NCT03123016","description":"Vitiligo","metadata":null},{"id":"378a277759f449e7b1e8d267a7d80207","type":"TRIAL","name":"Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT01614509","description":"Branch Retinal Vein Occlusion","metadata":null},{"id":"691f1f5a0b9444719b43447f906cb221","type":"TRIAL","name":"Combined Treatment for Alcohol-Dependent Individuals With PTSD","canonical_id":"clinicaltrials.gov:NCT00262223","description":"Stress Disorders, Post-Traumatic; Alcohol Abuse; Substance-Related Disorders","metadata":null},{"id":"f00e17ae960f45b5935baf344e330f9f","type":"TRIAL","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","canonical_id":"clinicaltrials.gov:NCT03937830","description":"Hepatocellular Cancer; Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma","metadata":null},{"id":"c0152ea5738e475d87c7d21499f6d490","type":"TRIAL","name":"Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression","canonical_id":"clinicaltrials.gov:NCT03765138","description":"PTSD; MDD","metadata":null},{"id":"7e47e11b6e064719b751031fd11dcba7","type":"TRIAL","name":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","canonical_id":"clinicaltrials.gov:NCT01404949","description":"Acute Promyelocytic Leukemia","metadata":null},{"id":"c227ea2deacf4910a3ad166df25187d3","type":"TRIAL","name":"Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02618356","description":"Metastatic Colon Cancer","metadata":null},{"id":"ce8013ce773141f89bc4477b42abf5fe","type":"TRIAL","name":"Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00046137","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"29bfaf88fb3b4b9b90d3b6df0dae8b8a","type":"TRIAL","name":"Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.","canonical_id":"clinicaltrials.gov:NCT03919266","description":"Acute Chest Syndrome; Sickle Cell Disease","metadata":null},{"id":"57862bcccfce4f79b32450bd05a095d6","type":"TRIAL","name":"Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study","canonical_id":"clinicaltrials.gov:NCT00676559","description":"Diabetic Macular Edema","metadata":null},{"id":"c38176ed3a074c0d9823b55088c1190a","type":"DISEASE","name":"Combined hyperlipidemia","canonical_id":"orphanet:79211","description":null,"metadata":null},{"id":"8443bf744b1647a89a28fa3f1768ba99","type":"TRIAL","name":"Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00707070","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"038a253b834944da921b0f4ee2eb2723","type":"TRIAL","name":"Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA","canonical_id":"clinicaltrials.gov:NCT06591351","description":"Ischemic Stroke","metadata":null},{"id":"259e2c209f3f40b0983b31d438155d8b","type":"TRIAL","name":"Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA","canonical_id":"clinicaltrials.gov:NCT06591299","description":"Ischemic Stroke","metadata":null},{"id":"d565ad8f58d94ed2b4452562596b2aa8","type":"TRIAL","name":"Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity","canonical_id":"clinicaltrials.gov:NCT06315972","description":"Schizophrenia","metadata":null},{"id":"82620cc4349e4d8b80f38ddbaec55944","type":"TRIAL","name":"Combining Data Sources to Identify Effect Moderation for Personalized Mental Health","canonical_id":"clinicaltrials.gov:NCT05267873","description":"Depressive Disorder, Major","metadata":null},{"id":"b3a0f8f4e36749488e04de449859a702","type":"TRIAL","name":"Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia","canonical_id":"clinicaltrials.gov:NCT03109314","description":"Amblyopia","metadata":null},{"id":"ba37433f5310469baed418671c591399","type":"TRIAL","name":"Combining Epigenetic And Immune Therapy to Beat Cancer.","canonical_id":"clinicaltrials.gov:NCT04705818","description":"Advanced Solid Tumor; Advanced Colorectal Carcinoma; Advanced Soft-tissue Sarcoma; Advanced Pancreatic Adenocarcinoma; Adult Solid Tumor","metadata":null},{"id":"68653d1c77ed4af6afa567ba0b039aa6","type":"TRIAL","name":"Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00260364","description":"Pancreatic Cancer","metadata":null},{"id":"18c7e1be3456434d86860a5cae101e8c","type":"TRIAL","name":"Combining ICI With SBRT or HypoFrx-RT for ES NSCLC","canonical_id":"clinicaltrials.gov:NCT05451173","description":"Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III","metadata":null},{"id":"b4fe76c2faf64ca6b7d125e79097ee72","type":"TRIAL","name":"Combining Lesinurad With Allopurinol in Inadequate Responders","canonical_id":"clinicaltrials.gov:NCT01493531","description":"Gout","metadata":null},{"id":"e1624062489a41c78ed2a4ffc65fde19","type":"TRIAL","name":"Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study","canonical_id":"clinicaltrials.gov:NCT00769158","description":"Alcoholism","metadata":null},{"id":"112384c87ee546a2a6ca4abe664eb780","type":"TRIAL","name":"Combining Medications to Enhance Depression Outcomes","canonical_id":"clinicaltrials.gov:NCT00590863","description":"Major Depressive Disorder","metadata":null},{"id":"252817e8d7c04a80bdf53aef366db481","type":"TRIAL","name":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05694936","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"98052235fc3e438491001014fd3af082","type":"TRIAL","name":"Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT03088176","description":"Melanoma; BRAF Gene Mutation","metadata":null},{"id":"fde9adeeaff943738b59d24824fd60d3","type":"TRIAL","name":"Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT05838599","description":"Mycosis Fungoides","metadata":null},{"id":"27d3c3922c8c449abedfb1798e10e927","type":"TRIAL","name":"Combining Varenicline and Guanfacine for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT04198116","description":"Smoking Cessation","metadata":null},{"id":"af6adcee35d5470ca59ba98c489090ed","type":"TRIAL","name":"Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00467766","description":"Alzheimer Disease; Caregivers","metadata":null},{"id":"2ac737fc449b4aa193b625705d35ccdd","type":"TRIAL","name":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","canonical_id":"clinicaltrials.gov:NCT06463457","description":"Prostate Cancer; Advanced Prostate Cancer; Hormone Sensitive Prostate Cancer","metadata":null},{"id":"00d7496a5ed947c7ae71c7f9a2666db8","type":"DISEASE","name":"Common cold","canonical_id":"mesh:D003139","description":null,"metadata":null},{"id":"ddf28e9ea0224ff99776f58a6bbef8a8","type":"TRIAL","name":"Community Based Trial for AMEVIVE\u00ae","canonical_id":"clinicaltrials.gov:NCT00168753","description":"Moderate to Severe Chronic Plaque Psoriasis","metadata":null},{"id":"1929ed47e4844902ba90b991742a0e89","type":"TRIAL","name":"Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00866996","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"aa4aa464068c43968aa5facd26671d52","type":"TRIAL","name":"Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery","canonical_id":"clinicaltrials.gov:NCT01444612","description":"Thrombosis, Venous","metadata":null},{"id":"24f255b4d1ce4cbb89a2dc1eb8b74a79","type":"TRIAL","name":"Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.","canonical_id":"clinicaltrials.gov:NCT04609748","description":"Temporomandibular Joint Disorders; Temporomandibular Joint Dysfunction Syndrome; Temporomandibular Joint Pain","metadata":null},{"id":"0d740da5c2b24c87a7f2a2691be5b9e2","type":"TRIAL","name":"Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital","canonical_id":"clinicaltrials.gov:NCT05706727","description":"Hemodynamic Stability","metadata":null},{"id":"482c89966ed24bd397053b3b1fe26265","type":"TRIAL","name":"Comparative Antiresorptive Efficacy Discontinuation of Denosumab","canonical_id":"clinicaltrials.gov:NCT03623633","description":"Osteoporosis, Postmenopausal; Osteoporosis","metadata":null},{"id":"8514464450db41c0b63f279fcd513d82","type":"TRIAL","name":"Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination","canonical_id":"clinicaltrials.gov:NCT05533073","description":"Healthy","metadata":null},{"id":"9d0d79032a5f479cbcd6bd055d80ab5a","type":"TRIAL","name":"Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State","canonical_id":"clinicaltrials.gov:NCT00647738","description":"Healthy","metadata":null},{"id":"6174d22352c74cd2b6a3302934a24995","type":"TRIAL","name":"Comparative Bioavailability Study of Codeine Sulfate","canonical_id":"clinicaltrials.gov:NCT01010152","description":"Pain","metadata":null},{"id":"e13062b100de4e479eeb55f96552c586","type":"TRIAL","name":"Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT00839072","description":"Healthy","metadata":null},{"id":"181d2a85f6084b698b924d1489b320e6","type":"TRIAL","name":"Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex\u00ae in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02954276","description":"Migraine","metadata":null},{"id":"1089505983634371943af8eb3ec42618","type":"TRIAL","name":"Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT05549583","description":"Bioequivalence; Type 2 Diabetes","metadata":null},{"id":"4318a2bd8b7c4d8ea9b60f5177b6e938","type":"TRIAL","name":"Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01121913","description":"Healthy","metadata":null},{"id":"c73a8d0a7660434eb3d0dba4457dcc70","type":"TRIAL","name":"Comparative Bioavailability of Risperidone","canonical_id":"clinicaltrials.gov:NCT03527186","description":"Schizophrenia","metadata":null},{"id":"45ef3eedb80948d8b492c947b68c5f54","type":"TRIAL","name":"Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","canonical_id":"clinicaltrials.gov:NCT06252441","description":"Post ERCP Pancreatitis","metadata":null},{"id":"b314a5e1d6de4a15b72f74506f99b9ac","type":"TRIAL","name":"Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT06995339","description":"Gout","metadata":null},{"id":"4421ab26a0804a65bfeb9b18ec77e42e","type":"TRIAL","name":"Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT02478047","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"48ab426538564243bab9c0a0906939a5","type":"TRIAL","name":"Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne","canonical_id":"clinicaltrials.gov:NCT04582383","description":"Acne","metadata":null},{"id":"3c2b2558960442b382b4a0f88ffc62cd","type":"TRIAL","name":"Comparative Effectiveness of COPD Treatments","canonical_id":"clinicaltrials.gov:NCT03376295","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"312f3cfe594f46c8bf4a912d097b64a8","type":"TRIAL","name":"Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls","canonical_id":"clinicaltrials.gov:NCT05880862","description":"Urinary Bladder, Overactive; Urinary Incontinence; Accidental Falls","metadata":null},{"id":"21c030ceac2b4b6c876b24367d4f6be6","type":"TRIAL","name":"Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype","canonical_id":"clinicaltrials.gov:NCT07795086","description":"Chronic Obstructive Pulmonary Disease With Exacerbation","metadata":null},{"id":"22bd5ba1364f4e01b734a01f8397904f","type":"TRIAL","name":"Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US","canonical_id":"clinicaltrials.gov:NCT05260684","description":"Melanoma","metadata":null},{"id":"203080e3b4a44b32bdeb99aec68d8cbf","type":"TRIAL","name":"Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT06914141","description":"Diabetes Mellitus, Type 2; HFpEF - Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"560aca6285e44ec997283927f3e617ff","type":"TRIAL","name":"Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.","canonical_id":"clinicaltrials.gov:NCT04254042","description":"Hypertension","metadata":null},{"id":"59bf041e40e14e0591f9aa8a21d82230","type":"TRIAL","name":"Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance","canonical_id":"clinicaltrials.gov:NCT00162786","description":"Healthy","metadata":null},{"id":"287d379b2a7e4f508f46a23bc3b16df9","type":"TRIAL","name":"Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT01257386","description":"Active Ulcerative Colitis","metadata":null},{"id":"5e53823731c24c4380a8227057b7f3d0","type":"TRIAL","name":"Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT07199088","description":"Acute Decompensated Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic","metadata":null},{"id":"acc15d7a334c48f08de77ad1a850af47","type":"TRIAL","name":"Comparative Efficacy of 4 Oral Analgesics","canonical_id":"clinicaltrials.gov:NCT02455518","description":"Pain","metadata":null},{"id":"e37e39174e2842a2995c0d3f47bc2dc6","type":"TRIAL","name":"Comparative Efficacy of IV Dexamethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED","canonical_id":"clinicaltrials.gov:NCT06980727","description":"Renal Colic","metadata":null},{"id":"423e869b7bec478991b6e36a7266976d","type":"TRIAL","name":"Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT07217587","description":"Myasthenia Gravis","metadata":null},{"id":"7d397165f8884e1bb7d80f124f270a37","type":"TRIAL","name":"Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD","canonical_id":"clinicaltrials.gov:NCT07541378","description":"COPD (Chronic Obstructive Pulmonary Disease)","metadata":null},{"id":"5b90408507e148ddbbb3f3d030b2cd2d","type":"TRIAL","name":"Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia","canonical_id":"clinicaltrials.gov:NCT06969417","description":"Herpes Zoster (HZ); Post Herpetic Neuralgia (PHN)","metadata":null},{"id":"0e48da921518421ba46a8e889e64af8a","type":"TRIAL","name":"Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel","canonical_id":"clinicaltrials.gov:NCT04079374","description":"Rheumatoid Arthritis","metadata":null},{"id":"b5ec38369d8f40b8bbc215156778470a","type":"TRIAL","name":"Comparative Efficacy, Safety, PK, and Immunogenicity Study","canonical_id":"clinicaltrials.gov:NCT05853354","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"5ba2be80e843479ba7a39528dea31450","type":"TRIAL","name":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","canonical_id":"clinicaltrials.gov:NCT00506415","description":"Alzheimer Disease","metadata":null},{"id":"a50f7376f023442180738445b861214b","type":"TRIAL","name":"Comparative Evaluation of Diclofenac Sodium and Ibuprofen for Post-Endodontic Pain Management","canonical_id":"clinicaltrials.gov:NCT07565012","description":"Irreversible Pulpitis; Post-endodontic Pain; Root Canal Treatment","metadata":null},{"id":"d528511c02104ebd8ee92aad81f8c7a1","type":"TRIAL","name":"Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I","canonical_id":"clinicaltrials.gov:NCT02981784","description":"Leukemia","metadata":null},{"id":"ba559f0d488845dab6e239f0c6d3c3fd","type":"TRIAL","name":"Comparative Evaluation of Transdermal and Oral Drugs for Management of Post-Endodontic Pain","canonical_id":"clinicaltrials.gov:NCT07610265","description":"Post Endodontic Pain","metadata":null},{"id":"a3b747a1ea4c4e18b714d2422d921057","type":"TRIAL","name":"Comparative Evaluation of the Effect of Prophylactic Intraligamentary Injection of Dexamethasone and Piroxicam on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis","canonical_id":"clinicaltrials.gov:NCT03745105","description":"Postoperative Pain","metadata":null},{"id":"6534c2a26d4944518d29ae13a626c58b","type":"TRIAL","name":"Comparative Evaluation of the Effectiveness of Diclofenac Sodium Versus Vitamin D on Myofascial Pain","canonical_id":"clinicaltrials.gov:NCT06111573","description":"Myofascial Pain Dysfunction Syndrome,Temporomandibular Joint","metadata":null},{"id":"0b2067e3783642c09c7dbde3d482fedf","type":"TRIAL","name":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","canonical_id":"clinicaltrials.gov:NCT03845049","description":"Macular Telangiectasia","metadata":null},{"id":"59a6a4b738804d35960ac46cddcac416","type":"TRIAL","name":"Comparative Pharmacokinetic Study of Aprepitant Injection in Humans","canonical_id":"clinicaltrials.gov:NCT06226506","description":"Healthy","metadata":null},{"id":"70fec3b581c8423d96feedfbf338639c","type":"TRIAL","name":"Comparative Pharmacokinetic Study of Ramelteon Modified-Release Tablets and Ramelteon Tablets in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06890715","description":"Chronic Insomnia Characterized","metadata":null},{"id":"a24e3f63ea6b468b840604b459830311","type":"TRIAL","name":"Comparative Pharmacokinetic Trial of RGB-03 and MabThera","canonical_id":"clinicaltrials.gov:NCT02371096","description":"Rheumatoid Arthritis","metadata":null},{"id":"27797f1bb94646b79804343f21a03ef4","type":"TRIAL","name":"Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04439929","description":"Healthy Participants","metadata":null},{"id":"241ae62404b746b0893e62621984659e","type":"TRIAL","name":"Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03010631","description":"Healthy Volunteers","metadata":null},{"id":"557824734a934cc19a51a3a71a424725","type":"TRIAL","name":"Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02525549","description":"Acne","metadata":null},{"id":"85968835afc44e1eb08b9b8ee89e5c06","type":"TRIAL","name":"Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT05574036","description":"Non Alcoholic Steatohepatitis; Hyperuricemia","metadata":null},{"id":"729fc85531424c67994c28a819a21d20","type":"TRIAL","name":"Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS","canonical_id":"clinicaltrials.gov:NCT06793904","description":"Polycystic Ovarian Syndrome (PCOS)","metadata":null},{"id":"17138a5832614fc58cc91b629bb78cb4","type":"TRIAL","name":"Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis","canonical_id":"clinicaltrials.gov:NCT05573204","description":"Non-alcoholic Steatohepatitis","metadata":null},{"id":"944300b7720c48b6a5ad2f3547875164","type":"TRIAL","name":"Comparative Study Between the Effect of Diclofanic and Ketorolac in Post Tonsillectomy Pain Management","canonical_id":"clinicaltrials.gov:NCT03178539","description":"Pain, Acute","metadata":null},{"id":"04f788dcf36b4156bb4f89db8eacfaff","type":"TRIAL","name":"Comparative Study Between the Efficacy of Verapamil and Bisoprolol on Reduction of Bleeding During Endoscopic Sinus Surgery Under General Anaesthesia.","canonical_id":"clinicaltrials.gov:NCT04356196","description":"Endoscopic Sinus Surgery; Heart Rate; Blood Loss","metadata":null},{"id":"e1ec77933dfe450ab384774f0c9bcbf9","type":"TRIAL","name":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","canonical_id":"clinicaltrials.gov:NCT00930189","description":"Subfoveal Choroidal Neovascularization","metadata":null},{"id":"b686a539de354177b0e88397a5b16173","type":"TRIAL","name":"Comparative Study for Medical Therapy for Lower Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT06707181","description":"Lower Ureteral Stones","metadata":null},{"id":"872cfee189b941b8b3be0b65c280c663","type":"TRIAL","name":"Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.","canonical_id":"clinicaltrials.gov:NCT02346578","description":"Castration-resistant Prostate Cancer","metadata":null},{"id":"e39724b7e1424239b3aa557ff3361817","type":"TRIAL","name":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis","canonical_id":"clinicaltrials.gov:NCT02305823","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"cf8233abcbd9429ba670b1d5d21ee989","type":"TRIAL","name":"Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients","canonical_id":"clinicaltrials.gov:NCT04873284","description":"Chemotherapy Induced Nausea and Vomiting; Pediatric Cancer Patients","metadata":null},{"id":"6eb1fa419a3e4cd6a5a8d154e0039fa9","type":"TRIAL","name":"Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine","canonical_id":"clinicaltrials.gov:NCT06265415","description":"Severe Preeclampsia","metadata":null},{"id":"237aad8217cd41fc859439f30fd310b7","type":"TRIAL","name":"Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy","canonical_id":"clinicaltrials.gov:NCT01324284","description":"Colorectal Carcinoma","metadata":null},{"id":"9bb7a0658f794bea94982dae40a6714e","type":"TRIAL","name":"Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections","canonical_id":"clinicaltrials.gov:NCT00690378","description":"Complicated Urinary Tract Infection","metadata":null},{"id":"c353bd46a1934b98b0f6d69d8034afe0","type":"TRIAL","name":"Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT00670475","description":"Osteoarthritis of the Knee","metadata":null},{"id":"15397215296741d39cda9422e19582c2","type":"TRIAL","name":"Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo","canonical_id":"clinicaltrials.gov:NCT01986270","description":"Migraine With or Without Aura","metadata":null},{"id":"3fa6ab401c564fc6bc0e76b51469f116","type":"TRIAL","name":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","canonical_id":"clinicaltrials.gov:NCT03549832","description":"HCV Coinfection","metadata":null},{"id":"80be5942e9f44fd0b884ff02f471e10e","type":"TRIAL","name":"Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity","canonical_id":"clinicaltrials.gov:NCT00800462","description":"Spinal Cord Injury; Neurogenic Detrusor Overactivity","metadata":null},{"id":"df7cb220681a44f5acf3560917067bf6","type":"TRIAL","name":"Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations","canonical_id":"clinicaltrials.gov:NCT02660840","description":"Bioequivalence Study in Healthy Subjects","metadata":null},{"id":"16574bbebf384f57aca5340fd4ce6681","type":"TRIAL","name":"Comparative Study on the Efficacy and Safety of Ondansetron Oral Membrane for the Prevention of Vomiting During Moderate Hypoemetic Chemotherapy","canonical_id":"clinicaltrials.gov:NCT06371014","description":"To Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy","metadata":null},{"id":"5de8c80fdc4f421fa31f3e2f738a158a","type":"TRIAL","name":"Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room","canonical_id":"clinicaltrials.gov:NCT01091337","description":"Asthma","metadata":null},{"id":"0156f099e50d4cf487048aa7fd472632","type":"TRIAL","name":"Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)","canonical_id":"clinicaltrials.gov:NCT07304817","description":"CKD; Cardiovascular Diseases; Heart Failure","metadata":null},{"id":"62a84420ae534159a8122a18e29b14cd","type":"TRIAL","name":"Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy","canonical_id":"clinicaltrials.gov:NCT02068443","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"3122c1a37edc4e81a1552d0be337f72c","type":"TRIAL","name":"Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00911807","description":"Alzheimer Disease","metadata":null},{"id":"98b626461eb641fb88c0afa1e2fcafbb","type":"TRIAL","name":"Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management","canonical_id":"clinicaltrials.gov:NCT02409433","description":"Seizures","metadata":null},{"id":"df00c8c452944ca3b9c597aa878f6562","type":"TRIAL","name":"Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C","canonical_id":"clinicaltrials.gov:NCT00216775","description":"Hepatitis C, Chronic","metadata":null},{"id":"faa69e7b5eb2440292aa5b4275aa0492","type":"TRIAL","name":"Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy","canonical_id":"clinicaltrials.gov:NCT04080076","description":"Renal Disease","metadata":null},{"id":"a92715807d00487bb1c1aa8bfc4184b3","type":"TRIAL","name":"Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)","canonical_id":"clinicaltrials.gov:NCT02933697","description":"Atrial Fibrillation; End-stage Kidney Disease","metadata":null},{"id":"596d19089d83415d8f083fae5af988f0","type":"TRIAL","name":"Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML","canonical_id":"clinicaltrials.gov:NCT00574873","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"71d64940f11240eea007da8c79f70bdd","type":"TRIAL","name":"Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00940953","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"bb5fd081b6274347a19eaf4c36bed9cf","type":"TRIAL","name":"Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation","canonical_id":"clinicaltrials.gov:NCT02922127","description":"Contraception","metadata":null},{"id":"2c62167cda06465492202d841966db9f","type":"TRIAL","name":"Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis","canonical_id":"clinicaltrials.gov:NCT02453490","description":"Colorectal Cancer; Liver Metastasis","metadata":null},{"id":"23e1cda52b1b4cfcbaee47721c3f3864","type":"TRIAL","name":"Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination","canonical_id":"clinicaltrials.gov:NCT01666678","description":"Therapeutic Equivalence","metadata":null},{"id":"c94b5fa7dd954c6eaa743be1cd85df1e","type":"TRIAL","name":"Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian","canonical_id":"clinicaltrials.gov:NCT05181124","description":"Anti-Ulcer Agents","metadata":null},{"id":"fffde847f9ea4d5b9da2671ffe28a222","type":"TRIAL","name":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01213836","description":"Schizophrenia","metadata":null},{"id":"909454ea523341858481e5a7f73aa2de","type":"TRIAL","name":"Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT07741331","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"fe3003c83a974b56b6c221147f961549","type":"TRIAL","name":"Compare the Efficacy and Safety of QL2302 Versus Tezspire\u00ae in Severe Asthma","canonical_id":"clinicaltrials.gov:NCT07302516","description":"Asthma","metadata":null},{"id":"83a857fe733f432d81d109b8ae446b55","type":"TRIAL","name":"Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis","canonical_id":"clinicaltrials.gov:NCT01181531","description":"Hyperparathyroidism, Secondary","metadata":null},{"id":"bdc1db349a4d4a4bb8681471ba8129fa","type":"TRIAL","name":"Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program","canonical_id":"clinicaltrials.gov:NCT01009567","description":"Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"2b135a7ec6e641e3a8698b7a2e5b8a22","type":"TRIAL","name":"Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT05990829","description":"Diabetic Macular Edema; Pars Plana Vitrectomy; Dexamethasone Intravitreal Implant; Intraoperative Optical Coherence Tomography","metadata":null},{"id":"0b7307a182b745eea671da473d7bbf62","type":"TRIAL","name":"Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe","canonical_id":"clinicaltrials.gov:NCT02029625","description":"Dyslipidemia","metadata":null},{"id":"bdb37975917e4cf684ab4f4e705ee431","type":"TRIAL","name":"Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT01415128","description":"Erectile Dysfunction","metadata":null},{"id":"aca201bf77ff45faaedfd43611c5f15d","type":"TRIAL","name":"Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07384104","description":"Osteoporosis","metadata":null},{"id":"bd25b6961e47443fb52755df747214e2","type":"TRIAL","name":"Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus","canonical_id":"clinicaltrials.gov:NCT01010048","description":"Urinary Calculus","metadata":null},{"id":"6ccca5802e854f46aeed811578f4a559","type":"TRIAL","name":"Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients","canonical_id":"clinicaltrials.gov:NCT07012330","description":"Neuroendocrine (NE) Tumors","metadata":null},{"id":"ffa74dfa0f964a82be3e5f771a118e55","type":"TRIAL","name":"Comparing ARNI With ACE Inhibitor on Endothelial Function","canonical_id":"clinicaltrials.gov:NCT03119623","description":"Heart Failure With Reduced Ejection Fraction","metadata":null},{"id":"81ad9c719dee4a6ab171fe9064a3946c","type":"TRIAL","name":"Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB","canonical_id":"clinicaltrials.gov:NCT00073593","description":"Cardiac Surgery; Coronary Artery Bypass Surgery","metadata":null},{"id":"f756cb9ca3e44d8eb244bc54e784132c","type":"TRIAL","name":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","canonical_id":"clinicaltrials.gov:NCT06442267","description":"Respiratory Insufficiency; Circulatory Failure; Thromboembolism; Bleeding","metadata":null},{"id":"d1845a1508694519af3ea20b09c90b6d","type":"TRIAL","name":"Comparing Antipsychotic Medications in LBD Over Time","canonical_id":"clinicaltrials.gov:NCT05590637","description":"Parkinson's Disease Psychosis; Dementia With Lewy Bodies","metadata":null},{"id":"badcf3cd5d9f481ba29a46a60f3d737b","type":"TRIAL","name":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","canonical_id":"clinicaltrials.gov:NCT00915538","description":"Asthma","metadata":null},{"id":"4fb22e8d0d7a4f4da4f515dbe4824c76","type":"TRIAL","name":"Comparing Budesonide Via MAD or INSI Prospective Cohort Study","canonical_id":"clinicaltrials.gov:NCT04267042","description":"Chronic Rhinosinusitis With Nasal Polyps; Allergic Fungal Sinusitis","metadata":null},{"id":"e521ff555f1e4197b54da188f1f998f1","type":"TRIAL","name":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","canonical_id":"clinicaltrials.gov:NCT05561387","description":"Plasma Cell Myeloma","metadata":null},{"id":"a12549a8910d4d7e950e0f5cc1541555","type":"TRIAL","name":"Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT05642572","description":"Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"775f60283fca40698ff3b0c7f76c6ae5","type":"TRIAL","name":"Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01843062","description":"Differentiated Thyroid Cancer","metadata":null},{"id":"ea19aca8221e4a7a8f0f0e7f92f1d5d5","type":"TRIAL","name":"Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens","canonical_id":"clinicaltrials.gov:NCT01296464","description":"Parkinson's Disease","metadata":null},{"id":"ecf0bd3142ff42b4ae4bedf7fd67ad3e","type":"TRIAL","name":"Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms","canonical_id":"clinicaltrials.gov:NCT07136415","description":"Menopausal Women; Insomnia","metadata":null},{"id":"0a277c1fabf94144aa33c130acba4dcd","type":"TRIAL","name":"Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization","canonical_id":"clinicaltrials.gov:NCT03548454","description":"Chronic Pain","metadata":null},{"id":"0a91f2581ac940d993862a7ae185c197","type":"TRIAL","name":"Comparing Efficacy and Safety Between Pertuzumab\u00ae and Perjeta\u00ae in Neoadjuvant Treatment of HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04957212","description":"HER2-positive Breast Cancer","metadata":null},{"id":"ed8a9f5758164dd1bba77eab23502f2b","type":"TRIAL","name":"Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria","canonical_id":"clinicaltrials.gov:NCT07524920","description":"MDR Bacteria","metadata":null},{"id":"eecb06424e464bbdad113026c287cf56","type":"TRIAL","name":"Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT02621931","description":"Migraine","metadata":null},{"id":"7901b963dff04f12afa8c983b1db1cc6","type":"TRIAL","name":"Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals","canonical_id":"clinicaltrials.gov:NCT06875245","description":"Wet Age-related Macular Degeneration","metadata":null},{"id":"8ca4f75857a54f6384ea54031a488c14","type":"TRIAL","name":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT07178639","description":"Macular Oedema; Cataract Surgery; NSAID (Non-Steroidal Anti-Inflammatory Drug)","metadata":null},{"id":"d9c879d533434ee6bc82b6a7b58c9855","type":"TRIAL","name":"Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC","canonical_id":"clinicaltrials.gov:NCT01214343","description":"Advanced Hepatocellular Carcinoma; Carcinoma; Carcinoma, Hepatocellular; Liver Neoplasms; Neoplasms","metadata":null},{"id":"1c1f235003b3481698b8a2ea1c5ebf6b","type":"TRIAL","name":"Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED)","canonical_id":"clinicaltrials.gov:NCT03173456","description":"Musculoskeletal Pain","metadata":null},{"id":"fb80b8a4468642d08664be97567f2bd2","type":"TRIAL","name":"Comparing Glycemic Outcomes of Carbohydrate Counting vs. Fixed Mealtime Insulin Dosing in Hospitalized Patients With Hyperglycemia","canonical_id":"clinicaltrials.gov:NCT07808398","description":"Diabetes Type 2 on Insulin; Hypoglycemia (Diabetic); Hyperglycemia Due to Type 2 Diabetes Mellitus","metadata":null},{"id":"4c79bc591cd7481eb5c802abc528edd9","type":"TRIAL","name":"Comparing Haloperidol and Olanzapine in Treating Terminal Delirium","canonical_id":"clinicaltrials.gov:NCT04750395","description":"Delirium; Terminal Illness","metadata":null},{"id":"8ea4d2662c1c4ee793260ba0c1af7231","type":"TRIAL","name":"Comparing Immune Responses to Topical Imiquimod","canonical_id":"clinicaltrials.gov:NCT04809662","description":"Actinic Keratoses","metadata":null},{"id":"5c456f16a2c542d4b4178b0c41dd241b","type":"TRIAL","name":"Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT05303792","description":"B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma","metadata":null},{"id":"dd7eaa248c4e4c479ac1655ed79e14f3","type":"TRIAL","name":"Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT05139875","description":"Knee Osteoarthritis","metadata":null},{"id":"67f461242b7148bd8b1af7698a3ac72e","type":"TRIAL","name":"Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT03812523","description":"Chemotherapy-Induced Peripheral Neuropathy","metadata":null},{"id":"787fa35f14824770aff37c58ef098f62","type":"TRIAL","name":"Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)","canonical_id":"clinicaltrials.gov:NCT07655440","description":"Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine","metadata":null},{"id":"81c25d7426a54d85b5409385e478f7ef","type":"TRIAL","name":"Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts","canonical_id":"clinicaltrials.gov:NCT07498205","description":"Myelofibrosis; Myelofibrosis (MF)","metadata":null},{"id":"c460f1b390ff4b4694f6bfda6a00e0b9","type":"TRIAL","name":"Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period","canonical_id":"clinicaltrials.gov:NCT07090044","description":"Vein Occlusion; Macular Degeneration Choroidal Neovascularization; Macular Edema; Diabetic Retinopathy","metadata":null},{"id":"755be26db02645fb8ce76df477c31f27","type":"TRIAL","name":"Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma","canonical_id":"clinicaltrials.gov:NCT04982211","description":"Trauma and Stressor Related Disorders; Post Traumatic Stress Disorder; Acute Stress Disorder; Adjustment Disorders","metadata":null},{"id":"944d3c0822f24630b25ade8ae396d9d6","type":"TRIAL","name":"Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria","canonical_id":"clinicaltrials.gov:NCT07236372","description":"Acute Urticaria","metadata":null},{"id":"c41c4603521040dabd63adec7cc3fb35","type":"TRIAL","name":"Comparing Symbicort\u00ae As-Needed or Bricanyl As-Needed or Pulmicort\u00ae Once Daily + Bricanyl As-Needed in Asthma Patients","canonical_id":"clinicaltrials.gov:NCT00989833","description":"Exercise Induced Asthma","metadata":null},{"id":"c0c5e632787f4961966363e1918e0ea5","type":"TRIAL","name":"Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ.","canonical_id":"clinicaltrials.gov:NCT07114848","description":"Ureteral Stent-Related Symptom; Alpha Blocker; Anticholinergics; Ureter Calculi","metadata":null},{"id":"1c578ad5e0284b9eb4610006529e371d","type":"TRIAL","name":"Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response","canonical_id":"clinicaltrials.gov:NCT05466695","description":"Erectile Dysfunction and Neutrophil Lymphocyte Ratio","metadata":null},{"id":"17521e1b0e104fe1bb99a2a1d2d8e694","type":"TRIAL","name":"Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects","canonical_id":"clinicaltrials.gov:NCT00625196","description":"Asthma","metadata":null},{"id":"d1585ba7dc8c44298f59bc67b2a121cd","type":"TRIAL","name":"Comparing Various Treatments for Achieving and Maintaining Remission of Depression","canonical_id":"clinicaltrials.gov:NCT00227955","description":"Depression","metadata":null},{"id":"d88ca4254a1f428493bf1b911942b815","type":"TRIAL","name":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06169215","description":"Multiple Myeloma","metadata":null},{"id":"3b6deb088ad048b4a4a39be2027916f9","type":"TRIAL","name":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07488533","description":"Non-Clear Cell Renal Cell Carcinoma","metadata":null},{"id":"c6674d74d59c432893ea6655a4935289","type":"TRIAL","name":"Comparing the Effect of Melatonin, Diazepam, and Placebo on Decreasing the Level of Anxiety Preoperatively","canonical_id":"clinicaltrials.gov:NCT06103188","description":"Anxiety; Preoperative Anxiety","metadata":null},{"id":"2ede32d1c6434d66bc9630bae63247db","type":"TRIAL","name":"Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm","canonical_id":"clinicaltrials.gov:NCT00007605","description":"Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden","metadata":null},{"id":"a9d399811973499ea7522b7cfbaccbe3","type":"TRIAL","name":"Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure","canonical_id":"clinicaltrials.gov:NCT00924014","description":"Heart Failure","metadata":null},{"id":"4135c606aa2a4e5ab9755969398eb40e","type":"TRIAL","name":"Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)","canonical_id":"clinicaltrials.gov:NCT00885690","description":"Schizophrenia","metadata":null},{"id":"e2d8eb39bdaf4163b8042b581aecf35c","type":"TRIAL","name":"Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study","canonical_id":"clinicaltrials.gov:NCT07145281","description":"Gender Dysphoria, Adult; Blood Coagulation; Coagulation Factors; Transgender Persons, M01.777.500; Hemostasis; Transgender Women","metadata":null},{"id":"d7ce2045c3f34787a3310edd1efccac2","type":"TRIAL","name":"Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis","canonical_id":"clinicaltrials.gov:NCT04222114","description":"Stomach Neoplasms","metadata":null},{"id":"229988afee444358b2a1dc85fb7ca708","type":"TRIAL","name":"Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3","canonical_id":"clinicaltrials.gov:NCT02322788","description":"Asthma","metadata":null},{"id":"9c70c3f058ed4dc795c5e5fca9edd08a","type":"TRIAL","name":"Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge","canonical_id":"clinicaltrials.gov:NCT01402375","description":"Analgesia After ED Discharge for Extremity Injuries","metadata":null},{"id":"292f8f1e863947a0a0cb5d81dcdc6efb","type":"TRIAL","name":"Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars","canonical_id":"clinicaltrials.gov:NCT05573425","description":"Acne Scar","metadata":null},{"id":"6e57a89220b34a41a6d58028909acff4","type":"TRIAL","name":"Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion","canonical_id":"clinicaltrials.gov:NCT03329898","description":"Intrauterine Adhesion","metadata":null},{"id":"2b413d94deff4f85ac5ae74db9a5ab95","type":"TRIAL","name":"Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections","canonical_id":"clinicaltrials.gov:NCT07811999","description":"Healthy Participants","metadata":null},{"id":"313df02c26174e6fbd3402361c3b8951","type":"TRIAL","name":"Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03022201","description":"Parkinson's Disease,Idiopathic","metadata":null},{"id":"bac9524b03f045538b0b1c20074313d8","type":"TRIAL","name":"Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT00608673","description":"Discoid Lupus Erythematosus","metadata":null},{"id":"7195e2eca1694aa9b55df488c87b50cb","type":"TRIAL","name":"Comparision of Blood Pressure Variability Between Amlodipine and Losartan","canonical_id":"clinicaltrials.gov:NCT01964079","description":"Hypertension","metadata":null},{"id":"cee6454a619543078b3a0fddccd534f1","type":"TRIAL","name":"Comparison Between ABP 692 and Ocrevus\u00ae (Ocrelizumab)","canonical_id":"clinicaltrials.gov:NCT06700343","description":"Relapsing-remitting Multiple Sclerosis (RRMS)","metadata":null},{"id":"58ae951ab3124292acec9da5f9c8d435","type":"TRIAL","name":"Comparison Between Dexmeditomidine, Midazolam and Ketamine as a Sedative to Help Cannula Insertion in Pediatric Patient","canonical_id":"clinicaltrials.gov:NCT04704622","description":"Cannula Site Pain","metadata":null},{"id":"e4641824fc034b58b8aba959259a24d5","type":"TRIAL","name":"Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy","canonical_id":"clinicaltrials.gov:NCT00634491","description":"Contrast Induced Nephropathy","metadata":null},{"id":"6eb01f8fcfde472ca3b5cd793766f106","type":"TRIAL","name":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT07073768","description":"Diabetes Mellitus Type 2; Glycemic Control for Diabetes Mellitus","metadata":null},{"id":"681fb91cd4a842b28a929bc54e053328","type":"TRIAL","name":"Comparison Between External Oblique Intercostal Plane Block and Rectus Sheath Block Combined With Transversus Abdominis Plane Block","canonical_id":"clinicaltrials.gov:NCT07384000","description":"Pain Management; Anesthesia , Analgesia; Nerve Block","metadata":null},{"id":"88e2408b882045b1972006582ecb914f","type":"TRIAL","name":"Comparison Between Haparin and Herodin in HD","canonical_id":"clinicaltrials.gov:NCT06112262","description":"Haemodialysis","metadata":null},{"id":"f33836eeac1e49cea8789b2009c578b5","type":"TRIAL","name":"Comparison Between Intraligamentary Piroxicam and Articaine","canonical_id":"clinicaltrials.gov:NCT03612323","description":"Pulpitis - Irreversible","metadata":null},{"id":"a5f2a59122ab4738a98efc17629aca8f","type":"TRIAL","name":"Comparison Between Ketamine Intrathecal and iv Dexamethasone for Post Cesarean Analgesia","canonical_id":"clinicaltrials.gov:NCT06408974","description":"Post Cesarean Analgesia","metadata":null},{"id":"56be41faa8eb46aa93ed68e6ab44074d","type":"TRIAL","name":"Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients","canonical_id":"clinicaltrials.gov:NCT04461249","description":"Primary Open Angle Glaucoma","metadata":null},{"id":"7327c7e0e3d345bda5f8062e5893a3b6","type":"TRIAL","name":"Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT01870024","description":"Status Epilepticus; Epilepsy","metadata":null},{"id":"f6944ce56c44431eb8d153675db8da56","type":"TRIAL","name":"Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine","canonical_id":"clinicaltrials.gov:NCT01603940","description":"Hypertension; Diabetes Mellitus","metadata":null},{"id":"86f6e52510204f82b59ed44acafc3e0a","type":"TRIAL","name":"Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal","canonical_id":"clinicaltrials.gov:NCT01804075","description":"Neonatal Abstinence Syndrome","metadata":null},{"id":"fae0d9915697409da8b06ae46b1523f5","type":"TRIAL","name":"Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring","canonical_id":"clinicaltrials.gov:NCT03170596","description":"Atrophic Post Acne Scarring","metadata":null},{"id":"b0a0314f5130484c9ed2cdcfc133c0a5","type":"TRIAL","name":"Comparison Between Oral Melatonin and Hydroxyzine in Pediatric Patients Undergoing Adenotonsillectomy","canonical_id":"clinicaltrials.gov:NCT05680584","description":"Effect of Drug; Anxiety","metadata":null},{"id":"674a647f8d644fafa1ccb20b8fc6b446","type":"TRIAL","name":"Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)","canonical_id":"clinicaltrials.gov:NCT00458835","description":"Allergic Rhinitis","metadata":null},{"id":"60f5211577fa4fc2949eb321c5eb1a3e","type":"TRIAL","name":"Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study","canonical_id":"clinicaltrials.gov:NCT05818670","description":"BPH","metadata":null},{"id":"e6b665fd4d88435d9828fa3c2c8b2525","type":"TRIAL","name":"Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection","canonical_id":"clinicaltrials.gov:NCT04094467","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"12b0ea8f69b14042bbb5b0633ba6370b","type":"TRIAL","name":"Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT05373004","description":"Diabetic Nephropathy Type 2","metadata":null},{"id":"caf37463bb344f638983b3f18cbbeb63","type":"TRIAL","name":"Comparison Between the Use of Phentolamine Versus Glyceryl Trinitrate for Their Effect on Renal Function in Pre-eclampsia Patients in ICU","canonical_id":"clinicaltrials.gov:NCT05687669","description":"Pre-Eclampsia; Complicating Pregnancy; Pre-eclampsia Aggravated","metadata":null},{"id":"604a138d6277444dbde32515147cae56","type":"TRIAL","name":"Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis","canonical_id":"clinicaltrials.gov:NCT04445025","description":"Infertility; Endometriosis","metadata":null},{"id":"cd37f4b6800745e7a2423a4ec2e78a65","type":"TRIAL","name":"Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00542984","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"a16041b31f364a678c2ae9d97cc286a5","type":"TRIAL","name":"Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan","canonical_id":"clinicaltrials.gov:NCT00141154","description":"Low Back Pain","metadata":null},{"id":"ae5ffbd1fdba4d01a7554938bd297800","type":"TRIAL","name":"Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.","canonical_id":"clinicaltrials.gov:NCT06239389","description":"Beta-Thalassemia","metadata":null},{"id":"8e88914448394b62a3e7f5439dfa2bee","type":"TRIAL","name":"Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma.","canonical_id":"clinicaltrials.gov:NCT06013540","description":"Melasma","metadata":null},{"id":"cb0f98d71099451eb9ba3b0f23e88179","type":"TRIAL","name":"Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT06015152","description":"Scalp Psoriasis","metadata":null},{"id":"7a58019bfb3d40cb995699da08d738e1","type":"TRIAL","name":"Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR\u00ae Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma","canonical_id":"clinicaltrials.gov:NCT00268983","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"53f6fee56ef34d7bb68a2c7703fad556","type":"TRIAL","name":"Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)","canonical_id":"clinicaltrials.gov:NCT03532178","description":"Neuromuscular Blockade","metadata":null},{"id":"633ab9c8f56545469403c08f19c8996a","type":"TRIAL","name":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00667160","description":"Dermatitis, Atopic","metadata":null},{"id":"ad60644db592427f9683ec3d181cdaf1","type":"TRIAL","name":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00666159","description":"Dermatitis, Atopic","metadata":null},{"id":"63288a7185d046e38de2b35ab1abd9df","type":"TRIAL","name":"Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve","canonical_id":"clinicaltrials.gov:NCT02128360","description":"Infertility","metadata":null},{"id":"ce04ca9d3e5341cca82c9f8e4639d28f","type":"TRIAL","name":"Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles","canonical_id":"clinicaltrials.gov:NCT05767086","description":"Infertility","metadata":null},{"id":"47d0dfc4c49a402d8038e72128d74dab","type":"TRIAL","name":"Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT07495670","description":"Diabetes (DM); Retinopathy, Diabetic; Pupil Dilation","metadata":null},{"id":"83348451ef2f422c8703acd81725e940","type":"TRIAL","name":"Comparison of Absorption of Vaginal Diazepam Using Different Delivery Systems","canonical_id":"clinicaltrials.gov:NCT01696825","description":"Metabolism, Drug","metadata":null},{"id":"e3a9250cae5b4fdbb5cea18c7b0b3dc3","type":"TRIAL","name":"Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00706914","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"87378787c4f44cfa89980bcf794d397b","type":"TRIAL","name":"Comparison of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women","canonical_id":"clinicaltrials.gov:NCT02188225","description":"Hot Flash; Quality of Life","metadata":null},{"id":"40d569dd4e434d2aa0bc844ccceb8d0e","type":"TRIAL","name":"Comparison of Adding EMEND to PONV/PDNV Treatment Regimen","canonical_id":"clinicaltrials.gov:NCT01186029","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"eb456e67751245e38a1bac290064cbb5","type":"TRIAL","name":"Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study","canonical_id":"clinicaltrials.gov:NCT02612116","description":"Unstable Angina Pectoris","metadata":null},{"id":"409df1f4c52a496494d0729bccbc9c4d","type":"TRIAL","name":"Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00417170","description":"High Blood Pressure; Metabolic Syndrome; Insulin Resistance; Endothelial Dysfunction","metadata":null},{"id":"f801894a04f445dd8176c38b5717503f","type":"TRIAL","name":"Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms","canonical_id":"clinicaltrials.gov:NCT06966804","description":"Stent Related Symptoms","metadata":null},{"id":"49b36d2bff074cb492166177773beee0","type":"TRIAL","name":"Comparison of Amitriptyline to Lifestyle Modification as Intervention for Vestibular Migraine","canonical_id":"clinicaltrials.gov:NCT06417684","description":"Vestibular Migraine","metadata":null},{"id":"d9de5108cb784f31ba67aa91e74f5f41","type":"TRIAL","name":"Comparison of Analgesic Consumption Between Perioperative \u0131v Dexamethasone and Added to Femoral Block","canonical_id":"clinicaltrials.gov:NCT02090790","description":"Postoperative Pain","metadata":null},{"id":"3362046748b54416aa03549efdc53551","type":"TRIAL","name":"Comparison of Analgesic Effect and Prognosis of Butorphanol and Fentanyl in Patients With Mechanical Ventilation","canonical_id":"clinicaltrials.gov:NCT04315935","description":"Analgesia","metadata":null},{"id":"53f1eece3125431db1a40137fac1f910","type":"TRIAL","name":"Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia","canonical_id":"clinicaltrials.gov:NCT00738192","description":"Postoperative Pain","metadata":null},{"id":"f249472e27e04bd899776b295e03adba","type":"TRIAL","name":"Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction","canonical_id":"clinicaltrials.gov:NCT00213148","description":"Anovulation","metadata":null},{"id":"db9f7069a02d43d08bf7070d1149d11b","type":"TRIAL","name":"Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)","canonical_id":"clinicaltrials.gov:NCT00093158","description":"Unstable Angina; Myocardial Infarction; Acute Disease","metadata":null},{"id":"43aadda6328a460d8b59bffc774a9341","type":"TRIAL","name":"Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)","canonical_id":"clinicaltrials.gov:NCT07469072","description":"Continuous Renal Replacement Therapy (CRRT)","metadata":null},{"id":"e001d8ebd46e4167b8c80338582c4eab","type":"TRIAL","name":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","canonical_id":"clinicaltrials.gov:NCT03664180","description":"STEMI - ST Elevation Myocardial Infarction","metadata":null},{"id":"a7e2f8d7dfc041cea1e1f1628e44db6d","type":"TRIAL","name":"Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT00020657","description":"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"bdb2c4f76dff41619a67d1eed66b3708","type":"TRIAL","name":"Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT01660373","description":"Non-ST Segment Elevation Acute Coronary Syndrome","metadata":null},{"id":"b9d2859036f04244ba089d2e126539c7","type":"TRIAL","name":"Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs","canonical_id":"clinicaltrials.gov:NCT06933056","description":"Platelet Function and Reactivity Tests","metadata":null},{"id":"826ce31f79b24ee59fba7d5cb061a810","type":"TRIAL","name":"Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy","canonical_id":"clinicaltrials.gov:NCT01609153","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"bad2e06c567043deb577e66a46ef13a5","type":"TRIAL","name":"Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT00423878","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"ec2b70baecbc457a866f4ac2ae68745c","type":"TRIAL","name":"Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT00250744","description":"Cancer","metadata":null},{"id":"3de79e34324e47698edeeda7d64da625","type":"TRIAL","name":"Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00396760","description":"Bleeding and Cardiac Surgery; Allogeneic Blood Transfusion; Aortic Valve Replacement; Coronary Artery Bypass Graft Surgery","metadata":null},{"id":"c1af605ef7794ae7863a689768716bdd","type":"TRIAL","name":"Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI","canonical_id":"clinicaltrials.gov:NCT02334904","description":"First-Episode Psychosis; Bipolar Disorder","metadata":null},{"id":"f4b3239f5a344646b6a62595dbf95c45","type":"TRIAL","name":"Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany","canonical_id":"clinicaltrials.gov:NCT00406354","description":"Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder","metadata":null},{"id":"3f5e693d37d54d6189fe11416dccc181","type":"TRIAL","name":"Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00473174","description":"Hypertension","metadata":null},{"id":"d8ea293c62ff479eaf63501941ba1d4d","type":"TRIAL","name":"Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure","canonical_id":"clinicaltrials.gov:NCT04107220","description":"Heart Failure","metadata":null},{"id":"92aee52494ce4440b3249eeaaee758aa","type":"TRIAL","name":"Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan","canonical_id":"clinicaltrials.gov:NCT02958631","description":"Hypertension","metadata":null},{"id":"7f7c9ae3db574ecfade0701a3118cb7e","type":"TRIAL","name":"Comparison of Blood Pressure Medications on Metabolism","canonical_id":"clinicaltrials.gov:NCT00642434","description":"Diabetes","metadata":null},{"id":"d4f2beef49d04228a32bd7b5fb8bec70","type":"TRIAL","name":"Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02633774","description":"Persistent Atrial Fibrillation","metadata":null},{"id":"84a8c938dd5c4f46aedfab0b54e8b0c8","type":"TRIAL","name":"Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs","canonical_id":"clinicaltrials.gov:NCT00675207","description":"Primary Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"c98210672fae41abae0b862db2fd422e","type":"TRIAL","name":"Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01796899","description":"Healthy Volunteers","metadata":null},{"id":"1d6db178da2845e4b0ff805204b61386","type":"TRIAL","name":"Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)","canonical_id":"clinicaltrials.gov:NCT01708707","description":"Neonatal Abstinence Syndrome; Neonatal Withdrawal Syndrome","metadata":null},{"id":"6be2b0b740104b7ea248d6fe37d79832","type":"TRIAL","name":"Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy","canonical_id":"clinicaltrials.gov:NCT00510666","description":"Postoperative Pain; Hysterectomy","metadata":null},{"id":"a9d8fa4bb6f545188aeb937e5cdb96b2","type":"TRIAL","name":"Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge","canonical_id":"clinicaltrials.gov:NCT01107093","description":"Contraception","metadata":null},{"id":"901b411d81b4400fb5b845540693ba71","type":"TRIAL","name":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT02115750","description":"Rheumatoid Arthritis","metadata":null},{"id":"e0a3d125cc1546b09391cecefd5903c2","type":"TRIAL","name":"Comparison of CL Wear Between Two Allergy Drops","canonical_id":"clinicaltrials.gov:NCT00489398","description":"Allergic Conjunctivitis","metadata":null},{"id":"fccebae95d544fa6acaf8626bd08c13b","type":"TRIAL","name":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","canonical_id":"clinicaltrials.gov:NCT00332839","description":"Renal Transplantation","metadata":null},{"id":"741eb2621597465fa05eec9c3b72427e","type":"TRIAL","name":"Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01578655","description":"Prostate Cancer","metadata":null},{"id":"185b4faa8ecd4628a62c3566a05c3353","type":"TRIAL","name":"Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.","canonical_id":"clinicaltrials.gov:NCT03867994","description":"Contrast-induced Nephropathy","metadata":null},{"id":"6eb66b5f37cf4a129da176417905230f","type":"TRIAL","name":"Comparison of Chitosan, Ankaferd and Tranexamic Acid in Dental Extraction in Liver Pre-Transplant Children","canonical_id":"clinicaltrials.gov:NCT06457360","description":"Liver Cirrhosis","metadata":null},{"id":"9236cabaff0743fcabf740ab114af668","type":"TRIAL","name":"Comparison of Chlorpromazine or Pentobarbital Premedications for Pediatric Imaging Procedures","canonical_id":"clinicaltrials.gov:NCT04350528","description":"Children Sedation","metadata":null},{"id":"0ac17172dccf410882c4d6e47a0faa6d","type":"TRIAL","name":"Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)","canonical_id":"clinicaltrials.gov:NCT02829151","description":"Critical Limb Ischemia","metadata":null},{"id":"8efc9b1006924f3ca04c0eab847e08db","type":"TRIAL","name":"Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone","canonical_id":"clinicaltrials.gov:NCT00480844","description":"Schizophrenia","metadata":null},{"id":"bbac23451beb493b996e9f288f238252","type":"TRIAL","name":"Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02644499","description":"Rheumatoid Arthritis","metadata":null},{"id":"56442dbb964f48119eb0b9d5a2841b0f","type":"TRIAL","name":"Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features","canonical_id":"clinicaltrials.gov:NCT00202293","description":"Bipolar Disorder; Schizoaffective Disorder","metadata":null},{"id":"ffda15f7b4ad4981b3d71191a67375db","type":"TRIAL","name":"Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.","canonical_id":"clinicaltrials.gov:NCT02176642","description":"Urinary Urge Incontinence","metadata":null},{"id":"e56511efc9e94137839cbea0dc333772","type":"TRIAL","name":"Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children","canonical_id":"clinicaltrials.gov:NCT01450774","description":"Childhood Asthma","metadata":null},{"id":"ccf8210c68bd4374a8ae2fc41170cc52","type":"TRIAL","name":"Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00758368","description":"Parkinson's Disease","metadata":null},{"id":"8f66e6280687415294e61352d4b969e9","type":"TRIAL","name":"Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment","canonical_id":"clinicaltrials.gov:NCT01720485","description":"Allergic Rhinitis","metadata":null},{"id":"23b1246fdd8f44de90c210d9c8cb7683","type":"TRIAL","name":"Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment","canonical_id":"clinicaltrials.gov:NCT01529229","description":"Allergic Rhinitis","metadata":null},{"id":"ed77d61e8064465990eac926b78cd433","type":"TRIAL","name":"Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days.","canonical_id":"clinicaltrials.gov:NCT06729073","description":"Healthy Volunteer","metadata":null},{"id":"2fcdeb30582d4106aa850db3e2356391","type":"TRIAL","name":"Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT00001889","description":"Coronary Disease","metadata":null},{"id":"918e0279a6914380a2e05498948e1ea8","type":"TRIAL","name":"Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT07636057","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"31fdfe8ae47247eda3150d3ce03f45f4","type":"TRIAL","name":"Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease","canonical_id":"clinicaltrials.gov:NCT07104786","description":"Non Alcoholic Fatty Liver Disease","metadata":null},{"id":"72f49271021145bf89bd28bfb9fe80a7","type":"TRIAL","name":"Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT02294539","description":"Hypertension","metadata":null},{"id":"de408105c52d49aea9a445c8f5ee2dc5","type":"TRIAL","name":"Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice.","canonical_id":"clinicaltrials.gov:NCT06346743","description":"Physiological Neonatal Jaundice; Physiological Hyperbilirubinaemia","metadata":null},{"id":"347a2f684d4446c9aa9c1fc1ba854fda","type":"TRIAL","name":"Comparison of Effects of Scalp Block and Intravenous Esmolol on Hemodynamic Response Following the Skull Pins Application for Elective Supratentorial Craniotomy","canonical_id":"clinicaltrials.gov:NCT06268275","description":"Hemodynamic Instability","metadata":null},{"id":"655e88e9ff904096aa244f8f07ba5230","type":"TRIAL","name":"Comparison of Efficacy Between Combination of Amitriptyline-propranolol and Pizotifen for Migraine Prophylaxis.","canonical_id":"clinicaltrials.gov:NCT06158230","description":"Migraine","metadata":null},{"id":"0f858a2c899946989bd71fef10783365","type":"TRIAL","name":"Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.","canonical_id":"clinicaltrials.gov:NCT07055529","description":"Vitiligo, Generalized","metadata":null},{"id":"31956ce2c14143d0bc9e337b5627fae2","type":"TRIAL","name":"Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00752635","description":"Acne Vulgaris","metadata":null},{"id":"22a02cf948a545248d42268a2284b7fc","type":"TRIAL","name":"Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00799448","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"1ac05f8af7744a13a03b2a1e963dc9f0","type":"TRIAL","name":"Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks","canonical_id":"clinicaltrials.gov:NCT01068600","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"81ba2029990d49b4a72db7c5ce0dcf10","type":"TRIAL","name":"Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi","canonical_id":"clinicaltrials.gov:NCT07345507","description":"Melasma","metadata":null},{"id":"c76ea7d566e246c485102ad78e6a484a","type":"TRIAL","name":"Comparison of Efficacy of Naproxen Versus Ibuprofen","canonical_id":"clinicaltrials.gov:NCT04947566","description":"Pain, Postoperative","metadata":null},{"id":"e129d328a3ab47b985c1be914e35d150","type":"TRIAL","name":"Comparison of Efficacy of Topical Adaplene Gel Versus Crythotherapy in Recurrent Plantar Warts","canonical_id":"clinicaltrials.gov:NCT07016360","description":"Viral Warts","metadata":null},{"id":"d4fafa7696dd48ffb61f7afa2f9b1c36","type":"TRIAL","name":"Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain","canonical_id":"clinicaltrials.gov:NCT07532876","description":"Endometriosis (Diagnosis)","metadata":null},{"id":"a17854b748214e1fbec968597dddf025","type":"TRIAL","name":"Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT03087578","description":"Overactive Bladder","metadata":null},{"id":"c529af98b2a54b6d880bd0069ffb5f78","type":"TRIAL","name":"Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)","canonical_id":"clinicaltrials.gov:NCT06931704","description":"Multiple Myeloma","metadata":null},{"id":"416fa455fa3f425eabcdd02a9c6038fb","type":"TRIAL","name":"Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery","canonical_id":"clinicaltrials.gov:NCT07265050","description":"Emergence Agitation","metadata":null},{"id":"7e692fb7c86d44f5803552203066e061","type":"TRIAL","name":"Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01014689","description":"Acne Vulgaris","metadata":null},{"id":"7e7aaa5567514b4481b02d02c79f4124","type":"TRIAL","name":"Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain","canonical_id":"clinicaltrials.gov:NCT01846221","description":"Labor Pain","metadata":null},{"id":"13c6b0e114ee46769a44e653592ed267","type":"TRIAL","name":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT00160160","description":"Hypertension; Type 2 Diabetes","metadata":null},{"id":"99e75720303846059f0d95c879a9c250","type":"TRIAL","name":"Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)","canonical_id":"clinicaltrials.gov:NCT01534351","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"872d0511e4c04c2ea74370dc9a7b2201","type":"TRIAL","name":"Comparison of Five Treatments in Patients With Plantar Warts","canonical_id":"clinicaltrials.gov:NCT01059110","description":"Plantar Warts","metadata":null},{"id":"444f8a1e41304125a0905faf995b9a9f","type":"TRIAL","name":"Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00883233","description":"Acne","metadata":null},{"id":"761feb81a54049569e6f7872e4377138","type":"TRIAL","name":"Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus","canonical_id":"clinicaltrials.gov:NCT03758079","description":"Uremic Pruritus","metadata":null},{"id":"e04fd7e578e944819365083254c140ae","type":"TRIAL","name":"Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum","canonical_id":"clinicaltrials.gov:NCT02163434","description":"Hyperemesis Gravidarum","metadata":null},{"id":"cc2451ec97d44b39973281a0a5ac378f","type":"TRIAL","name":"Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT06993194","description":"Traumatic Brain Injury; Delirium; Agitation","metadata":null},{"id":"e9fd2510ec584464a5133fe9683f39e6","type":"TRIAL","name":"Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT04056169","description":"Acute Coronary Syndrome; Carotid Atherosclerotic Plaque With Inflammation","metadata":null},{"id":"3c82d35f1fb0472d8849a4f89f4b903a","type":"TRIAL","name":"Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement","canonical_id":"clinicaltrials.gov:NCT01331902","description":"Coronary Artery Disease; Myocardial Ischemia","metadata":null},{"id":"fa4b4db68c5b4468937dc7a403058597","type":"TRIAL","name":"Comparison of IV Fluid Loading and Ondansetron in Reduction of PONV After LC","canonical_id":"clinicaltrials.gov:NCT03141645","description":"Postoperative Nausea; Postoperative Vomiting; Postoperative Nausea and Vomiting","metadata":null},{"id":"cbf59735d33c4ddd8ed1a4d2a2dcd38d","type":"TRIAL","name":"Comparison of IV Nalbuphine Versus Ibuprofen for Postoperative Pain Control in Cesarean Section","canonical_id":"clinicaltrials.gov:NCT06594224","description":"Pain Management","metadata":null},{"id":"39188a5dd2b3478489e28f4b2d1a181b","type":"TRIAL","name":"Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment","canonical_id":"clinicaltrials.gov:NCT05642806","description":"Chronic Rhinosinusitis With Nasal Polyps; Asthma; Chronic Rhinosinusitis Without Nasal Polyps","metadata":null},{"id":"910dbd30f26b4235b6cc4857ff7da24d","type":"TRIAL","name":"Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin","canonical_id":"clinicaltrials.gov:NCT01352741","description":"Low Back Pain; Neuropathic Pain","metadata":null},{"id":"e4124be532af4dd0b1957ac3061d5aee","type":"TRIAL","name":"Comparison of Instillation and Packing in Mydriasis for Premature Infants","canonical_id":"clinicaltrials.gov:NCT00877175","description":"Preterm Infants","metadata":null},{"id":"726143b5702a43bc8cfab05c5e84b0dd","type":"TRIAL","name":"Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)","canonical_id":"clinicaltrials.gov:NCT00927615","description":"ST-Elevation Myocardial Infarction","metadata":null},{"id":"5d357df7208247bcb081027741fd4ac0","type":"TRIAL","name":"Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT03752190","description":"Adrenal Insufficiency","metadata":null},{"id":"4a0b5349d0cf40849093054d88b4ee40","type":"TRIAL","name":"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults","canonical_id":"clinicaltrials.gov:NCT01710787","description":"Anesthesia","metadata":null},{"id":"1115b918b4634224b7ad53bf85b09480","type":"TRIAL","name":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA\u00ae Ophthalmic Suspension and COSOPT\u00ae Ophthalmic Solution","canonical_id":"clinicaltrials.gov:NCT02325518","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"b8e7580040de47c99cbf33b7fc3a18da","type":"TRIAL","name":"Comparison of Intrathecal Morphine and Rectus Sheath Block for Postoperative Pain Management After Lower Abdominal Surgery With Midline Incision","canonical_id":"clinicaltrials.gov:NCT07489872","description":"Postoperative Analgesia; Pain Management","metadata":null},{"id":"a4051f90a2db49618a168437db04dc2e","type":"TRIAL","name":"Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia","canonical_id":"clinicaltrials.gov:NCT01161121","description":"Coronary Artery Disease","metadata":null},{"id":"29ca00fee60942e2aeb7a6f51cb4a165","type":"TRIAL","name":"Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT07163572","description":"Status Epilepticus","metadata":null},{"id":"a81489d767a442deac3328d8d6ff2858","type":"TRIAL","name":"Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery","canonical_id":"clinicaltrials.gov:NCT01171911","description":"Acute Coronary Syndrome; Coronary Artery Disease","metadata":null},{"id":"8fa6098e78e04bf894af8360268a48a7","type":"TRIAL","name":"Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia","canonical_id":"clinicaltrials.gov:NCT07572656","description":"Preeclampsia","metadata":null},{"id":"70aca519e4114dc2a478a775319f1468","type":"TRIAL","name":"Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer","canonical_id":"clinicaltrials.gov:NCT00247130","description":"Peptic Ulcers","metadata":null},{"id":"e16607a6d8d240228aa8de3dacde46a2","type":"TRIAL","name":"Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis","canonical_id":"clinicaltrials.gov:NCT00839488","description":"Stomach Ulcer","metadata":null},{"id":"cddaf81b9e534b0ea36917419996dbf5","type":"TRIAL","name":"Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT01807234","description":"Migraines","metadata":null},{"id":"aafa1ec6933843a8a4cf6201c6da62d5","type":"TRIAL","name":"Comparison of Lanreotide Autogel\u00ae and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","canonical_id":"clinicaltrials.gov:NCT00092287","description":"Malignant Carcinoid Syndrome","metadata":null},{"id":"057b5ecbb9434cf8b4beada410318362","type":"TRIAL","name":"Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT05712941","description":"Endometrial Carcinoma","metadata":null},{"id":"f48cc7589f024b9f99e8362090db3bfc","type":"TRIAL","name":"Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality","canonical_id":"clinicaltrials.gov:NCT01805817","description":"Contraceptive Methods Comparison","metadata":null},{"id":"36ce477dc24445e9b49b06b15094fcc8","type":"TRIAL","name":"Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate","canonical_id":"clinicaltrials.gov:NCT01106430","description":"Attention-Deficit/Hyperactivity Disorder","metadata":null},{"id":"fcc0c8e042ee46e793c9f2d533e5216a","type":"TRIAL","name":"Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin","canonical_id":"clinicaltrials.gov:NCT01517412","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"642b9e06c3f745978d1cb1c9fc065308","type":"TRIAL","name":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","canonical_id":"clinicaltrials.gov:NCT01610037","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"fa1195ae1b0844f7812abd20dc7d0665","type":"TRIAL","name":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","canonical_id":"clinicaltrials.gov:NCT01828697","description":"Deep Venous Thrombosis; Pulmonary Embolism","metadata":null},{"id":"6eabe7daee744da2aad0cab4a7651cda","type":"TRIAL","name":"Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism","canonical_id":"clinicaltrials.gov:NCT01956955","description":"This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.","metadata":null},{"id":"5462fef1be5d410e89461a5756c9ecda","type":"TRIAL","name":"Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications","canonical_id":"clinicaltrials.gov:NCT01096290","description":"Constipation","metadata":null},{"id":"9c75f400ffae405d8bf29fa7e7d85b2a","type":"TRIAL","name":"Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03807882","description":"Treatment Resistant Schizophrenia","metadata":null},{"id":"8da5165c08844667bc0d6300bc2f0be8","type":"TRIAL","name":"Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT06660693","description":"Colitis, Ulcerative","metadata":null},{"id":"07d427a984f14fb9b3a49e4742ee5607","type":"TRIAL","name":"Comparison of Medical Therapies in Marfan Syndrome.","canonical_id":"clinicaltrials.gov:NCT01295047","description":"Marfan Syndrome","metadata":null},{"id":"212215b894064fb5b1ca62f9281a050a","type":"TRIAL","name":"Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China","canonical_id":"clinicaltrials.gov:NCT02040246","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"49de6a75450d441ca73dec66d5e27e80","type":"TRIAL","name":"Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01465152","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"d8d8c269d10b4dee8ace8e46d7ab058e","type":"TRIAL","name":"Comparison of Milrinone and Epinephrine on TAPSE","canonical_id":"clinicaltrials.gov:NCT07144267","description":"Cardiac Anaesthesia; Cardiopulmonary Bypass","metadata":null},{"id":"5280c232b6c144228934af0c6c346069","type":"TRIAL","name":"Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT04561687","description":"Allergic Rhinitis","metadata":null},{"id":"f741975473834197b8a4638143fcf331","type":"TRIAL","name":"Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression","canonical_id":"clinicaltrials.gov:NCT01875224","description":"New Onset Diabetes After Transplant; Kidney Transplantation","metadata":null},{"id":"c72887ae94f142b688aac0dff3bba64e","type":"TRIAL","name":"Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI","canonical_id":"clinicaltrials.gov:NCT06375616","description":"Sepsis","metadata":null},{"id":"15e10de9338a425eba7cc6bef9f7daf7","type":"TRIAL","name":"Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept","canonical_id":"clinicaltrials.gov:NCT02095418","description":"Diabetes","metadata":null},{"id":"8e66b8d41d3145f2a30ceca5174b758c","type":"TRIAL","name":"Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis","canonical_id":"clinicaltrials.gov:NCT01148264","description":"Emesis","metadata":null},{"id":"484803601b514ebeb786c7d857e024e4","type":"TRIAL","name":"Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide","canonical_id":"clinicaltrials.gov:NCT03509545","description":"Body Weight Changes","metadata":null},{"id":"b5fdefcf683e430e994220bc99db95cd","type":"TRIAL","name":"Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT06913101","description":"Type 2 Diabetes Mellitus (T2DM)","metadata":null},{"id":"eaaf3c44f63d4341bf107db9601cb85c","type":"TRIAL","name":"Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00802100","description":"Schizophrenia","metadata":null},{"id":"7cf38f8faa5d4dae81393083ff887b7a","type":"TRIAL","name":"Comparison of Optimal Hypertension Regimens","canonical_id":"clinicaltrials.gov:NCT02847338","description":"Hypertension","metadata":null},{"id":"7df365bfd1e2415ab1862c979ff421af","type":"TRIAL","name":"Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT00659737","description":"Nausea; Vomiting","metadata":null},{"id":"a820a82cd54e424b85d3d6de93bf6523","type":"TRIAL","name":"Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy","canonical_id":"clinicaltrials.gov:NCT07163585","description":"Epilepsy","metadata":null},{"id":"d11240b1dd884c5fad6f10e31154dbbf","type":"TRIAL","name":"Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department","canonical_id":"clinicaltrials.gov:NCT03145467","description":"Acute Migraine Headache","metadata":null},{"id":"b0da3af64d12459b80bf4822f4960ab0","type":"TRIAL","name":"Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care","canonical_id":"clinicaltrials.gov:NCT04938388","description":"Diabetes Mellitus, Type 2; Glucose Metabolism Disorders (Including Diabetes Mellitus)","metadata":null},{"id":"b4655b003e5e47a381733d5c7648384b","type":"TRIAL","name":"Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT03408756","description":"Psoriasis Vulgaris","metadata":null},{"id":"95f56941294e474597f57a18d84f98eb","type":"TRIAL","name":"Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT02606253","description":"Heart Failure","metadata":null},{"id":"72d1d4c893bb4d98b65f1160e38aa4bc","type":"TRIAL","name":"Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose","canonical_id":"clinicaltrials.gov:NCT02864472","description":"Age-related Macular Degeneration","metadata":null},{"id":"d980745a907a4fcf9bc21efaaffc2051","type":"TRIAL","name":"Comparison of PET Amyloid Imaging in Japanese and Western Subjects","canonical_id":"clinicaltrials.gov:NCT02813070","description":"Mild Cognitive Impairment; Alzheimer's Disease; Healthy","metadata":null},{"id":"1e80f3f5bdbe468ebeeea39a9307259c","type":"TRIAL","name":"Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery","canonical_id":"clinicaltrials.gov:NCT02744508","description":"Orthopedic Surgery","metadata":null},{"id":"37986a10af7f41088678c0238656cde8","type":"TRIAL","name":"Comparison of Pantoprazole and Ranitidine in Dyspepsia","canonical_id":"clinicaltrials.gov:NCT01737840","description":"Dyspepsia","metadata":null},{"id":"8d23ca17f2054898a96acb08bac1b9e9","type":"TRIAL","name":"Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey","canonical_id":"clinicaltrials.gov:NCT06680206","description":"Migraine","metadata":null},{"id":"206d05d1e60e4496adb7ebe08e9481a4","type":"TRIAL","name":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","canonical_id":"clinicaltrials.gov:NCT00502099","description":"Hepatitis C","metadata":null},{"id":"be67108ea4f34d88afcfb1c65e355311","type":"TRIAL","name":"Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT03462069","description":"Diabetes Mellitus","metadata":null},{"id":"3c82e3acda8145b7929d9216605abf08","type":"TRIAL","name":"Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects","canonical_id":"clinicaltrials.gov:NCT00139581","description":"Atopic Dermatitis","metadata":null},{"id":"66a4d8ddae9649d3a20c3e514e28a3f6","type":"TRIAL","name":"Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)","canonical_id":"clinicaltrials.gov:NCT05981118","description":"ICD10 Code L40.9 for Psoriasis","metadata":null},{"id":"344675b7ac664ea487a66a25a744f9ff","type":"TRIAL","name":"Comparison of Postoperative Analgesia Between Intravenous Paracetamol and Intranasal Tapentadol","canonical_id":"clinicaltrials.gov:NCT05999890","description":"Lower Limb Fracture","metadata":null},{"id":"c715a5558d0a41c29777111d9c091ed8","type":"TRIAL","name":"Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00151450","description":"Anxiety","metadata":null},{"id":"24b5bff93a63464b8fded7cace6057ec","type":"TRIAL","name":"Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone","canonical_id":"clinicaltrials.gov:NCT06870266","description":"Ivf; Frozen Embryo Transfer (FET)","metadata":null},{"id":"d2d751a51b7a4c2cbba1616136dcbe09","type":"TRIAL","name":"Comparison of Preoperative Analgesics on the Efficacy of Inferior Alveolar Nerve Block.","canonical_id":"clinicaltrials.gov:NCT05488925","description":"Symptomatic Irreversible Pulpitis","metadata":null},{"id":"12e29d46132646d599017ae5146bd13b","type":"TRIAL","name":"Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)","canonical_id":"clinicaltrials.gov:NCT00066937","description":"Temporomandibular Joint Disorders","metadata":null},{"id":"b3e32a0c9eb743949cce0e0bbb3bfb9e","type":"TRIAL","name":"Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans","canonical_id":"clinicaltrials.gov:NCT01662297","description":"Insomnia; Mental Health Disorder; Substance Use Disorder","metadata":null},{"id":"7f80fcbafedd423892e339886ea5de10","type":"TRIAL","name":"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma","canonical_id":"clinicaltrials.gov:NCT00085735","description":"Medulloblastoma","metadata":null},{"id":"34c5e5cf213b448aa77230207ba84bd3","type":"TRIAL","name":"Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00670319","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"0eb0d19df6a7497fbc0130399aa2618c","type":"TRIAL","name":"Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss","canonical_id":"clinicaltrials.gov:NCT00163137","description":"Osteoporosis","metadata":null},{"id":"275d2483c1ed4cb8b28985a89f79b7e8","type":"TRIAL","name":"Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD","canonical_id":"clinicaltrials.gov:NCT04932980","description":"Wet Age-related Macular Degeneration","metadata":null},{"id":"35cfadea301c4e7caa80ab3ae9ccae78","type":"TRIAL","name":"Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol","canonical_id":"clinicaltrials.gov:NCT05435911","description":"Recovery","metadata":null},{"id":"410b1ba01f0946d29f449497a4edf412","type":"TRIAL","name":"Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT05397886","description":"Recovery","metadata":null},{"id":"0c83c5ec13b5414e9ffdf3d10677c262","type":"TRIAL","name":"Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia","canonical_id":"clinicaltrials.gov:NCT06513923","description":"Hip Fracture","metadata":null},{"id":"a0b8e6f5cbe54ef9a03f20c8261422db","type":"TRIAL","name":"Comparison of Rimegepant and Placebo for Pain in IBS","canonical_id":"clinicaltrials.gov:NCT06221111","description":"Irritable Bowel Syndrome","metadata":null},{"id":"c59df8ca66494fd4b3ec81e60f07d908","type":"TRIAL","name":"Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03426254","description":"Advanced or Recurrent Solid Tumors; Breast Neoplasm","metadata":null},{"id":"3eb92bce21aa4053819cc0a0128cfeac","type":"TRIAL","name":"Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid","canonical_id":"clinicaltrials.gov:NCT00845195","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"8d7b7ccbe2424a9197ea5c1bd7afbdd3","type":"TRIAL","name":"Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency","canonical_id":"clinicaltrials.gov:NCT01094600","description":"Pancreatic Cancer","metadata":null},{"id":"dd73797c79da45c2a8b8e399e7743f6b","type":"TRIAL","name":"Comparison of Sequential to Initial Combination Therapy in PAH","canonical_id":"clinicaltrials.gov:NCT06968962","description":"Pulmonary Arterial Hypertension (PAH)","metadata":null},{"id":"d9aec05b0c3848a7b7c71cb159a79b3d","type":"TRIAL","name":"Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT07398937","description":"Resectable Stage II-IIIa Squamous NSCLC","metadata":null},{"id":"6b1c0eeec19b42ed92989edca1e0d7f0","type":"TRIAL","name":"Comparison of Sevikar\u00ae and the Combination of Perindopril/Amlodipine on Central Blood Pressure","canonical_id":"clinicaltrials.gov:NCT01101009","description":"Hypertension","metadata":null},{"id":"30cf14dffa7a4e6299967c81ab1f838b","type":"TRIAL","name":"Comparison of Short-term Sustained-release Opioid in Open Abdominal Urologic Surgeries","canonical_id":"clinicaltrials.gov:NCT05375916","description":"Pain, Acute; Opioid Use","metadata":null},{"id":"9dc021312a35436681ccce9f1f8f7ad1","type":"TRIAL","name":"Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT06999135","description":"Tamsulosin; Silodosin; Medical Expulsive Therapy","metadata":null},{"id":"9d9e7dd64a2f4c54bfec7e829ddbb7c5","type":"TRIAL","name":"Comparison of Single and Combination Diuretics in Low-Renin Hypertension","canonical_id":"clinicaltrials.gov:NCT02351973","description":"Hypertension","metadata":null},{"id":"e77e3f09f9e24898807ce6abbf8deea6","type":"TRIAL","name":"Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound","canonical_id":"clinicaltrials.gov:NCT00655512","description":"Healthy","metadata":null},{"id":"764768d669754dbc8df961d728714262","type":"TRIAL","name":"Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03310944","description":"Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus","metadata":null},{"id":"68a4c2d0a45240d8961fb0596c0c1d36","type":"TRIAL","name":"Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension","canonical_id":"clinicaltrials.gov:NCT04331691","description":"Resistant Hypertension","metadata":null},{"id":"44fc4985e13e473db46276b9ee4a50cf","type":"TRIAL","name":"Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels","canonical_id":"clinicaltrials.gov:NCT05525338","description":"Drug Monitoring; Carcinoma, Non-Small-Cell Lung; Lung Cancer; Anaplastic Lymphoma Kinase Gene Mutation; Anaplastic Lymphoma Kinase Gene Translocation","metadata":null},{"id":"3909cee194a945d6bce647372c54241c","type":"TRIAL","name":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","canonical_id":"clinicaltrials.gov:NCT04739800","description":"Fallopian Tube Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Mucinous Adenocarcinoma; Recurrent Fallopian Tube Transitional Cell Carcinoma; Recurrent Fallopian Tub\u2026","metadata":null},{"id":"7dd12d12af3540e18048b8b6b2ebd410","type":"TRIAL","name":"Comparison of Sufentanil, Fentanyl and Remifentanil in Combination With Midazolam During Bronchoscopy Under Conscious Sedation","canonical_id":"clinicaltrials.gov:NCT03901716","description":"Sufentanil; Remifentanil; Fentanyl; Bronchoscopy; Narcotrend; Conscious Sedation","metadata":null},{"id":"5fc60a9df2fe4d90a9bb5ed5cb771802","type":"TRIAL","name":"Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)","canonical_id":"clinicaltrials.gov:NCT00724932","description":"Anesthesia, General","metadata":null},{"id":"1a5df35593eb4342ad04bd78ee08eedd","type":"TRIAL","name":"Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine","canonical_id":"clinicaltrials.gov:NCT01941628","description":"Cesarean Section","metadata":null},{"id":"d644e386f2294c388f99c49b126a0e5e","type":"TRIAL","name":"Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)","canonical_id":"clinicaltrials.gov:NCT02457130","description":"Coronary Artery Disease; Diabetes Mellitus. Type 2","metadata":null},{"id":"0b57becd1c4f438eb6147a872e47dd8e","type":"TRIAL","name":"Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment na\u00efve COPD Participants","canonical_id":"clinicaltrials.gov:NCT02665130","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"193581056f924b65bb8c222e37dddfda","type":"TRIAL","name":"Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00145106","description":"Acne Vulgaris","metadata":null},{"id":"94025799a39e4f7b8a4b6a75f03760a1","type":"TRIAL","name":"Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans","canonical_id":"clinicaltrials.gov:NCT02742467","description":"Hypertension","metadata":null},{"id":"d1357fe79f92441680b3a885cdaaae95","type":"TRIAL","name":"Comparison of Three Confirmatory Tests in the Diagnosis of Primary Aldosteronism","canonical_id":"clinicaltrials.gov:NCT04193137","description":"Primary Aldosteronism","metadata":null},{"id":"9baaf2e43cab47ca91d25e7912c0dddc","type":"TRIAL","name":"Comparison of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting (PONV) in Children","canonical_id":"clinicaltrials.gov:NCT01434017","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"bccb5e9cc3f0460d8d1ec1ac5c3e107c","type":"TRIAL","name":"Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00005962","description":"Leukemia","metadata":null},{"id":"96c2d0db347847649458df2fd214ac71","type":"TRIAL","name":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT02172443","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"d8cbedf49b33470980b8f570c3708db4","type":"TRIAL","name":"Comparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT07673094","description":"Acne Vulgaris","metadata":null},{"id":"83af0a7192b44128994ac2e98c49ee3e","type":"TRIAL","name":"Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure","canonical_id":"clinicaltrials.gov:NCT01023178","description":"Ovarian Failure, Premature","metadata":null},{"id":"431ee941d9a0432a879b1d132da44b46","type":"TRIAL","name":"Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma","canonical_id":"clinicaltrials.gov:NCT03457389","description":"Pituitary Adenoma; Prolactinoma; Pituitary Tumor; Recurrence Tumor","metadata":null},{"id":"26015a6a699743808f4c38737539183c","type":"TRIAL","name":"Comparison of Treatments in Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT05715385","description":"Diabetic Macular Edema","metadata":null},{"id":"dd6e710919cc45e4ab6715b0825fb930","type":"TRIAL","name":"Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient","canonical_id":"clinicaltrials.gov:NCT03360123","description":"Dental Anxiety","metadata":null},{"id":"c84e6101b5bb4f45bbf934ca0d6180cf","type":"TRIAL","name":"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00059839","description":"Lymphoma","metadata":null},{"id":"41f2858b6a9f4eb78a3a9f6af3369a17","type":"TRIAL","name":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00049595","description":"Lymphoma","metadata":null},{"id":"797d7e504d294b379367e77d52ecf4b0","type":"TRIAL","name":"Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes","canonical_id":"clinicaltrials.gov:NCT02964949","description":"Atrial Fibrillation","metadata":null},{"id":"da30ae0b3b1b4b249ac6fcacd7f4a395","type":"TRIAL","name":"Comparison of Two Kinds of Postoperative Analgesia After Amputation","canonical_id":"clinicaltrials.gov:NCT02114463","description":"Pain; Complications","metadata":null},{"id":"ff3bfb4247ad4cdaa7af63447f1a1418","type":"TRIAL","name":"Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome","canonical_id":"clinicaltrials.gov:NCT00429364","description":"Marfan Syndrome","metadata":null},{"id":"fbd4d064041541ce9e6d1517ea681011","type":"TRIAL","name":"Comparison of Two Pharmacological Treatments of Pedophilia","canonical_id":"clinicaltrials.gov:NCT00601276","description":"Pedophilia","metadata":null},{"id":"03309978e7cd4302b3b1125fa026a300","type":"TRIAL","name":"Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section","canonical_id":"clinicaltrials.gov:NCT03626753","description":"Cesarean Section; Complications, Wound, Infection (Following Delivery); Postoperative Pain; Spinal Anaesthesia During the Puerperium","metadata":null},{"id":"cf9ea8ab67ea49e9a6bf51e175862fd5","type":"TRIAL","name":"Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis","canonical_id":"clinicaltrials.gov:NCT03729310","description":"Chronic Sinusitis; Rhinosinusitis","metadata":null},{"id":"63b96c87688b4a68a08253bb52043979","type":"TRIAL","name":"Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)","canonical_id":"clinicaltrials.gov:NCT01448213","description":"Fuchs' Dystrophy; Bullous Keratopathy","metadata":null},{"id":"3b875fc7bbe145279c9fa4bd0f61e27b","type":"TRIAL","name":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","canonical_id":"clinicaltrials.gov:NCT01296412","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"8533be72536a48b48eed97283c1e5c78","type":"TRIAL","name":"Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation","canonical_id":"clinicaltrials.gov:NCT00445263","description":"CORONARY DISEASE","metadata":null},{"id":"21f3087036c14b869626a1b993c7300a","type":"TRIAL","name":"Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission","canonical_id":"clinicaltrials.gov:NCT00962767","description":"Leukemia, Myelocytic, Acute","metadata":null},{"id":"af1dc8fe45f843afac7f1da93a602792","type":"TRIAL","name":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","canonical_id":"clinicaltrials.gov:NCT05073692","description":"Type 2 Diabetes Mellitus; Cardiovascular Diseases","metadata":null},{"id":"b2166989e0b4472591ee89ac9dbafa27","type":"TRIAL","name":"Comparison of Vasopressin and Other Pressors in Septic Shock","canonical_id":"clinicaltrials.gov:NCT00269685","description":"Shock, Septic","metadata":null},{"id":"44b651062ae1477b933cf49a15cf1acb","type":"TRIAL","name":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT06025474","description":"Burning Mouth Syndrome","metadata":null},{"id":"fd30d900b7d148febc9ab02391ea5df6","type":"TRIAL","name":"Comparison of a \"Step-Up\" Versus a \"Step-Down\" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)","canonical_id":"clinicaltrials.gov:NCT00247715","description":"Dyspepsia; Gastrointestinal Diseases","metadata":null},{"id":"463d09a6c9cc40d993748c0b97e9f452","type":"TRIAL","name":"Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female","canonical_id":"clinicaltrials.gov:NCT06976424","description":"Hirsuitism","metadata":null},{"id":"7aa09dc02fa1483d929ce82a59296d7e","type":"TRIAL","name":"Comparison of a Prophylactic Intraligamentary Injection of Piroxicam Versus Mepecaine of Post-endodontic Pain","canonical_id":"clinicaltrials.gov:NCT03006107","description":"Pulpitis - Irreversible","metadata":null},{"id":"22ce70054e7d466ca6ae638505aa9cb4","type":"TRIAL","name":"Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty","canonical_id":"clinicaltrials.gov:NCT00567411","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"766bacc0716942fea2828916f0c90bb1","type":"TRIAL","name":"Comparison of the Anti-Inflammatory Efficacy of Preemptive Dexamethasone and Etoricoxib","canonical_id":"clinicaltrials.gov:NCT05142098","description":"Effect of Drug","metadata":null},{"id":"3afbe9d0cfcb4488942f50ba6e55cf20","type":"TRIAL","name":"Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose","canonical_id":"clinicaltrials.gov:NCT00302705","description":"Hypertension","metadata":null},{"id":"4229d6e5ac4d44f3b10e948ecbc14d2b","type":"TRIAL","name":"Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs","canonical_id":"clinicaltrials.gov:NCT00819741","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"b37506613b634124b7a73c94128bd61e","type":"TRIAL","name":"Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS","canonical_id":"clinicaltrials.gov:NCT07261072","description":"Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa); Secukinumab","metadata":null},{"id":"f47cee515b09485a8a8006ae031e1b18","type":"TRIAL","name":"Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT07850713","description":"Hyperuricemia; Renal Insufficiency, Chronic","metadata":null},{"id":"8e716a8ce8184be7b2a6f60e15d7b542","type":"TRIAL","name":"Comparison of the Effect of Cyclizine Versus Metoclopramide on Gastric Residual Volume in Patients Undergoing Bariatric Surgery: A Randomized Double-blinded Clinical Trial","canonical_id":"clinicaltrials.gov:NCT06789614","description":"Bariatric Surgery","metadata":null},{"id":"614f7a30884d44e5b8e6ffa1298d9848","type":"TRIAL","name":"Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT01631227","description":"Essential Hypertension","metadata":null},{"id":"5534f4543c904f3093879566f48cd47b","type":"TRIAL","name":"Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT01067430","description":"Rheumatoid Arthritis","metadata":null},{"id":"09b02d326c9e41279d431d3aeba1c667","type":"TRIAL","name":"Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00488176","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"5a7c30ff0db6412ea926e79f753b4a14","type":"TRIAL","name":"Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care","canonical_id":"clinicaltrials.gov:NCT06499116","description":"Migraine","metadata":null},{"id":"d602a6f015f44a9598124d525438b8b3","type":"TRIAL","name":"Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00503399","description":"Osteoporosis","metadata":null},{"id":"ff1397b6851f4a7696f435bb9fef98ac","type":"TRIAL","name":"Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06474182","description":"Multiple Myeloma; Total Knee Replacement","metadata":null},{"id":"00b556d0cd844774adbfbf63e96dd66c","type":"TRIAL","name":"Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)","canonical_id":"clinicaltrials.gov:NCT00867191","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"a369ee83e8174dc2924697a84767f27a","type":"TRIAL","name":"Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT07678073","description":"Kidney Disease, End-Stage; Kidney Transplant; Kidney; Kidney Disease; Renal Transplant","metadata":null},{"id":"eee23da315dc4000ad6f5654077a85bb","type":"TRIAL","name":"Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans","canonical_id":"clinicaltrials.gov:NCT01500317","description":"Effects of 2 Mu-opiates on Gastrointestinal Transit","metadata":null},{"id":"bb0a0764499e494dbaae41c5c8e49959","type":"TRIAL","name":"Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT07308964","description":"Thyroid Eye Disease; Thyroid Eye Disease, TED; Thyroid Eye Disease (TED)","metadata":null},{"id":"d51670488d654ab596c0990a2475188d","type":"TRIAL","name":"Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06344247","description":"Obesity; Chronic Kidney Diseases","metadata":null},{"id":"decd874b4db74614b6c459ae1e39d6fc","type":"TRIAL","name":"Comparison of the Efficacy of AZARGA\u00ae Versus COSOPT\u00ae in Patients With Open-Angled Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01111890","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"97176ecc6bcd4f1fbf07667281b397d9","type":"TRIAL","name":"Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07694674","description":"Inflamatory Bowel Disease; Crohn Disease (CD)","metadata":null},{"id":"31df6852fe45425587d33eca874e11c1","type":"TRIAL","name":"Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis","canonical_id":"clinicaltrials.gov:NCT04737343","description":"ANCA Associated Vasculitis; Maintenance Therapy","metadata":null},{"id":"70c4c646fee942df94d6f754f221f7f4","type":"TRIAL","name":"Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients","canonical_id":"clinicaltrials.gov:NCT04181567","description":"Major Depressive Disorder","metadata":null},{"id":"606cf76833434bd08c9f6b3772d6bd75","type":"TRIAL","name":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00822081","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"5e3b101b73e648ffa73efb0d171a8c2b","type":"TRIAL","name":"Comparison of the Pain Levels of Single-Dose Premedication With Piroxicam and Prednisolone on Post-Endodontic Pain in Single-Visit Root Canal Treatment of Premolars","canonical_id":"clinicaltrials.gov:NCT07281807","description":"Irreversible Pulpitis With Apical Periodontitis; Symptomatic Apical Periodontitis","metadata":null},{"id":"d785c6b9a14c426ead57f3b330d6932f","type":"TRIAL","name":"Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations","canonical_id":"clinicaltrials.gov:NCT01400165","description":"Healthy","metadata":null},{"id":"547c461b5e4a4cc79cbe63e4e9b79de4","type":"TRIAL","name":"Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations","canonical_id":"clinicaltrials.gov:NCT00676039","description":"Healthy","metadata":null},{"id":"2ef12281574e40c9863b51cfb215afcc","type":"TRIAL","name":"Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK","canonical_id":"clinicaltrials.gov:NCT05587231","description":"Steroid Ophthalmic Insert","metadata":null},{"id":"a7713295fd3f48e7be58e44e78f1456e","type":"TRIAL","name":"Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan","canonical_id":"clinicaltrials.gov:NCT06491940","description":"Proteinuria","metadata":null},{"id":"ffc618ba44fb4eaca7d297b228df3bee","type":"TRIAL","name":"Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study","canonical_id":"clinicaltrials.gov:NCT04412876","description":"Stress Urinary Incontinence","metadata":null},{"id":"4bcf6daaacf247408a9a31a1937462dd","type":"TRIAL","name":"Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study","canonical_id":"clinicaltrials.gov:NCT05946902","description":"Female Patients With Overactive Bladder Syndrome","metadata":null},{"id":"3d0c3eb29719407cb906954d1eef894b","type":"TRIAL","name":"Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis","canonical_id":"clinicaltrials.gov:NCT05697471","description":"Endometriosis","metadata":null},{"id":"60785d5d26e045908622b9edc3ab3327","type":"TRIAL","name":"Compassionate Use Ponatinib","canonical_id":"clinicaltrials.gov:NCT01549548","description":"Philadelphia Chromosome Positive (Ph+) Leukemias; Chronic Myeloid Leukemia","metadata":null},{"id":"d4d0ea1d27bc4f0da8f687a5a6c43ee6","type":"TRIAL","name":"Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy","canonical_id":"clinicaltrials.gov:NCT03532516","description":"Epilepsy","metadata":null},{"id":"fc93984ebc934c28bd1887f5ef7fca02","type":"TRIAL","name":"Compassionate Use Study of Methylnaltrexone","canonical_id":"clinicaltrials.gov:NCT01368562","description":"Opioid-induced Constipation","metadata":null},{"id":"e41ef37bd77b49b0b189b64fd4aedf2a","type":"TRIAL","name":"Compassionate Use for Subcutaneous (SC) Belimumab","canonical_id":"clinicaltrials.gov:NCT03125486","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"a9477a9472eb4bdc8b51f4dadd26e875","type":"TRIAL","name":"Compassionate Use of BYL 719 Alpelisib","canonical_id":"clinicaltrials.gov:NCT03941782","description":"Lymphangioma","metadata":null},{"id":"5624eee1f8d2478397c82ed2bc8f0adf","type":"TRIAL","name":"Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00021151","description":"Leukemia","metadata":null},{"id":"e856c9c132df49e0937316580afdc975","type":"TRIAL","name":"Compassionate Use of Domperidone for Refractory Gastroparesis","canonical_id":"clinicaltrials.gov:NCT04699591","description":"GERD; Gastroesophageal Reflux; Gastroparesis","metadata":null},{"id":"842589879eb34c3b90ef5e45a6a8e99d","type":"TRIAL","name":"Compassionate Use of Evinacumab","canonical_id":"clinicaltrials.gov:NCT06500598","description":"Pediatric Homozygous Familial Hypercholesterolemia (HoFH); Severe Hypertriglyceridemia (HTG); Dysbetalipoproteinemia (DBL)","metadata":null},{"id":"0dfd81be2c174deeb9b44ab567e05ad4","type":"TRIAL","name":"Compassionate Use of Ibalizumab for the Treatment of HIV Infection","canonical_id":"clinicaltrials.gov:NCT02028819","description":"Human Immunodeficiency Virus (HIV)","metadata":null},{"id":"ec8bb3a0d75c4eaea39ad1f45e1e74c7","type":"TRIAL","name":"Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia","canonical_id":"clinicaltrials.gov:NCT02835131","description":"Congenital Hyperinsulinism","metadata":null},{"id":"95238b59372b48978f95008472cd298c","type":"TRIAL","name":"Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements","canonical_id":"clinicaltrials.gov:NCT00642057","description":"Hyperkinetic Movement Disorders","metadata":null},{"id":"fa96d6f0baca45c4ab1965f6ece4c112","type":"TRIAL","name":"Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib","canonical_id":"clinicaltrials.gov:NCT03386071","description":"Progressive Metastatic Castrate Resistant Prostate Cancer","metadata":null},{"id":"650ddf7e1d554a74836859e3e7c510f3","type":"TRIAL","name":"Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline","canonical_id":"clinicaltrials.gov:NCT01435213","description":"Healthy","metadata":null},{"id":"db6df7fbd12243919d40c5a3ba924d7e","type":"TRIAL","name":"Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT02298933","description":"Thrombocytopenia; Alloimmune Platelet Refractoriness","metadata":null},{"id":"cc6aa237fe73480abae0a328bee897ec","type":"TRIAL","name":"Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00935883","description":"Age-Related Macular Degeneration","metadata":null},{"id":"5e53109055504ed9991a8a0d105b3691","type":"TRIAL","name":"Complementary Combination Therapy for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT02538744","description":"Cocaine Dependence","metadata":null},{"id":"ca74dffae25e49f5bcc372563f657fb3","type":"TRIAL","name":"Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT01851863","description":"Dyspepsia; Compliance; Depression","metadata":null},{"id":"366cd903683847f0b277d261c1208844","type":"TRIAL","name":"Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients","canonical_id":"clinicaltrials.gov:NCT00191802","description":"Osteoporosis","metadata":null},{"id":"d92473803ab94f81b10bf53aa9525c8e","type":"TRIAL","name":"Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm\u00b2 in Patients With Probable Alzheimer's Disease.","canonical_id":"clinicaltrials.gov:NCT00731224","description":"Alzheimer's Disease","metadata":null},{"id":"f2e215aa07ff484b8880baad5711081d","type":"TRIAL","name":"Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)","canonical_id":"clinicaltrials.gov:NCT00728494","description":"Hepatitis C, Chronic; Hepatitis C","metadata":null},{"id":"db2eb4963dbe454a9dfbe4d022f23dfa","type":"TRIAL","name":"Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)","canonical_id":"clinicaltrials.gov:NCT05067478","description":"Overactive Bladder","metadata":null},{"id":"75449b4fee0c4679b95af56411da25a2","type":"TRIAL","name":"Comprehensive Add on Study in Japan","canonical_id":"clinicaltrials.gov:NCT01204294","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"64f1c8f48a95421ab959d3d8197b7403","type":"TRIAL","name":"Comprehensive Magnetic Resonance of Peripheral Arterial Disease","canonical_id":"clinicaltrials.gov:NCT00587678","description":"Peripheral Artery Disease","metadata":null},{"id":"88f4e385887d43d29645dd706d287bb2","type":"TRIAL","name":"Concerta Treatment in Adults With ADHD NOS","canonical_id":"clinicaltrials.gov:NCT00181740","description":"ADHD NOS","metadata":null},{"id":"e9f73364b0db494c825ffc5a4aaf1461","type":"TRIAL","name":"Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children","canonical_id":"clinicaltrials.gov:NCT01065259","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"b1abd1b713b94b8fa6092ed0832e9fe6","type":"TRIAL","name":"Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy","canonical_id":"clinicaltrials.gov:NCT05000710","description":"Metastatic or Locally Advanced NSCLC","metadata":null},{"id":"b14ca75725104899a97cff22fc5ecf6a","type":"TRIAL","name":"Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT01063855","description":"Erectile Dysfunction; Sexual Dysfunction","metadata":null},{"id":"7c64e93cebf44bf1a0d422b46e64729e","type":"TRIAL","name":"Concurrent Bupropion / Varenicline for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT01303861","description":"Nicotine Dependence","metadata":null},{"id":"0f8bda0115104c08a3c9c061f6bf5d04","type":"TRIAL","name":"Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT04447612","description":"Nasopharyngeal Carcinoma","metadata":null},{"id":"57ebc3938e2d43bbb05f1cbf3526bce5","type":"TRIAL","name":"Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM","canonical_id":"clinicaltrials.gov:NCT06341595","description":"Gastric Cancer; Gastric Cancer Metastatic to Regional Lymph Nodes","metadata":null},{"id":"6929b49bb6c44be786d1aaa7e34de62d","type":"TRIAL","name":"Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT01462474","description":"Locally Advanced Nasopharyngeal Carcinoma","metadata":null},{"id":"a2f36d55bdd44e7d9767f763d952256a","type":"TRIAL","name":"Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors","canonical_id":"clinicaltrials.gov:NCT02921984","description":"Salivary Gland Tumors; Head and Neck Cancer","metadata":null},{"id":"11de1de1bbd2453daad9c81ab3807297","type":"TRIAL","name":"Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases","canonical_id":"clinicaltrials.gov:NCT02974803","description":"Melanoma; Brain Metastases","metadata":null},{"id":"9bd0d9bd688947ad9f00f4788b221674","type":"TRIAL","name":"Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC","canonical_id":"clinicaltrials.gov:NCT03694236","description":"Potentially Resectable Stage II/IIIa NSCLC","metadata":null},{"id":"592bd86434de436497d4dad7a1d06fcb","type":"DISEASE","name":"Condylomata Acuminata","canonical_id":"mesh:D003218","description":null,"metadata":null},{"id":"68adcf58d6674689a13ef8558b222142","type":"TRIAL","name":"Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00794157","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"507261da9eb64528b5f3aafa7ec5c4fb","type":"TRIAL","name":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","canonical_id":"clinicaltrials.gov:NCT02354235","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"cdf002cad93748438e0a5f7226938dac","type":"TRIAL","name":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","canonical_id":"clinicaltrials.gov:NCT02354222","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"6ad4c13ca237478d92eb68b961d3e7e1","type":"TRIAL","name":"Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery","canonical_id":"clinicaltrials.gov:NCT00838383","description":"Cardiac Surgery Subjects; Subjects Undergoing CABG and/or Cardiac Valve Replacement","metadata":null},{"id":"7ef564a370c3423eacfde9b6d5fc5597","type":"DISEASE","name":"Congenital adrenal hyperplasia","canonical_id":"mesh:D000312","description":null,"metadata":null},{"id":"0367e7107cb94644a2f8cdd5f43fd4ed","type":"DISEASE","name":"Congenital atresia of the pulmonary valve","canonical_id":"mesh:D018633","description":null,"metadata":null},{"id":"d4107659b6ef449cbca2b9a5ec54403f","type":"DISEASE","name":"Congenital atresia of tricuspid valve","canonical_id":"mesh:D018785","description":null,"metadata":null},{"id":"aa3ec93e4f8b44cc850b55df3916b140","type":"DISEASE","name":"Congenital generalized lipodystrophy","canonical_id":"mesh:D052497","description":null,"metadata":null},{"id":"5b42ff34480444c2ab6b11cce2fbd443","type":"DISEASE","name":"Congenital hypoplastic anemia","canonical_id":"mesh:D029503","description":null,"metadata":null},{"id":"fc6eb54f6cab422997062c370305eb3f","type":"DISEASE","name":"Congenital hypothyroidism","canonical_id":"mesh:D003409","description":null,"metadata":null},{"id":"8c75b97998bc42fba99a0b20d3407566","type":"DISEASE","name":"Congenital neutropenia","canonical_id":"mesh:C537592","description":null,"metadata":null},{"id":"9e928dc0c00d44dfa6084046892c42c5","type":"DISEASE","name":"Congenital toxoplasmosis","canonical_id":"mesh:D014125","description":null,"metadata":null},{"id":"96f312229b6e4236a00c7605dadaf067","type":"DISEASE","name":"Congestive heart failure","canonical_id":"mesh:D006333","description":null,"metadata":null},{"id":"4c5a0919df034ebcb7106b33ed99653d","type":"TRIAL","name":"Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study","canonical_id":"clinicaltrials.gov:NCT03000283","description":"Cerebral Hemorrhage; Cerebral Edema; Intracerebral Hemorrhage; Stroke","metadata":null},{"id":"9b06a6f612b6473a8978c018de216aec","type":"DISEASE","name":"Conjunctivitis, Bacterial","canonical_id":"mesh:D003234","description":null,"metadata":null},{"id":"7afe68c4cafb4b5bb116cd7c0428c2ad","type":"DISEASE","name":"Conjunctivitis, Inclusion","canonical_id":"mesh:D003235","description":null,"metadata":null},{"id":"e6387284903044e08bea284947c04170","type":"TRIAL","name":"Conservative Therapy Versus Epidural Steroids for Cervical Radiculopathy","canonical_id":"clinicaltrials.gov:NCT01144923","description":"Cervical Radiculopathy","metadata":null},{"id":"da42fa1ee8c3442fbaef2ceaf8951aea","type":"TRIAL","name":"Consistency of Response With Rimegepant in Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT06898047","description":"Migraine","metadata":null},{"id":"3069b99be18f43829daf71ac5e1a729a","type":"TRIAL","name":"Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT00722930","description":"Follicular Lymphoma","metadata":null},{"id":"9e0eb86189d94f80981ccea73939a097","type":"DISEASE","name":"Constipation","canonical_id":"mesh:D003248","description":null,"metadata":null},{"id":"f5a891e453524526ba96823b2bfc204d","type":"TRIAL","name":"Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00976209","description":"Vasomotor Rhinitis; Seasonal Allergic Rhinitis","metadata":null},{"id":"6f321c2869e94c64b5f02283b19dd3ae","type":"TRIAL","name":"Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00000375","description":"Major Depressive Disorder","metadata":null},{"id":"e511e6ee60a9494fb1998c00242ec6d3","type":"TRIAL","name":"Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML","canonical_id":"clinicaltrials.gov:NCT04842604","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"ecf720947ba74218a5ac23528a9d430f","type":"TRIAL","name":"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","canonical_id":"clinicaltrials.gov:NCT00790816","description":"Neoplasms, Breast","metadata":null},{"id":"662a554d043d4bef9865f087f29a2fc4","type":"TRIAL","name":"Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial","canonical_id":"clinicaltrials.gov:NCT01851850","description":"Parkinson Disease","metadata":null},{"id":"0b9fbf1cc83f40e385d27da05857cff6","type":"TRIAL","name":"Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers","canonical_id":"clinicaltrials.gov:NCT07791199","description":"Systemic Lupus Erythematosus; Sj\u00f6gren's Disease; Psoriasis; Psoriatic Arthritis","metadata":null},{"id":"565238cbedce428b8c2784b027328d59","type":"TRIAL","name":"Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease","canonical_id":"clinicaltrials.gov:NCT00200525","description":"Parkinson Disease","metadata":null},{"id":"91a08dbdca7841979f4391d30c4625f9","type":"TRIAL","name":"Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00320710","description":"Breast Cancer","metadata":null},{"id":"71814134f5514d3bb38780fbea941c11","type":"TRIAL","name":"Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months","canonical_id":"clinicaltrials.gov:NCT00200512","description":"Parkinson Disease","metadata":null},{"id":"312d073cf0cf4b18a43d40faa5aedfa3","type":"TRIAL","name":"Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone","canonical_id":"clinicaltrials.gov:NCT00968968","description":"Cancer","metadata":null},{"id":"4c64a0b8e8424cda802b5a982702d910","type":"TRIAL","name":"Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab","canonical_id":"clinicaltrials.gov:NCT02719613","description":"Multiple Myeloma","metadata":null},{"id":"dcdbf8262e8a4621badd0bd1ba9b48f2","type":"TRIAL","name":"Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography","canonical_id":"clinicaltrials.gov:NCT05271448","description":"Contrast-induced Nephropathy; Chronic Kidney Diseases; Ischemic Heart Disease","metadata":null},{"id":"ea5735e476de4ef1b8da0a18d8d734b0","type":"TRIAL","name":"Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT01482468","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"e84aaf971356498692803fe8c3ff8b27","type":"TRIAL","name":"Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures","canonical_id":"clinicaltrials.gov:NCT02604589","description":"Rib Fractures","metadata":null},{"id":"84becce243c84a4c962d765091bcb1ea","type":"TRIAL","name":"Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03362073","description":"Ketamine; Refractory Cancer Pain","metadata":null},{"id":"27162864f6f14a50956a5bd4ec56e55e","type":"TRIAL","name":"Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia","canonical_id":"clinicaltrials.gov:NCT04140396","description":"Rib Fractures","metadata":null},{"id":"aa9efd128fab40219c8c9c9eaf17a6c5","type":"TRIAL","name":"Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude","canonical_id":"clinicaltrials.gov:NCT00928655","description":"Obstructive Sleep Apnea Syndrome","metadata":null},{"id":"788ff34ab1824ec1b0cafb5c953a98d2","type":"TRIAL","name":"Contraceptive Hormones, Immunity, and Microbiome Evaluation","canonical_id":"clinicaltrials.gov:NCT03660046","description":"Hormonal Contraception","metadata":null},{"id":"8a835fd577824383b611c9a210f8ad59","type":"TRIAL","name":"Contribution of Ondansetron to Preventing Post-Dural Puncture Headaches Following Spinal Anesthesia","canonical_id":"clinicaltrials.gov:NCT06444737","description":"Post-Dural Puncture Headache","metadata":null},{"id":"eab8920a6b2d4ac685afd2e794571e65","type":"TRIAL","name":"Control Trial of Intermittent Hemodialysis With Regional Citrate VS Priming Heparin With Predilution in Patients at Risk of Bleeding","canonical_id":"clinicaltrials.gov:NCT03562754","description":"Hemodialysis","metadata":null},{"id":"36ff2ed1279840c592a815b53e15ef47","type":"TRIAL","name":"Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))","canonical_id":"clinicaltrials.gov:NCT01993108","description":"Healthy; Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"12a2b2f1feda4c8a9fe8d3a8a8a61946","type":"TRIAL","name":"Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem","canonical_id":"clinicaltrials.gov:NCT01408524","description":"Hypertension; Craniotomy","metadata":null},{"id":"910367d67779461cb03cef374d6292a2","type":"TRIAL","name":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","canonical_id":"clinicaltrials.gov:NCT04343222","description":"Intravitreal Injections; IVI","metadata":null},{"id":"2bbd3ce526cd4a779879cde85512264b","type":"TRIAL","name":"Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT02898454","description":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","metadata":null},{"id":"991a0bdbe7744dab905be7bad1e88371","type":"TRIAL","name":"Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)","canonical_id":"clinicaltrials.gov:NCT04289805","description":"Breast Neoplasm Malignant Female","metadata":null},{"id":"d179a6276bc241f7afcaf2131b68978f","type":"TRIAL","name":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00363519","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1f087cc6bf6b47ca9a1e640140593a7d","type":"TRIAL","name":"Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia","canonical_id":"clinicaltrials.gov:NCT00068081","description":"Herpes Zoster; Neuralgia; Pain; Peripheral Nervous System Diseases","metadata":null},{"id":"b909e8bd2a2749519255093d437895a3","type":"TRIAL","name":"Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT00083954","description":"Bipolar Disorder","metadata":null},{"id":"4b539964c03e44628a9e9f04ef016f75","type":"TRIAL","name":"Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT02014103","description":"Complication of Transplant","metadata":null},{"id":"0d6d525afec14f8ebd45ab33f07c14f6","type":"TRIAL","name":"Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis","canonical_id":"clinicaltrials.gov:NCT01478971","description":"Chronic Kidney Disease; Anemia","metadata":null},{"id":"92cb05fbd2a04c78a72fc30a11733594","type":"TRIAL","name":"Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT05627414","description":"Gastric Cancer","metadata":null},{"id":"3853f9da80b14ba1b6159aa2ee99b210","type":"TRIAL","name":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","canonical_id":"clinicaltrials.gov:NCT00256854","description":"Restless Legs Syndrome; Restless Legs Syndrome (RLS)","metadata":null},{"id":"e3b718ea75714c80ab162d3004908b60","type":"TRIAL","name":"Cooperative Group for Clinical Research in G-POEM (POP), Jiangsu, China","canonical_id":"clinicaltrials.gov:NCT03040817","description":"Gastric Peroral Endoscopic Pyloromyotomy (G-POEM)","metadata":null},{"id":"17d3168f690d423895f596cec9ae6680","type":"DRUG","name":"Copanlisib","canonical_id":"ncit:C96796","description":null,"metadata":null},{"id":"a445794ea909406f97af97f5ab80b3a4","type":"TRIAL","name":"Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT02631590","description":"Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor","metadata":null},{"id":"75c0702d966b4d669a2d1c26d298ed43","type":"TRIAL","name":"Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL","canonical_id":"clinicaltrials.gov:NCT04685915","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"afb27993cf514f9dbbcd7f318d8b07cf","type":"TRIAL","name":"Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT05687721","description":"Advanced Urothelial Carcinoma","metadata":null},{"id":"945b5d193bec4e7b8b058039f6e74f39","type":"TRIAL","name":"Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss","canonical_id":"clinicaltrials.gov:NCT02822482","description":"Carcinoma, Squamous Cell of Head and Neck","metadata":null},{"id":"0dfc8ebbab4c4cad871b0461d144ede1","type":"TRIAL","name":"Copd Exacerbation and Pulmonary Hypertension Trial","canonical_id":"clinicaltrials.gov:NCT04538976","description":"Acute Exacerbation of COPD","metadata":null},{"id":"6e1b924c26e74ec2a1294f3f1732c8e3","type":"TRIAL","name":"Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03844217","description":"Polyuria-polydipsia Syndrome","metadata":null},{"id":"d68d228f12624278b3787855e90c5b3e","type":"TRIAL","name":"Copper IUD Treatment Observation Study","canonical_id":"clinicaltrials.gov:NCT02519231","description":"Menorrhagia","metadata":null},{"id":"1040abcb13c6411488dc0f5157ffd5ee","type":"TRIAL","name":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","canonical_id":"clinicaltrials.gov:NCT04644016","description":"AML; ALL; MDS; MPD Withou Myelofibrosis; NHL or HL; Inherited Metabolic Disorders; Hemoglobinopathies; Bone Marrow Failure; HLH","metadata":null},{"id":"26efc59cd82b47ac879b248ced4d8203","type":"TRIAL","name":"Coreg and HSRs-Updated Analysis","canonical_id":"clinicaltrials.gov:NCT01316952","description":"Hypersensitivity","metadata":null},{"id":"022b5e28ab9240eaaf5869e7fd11147b","type":"TRIAL","name":"Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant","canonical_id":"clinicaltrials.gov:NCT03145025","description":"Uveitis, Posterior","metadata":null},{"id":"ea4411ed8bf6479ea3e92b20d1db6c82","type":"DISEASE","name":"Corneal ulcer","canonical_id":"mesh:D003320","description":null,"metadata":null},{"id":"42eaf17676e145cda5688814341ff897","type":"TRIAL","name":"Coronary Drug Project","canonical_id":"clinicaltrials.gov:NCT00000482","description":"Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia","metadata":null},{"id":"189537399283430e9bd4dec2f27cba4d","type":"TRIAL","name":"Coronary Drug Project Mortality Surveillance","canonical_id":"clinicaltrials.gov:NCT00000483","description":"Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia","metadata":null},{"id":"6494acf6f0f1402094d10f02abeeb8cc","type":"TRIAL","name":"Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin","canonical_id":"clinicaltrials.gov:NCT02791035","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"0dfbf7e03e5a4fdc92e4691997f7406a","type":"TRIAL","name":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","canonical_id":"clinicaltrials.gov:NCT03019887","description":"Schizophrenia Relapse","metadata":null},{"id":"4c2ee2c2913d410a93677f8bcb5b1526","type":"TRIAL","name":"Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients","canonical_id":"clinicaltrials.gov:NCT00165750","description":"Alzheimer's Disease","metadata":null},{"id":"1d3e3370ca0544d6b94d2ce442af4de1","type":"TRIAL","name":"Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT04613219","description":"Clinically Amyopathic Dermatomyisitis(CAMD)","metadata":null},{"id":"43afd7b08e7e4287aff49513c361d162","type":"TRIAL","name":"Correlation Study of Vascular Parameters in Hypertensive Men With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT01084187","description":"Erectile Dysfunction; Arterial Hypertension; Endothelial Dysfunction","metadata":null},{"id":"d84728ede86547b0a792ce67e5b3d540","type":"TRIAL","name":"Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05020860","description":"Breast Cancer; Breast Neoplasm; Breast Cancer Female; Breast Cancer Invasive; Breast Cancer Stage II; Breast Cancer Stage III; Triple Negative Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Triple Negative Breast Neoplasms; Estrogen Receptor-positive Breast Cancer","metadata":null},{"id":"2552915f4ced420682e56df2978339ca","type":"TRIAL","name":"Correlation of Endothelial Function and Early Coronary Artery Disease in Humans","canonical_id":"clinicaltrials.gov:NCT00271492","description":"Endothelial Dysfunction","metadata":null},{"id":"2901604dc52141b49d358aa42c31cc3f","type":"TRIAL","name":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","canonical_id":"clinicaltrials.gov:NCT05833399","description":"Substance Use Disorders; Substance Dependence","metadata":null},{"id":"1e8a6007817b4929805f5dfcc1146ff8","type":"TRIAL","name":"Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study","canonical_id":"clinicaltrials.gov:NCT01823159","description":"Epilepsy","metadata":null},{"id":"9126dce3b5224a29b4033a3fd256ba5a","type":"PROTEIN","name":"Corticosteroid 11-beta-dehydrogenase isozyme 1","canonical_id":"uniprot:P28845","description":null,"metadata":null},{"id":"141c3961e28b4507946cc61bcc2194b8","type":"TRIAL","name":"Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT01093261","description":"Traumatic Brain Injury; Trauma; Adrenal Insufficiency; Pneumonia","metadata":null},{"id":"ef533ff275074279a0d9ac4df8a078e6","type":"TRIAL","name":"Cortisol Response to Low Dose Cosyntropin Stimulation Test in the Late Afternoon","canonical_id":"clinicaltrials.gov:NCT03074123","description":"Adrenal Insufficiency","metadata":null},{"id":"d04a196df10a4c1db0d94ce9649dfa78","type":"TRIAL","name":"Cortisol and Nutritional Sympathetic Responsiveness","canonical_id":"clinicaltrials.gov:NCT01620684","description":"Metabolic Syndrome; Obesity; Insulin Resistance","metadata":null},{"id":"70c00c8652a944a5861464ba63377f3f","type":"TRIAL","name":"Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy","canonical_id":"clinicaltrials.gov:NCT07426484","description":"Cutaneous Squamous Cell Carcinoma; Skin Cancer","metadata":null},{"id":"43ce7533244648869a20ba7c11450d17","type":"TRIAL","name":"Cosopt Versus Xalatan","canonical_id":"clinicaltrials.gov:NCT00273429","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"1d11fc0858f3488994020410b245bc6d","type":"TRIAL","name":"Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis","canonical_id":"clinicaltrials.gov:NCT02022527","description":"Complications Due to Heart Valve Prosthesis","metadata":null},{"id":"fef3b709ea234bb5be0ea2244d701c63","type":"TRIAL","name":"Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode","canonical_id":"clinicaltrials.gov:NCT02918097","description":"Bipolar Disorder","metadata":null},{"id":"1b0ababdac734933aa97083d7d7c4801","type":"TRIAL","name":"Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder","canonical_id":"clinicaltrials.gov:NCT02901249","description":"Depression","metadata":null},{"id":"3d01bcff2ba945fdaea3ef4bcab46570","type":"TRIAL","name":"Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma","canonical_id":"clinicaltrials.gov:NCT01333800","description":"Asthma","metadata":null},{"id":"f39e8d04ded845139eaa4b3b3ee10385","type":"TRIAL","name":"Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","canonical_id":"clinicaltrials.gov:NCT07448402","description":"Psoriasis; Psoriasis Arthritis; Psoriasis (PsO)","metadata":null},{"id":"f62e7c06ad7242ed9d77c5c2e525829d","type":"DISEASE","name":"Costello syndrome","canonical_id":"mondo:0009026","description":null,"metadata":null},{"id":"30a4416bfc784b00a7568a7cd97df087","type":"TRIAL","name":"Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache","canonical_id":"clinicaltrials.gov:NCT02394457","description":"Postdural Puncture Headache","metadata":null},{"id":"4ca8f3c308794f308f416583402d8cd2","type":"DISEASE","name":"Cough","canonical_id":"hp:0012735","description":null,"metadata":null},{"id":"ae1c350ee280496386f7561be7035871","type":"DISEASE","name":"Cough","canonical_id":"mesh:D003371","description":null,"metadata":null},{"id":"5ceec87f936f498c91a481ffd5421204","type":"TRIAL","name":"Cough According to Stimulus Type in PD","canonical_id":"clinicaltrials.gov:NCT02390089","description":"Parkinson's Disease","metadata":null},{"id":"47aad620d24a4cae9575a89f42d089e5","type":"TRIAL","name":"Could Early Atorvastatin Offer Anti Inflammatory Effects Upon Brain in Traumatic Head Injury?","canonical_id":"clinicaltrials.gov:NCT04718155","description":"Traumatic Brain Injury","metadata":null},{"id":"c500efc9b8694ba6bfd924d4a1d36fcd","type":"TRIAL","name":"Counterpain PXM Versus Diclofenac Versus Piroxicam","canonical_id":"clinicaltrials.gov:NCT07475663","description":"Ankle Sprain; Back Pain; Osteoarthritis (OA) of the Knee; Tennis Elbow; Runner's Knee","metadata":null},{"id":"5b7867bf146a4943b96a43e9a5f943c4","type":"TRIAL","name":"Coxib-inhibition of Duodenal Polyp Growth in FAP","canonical_id":"clinicaltrials.gov:NCT00844727","description":"Duodenal Polyposis","metadata":null},{"id":"24fefe05911844dc8e8da6d2f9a34a74","type":"TRIAL","name":"Cranoc Lipid Study in Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00223041","description":"Renal Transplantation","metadata":null},{"id":"aae621ece2044a4c9b9dcc8a001f627c","type":"TRIAL","name":"Craving, Binge Eating and Obesity","canonical_id":"clinicaltrials.gov:NCT00414167","description":"Binge Eating Disorder; Obesity","metadata":null},{"id":"a9a8ec88fdde4eed8e9dbb51a1ca223c","type":"DRUG","name":"Crizotinib","canonical_id":"mesh:D000077547","description":null,"metadata":null},{"id":"599d0922df74454287729b10303ef566","type":"DRUG","name":"Crizotinib","canonical_id":"ncit:C74061","description":null,"metadata":null},{"id":"56c899e62e1b4c84aba16b5c34aa455a","type":"TRIAL","name":"Crizotinib Continuation Clinical Study","canonical_id":"clinicaltrials.gov:NCT05160922","description":"NSCLC; ALCL; IMT","metadata":null},{"id":"a4102201fb8c42d7ae146641f5ad1059","type":"TRIAL","name":"Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT02824094","description":"Neoplasms; Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"86abf41b3e404771bf4d3b6423369659","type":"TRIAL","name":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01606878","description":"Childhood Solid Neoplasm; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Neuroblastoma","metadata":null},{"id":"d8617acab33a44068bf8599f25d3ea5d","type":"TRIAL","name":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","canonical_id":"clinicaltrials.gov:NCT03620643","description":"Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation","metadata":null},{"id":"2bcdf6653e45430ebe511b15cd57bf87","type":"TRIAL","name":"Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)","canonical_id":"clinicaltrials.gov:NCT02499614","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"7ad205b85ad644e9be91777499ee085b","type":"TRIAL","name":"Crofelemer for Functional Diarrhea","canonical_id":"clinicaltrials.gov:NCT04486326","description":"Diarrhea","metadata":null},{"id":"0d58b9c26e284343a92a2338dd47a77c","type":"DISEASE","name":"Crohn disease","canonical_id":"mondo:0005011","description":null,"metadata":null},{"id":"d87804cc5e5e40d6ab430165a535399b","type":"DISEASE","name":"Crohn's disease","canonical_id":"mesh:D003424","description":null,"metadata":null},{"id":"a6b5fbe8b74e4df5a917364188b9aec9","type":"TRIAL","name":"Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg","canonical_id":"clinicaltrials.gov:NCT01716520","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"dec5c72486f94a41a32522d36b30531e","type":"TRIAL","name":"Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression","canonical_id":"clinicaltrials.gov:NCT06751784","description":"Working Memory; Mild to Moderate Depression","metadata":null},{"id":"e10a645104c140b19800dd51071ba30b","type":"TRIAL","name":"Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT01712139","description":"Hypertension","metadata":null},{"id":"7227d79f9b8347d99b13cbcaf6531d25","type":"TRIAL","name":"Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01712126","description":"Hypertension","metadata":null},{"id":"38bea55d8b214089bcc432eaae6a26bc","type":"TRIAL","name":"Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01530022","description":"Healthy","metadata":null},{"id":"acccc22974b64c3f990bff5afaa58182","type":"TRIAL","name":"Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge","canonical_id":"clinicaltrials.gov:NCT06069063","description":"Allergy to Cats","metadata":null},{"id":"a6b777e8c0ef4dc2b18c05ddc09f2a50","type":"TRIAL","name":"Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule","canonical_id":"clinicaltrials.gov:NCT03329001","description":"Neoplasms","metadata":null},{"id":"30565b9f9f3c4ec895dda3ef681774a6","type":"TRIAL","name":"Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT01959412","description":"Asthma","metadata":null},{"id":"f4d5a6d6648e4488b493efd0e7eebc12","type":"TRIAL","name":"Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects","canonical_id":"clinicaltrials.gov:NCT01462669","description":"Epilepsy","metadata":null},{"id":"2c2e06ee182c4753878c57faec1eba8f","type":"TRIAL","name":"Crossover Trial of AD109 in Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT04580394","description":"Obstructive Sleep Apnea","metadata":null},{"id":"142e6387ff9f49cbb304ef332945fa65","type":"DRUG","name":"Crotamiton","canonical_id":"mesh:C005553","description":null,"metadata":null},{"id":"9879e50d03db49f2964ce5ea6a1e5829","type":"DISEASE","name":"Crouzon syndrome","canonical_id":"mondo:0007405","description":null,"metadata":null},{"id":"cd798bcf7dcd4039b38b4dcb68ac55e4","type":"DISEASE","name":"Crouzon syndrome-acanthosis nigricans syndrome","canonical_id":"mondo:0012833","description":null,"metadata":null},{"id":"346eb55d015f40549cb62ee61e33ba29","type":"TRIAL","name":"Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel","canonical_id":"clinicaltrials.gov:NCT02925923","description":"Acute Coronary Syndrome; Angina, Unstable","metadata":null},{"id":"53c6ce6d545142cbbd6ada8fcda66ff6","type":"GO_TERM","name":"Cry-Per complex","canonical_id":"go:GO:1990512","description":"\"Nuclear transcriptional repressor complex that is capable of negatively regulating CLOCK-BMAL-dependent transactivation of genes in a delayed negative feedback manner which generates circadian rhythms.\" [GOC:bhm, PMID:24855952]","metadata":null},{"id":"39e1780da91342478899c20e47b0727b","type":"TRIAL","name":"Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial","canonical_id":"clinicaltrials.gov:NCT07847359","description":"Melanoma (Skin) Stage IV","metadata":null},{"id":"42312f88aa2443569942f79e0192812a","type":"TRIAL","name":"Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.","canonical_id":"clinicaltrials.gov:NCT07147088","description":"Advanced Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"4c121460a3f74e5a8292bf2228e5b9ed","type":"TRIAL","name":"Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06580665","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"3ac564ade4f940789f42022491c94ae8","type":"TRIAL","name":"Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT03136120","description":"Lung Diseases, Interstitial","metadata":null},{"id":"667aac4f2f974e578f7eefba8ca68f72","type":"TRIAL","name":"Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers","canonical_id":"clinicaltrials.gov:NCT06492070","description":"Cervical Carcinoma; Fallopian Tube Carcinoma; Malignant Solid Neoplasm; Malignant Uterine Neoplasm; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Vulvar Carcinoma","metadata":null},{"id":"e7813f3249ff496f8c84b668101024d2","type":"DISEASE","name":"Cryopyrin associated periodic syndrome","canonical_id":"mesh:D056587","description":null,"metadata":null},{"id":"919f96e167a04079b89b75d5c73fe883","type":"TRIAL","name":"Cryptococcal Antigen Screening Plus Sertraline","canonical_id":"clinicaltrials.gov:NCT03002012","description":"Cryptococcosis; Cryptococcal Infections; AIDS-Related Opportunistic Infections","metadata":null},{"id":"2ea1b8b0d39d4731b5e2422fad61b7eb","type":"DISEASE","name":"Cryptococcal meningitis","canonical_id":"mesh:D016919","description":null,"metadata":null},{"id":"73df9af8a52c4c6eb7aa86962531bf36","type":"DISEASE","name":"Cryptococcosis","canonical_id":"mesh:D003453","description":null,"metadata":null},{"id":"38d52a733745431ab8a609e583e87847","type":"TRIAL","name":"CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA","canonical_id":"clinicaltrials.gov:NCT07558434","description":"Severe Aplastic Anemia (SAA); Transfusion-dependent Non-severe Aplastic Anemia","metadata":null},{"id":"777c04fb62ea40eaa7c1003aeb18067c","type":"GO_TERM","name":"Ctf18 RFC-like complex","canonical_id":"go:GO:0031390","description":"\"A heptameric complex related to replication factor C, which loads the DNA polymerase processivity factor proliferating cell nuclear antigen (PCNA) onto DNA and plays a vital role in chromosome cohesion. In Saccharomyces the subunits are known as Ctf18p, Rfc2p, Rfc3p, Rfc4p, Rfc5p, Dcc1p, and Ctf8p.\" [PMID:14614842]","metadata":null},{"id":"f5b44945a1b44e2687f53f18cd5c5b65","type":"GO_TERM","name":"Cul2-RING ubiquitin ligase complex","canonical_id":"go:GO:0031462","description":"\"A ubiquitin ligase complex in which a cullin from the Cul2 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by an elongin-BC adaptor and a SOCS/BC box protein.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"2993d57aff2049bfa47965e748d90579","type":"GO_TERM","name":"Cul3-RING ubiquitin ligase complex","canonical_id":"go:GO:0031463","description":"\"A ubiquitin ligase complex in which a cullin from the Cul3 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by a BTB-domain-containing protein.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"1a06336c82c240e0a5dcba170bb3770a","type":"GO_TERM","name":"Cul4-RING E3 ubiquitin ligase complex","canonical_id":"go:GO:0080008","description":"\"A ubiquitin ligase complex in which a cullin from the Cul4 family and a RING domain protein form the catalytic core; substrate specificity is conferred by an adaptor protein.\" [PMID:16792691, PMID:18223036, PMID:18552200]","metadata":null},{"id":"de1dc564290a47a4b4abb4afffb47ae1","type":"GO_TERM","name":"Cul4A-RING E3 ubiquitin ligase complex","canonical_id":"go:GO:0031464","description":"\"A ubiquitin ligase complex in which a cullin from the Cul4A subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by an adaptor protein.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"20484b92f88a4e8c906af1e46a0a4d70","type":"GO_TERM","name":"Cul4B-RING E3 ubiquitin ligase complex","canonical_id":"go:GO:0031465","description":"\"A ubiquitin ligase complex in which a cullin from the Cul4B subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by unknown subunits.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"b8b9ea22f57742c99db1afdf0ce3dcff","type":"GO_TERM","name":"Cul5-RING ubiquitin ligase complex","canonical_id":"go:GO:0031466","description":"\"A ubiquitin ligase complex in which a cullin from the Cul5 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by an elongin-BC adaptor and a SOCS/BC box protein.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"749225c308194211ba5c2980e362fae1","type":"GO_TERM","name":"Cul7-RING ubiquitin ligase complex","canonical_id":"go:GO:0031467","description":"\"A ubiquitin ligase complex in which a cullin from the Cul7 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by a Skp1 linker and an F-box protein.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"3560a5316f8b486f9461db6435d3d556","type":"GO_TERM","name":"Cul8-RING ubiquitin ligase complex","canonical_id":"go:GO:0035361","description":"\"A ubiquitin ligase complex in which a cullin from the Cul8 subfamily and a RING domain protein form the catalytic core. In S. cerevisiae, Mms1p acts as the adaptor protein and substrate specificity is conferred by any of a number of different proteins.\" [GOC:krc, PMID:20139071]","metadata":null},{"id":"bee318a902ec4eb7a337c8efd14c26e5","type":"TRIAL","name":"Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization","canonical_id":"clinicaltrials.gov:NCT03072082","description":"Coronary Artery Disease(CAD)","metadata":null},{"id":"41d67c57d76d4b95b24d602dac76ba6f","type":"TRIAL","name":"Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization","canonical_id":"clinicaltrials.gov:NCT03072121","description":"Coronary Artery Disease(CAD)","metadata":null},{"id":"30dd725920f7482894e65f98cee56e78","type":"TRIAL","name":"Curing Atrial Fibrillation in Heart Failure","canonical_id":"clinicaltrials.gov:NCT00292162","description":"Chronic Heart Failure; Atrial Fibrillation","metadata":null},{"id":"3cc327ca5dff41ef8b049ab6b4683d5f","type":"TRIAL","name":"Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)","canonical_id":"clinicaltrials.gov:NCT05012865","description":"Renal Cell Carcinoma","metadata":null},{"id":"9a062ca30c5f4ade92d8fa664631ea87","type":"DISEASE","name":"Curry-Jones syndrome","canonical_id":"mondo:0011134","description":null,"metadata":null},{"id":"f1bfcad064cc4be398fd5277160e515f","type":"GO_TERM","name":"Cus cation efflux complex","canonical_id":"go:GO:1990398","description":"\"Transmembrane complex that mediates resistance to copper and silver by cation efflux directly from the cell using the proton-motive force. Spans the inner membrane, periplasm, and outer membrane. Primarily activated under anaerobic conditions by CusR and CusS but also expressed under extreme copper stress, in aerobic growth.\" [GOC:bhm, PMID:23122209]","metadata":null},{"id":"c60e1923334f4de28130f1442bc16880","type":"DISEASE","name":"Cushing syndrome","canonical_id":"mondo:0018912","description":null,"metadata":null},{"id":"9140bf4655d7473fa947369d57cdf5ca","type":"TRIAL","name":"Cutaneous Lupus Erythematosus and Elidel","canonical_id":"clinicaltrials.gov:NCT00222183","description":"Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid","metadata":null},{"id":"fa5851a8711347758aaaf37a8519431b","type":"TRIAL","name":"Cutaneous Lupus Medication Experience Study","canonical_id":"clinicaltrials.gov:NCT02176148","description":"Cutaneous Lupus","metadata":null},{"id":"75af580c8f6f45ffb11a931f27394838","type":"TRIAL","name":"Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure","canonical_id":"clinicaltrials.gov:NCT02448043","description":"Nail Growth Cessation; Intraocular Pressure","metadata":null},{"id":"bc8264d61f5148bebb292fdd39f1c1a3","type":"DISEASE","name":"Cutaneous anthrax","canonical_id":"mesh:C531621","description":null,"metadata":null},{"id":"9527021f4dd949388c9daeb47951e9a7","type":"DISEASE","name":"Cutaneous larva migrans","canonical_id":"mesh:D007815","description":null,"metadata":null},{"id":"cd459b4a9beb4dde84051f9ebaa37c37","type":"DISEASE","name":"Cutaneous leishmaniasis","canonical_id":"mesh:D016773","description":null,"metadata":null},{"id":"1852312de46f4a62b63646ef72212b04","type":"GO_TERM","name":"Cvt complex","canonical_id":"go:GO:0034270","description":"\"A protein complex that is involved in the Cvt pathway. In budding yeast, the Cvt complex consists of multimers of preApe1p.\" [GOC:rb, PMID:15659643]","metadata":null},{"id":"9ba517546a7d49819f3abbc83a0522da","type":"GO_TERM","name":"Cvt vesicle","canonical_id":"go:GO:0033107","description":"\"A cytosolic vesicle that is enclosed by a double membrane and is implicated in the cytoplasm to vacuole targeting pathway. These vesicles are found in the yeast S. cerevisiae, and contain vacuolar hydrolases, aminopeptidase I (Ape1p) and alpha-mannosidase (Ams1p).\" [GOC:rb, PMID:15138258]","metadata":null},{"id":"ea8f0ca49cc5487fa61d1d7f7eea1fec","type":"GO_TERM","name":"Cvt vesicle assembly","canonical_id":"go:GO:0071255","description":"\"A vesicle organization process that takes place as part of the Cvt pathway, and results in the formation of a double membrane-bounded cytosolic structure that sequesters precursor aminopeptidase I (prAPI).\" [GOC:rb, PMID:10966461, PMID:11085977]","metadata":null},{"id":"1f2c0a63b8e041cdaf5e0c6e5af394b8","type":"GO_TERM","name":"Cvt vesicle membrane","canonical_id":"go:GO:0033110","description":"\"Either of the two lipid bilayers surrounding a Cvt vesicle, a vesicle that functions in the cytoplasm-to-vacuole targeting (Cvt) pathway.\" [GOC:ecd, PMID:20065092]","metadata":null},{"id":"531ef98630374a1ab2adcac905e311fb","type":"GO_TERM","name":"Cyc8(Ssn6)-Tup1 general repressor complex","canonical_id":"go:GO:0160051","description":"\"A corepressor complex containing the WD-repeat protein Tup1p (S. cerevisiae) and Tup11/Tup12 (fission yeast) and the TPR repeat protein Cyc8p (S. cerevisiae) ssn6 (fission yeast) that is recruited to target genes by DNA-bound repressor proteins preferentially at regions where histones are deacetylated by the Clr6 class I HDAC, and recruits the SWI/SNF and SAGA complexes to promoters.\" [GOC:vw, PMID:10871883, PMID:17101775, PMID:22156212]","metadata":null},{"id":"a080fab1330248c49cbf96a3ef2e1f90","type":"DISEASE","name":"Cyclical neutropenia","canonical_id":"mesh:C536227","description":null,"metadata":null},{"id":"63c728950a6844bb8d63dff0d65370bb","type":"TRIAL","name":"Cyclizine Vs. Dexamethasone for Nausea and Vomiting Following Intrathecal Morphine in Cases of Cesarean Section","canonical_id":"clinicaltrials.gov:NCT03931135","description":"Spinal Anesthetics Causing Adverse Effects in Therapeutic Use","metadata":null},{"id":"c27e386a6c9f4e9a9eaf5d8d474ac181","type":"TRIAL","name":"Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT01479829","description":"Bipolar Depression","metadata":null},{"id":"e138ce0de6564d7499f655362bdff6a5","type":"DRUG","name":"Cyclopentolate","canonical_id":"mesh:D003519","description":null,"metadata":null},{"id":"d4a5ef37c7114dee8f4c60d80a780585","type":"TRIAL","name":"Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00275015","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"9f09464574f14bb7922eaf17247add09","type":"TRIAL","name":"Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)","canonical_id":"clinicaltrials.gov:NCT03088293","description":"Idiopathic Refractory Scleritis","metadata":null},{"id":"25367c9064974b94a0873e26f31bcd29","type":"TRIAL","name":"Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention","canonical_id":"clinicaltrials.gov:NCT04503616","description":"Graft-versus-host Disease","metadata":null},{"id":"155e512e7af446c1904ed4724a07f13a","type":"TRIAL","name":"Cycloplegic Refraction Among Children","canonical_id":"clinicaltrials.gov:NCT05442801","description":"Cycloplegia","metadata":null},{"id":"be357618c4724d3db3587a0ccde4c148","type":"TRIAL","name":"Cycloplegic Refraction in Pediatric Patients With Esotropia","canonical_id":"clinicaltrials.gov:NCT06077682","description":"Cycloplegia; Refractive Errors; Esotropia; Vision Disorders","metadata":null},{"id":"4b0b4fe89393413c835d62ad74f61ec5","type":"DRUG","name":"Cycloserine","canonical_id":"mesh:D003523","description":null,"metadata":null},{"id":"41274b19c0c1442a94a43af7a8fc10b9","type":"TRIAL","name":"Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis","canonical_id":"clinicaltrials.gov:NCT00426023","description":"Vernal Keratoconjunctivitis","metadata":null},{"id":"5563eb5493db493492e59d2001b24bef","type":"TRIAL","name":"Cyclosporin Implant to Treat Uveitis","canonical_id":"clinicaltrials.gov:NCT00001737","description":"Eye Disease; Inflammation; Uveitis","metadata":null},{"id":"a35fd7f86d08476ab3a9df1bfed0630d","type":"TRIAL","name":"Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01342887","description":"Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13\u2026","metadata":null},{"id":"c9e25baee15d4f20ba7d19640e9091bb","type":"GO_TERM","name":"Cypridina-luciferin 2-monooxygenase activity","canonical_id":"go:GO:0047712","description":"\"Catalysis of the reaction: Cypridina luciferin + O2 = oxidized Cypridina luciferin + CO2 + light.\" [EC:1.13.12.6]","metadata":null},{"id":"ecc0ab691dd24d8889932efb6631bcd5","type":"DRUG","name":"Cyproheptadine","canonical_id":"mesh:D003533","description":null,"metadata":null},{"id":"0eaeeca0df514fb1948a7c3d9b7387bc","type":"TRIAL","name":"Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer","canonical_id":"clinicaltrials.gov:NCT00949117","description":"Leukemia; Lymphoma; Malnutrition; Myelodysplastic Syndromes; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes","metadata":null},{"id":"47f9ac21cdb647a7bf9b28e6f0e227a8","type":"TRIAL","name":"Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment","canonical_id":"clinicaltrials.gov:NCT00066248","description":"Brain Tumor; Central Nervous System Tumors; Cachexia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Childhood Solid Tumor, Protocol Specific","metadata":null},{"id":"cc1c06606a0144249988422f9bc91ecb","type":"TRIAL","name":"Cyproheptadine as an Appetite Stimulant","canonical_id":"clinicaltrials.gov:NCT01314989","description":"Failure to Thrive","metadata":null},{"id":"85f2ba60e88149bdb763aa9d144fc6bd","type":"TRIAL","name":"Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial","canonical_id":"clinicaltrials.gov:NCT04820751","description":"Viral Pneumonia; Serotonin Syndrome; Platelet Dysfunction","metadata":null},{"id":"6794ada08ca64805b9e134282c05c468","type":"TRIAL","name":"Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00005623","description":"Hot Flashes; Prostate Cancer","metadata":null},{"id":"45090f55511447bca60aed42d6b85e3c","type":"TRIAL","name":"Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00363285","description":"Prostate Cancer","metadata":null},{"id":"3176589c8e0c463685fcb321ec2ad116","type":"GO_TERM","name":"Cys-tRNA(Pro) deacylase activity","canonical_id":"go:GO:0043907","description":"\"Catalysis of the reaction: L-cysteinyl-tRNA(Pro) + H2O = tRNA(Pro) + L-cysteine + H+.\" [GOC:jl, PMID:15886196, RHEA:25351]","metadata":null},{"id":"b4544299d47942e58832d2afcc1c3f92","type":"PROTEIN","name":"Cysteinyl leukotriene receptor 2","canonical_id":"uniprot:Q9NS75","description":null,"metadata":null},{"id":"9fe8810861d246419cf1a0ba4fdd4f7e","type":"DISEASE","name":"Cystic fibrosis of the lung","canonical_id":"mesh:D003550","description":null,"metadata":null},{"id":"cb95ea7c9a89429a9a3bdc798795acb2","type":"DISEASE","name":"Cystinosis","canonical_id":"mesh:D003554","description":null,"metadata":null},{"id":"81b0604c514d405088547b41a0cb7c56","type":"DISEASE","name":"Cystinuria","canonical_id":"mesh:D003555","description":null,"metadata":null},{"id":"4d07a958e00d4827b1a2fd0c95897fee","type":"DISEASE","name":"Cystitis","canonical_id":"mesh:D003556","description":null,"metadata":null},{"id":"ea072348337a402ea7107964daa80cf1","type":"DISEASE","name":"Cystitis, Interstitial","canonical_id":"mesh:D018856","description":null,"metadata":null},{"id":"3601c654f9af4b6aa0f2e637c174ee41","type":"TRIAL","name":"Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT00121303","description":"Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"8c628047403e490ea3349f2e0956b377","type":"PROTEIN","name":"Cytochrome b (Plasmodium falciparum)","canonical_id":"uniprot:Q02768","description":null,"metadata":null},{"id":"1ae0ad1586e542b28dbd5df837c22a9d","type":"TRIAL","name":"Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants","canonical_id":"clinicaltrials.gov:NCT00146497","description":"Premature Infants; Respiratory Distress Syndrome; Chronic Lung Disease; Bronchoalveolar Lavage Fluid; Cytokines","metadata":null},{"id":"798461e002574207b49ba6cb63f9dd71","type":"TRIAL","name":"Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis","canonical_id":"clinicaltrials.gov:NCT05491304","description":"Hemophagocytic Lymphohistiocytoses; Cytokine Storm","metadata":null},{"id":"658b6b75d8144311b132cbaa50721ae1","type":"DISEASE","name":"Cytomegalovirus Retinitis","canonical_id":"mesh:D017726","description":null,"metadata":null},{"id":"415253c7bd554a0a813df8678f61c478","type":"TRIAL","name":"Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02458716","description":"Metastatic Prostate Carcinoma; Metastatic Prostatic Adenocarcinoma; Prostate Carcinoma Metastatic to the Bone","metadata":null},{"id":"7f5e12eb88a240ee909666adbb4f7bee","type":"PROTEIN","name":"Cytosolic leucyl-tRNA synthetase","canonical_id":"uniprot:Q9HGT2","description":null,"metadata":null},{"id":"16e454c34632471ab475d0c006910fe6","type":"TRIAL","name":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","canonical_id":"clinicaltrials.gov:NCT05762003","description":"Multiple Sclerosis","metadata":null},{"id":"6fc85ebbc2e44e80b26ea37c0f10b4fc","type":"GO_TERM","name":"D(-)-tartrate dehydratase activity","canonical_id":"go:GO:0047808","description":"\"Catalysis of the reaction: D-tartrate = H2O + oxaloacetate.\" [EC:4.2.1.81, RHEA:18289]","metadata":null},{"id":"d6d0362f51c1447184e7944b1a270e08","type":"PROTEIN","name":"D(1A) dopamine receptor","canonical_id":"uniprot:P21728","description":null,"metadata":null},{"id":"4f273b7a08ee473d90bd2124b111e939","type":"GO_TERM","name":"D-4-hydroxyphenylglycine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047320","description":"\"Catalysis of the reaction: 2-oxoglutarate + D-4-hydroxyphenylglycine = 4-hydroxyphenylglyoxylate + L-glutamate.\" [RHEA:15589]","metadata":null},{"id":"e186e7b6a81544bc825fe82ed9146dbb","type":"GO_TERM","name":"D-Ala-D-Ala dipeptidase activity","canonical_id":"go:GO:0160237","description":"\"Catalysis of the reaction: D-alanyl-D-alanine + H2O = 2 D-alanine.\" [PMID:7873524, RHEA:20661]","metadata":null},{"id":"5b3909bbc2964da2af163bac9186b28c","type":"TRIAL","name":"D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)","canonical_id":"clinicaltrials.gov:NCT02651441","description":"Lung Cancer; Non-small Cell Lung Cancer","metadata":null},{"id":"79d4c72c07864f84acc02164331d92b0","type":"TRIAL","name":"D-Dimer Guided Oral Anticoagulant Treatment (OAT)","canonical_id":"clinicaltrials.gov:NCT00895505","description":"Deep Venous Thrombosis","metadata":null},{"id":"dbd744ae0992412fad3d28222539ae7a","type":"TRIAL","name":"D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00047476","description":"Fatigue; Neoplasms","metadata":null},{"id":"f42a082067804acabaa786bbd9627570","type":"GO_TERM","name":"D-alanine 2-hydroxymethyltransferase activity","canonical_id":"go:GO:0050413","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + D-alanine + H2O = (6S)-5,6,7,8-tetrahydrofolate + 2-methylserine.\" [EC:2.1.2.7, RHEA:10064]","metadata":null},{"id":"25b3a33f931d45e4b920a4b7fc975eb3","type":"GO_TERM","name":"D-alanine [D-alanyl carrier protein] ligase activity","canonical_id":"go:GO:0047473","description":"\"Catalysis of the ATP-dependent activation of D-alanine and its transfer as a thiol ester to the phosphopantheinyl prosthetic group of a D-alanyl carrier protein, according to the reaction: holo-[D-alanyl-carrier protein] + D-alanine + ATP = D-alanyl-[D-alanyl-carrier protein] + AMP + diphosphate.\" [RHEA:55132]","metadata":null},{"id":"00710837926142c59945d200b0c8f388","type":"GO_TERM","name":"D-alanine biosynthetic process","canonical_id":"go:GO:0030632","description":"\"The chemical reactions and pathways resulting in the formation of D-alanine, the D-enantiomer of the amino acid alanine, i.e (2R)-2-aminopropanoic acid.\" [GOC:jsg, GOC:mah]","metadata":null},{"id":"3d9b3b6e6d39402cabd666df9fc349b5","type":"GO_TERM","name":"D-alanine catabolic process","canonical_id":"go:GO:0055130","description":"\"The chemical reactions and pathways resulting in the breakdown of D-alanine.\" [GOC:curators]","metadata":null},{"id":"0b4efa3468be4a42a4f334d4fa8d919a","type":"GO_TERM","name":"D-alanine gamma-glutamyltransferase activity","canonical_id":"go:GO:0047811","description":"\"Catalysis of the reaction: D-alanine + L-glutamine = gamma-L-glutamyl-D-alanine + NH4.\" [RHEA:23556]","metadata":null},{"id":"4b7eacc2b59942c6aa01cff9c3708e65","type":"GO_TERM","name":"D-alanine import across plasma membrane","canonical_id":"go:GO:0170048","description":"\"The directed import of D-alanine from the extracellular region across the plasma membrane and into the cytosol.\" [PMID:22418438, PMID:25425233]","metadata":null},{"id":"0d9a1cec1c4546e280e1915ccf67471c","type":"GO_TERM","name":"D-alanine transmembrane transport","canonical_id":"go:GO:0042941","description":"\"The process in which D-alanine, the D-enantiomer of 2-aminopropanoic acid,  is transported across a lipid bilayer, from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GO:ew, GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"8905592a241b439c93b08e8968c28f3f","type":"GO_TERM","name":"D-alanine transmembrane transporter activity","canonical_id":"go:GO:0042944","description":"\"Enables the transfer of D-alanine from one side of a membrane to the other. D-alanine is the D-enantiomer of 2-aminopropanoic acid.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"4a4df285c972445d948b918807d67c12","type":"GO_TERM","name":"D-alanine-(R)-lactate ligase activity","canonical_id":"go:GO:0160220","description":"\"Catalysis of the reaction: (R)-lactate + ATP + D-alanine = ADP + D-alanyl-(R)-lactate + phosphate.\" [RHEA:37347]","metadata":null},{"id":"6065256ea12b4886b464a04db1a25649","type":"PROTEIN","name":"D-alanine--D-alanine ligase (Mycobacterium tuberculosis)","canonical_id":"uniprot:P9WP31","description":null,"metadata":null},{"id":"a02576f0dc524fc2ad83ac7475429fcf","type":"GO_TERM","name":"D-alanine-D-alanine ligase activity","canonical_id":"go:GO:0008716","description":"\"Catalysis of the reaction: 2 D-alanine + ATP = D-alanyl-D-alanine + ADP + 2 H+ + phosphate.\" [EC:6.3.2.4, RHEA:11224]","metadata":null},{"id":"322160ff166d4549bb3d01da0b7b31ce","type":"GO_TERM","name":"D-alanine-D-serine ligase activity","canonical_id":"go:GO:0160222","description":"\"Catalysis of the reaction: ATP + D-alanine + D-serine = ADP + D-alanyl-D-serine + H+ + phosphate.\" [EC:6.3.2.35, RHEA:27706]","metadata":null},{"id":"d75949dec98147e6b777072fcb097f76","type":"GO_TERM","name":"D-alanine-alanyl-poly(glycerolphosphate) ligase activity","canonical_id":"go:GO:0047481","description":"\"Catalysis of the reaction: alanyl-poly(glycerolphosphate) + D-alanine + ATP = D-alanyl-alanyl-poly(glycerolphosphate) + phosphate + ADP.\" [EC:6.3.2.16, MetaCyc:6.3.2.16-RXN]","metadata":null},{"id":"1cc45da75c9640c898c1606839d70203","type":"GO_TERM","name":"D-alanine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047810","description":"\"Catalysis of the reaction: D-alanine + 2-oxoglutarate = pyruvate + D-glutamate.\" [RHEA:15869]","metadata":null},{"id":"fb428a0320264b478b443fc6dd041f6f","type":"GO_TERM","name":"D-alanyl carrier activity","canonical_id":"go:GO:0036370","description":"\"Binding a D-alanine and presenting it for processing or offloading to a cognate enzyme. Covalently binds the D-alanine via a phosphopantetheine prosthetic group and mediates protein-protein interactions with the enzyme conferring specificity. The carrier protein provides an essential link between the D-alanine-D-alanyl carrier protein ligase and the incorporation of D-alanine into lipoteichoic acid by transferring activated D-alanine to cell membrane phosphatidylglycerol (PG).\" [GOC:crds, PMID:11222605, PMID:22750871, PMID:8682792]","metadata":null},{"id":"249c63d92d714c59a05c76b7dae9e3b0","type":"PROTEIN","name":"D-alanyl-D-alanine carboxypeptidase DacB (Escherichia coli)","canonical_id":"uniprot:P24228","description":null,"metadata":null},{"id":"f31c530617c94528bae127621cfe2428","type":"GO_TERM","name":"D-allose 6-phosphate isomerase activity","canonical_id":"go:GO:0008786","description":"\"Catalysis of the reaction: D-allose-6-phosphate = D-allulose-6-phosphate.\" [RHEA:28430]","metadata":null},{"id":"96883163448c412c9c603adee33e539e","type":"GO_TERM","name":"D-allose biosynthetic process","canonical_id":"go:GO:0019315","description":"\"The chemical reactions and pathways resulting in the formation of D-allose, the D-enantiomer of allo-hexose, an aldohexose similar to glucose.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"954cfcce5a1f4acc803f86649219e544","type":"GO_TERM","name":"D-allose catabolic process","canonical_id":"go:GO:0019316","description":"\"The chemical reactions and pathways resulting in the breakdown of D-allose, the D-enantiomer of allo-hexose, an aldohexose similar to glucose.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"2532c3e8e8d24a40a486980e0765485a","type":"GO_TERM","name":"D-allose kinase activity","canonical_id":"go:GO:0008787","description":"\"Catalysis of the reaction: ATP + D-allose = ADP + D-allose 6-phosphate.\" [EC:2.7.1.55]","metadata":null},{"id":"531568d32ab441d1ba1ff53384054eb3","type":"GO_TERM","name":"D-allose transmembrane transport","canonical_id":"go:GO:0015754","description":"\"The process in which D-allose is transported across a lipid bilayer, from one side of a membrane to the other. Allose is an aldohexose similar to glucose, differing only in the configuration of the hydroxyl group of C-3.\" [GOC:ai]","metadata":null},{"id":"0557f4a53d2d443c95509b1ad4a7981b","type":"GO_TERM","name":"D-amino acid catabolic process","canonical_id":"go:GO:0019478","description":"\"The chemical reactions and pathways resulting in the breakdown of D-amino acids, the D-enantiomers of amino acids.\" [GOC:ai, GOC:jsg]","metadata":null},{"id":"4a62c2a812a248a58538f33dac169921","type":"GO_TERM","name":"D-amino acid transmembrane transporter activity","canonical_id":"go:GO:0042943","description":"\"Enables the transfer of D-amino acids from one side of a membrane to the other. D-amino acids are the D-enantiomers of amino acids.\" [GOC:jl, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"a9cbc9ad26644508976a17b69814fa1a","type":"GO_TERM","name":"D-amino acid transport","canonical_id":"go:GO:0042940","description":"\"The directed movement of the D-enantiomer of an amino acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"df532d4bd5f14a17a925b95cfc5c2b4e","type":"GO_TERM","name":"D-amino-acid N-acetyltransferase activity","canonical_id":"go:GO:0047812","description":"\"Catalysis of the reaction: acetyl-CoA + a D-amino acid = CoA + an N-acetyl-D-amino-acid.\" [RHEA:20704]","metadata":null},{"id":"717ab969ee55448d9336c903cde91944","type":"GO_TERM","name":"D-amino-acid dehydrogenase activity","canonical_id":"go:GO:0008718","description":"\"Catalysis of the reaction: a D-alpha-amino acid + a quinone + H2O = a 2-oxocarboxylate + a quinol + NH4+.\" [RHEA:18125]","metadata":null},{"id":"66f2c96409ea486490998196eb7ccc20","type":"GO_TERM","name":"D-amino-acid dehydrogenase complex","canonical_id":"go:GO:0009324","description":"\"A protein complex that possesses D-amino-acid dehydrogenase activity.\" [GOC:mah]","metadata":null},{"id":"abf9a9f392f446d092c6fb2651e60d00","type":"GO_TERM","name":"D-amino-acid oxidase activity","canonical_id":"go:GO:0003884","description":"\"Catalysis of the reaction: a D-alpha-amino acid + H2O + O2 = a 2-oxocarboxylate + H2O2 + NH4+.\" [RHEA:21816]","metadata":null},{"id":"2e3c6da283c346ef8c77aa16ea416f6b","type":"GO_TERM","name":"D-aminoacyl-tRNA deacylase activity","canonical_id":"go:GO:0051499","description":"\"Catalysis of the reaction: a D-aminoacyl-tRNA + H2O = a D-alpha-amino acid + a tRNA + H+.  Removal of a D-amino acid from a charged tRNA.\" [PMID:14527667, RHEA:13953]","metadata":null},{"id":"b361b0ca49414115adbc77d73c6ebba1","type":"GO_TERM","name":"D-arabinitol 2-dehydrogenase activity","canonical_id":"go:GO:0047038","description":"\"Catalysis of the reaction: D-arabinitol + NAD+ = D-ribulose + H+ + NADH.\" [EC:1.1.1.250, RHEA:17389]","metadata":null},{"id":"e6688202c2c649e4b16e9196c0ba1b42","type":"GO_TERM","name":"D-arabinitol 4-dehydrogenase activity","canonical_id":"go:GO:0047813","description":"\"Catalysis of the reaction: D-arabinitol + NAD+ = D-xylulose + NADH.\" [EC:1.1.1.11, MetaCyc:D-ARABINITOL-4-DEHYDROGENASE-RXN]","metadata":null},{"id":"033be27b52bb44129eaf450271508b42","type":"GO_TERM","name":"D-arabinitol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0033709","description":"\"Catalysis of the reaction: D-arabinitol + NADP+ = D-ribulose + NADPH + H+. Can also produce D-ribulose.\" [EC:1.1.1.287]","metadata":null},{"id":"c248f7a8658e4aee897b88b929a7841d","type":"GO_TERM","name":"D-arabinokinase activity","canonical_id":"go:GO:0047814","description":"\"Catalysis of the reaction: D-arabinose + ATP = D-arabinose 5-phosphate + ADP.\" [EC:2.7.1.54, RHEA:24588]","metadata":null},{"id":"6a5c0fbb4e2f4b8d9df64b03f2e4c0ca","type":"GO_TERM","name":"D-arabinono-1,4-lactone oxidase activity","canonical_id":"go:GO:0003885","description":"\"Catalysis of the reaction: D-arabinono-1,4-lactone + O2 = dehydro-D-arabinono-1,4-lactone + H2O2 + H+.\" [EC:1.1.3.37, RHEA:23756]","metadata":null},{"id":"7867d731bb03451ea74d863dd6008a01","type":"GO_TERM","name":"D-arabinonolactonase activity","canonical_id":"go:GO:0047815","description":"\"Catalysis of the reaction: D-arabinono-1,4-lactone + H2O = D-arabinonate + H+.\" [EC:3.1.1.30, RHEA:23108]","metadata":null},{"id":"55647c1330604420a0ade063ef008074","type":"GO_TERM","name":"D-arabinose 1-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047816","description":"\"Catalysis of the reaction: D-arabinose + NAD+ = D-arabinono-1,4-lactone + NADH.\" [RHEA:20457]","metadata":null},{"id":"67331059aeaf450492495ac3d3aad86e","type":"GO_TERM","name":"D-arabinose 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0106271","description":"\"Catalysis of the reaction: D-arabinose + NADP+ = D-arabinono-1,4-lactone + NADPH.\" [RHEA:21892]","metadata":null},{"id":"38b344cef40e47d08b3f2e74b6adbf9e","type":"GO_TERM","name":"D-arabinose 1-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0045290","description":"\"Catalysis of the reaction: D-arabinose + NAD(P)+ = D-arabinono-1,4-lactone + NAD(P)H + H+.\" [EC:1.1.1.117]","metadata":null},{"id":"5b750e2bc128475787a66edc397e1c5d","type":"GO_TERM","name":"D-arabinose catabolic process","canonical_id":"go:GO:0019571","description":"\"The chemical reactions and pathways resulting in the breakdown of D-arabinose, the D-enantiomer of arabino-pentose.\" [GOC:jsg, GOC:mah]","metadata":null},{"id":"fae09e6e38484308a0e7cd0a22a96245","type":"GO_TERM","name":"D-arabitol catabolic process","canonical_id":"go:GO:0051159","description":"\"The chemical reactions and pathways resulting in the breakdown of D-arabitol, the pentitol derived from arabinose or lyxose by reduction of the aldehyde group. The D enantiomer is present in lichens and mushrooms.\" [ISBN:0198506732]","metadata":null},{"id":"cb5962463e16406a931116eb0b702b2c","type":"GO_TERM","name":"D-arginase activity","canonical_id":"go:GO:0047817","description":"\"Catalysis of the reaction: D-arginine + H2O = D-ornithine + urea.\" [EC:3.5.3.10, RHEA:12901]","metadata":null},{"id":"8470347b71c44aa3849e52da83d461f1","type":"GO_TERM","name":"D-aspartate import across plasma membrane","canonical_id":"go:GO:0070779","description":"\"The directed import of D-aspartate from the extracellular region across the plasma membrane and into the cytosol.\" [PMID:7914198]","metadata":null},{"id":"b36bd9a4ef3f49af987d14e8324972e8","type":"GO_TERM","name":"D-aspartate ligase activity","canonical_id":"go:GO:0034025","description":"\"Catalysis of the reaction: ATP + D-aspartate + [beta-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n = [beta-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-6-N-(beta-D-Asp)-L-Lys-D-Ala-D-Ala)]n + ADP + phosphate.\" [EC:6.3.1.12]","metadata":null},{"id":"4f46e183e0e74b15ad804966100ee67d","type":"GO_TERM","name":"D-aspartate oxidase activity","canonical_id":"go:GO:0008445","description":"\"Catalysis of the reaction: D-aspartate + H2O + O2 = H2O2 + NH4+ + oxaloacetate.\" [RHEA:12512]","metadata":null},{"id":"f4bd275736d04457941845a0cbd31ffc","type":"GO_TERM","name":"D-aspartate transmembrane transport","canonical_id":"go:GO:0070777","description":"\"The process in which D-aspartate, the D-enantiomer of the anion of (2R)-2-aminobutanedioic acid  is transported across a lipid bilayer, from one side of a membrane to the other, by means of some agent such as a transporter or pore.\" [GOC:mah, GOC:rph]","metadata":null},{"id":"1e858bea80654095a7bdbfa456d72de4","type":"GO_TERM","name":"D-aspartate transmembrane transporter activity","canonical_id":"go:GO:0140010","description":"\"Enables the transfer of D-aspartate from one side of a membrane to the other.\" [GO_REF:0000070, PMID:7914198]","metadata":null},{"id":"bfab5dd8fa894640b1e3c3ced12b275a","type":"GO_TERM","name":"D-benzoylarginine-4-nitroanilide amidase activity","canonical_id":"go:GO:0047415","description":"\"Catalysis of the reaction: N(2)-benzoyl-D-arginine-4-nitroanilide + H2O = 4-nitroaniline + N(2)-benzoyl-D-arginine + H+.\" [EC:3.5.1.72, RHEA:14421]","metadata":null},{"id":"4dc2d613a0f246589e70b4f54545cd64","type":"GO_TERM","name":"D-cysteine desulfhydrase activity","canonical_id":"go:GO:0019148","description":"\"Catalysis of the reaction: D-cysteine + H2O = hydrogen sulfide + pyruvate + NH4+ + H+.\" [RHEA:11268]","metadata":null},{"id":"1fde2d1985eb4a6a941617d5276619a2","type":"GO_TERM","name":"D-dopachrome decarboxylase activity","canonical_id":"go:GO:0033981","description":"\"Catalysis of the reaction: D-dopachrome + H+ = 5,6-dihydroxyindole + CO2.\" [EC:4.1.1.84, RHEA:18441]","metadata":null},{"id":"44847c8a0c78487bb34f4d35c2f7189b","type":"GO_TERM","name":"D-fructuronate reductase activity","canonical_id":"go:GO:0102501","description":"\"Catalysis of the reaction: D-mannonate + NADP = NADPH + H+ + D-fructuronate.\" [GOC:pz, PMID:22925190]","metadata":null},{"id":"499c459c28344a39be2abb810eafd9d2","type":"GO_TERM","name":"D-fuconate dehydratase activity","canonical_id":"go:GO:0047818","description":"\"Catalysis of the reaction: D-fuconate = 2-dehydro-3-deoxy-D-fuconate + H2O.\" [EC:4.2.1.67, RHEA:12949]","metadata":null},{"id":"f1c663fcf063473490c5137b06f62356","type":"GO_TERM","name":"D-galactarate biosynthetic process","canonical_id":"go:GO:0046357","description":"\"The chemical reactions and pathways resulting in the formation of galactarate, the anion of galactaric acid.\" [GOC:pr, ISBN:0198506732]","metadata":null},{"id":"87d01a80b5ce4620aeee758a74239a93","type":"GO_TERM","name":"D-galactarate catabolic process","canonical_id":"go:GO:0046392","description":"\"The chemical reactions and pathways resulting in the breakdown of D-galactarate, the anion of galactaric acid.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"4fd351f699804b798979a96ce36c9348","type":"GO_TERM","name":"D-galactonate catabolic process","canonical_id":"go:GO:0034194","description":"\"The chemical reactions and pathways resulting in the breakdown of D-galactonate, the anion of D-galactonic acid.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"5ef8eea999924077b39021b25300c9d9","type":"GO_TERM","name":"D-galactonate transmembrane transport","canonical_id":"go:GO:0042875","description":"\"The process in which D-galactonate, the D-enantiomer of galactonate, is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"33af945a9be94f6aa9788b233d6d7405","type":"GO_TERM","name":"D-galactonate:proton symporter activity","canonical_id":"go:GO:0042881","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-galactonate(out) + H+(out) = D-galactonate(in) + H+(in).\" [RHEA:29835]","metadata":null},{"id":"27a3f9bb8397496f9cfee699d0d3f990","type":"GO_TERM","name":"D-galactose-1-phosphate phosphatase activity","canonical_id":"go:GO:0070457","description":"\"Catalysis of the reaction: D-galactose-1-phosphate + H2O = D-galactose + phosphate.\" [GOC:mah, PMID:9462881]","metadata":null},{"id":"dce625bb4f7f481abc327bde040b0649","type":"GO_TERM","name":"D-galacturonate biosynthetic process","canonical_id":"go:GO:0033482","description":"\"The chemical reactions and pathways resulting in the formation of D-galacturonate, the D-enantiomer of galacturonate, the anion of galacturonic acid.\" [GOC:jsg, GOC:mah]","metadata":null},{"id":"24fae0507fbf4c4b9ab53fe69bb6d0eb","type":"GO_TERM","name":"D-galacturonate catabolic process","canonical_id":"go:GO:0019698","description":"\"The chemical reactions and pathways resulting in the breakdown of D-galacturonate, the D-enantiomer of galacturonate, the anion of galacturonic acid.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"c8a6df3785ca440b98d3b781318fc392","type":"GO_TERM","name":"D-galacturonate metabolic process","canonical_id":"go:GO:0046396","description":"\"The chemical reactions and pathways involving D-galacturonate, the D-enantiomer of galacturonate, the anion of galacturonic acid. D-galacturonic acid is a component of plant gums and bacterial cell walls.\" [GOC:ai, GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"1a088b7d1e4b49de8846fce92e5b0e6d","type":"GO_TERM","name":"D-galacturonate reductase activity","canonical_id":"go:GO:0102098","description":"\"Catalysis of the reaction: L-galactonate + NADP = aldehydo-D-galacturonate + NADPH + H+.\" [EC:1.1.1.365, GOC:pz]","metadata":null},{"id":"0b81ca9be8594914832489debb75eac6","type":"GO_TERM","name":"D-glucarate biosynthetic process","canonical_id":"go:GO:0042837","description":"\"The chemical reactions and pathways resulting in the formation of D-glucarate, the D-enantiomer of glucarate.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"7bd9a2a4cc8e436fb782923e5c9d6c4a","type":"GO_TERM","name":"D-glucarate catabolic process","canonical_id":"go:GO:0042838","description":"\"The chemical reactions and pathways resulting in the breakdown of D-glucarate, the D-enantiomer of glucarate.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"fd55777539e94e0fb8ad081676b745f4","type":"GO_TERM","name":"D-glucarate metabolic process","canonical_id":"go:GO:0042836","description":"\"The chemical reactions and pathways involving D-glucarate, the D-enantiomer of glucarate. D-glucarate is derived from either D-glucose or L-gulose.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"0b74a621d9d045a1893c16d0c6f83bc7","type":"GO_TERM","name":"D-glucarate transmembrane transport","canonical_id":"go:GO:0042870","description":"\"The process in which D-glucarate, the D-enantiomer of glucarate, is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl, GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"b9f0bc922ff248c4b3404931a51e4f60","type":"GO_TERM","name":"D-glucarate transmembrane transporter activity","canonical_id":"go:GO:0042878","description":"\"Enables the transfer of D-glucarate, the D-enantiomer of glucarate, from one side of a membrane to the other.\" [GOC:jl, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"6b0bba66d5d5421e8562e663be525d43","type":"GO_TERM","name":"D-gluconate biosynthetic process","canonical_id":"go:GO:0046178","description":"\"The chemical reactions and pathways resulting in the formation of D-gluconate, the anion of D-gluconic acid, the aldonic acid derived from glucose.\" [ISBN:0198506732]","metadata":null},{"id":"79d97c849fba436d9d08eb1a73c01b14","type":"GO_TERM","name":"D-gluconate metabolic process","canonical_id":"go:GO:0019521","description":"\"The chemical reactions and pathways involving D-gluconate, the anion of D-gluconic acid, the aldonic acid derived from glucose.\" [ISBN:0198506732]","metadata":null},{"id":"2164d08a703d46b8a01f4cf4e34a4c9f","type":"GO_TERM","name":"D-glucosamine biosynthetic process","canonical_id":"go:GO:0006042","description":"\"The chemical reactions and pathways resulting in the formation of glucosamine (2-amino-2-deoxyglucopyranose), an aminodeoxysugar that occurs in combined form in chitin.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"16b640edb2d1416da8ab42371a5b9021","type":"GO_TERM","name":"D-glucosamine catabolic process","canonical_id":"go:GO:0006043","description":"\"The chemical reactions and pathways resulting in the breakdown of glucosamine (2-amino-2-deoxyglucopyranose), an aminodeoxysugar that occurs in combined form in chitin.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"5c02dda264c44337922d5aa9cdaf77b9","type":"GO_TERM","name":"D-glucosamine metabolic process","canonical_id":"go:GO:0006041","description":"\"The chemical reactions and pathways involving glucosamine (2-amino-2-deoxyglucopyranose), an aminodeoxysugar that occurs in combined form in chitin.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"0e0c9fc37216489598ccda607db9fec9","type":"GO_TERM","name":"D-glucose binding","canonical_id":"go:GO:0005536","description":"\"Binding to D-enantiomers of glucose.\" [GOC:jl]","metadata":null},{"id":"ffe50b3455874bef8ed2b5e86b4f75a9","type":"GO_TERM","name":"D-glucose import across plasma membrane","canonical_id":"go:GO:0098708","description":"\"The directed movement of D-glucose from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"3f7d04dd6f644c2baaae3cee4dc985bd","type":"GO_TERM","name":"D-glucose transmembrane transport","canonical_id":"go:GO:1904659","description":"\"The process in which D-glucose is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:9090050]","metadata":null},{"id":"88eeb566bfe2474c8e467fee818e6c2d","type":"GO_TERM","name":"D-glucose transmembrane transporter activity","canonical_id":"go:GO:0055056","description":"\"Enables the transfer of the D-enantiomer of the hexose monosaccharide glucose from one side of a membrane to the other.\" [GOC:jid, GOC:jsg, GOC:mah]","metadata":null},{"id":"1cdf71b894bc4f25a2244f30e606ad1d","type":"GO_TERM","name":"D-glucose uniporter activity","canonical_id":"go:GO:0015304","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-glucose(out) = D-glucose(in).\" [TC:2.A.1.1.12, TC:2.A.1.1.4, TC:2.A.1.1.6]","metadata":null},{"id":"6b11330bca5f438aadc70276e2316718","type":"GO_TERM","name":"D-glucose:proton symporter activity","canonical_id":"go:GO:0005356","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-glucose + H+ = D-glucose + H+. Symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy.\" [GOC:mtg_transport]","metadata":null},{"id":"81992ee5a573474492822abed22beb00","type":"GO_TERM","name":"D-glucose:sodium symporter activity","canonical_id":"go:GO:0005412","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-glucose(out) + Na+(out) = D-glucose(in) + Na+(in).\" [TC:2.A.21.3.-]","metadata":null},{"id":"6acb7b2e34ac4c4f87f1a081a0f57b41","type":"GO_TERM","name":"D-glucuronate biosynthetic process","canonical_id":"go:GO:0042841","description":"\"The chemical reactions and pathways resulting in the formation of D-glucuronate, the D-enantiomer of glucuronate.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"cc1cac6d3ca649d6af8b8f80107fea8b","type":"GO_TERM","name":"D-glucuronate catabolic process","canonical_id":"go:GO:0042840","description":"\"The chemical reactions and pathways resulting in the breakdown of D-glucuronate, the D-enantiomer of glucuronate.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"76b7763301ec425a8ff5048d0ceec1aa","type":"GO_TERM","name":"D-glucuronate transmembrane transport","canonical_id":"go:GO:0042874","description":"\"The process in which D-glucuronate, the D-enantiomer of glucuronate, is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"be4e87d4da7c4e229ed15566425ebe27","type":"GO_TERM","name":"D-glucuronate transmembrane transporter activity","canonical_id":"go:GO:0042880","description":"\"Enables the transfer of D-glucuronate, the D-enantiomer of glucuronate, from one side of a membrane to the other.\" [GOC:jl, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"89ea626357c742babe7bf9805b066b76","type":"GO_TERM","name":"D-glutamate cyclase activity","canonical_id":"go:GO:0047820","description":"\"Catalysis of the reaction: D-glutamate = 5-oxo-D-proline + H2O.\" [RHEA:22360]","metadata":null},{"id":"e3c02bc53889476894a92a41bddeb61e","type":"GO_TERM","name":"D-glutamate oxidase activity","canonical_id":"go:GO:0047821","description":"\"Catalysis of the reaction: D-glutamate + H2O + O2 = 2-oxoglutarate + H2O2 + NH4+.\" [RHEA:10028]","metadata":null},{"id":"3d7f243a53b34bfeb388e3859dbfbba1","type":"GO_TERM","name":"D-glutamate/D-aspartate oxidase activity","canonical_id":"go:GO:0047819","description":"\"Catalysis of the reaction: D-glutamate + H2O + O2 = 2-oxoglutarate + NH3 + H2O2, and D-aspartate + H2O + O2 = oxaloacetate + NH3 + H2O2.\" [EC:1.4.3.15]","metadata":null},{"id":"747764c872674645a9f317a9d3de83de","type":"GO_TERM","name":"D-glutaminase activity","canonical_id":"go:GO:0050001","description":"\"Catalysis of the reaction: D-glutamine + H2O = D-glutamate + NH4+.\" [RHEA:22840]","metadata":null},{"id":"85765a6b368c4ae287fdac1bb8020f0c","type":"GO_TERM","name":"D-glutamyltransferase activity","canonical_id":"go:GO:0047823","description":"\"Catalysis of the reaction: D-glutamate + D-glutamine = gamma-D-glutamyl-D-glutamate + NH4+. Can also transfer additional glutamyl residues to a peptide, extending the polypeptide chain.\" [EC:2.3.2.1]","metadata":null},{"id":"8441776fd4ae4100830624a0b043ff21","type":"GO_TERM","name":"D-glycero-D-manno-heptose 7-phosphate biosynthetic process","canonical_id":"go:GO:2001061","description":"\"The chemical reactions and pathways resulting in the formation of a D-glycero-D-manno-heptose 7-phosphate.\" [GOC:mengo_curators]","metadata":null},{"id":"37dfe40a4b0a45889d1cc8e9a0d5a0ad","type":"GO_TERM","name":"D-glycero-D-manno-heptose 7-phosphate metabolic process","canonical_id":"go:GO:2001060","description":"\"The chemical reactions and pathways involving a D-glycero-D-manno-heptose 7-phosphate.\" [GOC:mengo_curators]","metadata":null},{"id":"5949ee41e7c84c008a55ebed4146d7ee","type":"GO_TERM","name":"D-glycero-beta-D-manno-heptose 1,7-bisphosphate 7-phosphatase activity","canonical_id":"go:GO:0034200","description":"\"Catalysis of the reaction: D-glycero-beta-D-manno-heptose 1,7-bisphosphate + H2O = D-glycero-beta-D-manno-heptose 1-phosphate + phosphate.\" [PMID:11279237, RHEA:28518]","metadata":null},{"id":"6b856fb022fa49ee953ccb5012201f03","type":"GO_TERM","name":"D-iditol 2-dehydrogenase activity","canonical_id":"go:GO:0047824","description":"\"Catalysis of the reaction: D-iditol + NAD+ = D-sorbose + NADH.\" [RHEA:12725]","metadata":null},{"id":"66ecf5840c4c429a8170e39c78e216a5","type":"GO_TERM","name":"D-inositol-3-phosphate glycosyltransferase activity","canonical_id":"go:GO:0102710","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-glucosamine + 1D-myo-inositol 3-phosphate = 1D-myo-inositol 2-acetamido-2-deoxy-alpha-D-glucopyranoside 3-phosphate + UDP + H+.\" [GOC:pz, RHEA:26188]","metadata":null},{"id":"ee06c2b59fb348ac8ad7bc9d1c2dc15d","type":"GO_TERM","name":"D-lactate dehydrogenase (FAD) activity","canonical_id":"go:GO:0140170","description":"\"Catalysis of the reaction: (R)-lactate + FAD + H+ = FADH2 + pyruvate.\" [RHEA:82479]","metadata":null},{"id":"b4ff441205484675bc199cc0016c8a40","type":"GO_TERM","name":"D-lactate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008720","description":"\"Catalysis of the reaction: (R)-lactate + NAD+ = H+ + NADH + pyruvate.\" [RHEA:16369]","metadata":null},{"id":"b3d80ead124d41a29d69da3968c4d430","type":"GO_TERM","name":"D-lactate dehydrogenase (cytochrome c-553) activity","canonical_id":"go:GO:0047051","description":"\"Catalysis of the reaction: (R)-lactate + 2 [Fe(III)cytochrome c553] = 2 [Fe(II)cytochrome c553] + 2 H+ + pyruvate.\" [RHEA:16465]","metadata":null},{"id":"3044323118da41238ac3de2d5d3b3206","type":"GO_TERM","name":"D-lactate dehydrogenase (cytochrome) activity","canonical_id":"go:GO:0004458","description":"\"Catalysis of the reaction: (R)-lactate + 2 [Fe(III)cytochrome c] = 2 [Fe(II)cytochrome c] + 2 H+ + pyruvate.\" [RHEA:13521]","metadata":null},{"id":"0e816a5d140e47a6b58338348d43778e","type":"GO_TERM","name":"D-lactate dehydrogenase (quinone) activity","canonical_id":"go:GO:0102029","description":"\"Catalysis of the reaction: (R)-lactate + an ubiquinone = pyruvate + an ubiquinol.\" [PMID:10944213, PMID:4575624, RHEA:51468]","metadata":null},{"id":"c151db64db8048d4bd8a744404e72a14","type":"GO_TERM","name":"D-lactate dehydrogenase activity","canonical_id":"go:GO:0047809","description":"\"Catalysis of the reaction: (R)-lactate + A = AH(2) + pyruvate.\" [RHEA:15089]","metadata":null},{"id":"a1f14dd7b33a424f9a3ad969c65e8c01","type":"GO_TERM","name":"D-lactate-2-sulfatase activity","canonical_id":"go:GO:0047825","description":"\"Catalysis of the reaction: (R)-2-O-sulfolactate + H2O = (R)-lactate + H+ + sulfate.\" [EC:3.1.6.17, RHEA:20337]","metadata":null},{"id":"4da45729a75d4b8fa48c2ba053665c33","type":"GO_TERM","name":"D-leucyl-tRNA(Leu) deacylase activity","canonical_id":"go:GO:0097358","description":"\"Catalysis of the reaction: D-leucyl-tRNA(Leu) = D-leucine + tRNA(Leu). Removal of a D-leucine from a charged tRNA(Leu).\" [GOC:se, PMID:10918062]","metadata":null},{"id":"fad24a053beb4e45bfcd2388f2058f69","type":"GO_TERM","name":"D-loop DNA binding","canonical_id":"go:GO:0062037","description":"\"Binding to a DNA D-loop. A D-loop is a three-stranded DNA structure formed by the invasion of a single DNA strand that base pairs with one strand of duplex DNA, while the rest of the double-stranded DNA does not unwind.\" [PMID:20924116]","metadata":null},{"id":"d81ff3c6335542d3a8650f1c5b13e5a2","type":"GO_TERM","name":"D-lysine 5,6-aminomutase activity","canonical_id":"go:GO:0047826","description":"\"Catalysis of the reaction: D-lysine = (2R,5S)-2,5-diaminohexanoate and (3S)-3,6-diaminohexanoate = (3S,5S)-3,5-diaminohexanoate.\" [EC:5.4.3.3]","metadata":null},{"id":"08e1044191f54ccb9aa280ee24d28850","type":"GO_TERM","name":"D-lysine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0043911","description":"\"Catalysis of the reaction: D-lysine + 2-oxoglutarate = 6-amino-2-oxohexanoate + L-glutamate.\" [PMID:17259313, RHEA:37587]","metadata":null},{"id":"2c45b9647d8243e693f9675f898ab009","type":"GO_TERM","name":"D-lysopine dehydrogenase activity","canonical_id":"go:GO:0047827","description":"\"Catalysis of the reaction: D-lysopine + H2O + NADP+ = L-lysine + H+ + NADPH + pyruvate.\" [EC:1.5.1.16, RHEA:17625]","metadata":null},{"id":"9961d4c6edf74b488a2cee31f201f4f0","type":"GO_TERM","name":"D-lyxose ketol-isomerase activity","canonical_id":"go:GO:0047828","description":"\"Catalysis of the reaction: D-lyxose = D-xylulose.\" [EC:5.3.1.15, RHEA:14201]","metadata":null},{"id":"393e72de0b844bb59d416591ce84dc01","type":"GO_TERM","name":"D-malate dehydrogenase (decarboxylating) (NAD+) activity","canonical_id":"go:GO:0046553","description":"\"Catalysis of the reaction: (R)-malate + NAD+ = CO2 + NADH + pyruvate.\" [RHEA:18365]","metadata":null},{"id":"817d6d22b9bd43c5887f6a5711818468","type":"GO_TERM","name":"D-mannitol oxidase activity","canonical_id":"go:GO:0050581","description":"\"Catalysis of the reaction: mannitol + O2 = mannose + H2O2.\" [EC:1.1.3.40, MetaCyc:1.1.3.40-RXN]","metadata":null},{"id":"fc674e09ee934da5bd6c224cc817ede2","type":"GO_TERM","name":"D-mannose binding","canonical_id":"go:GO:0005537","description":"\"Binding to mannose, a monosaccharide hexose, stereoisomeric with glucose, that occurs naturally only in polymerized forms called mannans.\" [GOC:jl, ISBN:0192800981]","metadata":null},{"id":"3d6c3da32b5442dfa51c38faf8a959d0","type":"GO_TERM","name":"D-methionine transmembrane transport","canonical_id":"go:GO:0048473","description":"\"The process in which D-methionine is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:mlg, PMID:12169620]","metadata":null},{"id":"4344ec3c9c6148ecaa3c16b5dd04ca32","type":"GO_TERM","name":"D-methionine:pyruvate transaminase activity","canonical_id":"go:GO:0047306","description":"\"Catalysis of the reaction: D-methionine + pyruvate = 4-methylthio-2-oxobutanoate + L-alanine.\" [RHEA:23836]","metadata":null},{"id":"5eb271d460d045a087f895a6910de1a7","type":"GO_TERM","name":"D-nopaline dehydrogenase activity","canonical_id":"go:GO:0047829","description":"\"Catalysis of the reaction: D-nopaline + NADP+ + H2O = L-arginine + 2-oxoglutarate + NADPH + H+.\" [RHEA:19637]","metadata":null},{"id":"dcbd6c9269254ad0a196e1ea0aa8847a","type":"GO_TERM","name":"D-octopine dehydrogenase activity","canonical_id":"go:GO:0047830","description":"\"Catalysis of the reaction: N2-(D-1-carboxyethyl)-L-arginine + NAD+ + H2O = L-arginine + pyruvate + NADH.\" [EC:1.5.1.11, MetaCyc:D-OCTOPINE-DEHYDROGENASE-RXN]","metadata":null},{"id":"3db0642c435c480ab9255c5e7349de93","type":"GO_TERM","name":"D-ornithine 4,5-aminomutase activity","canonical_id":"go:GO:0047831","description":"\"Catalysis of the reaction: D-ornithine = (2R,4S)-2,4-diaminopentanoate.\" [RHEA:14893]","metadata":null},{"id":"f7d0f51114e348dba2eb8c41dd53ebc4","type":"GO_TERM","name":"D-pinitol dehydrogenase activity","canonical_id":"go:GO:0047832","description":"\"Catalysis of the reaction: 5D-5-O-methyl-chiro-inositol + NADP+ = 2D-5-O-methyl-2,3,5/4,6-pentahydroxycyclohexanone + H+ + NADPH.\" [EC:1.1.1.142, RHEA:20437]","metadata":null},{"id":"795ed6f3ddd9472ab82e2f0d0d3e0cd8","type":"GO_TERM","name":"D-proline reductase activity","canonical_id":"go:GO:0050002","description":"\"Catalysis of the reaction: 5-aminopentanoate + [PrdC protein]-Se-L-selenocysteinyl-S-L-cysteine = [PrdC protein]-L-selenocysteine/L-cysteine + D-proline.\" [EC:1.21.4.1]","metadata":null},{"id":"8ea270fd906c4d6fb2260b8017f69e8a","type":"GO_TERM","name":"D-ribitol-5-phosphate cytidylyltransferase activity","canonical_id":"go:GO:0047349","description":"\"Catalysis of the reaction: D-ribitol 5-phosphate + CTP = CDP-ribitol + diphosphate.\" [EC:2.7.7.40, RHEA:12456]","metadata":null},{"id":"61af607cf5d04db284bb895ec176f985","type":"GO_TERM","name":"D-ribose 5-phosphate biosynthetic process","canonical_id":"go:GO:1901280","description":"\"The chemical reactions and pathways resulting in the formation of D-ribose 5-phosphate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00293]","metadata":null},{"id":"6e568c25abdd419ba601f135e694dda9","type":"GO_TERM","name":"D-ribose 5-phosphate catabolic process","canonical_id":"go:GO:1901279","description":"\"The chemical reactions and pathways resulting in the breakdown of D-ribose 5-phosphate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00293]","metadata":null},{"id":"9cbe0be3e3ee417a9962240f695574d6","type":"GO_TERM","name":"D-ribose biosynthetic process","canonical_id":"go:GO:0019302","description":"\"The chemical reactions and pathways resulting in the formation of D-ribose, (ribo-pentose).\" [ISBN:0198506732]","metadata":null},{"id":"3af7e4f580274e49b95b06d435e362b4","type":"GO_TERM","name":"D-ribose catabolic process","canonical_id":"go:GO:0019303","description":"\"The chemical reactions and pathways resulting in the breakdown of D-ribose (ribo-pentose).\" [ISBN:0198506732]","metadata":null},{"id":"27f951558b5c431d882b4fcc20ea4e58","type":"GO_TERM","name":"D-ribose metabolic process","canonical_id":"go:GO:0006014","description":"\"The chemical reactions and pathways involving D-ribose (ribo-pentose). As beta-D-ribofuranose, D-ribose forms the glycose group of all ribonucleosides, ribonucleotides and ribonucleic acids, and also of ribose phosphates, various glycosides, some coenzymes and some forms of vitamin B12.\" [ISBN:0198506732]","metadata":null},{"id":"74305f5ec6784078aa98eb822249b300","type":"GO_TERM","name":"D-ribose pyranase activity","canonical_id":"go:GO:0062193","description":"\"Catalysis of the reactions: beta-D-ribopyranose = beta-D-ribofuranose, and beta-allofuranose = beta-allopyranose.\" [EC:5.4.99.62]","metadata":null},{"id":"4080f2b61d0f4cecb4c3459e4aacbe7d","type":"GO_TERM","name":"D-ribose transmembrane transport","canonical_id":"go:GO:0015752","description":"\"The process in which D-ribose is transported across a lipid bilayer, from one side of a membrane to the other. As beta-D-ribofuranose, D-ribose forms the glycose group of all ribonucleosides, ribonucleotides and ribonucleic acids, and also of ribose phosphates, various glycosides, some coenzymes and some forms of vitamin B12.\" [GOC:ai]","metadata":null},{"id":"0477d4167e314f6f9a51fd380f22d969","type":"GO_TERM","name":"D-ribose transmembrane transporter activity","canonical_id":"go:GO:0015591","description":"\"Enables the transfer of D-ribose from one side of a membrane to the other. As beta-D-ribofuranose, D-ribose forms the glycose group of all ribonucleosides, ribonucleotides and ribonucleic acids, and also of ribose phosphates, various glycosides, some coenzymes and some forms of vitamin B12.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"b3c977334f1442f3a5c449a5c8533673","type":"GO_TERM","name":"D-ribulokinase activity","canonical_id":"go:GO:0019150","description":"\"Catalysis of the reaction: ATP + D-ribulose = ADP + D-ribulose 5-phosphate.\" [EC:2.7.1.47]","metadata":null},{"id":"59c1ad836c0d401ea001e12d786d6cf1","type":"GO_TERM","name":"D-ribulose-phosphate 3-epimerase activity","canonical_id":"go:GO:0004750","description":"\"Catalysis of the reaction: D-ribulose 5-phosphate = D-xylulose 5-phosphate.\" [EC:5.1.3.1, RHEA:13677]","metadata":null},{"id":"614b804be772490e93113fa8ad72670c","type":"GO_TERM","name":"D-sedoheptulose 7-phosphate isomerase activity","canonical_id":"go:GO:0008968","description":"\"Catalysis of the reaction: D-sedoheptulose-7-phosphate = D-alpha,beta-D-heptose 7-phosphate.\" [MetaCyc:RXN0-4301, PMID:11279237, PMID:8631969]","metadata":null},{"id":"9749ec09a99d427b952e1694f60aadbb","type":"GO_TERM","name":"D-series resolvin biosynthetic process","canonical_id":"go:GO:0106296","description":"\"The chemical reactions and pathways resulting in the formation of resolvin family D-series, hydroxy fatty acids derived from docosahexaenoic acid.\" [PMID:12391014]","metadata":null},{"id":"78e9030a5571490882b0df2aa510d985","type":"GO_TERM","name":"D-serine ammonia-lyase activity","canonical_id":"go:GO:0008721","description":"\"Catalysis of the reaction: D-serine = pyruvate + NH4+.\" [RHEA:13977]","metadata":null},{"id":"cfb0d4c66a8e462cad81cfaa029e571a","type":"GO_TERM","name":"D-serine biosynthetic process","canonical_id":"go:GO:0070179","description":"\"The chemical reactions and pathways resulting in the formation of D-serine, the D-enantiomer of serine, i.e. (2R)-2-amino-3-hydroxypropanoic acid. D-serine is often formed by racemization of L-serine.\" [CHEBI:16523, GOC:jsg, GOC:mah]","metadata":null},{"id":"b6556c5d976649d7b5481571ded90d52","type":"GO_TERM","name":"D-serine catabolic process","canonical_id":"go:GO:0036088","description":"\"The chemical reactions and pathways resulting in the breakdown of D-serine.\" [GOC:curators]","metadata":null},{"id":"44fba38b2642465189981d855c824687","type":"GO_TERM","name":"D-serine transmembrane transport","canonical_id":"go:GO:0042942","description":"\"The process in which of D-serine, the D-enantiomer of 2-amino-3-hydroxypropanoic acid is transported across a lipid bilayer, from one side of a membrane to the other, by means of some agent such as a transporter or pore.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"dacf97b4ce8c47e9a2047bb7277cec79","type":"GO_TERM","name":"D-serine transmembrane transporter activity","canonical_id":"go:GO:0042945","description":"\"Enables the transfer of D-serine from one side of a membrane to the other. D-serine is the D-enantiomer of 2-amino-3-hydroxypropanoic acid.\" [GOC:jl, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b81c0490344b4fa0b558f09cf5cfde08","type":"GO_TERM","name":"D-sorbitol biosynthetic process","canonical_id":"go:GO:0006061","description":"\"The chemical reactions and pathways resulting in the formation of sorbitol (D-glucitol), one of the ten stereoisomeric hexitols. It can be derived from glucose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"feaf3255bf8e4f1f8617341dbe6ac895","type":"GO_TERM","name":"D-sorbitol catabolic process","canonical_id":"go:GO:0006062","description":"\"The chemical reactions and pathways resulting in the breakdown of sorbitol (D-glucitol), one of the ten stereoisomeric hexitols. It can be derived from glucose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"9c2cec5780d040fbb881148eaf65e743","type":"GO_TERM","name":"D-sorbitol dehydrogenase (acceptor) activity","canonical_id":"go:GO:0047833","description":"\"Catalysis of the reaction: D-sorbitol + acceptor = L-sorbose + reduced acceptor.\" [RHEA:21320]","metadata":null},{"id":"2302da6a04024db6aef0d6186276566e","type":"GO_TERM","name":"D-sorbitol metabolic process","canonical_id":"go:GO:0006060","description":"\"The chemical reactions and pathways involving sorbitol (D-glucitol), one of the ten stereoisomeric hexitols. It can be derived from glucose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"1b2af4243a5844c6847e3de1c81a01b8","type":"GO_TERM","name":"D-tagatose 6-phosphate catabolic process","canonical_id":"go:GO:2001059","description":"\"The chemical reactions and pathways resulting in the breakdown of a D-tagatose 6-phosphate.\" [GOC:mengo_curators]","metadata":null},{"id":"4520e7ac006149cf936cab70278f9bc2","type":"GO_TERM","name":"D-threo-aldose 1-dehydrogenase activity","canonical_id":"go:GO:0047834","description":"\"Catalysis of the reaction: a D-threo-aldose + NAD+ = a D-threo-aldono-1,5-lactone + NADH.\" [EC:1.1.1.122, MetaCyc:D-THREO-ALDOSE-1-DEHYDROGENASE-RXN]","metadata":null},{"id":"42346a93663a401aa13a8da8141dbbf1","type":"GO_TERM","name":"D-threonine aldolase activity","canonical_id":"go:GO:0043876","description":"\"Catalysis of the reaction: D-threonine (or D-allo-threonine) = glycine + acetaldehyde.\" [MetaCyc:4.1.2.42-RXN, PMID:9642221]","metadata":null},{"id":"2037b080165e4b9594d8efebf156b5b7","type":"GO_TERM","name":"D-tryptophan N-acetyltransferase activity","canonical_id":"go:GO:0047835","description":"\"Catalysis of the reaction: D-tryptophan + acetyl-CoA = N-acetyl-D-tryptophan + CoA + H+.\" [RHEA:10060]","metadata":null},{"id":"90d4978eac2f49c389e1da824c7322b6","type":"GO_TERM","name":"D-tryptophan N-malonyltransferase activity","canonical_id":"go:GO:0047836","description":"\"Catalysis of the reaction: D-tryptophan + malonyl-CoA = N(2)-malonyl-D-tryptophan + CoA + H+.\" [EC:2.3.1.112, RHEA:23320]","metadata":null},{"id":"9847aee845bd41dbbc7e198c5ac14530","type":"GO_TERM","name":"D-type glycerophospholipase activity","canonical_id":"go:GO:0004630","description":"\"A glycerophospholipase activity that cleaves the second phosphodiester bond between the phosphate and phospholipid, releasing a phosphatidic acid.\" [PMID:30109646]","metadata":null},{"id":"06b75b1e5dfa49e182dc1a0cc95e862a","type":"GO_TERM","name":"D-tyrosyl-tRNA(Tyr) deacylase activity","canonical_id":"go:GO:0051500","description":"\"Catalysis of the reaction: D-tyrosyl-tRNATyr + H2O = D-tyrosine + tRNATyr. Removal of a D-tyrosine from a charged tRNA(Tyr).\" [PMID:14527667, RHEA:25347]","metadata":null},{"id":"3ce746b9853149c4a793108d6e1fbe45","type":"GO_TERM","name":"D-xylose 1-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047838","description":"\"Catalysis of the reaction: D-xylose + NAD+ = D-xylonolactone + NADH.\" [RHEA:13861]","metadata":null},{"id":"c97db2370f4041b79f01bf422e5a8555","type":"GO_TERM","name":"D-xylose 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047837","description":"\"Catalysis of the reaction: D-xylose + NADP+ = D-xylono-1,5-lactone + H+ + NADPH.\" [RHEA:22000]","metadata":null},{"id":"6880d38d9543496595510a48fed4460d","type":"GO_TERM","name":"D-xylose biosynthetic process","canonical_id":"go:GO:0042842","description":"\"The chemical reactions and pathways resulting in the formation of D-xylose, a naturally occurring plant polysaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"8635b9f602264039814938ec39f5ebb9","type":"GO_TERM","name":"D-xylose catabolic process","canonical_id":"go:GO:0042843","description":"\"The chemical reactions and pathways resulting in the breakdown of D-xylose, a naturally occurring plant polysaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"c2cca8877ea946cd854413cd03b14004","type":"GO_TERM","name":"D-xylose fermentation","canonical_id":"go:GO:0044577","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of xylose, an aldopentose, into ethanol.\" [GOC:mengo_curators, GOC:tt, PMID:26927067, PMID:30448678]","metadata":null},{"id":"be800e176afd4a2b8e85fc621574fa5e","type":"GO_TERM","name":"D-xylose metabolic process","canonical_id":"go:GO:0042732","description":"\"The chemical reactions and pathways involving D-xylose, a naturally occurring plant polysaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"66fbbd47389545b69b5f2f89814a3cf0","type":"GO_TERM","name":"D-xylose reductase (NADPH) activity","canonical_id":"go:GO:0032866","description":"\"Catalysis of the reaction: xylitol + NADP+ = D-xylose + NADPH + H+.\" [PMID:12724380, PMID:15184173, RHEA:27445]","metadata":null},{"id":"2d0373a061b04c648e53597d7d5f8426","type":"GO_TERM","name":"D-xylose transmembrane transport","canonical_id":"go:GO:0015753","description":"\"The process in which D-xylose is transported across a lipid bilayer, from one side of a membrane to the other. D-xylose (the naturally occurring enantiomer is always D-) is a constituent of plant polysaccharides.\" [GOC:ai]","metadata":null},{"id":"ddfb53e92eaf4a8dbdcdcab11a0a9a00","type":"GO_TERM","name":"D-xylose transmembrane transporter activity","canonical_id":"go:GO:0015148","description":"\"Enables the transfer of D-xylose from one side of a membrane to the other. D-xylose (the naturally occurring enantiomer is always D-) is a constituent of plant polysaccharides.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"60cb741d2406490daaa5126c2155842d","type":"GO_TERM","name":"D-xylose:proton symporter activity","canonical_id":"go:GO:0015519","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-xylose(out) + H+(out) = D-xylose(in) + H+(in).\" [TC:2.A.1.1.3]","metadata":null},{"id":"a8017b55e6bb414a9ee290e991e1bb31","type":"GO_TERM","name":"D-xylulokinase activity","canonical_id":"go:GO:0004856","description":"\"Catalysis of the reaction: D-xylulose + ATP = D-xylulose 5-phosphate + ADP + H+.\" [EC:2.7.1.17, RHEA:10964]","metadata":null},{"id":"f39b6a8d65814b7fb5de14d9d25df534","type":"GO_TERM","name":"D-xylulose 5-phosphate biosynthetic process","canonical_id":"go:GO:1901159","description":"\"The chemical reactions and pathways resulting in the formation of D-xylulose 5-phosphate.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"9a6eff3d87554b4b9aaed59deee70a85","type":"GO_TERM","name":"D-xylulose 5-phosphate metabolic process","canonical_id":"go:GO:0051167","description":"\"The chemical reactions and pathways involving D-xylulose 5-phosphate, a derivative of the ketopentose xylulose phosphorylated at the 5 carbon; it is an intermediate in the pentose phosphate pathway.\" [ISBN:0721662544]","metadata":null},{"id":"485e6c8a3d564e9f808a6e95ef8fc9d1","type":"GO_TERM","name":"D-xylulose reductase activity","canonical_id":"go:GO:0046526","description":"\"Catalysis of the reaction: NAD+ + xylitol = D-xylulose + H+ + NADH.\" [RHEA:20433]","metadata":null},{"id":"a9ae7815c9324d7e829573bf7688c048","type":"TRIAL","name":"D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement","canonical_id":"clinicaltrials.gov:NCT02203786","description":"Pathological Gambling","metadata":null},{"id":"3ee049ba59354366b4cc11c8aed4baaa","type":"GO_TERM","name":"D1 dopamine receptor binding","canonical_id":"go:GO:0031748","description":"\"Binding to a D1 dopamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"b8d78c0ebd0e42e4963da31c97cf419e","type":"TRIAL","name":"D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM","canonical_id":"clinicaltrials.gov:NCT07624513","description":"Multiple Myeloma","metadata":null},{"id":"053d61f0768e4a028182e3cb8bc6b519","type":"GO_TERM","name":"D2 dopamine receptor binding","canonical_id":"go:GO:0031749","description":"\"Binding to a D2 dopamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"202f9768957e4174ac65909f0d329c8b","type":"TRIAL","name":"D2212C00002 J-Phase II Study","canonical_id":"clinicaltrials.gov:NCT02036580","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"afd4702a55ab4711aa20e4a7bf53b1bc","type":"GENE","name":"D2HGDH","canonical_id":"hgnc:HGNC:28358","description":"D-2-hydroxyglutarate dehydrogenase","metadata":{"aliases":["MGC25181","D2HGD","FLJ42195"]}},{"id":"e19924a4ff6443c8ad4c5ea2a3f4933d","type":"GO_TERM","name":"D3 dopamine receptor binding","canonical_id":"go:GO:0031750","description":"\"Binding to a D3 dopamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7e01066567734cc3979aa547dc1f92ad","type":"GO_TERM","name":"D3 vitamins binding","canonical_id":"go:GO:1902271","description":"\"Binding to D3 vitamins.\" [GOC:bf, GOC:TermGenie, PMID:9127467]","metadata":null},{"id":"66390eac9d0441d4af45fc58b8054bc8","type":"GO_TERM","name":"D4 dopamine receptor binding","canonical_id":"go:GO:0031751","description":"\"Binding to a D4 dopamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9e1c0b0a746c48ed92851c86d44150a0","type":"GO_TERM","name":"D5 dopamine receptor binding","canonical_id":"go:GO:0031752","description":"\"Binding to a D5 dopamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c9085f14eaa84562bdf277ebd5d944ca","type":"TRIAL","name":"DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL","canonical_id":"clinicaltrials.gov:NCT03620578","description":"Non Hodgkin Lymphoma; Lymphoma, B-Cell; High-grade B-cell Lymphoma; MYC Translocation; BCL-2 Translocation","metadata":null},{"id":"77cd3d33a7ab4166973366e3f96053b4","type":"GENE","name":"DAAM1","canonical_id":"hgnc:HGNC:18142","description":"dishevelled associated activator of morphogenesis 1","metadata":{"aliases":["KIAA0666"]}},{"id":"5e4307dc94e24c6a98cdba52d33b34da","type":"GENE","name":"DAAM2","canonical_id":"hgnc:HGNC:18143","description":"dishevelled associated activator of morphogenesis 2","metadata":{"aliases":["KIAA0381","NPHS24"]}},{"id":"0b9c39c3f4ce4f2d8df76df8bd49b05d","type":"GENE","name":"DAAM2-AS1","canonical_id":"hgnc:HGNC:40830","description":"DAAM2 antisense RNA 1","metadata":null},{"id":"32888433d2b14c189160e3c5f0fddfb5","type":"GENE","name":"DAAM2-AS2","canonical_id":"hgnc:HGNC:59397","description":"DAAM2 antisense RNA 2","metadata":null},{"id":"c31b10916e5d4141ae40c5ce3fec504a","type":"GENE","name":"DAB1","canonical_id":"hgnc:HGNC:2661","description":"DAB adaptor protein 1","metadata":null},{"id":"32460c24622a4ce0ace94736a94b0730","type":"GENE","name":"DAB1-AS1","canonical_id":"hgnc:HGNC:49443","description":"DAB1 antisense RNA 1","metadata":null},{"id":"9efa03978bd04344a071a917477f7114","type":"GENE","name":"DAB2","canonical_id":"hgnc:HGNC:2662","description":null,"metadata":null},{"id":"cfc18117acfa42a7b942e1272de37806","type":"GENE","name":"DAB2IP","canonical_id":"hgnc:HGNC:17294","description":"DAB2 interacting protein","metadata":{"aliases":["AF9Q34","DIP1/2","KIAA1743","AIP1"]}},{"id":"853fd2aefac041b9b612494af1ba7d70","type":"GENE","name":"DACH1","canonical_id":"hgnc:HGNC:2663","description":null,"metadata":null},{"id":"c01c4adba69d414fbf1c9af55fe84457","type":"GENE","name":"DACH2","canonical_id":"hgnc:HGNC:16814","description":"dachshund family transcription factor 2","metadata":null},{"id":"416d7100e82b4cc69c4d5c3ce4e3a2a5","type":"GENE","name":"DACOR1","canonical_id":"hgnc:HGNC:51902","description":"DNMT1-associated colon cancer repressed lncRNA 1","metadata":{"aliases":["TCONS_00023265"]}},{"id":"42c19336b49144b7853daee531c116ee","type":"GENE","name":"DACT1","canonical_id":"hgnc:HGNC:17748","description":null,"metadata":null},{"id":"78d1831af18d4d8db7cd7b8fdee7a4aa","type":"GENE","name":"DACT2","canonical_id":"hgnc:HGNC:21231","description":null,"metadata":null},{"id":"cbce5027f6aa4ddfa95faf2ca9aa4377","type":"GENE","name":"DACT3","canonical_id":"hgnc:HGNC:30745","description":null,"metadata":null},{"id":"8a935f6d39834425a47c5760332d2ec2","type":"GENE","name":"DACT3-AS1","canonical_id":"hgnc:HGNC:44120","description":"DACT3 antisense RNA 1","metadata":null},{"id":"374a5fc1b6544be48c590a573a8d95df","type":"GENE","name":"DAD1","canonical_id":"hgnc:HGNC:2664","description":"defender against cell death 1","metadata":{"aliases":["OST2"]}},{"id":"e9d3274b0e4045a7950d61b6b069277c","type":"GENE","name":"DAD1P1","canonical_id":"hgnc:HGNC:18295","description":"defender against cell death 1 pseudogene 1","metadata":{"aliases":["DAD-R","DAD1L"]}},{"id":"22ba84a1e93245e5a664190669876497","type":"GENE","name":"DAG1","canonical_id":"hgnc:HGNC:2666","description":"dystroglycan 1","metadata":{"aliases":["A3a","156DAG","AGRNR","DAG"]}},{"id":"578fae5dd4da40139ee56527de4c4b87","type":"GENE","name":"DAGARR","canonical_id":"hgnc:HGNC:58123","description":"differentiation and growth arrest related lncRNA","metadata":{"aliases":["DAGAR"]}},{"id":"fc4096db2bda472f8334057d111c8d2a","type":"GENE","name":"DAGLA","canonical_id":"hgnc:HGNC:1165","description":"diacylglycerol lipase alpha","metadata":{"aliases":["KIAA0659","NSDDR","DAGLALPHA","C11orf11"]}},{"id":"abaaebfa886a431aa1b646ad3df43ffb","type":"GENE","name":"DAGLB","canonical_id":"hgnc:HGNC:28923","description":"diacylglycerol lipase beta","metadata":{"aliases":["KCCR13L","DAGLBETA"]}},{"id":"381bc1305c0c4cf1a568a865b343a062","type":"GENE","name":"DALIR","canonical_id":"hgnc:HGNC:51429","description":"DNMT1-associated long intergenic non-coding RNA","metadata":{"aliases":["DALI"]}},{"id":"f31b155ee5764cdabdf193e5e0978433","type":"GENE","name":"DALRD3","canonical_id":"hgnc:HGNC:25536","description":"DALR anticodon binding domain containing 3","metadata":{"aliases":["FLJ10496"]}},{"id":"0fe74f4f51d047a190cd340fba30327a","type":"GENE","name":"DANCR","canonical_id":"hgnc:HGNC:28964","description":"differentiation antagonizing non-protein coding RNA","metadata":{"aliases":["ANCR","AGU2","lncRNA-ANCR","KIAA0114","SNHG13"]}},{"id":"dd087866b0d44340b0e2f80e4bfa21f1","type":"GENE","name":"DAND5","canonical_id":"hgnc:HGNC:26780","description":"DAN domain BMP antagonist family member 5","metadata":{"aliases":["FLJ38607","CKTSF1B3","DANTE","GREM3","CER2","DTE","Coco"]}},{"id":"7fae6bbf92ff419eb43004ffd7c9ce84","type":"GENE","name":"DANT1","canonical_id":"hgnc:HGNC:50863","description":"DXZ4 associated non-coding transcript 1, proximal","metadata":null},{"id":"5ac48046dbc549aaab9ecf9383cf8d44","type":"GENE","name":"DANT2","canonical_id":"hgnc:HGNC:50862","description":"DXZ4 associated non-coding transcript 2, distal","metadata":null},{"id":"21c0307f3d5c4814b21a3bf677d76940","type":"GENE","name":"DAO","canonical_id":"hgnc:HGNC:2671","description":"D-amino acid oxidase","metadata":{"aliases":["DAMOX","DAAO"]}},{"id":"78d8236fa31f48b4955fcddc6aaf00e3","type":"GENE","name":"DAOA","canonical_id":"hgnc:HGNC:21191","description":"D-amino acid oxidase activator","metadata":{"aliases":["G72"]}},{"id":"cb6e851e3c5749d5aa8b3556935eae83","type":"GENE","name":"DAOA-AS1","canonical_id":"hgnc:HGNC:30243","description":"DAOA antisense RNA 1","metadata":{"aliases":["G30","DAOAAS","DAOA-AS"]}},{"id":"77134ea459ec44a0ae685477054c0af8","type":"GENE","name":"DAP","canonical_id":"hgnc:HGNC:2672","description":"death associated protein","metadata":{"aliases":["DAP1"]}},{"id":"ec7bee3638fb41cfb233e0b982abfe7d","type":"GENE","name":"DAP-DT","canonical_id":"hgnc:HGNC:55214","description":"DAP divergent transcript","metadata":null},{"id":"b40f44490fd4488ebb74ed2f5498c9d6","type":"GENE","name":"DAP3","canonical_id":"hgnc:HGNC:2673","description":null,"metadata":null},{"id":"518497c8d65a4addad876514095b3b2b","type":"GENE","name":"DAP3P1","canonical_id":"hgnc:HGNC:17624","description":"death associated protein 3 pseudogene 1","metadata":{"aliases":["MRPS29P1","DAP3P"]}},{"id":"536417b94c06413e9b0658be372d063d","type":"GENE","name":"DAP3P2","canonical_id":"hgnc:HGNC:29762","description":"death associated protein 3 pseudogene 2","metadata":{"aliases":["MRPS29P2"]}},{"id":"f01f7c6767a045c78d2b0a3d670f2b52","type":"TRIAL","name":"DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance","canonical_id":"clinicaltrials.gov:NCT04860011","description":"Heart Failure","metadata":null},{"id":"2af32a27f1214d5aab017025db979bf3","type":"GENE","name":"DAPK1","canonical_id":"hgnc:HGNC:2674","description":null,"metadata":null},{"id":"9786e45c1a4c417d8895105379f96b11","type":"GENE","name":"DAPK1-IT1","canonical_id":"hgnc:HGNC:43591","description":"DAPK1 intronic transcript 1","metadata":null},{"id":"18c218eba0214b729fc2559ed4e59912","type":"GO_TERM","name":"DAPK1-calmodulin complex","canonical_id":"go:GO:1990722","description":"\"A serine/threonine protein kinase complex involved in cell survival, apoptosis and autophagic cell death pathways. DAPK1 is activated by the dephosphorylation of a n-terminal serine and calcium-calmodulin binding.\" [GOC:bhm, PMID:20103772]","metadata":null},{"id":"f5541735f4c14630af32d75d2f327982","type":"GENE","name":"DAPK2","canonical_id":"hgnc:HGNC:2675","description":null,"metadata":null},{"id":"5f1f1acf92304facbbcb846c8ec6c943","type":"GENE","name":"DAPK3","canonical_id":"hgnc:HGNC:2676","description":"death associated protein kinase 3","metadata":{"aliases":["ZIP","ZIPK"]}},{"id":"9b15ede4947e4daaaf2c28cf60a8999f","type":"GENE","name":"DAPL1","canonical_id":"hgnc:HGNC:21490","description":"death associated protein like 1","metadata":null},{"id":"be7860d9bf78483290f18faa881435b8","type":"GENE","name":"DAPP1","canonical_id":"hgnc:HGNC:16500","description":"dual adaptor of phosphotyrosine and 3-phosphoinositides 1","metadata":{"aliases":["BAM32"]}},{"id":"52be7c671dfe4d39bbe84e25b6c3be20","type":"GENE","name":"DAPP1-AS1","canonical_id":"hgnc:HGNC:58858","description":"DAPP1 antisense RNA 1","metadata":null},{"id":"b7d6a509960f40de874bfe8ace1abdb7","type":"GENE","name":"DARS1","canonical_id":"hgnc:HGNC:2678","description":"aspartyl-tRNA synthetase 1","metadata":{"aliases":["DARS"]}},{"id":"0c2a8a246763491594f59d3c6ed3c333","type":"GENE","name":"DARS1-AS1","canonical_id":"hgnc:HGNC:40170","description":"DARS1 antisense RNA 1","metadata":{"aliases":["DARS-AS1"]}},{"id":"1a3a9e94e3774868bb6d43157d987922","type":"GENE","name":"DARS2","canonical_id":"hgnc:HGNC:25538","description":"aspartyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["FLJ10514","mtAspRS"]}},{"id":"a4d9bc4b308d45eeba5ed94b854827ed","type":"TRIAL","name":"DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT01322048","description":"Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Traumatic Brain Injury","metadata":null},{"id":"4c4eaa7d560e4c44a15a331c2c94568b","type":"GO_TERM","name":"DASH complex","canonical_id":"go:GO:0042729","description":"\"A large protein complex, containing around 8-10 subunits in yeast, including Duo1p, Dam1p, Dad1p and Ask1p. The complex forms part of the outer kinetochore, associates with microtubules when the kinetochore attaches to the spindle, and plays a role in spindle attachment, chromosome segregation and spindle stability.\" [GOC:jl, GOC:vw, PMID:11782438, PMID:11799062, PMID:15632076, PMID:15640796]","metadata":null},{"id":"4d087f5efa844f8db70f60dd991a4e07","type":"GENE","name":"DAW1","canonical_id":"hgnc:HGNC:26383","description":"dynein assembly factor with WD repeats 1","metadata":{"aliases":["FLJ25955","ODA16","DNAAF18","WDR69"]}},{"id":"ae9d12533ae740b6b18896c253e2edbd","type":"GENE","name":"DAXX","canonical_id":"hgnc:HGNC:2681","description":null,"metadata":null},{"id":"f90b8e4252d7455a942f24b0d6f5889c","type":"GENE","name":"DAZ1","canonical_id":"hgnc:HGNC:2682","description":"deleted in azoospermia 1","metadata":{"aliases":["SPGY","DAZ"]}},{"id":"b76e70effeb24385bb6105cee1b83628","type":"GENE","name":"DAZ2","canonical_id":"hgnc:HGNC:15964","description":"deleted in azoospermia 2","metadata":{"aliases":["pDP1678","MGC126442"]}},{"id":"d74904257c8c4978bf84dd02f2e8487b","type":"GENE","name":"DAZ3","canonical_id":"hgnc:HGNC:15965","description":"deleted in azoospermia 3","metadata":null},{"id":"2506a860829e489fb52e9db726861ed1","type":"GENE","name":"DAZ4","canonical_id":"hgnc:HGNC:15966","description":"deleted in azoospermia 4","metadata":null},{"id":"3e17f07713e1470c9486ce7ee5e31367","type":"GENE","name":"DAZAP1","canonical_id":"hgnc:HGNC:2683","description":"DAZ associated protein 1","metadata":{"aliases":["MGC19907"]}},{"id":"8dc979c772974d349a3631b40c706279","type":"GENE","name":"DAZAP2","canonical_id":"hgnc:HGNC:2684","description":"DAZ associated protein 2","metadata":{"aliases":["KIAA0058"]}},{"id":"698619e3791e4e8780b1e12d1757bc00","type":"GENE","name":"DAZAP2P1","canonical_id":"hgnc:HGNC:43869","description":"DAZ associated protein 2 pseudogene 1","metadata":null},{"id":"8c0aca435acc4928bbee6d417eab8d8d","type":"GENE","name":"DAZL","canonical_id":"hgnc:HGNC:2685","description":"deleted in azoospermia like","metadata":{"aliases":["DAZH","SPGYLA","MGC26406","DAZL1","DAZLA"]}},{"id":"222534d7e50e445db01e989af413f939","type":"GENE","name":"DBET","canonical_id":"hgnc:HGNC:43904","description":"D4Z4 binding element transcript","metadata":{"aliases":["DBE-T","DUX4L30"]}},{"id":"f6bacae96364487089347da6ff18bc5d","type":"GENE","name":"DBF4","canonical_id":"hgnc:HGNC:17364","description":null,"metadata":null},{"id":"34076482e3324fd99eef17c6b774d997","type":"GENE","name":"DBF4B","canonical_id":"hgnc:HGNC:17883","description":"DBF4B-CDC7 kinase regulatory subunit","metadata":{"aliases":["FLJ13087","DRF1","ASKL1","chifb","ZDBF1B"]}},{"id":"b4f4e1ed3a7f4dab9f1e98d3e7e68074","type":"GENE","name":"DBF4P1","canonical_id":"hgnc:HGNC:45059","description":"DBF4 pseudogene 1","metadata":null},{"id":"a653e5d2db0d4a7ab40a11044f3a746f","type":"GENE","name":"DBF4P2","canonical_id":"hgnc:HGNC:45060","description":"DBF4 pseudogene 2","metadata":null},{"id":"a17aa1c342394b7781bfcb721e467c1e","type":"GENE","name":"DBF4P3","canonical_id":"hgnc:HGNC:45061","description":"DBF4 pseudogene 3","metadata":null},{"id":"536285f1950e4e76a78a66a4b552eabd","type":"GENE","name":"DBH","canonical_id":"hgnc:HGNC:2689","description":null,"metadata":null},{"id":"1ab7068ae0814299ad741efa2876905b","type":"GENE","name":"DBH-AS1","canonical_id":"hgnc:HGNC:24155","description":"DBH antisense RNA 1","metadata":{"aliases":["BPR","NCRNA00118"]}},{"id":"dcdd8e68d6b44bdea0906cd2fe2c6ebb","type":"GENE","name":"DBI","canonical_id":"hgnc:HGNC:2690","description":null,"metadata":null},{"id":"86045de4af4d420c848e5fc30dc9a230","type":"GENE","name":"DBIL5P","canonical_id":"hgnc:HGNC:38519","description":"diazepam binding inhibitor-like 5, pseudogene","metadata":{"aliases":["ELP2P"]}},{"id":"dccd25b276dc45cc91d518d2b6f49222","type":"GENE","name":"DBIL5P2","canonical_id":"hgnc:HGNC:38518","description":"diazepam binding inhibitor-like 5 pseudogene 2","metadata":{"aliases":["ELP1P"]}},{"id":"b77fe20016684096b0946d750375d234","type":"GENE","name":"DBIP1","canonical_id":"hgnc:HGNC:2692","description":"DBI pseudogene 1","metadata":{"aliases":["DBIL2"]}},{"id":"53d679a52bc943aba9c48483d167abaf","type":"GENE","name":"DBIP2","canonical_id":"hgnc:HGNC:2691","description":"DBI pseudogene 2","metadata":{"aliases":["DBIL1"]}},{"id":"1040772c24324d639db43f1f3dcb70a7","type":"GENE","name":"DBIP3","canonical_id":"hgnc:HGNC:38517","description":"DBI pseudogene 3","metadata":null},{"id":"948ba398e3774e89b2e28c89c1b71d87","type":"GO_TERM","name":"DBIRD complex","canonical_id":"go:GO:0044609","description":"\"A protein complex that associates with mRNP particles and RNA polymerase II and is proposed to integrate transcript elongation with the regulation of alternative splicing. In humans it is composed of the proteins KIAA1967/DBC1 and ZNF326/ZIRD.\" [GOC:sp, PMID:22446626]","metadata":null},{"id":"d9f9d4341206437eb4de3b614002b4bf","type":"GENE","name":"DBN1","canonical_id":"hgnc:HGNC:2695","description":"drebrin 1","metadata":{"aliases":["D0S117E"]}},{"id":"34be93f571674d5e95b415cdd8bff28d","type":"GENE","name":"DBNDD1","canonical_id":"hgnc:HGNC:28455","description":"dysbindin domain containing 1","metadata":{"aliases":["MGC3101","FLJ12582"]}},{"id":"9b244bb2d9674719978f9727cdde947e","type":"GENE","name":"DBNDD2","canonical_id":"hgnc:HGNC:15881","description":"dysbindin domain containing 2","metadata":{"aliases":["HSMNP1","C20orf35"]}},{"id":"7ba038e836c149758e7b4bbb8cc750bf","type":"GENE","name":"DBNL","canonical_id":"hgnc:HGNC:2696","description":"drebrin like","metadata":{"aliases":["SH3P7","HIP-55","ABP1"]}},{"id":"411724b7772248049042a90e3a44b1cc","type":"GENE","name":"DBP","canonical_id":"hgnc:HGNC:2697","description":null,"metadata":null},{"id":"864fd6025a8e4f339b0d6f7676bf395b","type":"GENE","name":"DBR1","canonical_id":"hgnc:HGNC:15594","description":"debranching RNA lariats 1","metadata":null},{"id":"0c7742b64994476fb0545b6a9d72ea81","type":"GENE","name":"DBT","canonical_id":"hgnc:HGNC:2698","description":"dihydrolipoamide branched chain transacylase E2","metadata":{"aliases":["BCOADC-E2","BCKAD-E2","BCKDH-E2"]}},{"id":"2b686a791df14062bab0e93a649bebc8","type":"GENE","name":"DBTP1","canonical_id":"hgnc:HGNC:56480","description":"DBT pseudogene 1","metadata":null},{"id":"4f62bab5cce4452db08cc2ad7301d32e","type":"GENE","name":"DBX1","canonical_id":"hgnc:HGNC:33185","description":"developing brain homeobox 1","metadata":null},{"id":"75dc0ec6d3a146b18f485140b5c91658","type":"GENE","name":"DBX2","canonical_id":"hgnc:HGNC:33186","description":"developing brain homeobox 2","metadata":{"aliases":["FLJ16139"]}},{"id":"a30bb71a6dbf4beca0f07d72eba578d5","type":"GENE","name":"DBX2-AS1","canonical_id":"hgnc:HGNC:55479","description":"DBX2 antisense RNA 1","metadata":null},{"id":"ae36eeabb98941fdacf17220dc308c2c","type":"GENE","name":"DCAF1","canonical_id":"hgnc:HGNC:30911","description":"DDB1 and CUL4 associated factor 1","metadata":{"aliases":["KIAA0800","MGC102804","VPRBP"]}},{"id":"5e81596a4f78478ebbf8f790db35304a","type":"GENE","name":"DCAF10","canonical_id":"hgnc:HGNC:23686","description":"DDB1 and CUL4 associated factor 10","metadata":{"aliases":["MGC10765","FLJ23201","WDR32"]}},{"id":"064adc14090c4127a4e0b64d267a7468","type":"GENE","name":"DCAF11","canonical_id":"hgnc:HGNC:20258","description":"DDB1 and CUL4 associated factor 11","metadata":{"aliases":["PRO2389","GL014","WDR23"]}},{"id":"1272d0894fd240e9a64b225c870ba923","type":"GENE","name":"DCAF12","canonical_id":"hgnc:HGNC:19911","description":"DDB1 and CUL4 associated factor 12","metadata":{"aliases":["DKFZP434O125","MGC1058","CT102","TCC52","KIAA1892","WDR40A"]}},{"id":"cf01f491e20e421bb78553585c5b0b6f","type":"GENE","name":"DCAF12-AS1","canonical_id":"hgnc:HGNC:58097","description":"DCAF12 antisense RNA 1","metadata":{"aliases":["AL354989.1"]}},{"id":"0144c0a0ba974a159c7c3188f45e4b58","type":"GENE","name":"DCAF12L1","canonical_id":"hgnc:HGNC:29395","description":"DDB1 and CUL4 associated factor 12 like 1","metadata":{"aliases":["KIAA1892L","WDR40B"]}},{"id":"1bc61c862c204f479f1a1b841c1e9ae1","type":"GENE","name":"DCAF12L2","canonical_id":"hgnc:HGNC:32950","description":"DDB1 and CUL4 associated factor 12 like 2","metadata":{"aliases":["WDR40C"]}},{"id":"911593a4b0bd48e2a7ac82078f478912","type":"GENE","name":"DCAF13","canonical_id":"hgnc:HGNC:24535","description":"DDB1 and CUL4 associated factor 13","metadata":{"aliases":["DKFZP564O0463","Gm83","HSPC064","Sof1","WDSOF1"]}},{"id":"62f2a933075d414b9de87cb9184997b6","type":"GENE","name":"DCAF13P1","canonical_id":"hgnc:HGNC:43866","description":"DDB1 and CUL4 associated factor 13 pseudogene 1","metadata":null},{"id":"d1e247a6c9b5497d895a705efb513951","type":"GENE","name":"DCAF13P2","canonical_id":"hgnc:HGNC:43867","description":"DDB1 and CUL4 associated factor 13 pseudogene 2","metadata":null},{"id":"f656d80455214d5aa09c64b9a61d508a","type":"GENE","name":"DCAF13P3","canonical_id":"hgnc:HGNC:43868","description":"DDB1 and CUL4 associated factor 13 pseudogene 3","metadata":null},{"id":"221ae98ecf6e4d14b1d4358193c98014","type":"GENE","name":"DCAF15","canonical_id":"hgnc:HGNC:25095","description":"DDB1 and CUL4 associated factor 15","metadata":{"aliases":["MGC99481","C19orf72"]}},{"id":"2052495a51d546fc97a95cb47767f95f","type":"GENE","name":"DCAF16","canonical_id":"hgnc:HGNC:25987","description":"DDB1 and CUL4 associated factor 16","metadata":{"aliases":["FLJ20280","C4orf30"]}},{"id":"d6f3915737db4708868f5631cdc0933e","type":"GENE","name":"DCAF17","canonical_id":"hgnc:HGNC:25784","description":"DDB1 and CUL4 associated factor 17","metadata":{"aliases":["FLJ13096","C2orf37"]}},{"id":"c28acccfb51a47f7843130a8fe8e3366","type":"GENE","name":"DCAF4","canonical_id":"hgnc:HGNC:20229","description":"DDB1 and CUL4 associated factor 4","metadata":{"aliases":["DKFZp434K114","WDR21","WDR21A"]}},{"id":"4176283afa684c568a144d0285e6c2da","type":"GENE","name":"DCAF4L1","canonical_id":"hgnc:HGNC:27723","description":"DDB1 and CUL4 associated factor 4 like 1","metadata":{"aliases":["WDR21B"]}},{"id":"beb2b16a93a142b4962d907cfef099cd","type":"GENE","name":"DCAF4L2","canonical_id":"hgnc:HGNC:26657","description":"DDB1 and CUL4 associated factor 4 like 2","metadata":{"aliases":["WDR21C"]}},{"id":"2d02d94244da4f1d9e24bc6d612aa728","type":"GENE","name":"DCAF5","canonical_id":"hgnc:HGNC:20224","description":"DDB1 and CUL4 associated factor 5","metadata":{"aliases":["BCRP2","D14S1461E","BCRG2","KIAA1824","WDR22"]}},{"id":"ff96a4712fba45ed966fd17177c1aacb","type":"GENE","name":"DCAF6","canonical_id":"hgnc:HGNC:30002","description":"DDB1 and CUL4 associated factor 6","metadata":{"aliases":["PC326","IQWD1"]}},{"id":"9b954db7c99844a4adcb3ca704f8c703","type":"GENE","name":"DCAF7","canonical_id":"hgnc:HGNC:30915","description":"DDB1 and CUL4 associated factor 7","metadata":{"aliases":["HAN11","SWAN-1","WDR68"]}},{"id":"9a6d7cec1df5421ca1832727f8653860","type":"GENE","name":"DCAF8","canonical_id":"hgnc:HGNC:24891","description":"DDB1 and CUL4 associated factor 8","metadata":{"aliases":["H326","FLJ35857","WDR42A"]}},{"id":"546917f3440a4678a7511c1d6ce53daf","type":"GENE","name":"DCAF8-DT","canonical_id":"hgnc:HGNC:55792","description":"DCAF8 divergent transcript","metadata":null},{"id":"10da7bf8a22a49f8b08632a516542c65","type":"GENE","name":"DCAF8L1","canonical_id":"hgnc:HGNC:31810","description":"DDB1 and CUL4 associated factor 8 like 1","metadata":{"aliases":["WDR42B"]}},{"id":"6ffabab53f054c1ebe34337ede85cdab","type":"GENE","name":"DCAF8L2","canonical_id":"hgnc:HGNC:31811","description":"DDB1 and CUL4 associated factor 8 like 2","metadata":{"aliases":["WDR42C"]}},{"id":"c19ab40f2651479cad6abcb34ab8e315","type":"GENE","name":"DCAKD","canonical_id":"hgnc:HGNC:26238","description":"dephospho-CoA kinase domain containing","metadata":{"aliases":["FLJ22955"]}},{"id":"0445d233e5904e0ea8c607cae0a40af8","type":"GENE","name":"DCANP1","canonical_id":"hgnc:HGNC:24459","description":"dendritic cell associated nuclear protein 1","metadata":{"aliases":["DCNP1","C5orf20"]}},{"id":"3d109391c7514656a28f3501e78598dd","type":"GENE","name":"DCBLD1","canonical_id":"hgnc:HGNC:21479","description":"discoidin, CUB and LCCL domain containing 1","metadata":{"aliases":["MGC46341","dJ94G16.1"]}},{"id":"9c33fa19d3aa4ebf83c89b7a2fd78d98","type":"GENE","name":"DCBLD2","canonical_id":"hgnc:HGNC:24627","description":null,"metadata":null},{"id":"335bd0850d4d4c4dbd56d40f1d05cd59","type":"GENE","name":"DCC","canonical_id":"hgnc:HGNC:2701","description":null,"metadata":null},{"id":"64d3c5a97af24314b3601945dee9c91e","type":"GENE","name":"DCD","canonical_id":"hgnc:HGNC:14669","description":"dermcidin","metadata":{"aliases":["AIDD","PIF","DSEP","HCAP","DCD-1"]}},{"id":"a41f76dfda73400aa2bfb34094ebf208","type":"GENE","name":"DCDC1","canonical_id":"hgnc:HGNC:20625","description":"doublecortin domain containing 1","metadata":{"aliases":["FLJ46154","DCDC5"]}},{"id":"7ded1e5a037f4f39a0d178d6b0f9b883","type":"GENE","name":"DCDC2","canonical_id":"hgnc:HGNC:18141","description":null,"metadata":null},{"id":"b8ad56c0a70d4be0aca2e73ae91db268","type":"GENE","name":"DCDC2B","canonical_id":"hgnc:HGNC:32576","description":"doublecortin domain containing 2B","metadata":null},{"id":"48e1fb9611944958be7dd47310afdd12","type":"GENE","name":"DCDC2C","canonical_id":"hgnc:HGNC:32696","description":"doublecortin domain containing 2C","metadata":null},{"id":"8d62bffc94b24c5c943dae90c1985611","type":"GENE","name":"DCHS1","canonical_id":"hgnc:HGNC:13681","description":"dachsous cadherin-related 1","metadata":{"aliases":["FIB1","KIAA1773","FLJ11790","CDHR6","CDH25","PCDH16"]}},{"id":"c0c25a4b58db4c258655b9f916f751a9","type":"GENE","name":"DCHS1-AS1","canonical_id":"hgnc:HGNC:40650","description":"DCHS1 antisense RNA 1","metadata":null},{"id":"64dcd2d4208a4b83942ba25e3f5e77ec","type":"GENE","name":"DCHS2","canonical_id":"hgnc:HGNC:23111","description":"dachsous cadherin-related 2","metadata":{"aliases":["CDHJ","FLJ20047","PCDHJ","CDHR7","CDH27","PCDH23"]}},{"id":"fc023afcf8514facabaf07eba0964d07","type":"GENE","name":"DCHS2-AS1","canonical_id":"hgnc:HGNC:58900","description":"DCHS2 antisense RNA 1","metadata":null},{"id":"80ef3dbaad2b45659a41b7332b89bdc2","type":"GENE","name":"DCK","canonical_id":"hgnc:HGNC:2704","description":null,"metadata":null},{"id":"c8d2f886d13445ed992fb12407e07584","type":"GENE","name":"DCLK1","canonical_id":"hgnc:HGNC:2700","description":"doublecortin like kinase 1","metadata":{"aliases":["KIAA0369","DCLK","DCDC3A","DCAMKL1"]}},{"id":"f60566b4a9b341b8a8d36e185b755940","type":"GENE","name":"DCLK2","canonical_id":"hgnc:HGNC:19002","description":"doublecortin like kinase 2","metadata":{"aliases":["MGC45428","DCDC3","DCDC3B","DCK2","DCAMKL2"]}},{"id":"8d3d77e5901d4d1eb1a98cfb3f050a88","type":"GENE","name":"DCLK3","canonical_id":"hgnc:HGNC:19005","description":"doublecortin like kinase 3","metadata":{"aliases":["KIAA1765","DCDC3C","DCAMKL3"]}},{"id":"4f7b8b035a884558af73640dd05a1908","type":"GENE","name":"DCLRE1A","canonical_id":"hgnc:HGNC:17660","description":"DNA cross-link repair 1A","metadata":{"aliases":["SNM1","PSO2","KIAA0086","hSNM1"]}},{"id":"a56a9da35791415a9e5cb772e4087336","type":"GENE","name":"DCLRE1B","canonical_id":"hgnc:HGNC:17641","description":"DNA cross-link repair 1B","metadata":{"aliases":["SNM1B","FLJ12810","FLJ13998","APOLLO"]}},{"id":"209176c21e004af9bb9d247858ac97fe","type":"GENE","name":"DCLRE1C","canonical_id":"hgnc:HGNC:17642","description":"DNA cross-link repair 1C","metadata":{"aliases":["ARTEMIS","FLJ11360","SNM1C","A-SCID","SCIDA"]}},{"id":"4eed9ba378514752a02ab531cfed672b","type":"GENE","name":"DCLRE1CP1","canonical_id":"hgnc:HGNC:44877","description":"DNA cross-link repair 1C pseudogene 1","metadata":null},{"id":"812fdf885c3245eb949cacff56e201f3","type":"GENE","name":"DCN","canonical_id":"hgnc:HGNC:2705","description":null,"metadata":null},{"id":"49827f899fcf47feaf1bdaf1b0eac8b9","type":"GENE","name":"DCP1A","canonical_id":"hgnc:HGNC:18714","description":"decapping mRNA 1A","metadata":{"aliases":["HSA275986","SMIF","SMAD4IP1"]}},{"id":"6dc37a327bdb419d91b8fff4688c6a96","type":"GENE","name":"DCP1B","canonical_id":"hgnc:HGNC:24451","description":"decapping mRNA 1B","metadata":{"aliases":["FLJ31638"]}},{"id":"99686e20ef6d4441aa23c94355af0aff","type":"GENE","name":"DCP2","canonical_id":"hgnc:HGNC:24452","description":"decapping mRNA 2","metadata":{"aliases":["NUDT20"]}},{"id":"77b73bb3280a40928267c8a63f008531","type":"GENE","name":"DCPH1","canonical_id":"hgnc:HGNC:17872","description":"damage control phosphatase 1","metadata":{"aliases":["FLJ12910","C6orf211","ARMT1"]}},{"id":"3813875b59524f6b9d3a69d604b1adfe","type":"GENE","name":"DCPS","canonical_id":"hgnc:HGNC:29812","description":"decapping enzyme, scavenger","metadata":{"aliases":["HSPC015","HINT-5","HSL1","HINT5","DCS-1","DCS1"]}},{"id":"e32028a0a7df4f82a50fe3df9115b2e9","type":"GENE","name":"DCR","canonical_id":"hgnc:HGNC:2708","description":"Down syndrome chromosome region","metadata":{"aliases":["DSCR"]}},{"id":"19a4cca6e73c4aed8d6f75ece71a23c9","type":"GENE","name":"DCST1","canonical_id":"hgnc:HGNC:26539","description":"DC-STAMP domain containing 1","metadata":{"aliases":["FLJ32785"]}},{"id":"b0faa0f391c34896bf2c4f0ec1e80e95","type":"GENE","name":"DCST1-AS1","canonical_id":"hgnc:HGNC:41147","description":"DCST1 antisense RNA 1","metadata":{"aliases":["RP11-307C12.11"]}},{"id":"b754d88866474d1f89147fe00fd46522","type":"GENE","name":"DCST2","canonical_id":"hgnc:HGNC:26562","description":"DC-STAMP domain containing 2","metadata":{"aliases":["FLJ32934"]}},{"id":"aa8a714afb41467a906026a77d5714a3","type":"GENE","name":"DCSTAMP","canonical_id":"hgnc:HGNC:18549","description":"dendrocyte expressed seven transmembrane protein","metadata":{"aliases":["DC-STAMP","FIND","TM7SF4"]}},{"id":"388340dcacb14270a85729822555e358","type":"GENE","name":"DCT","canonical_id":"hgnc:HGNC:2709","description":null,"metadata":null},{"id":"7c902ceece0c4354b637afe90f2f142b","type":"GO_TERM","name":"DCT cell development","canonical_id":"go:GO:0072140","description":"\"The process whose specific outcome is the progression of a distal convoluted tubule cell over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"fb619bfd2b994b078a6b328d92532195","type":"GO_TERM","name":"DCT cell differentiation","canonical_id":"go:GO:0072069","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the distal convoluted tubule cells of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2ec503f2548e46918f73ac9b0e791c43","type":"GO_TERM","name":"DCT cell fate commitment","canonical_id":"go:GO:0072146","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a distal convoluted tubule cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"7cdb8dd854584b9f8a425f714563ae2f","type":"GENE","name":"DCTD","canonical_id":"hgnc:HGNC:2710","description":"dCMP deaminase","metadata":null},{"id":"d3fb336895d845babd16ffea1d2eda2d","type":"GENE","name":"DCTN1","canonical_id":"hgnc:HGNC:2711","description":"dynactin subunit 1","metadata":null},{"id":"1bf04078de804007b17fb2137390d01e","type":"GENE","name":"DCTN1-AS1","canonical_id":"hgnc:HGNC:44151","description":"DCTN1 antisense RNA 1","metadata":null},{"id":"68c5f9032af144bb8ece37b2f33f9caf","type":"GENE","name":"DCTN2","canonical_id":"hgnc:HGNC:2712","description":"dynactin subunit 2","metadata":{"aliases":["RBP50","DCTN-50"]}},{"id":"d508266dece44a24ba87b847ea7130d1","type":"GENE","name":"DCTN3","canonical_id":"hgnc:HGNC:2713","description":"dynactin subunit 3","metadata":{"aliases":["DCTN-22"]}},{"id":"21f643c34a3e4239bc49674629da74f9","type":"GENE","name":"DCTN4","canonical_id":"hgnc:HGNC:15518","description":"dynactin subunit 4","metadata":{"aliases":["Dyn4","p62"]}},{"id":"45b3755694d84f1dbac957d4658f5bd7","type":"GENE","name":"DCTN5","canonical_id":"hgnc:HGNC:24594","description":"dynactin subunit 5","metadata":{"aliases":["MGC3248","p25"]}},{"id":"1587778c63df48af9c196f8a5ea497e5","type":"GENE","name":"DCTN6","canonical_id":"hgnc:HGNC:16964","description":"dynactin subunit 6","metadata":{"aliases":["WS-3","p27"]}},{"id":"b2aff6cc25694b4b9bc69ad8a7532eb1","type":"GENE","name":"DCTN6-DT","canonical_id":"hgnc:HGNC:55241","description":"DCTN6 divergent transcript","metadata":null},{"id":"6cdbfc34d80d47c8b7b5bf314df077be","type":"GENE","name":"DCTPP1","canonical_id":"hgnc:HGNC:28777","description":"dCTP pyrophosphatase 1","metadata":{"aliases":["MGC5627","RS21C6","CDA03","XTP3TPA"]}},{"id":"979b82aea95648d5a5a61db392ba5186","type":"GENE","name":"DCUN1D1","canonical_id":"hgnc:HGNC:18184","description":"defective in cullin neddylation 1 domain containing 1","metadata":{"aliases":["RP42","SCRO","DCUN1L1","Tes3","SCCRO"]}},{"id":"5dbe12622aaa4226afd0e3c6a7d1b582","type":"GENE","name":"DCUN1D2","canonical_id":"hgnc:HGNC:20328","description":"defective in cullin neddylation 1 domain containing 2","metadata":{"aliases":["FLJ10704","FLJ20092","C13orf17"]}},{"id":"04f4dfd224cf444ba23aa7c72af614f9","type":"GENE","name":"DCUN1D2-AS","canonical_id":"hgnc:HGNC:39889","description":"DCUN1D2 antisense RNA","metadata":{"aliases":["DCUN1D2-AS2"]}},{"id":"7f3242c48dd7474495e1f6312328677d","type":"GENE","name":"DCUN1D3","canonical_id":"hgnc:HGNC:28734","description":"defective in cullin neddylation 1 domain containing 3","metadata":{"aliases":["MGC48972","FLJ41725","DKFZp686O0290","SCCRO3"]}},{"id":"97ff544f3799480c8d907bb3f6a6c6cf","type":"GENE","name":"DCUN1D4","canonical_id":"hgnc:HGNC:28998","description":"defective in cullin neddylation 1 domain containing 4","metadata":{"aliases":["KIAA0276"]}},{"id":"aa4ac1b3f5b04e8ea40e42726126f361","type":"GENE","name":"DCUN1D5","canonical_id":"hgnc:HGNC:28409","description":"defective in cullin neddylation 1 domain containing 5","metadata":{"aliases":["MGC2714","FLJ32431"]}},{"id":"5a39a4d36c1a4038aeec6870aeadf21b","type":"GENE","name":"DCX","canonical_id":"hgnc:HGNC:2714","description":"doublecortin","metadata":{"aliases":["SCLH","DC","LISX","DBCN","XLIS"]}},{"id":"ecc89b9ed358421c8ad02298d9a9be5e","type":"GENE","name":"DCXR","canonical_id":"hgnc:HGNC:18985","description":"dicarbonyl and L-xylulose reductase","metadata":{"aliases":["KIDCR","DCR","SDR20C1","HCR2","P34H"]}},{"id":"e7683ba9f2a04100b8637bae18eac6eb","type":"GENE","name":"DCXR-DT","canonical_id":"hgnc:HGNC:54083","description":"DCXR divergent transcript","metadata":{"aliases":["RP13-650J16.1"]}},{"id":"f6251eb33f2e4c919464af5a9e43035a","type":"TRIAL","name":"DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02875886","description":"Chronic Kidney Disease","metadata":null},{"id":"cb10b606e3fe4fc68dfb284175b59bcb","type":"GENE","name":"DDA1","canonical_id":"hgnc:HGNC:28360","description":"DET1 and DDB1 associated 1","metadata":{"aliases":["PCIA1","MGC2594","C19orf58"]}},{"id":"972beedfb0f34520b4afd226f3e8097e","type":"GENE","name":"DDAH1","canonical_id":"hgnc:HGNC:2715","description":"dimethylarginine dimethylaminohydrolase 1","metadata":{"aliases":["DDAH"]}},{"id":"b8065bdb361240ec863c09bf62eb0339","type":"GENE","name":"DDAH2","canonical_id":"hgnc:HGNC:2716","description":"DDAH family member 2, ADMA-independent","metadata":{"aliases":["G6A","DDAHII"]}},{"id":"08e98ef5e65a4e9b9777021b13307f8c","type":"GENE","name":"DDB1","canonical_id":"hgnc:HGNC:2717","description":null,"metadata":null},{"id":"f64230030d4b4aaf94dc240ee5bc0ff5","type":"GENE","name":"DDB2","canonical_id":"hgnc:HGNC:2718","description":null,"metadata":null},{"id":"f5f69ec055ad47e8b4d0d7f40fac3dd8","type":"GENE","name":"DDC","canonical_id":"hgnc:HGNC:2719","description":null,"metadata":null},{"id":"664eb55409dd407ca5155a3c13412a16","type":"PROTEIN","name":"DDC","canonical_id":"uniprot:P20711","description":null,"metadata":null},{"id":"d4dbce6c5c1e4647b67046603a221287","type":"GENE","name":"DDC-AS1","canonical_id":"hgnc:HGNC:40171","description":"DDC antisense RNA 1","metadata":null},{"id":"a0e657dff18147cbb859474d77dd5e7d","type":"GENE","name":"DDERMMAL","canonical_id":"hgnc:HGNC:59209","description":"DNA damage enabling regulator, melanocytic melanoma-associated lncRNA","metadata":null},{"id":"4709381575e740098dcb64b2ee8d7ba7","type":"GENE","name":"DDHD1","canonical_id":"hgnc:HGNC:19714","description":"DDHD domain containing 1","metadata":{"aliases":["KIAA1705","PA-PLA1","iPLA1alpha","PAPLA1","iPLA1\u03b1","SPG28"]}},{"id":"39ca30f6225a45f093ccfcf404d34920","type":"GENE","name":"DDHD1-DT","canonical_id":"hgnc:HGNC:55441","description":"DDHD1 divergent transcript","metadata":null},{"id":"48d6744cdee641b88ad77c32ca666eb4","type":"GENE","name":"DDHD2","canonical_id":"hgnc:HGNC:29106","description":"DDHD domain containing 2","metadata":{"aliases":["KIAA0725","SPG54","p125B","iPLA1gamma","iPLA1\u03b3","SAMWD1"]}},{"id":"5202d35d86034681860405bdbaa3294b","type":"TRIAL","name":"DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)","canonical_id":"clinicaltrials.gov:NCT02574845","description":"Healthy","metadata":null},{"id":"1a86fe0024eb4a43a4454ff5b3f8d373","type":"GENE","name":"DDI1","canonical_id":"hgnc:HGNC:18961","description":"DDI proteasomal shuttling factor 1","metadata":{"aliases":["FLJ36017"]}},{"id":"690d0859f16c4af8949b27d3bf6d76f3","type":"GENE","name":"DDI2","canonical_id":"hgnc:HGNC:24578","description":"DDI proteasomal shuttling factor 2","metadata":{"aliases":["MGC14844","RSC1A1"]}},{"id":"95c34ea159774aeda4ef675d1df62bff","type":"GENE","name":"DDIAS","canonical_id":"hgnc:HGNC:26351","description":"DNA damage induced apoptosis suppressor","metadata":{"aliases":["FLJ38838","FLJ25416","noxin","C11orf82"]}},{"id":"c2c2a843600c47dc960140693d869c55","type":"GENE","name":"DDIT3","canonical_id":"hgnc:HGNC:2726","description":null,"metadata":null},{"id":"6d257c85616747a3ba527dde46da768a","type":"GENE","name":"DDIT4","canonical_id":"hgnc:HGNC:24944","description":null,"metadata":null},{"id":"097020338cc7418aafefed97a33a8a84","type":"GENE","name":"DDIT4-AS1","canonical_id":"hgnc:HGNC:52379","description":"DDIT4 antisense RNA 1","metadata":{"aliases":["RP11-442H21.2"]}},{"id":"a8b374eee4e54853a03ec340a2184262","type":"GENE","name":"DDIT4L","canonical_id":"hgnc:HGNC:30555","description":"DNA damage inducible transcript 4 like","metadata":{"aliases":["REDD2","Rtp801L"]}},{"id":"a35b99b5757d4ebfb84ba23f94c4a341","type":"GENE","name":"DDIT4L-AS1","canonical_id":"hgnc:HGNC:55562","description":"DDIT4L antisense RNA 1","metadata":null},{"id":"2662d49d7b9a4c7281c296f8185d5f1b","type":"GENE","name":"DDN","canonical_id":"hgnc:HGNC:24458","description":"dendrin","metadata":{"aliases":["KIAA0749"]}},{"id":"42d927f5ab3440428e36e6ed3649d4ab","type":"GENE","name":"DDN-AS1","canonical_id":"hgnc:HGNC:53464","description":"DDN and PRKAG1 antisense RNA 1","metadata":{"aliases":["CAT1507"]}},{"id":"818ed3971d9b407a82750be163fba123","type":"GENE","name":"DDO","canonical_id":"hgnc:HGNC:2727","description":"D-aspartate oxidase","metadata":{"aliases":["DASOX","DASPO"]}},{"id":"3b01434f35ed4b8bb4d9fe4e9f02b8d7","type":"GENE","name":"DDOST","canonical_id":"hgnc:HGNC:2728","description":"dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit","metadata":{"aliases":["OST","KIAA0115","OST48","WBP1"]}},{"id":"dc4adc47fb4b40c0963846c99692b381","type":"GENE","name":"DDR1","canonical_id":"hgnc:HGNC:2730","description":"discoidin domain receptor tyrosine kinase 1","metadata":{"aliases":["RTK6","CD167","NTRK4","PTK3A","NEP","CAK","EDDR1"]}},{"id":"503f77e81fa4456ebfa8a761f0e6dc69","type":"GENE","name":"DDR1-DT","canonical_id":"hgnc:HGNC:28694","description":"DDR1 divergent transcript","metadata":{"aliases":["bPG70P20.2","bCX111D4.7","bQB10J12.1","TIGD1L","DDR1-AS1"]}},{"id":"50ddf4f9dd6940b6aaa5476110e385e8","type":"GENE","name":"DDR2","canonical_id":"hgnc:HGNC:2731","description":null,"metadata":null},{"id":"6b5d1a4b8e8c4f31a8a90e7388087972","type":"PROTEIN","name":"DDR2","canonical_id":"uniprot:Q16832","description":null,"metadata":null},{"id":"12767bbe590f4dfb8d9b9863af60ff99","type":"GENE","name":"DDRGK1","canonical_id":"hgnc:HGNC:16110","description":"DDRGK domain containing 1","metadata":{"aliases":["dJ1187M17.3","UFBP1","C20orf116"]}},{"id":"4f1420ebebe64b4b815ae4806e6b97ef","type":"GENE","name":"DDT","canonical_id":"hgnc:HGNC:2732","description":"D-dopachrome tautomerase","metadata":{"aliases":["DDCT","MIF2","MIF-2","D-DT"]}},{"id":"2335ac5b2475420481cb8cf603325473","type":"GO_TERM","name":"DDT-dehydrochlorinase activity","canonical_id":"go:GO:0018833","description":"\"Catalysis of the reaction: 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane = 1,1-dichloro-2,2-bis(4-chlorophenyl)ethylene + chloride + H+.\" [EC:4.5.1.1, RHEA:19217]","metadata":null},{"id":"b90be00ef1f94ee1840749d43301b85b","type":"GENE","name":"DDTL","canonical_id":"hgnc:HGNC:33446","description":"D-dopachrome tautomerase like","metadata":null},{"id":"3d15752fbe454f18a09e4f6c736aeefa","type":"GENE","name":"DDTP1","canonical_id":"hgnc:HGNC:44546","description":"DDT pseudogene 1","metadata":null},{"id":"91919176517f466db31943731a172c85","type":"GENE","name":"DDX1","canonical_id":"hgnc:HGNC:2734","description":"DEAD-box helicase 1","metadata":{"aliases":["TSLIG6","DBP-RB"]}},{"id":"f3fe37613c7546f084f83d4c0aa36a82","type":"GENE","name":"DDX10","canonical_id":"hgnc:HGNC:2735","description":"DEAD-box helicase 10","metadata":{"aliases":["HRH-J8","Dbp4"]}},{"id":"f6f44b01779f40659ff6dd7e6ffd8a17","type":"GENE","name":"DDX10P1","canonical_id":"hgnc:HGNC:44960","description":"DEAD-box helicase 10 pseudogene 1","metadata":null},{"id":"401d0de9182441b59594b77e853a965e","type":"GENE","name":"DDX10P2","canonical_id":"hgnc:HGNC:44961","description":"DEAD-box helicase 10 pseudogene 2","metadata":null},{"id":"4aeb1c4c2b1244b9b739cfb530926b76","type":"GENE","name":"DDX11","canonical_id":"hgnc:HGNC:2736","description":"DEAD/H-box helicase 11","metadata":{"aliases":["ChlR1","KRG-2","CHL1","WABS"]}},{"id":"fdfbaf4102d443489dfebbba96ebfabf","type":"GENE","name":"DDX11-AS1","canonical_id":"hgnc:HGNC:44176","description":"DDX11 antisense RNA 1","metadata":{"aliases":["CONCR","SCAT4"]}},{"id":"1e5605da4bda4ce4937f1cbb83c6752f","type":"GENE","name":"DDX11L1","canonical_id":"hgnc:HGNC:37102","description":"DEAD/H-box helicase 11 like 1 (pseudogene)","metadata":null},{"id":"0c3a6b2e54b943489a9b60156b6b25cd","type":"GENE","name":"DDX11L10","canonical_id":"hgnc:HGNC:14125","description":"DEAD/H-box helicase 11 like 10 (pseudogene)","metadata":{"aliases":["DDX11P","DDX11L1"]}},{"id":"52ba22693b9c49dcaa9f92332a1b90b6","type":"GENE","name":"DDX11L11","canonical_id":"hgnc:HGNC:37110","description":"DEAD/H-box helicase 11 like 11 (pseudogene)","metadata":null},{"id":"674b3ad675524d8bba9dccd97a10c8db","type":"GENE","name":"DDX11L12","canonical_id":"hgnc:HGNC:37111","description":"DEAD/H-box helicase 11 like 12","metadata":null},{"id":"bdf0f1fc039b461f923ecaaf73f0eb49","type":"GENE","name":"DDX11L13","canonical_id":"hgnc:HGNC:37112","description":"DEAD/H-box helicase 11 like 13","metadata":null},{"id":"cc436907b91e446794f689a5f40563d3","type":"GENE","name":"DDX11L15","canonical_id":"hgnc:HGNC:37114","description":"DEAD/H-box helicase 11 like 15 (pseudogene)","metadata":null},{"id":"23a472c927c34b4fa0fb6b62c33e3974","type":"GENE","name":"DDX11L16","canonical_id":"hgnc:HGNC:37115","description":"DEAD/H-box helicase 11 like 16 (pseudogene)","metadata":null},{"id":"23c17be7a4e7463fb2009084df2b883b","type":"GENE","name":"DDX11L17","canonical_id":"hgnc:HGNC:55080","description":"DEAD/H-box helicase 11 like 17 (pseudogene)","metadata":null},{"id":"22655b0f333342479ba0992c45f9483f","type":"GENE","name":"DDX11L2","canonical_id":"hgnc:HGNC:37103","description":"DEAD/H-box helicase 11 like 2 (pseudogene)","metadata":null},{"id":"014ef3d627dd465baa550bd8cf91b5ae","type":"GENE","name":"DDX11L3","canonical_id":"hgnc:HGNC:37104","description":"DEAD/H-box helicase 11 like 3 (pseudogene)","metadata":null},{"id":"aaafe0da4f6d4ded956f40e678f1d282","type":"GENE","name":"DDX11L4","canonical_id":"hgnc:HGNC:37105","description":"DEAD/H-box helicase 11 like 4 (pseudogene)","metadata":null},{"id":"09515cd941bc43b9acd2055034b65b4c","type":"GENE","name":"DDX11L5","canonical_id":"hgnc:HGNC:37106","description":"DEAD/H-box helicase 11 like 5 (pseudogene)","metadata":null},{"id":"3a5719f9cde24cb5808ccf43a4e685f0","type":"GENE","name":"DDX11L6","canonical_id":"hgnc:HGNC:37107","description":"DEAD/H-box helicase 11 like 6 (pseudogene)","metadata":null},{"id":"7acf9c465aef4f778df947c8ba08e3f8","type":"GENE","name":"DDX11L7","canonical_id":"hgnc:HGNC:37108","description":"DEAD/H-box helicase 11 like 7 (pseudogene)","metadata":null},{"id":"012bc8f40e8545139d82049f1121f409","type":"GENE","name":"DDX11L8","canonical_id":"hgnc:HGNC:37101","description":"DEAD/H-box helicase 11 like 8 (pseudogene)","metadata":null},{"id":"cd0e6fd6993f43f4a53e6bb6294b9be0","type":"GENE","name":"DDX11L9","canonical_id":"hgnc:HGNC:37109","description":"DEAD/H-box helicase 11 like 9 (pseudogene)","metadata":null},{"id":"255b6beb58f84ef691f5c3419cc24619","type":"GENE","name":"DDX12B","canonical_id":"hgnc:HGNC:38668","description":"DEAD/H-box helicase 12B (pseudogene)","metadata":null},{"id":"b5a10d78fe5949179ddde652b7cfc174","type":"GENE","name":"DDX12P","canonical_id":"hgnc:HGNC:2737","description":"DEAD/H-box helicase 12, pseudogene","metadata":{"aliases":["CHLR2","DDX12"]}},{"id":"4d22ba346cdf45ba8774469584609a4b","type":"GENE","name":"DDX17","canonical_id":"hgnc:HGNC:2740","description":"DEAD-box helicase 17","metadata":{"aliases":["P72"]}},{"id":"fbeef3227bb642a3a40ad39168163530","type":"GENE","name":"DDX18","canonical_id":"hgnc:HGNC:2741","description":null,"metadata":null},{"id":"bb2b21cf863c4ea19831288e8d677b17","type":"GENE","name":"DDX18P1","canonical_id":"hgnc:HGNC:20007","description":"DEAD-box helicase 18 pseudogene 1","metadata":null},{"id":"e547e6caedb241d4b5795a51f3ee0dbb","type":"GENE","name":"DDX18P2","canonical_id":"hgnc:HGNC:21432","description":"DEAD-box helicase 18 pseudogene 2","metadata":null},{"id":"34b22877b4644760878134f0906d70fc","type":"GENE","name":"DDX18P3","canonical_id":"hgnc:HGNC:33966","description":"DEAD-box helicase 18 pseudogene 3","metadata":null},{"id":"a816eded6bb0435caccaab422bb2199c","type":"GENE","name":"DDX18P4","canonical_id":"hgnc:HGNC:33967","description":"DEAD-box helicase 18 pseudogene 4","metadata":null},{"id":"25bca66b06a3476b964d03292a7e9010","type":"GENE","name":"DDX18P5","canonical_id":"hgnc:HGNC:33968","description":"DEAD-box helicase 18 pseudogene 5","metadata":null},{"id":"d5c601538a78424a9b3c456860e6ef0e","type":"GENE","name":"DDX18P6","canonical_id":"hgnc:HGNC:31126","description":"DEAD-box helicase 18 pseudogene 6","metadata":null},{"id":"1c6de7939bfc44259e38559c0a3c2204","type":"GENE","name":"DDX19A","canonical_id":"hgnc:HGNC:25628","description":"DEAD-box helicase 19A","metadata":{"aliases":["FLJ11126","DDX19L"]}},{"id":"d227219ebbf247f6b272214be8f92728","type":"GENE","name":"DDX19A-DT","canonical_id":"hgnc:HGNC:55349","description":"DDX19A divergent transcript","metadata":null},{"id":"11858435e78e4ee894c6a83772f76a6c","type":"GENE","name":"DDX19B","canonical_id":"hgnc:HGNC:2742","description":"DEAD-box helicase 19B","metadata":{"aliases":["DBP5","DDX19"]}},{"id":"54531408bd4546adbc0616e0020b5f71","type":"GENE","name":"DDX20","canonical_id":"hgnc:HGNC:2743","description":"DEAD-box helicase 20","metadata":{"aliases":["DP103","GEMIN3"]}},{"id":"af29fe817278414fb4892676a65a6057","type":"GENE","name":"DDX20P1","canonical_id":"hgnc:HGNC:44673","description":"DEAD-box helicase 20 pseudogene 1","metadata":null},{"id":"98c3ddb660954f1f8a0648b195c281df","type":"GENE","name":"DDX21","canonical_id":"hgnc:HGNC:2744","description":null,"metadata":null},{"id":"e389463857c34656a2499b0811e8730a","type":"GENE","name":"DDX23","canonical_id":"hgnc:HGNC:17347","description":"DEAD-box helicase 23","metadata":{"aliases":["Prp28","U5-100KD","PRPF28","SNRNP100"]}},{"id":"d7a903018ee046ee8a007b568712fe7e","type":"GENE","name":"DDX24","canonical_id":"hgnc:HGNC:13266","description":"DEAD-box helicase 24","metadata":null},{"id":"e48c812ba17149c9bc738eba3c7a8c26","type":"GENE","name":"DDX25","canonical_id":"hgnc:HGNC:18698","description":"DEAD-box helicase 25","metadata":{"aliases":["GRTH"]}},{"id":"6a5694edc6c5450e9f91328236408436","type":"GENE","name":"DDX25-AS1","canonical_id":"hgnc:HGNC:58188","description":"DDX25 antisense RNA 1","metadata":null},{"id":"5da4c12c026d40c19e6143f12f8957a6","type":"GENE","name":"DDX27","canonical_id":"hgnc:HGNC:15837","description":"DEAD-box helicase 27","metadata":{"aliases":["dJ686N3.1","DRS1"]}},{"id":"e31bb0066fc34239be47b9972a2514fc","type":"GENE","name":"DDX28","canonical_id":"hgnc:HGNC:17330","description":"DEAD-box helicase 28","metadata":{"aliases":["MDDX28","FLJ11282"]}},{"id":"6ca512d23f704a288297c872833a4390","type":"GENE","name":"DDX31","canonical_id":"hgnc:HGNC:16715","description":"DEAD-box helicase 31","metadata":{"aliases":["FLJ13633","FLJ23349","FLJ14578","PPP1R25"]}},{"id":"4c132c0af7d64601a7a19b72705302ac","type":"GENE","name":"DDX39A","canonical_id":"hgnc:HGNC:17821","description":"DExD-box helicase 39A","metadata":{"aliases":["DDXL","BAT1L","URH49","DDX39"]}},{"id":"015fa49f84ae4874a5ee0bae2f7ccf77","type":"GENE","name":"DDX39AP1","canonical_id":"hgnc:HGNC:39664","description":"DEAD-box helicase 39A pseudogene 1","metadata":null},{"id":"808837555d5043ada21a9ffa4a0792a7","type":"GENE","name":"DDX39B","canonical_id":"hgnc:HGNC:13917","description":"DExD-box helicase 39B","metadata":{"aliases":["D6S81E","Uap56","BAT1"]}},{"id":"f0cf2abafe9f4f6f8d96e4050a17b384","type":"GENE","name":"DDX39B-AS1","canonical_id":"hgnc:HGNC:39771","description":"DDX39B antisense RNA 1","metadata":null},{"id":"74c996177c944a76acae822b21f323c2","type":"GENE","name":"DDX39BP1","canonical_id":"hgnc:HGNC:33450","description":"DEAD-box helicase 39B pseudogene 1","metadata":{"aliases":["BAT1P1"]}},{"id":"97c6160843a24635b6a66ecd2812d174","type":"GENE","name":"DDX39BP2","canonical_id":"hgnc:HGNC:33461","description":"DEAD-box helicase 39B pseudogene 2","metadata":{"aliases":["BPG309N1.15","BAT1P2"]}},{"id":"f8fbb093f3e849609ed48bed32075664","type":"GENE","name":"DDX3ILA1","canonical_id":"hgnc:HGNC:55358","description":"DDX3 interacting lncRNA 1","metadata":{"aliases":["TCONS_00012883"]}},{"id":"475a5883096f46d0abeec64d9f87a6cf","type":"GENE","name":"DDX3P1","canonical_id":"hgnc:HGNC:42171","description":"DEAD-box helicase 3 pseudogene 1","metadata":{"aliases":["DDX3YP1"]}},{"id":"aaf47e11fb2849689f34586f20cf41a6","type":"GENE","name":"DDX3P2","canonical_id":"hgnc:HGNC:42172","description":"DEAD-box helicase 3 pseudogene 2","metadata":{"aliases":["DDX3YP2"]}},{"id":"ebe2cf301c2e4d5b8a8a93963342bef3","type":"GENE","name":"DDX3P3","canonical_id":"hgnc:HGNC:42173","description":"DEAD-box helicase 3 pseudogene 3","metadata":{"aliases":["DDX3YP3"]}},{"id":"8b1b2f91846246b8b4f93e3a6377057b","type":"GENE","name":"DDX3X","canonical_id":"hgnc:HGNC:2745","description":"DEAD-box helicase 3 X-linked","metadata":{"aliases":["DBX","HLP2","DDX14","CAP-Rf","DDX3"]}},{"id":"e3ac472f8d764dd884092e2d653a2eb4","type":"GENE","name":"DDX3Y","canonical_id":"hgnc:HGNC:2699","description":"DEAD-box helicase 3 Y-linked","metadata":{"aliases":["DBY"]}},{"id":"62134dc3d09348c88125cae9bf91e1cb","type":"GENE","name":"DDX4","canonical_id":"hgnc:HGNC:18700","description":"DEAD-box helicase 4","metadata":{"aliases":["VASA"]}},{"id":"2f90acb2bc304ddf81723543b5bab02d","type":"GENE","name":"DDX41","canonical_id":"hgnc:HGNC:18674","description":"DEAD-box helicase 41","metadata":{"aliases":["ABS","MGC8828"]}},{"id":"a15e2ef3d62d4066a7a9ed24984b1a82","type":"GENE","name":"DDX42","canonical_id":"hgnc:HGNC:18676","description":"DEAD-box helicase 42","metadata":{"aliases":["RNAHP","RHELP","SF3b125","SF3B8"]}},{"id":"1cb5858cd7c84647ba57e392b3e0dcef","type":"GENE","name":"DDX43","canonical_id":"hgnc:HGNC:18677","description":"DEAD-box helicase 43","metadata":{"aliases":["HAGE","DKFZp434H2114","CT13"]}},{"id":"f9cf261d44ae47ef8aabe09eb131e342","type":"GENE","name":"DDX43P1","canonical_id":"hgnc:HGNC:50780","description":"DEAD-box helicase 43 pseudogene 1","metadata":null},{"id":"7c84dc128f0d4298a7c5c5c900e4ee8c","type":"GENE","name":"DDX43P2","canonical_id":"hgnc:HGNC:50781","description":"DEAD-box helicase 43 pseudogene 2","metadata":null},{"id":"5cb5ab0f2e524c9d8a150d71da047a74","type":"GENE","name":"DDX43P3","canonical_id":"hgnc:HGNC:50782","description":"DEAD-box helicase 43 pseudogene 3","metadata":null},{"id":"07f3da6db2214a2e903bc97cb55ce637","type":"GENE","name":"DDX46","canonical_id":"hgnc:HGNC:18681","description":"DEAD-box helicase 46","metadata":{"aliases":["KIAA0801","FLJ25329","PRPF5","Prp5"]}},{"id":"968de43eacd54b36981ca3db554d0fc0","type":"GENE","name":"DDX47","canonical_id":"hgnc:HGNC:18682","description":"DEAD-box helicase 47","metadata":{"aliases":["DKFZp564O176","FLJ30012","HQ0256","RRP3"]}},{"id":"6f74c58d017e4c28a06b1c25154dc001","type":"GENE","name":"DDX49","canonical_id":"hgnc:HGNC:18684","description":"DEAD-box helicase 49","metadata":{"aliases":["FLJ10432","Dbp8"]}},{"id":"95150bcbed50439cb0588a75fdd17b19","type":"GENE","name":"DDX5","canonical_id":"hgnc:HGNC:2746","description":null,"metadata":null},{"id":"6a1a2c6d79454bc8806cb65b5ba24df1","type":"GENE","name":"DDX50","canonical_id":"hgnc:HGNC:17906","description":"DExD-box helicase 50","metadata":{"aliases":["GU2","MGC3199","GUB","RH-II/GuB"]}},{"id":"fcf265bded0c456599345098b3bb92fd","type":"GENE","name":"DDX50P1","canonical_id":"hgnc:HGNC:18974","description":"DEAD-box helicase 50 pseudogene 1","metadata":null},{"id":"468370e8185846939b0ff7c0e004fe3c","type":"GENE","name":"DDX50P2","canonical_id":"hgnc:HGNC:18975","description":"DEAD-box helicase 50 pseudogene 2","metadata":{"aliases":["RH_II/GuBp2"]}},{"id":"c68a218793ae46f78d3b85518a29a0e3","type":"GENE","name":"DDX51","canonical_id":"hgnc:HGNC:20082","description":"DEAD-box helicase 51","metadata":null},{"id":"f3fde5863a4c41ebb747131c79cbc4e3","type":"GENE","name":"DDX52","canonical_id":"hgnc:HGNC:20038","description":"DExD-box helicase 52","metadata":{"aliases":["ROK1"]}},{"id":"4253401f78844a5da47defb8ec84a8ed","type":"GENE","name":"DDX53","canonical_id":"hgnc:HGNC:20083","description":"DEAD-box helicase 53","metadata":{"aliases":["CAGE","CT26"]}},{"id":"25cb2d3713534354949bdd7ae877158c","type":"GENE","name":"DDX54","canonical_id":"hgnc:HGNC:20084","description":"DEAD-box helicase 54","metadata":{"aliases":["MGC2835","APR-5","DP97"]}},{"id":"ee3a9b3715b941c9917b38c044c9a59f","type":"GENE","name":"DDX55","canonical_id":"hgnc:HGNC:20085","description":"DEAD-box helicase 55","metadata":{"aliases":["KIAA1595"]}},{"id":"c62d352f64b04adca20f2d14cecd8e85","type":"GENE","name":"DDX55P1","canonical_id":"hgnc:HGNC:49852","description":"DEAD-box helicase 55 pseudogene 1","metadata":null},{"id":"a9886d1e662f4e85b74258d23881eb05","type":"GENE","name":"DDX56","canonical_id":"hgnc:HGNC:18193","description":"DEAD-box helicase 56","metadata":{"aliases":["NOH61"]}},{"id":"1cb61444bc1d498db4a1906b3471775a","type":"GENE","name":"DDX58","canonical_id":"hgnc:HGNC:19102","description":null,"metadata":null},{"id":"48681560b0a946a3b80b0657d3ef602f","type":"GENE","name":"DDX59","canonical_id":"hgnc:HGNC:25360","description":"DEAD-box helicase 59","metadata":{"aliases":["DKFZP564B1023","ZNHIT5"]}},{"id":"b632b5f21e89423ab4078cd00dd275df","type":"GENE","name":"DDX59-AS1","canonical_id":"hgnc:HGNC:41094","description":"DDX59 antisense RNA 1","metadata":null},{"id":"14ab64bde8824003a087ad24fa700d60","type":"GENE","name":"DDX5P1","canonical_id":"hgnc:HGNC:56581","description":"DDX5 pseudogene 1","metadata":null},{"id":"802fbd46cf374ded94c95d56e2010857","type":"GENE","name":"DDX6","canonical_id":"hgnc:HGNC:2747","description":"DEAD-box helicase 6","metadata":{"aliases":["RCK","Rck/p54","HLR2"]}},{"id":"05de1126838f4788b203a30ee94b560e","type":"GENE","name":"DDX60","canonical_id":"hgnc:HGNC:25942","description":"DExD/H-box helicase 60","metadata":{"aliases":["FLJ20035"]}},{"id":"8ffc257a26f84e6288ee309d245fee7d","type":"GENE","name":"DDX60L","canonical_id":"hgnc:HGNC:26429","description":"DExD/H-box 60 like","metadata":{"aliases":["FLJ31033"]}},{"id":"e5207ff098454582b78092b1b5495344","type":"GENE","name":"DDX6P1","canonical_id":"hgnc:HGNC:13948","description":"DEAD-box helicase 6 pseudogene 1","metadata":{"aliases":["DDX6-Lp","bA150A6.3","DDX6P"]}},{"id":"10e7b4025b1c48babdef4f8b2fea74bf","type":"GENE","name":"DDX6P2","canonical_id":"hgnc:HGNC:37806","description":"DEAD-box helicase 6 pseudogene 2","metadata":null},{"id":"85b0a09260c3400dadcfe5ae81066a78","type":"TRIAL","name":"DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%","canonical_id":"clinicaltrials.gov:NCT01342081","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"b0fc08eefa184747be526220a00e26f4","type":"TRIAL","name":"DE-111 Against Timolol Ophthalmic Solution 0.5%","canonical_id":"clinicaltrials.gov:NCT01342094","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"3170d71f0e154edfb0c39e928de200fd","type":"GO_TERM","name":"DEAD/H-box RNA helicase binding","canonical_id":"go:GO:0017151","description":"\"Binding to a DEAD/H-box RNA helicase.\" [GOC:jl]","metadata":null},{"id":"40740c4aa9ef498ca08adbdec58f1387","type":"GENE","name":"DEAF1","canonical_id":"hgnc:HGNC:14677","description":null,"metadata":null},{"id":"e1547f4f5f29439fadf26da90e6536d5","type":"TRIAL","name":"DEC-C and Thioguanine for R/R AML","canonical_id":"clinicaltrials.gov:NCT06351306","description":"Acute Myeloid Leukemia","metadata":null},{"id":"681239c2e9e442fbb2cae52ea67d4a72","type":"TRIAL","name":"DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure","canonical_id":"clinicaltrials.gov:NCT05276219","description":"Pulmonary Edema; Congestive Heart Failure; Acute Heart Failure","metadata":null},{"id":"feb0084cb26140269b977e406e67d15e","type":"GENE","name":"DECR1","canonical_id":"hgnc:HGNC:2753","description":"2,4-dienoyl-CoA reductase 1","metadata":{"aliases":["SDR18C1","DECR"]}},{"id":"6659a1845d2d451fbdf0ea639f042c98","type":"GENE","name":"DECR2","canonical_id":"hgnc:HGNC:2754","description":"2,4-dienoyl-CoA reductase 2","metadata":{"aliases":["PDCR","SDR17C1"]}},{"id":"d7eff8e82f9c4b7382f1b8bf9967387b","type":"GENE","name":"DEDD","canonical_id":"hgnc:HGNC:2755","description":null,"metadata":null},{"id":"4f9cc4e4ac934a8f8a084923b59e00f1","type":"GENE","name":"DEDD2","canonical_id":"hgnc:HGNC:24450","description":"death effector domain containing 2","metadata":{"aliases":["FLAME-3"]}},{"id":"05b60ad6efd3404fa2221149b854f1c9","type":"GENE","name":"DEF6","canonical_id":"hgnc:HGNC:2760","description":"DEF6 guanine nucleotide exchange factor","metadata":{"aliases":["IBP","SLAT","SWAP70L"]}},{"id":"7f9f0db709f041ca8e45eba9889fcca0","type":"GENE","name":"DEF8","canonical_id":"hgnc:HGNC:25969","description":"differentially expressed in FDCP 8 homolog","metadata":{"aliases":["FLJ20186"]}},{"id":"89be52acd61c402981128ff3574b4058","type":"GENE","name":"DEFA1","canonical_id":"hgnc:HGNC:2761","description":null,"metadata":null},{"id":"6c8061162a384ad5b38f5ae2b7879cb9","type":"GENE","name":"DEFA10P","canonical_id":"hgnc:HGNC:31801","description":"defensin alpha 10, pseudogene","metadata":null},{"id":"190c54640d6b4b89a60ae371945addef","type":"GENE","name":"DEFA11P","canonical_id":"hgnc:HGNC:33354","description":"defensin alpha 11, pseudogene","metadata":{"aliases":["DEFAP3"]}},{"id":"454a08383dd24b3aaa242707a58451d7","type":"GENE","name":"DEFA1A3","canonical_id":"hgnc:HGNC:32231","description":"defensin alpha 1 and alpha 3, variable copy number locus","metadata":{"aliases":["DEFA1","DEFA3","DEFT1P"]}},{"id":"9bd7b27077c44246a030265c9e932d1d","type":"GENE","name":"DEFA1B","canonical_id":"hgnc:HGNC:33596","description":"defensin alpha 1B","metadata":null},{"id":"2ca945f9e75040aca9f19ec570b17e13","type":"GENE","name":"DEFA3","canonical_id":"hgnc:HGNC:2762","description":null,"metadata":null},{"id":"6b1ea9861b94441c9a2e812083fd4cd1","type":"GENE","name":"DEFA4","canonical_id":"hgnc:HGNC:2763","description":"defensin alpha 4","metadata":{"aliases":["HP-4","DEF4"]}},{"id":"9bb51ca69deb42eb86b01f97f77305bb","type":"GENE","name":"DEFA5","canonical_id":"hgnc:HGNC:2764","description":null,"metadata":null},{"id":"940c36103138437baabc0a31752a0c59","type":"GENE","name":"DEFA6","canonical_id":"hgnc:HGNC:2765","description":null,"metadata":null},{"id":"409e1eddff5a4f5da9e423d56d49bb12","type":"GENE","name":"DEFA7P","canonical_id":"hgnc:HGNC:31798","description":"defensin alpha 7, pseudogene","metadata":{"aliases":["DEFA7"]}},{"id":"4dd1f688c002483b9c09d23f1c578f06","type":"GENE","name":"DEFA8P","canonical_id":"hgnc:HGNC:31799","description":"defensin alpha 8, pseudogene","metadata":{"aliases":["DEFAP1"]}},{"id":"821389b4a5c54861bece2964a5ab69c3","type":"GENE","name":"DEFA9P","canonical_id":"hgnc:HGNC:31800","description":"defensin alpha 9, pseudogene","metadata":{"aliases":["DEFAP2"]}},{"id":"4edf630126704b9695e713cdd5e383aa","type":"GENE","name":"DEFB1","canonical_id":"hgnc:HGNC:2766","description":null,"metadata":null},{"id":"6b1c4f2b3e944e1d9447c8e1f0d406d0","type":"GENE","name":"DEFB103A","canonical_id":"hgnc:HGNC:15967","description":null,"metadata":null},{"id":"628decbd27904b10b1525aa4944b7015","type":"GENE","name":"DEFB103B","canonical_id":"hgnc:HGNC:31702","description":"defensin beta 103B","metadata":null},{"id":"7a1a495d3dc94ffe973630dd39b63261","type":"GENE","name":"DEFB104A","canonical_id":"hgnc:HGNC:18115","description":"defensin beta 104A","metadata":{"aliases":["DEFB4","DEFB-4","DEFB104"]}},{"id":"4341b642235948268c0979c2c408f915","type":"GENE","name":"DEFB104B","canonical_id":"hgnc:HGNC:26165","description":"defensin beta 104B","metadata":null},{"id":"ff8aa7d0160942e38224053559603c01","type":"GENE","name":"DEFB105A","canonical_id":"hgnc:HGNC:18087","description":"defensin beta 105A","metadata":{"aliases":["DEFB-5","DEFB105"]}},{"id":"bc9a067521ec439c8cc545d8dbef0e1d","type":"GENE","name":"DEFB105B","canonical_id":"hgnc:HGNC:29930","description":"defensin beta 105B","metadata":null},{"id":"1fd083a843674a18a9a06921e2c06195","type":"GENE","name":"DEFB106A","canonical_id":"hgnc:HGNC:18088","description":"defensin beta 106A","metadata":{"aliases":["DEFB-6","DEFB106"]}},{"id":"9d0820cb07e041d3a22de64e2648a384","type":"GENE","name":"DEFB106B","canonical_id":"hgnc:HGNC:28879","description":"defensin beta 106B","metadata":null},{"id":"9c0f99bf5779434c938132beaccf4b12","type":"GENE","name":"DEFB107A","canonical_id":"hgnc:HGNC:18086","description":"defensin beta 107A","metadata":{"aliases":["DEFB-7","DEFB107"]}},{"id":"314a00b07bb844a7b40b6ea6d835632c","type":"GENE","name":"DEFB107B","canonical_id":"hgnc:HGNC:31918","description":"defensin beta 107B","metadata":{"aliases":["HsT21816"]}},{"id":"fa2bef8dc20c480b966d06fe3d1bf8bf","type":"GENE","name":"DEFB108A","canonical_id":"hgnc:HGNC:18089","description":"defensin beta 108A","metadata":{"aliases":["DEFB-8","DEFB108","DEFB108P1"]}},{"id":"1477d62c9b294c1aaa738901789f5dc1","type":"GENE","name":"DEFB108B","canonical_id":"hgnc:HGNC:29966","description":"defensin beta 108B","metadata":null},{"id":"9aa2c9a44d2049d487834c2fa6f292b5","type":"GENE","name":"DEFB108C","canonical_id":"hgnc:HGNC:30847","description":"defensin beta 108C","metadata":{"aliases":["DEFB108P2"]}},{"id":"0ad1b860497c4283a73b49e7a32195ed","type":"GENE","name":"DEFB108D","canonical_id":"hgnc:HGNC:26227","description":"defensin beta 108D (pseudogene)","metadata":{"aliases":["DEFB108P3"]}},{"id":"fa8f92df3e36449d85d9ec4dff8aee20","type":"GENE","name":"DEFB108E","canonical_id":"hgnc:HGNC:30174","description":"defensin beta 108E (pseudogene)","metadata":{"aliases":["DEFB108P4"]}},{"id":"86591f392ce048ebb8f88128afdba73c","type":"GENE","name":"DEFB108F","canonical_id":"hgnc:HGNC:38062","description":"defensin beta 108F (pseudogene)","metadata":{"aliases":["DEFB108P5"]}},{"id":"215d5473374d40a1ab27d2c92f6aec96","type":"GENE","name":"DEFB109A","canonical_id":"hgnc:HGNC:18090","description":"defensin beta 109A (pseudogene)","metadata":{"aliases":["DEFB-9","DEFB109","DEFB109P1"]}},{"id":"0b68bf6778f04d229b6037bcea41e1f8","type":"GENE","name":"DEFB109B","canonical_id":"hgnc:HGNC:33469","description":"defensin beta 109B","metadata":{"aliases":["DEFB109P1B"]}},{"id":"3d59f05fa1f5415f92fd026d4e1d4067","type":"GENE","name":"DEFB109C","canonical_id":"hgnc:HGNC:43844","description":"defensin beta 109C (gene/pseudogene)","metadata":null},{"id":"acd64eaf00a845aaa0e0e1801919ab63","type":"GENE","name":"DEFB109D","canonical_id":"hgnc:HGNC:30838","description":"defensin beta 109D (gene/pseudogene)","metadata":{"aliases":["DEFB109P3"]}},{"id":"d0384c93b5ca48acaf2695ad242a4669","type":"GENE","name":"DEFB109E","canonical_id":"hgnc:HGNC:30592","description":"defensin beta 109E (pseudogene)","metadata":{"aliases":["DEFB109P2"]}},{"id":"f9fa55f65cf247c48ce0186abf12e5a1","type":"GENE","name":"DEFB109F","canonical_id":"hgnc:HGNC:38066","description":"defensin beta 109F (pseudogene)","metadata":null},{"id":"036db01997bb45e9b0f8a3fb100a44a5","type":"GENE","name":"DEFB110","canonical_id":"hgnc:HGNC:18091","description":"defensin beta 110","metadata":{"aliases":["DEFB-10","DEFB-11","DEFB111"]}},{"id":"d4ba34b01a434ec58113c720871e35d7","type":"GENE","name":"DEFB112","canonical_id":"hgnc:HGNC:18093","description":"defensin beta 112","metadata":{"aliases":["DEFB-12"]}},{"id":"19bb37cea7b64c8992771a64168eda83","type":"GENE","name":"DEFB113","canonical_id":"hgnc:HGNC:18094","description":"defensin beta 113","metadata":{"aliases":["DEFB-13"]}},{"id":"16a6da82a07242b8abc509e72e7d7e9a","type":"GENE","name":"DEFB114","canonical_id":"hgnc:HGNC:18095","description":"defensin beta 114","metadata":{"aliases":["DEFB-14"]}},{"id":"ef7c5ff86bdd4810921611123249f1bf","type":"GENE","name":"DEFB115","canonical_id":"hgnc:HGNC:18096","description":"defensin beta 115","metadata":{"aliases":["DEFB-15"]}},{"id":"fbae64543a7d4bd28806ba219b7caa4b","type":"GENE","name":"DEFB116","canonical_id":"hgnc:HGNC:18097","description":"defensin beta 116","metadata":{"aliases":["DEFB-16"]}},{"id":"838742b636b84182a13fcfbd6d515988","type":"GENE","name":"DEFB117","canonical_id":"hgnc:HGNC:18098","description":"defensin beta 117 (pseudogene)","metadata":{"aliases":["DEFB-17"]}},{"id":"deb472d6d50f496894c131f9256729ae","type":"GENE","name":"DEFB118","canonical_id":"hgnc:HGNC:16196","description":"defensin beta 118","metadata":{"aliases":["dJ1018D12.3","DEFB-18","ESC42","C20orf63"]}},{"id":"5e2c0d96e821457296a7df99ae480796","type":"GENE","name":"DEFB119","canonical_id":"hgnc:HGNC:18099","description":"defensin beta 119","metadata":{"aliases":["DEFB-19","DEFB-20","DEFB120"]}},{"id":"824c7c4b61b34fbdba9d624a29c81c0d","type":"GENE","name":"DEFB121","canonical_id":"hgnc:HGNC:18101","description":"defensin beta 121","metadata":{"aliases":["DEFB-21"]}},{"id":"2e59cb7f81084903b75f1d5e98318fdc","type":"GENE","name":"DEFB122","canonical_id":"hgnc:HGNC:18102","description":"defensin beta 122 (pseudogene)","metadata":{"aliases":["DEFB-22","DEFB122P"]}},{"id":"9aa44a7137634e2e8550314a121f30a8","type":"GENE","name":"DEFB123","canonical_id":"hgnc:HGNC:18103","description":"defensin beta 123","metadata":{"aliases":["DEFB-23"]}},{"id":"f51ee45874ec438c87ac8951821ab56c","type":"GENE","name":"DEFB124","canonical_id":"hgnc:HGNC:18104","description":"defensin beta 124","metadata":{"aliases":["DEFB-24"]}},{"id":"72c9313b49304517acf27cf38ab0854b","type":"GENE","name":"DEFB125","canonical_id":"hgnc:HGNC:18105","description":"defensin beta 125","metadata":{"aliases":["DEFB-25"]}},{"id":"f4944f840c134c8da007dd1b194356a8","type":"GENE","name":"DEFB126","canonical_id":"hgnc:HGNC:15900","description":"defensin beta 126","metadata":{"aliases":["bA530N10.1","DEFB-26","C20orf8"]}},{"id":"2d8e574423a2476ea832b3990106f640","type":"GENE","name":"DEFB127","canonical_id":"hgnc:HGNC:16206","description":"defensin beta 127","metadata":{"aliases":["bA530N10.2","DEF-27","C20orf73"]}},{"id":"7f6ae578dcab4f209967985f57fd4a19","type":"GENE","name":"DEFB128","canonical_id":"hgnc:HGNC:18106","description":"defensin beta 128","metadata":{"aliases":["DEFB-28"]}},{"id":"8106a4c9ccc74d1cb5b984aa2ac60693","type":"GENE","name":"DEFB129","canonical_id":"hgnc:HGNC:16218","description":"defensin beta 129","metadata":{"aliases":["bA530N10.3","DEFB-29","C20orf87"]}},{"id":"27293c7e28f1410a81ef280b9608c85a","type":"GENE","name":"DEFB130A","canonical_id":"hgnc:HGNC:18107","description":"defensin beta 130A","metadata":{"aliases":["DEFB-30","DEFB30","DEFB130"]}},{"id":"ba8a4e339066407298c8e743a15dad36","type":"GENE","name":"DEFB130B","canonical_id":"hgnc:HGNC:39814","description":"defensin beta 130B","metadata":null},{"id":"046f04a0cff340469de6071495e2a1fe","type":"GENE","name":"DEFB130C","canonical_id":"hgnc:HGNC:43843","description":"defensin beta 130C (pseudogene)","metadata":null},{"id":"0104935c1b12481497cb495e3d030570","type":"GENE","name":"DEFB130D","canonical_id":"hgnc:HGNC:38059","description":"defensin beta 130D (pseudogene)","metadata":null},{"id":"598fa95e7a7342dc827921b69a0eae85","type":"GENE","name":"DEFB131A","canonical_id":"hgnc:HGNC:18108","description":"defensin beta 131A","metadata":{"aliases":["DEFB-31","DEFB131"]}},{"id":"9394405f398743bfb15c7757c1720847","type":"GENE","name":"DEFB131B","canonical_id":"hgnc:HGNC:38058","description":"defensin beta 131B","metadata":null},{"id":"2a1631763edb45f5ac9d09552d0f440a","type":"GENE","name":"DEFB131C","canonical_id":"hgnc:HGNC:38060","description":"defensin beta 131C (pseudogene)","metadata":null},{"id":"df566afab424427c8a6e824323aacd61","type":"GENE","name":"DEFB131D","canonical_id":"hgnc:HGNC:38061","description":"defensin beta 131D (pseudogene)","metadata":null},{"id":"79f5e299de0d491baad0c4807b592678","type":"GENE","name":"DEFB131E","canonical_id":"hgnc:HGNC:39765","description":"defensin beta 131E (pseudogene)","metadata":null},{"id":"b652fe50c14f46c097c6923f774d6fad","type":"GENE","name":"DEFB132","canonical_id":"hgnc:HGNC:33806","description":"defensin beta 132","metadata":{"aliases":["RP5-1103G7.6","DEFB32"]}},{"id":"41991926056c47a0b4d0caa4bad827d9","type":"GENE","name":"DEFB133","canonical_id":"hgnc:HGNC:31331","description":"defensin beta 133 (pseudogene)","metadata":null},{"id":"d1b60f96a07a4be29c061c0c7090abbc","type":"GENE","name":"DEFB134","canonical_id":"hgnc:HGNC:32399","description":"defensin beta 134","metadata":null},{"id":"c2b3e378b98f4058bbd8b3493cb32b77","type":"GENE","name":"DEFB135","canonical_id":"hgnc:HGNC:32400","description":"defensin beta 135","metadata":null},{"id":"6023cd35cda24dd7b98a665db3ab42d6","type":"GENE","name":"DEFB136","canonical_id":"hgnc:HGNC:34433","description":"defensin beta 136","metadata":{"aliases":["DEFB137"]}},{"id":"994ab52a35884dff9f5af66f28e42b95","type":"GENE","name":"DEFB4A","canonical_id":"hgnc:HGNC:2767","description":null,"metadata":null},{"id":"26cc8654fbf942deb52be950ec128100","type":"GENE","name":"DEFB4B","canonical_id":"hgnc:HGNC:30193","description":"defensin beta 4B","metadata":{"aliases":["DEFB4P"]}},{"id":"0d89fa94a55f435ab330b995285764af","type":"TRIAL","name":"DEFINE - Evaluating Therapies for COVID-19","canonical_id":"clinicaltrials.gov:NCT04473053","description":"COVID-19","metadata":null},{"id":"9047caf87a304340b0f205662b04bcbb","type":"GENE","name":"DEFT1P","canonical_id":"hgnc:HGNC:18339","description":"defensin theta 1, pseudogene","metadata":{"aliases":["DEFQ1","DEFT1"]}},{"id":"7d4091870da6439588d5bd26506cb01e","type":"GENE","name":"DEFT1P2","canonical_id":"hgnc:HGNC:33599","description":"defensin theta 1, pseudogene 2","metadata":null},{"id":"0d891dc77d1b4925b9a088f5a45e87b2","type":"GENE","name":"DEGS1","canonical_id":"hgnc:HGNC:13709","description":"delta 4-desaturase, sphingolipid 1","metadata":{"aliases":["MLD","Des-1","DES1","FADS7","DEGS-1"]}},{"id":"80dcda3dfd5741c8bc4a5feb59500427","type":"GENE","name":"DEGS2","canonical_id":"hgnc:HGNC:20113","description":"delta 4-desaturase, sphingolipid 2","metadata":{"aliases":["DES2","FADS8","C14orf66"]}},{"id":"165c539a7c024bc7bf17038301dd895c","type":"GENE","name":"DEK","canonical_id":"hgnc:HGNC:2768","description":null,"metadata":null},{"id":"7a702710c048434a90e55b3c63de3918","type":"GENE","name":"DEK-DT","canonical_id":"hgnc:HGNC:59367","description":"DEK divergent transcript","metadata":null},{"id":"55a90ddfd07b409da1cf03e09ec1a1b9","type":"GENE","name":"DELE1","canonical_id":"hgnc:HGNC:28969","description":"DAP3 binding cell death enhancer 1","metadata":{"aliases":["DELE","KIAA0141"]}},{"id":"a000b56f36f24bb28a2967159b5bb63b","type":"GENE","name":"DELE1-AS1","canonical_id":"hgnc:HGNC:59267","description":"DELE1 antisense RNA 1","metadata":null},{"id":"9a62a1e9fcdc42a1b5d5b360681d116f","type":"GENE","name":"DELEC1","canonical_id":"hgnc:HGNC:23658","description":"deleted in esophageal cancer 1","metadata":{"aliases":["CTS9","DEC1"]}},{"id":"bae3a97e915345e081b8d39f99f3a6b7","type":"GENE","name":"DEMA1","canonical_id":"hgnc:HGNC:34439","description":"DPM1 ER membrane anchor 1","metadata":{"aliases":["LOC339804","C2orf74"]}},{"id":"7287c600dcc34454ad87f0a2aa6e1227","type":"DISEASE","name":"DEND syndrome","canonical_id":"mondo:0019207","description":null,"metadata":null},{"id":"88a6f1fb693840e6b2b26fb648a43f3a","type":"GENE","name":"DENND10","canonical_id":"hgnc:HGNC:31793","description":"DENN domain containing 10","metadata":{"aliases":["FAM45A"]}},{"id":"eeae025b67a64c8cb2efc9b7bbb1f591","type":"GENE","name":"DENND10P1","canonical_id":"hgnc:HGNC:30886","description":"DENND10 pseudogene 1","metadata":{"aliases":["HT011","FAM45B","FAM45BP"]}},{"id":"862d8bad3ede4d3eab5428657fdf81b5","type":"GENE","name":"DENND11","canonical_id":"hgnc:HGNC:29472","description":"DENN domain containing 11","metadata":{"aliases":["LCHN","KIAA1147"]}},{"id":"3dfad64ab11148de9620a2922016ba62","type":"GENE","name":"DENND1A","canonical_id":"hgnc:HGNC:29324","description":"DENN domain containing 1A","metadata":{"aliases":["FLJ21129","FAM31A","KIAA1608"]}},{"id":"36b41f03b8a04ea09d99b7eb87b9a0c7","type":"GENE","name":"DENND1A-AS1","canonical_id":"hgnc:HGNC:58235","description":"DENND1A antisense RNA 1","metadata":null},{"id":"0a59c6a910e34df48f4e68134786898c","type":"GENE","name":"DENND1B","canonical_id":"hgnc:HGNC:28404","description":"DENN domain containing 1B","metadata":{"aliases":["MGC27044","FLJ20054","FAM31B","C1orf218"]}},{"id":"e6ae64fbdd234e338c7269a348ef8c93","type":"GENE","name":"DENND1C","canonical_id":"hgnc:HGNC:26225","description":"DENN domain containing 1C","metadata":{"aliases":["FLJ22757","FAM31C"]}},{"id":"fbb705a9322043fd823c64b539acc042","type":"GENE","name":"DENND1C-AS1","canonical_id":"hgnc:HGNC:59252","description":"DENND1C antisense RNA 1","metadata":{"aliases":["AC010503.4","CTD-2396E7.11"]}},{"id":"a155cd6b9d614b5898920a31904890cb","type":"GENE","name":"DENND2A","canonical_id":"hgnc:HGNC:22212","description":"DENN domain containing 2A","metadata":{"aliases":["FAM31D","KIAA1277"]}},{"id":"60dedb277c9e4ec2bea7a70498ec9d86","type":"GENE","name":"DENND2B","canonical_id":"hgnc:HGNC:11350","description":"DENN domain containing 2B","metadata":{"aliases":["HTS1","p126","ST5"]}},{"id":"433a94d990a1471899f8d3f303176025","type":"GENE","name":"DENND2B-AS1","canonical_id":"hgnc:HGNC:56176","description":"DENND2B antisense RNA 1","metadata":null},{"id":"d23d005b20664abc898852235e7fda72","type":"GENE","name":"DENND2C","canonical_id":"hgnc:HGNC:24748","description":"DENN domain containing 2C","metadata":{"aliases":["FLJ37099","DKFZp686G0351","DKFZp779P1149","dJ1156J9.1","RP5-1156J9.1"]}},{"id":"9f3ae061fcb642cda03ef350e8aabd77","type":"GENE","name":"DENND2D","canonical_id":"hgnc:HGNC:26192","description":"DENN domain containing 2D","metadata":{"aliases":["FLJ22457","RP5-1180E21.2"]}},{"id":"c445351e65b34b24a077df63cc109080","type":"GENE","name":"DENND3","canonical_id":"hgnc:HGNC:29134","description":"DENN domain containing 3","metadata":{"aliases":["KIAA0870"]}},{"id":"df9b1f73fb7e4a51a55822e317bd6c96","type":"GENE","name":"DENND3-AS1","canonical_id":"hgnc:HGNC:55537","description":"DENND3 antisense RNA 1","metadata":null},{"id":"add4499399f740868fb0ea8259616465","type":"GENE","name":"DENND4A","canonical_id":"hgnc:HGNC:24321","description":null,"metadata":null},{"id":"279cdcfe356849e8ac6d0e9a69fde708","type":"GENE","name":"DENND4B","canonical_id":"hgnc:HGNC:29044","description":"DENN domain containing 4B","metadata":{"aliases":["KIAA0476"]}},{"id":"aaf25ab639414b4db1875ee03891397c","type":"GENE","name":"DENND4C","canonical_id":"hgnc:HGNC:26079","description":"DENN domain containing 4C","metadata":{"aliases":["FLJ20686","bA513M16.3","RAB10GEF","C9orf55B","C9orf55"]}},{"id":"0a1d26a9d7f44d5b84136b85b98c8648","type":"GENE","name":"DENND5A","canonical_id":"hgnc:HGNC:19344","description":"DENN domain containing 5A","metadata":{"aliases":["KIAA1091","FLJ22354","FLJ33829","FLJ43455","RAB6IP1"]}},{"id":"81b526494e9d42b5836aeff686df7f98","type":"GENE","name":"DENND5B","canonical_id":"hgnc:HGNC:28338","description":"DENN domain containing 5B","metadata":{"aliases":["MGC24039"]}},{"id":"bf5d759113ba4675993dcca395376490","type":"GENE","name":"DENND5B-AS1","canonical_id":"hgnc:HGNC:42517","description":"DENND5B antisense RNA 1","metadata":null},{"id":"7dc7c248352a48798b479fa1f7f3ef25","type":"GENE","name":"DENND6A","canonical_id":"hgnc:HGNC:26635","description":"DENN domain containing 6A","metadata":{"aliases":["FLJ34969","AFI1A","FAM116A"]}},{"id":"244e053215fd45c5bb45dd1d2a067970","type":"GENE","name":"DENND6A-AS1","canonical_id":"hgnc:HGNC:41152","description":"DENND6A antisense RNA 1","metadata":null},{"id":"d3c18b54e58a4ee38e8e7a0e78a51aef","type":"GENE","name":"DENND6A-DT","canonical_id":"hgnc:HGNC:51592","description":"DENND6A divergent transcript","metadata":null},{"id":"a3efee68d1334beba712cbd7632f1ee3","type":"GENE","name":"DENND6B","canonical_id":"hgnc:HGNC:32690","description":"DENN domain containing 6B","metadata":{"aliases":["MGC33692","AFI1B","FAM116B"]}},{"id":"481d9f1dfd63483b97836e3b06f572be","type":"GENE","name":"DENR","canonical_id":"hgnc:HGNC:2769","description":"density regulated re-initiation and release factor","metadata":{"aliases":["DRP","DRP1","SMAP-3"]}},{"id":"4534bbd77d7e4190ad93202f77e920ee","type":"GENE","name":"DENRP1","canonical_id":"hgnc:HGNC:56955","description":"DENR pseudogene 1","metadata":null},{"id":"15356e9e25db400c912b8e124f0f1471","type":"GENE","name":"DENRP2","canonical_id":"hgnc:HGNC:56956","description":"DENR pseudogene 2","metadata":null},{"id":"98b44e11459c4d6096aceaf5a689400c","type":"GENE","name":"DENRP3","canonical_id":"hgnc:HGNC:56957","description":"DENR pseudogene 3","metadata":null},{"id":"f900d237c17d452b9cbbb30ea4dc646b","type":"GENE","name":"DENRP4","canonical_id":"hgnc:HGNC:56958","description":"DENR pseudogene 4","metadata":null},{"id":"55b9187a1c59476da974a8586ef324c9","type":"GENE","name":"DEPDC1","canonical_id":"hgnc:HGNC:22949","description":"DEP domain containing 1","metadata":{"aliases":["DEP.8","FLJ20354","SDP35","DEPDC1A"]}},{"id":"681cf3fcc5aa4614b27b7ae45b8ab769","type":"GENE","name":"DEPDC1-AS1","canonical_id":"hgnc:HGNC:50592","description":"DEPDC1 antisense RNA 1","metadata":null},{"id":"b40d6a82f2de499493bd0dcae599255f","type":"GENE","name":"DEPDC1-AS2","canonical_id":"hgnc:HGNC:58135","description":"DEPDC1 antisense RNA 2","metadata":{"aliases":["RP4-694A7.2"]}},{"id":"d3e4214150224867951e534f947dde72","type":"GENE","name":"DEPDC1B","canonical_id":"hgnc:HGNC:24902","description":"DEP domain containing 1B","metadata":{"aliases":["XTP1","BRCC3"]}},{"id":"bfb8bc5beec1400480f007ed60ec36b8","type":"GENE","name":"DEPDC1B-DT","canonical_id":"hgnc:HGNC:59058","description":"DEPDC1B divergent transcript","metadata":null},{"id":"8f3ea3b40c404139ac32207a8f9cab64","type":"GENE","name":"DEPDC1P1","canonical_id":"hgnc:HGNC:31125","description":"DEP domain containing 1 pseudogene 1","metadata":null},{"id":"91f43610d01a42d5ae3f462b2bca5ecf","type":"GENE","name":"DEPDC1P2","canonical_id":"hgnc:HGNC:33975","description":"DEP domain containing 1 pseudogene 2","metadata":null},{"id":"e396850e64754139821a1e42e81b1ee7","type":"GENE","name":"DEPDC4","canonical_id":"hgnc:HGNC:22952","description":"DEP domain containing 4","metadata":{"aliases":["DEP.4","FLJ33505"]}},{"id":"acfd6a5d86454fbab9a15db3df647acf","type":"GENE","name":"DEPDC5","canonical_id":"hgnc:HGNC:18423","description":"DEP domain containing 5, GATOR1 subcomplex subunit","metadata":{"aliases":["KIAA0645","DEP.5"]}},{"id":"e81e7d24664f47bcb6300242cc1d233b","type":"GENE","name":"DEPDC7","canonical_id":"hgnc:HGNC:29899","description":"DEP domain containing 7","metadata":null},{"id":"26bd7f5963a742639e8befe17e8e8a79","type":"GENE","name":"DEPP1","canonical_id":"hgnc:HGNC:23355","description":"DEPP autophagy regulator 1","metadata":{"aliases":["DEPP","FIG","Fseg","C10orf10"]}},{"id":"f9ad3e45c9674136884eb92dca6f985e","type":"GENE","name":"DEPTOR","canonical_id":"hgnc:HGNC:22953","description":"DEP domain containing MTOR interacting protein","metadata":{"aliases":["DEP.6","FLJ12428","DEPDC6"]}},{"id":"3efe2883baca40e8b4ee794ba2abe084","type":"GENE","name":"DEPTOR-AS1","canonical_id":"hgnc:HGNC:55602","description":"DEPTOR antisense RNA 1","metadata":{"aliases":["KB-1471A8.2"]}},{"id":"8b614150fb214b26a65bb7dd67f2e489","type":"GENE","name":"DERA","canonical_id":"hgnc:HGNC:24269","description":"deoxyribose-phosphate aldolase","metadata":{"aliases":["CGI-26","DEOC"]}},{"id":"9d90be0f81844cdd9ae1350923126afa","type":"GENE","name":"DERL1","canonical_id":"hgnc:HGNC:28454","description":"derlin 1","metadata":{"aliases":["MGC3067","PRO2577","FLJ13784","DER1","DER-1","derlin-1"]}},{"id":"85f5dbfa16e8421a9e7864f68e9c793c","type":"GENE","name":"DERL2","canonical_id":"hgnc:HGNC:17943","description":"derlin 2","metadata":{"aliases":["F-LAN-1","FLANa","F-LANa","CGI-101","derlin-2"]}},{"id":"1f22fdc15d5241b6a0a1780b36dd3b70","type":"GENE","name":"DERL3","canonical_id":"hgnc:HGNC:14236","description":"derlin 3","metadata":{"aliases":["FLJ43842","MGC71803","derlin-3","IZP6","C22orf14"]}},{"id":"0910986df2764a8f9bab9bb29b49d1d8","type":"GENE","name":"DERPC","canonical_id":"hgnc:HGNC:54084","description":"DERPC proline and glycine rich nuclear protein","metadata":null},{"id":"354d505c1aa64323bf20e6d636e6682e","type":"GENE","name":"DES","canonical_id":"hgnc:HGNC:2770","description":null,"metadata":null},{"id":"b114f393ac004e00bad12ca2a80c2aaa","type":"GENE","name":"DESI1","canonical_id":"hgnc:HGNC:24577","description":"desumoylating isopeptidase 1","metadata":{"aliases":["D15Wsu75e","DESI-1","POST","FAM152B","PPPDE2"]}},{"id":"1ea47185883b4d4b9b938f1149d03734","type":"GENE","name":"DESI2","canonical_id":"hgnc:HGNC:24264","description":"desumoylating isopeptidase 2","metadata":{"aliases":["CGI-146","FLJ21998","PNAS-4","DESI-2","C1orf121","FAM152A","PPPDE1"]}},{"id":"3b2632f5b94940f78622be9bac62cacf","type":"TRIAL","name":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","canonical_id":"clinicaltrials.gov:NCT00252863","description":"Asthma","metadata":null},{"id":"cd62a8576a2e4e8f8ea0642e030061df","type":"GENE","name":"DET1","canonical_id":"hgnc:HGNC:25477","description":"DET1 partner of COP1 E3 ubiquitin ligase","metadata":{"aliases":["FLJ10103"]}},{"id":"4d2b9806327f4abc8d42d3f4ac6eba7e","type":"TRIAL","name":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","canonical_id":"clinicaltrials.gov:NCT05722886","description":"Haematological Malignancy; Solid Tumour","metadata":null},{"id":"c623f75253734423935489a5987becdf","type":"TRIAL","name":"DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers","canonical_id":"clinicaltrials.gov:NCT05770037","description":"Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma; Solid Tumour","metadata":null},{"id":"cc94fb487c53495eae91ea1c135c9b4e","type":"TRIAL","name":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","canonical_id":"clinicaltrials.gov:NCT05768178","description":"Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic; Solid Tumour","metadata":null},{"id":"d75e5d5878f0438c82e53d9d5974b9e5","type":"TRIAL","name":"DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations","canonical_id":"clinicaltrials.gov:NCT06988475","description":"Solid Tumour; Haematological Malignancy; Malignant Neoplasm; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Malignancy; Glioma; Neuroblastoma; Gastric Cancer; Soft Tissue Sarcoma","metadata":null},{"id":"debcdffe126f4441b21a5f73512d4852","type":"GENE","name":"DEUP1","canonical_id":"hgnc:HGNC:26344","description":"deuterosome assembly protein 1","metadata":{"aliases":["FLJ25393","CCDC67"]}},{"id":"c5939726b3d849709f680fea8105b0cb","type":"TRIAL","name":"DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study","canonical_id":"clinicaltrials.gov:NCT06059495","description":"Adenocarcinoma - GEJ; Gastric Adenocarcinoma","metadata":null},{"id":"03b90de238e44efd938037d13b4e36fe","type":"GENE","name":"DEXI","canonical_id":"hgnc:HGNC:13267","description":"Dexi homolog","metadata":{"aliases":["MYLE"]}},{"id":"874be23fa0e4498097c6e382fb923e6b","type":"GENE","name":"DFFA","canonical_id":"hgnc:HGNC:2772","description":"DNA fragmentation factor subunit alpha","metadata":{"aliases":["DFF-45","DFF45","ICAD","DFF1"]}},{"id":"1f308c38c5774deeb59878409819522a","type":"GENE","name":"DFFB","canonical_id":"hgnc:HGNC:2773","description":"DNA fragmentation factor subunit beta","metadata":{"aliases":["CAD","CPAN","DFF-40","DFF40"]}},{"id":"b4eab22cb0594c6bbd1ad384791b87dc","type":"GENE","name":"DFFBP1","canonical_id":"hgnc:HGNC:49815","description":"DNA fragmentation factor subunit beta pseudogene 1","metadata":null},{"id":"d1ef2d29e28441a7a87c467c64fa4677","type":"GENE","name":"DGAT1","canonical_id":"hgnc:HGNC:2843","description":"diacylglycerol O-acyltransferase 1","metadata":{"aliases":["ARGP1","DGAT"]}},{"id":"be4f5a5f9c684801b6bb67ab0ce4698f","type":"GENE","name":"DGAT2","canonical_id":"hgnc:HGNC:16940","description":"diacylglycerol O-acyltransferase 2","metadata":null},{"id":"92dd8203170b454695dca543b75fac7f","type":"GENE","name":"DGAT2-DT","canonical_id":"hgnc:HGNC:27451","description":"DGAT2 divergent transcript","metadata":null},{"id":"b29c9c82d50f4d7db082fcfe00f589ed","type":"GENE","name":"DGAT2L6","canonical_id":"hgnc:HGNC:23250","description":"diacylglycerol O-acyltransferase 2 like 6","metadata":{"aliases":["DC3","FLJ25989"]}},{"id":"f39d01d0e74446acb97c823f3b5a289e","type":"GENE","name":"DGAT2L7P","canonical_id":"hgnc:HGNC:44367","description":"diacylglycerol O-acyltransferase 2 like 7, pseudogene","metadata":null},{"id":"fb8b2147ceb64c95864f06ed565ebf0d","type":"GENE","name":"DGCR","canonical_id":"hgnc:HGNC:2844","description":"DiGeorge syndrome chromosome region","metadata":{"aliases":["CATCH22"]}},{"id":"15cb518db3cd4414bb5a548c6f0713ce","type":"GENE","name":"DGCR11","canonical_id":"hgnc:HGNC:17226","description":"DiGeorge syndrome critical region gene 11","metadata":{"aliases":["DGS-D"]}},{"id":"6f7a7599cd714cc894d1f5db37f6fa78","type":"GENE","name":"DGCR2","canonical_id":"hgnc:HGNC:2845","description":"DiGeorge syndrome critical region gene 2","metadata":{"aliases":["KIAA0163","LAN","IDD","DGS-C","SEZ-12"]}},{"id":"03c62ef43c13455e9634ff2310180de1","type":"GENE","name":"DGCR5","canonical_id":"hgnc:HGNC:16757","description":null,"metadata":null},{"id":"cb9664944ae0404cb2a693f902b65c36","type":"GENE","name":"DGCR6","canonical_id":"hgnc:HGNC:2846","description":"DiGeorge syndrome critical region gene 6","metadata":null},{"id":"c2fd75a228634c41b4612f22a67ec382","type":"GENE","name":"DGCR6L","canonical_id":"hgnc:HGNC:18551","description":"DiGeorge syndrome critical region gene 6 like","metadata":{"aliases":["FLJ10666"]}},{"id":"a10a497fae3f4c26845b8f61968e046f","type":"GENE","name":"DGCR8","canonical_id":"hgnc:HGNC:2847","description":"DGCR8 microprocessor complex subunit","metadata":{"aliases":["DGCRK6","Gy1","pasha","C22orf12"]}},{"id":"9e2039e2d7ad4f97a9a4a8b258ab1050","type":"GENE","name":"DGKA","canonical_id":"hgnc:HGNC:2849","description":"diacylglycerol kinase alpha","metadata":{"aliases":["DGK-alpha","DAGK","DAGK1"]}},{"id":"042ff00bc0f44f758ca77668f8e0150d","type":"GENE","name":"DGKB","canonical_id":"hgnc:HGNC:2850","description":"diacylglycerol kinase beta","metadata":{"aliases":["KIAA0718","DGK","DGK-BETA","DAGK2"]}},{"id":"7b101a351d9a43b8b97abfd7cb36d069","type":"GENE","name":"DGKD","canonical_id":"hgnc:HGNC:2851","description":"diacylglycerol kinase delta","metadata":{"aliases":["KIAA0145","DGKdelta"]}},{"id":"2dd60d39b6bc4ae39317735688bffbd5","type":"GENE","name":"DGKE","canonical_id":"hgnc:HGNC:2852","description":"diacylglycerol kinase epsilon","metadata":{"aliases":["DAGK6","DGK"]}},{"id":"7cb95afaf35646eca589a9e0ca11da30","type":"GENE","name":"DGKG","canonical_id":"hgnc:HGNC:2853","description":null,"metadata":null},{"id":"cfcebab9cdd44e78be301c22cd901a80","type":"GENE","name":"DGKH","canonical_id":"hgnc:HGNC:2854","description":"diacylglycerol kinase eta","metadata":{"aliases":["DGKeta"]}},{"id":"d1c4ed916b794825bf8bae756c688e8b","type":"GENE","name":"DGKI","canonical_id":"hgnc:HGNC:2855","description":"diacylglycerol kinase iota","metadata":{"aliases":["DGK-IOTA"]}},{"id":"aa044a8ea1e442bcba3225879fc162eb","type":"GENE","name":"DGKK","canonical_id":"hgnc:HGNC:32395","description":"diacylglycerol kinase kappa","metadata":null},{"id":"c1497b2a2c7f43138f98857ff4680211","type":"GENE","name":"DGKQ","canonical_id":"hgnc:HGNC:2856","description":"diacylglycerol kinase theta","metadata":{"aliases":["DAGK","DAGK7","DAGK4"]}},{"id":"9793cbfef4c94d7b84010b9805d926f2","type":"GENE","name":"DGKZ","canonical_id":"hgnc:HGNC:2857","description":"diacylglycerol kinase zeta","metadata":{"aliases":["DAGK5","hDGKzeta","DGK-ZETA","DAGK6"]}},{"id":"ae8d4348eff045aebd7d74ce9ee0083f","type":"GENE","name":"DGKZP1","canonical_id":"hgnc:HGNC:39263","description":"diacylglycerol kinase zeta pseudogene 1","metadata":null},{"id":"212cc57069564f238aab6b00c6581235","type":"GENE","name":"DGLUCY","canonical_id":"hgnc:HGNC:20498","description":"D-glutamate cyclase","metadata":{"aliases":["FLJ39975","C14orf159"]}},{"id":"76863d21ab0f4471a5840da1791df66b","type":"GENE","name":"DGUOK","canonical_id":"hgnc:HGNC:2858","description":"deoxyguanosine kinase","metadata":{"aliases":["dGK"]}},{"id":"fc5eefeb32f540ca9dc68c782048606e","type":"GENE","name":"DGUOK-AS1","canonical_id":"hgnc:HGNC:43441","description":"DGUOK antisense RNA 1","metadata":null},{"id":"bf714865ebaa414bb604790b900fec6a","type":"GO_TERM","name":"DH domain binding","canonical_id":"go:GO:0097161","description":"\"Binding to a DH (Dbl homology) domain of a protein. The DH domain contains three structurally conserved regions separated by more variable regions. It is composed of 11 alpha helices that are folded into a flattened, elongated alpha-helix bundle in which two of the three conserved regions, conserved region 1 (CR1) and conserved region 3 (CR3), are exposed near the centre of one surface. CR1 and CR3, together with a part of alpha-6 and the DH/PH (pleckstrin homology) junction site, constitute the Rho GTPase interacting pocket.\" [GOC:yaf, InterPro:IPR000219, PMID:12775584]","metadata":null},{"id":"4ae1d86d05ec47599e60364379d9671d","type":"GENE","name":"DHCR24","canonical_id":"hgnc:HGNC:2859","description":null,"metadata":null},{"id":"b1f5b9691f7849a48ec5e521b91bbd87","type":"GENE","name":"DHCR24-DT","canonical_id":"hgnc:HGNC:53969","description":"DHCR24 divergent transcript","metadata":{"aliases":["ESSENCE"]}},{"id":"68e3e6dee331486b8a95be56c49fa970","type":"GENE","name":"DHCR7","canonical_id":"hgnc:HGNC:2860","description":"7-dehydrocholesterol reductase","metadata":{"aliases":["SLOS"]}},{"id":"0a62d8ecf24c4195894aabff525069bf","type":"GENE","name":"DHCR7-DT","canonical_id":"hgnc:HGNC:56822","description":"DHCR7 divergent transcript","metadata":{"aliases":["AP","lnc","AP002387.2","RP11-660L16.2"]}},{"id":"83f0229ea4514496a9513c85f38296ff","type":"GENE","name":"DHDDS","canonical_id":"hgnc:HGNC:20603","description":"dehydrodolichyl diphosphate synthase subunit","metadata":{"aliases":["HDS","FLJ13102","DS","RP59","hCIT"]}},{"id":"48b0947fe8294f00bc7217ab82ac65b1","type":"GENE","name":"DHDDS-AS1","canonical_id":"hgnc:HGNC:40925","description":"DHDDS antisense RNA 1","metadata":null},{"id":"153e24799d764a34ba86050e06a7e241","type":"GENE","name":"DHDH","canonical_id":"hgnc:HGNC:17887","description":"dihydrodiol dehydrogenase","metadata":{"aliases":["HUM2DD"]}},{"id":"65bd78fe4f564715938bab81fcd2a416","type":"GENE","name":"DHFR","canonical_id":"hgnc:HGNC:2861","description":null,"metadata":null},{"id":"990270d2d2824113889aad401f2c6214","type":"PROTEIN","name":"DHFR","canonical_id":"uniprot:P00374","description":null,"metadata":null},{"id":"e936810acb524501bc716862c33c3648","type":"GENE","name":"DHFR2","canonical_id":"hgnc:HGNC:27309","description":"dihydrofolate reductase 2","metadata":{"aliases":["FLJ16119","DHFRP4","DHFRL1"]}},{"id":"be2de29fda014d6e97ae5875715af1cf","type":"GENE","name":"DHFRP1","canonical_id":"hgnc:HGNC:2862","description":"dihydrofolate reductase pseudogene 1","metadata":null},{"id":"270d5702e54045a099afc4291d5c88f1","type":"GENE","name":"DHFRP2","canonical_id":"hgnc:HGNC:2863","description":"dihydrofolate reductase pseudogene 2","metadata":null},{"id":"ce974f12445c4b76bf9c8a9cc4247779","type":"GENE","name":"DHFRP3","canonical_id":"hgnc:HGNC:52354","description":"dihydrofolate reductase pseudogene 3","metadata":null},{"id":"8b3bd09b87c341a7914fa40c0ba70af3","type":"GENE","name":"DHFRP5","canonical_id":"hgnc:HGNC:52355","description":"dihydrofolate reductase pseudogene 5","metadata":null},{"id":"d8e7621e51c84ba38969beb2c82e8528","type":"GENE","name":"DHFRP6","canonical_id":"hgnc:HGNC:52356","description":"dihydrofolate reductase pseudogene 6","metadata":null},{"id":"4d155ef3b93747be9d266bbc6bb2d2cc","type":"GENE","name":"DHH","canonical_id":"hgnc:HGNC:2865","description":"desert hedgehog signaling molecule","metadata":{"aliases":["HHG-3","MGC35145"]}},{"id":"a81f2e7c2bd047b996fb70d1d38f2c1c","type":"GENE","name":"DHH-AS1","canonical_id":"hgnc:HGNC:58445","description":"DHH antisense RNA 1","metadata":null},{"id":"96638fd33eb34a969c1ee4eff9e1a45f","type":"GENE","name":"DHODH","canonical_id":"hgnc:HGNC:2867","description":"dihydroorotate dehydrogenase (quinone)","metadata":null},{"id":"21f1fb9978154ea79bbb1cea237bc484","type":"PROTEIN","name":"DHODH","canonical_id":"uniprot:Q02127","description":null,"metadata":null},{"id":"cdbea56625d14169ae2ecd11a4a1c116","type":"GENE","name":"DHPS","canonical_id":"hgnc:HGNC:2869","description":"deoxyhypusine synthase","metadata":{"aliases":["MIG13"]}},{"id":"045dabf64d984b19b3708da31ed81393","type":"GENE","name":"DHRS1","canonical_id":"hgnc:HGNC:16445","description":"dehydrogenase/reductase 1","metadata":{"aliases":["FLJ25430","MGC20204","SDR19C1"]}},{"id":"f1c7c5ffa789471ca57aa16d21dd7b45","type":"GENE","name":"DHRS11","canonical_id":"hgnc:HGNC:28639","description":"dehydrogenase/reductase 11","metadata":{"aliases":["MGC4172","SDR24C1"]}},{"id":"980ddce368504f82a523377d25cb0daf","type":"GENE","name":"DHRS12","canonical_id":"hgnc:HGNC:25832","description":"dehydrogenase/reductase 12","metadata":{"aliases":["FLJ13639","SDR40C1"]}},{"id":"287f703363264c18be070e33fe2d9360","type":"GENE","name":"DHRS13","canonical_id":"hgnc:HGNC:28326","description":"dehydrogenase/reductase 13","metadata":{"aliases":["MGC23280","SDR7C5"]}},{"id":"115efd69f02d4a8eaad39883d536c370","type":"GENE","name":"DHRS2","canonical_id":"hgnc:HGNC:18349","description":null,"metadata":null},{"id":"f499d0bb89174fe8ab6939cefdc5f921","type":"GENE","name":"DHRS3","canonical_id":"hgnc:HGNC:17693","description":"dehydrogenase/reductase 3","metadata":{"aliases":["retSDR1","Rsdr1","SDR1","RDH17","SDR16C1","CNALPTC1"]}},{"id":"0df7c250646c41b391c4a59b04e77741","type":"GENE","name":"DHRS4","canonical_id":"hgnc:HGNC:16985","description":"dehydrogenase/reductase 4","metadata":{"aliases":["SCAD-SRL","SDR-SRL","humNRDR","FLJ11008","SDR25C2"]}},{"id":"8fc8a35d7fee4cfd9424b9c716967f94","type":"GENE","name":"DHRS4-AS1","canonical_id":"hgnc:HGNC:23175","description":"DHRS4 antisense RNA 1","metadata":{"aliases":["PRO1488","AS1DHRS4","C14orf167"]}},{"id":"4ca530bb94254e958af69c25ad6622a6","type":"GENE","name":"DHRS4L1","canonical_id":"hgnc:HGNC:19732","description":"dehydrogenase/reductase 4 like 1 (pseudogene)","metadata":{"aliases":["SDR25C4P","SDR25C4"]}},{"id":"20f6506e7888471c923f5fa65246275e","type":"GENE","name":"DHRS4L2","canonical_id":"hgnc:HGNC:19731","description":"dehydrogenase/reductase 4 like 2","metadata":{"aliases":["SDR25C3"]}},{"id":"611418a6875c4e68a3976277c4d3eb31","type":"GENE","name":"DHRS7","canonical_id":"hgnc:HGNC:21524","description":"dehydrogenase/reductase 7","metadata":{"aliases":["retDSR4","SDR34C1"]}},{"id":"5d1138153ee84b318d7dd98b85e9c18e","type":"GENE","name":"DHRS7B","canonical_id":"hgnc:HGNC:24547","description":"dehydrogenase/reductase 7B","metadata":{"aliases":["DKFZp566O084","MGC8916","CGI-93","SDR32C1"]}},{"id":"04a8581b3b31406f87f0240a837f3353","type":"GENE","name":"DHRS7C","canonical_id":"hgnc:HGNC:32423","description":"dehydrogenase/reductase 7C","metadata":{"aliases":["SDR32C2"]}},{"id":"e5a9b57cb778464c8433b11c2aef6817","type":"GENE","name":"DHRS9","canonical_id":"hgnc:HGNC:16888","description":"dehydrogenase/reductase 9","metadata":{"aliases":["RDHL","3alpha-HSD","RETSDR8","RDH15","SDR9C4"]}},{"id":"e1b29e6c82fb450e9f6c693b52f85672","type":"GENE","name":"DHRSX","canonical_id":"hgnc:HGNC:18399","description":"dehydrogenase/reductase X-linked","metadata":{"aliases":["DHRS5X","DHRSXY","DHRSY","DHRS5Y","SDR46C1","SDR7C6"]}},{"id":"4043010b03cf41ff8a60adabd6a0ec19","type":"GENE","name":"DHRSX-IT1","canonical_id":"hgnc:HGNC:38713","description":"DHRSX intronic transcript 1","metadata":{"aliases":["DHRSX-IT","DHRSXIT1"]}},{"id":"08b0a8dc0fc44fd89189cd9dc8bfb9c9","type":"GENE","name":"DHTKD1","canonical_id":"hgnc:HGNC:23537","description":"dehydrogenase E1 and transketolase domain containing 1","metadata":{"aliases":["KIAA1630","MGC3090","DKFZP762M115","CMT2Q","OADC-E1","OADH-E1","E1a"]}},{"id":"a43f4465c25a4a5f926a9e7176c1e677","type":"GENE","name":"DHX15","canonical_id":"hgnc:HGNC:2738","description":"DEAH-box helicase 15","metadata":{"aliases":["HRH2","DBP1","Prp43","PrPp43p","PRPF43","DDX15"]}},{"id":"bcf36837da514e3581d2333aa26dd497","type":"GENE","name":"DHX16","canonical_id":"hgnc:HGNC:2739","description":"DEAH-box helicase 16","metadata":{"aliases":["DBP2","Prp2","PRPF2","DDX16"]}},{"id":"0b4567bc46d648538b7c0f492e996779","type":"GENE","name":"DHX29","canonical_id":"hgnc:HGNC:15815","description":"DExH-box helicase 29","metadata":{"aliases":["DDX29"]}},{"id":"851dd12f3a02482188ce0e4f422a3c4b","type":"GENE","name":"DHX30","canonical_id":"hgnc:HGNC:16716","description":"DExH-box helicase 30","metadata":{"aliases":["KIAA0890","FLJ11214","DDX30"]}},{"id":"892b2a93feca4abbbf85723b32b7c0da","type":"GENE","name":"DHX32","canonical_id":"hgnc:HGNC:16717","description":"DEAH-box helicase 32 (putative)","metadata":{"aliases":["FLJ10889","FLJ10694","DHLP1","DDX32"]}},{"id":"33985183c620453bb654b2eee12f767b","type":"GENE","name":"DHX33","canonical_id":"hgnc:HGNC:16718","description":"DEAH-box helicase 33","metadata":{"aliases":["FLJ21972","DKFZp762F2011","DDX33"]}},{"id":"96950809bf5f4b76a8267b94ef096f38","type":"GENE","name":"DHX33-DT","canonical_id":"hgnc:HGNC:52937","description":"DHX33 divergent transcript","metadata":null},{"id":"aac498a0fbf74262938b610dbd8673e3","type":"GENE","name":"DHX34","canonical_id":"hgnc:HGNC:16719","description":"DExH-box helicase 34","metadata":{"aliases":["KIAA0134","DDX34"]}},{"id":"41d827bd4f7a4d6ebc8fc594f23d0d4b","type":"GENE","name":"DHX35","canonical_id":"hgnc:HGNC:15861","description":"DEAH-box helicase 35","metadata":{"aliases":["FLJ22759","KAIA0875","C20orf15","DDX35"]}},{"id":"d537abbb5a444159bf4773042d09f6d8","type":"GENE","name":"DHX35-DT","canonical_id":"hgnc:HGNC:55365","description":"DHX35 divergent transcript","metadata":null},{"id":"36ad6c1d7e7d433696eefcb6cc36ca37","type":"GENE","name":"DHX36","canonical_id":"hgnc:HGNC:14410","description":"DEAH-box helicase 36","metadata":{"aliases":["MLEL1","KIAA1488","RHAU","DDX36"]}},{"id":"299d83402c734219b9baae05e4a998e3","type":"GENE","name":"DHX37","canonical_id":"hgnc:HGNC:17210","description":"DEAH-box helicase 37","metadata":{"aliases":["KIAA1517","MGC4322","MGC2695","Dhr1","DDX37"]}},{"id":"2e483c4597084d01bb9d09ca67d6d5b1","type":"GENE","name":"DHX38","canonical_id":"hgnc:HGNC:17211","description":"DEAH-box helicase 38","metadata":{"aliases":["Prp16","KIAA0224","hPrp16","PRPF16","DDX38"]}},{"id":"b8f4e23cb2af44eda0cefd6b89d5bbfc","type":"GENE","name":"DHX40","canonical_id":"hgnc:HGNC:18018","description":"DEAH-box helicase 40","metadata":{"aliases":["ARG147","PAD","FLJ22060","DDX40"]}},{"id":"fe197612ae7449dd9f539a3ce6842649","type":"GENE","name":"DHX40P1","canonical_id":"hgnc:HGNC:20687","description":"DEAH-box helicase 40 pseudogene 1","metadata":{"aliases":["DHX40P"]}},{"id":"51449648d85147f9a83f261bcb1024ff","type":"GENE","name":"DHX57","canonical_id":"hgnc:HGNC:20086","description":"DExH-box helicase 57","metadata":{"aliases":["DDX57"]}},{"id":"8d88bff97fae40a88803733656430b87","type":"GENE","name":"DHX58","canonical_id":"hgnc:HGNC:29517","description":"DExH-box helicase 58","metadata":{"aliases":["LGP2","D11LGP2"]}},{"id":"9cdc66d125fb48478b39a0f14686a15f","type":"GENE","name":"DHX8","canonical_id":"hgnc:HGNC:2749","description":"DEAH-box helicase 8","metadata":{"aliases":["HRH1","Prp22","PRPF22","Dhr2","DDX8"]}},{"id":"6539c65ec08c453c8f22c82c739693d4","type":"GENE","name":"DHX9","canonical_id":"hgnc:HGNC:2750","description":null,"metadata":null},{"id":"76acb8cbd854459da9562248eacfeb2f","type":"GENE","name":"DHX9-AS1","canonical_id":"hgnc:HGNC:56097","description":"DHX9 antisense RNA 1","metadata":null},{"id":"1e058033cc234154bdd9c48e5cd0bb83","type":"GENE","name":"DHX9P1","canonical_id":"hgnc:HGNC:2751","description":"DEAH-box helicase 9 pseudogene 1","metadata":{"aliases":["DDX9P","DHX9P"]}},{"id":"0de90ad2bb61468fac863a955f5b21d0","type":"GENE","name":"DIABLO","canonical_id":"hgnc:HGNC:21528","description":"diablo IAP-binding mitochondrial protein","metadata":{"aliases":["SMAC","DIABLO-S","FLJ25049","FLJ10537","DFNA64"]}},{"id":"0daaf4fbbee44fd4b79f4be668d89223","type":"TRIAL","name":"DIALYSIS-TIR Study","canonical_id":"clinicaltrials.gov:NCT06042153","description":"Type 2 Diabetes; End Stage Renal Disease on Dialysis","metadata":null},{"id":"0950521d51bd4e8ba2208816c0770208","type":"TRIAL","name":"DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury","canonical_id":"clinicaltrials.gov:NCT02110303","description":"Coronary Artery Disease","metadata":null},{"id":"6edc6e6557d64193936dd502254f4fdf","type":"GENE","name":"DIAPH1","canonical_id":"hgnc:HGNC:2876","description":"diaphanous related formin 1","metadata":{"aliases":["hDIA1","LFHL1","mDia1","DFNA1"]}},{"id":"796026213ce44cd290eb6f7072b5d8f9","type":"GENE","name":"DIAPH1-AS1","canonical_id":"hgnc:HGNC:40177","description":"DIAPH1 antisense RNA 1","metadata":null},{"id":"18f4243dca0e47c5a980f7cbba9ec6ba","type":"GENE","name":"DIAPH1-AS2","canonical_id":"hgnc:HGNC:59173","description":"DIAPH1 antisense RNA 2","metadata":null},{"id":"aa5a23459fc14cc3813de755b16cd211","type":"GENE","name":"DIAPH2","canonical_id":"hgnc:HGNC:2877","description":"diaphanous related formin 2","metadata":{"aliases":["POF","DIA","POF2","DIA2"]}},{"id":"3ea11734ee1446e9be00df91b8af29fa","type":"GENE","name":"DIAPH2-AS1","canonical_id":"hgnc:HGNC:16972","description":"DIAPH2 antisense RNA 1","metadata":null},{"id":"655834140a06442a8dfd5d8002e06b17","type":"GENE","name":"DIAPH3","canonical_id":"hgnc:HGNC:15480","description":"diaphanous related formin 3","metadata":{"aliases":["DRF3","FLJ34705","AN","NSDAN","AUNA1"]}},{"id":"6659b352a4034beca1cfe3829ce5a393","type":"GENE","name":"DIAPH3-AS1","canonical_id":"hgnc:HGNC:39915","description":"DIAPH3 antisense RNA 1","metadata":null},{"id":"7bc03915996841b0ae80fd4cb8def94b","type":"GENE","name":"DIAPH3-AS2","canonical_id":"hgnc:HGNC:39916","description":"DIAPH3 antisense RNA 2","metadata":null},{"id":"cad6156635cb417f8ab9427725d3f54b","type":"GO_TERM","name":"DIBOA-glucoside oxygenase activity","canonical_id":"go:GO:0102717","description":"\"Catalysis of the reaction: DIBOA beta-D-glucoside + 2-oxoglutarate + O2 = TRIBOA beta-D-glucoside + succinate + CO2.\" [RHEA:32115]","metadata":null},{"id":"b4b6d579702c448dad91e030fb96ace7","type":"GENE","name":"DICER1","canonical_id":"hgnc:HGNC:17098","description":null,"metadata":null},{"id":"798599f6e62a4d8ba70e3e41a96ac758","type":"GENE","name":"DICER1-AS1","canonical_id":"hgnc:HGNC:43017","description":"DICER1 antisense RNA 1","metadata":{"aliases":["FLJ45244","DICER1-AS"]}},{"id":"2baea07cf2c846528c09eb7ced218818","type":"GENE","name":"DIDO1","canonical_id":"hgnc:HGNC:2680","description":"death inducer-obliterator 1","metadata":{"aliases":["DIO1","dJ885L7.8","FLJ11265","KIAA0333","DIO-1","BYE1","C20orf158","DATF1"]}},{"id":"18c59672f6124c91a5c1e63a0ddf4057","type":"GO_TERM","name":"DIF dechlorinase activity","canonical_id":"go:GO:0099085","description":"\"Catalysis of the reaction: 1-[(3,5-dichloro-2,6-dihydroxy-4-methoxy)phenyl]hexan-1-one = 1-[(3-chloro-2,6-dihydroxy-4-methoxy)phenyl]hexan-1-one + Cl-.\" [PMID:1521542, PMID:22035794]","metadata":null},{"id":"c7b55a579fe242829fd004059c0fcc69","type":"GO_TERM","name":"DIF-1 biosynthetic process","canonical_id":"go:GO:0031148","description":"\"The chemical reactions and pathways resulting in the formation of 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one, also known as DIF-1, differentiation-inducing factor-1. DIF-1 is a secreted chlorinated molecule that controls cell fate during development of Dictyostelium cells.\" [GOC:mah, PMID:10706822]","metadata":null},{"id":"d1642eb02ff240eea930a593934a81b5","type":"GO_TERM","name":"DIM/DIP cell wall layer","canonical_id":"go:GO:0097735","description":"\"A section of the Actinobacterium-type cell wall composed of (phenyl)phthiocerol, phthiodiolone, phthiotriol dimycocerosate, diphthioceranate and other compounds.\" [GOC:pr]","metadata":null},{"id":"607dd7addb854a62aa5b7e03039a863d","type":"GO_TERM","name":"DIM/DIP cell wall layer assembly","canonical_id":"go:GO:0071770","description":"\"The aggregation, arrangement and bonding together of a set of components, including (phenyl)phthiocerol, phthiodiolone, phthiotriol dimycocerosate and diphthioceranate, to form the DIM/DIP layer of the Actinobacterium-type cell wall.\" [GOC:mah, GOC:pr, PMID:15653820, PMID:3149973]","metadata":null},{"id":"81d949db095f45568f75d26187e3d9f0","type":"GO_TERM","name":"DIMBOA glucoside beta-D-glucosidase activity","canonical_id":"go:GO:0102726","description":"\"Catalysis of the reaction: (2R)-DIMBOA glucoside + H2O = H+ + DIMBOA + beta-D-glucose.\" [EC:3.2.1.182, GOC:pz]","metadata":null},{"id":"c297a1b53fa34871b1b710d44cec02fe","type":"GENE","name":"DIMT1","canonical_id":"hgnc:HGNC:30217","description":"DIM1 rRNA methyltransferase and ribosome maturation factor","metadata":{"aliases":["HSA9761","DIMT1L"]}},{"id":"fd76e6417f79486c97affc66646e11a4","type":"GENE","name":"DIMT1P1","canonical_id":"hgnc:HGNC:52892","description":"DIM1 dimethyladenosine transferase 1 homolog pseudogene 1","metadata":null},{"id":"897bcd213b3445578ae1dd84a2354027","type":"GENE","name":"DINOL","canonical_id":"hgnc:HGNC:53146","description":"damage induced long noncoding RNA","metadata":{"aliases":["DINO"]}},{"id":"f61e35efb188475282387839995e400f","type":"GENE","name":"DIO1","canonical_id":"hgnc:HGNC:2883","description":"iodothyronine deiodinase 1","metadata":{"aliases":["TXDI1"]}},{"id":"5f612d1035294264834cd17b44a7a8c7","type":"PROTEIN","name":"DIO1","canonical_id":"uniprot:P49895","description":null,"metadata":null},{"id":"84ac9873906d4b37a02fe27f240b272e","type":"GENE","name":"DIO2","canonical_id":"hgnc:HGNC:2884","description":"iodothyronine deiodinase 2","metadata":{"aliases":["TXDI2","SelY","SELENOY"]}},{"id":"dfcc09d312714ac4a4c0c21316c3060e","type":"GENE","name":"DIO2-AS1","canonical_id":"hgnc:HGNC:44153","description":"DIO2 antisense RNA 1","metadata":null},{"id":"f02089e183b4404199a69c13b98fa0a0","type":"GENE","name":"DIO3","canonical_id":"hgnc:HGNC:2885","description":"iodothyronine deiodinase 3","metadata":{"aliases":["TXDI3"]}},{"id":"748e7af6518843eab61922017c45a057","type":"GENE","name":"DIO3OS","canonical_id":"hgnc:HGNC:20348","description":"DIO3 opposite strand upstream RNA","metadata":{"aliases":["NCRNA00041","DIO3-AS1","C14orf134"]}},{"id":"df68668912f14aa4befc7743f70be8ff","type":"GENE","name":"DIP2A","canonical_id":"hgnc:HGNC:17217","description":"DIP2 acetate--CoA ligase A","metadata":{"aliases":["Dip2","KIAA0184","C21orf106"]}},{"id":"85b1d05a3441493eb42ec787571ef5b6","type":"GENE","name":"DIP2A-DT","canonical_id":"hgnc:HGNC:58959","description":"DIP2A divergent transcript","metadata":null},{"id":"862add51da2c4deab4bf642756f2847f","type":"GENE","name":"DIP2A-IT1","canonical_id":"hgnc:HGNC:41430","description":"DIP2A intronic transcript 1","metadata":null},{"id":"81a206c2fe62474da244c21ca5247855","type":"GENE","name":"DIP2B","canonical_id":"hgnc:HGNC:29284","description":"DIP2 acetate--CoA ligase B (putative)","metadata":{"aliases":["KIAA1463","FLJ34278"]}},{"id":"340793696dce4611821beb0b4f3b3941","type":"GENE","name":"DIP2C","canonical_id":"hgnc:HGNC:29150","description":"DIP2 acetate--CoA ligase C (putative)","metadata":{"aliases":["KIAA0934"]}},{"id":"5ecd6b9a7bad41dd9ba67113d33fb0e7","type":"GENE","name":"DIP2C-AS1","canonical_id":"hgnc:HGNC:30724","description":"DIP2C antisense RNA 1","metadata":{"aliases":["FLJ38681","C10orf108","PRR26"]}},{"id":"35b869fd687e4abc90ed72b23b16215e","type":"GENE","name":"DIP2C-AS2","canonical_id":"hgnc:HGNC:58219","description":"DIP2C antisense RNA 2","metadata":null},{"id":"a9abd2073a844fa6bdd852d2bc4c4f84","type":"GENE","name":"DIP2C-AS3","canonical_id":"hgnc:HGNC:58383","description":"DIP2C antisense RNA 3","metadata":null},{"id":"1339bddf5c0c43a79a06c57fad39d0dc","type":"GENE","name":"DIPK1A","canonical_id":"hgnc:HGNC:32213","description":"divergent protein kinase domain 1A","metadata":{"aliases":["FLJ23493","FAM69A"]}},{"id":"7898f663ada7444b97f1caf36158421e","type":"GENE","name":"DIPK1B","canonical_id":"hgnc:HGNC:28290","description":"divergent protein kinase domain 1B","metadata":{"aliases":["MGC20262","C9orf136","FAM69B"]}},{"id":"c361087dbf2f494fb78064d64ad10e9c","type":"GENE","name":"DIPK1C","canonical_id":"hgnc:HGNC:31729","description":"divergent protein kinase domain 1C","metadata":{"aliases":["C18orf51","FAM69C"]}},{"id":"00db451060cf487cbbf7a59ae01f95f9","type":"GENE","name":"DIPK2A","canonical_id":"hgnc:HGNC:28490","description":"divergent protein kinase domain 2A","metadata":{"aliases":["MGC33365","DIA1","HASF","C3orf58"]}},{"id":"41b62cc0466b4f939c5e1e437bdbc10d","type":"GENE","name":"DIPK2B","canonical_id":"hgnc:HGNC:25866","description":"divergent protein kinase domain 2B","metadata":{"aliases":["FLJ14103","DIA1R","CXorf36"]}},{"id":"db181d4d759b467f9565a6b2518c7791","type":"GENE","name":"DIRAS1","canonical_id":"hgnc:HGNC:19127","description":"DIRAS family GTPase 1","metadata":{"aliases":["Di-Ras1","GBTS1","RIG"]}},{"id":"e23f80a961d94ac687919682b32b6bc1","type":"GENE","name":"DIRAS2","canonical_id":"hgnc:HGNC:19323","description":"DIRAS family GTPase 2","metadata":{"aliases":["Di-Ras2","DKFZp761C07121"]}},{"id":"46e0edae35204f8395392041c6d7823a","type":"GENE","name":"DIRAS3","canonical_id":"hgnc:HGNC:687","description":null,"metadata":null},{"id":"8c02bc92150d41548ac3dc8a25cf09f9","type":"GENE","name":"DIRC1","canonical_id":"hgnc:HGNC:15760","description":"disrupted in renal carcinoma 1","metadata":null},{"id":"93b4a95adaf447f59a1ff6fcc0726132","type":"GENE","name":"DIRC3","canonical_id":"hgnc:HGNC:17805","description":"disrupted in renal carcinoma 3","metadata":{"aliases":["FLJ14199"]}},{"id":"a3b38c107e2947bf98d77422d4e40cf3","type":"GENE","name":"DIS3","canonical_id":"hgnc:HGNC:20604","description":"DIS3 exosome endoribonuclease and 3'-5' exoribonuclease","metadata":{"aliases":["dis3p","RRP44","EXOSC11","KIAA1008"]}},{"id":"0b0b71039c764426bd34c861e85b318a","type":"GENE","name":"DIS3L","canonical_id":"hgnc:HGNC:28698","description":"DIS3 like exosome 3'-5' exoribonuclease","metadata":{"aliases":["MGC4562","FLJ38088","KIAA1955","DIS3L1"]}},{"id":"d1d089c4dcbc49d3b886b6369de1a9b2","type":"GENE","name":"DIS3L-AS1","canonical_id":"hgnc:HGNC:55369","description":"DIS3L antisense RNA 1","metadata":null},{"id":"c265d4f982bc4b32b209b43f937a12af","type":"GENE","name":"DIS3L2","canonical_id":"hgnc:HGNC:28648","description":"DIS3 like 3'-5' exoribonuclease 2","metadata":{"aliases":["FLJ36974","MGC42174","FAM6A"]}},{"id":"5ab4b749d534491f833900092896faa0","type":"GENE","name":"DIS3L2P1","canonical_id":"hgnc:HGNC:14021","description":"DIS3 like 3'-5' exoribonuclease 2 pseudogene 1","metadata":{"aliases":["FAM6B","DIS3L2P"]}},{"id":"771b83ee6c224520b856f9457b9909d9","type":"GENE","name":"DISC1","canonical_id":"hgnc:HGNC:2888","description":null,"metadata":null},{"id":"93ec0766745d402cbc86bb3e6ca16cc9","type":"GENE","name":"DISC1-IT1","canonical_id":"hgnc:HGNC:41325","description":"DISC1 intronic transcript 1","metadata":null},{"id":"e6911c36e5ea42e197386e7919ecc870","type":"GENE","name":"DISC1FP1","canonical_id":"hgnc:HGNC:33625","description":"DISC1 fusion partner 1","metadata":{"aliases":["Boymaw"]}},{"id":"4885a010a8f04ff787bf9f523cea3cfa","type":"GENE","name":"DISC2","canonical_id":"hgnc:HGNC:2889","description":"disrupted in schizophrenia 2","metadata":{"aliases":["DISC1-AS1","DISC1OS","NCRNA00015"]}},{"id":"6fc477bb3feb4485a9068b456b60e0c3","type":"TRIAL","name":"DISE in Pediatric Sleep Disordered Breathing","canonical_id":"clinicaltrials.gov:NCT06756971","description":"Sleep Disordered Breathing; Drug Induced Sleep Disorder","metadata":null},{"id":"827ef7fb7d834838a063129aab97b2bd","type":"GENE","name":"DISP1","canonical_id":"hgnc:HGNC:19711","description":"dispatched RND transporter family member 1","metadata":{"aliases":["DISPA","MGC13130","DKFZP434I0428","MGC16796"]}},{"id":"2f1068d0ed0346e39ecd7b1febbbf19c","type":"GENE","name":"DISP2","canonical_id":"hgnc:HGNC:19712","description":"dispatched RND transporter family member 2","metadata":{"aliases":["DISPB","KIAA1742","HsT16908","LINC00594","C15orf36"]}},{"id":"913928b9afe54b57aa4574dd3a44894a","type":"GENE","name":"DISP3","canonical_id":"hgnc:HGNC:29251","description":"dispatched RND transporter family member 3","metadata":{"aliases":["KIAA1337","PTCHD2"]}},{"id":"7d3b504d6eea47b5a1449d1a24de0be4","type":"GENE","name":"DIXDC1","canonical_id":"hgnc:HGNC:23695","description":"DIX domain containing 1","metadata":{"aliases":["KIAA1735","Dixin"]}},{"id":"fa95fc083819493aa093600a34eafb2c","type":"TRIAL","name":"DIabetic Retinopathy Candesartan Trials.","canonical_id":"clinicaltrials.gov:NCT00252720","description":"Type 1 Diabetes","metadata":null},{"id":"32c16352a2f2431ab4c4eb2dfb1f9bd5","type":"TRIAL","name":"DIalysis Symptom COntrol-Restless Legs Syndrome Trial","canonical_id":"clinicaltrials.gov:NCT03806530","description":"End Stage Renal Disease; Restless Legs Syndrome","metadata":null},{"id":"c548c98293084339aa50217ebe8c5e68","type":"GENE","name":"DKC1","canonical_id":"hgnc:HGNC:2890","description":"dyskerin pseudouridine synthase 1","metadata":{"aliases":["XAP101","dyskerin","NAP57","NOLA4","Cbf5","DKC"]}},{"id":"a343bb72abe44ae28bd239c1a91dfeae","type":"GENE","name":"DKK1","canonical_id":"hgnc:HGNC:2891","description":null,"metadata":null},{"id":"bc8ecc73adaa4be4840b53bbad988ea6","type":"GENE","name":"DKK2","canonical_id":"hgnc:HGNC:2892","description":"dickkopf Wnt signaling pathway inhibitor 2","metadata":null},{"id":"6cbe9c507dea41858379ba9a2740e2da","type":"GENE","name":"DKK2-AS1","canonical_id":"hgnc:HGNC:58864","description":"DKK2 antisense RNA 1","metadata":null},{"id":"301891b58f2f44abb15041daf67ce37f","type":"GENE","name":"DKK2-AS2","canonical_id":"hgnc:HGNC:58865","description":"DKK2 antisense RNA 2","metadata":null},{"id":"ead3a551cebd4d8eaa03531678df20a0","type":"GENE","name":"DKK3","canonical_id":"hgnc:HGNC:2893","description":null,"metadata":null},{"id":"e892dee26cbb42ab8370f2426867a2a1","type":"GENE","name":"DKK4","canonical_id":"hgnc:HGNC:2894","description":null,"metadata":null},{"id":"31547962bbd54d369df86139a4efe44b","type":"GENE","name":"DKKL1","canonical_id":"hgnc:HGNC:16528","description":"dickkopf like acrosomal protein 1","metadata":{"aliases":["SGY-1","CT34"]}},{"id":"ab1de8f5646e42628aefb26a4adc940b","type":"GENE","name":"DKKL1P1","canonical_id":"hgnc:HGNC:16593","description":"DKKL1 pseudogene 1","metadata":{"aliases":["dJ854E16.1","DKKL2"]}},{"id":"71785f36a8e14e7fb814c0644f123e27","type":"TRIAL","name":"DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil","canonical_id":"clinicaltrials.gov:NCT02711683","description":"Alzheimer's Disease","metadata":null},{"id":"ece8d1b58fd44af7b614683d4365cebd","type":"GENE","name":"DLAT","canonical_id":"hgnc:HGNC:2896","description":"dihydrolipoamide S-acetyltransferase","metadata":{"aliases":["PDC-E2","E2","DLTA"]}},{"id":"7cd5b18265b44a8eac86cd82c96bfc29","type":"TRIAL","name":"DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis","canonical_id":"clinicaltrials.gov:NCT01942122","description":"Endometrioma; Visual Analogue Pain Scale: Moderate or Severe Pain","metadata":null},{"id":"668d08ad753a4eef8e3fc66b1c6a0648","type":"GENE","name":"DLC1","canonical_id":"hgnc:HGNC:2897","description":"DLC1 Rho GTPase activating protein","metadata":{"aliases":["HP","ARHGAP7","STARD12","DLC-1","p122-RhoGAP"]}},{"id":"7bb2b070c4f14e458dc3cb7a2bcd893a","type":"GENE","name":"DLD","canonical_id":"hgnc:HGNC:2898","description":"dihydrolipoamide dehydrogenase","metadata":{"aliases":["DLDH","E3","OGDC-E3","LAD","GCSL"]}},{"id":"ddaaadcd8aa64b428b10f7c0ec6e8633","type":"GENE","name":"DLEC1","canonical_id":"hgnc:HGNC:2899","description":"DLEC1 cilia and flagella associated protein","metadata":{"aliases":["DLC1","CFAP81","FAP81"]}},{"id":"f1f4030b10d44e0a88c67ef9fb36e6ed","type":"GENE","name":"DLEC1P1","canonical_id":"hgnc:HGNC:44545","description":"DLEC1 pseudogene 1","metadata":null},{"id":"6e17784a0e2f4f43b122dd4b1af5b512","type":"GENE","name":"DLEU1","canonical_id":"hgnc:HGNC:13747","description":"deleted in lymphocytic leukemia 1","metadata":{"aliases":["LEU1","XTP6","NCRNA00021","LINC00021","BCMS1","DLB1","BCMS"]}},{"id":"ba8cdabe2795496a87d006b83a029153","type":"GENE","name":"DLEU1-AS1","canonical_id":"hgnc:HGNC:50496","description":"DLEU1 antisense RNA 1","metadata":{"aliases":["LINC01308"]}},{"id":"ef2e40f20ff9487287c91b1cef534a80","type":"GENE","name":"DLEU2","canonical_id":"hgnc:HGNC:13748","description":"deleted in lymphocytic leukemia 2","metadata":{"aliases":["LEU2","TRIM13OS","NCRNA00022","LINC00022","MIR15AHG","DLB2","BCMSUN","RFP2OS"]}},{"id":"0f89b9e39e9a46f5a1238e8b5bc7ebbc","type":"GENE","name":"DLEU2L","canonical_id":"hgnc:HGNC:13225","description":"deleted in lymphocytic leukemia 2 like","metadata":{"aliases":["BCMSUNL"]}},{"id":"8ad2facd4b6349db9c75494499a291fa","type":"GENE","name":"DLEU7","canonical_id":"hgnc:HGNC:17567","description":"deleted in lymphocytic leukemia 7","metadata":{"aliases":["FLJ44882"]}},{"id":"6f5e0568c76e40ebaf98347bc55418b0","type":"GENE","name":"DLEU7-AS1","canonical_id":"hgnc:HGNC:39966","description":"DLEU7 antisense RNA 1","metadata":null},{"id":"036408dcb6a348508f46ee4da058df15","type":"GENE","name":"DLG1","canonical_id":"hgnc:HGNC:2900","description":null,"metadata":null},{"id":"7fb85b30442e4e4784dfeb81a804babe","type":"GENE","name":"DLG1-AS1","canonical_id":"hgnc:HGNC:44154","description":"DLG1 antisense RNA 1","metadata":null},{"id":"3c6b57b5cbdf4778a7796e10e9d18284","type":"GENE","name":"DLG2","canonical_id":"hgnc:HGNC:2901","description":"discs large MAGUK scaffold protein 2","metadata":{"aliases":["PSD-93","PSD93","chapsyn-110","PPP1R58"]}},{"id":"fa75e47d82f847bea89a687773edb8f6","type":"GENE","name":"DLG2-AS1","canonical_id":"hgnc:HGNC:37132","description":"DLG2 antisense RNA 1","metadata":{"aliases":["PSZA11q14","SZ-1","DLG2AS","DLG2-AS"]}},{"id":"6648f813afa04942a702118b25243315","type":"GENE","name":"DLG2-AS2","canonical_id":"hgnc:HGNC:40179","description":"DLG2 antisense RNA 2","metadata":null},{"id":"b650900881944f1dbe045bc730bbd24f","type":"GENE","name":"DLG3","canonical_id":"hgnc:HGNC:2902","description":"discs large MAGUK scaffold protein 3","metadata":{"aliases":["NE-Dlg","SAP102","SAP-102","NEDLG","KIAA1232","MRX90","PPP1R82"]}},{"id":"34c2dc364d6d4b68bab9d6acfcc4dd35","type":"GENE","name":"DLG3-AS1","canonical_id":"hgnc:HGNC:40182","description":"DLG3 antisense RNA 1","metadata":null},{"id":"53c989ac7c54492b8dcd075cebaf00ef","type":"GENE","name":"DLG4","canonical_id":"hgnc:HGNC:2903","description":null,"metadata":null},{"id":"5f352acdec2d4cd9969f1729abf5c690","type":"GENE","name":"DLG5","canonical_id":"hgnc:HGNC:2904","description":"discs large MAGUK scaffold protein 5","metadata":{"aliases":["P-dlg","KIAA0583"]}},{"id":"7f9d452ef6cf44dd9e6c83a7467e2ff8","type":"GENE","name":"DLG5-AS1","canonical_id":"hgnc:HGNC:45109","description":"DLG5 antisense RNA 1","metadata":null},{"id":"10a1598c690a4bccb15ce8e17bc89f2c","type":"GENE","name":"DLGAP1","canonical_id":"hgnc:HGNC:2905","description":"DLG associated protein 1","metadata":{"aliases":["GKAP","SAPAP1","DAP-1"]}},{"id":"49cbd63fea0f41929d6c1c555b22b57f","type":"GENE","name":"DLGAP1-AS1","canonical_id":"hgnc:HGNC:31676","description":"DLGAP1 antisense RNA 1","metadata":{"aliases":["HsT914","FLJ35776"]}},{"id":"46c5f646010243abb83cfa483b879805","type":"GENE","name":"DLGAP1-AS2","canonical_id":"hgnc:HGNC:28146","description":"DLGAP1 antisense RNA 2","metadata":{"aliases":["MGC11082"]}},{"id":"612a3d5d091b4d2d8862e0bb6bda549f","type":"GENE","name":"DLGAP1-AS3","canonical_id":"hgnc:HGNC:27317","description":"DLGAP1 antisense RNA 3","metadata":null},{"id":"79238ba46aeb4c45bfd83f5a35589144","type":"GENE","name":"DLGAP1-AS4","canonical_id":"hgnc:HGNC:44333","description":"DLGAP1 antisense RNA 4","metadata":null},{"id":"ec72e871867c4352a0315f9fa5d1b525","type":"GENE","name":"DLGAP1-AS5","canonical_id":"hgnc:HGNC:27586","description":"DLGAP1 antisense RNA 5","metadata":null},{"id":"4f410a3c29fd4d7eb9ec1b224b7625f6","type":"GENE","name":"DLGAP1-AS6","canonical_id":"hgnc:HGNC:58109","description":"DLGAP1 antisense RNA 6","metadata":{"aliases":["RP11-874J12.4"]}},{"id":"4f1b7f339be149e3ac6d0c50f364922b","type":"GENE","name":"DLGAP2","canonical_id":"hgnc:HGNC:2906","description":"DLG associated protein 2","metadata":{"aliases":["DAP-2","ERICH1-AS1","C8orf68"]}},{"id":"05916bd3e6c0450e886bb7d077cbfa28","type":"GENE","name":"DLGAP2-AS1","canonical_id":"hgnc:HGNC:50467","description":"DLGAP2 antisense RNA 1","metadata":null},{"id":"1397c87b9cd94ae78bd67d343192a32d","type":"GENE","name":"DLGAP3","canonical_id":"hgnc:HGNC:30368","description":"DLG associated protein 3","metadata":{"aliases":["SAPAP3","DAP3"]}},{"id":"350be307ef6d409ba9a62528de262aac","type":"GENE","name":"DLGAP4","canonical_id":"hgnc:HGNC:24476","description":"DLG associated protein 4","metadata":{"aliases":["DAP4","KIAA0964","SAPAP4"]}},{"id":"e8d9049cdd5e4383b11401d9a28782e8","type":"GENE","name":"DLGAP4-AS1","canonical_id":"hgnc:HGNC:51223","description":"DLGAP4 antisense RNA 1","metadata":{"aliases":["CCAT7"]}},{"id":"8412ba7c35154214816d92696e91ba7b","type":"GENE","name":"DLGAP5","canonical_id":"hgnc:HGNC:16864","description":"DLG associated protein 5","metadata":{"aliases":["KIAA0008","DLG1","HURP","DLG7"]}},{"id":"6c172d66bb974ac79aa478b579e1bd39","type":"GENE","name":"DLGAP5P1","canonical_id":"hgnc:HGNC:23945","description":"DLGAP5 pseudogene 1","metadata":null},{"id":"a69105fffa4d4615be6cf954e7e72b0d","type":"GENE","name":"DLGAP5P2","canonical_id":"hgnc:HGNC:55016","description":"DLGAP5 pseudogene 2","metadata":null},{"id":"7d262b6c4d0044e398d95993b9d68a21","type":"GENE","name":"DLK1","canonical_id":"hgnc:HGNC:2907","description":null,"metadata":null},{"id":"c03bd873f69945d7b1bffe1230ed79e0","type":"GENE","name":"DLK2","canonical_id":"hgnc:HGNC:21113","description":"delta like non-canonical Notch ligand 2","metadata":{"aliases":["MGC2487","EGFL9"]}},{"id":"0e4417cbe5cb4b659b15f13202a2baad","type":"GENE","name":"DLL1","canonical_id":"hgnc:HGNC:2908","description":"delta like canonical Notch ligand 1","metadata":null},{"id":"c9677800a5034bfc8ee0ee3589cb3297","type":"GENE","name":"DLL3","canonical_id":"hgnc:HGNC:2909","description":"delta like canonical Notch ligand 3","metadata":{"aliases":["SCDO1"]}},{"id":"0403054fa7914f49a4c51db79ea612ac","type":"GENE","name":"DLL4","canonical_id":"hgnc:HGNC:2910","description":null,"metadata":null},{"id":"b3d7e711600b4b1997b4c7a7bff27060","type":"GENE","name":"DLST","canonical_id":"hgnc:HGNC:2911","description":"dihydrolipoamide S-succinyltransferase","metadata":{"aliases":["OGDC-E2","KGD2","DLTS"]}},{"id":"e9275c31392d4b5580dee4250eca4055","type":"GENE","name":"DLSTP1","canonical_id":"hgnc:HGNC:2912","description":"dihydrolipoamide S-succinyltransferase pseudogene 1","metadata":{"aliases":["DLSTP"]}},{"id":"3e7e550d8a724daf9fca3d75213bed30","type":"GENE","name":"DLX1","canonical_id":"hgnc:HGNC:2914","description":"distal-less homeobox 1","metadata":null},{"id":"8a1feb0dfe5f4b5da232267d2bb98098","type":"GENE","name":"DLX1-AS1","canonical_id":"hgnc:HGNC:58943","description":"DLX1 antisense RNA 1","metadata":{"aliases":["uc.99","uc.98"]}},{"id":"370ce4b8e9ed4698b4f9f3425c09674a","type":"GENE","name":"DLX2","canonical_id":"hgnc:HGNC:2915","description":"distal-less homeobox 2","metadata":{"aliases":["TES-1"]}},{"id":"83e50250686d492281e95dc645a7cd91","type":"GENE","name":"DLX2-DT","canonical_id":"hgnc:HGNC:50638","description":"DLX2 divergent transcript","metadata":{"aliases":["TCONS_00003049","DLX2-AS1"]}},{"id":"915e1341840f47078aa64ae86bf086ca","type":"GENE","name":"DLX3","canonical_id":"hgnc:HGNC:2916","description":null,"metadata":null},{"id":"2b736bae25f44c52839202d4521d7cb2","type":"GENE","name":"DLX4","canonical_id":"hgnc:HGNC:2917","description":null,"metadata":null},{"id":"29a684370ac84bd999fbe540100d0472","type":"GENE","name":"DLX5","canonical_id":"hgnc:HGNC:2918","description":null,"metadata":null},{"id":"ff03e66045c546008ef41570bfffc167","type":"GENE","name":"DLX6","canonical_id":"hgnc:HGNC:2919","description":"distal-less homeobox 6","metadata":null},{"id":"6e1335a00c2e47548a69a9f357f963a8","type":"GENE","name":"DLX6-AS1","canonical_id":"hgnc:HGNC:37151","description":"DLX6 antisense RNA 1","metadata":{"aliases":["uc.221","uc.220","FLJ34048","Evf-2","NCRNA00212"]}},{"id":"476c49d695f04f1cb0944f84d213dd87","type":"GENE","name":"DM1-AS","canonical_id":"hgnc:HGNC:53125","description":"DM1 locus antisense RNA","metadata":null},{"id":"062448409978493da948240dd261aabc","type":"GENE","name":"DMAC1","canonical_id":"hgnc:HGNC:30536","description":"distal membrane arm assembly component 1","metadata":{"aliases":["MGC4730","C9orf123","TMEM261"]}},{"id":"5c93442daeac403796f103947bba4766","type":"GENE","name":"DMAC1P1","canonical_id":"hgnc:HGNC:49128","description":"DMAC1 pseudogene 1","metadata":{"aliases":["TMEM261P1"]}},{"id":"a9c2e14e046042d5bbcb19afa16de756","type":"GENE","name":"DMAC2","canonical_id":"hgnc:HGNC:25496","description":"distal membrane arm assembly component 2","metadata":{"aliases":["FLJ10241","ATP5SL"]}},{"id":"6200395c56bf4fddbd193ecb59ff92e5","type":"GENE","name":"DMAC2L","canonical_id":"hgnc:HGNC:18799","description":"distal membrane arm assembly component 2 like","metadata":{"aliases":["HSU79253","ATPW","ATP5S"]}},{"id":"b9da847476c44a299718a42c21535993","type":"GENE","name":"DMAP1","canonical_id":"hgnc:HGNC:18291","description":null,"metadata":null},{"id":"8e78c9f8092d40fb8bc81574db3ca3e5","type":"GENE","name":"DMBT1","canonical_id":"hgnc:HGNC:2926","description":"deleted in malignant brain tumors 1","metadata":{"aliases":["GP340","SALSA","Gp-340"]}},{"id":"24194d8843b2498cb2639e2700759816","type":"GENE","name":"DMBT1L1","canonical_id":"hgnc:HGNC:49497","description":"deleted in malignant brain tumors 1 like 1 (pseudogene)","metadata":{"aliases":["DMBT1L1P","DMBT1P1"]}},{"id":"4322d753ca744c0598d915ba1e636df8","type":"GENE","name":"DMBX1","canonical_id":"hgnc:HGNC:19026","description":"diencephalon/mesencephalon homeobox 1","metadata":{"aliases":["PAXB","MBX","Atx","OTX3"]}},{"id":"20e3627446c24cf3bc4521029e411728","type":"GENE","name":"DMC1","canonical_id":"hgnc:HGNC:2927","description":null,"metadata":null},{"id":"0974b74ffc6147719720732a4db88a0b","type":"GENE","name":"DMD","canonical_id":"hgnc:HGNC:2928","description":null,"metadata":null},{"id":"5c1a458139a04be2b4a70324b55f9ae8","type":"GENE","name":"DMD-AS3","canonical_id":"hgnc:HGNC:40185","description":"DMD antisense RNA 3","metadata":null},{"id":"b8912a1b06c24ebb97be15e6165a7d7b","type":"GENE","name":"DMGDH","canonical_id":"hgnc:HGNC:24475","description":"dimethylglycine dehydrogenase","metadata":{"aliases":["ME2GLYDH"]}},{"id":"7571befc6b5147d4927d57d7b9d87b0a","type":"GENE","name":"DMKN","canonical_id":"hgnc:HGNC:25063","description":"dermokine","metadata":{"aliases":["ZD52F10"]}},{"id":"77e64d560e1e4dce9700aa0e279660c9","type":"GO_TERM","name":"DMNT synthase activity","canonical_id":"go:GO:0102171","description":"\"Catalysis of the reaction: (3S,6E)-nerolidol + O2 + reduced [NADPH--hemoprotein reductase] = (3E)-4,8-dimethylnona-1,3,7-triene + but-3-en-2-one + H+ + 2 H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:55424]","metadata":null},{"id":"ec5193e410ea4086af0934d58108251c","type":"GENE","name":"DMP1","canonical_id":"hgnc:HGNC:2932","description":"dentin matrix acidic phosphoprotein 1","metadata":null},{"id":"e6483b7983934c64ab4d1fe7b36cc318","type":"GENE","name":"DMP1-AS1","canonical_id":"hgnc:HGNC:58144","description":"DMP1 and DSPP antisense RNA 1","metadata":{"aliases":["AC093895.1","lnc-SPARCL1-1"]}},{"id":"dd2de1816fca4806a2a9e15a0f1ac625","type":"GENE","name":"DMPK","canonical_id":"hgnc:HGNC:2933","description":null,"metadata":null},{"id":"4d3aa190f85d4454b162c37d63defb62","type":"GENE","name":"DMRT1","canonical_id":"hgnc:HGNC:2934","description":null,"metadata":null},{"id":"c599a9bbe73c4ecbb85c269b09ba2c3f","type":"GENE","name":"DMRT2","canonical_id":"hgnc:HGNC:2935","description":"doublesex and mab-3 related transcription factor 2","metadata":null},{"id":"9540bdfa3916413da92b84e4fc924047","type":"GENE","name":"DMRT3","canonical_id":"hgnc:HGNC:13909","description":"doublesex and mab-3 related transcription factor 3","metadata":{"aliases":["DMRTA3"]}},{"id":"58faa54cc6764873aea4b8744fa0a24d","type":"GENE","name":"DMRTA1","canonical_id":"hgnc:HGNC:13826","description":"DMRT like family A1","metadata":{"aliases":["DMRT4"]}},{"id":"a4fbd5722c06417481cda8360fe70410","type":"GENE","name":"DMRTA2","canonical_id":"hgnc:HGNC:13908","description":"DMRT like family A2","metadata":{"aliases":["DMRT5"]}},{"id":"82290424c8e842e4858b5be44535f7c6","type":"GENE","name":"DMRTB1","canonical_id":"hgnc:HGNC:13913","description":"DMRT like family B with proline rich C-terminal 1","metadata":{"aliases":["DMRT6"]}},{"id":"beb49a1dc8854fe490c55c9ee7c2ea80","type":"GENE","name":"DMRTC1","canonical_id":"hgnc:HGNC:13910","description":"DMRT like family C1","metadata":{"aliases":["DMRT8"]}},{"id":"eb708727583449b9aeff7783aff24b48","type":"GENE","name":"DMRTC1B","canonical_id":"hgnc:HGNC:31686","description":"DMRT like family C1B","metadata":null},{"id":"4f1e1e3f59cc4992be9e404c1fdb65dc","type":"GENE","name":"DMRTC2","canonical_id":"hgnc:HGNC:13911","description":"DMRT like family C2","metadata":{"aliases":["DMRT7"]}},{"id":"8ef99e6ba4a54b408ab0fe4a3ee85927","type":"GENE","name":"DMTF1","canonical_id":"hgnc:HGNC:14603","description":"cyclin D binding myb like transcription factor 1","metadata":{"aliases":["DMP1","DMTF","hDMP1","MRUL"]}},{"id":"c54a0391081b4b439fd67bf653566c3a","type":"GENE","name":"DMTF1-AS1","canonical_id":"hgnc:HGNC:55864","description":"DMTF1 antisense RNA 1","metadata":null},{"id":"56cc33eb8cda4da0aa766ca7081b5312","type":"GENE","name":"DMTN","canonical_id":"hgnc:HGNC:3382","description":"dematin actin binding protein","metadata":{"aliases":["DMT","EPB49"]}},{"id":"911462a76749449185960dea04ab2008","type":"GENE","name":"DMWD","canonical_id":"hgnc:HGNC:2936","description":"DM1 locus, WD repeat containing","metadata":{"aliases":["DMR-N9","gene59","D19S593E"]}},{"id":"d7df7ee0061448d69346c5e3ae54211e","type":"GENE","name":"DMXL1","canonical_id":"hgnc:HGNC:2937","description":"Dmx like 1","metadata":null},{"id":"dcbdd89708bc41bea62c9f6ee2b0b707","type":"GENE","name":"DMXL1-DT","canonical_id":"hgnc:HGNC:55568","description":"DMXL1 divergent transcript","metadata":null},{"id":"73031ffb222b48c4852f52572443624f","type":"GENE","name":"DMXL2","canonical_id":"hgnc:HGNC:2938","description":"Dmx like 2","metadata":{"aliases":["RC3","KIAA0856","DFNA71"]}},{"id":"298e2e0e9a4747b397ef0be648d4fa29","type":"GO_TERM","name":"DN2 thymocyte differentiation","canonical_id":"go:GO:1904155","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a DN2 thymocyte. A DN2 thymocyte is a CD4-,CD8- thymocyte that is also CD44+,CD25-.\" [GO_REF:0000086, GOC:dph, GOC:TermGenie, PMID:25398325]","metadata":null},{"id":"f47ab6a21050477a984aca36de883f32","type":"GO_TERM","name":"DN3 thymocyte differentiation","canonical_id":"go:GO:1904156","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a DN3 thymocyte. A DN3 thymocyte is a CD4-,CD8- thymocyte that is also CD44+,CD25+.\" [GO_REF:0000086, GOC:dph, GOC:TermGenie, PMID:25398325]","metadata":null},{"id":"bfbbac5ff09a4ea88124d06a46240e45","type":"GO_TERM","name":"DN4 thymocyte differentiation","canonical_id":"go:GO:1904157","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a DN4 thymocyte. A DN4 thymocyte is a CD4-,CD8- thymocyte that is also CD44-,CD25-.\" [GO_REF:0000086, GOC:dph, GOC:TermGenie, PMID:25398325]","metadata":null},{"id":"299e28eab41d44a493084e62c3c077b0","type":"GO_TERM","name":"DNA (6-4) photolyase activity","canonical_id":"go:GO:0003914","description":"\"Catalysis of the reaction: pyrimidine-pyrimidone (6-4) photoproduct (in DNA) = 2 pyrimidine residues (in DNA). Catalyzes the reactivation of ultraviolet-irradiated DNA.\" [GOC:mah, PMID:11124949]","metadata":null},{"id":"8caba18289024a3b984f822051e7ae15","type":"GO_TERM","name":"DNA (cytosine-5-)-methyltransferase activity","canonical_id":"go:GO:0003886","description":"\"Catalysis of the reaction: a 2'-deoxycytidine in DNA + S-adenosyl-L-methionine = a 5-methyl-2'-deoxycytidine in DNA + H+ + S-adenosyl-L-homocysteine.\" [RHEA:13681]","metadata":null},{"id":"f0168c10c16b411aa244950a94dfe1f8","type":"GO_TERM","name":"DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates","canonical_id":"go:GO:0051718","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + CpG (in DNA) = S-adenosyl-L-homocysteine + 5-MeCpG (in DNA).\" [PMID:15689527]","metadata":null},{"id":"4aad2f8c646f4654becd63ae929e772b","type":"GO_TERM","name":"DNA (cytosine-5-)-methyltransferase activity, acting on CpN substrates","canonical_id":"go:GO:0051719","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + DNA containing CpN = S-adenosyl-L-homocysteine + DNA containing 5-MeCpN.\" [PMID:15689527]","metadata":null},{"id":"b7893149eda84de6bbe4f2016b6446ef","type":"GO_TERM","name":"DNA (cytosine-5-)-methyltransferase activity, acting on CpNpG substrates","canonical_id":"go:GO:0051720","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + DNA containing CpNpG = S-adenosyl-L-homocysteine + DNA containing 5-MeCpNpG.\" [PMID:15689527]","metadata":null},{"id":"8ac70c9ae89246c18573d91035bb6fcb","type":"GO_TERM","name":"DNA 5'-adenosine monophosphate hydrolase activity","canonical_id":"go:GO:0033699","description":"\"Catalysis of the reactions: a 5'-end adenosine-5'-diphospho-5'-2'-deoxyribonucleoside-DNA + H2O = a 5'-end 5'-phospho-2'-deoxyribonucleoside-DNA + AMP + 2 H+; and: a 5'-end adenosine-5'-diphospho-5'-ribonucleoside-2'-deoxyribonucleotide-DNA + H2O = a 5'-end 5'-phospho-ribonucleoside-2'-deoxyribonucleotide-DNA + AMP + 2 H+. Nucleophilic release of a covalently linked adenylate residue from a DNA strand, leaving a 5' phosphate terminus.\" [EC:3.6.1.71, GOC:mah, PMID:16547001, PMID:17276982]","metadata":null},{"id":"7c4b8a6f2eae4c69a0cbf242d2a87dc8","type":"GO_TERM","name":"DNA 5-methylcytosine dioxygenase activity","canonical_id":"go:GO:0070579","description":"\"Catalysis of the reaction: 5-methylcytosine (5mC) in DNA + 2-oxoglutarate + O2 = 5-hydroxymethylcytosine (5hmC) in DNA + succinate + CO2. This reaction is the first step in the removal of cytosine methylated on position 5 in double-stranded DNA. This activity can iteratively oxidize 5hmC to 5-formylcytosine (5fC) and to 5-carboxylcytosine (5caC).\" [EC:1.14.11.80, PMID:19372391, PMID:21496894, PMID:21778364]","metadata":null},{"id":"f5285408002c4bf5a1e6370d2cc4ee8e","type":"GO_TERM","name":"DNA ADP-ribosylation","canonical_id":"go:GO:0030592","description":"\"The covalent attachment of an ADP-ribosyl group to a residue in double-stranded DNA.\" [PMID:11592983, PMID:27471034, PMID:29361132, PMID:29520010]","metadata":null},{"id":"aba8b1d9a87a4bc6b69c8f231aaa7362","type":"GO_TERM","name":"DNA N-glycosylase activity","canonical_id":"go:GO:0019104","description":"\"Catalysis of the removal of damaged bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site.\" [GOC:elh, PMID:11554296]","metadata":null},{"id":"b266c66aad824ed5abe9eddc23011b1c","type":"GO_TERM","name":"DNA N6-methyladenine demethylase activity","canonical_id":"go:GO:0141131","description":"\"Catalysis of the reaction: 2-oxoglutarate + an N6-methyl-2'-deoxyadenosine in DNA + O2 = a 2'-deoxyadenosine in DNA + CO2 + formaldehyde + succinate.\" [RHEA:49524]","metadata":null},{"id":"32392ea148d7409d83d75040edfc08d1","type":"GO_TERM","name":"DNA alkylation repair","canonical_id":"go:GO:0006307","description":"\"The repair of alkylation damage in DNA, e.g. the removal of a non-physiological alkyl group from a nucleobase. This is usually mediated by DNA alkyltransferases.\" [PMID:10946226, PMID:35543797]","metadata":null},{"id":"21fc1eb13c8a4a61a656e8e6eefa8c78","type":"GO_TERM","name":"DNA alpha-glucosyltransferase activity","canonical_id":"go:GO:0033820","description":"\"Catalysis of the transfer of an alpha-D-glucosyl residue from UDP-glucose to a hydroxymethylcytosine residue in DNA.\" [EC:2.4.1.26]","metadata":null},{"id":"912854bdbcea4c89b640f2f422a01454","type":"GO_TERM","name":"DNA amplification","canonical_id":"go:GO:0006277","description":"\"The process in which the number of copies of a gene is increased in certain cells as extra copies of DNA are made in response to certain signals of cell development or of stress from the environment.\" [ISBN:0721601464]","metadata":null},{"id":"bf0a23390b71463a8b181317d8906ec0","type":"GO_TERM","name":"DNA bending complex","canonical_id":"go:GO:1990104","description":"\"A protein-DNA complex that contains DNA in combination with a protein which binds to and bends DNA. Often plays a role in DNA compaction.\" [GOC:bhm, PMID:17097674]","metadata":null},{"id":"195259afb5cf4c30932d56cc687d3a2a","type":"GO_TERM","name":"DNA beta-glucosyltransferase activity","canonical_id":"go:GO:0033821","description":"\"Catalysis of the transfer of a beta-D-glucosyl residue from UDP-glucose to a hydroxymethylcytosine residue in DNA.\" [EC:2.4.1.27]","metadata":null},{"id":"67096087925a496e843825c0db523bbf","type":"GO_TERM","name":"DNA binding","canonical_id":"go:GO:0003677","description":"\"Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid).\" [GOC:dph, GOC:jl, GOC:tb, GOC:vw]","metadata":null},{"id":"b74fdecdc59144239f35b1ab6b5a9241","type":"GO_TERM","name":"DNA binding domain binding","canonical_id":"go:GO:0050692","description":"\"Binding to a protein's DNA binding domain (DBD).\" [PMID:9682036]","metadata":null},{"id":"e5e5e070e37147fea23a69ba289ddd2d","type":"GO_TERM","name":"DNA binding, bending","canonical_id":"go:GO:0008301","description":"\"The activity of binding selectively and non-covalently to and distorting the original structure of DNA, typically a straight helix, into a bend, or increasing the bend if the original structure was intrinsically bent due to its sequence.\" [GOC:krc, GOC:vw, PMID:10710711, PMID:19037758]","metadata":null},{"id":"f6a6c09f572a44c080b644ed2d1b791d","type":"GO_TERM","name":"DNA biosynthetic process","canonical_id":"go:GO:0071897","description":"\"The biosynthetic process resulting in the formation of DNA.\" [GOC:mah]","metadata":null},{"id":"630c36c56efa4eb183ba4bbf4923b1cb","type":"GO_TERM","name":"DNA catabolic process","canonical_id":"go:GO:0006308","description":"\"The cellular DNA metabolic process resulting in the breakdown of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"2b644bfa07514748b4c2b731aefce86c","type":"GO_TERM","name":"DNA clamp loader activity","canonical_id":"go:GO:0003689","description":"\"Facilitating the opening of the ring structure of the PCNA complex, or any of the related sliding clamp complexes, and their closing around the DNA duplex, driven by ATP hydrolysis.\" [GOC:mah, GOC:vw, PMID:16082778]","metadata":null},{"id":"85abe66aa03d42e0a09b45e361fcbab5","type":"GO_TERM","name":"DNA clamp unloader activity","canonical_id":"go:GO:0061860","description":"\"Facilitating the opening of the ring structure of the PCNA complex, or any of the related sliding clamp complexes, and their removal from the DNA duplex, driven by ATP hydrolysis.\" [GOC:vw, PMID:23499004]","metadata":null},{"id":"96a1e9e837f7458a88039298bf02866a","type":"GO_TERM","name":"DNA conformation change","canonical_id":"go:GO:0071103","description":"\"A cellular process that results in a change in the spatial configuration of a DNA molecule. A conformation change can bend DNA, or alter the, twist, writhe, or linking number of a DNA molecule.\" [GOC:mah]","metadata":null},{"id":"91d74e9cbcf34bc6a1052f6119d98eea","type":"GO_TERM","name":"DNA cytosine deamination","canonical_id":"go:GO:0070383","description":"\"The removal of an amino group from a cytosine residue in DNA, forming a uracil residue.\" [GOC:mah]","metadata":null},{"id":"b824f40a77a5456b8803e21b6a744e83","type":"GO_TERM","name":"DNA damage checkpoint signaling","canonical_id":"go:GO:0000077","description":"\"A signal transduction process that contributes to a DNA damage checkpoint.\" [GOC:mah]","metadata":null},{"id":"1eecf17ec634441197874232a93a651e","type":"GO_TERM","name":"DNA damage response","canonical_id":"go:GO:0006974","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.\" [GOC:curators]","metadata":null},{"id":"dfe929a969c54f359654920f857e5b84","type":"GO_TERM","name":"DNA damage response, signal transduction by p53 class mediator","canonical_id":"go:GO:0030330","description":"\"A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.\" [GOC:curators]","metadata":null},{"id":"6bafa5d65b8f46c4a4b2e7fb5becec9c","type":"GO_TERM","name":"DNA damage response, signal transduction resulting in transcription","canonical_id":"go:GO:0042772","description":"\"A cascade of processes initiated in response to the detection of DNA damage, and resulting in the induction of transcription.\" [GOC:curators]","metadata":null},{"id":"b24794ba62184dd7ae4a8ae42fcefd33","type":"GO_TERM","name":"DNA damage sensor activity","canonical_id":"go:GO:0140612","description":"\"A molecule that recognises toxic DNA structures, for example, double-strand breaks or collapsed replication forks, and initiates a signaling response.\" [PMID:31995034]","metadata":null},{"id":"ef2ed1b62d2e49d693fac47c3a8ee6ba","type":"GO_TERM","name":"DNA damage tolerance","canonical_id":"go:GO:0006301","description":"\"A process that promotes the bypass of single-stranded DNA lesions encountered by DNA polymerases during DNA replication, thereby preventing replication fork stalling and allowing completion of DNA replication without removing the damage.\" [PMID:18157158, PMID:26322163, PMID:31251805]","metadata":null},{"id":"6af179316ad346a49d57e42f2cf18018","type":"GO_TERM","name":"DNA dealkylation","canonical_id":"go:GO:0035510","description":"\"The removal of an alkyl group from one or more nucleotides within an DNA molecule.\" [GOC:bf]","metadata":null},{"id":"0012eac5db854d0c882d9fe477a079c7","type":"GO_TERM","name":"DNA deamination","canonical_id":"go:GO:0045006","description":"\"The removal of an amino group from a nucleotide base in DNA. An example is the deamination of cytosine to produce uracil.\" [GOC:ai]","metadata":null},{"id":"7a2feac47cc44ece89eb3a46ac42cb4e","type":"GO_TERM","name":"DNA demethylase activity","canonical_id":"go:GO:0035514","description":"\"Catalysis of the removal of a methyl group from one or more nucleosides within a DNA molecule.\" [GOC:bf]","metadata":null},{"id":"9892cd26ddbe48369f362a2e55468b80","type":"GO_TERM","name":"DNA double-strand break attachment to nuclear envelope","canonical_id":"go:GO:1990683","description":"\"A process in which the DNA double-strand breaks are attached to the inner surface of the nuclear envelope proximal to the spindle pole body, or iMTOCs.\" [PMID:24943839]","metadata":null},{"id":"343c9a25d38d48549ab46411406ad64c","type":"GO_TERM","name":"DNA double-strand break processing","canonical_id":"go:GO:0000729","description":"\"The 5' to 3' exonucleolytic resection of the DNA at the site of the break to form a 3' single-strand DNA overhang.\" [PMID:10357855]","metadata":null},{"id":"8516d3cb42c1441ab2c24ae9026b4b6a","type":"GO_TERM","name":"DNA double-strand break processing involved in repair via single-strand annealing","canonical_id":"go:GO:0010792","description":"\"The 5' to 3' exonucleolytic resection of the DNA at the site of the break to form a 3' single-strand DNA overhang that results in the repair of a double strand break via single-strand annealing.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"cd473d9fa2cf47989e0caaab943b605b","type":"GO_TERM","name":"DNA double-strand break processing involved in repair via synthesis-dependent strand annealing","canonical_id":"go:GO:0010791","description":"\"The 5' to 3' exonucleolytic resection of the DNA at the site of the break to form a 3' single-strand DNA overhang that results in the repair of a double strand break via synthesis-dependent strand annealing.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1d15501a777a459995c52a0a0fbefd5f","type":"GO_TERM","name":"DNA end binding","canonical_id":"go:GO:0045027","description":"\"Binding to DNA ends exposed by the creation of double-strand breaks (DSBs).\" [GOC:jl]","metadata":null},{"id":"a22866c699544cb083b1d5cef782e758","type":"GO_TERM","name":"DNA endonuclease activity","canonical_id":"go:GO:0004520","description":"\"Catalysis of the cleavage of ester linkages within deoxyribonucleic acid by creating internal breaks.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"94ec9d4ddfac4b8baf2a7a40a25effcf","type":"GO_TERM","name":"DNA endonuclease activity, producing 3'-phosphomonoesters","canonical_id":"go:GO:0016889","description":"\"Catalysis of the hydrolysis of ester linkages within deoxyribonucleic acids by creating internal breaks to yield 3'-phosphomonoesters.\" [GOC:ai]","metadata":null},{"id":"a34a74061d424e538f577bc638b95559","type":"GO_TERM","name":"DNA endonuclease activity, producing 5'-phosphomonoesters","canonical_id":"go:GO:0016888","description":"\"Catalysis of the hydrolysis of ester linkages within deoxyribonucleic acids by creating internal breaks to yield 5'-phosphomonoesters.\" [GOC:ai]","metadata":null},{"id":"bdf8d1cb533c4567a2b9bb59ea34ad76","type":"GO_TERM","name":"DNA endoreduplication","canonical_id":"go:GO:0042023","description":"\"Regulated re-replication of DNA within a single cell cycle, resulting in an increased cell ploidy. An example of this process occurs in the synthesis of Drosophila salivary gland cell polytene chromosomes.\" [GOC:jl, GOC:vw]","metadata":null},{"id":"ed76d2acb5184e84bc3308995eef51dc","type":"GO_TERM","name":"DNA exonuclease activity","canonical_id":"go:GO:0004529","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' or 3' terminus of a DNA molecule.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"777cc9cb43744e2291bba3898abd9816","type":"GO_TERM","name":"DNA exonuclease activity, producing 5'-phosphomonoesters","canonical_id":"go:GO:0016895","description":"\"Catalysis of the hydrolysis of ester linkages within deoxyribonucleic acids by removing nucleotide residues from the 3' or 5' end to yield 5' phosphomonoesters.\" [GOC:ai]","metadata":null},{"id":"e0bc420723e54d7db68b9e2ed4710148","type":"GO_TERM","name":"DNA geometric change","canonical_id":"go:GO:0032392","description":"\"The process in which a transformation is induced in the geometry of a DNA double helix, resulting in a change in twist, writhe, or both, but with no change in linking number. Includes the unwinding of double-stranded DNA by helicases.\" [GOC:mah]","metadata":null},{"id":"8dfc85ad96ae48eba1620539fe350f3a","type":"GO_TERM","name":"DNA gyrase complex","canonical_id":"go:GO:0120217","description":"\"A bacterial type IIA topoisomerase that is unique in its function of introducing negative supercoils into DNA at the expense of ATP hydrolysis and is also capable of relaxing positive supercoils, an activity shared with topoisomerase IV. Typically, it is composed of two copies each of an A subunit (GyrA) and a B subunit (GyrB).\" [GOC:bhm, GOC:krc, PMID:1657531, PMID:20675723, Wikipedia:DNA_gyrase]","metadata":null},{"id":"6581c0f7b94a4d429507c4296473b07d","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:P0AES4","description":null,"metadata":null},{"id":"15d82f2d8d49485eb2394c7b42376319","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:D8GUW8","description":null,"metadata":null},{"id":"90c91881cc6e4e2c84f249311956faab","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:Q7VKW4","description":null,"metadata":null},{"id":"94993338a4b542b1ad31aa1e68063059","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:Q2G2Q0","description":null,"metadata":null},{"id":"63720739472d4f0f96a5e922b85e0174","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:P0AES5","description":null,"metadata":null},{"id":"866dd138401e4b16bfff3a320ed2c1a2","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:A0A156YKX6","description":null,"metadata":null},{"id":"226ce3b25fdc4dc78ff960f1f9ddc8a9","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:P72524","description":null,"metadata":null},{"id":"31101e4bc73d492585f4b08a8f0fd7bb","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:R4Y7H5","description":null,"metadata":null},{"id":"c69eaf9611694f378683841819591be5","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:P0DG02","description":null,"metadata":null},{"id":"daaaf178b34b46e1b2cb9aac4575ae0d","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:A0A717UR96","description":null,"metadata":null},{"id":"d6c6f342cb65421cba5d7d1c451f1a08","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:A6TBT6","description":null,"metadata":null},{"id":"693c33ea07274863b09bfb5441156cf9","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:A0A0E1NU92","description":null,"metadata":null},{"id":"ae871607828a4b2c898dedefd9231164","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:P22446","description":null,"metadata":null},{"id":"bf81a7dc6ccc404e9f1c1559470fc840","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:Q9L7Q5","description":null,"metadata":null},{"id":"7b6b52375de84dc38ac85cd81a6374d9","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:O84192","description":null,"metadata":null},{"id":"8aa23653156c435faf98d0cc3b7a1fe9","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:P48371","description":null,"metadata":null},{"id":"b8a39b79d70b4448bb0b854d9d79e5c1","type":"PROTEIN","name":"DNA gyrase subunit A","canonical_id":"uniprot:W1DID1","description":null,"metadata":null},{"id":"64cb18490b0a4c088f66ddc4e24e8bf6","type":"PROTEIN","name":"DNA gyrase subunit A (Chlamydia pneumoniae)","canonical_id":"uniprot:Q9Z8R4","description":null,"metadata":null},{"id":"b7aca57c78f4400b8a82dcffa483bdc1","type":"GO_TERM","name":"DNA hairpin binding","canonical_id":"go:GO:0032448","description":"\"Binding to a DNA region containing a hairpin. A hairpin structure forms when a DNA strand folds back on itself and intrachain base pairing occurs between inverted repeat sequences.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"4f801be3654f474fad02acaffe31f64c","type":"GO_TERM","name":"DNA helicase A complex","canonical_id":"go:GO:0033203","description":"\"A homohexameric protein complex that possesses DNA helicase activity; associates with DNA polymerase alpha-primase and translocates in the 5' to 3' direction.\" [PMID:9341218]","metadata":null},{"id":"73360729ba434698b6beefd30b7357db","type":"GO_TERM","name":"DNA helicase activity","canonical_id":"go:GO:0003678","description":"\"Unwinding of a DNA helix, driven by ATP hydrolysis.\" [GOC:jl]","metadata":null},{"id":"9ce42329fecf4eecb0845561a769d804","type":"GO_TERM","name":"DNA helicase complex","canonical_id":"go:GO:0033202","description":"\"A protein complex that possesses DNA helicase activity.\" [GOC:mah]","metadata":null},{"id":"c2a7f173f8a44a5c99f2cf6fc8124012","type":"GO_TERM","name":"DNA import into cell involved in transformation","canonical_id":"go:GO:0009290","description":"\"The directed movement of DNA into a cell that contributes to the process of transformation, the uptake of foreign genetic material into a cell.\" [GOC:ai]","metadata":null},{"id":"05e5df42bf28406e8ddad6ddbaa5a995","type":"GO_TERM","name":"DNA insertion or deletion binding","canonical_id":"go:GO:0032135","description":"\"Binding to a double-stranded DNA region containing an insertion or a deletion.\" [GOC:vk]","metadata":null},{"id":"a5e7bb04033e4a69a4d5b0e0f081927b","type":"GO_TERM","name":"DNA integration","canonical_id":"go:GO:0015074","description":"\"The process in which a DNA segment is incorporated into another, usually larger, DNA molecule such as a chromosome.\" [GOC:mah]","metadata":null},{"id":"8ecc8b0edea345b2b8213b82a9454cc6","type":"GO_TERM","name":"DNA integrity checkpoint signaling","canonical_id":"go:GO:0031570","description":"\"A signaling process that controls cell cycle progression in response to changes in DNA structure by monitoring the integrity of the DNA. The DNA integrity checkpoint begins with detection of DNA damage, defects in DNA structure or DNA replication, and progresses through signal transduction and ends with cell cycle effector processes.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"bb2556ea7777468fa8bad9e3e3be6603","type":"GO_TERM","name":"DNA ligase (ATP) activity","canonical_id":"go:GO:0003910","description":"\"Catalysis of the reaction: ATP + deoxyribonucleotide(n) + deoxyribonucleotide(m) = AMP + diphosphate + deoxyribonucleotide(n+m).\" [EC:6.5.1.1]","metadata":null},{"id":"797726f0fa17461d9747a068682b16e4","type":"GO_TERM","name":"DNA ligase (NAD+) activity","canonical_id":"go:GO:0003911","description":"\"Catalysis of the reaction: NAD+ + deoxyribonucleotide(n) + deoxyribonucleotide(m) = AMP + nicotinamide nucleotide + deoxyribonucleotide(n+m).\" [EC:6.5.1.2]","metadata":null},{"id":"d6f939a153cd4e04966bab18cab01788","type":"GO_TERM","name":"DNA ligase III-XRCC1 complex","canonical_id":"go:GO:0070421","description":"\"A protein complex that contains DNA ligase III and XRCC1, and is involved in base excision repair.\" [PMID:15141024, PMID:7760816]","metadata":null},{"id":"18643f1a2fe74eb08c5c31e9574cd5e1","type":"GO_TERM","name":"DNA ligase IV complex","canonical_id":"go:GO:0032807","description":"\"A eukaryotically conserved protein complex that contains DNA ligase IV and is involved in DNA repair by non-homologous end joining; in addition to the ligase, the complex also contains XRCC4 or a homolog, e.g. Saccharomyces Lif1p.\" [PMID:16314503]","metadata":null},{"id":"ce1f7b6c2e5544398b35ecd4fa4e1979","type":"GO_TERM","name":"DNA ligase activity","canonical_id":"go:GO:0003909","description":"\"Catalysis of the formation of a phosphodiester bond between the 3'-hydroxyl group at the end of one DNA chain and the 5'-phosphate group at the end of another. This reaction requires an energy source such as ATP or NAD+.\" [ISBN:0716720094]","metadata":null},{"id":"d65ef805d38e4a7fbd2035d5fa658e7f","type":"GO_TERM","name":"DNA loop anchor binding","canonical_id":"go:GO:0141094","description":"\"Binding to a DNA loop anchor, a region of chromosome that defines the ends of a DNA loop where two parts of same DNA strand are held in close physical proximity. For example, in animals, the anchors of DNA loops are convergently oriented CTCF binding sites during interphase.\" [PMID:25497547, PMID:26499245]","metadata":null},{"id":"b379a581cc844c4bb87f5b81ff8a1546","type":"GO_TERM","name":"DNA metabolic process","canonical_id":"go:GO:0006259","description":"\"Any cellular metabolic process involving deoxyribonucleic acid. This is one of the two main types of nucleic acid, consisting of a long, unbranched macromolecule formed from one, or more commonly, two, strands of linked deoxyribonucleotides.\" [ISBN:0198506732]","metadata":null},{"id":"03784c62d44946c9ad648c70ed51c51b","type":"GO_TERM","name":"DNA methylation-dependent constitutive heterochromatin formation","canonical_id":"go:GO:0006346","description":"\"Formation of constitutive heterochromatin by a pathway that includes methylation of genomic DNA such as CpG islands.\" [GOC:mah]","metadata":null},{"id":"7941c333bbbb46aea794e7e72ad10d53","type":"GO_TERM","name":"DNA methyltransferase complex","canonical_id":"go:GO:0140020","description":"\"A protein complex that possesses DNA methyltransferase activity.\" [PMID:20939822, PMID:24947342]","metadata":null},{"id":"f5d525869b6f471dba849a6d79205f5e","type":"GO_TERM","name":"DNA modification","canonical_id":"go:GO:0006304","description":"\"The covalent alteration of one or more nucleotide sites in DNA, resulting in a change in its properties.\" [GOC:jl, GOC:ma]","metadata":null},{"id":"2e6d67a59e4d4dca81d2ff06dc99d336","type":"GO_TERM","name":"DNA negative supercoiling activity","canonical_id":"go:GO:0034335","description":"\"Catalytic introduction of negative supercoils into a DNA molecule or region thereof. In bacteria, negative supercoils are only introduced by DNA gyrase, a type II topoisomerase, but not all DNA gyrases are capable of introducing supercoils. In bacteria, the level of supercoiling varies widely between species and has been characterized properly in only a handful of organisms. The best characterized enzyme, from E.coli, is exceptionally proficient at supercoiling and this ability is not representative of all bacteria.\" [GOC:bhm, GOC:krc, GOC:mah, WikiPedia:DNA_gyrase]","metadata":null},{"id":"9c70f959bf2342a4a432ad2f00a3fcdc","type":"GO_TERM","name":"DNA nuclease activity","canonical_id":"go:GO:0004536","description":"\"Catalysis of the cleavage of ester linkages within deoxyribonucleic acid.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"6437249ca9d642f79c72699c78f27ae6","type":"GO_TERM","name":"DNA nucleotidylexotransferase activity","canonical_id":"go:GO:0003912","description":"\"Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1); template-independent extension of the 3'-end of a DNA strand by one nucleotide at a time.\" [EC:2.7.7.31]","metadata":null},{"id":"8604c8960bf146cb813e5882b7cdcc29","type":"GO_TERM","name":"DNA photolyase activity","canonical_id":"go:GO:0003913","description":"\"Catalysis of the repair of a photoproduct resulting from ultraviolet irradiation of two adjacent pyrimidine residues in DNA.\" [GOC:mah, PMID:11124949]","metadata":null},{"id":"56fc48f0e12a4da89ce40873ad6a4ae9","type":"GO_TERM","name":"DNA polymerase III complex","canonical_id":"go:GO:0009360","description":"\"The DNA polymerase III holoenzyme is a complex that contains 10 different types of subunits. These subunits are organized into 3 functionally essential sub-assemblies: the pol III core, the beta sliding clamp processivity factor and the clamp-loading complex. The pol III core carries out the polymerase and the 3'-5' exonuclease proofreading activities. The polymerase is tethered to the template via the sliding clamp processivity factor. The clamp-loading complex assembles the beta processivity factor onto the primer template and plays a central role in the organization and communication at the replication fork.\" [PMID:11525729, PMID:12940977, UniProt:P06710]","metadata":null},{"id":"b18b6bb070e1487ab59c3d2de878b907","type":"GO_TERM","name":"DNA polymerase III, beta sliding clamp processivity factor complex","canonical_id":"go:GO:0044775","description":"\"A subcomplex of the DNA polymerase III holoenzyme which is responsible for tethering the catalytic subunit of DNA polymerase to DNA during high-speed replication. The complex is homodimeric in prokaryotes, and homotrimeric in other species.\" [GOC:jl, UniProt:O73947]","metadata":null},{"id":"28e6158769d544b6ba89e8cdb8441b93","type":"GO_TERM","name":"DNA polymerase III, clamp loader chi/psi subcomplex","canonical_id":"go:GO:0043847","description":"\"A dimer composed of the chi and psi subunits which is a subassembly of the DNA polymerase III clamp loader complex and serves as a bridge between the DnaX complex and the single-stranded DNA-binding protein (SSB).\" [PMID:12940977]","metadata":null},{"id":"02ef5bac442a4ad383cef4ece65b81ea","type":"GO_TERM","name":"DNA polymerase III, clamp loader complex","canonical_id":"go:GO:0043846","description":"\"A heptamer that includes the tau and gamma products of the dnaX gene and the chi/psi subcomplex. Confers structural asymmetry that allows the polymerase to replicate both leading and lagging strands.\" [PMID:12940977]","metadata":null},{"id":"87fd29962f164f71836e9e24532ffa4c","type":"GO_TERM","name":"DNA polymerase III, core complex","canonical_id":"go:GO:0044776","description":"\"The DNA polymerase III core complex consists of the alpha,epsilon and theta subunits and is carries out the polymerase and the 3'-5' exonuclease proofreading activities.\" [GOC:jl, UniProt:P06710]","metadata":null},{"id":"e52c22f6ede44ae9afce61aafdb80997","type":"GO_TERM","name":"DNA polymerase III, proofreading complex","canonical_id":"go:GO:0043845","description":"\"A subcomplex of DNA polymerase III composed of the epsilon subunit which has proofreading activity, and the theta subunit which enhances the epsilon subunit's proofreading activity.\" [PMID:16973612, Wikipedia:Pol_III]","metadata":null},{"id":"35d8c6ebc2264ab49dd24818f3ada8e6","type":"GO_TERM","name":"DNA polymerase V complex","canonical_id":"go:GO:0009355","description":"\"A DNA polymerase complex that contains two UmuD' and one UmuC subunits, and acts in translesion DNA synthesis.\" [PMID:10430871, PMID:10542196]","metadata":null},{"id":"a55f13127e4349b19ee829701a5ccc74","type":"GO_TERM","name":"DNA polymerase activity","canonical_id":"go:GO:0034061","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) = diphosphate + DNA(n+1).\" [RHEA:22508]","metadata":null},{"id":"1bed87feb13a49e390c0f95e1d59d20c","type":"GO_TERM","name":"DNA polymerase binding","canonical_id":"go:GO:0070182","description":"\"Binding to a DNA polymerase.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ebe81ff318274ded9d76cbaa60be69ef","type":"PROTEIN","name":"DNA polymerase catalytic subunit","canonical_id":"uniprot:P09252","description":null,"metadata":null},{"id":"0536858456324775848bbd653095ec14","type":"PROTEIN","name":"DNA polymerase catalytic subunit (Human herpesvirus 1)","canonical_id":"uniprot:P04293","description":null,"metadata":null},{"id":"63bc619ac8c445edaee5a79c69543fe7","type":"GO_TERM","name":"DNA polymerase complex","canonical_id":"go:GO:0042575","description":"\"A protein complex that possesses DNA polymerase activity and is involved in template directed synthesis of DNA.\" [GOC:jl, PMID:12045093]","metadata":null},{"id":"3839889748784a758342b6b28e627202","type":"GO_TERM","name":"DNA polymerase processivity factor activity","canonical_id":"go:GO:0030337","description":"\"An enzyme regulator activity that increases the processivity of polymerization by DNA polymerase, by allowing the polymerase to move rapidly along DNA while remaining topologically bound to it.\" [GOC:mah, PMID:7903401, PMID:8087839]","metadata":null},{"id":"a0623941529c4d5f94676fc8e6c5df33","type":"GO_TERM","name":"DNA polymerase processivity factor complex","canonical_id":"go:GO:0044796","description":"\"A protein complex which is capable of increasing the processivity of nucleotide polymerization by DNA polymerase as a part of DNA replication.\" [GOC:bhm, GOC:jl]","metadata":null},{"id":"6b39cdbc41544331a0cde878d249feb3","type":"GO_TERM","name":"DNA protection","canonical_id":"go:GO:0042262","description":"\"Any process in which DNA is protected from damage by, for example, oxidative stress.\" [GOC:jl]","metadata":null},{"id":"74cefcb74e954d689872b33a08ec5b0a","type":"GO_TERM","name":"DNA recombinase assembly","canonical_id":"go:GO:0000730","description":"\"The aggregation, arrangement and bonding together of strand exchange proteins (recombinases) into higher order oligomers on single-stranded DNA.\" [PMID:10357855]","metadata":null},{"id":"2ab9259e36cb4ab79f33bf7c9228b6d7","type":"GO_TERM","name":"DNA recombinase auxiliary factor complex","canonical_id":"go:GO:0120231","description":"\"A protein complex that binds to a recombinase and incrseases its activity.\" [PMID:32414915]","metadata":null},{"id":"812038efd28e473595b393017147fa11","type":"GO_TERM","name":"DNA recombinase complex","canonical_id":"go:GO:0097519","description":"\"A protein-DNA complex consisting of a higher-order oligomer of strand exchange proteins (recombinases) on single-stranded DNA.\" [GOC:cjm, PMID:10357855]","metadata":null},{"id":"c3f18a45a70747d1806a62d8698a36a5","type":"GO_TERM","name":"DNA recombinase disassembly","canonical_id":"go:GO:1990986","description":"\"The disaggregation of a DNA recombinase complex into its constituent strand exchange proteins (recombinases).\" [GOC:pg, PMID:19540122]","metadata":null},{"id":"a63d14e7c530420ab0c7978058703b63","type":"GO_TERM","name":"DNA recombinase mediator complex","canonical_id":"go:GO:0033061","description":"\"A protein complex containing accessory proteins which bind a recombinase (e.g. Rad51) and bind single-stranded DNA (ssDNA), and promote nucleation of the recombinase onto ssDNA through facilitating recombinase-RPA exchange.\" [GOC:elh, GOC:mah, GOC:vw, InterPro:IPR003488, PMID:12912992, PMID:32414915]","metadata":null},{"id":"27266acc303444eaa37369214188cde7","type":"GO_TERM","name":"DNA recombinase mediator complex assembly","canonical_id":"go:GO:1903871","description":"\"The aggregation, arrangement and bonding together of a set of components to form a DNA recombinase mediator complex.\" [GO_REF:0000079, GOC:rb, GOC:TermGenie, PMID:18347097]","metadata":null},{"id":"64b9d8dfff3c4185acd14d9c08a7c1dc","type":"GO_TERM","name":"DNA recombination","canonical_id":"go:GO:0006310","description":"\"Any process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents. In eukaryotes genetic recombination can occur by chromosome assortment, intrachromosomal recombination, or nonreciprocal interchromosomal recombination. Interchromosomal recombination occurs by crossing over. In bacteria it may occur by genetic transformation, conjugation, transduction, or F-duction.\" [ISBN:0198506732]","metadata":null},{"id":"662f16aa45be4fd59069a32e5ceced63","type":"GO_TERM","name":"DNA repair","canonical_id":"go:GO:0006281","description":"\"The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.\" [PMID:11563486]","metadata":null},{"id":"62b56bc765794ac8917644809d7f9019","type":"GO_TERM","name":"DNA repair complex","canonical_id":"go:GO:1990391","description":"\"A protein complex involved in DNA repair processes including direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.\" [GOC:bhm, PMID:17217467, PMID:20551348, PMID:22749910, PMID:24192350]","metadata":null},{"id":"49dd81b54f0744eebd525f15f3b79a79","type":"GO_TERM","name":"DNA repair complex assembly","canonical_id":"go:GO:0090735","description":"\"The aggregation, arrangement and bonding together of a set of components to form a DNA repair complex.\" [GOC:pg, PMID:27113759, PMID:27233470]","metadata":null},{"id":"35f84a8fb0124f30b751bb4e60cc3feb","type":"GO_TERM","name":"DNA repair-dependent chromatin remodeling","canonical_id":"go:GO:0140861","description":"\"A chromatin remodeling process that allows DNA repair enzyme to access genomic DNA and repair DNA lesions.\" [PMID:15528408, PMID:28053344, PMID:29095668, PMID:35689883]","metadata":null},{"id":"b64e798c56da4b01874cc551a20322b1","type":"GO_TERM","name":"DNA replication","canonical_id":"go:GO:0006260","description":"\"The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by the origin recognition complex, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.\" [GOC:mah]","metadata":null},{"id":"90475f1d8908442a8de82cc8643523b8","type":"GO_TERM","name":"DNA replication checkpoint signaling","canonical_id":"go:GO:0000076","description":"\"A signal transduction process that contributes to a DNA replication checkpoint, that prevents the initiation of nuclear division until DNA replication is complete, thereby ensuring that progeny inherit a full complement of the genome.\" [GOC:curators, GOC:rn, PMID:11728327, PMID:12537518]","metadata":null},{"id":"a7756a381ff2490a9911bb3a3c664453","type":"GO_TERM","name":"DNA replication factor A complex","canonical_id":"go:GO:0005662","description":"\"A conserved heterotrimeric complex that binds nonspecifically to single-stranded DNA and is required for multiple processes in eukaryotic DNA metabolism, including DNA replication, DNA repair, and recombination. In all eukaryotic organisms examined the complex is composed of subunits of approximately 70, 30, and 14 kDa.\" [PMID:9242902]","metadata":null},{"id":"2bd39841609b429cb48fcfbe2f383e37","type":"GO_TERM","name":"DNA replication factor C complex","canonical_id":"go:GO:0005663","description":"\"A complex that loads the DNA polymerase processivity factor proliferating cell nuclear antigen (PCNA) onto DNA, thereby permitting processive DNA synthesis catalyzed by DNA polymerase. In eukaryotes the complex consists of five polypeptides.\" [PMID:14614842, PMID:14646196, PMID:16172520]","metadata":null},{"id":"276a82c7ecc6405abc5b41d5b68c25f2","type":"GO_TERM","name":"DNA replication factor C core complex","canonical_id":"go:GO:0070517","description":"\"A protein complex containing three of the five subunits of eukaryotic replication factor C, those corresponding to human p40, p38, and p37.\" [PMID:8692848, PMID:9228079, PMID:9582326]","metadata":null},{"id":"19a1e08f277347888e2f80f19f2f5a51","type":"GO_TERM","name":"DNA replication initiation","canonical_id":"go:GO:0006270","description":"\"The process in which DNA-dependent DNA replication is started; it begins when specific sequences, known as origins of replication, are recognized and bound by the origin recognition complex, followed by DNA unwinding.\" [PMID:28209641]","metadata":null},{"id":"ee4da438939d4544a244cb36589080be","type":"GO_TERM","name":"DNA replication origin binding","canonical_id":"go:GO:0003688","description":"\"Binding to a DNA replication origin, a unique DNA sequence of a replicon at which DNA replication is initiated and proceeds bidirectionally or unidirectionally.\" [GOC:curators]","metadata":null},{"id":"7a80c697b8a744088c3c6b7cd415c9d2","type":"GO_TERM","name":"DNA replication preinitiation complex","canonical_id":"go:GO:0031261","description":"\"A protein-DNA complex assembled at eukaryotic DNA replication origins immediately prior to the initiation of DNA replication. The preinitiation complex is formed by the assembly of additional proteins onto an existing prereplicative complex. In budding yeast, the additional proteins might include Cdc45p, Sld2p, Sld3p, Dpb11p, DNA polymerases, and others; in fission yeast the GINS complex is present.\" [GOC:bf, GOC:hjd, GOC:jl, GOC:pr, GOC:rb, GOC:vw, PMID:12694535, PMID:15194812, PMID:17230184]","metadata":null},{"id":"7f8fb11175ee4505be4763777eadd2b0","type":"GO_TERM","name":"DNA replication preinitiation complex assembly","canonical_id":"go:GO:0071163","description":"\"The aggregation, arrangement and bonding together of a set of components to form the DNA replication preinitiation complex, a protein-DNA complex that is assembled at DNA replication origins as part of initiation of DNA replication. The complex consists of proteins that initiate the DNA binding, melt the helix and enable helicase activity.\" [GOC:mah, PMID:28209641]","metadata":null},{"id":"45a0447a53f0484794d6a547ce9098df","type":"GO_TERM","name":"DNA replication proofreading","canonical_id":"go:GO:0045004","description":"\"Correction of replication errors by DNA polymerase using a 3'-5' exonuclease activity.\" [GOC:ai]","metadata":null},{"id":"3c6a597bb9f24e0badf2840a0366bf5e","type":"GO_TERM","name":"DNA replication termination","canonical_id":"go:GO:0006274","description":"\"The process in which DNA replication at a replication fork ceases; occurs when the replication fork reaches a specific termination site or when two replication forks meet.\" [GOC:mah, PMID:10209736, PMID:12009298]","metadata":null},{"id":"f3ce923e2137413b87d5396f74e00bdf","type":"GO_TERM","name":"DNA replication termination region","canonical_id":"go:GO:0097047","description":"\"A chromosomal region that contains fork pausing elements influencing the progression and merging of DNA replication forks.\" [GOC:mcc, GOC:pr, PMID:20797631]","metadata":null},{"id":"c12bea2ce98047609ccd7fd66befc1b1","type":"GO_TERM","name":"DNA replication, Okazaki fragment processing","canonical_id":"go:GO:0033567","description":"\"The DNA metabolic process, occurring during lagging strand synthesis, by which RNA primers are removed from Okazaki fragments, the resulting gaps filled by DNA polymerization, and the ends ligated to form a continuous strand.\" [GOC:mah, ISBN:0716720094]","metadata":null},{"id":"f40ad6adca7a4af69d982893ccc96059","type":"GO_TERM","name":"DNA replication, removal of RNA primer","canonical_id":"go:GO:0043137","description":"\"Removal of the Okazaki RNA primer from the lagging strand of replicating DNA, by a combination of the actions of DNA polymerase, DNA helicase and an endonuclease.\" [GOC:jl, PMID:12424238]","metadata":null},{"id":"5bd37ea5b2fd4ff5a5371814af784b6c","type":"GO_TERM","name":"DNA replication, synthesis of primer","canonical_id":"go:GO:0006269","description":"\"The synthesis of a short nucleotide polymer using one strand of unwound DNA as a template. The product is usually a RNA molecule between 4-15 nucleotides long that provides a free 3'-OH that can be extended by DNA-directed DNA polymerases. In certain conditions, for example in response to DNA damage, some primases synthesize a DNA primer.\" [PMID:11395402, PMID:38203225, PMID:38492718]","metadata":null},{"id":"52ad1042594749eaa2098ef457a964b9","type":"GO_TERM","name":"DNA replication-dependent chromatin assembly","canonical_id":"go:GO:0006335","description":"\"The formation of nucleosomes on newly synthesized DNA, coupled to strand elongation.\" [GOC:mah, PMID:28053344]","metadata":null},{"id":"f57123acafe34ade9bccc5739c82cfdf","type":"GO_TERM","name":"DNA replication-dependent chromatin disassembly","canonical_id":"go:GO:0140889","description":"\"The disruption of nucleosomes during DNA replication to allow the replication machinery to access the DNA.\" [PMID:34471130, PMID:35308047]","metadata":null},{"id":"e01157d2e47949c3bb921967d1d4fad4","type":"GO_TERM","name":"DNA restriction-modification system","canonical_id":"go:GO:0009307","description":"\"A defense process found in many bacteria and archaea that protects the organism from invading foreign DNA by cleaving it with a restriction endonuclease. The organism's own DNA is protected by methylation of a specific nucleotide, which occurs immediately following replication, in the same target site as the restriction enzyme.\" [GOC:jl, UniProtKB-KW:KW-0680]","metadata":null},{"id":"ef3816150e1747ac94e2f56a5baccf11","type":"GO_TERM","name":"DNA secondary structure binding","canonical_id":"go:GO:0000217","description":"\"Binding to a DNA secondary structure element such as a four-way junction, a bubble, a loop, Y-form DNA, or a double-strand/single-strand junction.\" [GOC:krc]","metadata":null},{"id":"a16c8aea3f15453a8f086910c070e9e0","type":"GO_TERM","name":"DNA secretion by the type IV secretion system","canonical_id":"go:GO:0044098","description":"\"The controlled release of DNA by a cell, via the type IV secretion system.\" [GOC:pamgo_curators]","metadata":null},{"id":"42c842a5afb344e0b67c56944550d0e3","type":"GO_TERM","name":"DNA strand displacement","canonical_id":"go:GO:0000732","description":"\"The rejection of the broken 3' single-strand DNA molecule that formed heteroduplex DNA with its complement in an intact duplex DNA. The Watson-Crick base pairing in the original duplex is restored. The rejected 3' single-strand DNA molecule reanneals with its original complement to reform two intact duplex molecules.\" [PMID:10357855]","metadata":null},{"id":"6168cf86a7f54a65a260b963b567d406","type":"GO_TERM","name":"DNA strand elongation","canonical_id":"go:GO:0022616","description":"\"The DNA metabolic process in which an existing DNA strand is extended by activities including the addition of nucleotides to the 3' end of the strand.\" [GOC:isa_complete, GOC:mah]","metadata":null},{"id":"0c39b238b20e414a951a3ef6d00372f5","type":"GO_TERM","name":"DNA strand elongation involved in DNA replication","canonical_id":"go:GO:0006271","description":"\"The process in which an existing DNA strand is extended by activities including the addition of nucleotides to the 3' end of the strand, complementary to an existing template, as part of DNA replication.\" [GOC:mah, ISBN:071673706X, ISBN:0815316194]","metadata":null},{"id":"b16ee1ea41814140b5cd29b9062eefbd","type":"GO_TERM","name":"DNA strand elongation involved in cell cycle DNA replication","canonical_id":"go:GO:1902296","description":"\"Any DNA strand elongation that is involved in cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"f285306ad10a485abda0747d1c304da4","type":"GO_TERM","name":"DNA strand elongation involved in mitotic DNA replication","canonical_id":"go:GO:1902983","description":"\"Any DNA strand elongation involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"bced1b76d47643fb949899cb194c1879","type":"GO_TERM","name":"DNA strand elongation involved in nuclear cell cycle DNA replication","canonical_id":"go:GO:1902319","description":"\"Any DNA strand elongation that is involved in nuclear cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"afc7513750b54324b7b796978f7b5d02","type":"GO_TERM","name":"DNA strand exchange activator activity","canonical_id":"go:GO:0140619","description":"\"Binds to and increases a DNA strand exchange activity.\" [PMID:33493431]","metadata":null},{"id":"267d0069333f4581b238e5b7cd630123","type":"GO_TERM","name":"DNA strand exchange activity","canonical_id":"go:GO:0000150","description":"\"Catalysis of the identification and base-pairing of homologous sequences between single-stranded DNA and double-stranded DNA.\" [GOC:elh]","metadata":null},{"id":"fb50e2104717479da28659790e16cafb","type":"GO_TERM","name":"DNA strand exchange inhibitor activity","canonical_id":"go:GO:0140620","description":"\"Binds to and stops, prevents or reduces a DNA strand exchange activity.\" [PMID:33493431]","metadata":null},{"id":"d14f78ea2b3640b9b9ebed8c8986c97c","type":"GO_TERM","name":"DNA strand invasion","canonical_id":"go:GO:0042148","description":"\"The process in which the nucleoprotein complex (composed of the broken single-strand DNA and the recombinase) searches and identifies a region of homology in intact duplex DNA. The broken single-strand DNA displaces the like strand and forms Watson-Crick base pairs with its complement, forming a duplex in which each strand is from one of the two recombining DNA molecules.\" [GOC:elh, PMID:10357855]","metadata":null},{"id":"5e67c42faaf64cae99f4305bf3515a5f","type":"GO_TERM","name":"DNA strand resection involved in replication fork processing","canonical_id":"go:GO:0110025","description":"\"The 5' to 3' exonucleolytic resection of DNA at the site of a stalled replication fork that contributes to replication fork processing.\" [GOC:mah, PMID:28475874]","metadata":null},{"id":"f51cd8ff3ca74879861f9f38878c934f","type":"GO_TERM","name":"DNA synthesis involved in DNA repair","canonical_id":"go:GO:0000731","description":"\"Synthesis of DNA that proceeds from the broken 3' single-strand DNA end and uses the homologous intact duplex as the template.\" [PMID:10357855]","metadata":null},{"id":"e8e730a6ca81441aa89058e28bc8b48c","type":"GO_TERM","name":"DNA synthesis involved in DNA replication","canonical_id":"go:GO:0090592","description":"\"Synthesis of DNA that is a part of the process of duplicating one or more molecules of DNA.\" [GOC:vw]","metadata":null},{"id":"5c7fdaeded1949c18a972e39ebd0dcdf","type":"GO_TERM","name":"DNA synthesis involved in UV-damage excision repair","canonical_id":"go:GO:1904161","description":"\"Any DNA synthesis that is involved in UV-damage excision repair.\" [GO_REF:0000060, GOC:TermGenie, PMID:10704216]","metadata":null},{"id":"26e70d09d6de446ab740438ede8b014c","type":"GO_TERM","name":"DNA synthesis involved in double-strand break repair via homologous recombination","canonical_id":"go:GO:0043150","description":"\"The synthesis of DNA that contributes to the process of double-strand break repair via homologous recombination.\" [GOC:curators]","metadata":null},{"id":"a4dc0e2fccf44753a58dc0d540132313","type":"GO_TERM","name":"DNA synthesis involved in mitochondrial DNA replication","canonical_id":"go:GO:0110166","description":"\"Any DNA biosynthetic process that is involved in mitochondrial DNA replication.\" [PMID:28408491, PMID:29931097]","metadata":null},{"id":"fac1d29046aa43c8b2a95c82e3cd425f","type":"GO_TERM","name":"DNA synthesis involved in mitotic DNA replication","canonical_id":"go:GO:1904860","description":"\"Any DNA biosynthetic process that is involved in mitotic DNA replication.\" [GO_REF:0000060, GOC:TermGenie, PMID:16849602]","metadata":null},{"id":"dc13c75011134bdfb2e13b5e027f8390","type":"GO_TERM","name":"DNA template activity","canonical_id":"go:GO:0000497","description":"\"Binding to nucleic acid via hydrogen bonds between the bases of a gene product molecule and the bases of a target DNA molecule.\" [GOC:krc]","metadata":null},{"id":"c2d901b1a55245429e5ab677a8ce041b","type":"PROTEIN","name":"DNA topoisomerase 4 subunit A","canonical_id":"uniprot:P48374","description":null,"metadata":null},{"id":"0a863a438b8c42dca73afef049b46a8e","type":"PROTEIN","name":"DNA topoisomerase 4 subunit A (Chlamydial pneumoniae)","canonical_id":"uniprot:Q9Z7I9","description":null,"metadata":null},{"id":"32861db7e7944d97b60f1beb282a112a","type":"PROTEIN","name":"DNA topoisomerase 4 subunit A (Escherichia coli)","canonical_id":"uniprot:P0AFI2","description":null,"metadata":null},{"id":"e85ddb908d614e3ebeb25e08d1433bd7","type":"PROTEIN","name":"DNA topoisomerase 4 subunit A (Klebsiella pneumoniae)","canonical_id":"uniprot:A0A0C4MI94","description":null,"metadata":null},{"id":"f25395fdd6d046f08af3192eb4299ae7","type":"PROTEIN","name":"DNA topoisomerase 4 subunit A (Mycoplasma pneumoniae)","canonical_id":"uniprot:P75352","description":null,"metadata":null},{"id":"d696f2bc77694025985aadc564552f4c","type":"PROTEIN","name":"DNA topoisomerase 4 subunit A (Staphylococcus aureus)","canonical_id":"uniprot:Q2FYS4","description":null,"metadata":null},{"id":"5f64f92af8e94177a05e7525863814d0","type":"PROTEIN","name":"DNA topoisomerase I","canonical_id":"uniprot:Q9NJG8","description":null,"metadata":null},{"id":"750c6661a0c042d88b7be3e6924d0b40","type":"GO_TERM","name":"DNA topoisomerase III-beta-TDRD3 complex","canonical_id":"go:GO:0140225","description":"\"A protein complex that has DNA topoisomerase type I and RNA topoisomerase activities.\" [GOC:lnp, PMID:23912945, PMID:28176834]","metadata":null},{"id":"d1661154d78a4eb3aaafc0be94c2cde0","type":"GO_TERM","name":"DNA topoisomerase IV complex","canonical_id":"go:GO:0009340","description":"\"A heterodimeric enzyme, which in most bacterial species is composed of two subunits, ParC and ParE. Functions in chromosome segregation and can relax supercoiled DNA.\" [GOC:jl, PMID:7783632]","metadata":null},{"id":"dbe0b1c2fa974b50bcccc24615e6e144","type":"GO_TERM","name":"DNA topoisomerase activity","canonical_id":"go:GO:0003916","description":"\"Catalysis of the transient cleavage and passage of individual DNA strands or double helices through one another, resulting a topological transformation in double-stranded DNA.\" [GOC:mah, PMID:8811192]","metadata":null},{"id":"8372197d0caa41418148326bbfb27a67","type":"GO_TERM","name":"DNA topoisomerase binding","canonical_id":"go:GO:0044547","description":"\"Binding to a DNA topoisomerase.\" [GOC:jl]","metadata":null},{"id":"032bc5c3c1bc4ed18440630737f7b143","type":"GO_TERM","name":"DNA topoisomerase type I (single strand cut, ATP-independent) activity","canonical_id":"go:GO:0003917","description":"\"Catalysis of a DNA topological transformation by transiently cleaving one DNA strand at a time to allow passage of another strand; changes the linking number by +1 per catalytic cycle.\" [PMID:8811192]","metadata":null},{"id":"7e7556b1d14b445b89294a288ecb1207","type":"GO_TERM","name":"DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activator activity","canonical_id":"go:GO:0072587","description":"\"Binds to and increases the activity of ATP-hydrolyzing DNA topoisomerase. DNA topoisomerase (ATP-hydrolyzing) regulator activity catalyzes a DNA topological transformation by transiently cleaving a pair of complementary DNA strands to form a gate through which a second double-stranded DNA segment is passed, after which the severed strands in the first DNA segment are rejoined; product release is coupled to ATP binding and hydrolysis; changes the linking number in multiples of 2.\" [GOC:mah]","metadata":null},{"id":"0b17e379db1340619f6bfebc9fb490b1","type":"GO_TERM","name":"DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity","canonical_id":"go:GO:0003918","description":"\"Catalysis of a DNA topological transformation by transiently cleaving a pair of complementary DNA strands to form a gate through which a second double-stranded DNA segment is passed, after which the severed strands in the first DNA segment are rejoined, driven by ATP hydrolysis. The enzyme changes the linking number in multiples of 2.\" [PMID:8811192]","metadata":null},{"id":"1b1634fc067140d78e868da949d3a884","type":"GO_TERM","name":"DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex","canonical_id":"go:GO:0009330","description":"\"Complex that possesses DNA topoisomerase II (double strand cut, ATP-hydrolyzing) activity.\" [GOC:bhm, GOC:krc, GOC:mah, WikiPedia:Type_II_topoisomerase]","metadata":null},{"id":"68e2ebe3757c4eb098ffef86550249c0","type":"GO_TERM","name":"DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) inhibitor activity","canonical_id":"go:GO:0008657","description":"\"Binds to and stops, prevents or reduces the activity of ATP-hydrolyzing DNA topoisomerase. ATP-hydrolyzing DNA topoisomerase catalyzes the DNA topological transformation by transiently cleaving a pair of complementary DNA strands to form a gate through which a second double-stranded DNA segment is passed, after which the severed strands in the first DNA segment are rejoined; product release is coupled to ATP binding and hydrolysis; changes the linking number in multiples of 2.\" [GOC:mah]","metadata":null},{"id":"c8bb57a6f75d479cb8621a4ede0de628","type":"GO_TERM","name":"DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) regulator activity","canonical_id":"go:GO:0072586","description":"\"Binds to and modulates the activity of ATP-hydrolyzing DNA topoisomerase. DNA topoisomerase (ATP-hydrolyzing) regulator activity catalyzes a DNA topological transformation by transiently cleaving a pair of complementary DNA strands to form a gate through which a second double-stranded DNA segment is passed, after which the severed strands in the first DNA segment are rejoined; product release is coupled to ATP binding and hydrolysis; changes the linking number in multiples of 2.\" [GOC:mah]","metadata":null},{"id":"b0126c6383a24cb1b7878a4c2f623d33","type":"GO_TERM","name":"DNA topological change","canonical_id":"go:GO:0006265","description":"\"The process in which a transformation is induced in the topological structure of a double-stranded DNA helix, resulting in a change in linking number.\" [ISBN:071673706X, ISBN:0935702490]","metadata":null},{"id":"8101625eea8e455da5de91f2167118d5","type":"GO_TERM","name":"DNA translocase activity","canonical_id":"go:GO:0015616","description":"\"Generation of movement along a single- or double-stranded DNA molecule, driven by ATP hydrolysis.\" [GOC:mah, PMID:16428451, PMID:17631491]","metadata":null},{"id":"ecff2ed9bd074571b12a082c4c8dd5de","type":"GO_TERM","name":"DNA transmembrane transporter activity","canonical_id":"go:GO:0051035","description":"\"Enables the transfer of DNA, deoxyribonucleic acid, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"6d5ef399b90a41e4a7d3b6d67ca0ef32","type":"GO_TERM","name":"DNA transport","canonical_id":"go:GO:0051027","description":"\"The directed movement of RNA, deoxyribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f36230e69635453cbfb078a67ff1cce2","type":"GO_TERM","name":"DNA transposition","canonical_id":"go:GO:0006313","description":"\"A type of transposition in which a transposable element (transposon) is moved to another part of a genome, either by a cut-and-paste mechanism or a replicative mechanism.\" [ISBN:0198506732, ISBN:1555812090, PMID:26846462, PMID:30416149, PMID:32588192]","metadata":null},{"id":"ec619d823f8f43f294c7bbfaa24e2232","type":"GO_TERM","name":"DNA-(abasic site) binding","canonical_id":"go:GO:0140431","description":"\"Binding to a DNA site that has neither a purine nor a pyrimidine base. Apurinic sites can form spontaneously or when DNA glycosylase removes a damaged base.\" [PMID:23245849]","metadata":null},{"id":"a826c45ce0be44739df87058bb7527a9","type":"GO_TERM","name":"DNA-(apurinic or apyrimidinic site) endonuclease activity","canonical_id":"go:GO:0003906","description":"\"Catalysis of the cleavage of the C-O-P bond in the AP site created when DNA glycosylase removes a damaged base, involved in the DNA base excision repair pathway (BER).\" [Wikipedia:AP_endonuclease]","metadata":null},{"id":"1ebbf3fbba9b4e9a9cd8de09660e5e39","type":"GO_TERM","name":"DNA-1,N6-ethenoadenine N-glycosylase activity","canonical_id":"go:GO:0052820","description":"\"Catalysis of the reaction: DNA with 1-N6-ethenoadenine + H2O = DNA with abasic site + 1-N6-ethenoadenine. This reaction is the removal of 1,N6-ethenoadenine by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar.\" [PMID:21960007]","metadata":null},{"id":"a53d3211c4fe4a0bb3864e57e8be8e17","type":"GO_TERM","name":"DNA-3'-diphospho-5'-guanosine diphosphatase activity","canonical_id":"go:GO:0120108","description":"\"Catalysis of the reaction: a 3'-end 2'-deoxyribonucleotide-3'-diphospho-5'-guanosine-DNA + H2O = a 3'-end 2'-deoxyribonucleotide 3'-phosphate-DNA + GMP + 2 H+.\" [PMID:26007660, RHEA:52140]","metadata":null},{"id":"c951648c657c4c3e97de8d1a7173449c","type":"GO_TERM","name":"DNA-3-methyladenine glycosylase activity","canonical_id":"go:GO:0008725","description":"\"Catalysis of the reaction: DNA containing 3-methyladenine + H2O = DNA with abasic site + 3-methyladenine. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the damaged DNA 3-methyladenine and the deoxyribose sugar to remove the 3-methyladenine, leaving an abasic site.\" [EC:3.2.2.20, GOC:elh, PMID:10872450, PMID:9224623]","metadata":null},{"id":"47f3587eeb924111972bf9425e671c90","type":"GO_TERM","name":"DNA-3-methylbase glycosylase activity","canonical_id":"go:GO:0043733","description":"\"Catalysis of the reaction: DNA containing 3-methylbase + H2O = DNA with abasic site + 3-methylbase. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the damaged DNA 3-methylpurine or 3-methylpyrimidine base and the deoxyribose sugar to remove the methylated base, leaving an apurinic or apyrimidinic site.\" [PMID:10777493, PMID:14517230]","metadata":null},{"id":"6def6cc3cd114d909132114576f19972","type":"GO_TERM","name":"DNA-3-methylguanine glycosylase activity","canonical_id":"go:GO:0052822","description":"\"Catalysis of the reaction: DNA containing 3-methylguanine + H2O = DNA with abasic site + 3-methylguanine. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the damaged DNA 3-methylguanine and the deoxyribose sugar to remove the 3-methylguanine, leaving an abasic site.\" [GOC:elh, PMID:10872450, PMID:9224623]","metadata":null},{"id":"1473839db0914415be8f18cc5746be94","type":"GO_TERM","name":"DNA-5-methylcytosine glycosylase activity","canonical_id":"go:GO:1990053","description":"\"Catalysis of the reaction: DNA containing 5-methylcytosine + H2O = DNA with abasic site + 5-methylcytosine. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the DNA 5-methylcytosine and the deoxyribose sugar to remove the 5-methylcytosine, leaving an abasic site.\" [PMID:23316050]","metadata":null},{"id":"6b30b6677d484ef4944b0771493e0948","type":"GO_TERM","name":"DNA-7-methyladenine glycosylase activity","canonical_id":"go:GO:0052821","description":"\"Catalysis of the reaction: DNA containing 7-methyladenine + H2O = DNA with abasic site + 7-methyladenine. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the damaged DNA 7-methyladenine and the deoxyribose sugar to remove the 7-methyladenine, leaving an abasic site.\" [GOC:jl, PMID:16468998]","metadata":null},{"id":"abe4457c20e7494ca801af13b9255e18","type":"GO_TERM","name":"DNA-7-methylguanine glycosylase activity","canonical_id":"go:GO:0043916","description":"\"Catalysis of the reaction: DNA containing 7-methylguanine + H2O = DNA with abasic site + 7-methylguanine. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the damaged DNA 7-methylguanine and the deoxyribose sugar to remove the 7-methylguanine, leaving an abasic site.\" [GOC:jl, PMID:16468998]","metadata":null},{"id":"c43de508b4df45b496212990983deda0","type":"GO_TERM","name":"DNA-DNA tethering activity","canonical_id":"go:GO:0106260","description":"\"Bridging together two regions of a DNA molecule.\" [PMID:29358048, PMID:30626735]","metadata":null},{"id":"c101429627dd49d69cef06faaa06eb18","type":"GO_TERM","name":"DNA-binding transcription activator activity","canonical_id":"go:GO:0001216","description":"\"A DNA-binding transcription factor activity that activates or increases transcription of specific gene sets.\" [GOC:txnOH-2018]","metadata":null},{"id":"a63fed74754a4f1bbe31703821e85e6b","type":"GO_TERM","name":"DNA-binding transcription activator activity, RNA polymerase II-specific","canonical_id":"go:GO:0001228","description":"\"A DNA-binding transcription factor activity that activates or increases transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:aruk, GOC:txnOH-2018, PMID:20737563, PMID:27145859]","metadata":null},{"id":"cc387338eed642ffb3c38dff75d89d39","type":"GO_TERM","name":"DNA-binding transcription factor activity","canonical_id":"go:GO:0003700","description":"\"A transcription regulator activity that modulates transcription of gene sets via selective and non-covalent binding to a specific double-stranded genomic DNA sequence (sometimes referred to as a motif) within a cis-regulatory region. Regulatory regions include promoters (proximal and distal) and enhancers. Genes are transcriptional units, and include bacterial operons.\" [GOC:txnOH-2018]","metadata":null},{"id":"6db1473267a04d60a0773d4c7d42506e","type":"GO_TERM","name":"DNA-binding transcription factor activity, RNA polymerase II-specific","canonical_id":"go:GO:0000981","description":"\"A DNA-binding transcription factor activity that modulates the transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:txnOH-2018]","metadata":null},{"id":"ee67b20a60524ad3a387fd6dabc0abc0","type":"GO_TERM","name":"DNA-binding transcription factor binding","canonical_id":"go:GO:0140297","description":"\"Binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription.\" [GOC:txnOH-2018]","metadata":null},{"id":"678f2a59203b411c858ed2c5cb0dcbdd","type":"GO_TERM","name":"DNA-binding transcription repressor activity","canonical_id":"go:GO:0001217","description":"\"A DNA-binding transcription factor activity that represses or decreases the transcription of specific gene sets.\" [GOC:txnOH-2018]","metadata":null},{"id":"68feb22e0ffd4420a4cebc75dd7c26de","type":"GO_TERM","name":"DNA-binding transcription repressor activity, RNA polymerase II-specific","canonical_id":"go:GO:0001227","description":"\"A DNA-binding transcription factor activity that represses or decreases the transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:txnOH-2018]","metadata":null},{"id":"7670c69776f849c781170298a84386e3","type":"GO_TERM","name":"DNA-binding transcription repressor activity, RNA polymerase III-specific","canonical_id":"go:GO:0106250","description":"\"A DNA-binding transcription factor activity that represses or decreases the transcription of specific genes sets transcribed by RNA polymerase III.\" [GOC:txnOH-2018, PMID:15590667, PMID:31833215]","metadata":null},{"id":"48dd7a200b794f07863e0f98d1e0ee89","type":"GO_TERM","name":"DNA-deoxyinosine glycosylase activity","canonical_id":"go:GO:0033958","description":"\"Catalysis of the hydrolysis of DNA and polynucleotides, releasing free hypoxanthine.\" [EC:3.2.2.15]","metadata":null},{"id":"e86bfa58481144bb856054ff04d215fe","type":"GO_TERM","name":"DNA-dependent protein kinase activity","canonical_id":"go:GO:0004677","description":"\"DNA dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein.\" [GOC:mah]","metadata":null},{"id":"b613748f96cc43a19b27c516b4475afd","type":"GO_TERM","name":"DNA-dependent protein kinase complex","canonical_id":"go:GO:0070418","description":"\"A protein complex that is involved in the repair of DNA double-strand breaks and, in mammals, V(D)J recombination events. It consists of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and the DNA end-binding heterodimer Ku.\" [GOC:mah, PMID:10854421, PMID:12235392]","metadata":null},{"id":"9fa1feb782184b39b79ade55cb6edcb5","type":"GO_TERM","name":"DNA-dependent protein kinase-DNA ligase 4 complex","canonical_id":"go:GO:0005958","description":"\"A large protein complex which is involved in the repair of DNA double-strand breaks and, in mammals, V(D)J recombination events. It consists of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), the DNA end-binding heterodimer Ku, the nuclear phosphoprotein XRCC4 or a homolog thereof, and DNA ligase IV.\" [GOC:jl, GOC:mah, PMID:10854421, PMID:12235392, PMID:17072889]","metadata":null},{"id":"aa120828b38f4f5fa895a10864fbcf41","type":"GO_TERM","name":"DNA-directed DNA polymerase activity","canonical_id":"go:GO:0003887","description":"\"Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1); DNA-template-directed extension of the 3'-end of a DNA strand by one nucleotide at a time.\" [EC:2.7.7.7, GOC:vw]","metadata":null},{"id":"a90d261ddbf64f57b8be228f052ac49b","type":"GO_TERM","name":"DNA-directed RNA polymerase activity","canonical_id":"go:GO:0003899","description":"\"Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1). Utilizes a DNA template, i.e. the catalysis of DNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time. Can initiate a chain 'de novo'.\" [EC:2.7.7.6]","metadata":null},{"id":"9aacefe2fc8d45dc9f5c220e0007fe77","type":"GO_TERM","name":"DNA-directed RNA polymerase complex","canonical_id":"go:GO:0000428","description":"\"A protein complex that possesses DNA-directed RNA polymerase activity.\" [GOC:krc]","metadata":null},{"id":"208bccfb654f4cbfa0e31614f5827f82","type":"PROTEIN","name":"DNA-directed RNA polymerase subunit beta","canonical_id":"uniprot:P9WGY7","description":null,"metadata":null},{"id":"82adc98cae25437dbc95daf2d0d49470","type":"PROTEIN","name":"DNA-directed RNA polymerase subunit beta","canonical_id":"uniprot:P0A8V2","description":null,"metadata":null},{"id":"0f766fc09216411e9cbf551bf88df495","type":"PROTEIN","name":"DNA-directed RNA polymerase subunit beta (Mycobacterium tuberculosis)","canonical_id":"uniprot:P9WGY9","description":null,"metadata":null},{"id":"66f7d946b3de4b42886096cb4f3048b9","type":"GO_TERM","name":"DNA-mediated transformation","canonical_id":"go:GO:0009294","description":"\"The direct uptake and incorporation of exogenous genetic material (DNA or RNA) into a cell from its surroundings through the cell envelope.\" [PMID:12706993, PMID:24509783, PMID:27826682]","metadata":null},{"id":"b75505105aae403fa3c7048f4048e6e0","type":"GO_TERM","name":"DNA-methyltransferase activity","canonical_id":"go:GO:0009008","description":"\"Catalysis of the transfer of a methyl group to a DNA molecule.\" [GOC:jl, ISBN:0198506732, PMID:7862522]","metadata":null},{"id":"e7d41136d9124478924afa87b90ced0d","type":"GO_TERM","name":"DNA-templated DNA replication","canonical_id":"go:GO:0006261","description":"\"A DNA replication process that uses parental DNA as a template for the DNA-dependent DNA polymerases that synthesize the new strands.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"45f1c22b3ca84178a09030262145aa38","type":"GO_TERM","name":"DNA-templated DNA replication maintenance of fidelity","canonical_id":"go:GO:0045005","description":"\"A DNA metabolic process that prevents or corrects errors to ensure that DNA is replicated accurately. Errors can be corrected either by intrinsic DNA polymerase proofreading activity or via mismatch repair.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"91cfae8542b3457295697ba2b96624c0","type":"GO_TERM","name":"DNA-templated transcription","canonical_id":"go:GO:0006351","description":"\"The synthesis of an RNA transcript from a DNA template.\" [GOC:jl, GOC:txnOH]","metadata":null},{"id":"c82cfb03d9dc4932b550833c0c0b2e10","type":"GO_TERM","name":"DNA-templated transcription elongation","canonical_id":"go:GO:0006354","description":"\"The extension of an RNA molecule after transcription initiation and promoter clearance at a DNA-dependent RNA polymerase promoter by the addition of ribonucleotides catalyzed by an RNA polymerase.\" [GOC:mah, GOC:txnOH, PMID:15020047, PMID:18280161]","metadata":null},{"id":"ea669ee2f6c64d16b10a305bf3f9aef2","type":"GO_TERM","name":"DNA-templated transcription initiation","canonical_id":"go:GO:0006352","description":"\"The initial step of transcription, consisting of the assembly of the RNA polymerase preinitiation complex (PIC) at a gene promoter, as well as the formation of the first few bonds of the RNA transcript. Transcription initiation includes abortive initiation events, which occur when the first few nucleotides are repeatedly synthesized and then released, and ends when promoter clearance takes place.\" [GOC:jid, GOC:txnOH, PMID:18280161]","metadata":null},{"id":"fb4817d3d8d64212a7551a90f2cefa43","type":"GO_TERM","name":"DNA-templated transcription open complex formation","canonical_id":"go:GO:0001112","description":"\"Any process involved in the melting of the DNA hybrid of the core promoter region within the transcriptional closed complex of an RNA polymerase preinitiation complex (PIC) to produce an open complex where the DNA duplex around the transcription initiation site is unwound to form the transcription bubble.\" [GOC:txnOH, PMID:15020047, PMID:18280161]","metadata":null},{"id":"ae547704b9fd4ec88e586256f1b7e130","type":"GO_TERM","name":"DNA-templated transcription termination","canonical_id":"go:GO:0006353","description":"\"The completion of transcription: the RNA polymerase pauses, the RNA-DNA hybrid dissociates, followed by the release of the RNA polymerase from its DNA template.\" [GOC:txnOH, PMID:15020047, PMID:18280161, PMID:30978344]","metadata":null},{"id":"4ebb29d2ea5f4dd4bc25e7f42d7a24ab","type":"GO_TERM","name":"DNA-templated transcriptional start site selection","canonical_id":"go:GO:0001173","description":"\"Any process involved in the selection of the specific location within the template strand of a DNA-dependent RNA polymerase promoter for hybridization of the cognate ribonucleotides and formation of first phosphodiester bond within the nascent transcript.\" [GOC:txnOH, PMID:16826228, PMID:18846104]","metadata":null},{"id":"eee9a0458c8a4a7bb39321afecf70cf6","type":"GO_TERM","name":"DNA-templated viral transcription","canonical_id":"go:GO:0039695","description":"\"A transcription process that uses a viral DNA as a template.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"7e812da12f4b48e892a883308cf9150c","type":"GO_TERM","name":"DNA/DNA annealing activity","canonical_id":"go:GO:1990814","description":"\"An activity that facilitates the formation of a complementary double-stranded DNA molecule.\" [PMID:22888405, PMID:25520186]","metadata":null},{"id":"144f30c6b8bc4d22b8c9da66a3ed1d8f","type":"GO_TERM","name":"DNA/RNA helicase activity","canonical_id":"go:GO:0033677","description":"\"Unwinding of a DNA/RNA duplex, i.e. a double helix in which a strand of DNA pairs with a complementary strand of RNA, driven by ATP hydrolysis.\" [GOC:mah]","metadata":null},{"id":"c6b4118ea67846ce8580f1decdfbb73a","type":"GO_TERM","name":"DNA/RNA hybrid annealing activity","canonical_id":"go:GO:0097098","description":"\"An activity that facilitates the base-pairing of single-stranded RNA to double-stranded DNA resulting in the formation of R-loops.\" [GOC:imk, PMID:21699496]","metadata":null},{"id":"0761db2928df40cc8461669c31672b35","type":"GO_TERM","name":"DNA/RNA hybrid binding","canonical_id":"go:GO:0071667","description":"\"Binding to a RNA/DNA hybrid.\" [GOC:ecd]","metadata":null},{"id":"34e9f0a4f1254f68b60a3bd98f0f4da4","type":"GENE","name":"DNA2","canonical_id":"hgnc:HGNC:2939","description":"DNA replication helicase/nuclease 2","metadata":{"aliases":["KIAA0083","DNA2L"]}},{"id":"c6ec17bd3c1c417d8da4ce47174a89e7","type":"GENE","name":"DNAAF1","canonical_id":"hgnc:HGNC:30539","description":"dynein axonemal assembly factor 1","metadata":{"aliases":["FLJ25330","ODA7","CILD13","swt","DAU1","LRRC50"]}},{"id":"1d838fb3547a49629aac570a2902cff5","type":"GENE","name":"DNAAF10","canonical_id":"hgnc:HGNC:25176","description":"dynein axonemal assembly factor 10","metadata":{"aliases":["FLJ31741","Monad","WDR92"]}},{"id":"1a89c371b617423bbe85d31cff8417b2","type":"GENE","name":"DNAAF11","canonical_id":"hgnc:HGNC:16725","description":"dynein axonemal assembly factor 11","metadata":{"aliases":["TSLRP","LRTP","CILD19","tilB","LRRC6"]}},{"id":"1201887403e64102b4487c4256d13677","type":"GENE","name":"DNAAF11P1","canonical_id":"hgnc:HGNC:51151","description":"DNAAF11 pseudogene 1","metadata":{"aliases":["LRRC6P1"]}},{"id":"508a617dbe194a9a9c6bfa9c4c1d5ce9","type":"GENE","name":"DNAAF19","canonical_id":"hgnc:HGNC:32700","description":"dynein axonemal assembly factor 19","metadata":{"aliases":["FLJ13094","FLJ34211","PR46b","CILD17","CCDC103"]}},{"id":"636e8eb777e5497ea14bb66341661667","type":"GENE","name":"DNAAF2","canonical_id":"hgnc:HGNC:20188","description":"dynein axonemal assembly factor 2","metadata":{"aliases":["FLJ10563","KTU","pf13","CILD10","C14orf104"]}},{"id":"d5da36a5a7f646d8ab733bc311aa48d9","type":"GENE","name":"DNAAF3","canonical_id":"hgnc:HGNC:30492","description":"dynein axonemal assembly factor 3","metadata":{"aliases":["FLJ40069","FLJ36139","pf22","PCD","C19orf51","CILD2"]}},{"id":"40f2608dbc9245ec996105a18dc3c4b5","type":"GENE","name":"DNAAF3-AS1","canonical_id":"hgnc:HGNC:55292","description":"DNAAF3 antisense RNA 1","metadata":null},{"id":"07389cd874464bdbaed7624196c54a6f","type":"GENE","name":"DNAAF4","canonical_id":"hgnc:HGNC:21493","description":null,"metadata":null},{"id":"147daa230ea74f9eacb6d58f2b7a849f","type":"GENE","name":"DNAAF4-CCPG1","canonical_id":"hgnc:HGNC:43019","description":"DNAAF4-CCPG1 readthrough (NMD candidate)","metadata":{"aliases":["DYX1C1-CCPG1"]}},{"id":"3ba1b19e23bf4ef2b2576acd0ab92fdc","type":"GENE","name":"DNAAF5","canonical_id":"hgnc:HGNC:26013","description":"dynein axonemal assembly factor 5","metadata":{"aliases":["FLJ20397","FLJ31671","FLJ39381","FLJ25564","CILD18","HEATR2"]}},{"id":"ee6c721b20df4d97ba8443d9a9750229","type":"GENE","name":"DNAAF6","canonical_id":"hgnc:HGNC:28570","description":"dynein axonemal assembly factor 6","metadata":{"aliases":["MGC35261","NYSAR97","TWISTER","CXorf41","PIH1D3"]}},{"id":"3aa4eb063b914926bbfa425a89d8d983","type":"GENE","name":"DNAAF8","canonical_id":"hgnc:HGNC:25081","description":"dynein axonemal assembly factor 8","metadata":{"aliases":["FLJ43261","DKFZp686H2240","Daap1","C16orf71"]}},{"id":"02ba8302c7ea40f39829a522b8864aaf","type":"GENE","name":"DNAAF9","canonical_id":"hgnc:HGNC:17721","description":"dynein axonemal assembly factor 9","metadata":{"aliases":["DKFZp434N061","C20orf194"]}},{"id":"ef7bf4f987ec4974b6afa7f379403602","type":"GENE","name":"DNAH1","canonical_id":"hgnc:HGNC:2940","description":"dynein axonemal heavy chain 1","metadata":{"aliases":["XLHSRF-1","DNAHC1","HDHC7","HL-11","HL11"]}},{"id":"1ce84b2256864665852ebc4ec65c3690","type":"GENE","name":"DNAH10","canonical_id":"hgnc:HGNC:2941","description":"dynein axonemal heavy chain 10","metadata":{"aliases":["FLJ43808"]}},{"id":"c20d10a427fd4cb0ad3499b431f55489","type":"GENE","name":"DNAH10OS","canonical_id":"hgnc:HGNC:37121","description":"dynein axonemal heavy chain 10 opposite strand","metadata":{"aliases":["FLJ45278"]}},{"id":"8ee8f33baa9543968c440690981dca06","type":"GENE","name":"DNAH11","canonical_id":"hgnc:HGNC:2942","description":"dynein axonemal heavy chain 11","metadata":{"aliases":["Dnahc11","DPL11","CILD7","DNAHC11","DNAHBL","DNHBL"]}},{"id":"fc9a911833164f29b737906896b22b98","type":"GENE","name":"DNAH12","canonical_id":"hgnc:HGNC:2943","description":"dynein axonemal heavy chain 12","metadata":{"aliases":["DLP12","Dnahc3","HL-19","hdhc3","DHC3","FLJ40427","FLJ44290","DNHD2","DNAH12L","DNAH7L"]}},{"id":"23b4436c0a9d4e8f961e50b5d92bf8bf","type":"GENE","name":"DNAH14","canonical_id":"hgnc:HGNC:2945","description":"dynein axonemal heavy chain 14","metadata":{"aliases":["Dnahc14","HL-18","HL18","DKFZp781B1548","MGC27277","C1orf67"]}},{"id":"68c4be73cf8e474c962aeaa59b6631b3","type":"GENE","name":"DNAH17","canonical_id":"hgnc:HGNC:2946","description":"dynein axonemal heavy chain 17","metadata":{"aliases":["DNEL2","FLJ40457","DNAHL1"]}},{"id":"a01f65d0402a427786bfa928c19f8433","type":"GENE","name":"DNAH17-AS1","canonical_id":"hgnc:HGNC:48594","description":"DNAH17 antisense RNA 1","metadata":null},{"id":"077bd662b8f248ec99325c423a812ff3","type":"GENE","name":"DNAH2","canonical_id":"hgnc:HGNC:2948","description":"dynein axonemal heavy chain 2","metadata":{"aliases":["KIAA1503","FLJ46675","DNHD3"]}},{"id":"74990d4665854a7e9463a0e11db018d9","type":"GENE","name":"DNAH3","canonical_id":"hgnc:HGNC:2949","description":"dynein axonemal heavy chain 3","metadata":{"aliases":["Dnahc3b","DLP3","Hsadhc3","DKFZp434N074"]}},{"id":"0a916e41397645929916d9e977b2cb4c","type":"GENE","name":"DNAH5","canonical_id":"hgnc:HGNC:2950","description":"dynein axonemal heavy chain 5","metadata":{"aliases":["Dnahc5","HL1","PCD","CILD3","KTGNR"]}},{"id":"b7c54e566ea546b0bda5e361d40834ca","type":"GENE","name":"DNAH5-AS1","canonical_id":"hgnc:HGNC:40187","description":"DNAH5 antisense RNA 1","metadata":{"aliases":["LncDNAH5"]}},{"id":"3d1b3fdbcfe44d2a85233bcd35648018","type":"GENE","name":"DNAH5-AS2","canonical_id":"hgnc:HGNC:59003","description":"DNAH5 antisense RNA 2","metadata":null},{"id":"e32f15ed2a464a59be6558a21f943787","type":"GENE","name":"DNAH6","canonical_id":"hgnc:HGNC:2951","description":"dynein axonemal heavy chain 6","metadata":{"aliases":["Dnahc6","HL-2","FLJ37357","DNHL1"]}},{"id":"88e95ba534be42f99790c5e21f4c6b39","type":"GENE","name":"DNAH7","canonical_id":"hgnc:HGNC:18661","description":"dynein axonemal heavy chain 7","metadata":{"aliases":["KIAA0944"]}},{"id":"79bd93d835b54cdeb53d422311517a80","type":"GENE","name":"DNAH8","canonical_id":"hgnc:HGNC:2952","description":"dynein axonemal heavy chain 8","metadata":{"aliases":["hdhc9"]}},{"id":"57d37305b2354f70bc7a8bec895a3d6c","type":"GENE","name":"DNAH8-AS1","canonical_id":"hgnc:HGNC:40188","description":"DNAH8 antisense RNA 1","metadata":{"aliases":["lnc-SAYSD1-1"]}},{"id":"1e6b014c75104cfdadc7dfbbfaf82448","type":"GENE","name":"DNAH8-DT","canonical_id":"hgnc:HGNC:55663","description":"DNAH8 divergent transcript","metadata":null},{"id":"509d23150ca240e6be2419e78da7b03b","type":"GENE","name":"DNAH9","canonical_id":"hgnc:HGNC:2953","description":"dynein axonemal heavy chain 9","metadata":{"aliases":["Dnahc9","KIAA0357","HL20","HL-20","DNAL1","DYH9","DNAH17L"]}},{"id":"df16791cfac04806b0a04d849f5b9e44","type":"GENE","name":"DNAI1","canonical_id":"hgnc:HGNC:2954","description":"dynein axonemal intermediate chain 1","metadata":{"aliases":["DIC1","PCD","CILD1","oda6"]}},{"id":"22a303fef16b4880b9ffddcf576ecd89","type":"GENE","name":"DNAI2","canonical_id":"hgnc:HGNC:18744","description":"dynein axonemal intermediate chain 2","metadata":{"aliases":["CILD9","DIC2","oda6"]}},{"id":"6d3a8507fdf64cce8ca3a5ad4c7ba8fc","type":"GENE","name":"DNAI3","canonical_id":"hgnc:HGNC:30711","description":"dynein axonemal intermediate chain 3","metadata":{"aliases":["DIC3","FLJ30067","NYD-SP29","WDR63"]}},{"id":"aac03b1daa9346a1a2d205bcef71a31f","type":"GENE","name":"DNAI4","canonical_id":"hgnc:HGNC:26252","description":"dynein axonemal intermediate chain 4","metadata":{"aliases":["DIC4","FLJ23129","WDR78"]}},{"id":"9f8a541189224369b8e1ce6aff098fde","type":"GENE","name":"DNAI7","canonical_id":"hgnc:HGNC:29599","description":"dynein axonemal intermediate chain 7","metadata":{"aliases":["LAS1","FLJ10921","PPP1R54","CASC1","CFAP94"]}},{"id":"46d7f56c604d40a882fc38ddca8c6fd8","type":"GENE","name":"DNAJA1","canonical_id":"hgnc:HGNC:5229","description":"DnaJ heat shock protein family (Hsp40) member A1","metadata":{"aliases":["HSPF4","hdj-2","dj-2","NEDD7","HSJ2"]}},{"id":"469a2c595bf844ed880baddd931797c7","type":"GENE","name":"DNAJA1P1","canonical_id":"hgnc:HGNC:39337","description":"DnaJ heat shock protein family (Hsp40) member A1 pseudogene 1","metadata":null},{"id":"18eaeb05e4774009a3b8a4ab02696a44","type":"GENE","name":"DNAJA1P2","canonical_id":"hgnc:HGNC:39338","description":"DnaJ heat shock protein family (Hsp40) member A1 pseudogene 2","metadata":null},{"id":"ff21ff0ee87e488eb1cc2c277191dde9","type":"GENE","name":"DNAJA1P3","canonical_id":"hgnc:HGNC:39339","description":"DnaJ heat shock protein family (Hsp40) member A1 pseudogene 3","metadata":null},{"id":"3dc5afb95fb04b6b8a1110ddeb58bf44","type":"GENE","name":"DNAJA1P4","canonical_id":"hgnc:HGNC:39340","description":"DnaJ heat shock protein family (Hsp40) member A1 pseudogene 4","metadata":null},{"id":"3c39b144c1d6428c90519d5ab015ea94","type":"GENE","name":"DNAJA1P5","canonical_id":"hgnc:HGNC:39341","description":"DnaJ heat shock protein family (Hsp40) member A1 pseudogene 5","metadata":null},{"id":"951d3426cae046d99b5df26489a5ea0f","type":"GENE","name":"DNAJA1P6","canonical_id":"hgnc:HGNC:39342","description":"DnaJ heat shock protein family (Hsp40) member A1 pseudogene 6","metadata":null},{"id":"da2e84b2ff1e4ff991851f21c95da442","type":"GENE","name":"DNAJA2","canonical_id":"hgnc:HGNC:14884","description":"DnaJ heat shock protein family (Hsp40) member A2","metadata":{"aliases":["HIRIP4","DNAJ","CPR3","DNJ3"]}},{"id":"43daab369bd54051b2c727189141deb2","type":"GENE","name":"DNAJA2-DT","canonical_id":"hgnc:HGNC:55375","description":"DNAJA2 divergent transcript","metadata":null},{"id":"6e39763628284e32a4a9720648b4cc71","type":"GENE","name":"DNAJA3","canonical_id":"hgnc:HGNC:11808","description":"DnaJ heat shock protein family (Hsp40) member A3","metadata":{"aliases":["hTid-1","Tid1-S","Tid1-L","TID1"]}},{"id":"c90c145fed2b49bf87273cf678d1c816","type":"GENE","name":"DNAJA4","canonical_id":"hgnc:HGNC:14885","description":"DnaJ heat shock protein family (Hsp40) member A4","metadata":{"aliases":["PRO1472"]}},{"id":"c63b52652f334431a96202fbd55d0796","type":"GENE","name":"DNAJA4-DT","canonical_id":"hgnc:HGNC:55412","description":"DNAJA4 divergent transcript","metadata":null},{"id":"096bcaa27bf04bdf91f6d34e333ab51c","type":"GENE","name":"DNAJB1","canonical_id":"hgnc:HGNC:5270","description":"DnaJ heat shock protein family (Hsp40) member B1","metadata":{"aliases":["Hsp40","Sis1","RSPH16B","HSPF1"]}},{"id":"d0d45ac0d7bc42bba35d66be862fe0e4","type":"GENE","name":"DNAJB11","canonical_id":"hgnc:HGNC:14889","description":"DnaJ heat shock protein family (Hsp40) member B11","metadata":{"aliases":["EDJ","HEDJ","ERdj3"]}},{"id":"4ef5ebeca5f54cefa0c67c97124f4b80","type":"GENE","name":"DNAJB12","canonical_id":"hgnc:HGNC:14891","description":"DnaJ heat shock protein family (Hsp40) member B12","metadata":{"aliases":["DJ10","FLJ20027"]}},{"id":"0ec63b6eb05d4c4aaa0cd71142b1e366","type":"GENE","name":"DNAJB12P1","canonical_id":"hgnc:HGNC:54762","description":"DNAJB12 pseudogene 1","metadata":null},{"id":"9ad22f5c6fb648f082d5a50eef6019c3","type":"GENE","name":"DNAJB13","canonical_id":"hgnc:HGNC:30718","description":"DnaJ heat shock protein family (Hsp40) member B13","metadata":{"aliases":["TSARG6","RSPH16A"]}},{"id":"88ba14a7cb1c44949f5488f37ea012a9","type":"GENE","name":"DNAJB14","canonical_id":"hgnc:HGNC:25881","description":"DnaJ heat shock protein family (Hsp40) member B14","metadata":{"aliases":["FLJ14281"]}},{"id":"6379b372beb54e6fb01158d4fc7f8b56","type":"GENE","name":"DNAJB1P1","canonical_id":"hgnc:HGNC:24988","description":"DNAJB1 pseudogene 1","metadata":{"aliases":["psiHSP40","DNAJB1P"]}},{"id":"4d2184ae12e94eb49b47c95ff76ae97c","type":"GENE","name":"DNAJB1P2","canonical_id":"hgnc:HGNC:56478","description":"DNAJB1 pseudogene 2","metadata":null},{"id":"e7d85e4114914e5abb33428af679900a","type":"GENE","name":"DNAJB2","canonical_id":"hgnc:HGNC:5228","description":"DnaJ heat shock protein family (Hsp40) member B2","metadata":{"aliases":["HSPF3","CMT2T","HSJ1"]}},{"id":"e49c9f0f61cc48e88a734e88e8107dbd","type":"GENE","name":"DNAJB3P","canonical_id":"hgnc:HGNC:32397","description":"DnaJ heat shock protein family (Hsp40) member B3, pseudogene","metadata":{"aliases":["HCG3","DNAJB3"]}},{"id":"ac9c28ab1d1d4a12a3dd660579402d14","type":"GENE","name":"DNAJB4","canonical_id":"hgnc:HGNC:14886","description":null,"metadata":null},{"id":"063a6ef35edc4ace8582734a3947ceac","type":"GENE","name":"DNAJB5","canonical_id":"hgnc:HGNC:14887","description":"DnaJ heat shock protein family (Hsp40) member B5","metadata":{"aliases":["Hsc40"]}},{"id":"3794bff4f0044ce3bf722cf329401e04","type":"GENE","name":"DNAJB5-DT","canonical_id":"hgnc:HGNC:49846","description":"DNAJB5 divergent transcript","metadata":{"aliases":["DNAJB5-AS1"]}},{"id":"bc3fa5992cbf454c88ac11905371c5a0","type":"GENE","name":"DNAJB5P1","canonical_id":"hgnc:HGNC:50449","description":"DnaJ heat shock protein family (Hsp40) member B5 pseudogene 1","metadata":null},{"id":"813b17ce57874297b7eca68ed8f2b372","type":"GENE","name":"DNAJB6","canonical_id":"hgnc:HGNC:14888","description":"DnaJ heat shock protein family (Hsp40) member B6","metadata":{"aliases":["MRJ","LGMD1D"]}},{"id":"931273891c63412eacfe90e091860b3c","type":"GENE","name":"DNAJB6P1","canonical_id":"hgnc:HGNC:54754","description":"DNAJB6 pseudogene 1","metadata":null},{"id":"f6c33b571be849b89c3217fce5cd82a8","type":"GENE","name":"DNAJB6P2","canonical_id":"hgnc:HGNC:54755","description":"DNAJB6 pseudogene 2","metadata":null},{"id":"ac1405321914478aa4dcc039c4f6b935","type":"GENE","name":"DNAJB6P3","canonical_id":"hgnc:HGNC:54756","description":"DNAJB6 pseudogene 3","metadata":null},{"id":"912ea63cc1f642ddbaa4b8860edff14b","type":"GENE","name":"DNAJB6P4","canonical_id":"hgnc:HGNC:54757","description":"DNAJB6 pseudogene 4","metadata":null},{"id":"7480f88da19241e0981e45b998216953","type":"GENE","name":"DNAJB6P5","canonical_id":"hgnc:HGNC:54758","description":"DNAJB6 pseudogene 5","metadata":null},{"id":"38a2ef9c071f4a548fc70057e7322c10","type":"GENE","name":"DNAJB6P6","canonical_id":"hgnc:HGNC:54759","description":"DNAJB6 pseudogene 6","metadata":null},{"id":"eb6f5f5c21bc4ba1870fff0c10a18048","type":"GENE","name":"DNAJB6P7","canonical_id":"hgnc:HGNC:54760","description":"DNAJB6 pseudogene 7","metadata":null},{"id":"dc314b9cd1104070b7fec84a85b2ac6f","type":"GENE","name":"DNAJB6P8","canonical_id":"hgnc:HGNC:54761","description":"DNAJB6 pseudogene 8","metadata":null},{"id":"762e0c6db6cf46a5b665f3b104f9215a","type":"GENE","name":"DNAJB7","canonical_id":"hgnc:HGNC:24986","description":"DnaJ heat shock protein family (Hsp40) member B7","metadata":{"aliases":["HSC3"]}},{"id":"a041ea2748a74dae9346508a757ff66d","type":"GENE","name":"DNAJB8","canonical_id":"hgnc:HGNC:23699","description":"DnaJ heat shock protein family (Hsp40) member B8","metadata":{"aliases":["MGC33884","CT156"]}},{"id":"630c82c929d040d8a7a1e2f1840adcde","type":"GENE","name":"DNAJB8-AS1","canonical_id":"hgnc:HGNC:41029","description":"DNAJB8 antisense RNA 1","metadata":null},{"id":"bf75135cc6b0402ebc07bb5261202f8a","type":"GENE","name":"DNAJB9","canonical_id":"hgnc:HGNC:6968","description":"DnaJ heat shock protein family (Hsp40) member B9","metadata":{"aliases":["MDG1"]}},{"id":"d49c07a2692e4e109e3667f2373c172d","type":"GENE","name":"DNAJC1","canonical_id":"hgnc:HGNC:20090","description":"DnaJ heat shock protein family (Hsp40) member C1","metadata":{"aliases":["DNAJL1","ERdj1","MTJ1"]}},{"id":"25a89554a69c4237b7577f8b8c36d478","type":"GENE","name":"DNAJC10","canonical_id":"hgnc:HGNC:24637","description":"DnaJ heat shock protein family (Hsp40) member C10","metadata":{"aliases":["ERdj5","PDIA19"]}},{"id":"84ace9f52575489887dfd7ea39567c38","type":"GENE","name":"DNAJC11","canonical_id":"hgnc:HGNC:25570","description":"DnaJ heat shock protein family (Hsp40) member C11","metadata":{"aliases":["FLJ10737"]}},{"id":"71d1c4798cdf4a67b1d24aecaf346af7","type":"GENE","name":"DNAJC12","canonical_id":"hgnc:HGNC:28908","description":null,"metadata":null},{"id":"4088bfcdb3d84aed97bba7afdbc252a0","type":"GENE","name":"DNAJC13","canonical_id":"hgnc:HGNC:30343","description":"DnaJ heat shock protein family (Hsp40) member C13","metadata":{"aliases":["RME8","KIAA0678"]}},{"id":"3fab147258b941d4b68869133901547f","type":"GENE","name":"DNAJC14","canonical_id":"hgnc:HGNC:24581","description":"DnaJ heat shock protein family (Hsp40) member C14","metadata":{"aliases":["DNAJ","DRIP78","HDJ3","LIP6","FLJ32792"]}},{"id":"7192c5568c934452a1ddcc419c0d7269","type":"GENE","name":"DNAJC15","canonical_id":"hgnc:HGNC:20325","description":"DnaJ heat shock protein family (Hsp40) member C15","metadata":{"aliases":["MCJ","DNAJD1"]}},{"id":"4f54efe6b42149f78a383cb476fa2897","type":"GENE","name":"DNAJC16","canonical_id":"hgnc:HGNC:29157","description":"DnaJ heat shock protein family (Hsp40) member C16","metadata":{"aliases":["KIAA0962"]}},{"id":"50aeb05701294d36912536693cde1ad4","type":"GENE","name":"DNAJC17","canonical_id":"hgnc:HGNC:25556","description":"DnaJ heat shock protein family (Hsp40) member C17","metadata":{"aliases":["FLJ10634"]}},{"id":"731caafbebe5461d887e60487fe56977","type":"GENE","name":"DNAJC17P1","canonical_id":"hgnc:HGNC:54782","description":"DNAJC17 pseudogene 1","metadata":null},{"id":"243e0328097348fdbde6e0810cd33f28","type":"GENE","name":"DNAJC18","canonical_id":"hgnc:HGNC:28429","description":"DnaJ heat shock protein family (Hsp40) member C18","metadata":{"aliases":["MGC29463"]}},{"id":"ed5dd77dc5ef4a14a7b5ea02638fc773","type":"GENE","name":"DNAJC18-AS1","canonical_id":"hgnc:HGNC:59151","description":"DNAJC18 antisense RNA 1","metadata":null},{"id":"1c91b2f816614be28037b267487e47a1","type":"GENE","name":"DNAJC19","canonical_id":"hgnc:HGNC:30528","description":"DnaJ heat shock protein family (Hsp40) member C19","metadata":{"aliases":["TIMM14","Tim14","Pam18"]}},{"id":"ed1318451508449eba4fa477717237e9","type":"GENE","name":"DNAJC19P1","canonical_id":"hgnc:HGNC:45064","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 1","metadata":null},{"id":"57fd0564d9f6443aaadbee0cb4654ddb","type":"GENE","name":"DNAJC19P2","canonical_id":"hgnc:HGNC:45065","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 2","metadata":null},{"id":"acc353f1882e4d1cabc6ece54ceb2abd","type":"GENE","name":"DNAJC19P3","canonical_id":"hgnc:HGNC:45066","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 3","metadata":null},{"id":"47eeb34593ad46ca95cedadb009d9c98","type":"GENE","name":"DNAJC19P4","canonical_id":"hgnc:HGNC:45067","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 4","metadata":null},{"id":"bdf7eeb094474ecaa30d2680eaa87245","type":"GENE","name":"DNAJC19P5","canonical_id":"hgnc:HGNC:45068","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 5","metadata":null},{"id":"314fde9852ee4f4eb074003c166828c3","type":"GENE","name":"DNAJC19P6","canonical_id":"hgnc:HGNC:45069","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 6","metadata":null},{"id":"e22808bb154341c8a2d7871f2fc40afb","type":"GENE","name":"DNAJC19P7","canonical_id":"hgnc:HGNC:45070","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 7","metadata":null},{"id":"ef8e0eac7b6b48c9ac1322e39d98b12e","type":"GENE","name":"DNAJC19P8","canonical_id":"hgnc:HGNC:45071","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 8","metadata":null},{"id":"624953a12cf640059a13314be6d3e525","type":"GENE","name":"DNAJC19P9","canonical_id":"hgnc:HGNC:45072","description":"DnaJ heat shock protein family (Hsp40) member C19 pseudogene 9","metadata":null},{"id":"851dd52344fa4f0cbc7190a787ec69a0","type":"GENE","name":"DNAJC2","canonical_id":"hgnc:HGNC:13192","description":"DnaJ heat shock protein family (Hsp40) member C2","metadata":{"aliases":["MPP11","MPHOSPH11","ZUO1","zuotin","ZRF1"]}},{"id":"a84c3240d5064a1eb07754e2aab3dcc0","type":"GENE","name":"DNAJC21","canonical_id":"hgnc:HGNC:27030","description":"DnaJ heat shock protein family (Hsp40) member C21","metadata":{"aliases":["GS3","DNAJA5","JJJ1"]}},{"id":"17ef1f0e4239413b855257be36556733","type":"GENE","name":"DNAJC21-AS1","canonical_id":"hgnc:HGNC:59026","description":"DNAJC21 antisense RNA 1","metadata":null},{"id":"f41d514f067447ddb6a8cc7cf8b7124c","type":"GENE","name":"DNAJC22","canonical_id":"hgnc:HGNC:25802","description":"DnaJ heat shock protein family (Hsp40) member C22","metadata":{"aliases":["wus","FLJ13236"]}},{"id":"b6e9ad4b5285443ea6db24823b2ae08c","type":"GENE","name":"DNAJC24","canonical_id":"hgnc:HGNC:26979","description":"DnaJ heat shock protein family (Hsp40) member C24","metadata":{"aliases":["JJJ3","ZCSL3","DPH4"]}},{"id":"1bcf9e412df24a62be0e3a1489f5498f","type":"GENE","name":"DNAJC25","canonical_id":"hgnc:HGNC:34187","description":"DnaJ heat shock protein family (Hsp40) member C25","metadata":{"aliases":["bA16L21.2.1"]}},{"id":"f0cd7803b7624190b0b3e8820c9cbcf1","type":"GENE","name":"DNAJC25-GNG10","canonical_id":"hgnc:HGNC:37501","description":"DNAJC25-GNG10 readthrough","metadata":null},{"id":"f7c8aa9d34ea453ab4fc4b05695b5f9d","type":"GENE","name":"DNAJC27","canonical_id":"hgnc:HGNC:30290","description":"DnaJ heat shock protein family (Hsp40) member C27","metadata":{"aliases":["RabJS","RBJ"]}},{"id":"4643f185482e4725ab3201791fa4a747","type":"GENE","name":"DNAJC27-AS1","canonical_id":"hgnc:HGNC:42943","description":"DNAJC27 antisense RNA 1","metadata":null},{"id":"8caa260aa3094ca698646567babcf132","type":"GENE","name":"DNAJC28","canonical_id":"hgnc:HGNC:1297","description":"DnaJ heat shock protein family (Hsp40) member C28","metadata":{"aliases":["C21orf78","C21orf55"]}},{"id":"86936822528a4b799d6885e9b695bbee","type":"GENE","name":"DNAJC2P1","canonical_id":"hgnc:HGNC:56928","description":"DNAJC2 pseudogene 1","metadata":null},{"id":"6cd14b1ca6804a8ba4358b233cce7fa8","type":"GENE","name":"DNAJC3","canonical_id":"hgnc:HGNC:9439","description":null,"metadata":null},{"id":"ebdc621a301c4b2fb2d3a9f6669a8f5b","type":"GENE","name":"DNAJC3-DT","canonical_id":"hgnc:HGNC:39808","description":"DNAJC3 divergent transcript","metadata":{"aliases":["DNAJC3-AS1"]}},{"id":"5dc02b63960848eeb425a6c2db2c09e9","type":"GENE","name":"DNAJC30","canonical_id":"hgnc:HGNC:16410","description":"DnaJ heat shock protein family (Hsp40) member C30","metadata":{"aliases":["WBSCR18"]}},{"id":"f08c734be2e1479995766f020d8891f2","type":"GENE","name":"DNAJC4","canonical_id":"hgnc:HGNC:5271","description":"DnaJ heat shock protein family (Hsp40) member C4","metadata":{"aliases":["MCG18","HSPF2"]}},{"id":"75fa03b716e749b2ae3ac60049e04f52","type":"GENE","name":"DNAJC5","canonical_id":"hgnc:HGNC:16235","description":"DnaJ heat shock protein family (Hsp40) member C5","metadata":{"aliases":["FLJ00118","FLJ13070","DNAJC5A","CLN4"]}},{"id":"2e1a160632184bd090dc2b94381bdaf4","type":"GENE","name":"DNAJC5B","canonical_id":"hgnc:HGNC:24138","description":"DnaJ heat shock protein family (Hsp40) member C5 beta","metadata":{"aliases":["MGC26226","CSP-beta"]}},{"id":"a8bcf43377414ee398e08dac3464923c","type":"GENE","name":"DNAJC5G","canonical_id":"hgnc:HGNC:24844","description":"DnaJ heat shock protein family (Hsp40) member C5 gamma","metadata":{"aliases":["FLJ40417","CSP-gamma"]}},{"id":"68c7fdb0cbdf4a09bea5b6fde5e22acf","type":"GENE","name":"DNAJC6","canonical_id":"hgnc:HGNC:15469","description":"DnaJ heat shock protein family (Hsp40) member C6","metadata":{"aliases":["KIAA0473","PARK19"]}},{"id":"57d9273f1f5547d1842fca5852358b77","type":"GENE","name":"DNAJC6-AS1","canonical_id":"hgnc:HGNC:58071","description":"DNAJC6 antisense RNA 1","metadata":{"aliases":["AL139294.1"]}},{"id":"f5b05ea61a764cc38a490ab4fb3e02dc","type":"GENE","name":"DNAJC7","canonical_id":"hgnc:HGNC:12392","description":"DnaJ heat shock protein family (Hsp40) member C7","metadata":{"aliases":["TPR2","TTC2"]}},{"id":"ae1e594d9d7946e58331cddf011ff44e","type":"GENE","name":"DNAJC8","canonical_id":"hgnc:HGNC:15470","description":"DnaJ heat shock protein family (Hsp40) member C8","metadata":{"aliases":["SPF31"]}},{"id":"eee0b7095fa74c8b955c63f9e5b52984","type":"GENE","name":"DNAJC8P1","canonical_id":"hgnc:HGNC:19928","description":"DNAJC8 pseudogene 1","metadata":null},{"id":"2de9d3bd73be433686b21c5428af8029","type":"GENE","name":"DNAJC8P2","canonical_id":"hgnc:HGNC:56540","description":"DNAJC8 pseudogene 2","metadata":null},{"id":"774beffd9a6f49cfbfa0773d8a5587e7","type":"GENE","name":"DNAJC8P3","canonical_id":"hgnc:HGNC:56541","description":"DNAJC8 pseudogene","metadata":null},{"id":"c1c67777c013444c880fe20ee0bb4632","type":"GENE","name":"DNAJC8P4","canonical_id":"hgnc:HGNC:56542","description":"DNAJC8 pseudogene 4","metadata":null},{"id":"ec33932ac7154b49a704f9a46fdcf084","type":"GENE","name":"DNAJC9","canonical_id":"hgnc:HGNC:19123","description":"DnaJ heat shock protein family (Hsp40) member C9","metadata":{"aliases":["JDD1","SB73"]}},{"id":"9cff0337261f4107a162802758cc371b","type":"GENE","name":"DNAJC9-AS1","canonical_id":"hgnc:HGNC:31432","description":"DNAJC9 and MRPS16 antisense RNA 1","metadata":{"aliases":["bA537A6.3","C10orf103"]}},{"id":"2727ad0ce9d640a58082e35f71a15b8b","type":"GENE","name":"DNAJC9P1","canonical_id":"hgnc:HGNC:56947","description":"DNAJC9 pseudogene 1","metadata":null},{"id":"5e50708a5ddf4b1e9e49cfcf2d8a1197","type":"GENE","name":"DNAL1","canonical_id":"hgnc:HGNC:23247","description":"dynein axonemal light chain 1","metadata":{"aliases":["MGC12435","1700010H15RiK","CILD16","C14orf168"]}},{"id":"8851247f61bd4cf4a3fa23e678fcb70a","type":"GENE","name":"DNAL4","canonical_id":"hgnc:HGNC:2955","description":"dynein axonemal light chain 4","metadata":{"aliases":["dJ327J16","PIG27"]}},{"id":"d91a3db170034e22be4e3bd2b295f3a4","type":"GENE","name":"DNALI1","canonical_id":"hgnc:HGNC:14353","description":"dynein axonemal light intermediate chain 1","metadata":{"aliases":["P28","hp28","dJ423B22.5"]}},{"id":"3a6ac7b87be3487a856b88e65846415e","type":"GENE","name":"DNASE1","canonical_id":"hgnc:HGNC:2956","description":null,"metadata":null},{"id":"f8287e73f771495ea44b398fffe67583","type":"GENE","name":"DNASE1L1","canonical_id":"hgnc:HGNC:2957","description":"deoxyribonuclease 1 like 1","metadata":{"aliases":["DNAS1L1","XIB","DNASEX","DNL1L"]}},{"id":"324caa4c7c4a42bcb852348e70422915","type":"GENE","name":"DNASE1L2","canonical_id":"hgnc:HGNC:2958","description":"deoxyribonuclease 1 like 2","metadata":{"aliases":["DNAS1L2"]}},{"id":"8797dd95dc1944a686fabc4203d18525","type":"GENE","name":"DNASE1L3","canonical_id":"hgnc:HGNC:2959","description":"deoxyribonuclease 1L3","metadata":{"aliases":["DNAS1L3","LSD","D3"]}},{"id":"078cf62ab8d84dd3ab5f2620744eb52b","type":"GENE","name":"DNASE2","canonical_id":"hgnc:HGNC:2960","description":null,"metadata":null},{"id":"306059643baf4c73b56de8487e1e78fc","type":"GENE","name":"DNASE2B","canonical_id":"hgnc:HGNC:28875","description":null,"metadata":null},{"id":"c6f7e53d8890468597ad3c034be72eb6","type":"GENE","name":"DND1","canonical_id":"hgnc:HGNC:23799","description":"DND microRNA-mediated repression inhibitor 1","metadata":{"aliases":["MGC34750","RBMS4"]}},{"id":"014f51fbf5904a4e910b214fa33f1da9","type":"GENE","name":"DND1P1","canonical_id":"hgnc:HGNC:31444","description":"DND microRNA-mediated repression inhibitor 1 pseudogene 1","metadata":null},{"id":"831c0fe86811488b9458802557a442e6","type":"GENE","name":"DND1P2","canonical_id":"hgnc:HGNC:31445","description":"DND microRNA-mediated repression inhibitor 1 pseudogene 2","metadata":null},{"id":"29a9028d94794a57b636e877a7c0c29c","type":"GENE","name":"DNER","canonical_id":"hgnc:HGNC:24456","description":"delta/notch like EGF repeat containing","metadata":{"aliases":["UNQ26","bet"]}},{"id":"3334aa4b0ba442e38abbfebeb76445ab","type":"GENE","name":"DNHD1","canonical_id":"hgnc:HGNC:26532","description":"dynein heavy chain domain 1","metadata":{"aliases":["FLJ32752","FLJ46184","FLJ35709","DKFZp686J0796","DHCD1","C11orf47","DNHD1L","CCDC35"]}},{"id":"6eab0048ac3b4aad907eba3119b9ec1d","type":"GENE","name":"DNLZ","canonical_id":"hgnc:HGNC:33879","description":"DNL-type zinc finger","metadata":{"aliases":["RP11-413M3.2","ZIM17","bA413M3.2","TIMM15","HEP","C9orf151"]}},{"id":"a1d5d498ec414870875480c445b4b359","type":"GENE","name":"DNM1","canonical_id":"hgnc:HGNC:2972","description":"dynamin 1","metadata":{"aliases":["DNM"]}},{"id":"50f2a32e2d2a40ff9f65b7ee414c28ed","type":"GENE","name":"DNM1L","canonical_id":"hgnc:HGNC:2973","description":"dynamin 1L","metadata":{"aliases":["DRP1","DVLP","HDYNIV","DYMPLE","VPS1"]}},{"id":"3877e3b79a6742b8a221752f3e598965","type":"GENE","name":"DNM1P17","canonical_id":"hgnc:HGNC:21134","description":"dynamin 1 pseudogene 17","metadata":{"aliases":["DNM1DN17@","DNM1DN17"]}},{"id":"c119a00960fd4099b5809b3fe523050b","type":"GENE","name":"DNM1P18","canonical_id":"hgnc:HGNC:21135","description":"dynamin 1 pseudogene 18","metadata":{"aliases":["DNM1DN18"]}},{"id":"7ff159bfe7cb46a197c0e11fb25c2bd4","type":"GENE","name":"DNM1P19","canonical_id":"hgnc:HGNC:21136","description":"dynamin 1 pseudogene 19","metadata":{"aliases":["DNM1DN19"]}},{"id":"16a69b4227a843968bdf809c463fedb8","type":"GENE","name":"DNM1P24","canonical_id":"hgnc:HGNC:35171","description":"dynamin 1 pseudogene 24","metadata":{"aliases":["DNM1DN15-1","DNM1DN15@"]}},{"id":"167088c976e94aa6806fdc32b27b40ce","type":"GENE","name":"DNM1P25","canonical_id":"hgnc:HGNC:35172","description":"dynamin 1 pseudogene 25","metadata":{"aliases":["DNM1DN15-3","DNM1DN15@"]}},{"id":"79b07608c4b14da8894ace6646229dac","type":"GENE","name":"DNM1P26","canonical_id":"hgnc:HGNC:35173","description":"dynamin 1 pseudogene 26","metadata":{"aliases":["DNM1DN16-1","DNM1DN16@"]}},{"id":"0e2b3390f56b4c6881ffa2095bf01e76","type":"GENE","name":"DNM1P27","canonical_id":"hgnc:HGNC:35174","description":"dynamin 1 pseudogene 27","metadata":{"aliases":["DNM1DN16-3","DNM1DN16@"]}},{"id":"d1be49aac65d4ca595866c5b8b5637ae","type":"GENE","name":"DNM1P28","canonical_id":"hgnc:HGNC:35175","description":"dynamin 1 pseudogene 28","metadata":{"aliases":["DNM1DN3-1","DNM1DN3-3","DNM1DN3@"]}},{"id":"92bcf42277ae4b03b28e07259b57fb3c","type":"GENE","name":"DNM1P29","canonical_id":"hgnc:HGNC:35176","description":"dynamin 1 pseudogene 29","metadata":{"aliases":["DNM1DN3-2","DNM1DN3@"]}},{"id":"5d59ee7812094df182944fcb8b3cc610","type":"GENE","name":"DNM1P30","canonical_id":"hgnc:HGNC:35177","description":"dynamin 1 pseudogene 30","metadata":{"aliases":["DNM1DN3-4","DNM1DN4-3","DNM1DN3@","DNM1DN4@"]}},{"id":"c743258a3d704fb6b715684383f27bbe","type":"GENE","name":"DNM1P31","canonical_id":"hgnc:HGNC:35178","description":"dynamin 1 pseudogene 31","metadata":{"aliases":["DNM1DN4-2","DNM1DN4@"]}},{"id":"e5225f24d9054f0d80b65754dc121206","type":"GENE","name":"DNM1P32","canonical_id":"hgnc:HGNC:35179","description":"dynamin 1 pseudogene 32","metadata":{"aliases":["DNM1DN4-5","DNM1DN4@"]}},{"id":"8e03a10bd0294b7fa0f88d4890421389","type":"GENE","name":"DNM1P33","canonical_id":"hgnc:HGNC:35180","description":"dynamin 1 pseudogene 33","metadata":{"aliases":["DNM1DN7-2","DNM1DN7@"]}},{"id":"18f4aadabb3544ce95de663b705c515d","type":"GENE","name":"DNM1P34","canonical_id":"hgnc:HGNC:35181","description":"dynamin 1 pseudogene 34","metadata":{"aliases":["DNM1DN8-1","DNM1DN8-5","DNM1DN8@"]}},{"id":"cb2d12bec8214131af12c2efc1158e19","type":"GENE","name":"DNM1P35","canonical_id":"hgnc:HGNC:35182","description":"dynamin 1 pseudogene 35","metadata":{"aliases":["DNM1DN8-2","DNM1DN8@"]}},{"id":"f32417e5e19741ee97a9cbdfd7396701","type":"GENE","name":"DNM1P36","canonical_id":"hgnc:HGNC:35186","description":"dynamin 1 pseudogene 36","metadata":{"aliases":["DNM1DN8-3","DNM1DN8@"]}},{"id":"87212f337a1e49dc8a553b7a78cc2d4c","type":"GENE","name":"DNM1P37","canonical_id":"hgnc:HGNC:35187","description":"dynamin 1 pseudogene 37","metadata":{"aliases":["DNM1DN10-1","DNM1DN10@"]}},{"id":"008b1414b776499fbd44b72debfe885d","type":"GENE","name":"DNM1P38","canonical_id":"hgnc:HGNC:35188","description":"dynamin 1 pseudogene 38","metadata":{"aliases":["DNM1DN10-2","DNM1DN11-8","DNM1DN10@","DNM1P42","DNM1DN11@"]}},{"id":"0f3416f370a742ff80ee53aba0401e82","type":"GENE","name":"DNM1P39","canonical_id":"hgnc:HGNC:35189","description":"dynamin 1 pseudogene 39","metadata":{"aliases":["DNM1DN11-3","DNM1DN11@"]}},{"id":"0aa76d1da7eb460e93ecdf5a1c685a0f","type":"GENE","name":"DNM1P40","canonical_id":"hgnc:HGNC:35190","description":"dynamin 1 pseudogene 40","metadata":{"aliases":["DNM1DN11-5","DNM1DN11@"]}},{"id":"4970e7193ac6443c86e6f13877ad1939","type":"GENE","name":"DNM1P41","canonical_id":"hgnc:HGNC:35191","description":"dynamin 1 pseudogene 41","metadata":{"aliases":["DNM1DN11-6","DNM1DN11@"]}},{"id":"6e5b6fe6da654652910b6990cab2eef9","type":"GENE","name":"DNM1P43","canonical_id":"hgnc:HGNC:35193","description":"dynamin 1 pseudogene 43","metadata":{"aliases":["DNM1DN11-10","DNM1DN11@"]}},{"id":"110449ca945b4ea29954d377e4a1b039","type":"GENE","name":"DNM1P44","canonical_id":"hgnc:HGNC:35194","description":"dynamin 1 pseudogene 44","metadata":{"aliases":["DNM1DN11-13","DNM1DN11@"]}},{"id":"0a899b12219c4f0fb7cfa2b1b4cb35eb","type":"GENE","name":"DNM1P45","canonical_id":"hgnc:HGNC:35195","description":"dynamin 1 pseudogene 45","metadata":{"aliases":["DNM1DN12-2","DNM1DN12@"]}},{"id":"65e6da96d32f4e7096adb2f8e7246a14","type":"GENE","name":"DNM1P46","canonical_id":"hgnc:HGNC:35199","description":"dynamin 1 pseudogene 46","metadata":{"aliases":["DNM1DN14.2","FLJ45937","DKFZp434I1020","DNM1DN14@","C15orf51"]}},{"id":"a8ff1b29467a4dd090a78da322dc3226","type":"GENE","name":"DNM1P47","canonical_id":"hgnc:HGNC:35200","description":"dynamin 1 pseudogene 47","metadata":{"aliases":["DNM1DN14-3","DNM1DN14@"]}},{"id":"4188a5f6aefa48318f224c76bc4fea9b","type":"GENE","name":"DNM1P48","canonical_id":"hgnc:HGNC:38801","description":"dynamin 1 pseudogene 48","metadata":null},{"id":"879f497e62d849afae06427e0a5e3ad2","type":"GENE","name":"DNM1P49","canonical_id":"hgnc:HGNC:47040","description":"dynamin 1 pseudogene 49","metadata":{"aliases":["DNM1DN8@"]}},{"id":"71c99ddf72a54e07a46df98f46c6672c","type":"GENE","name":"DNM1P5","canonical_id":"hgnc:HGNC:21122","description":"dynamin 1 pseudogene 5","metadata":{"aliases":["DNM1DN5@","DNM1DN5"]}},{"id":"f08bb457271d4db9af4f8e4b8ccabfa9","type":"GENE","name":"DNM1P50","canonical_id":"hgnc:HGNC:48499","description":"dynamin 1 pseudogene 50","metadata":null},{"id":"21ce43ee54cc4629baccdd53cd4427dd","type":"GENE","name":"DNM1P51","canonical_id":"hgnc:HGNC:48500","description":"dynamin 1 pseudogene 51","metadata":null},{"id":"c0e9f489fc134a79903f086aac36c7b6","type":"GENE","name":"DNM1P9","canonical_id":"hgnc:HGNC:21126","description":"dynamin 1 pseudogene 9","metadata":{"aliases":["DNM1DN9-1","DNM1DN9@","DNM1DN9"]}},{"id":"c27c783915bb4303ae2c00751f55d5b5","type":"GENE","name":"DNM2","canonical_id":"hgnc:HGNC:2974","description":"dynamin 2","metadata":{"aliases":["DYNII","DYN2","CMTDIB","CMTDI1","DI-CMTB","CMT2M"]}},{"id":"edf08ae86f4a47faaf1ea5ef0db6c781","type":"GENE","name":"DNM3","canonical_id":"hgnc:HGNC:29125","description":null,"metadata":null},{"id":"00bfed5ecace470195f05558bce87ace","type":"GENE","name":"DNM3-IT1","canonical_id":"hgnc:HGNC:41494","description":"DNM3 intronic transcript 1","metadata":null},{"id":"2854a4811d8646fea912a893bfe0b459","type":"GENE","name":"DNM3OS","canonical_id":"hgnc:HGNC:41228","description":"DNM3 opposite strand/antisense RNA","metadata":{"aliases":["MIR199A2HG","DNM3-AS1"]}},{"id":"0cd1ab2030d1437e9aaea44ddfc80fa7","type":"GENE","name":"DNMBP","canonical_id":"hgnc:HGNC:30373","description":"dynamin binding protein","metadata":{"aliases":["KIAA1010","Tuba","ARHGEF36"]}},{"id":"a59f1fcaa13c46428f49ae6c7a194c3b","type":"GENE","name":"DNMBP-AS1","canonical_id":"hgnc:HGNC:20431","description":"DNMBP antisense RNA 1","metadata":{"aliases":["FLJ40792","bA287G8.2","NCRNA00093"]}},{"id":"52499032e4b248f8aef9126745356dda","type":"GENE","name":"DNMT1","canonical_id":"hgnc:HGNC:2976","description":null,"metadata":null},{"id":"c6b379e23c4648fa8e3085e21f10952a","type":"GENE","name":"DNMT3A","canonical_id":"hgnc:HGNC:2978","description":null,"metadata":null},{"id":"93918b57bffa40b5a4a7704d5c48d582","type":"GENE","name":"DNMT3AP1","canonical_id":"hgnc:HGNC:23164","description":"DNA methyltransferase 3A pseudogene 1","metadata":null},{"id":"552acab461864d82b94673ddfbbc41d9","type":"GENE","name":"DNMT3B","canonical_id":"hgnc:HGNC:2979","description":null,"metadata":null},{"id":"e1b9348171624087b7e5fa76a0e61c71","type":"GENE","name":"DNMT3L","canonical_id":"hgnc:HGNC:2980","description":null,"metadata":null},{"id":"8690193b1a83435ea8456df2583a9515","type":"GENE","name":"DNMT3L-AS1","canonical_id":"hgnc:HGNC:40189","description":"DNMT3L antisense RNA 1","metadata":null},{"id":"e9f3f43a3ecf41fa9cda3c5e0cc097b0","type":"GENE","name":"DNPEP","canonical_id":"hgnc:HGNC:2981","description":"aspartyl aminopeptidase","metadata":{"aliases":["DAP","ASPEP"]}},{"id":"f162bc2651a247e6adcbbd3f0ab06efb","type":"GENE","name":"DNPEP-AS1","canonical_id":"hgnc:HGNC:55789","description":"DNPEP antisense RNA 1","metadata":null},{"id":"e6cffa00700c42c8b7c3b825a6302353","type":"GENE","name":"DNPH1","canonical_id":"hgnc:HGNC:21218","description":"2'-deoxynucleoside 5'-phosphate N-hydrolase 1","metadata":{"aliases":["rcl","dJ330M21.3","C6orf108"]}},{"id":"b72df9594d0d430b9bbeb880b2d7fb41","type":"GENE","name":"DNTT","canonical_id":"hgnc:HGNC:2983","description":"DNA nucleotidylexotransferase","metadata":{"aliases":["TDT","TdT"]}},{"id":"39ea94c0067d4dca97d542c4012aa10c","type":"GENE","name":"DNTTIP1","canonical_id":"hgnc:HGNC:16160","description":"deoxynucleotidyltransferase terminal interacting protein 1","metadata":{"aliases":["dJ447F3.4","Tdif1","C20orf167"]}},{"id":"6b5e5abb8b7b4b0f8eec880562da202d","type":"GENE","name":"DNTTIP2","canonical_id":"hgnc:HGNC:24013","description":"deoxynucleotidyltransferase terminal interacting protein 2","metadata":{"aliases":["HSU15552","ERBP","TdIF2"]}},{"id":"cb39a6b9c9e74372a596f60eec1823c5","type":"TRIAL","name":"DOAC - Dosing Options in AntiCoagulation Prophylaxis","canonical_id":"clinicaltrials.gov:NCT07005024","description":"Cancer; VTE (Venous Thromboembolism)","metadata":null},{"id":"9fd3df08bd0e416e879df1b4ac3fffd9","type":"TRIAL","name":"DOAC Versus VKA After Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT04002011","description":"Anticoagulant-induced Bleeding","metadata":null},{"id":"5200504082134455a656f214477f496a","type":"GENE","name":"DOC2A","canonical_id":"hgnc:HGNC:2985","description":"double C2 domain alpha","metadata":null},{"id":"fe60a89e00c44457ac133c4d61201bb0","type":"GENE","name":"DOC2B","canonical_id":"hgnc:HGNC:2986","description":"double C2 domain beta","metadata":{"aliases":["DOC2BL"]}},{"id":"1d613aec2c7c4fbcb22902641a4466aa","type":"GENE","name":"DOC2GP","canonical_id":"hgnc:HGNC:37962","description":"double C2 domain gamma, pseudogene","metadata":null},{"id":"6d57aee1d9cb44acbed0a275603c0a9a","type":"GENE","name":"DOCK1","canonical_id":"hgnc:HGNC:2987","description":null,"metadata":null},{"id":"56059a654f2747238783c3bec48481c1","type":"GENE","name":"DOCK1-AS1","canonical_id":"hgnc:HGNC:58348","description":"DOCK1 antisense RNA 1","metadata":null},{"id":"1d86e0ee20b4408990732116052473e4","type":"GENE","name":"DOCK10","canonical_id":"hgnc:HGNC:23479","description":"dedicator of cytokinesis 10","metadata":{"aliases":["ZIZ3","KIAA0694"]}},{"id":"4fa2d88ffe2b40818dfde5a6da78ac37","type":"GENE","name":"DOCK11","canonical_id":"hgnc:HGNC:23483","description":"dedicator of cytokinesis 11","metadata":{"aliases":["FLJ32122","FLJ43653","ZIZ2","ACG"]}},{"id":"925b4a12cae949d3bca027d058c252ea","type":"GENE","name":"DOCK11P1","canonical_id":"hgnc:HGNC:31719","description":"dedicator of cytokinesis 11 pseudogene 1","metadata":null},{"id":"88cc5d311b4846aca116d3577269d1c2","type":"GENE","name":"DOCK2","canonical_id":"hgnc:HGNC:2988","description":"dedicator of cytokinesis 2","metadata":{"aliases":["KIAA0209"]}},{"id":"513392b90fe7428aa9366c71e952beb5","type":"GENE","name":"DOCK2-AS1","canonical_id":"hgnc:HGNC:40190","description":"DOCK2 antisense RNA 1","metadata":null},{"id":"88c6193daa6e4c54bbd91ccdc23d4bb4","type":"GENE","name":"DOCK3","canonical_id":"hgnc:HGNC:2989","description":"dedicator of cytokinesis 3","metadata":{"aliases":["KIAA0299","MOCA","PBP"]}},{"id":"36ae98c32e7045a289ab607ac35518d9","type":"GENE","name":"DOCK4","canonical_id":"hgnc:HGNC:19192","description":"dedicator of cytokinesis 4","metadata":{"aliases":["FLJ34238","KIAA0716"]}},{"id":"983e64c8ee5d4262942adf715a5981fa","type":"GENE","name":"DOCK4-AS1","canonical_id":"hgnc:HGNC:40876","description":"DOCK4 antisense RNA 1","metadata":null},{"id":"5efd3c5a18ca4ab8a966f66b4d9f123b","type":"GENE","name":"DOCK4-AS2","canonical_id":"hgnc:HGNC:59254","description":"DOCK4 antisense RNA 2","metadata":{"aliases":["AC003077.1"]}},{"id":"f50083b630524c529aa10ed3c410683e","type":"GENE","name":"DOCK5","canonical_id":"hgnc:HGNC:23476","description":"dedicator of cytokinesis 5","metadata":{"aliases":["FLJ21034"]}},{"id":"5c02473845024244b34a13e7819d6821","type":"GENE","name":"DOCK6","canonical_id":"hgnc:HGNC:19189","description":"dedicator of cytokinesis 6","metadata":{"aliases":["KIAA1395","ZIR1"]}},{"id":"ce58f73a08414bb7a7985de21cd9ff5f","type":"GENE","name":"DOCK6-AS1","canonical_id":"hgnc:HGNC:56684","description":"DOCK6 antisense RNA 1","metadata":{"aliases":["AC011472.4"]}},{"id":"2b297fb6024c4b0c887de4dd05bbebfc","type":"GENE","name":"DOCK7","canonical_id":"hgnc:HGNC:19190","description":"dedicator of cytokinesis 7","metadata":{"aliases":["KIAA1771","ZIR2"]}},{"id":"1e5ac949f99f4619b54d86e798f4a852","type":"GENE","name":"DOCK7-DT","canonical_id":"hgnc:HGNC:55670","description":"DOCK7 divergent transcript","metadata":null},{"id":"c1f20ce787e249f5a92c57533feb4478","type":"GENE","name":"DOCK8","canonical_id":"hgnc:HGNC:19191","description":"dedicator of cytokinesis 8","metadata":{"aliases":["FLJ00026","FLJ00152","ZIR8","FLJ00346"]}},{"id":"f8918dd258d348aa8374f6ec3330b4c1","type":"GENE","name":"DOCK8-AS1","canonical_id":"hgnc:HGNC:26436","description":"DOCK8 antisense RNA 1","metadata":{"aliases":["FLJ31158","C9orf66"]}},{"id":"3d484cb6e6514740aed8569da50d08b2","type":"GENE","name":"DOCK8-AS2","canonical_id":"hgnc:HGNC:55822","description":"DOCK8 antisense RNA 2","metadata":null},{"id":"dbc3e0d9389e46aa9d7a4b228c01830e","type":"GENE","name":"DOCK9","canonical_id":"hgnc:HGNC:14132","description":"dedicator of cytokinesis 9","metadata":{"aliases":["KIAA1058","ZIZ1"]}},{"id":"7bb191a7c04e4f399bfe7cea88d78630","type":"GENE","name":"DOCK9-AS1","canonical_id":"hgnc:HGNC:40672","description":"DOCK9 antisense RNA 1","metadata":null},{"id":"1d099d8f537b421f983b92aa5cbbf8a5","type":"GENE","name":"DOCK9-DT","canonical_id":"hgnc:HGNC:43696","description":"DOCK9 divergent transcript","metadata":{"aliases":["DOCK9-AS2"]}},{"id":"b86e7e1621ed4d3aa4f1a61a208e34be","type":"GENE","name":"DOHH","canonical_id":"hgnc:HGNC:28662","description":"deoxyhypusine hydroxylase","metadata":{"aliases":["MGC4293","HLRC1"]}},{"id":"f2357752d927482cbfdd72f8e6b79467","type":"GENE","name":"DOK1","canonical_id":"hgnc:HGNC:2990","description":null,"metadata":null},{"id":"0288c96c83c34132964bc62a43b31aaa","type":"GENE","name":"DOK2","canonical_id":"hgnc:HGNC:2991","description":"docking protein 2","metadata":{"aliases":["p56dok-2","Dok-2"]}},{"id":"8bc5c45b06534b0d9d51818006b698bc","type":"GENE","name":"DOK3","canonical_id":"hgnc:HGNC:24583","description":"docking protein 3","metadata":{"aliases":["FLJ22570"]}},{"id":"75dc326227bd46219af8965d31b5abde","type":"GENE","name":"DOK4","canonical_id":"hgnc:HGNC:19868","description":"docking protein 4","metadata":{"aliases":["FLJ10488"]}},{"id":"c065d1abbc0445a890025dbe0c076402","type":"GENE","name":"DOK5","canonical_id":"hgnc:HGNC:16173","description":"docking protein 5","metadata":{"aliases":["dJ805C22.1","C20orf180"]}},{"id":"13a7cae556464691af15a7d3f64ea166","type":"GENE","name":"DOK6","canonical_id":"hgnc:HGNC:28301","description":"docking protein 6","metadata":{"aliases":["MGC20785","HsT3226","DOK5L"]}},{"id":"4600767959d040328798dd9b63fd63d1","type":"GENE","name":"DOK7","canonical_id":"hgnc:HGNC:26594","description":"docking protein 7","metadata":{"aliases":["FLJ33718","FLJ39137","Dok-7","C4orf25"]}},{"id":"a67eab5586aa42aa840723bf9a639a30","type":"GENE","name":"DOLK","canonical_id":"hgnc:HGNC:23406","description":"dolichol kinase","metadata":{"aliases":["KIAA1094","DK1","TMEM15"]}},{"id":"3c2c333de3c1406f99cf3177f22bc6a5","type":"GENE","name":"DOLPP1","canonical_id":"hgnc:HGNC:29565","description":"dolichyldiphosphatase 1","metadata":{"aliases":["LSFR2"]}},{"id":"dc668bdc5f9d416a929bafce1778913d","type":"GENE","name":"DONSON","canonical_id":"hgnc:HGNC:2993","description":"DNA replication fork stabilization factor DONSON","metadata":{"aliases":["B17","C2TA","DKFZP434M035","C21orf60"]}},{"id":"32204df62bd343ec982a31ece773ae33","type":"GENE","name":"DONSONP1","canonical_id":"hgnc:HGNC:56539","description":"DONSON pseudogene 1","metadata":null},{"id":"6735744b2c0b4c42ab1429e29d299352","type":"GENE","name":"DOP1A","canonical_id":"hgnc:HGNC:21194","description":"DOP1 leucine zipper like protein A","metadata":{"aliases":["dJ202D23.2","KIAA1117","DOPEY1"]}},{"id":"01efdcbf922c433c83ab19d7b70bd79e","type":"GENE","name":"DOP1B","canonical_id":"hgnc:HGNC:1291","description":"DOP1 leucine zipper like protein B","metadata":{"aliases":["KIAA0933","C21orf5","DOPEY2"]}},{"id":"f61e3660dffd429a9307fb4a143164ca","type":"TRIAL","name":"DORA and LP in Alzheimer's Disease Biomarkers","canonical_id":"clinicaltrials.gov:NCT06274528","description":"Alzheimer Disease","metadata":null},{"id":"77b0ffd255eb4a0fbc685a1622852360","type":"TRIAL","name":"DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension","canonical_id":"clinicaltrials.gov:NCT00389779","description":"Hypertension","metadata":null},{"id":"7a7cb256ea92412d8fec82865ae95fe0","type":"TRIAL","name":"DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension","canonical_id":"clinicaltrials.gov:NCT00389675","description":"Hypertension","metadata":null},{"id":"4e2f01f329084bb1be286b4eb84940d9","type":"GENE","name":"DORIP1","canonical_id":"hgnc:HGNC:19834","description":"dopamine receptor interacting protein 1","metadata":{"aliases":["DRIP-1","DRIP1","C14orf28"]}},{"id":"5dce630ce8ad4c25999d46bd8d570be7","type":"GENE","name":"DOT1L","canonical_id":"hgnc:HGNC:24948","description":"DOT1 like histone lysine methyltransferase","metadata":{"aliases":["KIAA1814","DOT1","KMT4"]}},{"id":"537d765f43044c2eb9a68615835b6dab","type":"GENE","name":"DOT1L-AS1","canonical_id":"hgnc:HGNC:58317","description":"DOT1L antisense RNA 1","metadata":null},{"id":"921ec452bf244633b1a319e07d85612d","type":"TRIAL","name":"DOX as a Potential Treatment for Methamphetamine Dependence","canonical_id":"clinicaltrials.gov:NCT02785393","description":"Substance-Related Disorders","metadata":null},{"id":"8c87e7d15e5641ac8e13e06fd53d630e","type":"TRIAL","name":"DOXAZOSIN FOR PTSD","canonical_id":"clinicaltrials.gov:NCT02308202","description":"PTSD","metadata":null},{"id":"0d26baa38d6c4c0da503605e2b6aed5d","type":"TRIAL","name":"DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT05728814","description":"Endometrial Cancer","metadata":null},{"id":"c9f432939bc741abbe07b53db8cc0077","type":"TRIAL","name":"DP-R213 Pharmacokinetics Study","canonical_id":"clinicaltrials.gov:NCT02762643","description":"Healthy","metadata":null},{"id":"4f3239e8b2ab47a8a36ce5bfd56d4949","type":"TRIAL","name":"DP-R213 Phase 1 Pharmacokinetics Study","canonical_id":"clinicaltrials.gov:NCT03010267","description":"Healthy","metadata":null},{"id":"a8363cc5ae1a4287aae65cab6fc1aff1","type":"GENE","name":"DPAGT1","canonical_id":"hgnc:HGNC:2995","description":"dolichyl-phosphate N-acetylglucosaminephosphotransferase 1","metadata":{"aliases":["GPT","D11S366","DGPT","ALG7","CDG-Ij","DPAGT2","DPAGT"]}},{"id":"36cc657f7275458aa20df234822ef9ac","type":"GENE","name":"DPCD","canonical_id":"hgnc:HGNC:24542","description":"deleted in primary ciliary dyskinesia homolog (mouse)","metadata":{"aliases":["DKFZP566F084","RP11-529I10.4"]}},{"id":"a6de573b0f744723b9f2de24f5aceb98","type":"GENE","name":"DPEP1","canonical_id":"hgnc:HGNC:3002","description":"dipeptidase 1","metadata":null},{"id":"813d3cd860724949abb58dc7e26b9842","type":"PROTEIN","name":"DPEP1","canonical_id":"uniprot:P16444","description":null,"metadata":null},{"id":"4d61fe00b68a4c30afcfacba0c45daed","type":"GENE","name":"DPEP2","canonical_id":"hgnc:HGNC:23028","description":"dipeptidase 2","metadata":null},{"id":"e24674d6ba2d4fec8042b5cfc69f3a66","type":"GENE","name":"DPEP2NB","canonical_id":"hgnc:HGNC:52385","description":"DPEP2 neighbor","metadata":null},{"id":"8da37f49c2eb41df91f2b6904974b768","type":"GENE","name":"DPEP3","canonical_id":"hgnc:HGNC:23029","description":"dipeptidase 3","metadata":null},{"id":"b5d8963f13db43f989e887d0bf19b88a","type":"GENE","name":"DPF1","canonical_id":"hgnc:HGNC:20225","description":"double PHD fingers 1","metadata":{"aliases":["neuro-d4","NEUD4","BAF45b","SMARCG1"]}},{"id":"1f2e680f351b4a1ba9613505e5c6213c","type":"GENE","name":"DPF2","canonical_id":"hgnc:HGNC:9964","description":"double PHD fingers 2","metadata":{"aliases":["ubi-d4","BAF45d","SMARCG2","REQ"]}},{"id":"802b74c1782f4f9ca82d80cca48b6648","type":"GENE","name":"DPF3","canonical_id":"hgnc:HGNC:17427","description":"double PHD fingers 3","metadata":{"aliases":["cer-d4","Cerd4","FLJ14079","BAF45c","SMARCG3"]}},{"id":"5f3486f64eaf4c048bffa3db96ae7fef","type":"GENE","name":"DPH1","canonical_id":"hgnc:HGNC:3003","description":"diphthamide biosynthesis 1","metadata":{"aliases":["OVCA1","DPH2L","DPH2L1"]}},{"id":"e13bc14e28be4301ae3be13d8f6669f9","type":"GENE","name":"DPH1-AS1","canonical_id":"hgnc:HGNC:56040","description":"DPH1 antisense RNA 1","metadata":{"aliases":["RP11-667K14.3"]}},{"id":"621d242f30d248f9aea9dc4315432b08","type":"GENE","name":"DPH2","canonical_id":"hgnc:HGNC:3004","description":"diphthamide biosynthesis 2","metadata":{"aliases":["DPH2L2"]}},{"id":"6a53e36e704743ccabb22298a28ee1b5","type":"GENE","name":"DPH3","canonical_id":"hgnc:HGNC:27717","description":"diphthamide biosynthesis 3","metadata":{"aliases":["DESR1","DELGIP1","MGC20197","KTI11","DELGIP","DPH3A","ZCSL2"]}},{"id":"9e6a0ede96ce463d8db91fc340fa8d97","type":"GENE","name":"DPH3P1","canonical_id":"hgnc:HGNC:16136","description":"diphthamide biosynthesis 3 pseudogene 1","metadata":{"aliases":["dJ885L7.5","C20orf143","ZCSL1","DPH3B"]}},{"id":"26052af9f7944d6ab59df282b7bbfa54","type":"GENE","name":"DPH3P2","canonical_id":"hgnc:HGNC:38719","description":"diphthamide biosynthesis 3 pseudogene 2","metadata":null},{"id":"e13450fcf9724625a81f40359a1357f9","type":"GENE","name":"DPH5","canonical_id":"hgnc:HGNC:24270","description":"diphthamide biosynthesis 5","metadata":{"aliases":["CGI-30"]}},{"id":"2ee42c52596143fc9456aa119e4018bb","type":"GENE","name":"DPH5-DT","canonical_id":"hgnc:HGNC:53720","description":"DPH5 divergent transcript","metadata":null},{"id":"25cfa872f65f48c8bdc9ccd86b9d686f","type":"GENE","name":"DPH6","canonical_id":"hgnc:HGNC:30543","description":"diphthamine biosynthesis 6","metadata":{"aliases":["MGC14798","ATPBD4"]}},{"id":"4db22e6040364297b804f986d3eeca1c","type":"GENE","name":"DPH6-DT","canonical_id":"hgnc:HGNC:44147","description":"DPH6 divergent transcript","metadata":{"aliases":["uc.382","ATPBD4-AS1","DPH6-AS1"]}},{"id":"d1b300cc10364b32ab8dd62265cb931d","type":"GENE","name":"DPH7","canonical_id":"hgnc:HGNC:25199","description":"diphthamide biosynthesis 7","metadata":{"aliases":["FLJ90634","RRT2","C9orf112","WDR85"]}},{"id":"2f0e7b96d6f54d928d08c0c96bc0578c","type":"GENE","name":"DPM1","canonical_id":"hgnc:HGNC:3005","description":"dolichyl-phosphate mannosyltransferase subunit 1, catalytic","metadata":{"aliases":["MPDS","CDGIE"]}},{"id":"48457826017b40078d163e46919229a6","type":"GENE","name":"DPM2","canonical_id":"hgnc:HGNC:3006","description":"dolichyl-phosphate mannosyltransferase subunit 2, regulatory","metadata":{"aliases":["MGC21559","MGC111193"]}},{"id":"b7c49d6c4f074b239ed100d0307dd710","type":"GENE","name":"DPM3","canonical_id":"hgnc:HGNC:3007","description":"dolichyl-phosphate mannosyltransferase subunit 3, regulatory","metadata":{"aliases":["MGC34275","MGC125904","MGC125905"]}},{"id":"b6085cb02a1b42aaa9bdaf7a581b42c4","type":"TRIAL","name":"DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT","canonical_id":"clinicaltrials.gov:NCT05847283","description":"Diminished Ovarian Reserve","metadata":null},{"id":"189283ea758e4a57b644729478ca4aed","type":"TRIAL","name":"DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01472432","description":"Chronic Foot Ulcers","metadata":null},{"id":"616599601dda4a188912c34bda7f11f1","type":"TRIAL","name":"DPP-4 Inhibition, Incretins and Islet Function","canonical_id":"clinicaltrials.gov:NCT02089438","description":"Type 2 Diabetes","metadata":null},{"id":"b6639bb8219146bc89c75183dc2a51de","type":"TRIAL","name":"DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01588587","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1b552816afc047b79a41ee9e86a66085","type":"GENE","name":"DPP10","canonical_id":"hgnc:HGNC:20823","description":"dipeptidyl peptidase like 10","metadata":{"aliases":["DPRP3","DPL2","DPPY"]}},{"id":"c249b3d6507f4ead8f30596f01c92c2f","type":"GENE","name":"DPP10-AS1","canonical_id":"hgnc:HGNC:40941","description":"DPP10 antisense RNA 1","metadata":{"aliases":["BC032913"]}},{"id":"491041714aad43658fd357d74a92763c","type":"GENE","name":"DPP10-AS2","canonical_id":"hgnc:HGNC:40940","description":"DPP10 antisense RNA 2","metadata":null},{"id":"7e74bcc83cec48c39b1c28244cb62d49","type":"GENE","name":"DPP10-AS3","canonical_id":"hgnc:HGNC:40939","description":"DPP10 antisense RNA 3","metadata":null},{"id":"5a4e2417ebcf43e2b581649c86474eee","type":"GENE","name":"DPP3","canonical_id":"hgnc:HGNC:3008","description":"dipeptidyl peptidase 3","metadata":null},{"id":"42a225f625554692b7b5fcb2f1fdf73e","type":"GENE","name":"DPP3-DT","canonical_id":"hgnc:HGNC:55494","description":"DPP3 divergent transcript","metadata":null},{"id":"f1611c68460540018dcbd8c0449f239b","type":"GENE","name":"DPP3P1","canonical_id":"hgnc:HGNC:51349","description":"DPP3 pseudogene 1","metadata":null},{"id":"6a76e87ffa884310a094a8e5721ae87a","type":"GENE","name":"DPP3P2","canonical_id":"hgnc:HGNC:51350","description":"DPP3 pseudogene 2","metadata":null},{"id":"126c109b9945421c96756c674a47fe8a","type":"GENE","name":"DPP4","canonical_id":"hgnc:HGNC:3009","description":"dipeptidyl peptidase 4","metadata":{"aliases":["DPPIV","CD26","ADCP2"]}},{"id":"aa2bcaffd7e04b51b38985be539c1b87","type":"PROTEIN","name":"DPP4","canonical_id":"uniprot:P27487","description":null,"metadata":null},{"id":"ee85cd1a05da44379b98b243710c7663","type":"TRIAL","name":"DPP4 Inhibitor on Glycemic Variability","canonical_id":"clinicaltrials.gov:NCT04654676","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"be3673f32b174d8698cf9c015b923cad","type":"GENE","name":"DPP4-DT","canonical_id":"hgnc:HGNC:40191","description":"DPP4 divergent transcript","metadata":null},{"id":"f50c6e8d3ea04e6ea5a6510b50bcf994","type":"GENE","name":"DPP6","canonical_id":"hgnc:HGNC:3010","description":"dipeptidyl peptidase like 6","metadata":{"aliases":["DPPX","DPL1"]}},{"id":"61cfe3d69e3248c29e091ebfb49d875e","type":"GENE","name":"DPP6-AS1","canonical_id":"hgnc:HGNC:40194","description":"DPP6 antisense RNA 1","metadata":null},{"id":"53781f3e4f564139a144cf47e9fe6633","type":"GENE","name":"DPP7","canonical_id":"hgnc:HGNC:14892","description":"dipeptidyl peptidase 7","metadata":{"aliases":["DPPII","DPP2"]}},{"id":"f4977e23a900489398ca6ad1c7ddd6e4","type":"GENE","name":"DPP8","canonical_id":"hgnc:HGNC:16490","description":"dipeptidyl peptidase 8","metadata":{"aliases":["DP8","DPRP1","MSTP141","FLJ14920","FLJ20283","MGC26191"]}},{"id":"5128297d75b24c89b8f4e4ff3ba729a6","type":"GENE","name":"DPP9","canonical_id":"hgnc:HGNC:18648","description":"dipeptidyl peptidase 9","metadata":null},{"id":"e68d10f103d64d5fb2cbae22e4492377","type":"GENE","name":"DPP9-AS1","canonical_id":"hgnc:HGNC:50706","description":"DPP9 antisense RNA 1","metadata":null},{"id":"508ddc85caeb4b8cae37c4e91ee368be","type":"GENE","name":"DPPA2","canonical_id":"hgnc:HGNC:19197","description":"developmental pluripotency associated 2","metadata":{"aliases":["PESCRG1","CT100"]}},{"id":"1302b3a43dfd4c448c9e0f0147ed1fb5","type":"GENE","name":"DPPA2P1","canonical_id":"hgnc:HGNC:38448","description":"developmental pluripotency associated 2 pseudogene 1","metadata":null},{"id":"12965d26062b4f0b8f22035f177f5dd8","type":"GENE","name":"DPPA2P2","canonical_id":"hgnc:HGNC:44627","description":"developmental pluripotency associated 2 pseudogene 2","metadata":null},{"id":"9edf57ff9b3d400885cb23c33996b6dc","type":"GENE","name":"DPPA2P3","canonical_id":"hgnc:HGNC:44628","description":"developmental pluripotency associated 2 pseudogene 3","metadata":null},{"id":"cdd6dbc21f4c4d9991f5037e7176b3fa","type":"GENE","name":"DPPA2P4","canonical_id":"hgnc:HGNC:44629","description":"developmental pluripotency associated 2 pseudogene 4","metadata":null},{"id":"5801e5ff151a4191bc1776f0b4a7cb95","type":"GENE","name":"DPPA3","canonical_id":"hgnc:HGNC:19199","description":"developmental pluripotency associated 3","metadata":{"aliases":["Stella","Pgc7"]}},{"id":"9dbfc9bbe2a24c99be1365f19f14ba17","type":"GENE","name":"DPPA3P1","canonical_id":"hgnc:HGNC:32345","description":"DPPA3 pseudogene 1","metadata":null},{"id":"ff95a888afae4874ab90ce509979d674","type":"GENE","name":"DPPA3P10","canonical_id":"hgnc:HGNC:56544","description":"DPPA3 pseudogene 10","metadata":null},{"id":"8f3fcf92a2e648b2ad7f234e31ff2961","type":"GENE","name":"DPPA3P11","canonical_id":"hgnc:HGNC:56545","description":"DPPA3 pseudogene 11","metadata":null},{"id":"d4ab2ba91a29482594635a3dee3c3990","type":"GENE","name":"DPPA3P12","canonical_id":"hgnc:HGNC:56543","description":"DPPA3 pseudogene 12","metadata":null},{"id":"a39fcae22f4a454596ad36d193c840df","type":"GENE","name":"DPPA3P2","canonical_id":"hgnc:HGNC:20417","description":"DPPA3 pseudogene 2","metadata":{"aliases":["STELLAR"]}},{"id":"a8a8be618457473eb57f3a1a14d03616","type":"GENE","name":"DPPA3P3","canonical_id":"hgnc:HGNC:49062","description":"DPPA3 pseudogene 3","metadata":null},{"id":"46cf139972ef4b7f86653eace8afdfee","type":"GENE","name":"DPPA3P4","canonical_id":"hgnc:HGNC:56532","description":"DPPA3 pseudogene 4","metadata":null},{"id":"60f6fb86a5754f17b3727fc5949e3fb6","type":"GENE","name":"DPPA3P5","canonical_id":"hgnc:HGNC:56533","description":"DPPA3 pseudogene 5","metadata":null},{"id":"6bda632263db4c8585953cf8c946dbc5","type":"GENE","name":"DPPA3P6","canonical_id":"hgnc:HGNC:56534","description":"DPPA3 pseudogene 6","metadata":null},{"id":"2b75e39ec84548758351dcc6b4985f53","type":"GENE","name":"DPPA3P7","canonical_id":"hgnc:HGNC:56535","description":"DPPA3 pseudogene 7","metadata":null},{"id":"9b1ae9cd60c54bb9bf126dc91ebb9128","type":"GENE","name":"DPPA3P8","canonical_id":"hgnc:HGNC:56536","description":"DPPA3 pseudogene 8","metadata":null},{"id":"d599a565728d4d8ab11db93b2d5ce20b","type":"GENE","name":"DPPA3P9","canonical_id":"hgnc:HGNC:56537","description":"DPPA3 pseudogene 9","metadata":null},{"id":"9982955999b04932bcf29d02a3f7e884","type":"GENE","name":"DPPA4","canonical_id":"hgnc:HGNC:19200","description":"developmental pluripotency associated 4","metadata":{"aliases":["FLJ10713"]}},{"id":"0667ad0311e140d4bf4e3e520ffb09d9","type":"GENE","name":"DPPA4P1","canonical_id":"hgnc:HGNC:44903","description":"developmental pluripotency associated 4 pseudogene 1","metadata":null},{"id":"7d058e59285149c4a4abac61aae39dde","type":"GENE","name":"DPPA4P2","canonical_id":"hgnc:HGNC:56530","description":"DPPA4 pseudogene 2","metadata":null},{"id":"ef8c577ab34341b1aa43e9b6d4e31e2d","type":"GENE","name":"DPPA4P3","canonical_id":"hgnc:HGNC:56531","description":"DPPA4 pseudogene 3","metadata":null},{"id":"92678edd82a142088bc65bf8f4dedec2","type":"GENE","name":"DPPA5","canonical_id":"hgnc:HGNC:19201","description":"developmental pluripotency associated 5","metadata":{"aliases":["Esg1"]}},{"id":"4e090c0d3a0148ac9a904e4f77e3e477","type":"GENE","name":"DPPA5P1","canonical_id":"hgnc:HGNC:43752","description":"developmental pluripotency associated 5 pseudogene 1","metadata":null},{"id":"e9d27ec9c75f4d518f006c9d573c3273","type":"GENE","name":"DPPA5P2","canonical_id":"hgnc:HGNC:43754","description":"developmental pluripotency associated 5 pseudogene 2","metadata":null},{"id":"4e7a93e7aa774af7915cf3a306749013","type":"GENE","name":"DPPA5P3","canonical_id":"hgnc:HGNC:44688","description":"developmental pluripotency associated 5 pseudogene 3","metadata":null},{"id":"ef4010576717417ab1a51203820ba7d6","type":"GENE","name":"DPPA5P4","canonical_id":"hgnc:HGNC:49665","description":"developmental pluripotency associated 5 pseudogene 4","metadata":null},{"id":"8ae130a96b2f4a949f3812485d588823","type":"GENE","name":"DPRX","canonical_id":"hgnc:HGNC:32166","description":"divergent-paired related homeobox","metadata":null},{"id":"57a70ede4e4c4838aa28d14f3ba4210c","type":"GENE","name":"DPRXP1","canonical_id":"hgnc:HGNC:32167","description":"divergent-paired related homeobox pseudogene 1","metadata":null},{"id":"a4aaadd0a498434b9a068f84ebbd4bdb","type":"GENE","name":"DPRXP2","canonical_id":"hgnc:HGNC:32168","description":"divergent-paired related homeobox pseudogene 2","metadata":null},{"id":"694974d1e06645c69b9f9e7429467ef8","type":"GENE","name":"DPRXP3","canonical_id":"hgnc:HGNC:32169","description":"divergent-paired related homeobox pseudogene 3","metadata":null},{"id":"696f0a755bd94047a532345fb47ad51c","type":"GENE","name":"DPRXP4","canonical_id":"hgnc:HGNC:32170","description":"divergent-paired related homeobox pseudogene 4","metadata":null},{"id":"8ae9ce6ced76477f8c3507a9480040b8","type":"GENE","name":"DPRXP5","canonical_id":"hgnc:HGNC:32171","description":"divergent-paired related homeobox pseudogene 5","metadata":null},{"id":"ce42be82be154d3a950d59d8c735d4c2","type":"GENE","name":"DPRXP6","canonical_id":"hgnc:HGNC:32172","description":"divergent-paired related homeobox pseudogene 6","metadata":null},{"id":"ebb589b892db4e9a8288bbcd6bf51d87","type":"GENE","name":"DPRXP7","canonical_id":"hgnc:HGNC:32173","description":"divergent-paired related homeobox pseudogene 7","metadata":null},{"id":"e81309a1b028432680c04b6fcb4cfb71","type":"GO_TERM","name":"DPS complex","canonical_id":"go:GO:1990567","description":"\"A protein serine/threonine phosphatase complex that in S. pombe consists of the proteins Dis2, Ppn1, and Swd22.\" [PMID:24945319]","metadata":null},{"id":"fe1f038d0b3642169e0cf0ae064ba136","type":"GENE","name":"DPT","canonical_id":"hgnc:HGNC:3011","description":"dermatopontin","metadata":null},{"id":"cfa9476c4e9c4977aa9c49727d6b18d3","type":"GENE","name":"DPY19L1","canonical_id":"hgnc:HGNC:22205","description":"dpy-19 like C-mannosyltransferase 1","metadata":{"aliases":["KIAA0877"]}},{"id":"62d77cca8c5c4b51b20996b7b4cff035","type":"GENE","name":"DPY19L1P1","canonical_id":"hgnc:HGNC:22395","description":"DPY19L1 pseudogene 1","metadata":null},{"id":"b4e81ba23cc040c08f3cd17aff7b36fb","type":"GENE","name":"DPY19L1P2","canonical_id":"hgnc:HGNC:22851","description":"DPY19L1 pseudogene 2","metadata":{"aliases":["THC1072510"]}},{"id":"6230adcdf0704e9787afac16eb0ff5f8","type":"GENE","name":"DPY19L2","canonical_id":"hgnc:HGNC:19414","description":"dpy-19 like 2","metadata":{"aliases":["FLJ32949","SPATA34"]}},{"id":"c263b299884e42ac9ee0c46c92b6cddf","type":"GENE","name":"DPY19L2P1","canonical_id":"hgnc:HGNC:22305","description":"DPY19L2 pseudogene 1","metadata":null},{"id":"33c68b5799ee44e9af2d294e0ca8b927","type":"GENE","name":"DPY19L2P2","canonical_id":"hgnc:HGNC:21764","description":"DPY19L2 pseudogene 2","metadata":{"aliases":["DKFZp434E092","FLJ36166"]}},{"id":"20c9c583c816458d9db514b7f7d6926b","type":"GENE","name":"DPY19L2P3","canonical_id":"hgnc:HGNC:22367","description":"DPY19L2 pseudogene 3","metadata":null},{"id":"1aa9e05e7f7d4a5fa8365847c1c132bb","type":"GENE","name":"DPY19L2P4","canonical_id":"hgnc:HGNC:22176","description":"DPY19L2 pseudogene 4","metadata":{"aliases":["IMAGE:5295327"]}},{"id":"7876e5dee7104ab5a451e557f69c7bb1","type":"GENE","name":"DPY19L2P5","canonical_id":"hgnc:HGNC:51620","description":"DPY19L2 pseudogene 5","metadata":null},{"id":"4f2d5d6b9a8a4ec8a1e928ab5d147fb6","type":"GENE","name":"DPY19L3","canonical_id":"hgnc:HGNC:27120","description":"dpy-19 like C-mannosyltransferase 3","metadata":null},{"id":"838f27a069654579b6e81580b37d35f7","type":"GENE","name":"DPY19L3-DT","canonical_id":"hgnc:HGNC:55307","description":"DPY19L3 divergent transcript","metadata":null},{"id":"a141755f31924c27998d237a81b2364b","type":"GENE","name":"DPY19L4","canonical_id":"hgnc:HGNC:27829","description":"dpy-19 like 4","metadata":null},{"id":"557c302ede1840bfa4d3a11a7a30d32c","type":"GENE","name":"DPY19L4P1","canonical_id":"hgnc:HGNC:53907","description":"DPY19L4 pseudogene 1","metadata":null},{"id":"6e36a4fa42d34dea8621db280df54f2d","type":"GENE","name":"DPY19L4P2","canonical_id":"hgnc:HGNC:53908","description":"DPY19L4 pseudogene 2","metadata":null},{"id":"4ba99135ab754380a33c6c18577d8aff","type":"GENE","name":"DPY30","canonical_id":"hgnc:HGNC:24590","description":"dpy-30 histone methyltransferase complex regulatory subunit","metadata":{"aliases":["Saf19","HDPY-30","Cps25"]}},{"id":"f3b766791caf40cb80102dc9aeea1f2d","type":"GENE","name":"DPYD","canonical_id":"hgnc:HGNC:3012","description":"dihydropyrimidine dehydrogenase","metadata":{"aliases":["DPD","DHPDHase"]}},{"id":"3564a3524dd841dea029e17d1cd67f3a","type":"GENE","name":"DPYD-AS1","canonical_id":"hgnc:HGNC:40195","description":"DPYD antisense RNA 1","metadata":null},{"id":"6266df595d4c409386ccba78831f666b","type":"GENE","name":"DPYD-AS2","canonical_id":"hgnc:HGNC:40196","description":"DPYD antisense RNA 2","metadata":null},{"id":"972713603e6240e1940f097a5b1be34f","type":"GENE","name":"DPYD-IT1","canonical_id":"hgnc:HGNC:41326","description":"DPYD intronic transcript 1","metadata":null},{"id":"dbdebc03b26d4da99a37da5bf4547fe8","type":"GENE","name":"DPYS","canonical_id":"hgnc:HGNC:3013","description":"dihydropyrimidinase","metadata":{"aliases":["DHPase"]}},{"id":"edfd686e875749cdb8cdb7f3696108a6","type":"GENE","name":"DPYSL2","canonical_id":"hgnc:HGNC:3014","description":null,"metadata":null},{"id":"665a622c173a46539010c60a7ff7720a","type":"GENE","name":"DPYSL3","canonical_id":"hgnc:HGNC:3015","description":"dihydropyrimidinase like 3","metadata":{"aliases":["DRP-3","ULIP","CRMP4"]}},{"id":"d15c443e14fa4a3abb1b564d93623808","type":"GENE","name":"DPYSL4","canonical_id":"hgnc:HGNC:3016","description":"dihydropyrimidinase like 4","metadata":{"aliases":["ULIP4","DRP-4","CRMP3"]}},{"id":"23eacd10a04f4813af8c1669b85d1fd0","type":"GENE","name":"DPYSL5","canonical_id":"hgnc:HGNC:20637","description":"dihydropyrimidinase like 5","metadata":{"aliases":["CRMP5","Ulip6","CRMP-5","CRAM","CV2"]}},{"id":"dd7c32b08bb744eb840e2e0cfc1740ef","type":"GENE","name":"DQX1","canonical_id":"hgnc:HGNC:20410","description":"DEAQ-box RNA dependent ATPase 1","metadata":{"aliases":["FLJ23757"]}},{"id":"9226195265794ceaa715ea3c04423941","type":"GENE","name":"DR1","canonical_id":"hgnc:HGNC:3017","description":null,"metadata":null},{"id":"cac15c821cb64f079294044f6d615376","type":"TRIAL","name":"DRACULA1 Partum Depression: an Integrated Molecular-pharmaco-imaging Study\")","canonical_id":"clinicaltrials.gov:NCT06131255","description":"Post-partum Depression","metadata":null},{"id":"3d1ccf33f31d460d9435c14b5a800738","type":"GENE","name":"DRAIC","canonical_id":"hgnc:HGNC:27082","description":"downregulated RNA in cancer, inhibitor of cell invasion and migration","metadata":null},{"id":"4f90be4b5e7c4a1a8ab4941285020645","type":"GENE","name":"DRAM1","canonical_id":"hgnc:HGNC:25645","description":null,"metadata":null},{"id":"5e95289d00054ca0becf740795656eec","type":"GENE","name":"DRAM1-AS1","canonical_id":"hgnc:HGNC:53335","description":"DRAM1 antisense RNA 1","metadata":null},{"id":"90bc5325fd1d403b9d1379b34c6a4fe9","type":"GENE","name":"DRAM2","canonical_id":"hgnc:HGNC:28769","description":"DNA damage regulated autophagy modulator 2","metadata":{"aliases":["MGC54289","PRO180","WWFQ154","RP5-1180E21.1","TMEM77"]}},{"id":"93337f427d6e4fa1a7f20a6f7b6384ac","type":"GENE","name":"DRAP1","canonical_id":"hgnc:HGNC:3019","description":null,"metadata":null},{"id":"44d3a53ca1d14b1c893294b6488fa2f0","type":"GENE","name":"DRAXIN","canonical_id":"hgnc:HGNC:25054","description":"dorsal inhibitory axon guidance protein","metadata":{"aliases":["FLJ34999","Neucrin","C1orf187"]}},{"id":"82c0874bf4c449849244887e85402024","type":"GENE","name":"DRAXINP1","canonical_id":"hgnc:HGNC:44334","description":"dorsal inhibitory axon guidance protein pseudogene 1","metadata":null},{"id":"10ff16a43ed644a8b180df231639e207","type":"GENE","name":"DRC1","canonical_id":"hgnc:HGNC:24245","description":"dynein regulatory complex subunit 1","metadata":{"aliases":["MGC16372","FLJ32660","CILD21","C2orf39","CCDC164"]}},{"id":"354aefbe66264c0e81ef7bcd8cbe02b7","type":"GENE","name":"DRC10","canonical_id":"hgnc:HGNC:25168","description":"dynein regulatory complex subunit 10","metadata":{"aliases":["DRC10","CFAP84"]}},{"id":"e45d75746e594114b42584fa264250a4","type":"GENE","name":"DRC11","canonical_id":"hgnc:HGNC:26195","description":"dynein regulatory complex subunit 11","metadata":{"aliases":["FLJ22527","IQCA"]}},{"id":"480027c7240a48ec8d3766839c78bf8b","type":"GENE","name":"DRC11L","canonical_id":"hgnc:HGNC:22831","description":"dynein regulatory complex subunit 11 like","metadata":{"aliases":["TCAG_9762","IQCA1P1","IQCA1L"]}},{"id":"565e990d86af4a52947e8004069a88ab","type":"GENE","name":"DRC12","canonical_id":"hgnc:HGNC:27446","description":"dynein regulatory complex subunit 12 homolog","metadata":{"aliases":["LOC283152","CCDC153"]}},{"id":"f631f4b3d133418cb3030a4accee6fb7","type":"GENE","name":"DRC2","canonical_id":"hgnc:HGNC:29937","description":"dynein regulatory complex subunit 2","metadata":{"aliases":["NYD-SP28","FLJ35732","FAP250","CFAP250","CILD27","DRC2","CCDC65"]}},{"id":"00d1d7c1dbe648e587758d1a7362bb68","type":"GENE","name":"DRC3","canonical_id":"hgnc:HGNC:25384","description":"dynein regulatory complex subunit 3","metadata":{"aliases":["DKFZP586M1120","CFAP134","LRRC48"]}},{"id":"c8caca38a9cc4304baa5350901143f9e","type":"GENE","name":"DRC4","canonical_id":"hgnc:HGNC:4166","description":"dynein regulatory complex subunit 4","metadata":{"aliases":["GAS11","GAS8"]}},{"id":"837eee9c5a154f058f93ce6828402b5c","type":"GENE","name":"DRC5","canonical_id":"hgnc:HGNC:11693","description":"dynein regulatory complex subunit 5","metadata":{"aliases":["D6S46","MGC33600","FAP155","TCTE1"]}},{"id":"b624aa5ca9604f89ae7b8a2f37848605","type":"GENE","name":"DRC7","canonical_id":"hgnc:HGNC:25289","description":"dynein regulatory complex subunit 7","metadata":{"aliases":["DKFZp434I099","FAP50","CFAP50","C16orf50","CCDC135"]}},{"id":"88762070df62420b8a0edf03644a703e","type":"GENE","name":"DRC8","canonical_id":"hgnc:HGNC:28166","description":"dynein regulatory complex subunit 8","metadata":{"aliases":["MGC12458","DRC8","CFAP200","EFCAB2"]}},{"id":"0cf0c4a4d7c147a88472e090784719c4","type":"GENE","name":"DRC9","canonical_id":"hgnc:HGNC:25251","description":"dynein regulatory complex subunit 9","metadata":{"aliases":["DKFZp434B227","DRC9","CFAP122","IQCG"]}},{"id":"5b8769061bb74bc8b9fc52c986222b05","type":"GENE","name":"DRD1","canonical_id":"hgnc:HGNC:3020","description":null,"metadata":null},{"id":"ce6418a2e2ad4a449dce8473089e929b","type":"GENE","name":"DRD2","canonical_id":"hgnc:HGNC:3023","description":null,"metadata":null},{"id":"e4b971a0a42946d9b05b4ba727ef4d5b","type":"PROTEIN","name":"DRD2","canonical_id":"uniprot:P14416","description":null,"metadata":null},{"id":"ab9d75b015da47f0b9e32e4602bf29e2","type":"GENE","name":"DRD3","canonical_id":"hgnc:HGNC:3024","description":"dopamine receptor D3","metadata":null},{"id":"56f057c105224e818212ffe0d10834b1","type":"PROTEIN","name":"DRD3","canonical_id":"uniprot:P35462","description":null,"metadata":null},{"id":"8bda7b0911214eb3b0ae5718aada5f4a","type":"GENE","name":"DRD4","canonical_id":"hgnc:HGNC:3025","description":"dopamine receptor D4","metadata":null},{"id":"cc553cd39c234905ae73948deab085d2","type":"GENE","name":"DRD5","canonical_id":"hgnc:HGNC:3026","description":"dopamine receptor D5","metadata":{"aliases":["DRD1B","DRD1L2"]}},{"id":"7a2fd57cf29c45cba5d61d65f938271d","type":"GENE","name":"DRD5P1","canonical_id":"hgnc:HGNC:3027","description":"DRD5 pseudogene 1","metadata":null},{"id":"b5d52385fa4046eeb6688dabe2285a7b","type":"GENE","name":"DRD5P2","canonical_id":"hgnc:HGNC:3028","description":"DRD5 pseudogene 2","metadata":null},{"id":"ecd718b315144fdfaf3d203fd6cabcc7","type":"GENE","name":"DRD5P3","canonical_id":"hgnc:HGNC:59179","description":"DRD5 pseudogene 3","metadata":null},{"id":"7275e636731644988d660da5cf459b40","type":"GENE","name":"DRD5P4","canonical_id":"hgnc:HGNC:59180","description":"DRD5 pseudogene 4","metadata":null},{"id":"ce05bbec1b0945c683d9a3a715ef09fc","type":"GENE","name":"DRG1","canonical_id":"hgnc:HGNC:3029","description":"developmentally regulated GTP binding protein 1","metadata":{"aliases":["NEDD3"]}},{"id":"7d57cdbb78fe4ac48e0f68df2c8778ef","type":"GENE","name":"DRG1P1","canonical_id":"hgnc:HGNC:54701","description":"DRG1 pseudogene 1","metadata":null},{"id":"8f16ac54060b4e7ca4655fdefdcdbec0","type":"GENE","name":"DRG1P2","canonical_id":"hgnc:HGNC:56484","description":"DRG1 pseudogene 2","metadata":null},{"id":"d6b9d0b0a428424d957b001aaef7415e","type":"GENE","name":"DRG2","canonical_id":"hgnc:HGNC:3030","description":null,"metadata":null},{"id":"3dbf34ff3e06412090e4a964f2148ff2","type":"GENE","name":"DRGX","canonical_id":"hgnc:HGNC:21536","description":"dorsal root ganglia homeobox","metadata":{"aliases":["DRG11","PRRXL1"]}},{"id":"49852d48a335470f8ab5a96fa5e0f514","type":"GENE","name":"DRICH1","canonical_id":"hgnc:HGNC:28031","description":"aspartate rich 1","metadata":{"aliases":["C22orf43"]}},{"id":"4995e2da84094f17807035519c1f8996","type":"GO_TERM","name":"DRM complex","canonical_id":"go:GO:0070176","description":"\"A transcriptional repressor complex that contains the lin-9, lin-35, lin-37, lin-52, lin-53, lin-5is involved in 4-, dpl-1 and efl-1 proteins, and is involved in cell fate specification.\" [PMID:17075059]","metadata":null},{"id":"511af718e62a4cd7abec50f0b3f35963","type":"GENE","name":"DROSHA","canonical_id":"hgnc:HGNC:17904","description":null,"metadata":null},{"id":"b59fd782388d48738d474b8447efe274","type":"TRIAL","name":"DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","canonical_id":"clinicaltrials.gov:NCT06027086","description":"Fibrolamellar Hepatocellular Carcinoma","metadata":null},{"id":"e188a4c2b1644d4884501775be999c03","type":"GENE","name":"DRP2","canonical_id":"hgnc:HGNC:3032","description":"dystrophin related protein 2","metadata":null},{"id":"eb36cbbb55e04162817091caed344b53","type":"TRIAL","name":"DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone","canonical_id":"clinicaltrials.gov:NCT04359823","description":"Actinic Porokeratosis","metadata":null},{"id":"b7e2c6d70af741f2afbc23d4acebfaa8","type":"GENE","name":"DSC1","canonical_id":"hgnc:HGNC:3035","description":"desmocollin 1","metadata":{"aliases":["CDHF1"]}},{"id":"a76d19663c524ab796a4ab034d16fe71","type":"GENE","name":"DSC2","canonical_id":"hgnc:HGNC:3036","description":null,"metadata":null},{"id":"baa147a17eb44332a0c2ba4007b91a74","type":"GENE","name":"DSC3","canonical_id":"hgnc:HGNC:3037","description":"desmocollin 3","metadata":{"aliases":["CDHF3","DSC","DSC1","DSC2","DSC4"]}},{"id":"1054efb911b74bb7a760cf1ee68d889c","type":"GENE","name":"DSCAM","canonical_id":"hgnc:HGNC:3039","description":"DS cell adhesion molecule","metadata":{"aliases":["CHD2-42","CHD2-52"]}},{"id":"5a33371bb89a4fa3b1f3aa6f121000eb","type":"GENE","name":"DSCAM-AS1","canonical_id":"hgnc:HGNC:40197","description":"DSCAM antisense RNA 1","metadata":{"aliases":["M41"]}},{"id":"2b0df98e9a9b4b5f89ca89abc83208fa","type":"GENE","name":"DSCAM-IT1","canonical_id":"hgnc:HGNC:41327","description":"DSCAM intronic transcript 1","metadata":null},{"id":"cce225446a7c49cb810112acbce723c1","type":"GENE","name":"DSCAML1","canonical_id":"hgnc:HGNC:14656","description":"DS cell adhesion molecule like 1","metadata":{"aliases":["KIAA1132"]}},{"id":"2e2440cf26284512ad350e8e7b3da401","type":"GENE","name":"DSCAS","canonical_id":"hgnc:HGNC:51116","description":"DSC1/DSC2 antisense RNA","metadata":null},{"id":"97cfe9c0026e4f14bc8a55aadde6a1e6","type":"GENE","name":"DSCC1","canonical_id":"hgnc:HGNC:24453","description":"DNA replication and sister chromatid cohesion 1","metadata":{"aliases":["DCC1","hDCC1","MGC5528"]}},{"id":"9ac0a7220f6d4d0bb202f6282ab13bcc","type":"GENE","name":"DSCR10","canonical_id":"hgnc:HGNC:16302","description":"Down syndrome critical region 10","metadata":null},{"id":"33413be11edf48ab8003a2fdb63de48a","type":"GENE","name":"DSCR4","canonical_id":"hgnc:HGNC:3045","description":"Down syndrome critical region 4","metadata":{"aliases":["DCRB"]}},{"id":"d6dd1f8f8177493fb487d76a6e24b569","type":"GENE","name":"DSCR4-IT1","canonical_id":"hgnc:HGNC:41328","description":"DSCR4 intronic transcript 1","metadata":null},{"id":"809195431ffd4f4a843a5a70f92ac0d2","type":"GENE","name":"DSCR8","canonical_id":"hgnc:HGNC:16707","description":"Down syndrome critical region 8","metadata":{"aliases":["MTAG2","CT25.1a","CT25.1b","MMA-1a","MMA-1b","C21orf65"]}},{"id":"b1739a28b5ae4c21bbad5975f2ccdebb","type":"GENE","name":"DSCR9","canonical_id":"hgnc:HGNC:16301","description":"Down syndrome critical region 9","metadata":{"aliases":["NCRNA00038"]}},{"id":"9aecceffe7cf482786b067b6111a27c2","type":"GENE","name":"DSE","canonical_id":"hgnc:HGNC:21144","description":"dermatan sulfate epimerase","metadata":{"aliases":["DSEPI","DS-Epi1","SART2"]}},{"id":"080603c16ac944be9a8875888ebce4ad","type":"GENE","name":"DSEL","canonical_id":"hgnc:HGNC:18144","description":"dermatan sulfate epimerase like","metadata":{"aliases":["NCAG1","FLJ11477","DE-epi2","C18orf4"]}},{"id":"b4407cdec6c44eb8a1b59245a14a4fce","type":"GENE","name":"DSEL-AS1","canonical_id":"hgnc:HGNC:55325","description":"DSEL antisense RNA 1","metadata":null},{"id":"72d4324b9c474307bea481555c21dcb4","type":"GENE","name":"DSG1","canonical_id":"hgnc:HGNC:3048","description":"desmoglein 1","metadata":{"aliases":["CDHF4","DSG"]}},{"id":"384a27f690c44d94b357454c8d103d5c","type":"GENE","name":"DSG1-AS1","canonical_id":"hgnc:HGNC:51115","description":"DSG1 antisense RNA 1","metadata":null},{"id":"d20d5ac10f10400d917d3648e8ab7626","type":"GENE","name":"DSG2","canonical_id":"hgnc:HGNC:3049","description":"desmoglein 2","metadata":{"aliases":["CDHF5"]}},{"id":"5764aa90ff6c492396f9f98306f0f1f4","type":"GENE","name":"DSG2-AS1","canonical_id":"hgnc:HGNC:51311","description":"DSG2 antisense RNA 1","metadata":null},{"id":"dce814c7b40d4c4c820a2ea0a2b17867","type":"GENE","name":"DSG3","canonical_id":"hgnc:HGNC:3050","description":"desmoglein 3","metadata":{"aliases":["CDHF6"]}},{"id":"db4d77db73ac49d7913c8b51e82a0815","type":"GENE","name":"DSG4","canonical_id":"hgnc:HGNC:21307","description":null,"metadata":null},{"id":"785014af748d4ab2ac87b5125a0fa81d","type":"GO_TERM","name":"DSIF complex","canonical_id":"go:GO:0032044","description":"\"A heterodimeric protein complex formed of Spt4 and Spt5 proteins which is expressed in eukaryotes from yeast to man. DSIF is an inhibitory elongation factor that promotes RNA polymerase II transcriptional pausing, but can also stimulate transcriptional elongation under certain conditions, and may play a role in RNA processing via its physical association with mRNA capping enzymes.\" [PMID:12242279, PMID:12653964, PMID:12676794, PMID:16581788, PMID:19460865]","metadata":null},{"id":"bd426f07ade84f00976254a483b1a32b","type":"GENE","name":"DSN1","canonical_id":"hgnc:HGNC:16165","description":"DSN1 component of MIS12 kinetochore complex","metadata":{"aliases":["dJ469A13.2","MIS13","KNL3","hKNL-3","C20orf172"]}},{"id":"782b5c70d8d841d488aecb3600482060","type":"GENE","name":"DSP","canonical_id":"hgnc:HGNC:3052","description":"desmoplakin","metadata":{"aliases":["KPPS2","PPKS2","DPI","DPII","DP"]}},{"id":"ca07bffd903c41ae97c234c81bb78ef8","type":"TRIAL","name":"DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07545954","description":"Small-cell Lung Cancer; Small Cell Lung Cancer Extensive Stage","metadata":null},{"id":"cf0130ffcbf9482da73c535a2336a69e","type":"GENE","name":"DSP-AS1","canonical_id":"hgnc:HGNC:56039","description":"DSP antisense RNA 1","metadata":{"aliases":["RP3-512B11.3","ABL"]}},{"id":"b1731ab58d054da9a92f4f8c43533740","type":"GENE","name":"DSPP","canonical_id":"hgnc:HGNC:3054","description":"dentin sialophosphoprotein","metadata":{"aliases":["DMP3","DFNA39","DGI1"]}},{"id":"38a201cb938848efbc42ab61cce93875","type":"GENE","name":"DST","canonical_id":"hgnc:HGNC:1090","description":null,"metadata":null},{"id":"cce5e678cc5d48bfa73886042cd7a280","type":"GENE","name":"DST-AS1","canonical_id":"hgnc:HGNC:40098","description":"DST antisense RNA 1","metadata":null},{"id":"eb9a370b37114a50bd2ed3eb459e1c68","type":"GENE","name":"DSTN","canonical_id":"hgnc:HGNC:15750","description":"destrin, actin depolymerizing factor","metadata":{"aliases":["ADF","ACTDP"]}},{"id":"3da65a8306fe40cf9d1f685b4e9fea94","type":"GENE","name":"DSTNP1","canonical_id":"hgnc:HGNC:23769","description":"DSTN pseudogene 1","metadata":null},{"id":"0be8d9844ce744abaacb6b4932ce56ef","type":"GENE","name":"DSTNP2","canonical_id":"hgnc:HGNC:34546","description":"DSTN pseudogene 2","metadata":null},{"id":"6ff5b3c2677948bbbbdae3088ee0acc9","type":"GENE","name":"DSTNP3","canonical_id":"hgnc:HGNC:34547","description":"DSTN pseudogene 3","metadata":null},{"id":"82bf391cd3e3491baad8cef4aa60a348","type":"GENE","name":"DSTNP4","canonical_id":"hgnc:HGNC:44548","description":"DSTN pseudogene 4","metadata":null},{"id":"ed3500452fcf46eda30228fee7560d7c","type":"GENE","name":"DSTNP5","canonical_id":"hgnc:HGNC:44549","description":"DSTN pseudogene 5","metadata":null},{"id":"0581a9aabc624c43b92e662912d22dc6","type":"GENE","name":"DSTYK","canonical_id":"hgnc:HGNC:29043","description":"dual serine/threonine and tyrosine protein kinase","metadata":{"aliases":["KIAA0472","DustyPK","RIP5","RIPK5","SPG23"]}},{"id":"d87356a82c644970bf34b348d1ea6da7","type":"TRIAL","name":"DTA (Dopaminergic Therapy for Anhedonia) Study","canonical_id":"clinicaltrials.gov:NCT04723147","description":"Depression; Anhedonia","metadata":null},{"id":"4ac8ac14ca2848d19044a3f84955c068","type":"GENE","name":"DTD1","canonical_id":"hgnc:HGNC:16219","description":"D-aminoacyl-tRNA deacylase 1","metadata":{"aliases":["DUEB","MGC119131","MGC41905","bA379J5.3","bA555E18.1","pqn-68","C20orf88","HARS2"]}},{"id":"e96145eca7b04f5aa7499eb835948351","type":"GENE","name":"DTD1-AS1","canonical_id":"hgnc:HGNC:40762","description":"DTD1 antisense RNA 1","metadata":null},{"id":"1d61d1b775e64d63a61d65eb464e893f","type":"GENE","name":"DTD2","canonical_id":"hgnc:HGNC:20277","description":"D-aminoacyl-tRNA deacylase 2","metadata":{"aliases":["MGC9912","C14orf126"]}},{"id":"ce8ef2ca7da74fcab5b21c1728b606df","type":"GENE","name":"DTHD1","canonical_id":"hgnc:HGNC:37261","description":"death domain containing 1","metadata":{"aliases":["FLJ16686"]}},{"id":"d2b2d7fc5c904b59809356cbb347843a","type":"GENE","name":"DTHD1-AS1","canonical_id":"hgnc:HGNC:58756","description":"DTHD1 antisense RNA 1","metadata":null},{"id":"70b4ba491dab484babfebabd8a2c54ea","type":"GENE","name":"DTL","canonical_id":"hgnc:HGNC:30288","description":"denticleless E3 ubiquitin protein ligase adapter","metadata":{"aliases":["RAMP","L2DTL","DCAF2","CDT2"]}},{"id":"cde1e9b9cea0455982321da55bb0cb33","type":"GENE","name":"DTNA","canonical_id":"hgnc:HGNC:3057","description":"dystrobrevin alpha","metadata":{"aliases":["D18S892E","DTN","DTN-1","DTN-2","DTN-3","DRP3"]}},{"id":"f1632fb53d174d0096131f4912d9a1b3","type":"GENE","name":"DTNA-AS1","canonical_id":"hgnc:HGNC:58208","description":"DTNA antisense RNA 1","metadata":null},{"id":"71ea8747a9cf41bdb3e6fb7d5322850c","type":"GENE","name":"DTNB","canonical_id":"hgnc:HGNC:3058","description":"dystrobrevin beta","metadata":null},{"id":"98462a39e33d436989454f8d380ba7bb","type":"GENE","name":"DTNB-AS1","canonical_id":"hgnc:HGNC:40198","description":"DTNB antisense RNA 1","metadata":null},{"id":"640f7637a23045edaf6b047a74b05a8d","type":"GENE","name":"DTNBP1","canonical_id":"hgnc:HGNC:17328","description":"dystrobrevin binding protein 1","metadata":{"aliases":["Dysbindin","My031","HPS7","DBND","BLOC1S8"]}},{"id":"f7f7e69e973042dda5a01c3d9411e1bd","type":"GENE","name":"DTNBP1-AS1","canonical_id":"hgnc:HGNC:58090","description":"DTNBP1 antisense RNA 1","metadata":null},{"id":"38205b12c57241fc886451bbcea290f7","type":"GENE","name":"DTNBP1-AS2","canonical_id":"hgnc:HGNC:59360","description":"DTNBP1 antisense RNA 2","metadata":null},{"id":"70312e6177f1438a86ee2c60aed8d1eb","type":"GENE","name":"DTWD1","canonical_id":"hgnc:HGNC:30926","description":"DTW motif tRNA-uridine aminocarboxypropyltransferase 1","metadata":{"aliases":["MDS009","MGC111207"]}},{"id":"5351f29b3eea4d58be6f27c634c8d006","type":"GENE","name":"DTWD1P1","canonical_id":"hgnc:HGNC:56550","description":"DTWD1 pseudogene 1","metadata":null},{"id":"888d66b28e394caeb4802f8442a9d702","type":"GENE","name":"DTWD1P2","canonical_id":"hgnc:HGNC:56551","description":"DTWD1 pseudogene 2","metadata":null},{"id":"25dc24d5198d42d1aeb6d75800513b4f","type":"GENE","name":"DTWD2","canonical_id":"hgnc:HGNC:19334","description":"DTW motif tRNA-uridine aminocarboxypropyltransferase 2","metadata":{"aliases":["FLJ33977"]}},{"id":"52b26ec111a640c78dfd09b4b5c01fa0","type":"GENE","name":"DTX1","canonical_id":"hgnc:HGNC:3060","description":"deltex E3 ubiquitin ligase 1","metadata":{"aliases":["hDx-1","RNF140"]}},{"id":"22249689afd44e3bb01dea6a4e28a218","type":"GENE","name":"DTX2","canonical_id":"hgnc:HGNC:15973","description":"deltex E3 ubiquitin ligase 2","metadata":{"aliases":["RNF58","KIAA1528"]}},{"id":"d4d1508995f0498087db09a5bd5f2630","type":"GENE","name":"DTX2P1","canonical_id":"hgnc:HGNC:42352","description":"DTX2 pseudogene 1","metadata":null},{"id":"c74639a741654b0ead7e2e91c1108714","type":"GENE","name":"DTX2P1-UPK3BP1-PMS2P11","canonical_id":"hgnc:HGNC:42360","description":"DTX2P1-UPK3BP1-PMS2P11 readthrough, transcribed pseudogene","metadata":null},{"id":"1253ca5bf3c04fa7b792aefddf058545","type":"GENE","name":"DTX3","canonical_id":"hgnc:HGNC:24457","description":"deltex E3 ubiquitin ligase 3","metadata":{"aliases":["FLJ34766","RNF154"]}},{"id":"00bae2be3fd4410b801a9bfa790b2b7e","type":"GENE","name":"DTX3L","canonical_id":"hgnc:HGNC:30323","description":"deltex E3 ubiquitin ligase 3L","metadata":{"aliases":["BBAP","RNF143"]}},{"id":"21e04ff5fe8d4448867d76b1c594e8d0","type":"GENE","name":"DTX4","canonical_id":"hgnc:HGNC:29151","description":"deltex E3 ubiquitin ligase 4","metadata":{"aliases":["KIAA0937","RNF155"]}},{"id":"7f33517f21e9410385c48a3e5b6f9eac","type":"GENE","name":"DTYMK","canonical_id":"hgnc:HGNC:3061","description":"deoxythymidylate kinase","metadata":{"aliases":["CDC8","TYMK","TMPK"]}},{"id":"e763162c6c044b4fb480fe3c26391974","type":"GENE","name":"DUBR","canonical_id":"hgnc:HGNC:48569","description":"DPPA2 upstream binding RNA","metadata":{"aliases":["LINC00883"]}},{"id":"b5af9a2638cc44eebf76da6e43609a3e","type":"GO_TERM","name":"DUBm complex","canonical_id":"go:GO:0071819","description":"\"A protein complex that forms part of SAGA-type complexes SAGA and SLIK, and mediates deubiquitination of histone H2B. In S. cerevisiae, the DUBm consists of the proteins Ubp8p, Sgf11p, Sus1p, and Sgf73p.\" [PMID:19226466, PMID:20395473]","metadata":null},{"id":"7eab3550220945239e24245e41a2f88b","type":"GENE","name":"DUOX1","canonical_id":"hgnc:HGNC:3062","description":"dual oxidase 1","metadata":{"aliases":["NOXEF1","THOX1","LNOX1"]}},{"id":"4e63694161d342fc8c87212dfbe13c0c","type":"GENE","name":"DUOX2","canonical_id":"hgnc:HGNC:13273","description":"dual oxidase 2","metadata":{"aliases":["P138-TOX","P138(TOX)","THOX2","LNOX2"]}},{"id":"bdfdd320391f466a98480a0dfbb9537f","type":"GENE","name":"DUOXA1","canonical_id":"hgnc:HGNC:26507","description":"dual oxidase maturation factor 1","metadata":{"aliases":["FLJ32334","NUMBIP","NIP","mol"]}},{"id":"676ee942c80d45fc83d7e2b4c5987f7d","type":"GENE","name":"DUOXA2","canonical_id":"hgnc:HGNC:32698","description":"dual oxidase maturation factor 2","metadata":null},{"id":"60fe9cb8877c42de9cc013628be6456b","type":"GENE","name":"DUS1L","canonical_id":"hgnc:HGNC:30086","description":"dihydrouridine synthase 1 like","metadata":{"aliases":["PP3111","DUS1"]}},{"id":"050e6bc2056647c4afc8a113bb7793b3","type":"GENE","name":"DUS2","canonical_id":"hgnc:HGNC:26014","description":"dihydrouridine synthase 2","metadata":{"aliases":["FLJ20399","SMM1","DUS2L"]}},{"id":"a1096216b5e84031ad14f589c6a6434b","type":"GENE","name":"DUS3L","canonical_id":"hgnc:HGNC:26920","description":"dihydrouridine synthase 3 like","metadata":{"aliases":["DUS3","FLJ13896"]}},{"id":"56ca3d3f203e4daca3c38fdb164c10f7","type":"GENE","name":"DUS4L","canonical_id":"hgnc:HGNC:21517","description":"dihydrouridine synthase 4 like","metadata":{"aliases":["PP35","DUS4"]}},{"id":"dab79c4fe9d04b36be83ca289088a659","type":"GENE","name":"DUS4L-BCAP29","canonical_id":"hgnc:HGNC:54422","description":"DUS4L-BCAP29 readthrough","metadata":null},{"id":"fd0999ef10e34c138b33af9fb429bfaa","type":"GENE","name":"DUSP1","canonical_id":"hgnc:HGNC:3064","description":null,"metadata":null},{"id":"40b89fb45dca4d7bb99048e445260c8f","type":"GENE","name":"DUSP1-AS1","canonical_id":"hgnc:HGNC:59305","description":"DUSP1 antisense RNA 1","metadata":null},{"id":"3a57e472fcf84c60ae8582bf6c87b426","type":"GENE","name":"DUSP10","canonical_id":"hgnc:HGNC:3065","description":null,"metadata":null},{"id":"c30dba58fc2c479a803e859c12d3be3b","type":"GENE","name":"DUSP11","canonical_id":"hgnc:HGNC:3066","description":"dual specificity phosphatase 11","metadata":{"aliases":["PIR1"]}},{"id":"c0f4e30a1a0a493facac6b9a839facb7","type":"GENE","name":"DUSP12","canonical_id":"hgnc:HGNC:3067","description":"dual specificity phosphatase 12","metadata":{"aliases":["YVH1","DUSP1"]}},{"id":"4ec703dc26fd4177927101c6cf4f7d37","type":"GENE","name":"DUSP12P1","canonical_id":"hgnc:HGNC:49059","description":"dual specificity phosphatase 12 pseudogene 1","metadata":null},{"id":"653f1d75d4c8483c822fa13f93a259a8","type":"GENE","name":"DUSP13A","canonical_id":"hgnc:HGNC:56772","description":"dual specificity phosphatase 13A","metadata":{"aliases":["MDSP","BEDP"]}},{"id":"d2ff05fd74c542639093d5d5c03e7648","type":"GENE","name":"DUSP13B","canonical_id":"hgnc:HGNC:19681","description":"dual specificity phosphatase 13B","metadata":{"aliases":["TMDP","SKRP4","DUSP13"]}},{"id":"e27c3924fca64e04a7ebd88a8f37bb37","type":"GENE","name":"DUSP14","canonical_id":"hgnc:HGNC:17007","description":"dual specificity phosphatase 14","metadata":{"aliases":["MKP-L","MKP6"]}},{"id":"0271d13161e14671942ef0e129ce8324","type":"GENE","name":"DUSP15","canonical_id":"hgnc:HGNC:16236","description":"dual specificity phosphatase 15","metadata":{"aliases":["bA243J16.6","VHY","FLJ20645","bA243J16.5","C20orf57"]}},{"id":"944b69b8288f42858791872942487b20","type":"GENE","name":"DUSP16","canonical_id":"hgnc:HGNC:17909","description":"dual specificity phosphatase 16","metadata":{"aliases":["MKP-7","KIAA1700","MKP7"]}},{"id":"581bf2729f3346bfbd3e7f036270376f","type":"GENE","name":"DUSP18","canonical_id":"hgnc:HGNC:18484","description":"dual specificity phosphatase 18","metadata":{"aliases":["DUSP20"]}},{"id":"a00e500709f844baa97ab75bb346318b","type":"GENE","name":"DUSP19","canonical_id":"hgnc:HGNC:18894","description":"dual specificity phosphatase 19","metadata":{"aliases":["SKRP1","DUSP17"]}},{"id":"19226cd1e7fa4962b06f9582aece81d3","type":"GENE","name":"DUSP2","canonical_id":"hgnc:HGNC:3068","description":"dual specificity phosphatase 2","metadata":{"aliases":["PAC-1"]}},{"id":"4dba58aa5d8e45648338fffe00594a47","type":"GENE","name":"DUSP21","canonical_id":"hgnc:HGNC:20476","description":"dual specificity phosphatase 21","metadata":null},{"id":"9461dba5f4ee4d40aa39036446a8e60f","type":"GENE","name":"DUSP22","canonical_id":"hgnc:HGNC:16077","description":"dual specificity phosphatase 22","metadata":{"aliases":["MKPX","JSP1","JKAP","VHX"]}},{"id":"5c3e7b6043524d05a0a0216db45b990f","type":"GENE","name":"DUSP22-AS1","canonical_id":"hgnc:HGNC:59323","description":"DUSP22 antisense RNA 1","metadata":null},{"id":"eb86bb46973c4054a22e5017a2c1352b","type":"GENE","name":"DUSP23","canonical_id":"hgnc:HGNC:21480","description":"dual specificity phosphatase 23","metadata":{"aliases":["FLJ20442","DUSP25"]}},{"id":"caaecc11cb06451ba6d16fc13891c066","type":"GENE","name":"DUSP26","canonical_id":"hgnc:HGNC:28161","description":"dual specificity phosphatase 26","metadata":{"aliases":["MGC1136","DUSP24","NEAP"]}},{"id":"b34c8194af6a420bb32508c297acc18d","type":"GENE","name":"DUSP28","canonical_id":"hgnc:HGNC:33237","description":"dual specificity phosphatase 28","metadata":{"aliases":["VHP","DUSP26"]}},{"id":"a79b7a46e7da4f74b07d30772e64779b","type":"GENE","name":"DUSP29","canonical_id":"hgnc:HGNC:23481","description":"dual specificity phosphatase 29","metadata":{"aliases":["DUSP27","DUPD1"]}},{"id":"9d278f71511b48c9bbbcd9820ab11c05","type":"GENE","name":"DUSP3","canonical_id":"hgnc:HGNC:3069","description":"dual specificity phosphatase 3","metadata":{"aliases":["VHR"]}},{"id":"9036edd8855344e1a899f30d08974406","type":"GENE","name":"DUSP4","canonical_id":"hgnc:HGNC:3070","description":null,"metadata":null},{"id":"d836b0fa85174454af8409a5888e38be","type":"GENE","name":"DUSP5","canonical_id":"hgnc:HGNC:3071","description":"dual specificity phosphatase 5","metadata":{"aliases":["HVH3"]}},{"id":"cc196bbbabf140caab4e964c1e9fac43","type":"GENE","name":"DUSP5-DT","canonical_id":"hgnc:HGNC:55154","description":"DUSP5 divergent transcript","metadata":null},{"id":"90cbdfcfe4c24129bb9992c3002756d7","type":"GENE","name":"DUSP5P1","canonical_id":"hgnc:HGNC:32020","description":"dual specificity phosphatase 5 pseudogene 1","metadata":{"aliases":["FLJ34941","DUSP5P"]}},{"id":"1fd8cd43bd1247038d3d14c5bd9cdba4","type":"GENE","name":"DUSP5P2","canonical_id":"hgnc:HGNC:44482","description":"dual specificity phosphatase 5 pseudogene 2","metadata":null},{"id":"8e0159e8b15a47d68a7070c8e948310b","type":"GENE","name":"DUSP6","canonical_id":"hgnc:HGNC:3072","description":null,"metadata":null},{"id":"aa307ec5d03b4822a352598a3e3cac79","type":"GENE","name":"DUSP7","canonical_id":"hgnc:HGNC:3073","description":"dual specificity phosphatase 7","metadata":{"aliases":["MKP-X","PYST2"]}},{"id":"273857df3d9e4f2c82e5576deada1d21","type":"GENE","name":"DUSP8","canonical_id":"hgnc:HGNC:3074","description":"dual specificity phosphatase 8","metadata":{"aliases":["HVH-5","HB5","FLJ42958","C11orf81"]}},{"id":"ea1c7a8011ea44609bbe52ccfbf83c22","type":"GENE","name":"DUSP8P1","canonical_id":"hgnc:HGNC:3075","description":"dual specificity phosphatase 8 pseudogene 1","metadata":{"aliases":["HVH4","DUSP8P","DUSP8P3","DUSPP"]}},{"id":"3c300cd63c6843d785271a21da428a19","type":"GENE","name":"DUSP8P2","canonical_id":"hgnc:HGNC:45001","description":"dual specificity phosphatase 8 pseudogene 2","metadata":{"aliases":["DUSP8P4"]}},{"id":"fa6117a7654443ca83bab1e25dc750cb","type":"GENE","name":"DUSP8P5","canonical_id":"hgnc:HGNC:45003","description":"dual specificity phosphatase 8 pseudogene 5","metadata":null},{"id":"41e158581605456f99bbb4405331e3ae","type":"GENE","name":"DUSP9","canonical_id":"hgnc:HGNC:3076","description":"dual specificity phosphatase 9","metadata":{"aliases":["MKP-4","MKP4"]}},{"id":"aa0bbe47c85546858e00758e36c438d9","type":"GENE","name":"DUT","canonical_id":"hgnc:HGNC:3078","description":"deoxyuridine triphosphatase","metadata":{"aliases":["dUTPase"]}},{"id":"e2096ed0a49f406c930ab26713876107","type":"GENE","name":"DUT-AS1","canonical_id":"hgnc:HGNC:55420","description":"DUT antisense RNA 1","metadata":null},{"id":"35b62551136942988a1b57c84db40cba","type":"GENE","name":"DUTP1","canonical_id":"hgnc:HGNC:31956","description":"deoxyuridine triphosphatase pseudogene 1","metadata":{"aliases":["DUTL"]}},{"id":"433e9d0ed6414438aa59b78032c2beb2","type":"GENE","name":"DUTP2","canonical_id":"hgnc:HGNC:39515","description":"deoxyuridine triphosphatase pseudogene 2","metadata":null},{"id":"6efd9ae9e4254e74bacd07af6223230a","type":"GENE","name":"DUTP3","canonical_id":"hgnc:HGNC:39516","description":"deoxyuridine triphosphatase pseudogene 3","metadata":null},{"id":"1094acde104b4e628ac28b07613926e7","type":"GENE","name":"DUTP4","canonical_id":"hgnc:HGNC:39517","description":"deoxyuridine triphosphatase pseudogene 4","metadata":null},{"id":"e814584c2ba1489f9fb811e9e9043978","type":"GENE","name":"DUTP5","canonical_id":"hgnc:HGNC:39518","description":"deoxyuridine triphosphatase pseudogene 5","metadata":null},{"id":"0217d987abf44a808eeb607e409f0d37","type":"GENE","name":"DUTP6","canonical_id":"hgnc:HGNC:39519","description":"deoxyuridine triphosphatase pseudogene 6","metadata":null},{"id":"5644494877904f60a345212d2bee2913","type":"GENE","name":"DUTP7","canonical_id":"hgnc:HGNC:39520","description":"deoxyuridine triphosphatase pseudogene 7","metadata":null},{"id":"6437d470bda24959bb80b3f8498de71b","type":"GENE","name":"DUTP8","canonical_id":"hgnc:HGNC:39521","description":"deoxyuridine triphosphatase pseudogene 8","metadata":null},{"id":"e55dddd85eff416199a0472046c9f0c3","type":"GENE","name":"DUX1","canonical_id":"hgnc:HGNC:3079","description":"double homeobox 1","metadata":null},{"id":"1586eb3200d346e99328baada879c7c6","type":"GENE","name":"DUX3","canonical_id":"hgnc:HGNC:3081","description":"double homeobox 3","metadata":null},{"id":"71556c2d55364876923a6090cde1f7c1","type":"GENE","name":"DUX4","canonical_id":"hgnc:HGNC:50800","description":null,"metadata":null},{"id":"33bbe01b65b54635992d98e44637e3ce","type":"GENE","name":"DUX4L1","canonical_id":"hgnc:HGNC:3082","description":"double homeobox 4 like 1 (pseudogene)","metadata":{"aliases":["DUX4"]}},{"id":"d2b20d813e0247d495969e672d4f782a","type":"GENE","name":"DUX4L10","canonical_id":"hgnc:HGNC:31354","description":"double homeobox 4 like 10 (pseudogene)","metadata":{"aliases":["DUX10"]}},{"id":"8528da1f09954c488f943ee963a76efc","type":"GENE","name":"DUX4L11","canonical_id":"hgnc:HGNC:38687","description":"double homeobox 4 like 11 (pseudogene)","metadata":null},{"id":"808d9ef4057341df82f69005ce16ff4c","type":"GENE","name":"DUX4L12","canonical_id":"hgnc:HGNC:38671","description":"double homeobox 4 like 12 (pseudogene)","metadata":null},{"id":"f37d04a614a1450f87eb75117e8bf6c7","type":"GENE","name":"DUX4L13","canonical_id":"hgnc:HGNC:38672","description":"double homeobox 4 like 13 (pseudogene)","metadata":null},{"id":"83916667311042c982c6738f955b2272","type":"GENE","name":"DUX4L14","canonical_id":"hgnc:HGNC:38673","description":"double homeobox 4 like 14 (pseudogene)","metadata":null},{"id":"a136a2a4004240978904004a23ccdcbe","type":"GENE","name":"DUX4L15","canonical_id":"hgnc:HGNC:38674","description":"double homeobox 4 like 15 (pseudogene)","metadata":null},{"id":"551c26a22b7a475cb8d243af06a6fa18","type":"GENE","name":"DUX4L16","canonical_id":"hgnc:HGNC:37719","description":"double homeobox 4 like 16 (pseudogene)","metadata":{"aliases":["DUXY1"]}},{"id":"2e3c9148bb654464955c52a97a8a5e36","type":"GENE","name":"DUX4L17","canonical_id":"hgnc:HGNC:37717","description":"double homeobox 4 like 17 (pseudogene)","metadata":{"aliases":["DUXY3"]}},{"id":"0b6460f688e3409c97f0340de4a54f54","type":"GENE","name":"DUX4L18","canonical_id":"hgnc:HGNC:37716","description":"double homeobox 4 like 18 (pseudogene)","metadata":{"aliases":["DUXY2"]}},{"id":"94286509203745589608e6f5267c0589","type":"GENE","name":"DUX4L19","canonical_id":"hgnc:HGNC:37718","description":"double homeobox 4 like 19 (pseudogene)","metadata":{"aliases":["DUXY4"]}},{"id":"8d1b986e0838470f93536bb87223a9bc","type":"GENE","name":"DUX4L2","canonical_id":"hgnc:HGNC:37267","description":"double homeobox 4 like 2 (pseudogene)","metadata":null},{"id":"683ca751522d49f3bd2c8cc057de03d6","type":"GENE","name":"DUX4L20","canonical_id":"hgnc:HGNC:50801","description":"double homeobox 4 like 20 (pseudogene)","metadata":null},{"id":"e7bd5a3ec95346be8c80cbc51e3f73b8","type":"GENE","name":"DUX4L21","canonical_id":"hgnc:HGNC:50802","description":"double homeobox 4 like 21 (pseudogene)","metadata":null},{"id":"4152acb46e2e4e63a85ded56e40dd748","type":"GENE","name":"DUX4L22","canonical_id":"hgnc:HGNC:50803","description":"double homeobox 4 like 22 (pseudogene)","metadata":null},{"id":"167bd0c4e2b14198b00c9eed291d820f","type":"GENE","name":"DUX4L23","canonical_id":"hgnc:HGNC:50804","description":"double homeobox 4 like 23 (pseudogene)","metadata":null},{"id":"dbf882db8e124415a9000983c49efe24","type":"GENE","name":"DUX4L24","canonical_id":"hgnc:HGNC:50805","description":"double homeobox 4 like 24 (pseudogene)","metadata":null},{"id":"f227f54ad60045879a674f7794b667d3","type":"GENE","name":"DUX4L25","canonical_id":"hgnc:HGNC:50806","description":"double homeobox 4 like 25 (pseudogene)","metadata":null},{"id":"85c7a5968132450f8328a0fb6f8d4027","type":"GENE","name":"DUX4L26","canonical_id":"hgnc:HGNC:50807","description":"double homeobox 4 like 26 (pseudogene)","metadata":null},{"id":"58e63e09c18e44079961d21d04774e12","type":"GENE","name":"DUX4L27","canonical_id":"hgnc:HGNC:50808","description":"double homeobox 4 like 27 (pseudogene)","metadata":null},{"id":"27f8ecb9945147fb8f54376c55037d04","type":"GENE","name":"DUX4L28","canonical_id":"hgnc:HGNC:51605","description":"double homeobox 4 like 28 (pseudogene)","metadata":null},{"id":"1264d724dfdc434c99618b6ffb19e361","type":"GENE","name":"DUX4L29","canonical_id":"hgnc:HGNC:51606","description":"double homeobox 4 like 29 (pseudogene)","metadata":null},{"id":"514ab36e35e348e489cc5ec16f64e6db","type":"GENE","name":"DUX4L3","canonical_id":"hgnc:HGNC:38688","description":"double homeobox 4 like 3 (pseudogene)","metadata":null},{"id":"fc3d84a619d042ecabc9fcac7618ec2c","type":"GENE","name":"DUX4L31","canonical_id":"hgnc:HGNC:51770","description":"double homeobox 4 like 31 (pseudogene)","metadata":null},{"id":"f02a5432fe984783a7e1d6b0009b6ff1","type":"GENE","name":"DUX4L32","canonical_id":"hgnc:HGNC:51771","description":"double homeobox 4 like 32 (pseudogene)","metadata":null},{"id":"ec2881a2dca54e48963b29a4180d5bce","type":"GENE","name":"DUX4L33","canonical_id":"hgnc:HGNC:51789","description":"double homeobox 4 like 33 (pseudogene)","metadata":null},{"id":"172d0d0cb7784f0ba97017a2f9688588","type":"GENE","name":"DUX4L34","canonical_id":"hgnc:HGNC:51772","description":"double homeobox 4 like 34 (pseudogene)","metadata":null},{"id":"6cfce8088ccb493aa27155f8988a957d","type":"GENE","name":"DUX4L35","canonical_id":"hgnc:HGNC:51773","description":"double homeobox 4 like 35 (pseudogene)","metadata":null},{"id":"1bd636c252704936b6f79439992d6737","type":"GENE","name":"DUX4L36","canonical_id":"hgnc:HGNC:51774","description":"double homeobox 4 like 36 (pseudogene)","metadata":null},{"id":"a2419cb4820545409a45e5c8b99ce7ba","type":"GENE","name":"DUX4L37","canonical_id":"hgnc:HGNC:51775","description":"double homeobox 4 like 37 (pseudogene)","metadata":null},{"id":"524a6c8d830f4e9c8536193b4bb0f32f","type":"GENE","name":"DUX4L38","canonical_id":"hgnc:HGNC:51776","description":"double homeobox 4 like 38 (pseudogene)","metadata":null},{"id":"c928a857d3a34dcebb282604779d6c50","type":"GENE","name":"DUX4L39","canonical_id":"hgnc:HGNC:51777","description":"double homeobox 4 like 39 (pseudogene)","metadata":null},{"id":"1314763f8aff4644a179266d16ef50f6","type":"GENE","name":"DUX4L4","canonical_id":"hgnc:HGNC:38686","description":"double homeobox 4 like 4 (pseudogene)","metadata":null},{"id":"8f7de14064e34ab79bfe9b155f789e2d","type":"GENE","name":"DUX4L40","canonical_id":"hgnc:HGNC:51778","description":"double homeobox 4 like 40 (pseudogene)","metadata":null},{"id":"984a0b53b1a74ed9897a7a914042656e","type":"GENE","name":"DUX4L41","canonical_id":"hgnc:HGNC:51779","description":"double homeobox 4 like 41 (pseudogene)","metadata":null},{"id":"4cd655fd70dd4c4bb3cbaf6ac5a0ce19","type":"GENE","name":"DUX4L42","canonical_id":"hgnc:HGNC:51780","description":"double homeobox 4 like 42 (pseudogene)","metadata":null},{"id":"74d42d211851473eb4d4f1d21b588edf","type":"GENE","name":"DUX4L43","canonical_id":"hgnc:HGNC:51781","description":"double homeobox 4 like 43 (pseudogene)","metadata":null},{"id":"5df2d8b0b4fe4feba4d92aa39878b4ea","type":"GENE","name":"DUX4L44","canonical_id":"hgnc:HGNC:51782","description":"double homeobox 4 like 44 (pseudogene)","metadata":null},{"id":"e1e21047019e442daa15829c3d15fef1","type":"GENE","name":"DUX4L45","canonical_id":"hgnc:HGNC:51783","description":"double homeobox 4 like 45 (pseudogene)","metadata":null},{"id":"1e9fc63802df48138876d91446f4b50c","type":"GENE","name":"DUX4L46","canonical_id":"hgnc:HGNC:51784","description":"double homeobox 4 like 46 (pseudogene)","metadata":null},{"id":"60b15068ec144d35bd0d98b6266e58c4","type":"GENE","name":"DUX4L47","canonical_id":"hgnc:HGNC:51785","description":"double homeobox 4 like 47 (pseudogene)","metadata":null},{"id":"4d13ea6e91db4b719f07cd30eb8c85e5","type":"GENE","name":"DUX4L48","canonical_id":"hgnc:HGNC:51786","description":"double homeobox 4 like 48 (pseudogene)","metadata":null},{"id":"4ba513ff4ac744d79ec905ca4a24c3cd","type":"GENE","name":"DUX4L49","canonical_id":"hgnc:HGNC:51787","description":"double homeobox 4 like 49 (pseudogene)","metadata":null},{"id":"713126cf7f7f4218b37031875c20d0df","type":"GENE","name":"DUX4L5","canonical_id":"hgnc:HGNC:38689","description":"double homeobox 4 like 5 (pseudogene)","metadata":null},{"id":"2ecc586068af4c7bb0d76fa8b56c012c","type":"GENE","name":"DUX4L50","canonical_id":"hgnc:HGNC:51788","description":"double homeobox 4 like 50 (pseudogene)","metadata":null},{"id":"967aec4f90714590aa5085df1de1644e","type":"GENE","name":"DUX4L51","canonical_id":"hgnc:HGNC:51810","description":"double homeobox 4 like 51 (pseudogene)","metadata":null},{"id":"46e0245d66fb4e17bc6ffbd9a66173c3","type":"GENE","name":"DUX4L52","canonical_id":"hgnc:HGNC:51811","description":"double homeobox 4 like 52 (pseudogene)","metadata":null},{"id":"a0e5ea2cfbac41189e49cf1107854f95","type":"GENE","name":"DUX4L6","canonical_id":"hgnc:HGNC:37265","description":"double homeobox 4 like 6 (pseudogene)","metadata":null},{"id":"604acae6bfec4510a6b71321aa96c6e5","type":"GENE","name":"DUX4L7","canonical_id":"hgnc:HGNC:37266","description":"double homeobox 4 like 7 (pseudogene)","metadata":null},{"id":"0aa3ed631c724ea5a78e61f30d2e4d04","type":"GENE","name":"DUX4L8","canonical_id":"hgnc:HGNC:38670","description":"double homeobox 4 like 8 (pseudogene)","metadata":{"aliases":["DUX2"]}},{"id":"9fdb6dbd08424c65959cd843aff2f613","type":"GENE","name":"DUX4L9","canonical_id":"hgnc:HGNC:33855","description":"double homeobox 4 like 9 (pseudogene)","metadata":null},{"id":"dccc04888b7c4b7cb0997585f870cde5","type":"GENE","name":"DUX5","canonical_id":"hgnc:HGNC:3083","description":"double homeobox 5","metadata":null},{"id":"3f52edf8a6454897bb333a09b0084eb8","type":"GENE","name":"DUXA","canonical_id":"hgnc:HGNC:32179","description":"double homeobox A","metadata":null},{"id":"630581f152aa43b5a41e639c95e98b6c","type":"GENE","name":"DUXAP1","canonical_id":"hgnc:HGNC:32180","description":"double homeobox A pseudogene 1","metadata":null},{"id":"ac00cb1ae629410f8552374ff4a045b8","type":"GENE","name":"DUXAP10","canonical_id":"hgnc:HGNC:32189","description":"double homeobox A pseudogene 10","metadata":null},{"id":"cc2726bcf06948f584a7f503ed0424d3","type":"GENE","name":"DUXAP11","canonical_id":"hgnc:HGNC:51812","description":"double homeobox A pseudogene 11","metadata":null},{"id":"138e697e444147869a33182af370113c","type":"GENE","name":"DUXAP12","canonical_id":"hgnc:HGNC:51813","description":"double homeobox A pseudogene 12","metadata":null},{"id":"67c20c9d8443405a8fd1139a2f0d124e","type":"GENE","name":"DUXAP2","canonical_id":"hgnc:HGNC:32181","description":"double homeobox A pseudogene 2","metadata":null},{"id":"9718de7478d8471bbe71072d32beb234","type":"GENE","name":"DUXAP3","canonical_id":"hgnc:HGNC:32182","description":"double homeobox A pseudogene 3","metadata":null},{"id":"495086f4f54c48fc9185a78ae82fdfa5","type":"GENE","name":"DUXAP4","canonical_id":"hgnc:HGNC:32183","description":"double homeobox A pseudogene 4","metadata":null},{"id":"68c27b85e77f453b91b19fce14b4d64e","type":"GENE","name":"DUXAP5","canonical_id":"hgnc:HGNC:32184","description":"double homeobox A pseudogene 5","metadata":null},{"id":"4a72d23dd78c4f91a53156102445aaaa","type":"GENE","name":"DUXAP6","canonical_id":"hgnc:HGNC:32185","description":"double homeobox A pseudogene 6","metadata":null},{"id":"8b569db8d8ea4b97ae42194b4278896e","type":"GENE","name":"DUXAP7","canonical_id":"hgnc:HGNC:32186","description":"double homeobox A pseudogene 7","metadata":null},{"id":"2ecb1d64ff1046c293d9e60d301f9efc","type":"GENE","name":"DUXAP8","canonical_id":"hgnc:HGNC:32187","description":"double homeobox A pseudogene 8","metadata":null},{"id":"8bcbbc8ab4874cf6bab151407e7c869c","type":"GENE","name":"DUXAP9","canonical_id":"hgnc:HGNC:32188","description":"double homeobox A pseudogene 9","metadata":{"aliases":["FLJ39632","lncRNA-CTD903","LNMAT1","SAN","LINC01296"]}},{"id":"4151653f83034ca29a52fbb727e164b5","type":"GENE","name":"DUXB","canonical_id":"hgnc:HGNC:33345","description":"double homeobox B","metadata":null},{"id":"a41a929f35e84c4f8c754a1c8123203f","type":"TRIAL","name":"DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT07853053","description":"Bladder Cancer","metadata":null},{"id":"17a047f4594c421fa173cdffa0168e63","type":"TRIAL","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06178159","description":"Breast Cancer","metadata":null},{"id":"d486fe0946fc4544b16a3dd9ad03ac51","type":"GENE","name":"DVL1","canonical_id":"hgnc:HGNC:3084","description":"dishevelled segment polarity protein 1","metadata":null},{"id":"a7f4c8b7d1b043b388e208bf4f811e43","type":"GENE","name":"DVL1P1","canonical_id":"hgnc:HGNC:3085","description":"dishevelled segment polarity protein 1 pseudogene 1","metadata":{"aliases":["DVL-22","DVL1L1"]}},{"id":"da2aa18a4afd4aaf971dc3dd99e5a33e","type":"GENE","name":"DVL2","canonical_id":"hgnc:HGNC:3086","description":"dishevelled segment polarity protein 2","metadata":null},{"id":"9283c28bd1bb4ab99545c059d973076f","type":"GENE","name":"DVL3","canonical_id":"hgnc:HGNC:3087","description":"dishevelled segment polarity protein 3","metadata":{"aliases":["KIAA0208"]}},{"id":"68d97a2726f446fba86b8a2d50dca5d8","type":"GENE","name":"DXO","canonical_id":"hgnc:HGNC:2992","description":"decapping exoribonuclease","metadata":{"aliases":["DOM3L","DOM3Z"]}},{"id":"d664b48bfbfb4bdfa3e162fba992dc84","type":"GENE","name":"DYDC1","canonical_id":"hgnc:HGNC:23460","description":"DPY30 domain containing 1","metadata":{"aliases":["bA36D19.5","DPY30D1"]}},{"id":"ac966809088d44de9392f04e180316b6","type":"GENE","name":"DYDC2","canonical_id":"hgnc:HGNC:23468","description":"DPY30 domain containing 2","metadata":{"aliases":["bA36D19.6","MGC16186"]}},{"id":"d4fea14b5ac14493bf1c4431e6ba815b","type":"TRIAL","name":"DYG Versus Cetrorelix in Oocyte Donation","canonical_id":"clinicaltrials.gov:NCT05577806","description":"Infertility, Female; Fertility Disorders","metadata":null},{"id":"6c279ecfbff84955b2fdd59148be03e4","type":"GENE","name":"DYM","canonical_id":"hgnc:HGNC:21317","description":"dymeclin","metadata":{"aliases":["FLJ20071","DMC","SMC"]}},{"id":"ccda5043f53947bebc5eabba9aad1fd5","type":"GENE","name":"DYM-AS1","canonical_id":"hgnc:HGNC:37046","description":"DYM antisense RNA 1","metadata":null},{"id":"53277d0d5bfa45df839f4fd38a1b9bbd","type":"GENE","name":"DYNAP","canonical_id":"hgnc:HGNC:26808","description":"dynactin associated protein","metadata":{"aliases":["FLJ39106","C18orf26"]}},{"id":"237abf6f771d4e129a79415fef20bd25","type":"GENE","name":"DYNAPP1","canonical_id":"hgnc:HGNC:56221","description":"DYNAP pseudogene 1","metadata":null},{"id":"b6a0dec8adb54c84b8ae10d395851a0b","type":"GENE","name":"DYNAPP2","canonical_id":"hgnc:HGNC:56222","description":"DYNAP pseudogene 2","metadata":null},{"id":"8f5a397cbc344eaf9f27dce8d8ec67ab","type":"GENE","name":"DYNAPP3","canonical_id":"hgnc:HGNC:56223","description":"DYNAP pseudogene 3","metadata":null},{"id":"2de5d36f28454d308d97aaa87ab92dc9","type":"GENE","name":"DYNC1H1","canonical_id":"hgnc:HGNC:2961","description":"dynein cytoplasmic 1 heavy chain 1","metadata":{"aliases":["Dnchc1","HL-3","p22","DHC1","CMT2O","DNECL","DNCL","DNCH1"]}},{"id":"837d5d27ab7049019a3c9727382a9d9c","type":"GENE","name":"DYNC1I1","canonical_id":"hgnc:HGNC:2963","description":"dynein cytoplasmic 1 intermediate chain 1","metadata":{"aliases":["DNCIC1","DNCI1"]}},{"id":"c5a16318cb4b4fb88a5f710cf4bd164f","type":"GENE","name":"DYNC1I2","canonical_id":"hgnc:HGNC:2964","description":"dynein cytoplasmic 1 intermediate chain 2","metadata":{"aliases":["DIC74","DNCI2"]}},{"id":"e42615092ab94ff59c67fdb09126a620","type":"GENE","name":"DYNC1I2P1","canonical_id":"hgnc:HGNC:45012","description":"dynein cytoplasmic 1 intermediate chain 2 pseudogene 1","metadata":null},{"id":"8f8c22cb984d4d0fafd4772cf2b20f82","type":"GENE","name":"DYNC1LI1","canonical_id":"hgnc:HGNC:18745","description":"dynein cytoplasmic 1 light intermediate chain 1","metadata":{"aliases":["DNCLI1"]}},{"id":"84936c26c76646879209dccc4e18d108","type":"GENE","name":"DYNC1LI2","canonical_id":"hgnc:HGNC:2966","description":"dynein cytoplasmic 1 light intermediate chain 2","metadata":{"aliases":["DNCLI2"]}},{"id":"810adb7b42d84961bdfa589d095697e4","type":"GENE","name":"DYNC1LI2-DT","canonical_id":"hgnc:HGNC:52990","description":"DYNC1LI2 divergent transcript","metadata":null},{"id":"d5d1bce9254b464aaafd9f9a58ca019b","type":"GENE","name":"DYNC2H1","canonical_id":"hgnc:HGNC:2962","description":"dynein cytoplasmic 2 heavy chain 1","metadata":{"aliases":["hdhc11","DHC2","DHC1b","DYH1B","DNCH2"]}},{"id":"55dc48805a344dfa91b9b85eb0f97339","type":"GENE","name":"DYNC2I1","canonical_id":"hgnc:HGNC:21862","description":"dynein 2 intermediate chain 1","metadata":{"aliases":["FLJ10300","FAP163","CFAP163","DIC6","WDR60"]}},{"id":"90499cd530c348ee8b5de3fa6b1b1c4b","type":"GENE","name":"DYNC2I2","canonical_id":"hgnc:HGNC:28296","description":"dynein 2 intermediate chain 2","metadata":{"aliases":["DIC5","MGC20486","bA216B9.3","FAP133","CFAP133","WDR34"]}},{"id":"828cb44929cc497abd40fc1005f268e4","type":"GENE","name":"DYNC2LI1","canonical_id":"hgnc:HGNC:24595","description":"dynein cytoplasmic 2 light intermediate chain 1","metadata":{"aliases":["D2LIC","LIC3","CGI-60","DKFZP564A033"]}},{"id":"4a5262556abe411d9156b24ae08c66fc","type":"GENE","name":"DYNLL1","canonical_id":"hgnc:HGNC:15476","description":"dynein light chain LC8-type 1","metadata":{"aliases":["hdlc1","DLC1","PIN","LC8","DLC8","DNCL1"]}},{"id":"66d44572cb904d7d9e8e8fd4343a601c","type":"GENE","name":"DYNLL1P1","canonical_id":"hgnc:HGNC:20723","description":"dynein light chain LC8-type 1 pseudogene 1","metadata":{"aliases":["DNCL1P1"]}},{"id":"fb3b025ff90d4039bbe9dc8c8d6f6621","type":"GENE","name":"DYNLL1P2","canonical_id":"hgnc:HGNC:20724","description":"dynein light chain LC8-type 1 pseudogene 2","metadata":{"aliases":["DNCL1P2"]}},{"id":"542275e9f132458aba9669603e938c90","type":"GENE","name":"DYNLL1P3","canonical_id":"hgnc:HGNC:49654","description":"dynein light chain LC8-type 1 pseudogene 3","metadata":null},{"id":"9faec0d9a3da4eba83af9afd4d15b27e","type":"GENE","name":"DYNLL1P4","canonical_id":"hgnc:HGNC:49655","description":"dynein light chain LC8-type 1 pseudogene 4","metadata":null},{"id":"e43bf24ab0724cd58fbd3c525c5c406a","type":"GENE","name":"DYNLL1P5","canonical_id":"hgnc:HGNC:49656","description":"dynein light chain LC8-type 1 pseudogene 5","metadata":null},{"id":"6b4d54ba7bdb459e98e8a96767873e9d","type":"GENE","name":"DYNLL1P6","canonical_id":"hgnc:HGNC:49657","description":"dynein light chain LC8-type 1 pseudogene 6","metadata":null},{"id":"0bfe1f9632464505bdcb097681a6d2f5","type":"GENE","name":"DYNLL1P7","canonical_id":"hgnc:HGNC:49658","description":"dynein light chain LC8-type 1 pseudogene 7","metadata":null},{"id":"f808d968989b40629f8d4678a369c531","type":"GENE","name":"DYNLL2","canonical_id":"hgnc:HGNC:24596","description":"dynein light chain LC8-type 2","metadata":{"aliases":["MGC17810","Dlc2","DNCL1B","RSPH22"]}},{"id":"8c5fc068abc9495281ed9516772a9bee","type":"GENE","name":"DYNLL2-DT","canonical_id":"hgnc:HGNC:52833","description":"DYNLL2 divergent transcript","metadata":null},{"id":"bcb3406f2553438eaabc7c09f0b25ae6","type":"GENE","name":"DYNLRB1","canonical_id":"hgnc:HGNC:15468","description":"dynein light chain roadblock-type 1","metadata":{"aliases":["DNLC2A","ROBLD1","DNCL2A"]}},{"id":"73b47217d60049228de5c3a58142a0f7","type":"GENE","name":"DYNLRB2","canonical_id":"hgnc:HGNC:15467","description":"dynein light chain roadblock-type 2","metadata":{"aliases":["DNLC2B","ROBLD2","DNCL2B"]}},{"id":"1cb4d5842f36493781e7a348f3a99207","type":"GENE","name":"DYNLRB2-AS1","canonical_id":"hgnc:HGNC:55405","description":"DYNLRB2 antisense RNA 1","metadata":null},{"id":"cd773a022dbe491ca92bcd19f81958c0","type":"GENE","name":"DYNLT1","canonical_id":"hgnc:HGNC:11697","description":"dynein light chain Tctex-type 1","metadata":{"aliases":["Tctex-1","TCTEX1","TCTEL1"]}},{"id":"8331eb35067f4f7587317041eb0ec105","type":"GENE","name":"DYNLT2","canonical_id":"hgnc:HGNC:11695","description":"dynein light chain Tctex-type 2","metadata":{"aliases":["TCTEX1D3","TCTEX2","Tctex4","oda12","TCTE3"]}},{"id":"ddd5c5772ba940418b68d76b265209b7","type":"GENE","name":"DYNLT2B","canonical_id":"hgnc:HGNC:28482","description":"dynein light chain Tctex-type 2B","metadata":{"aliases":["MGC33212","TCTEX1D2"]}},{"id":"97891f2c40ce4209a1fa8d562e0ea730","type":"GENE","name":"DYNLT3","canonical_id":"hgnc:HGNC:11694","description":"dynein light chain Tctex-type 3","metadata":{"aliases":["TCTEX1L","TCTE1L"]}},{"id":"a60590f599c54cefaaf808a28e5fbc29","type":"GENE","name":"DYNLT3P1","canonical_id":"hgnc:HGNC:16571","description":"dynein light chain Tctex-type 3 pseudogene 1","metadata":{"aliases":["dJ531H16.2","TCTE1P"]}},{"id":"7ce8796b97904380af7eca2475f2e770","type":"GENE","name":"DYNLT3P2","canonical_id":"hgnc:HGNC:37081","description":"dynein light chain Tctex-type 3 pseudogene 2","metadata":null},{"id":"5e2553ca6ce14e648be1031825cfeb57","type":"GENE","name":"DYNLT4","canonical_id":"hgnc:HGNC:32315","description":"dynein light chain Tctex-type 4","metadata":{"aliases":["TCTEX1D4"]}},{"id":"3c88612a21e7416f980f8c0683b0cea4","type":"GENE","name":"DYNLT5","canonical_id":"hgnc:HGNC:26882","description":"dynein light chain Tctex-type family member 5","metadata":{"aliases":["FLJ40873","TCTEX1D1"]}},{"id":"597d45dc3c424ae591d1b596613beca5","type":"GENE","name":"DYRK1A","canonical_id":"hgnc:HGNC:3091","description":null,"metadata":null},{"id":"7ead4352aceb4e18bcf851d52a955966","type":"GENE","name":"DYRK1B","canonical_id":"hgnc:HGNC:3092","description":"dual specificity tyrosine phosphorylation regulated kinase 1B","metadata":{"aliases":["MIRK"]}},{"id":"b753b03ccf404600a7f73e99c7d6d6dd","type":"GENE","name":"DYRK2","canonical_id":"hgnc:HGNC:3093","description":"dual specificity tyrosine phosphorylation regulated kinase 2","metadata":null},{"id":"4c886a730dad487cbf21ca4747730ea3","type":"GENE","name":"DYRK3","canonical_id":"hgnc:HGNC:3094","description":"dual specificity tyrosine phosphorylation regulated kinase 3","metadata":{"aliases":["RED","REDK","hYAK3-2"]}},{"id":"b62a993f82d543d3b0a145e67e30cbac","type":"GENE","name":"DYRK3-AS1","canonical_id":"hgnc:HGNC:40199","description":"DYRK3 antisense RNA 1","metadata":null},{"id":"77ed02c7eb514dc49ba28d26f314a8c4","type":"GENE","name":"DYRK4","canonical_id":"hgnc:HGNC:3095","description":"dual specificity tyrosine phosphorylation regulated kinase 4","metadata":null},{"id":"aa3acb66950048a9b8e1195c61c82c67","type":"GENE","name":"DYSF","canonical_id":"hgnc:HGNC:3097","description":"dysferlin","metadata":{"aliases":["FER1L1","LGMD2B"]}},{"id":"5fee5e1d02524696a6db7af6c35c9a4f","type":"GENE","name":"DYTN","canonical_id":"hgnc:HGNC:23279","description":"dystrotelin","metadata":null},{"id":"0edf0cc12f7844b4a477681e8425096f","type":"TRIAL","name":"DYmista NAsal Spray in CHInese Patients","canonical_id":"clinicaltrials.gov:NCT03599791","description":"Allergic Rhinitis","metadata":null},{"id":"64326245f54944318c49a6b001f54f46","type":"GENE","name":"DZANK1","canonical_id":"hgnc:HGNC:15858","description":"double zinc ribbon and ankyrin repeat domains 1","metadata":{"aliases":["FLJ10600","dJ568F9.2","FLJ30892","bA189K21.8","ANKRD64","C20orf84","C20orf12"]}},{"id":"6f72e8b3faeb440c911f3352de1c5ed8","type":"GENE","name":"DZIP1","canonical_id":"hgnc:HGNC:20908","description":"DAZ interacting zinc finger protein 1","metadata":{"aliases":["KIAA0996","DZIP"]}},{"id":"9560443900a14205a767a9e46b3eba80","type":"GENE","name":"DZIP1L","canonical_id":"hgnc:HGNC:26551","description":"DAZ interacting zinc finger protein 1 like","metadata":{"aliases":["FLJ32844","DZIP2"]}},{"id":"c9c4d2ac792d45ebbe6b80fb442dfc07","type":"GENE","name":"DZIP3","canonical_id":"hgnc:HGNC:30938","description":"DAZ interacting zinc finger protein 3","metadata":{"aliases":["hRUL138","PPP1R66"]}},{"id":"89a1af41303f472ea91cffbc0e182ad3","type":"TRIAL","name":"Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement","canonical_id":"clinicaltrials.gov:NCT00152971","description":"Arthroplasty, Replacement, Knee; Thromboembolism","metadata":null},{"id":"d413d4d54ca544078530c59cecea9917","type":"TRIAL","name":"Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)","canonical_id":"clinicaltrials.gov:NCT02872649","description":"Thrombosis; Bleeding","metadata":null},{"id":"5f686a531f6943e3a893cf7bce5434ee","type":"TRIAL","name":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","canonical_id":"clinicaltrials.gov:NCT06650501","description":"Staphylococcus Aureus Endocarditis; Staphylococcus Aureus Septicemia; Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Bloodstream Infection; S. Aureus Bacteremia; S. Aureus Bloodstream Infection","metadata":null},{"id":"ab7801f0a0e2423b8e4f02681f730e11","type":"DRUG","name":"Dabrafenib","canonical_id":"ncit:C82386","description":null,"metadata":null},{"id":"7d93e16e77c74d8da0688d14b25d1fd0","type":"TRIAL","name":"Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT01701037","description":"Recurrent Melanoma; Stage IIB Melanoma (Locally Advanced); Stage IIC Melanoma (Locally Advanced); Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma (Limited, Resectable)","metadata":null},{"id":"f8f1507a1c754af5bd3beb40b781719a","type":"TRIAL","name":"Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma","canonical_id":"clinicaltrials.gov:NCT01597908","description":"Melanoma","metadata":null},{"id":"1c471ef5c8684b45acf3ded3e0332157","type":"TRIAL","name":"Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01723202","description":"Follicular Thyroid Cancer; Insular Thyroid Cancer; Papillary Thyroid Cancer; Recurrent Thyroid Cancer","metadata":null},{"id":"8f1831290a3b4aec97c283b977485454","type":"TRIAL","name":"Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT01947023","description":"Metastatic Thyroid Gland Carcinoma; Unresectable Thyroid Gland Carcinoma","metadata":null},{"id":"0b6cf842b85c4803a9b3a0e812f40873","type":"TRIAL","name":"Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors","canonical_id":"clinicaltrials.gov:NCT01713972","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"e5a42d0e12654506bfab952523cc3b09","type":"TRIAL","name":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","canonical_id":"clinicaltrials.gov:NCT02224781","description":"Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Recurrent Melanoma; Unresectable Melanoma","metadata":null},{"id":"9c6a5949f30146d885be7b4579fa486d","type":"TRIAL","name":"Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease","canonical_id":"clinicaltrials.gov:NCT02281760","description":"BRAF V600E Mutation","metadata":null},{"id":"1d30b553ea4e424f9599c2556e9caccd","type":"TRIAL","name":"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","canonical_id":"clinicaltrials.gov:NCT02257424","description":"Advanced BRAF Mutant Melanoma","metadata":null},{"id":"48b6f2a392054f94a945d800e500bfed","type":"DRUG","name":"Dabrafenib/Trametinib Regimen","canonical_id":"ncit:C154325","description":null,"metadata":null},{"id":"848386cd1f8e425985aed2808be6beee","type":"DRUG","name":"Dacarbazine","canonical_id":"mesh:D003606","description":null,"metadata":null},{"id":"622b98c7df63434ca142761196b312a2","type":"TRIAL","name":"Dacarbazine and Carmustine in Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01692691","description":"Melanoma Metastatic","metadata":null},{"id":"fb39131b06bd47f893ba7fb6f6dafdfb","type":"TRIAL","name":"Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis","canonical_id":"clinicaltrials.gov:NCT00043667","description":"Uveitis","metadata":null},{"id":"deff2a218a864167a5cacb2ddcedb0a0","type":"TRIAL","name":"Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis","canonical_id":"clinicaltrials.gov:NCT00070759","description":"Uveitis","metadata":null},{"id":"ee692be50978497d96938bc8cb10dff5","type":"TRIAL","name":"Daclizumab to Treat Wegener's Granulomatosis","canonical_id":"clinicaltrials.gov:NCT00040248","description":"Wegener's Granulomatosis","metadata":null},{"id":"28ca1a60ceca415eaf270deecc66426e","type":"DRUG","name":"Dacomitinib","canonical_id":"ncit:C53398","description":null,"metadata":null},{"id":"26c1df15f6ae44bbb6dd568747b2da37","type":"DISEASE","name":"Dacryocystitis","canonical_id":"mesh:D003607","description":null,"metadata":null},{"id":"e6d2bbfddd224032b7493e4103351bc3","type":"DRUG","name":"Dactinomycin","canonical_id":"mesh:D003609","description":null,"metadata":null},{"id":"f4e67477cf5343a194f1c82f45a54939","type":"DRUG","name":"Dactolisib","canonical_id":"ncit:C74072","description":null,"metadata":null},{"id":"96c6ea4659144a47bdc1db8081005dca","type":"TRIAL","name":"Daily Doxycycline for Early Syphillis","canonical_id":"clinicaltrials.gov:NCT06683638","description":"Syphilis","metadata":null},{"id":"7cb9169a49b347c281cb1e671fd428e1","type":"TRIAL","name":"Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma","canonical_id":"clinicaltrials.gov:NCT02048722","description":"Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma","metadata":null},{"id":"2092c8b4e64549c9a87244d44820ff6f","type":"TRIAL","name":"Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients","canonical_id":"clinicaltrials.gov:NCT07391579","description":"Erectile Dysfunctions","metadata":null},{"id":"1bee5bbb9086414689ec4acb07876ae1","type":"TRIAL","name":"Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT07753720","description":"Erectile Dysfunction; Tadalafil","metadata":null},{"id":"88552d599c5847f5b4d280e5d28a4dd7","type":"TRIAL","name":"Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06243185","description":"Recurrent Ovarian Carcinoma","metadata":null},{"id":"2a0456e19e1b4e7f8098bb272d1d2d2b","type":"TRIAL","name":"Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05574881","description":"Breast Cancer","metadata":null},{"id":"1abe54c4f4b64fc78485afc9fdb8ddc4","type":"DRUG","name":"Danazol","canonical_id":"mesh:D003613","description":null,"metadata":null},{"id":"9f38eb4c26ca4159ac765b0baf320699","type":"TRIAL","name":"Danazol Treatment in Endometriosis Women Before IVF","canonical_id":"clinicaltrials.gov:NCT01779232","description":"Endometriosis; Ovarian Cysts; Infertility","metadata":null},{"id":"7d0c7c31fb1f4a2d9dafcb06206dbd75","type":"TRIAL","name":"Danazol for Genetic Bone Marrow and Lung Disorders","canonical_id":"clinicaltrials.gov:NCT01441037","description":"Aplastic Anemia","metadata":null},{"id":"07dfc1426c9041e5a89a3adc85f7ae99","type":"TRIAL","name":"Danazol for Treatment of Cytopenias in Patients With Cirrhosis","canonical_id":"clinicaltrials.gov:NCT04873102","description":"Cirrhosis, Liver; Cytopenia","metadata":null},{"id":"80af88c1e50c48e38a4f4cac420da6d9","type":"TRIAL","name":"Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT00003946","description":"Endometrial Cancer","metadata":null},{"id":"91430f949830499a9724cde82ca8fec9","type":"TRIAL","name":"Danish Hypertension Prevention Project - DHYPP","canonical_id":"clinicaltrials.gov:NCT00150631","description":"Hypertension","metadata":null},{"id":"df5461d28eeb4e2789299174be86f939","type":"DRUG","name":"Dantrolene","canonical_id":"mesh:D003620","description":null,"metadata":null},{"id":"e31663ed6f874d839c252fe1efd9f0de","type":"TRIAL","name":"Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)","canonical_id":"clinicaltrials.gov:NCT00796900","description":"Hyperthermia","metadata":null},{"id":"1ae52c29e2934e79bea59f9a1d5f621e","type":"TRIAL","name":"Dantrolene in Statin-induced Myopathy","canonical_id":"clinicaltrials.gov:NCT06966843","description":"Statins Induced Myopathy","metadata":null},{"id":"e4ebb5ad631b4ddc90a6b66703ac98af","type":"TRIAL","name":"Dapa Acute Heart Failure Study","canonical_id":"clinicaltrials.gov:NCT05759000","description":"Heart Failure","metadata":null},{"id":"b0f420b54d74445b8588f4e9fba9b636","type":"TRIAL","name":"Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment","canonical_id":"clinicaltrials.gov:NCT02965443","description":"Type 2 Diabetes","metadata":null},{"id":"b0a961536cbb4fa190d4ab1e1fabb174","type":"TRIAL","name":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02518945","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"0125e271d3d244a09b61819c64e7149e","type":"TRIAL","name":"Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT02653482","description":"Chronic Heart Failure With Reduced Systolic Function","metadata":null},{"id":"641c12dfa4d74b3c8f903dd0d1412b45","type":"TRIAL","name":"Dapagliflozin Efficacy and Action in PCOS","canonical_id":"clinicaltrials.gov:NCT04213677","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"a80270a7b506481e9917120d42c832ea","type":"TRIAL","name":"Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02268214","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"471984096aeb4abca7d4b7c7f0803177","type":"TRIAL","name":"Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)","canonical_id":"clinicaltrials.gov:NCT04363697","description":"Acute Heart Failure; Heart Failure","metadata":null},{"id":"801b6f798193409d9e5a4ac0575f652c","type":"TRIAL","name":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","canonical_id":"clinicaltrials.gov:NCT06887062","description":"Large Vessel Vasculitis; Giant Cell Arteritis (GCA); Takayasu Arteritis","metadata":null},{"id":"59bfdf6eeed74d8091be5126120f1431","type":"TRIAL","name":"Dapagliflozin in Depression","canonical_id":"clinicaltrials.gov:NCT07239011","description":"Depression","metadata":null},{"id":"5693cce00de74573aaaa70462add450e","type":"TRIAL","name":"Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.","canonical_id":"clinicaltrials.gov:NCT05849220","description":"NAFLD Cirrhosis","metadata":null},{"id":"a665182adaa8431dbb9d4c9eaaea4362","type":"TRIAL","name":"Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT06510270","description":"Heart Failure with Preserved Ejection Fraction","metadata":null},{"id":"75b063550de54c848f5eb2fef4f4a93b","type":"TRIAL","name":"Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT05435235","description":"Acute Kidney Injury; Percutaneous Coronary Intervention","metadata":null},{"id":"d2135d931df74e32b501e28a9d2146f9","type":"TRIAL","name":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00834210","description":"Acne Vulgaris","metadata":null},{"id":"4448ec6d39954ffd91be24a78b54850d","type":"TRIAL","name":"Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00835198","description":"Acne Vulgaris","metadata":null},{"id":"255005ac807942bfad3300066b49a1d3","type":"TRIAL","name":"Daratumumab (HuMax\u00ae-CD38) Safety Study in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00574288","description":"Multiple Myeloma","metadata":null},{"id":"e820577168274f8fa19932acc6511829","type":"TRIAL","name":"Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial","canonical_id":"clinicaltrials.gov:NCT05898646","description":"AL Amyloidosis","metadata":null},{"id":"c0ee6bad9db54d448ef115aa152efee0","type":"TRIAL","name":"Daratumumab and Belatacept for Desensitization","canonical_id":"clinicaltrials.gov:NCT04827979","description":"Highly Sensitized Prospective Kidney Transplant Recipients","metadata":null},{"id":"b678ba35c59b4b1b991d3bc75ab46005","type":"TRIAL","name":"Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT03537599","description":"Minimal Residual Disease; Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia","metadata":null},{"id":"ac878f4740974fdea27f6e9d82b3a02a","type":"TRIAL","name":"Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study","canonical_id":"clinicaltrials.gov:NCT04230304","description":"Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma","metadata":null},{"id":"9fd6e765e8c54fd488167bd18dd229f3","type":"TRIAL","name":"Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03695744","description":"Multiple Myeloma; Myeloma","metadata":null},{"id":"1c34698629ca4b5691cf336294e383f6","type":"TRIAL","name":"Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03177460","description":"Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Testosterone Greater Than 150 ng/dL","metadata":null},{"id":"e41a5493bb6d46d7859fc24f72bd0d0b","type":"TRIAL","name":"Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03701321","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"d0e716b6d73843a796c24e3f36f31d14","type":"TRIAL","name":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03500445","description":"Myeloma; Multiple Myeloma","metadata":null},{"id":"6218913b19894c88857888fc069cac88","type":"TRIAL","name":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT03283917","description":"Newly Diagnosed Primary Amyloidosis; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis","metadata":null},{"id":"4d6e2e76c99f4c7eaf16bc7120c6a0fd","type":"TRIAL","name":"Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab","canonical_id":"clinicaltrials.gov:NCT04270175","description":"Amyloid; AL Amyloidosis; Refractory AL Amyloidosis","metadata":null},{"id":"07829db59f0940fb99f1e7a93b003237","type":"TRIAL","name":"Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure","canonical_id":"clinicaltrials.gov:NCT04352205","description":"Plasma Cell Myeloma; Renal Failure","metadata":null},{"id":"b92407414c5a45589f97808a7f4b0c88","type":"TRIAL","name":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","canonical_id":"clinicaltrials.gov:NCT03896737","description":"Multiple Myeloma","metadata":null},{"id":"219b1d0993ba4541a14e996a2d9eb6f0","type":"DRUG","name":"Darifenacin","canonical_id":"mesh:C101207","description":null,"metadata":null},{"id":"d831e94c13d0405ab4ac510dde168dce","type":"TRIAL","name":"Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1","canonical_id":"clinicaltrials.gov:NCT06616675","description":"HTLV-1; Overactive Bladder Syndrome","metadata":null},{"id":"eb526ed0cb224a4fad31c37a58523c2a","type":"TRIAL","name":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","canonical_id":"clinicaltrials.gov:NCT05771896","description":"Metastatic Prostate Cancer","metadata":null},{"id":"4fbf58cbace34e6bbe7b48894df46e35","type":"TRIAL","name":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02799602","description":"Metastatic Hormone-sensitive Prostate Cancer","metadata":null},{"id":"fccdaa7bd76745de959b65e7a57ae538","type":"TRIAL","name":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","canonical_id":"clinicaltrials.gov:NCT05694819","description":"Salivary Gland Cancer","metadata":null},{"id":"78c7a2021b1e4c7e9236ab72ff654031","type":"DRUG","name":"Darunavir","canonical_id":"mesh:D000069454","description":null,"metadata":null},{"id":"ef43e6eeabc84f93b6345985b6ce1335","type":"TRIAL","name":"Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies","canonical_id":"clinicaltrials.gov:NCT06398457","description":"Hematologic Malignancy; Bone Marrow Transplant Rejection; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Acute Lymphoblastic Leukemia (ALL), Adult; Multiple Myeloma; Aplastic Anemia; Lymphoma; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Chronic Myeloid Leukemia; Myelofibrosis","metadata":null},{"id":"55cf4d8aa5d84c0daa8f753be97c6b6c","type":"DRUG","name":"Dasabuvir","canonical_id":"mesh:C588260","description":null,"metadata":null},{"id":"a1509e150d1f4828857bdad923e3c962","type":"DRUG","name":"Dasatinib","canonical_id":"mesh:D000069439","description":null,"metadata":null},{"id":"b9c9fe8c730643faa17978e0231b5901","type":"DRUG","name":"Dasatinib","canonical_id":"ncit:C38713","description":null,"metadata":null},{"id":"fb4a23b5f32e4950b73b0ca554c0a7f3","type":"TRIAL","name":"Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)","canonical_id":"clinicaltrials.gov:NCT01218477","description":"Leukemia","metadata":null},{"id":"989e7a49cd8a476c969e550c389a5dbc","type":"TRIAL","name":"Dasatinib Holiday for Improved Tolerability","canonical_id":"clinicaltrials.gov:NCT02890784","description":"Myeloid Leukemia, Chronic","metadata":null},{"id":"4e16658a080d4b0dbeb3d55e5ba51801","type":"TRIAL","name":"Dasatinib Versus Nilotinib for Treatment Na\u00efve Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03079505","description":"Chronic Myeloid Leukemia - Chronic Phase","metadata":null},{"id":"7b242cbb3be443909cb0a8154b51eb72","type":"TRIAL","name":"Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL","canonical_id":"clinicaltrials.gov:NCT01173679","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"71aa15860eea4f05962093f5b26d0c86","type":"TRIAL","name":"Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery","canonical_id":"clinicaltrials.gov:NCT01234935","description":"Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer","metadata":null},{"id":"93988e1a4820406390de20e35a0b7a43","type":"TRIAL","name":"Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT02689440","description":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","metadata":null},{"id":"1f0e79ca3e964410b46494e4ebf421ba","type":"TRIAL","name":"Dasatinib for HIV-1 Reservoir Reduction","canonical_id":"clinicaltrials.gov:NCT07342491","description":"HIV Infections","metadata":null},{"id":"8aabc39438da467fa3e42a1dc30bd6c0","type":"TRIAL","name":"Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab","canonical_id":"clinicaltrials.gov:NCT04164069","description":"Advanced Colorectal Carcinoma; Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Esophageal Cancer; Pancreatic Cancer; Bile Duct Cancer; Gastric Cancer; Gall Bladder Cancer; Small Bowel Adenocarcinoma","metadata":null},{"id":"929ed8c19a0740a08a92b318992369ca","type":"TRIAL","name":"Dasatinib in Combination With Revlimid (and Dexamethasone)","canonical_id":"clinicaltrials.gov:NCT00560391","description":"Multiple Myeloma","metadata":null},{"id":"cc615e8155274f898abaf9251c5ffe93","type":"TRIAL","name":"Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01441882","description":"Refractory Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia","metadata":null},{"id":"03ac5015686e4c0ea63f155ec3b9a7cb","type":"TRIAL","name":"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00700882","description":"Melanoma (Skin)","metadata":null},{"id":"e81e9510950d4f4eb8c0d0d47b0d51fe","type":"TRIAL","name":"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00869401","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"bf75426af4ac4326b14bdb10d5328058","type":"TRIAL","name":"Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT01015222","description":"Advanced Cancer","metadata":null},{"id":"0a98ee1d083e464b8ac620a6d3872353","type":"TRIAL","name":"Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00788125","description":"Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor; Unspecified Childhood Solid Tumor, Protocol Specific","metadata":null},{"id":"273a0a76fb474069869a467ecd49470f","type":"TRIAL","name":"Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02389309","description":"Advanced Malignant Solid Neoplasm; Recurrent Brain Neoplasm; Recurrent Malignant Solid Neoplasm; Refractory Brain Neoplasm","metadata":null},{"id":"9dca3c0453fd4347b391f2bbd4ccef9a","type":"TRIAL","name":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene","canonical_id":"clinicaltrials.gov:NCT05125237","description":"Hypertension","metadata":null},{"id":"f544465f279c43ab9d69cee2c73410bf","type":"TRIAL","name":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol","canonical_id":"clinicaltrials.gov:NCT05794997","description":"Hypertension","metadata":null},{"id":"8be801ed8f91444c9d138fe8d43aecd4","type":"TRIAL","name":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol","canonical_id":"clinicaltrials.gov:NCT04746989","description":"Gout","metadata":null},{"id":"35d4e6fdc76f4ec8a0c579bbcf3eba31","type":"TRIAL","name":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","canonical_id":"clinicaltrials.gov:NCT04676243","description":"Acute Myeloid Leukemia","metadata":null},{"id":"44fd05465bee440aaad299aa6fe23ebc","type":"TRIAL","name":"Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00651261","description":"Leukemia","metadata":null},{"id":"a80a11ae77b549aa994f23b1c9c633f6","type":"GO_TERM","name":"Dbf4-dependent protein kinase complex","canonical_id":"go:GO:0031431","description":"\"A heterodimeric protein complex required for the activation of DNA replication origins; comprises a catalytic subunit and a regulatory subunit (in Saccharomyces, Cdc7p and Dbf4p, respectively); complexes identified in other species generally contain proteins related to the Saccharomyces proteins.\" [PMID:12045100]","metadata":null},{"id":"9ed94676c3ea4129a58ef1a55fc89877","type":"GO_TERM","name":"Ddb1-Ckn1 complex","canonical_id":"go:GO:0070912","description":"\"A heterodimeric nucleotide-excision repair complex that is involved in transcription-coupled repair. The subunits are known as Ddb1 and Ckn1 in S. pombe; Ddb1 contains a motif called the DDB-box that interacts with adaptor proteins for DDB1/cullin 4 ubiquitin ligases.\" [PMID:18794354]","metadata":null},{"id":"d26c822cdd7c462ea663c7066c2763a0","type":"GO_TERM","name":"Ddb1-Wdr21 complex","canonical_id":"go:GO:0070913","description":"\"A heterodimeric nucleotide-excision repair complex that is involved in transcription-coupled repair. The subunits are known as Ddb1 and Wdr21 in S. pombe; Ddb1 contains a motif called the DDB-box that interacts with adaptor proteins for DDB1/cullin 4 ubiquitin ligases.\" [PMID:18794354]","metadata":null},{"id":"71b552a5d21a4c18a233d9408a959eb3","type":"TRIAL","name":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07421141","description":"Breast Cancer; HER2-positive Breast Cancer; Early Breast Cancer","metadata":null},{"id":"8bc033301bd44ba298acd5c0227552b0","type":"TRIAL","name":"De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07303686","description":"Crohn Disease (CD); Ulcerative Colitis (UC)","metadata":null},{"id":"eee479eaefdf4e8a9838de2a6d9279ed","type":"TRIAL","name":"Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.","canonical_id":"clinicaltrials.gov:NCT06374043","description":"Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria","metadata":null},{"id":"c5532aef2fb44e7da1cc90eeb2f4d7a7","type":"TRIAL","name":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","canonical_id":"clinicaltrials.gov:NCT02314481","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"6acf01b9cfb14ecdb48b65ee5f1eb99b","type":"TRIAL","name":"Decision Support for Intraoperative Low Blood Pressure","canonical_id":"clinicaltrials.gov:NCT02726620","description":"Hypotension","metadata":null},{"id":"9d1aeafe00e84d8fa444d07a727158e9","type":"DRUG","name":"Decitabine","canonical_id":"ncit:C981","description":null,"metadata":null},{"id":"d9a8d47b4b774c45963a4138ba18af8a","type":"TRIAL","name":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","canonical_id":"clinicaltrials.gov:NCT05010772","description":"Acute Myeloid Leukemia","metadata":null},{"id":"567d88b976cc4b39b8798ae03065aba1","type":"TRIAL","name":"Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia","canonical_id":"clinicaltrials.gov:NCT01794702","description":"Leukemia","metadata":null},{"id":"ec29049039874cb1b33be3c3ffe17182","type":"TRIAL","name":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT04282187","description":"Acute Myeloid Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis","metadata":null},{"id":"b8b3c2c6b0124046a747b693352eda21","type":"TRIAL","name":"Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00701298","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"1dc5e46ac1934b3baa2a66ad1249dba5","type":"TRIAL","name":"Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)","canonical_id":"clinicaltrials.gov:NCT00903760","description":"Myelodysplastic Syndrome","metadata":null},{"id":"9123d0bf47fd452296efdadf2358c6b3","type":"TRIAL","name":"Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00968071","description":"Acute Myelogenous Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"e69bdffdd8a948f4b8838a606da69fc0","type":"TRIAL","name":"Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01846624","description":"Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults; AML (Adult) With 11q23 (MLL) Abnormalities; AML (Adult) With Del (5q); AML (Adult) With Inv (16) (p13; q22); AML (Adult) With t (16;16) (p13; q22); AML (Adult) With t (8; 21) (q22; q22); Secondary AML (Adult); Untreated AML (Adult)","metadata":null},{"id":"db692e09818d492e9c13227a05867604","type":"TRIAL","name":"Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT00382200","description":"Myelodysplastic Syndromes","metadata":null},{"id":"4be7c5002a75434daf5b584492a902c6","type":"TRIAL","name":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05037500","description":"Castration-Resistant Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"dc4ba56bf39d4f3f81275250367fdfab","type":"TRIAL","name":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04774393","description":"Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"ae5b25e8548740b2a20ba0f0575fcfba","type":"DISEASE","name":"Decreased circulating immunoglobulin concentration","canonical_id":"hp:0004313","description":null,"metadata":null},{"id":"8841a1bfe4874cea854592fd15176129","type":"DISEASE","name":"Decreased respiratory function","canonical_id":"mesh:D012131","description":null,"metadata":null},{"id":"2a97dd4af79a4b3f8606dae270ed81bf","type":"TRIAL","name":"Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04939467","description":"Drug Drug Interaction","metadata":null},{"id":"bfa84369b0b240bc8cf226bee7994909","type":"TRIAL","name":"Deep Brain Stimulation of NAc/ALIC to Prevent Treatment-Refractory Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT02601677","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"9ae69d5cb5a04883b598b83dbfb64c7a","type":"TRIAL","name":"Deep sequencIng in Cutaneous Squamous CEll caRciNomas","canonical_id":"clinicaltrials.gov:NCT05878288","description":"Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Neoplasms; Non-melanoma Skin Cancer","metadata":null},{"id":"cde072205b4e4962b7a82ff23941e964","type":"TRIAL","name":"Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05516628","description":"Hepatocellular Carcinoma","metadata":null},{"id":"93e07b54e6e742a1aa629e0ff10e1b92","type":"DRUG","name":"Deferasirox","canonical_id":"mesh:C415250","description":null,"metadata":null},{"id":"159e79ef8975423da749de57db995f5d","type":"DISEASE","name":"Deficiency of mevalonate kinase","canonical_id":"mesh:D054078","description":null,"metadata":null},{"id":"13b7b6250155432eabb360e1c86f3e04","type":"TRIAL","name":"Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05809583","description":"Ulcerative Colitis","metadata":null},{"id":"be69b78e45864f3ba35f2153595541f2","type":"TRIAL","name":"Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis","canonical_id":"clinicaltrials.gov:NCT04642391","description":"Cirrhosis; Adrenal Insufficiency","metadata":null},{"id":"7abdb307129c4501aa593c6c90101490","type":"TRIAL","name":"Degarelix in the Treatment of Endometriosis Recurrence","canonical_id":"clinicaltrials.gov:NCT01712763","description":"Endometriosis","metadata":null},{"id":"705e7ccf60b94d3c8eadecb19a8e33ce","type":"DRUG","name":"Delavirdine","canonical_id":"mesh:D020008","description":null,"metadata":null},{"id":"ca8e0c51dcb542f58475d38aab2ceb96","type":"TRIAL","name":"Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study","canonical_id":"clinicaltrials.gov:NCT07572032","description":"Heart Failure Due to Coronary Artery Disease; Valvular Cardiomyopathy; Heart Failure","metadata":null},{"id":"e410876098584a14b58f5b9e09c3a872","type":"TRIAL","name":"Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children","canonical_id":"clinicaltrials.gov:NCT03826901","description":"Atopic Dermatitis","metadata":null},{"id":"a3f6f35f12b54460b03989fb8a70a909","type":"TRIAL","name":"Delirium Reduction With Ramelteon","canonical_id":"clinicaltrials.gov:NCT05069428","description":"Delirium","metadata":null},{"id":"0cb14cba0f0c44a0a1018c0e1437dc72","type":"TRIAL","name":"Delirium in Elderly Patients With Trauma of the Hip","canonical_id":"clinicaltrials.gov:NCT02689024","description":"Hip Fractures; Anesthesia","metadata":null},{"id":"aeb539ee1c25439b8b49fad8d1637369","type":"TRIAL","name":"Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells","canonical_id":"clinicaltrials.gov:NCT03107416","description":"Unresectable Hepatocellular Carcinoma","metadata":null},{"id":"15ef05c6bb74495e9590fc741daf07ab","type":"GO_TERM","name":"Delta1 complex","canonical_id":"go:GO:0070763","description":"\"A protein complex that consists of homodimer of the Notch ligand Delta1.\" [PMID:12794186]","metadata":null},{"id":"dc181ba1af4c430198b2628bdf541573","type":"GO_TERM","name":"Delta14-sterol reductase activity","canonical_id":"go:GO:0050613","description":"\"Catalysis of the reaction: NADP+ + 4,4-dimethyl-5-alpha-cholesta-8,24-dien-3-beta-ol = NADPH + H+ + 4,4-dimethyl-5-alpha-cholesta-8,14,24-trien-3-beta-ol.\" [EC:1.3.1.70]","metadata":null},{"id":"873fe1cf021e4a68a23645c7a9a22441","type":"GO_TERM","name":"Delta24(24-1) sterol reductase activity","canonical_id":"go:GO:0000246","description":"\"Catalysis of the reaction: ergosterol + NADP+ = ergosta-5,7,22,24(24(1))-tetraen-3beta-ol + H+ + NADPH.\" [EC:1.3.1.71, RHEA:18501]","metadata":null},{"id":"31972a32a07747cea0cf03da671f940e","type":"GO_TERM","name":"Delta24-sterol reductase activity","canonical_id":"go:GO:0050614","description":"\"Catalysis of the reaction: NADP+ + 5-alpha-cholest-7-en-3-beta-ol = NADPH + H+ + 5-alpha-cholesta-7,24-dien-3-beta-ol.\" [EC:1.3.1.72]","metadata":null},{"id":"e0802ed7a5ae492998b76eb9bd56c7d3","type":"GO_TERM","name":"Delta4-3-oxosteroid 5beta-reductase activity","canonical_id":"go:GO:0047787","description":"\"Catalysis of the reaction: a 3-oxo-5beta-steroid + NADP+ = a 3-oxo-Delta(4)-steroid + H+ + NADPH. The enzyme from human efficiently catalyzes the reduction of progesterone, androstenedione, 17alpha-hydroxyprogesterone and testosterone to 5beta-reduced metabolites; it can also act on aldosterone, corticosterone and cortisol, but to a lesser extent. The bile acid intermediates 7alpha,12alpha-dihydroxy-4-cholesten-3- one and 7alpha-hydroxy-4-cholesten-3-one can also act as substrates.\" [EC:1.3.1.3]","metadata":null},{"id":"a8c7ffbdb52849cc913711cdbfe16338","type":"DISEASE","name":"Dementia","canonical_id":"mesh:D003704","description":null,"metadata":null},{"id":"3b5ac0b3bf954984b7a1838c4c510bf8","type":"TRIAL","name":"Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT","canonical_id":"clinicaltrials.gov:NCT05783934","description":"Multiple Sclerosis","metadata":null},{"id":"ea9e0f43e6ca4c5bbfc3acbb461fa5dc","type":"TRIAL","name":"Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors","canonical_id":"clinicaltrials.gov:NCT01902771","description":"Glioma; Brain Cancer; Brain Tumor; Glioblastoma Multiforme; High Grade Glioma","metadata":null},{"id":"70fee6041e8e4a18851c1196fab04ae5","type":"TRIAL","name":"Denosumab Adherence Preference Satisfaction Study","canonical_id":"clinicaltrials.gov:NCT00518531","description":"Osteoporosis","metadata":null},{"id":"48c3e226294b44928cc836a31e4bfcaf","type":"TRIAL","name":"Denosumab Safety Assessment in Multiple Observational Databases","canonical_id":"clinicaltrials.gov:NCT02520362","description":"Osteoporosis","metadata":null},{"id":"1beb835c7f9342e8aaec63ccc460b02e","type":"TRIAL","name":"Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis","canonical_id":"clinicaltrials.gov:NCT03040765","description":"Thalassemia Majors (Beta-Thalassemia Major); Osteoporosis","metadata":null},{"id":"c53015129e194b36b8462aba9f641551","type":"TRIAL","name":"Denosumab and Screw Fixation for Osteoporotic Compression Fracture","canonical_id":"clinicaltrials.gov:NCT05065164","description":"Denosumab Allergy","metadata":null},{"id":"4256273637434e65938494c98b0a2aff","type":"TRIAL","name":"Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT03792763","description":"Multiple Myeloma","metadata":null},{"id":"767fe79326024ce8b6a7cac8a3e4573b","type":"TRIAL","name":"Denosumab for Treating Periprosthetic Osteolysis.","canonical_id":"clinicaltrials.gov:NCT02299817","description":"Osteolysis","metadata":null},{"id":"13cd98ce19ca422e8f67c1d794282f1b","type":"TRIAL","name":"Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT02632916","description":"Osteoporosis","metadata":null},{"id":"f6ea1886c7334e339d5d2d18e720f8e7","type":"TRIAL","name":"Denosumab vs Alendronate After Vertebroplasty","canonical_id":"clinicaltrials.gov:NCT05662358","description":"Denosumab Allergy","metadata":null},{"id":"89e05867c059493c9609f278d4881fea","type":"TRIAL","name":"Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00073164","description":"Schizophrenia","metadata":null},{"id":"7430d1bf22dd4f6782c33fd31e0b0dae","type":"TRIAL","name":"Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine","canonical_id":"clinicaltrials.gov:NCT05948553","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"4ddc8d5f90e6407495afe737a2b9906a","type":"TRIAL","name":"Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone","canonical_id":"clinicaltrials.gov:NCT05948579","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"e69314627e714f55b3e88daec08e78a9","type":"TRIAL","name":"Department of Defense PTSD Adaptive Platform Trial - Master Protocol","canonical_id":"clinicaltrials.gov:NCT05422612","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"5231c73567bd4f948ae9d0a019c4efa4","type":"TRIAL","name":"Depemokimab Asthma Imaging and Bronchoscopy Sub-Study","canonical_id":"clinicaltrials.gov:NCT06979323","description":"Asthma","metadata":null},{"id":"97022d2faed34525b61bbca9324bb8e3","type":"TRIAL","name":"Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation","canonical_id":"clinicaltrials.gov:NCT06959095","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"8090a3124d0e4b078e2121a55e9d5893","type":"TRIAL","name":"Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)","canonical_id":"clinicaltrials.gov:NCT06961214","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"350f35752c374b54b5c0532ca84c2c7f","type":"TRIAL","name":"Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial","canonical_id":"clinicaltrials.gov:NCT05334368","description":"Hypereosinophilic Syndrome","metadata":null},{"id":"47c2c99836f34e96a3c62b58330d4001","type":"TRIAL","name":"Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood","canonical_id":"clinicaltrials.gov:NCT02509767","description":"Contraception","metadata":null},{"id":"9e77367803c844ce85318fe6d11b5f30","type":"TRIAL","name":"Deposition of Inhaled Prolastin in Cystic Fibrosis Patients","canonical_id":"clinicaltrials.gov:NCT00486837","description":"Cystic Fibrosis","metadata":null},{"id":"e08b057251134c8fb7efca4215aa0396","type":"TRIAL","name":"Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT","canonical_id":"clinicaltrials.gov:NCT01471145","description":"Opioid-Related Disorders; Heroin Dependence","metadata":null},{"id":"04f2718b86004f9da6ebced8c8b4f7f5","type":"TRIAL","name":"Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo","canonical_id":"clinicaltrials.gov:NCT02604446","description":"Joint Diseases","metadata":null},{"id":"0c22f9ab48b64537961391164363c9df","type":"TRIAL","name":"Depression Related Improvement With Vardenafil for Erectile Response","canonical_id":"clinicaltrials.gov:NCT00661219","description":"Erectile Dysfunction; Depression","metadata":null},{"id":"701283b1b0ff4e0d8b4d2825e16f29e0","type":"TRIAL","name":"Depression and Health Outcomes in Refractory Epilepsy","canonical_id":"clinicaltrials.gov:NCT00026637","description":"Depression; Epilepsy","metadata":null},{"id":"fa60cbf59d43426cb6390b0f73ef98d8","type":"TRIAL","name":"Depression, Epinephrine, and Platelet Function","canonical_id":"clinicaltrials.gov:NCT00166114","description":"Major Depressive Disorder","metadata":null},{"id":"45e063f0bc454062afe992f48803ee25","type":"DISEASE","name":"Depressive disorder","canonical_id":"mesh:D003866","description":null,"metadata":null},{"id":"e232609eb86441ddaf1e444d4b47914f","type":"TRIAL","name":"Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer","canonical_id":"clinicaltrials.gov:NCT00091195","description":"Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer","metadata":null},{"id":"103c836f8beb49fcb2df1f5ba72a6d96","type":"TRIAL","name":"Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT00084682","description":"Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx","metadata":null},{"id":"12e2fef69b8a444db59dcf044744028c","type":"GO_TERM","name":"Derlin-1 retrotranslocation complex","canonical_id":"go:GO:0036513","description":"\"A protein complex that functions in the retrotranslocation step of ERAD (ER-associated protein degradation), and includes at its core Derlin-1 oligomers forming a retrotranslocation channel.\" [GOC:bf, GOC:PARL, PMID:15215856, PMID:16186510]","metadata":null},{"id":"9e1f5d9f95e547ad8fb084314c8cb842","type":"GO_TERM","name":"Derlin-1-VIMP complex","canonical_id":"go:GO:0036502","description":"\"A protein complex containing, in mammals, Derlin-1 and VCP-interacting membrane protein (VIMP). The complex links the p97/VCP-containing ATPase complex with Derlin-1 during translocation of protein substrates from the endoplasmic reticulum to the cytosol for degradation by the cytosolic proteasome.\" [GOC:bf, GOC:PARL, PMID:15215856, PMID:16186510]","metadata":null},{"id":"35843c23c6724ab69934ed907f456796","type":"DISEASE","name":"Dermatitis herpetiformis","canonical_id":"mesh:D003874","description":null,"metadata":null},{"id":"984ad15c4ece446b9e837ee72224df5e","type":"DISEASE","name":"Dermatitis, Contact","canonical_id":"mesh:D003877","description":null,"metadata":null},{"id":"5829d8bc27574f9884d087dd286007bf","type":"DISEASE","name":"Dermatitis, Exfoliative","canonical_id":"mesh:D003873","description":null,"metadata":null},{"id":"f38791f2bb1543fd9557364158917a5a","type":"DISEASE","name":"Dermatofibrosarcoma","canonical_id":"mesh:D018223","description":null,"metadata":null},{"id":"d7f059a7ed2d4a258a60d07816e8eea7","type":"DISEASE","name":"Dermatomyositis","canonical_id":"mesh:D003882","description":null,"metadata":null},{"id":"f6a2ccaa48ed4c2a9b1a51d63d8bd1e6","type":"DISEASE","name":"Dermatosis","canonical_id":"mesh:D012871","description":null,"metadata":null},{"id":"7845d5a571534418a3680be56734813e","type":"TRIAL","name":"Descemet Endothelial Thickness Comparison Trial","canonical_id":"clinicaltrials.gov:NCT02373137","description":"Keratoplasty; Grafting, Corneal; Transplantation, Corneal; Transplantation, Cornea; Keratoplasty, Lamellar","metadata":null},{"id":"7e5773391e084688bbacabc08fdf785b","type":"TRIAL","name":"Descemet Endothelial Thickness Comparison Trial I","canonical_id":"clinicaltrials.gov:NCT05289661","description":"Fuchs","metadata":null},{"id":"4b693a368cc24c899aea698367f06d0b","type":"TRIAL","name":"Descemet Endothelial Thickness Comparison Trial II","canonical_id":"clinicaltrials.gov:NCT05275972","description":"Fuchs; Fuchs Dystrophy; Fuchs' Endothelial Dystrophy","metadata":null},{"id":"e3ab979f6e624a7eacd7b13c13ab8c2b","type":"TRIAL","name":"Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France","canonical_id":"clinicaltrials.gov:NCT01552005","description":"Type 2 Diabetes Mellitus (T2D)","metadata":null},{"id":"99c4e67c1cf44c5fa69b3cf405b423dd","type":"TRIAL","name":"Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)","canonical_id":"clinicaltrials.gov:NCT05764317","description":"Arterial Hypertension; HTN","metadata":null},{"id":"1090466a7a8149a7b2bbf6c617f4db87","type":"TRIAL","name":"Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant","canonical_id":"clinicaltrials.gov:NCT01025193","description":"Desensitization","metadata":null},{"id":"57cd21d0576e4757b2a1dec3e6dddfad","type":"TRIAL","name":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","canonical_id":"clinicaltrials.gov:NCT03435003","description":"Post-operative Nausea and Vomiting; Laparoscopic Sleeve Gastrectomy","metadata":null},{"id":"0f8b0915801c41d9aa8a749d77089485","type":"TRIAL","name":"Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT01899326","description":"DS (Durie/Salmon) Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"2bce74efe1664b38977e5d352b5a8fe2","type":"TRIAL","name":"Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression","canonical_id":"clinicaltrials.gov:NCT00320632","description":"Depression","metadata":null},{"id":"52a07d4110ce40b5ba2d7592c9034323","type":"TRIAL","name":"Desipramine in Infantile Neuroaxonal Dystrophy (INAD).","canonical_id":"clinicaltrials.gov:NCT03726996","description":"Infantile Neuroaxonal Dystrophy","metadata":null},{"id":"a844047faff842a8a711bafca648135e","type":"TRIAL","name":"Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria","canonical_id":"clinicaltrials.gov:NCT01444196","description":"Urticaria","metadata":null},{"id":"6c3aaca348814b59891d061b2940c6ea","type":"TRIAL","name":"Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00816972","description":"Post-nasal Drip; Seasonal Allergic Rhinitis; Rhinorrhea","metadata":null},{"id":"8f085cf8884140bebd306531d59c6686","type":"TRIAL","name":"Desloratadine as Adjunct Therapy for Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT07632872","description":"Rheumatoid Arthritis (RA); Rheumatoid Arthritis","metadata":null},{"id":"cfe7356416484a6cb949307cb3a1bc58","type":"TRIAL","name":"Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu","canonical_id":"clinicaltrials.gov:NCT02904304","description":"Cold","metadata":null},{"id":"0650966f84a2419580ce2f777b6506d6","type":"DRUG","name":"Desmopressin","canonical_id":"mesh:D003894","description":null,"metadata":null},{"id":"e706e561b8454357bf4b14ad231fc6be","type":"DRUG","name":"Desoximetasone","canonical_id":"mesh:D003899","description":null,"metadata":null},{"id":"7138c6cd38ab4bbab93b8a0acc79b629","type":"TRIAL","name":"Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study","canonical_id":"clinicaltrials.gov:NCT01018134","description":"Psoriasis","metadata":null},{"id":"0e94dc37c39042ae9d855fc588b9eb97","type":"TRIAL","name":"Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study","canonical_id":"clinicaltrials.gov:NCT01043393","description":"Psoriasis","metadata":null},{"id":"6feeb0f02e0b47cf86371fd44b0a491d","type":"TRIAL","name":"Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache","canonical_id":"clinicaltrials.gov:NCT07359248","description":"Tension Type Headache","metadata":null},{"id":"c70f663738864118b49d91792a50ee3f","type":"TRIAL","name":"Desvenlafaxine for Preventive Treatment of Frequent Migraines","canonical_id":"clinicaltrials.gov:NCT07385755","description":"Migraine","metadata":null},{"id":"8073dccc4f554627903aad440a7234b7","type":"TRIAL","name":"Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen","canonical_id":"clinicaltrials.gov:NCT02819921","description":"Hot Flashes; Breast Neoplasms","metadata":null},{"id":"9f05c0b3e2914e7d81ad088b63d5d77d","type":"TRIAL","name":"Desvenlafaxine in Opioid-Dependent Patients","canonical_id":"clinicaltrials.gov:NCT02200406","description":"Depression; Opioid Dependence; Methadone Treatment","metadata":null},{"id":"3e6f16bd130c4f9f82da0afbf5a5f617","type":"TRIAL","name":"Desvenlafaxine vs. Placebo Treatment of Chronic Depression","canonical_id":"clinicaltrials.gov:NCT01537068","description":"Dysthymic Disorder; Dysthymia; Chronic Depressive Disorder","metadata":null},{"id":"b9cf9a531b314d6985e43b8c68f5a8ae","type":"TRIAL","name":"Detecting an Early Response to Donepezil With Measures of Visual Attention","canonical_id":"clinicaltrials.gov:NCT03073876","description":"Alzheimer Disease","metadata":null},{"id":"b73dbfbb47ab4513a3195611dc145f40","type":"TRIAL","name":"Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography","canonical_id":"clinicaltrials.gov:NCT03779815","description":"Multiple Myeloma","metadata":null},{"id":"3c55d4a0bc26477cb96a60054949d741","type":"TRIAL","name":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","canonical_id":"clinicaltrials.gov:NCT05625087","description":"Breast Cancer Stage IV","metadata":null},{"id":"128f8c00e20b46aebef60c1b26900bc7","type":"TRIAL","name":"Determinants of Warfarin Metabolism","canonical_id":"clinicaltrials.gov:NCT00162474","description":"Healthy","metadata":null},{"id":"b7bd34edf0b747b1a74ff742258048a7","type":"TRIAL","name":"Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.","canonical_id":"clinicaltrials.gov:NCT01636908","description":"Cancer; Advanced Solid Tumors","metadata":null},{"id":"e4ba1ff326bc4b49b4d8ddfe012811f9","type":"TRIAL","name":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT00758199","description":"Cataracts","metadata":null},{"id":"808d24c9df694a4289c48d5b09320d7e","type":"TRIAL","name":"Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists","canonical_id":"clinicaltrials.gov:NCT07702461","description":"Obesity & Overweight; Diabetes (DM)","metadata":null},{"id":"d336021fc2d5435aaae8032092b19219","type":"TRIAL","name":"Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents","canonical_id":"clinicaltrials.gov:NCT00321711","description":"MDS; Myelodysplastic Syndromes; Thrombocytopenia","metadata":null},{"id":"b404c3c228934c2789c8586602fe6642","type":"TRIAL","name":"Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT02846701","description":"Neuropathic Pain","metadata":null},{"id":"5a09835529c64670bf697e35ad9ff0b6","type":"TRIAL","name":"Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users","canonical_id":"clinicaltrials.gov:NCT03152123","description":"Healthy; Drug Abuse","metadata":null},{"id":"0b2ec20d2d584c35bed2dca78f5be108","type":"TRIAL","name":"Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)","canonical_id":"clinicaltrials.gov:NCT05925803","description":"Systemic Sclerosis; Scleroderma","metadata":null},{"id":"fa5a727586d741bea8f6c8afd47a07b8","type":"TRIAL","name":"Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02765724","description":"Myelofibrosis","metadata":null},{"id":"abc598b4b5804f62a24a0762ad1b7be7","type":"TRIAL","name":"Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06607744","description":"MDD","metadata":null},{"id":"ce0f5906962544f8a28257407ae3a5bf","type":"TRIAL","name":"Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.","canonical_id":"clinicaltrials.gov:NCT02417831","description":"Prostatic Hyperplasia","metadata":null},{"id":"3771c6faff9741528fef5fe40b95c14b","type":"TRIAL","name":"Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.","canonical_id":"clinicaltrials.gov:NCT02417844","description":"Prostatic Hyperplasia","metadata":null},{"id":"a67954a2d1eb476286fc03ee8f2196e1","type":"TRIAL","name":"Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas","canonical_id":"clinicaltrials.gov:NCT03971734","description":"High Grade Glioma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioblastoma","metadata":null},{"id":"3949781b12a049b4afbde5b22f45195c","type":"TRIAL","name":"Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01040403","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"97dfb0498c9b4e4c8f39cbfed3786b5a","type":"TRIAL","name":"Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)","canonical_id":"clinicaltrials.gov:NCT04245748","description":"Anxious Depression; Depression","metadata":null},{"id":"495bc7a886d145c0b1b3c71a1d94f721","type":"TRIAL","name":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT04218552","description":"Hypertension,Essential","metadata":null},{"id":"f07567c0cd8c4c7f9a5ce687f5c4f2c1","type":"TRIAL","name":"Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00183612","description":"Bipolar Disorder; Psychotic Disorders","metadata":null},{"id":"efb41bd794dd45cb9e7fee37d34d42f1","type":"TRIAL","name":"Detoxification From the Lipid Tract","canonical_id":"clinicaltrials.gov:NCT06357104","description":"COVID-19 Vaccine Adverse Reaction","metadata":null},{"id":"12133b9d192646fea7a26ec8e19b056b","type":"TRIAL","name":"Deucravacitinib Rosacea","canonical_id":"clinicaltrials.gov:NCT06532136","description":"Papulopustular Rosacea","metadata":null},{"id":"c8e458bb0fb746e195e4f49223e8bc76","type":"TRIAL","name":"Deucravacitinib for the Treatment of Palmoplantar Pustulosis","canonical_id":"clinicaltrials.gov:NCT05710185","description":"Palmoplantar Pustulosis","metadata":null},{"id":"ee84393539ec47778f33d9e7598df047","type":"TRIAL","name":"Deucravacitinib in PG","canonical_id":"clinicaltrials.gov:NCT05821374","description":"Pyoderma Gangrenosum","metadata":null},{"id":"32e34ba9dac24c5496bf427c80dfadef","type":"TRIAL","name":"Deucravacitinib in the Treatment of Cicatricial Alopecias","canonical_id":"clinicaltrials.gov:NCT07508488","description":"Central Centrifugal Cicatricial Alopecia; Frontal Fibrosing Alopecia","metadata":null},{"id":"41b81f65625e452994ea234fbb0e343c","type":"DRUG","name":"Deutetrabenazine","canonical_id":"mesh:C000609690","description":null,"metadata":null},{"id":"8919224e348a4cd5837b6daac0f4abea","type":"TRIAL","name":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","canonical_id":"clinicaltrials.gov:NCT06997198","description":"Tardive Dyskinesia; Intellectual Disability; Developmental Disabilities","metadata":null},{"id":"863cbae2662043f09948e3bb32b11e0e","type":"TRIAL","name":"Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01576185","description":"Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies","metadata":null},{"id":"c51d9608d4f041be85149dafd4522f89","type":"TRIAL","name":"Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning","canonical_id":"clinicaltrials.gov:NCT00935246","description":"Depression; Continuous Antidepressant Abuse; Adverse Reaction to Drug","metadata":null},{"id":"cf1fae30ef894f1dbabde90f09ed8eca","type":"TRIAL","name":"Development of Ibudilast for Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT02025998","description":"Alcohol Use Disorders","metadata":null},{"id":"9a2c820e53ca44bba36309bb66325ae7","type":"TRIAL","name":"Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT02503865","description":"Metabolic Syndrome","metadata":null},{"id":"ea7bd06ad0e84c01ad638aa9178568dd","type":"TRIAL","name":"Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT01976078","description":"Pharmacokinetics; Voriconazole","metadata":null},{"id":"6611d7f79d0b4bccb3f5271764c38f21","type":"TRIAL","name":"Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio\u00ae) in Patients With ulcErative ColiTis (DETECT)","canonical_id":"clinicaltrials.gov:NCT02878083","description":"ULCERATIVE COLITIS","metadata":null},{"id":"904c9ee274b54259ae5ee225c07efdfd","type":"TRIAL","name":"Dexamethasone Before Elective Cesarean Section at Term in Reducing Neonatal Respiratory Distress Syndrome","canonical_id":"clinicaltrials.gov:NCT04816097","description":"C08.381.840.500.475; C08.381.840.500.737","metadata":null},{"id":"7c5bda5b49424c05bc6f4daabd376401","type":"TRIAL","name":"Dexamethasone Compared With Dexmedetomidine as an Adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block","canonical_id":"clinicaltrials.gov:NCT02787018","description":"Brachial Plexus Block","metadata":null},{"id":"43c1f780148f4fa799b1a548cd487053","type":"TRIAL","name":"Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients","canonical_id":"clinicaltrials.gov:NCT04538820","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"41e32b93224b449aa763de3a23e15f3f","type":"TRIAL","name":"Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel","canonical_id":"clinicaltrials.gov:NCT02491411","description":"Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer","metadata":null},{"id":"7e9d049c451642dda635772f8f8e5c8c","type":"TRIAL","name":"Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders","canonical_id":"clinicaltrials.gov:NCT02266433","description":"DeQuervains Tenosynovitis; Lateral Epicondylitis; Tennis Elbow; Trigger Finger; Tenosynovitis; Inflammatory Disease","metadata":null},{"id":"3b60a814637549c18bb996affce76d41","type":"TRIAL","name":"Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure","canonical_id":"clinicaltrials.gov:NCT00416897","description":"Multiple Myeloma and Plasma Cell Neoplasm; Renal Failure","metadata":null},{"id":"f4b7c033c4204fe6a460deaeb78df9e9","type":"TRIAL","name":"Dexamethasone for Post Traumatic Headache","canonical_id":"clinicaltrials.gov:NCT04799015","description":"Post-Traumatic Headache","metadata":null},{"id":"4547dc5c5a3343b6ac4ec2f2d4865d4f","type":"TRIAL","name":"Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00316927","description":"Prostate Cancer","metadata":null},{"id":"a00b52643bc14074a44944e71cfb7aff","type":"TRIAL","name":"Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP","canonical_id":"clinicaltrials.gov:NCT02400047","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"6b54b7a0e4374dcea52ba13f70ac9e10","type":"TRIAL","name":"Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03605719","description":"Recurrent Plasma Cell Myeloma","metadata":null},{"id":"8b0591ae6bde49b589f02f7ee301c5dd","type":"TRIAL","name":"Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery","canonical_id":"clinicaltrials.gov:NCT03172988","description":"Carcinoma, Non-Small-Cell Lung; Surgery; Dexamethasone; Flubiprofen Axetil; Long-term Effects Secondary to Cancer Therapy in Adults","metadata":null},{"id":"b33eea643c3e4c99a6aa23d9da97476a","type":"DRUG","name":"Dexamfetamine","canonical_id":"mesh:D003913","description":null,"metadata":null},{"id":"19f73e65c51b406da3fbb47f357740bc","type":"TRIAL","name":"Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia","canonical_id":"clinicaltrials.gov:NCT02363075","description":"Glioma","metadata":null},{"id":"b185360714a0474a91ff26aa0f921654","type":"DRUG","name":"Dexbrompheniramine","canonical_id":"mesh:C015121","description":null,"metadata":null},{"id":"2e04d498580b424c93dc29b91af7e867","type":"DRUG","name":"Dexchlorpheniramine","canonical_id":"mesh:C018904","description":null,"metadata":null},{"id":"d197c5788a154f82948074a03ecf123a","type":"TRIAL","name":"Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT02568735","description":"Pain, Postoperative","metadata":null},{"id":"858b5dd1ed5047368c819e6a5a47c5f7","type":"DRUG","name":"Dexlansoprazole","canonical_id":"mesh:D064748","description":null,"metadata":null},{"id":"0568b47a7fa14ba194c1b70f1b5219a5","type":"TRIAL","name":"Dexmed/Buspirone Synergism on Shivering","canonical_id":"clinicaltrials.gov:NCT00334360","description":"Hypothermia","metadata":null},{"id":"e3019a30d84841e692ab890a0b74d32a","type":"TRIAL","name":"Dexmedetomidine Cycling and Sleep in the Pediatric ICU","canonical_id":"clinicaltrials.gov:NCT05003102","description":"Critical Illness; Sedation Complication; Delirium","metadata":null},{"id":"fffaee6994354f8d859bc79ac1883c8e","type":"TRIAL","name":"Dexmedetomidine Versus Dexmedetomidine with Ketamine in Mechanically Ventilated ARDS Patients","canonical_id":"clinicaltrials.gov:NCT05951387","description":"Haemodynamic Instability","metadata":null},{"id":"6b20b92d8588490d9bad4f41e32be37a","type":"TRIAL","name":"Dexmedetomidine Versus Ketamine as Adjuvants in Bariatric Surgery","canonical_id":"clinicaltrials.gov:NCT06738043","description":"Obesity; Postoperative Pain; Bariatric Surgery","metadata":null},{"id":"8769c543f0d4484f8987654d70493e64","type":"TRIAL","name":"Dexmedetomidine Versus Lidocaine Infusions as Adjuvants to General Anesthesia for Chronic Pain Management After Mastectomy","canonical_id":"clinicaltrials.gov:NCT06910644","description":"Dexmedetomidine; Lidocaine; Infusion; Adjuvants; General Anesthesia; Chronic Pain; Mastectomy","metadata":null},{"id":"eecc014f13fa456c96679725ac554a55","type":"TRIAL","name":"Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery","canonical_id":"clinicaltrials.gov:NCT03067896","description":"Cesarean Section","metadata":null},{"id":"ac67147da88f432ca91d8d270c39093a","type":"TRIAL","name":"Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children","canonical_id":"clinicaltrials.gov:NCT01091818","description":"Sedation","metadata":null},{"id":"2df74cd991704d19acf28db9bda87473","type":"TRIAL","name":"Dexmedetomidine Versus Nalbuphine as an Adjuvant to Intrathecal Bupivacaine","canonical_id":"clinicaltrials.gov:NCT05347173","description":"Analgesia","metadata":null},{"id":"340010efebac480498d75a4096178b8e","type":"TRIAL","name":"Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients","canonical_id":"clinicaltrials.gov:NCT02606409","description":"Trauma","metadata":null},{"id":"d4a3972547634bea9ead9aa51f8b6785","type":"TRIAL","name":"Dexmedetomidine and Agitation After Nasal Surgery","canonical_id":"clinicaltrials.gov:NCT06867302","description":"Nasal Disease; Agitation, Emergence","metadata":null},{"id":"656f4b5307e9446ab5d102640d718958","type":"TRIAL","name":"Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction","canonical_id":"clinicaltrials.gov:NCT03892512","description":"Cognitive Dysfunction","metadata":null},{"id":"217c5661fca848b18e59f18b62c7eb98","type":"TRIAL","name":"Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation","canonical_id":"clinicaltrials.gov:NCT00839605","description":"Esophageal Cancer; Lung Cancer; Chest Wall Disorders","metadata":null},{"id":"4a9994d06054460fbef51a134bac02a5","type":"TRIAL","name":"Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block.","canonical_id":"clinicaltrials.gov:NCT06490614","description":"Anterior Cervical Discectomy and Fusion (ACDF)","metadata":null},{"id":"1468e1d3fe1849c190b6dec90589f8a2","type":"TRIAL","name":"Dexmedetomidine for Analgosedation to Newborn Infants During Neonatal Intensive Care","canonical_id":"clinicaltrials.gov:NCT06482775","description":"Intensive Care, Neonatal; Analgesia; Hypnotics and Sedatives","metadata":null},{"id":"5b03f40039e14366b41fb00f9c0fd56f","type":"TRIAL","name":"Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery","canonical_id":"clinicaltrials.gov:NCT04730609","description":"Shivering; Dose Finding Study","metadata":null},{"id":"b65b2186cec7446080de0bd709a965e0","type":"TRIAL","name":"Dexmedetomidine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT02031510","description":"Elective Laparoscopic Cholecystectomy","metadata":null},{"id":"3f8ae662e1ec4f9489443471f45e06ad","type":"TRIAL","name":"Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02550795","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"065e99caca654c0a8614a8d1fb7084f1","type":"TRIAL","name":"Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation","canonical_id":"clinicaltrials.gov:NCT01151865","description":"Delirium","metadata":null},{"id":"8fb4c18f1f504b10817c31e05a3d829b","type":"TRIAL","name":"Dexmedetomidine-propofol-remifentanil Anaesthesia and Reactivity to Noxious Stimuli","canonical_id":"clinicaltrials.gov:NCT01076790","description":"Anaesthesia","metadata":null},{"id":"63cb904622584342a5216b03527900a2","type":"DRUG","name":"Dexmethylphenidate","canonical_id":"mesh:D064699","description":null,"metadata":null},{"id":"217d11a552294dc4bd34058c0019d471","type":"TRIAL","name":"Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00829712","description":"Healthy","metadata":null},{"id":"6c494477f112498a9d94fe15a68a10e9","type":"TRIAL","name":"Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00829673","description":"Healthy","metadata":null},{"id":"acb2852714ea4ecb8e43995872b6c3fe","type":"TRIAL","name":"Dexmetomidine in Children Undergoing General Anaesthesia","canonical_id":"clinicaltrials.gov:NCT03923075","description":"Anesthesia","metadata":null},{"id":"3d7c363bb2e54df6b95843a73f7a4aef","type":"TRIAL","name":"Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT04046939","description":"Eosinophilic Asthma; Asthma","metadata":null},{"id":"58ca5ca5c5aa4e9f9febfd50ec230e03","type":"TRIAL","name":"Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study","canonical_id":"clinicaltrials.gov:NCT01597310","description":"Healthy Volunteers","metadata":null},{"id":"12ee7d62cf42403ca11a8d491e3d708f","type":"TRIAL","name":"Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers","canonical_id":"clinicaltrials.gov:NCT03589729","description":"Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Myeloid Sarcoma; Myeloproliferative Neoplasm; Philadelphia Chromosome Positive","metadata":null},{"id":"20378079db17489698cb170cab51c035","type":"TRIAL","name":"Dextenza With ILUX for Treatment of MGD","canonical_id":"clinicaltrials.gov:NCT04658927","description":"Meibomian Gland Dysfunction; Evaporative Dry Eye","metadata":null},{"id":"9d42ff92e62a46e691ef5639a898f038","type":"DRUG","name":"Dezocine","canonical_id":"mesh:C010827","description":null,"metadata":null},{"id":"37733af4f1ec4dfa96d026c840d9cb1e","type":"TRIAL","name":"Dezocine for Prevention of Catheter-related Bladder Discomfort","canonical_id":"clinicaltrials.gov:NCT03147066","description":"Catheter Related Bladder Discomfort","metadata":null},{"id":"475139d109004faca6db3d4d3534fbf9","type":"TRIAL","name":"DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study","canonical_id":"clinicaltrials.gov:NCT05727579","description":"Diabetes Mellitus; Diabetic Kidney Disease; Hypertension","metadata":null},{"id":"ed6ac24fddf5444cac7b56b0ca87cc75","type":"TRIAL","name":"DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT06983054","description":"Type 2 Diabetes","metadata":null},{"id":"2e25432dd15d40639a81c17c087e8226","type":"GO_TERM","name":"DiaA complex","canonical_id":"go:GO:1990125","description":"\"A homotetrameric protein complex consisting of a symmetrical pair of DiaA homodimers. Facilitates DnaA binding to the origin of replication during replication initiation.\" [GOC:bhm, PMID:17699754]","metadata":null},{"id":"60301524d0bf447a944b436218d83031","type":"TRIAL","name":"Diabetes & Vardenafil","canonical_id":"clinicaltrials.gov:NCT02219646","description":"Type 2 Diabetes Mellitus (T2DM); Endothelial Dysfunction; Erectile Dysfunction","metadata":null},{"id":"fb2208e487fb41abbd6eb50c2b71e2d6","type":"TRIAL","name":"Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide","canonical_id":"clinicaltrials.gov:NCT00279045","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"bc850169e53042fa9253771b3e4eb1c6","type":"TRIAL","name":"Diabetes Therapy to Improve BMI and Lung Function in CF","canonical_id":"clinicaltrials.gov:NCT00072904","description":"Cystic Fibrosis; Diabetes Mellitus","metadata":null},{"id":"980aa21f701444a39a6d6e0fc9341283","type":"TRIAL","name":"Diabetes in Neuropsychiatric Disorders","canonical_id":"clinicaltrials.gov:NCT00446992","description":"Schizophrenia","metadata":null},{"id":"a3a93a9236434791a565fccda97495a2","type":"DISEASE","name":"Diabetes mellitus","canonical_id":"mesh:D003920","description":null,"metadata":null},{"id":"9408d8ccc1384e65b5c35e63f02346e7","type":"DISEASE","name":"Diabetes mellitus type 1","canonical_id":"mesh:D003922","description":null,"metadata":null},{"id":"5a889af1ee844232b55660e7132eff9c","type":"DISEASE","name":"Diabetes mellitus type 2","canonical_id":"mesh:D003924","description":null,"metadata":null},{"id":"458281722c454e7daa1d061bccd51e9b","type":"DISEASE","name":"Diabetic Nephropathies","canonical_id":"mesh:D003928","description":null,"metadata":null},{"id":"094d7daacc4a4e78a356e3cf2bdcf23c","type":"TRIAL","name":"Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA\u00ae","canonical_id":"clinicaltrials.gov:NCT01591902","description":"Diabetic Retinopathy; HIV","metadata":null},{"id":"bb0877eb9f564139838f831f9e596821","type":"TRIAL","name":"Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm","canonical_id":"clinicaltrials.gov:NCT03478306","description":"Diabetic Retinopathy; Melatonin; Circadian Dysrhythmia; Circadian Rhythm Sleep Disorder, Unspecified Type","metadata":null},{"id":"df860f6c082b4c6f87611faac18051dd","type":"DISEASE","name":"Diabetic complication","canonical_id":"mesh:D048909","description":null,"metadata":null},{"id":"e8d14cf590c4471f9efbdc9fbb277ad3","type":"DISEASE","name":"Diabetic retinopathy","canonical_id":"mesh:D003930","description":null,"metadata":null},{"id":"7a8d969029ee495fb34bf34299c62515","type":"PROTEIN","name":"Diacylglycerol O-acyltransferase 1","canonical_id":"uniprot:O75907","description":null,"metadata":null},{"id":"115469cc6c6048b7973c0a48c2350c5e","type":"TRIAL","name":"Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure","canonical_id":"clinicaltrials.gov:NCT02546583","description":"Heart Failure","metadata":null},{"id":"c1d5745a6a5340b78c0fce75090a195b","type":"TRIAL","name":"Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study","canonical_id":"clinicaltrials.gov:NCT02081404","description":"Non-erosive Reflux Disease","metadata":null},{"id":"c9d573a419bf47d989ccd755bea347c4","type":"TRIAL","name":"Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome","canonical_id":"clinicaltrials.gov:NCT02368379","description":"Prader Willi Syndrome; Adrenal Insufficiency","metadata":null},{"id":"cc28b76946544b41bd9135e1d469f239","type":"TRIAL","name":"Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity","canonical_id":"clinicaltrials.gov:NCT00917345","description":"Primary Aldosteronism","metadata":null},{"id":"ce38cb82052a4b488e9961f6c9e526b6","type":"TRIAL","name":"Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis","canonical_id":"clinicaltrials.gov:NCT05015829","description":"Aortic Valve Stenosis; Valvular Stenosis; Valvular Heart Disease","metadata":null},{"id":"218f5566310f4b70b2b9da01d601825f","type":"TRIAL","name":"Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.","canonical_id":"clinicaltrials.gov:NCT00407784","description":"Hyperaldosteronism; Hypertension","metadata":null},{"id":"dafd5687d35c4c09887f427584a6866f","type":"TRIAL","name":"Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT01446094","description":"Coronary Artery Disease","metadata":null},{"id":"89abab3c525a42918435b791420b91a3","type":"TRIAL","name":"Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression","canonical_id":"clinicaltrials.gov:NCT06510894","description":"Cardiac Sarcoidosis","metadata":null},{"id":"7393d15fec8a4f67972824a6b43834f4","type":"DISEASE","name":"Diaper Rash","canonical_id":"mesh:D003963","description":null,"metadata":null},{"id":"17cb866ddee84ab7bb44cac291421a7e","type":"TRIAL","name":"Diaphragmatic Ultrasound With Theophylline Therapeutic Trials","canonical_id":"clinicaltrials.gov:NCT04269187","description":"Diaphragmatic Dysfunction in Critically Ill Patients","metadata":null},{"id":"a1de69fdd57b4d9195ef4df5d1c500ff","type":"DISEASE","name":"Diarrhea","canonical_id":"mesh:D003967","description":null,"metadata":null},{"id":"126915b5a3bb4cf296bc62261372482c","type":"TRIAL","name":"Diarrhea Predominant Irritable Bowel Syndrome in Females","canonical_id":"clinicaltrials.gov:NCT00461526","description":"Irritable Bowel Syndrome","metadata":null},{"id":"6cc1f843b6ba4aa4a2e2c7e974fdbb71","type":"TRIAL","name":"Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02910219","description":"Breast Cancer","metadata":null},{"id":"ca5a00ceb9b24337bdbb158682828d71","type":"DRUG","name":"Diazepam","canonical_id":"mesh:D003975","description":null,"metadata":null},{"id":"6ee7680d3e7d4612b92c86da28da0651","type":"TRIAL","name":"Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study","canonical_id":"clinicaltrials.gov:NCT03953820","description":"Epilepsy","metadata":null},{"id":"5f8c680de8264304a2a6b5ba542ff28b","type":"TRIAL","name":"Diazepam Use With Standard Management for Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT02646124","description":"Low Back Pain","metadata":null},{"id":"8432951ca19d404d807d6b5a6a2ccc52","type":"TRIAL","name":"Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.","canonical_id":"clinicaltrials.gov:NCT01233791","description":"Female Patients With High Tone Pelvic Floor Dysfunction","metadata":null},{"id":"ea2664a1c1ae40b3a9d4b23f3d37926e","type":"DRUG","name":"Dichloroacetic Acid","canonical_id":"mesh:D003999","description":null,"metadata":null},{"id":"0c442c48ef3a45a3a5cbac4e624e12a1","type":"TRIAL","name":"Dichotic Listening as a Predictor of Medication Response in Depression","canonical_id":"clinicaltrials.gov:NCT00296725","description":"Major Depression; Dysthymia; Depressive Disorder Not Otherwise Specified","metadata":null},{"id":"f152343dbc9b49f4a97e89572aae5a76","type":"TRIAL","name":"Dichotic Listening as a Predictor of Medication Response in Depression","canonical_id":"clinicaltrials.gov:NCT00404755","description":"Major Depressive Disorder; Dysthymia","metadata":null},{"id":"a8d75269580b4593af21c18a6dee66b1","type":"TRIAL","name":"Diclofenac Potassium on IANB Efficacy in Symptomatic Irreversible Pulpitis","canonical_id":"clinicaltrials.gov:NCT03163420","description":"Irreversible Pulpitis","metadata":null},{"id":"88d2ef2402f540ce9fad44f420939de7","type":"TRIAL","name":"Diclofenac for Prevention of Post-ERC Pancreatitis","canonical_id":"clinicaltrials.gov:NCT03595150","description":"Common Bile Duct Diseases","metadata":null},{"id":"fa9fb96173154061a7d02c57206b3965","type":"DRUG","name":"Dicloxacillin","canonical_id":"mesh:D004009","description":null,"metadata":null},{"id":"4b6510462177449b8fbd42274bef7143","type":"DRUG","name":"Dicycloverine","canonical_id":"mesh:D004025","description":null,"metadata":null},{"id":"3cc28cd733eb4bd488a35b9bb8eb6d88","type":"TRIAL","name":"Diesel Exhaust and Vascular Function","canonical_id":"clinicaltrials.gov:NCT01508637","description":"Cardiovascular Effects","metadata":null},{"id":"01b10ee1a4aa45528d128ffb4be38aca","type":"TRIAL","name":"Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT00246376","description":"Cardiovascular Diseases; Heart Diseases; HIV Infections; Hyperlipidemia; Hypertriglyceridemia; Insulin Resistance; Atherosclerosis","metadata":null},{"id":"1354b2ef1f9c4da78333e1766f2a659f","type":"TRIAL","name":"Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00607945","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"15f148cb1d074fc98c3cdf4aca917986","type":"TRIAL","name":"Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT01846962","description":"Eosinophilic Esophagitis","metadata":null},{"id":"318050d2f1fc47d89983264955cab160","type":"DRUG","name":"Diethylcarbamazine","canonical_id":"mesh:D004049","description":null,"metadata":null},{"id":"85e0b38b83dd402e835389bd7c08a110","type":"TRIAL","name":"Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT07526324","description":"Itching Symptoms; CKD 5D, Hemodialysis","metadata":null},{"id":"e02d4ee99be144098527560c82195fe9","type":"TRIAL","name":"Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts","canonical_id":"clinicaltrials.gov:NCT04310995","description":"Coronary Artery Bypass Graft; Radial Artery Grafts; Antispastic Therapy; Pilot Study","metadata":null},{"id":"5974b996164042ffb23a4a84f6ab972b","type":"TRIAL","name":"Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT00888186","description":"Parkinson Disease; Dyskinesias","metadata":null},{"id":"a083a8c3647340aaad3a0dd6a4815ce8","type":"TRIAL","name":"Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","canonical_id":"clinicaltrials.gov:NCT07147101","description":"Advanced Hepatocellular Carcinoma (HCC)","metadata":null},{"id":"1f819d3a36aa4fc29d039b8f72aa0be1","type":"TRIAL","name":"Different Metabolic Effects of Statins","canonical_id":"clinicaltrials.gov:NCT01011127","description":"Hypercholesterolemia","metadata":null},{"id":"73a9838cc4734ed48c06cbf7039f6f8d","type":"TRIAL","name":"Different Methods of Tranexamic Acid Application in Controlling Peri Operative Bleeding in Gynecomastia Surgery","canonical_id":"clinicaltrials.gov:NCT06509256","description":"Pharmacological-Aggravated Urticaria","metadata":null},{"id":"9231f23e1e3c4ef7881a2b4d9c5d0d61","type":"TRIAL","name":"Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients","canonical_id":"clinicaltrials.gov:NCT03078257","description":"Coronary Artery Disease","metadata":null},{"id":"3f7cac88ca79455c864aef437a3cac4d","type":"TRIAL","name":"Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)","canonical_id":"clinicaltrials.gov:NCT00257751","description":"Coronary Artery Disease","metadata":null},{"id":"f1b47c3e65334183a0b5bba3563a0335","type":"TRIAL","name":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","canonical_id":"clinicaltrials.gov:NCT00550992","description":"Leukemia","metadata":null},{"id":"4c718ec16e154273bfdc91e4220094bc","type":"TRIAL","name":"Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation","canonical_id":"clinicaltrials.gov:NCT00487032","description":"Allergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa","metadata":null},{"id":"bd2091715b0a4d0aaaf84e73f2b88570","type":"TRIAL","name":"Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy","canonical_id":"clinicaltrials.gov:NCT01560091","description":"Kidney Stones","metadata":null},{"id":"2a5fb282d63d4cd593edd23d3101bfb9","type":"TRIAL","name":"Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation","canonical_id":"clinicaltrials.gov:NCT01291056","description":"Mood","metadata":null},{"id":"c1a3af7cdab6471f85f9bb2bf3240896","type":"TRIAL","name":"Differential Effects of Zolpidem Versus Ramelteon in Burned Children","canonical_id":"clinicaltrials.gov:NCT00539110","description":"Sleep; Burns","metadata":null},{"id":"64d069781916492e83022e3cd130f730","type":"TRIAL","name":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00996697","description":"COPD","metadata":null},{"id":"97bbcb9c2d444ab1a4dcd210bee9912d","type":"TRIAL","name":"Differin\u00ae Gel x12 Wks vs Tazorac\u00ae Cream x12 Wks vs Differin\u00ae x6 Wks Switched to Tazorac\u00ae x6 Wks for Treatment of Acne","canonical_id":"clinicaltrials.gov:NCT00469755","description":"Acne Vulgaris","metadata":null},{"id":"7ce350cb3b4b43959aa9acfa39f5bedd","type":"TRIAL","name":"Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser","canonical_id":"clinicaltrials.gov:NCT00668239","description":"Macular Edema","metadata":null},{"id":"88126749a2ad430b9f26c7421ee928da","type":"DISEASE","name":"Diffuse non-Hodgkin's lymphoma, large cell","canonical_id":"mesh:D016403","description":null,"metadata":null},{"id":"1b8ef7634cef44cb80d9efe2ae48abf1","type":"DRUG","name":"Diflorasone diacetate","canonical_id":"mesh:C014477","description":null,"metadata":null},{"id":"8ee76685912b46da8380d8cdd91bb2a9","type":"TRIAL","name":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06059118","description":"Prostate Cancer","metadata":null},{"id":"1cabc5b911904e83b387fcd74af6c8af","type":"TRIAL","name":"Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT01124045","description":"Cataracts; Inflammation","metadata":null},{"id":"3832f8ee30b9443b9ae9951666ef2d9e","type":"TRIAL","name":"Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.","canonical_id":"clinicaltrials.gov:NCT04631315","description":"Cataract","metadata":null},{"id":"14cdb4de3c3b4d73aa5e2692355314bf","type":"TRIAL","name":"Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine","canonical_id":"clinicaltrials.gov:NCT00775463","description":"Systemic Sclerosis; Scleroderma","metadata":null},{"id":"e2f0fcaac6e04e5a919477a3cff34ffb","type":"TRIAL","name":"Digoxin After Acute Heart Failure (DIG-DICA)","canonical_id":"clinicaltrials.gov:NCT07321509","description":"Acute Heart Failure (AHF)","metadata":null},{"id":"f497d8d80d634c68b7de75416cc6e6a3","type":"TRIAL","name":"Digoxin Medulloblastoma Study","canonical_id":"clinicaltrials.gov:NCT06701812","description":"Medulloblastoma; Medulloblastoma, Non-WNT/Non-SHH","metadata":null},{"id":"5ba5765904ea4a938ccffc2052ebca6d","type":"TRIAL","name":"Digoxin Short Term Treatment Assessment Randomized Trial in AHF","canonical_id":"clinicaltrials.gov:NCT02544815","description":"Acute Heart Failure","metadata":null},{"id":"143c7f6d7d16439889ac539b0aa6b626","type":"TRIAL","name":"Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma","canonical_id":"clinicaltrials.gov:NCT05507775","description":"Non-Medullary Thyroid Carcinoma","metadata":null},{"id":"6d62701a4f634076aecd9c0369459d6c","type":"DRUG","name":"Dihydroergotamine","canonical_id":"mesh:D004087","description":null,"metadata":null},{"id":"ac2e9e85a8d341519961d8fee9a27f15","type":"PROTEIN","name":"Dihydropteroate synthase","canonical_id":"uniprot:U5EHR3","description":null,"metadata":null},{"id":"79bb28b317554dcc85b08d132a117a09","type":"PROTEIN","name":"Dihydropteroate synthase","canonical_id":"uniprot:Q8GND6","description":null,"metadata":null},{"id":"08bdab06e12245a8929f14d081d736de","type":"PROTEIN","name":"Dihydropteroate synthase","canonical_id":"uniprot:O44030","description":null,"metadata":null},{"id":"20c8cdc2d2a84472bccef84dfb1b45a8","type":"PROTEIN","name":"Dihydropteroate synthase (Cutibacterium acnes)","canonical_id":"uniprot:A0A2B7ICU0","description":null,"metadata":null},{"id":"1a48b1e6611c41839c60c149545623df","type":"PROTEIN","name":"Dihydropteroate synthase (Mycobacterium leprae)","canonical_id":"uniprot:P0C0X1","description":null,"metadata":null},{"id":"d2da7ef19c6e432cb74a8d58079722d6","type":"PROTEIN","name":"Dihydropteroate synthase (Mycobacterium lepromatosis)","canonical_id":"uniprot:A0A0F4ER22","description":null,"metadata":null},{"id":"f83d8cfec49e4afcb4fb24a59a42e254","type":"PROTEIN","name":"Dihydropyrimidine dehydrogenase","canonical_id":"uniprot:Q12882","description":null,"metadata":null},{"id":"bf9fdb05f6af4609bd9968130d6d78b2","type":"DRUG","name":"Dihydrotachysterol","canonical_id":"mesh:D004097","description":null,"metadata":null},{"id":"776d751c15544d8bb68ff300c759c1d9","type":"TRIAL","name":"Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study","canonical_id":"clinicaltrials.gov:NCT00219479","description":"Seizures","metadata":null},{"id":"7d54e6223f8643ae92c6711a8af3ae9a","type":"TRIAL","name":"Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers","canonical_id":"clinicaltrials.gov:NCT02801305","description":"Digital Ulcer of Scleroderma","metadata":null},{"id":"b7473c32165842d0931050f66d7cbd2f","type":"TRIAL","name":"Diltiazem in Jervell and Lange-Nielsen Syndrome","canonical_id":"clinicaltrials.gov:NCT06534671","description":"Jervell and Lange Nielsen Syndrome","metadata":null},{"id":"b43ae033135c466e875b9874c3ac53a0","type":"TRIAL","name":"Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment","canonical_id":"clinicaltrials.gov:NCT02859103","description":"Depression; Anhedonia","metadata":null},{"id":"a519b3e44f834be79e88cba0789cdbf2","type":"DRUG","name":"Dimethicone","canonical_id":"mesh:C501844","description":null,"metadata":null},{"id":"eed3258ff99544218ed4fe421869b2b7","type":"TRIAL","name":"Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01711528","description":"Recurrent Plasma Cell Myeloma","metadata":null},{"id":"6f814a34843c4ea283511d5cb7f45d1b","type":"TRIAL","name":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT06172296","description":"Ganglioneuroblastoma, Nodular; Neuroblastoma","metadata":null},{"id":"1a2248a8146747a59c05e563a74084eb","type":"TRIAL","name":"Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03098030","description":"Small Cell Lung Cancer","metadata":null},{"id":"3fa53e7750ef4403bca60008bd89016a","type":"TRIAL","name":"Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT02484443","description":"Metastatic Malignant Neoplasm in the Lung; Metastatic Osteosarcoma; Recurrent Osteosarcoma","metadata":null},{"id":"7db06e49561249a7a252319a4a16ed15","type":"TRIAL","name":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT03786783","description":"Ganglioneuroblastoma; High Risk Neuroblastoma","metadata":null},{"id":"2dabb61a048c44aab6676c948a3bfb7a","type":"TRIAL","name":"Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT07688252","description":"High Risk Neuroblastoma","metadata":null},{"id":"43d76e6f45df4fcc9d1167d3b305f4da","type":"TRIAL","name":"Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT02134249","description":"Infertility","metadata":null},{"id":"32ea4e4cef244175af64a6c08b90e175","type":"DRUG","name":"Diphenhydramine","canonical_id":"mesh:D004155","description":null,"metadata":null},{"id":"6a8b03100f1d4585bab8a59fda6d9b53","type":"TRIAL","name":"Diphenhydramine in Catheter Related Bladder Discomfort","canonical_id":"clinicaltrials.gov:NCT06345261","description":"Catheter Complications","metadata":null},{"id":"e7cb841fdc0149f195ef64cdef02a560","type":"DISEASE","name":"Diphtheria","canonical_id":"mesh:D004165","description":null,"metadata":null},{"id":"6d12a71dca4c45d5982c399f2f7fa10f","type":"DRUG","name":"Dipyridamole","canonical_id":"mesh:D004176","description":null,"metadata":null},{"id":"cae2ca5c95d64fdb87130d765eb3e451","type":"TRIAL","name":"Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT01781611","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"e158813a11eb441baa96e9bcb458ae7c","type":"TRIAL","name":"Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects","canonical_id":"clinicaltrials.gov:NCT07738562","description":"Preeclampsia (PE); Hypertension ,Pregnancy","metadata":null},{"id":"82bda141bbb940b4ac493b898c36c3e8","type":"TRIAL","name":"Dipyridamole for Immune Activation in HIV","canonical_id":"clinicaltrials.gov:NCT02121756","description":"HIV Infection","metadata":null},{"id":"bcdf6ac204f14647aeb6087231b996eb","type":"TRIAL","name":"Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19","canonical_id":"clinicaltrials.gov:NCT04391179","description":"COVID; Corona Virus Infection; Covid-19; SARS-CoV-2 Infection","metadata":null},{"id":"4b1337a9070c408da30cbb2043cb5497","type":"TRIAL","name":"Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT00448214","description":"Atrial Fibrillation","metadata":null},{"id":"06d4f41111b74f25b3eb9dfcef35cbed","type":"TRIAL","name":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","canonical_id":"clinicaltrials.gov:NCT02744092","description":"Cancer; Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Blood Clot","metadata":null},{"id":"dcd575e7fae74323bd6eede56962fc91","type":"TRIAL","name":"Direct Oral Anticoagulants and Venous Thromboembolism","canonical_id":"clinicaltrials.gov:NCT02833987","description":"Venous Thromboembolism; Major Bleed","metadata":null},{"id":"847322b499fd4362a1dd54d9353cd8a6","type":"TRIAL","name":"Direct Renin Inhibition Effects on Atherosclerotic Biomarkers","canonical_id":"clinicaltrials.gov:NCT00818779","description":"Coronary Artery Disease; Type 2 Diabetes Mellitus","metadata":null},{"id":"0338f27aba994259922e793c37941072","type":"TRIAL","name":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03432741","description":"Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7","metadata":null},{"id":"2a3a46490f8d40028a10efcfa829396d","type":"DISEASE","name":"Discoid lupus erythematosus","canonical_id":"mesh:D008179","description":null,"metadata":null},{"id":"0a625d61531a4350a7556ff303d0f791","type":"TRIAL","name":"Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01014585","description":"Fibromyalgia","metadata":null},{"id":"21b011265dd9465f9971a5f51d7f274c","type":"TRIAL","name":"Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT03018743","description":"Premature Ejaculation","metadata":null},{"id":"1af7bdd82924486f92a1648f81fdf31d","type":"TRIAL","name":"Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience","canonical_id":"clinicaltrials.gov:NCT05074485","description":"Pain","metadata":null},{"id":"e57cf96d0ebb4995b0bb6b9956d90b13","type":"TRIAL","name":"Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT04840979","description":"Alzheimer Disease","metadata":null},{"id":"16a5559ed9cf4b02828b48b4a7f96d84","type":"TRIAL","name":"Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod","canonical_id":"clinicaltrials.gov:NCT01499667","description":"Relapsing Remitting Multiple Sclerosis (RRMS)","metadata":null},{"id":"36517b4500024d7688984c9616e58dc6","type":"DISEASE","name":"Disease caused by rickettsiae","canonical_id":"mesh:D012282","description":null,"metadata":null},{"id":"f37644a511464072976ffce1ed72792c","type":"TRIAL","name":"Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research","canonical_id":"clinicaltrials.gov:NCT01617590","description":"Rheumatoid Arthritis","metadata":null},{"id":"92d9041bdefc407887f15e147eb2da20","type":"TRIAL","name":"Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial","canonical_id":"clinicaltrials.gov:NCT06278870","description":"HER2-positive Metastatic Breast Cancer; First-line Treatment","metadata":null},{"id":"45ec8916e5e74b91b5ff35c9139d17e9","type":"TRIAL","name":"Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT06187506","description":"Non-muscle Invasive Bladder Cancer; HER-2 Protein Overexpression","metadata":null},{"id":"e7567cf4168d4d7abad6d7eb1259ba65","type":"TRIAL","name":"Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression","canonical_id":"clinicaltrials.gov:NCT05661357","description":"HER2; Colorectal Cancer","metadata":null},{"id":"acc882e515da423d98ca5b0d77e80dc7","type":"TRIAL","name":"Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT05720533","description":"Gastric Cancer","metadata":null},{"id":"74b7e530ea364f75a5d55a628b760ed0","type":"TRIAL","name":"Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression","canonical_id":"clinicaltrials.gov:NCT06560528","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"3a7458a60e3d4dc396209918428fb0ca","type":"TRIAL","name":"Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable","canonical_id":"clinicaltrials.gov:NCT05495724","description":"Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma","metadata":null},{"id":"9c4641fd31bf49b29edaeccb794c9555","type":"TRIAL","name":"Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","canonical_id":"clinicaltrials.gov:NCT07446452","description":"HER2-low Breast Cancer","metadata":null},{"id":"5fec07866a644c6da59a0936f4a16a0a","type":"TRIAL","name":"Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06383533","description":"Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation","metadata":null},{"id":"b9cec7a220ad4b3dbe4c020542b1ab4a","type":"TRIAL","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT07159217","description":"Biliary Tract Cancer; Disitamab Vedotin; Lenvatinib; Immune Checkpoint Inhibitors","metadata":null},{"id":"86e4c2302c5a4380918f8caec65fb0f2","type":"TRIAL","name":"Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT07498907","description":"Upper Tract Urothelial Carcinoma","metadata":null},{"id":"59ca9bdd1fc747849811b82eed97bd00","type":"TRIAL","name":"Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens","canonical_id":"clinicaltrials.gov:NCT06572319","description":"HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"735b91c7b5d14b93b1c138c8744b70d5","type":"TRIAL","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","canonical_id":"clinicaltrials.gov:NCT05911295","description":"Urothelial Carcinoma","metadata":null},{"id":"1f48ed26a23f42aea9ca27c23e5f9fe3","type":"TRIAL","name":"Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression","canonical_id":"clinicaltrials.gov:NCT06749860","description":"Lung Cancer","metadata":null},{"id":"d439c0839c554aacbb756004d643baed","type":"TRIAL","name":"Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06227156","description":"Castration-resistant Prostate Cancer","metadata":null},{"id":"1f30200cd5a24512b00435fc1bd50986","type":"TRIAL","name":"Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05726175","description":"Breast Cancer","metadata":null},{"id":"4dcd02eb377245faa043a4f45f30eb50","type":"DISEASE","name":"Disorder of biliary tract","canonical_id":"mesh:D001660","description":null,"metadata":null},{"id":"0257ca8de4f344bcb6e0a994ae9d1111","type":"DISEASE","name":"Disorder of carbohydrate metabolism","canonical_id":"orphanet:79161","description":null,"metadata":null},{"id":"f78b425e30ad4c7db648957e1277f6a0","type":"DISEASE","name":"Disorder of the urea cycle metabolism","canonical_id":"mesh:D056806","description":null,"metadata":null},{"id":"da20557440fb46c0b2bc2ce14070091e","type":"TRIAL","name":"Disparities in Emergency Contraceptive Metabolism Dictate Efficacy","canonical_id":"clinicaltrials.gov:NCT05674513","description":"Contraceptive Usage","metadata":null},{"id":"097abf64a02746509e139ba93d49297d","type":"DISEASE","name":"Disruptive behavior disorder","canonical_id":"mesh:D019958","description":null,"metadata":null},{"id":"f4b2627d05c64b2f9ded501a5ec2e859","type":"DISEASE","name":"Disseminated candidiasis","canonical_id":"mesh:C536777","description":null,"metadata":null},{"id":"c6d80990cdc8492a988024a1ef3fcbee","type":"DISEASE","name":"Disseminated intravascular coagulation","canonical_id":"mesh:D004211","description":null,"metadata":null},{"id":"291b833447f74f14a09fe360c7371e0e","type":"TRIAL","name":"Disturbed Sleep Model Study.","canonical_id":"clinicaltrials.gov:NCT00440323","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"d7e3baa02d0841a696de79abe8fdfa5e","type":"TRIAL","name":"Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing","canonical_id":"clinicaltrials.gov:NCT03746002","description":"Fluid Overload; Heart Failure Acute","metadata":null},{"id":"6fb098d8b0004b009e9ab99d0221b01b","type":"TRIAL","name":"Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance","canonical_id":"clinicaltrials.gov:NCT05986773","description":"Acute Heart Failure; Diuretic Resistance","metadata":null},{"id":"c8d2af851d1c47d8857048e81a7705a2","type":"TRIAL","name":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","canonical_id":"clinicaltrials.gov:NCT05411991","description":"Acute Heart Failure; Diuretics Drug Reactions","metadata":null},{"id":"81a4f03d45fd42849932e8ffa13d8c5d","type":"TRIAL","name":"Diuretic Use in Hemodialysis Patients With Residual Renal Function","canonical_id":"clinicaltrials.gov:NCT05915286","description":"End Stage Renal Disease on Dialysis","metadata":null},{"id":"5b6bfbd31fc849eca242064d2f81b122","type":"TRIAL","name":"Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion","canonical_id":"clinicaltrials.gov:NCT00806910","description":"Heart Failure","metadata":null},{"id":"c8dd197676de4bdd8ae1860b1b5dea74","type":"TRIAL","name":"Diuretic/Cool Dialysate Trial","canonical_id":"clinicaltrials.gov:NCT02593526","description":"Chronic Kidney Insufficiency","metadata":null},{"id":"c4afa5620bad432d9f686f8080b0a5b9","type":"TRIAL","name":"Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension","canonical_id":"clinicaltrials.gov:NCT00971165","description":"Hypertension; Cardiovascular Disease","metadata":null},{"id":"499b589691814a6cb99486e79d84d6af","type":"TRIAL","name":"Diuretics and Volume Overload in Early CKD","canonical_id":"clinicaltrials.gov:NCT05171686","description":"Chronic Kidney Disease; Hypertension","metadata":null},{"id":"4171c79033664643b983f65f6d254b19","type":"TRIAL","name":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","canonical_id":"clinicaltrials.gov:NCT06218199","description":"Heart Failure, Congestive","metadata":null},{"id":"098e25e2bfc04f92bb652ea7461e7623","type":"TRIAL","name":"Diuretics, Hypertension, and Arrhythmias Clinical Trial","canonical_id":"clinicaltrials.gov:NCT00000525","description":"Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Arrest; Heart Diseases; Hypertension","metadata":null},{"id":"90efb79e4a1142b8a96de854608e2e8a","type":"TRIAL","name":"Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%","canonical_id":"clinicaltrials.gov:NCT00347802","description":"Glaucoma","metadata":null},{"id":"f0a26bac278c49148a809a6f71e3819c","type":"DRUG","name":"Divarasib","canonical_id":"ncit:C173995","description":null,"metadata":null},{"id":"cd674b5d7c7b4be393d7de79acc55db2","type":"TRIAL","name":"Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin","canonical_id":"clinicaltrials.gov:NCT01723527","description":"Cocaine-Related Disorders; HIV; Heroin Dependence","metadata":null},{"id":"09f0e996612a485da095c13c7ee61cab","type":"TRIAL","name":"Divided or Single Exposure (DOSE) Study","canonical_id":"clinicaltrials.gov:NCT05459402","description":"Opioid Use Disorder; Chronic Pain; Methadone","metadata":null},{"id":"f3d5ce5a135f4b898298af2249bd4553","type":"GO_TERM","name":"DnaA-DiaA complex","canonical_id":"go:GO:1990102","description":"\"A protein-DNA complex containing a tetramer of DiaA attached to multiple DnaA molecule bound to oriC DNA. Regulates timely initiation of chromosomal replication during the cell cycle by stimulating assembly of DnaA-oriC complexes, conformational changes in ATP-DnaA initiation complexes, and unwinding of oriC duplex DNA.\" [GOC:bhm, PMID:15326179, PMID:17699754]","metadata":null},{"id":"d39d2898946245a3999ac9b0aa01d7ae","type":"GO_TERM","name":"DnaA-DnaB-DnaC complex","canonical_id":"go:GO:1990157","description":"\"A protein-DNA complex consisting of the helicase loading complex DnaB-DnaC bound to the DNA-bound DNA replication initiation protein DnaA. Essential for DNA replication initiation.\" [GOC:bhm, PMID:20129058]","metadata":null},{"id":"1b0cd9c17e724817815af9e7cb692beb","type":"GO_TERM","name":"DnaA-Dps complex","canonical_id":"go:GO:1990084","description":"\"A protein complex that negatively regulates strand-opening at the origin of replication, thereby interfering with replication initiation. This complex is thought to be involved in the regulation of replication under oxidative stress conditions. In E. coli, this complex is composed of DnaA and Dps.\" [GOC:bhm, PMID:18284581]","metadata":null},{"id":"52bcc95032314fb4905290902f214495","type":"GO_TERM","name":"DnaA-HU complex","canonical_id":"go:GO:1990103","description":"\"A protein-DNA complex containing DNA-bound DnaA attached to HU. HU is a dimer encoded by two closely related genes. Essential for the initiation of replication in bacteria; stimulates the DnaA-dependent unwinding of oriC.\" [GOC:bhm, PMID:18179598]","metadata":null},{"id":"f3e1fc3d6f504e76b69812f82f39f8c1","type":"GO_TERM","name":"DnaA-Hda complex","canonical_id":"go:GO:1990083","description":"\"A protein complex that inactivates the function of DnaA by inhibiting the phosphorylation of DnaA-ADP to DnaA-ATP and thereby preventing multiple events of replication initiation. In E. coli, this complex is composed of DnaA and Hda.\" [GOC:bhm, PMID:21708944]","metadata":null},{"id":"aa0d9dd7e28243fdb8651b29c0fce6ad","type":"GO_TERM","name":"DnaA-L2 complex","canonical_id":"go:GO:1990082","description":"\"A protein complex that inhibits unwinding of DNA at the origin of replication and assembly of the pre-primosome. In E. coli, this complex is composed of DnaA and of the ribosomal protein L2.\" [GOC:bhm, PMID:21288885]","metadata":null},{"id":"0bf5b946b78f485ea519c1f4235c706b","type":"GO_TERM","name":"DnaA-oriC complex","canonical_id":"go:GO:1990101","description":"\"A protein-DNA complex containing the initiator protein DnaA bound to high-affinity recognition sites in the unique origin of replication, oriC. DnaA-oriC binding is the first step in assembly of a bacterial pre-replicative complex (pre-RC) and is responsible for the timely initiation of replication once per cell cycle.\" [GOC:bhm, PMID:19833870]","metadata":null},{"id":"5c3da31e96574243b63421f13e442e5a","type":"GO_TERM","name":"DnaB helicase complex","canonical_id":"go:GO:1990161","description":"\"A homohexameric protein complex that possesses DNA helicase activity; functions during DNA replication and repair.\" [GOC:bhm, PMID:17947583]","metadata":null},{"id":"988f003557314e4ebf5b6c65b3c55e1b","type":"GO_TERM","name":"DnaB-DnaC complex","canonical_id":"go:GO:1990100","description":"\"A protein complex containing homohexameric DNA helicase DnaB, and the DNA helicase loader DnaC. The helicase loader DnaC delivers DnaB to the chromosomal origin (oriC).\" [GOC:bhm, PMID:20129058]","metadata":null},{"id":"dcc13f693fcd4bf69bae8e63c8c843e6","type":"GO_TERM","name":"DnaB-DnaC-DnaT-PriA-PriB complex","canonical_id":"go:GO:1990158","description":"\"A protein-DNA complex consisting of the helicase loading complex DnaB-DnaC, replication restart proteins DnaT, PriA and PriB, and associated DNA. Involved in the restart of DNA replication after a stalled replication fork has been repaired.\" [GOC:bhm, PMID:8663105]","metadata":null},{"id":"9fb69c4d9ea34544a4173aef5ae7df32","type":"GO_TERM","name":"DnaB-DnaC-DnaT-PriA-PriC complex","canonical_id":"go:GO:1990159","description":"\"A protein-DNA complex consisting of the helicase loading complex DnaB-DnaC, replication restart proteins DnaT, PriA and PriC, and associated DNA. Involved in the restart of DNA replication after a stalled replication fork has been repaired.\" [GOC:bhm, PMID:8663105]","metadata":null},{"id":"d843d0587abd4f7787e4903747488e24","type":"GO_TERM","name":"DnaB-DnaC-Rep-PriC complex","canonical_id":"go:GO:1990160","description":"\"A protein-DNA complex consisting of the helicase loading complex DnaB-DnaC, replication restart proteins Rep and PriC, and associated DNA. Involved in the restart of DNA replication after a stalled replication fork has been repaired.\" [GOC:bhm, PMID:19941825, PMID:8663105]","metadata":null},{"id":"cd50ac97bede4621be1cd5f8b2c086e8","type":"GO_TERM","name":"DnaB-DnaG complex","canonical_id":"go:GO:1990156","description":"\"A protein complex containing homohexameric DnaB helicase, and DnaG (a primase). Facilitates the unwinding of double-stranded DNA and the synthesis of RNA primer sequences during DNA replication and repair in Prokaryotes.\" [GOC:bhm, PMID:14557266]","metadata":null},{"id":"85cbd83491824c468a341b8f54dca18c","type":"TRIAL","name":"Do Acid Sensing Ion Channels Contribute to Heartburn?","canonical_id":"clinicaltrials.gov:NCT01095133","description":"Gastroesophageal Reflux Disease; Heartburn","metadata":null},{"id":"50be7aae77bf48798a736df98014d892","type":"TRIAL","name":"Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?","canonical_id":"clinicaltrials.gov:NCT01526213","description":"Food-drug Interaction","metadata":null},{"id":"d858a100827d42a2a71b53a107802e5c","type":"TRIAL","name":"Do HMG CoA Reductase Inhibitors Affect Abeta Levels?","canonical_id":"clinicaltrials.gov:NCT00303277","description":"Alzheimer's Disease; Aging","metadata":null},{"id":"757683333a764b4d98213e286dd38abd","type":"GO_TERM","name":"Doa10p ubiquitin ligase complex","canonical_id":"go:GO:0000837","description":"\"A multiprotein complex that recognizes and ubiquitinates membrane proteins with misfolded cytosolic domains during ER-associated protein degradation (ERAD). In S. cerevisiae, this complex contains the ubiquitin ligase Ssm4p/Doa10p.\" [GOC:elh, PMID:16873066]","metadata":null},{"id":"d42009b27fc749bcb31c8c2f25849be6","type":"TRIAL","name":"Dobutamaine Versus Milrinone in Cardiorenal Syndrome","canonical_id":"clinicaltrials.gov:NCT02644057","description":"Cardiorenal Syndrome","metadata":null},{"id":"2560a0f84394460789b350fdf209b1f2","type":"TRIAL","name":"Dobutamine Versus Milrinone in Management of Critically Ill Low Cardiac Output Pediatric Patients at Cairo University Children's Hospital","canonical_id":"clinicaltrials.gov:NCT05999487","description":"Dobutamine, Milrinone , Pediatrics , Low Cardiac Output","metadata":null},{"id":"f47320c417fe457fb141ec3b1c1c0e6f","type":"DRUG","name":"Docetaxel","canonical_id":"ncit:C1526","description":null,"metadata":null},{"id":"5019eeb88be6430688636a5c5e3c3b70","type":"TRIAL","name":"Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)","canonical_id":"clinicaltrials.gov:NCT00040885","description":"Anorexia; Cachexia; Fatigue; Lung Cancer","metadata":null},{"id":"c052f844e36f4ec8807dfbb21b7f95d9","type":"TRIAL","name":"Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway","canonical_id":"clinicaltrials.gov:NCT02598895","description":"Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Cancer","metadata":null},{"id":"cc39f30e65bc4cf48772219206ae80d9","type":"TRIAL","name":"Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00136526","description":"Prostate Cancer","metadata":null},{"id":"d3308b5cb18c45e08c5a04a014c5718f","type":"TRIAL","name":"Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00225420","description":"Prostate Cancer","metadata":null},{"id":"a6ee0aa0305d49a4aee0a5c5937198d5","type":"TRIAL","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02003209","description":"HER2-Positive Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7","metadata":null},{"id":"930cdbc438cc4e08806c244865770b5c","type":"TRIAL","name":"Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency","canonical_id":"clinicaltrials.gov:NCT03442556","description":"ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Homologous Recombination Deficiency; Prostate Carcinoma Metastatic in the Bone; PSA Level Greater Than or Equal to Two; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7","metadata":null},{"id":"7acc4c14c8df4ff49b0c0fc0229a0e51","type":"TRIAL","name":"Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01468532","description":"Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"736a1c5431eb40a2ba28f7867bbbe667","type":"TRIAL","name":"Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00099086","description":"Prostate Cancer","metadata":null},{"id":"ad23f7dcd335469bac9ccd5518be7bac","type":"DRUG","name":"Docosanol","canonical_id":"mesh:C529236","description":null,"metadata":null},{"id":"cc1d7b1a4a2e4ef1a5855b0edbc08fb3","type":"TRIAL","name":"Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia","canonical_id":"clinicaltrials.gov:NCT04699383","description":"Cutaneous Leishmaniasis","metadata":null},{"id":"51be049cbbe24fc1a1de74a61484eb3e","type":"TRIAL","name":"Does Adding Spinal Anaesthesia to a General Anaesthetic Technique Influence Readiness for Discharge in Patients Having Hand Assisted Laparoscopic Live Donor Nephrectomy","canonical_id":"clinicaltrials.gov:NCT02700217","description":"Surgery","metadata":null},{"id":"63adf55d494f4bd9b6d75f0f71e358c7","type":"TRIAL","name":"Does Allopurinol Prolong a Treated, Acute Gout Flare?","canonical_id":"clinicaltrials.gov:NCT01988402","description":"Gout","metadata":null},{"id":"fc8d893e422349c6bd160b7f964b5ec0","type":"TRIAL","name":"Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?","canonical_id":"clinicaltrials.gov:NCT00430170","description":"Cardiovascular Disease; Ischemia-Reperfusion Injury","metadata":null},{"id":"2c84125114a6497a884afd83ec71f5bc","type":"TRIAL","name":"Does Clinical Response Correlate With Serum Certolizumab Levels?","canonical_id":"clinicaltrials.gov:NCT02597829","description":"Crohn's Disease","metadata":null},{"id":"5c537a72b50642f5ab1560217f282d05","type":"TRIAL","name":"Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?","canonical_id":"clinicaltrials.gov:NCT01730846","description":"Smoking","metadata":null},{"id":"9758d394505b4c86b9d03f5ce0fe844f","type":"TRIAL","name":"Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?","canonical_id":"clinicaltrials.gov:NCT01667497","description":"Cognitive Fatigue","metadata":null},{"id":"fed6cc05d1bb4c10a4cbdb68c24cccf6","type":"TRIAL","name":"Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?","canonical_id":"clinicaltrials.gov:NCT00208897","description":"Major Depressive Disorder","metadata":null},{"id":"ae7a890f0f39486e82d7174a6ab6a649","type":"TRIAL","name":"Does Guanfacine Attenuate Stress-Induced Drinking?","canonical_id":"clinicaltrials.gov:NCT02164422","description":"Alcohol Drinking","metadata":null},{"id":"22888b86dc54429885293df6a73b593c","type":"TRIAL","name":"Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?","canonical_id":"clinicaltrials.gov:NCT04374942","description":"Pre-Exposure Prophylaxis; Coronavirus; SARS-CoV 2","metadata":null},{"id":"d3008365313e43c6a92f8b4e4c571a3c","type":"TRIAL","name":"Does Meloxicam Provide as Much Pain Relief as Opioids After Shoulder Surgery?","canonical_id":"clinicaltrials.gov:NCT04725357","description":"Shoulder Pain","metadata":null},{"id":"5e9651070cda45c993d5df3698e3088a","type":"TRIAL","name":"Does Montelukast Decrease Post Adenotonsillectomy Pain in Children","canonical_id":"clinicaltrials.gov:NCT02793375","description":"Pain","metadata":null},{"id":"7ac65acafb3d45fc82703023d356b4e8","type":"TRIAL","name":"Does Omeprazole Decrease Intestinal Calcium Absorption?","canonical_id":"clinicaltrials.gov:NCT00582972","description":"Osteoporosis; Achlorhydria; GERD; Hip Fracture","metadata":null},{"id":"ae6a93788a324a19b8c0dc31a80a0e28","type":"TRIAL","name":"Does Optimal Control of Pre-operative Chronic and Acute Pain Predict Improved Function After Orthopedic Surgery?","canonical_id":"clinicaltrials.gov:NCT00581685","description":"Osteoarthritis","metadata":null},{"id":"3bbb3457236e411f8ead9ebf18e2a3a3","type":"TRIAL","name":"Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?","canonical_id":"clinicaltrials.gov:NCT02090244","description":"Spinal Stenosis","metadata":null},{"id":"04eb07948fae4fc5a1bcd0ed433fbcb8","type":"TRIAL","name":"Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?","canonical_id":"clinicaltrials.gov:NCT01127607","description":"ADHD","metadata":null},{"id":"39885f98dd1248b7881a1e2112944ab2","type":"TRIAL","name":"Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?","canonical_id":"clinicaltrials.gov:NCT01040819","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"9209661cd10941219242d94460fc18b2","type":"TRIAL","name":"Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?","canonical_id":"clinicaltrials.gov:NCT02688738","description":"Propionibacterium","metadata":null},{"id":"68182412060449fd9105f63e6f3ea7b4","type":"TRIAL","name":"Does Reducing Spasticity Permit an Increase in Strength?","canonical_id":"clinicaltrials.gov:NCT00255073","description":"Spastic Diplegic Cerebral Palsy","metadata":null},{"id":"86d752611276488d9348a02b7801030a","type":"TRIAL","name":"Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?","canonical_id":"clinicaltrials.gov:NCT03054285","description":"Seizures; Traumatic Brain Injury","metadata":null},{"id":"a72dba04e3c145979dfb0fac6b319e91","type":"TRIAL","name":"Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?","canonical_id":"clinicaltrials.gov:NCT02908490","description":"Arthritis, Rheumatoid; Atherosclerosis","metadata":null},{"id":"6cdd211163154a2fbd1bcc77f1ab34b6","type":"TRIAL","name":"Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter?","canonical_id":"clinicaltrials.gov:NCT03102645","description":"Urinary Incontinence, Stress; Fecal Incontinence","metadata":null},{"id":"eb58628195e04b679602b18f53bdc178","type":"TRIAL","name":"Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy","canonical_id":"clinicaltrials.gov:NCT00409227","description":"Urolithiasis; Nephrolithiasis; Ureterolithiasis","metadata":null},{"id":"42c57ad374e94d54b621f95939a9d487","type":"TRIAL","name":"Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?","canonical_id":"clinicaltrials.gov:NCT01856127","description":"Sexual Dysfunction; Major Depressive Disorder","metadata":null},{"id":"d83c4af74dcb43d8a7d2e8228fb32d23","type":"TRIAL","name":"Does Visceral Manipulation Works in Treating Functional Dyspepsia?","canonical_id":"clinicaltrials.gov:NCT01021475","description":"Functional Dyspepsia","metadata":null},{"id":"ab8df098569e425a977a57d87634038a","type":"TRIAL","name":"Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?","canonical_id":"clinicaltrials.gov:NCT00360282","description":"Migraine","metadata":null},{"id":"08885de412d74d6ab8b48446ced9f1b1","type":"TRIAL","name":"Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?","canonical_id":"clinicaltrials.gov:NCT00945347","description":"Cystic Fibrosis","metadata":null},{"id":"286a7bc408f54ecdadf53bd0f9264e79","type":"TRIAL","name":"Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?","canonical_id":"clinicaltrials.gov:NCT01002534","description":"Cystic Fibrosis","metadata":null},{"id":"452df16ef7d84be7844a7856a85d4c4f","type":"TRIAL","name":"Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?","canonical_id":"clinicaltrials.gov:NCT00457405","description":"Ischemia-Reperfusion Injury; Atherosclerosis","metadata":null},{"id":"ae83ba9433c54865810def8236c28d4d","type":"TRIAL","name":"Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?","canonical_id":"clinicaltrials.gov:NCT00486902","description":"Ketamine Adverse Reaction; Effects of; Anesthesia, Spinal and Epidural, in Pregnancy; Complication of Labor and/or Delivery","metadata":null},{"id":"4db0730660754deb9e17cd405b73a3be","type":"TRIAL","name":"Does the Volume of Medication Affect the Success of Labor Epidural Analgesia","canonical_id":"clinicaltrials.gov:NCT07684365","description":"Labor Pain and to Reduce Pain","metadata":null},{"id":"890fa1af45e14b098b6fdb01daf29978","type":"TRIAL","name":"Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy","canonical_id":"clinicaltrials.gov:NCT02550119","description":"Malignant Digestive System Neoplasm; Nausea and Vomiting","metadata":null},{"id":"c67626f96ae14011876c5f7a8336ab53","type":"GO_TERM","name":"Dom34-Hbs1 complex","canonical_id":"go:GO:1990533","description":"\"A protein complex consisting of one subunit known as Dom34 or Pelota that has similarity to translation termination factor eRF1, and another subunit, Hbs1, that is a GTPase with similarity to translation termination factor eRF3. The Dom34-Hbs1 complex has a role in cotranslational mRNA quality control by promoting ribosomal subunit dissociation and peptidyl-tRNA release when translation is stalled, facilitating no-go decay and nonstop decay.\" [GOC:mcc, PMID:20890290, PMID:21102444, PMID:21448132, PMID:22503425]","metadata":null},{"id":"f4e0f9f646044e4ead63571e1b2b190b","type":"TRIAL","name":"Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy","canonical_id":"clinicaltrials.gov:NCT02494687","description":"Oncology Patients With Gastroparesis","metadata":null},{"id":"55c64956d1c24c1d913e562c6ed9d22d","type":"TRIAL","name":"Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders","canonical_id":"clinicaltrials.gov:NCT02567175","description":"Gastroesophageal Reflux; Gastroparesis; Chronic Constipation With Overflow; Pseudo Obstruction","metadata":null},{"id":"07779bc18b37410e9dfb548aaf62b0ce","type":"TRIAL","name":"Domperidone Expanded Access Treatment Program","canonical_id":"clinicaltrials.gov:NCT04996134","description":"Gastroparesis","metadata":null},{"id":"4555137130eb41aa8047a760ca19b876","type":"TRIAL","name":"Domperidone and Risk of Serious Cardiac Events in Postpartum Women","canonical_id":"clinicaltrials.gov:NCT04024865","description":"Ventricular Tachyarrhythmia; Sudden Cardiac Death; Lactation; Breast Feeding","metadata":null},{"id":"369b221b4c944bb7983f109931088014","type":"TRIAL","name":"Domperidone and Risk of Sudden Cardiac Death","canonical_id":"clinicaltrials.gov:NCT02500108","description":"Parkinson's Disease","metadata":null},{"id":"d4965f02bfac4b359edfd04e5fe57130","type":"TRIAL","name":"Domperidone and the Risk of Serious Adverse Events","canonical_id":"clinicaltrials.gov:NCT07098078","description":"Chronic Kidney Disease (CKD)","metadata":null},{"id":"74c37380c1c140568d82d56d599aa1dc","type":"TRIAL","name":"Domperidone for Gastroparesis in Solid Organ Transplantation","canonical_id":"clinicaltrials.gov:NCT00552422","description":"Gastroparesis; Gastroesophageal Reflux","metadata":null},{"id":"f9080b9040724395b40689e615c63e6e","type":"TRIAL","name":"Domperidone for Relief of Gastrointestinal Disorders","canonical_id":"clinicaltrials.gov:NCT00761254","description":"Gastroparesis; GERD; Esophagitis; Dyspepsia; Chronic Idiopathic Constipation; Nausea; Vomiting","metadata":null},{"id":"2f61143fbcf2453da81b5bb019d01262","type":"TRIAL","name":"Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis","canonical_id":"clinicaltrials.gov:NCT01711918","description":"Patients With Gastroparesis Who Have Failed Standard Therapy","metadata":null},{"id":"0d2db8390fda4aa3884eebd76992ae68","type":"TRIAL","name":"Domperidone in Refractory Gastroparesis","canonical_id":"clinicaltrials.gov:NCT00760461","description":"Gastroparesis","metadata":null},{"id":"dac5da68ac284abf8bd5bcc5e52ac7b3","type":"TRIAL","name":"Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)","canonical_id":"clinicaltrials.gov:NCT02308137","description":"Multiple Sclerosis, Secondary Progressive","metadata":null},{"id":"d8528d375da24af0b47aaf5fad6bdb03","type":"TRIAL","name":"Domperidone in Treating Patients With Gastrointestinal Disorders","canonical_id":"clinicaltrials.gov:NCT01696734","description":"Digestive System Disorder; Dyspepsia; Esophagitis; Gastroesophageal Reflux Disease; Gastroparesis; Heartburn; Nausea and Vomiting","metadata":null},{"id":"b8defbe383294c87991f98e62b67b696","type":"TRIAL","name":"Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk","canonical_id":"clinicaltrials.gov:NCT06685289","description":"Biliary Malignant Tumors","metadata":null},{"id":"54e0ea9a3b6c4752a21719d5f0132906","type":"TRIAL","name":"Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT01743976","description":"Neuropathic Pain","metadata":null},{"id":"f58d01cb6460425abb6c8851ba8515fc","type":"TRIAL","name":"Donepezil Treatment for Sleep Apnea Patients","canonical_id":"clinicaltrials.gov:NCT00912457","description":"Obstructive Sleep Apnea","metadata":null},{"id":"91e5d70bca574da1a62d6f4be97c4d05","type":"TRIAL","name":"Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00006349","description":"Cognitive/Functional Effects; Delirium; Depression; Lung Cancer; Radiation Toxicity","metadata":null},{"id":"7c757a9f31944afbbc8a575848e14f84","type":"TRIAL","name":"Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study","canonical_id":"clinicaltrials.gov:NCT05254639","description":"Digestive Oncology; Supportive Care","metadata":null},{"id":"a79aaaa1c7fd4505be7a72c6c91173c3","type":"DISEASE","name":"Donohue syndrome","canonical_id":"mondo:0009517","description":null,"metadata":null},{"id":"6db2e0c74b504502b0ddb8b7e8f1d1c5","type":"TRIAL","name":"Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant","canonical_id":"clinicaltrials.gov:NCT01280955","description":"Failure of Bone Marrow Graft","metadata":null},{"id":"fc1e700a04d8499890c5b1a2af8c01f2","type":"TRIAL","name":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06203912","description":"Recurrent Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"c4ffccfde9a143d0b6f82cae910415ca","type":"TRIAL","name":"Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer","canonical_id":"clinicaltrials.gov:NCT00627666","description":"Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms","metadata":null},{"id":"77e8e77410ee4b11a34e8d58562b5f02","type":"TRIAL","name":"Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00720447","description":"Lymphoma","metadata":null},{"id":"80e0b0431806435790572c2522c28c5d","type":"TRIAL","name":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","canonical_id":"clinicaltrials.gov:NCT00816413","description":"Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Nonmalignant Neoplasm","metadata":null},{"id":"e8d669416f1d4c2cb4c50fc1eb211ce4","type":"TRIAL","name":"Dopamine Action on Metabolism in Relation to Genotype","canonical_id":"clinicaltrials.gov:NCT03525002","description":"Obesity","metadata":null},{"id":"1490e76bb3c4442dad5aab7b01a543d7","type":"TRIAL","name":"Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas","canonical_id":"clinicaltrials.gov:NCT02288962","description":"Pituitary Neoplasms; Adenoma","metadata":null},{"id":"f4710199109e4fd9809affcf049a781c","type":"TRIAL","name":"Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT02262923","description":"in Vitro Fertilization; Poor Responder","metadata":null},{"id":"e7623506d462411b9c8ada5dc246581e","type":"TRIAL","name":"Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT02542410","description":"Endometriosis","metadata":null},{"id":"fe6fd86e640e451596e0b98325b52c8f","type":"TRIAL","name":"Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa","canonical_id":"clinicaltrials.gov:NCT04128683","description":"Anorexia Nervosa","metadata":null},{"id":"4046b835bfb74f93a6a8445e0b6925c4","type":"TRIAL","name":"Dopamine Responsivity in Gamblers","canonical_id":"clinicaltrials.gov:NCT02772978","description":"Pathological Gambling","metadata":null},{"id":"eec22bb0f39a4c15bd6ac41deb491d24","type":"TRIAL","name":"Dopamine and Cognition","canonical_id":"clinicaltrials.gov:NCT05884671","description":"Sulpiride's Effect on Striatal BOLD Signal During Working Memory Gating; Interaction of Sulpiride, Average Reward Rate and Evidence Accumulation; Interaction of Sulpiride, Average Reward Rate and Cognitive Effort","metadata":null},{"id":"26cf62f67cae4691b9d0b19511dfe981","type":"TRIAL","name":"Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity","canonical_id":"clinicaltrials.gov:NCT02557984","description":"Addiction","metadata":null},{"id":"64e78cfd9aa843f1a7df1187a128ad69","type":"TRIAL","name":"Dopaminergic Effects on Brown Adipose Tissue","canonical_id":"clinicaltrials.gov:NCT02428933","description":"Obesity","metadata":null},{"id":"a63b2c90d4ec44d89ecc470c8500f179","type":"TRIAL","name":"Dopaminergic Mechanisms Underlying Human Social Behavior","canonical_id":"clinicaltrials.gov:NCT04205994","description":"Decision Making; Executive Function; Dopamine","metadata":null},{"id":"e4a87c2809e04c7d8dd44b60351cc8f0","type":"TRIAL","name":"Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark/Light Transitions","canonical_id":"clinicaltrials.gov:NCT00280501","description":"Regional Blood Flow; Ocular Physiology","metadata":null},{"id":"bcace697fdd14cb7b1531dc96a3539ec","type":"TRIAL","name":"Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor","canonical_id":"clinicaltrials.gov:NCT02929485","description":"Addiction","metadata":null},{"id":"858c6508d8cf4fc98702345b57d2cb4b","type":"DRUG","name":"Doripenem","canonical_id":"mesh:C099245","description":null,"metadata":null},{"id":"9c1e16656f3b40e98a002808b2570a0d","type":"DRUG","name":"Dornase alfa","canonical_id":"mesh:C568813","description":null,"metadata":null},{"id":"bdd2ce35eb2d4dc48bcabe7826c0667f","type":"TRIAL","name":"Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety","canonical_id":"clinicaltrials.gov:NCT05857267","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"3c13fa68259a44648f496d523c382fb3","type":"TRIAL","name":"Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration","canonical_id":"clinicaltrials.gov:NCT02707458","description":"Dementia of the Alzheimer Type; Age-related Cognitive Decline; Mild Cognitive Impairment Due to Alzheimer Disease","metadata":null},{"id":"4e4643f5237347549b5da2f491a2a44b","type":"TRIAL","name":"Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome","canonical_id":"clinicaltrials.gov:NCT04066088","description":"Prader-Willi Syndrome","metadata":null},{"id":"78616b63152543eda3fac863f22b7168","type":"TRIAL","name":"Dose Dense TC + Pegfilgrastim Support for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01671319","description":"Female Breast Cancer","metadata":null},{"id":"ba97cb08d2f141719a05adb2297278af","type":"TRIAL","name":"Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT01495793","description":"Restless Legs Syndrome","metadata":null},{"id":"df1e350a858f4d20a6b7dc2783e9c1ac","type":"TRIAL","name":"Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose","canonical_id":"clinicaltrials.gov:NCT01465243","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"ca5e47532daf429bbfb1e27bd805c74d","type":"TRIAL","name":"Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML","canonical_id":"clinicaltrials.gov:NCT00583102","description":"Acute Myeloid Leukemia","metadata":null},{"id":"1f221ad9bc3a4dadb720608ac245f35b","type":"TRIAL","name":"Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00701688","description":"Oral Mucositis; Hematopoietic Stem Cell Transplantation","metadata":null},{"id":"072df13e27de48d3a82b89f5861e6fb5","type":"TRIAL","name":"Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01324583","description":"Prostate Cancer","metadata":null},{"id":"ac811dd0ffe248a58ff7351f8e7b160c","type":"TRIAL","name":"Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma","canonical_id":"clinicaltrials.gov:NCT00681798","description":"Pancreatic Cancer","metadata":null},{"id":"6bda7e13b7ad4b0d8fd2129547228f73","type":"TRIAL","name":"Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function","canonical_id":"clinicaltrials.gov:NCT04522908","description":"Hepatocellular Carcinoma (HCC); Second Line Treatment","metadata":null},{"id":"769b4ec256004757991fe64671ed0260","type":"TRIAL","name":"Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)","canonical_id":"clinicaltrials.gov:NCT01364415","description":"Neuroendocrine Tumors","metadata":null},{"id":"b51c594bec2746b5911a6d6a8fa3127a","type":"TRIAL","name":"Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)","canonical_id":"clinicaltrials.gov:NCT04544995","description":"Neoplasms","metadata":null},{"id":"60b2a55c012e41c284ddf0f50b8e699f","type":"TRIAL","name":"Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03150056","description":"Solid Tumours","metadata":null},{"id":"1835c90fd0b543dc8a988a9b136e188e","type":"TRIAL","name":"Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT02457598","description":"B-cell Malignancies","metadata":null},{"id":"25ae5e41e81240f8b33de7786edb3fa9","type":"TRIAL","name":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","canonical_id":"clinicaltrials.gov:NCT02723955","description":"Neoplasms","metadata":null},{"id":"6a7f1c7c7e0f4aa49947d5bb93b6be46","type":"TRIAL","name":"Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT06769490","description":"Acute Myeloid Leukemia","metadata":null},{"id":"274aa710771d4a3bac9e2cf5cf17767a","type":"TRIAL","name":"Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease","canonical_id":"clinicaltrials.gov:NCT01690390","description":"NSCLC","metadata":null},{"id":"b07072e02eee41e989936fe783e2fdf6","type":"TRIAL","name":"Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression","canonical_id":"clinicaltrials.gov:NCT00042575","description":"Major Depressive Disorder","metadata":null},{"id":"9888d86f2ffc4cbd9222ea427d620c1f","type":"TRIAL","name":"Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02446236","description":"Mantle Cell Lymphoma","metadata":null},{"id":"aa86c0d844e841a087c719e547cc8405","type":"TRIAL","name":"Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations","canonical_id":"clinicaltrials.gov:NCT01835665","description":"Progranulin Mutation Carriers","metadata":null},{"id":"f69f5969d93a4777b1cb08780c2ea0d2","type":"TRIAL","name":"Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)","canonical_id":"clinicaltrials.gov:NCT00239486","description":"Restless Legs Syndrome","metadata":null},{"id":"dfbe04ff37164582952733e9ceb1169e","type":"TRIAL","name":"Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00819156","description":"Prostate Cancer","metadata":null},{"id":"70a09d6150fc453c845aae94e945a80f","type":"TRIAL","name":"Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT00900146","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"f11751948c4f47389516b0ee37a993f1","type":"TRIAL","name":"Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke?","canonical_id":"clinicaltrials.gov:NCT00606203","description":"Ischemic Stroke; Depression","metadata":null},{"id":"b50129bd19dc43c0a0010b919998b74b","type":"TRIAL","name":"Dose Optimization Study of Idelalisib in Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT02536300","description":"Follicular Lymphoma","metadata":null},{"id":"e2b45a75d6064ef1a800be6587de02a4","type":"TRIAL","name":"Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02183480","description":"Healthy","metadata":null},{"id":"afc26d155b8b4abbbcb61dbb601a1170","type":"TRIAL","name":"Dose Range Study of CD5789 in Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01616654","description":"Acne Vulgaris","metadata":null},{"id":"1b9bf65c4f184029a2769a978cf671d8","type":"TRIAL","name":"Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma","canonical_id":"clinicaltrials.gov:NCT01000506","description":"Asthma","metadata":null},{"id":"5e8be0c1b8964b90847bff38b455a66d","type":"TRIAL","name":"Dose Ranging Study for Indacaterol in Japanese Asthma Patients","canonical_id":"clinicaltrials.gov:NCT00403754","description":"Asthma","metadata":null},{"id":"8424e63b69934542bbf0aa874e630ab9","type":"TRIAL","name":"Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00409357","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"98e9a1f40752493182f4dba05cccf035","type":"TRIAL","name":"Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00403845","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"37d686c8d3974b9c9cbbcc47d4601092","type":"TRIAL","name":"Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT01134055","description":"Macular Degeneration","metadata":null},{"id":"d973fec3bf9f4173896fd6448f8e16d0","type":"TRIAL","name":"Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism","canonical_id":"clinicaltrials.gov:NCT00004699","description":"Hyperinsulinism","metadata":null},{"id":"bf2d64a76fbe4a69b13b4e958be8c70f","type":"TRIAL","name":"Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT01430442","description":"Migraine; Acute Treatment of Migraine","metadata":null},{"id":"4ac1ed698ecb4a209e9a7d6ffc2a9a43","type":"TRIAL","name":"Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00299871","description":"Type 2 Diabetes","metadata":null},{"id":"28eade250ad545b0bed581828105b724","type":"TRIAL","name":"Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome","canonical_id":"clinicaltrials.gov:NCT04147650","description":"Dry Eye Syndrome; Keratoconjunctivitis Sicca","metadata":null},{"id":"0ce3ad5868a94d239347f23562108960","type":"TRIAL","name":"Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT01061723","description":"Ankylosing Spondylitis","metadata":null},{"id":"2d8818cdc43d455ab24d4aaed428ccd2","type":"TRIAL","name":"Dose Ranging of GSK2336805 in Combination Therapy","canonical_id":"clinicaltrials.gov:NCT01648140","description":"Hepatitis C, Chronic","metadata":null},{"id":"598983b008a644f68f7359d3e6cae4df","type":"TRIAL","name":"Dose Ranging, Safety and Tolerability of TOPROL-XL\u00ae Extended-Release Tablets in Hypertensive Pediatric Subjects","canonical_id":"clinicaltrials.gov:NCT00255528","description":"Hypertension","metadata":null},{"id":"94ecccc66a6f457c836f67f6ec64c9d6","type":"TRIAL","name":"Dose Reduction and Discontinuation With Anti-Fibrotic Medications","canonical_id":"clinicaltrials.gov:NCT05779007","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"8b1527b40e1e4862bcfa87976eac59a0","type":"TRIAL","name":"Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis","canonical_id":"clinicaltrials.gov:NCT04340076","description":"Psoriasis; Psoriasis Vulgaris","metadata":null},{"id":"bd9ef8e3e2df4344964f5d8f95dc1cf2","type":"TRIAL","name":"Dose Response Study of Nitisinone in Alkaptonuria","canonical_id":"clinicaltrials.gov:NCT01828463","description":"Alkaptonuria","metadata":null},{"id":"ecc9275caa114434bf24b9615edfc603","type":"TRIAL","name":"Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure","canonical_id":"clinicaltrials.gov:NCT00435162","description":"Hypertension","metadata":null},{"id":"4904de34c99148c3a38590b5d51bfacb","type":"TRIAL","name":"Dose Systemic Lidocaine Improve the Quality of Recovery After Colorectal Endoscopic Submucosal Dissection","canonical_id":"clinicaltrials.gov:NCT05750056","description":"Postoperative Recovery","metadata":null},{"id":"3acda34fa0b046f3a4ca16a19df98f46","type":"TRIAL","name":"Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02177305","description":"Healthy","metadata":null},{"id":"c46c53830ab648c1aba358d86eb4c18a","type":"TRIAL","name":"Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal","canonical_id":"clinicaltrials.gov:NCT02260037","description":"Healthy","metadata":null},{"id":"dbe96cf1bd584d63b589025cadc43256","type":"TRIAL","name":"Dose, Effects and Characteristics of Pilocarpine","canonical_id":"clinicaltrials.gov:NCT00803803","description":"Open-angle Glaucoma","metadata":null},{"id":"c3ff539caea442018d2c2ee57f722b57","type":"TRIAL","name":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00001337","description":"Diffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-cell Lymphoma; Burkitt Lymphoma; Anaplastic Large-Cell Lymphoma; Gray Zone Lymphoma","metadata":null},{"id":"2f0f237479d1426d9330787b0cf7e10d","type":"TRIAL","name":"Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma","canonical_id":"clinicaltrials.gov:NCT00826241","description":"Brain Tumors; Spinal Cord Tumors","metadata":null},{"id":"d9361df4c91c45029f15cf475aa44eac","type":"TRIAL","name":"Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT02829840","description":"Leukemia; FLT3-Mutated Acute Myeloid Leukemia; FLT3-Mutated High-Risk Myelodysplastic Syndrome","metadata":null},{"id":"df558d90a38548a99371909c3a6a1fa5","type":"TRIAL","name":"Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01738594","description":"Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIIA Mycosis Fungoides/Sezary Syndrome; Stage IIIB Mycosis Fungoides/Sezary S\u2026","metadata":null},{"id":"b34115bd59b44593a7187e08d78c1fef","type":"TRIAL","name":"Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis","canonical_id":"clinicaltrials.gov:NCT03598036","description":"Focal Segmental Glomerulosclerosis","metadata":null},{"id":"d87d1407aa1b4cd6a99c8520add46422","type":"TRIAL","name":"Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD","canonical_id":"clinicaltrials.gov:NCT06828887","description":"MDD","metadata":null},{"id":"24392f0294e04b96880a41982996123f","type":"TRIAL","name":"Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)","canonical_id":"clinicaltrials.gov:NCT00560833","description":"Menopause; Vasomotor Symptoms","metadata":null},{"id":"39b4cb4207274546b60142d8e5573708","type":"TRIAL","name":"Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02570165","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"613fb12fc8164bb28bf6db4b5c69f115","type":"TRIAL","name":"Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07068568","description":"Basal Cell Cancer; Eyelid Tumor; Basal Cell Carcinoma (BCC); Basal Cell Carcinoma of the Head and Neck","metadata":null},{"id":"981b072f4def4f1cb3c2b9df17293a02","type":"TRIAL","name":"Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures","canonical_id":"clinicaltrials.gov:NCT01721317","description":"Seizures","metadata":null},{"id":"9ba9790214d145c99675a195be4f25cb","type":"TRIAL","name":"Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)","canonical_id":"clinicaltrials.gov:NCT00500331","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"191a248ee9264b91b6d5ebfaf7403e2a","type":"TRIAL","name":"Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)","canonical_id":"clinicaltrials.gov:NCT03879772","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"5f0baae128e44aea83aff09524d0596d","type":"TRIAL","name":"Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT00762073","description":"Eosinophilic Esophagitis (EoE)","metadata":null},{"id":"dfcbf57414f44c0a8b106bbf9bd66d83","type":"TRIAL","name":"Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19","canonical_id":"clinicaltrials.gov:NCT04784754","description":"COVID-19","metadata":null},{"id":"2245ce14a4d741168df2573fb00e4ed4","type":"TRIAL","name":"Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1","canonical_id":"clinicaltrials.gov:NCT00784147","description":"HIV","metadata":null},{"id":"b849935a317a4d67a790fc747180b81e","type":"TRIAL","name":"Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK","canonical_id":"clinicaltrials.gov:NCT01960374","description":"Healthy Volunteers Pharmacokinetic Study","metadata":null},{"id":"a3eb932b42d246a98a98a383b11c65cb","type":"TRIAL","name":"Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05622136","description":"Liver Cancer; Hepatocellular Carcinoma","metadata":null},{"id":"ca69383d75804871ab5d58f1fed88df8","type":"TRIAL","name":"Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM","canonical_id":"clinicaltrials.gov:NCT05697510","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"b1c212dbab6a41a1a899403daec5f855","type":"TRIAL","name":"Dose-finding Pharmacokinetic Study in Healthy Males","canonical_id":"clinicaltrials.gov:NCT03055936","description":"Healthy Volunteers","metadata":null},{"id":"8b657f6cd6a3455b9dbdd874db08b59a","type":"TRIAL","name":"Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD","canonical_id":"clinicaltrials.gov:NCT00032773","description":"Acute Graft Versus Host Disease","metadata":null},{"id":"a781f97f039e4bb59f6a1dcd43a1eb0d","type":"TRIAL","name":"Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02215096","description":"Neoplasms","metadata":null},{"id":"7f0333a9d7394297867157fcd1a2899c","type":"TRIAL","name":"Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT00402337","description":"Chronic Constipation","metadata":null},{"id":"0af6153c689c4db18279e67b8731fb52","type":"TRIAL","name":"Dose-ranging Study in Patients With Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02459899","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"bb189578e8e34b9a9aa65f3c0ac10d68","type":"TRIAL","name":"Dose-ranging Study of Nemolizumab in Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03100344","description":"Atopic Dermatitis","metadata":null},{"id":"58cebe109bd64284b2c5e5a954867da5","type":"TRIAL","name":"Dose-ranging Study of Tranexamic Acid in Valve Surgery","canonical_id":"clinicaltrials.gov:NCT01191554","description":"Hemorrhage; Valvular Heart Surgery","metadata":null},{"id":"7eb75fecc58b4d0ea9a9409f586e131f","type":"TRIAL","name":"Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)","canonical_id":"clinicaltrials.gov:NCT00807053","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"32c7c23adc5a49d0a845329ee02e2182","type":"TRIAL","name":"Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.","canonical_id":"clinicaltrials.gov:NCT03725722","description":"Atopic Dermatitis","metadata":null},{"id":"3cc06c5b531248d1ba426ba006ba23a4","type":"TRIAL","name":"Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies","canonical_id":"clinicaltrials.gov:NCT01224821","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"229d037375494910a54e15def88f2ba5","type":"TRIAL","name":"Dosing Flexibility Study in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00580840","description":"Rheumatoid Arthritis","metadata":null},{"id":"80321592ac6b4a7a9f77dc4c18e557d7","type":"TRIAL","name":"Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant","canonical_id":"clinicaltrials.gov:NCT01106027","description":"Kidney Transplant","metadata":null},{"id":"74f5636a026042669e65b084e5f7f084","type":"TRIAL","name":"Dostarlimab and Cobolimab in Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT06238635","description":"Cervical Cancer; Advanced Cervical Carcinoma; Metastatic Cervical Cancer; Metastatic Cervical Carcinoma; Recurrent Cervical Carcinoma","metadata":null},{"id":"a95d5be983f8416ebd69a4cf2f042f2a","type":"TRIAL","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","canonical_id":"clinicaltrials.gov:NCT06333314","description":"Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma","metadata":null},{"id":"8003cab967474c4e9dc71b33250223ff","type":"TRIAL","name":"Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia","canonical_id":"clinicaltrials.gov:NCT05405192","description":"Gestational Trophoblastic Neoplasia","metadata":null},{"id":"9958a499b02243109baa2ad55f6b9840","type":"TRIAL","name":"Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma","canonical_id":"clinicaltrials.gov:NCT07336147","description":"Female","metadata":null},{"id":"31db239445694bdfa69d868c1c32d713","type":"TRIAL","name":"Double Blind Crossover Comparison of Diuretics in the Young","canonical_id":"clinicaltrials.gov:NCT00429897","description":"Low-Renin Hypertension","metadata":null},{"id":"2f07a19be74f425bb6dc3a832253b8ca","type":"TRIAL","name":"Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction","canonical_id":"clinicaltrials.gov:NCT03065998","description":"Drug Abuse","metadata":null},{"id":"f4094f671c274a419b742da9ad4cce2a","type":"TRIAL","name":"Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT00527683","description":"Cocaine Dependence","metadata":null},{"id":"8cd2bb1623e4401cb79fdc693513094d","type":"TRIAL","name":"Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission","canonical_id":"clinicaltrials.gov:NCT05636293","description":"Celiac Disease","metadata":null},{"id":"3ccd8e184a5c4b9a98abb7464fa73212","type":"TRIAL","name":"Double Dose 4-AP on Functional Recovery After Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT06853015","description":"SCI - Spinal Cord Injury","metadata":null},{"id":"b6896c76d57c4fdeae87e1bc3d746624","type":"TRIAL","name":"Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI","canonical_id":"clinicaltrials.gov:NCT06441045","description":"Leptomeningeal Metastasis","metadata":null},{"id":"af55c933fb7144e7ad8a118d1311a065","type":"TRIAL","name":"Double J Stenting and Sildosin After URSL for Lower Ureteric Stones","canonical_id":"clinicaltrials.gov:NCT05823662","description":"Lower Ureteric Stones; Ureteroscopic Lithotripsy; DJ Stenting","metadata":null},{"id":"e455b69279424969941c9c70ee944c22","type":"TRIAL","name":"Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response","canonical_id":"clinicaltrials.gov:NCT03400722","description":"Infertility, Female; Ovarian Stimulation; In Vitro Fertilisation","metadata":null},{"id":"d082ff6901034fcfa9280980fd575178","type":"TRIAL","name":"Double Therapy With IFN-beta 1b and Hydroxychloroquine","canonical_id":"clinicaltrials.gov:NCT04350281","description":"COVID","metadata":null},{"id":"1fe18d33160243fd90de86064769dc09","type":"TRIAL","name":"Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50\u00b5g/g Cream Versus Vehicle Cream in Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02556788","description":"Acne Vulgaris","metadata":null},{"id":"d67751a52e6142e482f41e2f74e4b8fa","type":"TRIAL","name":"Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)","canonical_id":"clinicaltrials.gov:NCT00002186","description":"Herpes Simplex; HIV Infections","metadata":null},{"id":"6327373a2a0640818b0cde17cc8b353e","type":"TRIAL","name":"Double-Blind Study of Miglitol in Japanese With type2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00380822","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"3a21211070354067a2839996fe95a586","type":"TRIAL","name":"Double-Blind Treatment of Major Depressive Disorder With Vilazodone","canonical_id":"clinicaltrials.gov:NCT01742832","description":"Major Depressive Disorder","metadata":null},{"id":"a975635b3c314a16a629ed15619bfa5f","type":"TRIAL","name":"Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide","canonical_id":"clinicaltrials.gov:NCT00334399","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"124ce714d7894dbc8664b9eef0265fe7","type":"TRIAL","name":"Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment","canonical_id":"clinicaltrials.gov:NCT00213070","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"56a8ea38748847e58702c4c1e505b374","type":"TRIAL","name":"Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT00652808","description":"Osteoarthritis; Knee","metadata":null},{"id":"f9fe9a39acaf4ed78cca7e88410ec12a","type":"TRIAL","name":"Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.","canonical_id":"clinicaltrials.gov:NCT00562055","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"a5ed4fa053504c23afd45a330539cc1a","type":"TRIAL","name":"Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects","canonical_id":"clinicaltrials.gov:NCT01126970","description":"Obesity","metadata":null},{"id":"4a67a8d68dcb4c4db62cd3ad8d79496b","type":"TRIAL","name":"Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction","canonical_id":"clinicaltrials.gov:NCT00650039","description":"Pain","metadata":null},{"id":"b68e78b4d00848f89600fd9db7b0966f","type":"TRIAL","name":"Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)","canonical_id":"clinicaltrials.gov:NCT02577003","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"8ef96627255f443e824f94b83f145919","type":"TRIAL","name":"Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors","canonical_id":"clinicaltrials.gov:NCT06162663","description":"Breast Cancer; Insomnia","metadata":null},{"id":"ef2fd2948f504d3baf25d78032d8b366","type":"TRIAL","name":"Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)","canonical_id":"clinicaltrials.gov:NCT02577016","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"0fadffe92c3544659589889b54abdc48","type":"TRIAL","name":"Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption","canonical_id":"clinicaltrials.gov:NCT02655965","description":"Locoregional Analgesia in Breast Surgery","metadata":null},{"id":"18b11af5fa394e598c25d16f4dfd2e7f","type":"TRIAL","name":"Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT01395953","description":"Autism Spectrum Disorder (ASD)","metadata":null},{"id":"3e062f10a14f4182adc3699d7870c452","type":"TRIAL","name":"Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma","canonical_id":"clinicaltrials.gov:NCT01405963","description":"Asthma","metadata":null},{"id":"e2b9b7150046490095a80467debba5bf","type":"TRIAL","name":"Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment","canonical_id":"clinicaltrials.gov:NCT00935675","description":"Carcinomas","metadata":null},{"id":"48ce3f19be834bf5aaa752e6b75967a0","type":"TRIAL","name":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT00464269","description":"Epilepsy","metadata":null},{"id":"54bbd8b0794d4a749b90bd0a3259b690","type":"TRIAL","name":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT00490035","description":"Epilepsy","metadata":null},{"id":"f2a72ff09ec245eaa8b16d300b72238c","type":"TRIAL","name":"Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis","canonical_id":"clinicaltrials.gov:NCT00317499","description":"Psoriatic Arthritis; Psoriasis","metadata":null},{"id":"13a0a46aa9b94af79b4fa0c562ce5a79","type":"TRIAL","name":"Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT06830798","description":"Delayed Graft Function; DGF; Kidney Transplant","metadata":null},{"id":"58c2f3adb8bd4f7fba446d6f5f1a26b0","type":"TRIAL","name":"Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT02558374","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"5794b6d2370540ad9c25566e848096d8","type":"TRIAL","name":"Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)","canonical_id":"clinicaltrials.gov:NCT01600170","description":"HIV Dementia","metadata":null},{"id":"08eb5899f8de4b6a93e9171375529d65","type":"DRUG","name":"Doxazosin","canonical_id":"mesh:D017292","description":null,"metadata":null},{"id":"3ac49e49bda24a1481d7e5d563bebca1","type":"TRIAL","name":"Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT00295555","description":"Diabetes Mellitus; Essential Hypertension; Renal Failure","metadata":null},{"id":"54f8e3377c4545c881a01294db2b5435","type":"TRIAL","name":"Doxazosin and Ramipril in Hypertension","canonical_id":"clinicaltrials.gov:NCT02901977","description":"Hypertension","metadata":null},{"id":"8a6d6a6a62a64c7a87a3583cff031cb8","type":"TRIAL","name":"Doxazosin for Psychostimulant Dependence","canonical_id":"clinicaltrials.gov:NCT01371851","description":"Methamphetamine or Cocaine Dependence","metadata":null},{"id":"b1a5b6f34dcb4cf0bc8d4d84d2ee8b50","type":"TRIAL","name":"Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT07598734","description":"Sleep Quality Post-TKA; Postoperative Knee Function; Quality of Life After Primary TKA","metadata":null},{"id":"9067b771fab84f9d82a6bf5cbddee15b","type":"TRIAL","name":"Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02062632","description":"Esophageal Carcinoma; Hypopharyngeal Carcinoma; Laryngeal Carcinoma; Lymphoma; Mesothelioma; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pleura; Metastatic Malignant Neoplasm in the Spinal Cord; Non-Small Cell Lung Carcinoma; Sarcoma; Small Cell Lung Carcinoma; Thymic Carcinoma; Thymoma; Thyroid Gland Carcinoma","metadata":null},{"id":"e5f0c1e0779b445496043c4d94595113","type":"TRIAL","name":"Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01156142","description":"Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain","metadata":null},{"id":"05b66ef7e0994a798d710befc23a069f","type":"TRIAL","name":"Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT06017895","description":"Swallowing-induced Pain","metadata":null},{"id":"dbb2d56925d84ed48f145da58b1a14dd","type":"TRIAL","name":"Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02229539","description":"Acute Oral Mucositis Pain","metadata":null},{"id":"d6ed40e6e5e447c08ac8edd7600b03e4","type":"TRIAL","name":"Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers","canonical_id":"clinicaltrials.gov:NCT01375699","description":"Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer","metadata":null},{"id":"a2c7daf4ad524d67a379274e0f533d9a","type":"TRIAL","name":"Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00436566","description":"Breast Cancer; Cardiac Toxicity","metadata":null},{"id":"ab2f7c6b819b4bafbfc51069bbd72428","type":"TRIAL","name":"Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04639843","description":"Adult T-cell Leukemia/Lymphoma; Extranodal NK-/T-cell Lymphoma, Nasal Type; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma; Hepatosplenic T-cell Lymphoma","metadata":null},{"id":"9d78638d08044efcaecb212d601c11a3","type":"TRIAL","name":"Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00829790","description":"Healthy","metadata":null},{"id":"e89465aec351446f9305fdeabcebe66d","type":"TRIAL","name":"Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP","canonical_id":"clinicaltrials.gov:NCT04050540","description":"HIV Infections; HIV/AIDS; Neisseria Gonorrheae Infection; Chlamydia Trachomatis Infection; Syphilis Infection","metadata":null},{"id":"13f2dfa99876426ea24d012ff7a23b65","type":"TRIAL","name":"Doxycycline for the Treatment of Nodding Syndrome","canonical_id":"clinicaltrials.gov:NCT02850913","description":"Seizures","metadata":null},{"id":"35c6bee9c5214ff88b63a6b545ca8da1","type":"TRIAL","name":"Doxycycline in Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT06329882","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"8f2486b4304443c38e91c58c1067a357","type":"TRIAL","name":"Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial","canonical_id":"clinicaltrials.gov:NCT02207556","description":"Primary Systemic Amyloidosis","metadata":null},{"id":"a7025579b3544e10a4bf3d7d33e3c2b0","type":"DISEASE","name":"Dravet syndrome","canonical_id":"mondo:0100135","description":null,"metadata":null},{"id":"89fc1610ba00441b8e2207f6acb4447f","type":"TRIAL","name":"Dronedarone Rhythm Intervention for Early Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT07270848","description":"Atrial Fibrillation (AF)","metadata":null},{"id":"23d42f0a8ae84c79a7bfa7c5610190ba","type":"DISEASE","name":"Drooling","canonical_id":"hp:0002307","description":null,"metadata":null},{"id":"b50b33f4e3a042c09c0c328603703bc4","type":"TRIAL","name":"Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.","canonical_id":"clinicaltrials.gov:NCT01182194","description":"Healthy","metadata":null},{"id":"f82fda9e7f484dc58386d0d8f5ddf239","type":"DRUG","name":"Drostanolone","canonical_id":"mesh:C100263","description":null,"metadata":null},{"id":"e76115e044464650b822bcfadfffdc58","type":"DRUG","name":"Drostanolone propionate","canonical_id":"mesh:C007561","description":null,"metadata":null},{"id":"10fe0a0964294ad287419381861a8e76","type":"DRUG","name":"Droxidopa","canonical_id":"mesh:D015103","description":null,"metadata":null},{"id":"01b5c85535d34eca8e0e9af6a48f356b","type":"TRIAL","name":"Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline","canonical_id":"clinicaltrials.gov:NCT00779259","description":"Pharmacokinetics","metadata":null},{"id":"0b262c123bd94392b6cd21845c237e33","type":"TRIAL","name":"Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg","canonical_id":"clinicaltrials.gov:NCT00272805","description":"Chronic Heart Failure","metadata":null},{"id":"8eb899c9ef354031bcbfeb7f6990ebed","type":"TRIAL","name":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","canonical_id":"clinicaltrials.gov:NCT05543122","description":"Breast Feeding","metadata":null},{"id":"d7986dc0af4f488bb380ce6b1ca00313","type":"TRIAL","name":"Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients","canonical_id":"clinicaltrials.gov:NCT01525628","description":"Hepatitis C, Chronic","metadata":null},{"id":"b67f619535fc43339d9284436fd6167a","type":"TRIAL","name":"Drug Drug Interaction Study Of Crizotinib With Esomeprazole.","canonical_id":"clinicaltrials.gov:NCT01549574","description":"Healthy","metadata":null},{"id":"c74f6d80598142b7813a6e3fea14d69c","type":"TRIAL","name":"Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men","canonical_id":"clinicaltrials.gov:NCT04713254","description":"Healthy","metadata":null},{"id":"727d14bdcb9147bb97a26e70ad1f5109","type":"TRIAL","name":"Drug Interaction Between Ritonavir And Sitaxsentan","canonical_id":"clinicaltrials.gov:NCT01251848","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"57fc00bccd454ee2847d3037f758fa33","type":"TRIAL","name":"Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers","canonical_id":"clinicaltrials.gov:NCT02404805","description":"HIV; Hepatitis C","metadata":null},{"id":"e0199f86c7aa4782aa633d3a2c840f81","type":"TRIAL","name":"Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin","canonical_id":"clinicaltrials.gov:NCT00722956","description":"Healthy Volunteers; Pharmacokinetics","metadata":null},{"id":"55e4c12843a54f279b7ce255e84b8d39","type":"TRIAL","name":"Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin","canonical_id":"clinicaltrials.gov:NCT00723424","description":"Healthy Volunteers; Pharmacokinetics","metadata":null},{"id":"0e90288d4c4d4f5782e3eea3d7cf4d4c","type":"TRIAL","name":"Drug Interaction Study Between AZD3480 and Cytochrome P450","canonical_id":"clinicaltrials.gov:NCT00692510","description":"Metabolism; Alzheimer's Disease","metadata":null},{"id":"d085dc6777cf471e883afa66222865e9","type":"TRIAL","name":"Drug Interaction Study Between Bosutinib And Dabigatran","canonical_id":"clinicaltrials.gov:NCT02102633","description":"Healthy","metadata":null},{"id":"a332a64dbacb489ba0d322abe8b72f6a","type":"TRIAL","name":"Drug Interaction Study Between Dorzagliatin and Empagliflozin","canonical_id":"clinicaltrials.gov:NCT03790787","description":"Patients","metadata":null},{"id":"b669e5b9daba4bfaa7a584fbe05d021c","type":"TRIAL","name":"Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.","canonical_id":"clinicaltrials.gov:NCT00833378","description":"Hepatitis C","metadata":null},{"id":"f47767ea68c6438984708584646c10ea","type":"TRIAL","name":"Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir","canonical_id":"clinicaltrials.gov:NCT00365339","description":"HIV Infections","metadata":null},{"id":"50093bfbf5fc4d53a1a579cfc5440454","type":"TRIAL","name":"Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT04023760","description":"Pharmacokinetics; Kidney Transplant; Lung Transplant","metadata":null},{"id":"16d9d579b8f4461e91cc2f2ccbb66012","type":"TRIAL","name":"Drug Interaction Study of Avanafil and Enalapril or Amlodipine","canonical_id":"clinicaltrials.gov:NCT01117038","description":"Erectile Dysfunction","metadata":null},{"id":"6ca2c91976e041ef91b071956f692a80","type":"TRIAL","name":"Drug Interaction Study of CT1812 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03716427","description":"Healthy Volunteers","metadata":null},{"id":"40662e69bea2495397658e5bd9e8f406","type":"TRIAL","name":"Drug Interaction Study of Colchicine and Theophylline","canonical_id":"clinicaltrials.gov:NCT01601132","description":"Healthy","metadata":null},{"id":"610b9ef12c7f4f8bae9fea46f33f600f","type":"TRIAL","name":"Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs","canonical_id":"clinicaltrials.gov:NCT00920088","description":"Healthy Subjects; Infection, Human Immunodeficiency Virus","metadata":null},{"id":"8ad50523ce904ee0b5c7b568c7fca50c","type":"TRIAL","name":"Drug Interaction Study of Digoxin and BI 10773","canonical_id":"clinicaltrials.gov:NCT01306175","description":"Healthy","metadata":null},{"id":"3a9fc6261ef84329bba3bd24bff0f540","type":"TRIAL","name":"Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT03390465","description":"Drug-Drug Interaction","metadata":null},{"id":"b4f91516d17a492ea4cfbdff06ced3da","type":"TRIAL","name":"Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil","canonical_id":"clinicaltrials.gov:NCT00474201","description":"Healthy Volunteers","metadata":null},{"id":"4332edaa765146a9b902fac69950149d","type":"TRIAL","name":"Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin","canonical_id":"clinicaltrials.gov:NCT02542969","description":"Healthy","metadata":null},{"id":"8f19062a86494ced804abbc6036b267f","type":"TRIAL","name":"Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT00777855","description":"Healthy","metadata":null},{"id":"eb8d4e7cde0547d5bef9e248b1c0cad9","type":"TRIAL","name":"Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02495831","description":"Healthy","metadata":null},{"id":"41475239ceea4f7a9ac2d92111d1dbd6","type":"TRIAL","name":"Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01662999","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f88e1afa0d624241b22a09536bd5b8c9","type":"TRIAL","name":"Drug Interaction Study of Simvastatin and Dabigatran","canonical_id":"clinicaltrials.gov:NCT03728101","description":"Healthy","metadata":null},{"id":"5fd4ee326e96449987754a4076b5be3e","type":"TRIAL","name":"Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites","canonical_id":"clinicaltrials.gov:NCT04149678","description":"Healthy Volunteers","metadata":null},{"id":"130d21c8245a4ff4a7a2719edc8fce8d","type":"TRIAL","name":"Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder","canonical_id":"clinicaltrials.gov:NCT02537873","description":"Cocaine Use Disorder","metadata":null},{"id":"f259ccc8627640ffbf0cb26086f1d466","type":"TRIAL","name":"Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT03143855","description":"Opioid Abuse; Opioid Dependence; Opioid-Related Disorders; Opioid Use","metadata":null},{"id":"8a2aaa7b6f1b4693a6f0b935cdab7df2","type":"TRIAL","name":"Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT05992428","description":"Healthy","metadata":null},{"id":"e4df924457944015a9617cb1d152014e","type":"TRIAL","name":"Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases","canonical_id":"clinicaltrials.gov:NCT06285539","description":"Behcet's Disease; Idiopathic Inflammatory Myopathies; IgG4-related Disease","metadata":null},{"id":"50e4562ac8c84bf1b7220bf21ce47087","type":"TRIAL","name":"Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)","canonical_id":"clinicaltrials.gov:NCT00604812","description":"Migraine Disorders","metadata":null},{"id":"9debe400eb254af2916f5e36254e4551","type":"TRIAL","name":"Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity","canonical_id":"clinicaltrials.gov:NCT01351753","description":"Obesity; Metabolic Syndrome X","metadata":null},{"id":"b998ad11f5ce4452bd3385fabada0d6e","type":"TRIAL","name":"Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People","canonical_id":"clinicaltrials.gov:NCT02308254","description":"Diabetes Mellitus; Gastroparesis","metadata":null},{"id":"27d11c8ba6764cf1b40b4812821a96e4","type":"TRIAL","name":"Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)","canonical_id":"clinicaltrials.gov:NCT00772941","description":"Smoking Cessation","metadata":null},{"id":"8ed7d8165fe040af83a031cdaeb8c4e2","type":"TRIAL","name":"Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet","canonical_id":"clinicaltrials.gov:NCT01376193","description":"Migraine Disorders","metadata":null},{"id":"f2a019d2e5f7413db9e85613d449da5f","type":"TRIAL","name":"Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)","canonical_id":"clinicaltrials.gov:NCT03342690","description":"Chronic Heart Failure","metadata":null},{"id":"5102847ff6134c7680404ee872ea6924","type":"TRIAL","name":"Drug and Non-Drug Treatment Of Severe Migraine","canonical_id":"clinicaltrials.gov:NCT00910689","description":"Migraine Headache","metadata":null},{"id":"17078ff08b3740f780cf30dc80038c2a","type":"TRIAL","name":"Drug and Talk Therapy for Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01038323","description":"Fibromyalgia","metadata":null},{"id":"0cfc9a777c364fffbe4473393877a2a9","type":"DISEASE","name":"Drug resistant tuberculosis","canonical_id":"mesh:D018088","description":null,"metadata":null},{"id":"568a7a1557014ca9a3b62fbb3027ff94","type":"TRIAL","name":"Drug to Drug Interaction Study With Ipragliflozin and Furosemide","canonical_id":"clinicaltrials.gov:NCT01611415","description":"Healthy Subjects; Pharmacokinetics of Ipragliflozin","metadata":null},{"id":"441e2b1f0c6745568288ef41ec142228","type":"TRIAL","name":"Drug-Drug Interaction (DDI) Study for TD-9855","canonical_id":"clinicaltrials.gov:NCT03432793","description":"Drug Drug Interaction (DDI)","metadata":null},{"id":"8d76885d5b32462d9e36d0526da6b26e","type":"TRIAL","name":"Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT06379958","description":"Pharmacokinetics","metadata":null},{"id":"a14d3d524e974bfba0a4abfc9288234a","type":"TRIAL","name":"Drug-Drug Interaction Between Colchicine and Ritonavir","canonical_id":"clinicaltrials.gov:NCT00983515","description":"Pharmacokinetics","metadata":null},{"id":"530367ad63394c80995e62f1cdbee354","type":"TRIAL","name":"Drug-Drug Interaction Between Colchicine and Verapamil ER","canonical_id":"clinicaltrials.gov:NCT00983242","description":"Pharmacokinetics","metadata":null},{"id":"4fd35718d9fe47be8fcbbb2fa1b919ad","type":"TRIAL","name":"Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)","canonical_id":"clinicaltrials.gov:NCT01907724","description":"Hepatitis C, Chronic","metadata":null},{"id":"e1b939756b794adc97194cb9f35a7afa","type":"TRIAL","name":"Drug-Drug Interaction Between Rifampin and Fluvastatin","canonical_id":"clinicaltrials.gov:NCT04029584","description":"Drug-drug Interaction","metadata":null},{"id":"346c5a9287cf4c1b82a4b95ee446125e","type":"TRIAL","name":"Drug-Drug Interaction Potential of Mavorixafor","canonical_id":"clinicaltrials.gov:NCT06914869","description":"Healthy Participants","metadata":null},{"id":"9b2f573bd652412ea141620034ac20bf","type":"TRIAL","name":"Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone","canonical_id":"clinicaltrials.gov:NCT00785213","description":"Healthy","metadata":null},{"id":"fe3e9f83bb9a4a6f92593913c1bc44e2","type":"TRIAL","name":"Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam","canonical_id":"clinicaltrials.gov:NCT02370615","description":"Japanese Healthy Adult Males","metadata":null},{"id":"0464058877a54e53be0b14d194249c02","type":"TRIAL","name":"Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02224053","description":"Healthy Volunteer","metadata":null},{"id":"a48e114edf1a42fd9c6e689eb0bd84bf","type":"TRIAL","name":"Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)","canonical_id":"clinicaltrials.gov:NCT06919991","description":"Healthy Participants","metadata":null},{"id":"4a1852faf5ca4ae3b4362df83dfc1064","type":"TRIAL","name":"Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates","canonical_id":"clinicaltrials.gov:NCT05064488","description":"Healthy","metadata":null},{"id":"631d1f8629da436db8ef64bafe0ec088","type":"TRIAL","name":"Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT04650542","description":"Drug-drug Interaction","metadata":null},{"id":"4f390d17ce094473afa050d3ef83ebe2","type":"TRIAL","name":"Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil","canonical_id":"clinicaltrials.gov:NCT00566865","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"34a59691520444549f6bb34a0061998e","type":"TRIAL","name":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT05657613","description":"Drug Interactions","metadata":null},{"id":"044899e1d0fa4985b230fcfd6f11c4d3","type":"TRIAL","name":"Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives","canonical_id":"clinicaltrials.gov:NCT03954366","description":"Neoplasms","metadata":null},{"id":"d85c5ef4465f4d0da57946b6d079da65","type":"TRIAL","name":"Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin","canonical_id":"clinicaltrials.gov:NCT03801746","description":"Drug Interaction Potentiation","metadata":null},{"id":"2a84cc3f26f944cf9d9f8d1b41cbc887","type":"TRIAL","name":"Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin","canonical_id":"clinicaltrials.gov:NCT03801733","description":"Drug Interaction Potentiation","metadata":null},{"id":"acd1ab39dcba48349f7da3d13e4cb275","type":"TRIAL","name":"Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT01178853","description":"Healthy","metadata":null},{"id":"597994da138342cfa5774bc85a9694e6","type":"TRIAL","name":"Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01976572","description":"Hyperphosphatemia; Chronic Kidney Disease","metadata":null},{"id":"29be12e15ee24c49901f2daf0a08fcc8","type":"TRIAL","name":"Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite","canonical_id":"clinicaltrials.gov:NCT04902105","description":"Drug Interaction","metadata":null},{"id":"0e1dd1eea4704e64aeb607727f4fa657","type":"TRIAL","name":"Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin","canonical_id":"clinicaltrials.gov:NCT05306379","description":"Drug-drug Interaction","metadata":null},{"id":"f2c72548814c4593bfb260b056248350","type":"TRIAL","name":"Drug-Drug Interaction Study: ASP2151 and Montelukast","canonical_id":"clinicaltrials.gov:NCT02321748","description":"Healthy","metadata":null},{"id":"3a130768d5e24550ab9fc06acd77dff5","type":"TRIAL","name":"Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).","canonical_id":"clinicaltrials.gov:NCT06406400","description":"Opioid Use Disorder","metadata":null},{"id":"f249d5aaf51d49a693425efda39e92d9","type":"TRIAL","name":"Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06232109","description":"Drug Drug Interaction","metadata":null},{"id":"eccfd732192c43debfe1b1d0a51ce661","type":"TRIAL","name":"Drug-Drug Interactions of JMKX003142 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07565441","description":"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","metadata":null},{"id":"c164530b2a934a83b15d1a09d949327b","type":"TRIAL","name":"Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)","canonical_id":"clinicaltrials.gov:NCT01346865","description":"Coronary Artery Disease","metadata":null},{"id":"503c40d3101e483aa2e5adbbbf29bc08","type":"TRIAL","name":"Drug-Food Interaction Study of Seville Orange Juice and Colchicine","canonical_id":"clinicaltrials.gov:NCT00960193","description":"Healthy","metadata":null},{"id":"e78967058b784aaa9e2550b9af14564e","type":"TRIAL","name":"Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02807116","description":"Healthy Subjects","metadata":null},{"id":"1220663ed80641d98a5c081730fd40f1","type":"TRIAL","name":"Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03530995","description":"Drug-drug Interaction; Autoimmune Diseases; Fibrotic Disease","metadata":null},{"id":"6a7c5c04c40b4c4ba0a8f2b1718c3e18","type":"TRIAL","name":"Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)","canonical_id":"clinicaltrials.gov:NCT02152969","description":"Hypertension","metadata":null},{"id":"7361badc02a94bcc953f8095fb2bb9b2","type":"TRIAL","name":"Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05147727","description":"Tumor","metadata":null},{"id":"cc63e7272bdc41a3a52f9133cb163371","type":"TRIAL","name":"Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole","canonical_id":"clinicaltrials.gov:NCT01913379","description":"Healthy Subjects; Pharmacokinetics; Drug-Drug Interaction","metadata":null},{"id":"1afadc510f8a40efa93a62a94acb8871","type":"TRIAL","name":"Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07824193","description":"Drug Drug Interaction","metadata":null},{"id":"63d9d2bd98bc4d5badf34502833c6aa9","type":"TRIAL","name":"Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02281370","description":"Purpura, Thrombocytopenic, Idiopathic","metadata":null},{"id":"955d6ba1c465480996863e72ad2331a0","type":"TRIAL","name":"Drug-drug Interaction Study of FYU-981 and Oxaprozin","canonical_id":"clinicaltrials.gov:NCT03350386","description":"Healthy","metadata":null},{"id":"8eccb8eb450f4c658d3c19b6ae103159","type":"TRIAL","name":"Drug-drug Interaction Study of Gepotidacin","canonical_id":"clinicaltrials.gov:NCT04493931","description":"Infections, Bacterial","metadata":null},{"id":"ce44d4dec6ee423bb7cdbf4f0d28c55a","type":"TRIAL","name":"Drug-drug Interaction Study of KL1333 in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04643249","description":"Mitochondrial Disease","metadata":null},{"id":"cdf59549942b4867bd14865b72c9a093","type":"TRIAL","name":"Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT04818086","description":"Drug Interaction; Analgesics; Opioid Use Disorder","metadata":null},{"id":"df8545798cc3485497a0e09beb2df361","type":"TRIAL","name":"Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A","canonical_id":"clinicaltrials.gov:NCT03624959","description":"Healthy Volunteer","metadata":null},{"id":"0b833b3567264cdc919c690e09ce27f7","type":"TRIAL","name":"Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response","canonical_id":"clinicaltrials.gov:NCT03694119","description":"Healthy Volunteer","metadata":null},{"id":"55c885d23dbb430eb1022a380d5afd1f","type":"TRIAL","name":"Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)","canonical_id":"clinicaltrials.gov:NCT03979989","description":"Pharmacokinetic","metadata":null},{"id":"a60063e94ff0434ebbe1884781b49a67","type":"TRIAL","name":"Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4","canonical_id":"clinicaltrials.gov:NCT03556592","description":"Atopic Dermatitis","metadata":null},{"id":"030fa76d3cff49fa97931815ddcea564","type":"TRIAL","name":"Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion","canonical_id":"clinicaltrials.gov:NCT04664725","description":"Prostate Cancer Patients","metadata":null},{"id":"d8f0cbf8b104413ab75df24e1573c6da","type":"TRIAL","name":"Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT07796191","description":"Healthy Adult Participants","metadata":null},{"id":"0ddd467f403340e09b103fe3a98f8653","type":"TRIAL","name":"Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin","canonical_id":"clinicaltrials.gov:NCT06031454","description":"Drug Drug Interaction","metadata":null},{"id":"431c713e11bc4e118bd18f39199fd40b","type":"TRIAL","name":"Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin","canonical_id":"clinicaltrials.gov:NCT07362030","description":"Obesity","metadata":null},{"id":"748518685826405a8085c50987191274","type":"TRIAL","name":"Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid","canonical_id":"clinicaltrials.gov:NCT05954624","description":"Drug Drug Interaction","metadata":null},{"id":"f9389ee1927a49a89658676021aae464","type":"TRIAL","name":"Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)","canonical_id":"clinicaltrials.gov:NCT00133237","description":"Coronary Disease","metadata":null},{"id":"3bc830588b2140f68bb6477e5b541820","type":"TRIAL","name":"Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid","canonical_id":"clinicaltrials.gov:NCT01634100","description":"Healthy","metadata":null},{"id":"7821cb59c9ab4b2baa6bd840a7f50cbf","type":"TRIAL","name":"Drugs to Reduce the Side Effects of Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00003213","description":"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"2e90c2ba667b4f00a06ead283e875bc7","type":"TRIAL","name":"Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma","canonical_id":"clinicaltrials.gov:NCT03827070","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"ed94d7a4f70e44569cb3dc4dd5d6d33f","type":"GO_TERM","name":"Dsc E3 ubiquitin ligase complex","canonical_id":"go:GO:0044695","description":"\"An E3 ubiquitin ligase complex localized to the ER and Golgi membrane. In fission yeast comprises Dsc1, 2, 3 and 4. Involved in the processes of fission yeast sre1 (human SREBP) transcriptional activator proteolytic cleavage, the multivesicular body (MVB) pathway, and a post-endoplasmic reticulum pathway for protein catabolism.\" [GOC:mah, GOC:vw, PMID:21504829]","metadata":null},{"id":"727cb998f41e4611b3fc1e7946272e19","type":"GO_TERM","name":"Dsc E3 ubiquitin ligase complex assembly","canonical_id":"go:GO:1990155","description":"\"The aggregation, arrangement and bonding together of a set of components to form a Dsc E3 ubiquitin ligase complex, an E3 ubiquitin ligase complex localized to the ER and Golgi membrane.\" [GOC:mah, PMID:23760507]","metadata":null},{"id":"dc0fee7373f04024bf9262b314257fe6","type":"GO_TERM","name":"Dsl1/NZR complex","canonical_id":"go:GO:0070939","description":"\"A multisubunit tethering complex, i.e. a protein complex involved in mediating the initial interaction between vesicles and the membranes with which they fuse, that is involved in trafficking from the Golgi apparatus to the ER. In Saccharomyces cerevisiae the Dsl1p complex contains Dsl1p, Tip20p, and Sec39p.\" [GOC:jh, GOC:mah, PMID:19151722, PMID:21550981]","metadata":null},{"id":"1271896145e94896b846aa8ea40b556c","type":"TRIAL","name":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT03551964","description":"Acute Myocardial Infarction; Cardiogenic Shock","metadata":null},{"id":"697011caa5e44dc2958941828cc087c9","type":"TRIAL","name":"Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT02979977","description":"Squamous Cell Cancers of the Head and Neck","metadata":null},{"id":"6ccc6e9e2a4c4a2aa36aad5b80eb32c8","type":"TRIAL","name":"Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention","canonical_id":"clinicaltrials.gov:NCT07581808","description":"Hypercholesterolemia; Atherosclerotic Cardiovascular Disease (ASCVD)","metadata":null},{"id":"0f50c1ad36e345f29e88db58ac77494d","type":"TRIAL","name":"Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01919879","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"83286215b2684aa3bc551fbdb6acbe5e","type":"TRIAL","name":"Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: Effect on Pain Control","canonical_id":"clinicaltrials.gov:NCT02858622","description":"Renal Failure","metadata":null},{"id":"1cb962dd0d5343aa81c42f3437d368e4","type":"TRIAL","name":"Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT04262193","description":"Opioid-use Disorder; Sleep","metadata":null},{"id":"7877149b59b34c57ad050ac30abb0165","type":"DISEASE","name":"Duchenne muscular dystrophy","canonical_id":"mondo:0010679","description":null,"metadata":null},{"id":"75e22b08f80a480ea8a4fff6761990f6","type":"DRUG","name":"Dulaglutide","canonical_id":"mesh:C555680","description":null,"metadata":null},{"id":"5c4112731ae44f1d9b02f8ce7e947060","type":"TRIAL","name":"Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables","canonical_id":"clinicaltrials.gov:NCT03824002","description":"Diabetes Mellitus","metadata":null},{"id":"d5ab2760e5bc471fac04fd59a6a98f46","type":"TRIAL","name":"Duloxetine Combined With Intra-articular Injection of Corticosteroid and Hyaluronic Acid Reduces Pain in the Treatment of Knee Osteoarthritis Patients","canonical_id":"clinicaltrials.gov:NCT04117893","description":"Osteoarthritis, Knee; Chronic Pain","metadata":null},{"id":"25bfd91e924a4b909e4a53a718d5d2bf","type":"TRIAL","name":"Duloxetine Versus Placebo in Chronic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT00408876","description":"Back Pain Without Radiation","metadata":null},{"id":"7f49ff8224c04fe5806d94543b1169d9","type":"TRIAL","name":"Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00036309","description":"Depressive Disorder","metadata":null},{"id":"73ad2e405020473f8a819790add67046","type":"TRIAL","name":"Duloxetine for Major Depression in Peri-/Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00889369","description":"Major Depressive Disorder","metadata":null},{"id":"cc36758bc8f947a18174339824af5294","type":"TRIAL","name":"Duloxetine for the Treatment of Dysthymia","canonical_id":"clinicaltrials.gov:NCT00185575","description":"Depressive Disorder","metadata":null},{"id":"378fc9047ffc42179e738588381badc1","type":"TRIAL","name":"Duloxetine in Inflammatory Bowel Diseases","canonical_id":"clinicaltrials.gov:NCT07431606","description":"Inflammatory Bowel Diseases","metadata":null},{"id":"dc583f85678d4bcb972eea3ac31e1b45","type":"TRIAL","name":"Duloxetine in the Treatment of Stress Urinary Incontinence.","canonical_id":"clinicaltrials.gov:NCT00191087","description":"Urinary Incontinence, Stress","metadata":null},{"id":"85178b8ea4e248b79e7dedda30eff862","type":"TRIAL","name":"Duloxetine vs. Active Comparator in the Treatment of Patients With Depression","canonical_id":"clinicaltrials.gov:NCT00071695","description":"Depression","metadata":null},{"id":"4829dccaf38242bc8977c2e651712b72","type":"DISEASE","name":"Duodenal Ulcer","canonical_id":"mesh:D004381","description":null,"metadata":null},{"id":"ad8bb4cd9f094adca107a66151dd6bac","type":"TRIAL","name":"Dupilumab Compassionate Use Study","canonical_id":"clinicaltrials.gov:NCT03020810","description":"Asthma","metadata":null},{"id":"6c505a05e80043fbb02a800b5b78cfe5","type":"TRIAL","name":"Dupilumab for Aspirin-exacerbated Respiratory Disease","canonical_id":"clinicaltrials.gov:NCT03595488","description":"Aspirin-exacerbated Respiratory Disease","metadata":null},{"id":"d2023e0234674275ba75e3815a1208ed","type":"TRIAL","name":"Dupilumab for Eosinophilic Esophagitis With Severe Strictures","canonical_id":"clinicaltrials.gov:NCT06352073","description":"Eosinophilic Esophagitis; EoE","metadata":null},{"id":"7431fbaf64ae4b188cff61694d57832a","type":"TRIAL","name":"Dupilumab in Chronic Spontaneous Urticaria","canonical_id":"clinicaltrials.gov:NCT03749135","description":"Chronic Spontaneous Urticaria; Recurrent Angioedema","metadata":null},{"id":"c215bf6a29b24c708f81a67b4b0ed050","type":"TRIAL","name":"Dupilumab in Type 2-Inflamed COPD Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study","canonical_id":"clinicaltrials.gov:NCT07788092","description":"COPD (Chronic Obstructive Pulmonary Disease); COPD; Eosinophilia","metadata":null},{"id":"5e60028780b64c229f8f068adaaa7aaf","type":"TRIAL","name":"Dupilumab in the Treatment of Pediatric Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT05866562","description":"Alopecia Areata","metadata":null},{"id":"8f7f204720624252b1c31287af4687fa","type":"TRIAL","name":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-na\u00efve Neovascular Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT06890026","description":"Neovascular Age-Related Macular Degeneration (nAMD); Treatment-na\u00efve","metadata":null},{"id":"3889abfe984a48a1b36a44d6f797c742","type":"TRIAL","name":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT05366868","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"80beda91db82413d9e22706bde4e749d","type":"TRIAL","name":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","canonical_id":"clinicaltrials.gov:NCT01516879","description":"Hypercholesterolemia","metadata":null},{"id":"8121b41ca4444aa1a4fb4210b3b3470f","type":"TRIAL","name":"Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening","canonical_id":"clinicaltrials.gov:NCT06000501","description":"Adult Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"efa1bd8c11c44f8cb544bde0be4b4e54","type":"TRIAL","name":"Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge","canonical_id":"clinicaltrials.gov:NCT02622243","description":"Asthma","metadata":null},{"id":"c181113e424743978f6941ead4a05454","type":"TRIAL","name":"Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin","canonical_id":"clinicaltrials.gov:NCT03095274","description":"Neuroendocrine Tumors; Neuroendocrine Neoplasm of Lung","metadata":null},{"id":"4191c032f9e54b2dacce313932e02398","type":"TRIAL","name":"Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02904954","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"3740d1df7d584f8290b1af522e6b00d9","type":"TRIAL","name":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","canonical_id":"clinicaltrials.gov:NCT03472274","description":"Bladder Cancer","metadata":null},{"id":"28534bf1ac1f4cc3b3ee82093c49746e","type":"TRIAL","name":"Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT03482102","description":"Hepatocellular Carcinoma; Biliary Tract Cancer","metadata":null},{"id":"7756cc634e634315ab4759ade84c7463","type":"TRIAL","name":"Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity","canonical_id":"clinicaltrials.gov:NCT03784066","description":"Oral Cavity Squamous Cell Carcinoma","metadata":null},{"id":"743e37e56ad749daa13b03aaf4c14564","type":"TRIAL","name":"Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03911557","description":"Tumor, Solid","metadata":null},{"id":"cb375cebcc4a479eaa4c56b6fdc7caf0","type":"TRIAL","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","canonical_id":"clinicaltrials.gov:NCT03837899","description":"Pediatric Cancer; Solid Tumor Pediatric; Hematological Malignancies","metadata":null},{"id":"b7e07046b0184c51bcfcbe447b28b212","type":"TRIAL","name":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","canonical_id":"clinicaltrials.gov:NCT05451043","description":"Pancreatic Cancer; Hepatocellular Cancer; Biliary Tract Cancer; Cholangiocarcinoma","metadata":null},{"id":"bfb73d277ff748849d0fb11d0f00cff5","type":"TRIAL","name":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","canonical_id":"clinicaltrials.gov:NCT02879162","description":"Advanced Rare Tumours","metadata":null},{"id":"704c91e91bfa4c9b8dcc8e1edb33ea22","type":"TRIAL","name":"Durvalumab and Tremelimumab \u00b1 Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT03057106","description":"Lung Cancer Metastatic","metadata":null},{"id":"b98b2261ade84dd2a0ed75a97c55f443","type":"TRIAL","name":"Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma","canonical_id":"clinicaltrials.gov:NCT03161223","description":"Lymphoma, T-Cell","metadata":null},{"id":"f1b0aecfe4934fc49d3a1272224aa0dd","type":"TRIAL","name":"Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03522584","description":"Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"5fb168072dd64c34bbf8767b67eee33c","type":"DRUG","name":"Dutasteride","canonical_id":"mesh:D000068538","description":null,"metadata":null},{"id":"61b28e2ff3554eb0964660dccd792858","type":"TRIAL","name":"Dutch Cangrelor Registry","canonical_id":"clinicaltrials.gov:NCT04138641","description":"STEMI - ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI; Coronary Artery Disease","metadata":null},{"id":"01be0221355c49b9aa3811896ff5a622","type":"TRIAL","name":"Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)","canonical_id":"clinicaltrials.gov:NCT04487886","description":"COVID-19","metadata":null},{"id":"b0f2fc1b1ac14c4594141ef3a4aba67b","type":"TRIAL","name":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","canonical_id":"clinicaltrials.gov:NCT04890236","description":"Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"bc910730a9fd48f99203ba671920c7ab","type":"TRIAL","name":"Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy","canonical_id":"clinicaltrials.gov:NCT05044039","description":"Non-Hodgkin Lymphoma; Acute Lymphocytic Leukemia","metadata":null},{"id":"54ababf4b8d3486eab6fd8c0f36fa3d1","type":"TRIAL","name":"Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT04331119","description":"T-Cell Lymphoma","metadata":null},{"id":"b273d86e5ae54ac6a9d7e4a5972244d4","type":"TRIAL","name":"Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT07293403","description":"Follicular Helper T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified","metadata":null},{"id":"0112010e707b4a9eb27655704d9aa145","type":"TRIAL","name":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","canonical_id":"clinicaltrials.gov:NCT05057247","description":"Squamous Cell Carcinoma of the Head and Neck (SCCHN); Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Head and Neck Cancer; Advanced Head and Neck Cancer; Advanced Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"8c0230f55985423b8c292d4bbd74956a","type":"TRIAL","name":"Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)","canonical_id":"clinicaltrials.gov:NCT02292225","description":"Lymphocytic Leukemia, Chronic; Lymphoma, Small Lymphocytic","metadata":null},{"id":"f33273c9bb68446d96798f62a35ab292","type":"TRIAL","name":"Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)","canonical_id":"clinicaltrials.gov:NCT02605694","description":"Lymphoma","metadata":null},{"id":"bdc8b0e66d534644884b3d2096d7b2c5","type":"TRIAL","name":"Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome","canonical_id":"clinicaltrials.gov:NCT04652960","description":"Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8","metadata":null},{"id":"87c057ac9e4c4622bccae4bc46049484","type":"TRIAL","name":"Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT03892044","description":"Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Richter Syndrome; Small Lymphocytic Lymphoma; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"e5626e96382c482294b1b0952ffa0f58","type":"TRIAL","name":"Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT06810778","description":"T-cell-prolymphocytic Leukemia; Cutaneous T-Cell Lymphoma Refractory","metadata":null},{"id":"27cb4f5e978e4d0e8bdd7af54e2c5da8","type":"TRIAL","name":"Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS","canonical_id":"clinicaltrials.gov:NCT03534323","description":"Chronic Lymphocytic Leukemia; Richter Syndrome","metadata":null},{"id":"e818b119e8b44779be138fa061e68092","type":"TRIAL","name":"Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT04209621","description":"Small Lymphocytic Leukemia (SLL); Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"a8f35bbbd33745e3a5f6a1eeff8f3705","type":"TRIAL","name":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","canonical_id":"clinicaltrials.gov:NCT05065866","description":"Non Hodgkin Lymphoma; Hodgkin Lymphoma; Myeloma; Lymphocytic Leukemia","metadata":null},{"id":"81878e870c0643ee859a08511e3c88ef","type":"TRIAL","name":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","canonical_id":"clinicaltrials.gov:NCT04688658","description":"Unresectable Melanoma","metadata":null},{"id":"1ced0389f48f44c98ed2dc63d82a7c08","type":"TRIAL","name":"Duvelisib to Combat COVID-19","canonical_id":"clinicaltrials.gov:NCT04372602","description":"COVID-19","metadata":null},{"id":"6dc04e94547e4ba5837279a76308a33e","type":"GO_TERM","name":"Dxr protein complex","canonical_id":"go:GO:1990065","description":"\"A protein complex that is involved in the MEP pathway of IPP biosynthesis. It catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP).\" [GOC:bhm, PMID:15339150]","metadata":null},{"id":"b73c0dd0be1944c8a668595d967388ab","type":"TRIAL","name":"Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes","canonical_id":"clinicaltrials.gov:NCT05972902","description":"IVF","metadata":null},{"id":"756e4ddaed134045b4b0d3f3868b13af","type":"TRIAL","name":"Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI","canonical_id":"clinicaltrials.gov:NCT05751681","description":"Ovary Cyst; Fertility Issues","metadata":null},{"id":"aee17eed6c764b4bab4ac46cde8c2938","type":"TRIAL","name":"Dymista Allergen Chamber - Onset of Action Study","canonical_id":"clinicaltrials.gov:NCT04652245","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"837b130915074a19ad183fa125970e38","type":"TRIAL","name":"Dymista in Chinese Adolescents","canonical_id":"clinicaltrials.gov:NCT07597473","description":"Allergic Rhinitis Due to Allergens","metadata":null},{"id":"b390acbe8a9048b8aa2f02a6ce3b61ee","type":"TRIAL","name":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT01599832","description":"Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer","metadata":null},{"id":"081d528c4ec34c62a5acd07cf5983ef6","type":"TRIAL","name":"Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation","canonical_id":"clinicaltrials.gov:NCT03297385","description":"Prostate Cancer; DNA; Androgen Receptor Abnormal","metadata":null},{"id":"8e7d03235f8f4f9aa3a5a5503d722805","type":"DRUG","name":"Dyphylline","canonical_id":"mesh:D004400","description":null,"metadata":null},{"id":"6f2908a8aeef41ec88efa8070289f537","type":"DISEASE","name":"Dysentery","canonical_id":"mesh:D004403","description":null,"metadata":null},{"id":"47f86d59e6834362837f9a087b2a35f7","type":"TRIAL","name":"Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen","canonical_id":"clinicaltrials.gov:NCT01003249","description":"Overactive Bladder; Constipation; Lower Urinary Tract Symptoms","metadata":null},{"id":"f7ccfc383df44951ba1d2354194dcc8d","type":"DISEASE","name":"Dysfunctional uterine bleeding","canonical_id":"mesh:D008796","description":null,"metadata":null},{"id":"7c3c3eae297c488a9423132bc432a5f9","type":"TRIAL","name":"Dyslipidemia Study Investigating The Increase In \"Good Cholesterol\"","canonical_id":"clinicaltrials.gov:NCT00169559","description":"Dyslipidaemias","metadata":null},{"id":"18be91ddd480478fa51f438560994f35","type":"DISEASE","name":"Dysmenorrhea","canonical_id":"hp:0100607","description":null,"metadata":null},{"id":"d8d13e18b42e4749861358c6a4d87ff2","type":"DISEASE","name":"Dysmenorrhea","canonical_id":"mesh:D004412","description":null,"metadata":null},{"id":"e907a203d0584fe08ff3e51c41dfc95c","type":"DISEASE","name":"Dyspareunia","canonical_id":"hp:0030016","description":null,"metadata":null},{"id":"ba0a5f90f87b4cd1b8656ae4a83d566e","type":"DISEASE","name":"Dyspareunia","canonical_id":"mesh:D004414","description":null,"metadata":null},{"id":"fe87a79da9554e74a203b38d86786a6b","type":"DISEASE","name":"Dyspepsia","canonical_id":"mesh:D004415","description":null,"metadata":null},{"id":"00871bd61b904eeb953686e1c9440147","type":"DISEASE","name":"Dyspnea","canonical_id":"mesh:D004417","description":null,"metadata":null},{"id":"cb051c3ace7548d68378d8e5ab711753","type":"TRIAL","name":"Dysregulation of FSH in Obesity: Functional and Statistical Analysis","canonical_id":"clinicaltrials.gov:NCT02478775","description":"Obesity; Fertility","metadata":null},{"id":"fece58f183914b2dba124e21ef3a16d3","type":"PROTEIN","name":"Dystrophin","canonical_id":"uniprot:P11532","description":null,"metadata":null},{"id":"8c856bb98f7e43679fab5cb5a822cc4c","type":"TRIAL","name":"E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy","canonical_id":"clinicaltrials.gov:NCT02879006","description":"Food Allergy","metadata":null},{"id":"e2a538ad05df4565ad4e5540f9523fdd","type":"TRIAL","name":"E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02279394","description":"Smoldering Myeloma; Smoldering Multiple Myeloma","metadata":null},{"id":"84b9af3bd1264cf3a2c4d3dd429190b4","type":"GO_TERM","name":"E-box binding","canonical_id":"go:GO:0070888","description":"\"Binding to an E-box, a DNA motif with the consensus sequence CANNTG that is found in the promoters of a wide array of genes expressed in neurons, muscle and other tissues.\" [GOC:BHF, GOC:vk, PMID:11812799]","metadata":null},{"id":"980c9492407e407f82e836627d53a342","type":"GO_TERM","name":"E-series resolvin biosynthetic process","canonical_id":"go:GO:0106297","description":"\"The chemical reactions and pathways resulting in the formation of resolvin family E-series, hydroxy fatty acids derived from icosapentaenoic acid.\" [PMID:21206090]","metadata":null},{"id":"ebfb68d1a6a94700957ffa68c4be7403","type":"GO_TERM","name":"E.F.G complex","canonical_id":"go:GO:0034692","description":"\"A protein complex that comprises three core spliceosomal proteins, designated E, F, and G. Formation of the E.F.G complex is essential but not sufficient for the formation of a stable U1 snRNP complex.\" [PMID:8641291]","metadata":null},{"id":"c3541c38342b4d55af90a37e64be1d0e","type":"TRIAL","name":"E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy","canonical_id":"clinicaltrials.gov:NCT01986764","description":"Planned RRSO","metadata":null},{"id":"9f97371dffa44fa98255da5123fb4ff7","type":"GENE","name":"E2F1","canonical_id":"hgnc:HGNC:3113","description":null,"metadata":null},{"id":"ec5783b8131046b69639849dccdbf936","type":"GENE","name":"E2F2","canonical_id":"hgnc:HGNC:3114","description":null,"metadata":null},{"id":"e0dc43bad95744af8061bc4f13333bf5","type":"GENE","name":"E2F3","canonical_id":"hgnc:HGNC:3115","description":null,"metadata":null},{"id":"6ee494f8ef1e4b3ca45a86c8724331d4","type":"GENE","name":"E2F3-AS1","canonical_id":"hgnc:HGNC:59370","description":"E2F3 antisense RNA 1","metadata":null},{"id":"f9549dfc7e7c456e898dce7fb119e6a3","type":"GENE","name":"E2F3-IT1","canonical_id":"hgnc:HGNC:41329","description":"E2F3 intronic transcript 1","metadata":{"aliases":["RBAT1"]}},{"id":"5944c43aef074bacb7cb06be70724e41","type":"GENE","name":"E2F3P1","canonical_id":"hgnc:HGNC:3116","description":"E2F transcription factor 3 pseudogene 1","metadata":null},{"id":"94b00ce2c7bb49b4b070f7906fae73d8","type":"GENE","name":"E2F3P2","canonical_id":"hgnc:HGNC:3117","description":"E2F transcription factor 3 pseudogene 2","metadata":null},{"id":"740c5a1b64f84e60aa8e11a6886ef118","type":"GENE","name":"E2F4","canonical_id":"hgnc:HGNC:3118","description":null,"metadata":null},{"id":"805667dfd0f14c6fb8c7447ce13bbe36","type":"GENE","name":"E2F4P1","canonical_id":"hgnc:HGNC:38684","description":"E2F transcription factor 4 pseudogene 1","metadata":null},{"id":"e6527ec7ceae4223825eb0310d674527","type":"GENE","name":"E2F5","canonical_id":"hgnc:HGNC:3119","description":null,"metadata":null},{"id":"8ac175b57bab4baf9c3cadfc20dddd5a","type":"GENE","name":"E2F5-DT","canonical_id":"hgnc:HGNC:55393","description":"E2F5 divergent transcript","metadata":null},{"id":"7da72c77b2c8433fb0a1bec2e5119e4b","type":"GENE","name":"E2F6","canonical_id":"hgnc:HGNC:3120","description":null,"metadata":null},{"id":"eb37dc29540048818db6705662e755d8","type":"GENE","name":"E2F6P1","canonical_id":"hgnc:HGNC:51449","description":"E2F transcription factor 6 pseudogene 1","metadata":null},{"id":"408f837727654f829c8b476b141669f1","type":"GENE","name":"E2F6P2","canonical_id":"hgnc:HGNC:51450","description":"E2F transcription factor 6 pseudogene 2","metadata":null},{"id":"c59ab827b922462681d42dba218d180f","type":"GENE","name":"E2F6P3","canonical_id":"hgnc:HGNC:51451","description":"E2F transcription factor 6 pseudogene 3","metadata":null},{"id":"567f871f65a44785a79ae50ebee0f9d0","type":"GENE","name":"E2F6P4","canonical_id":"hgnc:HGNC:51452","description":"E2F transcription factor 6 pseudogene 4","metadata":null},{"id":"0fac395ca6974884a310a68fcce0e6ab","type":"GENE","name":"E2F7","canonical_id":"hgnc:HGNC:23820","description":null,"metadata":null},{"id":"f67b04cd753e46399cad26374340bdc3","type":"GENE","name":"E2F8","canonical_id":"hgnc:HGNC:24727","description":null,"metadata":null},{"id":"54df50995d4f461792cefa080933d441","type":"TRIAL","name":"E3-Hormone Refractory Prostrate Cancer Taxotere Combination","canonical_id":"clinicaltrials.gov:NCT00498797","description":"Prostate Cancer; Metastatic; Hormone Refractory","metadata":null},{"id":"cc0169f009ae47efb29e35890763be4c","type":"GENE","name":"E4F1","canonical_id":"hgnc:HGNC:3121","description":null,"metadata":null},{"id":"b6d5e7cdc6634fe7b67904dd7d56679b","type":"TRIAL","name":"E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)","canonical_id":"clinicaltrials.gov:NCT03332589","description":"Malignant Melanoma; Brain Metastases","metadata":null},{"id":"f6f5a6bb093545cdbe61552caa71a5c1","type":"TRIAL","name":"E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT05388877","description":"Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Melanoma","metadata":null},{"id":"b6130371956746b18c5e05986fa31d14","type":"TRIAL","name":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","canonical_id":"clinicaltrials.gov:NCT02858310","description":"Papillomavirus Infections; Cervical Intraepithelial Neoplasia; Carcinoma In Situ; Vulvar Neoplasms; Vulvar Diseases","metadata":null},{"id":"06adeeceb33f4b65b09d152c5a2ac419","type":"TRIAL","name":"E7389 in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00047034","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"553ca5e932984697b94bf50008946625","type":"TRIAL","name":"EAA/Therapy for Treating Children With ADHD","canonical_id":"clinicaltrials.gov:NCT02482649","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"7956ee2d8af1411d80a4b88abc87055d","type":"GENE","name":"EAF1","canonical_id":"hgnc:HGNC:20907","description":null,"metadata":null},{"id":"689e097b357042efbaa3253f6b2e16ac","type":"GENE","name":"EAF1-AS1","canonical_id":"hgnc:HGNC:42328","description":"EAF1 antisense RNA 1","metadata":null},{"id":"24762abbc70145d79f52944bbe28959f","type":"GENE","name":"EAF2","canonical_id":"hgnc:HGNC:23115","description":null,"metadata":null},{"id":"c7fb79ccd0044aecaf5a2aa3e46c0fef","type":"GENE","name":"EAPP","canonical_id":"hgnc:HGNC:19312","description":null,"metadata":null},{"id":"68b1e3e93c2345a2b4fc6445a8d52f0a","type":"TRIAL","name":"EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA","canonical_id":"clinicaltrials.gov:NCT00562588","description":"Cerebrovascular Accident","metadata":null},{"id":"411c61280aec4785a088df66f0f3eae3","type":"TRIAL","name":"EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00089895","description":"Myocardial Ischemia; Acute Coronary Syndrome","metadata":null},{"id":"77628efa6ac94bf3a6bbdfa722141ee4","type":"GO_TERM","name":"EARP complex","canonical_id":"go:GO:1990745","description":"\"A quatrefoil tethering complex required for endocytic recycling.\" [PMID:25799061]","metadata":null},{"id":"ce8e131eab7a4e8c9a9417ad7d99ff8f","type":"GENE","name":"EARS2","canonical_id":"hgnc:HGNC:29419","description":"glutamyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["KIAA1970","MSE1","mtGlnRS"]}},{"id":"b996eb11c5a84e52a59c74642f781dfb","type":"TRIAL","name":"EASE (Efficacy of ATX01 Study in Erythromelalgia)","canonical_id":"clinicaltrials.gov:NCT05917912","description":"Erythromelalgia","metadata":null},{"id":"f49dce22cc4f40df8937a3f412b55ef7","type":"TRIAL","name":"EASSI - Evaluation of the Safety of Self-Administration With Icatibant","canonical_id":"clinicaltrials.gov:NCT00997204","description":"Hereditary Angioedema","metadata":null},{"id":"5a9772fda9c64a0cb323d33be54ea7a9","type":"TRIAL","name":"EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding","canonical_id":"clinicaltrials.gov:NCT01084993","description":"Coronary Artery Disease","metadata":null},{"id":"400f01ceaffc432da9523dfb50ccf67b","type":"GENE","name":"EBAG9","canonical_id":"hgnc:HGNC:3123","description":"estrogen receptor binding site associated antigen 9","metadata":{"aliases":["EB9","RCAS1","PDAF"]}},{"id":"8589bd7095084f4c87408e9197344db1","type":"GENE","name":"EBAG9P1","canonical_id":"hgnc:HGNC:45233","description":"EBAG9 pseudogene 1","metadata":null},{"id":"b9d2652b9c804b41a3964d4ce5288b89","type":"GENE","name":"EBF1","canonical_id":"hgnc:HGNC:3126","description":null,"metadata":null},{"id":"47f12a618f5d491b8b9a1a764dadc734","type":"GENE","name":"EBF1-AS1","canonical_id":"hgnc:HGNC:40201","description":"EBF1 antisense RNA 1","metadata":null},{"id":"84165f72364240428656b8af44521090","type":"GENE","name":"EBF2","canonical_id":"hgnc:HGNC:19090","description":"EBF transcription factor 2","metadata":{"aliases":["FLJ11500","COE2"]}},{"id":"fcad28b3ce6b40a78e1a94a8f5cc304c","type":"GENE","name":"EBF3","canonical_id":"hgnc:HGNC:19087","description":null,"metadata":null},{"id":"bb30a3fd0ba14e4d8824f78bed25e68a","type":"GENE","name":"EBF3-AS1","canonical_id":"hgnc:HGNC:56218","description":"EBF3 antisense RNA 1","metadata":null},{"id":"1b181c52fed14e6d83aff0de41446b5c","type":"GENE","name":"EBF4","canonical_id":"hgnc:HGNC:29278","description":"EBF transcription factor 4","metadata":{"aliases":["KIAA1442","COE4","RP5-860F19.3","O/E-4"]}},{"id":"1eb72422470f4c28abdb6931ac213df2","type":"GENE","name":"EBI3","canonical_id":"hgnc:HGNC:3129","description":null,"metadata":null},{"id":"f6f177d8f005437d80e17e17e4494255","type":"TRIAL","name":"EBIO - Enthesitis Biopsy Study","canonical_id":"clinicaltrials.gov:NCT04887597","description":"Psoriatic Arthritis; Enthesitis; Biopsy","metadata":null},{"id":"485db612b5564517a54075784be4dcf3","type":"GENE","name":"EBLN1","canonical_id":"hgnc:HGNC:39430","description":"endogenous Bornavirus like nucleoprotein 1","metadata":null},{"id":"7a5dd2e3746345e793f3358718cc673b","type":"GENE","name":"EBLN2","canonical_id":"hgnc:HGNC:25493","description":"endogenous Bornavirus like nucleoprotein 2","metadata":null},{"id":"ab5f169a93604211a002479a205cc6e3","type":"GENE","name":"EBLN3P","canonical_id":"hgnc:HGNC:50682","description":"endogenous Bornavirus like nucleoprotein 3, pseudogene","metadata":{"aliases":["LOC100506710","EBLN3"]}},{"id":"6c4aa828793d4ccca07bda2567d6d4b9","type":"TRIAL","name":"EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network","canonical_id":"clinicaltrials.gov:NCT01748123","description":"Hypertension","metadata":null},{"id":"1517cf23b76d44e48385df7a323135b7","type":"GENE","name":"EBNA1BP2","canonical_id":"hgnc:HGNC:15531","description":null,"metadata":null},{"id":"ee207f6bf0e54169b8d5eb05b4d319ee","type":"GENE","name":"EBP","canonical_id":"hgnc:HGNC:3133","description":"EBP cholestenol delta-isomerase","metadata":{"aliases":["D8D7I","CPX","CPXD","CHO2","CDPX2"]}},{"id":"aa8745c683c34c68a90928065b2fe380","type":"GENE","name":"EBPL","canonical_id":"hgnc:HGNC:18061","description":"EBP like","metadata":{"aliases":["EBRP"]}},{"id":"ffbd1a4c44834743bb250da8868b5ffe","type":"GENE","name":"EBVM1","canonical_id":"hgnc:HGNC:3142","description":"Epstein Barr virus modification site 1","metadata":null},{"id":"52b78dd5fce8494fa9ebe6e50406e201","type":"GENE","name":"EBVS1","canonical_id":"hgnc:HGNC:3143","description":"Epstein Barr virus integration site 1","metadata":null},{"id":"a8f3b03acbc248afab95c6459dcf312d","type":"TRIAL","name":"EC905 Pharmacokinetic Profile Study","canonical_id":"clinicaltrials.gov:NCT02634489","description":"Phase 1; Healthy; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms","metadata":null},{"id":"e7f673a85c794243a36f83e4c1deab62","type":"GENE","name":"ECD","canonical_id":"hgnc:HGNC:17029","description":null,"metadata":null},{"id":"3d323975008345279c68a3f6335478a4","type":"GENE","name":"ECE1","canonical_id":"hgnc:HGNC:3146","description":null,"metadata":null},{"id":"687d374e1cc742709732320462f23e1b","type":"GENE","name":"ECE1-AS1","canonical_id":"hgnc:HGNC:40203","description":"ECE1 antisense RNA 1","metadata":null},{"id":"ab10ba6502c54b40bfa0e6a4c054b8b3","type":"GENE","name":"ECE2","canonical_id":"hgnc:HGNC:13275","description":"endothelin converting enzyme 2","metadata":{"aliases":["KIAA0604","MGC2408"]}},{"id":"d3bdfc019bba473594bc70fb9be35e0a","type":"GENE","name":"ECEL1","canonical_id":"hgnc:HGNC:3147","description":"endothelin converting enzyme like 1","metadata":{"aliases":["XCE","DINE"]}},{"id":"5a5a8b4ef402410f9d2fda49b8944719","type":"GENE","name":"ECEL1P1","canonical_id":"hgnc:HGNC:14017","description":"endothelin converting enzyme like 1 pseudogene 1","metadata":null},{"id":"5b410f0797ba440694b3e5b3268d88c8","type":"GENE","name":"ECEL1P2","canonical_id":"hgnc:HGNC:14019","description":"endothelin converting enzyme like 1 pseudogene 2","metadata":{"aliases":["ECEL2"]}},{"id":"683f3b24ab2c4c96959e3920339a413d","type":"GENE","name":"ECEL1P3","canonical_id":"hgnc:HGNC:14018","description":"endothelin converting enzyme like 1 pseudogene 3","metadata":null},{"id":"6df973eb20334ec3882f970f29e646f4","type":"TRIAL","name":"ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization","canonical_id":"clinicaltrials.gov:NCT03370536","description":"Atrial Fibrillation; Persistent Atrial Fibrillation","metadata":null},{"id":"9311ef2c1d43467eaa96ab3c45b09d12","type":"GENE","name":"ECH1","canonical_id":"hgnc:HGNC:3149","description":"enoyl-CoA hydratase 1","metadata":{"aliases":["HPXEL"]}},{"id":"dd5828e9447140e59ff281c975223bb2","type":"GENE","name":"ECHDC1","canonical_id":"hgnc:HGNC:21489","description":"ethylmalonyl-CoA decarboxylase 1","metadata":{"aliases":["dJ351K20.2"]}},{"id":"d3fc6d2cd06349fc87758123e5d83b45","type":"GENE","name":"ECHDC2","canonical_id":"hgnc:HGNC:23408","description":"enoyl-CoA hydratase domain containing 2","metadata":{"aliases":["FLJ10948"]}},{"id":"15e95879fea945658544c87af1a59fdb","type":"GENE","name":"ECHDC3","canonical_id":"hgnc:HGNC:23489","description":"enoyl-CoA hydratase domain containing 3","metadata":{"aliases":["FLJ20909"]}},{"id":"f3c48271dd1b42be9d7cc5771103699a","type":"GENE","name":"ECHS1","canonical_id":"hgnc:HGNC:3151","description":"enoyl-CoA hydratase, short chain 1","metadata":{"aliases":["SCEH"]}},{"id":"106fb7397ddd471386cfc9e38207c1df","type":"GENE","name":"ECI1","canonical_id":"hgnc:HGNC:2703","description":"enoyl-CoA delta isomerase 1","metadata":{"aliases":["DCI"]}},{"id":"c9a49871d7b04162b4d1e8d83c39ddbb","type":"GENE","name":"ECI1-AS1","canonical_id":"hgnc:HGNC:56088","description":"ECI1 antisense RNA 1","metadata":null},{"id":"19cf0bd7d1884f529bd15e521291d664","type":"GENE","name":"ECI2","canonical_id":"hgnc:HGNC:14601","description":"enoyl-CoA delta isomerase 2","metadata":{"aliases":["ACBD2","DRS1","HCA88","PECI"]}},{"id":"d3618e47f7384d3696a64a79e3f4c314","type":"GENE","name":"ECI2-DT","canonical_id":"hgnc:HGNC:54425","description":"ECI2 divergent transcript","metadata":null},{"id":"ef853b54e45f4310a8a4e02c1d93254a","type":"GENE","name":"ECM1","canonical_id":"hgnc:HGNC:3153","description":null,"metadata":null},{"id":"be8d9b6d2f944a938f18588bca8a6b99","type":"GENE","name":"ECM1P1","canonical_id":"hgnc:HGNC:49736","description":"extracellular matrix protein 1 pseudogene 1","metadata":null},{"id":"7733b61d0fde4c59bac3af64af899932","type":"GENE","name":"ECM1P2","canonical_id":"hgnc:HGNC:49737","description":"extracellular matrix protein 1 pseudogene 2","metadata":null},{"id":"04621483137d4675b70288a1c179e23f","type":"GENE","name":"ECM2","canonical_id":"hgnc:HGNC:3154","description":"extracellular matrix protein 2","metadata":null},{"id":"15d67521a0ae46229c7f69defdb63c8a","type":"GENE","name":"ECMXP","canonical_id":"hgnc:HGNC:55152","description":"extracellular matrix protein X-linked, pseudogene","metadata":null},{"id":"e365ee41c4ad40399c1a678e2b97508c","type":"GENE","name":"ECPAS","canonical_id":"hgnc:HGNC:29020","description":"Ecm29 proteasome adaptor and scaffold","metadata":{"aliases":["FLJ22036","ECM29","KIAA0368"]}},{"id":"90672b4f231f4178aca07428b28133fa","type":"GENE","name":"ECRG4","canonical_id":"hgnc:HGNC:24642","description":"ECRG4 augurin precursor","metadata":{"aliases":["augurin","C2orf40"]}},{"id":"175204d2d70c4028b98805e140598429","type":"GENE","name":"ECSCR","canonical_id":"hgnc:HGNC:35454","description":"endothelial cell surface expressed chemotaxis and apoptosis regulator","metadata":{"aliases":["ECSM2","ARIA"]}},{"id":"388017a778b44ffbb8612d718c1a552b","type":"GENE","name":"ECSIT","canonical_id":"hgnc:HGNC:29548","description":"ECSIT signaling integrator","metadata":{"aliases":["SITPEC"]}},{"id":"2addbb2479684680b05400813419be04","type":"GENE","name":"ECT2","canonical_id":"hgnc:HGNC:3155","description":null,"metadata":null},{"id":"0c3d8c8a3dc749dd94dd0ef903612159","type":"GENE","name":"ECT2L","canonical_id":"hgnc:HGNC:21118","description":"epithelial cell transforming 2 like","metadata":{"aliases":["ARHGEF32","FBXO49","LFDH","C6orf91"]}},{"id":"19fc3fffcfc14b35bf2f0df03996927d","type":"TRIAL","name":"ED Initiated Oral Naltrexone for AUD","canonical_id":"clinicaltrials.gov:NCT04817410","description":"Alcohol Use Disorder","metadata":null},{"id":"474cef822c974c3daf6583e16a4bcf75","type":"GENE","name":"EDA","canonical_id":"hgnc:HGNC:3157","description":null,"metadata":null},{"id":"faa93a4e83d74017afaa69bf3b3e1534","type":"GENE","name":"EDA2R","canonical_id":"hgnc:HGNC:17756","description":"ectodysplasin A2 receptor","metadata":{"aliases":["XEDAR","EDA-A2R","EDAA2R","TNFRSF27"]}},{"id":"cdd2d30df2f742a59cdfd8d1e3911b26","type":"GENE","name":"EDAR","canonical_id":"hgnc:HGNC:2895","description":"ectodysplasin A receptor","metadata":{"aliases":["ED5","EDA3","ED1R","EDA1R","ED3","DL"]}},{"id":"a7c5343211a34a44894e8e17a1a57774","type":"GENE","name":"EDARADD","canonical_id":"hgnc:HGNC:14341","description":"EDAR associated via death domain","metadata":{"aliases":["CR"]}},{"id":"560b9fbb4b4f426393270575ecfdb948","type":"GENE","name":"EDC3","canonical_id":"hgnc:HGNC:26114","description":"enhancer of mRNA decapping 3","metadata":{"aliases":["FLJ21128","hYjeF_N2-15q23","YJEFN2","LSM16","YJDC"]}},{"id":"9c2e04a962a545ce88903f29f906bf47","type":"GENE","name":"EDC4","canonical_id":"hgnc:HGNC:17157","description":"enhancer of mRNA decapping 4","metadata":{"aliases":["RCD-8","Ge-1","HEDLS"]}},{"id":"d6333b8948224cd8a0f4cbfa4258c5ff","type":"GENE","name":"EDDM13","canonical_id":"hgnc:HGNC:53168","description":"epididymal protein 13","metadata":null},{"id":"2e5f881e14fa4574a0c2405947767b2b","type":"GENE","name":"EDDM3A","canonical_id":"hgnc:HGNC:16978","description":"epididymal protein 3A","metadata":{"aliases":["HE3-ALPHA","FAM12A"]}},{"id":"7ef375de3430492c888a666dfb354b6c","type":"GENE","name":"EDDM3B","canonical_id":"hgnc:HGNC:19223","description":"epididymal protein 3B","metadata":{"aliases":["HE3-BETA","FAM12B"]}},{"id":"c25f3c3c34014d92bf903d4cad78ac80","type":"GENE","name":"EDDM3CP","canonical_id":"hgnc:HGNC:19224","description":"epididymal protein 3C, pseudogene","metadata":{"aliases":["HE3-GAMMA","FAM12CP"]}},{"id":"e600729cf1af445382d5d41af5b88107","type":"GENE","name":"EDDM3DP","canonical_id":"hgnc:HGNC:37707","description":"epididymal protein 3D, pseudogene","metadata":null},{"id":"871aaa83c37d491eb22a7a1c1f9804d6","type":"GENE","name":"EDEM1","canonical_id":"hgnc:HGNC:18967","description":"ER degradation enhancing alpha-mannosidase like protein 1","metadata":{"aliases":["KIAA0212","EDEM"]}},{"id":"1d3babce464f47dc91cd3e2811db33a5","type":"GENE","name":"EDEM2","canonical_id":"hgnc:HGNC:15877","description":null,"metadata":null},{"id":"b8711852a7fc41c0b6af20da42dc4cc8","type":"GENE","name":"EDEM3","canonical_id":"hgnc:HGNC:16787","description":"ER degradation enhancing alpha-mannosidase like protein 3","metadata":{"aliases":["C1orf22"]}},{"id":"5b0190d7d3ca42db86d8e8bb0e36eec0","type":"GENE","name":"EDF1","canonical_id":"hgnc:HGNC:3164","description":"endothelial differentiation related factor 1","metadata":{"aliases":["EDF-1","CFAP280"]}},{"id":"6cc99b8f9b0241bdb0b6621bd4eeb6e8","type":"GENE","name":"EDIL3","canonical_id":"hgnc:HGNC:3173","description":"EGF like and discoidin domains 3","metadata":{"aliases":["DEL1"]}},{"id":"ca7273b4e2f0487abce6586e5a5c230d","type":"GENE","name":"EDIL3-DT","canonical_id":"hgnc:HGNC:40204","description":"EDIL3 divergent transcript","metadata":null},{"id":"64710ef2fdb14fe087376c7ffa1f71f4","type":"GENE","name":"EDN1","canonical_id":"hgnc:HGNC:3176","description":null,"metadata":null},{"id":"39aed50de81142c9b4eca0cc41e330de","type":"GENE","name":"EDN1-AS1","canonical_id":"hgnc:HGNC:59347","description":"EDN1 antisense RNA 1","metadata":null},{"id":"685a7eaf101047b5818ebb33e5314090","type":"GENE","name":"EDN2","canonical_id":"hgnc:HGNC:3177","description":"endothelin 2","metadata":{"aliases":["ET2"]}},{"id":"221501087b7f480cabee526b649a419f","type":"GENE","name":"EDN3","canonical_id":"hgnc:HGNC:3178","description":"endothelin 3","metadata":{"aliases":["ET3"]}},{"id":"7f63ae768cfd4e48bca3bd495857513b","type":"GENE","name":"EDNRA","canonical_id":"hgnc:HGNC:3179","description":"endothelin receptor type A","metadata":{"aliases":["ET-A","ETA-R","hET-AR"]}},{"id":"6d7cf337493b44cfb1ede07b1c452f49","type":"PROTEIN","name":"EDNRA","canonical_id":"uniprot:P25101","description":null,"metadata":null},{"id":"9950216c37914497a4416bd3520787a4","type":"GENE","name":"EDNRB","canonical_id":"hgnc:HGNC:3180","description":null,"metadata":null},{"id":"d4d9003bf3ac4d16ab7c47c622559390","type":"PROTEIN","name":"EDNRB","canonical_id":"uniprot:P24530","description":null,"metadata":null},{"id":"7ae3b4271f3947298799688b5c66287f","type":"GENE","name":"EDNRB-AS1","canonical_id":"hgnc:HGNC:49045","description":"EDNRB antisense RNA 1","metadata":null},{"id":"c777a08b57104e1d9f09cd8aa0431b34","type":"TRIAL","name":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","canonical_id":"clinicaltrials.gov:NCT02858804","description":"Mantle Cell Lymphoma","metadata":null},{"id":"d523ef5f4eea4ab8b1cd977cb1014f5f","type":"GENE","name":"EDRF1","canonical_id":"hgnc:HGNC:24640","description":"erythroid differentiation regulatory factor 1","metadata":{"aliases":["DKFZp586F1019","FLJ21617","C10orf137"]}},{"id":"be3f92b4f47c497a8c0bc03310689417","type":"GENE","name":"EDRF1-AS1","canonical_id":"hgnc:HGNC:49501","description":"EDRF1 antisense RNA 1","metadata":null},{"id":"ba28493b2d9d42238e065d506e040115","type":"GENE","name":"EDRF1-DT","canonical_id":"hgnc:HGNC:54128","description":"EDRF1 divergent transcript","metadata":null},{"id":"891de34538b741b1ab5cc1118002d47c","type":"GO_TERM","name":"EDS1 disease-resistance complex","canonical_id":"go:GO:0106093","description":"\"A plant complex involved in basal disease resistance and resistance (R) gene-mediated effector triggered immunity (ETI). Regulates accumulation of the hormone salicylic acid (SA) which is a necessary component of systemic immunity. Involved in responds to bacteria, viruses and oomycetes.\" [GOC:bhm, PMID:11574472, PMID:16040633]","metadata":null},{"id":"df69f19055394f70b4bf47013c18a165","type":"GENE","name":"EEA1","canonical_id":"hgnc:HGNC:3185","description":"early endosome antigen 1","metadata":{"aliases":["ZFYVE2"]}},{"id":"3a64faefe7c94512b87a01c13c1caa24","type":"GENE","name":"EED","canonical_id":"hgnc:HGNC:3188","description":null,"metadata":null},{"id":"9b0c18c9da59464b9ca58e75d86bcd59","type":"GENE","name":"EEDP1","canonical_id":"hgnc:HGNC:55143","description":"EED pseudogene 1","metadata":null},{"id":"2321815afbb84a4ea23e0a441aed9036","type":"GENE","name":"EEF1A1","canonical_id":"hgnc:HGNC:3189","description":"eukaryotic translation elongation factor 1 alpha 1","metadata":{"aliases":["EE1A1","EF1A1","EF1alpha1","EF1A","EEF1A","LENG7"]}},{"id":"bab9ae4437e442f796eada87f67b6dfe","type":"GENE","name":"EEF1A1-AS1","canonical_id":"hgnc:HGNC:40206","description":"EEF1A1 antisense RNA 1","metadata":null},{"id":"89a59d103db740798b9f7367285fb868","type":"GENE","name":"EEF1A1P1","canonical_id":"hgnc:HGNC:3191","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 1","metadata":{"aliases":["EEF1A1P"]}},{"id":"8521033aadc349ee99fa9630595b5283","type":"GENE","name":"EEF1A1P10","canonical_id":"hgnc:HGNC:3205","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 10","metadata":{"aliases":["EEF1AL8"]}},{"id":"2051ee3ee87749b099e878e19d8a86dd","type":"GENE","name":"EEF1A1P11","canonical_id":"hgnc:HGNC:3206","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 11","metadata":{"aliases":["EEF1AL9"]}},{"id":"23362c712f58437ea4f47883c913ce39","type":"GENE","name":"EEF1A1P12","canonical_id":"hgnc:HGNC:3195","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 12","metadata":{"aliases":["EEF1AL10"]}},{"id":"b935053f8955465ca7c0e2dab8b6f95d","type":"GENE","name":"EEF1A1P13","canonical_id":"hgnc:HGNC:3196","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 13","metadata":{"aliases":["EEF1AL11"]}},{"id":"90bf1e9150dc4fa08f1c322c98bfb016","type":"GENE","name":"EEF1A1P14","canonical_id":"hgnc:HGNC:3197","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 14","metadata":{"aliases":["EEF1AL12"]}},{"id":"d9bb5e4126ac4e1f8c8cd0f90de48300","type":"GENE","name":"EEF1A1P15","canonical_id":"hgnc:HGNC:3198","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 15","metadata":{"aliases":["EEF1AL13"]}},{"id":"c3c7f0dccd2242f596e6e2c0d554ed0c","type":"GENE","name":"EEF1A1P16","canonical_id":"hgnc:HGNC:37889","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 16","metadata":null},{"id":"056aa7ef09634e26b8f118cb3b174b00","type":"GENE","name":"EEF1A1P17","canonical_id":"hgnc:HGNC:37890","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 17","metadata":null},{"id":"1fc2636819254e77b49c4f9cbfacdfb9","type":"GENE","name":"EEF1A1P18","canonical_id":"hgnc:HGNC:37891","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 18","metadata":null},{"id":"56650c9d893f4715b02b3dcf952a273b","type":"GENE","name":"EEF1A1P19","canonical_id":"hgnc:HGNC:37892","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 19","metadata":null},{"id":"a1d68ad912264733b94618105be53ccd","type":"GENE","name":"EEF1A1P2","canonical_id":"hgnc:HGNC:20008","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 2","metadata":null},{"id":"b87750f62529468b8a47cff85208a350","type":"GENE","name":"EEF1A1P20","canonical_id":"hgnc:HGNC:37893","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 20","metadata":null},{"id":"7321154c5b4745eab64ac9a5e154d572","type":"GENE","name":"EEF1A1P21","canonical_id":"hgnc:HGNC:37894","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 21","metadata":null},{"id":"bbcae06c7f1544998ee8b0272d6abc8c","type":"GENE","name":"EEF1A1P22","canonical_id":"hgnc:HGNC:37895","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 22","metadata":null},{"id":"c1afb436633d4677a0d404b4534df3ff","type":"GENE","name":"EEF1A1P23","canonical_id":"hgnc:HGNC:37896","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 23","metadata":null},{"id":"c1173eb54de14da28ac619876fc632be","type":"GENE","name":"EEF1A1P24","canonical_id":"hgnc:HGNC:37897","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 24","metadata":null},{"id":"a46c57d294e646c38e872a244e500ebe","type":"GENE","name":"EEF1A1P25","canonical_id":"hgnc:HGNC:37898","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 25","metadata":null},{"id":"be091e21a8c141e18fe00dc6a44a8212","type":"GENE","name":"EEF1A1P26","canonical_id":"hgnc:HGNC:37899","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 26","metadata":null},{"id":"82d551a753624f44bc66cd356e9ed243","type":"GENE","name":"EEF1A1P27","canonical_id":"hgnc:HGNC:37900","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 27","metadata":null},{"id":"627e011abfba46ac93390c2314d78c06","type":"GENE","name":"EEF1A1P28","canonical_id":"hgnc:HGNC:37902","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 28","metadata":null},{"id":"d74af9c5382843849590387868287323","type":"GENE","name":"EEF1A1P29","canonical_id":"hgnc:HGNC:37904","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 29","metadata":null},{"id":"df6aae5683dc468f9b9fa81ec03674d2","type":"GENE","name":"EEF1A1P3","canonical_id":"hgnc:HGNC:3194","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 3","metadata":{"aliases":["EEF1AL","EEF1AL1"]}},{"id":"50cfd27902164882976d706b4714b8d8","type":"GENE","name":"EEF1A1P30","canonical_id":"hgnc:HGNC:37906","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 30","metadata":null},{"id":"4da8d419da56441483f9d7b0954ec026","type":"GENE","name":"EEF1A1P31","canonical_id":"hgnc:HGNC:37908","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 31","metadata":null},{"id":"d0bfbae12e8446eca9021b5385e0c6d5","type":"GENE","name":"EEF1A1P32","canonical_id":"hgnc:HGNC:37909","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 32","metadata":null},{"id":"345971774bef40628ecf99f02e9305aa","type":"GENE","name":"EEF1A1P33","canonical_id":"hgnc:HGNC:37911","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 33","metadata":null},{"id":"e584dba9c42144a9a45e13121dfb510e","type":"GENE","name":"EEF1A1P34","canonical_id":"hgnc:HGNC:37912","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 34","metadata":null},{"id":"a657b0b60c094da4a3c485e7e1294f38","type":"GENE","name":"EEF1A1P35","canonical_id":"hgnc:HGNC:37913","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 35","metadata":null},{"id":"33116c6113894351ab388389885984ef","type":"GENE","name":"EEF1A1P36","canonical_id":"hgnc:HGNC:37914","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 36","metadata":null},{"id":"e812aafa8e644f3cbb03c2733663d2f8","type":"GENE","name":"EEF1A1P37","canonical_id":"hgnc:HGNC:37915","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 37","metadata":null},{"id":"8f453fda36e643babb3a6e5b8f2f209a","type":"GENE","name":"EEF1A1P38","canonical_id":"hgnc:HGNC:37916","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 38","metadata":null},{"id":"f58ae2cebfbb42e9be4ef64a213f0bbb","type":"GENE","name":"EEF1A1P39","canonical_id":"hgnc:HGNC:37917","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 39","metadata":null},{"id":"a35e339e327340c0b154c29624c313df","type":"GENE","name":"EEF1A1P4","canonical_id":"hgnc:HGNC:3199","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 4","metadata":{"aliases":["EEF1AL2"]}},{"id":"9f6bc0f1f9324cb397259ce35233f8e5","type":"GENE","name":"EEF1A1P40","canonical_id":"hgnc:HGNC:37918","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 40","metadata":null},{"id":"2a4b43eea3764a2a8f9a2d3903500b09","type":"GENE","name":"EEF1A1P41","canonical_id":"hgnc:HGNC:38799","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 41","metadata":null},{"id":"2443ac56dd0245ae9d7ef93e160735e1","type":"GENE","name":"EEF1A1P42","canonical_id":"hgnc:HGNC:48927","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 42","metadata":null},{"id":"3ee4f5a36b3d40e1ba684c99c1cd0d17","type":"GENE","name":"EEF1A1P43","canonical_id":"hgnc:HGNC:3193","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 43","metadata":{"aliases":["EEF1A3"]}},{"id":"8863b856633948b6aa3eec2558006670","type":"GENE","name":"EEF1A1P44","canonical_id":"hgnc:HGNC:56201","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 44","metadata":null},{"id":"830ee7a3541f41409ec3b3ad2dc77669","type":"GENE","name":"EEF1A1P45","canonical_id":"hgnc:HGNC:56202","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 45","metadata":null},{"id":"c8fb811e52d64606a5e75b4bb3cdf718","type":"GENE","name":"EEF1A1P46","canonical_id":"hgnc:HGNC:56203","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 46","metadata":null},{"id":"d9663ac91baf45428b620b523a23e106","type":"GENE","name":"EEF1A1P47","canonical_id":"hgnc:HGNC:56204","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 47","metadata":null},{"id":"12ed8e6059564f3cb821f5fc64f5829d","type":"GENE","name":"EEF1A1P48","canonical_id":"hgnc:HGNC:56205","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 48","metadata":null},{"id":"003d967b3e46448ab125f8df6e8f481c","type":"GENE","name":"EEF1A1P49","canonical_id":"hgnc:HGNC:56206","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 49","metadata":null},{"id":"4886aa9f83bc40418198626df5919bfc","type":"GENE","name":"EEF1A1P5","canonical_id":"hgnc:HGNC:3200","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 5","metadata":{"aliases":["EEF1AL3"]}},{"id":"5ac6048f59dd45498f546529f32a2a20","type":"GENE","name":"EEF1A1P50","canonical_id":"hgnc:HGNC:56207","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 50","metadata":null},{"id":"71714046fd604994a658f58d85c57302","type":"GENE","name":"EEF1A1P6","canonical_id":"hgnc:HGNC:3201","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 6","metadata":{"aliases":["EEF1AL4"]}},{"id":"751af8b31d5546e5abaec63ad749fee4","type":"GENE","name":"EEF1A1P7","canonical_id":"hgnc:HGNC:3202","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 7","metadata":{"aliases":["EEF1AL5"]}},{"id":"d24c40d9c6a24e34b6e6f439095dd05b","type":"GENE","name":"EEF1A1P8","canonical_id":"hgnc:HGNC:3203","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 8","metadata":{"aliases":["EEF1AL6"]}},{"id":"ecf2645ce1c94223bc5165b0b8903417","type":"GENE","name":"EEF1A1P9","canonical_id":"hgnc:HGNC:3204","description":"eukaryotic translation elongation factor 1 alpha 1 pseudogene 9","metadata":{"aliases":["EEF1AL7"]}},{"id":"88894390858c4608af72621832ea68f5","type":"GENE","name":"EEF1A2","canonical_id":"hgnc:HGNC:3192","description":"eukaryotic translation elongation factor 1 alpha 2","metadata":{"aliases":["EEF1AL","HS1","STNL","STN"]}},{"id":"ff4dbc7e969245d4ab661f2eb103faac","type":"GENE","name":"EEF1AKMT1","canonical_id":"hgnc:HGNC:27351","description":"EEF1A lysine methyltransferase 1","metadata":{"aliases":["N6AMT2"]}},{"id":"05cbc6767cf9418cb3838ebc16c619d5","type":"GENE","name":"EEF1AKMT2","canonical_id":"hgnc:HGNC:33787","description":"EEF1A lysine methyltransferase 2","metadata":{"aliases":["Efm4","C10orf138","METTL10"]}},{"id":"e7377cd306c249398bc2f3844dee312c","type":"GENE","name":"EEF1AKMT3","canonical_id":"hgnc:HGNC:24936","description":"EEF1A lysine methyltransferase 3","metadata":{"aliases":["DKFZP586D0919","FAM119B","METTL21B"]}},{"id":"33447a602c6c44e88efe0d09e0797660","type":"GENE","name":"EEF1AKMT4","canonical_id":"hgnc:HGNC:53611","description":"EEF1A lysine methyltransferase 4","metadata":null},{"id":"7e0bdb828529417a99a477ff7f1e3d5a","type":"GENE","name":"EEF1AKMT4-ECE2","canonical_id":"hgnc:HGNC:53615","description":"EEF1AKMT4-ECE2 readthrough","metadata":null},{"id":"abfbde1109584944ad70554e994dc060","type":"GENE","name":"EEF1B2","canonical_id":"hgnc:HGNC:3208","description":"eukaryotic translation elongation factor 1 beta 2","metadata":null},{"id":"84a2c67ae08546ccaffbb0d980f8680c","type":"GENE","name":"EEF1B2P1","canonical_id":"hgnc:HGNC:3207","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 1","metadata":{"aliases":["EEF1B1"]}},{"id":"c432ef33d7de4f91ae594dd656a4295f","type":"GENE","name":"EEF1B2P2","canonical_id":"hgnc:HGNC:3209","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 2","metadata":{"aliases":["BETA-3","EEF-1BETA5A","EEF-1","EEF1B","EEF1B3"]}},{"id":"0042160ad5774e27a3076451c39a52ce","type":"GENE","name":"EEF1B2P3","canonical_id":"hgnc:HGNC:3210","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 3","metadata":{"aliases":["EEF1B4"]}},{"id":"bd30b2eebd1e43d7963d3940b580d0b2","type":"GENE","name":"EEF1B2P4","canonical_id":"hgnc:HGNC:32475","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 4","metadata":null},{"id":"4773709d863f40ab81c6bf00a13d5bf4","type":"GENE","name":"EEF1B2P5","canonical_id":"hgnc:HGNC:32476","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 5","metadata":null},{"id":"d132cc8c340a40f1930f55196d156ef7","type":"GENE","name":"EEF1B2P6","canonical_id":"hgnc:HGNC:51453","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 6","metadata":null},{"id":"b06031c2bb99413aa947da44e7baae10","type":"GENE","name":"EEF1B2P7","canonical_id":"hgnc:HGNC:51454","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 7","metadata":null},{"id":"81387d9e2c65433ca0400994acf55ad1","type":"GENE","name":"EEF1B2P8","canonical_id":"hgnc:HGNC:51455","description":"eukaryotic translation elongation factor 1 beta 2 pseudogene 8","metadata":null},{"id":"01fa47a84255453584b1beac61852ec9","type":"GENE","name":"EEF1D","canonical_id":"hgnc:HGNC:3211","description":"eukaryotic translation elongation factor 1 delta","metadata":{"aliases":["EF-1D","FLJ20897"]}},{"id":"14eb94864aec4624b180acff78e363b0","type":"GENE","name":"EEF1DP1","canonical_id":"hgnc:HGNC:32474","description":"eukaryotic translation elongation factor 1 delta pseudogene 1","metadata":null},{"id":"f6f31c99831d48d6a6635bc272c11f74","type":"GENE","name":"EEF1DP2","canonical_id":"hgnc:HGNC:33523","description":"eukaryotic translation elongation factor 1 delta pseudogene 2","metadata":null},{"id":"e69c1f66c6ce4030873a4b2a8c895dc4","type":"GENE","name":"EEF1DP3","canonical_id":"hgnc:HGNC:30486","description":"eukaryotic translation elongation factor 1 delta pseudogene 3","metadata":null},{"id":"1b740271835c4b97b340827a256a7e88","type":"GENE","name":"EEF1DP4","canonical_id":"hgnc:HGNC:22598","description":"eukaryotic translation elongation factor 1 delta pseudogene 4","metadata":{"aliases":["FLJ26697"]}},{"id":"d3c83a6e3fd24b5abc995e9b8a275c72","type":"GENE","name":"EEF1DP5","canonical_id":"hgnc:HGNC:33524","description":"eukaryotic translation elongation factor 1 delta pseudogene 5","metadata":null},{"id":"b9fec5e096a54a669aadd27ba35bd482","type":"GENE","name":"EEF1DP6","canonical_id":"hgnc:HGNC:51456","description":"eukaryotic translation elongation factor 1 delta pseudogene 6","metadata":null},{"id":"4ae57f1ce78d46fcbb9cd97985bb7bef","type":"GENE","name":"EEF1DP7","canonical_id":"hgnc:HGNC:51457","description":"eukaryotic translation elongation factor 1 delta pseudogene 7","metadata":null},{"id":"e03adf02e41b4a56a1cf6b816db5d094","type":"GENE","name":"EEF1DP8","canonical_id":"hgnc:HGNC:51458","description":"eukaryotic translation elongation factor 1 delta pseudogene 8","metadata":null},{"id":"8653f7973f814116ab29844499a72e76","type":"GENE","name":"EEF1E1","canonical_id":"hgnc:HGNC:3212","description":"eukaryotic translation elongation factor 1 epsilon 1","metadata":{"aliases":["AIMP3","P18"]}},{"id":"eb8c8650143245bea0121588fd367fbd","type":"GENE","name":"EEF1E1-BLOC1S5","canonical_id":"hgnc:HGNC:49187","description":"EEF1E1-BLOC1S5 readthrough (NMD candidate)","metadata":null},{"id":"a302916424a34bd59e61e4403eba4e63","type":"GENE","name":"EEF1E1P1","canonical_id":"hgnc:HGNC:51459","description":"eukaryotic translation elongation factor 1 epsilon 1 pseudogene 1","metadata":null},{"id":"1b29b490f5704ba8ab029c21cbad404b","type":"GENE","name":"EEF1G","canonical_id":"hgnc:HGNC:3213","description":"eukaryotic translation elongation factor 1 gamma","metadata":{"aliases":["EF1G"]}},{"id":"960bfec7402f4c718307bf63c32b1e8a","type":"GENE","name":"EEF1GP1","canonical_id":"hgnc:HGNC:44556","description":"eukaryotic translation elongation factor 1 gamma pseudogene 1","metadata":null},{"id":"86b7063e43d146e88650a3e2101deb35","type":"GENE","name":"EEF1GP2","canonical_id":"hgnc:HGNC:44557","description":"eukaryotic translation elongation factor 1 gamma pseudogene 2","metadata":null},{"id":"4ed09b6a61e9417cae86eb0fcfb1bb38","type":"GENE","name":"EEF1GP3","canonical_id":"hgnc:HGNC:44558","description":"eukaryotic translation elongation factor 1 gamma pseudogene 3","metadata":null},{"id":"0eaed7b8381747a0a7f0216c40cbfbbf","type":"GENE","name":"EEF1GP4","canonical_id":"hgnc:HGNC:44559","description":"eukaryotic translation elongation factor 1 gamma pseudogene 4","metadata":null},{"id":"1829312ff24b473ba7bc347f109d8c78","type":"GENE","name":"EEF1GP5","canonical_id":"hgnc:HGNC:44560","description":"eukaryotic translation elongation factor 1 gamma pseudogene 5","metadata":null},{"id":"ddaefc121118413598f473fb9b291a58","type":"GENE","name":"EEF1GP6","canonical_id":"hgnc:HGNC:44561","description":"eukaryotic translation elongation factor 1 gamma pseudogene 6","metadata":null},{"id":"409a362f12424c0aa4876ad5f0b5aa73","type":"GENE","name":"EEF1GP7","canonical_id":"hgnc:HGNC:44562","description":"eukaryotic translation elongation factor 1 gamma pseudogene 7","metadata":null},{"id":"d48a8fec4742480da2733af37ec103e8","type":"GENE","name":"EEF1GP8","canonical_id":"hgnc:HGNC:44563","description":"eukaryotic translation elongation factor 1 gamma pseudogene 8","metadata":null},{"id":"2b8b6ce29aec42b88b7fc1aae353cefb","type":"GENE","name":"EEF2","canonical_id":"hgnc:HGNC:3214","description":"eukaryotic translation elongation factor 2","metadata":{"aliases":["EEF-2","EF2"]}},{"id":"12e7dfc338bc4976878879cd263f0785","type":"PROTEIN","name":"EEF2","canonical_id":"uniprot:P13639","description":null,"metadata":null},{"id":"911590665ad84e3795743b54a1699670","type":"GENE","name":"EEF2K","canonical_id":"hgnc:HGNC:24615","description":"eukaryotic elongation factor 2 kinase","metadata":{"aliases":["eEF-2K","CaMKIII"]}},{"id":"f68e21c209f54f15bd4b10c19fa93bb8","type":"GENE","name":"EEF2KMT","canonical_id":"hgnc:HGNC:32221","description":"eukaryotic elongation factor 2 lysine methyltransferase","metadata":{"aliases":["SB153","MGC19636","EFM3","FAM86A"]}},{"id":"4e867043e3d048a3a221cb12a3dcaa5b","type":"GENE","name":"EEFSEC","canonical_id":"hgnc:HGNC:24614","description":"eukaryotic elongation factor, selenocysteine-tRNA specific","metadata":{"aliases":["SELB","EFSEC"]}},{"id":"ba38ad8162c547b1aac75667fd272631","type":"GENE","name":"EEIG1","canonical_id":"hgnc:HGNC:31419","description":"estrogen-induced osteoclastogenesis regulator 1","metadata":{"aliases":["Eeig1","bA203J24.7","SYM-3A","C9orf132","FAM102A"]}},{"id":"0c37fb5e667e48e0be541ff168a3c208","type":"GENE","name":"EEIG2","canonical_id":"hgnc:HGNC:27637","description":"EEIG family member 2","metadata":{"aliases":["DKFZp779B126","SYM-3B","FAM102B"]}},{"id":"b4cce99222ed4be8a23ce7697b74fca1","type":"GENE","name":"EEPD1","canonical_id":"hgnc:HGNC:22223","description":"endonuclease/exonuclease/phosphatase family domain containing 1","metadata":{"aliases":["KIAA1706"]}},{"id":"76a151ba076540e58fd1a9e4192f4457","type":"GENE","name":"EFCAB10","canonical_id":"hgnc:HGNC:34531","description":"EF-hand calcium binding domain 10","metadata":null},{"id":"542c3e2e6c594bbe9394f06fad6238e7","type":"GENE","name":"EFCAB10-AS1","canonical_id":"hgnc:HGNC:56350","description":"EFCAB10 antisense RNA 1","metadata":null},{"id":"d058eb9d17b541bc87d08997850f74e2","type":"GENE","name":"EFCAB11","canonical_id":"hgnc:HGNC:20357","description":"EF-hand calcium binding domain 11","metadata":{"aliases":["C14orf143"]}},{"id":"8d3b5d7d969849a5a14d877a4ff7c43e","type":"GENE","name":"EFCAB12","canonical_id":"hgnc:HGNC:28061","description":"EF-hand calcium binding domain 12","metadata":{"aliases":["C3orf25"]}},{"id":"af65b6d2e82541d4995dd5b8f9c8fd45","type":"GENE","name":"EFCAB13","canonical_id":"hgnc:HGNC:26864","description":"EF-hand calcium binding domain 13","metadata":{"aliases":["FLJ40342","C17orf57"]}},{"id":"3a4db106d41743c88062dd999dd2f524","type":"GENE","name":"EFCAB13-DT","canonical_id":"hgnc:HGNC:55338","description":"EFCAB13 divergent transcript","metadata":{"aliases":["THCAT158"]}},{"id":"cca95143454e4190b24c42b2677e36bb","type":"GENE","name":"EFCAB14","canonical_id":"hgnc:HGNC:29051","description":"EF-hand calcium binding domain 14","metadata":{"aliases":["KIAA0494"]}},{"id":"91203fd29bb9434da46c9a09edac3818","type":"GENE","name":"EFCAB14-AS1","canonical_id":"hgnc:HGNC:44108","description":"EFCAB14 antisense RNA 1","metadata":{"aliases":["KIAA0494-AS1"]}},{"id":"30797ca7c2da4ff99d87460a82230a31","type":"GENE","name":"EFCAB14P1","canonical_id":"hgnc:HGNC:44648","description":"EF-hand calcium binding domain 14 pseudogene 1","metadata":null},{"id":"17b2558691814600b09a5b9a8e4d260e","type":"GENE","name":"EFCAB15P","canonical_id":"hgnc:HGNC:55140","description":"EF-hand calcium binding domain 15, pseudogene","metadata":null},{"id":"147700ad06294ff98079083a82b5fffa","type":"GENE","name":"EFCAB2-AS1","canonical_id":"hgnc:HGNC:58101","description":"EFCAB2 antisense RNA 1","metadata":{"aliases":["RP11-156E8.1"]}},{"id":"167ae8cca342466bb7bd2b60877af650","type":"GENE","name":"EFCAB3","canonical_id":"hgnc:HGNC:26379","description":"EF-hand calcium binding domain 3","metadata":{"aliases":["FLJ25818"]}},{"id":"b48e9f12410b4626b986fc24d8e1db73","type":"GENE","name":"EFCAB3P1","canonical_id":"hgnc:HGNC:56232","description":"EFCAB3 pseudogene 1","metadata":null},{"id":"c07cecb1477a4c4fb89261a310412fc9","type":"GENE","name":"EFCAB5","canonical_id":"hgnc:HGNC:24801","description":"EF-hand calcium binding domain 5","metadata":{"aliases":["FLJ46247"]}},{"id":"6effeb7c92c6451ab53434559c75a721","type":"GENE","name":"EFCAB6","canonical_id":"hgnc:HGNC:24204","description":"EF-hand calcium binding domain 6","metadata":{"aliases":["FLJ23588","DJBP","HSCBCIP1","KIAA1672","dJ185D5.1"]}},{"id":"c56295fbc9434fee92019f65647f846f","type":"GENE","name":"EFCAB6-AS1","canonical_id":"hgnc:HGNC:39999","description":"EFCAB6 antisense RNA 1","metadata":{"aliases":["CITF22-123F2.1"]}},{"id":"8f78803e4eff428aaf2c93e90de0ae35","type":"GENE","name":"EFCAB6-DT","canonical_id":"hgnc:HGNC:55371","description":"EFCAB6 divergent transcript","metadata":null},{"id":"230f0c2f74c44042bab2ebc0d31c14bf","type":"GENE","name":"EFCAB7","canonical_id":"hgnc:HGNC:29379","description":"EF-hand calcium binding domain 7","metadata":{"aliases":["KIAA1799","RP4-534K7.1"]}},{"id":"10bf5b2532b245df8b5a90085f010657","type":"GENE","name":"EFCAB8","canonical_id":"hgnc:HGNC:34532","description":"EF-hand calcium binding domain 8","metadata":null},{"id":"64db6ae0235f42229f6ed32acf9bd235","type":"GENE","name":"EFCAB9","canonical_id":"hgnc:HGNC:34530","description":"EF-hand calcium binding domain 9","metadata":null},{"id":"78bf295d396b4358b8722d945b1cfa87","type":"GENE","name":"EFCC1","canonical_id":"hgnc:HGNC:25692","description":"EF-hand and coiled-coil domain containing 1","metadata":{"aliases":["FLJ12057","C3orf73","CCDC48"]}},{"id":"738d3905bf6344f5aaadd588211af7a4","type":"GENE","name":"EFEMP1","canonical_id":"hgnc:HGNC:3218","description":"EGF-like fibulin extracellular matrix protein 1","metadata":{"aliases":["S1-5","FBLN3","MTLV","DHRD","FBNL"]}},{"id":"3ea1b3c8f98a482da0a72ac9e9f048d7","type":"GENE","name":"EFEMP2","canonical_id":"hgnc:HGNC:3219","description":"EGF-like fibulin extracellular matrix protein 2","metadata":{"aliases":["FBLN4","UPH1"]}},{"id":"b569bad4f93a4868a53a5b79c1b96b59","type":"GO_TERM","name":"EFF-1 complex","canonical_id":"go:GO:1990392","description":"\"A trimeric cell-cell fusion complex that serves as a scaffold for zippering up the extracellular domains, bringing the transmembrane segments into close proximity such that they can continue zippering within the two membranes into one. Two prefusion monomers cluster at the surface of adjacent cells. Parallel EFF-1 interactions occur across cells and a third monomer, which can come from either cell, adds on to make an intermediate, extended trimer.\" [GOC:bhm, PMID:24725407]","metadata":null},{"id":"449dea19bdeb4546880994b0fc23aa1f","type":"TRIAL","name":"EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION","canonical_id":"clinicaltrials.gov:NCT03806062","description":"Insufficient Lactation","metadata":null},{"id":"05d3af1c64334777bd966935d2c679bc","type":"TRIAL","name":"EFFECT OF ZOLPIDEM ON SLEEP QUALITY AND OPIOID CONSUMPTION FOLLOWING PRIMARY TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL","canonical_id":"clinicaltrials.gov:NCT07801742","description":"Postoperative Pain Management in Total Knee Arthroplasty","metadata":null},{"id":"b029bc7db0bc4a788e8d761c810f97df","type":"TRIAL","name":"EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL","canonical_id":"clinicaltrials.gov:NCT06847204","description":"COVID - 19","metadata":null},{"id":"a2c0da2dfb1f445f9a34612dde636f96","type":"GENE","name":"EFHB","canonical_id":"hgnc:HGNC:26330","description":"EF-hand domain family member B","metadata":{"aliases":["FLJ25200","CFAP21"]}},{"id":"360fe79c6b1848c38fc75f3b53e92e1d","type":"GENE","name":"EFHC1","canonical_id":"hgnc:HGNC:16406","description":"EF-hand domain containing 1","metadata":{"aliases":["FLJ10466","RIB72","POC9","EJM1","EJM"]}},{"id":"0d5e0a51964e433585b5637bc592dcd8","type":"GENE","name":"EFHC2","canonical_id":"hgnc:HGNC:26233","description":"EF-hand domain containing 2","metadata":{"aliases":["FLJ22843","MRX74"]}},{"id":"1e74d02ae74847d29edecd66958d3fa5","type":"GENE","name":"EFHD1","canonical_id":"hgnc:HGNC:29556","description":"EF-hand domain family member D1","metadata":{"aliases":["FLJ13612"]}},{"id":"442be26ed4b649e085137eb3558b8043","type":"GENE","name":"EFHD2","canonical_id":"hgnc:HGNC:28670","description":"EF-hand domain family member D2","metadata":{"aliases":["MGC4342"]}},{"id":"d13e07d747be4caa949933764b530088","type":"GENE","name":"EFHD2-AS1","canonical_id":"hgnc:HGNC:55801","description":"EFHD2 antisense RNA 1","metadata":null},{"id":"52b23db7d78f4c5eaa9774a36ad07783","type":"GENE","name":"EFL1","canonical_id":"hgnc:HGNC:25789","description":"elongation factor like GTPase 1","metadata":{"aliases":["FLJ13119","FAM42A","HsT19294","RIA1","EFTUD1"]}},{"id":"d066a50d8a074840affde48090a682d5","type":"GENE","name":"EFL1P1","canonical_id":"hgnc:HGNC:31739","description":"elongation factor like GTPase 1 pseudogene 1","metadata":{"aliases":["HsT19321","FAM42B","EFTUD1P1"]}},{"id":"d99c36b98ce34895822e8d7d1a35d8e8","type":"GENE","name":"EFL1P2","canonical_id":"hgnc:HGNC:44202","description":"elongation factor like GTPase 1 pseudogene 2","metadata":{"aliases":["EFTUD1P2"]}},{"id":"2a19b7ac067a45e4b09f27ba5006e4e6","type":"GENE","name":"EFNA1","canonical_id":"hgnc:HGNC:3221","description":"ephrin A1","metadata":{"aliases":["LERK1","ECKLG","GMAN","TNFAIP4","EPLG1"]}},{"id":"e0775009fc374078a2289fa4793a3373","type":"GENE","name":"EFNA2","canonical_id":"hgnc:HGNC:3222","description":"ephrin A2","metadata":{"aliases":["ELF-1","LERK6","EPLG6"]}},{"id":"491849e42f11489ea50e4a169cfa89d7","type":"GENE","name":"EFNA3","canonical_id":"hgnc:HGNC:3223","description":"ephrin A3","metadata":{"aliases":["LERK3","Ehk1-L","EPLG3"]}},{"id":"f28f0dba4e9843c498335d3c0af6eded","type":"GENE","name":"EFNA4","canonical_id":"hgnc:HGNC:3224","description":"ephrin A4","metadata":{"aliases":["LERK4","EPLG4"]}},{"id":"97c5fddd18d04857b9d54dca47f8d34b","type":"GENE","name":"EFNA5","canonical_id":"hgnc:HGNC:3225","description":"ephrin A5","metadata":{"aliases":["AF1","LERK7","EPLG7"]}},{"id":"46a491a14396479da7341a09a15fae1d","type":"GENE","name":"EFNA5-AS1","canonical_id":"hgnc:HGNC:59105","description":"EFNA5 antisense RNA 1","metadata":null},{"id":"f33ddfe04ff2463f9a882658f9869e26","type":"GENE","name":"EFNB1","canonical_id":"hgnc:HGNC:3226","description":"ephrin B1","metadata":{"aliases":["LERK2","Elk-L","EPLG2","CFNS"]}},{"id":"fb77e463b97f41d7a7e1ba489cfbb0f0","type":"GENE","name":"EFNB2","canonical_id":"hgnc:HGNC:3227","description":"ephrin B2","metadata":{"aliases":["LERK5","Htk-L","HTKL","MGC126226","MGC126227","MGC126228","EPLG5"]}},{"id":"f0a998ee516743229e25bfcb7fc3fe3e","type":"GENE","name":"EFNB3","canonical_id":"hgnc:HGNC:3228","description":null,"metadata":null},{"id":"5ab1bf68afd346eb898d99c96e62c10b","type":"GENE","name":"EFR3A","canonical_id":"hgnc:HGNC:28970","description":"EFR3 homolog A","metadata":{"aliases":["KIAA0143"]}},{"id":"a9e48efa55114e308dc87fd203892a0a","type":"GENE","name":"EFR3B","canonical_id":"hgnc:HGNC:29155","description":"EFR3 homolog B","metadata":{"aliases":["FLJ37871","KIAA0953"]}},{"id":"0cca3211a8594c09aa1328a818ff5f81","type":"GENE","name":"EFS","canonical_id":"hgnc:HGNC:16898","description":"embryonal Fyn-associated substrate","metadata":{"aliases":["EFS2","EFS1","HEFS","SIN","CASS3"]}},{"id":"08192ca4efbf455b9c509faea7e41809","type":"GENE","name":"EFTUD2","canonical_id":"hgnc:HGNC:30858","description":"elongation factor Tu GTP binding domain containing 2","metadata":{"aliases":["U5-116KD","Snrp116","Snu114","SNRNP116"]}},{"id":"9e9fe8cae80348b4adc6c1417d5aeafa","type":"GO_TERM","name":"EGAD pathway","canonical_id":"go:GO:0140624","description":"\"The protein catabolic pathway which selectively extracts ER-resident membrane proteins exported to the Golgi and endosomes for degradation by cytosolic proteasomes. It begins with phosphorylation of the ER-resident membrane protein, which triggers export of the protein from the ER to the Golgi and endosomes, followed by polyubiquitination by the Dsc E3 ubiquitin ligase complex and extraction of the ubiquitinated target, and ends with proteasomal degradation.\" [PMID:31368600]","metadata":null},{"id":"52fbed28e7c94eb1bf20c36b770c115a","type":"GENE","name":"EGF","canonical_id":"hgnc:HGNC:3229","description":null,"metadata":null},{"id":"c07b65356c66408e9ec6a37ae5f538a0","type":"GO_TERM","name":"EGF repeat binding","canonical_id":"go:GO:0061788","description":"\"Binding to Epidermal Growth Factor (EGF) repeats.\" [GOC:25700513, GOC:dph, PMID:25155514]","metadata":null},{"id":"0d252839e94b4ae4906a7abe44e129d0","type":"GO_TERM","name":"EGF-domain serine glucosyltransferase activity","canonical_id":"go:GO:0140561","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + [protein with EGF-like domain]-L-serine = UDP + [protein with EGF-like domain]-3-O-(beta-D-glucosyl)-L-serine.\" [RHEA:58116]","metadata":null},{"id":"f31db1ba73bc4c609c0e8c41d0048807","type":"GO_TERM","name":"EGF-domain serine xylosyltransferase activity","canonical_id":"go:GO:0140562","description":"\"Catalyses the reaction: UDP-alpha-D-xylose + [protein with EGF-like domain]-L-serine = UDP + [protein with EGF-like domain]-3-O-(beta-D-xylosyl)-L-serine.\" [RHEA:62016]","metadata":null},{"id":"9d906f8924364340a7f256415889e033","type":"GENE","name":"EGFEM1P","canonical_id":"hgnc:HGNC:25149","description":"EGF like and EMI domain containing 1, pseudogene","metadata":{"aliases":["C3orf50","NCRNA00259"]}},{"id":"6bb3c55fca8d4578befa6452ef154389","type":"GENE","name":"EGFL6","canonical_id":"hgnc:HGNC:3235","description":"EGF like domain multiple 6","metadata":{"aliases":["MAEG"]}},{"id":"f69367aa79914258bc54a5c9e1a6d9df","type":"GENE","name":"EGFL7","canonical_id":"hgnc:HGNC:20594","description":"EGF like domain multiple 7","metadata":{"aliases":["ZNEU1"]}},{"id":"bcfdbe07aa824f2a9aac2294344a904a","type":"GENE","name":"EGFL8","canonical_id":"hgnc:HGNC:13944","description":"EGF like domain multiple 8","metadata":{"aliases":["NG3","C6orf8"]}},{"id":"1d32da8a213f4b90ab25108bac45f6a6","type":"GENE","name":"EGFLAM","canonical_id":"hgnc:HGNC:26810","description":"EGF like, fibronectin type III and laminin G domains","metadata":{"aliases":["FLJ39155","AGRINL","AGRNL","PIKA"]}},{"id":"a772feeb06954dd286e27543cecfb35b","type":"GENE","name":"EGFLAM-AS1","canonical_id":"hgnc:HGNC:41169","description":"EGFLAM antisense RNA 1","metadata":{"aliases":["lncRNA-LOWEG","CTD-2108O9.1"]}},{"id":"26b0f86308464affbcb52bde34a4390f","type":"GENE","name":"EGFLAM-AS2","canonical_id":"hgnc:HGNC:41168","description":"EGFLAM antisense RNA 2","metadata":null},{"id":"cf578aa6974b4e2bab55e0267334802c","type":"GENE","name":"EGFLAM-AS3","canonical_id":"hgnc:HGNC:41167","description":"EGFLAM antisense RNA 3","metadata":null},{"id":"177268c3861e44cda46af3b148a1b943","type":"GENE","name":"EGFLAM-AS4","canonical_id":"hgnc:HGNC:41166","description":"EGFLAM antisense RNA 4","metadata":null},{"id":"4ce4e6c55b2748d383473f11f9943a47","type":"GENE","name":"EGFLAM-AS5","canonical_id":"hgnc:HGNC:58126","description":"EGFLAM antisense RNA 5","metadata":{"aliases":["AC010457.1"]}},{"id":"834075b14b7a45e693787e31c341c575","type":"GENE","name":"EGFLAM-AS6","canonical_id":"hgnc:HGNC:59029","description":"EGFLAM antisense RNA 6","metadata":null},{"id":"b1f866c04fab44608d8643d364e2ff3c","type":"GENE","name":"EGFLAM-AS7","canonical_id":"hgnc:HGNC:59030","description":"EGFLAM antisense RNA 7","metadata":null},{"id":"48a1d9d4ed9b492c9c243c6d17fb790b","type":"GENE","name":"EGFR","canonical_id":"hgnc:HGNC:3236","description":null,"metadata":null},{"id":"16775c6f74224ebb8c5a7c248eba0ea5","type":"PROTEIN","name":"EGFR","canonical_id":"uniprot:P00533","description":null,"metadata":null},{"id":"c09659a30ac545608f6161d4dba2f529","type":"GENE","name":"EGFR","canonical_id":"ensembl:ENSG00000146648","description":null,"metadata":null},{"id":"f521b741a16e48fe86eff9ef9694039d","type":"BIOMARKER","name":"EGFR A289V","canonical_id":"civic:970","description":null,"metadata":null},{"id":"ccef674c2f3445779e0501be2c8c7dc9","type":"BIOMARKER","name":"EGFR A763_Y764insFQEA","canonical_id":"civic:1423","description":null,"metadata":null},{"id":"6961ac3ae9d845d0820e77e424630fb5","type":"BIOMARKER","name":"EGFR A767_V769dupASV","canonical_id":"civic:1487","description":null,"metadata":null},{"id":"38f38f8c169e42408273a020436e30b0","type":"BIOMARKER","name":"EGFR A864T","canonical_id":"civic:1161","description":null,"metadata":null},{"id":"d8a9e1dcf5404f1faf780ebbf0caac75","type":"BIOMARKER","name":"EGFR Amplification","canonical_id":"civic:190","description":null,"metadata":null},{"id":"26681850f18a4df5ab4f58b653a76066","type":"BIOMARKER","name":"EGFR Amplification AND EGFR EGFRVIII","canonical_id":"civic:4245","description":null,"metadata":null},{"id":"2d55b80e94d34340b52356ef8b62b0a1","type":"BIOMARKER","name":"EGFR Amplification AND EGFR::SEPTIN14 Fusion","canonical_id":"civic:4175","description":null,"metadata":null},{"id":"b5b570826b664ec69d45cb961f52b6b2","type":"BIOMARKER","name":"EGFR C797S","canonical_id":"civic:411","description":null,"metadata":null},{"id":"a6b05948749a46379ef1c50c2e783851","type":"BIOMARKER","name":"EGFR C797Y","canonical_id":"civic:1482","description":null,"metadata":null},{"id":"858063f392da48988adb77478778ef57","type":"BIOMARKER","name":"EGFR Copy Number Variation","canonical_id":"civic:191","description":null,"metadata":null},{"id":"5f085225031f450395e0991f72a7390c","type":"BIOMARKER","name":"EGFR D761Y","canonical_id":"civic:693","description":null,"metadata":null},{"id":"2a0ebccbff204220a99481aa09ae2d56","type":"BIOMARKER","name":"EGFR D770_N771insG","canonical_id":"civic:1420","description":null,"metadata":null},{"id":"1640d91873014f3187a5b7998b5f28af","type":"BIOMARKER","name":"EGFR D770_N771insGL","canonical_id":"civic:1422","description":null,"metadata":null},{"id":"8085ea0f56e54cd79ae1b6347f663ca7","type":"BIOMARKER","name":"EGFR D770_N771insGT","canonical_id":"civic:1474","description":null,"metadata":null},{"id":"6a215ec000634be281e502768fa7a8ef","type":"BIOMARKER","name":"EGFR D770_N771insGT OR EGFR D770_N771insD OR EGFR D770_N771insF OR EGFR D770_N771insGD OR EGFR D770_N771insT OR EGFR N771delinsCH OR EGFR N771delinsGF OR EGFR N771delinsRD OR EGFR N771delinsSQRGH OR EGFR N771_P772insDN","canonical_id":"civic:5688","description":null,"metadata":null},{"id":"b7a046fe83664815ba013ac99aa6cbe8","type":"BIOMARKER","name":"EGFR D770_N771insNPG","canonical_id":"civic:1477","description":null,"metadata":null},{"id":"128b5df858494896b4b75b6e916697d1","type":"BIOMARKER","name":"EGFR D770_N771insSVD","canonical_id":"civic:1353","description":null,"metadata":null},{"id":"b8d37552937d4824bdaea4cd1244ed07","type":"BIOMARKER","name":"EGFR D770delinsGY","canonical_id":"civic:2090","description":null,"metadata":null},{"id":"25296f709de749178ee2216c86188677","type":"BIOMARKER","name":"EGFR D770delinsGY OR EGFR D770_N771insY OR EGFR N771_P772insT OR EGFR H773_V774insGNPH OR EGFR A767_S768insTLA OR EGFR S768_V769insLDS OR EGFR V769_D770insCV OR EGFR V769_D770insGA OR EGFR V769_D770insGVASV OR EGFR D770delinsAS","canonical_id":"civic:5687","description":null,"metadata":null},{"id":"17942abe075e4be198fd51e856bd2f95","type":"BIOMARKER","name":"EGFR E114K","canonical_id":"civic:3332","description":null,"metadata":null},{"id":"6e6506bc55b34c9abdc3e3a938bfedf1","type":"BIOMARKER","name":"EGFR E734Q","canonical_id":"civic:1480","description":null,"metadata":null},{"id":"203031d5783c47f29cd84d9287564ca3","type":"BIOMARKER","name":"EGFR E746G","canonical_id":"civic:705","description":null,"metadata":null},{"id":"70d0f007e91f48b5816afcd469afac8c","type":"BIOMARKER","name":"EGFR E746_A750del","canonical_id":"civic:976","description":null,"metadata":null},{"id":"e13a406f16b14caa8e1cbae7eab335d7","type":"BIOMARKER","name":"EGFR E746_T751>I","canonical_id":"civic:977","description":null,"metadata":null},{"id":"a856a0ce7bab4b8d9b0b055f01c37d12","type":"BIOMARKER","name":"EGFR E868G","canonical_id":"civic:1390","description":null,"metadata":null},{"id":"4e965022743a4ac290a4d9326e362f0f","type":"BIOMARKER","name":"EGFR Exon 18 Overexpression","canonical_id":"civic:371","description":null,"metadata":null},{"id":"b4b4bf505e144d8997cfe32b3348ab01","type":"BIOMARKER","name":"EGFR Exon 19 Deletion","canonical_id":"civic:133","description":null,"metadata":null},{"id":"c9c00a042a964c5a8224d474ef4d203d","type":"BIOMARKER","name":"EGFR Exon 20 Insertion","canonical_id":"civic:707","description":null,"metadata":null},{"id":"bc7a01b8f8b045c4be00a3886c63c6a1","type":"BIOMARKER","name":"EGFR Exon 4 Deletion","canonical_id":"civic:248","description":null,"metadata":null},{"id":"6b778a6492544288a2e2dc25e7baffc9","type":"BIOMARKER","name":"EGFR Expression","canonical_id":"civic:350","description":null,"metadata":null},{"id":"8f020266aebb4a22b855284b31eb9e68","type":"BIOMARKER","name":"EGFR H773_V774insH OR EGFR D770_N771insG OR EGFR H773_V774insNPH OR EGFR A763_Y764insFQEA OR EGFR V774_C775insHV OR EGFR H773_V774insPH OR EGFR H773_V774insAH OR EGFR D770_N771insH OR EGFR N771dup","canonical_id":"civic:5691","description":null,"metadata":null},{"id":"9d29630bc72e4c558e17e805ccabe6d0","type":"BIOMARKER","name":"EGFR H773delinsYNPY OR EGFR H773delinsYPNPY OR EGFR H773_V774insHPH OR EGFR H773_V774insTH OR EGFR C775_R776insNPHVC","canonical_id":"civic:5690","description":null,"metadata":null},{"id":"c222ec523afb4ec5812e8502f99c1139","type":"BIOMARKER","name":"EGFR L858R OR EGFR Exon 19 Deletion","canonical_id":"civic:4432","description":null,"metadata":null},{"id":"f8fb7d9161d34c85a6c4aeb3948dca90","type":"BIOMARKER","name":"EGFR S768_D770dup OR EGFR A767_V769dupASV","canonical_id":"civic:5782","description":null,"metadata":null},{"id":"16493cee8e344fcd857a96f5bf0a39e5","type":"BIOMARKER","name":"EGFR T790M AND EGFR Exon 19 Deletion","canonical_id":"civic:4659","description":null,"metadata":null},{"id":"43ea557c39394014a1d032555a0f7390","type":"BIOMARKER","name":"EGFR T790M AND EGFR Exon 19 Deletion AND EGFR C797S","canonical_id":"civic:5513","description":null,"metadata":null},{"id":"cb1ab52514fb489dade93c82e3fcc403","type":"BIOMARKER","name":"EGFR T790M AND EGFR Exon 19 del","canonical_id":"civic:5927","description":null,"metadata":null},{"id":"4cee68646e344e9c854667be5ba305c4","type":"GENE","name":"EGFR-AS1","canonical_id":"hgnc:HGNC:40207","description":"EGFR antisense RNA 1","metadata":null},{"id":"7c0fca2a67dd4516a32635f7b359535a","type":"GO_TERM","name":"EGFR-Grb2-Sos complex","canonical_id":"go:GO:0070620","description":"\"A protein complex that contains the epidermal growth factor receptor (EGFR), Grb2 and the guanine nucleotide exchange factor Sos (or an ortholog thereof, such as mSos1), and is involved in linking EGFR activation to the p21-Ras pathway.\" [GOC:mah, PMID:7798267, PMID:8940013]","metadata":null},{"id":"ce7ab25c4c0242788a7898db70472ad3","type":"GO_TERM","name":"EGFR-Shc-Grb2-Sos complex","canonical_id":"go:GO:0070621","description":"\"A protein complex that contains the epidermal growth factor receptor (EGFR), Grb2, the adaptor protein SHC and the guanine nucleotide exchange factor Sos (or an ortholog thereof, such as mSos1), and is involved in linking EGFR activation to the p21-Ras pathway.\" [GOC:mah, PMID:7798267, PMID:8940013]","metadata":null},{"id":"aa2e7748a6654bb7b129bfc7f191ea7c","type":"TRIAL","name":"EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC","canonical_id":"clinicaltrials.gov:NCT03720873","description":"EGFR Gene Mutation","metadata":null},{"id":"1a3e7e4f05424c719fc23b40d4fcbcf4","type":"DISEASE","name":"EGFR-related lung cancer","canonical_id":"efo:0022194","description":null,"metadata":null},{"id":"e1b6362ab81a493e87a1e9c42dd7bcec","type":"GO_TERM","name":"EGFR:ERBB2 complex","canonical_id":"go:GO:0038142","description":"\"A heterodimeric complex between the tyrosine kinase receptor ERBB2 and a ligand-activated epidermal growth factor receptor (EGFR/ERBB1). ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as EGFR.\" [GOC:signaling, PMID:16460914, PMID:1973074]","metadata":null},{"id":"6912bc892182479f86c8caa52d3ff4e5","type":"GENE","name":"EGILA","canonical_id":"hgnc:HGNC:54482","description":"EGFR interacting lncRNA","metadata":{"aliases":["Lnc-EGFR"]}},{"id":"9c0303b6000140f5b663a49e9d3a70b6","type":"GENE","name":"EGLN1","canonical_id":"hgnc:HGNC:1232","description":null,"metadata":null},{"id":"0230f7efaf0548d3a3d425a6d0f6390a","type":"GENE","name":"EGLN1P1","canonical_id":"hgnc:HGNC:44481","description":"egl-9 family hypoxia inducible factor 1 pseudogene 1","metadata":null},{"id":"0d37ec2217c64992934727025df3d758","type":"GENE","name":"EGLN2","canonical_id":"hgnc:HGNC:14660","description":null,"metadata":null},{"id":"28eae67ea7eb4827b6b78d7c794c76c5","type":"GENE","name":"EGLN3","canonical_id":"hgnc:HGNC:14661","description":null,"metadata":null},{"id":"306e0752013c41f0ab2525c84aa08471","type":"GENE","name":"EGLN3-AS1","canonical_id":"hgnc:HGNC:49077","description":"EGLN3 antisense RNA 1","metadata":null},{"id":"6625e6947ddd4cb6953c01dc3e098fff","type":"GENE","name":"EGLN3P1","canonical_id":"hgnc:HGNC:49857","description":"egl-9 family hypoxia-inducible factor 3 pseudogene 1","metadata":null},{"id":"7d74f401074644f68bfcbcc2c68f57a5","type":"GENE","name":"EGOT","canonical_id":"hgnc:HGNC:37129","description":"eosinophil granule ontogeny transcript","metadata":{"aliases":["EGO","NCRNA00190"]}},{"id":"1f0ffafe041c452fb96751ae9f3b3cd6","type":"GENE","name":"EGR1","canonical_id":"hgnc:HGNC:3238","description":null,"metadata":null},{"id":"030fdde4841a41f5a8f17a7223699fcc","type":"GENE","name":"EGR2","canonical_id":"hgnc:HGNC:3239","description":null,"metadata":null},{"id":"c598bb8dff864fe1809daa3fcfc3a0a0","type":"GENE","name":"EGR3","canonical_id":"hgnc:HGNC:3240","description":null,"metadata":null},{"id":"0670195eb0934faeb9113caf89e67cab","type":"GENE","name":"EGR3-AS1","canonical_id":"hgnc:HGNC:58186","description":"EGR3 and PEBP4 antisense RNA 1","metadata":null},{"id":"d27ec8f881874dbb8d93a3dee295e22a","type":"GENE","name":"EGR4","canonical_id":"hgnc:HGNC:3241","description":"early growth response 4","metadata":{"aliases":["NGFI-C","PAT133"]}},{"id":"8215ac064bc548ea9792b9fd3b4dd53a","type":"GO_TERM","name":"EH domain binding","canonical_id":"go:GO:1990175","description":"\"Binding to an EH domain of a protein. The EH stand for Eps15 homology. This was originally identified as a motif present in three copies at the NH2-termini of Eps15 and of the related molecule Eps15R.\" [GOC:hjd, PMID:11911876, PMID:21115825]","metadata":null},{"id":"c48233fe024044dd93e0da72e4d0edd2","type":"GENE","name":"EHBP1","canonical_id":"hgnc:HGNC:29144","description":"EH domain binding protein 1","metadata":{"aliases":["KIAA0903","NACSIN"]}},{"id":"d2676db3391a438ea6f0b3bc09bff2b9","type":"GENE","name":"EHBP1-AS1","canonical_id":"hgnc:HGNC:55766","description":"EHBP1 antisense RNA 1","metadata":null},{"id":"92bb163724104c0ab5effb4c919d1ba6","type":"GENE","name":"EHBP1L1","canonical_id":"hgnc:HGNC:30682","description":"EH domain binding protein 1 like 1","metadata":{"aliases":["DKFZp762C186","TANGERIN"]}},{"id":"60e30bb21869458bb7e527904aa7829f","type":"GENE","name":"EHD1","canonical_id":"hgnc:HGNC:3242","description":"EH domain containing 1","metadata":{"aliases":["H-PAST","HPAST1","FLJ42622","FLJ44618","PAST1"]}},{"id":"c2d8b04653d24f0f8bda6263db40931d","type":"GENE","name":"EHD2","canonical_id":"hgnc:HGNC:3243","description":"EH domain containing 2","metadata":{"aliases":["PAST2"]}},{"id":"b60b795c0b504526aaa8f9187c6365d3","type":"GENE","name":"EHD3","canonical_id":"hgnc:HGNC:3244","description":"EH domain containing 3","metadata":{"aliases":["PAST3"]}},{"id":"56341f3ad46e40ddb112d63bb995e06c","type":"GENE","name":"EHD4","canonical_id":"hgnc:HGNC:3245","description":"EH domain containing 4","metadata":{"aliases":["PAST4"]}},{"id":"7b251106f29e4bc6bca55bc03f12abe3","type":"GENE","name":"EHD4-AS1","canonical_id":"hgnc:HGNC:51418","description":"EHD4 antisense RNA 1","metadata":null},{"id":"5dd3b31e49414dcaa311fb3bdbb54581","type":"GENE","name":"EHF","canonical_id":"hgnc:HGNC:3246","description":null,"metadata":null},{"id":"4b55a8847ad440a0966c5e7aea8a8013","type":"GENE","name":"EHHADH","canonical_id":"hgnc:HGNC:3247","description":"enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase","metadata":{"aliases":["ECHD"]}},{"id":"c6ca56e14424405993b790ecd0e4eddc","type":"GENE","name":"EHHADH-AS1","canonical_id":"hgnc:HGNC:44133","description":"EHHADH antisense RNA 1","metadata":null},{"id":"03f2725923e5472d9334c09c7376ea39","type":"GENE","name":"EHMT1","canonical_id":"hgnc:HGNC:24650","description":"euchromatic histone lysine methyltransferase 1","metadata":{"aliases":["Eu-HMTase1","FLJ12879","KIAA1876","bA188C12.1","KMT1D","FLJ40292","GLP","EHMT1-IT1"]}},{"id":"551e07238435483ba94aa0f25c6a793f","type":"GENE","name":"EHMT2","canonical_id":"hgnc:HGNC:14129","description":null,"metadata":null},{"id":"e65f0b225894496b9f6c600ebaaa993b","type":"GENE","name":"EHMT2-AS1","canonical_id":"hgnc:HGNC:39751","description":"EHMT2 and SLC44A4 antisense RNA 1","metadata":null},{"id":"8792202e1c924dd4a3d4ed8ec3489a77","type":"GENE","name":"EI24","canonical_id":"hgnc:HGNC:13276","description":"EI24 autophagy associated transmembrane protein","metadata":{"aliases":["PIG8","TP53I8","EPG4"]}},{"id":"b13912e9c1964a8eb556bf8156209c9e","type":"GENE","name":"EI24P1","canonical_id":"hgnc:HGNC:44586","description":"EI24 pseudogene 1","metadata":null},{"id":"277f3bd736234a7e9389d469721bfecf","type":"GENE","name":"EI24P2","canonical_id":"hgnc:HGNC:44587","description":"EI24 pseudogene 2","metadata":null},{"id":"86f90447272041ffbcc2ac11ffe84b76","type":"GENE","name":"EI24P3","canonical_id":"hgnc:HGNC:44588","description":"EI24 pseudogene 3","metadata":null},{"id":"8a9c67b347a44ea6b1341719f8cc1be4","type":"GENE","name":"EI24P4","canonical_id":"hgnc:HGNC:44589","description":"EI24 pseudogene 4","metadata":null},{"id":"d20e2f31f65740459e71f97276f5ce17","type":"GENE","name":"EI24P5","canonical_id":"hgnc:HGNC:44590","description":"EI24 pseudogene 5","metadata":null},{"id":"dd0f1ab1d23f490a978acbba1ccf5048","type":"GENE","name":"EI24P6","canonical_id":"hgnc:HGNC:56586","description":"EI24 pseudogene 6","metadata":null},{"id":"6c6f401d8cc34d139072226fdde3e775","type":"GENE","name":"EID1","canonical_id":"hgnc:HGNC:1191","description":"EP300 interacting inhibitor of differentiation 1","metadata":{"aliases":["EID-1","C15orf3","CRI1"]}},{"id":"8d3fcdcf4c8a498fad5848dd7dd109db","type":"GENE","name":"EID2","canonical_id":"hgnc:HGNC:28292","description":"EP300 interacting inhibitor of differentiation 2","metadata":{"aliases":["EID-2","MGC20452","CRI2"]}},{"id":"a5f86315b4454403856ec2d8f4c757cd","type":"GENE","name":"EID2B","canonical_id":"hgnc:HGNC:26796","description":"EP300 interacting inhibitor of differentiation 2B","metadata":{"aliases":["EID-3","FLJ38944"]}},{"id":"63c3f73777454a4084e8062cc78d739e","type":"GENE","name":"EID3","canonical_id":"hgnc:HGNC:32961","description":"EP300 interacting inhibitor of differentiation 3","metadata":{"aliases":["FLJ25832","NSMCE4B","NSE4B"]}},{"id":"a308b30e606c4f0a81460f75e1a60328","type":"GENE","name":"EIF1","canonical_id":"hgnc:HGNC:3249","description":"eukaryotic translation initiation factor 1","metadata":{"aliases":["EIF-1","ISO1","A121","SUI1","EIF1A"]}},{"id":"cce8c37165eb4e3ba20196050e903c47","type":"GENE","name":"EIF1AD","canonical_id":"hgnc:HGNC:28147","description":"eukaryotic translation initiation factor 1A domain containing","metadata":{"aliases":["MGC11102","haponin"]}},{"id":"d8c98ccf531547029c7c989e6eb9e125","type":"GENE","name":"EIF1AX","canonical_id":"hgnc:HGNC:3250","description":"eukaryotic translation initiation factor 1A X-linked","metadata":{"aliases":["eIF-1A","eIF-4C","EIF4C","EIF1A"]}},{"id":"01eba824f6e440f7864e082006658340","type":"GENE","name":"EIF1AX-AS1","canonical_id":"hgnc:HGNC:40208","description":"EIF1AX antisense RNA 1","metadata":null},{"id":"31e342d3d3b04e9385caf56fceaf215e","type":"GENE","name":"EIF1AXP1","canonical_id":"hgnc:HGNC:19900","description":"EIF1AX pseudogene 1","metadata":{"aliases":["EIF1AP1"]}},{"id":"38a3aed7793046d1870ad60b50122e6a","type":"GENE","name":"EIF1AXP2","canonical_id":"hgnc:HGNC:44295","description":"EIF1AX pseudogene 2","metadata":null},{"id":"c310597368e241fe84089d1ccf980151","type":"GENE","name":"EIF1AY","canonical_id":"hgnc:HGNC:3252","description":"eukaryotic translation initiation factor 1A Y-linked","metadata":null},{"id":"a853bf83725145c9a5fb0d21224177ad","type":"GENE","name":"EIF1B","canonical_id":"hgnc:HGNC:30792","description":"eukaryotic translation initiation factor 1B","metadata":{"aliases":["GC20"]}},{"id":"123ccb01029f4bf99775918b96f753b7","type":"GENE","name":"EIF1P1","canonical_id":"hgnc:HGNC:49614","description":"eukaryotic translation initiation factor 1 pseudogene 1","metadata":null},{"id":"91a9170fb08348e4a004dd3fc2c6c1a4","type":"GENE","name":"EIF1P2","canonical_id":"hgnc:HGNC:49615","description":"eukaryotic translation initiation factor 1 pseudogene 2","metadata":null},{"id":"80de83c6d6ef42c89446bc2af3b02917","type":"GENE","name":"EIF1P3","canonical_id":"hgnc:HGNC:49616","description":"eukaryotic translation initiation factor 1 pseudogene 3","metadata":null},{"id":"15ec9b41253f4645a6fce5636f159a37","type":"GENE","name":"EIF1P4","canonical_id":"hgnc:HGNC:49617","description":"eukaryotic translation initiation factor 1 pseudogene 4","metadata":null},{"id":"bf32a5220bfe45b09f3b38f97d6b967e","type":"GENE","name":"EIF1P5","canonical_id":"hgnc:HGNC:49618","description":"eukaryotic translation initiation factor 1 pseudogene 5","metadata":null},{"id":"723779a0fde542959d79a38645b6e985","type":"GENE","name":"EIF1P6","canonical_id":"hgnc:HGNC:49619","description":"eukaryotic translation initiation factor 1 pseudogene 6","metadata":null},{"id":"e910c0e1f3304b4abe3820b1d769c3a2","type":"GENE","name":"EIF1P7","canonical_id":"hgnc:HGNC:49620","description":"eukaryotic translation initiation factor 1 pseudogene 7","metadata":null},{"id":"62502c63d00f4598b5e73bf3464c2592","type":"GENE","name":"EIF2A","canonical_id":"hgnc:HGNC:3254","description":"eukaryotic translation initiation factor 2A","metadata":{"aliases":["EIF-2A"]}},{"id":"de24ff3a85534ff6b04fcf7e90477fa9","type":"GENE","name":"EIF2AK1","canonical_id":"hgnc:HGNC:24921","description":null,"metadata":null},{"id":"c739f65dd93a48f6b33d6891bc51a894","type":"GENE","name":"EIF2AK1P1","canonical_id":"hgnc:HGNC:56553","description":"EIF2AK1 pseudogene 1","metadata":null},{"id":"a76b24d0448e406a9085ee7305cf6b64","type":"GENE","name":"EIF2AK2","canonical_id":"hgnc:HGNC:9437","description":null,"metadata":null},{"id":"7b1079ebc74543bc9b69b70a6d058ad6","type":"GENE","name":"EIF2AK3","canonical_id":"hgnc:HGNC:3255","description":"eukaryotic translation initiation factor 2 alpha kinase 3","metadata":{"aliases":["PEK","PERK"]}},{"id":"efecc13a8b074e65977af81f4913f76f","type":"GENE","name":"EIF2AK3-AS1","canonical_id":"hgnc:HGNC:58177","description":"EIF2AK3 antisense RNA 1","metadata":null},{"id":"06e29d6f49dd41fe9af32e65c923a98a","type":"GENE","name":"EIF2AK3-DT","canonical_id":"hgnc:HGNC:54066","description":"EIF2AK3 divergent transcript","metadata":null},{"id":"cd7e43b633c14d629d05880311000e7a","type":"GENE","name":"EIF2AK4","canonical_id":"hgnc:HGNC:19687","description":"eukaryotic translation initiation factor 2 alpha kinase 4","metadata":{"aliases":["GCN2","KIAA1338"]}},{"id":"e1b8efa719f44638873c3d60432ee4c4","type":"GENE","name":"EIF2AP1","canonical_id":"hgnc:HGNC:39495","description":"eukaryotic translation initiation factor 2A pseudogene 1","metadata":null},{"id":"d2a9779fd81746709aaffa4ed598caaa","type":"GENE","name":"EIF2AP2","canonical_id":"hgnc:HGNC:39496","description":"eukaryotic translation initiation factor 2A pseudogene 2","metadata":null},{"id":"dc127307441d4084b11f31aca0f759d7","type":"GENE","name":"EIF2AP3","canonical_id":"hgnc:HGNC:39497","description":"eukaryotic translation initiation factor 2A pseudogene 3","metadata":null},{"id":"394962ff5a7a411082aa9b6dee421ea9","type":"GENE","name":"EIF2AP4","canonical_id":"hgnc:HGNC:39498","description":"eukaryotic translation initiation factor 2A pseudogene 4","metadata":null},{"id":"d6c02fc06576431ea7727567882f69eb","type":"GENE","name":"EIF2B1","canonical_id":"hgnc:HGNC:3257","description":"eukaryotic translation initiation factor 2B subunit alpha","metadata":{"aliases":["EIF-2Balpha","EIF-2B","EIF2BA","EIF2Balpha","EIF2B"]}},{"id":"3bda56476f2c4e5a9c27721ede20a9f1","type":"GENE","name":"EIF2B2","canonical_id":"hgnc:HGNC:3258","description":"eukaryotic translation initiation factor 2B subunit beta","metadata":{"aliases":["EIF2B","EIF-2Bbeta","EIF2Bbeta"]}},{"id":"be411ab6f66a4a79a596d15c3a0e686f","type":"GENE","name":"EIF2B3","canonical_id":"hgnc:HGNC:3259","description":"eukaryotic translation initiation factor 2B subunit gamma","metadata":{"aliases":["EIF2Bgamma","EIF-2B"]}},{"id":"3c9963dfccab491980f687356d934e97","type":"GENE","name":"EIF2B4","canonical_id":"hgnc:HGNC:3260","description":"eukaryotic translation initiation factor 2B subunit delta","metadata":{"aliases":["EIF2Bdelta","EIF-2B","DKFZP586J0119","EIF2B"]}},{"id":"c01c9803bf724260bb642f0617ea57d2","type":"GENE","name":"EIF2B5","canonical_id":"hgnc:HGNC:3261","description":"eukaryotic translation initiation factor 2B subunit epsilon","metadata":{"aliases":["EIF2Bepsilon","EIF-2B"]}},{"id":"d4741f04a503404f9342a1d71f298fac","type":"GENE","name":"EIF2B5-DT","canonical_id":"hgnc:HGNC:55202","description":"EIF2B5 divergent transcript","metadata":null},{"id":"92cc76e2d8b3434e817f7a2429ed967d","type":"GENE","name":"EIF2D","canonical_id":"hgnc:HGNC:6583","description":"eukaryotic translation initiation factor 2D","metadata":{"aliases":["LGTN"]}},{"id":"fde0e64668c74c9d89d9e0dfcda0df03","type":"GENE","name":"EIF2S1","canonical_id":"hgnc:HGNC:3265","description":"eukaryotic translation initiation factor 2 subunit alpha","metadata":{"aliases":["EIF-2alpha","EIF2A","EIF2"]}},{"id":"ab9678aabb294062a18e14be15bc796c","type":"GENE","name":"EIF2S2","canonical_id":"hgnc:HGNC:3266","description":"eukaryotic translation initiation factor 2 subunit beta","metadata":{"aliases":["EIF2beta","PPP1R67","EIF2"]}},{"id":"4076a72e0c6f4bdfafb9d388b2c82b48","type":"GENE","name":"EIF2S2P1","canonical_id":"hgnc:HGNC:20009","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 1","metadata":{"aliases":["EIF2S2P"]}},{"id":"c7cfaf5411e7406987a7b71b2c48153f","type":"GENE","name":"EIF2S2P2","canonical_id":"hgnc:HGNC:24654","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 2","metadata":{"aliases":["bcm2636"]}},{"id":"400bf5dfbce34049acaeef1d339d5af8","type":"GENE","name":"EIF2S2P3","canonical_id":"hgnc:HGNC:31664","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 3","metadata":null},{"id":"7f60ae221fba448792daabf886e1c032","type":"GENE","name":"EIF2S2P4","canonical_id":"hgnc:HGNC:37626","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 4","metadata":null},{"id":"678fb53b851e40c98fddce1716bd59eb","type":"GENE","name":"EIF2S2P5","canonical_id":"hgnc:HGNC:37793","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 5","metadata":null},{"id":"918be0b3b15f47faa1ecc4a4098d78e8","type":"GENE","name":"EIF2S2P6","canonical_id":"hgnc:HGNC:37794","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 6","metadata":null},{"id":"89455cb7dee343f899f93c756c7bad58","type":"GENE","name":"EIF2S2P7","canonical_id":"hgnc:HGNC:37795","description":"eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 7","metadata":null},{"id":"117f9df8531e4817a7ad8d4edb0072d9","type":"GENE","name":"EIF2S3","canonical_id":"hgnc:HGNC:3267","description":"eukaryotic translation initiation factor 2 subunit gamma","metadata":{"aliases":["EIF2gamma","EIF2G"]}},{"id":"0f8d47c00a37480ea4bb00aeb0d9f4ae","type":"GENE","name":"EIF2S3B","canonical_id":"hgnc:HGNC:43863","description":"eukaryotic translation initiation factor 2 subunit gamma B","metadata":{"aliases":["eIF2gA","eIF-2-gamma2"]}},{"id":"2b5834a7f1d64adb8e1db0526db7742e","type":"GENE","name":"EIF2S3P1","canonical_id":"hgnc:HGNC:58486","description":"EIF2S3 pseudogene 1","metadata":null},{"id":"5780c76ef895489da7e2dea1da6fd17e","type":"GENE","name":"EIF2S3P2","canonical_id":"hgnc:HGNC:58487","description":"EIF2S3 pseudogene 2","metadata":null},{"id":"eb40c105a1ce439491b27ce971f6a0c2","type":"GENE","name":"EIF3A","canonical_id":"hgnc:HGNC:3271","description":"eukaryotic translation initiation factor 3 subunit A","metadata":{"aliases":["eIF3-theta","eIF3-p170","KIAA0139","TIF32","EIF3","EIF3S10"]}},{"id":"f55672c663f64edbae9259176d21ef5a","type":"GENE","name":"EIF3B","canonical_id":"hgnc:HGNC:3280","description":"eukaryotic translation initiation factor 3 subunit B","metadata":{"aliases":["PRT1","EIF3S9"]}},{"id":"daaab633c35d4601813b10491cb11c1c","type":"GENE","name":"EIF3C","canonical_id":"hgnc:HGNC:3279","description":"eukaryotic translation initiation factor 3 subunit C","metadata":{"aliases":["eIF3-p110","EIF3S8"]}},{"id":"24104ef475ef4eaabec136b784b65d19","type":"GENE","name":"EIF3CL","canonical_id":"hgnc:HGNC:26347","description":"eukaryotic translation initiation factor 3 subunit C like","metadata":null},{"id":"94d577cbdf754191800a81cb2e46b129","type":"GENE","name":"EIF3D","canonical_id":"hgnc:HGNC:3278","description":"eukaryotic translation initiation factor 3 subunit D","metadata":{"aliases":["eIF3-p66","eIF3-zeta","EIF3S7"]}},{"id":"eea1a735090e4311b69dd1b37d976e55","type":"GENE","name":"EIF3E","canonical_id":"hgnc:HGNC:3277","description":"eukaryotic translation initiation factor 3 subunit E","metadata":{"aliases":["eIF3-p48","INT6","EIF3S6"]}},{"id":"1afbd618d05d4535bf72f0f3b4e4fd54","type":"GENE","name":"EIF3EP1","canonical_id":"hgnc:HGNC:6102","description":"EIF3E pseudogene 1","metadata":{"aliases":["INT6P1","EIF3S6P1","EIF3EP"]}},{"id":"0bf95114c2e1413683e18a570352e29a","type":"GENE","name":"EIF3EP2","canonical_id":"hgnc:HGNC:37919","description":"EIF3E pseudogene 2","metadata":null},{"id":"9fd69b56cb0d45769336fd1a06621645","type":"GENE","name":"EIF3EP3","canonical_id":"hgnc:HGNC:37920","description":"EIF3E pseudogene 3","metadata":null},{"id":"2ff4bc0f8d4948539b05fb920ff163f7","type":"GENE","name":"EIF3EP4","canonical_id":"hgnc:HGNC:37921","description":"EIF3E pseudogene 4","metadata":null},{"id":"567e755320b6404eae98177cc3782434","type":"GENE","name":"EIF3F","canonical_id":"hgnc:HGNC:3275","description":"eukaryotic translation initiation factor 3 subunit F","metadata":{"aliases":["eIF3-epsilon","eIF3-p47","EIF3S5"]}},{"id":"a4d281f757ad4fa981da23fb4c2d9da4","type":"GENE","name":"EIF3FP1","canonical_id":"hgnc:HGNC:3276","description":"eukaryotic translation initiation factor 3 subunit F pseudogene 1","metadata":{"aliases":["EIF3S5P","EIF3FP"]}},{"id":"ef91be9b0e514a67aa8a291988c3a7d7","type":"GENE","name":"EIF3FP2","canonical_id":"hgnc:HGNC:28863","description":"eukaryotic translation initiation factor 3 subunit F pseudogene 2","metadata":{"aliases":["IFP38"]}},{"id":"b7018f4b23ae4bdc9ec21b6869e37351","type":"GENE","name":"EIF3FP3","canonical_id":"hgnc:HGNC:37625","description":"eukaryotic translation initiation factor 3 subunit F pseudogene 3","metadata":null},{"id":"8dc32ce0f73c413f80f51308c8ad4e36","type":"GENE","name":"EIF3G","canonical_id":"hgnc:HGNC:3274","description":"eukaryotic translation initiation factor 3 subunit G","metadata":{"aliases":["eIF3-delta","eIF3-p44","EIF3S4"]}},{"id":"ef541269d31a488ca1684a010f064763","type":"GENE","name":"EIF3H","canonical_id":"hgnc:HGNC:3273","description":"eukaryotic translation initiation factor 3 subunit H","metadata":{"aliases":["eIF3-gamma","eIF3-p40","EIF3S3"]}},{"id":"e944bee897124e0ba5947db488208312","type":"GENE","name":"EIF3I","canonical_id":"hgnc:HGNC:3272","description":"eukaryotic translation initiation factor 3 subunit I","metadata":{"aliases":["TRIP-1","eIF3-beta","eIF3-p36","EIF3S2"]}},{"id":"50b509c58ef74cb8a24926f7b6a89d57","type":"GENE","name":"EIF3IP1","canonical_id":"hgnc:HGNC:13277","description":"eukaryotic translation initiation factor 3 subunit I pseudogene 1","metadata":{"aliases":["RG208K23"]}},{"id":"a2ee2d201b094d7fb562d9dfdd3cb46a","type":"GENE","name":"EIF3IP2","canonical_id":"hgnc:HGNC:58607","description":"EIF3I pseudogene 2","metadata":null},{"id":"2213a90c467a46f29e51e6a257856edb","type":"GENE","name":"EIF3J","canonical_id":"hgnc:HGNC:3270","description":"eukaryotic translation initiation factor 3 subunit J","metadata":{"aliases":["eIF3-p35","eIF3-alpha","EIF3S1"]}},{"id":"1dc12d982f27477f859abb71236cab4d","type":"GENE","name":"EIF3J-DT","canonical_id":"hgnc:HGNC:48616","description":"EIF3J divergent transcript","metadata":{"aliases":["EIF3J-AS1"]}},{"id":"68c3be78748945dfa2d0e9b7a2e0faff","type":"GENE","name":"EIF3JP1","canonical_id":"hgnc:HGNC:55005","description":"EIF3J pseudogene 1","metadata":null},{"id":"750cc80d0e80471a8c16714b6b08e0e9","type":"GENE","name":"EIF3JP2","canonical_id":"hgnc:HGNC:56558","description":"EIF3J pseudogene 2","metadata":null},{"id":"702d61370e9443cb9fc8318dad1cc6d1","type":"GENE","name":"EIF3JP3","canonical_id":"hgnc:HGNC:56559","description":"EIF3J pseudogene 3","metadata":null},{"id":"b742e89a53654b919a2edc3c2599484e","type":"GENE","name":"EIF3K","canonical_id":"hgnc:HGNC:24656","description":"eukaryotic translation initiation factor 3 subunit K","metadata":{"aliases":["PRO1474","HSPC029","PTD001","PLAC-24","M9","ARG134","EIF3S12"]}},{"id":"bf82a7b4af3448aa9ad34fde90e976eb","type":"GENE","name":"EIF3KP1","canonical_id":"hgnc:HGNC:44016","description":"eukaryotic translation initiation factor 3 subunit K pseudogene 1","metadata":null},{"id":"4399c76be4544ef68c6884f9f120d310","type":"GENE","name":"EIF3KP2","canonical_id":"hgnc:HGNC:44017","description":"eukaryotic translation initiation factor 3 subunit K pseudogene 2","metadata":null},{"id":"b59a3e3ad252486595370f01476b5073","type":"GENE","name":"EIF3KP3","canonical_id":"hgnc:HGNC:44018","description":"eukaryotic translation initiation factor 3 subunit K pseudogene 3","metadata":null},{"id":"f28b282042ee46b2bfd92ef5f43c80ed","type":"GENE","name":"EIF3L","canonical_id":"hgnc:HGNC:18138","description":"eukaryotic translation initiation factor 3 subunit L","metadata":{"aliases":["HSPC021","HSPC025","EIF3S11","EIF3S6IP","EIF3EIP"]}},{"id":"9bb9760e3ebc41079ff098e98b093eb0","type":"GENE","name":"EIF3LP1","canonical_id":"hgnc:HGNC:20010","description":"eukaryotic translation initiation factor 3 subunit L pseudogene 1","metadata":{"aliases":["EIF3S6IPP","EIF3EIPP1"]}},{"id":"3a26bd5922f249cb866204eafb9297dd","type":"GENE","name":"EIF3LP2","canonical_id":"hgnc:HGNC:24657","description":"eukaryotic translation initiation factor 3 subunit L pseudogene 2","metadata":{"aliases":["EIF3S6IPP2","EIF3EIPP2"]}},{"id":"153e9bafb47b41a6ba119201da28afd2","type":"GENE","name":"EIF3LP3","canonical_id":"hgnc:HGNC:44976","description":"eukaryotic translation initiation factor 3 subunit L pseudogene 3","metadata":null},{"id":"bd2fe8973d5343d898b9eef62e8c2b9c","type":"GENE","name":"EIF3M","canonical_id":"hgnc:HGNC:24460","description":null,"metadata":null},{"id":"930fe2e4f0d64472a167b382b1a0ad99","type":"GENE","name":"EIF3MP1","canonical_id":"hgnc:HGNC:55006","description":"EIF3M pseudogene 1","metadata":null},{"id":"d37d544219ae4ed0a1882a91b71202de","type":"GENE","name":"EIF4A1","canonical_id":"hgnc:HGNC:3282","description":"eukaryotic translation initiation factor 4A1","metadata":{"aliases":["DDX2A","EIF-4A","EIF4A"]}},{"id":"525d761b06e74886909501ca26b6e1f7","type":"GENE","name":"EIF4A1P1","canonical_id":"hgnc:HGNC:3283","description":"eukaryotic translation initiation factor 4A1 pseudogene 1","metadata":{"aliases":["EIF4A1P"]}},{"id":"f1b3401acdce44eaba3e7d0e0488ea70","type":"GENE","name":"EIF4A1P10","canonical_id":"hgnc:HGNC:37930","description":"eukaryotic translation initiation factor 4A1 pseudogene 10","metadata":null},{"id":"c32ca163e0b84770a8913afbc36f111e","type":"GENE","name":"EIF4A1P11","canonical_id":"hgnc:HGNC:37932","description":"eukaryotic translation initiation factor 4A1 pseudogene 11","metadata":null},{"id":"263eada40e844976b296dad34958cdc2","type":"GENE","name":"EIF4A1P12","canonical_id":"hgnc:HGNC:37933","description":"eukaryotic translation initiation factor 4A1 pseudogene 12","metadata":null},{"id":"f7c912dc96ad49f0a2bbade6344a597d","type":"GENE","name":"EIF4A1P13","canonical_id":"hgnc:HGNC:37934","description":"eukaryotic translation initiation factor 4A1 pseudogene 13","metadata":null},{"id":"5bdf669c3cc24a6699349e40b1f83778","type":"GENE","name":"EIF4A1P2","canonical_id":"hgnc:HGNC:23946","description":"eukaryotic translation initiation factor 4A1 pseudogene 2","metadata":null},{"id":"6cdbd1297b934db29819e9187ce037d1","type":"GENE","name":"EIF4A1P3","canonical_id":"hgnc:HGNC:37922","description":"eukaryotic translation initiation factor 4A1 pseudogene 3","metadata":null},{"id":"096fec4ea16c42819602945559867c64","type":"GENE","name":"EIF4A1P4","canonical_id":"hgnc:HGNC:37923","description":"eukaryotic translation initiation factor 4A1 pseudogene 4","metadata":null},{"id":"dee911fb1cc642f18640e5b3a9e3c514","type":"GENE","name":"EIF4A1P5","canonical_id":"hgnc:HGNC:37924","description":"eukaryotic translation initiation factor 4A1 pseudogene 5","metadata":null},{"id":"135a575a0eba4396af170428e09cdc98","type":"GENE","name":"EIF4A1P6","canonical_id":"hgnc:HGNC:37925","description":"eukaryotic translation initiation factor 4A1 pseudogene 6","metadata":null},{"id":"ecbcac62044b49fe946214afbfcc65d9","type":"GENE","name":"EIF4A1P7","canonical_id":"hgnc:HGNC:37926","description":"eukaryotic translation initiation factor 4A1 pseudogene 7","metadata":null},{"id":"ee1ca35ad7394e07b0b70c4698962b6c","type":"GENE","name":"EIF4A1P8","canonical_id":"hgnc:HGNC:37927","description":"eukaryotic translation initiation factor 4A1 pseudogene 8","metadata":null},{"id":"b87957c047db4a048e91a4cefb46d1e1","type":"GENE","name":"EIF4A1P9","canonical_id":"hgnc:HGNC:37928","description":"eukaryotic translation initiation factor 4A1 pseudogene 9","metadata":null},{"id":"7f224c3c023547c3b8a3bd0217c90825","type":"GENE","name":"EIF4A2","canonical_id":"hgnc:HGNC:3284","description":"eukaryotic translation initiation factor 4A2","metadata":{"aliases":["DDX2B","EIF4A","BM-010","EIF4F"]}},{"id":"e90ef9dd2d4b464cbaffbc3b4731dee0","type":"GENE","name":"EIF4A2P1","canonical_id":"hgnc:HGNC:37929","description":"eukaryotic translation initiation factor 4A2 pseudogene 1","metadata":null},{"id":"357ad679b7f7492891a522cb2040c342","type":"GENE","name":"EIF4A2P2","canonical_id":"hgnc:HGNC:45099","description":"eukaryotic translation initiation factor 4A2 pseudogene 2","metadata":null},{"id":"051448a9f6b54fab97df0daa60bb83a4","type":"GENE","name":"EIF4A2P3","canonical_id":"hgnc:HGNC:45100","description":"eukaryotic translation initiation factor 4A2 pseudogene 3","metadata":null},{"id":"0925a3ab5db842f29c102539a51cd6f6","type":"GENE","name":"EIF4A2P4","canonical_id":"hgnc:HGNC:45101","description":"eukaryotic translation initiation factor 4A2 pseudogene 4","metadata":null},{"id":"cde9d625ec464b2aa811160e93e64e11","type":"GENE","name":"EIF4A2P5","canonical_id":"hgnc:HGNC:45102","description":"eukaryotic translation initiation factor 4A2 pseudogene 5","metadata":null},{"id":"4eb7990981244241b0d937b7bc22b5c6","type":"GENE","name":"EIF4A3","canonical_id":"hgnc:HGNC:18683","description":"eukaryotic translation initiation factor 4A3","metadata":{"aliases":["KIAA0111","EIF4AIII","Fal1","DDX48"]}},{"id":"1f9b5a528de84b57b3dfb75dd9cbf3ba","type":"GENE","name":"EIF4A3P1","canonical_id":"hgnc:HGNC:51460","description":"eukaryotic translation initiation factor 4A3 pseudogene 1","metadata":null},{"id":"e5b245c5938d4a668a5fb639eb616b20","type":"GENE","name":"EIF4B","canonical_id":"hgnc:HGNC:3285","description":"eukaryotic translation initiation factor 4B","metadata":null},{"id":"c67df6cccd7d4e628c1d1db3a1adbd1c","type":"GENE","name":"EIF4BP1","canonical_id":"hgnc:HGNC:19929","description":"eukaryotic translation initiation factor 4B pseudogene 1","metadata":{"aliases":["EIF4BP"]}},{"id":"4354e48de57a483e8f75739633b3c9c9","type":"GENE","name":"EIF4BP2","canonical_id":"hgnc:HGNC:37935","description":"eukaryotic translation initiation factor 4B pseudogene 2","metadata":null},{"id":"e1b7f9aaba0c43f4b38e914116684734","type":"GENE","name":"EIF4BP3","canonical_id":"hgnc:HGNC:37936","description":"eukaryotic translation initiation factor 4B pseudogene 3","metadata":null},{"id":"80c1a4bf4ed0448b806d9e9ab533553b","type":"GENE","name":"EIF4BP4","canonical_id":"hgnc:HGNC:37937","description":"eukaryotic translation initiation factor 4B pseudogene 4","metadata":null},{"id":"1dcfaf4d8e544f52a223e676cb9b0f84","type":"GENE","name":"EIF4BP5","canonical_id":"hgnc:HGNC:37938","description":"eukaryotic translation initiation factor 4B pseudogene 5","metadata":null},{"id":"150b3de1748c4f2f8978983a997ffeda","type":"GENE","name":"EIF4BP6","canonical_id":"hgnc:HGNC:37939","description":"eukaryotic translation initiation factor 4B pseudogene 6","metadata":null},{"id":"63ad091ef55d4b66bc5fc876a3f7f98f","type":"GENE","name":"EIF4BP7","canonical_id":"hgnc:HGNC:37940","description":"eukaryotic translation initiation factor 4B pseudogene 7","metadata":null},{"id":"216acf28928d40268645399b5ec2adcc","type":"GENE","name":"EIF4BP8","canonical_id":"hgnc:HGNC:37941","description":"eukaryotic translation initiation factor 4B pseudogene 8","metadata":null},{"id":"8ed0d85665704c638b95d56c0467c548","type":"GENE","name":"EIF4BP9","canonical_id":"hgnc:HGNC:37942","description":"eukaryotic translation initiation factor 4B pseudogene 9","metadata":null},{"id":"8da550dc968c46dd9ae7180b79d76b89","type":"GENE","name":"EIF4E","canonical_id":"hgnc:HGNC:3287","description":"eukaryotic translation initiation factor 4E","metadata":{"aliases":["EIF4E1","EIF4EL1","EIF4F"]}},{"id":"92062cc85883412ca9b5433ea1718356","type":"GENE","name":"EIF4E1B","canonical_id":"hgnc:HGNC:33179","description":"eukaryotic translation initiation factor 4E family member 1B","metadata":{"aliases":["FLJ36951"]}},{"id":"6b4a1bb596dd4f32aea2813810e3a640","type":"GENE","name":"EIF4E2","canonical_id":"hgnc:HGNC:3293","description":"eukaryotic translation initiation factor 4E family member 2","metadata":{"aliases":["IF4e","4EHP","EIF4EL3"]}},{"id":"c3f718c62e7748b3aafa5ae0d198e651","type":"GENE","name":"EIF4E2P1","canonical_id":"hgnc:HGNC:16237","description":"eukaryotic translation initiation factor 4E family member 2 pseudogene 1","metadata":{"aliases":["dJ1049G11.3","EIF4EL4"]}},{"id":"d42dda58f95f453db018961706a3b352","type":"GENE","name":"EIF4E2P2","canonical_id":"hgnc:HGNC:51464","description":"eukaryotic translation initiation factor 4E family member 2 pseudogene 2","metadata":null},{"id":"64c411a9ffbc4f93a1a69effb1624988","type":"GENE","name":"EIF4E3","canonical_id":"hgnc:HGNC:31837","description":"eukaryotic translation initiation factor 4E family member 3","metadata":{"aliases":["MGC39820"]}},{"id":"187f0af60e134c92bababd30b5cebb58","type":"GENE","name":"EIF4EBP1","canonical_id":"hgnc:HGNC:3288","description":"eukaryotic translation initiation factor 4E binding protein 1","metadata":{"aliases":["PHAS-I","4E-BP1"]}},{"id":"d19104bf6a7a4c8bb1f3bf9944a69f62","type":"GENE","name":"EIF4EBP1P1","canonical_id":"hgnc:HGNC:20160","description":"eukaryotic translation initiation factor 4E binding protein 1 pseudogene 1","metadata":{"aliases":["EIF4EBP1P"]}},{"id":"f06d317f4f0d47bdb0d4ede52f48e0bb","type":"GENE","name":"EIF4EBP1P2","canonical_id":"hgnc:HGNC:44047","description":"eukaryotic translation initiation factor 4E binding protein 1 pseudogene 2","metadata":null},{"id":"c4b96bc415ea451a9c07b4463071476d","type":"GENE","name":"EIF4EBP2","canonical_id":"hgnc:HGNC:3289","description":"eukaryotic translation initiation factor 4E binding protein 2","metadata":null},{"id":"8061f9e433b5469bb5c57a5105516397","type":"GENE","name":"EIF4EBP2P1","canonical_id":"hgnc:HGNC:16596","description":"eukaryotic translation initiation factor 4E binding protein 2 pseudogene 1","metadata":{"aliases":["dJ862K6.3","EIF4EBP2P"]}},{"id":"4e0e86863f63401abbe9b8429c51d464","type":"GENE","name":"EIF4EBP2P2","canonical_id":"hgnc:HGNC:49317","description":"eukaryotic translation initiation factor 4E binding protein 2 pseudogene 2","metadata":null},{"id":"092f678571f94e3482c35abdc558b9ca","type":"GENE","name":"EIF4EBP2P3","canonical_id":"hgnc:HGNC:49318","description":"eukaryotic translation initiation factor 4E binding protein 2 pseudogene 3","metadata":null},{"id":"2ff69e81019f434c97d1780a493fd628","type":"GENE","name":"EIF4EBP3","canonical_id":"hgnc:HGNC:3290","description":"eukaryotic translation initiation factor 4E binding protein 3","metadata":{"aliases":["4E-BP3"]}},{"id":"c022263e7ebd4462a07b4a41ff3878d8","type":"GENE","name":"EIF4ENIF1","canonical_id":"hgnc:HGNC:16687","description":"eukaryotic translation initiation factor 4E nuclear import factor 1","metadata":{"aliases":["4E-T","FLJ21601","Clast4","2610509L04Rik"]}},{"id":"42dabe9525ea4ab69ef5a85b89bfac51","type":"GENE","name":"EIF4EP1","canonical_id":"hgnc:HGNC:3292","description":"eukaryotic translation initiation factor 4E pseudogene 1","metadata":{"aliases":["dJ1022P6.3","EIF4EL2"]}},{"id":"3c5d7d9ca88c474d992d514cc3b18a23","type":"GENE","name":"EIF4EP2","canonical_id":"hgnc:HGNC:32428","description":"eukaryotic translation initiation factor 4E pseudogene 2","metadata":null},{"id":"eb549b6ae6674aedb5ff2f52ec56c0e5","type":"GENE","name":"EIF4EP3","canonical_id":"hgnc:HGNC:51461","description":"eukaryotic translation initiation factor 4E pseudogene 3","metadata":null},{"id":"c73577c284344c3bb20dfa0963f1d5e3","type":"GENE","name":"EIF4EP4","canonical_id":"hgnc:HGNC:51462","description":"eukaryotic translation initiation factor 4E pseudogene 4","metadata":null},{"id":"0d6dc5e664c5425d9c31bb10ebfa10a1","type":"GENE","name":"EIF4EP5","canonical_id":"hgnc:HGNC:51463","description":"eukaryotic translation initiation factor 4E pseudogene 5","metadata":null},{"id":"c2e371a9aadf41c3b7dcf594c284f28d","type":"GENE","name":"EIF4G1","canonical_id":"hgnc:HGNC:3296","description":"eukaryotic translation initiation factor 4 gamma 1","metadata":{"aliases":["p220","PARK18","EIF4G","EIF4F"]}},{"id":"1be360e6788c4fc18bfe73dc6cbb25c4","type":"GENE","name":"EIF4G2","canonical_id":"hgnc:HGNC:3297","description":"eukaryotic translation initiation factor 4 gamma 2","metadata":{"aliases":["DAP5","NAT1","p97"]}},{"id":"72915c6200aa45be869e336c5150745f","type":"GENE","name":"EIF4G3","canonical_id":"hgnc:HGNC:3298","description":"eukaryotic translation initiation factor 4 gamma 3","metadata":{"aliases":["eIF4GII"]}},{"id":"96f4fcb4ef6d4b1dbedb76e1906e72dd","type":"GENE","name":"EIF4H","canonical_id":"hgnc:HGNC:12741","description":"eukaryotic translation initiation factor 4H","metadata":{"aliases":["WSCR1","KIAA0038","WBSCR1"]}},{"id":"b887c70879dd4dc183ab2d146e9a87f3","type":"GENE","name":"EIF4HP1","canonical_id":"hgnc:HGNC:49035","description":"eukaryotic translation initiation factor 4H pseudogene 1","metadata":null},{"id":"e988645a7b1143d0b85f866193e1f77a","type":"GENE","name":"EIF4HP2","canonical_id":"hgnc:HGNC:49036","description":"eukaryotic translation initiation factor 4H pseudogene 2","metadata":null},{"id":"e3022f40b52d4970a2d1cfdf89f1bf81","type":"GENE","name":"EIF5","canonical_id":"hgnc:HGNC:3299","description":"eukaryotic translation initiation factor 5","metadata":null},{"id":"fd37c8dd84b04c77850f03145bdd91fa","type":"GENE","name":"EIF5-DT","canonical_id":"hgnc:HGNC:56080","description":"EIF5 divergent transcript","metadata":null},{"id":"b6da97285a4b49ba900b47314207f63d","type":"GENE","name":"EIF5A","canonical_id":"hgnc:HGNC:3300","description":"eukaryotic translation initiation factor 5A","metadata":{"aliases":["eIF-4D","EIF5A1","EIF-5A","MGC99547","MGC104255"]}},{"id":"2ab4a2eafa954997a1e08651b99fb1bf","type":"GENE","name":"EIF5A2","canonical_id":"hgnc:HGNC:3301","description":"eukaryotic translation initiation factor 5A2","metadata":null},{"id":"85c61fc7990c4c3689220feecfb098ba","type":"GENE","name":"EIF5A2P1","canonical_id":"hgnc:HGNC:51467","description":"eukaryotic translation initiation factor 5A2 pseudogene 1","metadata":null},{"id":"613075e405f842f1bcfa41b2e62601fd","type":"GENE","name":"EIF5AL1","canonical_id":"hgnc:HGNC:17419","description":"eukaryotic translation initiation factor 5A like 1","metadata":{"aliases":["bA342M3.3","EIF5AP1"]}},{"id":"3fd8f16936bd44948b553c71e02a56e4","type":"GENE","name":"EIF5AP2","canonical_id":"hgnc:HGNC:3303","description":"eukaryotic translation initiation factor 5A pseudogene 2","metadata":null},{"id":"39b68ecdb665454ca9aa1396d0e3f31a","type":"GENE","name":"EIF5AP3","canonical_id":"hgnc:HGNC:3304","description":"eukaryotic translation initiation factor 5A pseudogene 3","metadata":null},{"id":"d5d25e6263774d2a87957d1b607d1c3d","type":"GENE","name":"EIF5AP4","canonical_id":"hgnc:HGNC:31442","description":"eukaryotic translation initiation factor 5A pseudogene 4","metadata":{"aliases":["EIF5AL3"]}},{"id":"d2a82bb7ca5b4458a2af3a22aa542f2f","type":"GENE","name":"EIF5B","canonical_id":"hgnc:HGNC:30793","description":"eukaryotic translation initiation factor 5B","metadata":{"aliases":["IF2","KIAA0741","DKFZp434I036","FLJ10524"]}},{"id":"0f71c5e16bd543de99f91af3a8b9f0c7","type":"GENE","name":"EIF5P1","canonical_id":"hgnc:HGNC:51465","description":"eukaryotic translation initiation factor 5 pseudogene 1","metadata":null},{"id":"0fcdc1ad8cae4ffeb4aaf5532d2bc86b","type":"GENE","name":"EIF5P2","canonical_id":"hgnc:HGNC:51466","description":"eukaryotic translation initiation factor 5 pseudogene 2","metadata":null},{"id":"6fe0d3a201bc45c7b907e06a67b141cd","type":"GENE","name":"EIF6","canonical_id":"hgnc:HGNC:6159","description":"eukaryotic translation initiation factor 6","metadata":{"aliases":["p27BBP","b(2)gcn","EIF3A","ITGB4BP"]}},{"id":"1b81c845ff8346b8a6ad44764bb686c7","type":"TRIAL","name":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","canonical_id":"clinicaltrials.gov:NCT02234843","description":"Venous Thromboembolism","metadata":null},{"id":"842622e562a24e888f5ba7a246344538","type":"GENE","name":"EIPR1","canonical_id":"hgnc:HGNC:12383","description":"EARP complex and GARP complex interacting protein 1","metadata":{"aliases":["EIPR-1","TSSC1"]}},{"id":"46ee7d07e013442a8a271de2f14832dc","type":"GENE","name":"EIPR1-IT1","canonical_id":"hgnc:HGNC:41392","description":"EIPR1 intronic transcript 1","metadata":{"aliases":["TSSC1-IT1"]}},{"id":"e7eaf7b562034e7eb5c2a6812cff942f","type":"GO_TERM","name":"EKC/KEOPS complex","canonical_id":"go:GO:0000408","description":"\"A protein complex involved in t6A tRNA modification. For example, in Saccharomyces cerevisiae the complex contains Bud32p, Kae1p, Gon7p, Cgi121p, and Pcc1p.\" [GOC:elh, GOC:vw, PMID:16564010, PMID:16874308, PMID:21183954, PMID:23945934]","metadata":null},{"id":"fa4235061124487cbbc57a40e3dc2bcf","type":"GENE","name":"ELAC1","canonical_id":"hgnc:HGNC:14197","description":"elaC ribonuclease Z 1","metadata":{"aliases":["D29"]}},{"id":"91012d77cb93416d9448ac84564540ef","type":"GENE","name":"ELAC2","canonical_id":"hgnc:HGNC:14198","description":"elaC ribonuclease Z 2","metadata":{"aliases":["FLJ10530","HPC2"]}},{"id":"5006f311bf5e4da2aefe03b07c05432a","type":"GENE","name":"ELANE","canonical_id":"hgnc:HGNC:3309","description":null,"metadata":null},{"id":"b8712fd0019b4d1ca38bb6b785c5d311","type":"PROTEIN","name":"ELANE","canonical_id":"uniprot:P08246","description":null,"metadata":null},{"id":"5e2cb5b2c21041ad8723826bc03130f3","type":"GENE","name":"ELAPOR1","canonical_id":"hgnc:HGNC:29618","description":"endosome-lysosome associated apoptosis and autophagy regulator 1","metadata":{"aliases":["maba1","EIG121","KIAA1324"]}},{"id":"5a2ab5e15b784ff19a87cf7229789a71","type":"GENE","name":"ELAPOR2","canonical_id":"hgnc:HGNC:21945","description":"endosome-lysosome associated apoptosis and autophagy regulator family member 2","metadata":{"aliases":["FLJ31340","EIG121L","KIAA1324L"]}},{"id":"c8364acc048d43e5b252207581cd2b33","type":"GENE","name":"ELAVL1","canonical_id":"hgnc:HGNC:3312","description":null,"metadata":null},{"id":"f9161ced36ff463ab8ddb4899f51eb92","type":"GENE","name":"ELAVL2","canonical_id":"hgnc:HGNC:3313","description":"ELAV like RNA binding protein 2","metadata":{"aliases":["HuB","HEL-N1"]}},{"id":"a319ede0b0cf4e6f89b0d0b29b90188e","type":"GENE","name":"ELAVL3","canonical_id":"hgnc:HGNC:3314","description":"ELAV like RNA binding protein 3","metadata":{"aliases":["HUC","PLE21","DKFZp547J036","HUCL","MGC20653"]}},{"id":"ee6c58516416493784715a242b4c680a","type":"GENE","name":"ELAVL4","canonical_id":"hgnc:HGNC:3315","description":"ELAV like RNA binding protein 4","metadata":{"aliases":["PNEM","HUD"]}},{"id":"7534d47aedb94c93ad71f5685edc7f1d","type":"GENE","name":"ELAVL4-AS1","canonical_id":"hgnc:HGNC:40210","description":"ELAVL4 antisense RNA 1","metadata":null},{"id":"db35955168094f2ebc984f9257ab0eb0","type":"GENE","name":"ELDR","canonical_id":"hgnc:HGNC:49511","description":"EGFR long non-coding downstream RNA","metadata":{"aliases":["Fabl","LINC01156"]}},{"id":"6b971c1d2a3e49d3b2aa8bd39d402f09","type":"GENE","name":"ELF1","canonical_id":"hgnc:HGNC:3316","description":null,"metadata":null},{"id":"c3964783a10940d68f86ac5f16d0d0a6","type":"GENE","name":"ELF2","canonical_id":"hgnc:HGNC:3317","description":null,"metadata":null},{"id":"6ff96a49ed86405094a2cdb58896e797","type":"GENE","name":"ELF2-DT","canonical_id":"hgnc:HGNC:58885","description":"ELF2 divergent transcript","metadata":null},{"id":"3e9062edcccb429084959d109466011f","type":"GENE","name":"ELF2P1","canonical_id":"hgnc:HGNC:33539","description":"ELF2 pseudogene 1","metadata":null},{"id":"28751153df9f4e17a61cad3d8584099d","type":"GENE","name":"ELF2P2","canonical_id":"hgnc:HGNC:24610","description":"ELF2 pseudogene 2","metadata":null},{"id":"9d9b36ca2bce4c5baaa231c42afa3292","type":"GENE","name":"ELF2P3","canonical_id":"hgnc:HGNC:24611","description":"ELF2 pseudogene 3","metadata":null},{"id":"33e2b058ca524da1bf9a0f2728a21b87","type":"GENE","name":"ELF2P4","canonical_id":"hgnc:HGNC:33540","description":"ELF2 pseudogene 4","metadata":null},{"id":"ffe2d47a15f247e082e02e9686dc8c59","type":"GENE","name":"ELF3","canonical_id":"hgnc:HGNC:3318","description":null,"metadata":null},{"id":"a6f842593b764f20ba12c2a0c8842d2e","type":"GENE","name":"ELF3-AS1","canonical_id":"hgnc:HGNC:40211","description":"ELF3 antisense RNA 1","metadata":{"aliases":["ENST00000415582","SCAT7"]}},{"id":"237ae03d57a8483aacfe5ae4f18c85de","type":"GENE","name":"ELF4","canonical_id":"hgnc:HGNC:3319","description":null,"metadata":null},{"id":"7c1609bf8ebc479994ae99d2b4e5589f","type":"GENE","name":"ELF5","canonical_id":"hgnc:HGNC:3320","description":"E74 like ETS transcription factor 5","metadata":null},{"id":"92062854f5d84ae6b0a0aa38714e4de5","type":"GENE","name":"ELFN1","canonical_id":"hgnc:HGNC:33154","description":"extracellular leucine rich repeat and fibronectin type III domain containing 1","metadata":{"aliases":["PPP1R28"]}},{"id":"42cc43e7fcb44ccbb201d02ad9a9d260","type":"GENE","name":"ELFN1-AS1","canonical_id":"hgnc:HGNC:39071","description":"ELFN1 antisense RNA 1","metadata":{"aliases":["MYCLo-2"]}},{"id":"6651d1a7964044739368911e297a57c1","type":"GENE","name":"ELFN2","canonical_id":"hgnc:HGNC:29396","description":"extracellular leucine rich repeat and fibronectin type III domain containing 2","metadata":{"aliases":["dJ63G5.3","KIAA1904","LRRC62","PPP1R29"]}},{"id":"1cf92aeec8cd4555b8d641c6bcd321b1","type":"GENE","name":"ELFN2-AS1","canonical_id":"hgnc:HGNC:58610","description":"ELFN2 antisense RNA 1","metadata":null},{"id":"dd312e732cec40a5bcd5b4fb4305fa28","type":"TRIAL","name":"ELISA in Relapsed/Refractory MM","canonical_id":"clinicaltrials.gov:NCT06832865","description":"Relapsed Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma","metadata":null},{"id":"7db912aa15234e7bbce3306be20b14ef","type":"GENE","name":"ELK1","canonical_id":"hgnc:HGNC:3321","description":null,"metadata":null},{"id":"4e37064d5d08485c94e312e40b4e7fa5","type":"GENE","name":"ELK1P1","canonical_id":"hgnc:HGNC:39021","description":"ELK1 pseudogene 1","metadata":null},{"id":"880f420252b249b5a64257d679972248","type":"GENE","name":"ELK2AP","canonical_id":"hgnc:HGNC:3323","description":"ETS transcription factor ELK2A, pseudogene","metadata":{"aliases":["ELK2.1","ELK2","ELK2P1"]}},{"id":"9479fbcda3f1488a8041374d33a54e0d","type":"GENE","name":"ELK2BP","canonical_id":"hgnc:HGNC:3324","description":"ETS transcription factor ELK2B, pseudogene","metadata":{"aliases":["ELK2.2","ELK2P2"]}},{"id":"77c14fbc39e94821af07660ea33b9936","type":"GENE","name":"ELK3","canonical_id":"hgnc:HGNC:3325","description":null,"metadata":null},{"id":"fedd3194999b45e1be64a7f7e35ab296","type":"GENE","name":"ELK4","canonical_id":"hgnc:HGNC:3326","description":null,"metadata":null},{"id":"83df5d9ceb834527a0399c4f9d55516d","type":"GENE","name":"ELL","canonical_id":"hgnc:HGNC:23114","description":null,"metadata":null},{"id":"c9eddc14a6dc4eed9091492b88d79f81","type":"GENE","name":"ELL2","canonical_id":"hgnc:HGNC:17064","description":"elongation factor for RNA polymerase II 2","metadata":{"aliases":["MRCCAT1"]}},{"id":"6d7f6adccdb74532ab6ab83f3dc0a207","type":"GENE","name":"ELL2P1","canonical_id":"hgnc:HGNC:39343","description":"elongation factor for RNA polymerase II 2 pseudogene 1","metadata":null},{"id":"a1de2ea84db94c26a2f81f1143539ee4","type":"GENE","name":"ELL2P2","canonical_id":"hgnc:HGNC:39344","description":"elongation factor for RNA polymerase II 2 pseudogene 2","metadata":null},{"id":"19e1b0e3c14d453ab38067740f8b97af","type":"GENE","name":"ELL2P3","canonical_id":"hgnc:HGNC:39345","description":"elongation factor for RNA polymerase II 2 pseudogene 3","metadata":null},{"id":"bfcf1c671f1b4b0d8c8be0d7e99c6b4b","type":"GENE","name":"ELL2P4","canonical_id":"hgnc:HGNC:39346","description":"elongation factor for RNA polymerase II 2 pseudogene 4","metadata":null},{"id":"101892cfa5424ee393741410b631f495","type":"GENE","name":"ELL3","canonical_id":"hgnc:HGNC:23113","description":"elongation factor for RNA polymerase II 3","metadata":{"aliases":["FLJ22637"]}},{"id":"583cc6ab8c114c7da4879075a81894f4","type":"GENE","name":"ELMO1","canonical_id":"hgnc:HGNC:16286","description":"engulfment and cell motility 1","metadata":{"aliases":["KIAA0281","CED12","ELMO-1","CED-12"]}},{"id":"295e4e8800c248b2b88b3c8430bb4949","type":"GENE","name":"ELMO1-AS1","canonical_id":"hgnc:HGNC:40765","description":"ELMO1 antisense RNA 1","metadata":null},{"id":"ad1742dc9962464087f3361f3204883c","type":"GENE","name":"ELMO2","canonical_id":"hgnc:HGNC:17233","description":"engulfment and cell motility 2","metadata":{"aliases":["CED12","ELMO-2","CED-12","KIAA1834","FLJ11656"]}},{"id":"f48ae945c19d423e9927c42820b3a2d7","type":"GENE","name":"ELMO2P1","canonical_id":"hgnc:HGNC:38008","description":"engulfment and cell motility 2 pseudogene 1","metadata":null},{"id":"62418776ee234cc597f99b0b18616f1d","type":"GENE","name":"ELMO3","canonical_id":"hgnc:HGNC:17289","description":null,"metadata":null},{"id":"665bc82c6f214f22ae8711d969c38145","type":"GENE","name":"ELMOD1","canonical_id":"hgnc:HGNC:25334","description":"ELMO domain containing 1","metadata":{"aliases":["DKFZp547C176"]}},{"id":"5b24345037144f8397a529f1a24256d4","type":"GENE","name":"ELMOD2","canonical_id":"hgnc:HGNC:28111","description":"ELMO domain containing 2","metadata":{"aliases":["MGC10084"]}},{"id":"823f55f2d77f45e29e97c57cbde5fe51","type":"GENE","name":"ELMOD3","canonical_id":"hgnc:HGNC:26158","description":"ELMO domain containing 3","metadata":{"aliases":["FLJ21977","RBM29","RBED1","DFNB88"]}},{"id":"e5b3266bbb104d12b630826fb450d51c","type":"GENE","name":"ELN","canonical_id":"hgnc:HGNC:3327","description":null,"metadata":null},{"id":"7027d7ff05c144de86d33d5515583067","type":"GENE","name":"ELN-AS1","canonical_id":"hgnc:HGNC:40212","description":"ELN antisense RNA 1","metadata":{"aliases":["CTB-51J22.1"]}},{"id":"328df048a5f84de59f6b4b25d31fc3eb","type":"GENE","name":"ELOA","canonical_id":"hgnc:HGNC:11620","description":"elongin A","metadata":{"aliases":["SIII","TCEB3A","ELOA1","TCEB3"]}},{"id":"78cc4bfb398d4e6d9682c43612779883","type":"GENE","name":"ELOA-AS1","canonical_id":"hgnc:HGNC:50582","description":"ELOA antisense RNA 1","metadata":{"aliases":["TCEB3-AS1"]}},{"id":"55892607d4de49bcb68ffb9ef64b4c08","type":"GENE","name":"ELOA2","canonical_id":"hgnc:HGNC:30771","description":"elongin A2","metadata":{"aliases":["HsT832","TCEB3L","TCEB3B"]}},{"id":"94d3d0bec7464d7480e1c3f36d730f01","type":"GENE","name":"ELOA3BP","canonical_id":"hgnc:HGNC:31007","description":"elongin A3 family member B, pseudogene","metadata":{"aliases":["HsT828","TCEB3CL","ELOA3B"]}},{"id":"3248684894e14a7fb97b83cc781d7cbe","type":"GENE","name":"ELOA3CP","canonical_id":"hgnc:HGNC:52410","description":"elongin A3 family member C, pseudogene","metadata":{"aliases":["ELOA3C"]}},{"id":"6a123bafa5d24f10a5f816ded2613b83","type":"GENE","name":"ELOA3DP","canonical_id":"hgnc:HGNC:33511","description":"elongin A3 family member D, pseudogene","metadata":{"aliases":["TCEB3CL2","ELOA3D"]}},{"id":"5a8c45ac1064482eaa4365d777fe227e","type":"GENE","name":"ELOA3P","canonical_id":"hgnc:HGNC:24617","description":"elongin A3, pseudogene","metadata":{"aliases":["HsT829","TCEB3L2","ELOA3A","ELOA3AP","TCEB3C","ELOA3"]}},{"id":"6d9780dddb144b55bf61f279e0c0a920","type":"GENE","name":"ELOAP1","canonical_id":"hgnc:HGNC:54534","description":"ELOA pseudogene 1","metadata":null},{"id":"a1bc8d59d74643c28cd7c39c68317ca6","type":"GENE","name":"ELOB","canonical_id":"hgnc:HGNC:11619","description":"elongin B","metadata":{"aliases":["SIII","TCEB2"]}},{"id":"012900e1cda94949b339903744ea65e7","type":"GENE","name":"ELOBP1","canonical_id":"hgnc:HGNC:39719","description":"elongin B pseudogene 1","metadata":{"aliases":["TCEB2P1"]}},{"id":"c55034d8455e4b8d89cab63eec754cc8","type":"GENE","name":"ELOBP2","canonical_id":"hgnc:HGNC:39720","description":"elongin B pseudogene 2","metadata":{"aliases":["TCEB2P2"]}},{"id":"6f92d1fc03cc41ec97a34a24b733fd0d","type":"GENE","name":"ELOBP3","canonical_id":"hgnc:HGNC:39721","description":"elongin B pseudogene 3","metadata":{"aliases":["TCEB2P3"]}},{"id":"01177edc1def4124a715f38db9685bd2","type":"GENE","name":"ELOBP4","canonical_id":"hgnc:HGNC:39722","description":"elongin B pseudogene 4","metadata":{"aliases":["TCEB2P4"]}},{"id":"5114fa21c7ab43a9b83da8c68755fc58","type":"GENE","name":"ELOC","canonical_id":"hgnc:HGNC:11617","description":"elongin C","metadata":{"aliases":["SIII","TCEB1"]}},{"id":"f7fdfad4d0994cea944caf5901bd3f7c","type":"GENE","name":"ELOCP10","canonical_id":"hgnc:HGNC:38146","description":"elongin C pseudogene 10","metadata":{"aliases":["TCEB1P10"]}},{"id":"791f0c6a53a14b40bb23c9ba47ebf28a","type":"GENE","name":"ELOCP11","canonical_id":"hgnc:HGNC:38147","description":"elongin C pseudogene 11","metadata":{"aliases":["TCEB1P11"]}},{"id":"f7f1f112f98049d992070fb7ffb6cc39","type":"GENE","name":"ELOCP12","canonical_id":"hgnc:HGNC:38148","description":"elongin C pseudogene 12","metadata":{"aliases":["TCEB1P12"]}},{"id":"4e7393087b294664a48c4d84b7deaa49","type":"GENE","name":"ELOCP13","canonical_id":"hgnc:HGNC:38149","description":"elongin C pseudogene 13","metadata":{"aliases":["TCEB1P13"]}},{"id":"67ccc1af3a8641dab08fce082967dd0b","type":"GENE","name":"ELOCP14","canonical_id":"hgnc:HGNC:38150","description":"elongin C pseudogene 14","metadata":{"aliases":["TCEB1P14"]}},{"id":"52893f7e8cf54b1dbab995b5a28ced10","type":"GENE","name":"ELOCP15","canonical_id":"hgnc:HGNC:38151","description":"elongin C pseudogene 15","metadata":{"aliases":["TCEB1P15"]}},{"id":"85752b9bf9e84b48bf9d54c4d1942bc7","type":"GENE","name":"ELOCP16","canonical_id":"hgnc:HGNC:38152","description":"elongin C pseudogene 16","metadata":{"aliases":["TCEB1P16"]}},{"id":"2ec3459ef7dd40c0a8e21215ed18248d","type":"GENE","name":"ELOCP17","canonical_id":"hgnc:HGNC:38153","description":"elongin C pseudogene 17","metadata":{"aliases":["TCEB1P17"]}},{"id":"fa18128249da4367940985f7cc37253c","type":"GENE","name":"ELOCP18","canonical_id":"hgnc:HGNC:38154","description":"elongin C pseudogene 18","metadata":{"aliases":["TCEB1P18"]}},{"id":"22eb2e6f7d8b415887b3a36ea9fd014c","type":"GENE","name":"ELOCP19","canonical_id":"hgnc:HGNC:38155","description":"elongin C pseudogene 19","metadata":{"aliases":["TCEB1P19"]}},{"id":"3f2e2d1ca5804191ac28548d8cc433ad","type":"GENE","name":"ELOCP2","canonical_id":"hgnc:HGNC:17762","description":"elongin C pseudogene 2","metadata":{"aliases":["TCEB1P2"]}},{"id":"2e9bbd98c2b445d1bad157d6314c7ed9","type":"GENE","name":"ELOCP20","canonical_id":"hgnc:HGNC:38156","description":"elongin C pseudogene 20","metadata":{"aliases":["TCEB1P20"]}},{"id":"fd9ff4e4cd8b44068c2ac38509b884c1","type":"GENE","name":"ELOCP21","canonical_id":"hgnc:HGNC:38157","description":"elongin C pseudogene 21","metadata":{"aliases":["TCEB1P21"]}},{"id":"c3e274a1d82e4133a52423c40e270aa9","type":"GENE","name":"ELOCP22","canonical_id":"hgnc:HGNC:38158","description":"elongin C pseudogene 22","metadata":{"aliases":["TCEB1P22"]}},{"id":"48709eb84e0743cd9ddb0b7815658a44","type":"GENE","name":"ELOCP23","canonical_id":"hgnc:HGNC:38159","description":"elongin C pseudogene 23","metadata":{"aliases":["TCEB1P23"]}},{"id":"b8d4684184ae4274848054ced1dafac6","type":"GENE","name":"ELOCP24","canonical_id":"hgnc:HGNC:38160","description":"elongin C pseudogene 24","metadata":{"aliases":["TCEB1P25","TCEB1P24"]}},{"id":"c28df8fbe7e944f681885273017cd0e4","type":"GENE","name":"ELOCP26","canonical_id":"hgnc:HGNC:38731","description":"elongin C pseudogene 26","metadata":{"aliases":["TCEB1P26"]}},{"id":"a880830afc2743fcbf80b11fd50bd1cd","type":"GENE","name":"ELOCP27","canonical_id":"hgnc:HGNC:31692","description":"elongin C pseudogene 27","metadata":{"aliases":["TCEB1P27"]}},{"id":"38aeff0a1833457cb77b072d281ee0bf","type":"GENE","name":"ELOCP28","canonical_id":"hgnc:HGNC:49169","description":"elongin C pseudogene 28","metadata":{"aliases":["TCEB1P28"]}},{"id":"7ad9f1a8dfd645ffb1a365e13231daea","type":"GENE","name":"ELOCP29","canonical_id":"hgnc:HGNC:49170","description":"elongin C pseudogene 29","metadata":{"aliases":["TCEB1P29"]}},{"id":"ff6dcd4676af4be983790c5c0a445c72","type":"GENE","name":"ELOCP3","canonical_id":"hgnc:HGNC:29457","description":"elongin C pseudogene 3","metadata":{"aliases":["dJ254P11.1","TCEB1P3"]}},{"id":"1a75cd4ed4894c499647e0703179aacc","type":"GENE","name":"ELOCP30","canonical_id":"hgnc:HGNC:49171","description":"elongin C pseudogene 30","metadata":{"aliases":["TCEB1P30"]}},{"id":"5936be6cd4e64b26ad225f9026e7001e","type":"GENE","name":"ELOCP31","canonical_id":"hgnc:HGNC:49172","description":"elongin C pseudogene 31","metadata":{"aliases":["TCEB1P31"]}},{"id":"d94a6b357893418bbc8b94819bd35331","type":"GENE","name":"ELOCP32","canonical_id":"hgnc:HGNC:49173","description":"elongin C pseudogene 32","metadata":{"aliases":["TCEB1P32"]}},{"id":"ef73808d740f4fba97601a14792de07a","type":"GENE","name":"ELOCP33","canonical_id":"hgnc:HGNC:49174","description":"elongin C pseudogene 33","metadata":{"aliases":["TCEB1P33"]}},{"id":"dfd10367c9124410ab4d8c9e766815ed","type":"GENE","name":"ELOCP34","canonical_id":"hgnc:HGNC:49175","description":"elongin C pseudogene 34","metadata":{"aliases":["TCEB1P34"]}},{"id":"88ae81e7563e4ea9a0821e58d926f70b","type":"GENE","name":"ELOCP35","canonical_id":"hgnc:HGNC:49176","description":"elongin C pseudogene 35","metadata":{"aliases":["TCEB1P35"]}},{"id":"b3f7774b58a342e39aa84d943d976158","type":"GENE","name":"ELOCP36","canonical_id":"hgnc:HGNC:54973","description":"elongin C pseudogene 36","metadata":null},{"id":"6e3dbf8ffc354e6bad986759ee8ad43a","type":"GENE","name":"ELOCP4","canonical_id":"hgnc:HGNC:38141","description":"elongin C pseudogene 4","metadata":{"aliases":["TCEB1P4"]}},{"id":"cf043eed0bb04183b562142c89d5bc84","type":"GENE","name":"ELOCP5","canonical_id":"hgnc:HGNC:38140","description":"elongin C pseudogene 5","metadata":{"aliases":["TCEB1P5"]}},{"id":"33e30b79dbc84dcebb862e238ed896d9","type":"GENE","name":"ELOCP6","canonical_id":"hgnc:HGNC:38142","description":"elongin C pseudogene 6","metadata":{"aliases":["TCEB1P6"]}},{"id":"3380c2c03d5e42e58f3f228c318593bb","type":"GENE","name":"ELOCP7","canonical_id":"hgnc:HGNC:38143","description":"elongin C pseudogene 7","metadata":{"aliases":["TCEB1P7"]}},{"id":"6fa9407a7a194a63a50154895f514dae","type":"GENE","name":"ELOCP8","canonical_id":"hgnc:HGNC:38144","description":"elongin C pseudogene 8","metadata":{"aliases":["TCEB1P8"]}},{"id":"0bdc1f01f58541948aa75562edce245b","type":"GENE","name":"ELOCP9","canonical_id":"hgnc:HGNC:38145","description":"elongin C pseudogene 9","metadata":{"aliases":["TCEB1P9"]}},{"id":"c5b2b70d216d49a18da07c1600c00051","type":"GENE","name":"ELOF1","canonical_id":"hgnc:HGNC:28691","description":"elongation factor 1","metadata":{"aliases":["MGC4549","ELF1"]}},{"id":"ec25abf3cbeb4ccd804373858b5d9ad9","type":"GENE","name":"ELOVL1","canonical_id":"hgnc:HGNC:14418","description":"ELOVL fatty acid elongase 1","metadata":{"aliases":["Ssc1"]}},{"id":"61f492a0e1d94af7815bb8902c523742","type":"GENE","name":"ELOVL2","canonical_id":"hgnc:HGNC:14416","description":"ELOVL fatty acid elongase 2","metadata":{"aliases":["Ssc2"]}},{"id":"e355df3b2ea84bba8d57850572ba31b0","type":"GENE","name":"ELOVL2-AS1","canonical_id":"hgnc:HGNC:44156","description":"ELOVL2 antisense RNA 1","metadata":null},{"id":"2fadc87d596441a78195f95376e3bada","type":"GENE","name":"ELOVL3","canonical_id":"hgnc:HGNC:18047","description":"ELOVL fatty acid elongase 3","metadata":{"aliases":["CIG-30"]}},{"id":"433a51b5dee546e7aa2f5178906a617a","type":"GENE","name":"ELOVL4","canonical_id":"hgnc:HGNC:14415","description":"ELOVL fatty acid elongase 4","metadata":{"aliases":["CT118","STGD2","STGD3","SCA34"]}},{"id":"533ebb154f6e4c2e93a93fdf31c0f8ce","type":"GENE","name":"ELOVL5","canonical_id":"hgnc:HGNC:21308","description":"ELOVL fatty acid elongase 5","metadata":{"aliases":["HELO1","dJ483K16.1","SCA38"]}},{"id":"9bbbb5ed55a84a0a89130a2f30db01d4","type":"GENE","name":"ELOVL6","canonical_id":"hgnc:HGNC:15829","description":"ELOVL fatty acid elongase 6","metadata":{"aliases":["FLJ23378","MGC5487","LCE"]}},{"id":"2cae83e3649942188e29c8ae5505d588","type":"GENE","name":"ELOVL6-AS1","canonical_id":"hgnc:HGNC:58869","description":"ELOVL6 antisense RNA 1","metadata":null},{"id":"40541f4cc64346498faed836f388241b","type":"GENE","name":"ELOVL7","canonical_id":"hgnc:HGNC:26292","description":"ELOVL fatty acid elongase 7","metadata":{"aliases":["FLJ23563"]}},{"id":"3658d39c037e45b0aeffa4fe20fb5111","type":"GENE","name":"ELP1","canonical_id":"hgnc:HGNC:5959","description":"elongator acetyltransferase complex subunit 1","metadata":{"aliases":["IKAP","TOT1","IKI3","DYS","IKBKAP"]}},{"id":"215fdf593dc74ee394929b4c3add22b6","type":"GENE","name":"ELP2","canonical_id":"hgnc:HGNC:18248","description":"elongator acetyltransferase complex subunit 2","metadata":{"aliases":["FLJ10879","StIP","STATIP1"]}},{"id":"f2af44d7d8564d7283550b2b3d40487b","type":"GENE","name":"ELP3","canonical_id":"hgnc:HGNC:20696","description":"elongator acetyltransferase complex subunit 3","metadata":{"aliases":["FLJ10422","KAT9"]}},{"id":"d5b43238a07e4e52a602ad10cbfb34c1","type":"GENE","name":"ELP4","canonical_id":"hgnc:HGNC:1171","description":"elongator acetyltransferase complex subunit 4","metadata":{"aliases":["PAXNEB","C11orf19"]}},{"id":"8daeec155db44508a10c164c9e5c3e4a","type":"GENE","name":"ELP4-AS1","canonical_id":"hgnc:HGNC:58222","description":"ELP4 antisense RNA 1","metadata":null},{"id":"b7d9a5ae9d144e4ab9bec95f9de33aa2","type":"GENE","name":"ELP5","canonical_id":"hgnc:HGNC:30617","description":"elongator acetyltransferase complex subunit 5","metadata":{"aliases":["DERP6","C17orf81"]}},{"id":"afa93b4bbb064797a99c992a960cbf5d","type":"GENE","name":"ELP6","canonical_id":"hgnc:HGNC:25976","description":"elongator acetyltransferase complex subunit 6","metadata":{"aliases":["FLJ20211","TMEM103","C3orf75"]}},{"id":"fcabd921e7cd4db18d7a1ad997556e2e","type":"GENE","name":"ELSPBP1","canonical_id":"hgnc:HGNC:14417","description":"epididymal sperm binding protein 1","metadata":{"aliases":["HE12","E12","EDDM12"]}},{"id":"f310f39a6f454775b2233b6e4605ea4a","type":"GO_TERM","name":"ELYC domain binding","canonical_id":"go:GO:0090542","description":"\"Binding to a ELYC protein domain. The ELYC domain is an approximately 150 amino acid sequence which contains a highly conserved tetrapeptide sequence, ELYC.\" [GOC:pm, PMID:18032582, PMID:19525971]","metadata":null},{"id":"79e642bd8c574c3e853a49ba20312628","type":"GENE","name":"EMB","canonical_id":"hgnc:HGNC:30465","description":"embigin","metadata":{"aliases":["MGC71745","GP70"]}},{"id":"ba056a70be114365a5d3cd656476a95d","type":"GENE","name":"EMB-AS1","canonical_id":"hgnc:HGNC:59039","description":"EMB antisense RNA 1","metadata":null},{"id":"c5f0600929b14ce6a99821128126dfa3","type":"GENE","name":"EMBP1","canonical_id":"hgnc:HGNC:38661","description":"embigin pseudogene 1","metadata":null},{"id":"d22966f11de4454aaf45eec273d341cf","type":"GO_TERM","name":"EMC complex","canonical_id":"go:GO:0072546","description":"\"A transmembrane protein complex located in the endoplasmic reticulum (ER) involved in the insertion of newly synthesized proteins in the membrane of the ER. In S. cerevisiae, it has six members: EMC1, EMC2, AIM27, EMC4, KRE27, and EMC6.\" [PMID:29242231, PMID:30415835, PMID:32459176]","metadata":null},{"id":"b433dd75d1144fe580eba3192880a99f","type":"GENE","name":"EMC1","canonical_id":"hgnc:HGNC:28957","description":"ER membrane protein complex subunit 1","metadata":{"aliases":["KIAA0090"]}},{"id":"23dab60b313d4b37937fbd82927343ea","type":"GENE","name":"EMC1-AS1","canonical_id":"hgnc:HGNC:54050","description":"EMC1 antisense RNA 1","metadata":null},{"id":"ee0cab6cf45446dc9fac8f8bdee0ee56","type":"GENE","name":"EMC10","canonical_id":"hgnc:HGNC:27609","description":"ER membrane protein complex subunit 10","metadata":{"aliases":["INM02","HSS1","HSM1","C19orf63"]}},{"id":"87e2a6e324c842be8d114ed44132146f","type":"GENE","name":"EMC2","canonical_id":"hgnc:HGNC:28963","description":"ER membrane protein complex subunit 2","metadata":{"aliases":["KIAA0103","TTC35"]}},{"id":"a68a8bcdc58149c5849e4437f41bf0a5","type":"GENE","name":"EMC3","canonical_id":"hgnc:HGNC:23999","description":"ER membrane protein complex subunit 3","metadata":{"aliases":["TMEM111"]}},{"id":"ee7c963bcf4b4c4b80814e7511efcbf0","type":"GENE","name":"EMC3-AS1","canonical_id":"hgnc:HGNC:49223","description":"EMC3 antisense RNA 1","metadata":null},{"id":"dde3ba70b44043a1874479be2adc3548","type":"GENE","name":"EMC4","canonical_id":"hgnc:HGNC:28032","description":"ER membrane protein complex subunit 4","metadata":{"aliases":["FLJ90746","MGC24415","PIG17","TMEM85"]}},{"id":"25fdfdb5162247aa8acabd3ad6fd9161","type":"GENE","name":"EMC6","canonical_id":"hgnc:HGNC:28430","description":"ER membrane protein complex subunit 6","metadata":{"aliases":["MGC2963","RAB5IFL","TMEM93"]}},{"id":"d64b7e10a78b4b76aa6a0bd58a8df651","type":"GENE","name":"EMC7","canonical_id":"hgnc:HGNC:24301","description":"ER membrane protein complex subunit 7","metadata":{"aliases":["C11orf3","C15orf24"]}},{"id":"11fd7147ae6c41f59224500014dc4cde","type":"GENE","name":"EMC8","canonical_id":"hgnc:HGNC:7864","description":"ER membrane protein complex subunit 8","metadata":{"aliases":["FAM158B","C16orf4","NOC4","C16orf2","COX4NB"]}},{"id":"b35683e84993493fb04a88ee22ab58dd","type":"GENE","name":"EMC9","canonical_id":"hgnc:HGNC:20273","description":"ER membrane protein complex subunit 9","metadata":{"aliases":["CGI-112","C14orf122","FAM158A"]}},{"id":"934efcc1dc1b4ba68ad38f5a37056192","type":"GENE","name":"EMCN","canonical_id":"hgnc:HGNC:16041","description":"endomucin","metadata":{"aliases":["MUC14"]}},{"id":"7c31111a779a46c0b5bb546aea1731b7","type":"GENE","name":"EMCN-AS1","canonical_id":"hgnc:HGNC:58859","description":"EMCN antisense RNA 1","metadata":null},{"id":"be8274510d174a53ad903d945584fe5f","type":"GENE","name":"EMD","canonical_id":"hgnc:HGNC:3331","description":"emerin","metadata":{"aliases":["STA","LEMD5"]}},{"id":"d46a5b2b46d741ac8b10b55075050680","type":"GENE","name":"EME1","canonical_id":"hgnc:HGNC:24965","description":"essential meiotic structure-specific endonuclease 1","metadata":{"aliases":["FLJ31364","MMS4L","SLX2A"]}},{"id":"f858446d447644d8b2c6ae265955fc79","type":"GENE","name":"EME2","canonical_id":"hgnc:HGNC:27289","description":"essential meiotic structure-specific endonuclease subunit 2","metadata":{"aliases":["FLJ00151","SLX2B"]}},{"id":"20985b53db214b79a9285787f6a1e28c","type":"GENE","name":"EMG1","canonical_id":"hgnc:HGNC:16912","description":"EMG1 N1-specific pseudouridine methyltransferase","metadata":{"aliases":["C2F","NEP1","Grcc2f"]}},{"id":"f7a8c4ca33e64a08aa64493c32a6b3fe","type":"GENE","name":"EMICERI","canonical_id":"hgnc:HGNC:53656","description":"EQTN MOB3B IFNK C9orf72 enhancer RNA I","metadata":{"aliases":["TCONS_00015940"]}},{"id":"e8926baf6782411cae6a1cf6ee6f944f","type":"GENE","name":"EMID1","canonical_id":"hgnc:HGNC:18036","description":"EMI domain containing 1","metadata":{"aliases":["EMU1","hEmu1","EMI5"]}},{"id":"2117857e43f8485ab7898e3e1574ffe4","type":"GO_TERM","name":"EMILIN complex","canonical_id":"go:GO:1990971","description":"\"The elastin microfibril interface located protein (EMILINs) are glycoprotein complexes of the C1q/TNF superfamily characterized by an N-terminal EMI domain. EMILIN homotrimers assemble to form supramolecular EMILIN structures.\" [PMID:10821830]","metadata":null},{"id":"9029443319f348ac8017193442866d69","type":"GENE","name":"EMILIN1","canonical_id":"hgnc:HGNC:19880","description":"elastin microfibril interfacer 1","metadata":{"aliases":["DKFZp586M121","gp115","EMILIN"]}},{"id":"51b470d2bdd64673bc4547c147ccba50","type":"GENE","name":"EMILIN2","canonical_id":"hgnc:HGNC:19881","description":"elastin microfibril interfacer 2","metadata":{"aliases":["FLJ33200","FOAP-10"]}},{"id":"4c565aaa675940d7b9faf0cdd978868a","type":"GENE","name":"EMILIN3","canonical_id":"hgnc:HGNC:16123","description":"elastin microfibril interfacer 3","metadata":{"aliases":["dJ620E11.4","C20orf130","EMILIN5"]}},{"id":"1a61d49464674bb49ad032f1d620c471","type":"TRIAL","name":"EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)","canonical_id":"clinicaltrials.gov:NCT06923761","description":"Advanced Solid Malignancy","metadata":null},{"id":"69ae67212f5c4ef2912d3a203bba8fae","type":"GENE","name":"EML1","canonical_id":"hgnc:HGNC:3330","description":"EMAP like 1","metadata":{"aliases":["EMAP","HuEMAP","ELP79","EMAPL"]}},{"id":"b6146221955e410389762ce125f27129","type":"GENE","name":"EML2","canonical_id":"hgnc:HGNC:18035","description":"EMAP like 2","metadata":{"aliases":["EMAP2","ELP70","EMAP-2"]}},{"id":"db14cd7f071a4d4f8ede225365a1c4ce","type":"GENE","name":"EML2-AS1","canonical_id":"hgnc:HGNC:48331","description":"EML2 antisense RNA 1","metadata":{"aliases":["C19orf83"]}},{"id":"891e2b940d884d8993f729fd63a34017","type":"GENE","name":"EML3","canonical_id":"hgnc:HGNC:26666","description":"EMAP like 3","metadata":{"aliases":["FLJ35827","ELP95"]}},{"id":"55c96df9697440a88303d16d4f17669b","type":"GENE","name":"EML4","canonical_id":"hgnc:HGNC:1316","description":"EMAP like 4","metadata":{"aliases":["ROPP120","ELP120","C2orf2"]}},{"id":"9a705f8fe729476081b0d4900502dff6","type":"GENE","name":"EML4-AS1","canonical_id":"hgnc:HGNC:40112","description":"EML4 antisense RNA 1","metadata":null},{"id":"4cd18e83260548ba9ce26b155fb4612d","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK Amplification","canonical_id":"civic:4172","description":null,"metadata":null},{"id":"663fdc12afbc410ebe27cdff969ce293","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK C1156Y","canonical_id":"civic:4225","description":null,"metadata":null},{"id":"01cc7604c7274863936553cd6b344b64","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK F1174L","canonical_id":"civic:5734","description":null,"metadata":null},{"id":"6e80aa0fd019419eb7ab0c2f8a4e74f3","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK F1245C","canonical_id":"civic:4221","description":null,"metadata":null},{"id":"bb6bc574c29448948d6a3e07902f6843","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK G1202R","canonical_id":"civic:4237","description":null,"metadata":null},{"id":"f1df429570544443aeaa411843443c0f","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M","canonical_id":"civic:4329","description":null,"metadata":null},{"id":"07e2f096eb5a4fa2acffe1783d41e2a9","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK G1269A","canonical_id":"civic:4312","description":null,"metadata":null},{"id":"13dd9cf025cc476893644ade2746407c","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK I1171N AND ALK L1196M","canonical_id":"civic:4328","description":null,"metadata":null},{"id":"4b0a9cfd804d47ac94137c0efce820e8","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK I1171S","canonical_id":"civic:4357","description":null,"metadata":null},{"id":"13b68857f6ef47918e63eb49d3a58ff1","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK L1152R","canonical_id":"civic:4255","description":null,"metadata":null},{"id":"5f864920a1d145eb9e570cf6b458efd9","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK L1196M","canonical_id":"civic:4230","description":null,"metadata":null},{"id":"2588ccb4de61491ea7e8565ea7e67af3","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y","canonical_id":"civic:4253","description":null,"metadata":null},{"id":"c3ecf486c65d432fa3c216d8a0d5bbd0","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK S1206Y","canonical_id":"civic:4309","description":null,"metadata":null},{"id":"7e442f9be776409b89923c415a05ab5d","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK T1151dup","canonical_id":"civic:4308","description":null,"metadata":null},{"id":"52208f83e1184d6cbeb1473a883b615e","type":"BIOMARKER","name":"EML4::ALK Fusion AND ALK V1180L","canonical_id":"civic:4351","description":null,"metadata":null},{"id":"2125c9848e2949fdbd9994b0c1d355b6","type":"GENE","name":"EML5","canonical_id":"hgnc:HGNC:18197","description":"EMAP like 5","metadata":{"aliases":["HuEMAP-2","EMAP-2","FAP16"]}},{"id":"ec31cb9912e546e5962b88ed6a68d6aa","type":"GENE","name":"EML6","canonical_id":"hgnc:HGNC:35412","description":"EMAP like 6","metadata":{"aliases":["FLJ42562"]}},{"id":"5fde076853b24e819b7dcbf9e32dfaf3","type":"GENE","name":"EML6-AS1","canonical_id":"hgnc:HGNC:41299","description":"EML6 antisense RNA 1","metadata":null},{"id":"c14589232c77487ebeff5a57bd815097","type":"GENE","name":"EMP1","canonical_id":"hgnc:HGNC:3333","description":"epithelial membrane protein 1","metadata":{"aliases":["TMP","CL-20"]}},{"id":"aac0e7a23f4e486e808b816d9270150a","type":"GENE","name":"EMP2","canonical_id":"hgnc:HGNC:3334","description":"epithelial membrane protein 2","metadata":{"aliases":["XMP"]}},{"id":"273879a01b5248ed980d79a84781401b","type":"GENE","name":"EMP2P1","canonical_id":"hgnc:HGNC:54651","description":"EMP2 pseudogene 1","metadata":null},{"id":"f79cf3e6565c4eed8b407f7cffcb277f","type":"GENE","name":"EMP3","canonical_id":"hgnc:HGNC:3335","description":"epithelial membrane protein 3 (MAM blood group)","metadata":{"aliases":["YMP"]}},{"id":"0754dbc7c98c4b02846a1de8b9d5345e","type":"TRIAL","name":"EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT05584319","description":"Heart Failure; Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"d18efb54e1c7489ab08ae952bba2ee58","type":"TRIAL","name":"EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance","canonical_id":"clinicaltrials.gov:NCT00618072","description":"Hyperinsulinemia; Insulin Resistance; Obesity","metadata":null},{"id":"f7361b3abe7546d39b30762b5ffa24d0","type":"GENE","name":"EMSLR","canonical_id":"hgnc:HGNC:54408","description":"E2F1 mRNA stabilizing lncRNA","metadata":{"aliases":["EMS","BCCE4"]}},{"id":"2646487b7d48495dbecf8e081b9058b4","type":"GENE","name":"EMSY","canonical_id":"hgnc:HGNC:18071","description":null,"metadata":null},{"id":"93457b0c56b146b9aa2dc6f1febee155","type":"GENE","name":"EMSY-DT","canonical_id":"hgnc:HGNC:55507","description":"EMSY divergent transcript","metadata":null},{"id":"ec74cf2d82ae4256b5e572a3b84256a4","type":"GENE","name":"EMX1","canonical_id":"hgnc:HGNC:3340","description":"empty spiracles homeobox 1","metadata":null},{"id":"21075e1b07c44c589c0618f2a3d32e29","type":"GENE","name":"EMX2","canonical_id":"hgnc:HGNC:3341","description":null,"metadata":null},{"id":"632a8e067d4e4f3aa753effae0a083a9","type":"GENE","name":"EMX2OS","canonical_id":"hgnc:HGNC:18511","description":"EMX2 opposite strand/antisense RNA","metadata":{"aliases":["NCRNA00045","EMX2-AS1"]}},{"id":"a355ff9719f042c49d007d87210c06fa","type":"GENE","name":"EN1","canonical_id":"hgnc:HGNC:3342","description":null,"metadata":null},{"id":"a459f14fa4154f6081a1f14c35fcda95","type":"GENE","name":"EN2","canonical_id":"hgnc:HGNC:3343","description":"engrailed homeobox 2","metadata":null},{"id":"84a08e872cf340acafe6608bc45a6ee9","type":"GENE","name":"EN2-DT","canonical_id":"hgnc:HGNC:55659","description":"EN2 divergent transcript","metadata":null},{"id":"1c7b8eee8df342a6827741ef76022a20","type":"TRIAL","name":"ENAC Blockade and Arterial Stiffness","canonical_id":"clinicaltrials.gov:NCT03837626","description":"Overweight and Obesity; Insulin Resistance","metadata":null},{"id":"1197aef603e44ce6945f3c99144585c5","type":"GENE","name":"ENAH","canonical_id":"hgnc:HGNC:18271","description":"ENAH actin regulator","metadata":{"aliases":["FLJ10773","NDPP1","MENA"]}},{"id":"7a5d8f3241ec4914b2f1260cf8e030bc","type":"GENE","name":"ENAHP1","canonical_id":"hgnc:HGNC:56618","description":"ENAH pseudogene 1","metadata":null},{"id":"d9c1819342c549169af8af1db62c7895","type":"GENE","name":"ENAM","canonical_id":"hgnc:HGNC:3344","description":"enamelin","metadata":{"aliases":["AIH2"]}},{"id":"7342222107ba4095b3d387ed8fe9dc23","type":"GENE","name":"ENAM-AS1","canonical_id":"hgnc:HGNC:58806","description":"ENAM and JCHAIN antisense RNA 1","metadata":null},{"id":"cf9966d821314ce7bf33e40c9fd06061","type":"GENE","name":"ENC1","canonical_id":"hgnc:HGNC:3345","description":"ectodermal-neural cortex 1","metadata":{"aliases":["PIG10","ENC-1","TP53I10","KLHL37","NRPB"]}},{"id":"a4b65ef02d3741638026baf2e330675f","type":"TRIAL","name":"ENCOrafenib With Binimetinib in bRAF NSCLC","canonical_id":"clinicaltrials.gov:NCT04526782","description":"Non Small Cell Lung Cancer; BRAF V600E","metadata":null},{"id":"d0673ac2120c4ce9a6e25a7aeace461e","type":"GENE","name":"ENDOD1","canonical_id":"hgnc:HGNC:29129","description":"endonuclease domain containing 1","metadata":{"aliases":["KIAA0830"]}},{"id":"6d00cb2ed8fa4113801edc116802bfc9","type":"GENE","name":"ENDOG","canonical_id":"hgnc:HGNC:3346","description":"endonuclease G","metadata":null},{"id":"b8c5cd4dd8194dcfa9f383f442b472ec","type":"TRIAL","name":"ENDOTHELION Study Group: Effect of Bosentan in NAION Patients","canonical_id":"clinicaltrials.gov:NCT02377271","description":"Ischemic Optic Neuropathy","metadata":null},{"id":"9f9991282d81481e98c5b2c3815a6b65","type":"GENE","name":"ENDOU","canonical_id":"hgnc:HGNC:14369","description":"endonuclease, poly(U) specific","metadata":{"aliases":["PP11","P11","PRSS26"]}},{"id":"8553bd45acd24f8282d28368f45f9ef0","type":"GENE","name":"ENDOV","canonical_id":"hgnc:HGNC:26640","description":"endonuclease V","metadata":{"aliases":["FLJ35220"]}},{"id":"f04e73fc1af24b6c8c02c491dbb0033a","type":"TRIAL","name":"ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial","canonical_id":"clinicaltrials.gov:NCT01913483","description":"Peripheral Endovascular Interventions; Bleeding","metadata":null},{"id":"c30782fa11af49ef80b2c0ac9319d27b","type":"GENE","name":"ENEMAL","canonical_id":"hgnc:HGNC:56747","description":"enhancer lncRNA neighbor of NEAT1 and MALAT1","metadata":null},{"id":"63ddc41a162e4024a27ddc2d192bf787","type":"GENE","name":"ENG","canonical_id":"hgnc:HGNC:3349","description":null,"metadata":null},{"id":"4720cd7c81e24bbfa2bc1d0a0a245ea0","type":"GENE","name":"ENGASE","canonical_id":"hgnc:HGNC:24622","description":"endo-beta-N-acetylglucosaminidase","metadata":{"aliases":["FLJ21865"]}},{"id":"fd75987b17264645a3d810de7acc0f75","type":"TRIAL","name":"ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","canonical_id":"clinicaltrials.gov:NCT03602560","description":"Primary Biliary Cholangitis","metadata":null},{"id":"0fbc2953969a47b7ae505566d73683b4","type":"GENE","name":"ENHO","canonical_id":"hgnc:HGNC:24838","description":"energy homeostasis associated","metadata":{"aliases":["UNQ470","C9orf165"]}},{"id":"44cf67a1ea804874af7e1a81b5823fa3","type":"GENE","name":"ENHO-AS1","canonical_id":"hgnc:HGNC:58225","description":"ENHO antisense RNA 1","metadata":null},{"id":"ccd38f8fd1504378803adf3679883884","type":"GENE","name":"ENKD1","canonical_id":"hgnc:HGNC:25246","description":"enkurin domain containing 1","metadata":{"aliases":["DKFZP434A1319","FBB11","C16orf48"]}},{"id":"b5803ddd3c0d47ce851dfb6d71e67381","type":"GENE","name":"ENKUR","canonical_id":"hgnc:HGNC:28388","description":"enkurin, TRPC channel interacting protein","metadata":{"aliases":["MGC26778","enkurin","CFAP106","C10orf63"]}},{"id":"3eb0dc2769f44129b45588e6dc486b92","type":"TRIAL","name":"ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence","canonical_id":"clinicaltrials.gov:NCT03218592","description":"HIV/AIDS","metadata":null},{"id":"c5b0c426327d416ab2fa784c411ae496","type":"GENE","name":"ENO1","canonical_id":"hgnc:HGNC:3350","description":null,"metadata":null},{"id":"38a90b21b69e4dc1a072ec83dac6c28b","type":"GENE","name":"ENO1-AS1","canonical_id":"hgnc:HGNC:40214","description":"ENO1 antisense RNA 1","metadata":null},{"id":"33e885fd38fc45ca9347db52764a0c78","type":"GENE","name":"ENO1P1","canonical_id":"hgnc:HGNC:3352","description":"enolase 1 pseudogene 1","metadata":{"aliases":["ENO1P"]}},{"id":"aa30a090d0f64c93897ba3c044cc1129","type":"GENE","name":"ENO1P2","canonical_id":"hgnc:HGNC:37943","description":"enolase 1 pseudogene 2","metadata":null},{"id":"e89ad2d07ce745e7b333cb81e1ea7e12","type":"GENE","name":"ENO1P3","canonical_id":"hgnc:HGNC:37944","description":"enolase 1 pseudogene 3","metadata":null},{"id":"c6dd73d9824648b58a8b876d7d9ea1ad","type":"GENE","name":"ENO1P4","canonical_id":"hgnc:HGNC:37945","description":"enolase 1 pseudogene 4","metadata":null},{"id":"83294168cd19424896c607f25c892096","type":"GENE","name":"ENO2","canonical_id":"hgnc:HGNC:3353","description":"enolase 2","metadata":{"aliases":["NSE"]}},{"id":"fc898652d9ff41be99a2d6f8bb53e9f9","type":"GENE","name":"ENO3","canonical_id":"hgnc:HGNC:3354","description":"enolase 3","metadata":null},{"id":"6a0ba81a31494a469594699ae05eeaec","type":"GENE","name":"ENO4","canonical_id":"hgnc:HGNC:31670","description":"enolase 4","metadata":{"aliases":["AC023283.3","C10orf134"]}},{"id":"37d5b534f8ae49f68a79835eadcccef0","type":"GENE","name":"ENOPH1","canonical_id":"hgnc:HGNC:24599","description":"enolase-phosphatase 1","metadata":{"aliases":["MASA","E1","mtnC"]}},{"id":"f019d556469340aeba912c3a53e3b5ba","type":"GENE","name":"ENOPH1P1","canonical_id":"hgnc:HGNC:56617","description":"ENOPH1 pseudogene 1","metadata":null},{"id":"e60bdbec45734936b9994f12c066f9d3","type":"GENE","name":"ENOSF1","canonical_id":"hgnc:HGNC:30365","description":"enolase superfamily member 1","metadata":{"aliases":["HSRTSBETA","rTS","TYMSAS","FUCD"]}},{"id":"694032537fb045b3805686326e4cfef3","type":"GENE","name":"ENOX1","canonical_id":"hgnc:HGNC:25474","description":"ecto-NOX disulfide-thiol exchanger 1","metadata":{"aliases":["FLJ10094","PIG38","CNOX","cCNOX"]}},{"id":"cd4d67bd2afb40c899730ff3fbe6bbcf","type":"GENE","name":"ENOX1-AS1","canonical_id":"hgnc:HGNC:42396","description":"ENOX1 antisense RNA 1","metadata":null},{"id":"7902582b35694ced902833d8c69b0161","type":"GENE","name":"ENOX1-AS2","canonical_id":"hgnc:HGNC:42397","description":"ENOX1 antisense RNA 2","metadata":null},{"id":"29ecbe1f5dbd4c2c83e5fba2ec772f9c","type":"GENE","name":"ENOX2","canonical_id":"hgnc:HGNC:2259","description":"ecto-NOX disulfide-thiol exchanger 2","metadata":{"aliases":["APK1","tNOX","COVA1"]}},{"id":"cb7bf32e856c4ca1a0860dd7e42b142f","type":"GENE","name":"ENOX2-AS1","canonical_id":"hgnc:HGNC:56096","description":"ENOX2 antisense RNA 1","metadata":null},{"id":"0123af48812e4460afc31ccf11fa281c","type":"GENE","name":"ENPEP","canonical_id":"hgnc:HGNC:3355","description":"glutamyl aminopeptidase","metadata":{"aliases":["gp160","CD249"]}},{"id":"a6099efd76194cb29b1bdd209f460fe7","type":"GENE","name":"ENPEPP1","canonical_id":"hgnc:HGNC:58606","description":"ENPEP pseudogene 1","metadata":null},{"id":"60d6679ddfe34255b0637cca6787ebb2","type":"GENE","name":"ENPP1","canonical_id":"hgnc:HGNC:3356","description":"ectonucleotide pyrophosphatase/phosphodiesterase 1","metadata":{"aliases":["PC-1","PCA1","NPPS","M6S1","PDNP1"]}},{"id":"75af320bfee14c558d3c1b181a6a07d6","type":"GENE","name":"ENPP2","canonical_id":"hgnc:HGNC:3357","description":null,"metadata":null},{"id":"2a07212294e649db825501248ccef4a3","type":"GENE","name":"ENPP3","canonical_id":"hgnc:HGNC:3358","description":"ectonucleotide pyrophosphatase/phosphodiesterase 3","metadata":{"aliases":["PD-IBETA","gp130RB13-6","B10","CD203c","PDNP3"]}},{"id":"8edd19053cf2470090ae1dff182a3b15","type":"GENE","name":"ENPP4","canonical_id":"hgnc:HGNC:3359","description":"ectonucleotide pyrophosphatase/phosphodiesterase 4","metadata":{"aliases":["NPP4","KIAA0879","AP3Aase"]}},{"id":"984f9d6dedda47989ae0a392f8038c08","type":"GENE","name":"ENPP5","canonical_id":"hgnc:HGNC:13717","description":"ectonucleotide pyrophosphatase/phosphodiesterase family member 5","metadata":null},{"id":"40bc3c5e769c4167948fdbe6fd9ffee0","type":"GENE","name":"ENPP6","canonical_id":"hgnc:HGNC:23409","description":"ectonucleotide pyrophosphatase/phosphodiesterase 6","metadata":{"aliases":["MGC33971"]}},{"id":"2f0915ee5dab47978e69bf2915edbf94","type":"GENE","name":"ENPP7","canonical_id":"hgnc:HGNC:23764","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7","metadata":{"aliases":["alk-SMase","NPP7"]}},{"id":"8cdf2da9aae440b4b7c5d292676c5270","type":"GENE","name":"ENPP7P1","canonical_id":"hgnc:HGNC:48699","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 1","metadata":null},{"id":"95d7d67162d442c79dfc0a6d4dd6fc0d","type":"GENE","name":"ENPP7P10","canonical_id":"hgnc:HGNC:48693","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 10","metadata":null},{"id":"fa727bde210b4024a78f0641de5fd72e","type":"GENE","name":"ENPP7P11","canonical_id":"hgnc:HGNC:48694","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 11","metadata":null},{"id":"36ac3c28b13f4d25b3a15757d1205a65","type":"GENE","name":"ENPP7P12","canonical_id":"hgnc:HGNC:48697","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 12","metadata":null},{"id":"21db23377c49480eb28d6c9daa02c457","type":"GENE","name":"ENPP7P13","canonical_id":"hgnc:HGNC:48696","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 13","metadata":{"aliases":["DUNQU1"]}},{"id":"9f8b2253ce004cc5b187339949a5b05a","type":"GENE","name":"ENPP7P14","canonical_id":"hgnc:HGNC:51387","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 14","metadata":null},{"id":"4691beccf14e4f19af2ab961408185d1","type":"GENE","name":"ENPP7P15","canonical_id":"hgnc:HGNC:55616","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 15","metadata":null},{"id":"1a592260822943c5ae0030ba9812256b","type":"GENE","name":"ENPP7P2","canonical_id":"hgnc:HGNC:48685","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 2","metadata":null},{"id":"90b2745831bb4e40ba0a1f8fccc5382f","type":"GENE","name":"ENPP7P3","canonical_id":"hgnc:HGNC:48686","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 3","metadata":null},{"id":"c274515179734a9aadc2db6ec0a2313e","type":"GENE","name":"ENPP7P4","canonical_id":"hgnc:HGNC:48687","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 4","metadata":null},{"id":"35ac864081ba4eb5833685978c5db59a","type":"GENE","name":"ENPP7P5","canonical_id":"hgnc:HGNC:48688","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 5","metadata":null},{"id":"b2cf32782ba948ad80aa17be3636c950","type":"GENE","name":"ENPP7P6","canonical_id":"hgnc:HGNC:48698","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 6","metadata":null},{"id":"0e2128225d3248b6acf351cc2edbe628","type":"GENE","name":"ENPP7P7","canonical_id":"hgnc:HGNC:48690","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 7","metadata":null},{"id":"828e52fc01ee4e7b89caae41f3a7ddca","type":"GENE","name":"ENPP7P8","canonical_id":"hgnc:HGNC:48691","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 8","metadata":null},{"id":"cb19ab7d8b284492b79c8d3ff54b3ec9","type":"GENE","name":"ENPP7P9","canonical_id":"hgnc:HGNC:48692","description":"ectonucleotide pyrophosphatase/phosphodiesterase 7 pseudogene 9","metadata":null},{"id":"c12e5fa78cf742b1ae765365c7d9c3c3","type":"GENE","name":"ENSA","canonical_id":"hgnc:HGNC:3360","description":"endosulfine alpha","metadata":{"aliases":["MGC4319","MGC8394","MGC78563","ARPP-19e"]}},{"id":"f9e2b365d532434f84c7937676a662f0","type":"GENE","name":"ENSAP1","canonical_id":"hgnc:HGNC:16588","description":"endosulfine alpha pseudogene 1","metadata":{"aliases":["dJ822J19.1","ENSAP"]}},{"id":"87af072441a4415b85144e945e7dca36","type":"GENE","name":"ENSAP2","canonical_id":"hgnc:HGNC:20011","description":"endosulfine alpha pseudogene 2","metadata":null},{"id":"a29e2a46ac6f4236be95866fd9e15f27","type":"GENE","name":"ENSAP3","canonical_id":"hgnc:HGNC:37946","description":"endosulfine alpha pseudogene 3","metadata":null},{"id":"b592e33779024609af826b96e59aa815","type":"GENE","name":"ENTHD1","canonical_id":"hgnc:HGNC:26352","description":"ENTH domain containing 1","metadata":{"aliases":["FLJ25421"]}},{"id":"4b28489cdf47475e9d3042582561837c","type":"GENE","name":"ENTPD1","canonical_id":"hgnc:HGNC:3363","description":"ectonucleoside triphosphate diphosphohydrolase 1","metadata":{"aliases":["ATP-DPH","NTPDase-1","ATPDase","SPG64","CD39"]}},{"id":"6a1e24846bee4bfa91b195b97f1afedb","type":"GENE","name":"ENTPD1-AS1","canonical_id":"hgnc:HGNC:45203","description":"ENTPD1 antisense RNA 1","metadata":null},{"id":"c9fec435d4384c9483e7f90346d14a1d","type":"GENE","name":"ENTPD2","canonical_id":"hgnc:HGNC:3364","description":"ectonucleoside triphosphate diphosphohydrolase 2","metadata":{"aliases":["NTPDase-2","CD39L1"]}},{"id":"9b1474defe504fb8abd0274dc7cb073f","type":"GENE","name":"ENTPD3","canonical_id":"hgnc:HGNC:3365","description":"ectonucleoside triphosphate diphosphohydrolase 3","metadata":{"aliases":["NTPDase-3","HB6","CD39L3"]}},{"id":"a4959a6a1bc045c295c5fe7b328a62db","type":"GENE","name":"ENTPD3-AS1","canonical_id":"hgnc:HGNC:26710","description":"ENTPD3, EIF1B and MYRIP antisense RNA 1","metadata":{"aliases":["FLJ36665","EIF1B-AS1"]}},{"id":"f354953b6d88437ea41bc1fbf5444533","type":"GENE","name":"ENTPD4","canonical_id":"hgnc:HGNC:14573","description":"ectonucleoside triphosphate diphosphohydrolase 4","metadata":{"aliases":["LALP70","LAP70","KIAA0392","NTPDase-4","UDPase","LYSAL1"]}},{"id":"3d22365f39e041cf96a238c640b90d91","type":"GENE","name":"ENTPD4-DT","canonical_id":"hgnc:HGNC:55536","description":"ENTPD4 divergent transcript","metadata":null},{"id":"ae37221c80bd4942893c022ab7ba7d3e","type":"GENE","name":"ENTPD5","canonical_id":"hgnc:HGNC:3367","description":"ectonucleoside triphosphate diphosphohydrolase 5","metadata":{"aliases":["NTPDase-5","CD39L4","PCPH"]}},{"id":"7549c7149ad249e7b95167458203b279","type":"GENE","name":"ENTPD6","canonical_id":"hgnc:HGNC:3368","description":"ectonucleoside triphosphate diphosphohydrolase 6","metadata":{"aliases":["NTPDase-6","dJ738P15.3","CD39L2","IL6ST2"]}},{"id":"56d81179183c46258c2ccfc6047f07af","type":"GENE","name":"ENTPD7","canonical_id":"hgnc:HGNC:19745","description":"ectonucleoside triphosphate diphosphohydrolase 7","metadata":{"aliases":["LALP1","FLJ30978"]}},{"id":"c6df5dc4483243f79c0781d984a3eee6","type":"GENE","name":"ENTPD8","canonical_id":"hgnc:HGNC:24860","description":"ectonucleoside triphosphate diphosphohydrolase 8","metadata":{"aliases":["UNQ2492","NTPDase-8"]}},{"id":"f29b6cbc6f68456886a7ce7cf4cf1323","type":"GENE","name":"ENTR1","canonical_id":"hgnc:HGNC:10667","description":"endosome associated trafficking regulator 1","metadata":{"aliases":["NY-CO-3","SDCCAG3"]}},{"id":"fa16b5986cfb4bd0a3d91b22f23f53af","type":"GENE","name":"ENTR1P1","canonical_id":"hgnc:HGNC:29375","description":"ENTR1 pseudogene 1","metadata":{"aliases":["SDCCAG3L","SDCCAG3P1"]}},{"id":"b669a82971fa469f96e94dfadc6c9857","type":"GENE","name":"ENTR1P2","canonical_id":"hgnc:HGNC:39164","description":"ENTR1 pseudogene 2","metadata":{"aliases":["SDCCAG3P2"]}},{"id":"2b5e13a0b403479392ba3dfcac5fa115","type":"GENE","name":"ENTREP1","canonical_id":"hgnc:HGNC:24820","description":"endosomal transmembrane epsin interactor 1","metadata":{"aliases":["X123","ENTREP","C9orf61","FAM189A2"]}},{"id":"f38d39f5e6b642ef954bc5dc872b17bb","type":"GENE","name":"ENTREP2","canonical_id":"hgnc:HGNC:29075","description":"endosomal transmembrane epsin interactor 2","metadata":{"aliases":["KIAA0574","TMEM228","FAM189A1"]}},{"id":"ced21440fd994d7d814da56f2f0bf165","type":"GENE","name":"ENTREP3","canonical_id":"hgnc:HGNC:1233","description":"endosomal transmembrane epsin interactor 3","metadata":{"aliases":["cote1","C1orf2","FAM189B"]}},{"id":"6915421e9ccd4044bcddaba36c45fde8","type":"TRIAL","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04891198","description":"Solid Tumor","metadata":null},{"id":"8534c57b607d4ee2a8c74dae8e59af43","type":"GENE","name":"ENY2","canonical_id":"hgnc:HGNC:24449","description":"ENY2 transcription and export complex 2 subunit","metadata":{"aliases":["DC6","FLJ20480","Sus1"]}},{"id":"3a51c6b27e7a4a8eae936dc776b4f3f0","type":"GENE","name":"EOGT","canonical_id":"hgnc:HGNC:28526","description":"EGF domain specific O-linked N-acetylglucosamine transferase","metadata":{"aliases":["AER61","FLJ33770","C3orf64"]}},{"id":"e364653168ea44bca200a374b82287ca","type":"GENE","name":"EOGT-DT","canonical_id":"hgnc:HGNC:55605","description":"EOGT divergent transcript","metadata":null},{"id":"38dcc127ccfa4a9eab4309c323b76a67","type":"GENE","name":"EOLA1","canonical_id":"hgnc:HGNC:28089","description":"endothelium and lymphocyte associated ASCH domain 1","metadata":{"aliases":["CXorf40","CXorf40A"]}},{"id":"53cf30d586d4493ebad3ecb1a924b604","type":"GENE","name":"EOLA1-DT","canonical_id":"hgnc:HGNC:44265","description":"EOLA1 divergent transcript","metadata":{"aliases":["lnc-CPLC","LINC00893"]}},{"id":"f51956c088844b0ba6e31e247d56d593","type":"GENE","name":"EOLA2","canonical_id":"hgnc:HGNC:17402","description":"endothelium and lymphocyte associated ASCH domain 2","metadata":{"aliases":["CXorf40B"]}},{"id":"783c13f83efe4c15adf456c7910c0f88","type":"GENE","name":"EOLA2-DT","canonical_id":"hgnc:HGNC:48579","description":"EOLA2 divergent transcript","metadata":{"aliases":["LINC00894"]}},{"id":"ab9fd1ce70c646969a59a7bcb3fcf180","type":"GENE","name":"EOMES","canonical_id":"hgnc:HGNC:3372","description":null,"metadata":null},{"id":"dfedcb7f3a334815a512fb770c742af2","type":"GO_TERM","name":"EP1 subtype prostaglandin E2 receptor binding","canonical_id":"go:GO:0031864","description":"\"Binding to an EP1 subtype prostaglandin E2 receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"2d18a4c4661a4084af81abe4cc0a8eea","type":"GO_TERM","name":"EP2 subtype prostaglandin E2 receptor binding","canonical_id":"go:GO:0031865","description":"\"Binding to an EP2 subtype prostaglandin E2 receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c2bf1192dd4e4bdaa6563e3bee3ad45d","type":"GO_TERM","name":"EP3 subtype prostaglandin E2 receptor binding","canonical_id":"go:GO:0031866","description":"\"Binding to an EP3 subtype prostaglandin E2 receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"58e819fb924847fab663df55358e0635","type":"GENE","name":"EP300","canonical_id":"hgnc:HGNC:3373","description":null,"metadata":null},{"id":"e1690a3e99d04401bb9e527ff9f9e26c","type":"GENE","name":"EP300-AS1","canonical_id":"hgnc:HGNC:50504","description":"EP300 antisense RNA 1","metadata":null},{"id":"80da9b5bd061426e9ad52fd5c1de27bb","type":"GO_TERM","name":"EP4 subtype prostaglandin E2 receptor binding","canonical_id":"go:GO:0031867","description":"\"Binding to an EP4 subtype prostaglandin E2 receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"35e0a3c0b3bc4e6aa6f0c4574e256c0e","type":"GENE","name":"EP400","canonical_id":"hgnc:HGNC:11958","description":"E1A binding protein p400","metadata":{"aliases":["CAGH32","KIAA1498","P400","KIAA1818","DKFZP434I225","TNRC12"]}},{"id":"1254288e12914786a29456022ea4b444","type":"GENE","name":"EP400P1","canonical_id":"hgnc:HGNC:26602","description":"EP400 pseudogene 1","metadata":{"aliases":["FLJ33915","EP400NL"]}},{"id":"e4f92e90ff5e4f87ba7931eba13cfd48","type":"GENE","name":"EPAS1","canonical_id":"hgnc:HGNC:3374","description":null,"metadata":null},{"id":"7f3a25fd82624f9fbafa7ebda88ea50a","type":"GENE","name":"EPB41","canonical_id":"hgnc:HGNC:3377","description":"erythrocyte membrane protein band 4.1","metadata":{"aliases":["4.1R","EL1"]}},{"id":"3c8cefae03f04bcfb6961dc686060ffd","type":"GENE","name":"EPB41L1","canonical_id":"hgnc:HGNC:3378","description":"erythrocyte membrane protein band 4.1 like 1","metadata":{"aliases":["KIAA0338","4.1N"]}},{"id":"35f7b3f6b6844deeaf27021c455c592c","type":"GENE","name":"EPB41L1-AS1","canonical_id":"hgnc:HGNC:55728","description":"EPB41L1 antisense RNA 1","metadata":{"aliases":["AL121895.1"]}},{"id":"6db79cb0de1d4cbdb44d8d40bb9bd11b","type":"GENE","name":"EPB41L2","canonical_id":"hgnc:HGNC:3379","description":"erythrocyte membrane protein band 4.1 like 2","metadata":{"aliases":["4.1-G","4.1G"]}},{"id":"75167d8a6baa4ef89b5045623d8c6ace","type":"GENE","name":"EPB41L3","canonical_id":"hgnc:HGNC:3380","description":null,"metadata":null},{"id":"fb6a0715c5cf427eba960a87fd4302fb","type":"GENE","name":"EPB41L3-AS1","canonical_id":"hgnc:HGNC:58202","description":"EPB41L3 antisense RNA 1","metadata":null},{"id":"0cdafdf6afbd4122b9fa2d9f56b4ab3f","type":"GENE","name":"EPB41L4A","canonical_id":"hgnc:HGNC:13278","description":"erythrocyte membrane protein band 4.1 like 4A","metadata":{"aliases":["NBL4"]}},{"id":"d74647d16e424d51af6bafc9349a70a0","type":"GENE","name":"EPB41L4A-AS1","canonical_id":"hgnc:HGNC:30749","description":"EPB41L4A antisense RNA 1","metadata":{"aliases":["EAS1","TIGA1","C5orf26","NCRNA00219"]}},{"id":"9a1fabe5f0394bfaa9cc8e08fb47fc74","type":"GENE","name":"EPB41L4A-AS2","canonical_id":"hgnc:HGNC:59110","description":"EPB41L4A antisense RNA 2","metadata":null},{"id":"2028919c81f54200992260653d913846","type":"GENE","name":"EPB41L4A-AS3","canonical_id":"hgnc:HGNC:59111","description":"EPB41L4A antisense RNA 3","metadata":null},{"id":"37808e031b7849d389245aa402fa3547","type":"GENE","name":"EPB41L4A-DT","canonical_id":"hgnc:HGNC:25643","description":"EPB41L4A divergent transcript","metadata":{"aliases":["FLJ11235","EPB41L4A-AS2"]}},{"id":"01bc125fc16942099be54d4678bd408e","type":"GENE","name":"EPB41L4B","canonical_id":"hgnc:HGNC:19818","description":null,"metadata":null},{"id":"31fde53c83334aa5bcc3d37cebd4e445","type":"GENE","name":"EPB41L5","canonical_id":"hgnc:HGNC:19819","description":"erythrocyte membrane protein band 4.1 like 5","metadata":{"aliases":["KIAA1548","FLJ12957","BE37","YMO1","YRT","LULU","LULU1"]}},{"id":"205f96db52b141f390509f1dafbce31c","type":"GENE","name":"EPB42","canonical_id":"hgnc:HGNC:3381","description":"erythrocyte membrane protein band 4.2","metadata":{"aliases":["PA","MGC116735","MGC116737"]}},{"id":"53d184feed674efaad6062967a4d7886","type":"GENE","name":"EPC1","canonical_id":"hgnc:HGNC:19876","description":"enhancer of polycomb 1","metadata":{"aliases":["Epl1"]}},{"id":"3030c1dd15494a508a277557074a6ce2","type":"GENE","name":"EPC1-AS1","canonical_id":"hgnc:HGNC:50717","description":"EPC1 antisense RNA 1","metadata":null},{"id":"c27fccf17a4f43fe8ce13b8d19e4c9a2","type":"GENE","name":"EPC1-AS2","canonical_id":"hgnc:HGNC:56646","description":"EPC1 antisense RNA 2","metadata":null},{"id":"0035fc48bad343aca20bca1ce1b973c2","type":"GENE","name":"EPC2","canonical_id":"hgnc:HGNC:24543","description":"enhancer of polycomb 2","metadata":{"aliases":["DKFZP566F2124"]}},{"id":"282437043e304f2682dd31f14253ff14","type":"GENE","name":"EPCAM","canonical_id":"hgnc:HGNC:11529","description":null,"metadata":null},{"id":"c6b4358b4b67437fa76fedb4459e076e","type":"PROTEIN","name":"EPCAM","canonical_id":"uniprot:P16422","description":null,"metadata":null},{"id":"6d5425fc25c4419b897df503ac795d9b","type":"GENE","name":"EPCAM-DT","canonical_id":"hgnc:HGNC:52639","description":"EPCAM divergent transcript","metadata":null},{"id":"b1d72cbfb4814ee8bf0cb93ec7479879","type":"GENE","name":"EPCART","canonical_id":"hgnc:HGNC:51792","description":"ERG-positive prostate cancer associated androgen responsive transcript","metadata":{"aliases":["TPCAT-2-180961","PRCAT122","PCAT-2-180961"]}},{"id":"4de79d153d4b415c8165391b67f676e0","type":"GENE","name":"EPCIP","canonical_id":"hgnc:HGNC:1305","description":"exosomal polycystin 1 interacting protein","metadata":{"aliases":["B37","PRED81","CU062","C21orf120","C21orf62"]}},{"id":"0e1c97fa493b49f89da8140349e801f4","type":"GENE","name":"EPCIP-AS1","canonical_id":"hgnc:HGNC:1290","description":"EPCIP antisense RNA 1","metadata":{"aliases":["C21orf49","C21orf62-AS1"]}},{"id":"6ecac0e750df4be0bda190e257125644","type":"GENE","name":"EPDR1","canonical_id":"hgnc:HGNC:17572","description":"ependymin related 1","metadata":{"aliases":["MERP-1","MERP1","UCC1","EPDR"]}},{"id":"18a151c192394cada8cf7c670a2c367f","type":"GENE","name":"EPG5","canonical_id":"hgnc:HGNC:29331","description":"ectopic P-granules 5 autophagy tethering factor","metadata":{"aliases":["hEPG5","KIAA1632"]}},{"id":"2abab7409d6940cd830fca2059e1ff5c","type":"GENE","name":"EPGN","canonical_id":"hgnc:HGNC:17470","description":"epithelial mitogen","metadata":{"aliases":["EPG","PRO9904","ALGV3072"]}},{"id":"d05a212d3885493e9bee97bb31bff1ea","type":"GENE","name":"EPHA1","canonical_id":"hgnc:HGNC:3385","description":"EPH receptor A1","metadata":{"aliases":["EPH","EPHT","EPHT1"]}},{"id":"05e707abf70e411eb3e68a82e6a0daa9","type":"GENE","name":"EPHA1-AS1","canonical_id":"hgnc:HGNC:27799","description":"EPHA1 antisense RNA 1","metadata":null},{"id":"e103fde2af1647a4a71a58588cc4bd3d","type":"GENE","name":"EPHA10","canonical_id":"hgnc:HGNC:19987","description":"EPH receptor A10","metadata":{"aliases":["FLJ16103","FLJ33655"]}},{"id":"9f71479a4ee44533b1ebfdfd2ef1f719","type":"GENE","name":"EPHA2","canonical_id":"hgnc:HGNC:3386","description":null,"metadata":null},{"id":"542bfaf9065f418abc629342a9b724e3","type":"PROTEIN","name":"EPHA2","canonical_id":"uniprot:P29317","description":null,"metadata":null},{"id":"abfeadcaaad5448f915d0ceaa501cd1d","type":"GENE","name":"EPHA2-AS1","canonical_id":"hgnc:HGNC:40216","description":"EPHA2 antisense RNA 1","metadata":null},{"id":"dfdaf896d73c4a548ee9820bef087c23","type":"GENE","name":"EPHA3","canonical_id":"hgnc:HGNC:3387","description":null,"metadata":null},{"id":"e1e6006f70a746ebbf971f24ed67905a","type":"GENE","name":"EPHA4","canonical_id":"hgnc:HGNC:3388","description":"EPH receptor A4","metadata":{"aliases":["Hek8","TYRO1"]}},{"id":"7776c61b06cc4a848c59d33b781cf9cc","type":"GENE","name":"EPHA5","canonical_id":"hgnc:HGNC:3389","description":"EPH receptor A5","metadata":{"aliases":["Hek7","TYRO4","CEK7","EHK1"]}},{"id":"e10127bb02494aa2903361d68e87b96f","type":"GENE","name":"EPHA5-AS1","canonical_id":"hgnc:HGNC:50602","description":"EPHA5 antisense RNA 1","metadata":null},{"id":"15166577e571429cab6b5b8ebfc7a250","type":"GENE","name":"EPHA5-AS2","canonical_id":"hgnc:HGNC:58800","description":"EPHA5 antisense RNA 2","metadata":null},{"id":"6b39afcb283a47c38f99d42ec8e99e1e","type":"GENE","name":"EPHA6","canonical_id":"hgnc:HGNC:19296","description":"EPH receptor A6","metadata":{"aliases":["FLJ35246"]}},{"id":"07d2bd6abaff458294ea9850eff5e19f","type":"GENE","name":"EPHA7","canonical_id":"hgnc:HGNC:3390","description":"EPH receptor A7","metadata":{"aliases":["Hek11"]}},{"id":"fbf51f31ce9047f283b00ed05083eeb7","type":"GENE","name":"EPHA8","canonical_id":"hgnc:HGNC:3391","description":"EPH receptor A8","metadata":{"aliases":["Hek3","EEK"]}},{"id":"41128041f4874a6199e73b6bea413a5f","type":"GENE","name":"EPHB1","canonical_id":"hgnc:HGNC:3392","description":"EPH receptor B1","metadata":{"aliases":["Hek6","EPHT2"]}},{"id":"22d9281c220f43b1a68495d6ebb55929","type":"GENE","name":"EPHB2","canonical_id":"hgnc:HGNC:3393","description":null,"metadata":null},{"id":"1f403064a9f84819beee02151e5a5a9b","type":"GENE","name":"EPHB3","canonical_id":"hgnc:HGNC:3394","description":"EPH receptor B3","metadata":{"aliases":["Hek2","Tyro6","ETK2"]}},{"id":"6864e55e00fb4ce0a42225b18b0d5097","type":"GENE","name":"EPHB4","canonical_id":"hgnc:HGNC:3395","description":"EPH receptor B4","metadata":{"aliases":["Tyro11","HTK"]}},{"id":"3e47eb437fec40a1ade77f89728ccb36","type":"GENE","name":"EPHB6","canonical_id":"hgnc:HGNC:3396","description":"EPH receptor B6","metadata":{"aliases":["HEP"]}},{"id":"e3712a4baf634807a90b7935925bc532","type":"GENE","name":"EPHX1","canonical_id":"hgnc:HGNC:3401","description":"epoxide hydrolase 1","metadata":{"aliases":["EPHX"]}},{"id":"b172b45984294375963173f95636d843","type":"GENE","name":"EPHX2","canonical_id":"hgnc:HGNC:3402","description":"epoxide hydrolase 2","metadata":{"aliases":["ABHD20","sEH"]}},{"id":"af730c74ef8b4d709f48300f22c6b4de","type":"GENE","name":"EPHX3","canonical_id":"hgnc:HGNC:23760","description":"epoxide hydrolase 3","metadata":{"aliases":["FLJ22408","ABHD9"]}},{"id":"b383da611c1e4e2a942428e958d4d955","type":"GENE","name":"EPHX4","canonical_id":"hgnc:HGNC:23758","description":"epoxide hydrolase 4","metadata":{"aliases":["EPHXRP","FLJ90341","EH4","ABHD7"]}},{"id":"7797e9cd61084e83bc3ef004a32b6e30","type":"GENE","name":"EPIC1","canonical_id":"hgnc:HGNC:27672","description":"epigenetically induced MYC interacting lncRNA 1","metadata":{"aliases":["Lnc-EPIC1"]}},{"id":"8f1e2c4577cf42a3aebf4932bfe2c0d9","type":"GENE","name":"EPIST","canonical_id":"hgnc:HGNC:49679","description":"esophagus epithelial intergenic associated transcript","metadata":{"aliases":["XLH-36","CTC-276P9.1","Epist","C5orf66-AS1"]}},{"id":"424771e037b444c59bd80908e9c79d4a","type":"TRIAL","name":"EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety","canonical_id":"clinicaltrials.gov:NCT01834768","description":"Chronic Kidney Insufficiency; Kidney Transplantation","metadata":null},{"id":"ba7b5e163e704849b96b35ebafb0a97a","type":"GENE","name":"EPM2A","canonical_id":"hgnc:HGNC:3413","description":"EPM2A glucan phosphatase, laforin","metadata":{"aliases":["LDE","LD"]}},{"id":"866c6f04cb984f5aa1a1bf6a68c64e30","type":"GENE","name":"EPM2A-DT","canonical_id":"hgnc:HGNC:48990","description":"EPM2A divergent transcript","metadata":{"aliases":["FBXO30-DT"]}},{"id":"d737a3ec01b64908b9b1c7159b184369","type":"GENE","name":"EPM2AIP1","canonical_id":"hgnc:HGNC:19735","description":"EPM2A interacting protein 1","metadata":{"aliases":["KIAA0766","FLJ11207"]}},{"id":"140b1199e1264a4b94c3d7b0cbdec836","type":"GENE","name":"EPN1","canonical_id":"hgnc:HGNC:21604","description":"epsin 1","metadata":null},{"id":"e1e6aa32bfec48c38e68f9072d6e69fb","type":"GENE","name":"EPN2","canonical_id":"hgnc:HGNC:18639","description":"epsin 2","metadata":{"aliases":["KIAA1065","EHB21"]}},{"id":"7d46e13ce87d447da1bd1a8d475173b2","type":"GENE","name":"EPN2-AS1","canonical_id":"hgnc:HGNC:40849","description":"EPN2 antisense RNA 1","metadata":null},{"id":"ede5422c1f30406abdfedc1c5de5c2bc","type":"GENE","name":"EPN2-IT1","canonical_id":"hgnc:HGNC:41445","description":"EPN2 intronic transcript 1","metadata":null},{"id":"1beb3f526c214cb587260b6af48c2e7f","type":"GENE","name":"EPN3","canonical_id":"hgnc:HGNC:18235","description":"epsin 3","metadata":{"aliases":["FLJ20778","MGC129899"]}},{"id":"b7bec765cf884eafabd68dbc4548eaed","type":"GENE","name":"EPO","canonical_id":"hgnc:HGNC:3415","description":null,"metadata":null},{"id":"c870425ffb6940e38aad22ba882ca8b2","type":"GENE","name":"EPOP","canonical_id":"hgnc:HGNC:34493","description":"elongin BC and polycomb repressive complex 2 associated protein","metadata":{"aliases":["LOC100170841","PRR28","C17orf96"]}},{"id":"e32d6d140c93449da297e844045d351c","type":"GENE","name":"EPOR","canonical_id":"hgnc:HGNC:3416","description":null,"metadata":null},{"id":"14530c7d6db84ca9b5eb5ce172f04f3a","type":"PROTEIN","name":"EPOR","canonical_id":"uniprot:P19235","description":null,"metadata":null},{"id":"6738829914d2435299142464cabd7485","type":"GENE","name":"EPPIN","canonical_id":"hgnc:HGNC:15932","description":"epididymal peptidase inhibitor","metadata":{"aliases":["EPPIN1","EPPIN2","EPPIN3","dJ461P17.2","WAP7","WFDC7","CT71","SPINLW1"]}},{"id":"468c30a8b1c445a2ba51db30cd752675","type":"GENE","name":"EPPIN-WFDC6","canonical_id":"hgnc:HGNC:38825","description":"EPPIN-WFDC6 readthrough","metadata":{"aliases":["SPINLW1-WFDC6"]}},{"id":"5a846a781e36437fb9228580f9a40389","type":"GENE","name":"EPPK1","canonical_id":"hgnc:HGNC:15577","description":"epiplakin 1","metadata":{"aliases":["EPIPL1"]}},{"id":"606adec6aa7f42e1b50e440f3cc82099","type":"GENE","name":"EPRS1","canonical_id":"hgnc:HGNC:3418","description":"glutamyl-prolyl-tRNA synthetase 1","metadata":{"aliases":["EARS","PARS","GLUPRORS","QPRS","QARS","EPRS"]}},{"id":"4ef2d97f6ca049fa9b8e1d6888d4b2a2","type":"GENE","name":"EPS15","canonical_id":"hgnc:HGNC:3419","description":"epidermal growth factor receptor pathway substrate 15","metadata":{"aliases":["AF-1P","MLLT5"]}},{"id":"e48346d41db9466cbc86191f8da17bb7","type":"GENE","name":"EPS15-AS1","canonical_id":"hgnc:HGNC:40219","description":"EPS15 antisense RNA 1","metadata":null},{"id":"c23142c8dc594adaa45a331f003dfbb6","type":"GENE","name":"EPS15L1","canonical_id":"hgnc:HGNC:24634","description":"epidermal growth factor receptor pathway substrate 15 like 1","metadata":{"aliases":["eps15R"]}},{"id":"05adc54a5641405e95ad593d5b7bec55","type":"GENE","name":"EPS15P1","canonical_id":"hgnc:HGNC:18166","description":"epidermal growth factor receptor pathway substrate 15 pseudogene 1","metadata":{"aliases":["PRO1866","EPS15L2"]}},{"id":"c53b601243a44d3c9e846f3741422e60","type":"GENE","name":"EPS8","canonical_id":"hgnc:HGNC:3420","description":"EGFR pathway substrate 8, signaling adaptor","metadata":null},{"id":"8cea0a797fc14acd9532b29556973ebf","type":"GENE","name":"EPS8L1","canonical_id":"hgnc:HGNC:21295","description":"EPS8 signaling adaptor L1","metadata":{"aliases":["FLJ20258","DRC3","MGC23164","MGC4642"]}},{"id":"60e27171bfb54afe8985f861f288225b","type":"GENE","name":"EPS8L2","canonical_id":"hgnc:HGNC:21296","description":"EPS8 signaling adaptor L2","metadata":{"aliases":["FLJ21935","FLJ22171","MGC3088"]}},{"id":"5b29ab6ba254445ba0ac9c215b57c8e2","type":"GENE","name":"EPS8L3","canonical_id":"hgnc:HGNC:21297","description":"EPS8 signaling adaptor L3","metadata":{"aliases":["FLJ21522","MGC16817"]}},{"id":"d5da4fd983fe4a43be87cf210ec940eb","type":"GENE","name":"EPSTI1","canonical_id":"hgnc:HGNC:16465","description":null,"metadata":null},{"id":"8e0fe2f3d17847e1a76d4c575412bc71","type":"GENE","name":"EPX","canonical_id":"hgnc:HGNC:3423","description":"eosinophil peroxidase","metadata":{"aliases":["EPO","EPP","EPX-PEN"]}},{"id":"447c8e55f33e42848fbad6e31ee84fee","type":"GENE","name":"EPYC","canonical_id":"hgnc:HGNC:3053","description":"epiphycan","metadata":{"aliases":["Pg-Lb","SLRR3B","DSPG3"]}},{"id":"d859bba66257492887b399fb8db59c38","type":"GENE","name":"EQTN","canonical_id":"hgnc:HGNC:1359","description":"equatorin","metadata":{"aliases":["AFAF","SPACA8","equatorin","C9orf11"]}},{"id":"584056dc6adb447c89b526be5648190e","type":"GO_TERM","name":"ER body","canonical_id":"go:GO:0010168","description":"\"A novel compartment found in plant cells that is derived from the ER. The structures have a characteristic shape and size (10 mm long and 0.5 mm wide) and are surrounded with ribosomes. They have been found in Arabidopsis thaliana and related Brassicaceae species.\" [PMID:11577182]","metadata":null},{"id":"ef07cc4dab4a475d9f890c4c77b33d1e","type":"GO_TERM","name":"ER body organization","canonical_id":"go:GO:0080119","description":"\"A process that is carried out at the cellular level which results in the formation of ER (endoplasmic reticulum) body. ER body is a compartment found in plant cells that is derived from the ER. The structures have a characteristic shape and size (10 mm long and 0.5 mm wide) and are surrounded with ribosomes. They have been found in Arabidopsis thaliana and related Brassicaceae species.\" [PMID:18780803, PMID:19147648]","metadata":null},{"id":"feac964171c44fb18855ed11a5e13d7a","type":"GO_TERM","name":"ER lumen protein retrieval receptor activity","canonical_id":"go:GO:0046923","description":"\"Binding to an endoplasmic reticulum (ER) retention sequence, a short stretch of amino acids found in a protein that acts as a signal to retain the protein within the ER.\" [GOC:ai]","metadata":null},{"id":"555c9e6436164e349f11a8a86a72f7a9","type":"GO_TERM","name":"ER membrane insertion complex","canonical_id":"go:GO:0072379","description":"\"A protein complex that is involved in the post-translational delivery of tail-anchored (TA) membrane proteins to the endoplasmic reticulum. TA membrane proteins, also called type II transmembrane proteins, contain a single C-terminal transmembrane region. Some ER membrane insertion complex subunits are conserved between different species such as mammals and budding yeast.\" [GOC:mah, PMID:20676083, PMID:20850366]","metadata":null},{"id":"e9b14c7d68664566897d10682cd05e80","type":"GO_TERM","name":"ER overload response","canonical_id":"go:GO:0006983","description":"\"The series of molecular signals initiated by the accumulation of normal or misfolded proteins in the endoplasmic reticulum and leading to activation of transcription by NF-kappaB.\" [PMID:10390516]","metadata":null},{"id":"27e06ee40d4549aea7596c1e0badaead","type":"GO_TERM","name":"ER to Golgi ceramide transport","canonical_id":"go:GO:0035621","description":"\"The directed movement of a ceramide from the endoplasmic reticulum (ER) to the Golgi. Ceramides are a class of lipid composed of sphingosine linked to a fatty acid.\" [GOC:sart, PMID:14685229]","metadata":null},{"id":"339b7d58916f4d948854eb543786796c","type":"GO_TERM","name":"ER to Golgi transport vesicle membrane","canonical_id":"go:GO:0012507","description":"\"The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi.\" [GOC:ai, GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"aa0d4ddd1f494864a355d2cf89c50dc8","type":"GO_TERM","name":"ER to chloroplast lipid transport","canonical_id":"go:GO:1990052","description":"\"The directed movement of a lipid from the endoplasmic reticulum (ER) to the chloroplast.\" [PMID:18689504]","metadata":null},{"id":"182cc5cb79f44957a86f6d7bcaecee46","type":"GO_TERM","name":"ER ubiquitin ligase complex","canonical_id":"go:GO:0000835","description":"\"A ubiquitin ligase complex found in the ER.\" [GOC:elh]","metadata":null},{"id":"ca09a70cd96a4b61b9804faab3cfc189","type":"TRIAL","name":"ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)","canonical_id":"clinicaltrials.gov:NCT04669587","description":"Estrogen Receptor-Positive; HER2-Negative; Locally Advanced Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"3497f527ebc447b9b0cdcfef015517a5","type":"GO_TERM","name":"ER-dependent peroxisome localization","canonical_id":"go:GO:0106101","description":"\"A process in which a protein is transported to, or maintained at, a location in a peroxisome via the endoplasmic reticulum.\" [GOC:pga, PMID:19479899, PMID:26408931]","metadata":null},{"id":"766635a945b1481abd7e09aa467cb93c","type":"GO_TERM","name":"ER-dependent peroxisome organization","canonical_id":"go:GO:0032581","description":"\"A process of peroxisome organization in which assembly or arrangement of constituent parts takes place in the endoplasmic reticulum.\" [GOC:mah, PMID:16717127, PMID:17646399]","metadata":null},{"id":"a29ea4a7f73b428ea74bdfd92a8f4595","type":"GO_TERM","name":"ER-nucleus signaling pathway","canonical_id":"go:GO:0006984","description":"\"The series of molecular signals that conveys information from the endoplasmic reticulum to the nucleus, usually resulting in a change in transcriptional regulation.\" [GOC:mah]","metadata":null},{"id":"4a26739999b745a98b5ffe5c79ac0ac4","type":"GO_TERM","name":"ER-to-endosome phospholipid transfer complex","canonical_id":"go:GO:0140622","description":"\"Lipid transfer complex that is responsible for the non-vesicular transport of phospholipids, such as phosphatidylserine, from the endoplasmic reticulum to the endosome. It resides in the endosomal (acceptor) membrane and binds to specific lipids on the donor membrane at the ER-endosome contact site.\" [GOC:lnp, PMID:20016005, PMID:24366873]","metadata":null},{"id":"1efdd5ce26e64b93b7ee96f391a314d4","type":"GO_TERM","name":"ERAD pathway","canonical_id":"go:GO:0036503","description":"\"The protein catabolic pathway which targets endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. It begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein modifications necessary for correct substrate transfer (e.g. ubiquitination), transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome.\" [GOC:bf, GOC:PARL, PMID:20940304, PMID:21969857]","metadata":null},{"id":"9c65302233424f4082a856854d231077","type":"GENE","name":"ERAL1","canonical_id":"hgnc:HGNC:3424","description":"Era like 12S mitochondrial rRNA chaperone 1","metadata":{"aliases":["HERA-B"]}},{"id":"06953b25c6b142f5b8ec29ffaca570d2","type":"GENE","name":"ERAP1","canonical_id":"hgnc:HGNC:18173","description":null,"metadata":null},{"id":"63cdaae942254e6cae0d1ba40cbbb0bd","type":"GENE","name":"ERAP1-AS1","canonical_id":"hgnc:HGNC:59101","description":"ERAP1 antisense RNA 1","metadata":null},{"id":"86681419d29c4bcf9a19d1ad2a362480","type":"GENE","name":"ERAP2","canonical_id":"hgnc:HGNC:29499","description":null,"metadata":null},{"id":"81832801e2d54fb3b7c94f802a2fe713","type":"GENE","name":"ERAS","canonical_id":"hgnc:HGNC:5174","description":"ES cell expressed Ras","metadata":{"aliases":["HRAS2","HRASP"]}},{"id":"0fdc2db81fe44d628494552f3c550e85","type":"GO_TERM","name":"ERBB signaling pathway","canonical_id":"go:GO:0038127","description":"\"The series of molecular signals initiated by binding of a ligand to a member of the ERBB family of receptor tyrosine kinases on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:jc, PMID:16460914, Wikipedia:ErbB]","metadata":null},{"id":"518481f571b047f091ae0c6e6c155a0f","type":"GENE","name":"ERBB2","canonical_id":"hgnc:HGNC:3430","description":null,"metadata":null},{"id":"b1321959caf94fd9a9a534987cc56f7a","type":"GENE","name":"ERBB2","canonical_id":"ensembl:ENSG00000141736","description":null,"metadata":null},{"id":"f84e59dd933b40f099a23062423ca7fa","type":"PROTEIN","name":"ERBB2","canonical_id":"uniprot:P04626","description":null,"metadata":null},{"id":"af14bbc2fb1c491b8e25ea4723176e1c","type":"BIOMARKER","name":"ERBB2 A775_G776insTVMA","canonical_id":"civic:4852","description":null,"metadata":null},{"id":"30515a73b4e14571b3292c013208e4ee","type":"BIOMARKER","name":"ERBB2 A775_G776insV","canonical_id":"civic:4853","description":null,"metadata":null},{"id":"8782a27b12654a98a6eaf996cc372577","type":"BIOMARKER","name":"ERBB2 A775_G776insVVMA","canonical_id":"civic:4854","description":null,"metadata":null},{"id":"4de27bff9bee4e1aa5e418c938cec6d3","type":"BIOMARKER","name":"ERBB2 A775_G776insYVMA ","canonical_id":"civic:4463","description":null,"metadata":null},{"id":"36f54a02b6974df29a29c250a51bddb4","type":"BIOMARKER","name":"ERBB2 Activating Mutation","canonical_id":"civic:2526","description":null,"metadata":null},{"id":"78edb220d8e84395a2b94b88b58f8d55","type":"BIOMARKER","name":"ERBB2 Amplification","canonical_id":"civic:302","description":null,"metadata":null},{"id":"5e630580927845bb9e421008862f246a","type":"BIOMARKER","name":"ERBB2 D769H","canonical_id":"civic:35","description":null,"metadata":null},{"id":"818180a532824ff883989b4b3548d7bd","type":"BIOMARKER","name":"ERBB2 D769Y","canonical_id":"civic:36","description":null,"metadata":null},{"id":"c09cbe65795546bbbfb1a17501f74496","type":"BIOMARKER","name":"ERBB2 Exon 20 Insertion","canonical_id":"civic:2723","description":null,"metadata":null},{"id":"43ceab292f134fe687c25e7e2e11ebe3","type":"BIOMARKER","name":"ERBB2 G292R","canonical_id":"civic:4772","description":null,"metadata":null},{"id":"e506d31763604ccd9ac533762085251d","type":"BIOMARKER","name":"ERBB2 G309A","canonical_id":"civic:38","description":null,"metadata":null},{"id":"e477bfae8cdd401286c72a3e085c4770","type":"BIOMARKER","name":"ERBB2 G776L","canonical_id":"civic:794","description":null,"metadata":null},{"id":"28090fe8b2b246f1a8ce1f32b0e36cb6","type":"BIOMARKER","name":"ERBB2 G776_V777delinsVCD","canonical_id":"civic:4855","description":null,"metadata":null},{"id":"8bb010aab3334838b70f43b0e4b1b46a","type":"BIOMARKER","name":"ERBB2 G776delinsCV","canonical_id":"civic:4856","description":null,"metadata":null},{"id":"46b476c5c009460bbe80bf5ac6e560bb","type":"BIOMARKER","name":"ERBB2 G776delinsLC","canonical_id":"civic:4857","description":null,"metadata":null},{"id":"458afebf0fbe4a22af9d39d32d6519eb","type":"BIOMARKER","name":"ERBB2 G776delinsVC","canonical_id":"civic:4467","description":null,"metadata":null},{"id":"64b220b81d8840f1a0855be1cbf11189","type":"BIOMARKER","name":"ERBB2 G778_P780dup","canonical_id":"civic:4464","description":null,"metadata":null},{"id":"4a4bb563c7724d2b8903df4c3cbd4ca5","type":"BIOMARKER","name":"ERBB2 G778_S779insLPS","canonical_id":"civic:4858","description":null,"metadata":null},{"id":"db0e11f7ad99484eb2b9c3823235d7ec","type":"BIOMARKER","name":"ERBB2 H878Y","canonical_id":"civic:848","description":null,"metadata":null},{"id":"6fbb4384aabe49b48ca7df01388bec64","type":"BIOMARKER","name":"ERBB2 Kinase Domain Mutation","canonical_id":"civic:409","description":null,"metadata":null},{"id":"91c33d7d444b42aea2565a05526e680d","type":"BIOMARKER","name":"ERBB2 Kinase Domain Mutation OR ERBB2 Exon 20 Insertion","canonical_id":"civic:5862","description":null,"metadata":null},{"id":"561dad91f3394148b591e2fbef1cd9cc","type":"BIOMARKER","name":"ERBB2 L755A","canonical_id":"civic:4780","description":null,"metadata":null},{"id":"0eaf03cb36d34c5a81a3fd7f8f676631","type":"BIOMARKER","name":"ERBB2 L755M","canonical_id":"civic:4783","description":null,"metadata":null},{"id":"18d5ec3009494819a056ecb59e2aec78","type":"BIOMARKER","name":"ERBB2 L755P","canonical_id":"civic:1278","description":null,"metadata":null},{"id":"8c160e57b73c4abf91ba294b96696a9c","type":"BIOMARKER","name":"ERBB2 L755P OR ERBB2 G776V OR ERBB2 G776delinsVC OR ERBB2 P780_Y781insGSP","canonical_id":"civic:5606","description":null,"metadata":null},{"id":"bc5b8f9b1f09422099ded392a9f96918","type":"BIOMARKER","name":"ERBB2 L755S","canonical_id":"civic:39","description":null,"metadata":null},{"id":"dd2924c6e1cf4ed9b6311fc5b6e03661","type":"BIOMARKER","name":"ERBB2 L755W","canonical_id":"civic:40","description":null,"metadata":null},{"id":"74d4bcbe67e04caeb45efbea48767fc1","type":"BIOMARKER","name":"ERBB2 L755_T759del","canonical_id":"civic:37","description":null,"metadata":null},{"id":"d6d491b4039f4fadb39e76d35135c128","type":"BIOMARKER","name":"ERBB2 L866M","canonical_id":"civic:492","description":null,"metadata":null},{"id":"f45cd706974b4985b64308587db428df","type":"BIOMARKER","name":"ERBB2 M774DELINSWLV","canonical_id":"civic:796","description":null,"metadata":null},{"id":"f3aff790355f4e8c91e2d2c12532558b","type":"BIOMARKER","name":"ERBB2 Mutation","canonical_id":"civic:662","description":null,"metadata":null},{"id":"d7002219069349788a5f23cb91f13b8d","type":"BIOMARKER","name":"ERBB2 Mutation OR ERBB3 Mutation","canonical_id":"civic:4706","description":null,"metadata":null},{"id":"efc5c95164934bd2b5899a3b440110cf","type":"BIOMARKER","name":"ERBB2 N857S","canonical_id":"civic:847","description":null,"metadata":null},{"id":"c7a390d1b96a4eb0a601f57d73128b99","type":"BIOMARKER","name":"ERBB2 Overexpression","canonical_id":"civic:849","description":null,"metadata":null},{"id":"71666e5c82d0465fbecb0298dc1f5e2f","type":"BIOMARKER","name":"ERBB2 R678Q","canonical_id":"civic:42","description":null,"metadata":null},{"id":"bd30139b34f249e1965eebd761a8b184","type":"BIOMARKER","name":"ERBB2 R896C","canonical_id":"civic:43","description":null,"metadata":null},{"id":"059c3e38a10141a78f28608a06282546","type":"BIOMARKER","name":"ERBB2 S310F","canonical_id":"civic:4470","description":null,"metadata":null},{"id":"ba4e26bb7aa7476491599abf2cd50d12","type":"BIOMARKER","name":"ERBB2 S310F/Y","canonical_id":"civic:493","description":null,"metadata":null},{"id":"83595103962f454692a5d092805747d3","type":"BIOMARKER","name":"ERBB2 Y772_A775dup OR ERBB2 G778_P780dup OR ERBB2 G776delinsVC OR ERBB2 V659E OR ERBB2 S310F OR ERBB2 G776delinsLC","canonical_id":"civic:5861","description":null,"metadata":null},{"id":"a226885689c14cdab60ec08c40a0bd08","type":"GO_TERM","name":"ERBB2 signaling pathway","canonical_id":"go:GO:0038128","description":"\"The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB2 on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription. ERBB2 receptors are themselves unable to bind to ligands, but act as a signal-amplifying tyrosine kinase within a heterodimeric pair.\" [GOC:jc, PMID:16460914]","metadata":null},{"id":"98e9e960e0ba48769fcfe3ddec2e2d06","type":"GO_TERM","name":"ERBB2-EGFR signaling pathway","canonical_id":"go:GO:0038134","description":"\"The series of molecular signals initiated by binding of a ligand to an epidermal growth factor receptor (EGFR/ERBB1) on the surface of a cell, followed by transmission of the signal by a heterodimeric complex of ERBB2 and EGFR. ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as EGFR.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"e5898b2ccb5f4b0b8a064ea91d272f06","type":"GO_TERM","name":"ERBB2-ERBB3 signaling pathway","canonical_id":"go:GO:0038133","description":"\"The series of molecular signals initiated by binding of a ligand to a ERBB3 receptor on the surface of a cell, followed by transmission of the signal by a heterodimeric complex of ERBB2 and ERBB3. ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as ERBB3. ERBB3 also has impaired kinase activity and relies on ERBB2 for activation and signal transmission.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"b0231b2ac3e64b8eaf1354b6723b048b","type":"GO_TERM","name":"ERBB2-ERBB4 signaling pathway","canonical_id":"go:GO:0038135","description":"\"The series of molecular signals initiated by binding of a ligand to a ERBB4 receptor on the surface of a cell, followed by transmission of the signal by a heterodimeric complex of ERBB2 and ERBB4. ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as ERBB4.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"735008e78b6f44498e9f3eb2dcc7d828","type":"GENE","name":"ERBB3","canonical_id":"hgnc:HGNC:3431","description":null,"metadata":null},{"id":"be4a543e3d824fa09010a78a01b94cec","type":"GO_TERM","name":"ERBB3 signaling pathway","canonical_id":"go:GO:0038129","description":"\"The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB3 on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. ERBB3 receptors have impaired kinase activity and rely on the kinase activity of the heterodimer partner for activation and signal transmission.\" [GOC:jc, PMID:16460914]","metadata":null},{"id":"170530607ef641aebbb35eabd40e4d40","type":"GO_TERM","name":"ERBB3-ERBB4 signaling pathway","canonical_id":"go:GO:0038136","description":"\"The series of molecular signals transmitted by a heterodimeric complex of the tyrosine kinase receptors ERBB3 and ERBB4. The pathway begins with binding of a ligand to either cell surface receptor, or the dimeric receptor complex, and ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"dd3ae40d113a4e96a42fe47913e8ca1c","type":"GO_TERM","name":"ERBB3:ERBB2 complex","canonical_id":"go:GO:0038143","description":"\"A heterodimeric complex between the tyrosine kinase receptor ERBB2 and a ligand-activated receptor ERBB3. ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as ERBB3.\" [GOC:signaling, PMID:16460914, PMID:8665853]","metadata":null},{"id":"275732f023b041b8961fd34d5bb6cb8e","type":"GENE","name":"ERBB4","canonical_id":"hgnc:HGNC:3432","description":null,"metadata":null},{"id":"456bef1b71754598b07f471fbdc963c8","type":"PROTEIN","name":"ERBB4","canonical_id":"uniprot:Q15303","description":null,"metadata":null},{"id":"16d7ea39bf2f40cbb36c2adc1bfa0812","type":"GO_TERM","name":"ERBB4 signaling pathway","canonical_id":"go:GO:0038130","description":"\"The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB4 on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:jc, PMID:16460914]","metadata":null},{"id":"4ec81028842d406a8605b2a2c33bfc18","type":"GO_TERM","name":"ERBB4-EGFR complex","canonical_id":"go:GO:0038139","description":"\"A heterodimeric complex between the tyrosine kinase receptors ERBB4 (also called HER4) and epidermal growth factor receptor (EGFR/ERBB1).\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"f3b71472d71a4352b688955498970834","type":"GO_TERM","name":"ERBB4-EGFR signaling pathway","canonical_id":"go:GO:0038137","description":"\"The series of molecular signals transmitted by a heterodimeric complex of the tyrosine kinase receptors EGFR (epidermal growth factor receptor/ERBB1) and ERBB4. The pathway begins with binding of a ligand to either cell surface receptor, or the dimeric receptor complex, and ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"d19f4834da054072855e0193155b6512","type":"GO_TERM","name":"ERBB4-ERBB3 complex","canonical_id":"go:GO:0038140","description":"\"A heterodimeric complex between the tyrosine kinase receptors ERBB4 (also called HER4) and ERBB3 (also called HER3). ERBB3 has impaired kinase activity so relies on the kinase activity of its heterodimer partner for activation and signal transmission.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"881e9c82184445b98ee98da4e401bc47","type":"GO_TERM","name":"ERBB4-ERBB4 complex","canonical_id":"go:GO:0038141","description":"\"A homodimeric complex containing two monomers of the tyrosine kinase receptor ERBB4 (also called HER4).\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"ce340bc06bc8462595eec387474a3050","type":"GO_TERM","name":"ERBB4-ERBB4 signaling pathway","canonical_id":"go:GO:0038138","description":"\"The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor ERBB4, followed by ligand-induced homodimerization of ERBB4 and transmission of the signal into the cell by the homodimeric ERBB4 complex. The pathway ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:16460914]","metadata":null},{"id":"5bb09f210c06442d8490e5daa3b63395","type":"GO_TERM","name":"ERBB4:ERBB2 complex","canonical_id":"go:GO:0038144","description":"\"A heterodimeric complex between the tyrosine kinase receptor ERBB2 and a ligand-activated receptor ERBB4. ERBB2, which does not bind any known ligand, is activated through formation of a heterodimer with another ligand-activated ERBB family member such as ERBB4.\" [GOC:signaling, PMID:16460914, PMID:16978839]","metadata":null},{"id":"6fa6472377c04c469ecdf43e48dfe2e3","type":"GENE","name":"ERBIN","canonical_id":"hgnc:HGNC:15842","description":"erbb2 interacting protein","metadata":{"aliases":["LAP2","ERBB2IP"]}},{"id":"b4bea7ed08a04cc59053f43344a9c94b","type":"GENE","name":"ERBIN-DT","canonical_id":"hgnc:HGNC:55270","description":"ERBIN divergent transcript","metadata":null},{"id":"49cb22577d30453292e26360e62b586e","type":"GENE","name":"ERC1","canonical_id":"hgnc:HGNC:17072","description":"ELKS/RAB6-interacting/CAST family member 1","metadata":{"aliases":["ELKS","KIAA1081","CAST2","MGC12974","RAB6IP2"]}},{"id":"9976c507aafd473b87efbe18fbcff9db","type":"GENE","name":"ERC1-AS1","canonical_id":"hgnc:HGNC:40791","description":"ERC1 antisense RNA 1","metadata":null},{"id":"a7cfa12c43224db8bdebfa5225628e3a","type":"GENE","name":"ERC2","canonical_id":"hgnc:HGNC:31922","description":"ELKS/RAB6-interacting/CAST family member 2","metadata":{"aliases":["CAST","CAST1","KIAA0378","SPBC110","Spc110","ELKSL"]}},{"id":"b30218811568476394d9fb6643f20eb7","type":"GENE","name":"ERC2-AS1","canonical_id":"hgnc:HGNC:58405","description":"ERC2 antisense RNA 1","metadata":null},{"id":"00ab39f087c04ca494eb0a99df967b53","type":"GENE","name":"ERC2-IT1","canonical_id":"hgnc:HGNC:1229","description":"ERC2 intronic transcript 1","metadata":{"aliases":["Po42","C1orf1","C3orf51"]}},{"id":"a39363e007ed4f1d87bc48a62263f53f","type":"GENE","name":"ERCC1","canonical_id":"hgnc:HGNC:3433","description":null,"metadata":null},{"id":"2d82144bb1004875b55e9b7e848bdd6d","type":"GENE","name":"ERCC2","canonical_id":"hgnc:HGNC:3434","description":null,"metadata":null},{"id":"c3e664330c594bb29d8d120d44c10bad","type":"GENE","name":"ERCC3","canonical_id":"hgnc:HGNC:3435","description":"ERCC excision repair 3, TFIIH core complex helicase subunit","metadata":{"aliases":["XPB","BTF2","RAD25","Ssl2"]}},{"id":"83bc5e24f08f4dafafce9cf2fed7028e","type":"GENE","name":"ERCC4","canonical_id":"hgnc:HGNC:3436","description":null,"metadata":null},{"id":"2016ca95355e4966b38cbb485711abab","type":"GO_TERM","name":"ERCC4-ERCC1 complex","canonical_id":"go:GO:0070522","description":"\"A heterodimeric nucleotide-excision repair complex that has endonuclease activity specific for bubble structures characteristic of certain DNA lesions. The subunits are known as XPF/ERCC4 and ERCC1 in mammals, and Rad1p and Rad10p in S. cerevisiae.\" [PMID:14734547]","metadata":null},{"id":"25cd6053164b4eddacda144aceb5373f","type":"GENE","name":"ERCC5","canonical_id":"hgnc:HGNC:3437","description":null,"metadata":null},{"id":"f1a4b629e993429f9293a5ddfe1c66d9","type":"GENE","name":"ERCC6","canonical_id":"hgnc:HGNC:3438","description":"ERCC excision repair 6, chromatin remodeling factor","metadata":{"aliases":["CSB","RAD26","ARMD5","CKN2"]}},{"id":"eac9a01621ad4efea5f02ca55b00dcd3","type":"GENE","name":"ERCC6L","canonical_id":"hgnc:HGNC:20794","description":"ERCC excision repair 6 like DNA helicase","metadata":{"aliases":["FLJ20105","PICH","RAD26L"]}},{"id":"cd46b8eb82ce4e2d8f52e977959dc4e6","type":"GENE","name":"ERCC6L2","canonical_id":"hgnc:HGNC:26922","description":"ERCC excision repair 6 like 2","metadata":{"aliases":["FLJ37706","RAD26L","HEBO","C9orf102"]}},{"id":"dcd8851f5e994605bcdcfdfbb950c301","type":"GENE","name":"ERCC6L2-AS1","canonical_id":"hgnc:HGNC:27858","description":"ERCC6L2 antisense RNA 1","metadata":{"aliases":["C9orf130","LINC00476"]}},{"id":"c090f093acfd40e68c55a85813fe890a","type":"GENE","name":"ERCC8","canonical_id":"hgnc:HGNC:3439","description":"ERCC excision repair 8, CSA ubiquitin ligase complex subunit","metadata":{"aliases":["CSA","CKN1"]}},{"id":"8749c262566e403797fd55665798829f","type":"GENE","name":"ERCC8-AS1","canonical_id":"hgnc:HGNC:40220","description":"ERCC8 antisense RNA 1","metadata":null},{"id":"21621f3cd6bd450eb2657eaa444b7f19","type":"GENE","name":"ERDA1","canonical_id":"hgnc:HGNC:3442","description":"expanded repeat domain, CAG/CTG 1","metadata":null},{"id":"dcd0c503cb2f4291800925d22946e5b6","type":"GENE","name":"EREG","canonical_id":"hgnc:HGNC:3443","description":null,"metadata":null},{"id":"ba3b3654d4794ad784bc1732ae21b601","type":"GENE","name":"EREG-AS1","canonical_id":"hgnc:HGNC:58817","description":"EREG, EPGN and MTHFD2L antisense RNA 1","metadata":null},{"id":"a88d9a37252d48f08845c8a217432dcd","type":"GENE","name":"ERF","canonical_id":"hgnc:HGNC:3444","description":null,"metadata":null},{"id":"aeb438e330ec4c9786baf9c28d3c2c9b","type":"GENE","name":"ERFE","canonical_id":"hgnc:HGNC:26727","description":"erythroferrone","metadata":{"aliases":["FLJ37034","CTRP15","C1QTNF15","FAM132B"]}},{"id":"9f2e14e1a04546e89e691d47cc9dbd04","type":"GENE","name":"ERFL","canonical_id":"hgnc:HGNC:53894","description":"ETS repressor factor like","metadata":{"aliases":["erfl1"]}},{"id":"35f92e14ccba4425a4d113b60b8a6576","type":"GENE","name":"ERG","canonical_id":"hgnc:HGNC:3446","description":null,"metadata":null},{"id":"73b8a2e915394c949c8ccbe64095807b","type":"GENE","name":"ERG28","canonical_id":"hgnc:HGNC:1187","description":"ergosterol biosynthesis 28 homolog","metadata":{"aliases":["NET51","C14orf1"]}},{"id":"f5d7b4f66ec445a88a65d67f091096f7","type":"GENE","name":"ERGIC1","canonical_id":"hgnc:HGNC:29205","description":"endoplasmic reticulum-golgi intermediate compartment 1","metadata":{"aliases":["ERGIC32","ERGIC-32","KIAA1181","NET24"]}},{"id":"b675ae6a15c342e2b3ee65536ea3452c","type":"GENE","name":"ERGIC2","canonical_id":"hgnc:HGNC:30208","description":"ERGIC and golgi 2","metadata":{"aliases":["PTX1","Erv41"]}},{"id":"80475c6a893f4b53bb667b242c2a4a39","type":"GENE","name":"ERGIC3","canonical_id":"hgnc:HGNC:15927","description":"ERGIC and golgi 3","metadata":{"aliases":["CGI-54","PRO0989","NY-BR-84","Erv46","SDBCAG84","C20orf47"]}},{"id":"9f3c0ac1c6ff489b98d0a7a948e5f0da","type":"GENE","name":"ERH","canonical_id":"hgnc:HGNC:3447","description":"ERH mRNA splicing and mitosis factor","metadata":{"aliases":["DROER"]}},{"id":"8f22cf0c12264d79b25bbac0419a449a","type":"GENE","name":"ERHP1","canonical_id":"hgnc:HGNC:41916","description":"ERH pseudogene 1","metadata":null},{"id":"f698700973e849c6a34dfadd8ed6198c","type":"GENE","name":"ERHP2","canonical_id":"hgnc:HGNC:41917","description":"ERH pseudogene 2","metadata":null},{"id":"734da7485fbe4903ba561db23bec878a","type":"GENE","name":"ERI1","canonical_id":"hgnc:HGNC:23994","description":"exoribonuclease 1","metadata":{"aliases":["3'HEXO","THEX1"]}},{"id":"d511e04acec14293aa068c07656029fe","type":"GENE","name":"ERI2","canonical_id":"hgnc:HGNC:30541","description":"ERI1 exoribonuclease family member 2","metadata":{"aliases":["KIAA1504","MGC16943","ZGRF5","EXOD1"]}},{"id":"07d90f24d48e4d59a9e60dedca5dee46","type":"GENE","name":"ERI3","canonical_id":"hgnc:HGNC:17276","description":"ERI1 exoribonuclease family member 3","metadata":{"aliases":["FLJ22943","PINT1","PRNPIP"]}},{"id":"7d77865b0816406298d1b7c19006180f","type":"GENE","name":"ERI3-IT1","canonical_id":"hgnc:HGNC:41431","description":"ERI3 intronic transcript 1","metadata":null},{"id":"efc6343d6a654a5eac6a725b7e0e07a5","type":"GENE","name":"ERICD","canonical_id":"hgnc:HGNC:49404","description":null,"metadata":null},{"id":"66a7f145be924a8d8a10393dcbc50b7b","type":"GENE","name":"ERICH1","canonical_id":"hgnc:HGNC:27234","description":"glutamate rich 1","metadata":null},{"id":"5b2e185e4e0f46a595d699516d578600","type":"GENE","name":"ERICH2","canonical_id":"hgnc:HGNC:44395","description":"glutamate rich 2","metadata":null},{"id":"8d74ec08db644771826d2c2d23095388","type":"GENE","name":"ERICH2-DT","canonical_id":"hgnc:HGNC:55686","description":"ERICH2 divergent transcript","metadata":{"aliases":["uc.95"]}},{"id":"ec7b28f3e8c9410c83382a0242e4fac8","type":"GENE","name":"ERICH3","canonical_id":"hgnc:HGNC:25346","description":"glutamate rich 3","metadata":{"aliases":["DKFZp547I048","RP11-653A5.1","C1orf173"]}},{"id":"57c3329c1c2748ebbc2328d4af39979a","type":"GENE","name":"ERICH3-AS1","canonical_id":"hgnc:HGNC:41093","description":"ERICH3 antisense RNA 1","metadata":null},{"id":"745a2db8aee143e2a40169b5c3763885","type":"GENE","name":"ERICH4","canonical_id":"hgnc:HGNC:34497","description":"glutamate rich 4","metadata":{"aliases":["LOC100170765","C19orf69"]}},{"id":"4b63418655584534a7346f7d8e4c0d87","type":"GENE","name":"ERICH5","canonical_id":"hgnc:HGNC:26823","description":"glutamate rich 5","metadata":{"aliases":["FLJ39553","C8orf47"]}},{"id":"c7f9f66aeda44e34aa05650bbb398901","type":"GENE","name":"ERICH6","canonical_id":"hgnc:HGNC:28602","description":"glutamate rich 6","metadata":{"aliases":["MGC39662","ERICH6A","C3orf44","FAM194A"]}},{"id":"79620f0486c14576aab5cdd3339b541c","type":"GENE","name":"ERICH6-AS1","canonical_id":"hgnc:HGNC:41205","description":"ERICH6 antisense RNA 1","metadata":null},{"id":"b6265b246ed84ba2a3585c2cc6719ad8","type":"GENE","name":"ERICH6B","canonical_id":"hgnc:HGNC:26523","description":"glutamate rich 6B","metadata":{"aliases":["FLJ32682","FAM194B"]}},{"id":"fcc5bbcedbef4dceb5cd2d1c74420cb6","type":"GO_TERM","name":"ERK1 and ERK2 cascade","canonical_id":"go:GO:0070371","description":"\"A MAPK cascade containing at least the ERK1 or ERK2 MAP kinases. It starts with the activation of a MAP3K, and the consecutive activation of a MPK2K and of ERK1 or ERK2. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinase in the downstream tier. The ERK1/ERK2 cascade is activated by mitogens, growth factors, G protein-coupled receptors, and results in cellular responses such as cell proliferation, cell differentiation and development.\" [PMID:20811974, PMID:23125017, PMID:28903453]","metadata":null},{"id":"2d55b70be5af4235b713b94376c0d67b","type":"GO_TERM","name":"ERK5 cascade","canonical_id":"go:GO:0070375","description":"\"A MAPK cascade containing at least the ERK5 MAP kinase (MAPK7; also called BMK1). It starts with the activation of a MAP3K, and the consecutive activation of a MPK2K and of ERK5. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinases in the downstream tier. The ERK5 cascade is activated by stress, mitogens, and by G protein-coupled receptors, and results in cellular responses such as cell growth, cell differentiation and development.\" [PMID:16376520, PMID:16880823, PMID:20811974, PMID:23125017, PMID:28903453]","metadata":null},{"id":"23d4d81a1afe46839cce42da2cfa9d18","type":"GENE","name":"ERLEC1","canonical_id":"hgnc:HGNC:25222","description":"endoplasmic reticulum lectin 1","metadata":{"aliases":["CL25084","XTP3TPB","XTP3-B","ERLECTIN","C2orf30"]}},{"id":"dcc6b9cfc1cc4458b536494436fb1b60","type":"GENE","name":"ERLEC1P1","canonical_id":"hgnc:HGNC:38012","description":"endoplasmic reticulum lectin 1 pseudogene 1","metadata":null},{"id":"f67d0d25c0354fe695f109ac7e833deb","type":"GENE","name":"ERLIN1","canonical_id":"hgnc:HGNC:16947","description":"ER lipid raft associated 1","metadata":{"aliases":["KE04","Erlin-1","SPG62","C10orf69","SPFH1"]}},{"id":"dede530f8cb64565a7eb534e593c29f9","type":"GENE","name":"ERLIN2","canonical_id":"hgnc:HGNC:1356","description":"ER lipid raft associated 2","metadata":{"aliases":["NET32","Erlin-2","C8orf2","SPFH2","SPG18"]}},{"id":"b2cd6ffceaaa4dceb6069c18f45b7846","type":"GENE","name":"ERLN","canonical_id":"hgnc:HGNC:40032","description":"endoregulin","metadata":{"aliases":["ELN","SMIM6","C17orf110"]}},{"id":"9d7c3c7b7f2842778f5777a4605b3ad6","type":"GENE","name":"ERLNC1","canonical_id":"hgnc:HGNC:41109","description":"estrogen receptor responsive lncRNA 1","metadata":{"aliases":["TC0101441","ElncRNA1"]}},{"id":"666a611f60ab4e9092e475509a92b549","type":"GENE","name":"ERMAP","canonical_id":"hgnc:HGNC:15743","description":"erythroblast membrane associated protein (Scianna blood group)","metadata":{"aliases":["BTN5","RD","SC"]}},{"id":"648d9c779fc84fc28aabf64c31e43697","type":"GENE","name":"ERMARD","canonical_id":"hgnc:HGNC:21056","description":"ER membrane associated RNA degradation","metadata":{"aliases":["FLJ11152","dJ266L20.3","C6orf70"]}},{"id":"4aa867e42e3f4e31b7e0f5953cc4690d","type":"GO_TERM","name":"ERMES complex","canonical_id":"go:GO:0032865","description":"\"A protein complex that links the endoplasmic reticulum with mitochondria and may have a role in promoting exchange of calcium and phospholipids between the two organelles.\" [GOC:mcc, PMID:19556461, PMID:29279306]","metadata":null},{"id":"057dbc91858c485883259b67ec804a67","type":"GENE","name":"ERMN","canonical_id":"hgnc:HGNC:29208","description":"ermin","metadata":{"aliases":["JN","ERMIN","KIAA1189"]}},{"id":"21634b7f27094d6f88b39f73a4d12458","type":"GENE","name":"ERMP1","canonical_id":"hgnc:HGNC:23703","description":"endoplasmic reticulum metallopeptidase 1","metadata":{"aliases":["FLJ23309","FXNA","KIAA1815"]}},{"id":"8023ff66a5654eefa8cfc92cf8e83548","type":"GENE","name":"ERN1","canonical_id":"hgnc:HGNC:3449","description":null,"metadata":null},{"id":"ea31d262178346308a88ffec97c981c3","type":"GENE","name":"ERN2","canonical_id":"hgnc:HGNC:16942","description":"endoplasmic reticulum to nucleus signaling 2","metadata":{"aliases":["IRE1b"]}},{"id":"8ad712c9ff8248a98a2911b3c4633ffa","type":"GENE","name":"ERO1A","canonical_id":"hgnc:HGNC:13280","description":null,"metadata":null},{"id":"b70631186bb5472fb48fa181ee4ecedd","type":"GENE","name":"ERO1B","canonical_id":"hgnc:HGNC:14355","description":"endoplasmic reticulum oxidoreductase 1 beta","metadata":{"aliases":["ERO1-L(beta)","Ero1beta","ERO1LB"]}},{"id":"1d7e3564b0be40dea3a9eead835ab573","type":"GENE","name":"ERP27","canonical_id":"hgnc:HGNC:26495","description":"endoplasmic reticulum protein 27","metadata":{"aliases":["FLJ32115","PDIA8","C12orf46"]}},{"id":"3a433578e3dd49ac81440bb9a539b814","type":"GENE","name":"ERP29","canonical_id":"hgnc:HGNC:13799","description":null,"metadata":null},{"id":"0a23a5f81fb24d09a8dfcb11f51faa93","type":"GENE","name":"ERP29P1","canonical_id":"hgnc:HGNC:24625","description":"endoplasmic reticulum lumenal protein 29 pseudogene 1","metadata":{"aliases":["ERP28P"]}},{"id":"47986d1bc06d4c6f8b22133062484052","type":"GENE","name":"ERP44","canonical_id":"hgnc:HGNC:18311","description":null,"metadata":null},{"id":"0d96beb9341e40d08cf9db9df34eab6a","type":"GENE","name":"ERRFI1","canonical_id":"hgnc:HGNC:18185","description":"ERBB receptor feedback inhibitor 1","metadata":{"aliases":["MIG-6","GENE-33","RALT"]}},{"id":"34527b316a244d81a8ad4eac6a27b600","type":"GENE","name":"ERRFI1-DT","canonical_id":"hgnc:HGNC:55646","description":"ERRFI1 divergent transcript","metadata":null},{"id":"ca430c37c1c347c8b403826daed1b7df","type":"TRIAL","name":"ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF","canonical_id":"clinicaltrials.gov:NCT05152940","description":"Heart Failure With Reduced Ejection Fraction; Congestion","metadata":null},{"id":"f6527589e0fc41c1879996a1ea12958b","type":"GENE","name":"ERV18-1","canonical_id":"hgnc:HGNC:41524","description":"endogenous retrovirus group 18 member 1","metadata":null},{"id":"d51342cab9d643378125b5602aaca5ab","type":"GENE","name":"ERV3-1","canonical_id":"hgnc:HGNC:3454","description":"endogenous retrovirus group 3 member 1, envelope","metadata":{"aliases":["H-PLK","HERV-R","ERV-R","envR","ERV3"]}},{"id":"adc172ec4eba44c5888435459b306946","type":"GENE","name":"ERV3-2","canonical_id":"hgnc:HGNC:22218","description":"endogenous retrovirus group 3 member 2","metadata":{"aliases":["KIAA1466"]}},{"id":"9a39e4433e8a4cdab7ad3cf64a8f4cf7","type":"GENE","name":"ERV9-1","canonical_id":"hgnc:HGNC:39060","description":"endogenous retrovirus group 9 member 1","metadata":{"aliases":["pTR2"]}},{"id":"33c8afdaf8ba4d78b9e04482c6f72d3d","type":"GENE","name":"ERVE-1","canonical_id":"hgnc:HGNC:14602","description":"endogenous retrovirus group E member 1","metadata":{"aliases":["HERV-E1","HERVE1","TCONS_00025599","ERVE1"]}},{"id":"35412114e33e4636815d52c09238403f","type":"GENE","name":"ERVE-2","canonical_id":"hgnc:HGNC:39048","description":"endogenous retrovirus group E member 2","metadata":null},{"id":"7f0a374d51be431d926ef3c51ca6e1b6","type":"GENE","name":"ERVE-3","canonical_id":"hgnc:HGNC:39049","description":"endogenous retrovirus group E member 3","metadata":null},{"id":"b6e95ea6faec4ba782b4883661284489","type":"GENE","name":"ERVE-4","canonical_id":"hgnc:HGNC:39050","description":"endogenous retrovirus group E member 4","metadata":null},{"id":"2af5eb04da3c47e49166e7993e326f7a","type":"GENE","name":"ERVE-5","canonical_id":"hgnc:HGNC:58089","description":"endogenous retrovirus group E member 5","metadata":{"aliases":["AC079466.1"]}},{"id":"a1e53c40f7204f94bd7af3cf2c52ac5f","type":"GENE","name":"ERVFC1-1","canonical_id":"hgnc:HGNC:38137","description":"endogenous retrovirus group FC1 member 1, envelope","metadata":{"aliases":["FLJ42291","envF(c)2","TCONS_l2_00027524"]}},{"id":"48ba1f86e7cd45509afa82c0fcf80d5e","type":"GENE","name":"ERVFH21-1","canonical_id":"hgnc:HGNC:39047","description":"endogenous retrovirus group FH21 member 1","metadata":{"aliases":["HERV-F(XA34)"]}},{"id":"176bb23131a540be8abdac108b5da379","type":"GENE","name":"ERVFRD-1","canonical_id":"hgnc:HGNC:33823","description":null,"metadata":null},{"id":"4254ecb458014883810190a36cef39c8","type":"GENE","name":"ERVFRD-2","canonical_id":"hgnc:HGNC:35201","description":"endogenous retrovirus group FRD member 2","metadata":{"aliases":["FLJ45949"]}},{"id":"a6ba5de6fca04c15849ea681787a4e52","type":"GENE","name":"ERVFRD-3","canonical_id":"hgnc:HGNC:49792","description":"endogenous retrovirus group FRD member 3","metadata":null},{"id":"a3d20067a4534b2baf1c7c6724769e86","type":"GENE","name":"ERVH-1","canonical_id":"hgnc:HGNC:39053","description":"endogenous retrovirus group H member 1","metadata":{"aliases":["HERV-H4p15.2"]}},{"id":"d3c3cdc087ce46c6a954e4742bf66c54","type":"GENE","name":"ERVH-10","canonical_id":"hgnc:HGNC:53423","description":"endogenous retrovirus group H member 10, envelope","metadata":{"aliases":["envH3","envH/p59"]}},{"id":"0aae6b2ff75b4912b5a668043df80bce","type":"GENE","name":"ERVH-2","canonical_id":"hgnc:HGNC:39054","description":"endogenous retrovirus group H member 2","metadata":{"aliases":["HERV-HX"]}},{"id":"4e29061a1aa64d36bd4df0167d4e668f","type":"GENE","name":"ERVH-3","canonical_id":"hgnc:HGNC:39055","description":"endogenous retrovirus group H member 3","metadata":{"aliases":["HERV-H/F","RP11-301G19.1","TCONS_l2_00025412"]}},{"id":"cb420ca37e354d94ad4b79393297a437","type":"GENE","name":"ERVH-4","canonical_id":"hgnc:HGNC:21344","description":"endogenous retrovirus group H member 4","metadata":{"aliases":["HERV-HD1"]}},{"id":"3d4e863c4ba74dd4beb3e9d27cd7a55b","type":"GENE","name":"ERVH-5","canonical_id":"hgnc:HGNC:39057","description":"endogenous retrovirus group H member 5","metadata":null},{"id":"cfe43cb557ff40d0be2d5cc2892f829e","type":"GENE","name":"ERVH-6","canonical_id":"hgnc:HGNC:39058","description":"endogenous retrovirus group H member 6","metadata":null},{"id":"f8ab1e4b0fc24771b52ba3594a9e9b61","type":"GENE","name":"ERVH-7","canonical_id":"hgnc:HGNC:39059","description":"endogenous retrovirus group H member 7","metadata":{"aliases":["TCONS_00022381"]}},{"id":"8434f74dcce84ebb93fe42fc48c6b521","type":"GENE","name":"ERVH-8","canonical_id":"hgnc:HGNC:53421","description":"endogenous retrovirus group H member 8, envelope","metadata":{"aliases":["envH1"]}},{"id":"fe4527cd3f15407e99157a53ffc5e5a1","type":"GENE","name":"ERVH-9","canonical_id":"hgnc:HGNC:53422","description":"endogenous retrovirus group H member 9, envelope","metadata":{"aliases":["envH2"]}},{"id":"0e2be990e6c0413e924331750db2c59e","type":"GENE","name":"ERVH48-1","canonical_id":"hgnc:HGNC:17216","description":"endogenous retrovirus group 48 member 1, envelope","metadata":{"aliases":["SUPYN","HERV-Fb1","C21orf105","NDUFV3-AS1"]}},{"id":"6fad929091b444308c079d86e3cb8997","type":"GENE","name":"ERVI-1","canonical_id":"hgnc:HGNC:39052","description":"endogenous retrovirus group I member 1","metadata":null},{"id":"f15a386c72b244d8b231096afa6eef06","type":"GENE","name":"ERVK-1","canonical_id":"hgnc:HGNC:39000","description":"endogenous retrovirus group K member 1","metadata":{"aliases":["c1_A"]}},{"id":"60c01e9efe0b4d0baa4d03a77128bb7c","type":"GENE","name":"ERVK-10","canonical_id":"hgnc:HGNC:39004","description":"endogenous retrovirus group K member 10","metadata":null},{"id":"976a2ab706a241c19668e16523fe6f06","type":"GENE","name":"ERVK-11","canonical_id":"hgnc:HGNC:39006","description":"endogenous retrovirus group K member 11","metadata":{"aliases":["c3_E","N8.4"]}},{"id":"d187f05d34b44d5c9052542bb6dd5a6d","type":"GENE","name":"ERVK-12","canonical_id":"hgnc:HGNC:39007","description":"endogenous retrovirus group K member 12","metadata":null},{"id":"d30025dfc0fd4b8ca02f2f2fd65a11e3","type":"GENE","name":"ERVK-13","canonical_id":"hgnc:HGNC:39008","description":"endogenous retrovirus group K member 13","metadata":{"aliases":["c3_D"]}},{"id":"1e0b98a0cee04ffa824f9f31b5c3c996","type":"GENE","name":"ERVK-14","canonical_id":"hgnc:HGNC:39019","description":"endogenous retrovirus group K member 14","metadata":{"aliases":["c7_B"]}},{"id":"cc566c236ec844969722f30bdc5326e9","type":"GENE","name":"ERVK-15","canonical_id":"hgnc:HGNC:39022","description":"endogenous retrovirus group K member 15","metadata":{"aliases":["c7_C","P1.10"]}},{"id":"3c4313bdfbd34b1c90dff8682ed9ba54","type":"GENE","name":"ERVK-16","canonical_id":"hgnc:HGNC:39023","description":"endogenous retrovirus group K member 16","metadata":{"aliases":["c10_A.","M3.8"]}},{"id":"89a6c915807e49449f141bd36cfc5702","type":"GENE","name":"ERVK-17","canonical_id":"hgnc:HGNC:39024","description":"endogenous retrovirus group K member 17","metadata":{"aliases":["c10_B"]}},{"id":"afb0b1ac591a4d229e27a4871a91e609","type":"GENE","name":"ERVK-18","canonical_id":"hgnc:HGNC:39025","description":"endogenous retrovirus group K member 18","metadata":{"aliases":["c1_C","HERV-K18"]}},{"id":"ec098c7859a44acd95fb5169d0bb649a","type":"GENE","name":"ERVK-19","canonical_id":"hgnc:HGNC:39026","description":"endogenous retrovirus group K member 19, envelope","metadata":{"aliases":["P1.8","HERV-K(C19)","envK3"]}},{"id":"2d200ce3e01c46c8afe8aef48a57fa85","type":"GENE","name":"ERVK-2","canonical_id":"hgnc:HGNC:39001","description":"endogenous retrovirus group K member 2","metadata":{"aliases":["c3_A"]}},{"id":"d012a88cf4044b5c8b7ec7093fdcd68c","type":"GENE","name":"ERVK-20","canonical_id":"hgnc:HGNC:39031","description":"endogenous retrovirus group K member 20","metadata":{"aliases":["c11_B"]}},{"id":"81b66bd967924d9c970b2336c3c9d090","type":"GENE","name":"ERVK-21","canonical_id":"hgnc:HGNC:39035","description":"endogenous retrovirus group K member 21, envelope","metadata":{"aliases":["c12_A","envK1"]}},{"id":"ff72c1b1d79b4906a4cb30ed11c4c40d","type":"GENE","name":"ERVK-22","canonical_id":"hgnc:HGNC:39036","description":"endogenous retrovirus group K member 22","metadata":{"aliases":["c19_A"]}},{"id":"4aab830159e8489f84962e4f5507621c","type":"GENE","name":"ERVK-23","canonical_id":"hgnc:HGNC:39037","description":"endogenous retrovirus group K member 23","metadata":{"aliases":["c21_A"]}},{"id":"3fe53c7544fd49b08c43040a4bc52cfd","type":"GENE","name":"ERVK-24","canonical_id":"hgnc:HGNC:39038","description":"endogenous retrovirus group K member 24","metadata":{"aliases":["c22_A","HERV-K101"]}},{"id":"d21a31e94d1f477aba21c4930045dcf8","type":"GENE","name":"ERVK-25","canonical_id":"hgnc:HGNC:39039","description":"endogenous retrovirus group K member 25","metadata":{"aliases":["c11_A"]}},{"id":"a957675200bb4308a04da5e41e6fe2c1","type":"GENE","name":"ERVK-26","canonical_id":"hgnc:HGNC:44979","description":"endogenous retrovirus group K member 26","metadata":null},{"id":"513b0772b2db4c7d8805537224d6742a","type":"GENE","name":"ERVK-27","canonical_id":"hgnc:HGNC:44980","description":"endogenous retrovirus group K member 27","metadata":null},{"id":"37d8be4a6fb14352b1201f8f18024e5c","type":"GENE","name":"ERVK-28","canonical_id":"hgnc:HGNC:44981","description":"endogenous retrovirus group K member 28","metadata":null},{"id":"4ddd0287714440d8aeed731ee1773b25","type":"GENE","name":"ERVK-29","canonical_id":"hgnc:HGNC:44982","description":"endogenous retrovirus group K member 29","metadata":null},{"id":"e9346c626173439fab230b78f29db797","type":"GENE","name":"ERVK-3","canonical_id":"hgnc:HGNC:39002","description":"endogenous retrovirus group K member 3","metadata":{"aliases":["c3_B"]}},{"id":"c8b6220b16c44576aa4a26bf84bf8989","type":"GENE","name":"ERVK-30","canonical_id":"hgnc:HGNC:51378","description":"endogenous retrovirus group K member 30","metadata":null},{"id":"26edd46884c24e73b7020a169928a364","type":"GENE","name":"ERVK-31","canonical_id":"hgnc:HGNC:51379","description":"endogenous retrovirus group K member 31","metadata":null},{"id":"2f20875df5fb4e4193a39b6df9703d57","type":"GENE","name":"ERVK-32","canonical_id":"hgnc:HGNC:53424","description":"endogenous retrovirus group K member 32, envelope","metadata":{"aliases":["envK4","HERV-K109"]}},{"id":"2f12e158daf8427e8e721cbb2417e1cf","type":"GENE","name":"ERVK-4","canonical_id":"hgnc:HGNC:13756","description":"endogenous retrovirus group K member 4","metadata":{"aliases":["HERV-K(I)","ERVK4"]}},{"id":"93198c4d100d4bd2a12004111b492f66","type":"GENE","name":"ERVK-5","canonical_id":"hgnc:HGNC:13757","description":"endogenous retrovirus group K member 5","metadata":{"aliases":["HERV-K(II)","ERVK5"]}},{"id":"9cc28144f3c041e5a66fa96c675de012","type":"GENE","name":"ERVK-6","canonical_id":"hgnc:HGNC:13915","description":"endogenous retrovirus group K member 6, envelope","metadata":{"aliases":["HERV-K(HML-2.HOM)","HERV-K108","HERV-K(C7)","envK2","ERVK6"]}},{"id":"7391b70dd4fb4340ba52b4d32e654d35","type":"GENE","name":"ERVK-7","canonical_id":"hgnc:HGNC:31828","description":"endogenous retrovirus group K member 7","metadata":{"aliases":["HERV-K(III)","HERV-K102","ERVK7"]}},{"id":"dd8f5e82e5e84046818aa267f7912972","type":"GENE","name":"ERVK-8","canonical_id":"hgnc:HGNC:32302","description":"endogenous retrovirus group K member 8, envelope","metadata":{"aliases":["HERV-K115","envK6","ERVK8"]}},{"id":"4b411bddde9742cda1c782a61649b83a","type":"GENE","name":"ERVK-9","canonical_id":"hgnc:HGNC:39005","description":"endogenous retrovirus group K member 9","metadata":null},{"id":"a75241755e8a49d6a14e509fb8ec86bf","type":"GENE","name":"ERVK11-1","canonical_id":"hgnc:HGNC:43647","description":"endogenous retrovirus group K11 member 1","metadata":null},{"id":"fb803ece7e1d4840b5c27004e66c8073","type":"GENE","name":"ERVK13-1","canonical_id":"hgnc:HGNC:27548","description":"endogenous retrovirus group K13 member 1","metadata":null},{"id":"69167ff7299441b7b60b2234a268f6fe","type":"GENE","name":"ERVK3-1","canonical_id":"hgnc:HGNC:30466","description":"endogenous retrovirus group K3 member 1","metadata":{"aliases":["HERV-K(HML6-1)"]}},{"id":"121191376df9478fbf6359e586cab2eb","type":"GENE","name":"ERVK3-2","canonical_id":"hgnc:HGNC:39040","description":"endogenous retrovirus group K3 member 2","metadata":{"aliases":["HML6-c14"]}},{"id":"3fb75993f4694255878ac2c030c264d7","type":"GENE","name":"ERVK3-3","canonical_id":"hgnc:HGNC:39108","description":"endogenous retrovirus group K3 member 3","metadata":{"aliases":["HML6-c5"]}},{"id":"881ad093e68e411ca02838249fa0ccc0","type":"GENE","name":"ERVK3-4","canonical_id":"hgnc:HGNC:39109","description":"endogenous retrovirus group K3 member 4","metadata":{"aliases":["HML6-c11"]}},{"id":"6deddd94b6a64994a0f9fdc261f0ae43","type":"GENE","name":"ERVK3-5","canonical_id":"hgnc:HGNC:39110","description":"endogenous retrovirus group K3 member 5","metadata":{"aliases":["HML6-c12"]}},{"id":"0a9a14933e164f5390efbfe7315487b2","type":"GENE","name":"ERVK3-6","canonical_id":"hgnc:HGNC:39111","description":"endogenous retrovirus group K3 member 6","metadata":{"aliases":["HML6-c19A"]}},{"id":"5216c425daa9452b924bc24861a9af35","type":"GENE","name":"ERVK3-7","canonical_id":"hgnc:HGNC:39112","description":"endogenous retrovirus group K3 member 7","metadata":{"aliases":["HML6-c19B"]}},{"id":"4f31df2a5e1441878a6692747ccd6f48","type":"GENE","name":"ERVK3-8","canonical_id":"hgnc:HGNC:39113","description":"endogenous retrovirus group K3 member 8","metadata":null},{"id":"752433fc6ce441a592ab7b6bb26dac31","type":"GENE","name":"ERVK9-1","canonical_id":"hgnc:HGNC:50898","description":"endogenous retrovirus group K9, member 1","metadata":null},{"id":"8713d0712dc6420b9af09347b38ee1b4","type":"GENE","name":"ERVK9-10","canonical_id":"hgnc:HGNC:51159","description":"endogenous retrovirus group K9, member 10","metadata":null},{"id":"20a6949674bc429f97d8eb8f22e1ee7a","type":"GENE","name":"ERVK9-11","canonical_id":"hgnc:HGNC:51160","description":"endogenous retrovirus group K9, member 11","metadata":null},{"id":"e6420072065c4dff8bc655d0ad0973dc","type":"GENE","name":"ERVK9-12","canonical_id":"hgnc:HGNC:53627","description":"endogenous retrovirus group K9, member 12","metadata":null},{"id":"073cebd297d1408595bf024701bd52f0","type":"GENE","name":"ERVK9-2","canonical_id":"hgnc:HGNC:50908","description":"endogenous retrovirus group K9, member 2","metadata":null},{"id":"e0ef82b5069f4320907cfbaeafcd5898","type":"GENE","name":"ERVK9-3","canonical_id":"hgnc:HGNC:50909","description":"endogenous retrovirus group K9, member 3","metadata":null},{"id":"b19ba38ad8a248d3849cdf4e09462a0d","type":"GENE","name":"ERVK9-4","canonical_id":"hgnc:HGNC:50910","description":"endogenous retrovirus group K9, member 4","metadata":null},{"id":"346a410da20645139234b7a45a032f29","type":"GENE","name":"ERVK9-5","canonical_id":"hgnc:HGNC:51154","description":"endogenous retrovirus group K9, member 5","metadata":null},{"id":"d8a7d159c42d4e1787e74b76752571bc","type":"GENE","name":"ERVK9-6","canonical_id":"hgnc:HGNC:51155","description":"endogenous retrovirus group K9, member 6","metadata":null},{"id":"ddfd64bee663496db4d5fd690262f569","type":"GENE","name":"ERVK9-7","canonical_id":"hgnc:HGNC:51156","description":"endogenous retrovirus group K9, member 7","metadata":null},{"id":"346e9f6682204056bcabb9cd41fc0843","type":"GENE","name":"ERVK9-8","canonical_id":"hgnc:HGNC:51157","description":"endogenous retrovirus group K9, member 8","metadata":null},{"id":"35b56c008fc24fa4ac253394c5a6bdb3","type":"GENE","name":"ERVK9-9","canonical_id":"hgnc:HGNC:51158","description":"endogenous retrovirus group K9, member 9","metadata":{"aliases":["TCONS_00025543"]}},{"id":"7c9ac10b8a534aa099e8b36c9a82eb36","type":"GENE","name":"ERVMER34-1","canonical_id":"hgnc:HGNC:42970","description":"endogenous retrovirus group MER34 member 1, envelope","metadata":{"aliases":["envMER34","HEMO"]}},{"id":"05c7a4ba0ec04508925ffb657b8b07c0","type":"GENE","name":"ERVMER61-1","canonical_id":"hgnc:HGNC:27919","description":"endogenous retrovirus group MER61 member 1","metadata":{"aliases":["TP53LC07","C1orf99"]}},{"id":"9973718f531a495a9a49b859363a9cda","type":"GENE","name":"ERVPABLB-1","canonical_id":"hgnc:HGNC:39042","description":"endogenous retrovirus group PABLB member 1, envelope","metadata":{"aliases":["envR(b)"]}},{"id":"29cc09c5e0f44116a17c856d3a039d05","type":"GENE","name":"ERVS71-1","canonical_id":"hgnc:HGNC:41525","description":"endogenous retrovirus group S71 member 1, envelope","metadata":{"aliases":["envT"]}},{"id":"01e1ae4f201d4fd882542a377f700c1f","type":"GENE","name":"ERVS71-2","canonical_id":"hgnc:HGNC:41526","description":"endogenous retrovirus group S71 member 2","metadata":{"aliases":["HERV-HC2"]}},{"id":"10b1e9f898b14ffc93ad4954078a1ddc","type":"GENE","name":"ERVV-1","canonical_id":"hgnc:HGNC:26501","description":"endogenous retrovirus group V member 1, envelope","metadata":{"aliases":["FLJ32214","HERV-V1","ENVV1"]}},{"id":"30b6a77349624182a4248ac140d203bb","type":"GENE","name":"ERVV-2","canonical_id":"hgnc:HGNC:39051","description":"endogenous retrovirus group V member 2, envelope","metadata":{"aliases":["ENVV2"]}},{"id":"d212297e478940b69734b993cc1095fb","type":"GENE","name":"ERVW-1","canonical_id":"hgnc:HGNC:13525","description":null,"metadata":null},{"id":"5e1d37db9bd744f297b9b207c57fd57b","type":"GENE","name":"ERVW-10","canonical_id":"hgnc:HGNC:49249","description":"endogenous retrovirus group W member 10","metadata":null},{"id":"d8f244e2075b46c1a5f9b49fcd5bd9a6","type":"GENE","name":"ERVW-11","canonical_id":"hgnc:HGNC:49250","description":"endogenous retrovirus group W member 11","metadata":null},{"id":"ce1e9ef25ff14256b92ef331b980232e","type":"GENE","name":"ERVW-12","canonical_id":"hgnc:HGNC:49251","description":"endogenous retrovirus group W member 12","metadata":null},{"id":"b38ef20ea81b4ddfadf2994c3b6b42ea","type":"GENE","name":"ERVW-13","canonical_id":"hgnc:HGNC:49252","description":"endogenous retrovirus group W member 13","metadata":null},{"id":"9bdb28caca18420f99052348b877d0d1","type":"GENE","name":"ERVW-14","canonical_id":"hgnc:HGNC:49253","description":"endogenous retrovirus group W member 14","metadata":null},{"id":"5481d4f5e23b41b9a2b9cdffa53ff495","type":"GENE","name":"ERVW-15","canonical_id":"hgnc:HGNC:49254","description":"endogenous retrovirus group W member 15","metadata":null},{"id":"8dbfb7f2cbf94ac5ba273f04debb7dcc","type":"GENE","name":"ERVW-16","canonical_id":"hgnc:HGNC:49255","description":"endogenous retrovirus group W member 16","metadata":null},{"id":"8d4f95798c544accb46e5e717c805991","type":"GENE","name":"ERVW-17","canonical_id":"hgnc:HGNC:49256","description":"endogenous retrovirus group W member 17","metadata":null},{"id":"9daac963858a40bdb95a00f5f932deca","type":"GENE","name":"ERVW-18","canonical_id":"hgnc:HGNC:49306","description":"endogenous retrovirus group W member 18","metadata":null},{"id":"dc74ee0d42624cb480f36e053e3e68e7","type":"GENE","name":"ERVW-19","canonical_id":"hgnc:HGNC:49307","description":"endogenous retrovirus group W member 19","metadata":null},{"id":"326eaf07892d4c25b0e8f77ad94546c3","type":"GENE","name":"ERVW-2","canonical_id":"hgnc:HGNC:37653","description":"endogenous retrovirus group W member 2","metadata":{"aliases":["NTrenv","ERVWE2"]}},{"id":"8475160cbfed4222becbec2ca5ec49b2","type":"GENE","name":"ERVW-20","canonical_id":"hgnc:HGNC:49308","description":"endogenous retrovirus group W member 20","metadata":null},{"id":"797288f4eaa7445fa896a6f4be9d0ddb","type":"GENE","name":"ERVW-21","canonical_id":"hgnc:HGNC:49309","description":"endogenous retrovirus group W member 21","metadata":null},{"id":"c32f32070a1c41e8ba77a0f16c58d628","type":"GENE","name":"ERVW-22","canonical_id":"hgnc:HGNC:49310","description":"endogenous retrovirus group W member 22","metadata":null},{"id":"9f3543f1d0a64c1b92ec308e32cb028d","type":"GENE","name":"ERVW-23","canonical_id":"hgnc:HGNC:49311","description":"endogenous retrovirus group W member 23","metadata":null},{"id":"5272e978cced4e2aa51fd40ec02d39f0","type":"GENE","name":"ERVW-24","canonical_id":"hgnc:HGNC:49312","description":"endogenous retrovirus group W member 24","metadata":null},{"id":"e495829169a94987a7443157c7889b13","type":"GENE","name":"ERVW-25","canonical_id":"hgnc:HGNC:49313","description":"endogenous retrovirus group W member 25","metadata":null},{"id":"8cb46b4ac182474f9bcf54e78e74c9f7","type":"GENE","name":"ERVW-26","canonical_id":"hgnc:HGNC:49314","description":"endogenous retrovirus group W member 26","metadata":null},{"id":"2e2b3e5c7f6e413eb446a38172ddf4af","type":"GENE","name":"ERVW-27","canonical_id":"hgnc:HGNC:49315","description":"endogenous retrovirus group W member 27","metadata":null},{"id":"c7dee77877454205a46f2a358e355db7","type":"GENE","name":"ERVW-28","canonical_id":"hgnc:HGNC:49316","description":"endogenous retrovirus group W member 28","metadata":null},{"id":"e0f29a56b9844cde9b9a4960a1bc6d52","type":"GENE","name":"ERVW-29","canonical_id":"hgnc:HGNC:49378","description":"endogenous retrovirus group W member 29","metadata":null},{"id":"862a8caabfc84a5cad3ef9ac5b5701cf","type":"GENE","name":"ERVW-3","canonical_id":"hgnc:HGNC:39041","description":"endogenous retrovirus group W member 3","metadata":{"aliases":["CL4"]}},{"id":"efb759d6226b41589236cbff6b306d63","type":"GENE","name":"ERVW-4","canonical_id":"hgnc:HGNC:39043","description":"endogenous retrovirus group W member 4","metadata":{"aliases":["C187-23"]}},{"id":"4ffc633dcecf45bbba86384123483252","type":"GENE","name":"ERVW-5","canonical_id":"hgnc:HGNC:39044","description":"endogenous retrovirus group W member 5","metadata":{"aliases":["CL2"]}},{"id":"075acbee42d842a09f8fd71fa110abd0","type":"GENE","name":"ERVW-6","canonical_id":"hgnc:HGNC:39045","description":"endogenous retrovirus group W member 6","metadata":null},{"id":"9924e6ce7c7549a09a0c9472148b3dfd","type":"GENE","name":"ERVW-7","canonical_id":"hgnc:HGNC:49246","description":"endogenous retrovirus group W member 7","metadata":null},{"id":"d12c223ecf034450b5f065d9da1eb0ac","type":"GENE","name":"ERVW-8","canonical_id":"hgnc:HGNC:49247","description":"endogenous retrovirus group W member 8","metadata":null},{"id":"44d53b9b659343ea87c1b8aaa7b1188a","type":"GENE","name":"ERVW-9","canonical_id":"hgnc:HGNC:49248","description":"endogenous retrovirus group W member 9","metadata":null},{"id":"191073124a8a4c888f76a6d5564a99ab","type":"TRIAL","name":"ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06532149","description":"NSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction","metadata":null},{"id":"680a252c34544060b5163bf8d4d3e659","type":"TRIAL","name":"ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure","canonical_id":"clinicaltrials.gov:NCT03416270","description":"Type 2 Diabetes Mellitus; Heart Failure","metadata":null},{"id":"9c2844351d3a427bb5aafa11a72c3aeb","type":"GENE","name":"ESA4","canonical_id":"hgnc:HGNC:3462","description":"esterase A4","metadata":null},{"id":"98f95d3261244a609000a48bff591e1a","type":"GENE","name":"ESAM","canonical_id":"hgnc:HGNC:17474","description":"endothelial cell adhesion molecule","metadata":{"aliases":["W117m"]}},{"id":"b4f12ce3efc848fbb03d2d4cbad18f3f","type":"GENE","name":"ESAM-AS1","canonical_id":"hgnc:HGNC:55558","description":"ESAM antisense RNA 1","metadata":null},{"id":"22028430f4b34bb0b6022bab3fdba854","type":"GENE","name":"ESAT","canonical_id":"hgnc:HGNC:3463","description":"esterase activator","metadata":null},{"id":"98c306efb9e94d69863be6d555c26ac2","type":"GENE","name":"ESB3","canonical_id":"hgnc:HGNC:3464","description":"esterase B3","metadata":null},{"id":"586f7a8ec90d45f1a1a023438d6cf156","type":"GO_TERM","name":"ESC/E(Z) complex","canonical_id":"go:GO:0035098","description":"\"A multimeric protein complex that can methylate lysine-27 and lysine-9 residues of histone H3. In Drosophila the core subunits of the complex include ESC, E(Z), CAF1 (NURF-55) and SU(Z)12. In mammals the core subunits of the complex include EED, EZH2, SUZ12 and RBBP4.\" [GOC:bf, GOC:krc, GOC:sp, PMID:12408863, PMID:12408864, PMID:17107999, PMID:20064375, PMID:31123059, PMID:33232890]","metadata":null},{"id":"bee9f5884e8f4e608999d9f723cf8bfb","type":"TRIAL","name":"ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes","canonical_id":"clinicaltrials.gov:NCT06469528","description":"Coronary Artery Disease","metadata":null},{"id":"4056f6a5ffd343a7a9f1e8b1de5da0ba","type":"GENE","name":"ESCO1","canonical_id":"hgnc:HGNC:24645","description":"establishment of sister chromatid cohesion N-acetyltransferase 1","metadata":{"aliases":["ESO1","EFO1","KIAA1911"]}},{"id":"69aa241fffca4062abb8143fe22f4f41","type":"GENE","name":"ESCO2","canonical_id":"hgnc:HGNC:27230","description":null,"metadata":null},{"id":"6d833ffcb89b451dbc8ecd4e0687f3f1","type":"GO_TERM","name":"ESCRT I complex","canonical_id":"go:GO:0000813","description":"\"An endosomal sorting complex required for transport. It consists of the class E vacuolar protein sorting (Vps) proteins and interacts with ubiquitinated cargoes.\" [GOC:rb, PMID:12892785, PMID:12900393]","metadata":null},{"id":"7df8bbd4aaf64aa8a2e60a29d03805c8","type":"GO_TERM","name":"ESCRT II complex","canonical_id":"go:GO:0000814","description":"\"An endosomal sorting complex required for transport and functions downstream of ESCRT I complex. It consists of the class E vacuolar protein sorting (Vps) proteins and is required for the membrane recruitment of ESCRT III complex and binds to ubiquitinated cargoes.\" [GOC:rb, PMID:12892785, PMID:12900393]","metadata":null},{"id":"f478c605803b4bb7a17a839d7b3678de","type":"GO_TERM","name":"ESCRT III complex","canonical_id":"go:GO:0000815","description":"\"A complex with membrane scission activity that plays a major role in many processes where membranes are remodelled - including endosomal transport (vesicle budding), nuclear envelope organisation (membrane closure, mitotic bridge cleavage), and cytokinesis (abscission).\" [PMID:17556548, PMID:22361144, PMID:28242692, PMID:31132588, PMID:32243490, PMID:34449766]","metadata":null},{"id":"ebb4efb8eeda42dea294bac1ad88e14f","type":"GO_TERM","name":"ESCRT III complex assembly","canonical_id":"go:GO:1904902","description":"\"The aggregation, arrangement and bonding together of a set of components to form an ESCRT III complex.\" [GO_REF:0000079, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20588296]","metadata":null},{"id":"35529fc4ea9d4e38bf9c59a46aa7006c","type":"GO_TERM","name":"ESCRT III complex disassembly","canonical_id":"go:GO:1904903","description":"\"The disaggregation of an ESCRT III complex into its constituent components.\" [GO_REF:0000079, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20588296]","metadata":null},{"id":"85cd4c93030446c2bc3c4060a72aae18","type":"GO_TERM","name":"ESCRT IV complex","canonical_id":"go:GO:1990621","description":"\"An ESCRT complex that has AAA-ATPase activity and is involved in ESCRT-mediated intralumenal vesicle formation and the final stages of cytokinesis. The complex catalyzes disassembly of the ESCRT III filament around the neck of the budding vesicle in an ATP-driven reaction, resulting in membrane scission and recycling of the ESCRT III components back to the cytosol. In yeast, it is formed by the AAA ATPase Vps4 and its cofactor Vta1.\" [GOC:bhm, GOC:ha, PMID:20653365, PMID:20696398, PMID:21925211, PMID:24456136, PMID:25164817, PMID:26775243]","metadata":null},{"id":"2b24b1726a274189b2c8897fed396b68","type":"GO_TERM","name":"ESCRT complex","canonical_id":"go:GO:0036452","description":"\"An endosomal sorting complex involved in membrane fission processes related to sorting of multivesicular bodies (MVB) in the endocytic pathway, cytokinesis and viral budding among other processes.\" [PMID:16689637, VZ:1536]","metadata":null},{"id":"33cc7ea2905f42488cc7a42da9ccd28a","type":"GO_TERM","name":"ESCRT complex assembly","canonical_id":"go:GO:1904895","description":"\"The aggregation, arrangement and bonding together of a set of components to form an ESCRT complex.\" [GO_REF:0000079, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21118109]","metadata":null},{"id":"5c73bb7bb38b4d169b1825c8ef947225","type":"GO_TERM","name":"ESCRT complex disassembly","canonical_id":"go:GO:1904896","description":"\"The disaggregation of an ESCRT complex into its constituent components.\" [GO_REF:0000079, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21118109]","metadata":null},{"id":"496e1d6aa3a1454898f5e02a3e971516","type":"GO_TERM","name":"ESCRT-0 complex","canonical_id":"go:GO:0033565","description":"\"A protein complex required for the recycling of Golgi proteins, formation of lumenal membranes and sorting of ubiquitinated proteins into those membranes. This complex includes Vps1p and Hse1p in yeast and the Hrs and STAM proteins in mammals.\" [GOC:rb, PMID:12055639, PMID:17543868]","metadata":null},{"id":"a58c0216fd4f4e2bb3cd45913e9bea3d","type":"GENE","name":"ESD","canonical_id":"hgnc:HGNC:3465","description":"esterase D","metadata":null},{"id":"60ee94c549e84bbb9672a11955d5cb1e","type":"GENE","name":"ESDP1","canonical_id":"hgnc:HGNC:56902","description":"ESD pseudogene 1","metadata":null},{"id":"14527d6198704e39912a3ba06514d51b","type":"GENE","name":"ESF1","canonical_id":"hgnc:HGNC:15898","description":"ESF1 nucleolar pre-rRNA processing protein","metadata":{"aliases":["bA526K24.1","C20orf6"]}},{"id":"2bc7dbe653ab4db98f3e43d2c587b413","type":"GENE","name":"ESM1","canonical_id":"hgnc:HGNC:3466","description":"endothelial cell specific molecule 1","metadata":null},{"id":"533da14b78b24664b3848d9e30b6d3fd","type":"GENE","name":"ESPL1","canonical_id":"hgnc:HGNC:16856","description":"extra spindle pole bodies like 1, separase","metadata":{"aliases":["KIAA0165","ESP1","SEPA"]}},{"id":"d454972cfe404ea5abe254a599109370","type":"GENE","name":"ESPL1P1","canonical_id":"hgnc:HGNC:59239","description":"ESPL1 pseudogene 1","metadata":null},{"id":"2009b190bc964f6bab6476e8ca3f9449","type":"GENE","name":"ESPN","canonical_id":"hgnc:HGNC:13281","description":"espin","metadata":{"aliases":["DFNB36"]}},{"id":"5b51ad8bda6e4bfdbc1b7fccecf571cd","type":"GENE","name":"ESPNL","canonical_id":"hgnc:HGNC:27937","description":"espin like","metadata":{"aliases":["FLJ42568"]}},{"id":"336997f8ad5b4e58a62851a3d0dfd0a8","type":"GENE","name":"ESPNP","canonical_id":"hgnc:HGNC:23285","description":"espin pseudogene","metadata":null},{"id":"1b4d1a7921f042b891e6b5393d8056c7","type":"TRIAL","name":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","canonical_id":"clinicaltrials.gov:NCT02613897","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"88e63293b5ca4a4abadbcf55e3fac2ab","type":"GENE","name":"ESR1","canonical_id":"hgnc:HGNC:3467","description":null,"metadata":null},{"id":"15c3164e692447038035e1293894836a","type":"PROTEIN","name":"ESR1","canonical_id":"uniprot:P03372","description":null,"metadata":null},{"id":"6c57ed4d890e47349bb9f8149f8ee78f","type":"GENE","name":"ESR1","canonical_id":"ensembl:ENSG00000091831","description":null,"metadata":null},{"id":"6b780766d0044dc88d2421184f997a57","type":"GENE","name":"ESR2","canonical_id":"hgnc:HGNC:3468","description":null,"metadata":null},{"id":"c80f181dbf4c46ecb246239b4efba3ea","type":"PROTEIN","name":"ESR2","canonical_id":"uniprot:Q92731","description":null,"metadata":null},{"id":"d596a052a39a4f06a4d9f94f57b0e0f1","type":"GENE","name":"ESRG","canonical_id":"hgnc:HGNC:39079","description":"embryonic stem cell related","metadata":{"aliases":["HESRG"]}},{"id":"da3bedc2c5e44b039c663cff955b2356","type":"GENE","name":"ESRP1","canonical_id":"hgnc:HGNC:25966","description":"epithelial splicing regulatory protein 1","metadata":{"aliases":["FLJ20171","RBM35A"]}},{"id":"e4ca0cd2483b4c7b886c105818e20073","type":"GENE","name":"ESRP2","canonical_id":"hgnc:HGNC:26152","description":"epithelial splicing regulatory protein 2","metadata":{"aliases":["FLJ21918","RBM35B"]}},{"id":"9a9598136ee544b38ac543c81dbe80d5","type":"GENE","name":"ESRRA","canonical_id":"hgnc:HGNC:3471","description":null,"metadata":null},{"id":"39d9816c9d424cc18e1f82b992785bef","type":"GENE","name":"ESRRAP1","canonical_id":"hgnc:HGNC:3472","description":"estrogen-related receptor alpha pseudogene 1","metadata":{"aliases":["ESRRAP"]}},{"id":"3f2fc2458fd8435fbef26819762bb4a7","type":"GENE","name":"ESRRAP2","canonical_id":"hgnc:HGNC:24647","description":"estrogen-related receptor alpha pseudogene 2","metadata":{"aliases":["ESTRRA"]}},{"id":"a658157a70104c65af5385221d1cff36","type":"GENE","name":"ESRRB","canonical_id":"hgnc:HGNC:3473","description":null,"metadata":null},{"id":"e148a15c9d9640d8b4400888a571291f","type":"GENE","name":"ESRRG","canonical_id":"hgnc:HGNC:3474","description":null,"metadata":null},{"id":"04a3273cc3d54e5f9988e90cad880dfa","type":"GENE","name":"ESS2","canonical_id":"hgnc:HGNC:16817","description":"ess-2 spliceosome associated protein","metadata":{"aliases":["DGSI","Es2el","ES2","DGS-H","ESS-2","bis1","DGCR13","DGCR14"]}},{"id":"1786a4ea73f14add9f818d33be141dea","type":"TRIAL","name":"ESSENTIAL-\"The Studies of Oral Enoximone Therapy in Advanced Heart Failure\"","canonical_id":"clinicaltrials.gov:NCT00051285","description":"Heart Failure, Congestive","metadata":null},{"id":"0856d00261e248bc9d59516702fdc1a6","type":"GENE","name":"ESX1","canonical_id":"hgnc:HGNC:14865","description":"ESX homeobox 1","metadata":{"aliases":["ESXR1","ESX1L"]}},{"id":"5e3670645a85483688d282ea9a0f426b","type":"GENE","name":"ESYT1","canonical_id":"hgnc:HGNC:29534","description":"extended synaptotagmin 1","metadata":{"aliases":["MBC2","KIAA0747","FAM62A"]}},{"id":"0027d376f58e40e8ad5ade37db1e75a3","type":"GENE","name":"ESYT2","canonical_id":"hgnc:HGNC:22211","description":"extended synaptotagmin 2","metadata":{"aliases":["KIAA1228","CHR2SYT","FAM62B"]}},{"id":"2fc2d34be86a49c784459396ba047c7f","type":"GENE","name":"ESYT3","canonical_id":"hgnc:HGNC:24295","description":"extended synaptotagmin 3","metadata":{"aliases":["CHR3SYT","FAM62C"]}},{"id":"80678379c3174c95acdd98c26c4f0cac","type":"TRIAL","name":"EScitalopram PIndolol ONset of Action","canonical_id":"clinicaltrials.gov:NCT01219686","description":"Unipolar Depression","metadata":null},{"id":"9d656f388a8d4b71b99358c3eddb95c0","type":"TRIAL","name":"ET-blockade and Exercise Induced Blood Flow in T2DM","canonical_id":"clinicaltrials.gov:NCT01779596","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"ac45276cc26f499da0e671c73ac8cac9","type":"TRIAL","name":"ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)","canonical_id":"clinicaltrials.gov:NCT05630612","description":"ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases","metadata":null},{"id":"93d0b063334943bead3af55a01d58cb0","type":"GENE","name":"ETAA1","canonical_id":"hgnc:HGNC:24648","description":"ETAA1 activator of ATR kinase","metadata":{"aliases":["ETAA16"]}},{"id":"67f1425f56454b27a568af3caa820f2f","type":"GENE","name":"ETDA","canonical_id":"hgnc:HGNC:53449","description":"embryonic testis differentiation homolog A","metadata":null},{"id":"d0a3a44db3ce4a5d89239ab516c7752a","type":"GENE","name":"ETDB","canonical_id":"hgnc:HGNC:44269","description":"embryonic testis differentiation homolog B","metadata":{"aliases":["LINC00633"]}},{"id":"dea8ecf479e44307bbd4424a29bd6cfe","type":"GENE","name":"ETDC","canonical_id":"hgnc:HGNC:53450","description":"embryonic testis differentiation homolog C","metadata":null},{"id":"c81c6cf104c34908bdb4e9fcd319b828","type":"GENE","name":"ETF1","canonical_id":"hgnc:HGNC:3477","description":null,"metadata":null},{"id":"badeb408210a4c04b07a94ff52720d42","type":"GENE","name":"ETF1P1","canonical_id":"hgnc:HGNC:3478","description":"eukaryotic translation termination factor 1 pseudogene 1","metadata":{"aliases":["HCGVII","SUP45L2"]}},{"id":"9bfb1a6ff2764c7e8e95fd04b633b55f","type":"GENE","name":"ETF1P2","canonical_id":"hgnc:HGNC:3479","description":"eukaryotic translation termination factor 1 pseudogene 2","metadata":{"aliases":["SUP45L3"]}},{"id":"59c9570c81894504b5205c9205065560","type":"GENE","name":"ETF1P3","canonical_id":"hgnc:HGNC:3480","description":"eukaryotic translation termination factor 1 pseudogene 3","metadata":{"aliases":["SUP45L4"]}},{"id":"caa2f8619305423bb6f76d2212ac709e","type":"GENE","name":"ETFA","canonical_id":"hgnc:HGNC:3481","description":"electron transfer flavoprotein subunit alpha","metadata":{"aliases":["GA2","EMA","MADD"]}},{"id":"1a00e1b1b3144faeae5087ef1c34df03","type":"GENE","name":"ETFB","canonical_id":"hgnc:HGNC:3482","description":"electron transfer flavoprotein subunit beta","metadata":null},{"id":"6675db0161a144c5a0865e3e5a5c77fa","type":"GENE","name":"ETFBKMT","canonical_id":"hgnc:HGNC:28739","description":"electron transfer flavoprotein subunit beta lysine methyltransferase","metadata":{"aliases":["DKFZp451L235","MGC50559","C12orf72","METTL20"]}},{"id":"be847bdcdfd3480aa27aa99ad0d2a74c","type":"GENE","name":"ETFDH","canonical_id":"hgnc:HGNC:3483","description":"electron transfer flavoprotein dehydrogenase","metadata":{"aliases":["ETFQO"]}},{"id":"859345e7935842d6bcee1d22a2b85226","type":"GENE","name":"ETFRF1","canonical_id":"hgnc:HGNC:27052","description":"electron transfer flavoprotein regulatory factor 1","metadata":{"aliases":["LYRM5"]}},{"id":"650f65aa21ae453ba08418578fbd8dad","type":"GENE","name":"ETFRF1P1","canonical_id":"hgnc:HGNC:56993","description":"ETFRF1 pseudogene 1","metadata":null},{"id":"86b7e54e348c492896c892d00e750423","type":"TRIAL","name":"ETHAN - ET for Male BC","canonical_id":"clinicaltrials.gov:NCT05501704","description":"Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma","metadata":null},{"id":"5361cf4e75bc49b18e324583c2cca89c","type":"GENE","name":"ETHE1","canonical_id":"hgnc:HGNC:23287","description":"ETHE1 persulfide dioxygenase","metadata":{"aliases":["YF13H12","HSCO"]}},{"id":"5e5a96b426564dbea285982a5cc3d947","type":"GENE","name":"ETNK1","canonical_id":"hgnc:HGNC:24649","description":"ethanolamine kinase 1","metadata":{"aliases":["EKI1","EKI"]}},{"id":"72ba74c7d1b344979cc58f42a7acf164","type":"GENE","name":"ETNK1-DT","canonical_id":"hgnc:HGNC:55486","description":"ETNK1 divergent transcript","metadata":null},{"id":"27bd3d71f98a4e3eaeb14c14e62b402e","type":"GENE","name":"ETNK2","canonical_id":"hgnc:HGNC:25575","description":null,"metadata":null},{"id":"2d3314e790504b2b90267f292dd38301","type":"GENE","name":"ETNPPL","canonical_id":"hgnc:HGNC:14404","description":"ethanolamine-phosphate phospho-lyase","metadata":{"aliases":["AGXT2L1"]}},{"id":"9b92c733398c44f7a27362d229d30f0a","type":"GENE","name":"ETS1","canonical_id":"hgnc:HGNC:3488","description":null,"metadata":null},{"id":"e508f24446304a199f660e5c8b02e939","type":"GENE","name":"ETS1-AS1","canonical_id":"hgnc:HGNC:53932","description":"ETS1 antisense RNA 1","metadata":{"aliases":["pancEts-1"]}},{"id":"602fef9280764361a1f30db3d9bf3097","type":"GENE","name":"ETS2","canonical_id":"hgnc:HGNC:3489","description":null,"metadata":null},{"id":"6ceee3697c134626bbb16f16d3c6c285","type":"GENE","name":"ETS2-AS1","canonical_id":"hgnc:HGNC:56712","description":"ETS2 antisense RNA 1","metadata":null},{"id":"86531b4c70144f9184152decc9ff6e41","type":"GENE","name":"ETS2P1","canonical_id":"hgnc:HGNC:55136","description":"ETS2 pseudogene 1","metadata":null},{"id":"acec6459fb5e4e9a86403ec7db3a9b7e","type":"GENE","name":"ETV1","canonical_id":"hgnc:HGNC:3490","description":null,"metadata":null},{"id":"5bd6437bfb2e4cbab9ab962ec21a6f73","type":"GENE","name":"ETV2","canonical_id":"hgnc:HGNC:3491","description":null,"metadata":null},{"id":"3ea2e659f0504a26bcfaf242775d2e07","type":"GENE","name":"ETV3","canonical_id":"hgnc:HGNC:3492","description":null,"metadata":null},{"id":"1725cbc4740c40bd8c1c23a50ef157a7","type":"GENE","name":"ETV3L","canonical_id":"hgnc:HGNC:33834","description":"ETS variant transcription factor 3 like","metadata":{"aliases":["FLJ16478"]}},{"id":"3993ce886d024044987fb5b888e029d7","type":"GENE","name":"ETV4","canonical_id":"hgnc:HGNC:3493","description":null,"metadata":null},{"id":"d63ca39384ad476faf9f7cfa8edeb9e6","type":"GENE","name":"ETV5","canonical_id":"hgnc:HGNC:3494","description":null,"metadata":null},{"id":"c41f7f26ba834c8fa7743c1bd207cfe4","type":"GENE","name":"ETV5-AS1","canonical_id":"hgnc:HGNC:40222","description":"ETV5 antisense RNA 1","metadata":null},{"id":"c6ce14ad15274f1a9abc6212ed1876ad","type":"GENE","name":"ETV6","canonical_id":"hgnc:HGNC:3495","description":null,"metadata":null},{"id":"d0f2b15325c14819b7782e6f6712c1c8","type":"GENE","name":"ETV7","canonical_id":"hgnc:HGNC:18160","description":null,"metadata":null},{"id":"179080f66a6e40bea3b15cb5c77e9337","type":"GENE","name":"ETV7-AS1","canonical_id":"hgnc:HGNC:40833","description":"ETV7 and PTX1 antisense RNA 1","metadata":null},{"id":"0b095d497191478cae288d66770d0abf","type":"TRIAL","name":"EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)","canonical_id":"clinicaltrials.gov:NCT06362668","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"b80279e443f9486d9520382e5e6d6911","type":"GENE","name":"EUDAL","canonical_id":"hgnc:HGNC:40252","description":"EGFR ubiquitination and degradation associated lncRNA","metadata":null},{"id":"1f4002122b404df89d0daa3387c859cd","type":"TRIAL","name":"EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC","canonical_id":"clinicaltrials.gov:NCT07647289","description":"Muscle-Invasive Bladder Cancer (MIBC)","metadata":null},{"id":"ab31a0cfb81649f783de8640ab2c0624","type":"GENE","name":"EVA1A","canonical_id":"hgnc:HGNC:25816","description":"eva-1 homolog A, regulator of programmed cell death","metadata":{"aliases":["FLJ13391","TMEM166","FAM176A"]}},{"id":"e3e9f371472841f590b5321a8f332df8","type":"GENE","name":"EVA1A-AS","canonical_id":"hgnc:HGNC:55283","description":"EVA1A antisense RNA","metadata":{"aliases":["EVA1A-AS1"]}},{"id":"ee50c0446385447d96a4eb2b94db50bf","type":"GENE","name":"EVA1B","canonical_id":"hgnc:HGNC:25558","description":"eva-1 homolog B","metadata":{"aliases":["FLJ10647","C1orf78","FAM176B"]}},{"id":"88e2a2b34c96467da253c009930ea307","type":"GENE","name":"EVA1C","canonical_id":"hgnc:HGNC:13239","description":"eva-1 homolog C","metadata":{"aliases":["B18","PRED34","B19","C21orf64","C21orf63","FAM176C"]}},{"id":"ae9848816e0c48049877f441a36d3fe8","type":"GENE","name":"EVA1CP1","canonical_id":"hgnc:HGNC:55735","description":"EVA1C pseudogene 1","metadata":null},{"id":"d4268d6e7e1541a0834f2f6259987ebd","type":"GENE","name":"EVA1CP2","canonical_id":"hgnc:HGNC:55736","description":"EVA1C pseudogene 2","metadata":null},{"id":"90bb62276c3d4089b0e9348ba82effdd","type":"GENE","name":"EVA1CP3","canonical_id":"hgnc:HGNC:55737","description":"EVA1C pseudogene 3","metadata":null},{"id":"61dd2cdfefd04d8b8571a2f00ab0d1ff","type":"GENE","name":"EVA1CP4","canonical_id":"hgnc:HGNC:55738","description":"EVA1C pseudogene 4","metadata":null},{"id":"323aab4af1da4d5d9ad0dbcb904b35f8","type":"GENE","name":"EVA1CP5","canonical_id":"hgnc:HGNC:55739","description":"EVA1C pseudogene 5","metadata":null},{"id":"9aaaed00f06d4386878b22e8fca18116","type":"GENE","name":"EVA1CP6","canonical_id":"hgnc:HGNC:55740","description":"EVA1C pseudogene 6","metadata":null},{"id":"afe43616e33e4df3a557f1e8342a7d6d","type":"GENE","name":"EVC","canonical_id":"hgnc:HGNC:3497","description":"EvC ciliary complex subunit 1","metadata":{"aliases":["DWF-1","EVC1"]}},{"id":"2d6fc6d3c59c4cb09269c31b826a4f49","type":"GENE","name":"EVC2","canonical_id":"hgnc:HGNC:19747","description":"EvC ciliary complex subunit 2","metadata":{"aliases":["LBN"]}},{"id":"48795e513c0649a4a6b69ce727604384","type":"TRIAL","name":"EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan","canonical_id":"clinicaltrials.gov:NCT00071331","description":"Congestive Heart Failure","metadata":null},{"id":"317cef5dea6348d2993325b80c7f73b9","type":"GENE","name":"EVI2A","canonical_id":"hgnc:HGNC:3499","description":"ecotropic viral integration site 2A","metadata":{"aliases":["EVDA","EVI2"]}},{"id":"0fc2097001974e5097b29bf7f8841249","type":"GENE","name":"EVI2B","canonical_id":"hgnc:HGNC:3500","description":"ecotropic viral integration site 2B","metadata":{"aliases":["D17S376","EVDB","CD361"]}},{"id":"058d9ef745db4aff9fc5f2606174748b","type":"GENE","name":"EVI5","canonical_id":"hgnc:HGNC:3501","description":"ecotropic viral integration site 5","metadata":{"aliases":["NB4S"]}},{"id":"fc1d4dbcf2964bf1a628b1d267c2f332","type":"GENE","name":"EVI5L","canonical_id":"hgnc:HGNC:30464","description":"ecotropic viral integration site 5 like","metadata":null},{"id":"3fdf6586fecf4ae4a2217df5ea70e6b9","type":"GENE","name":"EVL","canonical_id":"hgnc:HGNC:20234","description":"Enah/Vasp-like","metadata":{"aliases":["RNB6"]}},{"id":"ad220cdc7a66402da80ffa325cd72086","type":"GENE","name":"EVL-AS1","canonical_id":"hgnc:HGNC:58455","description":"EVL antisense RNA 1","metadata":null},{"id":"81e0a2df7e4c48c8b624e388de4648d1","type":"GENE","name":"EVPL","canonical_id":"hgnc:HGNC:3503","description":null,"metadata":null},{"id":"ec605993f4dd4acc890184a6909af944","type":"GENE","name":"EVPLL","canonical_id":"hgnc:HGNC:35236","description":"envoplakin like","metadata":null},{"id":"969a6d5b08314afc9dee12294381c2d8","type":"GENE","name":"EVX1","canonical_id":"hgnc:HGNC:3506","description":null,"metadata":null},{"id":"f0c3be8042a64843ba1204405ac398e6","type":"GENE","name":"EVX1-AS","canonical_id":"hgnc:HGNC:40223","description":"EVX1 antisense RNA","metadata":{"aliases":["EVX1-AS1","EVX1AS"]}},{"id":"0b5db27d92734b219e520f327ca33acd","type":"GENE","name":"EVX2","canonical_id":"hgnc:HGNC:3507","description":"even-skipped homeobox 2","metadata":null},{"id":"c1ffaa7712af4233964f0a73b41f2cf5","type":"TRIAL","name":"EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia","canonical_id":"clinicaltrials.gov:NCT00187889","description":"Ischemic Heart Disease","metadata":null},{"id":"80dc05496a444a71b33c26cabffc8d22","type":"GENE","name":"EWSAT1","canonical_id":"hgnc:HGNC:26596","description":"Ewing sarcoma associated transcript 1","metadata":{"aliases":["FLJ33768","TMEM84","NCRNA00277","LINC00277"]}},{"id":"cde581bcc3164b0cbe7e723e5cc2fce3","type":"GENE","name":"EWSR1","canonical_id":"hgnc:HGNC:3508","description":null,"metadata":null},{"id":"f1a0053809fc4239aadf2f66123ced85","type":"GENE","name":"EWSR1P1","canonical_id":"hgnc:HGNC:58372","description":"EWSR1 pseudogene 1","metadata":null},{"id":"6d36c7e77c4f456381a3316bba19001c","type":"GENE","name":"EWSR1P2","canonical_id":"hgnc:HGNC:58373","description":"EWSR1 pseudogene 2","metadata":null},{"id":"d1fb559ac0604dfd97bd97f83791e679","type":"GENE","name":"EXD1","canonical_id":"hgnc:HGNC:28507","description":"exonuclease 3'-5' domain containing 1","metadata":{"aliases":["MGC33637","EXDL1"]}},{"id":"41b5213a882d4a33864852d7cebfd895","type":"GENE","name":"EXD2","canonical_id":"hgnc:HGNC:20217","description":"exonuclease 3'-5' domain containing 2","metadata":{"aliases":["FLJ10738","C14orf114","EXDL2"]}},{"id":"17683c73f4e448c4950b52587c3e4663","type":"GENE","name":"EXD3","canonical_id":"hgnc:HGNC:26023","description":"exonuclease 3'-5' domain containing 3","metadata":{"aliases":["LOC54932","FLJ20433","mut-7","Nbr"]}},{"id":"e5fbb98cd76f4b2ba6e8044441661f94","type":"GENE","name":"EXO1","canonical_id":"hgnc:HGNC:3511","description":null,"metadata":null},{"id":"9971483956bc4c8389c0986aea23742f","type":"GENE","name":"EXO5","canonical_id":"hgnc:HGNC:26115","description":"exonuclease 5","metadata":{"aliases":["FLJ21144","C1orf176","DEM1"]}},{"id":"70c78e34e1f84b509a1e32a2965853a3","type":"GENE","name":"EXO5-DT","canonical_id":"hgnc:HGNC:55647","description":"EXO5 divergent transcript","metadata":null},{"id":"3ad6f0ac075740c8b5e79e99aba9adb7","type":"GENE","name":"EXOC1","canonical_id":"hgnc:HGNC:30380","description":"exocyst complex component 1","metadata":{"aliases":["SEC3","FLJ10893","BM-102","Sec3p","SEC3L1"]}},{"id":"0917728df5f240b69895e694b95e6d45","type":"GENE","name":"EXOC1-AS1","canonical_id":"hgnc:HGNC:58376","description":"EXOC1 antisense RNA 1","metadata":{"aliases":["AC110611.2"]}},{"id":"149d988e01804be88ff7b7c000f44c0e","type":"GENE","name":"EXOC1L","canonical_id":"hgnc:HGNC:53433","description":"exocyst complex component 1 like","metadata":null},{"id":"933120660bd3403d8f6b44e1cdb9e50a","type":"GENE","name":"EXOC1L-AS1","canonical_id":"hgnc:HGNC:58792","description":"EXOC1L antisense RNA 1","metadata":null},{"id":"77fb59b7befa4692b651eb10a3fb8c9f","type":"GENE","name":"EXOC2","canonical_id":"hgnc:HGNC:24968","description":"exocyst complex component 2","metadata":{"aliases":["FLJ11026","Sec5","SEC5L1"]}},{"id":"5ae58e01d4e34ffc87d98b8eef3798ae","type":"GENE","name":"EXOC2-AS1","canonical_id":"hgnc:HGNC:41075","description":"EXOC2 antisense RNA 1","metadata":null},{"id":"0ba123f3732d4f18adeacf0722e1da0b","type":"GENE","name":"EXOC2-AS2","canonical_id":"hgnc:HGNC:59325","description":"EXOC2 antisense RNA 2","metadata":null},{"id":"21bc51765aaa47a99d4a6d1962b795ae","type":"GENE","name":"EXOC3","canonical_id":"hgnc:HGNC:30378","description":"exocyst complex component 3","metadata":{"aliases":["Sec6","SEC6L1"]}},{"id":"5d67d808a0f94dcc9da0f7152cd6cae2","type":"GENE","name":"EXOC3-AS1","canonical_id":"hgnc:HGNC:25175","description":"EXOC3 antisense RNA 1","metadata":{"aliases":["C5orf55"]}},{"id":"6697058c04eb4e878d00c23a8cb368e6","type":"GENE","name":"EXOC3L1","canonical_id":"hgnc:HGNC:27540","description":"exocyst complex component 3 like 1","metadata":{"aliases":["FLJ35539","FLJ35587","EXOC3L"]}},{"id":"5cb2ac75bda94d3697aa1002063f579b","type":"GENE","name":"EXOC3L2","canonical_id":"hgnc:HGNC:30162","description":"exocyst complex component 3 like 2","metadata":{"aliases":["FLJ36147","XTP7"]}},{"id":"8bd72c92a740496b8fb6b5875f45e22b","type":"GENE","name":"EXOC3L4","canonical_id":"hgnc:HGNC:20120","description":"exocyst complex component 3 like 4","metadata":{"aliases":["C14orf73"]}},{"id":"cfdb40a21b0a4b63a3de0d9e86e1b3e0","type":"GENE","name":"EXOC4","canonical_id":"hgnc:HGNC:30389","description":"exocyst complex component 4","metadata":{"aliases":["KIAA1699","MGC27170","SEC8","Sec8p","SEC8L1"]}},{"id":"b78a46769ed9405ca909dc842ef2e250","type":"GENE","name":"EXOC5","canonical_id":"hgnc:HGNC:10696","description":"exocyst complex component 5","metadata":{"aliases":["SEC10","SEC10P","SEC10L1"]}},{"id":"337780a6b9b84c56bf3e53196bb375b1","type":"GENE","name":"EXOC5P1","canonical_id":"hgnc:HGNC:43870","description":"exocyst complex component 5 pseudogene 1","metadata":null},{"id":"3f218f3ac3b646f4a63c488534d69f54","type":"GENE","name":"EXOC6","canonical_id":"hgnc:HGNC:23196","description":"exocyst complex component 6","metadata":{"aliases":["SEC15L","FLJ1125","DKFZp761I2124","MGC33397","Sec15","EXOC6A","SEC15L1"]}},{"id":"949efcc24daf448fb9f411b49b6499b3","type":"GENE","name":"EXOC6B","canonical_id":"hgnc:HGNC:17085","description":"exocyst complex component 6B","metadata":{"aliases":["KIAA0919","SEC15L2","SEC15B"]}},{"id":"9366ea7806d74cfa82e3cc1d0ea8f7f2","type":"GENE","name":"EXOC7","canonical_id":"hgnc:HGNC:23214","description":"exocyst complex component 7","metadata":{"aliases":["EXO70","KIAA1067","YJL085W","Exo70p","BLOM4"]}},{"id":"27b4a106fc654bf2892eea3f7601dcd6","type":"GENE","name":"EXOC7P1","canonical_id":"hgnc:HGNC:43871","description":"EXOC7 pseudogene 1","metadata":null},{"id":"c593774aa53d4365848cbe19bf767159","type":"GENE","name":"EXOC8","canonical_id":"hgnc:HGNC:24659","description":"exocyst complex component 8","metadata":{"aliases":["SEC84","EXO84","Exo84p"]}},{"id":"7e2ab8eddf584a1c81849936abc25478","type":"GENE","name":"EXOG","canonical_id":"hgnc:HGNC:3347","description":"exo/endonuclease G","metadata":{"aliases":["ENGL-a","ENGL","ENGL-b","ENDOGL1","ENDOGL2"]}},{"id":"9ea38f8da1ca45988c2737549465ed03","type":"GENE","name":"EXOGP1","canonical_id":"hgnc:HGNC:44547","description":"EXOG pseudogene 1","metadata":null},{"id":"89ca126986ab4227aa78fc2cfd4c5758","type":"GENE","name":"EXOSC1","canonical_id":"hgnc:HGNC:17286","description":"exosome component 1","metadata":{"aliases":["hCsl4p","Csl4p","CSL4","Ski4p","SKI4","CGI-108","p13"]}},{"id":"44090315698d4424bd15cb2b1d3fc7ec","type":"GENE","name":"EXOSC10","canonical_id":"hgnc:HGNC:9138","description":"exosome component 10","metadata":{"aliases":["PM-Scl","PM/Scl-100","Rrp6p","RRP6","p2","p3","p4","PMSCL2"]}},{"id":"4b9d22d90108483f8db8f2d55fe80743","type":"GENE","name":"EXOSC10-AS1","canonical_id":"hgnc:HGNC:40456","description":"EXOSC10 antisense RNA 1","metadata":null},{"id":"bebc00a3919043d0bd5d9465f4443388","type":"GENE","name":"EXOSC2","canonical_id":"hgnc:HGNC:17097","description":"exosome component 2","metadata":{"aliases":["hRrp4p","Rrp4p","RRP4","p7"]}},{"id":"d704a802f4294c0d8f61f70db452fae0","type":"GENE","name":"EXOSC3","canonical_id":"hgnc:HGNC:17944","description":"exosome component 3","metadata":{"aliases":["hRrp40p","Rrp40p","RRP40","CGI-102","p10","hRrp-40"]}},{"id":"77df921dc7114130b866e920325711ab","type":"GENE","name":"EXOSC3P1","canonical_id":"hgnc:HGNC:33989","description":"exosome component 3 pseudogene 1","metadata":null},{"id":"f43afaa1d7c74304a0f113cd5e2ff3b9","type":"GENE","name":"EXOSC3P2","canonical_id":"hgnc:HGNC:33990","description":"exosome component 3 pseudogene 2","metadata":null},{"id":"7493db41ca8b4156a59dfc1861430df2","type":"GENE","name":"EXOSC4","canonical_id":"hgnc:HGNC:18189","description":"exosome component 4","metadata":{"aliases":["hRrp41p","FLJ20591","Rrp41p","RRP41","RRP41A","Ski6p","SKI6","p12A"]}},{"id":"9bab54c301b34834807329d8eb38ad76","type":"GENE","name":"EXOSC5","canonical_id":"hgnc:HGNC:24662","description":"exosome component 5","metadata":{"aliases":["hRrp46p","Rrp46p","RRP46","RRP41B","MGC12901","p12B"]}},{"id":"ee492e3b72554781be738442947253f5","type":"GENE","name":"EXOSC6","canonical_id":"hgnc:HGNC:19055","description":"exosome component 6","metadata":{"aliases":["MTR3","hMtr3p","Mtr3p","EAP4","p11"]}},{"id":"610356df43f24f169d4e96baf14e4c86","type":"GENE","name":"EXOSC7","canonical_id":"hgnc:HGNC:28112","description":"exosome component 7","metadata":{"aliases":["hRrp42p","Rrp42p","RRP42","EAP1","KIAA0116","p8"]}},{"id":"605a19338df6466ea01dd7fed10671b6","type":"GENE","name":"EXOSC8","canonical_id":"hgnc:HGNC:17035","description":"exosome component 8","metadata":{"aliases":["OIP2","RRP43","bA421P11.3","Rrp43p","EAP2","p9","CIP3"]}},{"id":"417a7e8419e0400c8e99b07357a8ab9d","type":"GENE","name":"EXOSC8P1","canonical_id":"hgnc:HGNC:56929","description":"EXOSC8 pseudogene 1","metadata":null},{"id":"5ca194c2e4a94c11acba88c2b694ea3b","type":"GENE","name":"EXOSC9","canonical_id":"hgnc:HGNC:9137","description":"exosome component 9","metadata":{"aliases":["PM/Scl-75","Rrp45p","RRP45","p5","p6","PMSCL1"]}},{"id":"aa953e17fc114b5c87c99c256f93c3b6","type":"GENE","name":"EXPH5","canonical_id":"hgnc:HGNC:30578","description":"exophilin 5","metadata":{"aliases":["SLAC2-B"]}},{"id":"b69bb00e0ce143ab8f21fa00990b64f0","type":"GENE","name":"EXT1","canonical_id":"hgnc:HGNC:3512","description":null,"metadata":null},{"id":"1ba3443840cb48f192bd68d98ed74881","type":"GO_TERM","name":"EXT1-EXT2 complex","canonical_id":"go:GO:0120504","description":"\"A heterodimeric complex capable of glycosyltransferase activity required for the elongation of heparan sulfate chains. In humans, the complex consists of EXT1 and EXT2. In Drosophila, the complex consists of ttv and sotv.\" [GOC:sjm, PMID:14998928, PMID:36402845, PMID:36593275]","metadata":null},{"id":"a7c7c768efe141b7b870a6cc5628da7c","type":"GENE","name":"EXT2","canonical_id":"hgnc:HGNC:3513","description":"exostosin glycosyltransferase 2","metadata":{"aliases":["SOTV"]}},{"id":"f626d928807c4467b69db57a2e653e5c","type":"TRIAL","name":"EXTEND EXpanding Treatment for Existing Neurological Disease","canonical_id":"clinicaltrials.gov:NCT02556099","description":"Sickle Cell Anemia","metadata":null},{"id":"20a006700d0f412b9762dbfad049f197","type":"GENE","name":"EXTL1","canonical_id":"hgnc:HGNC:3515","description":"exostosin like glycosyltransferase 1","metadata":{"aliases":["EXTL","MGC70794"]}},{"id":"ab6409769dc1445f827e956508aa46fa","type":"GENE","name":"EXTL2","canonical_id":"hgnc:HGNC:3516","description":"exostosin like glycosyltransferase 2","metadata":null},{"id":"17fb528b0fd844dabc79b6a986f6fea9","type":"GENE","name":"EXTL2P1","canonical_id":"hgnc:HGNC:3517","description":"exostosin like glycosyltransferase 2 pseudogene 1","metadata":{"aliases":["EXTL2P"]}},{"id":"df5f0c4c5d9140b1871fea402a601fa7","type":"GENE","name":"EXTL3","canonical_id":"hgnc:HGNC:3518","description":"exostosin like glycosyltransferase 3","metadata":{"aliases":["botv","REGR"]}},{"id":"1f8ede5b7a0e471cbf7cda9db8be65e5","type":"GENE","name":"EXTL3-AS1","canonical_id":"hgnc:HGNC:27985","description":"EXTL3 antisense RNA 1","metadata":{"aliases":["C8orf50"]}},{"id":"59ce3eea4ad54b11b66ccb2d3d34b290","type":"TRIAL","name":"EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial","canonical_id":"clinicaltrials.gov:NCT03932721","description":"Dyslipidemia Associated With Type II Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypertension Arterial","metadata":null},{"id":"d4b20455b96d47f9b6b52d79789f26a5","type":"GENE","name":"EYA1","canonical_id":"hgnc:HGNC:3519","description":"EYA transcriptional coactivator and phosphatase 1","metadata":{"aliases":["BOR"]}},{"id":"8b56ce2d5bdb444f91c7f991bc9be12b","type":"GENE","name":"EYA2","canonical_id":"hgnc:HGNC:3520","description":"EYA transcriptional coactivator and phosphatase 2","metadata":{"aliases":["EAB1"]}},{"id":"d5b7ed68936240a5a9bd3cc1655721e5","type":"GENE","name":"EYA2-AS1","canonical_id":"hgnc:HGNC:56333","description":"EYA2 antisense RNA 1","metadata":null},{"id":"5f5068668bbf43c1865f5ace113cc546","type":"GENE","name":"EYA3","canonical_id":"hgnc:HGNC:3521","description":null,"metadata":null},{"id":"13ccf28068464243af8e512cc534a735","type":"GENE","name":"EYA4","canonical_id":"hgnc:HGNC:3522","description":"EYA transcriptional coactivator and phosphatase 4","metadata":{"aliases":["DFNA10","CMD1J"]}},{"id":"adf4517f16254ecf94b49012c77dc213","type":"GENE","name":"EYA4-AS2","canonical_id":"hgnc:HGNC:58230","description":"EYA4 antisense RNA 2","metadata":null},{"id":"c41bccc06bef4766b567364e0fe2a725","type":"GENE","name":"EYS","canonical_id":"hgnc:HGNC:21555","description":"EGF-like photoreceptor maintenance factor","metadata":{"aliases":["dJ1018A4.2","bA166P24.2","SPAM","bA307F22.3","dJ303F19.1","bA74E24.1","C6orf180","EGFL11","RP25","EGFL10","C6orf178","C6orf179"]}},{"id":"3cb3e3d358b94b518ec33f878d493ba3","type":"GENE","name":"EZH1","canonical_id":"hgnc:HGNC:3526","description":"enhancer of zeste 1 polycomb repressive complex 2 subunit","metadata":{"aliases":["KIAA0388","KMT6B"]}},{"id":"fe6c87ddd7c64bd99a3e054b659c695c","type":"GENE","name":"EZH2","canonical_id":"hgnc:HGNC:3527","description":null,"metadata":null},{"id":"12276fe931284ddbbad6045296136dcf","type":"GENE","name":"EZH2","canonical_id":"ensembl:ENSG00000106462","description":null,"metadata":null},{"id":"6a9a502f6ce94ddeb55dc8140cbe2dab","type":"TRIAL","name":"EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma","canonical_id":"clinicaltrials.gov:NCT02601937","description":"Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of Ovary","metadata":null},{"id":"f6d95f83278c48c1b8b993f3a4468caf","type":"GENE","name":"EZH2P1","canonical_id":"hgnc:HGNC:39918","description":"enhancer of zeste 2 polycomb repressive complex 2 subunit pseudogene 1","metadata":null},{"id":"2042d558ff354a46883e16dc7544209e","type":"GENE","name":"EZHIP","canonical_id":"hgnc:HGNC:33738","description":"EZH inhibitory protein","metadata":{"aliases":["CATACOMB","CXorf67"]}},{"id":"c09f0a08a9824d18a83c8721ef4d0cb9","type":"GENE","name":"EZR","canonical_id":"hgnc:HGNC:12691","description":null,"metadata":null},{"id":"78a198d8033543ec813d5e8655649a44","type":"GENE","name":"EZR-AS1","canonical_id":"hgnc:HGNC:40609","description":"EZR antisense RNA 1","metadata":null},{"id":"8634ecb802914ac3bbff78f425b2a47d","type":"GENE","name":"EZRP1","canonical_id":"hgnc:HGNC:56464","description":"EZR pseudogene 1","metadata":null},{"id":"306cc75bd4d14e49a07578b013e92014","type":"TRIAL","name":"Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma","canonical_id":"clinicaltrials.gov:NCT00869141","description":"Glaucoma","metadata":null},{"id":"b72f7e70751a4cd7bd8cf8b32d5d0b6a","type":"TRIAL","name":"Early Access Program for Zolbetuximab","canonical_id":"clinicaltrials.gov:NCT06048081","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma Cancer; Metastatic Gastric Adenocarcinoma Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"37d8184dd58c4833844552c1e6bff082","type":"TRIAL","name":"Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen","canonical_id":"clinicaltrials.gov:NCT01254279","description":"Prostate Cancer Metastatic","metadata":null},{"id":"dc1a9b20e82a464d8102b59c3b2243c4","type":"TRIAL","name":"Early Administration of Romidepsin and 3BNC117 in Treatment-na\u00efve HIV Patients Starting ART","canonical_id":"clinicaltrials.gov:NCT03041012","description":"Hiv","metadata":null},{"id":"b20d8f6b54ff4747848d3422be6bac07","type":"TRIAL","name":"Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT05604638","description":"Acute Ischemic Stroke","metadata":null},{"id":"31aaba3e1dcc46278cfadd5040efd728","type":"TRIAL","name":"Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion","canonical_id":"clinicaltrials.gov:NCT07002476","description":"Stroke","metadata":null},{"id":"407798e51a4c48e99b8d37e492c8e428","type":"TRIAL","name":"Early Alirocumab to Reduce LDL-C in Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT03750760","description":"Myocardial Infarction; Dyslipidemias","metadata":null},{"id":"c4b3bcfd02444eeaa243785b2e0d85df","type":"TRIAL","name":"Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection","canonical_id":"clinicaltrials.gov:NCT03453281","description":"Diabetic Macular Edema; Diabetic Retinopathy; Clinically Significant Macular Edema","metadata":null},{"id":"3561e9dbb75543418d8308446aa6bced","type":"TRIAL","name":"Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)","canonical_id":"clinicaltrials.gov:NCT05193071","description":"Ischemic Stroke","metadata":null},{"id":"1c2817256ab8499a83aa48b945aa04e8","type":"TRIAL","name":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","canonical_id":"clinicaltrials.gov:NCT06594172","description":"Radiation Disease; Cognitive Impairment; Drug Effect","metadata":null},{"id":"92bfc99a1262433c81f619b39c6d5da8","type":"TRIAL","name":"Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function","canonical_id":"clinicaltrials.gov:NCT01837043","description":"Delayed Graft Function; Kidney Transplant","metadata":null},{"id":"8521675220f440d7bb7c4fdc67527154","type":"TRIAL","name":"Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00472082","description":"Kidney Transplantation; Chronic Kidney Failure","metadata":null},{"id":"d13cfbc1e3e54510a1567b63f9318146","type":"TRIAL","name":"Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging","canonical_id":"clinicaltrials.gov:NCT07624760","description":"Monoclonal Gammopathy; Monoclonal Gammopathy of Undetermined Significance (MGUS); Multiple Myeloma; AL Amyloidosis; Systemic Amyloidosis","metadata":null},{"id":"6e800e05ae9b42e6861f151ffd2c3913","type":"TRIAL","name":"Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption","canonical_id":"clinicaltrials.gov:NCT03710889","description":"Osteoporosis, Postmenopausal; Osteoporosis; Osteoporosis Vertebral; Osteoporosis Risk; Osteoporosis Fracture; Osteoporosis Localized to Spine; Osteoporosis, Age-Related; Osteoporosis Senile; Osteoporosis of Vertebrae","metadata":null},{"id":"3f6950533d164f43a782e6c215ecb921","type":"TRIAL","name":"Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT07392788","description":"Acute Heart Failure (AHF)","metadata":null},{"id":"7c1e3636deb0435497dc1eaed0b21483","type":"TRIAL","name":"Early Identification of Warfarin Maintenance Dosage","canonical_id":"clinicaltrials.gov:NCT01178034","description":"Atrial Fibrillation","metadata":null},{"id":"dfb7b720b3474d1ba000d47ed8f0dd14","type":"TRIAL","name":"Early Intervention With Acalabrutinib in Patients With High Risk CLL","canonical_id":"clinicaltrials.gov:NCT04660045","description":"Chronic Lymphocytic Leukemia; CLL/SLL","metadata":null},{"id":"ad0a1ffc04f948289737758a851c7681","type":"TRIAL","name":"Early Intervention With Fluoxetine in Autism","canonical_id":"clinicaltrials.gov:NCT00183339","description":"Autistic Disorder","metadata":null},{"id":"01dc3400e16342348bbbf92b76d6f696","type":"TRIAL","name":"Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT03753269","description":"ST Segment Elevation Myocardial Infarction","metadata":null},{"id":"a571d59f1ca342b38e5186d515687975","type":"TRIAL","name":"Early Manifest Glaucoma Trial (EMGT)","canonical_id":"clinicaltrials.gov:NCT00000132","description":"Open-Angle Glaucoma","metadata":null},{"id":"598b03a6fed243b7b5c2a781ce4772a0","type":"TRIAL","name":"Early Oxybutinin Treatment for Boys With Posterior Urethral Valves","canonical_id":"clinicaltrials.gov:NCT04526353","description":"Male Urogenital Diseases","metadata":null},{"id":"c75bac97fd3b40a9aaf64647f2ccce23","type":"TRIAL","name":"Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)","canonical_id":"clinicaltrials.gov:NCT04978597","description":"Parkinson","metadata":null},{"id":"f1caf841216f40b08600b0ce5b1debd0","type":"TRIAL","name":"Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis","canonical_id":"clinicaltrials.gov:NCT00204061","description":"Schizophrenia; Psychoses","metadata":null},{"id":"c99ee68dc9064216a39cd916adb6dfa0","type":"TRIAL","name":"Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy","canonical_id":"clinicaltrials.gov:NCT00166621","description":"Autism","metadata":null},{"id":"eb5b28b29c164a5ba7203e93403b6a38","type":"TRIAL","name":"Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)","canonical_id":"clinicaltrials.gov:NCT07072624","description":"Seizures; Traumatic Brain Injuries; Traumatic Brain Injury (TBI) Patients","metadata":null},{"id":"7adf851639a141c58cc9d8fab1d81273","type":"TRIAL","name":"Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the \"Grey Zone\"","canonical_id":"clinicaltrials.gov:NCT07844213","description":"Congenital Heart Disease, Pulmonary Hypertension","metadata":null},{"id":"0e4baf6f2f93441aab41017450da9935","type":"TRIAL","name":"Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT06967480","description":"Generalized Myasthenia Gravis; Anti-AChR Antibody Positive","metadata":null},{"id":"98c7c8757f74479ca1c0483b4abea2fa","type":"TRIAL","name":"Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT01539733","description":"Delirium; Advanced Cancer","metadata":null},{"id":"2c3fc7b1aaea4f05a35d89cbecbd5f20","type":"TRIAL","name":"Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques","canonical_id":"clinicaltrials.gov:NCT00243672","description":"Atherosclerosis","metadata":null},{"id":"2911309095954a53acd36e4b232bfdd5","type":"TRIAL","name":"Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)","canonical_id":"clinicaltrials.gov:NCT05321875","description":"Cardiomyopathy, Dilated","metadata":null},{"id":"562ea6911e3741238a1f04fbc8b0e620","type":"TRIAL","name":"Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT04303377","description":"ST-elevation Myocardial Infarction","metadata":null},{"id":"7e2e7797d57f4ec09e8ce5926587cef0","type":"TRIAL","name":"Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04447235","description":"Cancer; COVID; Coronavirus Infection","metadata":null},{"id":"846265f99b6c44fe9d383096e7d7a1bc","type":"TRIAL","name":"Early Treatment of ARNI on Myocardial Remodeling and Progress","canonical_id":"clinicaltrials.gov:NCT04342351","description":"Myocardial Infarction","metadata":null},{"id":"b33556ac5861463fa421e80809836386","type":"TRIAL","name":"Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)","canonical_id":"clinicaltrials.gov:NCT02290613","description":"Systemic Sclerosis; Pulmonary Hypertension","metadata":null},{"id":"6a368c159c6f4146b78a5afc9e201c45","type":"TRIAL","name":"Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection","canonical_id":"clinicaltrials.gov:NCT04920838","description":"Covid19; Covid19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2 Infection","metadata":null},{"id":"6dd94cbc95bf459ca7f6c0b56dbd40c5","type":"TRIAL","name":"Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor","canonical_id":"clinicaltrials.gov:NCT05508009","description":"SIOD; Cystinosis; FSGS; SLE Nephritis; CKD Stage 4","metadata":null},{"id":"18a87214e7f5461eb8d436038d217548","type":"TRIAL","name":"Early Vascular Adjustments During Hypertensive Pregnancy","canonical_id":"clinicaltrials.gov:NCT02531490","description":"Hypertension, Pregnancy-Induced; Pre-Eclampsia","metadata":null},{"id":"00f4d4d699214f11a558a9965f4d51ca","type":"TRIAL","name":"Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin","canonical_id":"clinicaltrials.gov:NCT03007524","description":"Acute Coronary Syndrome","metadata":null},{"id":"a8d50f0f0838490c9d2c3899e5eff391","type":"TRIAL","name":"Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis","canonical_id":"clinicaltrials.gov:NCT04855110","description":"Maternal Complications After Oral Anticoagulation When Initiated Early and Late After Caesarean Section Done for Patients With Mechanical Heart Valve Prosthesis","metadata":null},{"id":"3cd1f40ba5464481a289cc812fcede84","type":"TRIAL","name":"Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis","canonical_id":"clinicaltrials.gov:NCT07276425","description":"Prurigo Nodularis (PN)","metadata":null},{"id":"48aacd22a27c4a37b96c71f8f5e5e7f0","type":"TRIAL","name":"Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)","canonical_id":"clinicaltrials.gov:NCT07191145","description":"Post Traumatic Headache","metadata":null},{"id":"c7f1d0939c91425286fa18703a46e33c","type":"DISEASE","name":"Eaton-Lambert syndrome","canonical_id":"mesh:D015624","description":null,"metadata":null},{"id":"54e9866503324be5addac6348e61f9e2","type":"DRUG","name":"Ecallantide","canonical_id":"mesh:C511194","description":null,"metadata":null},{"id":"54e60d004567436f83e7ea492adecebe","type":"DISEASE","name":"Echinococcus granulosus infection of lung","canonical_id":"mesh:D004443","description":null,"metadata":null},{"id":"f103d70d35d04ad3a846db13fd610df1","type":"TRIAL","name":"Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin","canonical_id":"clinicaltrials.gov:NCT01354704","description":"Deep Vein Thrombosis; Venous Thrombosis; Adverse Effect of Anticoagulants","metadata":null},{"id":"c2af39225b7f4b3cbda282a0cefaaa4b","type":"TRIAL","name":"Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children","canonical_id":"clinicaltrials.gov:NCT00315536","description":"Urological Surgery","metadata":null},{"id":"dfea5e664d7040cf89f842888e60cf16","type":"DRUG","name":"Echothiophate Iodide","canonical_id":"mesh:D004456","description":null,"metadata":null},{"id":"9e4b821e6f124a8693f85ece55b734b6","type":"GO_TERM","name":"Ecsit-NDUFAF1 complex","canonical_id":"go:GO:0034985","description":"\"Any large protein complex that contains Ecsit and NDUFAF1, is located in the mitochondrion, and is involved in the assembly of complex I of the oxidative phosphorylation system. In mammalian cells, three complexes of approximately 500, 600, and 850 kDa containing the 45 kDa isoform of Ecsit and NDUFAF1 have been observed.\" [PMID:17344420]","metadata":null},{"id":"972601535ad74bb9be6752395dc384d8","type":"DRUG","name":"Eculizumab","canonical_id":"mesh:C481642","description":null,"metadata":null},{"id":"e8b065ef21d74397a0548d1eceaff174","type":"TRIAL","name":"Eculizumab (Soliris) in Covid-19 Infected Patients","canonical_id":"clinicaltrials.gov:NCT04288713","description":"Coronavirus","metadata":null},{"id":"23f9ca33e7944865bf9310f4dd0e363f","type":"TRIAL","name":"Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury","canonical_id":"clinicaltrials.gov:NCT01756508","description":"End-Stage Renal Disease; Kidney Failure; Graft Reperfusion Injury","metadata":null},{"id":"65fd8e236230435d831815bd3a6b1802","type":"TRIAL","name":"Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT06453135","description":"Kidney Transplantation","metadata":null},{"id":"955dda2d32264801acd4a1a507e27658","type":"TRIAL","name":"Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT01919346","description":"Delayed Graft Function; Kidney Transplantation; Complement Activity","metadata":null},{"id":"c2cdcf12441341c5b88498547042d8a8","type":"TRIAL","name":"Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China","canonical_id":"clinicaltrials.gov:NCT05886244","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"73a82469088f454abd0d78d41ed15a47","type":"TRIAL","name":"Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT03518203","description":"Thrombotic Microangiopathies; Atypical Hemolytic Uremic Syndrome; Multiple Organ Dysfunction Syndrome","metadata":null},{"id":"32f3be84bef34489b72779aa007451b9","type":"DISEASE","name":"Eczema","canonical_id":"mesh:D004485","description":null,"metadata":null},{"id":"4fd4e106c8d146c29edac384c2dc8f81","type":"DISEASE","name":"Edema","canonical_id":"mesh:D004487","description":null,"metadata":null},{"id":"7ce3766b48ff41dea8a271ff05e1743f","type":"GO_TERM","name":"Edg-1 sphingosine 1-phosphate receptor binding","canonical_id":"go:GO:0031754","description":"\"Binding to an Edg-1 sphingosine 1-phosphate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6c5e684d2c564859851e6c6af837f790","type":"GO_TERM","name":"Edg-2 lysophosphatidic acid receptor binding","canonical_id":"go:GO:0031755","description":"\"Binding to an Edg-2 lysophosphatidic acid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e52619773b0041efa98e61eb80bd2a82","type":"GO_TERM","name":"Edg-3 sphingosine 1-phosphate receptor binding","canonical_id":"go:GO:0031756","description":"\"Binding to an Edg-3 sphingosine 1-phosphate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cf0a83ce4a4e45aea97a8d11379f1e25","type":"GO_TERM","name":"Edg-4 lysophosphatidic acid receptor binding","canonical_id":"go:GO:0031757","description":"\"Binding to an Edg-4 lysophosphatidic acid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ca859a86c9a9481a9fdae29d45ec1e44","type":"GO_TERM","name":"Edg-5 sphingosine 1-phosphate receptor binding","canonical_id":"go:GO:0031758","description":"\"Binding to an Edg-5 sphingosine 1-phosphate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6e21eae163644fdeb1c51f13fb472b97","type":"GO_TERM","name":"Edg-6 sphingosine 1-phosphate receptor binding","canonical_id":"go:GO:0031759","description":"\"Binding to an Edg-6 sphingosine 1-phosphate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"83a5693737dc4c2398aa1cb5c380c33f","type":"GO_TERM","name":"Edg-7 lysophosphatidic acid receptor binding","canonical_id":"go:GO:0031760","description":"\"Binding to an Edg-7 lysophosphatidic acid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"34e23843cf91466e9eba82d688188b85","type":"TRIAL","name":"Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial","canonical_id":"clinicaltrials.gov:NCT07207057","description":"Parkinsons Disease (PD)","metadata":null},{"id":"dc9ba5c65ac245db8cd32670a552c219","type":"TRIAL","name":"EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)","canonical_id":"clinicaltrials.gov:NCT03950076","description":"Intracranial Hemorrhages; Atrial Fibrillation","metadata":null},{"id":"7b7ea995678e46c982b240a379e00d53","type":"TRIAL","name":"EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02561897","description":"Atrial Fibrillation","metadata":null},{"id":"478e1900585147ddbb0b7a29bb064fc5","type":"DRUG","name":"Edoxaban","canonical_id":"mesh:C552171","description":null,"metadata":null},{"id":"8735c26a27be4eed9d379d06cee7cca2","type":"TRIAL","name":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT02866175","description":"Atrial Fibrillation","metadata":null},{"id":"f8f8457183384313bcb372a2cdf5a682","type":"TRIAL","name":"Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)","canonical_id":"clinicaltrials.gov:NCT02951039","description":"Atrial Fibrillation","metadata":null},{"id":"9a9fd3cdc9174ded935e580018fcb938","type":"TRIAL","name":"Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)","canonical_id":"clinicaltrials.gov:NCT03247569","description":"Atrial Fibrillation","metadata":null},{"id":"04037caebaaa441e9bfcdbd3198e2065","type":"TRIAL","name":"Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)","canonical_id":"clinicaltrials.gov:NCT03247582","description":"Atrial Fibrillation","metadata":null},{"id":"19cf55ce69844d1aaa0fdc40cb4a4ce9","type":"TRIAL","name":"Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)","canonical_id":"clinicaltrials.gov:NCT02952599","description":"Venous Thromboembolism","metadata":null},{"id":"26aa62ac819f4096b48fd4619892c056","type":"TRIAL","name":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","canonical_id":"clinicaltrials.gov:NCT02072434","description":"Atrial Fibrillation","metadata":null},{"id":"151fa836a2c04ed190fedd0a3f67224f","type":"TRIAL","name":"Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib","canonical_id":"clinicaltrials.gov:NCT01847599","description":"Metastatic Breast Cancer; Colorectal Cancer","metadata":null},{"id":"5f33af84b01d4f86acc8fb18dc070d06","type":"TRIAL","name":"Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System","canonical_id":"clinicaltrials.gov:NCT01468545","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"0b891c8c2a444df9a1575a3f1ccc63df","type":"TRIAL","name":"Efalizumab for Eczema","canonical_id":"clinicaltrials.gov:NCT00146003","description":"Dermatitis, Atopic","metadata":null},{"id":"2d667b4dcda24fe590fd8bd78710a241","type":"TRIAL","name":"Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT00442650","description":"Moderate to Severe Psoriasis","metadata":null},{"id":"4f5177e7cb9d47b3ae6685458159073c","type":"TRIAL","name":"Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids","canonical_id":"clinicaltrials.gov:NCT00489216","description":"Graft Versus Host Disease","metadata":null},{"id":"b7b848169b03488d858f7653118bc886","type":"TRIAL","name":"Efalizumab in the Treatment of Alopecia, Phase II","canonical_id":"clinicaltrials.gov:NCT00746980","description":"Alopecia Totalis","metadata":null},{"id":"4fdc2aa6e6a44c6d9f669798aaac7237","type":"TRIAL","name":"Efalizumab to Treat Uveitis","canonical_id":"clinicaltrials.gov:NCT00280826","description":"Uveitis; Macular Edema","metadata":null},{"id":"0eeddc2499e746f9bbb3fe01a96690ca","type":"TRIAL","name":"Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT00005855","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"c2b20672c3d44a76800cf2d339dd5e03","type":"TRIAL","name":"Efavirenz and Ritonavir on Human Brain P-Glycoprotein","canonical_id":"clinicaltrials.gov:NCT01668147","description":"Drug Effects","metadata":null},{"id":"294794487e4543b4b8a2649980df59ce","type":"TRIAL","name":"Effect Camostat for Kidney Protection in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06794593","description":"Chronic Kidney Disease(CKD)","metadata":null},{"id":"0cb535c46fcb4c5e9dc8cf800d9a2e44","type":"TRIAL","name":"Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate","canonical_id":"clinicaltrials.gov:NCT07462065","description":"Infertility Treatment; Pregnancy Rates","metadata":null},{"id":"66f2c525b52c46adb1232de58a5f18cc","type":"TRIAL","name":"Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1","canonical_id":"clinicaltrials.gov:NCT00795444","description":"HIV-1","metadata":null},{"id":"19036458783a4a2994d18549526c1332","type":"TRIAL","name":"Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease","canonical_id":"clinicaltrials.gov:NCT03156231","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"38f4ab2e16e541f3b47521537d0ad63a","type":"TRIAL","name":"Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)","canonical_id":"clinicaltrials.gov:NCT02222441","description":"Healthy","metadata":null},{"id":"3bcd252eeb284474ba1f80fe34d859c1","type":"TRIAL","name":"Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan","canonical_id":"clinicaltrials.gov:NCT01251835","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"b0f43fb6d3194efd9a59a91c1b585b88","type":"TRIAL","name":"Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00859027","description":"Prostate Cancer","metadata":null},{"id":"b8970b7631864792b2bb754978510738","type":"TRIAL","name":"Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00306644","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1092ba31d7e74c0a8f76d9605152bfb2","type":"TRIAL","name":"Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00219271","description":"Prostate Cancer","metadata":null},{"id":"b7c4e843c65a4b17b42a5935a81b6287","type":"TRIAL","name":"Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05529355","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"e1b0df71aa094dfdb53ddb47433d3bba","type":"TRIAL","name":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","canonical_id":"clinicaltrials.gov:NCT02963922","description":"Metabolism and Nutrition Disorder; Obesity","metadata":null},{"id":"2e3fa09cab724d7389f5b726e8333c4c","type":"TRIAL","name":"Effect and Safety of Polyethylene Glycol Combined With Linaclotide on Colon Cleansing for Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT05137145","description":"Bowel Preparation","metadata":null},{"id":"f5a9f030694c4308bd52c834ae15fdf7","type":"TRIAL","name":"Effect of 0.1% Pilocarpine Mouthwash on Xerostomia","canonical_id":"clinicaltrials.gov:NCT01627626","description":"Xerostomia","metadata":null},{"id":"161be5baa6e34eff812ac469a5fc5b12","type":"TRIAL","name":"Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms","canonical_id":"clinicaltrials.gov:NCT02252367","description":"Prostatic Hyperplasia; Lower Urinary Tract Symptoms","metadata":null},{"id":"7b2152473d874d30988315b41d8453db","type":"TRIAL","name":"Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae","canonical_id":"clinicaltrials.gov:NCT00176995","description":"Pseudofolliculitis Barbae","metadata":null},{"id":"691a709ab0954f8fa2e2b91f34137bd1","type":"TRIAL","name":"Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.","canonical_id":"clinicaltrials.gov:NCT02278588","description":"Parkinson's Disease","metadata":null},{"id":"36c655dfabe14d9481e45c9672da569d","type":"TRIAL","name":"Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes","canonical_id":"clinicaltrials.gov:NCT00064714","description":"Diabetes Mellitus","metadata":null},{"id":"816a9a3c424849c984085ccb2bba343a","type":"TRIAL","name":"Effect of Abaloparatide on Lumbar Disc Degeneration","canonical_id":"clinicaltrials.gov:NCT03708926","description":"Degeneration Disc Intervertebral","metadata":null},{"id":"1937ce3a54ee46d5bac513979143ed8c","type":"TRIAL","name":"Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance","canonical_id":"clinicaltrials.gov:NCT05575180","description":"High Altitude Effects","metadata":null},{"id":"732c5ddc39be4f85b4b7b5ef306bd7b0","type":"TRIAL","name":"Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption","canonical_id":"clinicaltrials.gov:NCT02371473","description":"Central Sleep Apnea, Secondary","metadata":null},{"id":"e524e0d8c5fc496a811b88690f4dbf09","type":"TRIAL","name":"Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)","canonical_id":"clinicaltrials.gov:NCT06285760","description":"Heart Failure; Persistent Congestion","metadata":null},{"id":"47bde3a88ffc4a129c8c6851b0a773b4","type":"TRIAL","name":"Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude","canonical_id":"clinicaltrials.gov:NCT03536455","description":"Altitude Hypoxia","metadata":null},{"id":"810cd870fe5148209019f34d27d3b707","type":"TRIAL","name":"Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude","canonical_id":"clinicaltrials.gov:NCT03536429","description":"Altitude Hypoxia","metadata":null},{"id":"76fb8305aa18488993b1e711b766caf9","type":"TRIAL","name":"Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.","canonical_id":"clinicaltrials.gov:NCT03540914","description":"Altitude Hypoxia","metadata":null},{"id":"f92e15e6ab3143f6bf7a047f02801800","type":"TRIAL","name":"Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude","canonical_id":"clinicaltrials.gov:NCT03536507","description":"Altitude Hypoxia","metadata":null},{"id":"baa7b4d1ad4a4dbcb03df8607a5453aa","type":"TRIAL","name":"Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Respiratory Disease at Altitude","canonical_id":"clinicaltrials.gov:NCT03177850","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"a16abf583f744d5d8e5045dbf3f3f684","type":"TRIAL","name":"Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude","canonical_id":"clinicaltrials.gov:NCT03536520","description":"Altitude Hypoxia","metadata":null},{"id":"ce6e027da5624251a95472698ea4a3ca","type":"TRIAL","name":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","canonical_id":"clinicaltrials.gov:NCT06041789","description":"Osteoporosis","metadata":null},{"id":"89f9835cf1094edd82ed1155b887f9d3","type":"TRIAL","name":"Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas","canonical_id":"clinicaltrials.gov:NCT00567658","description":"Larynx Disease","metadata":null},{"id":"c4ef2f7884534fff91c5de7a2e8cacb6","type":"TRIAL","name":"Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients","canonical_id":"clinicaltrials.gov:NCT02424344","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"bca16449b6de4ee1a0951ef4ab97ba75","type":"TRIAL","name":"Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein","canonical_id":"clinicaltrials.gov:NCT02515526","description":"AOD Effects and Consequences","metadata":null},{"id":"ef0caaacd03c4e5fa57b2c76c02b04e4","type":"TRIAL","name":"Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00940862","description":"Psoriasis; Vascular Inflammation; Coronary Atherosclerosis","metadata":null},{"id":"8dfe925338024894ad2385fa0cc160f4","type":"TRIAL","name":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","canonical_id":"clinicaltrials.gov:NCT03693560","description":"Coronary Artery Disease; Diabetes Mellitus, Type 2","metadata":null},{"id":"3042fed78f3f4cbf825413c188f42054","type":"TRIAL","name":"Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.","canonical_id":"clinicaltrials.gov:NCT01304901","description":"Asthma; Acute Asthma","metadata":null},{"id":"20b889dff2d5415ba1345bb18bb5f671","type":"TRIAL","name":"Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response","canonical_id":"clinicaltrials.gov:NCT00501488","description":"Diabetes Mellitus","metadata":null},{"id":"c5f3872b3f9647929b867779aa9c6a0c","type":"TRIAL","name":"Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study","canonical_id":"clinicaltrials.gov:NCT03709381","description":"Adrenal Insufficiency; Osteopenia, Osteoporosis; Steroid Suppression of ACTH Secretion","metadata":null},{"id":"890ff344d260427999d7450444a7a1dc","type":"TRIAL","name":"Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01723735","description":"Hypercholesterolemia","metadata":null},{"id":"a972c1e9f8d04f21a5748e7296df4144","type":"TRIAL","name":"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03344692","description":"Type2 Diabetes","metadata":null},{"id":"5ada91cf58f5488096326dc88fa93680","type":"TRIAL","name":"Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound","canonical_id":"clinicaltrials.gov:NCT03529253","description":"Coronary Artery Disease; Angina Pectoris","metadata":null},{"id":"ab169aed3cac40f89653d794b26d412e","type":"TRIAL","name":"Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA","canonical_id":"clinicaltrials.gov:NCT05769478","description":"Botulism; Iatrogenic Botulism","metadata":null},{"id":"2ddaba4979c54163a65d96ff9d6505a4","type":"TRIAL","name":"Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT07008235","description":"Functional Dyspepsia","metadata":null},{"id":"180df8f96318473db949b4cb6dde92ef","type":"TRIAL","name":"Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension","canonical_id":"clinicaltrials.gov:NCT00693199","description":"Lower Urinary Tract Symptoms; Hypertension","metadata":null},{"id":"809bfd3c2f7d4afa9770fe2af83a601d","type":"TRIAL","name":"Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01552928","description":"Healthy","metadata":null},{"id":"825af7a93f0740eaba266bf3952d19cf","type":"TRIAL","name":"Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT06712030","description":"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","metadata":null},{"id":"b93500be2e6d419492ebea03aa660e61","type":"TRIAL","name":"Effect of Antenatal Corticosteroids on Neonatal Morbidity.","canonical_id":"clinicaltrials.gov:NCT03446937","description":"Neonatal Respiratory Distress Syndrome","metadata":null},{"id":"2c334e61f01c4168b7e906c507025f44","type":"TRIAL","name":"Effect of Anti-IgE in Chronic Urticaria","canonical_id":"clinicaltrials.gov:NCT00130234","description":"Urticaria","metadata":null},{"id":"6cf4d76eebbc44dcbcb0912e14fb1408","type":"TRIAL","name":"Effect of Anti-histamine in Prevention Systolic Hypotension After Protamine","canonical_id":"clinicaltrials.gov:NCT03583567","description":"Protamine Adverse Reaction","metadata":null},{"id":"3abbc87ccadc4d2ba90ab442a2bac58c","type":"TRIAL","name":"Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines","canonical_id":"clinicaltrials.gov:NCT04412044","description":"Asthma","metadata":null},{"id":"67cfc41483bb49d2b6f430bf443e366c","type":"TRIAL","name":"Effect of Antidepressants on Back Pain","canonical_id":"clinicaltrials.gov:NCT00018200","description":"Back Pain; Sciatica","metadata":null},{"id":"53073f1af5fa45a196913da7ddb71452","type":"TRIAL","name":"Effect of Antidepressants on White Matter Structure","canonical_id":"clinicaltrials.gov:NCT01492621","description":"Major Depression","metadata":null},{"id":"3dce5104a53d4eec9fb0500f3d2178bc","type":"TRIAL","name":"Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection","canonical_id":"clinicaltrials.gov:NCT02140450","description":"Intraocular Pressure Change in Intravitreal Injection","metadata":null},{"id":"c2f7036e86144d56b7b353368998aa43","type":"TRIAL","name":"Effect of Antihistamines on Ureteral Stent-Related Symptoms","canonical_id":"clinicaltrials.gov:NCT04726345","description":"Nephrolithiasis","metadata":null},{"id":"1677583a151a4229b1523553c159cb61","type":"TRIAL","name":"Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT02896621","description":"Hypertension; Sleep Apnea","metadata":null},{"id":"622fac89c360416eb38557fac578e8e6","type":"TRIAL","name":"Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement","canonical_id":"clinicaltrials.gov:NCT00668031","description":"Blood Loss, Surgical","metadata":null},{"id":"e5b5c405715144de93aef0b32f9befcf","type":"TRIAL","name":"Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery","canonical_id":"clinicaltrials.gov:NCT00327379","description":"Blood Loss, Surgical; Postoperative Hemorrhage","metadata":null},{"id":"1d2b3d304a2d4799a0112523c537d595","type":"TRIAL","name":"Effect of Atorvastatin on Carotid Intima Media Thickness","canonical_id":"clinicaltrials.gov:NCT04306627","description":"Essential Hypertension; Hypercholesterolemia","metadata":null},{"id":"46a4e14408e64762a9b3d5ddfeb014cb","type":"TRIAL","name":"Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism","canonical_id":"clinicaltrials.gov:NCT01160991","description":"Schizophrenia; Diabetes; Insulin Resistance","metadata":null},{"id":"ac5a90bd1c53495eb699bb91d9919686","type":"TRIAL","name":"Effect of BIA 9-1067 on Rasagiline Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT01532128","description":"Parkinson Disease","metadata":null},{"id":"592541f5f2714fa8a43567da8e5af34e","type":"TRIAL","name":"Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin","canonical_id":"clinicaltrials.gov:NCT03044873","description":"Autoimmune Diseases; Inflammatory Diseases","metadata":null},{"id":"5b93a6af35c8494ab7cc006e82d0c1e1","type":"TRIAL","name":"Effect of Baclofen to Prevent Post-Traumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT05877807","description":"Alcoholism; Post Traumatic Stress Disorder","metadata":null},{"id":"6a989037d5e0409cb149fea2bceedb30","type":"TRIAL","name":"Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women","canonical_id":"clinicaltrials.gov:NCT05604222","description":"Urgency Urinary Incontinence; Nocturia","metadata":null},{"id":"c392659250974597ad91cc3a53a99df5","type":"TRIAL","name":"Effect of Belimumab on Antibody Titers in Primary APS Patients","canonical_id":"clinicaltrials.gov:NCT06747312","description":"Antiphospholipid Syndrome (APS)","metadata":null},{"id":"4ea8c2a029094f65af42273a3e59e3d4","type":"TRIAL","name":"Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT00497003","description":"Endothelial Function; Beta Blocker","metadata":null},{"id":"343ac3029ae547bb8d09df53e4d0a64c","type":"TRIAL","name":"Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects","canonical_id":"clinicaltrials.gov:NCT00588965","description":"Long QT Syndrome; Cardiac Repolarization","metadata":null},{"id":"01cc40e52370408ca8c1bafbf271ba48","type":"TRIAL","name":"Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning","canonical_id":"clinicaltrials.gov:NCT03169426","description":"Myocardial Infarction","metadata":null},{"id":"1d54449349b04afcbaf266582bea363f","type":"TRIAL","name":"Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart","canonical_id":"clinicaltrials.gov:NCT01798992","description":"Idiopathic Dilated Cardiomyopathy","metadata":null},{"id":"d0493091a9a1495c83a2f69a77bd3dd6","type":"TRIAL","name":"Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects","canonical_id":"clinicaltrials.gov:NCT00983788","description":"Carnitine Palmitoyltransferase II Deficiency; Very Long Chain Acyl Coa Dehydrogenase Deficiency","metadata":null},{"id":"6f277e8892324372a80ca7cfe73b8f4b","type":"TRIAL","name":"Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass","canonical_id":"clinicaltrials.gov:NCT02952963","description":"Severe Obesity","metadata":null},{"id":"817805ccfc394fc294374ff3acc4008b","type":"TRIAL","name":"Effect of Bile Acids on GLP-1 Secretion","canonical_id":"clinicaltrials.gov:NCT01666223","description":"Type 2 Diabetes; Obesity","metadata":null},{"id":"23d79e1984404a5cbe25c2b1868e19d3","type":"TRIAL","name":"Effect of Bile Acids on the Secretion of Satiation Peptides in Humans","canonical_id":"clinicaltrials.gov:NCT01674946","description":"Echolocation","metadata":null},{"id":"f1e867997aca44de8becbe5f01d79204","type":"TRIAL","name":"Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT05499416","description":"Psoriasis Vulgaris; Active Psoriatic Arthritis","metadata":null},{"id":"1650525d73424b58a277e1d9cdb30684","type":"TRIAL","name":"Effect of Bitter in Overweight Female Volunteers","canonical_id":"clinicaltrials.gov:NCT04005781","description":"Obesity","metadata":null},{"id":"5a0b5c81bcdc4ffca1bf7a876f8c5247","type":"TRIAL","name":"Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01357109","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"69dc9995f61f47169883f6be103d02c7","type":"TRIAL","name":"Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema","canonical_id":"clinicaltrials.gov:NCT01574248","description":"ACE Inhibitor-associated Angioedema","metadata":null},{"id":"b1eaf0b10c9d47fd973ade9e4f5c59a8","type":"TRIAL","name":"Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients","canonical_id":"clinicaltrials.gov:NCT01621971","description":"Pulmonary Hypertension; Mitral Regurgitation","metadata":null},{"id":"49e5fbd0b5d34394bc03541f9ef90202","type":"TRIAL","name":"Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)","canonical_id":"clinicaltrials.gov:NCT01653262","description":"Epilepsy","metadata":null},{"id":"6f871eb9202a4049ad85b2d47307fc2f","type":"TRIAL","name":"Effect of Brivaracetam in Photosensitive Epileptic Subjects","canonical_id":"clinicaltrials.gov:NCT00401648","description":"Epilepsy","metadata":null},{"id":"8de24fb4d5ec4b8a887fc412498936fb","type":"TRIAL","name":"Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT03478280","description":"Psoriasis","metadata":null},{"id":"92b297868e38418bb833c47f5bbafb7e","type":"TRIAL","name":"Effect of Bromfenac on Pain Related to Pterygium Surgery","canonical_id":"clinicaltrials.gov:NCT04022811","description":"Pterygium; Pain","metadata":null},{"id":"e652f7b4e3a54418919a76959bdff857","type":"TRIAL","name":"Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study","canonical_id":"clinicaltrials.gov:NCT02133755","description":"PCOS; Insulin Resistance","metadata":null},{"id":"0ba3a6875e694d70ada3155985797ae4","type":"TRIAL","name":"Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT00998556","description":"Peripartum Cardiomyopathy","metadata":null},{"id":"b8286f57f70c40aaafa9dc868d31ea0d","type":"TRIAL","name":"Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use","canonical_id":"clinicaltrials.gov:NCT03266445","description":"Opioid-use Disorder; Pain, Acute; Surgery","metadata":null},{"id":"5a3c8d396bc54695984917b6dc30d691","type":"TRIAL","name":"Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients","canonical_id":"clinicaltrials.gov:NCT02043366","description":"Pain; Anesthesia","metadata":null},{"id":"1addf751796447bcb69462ddbf4d0409","type":"TRIAL","name":"Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain","canonical_id":"clinicaltrials.gov:NCT04477733","description":"Colonoscopy","metadata":null},{"id":"a1c6249594994a98a6bd044fd000dc67","type":"TRIAL","name":"Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection","canonical_id":"clinicaltrials.gov:NCT02306564","description":"Infertility","metadata":null},{"id":"6e70cbd82db8462c9b3eb7acccfd2c15","type":"TRIAL","name":"Effect of Cabergoline on Weight and Glucose Tolerance","canonical_id":"clinicaltrials.gov:NCT01395602","description":"Body Weight; Impaired Glucose Tolerance in Obese","metadata":null},{"id":"aea55ec80e99465ebf4d9b17372c41ae","type":"TRIAL","name":"Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer","canonical_id":"clinicaltrials.gov:NCT02592356","description":"Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma","metadata":null},{"id":"463520e117664e58b45b82ed36c0f7ee","type":"TRIAL","name":"Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity","canonical_id":"clinicaltrials.gov:NCT06978777","description":"Brown Adipose Tissue (BAT) Physiology; Cold Exposure","metadata":null},{"id":"f4f1e02b72e94f848d56600e111de2f8","type":"TRIAL","name":"Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl","canonical_id":"clinicaltrials.gov:NCT01074632","description":"Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder","metadata":null},{"id":"c13c3b5c32d74f949de7abeb7cd3b892","type":"TRIAL","name":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","canonical_id":"clinicaltrials.gov:NCT05513729","description":"Type 2 Diabetes Mellitus With Complication","metadata":null},{"id":"3d485b3bcc9441fa8b92e901746cd4ec","type":"TRIAL","name":"Effect of Capivasertib on ctDNA in ER Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06613516","description":"Breast Cancer; Oestrogen Receptor Positive Breast Cancer","metadata":null},{"id":"cc71a094caf54b5c8d57ef07a4e81d49","type":"TRIAL","name":"Effect of Captopril on GLS in Duchenne Myodystrophy","canonical_id":"clinicaltrials.gov:NCT06485661","description":"Effect of Drug","metadata":null},{"id":"db9077846b5e437a894ba0a313a33746","type":"TRIAL","name":"Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol","canonical_id":"clinicaltrials.gov:NCT01304069","description":"Healthy","metadata":null},{"id":"ba0eb5bde5604269a696377fd07e14e9","type":"TRIAL","name":"Effect of Celecoxib on Markers of Vascular Inflammation","canonical_id":"clinicaltrials.gov:NCT00471341","description":"Hypertension and Coronary Artery Disease","metadata":null},{"id":"936d9a322c4447b59b8fdcb4980c6d4b","type":"TRIAL","name":"Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS","canonical_id":"clinicaltrials.gov:NCT04147013","description":"Chronic Rhinosinusitis with Nasal Polyps; Aspirin-exacerbated Respiratory Disease","metadata":null},{"id":"2131ad5d2f034bb08efff74259bcb815","type":"TRIAL","name":"Effect of Choline Fenofibrate (SLV348) on Macular Edema","canonical_id":"clinicaltrials.gov:NCT00683176","description":"Diabetic Macular Edema","metadata":null},{"id":"746f83ca6a23443f8d00085eb07567a5","type":"TRIAL","name":"Effect of Ciclesonide on Exercise Induced Bronchoconstriction","canonical_id":"clinicaltrials.gov:NCT00525772","description":"Asthma","metadata":null},{"id":"6ae1f04db0a74359873126354b805cb4","type":"TRIAL","name":"Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)","canonical_id":"clinicaltrials.gov:NCT00305461","description":"Asthma","metadata":null},{"id":"00d1ee484a6444dd8417f4692e13c4fa","type":"TRIAL","name":"Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler","canonical_id":"clinicaltrials.gov:NCT00741286","description":"Cerebral Infarction","metadata":null},{"id":"3716c9c7e9c349dcb4fcfe9f590dde35","type":"TRIAL","name":"Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03248401","description":"Type 2 Diabetes Mellitus; Carotid Atherosclerosis","metadata":null},{"id":"bd8e266da73f4a11a76d7b3913e3c747","type":"TRIAL","name":"Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM","canonical_id":"clinicaltrials.gov:NCT02266030","description":"Coronary Artery Disease","metadata":null},{"id":"984939f907144af28d3a09857c4bae0c","type":"TRIAL","name":"Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX","canonical_id":"clinicaltrials.gov:NCT01366378","description":"Healthy Adult Subjects","metadata":null},{"id":"902ece0cec5b47198fbf7c15e52f8661","type":"TRIAL","name":"Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets","canonical_id":"clinicaltrials.gov:NCT00195936","description":"Hypophosphatemic Rickets, X-Linked Dominant","metadata":null},{"id":"860be764ff26496694c2dacb30d80f8e","type":"TRIAL","name":"Effect of Clemastine Fumarate on Color Vision in Healthy Controls","canonical_id":"clinicaltrials.gov:NCT02613091","description":"Healthy Subjects","metadata":null},{"id":"5e232ae3c1a043b88355f5aedd914b5a","type":"TRIAL","name":"Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients","canonical_id":"clinicaltrials.gov:NCT02913924","description":"Cannabis Use Disorder","metadata":null},{"id":"6b67913e5a82457fadac4914b66a5f52","type":"TRIAL","name":"Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism","canonical_id":"clinicaltrials.gov:NCT02312908","description":"REM Sleep Behavior Disorder","metadata":null},{"id":"6bee3571a3fa4cb4ad173aa96329f1a9","type":"TRIAL","name":"Effect of Clonidine on Responses to Imagery Scripts","canonical_id":"clinicaltrials.gov:NCT00318760","description":"Cocaine Abuse; Heroin Abuse","metadata":null},{"id":"72e10064eaa34b9bb36906995faeb2e1","type":"TRIAL","name":"Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05045638","description":"Healthy Participants","metadata":null},{"id":"fbb1af0b0d9b446d9610454a5ac0de97","type":"TRIAL","name":"Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01935700","description":"Hepatocellular Carcinoma; Metastasis; Invasion","metadata":null},{"id":"88819903c5a94406a5c529bbad037fb9","type":"TRIAL","name":"Effect of Colchicine on Range of Motion After Manipulation Under Anesthesia for the Stiff Total Knee Replacement","canonical_id":"clinicaltrials.gov:NCT02926248","description":"Manipulation Under Anesthesia","metadata":null},{"id":"720cd3fd7d4f410b977ff76f3df2c171","type":"TRIAL","name":"Effect of Combined Morphine and Duloxetine on Chronic Pain","canonical_id":"clinicaltrials.gov:NCT03249558","description":"Chronic Low Back Pain; Chronic Neck Pain","metadata":null},{"id":"0803d6afc57245dfb65c91636694e32f","type":"TRIAL","name":"Effect of Curcumin as Nutraceutical in Patients of Depression","canonical_id":"clinicaltrials.gov:NCT01022632","description":"Major Depressive Disorder","metadata":null},{"id":"a3883c0d4a97461483978f6771884c4e","type":"TRIAL","name":"Effect of DPP4 Inhibition on Growth Hormone Secretion","canonical_id":"clinicaltrials.gov:NCT01701973","description":"Obesity","metadata":null},{"id":"575060ffb2f94e85b85fa75766e768b1","type":"TRIAL","name":"Effect of DPP4 Inhibition on Vasoconstriction","canonical_id":"clinicaltrials.gov:NCT02639637","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c07579ad58c24249a2ef6cadee296bc1","type":"TRIAL","name":"Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02656160","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"70cc5126ea394e9284ec95643a35e980","type":"TRIAL","name":"Effect of Danazol on Endometrial \u03b1v\u03b23 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure","canonical_id":"clinicaltrials.gov:NCT03563664","description":"Unexplained Infertility","metadata":null},{"id":"7cc149806ff849ab88b07d08fc4c3bf6","type":"TRIAL","name":"Effect of Dapagliflozin on IAH in T1DM","canonical_id":"clinicaltrials.gov:NCT03556033","description":"Diabetes Mellitus, Type 1; Hypoglycemia; Hypoglycemia Unawareness","metadata":null},{"id":"975be2211ac143dc91ee118d08f0ccfc","type":"TRIAL","name":"Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients","canonical_id":"clinicaltrials.gov:NCT05735197","description":"Chronic Kidney Diseases; Bone Diseases, Metabolic","metadata":null},{"id":"d796301e5bf14b9c85ea35c0c12143f9","type":"TRIAL","name":"Effect of Delivery Route on PK of Sufentanil NanoTab","canonical_id":"clinicaltrials.gov:NCT01639729","description":"Pharmacokinetics","metadata":null},{"id":"98a599e972004310950a53c0c6f920c7","type":"TRIAL","name":"Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A","canonical_id":"clinicaltrials.gov:NCT02428478","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"8eaf79b3421c4a06805bd9b7bbf40604","type":"TRIAL","name":"Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B","canonical_id":"clinicaltrials.gov:NCT02436031","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"ea0344a9906e4132985bebde8ebd5d2f","type":"TRIAL","name":"Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia","canonical_id":"clinicaltrials.gov:NCT03096730","description":"Pain; Anesthesia","metadata":null},{"id":"3c345b216d9e445985756c49c29b7e76","type":"TRIAL","name":"Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient","canonical_id":"clinicaltrials.gov:NCT06993740","description":"Flap Monitoring; Inflammation; Thrombosis; Oxidative Stress; Glycocalyx; Anesthesia; Surgery; Flap Ischemia; Flap Necrosis; Flap Failure Risk Factors; Microsurgery","metadata":null},{"id":"1c286ec46001412dbf1fd6dd4a6dbcbb","type":"TRIAL","name":"Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS","canonical_id":"clinicaltrials.gov:NCT00463112","description":"Obesity; Polycystic Ovary Syndrome","metadata":null},{"id":"965242868057452ab5d9e043bbc8dffc","type":"TRIAL","name":"Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation","canonical_id":"clinicaltrials.gov:NCT05024799","description":"Respiratory Insufficiency","metadata":null},{"id":"f30ce7bbb4dc4aaabd938827082c061b","type":"TRIAL","name":"Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients","canonical_id":"clinicaltrials.gov:NCT00936923","description":"Renal Function Disorder","metadata":null},{"id":"a28365404d714b5786bd3d5179f59b85","type":"TRIAL","name":"Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy","canonical_id":"clinicaltrials.gov:NCT04893655","description":"General Anesthesia","metadata":null},{"id":"2e9dbb0281a841adb934c9360a9aa17c","type":"TRIAL","name":"Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy","canonical_id":"clinicaltrials.gov:NCT03662113","description":"Capsule Endoscopy; Pediatric Disorder","metadata":null},{"id":"568ca9499c014a95bc5d3a7de3bd201e","type":"TRIAL","name":"Effect of Domperidone on QT Interval in Premature Infants","canonical_id":"clinicaltrials.gov:NCT00238056","description":"Prematurity and Feeding Intolerance","metadata":null},{"id":"ed61877de2a043208427b7d6d8d1190a","type":"TRIAL","name":"Effect of Domperidone on the Nutrient Composition of Preterm Mother's Breast Milk","canonical_id":"clinicaltrials.gov:NCT00308334","description":"Low Breast Milk Supply","metadata":null},{"id":"b95ae18c51ea4a76a38b8199f565d49b","type":"TRIAL","name":"Effect of Dotinurad in Hyperuricemia With Hypertension","canonical_id":"clinicaltrials.gov:NCT06834230","description":"Hyperuricemia or Gout; Hypertension","metadata":null},{"id":"f44804ecd6c84fd398193c4d9f31f973","type":"TRIAL","name":"Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT01268709","description":"Irritable Bowel Syndrome","metadata":null},{"id":"aafaa5ad236c489c88a0034a880d8ada","type":"TRIAL","name":"Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS","canonical_id":"clinicaltrials.gov:NCT07318337","description":"PCOS (Polycystic Ovary Syndrome)","metadata":null},{"id":"2b94258a521249dba95b08375cb4a82e","type":"TRIAL","name":"Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis","canonical_id":"clinicaltrials.gov:NCT03675022","description":"Sleep Apnea; Rhinosinusitis Chronic","metadata":null},{"id":"f71700e059914297afb44a5b0d991363","type":"TRIAL","name":"Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)","canonical_id":"clinicaltrials.gov:NCT06665971","description":"Eosinophilic Esophagitis (EoE)","metadata":null},{"id":"4e7c8d33773e435d9fe51e2787690552","type":"TRIAL","name":"Effect of Early Treatment With Sivelestat Sodium in ARDS Patients","canonical_id":"clinicaltrials.gov:NCT05020210","description":"ARDS; Inflammatory Response","metadata":null},{"id":"2bc7d52e9ff54d16abd15fa455f1ce3d","type":"TRIAL","name":"Effect of Elagolix in Symptomatic Endometrioma in Comparison to Combined Oral Contraceptive Pill.","canonical_id":"clinicaltrials.gov:NCT07763847","description":"Endometrioma","metadata":null},{"id":"81892ab21d354b189055d8f1954ecd23","type":"TRIAL","name":"Effect of Electroacupuncture on Refractory Pain in Juvenile Rheumatoid Arthritis: Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT05504382","description":"Juvenile Rheumatoid Arthritis","metadata":null},{"id":"4ac7663618f84044a0c7615c71a75360","type":"TRIAL","name":"Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes","canonical_id":"clinicaltrials.gov:NCT04131582","description":"Prediabetic State; Insulin Resistance","metadata":null},{"id":"5709c263d2584554bd7d3d933d0e49b0","type":"TRIAL","name":"Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls","canonical_id":"clinicaltrials.gov:NCT01867307","description":"Diabetes Mellitus, Type 2; Healthy","metadata":null},{"id":"717dc217b4904ec1aa32cdf66bd991f8","type":"TRIAL","name":"Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D","canonical_id":"clinicaltrials.gov:NCT05140694","description":"Metabolic-associated Fatty Liver Disease; Type 2 Diabetes","metadata":null},{"id":"b10d5cf8b78f490ab01ff185ae64a29e","type":"TRIAL","name":"Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease","canonical_id":"clinicaltrials.gov:NCT05671991","description":"End Stage Renal Disease on Dialysis","metadata":null},{"id":"4d4e359370124519b595ad679d973163","type":"TRIAL","name":"Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT04961931","description":"Chronic Kidney Disease stage3","metadata":null},{"id":"0d8e1cba67214d15bcdf744e9b781b77","type":"TRIAL","name":"Effect of Empagliflozin on Ventricular Repolarization.","canonical_id":"clinicaltrials.gov:NCT04117763","description":"Diabetes Mellitus, Type 2; Coronary Heart Disease; Arrythmia, Cardiac","metadata":null},{"id":"90104a953a644ec6aaf1073da176d6e5","type":"TRIAL","name":"Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT06095492","description":"Kidney Transplant; Complications; Diabetes Mellitus","metadata":null},{"id":"b397227d03c043f198a24c59e99f824f","type":"TRIAL","name":"Effect of Entacapone on Bodyweight Loss in Obese Population","canonical_id":"clinicaltrials.gov:NCT02349243","description":"Obesity","metadata":null},{"id":"bb58550c13b34ece8fe253a8097e7e90","type":"TRIAL","name":"Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients","canonical_id":"clinicaltrials.gov:NCT01302236","description":"Hypertension; Chronic Kidney Disease.","metadata":null},{"id":"a50a96bb62594ef0b6326ffe5b2bdc37","type":"TRIAL","name":"Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01786551","description":"Systemic Proinflammatory State","metadata":null},{"id":"0856d39f53c34f46b27539f7302ae99b","type":"TRIAL","name":"Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms","canonical_id":"clinicaltrials.gov:NCT00772837","description":"Functional Dyspepsia; Helicobacter Pylori Infection","metadata":null},{"id":"d7846459bd7049ad94971ae70f74b3d2","type":"TRIAL","name":"Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT03912337","description":"Migraine","metadata":null},{"id":"02fc2123f3db4588bffaa20228839545","type":"TRIAL","name":"Effect of Ertugliflozin on Cardiac Function in Diabetes","canonical_id":"clinicaltrials.gov:NCT03717194","description":"Type2 Diabetes; Heart Failure","metadata":null},{"id":"2ce6bd14db374b98b037a35bcc42158c","type":"TRIAL","name":"Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD","canonical_id":"clinicaltrials.gov:NCT05644717","description":"Liver Fat; Liver Fibrosis; Glycemic Control; Body Weight Changes; Waist Circumference; Tolerance","metadata":null},{"id":"7182f52025634afa947d0724c036adea","type":"TRIAL","name":"Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00209807","description":"Major Depression; Pain; Abdominal Pain","metadata":null},{"id":"811ae710507647048cf6d1a9a2d936a0","type":"TRIAL","name":"Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome","canonical_id":"clinicaltrials.gov:NCT06013319","description":"Acute Respiratory Distress Syndrome","metadata":null},{"id":"2a95dd07f25547388bbc9aa5de7a32ac","type":"TRIAL","name":"Effect of Esmolol on Pain Due to Rocuronium","canonical_id":"clinicaltrials.gov:NCT01824758","description":"Injection Site Irritation","metadata":null},{"id":"560040eadbbb421ab6f235a1cd901ec3","type":"TRIAL","name":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)","canonical_id":"clinicaltrials.gov:NCT00393354","description":"Recurrent Low Back Pain","metadata":null},{"id":"75e4817075184141981fb0c5b49773a0","type":"TRIAL","name":"Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive","canonical_id":"clinicaltrials.gov:NCT07215806","description":"Healthy","metadata":null},{"id":"8133ce476542413a996f6d0e84a7001f","type":"TRIAL","name":"Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)","canonical_id":"clinicaltrials.gov:NCT04306471","description":"Critical Limb Ischemia","metadata":null},{"id":"2cb51d3ecb2b46d9b3de09e4ac2eae29","type":"TRIAL","name":"Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)","canonical_id":"clinicaltrials.gov:NCT03931161","description":"Carotid Artery Stenosis","metadata":null},{"id":"db2bc2850e4b4c15908c828551d85497","type":"TRIAL","name":"Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT03900026","description":"Coronary Artery Bypass Graft Surgery; Atherosclerosis; Vein Occlusion","metadata":null},{"id":"f15eee42bcd946fc96baace028bad6ad","type":"TRIAL","name":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional \u00df -Cell Mass","canonical_id":"clinicaltrials.gov:NCT00775684","description":"Pre-diabetes; Type 2 Diabetes","metadata":null},{"id":"bdb524d97e334129bb0cf489c7723921","type":"TRIAL","name":"Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","canonical_id":"clinicaltrials.gov:NCT00651391","description":"Hypercholesterolemia; Atherosclerosis","metadata":null},{"id":"b7e732a68de5456199582d5fc39a1ee7","type":"TRIAL","name":"Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina","canonical_id":"clinicaltrials.gov:NCT01549977","description":"Angina","metadata":null},{"id":"4dee3eb26f254417bf367aeb308cb2ac","type":"TRIAL","name":"Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.","canonical_id":"clinicaltrials.gov:NCT02866214","description":"Endothelial Dysfunction; Endstage Renal Disease","metadata":null},{"id":"8d335da7dca147bb836e3855db9d9f1a","type":"TRIAL","name":"Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout","canonical_id":"clinicaltrials.gov:NCT01078389","description":"Joint Damage","metadata":null},{"id":"d069f5e56073487a9de7311952e87033","type":"TRIAL","name":"Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment","canonical_id":"clinicaltrials.gov:NCT01082640","description":"Renal Impairment","metadata":null},{"id":"106585762126440cab97cec028805846","type":"TRIAL","name":"Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People","canonical_id":"clinicaltrials.gov:NCT00543647","description":"Healthy Volunteers","metadata":null},{"id":"73401aa1e0a64771922c71ea5df52afa","type":"TRIAL","name":"Effect of Fentanyl on Emergence Delirium (ED) on Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital (KNH)","canonical_id":"clinicaltrials.gov:NCT02753725","description":"Emergence Delirium","metadata":null},{"id":"cb60e0893a484146a235fef6f0679267","type":"TRIAL","name":"Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification","canonical_id":"clinicaltrials.gov:NCT03494257","description":"Cataract; Intraocular Pressure","metadata":null},{"id":"461e0dcad67f47a286d5bcfcb9f6da4e","type":"TRIAL","name":"Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane","canonical_id":"clinicaltrials.gov:NCT02157428","description":"Adverse Effect of Other General Anesthetics","metadata":null},{"id":"2db3664312cd40eeaaf3435b285a7276","type":"TRIAL","name":"Effect of Fluoxetine (Prozac) on Domestic Violence","canonical_id":"clinicaltrials.gov:NCT00011765","description":"Domestic Violence","metadata":null},{"id":"56e536d00140427e8e95e9a74297f8b5","type":"TRIAL","name":"Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00416403","description":"Breast Cancer","metadata":null},{"id":"bc0df19681d64ad0841366ed24a99fe6","type":"TRIAL","name":"Effect of Fluvastatin on Brown Fat Activity","canonical_id":"clinicaltrials.gov:NCT03189511","description":"Adipose Tissue, Brown; Insulin Resistance; Clinical Trial","metadata":null},{"id":"47bf26fda43a4d89b5979dd3cf18227e","type":"TRIAL","name":"Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients","canonical_id":"clinicaltrials.gov:NCT01832285","description":"SCHIZOPHRENIA 1 (Disorder)","metadata":null},{"id":"3819082ac17642e5a7ce4d3b782edf5b","type":"TRIAL","name":"Effect of Food on Opicapone","canonical_id":"clinicaltrials.gov:NCT03116308","description":"Parkinson Disease","metadata":null},{"id":"0c725b24ccc040fe9d0424de760036d9","type":"TRIAL","name":"Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02181309","description":"Healthy","metadata":null},{"id":"076bef56cc96474cac38ed66fc6b0902","type":"TRIAL","name":"Effect of Foot Massage Performed to the Mother After B\u0131rth on Breastfeed\u0131ng Success, Sleep Qual\u0131ty and Newborn Stress","canonical_id":"clinicaltrials.gov:NCT06786481","description":"Postpartum Women","metadata":null},{"id":"ad12fd7cbc444afea0b0fbd8199d6d8f","type":"TRIAL","name":"Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?","canonical_id":"clinicaltrials.gov:NCT00164801","description":"Non-Cardiac Chest Pain","metadata":null},{"id":"b09aa780ebe647b5beac6fa43129427f","type":"TRIAL","name":"Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00603031","description":"Type-1 Diabetes Mellitus","metadata":null},{"id":"a1ce93a9a8d24d74b5d7350c52e5dcf5","type":"TRIAL","name":"Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT00615212","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"6a6f946103424682aaa448eb1bfb5ca1","type":"TRIAL","name":"Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides","canonical_id":"clinicaltrials.gov:NCT00108511","description":"Hypertriglyceridemia","metadata":null},{"id":"baecbe8abad9475d8ecd73c20444ceb1","type":"TRIAL","name":"Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01385020","description":"Healthy Subjects","metadata":null},{"id":"cd53e87133e14c61ad2c0076f0de2246","type":"TRIAL","name":"Effect of Gene Variants on Dopamine Receptor Natriuretic Responses","canonical_id":"clinicaltrials.gov:NCT00592150","description":"Hypertension","metadata":null},{"id":"8f61f10688e745098179d62700b35e1e","type":"TRIAL","name":"Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia","canonical_id":"clinicaltrials.gov:NCT04401345","description":"Glycopyrrolate; Post-spinal Hypotension; Effect of Drug; Hemodynamic Instability","metadata":null},{"id":"befcf87f00a740b4bba47d374c79fb9a","type":"TRIAL","name":"Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT05331651","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"2c838c58da2149c59b8e4a9384134823","type":"TRIAL","name":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.","canonical_id":"clinicaltrials.gov:NCT04727671","description":"In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility; Polycystic Ovary Syndrome","metadata":null},{"id":"5470861c4cef4b4496441471b260d43e","type":"TRIAL","name":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.","canonical_id":"clinicaltrials.gov:NCT04724343","description":"In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility","metadata":null},{"id":"7d5cf9b4e23445f4b63bf032da67fd30","type":"TRIAL","name":"Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)","canonical_id":"clinicaltrials.gov:NCT01453725","description":"Spondylitis, Ankylosing","metadata":null},{"id":"0aa53f400d0747938a4b3ee99d323bca","type":"TRIAL","name":"Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section","canonical_id":"clinicaltrials.gov:NCT03318536","description":"Hypotension; Cesarean Section Complications","metadata":null},{"id":"c5dfa9052c0140e68ed5379fca2d5856","type":"TRIAL","name":"Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia","canonical_id":"clinicaltrials.gov:NCT01156051","description":"Attention-Deficit/Hyperactivity Disorder; Attention Deficit Disorder; Insomnia; Sleep Disorders","metadata":null},{"id":"4d5401c7f5c74a23be6b964e88625580","type":"TRIAL","name":"Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance","canonical_id":"clinicaltrials.gov:NCT01681264","description":"Chronic Pain","metadata":null},{"id":"a071f47d116a48edac5f3a2465657cc3","type":"TRIAL","name":"Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)","canonical_id":"clinicaltrials.gov:NCT02192398","description":"Chronic Pain","metadata":null},{"id":"b5a5a9bbb7714978a769b6dbd9511eea","type":"TRIAL","name":"Effect of HMP on Diabetic Microangiopaemia in T2DM","canonical_id":"clinicaltrials.gov:NCT05095922","description":"Diabetes Mellitus, Type 2; Diabetic Angiopathies","metadata":null},{"id":"c20ca7ede6c64f2788b55fc1dc4f661e","type":"TRIAL","name":"Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects\u3002","canonical_id":"clinicaltrials.gov:NCT07073157","description":"Health Volunteer","metadata":null},{"id":"7a231b8ef25c4150af1b2155d56c910f","type":"TRIAL","name":"Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite","canonical_id":"clinicaltrials.gov:NCT01480609","description":"Epilepsy","metadata":null},{"id":"664f7135620049248dd53fbe1f8f2494","type":"TRIAL","name":"Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products","canonical_id":"clinicaltrials.gov:NCT03205605","description":"Heat Effect","metadata":null},{"id":"497d7f461a8e4f7db89e6c3a69bdba0a","type":"TRIAL","name":"Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling","canonical_id":"clinicaltrials.gov:NCT02654236","description":"Alcohol Consumption","metadata":null},{"id":"4e4f3d789fdb4ee6bb2c4f237d95979d","type":"TRIAL","name":"Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD","canonical_id":"clinicaltrials.gov:NCT06449833","description":"Type2 Diabetes Mellitus; Nonalcoholic Fatty Liver Disease","metadata":null},{"id":"daae0704631f4bb691ee378c8cef1d64","type":"TRIAL","name":"Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib","canonical_id":"clinicaltrials.gov:NCT06997276","description":"Healthy; Hepatic Impairment","metadata":null},{"id":"4a31a6907f4f44409b33950e031ef08d","type":"TRIAL","name":"Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05088343","description":"Healthy Subjects","metadata":null},{"id":"d03d882dab6b4e40a9a823e187ae9783","type":"TRIAL","name":"Effect of High Dose Ciclesonide on Asthma Control","canonical_id":"clinicaltrials.gov:NCT01455194","description":"Bronchial Asthma","metadata":null},{"id":"68ed7a43b24b475e94f06cbdc0796a1f","type":"TRIAL","name":"Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT00930228","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"ee902efac2214b04a8d49c57e8ab588a","type":"TRIAL","name":"Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren","canonical_id":"clinicaltrials.gov:NCT00441064","description":"Hypertension","metadata":null},{"id":"444b462478fa451aa2b8605f5d259a02","type":"TRIAL","name":"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT05118542","description":"Hyperthyroidism; Graves Disease; Atherosclerosis of Artery; Pathophysiology","metadata":null},{"id":"36c781c2e5494362af847d6d87f5d655","type":"TRIAL","name":"Effect of Hyperuricaemia on Chronic Renal Disease","canonical_id":"clinicaltrials.gov:NCT03425708","description":"Hyperuricemia; Chronic Renal Disease","metadata":null},{"id":"7de11d2153cd414ea1e5af6e4ae5845d","type":"TRIAL","name":"Effect of Hypotensive Anesthesia on the Perfusion Index","canonical_id":"clinicaltrials.gov:NCT03059316","description":"Controlled Hypotension for Nasal Surgeries","metadata":null},{"id":"4bb299b0fba94f0884a2b2a0bcd8c0f7","type":"TRIAL","name":"Effect of IL--1\u03b2 Inhibition on Inflammation and Cardiovascular Risk","canonical_id":"clinicaltrials.gov:NCT02272946","description":"HIV; Cardiovascular Disease","metadata":null},{"id":"20b36499787d4830864c808c446902c4","type":"TRIAL","name":"Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation","canonical_id":"clinicaltrials.gov:NCT02784899","description":"Lung Cancer","metadata":null},{"id":"0203a3252807433b96de32196f7828bf","type":"TRIAL","name":"Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.","canonical_id":"clinicaltrials.gov:NCT02389088","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"d30560e2598c4cfbaf423947ce3adc61","type":"TRIAL","name":"Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease","canonical_id":"clinicaltrials.gov:NCT04308551","description":"Stable Coronary Heart Disease","metadata":null},{"id":"3908d911f57849908cc0ba198cb0039d","type":"TRIAL","name":"Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)","canonical_id":"clinicaltrials.gov:NCT00163332","description":"Asthma","metadata":null},{"id":"f5e7d5447ce745dfa65958d60161b38b","type":"TRIAL","name":"Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00427154","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"14e081c16c804731a4b32e13d84828b8","type":"TRIAL","name":"Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT01369017","description":"Healthy Control Subjects","metadata":null},{"id":"c4841be59e034a078bab40371c49b115","type":"TRIAL","name":"Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy","canonical_id":"clinicaltrials.gov:NCT06199778","description":"Traumatic Brain Injury","metadata":null},{"id":"53e04f7b93d54e25b48c41e0f45ddd3a","type":"TRIAL","name":"Effect of Intramuscular Progesterone Supplementation on Clinical and Ongoing Pregnancy Rates in Patients With Low Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Frozen Cycles","canonical_id":"clinicaltrials.gov:NCT04837768","description":"Serum Progesterone Levels; Progesterone Supplementation; Frozen Embryo Transfer; Clinical Pregnancy Rates; Ongoing Pregnancy Rates","metadata":null},{"id":"075170d6f2be4650a7ef59d2250c8765","type":"TRIAL","name":"Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.","canonical_id":"clinicaltrials.gov:NCT00395369","description":"Cardiac Surgery","metadata":null},{"id":"2d9d4efb2f20499b8e8feb7e0ded0ea1","type":"TRIAL","name":"Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery","canonical_id":"clinicaltrials.gov:NCT04598191","description":"Coronary Artery Occlusive Disease","metadata":null},{"id":"6b40081829a9409d83953c3bc9261c02","type":"TRIAL","name":"Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity","canonical_id":"clinicaltrials.gov:NCT03024957","description":"Immune System Suppression","metadata":null},{"id":"d37fa078ff4643db8313796d86e668b9","type":"TRIAL","name":"Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric","canonical_id":"clinicaltrials.gov:NCT06306040","description":"Emergence Delirium","metadata":null},{"id":"c52a1e808e7148ab8bdfbe6bee471686","type":"TRIAL","name":"Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease","canonical_id":"clinicaltrials.gov:NCT00371527","description":"Bronchitis","metadata":null},{"id":"520d2e768a054286bf2a1c5bc4b781aa","type":"TRIAL","name":"Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT00152698","description":"Hypercholesterolemia","metadata":null},{"id":"c9d09f246e8b44d794badc9ac8d5dc16","type":"TRIAL","name":"Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT00347087","description":"Chronic Heart Failure","metadata":null},{"id":"fe946f03a1c5455c8954eac406064807","type":"TRIAL","name":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","canonical_id":"clinicaltrials.gov:NCT06179485","description":"Post-Traumatic Stress Disorder; Acute Respiratory Failure","metadata":null},{"id":"8f198cc1c8154b55b00985d6c33ced4f","type":"TRIAL","name":"Effect of Ketamine, Amitriptyline and Their Combination on Itch","canonical_id":"clinicaltrials.gov:NCT06245564","description":"Itch","metadata":null},{"id":"9f22c0263dba4e699b36431ae201d081","type":"TRIAL","name":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","canonical_id":"clinicaltrials.gov:NCT05417997","description":"COVID-19 Respiratory Infection; FLU; Cold; Influenza; Bacterial Pneumonia; COVID-19 Pneumonia","metadata":null},{"id":"a566532e8d7c48b6922d2d6fa72e6838","type":"TRIAL","name":"Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU","canonical_id":"clinicaltrials.gov:NCT00838435","description":"Phenylketonuria","metadata":null},{"id":"0821611ad42745cc9464173eb19a7f1b","type":"TRIAL","name":"Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00651105","description":"Type-2 Diabetes; Healthy","metadata":null},{"id":"6f871264a42944e7b6d6010580f5c1af","type":"TRIAL","name":"Effect of LIXIsenatide on the Renal System","canonical_id":"clinicaltrials.gov:NCT02276196","description":"Diabetic Kidney Disease; Diabetic Nephropathy; Diabetes Mellitus; Glucagon-Like Peptide 1","metadata":null},{"id":"07063ad55f93419ba80a927bde97b94e","type":"TRIAL","name":"Effect of LMWH on Pregnancy Outcome in Women With Multiple Failures of IVF-ET","canonical_id":"clinicaltrials.gov:NCT03701750","description":"Infertility","metadata":null},{"id":"8114f8a444164c31ac6aabc8e636c71a","type":"TRIAL","name":"Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT00533858","description":"Hypertension","metadata":null},{"id":"8d3d090d836743b2a172070ae6020848","type":"TRIAL","name":"Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males","canonical_id":"clinicaltrials.gov:NCT01526083","description":"Healthy Volunteers","metadata":null},{"id":"9112c2b9e9d84168be0794e1149135d4","type":"TRIAL","name":"Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients","canonical_id":"clinicaltrials.gov:NCT00101374","description":"HIV Infections","metadata":null},{"id":"a9dc5e880864454ba854237145da46b7","type":"TRIAL","name":"Effect of Lifitegrast 5% on Tear Film Markers","canonical_id":"clinicaltrials.gov:NCT03952481","description":"Dry Eye; Dry Eye Syndromes; Dry Eyes Chronic","metadata":null},{"id":"03d0a1acab1e49dcb506a59225600915","type":"TRIAL","name":"Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms","canonical_id":"clinicaltrials.gov:NCT03451396","description":"Dry Eye","metadata":null},{"id":"b78b65357b2043aea2d5275e2396efc9","type":"TRIAL","name":"Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00933920","description":"Hypertension","metadata":null},{"id":"7c3f98028c744cb59d5c456cb7fd1087","type":"TRIAL","name":"Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01547104","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"5a47b81b25da41988950fda0f5a085d1","type":"TRIAL","name":"Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT02942602","description":"Hyperlipidemia","metadata":null},{"id":"ebcfb31b216e42cc85aa05b578e186bf","type":"TRIAL","name":"Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood","canonical_id":"clinicaltrials.gov:NCT02650206","description":"Diabetes Mellitus, Type 2; Diabetes Mellitus, Type II; Diabetes Mellitus, Adult-Onset; Inflammation","metadata":null},{"id":"5d67ef17ebd3408387fb835a78584b10","type":"TRIAL","name":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00393718","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"53f55b118cf64b9d9662192ac3ba1c24","type":"TRIAL","name":"Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent","canonical_id":"clinicaltrials.gov:NCT02660047","description":"Diabetes Mellitus Type 2; Metabolic Syndrome; Cardiovascular Disease; Diastolic Dysfunction; Fatty Liver","metadata":null},{"id":"fb8a05e78eec4c16bcf25b5db788a65c","type":"TRIAL","name":"Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02014740","description":"Type 2 Diabetes; Overweight; Obesity","metadata":null},{"id":"a0724a8881a3428eba2a3240be572de2","type":"TRIAL","name":"Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH","canonical_id":"clinicaltrials.gov:NCT01518166","description":"Diabetes; Healthy","metadata":null},{"id":"384459a22f2b42d6b911bfb01fdced8e","type":"TRIAL","name":"Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01508923","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"f998c0d5ee1945ee97a4e2e3df592632","type":"TRIAL","name":"Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01508949","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"ca2e07b2b762416d97cb6f6fd3aefe95","type":"TRIAL","name":"Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine","canonical_id":"clinicaltrials.gov:NCT02200991","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e712fa0f880f45c981d357753d217c96","type":"TRIAL","name":"Effect of Local Estriol Treatment Before Vaginal Repair Surgery","canonical_id":"clinicaltrials.gov:NCT06391372","description":"Pelvic Organ Prolapse; Pelvic Floor Disorders; Menopause; Vaginal Atrophy","metadata":null},{"id":"4a65226d69dc42239d75e602fa782a02","type":"TRIAL","name":"Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction","canonical_id":"clinicaltrials.gov:NCT01422733","description":"Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome","metadata":null},{"id":"a92f61567f874e209196e052d1bf0fab","type":"TRIAL","name":"Effect of Loratadine in Lymphangioleiomyomatosis","canonical_id":"clinicaltrials.gov:NCT05190627","description":"Lymphangioleiomyomatosis","metadata":null},{"id":"935fe33fe9cf45938fd23d973c533cba","type":"TRIAL","name":"Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)","canonical_id":"clinicaltrials.gov:NCT00423995","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"c35ef77b71464fd3b4df00b4a62665b1","type":"TRIAL","name":"Effect of Lorcaserin on Cannabis Withdrawal and Self-administration","canonical_id":"clinicaltrials.gov:NCT03253926","description":"Cannabis Use","metadata":null},{"id":"3e21c29fc9d8481ca8ca60eef5b74945","type":"TRIAL","name":"Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis","canonical_id":"clinicaltrials.gov:NCT02416102","description":"COPD; Chronic Bronchitis","metadata":null},{"id":"bc43d29009d546d4a6345e73af9d2fe8","type":"TRIAL","name":"Effect of Losartan or Eprosartan on Fructose Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT04954560","description":"Uric Acid Concentration, Serum, Quantitative Trait Locus 7","metadata":null},{"id":"75ca0e163f674772bcb3dda7f1f6cdfe","type":"TRIAL","name":"Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study","canonical_id":"clinicaltrials.gov:NCT00871455","description":"Spinal Cord Injury","metadata":null},{"id":"264666a473b74c47aae842254d6101cf","type":"TRIAL","name":"Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.","canonical_id":"clinicaltrials.gov:NCT01190020","description":"Chronic Constipation, Methanogenesis","metadata":null},{"id":"cad45c31efb041a38dc6fff1926c0d32","type":"TRIAL","name":"Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)","canonical_id":"clinicaltrials.gov:NCT01085643","description":"Constipation-predominant Irritable Bowel Syndrome","metadata":null},{"id":"2bb55e13f92b44ebb08fbb0ad2821114","type":"TRIAL","name":"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.","canonical_id":"clinicaltrials.gov:NCT01311700","description":"Myocardial Infarction","metadata":null},{"id":"4c8b6ebe8b524ba9bad9040fb0150e05","type":"TRIAL","name":"Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)","canonical_id":"clinicaltrials.gov:NCT00446381","description":"Proliferative Diabetic Retinopathy; Diabetic Macular Edema","metadata":null},{"id":"3cf0c406f3aa4373a696767ccb5ad62f","type":"TRIAL","name":"Effect of Maraviroc on Endothelial Function in HIV-Infected Patients","canonical_id":"clinicaltrials.gov:NCT00844519","description":"HIV Infection; Cardiovascular Disease; Inflammation; HIV Infections","metadata":null},{"id":"5ae3b0c0e0654848958a64f231d1078d","type":"TRIAL","name":"Effect of Melatonin in Pediatric Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT05570526","description":"Hemodialysis Complication; Oxidative Stress; Inflammation","metadata":null},{"id":"ebe4e865f37447f58b7a7dbf463470b7","type":"TRIAL","name":"Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT07334197","description":"Ppm, Cardiomyopathy","metadata":null},{"id":"fa297876e68b4f72b64e360f9d0890b3","type":"TRIAL","name":"Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates","canonical_id":"clinicaltrials.gov:NCT07850934","description":"Congenital Peumonia; Persistent Pulmonary Hypertension of Newborn; Congenital Diaphragmatic Hernia","metadata":null},{"id":"4fe4cf9dc16247f49bbd728b756f9ffc","type":"TRIAL","name":"Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy","canonical_id":"clinicaltrials.gov:NCT03590197","description":"Generalized Epilepsy","metadata":null},{"id":"d1ac1cda480b433e8914d65e4c3be5bb","type":"TRIAL","name":"Effect of Mepolizumab on Severe Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT04641741","description":"Asthma; Eosinophilic Asthma","metadata":null},{"id":"f2853a6ee3254e47ae185bc38332bd95","type":"TRIAL","name":"Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet","canonical_id":"clinicaltrials.gov:NCT00118950","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"220aee1a46fe4fa1be2107b61ef83233","type":"TRIAL","name":"Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization","canonical_id":"clinicaltrials.gov:NCT01363323","description":"Healthy Volunteers","metadata":null},{"id":"7e4a5f1d721043f28bde24bd6b0aafff","type":"TRIAL","name":"Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates","canonical_id":"clinicaltrials.gov:NCT01360372","description":"Tube Feeding","metadata":null},{"id":"67ff76649ca14ac0a502876e764c61f9","type":"TRIAL","name":"Effect of Methylnaltrexone on GI Transit in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01055704","description":"Gastric Motility Disorder","metadata":null},{"id":"965e8ad1f58f41b29462c0503747595c","type":"TRIAL","name":"Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine","canonical_id":"clinicaltrials.gov:NCT02403830","description":"Coronary Artery Disease","metadata":null},{"id":"8d50b00c86e34d0988cdffc071cd6515","type":"TRIAL","name":"Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty","canonical_id":"clinicaltrials.gov:NCT02332603","description":"Osteoarthrosis","metadata":null},{"id":"75e3123c5f5f49a18633ddea69b59757","type":"TRIAL","name":"Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients","canonical_id":"clinicaltrials.gov:NCT02445898","description":"Osteoarthrosis","metadata":null},{"id":"a6c34569e6b14ea992face3a2b9c86ba","type":"TRIAL","name":"Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache","canonical_id":"clinicaltrials.gov:NCT01791400","description":"Migraine Disorders","metadata":null},{"id":"c38ae58a25104de58f94150545c4f9da","type":"TRIAL","name":"Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT04133532","description":"Hypertrophic Cardiomyopathy","metadata":null},{"id":"b7044c98ba5a490c85cd2f9f695413a0","type":"TRIAL","name":"Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment","canonical_id":"clinicaltrials.gov:NCT04738149","description":"Vitiligo","metadata":null},{"id":"e814aa4b1df645c4baaccfb1b6c7c36b","type":"TRIAL","name":"Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation","canonical_id":"clinicaltrials.gov:NCT02325362","description":"Cystic Fibrosis","metadata":null},{"id":"d3afec88f0fe409a8f52aa69954fcb15","type":"TRIAL","name":"Effect of Milnacipran / Gabapentin in Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT05384210","description":"Fibromyalgia","metadata":null},{"id":"adc13438d0a24463b13580d67e90a0a1","type":"TRIAL","name":"Effect of Milnacipran in Chronic Neuropathic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT01225068","description":"Low Back Pain","metadata":null},{"id":"44a24e908cbe411dadc9b4cb024eb419","type":"TRIAL","name":"Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00793520","description":"Fibromyalgia","metadata":null},{"id":"bec6155ac895494db5cecb5cbf8020d3","type":"TRIAL","name":"Effect of Mirabegron on Promoting Brown Adipose Tissue Activation","canonical_id":"clinicaltrials.gov:NCT05779514","description":"Tumour","metadata":null},{"id":"ee2c115e19a94d67957af6f71a45891e","type":"TRIAL","name":"Effect of Montelukast Versus Co Enzyme in Sepsis","canonical_id":"clinicaltrials.gov:NCT05293132","description":"Sepsis","metadata":null},{"id":"55c36a81d536410db16696f233c28391","type":"TRIAL","name":"Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03393715","description":"Diabetes Mellitus, Type 2; Hypertension","metadata":null},{"id":"f8de157c16814e30a9e58abd2d9d904c","type":"TRIAL","name":"Effect of Morphine, Tramadol, and Ketorolac on Postoperative Stress and Immune Responses","canonical_id":"clinicaltrials.gov:NCT02449954","description":"Breast Cancer","metadata":null},{"id":"78796c6d72c0420c8cd70c401f745995","type":"TRIAL","name":"Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing IUD","canonical_id":"clinicaltrials.gov:NCT02799641","description":"Contraception","metadata":null},{"id":"2e6de44dc04343a2a52830dd76472cf3","type":"TRIAL","name":"Effect of Nafamostat on Postreperfusion Syndrome (PRS)","canonical_id":"clinicaltrials.gov:NCT01001403","description":"Liver Transplantation; Postreperfusion Syndrome","metadata":null},{"id":"0e521a805933497cbc51bfef817fd58d","type":"TRIAL","name":"Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity","canonical_id":"clinicaltrials.gov:NCT00947284","description":"Healthy","metadata":null},{"id":"f395f88849ef40dab8b856880cc69978","type":"TRIAL","name":"Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia","canonical_id":"clinicaltrials.gov:NCT04713358","description":"Resuscitation","metadata":null},{"id":"4661ad3d0d874b1c8c1105a446b552db","type":"TRIAL","name":"Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT01955707","description":"Acute Ischemic Stroke","metadata":null},{"id":"f0b10b24b8524aa294607068ab624073","type":"TRIAL","name":"Effect of Nebulized Milrinone on Right Ventricular Hemodynamics in Adult Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT05132153","description":"Anesthesia","metadata":null},{"id":"394ab0316c7544c19a386e485154aeae","type":"TRIAL","name":"Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10","canonical_id":"clinicaltrials.gov:NCT00000293","description":"Cocaine-Related Disorders","metadata":null},{"id":"43992f910f7e481f8967b4d9582d1747","type":"TRIAL","name":"Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome","canonical_id":"clinicaltrials.gov:NCT01625455","description":"Sezary Syndrome; Pruritus","metadata":null},{"id":"66f977e925154572adeeb83fa454021c","type":"TRIAL","name":"Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT02635542","description":"Neuromuscular Blockade; Postoperative Complications","metadata":null},{"id":"b15bd192164e4e17a3c79bb4f8e0db30","type":"TRIAL","name":"Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy","canonical_id":"clinicaltrials.gov:NCT01170845","description":"Esophageal Cancer","metadata":null},{"id":"71d28e6529ff4461906f17bf7070fd88","type":"TRIAL","name":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","canonical_id":"clinicaltrials.gov:NCT05616598","description":"Male Infertility; HCV","metadata":null},{"id":"1f32c6d4a0ff43428674cf1044b0b5b6","type":"TRIAL","name":"Effect of New Topical Preparation for Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT05899699","description":"Acne Vulgaris","metadata":null},{"id":"e1c2504aade04c52a3739b29c6fb6efc","type":"TRIAL","name":"Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment","canonical_id":"clinicaltrials.gov:NCT02788474","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"d56e3979b4ee4dc5a8e9dab45419f33b","type":"TRIAL","name":"Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients","canonical_id":"clinicaltrials.gov:NCT01065649","description":"Gastroesophageal Reflux Disease","metadata":null},{"id":"bb1fbbb27bd34f9095d265bdc3e5d712","type":"TRIAL","name":"Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia","canonical_id":"clinicaltrials.gov:NCT00547703","description":"Non Ulcer Dyspepsia","metadata":null},{"id":"c5f204bbbc9040c59592f5f969d7592e","type":"TRIAL","name":"Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT","canonical_id":"clinicaltrials.gov:NCT03253276","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"f39f69ba88e9405ea5302048853911b2","type":"TRIAL","name":"Effect of Omalizumab in the Skin of Food Allergy Patients","canonical_id":"clinicaltrials.gov:NCT06618963","description":"Food Allergy; Food Allergy in Children","metadata":null},{"id":"6782a63a35ba4aa0ac33780263bc7aff","type":"TRIAL","name":"Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04989829","description":"Advanced Solid Tumor","metadata":null},{"id":"12d0a5365f4b4e22b8bbbadf68dd4bcd","type":"TRIAL","name":"Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing Cleft Surgery","canonical_id":"clinicaltrials.gov:NCT07557576","description":"Cleft Lip Palate; Orofacial Cleft; Agitation, Emergence; Analgesia Assessment; Analgesia; Pediatric","metadata":null},{"id":"b1d7c48e887a46deac6ac66d23194040","type":"TRIAL","name":"Effect of Opioid-free Analgesia and Anesthesia on the Quality of Postoperative Recovery and Nausea Vomit in Patients Receiving Laparoscopic Sleeve Gastrectomy","canonical_id":"clinicaltrials.gov:NCT06305221","description":"Opioid-Free Anesthesia; Laparoscopic Sleeve Gastrectomy; Postoperative Vomiting; Postoperative Recovery","metadata":null},{"id":"83dc4c21ebf64f93aa5ed58eeb4cce07","type":"TRIAL","name":"Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver","canonical_id":"clinicaltrials.gov:NCT04976283","description":"Diabetes Mellitus, Type 2; NASH - Nonalcoholic Steatohepatitis; NAFLD","metadata":null},{"id":"b00fc1bbac064624ab900bf0fc2fe957","type":"TRIAL","name":"Effect of Oral Cimetidine in the Protoporphyrias","canonical_id":"clinicaltrials.gov:NCT05020184","description":"Erythropoietic Protoporphyria; X-linked Protoporphyria","metadata":null},{"id":"9269fd74bc3149e39612da13abc5c1bb","type":"TRIAL","name":"Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02365532","description":"Long QT Syndrome","metadata":null},{"id":"00965d139c104f29864f44c4ab6d8c27","type":"TRIAL","name":"Effect of Oral Procaterol on Postinfectious Persistent Cough","canonical_id":"clinicaltrials.gov:NCT02349919","description":"Cough","metadata":null},{"id":"0e7941af705b4a18898e6fff5ef51284","type":"TRIAL","name":"Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation","canonical_id":"clinicaltrials.gov:NCT03474614","description":"Cerebral Cavernous Malformations","metadata":null},{"id":"c92fa1902f1d463eb9c6e350d7b4a233","type":"TRIAL","name":"Effect of Orlistat in Body Composition","canonical_id":"clinicaltrials.gov:NCT00752726","description":"Obesity; Overweight","metadata":null},{"id":"00595ddf764b4523ab84dcd23b8c9201","type":"TRIAL","name":"Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial","canonical_id":"clinicaltrials.gov:NCT07747909","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"35ad935e10f4493a948059788fb09b0d","type":"TRIAL","name":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","canonical_id":"clinicaltrials.gov:NCT01076764","description":"Acute Coronary Syndrome","metadata":null},{"id":"222a4c2a0b0e431cb240270a0878fc0e","type":"TRIAL","name":"Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections","canonical_id":"clinicaltrials.gov:NCT05955885","description":"Cough; Upper Respiratory Tract Infections","metadata":null},{"id":"2f4ed310418f4ccaa72b0d98db62300b","type":"TRIAL","name":"Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation","canonical_id":"clinicaltrials.gov:NCT00610818","description":"Skin Rash","metadata":null},{"id":"1d67303aba4b488e942dda7efb4a21d2","type":"TRIAL","name":"Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female","canonical_id":"clinicaltrials.gov:NCT04563260","description":"Gallbladder Diseases","metadata":null},{"id":"8309aec3324c4244899051896c366a46","type":"TRIAL","name":"Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT05439798","description":"Laparoscopic Surgery; Pediatrics; Nausea and Vomiting, Postoperative; Antiemetics; Therapeutic Use","metadata":null},{"id":"a803cf1732f74837ace717645c4987db","type":"TRIAL","name":"Effect of Paracetamol and Ibuprofen Reducing Morphine Requirements After Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT04414995","description":"Analgesia","metadata":null},{"id":"ae84690f28a144b0b1a2c3ce6dc0cc98","type":"TRIAL","name":"Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)","canonical_id":"clinicaltrials.gov:NCT00826228","description":"Osteoporosis; Bone Loss; Spinal Cord Injury","metadata":null},{"id":"8cb730e81e4c4250ad26344c983f6f14","type":"TRIAL","name":"Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT00294866","description":"Kidney Failure","metadata":null},{"id":"7d23b10f7a3a4ff58cf906bffee08642","type":"TRIAL","name":"Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1","canonical_id":"clinicaltrials.gov:NCT00218439","description":"Tobacco Use Disorder","metadata":null},{"id":"4fd83bcea4a44a35bb0ea2207e918a87","type":"TRIAL","name":"Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas","canonical_id":"clinicaltrials.gov:NCT00929669","description":"Gonadotroph Adenomas","metadata":null},{"id":"444dc37d500348d784e715b6b23a0ba6","type":"TRIAL","name":"Effect of Pegvisomant on GH/IGF-I Relationship in GHD","canonical_id":"clinicaltrials.gov:NCT00468624","description":"Severe Adult Growth Hormone Deficiency","metadata":null},{"id":"50eda33c42e54f66b994fcb06151cb9a","type":"TRIAL","name":"Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT04557202","description":"Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones","metadata":null},{"id":"5647f2918ec145be861bcffe2f1a2a05","type":"TRIAL","name":"Effect of Perioperative Use of Glycopyrrolate on Lung Function in Patients Under General Anesthesia","canonical_id":"clinicaltrials.gov:NCT05693246","description":"Glycopyrrolate","metadata":null},{"id":"b09fd57307f340beab98ad485c822930","type":"TRIAL","name":"Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)","canonical_id":"clinicaltrials.gov:NCT03291288","description":"Drug Interaction Potential","metadata":null},{"id":"9c58c148f0094f52a54fd3c8c4d7ef4e","type":"TRIAL","name":"Effect of Pilocarpine in Patients With Xerostomia","canonical_id":"clinicaltrials.gov:NCT02982577","description":"Xerostomia","metadata":null},{"id":"cacaee22925c437bbfa50f4807e69408","type":"TRIAL","name":"Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema","canonical_id":"clinicaltrials.gov:NCT00946478","description":"Atopic Dermatitis","metadata":null},{"id":"260f80bfdb424c6d850ae7a19b24257a","type":"TRIAL","name":"Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function","canonical_id":"clinicaltrials.gov:NCT00845182","description":"Type 2 Diabetes; Healthy; Impaired Glucose Tolerance","metadata":null},{"id":"56b587bbc41748818ff1cf7693435716","type":"TRIAL","name":"Effect of Piroxicam on Ovulation","canonical_id":"clinicaltrials.gov:NCT01320709","description":"Contraception, Postcoital","metadata":null},{"id":"50a242f4f98d4c9ea214d07308c0cf03","type":"TRIAL","name":"Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia","canonical_id":"clinicaltrials.gov:NCT03097198","description":"Myopia","metadata":null},{"id":"4d162d23a0154022bb53594b7e8b0e63","type":"TRIAL","name":"Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome","canonical_id":"clinicaltrials.gov:NCT00839501","description":"Andersen-Tawil Syndrome","metadata":null},{"id":"d368787c3b1b45abac4a5ded746cc03e","type":"TRIAL","name":"Effect of Pravastatin on Endothelial Dysfunction Following a Single High Fat Meal","canonical_id":"clinicaltrials.gov:NCT00005117","description":"Heart Diseases","metadata":null},{"id":"c380c46a5908487f9a975418f4a188de","type":"TRIAL","name":"Effect of Preemptive Analgesia With Flurbiprofen Axetil on Perioperative Sleep Quality and Postoperative Pain in Patients Undergoing Laparoscopic Gynecological Surgery.","canonical_id":"clinicaltrials.gov:NCT04611763","description":"Flurbiprofen Axetil; Preemptive Analgesia; Postoperative Pain; Perioperative Sleep Quality; Postoperative Inflammatory Markers","metadata":null},{"id":"73bb611ed01147fb821aab146519df36","type":"TRIAL","name":"Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV","canonical_id":"clinicaltrials.gov:NCT03394222","description":"Lung Cancer","metadata":null},{"id":"b2541fc7840744829250bca3e8ced307","type":"TRIAL","name":"Effect of Preoperative Diclofenac Potassium Dose on Endodontic Pain","canonical_id":"clinicaltrials.gov:NCT07743372","description":"Symptomatic Irreversible Pulpitis (SIP)","metadata":null},{"id":"8df4e8b585ee4f18bc9161f741f9f014","type":"TRIAL","name":"Effect of Preoperative Tamsulosin on Postoperative Urinary Retention","canonical_id":"clinicaltrials.gov:NCT05753670","description":"Postoperative Retention of Urine","metadata":null},{"id":"db985b5f4b344d0c901aeae58e07d4a3","type":"TRIAL","name":"Effect of Probenecid on Pexidartinib Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT03138759","description":"Pharmacokinetics in Healthy Volunteers","metadata":null},{"id":"6d59d5dd3f22494db5247ff72faca43e","type":"TRIAL","name":"Effect of Probenecid on Synovial Fluid ATP Levels in CPPD","canonical_id":"clinicaltrials.gov:NCT02243631","description":"Calcium Pyrophosphate Deposition Disease","metadata":null},{"id":"c28c8f5313f74e5eb6f5e1c040291e02","type":"TRIAL","name":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","canonical_id":"clinicaltrials.gov:NCT01291641","description":"Hyperlipidemias","metadata":null},{"id":"72f1804e3a144cc7bf9d751caa3c87c8","type":"TRIAL","name":"Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.","canonical_id":"clinicaltrials.gov:NCT02129725","description":"Metabolic Syndrome","metadata":null},{"id":"30906a3ba38f4a0a8d1ab0aa7682a752","type":"TRIAL","name":"Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01294787","description":"COPD","metadata":null},{"id":"d09084d8716c4170a749821c3b025f0f","type":"TRIAL","name":"Effect of Quetiapine on Brain Activity Patterns in Patients With Heightened Risk of Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT02451306","description":"Depression; Bipolar Disorder","metadata":null},{"id":"18c46e2420894ed3b3c04ae464670d48","type":"TRIAL","name":"Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia","canonical_id":"clinicaltrials.gov:NCT05386784","description":"Postemenopusal Women With Osteopenia","metadata":null},{"id":"22776a76bd824101afddf2d3bef7a470","type":"TRIAL","name":"Effect of Ramelteon on Smoking Abstinence","canonical_id":"clinicaltrials.gov:NCT02560324","description":"Tobacco Use Disorder","metadata":null},{"id":"71a2a32a6443404597fddec339be68eb","type":"TRIAL","name":"Effect of Rasagiline on BIA 9-1067 Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT01532141","description":"Parkinson Disease","metadata":null},{"id":"735e7cf7332745049b6aadd5a90c3f32","type":"TRIAL","name":"Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography","canonical_id":"clinicaltrials.gov:NCT07077187","description":"PARKINSON DISEASE (Disorder)","metadata":null},{"id":"338b1c9602f04edaa02cd52a62d26eac","type":"TRIAL","name":"Effect of Remazolam on Anesthesia Recovery in Patients Undergoing Fundus Surgery","canonical_id":"clinicaltrials.gov:NCT06205719","description":"Remazolam Anesthesia; Postoperative Recovery","metadata":null},{"id":"1e19b6a424224c43968760bbc2324cea","type":"TRIAL","name":"Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)","canonical_id":"clinicaltrials.gov:NCT01948986","description":"Renal Impairment; Type 2 Diabetes Mellitus","metadata":null},{"id":"80ef3c6f16864797bde0a24b4c823f64","type":"TRIAL","name":"Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria","canonical_id":"clinicaltrials.gov:NCT00893425","description":"Proteinuria; Diabetic Nephropathy; Chronic Kidney Disease","metadata":null},{"id":"12599850885c47ebb8af4ee7ce814713","type":"TRIAL","name":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02046395","description":"Type 2 Diabetes; Hypertension","metadata":null},{"id":"532ca0ee273e4ac985b08f722d38409b","type":"TRIAL","name":"Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes","canonical_id":"clinicaltrials.gov:NCT00118963","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"8564c1d7ecf64f4186c08ae17b28aa1a","type":"TRIAL","name":"Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00399711","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"93266ffef5354d20a38336e26177e9eb","type":"TRIAL","name":"Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01605773","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"c9e296cc82e3447dab2a461ebbc161c3","type":"TRIAL","name":"Effect of Reslizumab in Chronic Rhinosinusitis","canonical_id":"clinicaltrials.gov:NCT02799446","description":"Sinusitis","metadata":null},{"id":"0a87c70236a046b79a02feb10017ed49","type":"TRIAL","name":"Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin","canonical_id":"clinicaltrials.gov:NCT03063580","description":"Diabetes Mellitus","metadata":null},{"id":"d51e964effc141769dec223c7058bda4","type":"TRIAL","name":"Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT03983239","description":"Healthy Volunteers","metadata":null},{"id":"04a8985fd26a4ce1be9849459ef69730","type":"TRIAL","name":"Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT00207090","description":"Advanced Solid Tumors; Neoplasms","metadata":null},{"id":"59c6e4c4ccd742d2869d90a2f883d8de","type":"TRIAL","name":"Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone","canonical_id":"clinicaltrials.gov:NCT00445575","description":"Fibrous Dysplasia of Bone","metadata":null},{"id":"de95ae051be7408789b6bdd92b850b47","type":"TRIAL","name":"Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT01473758","description":"Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation","metadata":null},{"id":"accf9826722c44f48ed329f86519b2f0","type":"TRIAL","name":"Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","canonical_id":"clinicaltrials.gov:NCT00424268","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"75643090be8c459d81c166d5e7c0900a","type":"TRIAL","name":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)","canonical_id":"clinicaltrials.gov:NCT00297102","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"78862d44967f4722bff1adc04af45baa","type":"TRIAL","name":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)","canonical_id":"clinicaltrials.gov:NCT00297115","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"abd824cefefd4f089a2d3d1620232a1c","type":"TRIAL","name":"Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)","canonical_id":"clinicaltrials.gov:NCT00313209","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"30cc8cd97589484aa0ab07b8f15db1f1","type":"TRIAL","name":"Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis","canonical_id":"clinicaltrials.gov:NCT03988816","description":"Bronchiectasis Adult","metadata":null},{"id":"2b2f1bd855ef4062879e678a62943981","type":"TRIAL","name":"Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type","canonical_id":"clinicaltrials.gov:NCT00639119","description":"Unverricht-Lundborg Syndrome","metadata":null},{"id":"fd803f9e75fb4b77a120a807f0ba6bf7","type":"TRIAL","name":"Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00549874","description":"Type 2 Diabetes","metadata":null},{"id":"484198588eea4fa59b93d4d97bbd25af","type":"TRIAL","name":"Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion","canonical_id":"clinicaltrials.gov:NCT01887704","description":"Coronary Artery Disease","metadata":null},{"id":"d28a83a13c0448bdb8fdfdff0a3a64ec","type":"TRIAL","name":"Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT01823770","description":"Restless Legs Syndrome (RLS)","metadata":null},{"id":"20faf35980f54d08ad82e065d1419a81","type":"TRIAL","name":"Effect of Rozerem on Sleep Among People With Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT01207050","description":"Insomnia; Brain Injury","metadata":null},{"id":"6ca48db334be42bab8de8fc7b22acd68","type":"TRIAL","name":"Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.","canonical_id":"clinicaltrials.gov:NCT01128582","description":"Gastroesophageal Reflux Disease; Chronic Insomnia","metadata":null},{"id":"bc6e9192bcaa46ae94aeca9438ae5d0d","type":"TRIAL","name":"Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-\u03b1 Blockers","canonical_id":"clinicaltrials.gov:NCT01217814","description":"Rheumatoid Arthritis","metadata":null},{"id":"31f61c3a50664b048d64b697e16b31ca","type":"TRIAL","name":"Effect of SIMBRINZA\u00ae Suspension as an Added Therapy to a Prostaglandin Analogue","canonical_id":"clinicaltrials.gov:NCT01937312","description":"Ocular Hypertension; Open Angle Glaucoma","metadata":null},{"id":"91e85b5c5f9446609fa7a8c2a543fe4b","type":"TRIAL","name":"Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population","canonical_id":"clinicaltrials.gov:NCT06674044","description":"Hyperlipidemias","metadata":null},{"id":"269dc58a3cef4f069ebc9878f42879e9","type":"TRIAL","name":"Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean","canonical_id":"clinicaltrials.gov:NCT01445964","description":"Healthy","metadata":null},{"id":"273384b2301c48fdb9b101ae35589ca3","type":"TRIAL","name":"Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia","canonical_id":"clinicaltrials.gov:NCT01214915","description":"Essential Thrombocythemia (ET)","metadata":null},{"id":"dc86a980f1224a82bf8336435018a885","type":"TRIAL","name":"Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT01979185","description":"Healthy","metadata":null},{"id":"56e226e284eb444ca5e2df303bb1053f","type":"TRIAL","name":"Effect of Safinamide on Parkinson's Disease Related Chronic Pain","canonical_id":"clinicaltrials.gov:NCT03841604","description":"Idiopathic Parkinson Disease","metadata":null},{"id":"f0494dff7fe0456c975be0c51cdabee0","type":"TRIAL","name":"Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03968744","description":"Idiopathic Parkinson's Disease (at Later Stage)","metadata":null},{"id":"1067c35212464055bac35c028a79bf58","type":"TRIAL","name":"Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients","canonical_id":"clinicaltrials.gov:NCT01271556","description":"Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients; Chronic Obstructive Pulmonary Disease; Bronchodilator Agents; Salmeterol","metadata":null},{"id":"d87d86b2117249449948049f0b8d2b15","type":"TRIAL","name":"Effect of Samples on Acne Treatment With Epiduo\u00ae Gel","canonical_id":"clinicaltrials.gov:NCT01504204","description":"Acne Vulgaris","metadata":null},{"id":"7da381eb27c649f0beeaec6921b5e488","type":"TRIAL","name":"Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites","canonical_id":"clinicaltrials.gov:NCT01552590","description":"Hyponatremia and Extracellular Fluid in Cirrhotic","metadata":null},{"id":"eab7ddd985f148faa015fe729b38a395","type":"TRIAL","name":"Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)","canonical_id":"clinicaltrials.gov:NCT04350216","description":"Rheumatoid Arthritis; Atherosclerosis","metadata":null},{"id":"12e7409d7d9d4e4a947ff85636f3e81b","type":"TRIAL","name":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03449758","description":"Rheumatoid Arthritis","metadata":null},{"id":"2e7cc0a0b5b647829b45a74c07df11ce","type":"TRIAL","name":"Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity","canonical_id":"clinicaltrials.gov:NCT01960205","description":"Prediabetes","metadata":null},{"id":"43b7e850003f4ab68e2eb666d6959d51","type":"TRIAL","name":"Effect of Secretin in Functional Dyspepsia and Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03617861","description":"Dyspepsia; Healthy","metadata":null},{"id":"3085802a3c094d799fbc9026e8996ef5","type":"TRIAL","name":"Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease","canonical_id":"clinicaltrials.gov:NCT07704190","description":"Cardiorenal Metabolic Syndrome; Atherosclerotic Cardiovascular Disease; Chronic Kidney Disease; Coronary Artery Disease; Hypertension; Type 2 Diabetes Mellitus; Peripheral Arterial Disease; Carotid Artery Stenosis","metadata":null},{"id":"790dfb902d2247b5ae11762fa1a41c12","type":"TRIAL","name":"Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men","canonical_id":"clinicaltrials.gov:NCT00850564","description":"Healthy Volunteers","metadata":null},{"id":"80cfac9b9116425eba86f860b30fe24d","type":"TRIAL","name":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","canonical_id":"clinicaltrials.gov:NCT06107153","description":"Type2diabetes","metadata":null},{"id":"27c5668e91ae4d768ff05284cbee37ee","type":"TRIAL","name":"Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease","canonical_id":"clinicaltrials.gov:NCT01948518","description":"Diffuse Parenchymal Lung Disease; Pulmonary Hypertension","metadata":null},{"id":"c98b60398c8f4a5e952e8d6fa577778c","type":"TRIAL","name":"Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States","canonical_id":"clinicaltrials.gov:NCT01538797","description":"Reflux Oesophagitis","metadata":null},{"id":"ae650256a6fb436a93301b1ba202353b","type":"TRIAL","name":"Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT03076970","description":"Migraine","metadata":null},{"id":"c3d45c9a2f124fa28dd42d6fe771d6e4","type":"TRIAL","name":"Effect of Smoking Reduction on Endothelial Glucocalyx and Vascular Function","canonical_id":"clinicaltrials.gov:NCT02307045","description":"Smoking Cessation","metadata":null},{"id":"03fae3f777bd41568ddf03698c6acc98","type":"TRIAL","name":"Effect of Some Drugs on Liver Fibrosis","canonical_id":"clinicaltrials.gov:NCT03770936","description":"Liver Fibroses","metadata":null},{"id":"98b5ced2a30040d0b521124f3cc6276f","type":"TRIAL","name":"Effect of Some Drugs on Rheumatoid Arithritis Activity","canonical_id":"clinicaltrials.gov:NCT03770923","description":"Rheumatoid Arthritis","metadata":null},{"id":"770a5ef1d3b04422811cb13fd6c2094f","type":"TRIAL","name":"Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)","canonical_id":"clinicaltrials.gov:NCT03521934","description":"Heart Failure; Type 2 Diabetes Mellitus","metadata":null},{"id":"e22f79be1b294a22b9b2681ff3fa8a8b","type":"TRIAL","name":"Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk","canonical_id":"clinicaltrials.gov:NCT03315143","description":"Heart Failure; Type 2 Diabetes Mellitus; Chronic Kidney Diseases","metadata":null},{"id":"8932b4061f5e4d18a4f49ed64f419eb9","type":"TRIAL","name":"Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)","canonical_id":"clinicaltrials.gov:NCT06005259","description":"Cardiotoxicity; Neoplasms; Chemotherapy Effect; Heart Failure","metadata":null},{"id":"b29a695c144f47348eeb5d3995d63220","type":"TRIAL","name":"Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","canonical_id":"clinicaltrials.gov:NCT00456365","description":"Polycystic Kidney, Autosomal Dominant","metadata":null},{"id":"4e0b6cd5804c48858b9375c936dcfba5","type":"TRIAL","name":"Effect of Statin Use on Aldosterone Secretion","canonical_id":"clinicaltrials.gov:NCT02871687","description":"Healthy Subjects","metadata":null},{"id":"cf532e0bc6d84f60b2408896cd7707fc","type":"TRIAL","name":"Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females","canonical_id":"clinicaltrials.gov:NCT02187562","description":"Healthy","metadata":null},{"id":"31d421c198734842a2ca26b802256974","type":"TRIAL","name":"Effect of Steroid Injections in a Knee With Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT01230424","description":"Osteoarthritis (OA) of the Knee","metadata":null},{"id":"1113f25b49e940ef90da9aef3b2fa5f8","type":"TRIAL","name":"Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover","canonical_id":"clinicaltrials.gov:NCT01249261","description":"Postmenopausal Women With Osteoporosis","metadata":null},{"id":"de85c4f3011e48f7b8e8eda17ca71fa2","type":"TRIAL","name":"Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02659150","description":"Rheumatoid Arthritis","metadata":null},{"id":"ea738bb1b707450d9d756433dcaef270","type":"TRIAL","name":"Effect of Sublingual Fentanyl on Breathlessness in COPD","canonical_id":"clinicaltrials.gov:NCT04004117","description":"Copd","metadata":null},{"id":"35b522d42b024d6f8ad55bac91813ca5","type":"TRIAL","name":"Effect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT02943356","description":"Erectile Dysfunction; Andropause","metadata":null},{"id":"2e7adea317cd42a2b2a202043b558280","type":"TRIAL","name":"Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients","canonical_id":"clinicaltrials.gov:NCT01291069","description":"Single Ventricle","metadata":null},{"id":"fa97102c2ba64327aa1acfa172d194a4","type":"TRIAL","name":"Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00422578","description":"Impotence; Erectile Dysfunction","metadata":null},{"id":"ad83500d47ba4704967cb2ba003fa918","type":"TRIAL","name":"Effect of Teduglutide on Gastric Emptying in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01209351","description":"Healthy Volunteers","metadata":null},{"id":"0c3e28daeb7d420bafc66322f5a98d85","type":"TRIAL","name":"Effect of Tepotinib on PK of CYP3A Substrate Midazolam","canonical_id":"clinicaltrials.gov:NCT03628339","description":"Healthy","metadata":null},{"id":"c54a7c8abb4946a093681be7b707f213","type":"TRIAL","name":"Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate","canonical_id":"clinicaltrials.gov:NCT03492437","description":"Healthy","metadata":null},{"id":"69e9331eef0c4c4a9b578da1697804e4","type":"TRIAL","name":"Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis","canonical_id":"clinicaltrials.gov:NCT07224269","description":"Amyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities","metadata":null},{"id":"b174c6921fcf49fcaff8ad4bab68785a","type":"TRIAL","name":"Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01863888","description":"Multiple Sclerosis","metadata":null},{"id":"d9076009dc0540e386c620e649fb3c6a","type":"TRIAL","name":"Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00343252","description":"Osteoporosis, Postmenopausal; Back Pain; Spinal Fracture","metadata":null},{"id":"22610e7e8b434751ba96e79a3379bb8e","type":"TRIAL","name":"Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures","canonical_id":"clinicaltrials.gov:NCT01896011","description":"Non Displaced Atypical Femoral Fractures","metadata":null},{"id":"0c0a5ac74d164efd9703e096ef2c5207","type":"TRIAL","name":"Effect of Testosterone Treatment on Drug Metabolism and Transport","canonical_id":"clinicaltrials.gov:NCT05116293","description":"Transgender Persons","metadata":null},{"id":"539129e91de847a6b723e67e6b1ec91a","type":"TRIAL","name":"Effect of Tetrabenazine on Stroop Interference in HD","canonical_id":"clinicaltrials.gov:NCT01834911","description":"Huntington Disease","metadata":null},{"id":"0b2f4f7dbfce4d99a8a1e3207268b969","type":"TRIAL","name":"Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT07046117","description":"Asthma Bronchiale; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","metadata":null},{"id":"61318a89e8314c3eb18b48534897860d","type":"TRIAL","name":"Effect of Theophylline in Pseudohypoparathyroidism","canonical_id":"clinicaltrials.gov:NCT03718403","description":"PHP Ia; PHP IB; Php1C","metadata":null},{"id":"c0e0fd1b3432411e9a7b39783fe6f4a9","type":"TRIAL","name":"Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients","canonical_id":"clinicaltrials.gov:NCT02853123","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"ea96d5f04807423c891f29feb290e466","type":"TRIAL","name":"Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients","canonical_id":"clinicaltrials.gov:NCT00157235","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"1d95082fde8644de93e7f53b776df043","type":"TRIAL","name":"Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT06525051","description":"Chronic Obstructive Pulmonary Disease; Glaucoma, Angle-Closure","metadata":null},{"id":"6748b32af30247de8be6884c12da971b","type":"TRIAL","name":"Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)","canonical_id":"clinicaltrials.gov:NCT05469659","description":"T2DM (Type 2 Diabetes Mellitus); Metformin; SGLT2-Inhibitors","metadata":null},{"id":"0c88788fbadc47b6a85a3c7ed5ca342a","type":"TRIAL","name":"Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients","canonical_id":"clinicaltrials.gov:NCT01439009","description":"Heart Failure","metadata":null},{"id":"c7b04dae61c7405ca9923c0720dad166","type":"TRIAL","name":"Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD","canonical_id":"clinicaltrials.gov:NCT03803124","description":"Polycystic Kidney, Autosomal Dominant","metadata":null},{"id":"022c176c4f564aba84d7ac37feab9fec","type":"TRIAL","name":"Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)","canonical_id":"clinicaltrials.gov:NCT00608777","description":"Plaque Psoriasis","metadata":null},{"id":"39678cc1270142448895567718c57e65","type":"TRIAL","name":"Effect of Topical Imiquimod on Lentigo Maligna","canonical_id":"clinicaltrials.gov:NCT01161888","description":"Lentigo Maligna","metadata":null},{"id":"356e765bf43f49ad887cebf67250c906","type":"TRIAL","name":"Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I","canonical_id":"clinicaltrials.gov:NCT01040130","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"2f8449414ba54c17ad6f6618c7906cf8","type":"TRIAL","name":"Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT06040190","description":"Burning Mouth Syndrome","metadata":null},{"id":"53588d6c50274268860c87c1032beade","type":"TRIAL","name":"Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT04932213","description":"Type 2 Diabetes Mellitus; Type 1 Diabetes Mellitus","metadata":null},{"id":"7ecf5f2693134468b2af9eed8f60a8ee","type":"TRIAL","name":"Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)","canonical_id":"clinicaltrials.gov:NCT03606590","description":"Hepatocellular Carcinoma","metadata":null},{"id":"9e7386a512f34d0f969b38869c8e63b8","type":"TRIAL","name":"Effect of Unilateral Erector Spinae Plane Block Versus Intrathecal Morphine on Early Mobilization After Hip Replacement","canonical_id":"clinicaltrials.gov:NCT06621849","description":"Pain, Postoperative","metadata":null},{"id":"12c90a339dec468c9b74b92d5e008e4a","type":"TRIAL","name":"Effect of Upstream High Bolus Dose of Tirofiban in Primary PCI for the Patients With STEMI on Short Term Outcome","canonical_id":"clinicaltrials.gov:NCT04111289","description":"High Bolus Dose of Tirofiban","metadata":null},{"id":"1c0b09a09cb14fadb2cdeb9711dccb52","type":"TRIAL","name":"Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00260325","description":"Pain; Hyperalgesia","metadata":null},{"id":"3cb65a47947c45b09fe368b66b8ccf53","type":"TRIAL","name":"Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02299310","description":"Chronic Kidney Disease","metadata":null},{"id":"fd3792718b494d57b65a047520751498","type":"TRIAL","name":"Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS","canonical_id":"clinicaltrials.gov:NCT00517179","description":"Prostatic Hyperplasia; Impotence","metadata":null},{"id":"391d9a2011e643a1b777ff19fcc7a9f7","type":"TRIAL","name":"Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis","canonical_id":"clinicaltrials.gov:NCT02344823","description":"Cirrhosis; Erectile Dysfunction","metadata":null},{"id":"3a727b255c1446aa9657db8a6ebd1d4f","type":"TRIAL","name":"Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders","canonical_id":"clinicaltrials.gov:NCT01000987","description":"Alcohol Reactivity","metadata":null},{"id":"d0daadc90c6146e38d5c9cfc2b71161d","type":"TRIAL","name":"Effect of Various Treatment Modalities on Dendritic Vial Ulcer","canonical_id":"clinicaltrials.gov:NCT05313828","description":"Corneal Ulcer","metadata":null},{"id":"b194b369765d4e83b917b177fddebea2","type":"TRIAL","name":"Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,","canonical_id":"clinicaltrials.gov:NCT07614438","description":"Anesthesia; Pulmonary Hypertension; Chronic Pulmonary Thromboembolism; Vasopressor","metadata":null},{"id":"6d279aa0627644cdbc451ed1365ae8a1","type":"TRIAL","name":"Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH","canonical_id":"clinicaltrials.gov:NCT00818870","description":"Gastroesophageal Reflux","metadata":null},{"id":"86a24d00edeb4fe7af14a98e074aff06","type":"TRIAL","name":"Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder","canonical_id":"clinicaltrials.gov:NCT06803485","description":"Somatic Symptom Disorder (DSM-V)","metadata":null},{"id":"91be5073dd474895942d0ee3cf9c64e3","type":"TRIAL","name":"Effect of Verapamil as an Adjuvant to Local Anaethetics in Supraclav Block for Hand Surgery","canonical_id":"clinicaltrials.gov:NCT06847620","description":"Hand Surgery","metadata":null},{"id":"2b06564884d14afab3733bf5ee3e153b","type":"TRIAL","name":"Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients","canonical_id":"clinicaltrials.gov:NCT03003143","description":"Autoimmune Encephalopathy","metadata":null},{"id":"1646c28218c04e728584c65dd6bb756e","type":"TRIAL","name":"Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy","canonical_id":"clinicaltrials.gov:NCT02030041","description":"Dyslipidemias","metadata":null},{"id":"b797f29cb9e34c53a4e23e698f944fa9","type":"TRIAL","name":"Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study","canonical_id":"clinicaltrials.gov:NCT03142620","description":"H. Pylori Infection","metadata":null},{"id":"034615ae5f4346ca8222500579c9a571","type":"TRIAL","name":"Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease","canonical_id":"clinicaltrials.gov:NCT04339751","description":"Cushing's Disease","metadata":null},{"id":"b94b585f18684dcaaa21cfa36245259f","type":"TRIAL","name":"Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT04456777","description":"Cognitive Deficit","metadata":null},{"id":"bc1643377cd74aa9ba2807d6e580d6a4","type":"TRIAL","name":"Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02932904","description":"Healthy Volunteers","metadata":null},{"id":"bf5426b9e07f4fa88f865cb12b7a1789","type":"TRIAL","name":"Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression.","canonical_id":"clinicaltrials.gov:NCT07590609","description":"Liver-Stagnation and Spleen-Deficiency; Severe Major Depression Disorder","metadata":null},{"id":"c7bbc63e744a497b90146e65d6abe621","type":"TRIAL","name":"Effect of Yohimbine on Colon Transit","canonical_id":"clinicaltrials.gov:NCT00217048","description":"Healthy Volunteers","metadata":null},{"id":"823755149ea24edabd9085433ce83dc9","type":"TRIAL","name":"Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis","canonical_id":"clinicaltrials.gov:NCT00237159","description":"Prostate Cancer Patients With Bone Metastasis","metadata":null},{"id":"fcfee43e41c741388ddc6298bef66db3","type":"TRIAL","name":"Effect of a Fibrate and a Statin on Endothelial Dysfunction","canonical_id":"clinicaltrials.gov:NCT00491400","description":"Diabetes Mellitus; Metabolic Syndrome","metadata":null},{"id":"55c14323994a4b03af2a7f7fe4940307","type":"TRIAL","name":"Effect of a GnRH Analog on Hepatic Steatosis","canonical_id":"clinicaltrials.gov:NCT06523530","description":"Metabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis","metadata":null},{"id":"92fd73b857364019948886fc8b6b5c7b","type":"TRIAL","name":"Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women","canonical_id":"clinicaltrials.gov:NCT03951402","description":"Prolonged QTc Interval; Pharmacokinetic","metadata":null},{"id":"d8f5f0a7a9b940d6a9830cfbb9a1123a","type":"TRIAL","name":"Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.","canonical_id":"clinicaltrials.gov:NCT00409942","description":"Congestive Heart Failure","metadata":null},{"id":"553e1b5ecf6a4c138566d3681fb06b70","type":"TRIAL","name":"Effect of a Proton Pump Inhibitor on the PK of Tepotinib","canonical_id":"clinicaltrials.gov:NCT03531762","description":"Healthy","metadata":null},{"id":"b363f91f9e9a4b56862ba127f5a08cf3","type":"TRIAL","name":"Effect of a Transversus Abdominis Plane Block on Wound Healing, Stress, and Immune Response After a Cesarean Delivery","canonical_id":"clinicaltrials.gov:NCT05840406","description":"Postoperative Pain; Cesarean Section; Wound Heal","metadata":null},{"id":"8ee2272f947a47e9b0678a74c330eab0","type":"TRIAL","name":"Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT01331317","description":"Cardiovascular Disease; Diabetic Nephropathy","metadata":null},{"id":"fdeb994fc7ba4a6d88d3d665fffb9407","type":"TRIAL","name":"Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia","canonical_id":"clinicaltrials.gov:NCT03192488","description":"Hypoxia, Altitude","metadata":null},{"id":"4dfc4e53ee4447aab46138d7a99fc570","type":"TRIAL","name":"Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women","canonical_id":"clinicaltrials.gov:NCT00096694","description":"HIV Infections","metadata":null},{"id":"8f31827f73e54781972f742c23ea7203","type":"TRIAL","name":"Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker","canonical_id":"clinicaltrials.gov:NCT04693897","description":"Overactive Bladder Syndrome; Detrusor Overactivity","metadata":null},{"id":"1da692c498894a088df35c6a188eda9d","type":"TRIAL","name":"Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)","canonical_id":"clinicaltrials.gov:NCT02373462","description":"Peripheral Artery Disease With Intermittent Claudication","metadata":null},{"id":"9d2d3602a8e548b8a624ccc39a2ab945","type":"TRIAL","name":"Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)","canonical_id":"clinicaltrials.gov:NCT06423716","description":"Knee Osteoarthritis","metadata":null},{"id":"11ea41d6f9f74bf095a00d9e8c2bf605","type":"TRIAL","name":"Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT00529750","description":"Hypertension","metadata":null},{"id":"736460dffee944b393c7fd0fc8027d6f","type":"TRIAL","name":"Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy","canonical_id":"clinicaltrials.gov:NCT03940391","description":"Endoscopy","metadata":null},{"id":"9dc6c3073ee84a5ba71523361441ed99","type":"TRIAL","name":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)","canonical_id":"clinicaltrials.gov:NCT02078973","description":"Nephropathy","metadata":null},{"id":"06f30f37540847af9c93a5989efb9e28","type":"TRIAL","name":"Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects","canonical_id":"clinicaltrials.gov:NCT01349114","description":"Diabetes; Pre-hypertension; Hypertension","metadata":null},{"id":"4a92331d77ff44a2a0d55db2f25653e8","type":"TRIAL","name":"Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg","canonical_id":"clinicaltrials.gov:NCT00687973","description":"Hypertension","metadata":null},{"id":"4c7c10a1baed4e7aab985764ab36064f","type":"TRIAL","name":"Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure","canonical_id":"clinicaltrials.gov:NCT06578520","description":"Heart Failure","metadata":null},{"id":"0489597fe86b4aba89067d37bef47e66","type":"TRIAL","name":"Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT04387604","description":"Diabetic Macular Edema","metadata":null},{"id":"66287495accf4299a86394617732baac","type":"TRIAL","name":"Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00602680","description":"Alzheimer's Disease","metadata":null},{"id":"880aff70eaa242da878a9b4bf9973591","type":"TRIAL","name":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.","canonical_id":"clinicaltrials.gov:NCT01533935","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"4831caa307574fc39c8a277e56332b72","type":"TRIAL","name":"Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma","canonical_id":"clinicaltrials.gov:NCT02177370","description":"Asthma","metadata":null},{"id":"ebf333d013654136bd6728c19f14235c","type":"TRIAL","name":"Effect on Primary Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT00909857","description":"Primary Dysmenorrhea","metadata":null},{"id":"6632897995b2443aba7b92dfb143fbb7","type":"TRIAL","name":"Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01713218","description":"Pancreatic Adenocarcinoma Resectable","metadata":null},{"id":"b81b129063db492bbc6b8585fe0f1090","type":"TRIAL","name":"Effect to Linaclotide on Colonic Motility","canonical_id":"clinicaltrials.gov:NCT06989268","description":"Chronic Constipation","metadata":null},{"id":"d0743aee236a444c82d24e0aaeaa9487","type":"TRIAL","name":"Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome","canonical_id":"clinicaltrials.gov:NCT06688838","description":"Blau Syndrome","metadata":null},{"id":"e5f5cee0b7d5437eb089ea9e6bf18200","type":"TRIAL","name":"Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine","canonical_id":"clinicaltrials.gov:NCT00904098","description":"Menstrual Migraine (MM) Headaches","metadata":null},{"id":"5556455d45444a549f72204fd12e408c","type":"TRIAL","name":"Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare","canonical_id":"clinicaltrials.gov:NCT04681482","description":"Atrial Fibrillation; Obesity; Anticoagulants","metadata":null},{"id":"0f52cd365d9f41e6800ff197b1a53deb","type":"TRIAL","name":"Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response","canonical_id":"clinicaltrials.gov:NCT00285376","description":"Depressive Disorder, Major","metadata":null},{"id":"7a6f1cf5ccce41fb97eefec3e268b851","type":"TRIAL","name":"Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3","canonical_id":"clinicaltrials.gov:NCT00565396","description":"Chronic Kidney Insufficiency; Angiotensin-Converting Enzyme Inhibitors; Angiotensin II Type 1 Receptor Blockers; Proteinuria","metadata":null},{"id":"81c7720ad1d54e6ea230c2a1fb850d54","type":"TRIAL","name":"Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT03606369","description":"Breast Neoplasm; Antineoplastic Agents; Antiemetics; Quality of Life","metadata":null},{"id":"ada78a6edb6a4d30b605f2ca072dddcc","type":"TRIAL","name":"Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States","canonical_id":"clinicaltrials.gov:NCT05329194","description":"Asthma","metadata":null},{"id":"6c483a408fd24695b7b62486f389571c","type":"TRIAL","name":"Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01795183","description":"Schizophrenia","metadata":null},{"id":"0ac7ec152765482fa4a95cc86638613d","type":"TRIAL","name":"Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection","canonical_id":"clinicaltrials.gov:NCT00147381","description":"Kidney Transplantation","metadata":null},{"id":"ac7b48091a9f49cb9236c383a96783c5","type":"TRIAL","name":"Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy","canonical_id":"clinicaltrials.gov:NCT05279807","description":"Hypertension","metadata":null},{"id":"ae56bc5681904be1882bf2c5dad31d85","type":"TRIAL","name":"Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy","canonical_id":"clinicaltrials.gov:NCT05257148","description":"Hypertension","metadata":null},{"id":"13fdb6fbb42943938f47584643f1fa5a","type":"TRIAL","name":"Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection","canonical_id":"clinicaltrials.gov:NCT04666272","description":"Melanoma","metadata":null},{"id":"4c1fd06cc66a425e96f6acbef0f0f64e","type":"TRIAL","name":"Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)","canonical_id":"clinicaltrials.gov:NCT00779636","description":"Allergic Airway Disease","metadata":null},{"id":"eb514dc57ae842e186ea2f687d32a275","type":"TRIAL","name":"Effectiveness and Safety of Firmagon\u00ae in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina","canonical_id":"clinicaltrials.gov:NCT01861236","description":"Advanced Hormone Dependent Prostate Cancer","metadata":null},{"id":"8d06be6554b24917acb5999e1763fa43","type":"TRIAL","name":"Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose","canonical_id":"clinicaltrials.gov:NCT00891813","description":"Secondary Hyperparathyroidism; Renal Insufficiency, Chronic; Parathyroid Hormone; Hemodialysis; Hypercalcemia","metadata":null},{"id":"d131326124504a4e8ceda0d70eaf1087","type":"TRIAL","name":"Effectiveness and Safety of InO\u00b1DLI for Relapsed B-ALL/LBL After Allo-HSCT","canonical_id":"clinicaltrials.gov:NCT06861348","description":"Leukemia, Lymphocytic, Acute","metadata":null},{"id":"dd858ca4f0b941d18898719b5561671e","type":"TRIAL","name":"Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia","canonical_id":"clinicaltrials.gov:NCT04359095","description":"COVID-19","metadata":null},{"id":"596f11d3eeef436cb9688fc20f7685f7","type":"TRIAL","name":"Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.","canonical_id":"clinicaltrials.gov:NCT05424523","description":"Allergic Asthma","metadata":null},{"id":"375fb60bc25046678ac4ca529f980810","type":"TRIAL","name":"Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients","canonical_id":"clinicaltrials.gov:NCT04527042","description":"Pulmonary Embolism","metadata":null},{"id":"845b8e96eab24f19ac4397ee945b089a","type":"TRIAL","name":"Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT01757769","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"27b644a93f0d41a8a6f89a71677cdfa2","type":"TRIAL","name":"Effectiveness and Safety of TENS Therapy for Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT06425224","description":"Premature Ejaculation; Sex Disorder; TEN","metadata":null},{"id":"90a3bd3d156c4afb9fe0d4b0172e72ec","type":"TRIAL","name":"Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia","canonical_id":"clinicaltrials.gov:NCT05990400","description":"Androgenetic Alopecia","metadata":null},{"id":"6e558beca63f48cb857c447a47580f42","type":"TRIAL","name":"Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT05705856","description":"Crohn Disease","metadata":null},{"id":"f7e8db1b3bc7442daa1227bcf752e4bd","type":"TRIAL","name":"Effectiveness and Tolerability of Eptinezumab","canonical_id":"clinicaltrials.gov:NCT06409845","description":"Migraine; Migraine With Aura; Migraine Without Aura; Chronic Migraine","metadata":null},{"id":"0edbe2449c3b45d4841187e252f7e017","type":"TRIAL","name":"Effectiveness if Premedication With Single Dose Piroxicam and Prednisolone After a Single Visit Root Canal Treatment .","canonical_id":"clinicaltrials.gov:NCT04124822","description":"Post-operative Endodontic Pain","metadata":null},{"id":"0c05e7ca74994f2c95aca34bf7c11f88","type":"TRIAL","name":"Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.","canonical_id":"clinicaltrials.gov:NCT01172639","description":"Rheumatoid Arthritis","metadata":null},{"id":"825fa63671774d7081aaf2933da26266","type":"TRIAL","name":"Effectiveness of 0.01% Atropine Sulfate Solution in Controlling of Myopia Progression in Children","canonical_id":"clinicaltrials.gov:NCT04338373","description":"Myopia","metadata":null},{"id":"34ed23b2e0b542aeb1b1c6cd43e56c4c","type":"TRIAL","name":"Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00654576","description":"Schizophrenia","metadata":null},{"id":"e8db0ebbb94f4108af9b7f0dd7e91ad6","type":"TRIAL","name":"Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa","canonical_id":"clinicaltrials.gov:NCT00685334","description":"Eating Disorders","metadata":null},{"id":"bb49bbb4f9464bd698ec32074a472faa","type":"TRIAL","name":"Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans","canonical_id":"clinicaltrials.gov:NCT02386293","description":"Hypertension; Obesity; Stress, Psychological; Blood Pressure","metadata":null},{"id":"6710192e3ab344f1bbfb5faaf53e4d23","type":"TRIAL","name":"Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients","canonical_id":"clinicaltrials.gov:NCT02602704","description":"Arthritis, Rheumatoid","metadata":null},{"id":"649ff3f52f174a80bad80c8af9d5e6e8","type":"TRIAL","name":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","canonical_id":"clinicaltrials.gov:NCT01914770","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"fe0e9b9e1d0349fba04e1fedfa79b0b1","type":"TRIAL","name":"Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA","canonical_id":"clinicaltrials.gov:NCT02910596","description":"Bladder Dysfunction","metadata":null},{"id":"67b65047234746de995e4d2fec443a23","type":"TRIAL","name":"Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication","canonical_id":"clinicaltrials.gov:NCT00424281","description":"ICU Patients 18 Years or Older.","metadata":null},{"id":"634d11f3f26349d8904f662167b99f96","type":"TRIAL","name":"Effectiveness of Brief Counseling for Weight Management","canonical_id":"clinicaltrials.gov:NCT00212199","description":"1. Obesity","metadata":null},{"id":"15e8253af12f4c24b9a420a2840671bb","type":"TRIAL","name":"Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting","canonical_id":"clinicaltrials.gov:NCT05266495","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"52c9d6a9b1864890a5f450fa9fedbe6e","type":"TRIAL","name":"Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (\"RIME\")","canonical_id":"clinicaltrials.gov:NCT00955162","description":"Opioid Dependency","metadata":null},{"id":"fafa8dc27ef2479d9abba116d05b3e1d","type":"TRIAL","name":"Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00149617","description":"Marijuana Abuse; Mood Disorders","metadata":null},{"id":"5ee19479a4134187902c7beb00ec9c00","type":"TRIAL","name":"Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning","canonical_id":"clinicaltrials.gov:NCT03925025","description":"Anticholinesterase Insecticide Poisoning; Pesticide Poisoning","metadata":null},{"id":"d9f972aa630949bb94781fcd0736a141","type":"TRIAL","name":"Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients","canonical_id":"clinicaltrials.gov:NCT00288717","description":"Hypertension","metadata":null},{"id":"d6eddce84874499bb1f8b426a1bc0383","type":"TRIAL","name":"Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair","canonical_id":"clinicaltrials.gov:NCT02752308","description":"Hypospadias","metadata":null},{"id":"ea0920899124409e849a6c27b4c3f291","type":"TRIAL","name":"Effectiveness of Digital Defocus Vision Training With Low-Concentration Atropine on the Prevention and Control of Myopia in Children: A Clinical Study","canonical_id":"clinicaltrials.gov:NCT07724210","description":"Myopia; Prevention and Control","metadata":null},{"id":"92f4fa0ebb6940a58fc5e76b53bee2d8","type":"TRIAL","name":"Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study","canonical_id":"clinicaltrials.gov:NCT02139007","description":"Osteoporosis","metadata":null},{"id":"9997d543aec44cf794be45fcbd197f1d","type":"TRIAL","name":"Effectiveness of Domperidone to Increase Breastmilk Supply in Mothers With Low Supply","canonical_id":"clinicaltrials.gov:NCT00284024","description":"Insufficient Breastmilk Production","metadata":null},{"id":"8bb922b3856f420eb55d7d9673848b70","type":"TRIAL","name":"Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline","canonical_id":"clinicaltrials.gov:NCT01703702","description":"Alzheimer's Disease","metadata":null},{"id":"4d94e973bdd34e13ba6753a18e4664bd","type":"TRIAL","name":"Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder","canonical_id":"clinicaltrials.gov:NCT00611923","description":"Premenstrual Syndrome","metadata":null},{"id":"9c5bdd1921954117bf102c7bc35acffb","type":"TRIAL","name":"Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02301494","description":"Mycosis Fungoides","metadata":null},{"id":"99849669177442d88bb7267d96b850f5","type":"TRIAL","name":"Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients","canonical_id":"clinicaltrials.gov:NCT00945308","description":"Acute Myocardial Infarction","metadata":null},{"id":"871631018ff54557be5ddfdfe96f286a","type":"TRIAL","name":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","canonical_id":"clinicaltrials.gov:NCT06879301","description":"Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO); Myopic Choroidal Neovascularisation","metadata":null},{"id":"83fd48f6e43648dc8f15c445b129b492","type":"TRIAL","name":"Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder","canonical_id":"clinicaltrials.gov:NCT00265109","description":"Body Dysmorphic Disorder","metadata":null},{"id":"ea8cc5b35b38485e8c502097d1884fd4","type":"TRIAL","name":"Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients","canonical_id":"clinicaltrials.gov:NCT02894151","description":"Clinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS","metadata":null},{"id":"97eceb1d579d4dca9c5d4c89fafa8247","type":"TRIAL","name":"Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity","canonical_id":"clinicaltrials.gov:NCT03481959","description":"Attention Deficit Hyperactivity Disorder (ADHD)","metadata":null},{"id":"ac674ee7d8f64020bf8ff709680bb133","type":"TRIAL","name":"Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia","canonical_id":"clinicaltrials.gov:NCT00832000","description":"Myotonia; Non-Dystrophic Myotonia","metadata":null},{"id":"35f84eac8d1344eaa99a15e76a1f0b68","type":"TRIAL","name":"Effectiveness of Mucolox\u00ae and Clonazepam in Treatment of Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT02690844","description":"Burning Mouth Syndrome","metadata":null},{"id":"da342362517b4e70aa919b80394c5712","type":"TRIAL","name":"Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals","canonical_id":"clinicaltrials.gov:NCT00249509","description":"Marijuana Abuse","metadata":null},{"id":"6b8d8da0c22a4784adfe6375d0e6ccf6","type":"TRIAL","name":"Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression","canonical_id":"clinicaltrials.gov:NCT00781326","description":"Depression","metadata":null},{"id":"c1bdbeab33844cbc98768d06e12a23d1","type":"TRIAL","name":"Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan","canonical_id":"clinicaltrials.gov:NCT02251613","description":"Allergic Conjunctivitis","metadata":null},{"id":"aa5bf2c7bb674f6d893a68bf88df3d11","type":"TRIAL","name":"Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab","canonical_id":"clinicaltrials.gov:NCT00804921","description":"Macular Edema; Diabetic Retinopathy; Macular Degeneration","metadata":null},{"id":"186c0f505ff24229b16f1086e57dd406","type":"TRIAL","name":"Effectiveness of Oral Boldo in Women With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT06162065","description":"Urinary Bladder, Overactive","metadata":null},{"id":"541eaafccecc45ec8399372c8983a4c3","type":"TRIAL","name":"Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07271069","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"32035ffffdea4c82a1cfae28fbd96696","type":"TRIAL","name":"Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults","canonical_id":"clinicaltrials.gov:NCT00376935","description":"HIV Infections","metadata":null},{"id":"671ed225c7ba476680b290efa1085e9f","type":"TRIAL","name":"Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets","canonical_id":"clinicaltrials.gov:NCT00417612","description":"Hypophosphatemia, Familial; Hyperparathyroidism","metadata":null},{"id":"5657f409410f474ab6967db785df7245","type":"TRIAL","name":"Effectiveness of Periocular Drug Injection in CATaract Surgery","canonical_id":"clinicaltrials.gov:NCT05158699","description":"Macular Edema; Cystoid Macular Edema; Retinal Disease; Cataract; Lens Diseases; Eye Diseases","metadata":null},{"id":"c4f06cab891c4021a80fdcf3fab5c670","type":"TRIAL","name":"Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00158223","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"fc4a4b3f657f4da58a23694c8c5088da","type":"TRIAL","name":"Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block","canonical_id":"clinicaltrials.gov:NCT05097768","description":"Symptomatic Irreversible Pulpitis","metadata":null},{"id":"9caaa8ecd46148d694243dbe293e0fc2","type":"TRIAL","name":"Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.","canonical_id":"clinicaltrials.gov:NCT02653339","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"f652f0472249417fb8b7747dfda7f554","type":"TRIAL","name":"Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1","canonical_id":"clinicaltrials.gov:NCT00218517","description":"Marijuana Abuse","metadata":null},{"id":"55cc35bb736d48eebebd9d108ad812e0","type":"TRIAL","name":"Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00249431","description":"Alcoholism; Gambling","metadata":null},{"id":"65e105222a2145539b3298d6a7ce3b18","type":"TRIAL","name":"Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.","canonical_id":"clinicaltrials.gov:NCT02090439","description":"Kidney Stone; Expulsive Medical Therapy","metadata":null},{"id":"f0745f50f877419291b8715eb659a234","type":"TRIAL","name":"Effectiveness of Theramine on Chronic Back Pain","canonical_id":"clinicaltrials.gov:NCT01468025","description":"Low Back Pain","metadata":null},{"id":"229c4093a2d9463da7fc9fa06d68e317","type":"TRIAL","name":"Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1","canonical_id":"clinicaltrials.gov:NCT00129298","description":"Cocaine-Related Disorders; Opiate Dependence","metadata":null},{"id":"e9a25a7f2af348eaa2338216ce4fed92","type":"TRIAL","name":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting \u03b22-agonists (LABA) Among COPD Patients in Taiwan","canonical_id":"clinicaltrials.gov:NCT05402020","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"272559f6151642aeae9f4b27245a704a","type":"TRIAL","name":"Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe","canonical_id":"clinicaltrials.gov:NCT02772640","description":"Hypercholesterolemia","metadata":null},{"id":"639d89e15a154609a1b6e99fd80fa2fd","type":"TRIAL","name":"Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis","canonical_id":"clinicaltrials.gov:NCT02635828","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"9f3b13e665e6409bb00735e811c42732","type":"TRIAL","name":"Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00435370","description":"Smoking Cessation; Schizophrenia","metadata":null},{"id":"bbacf17ad7e14547b0894d81e72bdbd9","type":"TRIAL","name":"Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02037165","description":"Healthy","metadata":null},{"id":"80669b73a214466cb362bef6dde70038","type":"TRIAL","name":"Effectiveness of Vedolizumab in CD Patients Na\u00efve to Anti-TNF","canonical_id":"clinicaltrials.gov:NCT02820493","description":"Crohn Disease","metadata":null},{"id":"e0710b4bd0804061af03d745d9977034","type":"TRIAL","name":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT01552902","description":"Attention-deficit/Hyperactivity Disorder","metadata":null},{"id":"7328e36bbcd94fe7a2f01ad0d433ab3d","type":"TRIAL","name":"Effectiveness of Ziprasidone for Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01198353","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"728d49434da2400ebcde86c771377b2e","type":"TRIAL","name":"Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images","canonical_id":"clinicaltrials.gov:NCT01672827","description":"Alzheimer's Disease; Mild Cognitive Impairment","metadata":null},{"id":"f838b0a47f8e4266848c114fbcbcfec8","type":"TRIAL","name":"Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01101152","description":"Healthy","metadata":null},{"id":"c3ac662952874f72b3f953df57cbd8aa","type":"TRIAL","name":"Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07416409","description":"Breast Neoplasms; Oncology; HER2-positive Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"abd0b41549dd463f86001f01891a41d2","type":"TRIAL","name":"Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa","canonical_id":"clinicaltrials.gov:NCT00203060","description":"Parkinson's Disease","metadata":null},{"id":"6e5faf27abe04c27a21b75ec8125106b","type":"TRIAL","name":"Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography","canonical_id":"clinicaltrials.gov:NCT01848899","description":"Coronary Artery Disease","metadata":null},{"id":"09a1f3ff61af4f93a94729896bcd5c5f","type":"TRIAL","name":"Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery","canonical_id":"clinicaltrials.gov:NCT07033442","description":"Anaesthesia; Intraocular Pressure; Trendelenburg Position; Robot Assisted Laparoscopic Radical Prostatectomy; Total Intravenous Anesthesia; Inhalation Anesthesia","metadata":null},{"id":"d02943c4e2814ad293e8e354bd097477","type":"TRIAL","name":"Effects Of Antidepressants On Sexual Functioning In Adults","canonical_id":"clinicaltrials.gov:NCT00051272","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"79bd1c5e40d04bdab39471609542293c","type":"TRIAL","name":"Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT00254956","description":"Respiratory Tract Diseases; Respiratory Hypersensitivity; Asthma","metadata":null},{"id":"aa5ad5d5f50b41ad930a1ad304ff7ffd","type":"TRIAL","name":"Effects Of Detrol LA On Memory And Cognition In Elderly Population","canonical_id":"clinicaltrials.gov:NCT00411437","description":"Memory; Cognition","metadata":null},{"id":"a51452b9897541fcb26c2fa0201d3058","type":"TRIAL","name":"Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis","canonical_id":"clinicaltrials.gov:NCT02264587","description":"Diabetic Gastroparesis","metadata":null},{"id":"0cceacff37b047f0afe1ad36ee479032","type":"TRIAL","name":"Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)","canonical_id":"clinicaltrials.gov:NCT00598611","description":"Chronic Urticaria","metadata":null},{"id":"ad87ab7b18d44063ab2cad7c4e715dd2","type":"TRIAL","name":"Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01596777","description":"Intestinal Obstruction","metadata":null},{"id":"f014826afa514f30ab14c5df42978131","type":"TRIAL","name":"Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT03333824","description":"Solid Tumours","metadata":null},{"id":"03f3ef9374d244038540fc59f1ac3981","type":"TRIAL","name":"Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure","canonical_id":"clinicaltrials.gov:NCT00517426","description":"Chronic Heart Failure","metadata":null},{"id":"cbd44b0646d8496895803418e93f2d15","type":"TRIAL","name":"Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates","canonical_id":"clinicaltrials.gov:NCT00286143","description":"Congenital Cystic Adenomatoid Malformation","metadata":null},{"id":"b3e69af6e8304abaa8329788eceb3dd5","type":"TRIAL","name":"Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT00464880","description":"Diabetes Type 2","metadata":null},{"id":"db0ffd1950be4cae816c02b36e5955c7","type":"TRIAL","name":"Effects of Alogliptin on Pancreatic Beta Cell Function","canonical_id":"clinicaltrials.gov:NCT01303055","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"d8a3e4e48f584c0abc298bd723e7d1a8","type":"TRIAL","name":"Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions","canonical_id":"clinicaltrials.gov:NCT01834729","description":"Constipation","metadata":null},{"id":"f9ced569dffa4003be3860d258b28292","type":"TRIAL","name":"Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function","canonical_id":"clinicaltrials.gov:NCT03082014","description":"Cerebral Small Vessel Diseases","metadata":null},{"id":"a816285323bf4e60ab1332caf8616a46","type":"TRIAL","name":"Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension","canonical_id":"clinicaltrials.gov:NCT00139555","description":"Hypertension; Left Ventricular Hypertrophy","metadata":null},{"id":"4c7d6c613af44e98b5f8ca69cb3dd9e2","type":"TRIAL","name":"Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00367978","description":"Hypertension","metadata":null},{"id":"04223816339e48db92270c78dddd09ef","type":"TRIAL","name":"Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00136773","description":"Albuminuria","metadata":null},{"id":"5b55a6016e714e459caa0ff81cb72103","type":"TRIAL","name":"Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease","canonical_id":"clinicaltrials.gov:NCT03587701","description":"Autoimmune Inner Ear Disease; Meniere's Disease","metadata":null},{"id":"e95c48d1402447e2995b33e53a16c25c","type":"TRIAL","name":"Effects of Analgesics in Cesarean Section Elective","canonical_id":"clinicaltrials.gov:NCT03386630","description":"Anesthesia; Functional","metadata":null},{"id":"5750467b178049ba9b54c31d758eed69","type":"TRIAL","name":"Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone","canonical_id":"clinicaltrials.gov:NCT01428193","description":"Polycystic Ovary Syndrome; Hyperandrogenism","metadata":null},{"id":"e3db5575b4f4434bbe0aafe16b27410c","type":"TRIAL","name":"Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT01011660","description":"Essential Hypertension","metadata":null},{"id":"c942eda37a7d4642a45bdd6a5adc9373","type":"TRIAL","name":"Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI","canonical_id":"clinicaltrials.gov:NCT01355991","description":"Spinal Cord Injury","metadata":null},{"id":"b99501ecbeda40209c2649cc1f64d9e2","type":"TRIAL","name":"Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA)","canonical_id":"clinicaltrials.gov:NCT01028534","description":"Obstructive Sleep Apnea; Hypertension","metadata":null},{"id":"d1c0664c695e40868ffbc56e61f3382f","type":"TRIAL","name":"Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine","canonical_id":"clinicaltrials.gov:NCT00564057","description":"HIV Infections; Hypertension","metadata":null},{"id":"9cf8e54d196941fc8436fe0da75ae78f","type":"TRIAL","name":"Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying","canonical_id":"clinicaltrials.gov:NCT02989467","description":"Healthy","metadata":null},{"id":"71aef4cbc48a41d7af047cf088504de3","type":"TRIAL","name":"Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT04013386","description":"Nausea and Vomiting, Postoperative","metadata":null},{"id":"10eed136a9174e58b38c69ea03c4874c","type":"TRIAL","name":"Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates","canonical_id":"clinicaltrials.gov:NCT00617955","description":"Cardiac Surgery","metadata":null},{"id":"aac4de2f484748438572aa16f59073bc","type":"TRIAL","name":"Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning","canonical_id":"clinicaltrials.gov:NCT01161277","description":"Psychosis; Schizophrenia","metadata":null},{"id":"3b2241f7d42a477bbcba8eac6dea4f50","type":"TRIAL","name":"Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.","canonical_id":"clinicaltrials.gov:NCT01924104","description":"To Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out Come","metadata":null},{"id":"e0eadbc4f4f2489cbd1a531e8a735e7f","type":"TRIAL","name":"Effects of Atomoxetine Treatment in Humans","canonical_id":"clinicaltrials.gov:NCT00611936","description":"Stress","metadata":null},{"id":"769ad6b1598846e8b62c10a9094163c1","type":"TRIAL","name":"Effects of Atorvastatin Versus Probucol on Small Dense LDL","canonical_id":"clinicaltrials.gov:NCT00276133","description":"Chronic Nephropathy","metadata":null},{"id":"281cb79113c940b894883d7ad0408c35","type":"TRIAL","name":"Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02182336","description":"Healthy","metadata":null},{"id":"e3b5302b928747a3962ecf2e0fa23fd3","type":"TRIAL","name":"Effects of Baclofen on Presynaptic Inhibition in Humans","canonical_id":"clinicaltrials.gov:NCT04471714","description":"Spasticity, Muscle; Spinal Cord Injuries","metadata":null},{"id":"4cbeabca5653455a9cdbcb2eab619be0","type":"TRIAL","name":"Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation","canonical_id":"clinicaltrials.gov:NCT00348101","description":"Coronary Artery Disease","metadata":null},{"id":"c6ec4bafc39a4621ae29a91d94775733","type":"TRIAL","name":"Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass","canonical_id":"clinicaltrials.gov:NCT02876484","description":"Severe Obesity","metadata":null},{"id":"5048dc56ccd84424837eae96d4f62a96","type":"TRIAL","name":"Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass","canonical_id":"clinicaltrials.gov:NCT02340247","description":"Severe Obesity","metadata":null},{"id":"d8c81f0c94014900bd7e260a15d87c32","type":"TRIAL","name":"Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT01762436","description":"Untreated Essential Hypertension","metadata":null},{"id":"f2a7b44eb18f4562b9f8f3e106f2e4ef","type":"TRIAL","name":"Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture","canonical_id":"clinicaltrials.gov:NCT01950169","description":"Hip Fracture","metadata":null},{"id":"dc631d35ec894831ba8d3b3d8c341b5c","type":"TRIAL","name":"Effects of Bisphosphonates on OI-Related Hearing Loss","canonical_id":"clinicaltrials.gov:NCT04152551","description":"Osteogenesis Imperfecta","metadata":null},{"id":"4c66ff727f524c4abfbe8d4c765a41cb","type":"TRIAL","name":"Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD","canonical_id":"clinicaltrials.gov:NCT05507242","description":"COPD; COPD Exacerbation; COPD Bronchitis; Airway Disease; Immune System Disorder","metadata":null},{"id":"662e83dcadb94771a23538e9cddd3717","type":"TRIAL","name":"Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)","canonical_id":"clinicaltrials.gov:NCT00154271","description":"Hypertension","metadata":null},{"id":"2f59cb25b71048ba96ee85b07f3ad722","type":"TRIAL","name":"Effects of Body Mass Index on the Hyperemic Response to Regadenoson","canonical_id":"clinicaltrials.gov:NCT00859833","description":"Obesity; Endothelial Dysfunction; Decreased Vascular Flow","metadata":null},{"id":"c3265380f7724812a4566afbf0cd23e6","type":"TRIAL","name":"Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia","canonical_id":"clinicaltrials.gov:NCT00260819","description":"Hypoxia-Induced Pulmonary Artery Hypertension","metadata":null},{"id":"02a07bb9acbc43faa5a6951ab855d43b","type":"TRIAL","name":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","canonical_id":"clinicaltrials.gov:NCT06785090","description":"Cataract; Cystoid Macular Edema After Phacoemulsification","metadata":null},{"id":"977240b49917407a864b8b5db63f7425","type":"TRIAL","name":"Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00202176","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"abfc9ff64da14dd98bf2f25b6e6d7677","type":"TRIAL","name":"Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects","canonical_id":"clinicaltrials.gov:NCT00691951","description":"Asthma","metadata":null},{"id":"578337b64f604a8cad38fbb2e7fd7aba","type":"TRIAL","name":"Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence","canonical_id":"clinicaltrials.gov:NCT00134914","description":"Opioid-Related Disorders","metadata":null},{"id":"27d862ec61cd48d2b01bc9ee152bbfd5","type":"TRIAL","name":"Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01546896","description":"Anxiety Disorder","metadata":null},{"id":"aff249f44a904a689bf3a4fd4cec024b","type":"TRIAL","name":"Effects of Buspirone Combined With Clozapine","canonical_id":"clinicaltrials.gov:NCT06906224","description":"Schizophrenia","metadata":null},{"id":"fa286c7b26f743cdb4feb8c3e6ddc126","type":"TRIAL","name":"Effects of Buspirone in Opiate Withdrawal","canonical_id":"clinicaltrials.gov:NCT00326235","description":"Heroin Dependence","metadata":null},{"id":"7b2558d62a4b4e2fbbb56a32bc86899b","type":"TRIAL","name":"Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects","canonical_id":"clinicaltrials.gov:NCT06039358","description":"Caffeine; Biomechanics; Fatigue; Injuries; Physical Activity","metadata":null},{"id":"2575855d99744fceab83f268496f8a87","type":"TRIAL","name":"Effects of Canagliflozin on Intravascular Volume and Hemodynamics","canonical_id":"clinicaltrials.gov:NCT03190798","description":"Type2 Diabetes Mellitus; Cardiovascular Diseases","metadata":null},{"id":"ffd1217a2c3743189b13d98c2c20b314","type":"TRIAL","name":"Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention","canonical_id":"clinicaltrials.gov:NCT06089577","description":"Coronary Artery Disease","metadata":null},{"id":"992f7a895f15464281a9d18f096aa0f6","type":"TRIAL","name":"Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00219284","description":"Parkinson's Disease With End of Dose Wearing Off","metadata":null},{"id":"ce9c10788a4347e087cbbc52a6be8052","type":"TRIAL","name":"Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy","canonical_id":"clinicaltrials.gov:NCT04939883","description":"Cancer","metadata":null},{"id":"2ea0c5787b9a4312a8ce78713d2feaa2","type":"TRIAL","name":"Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00730418","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"9f4be526a9ee4010b56ce65b258432a2","type":"TRIAL","name":"Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT00270348","description":"Asthma","metadata":null},{"id":"de9e00a282924b80beaae855ad62938c","type":"TRIAL","name":"Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness","canonical_id":"clinicaltrials.gov:NCT00573950","description":"Diabetes Mellitus, Type 2; Metabolic Syndrome X","metadata":null},{"id":"f63d64fb9bfb43fc967d537ebb2178e5","type":"TRIAL","name":"Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer","canonical_id":"clinicaltrials.gov:NCT03309436","description":"Infertility, Female; Clomiphene Citrate","metadata":null},{"id":"c1f9639ea63d4b0db44a67c9d5e32f31","type":"TRIAL","name":"Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01421706","description":"Healthy","metadata":null},{"id":"2b3e28f7e0ff4972897f6977cdeb70a5","type":"TRIAL","name":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT06756139","description":"Functional Dyspepsia; Self-help Mobile Cognitive Behavioral Therapy; Antipsychotic Drug","metadata":null},{"id":"413490ff480c4781809d3f4d314902fe","type":"TRIAL","name":"Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT02153983","description":"Obesity; Metabolic Disease","metadata":null},{"id":"368f31c1ce624855875ec2785d009f49","type":"TRIAL","name":"Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00130156","description":"High Blood Pressure","metadata":null},{"id":"216d5541bcd1496182002b533dcbbd51","type":"TRIAL","name":"Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS","canonical_id":"clinicaltrials.gov:NCT05981742","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"96e717461d6c4e83b03bf81d5f3945a4","type":"TRIAL","name":"Effects of Combined Rhodiola Rosea and Caffeine Supplementation on Dancesport Performance","canonical_id":"clinicaltrials.gov:NCT07690085","description":"Dancesport Performance","metadata":null},{"id":"c984707bf6334965ade80f394961bebc","type":"TRIAL","name":"Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin","canonical_id":"clinicaltrials.gov:NCT03131973","description":"Rheumatoid Arthritis","metadata":null},{"id":"75e65179903d4f3e8d41c1c50d3d4a82","type":"TRIAL","name":"Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients","canonical_id":"clinicaltrials.gov:NCT00409487","description":"Hypertension,; Obstructive Sleep Apnea","metadata":null},{"id":"82f1b713383c476186020b2209fb43bf","type":"TRIAL","name":"Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control","canonical_id":"clinicaltrials.gov:NCT02949934","description":"Alcohol Use Disorder","metadata":null},{"id":"491cd2ea0abd4cf4a4675290e0e2f50f","type":"TRIAL","name":"Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea","canonical_id":"clinicaltrials.gov:NCT04192487","description":"Acquired Immunodeficiency Syndrome; Healthy Volunteers; HIV/AIDS; HIV Diarrhea; Human Immunodeficiency Virus","metadata":null},{"id":"9dec390c2d5149abb5c4dfca50551911","type":"TRIAL","name":"Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients","canonical_id":"clinicaltrials.gov:NCT06938152","description":"Osteoporosis; Osteoporosis Postmenopausal","metadata":null},{"id":"6b9a65c6eb7141d0a4df5c249a600194","type":"TRIAL","name":"Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders","canonical_id":"clinicaltrials.gov:NCT02568007","description":"Feeding Behaviors","metadata":null},{"id":"72c6ffc489fd4886919272088022d925","type":"TRIAL","name":"Effects of DPP4 Inhibition on COVID-19","canonical_id":"clinicaltrials.gov:NCT04341935","description":"Coronavirus Infection; Type 2 Diabetes","metadata":null},{"id":"215766a2890449639d439ac92ba8d7cd","type":"TRIAL","name":"Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor","canonical_id":"clinicaltrials.gov:NCT03178591","description":"Diabetes Mellitus, Type 2; Ischemic Heart Disease","metadata":null},{"id":"5c124665b7d5490d82d24be302ff354f","type":"TRIAL","name":"Effects of Dalfampridine on Cognition in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02006160","description":"Multiple Sclerosis","metadata":null},{"id":"2d99a595443e43399a3941169c75137e","type":"TRIAL","name":"Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT02887677","description":"Diabetes Mellitus","metadata":null},{"id":"9e18705019504aef92354857f14c6143","type":"TRIAL","name":"Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD","canonical_id":"clinicaltrials.gov:NCT05359263","description":"Chronic Kidney Diseases","metadata":null},{"id":"b12fb00113a444b2b9bb9c67edc0d618","type":"TRIAL","name":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","canonical_id":"clinicaltrials.gov:NCT03714594","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"c31912ed073d4899b666804037bf713f","type":"TRIAL","name":"Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01206660","description":"Psoriasis","metadata":null},{"id":"e0b71363ac2642fbb4da8275bcbc0d19","type":"TRIAL","name":"Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01206387","description":"Psoriasis","metadata":null},{"id":"9e9d04d3a832468e8246b81f11579575","type":"TRIAL","name":"Effects of Diazepam on RNS Detections","canonical_id":"clinicaltrials.gov:NCT05273398","description":"Epilepsies, Partial","metadata":null},{"id":"8a09d29672364c64b52a80fb18bf82e7","type":"TRIAL","name":"Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease","canonical_id":"clinicaltrials.gov:NCT05461820","description":"Graves Disease; Relapse; Treatment; Drug Withdrawal","metadata":null},{"id":"c9b8ab3799c442979c9a0edb547b8c50","type":"TRIAL","name":"Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00712894","description":"Acute Myocardial Infarction; Percutaneous Coronary Intervention","metadata":null},{"id":"67354dfb728b4f3db1b80129df5aaced","type":"TRIAL","name":"Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients","canonical_id":"clinicaltrials.gov:NCT01271153","description":"Septic Shock","metadata":null},{"id":"4968ca705bf543208a96f856846922b6","type":"TRIAL","name":"Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone","canonical_id":"clinicaltrials.gov:NCT00533065","description":"Elderly","metadata":null},{"id":"5544258a4e9944f499e02fd97f8bea36","type":"TRIAL","name":"Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT03250741","description":"Alzheimer Disease","metadata":null},{"id":"fe3a2c8c84a9484b8f14ea6be8cd2faa","type":"TRIAL","name":"Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT00646841","description":"Hypertension","metadata":null},{"id":"b578ce7e9e114674a9c091373d430d7b","type":"TRIAL","name":"Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD","canonical_id":"clinicaltrials.gov:NCT03425617","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"1d5c75a3d6b64126b4a952be59a37b6d","type":"TRIAL","name":"Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study","canonical_id":"clinicaltrials.gov:NCT00491348","description":"Worry; Anxiety","metadata":null},{"id":"9bff03ccb3e04ede89de9f3aebf9e0b5","type":"TRIAL","name":"Effects of Edoxaban on Platelet Aggregation","canonical_id":"clinicaltrials.gov:NCT05122455","description":"SCAD; AMI","metadata":null},{"id":"521539190ed54368a801bdc51fd47790","type":"TRIAL","name":"Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery","canonical_id":"clinicaltrials.gov:NCT04450095","description":"Kidney Failure, Acute","metadata":null},{"id":"55eb51e639f24328abde21d5887bdc83","type":"TRIAL","name":"Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)","canonical_id":"clinicaltrials.gov:NCT02740179","description":"HIV","metadata":null},{"id":"6b7d3ffda815453b80ec1f82ee16261c","type":"TRIAL","name":"Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack","canonical_id":"clinicaltrials.gov:NCT00132093","description":"Myocardial Infarction","metadata":null},{"id":"e04bc35104624905bb85f0dc5f19e536","type":"TRIAL","name":"Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping","canonical_id":"clinicaltrials.gov:NCT06928766","description":"OSA - Obstructive Sleep Apnea","metadata":null},{"id":"5db0a477ee0e4e6d91b4e4aa589d0e45","type":"TRIAL","name":"Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT04575844","description":"Metabolic Syndrome","metadata":null},{"id":"7c9a351ae9cd4d24bcf27ab485b173bf","type":"TRIAL","name":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","canonical_id":"clinicaltrials.gov:NCT04626973","description":"Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"1fb94dba797846faa461ee599020977e","type":"TRIAL","name":"Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism","canonical_id":"clinicaltrials.gov:NCT00465751","description":"Metabolic Syndrome; Familial Hypertriglyceridemia; Familial Combined Hyperlipidemia","metadata":null},{"id":"741ba315bf5b4fecaafaebfd44d704c7","type":"TRIAL","name":"Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM","canonical_id":"clinicaltrials.gov:NCT00577590","description":"Diabetes Mellitus, Type II","metadata":null},{"id":"cc7a20c1375041f7979c734920ff4836","type":"TRIAL","name":"Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout","canonical_id":"clinicaltrials.gov:NCT04772352","description":"Nonalcoholic Fatty Liver Disease","metadata":null},{"id":"4cf81556f2074106afb2e459e4b8c811","type":"TRIAL","name":"Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033","canonical_id":"clinicaltrials.gov:NCT00376285","description":"Obesity","metadata":null},{"id":"141b621f97014133981ebab2afb2c417","type":"TRIAL","name":"Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)","canonical_id":"clinicaltrials.gov:NCT00396175","description":"Androgenetic Alopecia","metadata":null},{"id":"c293d408a5d64e4dac4decac9ba3383e","type":"TRIAL","name":"Effects of Flibanserin on the Pre- and Post-menopausal Female Brain","canonical_id":"clinicaltrials.gov:NCT02770768","description":"Hypoactive Sexual Desire Disorder","metadata":null},{"id":"e1d8290ca68d43b79036496b5efc9516","type":"TRIAL","name":"Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression","canonical_id":"clinicaltrials.gov:NCT00673270","description":"Renin Angiotensin","metadata":null},{"id":"5c0899632fb344179eb1cfc538a1b621","type":"TRIAL","name":"Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam","canonical_id":"clinicaltrials.gov:NCT05939674","description":"Flumazenil Adverse Reaction; Remimazolam; Hip Joint; Elderly Patients","metadata":null},{"id":"e0777b5ba31c45079d3f0c25334cdf39","type":"TRIAL","name":"Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01011036","description":"Pain","metadata":null},{"id":"7f34bb9b0af449aeb00d3f374aebde68","type":"TRIAL","name":"Effects of Genotype on CYP2C9 Drug Interactions","canonical_id":"clinicaltrials.gov:NCT01061112","description":"Healthy","metadata":null},{"id":"5571b14a50db4c8b9cb31123ba1dabe0","type":"TRIAL","name":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","canonical_id":"clinicaltrials.gov:NCT04662866","description":"Impaired Glucose Tolerance; Insulin Sensitivity; Glucose Metabolism Disorders","metadata":null},{"id":"fd0f5a1a02e4458992cf004e4242c71c","type":"TRIAL","name":"Effects of Glycopyrrolate on Heart Rate and Heart Rate Variability in Patients With Different Basic Heart Rate","canonical_id":"clinicaltrials.gov:NCT06237478","description":"Glycopyrrolate","metadata":null},{"id":"710ab2118b1f4c41ba561baa5e8786d2","type":"TRIAL","name":"Effects of Growth Hormone Releasing Hormone in HIV","canonical_id":"clinicaltrials.gov:NCT01263717","description":"HIV; HIV Lipodystrophy","metadata":null},{"id":"ce2aa45652754003b1d75a73cd3a826a","type":"TRIAL","name":"Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag","canonical_id":"clinicaltrials.gov:NCT00097474","description":"Jet Lag","metadata":null},{"id":"d9c874491c0f4b0ab21957bb69729172","type":"TRIAL","name":"Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01021865","description":"Coronary Artery Disease; Diabetes Mellitus Type 2","metadata":null},{"id":"be64bc8eb8cd4eb3b56cb4b9ef0c23c3","type":"TRIAL","name":"Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00223665","description":"Prostate Cancer","metadata":null},{"id":"9eddabcb90db445bbee66c3dc2bf65ee","type":"TRIAL","name":"Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis","canonical_id":"clinicaltrials.gov:NCT07169682","description":"Psoriasis; Cardiovascular Disease; Atherosclerosis","metadata":null},{"id":"1e0b06fbd78d4b2b9bc88c290f2c77b6","type":"TRIAL","name":"Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude","canonical_id":"clinicaltrials.gov:NCT00724321","description":"Hypoxic Pulmonary Vasoconstriction","metadata":null},{"id":"a903871c5c2d453aa5ad5ffdf2a4065f","type":"TRIAL","name":"Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients","canonical_id":"clinicaltrials.gov:NCT04927039","description":"Mediastinal Mass","metadata":null},{"id":"a92ae3e471df41c7a6102e78c50e3861","type":"TRIAL","name":"Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation","canonical_id":"clinicaltrials.gov:NCT02490657","description":"Video-assisted Thoracoscopic Surgery; Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"bfea5c09270c47979ce17ba2d0624ffe","type":"TRIAL","name":"Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia","canonical_id":"clinicaltrials.gov:NCT00244192","description":"COPD; Cachexia","metadata":null},{"id":"bdc2b6de5c444b49bb5718d2a7ef5741","type":"TRIAL","name":"Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT00703339","description":"Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension","metadata":null},{"id":"5a8e02cf591544d79c2ad031633c4f58","type":"TRIAL","name":"Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT07116681","description":"Pulmonary Hypertension","metadata":null},{"id":"cac6482b1424440f95df97f497df64a9","type":"TRIAL","name":"Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris","canonical_id":"clinicaltrials.gov:NCT00424801","description":"Microvascular Angina; Hypertension","metadata":null},{"id":"1f1b58156673436a996e8bb95a936cbe","type":"TRIAL","name":"Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT02131220","description":"Myocardial Infarction; Percutaneous Coronary Intervention; Thrombolytic Therapy","metadata":null},{"id":"d8c175d02b814476af26a49944690c1a","type":"TRIAL","name":"Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*","canonical_id":"clinicaltrials.gov:NCT01240889","description":"Allergy","metadata":null},{"id":"952b25a32d2a4f3ba5d63341019e191f","type":"TRIAL","name":"Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02953106","description":"Asthma, Allergic; Rhinitis,Allergic; Allergy","metadata":null},{"id":"c87f315a6c1a42e5aee9339c88157ba3","type":"TRIAL","name":"Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Free Flaps","canonical_id":"clinicaltrials.gov:NCT03288051","description":"Optimal Tissue Perfusion","metadata":null},{"id":"5e6c020721004fc6848025406488b09e","type":"TRIAL","name":"Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy","canonical_id":"clinicaltrials.gov:NCT00600158","description":"Postoperative Ileus","metadata":null},{"id":"4d9ee4f35662427da9cd2d580de725f0","type":"TRIAL","name":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone","canonical_id":"clinicaltrials.gov:NCT02875821","description":"Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)","metadata":null},{"id":"292eec014f674f8896f19f245b01470b","type":"TRIAL","name":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","canonical_id":"clinicaltrials.gov:NCT04537715","description":"All Malignancies; Advanced Malignancies; Hematologic Malignancy; Solid Tumor; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma (NHL); Diffuse Large B-Cell Lymphoma (DLBCL); Epithelioid Sarcoma (ES); Synovial Sarcoma; Renal Medullary Carcinoma; Mesothelioma; Rhabdoid Tumor","metadata":null},{"id":"f833700e160f410292d36dbe7be52b2c","type":"TRIAL","name":"Effects of Labetalol on Nicotine Administration in Humans - 14","canonical_id":"clinicaltrials.gov:NCT00000297","description":"Tobacco Use Disorder","metadata":null},{"id":"731b55819f14460d90e3f2fa2f650ae5","type":"TRIAL","name":"Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study","canonical_id":"clinicaltrials.gov:NCT01382017","description":"Healthy Male Volunteers","metadata":null},{"id":"d144256c77e7484c8a75dae7965ea88b","type":"TRIAL","name":"Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:","canonical_id":"clinicaltrials.gov:NCT02342977","description":"Osteoarthritis; Rheumatoid Arthritis; Avascular Necrosis","metadata":null},{"id":"bd463aa11d0148599b95c41be5978214","type":"TRIAL","name":"Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold","canonical_id":"clinicaltrials.gov:NCT05763329","description":"OSA","metadata":null},{"id":"4b7d482ce839427db52101ac0f545e1e","type":"TRIAL","name":"Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects","canonical_id":"clinicaltrials.gov:NCT06981195","description":"Opioid Use Disorder; Opioid Use; Insomnia; Orexin Antagonist","metadata":null},{"id":"70a7dfadeac34ad29d08ce6ce0e4a868","type":"TRIAL","name":"Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT07384429","description":"Parkinson's Disease; Insomnia; Motor Disorder","metadata":null},{"id":"9f439234e5a840e8807b14bcb6f59b51","type":"TRIAL","name":"Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving","canonical_id":"clinicaltrials.gov:NCT01496911","description":"Healthy Volunteers","metadata":null},{"id":"cffcb71b908342c6a3d26cf7eaacb537","type":"TRIAL","name":"Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock","canonical_id":"clinicaltrials.gov:NCT02963454","description":"Septic Shock","metadata":null},{"id":"3753b33016ea4b6e80da025e58b62cbf","type":"TRIAL","name":"Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT01835678","description":"Type 2-diabetes","metadata":null},{"id":"a58b67d9208746ccb3e270b56f3ed99d","type":"TRIAL","name":"Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01175473","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"df893786d02f4b75b8d2217c8740074a","type":"TRIAL","name":"Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02872090","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"1007cd23574647e991884332976fb66e","type":"TRIAL","name":"Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients","canonical_id":"clinicaltrials.gov:NCT02305940","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"add34466c9e74fb7be60306224876e4b","type":"TRIAL","name":"Effects of Losartan on Insulin Resistance in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT00663377","description":"Heart Failure","metadata":null},{"id":"d2de44caab954a419b75dfbcac7ee3ae","type":"TRIAL","name":"Effects of Lovastatin on Human Platelet Proteome","canonical_id":"clinicaltrials.gov:NCT02389868","description":"Blood Platelets Proteome","metadata":null},{"id":"0b0038f9fbc04891a796298be4dc81ff","type":"TRIAL","name":"Effects of Low Dose Naltrexone in Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00568555","description":"Fibromyalgia; Persian Gulf Syndrome","metadata":null},{"id":"3f5a0c81304d46d986cb4536b2f88fa0","type":"TRIAL","name":"Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations","canonical_id":"clinicaltrials.gov:NCT00671151","description":"COPD","metadata":null},{"id":"1050517d31c040e1acb4fe5907932820","type":"TRIAL","name":"Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients","canonical_id":"clinicaltrials.gov:NCT05635877","description":"Frailty; Esmolol; Myocardial Injury","metadata":null},{"id":"5e247ec8ced24e05bc2e8b09db25f94e","type":"TRIAL","name":"Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02647437","description":"Schizophrenia","metadata":null},{"id":"aa4442f5d84f49af93ddb61912579a03","type":"TRIAL","name":"Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT01460225","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"0f74a583aeb2472c86e7cb81b16af435","type":"TRIAL","name":"Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation","canonical_id":"clinicaltrials.gov:NCT01162863","description":"Irritable Bowel Syndrome; Constipation","metadata":null},{"id":"7b8fb1772ced4f5d8fd55a4cba86285d","type":"TRIAL","name":"Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit","canonical_id":"clinicaltrials.gov:NCT00844831","description":"Constipation","metadata":null},{"id":"34db9454e58a4c2caf6c1d26a26935d0","type":"TRIAL","name":"Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension","canonical_id":"clinicaltrials.gov:NCT00419796","description":"Osteoarthritis With Controlled Hypertension","metadata":null},{"id":"1565d926448746d48f086a85991ba18c","type":"TRIAL","name":"Effects of MDMA and Methylphenidate on Social Cognition","canonical_id":"clinicaltrials.gov:NCT01616407","description":"Social Cognition","metadata":null},{"id":"ddc6eec5a2384b2d92ef2e5b27a8c0dd","type":"TRIAL","name":"Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan","canonical_id":"clinicaltrials.gov:NCT01367535","description":"Healthy Adults","metadata":null},{"id":"7ea90abb2de545ee836826a8be25057b","type":"TRIAL","name":"Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05626322","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"739c4c2effa8497b9da19fe239c6db16","type":"TRIAL","name":"Effects of Melatonin in PCOS Women","canonical_id":"clinicaltrials.gov:NCT02663570","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"1729d0f10c984649b8f472eed8aa040d","type":"TRIAL","name":"Effects of Melatonin on Insomnia Symptoms in Older Adults","canonical_id":"clinicaltrials.gov:NCT00230737","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"047fac6185a248db961a1091c9543b7d","type":"TRIAL","name":"Effects of Melatonin on Sleep Architecture of Critically Ill Patients in the ICU","canonical_id":"clinicaltrials.gov:NCT07691996","description":"Critical Illness; ICU; ICU Hospitalization; Melatonin; Sleep","metadata":null},{"id":"77ee639c115144f793b4db1404effc01","type":"TRIAL","name":"Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension","canonical_id":"clinicaltrials.gov:NCT02963181","description":"Hypotension, Orthostatic; Hypertension; Autonomic Nervous System Diseases","metadata":null},{"id":"697d3c4487264811929f25fdfa1fa4cf","type":"TRIAL","name":"Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS","canonical_id":"clinicaltrials.gov:NCT00428311","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"75cf084de85149238d0dcc3a9595540a","type":"TRIAL","name":"Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.","canonical_id":"clinicaltrials.gov:NCT01596764","description":"Intestinal Obstruction","metadata":null},{"id":"cd7c68522d5f44bba1304f51499db55d","type":"TRIAL","name":"Effects of Methylphenidate (Ritalin\u00ae) on the Neural Basis of Anxiety","canonical_id":"clinicaltrials.gov:NCT02021214","description":"PTSD","metadata":null},{"id":"38d4e7caa27d4d438c5276cffdb43b18","type":"TRIAL","name":"Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning","canonical_id":"clinicaltrials.gov:NCT00418691","description":"Brain Tumor","metadata":null},{"id":"e19cedd3216e4359a9f2c1cd644e3091","type":"TRIAL","name":"Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome","canonical_id":"clinicaltrials.gov:NCT02297945","description":"Cushing's Syndrome","metadata":null},{"id":"0e10fc1bf5cc47f489e9e54625674319","type":"TRIAL","name":"Effects of Metyrapone in Patients With Hypercortisolism","canonical_id":"clinicaltrials.gov:NCT05255900","description":"Hypercortisolism","metadata":null},{"id":"5b53d58d64814cd8b38afc562aee6ffe","type":"TRIAL","name":"Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT01717404","description":"IBS","metadata":null},{"id":"222b80c8700e4bdf86fe69b1f1b14261","type":"TRIAL","name":"Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis","canonical_id":"clinicaltrials.gov:NCT00422396","description":"Hypertriglyceridemia With the Metabolic Syndrome","metadata":null},{"id":"505d7774167543c0b66a25f7d94ff4d9","type":"TRIAL","name":"Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin","canonical_id":"clinicaltrials.gov:NCT00213122","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"340f544efda24468893de5e8ff462146","type":"TRIAL","name":"Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)","canonical_id":"clinicaltrials.gov:NCT03822013","description":"GM2 Gangliosidosis; Supportive Care","metadata":null},{"id":"540513c571714cdc843935ef5c518ca3","type":"TRIAL","name":"Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients","canonical_id":"clinicaltrials.gov:NCT01294059","description":"Fibromyalgia","metadata":null},{"id":"0e51ccb7d4aa4ae6b53ceb22bfa2067a","type":"TRIAL","name":"Effects of Mineralocorticoid Receptor Stimulation on Cognition","canonical_id":"clinicaltrials.gov:NCT02478034","description":"Individuality","metadata":null},{"id":"60ce0feb2dbc47349269224f4e412121","type":"TRIAL","name":"Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00381485","description":"Asthma","metadata":null},{"id":"3643fc86980e4bf188ce34af50f90b9e","type":"TRIAL","name":"Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT00188383","description":"Hyperalgesia; Pain; Prostate Cancer","metadata":null},{"id":"3b207a449e3a4bd29e9dbd58da6f8d3b","type":"TRIAL","name":"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","canonical_id":"clinicaltrials.gov:NCT06409130","description":"Alcohol-related Liver Disease","metadata":null},{"id":"ec8f4224ef6245248fc0ff7e39866ce9","type":"TRIAL","name":"Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge","canonical_id":"clinicaltrials.gov:NCT01969617","description":"Alcohol Dependence","metadata":null},{"id":"9ff50c7a7d98426b956572f4a5bbbe5c","type":"TRIAL","name":"Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.","canonical_id":"clinicaltrials.gov:NCT00924833","description":"Hypoxia; Altitude; Heart Failure","metadata":null},{"id":"1e1f6cd5a8eb417cbd8c2693011f1839","type":"TRIAL","name":"Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3","canonical_id":"clinicaltrials.gov:NCT00000286","description":"Cocaine-Related Disorders","metadata":null},{"id":"8bba25bdb41f44c7a1806ca0c81d975a","type":"TRIAL","name":"Effects of Nimodipine on Alcohol Drinking","canonical_id":"clinicaltrials.gov:NCT07681869","description":"Alcohol Use Disorder","metadata":null},{"id":"4fb5be3d5e1649868add0508899dd0b7","type":"TRIAL","name":"Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma","canonical_id":"clinicaltrials.gov:NCT00701597","description":"Glaucoma; Blood Flow Velocity","metadata":null},{"id":"d79b6e4912a34b809afe707a9c45c3d1","type":"TRIAL","name":"Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude","canonical_id":"clinicaltrials.gov:NCT02233582","description":"High Altitude","metadata":null},{"id":"b1fc4df6dacd4e71a38549944c1defb6","type":"TRIAL","name":"Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans","canonical_id":"clinicaltrials.gov:NCT05073237","description":"Menopause; Prediabetes; Obesity","metadata":null},{"id":"1b7c6714e86c47a9939d012abf228336","type":"TRIAL","name":"Effects of Ocrevus in Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04387734","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"5b101f87baa14c82a7c0ff4b0453ac23","type":"TRIAL","name":"Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)","canonical_id":"clinicaltrials.gov:NCT01054300","description":"Diabetes Mellitus, Type 2; Adult","metadata":null},{"id":"8846240842fb4cf9a7b73a8fe2136c54","type":"TRIAL","name":"Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery","canonical_id":"clinicaltrials.gov:NCT05087615","description":"Bariatric Surgery Candidate; Perioperative Complication; Nausea; Vomiting, Postoperative; Drug Effect","metadata":null},{"id":"d0c07d64ff5f40ab89eac6b39e07e04d","type":"TRIAL","name":"Effects of One-to-one Service on the Continuation and Satisfaction of Contraceptive Use.","canonical_id":"clinicaltrials.gov:NCT05362019","description":"Contraception Behavior; Contraceptive Usage","metadata":null},{"id":"9a49da2fb5a54a38ad577dfcb30e06ba","type":"TRIAL","name":"Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT00404781","description":"Ischemic Heart Disease; Acute Coronary Syndromes","metadata":null},{"id":"d1ecfd3f11844cc3b3480a492ff8033e","type":"TRIAL","name":"Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT06346691","description":"COPD","metadata":null},{"id":"516c730a44ef4956b49cc922ac57ae95","type":"TRIAL","name":"Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume","canonical_id":"clinicaltrials.gov:NCT04885153","description":"Diabetic Retinopathy; Dyslipidemias; Diabetes Mellitus","metadata":null},{"id":"ef5c140097c141a8a3fc72408f1c9e89","type":"TRIAL","name":"Effects of Oral Tranexamic Acid Following Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT06479161","description":"Postoperative Pain","metadata":null},{"id":"54491faa9a1546339ff116bfa6df5d96","type":"TRIAL","name":"Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders","canonical_id":"clinicaltrials.gov:NCT04677491","description":"Vulvovaginal Signs and Symptoms; Genitourinary Syndrome of Menopause; Sexual; Disorder, Arousal, Female","metadata":null},{"id":"4fea046c9ed4422fa3c753aab128310c","type":"TRIAL","name":"Effects of Oxytocin on the Functional Architecture of the Brain Before and After Prolonged Naturalistic Fear Induction","canonical_id":"clinicaltrials.gov:NCT05896553","description":"Healthy","metadata":null},{"id":"09b12eba0dd545f7aad8e66568a0c1f3","type":"TRIAL","name":"Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients","canonical_id":"clinicaltrials.gov:NCT05320757","description":"Endometrial Cancer","metadata":null},{"id":"da2e3c1971f14e6f8847f91b5b89c82a","type":"TRIAL","name":"Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02948777","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1c0751a75a0b4721bd09564f2d47c010","type":"TRIAL","name":"Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery","canonical_id":"clinicaltrials.gov:NCT00543309","description":"Heart Defects, Congenital","metadata":null},{"id":"57b8cfb73b314216b5666f89393aad91","type":"TRIAL","name":"Effects of Peripherally Acting \u00b5-opioid Receptor Antagonists on Acute Pancreatitis","canonical_id":"clinicaltrials.gov:NCT04743570","description":"Acute Pancreatitis","metadata":null},{"id":"c669bc84328e49529ff192335d7db0fe","type":"TRIAL","name":"Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT04231708","description":"Opioid Use Disorder","metadata":null},{"id":"f0437bd833a643638741055fa55388f4","type":"TRIAL","name":"Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)","canonical_id":"clinicaltrials.gov:NCT01413958","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"ef5f664ac07b48f09d2f9c787c32a63d","type":"TRIAL","name":"Effects of Phenytoin on Cocaine Use in Humans - 2","canonical_id":"clinicaltrials.gov:NCT00000285","description":"Cocaine-Related Disorders","metadata":null},{"id":"1180bc517552446bb470344482178f20","type":"TRIAL","name":"Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT05859802","description":"Multiple Sclerosis","metadata":null},{"id":"b48ac730af894de78089525246d3751c","type":"TRIAL","name":"Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity","canonical_id":"clinicaltrials.gov:NCT00408850","description":"Metabolic Syndrome","metadata":null},{"id":"a16ab907c1214ef4a24769a59d41b487","type":"TRIAL","name":"Effects of Pioglitazone on Platelet Function","canonical_id":"clinicaltrials.gov:NCT00861341","description":"Diabetes; Platelet Function; Healthy","metadata":null},{"id":"303829457e3449f98926476238c7ecd9","type":"TRIAL","name":"Effects of Pioglitazone on Stress Reactivity and Alcohol Craving","canonical_id":"clinicaltrials.gov:NCT05107765","description":"Alcohol Use Disorder","metadata":null},{"id":"2da5bdfb1e754df3ab57e35640bb7ddc","type":"TRIAL","name":"Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01082588","description":"Schizophrenia; Schizoaffective Disorders; Schizophreniform Disorders","metadata":null},{"id":"adc8dcf064cc46b48d0f6064d56478ef","type":"TRIAL","name":"Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain","canonical_id":"clinicaltrials.gov:NCT04380298","description":"Pain; Supratentorial Brain Tumor","metadata":null},{"id":"d6d1d69bdcf040cdb737af8224a8e3d2","type":"TRIAL","name":"Effects of Propranolol on the Encoding and Retrieval of Emotional Material After Single Dose Administration in Healthy Young Subjects","canonical_id":"clinicaltrials.gov:NCT00889096","description":"Memory; Heart Rate; Skin Electric Conductance; Amylase; Propanolol","metadata":null},{"id":"8d69ba11b31a415a9f80cc5fa779428f","type":"TRIAL","name":"Effects of RG1068 (Secretin) on Information Processing in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00235274","description":"Schizophrenia","metadata":null},{"id":"2950b89a2ab64ddb9166a4aa8a1653ca","type":"TRIAL","name":"Effects of Ramelteon on Driving Ability","canonical_id":"clinicaltrials.gov:NCT00319215","description":"Insomnia","metadata":null},{"id":"431b62c4dc5d48318df115e9abd2105e","type":"TRIAL","name":"Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01442610","description":"Sleep Disturbances; Parkinsons's Disease","metadata":null},{"id":"19db14b21e534cf584f758a2aea10053","type":"TRIAL","name":"Effects of Repeat Dosing of GSK1521498","canonical_id":"clinicaltrials.gov:NCT00976105","description":"Obesity","metadata":null},{"id":"e9e8720dfe3449a2873e02c3caecdd94","type":"TRIAL","name":"Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05497674","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"9e3126363b9b4bfcbec9f1837eb56158","type":"TRIAL","name":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","canonical_id":"clinicaltrials.gov:NCT00948766","description":"Alzheimer's Disease","metadata":null},{"id":"b110435e057043fda53ea808e33f5703","type":"TRIAL","name":"Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals","canonical_id":"clinicaltrials.gov:NCT01862029","description":"Obesity","metadata":null},{"id":"d0615a0acc1d4999a9d86c6333bcfafc","type":"TRIAL","name":"Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa","canonical_id":"clinicaltrials.gov:NCT04779216","description":"Bone Density, Low; Bone Loss; Anorexia Nervosa; Eating Disorders","metadata":null},{"id":"395f5f50f3f04686abf85f9f732fc1b3","type":"TRIAL","name":"Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction","canonical_id":"clinicaltrials.gov:NCT00300911","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"716736cf08a0486cbc242c0ae802c222","type":"TRIAL","name":"Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)","canonical_id":"clinicaltrials.gov:NCT04304261","description":"Diabetes Mellitus, Type 2; Cognitive Functions Confusion","metadata":null},{"id":"f03850fc89da4979bcd9a10c89b0c0b5","type":"TRIAL","name":"Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.","canonical_id":"clinicaltrials.gov:NCT02887183","description":"Heart Failure","metadata":null},{"id":"d2d7bdf9d2cb4db8b592da0607012f42","type":"TRIAL","name":"Effects of Salmeterol on Walking Capacity in Patients With COPD","canonical_id":"clinicaltrials.gov:NCT00525564","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"c605ebeec93d482c9b4e9081496c988c","type":"TRIAL","name":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans","canonical_id":"clinicaltrials.gov:NCT02285985","description":"Type 2 Diabetes Mellitus (T2DM)","metadata":null},{"id":"147ddc68b93a4fb7aa1fab353f23886a","type":"TRIAL","name":"Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04352686","description":"Gastroesophageal Reflux","metadata":null},{"id":"b4d9d8bad38d47f48d34d98098b70341","type":"TRIAL","name":"Effects of Sex Steroids on the Serotonin System","canonical_id":"clinicaltrials.gov:NCT02715232","description":"Gender Dysphoria","metadata":null},{"id":"257e2a1457b04652956efe66678b256a","type":"TRIAL","name":"Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)","canonical_id":"clinicaltrials.gov:NCT00979940","description":"Coronary Artery Disease","metadata":null},{"id":"74c0dc61ec984e8f88bf2a4fe4d1fc91","type":"TRIAL","name":"Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects","canonical_id":"clinicaltrials.gov:NCT04097288","description":"Stress Urinary Incontinence; Fecal Incontinence","metadata":null},{"id":"ad9e392c7dd64a3b80444045a02f85d1","type":"TRIAL","name":"Effects of Sitagliptin in Relatives of T1D Patients","canonical_id":"clinicaltrials.gov:NCT05219409","description":"Type 1 Diabetes","metadata":null},{"id":"6684aade82a141faa30f51e76d5043a2","type":"TRIAL","name":"Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00660075","description":"Diabetes Mellitus; Postprandial Lipemia","metadata":null},{"id":"e7bf7366bf714cd8958665e27f170424","type":"TRIAL","name":"Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01477619","description":"Healthy Volunteers","metadata":null},{"id":"f7c06902b885407cbcd17ef881ca7e94","type":"TRIAL","name":"Effects of Spiolto\u00ae Respimat\u00ae (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects","canonical_id":"clinicaltrials.gov:NCT04231214","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"a269cbc67d4240e2967a016be5659ddd","type":"TRIAL","name":"Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT01468571","description":"Pulmonary Hypertension","metadata":null},{"id":"9518d6ace4a1471c8ee4dd5cb3b69140","type":"TRIAL","name":"Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels","canonical_id":"clinicaltrials.gov:NCT00330980","description":"Dyslipidemias","metadata":null},{"id":"a953384778184130b51f0bca55a610dd","type":"TRIAL","name":"Effects of Stress Hormones on Emotion and Cognition","canonical_id":"clinicaltrials.gov:NCT00032838","description":"Healthy","metadata":null},{"id":"f3ffad8209744b7780c3a77b8b489ee1","type":"TRIAL","name":"Effects of Stress and Drug-cue Exposure (SCM)","canonical_id":"clinicaltrials.gov:NCT03154567","description":"Marijuana Abuse","metadata":null},{"id":"4dcd8132f22f4022a71c4f57dcb2ca5f","type":"TRIAL","name":"Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)","canonical_id":"clinicaltrials.gov:NCT01293006","description":"Insomnia","metadata":null},{"id":"ab7239bd6bc74478b9a6c7b0f2b7029a","type":"TRIAL","name":"Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT01028924","description":"Healthy","metadata":null},{"id":"7d839f2dcfad464297726fca2c444d7c","type":"TRIAL","name":"Effects of Telomerase Reactivation With Danazol in Ovarian Function.","canonical_id":"clinicaltrials.gov:NCT04058678","description":"Ovarian Reserve","metadata":null},{"id":"a3dff40c9dc84d379e0eaf84372cd546","type":"TRIAL","name":"Effects of Teriparatide in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00079924","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"8d74c71005894790bb10b3a92385e18d","type":"TRIAL","name":"Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease","canonical_id":"clinicaltrials.gov:NCT03493412","description":"Peripheral Artery Disease; Peripheral Arterial Disease","metadata":null},{"id":"69ec4ab2a79447f4b6bc7119b79fc90a","type":"TRIAL","name":"Effects of Three Single Oral Doses of Trazodone on the QTc Interval Duration in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03516630","description":"Healthy","metadata":null},{"id":"60b93cab566646eabcbf9c1c398f9c95","type":"TRIAL","name":"Effects of Tildrakizumab on Epigenetic Age","canonical_id":"clinicaltrials.gov:NCT05110313","description":"Psoriasis; Aging; Epigenetic Disorder; Inflammation; Skin","metadata":null},{"id":"3b8b2aa5c1c14dd6a395fcab24f329b3","type":"TRIAL","name":"Effects of Tiotropium on Walking Capacity in Patients With COPD","canonical_id":"clinicaltrials.gov:NCT01307189","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"fad8852757be47c39f96074262da31d2","type":"TRIAL","name":"Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]","canonical_id":"clinicaltrials.gov:NCT04994574","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"c78dc314e198455ba03a4a95cb985b21","type":"TRIAL","name":"Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users","canonical_id":"clinicaltrials.gov:NCT02740582","description":"Alcohol Abuse; Impulsive Behavior","metadata":null},{"id":"9550364eee864dbca76ff48a9287db22","type":"TRIAL","name":"Effects of Tolcapone on Frontotemporal Dementia","canonical_id":"clinicaltrials.gov:NCT00604591","description":"Frontotemporal Lobar Degeneration","metadata":null},{"id":"670599397d1948f484e60684dea5204f","type":"TRIAL","name":"Effects of Tolvaptan in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01973140","description":"Healthy","metadata":null},{"id":"b5db03fb5dd44fb9a17784b19ed4d7c7","type":"TRIAL","name":"Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia","canonical_id":"clinicaltrials.gov:NCT01227512","description":"Hyponatremia; Dilutional Hyponatremia; Inappropriate ADH Syndrome","metadata":null},{"id":"d895eb2f61af4afcb8ebad25c270b8e6","type":"TRIAL","name":"Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology","canonical_id":"clinicaltrials.gov:NCT00317486","description":"Pulmonary Arterial Hypertension Related to Eisenmenger Physiology","metadata":null},{"id":"04b05023415741a1ae2e3b213c237d31","type":"TRIAL","name":"Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function","canonical_id":"clinicaltrials.gov:NCT04556461","description":"Atopic Dermatitis","metadata":null},{"id":"9a00b27d3722476b9605f3db1d45f036","type":"TRIAL","name":"Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation","canonical_id":"clinicaltrials.gov:NCT05378698","description":"Atopic Dermatitis","metadata":null},{"id":"5850395de1094cc9bffa900816fc5920","type":"TRIAL","name":"Effects of Transversus Abdominis Plane Block on Recovery Quality and Maternal-Neonatal Outcomes After Cesarean Delivery","canonical_id":"clinicaltrials.gov:NCT07478692","description":"Postoperative Pain After Cesarean Section","metadata":null},{"id":"ad28a336551049d0b0fe09ba8e8270c7","type":"TRIAL","name":"Effects of Treatment With Aprepitant (Emend\u00ae) in HIV Infected Individuals","canonical_id":"clinicaltrials.gov:NCT00428519","description":"HIV Infections","metadata":null},{"id":"5cb632caf4544558bed7dda47ed8749c","type":"TRIAL","name":"Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00111956","description":"Metabolic Syndrome X","metadata":null},{"id":"5d2a91f39293406eb51312e6943ec211","type":"TRIAL","name":"Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS","canonical_id":"clinicaltrials.gov:NCT00884481","description":"Relapsing-Remitting Multiple Sclerosis; Fatigue","metadata":null},{"id":"efb7f56e3d9d478088acc7423d21db3d","type":"TRIAL","name":"Effects of Ublituximab on Motor Functions in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT06629428","description":"Multiple Sclerosis (MS) - Relapsing-remitting","metadata":null},{"id":"6703f52696654d7d9c735245ff5c404b","type":"TRIAL","name":"Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome","canonical_id":"clinicaltrials.gov:NCT01291199","description":"Raynaud Syndrome","metadata":null},{"id":"89359346e8814172abb6a8d820491730","type":"TRIAL","name":"Effects of Vasopressors on Cerebral Hemodynamics in Patients With Carotid Endarterectomy (TCD Part)","canonical_id":"clinicaltrials.gov:NCT05665881","description":"Carotid Endarterectomy","metadata":null},{"id":"c8faf81bd6004078ad29a87da91ab18c","type":"TRIAL","name":"Effects of Vasopressors on Immune Response","canonical_id":"clinicaltrials.gov:NCT02675868","description":"Endotoxemia","metadata":null},{"id":"6be2f1d386cf470293d4a9766bd67825","type":"TRIAL","name":"Effects of Victoza\u00ae Versus Lyxumia\u00ae on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion","canonical_id":"clinicaltrials.gov:NCT02231658","description":"Diabetes Mellitus","metadata":null},{"id":"4562d9170ff0492a9a354bf434f59760","type":"TRIAL","name":"Effects of Vigabatrin on Cocaine Self-Administration","canonical_id":"clinicaltrials.gov:NCT00373581","description":"Cocaine Dependence","metadata":null},{"id":"b8d09eb2d79c4960b440efcd3d9fbd44","type":"TRIAL","name":"Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT01604213","description":"Type 2 Diabetes Mellitus; Ischemic Heart Disease","metadata":null},{"id":"99f06391e5a348b4bf4d55e445e30b21","type":"TRIAL","name":"Effects of Vildagliptine and Glimepiride on Glucose Variability","canonical_id":"clinicaltrials.gov:NCT01812122","description":"Diabetes Mellitus, Non-Insulin-Dependent","metadata":null},{"id":"38c4b747b71e4b898377cc259ad7d1a1","type":"TRIAL","name":"Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)","canonical_id":"clinicaltrials.gov:NCT00413972","description":"Hypercholesterolemia","metadata":null},{"id":"922d56f1c85745daa16ca599bfe76e55","type":"TRIAL","name":"Effects of Weight Loss in Obese Difficult-to-treat Asthmatics","canonical_id":"clinicaltrials.gov:NCT01047657","description":"Asthma; Obesity; Weight Loss","metadata":null},{"id":"54b40fb4adca4a6b98d6ad9efa453e3e","type":"TRIAL","name":"Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT03408015","description":"Ocular Discomfort; Ocular Inflammation; Dry Eye; Contact Lens Complication; Keratoconjunctivitis Sicca","metadata":null},{"id":"279abcc7e8c2446c934b7b63e0be9d5b","type":"TRIAL","name":"Effects of Yohimbine and Naltrexone on Sexual Function","canonical_id":"clinicaltrials.gov:NCT00042536","description":"Erectile Dysfunction","metadata":null},{"id":"6b6523d9c8e54651bce49ba17ca2698f","type":"TRIAL","name":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","canonical_id":"clinicaltrials.gov:NCT00580047","description":"Renal Insufficiency","metadata":null},{"id":"f38db4ed4e1245079f1fd794a491143e","type":"TRIAL","name":"Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density","canonical_id":"clinicaltrials.gov:NCT00431444","description":"Osteoporosis","metadata":null},{"id":"81bfc26e64b74a79803acb3870dfefe0","type":"TRIAL","name":"Effects of Zolpidem CR\u00ae in Sleep and Heart Recovery in Cardiac Intensive Care Unit Patients","canonical_id":"clinicaltrials.gov:NCT01920334","description":"Acute Coronary Syndrome; Sleep Deprivation","metadata":null},{"id":"7249bd11929c4247a4c9b3437500017c","type":"TRIAL","name":"Effects of a Cocoa Shot on the Human Brain 2","canonical_id":"clinicaltrials.gov:NCT02080845","description":"Caffeine","metadata":null},{"id":"f1b24879358348ad805ca6b99c4dc4cd","type":"TRIAL","name":"Effects of a Peripherally Acting \u00b5-opioid Receptor Antagonist on Recurrent Acute Pancreatitis","canonical_id":"clinicaltrials.gov:NCT04966559","description":"Pancreatitis, Acute","metadata":null},{"id":"9bafcf4ea6fb4ca68e8124c9b45e43f9","type":"TRIAL","name":"Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana","canonical_id":"clinicaltrials.gov:NCT00403117","description":"Marijuana Use","metadata":null},{"id":"56f9083fb7be471f9bda3876d160307c","type":"TRIAL","name":"Effects of a Single Dose of Amisulpride on Functional Brain Changes","canonical_id":"clinicaltrials.gov:NCT05347199","description":"Major Depressive Disorder","metadata":null},{"id":"ed8bacf57c9c4fadb8fa86e40fc1ad74","type":"TRIAL","name":"Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause\"","canonical_id":"clinicaltrials.gov:NCT03740009","description":"Perimenopausal Disorder; Depression","metadata":null},{"id":"e8ad2b254e6c4df7ab920459cf3ab049","type":"TRIAL","name":"Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress","canonical_id":"clinicaltrials.gov:NCT02432339","description":"Psychological Stress; Hypertension, Renal","metadata":null},{"id":"24cb438f8c0b4dedb5718946a6261621","type":"TRIAL","name":"Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome","canonical_id":"clinicaltrials.gov:NCT00309257","description":"Alport Syndrome","metadata":null},{"id":"6b25180ad1b94f1e9d562f5ebbf70977","type":"TRIAL","name":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","canonical_id":"clinicaltrials.gov:NCT04183868","description":"Type 2 Diabetes; Cardiovascular Risk Factor","metadata":null},{"id":"1b45f2220df6487b991e8119e9f31fd4","type":"TRIAL","name":"Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.","canonical_id":"clinicaltrials.gov:NCT03491696","description":"Depressive Disorder; Hormone Disturbance","metadata":null},{"id":"a726ff6b9e804e9d8a24a3b5ff05ad64","type":"TRIAL","name":"Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT00303459","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"bceb63e272ee4a46bdc6f6488e7cc119","type":"TRIAL","name":"Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus","canonical_id":"clinicaltrials.gov:NCT01215708","description":"Renal Calculi","metadata":null},{"id":"fbeb894423014959b9ccedfa1198e2a7","type":"TRIAL","name":"Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients","canonical_id":"clinicaltrials.gov:NCT01752543","description":"Heart Failure","metadata":null},{"id":"0762f5eab09c4e3998ce3201c339410e","type":"TRIAL","name":"Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study","canonical_id":"clinicaltrials.gov:NCT02601989","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"b58d067bbea1456d8b106ea57349de1d","type":"TRIAL","name":"Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients","canonical_id":"clinicaltrials.gov:NCT03784222","description":"First Episode Schizophrenia; Social Function; Cognition Function; Blonanserin","metadata":null},{"id":"5921004bc34b4363a9a8ef452bb4b4f5","type":"TRIAL","name":"Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p","canonical_id":"clinicaltrials.gov:NCT05850117","description":"Helicobacter Pylori Eradication","metadata":null},{"id":"39947b37abb34423a35ea2c9dc8f16a6","type":"TRIAL","name":"Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia","canonical_id":"clinicaltrials.gov:NCT02962401","description":"Waldenstrom Macroglobulinemia","metadata":null},{"id":"af189e48368d4d05830705b4bd891ab7","type":"TRIAL","name":"Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT04064411","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"121d8e820d0940948dc4387aa2280151","type":"TRIAL","name":"Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)","canonical_id":"clinicaltrials.gov:NCT00963573","description":"Rhinitis","metadata":null},{"id":"06940e50ddb54008ad521894756efe1a","type":"TRIAL","name":"Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03989349","description":"Moderate-to-Severe Atopic Dermatitis","metadata":null},{"id":"4834b63cdf184ba282e1340d02e955a4","type":"TRIAL","name":"Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension","canonical_id":"clinicaltrials.gov:NCT00350168","description":"Hypertension","metadata":null},{"id":"f49dcfd26c1f484d841266575929bc8a","type":"TRIAL","name":"Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00085891","description":"Schizophrenia","metadata":null},{"id":"fc79c95e015549f296f8c4c8f1cd05ec","type":"TRIAL","name":"Efficacy & Safety of Symbicort\u00ae TURBUHALER\u00ae 160/4.5 \u00b5g Twice Daily & Pulmicort\u00ae TURBUHALER\u00ae 200 \u00b5g Twice Daily + Theolong\u00ae Tablet 200 mg Twice Daily in Japanese Asthmatic Patients","canonical_id":"clinicaltrials.gov:NCT00252785","description":"Asthma","metadata":null},{"id":"ea963a2e3bd744f3bb4b5a1275eaba84","type":"TRIAL","name":"Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis","canonical_id":"clinicaltrials.gov:NCT00146627","description":"Trypanosomiasis, African","metadata":null},{"id":"17df2cef3ff744a0ae2ac608aae33ca6","type":"TRIAL","name":"Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.","canonical_id":"clinicaltrials.gov:NCT00858208","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"637f967fe7d8410a8f2857fb775492fb","type":"TRIAL","name":"Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic","canonical_id":"clinicaltrials.gov:NCT00553605","description":"Pain","metadata":null},{"id":"e8ff270a35164fe894adbbb6b85a7aee","type":"TRIAL","name":"Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)","canonical_id":"clinicaltrials.gov:NCT01387425","description":"Smoking Cessation; Diabetes","metadata":null},{"id":"6ddabd7be7364b6aae2db5655e81f1a2","type":"TRIAL","name":"Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT00141141","description":"Hypercholesterolemia","metadata":null},{"id":"38353530c9e14569b34053fb05f5900c","type":"TRIAL","name":"Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)","canonical_id":"clinicaltrials.gov:NCT04275180","description":"Acute Progressive Ischemic Stroke","metadata":null},{"id":"d032c17e43cb423fb29c80893170519d","type":"TRIAL","name":"Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT07052136","description":"Status Epilepticus","metadata":null},{"id":"dd1b5036b6b04ff68efa77d5d8a680b2","type":"TRIAL","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","canonical_id":"clinicaltrials.gov:NCT04655976","description":"Lung Cancer, Non-Small Cell","metadata":null},{"id":"774a78f2298048709eac31feab7463d2","type":"TRIAL","name":"Efficacy Comparison of Xalatan and Azopt on POAG and OH","canonical_id":"clinicaltrials.gov:NCT01084902","description":"Ocular Hypertension","metadata":null},{"id":"78691f0192d9496d9851c7b5dc0ab2b4","type":"TRIAL","name":"Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures","canonical_id":"clinicaltrials.gov:NCT02088957","description":"Nonconvulsive Electrographic Seizures","metadata":null},{"id":"0ac5cd8bc0e3419da3d8b923de260ba1","type":"TRIAL","name":"Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05079360","description":"Metastatic Breast Cancer","metadata":null},{"id":"1336fc4725e64dd9a6993762e6393733","type":"TRIAL","name":"Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)","canonical_id":"clinicaltrials.gov:NCT00426751","description":"Infarction, Myocardial","metadata":null},{"id":"2f11071687c44586ba30e11c2803651a","type":"TRIAL","name":"Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","canonical_id":"clinicaltrials.gov:NCT06260059","description":"Adult Congenital Heart Disease; Heart Failure","metadata":null},{"id":"9676eedeafb74b03bfe4207ab93aa1a1","type":"TRIAL","name":"Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT00418886","description":"Non Small Cell Lung Cancer; Lung Cancer","metadata":null},{"id":"d4097ec1e00741658cda4257a39cf3cd","type":"TRIAL","name":"Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00654706","description":"Schizophrenia; Cognition","metadata":null},{"id":"9c3223fd49874e06887329f98727f286","type":"TRIAL","name":"Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00159809","description":"Impotence; Depression","metadata":null},{"id":"e3c9bdf8310c4a898e1bd904b9654530","type":"TRIAL","name":"Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy","canonical_id":"clinicaltrials.gov:NCT00522015","description":"Progressive Supranuclear Palsy; Dementia","metadata":null},{"id":"37457d83236346abb5265c9ff9f5519a","type":"TRIAL","name":"Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type","canonical_id":"clinicaltrials.gov:NCT02186366","description":"Anxiety Disorders","metadata":null},{"id":"0b0efaf3cbd14bf2afe084b499034770","type":"TRIAL","name":"Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT01808313","description":"Vascular Disease","metadata":null},{"id":"05cf246bae924c6492f546d1ac98cfec","type":"TRIAL","name":"Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT01200472","description":"Erosive Osteoarthritis of the Hand","metadata":null},{"id":"67ff0c6237ba4ba9895981ef719bdb92","type":"TRIAL","name":"Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01743651","description":"Spasticity; Multiple Sclerosis","metadata":null},{"id":"633bdde6331548f484201dc2f00231ea","type":"TRIAL","name":"Efficacy Study of Canakinumab to Treat Urticaria","canonical_id":"clinicaltrials.gov:NCT01635127","description":"Chronic Idiopathic Urticaria","metadata":null},{"id":"539c37a0d1964ee09a576f3ed1f00fea","type":"TRIAL","name":"Efficacy Study of Cardizem in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT01645826","description":"Idiopathic Pulmonary Arterial Hypertension; Primary Pulmonary Hypertension; Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension","metadata":null},{"id":"bf0cd90a022a49a1a69322a0b0b3eb9c","type":"TRIAL","name":"Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT00938522","description":"Angioplasty, Transluminal, Percutaneous Coronary","metadata":null},{"id":"80d04a6668264ae3826fe3895e42d709","type":"TRIAL","name":"Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease","canonical_id":"clinicaltrials.gov:NCT01932203","description":"Cerebral Small Vessel Disease","metadata":null},{"id":"4ce74900105e4ea18aeb607439974bfc","type":"TRIAL","name":"Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00976092","description":"Myocardial Infarction","metadata":null},{"id":"ae05d1abdbdd498bbbf345d28d32184e","type":"TRIAL","name":"Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00817531","description":"Breast Cancer","metadata":null},{"id":"423f2af5fbab4a94917f1fdd60c7064c","type":"TRIAL","name":"Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)","canonical_id":"clinicaltrials.gov:NCT00419549","description":"ERCP; Pancreatitis","metadata":null},{"id":"0063bc4599114498b7e6c56fc379dd0c","type":"TRIAL","name":"Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis","canonical_id":"clinicaltrials.gov:NCT02024334","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"223883436b944379b365bfc02ea2b40b","type":"TRIAL","name":"Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT01093963","description":"Bipolar Depression","metadata":null},{"id":"cb42032858a84bff8ef88dd75e85cfdb","type":"TRIAL","name":"Efficacy Study of Nebulized Morphine and Intravenous Morphine in Post Traumatic Pain","canonical_id":"clinicaltrials.gov:NCT01123551","description":"Post Traumatic Pain","metadata":null},{"id":"1a2792960c0747adb24bbb8699ad8405","type":"TRIAL","name":"Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)","canonical_id":"clinicaltrials.gov:NCT02360956","description":"Coronary Atherosclerosis","metadata":null},{"id":"ae8ae9004b1d451096464c41a69477fa","type":"TRIAL","name":"Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye","canonical_id":"clinicaltrials.gov:NCT02697630","description":"Metastatic Uveal Melanoma","metadata":null},{"id":"addf1fefbd87423b9fee19df897e6dcb","type":"TRIAL","name":"Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia","canonical_id":"clinicaltrials.gov:NCT03804268","description":"Presbyopia","metadata":null},{"id":"c0f0552c05f14c25ac54c2c3f9d25084","type":"TRIAL","name":"Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00225277","description":"Diabetes Mellitus","metadata":null},{"id":"4427a0b1345441cea0ed66ba21a82ced","type":"TRIAL","name":"Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.","canonical_id":"clinicaltrials.gov:NCT00770497","description":"Inflammation; Hypertension","metadata":null},{"id":"e3c86fa26853491fbfd01c991dc3ddca","type":"TRIAL","name":"Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT01246362","description":"Knee Osteoarthritis","metadata":null},{"id":"09efedae13a94b8c8b38070b3ddb48b4","type":"TRIAL","name":"Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT01607320","description":"Polycystic Ovarian Syndrome","metadata":null},{"id":"3769c7294d884b77983f2c58218beef5","type":"TRIAL","name":"Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis","canonical_id":"clinicaltrials.gov:NCT00598533","description":"Coronary Heart Disease","metadata":null},{"id":"d39d84df63f6451bb62ab8743b0df3ea","type":"TRIAL","name":"Efficacy Study of SYN006 HFA MDI in Asthma Patients","canonical_id":"clinicaltrials.gov:NCT02162784","description":"Asthma","metadata":null},{"id":"208710684d704b5fa0ee2c6d68735b7e","type":"TRIAL","name":"Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment","canonical_id":"clinicaltrials.gov:NCT00191555","description":"Schizophrenia","metadata":null},{"id":"3b263dec59f94678ad2587356408733d","type":"TRIAL","name":"Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)","canonical_id":"clinicaltrials.gov:NCT01630967","description":"Prostate Neoplasm","metadata":null},{"id":"7df16d00d2fb40fa91a735dc2250c3ca","type":"TRIAL","name":"Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis","canonical_id":"clinicaltrials.gov:NCT00913315","description":"Prostatitis","metadata":null},{"id":"e5935522890541559297bf57413a947e","type":"TRIAL","name":"Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00570752","description":"Vascular Diseases","metadata":null},{"id":"5940c884481f4d1c84311d43e7722c36","type":"TRIAL","name":"Efficacy Study of \u03949-THC to Treat Chronic Abdominal Pain","canonical_id":"clinicaltrials.gov:NCT01318369","description":"Cannabinoid; Tetrahydrocannabinol; Chronic Pancreatitis; Abdominal Pain","metadata":null},{"id":"a2f9396c67ed4ae1a07686bfbdbe5ad9","type":"TRIAL","name":"Efficacy Study on Cognitive Functions in Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT00761670","description":"Schizophrenia","metadata":null},{"id":"6c9d497ffba2489592d0cbbdb7114b0d","type":"TRIAL","name":"Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty","canonical_id":"clinicaltrials.gov:NCT00354406","description":"Myocardial Infarction","metadata":null},{"id":"770334523f06477a900902002e835e08","type":"TRIAL","name":"Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00882687","description":"Allergic Conjunctivitis","metadata":null},{"id":"8684055f36584068813c521346328246","type":"TRIAL","name":"Efficacy Trial of CDB 2914 for Emergency Contraception","canonical_id":"clinicaltrials.gov:NCT00271583","description":"Emergency Contraception","metadata":null},{"id":"0b52d7cd23ed429b9b1d90975c0afbdb","type":"TRIAL","name":"Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients","canonical_id":"clinicaltrials.gov:NCT03640273","description":"Allergic Rhinitis; Adverse Drug Event; Quality of Life","metadata":null},{"id":"ddba5a4e85d845acb058e12aed289113","type":"TRIAL","name":"Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05296603","description":"Small Cell Lung Cancer","metadata":null},{"id":"394e9329c5734c05a0b4d24f58c6e387","type":"TRIAL","name":"Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control","canonical_id":"clinicaltrials.gov:NCT03386344","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"dddcf77e8095453d8a23cc6a1eac6cdc","type":"TRIAL","name":"Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy","canonical_id":"clinicaltrials.gov:NCT07461441","description":"Polypoidal Choroidal Vasculopathy (PCV); Age Related Macular Degeneration","metadata":null},{"id":"b094a666ca464f5c95720994dd7baa2c","type":"TRIAL","name":"Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT05262686","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"7d91d784fa144158a815b90d5c6e7546","type":"TRIAL","name":"Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive Angina","canonical_id":"clinicaltrials.gov:NCT07392281","description":"Non-Coronary Obstructive Angina","metadata":null},{"id":"e98227f73c6b445c9d5d0bedd3ce799c","type":"TRIAL","name":"Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence","canonical_id":"clinicaltrials.gov:NCT00727649","description":"Fecal Incontinence","metadata":null},{"id":"7997818026c8464c9dadc4fa59c925ca","type":"TRIAL","name":"Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression","canonical_id":"clinicaltrials.gov:NCT02650544","description":"Carcinoma, Non-Small-Cell Lung; Depression","metadata":null},{"id":"baeb1427f618410db656949d2d63a374","type":"TRIAL","name":"Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC","canonical_id":"clinicaltrials.gov:NCT07093762","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"54eb6a5b61c94a88846e96a97b2b5249","type":"TRIAL","name":"Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT06274996","description":"Inflammatory Bowel Diseases","metadata":null},{"id":"184c5c389fa54dd0a07f4981f19eb99d","type":"TRIAL","name":"Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy","canonical_id":"clinicaltrials.gov:NCT04309708","description":"Subarachnoid Hemorrhage","metadata":null},{"id":"2f44b61b009c4b1baef37ab8bf8f78b5","type":"TRIAL","name":"Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy","canonical_id":"clinicaltrials.gov:NCT02086487","description":"Myeloid Leukemia, Chronic","metadata":null},{"id":"8aa0d932625f44f4bd9ee8d57fab6061","type":"TRIAL","name":"Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA","canonical_id":"clinicaltrials.gov:NCT01024192","description":"Sleep Disorders","metadata":null},{"id":"a9f3a65db3a747399385c23713d2e93d","type":"TRIAL","name":"Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT03154385","description":"Immune Thrombocytopenia","metadata":null},{"id":"d544c84b02094133bcb428539481cf7a","type":"TRIAL","name":"Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin","canonical_id":"clinicaltrials.gov:NCT01703637","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"383e56a87fbc430ea3754c210b1067ab","type":"TRIAL","name":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","canonical_id":"clinicaltrials.gov:NCT00535366","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"563c26dff3bd4de28d261bce3246df37","type":"TRIAL","name":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00281567","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"7fa71f2be1f64732883cffbfa2af1fae","type":"TRIAL","name":"Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).","canonical_id":"clinicaltrials.gov:NCT02141113","description":"Adult Attention-Deficit Hyperactivity Disorder","metadata":null},{"id":"8f4d028fd71443509c81cbc59dc3156e","type":"TRIAL","name":"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan","canonical_id":"clinicaltrials.gov:NCT01812707","description":"Hypercholesterolemia","metadata":null},{"id":"7d4d2f135f0544a0a0f6fa224659d135","type":"TRIAL","name":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","canonical_id":"clinicaltrials.gov:NCT02107898","description":"Hypercholesterolemia","metadata":null},{"id":"f5106dcce04e4399b05cdda97c460dbd","type":"TRIAL","name":"Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris","canonical_id":"clinicaltrials.gov:NCT06654817","description":"Pemphigus; Pemphigus Vulgaris (PV)","metadata":null},{"id":"ba806fb3966145b5b3b7ddd055f40e65","type":"TRIAL","name":"Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.","canonical_id":"clinicaltrials.gov:NCT00035451","description":"Atrial Fibrillation","metadata":null},{"id":"0054ccf7a67846a6bddba3fa2cedc49b","type":"TRIAL","name":"Efficacy and Safety Evaluation of Neobianacid\u00ae in GERD and EPS","canonical_id":"clinicaltrials.gov:NCT03238534","description":"GERD; EPS","metadata":null},{"id":"215d5632fc854c8b8d67cf7309559404","type":"TRIAL","name":"Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT04202601","description":"Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"6fa88b9fb47b49b48825b9ca0b228ba9","type":"TRIAL","name":"Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","canonical_id":"clinicaltrials.gov:NCT04390594","description":"COVID-19","metadata":null},{"id":"50a31f8afac74ec8a91ee840dda96c01","type":"TRIAL","name":"Efficacy and Safety In Poorly Controlled Type 2 Diabetics","canonical_id":"clinicaltrials.gov:NCT00044460","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"c958ccf485da42689e4762e9e603b5eb","type":"TRIAL","name":"Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT04193306","description":"Cardiac Allograft Vasculopathy","metadata":null},{"id":"3389fb4c7f424333b4a8a434de398b00","type":"TRIAL","name":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT06141473","description":"Multiple Sclerosis","metadata":null},{"id":"6ea582b30d03499d82f3f795d5b87e87","type":"TRIAL","name":"Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)","canonical_id":"clinicaltrials.gov:NCT00621478","description":"Status Epilepticus","metadata":null},{"id":"11fcb33e59834d029bde4c5870b46dbb","type":"TRIAL","name":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel\u00ae 120 mg","canonical_id":"clinicaltrials.gov:NCT02651987","description":"Pancreatic Tumours; Midgut Neuroendocrine Tumours","metadata":null},{"id":"f72870b4918544d8afe710f04267ce74","type":"TRIAL","name":"Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01137526","description":"Alzheimer's Disease","metadata":null},{"id":"ede0e7dfec184d4bb2fbea602bc96ed6","type":"TRIAL","name":"Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT01468233","description":"Hidradenitis Suppurativa (HS)","metadata":null},{"id":"9c736bec6e26444cbc5a6c020258b7d3","type":"TRIAL","name":"Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT00286429","description":"Diabetes Mellitus","metadata":null},{"id":"76ead7b0d99740aaab4def20a4d668c2","type":"TRIAL","name":"Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT05437224","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"4cf7d018e7884b81b3cf50c6a84d9da4","type":"TRIAL","name":"Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism","canonical_id":"clinicaltrials.gov:NCT00633893","description":"Venous Thrombosis","metadata":null},{"id":"781baf7f6d7c4498af64edd214a8610d","type":"TRIAL","name":"Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03701763","description":"Psoriasis","metadata":null},{"id":"0c01293682b24e62b4adc225e6bb2340","type":"TRIAL","name":"Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02087943","description":"Dermatitis, Atopic Dermatitis","metadata":null},{"id":"6e96b4e0d08c4a47b1961d891ab5e739","type":"TRIAL","name":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT01172938","description":"Psoriatic Arthritis","metadata":null},{"id":"3ae7db5fc3c145ea9f9417bf69d3a529","type":"TRIAL","name":"Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)","canonical_id":"clinicaltrials.gov:NCT01307423","description":"Psoriatic Arthritis","metadata":null},{"id":"b3a9bb01c4a44fc1bd71ab188fed43bb","type":"TRIAL","name":"Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT00198588","description":"Heparin-Induced Thrombocytopenia","metadata":null},{"id":"db888acef8554081b95e26206286a174","type":"TRIAL","name":"Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia","canonical_id":"clinicaltrials.gov:NCT00944970","description":"Coronary Artery Disease","metadata":null},{"id":"dc35646a5a2943fba1f33787447275e7","type":"TRIAL","name":"Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","canonical_id":"clinicaltrials.gov:NCT01297517","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"f1eb893e75dc41399e8fe9754c540a5a","type":"TRIAL","name":"Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase","canonical_id":"clinicaltrials.gov:NCT00991146","description":"Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory Disease","metadata":null},{"id":"74450e0141da4acd9935a10cb15fa8be","type":"TRIAL","name":"Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy","canonical_id":"clinicaltrials.gov:NCT00975221","description":"Hyperparathyroidism, Primary; Hypercalcemia","metadata":null},{"id":"dd81fe384cfd411499e8f83fab662c32","type":"TRIAL","name":"Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00216281","description":"Schizophrenia","metadata":null},{"id":"6ac0777097ec435087d253c825acfe50","type":"TRIAL","name":"Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","canonical_id":"clinicaltrials.gov:NCT07343791","description":"DC-CIK Treatment; Regorafenib; Colorectal Cancer; Immune Combination Therapy; Iparomlimab and Tuvonralimab Injection","metadata":null},{"id":"e9538dd552514fc6a57e1e794e1abfa6","type":"TRIAL","name":"Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00895297","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"01873ff4f78e42db9d6c0866550c39be","type":"TRIAL","name":"Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)","canonical_id":"clinicaltrials.gov:NCT02320396","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"204addbaff3943a5bc1dae6e653ea3e2","type":"TRIAL","name":"Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression","canonical_id":"clinicaltrials.gov:NCT01974934","description":"Vascular Depression","metadata":null},{"id":"f23d9bbf046d4b43b0f390c609930cd4","type":"TRIAL","name":"Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter Trial","canonical_id":"clinicaltrials.gov:NCT07605130","description":"Intracranial Arteriosclerosis; Cognitive Impairment","metadata":null},{"id":"bf45090d8a42401db3f2bfcce1cea209","type":"TRIAL","name":"Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis","canonical_id":"clinicaltrials.gov:NCT00797225","description":"Endometriosis","metadata":null},{"id":"9750c44f5a4447b5bbe0b65d8af4e5ed","type":"TRIAL","name":"Efficacy and Safety Study of Elagolix in Women With Endometriosis","canonical_id":"clinicaltrials.gov:NCT00973973","description":"Endometriosis, Pain","metadata":null},{"id":"32ad9c3b23414016a1fb7ebbc62301c6","type":"TRIAL","name":"Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures","canonical_id":"clinicaltrials.gov:NCT00708071","description":"Facial Rhytidectomy (Face-lift)","metadata":null},{"id":"ca1814ab9be84ae992b188f7f43fbd19","type":"TRIAL","name":"Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone","canonical_id":"clinicaltrials.gov:NCT00171288","description":"Dyslipidemia","metadata":null},{"id":"56f70e96832f45bcb4ff064596cece59","type":"TRIAL","name":"Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","canonical_id":"clinicaltrials.gov:NCT04369469","description":"COVID-19 Severe Pneumonia; Acute Lung Injury; Acute Respiratory Distress Syndrome; Pneumonia, Viral","metadata":null},{"id":"0f4861d584fb4789811c0e2af6895474","type":"TRIAL","name":"Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT01282424","description":"Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"2dc899766de3436aa99c7c37cffa1dde","type":"TRIAL","name":"Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT00303056","description":"Joint Disease","metadata":null},{"id":"9a981b09e0f24482a6af457e1568bff2","type":"TRIAL","name":"Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations","canonical_id":"clinicaltrials.gov:NCT05607641","description":"Postsurgical Pain","metadata":null},{"id":"6d2c09b5cc024704a53cae80a08f35eb","type":"TRIAL","name":"Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy","canonical_id":"clinicaltrials.gov:NCT01215097","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"12a8afd2194f48f885e035c7926071f4","type":"TRIAL","name":"Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence","canonical_id":"clinicaltrials.gov:NCT02340481","description":"Diarrhea","metadata":null},{"id":"1b84c79d9ad447a0955f72f7d3e4ccad","type":"TRIAL","name":"Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT00212342","description":"Dysmenorrhea","metadata":null},{"id":"2cd9270e81174547ba14e0b5de958487","type":"TRIAL","name":"Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT00154219","description":"Osteoarthritis, Hip","metadata":null},{"id":"705239b26f894a669ed85a9def131ccd","type":"TRIAL","name":"Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer","canonical_id":"clinicaltrials.gov:NCT06385548","description":"Endometrial Cancer","metadata":null},{"id":"c266ec31e6014824835a05e4d9889000","type":"TRIAL","name":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00974090","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"8cc06e2d2dda4a0caa5928e6edb696f4","type":"TRIAL","name":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01026194","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f147a0007d4540339d3940078fc0e9e9","type":"TRIAL","name":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00628212","description":"Type 2 Diabetes","metadata":null},{"id":"6e7c3a28ddd8473d96fe62db0886db2c","type":"TRIAL","name":"Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome","canonical_id":"clinicaltrials.gov:NCT03995108","description":"WHIM Syndrome","metadata":null},{"id":"2ef7ce3bfc2146709d4778e27a650900","type":"TRIAL","name":"Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT02183025","description":"Dysmenorrhea","metadata":null},{"id":"9c87f68ffff24b6eb9b1360237efa856","type":"TRIAL","name":"Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03055195","description":"Dermatitis, Atopic","metadata":null},{"id":"999bc308f9194c12b03e042255dc9df3","type":"TRIAL","name":"Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA","canonical_id":"clinicaltrials.gov:NCT05855083","description":"Thrombotic Microangiopathies; Hematopoietic Stem Cell Transplantation","metadata":null},{"id":"c70e7ac8d65d47559509f7f743161070","type":"TRIAL","name":"Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults","canonical_id":"clinicaltrials.gov:NCT00344942","description":"Rhinitis","metadata":null},{"id":"5ec1417c6d9c4874a7bee1ff740d3f9c","type":"TRIAL","name":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT04620135","description":"Primary Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"8d7200fbffc34e63925b85f62bede7af","type":"TRIAL","name":"Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes","canonical_id":"clinicaltrials.gov:NCT01220622","description":"Stroke; Mild Cognitive Impairment","metadata":null},{"id":"3e8c9d5b7dbd42a1aa818e4f84182340","type":"TRIAL","name":"Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","canonical_id":"clinicaltrials.gov:NCT05327114","description":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","metadata":null},{"id":"2e2bed10d36a4cc68e973a71e8377467","type":"TRIAL","name":"Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation","canonical_id":"clinicaltrials.gov:NCT03925350","description":"Metastatic Melanoma","metadata":null},{"id":"a96f49540b084d45ad8e63ed1f260d86","type":"TRIAL","name":"Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.","canonical_id":"clinicaltrials.gov:NCT01924533","description":"Gastric Cancer","metadata":null},{"id":"9bce518af1da4f60a8b8fb9a902ae09f","type":"TRIAL","name":"Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)","canonical_id":"clinicaltrials.gov:NCT00561821","description":"Insomnia; Sleep Initiation and Maintenance Disorders; Mental Disorders; Dyssomnias; Sleep Disorders","metadata":null},{"id":"c40aabc8fa66478e99da2be89b3fa6cd","type":"TRIAL","name":"Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients","canonical_id":"clinicaltrials.gov:NCT01628393","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"cf52651a10294704b6c9929fd202a233","type":"TRIAL","name":"Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02047734","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"7b88c35b4adf49e5bb1d286402e7218d","type":"TRIAL","name":"Efficacy and Safety Study of Ozanimod in Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT01647516","description":"Ulcerative Colitis","metadata":null},{"id":"5d02b4038f624d7cb3c911e9ab5983d6","type":"TRIAL","name":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na\u00efve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)","canonical_id":"clinicaltrials.gov:NCT03829332","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"89426a0cffa64b348fcb9d6af1d2fab3","type":"TRIAL","name":"Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT01726816","description":"Diabetic Nephropathy","metadata":null},{"id":"589e750615a2479e9201430b88e45745","type":"TRIAL","name":"Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)","canonical_id":"clinicaltrials.gov:NCT01170429","description":"Cough Variant Asthma","metadata":null},{"id":"bfd93d3a795a48cc8a86f5e92efd0774","type":"TRIAL","name":"Efficacy and Safety Study of QVA149 in COPD Patients","canonical_id":"clinicaltrials.gov:NCT02487446","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"fbb25b8a38f148be9fc1bf1e7c6297c4","type":"TRIAL","name":"Efficacy and Safety Study of RAGWITEK\u2122 (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","canonical_id":"clinicaltrials.gov:NCT02478398","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"e604f4341dec4e7a855388f06f09f540","type":"TRIAL","name":"Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD","canonical_id":"clinicaltrials.gov:NCT05346354","description":"Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"9c3715896b0840e4adb40abac7d29050","type":"TRIAL","name":"Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years","canonical_id":"clinicaltrials.gov:NCT00538434","description":"Eosinophilic Esophagitis","metadata":null},{"id":"1fbd1ac61be94da7b51bdddf8408a09f","type":"TRIAL","name":"Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma","canonical_id":"clinicaltrials.gov:NCT00587288","description":"Asthma","metadata":null},{"id":"ddbb0ef7d9024c82b0b05058225d20a0","type":"TRIAL","name":"Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)","canonical_id":"clinicaltrials.gov:NCT05399485","description":"Migraine","metadata":null},{"id":"6bf78bbc62af46469cbd23b71933a850","type":"TRIAL","name":"Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)","canonical_id":"clinicaltrials.gov:NCT05399459","description":"Migraine","metadata":null},{"id":"6e44f4c76aea425da077bc2fd3dfcc7a","type":"TRIAL","name":"Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects","canonical_id":"clinicaltrials.gov:NCT05156398","description":"Migraine","metadata":null},{"id":"d3e274ac1202429ab08567ca0bae317e","type":"TRIAL","name":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","canonical_id":"clinicaltrials.gov:NCT05217927","description":"Migraine","metadata":null},{"id":"5e61cc3d48804807bf85739c274cc2c9","type":"TRIAL","name":"Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01675297","description":"Osteoporosis","metadata":null},{"id":"adeb57af2f924adeaae94e11f13ecae1","type":"TRIAL","name":"Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia","canonical_id":"clinicaltrials.gov:NCT06898983","description":"Cancer Treatment-induced Thrombocytopenia (CTIT)","metadata":null},{"id":"c289c5f724d449b099c8366b777aeaa1","type":"TRIAL","name":"Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)","canonical_id":"clinicaltrials.gov:NCT03189433","description":"Drug Toxicity Psychotropic Agents Psychostimulants","metadata":null},{"id":"35331eafae2f4f5282bccfab17556fd3","type":"TRIAL","name":"Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)","canonical_id":"clinicaltrials.gov:NCT01700192","description":"Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal","metadata":null},{"id":"9d2222c1fc8b49ed88e0e4adf7c01529","type":"TRIAL","name":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01436162","description":"Major Depressive Disorder","metadata":null},{"id":"7b0d98ef3d094ac78f2efd33b0fee6b9","type":"TRIAL","name":"Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00763347","description":"Diabetes Mellitus","metadata":null},{"id":"86714f9f3ad54c48877161d49f03e72a","type":"TRIAL","name":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","canonical_id":"clinicaltrials.gov:NCT02028884","description":"Neuromyelitis Optica (NMO); NMO Spectrum Disorder (NMOSD)","metadata":null},{"id":"c86273678d3648c0a95843e5b0a0ed4f","type":"TRIAL","name":"Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)","canonical_id":"clinicaltrials.gov:NCT02073279","description":"Neuromyelitis Optica (NMO); NMO Spectrum Disorder (NMOSD)","metadata":null},{"id":"091e59c57f5746f291b480dc1f746457","type":"TRIAL","name":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00885378","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"25ac4eaed0de4d36bf83beaa676d935d","type":"TRIAL","name":"Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)","canonical_id":"clinicaltrials.gov:NCT00890279","description":"Kidney, Polycystic, Autosomal Dominant","metadata":null},{"id":"33c27102033444e080f466f8d9ed7036","type":"TRIAL","name":"Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population","canonical_id":"clinicaltrials.gov:NCT00677391","description":"Obesity","metadata":null},{"id":"72d6727fed714754850347a00689bdf6","type":"TRIAL","name":"Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD","canonical_id":"clinicaltrials.gov:NCT00421122","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"c4b11189fa434af8808c109d77ef3c5a","type":"TRIAL","name":"Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02081599","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f64be3cc3f664480a3d8e51ae5cb712a","type":"TRIAL","name":"Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting","canonical_id":"clinicaltrials.gov:NCT01388920","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"39b4a04654e84527a239e6b80f7efe37","type":"TRIAL","name":"Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis","canonical_id":"clinicaltrials.gov:NCT03897075","description":"Chronic Plaque Psoriasis; Moderate to Severe Nail Psoriasis","metadata":null},{"id":"937332c7106e411aa504e879029c61d0","type":"TRIAL","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03485209","description":"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer; Carcinoma, Squamous Cell of Head and Neck","metadata":null},{"id":"e8bb07943e5a470b864291da23673995","type":"TRIAL","name":"Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema","canonical_id":"clinicaltrials.gov:NCT01651156","description":"Cardiac Edema","metadata":null},{"id":"3a85d241baac433fbc3a7df8528369fc","type":"TRIAL","name":"Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","canonical_id":"clinicaltrials.gov:NCT07179380","description":"Pulmonary Hypertension; Interstitial Lung Disease","metadata":null},{"id":"bc57ee5fdc65446dbe6d63e6b2ed9d8d","type":"TRIAL","name":"Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis","canonical_id":"clinicaltrials.gov:NCT01988103","description":"Psoriasis; Psoriatic Arthritis; Psoriasis Arthropatica","metadata":null},{"id":"59c7ab4e484248689b8ad263a4a4b050","type":"TRIAL","name":"Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo","canonical_id":"clinicaltrials.gov:NCT01049360","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"83b23f179a394919888ef32cc4f0e814","type":"TRIAL","name":"Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT00757692","description":"Prostate Cancer","metadata":null},{"id":"925dc09aa21d41e8812047b49dd1f66c","type":"TRIAL","name":"Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly","canonical_id":"clinicaltrials.gov:NCT00234572","description":"Acromegaly","metadata":null},{"id":"3144232970284d179f5ab7df37d5acee","type":"TRIAL","name":"Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01163266","description":"Depressive Disorder, Major","metadata":null},{"id":"53e1d490cd064a4fbb489ca9131f0fc4","type":"TRIAL","name":"Efficacy and Safety Study of XP12B in Women With Menorrhagia","canonical_id":"clinicaltrials.gov:NCT00386308","description":"Menorrhagia; Heavy Menstrual Bleeding","metadata":null},{"id":"69e5cbc0e9d145bf883f37ddd8f7d27d","type":"TRIAL","name":"Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT00705003","description":"Major Depressive Disorder","metadata":null},{"id":"cf545e7f4abf4532ad1d37a6d8415806","type":"TRIAL","name":"Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04730999","description":"Small Cell Lung Cancer","metadata":null},{"id":"4f1425489cd0402d83caf35f0faa0f91","type":"TRIAL","name":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","canonical_id":"clinicaltrials.gov:NCT03651128","description":"Multiple Myeloma","metadata":null},{"id":"7cbca412733e47a6adf6e5c8822efd38","type":"TRIAL","name":"Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.","canonical_id":"clinicaltrials.gov:NCT05110898","description":"Hypertension; Hypertension,Essential","metadata":null},{"id":"174a5d71eb034984889ebf9c4fe965fb","type":"TRIAL","name":"Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT02706678","description":"Renal Transplant Recipients","metadata":null},{"id":"b753e0ed6bff4005a149418f95ca516c","type":"TRIAL","name":"Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT02002403","description":"Diabetic Macular Edema","metadata":null},{"id":"0ecccf19f44642cba4c1dcb490ea1f04","type":"TRIAL","name":"Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure","canonical_id":"clinicaltrials.gov:NCT03772041","description":"Congestive Heart Failure","metadata":null},{"id":"f9cececc607f40b08dd25c70aad0576d","type":"TRIAL","name":"Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults","canonical_id":"clinicaltrials.gov:NCT03732638","description":"Migraine","metadata":null},{"id":"fd6e9f31095944ec8b8a2ef441383fab","type":"TRIAL","name":"Efficacy and Safety With Ziprasidone in First-episode Psychosis","canonical_id":"clinicaltrials.gov:NCT01157559","description":"First Episode Psychosis","metadata":null},{"id":"bc680b5cb1424472ae0b3b72ec9acfe0","type":"TRIAL","name":"Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study","canonical_id":"clinicaltrials.gov:NCT03545035","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"b096bba2d7364fd08cd475990b62f396","type":"TRIAL","name":"Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression","canonical_id":"clinicaltrials.gov:NCT07626892","description":"Myopia Progression; Atropine","metadata":null},{"id":"d04fd908bd464c7ab8f2673072f8c1f3","type":"TRIAL","name":"Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy\u00ae) in the Treatment of Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT02749656","description":"Scalp Psoriasis","metadata":null},{"id":"51953fa20bee428b8d44e6dce2e7e636","type":"TRIAL","name":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","canonical_id":"clinicaltrials.gov:NCT04991584","description":"Helicobacter Pylori Infection","metadata":null},{"id":"3ac1b6564cc74920b8e7ba40dd50d7c1","type":"TRIAL","name":"Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT02629861","description":"Migraine","metadata":null},{"id":"6c4148644e484dd08d1eba82774288be","type":"TRIAL","name":"Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT01316380","description":"Asthma","metadata":null},{"id":"8e3343372ea1415f856f2e61744dd661","type":"TRIAL","name":"Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03504852","description":"Moderate to Severe Chronic Plaque-type Psoriasis","metadata":null},{"id":"21903869d9e942d589189c67f298a207","type":"TRIAL","name":"Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma","canonical_id":"clinicaltrials.gov:NCT01122680","description":"Asthma","metadata":null},{"id":"4fcd69e57e3b4fa6b39ddcc29f8d7fcd","type":"TRIAL","name":"Efficacy and Safety of 400 \u03bcg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01636401","description":"COPD","metadata":null},{"id":"235692e53adc4591bcbcf01a0c8c8a68","type":"TRIAL","name":"Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis","canonical_id":"clinicaltrials.gov:NCT00537979","description":"Secondary Hyperparathyroidism; Dialysis","metadata":null},{"id":"519caec2780545ce92ee4cc22718282f","type":"TRIAL","name":"Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder","canonical_id":"clinicaltrials.gov:NCT02839200","description":"Insomnia Disorder","metadata":null},{"id":"5df034361e66457ba1f1871cd4c2ddac","type":"TRIAL","name":"Efficacy and Safety of ATL-962 in Obese Diabetics","canonical_id":"clinicaltrials.gov:NCT00156897","description":"Non-Insulin-Dependent Diabetes Mellitus; Obesity","metadata":null},{"id":"c8e9503236a04448914a57c79854540e","type":"TRIAL","name":"Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT05451615","description":"Abatacept; Treatment Compliance; Rheumatoid Arthritis","metadata":null},{"id":"f295d8d9d7224590a455f3a3f1558180","type":"TRIAL","name":"Efficacy and Safety of Abatacept in Patients With Primary Sj\u00f6gren's Syndrome","canonical_id":"clinicaltrials.gov:NCT02067910","description":"Sj\u00f6gren's Syndrome","metadata":null},{"id":"903c35719b8b4109ad26e78a9168a058","type":"TRIAL","name":"Efficacy and Safety of Aclidinium Bromide 400 \u00b5g BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01471171","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"d62632d933674353af10cc4c5676879e","type":"TRIAL","name":"Efficacy and Safety of Aclidinium Bromide 400 \u00b5g Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01462929","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"781522901357469fb12ae05b9ceaa873","type":"TRIAL","name":"Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","canonical_id":"clinicaltrials.gov:NCT01001494","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"4993bc22aff544659230d3b98c97614f","type":"TRIAL","name":"Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)","canonical_id":"clinicaltrials.gov:NCT00891462","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"1b4533d3b28b43e6bb6fa985773b99be","type":"TRIAL","name":"Efficacy and Safety of Actonel\u00ae After Denosumab Discontinuation in Postmenopausal Osteoporosis Women","canonical_id":"clinicaltrials.gov:NCT05630768","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"0a37c3f2d1554dfbb8b8f58a20a0c9ee","type":"TRIAL","name":"Efficacy and Safety of Adalimumab in Patients With Active Uveitis","canonical_id":"clinicaltrials.gov:NCT01138657","description":"Uveitis","metadata":null},{"id":"8f10bfa8d493481bbe20fde426388c9b","type":"TRIAL","name":"Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","canonical_id":"clinicaltrials.gov:NCT07093476","description":"T2DM; Diabete Type 2; DM","metadata":null},{"id":"c8169ef014a049d282896600fc138bdb","type":"TRIAL","name":"Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy","canonical_id":"clinicaltrials.gov:NCT00966576","description":"Glaucoma","metadata":null},{"id":"576881286a494d4fa0275f6e53cbc828","type":"TRIAL","name":"Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)","canonical_id":"clinicaltrials.gov:NCT02970292","description":"Schizophrenia","metadata":null},{"id":"a793f58390ef4724b143b5ec27e0a96a","type":"TRIAL","name":"Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan","canonical_id":"clinicaltrials.gov:NCT04288232","description":"Center-involved Diabetic Macular Edema","metadata":null},{"id":"6cf696f84aeb4b93ac58f2fa7e272884","type":"TRIAL","name":"Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female","canonical_id":"clinicaltrials.gov:NCT00679315","description":"Voiding Dysfunction","metadata":null},{"id":"54f90382f7e14f979e2dd73379b5d1a5","type":"TRIAL","name":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","canonical_id":"clinicaltrials.gov:NCT01644188","description":"Hypercholesterolemia","metadata":null},{"id":"ab2780aa47dd495ba217e22e763cbc77","type":"TRIAL","name":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","canonical_id":"clinicaltrials.gov:NCT01617655","description":"Hypercholesterolaemia","metadata":null},{"id":"aa7846439b5e438db69d38279465e137","type":"TRIAL","name":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","canonical_id":"clinicaltrials.gov:NCT01644175","description":"Hypercholesterolemia","metadata":null},{"id":"72717f1e04744e2bb0309dfc295054d2","type":"TRIAL","name":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","canonical_id":"clinicaltrials.gov:NCT02585778","description":"Hypercholesterolaemia","metadata":null},{"id":"b69d4512e6fb4f26a96d9ba9124c5cca","type":"TRIAL","name":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","canonical_id":"clinicaltrials.gov:NCT02642159","description":"Dyslipidemia","metadata":null},{"id":"8f5941223367448aa1823ec6a0e563a5","type":"TRIAL","name":"Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal","canonical_id":"clinicaltrials.gov:NCT00865020","description":"Hypertension","metadata":null},{"id":"0eb999bdd34e43f48db1d8de618be3ce","type":"TRIAL","name":"Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.","canonical_id":"clinicaltrials.gov:NCT00343551","description":"Essential Hypertension","metadata":null},{"id":"86df60c9f07240728cd3e7e29bc64a60","type":"TRIAL","name":"Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study","canonical_id":"clinicaltrials.gov:NCT00706134","description":"Hypertension","metadata":null},{"id":"aea0e863324f4237a621015929509e3d","type":"TRIAL","name":"Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension","canonical_id":"clinicaltrials.gov:NCT00853957","description":"Hypertension","metadata":null},{"id":"883d7097a20b444f9556e1df7bde1076","type":"TRIAL","name":"Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00262236","description":"Hypertension","metadata":null},{"id":"399917404ae54d38afbbfced6ee77348","type":"TRIAL","name":"Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT00409578","description":"Post Acute Coronary Syndrome; Myocardial Ischemia","metadata":null},{"id":"bf27b8f60faa4b80ade5939815c8af53","type":"TRIAL","name":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00765674","description":"Hypertension","metadata":null},{"id":"e38b3fc4ad004fd39e6ccbf6782609d9","type":"TRIAL","name":"Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00542269","description":"Hypertension With Metabolic Syndrome","metadata":null},{"id":"29b4fd158d17440daabf269345f73516","type":"TRIAL","name":"Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00286442","description":"Diabetes Mellitus","metadata":null},{"id":"8e17205266de4487b152e9d2517f3c77","type":"TRIAL","name":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","canonical_id":"clinicaltrials.gov:NCT00328627","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"56d14a7c0d4b45ea9d22715660bfb27f","type":"TRIAL","name":"Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics","canonical_id":"clinicaltrials.gov:NCT00707993","description":"Diabetes Mellitus","metadata":null},{"id":"7b04e3bdc15b4fb9a80a30d78df63d6a","type":"TRIAL","name":"Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan","canonical_id":"clinicaltrials.gov:NCT01318109","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"32bbab4412d2498b934a75522042ed25","type":"TRIAL","name":"Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan","canonical_id":"clinicaltrials.gov:NCT01318083","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c6f2fd7799ec47d2b07b8a6e35196a63","type":"TRIAL","name":"Efficacy and Safety of Alogliptin Used in Combination With \u03b1-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","canonical_id":"clinicaltrials.gov:NCT01263483","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"422c313bfa114cfca0b54c7697681865","type":"TRIAL","name":"Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive","canonical_id":"clinicaltrials.gov:NCT03794336","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"dc8b4e02cf6a4b76b3b901396e13c334","type":"TRIAL","name":"Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID","canonical_id":"clinicaltrials.gov:NCT02153632","description":"Parkinson's Disease; Levodopa Induced Dyskinesia (LID)","metadata":null},{"id":"f9f836ec494d415297249f579f4f1cec","type":"TRIAL","name":"Efficacy and Safety of Ambrisentan in Children 8-18yrs","canonical_id":"clinicaltrials.gov:NCT01332331","description":"Hypertension, Pulmonary","metadata":null},{"id":"d5a62d1988df44caa4ed4691fde1517b","type":"TRIAL","name":"Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT02446899","description":"Active Systemic Lupus Erythematosus","metadata":null},{"id":"dabbcfed1f744fe497ace119b52013ab","type":"TRIAL","name":"Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic Hepatectomy","canonical_id":"clinicaltrials.gov:NCT07826806","description":"Pain Management","metadata":null},{"id":"eff6a9007f434b29ab6e7751cfac3f4c","type":"TRIAL","name":"Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery","canonical_id":"clinicaltrials.gov:NCT07269106","description":"Ophthalmic Surgery; Postoperative Pain Management; Opioid Analgesia","metadata":null},{"id":"d686dadfc5674e0ba0ba94ff48348073","type":"TRIAL","name":"Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy","canonical_id":"clinicaltrials.gov:NCT00306150","description":"Blood Loss, Surgical; Postoperative Hemorrhage","metadata":null},{"id":"79a62e1a5eab464693c6873d7070591a","type":"TRIAL","name":"Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00216723","description":"Schizophrenia; Bipolar Disorder","metadata":null},{"id":"15da1cdfbebe40dbb362b9718162b30a","type":"TRIAL","name":"Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)","canonical_id":"clinicaltrials.gov:NCT00212836","description":"Schizophrenia","metadata":null},{"id":"766bc701bd7c4816a361fa879fe9bb69","type":"TRIAL","name":"Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)","canonical_id":"clinicaltrials.gov:NCT00145496","description":"Schizophrenia","metadata":null},{"id":"efc25a65d3d24c31944b12287cf5363d","type":"TRIAL","name":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","canonical_id":"clinicaltrials.gov:NCT01244815","description":"Bipolar Disorder, Pediatric","metadata":null},{"id":"d663dadcbb3e475db5e1f0bddc7bdee6","type":"TRIAL","name":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","canonical_id":"clinicaltrials.gov:NCT00212784","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"7288fb5545cf4990a645bc4a23dc7a3f","type":"TRIAL","name":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)","canonical_id":"clinicaltrials.gov:NCT00212771","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"679fd7121f6841f195d58163bc33626f","type":"TRIAL","name":"Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00156104","description":"Schizophrenia","metadata":null},{"id":"11e2d54c8838483c9d2ed8ef6666e48a","type":"TRIAL","name":"Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)","canonical_id":"clinicaltrials.gov:NCT00156117","description":"Schizophrenia","metadata":null},{"id":"665d0f8b8b9a4633a31c7cacb8ce1e0e","type":"TRIAL","name":"Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)","canonical_id":"clinicaltrials.gov:NCT00151424","description":"Schizophrenia","metadata":null},{"id":"ac521763076a488ab7c0b3921fd79330","type":"TRIAL","name":"Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)","canonical_id":"clinicaltrials.gov:NCT01396291","description":"Bipolar 1 Disorder","metadata":null},{"id":"c92b037d47f5498e81cf4e506bc1ab11","type":"TRIAL","name":"Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT04591808","description":"Dyslipidemias; Hypertension","metadata":null},{"id":"40dba0dcd9514ebaa4b7a373292e1b7d","type":"TRIAL","name":"Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population","canonical_id":"clinicaltrials.gov:NCT06789432","description":"Hyperlipidemia (E.G., Hypercholesterolemia)","metadata":null},{"id":"7e561280ba984553835d068feed19c6d","type":"TRIAL","name":"Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.","canonical_id":"clinicaltrials.gov:NCT05590598","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"f457c8415e464e9a88249e95758fdf08","type":"TRIAL","name":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00591773","description":"Hypertension","metadata":null},{"id":"a39c60b13d474857a520bb33ad79b8c1","type":"TRIAL","name":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00847626","description":"Hypertension","metadata":null},{"id":"3e86f93a87394dbe94688d530a24677f","type":"TRIAL","name":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00846365","description":"Essential Hypertension","metadata":null},{"id":"b3f439ab35be47c4bfe5134d83b8dfc0","type":"TRIAL","name":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","canonical_id":"clinicaltrials.gov:NCT01033071","description":"Essential Hypertension","metadata":null},{"id":"fd736a538ac544bc88ce07050620848d","type":"TRIAL","name":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00818883","description":"Essential Hypertension","metadata":null},{"id":"c8f060e82bdd48819aad87c2cbd52605","type":"TRIAL","name":"Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00601250","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"10d571b1efaa4819baef6ef750d32945","type":"TRIAL","name":"Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01036139","description":"Parkinson's Disease","metadata":null},{"id":"c78e4074b3c14d5f931aa04ee5701d3c","type":"TRIAL","name":"Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01066442","description":"Parkinson's Disease","metadata":null},{"id":"498d16890ef84264a91bc5b2e04d0c98","type":"TRIAL","name":"Efficacy and Safety of BGG492 in the Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT00892203","description":"Migraine","metadata":null},{"id":"d1b29dce48c14704bf18691ceee0ac20","type":"TRIAL","name":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00309608","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"d21bb8342db24a1d848f9b1860820f65","type":"TRIAL","name":"Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT02443298","description":"Asthma","metadata":null},{"id":"0985cdfa6b57453c98cc85648016c883","type":"TRIAL","name":"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.","canonical_id":"clinicaltrials.gov:NCT01227655","description":"Parkinson's Disease","metadata":null},{"id":"338e4ad69aa044f8aa1c47796d3bdbde","type":"TRIAL","name":"Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients","canonical_id":"clinicaltrials.gov:NCT06948357","description":"Presbyopia","metadata":null},{"id":"38e1227c006a4eca93ed86a6661af3b0","type":"TRIAL","name":"Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05316246","description":"NK/T Cell Lymphoma Nos","metadata":null},{"id":"ebb36bdf1ce047468f51b76201c2c9bc","type":"TRIAL","name":"Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02172807","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"f389eda09a724e94808957c07418a646","type":"TRIAL","name":"Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT05660655","description":"Rheumatoid Arthritis","metadata":null},{"id":"5a482a138a7348f89e6a3d3b3c5fe80e","type":"TRIAL","name":"Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT05792462","description":"NMO Spectrum Disorder","metadata":null},{"id":"9e59e529eb6645e5a52d0e56bb181bb6","type":"TRIAL","name":"Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study","canonical_id":"clinicaltrials.gov:NCT06158113","description":"Lichen Planus, Oral; Lichen Planus, Mucosal; Oral Lichen Planus","metadata":null},{"id":"0a033564cd5d44c5b0c0072394b2dd3b","type":"TRIAL","name":"Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19","canonical_id":"clinicaltrials.gov:NCT05056558","description":"Covid19","metadata":null},{"id":"23dba1cb04fa4797a50c93e501b16591","type":"TRIAL","name":"Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury","canonical_id":"clinicaltrials.gov:NCT06548802","description":"Pulmonary Injury After Intracerebral Hemorrhage","metadata":null},{"id":"b19d4bf000304533ab0ea7a781598b70","type":"TRIAL","name":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT01639339","description":"Lupus Nephritis","metadata":null},{"id":"f57137ba6a6f42e9bb56edcfae4cc940","type":"TRIAL","name":"Efficacy and Safety of Belimumab in SLE Patients","canonical_id":"clinicaltrials.gov:NCT04515719","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"a6152b4e95df43b99c66b12261f6a026","type":"TRIAL","name":"Efficacy and Safety of Belimumab in Subjects With Primary Sj\u00f6gren's Syndrome","canonical_id":"clinicaltrials.gov:NCT01160666","description":"Sj\u00f6gren's Syndrome","metadata":null},{"id":"651c4bb66fd748c49c3050babd9b5f0f","type":"TRIAL","name":"Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT04680975","description":"Diffuse Cutaneous Systemic Sclerosis","metadata":null},{"id":"4d6a3487c25c499da17c8b6dcc12079c","type":"TRIAL","name":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","canonical_id":"clinicaltrials.gov:NCT06381947","description":"Dyslipidemias; Statin Adverse Reaction; Cardiovascular Diseases; Lipid Metabolism Disorders","metadata":null},{"id":"0688440aeba04b28b4ee3b191f2ae67f","type":"TRIAL","name":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","canonical_id":"clinicaltrials.gov:NCT04157348","description":"Eosinophilic Granulomatous Vasculitis","metadata":null},{"id":"881facfd3630474fae82893ef8eb81fa","type":"TRIAL","name":"Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma","canonical_id":"clinicaltrials.gov:NCT01804218","description":"Mild Persistent Asthma, Uncomplicated","metadata":null},{"id":"dcf039edb1f245089ecf0a8a8b2fa422","type":"TRIAL","name":"Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy","canonical_id":"clinicaltrials.gov:NCT06443606","description":"BPC; Non Optimal Response to UDCA","metadata":null},{"id":"79c71e59b0994a4abdd42cb742e72f24","type":"TRIAL","name":"Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression","canonical_id":"clinicaltrials.gov:NCT06325605","description":"Adolescent Depression","metadata":null},{"id":"b2f32a5425b8408bac3e2558475f872f","type":"TRIAL","name":"Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment","canonical_id":"clinicaltrials.gov:NCT02371252","description":"Osteoporosis","metadata":null},{"id":"3b68bd6670a6454b8fdd409d4b852510","type":"TRIAL","name":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","canonical_id":"clinicaltrials.gov:NCT04533737","description":"Plaque Psoriasis; Psoriasis Vulgaris; Psoriasis","metadata":null},{"id":"2ab95ae2cfbb4ef6a0461379cb1a0949","type":"TRIAL","name":"Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","canonical_id":"clinicaltrials.gov:NCT01708629","description":"Plaque Psoriasis","metadata":null},{"id":"b7262c4d103c42419f2bf97ce1f593a7","type":"TRIAL","name":"Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04305327","description":"Psoriasis","metadata":null},{"id":"d54287677fb441f483bfdd2ecd5f469c","type":"TRIAL","name":"Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)","canonical_id":"clinicaltrials.gov:NCT04697953","description":"Age-related Macular Degeneration (AMD)","metadata":null},{"id":"db776eb7343f40b4a946d9ad4036de4f","type":"TRIAL","name":"Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT03917472","description":"Diabetic Macular Edema","metadata":null},{"id":"f614246e565d4945b3cb7573ac1075d1","type":"TRIAL","name":"Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT04079231","description":"Diabetic Macula Edema","metadata":null},{"id":"8b3fefc481eb40cdbe379916b1138c0f","type":"TRIAL","name":"Efficacy and Safety of Bromfenac Ophthalmic Solution","canonical_id":"clinicaltrials.gov:NCT00585975","description":"Cataract Surgery","metadata":null},{"id":"5e6568ba67df48ad8c7130194a5f19ec","type":"TRIAL","name":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT00703781","description":"Cataract","metadata":null},{"id":"bfd5ba134b5f4057983c65fdf2a0d32b","type":"TRIAL","name":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT00704418","description":"Cataract","metadata":null},{"id":"ef3db7af75c9470989d03395f28c5486","type":"TRIAL","name":"Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.","canonical_id":"clinicaltrials.gov:NCT03715153","description":"Autism Spectrum Disorder (ASD)","metadata":null},{"id":"8c53f698d6584c21a2cf105c093908c2","type":"TRIAL","name":"Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT03715166","description":"Autism Spectrum Disorder (ASD)","metadata":null},{"id":"3616e27314524ca9b10f8e03d70b0b71","type":"TRIAL","name":"Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity","canonical_id":"clinicaltrials.gov:NCT02519387","description":"Osteoarthritis; Rheumatoid Arthritis; Lower Back Pain; Joint Pain; Muscle Pain","metadata":null},{"id":"e2ed7fc6f73f4fcfa84c03f8c791efcf","type":"TRIAL","name":"Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH","canonical_id":"clinicaltrials.gov:NCT02915705","description":"X-Linked Hypophosphatemia","metadata":null},{"id":"7be6dfe928f6433b981505c346955ee3","type":"TRIAL","name":"Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo","canonical_id":"clinicaltrials.gov:NCT05430217","description":"Vertigo; Autonomic Dysfunction","metadata":null},{"id":"2e67694ebece4e7cb9b4d2a247c7edaa","type":"TRIAL","name":"Efficacy and Safety of Butorphanol Tartrate Injection for the Patients With Mechanical Ventilation","canonical_id":"clinicaltrials.gov:NCT05201560","description":"Analgesia; Hospital-acquired Infections","metadata":null},{"id":"e679deaff57148a286dd3f7b25addceb","type":"TRIAL","name":"Efficacy and Safety of CD5789 (Trifarotene) 50\u03bcg/g Cream Versus Vehicle Cream in Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02566369","description":"Acne Vulgaris","metadata":null},{"id":"33e3a3a232ad4db299965d83ae1b5702","type":"TRIAL","name":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT00216879","description":"Psoriasis of Scalp","metadata":null},{"id":"878e3eec49e14702a2293f815c6686dd","type":"TRIAL","name":"Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever","canonical_id":"clinicaltrials.gov:NCT01088880","description":"Familial Mediterranean Fever","metadata":null},{"id":"a284516dadc64473ade77da19c9a45ac","type":"TRIAL","name":"Efficacy and Safety of Canakinumab in Schnitzler Syndrome","canonical_id":"clinicaltrials.gov:NCT01276522","description":"Schnitzler Syndrome","metadata":null},{"id":"08586a8a82c342adaaeb3d27d78c604a","type":"TRIAL","name":"Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy","canonical_id":"clinicaltrials.gov:NCT00099268","description":"Parkinson's Disease","metadata":null},{"id":"04d47c1294c344faa3884861ea3f1fbb","type":"TRIAL","name":"Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)","canonical_id":"clinicaltrials.gov:NCT00620867","description":"Osteoarthritis, Knee","metadata":null},{"id":"469dd67ea7a844f2b731ad66380c6d1c","type":"TRIAL","name":"Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00639587","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"56fd1772530e4ef6a778ea9ce6874313","type":"TRIAL","name":"Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT02177422","description":"Hypertension","metadata":null},{"id":"ea18b85604604e9ca00797edf27b20ea","type":"TRIAL","name":"Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.","canonical_id":"clinicaltrials.gov:NCT00392288","description":"Asthma","metadata":null},{"id":"f1e15e5cbcdd4773b2403ef3de70d0eb","type":"TRIAL","name":"Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)","canonical_id":"clinicaltrials.gov:NCT00163436","description":"Asthma","metadata":null},{"id":"3056530191224309a7f997b3b5642f06","type":"TRIAL","name":"Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia","canonical_id":"clinicaltrials.gov:NCT02155881","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"1ba772162f85421ea9f4709585e244e0","type":"TRIAL","name":"Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)","canonical_id":"clinicaltrials.gov:NCT00163449","description":"Asthma","metadata":null},{"id":"e8e2ab7fce834eccb28e201a1460ba53","type":"TRIAL","name":"Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT","canonical_id":"clinicaltrials.gov:NCT03123406","description":"Hyperparathyroidism; Secondary, Renal","metadata":null},{"id":"623ebd199d3b4f4fbf3349524f0dced4","type":"TRIAL","name":"Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis","canonical_id":"clinicaltrials.gov:NCT02138838","description":"Chronic Kidney Disease, Secondary Hyperparathyroidism","metadata":null},{"id":"ac83f76e24c54a00938d8d97cd6fbdff","type":"TRIAL","name":"Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT01355276","description":"Dyspepsia","metadata":null},{"id":"bf14651c633f4608ae0aa196013d4ae1","type":"TRIAL","name":"Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT06403501","description":"Acne Vulgaris","metadata":null},{"id":"b103e4080db64428b043fc473a1752df","type":"TRIAL","name":"Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol","canonical_id":"clinicaltrials.gov:NCT01451645","description":"Intercritical Gout","metadata":null},{"id":"bc034b995c744c46b437f211e2115fc0","type":"TRIAL","name":"Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT03309592","description":"Portopulmonary Hypertension; Pulmonary Hypertension; Cirrhosis, Liver","metadata":null},{"id":"30559ccd54cd452f96c8a93c825a96a8","type":"TRIAL","name":"Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)","canonical_id":"clinicaltrials.gov:NCT05884372","description":"Osteoporosis in Postmenopausal Women","metadata":null},{"id":"d4c8805ab0af4108941af70bf821cbd7","type":"TRIAL","name":"Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","canonical_id":"clinicaltrials.gov:NCT06414759","description":"Acute Decompensated Heart Failure; Volume Overload; Edema","metadata":null},{"id":"9c8e1578b6604f5eb17e812df62b38cb","type":"TRIAL","name":"Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)","canonical_id":"clinicaltrials.gov:NCT01196546","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"17fcabd0858641f8b610f78ae0fb3b13","type":"TRIAL","name":"Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis","canonical_id":"clinicaltrials.gov:NCT01393548","description":"Nasal Congestion and Inflammations; Rhinitis","metadata":null},{"id":"c02f6360b15e46099c21a948651eab56","type":"TRIAL","name":"Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection","canonical_id":"clinicaltrials.gov:NCT02765490","description":"Hepatitis C, Chronic","metadata":null},{"id":"78c9787dddf54aba807768a7aa3d67a5","type":"TRIAL","name":"Efficacy and Safety of Cycloset\u00ae Compared With Placebo When Added to Metformin","canonical_id":"clinicaltrials.gov:NCT00441363","description":"Type 2 Diabetes","metadata":null},{"id":"82a7e3a2f7144912a6362708879ec577","type":"TRIAL","name":"Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.","canonical_id":"clinicaltrials.gov:NCT06272409","description":"Allergic Rhinitis","metadata":null},{"id":"03cfbebeea964d7990fd0bd8557df418","type":"TRIAL","name":"Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT04947631","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"e324263733c54555bb18c1d7607f964b","type":"TRIAL","name":"Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01071915","description":"Prostate Cancer","metadata":null},{"id":"f0034cd5523c4c1e9e2064d1997f0491","type":"TRIAL","name":"Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT05355818","description":"Chronic Hand Eczema","metadata":null},{"id":"0cbc20bfa3fe4f18bd567a68f537f0e1","type":"TRIAL","name":"Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT04871711","description":"Chronic Hand Eczema","metadata":null},{"id":"4e2fb86aa7bf4b2eb85cf4dea8cff7db","type":"TRIAL","name":"Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)","canonical_id":"clinicaltrials.gov:NCT04872101","description":"Chronic Hand Eczema","metadata":null},{"id":"d3dcdce3d3d94fbdb0a3087c3b80ac59","type":"TRIAL","name":"Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.","canonical_id":"clinicaltrials.gov:NCT03958955","description":"Discoid Lupus Erythematosus","metadata":null},{"id":"c074a62a732d40cb939aa103a7bbd26f","type":"TRIAL","name":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT05274750","description":"Nasal Polyps","metadata":null},{"id":"55177c3cdd19488abf12c8b7ae9951af","type":"TRIAL","name":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)","canonical_id":"clinicaltrials.gov:NCT05281523","description":"Nasal Polyps","metadata":null},{"id":"c4e7a2d1d30f42cba0343c9ba099a07c","type":"TRIAL","name":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)","canonical_id":"clinicaltrials.gov:NCT05263934","description":"Eosinophilic Granulomatosis With Polyangiitis","metadata":null},{"id":"297c54bdaa90476893cd86ade235b455","type":"TRIAL","name":"Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","canonical_id":"clinicaltrials.gov:NCT07701967","description":"Nasal Polyps","metadata":null},{"id":"5d6b3b25d98042b08a5240146729d77e","type":"TRIAL","name":"Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)","canonical_id":"clinicaltrials.gov:NCT00783146","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"24b152133bfb4b91b0c4a5911478d125","type":"TRIAL","name":"Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT05478499","description":"Psoriasis","metadata":null},{"id":"f60b7cfd31754321a0919d3dc1197aa7","type":"TRIAL","name":"Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT02846493","description":"Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"f26af1f42f26437d8df3cc99e9549fdb","type":"TRIAL","name":"Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS","canonical_id":"clinicaltrials.gov:NCT05872425","description":"PCOS","metadata":null},{"id":"516a87788680428989c7401902ca00be","type":"TRIAL","name":"Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer\uff1aa Phase II Study","canonical_id":"clinicaltrials.gov:NCT07093866","description":"mCRPC","metadata":null},{"id":"6c812708a9f4430bb7b656b049f1612f","type":"TRIAL","name":"Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT06015113","description":"Breast Cancer","metadata":null},{"id":"fadd589c391848628542e122d713e9e4","type":"TRIAL","name":"Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)","canonical_id":"clinicaltrials.gov:NCT05730699","description":"Neuromyelitis Optica Spectrum Disorders","metadata":null},{"id":"034e30a1ddfc49a4b3a635df911fd562","type":"TRIAL","name":"Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT02645981","description":"HCC","metadata":null},{"id":"5be29e0fc55f4934a318cedd25d50aae","type":"TRIAL","name":"Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia","canonical_id":"clinicaltrials.gov:NCT00165763","description":"Vascular Dementia","metadata":null},{"id":"4cba5ab6f10648e8bf50bc0b103bda7d","type":"TRIAL","name":"Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","canonical_id":"clinicaltrials.gov:NCT00688376","description":"Attention Impairment","metadata":null},{"id":"6f03ee257de04ea6840bfe0926ddbe39","type":"TRIAL","name":"Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock","canonical_id":"clinicaltrials.gov:NCT00604214","description":"Sepsis","metadata":null},{"id":"52e5391e03ad4c869878ccaa5ac07b37","type":"TRIAL","name":"Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients With Taxanes-induced Painful Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT04970121","description":"Chemotherapy-induced Peripheral Neuropathy; Pain; Solid Tumor","metadata":null},{"id":"7a85c0d4856c4e188fe84067cd4c8936","type":"TRIAL","name":"Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT05649579","description":"Bullous Pemphigoid","metadata":null},{"id":"0410e886c3f348b68ab80613bce83873","type":"TRIAL","name":"Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT00134134","description":"Hidradenitis Suppurativa","metadata":null},{"id":"ba7048d9229642e9a5c633cd5b994a0c","type":"TRIAL","name":"Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barr\u00e9 Syndrome(GREAT)","canonical_id":"clinicaltrials.gov:NCT07806916","description":"Guillain-Barr\u00e9 Syndrome","metadata":null},{"id":"e2cebf908e02475a9e3c117522b3d356","type":"TRIAL","name":"Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension","canonical_id":"clinicaltrials.gov:NCT04970108","description":"Hypertension Associated; Type II Diabetes Mellitus","metadata":null},{"id":"4d08dbd846ca4451913e7af2ef6f4417","type":"TRIAL","name":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","canonical_id":"clinicaltrials.gov:NCT02654054","description":"Uterine Fibroids; Heavy Menstrual Bleeding","metadata":null},{"id":"66e0ef30d46142e4b2ef514e7bd76c52","type":"TRIAL","name":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)","canonical_id":"clinicaltrials.gov:NCT02691494","description":"Uterine Fibroids; Heavy Menstrual Bleeding","metadata":null},{"id":"69b7d0af8d2340c5945e338e7bb64863","type":"TRIAL","name":"Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT00933634","description":"Atrial Fibrillation","metadata":null},{"id":"0fb76bf73aa84354be4e74890e5cd402","type":"TRIAL","name":"Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy","canonical_id":"clinicaltrials.gov:NCT00632385","description":"Migraine","metadata":null},{"id":"84d9c8d6c081482394ff0bbe4b50a950","type":"TRIAL","name":"Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)","canonical_id":"clinicaltrials.gov:NCT02773225","description":"Anemia, Aplastic","metadata":null},{"id":"52786692a55b491bb83a3964c3b9c7a6","type":"TRIAL","name":"Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","canonical_id":"clinicaltrials.gov:NCT04324021","description":"SARS-CoV-2","metadata":null},{"id":"2a6da9e8685147408e162c8bf7c88a49","type":"TRIAL","name":"Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment na\u00efve and Metformin Treated Type 2 Diabetes Patients","canonical_id":"clinicaltrials.gov:NCT01422876","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"238026b9b3ac443697cc9a7410c86304","type":"TRIAL","name":"Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT03832998","description":"Migraine","metadata":null},{"id":"4b60553ed9ad4d909619c0f5dc204b0d","type":"TRIAL","name":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","canonical_id":"clinicaltrials.gov:NCT02226003","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"79c28e50b40947928d01d9d1eadf137e","type":"TRIAL","name":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","canonical_id":"clinicaltrials.gov:NCT00166296","description":"Major Depressive Disorder; Hepatitis C, Chronic","metadata":null},{"id":"bcd5f406b36c484d8e57056061e1bece","type":"TRIAL","name":"Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.","canonical_id":"clinicaltrials.gov:NCT07549386","description":"Pain Management; Osteoarthritis","metadata":null},{"id":"3bbc64386a28454089d050e39a7b892a","type":"TRIAL","name":"Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain","canonical_id":"clinicaltrials.gov:NCT05995912","description":"Acute Pain; Postoperative Pain","metadata":null},{"id":"0b354b30c28a4c3792f2fd26949e42a9","type":"TRIAL","name":"Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07243639","description":"Ulcerative Colitis (Disorder)","metadata":null},{"id":"42b138f00014479a89da383089186783","type":"TRIAL","name":"Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients","canonical_id":"clinicaltrials.gov:NCT00154310","description":"Renal Transplantation","metadata":null},{"id":"ca97e8c2969741bf8d1ee6f15c891280","type":"TRIAL","name":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00965094","description":"Chronic Renal Failure","metadata":null},{"id":"69c8b9d3b5b1490b9b451bba4cc4c0e4","type":"TRIAL","name":"Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis","canonical_id":"clinicaltrials.gov:NCT04863014","description":"Hypertriglyceridemia","metadata":null},{"id":"1741f30f4b0544a2bfd8df376c3f90af","type":"TRIAL","name":"Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT03399786","description":"Homozygous Familial Hypercholesterolemia","metadata":null},{"id":"c282b2058c79492baf0ca8ca97564b95","type":"TRIAL","name":"Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout","canonical_id":"clinicaltrials.gov:NCT02139046","description":"Gout","metadata":null},{"id":"1d989f61a70943e5bc71aded63e62b59","type":"TRIAL","name":"Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults","canonical_id":"clinicaltrials.gov:NCT07531043","description":"Ocular Hyperemia","metadata":null},{"id":"60a4f12339b94ad09f2d54f306d0fe4b","type":"TRIAL","name":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","canonical_id":"clinicaltrials.gov:NCT07070713","description":"Metastatic Colorectal Cancer With Left-sided Primary Tumor; Immunotherapy","metadata":null},{"id":"40f01a3600924454b8ebbb7ac9ce1db9","type":"TRIAL","name":"Efficacy and Safety of FTY720 for Acute Stroke","canonical_id":"clinicaltrials.gov:NCT02002390","description":"Stroke; Vascular Accident; Cerebral Stroke; Ischemic Cerebrovascular Accident; Stroke, Acute","metadata":null},{"id":"7e6439e71dc947759f9feab7b4882665","type":"TRIAL","name":"Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin","canonical_id":"clinicaltrials.gov:NCT01956201","description":"Mixed Hyperlipidemia","metadata":null},{"id":"042ddda66d6040788d83f2201d05a6cf","type":"TRIAL","name":"Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA","canonical_id":"clinicaltrials.gov:NCT02965911","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"648adb63f2ea45ffad297dc3892b144c","type":"TRIAL","name":"Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00355134","description":"Multiple Sclerosis","metadata":null},{"id":"e7a213deb7b848a9808552d6993e5f98","type":"TRIAL","name":"Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase","canonical_id":"clinicaltrials.gov:NCT00340834","description":"Multiple Sclerosis","metadata":null},{"id":"557154a73105497ba6afc5e9a6b4ebae","type":"TRIAL","name":"Efficacy and Safety of Finl\u00e2ndia Hair Lotion Association on Androgenetic Alopecia","canonical_id":"clinicaltrials.gov:NCT04594018","description":"Androgenetic Alopecia","metadata":null},{"id":"dbfc8d8a6050403d94c34a184ed54d56","type":"TRIAL","name":"Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00441415","description":"Acne Vulgaris","metadata":null},{"id":"4111498010ca47e884e0d73f8fa03b4b","type":"TRIAL","name":"Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT04968158","description":"Acute Low Back Pain","metadata":null},{"id":"2bd035e890574d908e9860cf82203fe6","type":"TRIAL","name":"Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression","canonical_id":"clinicaltrials.gov:NCT01309945","description":"Depression","metadata":null},{"id":"fef5383984004444b3cda3f3207c3467","type":"TRIAL","name":"Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT01551173","description":"Lipid Metabolism Disorders","metadata":null},{"id":"4a1df2e9a8694cc395b16ee5ba5581a4","type":"TRIAL","name":"Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT00171236","description":"Heterozygous Familial Hypercholesterolemia; Mixed Dyslipidemia","metadata":null},{"id":"228dd5a6bdb84dbfaa1c8febca258783","type":"TRIAL","name":"Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT00136799","description":"Mixed Dyslipidemia; Hypercholesterolemia","metadata":null},{"id":"6c95751d53a8420cb1a4b6306054fdd7","type":"TRIAL","name":"Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction","canonical_id":"clinicaltrials.gov:NCT00171327","description":"Hypertension; Dyslipidemia","metadata":null},{"id":"4f376eb4792844f19b6a0c08898c8450","type":"TRIAL","name":"Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium","canonical_id":"clinicaltrials.gov:NCT00501852","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"04a5d1d03fb74e9c9e057b843c8b4c15","type":"TRIAL","name":"Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02238119","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"5dc614676ebd4469aba1cc7a2f2c54f5","type":"TRIAL","name":"Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression","canonical_id":"clinicaltrials.gov:NCT06977061","description":"Gastric Neoplasm","metadata":null},{"id":"43cfc13e622e4d0ea33d36015e4758e6","type":"TRIAL","name":"Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study","canonical_id":"clinicaltrials.gov:NCT05721651","description":"Gastric Cancer","metadata":null},{"id":"889ea21ab77e48a4a68c3f368cbfa826","type":"TRIAL","name":"Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)","canonical_id":"clinicaltrials.gov:NCT05522231","description":"Advanced Renal Cell Carcinoma","metadata":null},{"id":"1be9b2d3a0c34dbebd394f2ba795dce1","type":"TRIAL","name":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","canonical_id":"clinicaltrials.gov:NCT04134728","description":"Arthritis, Rheumatoid","metadata":null},{"id":"2f9cb5ac95804ad6a7381db66abf8a50","type":"TRIAL","name":"Efficacy and Safety of Gabapentin in Treating Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT01486706","description":"Urinary Urgency; Urinary Frequency; Nocturia; Incontinence; Detrusor Uninhibited Activity; Quality of Life","metadata":null},{"id":"682ff2649bda4fe3a149f513a37a7147","type":"TRIAL","name":"Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT06436534","description":"Rhinitis, Allergic","metadata":null},{"id":"0755be9a7158447db37ac1de902d7010","type":"TRIAL","name":"Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT03162055","description":"Chronic Obstructive Pulmonary Disease COPD","metadata":null},{"id":"ceddfcc8f0e6435b92df86abc1167b35","type":"TRIAL","name":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00550550","description":"Rhinoconjunctivitis; Rhinitis; Conjunctivitis; Allergy","metadata":null},{"id":"963e4a4e57b049679121b95710be7cd3","type":"TRIAL","name":"Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease","canonical_id":"clinicaltrials.gov:NCT05084404","description":"Nonalcoholic Fatty Liver; Nonalcoholic Steatohepatitis","metadata":null},{"id":"6ba3a95f9e2348f88384d4f8b821f476","type":"TRIAL","name":"Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT06441019","description":"Hepatocellular Carcinoma\uff0cBispecific Antibodies, HAIC, Ramucirumab","metadata":null},{"id":"7065509e9dcb4b5087bafbd729dfc9df","type":"TRIAL","name":"Efficacy and Safety of HB-1 for Panic Disorder","canonical_id":"clinicaltrials.gov:NCT06483789","description":"Panic Disorder; Mental Illness","metadata":null},{"id":"23fb91c6b0764172a43fcf48a82e69ea","type":"TRIAL","name":"Efficacy and Safety of High Dose Baclofen for Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT01980706","description":"Alcoholism","metadata":null},{"id":"726c559557f3415d90f7b917e16cc240","type":"TRIAL","name":"Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)","canonical_id":"clinicaltrials.gov:NCT06250400","description":"Chronic Spontaneous Urticaria","metadata":null},{"id":"fbb54d76dedd4bfdba3f9bcba13912d0","type":"TRIAL","name":"Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","canonical_id":"clinicaltrials.gov:NCT04411433","description":"Sars-CoV2; COVID-19","metadata":null},{"id":"ab41160fde7d4231b56dbd8c13c9c921","type":"TRIAL","name":"Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss","canonical_id":"clinicaltrials.gov:NCT06467526","description":"Sudden Hearing Loss","metadata":null},{"id":"6e9999114ef649dd9cf0e4852675a8d7","type":"TRIAL","name":"Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.","canonical_id":"clinicaltrials.gov:NCT05342558","description":"COPD","metadata":null},{"id":"8d31b8446e774f9a9858269109c027b4","type":"TRIAL","name":"Efficacy and Safety of IL-11 in DDAVP Unresponsive","canonical_id":"clinicaltrials.gov:NCT00994929","description":"Hemophilia A; Von Willebrand Disease","metadata":null},{"id":"e883af7f89d54694acaf146b4b25ae23","type":"TRIAL","name":"Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT01630083","description":"CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction; CLDN18.2-positive Adenocarcinoma of Esophagus; CLDN18.2-positive Gastric Adenocarcinoma","metadata":null},{"id":"9929646327c145d581b5c5b7fd5661f7","type":"TRIAL","name":"Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT01732926","description":"Indolent Non-Hodgkin's Lymphomas","metadata":null},{"id":"6fefedcabdf5473a8c5f6669295e10cd","type":"TRIAL","name":"Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT01732913","description":"Indolent Non-Hodgkin's Lymphomas","metadata":null},{"id":"79b50256b1074c3298853263d4eb6f29","type":"TRIAL","name":"Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01980888","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"abadc436899f4d02aa8f63f9ef78c66d","type":"TRIAL","name":"Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01659021","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"84dd328f3e804d99a840461c4f5f06de","type":"TRIAL","name":"Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion","canonical_id":"clinicaltrials.gov:NCT02044822","description":"B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion","metadata":null},{"id":"5d80ab50560a476ca34ca13a8e0e3ccf","type":"TRIAL","name":"Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00254202","description":"Schizophrenia","metadata":null},{"id":"61dbf69c3ef4412c8c36bbeaefa5b6c5","type":"TRIAL","name":"Efficacy and Safety of Imatinib in Chordoma","canonical_id":"clinicaltrials.gov:NCT00150072","description":"Chordoma","metadata":null},{"id":"a86198ca515d485cb9506c62a17a85b3","type":"TRIAL","name":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)","canonical_id":"clinicaltrials.gov:NCT03293485","description":"Complicated Intra-abdominal Infection; Complicated Urinary Tract Infection","metadata":null},{"id":"2ed3250508404472aef924de509d44d6","type":"TRIAL","name":"Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT01349010","description":"Hyperlipidemia","metadata":null},{"id":"7cba6988f82b4b5eb41f5114d001065d","type":"TRIAL","name":"Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma","canonical_id":"clinicaltrials.gov:NCT02892019","description":"Asthma","metadata":null},{"id":"c0abe5910fc546cb9abce938949fa5c7","type":"TRIAL","name":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00877383","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"c731168770ce45d689bd6134a14a8bb5","type":"TRIAL","name":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00846586","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"95cd0ab7367c464e91c219e321a23626","type":"TRIAL","name":"Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00792805","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"08918cbc86bf49c4841840b7234768bb","type":"TRIAL","name":"Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control","canonical_id":"clinicaltrials.gov:NCT00567996","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"73acd4ab2cef40c489eb315cef742a93","type":"TRIAL","name":"Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC","canonical_id":"clinicaltrials.gov:NCT07643350","description":"NSCLC","metadata":null},{"id":"1fc8c3120c494f45837c30ea2520776b","type":"TRIAL","name":"Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis","canonical_id":"clinicaltrials.gov:NCT05947669","description":"Colitis","metadata":null},{"id":"a20d40fddba94f7bac67220733a08a55","type":"TRIAL","name":"Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp","canonical_id":"clinicaltrials.gov:NCT02406014","description":"Actinic Keratosis (AK)","metadata":null},{"id":"c44e240a3eb649b5b61259d683047952","type":"TRIAL","name":"Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT01998984","description":"Actinic Keratosis","metadata":null},{"id":"5a9104f5075e4e1cafe876268af2125e","type":"TRIAL","name":"Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain","canonical_id":"clinicaltrials.gov:NCT01147289","description":"Lumbar Sciatic Pain","metadata":null},{"id":"a4937cf78c764c988e49f797062c7fa3","type":"TRIAL","name":"Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy","canonical_id":"clinicaltrials.gov:NCT05456698","description":"Acute Lymphocytic Leukemia","metadata":null},{"id":"0c98f2ed4d3549d79facc9c60be87a34","type":"TRIAL","name":"Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00267683","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"35a16d80329349ddae9ace4fff9213bc","type":"TRIAL","name":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","canonical_id":"clinicaltrials.gov:NCT02058147","description":"Type 2 Diabetes","metadata":null},{"id":"796393966aa24c47bd51a45ffbfba0e2","type":"TRIAL","name":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01476475","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"af78f17836354d2399d2cc25d3a7b476","type":"TRIAL","name":"Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo","canonical_id":"clinicaltrials.gov:NCT06293989","description":"Vertigo, Peripheral","metadata":null},{"id":"e217aa3812fd47a695f33cc4e28ad462","type":"TRIAL","name":"Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery","canonical_id":"clinicaltrials.gov:NCT06904248","description":"Participants With Acute Moderate to Severe Pain Following Abdominal Surgery","metadata":null},{"id":"98c857d8c81a4981accb5410a9e913c8","type":"TRIAL","name":"Efficacy and Safety of Intravenous Paracetamol in Manament of Labour Pain","canonical_id":"clinicaltrials.gov:NCT04744727","description":"Labor Pain","metadata":null},{"id":"2b76ef74cf944ce48c1e308c8de2e03f","type":"TRIAL","name":"Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT01971190","description":"Central Serous Chorioretinopathy","metadata":null},{"id":"eefcc9086dff4391baf6d7d1f91c5f8a","type":"TRIAL","name":"Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","canonical_id":"clinicaltrials.gov:NCT06595355","description":"Diabetic Macular Edema; Macular Edema; Retinal Neovascularization","metadata":null},{"id":"8b487458557e44c0af09d355fc8a3cb9","type":"TRIAL","name":"Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study","canonical_id":"clinicaltrials.gov:NCT07004335","description":"PD-(L)1; CTLA-4; Advanced Melanoma; Iparomlimab; Tuvonralimab; Bevacizumab","metadata":null},{"id":"b79d91d651dd4c9f98f4eeda77dc3dcd","type":"TRIAL","name":"Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT01442987","description":"Hypertension; Hyperlipidemia","metadata":null},{"id":"b16eb131e18c4d0183372feca177b3f2","type":"TRIAL","name":"Efficacy and Safety of Itolizumab in COVID-19 Complications","canonical_id":"clinicaltrials.gov:NCT04475588","description":"Acute Respiratory Distress Syndrome; Cytokine Release Syndrome; Covid19","metadata":null},{"id":"952ca135038d4493a7d69ba2f4d75ff6","type":"TRIAL","name":"Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis","canonical_id":"clinicaltrials.gov:NCT06374979","description":"Guttate Psoriasis","metadata":null},{"id":"0c320d2ee7d14deab654c60d5c926017","type":"TRIAL","name":"Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study","canonical_id":"clinicaltrials.gov:NCT06573593","description":"Alopecia Areata; Janus Kinase Inhibitors","metadata":null},{"id":"24c50c4fcb9c476d90f7b3befd6f682d","type":"TRIAL","name":"Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT03640481","description":"Chronic Graft-versus-host-disease","metadata":null},{"id":"bff8840191774fafbf601f05eb53e0dc","type":"TRIAL","name":"Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain","canonical_id":"clinicaltrials.gov:NCT00351104","description":"Sprain; Strain","metadata":null},{"id":"2968e9d1af8b4d9680f3cfc007767436","type":"TRIAL","name":"Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)","canonical_id":"clinicaltrials.gov:NCT00358436","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"c21dc5820f684655aeb164c28029d355","type":"TRIAL","name":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT01599104","description":"Essential Hypertension","metadata":null},{"id":"aa6ce80f45e94af8b2f7861ad3eabfd4","type":"TRIAL","name":"Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT00764751","description":"Psoriasis Vulgaris","metadata":null},{"id":"2ca0737fea7f4d3a9945e7120954ba76","type":"TRIAL","name":"Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT05886088","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1ba360494c264a5fada7481d7aa2a452","type":"TRIAL","name":"Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)","canonical_id":"clinicaltrials.gov:NCT07317934","description":"Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD","metadata":null},{"id":"e1055297f9894671a1bdea10f263a79f","type":"TRIAL","name":"Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects \u22651 Month to <4 Years With Partial-onset Seizures","canonical_id":"clinicaltrials.gov:NCT02477839","description":"Epilepsy With Partial-onset Seizures","metadata":null},{"id":"7b057cce420141ed8f6654fce8e2cfb1","type":"TRIAL","name":"Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)","canonical_id":"clinicaltrials.gov:NCT04180163","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"70af5e496e274c67b43911051a23a5b9","type":"TRIAL","name":"Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients","canonical_id":"clinicaltrials.gov:NCT01076803","description":"Malignant Intestinal Obstruction","metadata":null},{"id":"de3fb4c2e4ed4472a130ae1c7228f2a3","type":"TRIAL","name":"Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT00210457","description":"Acromegaly","metadata":null},{"id":"106dc907d910452490e09312b3197c0a","type":"TRIAL","name":"Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours","canonical_id":"clinicaltrials.gov:NCT02683941","description":"Neuroendocrine Tumors in Lung","metadata":null},{"id":"898979b8c28342e581856613128db135","type":"TRIAL","name":"Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems","canonical_id":"clinicaltrials.gov:NCT07480096","description":"Cirrhosis; Liver Cirrhosis; Sleep Quality; Insomnia; Hepatic Encephalopathy","metadata":null},{"id":"12704eebc6e54ffeb318476e53b34e46","type":"TRIAL","name":"Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT01093807","description":"Essential Hypertension","metadata":null},{"id":"71a01756a6084da19534bdb5dde4b902","type":"TRIAL","name":"Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01973231","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"2e1d8d30d6bf470491a4d3c25a292501","type":"TRIAL","name":"Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease","canonical_id":"clinicaltrials.gov:NCT06501326","description":"Non-alcoholic Fatty Liver Disease; Obesity","metadata":null},{"id":"4d3fb5bcdd934db8bded2fa3f66c038a","type":"TRIAL","name":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","canonical_id":"clinicaltrials.gov:NCT02752412","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"06d3dbc93461419ab71d55c3880e4397","type":"TRIAL","name":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01768559","description":"Type 2 Diabetes","metadata":null},{"id":"2b75c3b849894a74924176cca92328fc","type":"TRIAL","name":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01798706","description":"Type 2 Diabetes","metadata":null},{"id":"7972862629774ee38cc88ae4a45356ad","type":"TRIAL","name":"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin","canonical_id":"clinicaltrials.gov:NCT01169779","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d72cd3c659a04147bf8e1b8bc475daac","type":"TRIAL","name":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT04927299","description":"Essential Arterial Hypertension","metadata":null},{"id":"07deb76c80b442399df6f6c07ca97024","type":"TRIAL","name":"Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia","canonical_id":"clinicaltrials.gov:NCT03651102","description":"Thalassemia","metadata":null},{"id":"ee393f4bf44d4451b489ab67537bc71b","type":"TRIAL","name":"Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07697547","description":"Inflammatory Bowel Disease (IBD); Crohn's Disease","metadata":null},{"id":"ee4ae3e827cb4574941841d41af708b5","type":"TRIAL","name":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","canonical_id":"clinicaltrials.gov:NCT06387121","description":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","metadata":null},{"id":"9490a4bc05264e738b703e48968f27bf","type":"TRIAL","name":"Efficacy and Safety of Low-dose Ticagrelor","canonical_id":"clinicaltrials.gov:NCT03381742","description":"Coronary Artery Disease","metadata":null},{"id":"8ec98c7f9cb6428695e20593a792d1a4","type":"TRIAL","name":"Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation","canonical_id":"clinicaltrials.gov:NCT00380250","description":"Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"c86a9b79815c4ee98ef47b899bf29dbd","type":"TRIAL","name":"Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation","canonical_id":"clinicaltrials.gov:NCT00399542","description":"Irritable Bowel Syndrome; Constipation","metadata":null},{"id":"82cd1b7275f04d2c879040245853e86e","type":"TRIAL","name":"Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation","canonical_id":"clinicaltrials.gov:NCT07277907","description":"Slow Transit Constipation; Pharmacotherapy","metadata":null},{"id":"7a9d43d0b8e946868f231fe8b6cd541f","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib","canonical_id":"clinicaltrials.gov:NCT00267215","description":"Osteoarthritis","metadata":null},{"id":"b2236441b6354855b26de58a19b2626d","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout","canonical_id":"clinicaltrials.gov:NCT00170781","description":"Acute Gouty Arthritis","metadata":null},{"id":"ce0c7198d2564caeb8bed7ca003f1682","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery","canonical_id":"clinicaltrials.gov:NCT00333567","description":"Pain","metadata":null},{"id":"24505175e75544a085e0910d9d8a8628","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).","canonical_id":"clinicaltrials.gov:NCT00366938","description":"Osteoarthritis, Knee","metadata":null},{"id":"703a81ee77b8481988b7cacd429fa1e9","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","canonical_id":"clinicaltrials.gov:NCT00476034","description":"Osteoarthritis","metadata":null},{"id":"046446499d5748d2a9796191ec6ae9d2","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","canonical_id":"clinicaltrials.gov:NCT00367315","description":"Knee Osteoarthritis","metadata":null},{"id":"f9d0ce0c68cc4e2495140644c3d1efc5","type":"TRIAL","name":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)","canonical_id":"clinicaltrials.gov:NCT00475800","description":"Osteoarthritis","metadata":null},{"id":"edcf043614b64ad39c4c325c05950ef5","type":"TRIAL","name":"Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT07483385","description":"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation; Hematologic Disorders","metadata":null},{"id":"2162959753f14b988c23b6d312e8f066","type":"TRIAL","name":"Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)","canonical_id":"clinicaltrials.gov:NCT01790022","description":"Ankylosing Spondylitis","metadata":null},{"id":"6906c971c03b4165a1f8f6ff5f367111","type":"TRIAL","name":"Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT02789592","description":"REM Sleep Behavior Disorder; Parkinson Disease","metadata":null},{"id":"484d9659881a49feacb35f7f4009271e","type":"TRIAL","name":"Efficacy and Safety of Melatonin and Clonazepam for IRBD","canonical_id":"clinicaltrials.gov:NCT03255642","description":"REM Sleep Behavior Disorder","metadata":null},{"id":"dbd9a20d14dc42d4859c756eaa8d182c","type":"TRIAL","name":"Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis","canonical_id":"clinicaltrials.gov:NCT02229747","description":"Pharyngitis","metadata":null},{"id":"acbe80ad1f2942cf92a250b419e3c50d","type":"TRIAL","name":"Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression","canonical_id":"clinicaltrials.gov:NCT05373680","description":"Renal Insufficiency, Chronic","metadata":null},{"id":"5a4de127121f4b5b8e1b88703167afa7","type":"TRIAL","name":"Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis","canonical_id":"clinicaltrials.gov:NCT00845858","description":"Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying","metadata":null},{"id":"86fa89a47b56458097431a3651f36514","type":"TRIAL","name":"Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT00782067","description":"Leukemia","metadata":null},{"id":"470bd027d3094f2789999f56b76e2e4e","type":"TRIAL","name":"Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT04391478","description":"Persistent Pulmonary Hypertension","metadata":null},{"id":"1e5b708ebeef49f68d87b01d5de318c4","type":"TRIAL","name":"Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase","canonical_id":"clinicaltrials.gov:NCT02258607","description":"Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer","metadata":null},{"id":"ae5d2c419bc640239419d0346be033fc","type":"TRIAL","name":"Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01470053","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"4d01b0b7201348c4a50182ce6d369ed4","type":"TRIAL","name":"Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT00973115","description":"Hyperlipidemia","metadata":null},{"id":"6694ada8f6f24d26992ac03909aeab10","type":"TRIAL","name":"Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial","canonical_id":"clinicaltrials.gov:NCT04623684","description":"Retinopathy of Prematurity","metadata":null},{"id":"f74178c1b1b143abb74b37cf0a292620","type":"TRIAL","name":"Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening","canonical_id":"clinicaltrials.gov:NCT05043077","description":"Retinopathy of Prematurity","metadata":null},{"id":"990bfb845a1344d297e56b9e49f41e4b","type":"TRIAL","name":"Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation","canonical_id":"clinicaltrials.gov:NCT05555641","description":"Critical Illness; Anticoagulation","metadata":null},{"id":"e900126d615d46df8c5407c2d70b882f","type":"TRIAL","name":"Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation","canonical_id":"clinicaltrials.gov:NCT01993940","description":"Opioid-induced Constipation","metadata":null},{"id":"23f984ee409441e2b0dfd896c0801857","type":"TRIAL","name":"Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation","canonical_id":"clinicaltrials.gov:NCT01965158","description":"Opioid-induced Constipation","metadata":null},{"id":"562c6101a2064065adf9de8196977b16","type":"TRIAL","name":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03985943","description":"Moderate-to-Severe Atopic Dermatitis","metadata":null},{"id":"1ab97dc7194a4451b8252d15117471d9","type":"TRIAL","name":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable","canonical_id":"clinicaltrials.gov:NCT05056779","description":"Moderate-to-severe Atopic Dermatitis","metadata":null},{"id":"d8c79933a34e4dfda1f5f4ae95108f4d","type":"TRIAL","name":"Efficacy and Safety of NicVAX\u00ae Co-administered With Varenicline (Champix\u00ae)","canonical_id":"clinicaltrials.gov:NCT00995033","description":"Smoking Behavior; Smoking Lapse Behavior; Smoking Relapse Behavior","metadata":null},{"id":"3a4e55590e024d8eaf0f07eec15549f5","type":"TRIAL","name":"Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib","canonical_id":"clinicaltrials.gov:NCT00471328","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"eb4ec5e08f324e98a8afc343c3bdfdaf","type":"TRIAL","name":"Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment","canonical_id":"clinicaltrials.gov:NCT02802345","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"95d24904491c436a97fd8191fd2be1b9","type":"TRIAL","name":"Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT02308553","description":"Cutaneous Malignant Melanoma","metadata":null},{"id":"a3cfea35e220425d860ac1d2ce78e396","type":"TRIAL","name":"Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04217798","description":"Ovarian Cancer","metadata":null},{"id":"a0b50159ccb64e5bac04e9499a0c8365","type":"TRIAL","name":"Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05488990","description":"Psoriasis Vulgaris","metadata":null},{"id":"af6835df923945e0bd6ba6c19a32ef4a","type":"TRIAL","name":"Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis","canonical_id":"clinicaltrials.gov:NCT05450887","description":"Primary Biliary Cholangitis","metadata":null},{"id":"a06180213c8d455ebeddbae7a141bfc7","type":"TRIAL","name":"Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome","canonical_id":"clinicaltrials.gov:NCT05786768","description":"Steroid-Dependent Nephrotic Syndrome; Steroid-Sensitive Nephrotic Syndrome","metadata":null},{"id":"e035f407f12247228c5e5c72737b34d2","type":"TRIAL","name":"Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)","canonical_id":"clinicaltrials.gov:NCT01552122","description":"Osteoporosis; Postmenopausal Osteoporosis","metadata":null},{"id":"175d7bb5f9794dfeab2d5962c5286d72","type":"TRIAL","name":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04926818","description":"Multiple Sclerosis (MS)","metadata":null},{"id":"2f6f1fa0db1b4c39ada11dda5773c24f","type":"TRIAL","name":"Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris","canonical_id":"clinicaltrials.gov:NCT01920477","description":"Pemphigus Vulgaris","metadata":null},{"id":"1ddbe3f2c8b34dcda082683eda359260","type":"TRIAL","name":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT\u00ae in Essential Hypertension Control","canonical_id":"clinicaltrials.gov:NCT02483936","description":"Arterial Hypertension","metadata":null},{"id":"ca2b8312e0284e7aab7b6ff87d9ca200","type":"TRIAL","name":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","canonical_id":"clinicaltrials.gov:NCT02493322","description":"Essential Arterial Hypertension","metadata":null},{"id":"420f26f139114437bba219070bea33fe","type":"TRIAL","name":"Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00890591","description":"Essential Hypertension","metadata":null},{"id":"9fbb8231b98d48709fc57b5d696af4b0","type":"TRIAL","name":"Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria","canonical_id":"clinicaltrials.gov:NCT00481676","description":"Chronic Urticaria","metadata":null},{"id":"8a031ae87d2b4d5c8b81b404f89efba2","type":"TRIAL","name":"Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria","canonical_id":"clinicaltrials.gov:NCT02191072","description":"Urticaria","metadata":null},{"id":"b1b62dcd49864912ac554332837cffe9","type":"TRIAL","name":"Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT00046748","description":"Asthma","metadata":null},{"id":"cc23469963d84c6b9f7fd7860eb6b028","type":"TRIAL","name":"Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT05080322","description":"Allergic Rhinitis","metadata":null},{"id":"23de99fcba19447fb15fb9fde3390e0a","type":"TRIAL","name":"Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1","canonical_id":"clinicaltrials.gov:NCT02323529","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"ed44e36e10634736931f708898f1f670","type":"TRIAL","name":"Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)","canonical_id":"clinicaltrials.gov:NCT00190736","description":"ADHD","metadata":null},{"id":"21887e5526674fb08cbdda2ef92477ad","type":"TRIAL","name":"Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux","canonical_id":"clinicaltrials.gov:NCT06898268","description":"Gastroesophageal Reflux Disorder","metadata":null},{"id":"d39b8c6ef8e040a8a3d67f19102bb2e5","type":"TRIAL","name":"Efficacy and Safety of Oral Alitretinoin (Toctino\u00ae) in the Treatment of Patients With Cutaneous Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT01407679","description":"Lupus Erythematosus, Cutaneous","metadata":null},{"id":"8e567a0e71e44664a38d9ecbc92837eb","type":"TRIAL","name":"Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03703375","description":"Lymphoma, T-Cell","metadata":null},{"id":"c7d246d90d744872b46970307374cf42","type":"TRIAL","name":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","canonical_id":"clinicaltrials.gov:NCT03593018","description":"Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma","metadata":null},{"id":"ada541a074194aaaa8785a68740f4fb0","type":"TRIAL","name":"Efficacy and Safety of Oral Febuxostat in Participants With Gout","canonical_id":"clinicaltrials.gov:NCT00430248","description":"Gout","metadata":null},{"id":"8274021cdfda4fe4bf13813b5bd14edc","type":"TRIAL","name":"Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)","canonical_id":"clinicaltrials.gov:NCT00163527","description":"Asthma","metadata":null},{"id":"d56dd2bcb49b4aee834257800f11ac38","type":"TRIAL","name":"Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02863419","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"237fcb60a29944f29fad85b1e247baca","type":"TRIAL","name":"Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity","canonical_id":"clinicaltrials.gov:NCT00729469","description":"Atrophy; Vaginal Diseases","metadata":null},{"id":"0456252c56ff4bd9ad6940fa00f5ea93","type":"TRIAL","name":"Efficacy and Safety of PARPi to Treat Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02511223","description":"Pancreatic Cancer","metadata":null},{"id":"8ddc974d97bd47b7b746d9cd5a0ed8db","type":"TRIAL","name":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","canonical_id":"clinicaltrials.gov:NCT01854645","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"58014e5b1e044da1a768c9a2577d80b3","type":"TRIAL","name":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06143553","description":"Metastatic Breast Cancer (MBC)","metadata":null},{"id":"198f0161c6dc4f40a51d9a803416efdc","type":"TRIAL","name":"Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT01481831","description":"Neoplasms; Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"8d951e7ce1954c8ea6d1ae521fd07220","type":"TRIAL","name":"Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT01442376","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"2f18d7271b414c8b86acca23eeb5717c","type":"TRIAL","name":"Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT01436747","description":"Disorder of Transplanted Kidney; Proteinuria; Albuminuria","metadata":null},{"id":"f9a52cfc721a4fc99beb017d93441c49","type":"TRIAL","name":"Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT01024491","description":"Premature Ejaculation","metadata":null},{"id":"cbd5d6bfd97349caa58f049008900fae","type":"TRIAL","name":"Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease","canonical_id":"clinicaltrials.gov:NCT01374906","description":"Cushing's Disease","metadata":null},{"id":"d993de63fc6e40c6a5bf8cd545a83086","type":"TRIAL","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","canonical_id":"clinicaltrials.gov:NCT01137682","description":"Acromegaly","metadata":null},{"id":"8cf525ebd2b547cb8d68a593e0883281","type":"TRIAL","name":"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT00866697","description":"Ovarian Cancer","metadata":null},{"id":"b891a9243d574fd8834ef13a48b6198d","type":"TRIAL","name":"Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00314795","description":"Anemia; Chronic Kidney Disease; Chronic Renal Failure; Pure Red Cell Aplasia","metadata":null},{"id":"d0dba459b09c4e9999865300db3a8964","type":"TRIAL","name":"Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.","canonical_id":"clinicaltrials.gov:NCT00752791","description":"Anemia","metadata":null},{"id":"7140391bd0a14cce9ab5d8e7bc59c27c","type":"TRIAL","name":"Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","canonical_id":"clinicaltrials.gov:NCT00687219","description":"Hepatitis C, Chronic; Liver Cirrhosis","metadata":null},{"id":"a518dfdbb1954870ad462984f33ab685","type":"TRIAL","name":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).","canonical_id":"clinicaltrials.gov:NCT04949256","description":"Metastatic Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"ad37db4116e7451d95a1203a0730ee4b","type":"TRIAL","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","canonical_id":"clinicaltrials.gov:NCT04241185","description":"Urinary Bladder Neoplasms","metadata":null},{"id":"ba120465888b46b7b528260214a6165d","type":"TRIAL","name":"Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression","canonical_id":"clinicaltrials.gov:NCT04826510","description":"Depressive Disorder","metadata":null},{"id":"ca011bd5b70a4b14aa244bba19bb950c","type":"TRIAL","name":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT04531982","description":"Schizophrenia","metadata":null},{"id":"9c632a47ddcb4e4e9897930ee1e6e91c","type":"TRIAL","name":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)","canonical_id":"clinicaltrials.gov:NCT02970305","description":"Schizophrenia","metadata":null},{"id":"84519a2e9b6149f695e19fa38007140d","type":"TRIAL","name":"Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00130364","description":"Atopic Dermatitis","metadata":null},{"id":"ed73aeb210a34984b642313f44925eb1","type":"TRIAL","name":"Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris","canonical_id":"clinicaltrials.gov:NCT00372307","description":"Vitiligo Vulgaris","metadata":null},{"id":"5c535f1aaca24c8783f8e258a784dcfb","type":"TRIAL","name":"Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.","canonical_id":"clinicaltrials.gov:NCT00770835","description":"Diabetes Mellitus","metadata":null},{"id":"582ee688c85e4e14b3826d7b45f56e05","type":"TRIAL","name":"Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period","canonical_id":"clinicaltrials.gov:NCT02611687","description":"Narcolepsy With Cataplexy; Narcolepsy Without Cataplexy","metadata":null},{"id":"9a85865ac6574eb19de2c7fae0a4c39a","type":"TRIAL","name":"Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","canonical_id":"clinicaltrials.gov:NCT06803693","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"a98499e2304c4a4db4381859f8f61cf9","type":"TRIAL","name":"Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02916420","description":"Multiple Myeloma","metadata":null},{"id":"9a24464bbb1149c694da8bf23d662790","type":"TRIAL","name":"Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia","canonical_id":"clinicaltrials.gov:NCT02305355","description":"Diabetes Mellitus, Type 2; Hypertriglycemia","metadata":null},{"id":"f6ad4cd89c48457d85a07ecbc6cbad04","type":"TRIAL","name":"Efficacy and Safety of Probiotics for Anxiety Depression","canonical_id":"clinicaltrials.gov:NCT07331987","description":"Anxiety Depression","metadata":null},{"id":"ebab652b7009455981dcecfb248aa974","type":"TRIAL","name":"Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma","canonical_id":"clinicaltrials.gov:NCT01743885","description":"Hemangioma","metadata":null},{"id":"c64cf62f77e649998b998ce1af895c83","type":"TRIAL","name":"Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma","canonical_id":"clinicaltrials.gov:NCT01716754","description":"Asthma","metadata":null},{"id":"99bf37493e16490e8f2bdfa7ece4a6aa","type":"TRIAL","name":"Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01636076","description":"COPD","metadata":null},{"id":"f6121a14106f4dfd9b3d9f58f0ae3e27","type":"TRIAL","name":"Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00570778","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"aca6fb2c65d949f18dfd42c9f8334778","type":"TRIAL","name":"Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT00882518","description":"Schizophrenia","metadata":null},{"id":"a201b6aa1c3d4d72a05b65aa8ffb40b9","type":"TRIAL","name":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","canonical_id":"clinicaltrials.gov:NCT02307682","description":"Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization","metadata":null},{"id":"062f9e48784b48fca922cf5eecec3a56","type":"TRIAL","name":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","canonical_id":"clinicaltrials.gov:NCT02434328","description":"Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization","metadata":null},{"id":"b250d6ec97514a4fba27198812857db2","type":"TRIAL","name":"Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia","canonical_id":"clinicaltrials.gov:NCT00755508","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"893cc7d8dfbb411d9d3070bb927bebd0","type":"TRIAL","name":"Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder","canonical_id":"clinicaltrials.gov:NCT01467713","description":"Bipolar Disorder","metadata":null},{"id":"6d94483e8aff4fca8d588d302776beac","type":"TRIAL","name":"Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00325728","description":"Chronic Insomnia","metadata":null},{"id":"495eed52fcc047c59801b924a5e0bb79","type":"TRIAL","name":"Efficacy and Safety of Ramelteon on Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00915135","description":"Chronic Insomnia","metadata":null},{"id":"c42dbe2ced664e02ba374356f58819ae","type":"TRIAL","name":"Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants","canonical_id":"clinicaltrials.gov:NCT04987463","description":"Tuberous Sclerosis Complex","metadata":null},{"id":"b2ffbb7653364bb5b2ad071b937e398a","type":"TRIAL","name":"Efficacy and Safety of Rapid Titration Protocols of Lacosamide","canonical_id":"clinicaltrials.gov:NCT03607851","description":"Focal Epilepsy","metadata":null},{"id":"5d191fc3332e4092b73250e79e56116f","type":"TRIAL","name":"Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT05611372","description":"REM Sleep Behavior Disorder; Parkinson Disease; Synucleinopathies","metadata":null},{"id":"6b70fb544b1f49a3af859d3dc07d4688","type":"TRIAL","name":"Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)","canonical_id":"clinicaltrials.gov:NCT07596784","description":"Generalized Myasthenia Gravis; gMG","metadata":null},{"id":"7f15df6dfa634a579be705845cfba886","type":"TRIAL","name":"Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)","canonical_id":"clinicaltrials.gov:NCT05818267","description":"Colorectal Cancer","metadata":null},{"id":"bec073c338c64ae2ba702f66d875b734","type":"TRIAL","name":"Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.","canonical_id":"clinicaltrials.gov:NCT06846281","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"48fbaaf25d39483da480b4aae13583df","type":"TRIAL","name":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)","canonical_id":"clinicaltrials.gov:NCT05147220","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"79392d1a757f43e59ae9c36b36eadfdb","type":"TRIAL","name":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)","canonical_id":"clinicaltrials.gov:NCT05156281","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"e9dc4281e3774b2998052eb352b84d24","type":"TRIAL","name":"Efficacy and Safety of Remifentanil for Mechanically Ventilated Patients in Intensive Care Unit","canonical_id":"clinicaltrials.gov:NCT05641909","description":"Analgesia","metadata":null},{"id":"8083e0f3cd674abfb910301de16c4c46","type":"TRIAL","name":"Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs","canonical_id":"clinicaltrials.gov:NCT00491725","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"d8240e6a29424831b52843847c73f383","type":"TRIAL","name":"Efficacy and Safety of Repaglinide, Glurenorm\u00ae and Glucobay\u00ae in Chinese Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00568074","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"a42334792b5747358ab4b31f6f7ea82e","type":"TRIAL","name":"Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","canonical_id":"clinicaltrials.gov:NCT07284979","description":"Obesity","metadata":null},{"id":"472277c84e5147048e57fdae9f9601fa","type":"TRIAL","name":"Efficacy and Safety of Rimegepant for Acute Dizziness","canonical_id":"clinicaltrials.gov:NCT07435090","description":"Dizziness","metadata":null},{"id":"3bdd736436fc4dd9ac0abea80983ad73","type":"TRIAL","name":"Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00619957","description":"Other Osteoporosis","metadata":null},{"id":"b6af6008b61e458782c3a5897071019e","type":"TRIAL","name":"Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium","canonical_id":"clinicaltrials.gov:NCT02118688","description":"Delirium; Agitation","metadata":null},{"id":"8a2df847feba4c2f809c89a26f16c302","type":"TRIAL","name":"Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin","canonical_id":"clinicaltrials.gov:NCT03673605","description":"Mitral Valve Stenosis; Atrial Fibrillation","metadata":null},{"id":"5b64df944d5a4a61b3dfd59364045c58","type":"TRIAL","name":"Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia","canonical_id":"clinicaltrials.gov:NCT00099216","description":"Vascular Dementia","metadata":null},{"id":"abd635f98cbd43f18736ace44fcaa1de","type":"TRIAL","name":"Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT04384367","description":"Migraine","metadata":null},{"id":"3307f26b69154230b52ebba575f64cf7","type":"TRIAL","name":"Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study","canonical_id":"clinicaltrials.gov:NCT06648772","description":"Plaque Psoriasis","metadata":null},{"id":"2e7032bb58c346208fc1ee73e9edc24d","type":"TRIAL","name":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT06631170","description":"Atopic Dermatitis (AD)","metadata":null},{"id":"bebc60d453a84e1fb29f00ff3464d7c2","type":"TRIAL","name":"Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)","canonical_id":"clinicaltrials.gov:NCT00163475","description":"Asthma","metadata":null},{"id":"19b837f73f1d462a892080d2afed3812","type":"TRIAL","name":"Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)","canonical_id":"clinicaltrials.gov:NCT00073177","description":"Asthma","metadata":null},{"id":"a372f5220e1941189d2c98628d5a81d1","type":"TRIAL","name":"Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01796002","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"1b26114ceb9a41a6b7b39efc4a501b7a","type":"TRIAL","name":"Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT07206823","description":"Primacy Immune Thrombocytopenia","metadata":null},{"id":"54c294d0390548729a29a9ae264e23bd","type":"TRIAL","name":"Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome","canonical_id":"clinicaltrials.gov:NCT04371939","description":"Wiskott-Aldrich Syndrome","metadata":null},{"id":"40c0d933271740f790a25ded0865da3e","type":"TRIAL","name":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01575834","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"2f0cb0c4a06d4b8ea4933a16207bdf3b","type":"TRIAL","name":"Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera","canonical_id":"clinicaltrials.gov:NCT06290765","description":"Polycythemia Vera; Myeloproliferative Neoplasm","metadata":null},{"id":"69c454b9c6614b0f9f356e4a3c8fa877","type":"TRIAL","name":"Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria","canonical_id":"clinicaltrials.gov:NCT00199251","description":"Urticaria","metadata":null},{"id":"70545770b7d941eaaa8768b96b70c53e","type":"TRIAL","name":"Efficacy and Safety of Ryanodex\u00ae (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)","canonical_id":"clinicaltrials.gov:NCT02513095","description":"Heat Stroke","metadata":null},{"id":"bf7d2c98257b48ef94f2c3197afdd5f5","type":"TRIAL","name":"Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain","canonical_id":"clinicaltrials.gov:NCT04637529","description":"Osteoarthritis","metadata":null},{"id":"078e63717db14c809d43e86871698d2b","type":"TRIAL","name":"Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","canonical_id":"clinicaltrials.gov:NCT06040177","description":"Hepatocellular Carcinoma Non-resectable; Portal Vein Tumor Thrombus; Immune Checkpoint Inhibitors","metadata":null},{"id":"6282cc09f08741beacedeff80402dc20","type":"TRIAL","name":"Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00399464","description":"Prostatic Hyperplasia","metadata":null},{"id":"c8421ad90039484b9260865c8948875e","type":"TRIAL","name":"Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine","canonical_id":"clinicaltrials.gov:NCT00825058","description":"Major Depressive Disorders","metadata":null},{"id":"38a28d547833452892d30780f062aa8d","type":"TRIAL","name":"Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01187966","description":"Parkinson's Disease","metadata":null},{"id":"70f42db9cf4c4476b108061aad473437","type":"TRIAL","name":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","canonical_id":"clinicaltrials.gov:NCT02332590","description":"Rheumatoid Arthritis","metadata":null},{"id":"978d35c7e3934a54a9d9cee99965c700","type":"TRIAL","name":"Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT06926192","description":"Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa); Secukinumab","metadata":null},{"id":"42ac111ae3024a7e97a46178e5fb0bad","type":"TRIAL","name":"Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","canonical_id":"clinicaltrials.gov:NCT05090410","description":"Rheumatoid Arthritis; JAK Inhibitor; IL-6 Inhibitor; Musculoskeletal Ultrasound; Biomarker","metadata":null},{"id":"1586d218e08744949808c176fe431077","type":"TRIAL","name":"Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07733050","description":"Metastatic Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"0b98ee70039e493c9de1c095418e99c6","type":"TRIAL","name":"Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity","canonical_id":"clinicaltrials.gov:NCT05821543","description":"Obesity","metadata":null},{"id":"6fe2fd487fab4023be85b878dfeb7d72","type":"TRIAL","name":"Efficacy and Safety of Silodosin in the Treatment of Lower Urinary Tract Symptoms in Taiwanese Population.","canonical_id":"clinicaltrials.gov:NCT06332235","description":"Human Trichinellosis","metadata":null},{"id":"27e685adac8f4bf89dff97b44fb2b02b","type":"TRIAL","name":"Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT01533389","description":"Ureteral Stone","metadata":null},{"id":"60591354f30b4421a7c9fbb03ab4a045","type":"TRIAL","name":"Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT02106182","description":"Nocturia; Benign Prostatic Hyperplasia","metadata":null},{"id":"559f0e7002d34022bafe09b7bdae571c","type":"TRIAL","name":"Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder","canonical_id":"clinicaltrials.gov:NCT01228370","description":"Neurogenic Bladder; Voiding Dysfunction","metadata":null},{"id":"809e872fdaaf486b88d5766f10033457","type":"TRIAL","name":"Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04329650","description":"COVID-19","metadata":null},{"id":"51fcb627cb3144d78ba1eeb74588022a","type":"TRIAL","name":"Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy","canonical_id":"clinicaltrials.gov:NCT04069325","description":"Gout Flare","metadata":null},{"id":"c5096affa8754ad5a03a676761d50f41","type":"TRIAL","name":"Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)","canonical_id":"clinicaltrials.gov:NCT04745130","description":"Sintilimab, Cetuximab, Regorafenib,Combine,mCRC","metadata":null},{"id":"810c56e55a2540d0a0d89841e5c21679","type":"TRIAL","name":"Efficacy and Safety of Sirolimus in Combination With Tacrolimus","canonical_id":"clinicaltrials.gov:NCT00141804","description":"Kidney Transplantation","metadata":null},{"id":"e0f675e2d0274df7b60dfd914561e4d8","type":"TRIAL","name":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","canonical_id":"clinicaltrials.gov:NCT00993187","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1ad4540dc6554459bf187a82a4f4fc2b","type":"TRIAL","name":"Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS","canonical_id":"clinicaltrials.gov:NCT06387823","description":"Acute Respiratory Distress Syndrome","metadata":null},{"id":"7ef0a8f721ec41e78e5ff1c9dd6c837d","type":"TRIAL","name":"Efficacy and Safety of Sivelestat in Preventing Postoperative Acute Lung Injury or Acute Respiratory Distress Syndrome After Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT06276569","description":"Cardiac Disease","metadata":null},{"id":"9dc7241d8ecf40dfa25eaad38200ea2a","type":"TRIAL","name":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","canonical_id":"clinicaltrials.gov:NCT03434119","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"731a5cd23e9c4d799d095c902c82bbee","type":"TRIAL","name":"Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT00703365","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"fccf77227ba049b29c3cffeffc98ebec","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","canonical_id":"clinicaltrials.gov:NCT03332771","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"17b1ded1e63c478d9a04c6ee61f490e6","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin","canonical_id":"clinicaltrials.gov:NCT03351478","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"b83be470aed342cb8cad138511c2f21a","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise","canonical_id":"clinicaltrials.gov:NCT03760965","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"afd32970009b4d529db6c2b9c4beddd2","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea","canonical_id":"clinicaltrials.gov:NCT03761134","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"ef8ef1a698d24121ae3ca6b2e5811065","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents","canonical_id":"clinicaltrials.gov:NCT03285594","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a410296824d24c548221102098f58cd8","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","canonical_id":"clinicaltrials.gov:NCT03066830","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"28f98d2f026f48afa16451f0613bffec","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy","canonical_id":"clinicaltrials.gov:NCT02926937","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"429502a29ca54ee182b92f3208929007","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin","canonical_id":"clinicaltrials.gov:NCT02926950","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"bf1f40d49b3c40afa1ba2f75f02fa2ca","type":"TRIAL","name":"Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C","canonical_id":"clinicaltrials.gov:NCT02383940","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"02c97918662441e495d5c0c4259f8a5b","type":"TRIAL","name":"Efficacy and Safety of Sotalol in Children With Arrhythmia","canonical_id":"clinicaltrials.gov:NCT03895411","description":"Arrhythmia","metadata":null},{"id":"dfc5d1e6b0e0421aae898bf13f277db1","type":"TRIAL","name":"Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis","canonical_id":"clinicaltrials.gov:NCT07143864","description":"Primary Cutaneous Amyloidosis","metadata":null},{"id":"a3ff3ee7cf6941fea5242fc90d274b9f","type":"TRIAL","name":"Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome","canonical_id":"clinicaltrials.gov:NCT07240376","description":"Non-Allergic Rhinitis With Eosinophilia Syndrome","metadata":null},{"id":"bfe57f580f3e40b79ff2b620519527e7","type":"TRIAL","name":"Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00503763","description":"Smoldering Multiple Myeloma","metadata":null},{"id":"3df15281e8824b03bbee2447eb9fe501","type":"TRIAL","name":"Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT02638103","description":"Migraine","metadata":null},{"id":"8a8d91a365a24b40a1e3f01531eee69a","type":"TRIAL","name":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","canonical_id":"clinicaltrials.gov:NCT05263206","description":"Pruritus","metadata":null},{"id":"2324ee69f4ca415eb6654325bcafd124","type":"TRIAL","name":"Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)","canonical_id":"clinicaltrials.gov:NCT04571944","description":"Delirium","metadata":null},{"id":"4a8a938050dd4639b71441a85318bc7c","type":"TRIAL","name":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","canonical_id":"clinicaltrials.gov:NCT02738632","description":"Essential Hypertension","metadata":null},{"id":"645bf99abc1b4c70bb4012334610765e","type":"TRIAL","name":"Efficacy and Safety of Tadalafil in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT00334477","description":"Erectile Dysfunction","metadata":null},{"id":"9d53e5b82efd41608de96c2c8b91984a","type":"TRIAL","name":"Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00421083","description":"Erectile Dysfunction; Spinal Cord Injuries","metadata":null},{"id":"78f2399c54ff4a08ac78c82689597ee8","type":"TRIAL","name":"Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01120002","description":"Alzheimer's Disease","metadata":null},{"id":"a433a57530dc4dbe8e63d34137a57017","type":"TRIAL","name":"Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT01226147","description":"Lupus Nephritis","metadata":null},{"id":"8b9992d9d5af43b0ba7122903f553719","type":"TRIAL","name":"Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)","canonical_id":"clinicaltrials.gov:NCT01343355","description":"HTLV-I-Associated Myelopathy","metadata":null},{"id":"fcd4fcfd88ed408c827d031eb3393225","type":"TRIAL","name":"Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT00745069","description":"Osteoarthitis; Chronic Pain; Knee Pain","metadata":null},{"id":"91dc3050ed9c4eb9acec0523ad15052d","type":"TRIAL","name":"Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder","canonical_id":"clinicaltrials.gov:NCT01163032","description":"Non-24-Hour Sleep-Wake Disorder","metadata":null},{"id":"1b762131f6604fb99b8013ed6c3347e3","type":"TRIAL","name":"Efficacy and Safety of Tazarotene Gel in Nail Psoriasis","canonical_id":"clinicaltrials.gov:NCT02235480","description":"Nail Psoriasis","metadata":null},{"id":"463535b612df43e3a9f502735aaaea02","type":"TRIAL","name":"Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT06979271","description":"Telitacicept; Treatment Compliance; Rheumatoid Arthritis","metadata":null},{"id":"761cbf12a1b4490595566172978d244b","type":"TRIAL","name":"Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02916706","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"2c747d833bfe4090b0bcab669ade737e","type":"TRIAL","name":"Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02924064","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c15a9bb4365d486d8a6f164fa816e6da","type":"TRIAL","name":"Efficacy and Safety of Tetrabenazine in Chorea","canonical_id":"clinicaltrials.gov:NCT00219804","description":"Huntington's Disease","metadata":null},{"id":"ffc3e9f6c3e64fefac59175506ea60ad","type":"TRIAL","name":"Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis","canonical_id":"clinicaltrials.gov:NCT04851964","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"31703dbbaf2d4d5ab8f66e03c5dd6c9f","type":"TRIAL","name":"Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT05583227","description":"Eosinophilic Esophagitis","metadata":null},{"id":"67dd98a328884c5aa25102caae8f25c5","type":"TRIAL","name":"Efficacy and Safety of Therapy With Tri-Luma\u00ae Cream in Sequence With Glycolic Acid Peels for Melasma","canonical_id":"clinicaltrials.gov:NCT00472966","description":"Melasma","metadata":null},{"id":"8f63cb372cab4da0b8f7b19e92607ce1","type":"TRIAL","name":"Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.","canonical_id":"clinicaltrials.gov:NCT01120093","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"11af0ddb1a384ab6acbefd5de2602d62","type":"TRIAL","name":"Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)","canonical_id":"clinicaltrials.gov:NCT04229836","description":"Plaque Psoriasis","metadata":null},{"id":"c5ff77445e9f427490ab90d66f1f0e7e","type":"TRIAL","name":"Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy","canonical_id":"clinicaltrials.gov:NCT04263610","description":"Plaque Psoriasis","metadata":null},{"id":"66e4fa26776d40838480dd69153a504f","type":"TRIAL","name":"Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02172469","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"a57c249a9563485eb43c4c0f2963a3c3","type":"TRIAL","name":"Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg","canonical_id":"clinicaltrials.gov:NCT00350207","description":"Asthma","metadata":null},{"id":"83a6b70b3b704d949f5f90b5453de16d","type":"TRIAL","name":"Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)","canonical_id":"clinicaltrials.gov:NCT06037889","description":"Branch Atheromatous Disease","metadata":null},{"id":"d7a173c939674b91bc6f8863a462fccd","type":"TRIAL","name":"Efficacy and Safety of Tocilizumab in Adult's Still Disease","canonical_id":"clinicaltrials.gov:NCT01002781","description":"Adult's Still Disease","metadata":null},{"id":"0f58575ee4ca4d309b8d957d9484478a","type":"TRIAL","name":"Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT05067348","description":"Myasthenia Gravis, Generalized","metadata":null},{"id":"e95e65326bc2437c92b53a0911b75a99","type":"TRIAL","name":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder","canonical_id":"clinicaltrials.gov:NCT06270433","description":"Anhedonia","metadata":null},{"id":"894cb891219f4f54a6e943c47a409f18","type":"TRIAL","name":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder","canonical_id":"clinicaltrials.gov:NCT06278038","description":"Major Depression Disorder","metadata":null},{"id":"40e285441190466988962e9b0b3259dd","type":"TRIAL","name":"Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02160145","description":"Chronic Kidney Disease; Autosomal Dominant Polycystic Kidney Disease","metadata":null},{"id":"1352ba5357cc4cc989da245ebffcac88","type":"TRIAL","name":"Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00423007","description":"Allergic Conjunctivitis","metadata":null},{"id":"4c224d14486e4ea0b3d2d7e2110843bc","type":"TRIAL","name":"Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea","canonical_id":"clinicaltrials.gov:NCT06952517","description":"Papular-pustular Rosacea; Papulopustular Rosacea (PPR); Papulopustular Rosacea","metadata":null},{"id":"d167a041532343f99c9a10daf5087b85","type":"TRIAL","name":"Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)","canonical_id":"clinicaltrials.gov:NCT05194540","description":"Atopic Dermatitis","metadata":null},{"id":"48a78a0eceb4498ebc7f98cb7b918801","type":"TRIAL","name":"Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00966940","description":"Glaucoma","metadata":null},{"id":"deff82bcbd8f4915b4ffc65d5373b2cd","type":"TRIAL","name":"Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT04679935","description":"Age-related Macular Degeneration","metadata":null},{"id":"b9989e86ae2e468f917c7e0e720a112a","type":"TRIAL","name":"Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT02446912","description":"Active Systemic Lupus Erythematosus","metadata":null},{"id":"04e8f8ce4bda4be69279dbe297718b6c","type":"TRIAL","name":"Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate","canonical_id":"clinicaltrials.gov:NCT01078623","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"62dd546a650b4d4c987a720d12f107a4","type":"TRIAL","name":"Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT01235689","description":"Crohn's Disease","metadata":null},{"id":"fe1e389335424f0d83fca0393289dee3","type":"TRIAL","name":"Efficacy and Safety of Ustekinumab in Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT04117932","description":"Bullous Pemphigoid","metadata":null},{"id":"ec52f5d373f547e9b90c8fc852d70a24","type":"TRIAL","name":"Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients","canonical_id":"clinicaltrials.gov:NCT00650455","description":"Arthritis, Rheumatoid","metadata":null},{"id":"c59e2ef0f6444b3bac8391d07dcd4342","type":"TRIAL","name":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage","canonical_id":"clinicaltrials.gov:NCT00687206","description":"Hypertension; Ventricular Remodeling; Erectile Dysfunctions","metadata":null},{"id":"593276c5e6564ef1b966dfc37cc9e7ae","type":"TRIAL","name":"Efficacy and Safety of Valsartan and Amlodipine (\u00b1 HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","canonical_id":"clinicaltrials.gov:NCT00523744","description":"Hypertension","metadata":null},{"id":"e37ed8294ea646a2a8755baf4a145e95","type":"TRIAL","name":"Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension","canonical_id":"clinicaltrials.gov:NCT00400777","description":"Hypertension","metadata":null},{"id":"0bc8e5c09f6d4b2da68363c3ed73cf81","type":"TRIAL","name":"Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone","canonical_id":"clinicaltrials.gov:NCT00170963","description":"Hypertension","metadata":null},{"id":"1a80a8b43af94d77948721bc511d123f","type":"TRIAL","name":"Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT00537095","description":"Thyroid Neoplasms","metadata":null},{"id":"e8702d7aabbd4c66aac269a0f2c3de6a","type":"TRIAL","name":"Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00657644","description":"Erectile Dysfunction","metadata":null},{"id":"e35b9496b5164c3a906676664157c257","type":"TRIAL","name":"Efficacy and Safety of Varenicline Among HIV-infected Patients","canonical_id":"clinicaltrials.gov:NCT00918307","description":"HIV Infections; Tobacco Dependence","metadata":null},{"id":"db05e8647bbd446d824033e3b2cd5eda","type":"TRIAL","name":"Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT06095596","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"3cc0065b8aaa4f07900876e8dbd42f9c","type":"TRIAL","name":"Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT03035058","description":"Primary Sclerosing Cholangitis; Inflammatory Bowel Disease","metadata":null},{"id":"440cb8fe39264a4dae4b6203cab725fc","type":"TRIAL","name":"Efficacy and Safety of Vedolizumab in Biologic-na\u00efve Korean Patients With Moderate to Severe Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT04919252","description":"Crohn's Disease and Ulcerative Colitis","metadata":null},{"id":"497d49f8e57b4737b90b299edaa45410","type":"TRIAL","name":"Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH","canonical_id":"clinicaltrials.gov:NCT05546060","description":"Hemophagocytic Lymphohistiocytosis","metadata":null},{"id":"9ebf2e3fb26a42c98ef0929210e30241","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00110240","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1dfdb9f4be974be495cd7aebf0a5dd4a","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00102388","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"42de0ad4bbfe4f769493b1f762d8aaa2","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00099866","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"77cd44130c174fd2991a8b329683dd43","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia","canonical_id":"clinicaltrials.gov:NCT00101712","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"29f6c73950c04df3a31f258f44d4f0e6","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin","canonical_id":"clinicaltrials.gov:NCT00396071","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"78e53a30160d4480b58854547a3aad49","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00099918","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"2c68501791144256b5695dfae7d5cef7","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01224366","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"edb0687a10614b76a75df8edb4fda703","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00099892","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1a91cc2f6589494b8372e2f71ff7f4f5","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00101803","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"ed38381307614e6faf93de01250e32f0","type":"TRIAL","name":"Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance","canonical_id":"clinicaltrials.gov:NCT00237250","description":"Prediabetic State","metadata":null},{"id":"6fa0f4d0804846f6a48db02770a761a8","type":"TRIAL","name":"Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00672958","description":"Major Depressive Disorder","metadata":null},{"id":"8d5daa8f7aba4238b3e3909330e3f7c7","type":"TRIAL","name":"Efficacy and Safety of Xacrel\u00ae (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04966338","description":"Multiple Sclerosis; Relapsing-Remitting","metadata":null},{"id":"8248b05941934497a4c8f4759c5c6bcb","type":"TRIAL","name":"Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT07339566","description":"Nr-axial Spondyloarthritis; Non-Radiographical Axial Spondyloarthritis","metadata":null},{"id":"71cbed5c9acd4ea9876caf25c193cafc","type":"TRIAL","name":"Efficacy and Safety of Zactima\u2122 in Patients With Castration-refractory Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00659438","description":"Prostate Cancer","metadata":null},{"id":"d836cc7e8fee46a29734bdda5e14f3a8","type":"TRIAL","name":"Efficacy and Safety of Zolmitriptan by Sublingual Administration","canonical_id":"clinicaltrials.gov:NCT03377257","description":"Cluster Headache","metadata":null},{"id":"e4f84b7c79a94d72a8641a4440f0a5e1","type":"TRIAL","name":"Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT01390324","description":"Migraine; Headache","metadata":null},{"id":"e8ae64fce3ab48cc94eb81360512c5a2","type":"TRIAL","name":"Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.","canonical_id":"clinicaltrials.gov:NCT01726920","description":"Migraine; Headache","metadata":null},{"id":"92f511920c324f65a3c17a4fc4e81f9c","type":"TRIAL","name":"Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis","canonical_id":"clinicaltrials.gov:NCT00124475","description":"Hand Dermatoses","metadata":null},{"id":"c7cd6d4e2401422a839bc3ad54079bde","type":"TRIAL","name":"Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT00817063","description":"Eczema","metadata":null},{"id":"57f3597aded34fadaced6bd6744c1722","type":"TRIAL","name":"Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg","canonical_id":"clinicaltrials.gov:NCT01611077","description":"Hypertension","metadata":null},{"id":"7aa9baba23de483689a193990004d48f","type":"TRIAL","name":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","canonical_id":"clinicaltrials.gov:NCT07307235","description":"Type 2 Diabetes","metadata":null},{"id":"cd380ee2ad124900b1a823419a49f8b0","type":"TRIAL","name":"Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01125761","description":"Dermatitis","metadata":null},{"id":"96ef1ef81cc143a18b061261cadac3d8","type":"TRIAL","name":"Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission","canonical_id":"clinicaltrials.gov:NCT07644481","description":"AML (Acute Myelogenous Leukemia); Allogeneic Hematopoietic Stem Cell Transplantation Recipient","metadata":null},{"id":"d4853e02204747c68e45eb995f77e26d","type":"TRIAL","name":"Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment","canonical_id":"clinicaltrials.gov:NCT03025113","description":"Musculoskeletal Pain","metadata":null},{"id":"c8711ef1a9b94fe7b7c492169e2b2114","type":"TRIAL","name":"Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria","canonical_id":"clinicaltrials.gov:NCT05131204","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"136db745b6064394b9fd1c9b80c5f6ff","type":"TRIAL","name":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04276376","description":"Solid Tumor","metadata":null},{"id":"5dc67b8bc5ee4f8ebec87a7c383ccf55","type":"TRIAL","name":"Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05583110","description":"HER2-positive Metastatic Breast Cancer; Locally Advanced HER2 Positive Breast Carcinoma","metadata":null},{"id":"e5456917a8b1456d9ee89777231fd61c","type":"TRIAL","name":"Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.","canonical_id":"clinicaltrials.gov:NCT04882293","description":"Dyslipidemia Associated With Type II Diabetes Mellitus","metadata":null},{"id":"c8dbb1ba83e748ce84b2f8142f073e16","type":"TRIAL","name":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","canonical_id":"clinicaltrials.gov:NCT02787551","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"ac8d4c7cd9ef420c8e87a44a1f38aa5b","type":"TRIAL","name":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02058160","description":"Type 2 Diabetes","metadata":null},{"id":"9ae747a3523e47598e0324aa7de9870c","type":"TRIAL","name":"Efficacy and Safety of \u0392eta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction","canonical_id":"clinicaltrials.gov:NCT01825122","description":"Smoking Cessation","metadata":null},{"id":"e4eb2b688ede4795aa7a5ee627fec1da","type":"TRIAL","name":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","canonical_id":"clinicaltrials.gov:NCT01415518","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"4ec2c970d41b451c92d0e3a3f9076b82","type":"TRIAL","name":"Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test","canonical_id":"clinicaltrials.gov:NCT00578370","description":"Psoriasis","metadata":null},{"id":"472ca56805fc407f87ac75d867999afa","type":"TRIAL","name":"Efficacy and Tolerability of AZARGA\u00ae as Replacement Therapy in Patients on COMBIGAN\u00ae Therapy in Canada","canonical_id":"clinicaltrials.gov:NCT01415401","description":"Glaucoma; Ocular Hypertension; Open-angle Glaucoma","metadata":null},{"id":"b29a255717ef4e288526facb384c5837","type":"TRIAL","name":"Efficacy and Tolerability of Baclofen for Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00877734","description":"Alcohol Dependence","metadata":null},{"id":"2a842d81586d4465986ba6bdae702d30","type":"TRIAL","name":"Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00293839","description":"Urinary Incontinence","metadata":null},{"id":"9fcf3363f8604bb5a2a5fcb2cdcc248a","type":"TRIAL","name":"Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis","canonical_id":"clinicaltrials.gov:NCT07000630","description":"Palmoplantar Pustulosis","metadata":null},{"id":"26b8e28cd61c43ccbaaa1032903cd5df","type":"TRIAL","name":"Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01148472","description":"Major Depressive Disorder","metadata":null},{"id":"47ed01f449dc4eb88e45e9eb711d4123","type":"TRIAL","name":"Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease","canonical_id":"clinicaltrials.gov:NCT05768334","description":"NAFLD","metadata":null},{"id":"43cf6afdbd49487fa60a69f65c1fdbf9","type":"TRIAL","name":"Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis","canonical_id":"clinicaltrials.gov:NCT01011621","description":"Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis","metadata":null},{"id":"99a251da8a544b68920b1636964412c6","type":"TRIAL","name":"Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients","canonical_id":"clinicaltrials.gov:NCT03104621","description":"Primary Open-angle Glaucoma","metadata":null},{"id":"b69fd38e431e488481916cbc9a242aa6","type":"TRIAL","name":"Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use","canonical_id":"clinicaltrials.gov:NCT05509400","description":"Migraine","metadata":null},{"id":"f26a31fa96334a68aa31233900c6202d","type":"TRIAL","name":"Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications","canonical_id":"clinicaltrials.gov:NCT05518123","description":"Migraine","metadata":null},{"id":"75a19efb367a49a0b3064d064776799b","type":"TRIAL","name":"Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01006590","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7b898131fafb4b7a81f632ded17fe2ed","type":"TRIAL","name":"Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)","canonical_id":"clinicaltrials.gov:NCT01416636","description":"Non-operable Chronic Thromboembolic Pulmonary Hypertension","metadata":null},{"id":"c6807e95d15f4100924c36347b024477","type":"TRIAL","name":"Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics","canonical_id":"clinicaltrials.gov:NCT00458211","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"e6a6cb78a37a4c19a18ee80f8ae65b03","type":"TRIAL","name":"Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS","canonical_id":"clinicaltrials.gov:NCT07206706","description":"Management of Ureteric Stent Related LUTS and Pain","metadata":null},{"id":"49578a0ceb6b4c78811ed23cdb07efd7","type":"TRIAL","name":"Efficacy and Tolerability of Zolmitriptan Nasal Spray","canonical_id":"clinicaltrials.gov:NCT00617747","description":"Migraine","metadata":null},{"id":"9063ef061bfa42dd9b6ff65fe437c0f4","type":"TRIAL","name":"Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis","canonical_id":"clinicaltrials.gov:NCT05651880","description":"Active Non-anterior Non-infectious Uveitis","metadata":null},{"id":"80539d01ce404f33ae989d13396a61c8","type":"TRIAL","name":"Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension","canonical_id":"clinicaltrials.gov:NCT04128137","description":"Neurogenic Orthostatic Hypotension","metadata":null},{"id":"55e9619eaca14a31a6b200c764d53a74","type":"TRIAL","name":"Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo","canonical_id":"clinicaltrials.gov:NCT05917561","description":"Vitiligo","metadata":null},{"id":"75804033cd3a4846bb96b1bb55c99060","type":"TRIAL","name":"Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy","canonical_id":"clinicaltrials.gov:NCT00866554","description":"Prostate Cancer; Erectile Dysfunction; Lower Urinary Tract Symptoms","metadata":null},{"id":"38c48997c46c483fabc261dfbc9557c6","type":"TRIAL","name":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor \u03b1 (Anti-TNF\u03b1) Agents (CAIN457F2309 and CAIN457F2309E1)","canonical_id":"clinicaltrials.gov:NCT01350804","description":"Rheumatoid Arthritis","metadata":null},{"id":"2a80781ce9174e1090747e4a638403c8","type":"TRIAL","name":"Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy","canonical_id":"clinicaltrials.gov:NCT04309773","description":"Primary Sclerosing Cholangitis; Cholestasis","metadata":null},{"id":"7d2523eba7d24a168dbd91c58c23a9a2","type":"TRIAL","name":"Efficacy of 5% Chitosan Nanoparticle Paste in the Treatment of Recurrent Aphthous Stomatitis","canonical_id":"clinicaltrials.gov:NCT07702474","description":"Recurrent Aphthous Stomatitis; Oral Ulcers","metadata":null},{"id":"e672e09158154364a747f06b89265ec0","type":"TRIAL","name":"Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden","canonical_id":"clinicaltrials.gov:NCT04461795","description":"Migraine","metadata":null},{"id":"343a3b35a30946b0abab5b347331f43f","type":"TRIAL","name":"Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time","canonical_id":"clinicaltrials.gov:NCT00929279","description":"Acute Coronary Syndrome","metadata":null},{"id":"832d57cdcc0d40d0ac6e2dbb7ef12b99","type":"TRIAL","name":"Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-na\u00efve or Relapsed/Refractory CLL","canonical_id":"clinicaltrials.gov:NCT04883749","description":"Chronic Lymphoid Leukemia","metadata":null},{"id":"8702f7d16ec347288635ecd17a8a3e4e","type":"TRIAL","name":"Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","canonical_id":"clinicaltrials.gov:NCT00868231","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"50e3d176cfe94fcaae55d5dce55d65e8","type":"TRIAL","name":"Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery","canonical_id":"clinicaltrials.gov:NCT06887621","description":"Post Operative Nausea and Vomiting (PONV)","metadata":null},{"id":"7f45f63ff97c4512bdc5dcac04fc2adc","type":"TRIAL","name":"Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)","canonical_id":"clinicaltrials.gov:NCT04578236","description":"Covid19","metadata":null},{"id":"25b25eea94fc403da1fba249b2ae58ea","type":"TRIAL","name":"Efficacy of Aflibercept (Eylea\u00ae) on Choroidal Neovascularization (Type 3)","canonical_id":"clinicaltrials.gov:NCT02320474","description":"Type 3 Choroidal Neovascularization","metadata":null},{"id":"a419bd9c8bd94f7c9d05b2c57026d9ae","type":"TRIAL","name":"Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT01108393","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"bdf562a6a188479eb8129122e226210d","type":"TRIAL","name":"Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT03929718","description":"AFib","metadata":null},{"id":"2290142a03f8493380370a37feccc559","type":"TRIAL","name":"Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis","canonical_id":"clinicaltrials.gov:NCT01245140","description":"Psoriasis","metadata":null},{"id":"857c3375492e47bf91fa1029b08af8ba","type":"TRIAL","name":"Efficacy of Allopurinol and Dypiridamole in Acute Mania","canonical_id":"clinicaltrials.gov:NCT00560079","description":"Mania","metadata":null},{"id":"e5ae752c14004f1b8e7884e9ca3e6390","type":"TRIAL","name":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00432276","description":"Diabetes Mellitus","metadata":null},{"id":"e518914ffb32443c80df3978bc65b974","type":"TRIAL","name":"Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women","canonical_id":"clinicaltrials.gov:NCT05439902","description":"Multiple Sclerosis; Dysuria; Lower Urinary Tract Symptoms; Voiding Dysfunction; Urinary Retention","metadata":null},{"id":"36f5b5bcd7ea4feab2ea16cd4347329b","type":"TRIAL","name":"Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet","canonical_id":"clinicaltrials.gov:NCT01072669","description":"Ischemia","metadata":null},{"id":"0f4860feb4a2486eb6daf00c33e67a4b","type":"TRIAL","name":"Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00274391","description":"Cystic Fibrosis","metadata":null},{"id":"acaae739742942999417b92d099552f6","type":"TRIAL","name":"Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)","canonical_id":"clinicaltrials.gov:NCT00124306","description":"Bladder Diseases; Interstitial Cystitis","metadata":null},{"id":"132d7e34ab8a46a38799ab33936b7974","type":"TRIAL","name":"Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome","canonical_id":"clinicaltrials.gov:NCT05704400","description":"Nephrotic Syndrome","metadata":null},{"id":"3e8be9bd23c54250b2b63e44b92a2817","type":"TRIAL","name":"Efficacy of Antidepressants in Chronic Back Pain","canonical_id":"clinicaltrials.gov:NCT00964886","description":"Back Pain","metadata":null},{"id":"da02092c025e448c873e5f6049cb1433","type":"TRIAL","name":"Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","canonical_id":"clinicaltrials.gov:NCT07461545","description":"Cirrhosis; Splenectomy; Portal Vein Thrombosis; Hypertension, Portal","metadata":null},{"id":"5e8cf2a403e545808fc9f18bfcd67be2","type":"TRIAL","name":"Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT05045248","description":"Myasthenia Gravis; Ocular Myasthenia Gravis","metadata":null},{"id":"586c35ea171f400ea1c7970ff2e19524","type":"TRIAL","name":"Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects","canonical_id":"clinicaltrials.gov:NCT00255138","description":"Cancer; Cognitive Late Effects","metadata":null},{"id":"674f5de95af4498ab347191ef4de4a53","type":"TRIAL","name":"Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD","canonical_id":"clinicaltrials.gov:NCT01207622","description":"Attention Deficit Hyperactivity Disorder; Substance Use Disorder","metadata":null},{"id":"1a8cc516ae554305ab7c9e2da9d5999f","type":"TRIAL","name":"Efficacy of Auricular Acupressure Combined With Antihistamines in Patients With Wind-Heat Type Urticaria.","canonical_id":"clinicaltrials.gov:NCT07575464","description":"Auricular Acupressure; Wind-Heat Urticaria; Traditional Medicine","metadata":null},{"id":"7c960244a0734257b2f1fa712169ba81","type":"TRIAL","name":"Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis","canonical_id":"clinicaltrials.gov:NCT05626621","description":"Chronic Rhinitis","metadata":null},{"id":"a13a1d22a51442199592218641269530","type":"TRIAL","name":"Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects","canonical_id":"clinicaltrials.gov:NCT03945760","description":"Allergic Contact Dermatitis","metadata":null},{"id":"51f46f4832934086aad94ed0b2235568","type":"TRIAL","name":"Efficacy of Belatacept in Reducing DSA","canonical_id":"clinicaltrials.gov:NCT02078193","description":"Kidney Transplantation","metadata":null},{"id":"c5fbf1aa73d3471a828d6772e061bd0e","type":"TRIAL","name":"Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT00139360","description":"Metastatic Melanoma","metadata":null},{"id":"233c63e9f09b45b1817e45a45bc2e2f1","type":"TRIAL","name":"Efficacy of Bifeprunox in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00658645","description":"Schizophrenia","metadata":null},{"id":"c65048753530465b85d964b87ca6cbec","type":"TRIAL","name":"Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum","canonical_id":"clinicaltrials.gov:NCT07767864","description":"Pyoderma Gangrenosum","metadata":null},{"id":"835a25f5f83b46c5bebb1d9fa6ffcb5f","type":"TRIAL","name":"Efficacy of Biofeedback PFMT and Medication in Women With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT04477265","description":"Overactive Bladder","metadata":null},{"id":"4c90b44c29de4cc1bf8e78629632192b","type":"TRIAL","name":"Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT01367249","description":"Pain; Inflammation; Cataract","metadata":null},{"id":"4b9be7c7961d4d44b81b89122ba3ae05","type":"TRIAL","name":"Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury","canonical_id":"clinicaltrials.gov:NCT03496545","description":"Subarachnoid Hemorrhage; Subdural Hematoma; Traumatic Brain Injury; Ischemic Stroke; Fever; Intracerebral Hemorrhage","metadata":null},{"id":"fce82e517b644a02b8aa89e301579af4","type":"TRIAL","name":"Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models","canonical_id":"clinicaltrials.gov:NCT07005414","description":"Autism Spectrum Disorder","metadata":null},{"id":"d33e7996db014215b1033f637ae3ab96","type":"TRIAL","name":"Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome","canonical_id":"clinicaltrials.gov:NCT06465823","description":"Down Syndrome","metadata":null},{"id":"e73ad648dbb94696b2dc6aa475c89f65","type":"TRIAL","name":"Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT06779149","description":"Insomnia Disorder","metadata":null},{"id":"e29b19097d434d92bd607b210add2909","type":"TRIAL","name":"Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT00495183","description":"Cocaine Dependence","metadata":null},{"id":"ac0995d41eec4012aea8965baf12143b","type":"TRIAL","name":"Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients","canonical_id":"clinicaltrials.gov:NCT00495092","description":"Cocaine Related Disorders","metadata":null},{"id":"fb53d264f24742bf95ef49f8ad740d78","type":"TRIAL","name":"Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT00243464","description":"Psoriasis of Scalp","metadata":null},{"id":"15445af8ef2844d391829f6fbad46681","type":"TRIAL","name":"Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.","canonical_id":"clinicaltrials.gov:NCT00775840","description":"Heart Failure","metadata":null},{"id":"033ddcfd263e4bcf97d9f7291e1edfec","type":"TRIAL","name":"Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)","canonical_id":"clinicaltrials.gov:NCT04355429","description":"Pneumonia; Coronavirus Infection; COVID-19","metadata":null},{"id":"96a74340f6f9408bbafeb0bbf9bf2a44","type":"TRIAL","name":"Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva","canonical_id":"clinicaltrials.gov:NCT01690052","description":"Dry Mouth","metadata":null},{"id":"5e608654f0a8442991982a88b450c2d4","type":"TRIAL","name":"Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.","canonical_id":"clinicaltrials.gov:NCT03928145","description":"Hypertension","metadata":null},{"id":"405121d056924ab885faa1f46c1540ad","type":"TRIAL","name":"Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)","canonical_id":"clinicaltrials.gov:NCT00163462","description":"Asthma","metadata":null},{"id":"f5bfa2c4d85547d2bfb6b13baa19c7e7","type":"TRIAL","name":"Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)","canonical_id":"clinicaltrials.gov:NCT00163319","description":"Asthma","metadata":null},{"id":"6015d11cb6cc45ae98c8e45e9629cb46","type":"TRIAL","name":"Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)","canonical_id":"clinicaltrials.gov:NCT00163345","description":"Asthma","metadata":null},{"id":"ea0d7ec5e0cc411a882110fe730872fd","type":"TRIAL","name":"Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.","canonical_id":"clinicaltrials.gov:NCT00174720","description":"Asthma","metadata":null},{"id":"3e64075c96904b0fac90fd8b6ee16a6c","type":"TRIAL","name":"Efficacy of Cilostazol in Prevention of Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT05298696","description":"Peripheral Neuropathy; Breast Cancer","metadata":null},{"id":"fa5871d49b0945aaaac9e22880096056","type":"TRIAL","name":"Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT02417389","description":"Hyperparathyroidism, Primary; Osteoporosis","metadata":null},{"id":"2caa11fdd98a452d886c3796c52b1c4e","type":"TRIAL","name":"Efficacy of Clobetasol Vs Intralesional Triamcinolone in Lichen Planus Treatment","canonical_id":"clinicaltrials.gov:NCT07666620","description":"Hypertrophic Lichen Planus","metadata":null},{"id":"6a026cc7141945b78ad8a753a1d78c43","type":"TRIAL","name":"Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder","canonical_id":"clinicaltrials.gov:NCT07313371","description":"Cocaine Use Disorder; Crack Abuse or Dependence","metadata":null},{"id":"b1ef2ca4a0484942b56cf114795f46cb","type":"TRIAL","name":"Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia","canonical_id":"clinicaltrials.gov:NCT01266759","description":"Menorrhagia","metadata":null},{"id":"ce06a6d6a41b4a8298a206214bcff10a","type":"TRIAL","name":"Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease","canonical_id":"clinicaltrials.gov:NCT03263624","description":"Nail Psoriasis","metadata":null},{"id":"7886c6aad61f438aaeedd12447adbb52","type":"TRIAL","name":"Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts","canonical_id":"clinicaltrials.gov:NCT02048319","description":"Symptomatic Dominant Liver Cyst","metadata":null},{"id":"f2d75f9aef8b461db53e35981d77ebaa","type":"TRIAL","name":"Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01039090","description":"Parkinsons's Disease","metadata":null},{"id":"29c2f701c191423db22ca8c07bf691a5","type":"TRIAL","name":"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT06576375","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"43f05e9e239c4bde93cc2d7738abb843","type":"TRIAL","name":"Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women","canonical_id":"clinicaltrials.gov:NCT02143570","description":"Overactive Bladder","metadata":null},{"id":"478c59ae8b7048c383852ecbb8d0686d","type":"TRIAL","name":"Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD","canonical_id":"clinicaltrials.gov:NCT04301726","description":"Huntington Disease","metadata":null},{"id":"92c86d51c27a4111834dc71215da1724","type":"TRIAL","name":"Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection","canonical_id":"clinicaltrials.gov:NCT01257126","description":"Upper Respiratory Tract Infections","metadata":null},{"id":"ffbd580e8c0142378f8516e518b0c84e","type":"TRIAL","name":"Efficacy of Different Drugs to Control Post Root Canal Treatment Pain","canonical_id":"clinicaltrials.gov:NCT02417337","description":"Pain; Postoperative Pain; Irreversible Pulpitis","metadata":null},{"id":"5bd0f45a6abe4ab1b50473cf37abe502","type":"TRIAL","name":"Efficacy of Different Medications as Adjuvants in Ultrasound-guided Supraclavicular Brachial Plexus Block in Forearm Surgeries","canonical_id":"clinicaltrials.gov:NCT06949488","description":"Upper Limb Surgery; Brachial Plexus Blockade","metadata":null},{"id":"7c691b0b8d2c4523aef2f05445e40e73","type":"TRIAL","name":"Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia","canonical_id":"clinicaltrials.gov:NCT04222855","description":"Postpartum Preeclampsia","metadata":null},{"id":"5f5306fd5e7145529885430c3cd670b2","type":"TRIAL","name":"Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial","canonical_id":"clinicaltrials.gov:NCT04777045","description":"Microvascular Angina; Coronary Vasospasm; Microvascular Ischemia of Myocardium","metadata":null},{"id":"7587253b8a424137890241cccbb1f6a6","type":"TRIAL","name":"Efficacy of Diuretics in Kidney Disease","canonical_id":"clinicaltrials.gov:NCT04542304","description":"Chronic Kidney Disease; End Stage Renal Disease","metadata":null},{"id":"affd882c76c74ed29b80a898a43a4c2f","type":"TRIAL","name":"Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying (Gastro-TIR)","canonical_id":"clinicaltrials.gov:NCT06695962","description":"Type 1 Diabetic","metadata":null},{"id":"aa2ef829dc074c068d4f7f38ea801f60","type":"TRIAL","name":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT06572228","description":"Asthma","metadata":null},{"id":"48ff7c52f0cb459d9252f8de64f9f770","type":"TRIAL","name":"Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled Study","canonical_id":"clinicaltrials.gov:NCT06957834","description":"Melasma","metadata":null},{"id":"db6abe54e9a94f06b229e765ad1fd26f","type":"TRIAL","name":"Efficacy of Elidel Cream on Erosive Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT00130572","description":"Lichen Planus, Oral","metadata":null},{"id":"fa1d7f286df940819046146be7b445dc","type":"TRIAL","name":"Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q","canonical_id":"clinicaltrials.gov:NCT02928419","description":"Myelodysplastic Syndromes","metadata":null},{"id":"78a56186a2d94de5bfcaa717e4a97422","type":"TRIAL","name":"Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne","canonical_id":"clinicaltrials.gov:NCT01220102","description":"Acne","metadata":null},{"id":"c4f23fcc61a44887a2731c1d8ea04854","type":"TRIAL","name":"Efficacy of Erenumab in Chronic Cluster Headache","canonical_id":"clinicaltrials.gov:NCT04970355","description":"Cluster Headache; Trigeminal Autonomic Cephalalgias; Headache Disorders, Primary; Brain Disease","metadata":null},{"id":"47cca71e6121487d9e95ab86e07ffea7","type":"TRIAL","name":"Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00663689","description":"Non-Small Cell Lung Cancer; Brain Metastases","metadata":null},{"id":"f8ab031f17264d2899e75d134176a01a","type":"TRIAL","name":"Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments","canonical_id":"clinicaltrials.gov:NCT05769868","description":"Cirrhosis; Diabetes Mellitus; Oncologic Disorders","metadata":null},{"id":"f44b7737a5b8408fbd2ddcfb0b40d5ab","type":"TRIAL","name":"Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT00927004","description":"Osteoarthritis; Pain","metadata":null},{"id":"c6343399b7fc4a09a62f583f778588c7","type":"TRIAL","name":"Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET","canonical_id":"clinicaltrials.gov:NCT01374451","description":"Islet Cell Tumor","metadata":null},{"id":"68388e0dd9e84c28936d5fb7d2d9007e","type":"TRIAL","name":"Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients","canonical_id":"clinicaltrials.gov:NCT02022709","description":"Obsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders","metadata":null},{"id":"1c815975964b491e8b5d56351648d9bc","type":"TRIAL","name":"Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT00502541","description":"Diabetic Macular Edema","metadata":null},{"id":"97f05396c4d0462e87c36c90d070fef6","type":"TRIAL","name":"Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01469767","description":"Atopic Dermatitis","metadata":null},{"id":"b437477b33a542b9b6bcada236ec875d","type":"TRIAL","name":"Efficacy of Fluoxetine - a Trial in Stroke","canonical_id":"clinicaltrials.gov:NCT02683213","description":"Stroke","metadata":null},{"id":"2e64574bde2e4a5987288d70f80ee661","type":"TRIAL","name":"Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00385658","description":"Dyslipidemia","metadata":null},{"id":"3b16f4f3d722487a84e39a764850473a","type":"TRIAL","name":"Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction","canonical_id":"clinicaltrials.gov:NCT00460577","description":"Acute Bronchial Obstruction, Asthma","metadata":null},{"id":"053711dc47cd406d82b4b8f854f5a4f1","type":"TRIAL","name":"Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD","canonical_id":"clinicaltrials.gov:NCT01985581","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"9524cc0d6f6f4441937916f3b97992de","type":"TRIAL","name":"Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women","canonical_id":"clinicaltrials.gov:NCT07429734","description":"Overactive Bladder","metadata":null},{"id":"2639c68195234775bcd634f8d8e07c85","type":"TRIAL","name":"Efficacy of Gabapentin or Amitriptyline to Reduce Postoperative Pain After Lumbar Laminectomy and Diskectomy","canonical_id":"clinicaltrials.gov:NCT01014520","description":"Herniated Disc; Intervertebral Disc Displacement","metadata":null},{"id":"ff01fa6b4533477ea7008e6254a19dd3","type":"TRIAL","name":"Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation","canonical_id":"clinicaltrials.gov:NCT03270501","description":"Axial Spondyloarthritis","metadata":null},{"id":"f2ab98ba908e4a6dabc5ed80b5dc2610","type":"TRIAL","name":"Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT06931223","description":"Functioanl Dyspepsia","metadata":null},{"id":"b03d6a07d8be4c38a7f2935e78686348","type":"TRIAL","name":"Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease","canonical_id":"clinicaltrials.gov:NCT06945237","description":"Gastroesophageal Reflux Disease","metadata":null},{"id":"ee8c6946dfd746bc8559be0c98abd775","type":"TRIAL","name":"Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT02972502","description":"Headache, Migraine","metadata":null},{"id":"c59b9381e13546a5a316cb3045ce95df","type":"TRIAL","name":"Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS","canonical_id":"clinicaltrials.gov:NCT03402204","description":"Ischemic Stroke","metadata":null},{"id":"bbe1308d3dbf4b4b89b86f93e143264d","type":"TRIAL","name":"Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19","canonical_id":"clinicaltrials.gov:NCT04435808","description":"COVID-19","metadata":null},{"id":"5ba7122c8b8d48b39e0668e23fb3221d","type":"TRIAL","name":"Efficacy of Hydroxyzine for Patients With Panic Disorder","canonical_id":"clinicaltrials.gov:NCT05737511","description":"Panic Disorder","metadata":null},{"id":"66d635769eeb4537b9f93c057b52bec0","type":"TRIAL","name":"Efficacy of Hyperthermic Intraperitoneal Chemotherapy","canonical_id":"clinicaltrials.gov:NCT04861558","description":"Colorectal Cancer; Peritoneal Metastases","metadata":null},{"id":"aad33a853462415891abcd9565bcb90c","type":"TRIAL","name":"Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn","canonical_id":"clinicaltrials.gov:NCT01753128","description":"Gastroesophageal Reflux Disease","metadata":null},{"id":"b6904114b08e48d091fa2355b5a9e5d9","type":"TRIAL","name":"Efficacy of Indacaterol 150 \u00b5g Versus Formoterol","canonical_id":"clinicaltrials.gov:NCT01377428","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"d1c247ba65f04433886b0cfe545598a6","type":"TRIAL","name":"Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy","canonical_id":"clinicaltrials.gov:NCT02990221","description":"Actinic Keratosis","metadata":null},{"id":"2bb50978de6745f184c6cce2d94cd986","type":"TRIAL","name":"Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo","canonical_id":"clinicaltrials.gov:NCT03365141","description":"Vitiligo; Treatment; Intralesional Injection; Corticosteroid","metadata":null},{"id":"0bf52c43016847b2b421f051166e6cda","type":"TRIAL","name":"Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery","canonical_id":"clinicaltrials.gov:NCT01901393","description":"Pain","metadata":null},{"id":"d2e7fbba6599494a93a903a3829e3b3d","type":"TRIAL","name":"Efficacy of Intravenous Levetiracetam in Neonatal Seizures","canonical_id":"clinicaltrials.gov:NCT01720667","description":"Neonatal Seizures","metadata":null},{"id":"6911c8f8800542bcae6feed2a5fcafcb","type":"TRIAL","name":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","canonical_id":"clinicaltrials.gov:NCT03076112","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"2a8993a418b644e3aaa0a5ab0d1418b4","type":"TRIAL","name":"Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00500604","description":"Hypertension","metadata":null},{"id":"62617c41229544e09da9b0ecd5a33fa8","type":"TRIAL","name":"Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT00675194","description":"Gastric Cancer","metadata":null},{"id":"8f8956c609114ce6a5d1571c5332c3df","type":"TRIAL","name":"Efficacy of Islet After Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT00468117","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"0810867bb5584131b264539bf6feea3f","type":"TRIAL","name":"Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume","canonical_id":"clinicaltrials.gov:NCT07031479","description":"Feeding Intolerance","metadata":null},{"id":"a230746db90141d7ababebb0164b8cde","type":"TRIAL","name":"Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study","canonical_id":"clinicaltrials.gov:NCT00627133","description":"Seizure, Alcohol Related","metadata":null},{"id":"b38c2f2500c5401f807fdb1e2f52543c","type":"TRIAL","name":"Efficacy of Ketoprofen Before Hysterosalpingography","canonical_id":"clinicaltrials.gov:NCT02905045","description":"Pain Relief","metadata":null},{"id":"d42084d972b44cdb8ee9b5f065903216","type":"TRIAL","name":"Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia","canonical_id":"clinicaltrials.gov:NCT02199509","description":"Oromandibular Dystonia; Cranial Dystonia","metadata":null},{"id":"26f350ea030b461cb643d4e8d65d3b16","type":"TRIAL","name":"Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects","canonical_id":"clinicaltrials.gov:NCT00544388","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"19b63e495a834208b860d84fca71f8b5","type":"TRIAL","name":"Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders","canonical_id":"clinicaltrials.gov:NCT05134584","description":"Functional Dyspepsia; Constipation-predominant Irritable Bowel Syndrome","metadata":null},{"id":"563df619128e4b489b065793c6afb0f5","type":"TRIAL","name":"Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT03119584","description":"Chronic Constipation; Diabete Mellitus","metadata":null},{"id":"e80cea447ceb4df48ed4a218e3fc617a","type":"TRIAL","name":"Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy","canonical_id":"clinicaltrials.gov:NCT00591357","description":"Antibiotic-Associated Diarrhea; Clostridium Difficile","metadata":null},{"id":"7f1fed3e84964caabd5b5ccb72d3ac9e","type":"TRIAL","name":"Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis","canonical_id":"clinicaltrials.gov:NCT01245998","description":"Superficial Thrombophlebitis","metadata":null},{"id":"f1f32a2f1aed4e049b974633a0c1117b","type":"TRIAL","name":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","canonical_id":"clinicaltrials.gov:NCT07039877","description":"Acute Lymphobkastic Leukemia; Acute Lymphoblastic Leukaemia Recurrent; Philadelphia Chromosome Negative ALL","metadata":null},{"id":"48913cb527a24eca8fb6d2c597a65b7d","type":"TRIAL","name":"Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01564862","description":"Depressive Disorder, Major","metadata":null},{"id":"10ea11337aac4125a089ff6617b3643a","type":"TRIAL","name":"Efficacy of Lubiprostone in Combination With Standard PEG Preparation","canonical_id":"clinicaltrials.gov:NCT00689026","description":"Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2","metadata":null},{"id":"d4f835c8afb14ad99b6b6e806ac3e483","type":"TRIAL","name":"Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib","canonical_id":"clinicaltrials.gov:NCT00348491","description":"Pain","metadata":null},{"id":"931e1e2cbd8b4c6bb4f812c80889e9cf","type":"TRIAL","name":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT03244956","description":"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation","metadata":null},{"id":"09d1a67d659649caa6e2a810556bd304","type":"TRIAL","name":"Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07292012","description":"Crohn Disease (CD)","metadata":null},{"id":"a7a9a525e2274ceeb4b36d3631cc73e1","type":"TRIAL","name":"Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.","canonical_id":"clinicaltrials.gov:NCT03402815","description":"HIV Infection With Other Conditions; Cardiovascular Risk Factor; Atherosclerosis; Inflammation","metadata":null},{"id":"ad541db4dcfe4cecb41f66c07ce9736b","type":"TRIAL","name":"Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women","canonical_id":"clinicaltrials.gov:NCT01060696","description":"Infertility","metadata":null},{"id":"8a5a240298b34778b6d6155a5c281e0f","type":"TRIAL","name":"Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT05091385","description":"Asthma; Eosinophilic","metadata":null},{"id":"2a8b62d63a384f408fced411b321cda4","type":"TRIAL","name":"Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT04111315","description":"Low Back Pain","metadata":null},{"id":"97b87269772a454bb48d5711f8d3d0cc","type":"TRIAL","name":"Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial","canonical_id":"clinicaltrials.gov:NCT01573377","description":"Polycystic Ovary Syndrome; Insulin Resistance","metadata":null},{"id":"cad15a7d0fb34d30ab1fcbf682c4040b","type":"TRIAL","name":"Efficacy of Methimazole Dosing Algorithm","canonical_id":"clinicaltrials.gov:NCT05964452","description":"Graves Disease","metadata":null},{"id":"bbf4528fb9f64510acb47d935b32435f","type":"TRIAL","name":"Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients","canonical_id":"clinicaltrials.gov:NCT03560583","description":"Poor Responders in IVF","metadata":null},{"id":"be2e7610d9664ecdb4da27884d81f8ff","type":"TRIAL","name":"Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.","canonical_id":"clinicaltrials.gov:NCT05954962","description":"IVF","metadata":null},{"id":"9c77544530a64b3684e85ca77c6ddbe7","type":"TRIAL","name":"Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children","canonical_id":"clinicaltrials.gov:NCT06562036","description":"Persistent Pulmonary Hypertension of the Newborn","metadata":null},{"id":"b93213bf439b4fb6a4aa61fa0171ffc0","type":"TRIAL","name":"Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms","canonical_id":"clinicaltrials.gov:NCT04325880","description":"Ureteral Stent; Stent Related Symptoms","metadata":null},{"id":"1e614b12282240a0977ceb048ccbe9fb","type":"TRIAL","name":"Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT07521657","description":"Neurofibromatosis 1 (NF1)","metadata":null},{"id":"3d36c973298e4e5f876af849d2dc8004","type":"TRIAL","name":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","canonical_id":"clinicaltrials.gov:NCT02101268","description":"Primary Myelofibrosis (PMF); Post-polycythemia Vera (Post-PV); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","metadata":null},{"id":"b9dc36b6159b4fefb1c023639e94d1ac","type":"TRIAL","name":"Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","canonical_id":"clinicaltrials.gov:NCT06498440","description":"Open Angle Glaucoma; Ocular Hypertension; Postoperative Inflammation","metadata":null},{"id":"fb13dfea2e154e4190e92cafeb5e0f65","type":"TRIAL","name":"Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)","canonical_id":"clinicaltrials.gov:NCT04352400","description":"COVID19","metadata":null},{"id":"4531086885d74ffa93f3a0e196404e46","type":"TRIAL","name":"Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain","canonical_id":"clinicaltrials.gov:NCT00716807","description":"Temporomandibular Joint Dysfunction Syndrome; Burning Mouth Syndrome","metadata":null},{"id":"2a84271b77ef436da7790e3d0c929e46","type":"TRIAL","name":"Efficacy of Nalmefene in Patients With Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00812461","description":"Alcohol Dependence","metadata":null},{"id":"147a684fb154416db84d8b76806d7213","type":"TRIAL","name":"Efficacy of Nalmefene in Patients With Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00811720","description":"Alcohol Dependence","metadata":null},{"id":"185b6ef4a2244651adbc82da6224c7fe","type":"TRIAL","name":"Efficacy of Naproxen-codeine, Naproxen+Dexamethasone, and Naproxen on Myofascial Pain","canonical_id":"clinicaltrials.gov:NCT04066426","description":"Temporomandibular Disorder","metadata":null},{"id":"5ef2844d12c241ae973df550f0bbe702","type":"TRIAL","name":"Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD","canonical_id":"clinicaltrials.gov:NCT02504801","description":"Post Operative Complication, Pulmonary; Lung Cancer; COPD","metadata":null},{"id":"6df7646907164cf1a250fe6f0c74e93b","type":"TRIAL","name":"Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic","canonical_id":"clinicaltrials.gov:NCT01543165","description":"Renal Colic","metadata":null},{"id":"f4e14a3e69fa45c7a78c8e338e8384dc","type":"TRIAL","name":"Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.","canonical_id":"clinicaltrials.gov:NCT01289028","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"00b0519eaf4b4eab86bc139c038922ff","type":"TRIAL","name":"Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.","canonical_id":"clinicaltrials.gov:NCT01168050","description":"Malignant Skin Melanoma T0; Stage III Melanoma; Stage IV Melanoma; Amplification","metadata":null},{"id":"3e63fca7c9b9488a906dff97d3d637db","type":"TRIAL","name":"Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)","canonical_id":"clinicaltrials.gov:NCT01276756","description":"Chronic Hepatitis c","metadata":null},{"id":"7b29da6253854ee2a365d5ce988476e7","type":"TRIAL","name":"Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices","canonical_id":"clinicaltrials.gov:NCT02583698","description":"Acute on Chronic Liver Failure","metadata":null},{"id":"53d8d02dc10d43d0977b87c171989e1d","type":"TRIAL","name":"Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists","canonical_id":"clinicaltrials.gov:NCT00670930","description":"Allergic Asthma","metadata":null},{"id":"b423503c57a54a6e8a2531cd4b8778d8","type":"TRIAL","name":"Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain","canonical_id":"clinicaltrials.gov:NCT00383682","description":"Amputation; Chronic Pain","metadata":null},{"id":"e850a3daf1384cc9aefda62545cc42d9","type":"TRIAL","name":"Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.","canonical_id":"clinicaltrials.gov:NCT05926882","description":"Alopecia Areata","metadata":null},{"id":"1f53a95fd7594200a486227835119a62","type":"TRIAL","name":"Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS","canonical_id":"clinicaltrials.gov:NCT07242131","description":"Polycystic Ovary Syndrome (PCOS)","metadata":null},{"id":"e9dec62aace04132af79981899ecdf01","type":"TRIAL","name":"Efficacy of Oral Diltiazem on the Intraoperative Bleeding in Functional Endoscopic Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT03580590","description":"Hypotension on Induction","metadata":null},{"id":"30b344657ba946a4911e2e4b0d9d6270","type":"TRIAL","name":"Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children","canonical_id":"clinicaltrials.gov:NCT00912171","description":"Obstructive Sleep Apnea Syndrome","metadata":null},{"id":"a3bbe617528546069f9b6fc38584fa31","type":"TRIAL","name":"Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering","canonical_id":"clinicaltrials.gov:NCT07088601","description":"Post-Spinal Shivering","metadata":null},{"id":"d378bd5794b0480a84733ee18b9d9a84","type":"TRIAL","name":"Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor","canonical_id":"clinicaltrials.gov:NCT02989519","description":"Preterm Delivery","metadata":null},{"id":"6922a5d248df409ba789539317be832e","type":"TRIAL","name":"Efficacy of Oral Semaglutide in Overweight or Obesity","canonical_id":"clinicaltrials.gov:NCT05442450","description":"Obesity; Weight Loss","metadata":null},{"id":"ba2560430bb44b88981361138829d588","type":"TRIAL","name":"Efficacy of Oral Verapamil and Oral Diltiazim on Reduction of Intraoperative Bleeding During Endoscopic Sinus Surgery Under General Anesthesia","canonical_id":"clinicaltrials.gov:NCT04790331","description":"Verapamil; Diltiazim; FESS","metadata":null},{"id":"85ab29bfdcc64504b3832869186e1ad4","type":"TRIAL","name":"Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists","canonical_id":"clinicaltrials.gov:NCT00443872","description":"Parkinson's Disease","metadata":null},{"id":"d1a5bb8b4c0c448fbbb20825f2518ee4","type":"TRIAL","name":"Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT06482086","description":"Locally Advanced Thyroid Gland Carcinoma","metadata":null},{"id":"a8b7b58350d3476f8057ac74484a07f5","type":"TRIAL","name":"Efficacy of Oxybutynin in Paediatric Cystitis","canonical_id":"clinicaltrials.gov:NCT03877289","description":"Cystitis","metadata":null},{"id":"300db54753184835aecf4c35bb37e4e3","type":"TRIAL","name":"Efficacy of Palonosetron Plus Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Gynaecological Laparoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT07813897","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"ebdfa4de25a84118af361a955979166f","type":"TRIAL","name":"Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin","canonical_id":"clinicaltrials.gov:NCT00196664","description":"Chronic Hepatitis C","metadata":null},{"id":"872a9e9702b3481e846c2bb9e20235b9","type":"TRIAL","name":"Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults","canonical_id":"clinicaltrials.gov:NCT02354807","description":"Brown Fat","metadata":null},{"id":"4c591293bd454856a34b43c10b51b3e4","type":"TRIAL","name":"Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI","canonical_id":"clinicaltrials.gov:NCT06286059","description":"CA-AKI - Contrast-Associated Acute Kidney Injury; Coronary Artery Disease; Acute Coronary Syndrome; Adrenergic Receptor Antagonist Adverse Reaction","metadata":null},{"id":"6d3a3502236146a28e3c2c2924d8cd7a","type":"TRIAL","name":"Efficacy of Phenytoin Phonophoresis on Pressure Ulcer Healing","canonical_id":"clinicaltrials.gov:NCT05542589","description":"Pressure Ulcer","metadata":null},{"id":"19e8a377c900426bbbed596be4f29363","type":"TRIAL","name":"Efficacy of Pilocarpine 1% in Presbyopia","canonical_id":"clinicaltrials.gov:NCT05578001","description":"Presbyopia; Pseudophakia","metadata":null},{"id":"59991e217fde43b6b32144fb21eaa00e","type":"TRIAL","name":"Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye","canonical_id":"clinicaltrials.gov:NCT06752278","description":"Dry Eye Disease (DED)","metadata":null},{"id":"00fc693421e64711bb42fc619fba9206","type":"TRIAL","name":"Efficacy of Pimozide Augmentation for Clozapine Partial Response","canonical_id":"clinicaltrials.gov:NCT00374244","description":"Schizophrenia","metadata":null},{"id":"203230b6567643be92569f53c71d3780","type":"TRIAL","name":"Efficacy of Piroxicam as a Perioperative Analgesic for Patients Undergoing Fixation of Maxillofacial Fractures","canonical_id":"clinicaltrials.gov:NCT04062591","description":"Postoperative Pain","metadata":null},{"id":"9fac7d20630e4d6082e3f42fd344a482","type":"TRIAL","name":"Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.","canonical_id":"clinicaltrials.gov:NCT04688736","description":"Allergic Transfusion Reaction","metadata":null},{"id":"808174c892cc4268a0df6ee911c6161b","type":"TRIAL","name":"Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis","canonical_id":"clinicaltrials.gov:NCT00148837","description":"Hepatitis C, Chronic; Fibrosis","metadata":null},{"id":"7cbbe1b178e54f9db2d5e579ce3694cd","type":"TRIAL","name":"Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT03045016","description":"Acute Stress Disorder","metadata":null},{"id":"63f596c71ead4f12afdb4fa7fa179c1b","type":"TRIAL","name":"Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring","canonical_id":"clinicaltrials.gov:NCT07318870","description":"Focal Epilepsy","metadata":null},{"id":"3e6a8a403d7c480f816a56828899dde4","type":"TRIAL","name":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT06604117","description":"Ischemic Stroke; Atherosclerosis of Artery; Lipid Disorder; Statin","metadata":null},{"id":"ba774248b0e34f5da6d26d253e19eba4","type":"TRIAL","name":"Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT02241460","description":"Premature Ejaculation","metadata":null},{"id":"43ef74da61fc4c31883a940da12e3666","type":"TRIAL","name":"Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT01991119","description":"Atrial Fibrillation","metadata":null},{"id":"e26944645b394e3ebd0582c17b63a58b","type":"TRIAL","name":"Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness","canonical_id":"clinicaltrials.gov:NCT06310642","description":"AMS; Acute Mountain Sickness","metadata":null},{"id":"fad07adedf5447499609185b892e7a5a","type":"TRIAL","name":"Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","canonical_id":"clinicaltrials.gov:NCT07210112","description":"Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)","metadata":null},{"id":"99626b13c8924b61907a2ae3c86b88e7","type":"TRIAL","name":"Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy","canonical_id":"clinicaltrials.gov:NCT02839642","description":"Progressive Supranuclear Palsy (PSP)","metadata":null},{"id":"336fa18af7a446b0be836638fdb0986e","type":"TRIAL","name":"Efficacy of Ramelteon in Adults With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00672724","description":"Chronic Insomnia","metadata":null},{"id":"64f2ece843294a8ba51f2126ceb97613","type":"TRIAL","name":"Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT00492011","description":"Circadian Dysregulation","metadata":null},{"id":"3c18ff6bd9674de4bfe575706ad7cfbe","type":"TRIAL","name":"Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome","canonical_id":"clinicaltrials.gov:NCT00593736","description":"Sleep Disorders, Circadian Rhythm","metadata":null},{"id":"c9299342a3b1479da570d1f5fa224876","type":"TRIAL","name":"Efficacy of Ramelteon on Transient Insomnia in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT00671398","description":"Transient Insomnia","metadata":null},{"id":"7177d732e9fe499dba9e460a00a8fb4d","type":"TRIAL","name":"Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.","canonical_id":"clinicaltrials.gov:NCT01143584","description":"Macroprolactinoma","metadata":null},{"id":"ddc540d3a464441b89eaf7d4a2e053dd","type":"TRIAL","name":"Efficacy of Re-treatment With Cimzia\u00ae in Subject With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00329303","description":"Psoriasis","metadata":null},{"id":"a712500abd6649b5ad29f9d56f6118e5","type":"TRIAL","name":"Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD","canonical_id":"clinicaltrials.gov:NCT05133804","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"62756732adac46c7bf0251191c99c08f","type":"TRIAL","name":"Efficacy of Repaglinide in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01698931","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"df05e3d280ad4a7481b6260189858da7","type":"TRIAL","name":"Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma","canonical_id":"clinicaltrials.gov:NCT04710134","description":"Asthma; Eosinophilic","metadata":null},{"id":"443504954e834f9d9f794a268cf9caca","type":"TRIAL","name":"Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis","canonical_id":"clinicaltrials.gov:NCT02744482","description":"Prosthesis Loosening","metadata":null},{"id":"b32daea0d5d7472fbc6719fa30a87aed","type":"TRIAL","name":"Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis","canonical_id":"clinicaltrials.gov:NCT04122547","description":"Exacerbation Copd; Bronchiectasis; Lung Function Decreased","metadata":null},{"id":"975a5a6f7bd54d3e971539b9f00a596d","type":"TRIAL","name":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","canonical_id":"clinicaltrials.gov:NCT05323617","description":"Severe Aplastic Anemia (SAA)","metadata":null},{"id":"90815b7c23de42cfb4b0df979968e8d3","type":"TRIAL","name":"Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures","canonical_id":"clinicaltrials.gov:NCT06720350","description":"Osteoporosis in Post-menopausal Women","metadata":null},{"id":"68cc79622b8a439689505db785433b9b","type":"TRIAL","name":"Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria","canonical_id":"clinicaltrials.gov:NCT00199238","description":"URTICARIA","metadata":null},{"id":"53765ee746e7473c9fa367cfa46128d8","type":"TRIAL","name":"Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain","canonical_id":"clinicaltrials.gov:NCT02421913","description":"Postoperative Pain","metadata":null},{"id":"bfb5558373f64731bd4576d8460494a3","type":"TRIAL","name":"Efficacy of SMOF Lipid in the Management of Acute Poisoning With Clozapine","canonical_id":"clinicaltrials.gov:NCT06413589","description":"Acute Poisoning","metadata":null},{"id":"d3204f1fb271401aa22ee6f6c7a7c007","type":"TRIAL","name":"Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities","canonical_id":"clinicaltrials.gov:NCT01975480","description":"Generalized Anxiety Disorder","metadata":null},{"id":"af2b01a8b95a49f2a4c633be3d78c9f6","type":"TRIAL","name":"Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNF\u03b1-Inhibitor Treatment","canonical_id":"clinicaltrials.gov:NCT04632927","description":"Psoriatic Arthritis","metadata":null},{"id":"3628914be6ff4e06a6dfc35d58b19552","type":"TRIAL","name":"Efficacy of Selegiline in Negative Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00456976","description":"Schizophrenia","metadata":null},{"id":"9f0ba7c7be82415aa2e9b69be8d98c54","type":"TRIAL","name":"Efficacy of Self Vs. Physician Application of Triamcinolone-Econazole in Otomycosis","canonical_id":"clinicaltrials.gov:NCT06431542","description":"Otomycosis","metadata":null},{"id":"0ea7c3ee77e3441b8ef140a6905ca361","type":"TRIAL","name":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00351169","description":"Major Depressive Disorder","metadata":null},{"id":"2feb494a028b41a19c2f8718f16d71b9","type":"TRIAL","name":"Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)","canonical_id":"clinicaltrials.gov:NCT04107896","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"41447e2b6bfa4c97a93e5a31b58923ca","type":"TRIAL","name":"Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)","canonical_id":"clinicaltrials.gov:NCT02318693","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"aa2f4ae29c4b47b8a9280ac68513803c","type":"TRIAL","name":"Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant","canonical_id":"clinicaltrials.gov:NCT01559844","description":"Hepatitis C; Hepatocellular Carcinoma","metadata":null},{"id":"44904cca0b384a70bfe79eb17dedf4ef","type":"TRIAL","name":"Efficacy of Steroid Injection in Patients With Bifid Median Nerve Diagnosed Carpal Tunnel Syndrome","canonical_id":"clinicaltrials.gov:NCT06599086","description":"Carpal Tunnel Syndrome","metadata":null},{"id":"cb51f834e6ad441ba54d71aa069fffae","type":"TRIAL","name":"Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)","canonical_id":"clinicaltrials.gov:NCT04357808","description":"Covid-19","metadata":null},{"id":"c89cae28dce8462196a0307e513578e0","type":"TRIAL","name":"Efficacy of Subgingivally Delivered Doxycycline Plus Ketoprofen Gel as an Adjunct to Non-surgical Periodontal Treatment","canonical_id":"clinicaltrials.gov:NCT02538224","description":"Chronic Periodontitis","metadata":null},{"id":"37f9d20019d54ef1b836b19b38f484e1","type":"TRIAL","name":"Efficacy of Sumatriptan With Naprosyn in Migraine With Aura","canonical_id":"clinicaltrials.gov:NCT00893594","description":"Migraine With Aura","metadata":null},{"id":"8b7c9f88f30b4edbb7784f86dcd22fd7","type":"TRIAL","name":"Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT04706091","description":"Restless Legs Syndrome; Insomnia; Sleep Disorder","metadata":null},{"id":"7b5cde28d4de4fd7a73c3aa6d200b9ea","type":"TRIAL","name":"Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia","canonical_id":"clinicaltrials.gov:NCT03034018","description":"Insomnia","metadata":null},{"id":"58422fa125c6448892a8c9598d9d051f","type":"TRIAL","name":"Efficacy of Suvorexant on Post-operative Sleep Disturbance","canonical_id":"clinicaltrials.gov:NCT05823844","description":"Postoperative Insomnia; Postoperative Delirium","metadata":null},{"id":"ad8c24fdcfa540909b0cddb8802c0ac8","type":"TRIAL","name":"Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT02527564","description":"Insomnia; Bipolar Disorder","metadata":null},{"id":"c7cb87ce614a49b19fa6273e36fd96d2","type":"TRIAL","name":"Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5","canonical_id":"clinicaltrials.gov:NCT00651651","description":"Asthma","metadata":null},{"id":"14867fd5b559466894c41921f1fca486","type":"TRIAL","name":"Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB","canonical_id":"clinicaltrials.gov:NCT05494567","description":"Benign Prostatic Hyperplasia; Overactive Bladder","metadata":null},{"id":"5af5e297b163471fb1b08bbbe987eebd","type":"TRIAL","name":"Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy","canonical_id":"clinicaltrials.gov:NCT03595865","description":"Glaucoma; Drugs","metadata":null},{"id":"8a29672cc7a4497bb3849083c9ee83f3","type":"TRIAL","name":"Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature","canonical_id":"clinicaltrials.gov:NCT05288127","description":"HRD 100 Gene Expression High; Triple Negative Breast Cancer","metadata":null},{"id":"bb06bc9c4a0b4e1aa9ffffaf6bedaa34","type":"TRIAL","name":"Efficacy of Tazarotene in Treatment of Verruca Plana","canonical_id":"clinicaltrials.gov:NCT05314127","description":"Warts Flat","metadata":null},{"id":"c1049120a8ce4aceb97fc614ae83c2b3","type":"TRIAL","name":"Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy","canonical_id":"clinicaltrials.gov:NCT00738660","description":"Diabetic Nephropathy","metadata":null},{"id":"a6852991772e472a8b9fa7bcd2c49e66","type":"TRIAL","name":"Efficacy of Tezepelumab in Peanut Oral Immunotherapy","canonical_id":"clinicaltrials.gov:NCT07015996","description":"Peanut Allergy","metadata":null},{"id":"ffbad016462441daac1da7ee1cae5b08","type":"TRIAL","name":"Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT00488267","description":"Osteoarthritis","metadata":null},{"id":"e864cacf7f504c449127433c2decd54f","type":"TRIAL","name":"Efficacy of Three Antiemetics in Preventing Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT05533281","description":"Nausea and Vomiting","metadata":null},{"id":"8b68260c20e24ef5b1c05c6cd0765ef3","type":"TRIAL","name":"Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)","canonical_id":"clinicaltrials.gov:NCT00413764","description":"Sexual Dysfunction","metadata":null},{"id":"523f682a8632414ca94bef9129aaf7ef","type":"TRIAL","name":"Efficacy of Tocilizumab on Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04356937","description":"SARS-CoV 2","metadata":null},{"id":"da30e65c19414983976b523638b8b5e4","type":"TRIAL","name":"Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07235904","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"3b3746be455940eba2f97eac7b606b80","type":"TRIAL","name":"Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07659353","description":"Chrohn's Disease","metadata":null},{"id":"87502f16c5b84d30ac5776b025eb2f50","type":"TRIAL","name":"Efficacy of Topical 5-Fluorouracil Vs Calcipotriol As Photodynamic Therapy Pre-treatment for Field Actinic Keratoses","canonical_id":"clinicaltrials.gov:NCT06685588","description":"Actinic Keratosis of Face and Scalp; Actinic Keratoses","metadata":null},{"id":"b6c61099cadc4b3f85ff1b06809fd211","type":"TRIAL","name":"Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis","canonical_id":"clinicaltrials.gov:NCT05167760","description":"Synkinesis; Facial Nerve Palsy","metadata":null},{"id":"214747fe7d3942b6b78f234f9f2d764e","type":"TRIAL","name":"Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea","canonical_id":"clinicaltrials.gov:NCT00855595","description":"Papulopustular Rosacea","metadata":null},{"id":"979c74958e254d758a8c6080ca08d55c","type":"TRIAL","name":"Efficacy of Topical Calcipotriol-assisted AFL-PDT in Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02976727","description":"Actinic Dermatosis","metadata":null},{"id":"4a9fafb964aa4f21b210d17e93c59425","type":"TRIAL","name":"Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba","canonical_id":"clinicaltrials.gov:NCT03834935","description":"Pityriasis Alba","metadata":null},{"id":"c55f1f9645334406a951d7de89b0a4c8","type":"TRIAL","name":"Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT07635043","description":"Psoriasis (PsO)","metadata":null},{"id":"30353425b81b4a90a2dc840ac2293ed7","type":"TRIAL","name":"Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.","canonical_id":"clinicaltrials.gov:NCT04364555","description":"Oral Lichen Planus","metadata":null},{"id":"77efe627fd7c45008ac787a6cc66882e","type":"TRIAL","name":"Efficacy of Transcutaneous Electrical Neural Stimulation and Tadalafil in Men With Erectile Dysfunction: A Randomized, Double-Blind, Bi-centric, Placebo- and Sham-Controlled Trial","canonical_id":"clinicaltrials.gov:NCT07574268","description":"Erectile Dysfunction","metadata":null},{"id":"d124980ea4da459a867dcf9582a7a463","type":"TRIAL","name":"Efficacy of Traumatic Memory Modification Using Memory Reconsolidation and Propranolol Among Adolescents With PTSD","canonical_id":"clinicaltrials.gov:NCT04921982","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"7cca468de4b74b3ebc48a83d9ded2015","type":"TRIAL","name":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","canonical_id":"clinicaltrials.gov:NCT02003391","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"383cc99f5ab24a2f9d9f79a5b253eb2d","type":"TRIAL","name":"Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 na\u00efve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine","canonical_id":"clinicaltrials.gov:NCT00808002","description":"HIV Infections","metadata":null},{"id":"7ea1907efcbb46429ef777b005e7a88f","type":"TRIAL","name":"Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough","canonical_id":"clinicaltrials.gov:NCT05110144","description":"Refractory Chronic Cough","metadata":null},{"id":"96f9fd03c8ee46f2a6890772e7457c90","type":"TRIAL","name":"Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose","canonical_id":"clinicaltrials.gov:NCT07700446","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"d4c85f535e9b4f23966110458fbb1d26","type":"TRIAL","name":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","canonical_id":"clinicaltrials.gov:NCT02896582","description":"Mantle Cell Lymphoma","metadata":null},{"id":"4f534560ddd94b779d5612a7f2c5b29a","type":"TRIAL","name":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","canonical_id":"clinicaltrials.gov:NCT02475915","description":"Acute HIV Infection","metadata":null},{"id":"88590263780d4599967ffc4b817784a9","type":"TRIAL","name":"Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults","canonical_id":"clinicaltrials.gov:NCT05207085","description":"Trichotillomania (Hair-Pulling Disorder)","metadata":null},{"id":"613869128bfa4c1fbb255893747cd74c","type":"TRIAL","name":"Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT01694732","description":"Chronic Obstructive Pulmonary Disease; COPD Exacerbation; Smoking","metadata":null},{"id":"a5a0f674ca124651809b406af43f41ba","type":"TRIAL","name":"Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy","canonical_id":"clinicaltrials.gov:NCT04362735","description":"Crohn Disease","metadata":null},{"id":"9d0a9f814f9349d69f9c4d1afc7fa596","type":"TRIAL","name":"Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT02272517","description":"Major Depressive Disorder","metadata":null},{"id":"c2e3b0cf6d974a3f9e456f5bb50ef87b","type":"TRIAL","name":"Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT02279953","description":"Major Depressive Disorder","metadata":null},{"id":"46a7d97c7ca74bb68dc5b5c0d6b99c99","type":"TRIAL","name":"Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents","canonical_id":"clinicaltrials.gov:NCT00617695","description":"Migraine","metadata":null},{"id":"f4932d2d4eba475fb5d39d770f940837","type":"TRIAL","name":"Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT05184088","description":"Cardiac Amyloidosis; AL Amyloidosis; ATTR Amyloidosis","metadata":null},{"id":"6ae6c3c2b2aa4dacbe7bf2b049949235","type":"TRIAL","name":"Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma","canonical_id":"clinicaltrials.gov:NCT04462809","description":"Advanced Malignant Pleural or Peritoneal Mesothelioma","metadata":null},{"id":"e71a26754a714f98bc84720ae1ac4dd5","type":"TRIAL","name":"Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP","canonical_id":"clinicaltrials.gov:NCT04720261","description":"Thrombotic Thrombocytopenic Purpura, Acquired","metadata":null},{"id":"c174e2d557e549ba8193db0d99a47ae1","type":"TRIAL","name":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT05428488","description":"Rheumatoid Arthritis","metadata":null},{"id":"42945dc8d7ea46d798e59d6b3b3a0a90","type":"TRIAL","name":"Efficacy of a Topical Anesthetic Containing Lidocaine and Prilocaine in Treatment With CO2 Fractional Laser","canonical_id":"clinicaltrials.gov:NCT03366246","description":"Lidocaine Adverse Reaction; Prilocaine Adverse Reaction","metadata":null},{"id":"8da4cd12c41c4197a2bc440991f56520","type":"TRIAL","name":"Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order","canonical_id":"clinicaltrials.gov:NCT00282165","description":"Psychotic Disorders; Antisocial Personality Disorder; Impulse Regulation Disorder; Intermittent Explosive Disorder","metadata":null},{"id":"08cb801bd42048a0affc723a61504580","type":"TRIAL","name":"Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01029769","description":"Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder","metadata":null},{"id":"84da920142cc4887b6bbe8f07ce72b4b","type":"TRIAL","name":"Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development","canonical_id":"clinicaltrials.gov:NCT03780673","description":"Liver Cirrhoses","metadata":null},{"id":"93c313096d9447ddb40e9e6478abfd1b","type":"TRIAL","name":"Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial","canonical_id":"clinicaltrials.gov:NCT07263438","description":"Glioblastoma; Recurrence Tumor","metadata":null},{"id":"c56b92783d434b9ea7d988f77b776c54","type":"TRIAL","name":"Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT06265259","description":"Circulatory Shock","metadata":null},{"id":"524d31bb566a4c96a38c3b91a7abef3b","type":"TRIAL","name":"Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone","canonical_id":"clinicaltrials.gov:NCT00641043","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"2c0025802dc441f4b17b5929d37a1315","type":"TRIAL","name":"Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V","canonical_id":"clinicaltrials.gov:NCT07015931","description":"Acne Vulgaris","metadata":null},{"id":"91599a420964418d8b5693d3ec1eeea4","type":"TRIAL","name":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","canonical_id":"clinicaltrials.gov:NCT06262685","description":"Cardiovascular Diseases; Dyslipidemias; Statin Adverse Reaction; Pharmacogenic Myopathy","metadata":null},{"id":"e5329bd089bc43058ac4536ce7e80a2c","type":"TRIAL","name":"Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)","canonical_id":"clinicaltrials.gov:NCT03288870","description":"Non Small Cell Lung Cancer Stage IIIB; Non-Small Cell Carcinoma of Lung, TNM Stage 4","metadata":null},{"id":"8e028287efae408a8b03702167ffdecb","type":"TRIAL","name":"Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol","canonical_id":"clinicaltrials.gov:NCT01156844","description":"Persistent Asthma","metadata":null},{"id":"99eecdc7807e46a386e68b2a16139505","type":"TRIAL","name":"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02201108","description":"Multiple Sclerosis","metadata":null},{"id":"2dc5504ddc9c4dec8f01a4d1784a59b2","type":"TRIAL","name":"Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients","canonical_id":"clinicaltrials.gov:NCT03614741","description":"Acute Kidney Injury; Renal Replacement Therapy; Anticoagulants","metadata":null},{"id":"249dc6761ff641789ba78e06138f60a8","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01437397","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"8471ffb2f1474820b94b1e04f545560d","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01110889","description":"Major Depressive Disorder","metadata":null},{"id":"660de8474ce04237a05808513a582c64","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT01110902","description":"Major Depressive Disorder","metadata":null},{"id":"1bdf01d4ea2b4053aee1e9956f2377ee","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00467402","description":"Major Depressive Disorder","metadata":null},{"id":"528b44b9adf04a2d891418761f5c37d9","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00411242","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"e7887c3cd3074b63a3c1e21bbf01f50b","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00411099","description":"Major Depressive Disorder","metadata":null},{"id":"807fd737da344358bb32b5a01277940d","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.","canonical_id":"clinicaltrials.gov:NCT01598987","description":"Renal Function; Liver Transplant","metadata":null},{"id":"8010f9a9b7eb4e0fbeb99f3ddabde22a","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE","canonical_id":"clinicaltrials.gov:NCT01457430","description":"Hereditary Angioedema","metadata":null},{"id":"a1a495fb67764332b58febb1a7e85940","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors","canonical_id":"clinicaltrials.gov:NCT01529619","description":"Alzheimer's Disease","metadata":null},{"id":"9c857507f6154b23a2f8b2980f035e93","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01992159","description":"Postmenopausal Osteoporosis (PMO)","metadata":null},{"id":"e3a9e028507e4694aae29613885d2f67","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms","canonical_id":"clinicaltrials.gov:NCT00389831","description":"Restless Legs Syndrome","metadata":null},{"id":"629b44d1ca1a475c87d510c5cc670946","type":"TRIAL","name":"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01572792","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"0a50c552c5ff469f8ffda84958fe6e21","type":"TRIAL","name":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)","canonical_id":"clinicaltrials.gov:NCT07557420","description":"NMOSD; Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"4a965f0c9b4f4e12aee9f2672b9e48ce","type":"TRIAL","name":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","canonical_id":"clinicaltrials.gov:NCT06578949","description":"Paroxysmal Nocturnal Hemoglobinuria; PNH","metadata":null},{"id":"8d0290f924bd4e4d9526861767e8b695","type":"TRIAL","name":"Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload","canonical_id":"clinicaltrials.gov:NCT03255226","description":"Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload","metadata":null},{"id":"03f0935a33cd45829bf5394996be9079","type":"TRIAL","name":"Efficacy, Safety, Preference and Response Duration of Clobex\u00ae Spray and Taclonex\u00ae Ointment in Psoriasis","canonical_id":"clinicaltrials.gov:NCT00437255","description":"Plaque Psoriasis","metadata":null},{"id":"7dba3403291f414eba2216ce05bd10bc","type":"TRIAL","name":"Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS","canonical_id":"clinicaltrials.gov:NCT04429555","description":"Pneumonia, Viral","metadata":null},{"id":"b5b826918a4b420e94e4f97ca0b75f2b","type":"TRIAL","name":"Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01988493","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"04e44647f8534e49af33b510b9bb7732","type":"TRIAL","name":"Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial","canonical_id":"clinicaltrials.gov:NCT02784392","description":"Enteral Feeding Intolerance (EFI)","metadata":null},{"id":"6c1a571d42b544c79f4913bcccb62278","type":"TRIAL","name":"Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients","canonical_id":"clinicaltrials.gov:NCT07342803","description":"Allergic Asthma","metadata":null},{"id":"d9302bbcd6aa43bfbf258a2e3c003cd5","type":"TRIAL","name":"Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)","canonical_id":"clinicaltrials.gov:NCT03351608","description":"Neuromuscular Blockade","metadata":null},{"id":"ccca21eac1734adcadba62db0863e41c","type":"TRIAL","name":"Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01484119","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"a4e7082235224f5db0e82f60f6f40bd0","type":"TRIAL","name":"Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies","canonical_id":"clinicaltrials.gov:NCT00591201","description":"Spondylarthropathies","metadata":null},{"id":"86f8c493a83b4bc0bee1d327ad9bc428","type":"TRIAL","name":"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","canonical_id":"clinicaltrials.gov:NCT02421510","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"840cc5f7970244fc8beaa0b9b1b0144c","type":"TRIAL","name":"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","canonical_id":"clinicaltrials.gov:NCT02384941","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"7f0d6fa247f84e6f87d3e24050ec5808","type":"TRIAL","name":"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)","canonical_id":"clinicaltrials.gov:NCT01045161","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"1486906922af46a184a015c7fe0281ca","type":"TRIAL","name":"Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00171184","description":"Overactive Bladder","metadata":null},{"id":"c39126f87d01462cbc478ec9042859a7","type":"TRIAL","name":"Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females","canonical_id":"clinicaltrials.gov:NCT05461573","description":"Contraception; Change in Bone Mineral Density","metadata":null},{"id":"14abc5d73ac34eef933fe654affa8734","type":"TRIAL","name":"Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT03569475","description":"Major Depressive Disorder","metadata":null},{"id":"bb73c61660cd47baa54b75201aed6772","type":"TRIAL","name":"Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine","canonical_id":"clinicaltrials.gov:NCT01978496","description":"Migraine With or Without Aura","metadata":null},{"id":"000af855feda4ae18702c48535025218","type":"TRIAL","name":"Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease","canonical_id":"clinicaltrials.gov:NCT04102579","description":"Chorea, Huntington","metadata":null},{"id":"81cbb6c56b3645fbb80c8c42aef61345","type":"TRIAL","name":"Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects","canonical_id":"clinicaltrials.gov:NCT01708590","description":"Psoriasis","metadata":null},{"id":"d91ef90d80f5429393d8e1f2d1bf3be4","type":"TRIAL","name":"Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy","canonical_id":"clinicaltrials.gov:NCT01187888","description":"Progressive Supranuclear Palsy","metadata":null},{"id":"e42640a42ad043e28e6c4257b67de0f4","type":"TRIAL","name":"Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00301236","description":"ADHD, ADD","metadata":null},{"id":"5cbbd33408e246a7a93543110cb67259","type":"TRIAL","name":"Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15","canonical_id":"clinicaltrials.gov:NCT03554772","description":"Acute Pain","metadata":null},{"id":"6e37d1e2fddd4275b69eb471dcd157bd","type":"TRIAL","name":"Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension","canonical_id":"clinicaltrials.gov:NCT01850160","description":"Hypertension","metadata":null},{"id":"896a1c9605b1476c9d631bb90ec2fe76","type":"TRIAL","name":"Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT02445352","description":"Primary Hypercholesterolemia","metadata":null},{"id":"d4c078ac761e4080aaea65c25cd65b6d","type":"TRIAL","name":"Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00733954","description":"Plaque Psoriasis","metadata":null},{"id":"ee3c0d8d4ad54bab8ccf261a3415e0bc","type":"TRIAL","name":"Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","canonical_id":"clinicaltrials.gov:NCT01516424","description":"Schizophrenia","metadata":null},{"id":"54f99649119841f09a024409cb81743c","type":"TRIAL","name":"Efficiency of Bumetanide in Autistic Children","canonical_id":"clinicaltrials.gov:NCT01078714","description":"Autistics Children","metadata":null},{"id":"7ec2d804615742cc9ffbd4dc06b536f1","type":"TRIAL","name":"Efficiency of Donepezil in Elderly Patients for Prevention of POCD Dysfunction","canonical_id":"clinicaltrials.gov:NCT04423276","description":"Total Knee Arthroplasty; Fracture of Head of Femur Articular Displaced; Protrusion of Intervertebral Disc","metadata":null},{"id":"fdd0b2b9f1554b66a092cba00fbf64ad","type":"TRIAL","name":"Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo","canonical_id":"clinicaltrials.gov:NCT03535051","description":"Stable Vitiligo","metadata":null},{"id":"509402f42b934d2d8742096ac377cdac","type":"TRIAL","name":"Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)","canonical_id":"clinicaltrials.gov:NCT05009927","description":"Metastatic Gastrointestinal Stromal Tumor (GIST); C-KIT Mutation; Advanced Gastrointestinal Stromal Tumor (GIST)","metadata":null},{"id":"e73c8174593145aaa6675c7339994d2e","type":"TRIAL","name":"Efgartigimod for the Treatment of Acute Optic Neuritis","canonical_id":"clinicaltrials.gov:NCT06453694","description":"Optic Neuritis","metadata":null},{"id":"bbb5aa5e867444c18c159aeea59131d8","type":"TRIAL","name":"Efgartigimod in Anti-NMDA Receptor Encephalitis.","canonical_id":"clinicaltrials.gov:NCT07822776","description":"Encephalitis Autoimmune","metadata":null},{"id":"6de40fd0475f4e8ea8f3f58550f78357","type":"DRUG","name":"Efinaconazole","canonical_id":"mesh:C431707","description":null,"metadata":null},{"id":"2a5b5593f6d84c5a8edc2c00b95da956","type":"DRUG","name":"Eflornithine","canonical_id":"mesh:D000518","description":null,"metadata":null},{"id":"6301239be59e4831ac50d587c2e7fb47","type":"TRIAL","name":"Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas","canonical_id":"clinicaltrials.gov:NCT06465199","description":"Atypical Teratoid/Rhabdoid Tumor; Embryonal Tumor With Multilayered Rosettes; Ewing Sarcoma; Diffuse Intrinsic Pontine Glioma; Osteosarcoma; Neuroblastoma; DIPG Brain Tumor","metadata":null},{"id":"784bf495f5a84d269338418f41cb02aa","type":"TRIAL","name":"Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT04301843","description":"Neuroblastoma","metadata":null},{"id":"4de9fc20dabd4030a87fdadc5918e87d","type":"TRIAL","name":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT07321912","description":"Osteosarcoma; Ewing Sarcoma","metadata":null},{"id":"e7ca4c7aa5e74bea9291c82e7d5fa59a","type":"TRIAL","name":"Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda","canonical_id":"clinicaltrials.gov:NCT00489658","description":"Trypanosomiasis, African","metadata":null},{"id":"4f0d495fe1b846e79e0543ec73ee2201","type":"TRIAL","name":"Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia","canonical_id":"clinicaltrials.gov:NCT00006079","description":"Cervical Cancer; Precancerous Condition","metadata":null},{"id":"5df4a78b8ae7468590b73aeb900e6121","type":"TRIAL","name":"Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT00021294","description":"Non-melanomatous Skin Cancer; Precancerous/Nonmalignant Condition","metadata":null},{"id":"663f896812bc4245ba5af6f79c7917cf","type":"TRIAL","name":"Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps","canonical_id":"clinicaltrials.gov:NCT00118365","description":"Precancerous Condition","metadata":null},{"id":"d644a3307d984a668120d67645bb03af","type":"TRIAL","name":"Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin","canonical_id":"clinicaltrials.gov:NCT00601640","description":"Other Benign Neoplasm of Skin, Unspecified","metadata":null},{"id":"6bb1f0243bf44ae4a9c51c310a28a25b","type":"TRIAL","name":"Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00006101","description":"Prostate Cancer","metadata":null},{"id":"2729c7bab4b446f29cc75e40c75ca2ed","type":"TRIAL","name":"Eflornithine in Treating Patients With Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT00003814","description":"Bladder Cancer","metadata":null},{"id":"db4547ea60714f32817ba6532c6c0b28","type":"TRIAL","name":"Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus","canonical_id":"clinicaltrials.gov:NCT00003076","description":"Esophageal Cancer","metadata":null},{"id":"45c34779df7047c0ba2759fa560f48ff","type":"TRIAL","name":"Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer","canonical_id":"clinicaltrials.gov:NCT00005884","description":"Non-melanomatous Skin Cancer","metadata":null},{"id":"66a80e3eb03441098ff29897ac92f1db","type":"DRUG","name":"Efmoroctocog alfa","canonical_id":"mesh:C587014","description":null,"metadata":null},{"id":"d79a5d59536a4666891f8b7d4a0a9403","type":"DISEASE","name":"Eftrenonacog alfa","canonical_id":"mesh:C000599709","description":null,"metadata":null},{"id":"28e77fc5b3ae47148664b8849af231f6","type":"TRIAL","name":"Egrifta Replacement and Sleep Disordered Breathing","canonical_id":"clinicaltrials.gov:NCT01788462","description":"Lipodystrophy","metadata":null},{"id":"253eda0e807c472e91d4fbef36b2790b","type":"DISEASE","name":"Ehlers-Danlos syndrome, periodontal type 2","canonical_id":"mondo:0014954","description":null,"metadata":null},{"id":"68a1bcaae8714f7e93927923e949977a","type":"DISEASE","name":"Ehlers-Danlos syndrome, periodontitis type","canonical_id":"mondo:0007527","description":null,"metadata":null},{"id":"249f244dcde1463fa7a0bc7678f2be5e","type":"DISEASE","name":"Eiken syndrome","canonical_id":"mondo:0010803","description":null,"metadata":null},{"id":"bd7307f24c3c4e14b09809f0fa3e0a07","type":"TRIAL","name":"Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02288156","description":"Non-allergic Rhinitis","metadata":null},{"id":"462e0f6b8f56499ebe28723a80cee446","type":"TRIAL","name":"Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT07634601","description":"Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Recurrent Endometrial Carcinoma; Stage III Endometrial Cancer; Stage IV Endometrial Cancer","metadata":null},{"id":"f777a1f457b84f0e866ca97a3eefa5e7","type":"TRIAL","name":"Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)","canonical_id":"clinicaltrials.gov:NCT07395336","description":"Breast Cancer","metadata":null},{"id":"5c6bb8b2d3b34fd5a593dcc452ebcfcb","type":"TRIAL","name":"Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis","canonical_id":"clinicaltrials.gov:NCT00437658","description":"Endometriosis","metadata":null},{"id":"dd6d16efbde449a3908fab3df6ae8a1a","type":"TRIAL","name":"Elagolix for Fertility Enhancement Clinical Trial","canonical_id":"clinicaltrials.gov:NCT04039204","description":"Endometriosis; Unexplained Infertility","metadata":null},{"id":"2b1a4576ad934c6b886346d6b7ed863b","type":"TRIAL","name":"Electro-acupuncture and Flumazenil's Effect on Sedation","canonical_id":"clinicaltrials.gov:NCT02690389","description":"Acupuncture; General Anaesthesia; Sedation","metadata":null},{"id":"2f53f75b66144a4c860f158c44e975d2","type":"TRIAL","name":"Electroacupoint for Diminutive Milk Production","canonical_id":"clinicaltrials.gov:NCT06590805","description":"Physical Therapy; Electrotherapy; Dietary Modification","metadata":null},{"id":"e277b9187b7f4d96a525fbd96b202c01","type":"TRIAL","name":"Electroconvulsive Therapy in Clozapine Refractory Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00042224","description":"Schizophrenia","metadata":null},{"id":"fff57dcf07dc4e2eb64c4f4496291810","type":"TRIAL","name":"Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT06531837","description":"Chronic Pain","metadata":null},{"id":"548eb2b4159540f398ce2a5cf5a2e179","type":"TRIAL","name":"Electroencephalography (EEG) Biomarkers of Response in Depression","canonical_id":"clinicaltrials.gov:NCT00759122","description":"Major Depressive Disorder","metadata":null},{"id":"421d8d0b100c45acbb550bb185a41172","type":"TRIAL","name":"Electromagnetic Field Versus Diclofenac Drugs on Primary Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT03269591","description":"Electromagnetic Field; Dysmenorrhea","metadata":null},{"id":"389a407af49342fdb3c1c1cca41dfee3","type":"TRIAL","name":"Electromechanical Profiling of the Long-QT Syndrome (LQTS)","canonical_id":"clinicaltrials.gov:NCT04074122","description":"Long QT Syndrome; Sudden Cardiac Death; Ventricular Tachycardia","metadata":null},{"id":"4ecf177aadc641cfbf77ae4c568bfd7d","type":"PROTEIN","name":"Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial","canonical_id":"uniprot:Q16134","description":null,"metadata":null},{"id":"a76c50044c30457f9aa915903d2f709a","type":"TRIAL","name":"Electronic Training of Elderly Depression With Cognitive Impairment","canonical_id":"clinicaltrials.gov:NCT05588102","description":"Geriatric Depression; Cognitive Impairment","metadata":null},{"id":"d0a8d46cfbd2475c877e24e940da6716","type":"TRIAL","name":"Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)","canonical_id":"clinicaltrials.gov:NCT00000518","description":"Arrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases; Tachycardia, Ventricular; Ventricular Arrhythmia; Ventricular Fibrillation","metadata":null},{"id":"edddc36b27194746b37dca6028de699d","type":"TRIAL","name":"Electrophysiological Effects of Potential QT Prolonging Drugs","canonical_id":"clinicaltrials.gov:NCT05716854","description":"Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics","metadata":null},{"id":"623ea62a4d4247fa9b518796765dbbb3","type":"TRIAL","name":"Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia","canonical_id":"clinicaltrials.gov:NCT04692285","description":"Focal Dystonia","metadata":null},{"id":"6c78e39d6d164ebb979c8f946c47a5c3","type":"TRIAL","name":"Eletriptan Pharmacokinetics In Korean Males","canonical_id":"clinicaltrials.gov:NCT01139515","description":"Healthy","metadata":null},{"id":"b561f948d1234875be0232f3f5c3cd8c","type":"TRIAL","name":"Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study","canonical_id":"clinicaltrials.gov:NCT01859481","description":"Migraine Without Aura; Migraine With Aura","metadata":null},{"id":"9679377d75304757b924c7aa9c05157c","type":"TRIAL","name":"Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan","canonical_id":"clinicaltrials.gov:NCT01989936","description":"Migraine With or Without Aura","metadata":null},{"id":"7e24032a3a5549439b1a7184fe89469b","type":"TRIAL","name":"Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study","canonical_id":"clinicaltrials.gov:NCT01986088","description":"Migraine With or Without Aura","metadata":null},{"id":"cd85346575f64720ba9c6b799dd5fe0f","type":"TRIAL","name":"Elevation of Effect of Common Analgesic on Pulp Sensibility Tet","canonical_id":"clinicaltrials.gov:NCT07618494","description":"Pulpal Condition","metadata":null},{"id":"0b69544d23f7422f8d3b6e0ed8600aab","type":"GO_TERM","name":"Elg1 RFC-like complex","canonical_id":"go:GO:0031391","description":"\"A pentameric replication factor C (RLC) complex, which unloads the DNA polymerase processivity factor proliferating cell nuclear antigen (PCNA) from chromatin and has roles in telomere length regulation and other aspects of genome stability. In Saccharomyces the subunits are known as Elg1p, Rfc2p, Rfc3p, Rfc4p, and Rfc5p.\" [PMID:14614842, PMID:23499004, PMID:27664980]","metadata":null},{"id":"918dc718d7134201a1127a1a13c12ba1","type":"TRIAL","name":"Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment","canonical_id":"clinicaltrials.gov:NCT03845010","description":"Ventricular Premature Beats","metadata":null},{"id":"3bb1a8bf205f45d39ca93aa281e2eb11","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:P68790","description":null,"metadata":null},{"id":"167cacf9b8de4b97a2a778dd10c697d9","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q6FZB9","description":null,"metadata":null},{"id":"19a282bb29a84cabb0dc057bdfbff9f6","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:P75544","description":null,"metadata":null},{"id":"2e75ecc583f2481aac4d4191df43b0e5","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q57CQ5","description":null,"metadata":null},{"id":"380321baac514014856bf13fd9767e43","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q7VNA2","description":null,"metadata":null},{"id":"8fca221b538747268c6c16ef65504796","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:O84444","description":null,"metadata":null},{"id":"49138688f29e4bbb806127d7d9b45bc9","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:V5AL63","description":null,"metadata":null},{"id":"8aace7c1f2a74495a25ba36b88c2b7a0","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:P0A6M8","description":null,"metadata":null},{"id":"a02011fb91c74705b574304bad8abf9e","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:B4RQX2","description":null,"metadata":null},{"id":"0401ab23b72e401ea9722ccc5effb8d3","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q71WB8","description":null,"metadata":null},{"id":"ece8d15c2bc74798815e963277df8fb3","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:A2RCI2","description":null,"metadata":null},{"id":"aabee4ce6f564ef48d1f2ca0874be2d2","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:B2ISJ9","description":null,"metadata":null},{"id":"957e3b825a6445e3a863e7c5e1b45cd4","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:S7JCG1","description":null,"metadata":null},{"id":"b5efb39b9c1144ddb5d4d9f070d57723","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:B5RPN9","description":null,"metadata":null},{"id":"9bad1333255d400b959652973081fd17","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:R4Y4Z5","description":null,"metadata":null},{"id":"3cd01580486e43e29016bb91a72326c3","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q8KTC1","description":null,"metadata":null},{"id":"3236ecdc4cab4ba28e8def0770594277","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:B3CTE7","description":null,"metadata":null},{"id":"81da7e4a39a946d4a2a878ad99001c0e","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:A0A8A6J2U1","description":null,"metadata":null},{"id":"5d8be7f801244fe98d2d1cde5c669444","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q14JC2","description":null,"metadata":null},{"id":"7509eee026c847ecbb9d387f122d4ce1","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:Q8KTB2","description":null,"metadata":null},{"id":"4c3c0802268c4e9c9face2c08ca4d62a","type":"PROTEIN","name":"Elongation factor G","canonical_id":"uniprot:P41084","description":null,"metadata":null},{"id":"92c13e2a39b149c6a542db46c4463268","type":"PROTEIN","name":"Elongation factor G 1","canonical_id":"uniprot:Q92J93","description":null,"metadata":null},{"id":"bafc7948a1f140e9a2541df818791eb0","type":"PROTEIN","name":"Elongation factor G 1","canonical_id":"uniprot:Q9KUZ7","description":null,"metadata":null},{"id":"93568746134e46f1b4a8c14d9f486a51","type":"PROTEIN","name":"Elongation factor G 1","canonical_id":"uniprot:B6J5C9","description":null,"metadata":null},{"id":"12db0aa57a904ecc889e7732b479d814","type":"PROTEIN","name":"Elongation factor G 1","canonical_id":"uniprot:O83748","description":null,"metadata":null},{"id":"079313a33bf744d39e786506ced2c3b5","type":"DRUG","name":"Elotuzumab","canonical_id":"mesh:C546027","description":null,"metadata":null},{"id":"321d00dc586c4a84bcf4e11214d544d2","type":"TRIAL","name":"Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM","canonical_id":"clinicaltrials.gov:NCT06518551","description":"Myeloma; Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"e628ed93091a4a1da03790fbb71d0e61","type":"TRIAL","name":"Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide","canonical_id":"clinicaltrials.gov:NCT03411031","description":"Multiple Myeloma","metadata":null},{"id":"d5cd7bf746bf4f4393a4cc991064c41e","type":"TRIAL","name":"Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02420860","description":"Hematopoietic Cell Transplantation Recipient; Plasma Cell Myeloma","metadata":null},{"id":"d97db9dda8b04c8a91c0b68865979e73","type":"TRIAL","name":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT04517851","description":"Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis","metadata":null},{"id":"96dfd0b88ec64d24bfc16e464e34ec82","type":"TRIAL","name":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","canonical_id":"clinicaltrials.gov:NCT03948035","description":"Newly Diagnosed Multiple Myeloma","metadata":null},{"id":"e523c79a144e4080804719122e7ff624","type":"TRIAL","name":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","canonical_id":"clinicaltrials.gov:NCT04918147","description":"IgG4 Related Disease; IgG4-RD","metadata":null},{"id":"5c06ad9f6ba345c685a0e74b79b11e36","type":"TRIAL","name":"Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft","canonical_id":"clinicaltrials.gov:NCT03393273","description":"Multiple Myeloma","metadata":null},{"id":"d2d3583a70f64442945a0f7d4463a322","type":"TRIAL","name":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","canonical_id":"clinicaltrials.gov:NCT05981209","description":"Recurrent Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"771a2f8b6a5840bbb09b6d3145ae093a","type":"TRIAL","name":"Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06785415","description":"Recurrent Multiple Myeloma","metadata":null},{"id":"2aba5674e351475997e1cad16789e7af","type":"TRIAL","name":"Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT02843074","description":"Multiple Myeloma","metadata":null},{"id":"be0c1f85659844a49f4b6ddcceb9e29a","type":"TRIAL","name":"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03030261","description":"Multiple Myeloma in Relapse","metadata":null},{"id":"b0d052712dd9472983c298d0153963e7","type":"TRIAL","name":"Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05170789","description":"Relapsed Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"49bb1646a0044113beb42bbf86c3bc93","type":"TRIAL","name":"Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT02998645","description":"Severe Aplastic Anemia","metadata":null},{"id":"fc0717a9580c455ea8fa4d79b8b9f69e","type":"TRIAL","name":"Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT03437603","description":"Poor Graft Function","metadata":null},{"id":"3d7c8608cd0645038e554ad5ccb30fc9","type":"TRIAL","name":"Eltrombopag Phase III Study In Chinese Chronic ITP Patients","canonical_id":"clinicaltrials.gov:NCT01762761","description":"Purpura, Thrombocytopenic, Idiopathic and Hepatitis C","metadata":null},{"id":"6cab5830bd484530ac0100073c96c618","type":"TRIAL","name":"Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP","canonical_id":"clinicaltrials.gov:NCT04917679","description":"Thrombocytopenia","metadata":null},{"id":"28b9b05a486a433c9aaf7d308eba2680","type":"TRIAL","name":"Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP","canonical_id":"clinicaltrials.gov:NCT07687134","description":"Immune Thrombocytopenia","metadata":null},{"id":"9309910c09ae4e5c98c2337742ef8143","type":"TRIAL","name":"Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT02010645","description":"Leukemia","metadata":null},{"id":"203d2ce5f8344ab893e04eab141f84cf","type":"TRIAL","name":"Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)","canonical_id":"clinicaltrials.gov:NCT00902018","description":"Immune Thrombocytopenia","metadata":null},{"id":"4ee0dccfa1c541088c44d459cab22555","type":"TRIAL","name":"Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations","canonical_id":"clinicaltrials.gov:NCT06630221","description":"Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"8e672899c4974af9b4f853bf864a0300","type":"TRIAL","name":"Eltrombopag for Fanconi Anemia","canonical_id":"clinicaltrials.gov:NCT03206086","description":"Fanconi Anemia","metadata":null},{"id":"080849745f4542288651fec2f9b3d0d3","type":"TRIAL","name":"Eltrombopag for Treatment of Fanconi Anemia","canonical_id":"clinicaltrials.gov:NCT06045052","description":"Fanconi Anemia","metadata":null},{"id":"55e80d047f5a4b3aa74079be9a922bc6","type":"TRIAL","name":"Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT01491594","description":"Sarcoma, Soft Tissue; Osteosarcoma; Neoplasms, Connective and Soft Tissue","metadata":null},{"id":"c4831b63101745aa9d278fdb828b9071","type":"TRIAL","name":"Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects","canonical_id":"clinicaltrials.gov:NCT02404025","description":"Aplastic Anemia","metadata":null},{"id":"bf088ac239484bc38f4a6fa74d675147","type":"TRIAL","name":"Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT","canonical_id":"clinicaltrials.gov:NCT03515096","description":"Eltrombopag; Hematopoietic Stem Cell Transplantation; Thrombocytopenia","metadata":null},{"id":"71658ccd0f414783be7cfc2a96ccfacb","type":"TRIAL","name":"Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA","canonical_id":"clinicaltrials.gov:NCT03413306","description":"Acquired Aplastic Anemia","metadata":null},{"id":"df2d4d8ebd55420db69c9271d6492f42","type":"DRUG","name":"Elvitegravir","canonical_id":"mesh:C509700","description":null,"metadata":null},{"id":"8af5f6a5b9a747e199c361a7d535647a","type":"TRIAL","name":"Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study","canonical_id":"clinicaltrials.gov:NCT07486869","description":"Dermatomyositis; Dermatomyositis Sine Myositis; Dermatomyositis With Myopathy; Dermatomyositis With Respiratory Involvement; Dermatomyositis With Organ Involvement; Interstitial Lung Disease; Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)","metadata":null},{"id":"ac34053fb3da4d82b8b38938484bb95f","type":"TRIAL","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","canonical_id":"clinicaltrials.gov:NCT06550141","description":"Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; High-grade B-cell Lymphoma; Follicular Lymphoma","metadata":null},{"id":"e5e50953231c43e48cd050bc5f7acf24","type":"TRIAL","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","canonical_id":"clinicaltrials.gov:NCT07567014","description":"Multiple Myeloma; Large B-cell Lymphoma (LBCL)","metadata":null},{"id":"7e47d7e58d0f4393842032a5665d8a6c","type":"TRIAL","name":"Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)","canonical_id":"clinicaltrials.gov:NCT06694701","description":"Sepsis","metadata":null},{"id":"7d55ebc8cfa14deb9acd26dd6ad9d249","type":"TRIAL","name":"Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant","canonical_id":"clinicaltrials.gov:NCT06996119","description":"Acute Myeloid Leukemia; Graft Versus Host Disease; Myelodysplastic Syndrome","metadata":null},{"id":"c10229fb94b442709c2abead6a6e6773","type":"DISEASE","name":"Embolism","canonical_id":"mesh:D004617","description":null,"metadata":null},{"id":"3498f83db5ce41679ffcf8cb4d96130b","type":"DRUG","name":"Emedastine","canonical_id":"mesh:C043345","description":null,"metadata":null},{"id":"78d790881812469ea9ec8b37ccacc49f","type":"TRIAL","name":"Emend for Multiple-day Emetogenic Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00711555","description":"Nausea; Vomiting","metadata":null},{"id":"a4e9044b5a0a4a91b4c941c9f49fbf02","type":"TRIAL","name":"Emergence Agitation","canonical_id":"clinicaltrials.gov:NCT07253428","description":"Emergence Agitation; Nasal Surgery","metadata":null},{"id":"b0fba7746b8c4acd968bf6105ae47b75","type":"TRIAL","name":"Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine","canonical_id":"clinicaltrials.gov:NCT04908605","description":"Agitation","metadata":null},{"id":"1364c4ca4a284668a8117985660e41ff","type":"TRIAL","name":"Emergency Department-Initiated Medications for Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT05827159","description":"Alcohol Use Disorder","metadata":null},{"id":"a3ee81c4e6954155a7f2f2bd0681300b","type":"TRIAL","name":"Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial","canonical_id":"clinicaltrials.gov:NCT06488105","description":"Lipid Disorder; Hypercholesterolemia; Cardiovascular Diseases; Atherosclerosis","metadata":null},{"id":"e5935846f3774cd598e76cf6a9713a4f","type":"DISEASE","name":"Emery-Dreifuss muscular dystrophy","canonical_id":"mondo:0016830","description":null,"metadata":null},{"id":"67175ecbb2874cf6ab1cd267dd8d2560","type":"TRIAL","name":"Emgality for Migraine in Breastmilk","canonical_id":"clinicaltrials.gov:NCT06085144","description":"Migraine","metadata":null},{"id":"6e5153a6e2c24925bd2c1d8196170898","type":"TRIAL","name":"Emotion, Mood and Executive Function in Parkinson's Disease (PD)","canonical_id":"clinicaltrials.gov:NCT01385735","description":"Parkinson Disease","metadata":null},{"id":"05acdcaee24b4527983083ea4b68e49a","type":"TRIAL","name":"Emp-Activity: Empagliflozin Functional Capacity","canonical_id":"clinicaltrials.gov:NCT05350202","description":"Heart Failure","metadata":null},{"id":"bd2494edc8094ade80022ccc67b91c7d","type":"TRIAL","name":"Empagliflozin Treatment in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT06013865","description":"Kidney Transplant; Chronic Kidney Disease","metadata":null},{"id":"0a32dff4333d416ca09fd6edd58a1120","type":"TRIAL","name":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","canonical_id":"clinicaltrials.gov:NCT05174507","description":"Postprandial Hypoglycemia","metadata":null},{"id":"58d7ad8f16b84f39bda7beff1ddc686b","type":"TRIAL","name":"Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.","canonical_id":"clinicaltrials.gov:NCT07556094","description":"Obstructive Sleep Apnea (OSA); Sleep Apnea Syndrome, Obstructive; Heart Failure","metadata":null},{"id":"b34167e64a314d2980ea7b5e834849aa","type":"TRIAL","name":"Empagliflozin and Cardiac Remodelling in People Without Diabetes","canonical_id":"clinicaltrials.gov:NCT04461041","description":"Cardiovascular Diseases; Left Ventricular Hypertrophy","metadata":null},{"id":"63dc272488214b018d36caa695a7fe8c","type":"TRIAL","name":"Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT05776043","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"22ca150cc86e4507a7988d510942ff22","type":"TRIAL","name":"Empagliflozin for No-reflow Phenomenon in PCI for STEMI","canonical_id":"clinicaltrials.gov:NCT06342141","description":"STEMI; No-Reflow Phenomenon","metadata":null},{"id":"8fd6b04e8b5044f99e0a31c316de90f4","type":"TRIAL","name":"Empagliflozin in Post-Transplantation Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT03113110","description":"Posttransplant Diabetes Mellitus","metadata":null},{"id":"21c11c787e244967806c147a2e64b67f","type":"DISEASE","name":"Empyema of pleura","canonical_id":"mesh:D016724","description":null,"metadata":null},{"id":"b38e2b672e2444a883bc47d133647e9a","type":"GO_TERM","name":"EmrE multidrug transporter complex","canonical_id":"go:GO:1990207","description":"\"A transmembrane protein complex capable of transporting positively charged hydrophobic drugs across the plasma membrane thereby involved in conferring resistance to a wide range of toxic compounds (e.g. methyl viologen, ethidium bromide and acriflavine). It is commonly found in bacteria. In E. coli it forms a homodimer.\" [GOC:bhm, PMID:18024586]","metadata":null},{"id":"97ee93ff28ee483ea7df808d6803be9e","type":"TRIAL","name":"Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases","canonical_id":"clinicaltrials.gov:NCT07274709","description":"Advanced Breast Cancer","metadata":null},{"id":"555d4d0b1b414c44a0276bbc35cbfc4a","type":"TRIAL","name":"Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases","canonical_id":"clinicaltrials.gov:NCT07225790","description":"Advanced Breast Cancer","metadata":null},{"id":"c013dae655da47b686a0be47ef233b03","type":"TRIAL","name":"Emulation of the PALOMA-2 Trial","canonical_id":"clinicaltrials.gov:NCT07178743","description":"Advanced Breast Cancer","metadata":null},{"id":"980782d12ba74dfd9f2dc44eba0dd76b","type":"DRUG","name":"Enalapril","canonical_id":"mesh:D004656","description":null,"metadata":null},{"id":"9dc03b4e89ca42eb81564679193696c6","type":"TRIAL","name":"Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer","canonical_id":"clinicaltrials.gov:NCT00003070","description":"Cardiac Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific","metadata":null},{"id":"426047e336cd42d7a440b341ff7832e6","type":"DRUG","name":"Enalaprilat","canonical_id":"mesh:D015773","description":null,"metadata":null},{"id":"953d39bcb7944fca9d58cfed40ec80b3","type":"TRIAL","name":"Enantyum\u00ae IV Versus Piroxen\u00ae IM in Emergency Pain Management","canonical_id":"clinicaltrials.gov:NCT06404177","description":"Traumatic Injury","metadata":null},{"id":"74779a179a454e718c26e074c9e61646","type":"TRIAL","name":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT05441514","description":"Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"c5022b190e5d4235a0fa9b1e8ea1f912","type":"DISEASE","name":"Encephalitis due to Herpesvirus","canonical_id":"mesh:D020803","description":null,"metadata":null},{"id":"22d2f209fc774f61ba0e17fa7f5830d9","type":"DRUG","name":"Encorafenib","canonical_id":"ncit:C98283","description":null,"metadata":null},{"id":"e61760c89e03487d891c9036bd7df512","type":"DISEASE","name":"Endocarditis, Bacterial","canonical_id":"mesh:D004697","description":null,"metadata":null},{"id":"88574fcf39dc4eb79fd413ada6104487","type":"TRIAL","name":"Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01205685","description":"Hormone-sensitive Metastatic Breast Cancer","metadata":null},{"id":"e1ce0529d1a5411dbcdf10ea108ebed3","type":"TRIAL","name":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03425838","description":"Breast Neoplasm Female","metadata":null},{"id":"5262618e13f2478d8c137312344416de","type":"TRIAL","name":"Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.","canonical_id":"clinicaltrials.gov:NCT02668926","description":"Healthy","metadata":null},{"id":"3c4ba0c9c423404d9b121476c5ef38fb","type":"DISEASE","name":"Endometrial Cancer","canonical_id":"doid:1380","description":null,"metadata":null},{"id":"e1c4a47666284db499fc7bab8add5c67","type":"TRIAL","name":"Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line","canonical_id":"clinicaltrials.gov:NCT05201547","description":"Endometrial Cancer","metadata":null},{"id":"fc6c6f8ab03f48908dd39cdd62986ca7","type":"TRIAL","name":"Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women","canonical_id":"clinicaltrials.gov:NCT02440750","description":"Uterine Fibroids","metadata":null},{"id":"18ccb0d921c1484bb1cf95f3a26fcb2e","type":"TRIAL","name":"Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination","canonical_id":"clinicaltrials.gov:NCT00160316","description":"Postmenopause","metadata":null},{"id":"65eaf817ec864e8ca832ec1d889bf667","type":"DISEASE","name":"Endometrial Serous Adenocarcinoma","canonical_id":"doid:5750","description":null,"metadata":null},{"id":"cb33711bcef84ae8998f774fe73589dd","type":"TRIAL","name":"Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone","canonical_id":"clinicaltrials.gov:NCT06616077","description":"Endometrial Endocrine Regulation; Progesterone Supplementation in Women After Mifepristone","metadata":null},{"id":"7450b4365f054fd0989a8a8cbabf3f70","type":"DISEASE","name":"Endometrial carcinoma","canonical_id":"mesh:D016889","description":null,"metadata":null},{"id":"293be37de5a64349aa0daea1451c0963","type":"DISEASE","name":"Endometrioid Ovary Carcinoma","canonical_id":"doid:5828","description":null,"metadata":null},{"id":"7495c0a6b7304e478d643be1a6914095","type":"DISEASE","name":"Endometriosis","canonical_id":"mesh:D004715","description":null,"metadata":null},{"id":"d121054a82d74c0b90146e2a0028cfaa","type":"TRIAL","name":"Endometriosis : Traditional Medicine vs Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT00034047","description":"Endometriosis; Pelvic Pain","metadata":null},{"id":"a7602682178d4fcebcc51eb7ff4c710e","type":"TRIAL","name":"Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee","canonical_id":"clinicaltrials.gov:NCT05059626","description":"Endometriosis","metadata":null},{"id":"628510d89d6c438ebeeb08b9d883fb30","type":"DISEASE","name":"Endometritis","canonical_id":"mesh:D004716","description":null,"metadata":null},{"id":"42adc0a60505416a8228edf439ea3602","type":"TRIAL","name":"Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding","canonical_id":"clinicaltrials.gov:NCT00965900","description":"Variceal Bleeding; Cirrhosis","metadata":null},{"id":"e9e1399bcc7b4919aaff83d9fdfd6105","type":"TRIAL","name":"Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding","canonical_id":"clinicaltrials.gov:NCT00567216","description":"Liver Cirrhosis and Hepatoma.; Gastric Variceal Bleeding","metadata":null},{"id":"423d2125a53145d69b5cc11717bb55b8","type":"TRIAL","name":"Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas","canonical_id":"clinicaltrials.gov:NCT00517296","description":"Crohn Disease; Rectal Fistula","metadata":null},{"id":"cdfa5fe5ca664bcd934a9401162d2792","type":"TRIAL","name":"Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss","canonical_id":"clinicaltrials.gov:NCT05268627","description":"Obesity","metadata":null},{"id":"a89fe81108a4437ca2e03ac6f4d90bbc","type":"TRIAL","name":"Endothelial Dysfunction as a Risk Factor in HIV Study","canonical_id":"clinicaltrials.gov:NCT00039663","description":"HIV Infections","metadata":null},{"id":"2925a5e31a694754a2a71dec214fadd8","type":"TRIAL","name":"Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil","canonical_id":"clinicaltrials.gov:NCT00937144","description":"Sickle Cell Anemia","metadata":null},{"id":"3e3aa6b8656e41a1b90797f3e3b2bc88","type":"TRIAL","name":"Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)","canonical_id":"clinicaltrials.gov:NCT05373108","description":"Cardiac Allograft Vasculopathy","metadata":null},{"id":"b1b0756e9b1b434891b8ff294c5345de","type":"TRIAL","name":"Endotypic Traits and Obstructive Sleep Apnea Surgery","canonical_id":"clinicaltrials.gov:NCT05953610","description":"Obstructive Sleep Apnea","metadata":null},{"id":"0563b6f7f602444dade22ebc458568d6","type":"TRIAL","name":"Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein","canonical_id":"clinicaltrials.gov:NCT05001776","description":"Superficial Vein Thrombosis; Endovenous Laser Ablation","metadata":null},{"id":"cd33e7a4057e410e81eb3e7b322e46d3","type":"TRIAL","name":"Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT04912726","description":"Hypertension, Pulmonary","metadata":null},{"id":"eb5fb00c98974b189d5a6544f294e9b9","type":"TRIAL","name":"Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC","canonical_id":"clinicaltrials.gov:NCT07663747","description":"Urothelial Bladder Cancer","metadata":null},{"id":"e051db0ec4e742169dd7566b2227befd","type":"TRIAL","name":"Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT06809140","description":"Muscle Invasive Bladder Urothelial Carcinoma","metadata":null},{"id":"037c89d883654c929a26246598305bf6","type":"TRIAL","name":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","canonical_id":"clinicaltrials.gov:NCT06041503","description":"Adenocarcinoma of the Bladder; Squamous Cell Carcinoma of the Bladder; Testicular Germ Cell Tumors","metadata":null},{"id":"971eb58abc0240b18017d00eecffa46b","type":"TRIAL","name":"Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT06470282","description":"Bladder Cancer; Muscle-Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8","metadata":null},{"id":"a27bc3c709434a93b83f37a190445277","type":"TRIAL","name":"Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT05239624","description":"Urothelial Carcinoma","metadata":null},{"id":"a363354422d147b9adba11b6ff86f240","type":"TRIAL","name":"Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT04223856","description":"Urothelial Cancer","metadata":null},{"id":"87e59f10577547a9be513b02e8de86a6","type":"TRIAL","name":"Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT06394570","description":"Bladder Cancer","metadata":null},{"id":"e65ade62883a4b6ea4b2baa994fa9922","type":"TRIAL","name":"Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04754191","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"82f98efb49e74e758d5e93305146cc47","type":"TRIAL","name":"Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis","canonical_id":"clinicaltrials.gov:NCT06104618","description":"Metastatic Penile Squamous Cell Carcinoma; Stage III Penile Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Unresectable Penile Squamous Cell Carcinoma","metadata":null},{"id":"e567346404e64f1cbde9f081525eb42e","type":"TRIAL","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","canonical_id":"clinicaltrials.gov:NCT07566156","description":"Urothelial Cancer; Urinary Bladder Neoplasms","metadata":null},{"id":"1cd76c90ded342ee8ce8ab40ca3a665b","type":"TRIAL","name":"Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy","canonical_id":"clinicaltrials.gov:NCT07347314","description":"Advanced Small Bowel Adenocarcinoma","metadata":null},{"id":"9fc0bfa0a6dc4fe3b0115124c9f12e8f","type":"TRIAL","name":"Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)","canonical_id":"clinicaltrials.gov:NCT01549171","description":"Pregnancy","metadata":null},{"id":"fc975f31cbf446bc9aa04a5cf0f61753","type":"TRIAL","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","canonical_id":"clinicaltrials.gov:NCT06120140","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"55b2f4312872458481a31dc32ba0cec1","type":"TRIAL","name":"Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04368377","description":"Pneumonia, Viral; Corona Virus Infection; Respiratory Failure; Embolism and Thrombosis","metadata":null},{"id":"5e072eb1552847139a1331b7a2ab0970","type":"TRIAL","name":"Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT07315022","description":"Enhanced Recovery After Surgery; Multimodal Analgesia; Real-world Study; Transarterial Chemoembolization","metadata":null},{"id":"ed2816104ade435ebf6751d0c5a9e90e","type":"TRIAL","name":"Enhanced Recovery Pathway for Endoscopy","canonical_id":"clinicaltrials.gov:NCT04983498","description":"Enhanced Recovery Pathway; Endoscopy","metadata":null},{"id":"3d9a25a8c1c64579b2cad9e1a0602920","type":"TRIAL","name":"Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05212857","description":"Prostate Cancer","metadata":null},{"id":"fabd5208803d4a2ea97569e41ccf1682","type":"TRIAL","name":"Enhancement of Corticosteroid Efficacy in COPD","canonical_id":"clinicaltrials.gov:NCT02340520","description":"COPD","metadata":null},{"id":"744e8d00f0664a118cfb7636ed363742","type":"TRIAL","name":"Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation","canonical_id":"clinicaltrials.gov:NCT00853866","description":"Cerebral Stroke","metadata":null},{"id":"59b85634f7de43e5921384e656d9b705","type":"TRIAL","name":"Enhancement of Stroke Rehabilitation With Levodopa","canonical_id":"clinicaltrials.gov:NCT03735901","description":"Acute Stroke; Stroke Rehabilitation","metadata":null},{"id":"c2060bbd7c29429d8b3747dafb8e476a","type":"TRIAL","name":"Enhancing Amoxicillin Pharmacokinetics and Pharmacodynamics Parameters With Probenecid in Bone and Joint Infections","canonical_id":"clinicaltrials.gov:NCT07764302","description":"Osteoarticular Infections (OAIs)","metadata":null},{"id":"12f19ea774664d69a2837cceffe1d30d","type":"TRIAL","name":"Enhancing Conservative Treatment for Urge Incontinence","canonical_id":"clinicaltrials.gov:NCT00223821","description":"Urinary Incontinence","metadata":null},{"id":"4cd050aa0cd24e3e8c3549e77c4d8adc","type":"TRIAL","name":"Enhancing Memory Consolidation in Older Adults","canonical_id":"clinicaltrials.gov:NCT03657212","description":"Aging","metadata":null},{"id":"a95e44d795ff481699ca78138cf40ec8","type":"TRIAL","name":"Enhancing Mobility and Mental Health in Dementia Patients","canonical_id":"clinicaltrials.gov:NCT06611202","description":"Dementia","metadata":null},{"id":"89aaa1fce50a42368ae24398e8560e82","type":"TRIAL","name":"Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?","canonical_id":"clinicaltrials.gov:NCT01166958","description":"Osteoporosis","metadata":null},{"id":"9d19f2326289421e833fd345aad5a97d","type":"DRUG","name":"Enoxaparin","canonical_id":"mesh:D017984","description":null,"metadata":null},{"id":"0f6083c56fd3402dbc7bf1d7e1e8b49b","type":"TRIAL","name":"Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function","canonical_id":"clinicaltrials.gov:NCT03158792","description":"Venous Thromboembolism; Renal Impairment","metadata":null},{"id":"0fe727507dff41d594d7d046e1d53f8c","type":"TRIAL","name":"Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study","canonical_id":"clinicaltrials.gov:NCT03988231","description":"Venous Thromboembolism; Bleeding as Surgical Complication (Treatment); Deep Venous Thrombosis; Pulmonary Embolism","metadata":null},{"id":"32ce83a71bf14984a7ed8a1647d45d54","type":"TRIAL","name":"Enoxaparin Versus Unfractionated Heparin in PCI","canonical_id":"clinicaltrials.gov:NCT00439855","description":"Coronary Artery Disease","metadata":null},{"id":"ca0eedccea964faea0b38b5b69c0b14f","type":"TRIAL","name":"Enoxaparin and/or Minocycline in Acute Stroke","canonical_id":"clinicaltrials.gov:NCT00836355","description":"Acute Ischemic Stroke","metadata":null},{"id":"ff62c474997a4c33be0a10502b215495","type":"TRIAL","name":"Enoxaparin in Acute Venous Thromboembolic Disease","canonical_id":"clinicaltrials.gov:NCT00265993","description":"Venous Thrombosis","metadata":null},{"id":"31a2858c8fa34215838469e699264d4b","type":"TRIAL","name":"Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","canonical_id":"clinicaltrials.gov:NCT04427098","description":"COVID-19","metadata":null},{"id":"57a92c4396eb48cfbf70fdde2a50f2a8","type":"TRIAL","name":"Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT00077948","description":"Heart Failure, Congestive","metadata":null},{"id":"b60a534376e2444db61a00c71254e907","type":"PROTEIN","name":"Enoyl-[acyl-carrier-protein] reductase [NADH]","canonical_id":"uniprot:P9WGR1","description":null,"metadata":null},{"id":"7d395321bbb64742a45dd35a0864cad1","type":"TRIAL","name":"Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects","canonical_id":"clinicaltrials.gov:NCT03466736","description":"Alzheimer Disease; Mild Cognitive Impairment","metadata":null},{"id":"5ec93487a54f4c02b948954e6047b74a","type":"TRIAL","name":"Entacapone Augmentation for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00192855","description":"Schizophrenia","metadata":null},{"id":"a82c144d54794b5891e8803e1f03321a","type":"TRIAL","name":"Entacapone Combination With Imatinib for Treatment of GIST","canonical_id":"clinicaltrials.gov:NCT04006769","description":"Gastrointestinal Stromal Tumor, Malignant","metadata":null},{"id":"d5895a175da844fa830082430701fd3b","type":"TRIAL","name":"Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence","canonical_id":"clinicaltrials.gov:NCT07831187","description":"Glioblastoma","metadata":null},{"id":"34d56bd3a5c54da2aaaea473b832c634","type":"GO_TERM","name":"Enterobacter ribonuclease activity","canonical_id":"go:GO:0008847","description":"\"Catalysis of the endonucleolytic cleavage to 3'-phosphomononucleotides and 3'-phosphooligonucleotides with 2',3'-cyclic phosphate intermediates.\" [EC:4.6.1.21]","metadata":null},{"id":"f2f9d45ea85e42cf9f2d6d0ff9e8d80c","type":"DISEASE","name":"Enterobiasis","canonical_id":"mesh:D017229","description":null,"metadata":null},{"id":"4d95cc4781fc4bf0b332a28c1ba294e5","type":"DISEASE","name":"Enterocolitis","canonical_id":"mesh:D004760","description":null,"metadata":null},{"id":"3e2fe7b2159a4c8eb2e351182e34e090","type":"GO_TERM","name":"Entner-Doudoroff pathway","canonical_id":"go:GO:0061678","description":"\"A cellular carbohydrate catabolic process that converts a carbohydrate to pyruvate and either glyceraldehyde or glyceraldehyde-3 phosphate by dehydration and aldol cleavage via a gluconate or 6-phosphogluconate intermediate.\" [GOC:dph, PMID:12921536]","metadata":null},{"id":"f1779d4c39bd4ab7a5f182e344286f63","type":"DRUG","name":"Entrectinib","canonical_id":"ncit:C114984","description":null,"metadata":null},{"id":"ca78ed0f38d84e45a02610194eeb32d6","type":"TRIAL","name":"Entyvio (Vedolizumab) Long Term Safety Study","canonical_id":"clinicaltrials.gov:NCT02674308","description":"Ulcerative Colitis and Crohn's Disease","metadata":null},{"id":"2da1aab28a7e4d23a7f79a517dbe5ae4","type":"PROTEIN","name":"Env polyprotein","canonical_id":"uniprot:Q53I07","description":null,"metadata":null},{"id":"402c017d08484cf2b2300157a5166715","type":"TRIAL","name":"Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT05828381","description":"Immunotherapy;Envafolimab; Esophageal Cancer","metadata":null},{"id":"0ab1866e67d047c1834ed6ea8a42bbd8","type":"TRIAL","name":"Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07159191","description":"Advanced Renal Cell Carcinoma (aRCC)","metadata":null},{"id":"bdc5633ef3db43218c411aee5098e14e","type":"TRIAL","name":"Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05237349","description":"Metastatic or Recurrent Gastric Adenocarcinoma","metadata":null},{"id":"54b080203d0841e9aa7201c9ceb795d2","type":"TRIAL","name":"Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT05552651","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"d519f778f8064ccbb90bf1cd19ca101c","type":"TRIAL","name":"Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06218004","description":"Efficacy and Safety","metadata":null},{"id":"12ff0fada02345f2a67c2c6c6702fbed","type":"TRIAL","name":"Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05298020","description":"Advanced Pancreatic Cancer","metadata":null},{"id":"2d28abca3ac2491a81de39e455b4ebac","type":"TRIAL","name":"Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT05879796","description":"Cervical Cancer","metadata":null},{"id":"0f208ef76d2144199533480f24a31f5f","type":"TRIAL","name":"Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT05203276","description":"Lung Neoplasms","metadata":null},{"id":"a678d3764b044f79821e7e26edc15e5f","type":"TRIAL","name":"Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05551247","description":"Colorectal Neoplasms","metadata":null},{"id":"107eb3bdabcb45bdb819b3c0188bc758","type":"TRIAL","name":"Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC","canonical_id":"clinicaltrials.gov:NCT06013943","description":"Gallbladder Cancer","metadata":null},{"id":"bc7de48d385b4e9dbaa057527c5f9fda","type":"TRIAL","name":"Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients","canonical_id":"clinicaltrials.gov:NCT07142863","description":"Osteosarcoma; Neoadjuvant Therapy; Neoadjuvant Chemotherapy; PD-L1 Antibody; Envafolimab","metadata":null},{"id":"0d5d7e3c21bb473f986dd7b30e90859f","type":"TRIAL","name":"Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma","canonical_id":"clinicaltrials.gov:NCT06041724","description":"Advanced Mucosal Melanoma","metadata":null},{"id":"35792ea539d8484891a23aea149c79cd","type":"TRIAL","name":"Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT05534113","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"866d04a96c4e498aa583f6095b114f5f","type":"TRIAL","name":"Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.","canonical_id":"clinicaltrials.gov:NCT05397769","description":"Locally Advanced Nasopharyngeal Carcinoma; Envafolimab; Induction Chemotherapy; PD-L1","metadata":null},{"id":"8a4f4d8b00c9480285413b9a4174dd4c","type":"TRIAL","name":"Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT05910034","description":"Advanced Non-Small Cell Lung Cancer","metadata":null},{"id":"2425eb0d71324613bd3da3c5bce323c4","type":"TRIAL","name":"Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT05055167","description":"Non-small Cell Lung Cancer Stage IV","metadata":null},{"id":"944077df955c4637b07934ecf8fc0f33","type":"TRIAL","name":"Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05582109","description":"Objective Response Rate (ORR)","metadata":null},{"id":"4d00260efc6844b38f266ad2192d1fca","type":"TRIAL","name":"Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT05422183","description":"Ovarian Cancer, Epithelial","metadata":null},{"id":"2db82942b58046c0aeb1099b622a0e5a","type":"PROTEIN","name":"Envelope glycoprotein GP350 (Epstein-Barr virus)","canonical_id":"uniprot:P03200","description":null,"metadata":null},{"id":"d4f0134e31774f7aa091ba89d59f02cd","type":"DRUG","name":"Enviomycin","canonical_id":"mesh:D004776","description":null,"metadata":null},{"id":"7125f13afa564e2ab79df562dfd5a3a9","type":"TRIAL","name":"Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT02213107","description":"Prostate Cancer","metadata":null},{"id":"c51e0d77e645478c9785dec97b0d4131","type":"TRIAL","name":"Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)","canonical_id":"clinicaltrials.gov:NCT04332744","description":"Metastatic Prostate Cancer","metadata":null},{"id":"e8b822872bc84cdaa6bc1222f911eab9","type":"TRIAL","name":"Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression","canonical_id":"clinicaltrials.gov:NCT02555189","description":"Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer AJCC v7","metadata":null},{"id":"1a65d1961a574354a28b1966f3306253","type":"TRIAL","name":"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02522715","description":"Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v7","metadata":null},{"id":"55598cd142ae4126a3061ea6204f6a94","type":"TRIAL","name":"Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT02300610","description":"Bladder Cancer; Carcinoma, Transitional Cell; Renal Pelvis Cancer; Ureter Cancer; Urethra Cancer","metadata":null},{"id":"114dc08feea84a2f909e672c323fc5b7","type":"TRIAL","name":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02446405","description":"Prostatic Neoplasms","metadata":null},{"id":"f93dde74eacb4135ac687ee3254be35a","type":"TRIAL","name":"Eosinophilic Airway Inflammation and Mepolizumab","canonical_id":"clinicaltrials.gov:NCT00802438","description":"Asthma","metadata":null},{"id":"fa3d37cb3e5a45be9a554ef60ac73389","type":"DISEASE","name":"Eosinophilic asthma","canonical_id":"mesh:D011657","description":null,"metadata":null},{"id":"8d08ecba8ef94d7f86a44fceda655581","type":"TRIAL","name":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT06536049","description":"Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Grade 3b Follicular Lymphoma; Refractory High Gr\u2026","metadata":null},{"id":"089da85c480747fcbb7732856b8df560","type":"TRIAL","name":"Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients","canonical_id":"clinicaltrials.gov:NCT07714421","description":"Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; Primary Mediastinal Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"d5bb66eb44fa47d19193521861e156bd","type":"TRIAL","name":"Epcoritamab and Rituximab for First-line Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05783609","description":"Follicular Lymphoma; Low Grade Non-Hodgkin's Lymphoma, Adult","metadata":null},{"id":"04d2340b0bf44e07a9abd1e2efe148b7","type":"TRIAL","name":"Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT06575686","description":"Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma","metadata":null},{"id":"5de6482ea4564b22bb07011b43564a8c","type":"DRUG","name":"Ephedrine","canonical_id":"mesh:D004809","description":null,"metadata":null},{"id":"276bcc7abf074d2e9eac0cefea6f8c63","type":"TRIAL","name":"Ephedrine Versus Phenylephrine for Spinal Block - Related Hypotension in Cesarean Delivery","canonical_id":"clinicaltrials.gov:NCT06741410","description":"Spinal Anesthesia; Cesarean Delivery; Neonatal Acidosis","metadata":null},{"id":"66df3be436c545f5a19e5b6003f14cf9","type":"TRIAL","name":"Ephedrine vs Phenylephrine - ECG Changes","canonical_id":"clinicaltrials.gov:NCT01243970","description":"Spinal Anesthesia; Pregnancy","metadata":null},{"id":"a6422b43c16241439735bf0938d92f4d","type":"TRIAL","name":"Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00460083","description":"Atopic Dermatitis","metadata":null},{"id":"e3aab57f83be48cc8c420100fcc137f7","type":"TRIAL","name":"Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03519542","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"6e36b4964aeb4c2eaa1c1a5c5209144e","type":"DRUG","name":"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor","canonical_id":"ncit:C2167","description":null,"metadata":null},{"id":"23c16f9009ed4918b66b8647a9c824b5","type":"TRIAL","name":"Epidural Calcitonin in Lower Limb Amputation","canonical_id":"clinicaltrials.gov:NCT02115360","description":"Amputation Stumps","metadata":null},{"id":"24b453f1ebf5410eb8dfc2585ad4d295","type":"TRIAL","name":"Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT00003115","description":"Pain; Prostate Cancer","metadata":null},{"id":"23fa9c4357ab462390f4da27fe93c63d","type":"TRIAL","name":"Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus","canonical_id":"clinicaltrials.gov:NCT00707824","description":"Cesarean Section","metadata":null},{"id":"0f052e94b9184c888f06223fc06aa032","type":"TRIAL","name":"Epidural Steroids With Intrathecal Nalbuphine for Lower Abdominal Oncologic Surgery","canonical_id":"clinicaltrials.gov:NCT03276325","description":"Lower Abdominal Oncologic Surgery","metadata":null},{"id":"88fc643434d747e2949f4dd03612fcef","type":"DISEASE","name":"Epilepsy","canonical_id":"mesh:D004827","description":null,"metadata":null},{"id":"15e7bdc158d649439bca12b730ce8a8e","type":"TRIAL","name":"Epileptic Hippocampus in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT05899764","description":"Alzheimer Disease; Mild Cognitive Impairment","metadata":null},{"id":"ec5798a03c094b159acc0fbd6edfe86d","type":"DISEASE","name":"Epileptic encephalopathy","canonical_id":"hp:0200134","description":null,"metadata":null},{"id":"9cee233ab6434011adeb3aaa5433fa77","type":"DRUG","name":"Epinastine","canonical_id":"mesh:C053090","description":null,"metadata":null},{"id":"8cf0b0db8c92401ea49eaa88410ec3fb","type":"TRIAL","name":"Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02182518","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"a760db469cc249e6aa6b522c00d345bd","type":"TRIAL","name":"Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02182531","description":"Healthy","metadata":null},{"id":"0b36fa56a7e841b6880bb4fcc894198b","type":"TRIAL","name":"Epinephrine Versus Isoprenaline During Out-of-Hospital Cardiac Arrest With Asystole","canonical_id":"clinicaltrials.gov:NCT06473116","description":"Out-Of-Hospital Cardiac Arrest","metadata":null},{"id":"9999963a0a0d4f05add6cfc365cb1908","type":"DISEASE","name":"Epithelial Ovarian Cancer","canonical_id":"doid:2152","description":null,"metadata":null},{"id":"2630f16d308a4feabd2db0d6c8a9ac5a","type":"TRIAL","name":"Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01804777","description":"Proteinuria; Hypertension; Type II Diabetes","metadata":null},{"id":"e2567b30d00e4a68b64808d52d95e952","type":"TRIAL","name":"Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT07526857","description":"Diabetic Retinopathy, DR","metadata":null},{"id":"1519958ffea741989549d19cb7e75e2e","type":"DRUG","name":"Eplerenone","canonical_id":"mesh:D000077545","description":null,"metadata":null},{"id":"e131c31e55674e35a88c4a2b1183b48a","type":"TRIAL","name":"Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT02153125","description":"Central Serous Chorioretinopathy","metadata":null},{"id":"df0f345b2c304064a0f286e960e7ff75","type":"TRIAL","name":"Eplerenone Versus PDT: Comparative Study by OCTA","canonical_id":"clinicaltrials.gov:NCT05104138","description":"Central Serous Chorioretinopathy","metadata":null},{"id":"3666c3e7e69b4175a455586979eed7e3","type":"TRIAL","name":"Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy","canonical_id":"clinicaltrials.gov:NCT01521546","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"24c1b94ac70d4fbfaff7d0e6e56f92c9","type":"TRIAL","name":"Eplerenone in Systemic Right Ventricle","canonical_id":"clinicaltrials.gov:NCT00703352","description":"Transposition of Great Vessels; Atrial Switch Procedure","metadata":null},{"id":"1b3345d4a3a442f09d861ce17ab9e4e5","type":"TRIAL","name":"Eplerenone, ACE Inhibition and Albuminuria","canonical_id":"clinicaltrials.gov:NCT00315016","description":"Diabetic Nephropathy","metadata":null},{"id":"3851f64840684174966355b38a040015","type":"TRIAL","name":"Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT05847049","description":"Central Serous Chorioretinopathy","metadata":null},{"id":"dc52f367a2664131a6f0bc1b92f1554b","type":"TRIAL","name":"Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00082433","description":"Cancer; Breast Cancer","metadata":null},{"id":"a4d0f33c730c49a98286235073fda93f","type":"DRUG","name":"Eprosartan","canonical_id":"mesh:C068373","description":null,"metadata":null},{"id":"05c6ba35737849e3b72de8ae269162c6","type":"DRUG","name":"Eptifibatide","canonical_id":"mesh:C086648","description":null,"metadata":null},{"id":"448118cde1e44bbcac70c7e2038e6f0c","type":"TRIAL","name":"Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","canonical_id":"clinicaltrials.gov:NCT07347626","description":"Acute Ischemic Stroke","metadata":null},{"id":"d18fcde856cf4124a0102fa93336daa3","type":"TRIAL","name":"Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)","canonical_id":"clinicaltrials.gov:NCT03844594","description":"Acute Ischemic Stroke","metadata":null},{"id":"aa35f70fdf594fff92e437c5f6eb8a57","type":"TRIAL","name":"EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.","canonical_id":"clinicaltrials.gov:NCT05570149","description":"Migraine Disorders","metadata":null},{"id":"312697193f3649b6b176bac672862f0f","type":"TRIAL","name":"Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine","canonical_id":"clinicaltrials.gov:NCT04921384","description":"Migraine","metadata":null},{"id":"88c88a8151754bad8124f6777874eb5a","type":"TRIAL","name":"Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context","canonical_id":"clinicaltrials.gov:NCT06428838","description":"Migraine; Chronic Migraine","metadata":null},{"id":"5cae41492d8f4cd38077d198b81eca2a","type":"TRIAL","name":"Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension","canonical_id":"clinicaltrials.gov:NCT07645833","description":"Idiopathic Intracranial Hypertension (IIH)","metadata":null},{"id":"3779af248a4747fb938d6d37da40c754","type":"TRIAL","name":"Eptinezumab in Adults With Migraine and Medication Overuse Headache","canonical_id":"clinicaltrials.gov:NCT04772742","description":"Migraine; Medication Overuse Headache","metadata":null},{"id":"b9391047bcf84f0abbce9289d34697bd","type":"TRIAL","name":"Eptinezumab in Healthy Japanese Subjects","canonical_id":"clinicaltrials.gov:NCT04336449","description":"Healthy","metadata":null},{"id":"c9425eb9dd7541419d004df7e991e784","type":"TRIAL","name":"Eptinezumab in Participants With Episodic Cluster Headache","canonical_id":"clinicaltrials.gov:NCT04688775","description":"Cluster Headache, Episodic","metadata":null},{"id":"6c2e27b9af0249148aaee441e970deb1","type":"GO_TERM","name":"ErbB-2 class receptor binding","canonical_id":"go:GO:0005176","description":"\"Binding to a protein-tyrosine kinase receptor Neu/ErbB-2/HER2.\" [GOC:jl]","metadata":null},{"id":"c35f6ba381ea4c30828a3e6dc9ea1e59","type":"GO_TERM","name":"ErbB-3 class receptor binding","canonical_id":"go:GO:0043125","description":"\"Binding to the protein-tyrosine kinase receptor ErbB-3/HER3.\" [GOC:jl]","metadata":null},{"id":"a83e45e7157947d28e09fd85b875e1fa","type":"GO_TERM","name":"ErbB-4 class receptor binding","canonical_id":"go:GO:1990631","description":"\"Binding to the protein-tyrosine kinase receptor ErbB-4/HER4.\" [GOC:sl, PMID:18523588]","metadata":null},{"id":"48e34ce42eba46a9893ef8f7c83288d8","type":"DRUG","name":"Erdafitinib","canonical_id":"ncit:C103273","description":null,"metadata":null},{"id":"730cc16048b3458aaa46ecf935808e8c","type":"DISEASE","name":"Erectile Disfunction","canonical_id":"mesh:D007172","description":null,"metadata":null},{"id":"7b5ce81fb967413f9f7cb5d725a1e285","type":"TRIAL","name":"Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy","canonical_id":"clinicaltrials.gov:NCT03406169","description":"Erectile Dysfunction; Prostate Cancer","metadata":null},{"id":"a3093d24d13e4e5b8165d9359b95fd35","type":"TRIAL","name":"Erector Spinae Block Versus Thoracic Paravertebral Block for Postoperative Pain Control After Open Nephrectomy","canonical_id":"clinicaltrials.gov:NCT04719507","description":"Pain, Postoperative","metadata":null},{"id":"c9832b19b1754e5f9f11b3b6b85c788b","type":"TRIAL","name":"Erector Spinae Plane Block Versus Opioid Based General Anesthesia During Laparoscopic Bariatric Surgery","canonical_id":"clinicaltrials.gov:NCT03798522","description":"Bariatric Surgery Candidate; Morbid Obesity; Visceral Pain","metadata":null},{"id":"4fec2397deea4c73b973a2cd8ad495a4","type":"TRIAL","name":"Erector Spinae Plane Block in Scoliotic Adolescents","canonical_id":"clinicaltrials.gov:NCT03968146","description":"Scoliosis Idiopathic; Scoliosis; Adolescence; Erector Spinae Plane Block","metadata":null},{"id":"12558eca84e4406392fa9c77beaee40e","type":"TRIAL","name":"Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females","canonical_id":"clinicaltrials.gov:NCT02792517","description":"Headache, Migraine","metadata":null},{"id":"08ac8f8811c0436aa7a430b617ce3aac","type":"TRIAL","name":"Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine","canonical_id":"clinicaltrials.gov:NCT04252742","description":"Migraine","metadata":null},{"id":"4df287c3167144f8922ae1f061d1beff","type":"TRIAL","name":"Erenumab for Idiosyncratic Facial Pain","canonical_id":"clinicaltrials.gov:NCT04249427","description":"Facial Pain; Rhinosinusitis","metadata":null},{"id":"c1fd2bb15c8e4ac59d187f9829072696","type":"TRIAL","name":"Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.","canonical_id":"clinicaltrials.gov:NCT05142228","description":"Trigeminal Neuropathy","metadata":null},{"id":"5b4129c864974b7caf7e748e2fb05d8e","type":"DRUG","name":"Ergoloid mesylates","canonical_id":"mesh:D004877","description":null,"metadata":null},{"id":"7160dfb356a74f068bdd10db6cf8be57","type":"TRIAL","name":"Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02120469","description":"Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor-negative; Stage IV Breast Cancer; Triple-negative Breast Carcinoma","metadata":null},{"id":"7b03a2a7ab9648a9adfa235016b23f87","type":"TRIAL","name":"Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer","canonical_id":"clinicaltrials.gov:NCT01613768","description":"Recurrent Salivary Gland Cancer; Stage IVA Salivary Gland Cancer; Stage IVB Salivary Gland Cancer; Stage IVC Salivary Gland Cancer","metadata":null},{"id":"ca777ba0621d445e84cd5e37695f10e3","type":"TRIAL","name":"Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT02097238","description":"Recurrent Osteosarcoma","metadata":null},{"id":"446f31576ad5470e8f52618314fe1f2e","type":"TRIAL","name":"Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02263495","description":"Metastatic Breast Cancer","metadata":null},{"id":"f7f5240112b2419dac4bd1d59ef828c0","type":"TRIAL","name":"Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02551263","description":"Breast Cancer","metadata":null},{"id":"fd681c416fe24dcf843d21619ca4df92","type":"TRIAL","name":"Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05530057","description":"Advanced Breast Cancer","metadata":null},{"id":"5b6e08dda9be41bea0d98d3031faaca3","type":"TRIAL","name":"Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)","canonical_id":"clinicaltrials.gov:NCT03331250","description":"Angiosarcoma; Epithelioid Hemangioendothelioma","metadata":null},{"id":"31ad19c917794e278b0ccc28ba08791f","type":"TRIAL","name":"Eribulin in HER2 Negative Metastatic BrCa","canonical_id":"clinicaltrials.gov:NCT01827787","description":"Breast Cancer","metadata":null},{"id":"6f980e68d79f46bdb82eb98b4c8df269","type":"DRUG","name":"Erlotinib","canonical_id":"ncit:C65530","description":null,"metadata":null},{"id":"4cfa2bffe7e1456bab8a69102272b1c3","type":"TRIAL","name":"Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract","canonical_id":"clinicaltrials.gov:NCT01116622","description":"Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)","metadata":null},{"id":"19bb66dc0b78481c9dfacb2bdb24e15f","type":"TRIAL","name":"Erlotinib + Bevacizumab for PS 2 Chemotherapy Na\u00efve Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00367601","description":"Lung Cancer","metadata":null},{"id":"b23bdd828cf945d3b8a576fff7bf6687","type":"TRIAL","name":"Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)","canonical_id":"clinicaltrials.gov:NCT01091376","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"e09a487656a14d528b75939d3c505bde","type":"TRIAL","name":"Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00086879","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"09ac87d9ebfd43a4b5e30ac356f8be40","type":"TRIAL","name":"Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT01103375","description":"Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Tumor","metadata":null},{"id":"fc80c8bf5d924027a4194f8420d53600","type":"TRIAL","name":"Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy","canonical_id":"clinicaltrials.gov:NCT01180959","description":"Liver Cancer","metadata":null},{"id":"246383112d174ce99c22309a7a08dcb1","type":"TRIAL","name":"Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00100854","description":"Lung Cancer","metadata":null},{"id":"420f9e565bce4b5f8b3779d0f2903bde","type":"TRIAL","name":"Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00049101","description":"Colorectal Cancer","metadata":null},{"id":"5913265182b34522b4a8bd38a9d7ef3b","type":"TRIAL","name":"Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02206763","description":"EGFR Mutated EGFR TKI Naive Metastatic NSCLC","metadata":null},{"id":"0a8c9076e6784a94a15781617adb7a94","type":"TRIAL","name":"Erlotinib as Neoadjuvant Treatment in Patients With Stage \u2162A N2 NSCLC With Activating EGFR Mutation.","canonical_id":"clinicaltrials.gov:NCT01217619","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"34d084281614425d93d7f1e5024163ea","type":"TRIAL","name":"Erlotinib in Combination With Pralatrexate in Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT01532011","description":"Advanced Cancers; Solid Tumors","metadata":null},{"id":"c475bd796f96492cbf414deb7318a98f","type":"TRIAL","name":"Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00049283","description":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; St\u2026","metadata":null},{"id":"117cbc878a184835a4e87527c4405f9c","type":"TRIAL","name":"Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)","canonical_id":"clinicaltrials.gov:NCT04029480","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"2768b99b170c4a06bd0019e3e16d3894","type":"TRIAL","name":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT03640221","description":"Hypertension; Diabetes Mellitus, Type 2","metadata":null},{"id":"20d6c3c8dcaf48f0b0f135b2c98003d9","type":"TRIAL","name":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","canonical_id":"clinicaltrials.gov:NCT02099110","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"354124d7e8604ef585f2e49233542ed1","type":"TRIAL","name":"Ertugliflozin for Functional Mitral Regurgitation","canonical_id":"clinicaltrials.gov:NCT04231331","description":"Mitral Valve Insufficiency; Left Ventricular Systolic Dysfunction","metadata":null},{"id":"dff4ff62aa6744a5bb05e957d22df304","type":"TRIAL","name":"Ertugliflozin in Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT04438213","description":"Heart Failure","metadata":null},{"id":"d5d23df45ce44905b44eacc93977a002","type":"TRIAL","name":"Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study","canonical_id":"clinicaltrials.gov:NCT04600921","description":"Heart Failure With Reduced Ejection Fraction; Heart Failure With Mid Range Ejection Fraction; Implantable Cardioverter-Defibrillators; Cardiac Resynchronization Therapy","metadata":null},{"id":"cc0c63a4219242fba05a586b79cdf47f","type":"TRIAL","name":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","canonical_id":"clinicaltrials.gov:NCT01999218","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"3c9133ccd4a64443824cd50e82ee8e19","type":"TRIAL","name":"Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT07621380","description":"Type 2 Diabetes Mellitus Myocardial Infarction","metadata":null},{"id":"c595aeb1f7594aaeade9646b52057bf4","type":"TRIAL","name":"Ertugliflozin: Cardioprotective Effects on Epicardial Fat","canonical_id":"clinicaltrials.gov:NCT04167761","description":"Cardiovascular Diseases; Atherosclerosis; Type 2 Diabetes; Insulin Resistance","metadata":null},{"id":"efc9860cbe944f3ebfb17cfaff8064c3","type":"DISEASE","name":"Erysipelas","canonical_id":"mesh:D004886","description":null,"metadata":null},{"id":"2849f8ea2c7647538383f3ccea188939","type":"DISEASE","name":"Erysipeloid","canonical_id":"mesh:D004887","description":null,"metadata":null},{"id":"6eaf298a65cf4b4eb280426cc1312749","type":"DISEASE","name":"Erythema Multiforme","canonical_id":"mesh:D004892","description":null,"metadata":null},{"id":"e99f429698d9470c9c2b73420d71e5c1","type":"DISEASE","name":"Erythrasma","canonical_id":"mesh:D004894","description":null,"metadata":null},{"id":"d8e6598981b041b9a0733259f165fb34","type":"DISEASE","name":"Erythroleukemia, FAB M6","canonical_id":"mesh:D004915","description":null,"metadata":null},{"id":"9932d5514fad4d84a7e53348a6ba4e4e","type":"DISEASE","name":"Erythropoietic protoporphyria","canonical_id":"mesh:D046351","description":null,"metadata":null},{"id":"f6a3053b054240eb86d0842fdfdc8837","type":"TRIAL","name":"Escitalopram (Lexapro) for the Treatment of Postpartum Depression","canonical_id":"clinicaltrials.gov:NCT00833469","description":"Postpartum Depression","metadata":null},{"id":"16fd135ac9f6456f950632fc74c06595","type":"TRIAL","name":"Escitalopram in the Treatment of Dysthymic Disorder, Double Blind","canonical_id":"clinicaltrials.gov:NCT00220701","description":"Dysthymic Disorder","metadata":null},{"id":"9a11aec7b44c47ec949750eac17253da","type":"TRIAL","name":"Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.","canonical_id":"clinicaltrials.gov:NCT05096468","description":"Esketamine; Pregabalin; Acute Postoperative Pain; Neurosurgical Procedures; Perioperative Complication; Spinal Cord Neoplasms","metadata":null},{"id":"48a2d21429574ba58638bde8a29b6d54","type":"TRIAL","name":"Esketamine Versus Sufentanil for Sedation in Patients Undergoing ERCP","canonical_id":"clinicaltrials.gov:NCT07702240","description":"Biliary Tract Diseases; Procedural Sedation and Analgesia","metadata":null},{"id":"da1ba8b2c0da450083ec4e30243f8149","type":"TRIAL","name":"Esketamine and Butorphanol for Post-Lobectomy Pain","canonical_id":"clinicaltrials.gov:NCT06398834","description":"Esketamine; Pain; Post-thoracotomy Pain Syndrome; Thoracic Diseases","metadata":null},{"id":"f327fc0db2b8408fbf2d1d32fc665c53","type":"TRIAL","name":"Esmolol Infusion During Laminectomy: Effect on Quality of Recovery","canonical_id":"clinicaltrials.gov:NCT01179113","description":"Laminectomy","metadata":null},{"id":"c7be0dfc91114a8891b3e0b15033d5f6","type":"TRIAL","name":"Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia","canonical_id":"clinicaltrials.gov:NCT02841241","description":"Septic Shock","metadata":null},{"id":"9745135fa1284e21b0c80865972b6516","type":"TRIAL","name":"Esmolol Infusion in Patients Undergoing Craniotomy","canonical_id":"clinicaltrials.gov:NCT02455440","description":"Cerebral Arterial Disease; Cerebral Aneurysm","metadata":null},{"id":"c6cccf0196db4e5f8a9774bf6d2b48e1","type":"TRIAL","name":"Esmolol Pretreatment on Pain During Injection of Propofol","canonical_id":"clinicaltrials.gov:NCT01885364","description":"Pain","metadata":null},{"id":"90383291505c4f13a1cdea8ea5af0f2a","type":"TRIAL","name":"Esmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery","canonical_id":"clinicaltrials.gov:NCT07846722","description":"Pain, Acute Post-Operative; Dexmedetomidine; Analgesia; Esmolol; Nociceptive Pain; Laparoscopic Hysterectomy","metadata":null},{"id":"234044fd6be0495b8b99ca1d103a0628","type":"TRIAL","name":"Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT05073094","description":"Hypertrophic Obstructive Cardiomyopathy","metadata":null},{"id":"ed235675bb7946b68e8b54f8e8c1c22c","type":"TRIAL","name":"Esmolol for Treatment of Perioperative Tachycardia","canonical_id":"clinicaltrials.gov:NCT01208402","description":"High-risk, Non-cardiovascular Surgeries","metadata":null},{"id":"aec87d9590af47e1bf6eb8fe9c3f0936","type":"TRIAL","name":"Esmolol in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00959569","description":"Cardiac Surgery","metadata":null},{"id":"8e23c356cde14976903cc16b5202e9a1","type":"TRIAL","name":"Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01212874","description":"Hypertension","metadata":null},{"id":"69a87b6e259e4c36ae708e8797180cdd","type":"TRIAL","name":"Esmolol to Treat the Hemodynamic Effects of Septic Shock","canonical_id":"clinicaltrials.gov:NCT02369900","description":"Septic Shock; Hypotension; Tachycardia","metadata":null},{"id":"cb630216d7c041e0bae0c08703082558","type":"TRIAL","name":"Esmolol vs. Labetalol in Endoscopic Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT03661346","description":"Chronic Sinusitis","metadata":null},{"id":"176206b073284c8da99af743f9c444e2","type":"TRIAL","name":"Esmya Versus Surgery Before IVF/ICSI","canonical_id":"clinicaltrials.gov:NCT04028986","description":"Fibroid; Uterus Tumor, Complicating Pregnancy; Infertility, Female; Surgical Procedure, Unspecified","metadata":null},{"id":"3ad0fa9aa7f34b6ebcf3da0c290da34c","type":"TRIAL","name":"Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances","canonical_id":"clinicaltrials.gov:NCT02277886","description":"Gastroesophageal Reflux Disease; Heartburn; Sleep Disturbance","metadata":null},{"id":"0f6f0929cc5c418f9343dc7426c19d32","type":"TRIAL","name":"Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","canonical_id":"clinicaltrials.gov:NCT07312370","description":"Early Gastric Cancer; Gastric Dysplasia; Gastric Neoplasms; Peptic Ulcer With Haemorrhage; Gastric Ulcer","metadata":null},{"id":"bbb681fdc5d94b68bd15458b8dcab1e3","type":"TRIAL","name":"Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs","canonical_id":"clinicaltrials.gov:NCT00241553","description":"NSAIDs; Upper GI Symptoms","metadata":null},{"id":"88cc60ebb669461e92122c57e3d53f70","type":"TRIAL","name":"Esomeprazole or Pantoprazole in Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT03812419","description":"Kidney Transplant; Complications","metadata":null},{"id":"fcfd9d467ee14c138c33d3f91b8eff20","type":"TRIAL","name":"Esophageal capsa\u00efcin Infusion and Mucosal Integrity","canonical_id":"clinicaltrials.gov:NCT02603783","description":"TRPV1 Protein, Human; Capsaicin; Electric Impedance; Esophagus; Intracellular Space; Pain Measurement; Microscopy, Electron","metadata":null},{"id":"f3b9f054962640a59e39a16bce87fac3","type":"DISEASE","name":"Esophagitis, Peptic","canonical_id":"mesh:D004942","description":null,"metadata":null},{"id":"74b821c0a6954eb98820c6280f4dc285","type":"TISSUE","name":"Esophagus Gastroesophageal Junction","canonical_id":"uberon:UBERON:0004550","description":null,"metadata":null},{"id":"737def4363ef4288bedae6dd926294e4","type":"TISSUE","name":"Esophagus Mucosa","canonical_id":"uberon:UBERON:0006920","description":null,"metadata":null},{"id":"9ff3555cb7674d249a0ee7622d1bcdc1","type":"TISSUE","name":"Esophagus Muscularis","canonical_id":"uberon:UBERON:0004648","description":null,"metadata":null},{"id":"dedf42b4d7624fa386a9b9835092950d","type":"DISEASE","name":"Esotropia","canonical_id":"mesh:D004948","description":null,"metadata":null},{"id":"c4dbe5615f904ff993b6933f419ac081","type":"DISEASE","name":"Essential hypertension","canonical_id":"mesh:D000075222","description":null,"metadata":null},{"id":"1ea6dffa9469489e916489e9c6386bf6","type":"DISEASE","name":"Essential thrombocythemia","canonical_id":"mesh:D013920","description":null,"metadata":null},{"id":"4832d5711b3f49a2bcdbac390b5b38e4","type":"TRIAL","name":"Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)","canonical_id":"clinicaltrials.gov:NCT00442845","description":"Coronary Arteriosclerosis; Diabetes Mellitus, Type 2; Cerebrovascular Accident; Dyslipidemia; Peripheral Vascular Disease","metadata":null},{"id":"c2aff8ca9e2f4a4081d1d3cc064cf371","type":"TRIAL","name":"Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression","canonical_id":"clinicaltrials.gov:NCT05892744","description":"Major Depressive Disorder; Chronic Major Depression, Recurrent","metadata":null},{"id":"0a02cde7040744488f3830d0936a1098","type":"TRIAL","name":"Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue","canonical_id":"clinicaltrials.gov:NCT06784076","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"5ada4b625b7f4cd2918b5a166e42309a","type":"TRIAL","name":"Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer","canonical_id":"clinicaltrials.gov:NCT03010761","description":"Addiction","metadata":null},{"id":"578b894377d64aa0b5a35c42d59c0ab6","type":"TRIAL","name":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","canonical_id":"clinicaltrials.gov:NCT06881017","description":"Gastric Cancer; HER2 + Gastric Cancer; CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction; PD-L1 Positive","metadata":null},{"id":"9bdc5a54021e41699e2ff80a8d24fea9","type":"TRIAL","name":"Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)","canonical_id":"clinicaltrials.gov:NCT04209543","description":"Vasomotor Symptoms; Menopausal Symptoms","metadata":null},{"id":"fa38b4e22d3f4624a12b4c521d5fcb49","type":"TRIAL","name":"Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone","canonical_id":"clinicaltrials.gov:NCT01099748","description":"Healthy Volunteers","metadata":null},{"id":"9e176d2ded0444b28e5ffaa9eafa3749","type":"TRIAL","name":"Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01597895","description":"Healthy","metadata":null},{"id":"b395d06f73fd42f8a68f5b3acc7ac4a3","type":"TRIAL","name":"Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes","canonical_id":"clinicaltrials.gov:NCT00288353","description":"Schizophrenia; Schizoaffective Disorder; Bipolar Disorder","metadata":null},{"id":"d1c7fb53ae194a3f9bd7c520918db22d","type":"TRIAL","name":"Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab","canonical_id":"clinicaltrials.gov:NCT02275156","description":"Hyperlipidemia; Mixed Dyslipidemia","metadata":null},{"id":"953b9cd64bcb45e2a766830d42011715","type":"TRIAL","name":"Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04655040","description":"Healthy Participants","metadata":null},{"id":"27c68d6a87414604a2d081acabf6fa4f","type":"TRIAL","name":"Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy","canonical_id":"clinicaltrials.gov:NCT01631409","description":"Coronary Heart Disease (CHD)","metadata":null},{"id":"4801d5e298e844418592d54df9b26182","type":"DRUG","name":"Estradiol","canonical_id":"mesh:D004958","description":null,"metadata":null},{"id":"137fc1d51a1d4259889d9186af0a7378","type":"TRIAL","name":"Estradiol and Progesterone in Hospitalized COVID-19 Patients","canonical_id":"clinicaltrials.gov:NCT04865029","description":"Covid19","metadata":null},{"id":"c6007a05c7d349318638b00b85a8df0b","type":"DRUG","name":"Estramustine","canonical_id":"mesh:D004961","description":null,"metadata":null},{"id":"48bf01631de34b30a43e264806e25ba3","type":"TRIAL","name":"Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition","canonical_id":"clinicaltrials.gov:NCT01466114","description":"Relapsing-remitting Multiple Sclerosis; Secondary-progressive Multiple Sclerosis; Primary-progressive Multiple Sclerosis","metadata":null},{"id":"f74bca4e1cda44f499f0d4a9569a3d8b","type":"TRIAL","name":"Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings","canonical_id":"clinicaltrials.gov:NCT03343912","description":"Pregnancy","metadata":null},{"id":"3d10ece369c54174a3e4ee9f31474e68","type":"DISEASE","name":"Estrogen Receptor-positive Breast Cancer","canonical_id":"doid:0060075","description":null,"metadata":null},{"id":"53107b42927a4112884a91be548d0e33","type":"TRIAL","name":"Estrogen and Graft Atherosclerosis Research Trial (EAGER)","canonical_id":"clinicaltrials.gov:NCT00000605","description":"Cardiovascular Diseases; Coronary Arteriosclerosis; Coronary Disease; Heart Diseases; Myocardial Ischemia; Postmenopause","metadata":null},{"id":"1af7149e504e4e7da11533afc894a19f","type":"TRIAL","name":"Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia","canonical_id":"clinicaltrials.gov:NCT00227942","description":"Sleep Initiation and Maintenance Disorders; Depression","metadata":null},{"id":"91b84e4dbde243039facfe6c6266b536","type":"DISEASE","name":"Estrogen resistance syndrome","canonical_id":"efo:0009042","description":null,"metadata":null},{"id":"ffe4d2e525a645ff8e0cf4de97d49e04","type":"TRIAL","name":"Estrogen, Diabetes, and Endothelial Function","canonical_id":"clinicaltrials.gov:NCT04418908","description":"Type 1 Diabetes","metadata":null},{"id":"d2538bf6ee70490ab16a84c64c5b644b","type":"DRUG","name":"Estrone sulphate","canonical_id":"mesh:C009927","description":null,"metadata":null},{"id":"0304171c7a364387997a038dc73fdd2c","type":"DRUG","name":"Etanercept","canonical_id":"mesh:D000068800","description":null,"metadata":null},{"id":"7b7c74a1019c4e8da625167047d9f744","type":"TRIAL","name":"Etanercept SFP in RA Patients","canonical_id":"clinicaltrials.gov:NCT00413452","description":"Rheumatoid Arthritis","metadata":null},{"id":"a1438ebc58334e1da91f37fd43d8ee3c","type":"TRIAL","name":"Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study","canonical_id":"clinicaltrials.gov:NCT02489760","description":"Ankylosing Spondylitis","metadata":null},{"id":"5594aecacfb9454485e5741d416ed03d","type":"TRIAL","name":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","canonical_id":"clinicaltrials.gov:NCT01303874","description":"Rheumatoid Arthritis; Inflammatory Arthritis","metadata":null},{"id":"0a1510c1375a4f859c946f7bc17c2e9d","type":"TRIAL","name":"Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation","canonical_id":"clinicaltrials.gov:NCT00029328","description":"Respiratory Distress Syndrome, Adult; Bronchiolitis Obliterans; Pneumonia","metadata":null},{"id":"b0bcb59f8b46412c96884f5ebd5ab760","type":"TRIAL","name":"Etanercept for the Treatment of Chronic Urticaria","canonical_id":"clinicaltrials.gov:NCT01030120","description":"Chronic Idiopathic Urticaria","metadata":null},{"id":"0a742e9f2e034f7ba548d6040724cf36","type":"TRIAL","name":"Etanercept to Treat Wegener's Granulomatosis","canonical_id":"clinicaltrials.gov:NCT00001901","description":"Vasculitis; Wegener's Granulomatosis","metadata":null},{"id":"612dc78cfe56431babc03da5dd022799","type":"DRUG","name":"Eteplirsen","canonical_id":"mesh:C000611335","description":null,"metadata":null},{"id":"da06f8b65baa4b9483777f3a68dbd56b","type":"DRUG","name":"Ethambutol","canonical_id":"mesh:D004977","description":null,"metadata":null},{"id":"0173b88e3d26477f8d47cabd9b6e5344","type":"TRIAL","name":"Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.","canonical_id":"clinicaltrials.gov:NCT01323673","description":"Dermatitis, Chronic","metadata":null},{"id":"ebbd881a46d14bf288877c5ebf729ce2","type":"TRIAL","name":"Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation","canonical_id":"clinicaltrials.gov:NCT01103518","description":"Amenorrhea; Dysmenorrhea; Menstruation Disturbances; Hyperandrogenism","metadata":null},{"id":"af2e9b9c01214676a800a4ab6aabb436","type":"DRUG","name":"Ethinylestradiol","canonical_id":"mesh:D004997","description":null,"metadata":null},{"id":"28a7fc0c963a496f81d20afc48b921be","type":"DRUG","name":"Ethionamide","canonical_id":"mesh:D005000","description":null,"metadata":null},{"id":"c9426bdc50dd40b2ba78a2c92e84a043","type":"TRIAL","name":"Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00655811","description":"Healthy","metadata":null},{"id":"e1b536719e5447b3a6d84a740390c5a9","type":"DRUG","name":"Ethosuximide","canonical_id":"mesh:D005013","description":null,"metadata":null},{"id":"e8f62f04733641f39ae5faaac220bcea","type":"TRIAL","name":"Etodolac Nanogel as an Adjunct to Physiotherapy for Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT07308470","description":"Knee Osteoarthritis","metadata":null},{"id":"c3518a3c393343f7a60bda233e9b2de1","type":"TRIAL","name":"Etodolac and Post-bleaching Sensitivity","canonical_id":"clinicaltrials.gov:NCT02881619","description":"Medicaments Substances in Therapeutic Use","metadata":null},{"id":"2d5a8a3f44a14fba9978b2fe5ffc6005","type":"TRIAL","name":"Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT01968005","description":"Low Back Pain","metadata":null},{"id":"4e577cf8503a4a02b84e7d6af2cfc4c7","type":"TRIAL","name":"Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness","canonical_id":"clinicaltrials.gov:NCT02695381","description":"Acute Delayed Onset Muscle Soreness (DOMS)","metadata":null},{"id":"e8f4a760c80843ab9bd81405ffbd4752","type":"TRIAL","name":"Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial","canonical_id":"clinicaltrials.gov:NCT02643381","description":"Cardiopulmonary Arrest; Respiratory Arrest","metadata":null},{"id":"c992c0e7ade34627824364537f9db1e8","type":"TRIAL","name":"Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT07117877","description":"Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer; Ovarian Cancer (OvCa)","metadata":null},{"id":"bf46d81d53e84ec0aa2775452e921a6d","type":"TRIAL","name":"Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas","canonical_id":"clinicaltrials.gov:NCT00002876","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"b12cf69afffa4e56ad706ee227887a42","type":"TRIAL","name":"Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma","canonical_id":"clinicaltrials.gov:NCT00003573","description":"Brain Tumors; Central Nervous System Tumors","metadata":null},{"id":"1e3dfa99f59845de9e6a0bf93662420d","type":"TRIAL","name":"Etoposide and Celecoxib in Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT00551005","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"21a519b6e184493c9d8c4bbda675e661","type":"TRIAL","name":"Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT00351195","description":"Hepatocellular Carcinoma","metadata":null},{"id":"229d3a52b6fb497e8308d40da5826bcd","type":"TRIAL","name":"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT02538926","description":"B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B Lymphoblastic Lymphoma; Recurrent T Lymphoblastic Leukemia/Lymphoma; Refractory B Lymphoblastic Lymphoma; Refractory T Lymphoblastic Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma","metadata":null},{"id":"94e5d314836249ab863731804f309a99","type":"TRIAL","name":"Etoricoxib Versus Gabapentin for Knee Arthroscopy","canonical_id":"clinicaltrials.gov:NCT00799149","description":"Knee Arthroscopy","metadata":null},{"id":"e13ef059c20748348e3b5ed6ec82ae9e","type":"TRIAL","name":"Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain","canonical_id":"clinicaltrials.gov:NCT00855777","description":"Dental Extraction","metadata":null},{"id":"ab4453d593f54bff9768b44182ee90e0","type":"TRIAL","name":"Etoricoxib for Postoperative Pain After Thyroid Surgery","canonical_id":"clinicaltrials.gov:NCT00935116","description":"Acute Pain","metadata":null},{"id":"6315c997f6034ff3a5afb623d48d7467","type":"TRIAL","name":"Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder","canonical_id":"clinicaltrials.gov:NCT00876317","description":"Soft Tissue Injuries of the Shoulder; Tenosynovitis and Bursitis Affecting the Shoulder","metadata":null},{"id":"17ebe3022deb4f06854db46e08d6b8ce","type":"TRIAL","name":"Etoricoxib in Ear Nose Throat Surgery","canonical_id":"clinicaltrials.gov:NCT00756873","description":"Tonsillectomy","metadata":null},{"id":"b1cfc09b48594d49a635a11f40c10e07","type":"TRIAL","name":"Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT04144101","description":"Rheumatoid Arthritis","metadata":null},{"id":"63824898c7714621a235e6191a7189a1","type":"TRIAL","name":"Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00542087","description":"Osteoarthritis","metadata":null},{"id":"e6d9a152511d446d82d331237bbea34b","type":"TRIAL","name":"Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05061446","description":"Ulcerative Colitis","metadata":null},{"id":"06d3f34db1bf46ce840895db82341309","type":"TRIAL","name":"Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03996369","description":"Ulcerative Colitis","metadata":null},{"id":"a18b1110172840278705e4bed26e3fbf","type":"TRIAL","name":"Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT04607837","description":"Ulcerative Colitis","metadata":null},{"id":"3c76d725dbb349b08109c0cc7a8c9308","type":"TRIAL","name":"Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03945188","description":"Ulcerative Colitis","metadata":null},{"id":"63a18145718b440db0198e6dbef91d82","type":"TRIAL","name":"Etrasimod as Prevention of Pouchitis","canonical_id":"clinicaltrials.gov:NCT07486921","description":"Pouchitis","metadata":null},{"id":"2d7d4e69ae124f728f52d603e31968e2","type":"TRIAL","name":"Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis","canonical_id":"clinicaltrials.gov:NCT06521762","description":"Immune Checkpoint Inhibitor-Related Diarrhea and Colitis","metadata":null},{"id":"8503cdf1a146457ebd27920113c66a4b","type":"DRUG","name":"Etravirine","canonical_id":"mesh:C451734","description":null,"metadata":null},{"id":"b8c4d8d8a73a42f7b07e209ff201ec0f","type":"DRUG","name":"Etretinate","canonical_id":"mesh:D005050","description":null,"metadata":null},{"id":"25113a1748124abca145754b56b8db91","type":"DISEASE","name":"Eunuchism","canonical_id":"mesh:D005058","description":null,"metadata":null},{"id":"984013b1268645eea606ddf40c0e37a3","type":"TRIAL","name":"European Active Surveillance Study (EURAS)","canonical_id":"clinicaltrials.gov:NCT00302848","description":"Contraception","metadata":null},{"id":"bf7d94af90a845c8b9d21ed91d3f6cbd","type":"TRIAL","name":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","canonical_id":"clinicaltrials.gov:NCT01087723","description":"Acute Coronary Syndrome","metadata":null},{"id":"3ae1d7971b1f4bef920c283858fb544c","type":"TRIAL","name":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","canonical_id":"clinicaltrials.gov:NCT02813135","description":"Pediatric Cancer","metadata":null},{"id":"bf1b6d42d6b5434fa4aea0acbb4015ac","type":"TRIAL","name":"Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine","canonical_id":"clinicaltrials.gov:NCT01118273","description":"Sleep","metadata":null},{"id":"ab846c03d0f543b3822b04b2828488a6","type":"TRIAL","name":"Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets","canonical_id":"clinicaltrials.gov:NCT03847506","description":"Hypertension, Hyperlipidemia","metadata":null},{"id":"91c520ed2ac54c8ba2dd8a456ca747e1","type":"TRIAL","name":"Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.","canonical_id":"clinicaltrials.gov:NCT01625182","description":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","metadata":null},{"id":"a86c3018fc964fd1a6ab4442e40236e9","type":"TRIAL","name":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","canonical_id":"clinicaltrials.gov:NCT06542497","description":"Presbyopia","metadata":null},{"id":"ec8c8c8f5d0f42ec8e6879750f66d261","type":"TRIAL","name":"Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","canonical_id":"clinicaltrials.gov:NCT00698932","description":"Type 2 Diabetes","metadata":null},{"id":"778f497ef0494bd1aac0f18055f037d0","type":"TRIAL","name":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00661362","description":"Type 2 Diabetes","metadata":null},{"id":"7dc31c756aed4e0982e6e48a93511f44","type":"TRIAL","name":"Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT05324163","description":"KNEE OSTEOARTHRITIS","metadata":null},{"id":"2caa36f2bb5444568116059773afb7b9","type":"TRIAL","name":"Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE","canonical_id":"clinicaltrials.gov:NCT05001737","description":"Macrophage Activation Syndrome; Secondary Hemophagocytic Lymphohistiocytosis; Still Disease; Systemic Lupus Erythematosus; SJIA; AOSD; MAS","metadata":null},{"id":"5b0760754c874206a54e8d817fe642d4","type":"TRIAL","name":"Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma","canonical_id":"clinicaltrials.gov:NCT00267046","description":"Sarcoma; Oral Mucositis","metadata":null},{"id":"751884aae92549f4958c77c6949d3372","type":"TRIAL","name":"Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population","canonical_id":"clinicaltrials.gov:NCT00810316","description":"Pharmacokinetics","metadata":null},{"id":"4290c8b2793c46768256958bd4a24c99","type":"TRIAL","name":"Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)","canonical_id":"clinicaltrials.gov:NCT00386425","description":"Severe Sepsis","metadata":null},{"id":"b1e0776ecbb14d289daf4440fa2c0f5f","type":"TRIAL","name":"Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood","canonical_id":"clinicaltrials.gov:NCT00300469","description":"Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia","metadata":null},{"id":"f3f9bca9d3b1482e8961995502a7b8bd","type":"TRIAL","name":"Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT01071070","description":"Chronic Kidney Disease","metadata":null},{"id":"35064fb196dc46e29a5bcc4bd072bbc5","type":"TRIAL","name":"Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease","canonical_id":"clinicaltrials.gov:NCT03818685","description":"Breast Cancer; Triple Negative Breast Neoplasms","metadata":null},{"id":"a38bdf09b1644569a9b4f47cdfbd04a5","type":"TRIAL","name":"Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.","canonical_id":"clinicaltrials.gov:NCT01966107","description":"COPD; Chronic Obstructive Pulmonary Disease; Moderate to Very Severe COPD","metadata":null},{"id":"0ffcdf06196e4c1ba3495d391129a726","type":"TRIAL","name":"Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)","canonical_id":"clinicaltrials.gov:NCT07539090","description":"Healthy Participants","metadata":null},{"id":"0c30f454b45248b7a31dfcd5dfc9b2a1","type":"TRIAL","name":"Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat","canonical_id":"clinicaltrials.gov:NCT07171619","description":"Healthy","metadata":null},{"id":"4902fb5e9f2e424a98c77e22727b8f65","type":"TRIAL","name":"Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD","canonical_id":"clinicaltrials.gov:NCT02652598","description":"Brain Injuries, Traumatic; Neurocognitive Disorders; Brain Injuries","metadata":null},{"id":"7a3be44bcb9f4a4caee01ef3675d2681","type":"TRIAL","name":"Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","canonical_id":"clinicaltrials.gov:NCT07323095","description":"Chronic Kidney Disease","metadata":null},{"id":"947a391c6af94d4fa4c67e9a53e48d0e","type":"TRIAL","name":"Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","canonical_id":"clinicaltrials.gov:NCT05988697","description":"NSCLC; BRAF V600E Mutation; Advanced Cancer; Stage IIIB NSCLC; Stage IV NSCLC","metadata":null},{"id":"d8122f0395ce49dbb43023c0179b026e","type":"TRIAL","name":"Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT04233918","description":"Homozygous Familial Hypercholesterolemia","metadata":null},{"id":"3299541da14c4bff8b81a4e55b0dcb83","type":"TRIAL","name":"Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor","canonical_id":"clinicaltrials.gov:NCT01356849","description":"Chronic Kidney Disease; Diabetic Nephropathy","metadata":null},{"id":"16f525bcf8f64534adc31077dfc85567","type":"TRIAL","name":"Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients","canonical_id":"clinicaltrials.gov:NCT00422617","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"f18b23f5fbc046999eda5a06ed8aa49e","type":"TRIAL","name":"Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.","canonical_id":"clinicaltrials.gov:NCT01283542","description":"Non-functioning Pituitary Adenoma","metadata":null},{"id":"cdd4085cae854f1195f3d9a38e75c786","type":"TRIAL","name":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","canonical_id":"clinicaltrials.gov:NCT02104804","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"35d45fae894e451585e04f60d3a24490","type":"TRIAL","name":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","canonical_id":"clinicaltrials.gov:NCT02273050","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a0360fa871ef4143b62e008485143bed","type":"TRIAL","name":"Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy","canonical_id":"clinicaltrials.gov:NCT02742090","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"951258f89b26459ebaf1242a3ead0d85","type":"TRIAL","name":"Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT07367282","description":"Macular Degeneration","metadata":null},{"id":"756e0839b25747f98a982230f2cb2f2a","type":"TRIAL","name":"Evaluate the Efficacy of Fenofibrate on Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT02314533","description":"Microalbuminuria","metadata":null},{"id":"67f0a9db823049d886d157eae30cefaf","type":"TRIAL","name":"Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis","canonical_id":"clinicaltrials.gov:NCT02099695","description":"Hyperhidrosis","metadata":null},{"id":"19390671161f44dea78a0c46241c62d9","type":"TRIAL","name":"Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT03409744","description":"Homozygous Familial Hypercholesterolemia","metadata":null},{"id":"e643083a2f564308a825a8fdb7cdee60","type":"TRIAL","name":"Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT01366326","description":"Healthy Adult Subjects","metadata":null},{"id":"2b2f77924a334d458dc611f9a21c5aea","type":"TRIAL","name":"Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter","canonical_id":"clinicaltrials.gov:NCT01229254","description":"Atrial Fibrillation; Atrial Flutter","metadata":null},{"id":"06205e5c0e0745639134fcc3548271a9","type":"TRIAL","name":"Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT02472236","description":"Healthy","metadata":null},{"id":"a9ff3f459c18419f86c6f90211777857","type":"TRIAL","name":"Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)","canonical_id":"clinicaltrials.gov:NCT01148797","description":"Colchicine Resistant/Intolerant Familial Mediterranean Fever","metadata":null},{"id":"b18db3885ec440bb97553259c29c8269","type":"TRIAL","name":"Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","canonical_id":"clinicaltrials.gov:NCT00501293","description":"ADHD","metadata":null},{"id":"4c017741eb234337bb49258813fae06c","type":"TRIAL","name":"Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL","canonical_id":"clinicaltrials.gov:NCT05552937","description":"DLBCL","metadata":null},{"id":"846a620045864df3a8fed1ed37e9c2b5","type":"TRIAL","name":"Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06521255","description":"DLBCL","metadata":null},{"id":"175782eb914d4a13b7ad8b5c778385e3","type":"TRIAL","name":"Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00233675","description":"General Anxiety Disorder","metadata":null},{"id":"40a1028807c64b1194692efdfcfdcd82","type":"TRIAL","name":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT06351527","description":"Mature B-cell Malignancies","metadata":null},{"id":"edb3df961fec4024bfd6c11509335cfa","type":"TRIAL","name":"Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00062699","description":"End-Stage Kidney Disease","metadata":null},{"id":"a1e74ae24d7e48ed87c18d29f78e72d5","type":"TRIAL","name":"Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT02525796","description":"Primary Hyperparathyroidism","metadata":null},{"id":"9bb6185034124a688f75f34d3d39f955","type":"TRIAL","name":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin","canonical_id":"clinicaltrials.gov:NCT07201545","description":"Healthy Subjects","metadata":null},{"id":"1dd50f174e1c4d919314204a921a9896","type":"TRIAL","name":"Evaluating Buspirone to Treat Opioid Withdrawal","canonical_id":"clinicaltrials.gov:NCT05511909","description":"Opioid Use Disorder; Opioid Withdrawal; Opioid Craving; Anxiety","metadata":null},{"id":"976542efdbdb44ab9346bf479f4dd1e9","type":"TRIAL","name":"Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo","canonical_id":"clinicaltrials.gov:NCT02957682","description":"Hypercholesterolemia","metadata":null},{"id":"b406d9a731ed4d188ebe7ba85f200528","type":"TRIAL","name":"Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy","canonical_id":"clinicaltrials.gov:NCT03710356","description":"Telomere Shortening; Telomere Length, Mean Leukocyte","metadata":null},{"id":"5c59503041594b5d91b320f71fb6c11c","type":"TRIAL","name":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","canonical_id":"clinicaltrials.gov:NCT04645160","description":"Cholangiocarcinoma; Bile Duct Neoplasm; Biliary Tract Malignancy","metadata":null},{"id":"85142892a0c347d0854d187fb7c3ef5d","type":"TRIAL","name":"Evaluating Efgartigimod in Patients With Guillain-Barr\u00e9 Syndrome","canonical_id":"clinicaltrials.gov:NCT05701189","description":"Guillain-Barre Syndrome","metadata":null},{"id":"66a2c87d20474851b53b9e4d4070e4cc","type":"TRIAL","name":"Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07751133","description":"Prostate Cancer; mHSPC; mCRPC","metadata":null},{"id":"a8a8f5d4fc274d4b955fb5d5c6863cbd","type":"TRIAL","name":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","canonical_id":"clinicaltrials.gov:NCT00521222","description":"Asthma","metadata":null},{"id":"b0422440a1d040cea0031febb613b478","type":"TRIAL","name":"Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older","canonical_id":"clinicaltrials.gov:NCT01465997","description":"Epilepsy; Monotherapy","metadata":null},{"id":"690e4b9af2e44d7c897b770c9cd7b9df","type":"TRIAL","name":"Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure","canonical_id":"clinicaltrials.gov:NCT04071626","description":"Heart Failure, Diastolic; Diabetes Mellitus, Type 2","metadata":null},{"id":"6013c309c8d44d3a9393da26873c274e","type":"TRIAL","name":"Evaluating Muscle Weakness Improvement With Lorcaserin in ICU","canonical_id":"clinicaltrials.gov:NCT02523690","description":"Muscle Weakness; Sepsis","metadata":null},{"id":"f9ad27cbf9154c28a5218d7cb569fdd1","type":"TRIAL","name":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","canonical_id":"clinicaltrials.gov:NCT01129011","description":"Gastric Ulcer","metadata":null},{"id":"bda6e40021584cababcd07050c875fa0","type":"TRIAL","name":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","canonical_id":"clinicaltrials.gov:NCT00527787","description":"Gastric Ulcer","metadata":null},{"id":"3340c4e59d4a439eb734f5c89ec43bdc","type":"TRIAL","name":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","canonical_id":"clinicaltrials.gov:NCT07101445","description":"Multiple Myeloma","metadata":null},{"id":"4a23323bf98c421c8a765cccd8bc992f","type":"TRIAL","name":"Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML","canonical_id":"clinicaltrials.gov:NCT03727750","description":"ECG; Pharmacokinetics; Safety","metadata":null},{"id":"0f58dcf829174662a99b6cb8365bd381","type":"TRIAL","name":"Evaluating Smoking Cessation Interventions for PWH in South Africa","canonical_id":"clinicaltrials.gov:NCT05413122","description":"Smoking Cessation; HIV; Comorbidities and Coexisting Conditions","metadata":null},{"id":"6d7104d7042045b281cf988d69d87afb","type":"TRIAL","name":"Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body","canonical_id":"clinicaltrials.gov:NCT00800280","description":"Generalized Anxiety Disorder","metadata":null},{"id":"691b04f33ace4c1b87f439860fb264f5","type":"TRIAL","name":"Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT06660862","description":"Prostate Cancer","metadata":null},{"id":"8ed3df4a1fba463da4b955a386e9d1f0","type":"TRIAL","name":"Evaluating Treatment Resistant Dermatitis TaroIIR","canonical_id":"clinicaltrials.gov:NCT03050294","description":"Atopic Dermatitis; Psoriasis","metadata":null},{"id":"420ab7f8072145c6882bffc9d161e49d","type":"TRIAL","name":"Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea","canonical_id":"clinicaltrials.gov:NCT06312813","description":"Rosacea","metadata":null},{"id":"f22770ed7fd94c5c8d2a2e66ab47653d","type":"TRIAL","name":"Evaluating the Abuse Potential of NEURONTIN\u00ae When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience","canonical_id":"clinicaltrials.gov:NCT04570436","description":"Abuse Potential","metadata":null},{"id":"55237e0769a84ae2b0d4a6dd923ff66c","type":"TRIAL","name":"Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.","canonical_id":"clinicaltrials.gov:NCT03309865","description":"Ulcerative Colitis; Dietary Modification","metadata":null},{"id":"4833499e28af497098b91ba67c49a764","type":"TRIAL","name":"Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT06530290","description":"Parkinson Disease; Anxiety","metadata":null},{"id":"16559fad3a0e42e8b41b7743c7ba381e","type":"TRIAL","name":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","canonical_id":"clinicaltrials.gov:NCT01482767","description":"HIV Infections; Hepatitis C","metadata":null},{"id":"60e08980a343437da37db85609873c87","type":"TRIAL","name":"Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1\u039411 Variant","canonical_id":"clinicaltrials.gov:NCT06701396","description":"Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders; Gene Mutations and Other Alterations Nec","metadata":null},{"id":"0d84863b610d4782beedf1058e410df1","type":"TRIAL","name":"Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances","canonical_id":"clinicaltrials.gov:NCT05361707","description":"Autism Spectrum Disorder; Sleep Disorder; Neurological Disorder; Sleep Disturbance","metadata":null},{"id":"0585a657217c45f5aeef092e6afcfa68","type":"TRIAL","name":"Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS","canonical_id":"clinicaltrials.gov:NCT02231008","description":"Smith-Magenis Syndrome; Circadian","metadata":null},{"id":"4be0e9d6002944968d0f2fdb11746533","type":"TRIAL","name":"Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)","canonical_id":"clinicaltrials.gov:NCT04652882","description":"Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders","metadata":null},{"id":"0f786929a04b4b71a2daedbfdcc1944a","type":"TRIAL","name":"Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","canonical_id":"clinicaltrials.gov:NCT06953869","description":"Insomnia Disorder","metadata":null},{"id":"f7243bd26969451dace7289e930ddc94","type":"TRIAL","name":"Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia","canonical_id":"clinicaltrials.gov:NCT03373201","description":"Jet Lag Type Insomnia","metadata":null},{"id":"288f4ebc1bf94fe08893a97b31a02745","type":"TRIAL","name":"Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)","canonical_id":"clinicaltrials.gov:NCT00663130","description":"Erectile Dysfunction","metadata":null},{"id":"f7d718f9cfa44179b529ee9d11260378","type":"TRIAL","name":"Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine","canonical_id":"clinicaltrials.gov:NCT04158076","description":"Hypercholesterolemia; Hypertension","metadata":null},{"id":"de490591a1194cba9808ef80b5f28199","type":"TRIAL","name":"Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07059130","description":"Crohn Disease (CD); Crohns Disease; Ulcerative Colitis (UC)","metadata":null},{"id":"142e243e79d640a683e3cd67e5f125d4","type":"TRIAL","name":"Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT05143528","description":"Alzheimer Disease","metadata":null},{"id":"de41601bce624d2ebcb2fe8a09ae207b","type":"TRIAL","name":"Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH","canonical_id":"clinicaltrials.gov:NCT06677788","description":"Non-Alcoholic Steatohepatitis (NASH)","metadata":null},{"id":"4a33e60ed7d0443b9fc46285f5a7fb61","type":"TRIAL","name":"Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00654680","description":"Erectile Dysfunction","metadata":null},{"id":"50b0f608134d4fff8a73795379a3c0c7","type":"TRIAL","name":"Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension","canonical_id":"clinicaltrials.gov:NCT00668005","description":"Erectile Dysfunction","metadata":null},{"id":"a0e541617344409e97fbd5184aa17c83","type":"TRIAL","name":"Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study","canonical_id":"clinicaltrials.gov:NCT06841666","description":"ADHD; Primary Nocturnal Enuresis","metadata":null},{"id":"6de3a002255a4f609bc841adbc710936","type":"TRIAL","name":"Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast","canonical_id":"clinicaltrials.gov:NCT03812393","description":"Triple Negative Breast Cancer; Early-stage Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"9e7d086ee66c4afaa57bd33ff88b0a11","type":"TRIAL","name":"Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse","canonical_id":"clinicaltrials.gov:NCT00667979","description":"Erectile Dysfunction","metadata":null},{"id":"d2768e8d7bf8494a99f6e0f77a0bb003","type":"TRIAL","name":"Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.","canonical_id":"clinicaltrials.gov:NCT03577184","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"17d7c8fdfc0040649b55f3761278b68a","type":"TRIAL","name":"Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03764462","description":"Osteoporosis","metadata":null},{"id":"f6d9d4fc2b794ecfb807db55000f12c7","type":"TRIAL","name":"Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03824171","description":"Osteoporosis","metadata":null},{"id":"4356522f4a604a45a45661b3d0388d77","type":"TRIAL","name":"Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT02868060","description":"Immune Thrombocytopenia (ITP)","metadata":null},{"id":"07eaf477dd0144eba76b83695a90651a","type":"TRIAL","name":"Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine","canonical_id":"clinicaltrials.gov:NCT05378711","description":"Selective Mutism; Social Anxiety","metadata":null},{"id":"8a106d584e3349bc966e0f22c41141ba","type":"TRIAL","name":"Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone","canonical_id":"clinicaltrials.gov:NCT00925457","description":"Arrhythmias, Cardiac","metadata":null},{"id":"2f19ce037ba14ed2bf17f87a5041058e","type":"TRIAL","name":"Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women","canonical_id":"clinicaltrials.gov:NCT00912548","description":"Breast Cancer","metadata":null},{"id":"cdec2de49400432c81c5c4b2fb50054a","type":"TRIAL","name":"Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01403025","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"e474a41f9b6345c6ad3b82b590090e02","type":"TRIAL","name":"Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).","canonical_id":"clinicaltrials.gov:NCT05997277","description":"Hidradenitis Suppurativa","metadata":null},{"id":"0e72231dd4b048c1addafb3df24ec83c","type":"TRIAL","name":"Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load","canonical_id":"clinicaltrials.gov:NCT01933594","description":"HIV Infections","metadata":null},{"id":"a650cb85da8b4059a9af052131400a33","type":"TRIAL","name":"Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)","canonical_id":"clinicaltrials.gov:NCT00111475","description":"Idiopathic Thrombocytopenic Purpura","metadata":null},{"id":"d8378bd1c7fb4e599b377157974c221e","type":"TRIAL","name":"Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT03949894","description":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","metadata":null},{"id":"d3b909211ef341ec9d0f521f2ec91ada","type":"TRIAL","name":"Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.","canonical_id":"clinicaltrials.gov:NCT05161351","description":"Addiction Opiate","metadata":null},{"id":"a27ce5b243ac4e7ba6cc6385ee8fe1e5","type":"TRIAL","name":"Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major","canonical_id":"clinicaltrials.gov:NCT00336362","description":"Beta-Thalassemia","metadata":null},{"id":"8938396a07594875960ee9e2a160dab4","type":"TRIAL","name":"Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)","canonical_id":"clinicaltrials.gov:NCT00472290","description":"Hematology; MDS; Myelodysplastic Syndromes; Thrombocytopenia","metadata":null},{"id":"8efb6bc478bf4a399372b82c54ed685b","type":"TRIAL","name":"Evaluating the Safety of Zileuton (Zyflo\u00ae) in Combination With Dasatinib (Sprycel\u00ae) in Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT02047149","description":"Chronic Myelogenous Leukemia","metadata":null},{"id":"8459551a9ed8408f939cecd64695de58","type":"TRIAL","name":"Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone","canonical_id":"clinicaltrials.gov:NCT01849094","description":"Healthy; Heart Failure","metadata":null},{"id":"ed6c2d0af9e04b84aeacdd4dd60d28af","type":"TRIAL","name":"Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy","canonical_id":"clinicaltrials.gov:NCT00610532","description":"Epilepsy","metadata":null},{"id":"a4778d8c3bbf4e3c81545e7014149fd8","type":"TRIAL","name":"Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT05945875","description":"Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"1af55227aea04da796a361d41880cc1b","type":"TRIAL","name":"Evaluation Efficacy of Melatonin Gel as Adjunctive Therapy in Chronic Periodontitis","canonical_id":"clinicaltrials.gov:NCT05759416","description":"Chronic Periodontitis","metadata":null},{"id":"4644cf3e9d3e42ddba812c2a1ba72cc6","type":"TRIAL","name":"Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)","canonical_id":"clinicaltrials.gov:NCT00443053","description":"Thrombosis, Venous","metadata":null},{"id":"d483716724d4468985f7169a1ad1b1c9","type":"TRIAL","name":"Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate","canonical_id":"clinicaltrials.gov:NCT00327990","description":"Osteoporosis","metadata":null},{"id":"42a6dbf9b92b4732b47115fb5d2115ba","type":"TRIAL","name":"Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions","canonical_id":"clinicaltrials.gov:NCT00324116","description":"Macular Degeneration","metadata":null},{"id":"a4d1610292854dbcbe235a91ec8dfc17","type":"TRIAL","name":"Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement","canonical_id":"clinicaltrials.gov:NCT00648323","description":"Prostate","metadata":null},{"id":"e0714135557240c487d86107d619f9b9","type":"TRIAL","name":"Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo","canonical_id":"clinicaltrials.gov:NCT05950542","description":"Vitiligo, Generalized","metadata":null},{"id":"56bcd6d4f3d1437ea005bcbb6388425a","type":"TRIAL","name":"Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas\u00ae in Severe Chronic Obstructive Pulmonary Disease Patients","canonical_id":"clinicaltrials.gov:NCT01480661","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"c857925a11194e4f9a3d17e1dc957523","type":"TRIAL","name":"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","canonical_id":"clinicaltrials.gov:NCT03104842","description":"Multiple Myeloma","metadata":null},{"id":"0d00b00de63344829608d914c6955314","type":"TRIAL","name":"Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery","canonical_id":"clinicaltrials.gov:NCT02216266","description":"Suspected Delirium After Elective or Emergency Heart Surgery; CAM-ICU Diagnosed Delirium","metadata":null},{"id":"95c5b4ac800242cd8f9f00834c9dc0f8","type":"TRIAL","name":"Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00444548","description":"Healthy","metadata":null},{"id":"a022563f39d04bf1b0ae051e0f3ac0c4","type":"TRIAL","name":"Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT02974153","description":"Migraine Disorders","metadata":null},{"id":"3ad0869b58a74385a4d2982ace8edaf5","type":"TRIAL","name":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT00697099","description":"Venous Thromboembolism","metadata":null},{"id":"6931cd91122a4e5a87a51b637a0560cb","type":"TRIAL","name":"Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy","canonical_id":"clinicaltrials.gov:NCT05430828","description":"Hypercholesterolemia","metadata":null},{"id":"d5f2116e2e5348e6b7dcd8520b61068d","type":"TRIAL","name":"Evaluation of Adhesion and Dermal Tolerability of EMSAM","canonical_id":"clinicaltrials.gov:NCT00531596","description":"Healthy","metadata":null},{"id":"e58a90d2d401424eae9d45203a3ec12f","type":"TRIAL","name":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","canonical_id":"clinicaltrials.gov:NCT02289963","description":"Hypercholesterolemia","metadata":null},{"id":"0501ffa93afa41e2989f3e25108eb223","type":"TRIAL","name":"Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements","canonical_id":"clinicaltrials.gov:NCT01060865","description":"Blood Pressure, High","metadata":null},{"id":"ac6d66847e0a44cf80166d34c8709988","type":"TRIAL","name":"Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.","canonical_id":"clinicaltrials.gov:NCT00304434","description":"Influenza","metadata":null},{"id":"e363edd70bf942b5b7e31f09bd22265b","type":"TRIAL","name":"Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients","canonical_id":"clinicaltrials.gov:NCT01276223","description":"Dry Eye Disease","metadata":null},{"id":"cbfed949ff5c4c51b1932896b18499cd","type":"TRIAL","name":"Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin","canonical_id":"clinicaltrials.gov:NCT00039858","description":"Thrombocytopenia; Thrombosis","metadata":null},{"id":"bfc309d6cc3c49779795ee3b24f95edc","type":"TRIAL","name":"Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders","canonical_id":"clinicaltrials.gov:NCT01274026","description":"Phenylketonuria; Behavior and Behavior Mechanisms; PAH Gene Expression","metadata":null},{"id":"b89dafa3f6e74ed7b31a912e1b6d5a57","type":"TRIAL","name":"Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD","canonical_id":"clinicaltrials.gov:NCT07127926","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"5b7f97e441da472bb4148257e88a5dd7","type":"TRIAL","name":"Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia","canonical_id":"clinicaltrials.gov:NCT00904436","description":"Dyspnea; Tetraplegia","metadata":null},{"id":"d58b13ea76ca40298d2493eeb989e27d","type":"TRIAL","name":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT05579730","description":"Allergic Conjunctivitis","metadata":null},{"id":"d14dced7cb4b4f1d9e83caef7545f5be","type":"TRIAL","name":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT05591755","description":"Seasonal Allergic Conjunctivitis","metadata":null},{"id":"7e84101dbf8448368ee941957c6e72b7","type":"TRIAL","name":"Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME","canonical_id":"clinicaltrials.gov:NCT03384524","description":"Diabetic Macular Edema","metadata":null},{"id":"8c148dfcb4d746afa1d9c019a1fdac3e","type":"TRIAL","name":"Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)","canonical_id":"clinicaltrials.gov:NCT01147250","description":"Acute Coronary Syndrome","metadata":null},{"id":"9db4cabfbe58454e8924b7eee0a74d90","type":"TRIAL","name":"Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives","canonical_id":"clinicaltrials.gov:NCT02979197","description":"Hypertension","metadata":null},{"id":"48c483a3bd8149949f123c279c9524b7","type":"TRIAL","name":"Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT04804267","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"066f2374800442f1a5319da3a9c8ffa2","type":"TRIAL","name":"Evaluation of Clinical Equivalence Between Two Lubiprostone Products","canonical_id":"clinicaltrials.gov:NCT01372423","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"1dbd9cb2402f4b3f90022a7c4705ea8c","type":"TRIAL","name":"Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT01674530","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"57f162223a3247a9b3a31e1c9ab5501b","type":"TRIAL","name":"Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression","canonical_id":"clinicaltrials.gov:NCT00031317","description":"Panic Disorder","metadata":null},{"id":"f218e03270a74d7291a6921ec981a694","type":"TRIAL","name":"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety","canonical_id":"clinicaltrials.gov:NCT01142284","description":"Peripheral Artery Disease","metadata":null},{"id":"96701642752447d5a45f44e2d159a426","type":"TRIAL","name":"Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant","canonical_id":"clinicaltrials.gov:NCT01060787","description":"Inflammation; Uveitis","metadata":null},{"id":"eeb292e6f5cd4bbc891708849f38d51b","type":"TRIAL","name":"Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids","canonical_id":"clinicaltrials.gov:NCT04426734","description":"Non-infectious Anterior Uveitis","metadata":null},{"id":"ea95172e6df244499f4385ea6f78e90b","type":"TRIAL","name":"Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT03161756","description":"Melanoma Stage Iv; Melanoma Stage Iii; Melanoma","metadata":null},{"id":"c2e1dc21e7c4431a8a1dbaec8a631df5","type":"TRIAL","name":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","canonical_id":"clinicaltrials.gov:NCT00200902","description":"Depression","metadata":null},{"id":"9d2f660a30b245a1afbe0bd3f9aad7b8","type":"TRIAL","name":"Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria","canonical_id":"clinicaltrials.gov:NCT00724698","description":"Rhinitis; Urticaria","metadata":null},{"id":"04c0aabfce9441b3879c572ae17b46b5","type":"TRIAL","name":"Evaluation of Different Doses of Letrozole in Ectopic Pregnancy","canonical_id":"clinicaltrials.gov:NCT05198141","description":"Ectopic Pregnancy","metadata":null},{"id":"673f5cd0298a4a109ccc38c527d0865f","type":"TRIAL","name":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","canonical_id":"clinicaltrials.gov:NCT02528214","description":"Asthma","metadata":null},{"id":"e27d1b8b35e749f293de717b207f98a5","type":"TRIAL","name":"Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis","canonical_id":"clinicaltrials.gov:NCT01776684","description":"EGFR Mutation Positive Non-small Cell Lung Cancer","metadata":null},{"id":"f0762fe4db1c4c60a446172cdcba8e97","type":"TRIAL","name":"Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE)","canonical_id":"clinicaltrials.gov:NCT03549923","description":"Cardiogenic Shock","metadata":null},{"id":"075737328cdc424fa0995888f95a2f09","type":"TRIAL","name":"Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo","canonical_id":"clinicaltrials.gov:NCT04822584","description":"Vitiligo","metadata":null},{"id":"f032b039235943979cf545e6f0bab28c","type":"TRIAL","name":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT02984982","description":"Hypercholesterolemia; Acute Coronary Syndrome","metadata":null},{"id":"d54f2c34dd5b493a903bf4fe65f8a8e8","type":"TRIAL","name":"Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine","canonical_id":"clinicaltrials.gov:NCT00509470","description":"Essential Hypertension","metadata":null},{"id":"11259e9daec44544983737e54243ee2c","type":"TRIAL","name":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics","canonical_id":"clinicaltrials.gov:NCT00983385","description":"Chronic Pain; Low Back Pain","metadata":null},{"id":"d468e8d49d5c4d179e5f3ca29326ff6e","type":"TRIAL","name":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability","canonical_id":"clinicaltrials.gov:NCT00986258","description":"Pain; Chronic Pain; Low Back Pain; Neuropathic Pain; Nociceptive Pain","metadata":null},{"id":"a6399985650943a399ac5aec85485703","type":"TRIAL","name":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic","canonical_id":"clinicaltrials.gov:NCT00983073","description":"Chronic Pain; Osteoarthritis","metadata":null},{"id":"04395e1532e6468eb39d560efa4f2cfb","type":"TRIAL","name":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.","canonical_id":"clinicaltrials.gov:NCT00982280","description":"Chronic Pain; Osteoarthritis","metadata":null},{"id":"96779a099ffd478bb72032bbfbc3bf4a","type":"TRIAL","name":"Evaluation of Effects of Exercise Training and ARB in DM Patients","canonical_id":"clinicaltrials.gov:NCT01053026","description":"Vascular Function; Exercise Training","metadata":null},{"id":"d4088d9a9186420395d322b3aa37c486","type":"TRIAL","name":"Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT00657527","description":"Myocardial Ischaemia; Coronary Artery Disease","metadata":null},{"id":"4e8c402545314f86872f1a9ac0dfd1eb","type":"TRIAL","name":"Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01149330","description":"Acne Vulgaris","metadata":null},{"id":"522794374b7c4f82a1543632eede2931","type":"TRIAL","name":"Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT02183168","description":"Spondylitis, Ankylosing","metadata":null},{"id":"2d6e6fe4bb7e4982b336428d0b24da25","type":"TRIAL","name":"Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT01482884","description":"Ulcerative Colitis","metadata":null},{"id":"f57a99e6c246423ab58cf41c81eb3c55","type":"TRIAL","name":"Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00432757","description":"Allergic Conjunctivitis","metadata":null},{"id":"01334eb209b34995aa0550be550a0701","type":"TRIAL","name":"Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00445874","description":"Allergic Conjunctivitis","metadata":null},{"id":"4fb92fbf72d948ee9a34cb1199687b41","type":"TRIAL","name":"Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel\u00ae (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice","canonical_id":"clinicaltrials.gov:NCT00564187","description":"Hypertension","metadata":null},{"id":"5eee0f48975940a9a9f98b6360d77988","type":"TRIAL","name":"Evaluation of Efficacy of Dellegra in Exposure Unit","canonical_id":"clinicaltrials.gov:NCT02175485","description":"Rhinitis Allergic","metadata":null},{"id":"99e088c30d314b319fa13ef41fcf2f3c","type":"TRIAL","name":"Evaluation of Efficacy of Topical Flutamide in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT05478330","description":"Acne Vulgaris Superficial Mixed Comedonal and Inflammatory","metadata":null},{"id":"534cef22957d4bd4937ba8fe06aaca99","type":"TRIAL","name":"Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination","canonical_id":"clinicaltrials.gov:NCT03194126","description":"Medical; Abortion, Fetus","metadata":null},{"id":"06f01be4c59a435288ec9fc864868c43","type":"TRIAL","name":"Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events","canonical_id":"clinicaltrials.gov:NCT00346242","description":"Thalassemia","metadata":null},{"id":"c7609abff968457dbbe86f202ef2558d","type":"TRIAL","name":"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00050960","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"72427baf842840e289024c44586199af","type":"TRIAL","name":"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00050973","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"49de79ee121f4067bd80f63c179062da","type":"TRIAL","name":"Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01876784","description":"Differentiated Thyroid Cancer","metadata":null},{"id":"905986c021ec40119aebacd6ee75f48d","type":"TRIAL","name":"Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study","canonical_id":"clinicaltrials.gov:NCT02614196","description":"Migraine","metadata":null},{"id":"90a852c0f797433ca4e30d4ff81dcc4f","type":"TRIAL","name":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","canonical_id":"clinicaltrials.gov:NCT05879367","description":"Glioblastoma, IDH-wildtype; Glioblastoma; Glioblastoma Multiforme; Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype; GBM; Astrocytoma; Astrocytoma, IDH-Mutant","metadata":null},{"id":"73804e471077443e831fc5e99a4f47eb","type":"TRIAL","name":"Evaluation of Eflornithine on Facial and Forearm Skin","canonical_id":"clinicaltrials.gov:NCT00152048","description":"Hirsutism","metadata":null},{"id":"f18243cdb14b480c81ef87957aca00df","type":"TRIAL","name":"Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure","canonical_id":"clinicaltrials.gov:NCT01411735","description":"Heart Failure With Preserved Ejection Fraction; Heart Failure, Congestive","metadata":null},{"id":"4ff824453de84a569bc2fe46387f4276","type":"TRIAL","name":"Evaluation of Etomidate on Adrenal Function in Trauma Patients","canonical_id":"clinicaltrials.gov:NCT00462644","description":"Adrenal Insufficiency","metadata":null},{"id":"63156f9b12b3477e8ea587589ab4f71e","type":"TRIAL","name":"Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT02739984","description":"Hypercholesterolemia; Mixed Dyslipidemia; Type 2 Diabetes","metadata":null},{"id":"f870bc1c42c442d085391751e67fc5e7","type":"TRIAL","name":"Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid","canonical_id":"clinicaltrials.gov:NCT02360202","description":"Bullous Pemphigoid","metadata":null},{"id":"40944e1c8d784e5e8377aad6dea1dcbb","type":"TRIAL","name":"Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)","canonical_id":"clinicaltrials.gov:NCT05634707","description":"Primary Brain Tumor; Brain Tumor, Recurrent","metadata":null},{"id":"9a59e71236aa4b6187f093928047a1f0","type":"TRIAL","name":"Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm","canonical_id":"clinicaltrials.gov:NCT00911300","description":"Fibrillation, Atrial","metadata":null},{"id":"df2a103c28f145f5ab19bdab66403bb3","type":"TRIAL","name":"Evaluation of Food Effect on Pharmacokinetics of Vismodegib","canonical_id":"clinicaltrials.gov:NCT01174264","description":"Malignant Neoplasm","metadata":null},{"id":"f6ebd59b40264e49bdff6310d16a9a41","type":"TRIAL","name":"Evaluation of Galcanezumab in the Prevention of Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT02614261","description":"Chronic Migraine","metadata":null},{"id":"49731deeeaf045df8b03b70fb0b2a945","type":"TRIAL","name":"Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study","canonical_id":"clinicaltrials.gov:NCT02614183","description":"Migraine","metadata":null},{"id":"4206cd9267d04bae857c03202da9e31b","type":"TRIAL","name":"Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors","canonical_id":"clinicaltrials.gov:NCT05853458","description":"Polycythemia Vera","metadata":null},{"id":"1dc86e9e8fcf411ba302fb64b2e0164e","type":"TRIAL","name":"Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone","canonical_id":"clinicaltrials.gov:NCT00391846","description":"Heart Failure; Ventricular Dysfunction, Left","metadata":null},{"id":"919a13db700441378a2896e9dba8a655","type":"TRIAL","name":"Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia","canonical_id":"clinicaltrials.gov:NCT00056433","description":"Sickle Cell Anemia","metadata":null},{"id":"6afd89a872594b73bdb65d51c71203e3","type":"TRIAL","name":"Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06206278","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"4a9917b769f94b628e0e1cf3b0a91da3","type":"TRIAL","name":"Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment","canonical_id":"clinicaltrials.gov:NCT03452566","description":"Actinic Cheilitis","metadata":null},{"id":"15d43480e43c4dcdb5fccc5409dc3d0f","type":"TRIAL","name":"Evaluation of Inhaled Treatment in Sinusitis","canonical_id":"clinicaltrials.gov:NCT01907204","description":"Sinusitis","metadata":null},{"id":"723371282c50448d8bb3e3aaadb9b3c4","type":"TRIAL","name":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","canonical_id":"clinicaltrials.gov:NCT03798054","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"41cb9e587f22408f9775ae6ef9820211","type":"TRIAL","name":"Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)","canonical_id":"clinicaltrials.gov:NCT01565382","description":"Alzheimer's Disease","metadata":null},{"id":"1a7e39d35b8e45e8abec3a63372ceee2","type":"TRIAL","name":"Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty","canonical_id":"clinicaltrials.gov:NCT02427412","description":"Blood Loss; Postoperative Blood Loss; Thromboembolic Complications","metadata":null},{"id":"72c6dee88e154f3a867edc11907e5838","type":"TRIAL","name":"Evaluation of Intraocular Pressure Using Simbrinza\u2122 in Patients With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01978600","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"c29d4b65a03b4b76b74b9021a5a4a773","type":"TRIAL","name":"Evaluation of Intrathecal Hyperbaric Bupivacaine With Dexmedetomidine in Adults Undergoing Perianal Surgery","canonical_id":"clinicaltrials.gov:NCT07651488","description":"Duration of Analgesia; Pain Score","metadata":null},{"id":"5566e6dd414f4addac18056c4b696715","type":"TRIAL","name":"Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C","canonical_id":"clinicaltrials.gov:NCT00265642","description":"Hepatitis C, Chronic","metadata":null},{"id":"8bdf5f7dc19b4186928cd211143f5a83","type":"TRIAL","name":"Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.","canonical_id":"clinicaltrials.gov:NCT00714714","description":"Acne Vulgaris","metadata":null},{"id":"7964c23f6486419db167c57c4a13cef1","type":"TRIAL","name":"Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face","canonical_id":"clinicaltrials.gov:NCT00952523","description":"Acne Vulgaris","metadata":null},{"id":"0c038b7dc5164234b4f2572544d7a20d","type":"TRIAL","name":"Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01777191","description":"Plaque Psoriasis","metadata":null},{"id":"b9c17ddec3454c579b3586984d42dc1a","type":"TRIAL","name":"Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC","canonical_id":"clinicaltrials.gov:NCT06868732","description":"Advanced Non-small Cell Lung Cancer","metadata":null},{"id":"5ef777301b834bbf8db89c3fde23a8a9","type":"TRIAL","name":"Evaluation of Laser and Tranexamic Acid in Treatment of Melasma","canonical_id":"clinicaltrials.gov:NCT04599205","description":"Melasma","metadata":null},{"id":"428fd80188ee438bbbd7465ca6601f6f","type":"TRIAL","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","canonical_id":"clinicaltrials.gov:NCT05696626","description":"Metastatic Breast Cancer","metadata":null},{"id":"304cfa8f5f514c5eaf1ce213d8608f65","type":"TRIAL","name":"Evaluation of Local Doxycycline in Smokers With Chronic Periodontitis","canonical_id":"clinicaltrials.gov:NCT02726646","description":"Chronic Periodontitis","metadata":null},{"id":"d659bcb92d964aa2a82457bf36fa71dc","type":"TRIAL","name":"Evaluation of Long-Acting Muscarinic Antagonists in COPD","canonical_id":"clinicaltrials.gov:NCT02039050","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"8bfac45c90c8437ba08608c5e277abfd","type":"TRIAL","name":"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT01728077","description":"Epilepsy","metadata":null},{"id":"ff402246b4d14a5e9ef1ae133c827d4c","type":"TRIAL","name":"Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT02305979","description":"Leukemia; Lymphoma","metadata":null},{"id":"d82bb1db4ab3429686e8d723bbb98647","type":"TRIAL","name":"Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain","canonical_id":"clinicaltrials.gov:NCT01311336","description":"Pegfilgrastim-induced Back and Leg Pain","metadata":null},{"id":"7a385d2673c944acaf85164b117e5348","type":"TRIAL","name":"Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT00406107","description":"Branch Retinal Vein Occlusion","metadata":null},{"id":"9ec91bfdb83b480882233ce7f4872572","type":"TRIAL","name":"Evaluation of Melatonin's Effect on Pain and Blood Loss After Cesarean Section","canonical_id":"clinicaltrials.gov:NCT01572805","description":"Post Partum Haemorrhage in Patients Undergoing Cesarean Section","metadata":null},{"id":"01e5a95e1a094d9b9109f9883beccce0","type":"TRIAL","name":"Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors","canonical_id":"clinicaltrials.gov:NCT02975037","description":"Healthy","metadata":null},{"id":"48d0673674104bd9ae344e1ee6575af6","type":"TRIAL","name":"Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms","canonical_id":"clinicaltrials.gov:NCT07307261","description":"Ureteric Stent-related Morbidity","metadata":null},{"id":"29f2c66f2e344561811babf5515d63ab","type":"TRIAL","name":"Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers","canonical_id":"clinicaltrials.gov:NCT01926626","description":"Nicotine Dependence","metadata":null},{"id":"0a7c0e39766c44138eb6fdf3ea44f9a8","type":"TRIAL","name":"Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy","canonical_id":"clinicaltrials.gov:NCT00402376","description":"Heart Failure","metadata":null},{"id":"f063f0a4257a40738f0452a9b4f0125f","type":"TRIAL","name":"Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not","canonical_id":"clinicaltrials.gov:NCT04927949","description":"ST-elevation Myocardial Infarction","metadata":null},{"id":"dd0897a8249848b5b48d5f409062710f","type":"TRIAL","name":"Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study","canonical_id":"clinicaltrials.gov:NCT02934919","description":"Impulse Control Disorders; Parkinson Disease","metadata":null},{"id":"f7dcdf76ff0847698e8cdd7006b81cb3","type":"TRIAL","name":"Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer","canonical_id":"clinicaltrials.gov:NCT01185418","description":"Normal Volunteers","metadata":null},{"id":"777194f87c474623a3412e10cd7ffa10","type":"TRIAL","name":"Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04856475","description":"Breast Cancer; Brain Metastases","metadata":null},{"id":"d3b51ba491ab4d95b37e6d2819b7333e","type":"TRIAL","name":"Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06323655","description":"Healthy Volunteers","metadata":null},{"id":"9ed50bcbed634e94a56c19d805e745ab","type":"TRIAL","name":"Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab","canonical_id":"clinicaltrials.gov:NCT05037396","description":"Age-related Macular Degeneration (AMD)","metadata":null},{"id":"a4cd92aa81ce4de7ab17f054fc2a1246","type":"TRIAL","name":"Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients","canonical_id":"clinicaltrials.gov:NCT01560299","description":"Graves Disease","metadata":null},{"id":"a9ae3901df814cdca07311f3b57d8817","type":"TRIAL","name":"Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults","canonical_id":"clinicaltrials.gov:NCT01755676","description":"Obesity","metadata":null},{"id":"1aefc0d265684bcbadae4985ad211b1b","type":"TRIAL","name":"Evaluation of PET Scan Timing Relative to AV-45 Injection Time","canonical_id":"clinicaltrials.gov:NCT01565356","description":"Alzheimer's Disease","metadata":null},{"id":"872907e5dfe7429cafa57b0bdd9488f6","type":"TRIAL","name":"Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT05644561","description":"Generalized Myasthenia Gravis; gMG","metadata":null},{"id":"8429910c34a949ae91fe8b393315b11d","type":"TRIAL","name":"Evaluation of Periodontal Status and hsCRP Levels in Females With PCOS on CPA/EE Combination Drug Regimen","canonical_id":"clinicaltrials.gov:NCT05021861","description":"Periodontitis; Polycystic Ovary Syndrome; Gingivitis","metadata":null},{"id":"d6e44b45174b4172aa3bec2d355be898","type":"TRIAL","name":"Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop Hypertension","canonical_id":"clinicaltrials.gov:NCT02441842","description":"Perioperative Hypertension","metadata":null},{"id":"8e30ff3cfac242c49b6830f5cb262c65","type":"TRIAL","name":"Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)","canonical_id":"clinicaltrials.gov:NCT04700007","description":"Itch","metadata":null},{"id":"e25278d0bb67437094cffe47c3f688df","type":"TRIAL","name":"Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa","canonical_id":"clinicaltrials.gov:NCT04669678","description":"HIV Infections; Contraception; Drug-drug Interaction","metadata":null},{"id":"5290d83550a5419a825362d0fe3d54b6","type":"TRIAL","name":"Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT04425902","description":"HIV Infections","metadata":null},{"id":"45766043545a418fa39e67013d718485","type":"TRIAL","name":"Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)","canonical_id":"clinicaltrials.gov:NCT01223339","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"a034da21917c4c4fb0d42adff75c0dce","type":"TRIAL","name":"Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03733717","description":"Multiple Myeloma","metadata":null},{"id":"5e1d2bb076714e68856fd222a49359d2","type":"TRIAL","name":"Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00199225","description":"Human Experimentation (Human Volunteers)","metadata":null},{"id":"be19b7c577124a9c9536c806c8031b4e","type":"TRIAL","name":"Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives","canonical_id":"clinicaltrials.gov:NCT00508365","description":"Hypertension","metadata":null},{"id":"3c7b5ebe43fe49e28f0d336ff7ab593a","type":"TRIAL","name":"Evaluation of Pupil Dilation Speed With the MAP Dispenser","canonical_id":"clinicaltrials.gov:NCT04907474","description":"Mydriasis","metadata":null},{"id":"4a7561088eaf4003954f4c0db2f82373","type":"TRIAL","name":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT07175441","description":"Advanced Unresectable Hepatocellular Carcinoma","metadata":null},{"id":"ee25de451f9344d499e83a46d4831b46","type":"TRIAL","name":"Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy","canonical_id":"clinicaltrials.gov:NCT01420523","description":"Human Immunodeficiency Virus; Lipohypertrophy","metadata":null},{"id":"dbae4124a5494351907a0f1df2b66b09","type":"TRIAL","name":"Evaluation of Reader Training Processes","canonical_id":"clinicaltrials.gov:NCT02051790","description":"Alzheimer's Disease","metadata":null},{"id":"3cefb4945963473291cc65b5da7f6e16","type":"TRIAL","name":"Evaluation of Renal Drug Transport in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00690014","description":"Kidney Disease","metadata":null},{"id":"7a5373a7a63b466a9c47353d834c6b21","type":"TRIAL","name":"Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density","canonical_id":"clinicaltrials.gov:NCT04597931","description":"Osteoporosis Fracture; Spinal Cord Injuries","metadata":null},{"id":"6a0e5aa851a04ae489dd3d0d1f6823e2","type":"TRIAL","name":"Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging","canonical_id":"clinicaltrials.gov:NCT01174056","description":"Lung Inflammation","metadata":null},{"id":"9e83694bc48a4d77bdd91325eaf5c430","type":"TRIAL","name":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","canonical_id":"clinicaltrials.gov:NCT02777710","description":"Colorectal Cancer; Pancreatic Cancer; Metastatic Cancer; Advanced Cancer","metadata":null},{"id":"9add908bd2e749878d0fbd716c60d3f3","type":"TRIAL","name":"Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections","canonical_id":"clinicaltrials.gov:NCT03445195","description":"Complicated Urinary Tract Infection; Acute Pyelonephritis","metadata":null},{"id":"d6bd6049eacc40d0a8530d43a2f936ce","type":"TRIAL","name":"Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC","canonical_id":"clinicaltrials.gov:NCT00327340","description":"Prostate Cancer","metadata":null},{"id":"39dba6ba2414406890d3865fd2fadbb5","type":"TRIAL","name":"Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02074137","description":"Prostate Cancer Metastatic","metadata":null},{"id":"1192d3b0fb6d4e8a9490a9fdcdf6078d","type":"TRIAL","name":"Evaluation of Safety of ZyComb\u00ae In Patients With Common Cold - ZIP 3000 (XY-005-IM)","canonical_id":"clinicaltrials.gov:NCT00480194","description":"Common Cold","metadata":null},{"id":"0ecd9222eb73487aa9e403faa3dbdc49","type":"TRIAL","name":"Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants","canonical_id":"clinicaltrials.gov:NCT01700179","description":"Chronic Hepatitis C Infection","metadata":null},{"id":"ccc8f633cef0413b8e3cedffa39fc5f9","type":"TRIAL","name":"Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","canonical_id":"clinicaltrials.gov:NCT01061736","description":"Rheumatoid Arthritis","metadata":null},{"id":"a71b1a6547f543f5a73b69cc2a44d2db","type":"TRIAL","name":"Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)","canonical_id":"clinicaltrials.gov:NCT00727259","description":"Hepatitis C, Chronic","metadata":null},{"id":"25e25119e5014b8692b6e4dea5999300","type":"TRIAL","name":"Evaluation of Solanidine as an Exogenous Biomarker to Phenotype CYP2D6 Activity in Humans","canonical_id":"clinicaltrials.gov:NCT07817030","description":"Pharmacokinetic Study in Healthy Volunteers","metadata":null},{"id":"bdb20567e5f44f45b8d8c8aa33b23983","type":"TRIAL","name":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNF\u03b1 Inadequate Response","canonical_id":"clinicaltrials.gov:NCT06641089","description":"Arthritis, Psoriatic","metadata":null},{"id":"af6bbdbcbb164283909c237454bcf9b5","type":"TRIAL","name":"Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)","canonical_id":"clinicaltrials.gov:NCT06584942","description":"Cue-reactivity; Cannabis Use Disorder; Functional MRI; Orexin Antagonist","metadata":null},{"id":"932b849965ac484eb76ff6b4e5a2c633","type":"TRIAL","name":"Evaluation of Symptom-specific Goal Achievement","canonical_id":"clinicaltrials.gov:NCT00836823","description":"Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms","metadata":null},{"id":"74b6e14393684429aae2d5f9ebf38769","type":"TRIAL","name":"Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02614586","description":"Schizophrenia","metadata":null},{"id":"53a6c53a3dc74d5e93b074e9fd330169","type":"TRIAL","name":"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial","canonical_id":"clinicaltrials.gov:NCT03990896","description":"Breast Cancer","metadata":null},{"id":"712716b272f64afaa1e6703c7bdb40b0","type":"TRIAL","name":"Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02062489","description":"Breast Cancer","metadata":null},{"id":"4666f8c231ec41289a6065fb0327778d","type":"TRIAL","name":"Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy","canonical_id":"clinicaltrials.gov:NCT05243706","description":"Vinca Alkaloid Adverse Reaction","metadata":null},{"id":"cbb1584a649e4e2bb50eea893fedee25","type":"TRIAL","name":"Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis","canonical_id":"clinicaltrials.gov:NCT03520439","description":"Adenomyosis","metadata":null},{"id":"c7491c97e2674418aec9b1aa370f7b72","type":"TRIAL","name":"Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients","canonical_id":"clinicaltrials.gov:NCT06572553","description":"Age-Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion","metadata":null},{"id":"bf972ae73ad44980b82181dbc888eaeb","type":"TRIAL","name":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat\u00ae Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma","canonical_id":"clinicaltrials.gov:NCT01634113","description":"Asthma","metadata":null},{"id":"ebea5a9108714de2832e80f8ab4b8fca","type":"TRIAL","name":"Evaluation of Tiotropium 5 \u00b5g/Day Delivered Via the Respimat\u00ae Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)","canonical_id":"clinicaltrials.gov:NCT00772538","description":"Asthma","metadata":null},{"id":"8c7f11a0fde140a7bf66af61c373a056","type":"TRIAL","name":"Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT06387771","description":"Schizophrenia","metadata":null},{"id":"6532dc223fab4f0eb42eee0aede16d74","type":"TRIAL","name":"Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary","canonical_id":"clinicaltrials.gov:NCT00367263","description":"Asthma","metadata":null},{"id":"f1b5f72089dc4682858965bfc3e2a418","type":"TRIAL","name":"Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease","canonical_id":"clinicaltrials.gov:NCT01427244","description":"Paget's Disease of the Vulva","metadata":null},{"id":"6c70fdbaa9e1481c827fd25282768a4a","type":"TRIAL","name":"Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03225937","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"43390688e94646c9a18c748a50b6ae2d","type":"TRIAL","name":"Evaluation of Trazodone in OSA-MCI","canonical_id":"clinicaltrials.gov:NCT05209035","description":"Mild Cognitive Impairment; Obstructive Sleep Apnea","metadata":null},{"id":"24236b09ac7544009418e15c1845bfee","type":"TRIAL","name":"Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT01016834","description":"Migraine","metadata":null},{"id":"a544b41ed2cf4ab69d7280bd210bfb08","type":"TRIAL","name":"Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome","canonical_id":"clinicaltrials.gov:NCT06186648","description":"Richter Syndrome","metadata":null},{"id":"eab897b34b6946c7bd081f204041d7f6","type":"TRIAL","name":"Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin","canonical_id":"clinicaltrials.gov:NCT07084116","description":"Skin Tear; Solar Purpura; Dermatoporosis","metadata":null},{"id":"ed6c2281890e475e84dfdac4d5a4d9dd","type":"TRIAL","name":"Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases","canonical_id":"clinicaltrials.gov:NCT00623766","description":"Melanoma","metadata":null},{"id":"c7ac48545d9044f18148f7db9ac04fa3","type":"TRIAL","name":"Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions","canonical_id":"clinicaltrials.gov:NCT00294320","description":"Actinic Keratosis","metadata":null},{"id":"8ee66f5cdeb8462a9e1756772e64e65e","type":"TRIAL","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","canonical_id":"clinicaltrials.gov:NCT06824168","description":"Acute Myeloid Leukemia; Leukemia","metadata":null},{"id":"066b71e5181640c3a366dc6db1db7095","type":"TRIAL","name":"Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients","canonical_id":"clinicaltrials.gov:NCT01670552","description":"Acute and Chronic Inflammation; Dyspepsia","metadata":null},{"id":"696788e2eeac4e9ba741ef222127239f","type":"TRIAL","name":"Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)","canonical_id":"clinicaltrials.gov:NCT03180684","description":"Vulvar High Grade Squamous Intraepithelial Lesion (HSIL); Vulvar Dysplasia; Vulvar Intraepithelial Neoplasia (VIN); VIN2; VIN3; Pre-cancerous Lesions of the Vulva; Human Papillomavirus (HPV)","metadata":null},{"id":"4a41baf35c3245e09bc4de174ecc3f6a","type":"TRIAL","name":"Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT06689527","description":"Drug Interaction","metadata":null},{"id":"f29da723aac94e6dad69b26117d6b59d","type":"TRIAL","name":"Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06649409","description":"Pharmacodynamic","metadata":null},{"id":"d0806e7e54844a12a6238fab8e7af477","type":"TRIAL","name":"Evaluation of Volatile Organic Compounds in Mepolizumab Therapy","canonical_id":"clinicaltrials.gov:NCT04924478","description":"Asthma; Eosinophilic","metadata":null},{"id":"65d2e6ded70748708ac65356e5962e37","type":"TRIAL","name":"Evaluation of Votrient in Angiosarcoma","canonical_id":"clinicaltrials.gov:NCT02212015","description":"Angiosarcoma","metadata":null},{"id":"e8691d5e6a5b4b5e86ff23f3477a61a1","type":"TRIAL","name":"Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab","canonical_id":"clinicaltrials.gov:NCT03093155","description":"Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer","metadata":null},{"id":"4b56ee4227274f9a92941dfd29cdbe36","type":"TRIAL","name":"Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors","canonical_id":"clinicaltrials.gov:NCT01778686","description":"Healthy","metadata":null},{"id":"d327aff2d98049559782f57473f2700e","type":"TRIAL","name":"Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain","canonical_id":"clinicaltrials.gov:NCT03080051","description":"Progressive Supranuclear Palsy; Alzheimer Disease; Healthy Volunteers","metadata":null},{"id":"7c72ee98cb7242968bcd0abe01f7bf2c","type":"TRIAL","name":"Evaluation of a Cincalcet Suppression Test","canonical_id":"clinicaltrials.gov:NCT01103206","description":"Parathyroid Hormone Suppression Test With Cinacalcet","metadata":null},{"id":"aea8f073ee5f41d1af363ea0d156f1ef","type":"TRIAL","name":"Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1","canonical_id":"clinicaltrials.gov:NCT00000245","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"b2a5c183ab094cb28ced20e2792830e4","type":"TRIAL","name":"Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy","canonical_id":"clinicaltrials.gov:NCT04753749","description":"Myocardial Infarction, Acute; Coronary Artery Disease","metadata":null},{"id":"e1998fec8cd14ff985755801fdd1674d","type":"TRIAL","name":"Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01287364","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"4ac9cd4adddd47f09706b2937b67457d","type":"TRIAL","name":"Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors","canonical_id":"clinicaltrials.gov:NCT03571438","description":"Kidney Cancer","metadata":null},{"id":"dce0dfc46cbe4a0a99f1739eb176b58d","type":"TRIAL","name":"Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia","canonical_id":"clinicaltrials.gov:NCT03289728","description":"Myocardial Infarction","metadata":null},{"id":"a8e8d9e836394920b2ed91202e5779b8","type":"TRIAL","name":"Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect","canonical_id":"clinicaltrials.gov:NCT00121563","description":"Pain","metadata":null},{"id":"3e0b6738a65a4e0d9ff09a70160ab3ed","type":"TRIAL","name":"Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00872586","description":"Essential Hypertension","metadata":null},{"id":"8bb777fd4e7e47fd9153994df37b5238","type":"TRIAL","name":"Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models","canonical_id":"clinicaltrials.gov:NCT01615510","description":"Pain; Hyperalgesia; Allodynia","metadata":null},{"id":"33ac21fda05f4ba0b7d89d2ec73d9e48","type":"TRIAL","name":"Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran","canonical_id":"clinicaltrials.gov:NCT00757679","description":"Fibromyalgia Syndrome","metadata":null},{"id":"bc21c9f7793746fead75a6c2ab00f7c2","type":"TRIAL","name":"Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease","canonical_id":"clinicaltrials.gov:NCT00507832","description":"Prurigo Nodularis","metadata":null},{"id":"ecbba4701ce54cdd84d6cdfdea44a5ab","type":"TRIAL","name":"Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis","canonical_id":"clinicaltrials.gov:NCT00628290","description":"Schizophrenia","metadata":null},{"id":"34831ce35dae4fa7a63b08910fb08d9b","type":"TRIAL","name":"Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo","canonical_id":"clinicaltrials.gov:NCT03097861","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"cfd27c2414e84c619c06884929e28fc1","type":"TRIAL","name":"Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01572649","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"3cdb7376f40547b6a6ed080924caa3b7","type":"TRIAL","name":"Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.","canonical_id":"clinicaltrials.gov:NCT05288400","description":"Essential Hypertension","metadata":null},{"id":"22961f99eb2341e0bf22bed9f372dbab","type":"TRIAL","name":"Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT04085354","description":"Premature Ejaculation","metadata":null},{"id":"ca76ededdd554d17bcf6ac81ccdf41e3","type":"TRIAL","name":"Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients","canonical_id":"clinicaltrials.gov:NCT03141203","description":"Peripheral T Cell Lymphoma","metadata":null},{"id":"c4dba5a838e84c4489e674a5c21e09a3","type":"TRIAL","name":"Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis","canonical_id":"clinicaltrials.gov:NCT07411963","description":"Myasthenia Gravis","metadata":null},{"id":"876b89beb9cd4c60abc42ae8d1e7135b","type":"TRIAL","name":"Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)","canonical_id":"clinicaltrials.gov:NCT07714616","description":"Contraception","metadata":null},{"id":"d7403b55f7a94f149880add38c262596","type":"TRIAL","name":"Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis","canonical_id":"clinicaltrials.gov:NCT01737879","description":"Anemia","metadata":null},{"id":"f79a428506d245a281a727b587d2ee03","type":"TRIAL","name":"Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK","canonical_id":"clinicaltrials.gov:NCT00995995","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"75c459d1a4a047e482767376cb05e9a7","type":"TRIAL","name":"Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity","canonical_id":"clinicaltrials.gov:NCT02760901","description":"Cisplatin Nephrotoxicity","metadata":null},{"id":"8d7f174482ab4ef393b16df01a4508e5","type":"TRIAL","name":"Evaluation of the Effect of Appropriate Sedation for Patients After Gastrectomy: A Prospective Randomised Controlled Study","canonical_id":"clinicaltrials.gov:NCT02674737","description":"Postoperative Sedation,Gastrectomy, Enhanced Recovery After Surgery","metadata":null},{"id":"77b1283a49cd4efabf87b67ab38e3e61","type":"TRIAL","name":"Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant","canonical_id":"clinicaltrials.gov:NCT00565474","description":"Graft Vasculopathy","metadata":null},{"id":"515d77f6751048ad8d9d23fa010fbfee","type":"TRIAL","name":"Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection","canonical_id":"clinicaltrials.gov:NCT02710266","description":"Liver Disease","metadata":null},{"id":"bb0f3b740c9940648f47e95572e2b234","type":"TRIAL","name":"Evaluation of the Effect of Sevoflurane and Propofol Hypotensive Anesthesia on Blood Antioxidant Levels and HIF 1 Levels","canonical_id":"clinicaltrials.gov:NCT04246567","description":"Hypoxemia During Surgery; Hypoxia","metadata":null},{"id":"31c50d67e8e94c81b9a006d8c7e8ddbd","type":"TRIAL","name":"Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood","canonical_id":"clinicaltrials.gov:NCT04895423","description":"Atopic Dermatitis","metadata":null},{"id":"2d1865e6a6f74183b3374e57f0f18630","type":"TRIAL","name":"Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D","canonical_id":"clinicaltrials.gov:NCT00977080","description":"Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis","metadata":null},{"id":"911343fdd91a4071af481727e25ecbc5","type":"TRIAL","name":"Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT05344482","description":"Plaque Psoriasis","metadata":null},{"id":"1f75bd6ed92d4a2d968ef3e170599fb7","type":"TRIAL","name":"Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT04884503","description":"Burning Mouth Syndrome; Glossodynia","metadata":null},{"id":"22b03f288e0a4051a67e0c83d5f5e872","type":"TRIAL","name":"Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).","canonical_id":"clinicaltrials.gov:NCT05010876","description":"Covid19","metadata":null},{"id":"b03cabde54054c16a96145fa2a52f865","type":"TRIAL","name":"Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT02065791","description":"Diabetes Mellitus, Type 2; Diabetic Nephropathy","metadata":null},{"id":"0540edaac3ba45cdada9f81d7df952dd","type":"TRIAL","name":"Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01091220","description":"Sperm Quality","metadata":null},{"id":"a4508aed79ce46d7a07781067567b0a7","type":"TRIAL","name":"Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia","canonical_id":"clinicaltrials.gov:NCT00899587","description":"Diabetic Macular Ischemia","metadata":null},{"id":"0480dd2b79cd465c9457a9af32d90ae6","type":"TRIAL","name":"Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Occlusion Parameters","canonical_id":"clinicaltrials.gov:NCT05261971","description":"Occlusion; Quality of Life","metadata":null},{"id":"3385d4ff3fb74e43ae551d98920302f2","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab","canonical_id":"clinicaltrials.gov:NCT07836283","description":"Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis","metadata":null},{"id":"f9b41162beb04567bb4e148d8a241c48","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03899324","description":"Parkinson Disease","metadata":null},{"id":"3076216703b54e13bf0c8a5bdf28456a","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC","canonical_id":"clinicaltrials.gov:NCT07503379","description":"mHSPC","metadata":null},{"id":"283311c532494e9585881f36441b7491","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery","canonical_id":"clinicaltrials.gov:NCT00943098","description":"Dental Pain","metadata":null},{"id":"2c99f6a111de4452ae6480bbc80f022e","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis","canonical_id":"clinicaltrials.gov:NCT06174792","description":"Adenomyosis","metadata":null},{"id":"b38308605f594bcba4f5e93ef6721c0f","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes","canonical_id":"clinicaltrials.gov:NCT07117240","description":"Steroid-Induced Diabetes; Steroid-Induced Hyperglycemia; Diabetes","metadata":null},{"id":"fae774c526884ce793fcac105dc1f271","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness","canonical_id":"clinicaltrials.gov:NCT01557179","description":"The Primary Objective of This Study Was to Assess the Efficacy and Safety of Hyaluronic Acid Vaginal Gel in Treating Vaginal Dryness","metadata":null},{"id":"0fbbdb3f2d3c453da5ef8798ce24c72b","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)","canonical_id":"clinicaltrials.gov:NCT05204368","description":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","metadata":null},{"id":"7ec4f8ec056646b39da02e54b798395f","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT02544152","description":"Irritable Bowel Syndrome","metadata":null},{"id":"65e8942549c1417e9bf0ec5107f9634c","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT01184443","description":"Eating Disorder","metadata":null},{"id":"182d8ba2fea04692ac6930f6ee1897da","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07174011","description":"Alopecia; Alopecia Areata","metadata":null},{"id":"9e8e790ec2694b39ba6613255412e169","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents","canonical_id":"clinicaltrials.gov:NCT06816771","description":"Rhabdomyosarcoma, Recurrent, Refractory","metadata":null},{"id":"3a31e7908c024edfa901b7e5d28f0fde","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica","canonical_id":"clinicaltrials.gov:NCT03600818","description":"Polymyalgia Rheumatica","metadata":null},{"id":"1fae7faf629f469c8e5e5162cca12a57","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH","canonical_id":"clinicaltrials.gov:NCT00359905","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"e832f0d511b0402598c769f93ae74319","type":"TRIAL","name":"Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery","canonical_id":"clinicaltrials.gov:NCT03606785","description":"Colorectal Surgery","metadata":null},{"id":"fad8d08d9ff84dc58d6e6d7e7b4f434a","type":"TRIAL","name":"Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma","canonical_id":"clinicaltrials.gov:NCT04288700","description":"Infantile Hemangioma","metadata":null},{"id":"7b8fc61521d44a70904e1a7c32d77164","type":"TRIAL","name":"Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT05211154","description":"Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"b2a3299219de4876b4301f687fdbaeff","type":"TRIAL","name":"Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT07498309","description":"Vaso-Occlusive Crises; Sickle Cell Disease","metadata":null},{"id":"e5388d4cefc84bd3954149714f8224d7","type":"TRIAL","name":"Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.","canonical_id":"clinicaltrials.gov:NCT02323516","description":"Cancer","metadata":null},{"id":"3cf58905a1504a878a853ca7b79f5d3b","type":"TRIAL","name":"Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)","canonical_id":"clinicaltrials.gov:NCT06811831","description":"Coronary Microvascular Angina; Macitentan","metadata":null},{"id":"38968d3aa9ee4fd5adf0f61f0978e2b0","type":"TRIAL","name":"Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT01264237","description":"Postherpetic Neuralgia; Neuralgia","metadata":null},{"id":"a49cb368bdf64374966090f828fe3231","type":"TRIAL","name":"Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology","canonical_id":"clinicaltrials.gov:NCT02947880","description":"Autistic Disorder","metadata":null},{"id":"2f1b7a09532c44e7a3aa53762df34078","type":"TRIAL","name":"Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy","canonical_id":"clinicaltrials.gov:NCT01963195","description":"NSCLC","metadata":null},{"id":"ae40aa8990274effb32a81cff46a5bfb","type":"TRIAL","name":"Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia","canonical_id":"clinicaltrials.gov:NCT00630175","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"7f602b908f66410f8d5f68a46d3a9b5f","type":"TRIAL","name":"Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma","canonical_id":"clinicaltrials.gov:NCT00273910","description":"High-Risk Melanoma","metadata":null},{"id":"003e05fdc08b4d4c973fc1f1273b3f4f","type":"TRIAL","name":"Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria","canonical_id":"clinicaltrials.gov:NCT01940393","description":"Urticaria","metadata":null},{"id":"ef8e0bb7bc6e435f85e67d5bc1b067ed","type":"TRIAL","name":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","canonical_id":"clinicaltrials.gov:NCT02783430","description":"Depression","metadata":null},{"id":"f8fcd47318444e839681699343722b59","type":"TRIAL","name":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT02307396","description":"Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders","metadata":null},{"id":"f28f00aae90c4488addd5fcd95e68ca6","type":"TRIAL","name":"Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals","canonical_id":"clinicaltrials.gov:NCT03693872","description":"Parkinson Disease","metadata":null},{"id":"9a1dc584646646d1b9874624b033c58f","type":"TRIAL","name":"Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol","canonical_id":"clinicaltrials.gov:NCT01578057","description":"Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol","metadata":null},{"id":"bf076507f8724783925ebc56da60e5c7","type":"TRIAL","name":"Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant","canonical_id":"clinicaltrials.gov:NCT05959447","description":"Cough; Healthy","metadata":null},{"id":"e933090e887945a2bfb2e4296927409a","type":"TRIAL","name":"Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail","canonical_id":"clinicaltrials.gov:NCT02391688","description":"Drug Interaction","metadata":null},{"id":"28c22a52c0614304a5e74b6a9eb10858","type":"TRIAL","name":"Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks","canonical_id":"clinicaltrials.gov:NCT04410965","description":"Multiple Sclerosis","metadata":null},{"id":"f6dc67254a8d4ffb97c7972fabfe13ff","type":"TRIAL","name":"Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule","canonical_id":"clinicaltrials.gov:NCT05032690","description":"Healthy Participants","metadata":null},{"id":"6569df949cb24fae8c0d230c525a7029","type":"TRIAL","name":"Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane","canonical_id":"clinicaltrials.gov:NCT02104791","description":"Intra-amniotic Subclinical Infection.","metadata":null},{"id":"cbeda11ec49c44bcbdbceed34b92bebc","type":"TRIAL","name":"Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01504178","description":"Parkinson's Disease","metadata":null},{"id":"0893e61c628d4220a5abc0e6c9a7465d","type":"TRIAL","name":"Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00836485","description":"Allergic Conjunctivitis","metadata":null},{"id":"25b602df0c5a4fa88258f7e74d1e5a33","type":"TRIAL","name":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","canonical_id":"clinicaltrials.gov:NCT06875128","description":"Metastatic Breast Cancer in the Liver","metadata":null},{"id":"d6f776908eeb4cf183dc883ac44d61cf","type":"TRIAL","name":"Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00681772","description":"Erectile Dysfunction","metadata":null},{"id":"66034718784c405ab3a317b33fee6c69","type":"TRIAL","name":"Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).","canonical_id":"clinicaltrials.gov:NCT00665314","description":"Lymphoma; Non Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma","metadata":null},{"id":"e62d82bccbaf4b4b8db495dd4926dba7","type":"TRIAL","name":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)","canonical_id":"clinicaltrials.gov:NCT07218796","description":"Cataract; Glaucoma; Ocular Hypertension","metadata":null},{"id":"5267ac7c4923439f9e36f40632c69217","type":"TRIAL","name":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","canonical_id":"clinicaltrials.gov:NCT05815758","description":"Allergic Conjunctivitis","metadata":null},{"id":"6c7974b11ddc4f16ac8005aa10570d04","type":"TRIAL","name":"Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT05373901","description":"High-risk Neuroblastoma","metadata":null},{"id":"49ad4995ff8b4475b63bc0e09e52edeb","type":"TRIAL","name":"Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load","canonical_id":"clinicaltrials.gov:NCT05230368","description":"HIV-1-infection, Subtype b","metadata":null},{"id":"d9d71f78648c44bbb26037b3827bb5f7","type":"TRIAL","name":"Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged \u2265 6 Years to < 18 Years With Functional Constipation","canonical_id":"clinicaltrials.gov:NCT02766777","description":"Constipation - Functional","metadata":null},{"id":"f47938d3e2ea43e89d78aa2d7a036f89","type":"TRIAL","name":"Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02971423","description":"Acinetobacter Baumannii Infection","metadata":null},{"id":"0dbdf43627394799af6946e4fceb61ee","type":"TRIAL","name":"Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00772304","description":"Allergic Rhinitis","metadata":null},{"id":"1b01f271be43422ab572b71bdf325317","type":"TRIAL","name":"Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT02328209","description":"Exudative Age-related Macular Degeneration","metadata":null},{"id":"e2656e0ecc1745f4ad644e6f2951b87a","type":"TRIAL","name":"Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01048229","description":"Early-stage Parkinson's Disease","metadata":null},{"id":"c74d9d7f837f4b5f96acf8b4dda72473","type":"TRIAL","name":"Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)","canonical_id":"clinicaltrials.gov:NCT00913029","description":"Eye Diseases; Glaucoma, Open-Angle; Glaucoma","metadata":null},{"id":"251a26dad2b64db9b37e2a854c752b7b","type":"DRUG","name":"Everolimus","canonical_id":"ncit:C48387","description":null,"metadata":null},{"id":"18dc6b5bed50462aa7a41daf26a21edf","type":"TRIAL","name":"Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy","canonical_id":"clinicaltrials.gov:NCT01198158","description":"Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7","metadata":null},{"id":"2fe4e48724e5413e993df558105a75e0","type":"TRIAL","name":"Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers","canonical_id":"clinicaltrials.gov:NCT01624766","description":"Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm","metadata":null},{"id":"3e4a053a11f04215b6b3e222354b7654","type":"TRIAL","name":"Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01488487","description":"Advanced Adult Hepatocellular Carcinoma","metadata":null},{"id":"ffedfd1fc61b475aa94c592343d13da2","type":"TRIAL","name":"Evidence Based Management of Acute Biliary Pancreatitis","canonical_id":"clinicaltrials.gov:NCT04615702","description":"Acute Pancreatitis","metadata":null},{"id":"cc43780ef17a4aa490926c30e4d86248","type":"DRUG","name":"Evogliptin","canonical_id":"mesh:C502012","description":null,"metadata":null},{"id":"d01246d90ecd4d909c6f064dd38fa608","type":"TRIAL","name":"Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)","canonical_id":"clinicaltrials.gov:NCT02689362","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"014ab3ac6a4c4a009494d97b9779beda","type":"DRUG","name":"Evolocumab","canonical_id":"mesh:C577155","description":null,"metadata":null},{"id":"c2c39eed683348138606b66b630061c8","type":"TRIAL","name":"Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)","canonical_id":"clinicaltrials.gov:NCT05741086","description":"Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis","metadata":null},{"id":"1aeeb2f56ebb45ffbc9806bf9b9a7ded","type":"TRIAL","name":"Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT04659525","description":"Hypercholesterolemia; CKD Stage 5; Chronic Kidney Disease Requiring Chronic Dialysis","metadata":null},{"id":"951f293db7cd4499bf8635ba87b8eb39","type":"TRIAL","name":"Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients","canonical_id":"clinicaltrials.gov:NCT04397653","description":"Hypercholesterolemia; Chronic Kidney Disease Requiring Chronic Dialysis","metadata":null},{"id":"29871ec290f949e680a9213701e698d1","type":"TRIAL","name":"Evolocumab in Patients With Acute MI","canonical_id":"clinicaltrials.gov:NCT04082442","description":"Acute Coronary Syndrome","metadata":null},{"id":"50a2f8ee6d1b48728d8868c18ed44804","type":"TRIAL","name":"Evolution of Analgesic Tolerance With Opioids","canonical_id":"clinicaltrials.gov:NCT00275249","description":"Chronic Pain","metadata":null},{"id":"6eeb2a14b6ef47bebdc29c19718a5c93","type":"TRIAL","name":"Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.","canonical_id":"clinicaltrials.gov:NCT05708534","description":"Kidney Transplant Infection","metadata":null},{"id":"06320f9876574a568cccf973ff6066de","type":"DISEASE","name":"Ewing's sarcoma","canonical_id":"mesh:D012512","description":null,"metadata":null},{"id":"f5311c1e963e40949189e356f9048cbc","type":"TRIAL","name":"Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM","canonical_id":"clinicaltrials.gov:NCT05405244","description":"Overweight and Obesity; Eating Behavior","metadata":null},{"id":"617895b8c5974e26bef2e934ee1aa7d1","type":"TRIAL","name":"Examination of Efficacy and Safety of Baricitinib in RA Patients","canonical_id":"clinicaltrials.gov:NCT03755466","description":"Rheumatoid Arthritis","metadata":null},{"id":"4f625ee7cba142b58308398736497457","type":"TRIAL","name":"Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma","canonical_id":"clinicaltrials.gov:NCT01617746","description":"Asthma","metadata":null},{"id":"9aeff6bfc6044efc80868a982fa02c8a","type":"TRIAL","name":"Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers","canonical_id":"clinicaltrials.gov:NCT02491788","description":"Sleep Disorder, Shift-Work","metadata":null},{"id":"0ebc698aa80f460c9125ccbd2c570a17","type":"TRIAL","name":"Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus","canonical_id":"clinicaltrials.gov:NCT05306873","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"b9b388033fa24583b99daaadc85fc1ef","type":"TRIAL","name":"Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00925119","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"3de66110f41049bbb8c353af5d70032e","type":"TRIAL","name":"Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT05857748","description":"Dry Eye Disease","metadata":null},{"id":"db3fffad63bd46dcbcbf052a973a60cd","type":"TRIAL","name":"Examining the Effect of Burosumab on Muscle Function","canonical_id":"clinicaltrials.gov:NCT04146935","description":"X-linked Hypophosphatemia","metadata":null},{"id":"f9bab83667314a83b64c770b78b04cf0","type":"TRIAL","name":"Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study","canonical_id":"clinicaltrials.gov:NCT06705608","description":"Multiple Sclerosis; Skin Cancer; Skin Cancer Melanoma; Skin Cancers - Basal Cell Carcinoma; Skin Cancer, Squamous Cell; Multiple Sclerosis (MS) - Relapsing-remitting","metadata":null},{"id":"6d0fe7aef13545028ae63b7c54c266f1","type":"TRIAL","name":"Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT04287062","description":"Sleep Disturbance; Opioid-use Disorder","metadata":null},{"id":"a32c204da22742d4badcf2eba456407b","type":"DISEASE","name":"Exanthema","canonical_id":"mesh:D005076","description":null,"metadata":null},{"id":"2d89ad5b6ea643d6b670339e554278f5","type":"TRIAL","name":"Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)","canonical_id":"clinicaltrials.gov:NCT02660866","description":"Peripheral Arterial Disease","metadata":null},{"id":"48b33c4ed8f04e9b87fe38f45ff1136e","type":"TRIAL","name":"Excessive Crying in Children With Cerebral Palsy and Communication Deficits","canonical_id":"clinicaltrials.gov:NCT04523935","description":"Cerebral Palsy; Excessive Crying; Pain","metadata":null},{"id":"e72daf3ad2b74d27a51557d76db0d423","type":"TRIAL","name":"Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)","canonical_id":"clinicaltrials.gov:NCT01588717","description":"Hyperhydrosis; Depression","metadata":null},{"id":"77ddd9941207482ea430806ea5b7f816","type":"TRIAL","name":"Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin","canonical_id":"clinicaltrials.gov:NCT00449683","description":"Hyperhidrosis","metadata":null},{"id":"18ea53377ada45d0b9104281d051dff3","type":"DISEASE","name":"Excessive salivation","canonical_id":"mesh:D012798","description":null,"metadata":null},{"id":"b7acfa566746426bb6f3b0a1060052aa","type":"TRIAL","name":"Excimer Laser With Topical Agents in Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT05555797","description":"Psoriasis","metadata":null},{"id":"6c3503c3dc7a43b1a84aa3df4dff91a6","type":"TRIAL","name":"Exelon Patch and Combination With Memantine Comparative Trial","canonical_id":"clinicaltrials.gov:NCT01025466","description":"Alzheimer's Disease","metadata":null},{"id":"55f0c89bd4484fa9ad0710b4063049b5","type":"TRIAL","name":"Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00031889","description":"Prostate Cancer","metadata":null},{"id":"a47be805f8424ed8ae75dfc9d0362d41","type":"TRIAL","name":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","canonical_id":"clinicaltrials.gov:NCT02115282","description":"Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma","metadata":null},{"id":"e963f17c1ed14dcd8038191e55b9d37d","type":"TRIAL","name":"Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00810797","description":"Breast Cancer","metadata":null},{"id":"a68383bd5c2d471ab2d3bd81e4bb8fbd","type":"TRIAL","name":"Exendin PET/CT for Imaging of Paragangliomas","canonical_id":"clinicaltrials.gov:NCT05418907","description":"Paraganglioma","metadata":null},{"id":"ffe774fbdb7244db986bf2c171262316","type":"TRIAL","name":"Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.","canonical_id":"clinicaltrials.gov:NCT02768298","description":"Chronic Heart Failure With Reduced Ejection Fraction","metadata":null},{"id":"051d7b020e014fecb46c006670db56ae","type":"TRIAL","name":"Exercise Induced Bronchospasm in Children","canonical_id":"clinicaltrials.gov:NCT00273689","description":"Exercise Induced Bronchospasm","metadata":null},{"id":"7db99d87e5f2424ca47037125f299396","type":"TRIAL","name":"Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT06468371","description":"Hemodialysis; Restless Legs Syndrome; ESRD (End Stage Renal Disease); Diabetes Complications","metadata":null},{"id":"3b9412a94119456c9cc2546e0d015b79","type":"TRIAL","name":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","canonical_id":"clinicaltrials.gov:NCT06643221","description":"Leukemia; Hematopoetic Stem Cell Transplantation; Donor Lymphocyte Infusion; CAR T-Cell Therapy; Lymphoma; Cell Therapy","metadata":null},{"id":"c9a8c3bebf464aa6a55827d4b2a542e2","type":"TRIAL","name":"Exercise in Air Pollution and Lung Health in Asthmatics","canonical_id":"clinicaltrials.gov:NCT02252302","description":"Exercise-induced Bronchoconstriction; Air Pollution","metadata":null},{"id":"cd46705fce6047368ce6660cd4d14b60","type":"TRIAL","name":"Exercise or Relaxation for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT00921388","description":"Nicotine Dependence; Smoking Cessation","metadata":null},{"id":"4de6bf88f04f4d6aa897874751b85a68","type":"DISEASE","name":"Exocrine pancreatic insufficiency","canonical_id":"mesh:D010188","description":null,"metadata":null},{"id":"dd48a1d73e154848a5e14724abf887f7","type":"TRIAL","name":"Exogenous Melatonin in Postmenopausal Women with Insomnia","canonical_id":"clinicaltrials.gov:NCT05440734","description":"Insomnia","metadata":null},{"id":"9c53eae0be6c442db5a4ce2145f45836","type":"TRIAL","name":"Expanded Access Program for Maraviroc At Multiple Centers","canonical_id":"clinicaltrials.gov:NCT00426660","description":"HIV Infections","metadata":null},{"id":"291d79db11eb4b6eaca1841324fe1174","type":"TRIAL","name":"Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06931834","description":"Mitochondrial Disease; Chronic Kidney Disease","metadata":null},{"id":"ab7e9e2517c04448a6a0f355932b7d6d","type":"TRIAL","name":"Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL","canonical_id":"clinicaltrials.gov:NCT04300803","description":"DLBCL","metadata":null},{"id":"7b93e9ca0af346a9ba9df4edb6b26fec","type":"TRIAL","name":"Expanded Access Program of Ponatinib","canonical_id":"clinicaltrials.gov:NCT01592136","description":"Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","metadata":null},{"id":"220a0451fd0f43fabfce7c75e6a95101","type":"TRIAL","name":"Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy","canonical_id":"clinicaltrials.gov:NCT03433131","description":"Narcolepsy Without Cataplexy; Narcolepsy With Cataplexy","metadata":null},{"id":"db648a6c24994f958ec21f45e03fb0ee","type":"TRIAL","name":"Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy","canonical_id":"clinicaltrials.gov:NCT03863119","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"fab49d5065984f249d98b4195ab74187","type":"TRIAL","name":"Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03492489","description":"Cutaneous Squamous Cell Carcinoma","metadata":null},{"id":"52fa05f079594883b6aa06bca572c22a","type":"TRIAL","name":"Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT03025867","description":"Recurrent Ovarian Cancer","metadata":null},{"id":"dd78ccf2168b4d289c856f5f0f131e50","type":"TRIAL","name":"Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009","canonical_id":"clinicaltrials.gov:NCT05134922","description":"Breast Neoplasm Malignant Female","metadata":null},{"id":"9fa43cd15dd040dc8719482bcdb411bf","type":"TRIAL","name":"Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT04040894","description":"Thyroid Eye Disease; Graves' Orbitopathy","metadata":null},{"id":"e46e62c923bc4d83a0a2c3979b44f25a","type":"TRIAL","name":"Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02541643","description":"Multiple Myeloma","metadata":null},{"id":"104e833334c24d5ea347f96b4df2915d","type":"TRIAL","name":"Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome","canonical_id":"clinicaltrials.gov:NCT02189720","description":"Congenital Myasthenic Syndrome; Lambert-Eaton Myasthenic Syndrome; Nystagmus, Acquired","metadata":null},{"id":"474e2d5280a745af9842a059516bff88","type":"TRIAL","name":"Expanded Access Study Of BEXXAR\u00ae For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00268203","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"463e963724024a8b99fd0176155a6a4b","type":"TRIAL","name":"Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy","canonical_id":"clinicaltrials.gov:NCT02271139","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"c8124f3b5ab3417d85626995639c470b","type":"TRIAL","name":"Expanded Access Treatment Protocol CA204-143","canonical_id":"clinicaltrials.gov:NCT02368301","description":"Multiple Myeloma","metadata":null},{"id":"9dada9489cf1429580b136ef96a48e73","type":"TRIAL","name":"Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99","canonical_id":"clinicaltrials.gov:NCT00931086","description":"Rheumatoid Arthritis","metadata":null},{"id":"1674a2bdf098488eb6c09a4e028fd8fb","type":"TRIAL","name":"Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection","canonical_id":"clinicaltrials.gov:NCT04682834","description":"Complicated Urinary Tract Infection; Acute Pyelonephritis","metadata":null},{"id":"c9115c273b3f481d97cedeb3a97fb614","type":"TRIAL","name":"Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03424473","description":null,"metadata":null},{"id":"ddf7059c84f54d0b93f5f4880aee9b41","type":"TRIAL","name":"Expanded Access for Abatacept","canonical_id":"clinicaltrials.gov:NCT05170672","description":null,"metadata":null},{"id":"35ae6f26ca3042e29cca0b580446f6b7","type":"TRIAL","name":"Expanded Access for Apixaban","canonical_id":"clinicaltrials.gov:NCT05187286","description":null,"metadata":null},{"id":"2795182cb6f34be18f1e38b3eddbff01","type":"TRIAL","name":"Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab","canonical_id":"clinicaltrials.gov:NCT05170685","description":null,"metadata":null},{"id":"4619f79faac14411990c6d1c83f8af3c","type":"TRIAL","name":"Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT02136511","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"146d022d7ed548358df962307d42e981","type":"TRIAL","name":"Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults","canonical_id":"clinicaltrials.gov:NCT04583007","description":"Hereditary Angioedema (HAE); Angioedema","metadata":null},{"id":"feaa7f29ab93454ca8ac76d422e0852c","type":"TRIAL","name":"Expanded Access of Pimavanserin for Patients With PD Psychosis","canonical_id":"clinicaltrials.gov:NCT02762591","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"12324fd82828463896860e5d0bb8e36f","type":"TRIAL","name":"Expanded Access to Bimatoprost (Durysta)","canonical_id":"clinicaltrials.gov:NCT05338606","description":"Open-angle Glaucoma","metadata":null},{"id":"3ba288fd401342ca98f04048c0a586fa","type":"TRIAL","name":"Expanded Access to Burosumab","canonical_id":"clinicaltrials.gov:NCT03775187","description":"X-linked Hypophosphatemia; Tumor-Induced Osteomalacia","metadata":null},{"id":"e22b54aa42484baba2b89a8150b084ca","type":"TRIAL","name":"Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03126617","description":"Multiple Myeloma","metadata":null},{"id":"d67ead09b44d44739662f29156a64564","type":"TRIAL","name":"Expanded Access to Telisotuzumab Vedotin","canonical_id":"clinicaltrials.gov:NCT04830202","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"9b1531833a4f46b1b6fdf281e1b7f732","type":"TRIAL","name":"Expanded Access to Upadacitinib","canonical_id":"clinicaltrials.gov:NCT04159597","description":"Crohn Disease; Ulcerative Colitis; Idiopathic Arthritis (Including sJIA, pJIA, or JPsA); Atopic Dermatitis; Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Non-radiographic Axial; Spondyloarthritis; Giant Cell Arteritis; Systemic Lupus Erythematosus; Alopecia Areata; Non Segmental Vitiligo; Hidradenitis Suppurativa","metadata":null},{"id":"c264aa96091d475ebf090f03c484fa8a","type":"TRIAL","name":"Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01701323","description":"Acute Leukemia of Ambiguous Lineage; Acute Myeloid Leukemia","metadata":null},{"id":"9ed93de1bc1a4699924d5d1ffb37ca5e","type":"TRIAL","name":"Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib","canonical_id":"clinicaltrials.gov:NCT03746912","description":"Acute Myeloid Leukemia With Gene Mutations","metadata":null},{"id":"42a4939aee144aec82ce9bcd3aeb9eb2","type":"TRIAL","name":"Exparel vs Exparel Plus ACB in TKAs","canonical_id":"clinicaltrials.gov:NCT02365727","description":"Knee Osteoarthritis","metadata":null},{"id":"cc5c26defc1a4c17a5640cad45a2fd54","type":"TRIAL","name":"Experience With Topical Acne Treatment","canonical_id":"clinicaltrials.gov:NCT05582434","description":"Acne","metadata":null},{"id":"8941d44a82664b2f83514f7adc1c663b","type":"TRIAL","name":"Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01320501","description":"Non-small Cell Lung Cancer Metastatic","metadata":null},{"id":"264566c32a9e47cf8d601ceafea4b655","type":"TRIAL","name":"Expertise Asthma COPD Program with Digital Support","canonical_id":"clinicaltrials.gov:NCT05831566","description":"Asthma","metadata":null},{"id":"d42f441da3d5473c872fe8149215db66","type":"TRIAL","name":"Exploration of Gemfibrozil as a Treatment for AUD","canonical_id":"clinicaltrials.gov:NCT03539432","description":"Alcohol Use Disorder","metadata":null},{"id":"409f6dcf5392454980d9163e40866902","type":"TRIAL","name":"Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT06864936","description":"Multiple Sclerosis (MS) - Relapsing-remitting","metadata":null},{"id":"0b83407fa7494c0098ef7ad4ad45b7e4","type":"TRIAL","name":"Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB","canonical_id":"clinicaltrials.gov:NCT07160361","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"ef2dbfd78a1d47a59cea3c90db6b70f1","type":"TRIAL","name":"Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT07328802","description":"ORR,OS,PFS","metadata":null},{"id":"32ad7cfbdbfc4294aaa916dcb3b8384f","type":"TRIAL","name":"Exploratory Cognition Study of Sertindole in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00759421","description":"Schizophrenia","metadata":null},{"id":"8e958d86525f4a29b0e08a880fadc9a8","type":"TRIAL","name":"Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects","canonical_id":"clinicaltrials.gov:NCT04474405","description":"Alzheimer Disease","metadata":null},{"id":"ab4752660dc44aeaa95be746eb9eef1e","type":"TRIAL","name":"Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID\u00ae","canonical_id":"clinicaltrials.gov:NCT01352585","description":"Essential Thrombocythemia (ET)","metadata":null},{"id":"a8d1e304c31b416f9ee553659252a6eb","type":"TRIAL","name":"Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab\u00ae (Abciximab) in Acute MI Patients","canonical_id":"clinicaltrials.gov:NCT03087539","description":"Acute Myocardial Infarction","metadata":null},{"id":"c52ea30ce12741d0b63e5efd216878a2","type":"TRIAL","name":"Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness","canonical_id":"clinicaltrials.gov:NCT01018225","description":"Nocturia","metadata":null},{"id":"71649e7e57f74b24be702a80eec746c9","type":"TRIAL","name":"Exploratory Study for Allergy Relief Onset","canonical_id":"clinicaltrials.gov:NCT02722083","description":"Rhinitis, Allergic","metadata":null},{"id":"705bd0d77be9403d986f4f088baafe97","type":"TRIAL","name":"Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.","canonical_id":"clinicaltrials.gov:NCT02748902","description":"Verruca Vulgaris; Common Warts","metadata":null},{"id":"37de7e5d93ee46068961237a8f27ed8e","type":"TRIAL","name":"Exploratory Study of Inhaled Afatinib Dimaleate PK Profile","canonical_id":"clinicaltrials.gov:NCT06897735","description":"Lung Cancer; Oral Cancer; Melanoma","metadata":null},{"id":"035e55f4885c416bb53def613a9c8275","type":"TRIAL","name":"Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels","canonical_id":"clinicaltrials.gov:NCT00851370","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"d02f9470d0dc40f685d398553a503dea","type":"TRIAL","name":"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)","canonical_id":"clinicaltrials.gov:NCT01405820","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"1fc896da32ac41aa96f4446e38a46134","type":"TRIAL","name":"Exploratory Study to Compare the Effects of Tenelia\u00ae or Januvia\u00ae on Glucose Variability in add-on to Metformin (CGMS Study)","canonical_id":"clinicaltrials.gov:NCT02512523","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"98aa03c007b142b8a525c5cc87e1503d","type":"TRIAL","name":"Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne","canonical_id":"clinicaltrials.gov:NCT01106807","description":"Acne","metadata":null},{"id":"9979b0765a6d456c833c1b1f5c92d2f2","type":"TRIAL","name":"Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis","canonical_id":"clinicaltrials.gov:NCT06230354","description":"EGPA - Eosinophilic Granulomatosis With Polyangiitis","metadata":null},{"id":"9c8aaa6d07554c54bddd6fa109893567","type":"TRIAL","name":"Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)","canonical_id":"clinicaltrials.gov:NCT02284503","description":"Non-ST-elevation Acute Coronary Syndromes","metadata":null},{"id":"b679ad4b51f445bea4fd3f7950d28026","type":"TRIAL","name":"Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET","canonical_id":"clinicaltrials.gov:NCT01699828","description":"Smoking Cessation; Tobacco Use Cessation","metadata":null},{"id":"27b7afaaf8834833a057caab699da831","type":"TRIAL","name":"Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion","canonical_id":"clinicaltrials.gov:NCT01811056","description":"Termination of Pregnancy","metadata":null},{"id":"0dea1cf79e874fd4a1600f35de8b90a1","type":"TRIAL","name":"Exploring the Effects of Diazepam and Lorazepam","canonical_id":"clinicaltrials.gov:NCT00696033","description":"Healthy Subjects","metadata":null},{"id":"4a1275c83e724397ba78ba7933c28548","type":"TRIAL","name":"Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management","canonical_id":"clinicaltrials.gov:NCT06996561","description":"Cholecystectomy; Hernia, Abdominal; Appendectomy; Open Colorectal Surgery; Laparatomy; Postoperative Pain; Hysterectomy; Cystectomy","metadata":null},{"id":"31d6be3f300a450886aa6775b275beae","type":"TRIAL","name":"Exploring the PK of Different Doses of Naltrexone in Patients With AUD","canonical_id":"clinicaltrials.gov:NCT05919017","description":"AUD","metadata":null},{"id":"a90f2b9d1930403790c879cd811fb202","type":"TRIAL","name":"Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf","canonical_id":"clinicaltrials.gov:NCT05266469","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"b1ddc7166b5440d08df601c8fe48dae2","type":"TRIAL","name":"Exploring the Role of the GABAergic Modulation in Pain Transmission in Human","canonical_id":"clinicaltrials.gov:NCT03375034","description":"Neuropathic Pain","metadata":null},{"id":"65c3fa6b744d46b7b336f7f8945927b6","type":"TRIAL","name":"Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT06231459","description":"Hypercholesterolemia, Familial","metadata":null},{"id":"f2783b161b3443c9815544031962d3a3","type":"TRIAL","name":"Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies","canonical_id":"clinicaltrials.gov:NCT04457687","description":"Epilepsies, Myoclonic; Drug Resistant Epilepsy","metadata":null},{"id":"bc52570752214a1c8692a9ff118edb82","type":"TRIAL","name":"Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT02743806","description":"Colitis, Ulcerative; Crohn Disease","metadata":null},{"id":"84f84089f8dc473e8375998d44f62fe6","type":"TRIAL","name":"Extended Dosing With Eltrombopag for Severe Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT01891994","description":"Severe Aplastic Anemia (SAA)","metadata":null},{"id":"044d4e30c48e4fbe8baae74d458cdf66","type":"TRIAL","name":"Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01576640","description":"Nicotine Dependence; Schizophrenia","metadata":null},{"id":"f7e76a7f0e964fda9d89fb7a13ac06ca","type":"TRIAL","name":"Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction","canonical_id":"clinicaltrials.gov:NCT07115056","description":"ACL Injury; ACL Tears; ACL Surgery","metadata":null},{"id":"094b0cb1be914bd483e473ad08feb8c5","type":"TRIAL","name":"Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)","canonical_id":"clinicaltrials.gov:NCT01397422","description":"Dyskinesia; Levodopa Induced Dyskinesia; Parkinson's Disease","metadata":null},{"id":"56bcf93844e543c9860fabf0e5eeb464","type":"TRIAL","name":"Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion","canonical_id":"clinicaltrials.gov:NCT00190788","description":"Sepsis; Hypotension","metadata":null},{"id":"9c2b2f05358d4d77b0f7443a34c8a186","type":"TRIAL","name":"Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213","canonical_id":"clinicaltrials.gov:NCT05305989","description":"Chronic Graft-versus-host-disease","metadata":null},{"id":"a865de22a2fc444d9453648c02b61f53","type":"TRIAL","name":"Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry","canonical_id":"clinicaltrials.gov:NCT01999946","description":"Heroin Dependence; Opioid-Related Disorders","metadata":null},{"id":"8feda822060641578a06815119325b8d","type":"TRIAL","name":"Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity","canonical_id":"clinicaltrials.gov:NCT03662763","description":"Attention Deficit Disorder","metadata":null},{"id":"d996003d02f1418bbe7cb8e2770ea852","type":"PROTEIN","name":"Extended-spectrum beta-lactamase PER-1","canonical_id":"uniprot:P37321","description":null,"metadata":null},{"id":"f380fbd452384ae081c43949e50c6157","type":"TRIAL","name":"Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting","canonical_id":"clinicaltrials.gov:NCT00585351","description":"Stroke","metadata":null},{"id":"f7c1d2bf73c44053a110e17b3f614155","type":"TRIAL","name":"Extending Long-term Outcomes Through an Adaptive Aftercare Intervention","canonical_id":"clinicaltrials.gov:NCT02143063","description":"Cocaine Use Disorder; Contingency Management","metadata":null},{"id":"6c9eeedf227b432ebccc4448eae517bb","type":"TRIAL","name":"Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder","canonical_id":"clinicaltrials.gov:NCT03768726","description":"Bipolar Disorder","metadata":null},{"id":"55c863a7956040818b7c2f9023203951","type":"TRIAL","name":"Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)","canonical_id":"clinicaltrials.gov:NCT01236638","description":"Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"27dbf794068b49ca953b3279c4cd0d9b","type":"TRIAL","name":"Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00215657","description":"Prostate Cancer","metadata":null},{"id":"7449f59c81e847d99019befc899a679c","type":"TRIAL","name":"Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00117286","description":"Prostate Cancer","metadata":null},{"id":"b53283dfab834e0eb7f16407848cc286","type":"TRIAL","name":"Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT01118728","description":"Ankylosing Spondylitis","metadata":null},{"id":"5d2b48979ab64e988d01bdd4482c3205","type":"TRIAL","name":"Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT01227993","description":"Retinal Disease","metadata":null},{"id":"e75e5d8fad194bfd9836af5c8f7016c1","type":"TRIAL","name":"Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02536404","description":"Ulcerative Colitis","metadata":null},{"id":"d46b0cb505b34cbcaca25a211b234ad6","type":"TRIAL","name":"Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)","canonical_id":"clinicaltrials.gov:NCT01349907","description":"Bipolar Disorder","metadata":null},{"id":"e7ec1a56ba7d49ac803a2b624120de1c","type":"TRIAL","name":"Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002","canonical_id":"clinicaltrials.gov:NCT02282813","description":"Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency","metadata":null},{"id":"da72d9c1eccf43f1a73869c469df10b3","type":"TRIAL","name":"Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis","canonical_id":"clinicaltrials.gov:NCT02341417","description":"Secondary Hyperparathyroidism, Chronic Kidney Disease","metadata":null},{"id":"02bdbf176c8f4726a4dd476c03d064bd","type":"TRIAL","name":"Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)","canonical_id":"clinicaltrials.gov:NCT01539291","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"d3aa356b2c664e17a827ee511c47dbc7","type":"TRIAL","name":"Extension Study of Infigratinib in Children With Achondroplasia (ACH)","canonical_id":"clinicaltrials.gov:NCT05145010","description":"Achondroplasia","metadata":null},{"id":"a037708439b34b50822ba0d94a65c0b0","type":"TRIAL","name":"Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031","canonical_id":"clinicaltrials.gov:NCT00174447","description":"Schizophrenia","metadata":null},{"id":"42dd6c613ad84ca5b2266737a2297c04","type":"TRIAL","name":"Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03121586","description":"Schizophrenia","metadata":null},{"id":"e9c5ec251e2d4b31b5169355a155e506","type":"TRIAL","name":"Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease","canonical_id":"clinicaltrials.gov:NCT03623321","description":"Neuropsychiatric Symptoms Related to Neurodegenerative Disease","metadata":null},{"id":"ba51c3c4637b47d89c78ba2d158f2dd0","type":"TRIAL","name":"Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT05555615","description":"Irritability Associated With Autism Spectrum Disorder","metadata":null},{"id":"77eec5d63c874978b3f76d9936be4f2f","type":"TRIAL","name":"Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","canonical_id":"clinicaltrials.gov:NCT04000009","description":"Adjunctive Treatment of Major Depressive Disorder","metadata":null},{"id":"7faa2cc6c6624028bdbe6c40755743ea","type":"TRIAL","name":"Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00231998","description":"Atopic Dermatitis","metadata":null},{"id":"c259316546d44b14bd73268169599d5b","type":"TRIAL","name":"Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT04103450","description":"Overactive Bladder","metadata":null},{"id":"ffa873b1f4d943ef8f37c1ed295b3757","type":"TRIAL","name":"Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD","canonical_id":"clinicaltrials.gov:NCT00372489","description":"Chronic Renal Failure; Chronic Kidney Disease; Anemia","metadata":null},{"id":"a585fe28de114b44b2bbbe902fa75359","type":"TRIAL","name":"Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)","canonical_id":"clinicaltrials.gov:NCT00453973","description":"Chronic Renal Failure; Chronic Kidney Disease; Anemia","metadata":null},{"id":"7e9b523cd46444b39ac4f75f2ecb3bbc","type":"TRIAL","name":"Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT03706079","description":"Asthma","metadata":null},{"id":"e399e402289147db943b351d84c53ce5","type":"TRIAL","name":"Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites","canonical_id":"clinicaltrials.gov:NCT03665610","description":"Healthy Volunteers","metadata":null},{"id":"f95c3083ba274b3eb49b1be663e7a966","type":"TRIAL","name":"Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium","canonical_id":"clinicaltrials.gov:NCT01573572","description":"Age-Related Macular Degeneration; Retinal Vein Occlusion; Diabetic Macular Edema","metadata":null},{"id":"54d04f341777430fb456ef750f1edb73","type":"TRIAL","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","canonical_id":"clinicaltrials.gov:NCT06465433","description":"Hematologic Malignancies","metadata":null},{"id":"b2b453f767b04d44a781dc785e91e800","type":"TRIAL","name":"Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT01892436","description":"Psoriatic Arthritis","metadata":null},{"id":"d104c27cda374f6293fe8a19c8a94fc2","type":"TRIAL","name":"Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00139737","description":"Schizophrenia","metadata":null},{"id":"bd3942abe6fb462cb6d2743326bcc3c8","type":"TRIAL","name":"Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials","canonical_id":"clinicaltrials.gov:NCT03207256","description":"Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma","metadata":null},{"id":"e9393637d14f4d96b8e0303cab805c77","type":"TRIAL","name":"Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH","canonical_id":"clinicaltrials.gov:NCT02112487","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"c4c3e8d1f19c45119b5d1a96a6ca8ce3","type":"TRIAL","name":"Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00138515","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"bf80710f38074132ae7cd12a404afeb8","type":"TRIAL","name":"External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA","canonical_id":"clinicaltrials.gov:NCT05495204","description":"HIV-1-infection","metadata":null},{"id":"972152ec00d8427ab7cc64de8a453272","type":"TRIAL","name":"Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study","canonical_id":"clinicaltrials.gov:NCT06052020","description":"Stroke; Intracranial Atherosclerotic Stenosis","metadata":null},{"id":"cd4a7c2e18f44f42aecc9f37f7ec0f19","type":"TRIAL","name":"Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT06123364","description":"Overactive Bladder; Overactive Bladder Syndrome","metadata":null},{"id":"aa9201b2f5ac4550b92baadb63cc0bb4","type":"TRIAL","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04930653","description":"Folliculotropic Mycosis Fungoides; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Transformed Mycosis Fungoides","metadata":null},{"id":"4bd74936ae204e9d885f935130fec95a","type":"TRIAL","name":"Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)","canonical_id":"clinicaltrials.gov:NCT04558866","description":"Prostate Cancer","metadata":null},{"id":"5c275e233ed94b0c869b036a2e40b82c","type":"DISEASE","name":"Eye Diseases","canonical_id":"mesh:D005128","description":null,"metadata":null},{"id":"4ab642aa3ca047e2addbbd86f4900796","type":"TRIAL","name":"Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.","canonical_id":"clinicaltrials.gov:NCT03691636","description":"Dry Eye","metadata":null},{"id":"54ae5c2f13cb4a45a71a60f3c400ab65","type":"TRIAL","name":"Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)","canonical_id":"clinicaltrials.gov:NCT00651404","description":"Hypercholesterolemia; Atherosclerosis","metadata":null},{"id":"cdde507e36e04a9eaf82d4fb5336c5fd","type":"TRIAL","name":"Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)","canonical_id":"clinicaltrials.gov:NCT00653835","description":"Hypercholesterolaemia; Atherosclerosis","metadata":null},{"id":"b11a267089514b118900af4b0d1a0839","type":"TRIAL","name":"Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients","canonical_id":"clinicaltrials.gov:NCT01490229","description":"Coronary Artery Disease","metadata":null},{"id":"d2c618f1fb6f4cd68df614411dd5b711","type":"TRIAL","name":"Ezetimibe and Atorvastatin Therapy on TCFA","canonical_id":"clinicaltrials.gov:NCT02588235","description":"Coronary Artery Disease","metadata":null},{"id":"ed405f2d2e69445c8b210de11b83dea4","type":"TRIAL","name":"Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.","canonical_id":"clinicaltrials.gov:NCT03884127","description":"Hyperlipidemia","metadata":null},{"id":"e07d0b94ccff410cb68da417be50fdac","type":"TRIAL","name":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00782184","description":"Hypercholesterolemia","metadata":null},{"id":"9e2cae2ad6874d6ea07e156102983c3d","type":"TRIAL","name":"Ezetrol Post-Marketing Study","canonical_id":"clinicaltrials.gov:NCT00753883","description":"Hyperlipidemia","metadata":null},{"id":"be7404e4209d43b09d7b0f4c5d895339","type":"GO_TERM","name":"F bouton","canonical_id":"go:GO:1990025","description":"\"Synaptic bouton found in the ventral horn of the spinal cord. F boutons range in diameter from 0.5 to 7 um and contain flattened or pleomorphic synaptic vesicles.\" [NIF_Subcellular:nlx_subcell_100206]","metadata":null},{"id":"2f74fb551d92425db7a763788a9b4e4f","type":"GO_TERM","name":"F-9775A biosynthetic process","canonical_id":"go:GO:1900611","description":"\"The chemical reactions and pathways resulting in the formation of F-9775A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b6cdc88d016147cf9e8d1120db6e548e","type":"GO_TERM","name":"F-9775A catabolic process","canonical_id":"go:GO:1900610","description":"\"The chemical reactions and pathways resulting in the breakdown of F-9775A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c5f4238d3f934765b99871d8e1532508","type":"GO_TERM","name":"F-9775B biosynthetic process","canonical_id":"go:GO:1900614","description":"\"The chemical reactions and pathways resulting in the formation of F-9775B.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b3c431ab8c0c4d8293db9c2df4213fff","type":"GO_TERM","name":"F-9775B catabolic process","canonical_id":"go:GO:1900613","description":"\"The chemical reactions and pathways resulting in the breakdown of F-9775B.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e54263635c4d4b92aef637ef60129ea5","type":"GO_TERM","name":"F-actin capping protein complex","canonical_id":"go:GO:0008290","description":"\"A heterodimer consisting of alpha and beta subunits that binds to and caps the barbed ends of actin filaments, thereby regulating the polymerization of actin monomers but not severing actin filaments.\" [GOC:curators, ISBN:0198599560]","metadata":null},{"id":"25f288ad399a48e2b6edacad4bb63ae7","type":"GO_TERM","name":"F-actin monooxygenase activity","canonical_id":"go:GO:0120501","description":"\"Catalysis of the reaction: L-methionyl-[F-actin] + NADPH + O2 + H+ = L-methionyl-(R)-S-oxide-[F-actin] + NADP+ + H2O.\" [RHEA:51308]","metadata":null},{"id":"fe45621c18c048479527c18084baee75","type":"GO_TERM","name":"F-bar domain binding","canonical_id":"go:GO:1990808","description":"\"Binding to an F-BAR domain of a protein, a domain of about 60 residues that occurs in a wide range of cytoskeletal proteins.\" [PMID:20603077]","metadata":null},{"id":"416c998570c04c6ab8e9cbf377d15c44","type":"GO_TERM","name":"F-box domain binding","canonical_id":"go:GO:1990444","description":"\"Binding to an F-box domain of a protein.\" [GOC:bf, GOC:PARL, InterPro:IPR001810, PMID:12628165]","metadata":null},{"id":"a06d3abf598e405b8fe81d2e39e6fb1e","type":"GENE","name":"F10","canonical_id":"hgnc:HGNC:3528","description":null,"metadata":null},{"id":"370bc09c70ae473ba2e97e18b5959fa2","type":"PROTEIN","name":"F10","canonical_id":"uniprot:P00742","description":null,"metadata":null},{"id":"e4d9bd6e65034cfc885b24163f5dbbd2","type":"GENE","name":"F10-AS1","canonical_id":"hgnc:HGNC:40225","description":"F10 antisense RNA 1","metadata":null},{"id":"d3a5899bf8f64d3aa04727083522b76a","type":"GENE","name":"F10-AS2","canonical_id":"hgnc:HGNC:58130","description":"F10 antisense RNA 2","metadata":{"aliases":["SCAR-6"]}},{"id":"895f9600fc7c471ab64dd3e279ede8d2","type":"GENE","name":"F11","canonical_id":"hgnc:HGNC:3529","description":"coagulation factor XI","metadata":{"aliases":["FXI"]}},{"id":"1e66a5a4fede40ffa1ff12e448a79fef","type":"GENE","name":"F11-AS1","canonical_id":"hgnc:HGNC:27725","description":"F11 antisense RNA 1","metadata":null},{"id":"d955000a96ef43d7bc7e1b5e2ade1818","type":"GENE","name":"F11R","canonical_id":"hgnc:HGNC:14685","description":"F11 receptor","metadata":{"aliases":["PAM-1","JCAM","JAM-1","JAM-A","JAMA","CD321","JAM1"]}},{"id":"c1a11786d495452282c6120019952ae5","type":"GENE","name":"F12","canonical_id":"hgnc:HGNC:3530","description":null,"metadata":null},{"id":"ce76f6dbcc0f46f594a84b14a5c24c66","type":"GENE","name":"F13A1","canonical_id":"hgnc:HGNC:3531","description":null,"metadata":null},{"id":"8f438e7f53454028be971751506098a5","type":"GENE","name":"F13A1-AS1","canonical_id":"hgnc:HGNC:59341","description":"F13A1 antisense RNA 1","metadata":null},{"id":"f7a2ad3b9e7b4a29aed179da3d988f34","type":"GENE","name":"F13B","canonical_id":"hgnc:HGNC:3534","description":"coagulation factor XIII B chain","metadata":{"aliases":["FXIIIB"]}},{"id":"6c42126887744abea421838bbccc039c","type":"TRIAL","name":"F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05468294","description":"Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"97612280acab43679ef8d5f1284a64a1","type":"GENE","name":"F2","canonical_id":"hgnc:HGNC:3535","description":"coagulation factor II, thrombin","metadata":null},{"id":"0bae96686c0549fea966c66e354e70a2","type":"PROTEIN","name":"F2","canonical_id":"uniprot:P00734","description":null,"metadata":null},{"id":"59a504aeaf0b4b099bc4b402e971dadd","type":"GO_TERM","name":"F2-isoprostane catabolic process","canonical_id":"go:GO:0062233","description":"\"The chemical reactions and pathways resulting in the breakdown of F2-isoprostane.\" [PMID:16371369, PMID:25449649]","metadata":null},{"id":"21dd9a9e92ec433a95f1ff618e4503e8","type":"GENE","name":"F2R","canonical_id":"hgnc:HGNC:3537","description":null,"metadata":null},{"id":"6f6a91dde1d24b2296436dd5b1f101ef","type":"GENE","name":"F2R-AS1","canonical_id":"hgnc:HGNC:59083","description":"F2R and IQGAP2 antisense RNA 1","metadata":null},{"id":"ca0d3d874d9f4b018057f01240de9d46","type":"GENE","name":"F2RL1","canonical_id":"hgnc:HGNC:3538","description":"F2R like trypsin receptor 1","metadata":{"aliases":["PAR2","GPR11"]}},{"id":"d08919ad3f3e4f1bb413f4ae356dde16","type":"GENE","name":"F2RL2","canonical_id":"hgnc:HGNC:3539","description":"coagulation factor II thrombin receptor like 2","metadata":{"aliases":["PAR3"]}},{"id":"a99e343548984850b8aeaa04a245262e","type":"GENE","name":"F2RL3","canonical_id":"hgnc:HGNC:3540","description":"F2R like thrombin or trypsin receptor 3","metadata":{"aliases":["PAR4"]}},{"id":"4afd4682df864bc9bb2cf4484e55c98f","type":"GENE","name":"F3","canonical_id":"hgnc:HGNC:3541","description":null,"metadata":null},{"id":"19b05cd3e615480b8fef3e6ad575d007","type":"PROTEIN","name":"F3","canonical_id":"uniprot:P13726","description":null,"metadata":null},{"id":"752aed5d6e74457cabdc13e57771d19f","type":"GO_TERM","name":"F420-0 metabolic process","canonical_id":"go:GO:0052645","description":"\"The chemical reactions and pathways involving F420-0 (5-O-{[(1S)-1-carboxyethoxy](hydroxy)phosphoryl}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-10(4H)-yl)-D-ribitol), the fragment of coenzyme F420 remaining after formal hydrolytic removal of all of the glutamate residues.\" [GOC:curators]","metadata":null},{"id":"e5506bfa193c412387f6a45a4f59a91c","type":"GENE","name":"F5","canonical_id":"hgnc:HGNC:3542","description":"coagulation factor V","metadata":{"aliases":["fV"]}},{"id":"a60cb2e3a5ba47059eb778107d8fbc5d","type":"PROTEIN","name":"F5","canonical_id":"uniprot:P12259","description":null,"metadata":null},{"id":"62b41b7399c34da19b6ef9dd726e761d","type":"GENE","name":"F7","canonical_id":"hgnc:HGNC:3544","description":null,"metadata":null},{"id":"72f95c0078db4586ada37ba91f635cf3","type":"GENE","name":"F8","canonical_id":"hgnc:HGNC:3546","description":null,"metadata":null},{"id":"41dc6c4c0b3940a1ae7f36d5da0db53c","type":"PROTEIN","name":"F8","canonical_id":"uniprot:P00451","description":null,"metadata":null},{"id":"cdddbbdce4e745bcbfaac3235fb8ec06","type":"GENE","name":"F8A1","canonical_id":"hgnc:HGNC:3547","description":"coagulation factor VIII associated 1","metadata":{"aliases":["DXS522E","F8A"]}},{"id":"f880b4c5f4114bcdaa6ad4460d5ba23a","type":"GENE","name":"F8A2","canonical_id":"hgnc:HGNC:31849","description":"coagulation factor VIII associated 2","metadata":null},{"id":"3c19d796aecd49aaa701ce60011296fd","type":"GENE","name":"F8A3","canonical_id":"hgnc:HGNC:31850","description":"coagulation factor VIII associated 3","metadata":null},{"id":"2a9f1d1479b0409cb9dca81c6475097c","type":"GENE","name":"F9","canonical_id":"hgnc:HGNC:3551","description":null,"metadata":null},{"id":"08193cd3bc2443368da0023dbc68f6d9","type":"GENE","name":"FA2H","canonical_id":"hgnc:HGNC:21197","description":"fatty acid 2-hydroxylase","metadata":{"aliases":["FAAH","FLJ25287","FAXDC1","SPG35"]}},{"id":"790aec3ccef149d595baa45660dca89a","type":"GENE","name":"FAABTP","canonical_id":"hgnc:HGNC:25605","description":"fatty acid amide binding transmembrane protein","metadata":{"aliases":["FLJ10936","TMEM19"]}},{"id":"afed1bee783c479aa02b3c238e467db0","type":"GENE","name":"FAAH","canonical_id":"hgnc:HGNC:3553","description":null,"metadata":null},{"id":"99c145daf9f74f369f4301cbf72a5976","type":"GENE","name":"FAAH2","canonical_id":"hgnc:HGNC:26440","description":"fatty acid amide hydrolase 2","metadata":{"aliases":["RP11-479E16.1","FLJ31204","FAAH-2","AMDD"]}},{"id":"5e45dd1a44e748e1adadd2e69f40ed96","type":"GENE","name":"FAAHP1","canonical_id":"hgnc:HGNC:50679","description":"fatty acid amide hydrolase pseudogene 1","metadata":{"aliases":["FAAH-OUT","LINC00505"]}},{"id":"1f8d4f8e5c94406ab82cf75e96efce84","type":"GENE","name":"FAAP100","canonical_id":"hgnc:HGNC:26171","description":"FA core complex associated protein 100","metadata":{"aliases":["FLJ22175","C17orf70"]}},{"id":"135058e927064b3fa9d5e9303d6244a8","type":"GENE","name":"FAAP20","canonical_id":"hgnc:HGNC:26428","description":"FA core complex associated protein 20","metadata":{"aliases":["FLJ31031","C1orf86"]}},{"id":"cb09b509431e45f5a26c52a907ebec06","type":"GENE","name":"FAAP24","canonical_id":"hgnc:HGNC:28467","description":"FA core complex associated protein 24","metadata":{"aliases":["FLJ46828","MGC32020","C19orf40"]}},{"id":"b97ace611ccd4d0abc6142ac7dd9a1b6","type":"GENE","name":"FABP-AS1","canonical_id":"hgnc:HGNC:59256","description":"FABP cluster antisense RNA 1","metadata":null},{"id":"4c0a71d43f5c43d9b19a9acabe7a963c","type":"GENE","name":"FABP1","canonical_id":"hgnc:HGNC:3555","description":null,"metadata":null},{"id":"83d6a2daa3544e6a981647b6d5e88899","type":"GENE","name":"FABP12","canonical_id":"hgnc:HGNC:34524","description":"fatty acid binding protein 12","metadata":null},{"id":"8a4b2365b8ba4f2f9a0839bce08bfbf7","type":"GENE","name":"FABP12P1","canonical_id":"hgnc:HGNC:45176","description":"fatty acid binding protein 12 pseudogene 1","metadata":null},{"id":"4ee159d24d1648029960c1a4d26a8b21","type":"GENE","name":"FABP2","canonical_id":"hgnc:HGNC:3556","description":null,"metadata":null},{"id":"27a90c3218ff4baa9dce32549cd0fdb0","type":"GENE","name":"FABP3","canonical_id":"hgnc:HGNC:3557","description":"fatty acid binding protein 3","metadata":{"aliases":["H-FABP","O-FABP","MDGI","FABP11"]}},{"id":"d9da5ecab02e49e4a8c193dbbaf0b73d","type":"GENE","name":"FABP3P2","canonical_id":"hgnc:HGNC:3558","description":"fatty acid binding protein 3 pseudogene 2","metadata":{"aliases":["FABP3-ps","FABP3P"]}},{"id":"53d42d1865c643dc8f6daa132f2b2d9a","type":"GENE","name":"FABP4","canonical_id":"hgnc:HGNC:3559","description":null,"metadata":null},{"id":"cf5941bbbfe440c2a2cf6cf1476d7a23","type":"GENE","name":"FABP5","canonical_id":"hgnc:HGNC:3560","description":null,"metadata":null},{"id":"22fecad0de424ab58d14f5986c00bcc0","type":"GENE","name":"FABP5P1","canonical_id":"hgnc:HGNC:31059","description":"fatty acid binding protein 5 pseudogene 1","metadata":{"aliases":["FABP5","FABP5L1"]}},{"id":"416d7e13f20b44fca9d04a8c8fddeddb","type":"GENE","name":"FABP5P10","canonical_id":"hgnc:HGNC:31066","description":"fatty acid binding protein 5 pseudogene 10","metadata":{"aliases":["FABP5L10"]}},{"id":"1cb05f7056d347b7916b260ccf39dd2c","type":"GENE","name":"FABP5P11","canonical_id":"hgnc:HGNC:19328","description":"fatty acid binding protein 5 pseudogene 11","metadata":{"aliases":["FABP5P1","FABP5L11"]}},{"id":"c8b5b89c046e46c7a9bf009e72618057","type":"GENE","name":"FABP5P12","canonical_id":"hgnc:HGNC:31067","description":"fatty acid binding protein 5 pseudogene 12","metadata":{"aliases":["FABP5L12"]}},{"id":"eb556314e73d493e8bc92a791fe85ad7","type":"GENE","name":"FABP5P13","canonical_id":"hgnc:HGNC:38717","description":"fatty acid binding protein 5 pseudogene 13","metadata":{"aliases":["FABP5L13"]}},{"id":"004b044636114ee9af63ef01bfe122d4","type":"GENE","name":"FABP5P14","canonical_id":"hgnc:HGNC:31065","description":"fatty acid binding protein 5 pseudogene 14","metadata":{"aliases":["FABP5L14"]}},{"id":"cbebcfd470e9449caa14f7bd5d5b4d11","type":"GENE","name":"FABP5P15","canonical_id":"hgnc:HGNC:31071","description":"fatty acid binding protein 5 pseudogene 15","metadata":{"aliases":["FABP5L15"]}},{"id":"bebb54b132a54ac79decdce6d14fecfa","type":"GENE","name":"FABP5P2","canonical_id":"hgnc:HGNC:31060","description":"fatty acid binding protein 5 pseudogene 2","metadata":{"aliases":["FABP5L2"]}},{"id":"fbdde2d75cbb4248a61f8f8177ef73f2","type":"GENE","name":"FABP5P3","canonical_id":"hgnc:HGNC:22573","description":"fatty acid binding protein 5 pseudogene 3","metadata":{"aliases":["TCAG_1781704","FABP5L3"]}},{"id":"3b681826aee64ada926d01f61f4acbaf","type":"GENE","name":"FABP5P4","canonical_id":"hgnc:HGNC:31061","description":"fatty acid binding protein 5 pseudogene 4","metadata":{"aliases":["FABP5L4"]}},{"id":"990485da75014c0288e4f1faf9a14abc","type":"GENE","name":"FABP5P5","canonical_id":"hgnc:HGNC:31068","description":"fatty acid binding protein 5 pseudogene 5","metadata":{"aliases":["FABP5L5"]}},{"id":"3f2bef759ce644408ec3d3294aa159a8","type":"GENE","name":"FABP5P6","canonical_id":"hgnc:HGNC:31069","description":"fatty acid binding protein 5 pseudogene 6","metadata":{"aliases":["FABP5L6"]}},{"id":"78858804ab32441592ffa0cc91bb65ae","type":"GENE","name":"FABP5P7","canonical_id":"hgnc:HGNC:31070","description":"fatty acid binding protein 5 pseudogene 7","metadata":{"aliases":["FABP5L7"]}},{"id":"4018c8dcb2434191b01839326db90d9e","type":"GENE","name":"FABP5P8","canonical_id":"hgnc:HGNC:31063","description":"fatty acid binding protein 5 pseudogene 8","metadata":{"aliases":["FABP5L8"]}},{"id":"343319e90ee3465dbbc4de2949a698bf","type":"GENE","name":"FABP5P9","canonical_id":"hgnc:HGNC:31064","description":"fatty acid binding protein 5 pseudogene 9","metadata":{"aliases":["FABP5L9"]}},{"id":"279b65564aa14e89829425076c1f0802","type":"GENE","name":"FABP6","canonical_id":"hgnc:HGNC:3561","description":null,"metadata":null},{"id":"867f2b70d280449cb66ef674c378e0dc","type":"GENE","name":"FABP6-AS1","canonical_id":"hgnc:HGNC:40226","description":"FABP6 antisense RNA 1","metadata":null},{"id":"ecf43b986648472bb8270f817eb0718b","type":"GENE","name":"FABP7","canonical_id":"hgnc:HGNC:3562","description":null,"metadata":null},{"id":"4e22989101334ee6ad08ee739b46805e","type":"GENE","name":"FABP7P1","canonical_id":"hgnc:HGNC:41951","description":"fatty acid binding protein 7 pseudogene 1","metadata":null},{"id":"f3bc5285e49b4b1894d30886cb6b3c5e","type":"GENE","name":"FABP7P2","canonical_id":"hgnc:HGNC:41952","description":"fatty acid binding protein 7 pseudogene 2","metadata":null},{"id":"721bf1e1dd454cf8b8a51f963545dec5","type":"GENE","name":"FABP9","canonical_id":"hgnc:HGNC:3563","description":"fatty acid binding protein 9","metadata":{"aliases":["PERF","T-FABP","PERF15"]}},{"id":"cb43f267c9b543b7910afe463000a411","type":"DRUG","name":"FAC Regimen","canonical_id":"ncit:C138099","description":null,"metadata":null},{"id":"eadcc2c58362417eb520bd524088a7cd","type":"GO_TERM","name":"FACIT collagen complex","canonical_id":"go:GO:0140153","description":"\"A supramolecular complex formed by fibril-associated collagens with interrupted triple helices (FACIT) that associate with collagen fibrils and forms a link on large, banded fibrils.\" [PMID:1882421, PMID:21421911]","metadata":null},{"id":"244f95dd2e7244b799d9db002f5a1370","type":"GO_TERM","name":"FACIT collagen trimer","canonical_id":"go:GO:0005593","description":"\"A collagen trimer that associates with collagen fibrils and consists of collagen monomers that contain two or more relatively short triple-helical domains connected by non-triple-helical sequences.\" [PMID:21421911]","metadata":null},{"id":"8c769dd2f82d4a9194ef98770c3a45c6","type":"GO_TERM","name":"FACT complex","canonical_id":"go:GO:0035101","description":"\"A histone chaperone complex that facilitates nucleosome disassembly and reassembly upon DNA or RNA polymerase passage.\" [PMID:12934006, PMID:12934007, PMID:16678108, PMID:34731638]","metadata":null},{"id":"dc4cc0b60d5c4a5c9e39dde256cd3a8a","type":"GO_TERM","name":"FACT complex assembly","canonical_id":"go:GO:1905635","description":"\"The aggregation, arrangement and bonding together of a set of components to form a FACT complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"00f9ae42147a4a25886cf9026928fd3b","type":"GO_TERM","name":"FACT complex binding","canonical_id":"go:GO:0062059","description":"\"Binding to a FACT complex.\" [PMID:10682845]","metadata":null},{"id":"f7e352fab0d9437d9e78bd90923e13bc","type":"GO_TERM","name":"FAD binding","canonical_id":"go:GO:0071949","description":"\"Binding to the oxidized form, FAD, of flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:mah]","metadata":null},{"id":"299bd6c27daa4ebeb750b56559e0e793","type":"GO_TERM","name":"FAD biosynthetic process","canonical_id":"go:GO:0006747","description":"\"The chemical reactions and pathways resulting in the formation of FAD, the oxidized form of flavin-adenine dinucleotide.\" [GOC:ai, PMID:20822113]","metadata":null},{"id":"cb9e4d6cdaff41b4ab3c30dd0701b61d","type":"GO_TERM","name":"FAD diphosphatase activity","canonical_id":"go:GO:0047884","description":"\"Catalysis of the reaction: FAD + H2O = AMP + FMN.\" [RHEA:13889]","metadata":null},{"id":"e8a643c9fa3c4200919b2d4a185d646e","type":"GO_TERM","name":"FAD metabolic process","canonical_id":"go:GO:0046443","description":"\"The chemical reactions and pathways involving FAD, the oxidized form of flavin adenine dinucleotide.\" [PMID:20822113]","metadata":null},{"id":"341c156f3c3e469e999caca11fa697ee","type":"GO_TERM","name":"FAD transmembrane transport","canonical_id":"go:GO:0035350","description":"\"The process in which flavin-adenine dinucleotide (FAD) is transported across a membrane. FAD forms the coenzyme of the prosthetic group of various flavoprotein oxidoreductase enzymes, in which it functions as an electron acceptor by being reversibly converted to its reduced form.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"dedcc05302a04d0991adac44cdd7afde","type":"GO_TERM","name":"FAD transmembrane transporter activity","canonical_id":"go:GO:0015230","description":"\"Enables the directed movement of flavin-adenine dinucleotide (FAD) from one side of a membrane to the other. FAD forms the coenzyme of the prosthetic group of various flavoprotein oxidoreductase enzymes, in which it functions as an electron acceptor by being reversibly converted to its reduced form.\" [ISBN:0198506732]","metadata":null},{"id":"0234042b294e4406ba76fe9cd36fddba","type":"GO_TERM","name":"FAD transport","canonical_id":"go:GO:0015883","description":"\"The directed movement of flavin-adenine dinucleotide (FAD) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. FAD forms the coenzyme of the prosthetic group of various flavoprotein oxidoreductase enzymes, in which it functions as an electron acceptor by being reversibly converted to its reduced form.\" [ISBN:0198506732]","metadata":null},{"id":"e5fed46187104870836e1f21e5bcc3f6","type":"GO_TERM","name":"FAD-AMP lyase (cyclizing) activity","canonical_id":"go:GO:0034012","description":"\"Catalysis of the reaction: FAD = AMP + H+ + riboflavin cyclic-4',5'-phosphate.\" [RHEA:13729]","metadata":null},{"id":"a7155246d58342ddbbacd459b1ed26cd","type":"GO_TERM","name":"FAD-dependent H3K4me/H3K4me3 demethylase activity","canonical_id":"go:GO:0140682","description":"\"Catalysis of the removal of a methyl group from a di- or a monomethyl-lysine residue at position 4 of the histone H3 protein. This is a flavin adenine dinucleotide (FAD)-dependent amine oxidation reaction.\" [PMID:22473470]","metadata":null},{"id":"da45b57dda9549bc8e9c537623cd08a6","type":"GO_TERM","name":"FAD-dependent histone H3K9me/H3K9me2 demethylase activity","canonical_id":"go:GO:0140685","description":"\"Catalysis of the removal of a methyl group from a di- or a monomethyl-lysine residue at position 9 of the histone H3 protein. This is a flavin adenine dinucleotide (FAD)-dependent amine oxidation reaction.\" [PMID:22473470]","metadata":null},{"id":"d431568484054332b0066bc0a4a22106","type":"GO_TERM","name":"FAD-dependent urate hydroxylase activity","canonical_id":"go:GO:0102099","description":"\"Catalysis of the reaction: 7,9-dihydro-1H-purine-2,6,8(3H)-trione + NADH + H+ + O2 = 5-hydroxyisouric acid + NAD + H2O.\" [EC:1.14.13.113, GOC:pz]","metadata":null},{"id":"ed8083bfde4f43d290660137fb0783b1","type":"GENE","name":"FADD","canonical_id":"hgnc:HGNC:3573","description":null,"metadata":null},{"id":"6a71320a98ba4b6c9a5127e25f109519","type":"GO_TERM","name":"FADH2 binding","canonical_id":"go:GO:0071950","description":"\"Binding to the reduced form, FADH2, of flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:mah]","metadata":null},{"id":"fa2c732c519a40f29d4e8975f01ce58c","type":"GENE","name":"FADS1","canonical_id":"hgnc:HGNC:3574","description":"fatty acid desaturase 1","metadata":{"aliases":["D5D","FADSD5","TU12","FADS6","LLCDL1"]}},{"id":"699c396ca8ab4ddc81549249f5f5f868","type":"GENE","name":"FADS2","canonical_id":"hgnc:HGNC:3575","description":"fatty acid desaturase 2","metadata":{"aliases":["FADSD6","D6D","TU13","DES6","SLL0262","LLCDL2"]}},{"id":"43c16f7e26724c45a51291e0c77ea08f","type":"GENE","name":"FADS2B","canonical_id":"hgnc:HGNC:43618","description":"fatty acid desaturase 2B (pseudogene)","metadata":{"aliases":["FADS2BP","FADS2P1"]}},{"id":"2ab76120bdf54dad9208db9faf61df4c","type":"GENE","name":"FADS3","canonical_id":"hgnc:HGNC:3576","description":"fatty acid desaturase 3","metadata":{"aliases":["CYB5RP","LLCDL3"]}},{"id":"0a73cf8e70624fbfa15dc18f12d80c05","type":"GENE","name":"FADS6","canonical_id":"hgnc:HGNC:30459","description":"fatty acid desaturase 6","metadata":null},{"id":"abc453ce110c4c08b6ac23922f4185e7","type":"GENE","name":"FAF1","canonical_id":"hgnc:HGNC:3578","description":null,"metadata":null},{"id":"b0c98e61498f428195ecdd373d8c6a64","type":"GENE","name":"FAF1-AS1","canonical_id":"hgnc:HGNC:40228","description":"FAF1 antisense RNA 1","metadata":null},{"id":"61d0ad924e9e405ab3a3123f7617e6bc","type":"GENE","name":"FAF2","canonical_id":"hgnc:HGNC:24666","description":"Fas associated factor family member 2","metadata":{"aliases":["ETEA","KIAA0887","UBXN3B","UBXD8"]}},{"id":"8b40af22ddb740f4bfef59b110a3fcbb","type":"GENE","name":"FAF2P1","canonical_id":"hgnc:HGNC:45172","description":"Fas associated factor family member 2 pseudogene 1","metadata":null},{"id":"67b5af1d4c654e388fd9548fe078c6c1","type":"GENE","name":"FAH","canonical_id":"hgnc:HGNC:3579","description":"fumarylacetoacetate hydrolase","metadata":null},{"id":"5ff6858882af40928168cd8b00700c11","type":"GENE","name":"FAHD1","canonical_id":"hgnc:HGNC:14169","description":"FAH domain containing oxaloacetate decarboxylase 1","metadata":{"aliases":["DKFZP566J2046","C16orf36"]}},{"id":"aced8ac3e96c4b4888f73fcb4e4ce7c7","type":"GENE","name":"FAHD2A","canonical_id":"hgnc:HGNC:24252","description":"fumarylacetoacetate hydrolase domain containing 2A","metadata":{"aliases":["CGI-105"]}},{"id":"9fb9fa6178524949abe4b821c0c63e63","type":"GENE","name":"FAHD2B","canonical_id":"hgnc:HGNC:25318","description":"fumarylacetoacetate hydrolase domain containing 2B","metadata":{"aliases":["DKFZp434N062"]}},{"id":"4442cf9a9eab4d5bb1c5e58f3ec85d7e","type":"GENE","name":"FAHD2CP","canonical_id":"hgnc:HGNC:44135","description":"fumarylacetoacetate hydrolase domain containing 2C, pseudogene","metadata":null},{"id":"b66c8ce6a11b4d4dbbbe27b55f050bbe","type":"GENE","name":"FAHD2P1","canonical_id":"hgnc:HGNC:32441","description":"fumarylacetoacetate hydrolase domain containing 2 pseudogene 1","metadata":{"aliases":["FAHD2P"]}},{"id":"77f42cc964444c2da07794978b9545f7","type":"GO_TERM","name":"FAHFA hydrolase activity","canonical_id":"go:GO:0120573","description":"\"Catalysis of the hydrolysis of the ester bond in a fatty acid ester of a hydroxy fatty acid (FAHFA), yielding a free fatty acid and a hydroxy fatty acid. FAHFAs are a class of endogenous bioactive signaling lipids in which a fatty acid is esterified to a hydroxyl group on a second fatty acid backbone.\" [PMID:27018888, PMID:32152231]","metadata":null},{"id":"7c8f5e0837284c27bb95058f319966e9","type":"GENE","name":"FAIM","canonical_id":"hgnc:HGNC:18703","description":"Fas apoptotic inhibitory molecule","metadata":{"aliases":["FLJ10582","FAIM1"]}},{"id":"30f4519f2c0c459597149c8a0d6f40aa","type":"GENE","name":"FAIM2","canonical_id":"hgnc:HGNC:17067","description":"Fas apoptotic inhibitory molecule 2","metadata":{"aliases":["KIAA0950","LFG","NMP35","LIFEGUARD","TMBIM2","LFG2"]}},{"id":"0359c6f564544f1d8937f9f494d1ae47","type":"GO_TERM","name":"FAL1-SGD1 complex","canonical_id":"go:GO:0097078","description":"\"A protein complex involved in the 18S rRNA biogenesis. In S. cerevisiae this complex consists of Fal1p and Sgd1p and in humans this complex consists of NOM1 and eIF4AIII subunits.\" [GOC:rb, PMID:21576267]","metadata":null},{"id":"203c63960061496ebfde5304405fe5a5","type":"GENE","name":"FALEC","canonical_id":"hgnc:HGNC:43713","description":"focally amplified lncRNA regulator of ECM1","metadata":{"aliases":["ncRNA-a1","FAL1","LINC00568"]}},{"id":"7bc260dceb6b4190be0a49d64ff5467d","type":"GENE","name":"FAM106A","canonical_id":"hgnc:HGNC:25682","description":"family with sequence similarity 106 member A","metadata":{"aliases":["FLJ11800"]}},{"id":"188cf40af6c14bd186f5637b1d145cc1","type":"GENE","name":"FAM106B","canonical_id":"hgnc:HGNC:32450","description":"family with sequence similarity 106 member B","metadata":null},{"id":"0584e7047de74fcc88d1f9ead46783f2","type":"GENE","name":"FAM106C","canonical_id":"hgnc:HGNC:38396","description":"family with sequence similarity 106 member C","metadata":{"aliases":["FAM106CP"]}},{"id":"6c31c832949d4e57b535323e66a9013a","type":"GENE","name":"FAM106DP","canonical_id":"hgnc:HGNC:38397","description":"family with sequence similarity 106 member D, pseudogene","metadata":{"aliases":["FAM106D"]}},{"id":"943ded39a05b44cc9659610d7bf4af1f","type":"GENE","name":"FAM107A","canonical_id":"hgnc:HGNC:30827","description":"family with sequence similarity 107 member A","metadata":{"aliases":["DRR1","TU3A"]}},{"id":"6c8a28a1880040acbe227078e842d1fc","type":"GENE","name":"FAM107B","canonical_id":"hgnc:HGNC:23726","description":"family with sequence similarity 107 member B","metadata":{"aliases":["FLJ45505","MGC11034","HITS","C10orf45"]}},{"id":"4b8384ec34ed4adfa10fa1ca7f525c26","type":"GENE","name":"FAM110A","canonical_id":"hgnc:HGNC:16188","description":"family with sequence similarity 110 member A","metadata":{"aliases":["bA371L19.3","C20orf55"]}},{"id":"803e459ccd3242f98e46fa096d405c56","type":"GENE","name":"FAM110B","canonical_id":"hgnc:HGNC:28587","description":"family with sequence similarity 110 member B","metadata":{"aliases":["MGC39325","C8orf72"]}},{"id":"0753d559b6db407ca38cda589b9252b3","type":"GENE","name":"FAM110C","canonical_id":"hgnc:HGNC:33340","description":"family with sequence similarity 110 member C","metadata":null},{"id":"cf2862666e764292bf93026b4731816d","type":"GENE","name":"FAM110D","canonical_id":"hgnc:HGNC:25860","description":"family with sequence similarity 110 member D","metadata":{"aliases":["FLJ14050","GRRP1"]}},{"id":"ee686c7012054015bff6464baddcece4","type":"GENE","name":"FAM111A","canonical_id":"hgnc:HGNC:24725","description":"FAM111 trypsin like peptidase A","metadata":{"aliases":["FLJ22794","KIAA1895"]}},{"id":"8f4fb65ed01146beb808c86dc54d1567","type":"GENE","name":"FAM111A-DT","canonical_id":"hgnc:HGNC:53752","description":"FAM111A divergent transcript","metadata":null},{"id":"259c8266cde44952843367b03d25b08b","type":"GENE","name":"FAM111B","canonical_id":"hgnc:HGNC:24200","description":"FAM111 trypsin like peptidase B","metadata":{"aliases":["CANP"]}},{"id":"d8b8a060b1d341769caa6fc790365aee","type":"GENE","name":"FAM114A1","canonical_id":"hgnc:HGNC:25087","description":"family with sequence similarity 114 member A1","metadata":{"aliases":["Noxp20"]}},{"id":"1506f9ff271b46969633bf7b00d257e8","type":"GENE","name":"FAM114A2","canonical_id":"hgnc:HGNC:1333","description":"family with sequence similarity 114 member A2","metadata":{"aliases":["133K02","C5orf3"]}},{"id":"375260dbdd54436e9286229a3b7fcffe","type":"GENE","name":"FAM117A","canonical_id":"hgnc:HGNC:24179","description":"family with sequence similarity 117 member A","metadata":null},{"id":"c3faf09c8ca3471694128bfec15234b6","type":"GENE","name":"FAM117B","canonical_id":"hgnc:HGNC:14440","description":"family with sequence similarity 117 member B","metadata":{"aliases":["FLJ38771","ALS2CR13"]}},{"id":"5160d888d2734c319650a25f0cd4526b","type":"GENE","name":"FAM120A","canonical_id":"hgnc:HGNC:13247","description":"family with sequence similarity 120 member A","metadata":{"aliases":["KIAA0183","OSSA","C9orf10"]}},{"id":"a274d25344ae4b6792d2f96a15720e97","type":"GENE","name":"FAM120A2P","canonical_id":"hgnc:HGNC:31116","description":"family with sequence similarity 120A2, pseudogene","metadata":{"aliases":["bA165J3.3","C9orf129"]}},{"id":"0d93aa20701e4cc38062881aa17766ea","type":"GENE","name":"FAM120AOS","canonical_id":"hgnc:HGNC:23389","description":"family with sequence similarity 120 member A opposite strand","metadata":{"aliases":["C9orf10OS"]}},{"id":"629e6de682df4772bad04c7c07f5f7db","type":"GENE","name":"FAM120B","canonical_id":"hgnc:HGNC:21109","description":"family with sequence similarity 120 member B","metadata":{"aliases":["PGCC1","CCPG","SAN1","KIAA1838"]}},{"id":"8d16c844e7e64d9d92d8e046725d721d","type":"GENE","name":"FAM120C","canonical_id":"hgnc:HGNC:16949","description":"family with sequence similarity 120 member C","metadata":{"aliases":["ORF34","FLJ20506","CXorf17"]}},{"id":"bf33e43969244722956e69c4aeb70fed","type":"GENE","name":"FAM124A","canonical_id":"hgnc:HGNC:26413","description":"family with sequence similarity 124 member A","metadata":{"aliases":["FLJ30707"]}},{"id":"abd7b10752264a13a650f3b450cb4008","type":"GENE","name":"FAM124B","canonical_id":"hgnc:HGNC:26224","description":"family with sequence similarity 124 member B","metadata":{"aliases":["FLJ22746"]}},{"id":"73417a5ac4764465a2a5cbdc4259d344","type":"GENE","name":"FAM131A","canonical_id":"hgnc:HGNC:28308","description":"family with sequence similarity 131 member A","metadata":{"aliases":["MGC21688","C3orf40"]}},{"id":"16174877c9c64bbeb6667d6921347574","type":"GENE","name":"FAM131B","canonical_id":"hgnc:HGNC:22202","description":"family with sequence similarity 131 member B","metadata":{"aliases":["KIAA0773"]}},{"id":"6c78d40dbcb44d96a1af745b4490fcc4","type":"GENE","name":"FAM131B-AS1","canonical_id":"hgnc:HGNC:55208","description":"FAM131B antisense RNA 1","metadata":null},{"id":"22e143bc47c745c0bf882ad7c880af9d","type":"GENE","name":"FAM131B-AS2","canonical_id":"hgnc:HGNC:56141","description":"FAM131B antisense RNA 2","metadata":{"aliases":["PCAL7"]}},{"id":"c8afebf5dc064e5aa5ccae60b6b2c0d2","type":"GENE","name":"FAM131C","canonical_id":"hgnc:HGNC:26717","description":"family with sequence similarity 131 member C","metadata":{"aliases":["FLJ36766","C1orf117"]}},{"id":"3627d38cd6ae4a2a8223a2159836447c","type":"GENE","name":"FAM131C2P","canonical_id":"hgnc:HGNC:56213","description":"family with sequence similarity 131 member C2, pseudogene","metadata":null},{"id":"00e39d8d23da415ab36e3f93f9cc9009","type":"GENE","name":"FAM133A","canonical_id":"hgnc:HGNC:26748","description":"family with sequence similarity 133 member A","metadata":{"aliases":["RP1-32F7.2","FLJ37659","CT115"]}},{"id":"500160a21f934ffcb2a056fc43acc208","type":"GENE","name":"FAM133B","canonical_id":"hgnc:HGNC:28629","description":"family with sequence similarity 133 member B","metadata":{"aliases":["MGC40405"]}},{"id":"28630171d423421989ce7a6f508dc755","type":"GENE","name":"FAM133CP","canonical_id":"hgnc:HGNC:44190","description":"family with sequence similarity 133 member C, pseudogene","metadata":null},{"id":"f506dff854734914962fa2909cb1d2b5","type":"GENE","name":"FAM133DP","canonical_id":"hgnc:HGNC:44192","description":"family with sequence similarity 133 member D, pseudogene","metadata":null},{"id":"b7a4fbdcd5ed4570968413ecda429f75","type":"GENE","name":"FAM133EP","canonical_id":"hgnc:HGNC:54729","description":"family with sequence similarity 133 member E, pseudogene","metadata":null},{"id":"fa69dd51f63644d2b998ba52dad78196","type":"GENE","name":"FAM133FP","canonical_id":"hgnc:HGNC:54730","description":"family with sequence similarity 133 member F, pseudogene","metadata":null},{"id":"c8d62114f5c248658765ad1ae8bb2c66","type":"GENE","name":"FAM133GP","canonical_id":"hgnc:HGNC:54731","description":"family with sequence similarity 133 member G, pseudogene","metadata":null},{"id":"a6be8bb279cc416493e3de983d124b4b","type":"GENE","name":"FAM133HP","canonical_id":"hgnc:HGNC:58679","description":"family with sequence similarity 133 member H, pseudogene","metadata":null},{"id":"9c5aa5c934144831a2de08772b22ec72","type":"GENE","name":"FAM135A","canonical_id":"hgnc:HGNC:21084","description":"family with sequence similarity 135 member A","metadata":{"aliases":["FLJ20176","KIAA1411"]}},{"id":"48804c7a10184dbe95f6bfe282cc9097","type":"GENE","name":"FAM135A-AS1","canonical_id":"hgnc:HGNC:40955","description":"FAM135A antisense RNA 1","metadata":null},{"id":"fda1c2509c3645d492f0bdca3e24452f","type":"GENE","name":"FAM135B","canonical_id":"hgnc:HGNC:28029","description":"family with sequence similarity 135 member B","metadata":{"aliases":["C8ORFK32"]}},{"id":"c19e7ed14f2146c4b5cea0fc1967b8c7","type":"GENE","name":"FAM138A","canonical_id":"hgnc:HGNC:32334","description":"family with sequence similarity 138 member A","metadata":{"aliases":["F379"]}},{"id":"8e67fb9fd2614e519e84c342afae2d03","type":"GENE","name":"FAM138B","canonical_id":"hgnc:HGNC:33582","description":"family with sequence similarity 138 member B","metadata":{"aliases":["F379"]}},{"id":"bf640ae5fb9d446dba44a432f9b1ef26","type":"GENE","name":"FAM138C","canonical_id":"hgnc:HGNC:32333","description":"family with sequence similarity 138 member C","metadata":{"aliases":["F379"]}},{"id":"4a5d44dbe7234063beb5e61cca7e50c3","type":"GENE","name":"FAM138D","canonical_id":"hgnc:HGNC:33583","description":"family with sequence similarity 138 member D","metadata":{"aliases":["F379"]}},{"id":"3827e27e9aca4c29a91d6b7e2e18daa6","type":"GENE","name":"FAM138E","canonical_id":"hgnc:HGNC:32335","description":"family with sequence similarity 138 member E","metadata":{"aliases":["F379"]}},{"id":"6f9e7cc62c164caa86fba21e768de74d","type":"GENE","name":"FAM138F","canonical_id":"hgnc:HGNC:33581","description":"family with sequence similarity 138 member F","metadata":{"aliases":["F379"]}},{"id":"12d7e3246a3745ce9a7d26a5956cbc2e","type":"GENE","name":"FAM13A","canonical_id":"hgnc:HGNC:19367","description":"family with sequence similarity 13 member A","metadata":{"aliases":["KIAA0914","ARHGAP48","FAM13A1"]}},{"id":"bafc5fa35dae4dcca79fc9b68c7652bf","type":"GENE","name":"FAM13A-AS1","canonical_id":"hgnc:HGNC:19370","description":"FAM13A antisense RNA 1","metadata":{"aliases":["NCRNA00039","FAM13A1OS","FAM13AOS"]}},{"id":"4a25f68e3fa745b1ac8fe05949e38c66","type":"GENE","name":"FAM13B","canonical_id":"hgnc:HGNC:1335","description":"family with sequence similarity 13 member B","metadata":{"aliases":["N61","KHCHP","ARHGAP49","C5orf5","FAM13B1"]}},{"id":"a1f3addebe7e40458c87193ee4adab74","type":"GENE","name":"FAM13B-AS1","canonical_id":"hgnc:HGNC:55597","description":"FAM13B antisense RNA 1","metadata":null},{"id":"d593e1c77fa8493291843bdb0932b761","type":"GENE","name":"FAM13C","canonical_id":"hgnc:HGNC:19371","description":"family with sequence similarity 13 member C","metadata":{"aliases":["FAM13C1"]}},{"id":"823f9a31e9914fbfbade6c60e63f0115","type":"GENE","name":"FAM149A","canonical_id":"hgnc:HGNC:24527","description":"family with sequence similarity 149 member A","metadata":{"aliases":["DKFZP564J102","MST119","MSTP119"]}},{"id":"3e077c5ef1ee460d85a4227f505b8845","type":"GENE","name":"FAM149B1","canonical_id":"hgnc:HGNC:29162","description":"family with sequence similarity 149 member B1","metadata":{"aliases":["KIAA0974"]}},{"id":"13c4f53ab634458ca5ddfc0fd225023c","type":"GENE","name":"FAM149B1P1","canonical_id":"hgnc:HGNC:31735","description":"family with sequence similarity 149 member B1 pseudogene 1","metadata":{"aliases":["KIAA0974P","FAM149B2"]}},{"id":"b27acb8e4f7542f3ac1aa3670b6a0a79","type":"GENE","name":"FAM149C","canonical_id":"hgnc:HGNC:25320","description":"family with sequence similarity 149 member C","metadata":{"aliases":["DKFZP434N1817","C3orf20","FAM194C"]}},{"id":"c03934fdc2af4773ab636084afe15bae","type":"GENE","name":"FAM149DP","canonical_id":"hgnc:HGNC:55195","description":"family with sequence similarity 149 member D, pseudogene","metadata":{"aliases":["ENSG00000257943"]}},{"id":"d0cb0319b2a1453cabe5390feed3c622","type":"GENE","name":"FAM151A","canonical_id":"hgnc:HGNC:25032","description":"family with sequence similarity 151 member A","metadata":{"aliases":["MGC27169","C1orf179"]}},{"id":"62538913d815406880f8ecc6cdb303e8","type":"GENE","name":"FAM151AP1","canonical_id":"hgnc:HGNC:56626","description":"FAM151A pseudogene 1","metadata":null},{"id":"92379e09b31940abb90ed6a8245f29b4","type":"GENE","name":"FAM151B","canonical_id":"hgnc:HGNC:33716","description":"family with sequence similarity 151 member B","metadata":{"aliases":["UNQ9217"]}},{"id":"60c3fc7c6c3f425fa04ac8830bd9b732","type":"GENE","name":"FAM151B-DT","canonical_id":"hgnc:HGNC:55578","description":"FAM151B divergent transcript","metadata":{"aliases":["SLC7A11AR"]}},{"id":"e4998ac350a445c0bcb280efbe523229","type":"GENE","name":"FAM153A","canonical_id":"hgnc:HGNC:29940","description":"family with sequence similarity 153 member A","metadata":{"aliases":["NY-REN-7"]}},{"id":"7d0e58bf549542f38ff9043be4789ab3","type":"GENE","name":"FAM153A-AS1","canonical_id":"hgnc:HGNC:59169","description":"FAM153A antisense RNA 1","metadata":null},{"id":"6cf9634330d746099b3363768c9b801b","type":"GENE","name":"FAM153A-AS2","canonical_id":"hgnc:HGNC:59313","description":"FAM153A antisense RNA 2","metadata":null},{"id":"e8f59262c3f3416f99f29788c0028f72","type":"GENE","name":"FAM153B","canonical_id":"hgnc:HGNC:27323","description":"family with sequence similarity 153 member B","metadata":null},{"id":"fb934994a7f244d6a8e9ba2ea230ed65","type":"GENE","name":"FAM153CP","canonical_id":"hgnc:HGNC:33936","description":"family with sequence similarity 153 member C, pseudogene","metadata":{"aliases":["NY-REN-7-like","FAM153C"]}},{"id":"f3d01858965d45629a37864bee45a62b","type":"GENE","name":"FAM153DP","canonical_id":"hgnc:HGNC:55022","description":"family with sequence similarity 153 member D, pseudogene","metadata":null},{"id":"f0d12b0278124a52aa7a2de9cc9ef091","type":"GENE","name":"FAM156A","canonical_id":"hgnc:HGNC:30114","description":"family with sequence similarity 156 member A","metadata":{"aliases":["PRO0659","TMEM29"]}},{"id":"9e5793632c7c4168b38e031df950704e","type":"GENE","name":"FAM156B","canonical_id":"hgnc:HGNC:31962","description":"family with sequence similarity 156 member B","metadata":{"aliases":["TMEM29B"]}},{"id":"6de9aa3f0f3647f78ee61d7cc2515a21","type":"GENE","name":"FAM157A","canonical_id":"hgnc:HGNC:34079","description":"family with sequence similarity 157 member A","metadata":{"aliases":["GTF2IP18"]}},{"id":"e8d36253c27242c9be267d21f7e994a9","type":"GENE","name":"FAM157B","canonical_id":"hgnc:HGNC:34080","description":"family with sequence similarity 157 member B","metadata":null},{"id":"65e03dac904f4ecfbe627acc9fc4daaf","type":"GENE","name":"FAM157C","canonical_id":"hgnc:HGNC:34081","description":"family with sequence similarity 157 member C","metadata":{"aliases":["LINC02193"]}},{"id":"23eb3f8d23e64286afbce09d58fae68b","type":"GENE","name":"FAM157D","canonical_id":"hgnc:HGNC:56252","description":"family with sequence similarity 157 member D","metadata":null},{"id":"f21cadd2318d45ba9fac07300764b36b","type":"GENE","name":"FAM161A","canonical_id":"hgnc:HGNC:25808","description":"FAM161 centrosomal protein A","metadata":{"aliases":["FLJ13305","RP28"]}},{"id":"d4387213ef8b427dace76142269ed8e3","type":"GENE","name":"FAM161B","canonical_id":"hgnc:HGNC:19854","description":"FAM161 centrosomal protein B","metadata":{"aliases":["FLJ31697","C14orf44"]}},{"id":"0a156e8d453242d1ac5886d3a0560267","type":"GENE","name":"FAM162A","canonical_id":"hgnc:HGNC:17865","description":null,"metadata":null},{"id":"841baf7477ab4f72bb05ebf87090349c","type":"GENE","name":"FAM162B","canonical_id":"hgnc:HGNC:21549","description":"family with sequence similarity 162 member B","metadata":{"aliases":["bA86F4.2","C6orf189"]}},{"id":"ac3674768f7a4d48b870e6ec5d9eb364","type":"GENE","name":"FAM163A","canonical_id":"hgnc:HGNC:28274","description":"family with sequence similarity 163 member A","metadata":{"aliases":["MGC16664","NDSP","C1orf76"]}},{"id":"c28077c05bbf4fe7afe181c6279d5da1","type":"GENE","name":"FAM163B","canonical_id":"hgnc:HGNC:33277","description":"family with sequence similarity 163 member B","metadata":{"aliases":["C9orf166"]}},{"id":"c5897fecff0d4bc589f52e313ce24aaa","type":"GENE","name":"FAM167A","canonical_id":"hgnc:HGNC:15549","description":"family with sequence similarity 167 member A","metadata":{"aliases":["DIORA-1","C8orf13"]}},{"id":"775756c840954964b5db7a18a72da8bb","type":"GENE","name":"FAM167A-AS1","canonical_id":"hgnc:HGNC:15548","description":"FAM167A antisense RNA 1","metadata":{"aliases":["C8orf12"]}},{"id":"a3c6b11af2f44687aebada09ab177b26","type":"GENE","name":"FAM167B","canonical_id":"hgnc:HGNC:28133","description":"family with sequence similarity 167 member B","metadata":{"aliases":["MGC10820","DIORA-2","C1orf90"]}},{"id":"53a7ce07109b40819aca380a9d68a644","type":"GENE","name":"FAM168A","canonical_id":"hgnc:HGNC:28999","description":"family with sequence similarity 168 member A","metadata":{"aliases":["TCRP1","KIAA0280"]}},{"id":"19f97de064e0405b89c1f0dabd0e30b6","type":"GENE","name":"FAM168A-AS1","canonical_id":"hgnc:HGNC:58441","description":"FAM168A antisense RNA 1","metadata":null},{"id":"7c19ea9c9b6b4348b29ae91808895c7e","type":"GENE","name":"FAM168B","canonical_id":"hgnc:HGNC:27016","description":"family with sequence similarity 168 member B","metadata":{"aliases":["KIAA0280L","MANI"]}},{"id":"1378495bed2e4efca1db21c6ff8e1521","type":"GENE","name":"FAM169A","canonical_id":"hgnc:HGNC:29138","description":"family with sequence similarity 169 member A","metadata":{"aliases":["KIAA0888","SLAP75","SLAP"]}},{"id":"81d967e73ef0497fa09af5ff8f50619d","type":"GENE","name":"FAM169A-AS1","canonical_id":"hgnc:HGNC:56226","description":"FAM169A antisense RNA 1","metadata":{"aliases":["TP53LC02"]}},{"id":"b6f59a4dd0d041ffba14b79cb1e6253c","type":"GENE","name":"FAM169BP","canonical_id":"hgnc:HGNC:26835","description":"family with sequence similarity 169 member B, pseudogene","metadata":{"aliases":["FLJ39743","KIAA0888L","FAM169B"]}},{"id":"77e0367c90e9401083100131daaa1219","type":"GENE","name":"FAM170A","canonical_id":"hgnc:HGNC:27963","description":"family with sequence similarity 170 member A","metadata":{"aliases":["ZNFD"]}},{"id":"a8c1eaecd1834db197388b0088fb87e5","type":"GENE","name":"FAM170B","canonical_id":"hgnc:HGNC:19736","description":"family with sequence similarity 170 member B","metadata":{"aliases":["AC084727.4","C10orf73"]}},{"id":"98fe95ccb1fb40b99196c83ac7015a2d","type":"GENE","name":"FAM170B-AS1","canonical_id":"hgnc:HGNC:45006","description":"FAM170B antisense RNA 1","metadata":null},{"id":"e6cd134f69f34269b96f1f68d95c9208","type":"GENE","name":"FAM171A1","canonical_id":"hgnc:HGNC:23522","description":"family with sequence similarity 171 member A1","metadata":{"aliases":["FLJ12884","APCN","C10orf38"]}},{"id":"9526fde79ca041f7affaf46d03ab56fb","type":"GENE","name":"FAM171A1-AS1","canonical_id":"hgnc:HGNC:58382","description":"FAM171A1 antisense RNA 1","metadata":null},{"id":"54f922324a774abc91f990ef1770eda4","type":"GENE","name":"FAM171A2","canonical_id":"hgnc:HGNC:30480","description":"family with sequence similarity 171 member A2","metadata":{"aliases":["MGC34829"]}},{"id":"6f9934468f864ce682debbf7b40c2b6a","type":"GENE","name":"FAM171B","canonical_id":"hgnc:HGNC:29412","description":"family with sequence similarity 171 member B","metadata":{"aliases":["FLJ34104","KIAA1946"]}},{"id":"9c0ff6f2d5f64cc29a7e2e5a282216ee","type":"GENE","name":"FAM171B-AS1","canonical_id":"hgnc:HGNC:41242","description":"FAM171B and ITGAV antisense RNA 1","metadata":null},{"id":"8ebb4c4cf97f41ccb51d9f2d228c5082","type":"GENE","name":"FAM174A","canonical_id":"hgnc:HGNC:24943","description":"family with sequence similarity 174 member A","metadata":{"aliases":["UNQ1912","NS5ATP6","TMEM157"]}},{"id":"168c322447424c78bc6353accd1747e7","type":"GENE","name":"FAM174A-DT","canonical_id":"hgnc:HGNC:55584","description":"FAM174A divergent transcript","metadata":null},{"id":"0e64c745610549959b0e864dcb633a60","type":"GENE","name":"FAM174B","canonical_id":"hgnc:HGNC:34339","description":"family with sequence similarity 174 member B","metadata":{"aliases":["LOC400451","MGC102891"]}},{"id":"4d0069d793154cdab31da5b9f28d9142","type":"GENE","name":"FAM174C","canonical_id":"hgnc:HGNC:26073","description":"family with sequence similarity 174 member C","metadata":{"aliases":["FLJ20640","C19orf24"]}},{"id":"6f65b02aace345479258e494d8ce99be","type":"GENE","name":"FAM177A1","canonical_id":"hgnc:HGNC:19829","description":"family with sequence similarity 177 member A1","metadata":{"aliases":["C14orf24"]}},{"id":"c5ff17f7124b478c806dba1d01228be3","type":"GENE","name":"FAM177A1P1","canonical_id":"hgnc:HGNC:34441","description":"family with sequence similarity 177 member A1 pseudogene 1","metadata":{"aliases":["FAM177A2"]}},{"id":"d94f7850bbe044bba450b6a37f24607e","type":"GENE","name":"FAM177B","canonical_id":"hgnc:HGNC:34395","description":"family with sequence similarity 177 member B","metadata":{"aliases":["RP11-452F19.2","FLJ43505"]}},{"id":"312796f67d614698a127d2b118c2d148","type":"GENE","name":"FAM178B","canonical_id":"hgnc:HGNC:28036","description":"family with sequence similarity 178 member B","metadata":{"aliases":["LOC51252"]}},{"id":"0fb8caeb8c4d4948ba7a1f8fc1515b66","type":"GENE","name":"FAM180A","canonical_id":"hgnc:HGNC:33773","description":"family with sequence similarity 180 member A","metadata":{"aliases":["HWKM1940","UNQ1940"]}},{"id":"8ef3cc16571245cc8a3165132fff982c","type":"GENE","name":"FAM180B","canonical_id":"hgnc:HGNC:34451","description":"family with sequence similarity 180 member B","metadata":{"aliases":["LOC399888"]}},{"id":"e00b26481eb041f59d4ab4e7429ec1c5","type":"GENE","name":"FAM181A","canonical_id":"hgnc:HGNC:20491","description":"family with sequence similarity 181 member A","metadata":{"aliases":["C14orf152"]}},{"id":"5bc2dfb12031468a9e623c2c730a4204","type":"GENE","name":"FAM181A-AS1","canonical_id":"hgnc:HGNC:20133","description":"FAM181A antisense RNA 1","metadata":{"aliases":["C14orf86"]}},{"id":"096cd569ca85473ba33dc45172bd573b","type":"GENE","name":"FAM181B","canonical_id":"hgnc:HGNC:28512","description":"family with sequence similarity 181 member B","metadata":{"aliases":["LOC220382","MGC33846"]}},{"id":"4202368354f04238857c893ccb3aa9aa","type":"GENE","name":"FAM182A","canonical_id":"hgnc:HGNC:16222","description":"family with sequence similarity 182 member A","metadata":{"aliases":["bB329D4.1","C20orf91A","C20orf91"]}},{"id":"985611d25cd44de689d06767c72e0c5b","type":"GENE","name":"FAM182B","canonical_id":"hgnc:HGNC:34503","description":"family with sequence similarity 182 member B","metadata":null},{"id":"28862d1f1d1c4ad5975c389588ad68b7","type":"GENE","name":"FAM184A","canonical_id":"hgnc:HGNC:20991","description":"family with sequence similarity 184 member A","metadata":{"aliases":["FLJ13942","C6orf60"]}},{"id":"9ee3e0b61ad44798b25832df8f6dd7ce","type":"GENE","name":"FAM184B","canonical_id":"hgnc:HGNC:29235","description":"family with sequence similarity 184 member B","metadata":{"aliases":["KIAA1276"]}},{"id":"85b020fbfb864ac99ffe8041d7f265ad","type":"GENE","name":"FAM185A","canonical_id":"hgnc:HGNC:22412","description":"family with sequence similarity 185 member A","metadata":{"aliases":["MGC35361"]}},{"id":"d4a66efb81f44a4f9e52c4ed1cde3c9e","type":"GENE","name":"FAM185BP","canonical_id":"hgnc:HGNC:21813","description":"family with sequence similarity 185 member B, pseudogene","metadata":{"aliases":["FAM185B"]}},{"id":"8c5aa7a6e4054f279130a0185d282336","type":"GENE","name":"FAM186A","canonical_id":"hgnc:HGNC:26980","description":"family with sequence similarity 186 member A","metadata":{"aliases":["LOC121006"]}},{"id":"e417980c19944d58adfead1d989edbc9","type":"GENE","name":"FAM186B","canonical_id":"hgnc:HGNC:25296","description":"family with sequence similarity 186 member B","metadata":{"aliases":["DKFZP434J0113","C12orf25"]}},{"id":"07017467e31b4a1984ee463aa3b9b02f","type":"GENE","name":"FAM187A","canonical_id":"hgnc:HGNC:35153","description":"family with sequence similarity 187 member A","metadata":null},{"id":"f5bf9de242f74ae9ae3db93a6afe4ba2","type":"GENE","name":"FAM187B","canonical_id":"hgnc:HGNC:26366","description":"family with sequence similarity 187 member B","metadata":{"aliases":["FLJ25660","TMEM162"]}},{"id":"e997658662844c4c8ab2a45bba115cf4","type":"GENE","name":"FAM187B2P","canonical_id":"hgnc:HGNC:49213","description":"family with sequence similarity 187 member B2, pseudogene","metadata":null},{"id":"4efeb53d503043f49857341e42a6f7f5","type":"GENE","name":"FAM193A","canonical_id":"hgnc:HGNC:16822","description":"family with sequence similarity 193 member A","metadata":{"aliases":["RES4-22","C4orf8"]}},{"id":"5efcf4e8fcac4ee1b202f579c18b87e1","type":"GENE","name":"FAM193B","canonical_id":"hgnc:HGNC:25524","description":"family with sequence similarity 193 member B","metadata":{"aliases":["KIAA1931","FLJ10404","IRIZIO"]}},{"id":"cecc714f9f0043ef931a6cacf64acd09","type":"GENE","name":"FAM193B-DT","canonical_id":"hgnc:HGNC:55212","description":"FAM193B divergent transcript","metadata":null},{"id":"eb536b392db04ccfaed0e083db92c49a","type":"GENE","name":"FAM197Y2","canonical_id":"hgnc:HGNC:18848","description":"family with sequence similarity 197 Y-linked member 2","metadata":{"aliases":["CYorf16","FAM197Y2P"]}},{"id":"98412831b24e4317824fbe362ed531c6","type":"GENE","name":"FAM197Y3","canonical_id":"hgnc:HGNC:37465","description":"family with sequence similarity 197 Y-linked member 3","metadata":null},{"id":"f4b00f79eaa24e6c91096464ba540673","type":"GENE","name":"FAM197Y4","canonical_id":"hgnc:HGNC:37466","description":"family with sequence similarity 197 Y-linked member 4","metadata":{"aliases":["FAM197Y4P"]}},{"id":"cd33b1fb6b8842768548633b59f0ed28","type":"GENE","name":"FAM197Y5","canonical_id":"hgnc:HGNC:37467","description":"family with sequence similarity 197 Y-linked member 5","metadata":{"aliases":["FAM197Y5P"]}},{"id":"563484c3cde34d2faebc3e045c59e938","type":"GENE","name":"FAM197Y6","canonical_id":"hgnc:HGNC:37468","description":"family with sequence similarity 197 Y-linked member 6","metadata":null},{"id":"f8cd5baf69eb447ebff7cb4dd324aed0","type":"GENE","name":"FAM197Y7","canonical_id":"hgnc:HGNC:37469","description":"family with sequence similarity 197 Y-linked member 7","metadata":{"aliases":["FAM197Y7P"]}},{"id":"d92571e9201a4f4eb567159ce204ae8e","type":"GENE","name":"FAM197Y8","canonical_id":"hgnc:HGNC:37470","description":"family with sequence similarity 197 Y-linked member 8","metadata":null},{"id":"202e8061d6124b48b64f47fab5067aa8","type":"GENE","name":"FAM197Y9","canonical_id":"hgnc:HGNC:37477","description":"family with sequence similarity 197 Y-linked member 9","metadata":null},{"id":"ca0980e5c99b4a9c9cfa02eab87e0750","type":"GENE","name":"FAM199X","canonical_id":"hgnc:HGNC:25195","description":"family with sequence similarity 199, X-linked","metadata":{"aliases":["CXorf39"]}},{"id":"058422e647b04483b75796960ca0257f","type":"GENE","name":"FAM199YP","canonical_id":"hgnc:HGNC:23951","description":"family with sequence similarity 199, Y-linked, pseudogene","metadata":{"aliases":["FAM199Y"]}},{"id":"25a251c71175436c80aa8078af6eeb54","type":"GENE","name":"FAM201A","canonical_id":"hgnc:HGNC:27239","description":"family with sequence similarity 201 member A","metadata":{"aliases":["C9orf122"]}},{"id":"b51eccf0335842068e37ce7f88d42ea9","type":"GENE","name":"FAM201B","canonical_id":"hgnc:HGNC:27933","description":"family with sequence similarity 201 member B","metadata":null},{"id":"9f1e5fe9853147bca44544647e6a21c6","type":"GENE","name":"FAM204A","canonical_id":"hgnc:HGNC:25794","description":"family with sequence similarity 204 member A","metadata":{"aliases":["FLJ13188","bA319I23.1","C10orf84"]}},{"id":"a572ca4ad5194660aeed7cefda68504f","type":"GENE","name":"FAM204BP","canonical_id":"hgnc:HGNC:42011","description":"family with sequence similarity 204 member B, pseudogene","metadata":null},{"id":"88a43d5f7ec54d2cbd07bb8e73fc67c1","type":"GENE","name":"FAM204CP","canonical_id":"hgnc:HGNC:42012","description":"family with sequence similarity 204 member C, pseudogene","metadata":null},{"id":"e0c44872682d482ebf5f2d68434e94b3","type":"GENE","name":"FAM204DP","canonical_id":"hgnc:HGNC:42013","description":"family with sequence similarity 204 member D, pseudogene","metadata":null},{"id":"0536bb2f30754745962209ba0b948208","type":"GENE","name":"FAM209A","canonical_id":"hgnc:HGNC:16100","description":"family with sequence similarity 209 member A","metadata":{"aliases":["dJ1153D9.3","C20orf106"]}},{"id":"d822fdf4555d48778e39dc3275d6f0eb","type":"GENE","name":"FAM209B","canonical_id":"hgnc:HGNC:16101","description":"family with sequence similarity 209 member B","metadata":{"aliases":["dJ1153D9.4","C20orf107"]}},{"id":"51b71bf7357743b2a5668923ebeaeb1b","type":"GENE","name":"FAM20A","canonical_id":"hgnc:HGNC:23015","description":"FAM20A golgi associated secretory pathway pseudokinase","metadata":{"aliases":["DKFZp434F2322"]}},{"id":"58f6f146bb1d4acd9091c06d5b65e590","type":"GENE","name":"FAM20B","canonical_id":"hgnc:HGNC:23017","description":"FAM20B glycosaminoglycan xylosylkinase","metadata":{"aliases":["KIAA0475","GXK1"]}},{"id":"26b89f753c374085a799780ffc76f02c","type":"GENE","name":"FAM20BP1","canonical_id":"hgnc:HGNC:56575","description":"FAM20B pseudogene 1","metadata":null},{"id":"ea2a7aac2a36422792b2f85332a65b1d","type":"GENE","name":"FAM20C","canonical_id":"hgnc:HGNC:22140","description":"FAM20C golgi associated secretory pathway kinase","metadata":{"aliases":["IMAGE:4942737","DKFZp547D065","DMP4","G-CK"]}},{"id":"af48b2748e9e474189d176439edfc1d5","type":"GENE","name":"FAM215A","canonical_id":"hgnc:HGNC:17505","description":"family with sequence similarity 215 member A","metadata":{"aliases":["APR-2","LINC00530","C17orf88"]}},{"id":"f6e77e185e754c3a812d977f99efab9c","type":"GENE","name":"FAM215B","canonical_id":"hgnc:HGNC:43639","description":"family with sequence similarity 215 member B","metadata":{"aliases":["ARL17A-IT1"]}},{"id":"0d0a6261e6cd4d2b9b77489e1323c2c9","type":"GENE","name":"FAM216A","canonical_id":"hgnc:HGNC:30180","description":"family with sequence similarity 216 member A","metadata":{"aliases":["HSU79274","C12orf24"]}},{"id":"5488827180124a09adc7b6b357b22a3c","type":"GENE","name":"FAM216B","canonical_id":"hgnc:HGNC:26883","description":"family with sequence similarity 216 member B","metadata":{"aliases":["FLJ40919","C13orf30"]}},{"id":"265a8907e68f4cedad19f8e288175f16","type":"GENE","name":"FAM217A","canonical_id":"hgnc:HGNC:21362","description":"family with sequence similarity 217 member A","metadata":{"aliases":["MGC43581","C6orf146"]}},{"id":"1a53c13d2e034ce181f7c6341ade4604","type":"GENE","name":"FAM217AP1","canonical_id":"hgnc:HGNC:49613","description":"family with sequence similarity 217 member A pseudogene 1","metadata":null},{"id":"716f4c4bb7864accac9ee18bb8a933f8","type":"GENE","name":"FAM217B","canonical_id":"hgnc:HGNC:16170","description":"family with sequence similarity 217 member B","metadata":{"aliases":["dJ551D2.5","C20orf177"]}},{"id":"f7b64054b33e40d08356226774aea7f6","type":"GENE","name":"FAM218A","canonical_id":"hgnc:HGNC:26466","description":"family with sequence similarity 218 member A","metadata":{"aliases":["FLJ31659","TRIM61-AS1","C4orf39"]}},{"id":"6811cec287db4c088c84e07833a13428","type":"GENE","name":"FAM218BP","canonical_id":"hgnc:HGNC:43779","description":"family with sequence similarity 218 member B, pseudogene","metadata":null},{"id":"b605f176b23f4c749042710ae1e9a137","type":"GENE","name":"FAM219A","canonical_id":"hgnc:HGNC:19920","description":"family with sequence similarity 219 member A","metadata":{"aliases":["bA573M23.5","FLJ39031","C9orf25"]}},{"id":"c16a7b4ec7c848259f92b3cbc7fac64e","type":"GENE","name":"FAM219B","canonical_id":"hgnc:HGNC:24695","description":"family with sequence similarity 219 member B","metadata":{"aliases":["FLJ00005","C15orf17"]}},{"id":"9f5f173e7eb44f7f90022175b32f2768","type":"GENE","name":"FAM220A","canonical_id":"hgnc:HGNC:22422","description":"family with sequence similarity 220 member A","metadata":{"aliases":["SIPAR","MGC12966","ACPIN1","C7orf70"]}},{"id":"d5ab16f443ec4b10ab215908b3ba7974","type":"GENE","name":"FAM220BP","canonical_id":"hgnc:HGNC:23678","description":"family with sequence similarity 220 member B, pseudogene","metadata":{"aliases":["bA392E22.4","C9orf51"]}},{"id":"e334ae54e8b840bbb9c27977b5b6cfe4","type":"GENE","name":"FAM220CP","canonical_id":"hgnc:HGNC:43640","description":"family with sequence similarity 220 member C, pseudogene","metadata":null},{"id":"180cf3cafabf47c09667dc2a006a4bd7","type":"GENE","name":"FAM221A","canonical_id":"hgnc:HGNC:27977","description":"family with sequence similarity 221 member A","metadata":{"aliases":["FLJ45875","MGC72075","DKFZp686F0810","C7orf46"]}},{"id":"ca0cd546b99340179c670125d81c51be","type":"GENE","name":"FAM221B","canonical_id":"hgnc:HGNC:30762","description":"family with sequence similarity 221 member B","metadata":{"aliases":["C9orf128"]}},{"id":"2261c90916ab4da98d7ab7b099e11c6d","type":"GENE","name":"FAM222A","canonical_id":"hgnc:HGNC:25915","description":"family with sequence similarity 222 member A","metadata":{"aliases":["FLJ14721","C12orf34"]}},{"id":"aa67f08dccba4a5997f0190673505434","type":"GENE","name":"FAM222A-AS1","canonical_id":"hgnc:HGNC:28223","description":"FAM222A antisense RNA 1","metadata":null},{"id":"40509b0cda2b49ae93641c2e3616b506","type":"GENE","name":"FAM222B","canonical_id":"hgnc:HGNC:25563","description":"family with sequence similarity 222 member B","metadata":{"aliases":["FLJ10700","C17orf63"]}},{"id":"13d82988241a46c0b0f07dc3f0695d6e","type":"GENE","name":"FAM223A","canonical_id":"hgnc:HGNC:30612","description":"family with sequence similarity 223 member A","metadata":{"aliases":["SPCX","CXorf52","NCRNA00204","NCRNA00204A","LINC00204A"]}},{"id":"5887450a44284b0ba3f4e4a26097dc67","type":"GENE","name":"FAM223B","canonical_id":"hgnc:HGNC:34048","description":"family with sequence similarity 223 member B","metadata":{"aliases":["CXorf52B","NCRNA00204B","LINC00204B"]}},{"id":"8d0b3c3f603149dd9936b91a6ad30c80","type":"GENE","name":"FAM224A","canonical_id":"hgnc:HGNC:37736","description":"family with sequence similarity 224 member A","metadata":{"aliases":["NCRNA00230A","LINC00230A"]}},{"id":"b42380576f1441208c5791cf89bf2038","type":"GENE","name":"FAM224B","canonical_id":"hgnc:HGNC:37737","description":"family with sequence similarity 224 member B","metadata":{"aliases":["NCRNA00230B","LINC00230B"]}},{"id":"3398a0bce1ed430d87672989bbe51aa8","type":"GENE","name":"FAM225A","canonical_id":"hgnc:HGNC:27855","description":"family with sequence similarity 225 member A","metadata":{"aliases":["DKFZp686A0127","C9orf109","NCRNA00256A","LINC00256A"]}},{"id":"528c640573014d5189344eb95e841aed","type":"GENE","name":"FAM225B","canonical_id":"hgnc:HGNC:21865","description":"family with sequence similarity 225 member B","metadata":{"aliases":["C9orf110","NCRNA00256B","LINC00256B"]}},{"id":"2e7c3fd800764ec6b3eb669b0bbb78c1","type":"GENE","name":"FAM226A","canonical_id":"hgnc:HGNC:28544","description":"family with sequence similarity 226 member A","metadata":{"aliases":["MGC34827","CXorf50","NCRNA00246","NCRNA00246A","LINC00246A"]}},{"id":"ed83bbb320c44030b0c89ac8efb28270","type":"GENE","name":"FAM226B","canonical_id":"hgnc:HGNC:31964","description":"family with sequence similarity 226 member B","metadata":{"aliases":["CXorf50B","NCRNA00246B","LINC00246B"]}},{"id":"765ac4a74ec5474896e08e23793239be","type":"GENE","name":"FAM227A","canonical_id":"hgnc:HGNC:44197","description":"family with sequence similarity 227 member A","metadata":null},{"id":"fe462e33407546118104c7b77aa96401","type":"GENE","name":"FAM227B","canonical_id":"hgnc:HGNC:26543","description":"family with sequence similarity 227 member B","metadata":{"aliases":["FLJ32800","C15orf33"]}},{"id":"1c8d2669d3524153895baec1d5c98328","type":"GENE","name":"FAM228A","canonical_id":"hgnc:HGNC:34418","description":"family with sequence similarity 228 member A","metadata":{"aliases":["FLJ30851","C2orf84"]}},{"id":"3b5a1c5fd7a94573810e417437a36e21","type":"GENE","name":"FAM228B","canonical_id":"hgnc:HGNC:24736","description":"family with sequence similarity 228 member B","metadata":null},{"id":"7fc3bf7a5c0c47ca88e99f75fc802876","type":"GENE","name":"FAM229A","canonical_id":"hgnc:HGNC:44652","description":"family with sequence similarity 229 member A","metadata":null},{"id":"5a64216c3a4a47089b4796a96788a36b","type":"GENE","name":"FAM229B","canonical_id":"hgnc:HGNC:33858","description":"family with sequence similarity 229 member B","metadata":{"aliases":["DKFZp586F0922","LOC619208","C6orf225"]}},{"id":"5825a7e96e6f4ae8a7ca646e07bf831b","type":"GENE","name":"FAM230A","canonical_id":"hgnc:HGNC:45045","description":"family with sequence similarity 230 member A","metadata":{"aliases":["DGCR15"]}},{"id":"b3d8cdac39a64e1f9f5874907030f574","type":"GENE","name":"FAM230B","canonical_id":"hgnc:HGNC:32943","description":"family with sequence similarity 230 member B","metadata":{"aliases":["FLJ46366"]}},{"id":"33d3e44eba62440fbf2acf3d53965ff5","type":"GENE","name":"FAM230C","canonical_id":"hgnc:HGNC:24482","description":"family with sequence similarity 230 member C","metadata":{"aliases":["DKFZP434B061","NCRNA00281","LINC00281"]}},{"id":"28f80b4988a84323935c2f2e0cbf744d","type":"GENE","name":"FAM230D","canonical_id":"hgnc:HGNC:53910","description":"family with sequence similarity 230 member D","metadata":{"aliases":["AC008079.1","LINC02592"]}},{"id":"e4e947f34ca34f45ad61b0d3c6bdb31a","type":"GENE","name":"FAM230E","canonical_id":"hgnc:HGNC:52450","description":"family with sequence similarity 230 member E","metadata":{"aliases":["LINC01662"]}},{"id":"2e46de56577c4013a50e6f33301a5077","type":"GENE","name":"FAM230F","canonical_id":"hgnc:HGNC:52451","description":"family with sequence similarity 230 member F","metadata":{"aliases":["LINC01663"]}},{"id":"c348e93bcfae41218af7e2818b0a06ff","type":"GENE","name":"FAM230G","canonical_id":"hgnc:HGNC:52423","description":"family with sequence similarity 230 member G","metadata":{"aliases":["AC007731.1"]}},{"id":"58cbf0e123e04970b74351c8b70ff869","type":"GENE","name":"FAM230H","canonical_id":"hgnc:HGNC:53977","description":"family with sequence similarity 230 member H","metadata":{"aliases":["AP000552.1"]}},{"id":"e221d5c0da774225a975482b9c6c268c","type":"GENE","name":"FAM230I","canonical_id":"hgnc:HGNC:52446","description":"family with sequence similarity 230 member I","metadata":{"aliases":["LINC01658"]}},{"id":"b19f925bcc32487ab89086a46b3aa635","type":"GENE","name":"FAM230J","canonical_id":"hgnc:HGNC:52448","description":"family with sequence similarity 230 member J","metadata":{"aliases":["LINC01660"]}},{"id":"1163773f76784a53b6f9dc4d8aafa138","type":"GENE","name":"FAM234A","canonical_id":"hgnc:HGNC:14163","description":"family with sequence similarity 234 member A","metadata":{"aliases":["DKFZP761D0211","FLJ32603","C16orf9","ITFG3"]}},{"id":"66c13f2c755a49dd8e31ce77db6285f0","type":"GENE","name":"FAM234B","canonical_id":"hgnc:HGNC:29288","description":"family with sequence similarity 234 member B","metadata":{"aliases":["KIAA1467"]}},{"id":"e32e95d84c3d47d0a004c67d3e0eeba6","type":"GENE","name":"FAM236A","canonical_id":"hgnc:HGNC:44268","description":"family with sequence similarity 236 member A","metadata":{"aliases":["DMRTC1-AS1","LINC00684"]}},{"id":"4f933f133d64443591dc5c4374ccc39f","type":"GENE","name":"FAM236B","canonical_id":"hgnc:HGNC:52640","description":"family with sequence similarity 236 member B","metadata":null},{"id":"807c268ecf534929819a6c23b0ab3c05","type":"GENE","name":"FAM236C","canonical_id":"hgnc:HGNC:52641","description":"family with sequence similarity 236 member C","metadata":null},{"id":"d08e7f56ccf44548bad455edda783e52","type":"GENE","name":"FAM236D","canonical_id":"hgnc:HGNC:52642","description":"family with sequence similarity 236 member D","metadata":null},{"id":"d3bd0cc427e74ce3b410fe9daa272588","type":"GENE","name":"FAM237A","canonical_id":"hgnc:HGNC:52388","description":"family with sequence similarity 237 member A","metadata":{"aliases":["NPGL"]}},{"id":"281e664b614d46f9a6613ff5f475e050","type":"GENE","name":"FAM237B","canonical_id":"hgnc:HGNC:53217","description":"family with sequence similarity 237 member B","metadata":{"aliases":["NPGM"]}},{"id":"aef36717b8504b69b86fc7314cda833d","type":"GENE","name":"FAM238A","canonical_id":"hgnc:HGNC:17776","description":"family with sequence similarity 238 member A","metadata":{"aliases":["bA128B16.2","C10orf50","NCRNA00264","LINC00264"]}},{"id":"55dbacd3695140abb68cb030f5358608","type":"GENE","name":"FAM238B","canonical_id":"hgnc:HGNC:44917","description":"family with sequence similarity 238 member B","metadata":{"aliases":["LINC00202-2"]}},{"id":"7d8dcf702a65403a965a07ca74b6cf74","type":"GENE","name":"FAM238C","canonical_id":"hgnc:HGNC:24672","description":"family with sequence similarity 238 member C","metadata":{"aliases":["bB27G4.1","C10orf51","NCRNA00202","LINC00202","LINC00202-1"]}},{"id":"e6afc2e52ddc4fa99545cc79d8157d8b","type":"GENE","name":"FAM239C","canonical_id":"hgnc:HGNC:53416","description":"family with sequence similarity 239 member C","metadata":null},{"id":"7a73b69c92de456380c9c9b6ca8b89ba","type":"GENE","name":"FAM240A","canonical_id":"hgnc:HGNC:52390","description":"family with sequence similarity 240 member A","metadata":null},{"id":"6263a1c9628a4c85a08e22d53dc74339","type":"GENE","name":"FAM240B","canonical_id":"hgnc:HGNC:53430","description":"family with sequence similarity 240 member B","metadata":null},{"id":"191f20be0e014ccd85e9470d8dd25a9c","type":"GENE","name":"FAM240C","canonical_id":"hgnc:HGNC:54200","description":"family with sequence similarity 240 member C","metadata":null},{"id":"b204e9cc19e94bee876e6201e6333aea","type":"GENE","name":"FAM241A","canonical_id":"hgnc:HGNC:26813","description":"family with sequence similarity 241 member A","metadata":{"aliases":["FLJ39370","C4orf32"]}},{"id":"f8aaf11ba9f74e328349c68f7f614473","type":"GENE","name":"FAM241B","canonical_id":"hgnc:HGNC:23519","description":"family with sequence similarity 241 member B","metadata":{"aliases":["C10orf35"]}},{"id":"4e8863184b4947a1a6395ac976d027f7","type":"GENE","name":"FAM242A","canonical_id":"hgnc:HGNC:51597","description":"family with sequence similarity 242 member A","metadata":{"aliases":["TCONS_00028363","LINC01598"]}},{"id":"b89594969ee54495bc99bab30bc74c09","type":"GENE","name":"FAM242B","canonical_id":"hgnc:HGNC:53872","description":"family with sequence similarity 242 member B","metadata":null},{"id":"6c5987d3a13d4da9b87e469b835dc5b5","type":"GENE","name":"FAM242C","canonical_id":"hgnc:HGNC:53873","description":"family with sequence similarity 242 member C","metadata":null},{"id":"73b7a7db0f8c4184a846921802ed1d55","type":"GENE","name":"FAM242D","canonical_id":"hgnc:HGNC:53874","description":"family with sequence similarity 242 member D","metadata":null},{"id":"b8f3420d1fb741cdb72e7443ba4adf21","type":"GENE","name":"FAM242E","canonical_id":"hgnc:HGNC:53875","description":"family with sequence similarity 242 member E","metadata":null},{"id":"e50b0865d48b4b6ea4222945dd9df1ca","type":"GENE","name":"FAM242F","canonical_id":"hgnc:HGNC:53876","description":"family with sequence similarity 242 member F","metadata":null},{"id":"129432e09b4445b785da2fdc19e0265b","type":"GENE","name":"FAM245A","canonical_id":"hgnc:HGNC:45163","description":"family with sequence similarity 245 member A","metadata":{"aliases":["LINC00864"]}},{"id":"40feab40b7d14ecab94c4b7566aaff18","type":"GENE","name":"FAM245B","canonical_id":"hgnc:HGNC:54133","description":"family with sequence similarity 245 member B","metadata":null},{"id":"d4cab7b388ba4707994d967a3854b8c0","type":"GENE","name":"FAM246A","canonical_id":"hgnc:HGNC:54844","description":"family with sequence similarity 246 member A","metadata":null},{"id":"5977cb6763884150b21bfea65d6eb79c","type":"GENE","name":"FAM246B","canonical_id":"hgnc:HGNC:54843","description":"family with sequence similarity 246 member B","metadata":null},{"id":"1986730c477b4b44a4177c7e929b0602","type":"GENE","name":"FAM246C","canonical_id":"hgnc:HGNC:54842","description":"family with sequence similarity 246 member C (gene/pseudogene)","metadata":null},{"id":"a704ace7c02e42b59d7f678eab9e2dfc","type":"GENE","name":"FAM247A","canonical_id":"hgnc:HGNC:54926","description":"family with sequence similarity 247 member A","metadata":null},{"id":"f06eb638c552401b900d5fe5b0429241","type":"GENE","name":"FAM247B","canonical_id":"hgnc:HGNC:54927","description":"family with sequence similarity 247 member B","metadata":null},{"id":"9a01e160c69b47ec90082efc223746c2","type":"GENE","name":"FAM247C","canonical_id":"hgnc:HGNC:54928","description":"family with sequence similarity 247 member C","metadata":null},{"id":"83ea43dcda494853a4b70dd875de8b44","type":"GENE","name":"FAM247D","canonical_id":"hgnc:HGNC:54929","description":"family with sequence similarity 247 member D","metadata":null},{"id":"e6d72baf2fb54358b5746e8f878c5e40","type":"GENE","name":"FAM24A","canonical_id":"hgnc:HGNC:23470","description":"family with sequence similarity 24 member A","metadata":{"aliases":["AC073585.4"]}},{"id":"5f9f75c202d341c3b4a3ccb24e94a5b6","type":"GENE","name":"FAM24B","canonical_id":"hgnc:HGNC:23475","description":"family with sequence similarity 24 member B","metadata":{"aliases":["MGC45962","AC073585.2"]}},{"id":"c83ec0134fae4a70b2f5d74e9b595889","type":"GENE","name":"FAM25A","canonical_id":"hgnc:HGNC:23436","description":"family with sequence similarity 25 member A","metadata":{"aliases":["bA96C23.5"]}},{"id":"ff168c6a43304de3b6b4536937fc6ae3","type":"GENE","name":"FAM25BP","canonical_id":"hgnc:HGNC:23584","description":"family with sequence similarity 25 member B, pseudogene","metadata":{"aliases":["bA144G6.8","FAM25B"]}},{"id":"e98206466d58446d8337eb4c598b7690","type":"GENE","name":"FAM25C","canonical_id":"hgnc:HGNC:23586","description":"family with sequence similarity 25 member C","metadata":{"aliases":["bA164N7.4"]}},{"id":"bfe2d92515bb451aabb1aafa40d281a5","type":"GENE","name":"FAM25EP","canonical_id":"hgnc:HGNC:23587","description":"family with sequence similarity 25 member E, pseudogene","metadata":{"aliases":["AC012044.5","bA592B15.5","FAM25D","FAM25E"]}},{"id":"fdd9ac575b1742f092282c910d26e9d1","type":"GENE","name":"FAM25G","canonical_id":"hgnc:HGNC:23590","description":"family with sequence similarity 25 member G","metadata":{"aliases":["bA301J7.4"]}},{"id":"214143fd5543459fa4b94ddcd0fc5cf5","type":"GENE","name":"FAM27B","canonical_id":"hgnc:HGNC:23667","description":"family with sequence similarity 27 member B","metadata":{"aliases":["bA12A20.3","FAM27A2"]}},{"id":"dfd60a86a03d443aa29176e6d928e8ca","type":"GENE","name":"FAM27C","canonical_id":"hgnc:HGNC:23668","description":"family with sequence similarity 27 member C","metadata":{"aliases":["bA374M1.5","FAM27A3","bA7G23.5","FAM27A1","FAM27A"]}},{"id":"e757b3bea0b04191bda7c5e8a4516736","type":"GENE","name":"FAM27D1","canonical_id":"hgnc:HGNC:32015","description":"family with sequence similarity 27 member D1","metadata":{"aliases":["OTTHUMG00000013267"]}},{"id":"d670c5f8d6f94ff19faad136022399c2","type":"GENE","name":"FAM27E2","canonical_id":"hgnc:HGNC:32013","description":"family with sequence similarity 27 member E2","metadata":{"aliases":["FAM27E1"]}},{"id":"fd31f6427457457183e4cd2b51fa0ddc","type":"GENE","name":"FAM27E3","canonical_id":"hgnc:HGNC:28655","description":"family with sequence similarity 27 member E3","metadata":{"aliases":["MGC42630"]}},{"id":"4933cc086fc84f85870d49df8c640f27","type":"GENE","name":"FAM27E4","canonical_id":"hgnc:HGNC:44415","description":"family with sequence similarity 27 member E4","metadata":{"aliases":["FAM27E4P"]}},{"id":"279f3777e32b4796ab0c32c207fbcda5","type":"GENE","name":"FAM27E5","canonical_id":"hgnc:HGNC:32410","description":"family with sequence similarity E5","metadata":{"aliases":["MGC35151","FAM27L"]}},{"id":"294029d218c7483cb30eb44929d0e142","type":"GENE","name":"FAM30A","canonical_id":"hgnc:HGNC:19955","description":"family with sequence similarity 30 member A","metadata":{"aliases":["HSPC053","C14orf110","KIAA0125"]}},{"id":"45116959b0a94170ac6e4229a28c2582","type":"GENE","name":"FAM30B","canonical_id":"hgnc:HGNC:31023","description":"family with sequence similarity 30 member B","metadata":{"aliases":["HsT16028","KIAA0125P1"]}},{"id":"a0de3d3e3cd747a29792537f5e11d829","type":"GENE","name":"FAM30C","canonical_id":"hgnc:HGNC:31024","description":"family with sequence similarity 30 member C","metadata":{"aliases":["HsT16041","KIAA0125P2"]}},{"id":"c4dedb6298c542bfa77e86ef1b5ddf1c","type":"GENE","name":"FAM32A","canonical_id":"hgnc:HGNC:24563","description":"family with sequence similarity 32 member A","metadata":{"aliases":["DKFZP586O0120","OTAG-12"]}},{"id":"1c5e886ef3194980829751d5e36f9412","type":"GENE","name":"FAM32BP","canonical_id":"hgnc:HGNC:30945","description":"family with sequence similarity 32 member B, pseudogene","metadata":{"aliases":["FAM32B"]}},{"id":"a772db5d822d4e35a3341798c3628e13","type":"GENE","name":"FAM32CP","canonical_id":"hgnc:HGNC:34239","description":"family with sequence similarity 32 member C, pseudogene","metadata":{"aliases":["FAM32C"]}},{"id":"84d626c4b9c042689ee76110ffbf7a25","type":"GENE","name":"FAM32DP","canonical_id":"hgnc:HGNC:34240","description":"family with sequence similarity 32 member D, pseudogene","metadata":{"aliases":["FAM32D"]}},{"id":"9f83bad15fd048f3ac61caa07811b38e","type":"GENE","name":"FAM32EP","canonical_id":"hgnc:HGNC:34241","description":"family with sequence similarity 32 member E, pseudogene","metadata":{"aliases":["FAM32E"]}},{"id":"7bff60fc192f46f6ae24d1f3652b913b","type":"GENE","name":"FAM3A","canonical_id":"hgnc:HGNC:13749","description":"FAM3 metabolism regulating signaling molecule A","metadata":{"aliases":["DXS560S","2-19","XAP-7"]}},{"id":"e79a87aa08124490b0d1409c90908b83","type":"GENE","name":"FAM3B","canonical_id":"hgnc:HGNC:1253","description":"FAM3 metabolism regulating signaling molecule B","metadata":{"aliases":["D21M16SJHU19e","PRED44","2-21","ORF9","C21orf76","PANDER","C21orf11"]}},{"id":"614b5dcd3ffc40a39e5ac69f69b2153b","type":"GENE","name":"FAM3C","canonical_id":"hgnc:HGNC:18664","description":"FAM3 metabolism regulating signaling molecule C","metadata":{"aliases":["GS3876","ILEI"]}},{"id":"7d90f50705d344fe9f4d09f4813f218a","type":"GENE","name":"FAM3C2P","canonical_id":"hgnc:HGNC:34501","description":"family with sequence similarity 3 member C2, pseudogene","metadata":{"aliases":["FAM3C2"]}},{"id":"7aa3ca9d68704363934972bdd09cac2b","type":"GENE","name":"FAM3D","canonical_id":"hgnc:HGNC:18665","description":"FAM3 metabolism regulating signaling molecule D","metadata":{"aliases":["EF7","OIT1"]}},{"id":"8a6217b4f3ee421f93968f94605acac6","type":"GENE","name":"FAM3D-AS1","canonical_id":"hgnc:HGNC:41276","description":"FAM3D antisense RNA 1","metadata":{"aliases":["lnc-KCTD6-3"]}},{"id":"be73f4ebf49249ec9d6e9ec5a478699c","type":"GENE","name":"FAM41AY1","canonical_id":"hgnc:HGNC:23955","description":"family with sequence similarity 41 member A, Y-linked 1","metadata":{"aliases":["FAM41AY"]}},{"id":"ea05527f3afa43799870590af0cb808a","type":"GENE","name":"FAM41AY2","canonical_id":"hgnc:HGNC:37135","description":"family with sequence similarity 41 member A, Y-linked 2","metadata":null},{"id":"a4fa03c08aed4ef3a0f8186d5f012151","type":"GENE","name":"FAM41C","canonical_id":"hgnc:HGNC:27635","description":"family with sequence similarity 41 member C","metadata":null},{"id":"6b1233b7fd6f4c34b6a0c4f7ec33044d","type":"GENE","name":"FAM43A","canonical_id":"hgnc:HGNC:26888","description":"family with sequence similarity 43 member A","metadata":{"aliases":["FLJ90022"]}},{"id":"ca1f8896729945d6ad545a213ea78c55","type":"GENE","name":"FAM43B","canonical_id":"hgnc:HGNC:31791","description":"family with sequence similarity 43 member B","metadata":{"aliases":["FLJ44952"]}},{"id":"a790c828dfbe4e3d9aa7ef8e37f53fa2","type":"GENE","name":"FAM47A","canonical_id":"hgnc:HGNC:29962","description":"family with sequence similarity 47 member A","metadata":{"aliases":["MGC27003"]}},{"id":"c06c6a66c1e147f8a059121365575381","type":"GENE","name":"FAM47B","canonical_id":"hgnc:HGNC:26659","description":"family with sequence similarity 47 member B","metadata":{"aliases":["FLJ35782"]}},{"id":"38a6205ec79948cc934fc8e60fa1194c","type":"GENE","name":"FAM47C","canonical_id":"hgnc:HGNC:25301","description":"family with sequence similarity 47 member C","metadata":null},{"id":"50a41a345ba344a19a9256c8d942f7f4","type":"GENE","name":"FAM47DP","canonical_id":"hgnc:HGNC:34342","description":"family with sequence similarity 47 member D, pseudogene","metadata":null},{"id":"70f7cfc324a14bfcaeeea39819f2e75a","type":"GENE","name":"FAM47E","canonical_id":"hgnc:HGNC:34343","description":"family with sequence similarity 47 member E","metadata":{"aliases":["FLJ42946","LOC100129583"]}},{"id":"db44dab04ac740b283ffe4159d86ac75","type":"GENE","name":"FAM47E-STBD1","canonical_id":"hgnc:HGNC:44667","description":"FAM47E-STBD1 readthrough","metadata":null},{"id":"829063c7d0534377b7f9c5e1d0d7bc8d","type":"GENE","name":"FAM50A","canonical_id":"hgnc:HGNC:18786","description":"family with sequence similarity 50 member A","metadata":{"aliases":["DXS9928E","XAP5","HXC-26","9F"]}},{"id":"1d33f329f91e46409414bb125338a757","type":"GENE","name":"FAM50B","canonical_id":"hgnc:HGNC:18789","description":"family with sequence similarity 50 member B","metadata":{"aliases":["D6S2654E","X5L"]}},{"id":"140c11ccf21c4782b031777177a4f385","type":"GENE","name":"FAM50B-AS1","canonical_id":"hgnc:HGNC:59338","description":"FAM50B antisense RNA 1","metadata":null},{"id":"e8bc22d0f6944d7793ad2a313f751680","type":"GENE","name":"FAM53A","canonical_id":"hgnc:HGNC:31860","description":"family with sequence similarity 53 member A","metadata":{"aliases":["DNTNP"]}},{"id":"c49c40ddc7234e75a4152c609820746c","type":"GENE","name":"FAM53B","canonical_id":"hgnc:HGNC:28968","description":"family with sequence similarity 53 member B","metadata":{"aliases":["bA12J10.2","smp","KIAA0140"]}},{"id":"c5b77ec26ccd44f88a54054a5b3e7989","type":"GENE","name":"FAM53B-AS1","canonical_id":"hgnc:HGNC:49499","description":"FAM53B antisense RNA 1","metadata":null},{"id":"7dde2fc69ff043caa9e8b18938a22734","type":"GENE","name":"FAM53C","canonical_id":"hgnc:HGNC:1336","description":"family with sequence similarity 53 member C","metadata":{"aliases":["C5orf6"]}},{"id":"d6e73f83b3e64b58b793afc257679737","type":"GENE","name":"FAM57A","canonical_id":"hgnc:HGNC:29646","description":null,"metadata":null},{"id":"a4ffb408c032463d95307826030d7ac7","type":"GENE","name":"FAM66A","canonical_id":"hgnc:HGNC:30444","description":"family with sequence similarity 66 member A","metadata":null},{"id":"f4cdd76cb2e1482892a49548edf3488a","type":"GENE","name":"FAM66B","canonical_id":"hgnc:HGNC:28890","description":"family with sequence similarity 66 member B","metadata":null},{"id":"f88778c097dc4b8694c9d3f5fe013448","type":"GENE","name":"FAM66C","canonical_id":"hgnc:HGNC:21644","description":"family with sequence similarity 66 member C","metadata":null},{"id":"31397c3c8c524f7fb88230d6ed73061a","type":"GENE","name":"FAM66D","canonical_id":"hgnc:HGNC:24159","description":"family with sequence similarity 66 member D","metadata":null},{"id":"5c99205d215a4300aacd66cbcdfa2414","type":"GENE","name":"FAM66E","canonical_id":"hgnc:HGNC:18735","description":"family with sequence similarity 66 member E","metadata":null},{"id":"b0857e9c32af47d6a65f421ad7438a53","type":"GENE","name":"FAM74A1","canonical_id":"hgnc:HGNC:32029","description":"family with sequence similarity 74 member A1","metadata":{"aliases":["FAM74A5"]}},{"id":"a472f988a4d34c728848af32ecf5432e","type":"GENE","name":"FAM74A3","canonical_id":"hgnc:HGNC:32031","description":"family with sequence similarity 74 member A3","metadata":{"aliases":["OTTHUMG00000067149"]}},{"id":"b27364831d2341178451687233232ef4","type":"GENE","name":"FAM74A4","canonical_id":"hgnc:HGNC:32032","description":"family with sequence similarity 74 member A4","metadata":{"aliases":["FLJ45202","FAM74A2"]}},{"id":"5fd2070107114fa6917a4350cfce0f0b","type":"GENE","name":"FAM74A6","canonical_id":"hgnc:HGNC:34036","description":"family with sequence similarity 74 member A6","metadata":null},{"id":"023108e319f34682a0a015a807d7af77","type":"GENE","name":"FAM74A7","canonical_id":"hgnc:HGNC:34037","description":"family with sequence similarity 74 member A7","metadata":null},{"id":"8feea1c047ff4ffbbc4cad0630599e28","type":"GENE","name":"FAM76A","canonical_id":"hgnc:HGNC:28530","description":"family with sequence similarity 76 member A","metadata":{"aliases":["MGC34648"]}},{"id":"e4c6a0b9ee5c4117874092596188b96a","type":"GENE","name":"FAM76AP1","canonical_id":"hgnc:HGNC:56528","description":"FAM76A pseudogene 1","metadata":null},{"id":"e86be80e9e85454b8b7b350ec6fdbfda","type":"GENE","name":"FAM76B","canonical_id":"hgnc:HGNC:28492","description":"family with sequence similarity 76 member B","metadata":{"aliases":["MGC33371"]}},{"id":"11d1fcc2b3924e7286f6bb43925e6e8d","type":"GENE","name":"FAM78A","canonical_id":"hgnc:HGNC:25465","description":"family with sequence similarity 78 member A","metadata":{"aliases":["FLJ00024","C9orf59"]}},{"id":"e0f2b88a1fdb46eeb41e32ee48c649d3","type":"GENE","name":"FAM78B","canonical_id":"hgnc:HGNC:13495","description":"family with sequence similarity 78 member B","metadata":null},{"id":"66c01ceb1ea441adb98f30c493ab4e57","type":"GENE","name":"FAM78B-AS1","canonical_id":"hgnc:HGNC:40639","description":"FAM78B antisense RNA 1","metadata":null},{"id":"2a1d57a736cd481baf296b97037de33f","type":"GENE","name":"FAM81A","canonical_id":"hgnc:HGNC:28379","description":"family with sequence similarity 81 member A","metadata":{"aliases":["MGC26690"]}},{"id":"615c603b84074b1db2b969b22a10eced","type":"GENE","name":"FAM81B","canonical_id":"hgnc:HGNC:26335","description":"family with sequence similarity 81 member B","metadata":{"aliases":["FLJ25333"]}},{"id":"18bf5a09c8ba44d49141effddcec0f7c","type":"GENE","name":"FAM81B-DT","canonical_id":"hgnc:HGNC:59100","description":"FAM81B divergent transcript","metadata":null},{"id":"f87fa5329253448694fbaa80ce195575","type":"GENE","name":"FAM85A","canonical_id":"hgnc:HGNC:17606","description":"family with sequence similarity 85 member A","metadata":null},{"id":"c8a949ebdf4f44369e9d45c022734655","type":"GENE","name":"FAM85B","canonical_id":"hgnc:HGNC:32160","description":"family with sequence similarity 85 member B","metadata":{"aliases":["lncRNA-HEIM"]}},{"id":"dd3abf2adadb431892e414dfe94bfff4","type":"GENE","name":"FAM86B1","canonical_id":"hgnc:HGNC:28268","description":"family with sequence similarity 86 member B1 (gene/pseudogene)","metadata":{"aliases":["MGC16279"]}},{"id":"ff6c7d9a93b74c8a869af4ac6fac6a84","type":"GENE","name":"FAM86B2","canonical_id":"hgnc:HGNC:32222","description":"family with sequence similarity 86 member B2","metadata":null},{"id":"173d52497ad54c3d89159f3ec2a8bea8","type":"GENE","name":"FAM86B2-DT","canonical_id":"hgnc:HGNC:48726","description":"FAM86B2 divergent transcript","metadata":null},{"id":"02c18bca50844856ae6d94ce2b36bd0d","type":"GENE","name":"FAM86B3P","canonical_id":"hgnc:HGNC:44371","description":"family with sequence similarity 86 member B3, pseudogene","metadata":null},{"id":"a56d48da94ce43938c8746e1bdb7cc1d","type":"GENE","name":"FAM86C1P","canonical_id":"hgnc:HGNC:25561","description":"family with sequence similarity 86 member C1, pseudogene","metadata":{"aliases":["FLJ10661","FLJ27199","FAM86C","FAM86C1"]}},{"id":"b60c2bb5e90f429a9ebe1270316513d7","type":"GENE","name":"FAM86C2P","canonical_id":"hgnc:HGNC:42392","description":"family with sequence similarity 86 member C2, pseudogene","metadata":null},{"id":"68f78d11a72c41d5a5325c828b1b7296","type":"GENE","name":"FAM86DP","canonical_id":"hgnc:HGNC:32659","description":"family with sequence similarity 86 member D, pseudogene","metadata":{"aliases":["FAM86D"]}},{"id":"47895912f6024f3894f0f776f3ca5373","type":"GENE","name":"FAM86EP","canonical_id":"hgnc:HGNC:28017","description":"family with sequence similarity 86 member E, pseudogene","metadata":null},{"id":"61d260f58fe240c3a91e86739a2f1aac","type":"GENE","name":"FAM86FP","canonical_id":"hgnc:HGNC:42357","description":"family with sequence similarity 86 member F, pseudogene","metadata":null},{"id":"b8c4874f4fb046718579f5da52ad11fa","type":"GENE","name":"FAM86GP","canonical_id":"hgnc:HGNC:42358","description":"family with sequence similarity 86 member G, pseudogene","metadata":null},{"id":"c38f2f15ada3423eb9b5a8d51cdb1d9d","type":"GENE","name":"FAM86HP","canonical_id":"hgnc:HGNC:42359","description":"family with sequence similarity 86 member H, pseudogene","metadata":null},{"id":"7fd9ea57da704f2ea0b87e60992a1151","type":"GENE","name":"FAM86JP","canonical_id":"hgnc:HGNC:44097","description":"family with sequence similarity 86 member J, pseudogene","metadata":null},{"id":"30f609d9c5c147a798a859fecf4fe413","type":"GENE","name":"FAM86KP","canonical_id":"hgnc:HGNC:44098","description":"family with sequence similarity 86 member K, pseudogene","metadata":null},{"id":"0d0804a37fb54e3192727839993305d2","type":"GENE","name":"FAM86LP","canonical_id":"hgnc:HGNC:44099","description":"family with sequence similarity 86 member L, pseudogene","metadata":null},{"id":"398c32acdda14aa7801576d4e057b082","type":"GENE","name":"FAM86MP","canonical_id":"hgnc:HGNC:44100","description":"family with sequence similarity 86 member M, pseudogene","metadata":null},{"id":"f0974183c6c940d2b00145ebdb58924e","type":"GENE","name":"FAM87A","canonical_id":"hgnc:HGNC:27233","description":"family with sequence similarity 87 member A","metadata":null},{"id":"53ac97333dda415ea5ac05abd7f4a6b9","type":"GENE","name":"FAM87B","canonical_id":"hgnc:HGNC:32236","description":"family with sequence similarity 87 member B","metadata":{"aliases":["FLJ40008"]}},{"id":"7cc2cdf762a1437393041ac355d60c34","type":"GENE","name":"FAM88B","canonical_id":"hgnc:HGNC:31457","description":"family with sequence similarity 88 member B","metadata":null},{"id":"1c6fa92a739c424fb3a6ea81cc7cec74","type":"GENE","name":"FAM88C","canonical_id":"hgnc:HGNC:56159","description":"family with sequence similarity 88 member C","metadata":{"aliases":["Lnc-PPRL"]}},{"id":"b5ff444206664f17aef33f003ae9507f","type":"GENE","name":"FAM88D","canonical_id":"hgnc:HGNC:56160","description":"family with sequence similarity 88 member D","metadata":null},{"id":"ebbe49da26b24228aef37e3f4561c12c","type":"GENE","name":"FAM88E","canonical_id":"hgnc:HGNC:56161","description":"family with sequence similarity 88 member E","metadata":null},{"id":"1905c5d003954e2a95259f8f5768ba34","type":"GENE","name":"FAM88F","canonical_id":"hgnc:HGNC:56162","description":"family with sequence similarity 88 member F","metadata":null},{"id":"3dc8fbd7065b4266a9db30fe821cc14b","type":"GENE","name":"FAM89A","canonical_id":"hgnc:HGNC:25057","description":"family with sequence similarity 89 member A","metadata":{"aliases":["MGC15887","C1orf153"]}},{"id":"741bc73f13ed4c8b9636d2b4ce2d3643","type":"GENE","name":"FAM89B","canonical_id":"hgnc:HGNC:16708","description":"family with sequence similarity 89 member B","metadata":{"aliases":["MTVR1","LRAP25"]}},{"id":"e295bdc3a946411eb2ee529c0861ea66","type":"GENE","name":"FAM8A1","canonical_id":"hgnc:HGNC:16372","description":"family with sequence similarity 8 member A1","metadata":{"aliases":["AHCP"]}},{"id":"bed4dd0c820f44528e32e40008368b19","type":"GENE","name":"FAM8A1-DT","canonical_id":"hgnc:HGNC:59364","description":"FAM8A1 divergent transcript","metadata":null},{"id":"71d4f15e11e7431583be72c122c18212","type":"GENE","name":"FAM8A10P","canonical_id":"hgnc:HGNC:23871","description":"family with sequence similarity 8 member A10, pseudogene","metadata":null},{"id":"fea305d99ddb41d08839a4b1cb85a03c","type":"GENE","name":"FAM8A2P","canonical_id":"hgnc:HGNC:16373","description":"family with sequence similarity 8 member A2, pseudogene","metadata":null},{"id":"24d82c9ffa0d421d99ce65cb09e502d9","type":"GENE","name":"FAM8A3P","canonical_id":"hgnc:HGNC:16374","description":"family with sequence similarity 8 member A3, pseudogene","metadata":null},{"id":"4f36069abaff48bf9f4d7e66edb0f9e2","type":"GENE","name":"FAM8A4P","canonical_id":"hgnc:HGNC:16375","description":"family with sequence similarity 8 member A4, pseudogene","metadata":{"aliases":["FAM8A8P"]}},{"id":"61bf86be01f44aa0b4a112f1cf900eca","type":"GENE","name":"FAM8A5P","canonical_id":"hgnc:HGNC:16376","description":"family with sequence similarity 8 member A5, pseudogene","metadata":null},{"id":"54bc5c4b3c6c48d0b39b23623d694216","type":"GENE","name":"FAM8A6P","canonical_id":"hgnc:HGNC:16377","description":"family with sequence similarity 8 member A6, pseudogene","metadata":null},{"id":"a649945f672a49e8aee64a10d61901d7","type":"GENE","name":"FAM8A7P","canonical_id":"hgnc:HGNC:23868","description":"family with sequence similarity 8 member A7, pseudogene","metadata":null},{"id":"9b8461b2b6b34423bb7f2a5a0269f26b","type":"GENE","name":"FAM8A9P","canonical_id":"hgnc:HGNC:23870","description":"family with sequence similarity 8 member A9, pseudogene","metadata":null},{"id":"bdb815b1bc5e4535a634c97948f45ec6","type":"GENE","name":"FAM90A1","canonical_id":"hgnc:HGNC:25526","description":"family with sequence similarity 90 member A1","metadata":{"aliases":["FLJ10408"]}},{"id":"10b4052ad351483c886f4ffa72e6592f","type":"GENE","name":"FAM90A10","canonical_id":"hgnc:HGNC:32258","description":"family with sequence similarity 90 member A10","metadata":{"aliases":["FAM90A10P"]}},{"id":"13fb56d372ec4579885759b7ed43c250","type":"GENE","name":"FAM90A11","canonical_id":"hgnc:HGNC:32259","description":"family with sequence similarity 90 member A11","metadata":{"aliases":["FAM90A11P"]}},{"id":"dac2a19df41d4e3daddba55164d0580c","type":"GENE","name":"FAM90A12","canonical_id":"hgnc:HGNC:32260","description":"family with sequence similarity 90 member A12","metadata":{"aliases":["FAM90A12P"]}},{"id":"f16278c6d686458b8e939b8de765ae6a","type":"GENE","name":"FAM90A13","canonical_id":"hgnc:HGNC:32261","description":"family with sequence similarity 90 member A13","metadata":{"aliases":["FAM90A13P"]}},{"id":"4640161f05d54b2b9d35af9d2e51f116","type":"GENE","name":"FAM90A14","canonical_id":"hgnc:HGNC:32262","description":"family with sequence similarity 90 member A14","metadata":{"aliases":["FAM90A14P"]}},{"id":"668b513546c340cdb645692be10d649f","type":"GENE","name":"FAM90A15","canonical_id":"hgnc:HGNC:32263","description":"family with sequence similarity 90 member A15","metadata":{"aliases":["FAM90A15P"]}},{"id":"f523427718f9434f9a49f10621a7ae83","type":"GENE","name":"FAM90A16","canonical_id":"hgnc:HGNC:32264","description":"family with sequence similarity 90 member A16","metadata":{"aliases":["FAM90A16P"]}},{"id":"fadfa5cb7325448cb5e1b62028b52bc9","type":"GENE","name":"FAM90A17","canonical_id":"hgnc:HGNC:32265","description":"family with sequence similarity 90 member A17","metadata":{"aliases":["FAM90A17P"]}},{"id":"8ebdd131f51244e2a8da4edf91b4295e","type":"GENE","name":"FAM90A18","canonical_id":"hgnc:HGNC:32266","description":"family with sequence similarity 90 member A18","metadata":{"aliases":["FAM90A18P"]}},{"id":"f14d681308e54774b7d72deca7ca1374","type":"GENE","name":"FAM90A19","canonical_id":"hgnc:HGNC:32267","description":"family with sequence similarity 90 member A19","metadata":{"aliases":["FAM90A19P"]}},{"id":"f218758344cd467f9b3d52ea95afde87","type":"GENE","name":"FAM90A20","canonical_id":"hgnc:HGNC:32268","description":"family with sequence similarity 90 member A20","metadata":{"aliases":["FAM90A20P"]}},{"id":"8880e42b546b4747a182e25aee7ee538","type":"GENE","name":"FAM90A21P","canonical_id":"hgnc:HGNC:32269","description":"family with sequence similarity 90 member A21, pseudogene","metadata":null},{"id":"3760f7402168488ebfa189c8670213bd","type":"GENE","name":"FAM90A22","canonical_id":"hgnc:HGNC:32270","description":"family with sequence similarity 90 member A22","metadata":{"aliases":["FAM90A22P"]}},{"id":"65d3a599c6f44146a0cd8bcb4a0167fb","type":"GENE","name":"FAM90A23","canonical_id":"hgnc:HGNC:32271","description":"family with sequence similarity 90 member A23","metadata":{"aliases":["FAM90A23P"]}},{"id":"b94c5e480ebf45b7bf6a351afe510c30","type":"GENE","name":"FAM90A24","canonical_id":"hgnc:HGNC:32272","description":"family with sequence similarity 90 member A24","metadata":{"aliases":["FAM90A24P"]}},{"id":"031a1efe456a49dfad33c2c272e40b78","type":"GENE","name":"FAM90A25P","canonical_id":"hgnc:HGNC:32246","description":"family with sequence similarity 90 member A25, pseudogene","metadata":null},{"id":"d0e3a2d3eb7e40139734efd194ad2107","type":"GENE","name":"FAM90A26","canonical_id":"hgnc:HGNC:43746","description":"family with sequence similarity 90 member A26","metadata":{"aliases":["FAM90A26P"]}},{"id":"8520085ce1d64d87b8a19cfc5e64441b","type":"GENE","name":"FAM90A27P","canonical_id":"hgnc:HGNC:43617","description":"family with sequence similarity 90 member A27, pseudogene","metadata":null},{"id":"8d3a85d2e66647d1bef762e883094eb3","type":"GENE","name":"FAM90A28P","canonical_id":"hgnc:HGNC:43747","description":"family with sequence similarity 90 member A28, pseudogene","metadata":null},{"id":"513c113375164a0fa7938330b5135383","type":"GENE","name":"FAM90A2P","canonical_id":"hgnc:HGNC:32250","description":"family with sequence similarity 90 member A2, pseudogene","metadata":null},{"id":"a18dea0f9de04fcdafbb93fe1710e8bf","type":"GENE","name":"FAM90A3","canonical_id":"hgnc:HGNC:32251","description":"family with sequence similarity 90 member A3","metadata":{"aliases":["FAM90A3P"]}},{"id":"51910ffa6dac409da25876069417adb8","type":"GENE","name":"FAM90A4P","canonical_id":"hgnc:HGNC:32252","description":"family with sequence similarity 90 member A4, pseudogene","metadata":{"aliases":["FAM90A4"]}},{"id":"a54d57d94ecb4688922310eb4ce48308","type":"GENE","name":"FAM90A5","canonical_id":"hgnc:HGNC:32253","description":"family with sequence similarity 90 member A5","metadata":{"aliases":["FAM90A5P"]}},{"id":"06ee64c5ccb04047a82e60e2b7b380d2","type":"GENE","name":"FAM90A6P","canonical_id":"hgnc:HGNC:32254","description":"family with sequence similarity 90 member A6, pseudogene","metadata":null},{"id":"e36f5567ada44a0fbc8a10804d6b7a3a","type":"GENE","name":"FAM90A7","canonical_id":"hgnc:HGNC:32255","description":"family with sequence similarity 90 member A7","metadata":{"aliases":["FAM90A7P"]}},{"id":"7fc0104f25604dd19ac93287a57319b1","type":"GENE","name":"FAM90A8","canonical_id":"hgnc:HGNC:32256","description":"family with sequence similarity 90 member A8","metadata":{"aliases":["FAM90A8P"]}},{"id":"64641fa28a6a48ef8d8c33f827279022","type":"GENE","name":"FAM90A9","canonical_id":"hgnc:HGNC:32257","description":"family with sequence similarity 90 member A9","metadata":{"aliases":["FAM90A9P"]}},{"id":"76bf0b97ea8f482f8e87e9946e0c87ba","type":"GENE","name":"FAM91A1","canonical_id":"hgnc:HGNC:26306","description":"family with sequence similarity 91 member A1","metadata":{"aliases":["FLJ23790"]}},{"id":"860f85f42d0543298701c7a6d9d8c9ff","type":"GENE","name":"FAM91A2P","canonical_id":"hgnc:HGNC:51523","description":"family with sequence similarity 91 member A2, pseudogene","metadata":null},{"id":"16be386cb0724e2c84cc4d5b4dd7856d","type":"GENE","name":"FAM91A3P","canonical_id":"hgnc:HGNC:32273","description":"family with sequence similarity 91 member A3, pseudogene","metadata":null},{"id":"c5fcd4c2f63e4b9d9afc8ef4155d071e","type":"GENE","name":"FAM91A4P","canonical_id":"hgnc:HGNC:51524","description":"family with sequence similarity 91 member A4, pseudogene","metadata":null},{"id":"cff3dd21d4344a5992d390ddaee7df1f","type":"GENE","name":"FAM95A","canonical_id":"hgnc:HGNC:28069","description":"family with sequence similarity 95 member A","metadata":{"aliases":["DKFZp434H0923"]}},{"id":"81b7cfaef9b04063a6d7d1dd6c9b1f7c","type":"GENE","name":"FAM95B1","canonical_id":"hgnc:HGNC:32318","description":"family with sequence similarity 95 member B1","metadata":{"aliases":["PITAR","DKFZp686P0734"]}},{"id":"25d37701dd8b429eb8a9d9af48ad7546","type":"GENE","name":"FAM95C","canonical_id":"hgnc:HGNC:45272","description":"family with sequence similarity 95 member C","metadata":null},{"id":"1abaf263bb9a4776a7aeef4c953ade97","type":"GENE","name":"FAM98BP1","canonical_id":"hgnc:HGNC:58680","description":"family with sequence similarity 98 member B pseudogene 1","metadata":null},{"id":"65c60794ba2e43efb074c30534ae0967","type":"GENE","name":"FAM99A","canonical_id":"hgnc:HGNC:32368","description":"family with sequence similarity 99 member A","metadata":{"aliases":["FLJ42833"]}},{"id":"e48bc06a87304da19cd984c1dccc3076","type":"GENE","name":"FAM99B","canonical_id":"hgnc:HGNC:32369","description":"family with sequence similarity 99 member B","metadata":{"aliases":["DKFZp781M09150"]}},{"id":"5c95367aa30a4aee9d1f3d926a0d6bfb","type":"GENE","name":"FAM9A","canonical_id":"hgnc:HGNC:18403","description":"family with sequence similarity 9 member A","metadata":{"aliases":["TEX39A"]}},{"id":"57be829684ed4a05ba64e453ff38e187","type":"GENE","name":"FAM9B","canonical_id":"hgnc:HGNC:18404","description":"family with sequence similarity 9 member B","metadata":{"aliases":["TEX39B"]}},{"id":"390b8c20b02a46a8bc85317666697bb6","type":"GENE","name":"FAM9C","canonical_id":"hgnc:HGNC:18405","description":"family with sequence similarity 9 member C","metadata":{"aliases":["TEX39C"]}},{"id":"043eacbe796e48b7b63510f2ee3b6018","type":"GENE","name":"FAM9CP1","canonical_id":"hgnc:HGNC:55923","description":"FAM9C pseudogene 1","metadata":null},{"id":"36e1ecbf217e44cb82479cf25870b7de","type":"GENE","name":"FAN1","canonical_id":"hgnc:HGNC:29170","description":"FANCD2 and FANCI associated nuclease 1","metadata":{"aliases":["KIAA1018","MTMR15"]}},{"id":"7e405d81c95c4558b60e0ee99c66cf94","type":"GENE","name":"FANCA","canonical_id":"hgnc:HGNC:3582","description":null,"metadata":null},{"id":"739bd2a592f845e6a94b472dbb80cc05","type":"GENE","name":"FANCB","canonical_id":"hgnc:HGNC:3583","description":"FA complementation group B","metadata":{"aliases":["FAB","FLJ34064","FAAP95"]}},{"id":"bf159d6c3fd64ca3aba6cb529b2b3052","type":"GENE","name":"FANCC","canonical_id":"hgnc:HGNC:3584","description":"FA complementation group C","metadata":{"aliases":["FAC","FA3","FACC"]}},{"id":"16021eb93be34e70b99d3c718ab98f7e","type":"GENE","name":"FANCD2","canonical_id":"hgnc:HGNC:3585","description":"FA complementation group D2","metadata":{"aliases":["FAD","FA-D2","FACD","FANCD"]}},{"id":"f9e85062e63a4e2a96ea5db712dd3443","type":"GENE","name":"FANCD2OS","canonical_id":"hgnc:HGNC:28623","description":"FANCD2 opposite strand","metadata":{"aliases":["MGC40179","C3orf24"]}},{"id":"9727f4116449402eae0368598c945861","type":"GENE","name":"FANCD2P1","canonical_id":"hgnc:HGNC:44487","description":"FANCD2 pseudogene 1","metadata":null},{"id":"ba972b26df224a8d8504d76c280b0a5c","type":"GENE","name":"FANCD2P2","canonical_id":"hgnc:HGNC:44488","description":"FANCD2 pseudogene 2","metadata":null},{"id":"7e39952d5bb2430c9fa2187e7b3176b2","type":"GENE","name":"FANCE","canonical_id":"hgnc:HGNC:3586","description":"FA complementation group E","metadata":{"aliases":["FAE","FACE"]}},{"id":"eaed245541cf4a9c8cf7f7b95280a31a","type":"GENE","name":"FANCF","canonical_id":"hgnc:HGNC:3587","description":"FA complementation group F","metadata":{"aliases":["FAF"]}},{"id":"f7377c30907a4201a4919af571f7b9c8","type":"GENE","name":"FANCG","canonical_id":"hgnc:HGNC:3588","description":"FA complementation group G","metadata":{"aliases":["FAG","XRCC9"]}},{"id":"e67af7fd854e4703b2960dbe8b26ab09","type":"GENE","name":"FANCI","canonical_id":"hgnc:HGNC:25568","description":"FA complementation group I","metadata":{"aliases":["FLJ10719","KIAA1794"]}},{"id":"c5151adfe7cd4766bfd7fd3b93052452","type":"GENE","name":"FANCL","canonical_id":"hgnc:HGNC:20748","description":"FA complementation group L","metadata":{"aliases":["FLJ10335","FAAP43","Pog","PHF9"]}},{"id":"f508249f93434aabaf5f1410ed375f7e","type":"GENE","name":"FANCM","canonical_id":"hgnc:HGNC:23168","description":"FA complementation group M","metadata":{"aliases":["FAAP250","KIAA1596"]}},{"id":"f4cb3b24377c4ea6ab9df6c90c7f330c","type":"GO_TERM","name":"FANCM-MHF complex","canonical_id":"go:GO:0071821","description":"\"A protein complex contains the proteins FANCM and MHF, or their orthologs, plays an essential role in DNA remodeling, protects replication forks, and is conserved in eukaryotes.\" [GOC:mah, GOC:vw, PMID:20347428]","metadata":null},{"id":"9974ef951b6f409990fac8994b0afb37","type":"GENE","name":"FANK1","canonical_id":"hgnc:HGNC:23527","description":"fibronectin type III and ankyrin repeat domains 1","metadata":null},{"id":"78d3aa973d1a4708a3f48db7680e01b3","type":"GENE","name":"FANK1-AS1","canonical_id":"hgnc:HGNC:43915","description":"FANK1 antisense RNA 1","metadata":null},{"id":"1ef09658399c4323ab8c4c833cd4c57c","type":"GENE","name":"FAP","canonical_id":"hgnc:HGNC:3590","description":null,"metadata":null},{"id":"272d78d40ada4bc5aaf34c39f6e0fed6","type":"GO_TERM","name":"FAR/SIP/STRIPAK complex","canonical_id":"go:GO:0090443","description":"\"A conserved protein phosphatase type 2A complex which contains a protein phosphatase type 2A, a protein phosphatase regulatory subunit, a striatin, an FHA domain protein and other subunits (at least six proteins). In fission yeast this complex negatively regulate the septation initiation network at the spindle pole body.\" [GOC:vw, PMID:21561862, PMID:22119525]","metadata":null},{"id":"bd731d312b204dea97469f8235b56e18","type":"GENE","name":"FAR1","canonical_id":"hgnc:HGNC:26222","description":"fatty acyl-CoA reductase 1","metadata":{"aliases":["FLJ22728","SDR10E1","MLSTD2"]}},{"id":"80127955cd1c44c885e1094298be7fe0","type":"GENE","name":"FAR1-IT1","canonical_id":"hgnc:HGNC:41485","description":"FAR1 intronic transcript 1","metadata":null},{"id":"63865607b207492ebbafed4026284299","type":"GENE","name":"FAR1P1","canonical_id":"hgnc:HGNC:39675","description":"fatty acyl-CoA reductase 1 pseudogene 1","metadata":null},{"id":"d8e5a53a20ef4d029b53d3e1a97c6923","type":"GENE","name":"FAR2","canonical_id":"hgnc:HGNC:25531","description":"fatty acyl-CoA reductase 2","metadata":{"aliases":["FLJ10462","SDR10E2","MLSTD1"]}},{"id":"6c86c61b5a414fb78d09e0416ee1e3f6","type":"GENE","name":"FAR2-AS1","canonical_id":"hgnc:HGNC:58443","description":"FAR2 antisense RNA 1","metadata":null},{"id":"9d61b8e640874a6aa7e532e3625d4e29","type":"GENE","name":"FAR2P1","canonical_id":"hgnc:HGNC:49284","description":"fatty acyl-CoA reductase 2 pseudogene 1","metadata":{"aliases":["LOC440905"]}},{"id":"079649ab295d46328ef16d4e9a943644","type":"GENE","name":"FAR2P2","canonical_id":"hgnc:HGNC:49279","description":"fatty acyl-CoA reductase 2 pseudogene 2","metadata":null},{"id":"e6f55be6685e4782896ca0bbda949838","type":"GENE","name":"FAR2P3","canonical_id":"hgnc:HGNC:49285","description":"fatty acyl-CoA reductase 2 pseudogene 3","metadata":null},{"id":"d1f439020b244d06be2da3c33c8ccbb4","type":"GENE","name":"FAR2P4","canonical_id":"hgnc:HGNC:49286","description":"fatty acyl-CoA reductase 2 pseudogene 4","metadata":null},{"id":"b0ebc699e79249fb8747234b0c1ebe1b","type":"GENE","name":"FARP1","canonical_id":"hgnc:HGNC:3591","description":"FERM, ARH/RhoGEF and pleckstrin domain protein 1","metadata":{"aliases":["CDEP","PLEKHC2","MGC87400","PPP1R75","GLCC1"]}},{"id":"c4916eb6a65d4629a42a6de910bab141","type":"GENE","name":"FARP1-AS1","canonical_id":"hgnc:HGNC:40229","description":"FARP1 antisense RNA 1","metadata":null},{"id":"dc7fbb98b36b4a1d928e557aa3906ec0","type":"GENE","name":"FARP2","canonical_id":"hgnc:HGNC:16460","description":"FERM, ARH/RhoGEF and pleckstrin domain protein 2","metadata":{"aliases":["KIAA0793","FIR","PLEKHC3","FRG"]}},{"id":"bb77bebb3dcc480ca2a2f2d2a7abe8ea","type":"GENE","name":"FARS2","canonical_id":"hgnc:HGNC:21062","description":"phenylalanyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["dJ236A3.1","mtPheRS","FARS1"]}},{"id":"9541d3e0dd6d4f05a527655ebeddc30b","type":"GENE","name":"FARS2-AS1","canonical_id":"hgnc:HGNC:56121","description":"FARS2 antisense RNA 1","metadata":null},{"id":"f06dc9c9717d49c094528d2a455a895c","type":"GENE","name":"FARS2-AS2","canonical_id":"hgnc:HGNC:59339","description":"FARS2 antisense RNA 2","metadata":null},{"id":"50e72d61d5b44910ae25a428bce0e2fe","type":"GENE","name":"FARSA","canonical_id":"hgnc:HGNC:3592","description":"phenylalanyl-tRNA synthetase subunit alpha","metadata":{"aliases":["CML33","FARSL","FARSLA"]}},{"id":"e10d2f6a327540ba97819d962e2c72ec","type":"GENE","name":"FARSA-AS1","canonical_id":"hgnc:HGNC:50479","description":"FARSA antisense RNA 1","metadata":null},{"id":"3bf25e886c4140c0a98be1cb02f067f4","type":"GENE","name":"FARSB","canonical_id":"hgnc:HGNC:17800","description":"phenylalanyl-tRNA synthetase subunit beta","metadata":{"aliases":["PheHB","FRSB","FARSLB"]}},{"id":"330dfce5e92e419c891ab8b091c8645a","type":"GENE","name":"FARSBP1","canonical_id":"hgnc:HGNC:45115","description":"FARSB pseudogene 1","metadata":null},{"id":"933223e5ebb540c6ba9d63ee4d60811b","type":"GENE","name":"FAS","canonical_id":"hgnc:HGNC:11920","description":null,"metadata":null},{"id":"7ab3471c17714ffda2ba459d8f4c33ee","type":"GENE","name":"FAS-AS1","canonical_id":"hgnc:HGNC:37128","description":"FAS antisense RNA 1","metadata":{"aliases":["SAF","FASAS","FAS-AS"]}},{"id":"7578af2576d546cd96f9d1aafd9df555","type":"TRIAL","name":"FASCIA ILIACA BLOCK VERSUS INTRAVENOUS NALBUPHINE AS ANALGESIC METHOD BEFORE POSITIONING FOR SPINAL ANESTHESIA IN PATIENTS UNDERGOING SURGERY FOR HIP FRACTURES","canonical_id":"clinicaltrials.gov:NCT07613801","description":"Hip Fracture Surgeries","metadata":null},{"id":"78a125ba3c384861b59df8405b0df36e","type":"GENE","name":"FASLG","canonical_id":"hgnc:HGNC:11936","description":null,"metadata":null},{"id":"4f3d811840cf48108a0058fa221e5181","type":"GENE","name":"FASN","canonical_id":"hgnc:HGNC:3594","description":null,"metadata":null},{"id":"6b5b96aebfb6478c92aeda283a390372","type":"GENE","name":"FASTK","canonical_id":"hgnc:HGNC:24676","description":"Fas activated serine/threonine kinase","metadata":{"aliases":["FASTKD0","FAST"]}},{"id":"7800efaf46dd44d9bb54a04758b1e9ce","type":"GENE","name":"FASTKD1","canonical_id":"hgnc:HGNC:26150","description":"FASTK mitochondrial RNA regulator 1","metadata":{"aliases":["FLJ21901"]}},{"id":"8b83e3b5ec16423cad007cafe36736c3","type":"GENE","name":"FASTKD2","canonical_id":"hgnc:HGNC:29160","description":"FASTK mitochondrial RNA regulator 2","metadata":{"aliases":["KIAA0971"]}},{"id":"808e7410a9f4461da191542ef4f25526","type":"GENE","name":"FASTKD3","canonical_id":"hgnc:HGNC:28758","description":"FASTK mitochondrial RNA regulator 3","metadata":{"aliases":["MGC5297","FLJ23274"]}},{"id":"8097792a97a14ae09491ad0c00afab76","type":"GENE","name":"FASTKD4","canonical_id":"hgnc:HGNC:17443","description":"FASTK mitochondrial RNA regulator 4","metadata":{"aliases":["Cpr2","KIAA0948","H_TD2522F11.8","FASTKD4","TBRG4"]}},{"id":"874bd4a0300f42ea95619f70552b41ae","type":"GENE","name":"FASTKD5","canonical_id":"hgnc:HGNC:25790","description":"FASTK mitochondrial RNA regulator 5","metadata":{"aliases":["FLJ13149"]}},{"id":"631e8a8477eb40b1bc598ffd2ce118d7","type":"GENE","name":"FAT1","canonical_id":"hgnc:HGNC:3595","description":null,"metadata":null},{"id":"86bd28bf2b61483cb06d55f8e4f83917","type":"GO_TERM","name":"FAT10 activating enzyme activity","canonical_id":"go:GO:0019780","description":"\"Catalysis of the activation of the small ubiquitin-related modifier FAT10, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:mah]","metadata":null},{"id":"7778ce278fb143adb55e7d80a951e4a0","type":"GO_TERM","name":"FAT10 conjugating enzyme activity","canonical_id":"go:GO:0061652","description":"\"Isoenergetic transfer of FAT10 from one protein to another via the reaction X-FAT10 + Y = Y-FAT10 + X, where both the X-FAT10 and Y-FAT10 linkages are thioester bonds between the C-terminal amino acid of FAT10 and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"0fbe65a103bc431ababb11986eeeaf88","type":"GO_TERM","name":"FAT10 ligase activity","canonical_id":"go:GO:0061661","description":"\"Catalysis of the transfer of FAT10 to a substrate protein via the reaction X-FAT10 + S = X + S-FAT10, where X is either an E2 or E3 enzyme, the X-FAT10 linkage is a thioester bond, and the S-FAT10 linkage is an isopeptide bond between the C-terminal glycine of FAT10 and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"99b2925b3f554f7696db2e1e96f50b25","type":"GO_TERM","name":"FAT10 transferase activity","canonical_id":"go:GO:0019775","description":"\"Catalysis of the transfer of FAT10 from one protein to another via the reaction X-FAT10 + Y = Y-FAT10 + X, where both X-FAT10 and Y-FAT10 are covalent linkages.\" [GOC:dph, GOC:mah, PMID:12826404]","metadata":null},{"id":"dc629c6d1f454a3c91fefac27a9148c5","type":"GENE","name":"FAT1P1","canonical_id":"hgnc:HGNC:16582","description":"FAT atypical cadherin 1 pseudogene 1","metadata":{"aliases":["dJ697P8.1"]}},{"id":"5f9fc3a5c15140809108e512dfbf6ac5","type":"GENE","name":"FAT2","canonical_id":"hgnc:HGNC:3596","description":"FAT atypical cadherin 2","metadata":{"aliases":["MEGF1","CDHF8","HFAT2","CDHR9"]}},{"id":"5132a827913040c38bd6cf8e47e3c3fa","type":"GENE","name":"FAT3","canonical_id":"hgnc:HGNC:23112","description":"FAT atypical cadherin 3","metadata":{"aliases":["KIAA1989","CDHF15","CDHR10"]}},{"id":"f09a7456aeb44a27acef84206d6eb456","type":"GENE","name":"FAT4","canonical_id":"hgnc:HGNC:23109","description":"FAT atypical cadherin 4","metadata":{"aliases":["CDHF14","FAT-J","CDHR11"]}},{"id":"ca6ce5783de94e6b8d380966601c596e","type":"TRIAL","name":"FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab","canonical_id":"clinicaltrials.gov:NCT00383136","description":"Acute Myocardial Infarction","metadata":null},{"id":"50a3c837a86c414b85c4afccbcf50ceb","type":"GENE","name":"FATE1","canonical_id":"hgnc:HGNC:24683","description":"fetal and adult testis expressed 1","metadata":{"aliases":["FATE","CT43"]}},{"id":"bc95f0981076441bbfd1b0daffbb3bec","type":"GO_TERM","name":"FATZ binding","canonical_id":"go:GO:0051373","description":"\"Binding to a member of the FATZ family of proteins, filamin-, actinin-, and telethonin-binding proteins of the Z-disc of striated muscle. FATZ proteins are located in the Z-disc of the sarcomere and are involved in a complex network of interactions with other Z-band components.\" [PMID:10984498, PMID:11699871]","metadata":null},{"id":"9330cdce51df4b77b4c5b5ac14a0fca9","type":"GENE","name":"FAU","canonical_id":"hgnc:HGNC:3597","description":"FAU ubiquitin like and ribosomal protein S30 fusion","metadata":{"aliases":["RPS30","FLJ22986","Fub1","Fubi","MNSFbeta","asr1","S30","eS30"]}},{"id":"94f1ae1ed80141219c76996328249652","type":"GENE","name":"FAUP1","canonical_id":"hgnc:HGNC:17984","description":"FAU pseudogene 1","metadata":{"aliases":["FAU1P"]}},{"id":"ba261aecc0f94bc3b5134d335852fd72","type":"GENE","name":"FAUP2","canonical_id":"hgnc:HGNC:36535","description":"FAU pseudogene 2","metadata":null},{"id":"d2b620b45b4b466f8459b90b38cb9885","type":"GENE","name":"FAUP3","canonical_id":"hgnc:HGNC:36970","description":"FAU pseudogene 3","metadata":null},{"id":"021798a538e14390a2654cdef5c0c903","type":"GENE","name":"FAUP4","canonical_id":"hgnc:HGNC:56253","description":"FAU pseudogene 4","metadata":{"aliases":["PAARH"]}},{"id":"af838993c50c43769318b6bfad5293b7","type":"GENE","name":"FAXC","canonical_id":"hgnc:HGNC:20742","description":"failed axon connections homolog, metaxin like GST domain containing","metadata":{"aliases":["MGC2817","dJ273F20","C6orf168"]}},{"id":"0cc5839c92334a908c6f50d289d19a92","type":"GENE","name":"FAXDC2","canonical_id":"hgnc:HGNC:1334","description":"fatty acid hydroxylase domain containing 2","metadata":{"aliases":["FLJ13758","C5orf4"]}},{"id":"6ecefebf7f9b485c8c02431c8c8c3536","type":"GENE","name":"FBF1","canonical_id":"hgnc:HGNC:24674","description":"Fas binding factor 1","metadata":{"aliases":["FLJ00103","FBF-1","KIAA1863","ALB"]}},{"id":"8e2fb1e43a2b48999c2064df488bb632","type":"GENE","name":"FBH1","canonical_id":"hgnc:HGNC:13620","description":"F-box DNA helicase 1","metadata":{"aliases":["FLJ14590","Fbx18","FBXO18"]}},{"id":"29844976fe8a4ea99f835ef98f6e3dd2","type":"GENE","name":"FBL","canonical_id":"hgnc:HGNC:3599","description":"fibrillarin rRNA 2'-O-methyltransferase","metadata":{"aliases":["RNU3IP1","FLRN","FIB","Nop1"]}},{"id":"e80c79368ddd4add9048babecf68db8b","type":"GENE","name":"FBLIM1","canonical_id":"hgnc:HGNC:24686","description":"filamin binding LIM protein 1","metadata":{"aliases":["FBLP-1","CAL","migfilin"]}},{"id":"bf61b494afd345ff9746545c92b1419d","type":"GENE","name":"FBLIM1P1","canonical_id":"hgnc:HGNC:55107","description":"FBLIM1 pseudogene 1","metadata":null},{"id":"9ad159cd5e4e491baf35be193ef1f673","type":"GENE","name":"FBLIM1P2","canonical_id":"hgnc:HGNC:55108","description":"FBLIM1 pseudogene 2","metadata":null},{"id":"09ef2e14f88a4175b9a06800dfe4c9cf","type":"GENE","name":"FBLL1","canonical_id":"hgnc:HGNC:35458","description":"fibrillarin like rRNA 2'-O-methyltransferase 1","metadata":{"aliases":["LOC345630"]}},{"id":"d4f85f1c1649413fb54c65bdcbe2d99b","type":"GENE","name":"FBLN1","canonical_id":"hgnc:HGNC:3600","description":null,"metadata":null},{"id":"99681ab162e9448b8c268d41bc2d5426","type":"GENE","name":"FBLN2","canonical_id":"hgnc:HGNC:3601","description":"fibulin 2","metadata":null},{"id":"ce2b0dada4fb47a385c1da71624b7d26","type":"GENE","name":"FBLN5","canonical_id":"hgnc:HGNC:3602","description":"fibulin 5","metadata":{"aliases":["EVEC","UP50","DANCE","ARMD3"]}},{"id":"40cef446c9784e109b7b10acdfaac3c5","type":"GENE","name":"FBLN7","canonical_id":"hgnc:HGNC:26740","description":"fibulin 7","metadata":{"aliases":["FLJ37440","TM14"]}},{"id":"0dae24e9e7024a9597426cf2cc6e5cc6","type":"GENE","name":"FBLP1","canonical_id":"hgnc:HGNC:56806","description":"FBL pseudogene 1","metadata":null},{"id":"c4dfa9c4e9584ac4b5fb629790424998","type":"GENE","name":"FBN1","canonical_id":"hgnc:HGNC:3603","description":null,"metadata":null},{"id":"af06e39503064879a039fc5b2b3c9289","type":"GENE","name":"FBN1-DT","canonical_id":"hgnc:HGNC:55413","description":"FBN1 divergent transcript","metadata":null},{"id":"6e7fb86439174e0fb72c648e05a64c9e","type":"GENE","name":"FBN2","canonical_id":"hgnc:HGNC:3604","description":"fibrillin 2","metadata":{"aliases":["DA9","CCA"]}},{"id":"2e33971208174c4f83ec8be95975c01c","type":"GENE","name":"FBN3","canonical_id":"hgnc:HGNC:18794","description":"fibrillin 3","metadata":{"aliases":["KIAA1776"]}},{"id":"130220b58d74480eadda5932b192f002","type":"GENE","name":"FBP1","canonical_id":"hgnc:HGNC:3606","description":null,"metadata":null},{"id":"dece98caa17c44cd80ec83c0a5909c6c","type":"GENE","name":"FBP2","canonical_id":"hgnc:HGNC:3607","description":"fructose-bisphosphatase 2","metadata":null},{"id":"aa1897bcaa0447c39a42cda65353559c","type":"GENE","name":"FBP2P1","canonical_id":"hgnc:HGNC:49924","description":"fructose-bisphosphatase 2 pseudogene 1","metadata":null},{"id":"147388aa25f04ca3b7ae661f70dbb039","type":"GENE","name":"FBRS","canonical_id":"hgnc:HGNC:20442","description":"fibrosin","metadata":{"aliases":["FBS","FLJ11618","FBS1"]}},{"id":"d60c2563c21e4e60b5a4d5bdcf2b54a5","type":"GENE","name":"FBRSL1","canonical_id":"hgnc:HGNC:29308","description":"fibrosin like 1","metadata":{"aliases":["KIAA1545"]}},{"id":"54003fe518ab4d2ebbb3959cede9acff","type":"GENE","name":"FBRSL1P1","canonical_id":"hgnc:HGNC:56500","description":"FBRSL1 pseudogene 1","metadata":null},{"id":"503788278d5b46e78f26f6b90ac82996","type":"GENE","name":"FBXL12","canonical_id":"hgnc:HGNC:13611","description":"F-box and leucine rich repeat protein 12","metadata":{"aliases":["FLJ20188","Fbl12"]}},{"id":"0530c103720046fb88264f16b186dbc1","type":"GENE","name":"FBXL12P1","canonical_id":"hgnc:HGNC:54776","description":"FBXL12 pseudogene 1","metadata":null},{"id":"b636597652ce4f2993e5b0a529594ba7","type":"GENE","name":"FBXL13","canonical_id":"hgnc:HGNC:21658","description":"F-box and leucine rich repeat protein 13","metadata":{"aliases":["MGC21636","Fbl13","DRC6","CFAP169"]}},{"id":"d68098fd686642b0b6e46a5b9737202b","type":"GENE","name":"FBXL14","canonical_id":"hgnc:HGNC:28624","description":"F-box and leucine rich repeat protein 14","metadata":{"aliases":["MGC40195","Fbl14"]}},{"id":"d53526ad2e364267bca82e809a4d3994","type":"GENE","name":"FBXL15","canonical_id":"hgnc:HGNC:28155","description":"F-box and leucine rich repeat protein 15","metadata":{"aliases":["MGC11279","Fbl15","FBXO37"]}},{"id":"6a21602b40ff42e189924433ee869c58","type":"GENE","name":"FBXL16","canonical_id":"hgnc:HGNC:14150","description":"F-box and leucine rich repeat protein 16","metadata":{"aliases":["MGC33974","Fbl16","C16orf22"]}},{"id":"6eb3e614f9564e7780bccf73cda82488","type":"GENE","name":"FBXL17","canonical_id":"hgnc:HGNC:13615","description":"F-box and leucine rich repeat protein 17","metadata":{"aliases":["DKFZP434C1715","Fbx13","Fbl17","FBXO13"]}},{"id":"6d3023b33d6a4b2ebceeb85ed400a3c2","type":"GENE","name":"FBXL17-AS1","canonical_id":"hgnc:HGNC:59106","description":"FBXL17 antisense RNA 1","metadata":null},{"id":"32dc83b36c7d46c0bfa9a83bc7c16cf3","type":"GENE","name":"FBXL18","canonical_id":"hgnc:HGNC:21874","description":"F-box and leucine rich repeat protein 18","metadata":{"aliases":["FLJ11467","Fbl18"]}},{"id":"ce50f2261e47428585f3b6f4686db259","type":"GENE","name":"FBXL19","canonical_id":"hgnc:HGNC:25300","description":"F-box and leucine rich repeat protein 19","metadata":{"aliases":["DKFZp434K0410","Fbl19","JHDM1C","CXXC11"]}},{"id":"cbfefaa7abf749e8977fc563bb3c3c19","type":"GENE","name":"FBXL19-AS1","canonical_id":"hgnc:HGNC:27557","description":"FBXL19 antisense RNA 1","metadata":{"aliases":["MGC125469","MGC125470","MGC125472","NCRNA00095"]}},{"id":"9809925288a44e6c91a178a4b7e7fbed","type":"GENE","name":"FBXL2","canonical_id":"hgnc:HGNC:13598","description":"F-box and leucine rich repeat protein 2","metadata":{"aliases":["FBL2","FBL3"]}},{"id":"732e1a47219b432395af1db8e01deaef","type":"GENE","name":"FBXL20","canonical_id":"hgnc:HGNC:24679","description":"F-box and leucine rich repeat protein 20","metadata":{"aliases":["MGC15482","Fbl2","Fbl20"]}},{"id":"ac2fe6e268fb4b27b4cb45d0a13e710e","type":"GENE","name":"FBXL21P","canonical_id":"hgnc:HGNC:13600","description":"F-box and leucine rich repeat protein 21, pseudogene","metadata":{"aliases":["FBL3B","Fbl21","FBXL3B","FBXL3P","FBXL21"]}},{"id":"e60adcbca09645c28573267b0b354279","type":"GENE","name":"FBXL22","canonical_id":"hgnc:HGNC:27537","description":"F-box and leucine rich repeat protein 22","metadata":{"aliases":["Fbl22","FLJ39626"]}},{"id":"b599420180c341779733946a3623489d","type":"GENE","name":"FBXL3","canonical_id":"hgnc:HGNC:13599","description":"F-box and leucine rich repeat protein 3","metadata":{"aliases":["FBL3","FBL3A","FBXL3A"]}},{"id":"a19199c0dafc4f21b0b43f79adbf3e94","type":"GENE","name":"FBXL4","canonical_id":"hgnc:HGNC:13601","description":"F-box and leucine rich repeat protein 4","metadata":{"aliases":["FBL4","FBL5"]}},{"id":"4c0b5e434edc4998a38e466ca89f0d48","type":"GENE","name":"FBXL5","canonical_id":"hgnc:HGNC:13602","description":"F-box and leucine rich repeat protein 5","metadata":{"aliases":["FBL4","FBL5","FLR1","CC2D2A-AS1"]}},{"id":"497d947a20b2413990476e6e213adaf6","type":"GENE","name":"FBXL6","canonical_id":"hgnc:HGNC:13603","description":"F-box and leucine rich repeat protein 6","metadata":{"aliases":["FBL6"]}},{"id":"fbb8e479242e4698856bbc89691b2037","type":"GENE","name":"FBXL7","canonical_id":"hgnc:HGNC:13604","description":"F-box and leucine rich repeat protein 7","metadata":{"aliases":["KIAA0840","FBL7","FBL6"]}},{"id":"d5be496aa3b342338a70e06d5c96ee21","type":"GENE","name":"FBXL7-AS1","canonical_id":"hgnc:HGNC:59006","description":"FBXL7 antisense RNA 1","metadata":null},{"id":"90d0cf72986f4becac87e5ee8688a25c","type":"GENE","name":"FBXL7-AS2","canonical_id":"hgnc:HGNC:59007","description":"FBXL7 antisense RNA 2","metadata":null},{"id":"bc4b5dedac0a470eb31731e53f1073f1","type":"GENE","name":"FBXL8","canonical_id":"hgnc:HGNC:17875","description":"F-box and leucine rich repeat protein 8","metadata":{"aliases":["Fbl8"]}},{"id":"342661f98c624317bbe7d0e8f939a3a8","type":"GENE","name":"FBXL9P","canonical_id":"hgnc:HGNC:13605","description":"F-box and leucine rich repeat protein 9, pseudogene","metadata":{"aliases":["FBL9","FBXL9","LRRC29"]}},{"id":"ecaef2090f2c41b4b10216ed6c02a1a9","type":"GO_TERM","name":"FBXO family protein binding","canonical_id":"go:GO:0098770","description":"\"Binding to a member of the FBXO protein family. Members of this family have an F-box protein motif of approximately 50 amino acids that functions as a site of protein-protein interaction.\" [PMID:11178263]","metadata":null},{"id":"21cbab1860d24be49b1a6d5cf8e090a7","type":"GENE","name":"FBXO10","canonical_id":"hgnc:HGNC:13589","description":"F-box protein 10","metadata":{"aliases":["FBX10"]}},{"id":"bec298c02918486fa72de572141e6e4f","type":"GENE","name":"FBXO11","canonical_id":"hgnc:HGNC:13590","description":"F-box protein 11","metadata":{"aliases":["FBX11","UBR6"]}},{"id":"0e612f3f5b3448b987629935624a21ea","type":"GENE","name":"FBXO15","canonical_id":"hgnc:HGNC:13617","description":"F-box protein 15","metadata":{"aliases":["MGC39671","FBX15"]}},{"id":"62da9fa41c9f4db582f078a1134800a2","type":"GENE","name":"FBXO16","canonical_id":"hgnc:HGNC:13618","description":"F-box protein 16","metadata":{"aliases":["FBX16"]}},{"id":"fd46aa9484b4403cbee2197c61781a8d","type":"GENE","name":"FBXO16-AS1","canonical_id":"hgnc:HGNC:58255","description":"FBXO16 antisense RNA 1","metadata":null},{"id":"4aa0a572b21a43ecaa6ae8943aa11fd1","type":"GENE","name":"FBXO17","canonical_id":"hgnc:HGNC:18754","description":"F-box protein 17","metadata":{"aliases":["FBG4","FLJ25205","MGC9379","FLJ11798","Fbx17","FBXO26"]}},{"id":"213f17200ead4e50a08bbac4a05ad858","type":"GENE","name":"FBXO2","canonical_id":"hgnc:HGNC:13581","description":"F-box protein 2","metadata":{"aliases":["FBX2","Nfb42","Fbs1","Fbg1","OCP1"]}},{"id":"4861c9af258a4ab9800328df742980d4","type":"GENE","name":"FBXO21","canonical_id":"hgnc:HGNC:13592","description":"F-box protein 21","metadata":{"aliases":["FBX21","KIAA0875"]}},{"id":"52c9dcb189914c598695ec928f46caa3","type":"GENE","name":"FBXO22","canonical_id":"hgnc:HGNC:13593","description":"F-box protein 22","metadata":{"aliases":["FBX22","FISTC1"]}},{"id":"13a8c2f16d804d67a916afd3c88cbb2a","type":"GENE","name":"FBXO24","canonical_id":"hgnc:HGNC:13595","description":"F-box protein 24","metadata":{"aliases":["FBX24"]}},{"id":"7b4a7db498c64b43a8405ae3e4f3997f","type":"GENE","name":"FBXO25","canonical_id":"hgnc:HGNC:13596","description":"F-box protein 25","metadata":{"aliases":["FBX25"]}},{"id":"bcee66e30b2d45acbcbc89f84402ca6f","type":"GENE","name":"FBXO27","canonical_id":"hgnc:HGNC:18753","description":"F-box protein 27","metadata":{"aliases":["Fbg5","Fbx27"]}},{"id":"6994f385befb4b269ecefe38be1a04cc","type":"GENE","name":"FBXO28","canonical_id":"hgnc:HGNC:29046","description":"F-box protein 28","metadata":{"aliases":["FLJ10766","KIAA0483","Fbx28","CENP-30"]}},{"id":"de900c6af8b74b629e2c45d14483f428","type":"GENE","name":"FBXO3","canonical_id":"hgnc:HGNC:13582","description":"F-box protein 3","metadata":{"aliases":["FBX3","FBA"]}},{"id":"594d44d93e2440419bdc84c31c4dd7e3","type":"GENE","name":"FBXO3-DT","canonical_id":"hgnc:HGNC:51147","description":"FBXO3 divergent transcript","metadata":{"aliases":["FBXO3-AS1"]}},{"id":"08119a34bbdb45a3afc2ad6ed5bd32bd","type":"GENE","name":"FBXO30","canonical_id":"hgnc:HGNC:15600","description":"F-box protein 30","metadata":{"aliases":["MGC21674","Fbx30"]}},{"id":"8e9d40abc48f49b49152936adb3a2bf2","type":"GENE","name":"FBXO31","canonical_id":"hgnc:HGNC:16510","description":"F-box protein 31","metadata":{"aliases":["FBX14","FBXO14","Fbx31","MGC15419"]}},{"id":"efe3c1aeca9f43d39697bfe1c9f27c5b","type":"GENE","name":"FBXO32","canonical_id":"hgnc:HGNC:16731","description":null,"metadata":null},{"id":"45a2a13fe5284406aba666964f34c135","type":"GENE","name":"FBXO33","canonical_id":"hgnc:HGNC:19833","description":"F-box protein 33","metadata":{"aliases":["Fbx33"]}},{"id":"d678d2e78d074ec695d980d2d9b9ab1e","type":"GENE","name":"FBXO34","canonical_id":"hgnc:HGNC:20201","description":"F-box protein 34","metadata":{"aliases":["FLJ20725","Fbx34"]}},{"id":"b17d9d8ef170450ab1803414a4874c4d","type":"GENE","name":"FBXO34-AS1","canonical_id":"hgnc:HGNC:55450","description":"FBXO34 antisense RNA 1","metadata":null},{"id":"69c64919e6604ae38881ff3561a8d41f","type":"GENE","name":"FBXO36","canonical_id":"hgnc:HGNC:27020","description":"F-box protein 36","metadata":{"aliases":["Fbx36","FLJ37592"]}},{"id":"cf9c20027ed04f70af1a34f7829c0135","type":"GENE","name":"FBXO36-IT1","canonical_id":"hgnc:HGNC:41489","description":"FBXO36 intronic transcript 1","metadata":null},{"id":"c9608642defb443bb8281fba922cd550","type":"GENE","name":"FBXO36P1","canonical_id":"hgnc:HGNC:50363","description":"F-box protein 36 pseudogene 1","metadata":null},{"id":"a9eaa9911ee040f0bec243d176ad1e37","type":"GENE","name":"FBXO38","canonical_id":"hgnc:HGNC:28844","description":"F-box protein 38","metadata":{"aliases":["MOKA","SP329","FLJ13962","Fbx38"]}},{"id":"24505551e9a849c0b151892ea7922ada","type":"GENE","name":"FBXO38-DT","canonical_id":"hgnc:HGNC:55589","description":"FBXO38 divergent transcript","metadata":null},{"id":"4020915ac4764d5d95c08296382ea944","type":"GENE","name":"FBXO39","canonical_id":"hgnc:HGNC:28565","description":"F-box protein 39","metadata":{"aliases":["MGC35179","Fbx39","CT144"]}},{"id":"2aa1d955ec6643c6bf9b68ff0f6bceb4","type":"GENE","name":"FBXO4","canonical_id":"hgnc:HGNC:13583","description":"F-box protein 4","metadata":{"aliases":["FBX4"]}},{"id":"621877897337462da1a1b5bf8b9ad141","type":"GENE","name":"FBXO40","canonical_id":"hgnc:HGNC:29816","description":"F-box protein 40","metadata":{"aliases":["KIAA1195","Fbx40"]}},{"id":"5a7480b6b2984439b77a30ed28eca822","type":"GENE","name":"FBXO41","canonical_id":"hgnc:HGNC:29409","description":"F-box protein 41","metadata":{"aliases":["KIAA1940","Fbx41"]}},{"id":"13489e29347f4898b8a3e8b8b9e912ba","type":"GENE","name":"FBXO42","canonical_id":"hgnc:HGNC:29249","description":"F-box protein 42","metadata":{"aliases":["KIAA1332","Fbx42"]}},{"id":"131ca897cd3f4208a87a46909012e9c6","type":"GENE","name":"FBXO43","canonical_id":"hgnc:HGNC:28521","description":"F-box protein 43","metadata":{"aliases":["Fbx43"]}},{"id":"c99ee43e824a4d30907b0efcad46dfc5","type":"GENE","name":"FBXO44","canonical_id":"hgnc:HGNC:24847","description":"F-box protein 44","metadata":{"aliases":["FBX30","FBG3","MGC14140","Fbxo6a","Fbx44"]}},{"id":"cb04835c8c4a413db19c6c481780adcb","type":"GENE","name":"FBXO45","canonical_id":"hgnc:HGNC:29148","description":"F-box protein 45","metadata":{"aliases":["Fbx45"]}},{"id":"d00356e13632425486b7024933dc550e","type":"GENE","name":"FBXO46","canonical_id":"hgnc:HGNC:25069","description":"F-box protein 46","metadata":{"aliases":["20D7-FC4","Fbx46","FBXO34L"]}},{"id":"f5724b76b7ab4f86897531e5a27d6236","type":"GENE","name":"FBXO47","canonical_id":"hgnc:HGNC:31969","description":"F-box protein 47","metadata":null},{"id":"97a05e2960d54a02880d5bd605322662","type":"GENE","name":"FBXO48","canonical_id":"hgnc:HGNC:33857","description":"F-box protein 48","metadata":null},{"id":"1846511b4ef54d758199d2a85c52a03b","type":"GENE","name":"FBXO5","canonical_id":"hgnc:HGNC:13584","description":"F-box protein 5","metadata":{"aliases":["FBX5","Fbxo31","EMI1"]}},{"id":"eb70323d8bfc4b79abcc2df29bc38062","type":"GENE","name":"FBXO6","canonical_id":"hgnc:HGNC:13585","description":"F-box protein 6","metadata":{"aliases":["FBX6","FBG2","FBS2","Fbx6b"]}},{"id":"c3d0cf9e50ea42179459530ebb3381b0","type":"GENE","name":"FBXO7","canonical_id":"hgnc:HGNC:13586","description":"F-box protein 7","metadata":{"aliases":["FBX7","Fbx","PARK15"]}},{"id":"66bf782feebb443e80b2611d8791d054","type":"GENE","name":"FBXO8","canonical_id":"hgnc:HGNC:13587","description":"F-box protein 8","metadata":{"aliases":["FBX8","FBS"]}},{"id":"052ee1667635437595fb94eee0600c82","type":"GENE","name":"FBXO9","canonical_id":"hgnc:HGNC:13588","description":"F-box protein 9","metadata":{"aliases":["FBX9","NY-REN-57"]}},{"id":"c847de26e3064a3a866c483dd26cb023","type":"GENE","name":"FBXW10","canonical_id":"hgnc:HGNC:1211","description":"F-box and WD repeat domain containing 10","metadata":{"aliases":["SM2SH2","HREP","Fbw10","C17orf1","C17orf1A"]}},{"id":"dad5b991cd5247dc873eda6b93ced70f","type":"GENE","name":"FBXW10B","canonical_id":"hgnc:HGNC:14379","description":"F-box and WD repeat domain containing 10B","metadata":{"aliases":["HREP","SM25H2","FBXW10P1","CDRT1"]}},{"id":"d8060161cc4642b69e737b0ae982eeac","type":"GENE","name":"FBXW11","canonical_id":"hgnc:HGNC:13607","description":"F-box and WD repeat domain containing 11","metadata":{"aliases":["KIAA0696","Fbw1b","BTRCP2","BTRC2","Hos","Fbw11","FBXW1B"]}},{"id":"f71bc7b096bf4847a82038f4bc82c4f2","type":"GENE","name":"FBXW11P1","canonical_id":"hgnc:HGNC:1145","description":"F-box and WD repeat domain containing 11 pseudogene 1","metadata":{"aliases":["BTRC2P","FBXW1BP1","FBXW1BP"]}},{"id":"ac5b99b19b6947aa848253d14f0e852b","type":"GENE","name":"FBXW12","canonical_id":"hgnc:HGNC:20729","description":"F-box and WD repeat domain containing 12","metadata":{"aliases":["Fbw12","FBXO35"]}},{"id":"1eb0aba9ee2d48bd94960aa4daf48d76","type":"GENE","name":"FBXW2","canonical_id":"hgnc:HGNC:13608","description":"F-box and WD repeat domain containing 2","metadata":{"aliases":["FBW2","Md6","Fwd2"]}},{"id":"49cf127abd4d4785a4c72e0813cf1857","type":"GENE","name":"FBXW4","canonical_id":"hgnc:HGNC:10847","description":"F-box and WD repeat domain containing 4","metadata":{"aliases":["Fbw4","dactylin","SHFM3"]}},{"id":"bc52ed1df01e42d397ca8bbb60d0b8d5","type":"GENE","name":"FBXW4P1","canonical_id":"hgnc:HGNC:13609","description":"F-box and WD repeat domain containing 4 pseudogene 1","metadata":{"aliases":["FBW3","FBXW3","SHFM3P1"]}},{"id":"752845d4b5e342bda09bd1b1bd0dbbac","type":"GENE","name":"FBXW5","canonical_id":"hgnc:HGNC:13613","description":"F-box and WD repeat domain containing 5","metadata":{"aliases":["DKFZP434B205","MGC20962","Fbw5"]}},{"id":"d6e9fc82d9724d6183f5df98854d6fb5","type":"GENE","name":"FBXW7","canonical_id":"hgnc:HGNC:16712","description":"F-box and WD repeat domain containing 7","metadata":{"aliases":["AGO","FLJ11071","SEL-10","SEL10","FBW7","FBX30","CDC4","FBXW6"]}},{"id":"e50d2353881f45e1badd668136de1a0b","type":"GENE","name":"FBXW7-AS1","canonical_id":"hgnc:HGNC:52397","description":"FBXW7 antisense RNA 1","metadata":{"aliases":["DEAR","DEspR"]}},{"id":"c9b2c2a9a8fb4e8eb6fa00d633196d0f","type":"GENE","name":"FBXW8","canonical_id":"hgnc:HGNC:13597","description":"F-box and WD repeat domain containing 8","metadata":{"aliases":["FBX29","FBW6","FBW8","FBXO29"]}},{"id":"ee8394d233fb4942ac213d03b39ce812","type":"GENE","name":"FBXW9","canonical_id":"hgnc:HGNC:28136","description":"F-box and WD repeat domain containing 9","metadata":{"aliases":["MGC10870","Fbw9","MEC-15"]}},{"id":"c485c123dbd34c90bc406b96886ec57c","type":"GENE","name":"FCAMR","canonical_id":"hgnc:HGNC:24692","description":"Fc alpha and mu receptor","metadata":{"aliases":["FKSG87","FCA/MR","CD351","Fcalpha/muR"]}},{"id":"45504efb32b948108dd4aa7bd5fc6f51","type":"GENE","name":"FCAR","canonical_id":"hgnc:HGNC:3608","description":"Fc alpha receptor","metadata":{"aliases":["CD89","FcalphaRI","FcalphaR"]}},{"id":"2630d230d76a474eb9035fdb84b9960d","type":"GENE","name":"FCER1A","canonical_id":"hgnc:HGNC:3609","description":null,"metadata":null},{"id":"3ef0bb080fdf47948e13f6ff9ef8f83e","type":"GENE","name":"FCER1G","canonical_id":"hgnc:HGNC:3611","description":"Fc epsilon receptor Ig","metadata":{"aliases":["FcepsilonRIgamma"]}},{"id":"10b472043dd542dea0feae533c783c68","type":"GENE","name":"FCER2","canonical_id":"hgnc:HGNC:3612","description":null,"metadata":null},{"id":"f6d2ef6ae1224d47be4ddeddf2c89a35","type":"GENE","name":"FCF1","canonical_id":"hgnc:HGNC:20220","description":"FCF1 rRNA-processing protein","metadata":{"aliases":["CGI-35","Bka","UTP24","C14orf111"]}},{"id":"2be6cef8204d4b269dfaf4700668eb0d","type":"GENE","name":"FCF1P1","canonical_id":"hgnc:HGNC:44613","description":"FCF1 pseudogene 1","metadata":null},{"id":"23e92ec985fe437ebb10554912c9ec00","type":"GENE","name":"FCF1P10","canonical_id":"hgnc:HGNC:44622","description":"FCF1 pseudogene 10","metadata":null},{"id":"77622d5ae814493d88a8fb1435bc030c","type":"GENE","name":"FCF1P11","canonical_id":"hgnc:HGNC:44623","description":"FCF1 pseudogene 11","metadata":null},{"id":"946a5415666b4c28bf4f59e14cd99aad","type":"GENE","name":"FCF1P2","canonical_id":"hgnc:HGNC:44614","description":"FCF1 pseudogene 2","metadata":null},{"id":"013c72784dbe435580ad014352897db7","type":"GENE","name":"FCF1P3","canonical_id":"hgnc:HGNC:44615","description":"FCF1 pseudogene 3","metadata":null},{"id":"6522187f89ee4e04891de8380c1bd76f","type":"GENE","name":"FCF1P4","canonical_id":"hgnc:HGNC:44616","description":"FCF1 pseudogene 4","metadata":null},{"id":"9c598b124101452db8785c2aea5074e4","type":"GENE","name":"FCF1P5","canonical_id":"hgnc:HGNC:44617","description":"FCF1 pseudogene 5","metadata":null},{"id":"0dc4b96290c14fad99fa1e4fea68324b","type":"GENE","name":"FCF1P6","canonical_id":"hgnc:HGNC:44618","description":"FCF1 pseudogene 6","metadata":null},{"id":"9cd6084fd47047f08809f676bf33df5c","type":"GENE","name":"FCF1P7","canonical_id":"hgnc:HGNC:44619","description":"FCF1 pseudogene 7","metadata":null},{"id":"b22403f8783c4e53953ba90043e050f4","type":"GENE","name":"FCF1P8","canonical_id":"hgnc:HGNC:44620","description":"FCF1 pseudogene 8","metadata":null},{"id":"01a7386442ce4a708cabd3e4b9d80400","type":"GENE","name":"FCF1P9","canonical_id":"hgnc:HGNC:44621","description":"FCF1 pseudogene 9","metadata":null},{"id":"c738edb49c1a45db83dfecaca217ebb6","type":"GENE","name":"FCGBP","canonical_id":"hgnc:HGNC:13572","description":"Fc gamma binding protein","metadata":{"aliases":["FC(GAMMA)BP","FcgammaBP"]}},{"id":"3cc9c67c3a1f4296bc1effed75555498","type":"GENE","name":"FCGR1A","canonical_id":"hgnc:HGNC:3613","description":null,"metadata":null},{"id":"ec73174199544e70a70048b94ddbd039","type":"GENE","name":"FCGR1BP","canonical_id":"hgnc:HGNC:3614","description":"Fc gamma receptor Ib, pseudogene","metadata":{"aliases":["CD64b","FCGR1B"]}},{"id":"8fa1fafac3a04484afa02c971fcd2414","type":"GENE","name":"FCGR1CP","canonical_id":"hgnc:HGNC:3615","description":"Fc gamma receptor Ic, pseudogene","metadata":{"aliases":["CD64c","FCGR1C"]}},{"id":"03205bda0bce4cb9bd9b1fdd0c8115bb","type":"GENE","name":"FCGR2A","canonical_id":"hgnc:HGNC:3616","description":"Fc gamma receptor IIa","metadata":{"aliases":["CD32","CD32A","IGFR2","CDw32","Fc-gamma-RIIa","FcgammaRIIa","FCG2","FCGR2A1","FCGR2"]}},{"id":"a9f02663341840d18ba292de1a4cde52","type":"GENE","name":"FCGR2B","canonical_id":"hgnc:HGNC:3618","description":null,"metadata":null},{"id":"8423ffaa9b414fc8bd75686714e830cd","type":"GENE","name":"FCGR2C","canonical_id":"hgnc:HGNC:15626","description":"Fc gamma receptor IIc (gene/pseudogene)","metadata":{"aliases":["hFcRII-C","CD32C","Fc-gamma-RIIc","FcgammaRIIc"]}},{"id":"1230c494a1b74173952ac30223e3e7bd","type":"GENE","name":"FCGR3A","canonical_id":"hgnc:HGNC:3619","description":"Fc gamma receptor IIIa","metadata":{"aliases":["CD16","CD16a","FcgammaRIIIa","FcGRIIIA","FCGR3","FCG3"]}},{"id":"54445d84430a4ec4a074039ecee65889","type":"GENE","name":"FCGR3B","canonical_id":"hgnc:HGNC:3620","description":null,"metadata":null},{"id":"9cbbb2be131a4b988e245fa9ca723ddd","type":"GENE","name":"FCGRT","canonical_id":"hgnc:HGNC:3621","description":null,"metadata":null},{"id":"e29344af27ba42d4a623d1f15f0043e2","type":"PROTEIN","name":"FCGRT","canonical_id":"uniprot:P55899","description":null,"metadata":null},{"id":"dfa42c6f0d2348d2b5c5df5652ddc94f","type":"GENE","name":"FCHO1","canonical_id":"hgnc:HGNC:29002","description":"FCH and mu domain containing endocytic adaptor 1","metadata":{"aliases":["KIAA0290"]}},{"id":"a1f81b2febe94be88e003032ff7a5071","type":"GENE","name":"FCHO1-AS1","canonical_id":"hgnc:HGNC:58600","description":"FCHO1 antisense RNA 1","metadata":null},{"id":"2ed6788a1c4c4351ac7ffa038c5c2480","type":"GENE","name":"FCHO2","canonical_id":"hgnc:HGNC:25180","description":"FCH and mu domain containing endocytic adaptor 2","metadata":null},{"id":"fe332733ce1f474381fe0a78a50115f9","type":"GENE","name":"FCHO2-DT","canonical_id":"hgnc:HGNC:55232","description":"FCHO2 divergent transcript","metadata":{"aliases":["TCONS_00010375"]}},{"id":"f8928073833742e0b2086ffb66d2c2ac","type":"GENE","name":"FCHSD1","canonical_id":"hgnc:HGNC:25463","description":"FCH and double SH3 domains 1","metadata":{"aliases":["FLJ00007"]}},{"id":"ac56c6c6bd5a44be856e10e1ed2aff6f","type":"GENE","name":"FCHSD2","canonical_id":"hgnc:HGNC:29114","description":"FCH and double SH3 domains 2","metadata":{"aliases":["KIAA0769","SH3MD3"]}},{"id":"f2db995971f6460d94f266e3330ac7d2","type":"GENE","name":"FCMR","canonical_id":"hgnc:HGNC:14315","description":"Fc mu receptor","metadata":{"aliases":["TOSO","FcmuR","FAIM3"]}},{"id":"1463910721db43a1b904bb5de258342a","type":"GENE","name":"FCN1","canonical_id":"hgnc:HGNC:3623","description":"ficolin 1","metadata":{"aliases":["FCNM"]}},{"id":"71fd50b321b44e3ebf5ecb18864e43a1","type":"GENE","name":"FCN2","canonical_id":"hgnc:HGNC:3624","description":"ficolin 2","metadata":{"aliases":["P35","FCNL","EBP-37","ficolin-2"]}},{"id":"21e8b7d12b34435aab69c36ecd852b62","type":"GENE","name":"FCN3","canonical_id":"hgnc:HGNC:3625","description":"ficolin 3","metadata":{"aliases":["FCNH","HAKA1"]}},{"id":"57651a7a99c943e08e45b80e6c5203d5","type":"GENE","name":"FCRL1","canonical_id":"hgnc:HGNC:18509","description":"Fc receptor like 1","metadata":{"aliases":["FCRH1","IRTA5","IFGP1","CD307a"]}},{"id":"6df88ba96c60406b92461b0b6bfcc0f1","type":"GENE","name":"FCRL2","canonical_id":"hgnc:HGNC:14875","description":"Fc receptor like 2","metadata":{"aliases":["FCRH2","IRTA4","CD307b","SPAP1"]}},{"id":"57054e08680d417ea559001b4f3bdfec","type":"GENE","name":"FCRL3","canonical_id":"hgnc:HGNC:18506","description":"Fc receptor like 3","metadata":{"aliases":["FCRH3","IRTA3","IFGP3","SPAP2a","SPAP2","SPAP2b","SPAP2c","SPAP2d","SPAP2e","CD307c","MAIA"]}},{"id":"b34c3cb57abe4e6bafe61e4043b90584","type":"GENE","name":"FCRL3-AS1","canonical_id":"hgnc:HGNC:40842","description":"FCRL3 antisense RNA 1","metadata":null},{"id":"2ed67c56debd4d9ab4ec079b943fa2eb","type":"GENE","name":"FCRL4","canonical_id":"hgnc:HGNC:18507","description":"Fc receptor like 4","metadata":{"aliases":["FCRH4","IRTA1","IGFP2","CD307d"]}},{"id":"f631a52b54e84c9bb036d351072c4a83","type":"GENE","name":"FCRL4P1","canonical_id":"hgnc:HGNC:56400","description":"FCRL4 pseudogene 1","metadata":null},{"id":"714dfe309559497f90299e3e0e903ed4","type":"GENE","name":"FCRL5","canonical_id":"hgnc:HGNC:18508","description":"Fc receptor like 5","metadata":{"aliases":["FCRH5","IRTA2","BXMAS1","CD307e"]}},{"id":"ac5abd87697d4925919acc14c6afe8e9","type":"GENE","name":"FCRL6","canonical_id":"hgnc:HGNC:31910","description":"Fc receptor like 6","metadata":{"aliases":["IFGP6","FLJ16056","FcRH6"]}},{"id":"d44b4fda1262462a97d87cef786b2d5d","type":"GENE","name":"FCRL6P1","canonical_id":"hgnc:HGNC:49448","description":"Fc receptor like 6 pseudogene 1","metadata":null},{"id":"0a48a5c99d1e43c38f8c59606bcb8902","type":"GENE","name":"FCRLA","canonical_id":"hgnc:HGNC:18504","description":"Fc receptor like A","metadata":{"aliases":["MGC4595","FCRLc2","FCRLb","FCRLc1","FCRLd","FCRLe","FCRL","FREB","FCRLX","FCRLM1"]}},{"id":"21babcca367e49ab9bb1d0cc27cb55a4","type":"GENE","name":"FCRLB","canonical_id":"hgnc:HGNC:26431","description":"Fc receptor like B","metadata":{"aliases":["FLJ31052","FCRL2","FREB-2","FCRLY","FCRLM2"]}},{"id":"cc97823fdbd040c7b503ec99da74700d","type":"GENE","name":"FCSK","canonical_id":"hgnc:HGNC:29500","description":"fucose kinase","metadata":{"aliases":["FLJ39408","FUK"]}},{"id":"a4af0f8eccfb4b7c8b5757045038f99b","type":"TRIAL","name":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06519370","description":"Triple Negative Breast Cancer","metadata":null},{"id":"8b870cf8a3964b6c893454e90102ca32","type":"GENE","name":"FDCSP","canonical_id":"hgnc:HGNC:19215","description":"follicular dendritic cell secreted protein","metadata":{"aliases":["FDC-SP","C4orf7"]}},{"id":"26e77cec364342de9ded248cddec8710","type":"GENE","name":"FDFT1","canonical_id":"hgnc:HGNC:3629","description":null,"metadata":null},{"id":"73c6aa5890494467a7a8e2dd257a1b94","type":"GENE","name":"FDPS","canonical_id":"hgnc:HGNC:3631","description":null,"metadata":null},{"id":"89bd0569385b4cc2bfc5f82a2dc8bfbe","type":"PROTEIN","name":"FDPS","canonical_id":"uniprot:P14324","description":null,"metadata":null},{"id":"ce0f3d72485449d8a332a6e72c9226e7","type":"GENE","name":"FDPSP1","canonical_id":"hgnc:HGNC:3632","description":"farnesyl diphosphate synthase pseudogene 1","metadata":{"aliases":["CHR39A","FPSL1","FDPSL1"]}},{"id":"5e3724e3aa534cd0b3af3d27f563553f","type":"GENE","name":"FDPSP10","canonical_id":"hgnc:HGNC:39087","description":"farnesyl diphosphate synthase pseudogene 10","metadata":null},{"id":"47a8c383d5304c3880121474b2339a53","type":"GENE","name":"FDPSP2","canonical_id":"hgnc:HGNC:3633","description":"farnesyl diphosphate synthase pseudogene 2","metadata":{"aliases":["TCAG_1641456","FPSL2","FDPSL2","FDPSL2A"]}},{"id":"f01c8056842a4e62ad2ed11f423f2f2e","type":"GENE","name":"FDPSP3","canonical_id":"hgnc:HGNC:3634","description":"farnesyl diphosphate synthase pseudogene 3","metadata":{"aliases":["FPSL3","FDPSL3"]}},{"id":"fe8f4c8d574840baa567bab0f1ae027b","type":"GENE","name":"FDPSP4","canonical_id":"hgnc:HGNC:3635","description":"farnesyl diphosphate synthase pseudogene 4","metadata":{"aliases":["FPSL4","CHR39B","FDPSL4"]}},{"id":"280e691679ed445c8f9cdf654b272ac0","type":"GENE","name":"FDPSP5","canonical_id":"hgnc:HGNC:3636","description":"farnesyl diphosphate synthase pseudogene 5","metadata":{"aliases":["FPSL5","CHR39C","FDPSL5"]}},{"id":"d5dc3ad2183349f6bb5f29a7740780db","type":"GENE","name":"FDPSP6","canonical_id":"hgnc:HGNC:3637","description":"farnesyl diphosphate synthase pseudogene 6","metadata":{"aliases":["FDPSP"]}},{"id":"308ae3c4e3d84fe8a89ff4ebfb23b00a","type":"GENE","name":"FDPSP7","canonical_id":"hgnc:HGNC:33487","description":"farnesyl diphosphate synthase pseudogene 7","metadata":{"aliases":["FDPSL2B"]}},{"id":"d0ff6861fc7b4bdfaa13dace3df99bd2","type":"GENE","name":"FDPSP8","canonical_id":"hgnc:HGNC:39085","description":"farnesyl diphosphate synthase pseudogene 8","metadata":null},{"id":"1837e45985664791857c196577d2d16a","type":"GENE","name":"FDPSP9","canonical_id":"hgnc:HGNC:39086","description":"farnesyl diphosphate synthase pseudogene 9","metadata":null},{"id":"ff889202d4f748d8868b5c8d6734d57d","type":"GENE","name":"FDX1","canonical_id":"hgnc:HGNC:3638","description":"ferredoxin 1","metadata":{"aliases":["ADX","FDX"]}},{"id":"6711ed4bd7354962aa2eaa02cf0653dc","type":"GENE","name":"FDX1P1","canonical_id":"hgnc:HGNC:3640","description":"ferredoxin 1 pseudogene 1","metadata":{"aliases":["ADXP1","FDXP1"]}},{"id":"865494889fe041b18c1717234442f945","type":"GENE","name":"FDX1P2","canonical_id":"hgnc:HGNC:3641","description":"ferredoxin 1 pseudogene 2","metadata":{"aliases":["FDXP2"]}},{"id":"7ff10e0249f2411990e5a7fa6cfb0b9f","type":"GENE","name":"FDX2","canonical_id":"hgnc:HGNC:30546","description":"ferredoxin 2","metadata":{"aliases":["MGC19604","FDX1L"]}},{"id":"4dfe7b45125c4c05bd6ecca6c2ba8132","type":"GENE","name":"FDX2-ZGLP1","canonical_id":"hgnc:HGNC:59021","description":"FDX2-ZGLP1 readthrough (NMD candidate)","metadata":null},{"id":"2df9fd3f84244078a6b1fce2c70b1780","type":"GENE","name":"FDXACB1","canonical_id":"hgnc:HGNC:25110","description":"ferredoxin-fold anticodon binding domain containing 1","metadata":{"aliases":["LOC91893","hCG_2033039"]}},{"id":"db56fe52ae8b4a40b0b88c89eab2dcce","type":"GENE","name":"FDXR","canonical_id":"hgnc:HGNC:3642","description":null,"metadata":null},{"id":"f9558eac11c74bebb23af5656e6b9919","type":"DRUG","name":"FEC Regimen","canonical_id":"ncit:C63420","description":null,"metadata":null},{"id":"ac825acb7071400980c4d1ad89fe3c71","type":"GENE","name":"FECH","canonical_id":"hgnc:HGNC:3647","description":"ferrochelatase","metadata":null},{"id":"efe26ef5e7a04d94911e202759ed41eb","type":"GENE","name":"FECHP1","canonical_id":"hgnc:HGNC:3648","description":"ferrochelatase pseudogene 1","metadata":{"aliases":["FECHP"]}},{"id":"9638cb75310f4294ad8f6d9c91bd6f26","type":"GENE","name":"FEM1A","canonical_id":"hgnc:HGNC:16934","description":"fem-1 homolog A","metadata":null},{"id":"01b3739c3eec4c41bad31769fdc125dc","type":"GENE","name":"FEM1AP1","canonical_id":"hgnc:HGNC:17219","description":"fem-1 homolog A pseudogene 1","metadata":{"aliases":["FEM1DP"]}},{"id":"cc4ec40d8a024395a568075dccfe02a6","type":"GENE","name":"FEM1AP2","canonical_id":"hgnc:HGNC:39830","description":"fem-1 homolog A pseudogene 2","metadata":null},{"id":"cbf59a9cda7b4b83b3375c7fd6f40e9f","type":"GENE","name":"FEM1AP3","canonical_id":"hgnc:HGNC:39831","description":"fem-1 homolog A pseudogene 3","metadata":null},{"id":"9c88504060bc4101a166f6284bb07173","type":"GENE","name":"FEM1AP4","canonical_id":"hgnc:HGNC:39832","description":"fem-1 homolog A pseudogene 4","metadata":null},{"id":"27c5966e67a14f3d922d5c4a39cd8d2d","type":"GENE","name":"FEM1B","canonical_id":"hgnc:HGNC:3649","description":"fem-1 homolog B","metadata":null},{"id":"b95460e9907243cba62ac6a8d1f7b35a","type":"GENE","name":"FEM1C","canonical_id":"hgnc:HGNC:16933","description":"fem-1 homolog C","metadata":{"aliases":["KIAA1785","EUROIMAGE686608","EUROIMAGE783647","FEM1A"]}},{"id":"64efb1ddaad644de8540787429167b60","type":"GENE","name":"FEN1","canonical_id":"hgnc:HGNC:3650","description":"flap structure-specific endonuclease 1","metadata":{"aliases":["FEN-1","MF1","RAD2"]}},{"id":"2406be818cae4de2a50887ad23a12189","type":"GENE","name":"FEN1P1","canonical_id":"hgnc:HGNC:3651","description":"flap structure-specific endonuclease 1 pseudogene 1","metadata":{"aliases":["FENL1"]}},{"id":"ddde45b0cd27469e803fb88b07d339a1","type":"GENE","name":"FENDRR","canonical_id":"hgnc:HGNC:43894","description":"FOXF1 adjacent non-coding developmental regulatory RNA","metadata":{"aliases":["lincFOXF1","onco-lncRNA-21","FOXF1-AS1"]}},{"id":"34299ff7f2b44aa4b3f61e7c2c187e8c","type":"GENE","name":"FER","canonical_id":"hgnc:HGNC:3655","description":"FER tyrosine kinase","metadata":{"aliases":["TYK3","PPP1R74"]}},{"id":"77fb411fe3e94588a7f96271776a5d78","type":"GENE","name":"FER-AS1","canonical_id":"hgnc:HGNC:59107","description":"FER antisense RNA 1","metadata":null},{"id":"e91764bfa9af4ae492f4f75fd71b707e","type":"GENE","name":"FER-AS2","canonical_id":"hgnc:HGNC:59108","description":"FER antisense RNA 2","metadata":null},{"id":"bbdcb2f5d89d4774856dfaec9122671a","type":"GENE","name":"FER1L4","canonical_id":"hgnc:HGNC:15801","description":"fer-1 like family member 4 (pseudogene)","metadata":{"aliases":["FER1L4P","bA563A22B.1","dJ309K20.1","C20orf124"]}},{"id":"a3f0bee131b24e5abffb4b64589ac344","type":"GENE","name":"FER1L5","canonical_id":"hgnc:HGNC:19044","description":"fer-1 like family member 5","metadata":{"aliases":["DKFZp434I0121"]}},{"id":"91e345079f414cd6ae891951912a0a99","type":"GENE","name":"FER1L6","canonical_id":"hgnc:HGNC:28065","description":"fer-1 like family member 6","metadata":{"aliases":["C8ORFK23"]}},{"id":"12201135f247435cb1c97ebfe7519b1b","type":"GENE","name":"FER1L6-AS1","canonical_id":"hgnc:HGNC:26652","description":"FER1L6 antisense RNA 1","metadata":{"aliases":["FLJ35721","C8orf54"]}},{"id":"294f0d524f4642a6bec48f530cfe8ad4","type":"GENE","name":"FER1L6-AS2","canonical_id":"hgnc:HGNC:26534","description":"FER1L6 antisense RNA 2","metadata":{"aliases":["FLJ32770","C8orf78"]}},{"id":"5594bfad122e424bb572cbac16ff88cf","type":"GENE","name":"FERD3L","canonical_id":"hgnc:HGNC:16660","description":"Fer3 like bHLH transcription factor","metadata":{"aliases":["NATO3","N-TWIST","bHLHa31"]}},{"id":"49d091759c9940dab1dc5a5c93fa208a","type":"GENE","name":"FERMT1","canonical_id":"hgnc:HGNC:15889","description":"FERM domain containing kindlin 1","metadata":{"aliases":["FLJ20116","URP1","KIND1","UNC112A","C20orf42"]}},{"id":"c83aa006b7304f1cb356abac5d742e1e","type":"GENE","name":"FERMT2","canonical_id":"hgnc:HGNC:15767","description":"FERM domain containing kindlin 2","metadata":{"aliases":["mig-2","KIND2","UNC112B","PLEKHC1"]}},{"id":"17583bd1adda40978a8f204dfc81b683","type":"GENE","name":"FERMT3","canonical_id":"hgnc:HGNC:23151","description":"FERM domain containing kindlin 3","metadata":{"aliases":["URP2","KIND3","MIG2B","MGC10966","UNC112C"]}},{"id":"914c4529da5a4f81b4887f0d4f4a188a","type":"GENE","name":"FERP1","canonical_id":"hgnc:HGNC:26443","description":"FER tyrosine kinase pseudogene 1","metadata":{"aliases":["FERps","FERP"]}},{"id":"219f61f28cb144d99842c0740238e5af","type":"GENE","name":"FERRISR","canonical_id":"hgnc:HGNC:58367","description":"ferroptosis inhibiting SLC7A11 regulator","metadata":{"aliases":["FERRIN"]}},{"id":"f6101b8bfeb44cbca6202c6a0d4d5bfe","type":"GO_TERM","name":"FERRY complex","canonical_id":"go:GO:0160271","description":"\"A protein complex that directly interacts with mRNAs and Rab5, functions as a Rab5 effector, recruits mRNAs and ribosomes to early endosomes through direct mRNA-interaction, is composed of five subunits, TBCK, PPP1R21, FERRY3, CRYZL1 and GATD1 with a ratio of 1:2:1:2:4, respectively.\" [PMID:37267905, PMID:37267906]","metadata":null},{"id":"81dd218e5c9944b591fe80ba57031bc6","type":"GENE","name":"FERRY3","canonical_id":"hgnc:HGNC:1184","description":"FERRY endosomal RAB5 effector complex subunit 3","metadata":{"aliases":["Fy-3","C12orf4"]}},{"id":"9833a0f4cbef404091f1f672ab211651","type":"GENE","name":"FES","canonical_id":"hgnc:HGNC:3657","description":null,"metadata":null},{"id":"b9c252ac6bb4475d860bbc60772f730e","type":"TRIAL","name":"FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)","canonical_id":"clinicaltrials.gov:NCT01426555","description":"Osteoporosis","metadata":null},{"id":"cf8fda2ba5c742ad9aa2c2e6439e7526","type":"GENE","name":"FETUB","canonical_id":"hgnc:HGNC:3658","description":"fetuin B","metadata":null},{"id":"0a81bc2ee2774bc78e16cbc743bf5dc9","type":"GENE","name":"FEV","canonical_id":"hgnc:HGNC:18562","description":"FEV transcription factor, ETS family member","metadata":{"aliases":["Pet-1"]}},{"id":"1fcdedba13b7453bbcdf0c5108b30595","type":"GENE","name":"FEZ1","canonical_id":"hgnc:HGNC:3659","description":"fasciculation and elongation protein zeta 1","metadata":{"aliases":["UNC-76"]}},{"id":"f5a025c8b6114cbc8fc08eb194d8340e","type":"GENE","name":"FEZ2","canonical_id":"hgnc:HGNC:3660","description":"fasciculation and elongation protein zeta 2","metadata":null},{"id":"4282b978656e444db7700ca3ee047ce0","type":"GENE","name":"FEZF1","canonical_id":"hgnc:HGNC:22788","description":"FEZ family zinc finger 1","metadata":{"aliases":["ZNF312B"]}},{"id":"c28aafe8722045c2a7d5c3c57d9394ed","type":"GENE","name":"FEZF1-AS1","canonical_id":"hgnc:HGNC:41001","description":"FEZF1 antisense RNA 1","metadata":null},{"id":"d319fd8f20a7488a9ef4b1d73b5e9ccf","type":"GENE","name":"FEZF2","canonical_id":"hgnc:HGNC:13506","description":"FEZ family zinc finger 2","metadata":{"aliases":["FLJ10142","FKSG36","TOF","FEZL","Zfp312","ZNF312"]}},{"id":"7bbe979150d148838140c74d231ac995","type":"GENE","name":"FFAR1","canonical_id":"hgnc:HGNC:4498","description":"free fatty acid receptor 1","metadata":{"aliases":["FFA1R","GPR40"]}},{"id":"0d41ef9112f3480ca365b81681c1a9d3","type":"GENE","name":"FFAR2","canonical_id":"hgnc:HGNC:4501","description":"free fatty acid receptor 2","metadata":{"aliases":["FFA2R","GPR43"]}},{"id":"94da204058784e7694d960ef404790b1","type":"GENE","name":"FFAR3","canonical_id":"hgnc:HGNC:4499","description":"free fatty acid receptor 3","metadata":{"aliases":["FFA3R","GPR41"]}},{"id":"13672f7718d647b58c4501439711563a","type":"GENE","name":"FFAR4","canonical_id":"hgnc:HGNC:19061","description":"free fatty acid receptor 4","metadata":{"aliases":["PGR4","GPR129","GPR120","O3FAR1"]}},{"id":"f782317291df4e5293951f4905fd85f1","type":"GO_TERM","name":"FFAT motif binding","canonical_id":"go:GO:0033149","description":"\"Binding to a FFAT motif, a short motif containing diphenylalanine in an acidic tract that targets proteins to the cytosolic surface of the ER and to the nuclear membrane by binding directly to members of the VAP (VAMP-associated protein) protein family.\" [PMID:12727870, PMID:15455074, PMID:16004875]","metadata":null},{"id":"818bc43d59a14e3f984300afc8ba0521","type":"GENE","name":"FGA","canonical_id":"hgnc:HGNC:3661","description":null,"metadata":null},{"id":"104436ac083046ddaed88393de95af4b","type":"GENE","name":"FGB","canonical_id":"hgnc:HGNC:3662","description":null,"metadata":null},{"id":"f5885c7076864b45b02fcb79e938c97c","type":"GENE","name":"FGD1","canonical_id":"hgnc:HGNC:3663","description":"FYVE, RhoGEF and PH domain containing 1","metadata":{"aliases":["ZFYVE3","FGDY"]}},{"id":"a47f2ada6705492180e19a3ec8c22af3","type":"GENE","name":"FGD2","canonical_id":"hgnc:HGNC:3664","description":"FYVE, RhoGEF and PH domain containing 2","metadata":{"aliases":["ZFYVE4"]}},{"id":"098235f446f542bda50cd81a0a45e243","type":"GENE","name":"FGD3","canonical_id":"hgnc:HGNC:16027","description":"FYVE, RhoGEF and PH domain containing 3","metadata":{"aliases":["FLJ00004","ZFYVE5"]}},{"id":"455cd5f4c1864c79a64f5c73e08c8d27","type":"GENE","name":"FGD4","canonical_id":"hgnc:HGNC:19125","description":"FYVE, RhoGEF and PH domain containing 4","metadata":{"aliases":["FRABP","frabin","ZFYVE6","CMT4H"]}},{"id":"906d5a5d674049049ead85b31fca73b2","type":"GENE","name":"FGD5","canonical_id":"hgnc:HGNC:19117","description":"FYVE, RhoGEF and PH domain containing 5","metadata":{"aliases":["ZFYVE23","FLJ39957","FLJ00274"]}},{"id":"7a083caf69284432b65c8716d1363312","type":"GENE","name":"FGD5-AS1","canonical_id":"hgnc:HGNC:40410","description":"FGD5 antisense RNA 1","metadata":null},{"id":"9bc793e747274006a9563be411c97c47","type":"GENE","name":"FGD5P1","canonical_id":"hgnc:HGNC:44498","description":"FYVE, RhoGEF and PH domain containing 5 pseudogene 1","metadata":null},{"id":"1a0e4994da0a4026b94cd3adb9a1fbc2","type":"GENE","name":"FGD6","canonical_id":"hgnc:HGNC:21740","description":"FYVE, RhoGEF and PH domain containing 6","metadata":{"aliases":["ZFYVE24","FLJ11183"]}},{"id":"fadd8307fe0142b38e6a1f5f112417b1","type":"GENE","name":"FGF1","canonical_id":"hgnc:HGNC:3665","description":null,"metadata":null},{"id":"f7b7eaf1f442431b85a73991e6dd2832","type":"GENE","name":"FGF10","canonical_id":"hgnc:HGNC:3666","description":null,"metadata":null},{"id":"6b77c6c1abf5499cba2fd6c10515e866","type":"GENE","name":"FGF10-AS1","canonical_id":"hgnc:HGNC:49382","description":"FGF10 antisense RNA 1","metadata":{"aliases":["RP11-473L15.2"]}},{"id":"1194f5b4ee084d74966a3e30aecf626d","type":"GENE","name":"FGF11","canonical_id":"hgnc:HGNC:3667","description":"fibroblast growth factor 11","metadata":{"aliases":["FHF3","FLJ16061","MGC45269","MGC102953"]}},{"id":"6c686a2e532f462f99f979dddf493328","type":"GENE","name":"FGF12","canonical_id":"hgnc:HGNC:3668","description":"fibroblast growth factor 12","metadata":{"aliases":["FHF1","FGF12B"]}},{"id":"9e86ff776a08462cadd7d566f6ef3a49","type":"GENE","name":"FGF12-AS1","canonical_id":"hgnc:HGNC:40234","description":"FGF12 antisense RNA 1","metadata":null},{"id":"150ff1f1473e43ad94c6b46900d9ebf1","type":"GENE","name":"FGF12-AS2","canonical_id":"hgnc:HGNC:40235","description":"FGF12 antisense RNA 2","metadata":null},{"id":"c78571cd94a34601975115a882a5f35d","type":"GENE","name":"FGF12-AS3","canonical_id":"hgnc:HGNC:40236","description":"FGF12 antisense RNA 3","metadata":null},{"id":"57668ac268b045a099fe7830d360e2b5","type":"GENE","name":"FGF13","canonical_id":"hgnc:HGNC:3670","description":"fibroblast growth factor 13","metadata":{"aliases":["FHF2","FGF2","FLJ30672","LINC00889"]}},{"id":"9eedb1b62c8f43398501d48e3ed6dc4d","type":"GENE","name":"FGF13-AS1","canonical_id":"hgnc:HGNC:44264","description":"FGF13 antisense RNA 1","metadata":null},{"id":"c6ddbbaa70e9448fb48ec6bd32ef599a","type":"GENE","name":"FGF14","canonical_id":"hgnc:HGNC:3671","description":"fibroblast growth factor 14","metadata":{"aliases":["FHF4","SCA27"]}},{"id":"766e871270304ea190b413ca8299168d","type":"GENE","name":"FGF14-AS1","canonical_id":"hgnc:HGNC:40237","description":"FGF14 antisense RNA 1","metadata":null},{"id":"a8bcfb263e4f43fc8889cb0f0997358d","type":"GENE","name":"FGF14-AS2","canonical_id":"hgnc:HGNC:44368","description":"FGF14 antisense RNA 2","metadata":null},{"id":"567b8b0bc4fb4bb58085cc5c02510932","type":"GENE","name":"FGF14-IT1","canonical_id":"hgnc:HGNC:42774","description":"FGF14 intronic transcript 1","metadata":null},{"id":"dadf00a9b9d14482b1d9302972517fda","type":"GENE","name":"FGF16","canonical_id":"hgnc:HGNC:3672","description":null,"metadata":null},{"id":"14d4bdf4cf1542978655e02c57803f2f","type":"GENE","name":"FGF17","canonical_id":"hgnc:HGNC:3673","description":"fibroblast growth factor 17","metadata":{"aliases":["FGF-13"]}},{"id":"239ac75f22104dbd8db1b75f0730eb8f","type":"GENE","name":"FGF18","canonical_id":"hgnc:HGNC:3674","description":"fibroblast growth factor 18","metadata":{"aliases":["FGF-18","ZFGF5"]}},{"id":"59c2a24688a146cdaf6e6609b2d638b0","type":"GENE","name":"FGF19","canonical_id":"hgnc:HGNC:3675","description":null,"metadata":null},{"id":"6b602c0307c74c07ac610830b01187df","type":"GENE","name":"FGF2","canonical_id":"hgnc:HGNC:3676","description":null,"metadata":null},{"id":"e99042cfe1a64491a1a73e73ae42a433","type":"GENE","name":"FGF20","canonical_id":"hgnc:HGNC:3677","description":"fibroblast growth factor 20","metadata":null},{"id":"7ff6b68da1e2479f873c052cc902c78f","type":"GENE","name":"FGF21","canonical_id":"hgnc:HGNC:3678","description":null,"metadata":null},{"id":"8267593e6839499380066cd54a8382fd","type":"GENE","name":"FGF22","canonical_id":"hgnc:HGNC:3679","description":"fibroblast growth factor 22","metadata":null},{"id":"f1082a6b235d40c58b92d2e18039fb58","type":"GENE","name":"FGF23","canonical_id":"hgnc:HGNC:3680","description":"fibroblast growth factor 23","metadata":null},{"id":"98618087492942588792468fe374beb3","type":"PROTEIN","name":"FGF23","canonical_id":"uniprot:Q9GZV9","description":null,"metadata":null},{"id":"d63c96feb0b3429284d50b970c1b9929","type":"GENE","name":"FGF3","canonical_id":"hgnc:HGNC:3681","description":"fibroblast growth factor 3","metadata":{"aliases":["HBGF-3","INT2"]}},{"id":"5ce6b109dca842fcae40f246e0eda5b0","type":"GENE","name":"FGF4","canonical_id":"hgnc:HGNC:3682","description":null,"metadata":null},{"id":"d406782db53a4a0995bb38cdabd7c9ec","type":"GENE","name":"FGF5","canonical_id":"hgnc:HGNC:3683","description":"fibroblast growth factor 5","metadata":null},{"id":"9ccd82c4d21245a9af263a65a73475b1","type":"GENE","name":"FGF6","canonical_id":"hgnc:HGNC:3684","description":"fibroblast growth factor 6","metadata":null},{"id":"ff9babceef42434caf3ead06816f7bfa","type":"GENE","name":"FGF7","canonical_id":"hgnc:HGNC:3685","description":null,"metadata":null},{"id":"378b2c4a048e41b3b5850fc6243aba82","type":"GENE","name":"FGF7P1","canonical_id":"hgnc:HGNC:21455","description":"fibroblast growth factor 7 pseudogene 1","metadata":{"aliases":["HsT283"]}},{"id":"b70ad663d96a487e9a32a44f7cc92f51","type":"GENE","name":"FGF7P2","canonical_id":"hgnc:HGNC:17193","description":"fibroblast growth factor 7 pseudogene 2","metadata":{"aliases":["FGF7L"]}},{"id":"e97299b9035948da94caadbe4d013801","type":"GENE","name":"FGF7P3","canonical_id":"hgnc:HGNC:26671","description":"fibroblast growth factor 7 pseudogene 3","metadata":{"aliases":["KGFLP2"]}},{"id":"a83acc9a3cf74bf295e0d660b50bd35b","type":"GENE","name":"FGF7P4","canonical_id":"hgnc:HGNC:33587","description":"fibroblast growth factor 7 pseudogene 4","metadata":null},{"id":"e6c1afd5ace74716b96a060e11fbf3d8","type":"GENE","name":"FGF7P5","canonical_id":"hgnc:HGNC:33588","description":"fibroblast growth factor 7 pseudogene 5","metadata":null},{"id":"0d96bc90cdfe4f8f9e58abd15081452b","type":"GENE","name":"FGF7P6","canonical_id":"hgnc:HGNC:27852","description":"fibroblast growth factor 7 pseudogene 6","metadata":{"aliases":["KGFLP1"]}},{"id":"18c651e9a82e401ca1644d3af09de9c4","type":"GENE","name":"FGF7P7","canonical_id":"hgnc:HGNC:33589","description":"fibroblast growth factor 7 pseudogene 7","metadata":null},{"id":"ad5d33c654f149809291afdf67945181","type":"GENE","name":"FGF7P8","canonical_id":"hgnc:HGNC:34516","description":"fibroblast growth factor 7 pseudogene 8","metadata":null},{"id":"1d9da82786d742a489195a60de35c11f","type":"GENE","name":"FGF8","canonical_id":"hgnc:HGNC:3686","description":null,"metadata":null},{"id":"6693a035e1b84acd864d50772aa28f63","type":"GENE","name":"FGF9","canonical_id":"hgnc:HGNC:3687","description":null,"metadata":null},{"id":"abdd50515411495083162de91d964c76","type":"GENE","name":"FGFBP1","canonical_id":"hgnc:HGNC:19695","description":null,"metadata":null},{"id":"ba2028630a6e4c9dbf0a52481bc32b35","type":"GENE","name":"FGFBP2","canonical_id":"hgnc:HGNC:29451","description":"fibroblast growth factor binding protein 2","metadata":{"aliases":["KSP37"]}},{"id":"dd69e3981857420d9a371a1e728f1bb9","type":"GENE","name":"FGFBP3","canonical_id":"hgnc:HGNC:23428","description":"fibroblast growth factor binding protein 3","metadata":{"aliases":["MGC39320","C10orf13"]}},{"id":"cb5dc0ec0c9c421f9363bf7adc3f8ed5","type":"GENE","name":"FGFBP3-AS1","canonical_id":"hgnc:HGNC:58342","description":"FGFBP3 antisense RNA 1","metadata":null},{"id":"7823ce48a606498d8ba589cd975a1981","type":"GENE","name":"FGFR1","canonical_id":"hgnc:HGNC:3688","description":null,"metadata":null},{"id":"50f58b0c597849c0bec1488732284f1b","type":"GENE","name":"FGFR1","canonical_id":"ensembl:ENSG00000077782","description":null,"metadata":null},{"id":"d2c6c9bd5e53423e976b93409ab194cf","type":"PROTEIN","name":"FGFR1","canonical_id":"uniprot:P11362","description":null,"metadata":null},{"id":"1d1b71fdb53a47669dd8213b879db03c","type":"GENE","name":"FGFR1OP2","canonical_id":"hgnc:HGNC:23098","description":"FGFR1 oncogene partner 2","metadata":{"aliases":["DKFZp564O1863"]}},{"id":"420ffa9c767b4ffab366f19e1c744e62","type":"GENE","name":"FGFR1OP2P1","canonical_id":"hgnc:HGNC:39706","description":"FGFR1 oncogene partner 2 pseudogene 1","metadata":null},{"id":"a0a561066574454cb052176905142b8a","type":"GENE","name":"FGFR2","canonical_id":"hgnc:HGNC:3689","description":"fibroblast growth factor receptor 2","metadata":{"aliases":["CEK3","TK14","TK25","ECT1","K-SAM","CD332","KGFR","BEK","CFD1","JWS"]}},{"id":"874165e94a5141d4a97902d048d6c65d","type":"GENE","name":"FGFR2","canonical_id":"ensembl:ENSG00000066468","description":null,"metadata":null},{"id":"bdda9aee5cbc46dd8c132e776b4b0afd","type":"PROTEIN","name":"FGFR2","canonical_id":"uniprot:P21802","description":null,"metadata":null},{"id":"2deccd14767d48c8b93577bc4cdbbab6","type":"GENE","name":"FGFR3","canonical_id":"hgnc:HGNC:3690","description":null,"metadata":null},{"id":"3c95c0136adc4ae9b4cad30903a9d292","type":"GENE","name":"FGFR3","canonical_id":"ensembl:ENSG00000068078","description":null,"metadata":null},{"id":"807224e7fa554605a6e63770d6dab6ed","type":"PROTEIN","name":"FGFR3","canonical_id":"uniprot:P22607","description":null,"metadata":null},{"id":"230081f93e8a47bfb0b899a72ad29ebe","type":"GENE","name":"FGFR3P1","canonical_id":"hgnc:HGNC:21664","description":"fibroblast growth factor receptor 3 pseudogene 1","metadata":{"aliases":["D84394.2","FGFR3P","FGFR6"]}},{"id":"13336927e63c49569395fd943f84e5f3","type":"GENE","name":"FGFR3P2","canonical_id":"hgnc:HGNC:37947","description":"fibroblast growth factor receptor 3 pseudogene 2","metadata":null},{"id":"588b7d66abb747a89dca47ded25cbdeb","type":"GENE","name":"FGFR3P3","canonical_id":"hgnc:HGNC:37948","description":"fibroblast growth factor receptor 3 pseudogene 3","metadata":null},{"id":"34903636b06d432bbf12c9981ec9e548","type":"GENE","name":"FGFR3P4","canonical_id":"hgnc:HGNC:37949","description":"fibroblast growth factor receptor 3 pseudogene 4","metadata":null},{"id":"28c54fd62cf3435eac2c59a78d8a5706","type":"GENE","name":"FGFR3P5","canonical_id":"hgnc:HGNC:37950","description":"fibroblast growth factor receptor 3 pseudogene 5","metadata":null},{"id":"cb505f18da4149faa0bb4ff5e34ebd28","type":"GENE","name":"FGFR3P6","canonical_id":"hgnc:HGNC:37951","description":"fibroblast growth factor receptor 3 pseudogene 6","metadata":null},{"id":"85a87bada7404875b83b35991ae305dd","type":"GENE","name":"FGFR4","canonical_id":"hgnc:HGNC:3691","description":null,"metadata":null},{"id":"6c3487152a03433fb7a3ce03a5b3365d","type":"GENE","name":"FGFRL1","canonical_id":"hgnc:HGNC:3693","description":"fibroblast growth factor receptor like 1","metadata":{"aliases":["FGFR5"]}},{"id":"d8b3b7dbaffb4e188b8a8bf1fd47bdc7","type":"GENE","name":"FGG","canonical_id":"hgnc:HGNC:3694","description":null,"metadata":null},{"id":"235faabce6bb45d8b16ea06cb50c6946","type":"GENE","name":"FGGY","canonical_id":"hgnc:HGNC:25610","description":"FGGY carbohydrate kinase domain containing","metadata":{"aliases":["FLJ10986"]}},{"id":"eac28a46841d47c1ad938249e93b1804","type":"GENE","name":"FGGY-DT","canonical_id":"hgnc:HGNC:55265","description":"FGGY divergent transcript","metadata":null},{"id":"eda36f4cacb74bbca171f406b5789238","type":"GENE","name":"FGL1","canonical_id":"hgnc:HGNC:3695","description":null,"metadata":null},{"id":"a2c9fcf8bf9047e8854b8f2f7ab63225","type":"GENE","name":"FGL1-AS1","canonical_id":"hgnc:HGNC:58257","description":"FGL1 antisense RNA 1","metadata":null},{"id":"6c4564000d0e47609ffb8b2cb5afdbc0","type":"GENE","name":"FGL2","canonical_id":"hgnc:HGNC:3696","description":null,"metadata":null},{"id":"8ce715ad64994a37954c698adfd3c6cd","type":"GENE","name":"FGR","canonical_id":"hgnc:HGNC:3697","description":"FGR proto-oncogene, Src family tyrosine kinase","metadata":{"aliases":["c-fgr","p55c-fgr","SRC2"]}},{"id":"255dd3319e6c4caeb40ae1231fc5711b","type":"GENE","name":"FH","canonical_id":"hgnc:HGNC:3700","description":"fumarate hydratase","metadata":{"aliases":["FUM"]}},{"id":"353957fa81f34b28810a7bb2b7cebe89","type":"GO_TERM","name":"FH1 domain binding","canonical_id":"go:GO:0017058","description":"\"Binding to a FH1 domain of a protein, a proline-rich domain, usually located in front of a FH2 domain.\" [GOC:curators]","metadata":null},{"id":"2137dfe474b248f2a014349ebe1d7bd1","type":"GO_TERM","name":"FHA domain binding","canonical_id":"go:GO:0070975","description":"\"Binding to a FHA domain of a protein. The FHA domain is a phosphopeptide recognition domain found in many regulatory proteins, and consists of approximately 80-100 amino acid residues folded into an 11-stranded beta sandwich.\" [GOC:mah, InterPro:IPR000253]","metadata":null},{"id":"1ca46739457b4129ad1739687b1cb8be","type":"GENE","name":"FHAD1","canonical_id":"hgnc:HGNC:29408","description":"forkhead associated phosphopeptide binding domain 1","metadata":{"aliases":["KIAA1937"]}},{"id":"ae2eec7fae33471dadea1c85ce50b621","type":"GENE","name":"FHAD1-AS1","canonical_id":"hgnc:HGNC:41241","description":"FHAD1 antisense RNA 1","metadata":null},{"id":"eb3fd47127244160ac9908e20d702fe3","type":"GENE","name":"FHDC1","canonical_id":"hgnc:HGNC:29363","description":"FH2 domain containing 1","metadata":{"aliases":["KIAA1727","INF1"]}},{"id":"86e6195d6bb648d9a0a29ba6a1a3015f","type":"GENE","name":"FHDC1-AS1","canonical_id":"hgnc:HGNC:58897","description":"FHDC1 antisense RNA 1","metadata":null},{"id":"b837404f420e443f82dbaeefe1ee26a1","type":"GO_TERM","name":"FHF complex","canonical_id":"go:GO:0070695","description":"\"A protein complex that is composed of AKTIP/FTS, FAM160A2/p107FHIP, and one or more members of the Hook family of proteins, HOOK1, HOOK2, and HOOK3. The complex is thought to promote vesicle trafficking and/or fusion, and associates with the homotypic vesicular sorting complex (the HOPS complex).\" [GOC:ab, GOC:mah, PMID:18799622]","metadata":null},{"id":"46863dfc6c8645409f9541e07a193d95","type":"GENE","name":"FHIP1A","canonical_id":"hgnc:HGNC:34237","description":"FHF complex subunit HOOK interacting protein 1A","metadata":{"aliases":["FLJ43373","FHIP-L","FAM160A1"]}},{"id":"6b29061729fd4a2898e1d06d5926a5ed","type":"GENE","name":"FHIP1A-DT","canonical_id":"hgnc:HGNC:53123","description":"FHIP1A divergent transcript","metadata":{"aliases":["RP11-610P16.1","FAM160A1-DT"]}},{"id":"3413b744e1c44136b16a7964b8465fa9","type":"GENE","name":"FHIP1B","canonical_id":"hgnc:HGNC:25378","description":"FHF complex subunit HOOK interacting protein 1B","metadata":{"aliases":["FLJ22665","KIAA1759","DKFZP566M1046","FHIP","C11orf56","FAM160A2"]}},{"id":"5b85aa76b85f4d7bb06024bf33ae3cb9","type":"GENE","name":"FHIP2A","canonical_id":"hgnc:HGNC:29320","description":"FHF complex subunit HOOK interacting protein 2A","metadata":{"aliases":["bA106M7.3","KIAA1600","FAM160B1"]}},{"id":"a3052a1935cd41d8bbaf6c14ce14826e","type":"GENE","name":"FHIP2B","canonical_id":"hgnc:HGNC:16492","description":"FHF complex subunit HOOK interacting protein 2B","metadata":{"aliases":["FLJ21801","RAI16","FAM160B2"]}},{"id":"4c4bfee392f04084aac3aca792dce811","type":"GENE","name":"FHIT","canonical_id":"hgnc:HGNC:3701","description":null,"metadata":null},{"id":"cccbd45ec3ed4ae59a234c324a64ab53","type":"GENE","name":"FHL1","canonical_id":"hgnc:HGNC:3702","description":null,"metadata":null},{"id":"41aa598e45e44b12a893adaa3dd19703","type":"GENE","name":"FHL1P1","canonical_id":"hgnc:HGNC:56632","description":"FHL1 pseudogene 1","metadata":null},{"id":"d4426284b10446fea174017d093a07d1","type":"GENE","name":"FHL2","canonical_id":"hgnc:HGNC:3703","description":null,"metadata":null},{"id":"7a14eaba31384605b90cd82dba2fe7f5","type":"GO_TERM","name":"FHL2-CREB complex","canonical_id":"go:GO:0034980","description":"\"A protein complex that contains CREB and FHL2, and is involved in transcriptional regulation.\" [PMID:11046156]","metadata":null},{"id":"5b9ffdf91cb542199c4425ce4cd0dd9d","type":"GENE","name":"FHL3","canonical_id":"hgnc:HGNC:3704","description":"four and a half LIM domains 3","metadata":{"aliases":["SLIM2"]}},{"id":"f49b1d28587749f09f9135f45f7e715e","type":"GO_TERM","name":"FHL3-CREB complex","canonical_id":"go:GO:0034981","description":"\"A protein complex that contains CREB and FHL3, and is involved in transcriptional regulation.\" [PMID:11046156]","metadata":null},{"id":"1df49f627691427b88cca2840bb58b2e","type":"GENE","name":"FHL5","canonical_id":"hgnc:HGNC:17371","description":null,"metadata":null},{"id":"6bb72591df73469fb1f265e16a4cc132","type":"GENE","name":"FHOD1","canonical_id":"hgnc:HGNC:17905","description":"formin homology 2 domain containing 1","metadata":{"aliases":["FHOS"]}},{"id":"d76c11e3f486400db9309dbbc58ef76a","type":"GENE","name":"FHOD3","canonical_id":"hgnc:HGNC:26178","description":"formin homology 2 domain containing 3","metadata":{"aliases":["FHOS2","KIAA1695","FLJ22297","FLJ22717"]}},{"id":"d6ecded92f144130bbdff0f73c06e2e0","type":"GENE","name":"FHP1","canonical_id":"hgnc:HGNC:39442","description":"fumarate hydratase pseudogene 1","metadata":null},{"id":"51002d2091df426ea4ee63f97257e6b2","type":"GENE","name":"FHP2","canonical_id":"hgnc:HGNC:56714","description":"fumarate hydratase pseudogene 2","metadata":null},{"id":"1924aa0fe1d140debc214d7eb6308285","type":"GENE","name":"FIBCD1","canonical_id":"hgnc:HGNC:25922","description":"fibrinogen C domain containing 1","metadata":{"aliases":["FLJ14810"]}},{"id":"b2d9cd11477044a7997c3105eb6b3939","type":"GENE","name":"FIBCD1-AS1","canonical_id":"hgnc:HGNC:55657","description":"FIBCD1 antisense RNA 1","metadata":null},{"id":"1dae12d692b048d1a5fa043816b48e0e","type":"GENE","name":"FIBIN","canonical_id":"hgnc:HGNC:33747","description":"fin bud initiation factor homolog","metadata":{"aliases":["MGC24932"]}},{"id":"c5820ba67eb440b6875ccd89d8e94952","type":"GENE","name":"FIBP","canonical_id":"hgnc:HGNC:3705","description":"FGF1 intracellular binding protein","metadata":{"aliases":["FGFIBP"]}},{"id":"4531436eb67f4011b2f046388463e7ef","type":"GENE","name":"FICD","canonical_id":"hgnc:HGNC:18416","description":"FIC domain protein adenylyltransferase","metadata":{"aliases":["HYPE","HIP13"]}},{"id":"0c4b7ba6df1b4bb486617460de768160","type":"GENE","name":"FIG4","canonical_id":"hgnc:HGNC:16873","description":"FIG4 phosphoinositide 5-phosphatase","metadata":{"aliases":["SAC3","hSac3","dJ249I4.1","ALS11","CMT4J","KIAA0274"]}},{"id":"0aacf56d34d4454c8d492f0c2b069132","type":"GENE","name":"FIGLA","canonical_id":"hgnc:HGNC:24669","description":null,"metadata":null},{"id":"a7b99a82e94f40fda394eeb5ee83c1eb","type":"GENE","name":"FIGLAP1","canonical_id":"hgnc:HGNC:57010","description":"FIGLA pseudogene 1","metadata":null},{"id":"7505ccbd10fb45cfbedbb87ade324ec0","type":"GENE","name":"FIGN","canonical_id":"hgnc:HGNC:13285","description":"fidgetin, microtubule severing factor","metadata":null},{"id":"e9a17bca62b14b3792f3dca79be0817b","type":"GENE","name":"FIGNL1","canonical_id":"hgnc:HGNC:13286","description":"fidgetin like 1","metadata":null},{"id":"6ca87a9ddc2d451cb78836b1c9ae40d0","type":"GENE","name":"FIGNL2","canonical_id":"hgnc:HGNC:13287","description":"fidgetin like 2","metadata":null},{"id":"33f6cdcf4a4d45039c4a2a72f6763083","type":"GENE","name":"FIGNL2-DT","canonical_id":"hgnc:HGNC:53299","description":"FIGNL2 divergent transcript","metadata":null},{"id":"248301c394514291974d689e7d7c280e","type":"GENE","name":"FILIP1","canonical_id":"hgnc:HGNC:21015","description":"filamin A interacting protein 1","metadata":{"aliases":["FILIP","KIAA1275"]}},{"id":"b32329c45bf7443fa32032e11f3c0931","type":"GENE","name":"FILIP1-AS1","canonical_id":"hgnc:HGNC:40946","description":"FILIP1 antisense RNA 1","metadata":null},{"id":"ade7f9a070c0470a8e7b275dab40e7ec","type":"GENE","name":"FILIP1L","canonical_id":"hgnc:HGNC:24589","description":"filamin A interacting protein 1 like","metadata":{"aliases":["DOC-1","GIP130"]}},{"id":"816d3506bce94cbabdb7de7e1acc0b7e","type":"GENE","name":"FILNC1","canonical_id":"hgnc:HGNC:53755","description":"FOXO induced long non-coding RNA 1","metadata":null},{"id":"5a9a41c8d0b249f0a9d7bc89e00899d4","type":"GENE","name":"FIMP1","canonical_id":"hgnc:HGNC:26346","description":"fertilization-influencing membrane protein 1","metadata":{"aliases":["FLJ25404","FIMP","C16orf92"]}},{"id":"a6acb6b9e25c4aac825f6b0b363039cc","type":"GENE","name":"FIP1L1","canonical_id":"hgnc:HGNC:19124","description":"factor interacting with PAPOLA and CPSF1","metadata":{"aliases":["DKFZp586K0717","FIP1","hFip1"]}},{"id":"3a6f3b4fa3444c5ba17a4ef67bbe1ea8","type":"GENE","name":"FIP1L1-AS1","canonical_id":"hgnc:HGNC:58787","description":"FIP1L1 antisense RNA 1","metadata":null},{"id":"334fa8b8961b4b79a17041f152ab84a6","type":"GENE","name":"FIRRE","canonical_id":"hgnc:HGNC:49627","description":"firre intergenic repeating RNA element","metadata":{"aliases":["LINC01200"]}},{"id":"87152906925e4833a9ac2c679c5b9bdd","type":"GENE","name":"FIRRM","canonical_id":"hgnc:HGNC:25565","description":"FIGNL1 interacting regulator of recombination and mitosis","metadata":{"aliases":["FLJ10706","Apolo1","FLIP","MEICA1","C1orf112"]}},{"id":"7da0f38f5cb74c78a8c7155fbaa8def0","type":"GENE","name":"FIS1","canonical_id":"hgnc:HGNC:21689","description":"fission, mitochondrial 1","metadata":{"aliases":["CGI-135","H_NH0132A01.6","TTC11"]}},{"id":"8676ed17c85149838510541798aa72b8","type":"GENE","name":"FITM1","canonical_id":"hgnc:HGNC:33714","description":"fat storage inducing transmembrane protein 1","metadata":{"aliases":["FIT1"]}},{"id":"f6979b160ddb4cbd84261f595d78969a","type":"GENE","name":"FITM2","canonical_id":"hgnc:HGNC:16135","description":"fat storage inducing transmembrane protein 2","metadata":{"aliases":["dJ881L22.2","FIT2","C20orf142"]}},{"id":"ad7fe53ab5dc403881707ffdc2731620","type":"TRIAL","name":"FITMI - First In Treating Male Infertility","canonical_id":"clinicaltrials.gov:NCT05212337","description":"Infertility, Male","metadata":null},{"id":"6511628301c9482bbb42c87cd4995cc0","type":"GENE","name":"FIZ1","canonical_id":"hgnc:HGNC:25917","description":"FLT3 interacting zinc finger 1","metadata":{"aliases":["FLJ14768","ZNF798"]}},{"id":"6f752ff27e454443ace54b99cabdcf96","type":"GENE","name":"FJX1","canonical_id":"hgnc:HGNC:17166","description":"four-jointed box kinase 1","metadata":{"aliases":["FLJ22416","FLJ25593"]}},{"id":"f3d6db5172cf43c49ba1e014e4706026","type":"GO_TERM","name":"FK506 binding","canonical_id":"go:GO:0005528","description":"\"Binding to a 23-membered macrolide lactone FK506.\" [GOC:jl]","metadata":null},{"id":"3094df9c63a24af4a795ed9d426e94f2","type":"GENE","name":"FKBP10","canonical_id":"hgnc:HGNC:18169","description":"FKBP prolyl isomerase 10","metadata":{"aliases":["hFKBP65","FKBP65","FLJ22041","FKBP6","FLJ20683","FLJ23833"]}},{"id":"c8c821b3e1cf482e88c178a7090c64e8","type":"GENE","name":"FKBP11","canonical_id":"hgnc:HGNC:18624","description":"FKBP prolyl isomerase 11","metadata":{"aliases":["FKBP19"]}},{"id":"150a1a01385949588ef3b6cc5d19e336","type":"GENE","name":"FKBP14","canonical_id":"hgnc:HGNC:18625","description":"FKBP prolyl isomerase 14","metadata":{"aliases":["FLJ20731","FKBP22"]}},{"id":"9fb990567b7c4e37ab507d266ffd2f3b","type":"GENE","name":"FKBP14-AS1","canonical_id":"hgnc:HGNC:40990","description":"FKBP14 antisense RNA 1","metadata":null},{"id":"b2b935634b234aa8a72bd60699d41d60","type":"GENE","name":"FKBP15","canonical_id":"hgnc:HGNC:23397","description":"FKBP prolyl isomerase family member 15","metadata":{"aliases":["PPP1R76","FKBP133","WAFL","KIAA0674"]}},{"id":"3a2fe14dba1e4553974d0eb8ee5951d0","type":"GENE","name":"FKBP1A","canonical_id":"hgnc:HGNC:3711","description":"FKBP prolyl isomerase 1A","metadata":{"aliases":["FKBP-12","FKBP12","PKC12","PPIASE","FKBP12C","FKBP1"]}},{"id":"53b72f771889455e81f25e7d8b42470f","type":"PROTEIN","name":"FKBP1A","canonical_id":"uniprot:P62942","description":null,"metadata":null},{"id":"62d5b1d62ad848cab9a660a5c91646e4","type":"GENE","name":"FKBP1A-SDCBP2","canonical_id":"hgnc:HGNC:41997","description":"FKBP1A-SDCBP2 readthrough (NMD candidate)","metadata":null},{"id":"5ec03a4002f54fed8614d1f9ed0e133f","type":"GENE","name":"FKBP1AP1","canonical_id":"hgnc:HGNC:3714","description":"FKBP prolyl isomerase 1A pseudogene 1","metadata":{"aliases":["FKBP1P1"]}},{"id":"bf2bedd1390246ecb18e02c145cef527","type":"GENE","name":"FKBP1AP2","canonical_id":"hgnc:HGNC:3715","description":"FKBP prolyl isomerase 1A pseudogene 2","metadata":{"aliases":["FKBP1P2"]}},{"id":"a336a70b82404c21bd57b69d7e83c33a","type":"GENE","name":"FKBP1AP3","canonical_id":"hgnc:HGNC:3716","description":"FKBP prolyl isomerase 1A pseudogene 3","metadata":{"aliases":["FKBP1P3"]}},{"id":"e15414fd09bb486e9378a61fd506f3fb","type":"GENE","name":"FKBP1AP4","canonical_id":"hgnc:HGNC:3717","description":"FKBP prolyl isomerase 1A pseudogene 4","metadata":{"aliases":["FKBP1P4"]}},{"id":"75d406878ed94462a3bf5902ef8c82e6","type":"GENE","name":"FKBP1B","canonical_id":"hgnc:HGNC:3712","description":"FKBP prolyl isomerase 1B","metadata":{"aliases":["OTK4","FKBP12.6","PPIase","FKBP9","FKBP1L"]}},{"id":"a0babf065138430ea833345b89f88c09","type":"GENE","name":"FKBP1BP1","canonical_id":"hgnc:HGNC:52378","description":"FKBP prolyl isomerase 1B pseudogene 1","metadata":null},{"id":"5b2c7c62ec96469ab8c656f53032469a","type":"GENE","name":"FKBP1C","canonical_id":"hgnc:HGNC:21376","description":"FKBP prolyl isomerase family member 1C","metadata":{"aliases":["bA184C23.2"]}},{"id":"3480eb98aad04580af4f932a8e781d66","type":"GENE","name":"FKBP2","canonical_id":"hgnc:HGNC:3718","description":"FKBP prolyl isomerase 2","metadata":{"aliases":["FKBP-13","FKBP13","PPIase"]}},{"id":"b5adeb4b458148b18977a2edd241d48c","type":"GENE","name":"FKBP3","canonical_id":"hgnc:HGNC:3719","description":"FKBP prolyl isomerase 3","metadata":{"aliases":["FKBP-25","FKBP25"]}},{"id":"d8ef4f866eaf4eb39dc1437a45eb6793","type":"GENE","name":"FKBP4","canonical_id":"hgnc:HGNC:3720","description":null,"metadata":null},{"id":"eff710d9d581423ba807ef2ce2196e76","type":"GENE","name":"FKBP4P1","canonical_id":"hgnc:HGNC:44038","description":"FKBP prolyl isomerase 4 pseudogene 1","metadata":null},{"id":"02942af299b349a29fb1c1a0190ade65","type":"GENE","name":"FKBP4P2","canonical_id":"hgnc:HGNC:50371","description":"FKBP prolyl isomerase 4 pseudogene 2","metadata":null},{"id":"f66254f9df7f42298903a7a8f5e17fa7","type":"GENE","name":"FKBP4P6","canonical_id":"hgnc:HGNC:50375","description":"FKBP prolyl isomerase 4 pseudogene 6","metadata":{"aliases":["FKBP4P4","FKBP4P5"]}},{"id":"d69223654c4940bea859977f2617b85c","type":"GENE","name":"FKBP4P7","canonical_id":"hgnc:HGNC:50376","description":"FKBP prolyl isomerase 4 pseudogene 7","metadata":{"aliases":["FKBP4P3"]}},{"id":"a210ce54d40b47039c6bdae1b9b5671d","type":"GENE","name":"FKBP4P8","canonical_id":"hgnc:HGNC:50377","description":"FKBP prolyl isomerase 4 pseudogene 8","metadata":null},{"id":"7eb5facf8d974adba05022a5852083fc","type":"GENE","name":"FKBP5","canonical_id":"hgnc:HGNC:3721","description":"FKBP prolyl isomerase 5","metadata":{"aliases":["FKBP51","FKBP54","PPIase","P54","Ptg-10"]}},{"id":"4653403eeada4b02afee49a0051f69c6","type":"GENE","name":"FKBP6","canonical_id":"hgnc:HGNC:3722","description":"FKBP prolyl isomerase family member 6 (inactive)","metadata":{"aliases":["PPIase","FKBP36"]}},{"id":"affc3fd9ffa44c7cb817be7db632b17b","type":"GENE","name":"FKBP6P1","canonical_id":"hgnc:HGNC:56779","description":"FKBP6 pseudogene 1","metadata":null},{"id":"68d85007ff2d46b08231417656e00efe","type":"GENE","name":"FKBP6P2","canonical_id":"hgnc:HGNC:56780","description":"FKBP6 pseudogene 2","metadata":null},{"id":"f0b359bcef594c45b93c5731a673e176","type":"GENE","name":"FKBP7","canonical_id":"hgnc:HGNC:3723","description":"FKBP prolyl isomerase 7","metadata":{"aliases":["FKBP23"]}},{"id":"5467d30fd913430799d6fbfd33d68fa6","type":"GENE","name":"FKBP8","canonical_id":"hgnc:HGNC:3724","description":"FKBP prolyl isomerase 8","metadata":{"aliases":["FKBP38","FKBPr38"]}},{"id":"3a6f1f0c789e40a7baef15c61c54d27e","type":"GENE","name":"FKBP8-AS1","canonical_id":"hgnc:HGNC:58601","description":"FKBP8 antisense RNA 1","metadata":null},{"id":"352fb13d52824f5a8a6752890fc91afd","type":"GENE","name":"FKBP9","canonical_id":"hgnc:HGNC:3725","description":"FKBP prolyl isomerase 9","metadata":{"aliases":["FKBP60","FKBP63"]}},{"id":"d3a9a5aa8f9248b0b31919c45ee18db5","type":"GENE","name":"FKBP9P1","canonical_id":"hgnc:HGNC:23568","description":"FKBP prolyl isomerase 9 pseudogene 1","metadata":{"aliases":["MGC20531","FKBP9L"]}},{"id":"efbcd9e46b8f4a248b9bb5c0702dd760","type":"GENE","name":"FKBPL","canonical_id":"hgnc:HGNC:13949","description":"FKBP prolyl isomerase like","metadata":{"aliases":["DIR1","NG7","WISp39"]}},{"id":"5ae71c85f80e420a810d3e0d3fb925b3","type":"GENE","name":"FKRP","canonical_id":"hgnc:HGNC:17997","description":"fukutin related protein","metadata":{"aliases":["LGMD2I","MDC1C","FKTR"]}},{"id":"083d8e4fb9574266ad6f745ca0478f3f","type":"GENE","name":"FKTN","canonical_id":"hgnc:HGNC:3622","description":"fukutin","metadata":{"aliases":["LGMD2M","FCMD"]}},{"id":"2328b7465a0c465eaacc2e770c30b573","type":"GENE","name":"FKTN-AS1","canonical_id":"hgnc:HGNC:55797","description":"FKTN antisense RNA 1","metadata":null},{"id":"b62571043f9b42fca58e9005ace2cec0","type":"GENE","name":"FLACC1","canonical_id":"hgnc:HGNC:14439","description":"flagellum associated containing coiled-coil domains 1","metadata":{"aliases":["ALS2CR12"]}},{"id":"af3ad01a75b84666aa19216a1db0b9e3","type":"GENE","name":"FLAD1","canonical_id":"hgnc:HGNC:24671","description":"flavin adenine dinucleotide synthetase 1","metadata":{"aliases":["PP591","FAD1"]}},{"id":"757ea6f39c5847a9807a29956bc7c8a3","type":"TRIAL","name":"FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy","canonical_id":"clinicaltrials.gov:NCT06917313","description":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","metadata":null},{"id":"9958644f155b41e0b7b69f5667af4163","type":"GENE","name":"FLCN","canonical_id":"hgnc:HGNC:27310","description":"folliculin","metadata":{"aliases":["BHD","MGC17998","MGC23445","DENND8B"]}},{"id":"5fb765ac2e1542559407755feae9013a","type":"GENE","name":"FLG","canonical_id":"hgnc:HGNC:3748","description":null,"metadata":null},{"id":"a475ee0c4eba4cb5866a5768bf46f681","type":"GENE","name":"FLG2","canonical_id":"hgnc:HGNC:33276","description":"filaggrin 2","metadata":{"aliases":["IFPS"]}},{"id":"7da4f256afa3439ebcf7bff937af5b93","type":"GENE","name":"FLI1","canonical_id":"hgnc:HGNC:3749","description":null,"metadata":null},{"id":"536b359b672b41858d1b502ff823a5cc","type":"GENE","name":"FLICR","canonical_id":"hgnc:HGNC:53589","description":"FOXP3 regulating long intergenic non-coding RNA","metadata":null},{"id":"85cd4b108013453d94a0fccb28855eed","type":"GENE","name":"FLII","canonical_id":"hgnc:HGNC:3750","description":"FLII actin remodeling protein","metadata":{"aliases":["FLI","FLIL","Fli1","MGC39265"]}},{"id":"aec42a7247b041e6aef7df64a7594a19","type":"GENE","name":"FLNA","canonical_id":"hgnc:HGNC:3754","description":"filamin A","metadata":{"aliases":["ABP-280","FLN1","FLN","OPD2","OPD1"]}},{"id":"c44510d80acb42b3ae9637dceebebc8b","type":"GENE","name":"FLNB","canonical_id":"hgnc:HGNC:3755","description":"filamin B","metadata":{"aliases":["TAP","TABP","ABP-278","FH1","FLN1L","LRS1"]}},{"id":"80db4af284c14b78844c6b1cc2632323","type":"GENE","name":"FLNB-AS1","canonical_id":"hgnc:HGNC:40239","description":"FLNB antisense RNA 1","metadata":null},{"id":"4aacc59ea66a4aa09e3dcd820d0cb788","type":"GENE","name":"FLNC","canonical_id":"hgnc:HGNC:3756","description":"filamin C","metadata":{"aliases":["ABP-280","ABPL","FLN2"]}},{"id":"f06be78948384012a584afc8e4487861","type":"GENE","name":"FLNC-AS1","canonical_id":"hgnc:HGNC:53474","description":"FLNC antisense RNA 1","metadata":null},{"id":"8ed12d68bba34c1f914a1573364c8654","type":"TRIAL","name":"FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT01503372","description":"Advanced Gastric Cancer","metadata":null},{"id":"c8789b09a8c343b79633551dcb4e43ad","type":"TRIAL","name":"FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer","canonical_id":"clinicaltrials.gov:NCT02581462","description":"Stomach Cancer; Gastroesophageal Junction Cancer","metadata":null},{"id":"68439d58efed49cebd7654ad9c2eae1e","type":"TRIAL","name":"FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)","canonical_id":"clinicaltrials.gov:NCT02661971","description":"Stomach Cancer; Gastroesophageal Junction Cancer","metadata":null},{"id":"30846d0c6acd4b10bb1597990f85b5d7","type":"GENE","name":"FLOT1","canonical_id":"hgnc:HGNC:3757","description":"flotillin 1","metadata":null},{"id":"09a7552a45de4e258391ca2621c35b55","type":"GENE","name":"FLOT2","canonical_id":"hgnc:HGNC:3758","description":"flotillin 2","metadata":{"aliases":["ESA","ESA1","ECS-1","ECS1","M17S1"]}},{"id":"01b05c1df9b345f2a982ada5a3fe3ffc","type":"GENE","name":"FLRT1","canonical_id":"hgnc:HGNC:3760","description":"fibronectin leucine rich transmembrane protein 1","metadata":{"aliases":["MGC21624","SPG68"]}},{"id":"22adcba3d746421499b5f85c8a530398","type":"GENE","name":"FLRT2","canonical_id":"hgnc:HGNC:3761","description":"fibronectin leucine rich transmembrane protein 2","metadata":null},{"id":"dab54e2a36b3497891030c156825b91c","type":"GENE","name":"FLRT2-AS1","canonical_id":"hgnc:HGNC:55912","description":"FLRT2 antisense RNA 1","metadata":{"aliases":["AL049775.1"]}},{"id":"35818e3d921543c8a067aa086ca06a0d","type":"GENE","name":"FLRT3","canonical_id":"hgnc:HGNC:3762","description":"fibronectin leucine rich transmembrane protein 3","metadata":null},{"id":"45b3f3633c8645459e8acf2a59a62a5f","type":"GENE","name":"FLT1","canonical_id":"hgnc:HGNC:3763","description":null,"metadata":null},{"id":"dd454455f7cb434a92dfc711795758f8","type":"PROTEIN","name":"FLT1","canonical_id":"uniprot:P17948","description":null,"metadata":null},{"id":"e0b9c2a08f65427597f9bb7cfa8d0f59","type":"GENE","name":"FLT1P1","canonical_id":"hgnc:HGNC:44609","description":"FLT1 pseudogene 1","metadata":{"aliases":["LOC391533"]}},{"id":"42c3caaef51647a395786e29e83bda87","type":"GENE","name":"FLT3","canonical_id":"hgnc:HGNC:3765","description":null,"metadata":null},{"id":"7fc4bf5819494405831f77cc2fa522b5","type":"PROTEIN","name":"FLT3","canonical_id":"uniprot:P36888","description":null,"metadata":null},{"id":"68109097d9c446c780b3bc0524d8ca90","type":"GENE","name":"FLT3LG","canonical_id":"hgnc:HGNC:3766","description":"fms related receptor tyrosine kinase 3 ligand","metadata":null},{"id":"e9d42225b83e4041ae27608e9069ca15","type":"GENE","name":"FLT4","canonical_id":"hgnc:HGNC:3767","description":null,"metadata":null},{"id":"2d350ffed97845b294a806efd2ff1bc0","type":"PROTEIN","name":"FLT4","canonical_id":"uniprot:P35916","description":null,"metadata":null},{"id":"9b042cd3d1e041a89490c93ec4b40d64","type":"GENE","name":"FLVCR1","canonical_id":"hgnc:HGNC:24682","description":"FLVCR choline and heme transporter 1","metadata":{"aliases":["FLVCR","MFSD7B","PCA","SLC49A1","AXPC1"]}},{"id":"892692ed82a7457c8903545662a6824a","type":"GENE","name":"FLVCR1-DT","canonical_id":"hgnc:HGNC:39077","description":"FLVCR1 divergent transcript","metadata":{"aliases":["LQK1","NCRNA00292","FLVCR1-AS1"]}},{"id":"4137b9d9a3544e77a9383f96d601ac7c","type":"GENE","name":"FLVCR2","canonical_id":"hgnc:HGNC:20105","description":"FLVCR choline and putative heme transporter 2","metadata":{"aliases":["FLJ20371","MFSD7C","SLC49A2","CCT","C14orf58"]}},{"id":"c12a1e38807e4f408363faa4d78eb0d0","type":"GENE","name":"FLVCR2-AS1","canonical_id":"hgnc:HGNC:55854","description":"FLVCR2 antisense RNA 1","metadata":{"aliases":["AC007182.6"]}},{"id":"b1fb5c19cdb94822b9461b745b7603f1","type":"GENE","name":"FLYWCH1","canonical_id":"hgnc:HGNC:25404","description":"FLYWCH-type zinc finger 1","metadata":{"aliases":["DKFZp761A132"]}},{"id":"b58e56179246496ba84af2984e51876f","type":"GENE","name":"FLYWCH1-AS1","canonical_id":"hgnc:HGNC:58308","description":"FLYWCH1 antisense RNA 1","metadata":null},{"id":"74dbb7263b114405aff3f1a8f0422467","type":"GENE","name":"FLYWCH1P1","canonical_id":"hgnc:HGNC:38033","description":"FLYWCH-type zinc finger 1 pseudogene 1","metadata":null},{"id":"c107c9d265094486a2b25785ee5ee563","type":"GENE","name":"FLYWCH2","canonical_id":"hgnc:HGNC:25178","description":"FLYWCH family member 2","metadata":null},{"id":"41d181f773a7461eb0aa1c6811ece0ee","type":"TRIAL","name":"FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","canonical_id":"clinicaltrials.gov:NCT06409364","description":"Aneurysmal Subarachnoid Hemorrhage","metadata":null},{"id":"1f49d1644a4d4f52a02d36fdeca0857b","type":"TRIAL","name":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","canonical_id":"clinicaltrials.gov:NCT04149210","description":"Trachomatous Trichiasis (TT); Eye Diseases; Eyelid Diseases; Trachomatous; Trichiasis","metadata":null},{"id":"a8155cf342b842a58447fdbde93e67d3","type":"GENE","name":"FMC1","canonical_id":"hgnc:HGNC:26946","description":"formation of mitochondrial complex V assembly factor 1","metadata":{"aliases":["HSPC268","C7orf55"]}},{"id":"0027b8b870e84eaf83ca6b20a0eedc50","type":"GENE","name":"FMC1-LUC7L2","canonical_id":"hgnc:HGNC:44671","description":"FMC1-LUC7L2 readthrough","metadata":{"aliases":["C7orf55-LUC7L2"]}},{"id":"c966b5b40d984ecfb02cdf00d4624a09","type":"GO_TERM","name":"FMN adenylyltransferase activity","canonical_id":"go:GO:0003919","description":"\"Catalysis of the reaction: ATP + FMN = diphosphate + FAD.\" [EC:2.7.7.2, RHEA:17237]","metadata":null},{"id":"c10bbed873424975ad6baf29311708e4","type":"GO_TERM","name":"FMN binding","canonical_id":"go:GO:0010181","description":"\"Binding to flavin mono nucleotide. Flavin mono nucleotide (FMN) is the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:tb]","metadata":null},{"id":"396b87a909dc49219c67b82e3d074807","type":"GO_TERM","name":"FMN biosynthetic process","canonical_id":"go:GO:0009398","description":"\"The chemical reactions and pathways resulting in the formation of FMN, the oxidized form of flavin mononucleotide (riboflavin 5'-(dihydrogen phosphate)), which acts as a coenzyme for a number of oxidative enzymes including NADH dehydrogenase.\" [GOC:ai]","metadata":null},{"id":"6169c59067ff4588918f61d72eb11205","type":"GO_TERM","name":"FMN catabolic process","canonical_id":"go:GO:0032363","description":"\"The chemical reactions and pathways resulting in the breakdown of FMN, riboflavin 5'-(dihydrogen phosphate), a coenzyme for a number of oxidative enzymes including NADH dehydrogenase.\" [GOC:mah]","metadata":null},{"id":"2d852aa79aae4f1ba9167c99e3bdac53","type":"GO_TERM","name":"FMN hydrolase activity","canonical_id":"go:GO:0090711","description":"\"Catalysis of the reaction: FMN + H2O = phosphate + riboflavin.\" [PMID:16183635, RHEA:35587]","metadata":null},{"id":"0112cfc38a6d4f79ac162e35066a74ca","type":"GO_TERM","name":"FMN metabolic process","canonical_id":"go:GO:0046444","description":"\"The chemical reactions and pathways involving FMN, riboflavin 5'-(dihydrogen phosphate), a coenzyme for a number of oxidative enzymes including NADH dehydrogenase.\" [GOC:ai, PMID:20822113]","metadata":null},{"id":"f4f7f4b419364f4c8b833dc8dca59774","type":"GO_TERM","name":"FMN reductase (NADH) activity","canonical_id":"go:GO:0052874","description":"\"Catalysis of the reaction: FMNH2 + NAD+ = FMN + NADH + 2 H+.\" [RHEA:21620]","metadata":null},{"id":"78f50f04ac394502bf4f74125104e0a7","type":"GO_TERM","name":"FMN reductase (NADPH) activity","canonical_id":"go:GO:0052873","description":"\"Catalysis of the reaction: FMNH2 + NADP+ = FMN + NADPH + 2 H+.\" [RHEA:21624]","metadata":null},{"id":"56e0446e8d034c6d918a687b2590d6f5","type":"GO_TERM","name":"FMN reductase [NAD(P)H] activity","canonical_id":"go:GO:0008752","description":"\"Catalysis of the reaction: FMNH2 + NAD(P)+ = FMN + NAD(P)H + H+. This reaction can utilize NADH and NADPH with similar reaction rates.\" [EC:1.5.1.39]","metadata":null},{"id":"4b9baa5a847b4fb9b1776f4499b41e76","type":"GO_TERM","name":"FMN reductase complex","canonical_id":"go:GO:1990202","description":"\"A protein complex capable of FMN reductase activity. Reduces FMN to FMNH2 in a NAD(P)H-dependent manner. In E.coli, consists of a SsuE dimer.\" [GOC:bhm, PMID:10480865, PMID:16997955]","metadata":null},{"id":"bfdd2c24a6e7494b8304be6aac72e963","type":"GO_TERM","name":"FMN transmembrane transporter activity","canonical_id":"go:GO:0044610","description":"\"Enables the directed movement of flavine mononucleotide (FMN) from one side of a membrane to the other.\" [GOC:ans, PMID:22185573]","metadata":null},{"id":"1af90b43614048a08223f66efc674f25","type":"GO_TERM","name":"FMN-binding domain binding","canonical_id":"go:GO:0101016","description":"\"Binding to the FMN-binding domain of a protein.\" [PMID:15752726]","metadata":null},{"id":"e9c68e6ca2f243f2953747e11713f495","type":"GENE","name":"FMN1","canonical_id":"hgnc:HGNC:3768","description":"formin 1","metadata":{"aliases":["DKFZP686C2281","FLJ45135","MGC125288","MGC125289","LD","FMN"]}},{"id":"eb2c78dbdb94429c9a41d5c4636aad70","type":"GENE","name":"FMN2","canonical_id":"hgnc:HGNC:14074","description":null,"metadata":null},{"id":"95c19cf9d45a41aa865697cfb2531f48","type":"GENE","name":"FMN2P1","canonical_id":"hgnc:HGNC:54909","description":"FMN2 pseudogene 1","metadata":null},{"id":"1b0caaf7e37a4b378f35f205dc78bf6d","type":"GENE","name":"FMNL1","canonical_id":"hgnc:HGNC:1212","description":"formin like 1","metadata":{"aliases":["C17orf1","C17orf1B","FMNL"]}},{"id":"06426aa9369c439695d7ade5d6a97673","type":"GENE","name":"FMNL1-AS1","canonical_id":"hgnc:HGNC:55717","description":"FMNL1 antisense RNA 1","metadata":null},{"id":"170df691195e4e9fabf8dc348da51fa1","type":"GENE","name":"FMNL1-DT","canonical_id":"hgnc:HGNC:55311","description":"FMNL1 divergent transcript","metadata":{"aliases":["CTD-2020K17.1"]}},{"id":"72f684ac3d2d41a888502785a77bb3c9","type":"GENE","name":"FMNL2","canonical_id":"hgnc:HGNC:18267","description":"formin like 2","metadata":{"aliases":["KIAA1902","FHOD2"]}},{"id":"d2f2b5adbb414a9c9724d1c6eb4f2e1e","type":"GENE","name":"FMNL3","canonical_id":"hgnc:HGNC:23698","description":"formin like 3","metadata":{"aliases":["DKFZp762B245","MGC45819","WBP3"]}},{"id":"1041a9744c354272ba73cc9dd0fb0f1b","type":"GENE","name":"FMO1","canonical_id":"hgnc:HGNC:3769","description":"flavin containing dimethylaniline monoxygenase 1","metadata":null},{"id":"e0f9ec85026943fbaf18ed7750f58fa6","type":"GENE","name":"FMO1-AS1","canonical_id":"hgnc:HGNC:40240","description":"FMO1 antisense RNA 1","metadata":null},{"id":"986a2263e25d412dac07f1a4041e7709","type":"GENE","name":"FMO10P","canonical_id":"hgnc:HGNC:32211","description":"flavin containing dimethylaniline monoxygenase 10, pseudogene","metadata":null},{"id":"c99d5cfa97354addb9e2d7901d8ed143","type":"GENE","name":"FMO11P","canonical_id":"hgnc:HGNC:32212","description":"flavin containing dimethylaniline monoxygenase 11, pseudogene","metadata":null},{"id":"ead9b0a60b0b4d0cb502c232d0f79649","type":"GENE","name":"FMO2","canonical_id":"hgnc:HGNC:3770","description":"flavin containing dimethylaniline monoxygenase 2","metadata":null},{"id":"54771a3aa07f442fb5ecfe02b85392af","type":"GENE","name":"FMO3","canonical_id":"hgnc:HGNC:3771","description":null,"metadata":null},{"id":"6313b6eec4c645f3b7df2150628ad0bd","type":"GENE","name":"FMO4","canonical_id":"hgnc:HGNC:3772","description":null,"metadata":null},{"id":"fda5ed14a2df4bfdbeeda554f8d78291","type":"GENE","name":"FMO5","canonical_id":"hgnc:HGNC:3773","description":"flavin containing dimethylaniline monoxygenase 5","metadata":null},{"id":"ba852777c83e4cb0a118fae5b52917c7","type":"GENE","name":"FMO6P","canonical_id":"hgnc:HGNC:24024","description":"flavin containing dimethylaniline monoxygenase 6, pseudogene","metadata":{"aliases":["FMO6"]}},{"id":"7442501be7b540f7ba2bf10050d06988","type":"GENE","name":"FMO7P","canonical_id":"hgnc:HGNC:32208","description":"flavin containing dimethylaniline monoxygenase 7, pseudogene","metadata":null},{"id":"793fe8ebc1974cd1954cef1eec0d64fd","type":"GENE","name":"FMO8P","canonical_id":"hgnc:HGNC:32209","description":"flavin containing dimethylaniline monoxygenase 8, pseudogene","metadata":null},{"id":"d0531297b88a4e74943272f6422ddb6b","type":"GENE","name":"FMO9P","canonical_id":"hgnc:HGNC:32210","description":"flavin containing dimethylaniline monoxygenase 9, pseudogene","metadata":{"aliases":["RP11-45J16.2"]}},{"id":"931b89b80ad84bad96cc85496851da13","type":"GENE","name":"FMOD","canonical_id":"hgnc:HGNC:3774","description":"fibromodulin","metadata":{"aliases":["SLRR2E"]}},{"id":"2af022293f524a559f47ba32a926bf9b","type":"GENE","name":"FMR1","canonical_id":"hgnc:HGNC:3775","description":null,"metadata":null},{"id":"f073061b06fc4124afc08e24870c79be","type":"GENE","name":"FMR1-AS1","canonical_id":"hgnc:HGNC:39081","description":"FMR1 antisense RNA 1","metadata":{"aliases":["ASFMR1","FMR4","FMR5","FMR1AS","FMR1-AS"]}},{"id":"d4d2a35b34984a84a0d0a4aca1a1f80e","type":"GENE","name":"FMR1-IT1","canonical_id":"hgnc:HGNC:41333","description":"FMR1 intronic transcript 1","metadata":null},{"id":"5f7f496ac44f46d1ab73897aecff3f91","type":"GENE","name":"FMR1NB","canonical_id":"hgnc:HGNC:26372","description":"FMR1 neighbor","metadata":{"aliases":["FLJ25736","NY-SAR-35","CT37"]}},{"id":"1f33ca406d174dd787b937a867f0cbbb","type":"GO_TERM","name":"FMRP-CYFIP1 complex","canonical_id":"go:GO:0160209","description":"\"A protein-containing complex that contains the fragile X mental retardation protein (FMRP) and cytoplasmic FMRP Interacting protein 1 (CYIFIP1), and is capable of inhibiting translation initiation by binding to the eIF4F complex.\" [PMID:18805096, PMID:28183735]","metadata":null},{"id":"8b667645e137474eb32ac27a3a8bfa4a","type":"TRIAL","name":"FMS European Long-Term Study","canonical_id":"clinicaltrials.gov:NCT00757731","description":"Fibromyalgia Syndrome","metadata":null},{"id":"e66eac27e6e24c788a118f290064fc61","type":"TRIAL","name":"FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage","canonical_id":"clinicaltrials.gov:NCT05279677","description":"Colorectal Neoplasms Malignant","metadata":null},{"id":"d1d9ecfef6714ea4a352c4edffd43ebc","type":"GENE","name":"FN1","canonical_id":"hgnc:HGNC:3778","description":null,"metadata":null},{"id":"8e0ca71711f1462a93a4c4ced515159d","type":"GENE","name":"FN1-DT","canonical_id":"hgnc:HGNC:55775","description":"FN1 divergent transcript","metadata":null},{"id":"890189ef9fff4cb8a3a5a3866262ea6b","type":"GENE","name":"FN3K","canonical_id":"hgnc:HGNC:24822","description":"fructosamine 3 kinase","metadata":null},{"id":"cd413c494c37418c88015b2e4a6e4b29","type":"GENE","name":"FN3KRP","canonical_id":"hgnc:HGNC:25700","description":"fructosamine 3 kinase related protein","metadata":{"aliases":["FLJ12171","FN3KL"]}},{"id":"6fce10f2706b4a26a4d6093e1dc816ff","type":"GENE","name":"FNBP1","canonical_id":"hgnc:HGNC:17069","description":"formin binding protein 1","metadata":{"aliases":["FBP17","KIAA0554"]}},{"id":"11d7e0b30aef4560881b0cba0b1a13d9","type":"GENE","name":"FNBP1L","canonical_id":"hgnc:HGNC:20851","description":"formin binding protein 1 like","metadata":{"aliases":["TOCA1","FLJ20275","C1orf39"]}},{"id":"9a535df485fe4a068907ea5c68d72740","type":"GENE","name":"FNBP1P1","canonical_id":"hgnc:HGNC:44528","description":"formin binding protein 1 pseudogene 1","metadata":null},{"id":"769ae3b81d8a4221aabba5a5147363a5","type":"GENE","name":"FNBP1P2","canonical_id":"hgnc:HGNC:44527","description":"formin binding protein 1 pseudogene 2","metadata":null},{"id":"bb3e07bab621449eb66f1d7577a20dff","type":"GENE","name":"FNBP4","canonical_id":"hgnc:HGNC:19752","description":"formin binding protein 4","metadata":{"aliases":["KIAA1014"]}},{"id":"18c00fc4348143d8860fe2a254bac3e0","type":"GENE","name":"FNDC1","canonical_id":"hgnc:HGNC:21184","description":"fibronectin type III domain containing 1","metadata":{"aliases":["bA243O10.1","KIAA1866","dJ322A24.1","FNDC2"]}},{"id":"9b3d494b988545af80480e436b8d1655","type":"GENE","name":"FNDC1-AS1","canonical_id":"hgnc:HGNC:55706","description":"FNDC1 antisense RNA 1","metadata":null},{"id":"e332e342af7541d2b7ea8d88371e05b5","type":"GENE","name":"FNDC1-IT1","canonical_id":"hgnc:HGNC:41460","description":"FNDC1 intronic transcript 1","metadata":null},{"id":"5948bbf0ef6e4530ac17610b256d0863","type":"GENE","name":"FNDC10","canonical_id":"hgnc:HGNC:42951","description":"fibronectin type III domain containing 10","metadata":{"aliases":["C1orf233"]}},{"id":"4517e557755741fbb53fcf6a564aa4c6","type":"GENE","name":"FNDC11","canonical_id":"hgnc:HGNC:28764","description":"fibronectin type III domain containing 11","metadata":{"aliases":["MGC5356","C20orf195"]}},{"id":"2a79061a0c54456e9d4cc846815bf828","type":"GENE","name":"FNDC3A","canonical_id":"hgnc:HGNC:20296","description":"fibronectin type III domain containing 3A","metadata":{"aliases":["bA203I16.5","KIAA0970","FNDC3"]}},{"id":"9785f47b831a45069588116dde449b42","type":"GENE","name":"FNDC3B","canonical_id":"hgnc:HGNC:24670","description":"fibronectin type III domain containing 3B","metadata":{"aliases":["FAD104","DKFZp762K137","FLJ23399","PRO4979","YVTM2421"]}},{"id":"652143740002412fa87a2ddb95d1a52c","type":"GENE","name":"FNDC3CP","canonical_id":"hgnc:HGNC:35452","description":"fibronectin type III domain containing 3C, pseudogene","metadata":null},{"id":"c097165021b64979a453d64061e27f5e","type":"GENE","name":"FNDC4","canonical_id":"hgnc:HGNC:20239","description":"fibronectin type III domain containing 4","metadata":{"aliases":["FLJ22362","FRCP1"]}},{"id":"4bcaf71bc87a4ed9aea0583098fce01e","type":"GENE","name":"FNDC5","canonical_id":"hgnc:HGNC:20240","description":"fibronectin type III domain containing 5","metadata":{"aliases":["FRCP2"]}},{"id":"17b6886f91564ed69f2bb79244ff7eaa","type":"GENE","name":"FNDC7","canonical_id":"hgnc:HGNC:26668","description":"fibronectin type III domain containing 7","metadata":{"aliases":["FLJ35838"]}},{"id":"313eef4ec07d49c586e8ddbe742a5744","type":"GENE","name":"FNDC8","canonical_id":"hgnc:HGNC:25286","description":"fibronectin type III domain containing 8","metadata":{"aliases":["DKFZp434H2215"]}},{"id":"e51546a2811c46a3b2d09c4862f26c33","type":"GENE","name":"FNDC9","canonical_id":"hgnc:HGNC:33547","description":"fibronectin type III domain containing 9","metadata":{"aliases":["MGC27121","C5orf40"]}},{"id":"417a903e799b4af8934a498bc6f43933","type":"GO_TERM","name":"FNIP-folliculin RagC/D GAP","canonical_id":"go:GO:1990877","description":"\"A heterodimeric complex that functions as a GTPase-Activating Protein (GAP) Complex for members of the Rag family of GTPases. In the budding yeast, this complex contains Lst4 and Lst7, while the orthologous mammalian complex contains follicular (FLCN) and either follicular interacting protein 1 (FNIP1) or FNIP2.\" [GOC:rn, PMID:24095279, PMID:26387955, PMID:34805795]","metadata":null},{"id":"64a77be618f04f2495545c4ff1591bf4","type":"GENE","name":"FNIP1","canonical_id":"hgnc:HGNC:29418","description":"folliculin interacting protein 1","metadata":{"aliases":["KIAA1961"]}},{"id":"2364969cfe8f4dc0b24ea8319a214017","type":"GENE","name":"FNIP2","canonical_id":"hgnc:HGNC:29280","description":"folliculin interacting protein 2","metadata":{"aliases":["KIAA1450","FNIPL","MAPO1"]}},{"id":"977ce00e65f745258809e1c1dafecc2a","type":"GENE","name":"FNTA","canonical_id":"hgnc:HGNC:3782","description":"farnesyltransferase, CAAX box, subunit alpha","metadata":{"aliases":["FPTA","PGGT1A","PTAR2"]}},{"id":"8ba188ac85844265994838f2cd4cd422","type":"GENE","name":"FNTAP1","canonical_id":"hgnc:HGNC:3783","description":"farnesyltransferase, CAAX box, alpha pseudogene 1","metadata":{"aliases":["FNTAL1"]}},{"id":"05fdbd63fcb746139440474cc34ef998","type":"GENE","name":"FNTAP2","canonical_id":"hgnc:HGNC:3784","description":"farnesyltransferase, CAAX box, alpha pseudogene 2","metadata":{"aliases":["FNTAL2"]}},{"id":"319962ecf6bd4af596d2a6e5f5f283ed","type":"GENE","name":"FNTB","canonical_id":"hgnc:HGNC:3785","description":"farnesyltransferase, CAAX box, subunit beta","metadata":{"aliases":["FPTB"]}},{"id":"82ec5d6eb70442939c6133764d6e414e","type":"GENE","name":"FOCAD","canonical_id":"hgnc:HGNC:23377","description":"focadhesin","metadata":{"aliases":["FLJ20375","KIAA1797"]}},{"id":"321ee2e91a5c414bb14b7c9ce5bbe5a4","type":"GENE","name":"FOCAD-AS1","canonical_id":"hgnc:HGNC:49789","description":"FOCAD antisense RNA 1","metadata":null},{"id":"54e5304172d54306991bfa0e75296760","type":"TRIAL","name":"FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC","canonical_id":"clinicaltrials.gov:NCT07729605","description":"Colorectal Cancer Metastatic; Microsatellite Stable (MSS) Colorectal Cancer (CRC)","metadata":null},{"id":"0c48fe29d58841c9bd996ac6e6a9c869","type":"TRIAL","name":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02508077","description":"Recurrent Colorectal Carcinoma; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer","metadata":null},{"id":"81eb224ccd3a419ea50909dfe5695f52","type":"TRIAL","name":"FOLFIRINOX for 2nd-line Treatment of BTC","canonical_id":"clinicaltrials.gov:NCT03778593","description":"Biliary Tract Cancer","metadata":null},{"id":"ef2c250fc8da481292cd7eba0439199c","type":"DRUG","name":"FOLFOX-4 Regimen","canonical_id":"ncit:C63590","description":null,"metadata":null},{"id":"16f2953c926548d494a92c55883c6091","type":"TRIAL","name":"FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02063529","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"cace84f2e31549f8b6be284fbb131922","type":"GENE","name":"FOLH1","canonical_id":"hgnc:HGNC:3788","description":null,"metadata":null},{"id":"a981c1429c0c40da9d0d8661b211a09a","type":"GENE","name":"FOLH1B","canonical_id":"hgnc:HGNC:13636","description":"folate hydrolase 1B (pseudogene)","metadata":{"aliases":["PSMAL","FOLH2","FOLHP"]}},{"id":"2e384df5326a4a1796a411b5938d52f5","type":"GENE","name":"FOLR1","canonical_id":"hgnc:HGNC:3791","description":null,"metadata":null},{"id":"6bf75b05ec6f4f3b8d42ddafc3e662f4","type":"GENE","name":"FOLR1-AS1","canonical_id":"hgnc:HGNC:58347","description":"FOLR1 antisense RNA 1","metadata":null},{"id":"2251e578abd44979845662fcba98c7d2","type":"GENE","name":"FOLR1P1","canonical_id":"hgnc:HGNC:3792","description":"folate receptor 1 pseudogene 1","metadata":{"aliases":["FOLR1P"]}},{"id":"568ba5b2809c4a3dad97c971ea074be1","type":"GENE","name":"FOLR2","canonical_id":"hgnc:HGNC:3793","description":"folate receptor beta","metadata":{"aliases":["FR\u03b2"]}},{"id":"644fa17018944eef91307c02edf39bc2","type":"GENE","name":"FOLR3","canonical_id":"hgnc:HGNC:3795","description":"folate receptor gamma","metadata":{"aliases":["FR-G","FR\u03b3"]}},{"id":"81637b56aa294fe49ff77bf7ed7c31bc","type":"GENE","name":"FOLR3P1","canonical_id":"hgnc:HGNC:38074","description":"folate receptor 3 pseudogene 1","metadata":null},{"id":"2b30834a2755436891152072411aeece","type":"TRIAL","name":"FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05011188","description":"Metastatic Castration-resistant Prostate Cancer; Prostate Cancer","metadata":null},{"id":"eff8c568299644469b326f8c8eef3bab","type":"TRIAL","name":"FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3","canonical_id":"clinicaltrials.gov:NCT05614739","description":"Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms","metadata":null},{"id":"589a5aff167543ddb36e533fc5e0fe9f","type":"GENE","name":"FOS","canonical_id":"hgnc:HGNC:3796","description":null,"metadata":null},{"id":"72b2a0f898024a1b9fa7bda9b0b96de1","type":"GENE","name":"FOS-AS1","canonical_id":"hgnc:HGNC:58290","description":"FOS antisense RNA 1","metadata":null},{"id":"09cf5d1fda914fa9bfc984817a40b00a","type":"GENE","name":"FOSB","canonical_id":"hgnc:HGNC:3797","description":null,"metadata":null},{"id":"5999e56e9e8f47f7a088ac82a2cbb5b8","type":"GENE","name":"FOSL1","canonical_id":"hgnc:HGNC:13718","description":null,"metadata":null},{"id":"4f1a64f304b945a1a6862aa1ae6eb914","type":"GENE","name":"FOSL1P1","canonical_id":"hgnc:HGNC:44055","description":"FOSL1 pseudogene 1","metadata":null},{"id":"cc1bf9914c534962b7586617f2096446","type":"GENE","name":"FOSL2","canonical_id":"hgnc:HGNC:3798","description":null,"metadata":null},{"id":"6114f143df7b4328928ecbab83752f4a","type":"GENE","name":"FOSL2-AS1","canonical_id":"hgnc:HGNC:55784","description":"FOSL2 antisense RNA 1","metadata":null},{"id":"707cb8ddfb5e457b99c0817705f5ba86","type":"GENE","name":"FOXA1","canonical_id":"hgnc:HGNC:5021","description":null,"metadata":null},{"id":"3cc0868dfdc94cdfb3633d1fd6c0ccdc","type":"GENE","name":"FOXA2","canonical_id":"hgnc:HGNC:5022","description":null,"metadata":null},{"id":"3dfd255420cc4abfb94a9711bdb70e02","type":"GENE","name":"FOXA3","canonical_id":"hgnc:HGNC:5023","description":null,"metadata":null},{"id":"34003a76e1b041379c4f3ff03f557c3d","type":"GENE","name":"FOXB1","canonical_id":"hgnc:HGNC:3799","description":"forkhead box B1","metadata":{"aliases":["HFKH-5","FKH5"]}},{"id":"712dc7e948054c37a576996a61743fd3","type":"GENE","name":"FOXB2","canonical_id":"hgnc:HGNC:23315","description":"forkhead box B2","metadata":{"aliases":["bA159H20.4"]}},{"id":"e860bc164c9c404c982c4f9589319085","type":"GENE","name":"FOXC1","canonical_id":"hgnc:HGNC:3800","description":null,"metadata":null},{"id":"ecacb7a41ae34117bea4e3d714ed86fe","type":"GENE","name":"FOXC2","canonical_id":"hgnc:HGNC:3801","description":null,"metadata":null},{"id":"ee5a62056b534e3387d17b341a4a4452","type":"GENE","name":"FOXC2-AS1","canonical_id":"hgnc:HGNC:50665","description":"FOXC2 antisense RNA 1","metadata":{"aliases":["ODRUL"]}},{"id":"7ddb2d789e954e24ad8b8bfc69fdbddb","type":"GENE","name":"FOXCUT","canonical_id":"hgnc:HGNC:50650","description":"FOXC1 upstream transcript","metadata":{"aliases":["TCONS_00011636","LINC01379"]}},{"id":"511ddf2921c54f668ca5b1dc5ea40029","type":"GENE","name":"FOXD1","canonical_id":"hgnc:HGNC:3802","description":null,"metadata":null},{"id":"c1108857329d43eb8d87b8f00e825e0b","type":"GENE","name":"FOXD1-AS1","canonical_id":"hgnc:HGNC:50658","description":"FOXD1 antisense RNA 1","metadata":{"aliases":["TCONS_00009423"]}},{"id":"5f2458a375364a2981d25f0eae96b5f4","type":"GENE","name":"FOXD2","canonical_id":"hgnc:HGNC:3803","description":"forkhead box D2","metadata":{"aliases":["FREAC9","FKHL17"]}},{"id":"d482086f536944a08fa6e7a4ec5140f0","type":"GENE","name":"FOXD2-AS1","canonical_id":"hgnc:HGNC:44256","description":"FOXD2 adjacent opposite strand RNA 1","metadata":{"aliases":["MGC12982"]}},{"id":"7789fd5df7a0488cacd53d3c2309310d","type":"GENE","name":"FOXD3","canonical_id":"hgnc:HGNC:3804","description":null,"metadata":null},{"id":"4ad7473d7cad4e2a9f481c9bdf0a91c9","type":"GENE","name":"FOXD3-AS1","canonical_id":"hgnc:HGNC:40241","description":"FOXD3 antisense RNA 1","metadata":{"aliases":["pasFOXD3","FAST"]}},{"id":"b7b119b760234bc285cb0a78e12d1fd6","type":"GENE","name":"FOXD4","canonical_id":"hgnc:HGNC:3805","description":"forkhead box D4","metadata":{"aliases":["FREAC5","FOXD4a","FKHL9"]}},{"id":"db4985add99f4163934ba681b7fd2b57","type":"GENE","name":"FOXD4L1","canonical_id":"hgnc:HGNC:18521","description":"forkhead box D4 like 1","metadata":{"aliases":["FOXD5"]}},{"id":"e1dc8739b1f245908d3493918c9aabbe","type":"GENE","name":"FOXD4L3","canonical_id":"hgnc:HGNC:18523","description":"forkhead box D4 like 3","metadata":{"aliases":["OTTHUMG00000019959","FOXD6"]}},{"id":"a4a1d09cbe1b4139b7372cf36665341d","type":"GENE","name":"FOXD4L4","canonical_id":"hgnc:HGNC:23762","description":"forkhead box D4 like 4","metadata":{"aliases":["bA460E7.2","OTTHUMG00000013337","OTTHUMG00000066752","FOXD4L2"]}},{"id":"36852bfac10540fa9284e382dfc83eb2","type":"GENE","name":"FOXD4L5","canonical_id":"hgnc:HGNC:18522","description":"forkhead box D4 like 5","metadata":{"aliases":["bA15J10.2","OTTHUMG00000013332"]}},{"id":"7a4ef372854047539bcf7ce43c7a6c11","type":"GENE","name":"FOXD4L6","canonical_id":"hgnc:HGNC:31986","description":"forkhead box D4 like 6","metadata":{"aliases":["OTTHUMG00000066822"]}},{"id":"31bcda999ae642b4bb33077b0ce880d9","type":"GENE","name":"FOXE1","canonical_id":"hgnc:HGNC:3806","description":null,"metadata":null},{"id":"31cebcb448f644ba9e991a5b733e33f2","type":"GENE","name":"FOXE3","canonical_id":"hgnc:HGNC:3808","description":"forkhead box E3","metadata":{"aliases":["FREAC8","FKHL12"]}},{"id":"c83107710adb4755a5eeb63a28095763","type":"GENE","name":"FOXF1","canonical_id":"hgnc:HGNC:3809","description":null,"metadata":null},{"id":"878f10b1fae545be81c323371a3ad61f","type":"GENE","name":"FOXF2","canonical_id":"hgnc:HGNC:3810","description":null,"metadata":null},{"id":"c287231e6a3942a7a9596288fcb0ad54","type":"GENE","name":"FOXF2-AS1","canonical_id":"hgnc:HGNC:50670","description":"FOXF2 antisense RNA 1","metadata":{"aliases":["TCONS_00012639","FOXF2-DT","LINC01394"]}},{"id":"c172c34161874ba28c59c309d91df608","type":"GENE","name":"FOXG1","canonical_id":"hgnc:HGNC:3811","description":null,"metadata":null},{"id":"fcc7ebeb27e04ab9bb936ee3f78d99d2","type":"GENE","name":"FOXG1-AS1","canonical_id":"hgnc:HGNC:50663","description":"FOXG1 antisense RNA 1","metadata":{"aliases":["uc.361","FOXG1-AS"]}},{"id":"c5672302a84e4597b7727a0dac86790a","type":"GENE","name":"FOXH1","canonical_id":"hgnc:HGNC:3814","description":null,"metadata":null},{"id":"95ff738e9d5a44bcbceba21f98e0a1d8","type":"GENE","name":"FOXI1","canonical_id":"hgnc:HGNC:3815","description":null,"metadata":null},{"id":"a7689ddb67864ee5ab07c0cca35aec72","type":"GENE","name":"FOXI2","canonical_id":"hgnc:HGNC:32448","description":"forkhead box I2","metadata":{"aliases":["FLJ46831"]}},{"id":"c47ef704e0d948a5a07b5e677b6fffa2","type":"GENE","name":"FOXI3","canonical_id":"hgnc:HGNC:35123","description":"forkhead box I3","metadata":null},{"id":"0ae183961fdf46dfac2d8ac6be2b0be1","type":"GENE","name":"FOXJ1","canonical_id":"hgnc:HGNC:3816","description":null,"metadata":null},{"id":"2b80af2ee65049c5996ec7dae4e538ed","type":"GENE","name":"FOXJ2","canonical_id":"hgnc:HGNC:24818","description":"forkhead box J2","metadata":{"aliases":["FHX"]}},{"id":"5fd2c85d0f814d978203b7c87833bd74","type":"GENE","name":"FOXJ3","canonical_id":"hgnc:HGNC:29178","description":"forkhead box J3","metadata":{"aliases":["KIAA1041"]}},{"id":"458a8b2ae3c54c349ccee0072e621bed","type":"GENE","name":"FOXK1","canonical_id":"hgnc:HGNC:23480","description":"forkhead box K1","metadata":{"aliases":["IMAGE:5164497"]}},{"id":"1eb85c5a043245f7924547fefb352c7c","type":"GENE","name":"FOXK2","canonical_id":"hgnc:HGNC:6036","description":null,"metadata":null},{"id":"60bcff7395034a808d1f9981c2446936","type":"GENE","name":"FOXK2-AS1","canonical_id":"hgnc:HGNC:58306","description":"FOXK2 antisense RNA 1","metadata":null},{"id":"9741b994dc504a918fb040dcb04b202c","type":"GENE","name":"FOXL1","canonical_id":"hgnc:HGNC:3817","description":null,"metadata":null},{"id":"2439e99945c74da089acea238d3d04a5","type":"GENE","name":"FOXL2","canonical_id":"hgnc:HGNC:1092","description":null,"metadata":null},{"id":"f604747aa26a44ccaf4ed10c3a67a509","type":"GENE","name":"FOXL2NB","canonical_id":"hgnc:HGNC:34428","description":"FOXL2 neighbor","metadata":{"aliases":["FLJ43329","C3orf72"]}},{"id":"7b3f5fa0ff754a47a35d815092a351b0","type":"GENE","name":"FOXL3","canonical_id":"hgnc:HGNC:54201","description":"forkhead box L3","metadata":null},{"id":"2573032b40a64c299e5c3403cca2024b","type":"GENE","name":"FOXL3-OT1","canonical_id":"hgnc:HGNC:54640","description":"FOXL3 overlapping transcript 1","metadata":null},{"id":"3fbf3031d89c406fb32730bc36e9c939","type":"GENE","name":"FOXM1","canonical_id":"hgnc:HGNC:3818","description":null,"metadata":null},{"id":"8bd052a0991143f68380793310f957dd","type":"GENE","name":"FOXN1","canonical_id":"hgnc:HGNC:12765","description":null,"metadata":null},{"id":"1493dc38ed7c4fb798e3ebcd46073ce3","type":"GENE","name":"FOXN2","canonical_id":"hgnc:HGNC:5281","description":"forkhead box N2","metadata":{"aliases":["HTLF"]}},{"id":"11f88cd7752f49ccab79c02ca3379ba3","type":"GENE","name":"FOXN3","canonical_id":"hgnc:HGNC:1928","description":"forkhead box N3","metadata":{"aliases":["C14orf116","CHES1"]}},{"id":"7a92b1261c084842a0c3288de22eeba0","type":"GENE","name":"FOXN3-AS1","canonical_id":"hgnc:HGNC:44290","description":"FOXN3 antisense RNA 1","metadata":null},{"id":"6e870bac5e124c58bb71f048b43eb57e","type":"GENE","name":"FOXN3-AS2","canonical_id":"hgnc:HGNC:30119","description":"FOXN3 antisense RNA 2","metadata":{"aliases":["PRO1768"]}},{"id":"58fe5d608f4e4c03b8c7cf6d7a386d6e","type":"GENE","name":"FOXN3-AS3","canonical_id":"hgnc:HGNC:58157","description":"FOXN3 antisense RNA 3","metadata":null},{"id":"ddb1a64815a94aa4b0670d3f6cfb14b8","type":"GENE","name":"FOXN3-AS4","canonical_id":"hgnc:HGNC:58288","description":"FOXN3 antisense RNA 4","metadata":null},{"id":"8c366ac2a2f64fdcb867a8136ca602ea","type":"GENE","name":"FOXN3P1","canonical_id":"hgnc:HGNC:43882","description":"forkhead box N3 pseudogene 1","metadata":null},{"id":"2cad1f12728f41b7bf305548880b059e","type":"GENE","name":"FOXN3P2","canonical_id":"hgnc:HGNC:54995","description":"FOXN3 pseudogene 2","metadata":null},{"id":"c4d379733e4145e5b20fd1ac55e8eec8","type":"GENE","name":"FOXN4","canonical_id":"hgnc:HGNC:21399","description":null,"metadata":null},{"id":"4408c0dca17348f1beeed0db3c8493e4","type":"GENE","name":"FOXO1","canonical_id":"hgnc:HGNC:3819","description":null,"metadata":null},{"id":"0bce6720df3b428989303c8fc1398c9e","type":"GENE","name":"FOXO1B","canonical_id":"hgnc:HGNC:3820","description":"forkhead box O1B (pseudogene)","metadata":{"aliases":["FKHRP1"]}},{"id":"f03a37d5e4214880b7ede4ae1a4dbc31","type":"GENE","name":"FOXO3","canonical_id":"hgnc:HGNC:3821","description":null,"metadata":null},{"id":"c55603894c944d0ebf217954ac0056ed","type":"GENE","name":"FOXO3B","canonical_id":"hgnc:HGNC:3822","description":"forkhead box O3B","metadata":{"aliases":["FKHRL1P1"]}},{"id":"c19f3ec6c9e44faf855e1ce72be290b3","type":"GENE","name":"FOXO4","canonical_id":"hgnc:HGNC:7139","description":null,"metadata":null},{"id":"e4703b73bba1428bb97d48c4a32a781a","type":"GENE","name":"FOXO6","canonical_id":"hgnc:HGNC:24814","description":"forkhead box O6","metadata":null},{"id":"76cac41d7e3e493b9102128f9e978cb8","type":"GENE","name":"FOXO6-AS1","canonical_id":"hgnc:HGNC:41066","description":"FOXO6 antisense RNA 1","metadata":null},{"id":"2be0981f5b4d41a0b7e69f1194d10a64","type":"GENE","name":"FOXP1","canonical_id":"hgnc:HGNC:3823","description":null,"metadata":null},{"id":"e950b42a2b144a1485af4723984dc478","type":"GENE","name":"FOXP1-AS1","canonical_id":"hgnc:HGNC:41942","description":"FOXP1 antisense RNA 1","metadata":null},{"id":"6cf8b57d837e46409b86310a30878755","type":"GENE","name":"FOXP1-DT","canonical_id":"hgnc:HGNC:56284","description":"FOXP1 divergent transcript","metadata":null},{"id":"12076110513246eab0817f4e828f6f4f","type":"GENE","name":"FOXP1-IT1","canonical_id":"hgnc:HGNC:41335","description":"FOXP1 intronic transcript 1","metadata":null},{"id":"e0ffb726ed8e4811be31ef314bf89bad","type":"GENE","name":"FOXP2","canonical_id":"hgnc:HGNC:13875","description":null,"metadata":null},{"id":"84167701b4ca453e8305760c2838163a","type":"GENE","name":"FOXP3","canonical_id":"hgnc:HGNC:6106","description":null,"metadata":null},{"id":"79c8ba7c27cf488491a57606cdb21ad6","type":"GENE","name":"FOXP4","canonical_id":"hgnc:HGNC:20842","description":"forkhead box P4","metadata":{"aliases":["FLJ40908"]}},{"id":"4a16853a93104538bbd1d786822ea813","type":"GENE","name":"FOXP4-AS1","canonical_id":"hgnc:HGNC:50332","description":"FOXP4 antisense RNA 1","metadata":null},{"id":"3e04a6e1c33d4facbd2a278bba3230a1","type":"GENE","name":"FOXP4-AS2","canonical_id":"hgnc:HGNC:59402","description":"FOXP4 antisense RNA 2","metadata":null},{"id":"a2096b4ae9124ab99956fedf9d8d6643","type":"GENE","name":"FOXQ1","canonical_id":"hgnc:HGNC:20951","description":null,"metadata":null},{"id":"004459769af84ba19a9487ecad06f07e","type":"GENE","name":"FOXQ1-AS1","canonical_id":"hgnc:HGNC:59326","description":"FOXQ1 antisense RNA 1","metadata":null},{"id":"bcc835c8add542ad8de0b9f629a774af","type":"GENE","name":"FOXR1","canonical_id":"hgnc:HGNC:29980","description":"forkhead box R1","metadata":{"aliases":["DLNB13","FOXN5"]}},{"id":"b7b2018a1d994ddd978e9c5db7b7f6cb","type":"GENE","name":"FOXR2","canonical_id":"hgnc:HGNC:30469","description":"forkhead box R2","metadata":{"aliases":["MGC21658","FOXN6"]}},{"id":"c2a9b968d1214bf0a53eb85994d9863f","type":"GENE","name":"FOXRED1","canonical_id":"hgnc:HGNC:26927","description":"FAD dependent oxidoreductase domain containing 1","metadata":{"aliases":["H17"]}},{"id":"9a9da0cebf9e427c997b2744fb1114fd","type":"GENE","name":"FOXRED2","canonical_id":"hgnc:HGNC:26264","description":"FAD dependent oxidoreductase domain containing 2","metadata":{"aliases":["FLJ23322","ERFAD"]}},{"id":"79f94a493aaf4fd39a7a3ea6953a0eb4","type":"GENE","name":"FOXS1","canonical_id":"hgnc:HGNC:3735","description":"forkhead box S1","metadata":{"aliases":["FREAC10","FKHL18"]}},{"id":"3acc89edbd0048eebe43b16b5206e95b","type":"GENE","name":"FPASL","canonical_id":"hgnc:HGNC:56688","description":"fibroblast proliferation associated lncRNA","metadata":null},{"id":"9b50e017c2e2447884a5f8f66e5a9110","type":"GENE","name":"FPGS","canonical_id":"hgnc:HGNC:3824","description":null,"metadata":null},{"id":"1434a5f5b8be4aa4ae44257d7b3d6fa1","type":"GENE","name":"FPGT","canonical_id":"hgnc:HGNC:3825","description":"fucose-1-phosphate guanylyltransferase","metadata":{"aliases":["GFPP"]}},{"id":"d865fd379f704fc1a5341239ab2c01ef","type":"GENE","name":"FPGT-TNNI3K","canonical_id":"hgnc:HGNC:42952","description":"FPGT-TNNI3K readthrough","metadata":null},{"id":"1ad46363c7e34d0593d0e1f8089914f9","type":"TRIAL","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","canonical_id":"clinicaltrials.gov:NCT06909825","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"1c4f68317b17436b95402489866d400d","type":"GENE","name":"FPR1","canonical_id":"hgnc:HGNC:3826","description":"formyl peptide receptor 1","metadata":{"aliases":["FPR","FMLP"]}},{"id":"b200d210a632406fa04a8cf84b3f826b","type":"GENE","name":"FPR2","canonical_id":"hgnc:HGNC:3827","description":"formyl peptide receptor 2","metadata":{"aliases":["LXA4R","HM63","FPRH2","FMLPX","FPR2A","FMLP-R-II","ALXR","ALX","FPRL1"]}},{"id":"b83745b0c0d84986a8eb37a8d892cab6","type":"GENE","name":"FPR3","canonical_id":"hgnc:HGNC:3828","description":"formyl peptide receptor 3","metadata":{"aliases":["FPRH1","FMLPY","RMLP-R-I","FPRL2"]}},{"id":"db25b4fcf64e487394601cfd1e6cd558","type":"TRIAL","name":"FR901228 in Treating Patients With Hematologic Cancer","canonical_id":"clinicaltrials.gov:NCT00024180","description":"Leukemia; Lymphoma","metadata":null},{"id":"0bfb5f81e5ca45e2b13bae318f9eada0","type":"TRIAL","name":"FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00042822","description":"Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms","metadata":null},{"id":"18dfceb869f14289a13d8e5a881684d7","type":"TRIAL","name":"FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00077337","description":"Colorectal Cancer","metadata":null},{"id":"8e41ebeabb804fbfa45ce5a94673df43","type":"TRIAL","name":"FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00066638","description":"DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"428f90bfc0504e59b85f8a8869c86b86","type":"TRIAL","name":"FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00077194","description":"Lymphoma","metadata":null},{"id":"4fb4683db84144f69dc861530c50c31a","type":"GENE","name":"FRA10A","canonical_id":"hgnc:HGNC:3829","description":"fragile site, folic acid type, rare, fra(10)(q23.3) or fra(10)(q24.2)","metadata":null},{"id":"102c2b0effc447fca3e8c847aae2f305","type":"GENE","name":"FRA10AC1","canonical_id":"hgnc:HGNC:1162","description":"FRA10A associated CGG repeat 1","metadata":{"aliases":["C10orf4"]}},{"id":"29fe901fdc8e411fa3219cd5bffdcb9a","type":"GENE","name":"FRA10B","canonical_id":"hgnc:HGNC:3830","description":"fragile site, BrdU type, rare, fra(10)(q25.2)","metadata":null},{"id":"140bc8320ae2467ab083dc201dbac429","type":"GENE","name":"FRA10C","canonical_id":"hgnc:HGNC:3831","description":"fragile site, BrdU type, common, fra(10)(q21)","metadata":null},{"id":"9d937b9d1d5245be8b85d58f9e004f4c","type":"GENE","name":"FRA10D","canonical_id":"hgnc:HGNC:3832","description":"fragile site, aphidicolin type, common, fra(10)(q22.1)","metadata":null},{"id":"a7968160c6404511b81b63c1b9e38d76","type":"GENE","name":"FRA10E","canonical_id":"hgnc:HGNC:3833","description":"fragile site, aphidicolin type, common, fra(10)(q25.2)","metadata":null},{"id":"e22c5329d2914b4a8def85e04088ca4a","type":"GENE","name":"FRA10F","canonical_id":"hgnc:HGNC:3834","description":"fragile site, aphidicolin type, common, fra(10)(q26.1)","metadata":null},{"id":"53a674b743b94b0998e65422e3620984","type":"GENE","name":"FRA10G","canonical_id":"hgnc:HGNC:3835","description":"fragile site, aphidicolin type, common, fra(10)(q11.2)","metadata":null},{"id":"370abf2cf935439b8ca8798b8b23bf70","type":"GENE","name":"FRA11A","canonical_id":"hgnc:HGNC:3836","description":"fragile site, folic acid type, rare, fra(11)(q13.3)","metadata":null},{"id":"627825b3fa734f2a943b917289995ada","type":"GENE","name":"FRA11B","canonical_id":"hgnc:HGNC:3837","description":"fragile site, folic acid type, rare, fra(11)(q23.3)","metadata":null},{"id":"cab8dec2f7a344d1ad81b178fdb8d303","type":"GENE","name":"FRA11C","canonical_id":"hgnc:HGNC:3838","description":"fragile site, aphidicolin type, common, fra(11)(p15.1)","metadata":null},{"id":"4ba7f142a936413099895fcc3e6b450c","type":"GENE","name":"FRA11D","canonical_id":"hgnc:HGNC:3839","description":"fragile site, aphidicolin type, common, fra(11)(p14.2)","metadata":null},{"id":"d139adcef74f4a5f914730e81885b9a1","type":"GENE","name":"FRA11E","canonical_id":"hgnc:HGNC:3840","description":"fragile site, aphidicolin type, common, fra(11)(p13)","metadata":null},{"id":"49587385a3fb47b785819ef5baa902c4","type":"GENE","name":"FRA11F","canonical_id":"hgnc:HGNC:3841","description":"fragile site, aphidicolin type, common, fra(11)(q14.2)","metadata":null},{"id":"09611223c18f445289330ee088162a0d","type":"GENE","name":"FRA11G","canonical_id":"hgnc:HGNC:3842","description":"fragile site, aphidicolin type, common, fra(11)(q23.3)","metadata":null},{"id":"0d38794ef79b47b6a23cccf8ed6a37d9","type":"GENE","name":"FRA11H","canonical_id":"hgnc:HGNC:3843","description":"fragile site, aphidicolin type, common, fra(11)(q13)","metadata":null},{"id":"6814b7d1ce7b47479188839fefd9d41f","type":"GENE","name":"FRA11I","canonical_id":"hgnc:HGNC:3844","description":"fragile site, distamycin A type, rare, fra(11)(p15.1)","metadata":null},{"id":"aa51385637084454bd9c919b75960bd2","type":"GENE","name":"FRA12A","canonical_id":"hgnc:HGNC:3845","description":"fragile site, folic acid type, rare, fra(12)(q13.1)","metadata":null},{"id":"361ce0391b25498b921f9f8b01011828","type":"GENE","name":"FRA12B","canonical_id":"hgnc:HGNC:3846","description":"fragile site, aphidicolin type, common, fra(12)(q21.3)","metadata":null},{"id":"5dd417fba0034c2793ce202e0c657b57","type":"GENE","name":"FRA12C","canonical_id":"hgnc:HGNC:3847","description":"fragile site, BrdU type, rare, fra(12)(q24.2)","metadata":null},{"id":"b623022dca7945aa87a1b27ed8ef56f0","type":"GENE","name":"FRA12D","canonical_id":"hgnc:HGNC:3848","description":"fragile site, folic acid type, rare, fra(12)(q24.13)","metadata":null},{"id":"f4e395208cb5420b8b6a08202b020ddb","type":"GENE","name":"FRA12E","canonical_id":"hgnc:HGNC:3849","description":"fragile site, aphidicolin type, common, fra(12)(q24)","metadata":null},{"id":"25982dca3b404c73ad1120102c1fcbf9","type":"GENE","name":"FRA13A","canonical_id":"hgnc:HGNC:3850","description":"fragile site, aphidicolin type, common, fra(13)(q13.2)","metadata":null},{"id":"aef2231dddc045d39df8fa70433032ef","type":"GENE","name":"FRA13B","canonical_id":"hgnc:HGNC:3851","description":"fragile site, BrdU type, common, fra(13)(q21)","metadata":null},{"id":"754797375b154bddb9661e723db3aaa9","type":"GENE","name":"FRA13C","canonical_id":"hgnc:HGNC:3852","description":"fragile site, aphidicolin type, common, fra(13)(q21.2)","metadata":null},{"id":"425b02732cc046ea8f961aeba7568c53","type":"GENE","name":"FRA13D","canonical_id":"hgnc:HGNC:3853","description":"fragile site, aphidicolin type, common, fra(13)(q32)","metadata":null},{"id":"827163ce62a947c0aecb8a78a1e48718","type":"GENE","name":"FRA14B","canonical_id":"hgnc:HGNC:3854","description":"fragile site, aphidicolin type, common, fra(14)(q23)","metadata":null},{"id":"04221d63a1984e558cf6475bb59f255c","type":"GENE","name":"FRA14C","canonical_id":"hgnc:HGNC:3855","description":"fragile site, aphidicolin type, common, fra(14)(q24.1)","metadata":null},{"id":"99a4ed135d21460daae24f40e6b5a610","type":"GENE","name":"FRA15A","canonical_id":"hgnc:HGNC:3856","description":"fragile site, aphidicolin type, common, fra(15)(q22)","metadata":null},{"id":"48be45166d1c432ba6bc4e989f62478f","type":"GENE","name":"FRA16A","canonical_id":"hgnc:HGNC:3857","description":"fragile site, folic acid type, rare, fra(16)(p13.11)","metadata":null},{"id":"c629d8eec1fb4bbeade0611c16437c45","type":"GENE","name":"FRA16B","canonical_id":"hgnc:HGNC:3858","description":"fragile site, distamycin A type, rare, fra(16)(q22.1)","metadata":null},{"id":"55959cae22fb470ebb71414e32c8c48b","type":"GENE","name":"FRA16C","canonical_id":"hgnc:HGNC:3859","description":"fragile site, aphidicolin type, common, fra(16)(q22.1)","metadata":null},{"id":"8d1b4c257c384aa3967b03540f50c1d5","type":"GENE","name":"FRA16D","canonical_id":"hgnc:HGNC:3860","description":"fragile site, aphidicolin type, common, fra(16)(q23.2)","metadata":null},{"id":"a8c79a09c7fb49158f243c733430c146","type":"GENE","name":"FRA16E","canonical_id":"hgnc:HGNC:3861","description":"fragile site, distamycin A type, rare, fra(16)(p12.1)","metadata":null},{"id":"d6e4849656e046059d78aaf4be9276bf","type":"GENE","name":"FRA17A","canonical_id":"hgnc:HGNC:3862","description":"fragile site, distamycin A type, rare, fra(17)(p12)","metadata":null},{"id":"ed30a56538b34412b8fa4181b89221b3","type":"GENE","name":"FRA17B","canonical_id":"hgnc:HGNC:3863","description":"fragile site, aphidicolin type, common, fra(17)(q23.1)","metadata":null},{"id":"a9f9b35134454effa2cde436903bc3ec","type":"GENE","name":"FRA18A","canonical_id":"hgnc:HGNC:3864","description":"fragile site, aphidicolin type, common, fra(18)(q12.2)","metadata":null},{"id":"1c869f0cdb40420aa643c1e5f2a656f6","type":"GENE","name":"FRA18B","canonical_id":"hgnc:HGNC:3865","description":"fragile site, aphidicolin type, common, fra(18)(q21.3)","metadata":null},{"id":"9ed0d482074f4f98bb90dd5929403e66","type":"GENE","name":"FRA18C","canonical_id":"hgnc:HGNC:16929","description":"fragile site, aphidicolin type, common, fra(18)(q22.2)","metadata":null},{"id":"b78368abcf8545099bb6485bb8b830db","type":"GENE","name":"FRA19A","canonical_id":"hgnc:HGNC:3866","description":"fragile site, 5-azacytidine type, common, fra(19)(q13)","metadata":null},{"id":"8967f09dc5b64e5b87e85b2cb017a28a","type":"GENE","name":"FRA19B","canonical_id":"hgnc:HGNC:3867","description":"fragile site, folic acid type, rare, fra(19)(p13)","metadata":null},{"id":"7647568362254190997ea1ce8614c2b8","type":"GENE","name":"FRA1A","canonical_id":"hgnc:HGNC:3868","description":"fragile site, aphidicolin type, common, fra(1)(p36)","metadata":null},{"id":"dc6776eafe12482cab4a862c295410db","type":"GENE","name":"FRA1B","canonical_id":"hgnc:HGNC:3869","description":"fragile site, aphidicolin type, common, fra(1)(p32)","metadata":null},{"id":"bad4061f90b84318b3c9d8db7c15e372","type":"GENE","name":"FRA1C","canonical_id":"hgnc:HGNC:3870","description":"fragile site, aphidicolin type, common, fra(1)(p31.2)","metadata":null},{"id":"54d51fa46ade4c8198cc3f0b1361b33a","type":"GENE","name":"FRA1D","canonical_id":"hgnc:HGNC:3871","description":"fragile site, aphidicolin type, common, fra(1)(p22)","metadata":null},{"id":"062e629eeead455f9a9d05f709a45dcf","type":"GENE","name":"FRA1E","canonical_id":"hgnc:HGNC:3872","description":"fragile site, aphidicolin type, common, fra(1)(p21.2)","metadata":null},{"id":"8f0fcd6383f54510bd140694516cee81","type":"GENE","name":"FRA1F","canonical_id":"hgnc:HGNC:3873","description":"fragile site, aphidicolin type, common, fra(1)(q21)","metadata":null},{"id":"dcc58b74543345d99af0fb6d09bbee20","type":"GENE","name":"FRA1G","canonical_id":"hgnc:HGNC:3874","description":"fragile site, aphidicolin type, common, fra(1)(q25.1)","metadata":null},{"id":"3900eb7ee96a4bf7a2c2a284d230d7a3","type":"GENE","name":"FRA1H","canonical_id":"hgnc:HGNC:3875","description":"fragile site, 5-azacytidine type, common, fra(1)(q42)","metadata":null},{"id":"2fa01ad4d453491e9644995730a50323","type":"GENE","name":"FRA1I","canonical_id":"hgnc:HGNC:3876","description":"fragile site, aphidicolin type, common, fra(1)(q44)","metadata":null},{"id":"c8667e554b764723b27a54220ecd6141","type":"GENE","name":"FRA1J","canonical_id":"hgnc:HGNC:3877","description":"fragile site, 5-azacytidine type, common, fra(1)(q12)","metadata":null},{"id":"bcdab969e06340239d379813f59e4eef","type":"GENE","name":"FRA1K","canonical_id":"hgnc:HGNC:3878","description":"fragile site, aphidicolin type, common, fra(1)(q31)","metadata":null},{"id":"b92320da8e7c4523a535baa1bfaeca55","type":"GENE","name":"FRA1L","canonical_id":"hgnc:HGNC:3879","description":"fragile site, aphidicolin type, common, fra(1)(p31)","metadata":null},{"id":"ac25d378a8df45f48c49af33ec6fbca5","type":"GENE","name":"FRA1M","canonical_id":"hgnc:HGNC:3880","description":"fragile site, folic acid type, rare, fra(1)(p21.3)","metadata":null},{"id":"c02ac55e80224f6ca6a704cdf4e68736","type":"GENE","name":"FRA20A","canonical_id":"hgnc:HGNC:3881","description":"fragile site, folic acid type, rare, fra(20)(p11.23)","metadata":null},{"id":"3e17d88179794b5ebd2efa2fd47dc8da","type":"GENE","name":"FRA20B","canonical_id":"hgnc:HGNC:3882","description":"fragile site, aphidicolin type, common, fra(20)(p12.2)","metadata":null},{"id":"2f86668342bf448fa21879726c411241","type":"GENE","name":"FRA22A","canonical_id":"hgnc:HGNC:3883","description":"fragile site, folic acid type, rare, fra(22)(q13)","metadata":null},{"id":"504f77c1cad645d48feeb44b71df9bb7","type":"GENE","name":"FRA22B","canonical_id":"hgnc:HGNC:3884","description":"fragile site, aphidicolin type, common, fra(22)(q12.2)","metadata":null},{"id":"46d7643a05be475bb9f37bf164dd78e7","type":"GENE","name":"FRA2A","canonical_id":"hgnc:HGNC:3885","description":"fragile site, folic acid type, rare, fra(2)(q11.2)","metadata":null},{"id":"cc84de0dcf67487e97493c22fe3a8a1a","type":"GENE","name":"FRA2B","canonical_id":"hgnc:HGNC:3886","description":"fragile site, folic acid type, rare, fra(2)(q13)","metadata":null},{"id":"41f3813538b4448883f02121392fd3ac","type":"GENE","name":"FRA2C","canonical_id":"hgnc:HGNC:3887","description":"fragile site, aphidicolin type, common, fra(2)(p24.2)","metadata":null},{"id":"3119c107f35b4021add9250ded83969c","type":"GENE","name":"FRA2D","canonical_id":"hgnc:HGNC:3888","description":"fragile site, aphidicolin type, common, fra(2)(p16.2)","metadata":null},{"id":"d0b4d7ffc54e4e5882333f4a5d152c11","type":"GENE","name":"FRA2E","canonical_id":"hgnc:HGNC:3889","description":"fragile site, aphidicolin type, common, fra(2)(p13)","metadata":null},{"id":"a230b0aea703416ea3d5056827f619de","type":"GENE","name":"FRA2F","canonical_id":"hgnc:HGNC:3890","description":"fragile site, aphidicolin type, common, fra(2)(q21.3)","metadata":null},{"id":"765554cc0a80484a9e3f41a016764551","type":"GENE","name":"FRA2G","canonical_id":"hgnc:HGNC:3891","description":"fragile site, aphidicolin type, common, fra(2)(q31)","metadata":null},{"id":"d9298a83cb8d40cb9a2ce81e91135979","type":"GENE","name":"FRA2H","canonical_id":"hgnc:HGNC:3892","description":"fragile site, aphidicolin type, common, fra(2)(q32.1)","metadata":null},{"id":"4046d60be1764a1ca88f1af04808a697","type":"GENE","name":"FRA2I","canonical_id":"hgnc:HGNC:3893","description":"fragile site, aphidicolin type, common, fra(2)(q33)","metadata":null},{"id":"5dc228340a7144c9b9d24b37db2c9817","type":"GENE","name":"FRA2J","canonical_id":"hgnc:HGNC:3894","description":"fragile site, aphidicolin type, common, fra(2)(q37.3)","metadata":null},{"id":"9917ef24f05b40cab41ddc744d4edce1","type":"GENE","name":"FRA2K","canonical_id":"hgnc:HGNC:3895","description":"fragile site, folic acid type, rare, fra(2)(q22.3)","metadata":null},{"id":"6c28b3c4c4b74dc5ab8ca811e3903239","type":"GENE","name":"FRA3A","canonical_id":"hgnc:HGNC:3896","description":"fragile site, aphidicolin type, common, fra(3)(p24.2)","metadata":null},{"id":"575e367e05804465aedd4ef76854b652","type":"GENE","name":"FRA3B","canonical_id":"hgnc:HGNC:3897","description":"fragile site, aphidicolin type, common, fra(3)(p14.2)","metadata":null},{"id":"b6eae315f6014366aa5027ad5cde7de0","type":"GENE","name":"FRA3C","canonical_id":"hgnc:HGNC:3898","description":"fragile site, aphidicolin type, common, fra(3)(q27)","metadata":null},{"id":"7a6f494e97db40adbd96ff089f48a116","type":"GENE","name":"FRA3D","canonical_id":"hgnc:HGNC:3899","description":"fragile site, aphidicolin type, common, fra(3)(q25)","metadata":null},{"id":"6ca4d3a02e8b4e4f987844dd7aa64d91","type":"GENE","name":"FRA4A","canonical_id":"hgnc:HGNC:3900","description":"fragile site, aphidicolin type, common, fra(4)(p16.1)","metadata":null},{"id":"59b1126adcf84bb7a0156230693f287d","type":"GENE","name":"FRA4B","canonical_id":"hgnc:HGNC:3901","description":"fragile site, BrdU type, common, fra(4)(q12)","metadata":null},{"id":"0c8535519a78415384acc5824736121f","type":"GENE","name":"FRA4C","canonical_id":"hgnc:HGNC:3902","description":"fragile site, aphidicolin type, common, fra(4)(q31.1)","metadata":null},{"id":"d524ea26608e49e0a90f70cc5f1e014c","type":"GENE","name":"FRA4D","canonical_id":"hgnc:HGNC:3903","description":"fragile site, aphidicolin type, common, fra(4)(p15)","metadata":null},{"id":"df2dff9d8c8e415b8e51a5e72d785cf2","type":"GENE","name":"FRA5A","canonical_id":"hgnc:HGNC:3905","description":"fragile site, BrdU type, common, fra(5)(p13)","metadata":null},{"id":"8d8d85ed841a4d2ea8e254a1f2393e64","type":"GENE","name":"FRA5B","canonical_id":"hgnc:HGNC:3906","description":"fragile site, BrdU type, common, fra(5)(q15)","metadata":null},{"id":"390b157f40024e6db8d8490e292de676","type":"GENE","name":"FRA5C","canonical_id":"hgnc:HGNC:3907","description":"fragile site, aphidicolin type, common, fra(5)(q31.1)","metadata":null},{"id":"7e36cd4dcc544b70853981973db83bfe","type":"GENE","name":"FRA5D","canonical_id":"hgnc:HGNC:3908","description":"fragile site, aphidicolin type, common, fra(5)(q15)","metadata":null},{"id":"b8d469db27294c6292e4edd863ebe927","type":"GENE","name":"FRA5E","canonical_id":"hgnc:HGNC:3909","description":"fragile site, aphidicolin type, common, fra(5)(p14)","metadata":null},{"id":"c4d651de6746491c956ff437c1576832","type":"GENE","name":"FRA5F","canonical_id":"hgnc:HGNC:3910","description":"fragile site, aphidicolin type, common, fra(5)(q21)","metadata":null},{"id":"311e598a330042eba2c4da915626eebf","type":"GENE","name":"FRA5G","canonical_id":"hgnc:HGNC:3911","description":"fragile site, folic acid type, rare, fra(5)(q35)","metadata":null},{"id":"b77f5426ea7848ca9c1999eb6b2c6889","type":"GENE","name":"FRA6A","canonical_id":"hgnc:HGNC:3912","description":"fragile site, folic acid type, rare, fra(6)(p23)","metadata":null},{"id":"16e2ef04deea4f98bad7cb75709c23be","type":"GENE","name":"FRA6B","canonical_id":"hgnc:HGNC:3913","description":"fragile site, aphidicolin type, common, fra(6)(p25.1)","metadata":null},{"id":"8c91177bc25f462db7a714a117ad150e","type":"GENE","name":"FRA6C","canonical_id":"hgnc:HGNC:3914","description":"fragile site, aphidicolin type, common, fra(6)(p22.2)","metadata":null},{"id":"bb8d1aa60051477c813dde8bd1a8a452","type":"GENE","name":"FRA6D","canonical_id":"hgnc:HGNC:3915","description":"fragile site, BrdU type, common, fra(6)(q13)","metadata":null},{"id":"bbccd0fcec5640e18841baad17c702c2","type":"GENE","name":"FRA6E","canonical_id":"hgnc:HGNC:3916","description":"fragile site, aphidicolin type, common, fra(6)(q26)","metadata":null},{"id":"fad17e5367804eeca330ef8bfa0234ea","type":"GENE","name":"FRA6F","canonical_id":"hgnc:HGNC:3917","description":"fragile site, aphidicolin type, common, fra(6)(q21)","metadata":null},{"id":"f17d4707fea14482a635f08b91300b0d","type":"GENE","name":"FRA6G","canonical_id":"hgnc:HGNC:3918","description":"fragile site, aphidicolin type, common, fra(6)(q15)","metadata":null},{"id":"be232ec7471f4ae99144b45bcb927cc6","type":"GENE","name":"FRA7A","canonical_id":"hgnc:HGNC:3919","description":"fragile site, folic acid type, rare, fra(7)(p11.2)","metadata":null},{"id":"20d531bb88eb4d84a21a4e301169e958","type":"GENE","name":"FRA7B","canonical_id":"hgnc:HGNC:3920","description":"fragile site, aphidicolin type, common, fra(7)(p22)","metadata":null},{"id":"b18041abc7c345c988275bafb6fe8f97","type":"GENE","name":"FRA7C","canonical_id":"hgnc:HGNC:3921","description":"fragile site, aphidicolin type, common, fra(7)(p14.2)","metadata":null},{"id":"3152341bca9c4cd6a191c37bfc25fdf7","type":"GENE","name":"FRA7D","canonical_id":"hgnc:HGNC:3922","description":"fragile site, aphidicolin type, common, fra(7)(p13)","metadata":null},{"id":"3af0a1f6c3634d80aad7434589c72d39","type":"GENE","name":"FRA7E","canonical_id":"hgnc:HGNC:3923","description":"fragile site, aphidicolin type, common, fra(7)(q21.2)","metadata":null},{"id":"ed3f74ef9c43457fa0a3325ce99889fa","type":"GENE","name":"FRA7F","canonical_id":"hgnc:HGNC:3924","description":"fragile site, aphidicolin type, common, fra(7)(q22)","metadata":null},{"id":"ec69c248a8144fdcb2a0af9e25f3ac4e","type":"GENE","name":"FRA7G","canonical_id":"hgnc:HGNC:3925","description":"fragile site, aphidicolin type, common, fra(7)(q31.2)","metadata":{"aliases":["D7S486"]}},{"id":"346c0f7e880748898bfd46f1772f5dca","type":"GENE","name":"FRA7H","canonical_id":"hgnc:HGNC:3926","description":"fragile site, aphidicolin type, common, fra(7)(q32.3)","metadata":null},{"id":"e2515f20db644085905b24685eb45c58","type":"GENE","name":"FRA7I","canonical_id":"hgnc:HGNC:3927","description":"fragile site, aphidicolin type, common, fra(7)(q36)","metadata":null},{"id":"c1c8f4b9720c4702a0bd23030fa22b23","type":"GENE","name":"FRA7J","canonical_id":"hgnc:HGNC:3928","description":"fragile site, aphidicolin type, common, fra(7)(q11)","metadata":null},{"id":"e10c954d4a0341e7a7df10acbf37e175","type":"GENE","name":"FRA8A","canonical_id":"hgnc:HGNC:3929","description":"fragile site, folic acid type, rare, fra(8)(q22.3)","metadata":null},{"id":"da5c6d99e31748b3a6d55baa19d137bb","type":"GENE","name":"FRA8B","canonical_id":"hgnc:HGNC:3930","description":"fragile site, aphidicolin type, common, fra(8)(q22.1)","metadata":null},{"id":"ab23bbef85a74b1e85d420fbf031b176","type":"GENE","name":"FRA8C","canonical_id":"hgnc:HGNC:3931","description":"fragile site, aphidicolin type, common, fra(8)(q24.1)","metadata":null},{"id":"9c296a3223804426a2d17155197bdc48","type":"GENE","name":"FRA8D","canonical_id":"hgnc:HGNC:3932","description":"fragile site, aphidicolin type, common, fra(8)(q24.3)","metadata":null},{"id":"3ca4159e03414ec2b14d26f4e0135ccc","type":"GENE","name":"FRA8E","canonical_id":"hgnc:HGNC:3933","description":"fragile site, distamycin A type, rare, fra(8)(q24.1)","metadata":null},{"id":"1e6be0a2218540328eeea7a266ff17e8","type":"GENE","name":"FRA9A","canonical_id":"hgnc:HGNC:3935","description":"fragile site, folic acid type, rare, fra(9)(p21)","metadata":null},{"id":"1b10405d3bd1461997d93093b6dc0a9a","type":"GENE","name":"FRA9B","canonical_id":"hgnc:HGNC:3936","description":"fragile site, folic acid type, rare, fra(9)(q32)","metadata":null},{"id":"24b1482716a947c28594b9a80a7006af","type":"GENE","name":"FRA9C","canonical_id":"hgnc:HGNC:3937","description":"fragile site, BrdU type, common, fra(9)(p21)","metadata":null},{"id":"a3e81ad5241646e1aea09b7575416a23","type":"GENE","name":"FRA9D","canonical_id":"hgnc:HGNC:3938","description":"fragile site, aphidicolin type, common, fra(9)(q22.1)","metadata":null},{"id":"e935149a272c44f4b67671c812daace0","type":"GENE","name":"FRA9E","canonical_id":"hgnc:HGNC:3939","description":"fragile site, aphidicolin type, common, fra(9)(q32)","metadata":null},{"id":"26803d3fce554d7bb79925730f5eb75a","type":"GENE","name":"FRA9F","canonical_id":"hgnc:HGNC:3940","description":"fragile site, 5-azacytidine type, common, fra(9)(q12)","metadata":null},{"id":"46c294c0c2dd4aa188d533509e053872","type":"GENE","name":"FRAS1","canonical_id":"hgnc:HGNC:19185","description":"Fraser extracellular matrix complex subunit 1","metadata":{"aliases":["FLJ22031","FLJ14927","KIAA1500"]}},{"id":"906fc9c4eb014ced87465c54463ffc5b","type":"GENE","name":"FRAS1-AS1","canonical_id":"hgnc:HGNC:58833","description":"FRAS1 antisense RNA 1","metadata":null},{"id":"331c95f473f2402d9ab1d99c1997dc29","type":"GENE","name":"FRAT1","canonical_id":"hgnc:HGNC:3944","description":"FRAT regulator of Wnt signaling pathway 1","metadata":null},{"id":"d1ad160bef614ad78aa98c69ef8f9ed9","type":"GENE","name":"FRAT2","canonical_id":"hgnc:HGNC:16048","description":"FRAT regulator of Wnt signaling pathway 2","metadata":null},{"id":"14c9920c4477455facfa389b4ed52389","type":"GENE","name":"FRAXA","canonical_id":"hgnc:HGNC:3945","description":"fragile site, folic acid type, rare, fra(X)(q27.3) A","metadata":null},{"id":"1ce11073ff214bf98fd9100731fbf4e4","type":"GENE","name":"FRAXB","canonical_id":"hgnc:HGNC:3946","description":"fragile site, aphidicolin type, common, fra(X)(p22.31) B","metadata":null},{"id":"eaea56cc648041f3ad5b280112a70ec6","type":"GENE","name":"FRAXC","canonical_id":"hgnc:HGNC:3947","description":"fragile site, aphidicolin type, common, fra(X)(q22.1) C","metadata":null},{"id":"14cedf71fd084196b3a814d7751aa1e8","type":"GENE","name":"FRAXD","canonical_id":"hgnc:HGNC:3948","description":"fragile site, aphidicolin type, common, fra(X)(q27.2) D","metadata":null},{"id":"09961355b73643999d4c8b6756ee87d4","type":"GENE","name":"FRAXE","canonical_id":"hgnc:HGNC:3949","description":"fragile site, folic acid type, rare, fra(X)(q28) E","metadata":null},{"id":"9772cb4b5fcd4b1a99c95c5ee691b86e","type":"TRIAL","name":"FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period","canonical_id":"clinicaltrials.gov:NCT00921245","description":"Overactive Bladder","metadata":null},{"id":"99003fcc4c3443faa8317c7f67fae2df","type":"TRIAL","name":"FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT00325403","description":"Pulmonary Hypertension","metadata":null},{"id":"170b3f2f81c248b08c5056c3ee8b09b2","type":"TRIAL","name":"FREEDOM COVID-19 Anticoagulation Strategy","canonical_id":"clinicaltrials.gov:NCT04512079","description":"COVID-19; SARS-CoV-2","metadata":null},{"id":"4c98482f4595467c989c4c0cf5badd11","type":"TRIAL","name":"FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT00325442","description":"Pulmonary Hypertension","metadata":null},{"id":"29e760e0fdbb463f84086bc86a7c08af","type":"GENE","name":"FREM1","canonical_id":"hgnc:HGNC:23399","description":"FRAS1 related extracellular matrix 1","metadata":{"aliases":["FLJ25461","C9orf145","C9orf143","DKFZp686M16108","TILRR","C9orf154"]}},{"id":"04447c147c6b48b98130d38bbd7611a4","type":"GENE","name":"FREM2","canonical_id":"hgnc:HGNC:25396","description":"FRAS1 related extracellular matrix 2","metadata":{"aliases":["DKFZp686J0811"]}},{"id":"cf14f86c205a421ebf1a36293cd6cd44","type":"GENE","name":"FREM2-AS1","canonical_id":"hgnc:HGNC:39964","description":"FREM2 antisense RNA 1","metadata":null},{"id":"fbfaa7130a2b4f48ac8a2a75ebcaec00","type":"GENE","name":"FREM3","canonical_id":"hgnc:HGNC:25172","description":"FRAS1 related extracellular matrix 3","metadata":null},{"id":"48a3134ea2c444abb08af4ce1a4edf95","type":"GENE","name":"FREY1","canonical_id":"hgnc:HGNC:37213","description":"Frey regulator of sperm-oocyte fusion 1","metadata":{"aliases":["Frey","C11orf94"]}},{"id":"058fbbbc732a41aa8cbef288ea6f71f2","type":"GENE","name":"FRG1","canonical_id":"hgnc:HGNC:3954","description":"FSHD region gene 1","metadata":{"aliases":["FSG1","FRG1A"]}},{"id":"a014378c996747128bdba8daa7ab08a9","type":"GENE","name":"FRG1-DT","canonical_id":"hgnc:HGNC:51590","description":"FRG1 divergent transcript","metadata":null},{"id":"de500e90ffca424c843cad534d48558f","type":"GENE","name":"FRG1BP","canonical_id":"hgnc:HGNC:15792","description":"FSHD region gene 1 family member B, pseudogene","metadata":{"aliases":["bA348I14.2","C20orf80","FRG1B"]}},{"id":"4d838feabc404ac3ad62767f65075edd","type":"GENE","name":"FRG1CP","canonical_id":"hgnc:HGNC:51762","description":"FSHD region gene 1 family member C, pseudogene","metadata":null},{"id":"18e93fb36e96433aacddba69f6cca46e","type":"GENE","name":"FRG1DP","canonical_id":"hgnc:HGNC:51763","description":"FSHD region gene 1 family member D, pseudogene","metadata":null},{"id":"3a8cda218b52408cb5ee8d39dc595244","type":"GENE","name":"FRG1EP","canonical_id":"hgnc:HGNC:51764","description":"FSHD region gene 1 family member E, pseudogene","metadata":null},{"id":"9c3a0a92862a4759a145f972b5bf6fda","type":"GENE","name":"FRG1FP","canonical_id":"hgnc:HGNC:51765","description":"FSHD region gene 1 family member F, pseudogene","metadata":null},{"id":"787f26cfcbd746b89403c22210403129","type":"GENE","name":"FRG1GP","canonical_id":"hgnc:HGNC:51766","description":"FSHD region gene 1 family member G, pseudogene","metadata":null},{"id":"ae2509347c734f308c337c744591b15f","type":"GENE","name":"FRG1HP","canonical_id":"hgnc:HGNC:51767","description":"FSHD region gene 1 family member H, pseudogene","metadata":null},{"id":"fa31eb0fd15e4cd4bef27f96b848f1e0","type":"GENE","name":"FRG1JP","canonical_id":"hgnc:HGNC:51768","description":"FSHD region gene 1 family member J, pseudogene","metadata":null},{"id":"4a6dc273519642bfa4db872105f42d6d","type":"GENE","name":"FRG1KP","canonical_id":"hgnc:HGNC:51769","description":"FSHD region gene 1 family member K, pseudogene","metadata":null},{"id":"768779ce3335414a951923f98d32f567","type":"GENE","name":"FRG2","canonical_id":"hgnc:HGNC:19136","description":"FSHD region gene 2","metadata":{"aliases":["FRG2A"]}},{"id":"d9f079a8d402492a924a738a671a77ed","type":"GENE","name":"FRG2B","canonical_id":"hgnc:HGNC:33518","description":"FSHD region gene 2 family member B","metadata":null},{"id":"7c8409ccc0034ef1a3a4ff51fc5def45","type":"GENE","name":"FRG2C","canonical_id":"hgnc:HGNC:33626","description":"FSHD region gene 2 family member C","metadata":null},{"id":"bb89af8ad3c549fe86c4b38a54474b91","type":"GENE","name":"FRG2DP","canonical_id":"hgnc:HGNC:27093","description":"FSHD region gene 2 family member D, pseudogene","metadata":null},{"id":"210fc4e5496b4b14abff16efa4ae0664","type":"GENE","name":"FRG2EP","canonical_id":"hgnc:HGNC:51365","description":"FSHD region gene 2 family member E, pseudogene","metadata":null},{"id":"3411d3a348d7461db6234a3caff456c1","type":"GENE","name":"FRG2FP","canonical_id":"hgnc:HGNC:51366","description":"FSHD region gene 2 family member F, pseudogene","metadata":{"aliases":["TCONS_l2_00020053"]}},{"id":"a1d7ad79551c4b1abf4300f7cd5d58a5","type":"GENE","name":"FRG2GP","canonical_id":"hgnc:HGNC:51364","description":"FSHD region gene 2 family member G, pseudogene","metadata":null},{"id":"677d05c1544c49b2b0a01ccbd452c024","type":"GENE","name":"FRG2HP","canonical_id":"hgnc:HGNC:51794","description":"FSHD region gene 2 family member H, pseudogene","metadata":null},{"id":"255ba4634c6244c7a1fef0cf17248d38","type":"GENE","name":"FRG2IP","canonical_id":"hgnc:HGNC:51795","description":"FSHD region gene 2 family member I, pseudogene","metadata":null},{"id":"f91fe0b048264a8cba461d38db6eebc9","type":"GENE","name":"FRG2JP","canonical_id":"hgnc:HGNC:51796","description":"FSHD region gene 2 family member J, pseudogene","metadata":null},{"id":"3adb6ce6f69d4ea3ba0be3b8006b418c","type":"GENE","name":"FRG2KP","canonical_id":"hgnc:HGNC:51797","description":"FSHD region gene 2 family member K, pseudogene","metadata":null},{"id":"35efe44c547c469786a3edc567b50ea2","type":"GENE","name":"FRG2LP","canonical_id":"hgnc:HGNC:51798","description":"FSHD region gene 2 family member L, pseudogene","metadata":null},{"id":"e493926a64c24e8683307988115f1339","type":"GENE","name":"FRG2MP","canonical_id":"hgnc:HGNC:51799","description":"FSHD region gene 2 family member M, pseudogene","metadata":null},{"id":"3c8c43e9ef524d8280667cb997ffcc48","type":"GENE","name":"FRGCA","canonical_id":"hgnc:HGNC:51844","description":"FOXM1-regulated, gastric cancer associated","metadata":{"aliases":["LncRNA-AP001631.9"]}},{"id":"7b57b5b813f8421d9d663512ea280573","type":"GENE","name":"FRK","canonical_id":"hgnc:HGNC:3955","description":"fyn related Src family tyrosine kinase","metadata":{"aliases":["RAK","GTK","PTK5"]}},{"id":"a7f655b90bd64bbda93f2d3f4bcb4b13","type":"PROTEIN","name":"FRK","canonical_id":"uniprot:P42685","description":null,"metadata":null},{"id":"549743c456954f999e3271076a2c3ba9","type":"GENE","name":"FRMD1","canonical_id":"hgnc:HGNC:21240","description":"FERM domain containing 1","metadata":{"aliases":["FLJ00181","DKFZp434O0117","FLJ40260","FLJ22615","bA164L23.1"]}},{"id":"4b228af2334343048de744cee595318c","type":"GENE","name":"FRMD3","canonical_id":"hgnc:HGNC:24125","description":"FERM domain containing 3","metadata":{"aliases":["EPB41L4O","MGC20553"]}},{"id":"93c77ee4881f47638dbf4326634cf3ec","type":"GENE","name":"FRMD3-AS1","canonical_id":"hgnc:HGNC:55790","description":"FRMD3 antisense RNA 1","metadata":null},{"id":"54d3616eb41a4413b06cfba651561849","type":"GENE","name":"FRMD4A","canonical_id":"hgnc:HGNC:25491","description":"FERM domain containing 4A","metadata":{"aliases":["FLJ10210","KIAA1294","bA295P9.4","FRMD4"]}},{"id":"0272b37075a04bf3b260fd46ec5d1325","type":"GENE","name":"FRMD4A-AS1","canonical_id":"hgnc:HGNC:56672","description":"FRMD4A antisense RNA 1","metadata":{"aliases":["AL157392.2"]}},{"id":"caccef1432d949cebc378f325107a2b7","type":"GENE","name":"FRMD4A-AS2","canonical_id":"hgnc:HGNC:58179","description":"FRMD4A antisense RNA 2","metadata":null},{"id":"6666a5651e1b4c6ea9deb930712af7bc","type":"GENE","name":"FRMD4A-AS3","canonical_id":"hgnc:HGNC:58386","description":"FRMD4A antisense RNA 3","metadata":null},{"id":"c66ea3527dff4cc9880596e52350b009","type":"GENE","name":"FRMD4B","canonical_id":"hgnc:HGNC:24886","description":"FERM domain containing 4B","metadata":{"aliases":["KIAA1013","GRSP1"]}},{"id":"1dc32312bb01474a9165fa5175fbce01","type":"GENE","name":"FRMD5","canonical_id":"hgnc:HGNC:28214","description":null,"metadata":null},{"id":"a754d3f988db4a8c9a36495d2e057a86","type":"GENE","name":"FRMD6","canonical_id":"hgnc:HGNC:19839","description":"FERM domain containing 6","metadata":{"aliases":["MGC17921","willin","EX1","C14orf31"]}},{"id":"20b449b70b1b4d688927f7e3d7c5ef4f","type":"GENE","name":"FRMD6-AS1","canonical_id":"hgnc:HGNC:20129","description":"FRMD6 antisense RNA 1","metadata":{"aliases":["C14orf82"]}},{"id":"f5fa2f8f70ee46e0a3e1e596d4d21762","type":"GENE","name":"FRMD6-AS2","canonical_id":"hgnc:HGNC:43637","description":"FRMD6 antisense RNA 2","metadata":null},{"id":"03b9144d78864fb1a00ec5c02250752c","type":"GENE","name":"FRMD7","canonical_id":"hgnc:HGNC:8079","description":"FERM domain containing 7","metadata":{"aliases":["FLJ43346","NYS","NYS1"]}},{"id":"0fbf6e9cd6724ad3811eb65fd46a6e49","type":"GENE","name":"FRMD8","canonical_id":"hgnc:HGNC:25462","description":"FERM domain containing 8","metadata":{"aliases":["FLJ90369","FKSG44","iTAP"]}},{"id":"610a594bbe7f484fae3274a7d59db488","type":"GENE","name":"FRMD8P1","canonical_id":"hgnc:HGNC:24690","description":"FERM domain containing 8 pseudogene 1","metadata":{"aliases":["FKSG43"]}},{"id":"8ed94c0987574eb3a85e8fe3aeec0b58","type":"GENE","name":"FRMPD1","canonical_id":"hgnc:HGNC:29159","description":"FERM and PDZ domain containing 1","metadata":{"aliases":["KIAA0967","FRMD2"]}},{"id":"a28efc26db684fd48cf656e25e320f9d","type":"GENE","name":"FRMPD2","canonical_id":"hgnc:HGNC:28572","description":"FERM and PDZ domain containing 2","metadata":{"aliases":["MGC35285","PDZD5C","PDZK5C"]}},{"id":"921fe21c10c7491088da951042515b6f","type":"GENE","name":"FRMPD2B","canonical_id":"hgnc:HGNC:16843","description":"FERM and PDZ domain containing 2B (pseudogene)","metadata":{"aliases":["yX59F3.2","bA556L1.2","PDZK5A","PDZD5A","FRMPD2L1","FRMPD2P2","PDZK5B","PDZD5B","FRMPD2L2","FRMPD2P1"]}},{"id":"a1c60652cb6a4306b69297817d0846d9","type":"GENE","name":"FRMPD3","canonical_id":"hgnc:HGNC:29382","description":"FERM and PDZ domain containing 3","metadata":{"aliases":["RP5-1070B1.1","KIAA1817"]}},{"id":"a987fd2feab24bdc9fcb36eafe21d794","type":"GENE","name":"FRMPD3-AS1","canonical_id":"hgnc:HGNC:41239","description":"FRMPD3 antisense RNA 1","metadata":null},{"id":"2714addfd9734503826a4b1c0ab9b64c","type":"GENE","name":"FRMPD4","canonical_id":"hgnc:HGNC:29007","description":"FERM and PDZ domain containing 4","metadata":{"aliases":["Preso1","Preso","KIAA0316","PDZK10","PDZD10"]}},{"id":"54c0f2a8f0484d3f8849c7dded1a992e","type":"GENE","name":"FRMPD4-AS1","canonical_id":"hgnc:HGNC:41222","description":"FRMPD4 antisense RNA 1","metadata":null},{"id":"a302efa1d72946eaa2c2c7624d30b119","type":"GENE","name":"FRRS1","canonical_id":"hgnc:HGNC:27622","description":"ferric chelate reductase 1","metadata":{"aliases":["SDR2","SDFR2"]}},{"id":"859928e919e0433dbb6ab260be89fbae","type":"GENE","name":"FRRS1L","canonical_id":"hgnc:HGNC:1362","description":"ferric chelate reductase 1 like","metadata":{"aliases":["CG-6","C9orf4"]}},{"id":"e3d3db84feae4bbcb05e8c5e0d8721d8","type":"GENE","name":"FRS2","canonical_id":"hgnc:HGNC:16971","description":"fibroblast growth factor receptor substrate 2","metadata":{"aliases":["SNT-1","FRS2alpha","SNT1","FRS2A"]}},{"id":"48c3c7cc1b054f588c04175e2c6405d0","type":"GENE","name":"FRS3","canonical_id":"hgnc:HGNC:16970","description":"fibroblast growth factor receptor substrate 3","metadata":{"aliases":["SNT-2","FRS2beta","FRS2B"]}},{"id":"66f0e8237a964efb801ab0170798f2b2","type":"GENE","name":"FRY","canonical_id":"hgnc:HGNC:20367","description":"FRY microtubule binding protein","metadata":{"aliases":["bA37E23.1","13CDNA73","CG003","C13orf14"]}},{"id":"d742df332979437c97ac421b541aa10c","type":"GENE","name":"FRY-AS1","canonical_id":"hgnc:HGNC:39725","description":"FRY antisense RNA 1","metadata":null},{"id":"c2a8dec5b5ac496da7abd9c3b9e3d2cd","type":"GENE","name":"FRYL","canonical_id":"hgnc:HGNC:29127","description":"FRY like transcription coactivator","metadata":{"aliases":["DKFZp686E205","AF4p12","MOR2","KIAA0826"]}},{"id":"bfd28700a8c9489ea007bff013a907d9","type":"GENE","name":"FRYL-DT","canonical_id":"hgnc:HGNC:58785","description":"FRYL divergent transcript","metadata":null},{"id":"706d38e051e84e748eee226fff28c3b1","type":"GENE","name":"FRZB","canonical_id":"hgnc:HGNC:3959","description":"frizzled related protein","metadata":{"aliases":["FRZB-PEN","FRZB1","SRFP3","FRP-3","SFRP3","FRE","FRITZ","FRZB-1","FZRB","hFIZ"]}},{"id":"9946f08ee1704d46811af8860d5badef","type":"TRIAL","name":"FS VH S/D 500 S-apr in Vascular Surgery","canonical_id":"clinicaltrials.gov:NCT00892957","description":"Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses","metadata":null},{"id":"844408808a2447278efbf7c611c2912f","type":"GENE","name":"FSAF1","canonical_id":"hgnc:HGNC:25332","description":"40S small subunit processome assembly factor 1","metadata":{"aliases":["DKFZp547B1713","C1orf131"]}},{"id":"cf0712c8762f408f908e0037bcc4b0d2","type":"GENE","name":"FSBP","canonical_id":"hgnc:HGNC:43653","description":"fibrinogen silencer binding protein","metadata":null},{"id":"c7f888f58c694068ab2b31028e1abd40","type":"GENE","name":"FSCB","canonical_id":"hgnc:HGNC:20494","description":"fibrous sheath CABYR binding protein","metadata":{"aliases":["DKFZP434F1017","C14orf155"]}},{"id":"8ee5494a350e49cd93e7c1dcd0a880a2","type":"GENE","name":"FSCN1","canonical_id":"hgnc:HGNC:11148","description":"fascin actin-bundling protein 1","metadata":{"aliases":["p55","FLJ38511","SNL"]}},{"id":"714919ba3ccc475380d8a5e095508552","type":"GENE","name":"FSCN1P1","canonical_id":"hgnc:HGNC:49669","description":"fascin actin-bundling protein 1 pseudogene 1","metadata":null},{"id":"d8e5cc3b2cc74e45949b873da7131638","type":"GENE","name":"FSCN2","canonical_id":"hgnc:HGNC:3960","description":"fascin actin-bundling protein 2, retinal","metadata":{"aliases":["RP30","RFSN"]}},{"id":"0d2344e203a14e4e8b35eaf7ad9123b7","type":"GENE","name":"FSCN3","canonical_id":"hgnc:HGNC:3961","description":"fascin actin-bundling protein 3","metadata":null},{"id":"e0e568efe22549778254fc1e746b79ca","type":"GENE","name":"FSD1","canonical_id":"hgnc:HGNC:13745","description":"fibronectin type III and SPRY domain containing 1","metadata":{"aliases":["MGC3213","MIR1"]}},{"id":"eafeeca016a34f00bffddc74b064155c","type":"GENE","name":"FSD1L","canonical_id":"hgnc:HGNC:13753","description":"fibronectin type III and SPRY domain containing 1 like","metadata":{"aliases":["CSDUFD1","CCDC10","FSD1NL","FSD1CL"]}},{"id":"7e8e10a634fc47d1b9e4cbc3a4e7d291","type":"GENE","name":"FSD2","canonical_id":"hgnc:HGNC:18024","description":"fibronectin type III and SPRY domain containing 2","metadata":{"aliases":["RP11-127F21","SPRYD1"]}},{"id":"35d5d9f4d5eb4380b07981b09a53d4fa","type":"DRUG","name":"FSH","canonical_id":"gtopdb:1157","description":null,"metadata":null},{"id":"f052e8c0f193465daa72dc982a4ee4ad","type":"DRUG","name":"FSH","canonical_id":"chembl:CHEMBL2108427","description":null,"metadata":null},{"id":"1b66bb2067ba45a88c54ee7fff03cc82","type":"GENE","name":"FSHB","canonical_id":"hgnc:HGNC:3964","description":null,"metadata":null},{"id":"3861d3fde17e4be9a45116ee87770b45","type":"GENE","name":"FSHR","canonical_id":"hgnc:HGNC:3969","description":null,"metadata":null},{"id":"6d2c4b4b1e6a4e1b9a78eee94ae82254","type":"PROTEIN","name":"FSHR","canonical_id":"uniprot:P23945","description":null,"metadata":null},{"id":"9b9e29fb1c8148c186d3f407ef399129","type":"GENE","name":"FSIP1","canonical_id":"hgnc:HGNC:21674","description":"fibrous sheath interacting protein 1","metadata":{"aliases":["FLJ35989"]}},{"id":"9f9d78ce6b64485d8da0b8c523862eae","type":"GENE","name":"FSIP2","canonical_id":"hgnc:HGNC:21675","description":"fibrous sheath interacting protein 2","metadata":{"aliases":["FLJ34780"]}},{"id":"bbd38155695b4a689f9f8983790892f3","type":"GENE","name":"FSIP2-AS1","canonical_id":"hgnc:HGNC:40978","description":"FSIP2 antisense RNA 1","metadata":{"aliases":["FSIP2-AS2"]}},{"id":"b3e51b6c90074c95bb662d7fba5cb86f","type":"GENE","name":"FSIP2LP","canonical_id":"hgnc:HGNC:55625","description":"fibrous sheath interacting protein 2 like, pseudogene","metadata":null},{"id":"1435673e64a946c592b4af2e10ea4ddd","type":"GENE","name":"FST","canonical_id":"hgnc:HGNC:3971","description":null,"metadata":null},{"id":"67f55dcf83074b9a91b0134db84cfc3f","type":"GENE","name":"FSTL1","canonical_id":"hgnc:HGNC:3972","description":"follistatin like 1","metadata":{"aliases":["FRP","FSL1","OCC1","OCC-1","tsc36"]}},{"id":"ab98481a108940ac846e31c1aed47204","type":"GENE","name":"FSTL3","canonical_id":"hgnc:HGNC:3973","description":null,"metadata":null},{"id":"21141fb8f560485aaaafa6a99d81c070","type":"GENE","name":"FSTL4","canonical_id":"hgnc:HGNC:21389","description":"follistatin like 4","metadata":{"aliases":["KIAA1061"]}},{"id":"1bf8da125b844727a79999a671d1aac6","type":"GENE","name":"FSTL4-AS1","canonical_id":"hgnc:HGNC:58420","description":"FSTL4 antisense RNA 1","metadata":null},{"id":"fb3e3fd242dc49dc89c56e0e6f14bedb","type":"GENE","name":"FSTL4-AS2","canonical_id":"hgnc:HGNC:59133","description":"FSTL4 antisense RNA 2","metadata":null},{"id":"748e69e021f449e9b1f2ff7d0b2dd5df","type":"GENE","name":"FSTL4-AS3","canonical_id":"hgnc:HGNC:59134","description":"FSTL4 antisense RNA 3","metadata":null},{"id":"33ac146b7e4644d89b7897327b5bb73b","type":"GENE","name":"FSTL5","canonical_id":"hgnc:HGNC:21386","description":"follistatin like 5","metadata":{"aliases":["DKFZp566D234","KIAA1263"]}},{"id":"b77cf83556fe4c3981b71b1169f58d4f","type":"GENE","name":"FSTL5-AS1","canonical_id":"hgnc:HGNC:58417","description":"FSTL5 antisense RNA 1","metadata":null},{"id":"bd06ecc7e92c4fe795873a8317b3e653","type":"TRIAL","name":"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05395052","description":"Non Small Cell Lung Cancer; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Head and Neck Cancer; GastroEsophageal Cancer","metadata":null},{"id":"53c1f3164be64c1da90cd19f4d82a26c","type":"TRIAL","name":"FT538 in Subjects With Advanced Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT04614636","description":"Acute Myeloid Leukemia; AML, Adult; Multiple Myeloma; Myeloma","metadata":null},{"id":"7159832ab07f4cf9999cbd05b2969c66","type":"GENE","name":"FTCD","canonical_id":"hgnc:HGNC:3974","description":"formimidoyltransferase cyclodeaminase","metadata":null},{"id":"f0daa0e968414700b9679a98d7bdc398","type":"GENE","name":"FTCD-AS1","canonical_id":"hgnc:HGNC:40243","description":"FTCD antisense RNA 1","metadata":null},{"id":"6fe3ae626a7543579a0fa9dd27296bfc","type":"GENE","name":"FTCDNL1","canonical_id":"hgnc:HGNC:48661","description":"formiminotransferase cyclodeaminase N-terminal like","metadata":{"aliases":["FONG"]}},{"id":"68ce77e1def845a6ad89a4bbc5841864","type":"GENE","name":"FTH1","canonical_id":"hgnc:HGNC:3976","description":null,"metadata":null},{"id":"0b5b536607ac479297849008b40686af","type":"GENE","name":"FTH1P1","canonical_id":"hgnc:HGNC:3979","description":"ferritin heavy chain 1 pseudogene 1","metadata":{"aliases":["FTHL1"]}},{"id":"6e4c650980e24f6c8c7bfe5722a9bd9d","type":"GENE","name":"FTH1P10","canonical_id":"hgnc:HGNC:3980","description":"ferritin heavy chain 1 pseudogene 10","metadata":{"aliases":["FTHL10"]}},{"id":"0217d01b7d4441f6a1545f9432608e6e","type":"GENE","name":"FTH1P11","canonical_id":"hgnc:HGNC:3981","description":"ferritin heavy chain 1 pseudogene 11","metadata":{"aliases":["FTHL11"]}},{"id":"25c36a7042cc4bc38cb445c8c58983ef","type":"GENE","name":"FTH1P12","canonical_id":"hgnc:HGNC:3982","description":"ferritin heavy chain 1 pseudogene 12","metadata":{"aliases":["FTHL12"]}},{"id":"e63428fa6d1c4609898250d0ea3f52bb","type":"GENE","name":"FTH1P13","canonical_id":"hgnc:HGNC:3983","description":"ferritin heavy chain 1 pseudogene 13","metadata":{"aliases":["FTHP3","FTHL13"]}},{"id":"10c3bc35d785429082df7f2443779246","type":"GENE","name":"FTH1P14","canonical_id":"hgnc:HGNC:39090","description":"ferritin heavy chain 1 pseudogene 14","metadata":null},{"id":"4ac00e4784254e389f98c3211ee8335b","type":"GENE","name":"FTH1P15","canonical_id":"hgnc:HGNC:3985","description":"ferritin heavy chain 1 pseudogene 15","metadata":{"aliases":["FTHL15"]}},{"id":"967d63bbe0f84b1fa285d7b6a35fab56","type":"GENE","name":"FTH1P16","canonical_id":"hgnc:HGNC:3986","description":"ferritin heavy chain 1 pseudogene 16","metadata":{"aliases":["FTH2","FTHL16"]}},{"id":"b48244e16fd247d0810d651a5a2e06b2","type":"GENE","name":"FTH1P18","canonical_id":"hgnc:HGNC:3988","description":null,"metadata":null},{"id":"a4de7ceb6b0a45c8a959b6c7100c9075","type":"GENE","name":"FTH1P19","canonical_id":"hgnc:HGNC:33525","description":"ferritin heavy chain 1 pseudogene 19","metadata":{"aliases":["FTHL19"]}},{"id":"bbf3a2b3b3e943c987dcc8c43fc77986","type":"GENE","name":"FTH1P2","canonical_id":"hgnc:HGNC:3989","description":"ferritin heavy chain 1 pseudogene 2","metadata":{"aliases":["FTHL2"]}},{"id":"7f34eea99c624b4f93d8f4be14cd0fe0","type":"GENE","name":"FTH1P20","canonical_id":"hgnc:HGNC:37639","description":"ferritin heavy chain 1 pseudogene 20","metadata":{"aliases":["FTHL20"]}},{"id":"c22ed5cba9924c0397c2f55dd05375c4","type":"GENE","name":"FTH1P21","canonical_id":"hgnc:HGNC:3997","description":"ferritin heavy chain 1 pseudogene 21","metadata":{"aliases":["FTHP2","FTHL21"]}},{"id":"544436cb9b354dbaa6e5b009ebe3d423","type":"GENE","name":"FTH1P22","canonical_id":"hgnc:HGNC:37640","description":"ferritin heavy chain 1 pseudogene 22","metadata":{"aliases":["FTHL22"]}},{"id":"5814d7c8fded463cb3b2849db9c95736","type":"GENE","name":"FTH1P23","canonical_id":"hgnc:HGNC:37641","description":"ferritin heavy chain 1 pseudogene 23","metadata":{"aliases":["FTHL23"]}},{"id":"0ef6ff58e7104f1aaf66676a1404a16d","type":"GENE","name":"FTH1P24","canonical_id":"hgnc:HGNC:37642","description":"ferritin heavy chain 1 pseudogene 24","metadata":{"aliases":["TCLlnc1","FTHL24"]}},{"id":"95c5bd33fdb74c7190b452b58792456a","type":"GENE","name":"FTH1P25","canonical_id":"hgnc:HGNC:37643","description":"ferritin heavy chain 1 pseudogene 25","metadata":{"aliases":["FTHL25"]}},{"id":"b49ecff356c24e31ae6bb2428aa085f4","type":"GENE","name":"FTH1P26","canonical_id":"hgnc:HGNC:37644","description":"ferritin heavy chain 1 pseudogene 26","metadata":{"aliases":["FTHL26"]}},{"id":"a501d6c9293b4921bdabb7c63bc9e25b","type":"GENE","name":"FTH1P27","canonical_id":"hgnc:HGNC:39091","description":"ferritin heavy chain 1 pseudogene 27","metadata":null},{"id":"a25070d3ad214d948a7d869f7f47f007","type":"GENE","name":"FTH1P28","canonical_id":"hgnc:HGNC:56886","description":"ferritin heavy chain 1 pseudogene 28","metadata":null},{"id":"10cba03e3bc84eccb208886b6afa7ac8","type":"GENE","name":"FTH1P29","canonical_id":"hgnc:HGNC:56885","description":"ferritin heavy chain 1 pseudogene 29","metadata":null},{"id":"44a631b539f94fc9af94cd001386fe6f","type":"GENE","name":"FTH1P3","canonical_id":"hgnc:HGNC:3990","description":"ferritin heavy chain 1 pseudogene 3","metadata":{"aliases":["FTHL3"]}},{"id":"6fdc44d718ad42f19470eb12568f75b7","type":"GENE","name":"FTH1P4","canonical_id":"hgnc:HGNC:3991","description":"ferritin heavy chain 1 pseudogene 4","metadata":{"aliases":["FTHL4"]}},{"id":"4b858b32504b4bfe9e2890082f2cea75","type":"GENE","name":"FTH1P5","canonical_id":"hgnc:HGNC:3996","description":"ferritin heavy chain 1 pseudogene 5","metadata":{"aliases":["FTHP1","FTHL5"]}},{"id":"466e09d86eb4479bb081e635f719d1e7","type":"GENE","name":"FTH1P6","canonical_id":"hgnc:HGNC:39088","description":"ferritin heavy chain 1 pseudogene 6","metadata":null},{"id":"39524808b1e54c0f9e2b1017bcb58f69","type":"GENE","name":"FTH1P7","canonical_id":"hgnc:HGNC:3994","description":"ferritin heavy chain 1 pseudogene 7","metadata":{"aliases":["FTHL7"]}},{"id":"d9ca8989cb194946b7f4b84c0ad2af9b","type":"GENE","name":"FTH1P8","canonical_id":"hgnc:HGNC:3995","description":"ferritin heavy chain 1 pseudogene 8","metadata":{"aliases":["FTHL8"]}},{"id":"0ae8b915aa924ca38e0ec9a1adf4014a","type":"GENE","name":"FTH1P9","canonical_id":"hgnc:HGNC:39089","description":"ferritin heavy chain 1 pseudogene 9","metadata":null},{"id":"6a315b42f45d4f9da6f9765207c23638","type":"GENE","name":"FTHL17","canonical_id":"hgnc:HGNC:3987","description":"ferritin heavy chain like 17","metadata":{"aliases":["CT38"]}},{"id":"0b6062033fc84823b1684d7effa6aa10","type":"GENE","name":"FTL","canonical_id":"hgnc:HGNC:3999","description":"ferritin light chain","metadata":{"aliases":["MGC71996","NBIA3","FTL1"]}},{"id":"4fa14d013050436799eda1a9e29bef3c","type":"GENE","name":"FTLP1","canonical_id":"hgnc:HGNC:16547","description":"ferritin light chain pseudogene 1","metadata":{"aliases":["bA465L10.3","FTLP"]}},{"id":"24d7d7f26e5e49bebe0e06fe063f8250","type":"GENE","name":"FTLP10","canonical_id":"hgnc:HGNC:37959","description":"ferritin light chain pseudogene 10","metadata":null},{"id":"cc2a33780bb346649aaf79c639884f4c","type":"GENE","name":"FTLP11","canonical_id":"hgnc:HGNC:37960","description":"ferritin light chain pseudogene 11","metadata":null},{"id":"2913a27df66e4a8fa72fa78c954b01f5","type":"GENE","name":"FTLP12","canonical_id":"hgnc:HGNC:37961","description":"ferritin light chain pseudogene 12","metadata":null},{"id":"f9dcd91164a24ef7963b40adf7077caf","type":"GENE","name":"FTLP13","canonical_id":"hgnc:HGNC:37963","description":"ferritin light chain pseudogene 13","metadata":null},{"id":"88d44b95b3d849c4a10a4a29c70e3924","type":"GENE","name":"FTLP14","canonical_id":"hgnc:HGNC:37964","description":"ferritin light chain pseudogene 14","metadata":null},{"id":"0781c67167344d3aafe732b7e8c70720","type":"GENE","name":"FTLP15","canonical_id":"hgnc:HGNC:37965","description":"ferritin light chain pseudogene 15","metadata":null},{"id":"a7c5dffa186d4e8baaabdd583f8dc9b9","type":"GENE","name":"FTLP16","canonical_id":"hgnc:HGNC:37966","description":"ferritin light chain pseudogene 16","metadata":null},{"id":"0327846108ed446382c58a28a33d233a","type":"GENE","name":"FTLP17","canonical_id":"hgnc:HGNC:37967","description":"ferritin light chain pseudogene 17","metadata":null},{"id":"4a29c9cf3cd442428618ba277244fa98","type":"GENE","name":"FTLP18","canonical_id":"hgnc:HGNC:37968","description":"ferritin light chain pseudogene 18","metadata":null},{"id":"b2cd38fbfee4486aab16bdd2370c08c3","type":"GENE","name":"FTLP19","canonical_id":"hgnc:HGNC:37969","description":"ferritin light chain pseudogene 19","metadata":null},{"id":"80e9fb754603495199adab1458e67110","type":"GENE","name":"FTLP2","canonical_id":"hgnc:HGNC:4001","description":"ferritin light chain pseudogene 2","metadata":{"aliases":["FTLL2"]}},{"id":"6659e4d6e0a448e9835efa26d5d23d31","type":"GENE","name":"FTLP20","canonical_id":"hgnc:HGNC:56887","description":"ferritin light chain pseudogene 20","metadata":null},{"id":"63c09fb4e71a4fb297b8a3dcf5ea01dc","type":"GENE","name":"FTLP3","canonical_id":"hgnc:HGNC:4000","description":"ferritin light chain pseudogene 3","metadata":{"aliases":["dJ681N20.2","FTLL1"]}},{"id":"f57d657c4cb84d939d6518357bc2218d","type":"GENE","name":"FTLP4","canonical_id":"hgnc:HGNC:37952","description":"ferritin light chain pseudogene 4","metadata":null},{"id":"20b7d8bc05fa41cf9751d96ca25f9af2","type":"GENE","name":"FTLP5","canonical_id":"hgnc:HGNC:37953","description":"ferritin light chain pseudogene 5","metadata":null},{"id":"2c37b5a8757b4ea7a59abfc3d9051778","type":"GENE","name":"FTLP6","canonical_id":"hgnc:HGNC:37954","description":"ferritin light chain pseudogene 6","metadata":null},{"id":"f296c931ce644762b204f133c8d56bfe","type":"GENE","name":"FTLP7","canonical_id":"hgnc:HGNC:37955","description":"ferritin light chain pseudogene 7","metadata":null},{"id":"5133630d72cc40d2b2a2d95957e6f427","type":"GENE","name":"FTLP8","canonical_id":"hgnc:HGNC:37956","description":"ferritin light chain pseudogene 8","metadata":null},{"id":"2e2fbb94bd7f48ca933c185242b89508","type":"GENE","name":"FTLP9","canonical_id":"hgnc:HGNC:37958","description":"ferritin light chain pseudogene 9","metadata":null},{"id":"7d4be618f6a44fb097b9092aed6a74a3","type":"GENE","name":"FTMT","canonical_id":"hgnc:HGNC:17345","description":"ferritin mitochondrial","metadata":{"aliases":["MtF"]}},{"id":"d2df0f33da3d4536a4977b17881eb853","type":"GENE","name":"FTMT-DT","canonical_id":"hgnc:HGNC:59120","description":"FTMT divergent transcript","metadata":null},{"id":"d20dfbe85e9f45e08a02e81f83e20dfc","type":"GENE","name":"FTO","canonical_id":"hgnc:HGNC:24678","description":null,"metadata":null},{"id":"a81ccfc614644a239f7391e839f08dab","type":"GENE","name":"FTO-IT1","canonical_id":"hgnc:HGNC:43758","description":"FTO intronic transcript 1","metadata":null},{"id":"56d2916fa70c445fb361ceca1a87f048","type":"GENE","name":"FTOP1","canonical_id":"hgnc:HGNC:43759","description":"FTO pseudogene 1","metadata":null},{"id":"75936bd88cd54959ae79bf799f872ab9","type":"GENE","name":"FTSJ1","canonical_id":"hgnc:HGNC:13254","description":"FtsJ RNA 2'-O-methyltransferase 1","metadata":{"aliases":["JM23","CDLIV","SPB1","TRM7","TRMT7","MRX9","MRX44"]}},{"id":"95de49df5359416089a09c731ccc3522","type":"GENE","name":"FTSJ3","canonical_id":"hgnc:HGNC:17136","description":"FtsJ RNA 2'-O-methyltransferase 3","metadata":{"aliases":["SPB1"]}},{"id":"61a2c88ef6904068a6e47e517c36be71","type":"GENE","name":"FTX","canonical_id":"hgnc:HGNC:37190","description":"FTX transcript, XIST regulator","metadata":{"aliases":["LINC00182","FLJ33139","NCRNA00182","MIR374AHG"]}},{"id":"2d83ca25d11e4a50bbdcf9211ea8ae9a","type":"GENE","name":"FUBP1","canonical_id":"hgnc:HGNC:4004","description":null,"metadata":null},{"id":"d1cb07ea22a84dc29b9b09802f42462e","type":"GENE","name":"FUBP3","canonical_id":"hgnc:HGNC:4005","description":null,"metadata":null},{"id":"df28b92f2d7e48cdaa33f1e26b72ad88","type":"GENE","name":"FUCA1","canonical_id":"hgnc:HGNC:4006","description":"alpha-L-fucosidase 1","metadata":null},{"id":"49eb7e0a20434365b96be8217e1d99a0","type":"GENE","name":"FUCA1P1","canonical_id":"hgnc:HGNC:4007","description":"alpha-L-fucosidase 1 pseudogene 1","metadata":{"aliases":["FUCA1P"]}},{"id":"83d5c1a548d24fb7b43bdc2c401caba8","type":"GENE","name":"FUCA2","canonical_id":"hgnc:HGNC:4008","description":"alpha-L-fucosidase 2","metadata":{"aliases":["MGC1314","dJ20N2.5"]}},{"id":"69e9a3fef0c34b8d8115df3bf7f63e9b","type":"GENE","name":"FUNDC1","canonical_id":"hgnc:HGNC:28746","description":"FUN14 domain containing 1","metadata":{"aliases":["MGC51029"]}},{"id":"74a2e46f890f4d26a893ab795440ef93","type":"GENE","name":"FUNDC2","canonical_id":"hgnc:HGNC:24925","description":"FUN14 domain containing 2","metadata":{"aliases":["HCBP6","DC44"]}},{"id":"48eb8c43133947eb98f2ec7147f7b496","type":"GENE","name":"FUNDC2P1","canonical_id":"hgnc:HGNC:17253","description":"FUN14 domain containing 2 pseudogene 1","metadata":{"aliases":["FUNDC2P"]}},{"id":"46a5dc8bc7fe45f5b8592898bf4330ac","type":"GENE","name":"FUNDC2P2","canonical_id":"hgnc:HGNC:17247","description":"FUN14 domain containing 2 pseudogene 2","metadata":null},{"id":"86e9e7497f264747a2ed33b5d779ba1a","type":"GENE","name":"FUNDC2P3","canonical_id":"hgnc:HGNC:37970","description":"FUN14 domain containing 2 pseudogene 3","metadata":null},{"id":"3cea6a2270c545e38d72a61496d7c989","type":"GENE","name":"FUNDC2P4","canonical_id":"hgnc:HGNC:37971","description":"FUN14 domain containing 2 pseudogene 4","metadata":null},{"id":"d4890632907c4a868d6854ddc61938a3","type":"GENE","name":"FUOM","canonical_id":"hgnc:HGNC:24733","description":"fucose mutarotase","metadata":{"aliases":["FLJ26016","FucU","FucM","C10orf125"]}},{"id":"6633d3cd5438412da93f0d755b5d04ad","type":"GENE","name":"FURIN","canonical_id":"hgnc:HGNC:8568","description":null,"metadata":null},{"id":"b7cb5c93647544ca8c2918a7ecff246c","type":"GENE","name":"FUS","canonical_id":"hgnc:HGNC:4010","description":null,"metadata":null},{"id":"bd23b26335474f1396f6fe962713b37d","type":"BIOMARKER","name":"FUS::TFCP2 Fusion AND ALK Exon 2-18 Deletion","canonical_id":"civic:5452","description":null,"metadata":null},{"id":"95cfb3be432348da91954e60687a2c33","type":"TRIAL","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","canonical_id":"clinicaltrials.gov:NCT05749588","description":"Triple-negative Breast Cancer","metadata":null},{"id":"f91314073b794b4d807078ffc722bbf2","type":"GENE","name":"FUT1","canonical_id":"hgnc:HGNC:4012","description":"fucosyltransferase 1 (H blood group)","metadata":{"aliases":["H","HSC"]}},{"id":"c8e86fda9b624d5f97d76e178c0bd3d1","type":"GENE","name":"FUT2","canonical_id":"hgnc:HGNC:4013","description":null,"metadata":null},{"id":"f90b3a63bd634634b66d19d98bcbc1d7","type":"GENE","name":"FUT2BP","canonical_id":"hgnc:HGNC:44149","description":"fucosyltransferase 2B, pseudogene","metadata":{"aliases":["SEC1","SEC1P"]}},{"id":"acec3d686359488886c74770f940822c","type":"GENE","name":"FUT3","canonical_id":"hgnc:HGNC:4014","description":null,"metadata":null},{"id":"3463610bafbc47d5aa6fb77726c552d8","type":"GENE","name":"FUT4","canonical_id":"hgnc:HGNC:4015","description":null,"metadata":null},{"id":"ed68e80e038a495aa040b6379aee5690","type":"GENE","name":"FUT5","canonical_id":"hgnc:HGNC:4016","description":"fucosyltransferase 5","metadata":{"aliases":["FUC-TV"]}},{"id":"93be158f91aa4366af1e875579b617b7","type":"GENE","name":"FUT6","canonical_id":"hgnc:HGNC:4017","description":"fucosyltransferase 6","metadata":{"aliases":["FT1A","FCT3A","FucT-VI","FLJ40754"]}},{"id":"990d78366d5d46c083d5a1be026f743a","type":"GENE","name":"FUT7","canonical_id":"hgnc:HGNC:4018","description":null,"metadata":null},{"id":"db50801ff55241898286b2cc2792f485","type":"GENE","name":"FUT8","canonical_id":"hgnc:HGNC:4019","description":"fucosyltransferase 8","metadata":null},{"id":"14e4ce930da843f39e75bdbe62e87ac5","type":"GENE","name":"FUT8-AS1","canonical_id":"hgnc:HGNC:44294","description":"FUT8 antisense RNA 1","metadata":null},{"id":"e019e0f357fd42d4b7d1591cd1c00f4c","type":"GENE","name":"FUT9","canonical_id":"hgnc:HGNC:4020","description":"fucosyltransferase 9","metadata":{"aliases":["Fuc-TIX"]}},{"id":"ddf05cf69b5c4c50a1db587d7f8a261a","type":"GENE","name":"FUZ","canonical_id":"hgnc:HGNC:26219","description":"fuzzy planar cell polarity protein","metadata":{"aliases":["FLJ22688","Fy","CPLANE3"]}},{"id":"78ee4372b4d043e9b74f3e980847061f","type":"TRIAL","name":"FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study","canonical_id":"clinicaltrials.gov:NCT03926936","description":"Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor","metadata":null},{"id":"84dfc423c8734c86ba3caab33731e43f","type":"TRIAL","name":"FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test","canonical_id":"clinicaltrials.gov:NCT06193525","description":"Advanced Breast Cancer","metadata":null},{"id":"10749312c71d42fbbc48017e6bfe0b49","type":"GENE","name":"FXN","canonical_id":"hgnc:HGNC:3951","description":null,"metadata":null},{"id":"4d5876fafee44681b99bdd1ac867a4da","type":"GENE","name":"FXNP1","canonical_id":"hgnc:HGNC:20012","description":"frataxin pseudogene 1","metadata":{"aliases":["FRDAP"]}},{"id":"7a528359214e44809c0f86714abb62f2","type":"GENE","name":"FXNP2","canonical_id":"hgnc:HGNC:51607","description":"frataxin pseudogene 2","metadata":null},{"id":"3c35ae33e77a4c4f9a37e7a03984ca58","type":"GENE","name":"FXR1","canonical_id":"hgnc:HGNC:4023","description":"FMR1 autosomal homolog 1","metadata":null},{"id":"ce0cf8193d7c42b4b4dc10a6ee82a668","type":"GENE","name":"FXR2","canonical_id":"hgnc:HGNC:4024","description":null,"metadata":null},{"id":"0ab0995f2e414b08813080e89589e4e4","type":"GENE","name":"FXYD1","canonical_id":"hgnc:HGNC:4025","description":"FXYD domain containing ion transport regulator 1","metadata":{"aliases":["PLM"]}},{"id":"b6189121ab0d48a48560ed8efbf3562b","type":"GENE","name":"FXYD2","canonical_id":"hgnc:HGNC:4026","description":null,"metadata":null},{"id":"067ecfe3469448ab9a7e4039ab2be718","type":"GENE","name":"FXYD3","canonical_id":"hgnc:HGNC:4027","description":"FXYD domain containing ion transport regulator 3","metadata":{"aliases":["MAT-8","PLML"]}},{"id":"33f3d7808b5d486ea416852d7610ec90","type":"GENE","name":"FXYD4","canonical_id":"hgnc:HGNC:4028","description":"FXYD domain containing ion transport regulator 4","metadata":{"aliases":["CHIF"]}},{"id":"bb49aef258234a999e7a811a708409f2","type":"GENE","name":"FXYD5","canonical_id":"hgnc:HGNC:4029","description":"FXYD domain containing ion transport regulator 5","metadata":{"aliases":["OIT2"]}},{"id":"56c486a841444876868738ca442274a7","type":"GENE","name":"FXYD6","canonical_id":"hgnc:HGNC:4030","description":"FXYD domain containing ion transport regulator 6","metadata":null},{"id":"72d948e846824c2fbe2380e215a22614","type":"GENE","name":"FXYD6-AS1","canonical_id":"hgnc:HGNC:56067","description":"FXYD6 antisense RNA 1","metadata":null},{"id":"f7daa1757b5e489abac07459fbedf7a9","type":"GENE","name":"FXYD6-FXYD2","canonical_id":"hgnc:HGNC:39978","description":"FXYD6-FXYD2 readthrough","metadata":null},{"id":"c16eb7a4c7764ef1bfafb0e363ea5e2c","type":"GENE","name":"FXYD6P1","canonical_id":"hgnc:HGNC:4031","description":"FXYD domain containing ion transport regulator 6 pseudogene 1","metadata":null},{"id":"b690414e02b04faeab6e7270e401da4e","type":"GENE","name":"FXYD6P2","canonical_id":"hgnc:HGNC:4032","description":"FXYD domain containing ion transport regulator 6 pseudogene 2","metadata":null},{"id":"2fcc94532b2746939f7e00d978075ac9","type":"GENE","name":"FXYD6P3","canonical_id":"hgnc:HGNC:31124","description":"FXYD domain containing ion transport regulator 6 pseudogene 3","metadata":{"aliases":["FXYD8"]}},{"id":"31f3c6eca97d40f2a5e496cef713357c","type":"GENE","name":"FXYD7","canonical_id":"hgnc:HGNC:4034","description":"FXYD domain containing ion transport regulator 7","metadata":null},{"id":"577e663b538f472ab1b2f34e72125963","type":"GENE","name":"FYB1","canonical_id":"hgnc:HGNC:4036","description":"FYN binding protein 1","metadata":{"aliases":["SLAP-130","FYB-120/130","ADAP","FYB"]}},{"id":"91266063c76a49d38878be50fcb485ec","type":"GENE","name":"FYB2","canonical_id":"hgnc:HGNC:27295","description":"FYN binding protein 2","metadata":{"aliases":["RP4-758N20.2","FLJ43208","ARAP","C1orf168"]}},{"id":"5ef847bf4ce3435e8e006ac4fe15edfb","type":"GENE","name":"FYCO1","canonical_id":"hgnc:HGNC:14673","description":"FYVE and coiled-coil domain autophagy adaptor 1","metadata":{"aliases":["FLJ13335","ZFYVE7"]}},{"id":"6d457a7af42d454786c2375dbaecf5de","type":"GENE","name":"FYN","canonical_id":"hgnc:HGNC:4037","description":"FYN proto-oncogene, Src family tyrosine kinase","metadata":{"aliases":["SYN","SLK","MGC45350"]}},{"id":"0fddc9e91cde4a8dbbca40e254de38f1","type":"GENE","name":"FYRD1","canonical_id":"hgnc:HGNC:29551","description":"FYRN and FYRC domains INO80 complex interactor 1","metadata":{"aliases":["FLJ14621","TB-5","NIAM","TBRG1"]}},{"id":"a18cb3d25f31483a84d06056102fbce1","type":"GENE","name":"FYTTD1","canonical_id":"hgnc:HGNC:25407","description":"forty-two-three domain containing 1","metadata":{"aliases":["DKFZp761B1514","UIF"]}},{"id":"db2b7b1a7bf6477f9d64a221a0d71e25","type":"GENE","name":"FYTTD1P1","canonical_id":"hgnc:HGNC:38035","description":"forty-two-three domain containing 1 pseudogene 1","metadata":null},{"id":"d2154b247f7746e597ffc85b1531a599","type":"DRUG","name":"FYX-051","canonical_id":"mesh:C504882","description":null,"metadata":null},{"id":"d6eb3610f588406cba719838f0d5b5d8","type":"GO_TERM","name":"FYXD domain binding","canonical_id":"go:GO:0098750","description":"\"Binding to a FXYD domain.\" [GOC:dos, GOC:mr, PMID:10950925, PMID:16403837, PMID:18000745]","metadata":null},{"id":"039d907ce3ff48a399c989c1979d1aec","type":"GENE","name":"FZD1","canonical_id":"hgnc:HGNC:4038","description":null,"metadata":null},{"id":"e2b140925b0340dea5f479805b0b8c9b","type":"GENE","name":"FZD10","canonical_id":"hgnc:HGNC:4039","description":"frizzled class receptor 10","metadata":{"aliases":["CD350"]}},{"id":"b1e3f53df1ec41f2adb055ff6aebf057","type":"GENE","name":"FZD10-AS1","canonical_id":"hgnc:HGNC:48632","description":"FZD10 antisense RNA 1","metadata":{"aliases":["FLJ31485","FZD10-DT"]}},{"id":"1c7a4810b9134518849a43abd88deb9a","type":"GENE","name":"FZD2","canonical_id":"hgnc:HGNC:4040","description":"frizzled class receptor 2","metadata":null},{"id":"2992dca7882d4e27b1f5e1e41d08f000","type":"GENE","name":"FZD3","canonical_id":"hgnc:HGNC:4041","description":"frizzled class receptor 3","metadata":{"aliases":["Fz-3"]}},{"id":"c1cb462f84ca47b6b222b084d6d029fb","type":"GENE","name":"FZD4","canonical_id":"hgnc:HGNC:4042","description":"frizzled class receptor 4","metadata":{"aliases":["CD344","EVR1"]}},{"id":"9130d90e64f940889e29bea76f441af6","type":"GENE","name":"FZD4-DT","canonical_id":"hgnc:HGNC:54219","description":"FZD4 divergent transcript","metadata":null},{"id":"c4305460352143d096fc34022eed8184","type":"GENE","name":"FZD5","canonical_id":"hgnc:HGNC:4043","description":"frizzled class receptor 5","metadata":{"aliases":["HFZ5","DKFZP434E2135","C2orf31"]}},{"id":"7714367b908c44deba290b1b0abe2617","type":"GENE","name":"FZD6","canonical_id":"hgnc:HGNC:4044","description":"frizzled class receptor 6","metadata":{"aliases":["Hfz6"]}},{"id":"23d63ee950f84184ad378a29ab67d978","type":"GENE","name":"FZD7","canonical_id":"hgnc:HGNC:4045","description":"frizzled class receptor 7","metadata":{"aliases":["FzE3"]}},{"id":"3e7ba19a78ae49c5945ce824a4b3cc6f","type":"GENE","name":"FZD8","canonical_id":"hgnc:HGNC:4046","description":"frizzled class receptor 8","metadata":{"aliases":["FZ-8"]}},{"id":"b6d407652f6048f0a08c059a8681a990","type":"GENE","name":"FZD9","canonical_id":"hgnc:HGNC:4047","description":"frizzled class receptor 9","metadata":{"aliases":["FZD3","CD349"]}},{"id":"9a8de0a6a2fc4b0b911f03aa94aca86a","type":"GENE","name":"FZR1","canonical_id":"hgnc:HGNC:24824","description":"fizzy and cell division cycle 20 related 1","metadata":{"aliases":["HCDH1","CDH1","HCDH","FZR","FZR2","KIAA1242","CDC20C"]}},{"id":"92f4e98bf9e94193864dbaa906f86095","type":"DISEASE","name":"Fabry Disease","canonical_id":"mesh:D000795","description":null,"metadata":null},{"id":"85074e0b9f234cbfba68a21219efeb99","type":"TRIAL","name":"Facial Thermography Study of Levocetirizine Versus Cetirizine","canonical_id":"clinicaltrials.gov:NCT00150761","description":"Anti-allergic Agents","metadata":null},{"id":"82a030c4f7544a98be5d98458047c2c8","type":"TRIAL","name":"Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse","canonical_id":"clinicaltrials.gov:NCT01336348","description":"ST Segment Elevation Myocardial Infarction","metadata":null},{"id":"d562aca7e3ac4a27a41f03f7ea6dca61","type":"TRIAL","name":"Facilitation of Zolpidem (\u226510 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00492232","description":"Chronic Insomnia","metadata":null},{"id":"9472cc1d5bf04e2bbc0fd5345fe550c7","type":"TRIAL","name":"Facilitators and Barriers to Eptinezumab Administration in Thailand","canonical_id":"clinicaltrials.gov:NCT07035197","description":"Migraine; Treatment; Treatment Refusal","metadata":null},{"id":"873a5b1fd86c48e28cd5b0b1a1ac56d4","type":"DISEASE","name":"Factor VII deficiency","canonical_id":"mesh:D005168","description":null,"metadata":null},{"id":"fa4d40c8edbd49948b9db13840d1dd1b","type":"GO_TERM","name":"Factor XII activation","canonical_id":"go:GO:0002542","description":"\"Any process that activates Factor XII (Hageman factor). Factor XII is a protein synthesized by the liver that circulates in an inactive form until it encounters collagen or basement membrane or activated platelets (as occurs at the site of endothelial injury). Factor XII then undergoes a conformational change (becoming factor XIIa), exposing an active serine center that can subsequently cleave protein substrates and activate a variety of mediator systems. Factor XII is a participant in the clotting cascade as well as the kinin cascade.\" [GOC:jal, ISBN:0721601871]","metadata":null},{"id":"2d2cf6339ade4b678d41a76cf484e4eb","type":"TRIAL","name":"Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)","canonical_id":"clinicaltrials.gov:NCT00375609","description":"Thromboembolism","metadata":null},{"id":"d2c6dd9865404b3e8dc26080d1b5323a","type":"TRIAL","name":"Fade Upon TOF Stimulation Induced by Succinylcholine","canonical_id":"clinicaltrials.gov:NCT02425449","description":"Muscle Relaxants","metadata":null},{"id":"f45e7129de5e4edab6cb28ec3b7d05b5","type":"DISEASE","name":"Falciparum malaria","canonical_id":"mesh:D016778","description":null,"metadata":null},{"id":"b3b36a408cd44d648e858820ee832ff8","type":"TISSUE","name":"Fallopian Tube","canonical_id":"uberon:UBERON:0003889","description":null,"metadata":null},{"id":"20a8dd90d93c49aeae9f56e25af8409b","type":"DRUG","name":"Familial Mediterranean fever","canonical_id":"mesh:D010505","description":null,"metadata":null},{"id":"8cdea6df728141ef820a22902c63e592","type":"DISEASE","name":"Familial prostate cancer","canonical_id":"orphanet:1331","description":null,"metadata":null},{"id":"aa04fc6723254cfc870e24e51e5a6bff","type":"DISEASE","name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","canonical_id":"mesh:D053098","description":null,"metadata":null},{"id":"cb7515ab99ef4a0d997f9e6b34e9c6ac","type":"TRIAL","name":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","canonical_id":"clinicaltrials.gov:NCT02600741","description":"Schizophrenia","metadata":null},{"id":"32680146a6e74e71809c4015c3027a36","type":"TRIAL","name":"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05176080","description":"Metastatic Breast Cancer","metadata":null},{"id":"d5009de08e8540bbb3ec108fb307fd6e","type":"TRIAL","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","canonical_id":"clinicaltrials.gov:NCT05760378","description":"Triple-Negative Breast Cancer","metadata":null},{"id":"254630c6dca14dc18e2b17d14cd11618","type":"TRIAL","name":"Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)","canonical_id":"clinicaltrials.gov:NCT01392235","description":"Recurrent Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Carcinoma","metadata":null},{"id":"20ca725303aa4e01ae84760042097189","type":"DRUG","name":"Famotidine","canonical_id":"mesh:D015738","description":null,"metadata":null},{"id":"396fae984b5b4f2e8f3da3a086e832cd","type":"TRIAL","name":"Famotidine and Antacids for Treatment of Dyspepsia","canonical_id":"clinicaltrials.gov:NCT06241183","description":"Dyspepsia; GERD; Acid Reflux","metadata":null},{"id":"53e9c5b2eca64e4199bf976b51c9bca0","type":"TRIAL","name":"Famotidine for Levodopa-induced Dyskinesia in PD","canonical_id":"clinicaltrials.gov:NCT01937078","description":"Dyskinesia","metadata":null},{"id":"c6a49ee7518c4461931fdfa33eed2d46","type":"TRIAL","name":"Famotidine in Covid-19 Intensive Care Unit","canonical_id":"clinicaltrials.gov:NCT05122208","description":"COVID-19 Pandemic","metadata":null},{"id":"db3022d97dcc43718c88a091ebe8a3e8","type":"TRIAL","name":"Fampridine Pregnancy Exposure Registry","canonical_id":"clinicaltrials.gov:NCT01532154","description":"Multiple Sclerosis; Pregnancy","metadata":null},{"id":"2bed11f4bca249aa80718061f39eeaa3","type":"TRIAL","name":"Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis","canonical_id":"clinicaltrials.gov:NCT03164018","description":"Multiple Sclerosis","metadata":null},{"id":"03802b011e7c4fc09baf8925437352ef","type":"TRIAL","name":"Fampridine-SR and Optic Neuritis Recovery","canonical_id":"clinicaltrials.gov:NCT04148781","description":"Optic Neuritis","metadata":null},{"id":"5ba4556e7e914e55a868ec5aef3a411e","type":"GO_TERM","name":"Fanconi anaemia nuclear complex","canonical_id":"go:GO:0043240","description":"\"A protein complex composed of the Fanconi anaemia (FA) proteins including A, C, E, G and F (FANCA-F). Functions in the activation of the downstream protein FANCD2 by monoubiquitylation, and is essential for protection against chromosome breakage.\" [GOC:jl, PMID:12093742]","metadata":null},{"id":"f14793976b3a4510aef468eb14959223","type":"TRIAL","name":"Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR","canonical_id":"clinicaltrials.gov:NCT06790784","description":"Proliferative Diabetic Retinopathy (PDR)","metadata":null},{"id":"6d54664b6a9249a5a8827af766f62e45","type":"TRIAL","name":"Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT06742307","description":"Macular Degeneration Choroidal Neovascularization","metadata":null},{"id":"8606a0e65aa04f6692b6c5c94b5664f1","type":"TRIAL","name":"Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial","canonical_id":"clinicaltrials.gov:NCT07681167","description":"Central Serous Chorioretinopathy (CSC)","metadata":null},{"id":"a3fcae8cb19d4ccfb059b1edd9768ae7","type":"TRIAL","name":"Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT05941715","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"41477049059e4eb7a10d1ec9a68b6a8a","type":"DRUG","name":"Faropenem","canonical_id":"mesh:C528565","description":null,"metadata":null},{"id":"0b335eff07d74852a1595b3846869354","type":"GO_TERM","name":"Fas signaling pathway","canonical_id":"go:GO:0036337","description":"\"The series of molecular signals initiated by the binding of a ligand to a Fas receptor on the surface of the cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Fas is a death domain-containing member of the tumor necrosis factor receptor (TNFR) superfamily.\" [GOC:nhn, PMID:12040174, Wikipedia:Fas_receptor]","metadata":null},{"id":"429748d803484860a108343e7838c73d","type":"GO_TERM","name":"Fas-activated serine/threonine kinase activity","canonical_id":"go:GO:0033867","description":"\"Catalysis of the reaction: ATP + Fas-activated serine/threonine protein = ADP + Fas-activated serine/threonine phosphoprotein.\" [EC:2.7.11.8]","metadata":null},{"id":"efea268f70f54ae3b8e26e8984a3257f","type":"TRIAL","name":"Faslodex Advanced Breast Cancer Local Chinese Study","canonical_id":"clinicaltrials.gov:NCT00327769","description":"Advanced Breast Cancer","metadata":null},{"id":"0bb42c0082f74caebac945a023b45f5c","type":"TRIAL","name":"Fast & Fed Pharmacokinetic (PK) Study","canonical_id":"clinicaltrials.gov:NCT00692016","description":"Bioavailability","metadata":null},{"id":"674db148ea43468488c8bc65619a21ff","type":"TRIAL","name":"Fast Titration Of Quetiapine Versus Currently Approved Titration","canonical_id":"clinicaltrials.gov:NCT00254813","description":"Psychotic Disorders","metadata":null},{"id":"8844ee67248d4450a99a03cd159519c2","type":"TRIAL","name":"Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)","canonical_id":"clinicaltrials.gov:NCT00983996","description":"Healthy","metadata":null},{"id":"bd3b3b2382e941169510e13a8eadc812","type":"TRIAL","name":"Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel\u00ae Capsules 10 mg/20 mg","canonical_id":"clinicaltrials.gov:NCT00649519","description":"Healthy","metadata":null},{"id":"7687d45f249e49bf8e424c87b8bbdab1","type":"TRIAL","name":"Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin\u00ae Capsules 1 mg","canonical_id":"clinicaltrials.gov:NCT00648024","description":"Healthy","metadata":null},{"id":"fd32b0d918fc46d2a5a309e1cb24c36b","type":"TRIAL","name":"Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT\u00ae Tablets 20 mg/25 mg","canonical_id":"clinicaltrials.gov:NCT00649597","description":"Healthy","metadata":null},{"id":"41261eb6e3e941599d70e928b4bd708c","type":"TRIAL","name":"Fasting Study of Carvedilol Tablets 12.5 mg to Coreg\u00ae Tablets 12.5 mg","canonical_id":"clinicaltrials.gov:NCT00650416","description":"Healthy","metadata":null},{"id":"8962849011d24825a4a9a7495fcaf0d4","type":"TRIAL","name":"Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex\u00ae Pennkinetic\u00ae Extended Release Oral Suspension","canonical_id":"clinicaltrials.gov:NCT00853294","description":"Healthy","metadata":null},{"id":"cc30546ee4f24a3f870902ec2ea73b75","type":"TRIAL","name":"Fasting Study of Fexofenadine Tablets 180 mg and Allegra\u00ae Tablets 180 mg","canonical_id":"clinicaltrials.gov:NCT00649376","description":"Healthy","metadata":null},{"id":"82f0f481877d4c20931328a94463d683","type":"TRIAL","name":"Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg","canonical_id":"clinicaltrials.gov:NCT00648791","description":"Healthy","metadata":null},{"id":"8dda53f2c6cd44b7a4d776426b3aa498","type":"TRIAL","name":"Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane\u00ae Capsules 25 mg","canonical_id":"clinicaltrials.gov:NCT00648778","description":"Healthy","metadata":null},{"id":"82ebb8b54f9a468291833e31ac7cbcf1","type":"TRIAL","name":"Fasting Study of Meloxicam Tablets 15 mg and Mobic\u00ae Tablets 15 mg","canonical_id":"clinicaltrials.gov:NCT00649077","description":"Healthy","metadata":null},{"id":"45a28ba43ae74c5f89ef32cceb1c5440","type":"TRIAL","name":"Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn\u00ae Tablets 10 mg","canonical_id":"clinicaltrials.gov:NCT00650195","description":"Healthy","metadata":null},{"id":"a5c919243c4c4cd08d7d5579a64637a5","type":"TRIAL","name":"Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn\u00ae Tablets 2.5 mg","canonical_id":"clinicaltrials.gov:NCT00649051","description":"Healthy","metadata":null},{"id":"4ea9de50cdd147f2b330a90c5c5c6d7f","type":"TRIAL","name":"Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn\u00ae Tablets 5 mg","canonical_id":"clinicaltrials.gov:NCT00649181","description":"Healthy","metadata":null},{"id":"a2e2f63d5839417986f905e68c48477a","type":"TRIAL","name":"Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide\u00ae Tablets 80 mg/5 mg","canonical_id":"clinicaltrials.gov:NCT00647660","description":"Healthy","metadata":null},{"id":"48021197e8a34874b00ae659b5d4d753","type":"TRIAL","name":"Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar\u00ae Tablets 40 mg","canonical_id":"clinicaltrials.gov:NCT00649623","description":"Healthy","metadata":null},{"id":"5fccd033a39542a98a248352161364c1","type":"TRIAL","name":"Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL\u00ae Tablets 5 mg","canonical_id":"clinicaltrials.gov:NCT00650481","description":"Healthy","metadata":null},{"id":"c616140e264b437e9c474a61dcbc5841","type":"TRIAL","name":"Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex\u00ae Tablets 100 mg","canonical_id":"clinicaltrials.gov:NCT00648466","description":"Healthy","metadata":null},{"id":"037a02d44f3e46a795826311b2b00810","type":"TRIAL","name":"Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan\u00ae PM Extended-Release Capsules 300 mg","canonical_id":"clinicaltrials.gov:NCT00647673","description":"Healthy","metadata":null},{"id":"821a1cc7b2654f979589af24119257eb","type":"TRIAL","name":"Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan\u00ae PM Extended-Release Capsules 300 mg","canonical_id":"clinicaltrials.gov:NCT00648050","description":"Healthy","metadata":null},{"id":"ff35bfafdd1f47f29e7730e7b74e40ca","type":"TRIAL","name":"Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)","canonical_id":"clinicaltrials.gov:NCT04191954","description":"Retinopathy of Prematurity","metadata":null},{"id":"1c942f4838114179a457a367c1505cef","type":"TRIAL","name":"Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)","canonical_id":"clinicaltrials.gov:NCT06362707","description":"Cognitive Decline, Mild; Alzheimer Disease","metadata":null},{"id":"bde4bba8072648a28583eec0a6aeaa0f","type":"TRIAL","name":"Fasudil fOr redUcing elopemeNt and Spatial Disorientation","canonical_id":"clinicaltrials.gov:NCT04793659","description":"Dementia","metadata":null},{"id":"26524ed27ccb4d6db802d7e445e9a4ee","type":"TRIAL","name":"Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes","canonical_id":"clinicaltrials.gov:NCT00946192","description":"Exercise-related Amenorrhea","metadata":null},{"id":"33ed167c1aaa4bf49c9b523358f66246","type":"TRIAL","name":"Fatty Liver Study in Patients With Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT02365233","description":"Type II Diabetes; Nonalcoholic Fatty Liver","metadata":null},{"id":"4d94914568224393a65f97b590585f3f","type":"GO_TERM","name":"Fc receptor complex","canonical_id":"go:GO:0032997","description":"\"A protein complex composed of a subunit or subunits capable of binding the Fc portion of an immunoglobulin with additional signaling components. The complex functions as a receptor for immunoglobulin.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a066799f145742059a2cf43da46a451e","type":"GO_TERM","name":"Fc receptor mediated inhibitory signaling pathway","canonical_id":"go:GO:0002774","description":"\"The series of molecular signals generated as a consequence of the binding of the Fc portion of an immunoglobulin by an Fc receptor capable of inhibiting an immune effector process contributing to an immune response. The Fc portion of an immunoglobulin is its C-terminal constant region.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"2fd3e015ea624bdeab7d1aac09b3ce80","type":"GO_TERM","name":"Fc receptor mediated stimulatory signaling pathway","canonical_id":"go:GO:0002431","description":"\"The series of molecular signals generated as a consequence of a the binding of the Fc portion of an immunoglobulin by an Fc receptor capable of activating or perpetuating an immune response. The Fc portion of an immunoglobulin is its C-terminal constant region.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"c83282b3ea39462eadd97d28c13ff291","type":"GO_TERM","name":"Fc receptor signaling pathway","canonical_id":"go:GO:0038093","description":"\"The series of molecular signals initiated by the binding of the Fc portion of an immunoglobulin to an Fc receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. The Fc portion of an immunoglobulin is its C-terminal constant region.\" [GOC:phg, Wikipedia:Fc_receptor]","metadata":null},{"id":"870be9dade9e450cb5aaede1636b888d","type":"GO_TERM","name":"Fc receptor-mediated immune complex endocytosis","canonical_id":"go:GO:0160006","description":"\"An endocytosis process mediated by the Fc receptor for the purpose of delivery of antigen-bound immunoglobulin to an intracellular compartment where the antigen can be processed and loaded onto MHC molecules. This process selectively targets antigens for presentation by MHC class II or cross-presentation by MHC class I.\" [PMID:28389502, PMID:9143687, PMID:9463401]","metadata":null},{"id":"cc3f8723604a4ec3ac446a81927b9e3f","type":"GO_TERM","name":"Fc-alpha receptor I complex","canonical_id":"go:GO:0032999","description":"\"A protein complex composed of an Fc-alpha R alpha chain and an Fc-epsilon RI gamma chain dimer with or without additional signaling components. The complex functions primarily as an activating receptor for IgA.\" [GOC:add, ISBN:0781735149, PMID:12524384]","metadata":null},{"id":"25fa6399f1534bdc87cf66aaaa31a5df","type":"GO_TERM","name":"Fc-epsilon receptor I complex","canonical_id":"go:GO:0032998","description":"\"A protein complex composed of an Fc-epsilon RI alpha chain and an Fc-epsilon RI gamma chain dimer with or without an Fc-episilon RI beta chain and additional signaling components. The complex functions primarily as an activating receptor for IgE.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c25617d04dfc4c2997a4c9b760fe84ab","type":"GO_TERM","name":"Fc-epsilon receptor signaling pathway","canonical_id":"go:GO:0038095","description":"\"The series of molecular signals initiated by the binding of the Fc portion of immunoglobulin E (IgE) to an Fc-epsilon receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. The Fc portion of an immunoglobulin is its C-terminal constant region.\" [GOC:phg, PMID:12413516, PMID:15048725]","metadata":null},{"id":"ec2a254cc69d4d6390fa1c74b9e3fcf6","type":"GO_TERM","name":"Fc-gamma receptor I complex","canonical_id":"go:GO:0033000","description":"\"A protein complex composed of an Fc-gamma RI alpha chain and an Fc-epsilon RI gamma chain dimer with or without additional signaling components. The complex functions primarily as an activating receptor for IgG.\" [GOC:add, ISBN:0781735149, PMID:11244038, PMID:12413532]","metadata":null},{"id":"e4928594fe5d486bb92388a2dc7ab154","type":"GO_TERM","name":"Fc-gamma receptor I complex binding","canonical_id":"go:GO:0034988","description":"\"Binding to one or more specific sites on the Fc-gamma receptor I complex. The complex functions primarily as an activating receptor for IgG.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"54962b820256483697264503eeef45bd","type":"GO_TERM","name":"Fc-gamma receptor III complex","canonical_id":"go:GO:0033001","description":"\"A protein complex composed of an Fc-gamma RIII alpha chain and an Fc-epsilon RI gamma chain dimer with or without an Fc-epsilon RI beta chain and additional signaling components. The complex functions primarily as an activating receptor for IgG.\" [GOC:add, ISBN:0781735149, PMID:11244038, PMID:12413532]","metadata":null},{"id":"965c57a2fac14ec2a3fd06128d7cb658","type":"GO_TERM","name":"Fc-gamma receptor signaling pathway","canonical_id":"go:GO:0038094","description":"\"The series of molecular signals initiated by the binding of the Fc portion of immunoglobulin G (IgG) to an Fc-gamma receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. The Fc portion of an immunoglobulin is its C-terminal constant region.\" [GOC:phg, PMID:11244038]","metadata":null},{"id":"74e847d9c01248a1876639d70e47cb4b","type":"GO_TERM","name":"Fc-gamma receptor signaling pathway involved in phagocytosis","canonical_id":"go:GO:0038096","description":"\"An Fc-gamma receptor signaling pathway that contributes to the endocytic engulfment of external particulate material by phagocytes.\" [GOC:phg, PMID:12488490, PMID:15466916]","metadata":null},{"id":"ad688246349f42378d87850d918ad9ff","type":"TRIAL","name":"FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack","canonical_id":"clinicaltrials.gov:NCT06497374","description":"Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder; NMO Spectrum Disorder","metadata":null},{"id":"1d715654545b491aa47c876cb4de3165","type":"TRIAL","name":"Fearon Algorithm in Warfarin Patient Self-Management","canonical_id":"clinicaltrials.gov:NCT03911661","description":"Atrial Fibrillation; Venous Thromboses; Heart Valve Diseases","metadata":null},{"id":"b310e28105014db0abd2285b0295c4a1","type":"TRIAL","name":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT07027748","description":"Neuroblastoma; Neuroblastoma Recurrent; Relapsed Neuroblastoma; Refractory Neuroblastoma","metadata":null},{"id":"a9946728beb243f385939538d89f97a0","type":"TRIAL","name":"Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors","canonical_id":"clinicaltrials.gov:NCT00746603","description":"Carotid Artery Disease","metadata":null},{"id":"fe60c166ed09400d96d6b941c9eafc70","type":"TRIAL","name":"Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD","canonical_id":"clinicaltrials.gov:NCT00174551","description":"Stress Disorders, Post-Traumatic","metadata":null},{"id":"598dc3bbb3d14c05b30248816bd9379d","type":"TRIAL","name":"Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT01815528","description":"Recurrent Epithelial Ovarian Cancer","metadata":null},{"id":"7a807c7735b54d1a8c113c0808d3b786","type":"TRIAL","name":"Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03610438","description":"Acute Lymphoid Leukemia","metadata":null},{"id":"8e02a0155dac4bcd81f93c37b95e2f8c","type":"TRIAL","name":"Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT04658147","description":"Hepatocellular Carcinoma","metadata":null},{"id":"4707e200e75649fab504d253ff3ba136","type":"TRIAL","name":"Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection","canonical_id":"clinicaltrials.gov:NCT01141543","description":"Acute Myeloid Leukemia","metadata":null},{"id":"da47fa953f01418b853c3165a3cbe71f","type":"TRIAL","name":"Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer","canonical_id":"clinicaltrials.gov:NCT03838263","description":"Oropharynx Cancer","metadata":null},{"id":"929321e8ea844211bafdc24d1ff397bb","type":"TRIAL","name":"Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy","canonical_id":"clinicaltrials.gov:NCT01446991","description":"Prostate Cancer","metadata":null},{"id":"a33c3c5f3fb04f6198cd8a5e3f67dfb7","type":"TRIAL","name":"Feasibility of \"At-home\" Titration of Solifenacin","canonical_id":"clinicaltrials.gov:NCT00759577","description":"Overactive Bladder","metadata":null},{"id":"a4cb804c65c0430aa0f77fe23027788b","type":"TRIAL","name":"Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid","canonical_id":"clinicaltrials.gov:NCT00745485","description":"Osteoporosis","metadata":null},{"id":"fc72c05f68a04a199be4a879f410a583","type":"TRIAL","name":"Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors","canonical_id":"clinicaltrials.gov:NCT01965002","description":"Soft Tissue Neoplasms","metadata":null},{"id":"c02ae09aeb4a435cac50de4b53b9bd99","type":"TRIAL","name":"Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin","canonical_id":"clinicaltrials.gov:NCT02168491","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"20d6992165eb497cb4fabe786e1add9e","type":"TRIAL","name":"Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT05510115","description":"Polycystic Kidney, Autosomal Dominant","metadata":null},{"id":"c2c2c23b8fd8428e9dd5222b675c031a","type":"DRUG","name":"Febuxostat","canonical_id":"mesh:D000069465","description":null,"metadata":null},{"id":"6a3722c5eacb4f5b8c347e36959b7d20","type":"TRIAL","name":"Febuxostat 80 mg Tablets Relative to Feburic\u00ae 80 mg Tablets","canonical_id":"clinicaltrials.gov:NCT06233162","description":"Healthy Subjects","metadata":null},{"id":"68028594fddb4068bc63452af6149bee","type":"TRIAL","name":"Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones","canonical_id":"clinicaltrials.gov:NCT01077284","description":"Hyperuricosuria; Kidney Stones","metadata":null},{"id":"5e6af08f8c5a4130b7052031f7cbf8d6","type":"TRIAL","name":"Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy","canonical_id":"clinicaltrials.gov:NCT01984749","description":"Hyperuricemia","metadata":null},{"id":"2c2b30161177464da9b90d79cb965738","type":"TRIAL","name":"Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults","canonical_id":"clinicaltrials.gov:NCT03605212","description":"Tumor Lysis Syndrome","metadata":null},{"id":"2e1e18fa331d4756a49dd1693ef94864","type":"TRIAL","name":"Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)","canonical_id":"clinicaltrials.gov:NCT01328769","description":"Hypertension","metadata":null},{"id":"ee71ae0b07e74adc8ed038f98f68dd0b","type":"TRIAL","name":"Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)","canonical_id":"clinicaltrials.gov:NCT05690048","description":"Immunotherapy; HCC - Hepatocellular Carcinoma","metadata":null},{"id":"459eefe99fbd40829056002c669edc90","type":"TRIAL","name":"Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients","canonical_id":"clinicaltrials.gov:NCT04038619","description":"Colitis; Diarrhea; Malignant Genitourinary System Neoplasm; Melanoma; Lung Cancer; Ovarian Cancer; Uterine Cancer; Breast Cancer; Cervical Cancer","metadata":null},{"id":"a04e65c230a24ea1a2f4759673cc4a4b","type":"TRIAL","name":"Fed Study of (Parlodel\u00ae) 2.5 mg Bromocriptine Mesylate Tablets","canonical_id":"clinicaltrials.gov:NCT00650520","description":"Healthy","metadata":null},{"id":"a4d25abfbd924aafb6db5950f901c078","type":"TRIAL","name":"Fed Study of (Parlodel\u00ae) Bromocriptine Mesylate Capsules 5 mg","canonical_id":"clinicaltrials.gov:NCT00649168","description":"Healthy","metadata":null},{"id":"e03d8a46178649e19190e85f49124f9e","type":"TRIAL","name":"Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel\u00ae Capsules 10 mg/20 mg","canonical_id":"clinicaltrials.gov:NCT00649402","description":"Healhty","metadata":null},{"id":"f9316091574845b0b0861919913f47df","type":"TRIAL","name":"Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin\u00ae Capsules 1 mg","canonical_id":"clinicaltrials.gov:NCT00648765","description":"Healthy","metadata":null},{"id":"581cb51c288241c2af45c07d5edb9b0c","type":"TRIAL","name":"Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT\u00ae Tablets 20 mg/25 mg","canonical_id":"clinicaltrials.gov:NCT00649038","description":"Healthy","metadata":null},{"id":"9b722e44c3794d83ac39e9094880f6d8","type":"TRIAL","name":"Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex\u00ae Pennkinetic\u00ae Extended Release Oral Suspension","canonical_id":"clinicaltrials.gov:NCT00853190","description":"Healthy","metadata":null},{"id":"541943fd04e545068292082866c5bc33","type":"TRIAL","name":"Fed Study of Finasteride Tablets 5 mg and Proscar\u00ae Tablets 5 mg","canonical_id":"clinicaltrials.gov:NCT00650377","description":"Healthy","metadata":null},{"id":"eb62e349d21d4a92937ab40985dca554","type":"TRIAL","name":"Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide\u00ae Tablets 80 mg/5 mg","canonical_id":"clinicaltrials.gov:NCT00648297","description":"Healthy","metadata":null},{"id":"e2bf2ca54fc447efb1682c8d9e5aed24","type":"TRIAL","name":"Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar\u00ae Tablets 40 mg","canonical_id":"clinicaltrials.gov:NCT00648219","description":"Healthy","metadata":null},{"id":"ebdd5f3d325f45e791f30f9da9e8255d","type":"TRIAL","name":"Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04449250","description":"Healthy Volunteers in Fed and Fasted State","metadata":null},{"id":"8420830a5d444c58aa3e39653575cc44","type":"TRIAL","name":"Fedratinib in Combination With Nivolumab","canonical_id":"clinicaltrials.gov:NCT05393674","description":"Primary Myelofibrosis; Secondary Myelofibrosis","metadata":null},{"id":"96adeee58ef24974adb2a53eb8e9db88","type":"TRIAL","name":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","canonical_id":"clinicaltrials.gov:NCT05177211","description":"Myeloproliferative Neoplasm; Chronic Neutrophilic Leukemia; MDS","metadata":null},{"id":"0e3f948c827e4ec6957f0f6a253cbd07","type":"DRUG","name":"Felbamate","canonical_id":"mesh:C047360","description":null,"metadata":null},{"id":"a23957642a234262b6da12d8b81300d2","type":"DRUG","name":"Felbinac","canonical_id":"mesh:C012776","description":null,"metadata":null},{"id":"159c36dc32e44af8a056d6bc529baac8","type":"DISEASE","name":"Female infertility","canonical_id":"mesh:D007247","description":null,"metadata":null},{"id":"225d5d815ebd4bfc8ddf596acc455956","type":"DRUG","name":"Fenfluramine","canonical_id":"mesh:D005277","description":null,"metadata":null},{"id":"685aadadd2cd4adc85d8f3cfd380df70","type":"DRUG","name":"Fenofibrate","canonical_id":"mesh:D011345","description":null,"metadata":null},{"id":"8953136e6c9a4540bd5f26b7d47ffe6c","type":"TRIAL","name":"Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)","canonical_id":"clinicaltrials.gov:NCT07025005","description":"Peripheral Neuropathy; Multiple Myeloma, Neoplasms","metadata":null},{"id":"0a155a7445e544d680594ad7bcacf00c","type":"TRIAL","name":"Fenofibrate Treatment in SCI","canonical_id":"clinicaltrials.gov:NCT02455336","description":"Spinal Cord Injury; Dyslipidemia","metadata":null},{"id":"bfa1a7e7fde34278ad7f2935837b0130","type":"TRIAL","name":"Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)","canonical_id":"clinicaltrials.gov:NCT06365424","description":"Primary Biliary Cholangitis","metadata":null},{"id":"a9a45d271a7344009f8aa98390b42242","type":"TRIAL","name":"Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)","canonical_id":"clinicaltrials.gov:NCT07104201","description":"Primary Biliary Cholangitis (PBC)","metadata":null},{"id":"1e1f9a8aec7a44e19c664d6d04680817","type":"TRIAL","name":"Fenofibrate in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03829514","description":"Diabetes Mellitus, Type II","metadata":null},{"id":"3ff99411a56a46e492eb325a885db34b","type":"TRIAL","name":"Fenofibrate in Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05753267","description":"Inflammatory Bowel Diseases","metadata":null},{"id":"e6e6ae29ab594709bb29e39ab742b347","type":"TRIAL","name":"Fenoldopam and Acute Renal Failure","canonical_id":"clinicaltrials.gov:NCT00621790","description":"Acute Renal Failure","metadata":null},{"id":"9872b4ec29c74332a952da58c3b47f15","type":"TRIAL","name":"Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00557219","description":"Acute Renal Failure","metadata":null},{"id":"106e6b033aa14cb08bf2edaf900893de","type":"TRIAL","name":"Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass","canonical_id":"clinicaltrials.gov:NCT00747331","description":"Cardiac Complications; Cardiopulmonary Bypass","metadata":null},{"id":"d19bab9d7f8b437da9a99293901e1c6a","type":"TRIAL","name":"Fenoldopam for Prevention of Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT01690832","description":"Coronary Artery Disease","metadata":null},{"id":"d4622821b83c4c3e845f45b4703e8464","type":"TRIAL","name":"Fenoldopam in Pediatric Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00982527","description":"Kidney Failure, Acute","metadata":null},{"id":"746fdf5f25b44fce9619859cede7ee1b","type":"TRIAL","name":"Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants","canonical_id":"clinicaltrials.gov:NCT02620761","description":"Patent Ductus Arteriosus (PDA); Acute Kidney Injury (AKI)","metadata":null},{"id":"824bf00c413d4b48b8ce2b8d5e84276b","type":"TRIAL","name":"Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT03476369","description":"Percutaneous Coronary Intervention","metadata":null},{"id":"a7062b337521470b8578b9a60ff551a7","type":"DRUG","name":"Ferric carboxymaltose","canonical_id":"mesh:C522335","description":null,"metadata":null},{"id":"3cb2e7bb844a41c8950d1d176d8d80df","type":"TRIAL","name":"Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial","canonical_id":"clinicaltrials.gov:NCT03011684","description":"Infertility","metadata":null},{"id":"c36ea200063c4fc592ab2d33f3031089","type":"DRUG","name":"Fesoterodine","canonical_id":"mesh:C526675","description":null,"metadata":null},{"id":"5db8cab4891e432888033be07dea39dc","type":"DISEASE","name":"Fever","canonical_id":"hp:0001945","description":null,"metadata":null},{"id":"f5e1652099ed4290ab4d5542a5bdbe0a","type":"DISEASE","name":"Fever","canonical_id":"mesh:D005334","description":null,"metadata":null},{"id":"31f2d9f2fc544cb5940d401c5ee21c99","type":"DRUG","name":"Fexofenadine","canonical_id":"mesh:C093230","description":null,"metadata":null},{"id":"f45505942c9947aba56045ec5eee3679","type":"TRIAL","name":"Fexofenadine (Allegra\u00ae) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine","canonical_id":"clinicaltrials.gov:NCT00636870","description":"Allergic Rhinitis","metadata":null},{"id":"72192e9248d14a9797a12a68a6e7dbee","type":"TRIAL","name":"Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00835640","description":"Healthy","metadata":null},{"id":"4a8058cc322f4a93a031de4e0b1c435d","type":"TRIAL","name":"Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00741897","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"7fe8e9b96f3b4094a561918af8112191","type":"TRIAL","name":"Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis","canonical_id":"clinicaltrials.gov:NCT06466421","description":"Uremic Pruritus; Chronic Kidney Disease-associated Pruritus; Hemodialysis; End-stage Renal Disease; Renal Replacement Therapy; ESRD","metadata":null},{"id":"1000deedb6ee4ff1a6d74de006cc497e","type":"TRIAL","name":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT06785298","description":"Parkinson Disease","metadata":null},{"id":"1da465aefab94e22a186e7b3c52f3eb9","type":"TRIAL","name":"Fexofenadine in Patients With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT05264025","description":"Rheumatoid Arthritis","metadata":null},{"id":"c028588e2e3449c987a3ebd1d2b0b6d6","type":"TRIAL","name":"Fezolinetant and Vascular Health and Brain Health","canonical_id":"clinicaltrials.gov:NCT07606664","description":"Menopause Hot Flashes","metadata":null},{"id":"ccab1d64bb41478eb187a9dfb2c44570","type":"TRIAL","name":"Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06972875","description":"Prostate CA; Androgen Deprivation Therapy","metadata":null},{"id":"0c9f827393e540f9bea721a3705c1a92","type":"TRIAL","name":"Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial","canonical_id":"clinicaltrials.gov:NCT06617455","description":"Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Ductal Carcinoma In Situ; Localized Breast Carcinoma","metadata":null},{"id":"43121322deeb4024b297bf74be732a40","type":"TRIAL","name":"Fibrin Sealant for Cholangiotomy Closure Study","canonical_id":"clinicaltrials.gov:NCT02545153","description":"Common Bile Duct Gall Stones; Infection; Bile Leak","metadata":null},{"id":"cbe3fffcd52b4ca9bd09c775837dc218","type":"TRIAL","name":"Fibrin Sealant for the Sealing of Dura Sutures","canonical_id":"clinicaltrials.gov:NCT00681824","description":"Pathological Processes in the Posterior Fossa; Dura Defects","metadata":null},{"id":"6557991011b04e369ceedf8aa23df8b7","type":"DISEASE","name":"Fibrocystic breast changes","canonical_id":"mesh:D005348","description":null,"metadata":null},{"id":"e475d30ea721414190d2286da9f760b4","type":"DISEASE","name":"Fibromyalgia","canonical_id":"mesh:D005356","description":null,"metadata":null},{"id":"5badfc1fa17940b1ad519cb77ec6619a","type":"TRIAL","name":"Fibrosis and the Fontan","canonical_id":"clinicaltrials.gov:NCT04901975","description":"Single-ventricle","metadata":null},{"id":"f02daab0efe84bcaba22a70655b4ffe5","type":"TRIAL","name":"Fibrosis in Renal Allografts","canonical_id":"clinicaltrials.gov:NCT00493194","description":"Kidney Failure, Chronic; Transplantation; Immunosuppression; Interstitial Fibrosis","metadata":null},{"id":"f24c245040b14b559704c7b91d953f95","type":"TRIAL","name":"Figitumumab Combined With Pegvisomant For Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00976508","description":"Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma","metadata":null},{"id":"387941e696fb4a1c9f10f1b0baefc8e8","type":"TRIAL","name":"Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy","canonical_id":"clinicaltrials.gov:NCT02886728","description":"Rheumatoid Arthritis","metadata":null},{"id":"f7049660bde5436086a363cede03ffba","type":"TRIAL","name":"Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT06527534","description":"Rheumatoid Arthritis","metadata":null},{"id":"b28ace06bc194997acdef97f679ee75b","type":"TRIAL","name":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","canonical_id":"clinicaltrials.gov:NCT02873936","description":"Rheumatoid Arthritis","metadata":null},{"id":"e3c23a49d47d4dab82b3797c1f94a221","type":"TRIAL","name":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","canonical_id":"clinicaltrials.gov:NCT02889796","description":"Rheumatoid Arthritis","metadata":null},{"id":"27b0324fd367497cbe286c6c638557cf","type":"TRIAL","name":"Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT02914600","description":"Crohn's Disease","metadata":null},{"id":"97bd14bb669f4638a8b49e014d64f619","type":"TRIAL","name":"Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02914535","description":"Ulcerative Colitis","metadata":null},{"id":"9d231069c3d14f389f19cbceea1a2578","type":"DRUG","name":"Filgrastim","canonical_id":"mesh:D000069585","description":null,"metadata":null},{"id":"9f5052ed141f4e8ba0a59aca321570eb","type":"TRIAL","name":"Fimasartan in the Senior Subjects","canonical_id":"clinicaltrials.gov:NCT03246555","description":"The Elderly (\u2265 70 Years) With Essential Hypertension","metadata":null},{"id":"2e088c98d02642eda5c8b104cd99e4d2","type":"DRUG","name":"Finasteride","canonical_id":"mesh:D018120","description":null,"metadata":null},{"id":"405aecd12a7d4cd38ddf604466e97bed","type":"TRIAL","name":"Finasteride 5 mg Tablets, Non-fasting","canonical_id":"clinicaltrials.gov:NCT00835796","description":"Healthy","metadata":null},{"id":"237a4251f8e44976885a60dc5d8f08c3","type":"TRIAL","name":"Finasteride Treatment of Severe Nodulocystic Acne","canonical_id":"clinicaltrials.gov:NCT02502669","description":"NODULOCYSTIC ACNE","metadata":null},{"id":"5fa0f7134c7047d3a2917a09f97ccee7","type":"TRIAL","name":"Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery","canonical_id":"clinicaltrials.gov:NCT00438464","description":"Adenocarcinoma of the Prostate; Stage II Prostate Cancer","metadata":null},{"id":"08bb44b9834747c6b0cd243712da0e87","type":"TRIAL","name":"Finasteride, Dutasteride and Insulin Action","canonical_id":"clinicaltrials.gov:NCT01923090","description":"Healthy Volunteers","metadata":null},{"id":"f5027f0292074d169736808771815c32","type":"TRIAL","name":"Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam","canonical_id":"clinicaltrials.gov:NCT06563063","description":"Stomach Neoplasm","metadata":null},{"id":"fe9cf24a9e56468a80402f98be96e92b","type":"DRUG","name":"Fingolimod","canonical_id":"mesh:D000068876","description":null,"metadata":null},{"id":"c0955e741fde4bcb81a788ceb9032364","type":"TRIAL","name":"Fingolimod -Response According to Coping - Evaluation","canonical_id":"clinicaltrials.gov:NCT01420055","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"de9277457e314c7da2920257c1086702","type":"TRIAL","name":"Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage","canonical_id":"clinicaltrials.gov:NCT04088630","description":"Intracerebral Hemorrhage; Cerebral Edema; Stroke Hemorrhagic; Intracerebral Hemorrhage, Hypertensive; Intracerebral Hemorrhage Intraparenchymal","metadata":null},{"id":"54176b54c3e64d88a2ba9fdb46cfa58c","type":"TRIAL","name":"Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage","canonical_id":"clinicaltrials.gov:NCT06087965","description":"Intracerebral Hemorrhage","metadata":null},{"id":"00e7f13478e945bba70975dcf1433b17","type":"TRIAL","name":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01786265","description":"Prostate Adenocarcinoma; Recurrent Prostate Carcinoma","metadata":null},{"id":"8a8c67f51b7e4d3891c41f663d31b655","type":"TRIAL","name":"Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC","canonical_id":"clinicaltrials.gov:NCT07040072","description":"HNSCC","metadata":null},{"id":"dd80806c96484a1aaa41cce3b3bf4048","type":"TRIAL","name":"FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial","canonical_id":"clinicaltrials.gov:NCT07576452","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"4b4e5fc47de14a97834261039c24d0ef","type":"TRIAL","name":"Firdapse for Post-BOTOX Vocal Weakness","canonical_id":"clinicaltrials.gov:NCT05123053","description":"Vocal Weakness(Post-BOTOX Injection)","metadata":null},{"id":"8592518df1b54dc3937696ce15b18d3c","type":"TRIAL","name":"Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction","canonical_id":"clinicaltrials.gov:NCT03715998","description":"Myocardial Infarction","metadata":null},{"id":"39fceaeed95e4fbcab85f7f6ce0faa99","type":"TRIAL","name":"First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT00308750","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"ba4ab10cf75f4c5aaf2ee75443cd05ed","type":"TRIAL","name":"First Line Metastatic Breast Cancer Treatment (ESMERALDA)","canonical_id":"clinicaltrials.gov:NCT01941407","description":"Metastatic Breast Cancer","metadata":null},{"id":"52750035288347d2b573b3cc47981929","type":"TRIAL","name":"First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01521715","description":"Locally Advanced and/or Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma","metadata":null},{"id":"fb28dd59deb54224b3a2ccb5445cfd45","type":"TRIAL","name":"First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01337154","description":"Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion; Stage IV Non-small Cell Lung Cancer","metadata":null},{"id":"8553dc45c3eb46b59be719811f813745","type":"TRIAL","name":"First Line Therapy for High Risk Acute GVHD","canonical_id":"clinicaltrials.gov:NCT04061876","description":"aGVHD; Stem Cell Transplant Complications","metadata":null},{"id":"89a2aeee41c346c1b6cba08fd5daca46","type":"TRIAL","name":"First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib","canonical_id":"clinicaltrials.gov:NCT01289821","description":"Colorectal Neoplasms","metadata":null},{"id":"936befdfbdca4e5d95e3efc63720ba91","type":"TRIAL","name":"First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes","canonical_id":"clinicaltrials.gov:NCT04259801","description":"Healthy Volunteers; Overweight; Obesity; Diabetes Mellitus, Type 2","metadata":null},{"id":"f7fdec1c50514f07a507c6404d421876","type":"TRIAL","name":"First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01719627","description":"HIV","metadata":null},{"id":"79eb8382c767421f82aa2cc39ad17489","type":"TRIAL","name":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","canonical_id":"clinicaltrials.gov:NCT04504669","description":"Clear Cell Renal Cell Cancer; Non-Small-Cell Lung Cancer; Triple Negative Breast Neoplasms; Squamous Cell Cancer of Head and Neck; Small Cell Lung Cancer; Gastroesophageal Cancer; Melanoma; Cervical Cancer; Advanced Solid Tumours","metadata":null},{"id":"d726c96b1dd3410e94a7bb99b413b1a9","type":"TRIAL","name":"First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06491355","description":"Efficacy, Self; Safety Issues; Colo-rectal Cancer","metadata":null},{"id":"165841b94c5a476ba03b1b09ae96e4ec","type":"TRIAL","name":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06239467","description":"Advanced Cancer; Breast Cancer; Advanced Solid Tumors; PI3K Gene Mutation","metadata":null},{"id":"85916c2c1b924f8d8f413b9447887128","type":"TRIAL","name":"First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy","canonical_id":"clinicaltrials.gov:NCT06439914","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"9b06fb50649f4d5bbcc50a01f128f6ac","type":"TRIAL","name":"First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT05939076","description":"Atrial Fibrillation, Persistent","metadata":null},{"id":"27e439d2073e47a1891e589fafbe2813","type":"TRIAL","name":"First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06531447","description":"Breast Cancer","metadata":null},{"id":"c37e3b09bcaa4ea6b0fa96d15ebeeb68","type":"TRIAL","name":"First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT02883543","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"fbd7daf0030a430aa2b3cfa1f612ceeb","type":"TRIAL","name":"First-line Replacement Maintenance of Envafolimab in Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT05465733","description":"Non-Small-Cell Lung","metadata":null},{"id":"770d3dec2dc5464a921c14960a8e33db","type":"TRIAL","name":"First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients","canonical_id":"clinicaltrials.gov:NCT01646450","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"efd1ad8ccad8435f8bf24d29f9c11ad9","type":"TRIAL","name":"First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin","canonical_id":"clinicaltrials.gov:NCT00981058","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"99e1c91e09b54342b0799eed9de0c5bc","type":"TRIAL","name":"First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin","canonical_id":"clinicaltrials.gov:NCT00982111","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"08e58db62e414c5f964a71d59c5b19a2","type":"TRIAL","name":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT05586061","description":"HER2-positive Gastric Cancer","metadata":null},{"id":"de86a8150550439082078cd4eae7501a","type":"TRIAL","name":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","canonical_id":"clinicaltrials.gov:NCT05022030","description":"Colo-rectal Cancer; Capecitabine; Cetuximab","metadata":null},{"id":"b41abd9060af47b79b1cc10e1b09c82c","type":"TRIAL","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT07235930","description":"Non-Resectable Pancreas Carcinoma","metadata":null},{"id":"bc3179e7ac524781842bd3feaf80d1aa","type":"TRIAL","name":"Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia","canonical_id":"clinicaltrials.gov:NCT01480687","description":"Hypertension; Hypertriglyceridemia","metadata":null},{"id":"27aca276be3643849886b5347650d51e","type":"TRIAL","name":"Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder","canonical_id":"clinicaltrials.gov:NCT00996164","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"d62b9ca4bf5843ceb05bbaed442c4972","type":"TRIAL","name":"Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01357616","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"e2e0d61982b346d1a9a7f0da81024c48","type":"TRIAL","name":"Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD","canonical_id":"clinicaltrials.gov:NCT02683109","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"db956eda41ed401d966d9e2f15b6511c","type":"TRIAL","name":"Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children","canonical_id":"clinicaltrials.gov:NCT05214911","description":"Allergic Rhinitis","metadata":null},{"id":"7c21a14f8c314398bf3dc5faff9cd3ba","type":"TRIAL","name":"Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)","canonical_id":"clinicaltrials.gov:NCT01190254","description":"Schizophrenia, Paranoid; Schizophrenia, Disorganized; Schizophrenia, Undifferentiated","metadata":null},{"id":"9c26ff9f6b174232af24fd2070885d9d","type":"TRIAL","name":"Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting","canonical_id":"clinicaltrials.gov:NCT03627858","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"c37fb2428d7f449fbc4ef67490434826","type":"TRIAL","name":"Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06182774","description":"Multiple Myeloma","metadata":null},{"id":"9214d7c892294314a3a2be2b002697a1","type":"TRIAL","name":"Fixed vs Free Dose of ACEi/CCB Combination Therapy","canonical_id":"clinicaltrials.gov:NCT02995954","description":"Hypertension","metadata":null},{"id":"3b6dd28546d64d64ae6b1a9a310f7e92","type":"TRIAL","name":"Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Na\u00efve Advanced Stage Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT07126678","description":"Follicular Lymphoma; Treatment Naive","metadata":null},{"id":"6d679f0321e6448e8248952d8f73155f","type":"TRIAL","name":"Fixed-Free HTN Trial","canonical_id":"clinicaltrials.gov:NCT03578042","description":"Hypertension","metadata":null},{"id":"9c78c8ccb56b43f1b2b7bcf57a19bee3","type":"TRIAL","name":"Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults","canonical_id":"clinicaltrials.gov:NCT07626437","description":"Common Cold/Flu; Nasal Congestion; Nasal Obstruction","metadata":null},{"id":"3b99448ad8b74faf99c07fdf53eb3b84","type":"TRIAL","name":"Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil","canonical_id":"clinicaltrials.gov:NCT05683574","description":"Third Molar Extraction","metadata":null},{"id":"be19998101174e92b56bfe1852a10661","type":"TRIAL","name":"Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)","canonical_id":"clinicaltrials.gov:NCT00764478","description":"Bipolar 1 Disorder","metadata":null},{"id":"ae5e841d810e4951a1aeb4a093d8f5f8","type":"TRIAL","name":"Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","canonical_id":"clinicaltrials.gov:NCT00889863","description":"Systemic Juvenile Idiopathic Arthritis With Active Flare","metadata":null},{"id":"d87a689668894e58921822da7db976ad","type":"DRUG","name":"Flavoxate","canonical_id":"mesh:D005422","description":null,"metadata":null},{"id":"f6633a41cad146a58cac1a7e3dc3b7dd","type":"DRUG","name":"Flecainide","canonical_id":"mesh:D005424","description":null,"metadata":null},{"id":"8c03010ff8624317aba9619fa5ae7504","type":"TRIAL","name":"Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT07405671","description":"Atrial Fibrillation (AF); Coronary Artery Disease","metadata":null},{"id":"7fea9054ede6474ba2180a9e10e510e2","type":"GO_TERM","name":"Flemming body","canonical_id":"go:GO:0090543","description":"\"A cell part that is the central region of the midbody characterized by a gap in alpha-tubulin staining. It is a dense structure of antiparallel microtubules from the central spindle in the middle of the intercellular bridge.\" [GOC:pm, PMID:18641129, PMID:22522702]","metadata":null},{"id":"e368e7df370942deb69df77dfc91bcb1","type":"TRIAL","name":"Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00593879","description":"Major Depressive Disorder","metadata":null},{"id":"b5b3e5af4add44779fde4bca7201e37d","type":"TRIAL","name":"Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)","canonical_id":"clinicaltrials.gov:NCT01190267","description":"Schizophrenia, Paranoid; Schizophrenia, Disorganized; Schizophrenia, Undifferentiated","metadata":null},{"id":"57058b1df66845ca807aa846b7c1d219","type":"TRIAL","name":"Flibanserin (Addyi\u00ae) vs. Flibanserin and Sex Therapy","canonical_id":"clinicaltrials.gov:NCT02714049","description":"Hypoactive Sexual Desire Disorder","metadata":null},{"id":"4280bb0b8b294717b679681535ebfe3e","type":"TRIAL","name":"Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder","canonical_id":"clinicaltrials.gov:NCT00601367","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"a97db495811741a6933f07ea2bc960ed","type":"TRIAL","name":"Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women","canonical_id":"clinicaltrials.gov:NCT00277914","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"91bcdfd362954dde93d38b1d9e4f4606","type":"TRIAL","name":"Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00996372","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"637b0f41536a4a5da2df1e98e9cb7b5b","type":"TRIAL","name":"Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America","canonical_id":"clinicaltrials.gov:NCT01057901","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"4f26d0cd3fa547e5a3a9f0207b0cdfbf","type":"TRIAL","name":"Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04743934","description":"Prostate Adenocarcinoma","metadata":null},{"id":"e9f1d275219e43d2a7e541f8bf5ba0d1","type":"TRIAL","name":"Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients","canonical_id":"clinicaltrials.gov:NCT01138111","description":"Alzheimer Disease; Amyloid Beta-Protein","metadata":null},{"id":"d894b4cb61e44353b015114b29acd8ba","type":"TRIAL","name":"Florbetaben PET Imaging in PPA","canonical_id":"clinicaltrials.gov:NCT04720001","description":"Primary Progressive Aphasia; Alzheimer Disease","metadata":null},{"id":"c8dc051742ad42aaaca2e973fface8fb","type":"TRIAL","name":"Florbetaben for Imaging of Vascular Amyloid","canonical_id":"clinicaltrials.gov:NCT06091319","description":"Acute Coronary Syndrome; Stroke; Transient Ischemic Attack; Atherosclerosis of Artery","metadata":null},{"id":"79dabac08fae4563be76625cf2935d30","type":"TRIAL","name":"Florbetapir Calibration to the Centiloid Scale","canonical_id":"clinicaltrials.gov:NCT02120664","description":"Alzheimer's Disease","metadata":null},{"id":"3b280b2e395f416eb32661c0b8cad457","type":"TRIAL","name":"Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT00857532","description":"Parkinson's Disease","metadata":null},{"id":"7b004ce9b0634620b052098a2326501d","type":"TRIAL","name":"Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT02152956","description":"AML","metadata":null},{"id":"b0fb1e42d6be4fa18eaf1d7b8b69e9b3","type":"DRUG","name":"Fluconazole","canonical_id":"mesh:D015725","description":null,"metadata":null},{"id":"c7c34bea16b9487886fe1e55aab2e6ac","type":"TRIAL","name":"Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00004857","description":"Leukemia","metadata":null},{"id":"bd42e2ad8e5f4a4b8c5dfbdd6cf8edab","type":"TRIAL","name":"Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT00091143","description":"Melanoma (Skin)","metadata":null},{"id":"a57c0272da0d443bb7d23a362eaff7ea","type":"TRIAL","name":"Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders","canonical_id":"clinicaltrials.gov:NCT00397813","description":"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Essential Thrombocythemia; Myeloproliferative Neoplasm; Paroxysmal Nocturnal Hemoglobinuria; Polycythemia Vera; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ring Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilinea\u2026","metadata":null},{"id":"f22451301ff44b149dca74dc1ce9a3c5","type":"TRIAL","name":"Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib","canonical_id":"clinicaltrials.gov:NCT00036738","description":"Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Blastic Phase; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase of Disease; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Disease","metadata":null},{"id":"bf0f7764cffe4e3eb8ee29367c574803","type":"TRIAL","name":"Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies","canonical_id":"clinicaltrials.gov:NCT01056614","description":"Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Myeloid Leukemia in Remission; Chi\u2026","metadata":null},{"id":"4f31c2e155b34ec3be8338012a0c7fea","type":"TRIAL","name":"Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00907036","description":"Lymphoma","metadata":null},{"id":"f258ed5258e94b93b83c192a0699be7b","type":"TRIAL","name":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","canonical_id":"clinicaltrials.gov:NCT07396480","description":"Venentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Acute Myeloid Leucemia; Myeldysplastic Syndrome (MDS)","metadata":null},{"id":"d8d03d008cdd458fb245732a66b266e2","type":"TRIAL","name":"Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00073879","description":"Kidney Cancer","metadata":null},{"id":"9e7adb66c57240278d2777ae89f71e6c","type":"TRIAL","name":"Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline","canonical_id":"clinicaltrials.gov:NCT00794820","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"37eb9fcef6304e1aa9a0ecc71cf5b325","type":"TRIAL","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","canonical_id":"clinicaltrials.gov:NCT00254163","description":"B-Cell Chronic Lymphocytic Leukemia","metadata":null},{"id":"6063d1073049483aa282a1c5e0bb1d7f","type":"TRIAL","name":"Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00281931","description":"Prolymphocytic Leukemia","metadata":null},{"id":"e678db0bca8b41348cc72f4683708c24","type":"TRIAL","name":"Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01186458","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"87d108058da34ecfad38c01052e8a402","type":"TRIAL","name":"Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00083083","description":"Lung Cancer","metadata":null},{"id":"8159e1b1044349cc9c3c4748082f26c4","type":"TRIAL","name":"Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS","canonical_id":"clinicaltrials.gov:NCT04494789","description":"Critically Ill; Septic Shock","metadata":null},{"id":"783311736d17438095b6c484c5f2f460","type":"DRUG","name":"Fludrocortisone acetate","canonical_id":"mesh:C034635","description":null,"metadata":null},{"id":"47aa437110e34d8ca70c79503182be4a","type":"TRIAL","name":"Fludrocortisone and Information Processing in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01648998","description":"Depression","metadata":null},{"id":"6b2cbcc6b3c74b009d61de8c947d5da9","type":"TRIAL","name":"Fludrocortisone for Sudden Hearing Loss","canonical_id":"clinicaltrials.gov:NCT01186185","description":"Hearing Loss, Sensorineural","metadata":null},{"id":"e2000b6eb36448ccb32c81aabf3efc75","type":"TRIAL","name":"Fludrocortisone in Healthy Volunteers (AFLUCO4)","canonical_id":"clinicaltrials.gov:NCT02140918","description":"Healthy Volunteers","metadata":null},{"id":"9652242ab9464edfbb3d1237330d27cd","type":"TRIAL","name":"Fludrocortisone's Test in Salt Sensitivity","canonical_id":"clinicaltrials.gov:NCT01453959","description":"Hypertension","metadata":null},{"id":"b9d2ca5693d44aaaa424b013db32e770","type":"DRUG","name":"Fludroxycortide","canonical_id":"mesh:D005478","description":null,"metadata":null},{"id":"bb6da3adbfd140a981793b28c4b49c2d","type":"TRIAL","name":"Fluid Absorption in Patients Undergoing Operative Hysteroscopy; Results From a Prospective Controlled Study","canonical_id":"clinicaltrials.gov:NCT04328870","description":"Fluid Overload","metadata":null},{"id":"331161f5de75485fa7588347beaf637f","type":"TRIAL","name":"Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients","canonical_id":"clinicaltrials.gov:NCT06531369","description":"Flumazenil to Antagonize Remimazolam; Remimazolam; Renal Transplantation","metadata":null},{"id":"cd39239c9f2840fb940fed9cc6d72bd3","type":"TRIAL","name":"Flumazenil Reversal of Oral Triazolam","canonical_id":"clinicaltrials.gov:NCT00695630","description":"Dental Anxiety","metadata":null},{"id":"355f9f1fbf5142ddb0def75eea6dbe98","type":"TRIAL","name":"Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy","canonical_id":"clinicaltrials.gov:NCT07619092","description":"Depression - Major Depressive Disorder; Bipolar Disorder (BD); Functional Magnetic Resonance Imaging (fMRI); Cognition; Autobiographical Memory; Electroconvulsive Therapy; ECT; Treatment Outcome; Inpatients","metadata":null},{"id":"a4f158aaadab4fcc88eea46d5af25dfb","type":"TRIAL","name":"Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure","canonical_id":"clinicaltrials.gov:NCT02899156","description":"Hypoactive Delirium","metadata":null},{"id":"d52eea92c9d1460796efb6ec8d0002dd","type":"TRIAL","name":"Flumazenil for the Treatment of Primary Hypersomnia","canonical_id":"clinicaltrials.gov:NCT01183312","description":"Hypersomnia; Primary Hypersomnia; Idiopathic Hypersomnia; Narcolepsy Without Cataplexy","metadata":null},{"id":"17bab6f0ab614c66bafd38337abe456c","type":"DRUG","name":"Flumetasone","canonical_id":"mesh:D005443","description":null,"metadata":null},{"id":"612fec709c8f4460813522936b484c81","type":"DRUG","name":"Flunisolide","canonical_id":"mesh:C007734","description":null,"metadata":null},{"id":"6451cf5b04f143f487a1ec96386b1a13","type":"TRIAL","name":"Flunisolide HFA in Children With Small Airway Disease","canonical_id":"clinicaltrials.gov:NCT02404103","description":"Childhood Asthma","metadata":null},{"id":"41beeb99d561464f971d314f30065c33","type":"TRIAL","name":"Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT00344968","description":"Diabetic Macular Edema","metadata":null},{"id":"9f8ec1a33a7b49119732b155cdb5afe6","type":"TRIAL","name":"Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis","canonical_id":"clinicaltrials.gov:NCT05322070","description":"Uveitis, Posterior","metadata":null},{"id":"3a817d186381494ca6cd76bd2c74e056","type":"TRIAL","name":"Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina","canonical_id":"clinicaltrials.gov:NCT00770770","description":"Macular Edema; Retinal Vein Occlusion","metadata":null},{"id":"cf3d5c01e48a47e298e8f5a51631ec41","type":"TRIAL","name":"Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy","canonical_id":"clinicaltrials.gov:NCT00695318","description":"Age-Related Macular Degeneration","metadata":null},{"id":"2a481a948ed2463c932a4e8434bf2078","type":"TRIAL","name":"Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study","canonical_id":"clinicaltrials.gov:NCT01304706","description":"Diabetic Macular Edema","metadata":null},{"id":"09ecd7b93a7a49ea81dccfce5169dd6b","type":"DRUG","name":"Fluocinonide","canonical_id":"mesh:D005447","description":null,"metadata":null},{"id":"7ac278b203944ad4a355b2fcef23bc02","type":"TRIAL","name":"Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT01422408","description":"Breast Carcinoma","metadata":null},{"id":"87d06de8252941478dce5fe76bd1cee7","type":"TRIAL","name":"Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT06606808","description":"Ulcerative Colitis (UC); Crohn Disease (CD)","metadata":null},{"id":"9eb7150b53f54fbc9e5290899cfbcd85","type":"TRIAL","name":"Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy","canonical_id":"clinicaltrials.gov:NCT00986973","description":"Phenylketonuria","metadata":null},{"id":"b6ea36e5dac04bf8848d9fac7611b148","type":"DRUG","name":"Fluorometholone","canonical_id":"mesh:D005469","description":null,"metadata":null},{"id":"e6545640731745179f6a6f361d712145","type":"TRIAL","name":"Fluorometholone Study","canonical_id":"clinicaltrials.gov:NCT07308938","description":"Keratitis Bacterial; Corneal Ulcer (Diagnosis)","metadata":null},{"id":"e30ba90322264d819d03ee47373ea0b1","type":"TRIAL","name":"Fluorometholone as Ancillary Therapy for TT Surgery","canonical_id":"clinicaltrials.gov:NCT01949454","description":"Trichiasis; Trachoma; Bilamellar Tarsal Rotation","metadata":null},{"id":"175c1d0fa5bf4ca9b698d156ba5652e8","type":"DRUG","name":"Fluorouracil","canonical_id":"mesh:D005472","description":null,"metadata":null},{"id":"47cddf54bebc41a7a63a2a05c95a52cf","type":"DRUG","name":"Fluorouracil","canonical_id":"ncit:C505","description":null,"metadata":null},{"id":"750d0f00bc8944e1be36cf2c5d985ed4","type":"TRIAL","name":"Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00462735","description":"Head and Neck Cancer; Cancer of the Pharynx; Cancer of the Larynx; Nose Neoplasms; Paranasal Sinus Neoplasms; Cancer of the Oral Cavity","metadata":null},{"id":"19459802a1194c779fa2e6ddeeace097","type":"TRIAL","name":"Fluoxetine for Refractory Constipation","canonical_id":"clinicaltrials.gov:NCT06750445","description":"Refractory Constipation","metadata":null},{"id":"c62bdf186be2410a9ace2cfb5883a2ec","type":"TRIAL","name":"Fluoxetine in KCNC1-related Disorder","canonical_id":"clinicaltrials.gov:NCT06341127","description":"KCNC1 Related Disorder; Genetic Disease; Rare Diseases","metadata":null},{"id":"1911c6a1ee2c466f98e864fe8e2b0b55","type":"TRIAL","name":"Fluoxetine in Pediatric Body Dysmorphic Disorder","canonical_id":"clinicaltrials.gov:NCT00245635","description":"Body Dysmorphic Disorder","metadata":null},{"id":"33fe6d3a89e84aa19e9847fe731870c3","type":"TRIAL","name":"Fluoxetine to Reduce Intubation and Death After COVID19 Infection","canonical_id":"clinicaltrials.gov:NCT04377308","description":"COVID-19; Cytokine Storm","metadata":null},{"id":"39f98092a39c40a7be0607f1072f7c74","type":"DRUG","name":"Fluoxymesterone","canonical_id":"mesh:D005474","description":null,"metadata":null},{"id":"7764b0b6fca04be6b25f8f4e7924d7b8","type":"DRUG","name":"Flupentixol","canonical_id":"mesh:D005475","description":null,"metadata":null},{"id":"821784df84564de58d8fdcaf56085c19","type":"TRIAL","name":"Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder","canonical_id":"clinicaltrials.gov:NCT04970667","description":"Emotional Disorder; Neurologic Disorder","metadata":null},{"id":"b94409eb351843e9b4c6f1b9cd962115","type":"TRIAL","name":"Fluphenazine Decanoate for Psoriasis","canonical_id":"clinicaltrials.gov:NCT00356200","description":"Psoriasis","metadata":null},{"id":"5c4f85229c224073aa9bb748ca39768b","type":"TRIAL","name":"Fluphenazine Hydrochloride for Psoriasis","canonical_id":"clinicaltrials.gov:NCT00929578","description":"Psoriasis","metadata":null},{"id":"7609ff2ba55749d19d040f31607a8a7b","type":"TRIAL","name":"Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00335647","description":"Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"2606c0df86304c28bc8a690fddcbe84c","type":"TRIAL","name":"Flurbiprofen Tape for Treatment of Chronic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT00759330","description":"Chronic Low Back Pain","metadata":null},{"id":"8fa7f8cc9641477792336f8acfd7964e","type":"TRIAL","name":"Flushes and Sertraline Trial","canonical_id":"clinicaltrials.gov:NCT00283192","description":"Menopause-Hot Flashes","metadata":null},{"id":"f19a40e9331248479a0150be836357ce","type":"TRIAL","name":"Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate","canonical_id":"clinicaltrials.gov:NCT00006214","description":"Prostate Cancer","metadata":null},{"id":"2e978e98d28147d9a9506dc7b6cd05dc","type":"TRIAL","name":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00002881","description":"Prostate Cancer","metadata":null},{"id":"da45d317ea9340f2a800f7ec13341a71","type":"TRIAL","name":"Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine","canonical_id":"clinicaltrials.gov:NCT00435461","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"141da6c5d3e545dd8129733ed65bbfdd","type":"DRUG","name":"Fluticasone furoate","canonical_id":"mesh:C523187","description":null,"metadata":null},{"id":"ee12cf8cb9db4a70a7f052118d0b9f3b","type":"TRIAL","name":"Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults","canonical_id":"clinicaltrials.gov:NCT04265105","description":"Asthma","metadata":null},{"id":"afc4c7f86c1b462d86b1cb43627f4a4f","type":"TRIAL","name":"Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk","canonical_id":"clinicaltrials.gov:NCT00814723","description":"Hypercholesterolemia","metadata":null},{"id":"bfacd73d91cf41bdaeb04dc0eb4965db","type":"TRIAL","name":"Fluvastatin After Heart Transplantation","canonical_id":"clinicaltrials.gov:NCT00421005","description":"Heart Transplantation; Hypercholesterolemia","metadata":null},{"id":"3f7426ab606d492cb0a084bcdf71d3b1","type":"TRIAL","name":"Fluvastatin AmelIorates aTHerosclerosis Study","canonical_id":"clinicaltrials.gov:NCT01681199","description":"Coronary Heart Disease; Atherosclerosis","metadata":null},{"id":"2b8cec20b1b74fbc85fc2fcbe57cd1c5","type":"TRIAL","name":"Fluvastatin Versus Hepatitis C Virus","canonical_id":"clinicaltrials.gov:NCT00441493","description":"Hepatitis C","metadata":null},{"id":"1923f91db6d049ec81345f84940aaa88","type":"TRIAL","name":"Fluvastatin in Adults With Dislipidemia With History of Muscle Problems","canonical_id":"clinicaltrials.gov:NCT00125125","description":"Dyslipidemia","metadata":null},{"id":"9c0c595ac80743ea907e84c17df6cefd","type":"TRIAL","name":"Fluvastatin in the Therapy of Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT00171275","description":"Coronary Disease; Myocardial Infarction","metadata":null},{"id":"ac023507ea384ad690aba77fa31ddfe4","type":"TRIAL","name":"Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin","canonical_id":"clinicaltrials.gov:NCT00487318","description":"Chronic Hepatitis C","metadata":null},{"id":"62d3d5bc8dd8402a94e2f6c0934c6d89","type":"TRIAL","name":"Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients","canonical_id":"clinicaltrials.gov:NCT04718480","description":"Covid19","metadata":null},{"id":"51021eebbf154e049fcfa4f2b585b742","type":"TRIAL","name":"Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00353028","description":"Major Depressive Disorder","metadata":null},{"id":"f390d801a3ad48bf86f9bc96eb60abc8","type":"TRIAL","name":"Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00352768","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"8d577d62321a47019f9d3714b98ead66","type":"TRIAL","name":"Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?","canonical_id":"clinicaltrials.gov:NCT00655174","description":"Autism","metadata":null},{"id":"3e0e47dd4b65417e9646288cee86213f","type":"TRIAL","name":"Fluvoxamine for Adults With Mild to Moderate COVID-19","canonical_id":"clinicaltrials.gov:NCT04711863","description":"Severe Acute Respiratory Syndrome Coronavirus 2; Coronavirus Infection; Mild to Moderate COVID-19","metadata":null},{"id":"6209de792cf5449693ef1aa04cb7f390","type":"TRIAL","name":"Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia","canonical_id":"clinicaltrials.gov:NCT05216614","description":"COVID-19; Olfactory Disorder; Parosmia","metadata":null},{"id":"f702c3dc88734df6a5ca313fb8c44ed3","type":"TRIAL","name":"Focal Microvibration and Chronic Lumbosacral Radicular Pain","canonical_id":"clinicaltrials.gov:NCT06301061","description":"Pain, Chronic; Lumbosacral Radiculopathy; Radicular; Neuropathic","metadata":null},{"id":"11f16f18fb684217b2c58072fad82c70","type":"DISEASE","name":"Focal impaired awareness seizure","canonical_id":"hp:0002384","description":null,"metadata":null},{"id":"19b6a11fc37e4292abcb12e761469c0c","type":"DISEASE","name":"Focal-onset seizure","canonical_id":"hp:0007359","description":null,"metadata":null},{"id":"34867a7ca304424991f31b2c94cbd051","type":"TRIAL","name":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","canonical_id":"clinicaltrials.gov:NCT06975111","description":"Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular","metadata":null},{"id":"3613ab4382e247d695616f9d91a8e229","type":"PROTEIN","name":"Folate synthesis bifunctional protein","canonical_id":"uniprot:O84619","description":null,"metadata":null},{"id":"b087b237dc3b476b911063a2eed84b95","type":"DRUG","name":"Folic Acid","canonical_id":"mesh:D005492","description":null,"metadata":null},{"id":"695360b70e444acfb5b919cedfb52670","type":"DISEASE","name":"Folic Acid Deficiency","canonical_id":"mesh:D005494","description":null,"metadata":null},{"id":"28746d928186479bb0bee9c0405a8727","type":"TRIAL","name":"Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women","canonical_id":"clinicaltrials.gov:NCT01340521","description":"Infertility","metadata":null},{"id":"9a315e01ec264334855240663401237a","type":"DISEASE","name":"Follicular non-Hodgkin's lymphoma","canonical_id":"mesh:D008224","description":null,"metadata":null},{"id":"5f5c5c7f44664f2e840dd7f14c92ff66","type":"DISEASE","name":"Folliculitis","canonical_id":"mesh:D005499","description":null,"metadata":null},{"id":"6b3e42d63ca74fb381498ee65ed2185a","type":"TRIAL","name":"Follow on Study From RE-ALIGN","canonical_id":"clinicaltrials.gov:NCT01505881","description":"Thromboembolism; Heart Valve Prosthesis","metadata":null},{"id":"eda75658db9342e6b51776b9d168f191","type":"TRIAL","name":"Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).","canonical_id":"clinicaltrials.gov:NCT00291655","description":"Epilepsy","metadata":null},{"id":"25bae25faff54d27bf8245c8a6abc02b","type":"TRIAL","name":"Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis","canonical_id":"clinicaltrials.gov:NCT00124436","description":"Hand Dermatoses","metadata":null},{"id":"61d883f2bc0c48a6b6b59cafb987c3d6","type":"TRIAL","name":"Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril","canonical_id":"clinicaltrials.gov:NCT02654678","description":"Heart Failure; Dilated Cardiomyopathy; Congenital Heart Disease","metadata":null},{"id":"469167e7ef864c199762b28bb1a04f7a","type":"TRIAL","name":"Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)","canonical_id":"clinicaltrials.gov:NCT02878603","description":"Acquired Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"872438c7d5084e46bdaef49e7b8e1e97","type":"TRIAL","name":"Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy","canonical_id":"clinicaltrials.gov:NCT00175916","description":"Epilepsy","metadata":null},{"id":"f8a37e6bfed7404f996856f83cbf7bcc","type":"TRIAL","name":"Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT00927602","description":"Medical Patients; Renal Insufficiency","metadata":null},{"id":"f99024e59099459f9ba5b6ef300dd53c","type":"TRIAL","name":"Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.","canonical_id":"clinicaltrials.gov:NCT00256100","description":"Renal Failure","metadata":null},{"id":"bff1710e96b641f895f7019797f908e1","type":"TRIAL","name":"Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)","canonical_id":"clinicaltrials.gov:NCT00673439","description":"Heparin-Induced Thrombocytopenia","metadata":null},{"id":"73397d7587d3481a8c05a9a75314fafd","type":"TRIAL","name":"Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)","canonical_id":"clinicaltrials.gov:NCT00603824","description":"Heparin-Induced Thrombocytopenia","metadata":null},{"id":"dfce4ceea22a4e2e8fcdf8a092002fc5","type":"TRIAL","name":"Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer","canonical_id":"clinicaltrials.gov:NCT00381888","description":"Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Sarcoma; Thromboembolism; Vaginal Cancer; Vulvar Cancer","metadata":null},{"id":"95b61e6355054626807b7b838c090868","type":"TRIAL","name":"Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study","canonical_id":"clinicaltrials.gov:NCT00474591","description":"Coronary Bypass Graft Failure/Occlusion","metadata":null},{"id":"edb4f80978de482a9268e73d359ee0ac","type":"TRIAL","name":"Fontan Patients: Comprehensive Evaluation of Pulmonary Circulation and Ventricular Function","canonical_id":"clinicaltrials.gov:NCT01572363","description":"Congenital Heart Disease","metadata":null},{"id":"acc56ff2edbd4c7ebb5d1737368290ef","type":"TRIAL","name":"Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets","canonical_id":"clinicaltrials.gov:NCT05416957","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"944bfcb05b6b4809876f1c82a007f9db","type":"TRIAL","name":"Food Effect Study of Febuxostat XR in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02374164","description":"Gout","metadata":null},{"id":"60179df59acb44b0af871e5f5dce426e","type":"TRIAL","name":"Food Effect Study of Linerixibat Tablets in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05435170","description":"Pruritus","metadata":null},{"id":"f76f74cbc3a145b3a24a4786ec2621d7","type":"TRIAL","name":"Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg","canonical_id":"clinicaltrials.gov:NCT00648180","description":"Healthy","metadata":null},{"id":"ff124ffe02734cf39edac8ac43fee145","type":"TRIAL","name":"Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro\u00ae Tablets 20 mg","canonical_id":"clinicaltrials.gov:NCT00648661","description":"Healthy","metadata":null},{"id":"8dae92d66e57464b9d59486eea3c65be","type":"TRIAL","name":"Food Study of Fexofenadine Tablets 180 mg and Allegra\u00ae Tablets 180 mg","canonical_id":"clinicaltrials.gov:NCT00647985","description":"Healthy","metadata":null},{"id":"b41236d235cd47bca3dd8f980f0164b8","type":"TRIAL","name":"Food Study of Meloxicam Tablets 15 mg and Mobic\u00ae Tablets 15 mg","canonical_id":"clinicaltrials.gov:NCT00649675","description":"Healthy","metadata":null},{"id":"451b3e243beb4076850c31e1d9e2538f","type":"TRIAL","name":"Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT\u00ae Tablets 100/50 mg","canonical_id":"clinicaltrials.gov:NCT00649233","description":"Healthy","metadata":null},{"id":"f7943fe2d09645cab720e01a944a7df9","type":"TRIAL","name":"Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL\u00ae Tablets 5 mg","canonical_id":"clinicaltrials.gov:NCT00648843","description":"Healthy","metadata":null},{"id":"60f11101cae948d8b0d8b8d57b221ba1","type":"TRIAL","name":"Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan\u00ae PM Extended-Release Capsules 300 mg","canonical_id":"clinicaltrials.gov:NCT00648401","description":"Healthy","metadata":null},{"id":"98b566ed55c5427e810e5a8eb3dabb77","type":"TRIAL","name":"Forced Diuresis Versus Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT00298454","description":"Renal Failure; Critically Ill","metadata":null},{"id":"bc662f2c04ae41e281f5941169ebc007","type":"TRIAL","name":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","canonical_id":"clinicaltrials.gov:NCT02796651","description":"Chronic Obstructive Pulmonary Disease - COPD","metadata":null},{"id":"31e0d8a1f30642b7912462176d19c5de","type":"TRIAL","name":"Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT03846570","description":"Bronchiectasis","metadata":null},{"id":"c9aa93d797bd4c23801ad7de032a33b5","type":"TRIAL","name":"Fosamax for Childhood Cancer Survivors","canonical_id":"clinicaltrials.gov:NCT00391404","description":"Osteoporosis","metadata":null},{"id":"216a6b9715314b5c92533c17d364a832","type":"TRIAL","name":"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","canonical_id":"clinicaltrials.gov:NCT00895245","description":"Nausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Naso\u2026","metadata":null},{"id":"be8053f5ccf14cdd869de512c2fbf36d","type":"TRIAL","name":"Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01874119","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"55bab947a24d4ecda2e1c74c09999938","type":"TRIAL","name":"Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression","canonical_id":"clinicaltrials.gov:NCT03014297","description":"Neuroendocrine Tumors; Everolimus","metadata":null},{"id":"25ece04156524699a7c25aa864d87fa4","type":"TRIAL","name":"Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV","canonical_id":"clinicaltrials.gov:NCT07726433","description":"Chemotherapy-Induced Nausea and Vomiting (CINV)","metadata":null},{"id":"e8b67e0638954be69af58b4c17908064","type":"TRIAL","name":"Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07841210","description":"Solid Tumor Cancer","metadata":null},{"id":"a02fe7eb01db4d278a91c99ab31385a9","type":"TRIAL","name":"Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT07692451","description":"Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)","metadata":null},{"id":"5eee309804f64abe82b16c01cb046055","type":"TRIAL","name":"Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00135993","description":"Restless Legs Syndrome","metadata":null},{"id":"c6234017ba4e46e79c63370a3eb78bd1","type":"TRIAL","name":"Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy","canonical_id":"clinicaltrials.gov:NCT04923594","description":"Narcolepsy; Excessive Daytime Sleepiness; Cataplexy Narcolepsy","metadata":null},{"id":"c2eed96250034d378bbe2153a8c2c6a5","type":"TRIAL","name":"Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries","canonical_id":"clinicaltrials.gov:NCT03080935","description":"Dyslipidemia","metadata":null},{"id":"0481de26a3c74f65819b0a3219b3d9af","type":"TRIAL","name":"Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus","canonical_id":"clinicaltrials.gov:NCT04951206","description":"Vulvar Lichen Sclerosus","metadata":null},{"id":"d6994186db8e41f2bd51d225e2085c1a","type":"TRIAL","name":"Fracture (FX) Improvement With Teriparatide: FiX-IT Study","canonical_id":"clinicaltrials.gov:NCT01705587","description":"Osteoporosis; Atypical Femoral Fracture","metadata":null},{"id":"14434a43d25145f0a5f6a2b21c73e0c0","type":"TRIAL","name":"Fracture Recovery for Returning to Duty (Teriparatide STRONG)","canonical_id":"clinicaltrials.gov:NCT04589819","description":"Stress Fracture of Tibia or Fibula","metadata":null},{"id":"0da631b067c446e1aca913dfad36fc1e","type":"TRIAL","name":"Fracture Risk With Thiazolidinediones","canonical_id":"clinicaltrials.gov:NCT01055223","description":"Fractures, Bone; Type II Diabetes","metadata":null},{"id":"705a0e37338c4b48a17e779775a4a9fa","type":"TRIAL","name":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","canonical_id":"clinicaltrials.gov:NCT07297914","description":"Acute Lymphoblastic Leukemia (ALL); Stem Cell Transplant; Graft -Versus-host-disease","metadata":null},{"id":"86787c5fdde74a45a4a119ab5b7afb06","type":"TRIAL","name":"Framing Messages for Smoking Cessation With Bupropion - 6","canonical_id":"clinicaltrials.gov:NCT00104598","description":"Tobacco Use Disorder","metadata":null},{"id":"0cbe32b1685146aa8adc5d1c739be5ed","type":"TRIAL","name":"Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)","canonical_id":"clinicaltrials.gov:NCT02406586","description":"Hypertension; Diabetes","metadata":null},{"id":"1c3ff9e56a3f45eabfc55422415602de","type":"TRIAL","name":"Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1","canonical_id":"clinicaltrials.gov:NCT00131456","description":"Depression; Marijuana Abuse","metadata":null},{"id":"37e0b2e421b34223b722ea87ce59c491","type":"TRIAL","name":"Fremanezumab Managed Access Program for Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT03539393","description":"Migraine","metadata":null},{"id":"7687a078e7a5480eb2477245cead004d","type":"TRIAL","name":"Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45","canonical_id":"clinicaltrials.gov:NCT06173661","description":"Migraine; Menstrual Migraine; Menstrually Related Migraine","metadata":null},{"id":"0a48aeab6c89485e9c6df00349514b1b","type":"TRIAL","name":"Fremanezumab for the Prevention of Menstrually-related Migraine Attacks","canonical_id":"clinicaltrials.gov:NCT06659120","description":"Menstrual Migraine","metadata":null},{"id":"96da1dad6d5340109b09b806fef774c8","type":"TRIAL","name":"Fremanezumab, Migraine and Sleep","canonical_id":"clinicaltrials.gov:NCT04693533","description":"Migraine Disorders; Sleep Disorder","metadata":null},{"id":"c57cbc39ea544ef58348af5a4acaf62a","type":"TRIAL","name":"Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant","canonical_id":"clinicaltrials.gov:NCT07423442","description":"Noninfectious Posterior Uveitis; Uveitis, Posterior; Uveitic Macular Edema","metadata":null},{"id":"c5fe9f1e62b34c0bb11a1a871dc812df","type":"TRIAL","name":"Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.","canonical_id":"clinicaltrials.gov:NCT02696226","description":"Aortic Valve Disorder","metadata":null},{"id":"215c43df46f141779ee471a987d33e5a","type":"TRIAL","name":"Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00520052","description":"Osteoporosis","metadata":null},{"id":"7ed85637986748b0afe9415000698582","type":"GO_TERM","name":"Frizzled Nuclear Import pathway","canonical_id":"go:GO:0140709","description":"\"A type of non-canonical Wnt signaling in which Wnt binding to its receptor on the surface a the target cell results in internalization and cleavage of the frizzled receptor to yield a C-terminal fragment that is imported into the nucleus. The frizzled C-terminal fragment is incorporated into large ribonucleoprotein particles and stimulates their egress via nuclear budding.\" [PMID:22510459, PMID:22579286]","metadata":null},{"id":"312ccce68e9b4013b31777cc049ac7d1","type":"TRIAL","name":"Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression","canonical_id":"clinicaltrials.gov:NCT01896934","description":"Major Depressive Disorder","metadata":null},{"id":"9861eccc42f34834b8a63cf7798f51a5","type":"TRIAL","name":"Frontline Asciminib Combination in Chronic Phase CML","canonical_id":"clinicaltrials.gov:NCT03906292","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"e067bdf979bd4189a30316c8073e763e","type":"TRIAL","name":"Frovatriptan as a Transitional Therapy in Medication Overuse Headache","canonical_id":"clinicaltrials.gov:NCT01044251","description":"Medication Overuse Headache; Analgesic Overuse Headache","metadata":null},{"id":"923ba02d0cd749ff9d3b82cefb0496cc","type":"TRIAL","name":"Frozen Embryo Transfer With GnRH-antagonist Trial","canonical_id":"clinicaltrials.gov:NCT03763786","description":"Infertility","metadata":null},{"id":"94519362d1b7451291bb8f0458a513f1","type":"TRIAL","name":"Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06871527","description":"Gastric (Stomach) Cancer; Gastric Adenocarcinoma; Fruquintinib; PD-1 Inhibitor; Tislelizumab; GEJ Adenocarcinoma","metadata":null},{"id":"43c178a1a6c94e60b0407cae1f1cb6bf","type":"TRIAL","name":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06888037","description":"Gastric Adenocarcinoma; GEJ Adenocarcinoma; First-line Therapy; Maintenance Therapy; Fruquintinib; PD-1","metadata":null},{"id":"972f12e719394fa9b91c65d4f334a873","type":"TRIAL","name":"Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT07170982","description":"Endometrial Cancer","metadata":null},{"id":"86f394d330a34fa19d246200ef1d5dbd","type":"TRIAL","name":"Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy","canonical_id":"clinicaltrials.gov:NCT05435313","description":"Colorectal Cancer","metadata":null},{"id":"41d0445ce4404ea39c7ca8f7585bb3c0","type":"TRIAL","name":"Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05625737","description":"Stomach Neoplasms","metadata":null},{"id":"66c69999ed714ea5bd3f6198aa285aa5","type":"TRIAL","name":"Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06148402","description":"Unresectable/Metastatic Colorectal Cancer","metadata":null},{"id":"4d0f6ff1dbae4b6e9c371cef568a86e2","type":"TRIAL","name":"Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study","canonical_id":"clinicaltrials.gov:NCT07491159","description":"Colorectal Cancer","metadata":null},{"id":"fff49cf938a34289aa9f5df26523fc96","type":"TRIAL","name":"Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06011330","description":"Colorectal Cancer","metadata":null},{"id":"c954e01d2181462aa82d27ceec838d5b","type":"TRIAL","name":"Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05447715","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"dddf303b75bc4deb861ab26a088cb97e","type":"TRIAL","name":"Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC","canonical_id":"clinicaltrials.gov:NCT06010888","description":"Colorectal Cancer","metadata":null},{"id":"60b8ae90497544178ef4a742a56507a4","type":"TRIAL","name":"Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06417892","description":"Gastric Cancer","metadata":null},{"id":"3c71bc4ddc0540e1abf5c6b3e8da2f15","type":"TRIAL","name":"Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04582981","description":"Advanced Colorectal Carcinoma","metadata":null},{"id":"19ff330a8d2847a19b3e820df53ebdb0","type":"TRIAL","name":"Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04156958","description":"Biliary Tract Adenocarcinoma","metadata":null},{"id":"8ec651c7cbb342f19dd3bbc437972155","type":"TRIAL","name":"Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study","canonical_id":"clinicaltrials.gov:NCT06202417","description":"Colorectal Cancer; Refractory Colorectal Cancer; Metastatic Colorectal Cancer","metadata":null},{"id":"1e7fab614fec4a9b9cd0cb70b5914d8f","type":"TRIAL","name":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07051785","description":"Colorectal Cancer (CRC)","metadata":null},{"id":"a62a3217b6e54431bb1fcdb4835c3152","type":"GO_TERM","name":"FtsBL complex","canonical_id":"go:GO:1990588","description":"\"A protein complex required for prokaryotic cell division (FtsZ-dependent cytokinesis). Part of the divisome. Assembled independently of the other divisome components in the cytoplasm prior to transport to the cell septum. In E. coli consists of FtsB and FtsL.\" [GOC:bhm, PMID:15165235, PMID:21784946]","metadata":null},{"id":"dc43533674ae46dea57ad3d43102e612","type":"GO_TERM","name":"FtsQBL complex","canonical_id":"go:GO:1990587","description":"\"A protein complex required for prokaryotic cell division (FtsZ-dependent cytokinesis). Part of the divisome. Assembled independently of the other divisome components in the cytoplasm prior to transport to the cell septum. In E. coli consists of FtsB, FtsL and FtsQ.\" [GOC:bhm, PMID:15165235, PMID:21784946]","metadata":null},{"id":"41e24b2520ac43968b9d22c2a4881a8b","type":"GO_TERM","name":"FtsZ-dependent cytokinesis","canonical_id":"go:GO:0043093","description":"\"A cytokinesis process that involves a set of conserved proteins including FtsZ, and results in the formation of two similarly sized and shaped cells.\" [GOC:mah, ISBN:0815108893, PMID:12626683]","metadata":null},{"id":"bdaf5ccc535040eea4767f257093a3ad","type":"TRIAL","name":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT05582499","description":"Breast Neoplasm; Breast Cancer; Breast Tumors; Triple-Negative Breast Cancer (TNBC); HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer","metadata":null},{"id":"6c7608036bfb48d1ae1484013480301e","type":"TRIAL","name":"Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","canonical_id":"clinicaltrials.gov:NCT04394377","description":"Coronavirus Infection","metadata":null},{"id":"8a0da9f058a7468dac2bf7b1d2bd1867","type":"TRIAL","name":"Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)","canonical_id":"clinicaltrials.gov:NCT02181985","description":"Myocardial Infarction","metadata":null},{"id":"66b12a8b048847dc80f0c8a3699878cb","type":"TRIAL","name":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","canonical_id":"clinicaltrials.gov:NCT06985485","description":"Acute Lymphoblastic Leukemia; Immunotherapy; Blinatumomab; Inotuzumab Ozogamicin","metadata":null},{"id":"f97b05ffe5114812bcfea6b566cf2d43","type":"DRUG","name":"Fulvestrant","canonical_id":"ncit:C1379","description":null,"metadata":null},{"id":"b0dd7274a6574bcebc3a76723f929eb5","type":"TRIAL","name":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01992952","description":"Estrogen Receptor Positive Breast Cancer","metadata":null},{"id":"a7d4d03b7a4242e5a4c9bbe3adca7fe7","type":"TRIAL","name":"Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02530411","description":"Neoplasms","metadata":null},{"id":"5e26f4c966c04fb7affa25cc908c8883","type":"TRIAL","name":"Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01142401","description":"Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7","metadata":null},{"id":"ec568e6d99eb4e6a8a71bd0fc523603e","type":"TRIAL","name":"Fulvestrant in Treating Patients With Recurrent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00217464","description":"Prostate Cancer","metadata":null},{"id":"374cb2d9930043878ab32e5582ef4f16","type":"TRIAL","name":"Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response","canonical_id":"clinicaltrials.gov:NCT02495883","description":"Essential Tremor; Tremor","metadata":null},{"id":"18269bd8c3c6492a97a6c4ef5a92ce9d","type":"TRIAL","name":"Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT04512521","description":"Asthma; Eosinophilic","metadata":null},{"id":"8335372ab0dc400798c29fccb75a004d","type":"TRIAL","name":"Functional MRI (fMRI) in CGRP Induced Migraine","canonical_id":"clinicaltrials.gov:NCT00363532","description":"Migraine Without Aura","metadata":null},{"id":"edd8d36dbdbd4749a4ad196794460eff","type":"TRIAL","name":"Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT00609531","description":"Autism Spectrum Disorders","metadata":null},{"id":"a501358b970a4ee199832f7b19162789","type":"TRIAL","name":"Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients","canonical_id":"clinicaltrials.gov:NCT03722849","description":"Cough","metadata":null},{"id":"3662bf7159ca49a3922e462ca8a1fb7b","type":"TRIAL","name":"Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia","canonical_id":"clinicaltrials.gov:NCT00507546","description":"Insomnia; Spinal Cord Injury; Tetraplegia; Sleep Disorders","metadata":null},{"id":"e22eb22fb23b435fa9fd0cc5c6c2a881","type":"TRIAL","name":"Functional Respiratory Imaging Study (DARWiIN)","canonical_id":"clinicaltrials.gov:NCT04876677","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"6c01c8f1a8994aee8bd160128651c377","type":"TRIAL","name":"Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)","canonical_id":"clinicaltrials.gov:NCT03043924","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"9e9cd43a353843af816a4ab6b13fb47f","type":"DISEASE","name":"Fungal Infection","canonical_id":"mesh:D009181","description":null,"metadata":null},{"id":"f62c61c824964897a3b7373e838be6b7","type":"TRIAL","name":"Furosemide Stress Test to Predict Successful Liberation From RRT","canonical_id":"clinicaltrials.gov:NCT05612490","description":"Acute Kidney Injury","metadata":null},{"id":"515bcd08488a40b18f37f29a7bdfea09","type":"TRIAL","name":"Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts","canonical_id":"clinicaltrials.gov:NCT07307131","description":"Cutaneous Warts; Human Papilloma Virus (HPV)","metadata":null},{"id":"378e9d3b3098417e8e6a9911fab2c986","type":"DISEASE","name":"Furunculosis","canonical_id":"mesh:D005667","description":null,"metadata":null},{"id":"752951d2715a4f1fbdb85beeaf60e3e1","type":"DISEASE","name":"Fusariosis","canonical_id":"mesh:D060585","description":null,"metadata":null},{"id":"e127fdf7a31f4d00946cbae0b5005581","type":"GO_TERM","name":"Fused-Smurf ubiquitin ligase complex","canonical_id":"go:GO:1990353","description":"\"A ubiquitin ligase complex. In D. melanogaster, it regulates ubiquitination and proteolysis of the BMP receptor Thickveins in cystoblasts, potentially by controlling Tkv ubiquitination and degradation.\" [GOC:bhm, PMID:21145463]","metadata":null},{"id":"02b2188decc641e0a9add7cdf916e4af","type":"PROTEIN","name":"Fusion Proteins, bcr-abl","canonical_id":"uniprot:D016044","description":null,"metadata":null},{"id":"1b041f764d5f45b0b737b0b8d832d233","type":"PROTEIN","name":"Fusion glycoprotein F0","canonical_id":"uniprot:P13843","description":null,"metadata":null},{"id":"afe75e0249c249448b977386bd741d21","type":"TRIAL","name":"Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07594548","description":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Esophageal Adenocarcinoma; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophagea\u2026","metadata":null},{"id":"e6610173f3b047e5ac3d35fbd2a7fe66","type":"GO_TERM","name":"G protein activity","canonical_id":"go:GO:0003925","description":"\"A molecular function regulator that cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular processes. Intrinsic GTPase activity returns the G protein to its GDP-bound state. The return to the GDP-bound state can be accelerated by the action of a GTPase-activating protein (GAP).\" [PMID:16923326, PMID:24470015]","metadata":null},{"id":"1e703c5ff9f34a87ab83c230ba8a2043","type":"GO_TERM","name":"G protein-coupled ADP receptor activity","canonical_id":"go:GO:0001621","description":"\"Combining with ADP and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:mah, GOC:signaling, PMID:11196645]","metadata":null},{"id":"7e97161a8fcb44b39dd56800d42ec44d","type":"GO_TERM","name":"G protein-coupled ATP receptor activity","canonical_id":"go:GO:0045031","description":"\"Combining with ATP and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:mah]","metadata":null},{"id":"e53eff8748f94add9c2ceb5dd7da15be","type":"GO_TERM","name":"G protein-coupled GABA receptor activity","canonical_id":"go:GO:0004965","description":"\"Combining with the amino acid gamma-aminobutyric acid (GABA, 4-aminobutyrate) and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:ai, GOC:bf, IUPHAR_RECEPTOR:1276, Wikipedia:GABAB_receptor]","metadata":null},{"id":"71e5242274f44f4790f4d39d3f32835c","type":"GO_TERM","name":"G protein-coupled GABA receptor binding","canonical_id":"go:GO:0031795","description":"\"Binding to a G protein-coupled (metabotropic) GABA receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"418710f529bb4a9eac1246c5b4cf165d","type":"GO_TERM","name":"G protein-coupled GABA receptor complex","canonical_id":"go:GO:1902712","description":"\"A protein complex which is capable of G protein-coupled GABA receptor activity. In human, it is usually a heterodimer composed of GABA-B receptor subunits 1 and 2.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:18790874]","metadata":null},{"id":"e4ce8c20b6344be08c40c8140a270c59","type":"GO_TERM","name":"G protein-coupled UDP receptor activity","canonical_id":"go:GO:0045029","description":"\"Combining with a nucleotide and transmitting the signal to a heterotrimeric G-protein complex to initiate a change in cell activity, activated by UDP.\" [GOC:mah]","metadata":null},{"id":"72b5921a5bfa4314932ddb7a349b82cd","type":"GO_TERM","name":"G protein-coupled UTP receptor activity","canonical_id":"go:GO:0045030","description":"\"Combining with a nucleotide and transmitting the signal to a heterotrimeric G-protein complex to initiate a change in cell activity, activated by UTP.\" [GOC:mah]","metadata":null},{"id":"aa3925baa8dc4223977dfe9123d69eba","type":"GO_TERM","name":"G protein-coupled acetylcholine receptor activity","canonical_id":"go:GO:0016907","description":"\"Combining with acetylcholine and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:fj, GOC:mah]","metadata":null},{"id":"0e261dbd524941039a27ef3d7bdf0a10","type":"GO_TERM","name":"G protein-coupled acetylcholine receptor binding","canonical_id":"go:GO:0031789","description":"\"Binding to a G protein-coupled acetylcholine receptor.\" [GOC:bf, GOC:mah, GOC:nln]","metadata":null},{"id":"94473b5387c0414892c43726a2c5ee1a","type":"GO_TERM","name":"G protein-coupled acetylcholine receptor signaling pathway","canonical_id":"go:GO:0007213","description":"\"A G protein-coupled receptor signaling pathway initiated by a ligand binding to an acetylcholine receptor on the surface of a target cell, and ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"069e445a34124b959ef8110e9a638c2c","type":"GO_TERM","name":"G protein-coupled adenosine receptor activity","canonical_id":"go:GO:0001609","description":"\"Combining with adenosine and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:mah, PMID:9755289]","metadata":null},{"id":"50346663cc0d4c2fa31ba103f58e143a","type":"GO_TERM","name":"G protein-coupled adenosine receptor signaling pathway","canonical_id":"go:GO:0001973","description":"\"The series of molecular signals generated as a consequence of a receptor binding to extracellular adenosine and transmitting the signal to a heterotrimeric G-protein complex to initiate a change in cell activity.\" [GOC:dph]","metadata":null},{"id":"553d2cf066044fffbcf6dadfb5050ac8","type":"GO_TERM","name":"G protein-coupled amine receptor activity","canonical_id":"go:GO:0008227","description":"\"Combining with an extracellular amine and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:dph]","metadata":null},{"id":"a31f4f17f14342b3b2e6b710105059ea","type":"GO_TERM","name":"G protein-coupled bile acid receptor activity","canonical_id":"go:GO:0038182","description":"\"Combining with an extracellular bile acid and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [PMID:12524422, PMID:32480317, PMID:35415765, PMID:36409000]","metadata":null},{"id":"74ac6bbccd084ac78c85f671896f2a59","type":"GO_TERM","name":"G protein-coupled chemoattractant receptor activity","canonical_id":"go:GO:0001637","description":"\"Combining with a chemoattractant and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:mah]","metadata":null},{"id":"22b745f6fa884a6babae89c202294d7b","type":"GO_TERM","name":"G protein-coupled chemorepellent receptor activity","canonical_id":"go:GO:0140985","description":"\"Combining with a chemorepellent and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [PMID:30462573]","metadata":null},{"id":"4599980ae0c2424b8cd1951f1f925413","type":"GO_TERM","name":"G protein-coupled chemorepellent receptor signaling pathway","canonical_id":"go:GO:0140986","description":"\"A G protein-coupled receptor signaling pathway initiated by a chemorepellent binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. cytoskeleton reorganization.\" [PMID:30462573]","metadata":null},{"id":"1b6ef89c89a841aaa28e26b0d148579f","type":"GO_TERM","name":"G protein-coupled cytokinin receptor activity","canonical_id":"go:GO:0001647","description":"\"Combining with cytokinin and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:dph]","metadata":null},{"id":"d6bb17b8a8a84953a58a70b3c822218b","type":"GO_TERM","name":"G protein-coupled dopamine receptor signaling pathway","canonical_id":"go:GO:0007212","description":"\"A G protein-coupled receptor signaling pathway initiated by a dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [PMID:36757901]","metadata":null},{"id":"4baa7f07c1e14d9d824c562bce985a19","type":"GO_TERM","name":"G protein-coupled enkephalin receptor activity","canonical_id":"go:GO:0038046","description":"\"Combining with an enkephalin, and transmitting the signal across the membrane by activating an associated G-protein. A enkephalin is a pentapeptide (Tyr-Gly-Gly-Phe-Met or Tyr-Gly-Gly-Phe-Leu) involved in regulating nociception in the body.\" [GOC:bf, Wikipedia:Enkephalin]","metadata":null},{"id":"a023bbd507fa4b538809f2ad2eaa6ba2","type":"GO_TERM","name":"G protein-coupled estrogen receptor activity","canonical_id":"go:GO:0038054","description":"\"Combining with estrogen and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:signaling, PMID:17379646, PMID:20960099]","metadata":null},{"id":"31be0a9df196431091a26540d2121112","type":"GO_TERM","name":"G protein-coupled folate receptor activity","canonical_id":"go:GO:0106063","description":"\"Combining with folate and transmitting the signal from one side of the membrane to the other by activating an associated G-protein, initiating a change in cell activity.\" [PMID:26906738]","metadata":null},{"id":"f2a5dd05e4ad4ba3864fd9b1f0b00ccf","type":"GO_TERM","name":"G protein-coupled glucose receptor activity","canonical_id":"go:GO:1990576","description":"\"Combining with an extracellular glucose molecule and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [PMID:15667320]","metadata":null},{"id":"8e21fe22ef974b268aaa0e532cf580fd","type":"GO_TERM","name":"G protein-coupled glutamate receptor activity","canonical_id":"go:GO:0098988","description":"\"Combining with glutamate and transmitting a signal from one side of the membrane to the other by activating an associated G-protein, initiating a change in cell activity.\" [GOC:dos]","metadata":null},{"id":"247ddd8864d84128863ab9d7d806c0c3","type":"GO_TERM","name":"G protein-coupled glutamate receptor binding","canonical_id":"go:GO:0035256","description":"\"Binding to a G protein-coupled glutamate receptor (a metabotropic glutamate receptor).\" [GOC:bf, ISBN:0198506732, PMID:9069287]","metadata":null},{"id":"99d77f97ad844428ba9b02f9f523f5e1","type":"GO_TERM","name":"G protein-coupled glutamate receptor signaling pathway","canonical_id":"go:GO:0007216","description":"\"A G protein-coupled receptor signaling pathway initiated by glutamate binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:mah, GOC:signaling, PMID:9131252]","metadata":null},{"id":"0103c8b4aa7e4004969800c61f334b9d","type":"GO_TERM","name":"G protein-coupled glycine receptor activity","canonical_id":"go:GO:0160079","description":"\"Combining with glycine and transmitting the signal across the membrane by changing the activity of intracellular G protein signaling.\" [PMID:36996198]","metadata":null},{"id":"89b47465ee3a451ca7918d50f9f7012d","type":"GO_TERM","name":"G protein-coupled histamine receptor binding","canonical_id":"go:GO:0031806","description":"\"Binding to a G protein-coupled (metabotropic) histamine receptor.\" [GOC:mah, GOC:nln, PMID:12679144]","metadata":null},{"id":"1c7bd7062ed84e5284645bed381767fd","type":"GO_TERM","name":"G protein-coupled neurotensin receptor activity","canonical_id":"go:GO:0016492","description":"\"Combining with the tridecapeptide neurotensin to initiate a G-protein mediated change in cell activity. A G-protein is a signal transduction molecule that alternates between an inactive GDP-bound and an active GTP-bound state.\" [PMID:10390649]","metadata":null},{"id":"968d08d7899a4ade9ebb283c7af51cbd","type":"GO_TERM","name":"G protein-coupled neurotransmitter receptor activity","canonical_id":"go:GO:0099528","description":"\"Combining with a neurotransmitter and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:fj, GOC:mah]","metadata":null},{"id":"19e6446b972342b68752edb7784a62a4","type":"GO_TERM","name":"G protein-coupled nucleotide receptor activity","canonical_id":"go:GO:0001608","description":"\"Combining with a nucleotide and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:dph, IUPHAR_GPCR:1294]","metadata":null},{"id":"6a511600b9e144e9bfa8355847b4a99f","type":"GO_TERM","name":"G protein-coupled nucleotide receptor binding","canonical_id":"go:GO:0031811","description":"\"Binding to a G protein-coupled (metabotropic) nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"17943dc25e6d49b68ef009058a6d4908","type":"GO_TERM","name":"G protein-coupled olfactory receptor activity","canonical_id":"go:GO:0038022","description":"\"Combining with an odorant and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:sart, PMID:21041441]","metadata":null},{"id":"1c407ec170d2499a865ae95dd73ed1ca","type":"GO_TERM","name":"G protein-coupled opioid receptor activity","canonical_id":"go:GO:0004985","description":"\"Combining with an opioid (any narcotic derived from or resembling opium), and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:ai, GOC:bf, PMID:20494127]","metadata":null},{"id":"bceec240d4eb4e3eb47db4dde70b1dce","type":"GO_TERM","name":"G protein-coupled opioid receptor signaling pathway","canonical_id":"go:GO:0038003","description":"\"A G protein-coupled receptor signaling pathway initiated by an opioid binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:bf, PMID:20494127]","metadata":null},{"id":"45dc6fe25d874d12ad159a6cd054a6af","type":"GO_TERM","name":"G protein-coupled opsin signaling pathway","canonical_id":"go:GO:0016056","description":"\"A G protein-coupled receptor signaling pathway that starts with an opsin being activated by a photon, and ending with the light signal being trasmitted through the synapses. The signal can be transmitted via different Galpha subunits types: Go, Gs, Gq, and Gt.\" [GOC:bf, GOC:dph, GOC:hb, GOC:signaling, GOC:tb, PMID:19720651, PMID:36272560]","metadata":null},{"id":"cdebc7f2a4ca4d79b71d10cecd7c79fa","type":"GO_TERM","name":"G protein-coupled peptide receptor activity","canonical_id":"go:GO:0008528","description":"\"Combining with a peptide and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4285fc0ae3c44ae792baadb6eef7cce6","type":"GO_TERM","name":"G protein-coupled photoreceptor activity","canonical_id":"go:GO:0008020","description":"\"Combining with incidental electromagnetic radiation, particularly visible light, and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:dph, ISBN:0198506732]","metadata":null},{"id":"ab7bf1602e874be0a122cd3cd60eef5e","type":"GO_TERM","name":"G protein-coupled purinergic nucleotide receptor activity","canonical_id":"go:GO:0045028","description":"\"Combining with a purine nucleotide and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:mah, PMID:9755289]","metadata":null},{"id":"7f3c159386134f109f828d5c1a30acdb","type":"GO_TERM","name":"G protein-coupled purinergic nucleotide receptor signaling pathway","canonical_id":"go:GO:0035589","description":"\"A G protein-coupled receptor signaling pathway initiated by an extracellular purine nucleotide binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:BHF, PMID:9755289]","metadata":null},{"id":"e35443eeeac4480a885a206836a28b66","type":"GO_TERM","name":"G protein-coupled purinergic receptor signaling pathway","canonical_id":"go:GO:0035588","description":"\"A G protein-coupled receptor signaling pathway initiated by an extracellular purine or purine derivative binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:BHF, PMID:9755289]","metadata":null},{"id":"f7dfff20ca4842829de7c70860042f6a","type":"GO_TERM","name":"G protein-coupled pyrimidinergic nucleotide receptor activity","canonical_id":"go:GO:0071553","description":"\"Combining with a pyrimidine nucleotide and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:sl, PMID:10736418, PMID:12369950, PMID:15796906]","metadata":null},{"id":"0db43ed06a514b7cbd2ff01ff9b34cf2","type":"GO_TERM","name":"G protein-coupled receptor activity","canonical_id":"go:GO:0004930","description":"\"Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, Wikipedia:GPCR]","metadata":null},{"id":"8ccdaa68fbda40c5929b4d3417d3d7eb","type":"GO_TERM","name":"G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential","canonical_id":"go:GO:0099530","description":"\"A G protein-coupled receptor activity occurring in the postsynaptic membrane that is part of a GPCR signaling pathway that positively regulates ion channel activity in the postsynaptic membrane.\" [GOC:dos]","metadata":null},{"id":"08e5c47d52274ab788713bcec9a3a8b1","type":"GO_TERM","name":"G protein-coupled receptor binding","canonical_id":"go:GO:0001664","description":"\"Binding to a G protein-coupled receptor.\" [GOC:ceb, GOC:dph]","metadata":null},{"id":"c57fb858a00041d6a47142463c10f570","type":"GO_TERM","name":"G protein-coupled receptor catabolic process","canonical_id":"go:GO:1990172","description":"\"The chemical reactions and pathways resulting in the breakdown of a G protein-coupled receptor.\" [PMID:12142540, PMID:23954414]","metadata":null},{"id":"facde07cc4d644a180a28bd925d87297","type":"GO_TERM","name":"G protein-coupled receptor complex","canonical_id":"go:GO:0097648","description":"\"A protein complex that contains G protein-coupled receptors.\" [GOC:bhm]","metadata":null},{"id":"0428619b7f034088a664f4ec1c2c5ffa","type":"GO_TERM","name":"G protein-coupled receptor dimeric complex","canonical_id":"go:GO:0038037","description":"\"A protein complex that contains two G protein-coupled receptors.\" [GOC:al, GOC:bf, PMID:10713101]","metadata":null},{"id":"c991badd6ced4447a760c22dc05ed210","type":"GO_TERM","name":"G protein-coupled receptor heterodimeric complex","canonical_id":"go:GO:0038039","description":"\"A protein complex that contains two G protein-coupled receptors (GPCRs) of different subtypes. Formation of a GPCR heterodimer may alter the functional property of the GPCR.\" [GOC:al, GOC:bf, PMID:16109836, PMID:20150590]","metadata":null},{"id":"0995064610d3462fad9214dd6ddb14c3","type":"GO_TERM","name":"G protein-coupled receptor homodimeric complex","canonical_id":"go:GO:0038038","description":"\"A protein complex that contains two G protein-coupled receptors (GPCRs) of the same subtype. Formation of a GPCR homodimer may be important for the transport of newly formed receptors to the cell surface, and the function of the receptor.\" [GOC:al, GOC:bf, PMID:10713101, PMID:16670762]","metadata":null},{"id":"d220150c33f3421cacf4fe6af9586603","type":"GO_TERM","name":"G protein-coupled receptor internalization","canonical_id":"go:GO:0002031","description":"\"The process that results in the uptake of a G protein-coupled receptor into an endocytic vesicle.\" [PMID:8396717]","metadata":null},{"id":"3ff75e7dd1374bb780b281fb5ac522a6","type":"GO_TERM","name":"G protein-coupled receptor kinase activity","canonical_id":"go:GO:0004703","description":"\"Catalysis of the reaction: ATP + G protein-coupled receptor = ADP + G protein-coupled receptor phosphate.\" [GOC:dph]","metadata":null},{"id":"b00a38e866ba4c0f973a7d5f829532dd","type":"GO_TERM","name":"G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0007186","description":"\"The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane.\" [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor]","metadata":null},{"id":"fb37d6e203f74bf1ab98de0a2700e24a","type":"GO_TERM","name":"G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger","canonical_id":"go:GO:0007199","description":"\"The series of molecular signals generated as a consequence of a G protein-coupled receptor binding to its physiological ligand, followed by activation of guanylyl cyclase (GC) activity and a subsequent increase in the concentration of cyclic GMP (cGMP).\" [GOC:mah, GOC:signaling, ISBN:0815316194]","metadata":null},{"id":"53bc17b8769e478aa39a5a59fa24b17f","type":"GO_TERM","name":"G protein-coupled receptor signaling pathway involved in heart process","canonical_id":"go:GO:0086103","description":"\"An G protein-coupled receptor signaling pathway which contributes to a circulatory system process carried out by the heart.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, PMID:17376402]","metadata":null},{"id":"2f3bcacf754f438da74cffd3936a3b31","type":"GO_TERM","name":"G protein-coupled receptor signaling pathway involved in social behavior","canonical_id":"go:GO:1904068","description":"\"Any G protein-coupled receptor signaling pathway that is involved in social behavior.\" [GO_REF:0000060, GOC:kmv, GOC:TermGenie, PMID:22665789]","metadata":null},{"id":"fa37d28f625a4edf82ef04322b723d13","type":"GO_TERM","name":"G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger","canonical_id":"go:GO:0007187","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation or inhibition of a nucleotide cyclase activity and a subsequent change in the concentration of a cyclic nucleotide.\" [GOC:mah, GOC:signaling, ISBN:0815316194]","metadata":null},{"id":"8aaa588d3d284446b25d4ff53805a747","type":"GO_TERM","name":"G protein-coupled serotonin receptor activity","canonical_id":"go:GO:0004993","description":"\"Combining with the biogenic amine serotonin and transmitting the signal across the membrane by activating an associated G-protein. Serotonin (5-hydroxytryptamine) is a neurotransmitter and hormone found in vertebrates and invertebrates.\" [GOC:ai]","metadata":null},{"id":"9424efb0d78a4f8ea6bb493cb2d4a97a","type":"GO_TERM","name":"G protein-coupled serotonin receptor binding","canonical_id":"go:GO:0031821","description":"\"Binding to a metabotropic serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"8525bb926cb242b9a8d9569f9ce3015b","type":"GO_TERM","name":"G protein-coupled serotonin receptor complex","canonical_id":"go:GO:0098666","description":"\"A protein complex that is capable of G protein-coupled serotonin receptor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie]","metadata":null},{"id":"0a50c8d8191443d08d6210cce8da4717","type":"GO_TERM","name":"G protein-coupled serotonin receptor signaling pathway","canonical_id":"go:GO:0098664","description":"\"The series of molecular signals generated as a consequence of a G protein-coupled serotonin receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"ad2d3eb0a2da415f8fbf81366d58079b","type":"TRIAL","name":"G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00554463","description":"Lung Cancer","metadata":null},{"id":"34945f9923c14b139d601024e5293f32","type":"TRIAL","name":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00541125","description":"Colorectal Cancer","metadata":null},{"id":"3267eb37d6a640418739397ed26e12fb","type":"TRIAL","name":"G-CSF-Related Bone Pain and Supportive Care Strategies in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07192770","description":"Solid Tumors; Chemotherapy-induced Neutropenia","metadata":null},{"id":"f5be3c0e35e54671a018ba7f7a74916b","type":"TRIAL","name":"G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07184788","description":"Aggressive B-Cell Lymphoma","metadata":null},{"id":"c29af921660d4ee7be57807da853b20b","type":"GO_TERM","name":"G-protein activated inward rectifier potassium channel activity","canonical_id":"go:GO:0015467","description":"\"Enables the transmembrane transfer of a potassium ion by an inwardly-rectifying voltage-gated channel, where the inward rectification is due to a voltage-dependent block of the channel pore by a G protein. An inwardly rectifying current-voltage relation is one where at any given driving force the inward flow of K+ ions exceeds the outward flow for the opposite driving force.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"18e6d80b06a5440d9208cfbed6f823b1","type":"GO_TERM","name":"G-protein alpha(13)-synembrin complex","canonical_id":"go:GO:0071155","description":"\"A protein complex formed by the association of the guanine nucleotide exchange factor synembrin with the alpha(13) subunit of a heterotrimeric G protein.\" [GOC:mah, PMID:12509430]","metadata":null},{"id":"884a3b91d78349ce926ccd7db0f3edd5","type":"GO_TERM","name":"G-protein alpha(i)1-synembrin complex","canonical_id":"go:GO:0071154","description":"\"A protein complex formed by the association of the guanine nucleotide exchange factor synembrin with the alpha(i)1 subunit of a heterotrimeric G protein.\" [GOC:mah, PMID:12509430]","metadata":null},{"id":"9fd70ba3bdab4c27a7ea244b4b06f412","type":"GO_TERM","name":"G-protein alpha(o)-synembrin complex","canonical_id":"go:GO:0071153","description":"\"A protein complex formed by the association of the guanine nucleotide exchange factor synembrin with the alpha(o) subunit of a heterotrimeric G protein.\" [GOC:mah, PMID:12509430]","metadata":null},{"id":"ccaee1cdc5a7457b981e060c902ffb3d","type":"GO_TERM","name":"G-protein alpha(q)-synembrin complex","canonical_id":"go:GO:0071152","description":"\"A protein complex formed by the association of the guanine nucleotide exchange factor synembrin with the alpha(q) subunit of a heterotrimeric G protein.\" [GOC:mah, PMID:12509430]","metadata":null},{"id":"558d1697f9b541729b42e840b6b8dc33","type":"GO_TERM","name":"G-protein alpha-subunit binding","canonical_id":"go:GO:0001965","description":"\"Binding to a G-protein alpha subunit. The alpha subunit binds a guanine nucleotide.\" [GOC:hjd]","metadata":null},{"id":"d63a91e8a58e44b891eb3989e244ef82","type":"GO_TERM","name":"G-protein beta-subunit binding","canonical_id":"go:GO:0031681","description":"\"Binding to a G-protein beta subunit.\" [GOC:mah]","metadata":null},{"id":"cf8e13fdf46a43afab1f0e417a6ab8c4","type":"GO_TERM","name":"G-protein beta/gamma-Btk complex","canonical_id":"go:GO:0070441","description":"\"A protein complex formed by the association of the Bruton tyrosine protein kinase Btk, which is implicated in mammalian X-linked immunodeficiencies, with the beta and gamma subunits of a heterotrimeric G protein.\" [GOC:mah, PMID:7972043]","metadata":null},{"id":"cf69efcf281d4b8c9bf92f48b98b16ce","type":"GO_TERM","name":"G-protein beta/gamma-Raf-1 complex","canonical_id":"go:GO:0070422","description":"\"A protein complex formed by the association of the serine-threonine protein kinase Raf-1 with the beta and gamma subunits of a heterotrimeric G protein.\" [GOC:mah, PMID:7782277]","metadata":null},{"id":"8f39f18e7f594a40ab79533aaa4231a5","type":"GO_TERM","name":"G-protein beta/gamma-subunit complex","canonical_id":"go:GO:0031680","description":"\"The heterodimer formed by the beta and gamma subunits of a heterotrimeric G protein, which dissociates from the alpha subunit upon guanine nuclotide exchange.\" [GOC:mah]","metadata":null},{"id":"f2c227c7671d4276ad6ecf6503150ac1","type":"GO_TERM","name":"G-protein beta/gamma-subunit complex binding","canonical_id":"go:GO:0031683","description":"\"Binding to a complex of G-protein beta/gamma subunits.\" [GOC:nln, GOC:vw]","metadata":null},{"id":"ebeea83fd6474800be11cc82c9330b10","type":"GO_TERM","name":"G-protein gamma-subunit binding","canonical_id":"go:GO:0031682","description":"\"Binding to a G-protein gamma subunit.\" [GOC:mah]","metadata":null},{"id":"7203d6434086432aa3f313a3d62405c4","type":"GO_TERM","name":"G-protein gated monoatomic cation channel activity","canonical_id":"go:GO:0099100","description":"\"A cation channel activity that is gated by binding of a G-protein beta-gamma dimer.\" [GOC:dos]","metadata":null},{"id":"35d42d421c89448199e60801f83f2dd9","type":"GO_TERM","name":"G-protein gated monoatomic ion channel activity","canonical_id":"go:GO:0099099","description":"\"An ion channel activity that is gated by binding of a G-protein beta-gamma dimer.\" [GOC:dos, PMID:35704701, Wikipedia:G_protein-gated_ion_channel]","metadata":null},{"id":"406573012d784124a543a2180d55d7d8","type":"GO_TERM","name":"G-protein gated potassium channel activity","canonical_id":"go:GO:0099101","description":"\"A potassium channel activity that is gated by binding of a G-protein beta-gamma dimer.\" [GOC:dos, PMID:9429760]","metadata":null},{"id":"e990d936699a4d78b7ecccdd6c011955","type":"GO_TERM","name":"G-quadruplex DNA binding","canonical_id":"go:GO:0051880","description":"\"Binding to G-quadruplex DNA structures, in which groups of four guanines adopt a flat, cyclic Hoogsteen hydrogen-bonding arrangement known as a guanine tetrad. The stacking of guanine tetrads results in G-quadruplex DNA structures. G-quadruplex DNA can form under physiological conditions from some G-rich sequences, such as those found in telomeres, immunoglobulin switch regions, gene promoters, fragile X repeats, and the dimerization domain in the human immunodeficiency virus (HIV) genome.\" [PMID:16142245, PMID:9512530]","metadata":null},{"id":"c91a75b4842e481488dad68a1d8a2df4","type":"GO_TERM","name":"G-quadruplex DNA formation","canonical_id":"go:GO:0071919","description":"\"A DNA metabolic process that results in the formation of G-quadruplex DNA structures, in which groups of four guanines adopt a flat, cyclic Hoogsteen hydrogen-bonding arrangement known as a guanine tetrad or G-quartet. The stacking of several layers of G-quartets forms G-quadruplexes, in which one or more DNA single strands are assembled in parallel and/or antiparallel, with interactions that can be either intra- or intermolecular in nature.\" [GOC:sre, PMID:20098422]","metadata":null},{"id":"c7498d0f90d04b4086c8fb548e485c60","type":"GO_TERM","name":"G-quadruplex RNA binding","canonical_id":"go:GO:0002151","description":"\"Binding to a G-quadruplex RNA structure, in which groups of four guanines adopt a flat, cyclic hydrogen-bonding arrangement known as a guanine tetrad.\" [PMID:18294969, PMID:18568163, PMID:19330720]","metadata":null},{"id":"1b9e863267654153a5ef016cbaa7d1c0","type":"GO_TERM","name":"G-quadruplex unwinding activity","canonical_id":"go:GO:0160225","description":"\"Unwinding G-quadruplex structures in nucleic acids. A G-quadruplex is a specialized structure formed in DNA/RNA when sequences rich in guanine (G) assemble into a unique four-stranded arrangement.\" [PMID:1324186, PMID:26883636, PMID:34113828]","metadata":null},{"id":"10ac4211db15419c960c014c4b2dace5","type":"GO_TERM","name":"G-rich single-stranded DNA binding","canonical_id":"go:GO:1990955","description":"\"Binding to G-rich, single-stranded DNA.\" [GOC:hjd, PMID:8493094]","metadata":null},{"id":"29416f0aab7347c99b564102e9f451df","type":"GO_TERM","name":"G-rich strand telomeric DNA binding","canonical_id":"go:GO:0098505","description":"\"Binding to G-rich, single-stranded, telomere-associated DNA.\" [PMID:11349150]","metadata":null},{"id":"17acc80db50c47d9ab24ebd563830947","type":"GO_TERM","name":"G/T mismatch-specific thymine-DNA glycosylase activity","canonical_id":"go:GO:0141016","description":"\"Hydrolyzes mismatched double-stranded DNA and polynucleotides, releasing free thymine and leaving an apyrimidinic (AP) site.\" [EC:3.2.2.29, PMID:12711670]","metadata":null},{"id":"d5a95ea67e5f4397b10b5ca7997414b1","type":"GO_TERM","name":"G/U mismatch-specific uracil-DNA glycosylase activity","canonical_id":"go:GO:0043739","description":"\"Hydrolyzes mismatched double-stranded DNA and polynucleotides, releasing free uracil and leaving an apyrimidinic (AP) site.\" [EC:3.2.2.28, PMID:24739389]","metadata":null},{"id":"abcb52d572654353b8d5c5dd33e99b10","type":"GO_TERM","name":"G0 to G1 transition","canonical_id":"go:GO:0045023","description":"\"The mitotic cell cycle phase transition whose occurrence commits the cell from the G0 quiescent state to the G1 phase. Under certain conditions, cells exit the cell cycle during G1 and remain in the G0 state as nongrowing, non-dividing (quiescent) cells. Appropriate stimulation of such cells induces them to return to G1 and resume growth and division. The G0 to G1 transition is accompanied by many changes in the program of gene expression.\" [GOC:mtg_cell_cycle, ISBN:0716731363]","metadata":null},{"id":"be0cbd5d875a49bdb3942a106c913649","type":"GENE","name":"G0S2","canonical_id":"hgnc:HGNC:30229","description":null,"metadata":null},{"id":"7eb5ab106e8145c082121c99fdda7b82","type":"GO_TERM","name":"G1 phase","canonical_id":"go:GO:0051318","description":"\"The cell cycle 'gap' phase which is the interval between the completion of DNA segregation (usually by mitosis or meiosis) and the beginning of DNA synthesis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"fdb304a18860499c82dd307e49db84ea","type":"GO_TERM","name":"G1 to G0 transition","canonical_id":"go:GO:0070314","description":"\"A cell cycle arrest process that results in arrest during G1 phase, whereupon the cell enters a specialized resting state known as G0 or quiescence.\" [GOC:mah, GOC:mtg_cell_cycle, ISBN:0815316194]","metadata":null},{"id":"c3a08ef17b6146dfbbc6d04b7fd4f592","type":"GO_TERM","name":"G1 to G0 transition involved in cell differentiation","canonical_id":"go:GO:0070315","description":"\"A cell cycle arrest process that results in arrest during G1 phase, whereupon the cell enters G0 phase, in the context of cell differentiation.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"d0c97f783218487387b2a0d097d2dea2","type":"GO_TERM","name":"G1/S transition of mitotic cell cycle","canonical_id":"go:GO:0000082","description":"\"The mitotic cell cycle transition by which a cell in G1 commits to S phase. The process begins with the build up of G1 cyclin-dependent kinase (G1 CDK), resulting in the activation of transcription of G1 cyclins. The process ends with the positive feedback of the G1 cyclins on the G1 CDK which commits the cell to S phase, in which DNA replication is initiated.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"1718ec5750cc44689d5ff81ba761b4aa","type":"GO_TERM","name":"G2 phase","canonical_id":"go:GO:0051319","description":"\"The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation (usually by mitosis or meiosis).\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"51bcf91fd47c480197bf75af1207a7a2","type":"GO_TERM","name":"G2/M transition of mitotic cell cycle","canonical_id":"go:GO:0000086","description":"\"The mitotic cell cycle transition by which a cell in G2 commits to M phase. The process begins when the kinase activity of M cyclin/CDK complex reaches a threshold high enough for the cell cycle to proceed. This is accomplished by activating a positive feedback loop that results in the accumulation of unphosphorylated and active M cyclin/CDK complex.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"252d829045da493486868cc425836c71","type":"GO_TERM","name":"G2/MI transition of meiotic cell cycle","canonical_id":"go:GO:0008315","description":"\"The cell cycle process in which a cell progresses from meiotic G2 phase to M phase of meiosis I.\" [PMID:15084480]","metadata":null},{"id":"44f9f225b84142778ac175c0e463de9c","type":"GENE","name":"G2E3","canonical_id":"hgnc:HGNC:20338","description":"G2/M-phase specific E3 ubiquitin protein ligase","metadata":{"aliases":["FLJ20333","PHF7B","KIAA1333"]}},{"id":"9477a0b8ec724f14adbd1f45230360dd","type":"GENE","name":"G2E3-AS1","canonical_id":"hgnc:HGNC:53463","description":"G2E3 antisense RNA 1","metadata":{"aliases":["CAT1647","lincPRKD"]}},{"id":"89e7c4de353e46039bb1d88efce22113","type":"GENE","name":"G2E3P1","canonical_id":"hgnc:HGNC:56525","description":"G2E3 pseudogene 1","metadata":null},{"id":"831c203f9e91400599ecc0862396500a","type":"GENE","name":"G3BP1","canonical_id":"hgnc:HGNC:30292","description":"G3BP stress granule assembly factor 1","metadata":{"aliases":["HDH-VIII","G3BP"]}},{"id":"cad4723cef9f4768b580347b02a11517","type":"GENE","name":"G3BP1P1","canonical_id":"hgnc:HGNC:54590","description":"G3BP1 pseudogene 1","metadata":null},{"id":"5b4c73a96d2043c38bf7a8c9910d14e6","type":"GENE","name":"G3BP2","canonical_id":"hgnc:HGNC:30291","description":"G3BP stress granule assembly factor 2","metadata":{"aliases":["KIAA0660"]}},{"id":"cc232894fb3b4a879cf385817e679255","type":"TRIAL","name":"G56W1 in Women With Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT03720886","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"79e4f5d27ad14ece9fa813f9f1b17c3c","type":"GENE","name":"G6PC","canonical_id":"hgnc:HGNC:4056","description":null,"metadata":null},{"id":"0b4fba5b782d498597c10e65d4b640e4","type":"GENE","name":"G6PC2","canonical_id":"hgnc:HGNC:28906","description":"glucose-6-phosphatase catalytic subunit 2","metadata":{"aliases":["IGRP"]}},{"id":"ec8db834661f437ab15bf99f2ad69ad9","type":"GENE","name":"G6PC3","canonical_id":"hgnc:HGNC:24861","description":"glucose-6-phosphatase catalytic subunit 3","metadata":{"aliases":["UGRP"]}},{"id":"dc829e7a14104d7a818366b4ebb4f1a2","type":"GENE","name":"G6PD","canonical_id":"hgnc:HGNC:4057","description":null,"metadata":null},{"id":"2d46fe9d21704d66be1bc5463dac54d7","type":"GENE","name":"G6PR","canonical_id":"hgnc:HGNC:4059","description":"glucose-6-phosphatase regulator","metadata":{"aliases":["GSD1aSP"]}},{"id":"0139fe89c4fe42a7a4c674db6d2c2346","type":"TRIAL","name":"GA YAZ ACNE in China Phase III","canonical_id":"clinicaltrials.gov:NCT00818519","description":"Acne Vulgaris","metadata":null},{"id":"81bdd38a03a745bc9c93a443238b0a4c","type":"GENE","name":"GAA","canonical_id":"hgnc:HGNC:4065","description":"alpha glucosidase","metadata":null},{"id":"ef53fee0516d4c3e8b34fa0a1ef68b93","type":"PROTEIN","name":"GAA","canonical_id":"uniprot:P10253","description":null,"metadata":null},{"id":"8e12ad9d37154c41847d49d1de2c579a","type":"GO_TERM","name":"GAA codon-amino acid adaptor activity","canonical_id":"go:GO:0033459","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GAA codon.\" [GOC:mah]","metadata":null},{"id":"9aa1f4df69ef4a30870b48ea0bf8f346","type":"GENE","name":"GAB1","canonical_id":"hgnc:HGNC:4066","description":"GRB2 associated binding protein 1","metadata":{"aliases":["DFNB26"]}},{"id":"5c878192b9114f57a494a3e6a8d2985f","type":"GENE","name":"GAB2","canonical_id":"hgnc:HGNC:14458","description":"GRB2 associated binding protein 2","metadata":{"aliases":["KIAA0571"]}},{"id":"ce045d383ade4a7ba42cd93d410bbad3","type":"GENE","name":"GAB3","canonical_id":"hgnc:HGNC:17515","description":"GRB2 associated binding protein 3","metadata":null},{"id":"fb7c76f3fb554dae8bd48681b9850ee7","type":"GENE","name":"GAB4","canonical_id":"hgnc:HGNC:18325","description":"GRB2 associated binding protein family member 4","metadata":null},{"id":"dfbb830df7284e5a939826c58f6916bd","type":"TRIAL","name":"GABA Antagonist to Improve Reversal of Anesthesia With High-density EEG Surveillance","canonical_id":"clinicaltrials.gov:NCT04329585","description":"Moderate Sedation; Colonoscopy","metadata":null},{"id":"ac1eba1ab8b1485893a217ce5426dc04","type":"DISEASE","name":"GABA aminotransaminase deficiency","canonical_id":"mondo:0013166","description":null,"metadata":null},{"id":"9bd8db17024d44368dbde87bf1e0ffb0","type":"GO_TERM","name":"GABA biosynthetic process","canonical_id":"go:GO:0009449","description":"\"The chemical reactions and pathways resulting in the formation of gamma-aminobutyric acid (GABA, 4-aminobutyrate), an amino acid which acts as a neurotransmitter in some organisms.\" [GOC:ai]","metadata":null},{"id":"ea1735f1dc5b422aa0d26b18c7b32f91","type":"GO_TERM","name":"GABA catabolic process","canonical_id":"go:GO:0009450","description":"\"The chemical reactions and pathways resulting in the breakdown of gamma-aminobutyric acid (GABA).\" [GOC:curators]","metadata":null},{"id":"fba055c32d814bcbba9ef62a7fdbc37d","type":"GO_TERM","name":"GABA receptor activity","canonical_id":"go:GO:0016917","description":"\"Combining with gamma-aminobutyric acid (GABA), and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. (GABA, 4-aminobutyrate) is an amino acid which acts as a neurotransmitter in some organisms.\" [GOC:jl, GOC:signaling, PMID:10637650]","metadata":null},{"id":"d7cd87a4621141008215d2719495292f","type":"GO_TERM","name":"GABA receptor binding","canonical_id":"go:GO:0050811","description":"\"Binding to a gamma-aminobutyric acid (GABA, 4-aminobutyrate) receptor.\" [GOC:ai]","metadata":null},{"id":"f7bf9093091d4397ad3d58dca609163d","type":"GO_TERM","name":"GABA receptor complex","canonical_id":"go:GO:1902710","description":"\"A protein complex which is capable of GABA receptor activity. Upon binding of gamma-aminobutyric acid (GABA) it transmits the signal from one side of the membrane to the other to initiate a change in cell activity. Major inhibitory receptor in vertebrate brain. Also found in other vertebrate tissues, invertebrates and possibly in plants. Effective benzodiazepine receptor.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:18790874]","metadata":null},{"id":"5a75dc58ac4040d5af356ef49ffeca7d","type":"GO_TERM","name":"GABA shunt","canonical_id":"go:GO:0006540","description":"\"The chemical reactions and pathways resulting in the formation of succinate from L-glutamate via gamma-aminobutyrate (GABA), bypassing two steps of the TCA cycle. It operates through the sequential conversion of glutamate to GABA by glutamate decarboxylase, transamination of GABA to succinic semialdehyde by GABA transaminase, and oxidation of succinic semialdehyde to succinate by succinate semialdehyde dehydrogenase.\" [PMID:39703920]","metadata":null},{"id":"1aa4dd54dbe14bdbb6270693188d3345","type":"GO_TERM","name":"GABA-A receptor activity","canonical_id":"go:GO:0004890","description":"\"Combining with the amino acid gamma-aminobutyric acid (GABA, 4-aminobutyrate) to initiate a change in cell activity. GABA-A receptors function as chloride channels.\" [PMID:8974333]","metadata":null},{"id":"3d39e6006df94d579fb399a9d97c43f7","type":"GO_TERM","name":"GABA-A receptor complex","canonical_id":"go:GO:1902711","description":"\"A protein complex which is capable of GABA-A receptor activity. In human, it is usually composed of either two alpha, two beta and one gamma chain of the GABA-A receptor subunits or 5 chains of the GABA-A receptor subunits rho1-3 (formally known as GABA-C receptor).\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:18790874]","metadata":null},{"id":"691d1d6b4b6347d3b55b2377294cc4dd","type":"GO_TERM","name":"GABA-ergic synapse","canonical_id":"go:GO:0098982","description":"\"A synapse that uses GABA as a neurotransmitter. These synapses are typically inhibitory.\" [GOC:dos]","metadata":null},{"id":"900ea3b8361a4a46ac79ae9005520a16","type":"GO_TERM","name":"GABA-gated chloride ion channel activity","canonical_id":"go:GO:0022851","description":"\"Enables the transmembrane transfer of a chloride ion by a channel that opens when GABA has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"40ee49b6026a420faafe2e28b7e09cbf","type":"GENE","name":"GABARAP","canonical_id":"hgnc:HGNC:4067","description":"GABA type A receptor-associated protein","metadata":{"aliases":["MM46","ATG8A"]}},{"id":"adba4ca54e9c43159fcb2b3756f23db4","type":"GENE","name":"GABARAPL1","canonical_id":"hgnc:HGNC:4068","description":"GABA type A receptor associated protein like 1","metadata":{"aliases":["gec1","APG8L","ATG8L","ATG8B"]}},{"id":"6bc588c8b931488abb22bba1ace4ff07","type":"GENE","name":"GABARAPL1-AS1","canonical_id":"hgnc:HGNC:54822","description":"GABARAPL1 antisense RNA 1","metadata":null},{"id":"896bb15920804754975fb9edcc3e6fda","type":"GENE","name":"GABARAPL2","canonical_id":"hgnc:HGNC:13291","description":"GABA type A receptor associated protein like 2","metadata":{"aliases":["GEF2","ATG8","GATE16","GATE-16","ATG8C"]}},{"id":"aed676f04f504f6496c649f83d44ad27","type":"GENE","name":"GABARAPL3","canonical_id":"hgnc:HGNC:4069","description":"GABA type A receptor associated protein like 3 (pseudogene)","metadata":{"aliases":["ATG8D"]}},{"id":"2e99159972c8462590e6f0268daa29b0","type":"TRIAL","name":"GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation","canonical_id":"clinicaltrials.gov:NCT01291316","description":"Neuropathic Pain","metadata":null},{"id":"2ccc3d9193c4434489aabaa13eade4e8","type":"GO_TERM","name":"GABAergic neuron differentiation","canonical_id":"go:GO:0097154","description":"\"The process in which a neuroblast acquires the specialized structural and functional features of a GABAergic neuron.\" [GOC:kmv, PMID:11517269]","metadata":null},{"id":"e9fd1752b71049a0bfecbe70fbeb88cb","type":"GO_TERM","name":"GABAergic neuron differentiation in basal ganglia","canonical_id":"go:GO:0021858","description":"\"The process in which a neuroblast acquires the specialized structural and functional features of a GABAergic inhibitory neuron in the basal ganglia. Differentiation includes the processes involved in commitment of a neuroblast to a GABAergic neuron.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"ecd8b69b401746ed8fb15d4494feea29","type":"GENE","name":"GABBR1","canonical_id":"hgnc:HGNC:4070","description":"gamma-aminobutyric acid type B receptor subunit 1","metadata":{"aliases":["hGB1a","GPRC3A"]}},{"id":"2048d8e723244462b9918cb3d3c86818","type":"PROTEIN","name":"GABBR1","canonical_id":"uniprot:Q9UBS5","description":null,"metadata":null},{"id":"9ca30872930346e7aedad0a28772a16d","type":"GENE","name":"GABBR2","canonical_id":"hgnc:HGNC:4507","description":"gamma-aminobutyric acid type B receptor subunit 2","metadata":{"aliases":["HG20","GABABR2","GPRC3B","GPR51"]}},{"id":"b179f0f4ea7843bdb041d28f15e80bf4","type":"GENE","name":"GABPA","canonical_id":"hgnc:HGNC:4071","description":null,"metadata":null},{"id":"81d3637caea848969fb2d903100fef48","type":"GENE","name":"GABPAP1","canonical_id":"hgnc:HGNC:4072","description":"GABPA pseudogene 1","metadata":{"aliases":["E4TF1","E4TF1B","GABPB1","GABPAP"]}},{"id":"b8199166838d4da1961c21dd50e44c63","type":"GENE","name":"GABPB1","canonical_id":"hgnc:HGNC:4074","description":null,"metadata":null},{"id":"6fda2bc1d6fc4b7fa2eb40d4fe2e150e","type":"GENE","name":"GABPB1-AS1","canonical_id":"hgnc:HGNC:44157","description":"GABPB1 antisense RNA 1","metadata":null},{"id":"bdc0a8a001f949569a21cf9b053455a8","type":"GENE","name":"GABPB1-IT1","canonical_id":"hgnc:HGNC:25469","description":"GABPB1 intronic transcript","metadata":{"aliases":["FLJ10038"]}},{"id":"cb23387bfa794aacb52d252487ea460a","type":"GENE","name":"GABPB2","canonical_id":"hgnc:HGNC:28441","description":null,"metadata":null},{"id":"06c2103b71da4d9cb4d56d9406765fb3","type":"GENE","name":"GABRA1","canonical_id":"hgnc:HGNC:4075","description":"gamma-aminobutyric acid type A receptor subunit alpha1","metadata":{"aliases":["EJM5"]}},{"id":"49f58c73fc964d47a3cb96654d49e740","type":"PROTEIN","name":"GABRA1","canonical_id":"uniprot:P14867","description":null,"metadata":null},{"id":"40ae2b827929455b9a483a188ecf1e79","type":"GENE","name":"GABRA1-AS1","canonical_id":"hgnc:HGNC:59295","description":"GABRA1 antisense RNA 1","metadata":null},{"id":"15a6b183a21d45e69161c0084537df6f","type":"GENE","name":"GABRA2","canonical_id":"hgnc:HGNC:4076","description":"gamma-aminobutyric acid type A receptor subunit alpha2","metadata":null},{"id":"9d4304015d7d4027a451ee93d16dcf1c","type":"GENE","name":"GABRA2-AS1","canonical_id":"hgnc:HGNC:40247","description":"GABRA2 antisense RNA 1","metadata":null},{"id":"6acca7d350644e288eb69f5bcd3608eb","type":"GENE","name":"GABRA3","canonical_id":"hgnc:HGNC:4077","description":"gamma-aminobutyric acid type A receptor subunit alpha3","metadata":null},{"id":"78acade6a1ba48c5966188c27c01884e","type":"GENE","name":"GABRA3-AS1","canonical_id":"hgnc:HGNC:58378","description":"GABRA3 antisense RNA 1","metadata":null},{"id":"1b68bdb975324c52bda9ba82f77d7fda","type":"GENE","name":"GABRA4","canonical_id":"hgnc:HGNC:4078","description":"gamma-aminobutyric acid type A receptor subunit alpha4","metadata":null},{"id":"f7ee516f5f23406d976307ec334055b5","type":"GENE","name":"GABRA4-AS1","canonical_id":"hgnc:HGNC:58780","description":"GABRA4 and COX7B2 antisense RNA 1","metadata":null},{"id":"d8a9de2c628b41d386e5e7cba3ad5f62","type":"GENE","name":"GABRA5","canonical_id":"hgnc:HGNC:4079","description":"gamma-aminobutyric acid type A receptor subunit alpha5","metadata":null},{"id":"2d368002548f42ff8abecb5cd8a90da3","type":"GENE","name":"GABRA6","canonical_id":"hgnc:HGNC:4080","description":"gamma-aminobutyric acid type A receptor subunit alpha6","metadata":null},{"id":"374bce8b35e44dc692dd1c9a0a72c585","type":"GENE","name":"GABRA6-AS1","canonical_id":"hgnc:HGNC:40248","description":"GABRA6 antisense RNA 1","metadata":{"aliases":["ARBAG"]}},{"id":"780e8bc3905340d7b9d64d1bd280d44d","type":"GENE","name":"GABRB1","canonical_id":"hgnc:HGNC:4081","description":"gamma-aminobutyric acid type A receptor subunit beta1","metadata":null},{"id":"7701fe51d6704098808e691e07574ec7","type":"GENE","name":"GABRB2","canonical_id":"hgnc:HGNC:4082","description":"gamma-aminobutyric acid type A receptor subunit beta2","metadata":null},{"id":"c13291c19ac047c48d426373dc3f84a5","type":"GENE","name":"GABRB3","canonical_id":"hgnc:HGNC:4083","description":null,"metadata":null},{"id":"2d333741af9943ce96543dedc669ca6d","type":"GENE","name":"GABRD","canonical_id":"hgnc:HGNC:4084","description":"gamma-aminobutyric acid type A receptor subunit delta","metadata":{"aliases":["GABAARdelta"]}},{"id":"d2aa39c13ab84c5babd5038b4da025b9","type":"GENE","name":"GABRE","canonical_id":"hgnc:HGNC:4085","description":"gamma-aminobutyric acid type A receptor subunit epsilon","metadata":null},{"id":"0901cb15147b467296a74be6c83b77fa","type":"GENE","name":"GABRG1","canonical_id":"hgnc:HGNC:4086","description":"gamma-aminobutyric acid type A receptor subunit gamma1","metadata":null},{"id":"38c18730b3404709b423009e79ce8c33","type":"GENE","name":"GABRG2","canonical_id":"hgnc:HGNC:4087","description":"gamma-aminobutyric acid type A receptor subunit gamma2","metadata":null},{"id":"f0916102d42f4e4d9d093062c29726ec","type":"GENE","name":"GABRG3","canonical_id":"hgnc:HGNC:4088","description":"gamma-aminobutyric acid type A receptor subunit gamma3","metadata":null},{"id":"c0bd41f53c2047dcba4719e0fc71033d","type":"GENE","name":"GABRG3-AS1","canonical_id":"hgnc:HGNC:40249","description":"GABRG3 antisense RNA 1","metadata":null},{"id":"262ea60a17f64a9ba4541d6fc0df007e","type":"GENE","name":"GABRG3-AS2","canonical_id":"hgnc:HGNC:58464","description":"GABRG3 antisense RNA 2","metadata":null},{"id":"708c81658cbc4284bee7f873c984992f","type":"GENE","name":"GABRP","canonical_id":"hgnc:HGNC:4089","description":"gamma-aminobutyric acid type A receptor subunit pi","metadata":null},{"id":"b88a6640d7b640a799f89208a008d5f6","type":"GENE","name":"GABRP-AS1","canonical_id":"hgnc:HGNC:59302","description":"GABRP antisense RNA 1","metadata":null},{"id":"095526b5a8cd45df88279a417f2682dd","type":"GENE","name":"GABRQ","canonical_id":"hgnc:HGNC:14454","description":"gamma-aminobutyric acid type A receptor subunit theta","metadata":null},{"id":"a1f6164a95984c92b46133563ebd3522","type":"GENE","name":"GABRR1","canonical_id":"hgnc:HGNC:4090","description":"gamma-aminobutyric acid type A receptor subunit rho1","metadata":null},{"id":"652a6ef5a9a148c095af1b53fd9dfdd1","type":"GENE","name":"GABRR2","canonical_id":"hgnc:HGNC:4091","description":"gamma-aminobutyric acid type A receptor subunit rho2","metadata":null},{"id":"7d4ccd39c7524ceabc4fa9e5771b22b8","type":"GENE","name":"GABRR3","canonical_id":"hgnc:HGNC:17969","description":"gamma-aminobutyric acid type A receptor subunit rho3","metadata":null},{"id":"8721e625c0e9468cb6bd705df0d3d1f3","type":"GO_TERM","name":"GAC codon-amino acid adaptor activity","canonical_id":"go:GO:0033458","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GAC codon.\" [GOC:mah]","metadata":null},{"id":"705bfa73f08740ad8a7ed95984b6e163","type":"GENE","name":"GACAT1","canonical_id":"hgnc:HGNC:48336","description":"gastric cancer associated transcript 1","metadata":{"aliases":["LINC00876","AC096655.1-002"]}},{"id":"7243b5f1bef24660b1a70b2bb0aa44a8","type":"GENE","name":"GACAT2","canonical_id":"hgnc:HGNC:50516","description":"gastric cancer associated transcript 2","metadata":{"aliases":["HMlincRNA717","MTCL1-AS1"]}},{"id":"7f2a1d621da74fefa5381f458ae83310","type":"GENE","name":"GACAT3","canonical_id":"hgnc:HGNC:50847","description":"gastric cancer associated transcript 3","metadata":{"aliases":["lncRNA-AC130710","LINC01458"]}},{"id":"f5b0c12022034beb91b36ba0d403a72b","type":"GENE","name":"GAD1","canonical_id":"hgnc:HGNC:4092","description":null,"metadata":null},{"id":"0ce56361ec38488b83c941387bdf983a","type":"GENE","name":"GAD1-AS1","canonical_id":"hgnc:HGNC:40250","description":"GAD1 antisense RNA 1","metadata":{"aliases":["AC007405.2"]}},{"id":"6fd0759d95cc46899389e7fbe8fe119a","type":"GENE","name":"GAD2","canonical_id":"hgnc:HGNC:4093","description":"glutamate decarboxylase 2","metadata":{"aliases":["GAD65"]}},{"id":"d04ad3b8f28e4d4cb96082816adc2271","type":"GENE","name":"GAD3P","canonical_id":"hgnc:HGNC:55684","description":"glutamate decarboxylase family member 3, pseudogene","metadata":null},{"id":"58976b4575454c8590ee29bc150020e0","type":"GENE","name":"GADD45A","canonical_id":"hgnc:HGNC:4095","description":null,"metadata":null},{"id":"d0a63d88a56e4692b09517bc7a5348ac","type":"GENE","name":"GADD45AP1","canonical_id":"hgnc:HGNC:2725","description":"growth arrest and DNA damage inducible alpha pseudogene 1","metadata":{"aliases":["DDIT1L","GADD45AL"]}},{"id":"1cc9754e400c48b0b13a56479060c9ae","type":"GENE","name":"GADD45B","canonical_id":"hgnc:HGNC:4096","description":"growth arrest and DNA damage inducible beta","metadata":{"aliases":["GADD45BETA","DKFZP566B133","MYD118"]}},{"id":"4612150d98b64c1bba01a98fc95892f5","type":"GENE","name":"GADD45G","canonical_id":"hgnc:HGNC:4097","description":null,"metadata":null},{"id":"c50dd07fa36d4a3dbb46d272d283ac4f","type":"GENE","name":"GADD45GIP1","canonical_id":"hgnc:HGNC:29996","description":"GADD45G interacting protein 1","metadata":{"aliases":["PLINP-1","MGC4667","MGC4758","CKBBP2","PRG6","Plinp1","CRIF1","CKbetaBP2","mL64"]}},{"id":"4d0ad79a0d6f4f66b1ee9cdb03274a1c","type":"GENE","name":"GADL1","canonical_id":"hgnc:HGNC:27949","description":"GAD like acidic amino acid decarboxylase 1","metadata":null},{"id":"4b712f5807f54af1b1c08e9e14a2828e","type":"GO_TERM","name":"GAF domain binding","canonical_id":"go:GO:0036004","description":"\"Binding to a GAF protein domain.\" [GOC:yaf, InterPro:IPR003018]","metadata":null},{"id":"a14ec3303dea4b039b6e1f083e6679e0","type":"GO_TERM","name":"GAG codon-amino acid adaptor activity","canonical_id":"go:GO:0033460","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GAG codon.\" [GOC:mah]","metadata":null},{"id":"2ebb52ffee914660bf73de8b6ea09ab8","type":"GENE","name":"GAGE1","canonical_id":"hgnc:HGNC:4098","description":"G antigen 1","metadata":{"aliases":["CT4.1"]}},{"id":"88e88879bffc4e5d9e96e4be2dccf857","type":"GENE","name":"GAGE10","canonical_id":"hgnc:HGNC:30968","description":"G antigen 10","metadata":{"aliases":["OTTHUMG00000024136"]}},{"id":"6e70c47c84494d2c8ff69c963678d4a9","type":"GENE","name":"GAGE12B","canonical_id":"hgnc:HGNC:26779","description":"G antigen 12B","metadata":{"aliases":["OTTHUMG00000024142"]}},{"id":"cb29665cc6b743ebbd94beb9d6630d6d","type":"GENE","name":"GAGE12C","canonical_id":"hgnc:HGNC:28402","description":"G antigen 12C","metadata":{"aliases":["OTTHUMG00000024144"]}},{"id":"b9f24088a78f4aa8b0d1ed230140fae5","type":"GENE","name":"GAGE12D","canonical_id":"hgnc:HGNC:31904","description":"G antigen 12D","metadata":{"aliases":["OTTHUMG00000024145"]}},{"id":"87e90debc01443f4969e33fa6acc894d","type":"GENE","name":"GAGE12E","canonical_id":"hgnc:HGNC:31905","description":"G antigen 12E","metadata":{"aliases":["OTTHUMG00000024146"]}},{"id":"22fe49218c0f480a83cd4b6228a0b297","type":"GENE","name":"GAGE12F","canonical_id":"hgnc:HGNC:31906","description":"G antigen 12F","metadata":{"aliases":["OTTHUMG00000024147"]}},{"id":"f798ae3a54df4e16b545bdad0e05766b","type":"GENE","name":"GAGE12G","canonical_id":"hgnc:HGNC:31907","description":"G antigen 12G","metadata":{"aliases":["OTTHUMG00000024148"]}},{"id":"fc371d36c01d4004a36983d994e0c986","type":"GENE","name":"GAGE12H","canonical_id":"hgnc:HGNC:31908","description":"G antigen 12H","metadata":{"aliases":["OTTHUMG00000024149"]}},{"id":"4edbb0d3d57742878bc392831f9f51ec","type":"GENE","name":"GAGE12I","canonical_id":"hgnc:HGNC:4105","description":"G antigen 12I","metadata":{"aliases":["OTTHUMG00000067390","GAGE7B"]}},{"id":"5988851ff9834d3cbd2c932b99828090","type":"GENE","name":"GAGE12J","canonical_id":"hgnc:HGNC:17778","description":"G antigen 12J","metadata":{"aliases":["OTTHUMG00000024137","GAGE11"]}},{"id":"6512a914f0cb44da91ef906afde09faa","type":"GENE","name":"GAGE13","canonical_id":"hgnc:HGNC:29081","description":"G antigen 13","metadata":{"aliases":["OTTHUMG00000024138","GAGE12A"]}},{"id":"e6b021caed28408ab0ca79134a82ce6c","type":"GENE","name":"GAGE2A","canonical_id":"hgnc:HGNC:4099","description":"G antigen 2A","metadata":{"aliases":["CT4.2","GAGE2"]}},{"id":"786b3229d82f4c71a779e27b25ab56bc","type":"GENE","name":"GAGE2B","canonical_id":"hgnc:HGNC:31957","description":"G antigen 2B","metadata":null},{"id":"0db9969498ff40f79ec9c3da0f581582","type":"GENE","name":"GAGE2C","canonical_id":"hgnc:HGNC:31958","description":"G antigen 2C","metadata":null},{"id":"a715f393d1c14535a5e357c164e36e02","type":"GENE","name":"GAGE2D","canonical_id":"hgnc:HGNC:31959","description":"G antigen 2D","metadata":{"aliases":["GAGE8"]}},{"id":"ad46f2461c3849f698381372673fb1a1","type":"GENE","name":"GAGE2E","canonical_id":"hgnc:HGNC:31960","description":"G antigen 2E","metadata":{"aliases":["GAGE8"]}},{"id":"4d059e75b57847dd987b12056512caae","type":"GENE","name":"GAGE4","canonical_id":"hgnc:HGNC:4101","description":"G antigen 4","metadata":{"aliases":["CT4.4"]}},{"id":"eab5b18cce3740f0969b1a70122e7c64","type":"GENE","name":"GAGE5","canonical_id":"hgnc:HGNC:4102","description":"G antigen 5","metadata":{"aliases":["CT4.5"]}},{"id":"3ed8605775ec4da0820b66e5b85b42f7","type":"GENE","name":"GAGE6","canonical_id":"hgnc:HGNC:4103","description":"G antigen 6","metadata":{"aliases":["CT4.6"]}},{"id":"7a182c31dbb04842a0a072d9a1009c78","type":"GENE","name":"GAGE7","canonical_id":"hgnc:HGNC:4104","description":"G antigen 7","metadata":{"aliases":["GAGE-7","CT4.7"]}},{"id":"6160744e9db147e5a742717f936d1799","type":"GENE","name":"GAGE8","canonical_id":"hgnc:HGNC:4106","description":"G antigen 8","metadata":{"aliases":["CT4.8"]}},{"id":"889d8e1a4dee4833aeba04fc68b138af","type":"GO_TERM","name":"GAIT complex","canonical_id":"go:GO:0097452","description":"\"A protein complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. The complex binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs and suppresses their translation by blocking the recruitment of the 43S ribosomal complex to m7G cap-bound eIF4G. In humans it includes RPL13A, EPRS, SYNCRIP and GAPDH; mouse complexes lack SYNCRIP.\" [GOC:br, PMID:15479637, PMID:23071094]","metadata":null},{"id":"01e0c8fa64e74d86b1496ad9f9289847","type":"GENE","name":"GAK","canonical_id":"hgnc:HGNC:4113","description":"cyclin G associated kinase","metadata":{"aliases":["DNAJC26"]}},{"id":"402c2bef39f44cfe8f0b4dcf170e3857","type":"GENE","name":"GAK-AS1","canonical_id":"hgnc:HGNC:58707","description":"GAK antisense RNA 1","metadata":null},{"id":"2eea44c3e52b4fe3a9a356028a3309cc","type":"GENE","name":"GAL","canonical_id":"hgnc:HGNC:4114","description":"galanin and GMAP prepropeptide","metadata":{"aliases":["GMAP","GAL-GMAP","GLNN","GALN"]}},{"id":"047158df27234c32982a9fb59f4a16b6","type":"GENE","name":"GAL3ST1","canonical_id":"hgnc:HGNC:24240","description":"galactose-3-O-sulfotransferase 1","metadata":{"aliases":["CST"]}},{"id":"84c2e69ae4c64764914364bd5f6fa73f","type":"GENE","name":"GAL3ST2","canonical_id":"hgnc:HGNC:24869","description":"galactose-3-O-sulfotransferase 2","metadata":{"aliases":["GP3ST"]}},{"id":"a553fee7b8c64d67a7a6c07673df9eb9","type":"GENE","name":"GAL3ST2-AS1","canonical_id":"hgnc:HGNC:41068","description":"GAL3ST2 antisense RNA 1","metadata":null},{"id":"19fe2a1f2dd443f481764c51e1658764","type":"GENE","name":"GAL3ST3","canonical_id":"hgnc:HGNC:24144","description":"galactose-3-O-sulfotransferase 3","metadata":{"aliases":["GAL3ST2"]}},{"id":"f059030ce78142f3b8f1298a04eb3bc8","type":"GENE","name":"GAL3ST4","canonical_id":"hgnc:HGNC:24145","description":"galactose-3-O-sulfotransferase 4","metadata":{"aliases":["FLJ12116"]}},{"id":"c5d0d66a196c49af8e861a262b742607","type":"GENE","name":"GALC","canonical_id":"hgnc:HGNC:4115","description":"galactosylceramidase","metadata":null},{"id":"657e29626f74479eb8fa642c76844f8c","type":"GENE","name":"GALE","canonical_id":"hgnc:HGNC:4116","description":"UDP-galactose-4-epimerase","metadata":{"aliases":["SDR1E1"]}},{"id":"7b7f2df736d7429d8938fa5feccfc7cd","type":"GENE","name":"GALK1","canonical_id":"hgnc:HGNC:4118","description":"galactokinase 1","metadata":{"aliases":["GALK"]}},{"id":"ee45e5bc8b214a7b9da275e5d265496d","type":"GENE","name":"GALK2","canonical_id":"hgnc:HGNC:4119","description":"galactokinase 2","metadata":{"aliases":["GK2"]}},{"id":"e7c6052837aa4f3e8e1599dcd54a89cb","type":"GENE","name":"GALM","canonical_id":"hgnc:HGNC:24063","description":"galactose mutarotase","metadata":null},{"id":"696e08d6a5c54f9ba72e23c3d87f89fa","type":"GENE","name":"GALM-AS1","canonical_id":"hgnc:HGNC:41037","description":"GALM antisense RNA 1","metadata":null},{"id":"3538aa3051794de2bdd1dffa39d7e0d2","type":"GENE","name":"GALNS","canonical_id":"hgnc:HGNC:4122","description":"galactosamine (N-acetyl)-6-sulfatase","metadata":{"aliases":["GAS","GALNAC6S","GalN6S"]}},{"id":"2701e38979d84ea59032083718300fc3","type":"DRUG","name":"GALNS protein, human","canonical_id":"mesh:C102295","description":null,"metadata":null},{"id":"24b23852902b495396fdf26bb3795b20","type":"GENE","name":"GALNT1","canonical_id":"hgnc:HGNC:4123","description":"polypeptide N-acetylgalactosaminyltransferase 1","metadata":{"aliases":["GalNAc-T1"]}},{"id":"da509bf1675f4a49b96f4cd741128839","type":"GENE","name":"GALNT10","canonical_id":"hgnc:HGNC:19873","description":"polypeptide N-acetylgalactosaminyltransferase 10","metadata":{"aliases":["GalNAc-T10"]}},{"id":"6b5974946775406c8f07d51ba541bccd","type":"GENE","name":"GALNT10-DT","canonical_id":"hgnc:HGNC:59286","description":"GALNT10 divergent transcript","metadata":null},{"id":"e32ca4e8f93f4066a30145a036222560","type":"GENE","name":"GALNT11","canonical_id":"hgnc:HGNC:19875","description":"polypeptide N-acetylgalactosaminyltransferase 11","metadata":{"aliases":["GalNAc-T11"]}},{"id":"b52dc92df4454a8b8b57ef3a05336804","type":"GENE","name":"GALNT12","canonical_id":"hgnc:HGNC:19877","description":"polypeptide N-acetylgalactosaminyltransferase 12","metadata":{"aliases":["GalNAc-T12"]}},{"id":"1153de2316b34c2e8ef27ee4cc9d92da","type":"GENE","name":"GALNT13","canonical_id":"hgnc:HGNC:23242","description":"polypeptide N-acetylgalactosaminyltransferase 13","metadata":{"aliases":["KIAA1918","GalNAc-T13"]}},{"id":"4e64ee92d9f545a5b33b176df40112f2","type":"GENE","name":"GALNT13-AS1","canonical_id":"hgnc:HGNC:56700","description":"GALNT13 antisense RNA 1","metadata":{"aliases":["AC009227.1"]}},{"id":"cb516f758d84484a92f538304ce6cdb3","type":"GENE","name":"GALNT14","canonical_id":"hgnc:HGNC:22946","description":"polypeptide N-acetylgalactosaminyltransferase 14","metadata":{"aliases":["GalNac-T10","FLJ12691","GalNac-T14"]}},{"id":"9fbd17dcd8154d5c9631b173f6a2548a","type":"GENE","name":"GALNT15","canonical_id":"hgnc:HGNC:21531","description":"polypeptide N-acetylgalactosaminyltransferase 15","metadata":{"aliases":["GALNT7","pp-GalNAc-T15","GALNTL2"]}},{"id":"c7d4c78540b64e4c8de8e2b49dd99c74","type":"GENE","name":"GALNT16","canonical_id":"hgnc:HGNC:23233","description":"polypeptide N-acetylgalactosaminyltransferase 16","metadata":{"aliases":["KIAA1130","GalNAc-T16","GALNTL1"]}},{"id":"ac09bba06b2c435196086dd15e527a0c","type":"GENE","name":"GALNT16-AS1","canonical_id":"hgnc:HGNC:55435","description":"GALNT16 and EXD2 antisense RNA 1","metadata":null},{"id":"9d6bd10d5d374383bb98513d3e5aab27","type":"GENE","name":"GALNT17","canonical_id":"hgnc:HGNC:16347","description":"polypeptide N-acetylgalactosaminyltransferase 17","metadata":{"aliases":["GALNTL3","GalNAc-T5L","GalNAc-T19","GalNAc-T17","ppGalNAc-T17","WBSCR17"]}},{"id":"98a773141ddd4fb78798c9f4dfb2f292","type":"GENE","name":"GALNT18","canonical_id":"hgnc:HGNC:30488","description":"polypeptide N-acetylgalactosaminyltransferase 18","metadata":{"aliases":["MGC71806","GALNT15","GalNAc-T18","GALNTL4"]}},{"id":"e19e44a223764025a4f2f21eb11f42ff","type":"GENE","name":"GALNT18-AS1","canonical_id":"hgnc:HGNC:58440","description":"GALNT18 antisense RNA 1","metadata":null},{"id":"9c754f610a334728b5d90575327ff32f","type":"GENE","name":"GALNT2","canonical_id":"hgnc:HGNC:4124","description":"polypeptide N-acetylgalactosaminyltransferase 2","metadata":{"aliases":["GalNAc-T2"]}},{"id":"66e396458fb842c482e9c8b06b31fa10","type":"GENE","name":"GALNT3","canonical_id":"hgnc:HGNC:4125","description":null,"metadata":null},{"id":"36d23554f7d2483c974c435153ac67f1","type":"GENE","name":"GALNT4","canonical_id":"hgnc:HGNC:4126","description":"polypeptide N-acetylgalactosaminyltransferase 4","metadata":{"aliases":["GalNAc-T4"]}},{"id":"8679a9400d5e41e0b3d1825170c42ada","type":"GENE","name":"GALNT5","canonical_id":"hgnc:HGNC:4127","description":"polypeptide N-acetylgalactosaminyltransferase 5","metadata":{"aliases":["GalNAc-T5"]}},{"id":"58c455f915c94c03907607bc0b6827d6","type":"GENE","name":"GALNT6","canonical_id":"hgnc:HGNC:4128","description":"polypeptide N-acetylgalactosaminyltransferase 6","metadata":{"aliases":["GalNAc-T6"]}},{"id":"b9fce8dceec348f09214121a725b3c05","type":"GENE","name":"GALNT7","canonical_id":"hgnc:HGNC:4129","description":"polypeptide N-acetylgalactosaminyltransferase 7","metadata":{"aliases":["GALNAC-T7"]}},{"id":"4fdce5a7e4374b2a88ebf95fc2fdb62c","type":"GENE","name":"GALNT7-AS1","canonical_id":"hgnc:HGNC:58911","description":"GALNT7 antisense RNA 1","metadata":null},{"id":"bc191bae48ab463a88c748657065a0a1","type":"GENE","name":"GALNT7-DT","canonical_id":"hgnc:HGNC:55604","description":"GALNT7 divergent transcript","metadata":null},{"id":"f010a448c6594f5e94af002410782b40","type":"GENE","name":"GALNT8","canonical_id":"hgnc:HGNC:4130","description":"polypeptide N-acetylgalactosaminyltransferase 8","metadata":{"aliases":["GALNAC-T8"]}},{"id":"7b3b2c63cf884ea9ade8708dc2b4c946","type":"GENE","name":"GALNT9","canonical_id":"hgnc:HGNC:4131","description":"polypeptide N-acetylgalactosaminyltransferase 9","metadata":{"aliases":["GALNAC-T9"]}},{"id":"bb3dd69a16074c0bb1a90d4161732bef","type":"GENE","name":"GALNT9-AS1","canonical_id":"hgnc:HGNC:56353","description":"GALNT9 antisense RNA 1","metadata":null},{"id":"6ffac98f52484d1fa7358bfac8884670","type":"GENE","name":"GALNTL5","canonical_id":"hgnc:HGNC:21725","description":"polypeptide N-acetylgalactosaminyltransferase like 5","metadata":{"aliases":["GalNAc-T5L","GALNT15"]}},{"id":"412b14dcaf1242c4882c5048290644c8","type":"GENE","name":"GALNTL6","canonical_id":"hgnc:HGNC:33844","description":"polypeptide N-acetylgalactosaminyltransferase like 6","metadata":{"aliases":["GALNT17","GalNAc-T6L"]}},{"id":"2df17838f52a45d6971c9bb08c26c712","type":"GENE","name":"GALNTL6-AS1","canonical_id":"hgnc:HGNC:54079","description":"GALNTL6 antisense RNA 1","metadata":null},{"id":"79dd60de93824fe887251ffef75c5484","type":"GENE","name":"GALNTL6-AS2","canonical_id":"hgnc:HGNC:58909","description":"GALNTL6 antisense RNA 2","metadata":null},{"id":"71ccda45b39641ba8037da1802adaf85","type":"GENE","name":"GALNTL6-AS3","canonical_id":"hgnc:HGNC:58910","description":"GALNTL6 antisense RNA 3","metadata":null},{"id":"eb03368302f64fa4aff390bfb6868b1e","type":"GENE","name":"GALP","canonical_id":"hgnc:HGNC:24840","description":"galanin like peptide","metadata":{"aliases":["GAL"]}},{"id":"c34907b35d104712bb428b21d2af4406","type":"GENE","name":"GALR1","canonical_id":"hgnc:HGNC:4132","description":"galanin receptor 1","metadata":{"aliases":["GALNR1","GALNR"]}},{"id":"d321c3d920b849998970cfcd70cd46aa","type":"GENE","name":"GALR2","canonical_id":"hgnc:HGNC:4133","description":"galanin receptor 2","metadata":{"aliases":["GALNR2"]}},{"id":"39211ae8b66f401cbb9cf26787a64dcb","type":"GENE","name":"GALR3","canonical_id":"hgnc:HGNC:4134","description":"galanin receptor 3","metadata":null},{"id":"f2e12c34312d41ddaeb98baa04031ac6","type":"GENE","name":"GALT","canonical_id":"hgnc:HGNC:4135","description":null,"metadata":null},{"id":"4e81902d32ac441eb6134e022f39c687","type":"GENE","name":"GAMT","canonical_id":"hgnc:HGNC:4136","description":"guanidinoacetate N-methyltransferase","metadata":{"aliases":["PIG2","TP53I2"]}},{"id":"681a24b5bc8143b39fc1ea158b74f35c","type":"GENE","name":"GAMTP1","canonical_id":"hgnc:HGNC:33982","description":"guanidinoacetate N-methyltransferase pseudogene 1","metadata":{"aliases":["GAMTP"]}},{"id":"f52f89ff74cd4daeac71875ee1f0ddf0","type":"GENE","name":"GAMTP2","canonical_id":"hgnc:HGNC:37697","description":"guanidinoacetate N-methyltransferase pseudogene 2","metadata":null},{"id":"4509d3f73f384aec9a2ffce51399efbf","type":"GENE","name":"GAN","canonical_id":"hgnc:HGNC:4137","description":"gigaxonin","metadata":{"aliases":["GAN1","KLHL16","GIG"]}},{"id":"e209762833c14039aa6e12e729026089","type":"GENE","name":"GANAB","canonical_id":"hgnc:HGNC:4138","description":"glucosidase II alpha subunit","metadata":{"aliases":["GluII","G2AN","KIAA0088","GIIA","GIIalpha"]}},{"id":"61a1dc95c52e48c4b695e1fc8259b781","type":"GENE","name":"GANC","canonical_id":"hgnc:HGNC:4139","description":"glucosidase alpha, neutral C","metadata":null},{"id":"ba00251419204c6fb1ed3fc5e320808c","type":"GENE","name":"GAP43","canonical_id":"hgnc:HGNC:4140","description":"growth associated protein 43","metadata":{"aliases":["B-50","PP46","GAP-43"]}},{"id":"5748e5ff3b4e4076b91cbecc6fec0bd2","type":"GENE","name":"GAPDH","canonical_id":"hgnc:HGNC:4141","description":null,"metadata":null},{"id":"5a26463f57c94b849e166faffceab396","type":"GENE","name":"GAPDH-AS1","canonical_id":"hgnc:HGNC:58389","description":"GAPDH antisense RNA 1","metadata":null},{"id":"1bb952a1c8a94df08c769489aecdb70b","type":"GENE","name":"GAPDH-DT","canonical_id":"hgnc:HGNC:55492","description":"GAPDH divergent transcript","metadata":null},{"id":"8ecb727025e7429680f9b02c04a2b5cb","type":"GENE","name":"GAPDHP1","canonical_id":"hgnc:HGNC:4159","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 1","metadata":{"aliases":["GAPDP1","GAPDHL2","GAPDL2"]}},{"id":"2faebbdbf7144cec961863cfd9e80e6a","type":"GENE","name":"GAPDHP14","canonical_id":"hgnc:HGNC:4160","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 14","metadata":{"aliases":["GAPDP14"]}},{"id":"ea5671ee6720471e9ca875237d4e0ea4","type":"GENE","name":"GAPDHP15","canonical_id":"hgnc:HGNC:13950","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 15","metadata":{"aliases":["GAPDH-Lp","b55C20.4","GAPDP15"]}},{"id":"447630fd44884483b63918d6a36d4036","type":"GENE","name":"GAPDHP16","canonical_id":"hgnc:HGNC:23768","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 16","metadata":{"aliases":["GAPDP16"]}},{"id":"96b68a2f17a841d9b9b72d3ac932aa02","type":"GENE","name":"GAPDHP17","canonical_id":"hgnc:HGNC:37765","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 17","metadata":{"aliases":["GAPDHP18"]}},{"id":"c47759b986d54661a49ff16913374fb1","type":"GENE","name":"GAPDHP19","canonical_id":"hgnc:HGNC:23947","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 19","metadata":null},{"id":"95f9348455bf4c9891b1d597afcefcbd","type":"GENE","name":"GAPDHP2","canonical_id":"hgnc:HGNC:16577","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 2","metadata":{"aliases":["dJ585I14.1","GAPDP2"]}},{"id":"747fb7c5cfee48a984797c8cadc7b625","type":"GENE","name":"GAPDHP20","canonical_id":"hgnc:HGNC:37772","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 20","metadata":null},{"id":"17adf4c10985431da873aeb7745e2a66","type":"GENE","name":"GAPDHP21","canonical_id":"hgnc:HGNC:37773","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 21","metadata":null},{"id":"6eea5731dd0e4e358dcda6c070563fc2","type":"GENE","name":"GAPDHP22","canonical_id":"hgnc:HGNC:37774","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 22","metadata":null},{"id":"f34817b3b7f54d24a530f8da490a4f14","type":"GENE","name":"GAPDHP23","canonical_id":"hgnc:HGNC:37775","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 23","metadata":null},{"id":"92d33519ccbd47cfae5979ef46a96d97","type":"GENE","name":"GAPDHP24","canonical_id":"hgnc:HGNC:37776","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 24","metadata":null},{"id":"ab9e878bbe604304a5b7cfb495cc2887","type":"GENE","name":"GAPDHP25","canonical_id":"hgnc:HGNC:37777","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 25","metadata":null},{"id":"47fbef9695be4223a96df59007c53d81","type":"GENE","name":"GAPDHP26","canonical_id":"hgnc:HGNC:37778","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 26","metadata":null},{"id":"1ae0fc2aa96b4f5dad225bae9af760bb","type":"GENE","name":"GAPDHP27","canonical_id":"hgnc:HGNC:37779","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 27","metadata":null},{"id":"dccd63e5dadc41d6b356db0eb71def3a","type":"GENE","name":"GAPDHP28","canonical_id":"hgnc:HGNC:37780","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 28","metadata":null},{"id":"045285fe57f740c395d542ab24d2ab03","type":"GENE","name":"GAPDHP29","canonical_id":"hgnc:HGNC:37781","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 29","metadata":null},{"id":"81487a4b3ae4435c9c4bde2e52b68dfc","type":"GENE","name":"GAPDHP30","canonical_id":"hgnc:HGNC:37782","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 30","metadata":null},{"id":"046ede06708946238bc4fad5848bb82f","type":"GENE","name":"GAPDHP31","canonical_id":"hgnc:HGNC:37783","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 31","metadata":null},{"id":"a81e0cbfc6fa464f85dee4cc53b9eeeb","type":"GENE","name":"GAPDHP32","canonical_id":"hgnc:HGNC:37784","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 32","metadata":null},{"id":"1c11ad1048524a57b233e62198a3fd29","type":"GENE","name":"GAPDHP33","canonical_id":"hgnc:HGNC:37785","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 33","metadata":null},{"id":"bc3e56fc5dc147dd899d24ca048de302","type":"GENE","name":"GAPDHP34","canonical_id":"hgnc:HGNC:37786","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 34","metadata":null},{"id":"6a691d47e1a5409d81af8d42116fd8c5","type":"GENE","name":"GAPDHP35","canonical_id":"hgnc:HGNC:37789","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 35","metadata":null},{"id":"87c5611e05904d4a853c629042c14ce6","type":"GENE","name":"GAPDHP36","canonical_id":"hgnc:HGNC:37790","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 36","metadata":null},{"id":"c45d7d304b624932af05a6c61cea9a94","type":"GENE","name":"GAPDHP37","canonical_id":"hgnc:HGNC:37791","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 37","metadata":null},{"id":"a8e5765610d04f10832897a372213057","type":"GENE","name":"GAPDHP38","canonical_id":"hgnc:HGNC:37792","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 38","metadata":null},{"id":"72a6b02b3e914298907b89ff715b7f4e","type":"GENE","name":"GAPDHP39","canonical_id":"hgnc:HGNC:37796","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 39","metadata":null},{"id":"c04f6a73b97b461f8cf06b85de0fd3d5","type":"GENE","name":"GAPDHP40","canonical_id":"hgnc:HGNC:37797","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 40","metadata":null},{"id":"0046e461b2be4d5791c7a2dd621cc758","type":"GENE","name":"GAPDHP41","canonical_id":"hgnc:HGNC:37798","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 41","metadata":null},{"id":"72b9e0a2e4b34ac296aae37d8c20aeaf","type":"GENE","name":"GAPDHP42","canonical_id":"hgnc:HGNC:37799","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 42","metadata":null},{"id":"d52fe7e7d02f410ba502ff27021d71d7","type":"GENE","name":"GAPDHP43","canonical_id":"hgnc:HGNC:37800","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 43","metadata":null},{"id":"024a5ec3efc44c498bad057bb312adf9","type":"GENE","name":"GAPDHP44","canonical_id":"hgnc:HGNC:37801","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 44","metadata":null},{"id":"3d0fd9b169c146d29ecf90d8004287b2","type":"GENE","name":"GAPDHP45","canonical_id":"hgnc:HGNC:37802","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 45","metadata":null},{"id":"c2c6af26f7d44c40b7e37359f17f167a","type":"GENE","name":"GAPDHP46","canonical_id":"hgnc:HGNC:37804","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 46","metadata":null},{"id":"3b19ed1bcf3f40b5b92751bd91b3c85c","type":"GENE","name":"GAPDHP47","canonical_id":"hgnc:HGNC:37803","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 47","metadata":null},{"id":"b21e6b6f2c6a42ba97fe6ac86039a5f4","type":"GENE","name":"GAPDHP48","canonical_id":"hgnc:HGNC:37805","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 48","metadata":null},{"id":"5d751dc84a6a4901bf6d97aeb29b09ad","type":"GENE","name":"GAPDHP49","canonical_id":"hgnc:HGNC:38555","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 49","metadata":null},{"id":"c3783b366cde44cca74d7d232ac81bda","type":"GENE","name":"GAPDHP50","canonical_id":"hgnc:HGNC:38556","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 50","metadata":null},{"id":"f98a3413f77844a69b501cc4f7f8d33e","type":"GENE","name":"GAPDHP51","canonical_id":"hgnc:HGNC:38557","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 51","metadata":null},{"id":"a84764e53956474b9929c1d9ea10a5d2","type":"GENE","name":"GAPDHP52","canonical_id":"hgnc:HGNC:38558","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 52","metadata":null},{"id":"ac78d1ba38e447cfb43d94ebae39e09c","type":"GENE","name":"GAPDHP53","canonical_id":"hgnc:HGNC:38559","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 53","metadata":null},{"id":"80c401072a2e4bd28ecb0257cd51ee5a","type":"GENE","name":"GAPDHP54","canonical_id":"hgnc:HGNC:38560","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 54","metadata":null},{"id":"0ec8be41806b4c09b1020c8c75225355","type":"GENE","name":"GAPDHP55","canonical_id":"hgnc:HGNC:38561","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 55","metadata":null},{"id":"f4b1b08455a648a7b54d96aa0db40071","type":"GENE","name":"GAPDHP56","canonical_id":"hgnc:HGNC:38562","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 56","metadata":null},{"id":"c71f0e334ead42aca2d5f7ea1457acf1","type":"GENE","name":"GAPDHP57","canonical_id":"hgnc:HGNC:38563","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 57","metadata":null},{"id":"3d66f41515be43d0903de3a474c8790b","type":"GENE","name":"GAPDHP58","canonical_id":"hgnc:HGNC:4142","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 58","metadata":{"aliases":["GAPDL1","GAPDHL1"]}},{"id":"ea083d2ffc864e76886cd863d8789419","type":"GENE","name":"GAPDHP59","canonical_id":"hgnc:HGNC:4152","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 59","metadata":{"aliases":["GAPDL3","GAPDHL3"]}},{"id":"0c9b857c0ccb461287ef491869f7d4e6","type":"GENE","name":"GAPDHP60","canonical_id":"hgnc:HGNC:4153","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 60","metadata":{"aliases":["GAPDL4","GAPDHL4"]}},{"id":"f56b35fd05d34f279fe30a734caa1dae","type":"GENE","name":"GAPDHP61","canonical_id":"hgnc:HGNC:4155","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 61","metadata":{"aliases":["GAPDL6","GAPDHL6"]}},{"id":"029837ca2dd94230b57e93d1ade66afa","type":"GENE","name":"GAPDHP62","canonical_id":"hgnc:HGNC:4156","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 62","metadata":{"aliases":["GAPDL7","GAPDHL7"]}},{"id":"8330b9b6a6ca45f8ba01528563a68e63","type":"GENE","name":"GAPDHP63","canonical_id":"hgnc:HGNC:4157","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 63","metadata":{"aliases":["GAPDL8","GAPDHL8"]}},{"id":"258fde024e1e44fe926c66f6328e73f0","type":"GENE","name":"GAPDHP64","canonical_id":"hgnc:HGNC:4158","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 64","metadata":{"aliases":["GAPDL9","GAPDHL9"]}},{"id":"0e072fdc3b084ee8bbccd31a939b360a","type":"GENE","name":"GAPDHP65","canonical_id":"hgnc:HGNC:4143","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 65","metadata":{"aliases":["GAPDL10","GAPDHL10"]}},{"id":"6071015afa4e4a59bbbdf5a90dd6342a","type":"GENE","name":"GAPDHP66","canonical_id":"hgnc:HGNC:4144","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 66","metadata":{"aliases":["GAPDL11","GAPDHL11"]}},{"id":"8c39a67c75ad4bc9880bcd8576482a66","type":"GENE","name":"GAPDHP67","canonical_id":"hgnc:HGNC:4145","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 67","metadata":{"aliases":["GAPDL12","GAPDHL12"]}},{"id":"a63606d0736f43fe85c6d342f10e5fd6","type":"GENE","name":"GAPDHP68","canonical_id":"hgnc:HGNC:4146","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 68","metadata":{"aliases":["GAPDL13","GAPDHL13"]}},{"id":"6f9e4ee8b8134b18b1bd679274976bdd","type":"GENE","name":"GAPDHP69","canonical_id":"hgnc:HGNC:4147","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 69","metadata":{"aliases":["GAPDL14","GAPDHL14"]}},{"id":"26055e3a666945129f7cdd6387affffd","type":"GENE","name":"GAPDHP70","canonical_id":"hgnc:HGNC:4148","description":"glyceraldehyde 3 phosphate dehydrogenase pseudogene 70","metadata":{"aliases":["GAPDL15","GAPDHL15"]}},{"id":"aaf3eb53d2c24a3da4a43c75b8d899d4","type":"GENE","name":"GAPDHP71","canonical_id":"hgnc:HGNC:4149","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 71","metadata":{"aliases":["GAPDL16","GAPDHL16"]}},{"id":"1622e92397a1447bbb05bac597548500","type":"GENE","name":"GAPDHP72","canonical_id":"hgnc:HGNC:22955","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 72","metadata":{"aliases":["GAPDL18","GAPDHL18"]}},{"id":"dcbfd578f4914d8c9836283181d35832","type":"GENE","name":"GAPDHP73","canonical_id":"hgnc:HGNC:22956","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 73","metadata":{"aliases":["GAPDL19","GAPDHL19"]}},{"id":"158d8609bf704857af05ed11d0ae82b7","type":"GENE","name":"GAPDHP74","canonical_id":"hgnc:HGNC:50647","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 74","metadata":null},{"id":"fdbfe0dda9c04dee955064e35625001c","type":"GENE","name":"GAPDHP75","canonical_id":"hgnc:HGNC:50648","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 75","metadata":null},{"id":"abac59edf3204126b7f9867d8875613e","type":"GENE","name":"GAPDHP76","canonical_id":"hgnc:HGNC:50649","description":"glyceraldehyde-3-phosphate dehydrogenase pseudogene 76","metadata":null},{"id":"10a062f3f0f540ea98937fc2551fe233","type":"GENE","name":"GAPDHP77","canonical_id":"hgnc:HGNC:55049","description":"GAPDH pseudogene 77","metadata":null},{"id":"b1e993e4d5e2490f980f0d7e30193f68","type":"GENE","name":"GAPDHS","canonical_id":"hgnc:HGNC:24864","description":"glyceraldehyde-3-phosphate dehydrogenase, spermatogenic","metadata":{"aliases":["GAPDH-2","GAPD2","GAPDS"]}},{"id":"5af5580a87844dd0ac1e641b7fbfea65","type":"GENE","name":"GAPLINC","canonical_id":"hgnc:HGNC:51308","description":"gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA","metadata":{"aliases":["TCONS_00026238","lncRNA-uc002kmd.1","RP11-838N2.4","LINC01540"]}},{"id":"2ee222738e79480fa06f5ff712f8c61b","type":"GENE","name":"GAPT","canonical_id":"hgnc:HGNC:26588","description":"GRB2 binding adaptor protein, transmembrane","metadata":{"aliases":["FLJ33641","C5orf29"]}},{"id":"983c2495137d4270ab2009e61e02639f","type":"GENE","name":"GAPVD1","canonical_id":"hgnc:HGNC:23375","description":"GTPase activating protein and VPS9 domains 1","metadata":{"aliases":["DKFZP434C212","KIAA1521"]}},{"id":"68a7ad5a89674a17a48d6925fa960ef5","type":"GENE","name":"GAR1","canonical_id":"hgnc:HGNC:14264","description":"GAR1 ribonucleoprotein","metadata":{"aliases":["NOLA1"]}},{"id":"e660d153777f4149a1614ae2faf4693a","type":"GENE","name":"GAR1-DT","canonical_id":"hgnc:HGNC:55191","description":"GAR1 divergent transcript","metadata":null},{"id":"301b26c1d85941b2bb701a7750181c2e","type":"GENE","name":"GAREM1","canonical_id":"hgnc:HGNC:26136","description":"GRB2 associated regulator of MAPK1 subtype 1","metadata":{"aliases":["FLJ21610","C18orf11","FAM59A","GAREM"]}},{"id":"87cc1021a2d141289214d4f044aac659","type":"GENE","name":"GAREM2","canonical_id":"hgnc:HGNC:27172","description":"GRB2 associated regulator of MAPK1 subtype 2","metadata":{"aliases":["KIAA2038","FLJ00375","FAM59B","GAREML"]}},{"id":"dcfb82567ccd4cc3afdb909e46a357db","type":"GENE","name":"GARIN1A","canonical_id":"hgnc:HGNC:27998","description":"golgi associated RAB2 interactor 1A","metadata":{"aliases":["GARI","FAM137B","FAM71F2"]}},{"id":"1a59e974a85c4bea8fc968411dc82fe5","type":"GENE","name":"GARIN1B","canonical_id":"hgnc:HGNC:30704","description":"golgi associated RAB2 interactor 1B","metadata":{"aliases":["NYD-SP18","GARI-L1","FAM137A","FAM71F1"]}},{"id":"c0c3b0cfb9ec43558b548bd523863008","type":"GENE","name":"GARIN2","canonical_id":"hgnc:HGNC:20101","description":"golgi associated RAB2 interactor family member 2","metadata":{"aliases":["GARI-L2","C14orf54","FAM71D"]}},{"id":"019da0095e4f40b3a31b8f4189c35a44","type":"GENE","name":"GARIN3","canonical_id":"hgnc:HGNC:28397","description":"golgi associated RAB2 interactor family member 3","metadata":{"aliases":["MGC26988","GARI-L3","FAM71B"]}},{"id":"ef5907118c3c447896c54d2e1e4f7b8d","type":"GENE","name":"GARIN3P1","canonical_id":"hgnc:HGNC:49805","description":"GARIN3 pseudogene 1","metadata":{"aliases":["FAM71BP1"]}},{"id":"298cf17c42dd46f8ace729cb68cec3df","type":"GENE","name":"GARIN4","canonical_id":"hgnc:HGNC:26541","description":"golgi associated RAB2 interactor family member 4","metadata":{"aliases":["FLJ32796","GARI-L4","FAM71A"]}},{"id":"fcf1b1a1412c43a88c90055075147cd1","type":"GENE","name":"GARIN5A","canonical_id":"hgnc:HGNC:25107","description":"golgi associated RAB2 interactor 5A","metadata":{"aliases":["GARIL5","FAM71E1"]}},{"id":"27e2d8d09cb546c79d8b94e8f2099663","type":"GENE","name":"GARIN5B","canonical_id":"hgnc:HGNC:25278","description":"golgi associated RAB2 interactor family member 5B","metadata":{"aliases":["DKFZp434G1729","C19orf16","FAM71E2"]}},{"id":"3afbab7b04604bccae11064a0693ef6d","type":"GENE","name":"GARIN6","canonical_id":"hgnc:HGNC:28594","description":"golgi associated RAB2 interactor family member 6","metadata":{"aliases":["MGC39520","FAM71C"]}},{"id":"c1cbefb8c27843c7bf93919ce6c0dfbf","type":"GENE","name":"GARNL3","canonical_id":"hgnc:HGNC:25425","description":"GTPase activating Rap/RanGAP domain like 3","metadata":{"aliases":["DKFZp761J1523","bA356B19.1"]}},{"id":"cc19eb40009b4d4e8b5650bda2961e1a","type":"GO_TERM","name":"GARP complex","canonical_id":"go:GO:0000938","description":"\"A quatrefoil tethering complex required for retrograde traffic from the early endosome back to the late Golgi and biogenesis of cytoplasmic vesicles.\" [GOC:clt, GOC:rn, PMID:10637310, PMID:12077354, PMID:12446664]","metadata":null},{"id":"eb97faf9c4b44b34b66959c4fe0f529e","type":"GO_TERM","name":"GARP complex binding","canonical_id":"go:GO:0062069","description":"\"Binding to a GARP complex.\" [PMID:20163565]","metadata":null},{"id":"81ad45a9d3d74eba90c59ef9f227790b","type":"GENE","name":"GARRE1","canonical_id":"hgnc:HGNC:29016","description":"granule associated Rac and RHOG effector 1","metadata":{"aliases":["MiniBAR","KIAA0355"]}},{"id":"14fcc6a72a5a40a28055dfe4444cca1b","type":"GENE","name":"GARS1","canonical_id":"hgnc:HGNC:4162","description":"glycyl-tRNA synthetase 1","metadata":{"aliases":["GlyRS","DSMAV","SMAD1","CMT2D","GARS"]}},{"id":"d1dd50b4420b42088e1c93c2bb4f07e9","type":"GENE","name":"GARS1-DT","canonical_id":"hgnc:HGNC:48951","description":"GARS1 divergent transcript","metadata":{"aliases":["AC005154.6","AC005154.1","GARS-DT"]}},{"id":"789a0417ff79484abe833b0f276dd38a","type":"GENE","name":"GARS1P1","canonical_id":"hgnc:HGNC:50480","description":"glycyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["GARSP1"]}},{"id":"40d40e4ef60447869a993bb7a9142670","type":"GENE","name":"GART","canonical_id":"hgnc:HGNC:4163","description":"phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase","metadata":{"aliases":["GARS-AIRS-GART","PRGS","PGFT"]}},{"id":"998d5f40800c423da7d8765e7dc6463a","type":"PROTEIN","name":"GART","canonical_id":"uniprot:P22102","description":null,"metadata":null},{"id":"e21fc7c98365450aad8b81093fec38cc","type":"GENE","name":"GAS1","canonical_id":"hgnc:HGNC:4165","description":"growth arrest specific 1","metadata":null},{"id":"8f027ebb185b4cd59689104fd90d4a8e","type":"GENE","name":"GAS1RR","canonical_id":"hgnc:HGNC:52261","description":"GAS1 adjacent regulatory RNA","metadata":{"aliases":["LncRNA-Hh","RP11-276H19.1"]}},{"id":"9cfebf7b0ad24dc6a7f137102a83b57e","type":"GENE","name":"GAS2","canonical_id":"hgnc:HGNC:4167","description":null,"metadata":null},{"id":"2b4c547e21d64358a81a791b9f7a8628","type":"GENE","name":"GAS2L1","canonical_id":"hgnc:HGNC:16955","description":"growth arrest specific 2 like 1","metadata":{"aliases":["GAR22"]}},{"id":"99e0324492234d8bb53228c0d27e9186","type":"GENE","name":"GAS2L1P1","canonical_id":"hgnc:HGNC:50293","description":"growth arrest specific 2 like 1 pseudogene 1","metadata":null},{"id":"7b1d30aaf00747f8a3646eda06046506","type":"GENE","name":"GAS2L1P2","canonical_id":"hgnc:HGNC:27986","description":"growth arrest specific 2 like 1 pseudogene 2","metadata":null},{"id":"a8226e22419844e48dd0084ac3f230db","type":"GENE","name":"GAS2L2","canonical_id":"hgnc:HGNC:24846","description":"growth arrest specific 2 like 2","metadata":{"aliases":["GAR17"]}},{"id":"a3494789583b4a5eb6d57533205b339a","type":"GENE","name":"GAS2L3","canonical_id":"hgnc:HGNC:27475","description":"growth arrest specific 2 like 3","metadata":null},{"id":"a1e2b6fc0cff46489fc8699c6da621ac","type":"GENE","name":"GAS5","canonical_id":"hgnc:HGNC:16355","description":"growth arrest specific 5","metadata":{"aliases":["SNHG2","NCRNA00030"]}},{"id":"a4711cdcef004bd693eea526ff764b69","type":"GENE","name":"GAS5-AS1","canonical_id":"hgnc:HGNC:44119","description":"GAS5 antisense RNA 1","metadata":null},{"id":"5a92df8304e74e699a021f3b688543c1","type":"GENE","name":"GAS6","canonical_id":"hgnc:HGNC:4168","description":"growth arrest specific 6","metadata":{"aliases":["AXSF","FLJ34709","DKFZp666G247","AXLLG"]}},{"id":"d37c998de26e4b2192cc270d88b2c227","type":"GENE","name":"GAS6-AS1","canonical_id":"hgnc:HGNC:39826","description":"GAS6 antisense RNA 1","metadata":null},{"id":"837e80a1b75045c598a36a80dffa2ac2","type":"GENE","name":"GAS6-DT","canonical_id":"hgnc:HGNC:43694","description":"GAS6 divergent transcript","metadata":{"aliases":["FLJ44054","GAS6-AS2"]}},{"id":"9b81829fa5da432e8d3f71bd54b925ca","type":"GENE","name":"GAS7","canonical_id":"hgnc:HGNC:4169","description":"growth arrest specific 7","metadata":{"aliases":["KIAA0394","MGC1348"]}},{"id":"30f03d81746049779d20fb503c26769a","type":"GENE","name":"GAS8-AS1","canonical_id":"hgnc:HGNC:1197","description":"GAS8 antisense RNA 1","metadata":{"aliases":["C16orf3"]}},{"id":"a1182adfd9fd4e8687d86be0cbc066cb","type":"GENE","name":"GASAL1","canonical_id":"hgnc:HGNC:53461","description":"growth arrest associated lncRNA 1","metadata":{"aliases":["GASL1"]}},{"id":"ecd17fae6aaf4e1b99e705711f5514f9","type":"GENE","name":"GASK1A","canonical_id":"hgnc:HGNC:24485","description":"golgi associated kinase 1A","metadata":{"aliases":["DKFZP434B172","C3orf41","FAM198A"]}},{"id":"15f81c0ae3cc4971a8759c7f47ba092d","type":"GENE","name":"GASK1B","canonical_id":"hgnc:HGNC:25312","description":"golgi associated kinase 1B","metadata":{"aliases":["FLJ38155","DKFZp434L142","ENED","C4orf18","FAM198B"]}},{"id":"edf34e6c430a4d2895828cec0bbda581","type":"GENE","name":"GASK1B-AS1","canonical_id":"hgnc:HGNC:53132","description":"GASK1B antisense RNA 1","metadata":{"aliases":["FAM198B-AS1"]}},{"id":"075b784fd1ca40a29eca9f5e4a90f294","type":"GENE","name":"GAST","canonical_id":"hgnc:HGNC:4164","description":null,"metadata":null},{"id":"b77664e7c78644bcb9547dbad7ed01a0","type":"GENE","name":"GATA1","canonical_id":"hgnc:HGNC:4170","description":null,"metadata":null},{"id":"ceac7b4ee40d418b9574a8d839c2dcd7","type":"GO_TERM","name":"GATA1-TAL1-TCF3-Lmo2 complex","canonical_id":"go:GO:0070353","description":"\"A protein complex that contains the zinc finger transcription factor GATA1, the LIM domain protein Lmo2 (RBTN2), the basic helix-loop-helix protein TAL1 and its binding partner TCF3. The complex is involved transcriptional regulation in hematopoiesis.\" [PMID:7568177]","metadata":null},{"id":"bcc23aab7b914cecb49345aa911e485b","type":"GENE","name":"GATA2","canonical_id":"hgnc:HGNC:4171","description":null,"metadata":null},{"id":"be65bbd8518b4bed806d8b9b6f8206e0","type":"GENE","name":"GATA2-AS1","canonical_id":"hgnc:HGNC:51108","description":"GATA2 antisense RNA 1","metadata":{"aliases":["GATA2AS"]}},{"id":"64216b844c774f43bf8045770be2259b","type":"GO_TERM","name":"GATA2-TAL1-TCF3-Lmo2 complex","canonical_id":"go:GO:0070354","description":"\"A protein complex that contains the zinc finger transcription factor GATA2, the LIM domain protein Lmo2 (RBTN2), the basic helix-loop-helix protein TAL1 and its binding partner TCF3. The complex is involved transcriptional regulation in hematopoiesis.\" [PMID:7568177]","metadata":null},{"id":"2c0954a3eae14d3388ee4a6370500ed7","type":"GENE","name":"GATA3","canonical_id":"hgnc:HGNC:4172","description":null,"metadata":null},{"id":"3057666f964b404b8db14fa8d0b7aa9d","type":"GENE","name":"GATA3-AS1","canonical_id":"hgnc:HGNC:33786","description":"GATA3 antisense RNA 1","metadata":null},{"id":"a68a6f9aa8f2447690e2f570bb7ed79b","type":"GENE","name":"GATA4","canonical_id":"hgnc:HGNC:4173","description":null,"metadata":null},{"id":"477c1d52ad184c26a1c433be212b50b9","type":"GENE","name":"GATA5","canonical_id":"hgnc:HGNC:15802","description":null,"metadata":null},{"id":"b66d5d994f574ee58e389890992b2d31","type":"GENE","name":"GATA6","canonical_id":"hgnc:HGNC:4174","description":null,"metadata":null},{"id":"cd9acb43570c4f80ab585926238cdc3c","type":"GENE","name":"GATA6-AS1","canonical_id":"hgnc:HGNC:48840","description":"GATA6 antisense RNA 1","metadata":{"aliases":["locus5689","BM742401"]}},{"id":"554970c169b949baa6f94efb7fa233a3","type":"GENE","name":"GATA6-AS2","canonical_id":"hgnc:HGNC:58686","description":"GATA6 antisense RNA 2","metadata":{"aliases":["RP11-627G18.1"]}},{"id":"325a9c98c9464b6ab400b1b90268cfda","type":"GENE","name":"GATAD1","canonical_id":"hgnc:HGNC:29941","description":"GATA zinc finger domain containing 1","metadata":{"aliases":["ODAG","RG083M05.2","FLJ22489"]}},{"id":"8ac8f737b1fb4992a2e3bd65b46e5702","type":"GENE","name":"GATAD2A","canonical_id":"hgnc:HGNC:29989","description":"GATA zinc finger domain containing 2A","metadata":{"aliases":["p66alpha"]}},{"id":"a5060aa8c4fc44719c15fa53653e8637","type":"GENE","name":"GATAD2B","canonical_id":"hgnc:HGNC:30778","description":"GATA zinc finger domain containing 2B","metadata":{"aliases":["P66beta"]}},{"id":"70138a3bfc1e4818811cccd59a5b7ab4","type":"GENE","name":"GATB","canonical_id":"hgnc:HGNC:8849","description":"glutamyl-tRNA amidotransferase subunit B","metadata":{"aliases":["PET112L","PET112"]}},{"id":"9bc80a7a987b46878461f16e2874a3ba","type":"GENE","name":"GATB-AS1","canonical_id":"hgnc:HGNC:58895","description":"GATB antisense RNA 1","metadata":null},{"id":"ae3b99f83faa4c25ad19153338c9d0e5","type":"GENE","name":"GATC","canonical_id":"hgnc:HGNC:25068","description":"glutamyl-tRNA amidotransferase subunit C","metadata":{"aliases":["FLJ37000","15E1.2"]}},{"id":"96afd8d1b8254664affedab437d8aeac","type":"GENE","name":"GATD1","canonical_id":"hgnc:HGNC:26616","description":"glutamine amidotransferase class 1 domain containing 1","metadata":{"aliases":["FLJ34283","Fy-5","FERRY5","PDDC1"]}},{"id":"69702ced1e9d4f639a8d14e5ff617503","type":"GENE","name":"GATD1-DT","canonical_id":"hgnc:HGNC:29907","description":"GATD1 divergent transcript","metadata":null},{"id":"2a62cd23c95b45d289f5ffd951c3ce49","type":"GENE","name":"GATD3","canonical_id":"hgnc:HGNC:1273","description":"glutamine amidotransferase class 1 domain containing 3","metadata":{"aliases":["KNP-Ia","GT335","ES1","HES1","D21S2048E","KNPI","KNPH","KNP-I","C21orf33","GATD3A"]}},{"id":"f79f69bcdae34aecbd11255e278abb52","type":"TRIAL","name":"GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06522386","description":"Mantle Cell Lymphoma","metadata":null},{"id":"cc7531755bec429f97b6920b13d9e029","type":"GENE","name":"GATM","canonical_id":"hgnc:HGNC:4175","description":"glycine amidinotransferase","metadata":{"aliases":["AGAT"]}},{"id":"497f2baca72e47adabdd3fb7c21d9bcc","type":"GO_TERM","name":"GATOR1 complex","canonical_id":"go:GO:1990130","description":"\"A GTPase-activating protein (GAP) complex that regulates TORC1 signaling by interacting with the Rag GTPase. In human, the GATOR1 complex consists of DEPDC5, NPRL2, and NPRL3. In S. cerevisiae, this complex is referred to as SEACIT and contains the Iml1p, Npr2p, and Npr3p proteins.\" [GOC:krc, GOC:rb, PMID:21900499, PMID:23723238, PMID:23974112, PMID:25934700, PMID:28199306, PMID:29199950]","metadata":null},{"id":"acddf8112c044e5c889e9641fef35fb6","type":"GO_TERM","name":"GATOR1 complex binding","canonical_id":"go:GO:0106080","description":"\"Binding to a GATOR1 complex.\" [PMID:28199306]","metadata":null},{"id":"93b849aafd524d7ebbb29020c728879a","type":"GO_TERM","name":"GATOR2 complex","canonical_id":"go:GO:0061700","description":"\"A multiprotein subcomplex of the GATOR complex that regulates TORC1 signaling by interacting with the Rag GTPase. In human, this complex consists of WDR24, WDR59, MIOS, SEH1L, and SEC13. In S. cerevisiae, this complex is referred to as SEACAT and contains the Sea2p, Sea3p, Sea4p, Seh1p, Sec13p proteins.\" [GOC:krc, GOC:rb, PMID:23723238, PMID:25934700]","metadata":null},{"id":"69bd28be8cb740be8990236d307cdc9c","type":"GO_TERM","name":"GAU codon-amino acid adaptor activity","canonical_id":"go:GO:0033457","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GAU codon.\" [GOC:mah]","metadata":null},{"id":"7ed74d4ba75d4e1c99d70d3e6d1eb6cc","type":"GENE","name":"GAU1","canonical_id":"hgnc:HGNC:53880","description":"GALNT8 antisense upstream 1","metadata":{"aliases":["GALNT8-DT"]}},{"id":"b0cdb69687d34e3daeea5a5337dfc5ca","type":"GENE","name":"GBA","canonical_id":"hgnc:HGNC:4177","description":null,"metadata":null},{"id":"a00ef32b2c1c4350b21e5ff762d83846","type":"GENE","name":"GBA1LP","canonical_id":"hgnc:HGNC:4178","description":"glucosylceramidase beta 1 like, pseudogene","metadata":{"aliases":["GBAP","GBAP1"]}},{"id":"1bbcab9def40445886a20821bf8120e7","type":"GENE","name":"GBA2","canonical_id":"hgnc:HGNC:18986","description":"glucosylceramidase beta 2","metadata":{"aliases":["KIAA1605","AD035","DKFZp762K054","SPG46"]}},{"id":"9b1f448574f2409eb4ccd712e603de25","type":"GENE","name":"GBA3","canonical_id":"hgnc:HGNC:19069","description":"glucosylceramidase beta 3 (gene/pseudogene)","metadata":{"aliases":["GLUC","KLrP","CBGL1"]}},{"id":"c4ce987b64df468eb2af27e3481962e0","type":"GENE","name":"GBA3-AS1","canonical_id":"hgnc:HGNC:58743","description":"GBA3 antisense RNA 1","metadata":null},{"id":"f35916d256054bb397462b977425a01c","type":"GO_TERM","name":"GBAF complex","canonical_id":"go:GO:0140288","description":"\"A SWI/SNF subcomplex that incorporates two mutually exclusive paralogs, GLTSCR1 (glioma tumor suppressor candidate region gene 1) or GLTSCR1L (GLTSCR1-like), BRD9 (bromodomain-containing 9) and the BAF subunits BAF155, BAF60, SS18, BAF53a, and BRG1/BRM.\" [PMID:29374058]","metadata":null},{"id":"bf2beb4121a54f9ca38b937511b58e7f","type":"GO_TERM","name":"GBD domain binding","canonical_id":"go:GO:0032427","description":"\"Binding to a GTPase protein binding domain (GDB) domain. The GBD is a short motif, including a minimum region of 16 amino acids, identified in proteins that bind to small GTPases such as Cdc42 and Rac.\" [GOC:mah, GOC:pg, PMID:9119069]","metadata":null},{"id":"f08aa90f6d134b7dac1b9fa8f0173d0d","type":"GENE","name":"GBE1","canonical_id":"hgnc:HGNC:4180","description":"1,4-alpha-glucan branching enzyme 1","metadata":null},{"id":"605df333aeb546fe848586c3234af07a","type":"GENE","name":"GBF1","canonical_id":"hgnc:HGNC:4181","description":"golgi brefeldin A resistant guanine nucleotide exchange factor 1","metadata":{"aliases":["KIAA0248","ARF1GEF"]}},{"id":"01214e5ae4e2437db463c13d18f5891e","type":"GENE","name":"GBGT1","canonical_id":"hgnc:HGNC:20460","description":"globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 (FORS blood group)","metadata":{"aliases":["UDP-GalNAc","A3GALNT","MGC44848","FS"]}},{"id":"bd494281f243424a9ce78a1f6de69671","type":"GENE","name":"GBP1","canonical_id":"hgnc:HGNC:4182","description":null,"metadata":null},{"id":"e9be0d81e9d6464c842262af04286ff6","type":"GENE","name":"GBP1P1","canonical_id":"hgnc:HGNC:39561","description":"guanylate binding protein 1 pseudogene 1","metadata":{"aliases":["LIMIT"]}},{"id":"e7742d17cf5b47e89e96e8244ea9fd71","type":"GENE","name":"GBP2","canonical_id":"hgnc:HGNC:4183","description":"guanylate binding protein 2","metadata":null},{"id":"20351eb1cfd24bfeb73be26e8f3243b8","type":"GENE","name":"GBP3","canonical_id":"hgnc:HGNC:4184","description":"guanylate binding protein 3","metadata":{"aliases":["FLJ10961"]}},{"id":"5cf643fb9a1e44baa672a524e3b69ec9","type":"GENE","name":"GBP4","canonical_id":"hgnc:HGNC:20480","description":"guanylate binding protein 4","metadata":{"aliases":["Mpa2"]}},{"id":"a52b682c2c1c42e69ad1f464cc2b3eca","type":"GENE","name":"GBP5","canonical_id":"hgnc:HGNC:19895","description":"guanylate binding protein 5","metadata":null},{"id":"5efbf4384294487e818ccac3e4b9ceb5","type":"GENE","name":"GBP6","canonical_id":"hgnc:HGNC:25395","description":"guanylate binding protein family member 6","metadata":{"aliases":["DKFZp686G0786"]}},{"id":"d8523b203a3b4cbdbb2da489c7726f69","type":"GENE","name":"GBP7","canonical_id":"hgnc:HGNC:29606","description":"guanylate binding protein 7","metadata":{"aliases":["FLJ38822","GBP4L"]}},{"id":"5db4b20703244ae5a09b58105a421605","type":"GENE","name":"GBX1","canonical_id":"hgnc:HGNC:4185","description":"gastrulation brain homeobox 1","metadata":null},{"id":"7ab6e9d1b7294210a693f61c7157ef15","type":"GENE","name":"GBX2","canonical_id":"hgnc:HGNC:4186","description":null,"metadata":null},{"id":"d44ca306fb5845d685f7e9e6c7a89bc0","type":"GENE","name":"GBX2-AS1","canonical_id":"hgnc:HGNC:55714","description":"GBX2 and ASB18 antisense RNA 1","metadata":{"aliases":["AC079135.1"]}},{"id":"3ec3c3b7cf2a41bbab325ff946b989ca","type":"GENE","name":"GC","canonical_id":"hgnc:HGNC:4187","description":null,"metadata":null},{"id":"f8f43ded8b624535a8069f3b0c6409f9","type":"GO_TERM","name":"GC-box binding","canonical_id":"go:GO:0140728","description":"\"Binding to a GC-box, a DNA motif with the consensus sequence GGGCGG that is located upstream of the start point of eukaryotic transcription units. The GC-box may occur in multiple copies or in either orientation relative to the transcription start site.\" [PMID:14701757]","metadata":null},{"id":"772387a61da04e36be2cb05f1fc2405d","type":"GENE","name":"GCA","canonical_id":"hgnc:HGNC:15990","description":"grancalcin","metadata":{"aliases":["GCL"]}},{"id":"9f6e091f157e42d6a3f670b178f0541d","type":"GO_TERM","name":"GCA codon-amino acid adaptor activity","canonical_id":"go:GO:0033455","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GCA codon.\" [GOC:mah]","metadata":null},{"id":"6bee06a07d254c5abbd3d2032d5edee2","type":"GENE","name":"GCASPC","canonical_id":"hgnc:HGNC:52281","description":"gall bladder cancer associated suppressor of pyruvate carboxylase lncRNA","metadata":{"aliases":["TCONS_00011605","RP1-56L9.7-001","lnc-SOD2-1"]}},{"id":"af5b1ff5970a4cf1b5f9df29caa2baf2","type":"GENE","name":"GCAT","canonical_id":"hgnc:HGNC:4188","description":"glycine C-acetyltransferase","metadata":{"aliases":["KBL"]}},{"id":"8a27ee6bbd354d589119d29cc458acee","type":"GENE","name":"GCATP1","canonical_id":"hgnc:HGNC:20013","description":"glycine C-acetyltransferase pseudogene 1","metadata":{"aliases":["GCATP"]}},{"id":"255490e633f94be286201e840a195068","type":"GENE","name":"GCAWKR","canonical_id":"hgnc:HGNC:53740","description":"gastric cancer associated WDR5 and KAT2A binding lncRNA","metadata":null},{"id":"48a908f3714b4b80ae63e37b9ced4b83","type":"TRIAL","name":"GCC Agonist Signal in the Small Intestine","canonical_id":"clinicaltrials.gov:NCT05107219","description":"Barrett Esophagus; Gastroesophageal Reflux Disease; Malignant Digestive System Neoplasm","metadata":null},{"id":"5c7ecc199bfc4d9db19976edf178396f","type":"GO_TERM","name":"GCC codon-amino acid adaptor activity","canonical_id":"go:GO:0033454","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GCC codon.\" [GOC:mah]","metadata":null},{"id":"2b13267a01344e1db7a057d418e9e919","type":"GENE","name":"GCC1","canonical_id":"hgnc:HGNC:19095","description":"GRIP and coiled-coil domain containing 1","metadata":{"aliases":["FLJ22035","GCC88","GCC1P","MGC20706"]}},{"id":"dc53711dd636441a9f02cb5c4c162fe1","type":"GENE","name":"GCC2","canonical_id":"hgnc:HGNC:23218","description":"GRIP and coiled-coil domain containing 2","metadata":{"aliases":["GCC185","KIAA0336"]}},{"id":"72ac689d737543a8b64c2e1eb41d043c","type":"GENE","name":"GCC2-AS1","canonical_id":"hgnc:HGNC:28126","description":"GCC2 antisense RNA 1","metadata":null},{"id":"29f5558b7f3b49288f9c30c16b4cbe2c","type":"GENE","name":"GCDH","canonical_id":"hgnc:HGNC:4189","description":"glutaryl-CoA dehydrogenase","metadata":{"aliases":["ACAD5","GCD"]}},{"id":"6c0484fe47694c78ab2be7d347d3e5f0","type":"GENE","name":"GCFC2","canonical_id":"hgnc:HGNC:1317","description":"GC-rich sequence DNA-binding factor 2","metadata":{"aliases":["DNABF","GCF","TCF9","C2orf3"]}},{"id":"5283b0cf5afa4b4e84fc0ed57055ce6f","type":"GENE","name":"GCG","canonical_id":"hgnc:HGNC:4191","description":null,"metadata":null},{"id":"1a13991d4ffc4c019c0632ddf48fcce5","type":"GO_TERM","name":"GCG codon-amino acid adaptor activity","canonical_id":"go:GO:0033456","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GCG codon.\" [GOC:mah]","metadata":null},{"id":"0694fabe03d744f0a9e40c8f96a71f91","type":"GENE","name":"GCGR","canonical_id":"hgnc:HGNC:4192","description":null,"metadata":null},{"id":"d78df1ce54a94121a73e2108f6c00d4d","type":"PROTEIN","name":"GCGR","canonical_id":"uniprot:P47871","description":null,"metadata":null},{"id":"0f663786666f40f0bd51a4de8fc51fd4","type":"DISEASE","name":"GCGR-related hyperglucagonemia","canonical_id":"mondo:0018582","description":null,"metadata":null},{"id":"6f91bf64132f4ebcb04aca40d138c1bd","type":"GENE","name":"GCH1","canonical_id":"hgnc:HGNC:4193","description":"GTP cyclohydrolase 1","metadata":{"aliases":["GTPCH1","DYT5a","GCH","DYT5","DYT14"]}},{"id":"1d7c54132a694c02aa05a22695eb3ee3","type":"GO_TERM","name":"GCH1 complex","canonical_id":"go:GO:0034615","description":"\"A protein complex that possesses GTP cyclohydrolase I activity. In E. coli and human, the complex is a homodecamer, and monomers are catalytically inactive.\" [PMID:16696853]","metadata":null},{"id":"f0dec3536895414abd2848b5c92822d0","type":"GENE","name":"GCHFR","canonical_id":"hgnc:HGNC:4194","description":"GTP cyclohydrolase I feedback regulator","metadata":{"aliases":["GFRP","HsT16933"]}},{"id":"5d6b49eee27d43ab8394b7d865ff1b72","type":"GENE","name":"GCK","canonical_id":"hgnc:HGNC:4195","description":null,"metadata":null},{"id":"e2aa3300dd044dffa7ae7897813d3e22","type":"GENE","name":"GCKR","canonical_id":"hgnc:HGNC:4196","description":"glucokinase regulator","metadata":null},{"id":"69f1ed2a7198405f8a15bac1f1cb93e6","type":"GENE","name":"GCLC","canonical_id":"hgnc:HGNC:4311","description":null,"metadata":null},{"id":"427140b395e74de5b95c0986cd6700b9","type":"GENE","name":"GCLC-AS1","canonical_id":"hgnc:HGNC:56649","description":"GCLC antisense RNA 1","metadata":{"aliases":["AL033397.2"]}},{"id":"0b48647ea4f34bca891d58744b4e487a","type":"GENE","name":"GCLM","canonical_id":"hgnc:HGNC:4312","description":"glutamate-cysteine ligase modifier subunit","metadata":{"aliases":["GLCLR"]}},{"id":"8d0accfc60fe41629ea28e0a68077b62","type":"GENE","name":"GCM1","canonical_id":"hgnc:HGNC:4197","description":null,"metadata":null},{"id":"b8d1d0b97be44e36b22c29529947094a","type":"GENE","name":"GCM1P1","canonical_id":"hgnc:HGNC:57011","description":"GCM1 pseudogene 1","metadata":null},{"id":"9485ceae8b9f43f19304feb141a4225a","type":"GENE","name":"GCM2","canonical_id":"hgnc:HGNC:4198","description":null,"metadata":null},{"id":"f0e0bd011ce643448cc650faf91ecdef","type":"GENE","name":"GCM2-AS1","canonical_id":"hgnc:HGNC:40253","description":"GCM2 antisense RNA 1","metadata":null},{"id":"010cf9ee697c46f0aaf26ae4fc746a37","type":"GENE","name":"GCN1","canonical_id":"hgnc:HGNC:4199","description":"GCN1 activator of EIF2AK4","metadata":{"aliases":["KIAA0219","GCN1L","GCN1L1"]}},{"id":"fcef4d5e07394f31ba3ea7f5f41cbec8","type":"GO_TERM","name":"GCN2-mediated signaling","canonical_id":"go:GO:0140469","description":"\"A series of reactions in which a signal is passed on to downstream proteins within the cell via GCN2 (also known as EIF2AK4), an intracellular protein kinase that is activated by stress signals, such as amino acid starvation.\" [PMID:27629041]","metadata":null},{"id":"25c303c84d98469eb83bb1aee95f94d1","type":"GENE","name":"GCNA","canonical_id":"hgnc:HGNC:15805","description":"germ cell nuclear acidic peptidase","metadata":{"aliases":["NAAR1","ACRC"]}},{"id":"3b8749dd8e644ff6bc6d71b8300e623b","type":"GENE","name":"GCNAP1","canonical_id":"hgnc:HGNC:52401","description":"GCNA pseudogene 1","metadata":null},{"id":"b360d948b66f426bbd025ab1965ff6aa","type":"GENE","name":"GCNT1","canonical_id":"hgnc:HGNC:4203","description":"glucosaminyl (N-acetyl) transferase 1","metadata":{"aliases":["C2GNT","NAGCT2","NACGT2"]}},{"id":"3b99ebee00544414949c4bff3ece07dc","type":"GENE","name":"GCNT1P1","canonical_id":"hgnc:HGNC:16532","description":"glucosaminyl (N-acetyl) transferase 1 pseudogene 1","metadata":{"aliases":["bA189K21.2","GCNT1P"]}},{"id":"f8f626fdfd224850abc4b845c725bc65","type":"GENE","name":"GCNT1P2","canonical_id":"hgnc:HGNC:37972","description":"glucosaminyl (N-acetyl) transferase 1, core 2 pseudogene 2","metadata":null},{"id":"0b3298a79e584724a0608cf4831d3730","type":"GENE","name":"GCNT1P3","canonical_id":"hgnc:HGNC:37973","description":"glucosaminyl (N-acetyl) transferase 1 pseudogene 3","metadata":null},{"id":"9fffd697db4949a79491dde70a134aae","type":"GENE","name":"GCNT1P4","canonical_id":"hgnc:HGNC:37974","description":"glucosaminyl (N-acetyl) transferase 1 pseudogene 4","metadata":null},{"id":"ac2cc144d1b14e20a7eeffa4e5e34c88","type":"GENE","name":"GCNT1P5","canonical_id":"hgnc:HGNC:37975","description":"glucosaminyl (N-acetyl) transferase 1 pseudogene 5","metadata":null},{"id":"27d693cbbe6f4ea4846cc4ae66b49933","type":"GENE","name":"GCNT2","canonical_id":"hgnc:HGNC:4204","description":"glucosaminyl (N-acetyl) transferase 2 (I blood group)","metadata":{"aliases":["IGNT","NAGCT1","bA421M1.1","bA360O19.2","ULG3","NACGT1","II","GCNT5","CCAT"]}},{"id":"78239514506a40a0ad99bdf50df0d810","type":"GENE","name":"GCNT2-AS1","canonical_id":"hgnc:HGNC:59344","description":"GCNT2 antisense RNA 1","metadata":null},{"id":"6643ce5bf5874f559eb0ac2eb176a982","type":"GENE","name":"GCNT2P1","canonical_id":"hgnc:HGNC:21623","description":"GCNT2 pseudogene 1","metadata":{"aliases":["bA421M1.3","GCNT6","GCNT2P"]}},{"id":"d4a06e5f9c5248bf8a9c05d706913e2c","type":"GENE","name":"GCNT3","canonical_id":"hgnc:HGNC:4205","description":"glucosaminyl (N-acetyl) transferase 3, mucin type","metadata":{"aliases":["C2GnT-M","C2/4GnT","C2GnT2"]}},{"id":"a6d592aaa6124b6daa59d920b2b0efba","type":"GENE","name":"GCNT4","canonical_id":"hgnc:HGNC:17973","description":"glucosaminyl (N-acetyl) transferase 4","metadata":{"aliases":["C2GNT3","LINC01336"]}},{"id":"2c43ee949cd241038b6cbb0fb1fcb9a4","type":"GENE","name":"GCNT7","canonical_id":"hgnc:HGNC:16099","description":"glucosaminyl (N-acetyl) transferase family member 7","metadata":{"aliases":["dJ1153D9.2","C20orf105"]}},{"id":"eec1113a65af48cf8b12bc663214cbf2","type":"GENE","name":"GCOM1","canonical_id":"hgnc:HGNC:26424","description":"GCOM1, MYZAP-POLR2M combined locus","metadata":{"aliases":["FLJ30973","GRINL1A","MYZAP-POLR2M"]}},{"id":"31c193cc8e6f42a3b96dcc91853c1f3e","type":"GENE","name":"GCSAM","canonical_id":"hgnc:HGNC:20253","description":null,"metadata":null},{"id":"f84fc681be524531b2e6db3f2f219e51","type":"GENE","name":"GCSAML","canonical_id":"hgnc:HGNC:29583","description":"germinal center associated signaling and motility like","metadata":{"aliases":["FLJ44728","C1orf150"]}},{"id":"d485f6e7816342ca820536ab9bc26364","type":"GENE","name":"GCSAML-AS1","canonical_id":"hgnc:HGNC:41244","description":"GCSAML antisense RNA 1","metadata":null},{"id":"d08994f9daff4ef49562c35bb48a539e","type":"GENE","name":"GCSH","canonical_id":"hgnc:HGNC:4208","description":"glycine cleavage system protein H","metadata":null},{"id":"ca89832a5b7546b9bbb2b69d0709e4a9","type":"GENE","name":"GCSHP1","canonical_id":"hgnc:HGNC:43922","description":"GCSH pseudogene 1","metadata":null},{"id":"b266314f9e194d3dabd8b0d5dd6fca27","type":"GENE","name":"GCSHP2","canonical_id":"hgnc:HGNC:43927","description":"GCSH pseudogene 2","metadata":null},{"id":"5dd8eadf9d684996a7a278a926f562cc","type":"GENE","name":"GCSHP3","canonical_id":"hgnc:HGNC:43929","description":"GCSH pseudogene 3","metadata":null},{"id":"7b2b186b0d45401aa440dfda7baa77f0","type":"GENE","name":"GCSHP4","canonical_id":"hgnc:HGNC:43930","description":"GCSH pseudogene 4","metadata":null},{"id":"bb96f2a576704efcb35146dbe4c713e7","type":"GENE","name":"GCSHP5","canonical_id":"hgnc:HGNC:44195","description":"GCSH pseudogene 5","metadata":null},{"id":"02849e6b7a964d989d55e053c15b22ab","type":"GENE","name":"GCSHP6","canonical_id":"hgnc:HGNC:56417","description":"GCSH pseudogene 6","metadata":null},{"id":"bd3e14765a5046e0a701f593a2242e3e","type":"GENE","name":"GCSHP7","canonical_id":"hgnc:HGNC:59186","description":"GCSH pseudogene 7","metadata":null},{"id":"8b0c190f8af5460e8ba67589c1ed5964","type":"GENE","name":"GCSHP8","canonical_id":"hgnc:HGNC:59187","description":"GCSH pseudogene 8","metadata":null},{"id":"50052572ca2e4df8b8561c660662982b","type":"GENE","name":"GCSHP9","canonical_id":"hgnc:HGNC:59188","description":"GCSH pseudogene 9","metadata":null},{"id":"be826048e58343a29c02e7a39be82979","type":"GENE","name":"GCSIR","canonical_id":"hgnc:HGNC:54400","description":"GPR55 cis regulatory suppressor of immune response RNA","metadata":{"aliases":["Lnc-ITM2C-1"]}},{"id":"b4e5977f4dcd498e9fd3e27caf6ad346","type":"GO_TERM","name":"GCU codon-amino acid adaptor activity","canonical_id":"go:GO:0033453","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GCU codon.\" [GOC:mah]","metadata":null},{"id":"1112f4897f134075a361ce51bdff535e","type":"GENE","name":"GDA","canonical_id":"hgnc:HGNC:4212","description":null,"metadata":null},{"id":"3d89c4f24418461cb325693e4339e4fb","type":"GENE","name":"GDAP1","canonical_id":"hgnc:HGNC:15968","description":null,"metadata":null},{"id":"80715b9b6c4a4596ac5f4fcbac45c3c5","type":"GENE","name":"GDAP1L1","canonical_id":"hgnc:HGNC:4213","description":"ganglioside induced differentiation associated protein 1 like 1","metadata":null},{"id":"427a5cd66efc4174bcfeb6d175adcde9","type":"GENE","name":"GDAP2","canonical_id":"hgnc:HGNC:18010","description":"ganglioside induced differentiation associated protein 2","metadata":{"aliases":["FLJ20142","dJ776P7.1","MACROD3"]}},{"id":"783e2e2676594ac0bc1f09881c7c4bbc","type":"TRIAL","name":"GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00980343","description":"Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor","metadata":null},{"id":"e576158d7eb3441dbbbf712e70c072c6","type":"TRIAL","name":"GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment","canonical_id":"clinicaltrials.gov:NCT00822458","description":"Recurrent Childhood Medulloblastoma","metadata":null},{"id":"0875461be79940c08786086b94819b95","type":"GENE","name":"GDE1","canonical_id":"hgnc:HGNC:29644","description":"glycerophosphodiester phosphodiesterase 1","metadata":{"aliases":["MIR16"]}},{"id":"1e884c648bd44a238fdf1e2a0c4e4f1e","type":"GENE","name":"GDF1","canonical_id":"hgnc:HGNC:4214","description":"growth differentiation factor 1","metadata":null},{"id":"50843af9623047919128fa213537fb79","type":"GENE","name":"GDF10","canonical_id":"hgnc:HGNC:4215","description":"growth differentiation factor 10","metadata":{"aliases":["BMP-3b"]}},{"id":"7fea03fe46ba4c6ea2d3ac2fdf105413","type":"GENE","name":"GDF11","canonical_id":"hgnc:HGNC:4216","description":"growth differentiation factor 11","metadata":{"aliases":["BMP-11","BMP11"]}},{"id":"e5a9e067349448a9a0bf92274e752261","type":"GENE","name":"GDF15","canonical_id":"hgnc:HGNC:30142","description":null,"metadata":null},{"id":"70bfd9029cc646b1990c0944b133e9ae","type":"GO_TERM","name":"GDF15-GFRAL signaling pathway","canonical_id":"go:GO:0160144","description":"\"The series of molecular signals initiated by GDF15 binding to GFRAL coreceptor, triggering RET autophosphorylation and activation, in response to stress.\" [PMID:30639358, PMID:31535977, PMID:33593916, PMID:37437602]","metadata":null},{"id":"30ece0634e894e1e9444f9ddb3bea7c2","type":"GENE","name":"GDF2","canonical_id":"hgnc:HGNC:4217","description":"growth differentiation factor 2","metadata":{"aliases":["BMP-9","BMP9"]}},{"id":"5368bfb0ac1a4a5da6549716fd7202e7","type":"GENE","name":"GDF3","canonical_id":"hgnc:HGNC:4218","description":null,"metadata":null},{"id":"48a0ff604c914792bd4284c296c05606","type":"GENE","name":"GDF5","canonical_id":"hgnc:HGNC:4220","description":null,"metadata":null},{"id":"d1326ca71aca478c8f38299d6ca23361","type":"GENE","name":"GDF5-AS1","canonical_id":"hgnc:HGNC:33435","description":"GDF5 antisense RNA 1","metadata":{"aliases":["GDF5OS"]}},{"id":"25cbaef3610845edaa1a379352e8d303","type":"GENE","name":"GDF6","canonical_id":"hgnc:HGNC:4221","description":"growth differentiation factor 6","metadata":{"aliases":["BMP13","KFS","KFS1","SGM1"]}},{"id":"23eb80ad2ca242d5a36812b6c2faabd6","type":"GENE","name":"GDF7","canonical_id":"hgnc:HGNC:4222","description":"growth differentiation factor 7","metadata":{"aliases":["BMP12"]}},{"id":"5e2d034ef4cd417da542282c65426443","type":"GENE","name":"GDF9","canonical_id":"hgnc:HGNC:4224","description":"growth differentiation factor 9","metadata":null},{"id":"d7235adac44e4d64a706493abc6be60d","type":"GENE","name":"GDI1","canonical_id":"hgnc:HGNC:4226","description":"GDP dissociation inhibitor 1","metadata":{"aliases":["RABGDIA","XAP-4","OPHN2","FLJ41411","MRX48","MRX41","GDIL"]}},{"id":"b711cc4fa3e54ff0a5a9c2c9533e829a","type":"GENE","name":"GDI2","canonical_id":"hgnc:HGNC:4227","description":"GDP dissociation inhibitor 2","metadata":{"aliases":["RABGDIB"]}},{"id":"a78786e8b9ae461a96aba2e4446642d9","type":"GENE","name":"GDI2P1","canonical_id":"hgnc:HGNC:4228","description":"GDP dissociation inhibitor 2 pseudogene 1","metadata":{"aliases":["GDI2P"]}},{"id":"8de5a24898614da0a35f6a1dd3ea2fc1","type":"GENE","name":"GDI2P2","canonical_id":"hgnc:HGNC:37976","description":"GDP dissociation inhibitor 2 pseudogene 2","metadata":null},{"id":"7b237e8755d3484aaa136464e967caaa","type":"GENE","name":"GDNF","canonical_id":"hgnc:HGNC:4232","description":null,"metadata":null},{"id":"498bd1ead1f64165b37d910d6e7d85af","type":"GENE","name":"GDNF-AS1","canonical_id":"hgnc:HGNC:43592","description":"GDNF antisense RNA 1","metadata":{"aliases":["GDNFOS","LINC02110"]}},{"id":"b06fd5bb0bc04f4080a47401e4bccc89","type":"GO_TERM","name":"GDP binding","canonical_id":"go:GO:0019003","description":"\"Binding to GDP, guanosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"b2e4907e8df742fc995dd28432cfb268","type":"GO_TERM","name":"GDP biosynthetic process","canonical_id":"go:GO:0046711","description":"\"The chemical reactions and pathways resulting in the formation of GDP, guanosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"0517e8671bb949ef88f7fe2c014b1fd5","type":"GO_TERM","name":"GDP catabolic process","canonical_id":"go:GO:0046712","description":"\"The chemical reactions and pathways resulting in the breakdown of GDP, guanosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"a8f69518ce2d498c8a4d23c4f5b46f12","type":"GO_TERM","name":"GDP metabolic process","canonical_id":"go:GO:0046710","description":"\"The chemical reactions and pathways involving GDP, guanosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"f712045a5117475e88a908c6cd039359","type":"GO_TERM","name":"GDP phosphatase activity","canonical_id":"go:GO:0004382","description":"\"Catalysis of the reaction: GDP + H2O = GMP + phosphate.\" [PMID:2989286, RHEA:22156]","metadata":null},{"id":"2314bfd512db46adb950bc221e33213e","type":"GO_TERM","name":"GDP-2,4-diacetamido-2,4,6-trideoxy-alpha-D-glucopyranose hydrolase/2-epimerase activity","canonical_id":"go:GO:0102224","description":"\"Catalysis of the reaction: GDP-N,N'-diacetylbacillosamine + H2O = 2,4-diacetamido-2,4,6-trideoxy-alpha-D-mannopyranose + GDP + H+.\" [RHEA:46316]","metadata":null},{"id":"fd6919c06f984ac0a95724211c6711c5","type":"GO_TERM","name":"GDP-4-dehydro-6-deoxy-D-mannose reductase activity","canonical_id":"go:GO:0033705","description":"\"Catalysis of the reaction: GDP-6-deoxy-D-mannose + NAD(P)+ = GDP-4-dehydro-6-deoxy-D-mannose + NAD(P)H + H+.\" [EC:1.1.1.281]","metadata":null},{"id":"a9c1118047314d4c949373ed8abf1a89","type":"GO_TERM","name":"GDP-4-dehydro-D-rhamnose reductase activity","canonical_id":"go:GO:0042356","description":"\"Catalysis of the reaction: GDP-6-deoxy-D-mannose + NAD(P)+ = GDP-4-dehydro-6-deoxy-D-mannose + NAD(P)H + H+. In the reverse reaction, a mixture of GDP-D-rhamnose and its C-4 epimer is formed.\" [EC:1.1.1.187]","metadata":null},{"id":"58cfe677220b4beb8488e891b9a4b15b","type":"GO_TERM","name":"GDP-6-deoxy-D-talose 4-dehydrogenase activity","canonical_id":"go:GO:0047916","description":"\"Catalysis of the reaction: GDP-6-deoxy-D-talose + NAD(P)+ = GDP-4-dehydro-6-deoxy-D-talose + NAD(P)H + H+.\" [EC:1.1.1.135, MetaCyc:GDP-6-DEOXY-D-TALOSE-4-DEHYDROGENASE-RXN]","metadata":null},{"id":"ce9390290b724ac18997ec9cf29b9153","type":"GO_TERM","name":"GDP-D-glucose phosphorylase activity","canonical_id":"go:GO:0080048","description":"\"Catalysis of the reaction: GDP-alpha-D-glucose + phosphate = alpha-D-glucose-1-phosphate + GDP.\" [PMID:17462988, PMID:18463094]","metadata":null},{"id":"d821a1ea47114d0881a57b7e4a29b22e","type":"GO_TERM","name":"GDP-D-rhamnose biosynthetic process","canonical_id":"go:GO:0019306","description":"\"The chemical reactions and pathways resulting in the formation of GDP-D-rhamnose, a substance composed of rhamnose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"78e6feb1ff8341fcb7e6fd59512ead99","type":"GO_TERM","name":"GDP-L-fucose biosynthetic process","canonical_id":"go:GO:0042350","description":"\"The chemical reactions and pathways resulting in the formation of GDP-L-fucose, a substance composed of L-fucose in glycosidic linkage with guanosine diphosphate.\" [GOC:jl]","metadata":null},{"id":"ac7721dd396c4bccbfed98c6998b4243","type":"GO_TERM","name":"GDP-L-fucose metabolic process","canonical_id":"go:GO:0046368","description":"\"The chemical reactions and pathways involving GDP-L-fucose, a substance composed of L-fucose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"54157b94422e49c8b683c58adc04a572","type":"GO_TERM","name":"GDP-L-fucose salvage","canonical_id":"go:GO:0042352","description":"\"The formation of GDP-L-fucose from L-fucose, without de novo synthesis. L-fucose is phosphorylated by fucokinase and then converted by fucose-1-phosphate guanylyltransferase (EC:2.7.7.30).\" [GOC:ma]","metadata":null},{"id":"4dbb664132e74b3581e2dae0f71fad1e","type":"GO_TERM","name":"GDP-L-fucose synthase activity","canonical_id":"go:GO:0050577","description":"\"Catalysis of the reaction: GDP-L-fucose + NAD+ = GDP-4-dehydro-6-deoxy-D-mannose + NADH + H+.\" [EC:1.1.1.271, MetaCyc:1.1.1.271-RXN]","metadata":null},{"id":"1aece24223114b0382fae2d3b92d37ce","type":"GO_TERM","name":"GDP-L-galactose biosynthetic process","canonical_id":"go:GO:0033472","description":"\"The chemical reactions and pathways resulting in the formation of GDP-L-galactose, a substance composed of L-galactose in glycosidic linkage with guanosine diphosphate.\" [GOC:mah]","metadata":null},{"id":"7b260a37eac342ac90d20ff59d9e0ec3","type":"GO_TERM","name":"GDP-L-galactose phosphorylase activity","canonical_id":"go:GO:0080047","description":"\"Catalysis of the reaction: GDP-beta-L-galactose + phosphate = beta-L-galactose-1-phosphate + GDP.\" [PMID:17462988, PMID:18463094, RHEA:27698]","metadata":null},{"id":"bd96af08d19c40a3b15e313c7ba27678","type":"GO_TERM","name":"GDP-Man:Man(1)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase activity","canonical_id":"go:GO:0004378","description":"\"Catalysis of the reaction: a beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + GDP-alpha-D-mannose = an alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + GDP + H+.\" [RHEA:29515]","metadata":null},{"id":"f0b86774529b4e1a913af9c89a2d5eb6","type":"GO_TERM","name":"GDP-Man:Man(2)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase activity","canonical_id":"go:GO:0102704","description":"\"Catalysis of the reaction: an alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + GDP-alpha-D-mannose = an alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + GDP + H+.\" [RHEA:29519]","metadata":null},{"id":"4f4919a3d1ff447ba761242c0056949b","type":"GO_TERM","name":"GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity","canonical_id":"go:GO:0004377","description":"\"Catalysis of the reaction: an alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + 2 GDP-alpha-D-mannose = an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + 2 GDP + 2 H+.\" [RHEA:29523]","metadata":null},{"id":"cee99204d7264ff6bc5bac2be3141589","type":"GO_TERM","name":"GDP-alpha-D-mannosylchitobiosyldiphosphodolichol biosynthetic process","canonical_id":"go:GO:0019347","description":"\"The chemical reactions and pathways resulting in the formation of GDP-alpha-D-mannosylchitobiosyldiphosphodolichol, a substance composed of mannosylchitobiosyldiphosphodolichol in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"c1b2022acd854ad89039f813a7bd08cc","type":"GO_TERM","name":"GDP-dissociation inhibitor activity","canonical_id":"go:GO:0005092","description":"\"Prevents the dissociation of GDP from a GTPase, thereby preventing GTP from binding.\" [GOC:mah]","metadata":null},{"id":"b039973bffd143d39a279f64fc976a86","type":"GO_TERM","name":"GDP-dissociation inhibitor binding","canonical_id":"go:GO:0051021","description":"\"Binding to a GDP-dissociation inhibitor protein.\" [GOC:ai]","metadata":null},{"id":"2707e13810ca4b34b8429d79e827eb0b","type":"GO_TERM","name":"GDP-fucose import into Golgi lumen","canonical_id":"go:GO:0036085","description":"\"The directed movement of GDP-fucose into the Golgi lumen. GDP-fucose is a substance composed of fucose in glycosidic linkage with guanosine diphosphate.\" [GOC:sart, PMID:3458237]","metadata":null},{"id":"9b62fad85bcf4f7390c158ffc5a7c1f4","type":"GO_TERM","name":"GDP-fucose import into endoplasmic reticulum lumen","canonical_id":"go:GO:0036084","description":"\"The directed movement of GDP-fucose into the endoplasmic reticulum lumen. GDP-fucose is a substance composed of fucose in glycosidic linkage with guanosine diphosphate.\" [GOC:sart, PMID:3458237]","metadata":null},{"id":"b46e22b4511d4e0b88a5e96c11bd4e81","type":"GO_TERM","name":"GDP-fucose transmembrane transport","canonical_id":"go:GO:0015783","description":"\"The directed movement of GDP-fucose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. GDP-fucose is a substance composed of fucose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"25892977e0604072a1a34ede345aca2f","type":"GO_TERM","name":"GDP-fucose transmembrane transporter activity","canonical_id":"go:GO:0005457","description":"\"Enables the transfer of a GDP-fucose from one side of a membrane to the other. GDP-fucose is a substance composed of fucose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"7b25597578d84589ba0d922f6780c189","type":"GO_TERM","name":"GDP-galactose:glucose-1-phosphate guanylyltransferase activity","canonical_id":"go:GO:0010472","description":"\"Catalysis of the reaction: GDP-beta-L-galactose + alpha-D-glucose 1-phosphate = beta-L-galactose-1-phosphate + GDP-alpha-D-glucose.\" [PMID:17485667, RHEA:65712]","metadata":null},{"id":"23b1fd99ed5b48d0b9429b747a6fabfc","type":"GO_TERM","name":"GDP-galactose:mannose-1-phosphate guanylyltransferase activity","canonical_id":"go:GO:0010471","description":"\"Catalysis of the reaction: GDP-beta-L-galactose + alpha-D-mannose 1-phosphate = GDP-alpha-D-mannose + beta-L-galactose-1-phosphate.\" [PMID:17485667, RHEA:65708]","metadata":null},{"id":"2ff34e1ee0994eeb82faec5dff3128dc","type":"GO_TERM","name":"GDP-galactose:myoinositol-1-phosphate guanylyltransferase activity","canonical_id":"go:GO:0010473","description":"\"Catalysis of the reaction: GDP-L-galactose + myo-inositol 1-phosphate = alpha-L-galactose-1-phosphate + GDP-myoinositol.\" [PMID:17485667]","metadata":null},{"id":"2c855bb0b3634663a31f86549332d170","type":"GO_TERM","name":"GDP-glucosidase activity","canonical_id":"go:GO:0047917","description":"\"Catalysis of the reaction: GDP-D-glucose + H2O = D-glucose + GDP + H+.\" [EC:3.2.1.42, RHEA:15049]","metadata":null},{"id":"62f2780ace3f4febbf3bcfa6c33180f3","type":"GO_TERM","name":"GDP-mannose 3,5-epimerase activity","canonical_id":"go:GO:0047918","description":"\"Catalysis of the reaction: GDP-mannose = GDP-L-galactose.\" [PMID:16366586, PMID:8910301]","metadata":null},{"id":"04a4f799e5254fa1a34954f4c674a6c8","type":"GO_TERM","name":"GDP-mannose 4,6-dehydratase activity","canonical_id":"go:GO:0008446","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose = GDP-4-dehydro-6-deoxy-alpha-D-mannose + H2O.\" [EC:4.2.1.47, RHEA:23820]","metadata":null},{"id":"9478cf9b4a924bc089c5f0be1c1e9915","type":"GO_TERM","name":"GDP-mannose 6-dehydrogenase activity","canonical_id":"go:GO:0047919","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose + H2O + 2 NAD+ = GDP-D-mannuronate + 3 H+ + 2 NADH.\" [EC:1.1.1.132, RHEA:21728]","metadata":null},{"id":"d949a73c593341cea7d655da29a8e06e","type":"GO_TERM","name":"GDP-mannose biosynthetic process","canonical_id":"go:GO:0009298","description":"\"The chemical reactions and pathways resulting in the formation of GDP-mannose, a substance composed of mannose in glycosidic linkage with guanosine diphosphate.\" [MetaCyc:PWY-5659]","metadata":null},{"id":"f91fa5bf4ce44938bbe19cbc55433fab","type":"GO_TERM","name":"GDP-mannose hydrolase activity","canonical_id":"go:GO:0052751","description":"\"Catalysis of the reaction: GDP-mannose + H2O = GMP + mannose-1-phosphate.\" [PMID:16766526]","metadata":null},{"id":"1012c364b94045b4bc48e9fcbfce65c6","type":"GO_TERM","name":"GDP-mannose mannosyl hydrolase activity","canonical_id":"go:GO:0008727","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose + H2O = GDP + D-mannose + H+.\" [MetaCyc:GDPMANMANHYDRO-RXN]","metadata":null},{"id":"391b4c1808cd4f3dadfdd922f9af6781","type":"GO_TERM","name":"GDP-mannose metabolic process","canonical_id":"go:GO:0019673","description":"\"The chemical reactions and pathways involving GDP-mannose, a substance composed of mannose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"2691889939a94fecbc7d124b99726fd3","type":"GO_TERM","name":"GDP-mannose pyrophosphorylase complex","canonical_id":"go:GO:0120508","description":"\"A protein complex capable of catalyzing the reaction of GTP and mannose-1-phosphate to form GDP-mannose. The complex is a homodimer in most bacteria and a heterodimer in most eukaryotes. In humans, it is composed of a catalytic beta subunit (GMPPB) and a regulatory alpha subunit (GMPPA).\" [GOC:sjm, PMID:33986552]","metadata":null},{"id":"5b7f6085c8114fd38ea81f3b59944ec7","type":"GO_TERM","name":"GDP-mannose transmembrane transport","canonical_id":"go:GO:1990570","description":"\"The process in which GDP-mannose is transported across a membrane.\" [PMID:9395539]","metadata":null},{"id":"bbfd182ad0b54e3bb792507d2fe47f16","type":"GO_TERM","name":"GDP-mannose transmembrane transporter activity","canonical_id":"go:GO:0005458","description":"\"Enables the transfer of a GDP-mannose from one side of a membrane to the other. GDP-mannose is a substance composed of mannose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"16c21e5ced8a452195399e599d1ed55a","type":"GO_TERM","name":"GDP-mannose:serine-protein mannose-1-phosphotransferase activity","canonical_id":"go:GO:0018422","description":"\"Catalysis of the transfer of mannose-1-phosphate to a serine residue in a protein.\" [GOC:mah, PMID:10037765]","metadata":null},{"id":"95b4287ccfe8442db410322662027da4","type":"GO_TERM","name":"GDP-perosamine synthase activity","canonical_id":"go:GO:0102933","description":"\"Catalysis of the reaction: GDP-alpha-D-perosamine + 2-oxoglutarate = GDP-4-dehydro-alpha-D-rhamnose + L-glutamate.\" [RHEA:36779]","metadata":null},{"id":"d004fa70b5e644f9b7f6e968bac99759","type":"GENE","name":"GDPD1","canonical_id":"hgnc:HGNC:20883","description":"glycerophosphodiester phosphodiesterase domain containing 1","metadata":{"aliases":["FLJ37451","GDE4"]}},{"id":"8845a73bd0994769b92fdc35e7cf78e4","type":"GENE","name":"GDPD2","canonical_id":"hgnc:HGNC:25974","description":"glycerophosphodiester phosphodiesterase domain containing 2","metadata":{"aliases":["OBDPF","FLJ20207","GDE3"]}},{"id":"e8dbcb028e5c46c2831e42b5e7b35537","type":"GENE","name":"GDPD3","canonical_id":"hgnc:HGNC:28638","description":"glycerophosphodiester phosphodiesterase domain containing 3","metadata":{"aliases":["MGC4171"]}},{"id":"1651b01bcb364c50ae59bd54ee5a3153","type":"GENE","name":"GDPD4","canonical_id":"hgnc:HGNC:24849","description":"glycerophosphodiester phosphodiesterase domain containing 4","metadata":{"aliases":["GDE6"]}},{"id":"7bc6a9ba9f70436cb1531b35ed947205","type":"GENE","name":"GDPD5","canonical_id":"hgnc:HGNC:28804","description":"glycerophosphodiester phosphodiesterase domain containing 5","metadata":{"aliases":["PP1665","GDE2"]}},{"id":"63dd7d0bbf3d47139ae80b53a2c710c0","type":"GENE","name":"GDPGP1","canonical_id":"hgnc:HGNC:34360","description":"GDP-D-glucose phosphorylase 1","metadata":{"aliases":["C15orf58"]}},{"id":"76d14c829dcf4f5b93881a5bf190ac4c","type":"GENE","name":"GEM","canonical_id":"hgnc:HGNC:4234","description":"GTP binding protein overexpressed in skeletal muscle","metadata":{"aliases":["KIR"]}},{"id":"0d32a2b881864d57b0fc42a35aa9223b","type":"TRIAL","name":"GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05861336","description":"Pancreatic Cancer","metadata":null},{"id":"354cb68975ae4d19890c7a24e0cc4e5a","type":"GENE","name":"GEMIN2","canonical_id":"hgnc:HGNC:10884","description":"gem nuclear organelle associated protein 2","metadata":{"aliases":["SIP1"]}},{"id":"83faafca96a74fea89a62b6945a85c65","type":"GENE","name":"GEMIN2P1","canonical_id":"hgnc:HGNC:49561","description":"gem nuclear organelle associated protein 2 pseudogene 1","metadata":null},{"id":"21cc8e36bc0645a8a86e2b5ac5a1e4a6","type":"GENE","name":"GEMIN2P2","canonical_id":"hgnc:HGNC:49562","description":"gem nuclear organelle associated protein 2 pseudogene 2","metadata":null},{"id":"46a2049e29a6481c9025100b58c554d7","type":"GENE","name":"GEMIN4","canonical_id":"hgnc:HGNC:15717","description":"gem nuclear organelle associated protein 4","metadata":{"aliases":["HHRF-1","DKFZP434B131","p97","DKFZP434D174","HC56","HCAP1"]}},{"id":"30a3596de6c74269b37f2506c891a1d5","type":"GENE","name":"GEMIN5","canonical_id":"hgnc:HGNC:20043","description":"gem nuclear organelle associated protein 5","metadata":null},{"id":"34a90b1bf8ff42d594f37aa811df0e8b","type":"GENE","name":"GEMIN6","canonical_id":"hgnc:HGNC:20044","description":"gem nuclear organelle associated protein 6","metadata":{"aliases":["FLJ23459"]}},{"id":"cc8c6340e8e8423c9503508081591754","type":"GENE","name":"GEMIN7","canonical_id":"hgnc:HGNC:20045","description":"gem nuclear organelle associated protein 7","metadata":{"aliases":["FLJ13956"]}},{"id":"6ef0c61565664562992f3cabb6a86311","type":"GENE","name":"GEMIN7-AS1","canonical_id":"hgnc:HGNC:53773","description":"GEMIN7 antisense RNA 1","metadata":null},{"id":"2f4c365da40a48268b01c62bf90b6ec6","type":"GENE","name":"GEMIN7P1","canonical_id":"hgnc:HGNC:54938","description":"GEMIN7 pseudogene 1","metadata":null},{"id":"97138d003acf4fbbb69d65511f98f3b3","type":"GENE","name":"GEMIN8","canonical_id":"hgnc:HGNC:26044","description":"gem nuclear organelle associated protein 8","metadata":{"aliases":["FLJ20514","FAM51A1"]}},{"id":"bc00998203aa4a34b4a811ea218a5c95","type":"GENE","name":"GEMIN8P1","canonical_id":"hgnc:HGNC:31818","description":"gem nuclear organelle associated protein 8 pseudogene 1","metadata":{"aliases":["FAM51A2P","GEMIN8P"]}},{"id":"7915deae1d8847a697f8952f436ff314","type":"GENE","name":"GEMIN8P2","canonical_id":"hgnc:HGNC:37977","description":"gem nuclear organelle associated protein 8 pseudogene 2","metadata":null},{"id":"7c92c1769dab44eb97508b87e544e65d","type":"GENE","name":"GEMIN8P3","canonical_id":"hgnc:HGNC:37978","description":"gem nuclear organelle associated protein 8 pseudogene 3","metadata":null},{"id":"a5dfa31da74848058da0aa650bb223c9","type":"GENE","name":"GEMIN8P4","canonical_id":"hgnc:HGNC:37979","description":"gem nuclear organelle associated protein 8 pseudogene 4","metadata":null},{"id":"732f69d75cf74bf195a70eea2a7603f6","type":"TRIAL","name":"GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma","canonical_id":"clinicaltrials.gov:NCT05668884","description":"Biliary Tract Carcinoma","metadata":null},{"id":"2267a6a92c7f4f03bdc3fac5587007b3","type":"GENE","name":"GEN1","canonical_id":"hgnc:HGNC:26881","description":"GEN1 structure-specific endonuclease","metadata":{"aliases":["FLJ40869","Gen"]}},{"id":"b962c06aef6e403e9576024296e9c2e1","type":"GO_TERM","name":"GET complex","canonical_id":"go:GO:0043529","description":"\"An endoplasmic reticulum protein-containing complex that is conserved in eukaryotics and that mediates the insertion of tail-anchored proteins into the ER membrane. In yeast, includes Get1p, Get2p and Get3p proteins.\" [GOC:krc, GOC:vw, PMID:16269340, PMID:18724936, PMID:32910895]","metadata":null},{"id":"deb6a0a6ea17414faab369d041d581f9","type":"GENE","name":"GET1","canonical_id":"hgnc:HGNC:12790","description":"guided entry of tail-anchored proteins factor 1","metadata":{"aliases":["CHD5","WRB"]}},{"id":"d6a29f2f875d4c5a9dc0669c2f1a1e95","type":"GENE","name":"GET1-SH3BGR","canonical_id":"hgnc:HGNC:54635","description":"GET1-SH3BGR readthrough","metadata":null},{"id":"cd7e14244b1e4954891b124fe7f53a87","type":"GENE","name":"GET1P1","canonical_id":"hgnc:HGNC:44010","description":"GET1 pseudogene 1","metadata":{"aliases":["WRBP1"]}},{"id":"567f4d3c941140dea1a87e0660d9631a","type":"GENE","name":"GET3","canonical_id":"hgnc:HGNC:752","description":"guided entry of tail-anchored proteins factor 3, ATPase","metadata":{"aliases":["ARSA-I","TRC40","ASNA1"]}},{"id":"53e67268bc87413f9aa6cfd6a79f1a05","type":"GENE","name":"GET4","canonical_id":"hgnc:HGNC:21690","description":"guided entry of tail-anchored proteins factor 4","metadata":{"aliases":["CGI-20","H_NH1244M04.5","CEE","TRC35","C7orf20"]}},{"id":"4638a89f9a424c41af4c4ebba3ef8b46","type":"GENE","name":"GET4-AS1","canonical_id":"hgnc:HGNC:58398","description":"GET4 antisense RNA 1","metadata":null},{"id":"34cfdb0d32df481ba7f7d30ff0b0a7f6","type":"GENE","name":"GFAP","canonical_id":"hgnc:HGNC:4235","description":null,"metadata":null},{"id":"4339f17d3a2e465686753e5957f24ae0","type":"GENE","name":"GFER","canonical_id":"hgnc:HGNC:4236","description":null,"metadata":null},{"id":"cc62430a93f64a978d71d616964a3fe6","type":"GENE","name":"GFI1","canonical_id":"hgnc:HGNC:4237","description":null,"metadata":null},{"id":"e7cadf5551824ed782fa03e2f97f30f5","type":"GENE","name":"GFI1B","canonical_id":"hgnc:HGNC:4238","description":null,"metadata":null},{"id":"db75cd2d770d4a648d37dbc22cd1e791","type":"GENE","name":"GFM1","canonical_id":"hgnc:HGNC:13780","description":"G elongation factor mitochondrial 1","metadata":{"aliases":["EF-G1mt","mtEFG1","EFGM","GFM","EGF1","mtEF-G1"]}},{"id":"158377108ad4455783b78edd87b07b40","type":"GENE","name":"GFM2","canonical_id":"hgnc:HGNC:29682","description":"GTP dependent ribosome recycling factor mitochondrial 2","metadata":{"aliases":["mtEFG2","EFG2","FLJ21661","EF-G2mt"]}},{"id":"13c8f5c019c64db99dfcc89897a764e7","type":"GENE","name":"GFOD1","canonical_id":"hgnc:HGNC:21096","description":"Gfo/Idh/MocA-like oxidoreductase domain containing 1","metadata":{"aliases":["FLJ20330","ADG-90","C6orf114"]}},{"id":"467e4ef5147042439e32d4d3b88be81a","type":"GENE","name":"GFOD1-AS1","canonical_id":"hgnc:HGNC:40956","description":"GFOD1 antisense RNA 1","metadata":null},{"id":"9bf24578aa0e43cd94022c511895072f","type":"GENE","name":"GFOD1-AS2","canonical_id":"hgnc:HGNC:59354","description":"GFOD1 antisense RNA 2","metadata":null},{"id":"3adc24f687774895a19ef053344347b7","type":"GENE","name":"GFOD2","canonical_id":"hgnc:HGNC:28159","description":"Gfo/Idh/MocA-like oxidoreductase domain containing 2","metadata":{"aliases":["FLJ23802","MGC11335"]}},{"id":"f922612eb8b047bcada341ef8e6a51d2","type":"GENE","name":"GFOD3P","canonical_id":"hgnc:HGNC:29052","description":"Gfo/Idh/MocA-like oxidoreductase domain containing 3, pseudogene","metadata":{"aliases":["PDAM","KIAA0495","TP73-AS1"]}},{"id":"1e4b5cb774d943f8a85a6c8b65c29729","type":"GENE","name":"GFPT1","canonical_id":"hgnc:HGNC:4241","description":"glutamine--fructose-6-phosphate transaminase 1","metadata":{"aliases":["GFAT","GFA","GFAT1","GFPT"]}},{"id":"9c869f38142a4f719a2f6deb2cb522f0","type":"GENE","name":"GFPT2","canonical_id":"hgnc:HGNC:4242","description":"glutamine--fructose-6-phosphate transaminase 2","metadata":{"aliases":["GFAT2"]}},{"id":"6023f018fe044286beb68fcf7fa7fc3f","type":"GENE","name":"GFRA1","canonical_id":"hgnc:HGNC:4243","description":"GDNF family receptor alpha 1","metadata":{"aliases":["RETL1","GDNFR","GFR-ALPHA-1","RET1L","TRNR1","GDNFRA"]}},{"id":"25818e4a8a064c509c867f5bc2a01a79","type":"GENE","name":"GFRA2","canonical_id":"hgnc:HGNC:4244","description":"GDNF family receptor alpha 2","metadata":{"aliases":["RETL2","GDNFRB","NTNRA","TRNR2"]}},{"id":"daa07f9628c345219ddb820572d9177f","type":"GENE","name":"GFRA3","canonical_id":"hgnc:HGNC:4245","description":"GDNF family receptor alpha 3","metadata":{"aliases":["GFRa-3"]}},{"id":"24fe9b8698a94af483b38e874a17b33e","type":"GENE","name":"GFRA4","canonical_id":"hgnc:HGNC:13821","description":"GDNF family receptor alpha 4","metadata":null},{"id":"d49e30fdf7444c309214ce22fc1c83a6","type":"GENE","name":"GFRAL","canonical_id":"hgnc:HGNC:32789","description":"GDNF family receptor alpha like","metadata":{"aliases":["GRAL","UNQ9356","bA360D14.1","C6orf144"]}},{"id":"fc436470275f41178e3e91325bd62b8f","type":"GENE","name":"GFUS","canonical_id":"hgnc:HGNC:12390","description":"GDP-L-fucose synthase","metadata":{"aliases":["FX","P35B","SDR4E1","TSTA3"]}},{"id":"ee66cba046a24d8fb4e9941427388cd4","type":"GENE","name":"GFY","canonical_id":"hgnc:HGNC:44663","description":"golgi associated olfactory signaling regulator","metadata":{"aliases":["Goofy"]}},{"id":"a8d1d604b8ca44c7bcd2868cd57b66d5","type":"GO_TERM","name":"GGA codon-amino acid adaptor activity","canonical_id":"go:GO:0033463","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GGA codon.\" [GOC:mah]","metadata":null},{"id":"183e0fbe244744d8a8a30cec492813ee","type":"GENE","name":"GGA1","canonical_id":"hgnc:HGNC:17842","description":"golgi associated, gamma adaptin ear containing, ARF binding protein 1","metadata":null},{"id":"5f5699624c3147898824a9acc685a26a","type":"GENE","name":"GGA2","canonical_id":"hgnc:HGNC:16064","description":"golgi associated, gamma adaptin ear containing, ARF binding protein 2","metadata":{"aliases":["VEAR","KIAA1080"]}},{"id":"26f47f6c3bf2468db1ba804915091551","type":"GENE","name":"GGA3","canonical_id":"hgnc:HGNC:17079","description":"golgi associated, gamma adaptin ear containing, ARF binding protein 3","metadata":{"aliases":["KIAA0154"]}},{"id":"012c4b742b9344b799c2f840b32538ee","type":"GENE","name":"GGACT","canonical_id":"hgnc:HGNC:25100","description":"gamma-glutamylamine cyclotransferase","metadata":{"aliases":["A2LD1"]}},{"id":"8ceb47dcbc7249e8b26f4cde97c14f29","type":"GO_TERM","name":"GGC codon-amino acid adaptor activity","canonical_id":"go:GO:0033462","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GGC codon.\" [GOC:mah]","metadata":null},{"id":"9a4652764e25402b89c4992ddb31828d","type":"GENE","name":"GGCT","canonical_id":"hgnc:HGNC:21705","description":"gamma-glutamylcyclotransferase","metadata":{"aliases":["MGC3077","CRF21","Ggc","C7orf24","GCTG"]}},{"id":"ef8327cfbcac41589f5f698be56592ee","type":"GENE","name":"GGCTP1","canonical_id":"hgnc:HGNC:54609","description":"GGCT pseudogene 1","metadata":null},{"id":"dc80d0aa9443422c8d5f55deb163ae59","type":"GENE","name":"GGCTP2","canonical_id":"hgnc:HGNC:54610","description":"GGCT pseudogene 2","metadata":null},{"id":"bd68d86a560d43268c1fc3073d52c452","type":"GENE","name":"GGCTP3","canonical_id":"hgnc:HGNC:54611","description":"GGCT pseudogene 3","metadata":null},{"id":"3391131dd5224023aec754860c535c9f","type":"GENE","name":"GGCX","canonical_id":"hgnc:HGNC:4247","description":"gamma-glutamyl carboxylase","metadata":{"aliases":["VKCFD1"]}},{"id":"4a736f88f9fe4de5a0683d4d70d502d9","type":"PROTEIN","name":"GGCX","canonical_id":"uniprot:P38435","description":null,"metadata":null},{"id":"24e4b1f8dfa7481a9c4ed682a04c3eda","type":"GO_TERM","name":"GGG codon-amino acid adaptor activity","canonical_id":"go:GO:0033464","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GGG codon.\" [GOC:mah]","metadata":null},{"id":"2d2b3f1123464e95b14031372ba86637","type":"GENE","name":"GGH","canonical_id":"hgnc:HGNC:4248","description":"gamma-glutamyl hydrolase","metadata":{"aliases":["GATD10"]}},{"id":"583cf70134a74ca3a0463a696fc8759f","type":"GENE","name":"GGN","canonical_id":"hgnc:HGNC:18869","description":"gametogenetin","metadata":{"aliases":["FLJ35713","MGC33369"]}},{"id":"cae0a18d1d47459180412806a6857f51","type":"GENE","name":"GGNBP1","canonical_id":"hgnc:HGNC:19427","description":"gametogenetin binding protein 1 (pseudogene)","metadata":null},{"id":"5b6ab34c128846fe835338cb009ab166","type":"GENE","name":"GGNBP2","canonical_id":"hgnc:HGNC:19357","description":"gametogenetin binding protein 2","metadata":{"aliases":["ZFP403","LZK1","FLJ22561","FLJ21230","DIF-3","DIF3","ZNF403"]}},{"id":"6af27808b0f44613b931da45d6e080b8","type":"GENE","name":"GGPS1","canonical_id":"hgnc:HGNC:4249","description":null,"metadata":null},{"id":"b4e2e63f9e3140978ca6ed520622d83d","type":"GENE","name":"GGT1","canonical_id":"hgnc:HGNC:4250","description":"gamma-glutamyltransferase 1","metadata":{"aliases":["D22S672","D22S732","CD224","GGT"]}},{"id":"be5384b32833496680fb10cf8bf60ba7","type":"GENE","name":"GGT2P","canonical_id":"hgnc:HGNC:4251","description":"gamma-glutamyltransferase 2, pseudogene","metadata":{"aliases":["GGT","GGT2"]}},{"id":"b2564cec9d2340f699b0f2c8de6d92b8","type":"GENE","name":"GGT3P","canonical_id":"hgnc:HGNC:4252","description":"gamma-glutamyltransferase 3 pseudogene","metadata":{"aliases":["GGT3"]}},{"id":"e7cd7a5938d14e7695f34dbd274fb3e2","type":"GENE","name":"GGT4P","canonical_id":"hgnc:HGNC:33207","description":"gamma-glutamyltransferase 4 pseudogene","metadata":null},{"id":"4a91217d82e34b39a9189bac46deb362","type":"GENE","name":"GGT5","canonical_id":"hgnc:HGNC:4260","description":"gamma-glutamyltransferase 5","metadata":{"aliases":["GGT-REL","GGTLA1"]}},{"id":"1b6a0209cdeb41579de1a74bd3c182d6","type":"GENE","name":"GGT6","canonical_id":"hgnc:HGNC:26891","description":"gamma-glutamyltransferase 6","metadata":{"aliases":["FLJ90165"]}},{"id":"0889e9c03eac45cd89e6b8315d1b0e8c","type":"GENE","name":"GGT7","canonical_id":"hgnc:HGNC:4259","description":"gamma-glutamyltransferase 7","metadata":{"aliases":["D20S101","dJ18C9.2","GGTL5","GGTL3"]}},{"id":"9cc62dfda10f47ba951aaf530c058337","type":"GENE","name":"GGT8P","canonical_id":"hgnc:HGNC:33438","description":"gamma-glutamyltransferase 8 pseudogene","metadata":{"aliases":["FLJ31276","GGT1P1"]}},{"id":"fcadc14eb7744ed7aee387cef7414f01","type":"GENE","name":"GGTA1","canonical_id":"hgnc:HGNC:4253","description":"glycoprotein alpha-galactosyltransferase 1 (inactive)","metadata":{"aliases":["GLYT2","GGTA","GGTA1P"]}},{"id":"a68d55f386a54980970c50957e75d68b","type":"GENE","name":"GGTA2P","canonical_id":"hgnc:HGNC:4254","description":"glycoprotein alpha-galactosyltransferase 2, pseudogene","metadata":{"aliases":["HGT2","GLYT2L","GLYT3","GGTA1P"]}},{"id":"a66c023086eb4df38db41f44c6c38e0b","type":"GENE","name":"GGTLC1","canonical_id":"hgnc:HGNC:16437","description":"gamma-glutamyltransferase light chain 1","metadata":{"aliases":["dJ831C21.2","dJ831C21.1","GGTLA4","GGTLA3"]}},{"id":"da0d9235968b48148a51fa2afbbf72ea","type":"GENE","name":"GGTLC2","canonical_id":"hgnc:HGNC:18596","description":"gamma-glutamyltransferase light chain 2","metadata":{"aliases":["GGTL4"]}},{"id":"138ce15b91704f6c8a8132a4dc67ca06","type":"GENE","name":"GGTLC3","canonical_id":"hgnc:HGNC:33426","description":"gamma-glutamyltransferase light chain family member 3","metadata":null},{"id":"3c11efaf4010453faa5eab8ebbff8e59","type":"GENE","name":"GGTLC4P","canonical_id":"hgnc:HGNC:33428","description":"gamma-glutamyltransferase light chain 4 pseudogene","metadata":null},{"id":"83a55c9f458e47b19e6dce6295769174","type":"GENE","name":"GGTLC5P","canonical_id":"hgnc:HGNC:33427","description":"gamma-glutamyltransferase light chain 5 pseudogene","metadata":null},{"id":"f06b5cc017294761926c21848b3f6ba1","type":"GO_TERM","name":"GGU codon-amino acid adaptor activity","canonical_id":"go:GO:0033461","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GGU codon.\" [GOC:mah]","metadata":null},{"id":"b2c5712bb6be408e9031d81cfe270986","type":"GENE","name":"GH1","canonical_id":"hgnc:HGNC:4261","description":null,"metadata":null},{"id":"484094480fb84fd2a921b3d7c6cd35fb","type":"GENE","name":"GH2","canonical_id":"hgnc:HGNC:4262","description":null,"metadata":null},{"id":"4b7c6a9f1d7a417393c9e6357ec5cdbd","type":"GENE","name":"GHDC","canonical_id":"hgnc:HGNC:24438","description":"GH3 domain containing","metadata":{"aliases":["LGP1"]}},{"id":"b0291f10cfbe4b1d8bae56ffe80dd8b4","type":"GENE","name":"GHET1","canonical_id":"hgnc:HGNC:49425","description":"gastric carcinoma proliferation enhancing transcript 1","metadata":{"aliases":["lncRNA-GHET1","GHET-1"]}},{"id":"7b46f0ed775d45418becac2bab60b303","type":"GENE","name":"GHITM","canonical_id":"hgnc:HGNC:17281","description":"growth hormone inducible transmembrane protein","metadata":{"aliases":["HSPC282","PTD010","DERP2","My021","TMBIM5","MICS1"]}},{"id":"e6b2421a4322434d893e9c5da1da33fc","type":"GENE","name":"GHR","canonical_id":"hgnc:HGNC:4263","description":null,"metadata":null},{"id":"afc2b4e45698400383c8da9ae71e5220","type":"PROTEIN","name":"GHR","canonical_id":"uniprot:P10912","description":null,"metadata":null},{"id":"6711d60e63644afe9c506139e02cfd06","type":"GENE","name":"GHRH","canonical_id":"hgnc:HGNC:4265","description":"growth hormone releasing hormone","metadata":{"aliases":["GHRF"]}},{"id":"e847c628656745bda0a627f66a7251ba","type":"GENE","name":"GHRHR","canonical_id":"hgnc:HGNC:4266","description":"growth hormone releasing hormone receptor","metadata":null},{"id":"e81c390fec12499482cda410fd05fb49","type":"PROTEIN","name":"GHRHR","canonical_id":"uniprot:Q02643","description":null,"metadata":null},{"id":"542c71234e494081a8e2d26df49f2db4","type":"GENE","name":"GHRL","canonical_id":"hgnc:HGNC:18129","description":"ghrelin and obestatin prepropeptide","metadata":{"aliases":["MTLRP","ghrelin","obestatin"]}},{"id":"1ae722a20cc144fca0f4c36896c635e8","type":"GENE","name":"GHRLOS","canonical_id":"hgnc:HGNC:33885","description":"ghrelin opposite strand/antisense RNA","metadata":{"aliases":["NCRNA00068","GHRL-AS1"]}},{"id":"5a5effbd29434ce69be760cf30955843","type":"GENE","name":"GHSR","canonical_id":"hgnc:HGNC:4267","description":"growth hormone secretagogue receptor","metadata":{"aliases":["GHS-R1a","GHS-R","GHSR-1a"]}},{"id":"2d60058f89524c2abbe9aeebac56ca7c","type":"PROTEIN","name":"GHSR","canonical_id":"uniprot:Q92847","description":null,"metadata":null},{"id":"ea4fef4fb86a427b9e366fa2c9f5b35e","type":"GO_TERM","name":"GID complex","canonical_id":"go:GO:0034657","description":"\"A protein complex with ubiquitin ligase activity that, in Saccharomyces cerevisiae, is involved in proteasomal degradation of fructose-1,6-bisphosphatase (FBPase) and phosphoenolpyruvate carboxykinase during the transition from gluconeogenic to glycolytic growth conditions. It appears to play a broader role in cellular homeostasis and development in other species.\" [PMID:12686616, PMID:18508925, PMID:35682545]","metadata":null},{"id":"2c8c1e563b8148a9873027b9384b4459","type":"GENE","name":"GID4","canonical_id":"hgnc:HGNC:28453","description":"GID complex subunit 4 homolog","metadata":{"aliases":["VID24","C17orf39"]}},{"id":"1707c30b79674b3c917beb69666a8155","type":"GENE","name":"GID8","canonical_id":"hgnc:HGNC:15857","description":"GID complex subunit 8 homolog","metadata":{"aliases":["FLJ20602","bA305P22.1","TWA1","C20orf11"]}},{"id":"d61395f1623c4d3390d06046337eda4e","type":"GENE","name":"GIGYF1","canonical_id":"hgnc:HGNC:9126","description":"GRB10 interacting GYF protein 1","metadata":{"aliases":["GYF1","PERQ1"]}},{"id":"c98437b3103548129781001b348151b4","type":"GENE","name":"GIGYF2","canonical_id":"hgnc:HGNC:11960","description":"GRB10 interacting GYF protein 2","metadata":{"aliases":["KIAA0642","GYF2","PERQ2","PERQ3","TNRC15","PARK11"]}},{"id":"11519d1f69dc44cb97722032d1e38cf3","type":"GENE","name":"GIHCG","canonical_id":"hgnc:HGNC:52649","description":"GIHCG inhibitor of miR-200b/200a/429 expression","metadata":{"aliases":["lncRNA-GIHCG"]}},{"id":"cfc5ff4a8c9840008f2f302e8c0bbc6f","type":"TRIAL","name":"GILT Docetaxel - Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00174629","description":"Lung Neoplasms","metadata":null},{"id":"1fec1ad9c435421eb641a07ee4f76639","type":"GENE","name":"GIMAP1","canonical_id":"hgnc:HGNC:23237","description":"GTPase, IMAP family member 1","metadata":{"aliases":["HIMAP1","IMAP38","IMAP1","IAN2"]}},{"id":"7a7f92384d90448383f9ffc913c536e1","type":"GENE","name":"GIMAP1-GIMAP5","canonical_id":"hgnc:HGNC:51257","description":"GIMAP1-GIMAP5 readthrough","metadata":null},{"id":"2af2ed4a968a4eadbae517cadc973856","type":"GENE","name":"GIMAP2","canonical_id":"hgnc:HGNC:21789","description":"GTPase, IMAP family member 2","metadata":{"aliases":["DKFZp586D0824","HIMAP2","IMAP2","IAN12"]}},{"id":"f685fd06f49b49e492d4c11fb1846299","type":"GENE","name":"GIMAP3P","canonical_id":"hgnc:HGNC:30975","description":"GTPase, IMAP family member 3 pseudogene","metadata":{"aliases":["GIMAP3","IAN4P"]}},{"id":"54a6cd0d44ce4e57866b71f41fac81fd","type":"GENE","name":"GIMAP4","canonical_id":"hgnc:HGNC:21872","description":"GTPase, IMAP family member 4","metadata":{"aliases":["HIMAP4","FLJ11110","IMAP4","IAN1"]}},{"id":"cce0952bb136474ea364313a21fa8115","type":"GENE","name":"GIMAP5","canonical_id":"hgnc:HGNC:18005","description":"GTPase, IMAP family member 5","metadata":{"aliases":["HIMAP3","IAN5","IAN4L1"]}},{"id":"d00e8dd60bde40f58d33606caa86af4a","type":"GENE","name":"GIMAP6","canonical_id":"hgnc:HGNC:21918","description":"GTPase, IMAP family member 6","metadata":{"aliases":["FLJ22690","IAN6"]}},{"id":"f8966a12181d46ef8da9dd2b065c28f2","type":"GENE","name":"GIMAP7","canonical_id":"hgnc:HGNC:22404","description":"GTPase, IMAP family member 7","metadata":{"aliases":["MGC27027","IAN7"]}},{"id":"74ebadfefe3c462fbc90a7974dc2f0ea","type":"GENE","name":"GIMAP8","canonical_id":"hgnc:HGNC:21792","description":"GTPase, IMAP family member 8","metadata":{"aliases":["DKFZp667I133","hIAN6","IAN9"]}},{"id":"ba7904b169944a85a42f947807749188","type":"GENE","name":"GIMD1","canonical_id":"hgnc:HGNC:44141","description":"GIMAP family P-loop NTPase domain containing 1","metadata":null},{"id":"c298396a09db42d0aa20136c894d6d2c","type":"GENE","name":"GIN1","canonical_id":"hgnc:HGNC:25959","description":"gypsy retrotransposon integrase 1","metadata":{"aliases":["FLJ20125","GIN-1","TGIN1","ZH2C2"]}},{"id":"bca14862d07b4293a19486fcc687c7a6","type":"GENE","name":"GINM1","canonical_id":"hgnc:HGNC:21074","description":"glycosylated integral membrane protein 1","metadata":{"aliases":["dJ12G14.2","C6orf72"]}},{"id":"b0b1eb587b2743a2b2729e066dc14287","type":"GO_TERM","name":"GINS complex","canonical_id":"go:GO:0000811","description":"\"A heterotetrameric protein complex that associates with replication origins, where it is required for the initiation of DNA replication, and with replication forks.\" [GOC:rb, GOC:rn, PMID:12730134, PMID:16990792, PMID:17467990]","metadata":null},{"id":"8df2586bf3c54cf88e3551a583dfbd2f","type":"GO_TERM","name":"GINS complex assembly","canonical_id":"go:GO:0071165","description":"\"The aggregation, arrangement and bonding together of a set of components to form a GINS complex, a heterotetrameric protein complex that associates with DNA replication origins and replication forks.\" [GOC:mah, PMID:16990792]","metadata":null},{"id":"e91900fada6d432cabb134fc9015e8b9","type":"GENE","name":"GINS1","canonical_id":"hgnc:HGNC:28980","description":"GINS complex subunit 1","metadata":{"aliases":["KIAA0186","PSF1"]}},{"id":"486b8b362c674d91a60dbf9174368698","type":"GENE","name":"GINS2","canonical_id":"hgnc:HGNC:24575","description":"GINS complex subunit 2","metadata":{"aliases":["PSF2","Pfs2"]}},{"id":"420023e4656745b181aae5b257922a62","type":"GENE","name":"GINS3","canonical_id":"hgnc:HGNC:25851","description":null,"metadata":null},{"id":"26037d6c97ad4616ab2e8c8e37413c43","type":"GENE","name":"GINS4","canonical_id":"hgnc:HGNC:28226","description":"GINS complex subunit 4","metadata":{"aliases":["MGC14799","SLD5"]}},{"id":"5a4a753899ee4954bd6f5f0d2efe3f20","type":"GENE","name":"GIP","canonical_id":"hgnc:HGNC:4270","description":"gastric inhibitory polypeptide","metadata":null},{"id":"d7e7b394c93a403f979e55568c3b675d","type":"GENE","name":"GIPC1","canonical_id":"hgnc:HGNC:1226","description":"GIPC PDZ domain containing family member 1","metadata":{"aliases":["TIP-2","Hs.6454","GIPC","SEMCAP","GLUT1CBP","SYNECTIN","NIP","C19orf3","RGS19IP1"]}},{"id":"435564903ad94ec493907d124bde9514","type":"GENE","name":"GIPC2","canonical_id":"hgnc:HGNC:18177","description":"GIPC PDZ domain containing family member 2","metadata":{"aliases":["FLJ20075","SEMCAP-2"]}},{"id":"cd9222d467294e7c9fd082a3040ad1c9","type":"GENE","name":"GIPC3","canonical_id":"hgnc:HGNC:18183","description":"GIPC PDZ domain containing family member 3","metadata":{"aliases":["DFNB95","C19orf64","DFNB72","DFNB15"]}},{"id":"28b1074a13164bacaf2baf3c4f851aba","type":"GENE","name":"GIPR","canonical_id":"hgnc:HGNC:4271","description":null,"metadata":null},{"id":"598e929c0ba64991b93ccfe235495d6f","type":"GENE","name":"GIRGL","canonical_id":"hgnc:HGNC:55702","description":"glutamine insufficiency regulator of glutaminase lncRNA","metadata":{"aliases":["MACC1-DT"]}},{"id":"04f96b7613af441b9fdd7d2b480e7fcf","type":"DISEASE","name":"GIST-plus syndrome","canonical_id":"efo:0010279","description":null,"metadata":null},{"id":"d0a27a4b04514b36931e8a5d6ee8c183","type":"GENE","name":"GIT1","canonical_id":"hgnc:HGNC:4272","description":"GIT ArfGAP 1","metadata":null},{"id":"4297a6dacd354c1b8f8b89b13496cd1e","type":"GENE","name":"GIT2","canonical_id":"hgnc:HGNC:4273","description":"GIT ArfGAP 2","metadata":{"aliases":["KIAA0148","PKL"]}},{"id":"addf3a401656478f848f18e9d7a298f6","type":"GENE","name":"GJA1","canonical_id":"hgnc:HGNC:4274","description":null,"metadata":null},{"id":"d50aefc8ff0b45d58ff8928f411a682e","type":"GENE","name":"GJA10","canonical_id":"hgnc:HGNC:16995","description":"gap junction protein alpha 10","metadata":{"aliases":["CX62"]}},{"id":"299f63cd6bc242439565e21f2e9b7b94","type":"GENE","name":"GJA1P1","canonical_id":"hgnc:HGNC:4275","description":"gap junction protein alpha 1 pseudogene 1","metadata":null},{"id":"28a287b2e5994f37834a0bc2d114ec13","type":"GENE","name":"GJA3","canonical_id":"hgnc:HGNC:4277","description":"gap junction protein alpha 3","metadata":{"aliases":["CX46","CZP3"]}},{"id":"e286413be40141d388df681e92f97611","type":"GENE","name":"GJA4","canonical_id":"hgnc:HGNC:4278","description":"gap junction protein alpha 4","metadata":{"aliases":["CX37"]}},{"id":"444a767160bc4b2cb43eeade32e1aa27","type":"GENE","name":"GJA5","canonical_id":"hgnc:HGNC:4279","description":null,"metadata":null},{"id":"0fe0a62966e0433696777bf71559ccf7","type":"GENE","name":"GJA6P","canonical_id":"hgnc:HGNC:32542","description":"gap junction protein alpha 6, pseudogene","metadata":null},{"id":"aad5fd5d5b354eaea9dafb822fa7ccc8","type":"GENE","name":"GJA8","canonical_id":"hgnc:HGNC:4281","description":"gap junction protein alpha 8","metadata":{"aliases":["CX50","CAE1","CZP1","CAE"]}},{"id":"95cbc03c84894a96a7553daf9215acd8","type":"GENE","name":"GJA9","canonical_id":"hgnc:HGNC:19155","description":"gap junction protein alpha 9","metadata":{"aliases":["CX59","CX58","GJA10"]}},{"id":"e6cc09406a524bd88baf887f69b95f78","type":"GENE","name":"GJB1","canonical_id":"hgnc:HGNC:4283","description":null,"metadata":null},{"id":"db5cfa10956845b59fa8d1486d719167","type":"GENE","name":"GJB2","canonical_id":"hgnc:HGNC:4284","description":"gap junction protein beta 2","metadata":{"aliases":["CX26","NSRD1","DFNB1","DFNA3"]}},{"id":"d873a42ab77c4a78b67f63926612f14c","type":"GENE","name":"GJB3","canonical_id":"hgnc:HGNC:4285","description":"gap junction protein beta 3","metadata":{"aliases":["CX31","DFNA2","EKV"]}},{"id":"4d3cdfe613484136af1c824809097318","type":"GENE","name":"GJB4","canonical_id":"hgnc:HGNC:4286","description":"gap junction protein beta 4","metadata":{"aliases":["CX30.3"]}},{"id":"8a32c993509f4663aaf8d86ba1aea5d1","type":"GENE","name":"GJB5","canonical_id":"hgnc:HGNC:4287","description":"gap junction protein beta 5","metadata":{"aliases":["CX31.1"]}},{"id":"99e319e61e9e470dbc5e0d5959aeb487","type":"GENE","name":"GJB6","canonical_id":"hgnc:HGNC:4288","description":"gap junction protein beta 6","metadata":{"aliases":["EDH","HED","CX30","DFNA3","ED2"]}},{"id":"a940505b8a2f4a92a8a8e8fd2ae422a5","type":"GENE","name":"GJB7","canonical_id":"hgnc:HGNC:16690","description":"gap junction protein beta 7","metadata":{"aliases":["CX25","bA136M9.1"]}},{"id":"337ec137564b4a95a708969dfc8f7c5e","type":"GENE","name":"GJC1","canonical_id":"hgnc:HGNC:4280","description":"gap junction protein gamma 1","metadata":{"aliases":["CX45","GJA7"]}},{"id":"a33f4e0b763b455ea3cd100e9511c037","type":"GENE","name":"GJC2","canonical_id":"hgnc:HGNC:17494","description":null,"metadata":null},{"id":"5169ca3d4fe141d18e553e5326de0cac","type":"GENE","name":"GJC3","canonical_id":"hgnc:HGNC:17495","description":"gap junction protein gamma 3","metadata":{"aliases":["CX30.2","CX29","GJE1"]}},{"id":"b61e1e8fe4b8412f865b22dbac39c579","type":"GENE","name":"GJD2","canonical_id":"hgnc:HGNC:19154","description":null,"metadata":null},{"id":"c38a4dd4ba1147b1ab4d2397f74f2f8b","type":"GENE","name":"GJD2-DT","canonical_id":"hgnc:HGNC:55560","description":"GJD2 divergent transcript","metadata":null},{"id":"a7794c2af5be4bf5bfc3a43a78a4313d","type":"GENE","name":"GJD3","canonical_id":"hgnc:HGNC:19147","description":"gap junction protein delta 3","metadata":{"aliases":["CX31.9","GJA11","Cx30.2","GJC1"]}},{"id":"40a48ee39a344d2bb4f181b18eddad08","type":"GENE","name":"GJD3-AS1","canonical_id":"hgnc:HGNC:56092","description":"GJD3 antisense RNA 1","metadata":{"aliases":["UPLA1"]}},{"id":"4044b299c45c4ed89b0c4c9d60e675a5","type":"GENE","name":"GJD4","canonical_id":"hgnc:HGNC:23296","description":"gap junction protein delta 4","metadata":{"aliases":["CX40.1","FLJ90023"]}},{"id":"149d316bca9246a1afd3a2e248bcda64","type":"GENE","name":"GJD4-AS1","canonical_id":"hgnc:HGNC:58343","description":"GJD4 antisense RNA 1","metadata":null},{"id":"6f3f5648494943f8a7fe893fb0492c1c","type":"GENE","name":"GJE1","canonical_id":"hgnc:HGNC:33251","description":"gap junction protein epsilon 1","metadata":{"aliases":["CX23"]}},{"id":"0c7a807bf7c3476b9f518728b382e003","type":"GENE","name":"GK","canonical_id":"hgnc:HGNC:4289","description":null,"metadata":null},{"id":"e5c74a8b7679429890943640699ace45","type":"GENE","name":"GK-AS1","canonical_id":"hgnc:HGNC:40255","description":"GK antisense RNA 1","metadata":null},{"id":"6d3ed97fb0754275ad6c14e30448fb6d","type":"GENE","name":"GK-IT1","canonical_id":"hgnc:HGNC:41339","description":"GK intronic transcript 1","metadata":null},{"id":"df321178dd034b0ba85dbab5619210c6","type":"GENE","name":"GK2","canonical_id":"hgnc:HGNC:4291","description":"glycerol kinase 2","metadata":{"aliases":["GKTA","GKP2"]}},{"id":"b8197e33b0384b159744ed9bba1ca79a","type":"GENE","name":"GK3","canonical_id":"hgnc:HGNC:4292","description":"glycerol kinase 3","metadata":{"aliases":["GKTB","GKP3","GK3P"]}},{"id":"aa4675b5d9e24a7b933abdad4059de8c","type":"GENE","name":"GK4P","canonical_id":"hgnc:HGNC:4295","description":"glycerol kinase 4 pseudogene","metadata":{"aliases":["GKP6"]}},{"id":"a3eb5f61c44d43aea5d4318d3a47f1e2","type":"GENE","name":"GK5","canonical_id":"hgnc:HGNC:28635","description":"glycerol kinase 5","metadata":{"aliases":["MGC40579"]}},{"id":"3306fb566d7749889eeb77f2deb743bc","type":"GENE","name":"GK6P","canonical_id":"hgnc:HGNC:23263","description":"glycerol kinase 6 pseudogene","metadata":{"aliases":["GK7P","GKP1"]}},{"id":"86a95873886949a9bac79068254f692b","type":"GENE","name":"GKAP1","canonical_id":"hgnc:HGNC:17496","description":"G kinase anchoring protein 1","metadata":{"aliases":["GKAP42","FKSG21"]}},{"id":"649750c13685460f88ee1b2c8678069c","type":"GENE","name":"GKN1","canonical_id":"hgnc:HGNC:23217","description":"gastrokine 1","metadata":{"aliases":["AMP18","CA11","BRICD1"]}},{"id":"d3a51586d32245349219f7293dfe8501","type":"GENE","name":"GKN2","canonical_id":"hgnc:HGNC:24588","description":null,"metadata":null},{"id":"5cf6574704e44a21b72f92c7e78ed1b7","type":"GENE","name":"GKN3P","canonical_id":"hgnc:HGNC:37701","description":"gastrokine 3, pseudogene","metadata":null},{"id":"68acf77ca3c747358dfe5a41460f4f42","type":"GENE","name":"GLA","canonical_id":"hgnc:HGNC:4296","description":"galactosidase alpha","metadata":{"aliases":["GALA"]}},{"id":"7a5e6b8c4d1e478284935ccbfa435ba8","type":"TRIAL","name":"GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04051996","description":"ACUTE MYELOID LEUKEMIA","metadata":null},{"id":"9a0e802559a4450783ab361d61fc7000","type":"GENE","name":"GLB1","canonical_id":"hgnc:HGNC:4298","description":"galactosidase beta 1","metadata":{"aliases":["EBP","ELNR1"]}},{"id":"20255442cd6e4348ae5545d3f3dc83f8","type":"GENE","name":"GLB1L","canonical_id":"hgnc:HGNC:28129","description":"galactosidase beta 1 like","metadata":{"aliases":["MGC10771"]}},{"id":"377340a3fb5b4e4a96eb51b1c03c0def","type":"GENE","name":"GLB1L2","canonical_id":"hgnc:HGNC:25129","description":"galactosidase beta 1 like 2","metadata":null},{"id":"34fe9a437362471eba6701e7e62059d3","type":"GENE","name":"GLB1L3","canonical_id":"hgnc:HGNC:25147","description":"galactosidase beta 1 like 3","metadata":{"aliases":["FLJ90231"]}},{"id":"8c087cb0f6544185a74a3860404f6056","type":"GENE","name":"GLCCI1","canonical_id":"hgnc:HGNC:18713","description":"glucocorticoid induced 1","metadata":{"aliases":["GIG18","FAM117C","TSSN1"]}},{"id":"7b2c923c212e41afb651b07090e01350","type":"GENE","name":"GLCCI1-DT","canonical_id":"hgnc:HGNC:40852","description":"GLCCI1 divergent transcript","metadata":null},{"id":"5ae5dbf6625c46a39ce0e071c538861d","type":"GENE","name":"GLCE","canonical_id":"hgnc:HGNC:17855","description":null,"metadata":null},{"id":"6764cb1c42db44a38cf435ecec263157","type":"GENE","name":"GLDC","canonical_id":"hgnc:HGNC:4313","description":"glycine decarboxylase","metadata":{"aliases":["GCSP","NKH"]}},{"id":"476fc4b0c90940c4886b0fe4f206bc82","type":"GENE","name":"GLDCP1","canonical_id":"hgnc:HGNC:4314","description":"glycine decarboxylase pseudogene 1","metadata":{"aliases":["GLDCP"]}},{"id":"4789fd6013394c53bb3d745886c4d737","type":"GENE","name":"GLDN","canonical_id":"hgnc:HGNC:29514","description":"gliomedin","metadata":{"aliases":["CRG-L2","CLOM","colmedin","UNC-122","COLM"]}},{"id":"67f5fb26f75040598750fe512e846a69","type":"GENE","name":"GLE1","canonical_id":"hgnc:HGNC:4315","description":"GLE1 RNA export mediator","metadata":{"aliases":["hGLE1","GLE1L","LCCS1"]}},{"id":"7bdd3e0596de421d9c4f0a903d449b1f","type":"GENE","name":"GLELR","canonical_id":"hgnc:HGNC:58984","description":"glial cell enriched regulatory lncRNA","metadata":null},{"id":"459a5e5593a8479f83f2cad657418c4f","type":"GENE","name":"GLG1","canonical_id":"hgnc:HGNC:4316","description":"golgi glycoprotein 1","metadata":{"aliases":["MG-160","ESL-1","CFR-1"]}},{"id":"20b1f4b73fc94402846518cce06323df","type":"GO_TERM","name":"GLI-SUFU complex","canonical_id":"go:GO:1990788","description":"\"A protein repressing GLI's transcription factor activity when SMO signaling is inactive. Upon ligand binding to the upstream receptor PTC (Patched) GLI dissociates from SUFU and activates transcription of hedgehog-target genes. In mammals it consists of SUFU and one of the GLI family proteins.\" [GOC:bhm, PMID:24311597]","metadata":null},{"id":"e5c25c6433e84a4e90de5bbfd20bb7cd","type":"GENE","name":"GLI1","canonical_id":"hgnc:HGNC:4317","description":null,"metadata":null},{"id":"041e3cff9b0847be88a959098cae0e19","type":"GENE","name":"GLI2","canonical_id":"hgnc:HGNC:4318","description":null,"metadata":null},{"id":"ffe3d0d9d9234eadba2baa6970d3aa52","type":"GENE","name":"GLI3","canonical_id":"hgnc:HGNC:4319","description":null,"metadata":null},{"id":"e0a0a3d31e464b098eadbe77d2fd295b","type":"GENE","name":"GLI4","canonical_id":"hgnc:HGNC:4320","description":"GLI family zinc finger 4","metadata":{"aliases":["HKR4","ZNF928"]}},{"id":"a4b859ca942e460fa60d6e0bae6261c8","type":"GENE","name":"GLIDR","canonical_id":"hgnc:HGNC:48823","description":"glioblastoma down-regulated RNA","metadata":{"aliases":["MGC21881","TCONS_00015562","FAM88A","LINC01172"]}},{"id":"7414a90856ff446f86ee8a2f41024e10","type":"GENE","name":"GLIPR1","canonical_id":"hgnc:HGNC:17001","description":"GLI pathogenesis related 1","metadata":{"aliases":["RTVP1","GliPR"]}},{"id":"b3433f35c22d4b25ba31e058fd30ce85","type":"GENE","name":"GLIPR1-AS1","canonical_id":"hgnc:HGNC:56075","description":"GLIPR1 antisense RNA 1","metadata":{"aliases":["RP11-585P4.5"]}},{"id":"4c1f9f6355994e3d9dcb7f992d8076a7","type":"GENE","name":"GLIPR1L1","canonical_id":"hgnc:HGNC:28392","description":"GLIPR1 like 1","metadata":{"aliases":["MGC26856"]}},{"id":"4ca3c6bcb6724569aaeb4cbc40f654ed","type":"GENE","name":"GLIPR1L2","canonical_id":"hgnc:HGNC:28592","description":"GLIPR1 like 2","metadata":{"aliases":["MGC39497"]}},{"id":"f153ed77a7f8486481ba8be4e8e7b4e8","type":"GENE","name":"GLIPR2","canonical_id":"hgnc:HGNC:18007","description":"GLI pathogenesis related 2","metadata":{"aliases":["GAPR-1","C9orf19"]}},{"id":"cf313d01e78d431894afe41d08611e0b","type":"GENE","name":"GLIS1","canonical_id":"hgnc:HGNC:29525","description":"GLIS family zinc finger 1","metadata":{"aliases":["FLJ36155"]}},{"id":"22e7b99718244e45a044011bd1db6f1b","type":"GENE","name":"GLIS2","canonical_id":"hgnc:HGNC:29450","description":"GLIS family zinc finger 2","metadata":{"aliases":["NPHP7"]}},{"id":"795ccece19704cd2b6f32a4745cf9784","type":"GENE","name":"GLIS2-AS1","canonical_id":"hgnc:HGNC:51381","description":"GLIS2 antisense RNA 1","metadata":null},{"id":"b497569721694dbbb418dc544b2a718a","type":"GENE","name":"GLIS3","canonical_id":"hgnc:HGNC:28510","description":null,"metadata":null},{"id":"69121f799129457785bc4f9406dec716","type":"GENE","name":"GLIS3-AS1","canonical_id":"hgnc:HGNC:28260","description":"GLIS3 antisense RNA 1","metadata":{"aliases":["MGC16153","C9orf70"]}},{"id":"9862e382d0bb43b8a7ffa6a9f7e7982c","type":"GENE","name":"GLIS3-AS2","canonical_id":"hgnc:HGNC:55796","description":"GLIS3 antisense RNA 2","metadata":null},{"id":"0824c1d37a924786b6bbe2fcc588676c","type":"GENE","name":"GLMN","canonical_id":"hgnc:HGNC:14373","description":"glomulin, FKBP associated protein","metadata":{"aliases":["FAP48","FAP68","GLML","GVM","FKBPAP","VMGLOM"]}},{"id":"8f7b119c32d444d69281548b45cd27fc","type":"GENE","name":"GLMP","canonical_id":"hgnc:HGNC:29436","description":"glycosylated lysosomal membrane protein","metadata":{"aliases":["MGC31963","NCU-G1","lnc-UCID","C1orf85"]}},{"id":"c420cfa1184b47b0b8353012641d50b2","type":"GENE","name":"GLO1","canonical_id":"hgnc:HGNC:4323","description":"glyoxalase I","metadata":{"aliases":["GLOD1"]}},{"id":"e7f8c6b7b6484d458428cf4092d54bef","type":"GENE","name":"GLOD4","canonical_id":"hgnc:HGNC:14111","description":"glyoxalase domain containing 4","metadata":{"aliases":["CGI-150","HC71","C17orf25"]}},{"id":"6d2dc2921c4e4689928696a43c145246","type":"GENE","name":"GLOD5","canonical_id":"hgnc:HGNC:33358","description":"glyoxalase domain containing 5","metadata":null},{"id":"a11460d031444318a0d947e71e1178cb","type":"TRIAL","name":"GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01592279","description":"Uncontrolled Type 1 Diabetic Patients","metadata":null},{"id":"ad041854098b4bc9bab3ac64c2ae3ba4","type":"TRIAL","name":"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","canonical_id":"clinicaltrials.gov:NCT00707031","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1ca05ddcbee3463f9dc9dbc338b1c351","type":"TRIAL","name":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)","canonical_id":"clinicaltrials.gov:NCT00905255","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"999083a7102f475cb8228b0b5a39790a","type":"TRIAL","name":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","canonical_id":"clinicaltrials.gov:NCT00866658","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"644aa796736c4358aa7dee9c7c2852e2","type":"TRIAL","name":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","canonical_id":"clinicaltrials.gov:NCT00763451","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"9c18d324aceb4b5781004985be750cfb","type":"TRIAL","name":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","canonical_id":"clinicaltrials.gov:NCT00763815","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"5346ae4962a74f7c985e705626491f2b","type":"TRIAL","name":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","canonical_id":"clinicaltrials.gov:NCT00713830","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"866ad25f47b94f178b12ab003c95627e","type":"GENE","name":"GLP1R","canonical_id":"hgnc:HGNC:4324","description":"glucagon like peptide 1 receptor","metadata":{"aliases":["GLP-1R"]}},{"id":"6cd0f5f723be43cbbae232af68585dd9","type":"PROTEIN","name":"GLP1R","canonical_id":"uniprot:P43220","description":null,"metadata":null},{"id":"1764b02c4ed747e4bb64c79d810fca80","type":"GENE","name":"GLP2R","canonical_id":"hgnc:HGNC:4325","description":"glucagon like peptide 2 receptor","metadata":null},{"id":"18ad3263a72f4bed8c38e802484f6b07","type":"PROTEIN","name":"GLP2R","canonical_id":"uniprot:O95838","description":null,"metadata":null},{"id":"5eceb98b2742415fa73d384e52885ccc","type":"GENE","name":"GLRA1","canonical_id":"hgnc:HGNC:4326","description":null,"metadata":null},{"id":"009f12adff254594b50c42f45ad20c3d","type":"PROTEIN","name":"GLRA1","canonical_id":"uniprot:P23415","description":null,"metadata":null},{"id":"fddf3e77973f483cbb05af690fe5d5bd","type":"GENE","name":"GLRA1-AS1","canonical_id":"hgnc:HGNC:59284","description":"GLRA1 antisense RNA 1","metadata":null},{"id":"796d8dacf1864881a029ecc9a97d6a8a","type":"GENE","name":"GLRA2","canonical_id":"hgnc:HGNC:4327","description":"glycine receptor alpha 2","metadata":{"aliases":["GLR"]}},{"id":"e5c49f3a8089473bb4587d097af0ba8d","type":"GENE","name":"GLRA3","canonical_id":"hgnc:HGNC:4328","description":"glycine receptor alpha 3","metadata":null},{"id":"42d5dd8f89e141d8ba41bc024dce8d32","type":"GENE","name":"GLRA4","canonical_id":"hgnc:HGNC:31715","description":"glycine receptor alpha 4 (pseudogene)","metadata":{"aliases":["GLRA4P"]}},{"id":"b1c6a365bab24764a26aeeaa13f57e44","type":"GENE","name":"GLRB","canonical_id":"hgnc:HGNC:4329","description":"glycine receptor beta","metadata":null},{"id":"e0f3144973f4442bb894a27be8c43fc1","type":"GENE","name":"GLRX","canonical_id":"hgnc:HGNC:4330","description":"glutaredoxin","metadata":{"aliases":["GRX","GRX1"]}},{"id":"9c489d64c4d64492b9453366afd843b9","type":"GENE","name":"GLRX2","canonical_id":"hgnc:HGNC:16065","description":"glutaredoxin 2","metadata":{"aliases":["GRX2","bA101E13.1"]}},{"id":"5abd33dbf943484089050a88307e84d3","type":"GENE","name":"GLRX3","canonical_id":"hgnc:HGNC:15987","description":"glutaredoxin 3","metadata":{"aliases":["PICOT","bA500G10.4","GRX3","GLRX4","GRX4","TXNL2"]}},{"id":"2cdcd38d06dc4352a44d9b8ab45cf08e","type":"GENE","name":"GLRX3P1","canonical_id":"hgnc:HGNC:49787","description":"glutaredoxin 3 pseudogene 1","metadata":null},{"id":"e1bf92fb93514254a7defd31d09d76e7","type":"GENE","name":"GLRX3P2","canonical_id":"hgnc:HGNC:49788","description":"glutaredoxin 3 pseudogene 2","metadata":null},{"id":"e9f626f2bd2e42e3b6c18259e8fc688e","type":"GENE","name":"GLRX5","canonical_id":"hgnc:HGNC:20134","description":"glutaredoxin 5","metadata":{"aliases":["PR01238","GRX5","C14orf87"]}},{"id":"d2e6446e336a4d16b1b23bfc5e98bde4","type":"GENE","name":"GLRX5P1","canonical_id":"hgnc:HGNC:55062","description":"GLRX5 pseudogene 1","metadata":null},{"id":"11a9af410f3d4ad4af370f307372eaf3","type":"GENE","name":"GLRX5P2","canonical_id":"hgnc:HGNC:55063","description":"GLR5 pseudogene 2","metadata":null},{"id":"3790d56f32ac4243b18f2ee8664bd30d","type":"GENE","name":"GLRX5P3","canonical_id":"hgnc:HGNC:55064","description":"GLRX5 pseudogene 3","metadata":null},{"id":"f9498a11b2b54519abc7bb478599fa64","type":"GENE","name":"GLRXP1","canonical_id":"hgnc:HGNC:16544","description":"glutaredoxin pseudogene 1","metadata":{"aliases":["bA425M5.1","GLRXP"]}},{"id":"1d82c049ef1947cba90aa9acba0235fe","type":"GENE","name":"GLRXP2","canonical_id":"hgnc:HGNC:18376","description":"glutaredoxin pseudogene 2","metadata":null},{"id":"f929f8bc65c8446b99d693ca8ddbbaa9","type":"GENE","name":"GLRXP3","canonical_id":"hgnc:HGNC:34049","description":"glutaredoxin pseudogene 3","metadata":{"aliases":["GLRXL"]}},{"id":"e2f7cecbfb2d4467b7bbf0134dccd545","type":"GENE","name":"GLS","canonical_id":"hgnc:HGNC:4331","description":null,"metadata":null},{"id":"27a6a4b5a13740d0a285911b2134bc17","type":"GENE","name":"GLS2","canonical_id":"hgnc:HGNC:29570","description":"glutaminase 2","metadata":{"aliases":["GA","GLS","LGA","hLGA"]}},{"id":"6e2cd570279e42188ea9f04c63601d78","type":"GENE","name":"GLT1D1","canonical_id":"hgnc:HGNC:26483","description":"glycosyltransferase 1 domain containing 1","metadata":{"aliases":["FLJ31978"]}},{"id":"640a30602bd1456897a272c46555cdda","type":"GENE","name":"GLT6D1","canonical_id":"hgnc:HGNC:23671","description":"glycosyltransferase 6 domain containing 1","metadata":{"aliases":["GLTDC1"]}},{"id":"a9e6e1fafcf9452e9c6168715fa72da7","type":"GENE","name":"GLT8D1","canonical_id":"hgnc:HGNC:24870","description":"glycosyltransferase 8 domain containing 1","metadata":{"aliases":["AD-017","FLJ14611"]}},{"id":"ea4e4bb05cee41eaa28d4f9859e3b43a","type":"GENE","name":"GLT8D2","canonical_id":"hgnc:HGNC:24890","description":"glycosyltransferase 8 domain containing 2","metadata":{"aliases":["FLJ31494"]}},{"id":"e5bba788f93c48528fc9216f28a5c107","type":"GENE","name":"GLTC1","canonical_id":"hgnc:HGNC:56861","description":"glycolysis associated regulator of LDHA post-transcriptional modification 1","metadata":{"aliases":["lnc-UNC93B1-1","GLTC"]}},{"id":"e0cce9d3fef041caa0cbdc6e4858491b","type":"GENE","name":"GLTP","canonical_id":"hgnc:HGNC:24867","description":"glycolipid transfer protein","metadata":null},{"id":"e94ea06e2d4e42f1887e160f21d03bbb","type":"GENE","name":"GLTPD2","canonical_id":"hgnc:HGNC:33756","description":"glycolipid transfer protein domain containing 2","metadata":null},{"id":"9498ac4725f74382a3b0959c0c78dba1","type":"GENE","name":"GLTPP1","canonical_id":"hgnc:HGNC:33991","description":"glycolipid transfer protein pseudogene 1","metadata":null},{"id":"81f3496033fd47b59e5da10a70154c3d","type":"GENE","name":"GLUD1","canonical_id":"hgnc:HGNC:4335","description":"glutamate dehydrogenase 1","metadata":{"aliases":["GDH","GDH1","hGDH1","GLUD"]}},{"id":"049a137439a44eaca475c0a92af758a9","type":"GENE","name":"GLUD1P2","canonical_id":"hgnc:HGNC:4337","description":"glutamate dehydrogenase 1 pseudogene 2","metadata":{"aliases":["bA342C24.3","GLUDP2","GLUD1P7","GLUDP7"]}},{"id":"c0ae0c26bbd94ca6a116d2bb9dd65ef4","type":"GENE","name":"GLUD1P3","canonical_id":"hgnc:HGNC:4338","description":"glutamate dehydrogenase 1 pseudogene 3","metadata":{"aliases":["Em:AC022400.11","GLUDP3","C10orf102"]}},{"id":"835776b58621442cb5167d93a3c46ded","type":"GENE","name":"GLUD1P4","canonical_id":"hgnc:HGNC:4339","description":"glutamate dehydrogenase 1 pseudogene 4","metadata":{"aliases":["GLUDP4"]}},{"id":"805398f7dc4d4d6595e4868abb000d35","type":"GENE","name":"GLUD1P5","canonical_id":"hgnc:HGNC:4340","description":"glutamate dehydrogenase 1 pseudogene 5","metadata":{"aliases":["GLUDP5"]}},{"id":"59d57b874d854661ba4e26bd7b67c036","type":"GENE","name":"GLUD1P6","canonical_id":"hgnc:HGNC:23610","description":"glutamate dehydrogenase 1 pseudogene 6","metadata":{"aliases":["bK2173J9.1","bA144G6.5","GLUDP6","GLUD1P8","GLUDP8"]}},{"id":"40b761766af24c16b53814866a228869","type":"GENE","name":"GLUD1P9","canonical_id":"hgnc:HGNC:37696","description":"glutamate dehydrogenase 1 pseudogene 9","metadata":null},{"id":"78068cc85fa440128645ea09e65f4484","type":"GENE","name":"GLUD2","canonical_id":"hgnc:HGNC:4336","description":"glutamate dehydrogenase 2","metadata":{"aliases":["GLUDP1"]}},{"id":"01393ae06fcd45609ad23276c5d59ccb","type":"GENE","name":"GLUL","canonical_id":"hgnc:HGNC:4341","description":"glutamate-ammonia ligase","metadata":{"aliases":["GLNS"]}},{"id":"365c2acbb0614385883c56add8a8ac6c","type":"GENE","name":"GLULP1","canonical_id":"hgnc:HGNC:4342","description":"glutamate-ammonia ligase pseudogene 1","metadata":{"aliases":["GLULL1"]}},{"id":"096be3423afc481da8c527884de11499","type":"GENE","name":"GLULP2","canonical_id":"hgnc:HGNC:4343","description":"glutamate-ammonia ligase pseudogene 2","metadata":{"aliases":["GLULL2"]}},{"id":"dd94ccdebfa04d518e165ccc3451bc83","type":"GENE","name":"GLULP3","canonical_id":"hgnc:HGNC:4344","description":"glutamate-ammonia ligase pseudogene 3","metadata":{"aliases":["GLULL3"]}},{"id":"8c8890e3bf7949bdac0afa18092bd284","type":"GENE","name":"GLULP4","canonical_id":"hgnc:HGNC:4345","description":"glutamate-ammonia ligase pseudogene 4","metadata":{"aliases":["GLULP"]}},{"id":"5cc6cf7f09ea4a29b6ca940d2cd5a864","type":"GENE","name":"GLULP5","canonical_id":"hgnc:HGNC:37989","description":"glutamate-ammonia ligase pseudogene 5","metadata":null},{"id":"af1e571da5514d25be69f9575c97eda7","type":"GENE","name":"GLULP6","canonical_id":"hgnc:HGNC:37990","description":"glutamate-ammonia ligase pseudogene 6","metadata":null},{"id":"6629acbf099c4ff59deb3de74c318422","type":"GENE","name":"GLYAT","canonical_id":"hgnc:HGNC:13734","description":"glycine-N-acyltransferase","metadata":{"aliases":["GAT","ACGNAT"]}},{"id":"11c465c3f6814c9a97ab58a225065a35","type":"GENE","name":"GLYATL1","canonical_id":"hgnc:HGNC:30519","description":"glycine-N-acyltransferase like 1","metadata":{"aliases":["MGC15397","FLJ34646"]}},{"id":"7454ecca9b40432a9a6c3f511c8abd18","type":"GENE","name":"GLYATL1-AS1","canonical_id":"hgnc:HGNC:58086","description":"GLYATL1 antisense RNA 1","metadata":null},{"id":"c86beae6be1f4bed9552596f41b16edc","type":"GENE","name":"GLYATL1B","canonical_id":"hgnc:HGNC:37865","description":"glycine-N-acyltransferase like 1B","metadata":{"aliases":["GLYATL1P3"]}},{"id":"9a555d78a694437f87346d0472ab376e","type":"GENE","name":"GLYATL1P1","canonical_id":"hgnc:HGNC:37866","description":"glycine-N-acyltransferase like 1 pseudogene 1","metadata":null},{"id":"8457df3e2f7942918181d6912f00de03","type":"GENE","name":"GLYATL1P2","canonical_id":"hgnc:HGNC:37863","description":"glycine-N-acyltransferase like 1 pseudogene 2","metadata":null},{"id":"23602180879249dbab4e03da2804eb8c","type":"GENE","name":"GLYATL1P4","canonical_id":"hgnc:HGNC:37864","description":"glycine-N-acyltransferase like 1 pseudogene 4","metadata":null},{"id":"22f909b9d4174b309cc9ba8598ab9fe0","type":"GENE","name":"GLYATL2","canonical_id":"hgnc:HGNC:24178","description":"glycine-N-acyltransferase like 2","metadata":{"aliases":["BXMAS2-10","MGC24009"]}},{"id":"acd2e6f2e5994060920b698702b8f0de","type":"GENE","name":"GLYATL3","canonical_id":"hgnc:HGNC:21349","description":"glycine-N-acyltransferase like 3","metadata":{"aliases":["bA28H17.2","C6orf140"]}},{"id":"f35b13aad7af4e239b4c01ec6063116a","type":"GENE","name":"GLYCAM1","canonical_id":"hgnc:HGNC:18023","description":"glycosylation dependent cell adhesion molecule 1 (pseudogene)","metadata":{"aliases":["GLYCAM1P"]}},{"id":"0a1764c1d4e3499f9d1cfff9df5b21c7","type":"GENE","name":"GLYCTK","canonical_id":"hgnc:HGNC:24247","description":"glycerate kinase","metadata":{"aliases":["HBEBP4","HBEBP2"]}},{"id":"6ae46e18d663436cb0c5f2223d458ca6","type":"GENE","name":"GLYCTK-AS1","canonical_id":"hgnc:HGNC:41043","description":"GLYCTK antisense RNA 1","metadata":null},{"id":"81b23aa45e3c4fe796feef9202587c06","type":"GENE","name":"GLYR1","canonical_id":"hgnc:HGNC:24434","description":"glyoxylate reductase 1 homolog","metadata":{"aliases":["BM045","HIBDL","NP60","N-PAC"]}},{"id":"16f114b8449f43a1a49c642d3387588a","type":"GENE","name":"GLYR1P1","canonical_id":"hgnc:HGNC:56963","description":"GLYR1 pseudogene 1","metadata":null},{"id":"93d0bb3a82cc46e6bf264938975d3379","type":"GENE","name":"GM2A","canonical_id":"hgnc:HGNC:4367","description":null,"metadata":null},{"id":"1802bdf4be6b4bc790ff05ebe97f6b83","type":"GENE","name":"GM2AP1","canonical_id":"hgnc:HGNC:4368","description":"GM2A pseudogene 1","metadata":{"aliases":["GM2AP"]}},{"id":"10604db29b5b4cf38de5ce90eb41e783","type":"GENE","name":"GM2AP2","canonical_id":"hgnc:HGNC:38002","description":"GM2A pseudogene 2","metadata":null},{"id":"e0c6b2af9f694977803189f22d2d69c7","type":"GENE","name":"GMCL1","canonical_id":"hgnc:HGNC:23843","description":"germ cell-less 1, spermatogenesis associated","metadata":{"aliases":["FLJ13057","BTBD13","GCL1","SPATA29"]}},{"id":"e581cc88c154403bb50a4244ea386d35","type":"GENE","name":"GMCL1P2","canonical_id":"hgnc:HGNC:42863","description":"GMCL1 pseudogene 2","metadata":null},{"id":"d7740977e96f4090962ad4b9179d3239","type":"GENE","name":"GMCL2","canonical_id":"hgnc:HGNC:19717","description":"germ cell-less 2, spermatogenesis associated","metadata":{"aliases":["GCL","GMCL1L","GMCL1P1"]}},{"id":"7b41f74102e24612b0bb93c8e983bae5","type":"GENE","name":"GMDS","canonical_id":"hgnc:HGNC:4369","description":"GDP-mannose 4,6-dehydratase","metadata":{"aliases":["GMD","SDR3E1"]}},{"id":"d615e22bb54a42399c8063716d8e49d0","type":"GENE","name":"GMDS-AS2","canonical_id":"hgnc:HGNC:59327","description":"GMDS antisense RNA 2","metadata":null},{"id":"09697115ffee44c88d402d06b63fd344","type":"GENE","name":"GMDS-AS3","canonical_id":"hgnc:HGNC:59328","description":"GMDS antisense RNA 3","metadata":null},{"id":"ce2e9a03cabc40ca84b60d88a1b187b7","type":"GENE","name":"GMDS-DT","canonical_id":"hgnc:HGNC:48993","description":"GMDS divergent transcript","metadata":{"aliases":["GMDS-AS1"]}},{"id":"5e6b312b0bc4460a8d677db1a16a0b5c","type":"GENE","name":"GMEB1","canonical_id":"hgnc:HGNC:4370","description":"glucocorticoid modulatory element binding protein 1","metadata":{"aliases":["P96PIF","PIF96"]}},{"id":"bd7589873bd047ab8543c94e9fc03820","type":"GENE","name":"GMEB2","canonical_id":"hgnc:HGNC:4371","description":"glucocorticoid modulatory element binding protein 2","metadata":{"aliases":["P79PIF","KIAA1269","PIF79"]}},{"id":"f6070b42cdd948628258ad8bc209a6b8","type":"GENE","name":"GMFB","canonical_id":"hgnc:HGNC:4373","description":"glia maturation factor beta","metadata":{"aliases":["GMF"]}},{"id":"5a0810c4453e4c36ab2832983e5ee49b","type":"GENE","name":"GMFBP1","canonical_id":"hgnc:HGNC:38654","description":"glia maturation factor beta pseudogene 1","metadata":null},{"id":"8f3f7853e97840d9936af183fe76baa1","type":"GENE","name":"GMFG","canonical_id":"hgnc:HGNC:4374","description":"glia maturation factor gamma","metadata":null},{"id":"74bad3da00c24502894575b76b4b81f6","type":"GENE","name":"GMIP","canonical_id":"hgnc:HGNC:24852","description":"GEM interacting protein","metadata":{"aliases":["ARHGAP46"]}},{"id":"aa643098150040f2a35001e3bae48fcd","type":"GENE","name":"GML","canonical_id":"hgnc:HGNC:4375","description":null,"metadata":null},{"id":"f4af573d8e844316921cb713f40b5f8f","type":"GENE","name":"GMNC","canonical_id":"hgnc:HGNC:40049","description":"geminin coiled-coil domain containing","metadata":{"aliases":["GEMC1"]}},{"id":"7725bc47b7a741fc81bd4c4282262981","type":"GENE","name":"GMNN","canonical_id":"hgnc:HGNC:17493","description":"geminin DNA replication inhibitor","metadata":{"aliases":["Gem"]}},{"id":"87bf6dac8463416f98f4b29e18182dc6","type":"GO_TERM","name":"GMP binding","canonical_id":"go:GO:0019002","description":"\"Binding to GMP, guanosine monophosphate.\" [GOC:ai]","metadata":null},{"id":"ab2618fc004b4e24b0ddd21684096e76","type":"GO_TERM","name":"GMP biosynthetic process","canonical_id":"go:GO:0006177","description":"\"The chemical reactions and pathways resulting in the formation of GMP, guanosine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"8c8130a716944b77bbc3d34815a55727","type":"GO_TERM","name":"GMP catabolic process","canonical_id":"go:GO:0046038","description":"\"The chemical reactions and pathways resulting in the breakdown of GMP, guanosine monophosphate.\" [GOC:curators]","metadata":null},{"id":"088b28767fa847b8a73bd386de9db8e6","type":"GO_TERM","name":"GMP kinase activity","canonical_id":"go:GO:0004385","description":"\"Catalysis of the reaction: ATP + GMP = ADP + GDP.\" [RHEA:20780]","metadata":null},{"id":"628d08c1c3934d9faab92375ee5aff96","type":"GO_TERM","name":"GMP metabolic process","canonical_id":"go:GO:0046037","description":"\"The chemical reactions and pathways involving GMP, guanosine monophosphate.\" [GOC:curators]","metadata":null},{"id":"7927a292cda04833be799a13ff594471","type":"GO_TERM","name":"GMP reductase activity","canonical_id":"go:GO:0003920","description":"\"Catalysis of the reaction: IMP + NADP+ + NH4 = GMP + 2 H+ + NADPH.\" [EC:1.7.1.7, RHEA:17185]","metadata":null},{"id":"351086bfba2e4234b7ab3d445decc48b","type":"GO_TERM","name":"GMP reductase complex","canonical_id":"go:GO:1902560","description":"\"An oxidoreductase complex which is capable of GMP reductase activity. It catalyses the irreversible reaction: GMP + 2 H+ + NADPH => IMP + NADP+ + NH4.\" [GOC:bhm, GOC:TermGenie, PMID:12009299]","metadata":null},{"id":"0308d409c1534e229737b429b1ea2d45","type":"GO_TERM","name":"GMP salvage","canonical_id":"go:GO:0032263","description":"\"Any process which produces guanosine monophosphate from derivatives of it, without de novo synthesis.\" [GOC:mah]","metadata":null},{"id":"15f8f09ca92243bc8d8fc99f4d6da150","type":"GO_TERM","name":"GMP synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0003922","description":"\"Catalysis of the reaction: ATP + XMP + L-glutamine + H2O = AMP + diphosphate + GMP + L-glutamate + 2H+.\" [RHEA:11680]","metadata":null},{"id":"2e7e09028f5d473bb8fa425c75539ad6","type":"GO_TERM","name":"GMP synthase activity","canonical_id":"go:GO:0003921","description":"\"Catalysis of the reaction: ATP + XMP + NH4+ = AMP + diphosphate + GMP + 2H+.\" [RHEA:18301]","metadata":null},{"id":"7d26e87545c84803af2ba2b9a3572db6","type":"GENE","name":"GMPPA","canonical_id":"hgnc:HGNC:22923","description":"GDP-mannose pyrophosphorylase A","metadata":null},{"id":"44116267c4dd4eac9def002645491057","type":"GENE","name":"GMPPB","canonical_id":"hgnc:HGNC:22932","description":"GDP-mannose pyrophosphorylase B","metadata":{"aliases":["KIAA1851"]}},{"id":"b8374422388140a380cfeaa2de18d5f5","type":"GENE","name":"GMPR","canonical_id":"hgnc:HGNC:4376","description":"guanosine monophosphate reductase","metadata":{"aliases":["GMPR1","hGMPR-I"]}},{"id":"2202d36fedb94125acc4221edc56dd60","type":"GENE","name":"GMPR-AS1","canonical_id":"hgnc:HGNC:59361","description":"GMPR antisense RNA 1","metadata":null},{"id":"50b6988f358a4586b2689a91724213c3","type":"GENE","name":"GMPR2","canonical_id":"hgnc:HGNC:4377","description":"guanosine monophosphate reductase 2","metadata":{"aliases":["hGMPR-II"]}},{"id":"7a891fcf5edd42338015c6ee66aa81ac","type":"GENE","name":"GMPS","canonical_id":"hgnc:HGNC:4378","description":null,"metadata":null},{"id":"6c82623525434c08a33cc341771de750","type":"GENE","name":"GMPSP1","canonical_id":"hgnc:HGNC:39428","description":"GMPS pseudogene 1","metadata":null},{"id":"cd3ca94a79ac4a2ab17458a2503f181b","type":"GENE","name":"GNA11","canonical_id":"hgnc:HGNC:4379","description":"G protein subunit alpha 11","metadata":{"aliases":["FBH","FBH2","FHH2","HHC2"]}},{"id":"25f80ee8ac0543a2a926768383735b6b","type":"GENE","name":"GNA12","canonical_id":"hgnc:HGNC:4380","description":"G protein subunit alpha 12","metadata":{"aliases":["gep"]}},{"id":"13b662c064f24486b1e91157be4700c8","type":"GENE","name":"GNA13","canonical_id":"hgnc:HGNC:4381","description":"G protein subunit alpha 13","metadata":{"aliases":["G13","MGC46138"]}},{"id":"b1c17782875b466a93abd9996867891a","type":"GENE","name":"GNA13P1","canonical_id":"hgnc:HGNC:54705","description":"GNA13 pseudogene 1","metadata":null},{"id":"7fe2dacb4a7a4303b9aef5d614279c35","type":"GENE","name":"GNA14","canonical_id":"hgnc:HGNC:4382","description":"G protein subunit alpha 14","metadata":null},{"id":"9d750836dfb946b5be79da865dfa0b4c","type":"GENE","name":"GNA14-AS1","canonical_id":"hgnc:HGNC:50451","description":"GNA14 antisense RNA 1","metadata":null},{"id":"3afb30b3796146a8bea167f64af26a95","type":"GENE","name":"GNA15","canonical_id":"hgnc:HGNC:4383","description":"G protein subunit alpha 15","metadata":{"aliases":["GNA16"]}},{"id":"175ef6568b294a41b9bd77fa34c6e298","type":"GENE","name":"GNA15-DT","canonical_id":"hgnc:HGNC:55293","description":"GNA15 divergent transcript","metadata":null},{"id":"2e5382fa19fc4ba881cf9a292de518fd","type":"GENE","name":"GNAI1","canonical_id":"hgnc:HGNC:4384","description":"G protein subunit alpha i1","metadata":null},{"id":"7b272c1e7a16459c8fe457efeeb61208","type":"GENE","name":"GNAI2","canonical_id":"hgnc:HGNC:4385","description":"G protein subunit alpha i2","metadata":{"aliases":["GIP","GNAI2B"]}},{"id":"e35ccff1e4c84b4b851b2f891ce4cf15","type":"GENE","name":"GNAI2P1","canonical_id":"hgnc:HGNC:4386","description":"G protein subunit alpha i2 pseudogene 1","metadata":{"aliases":["GNAI2A","GNAI2L"]}},{"id":"5c9909990bb84e7ca65478601a2fa991","type":"GENE","name":"GNAI2P2","canonical_id":"hgnc:HGNC:45110","description":"G protein subunit alpha i2 pseudogene 2","metadata":null},{"id":"4713659f7b864453a8ec6a79290834a8","type":"GENE","name":"GNAI3","canonical_id":"hgnc:HGNC:4387","description":"G protein subunit alpha i3","metadata":{"aliases":["87U6"]}},{"id":"08b14044cf5c495fa165fad38eb58121","type":"GENE","name":"GNAL","canonical_id":"hgnc:HGNC:4388","description":"G protein subunit alpha L","metadata":null},{"id":"1b21505d879744e8805999d083cf6e26","type":"GENE","name":"GNAO1","canonical_id":"hgnc:HGNC:4389","description":"G protein subunit alpha o1","metadata":{"aliases":["G-ALPHA-o"]}},{"id":"42cac6d76a574f32a61cbc4db6d1ecf5","type":"GENE","name":"GNAO1-DT","canonical_id":"hgnc:HGNC:27543","description":"GNAO1 divergent transcript","metadata":{"aliases":["GNAO1-AS1"]}},{"id":"d9a26ef0a9d249278403dfdd0fa97829","type":"GENE","name":"GNAQ","canonical_id":"hgnc:HGNC:4390","description":"G protein subunit alpha q","metadata":{"aliases":["G-ALPHA-q","GAQ"]}},{"id":"a4f5b04263d549548e96a7ac6373cf5f","type":"GENE","name":"GNAQP1","canonical_id":"hgnc:HGNC:4391","description":"G protein subunit alpha q pseudogene 1","metadata":{"aliases":["GNAQP"]}},{"id":"6ed899191a354e93b5bf95899133ffe5","type":"GENE","name":"GNAS","canonical_id":"hgnc:HGNC:4392","description":null,"metadata":null},{"id":"7d6d4d42829e4130a6896a5ce4672231","type":"GENE","name":"GNAS-AS1","canonical_id":"hgnc:HGNC:24872","description":"GNAS antisense RNA 1","metadata":{"aliases":["SANG","NESP-AS","NESPAS","GNAS1AS","NCRNA00075","GNASAS","GNAS-AS"]}},{"id":"4d67c95ce61e4d1f96605cef6476d540","type":"GENE","name":"GNAT1","canonical_id":"hgnc:HGNC:4393","description":"G protein subunit alpha transducin 1","metadata":{"aliases":["CSNBAD3"]}},{"id":"c946640e1f534ecdb300f726a5112ce0","type":"GENE","name":"GNAT2","canonical_id":"hgnc:HGNC:4394","description":"G protein subunit alpha transducin 2","metadata":{"aliases":["ACHM4"]}},{"id":"6212f7ac05644c13becc571c09afbbb3","type":"GENE","name":"GNAT3","canonical_id":"hgnc:HGNC:22800","description":"G protein subunit alpha transducin 3","metadata":{"aliases":["gustducin","GDCA"]}},{"id":"bbb670cbc2ea4d9bb408016325c5cf28","type":"GENE","name":"GNAZ","canonical_id":"hgnc:HGNC:4395","description":"G protein subunit alpha z","metadata":null},{"id":"bde39e80792d460d83fa9aea1e7982b0","type":"GENE","name":"GNB1","canonical_id":"hgnc:HGNC:4396","description":"G protein subunit beta 1","metadata":null},{"id":"99d4b712005a42258a9a4a81beb1704e","type":"GENE","name":"GNB1-DT","canonical_id":"hgnc:HGNC:55772","description":"GNB1 divergent transcript","metadata":null},{"id":"a5f26954add440c8a369cdf3e1082fe0","type":"GENE","name":"GNB1L","canonical_id":"hgnc:HGNC:4397","description":"G protein subunit beta 1 like","metadata":{"aliases":["GY2","WDR14"]}},{"id":"c527ddc8d5cc4aadbefd69021a7bc7c9","type":"GENE","name":"GNB2","canonical_id":"hgnc:HGNC:4398","description":"G protein subunit beta 2","metadata":null},{"id":"94358da64df845caad7f58203770b9d0","type":"GENE","name":"GNB3","canonical_id":"hgnc:HGNC:4400","description":"G protein subunit beta 3","metadata":null},{"id":"b7cf97c521d94603a3f85c32095b6915","type":"GENE","name":"GNB4","canonical_id":"hgnc:HGNC:20731","description":"G protein subunit beta 4","metadata":null},{"id":"5b1dbc6a014d4223b79933018361fe45","type":"GENE","name":"GNB5","canonical_id":"hgnc:HGNC:4401","description":"G protein subunit beta 5","metadata":{"aliases":["GB5"]}},{"id":"7975e9daf3924445868bf75733e00393","type":"GENE","name":"GNE","canonical_id":"hgnc:HGNC:23657","description":"glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase","metadata":{"aliases":["Uae1","IBM2"]}},{"id":"a2ca15ace6bd4a36b0bc7ab774a69a2e","type":"GENE","name":"GNG10","canonical_id":"hgnc:HGNC:4402","description":"G protein subunit gamma 10","metadata":null},{"id":"558febe340fc48169d030ce9a2b0136d","type":"GENE","name":"GNG10P1","canonical_id":"hgnc:HGNC:49502","description":"G protein subunit gamma 10 pseudogene 1","metadata":null},{"id":"046a80fa84df4a398781c451fd138684","type":"GENE","name":"GNG11","canonical_id":"hgnc:HGNC:4403","description":"G protein subunit gamma 11","metadata":{"aliases":["GNGT11"]}},{"id":"47668fe3f82b4b6c8501983bd4bfa23c","type":"GENE","name":"GNG12","canonical_id":"hgnc:HGNC:19663","description":"G protein subunit gamma 12","metadata":null},{"id":"35dccd7e83134d79afaa68e61553d5e2","type":"GENE","name":"GNG12-AS1","canonical_id":"hgnc:HGNC:43938","description":"GNG12, DIRAS3 and WLS antisense RNA 1","metadata":null},{"id":"244600f7c3714ea18b94f7659f6ac883","type":"GENE","name":"GNG13","canonical_id":"hgnc:HGNC:14131","description":"G protein subunit gamma 13","metadata":{"aliases":["h2-35","G(gamma)13"]}},{"id":"4f4ac306eec741419617a348ba06e6a5","type":"GENE","name":"GNG14","canonical_id":"hgnc:HGNC:53439","description":"G protein subunit gamma 14","metadata":null},{"id":"5d2b5a08c027423089da110c0cee7f59","type":"GENE","name":"GNG2","canonical_id":"hgnc:HGNC:4404","description":"G protein subunit gamma 2","metadata":null},{"id":"e510dbae80944377b4ee8044f5b197a7","type":"GENE","name":"GNG3","canonical_id":"hgnc:HGNC:4405","description":"G protein subunit gamma 3","metadata":null},{"id":"21b638d72f624f8c97374859d649e683","type":"GENE","name":"GNG4","canonical_id":"hgnc:HGNC:4407","description":"G protein subunit gamma 4","metadata":null},{"id":"102ba8ea5f4a43648af2611bda7d85c9","type":"GENE","name":"GNG5","canonical_id":"hgnc:HGNC:4408","description":"G protein subunit gamma 5","metadata":null},{"id":"63bab5744e4446fdbe95e7c166a1c7bf","type":"GENE","name":"GNG5B","canonical_id":"hgnc:HGNC:24826","description":"G protein subunit gamma 5B","metadata":{"aliases":["GNG5P2"]}},{"id":"b8a6b71801db4a698d16d31ecd6f328c","type":"GENE","name":"GNG5P1","canonical_id":"hgnc:HGNC:4409","description":"G protein subunit gamma 5 pseudogene 1","metadata":{"aliases":["GNG5P"]}},{"id":"5ad99fdef21b4fc296ee8b68fff731a6","type":"GENE","name":"GNG5P3","canonical_id":"hgnc:HGNC:33552","description":"G protein subunit gamma 5 pseudogene 3","metadata":null},{"id":"a1e5109fc2574c73a505c412bfeb507d","type":"GENE","name":"GNG5P4","canonical_id":"hgnc:HGNC:33553","description":"G protein subunit gamma 5 pseudogene 4","metadata":null},{"id":"5898dd81bfef46ae9900a4fb2e4f0754","type":"GENE","name":"GNG5P5","canonical_id":"hgnc:HGNC:33554","description":"G protein subunit gamma 5 pseudogene 5","metadata":null},{"id":"b0da5ca87d2d42e3909f2d396c24ea94","type":"GENE","name":"GNG7","canonical_id":"hgnc:HGNC:4410","description":"G protein subunit gamma 7","metadata":{"aliases":["FLJ00058"]}},{"id":"a3dac180ce194fa997244061f650242c","type":"GENE","name":"GNG8","canonical_id":"hgnc:HGNC:19664","description":"G protein subunit gamma 8","metadata":null},{"id":"a0828998840b40bc86d30869c4187c03","type":"GENE","name":"GNGT1","canonical_id":"hgnc:HGNC:4411","description":"G protein subunit gamma transducin 1","metadata":{"aliases":["GNG1"]}},{"id":"1d50827074ea4d30998b55a6f57275fc","type":"GENE","name":"GNGT2","canonical_id":"hgnc:HGNC:4412","description":"G protein subunit gamma transducin 2","metadata":{"aliases":["GNG9"]}},{"id":"3cb979b16c3b4648866f8f5ad633dd4c","type":"GENE","name":"GNL1","canonical_id":"hgnc:HGNC:4413","description":"G protein nucleolar 1","metadata":{"aliases":["HSR1"]}},{"id":"32c0f34b654f4e2391ddbf2402c7b736","type":"GENE","name":"GNL2","canonical_id":"hgnc:HGNC:29925","description":"G protein nucleolar 2","metadata":{"aliases":["Ngp-1","HUMAUANTIG","Nog2","Nug2"]}},{"id":"d29bd18f25604e798b30411854b7ff40","type":"GENE","name":"GNL2P1","canonical_id":"hgnc:HGNC:50779","description":"G protein nucleolar 2 pseudogene 1","metadata":null},{"id":"304b306573eb422694f7f6492d7aff33","type":"GENE","name":"GNL3","canonical_id":"hgnc:HGNC:29931","description":"G protein nucleolar 3","metadata":{"aliases":["C77032","E2IG3","MGC800","NS","Nug1"]}},{"id":"746fd66540ee41489fd1c9bbab64abb6","type":"GENE","name":"GNL3L","canonical_id":"hgnc:HGNC:25553","description":"G protein nucleolar 3 like","metadata":{"aliases":["FLJ10613","GNL3B"]}},{"id":"98358e557e084a5fb95e0391ad8ca815","type":"GENE","name":"GNL3LP1","canonical_id":"hgnc:HGNC:25733","description":"G protein nucleolar 3 like pseudogene 1","metadata":{"aliases":["FLJ12595","GNL3LP"]}},{"id":"8c77ab09bb4b4699ab674c97c47f2e79","type":"GENE","name":"GNLY","canonical_id":"hgnc:HGNC:4414","description":null,"metadata":null},{"id":"0d668e09a06f4fc7aecb07c332021de3","type":"GENE","name":"GNMT","canonical_id":"hgnc:HGNC:4415","description":null,"metadata":null},{"id":"3b9b570388b64d58a45452e99a21a06e","type":"GENE","name":"GNPAT","canonical_id":"hgnc:HGNC:4416","description":"glyceronephosphate O-acyltransferase","metadata":{"aliases":["DHAPAT","DAPAT","DAP-AT"]}},{"id":"ea2ee09f03164bcd8c0387582d34de7e","type":"GENE","name":"GNPATP","canonical_id":"hgnc:HGNC:34031","description":"glyceronephosphate O-acyltransferase pseudogene","metadata":null},{"id":"79aa0b047d314fcbab1e9e464f9049aa","type":"GENE","name":"GNPDA1","canonical_id":"hgnc:HGNC:4417","description":"glucosamine-6-phosphate deaminase 1","metadata":{"aliases":["GNPDA","HLN","GPI","KIAA0060","GNPI"]}},{"id":"e3661011eecf4d018e01f3369746e8f2","type":"GENE","name":"GNPDA2","canonical_id":"hgnc:HGNC:21526","description":"glucosamine-6-phosphate deaminase 2","metadata":{"aliases":["SB52"]}},{"id":"3436662c2a4547c18d9b7685c9d7705f","type":"GENE","name":"GNPNAT1","canonical_id":"hgnc:HGNC:19980","description":"glucosamine-phosphate N-acetyltransferase 1","metadata":{"aliases":["Gpnat1","FLJ10607"]}},{"id":"1e6dc1f45d1a4a59824af8afc2af017f","type":"GENE","name":"GNPNAT1-DT","canonical_id":"hgnc:HGNC:59260","description":"GNPNAT1 divergent transcript","metadata":{"aliases":["AL139317.5"]}},{"id":"55492f67304643e39a8c0f3cd7a91cb0","type":"GENE","name":"GNPNAT1P1","canonical_id":"hgnc:HGNC:58524","description":"GNPNAT1 pseudogene 1","metadata":null},{"id":"c7ec28aaad3b481a95fa7cda6833ba91","type":"GENE","name":"GNPNAT1P2","canonical_id":"hgnc:HGNC:58525","description":"GNPNAT1 pseudogene 2","metadata":null},{"id":"a5f230b702d54a91b495a50b3fdac0da","type":"GENE","name":"GNPNAT1P3","canonical_id":"hgnc:HGNC:58526","description":"GNPNAT1 pseudogene 3","metadata":null},{"id":"7d9fe4b0dc534a82bea95203005fc51a","type":"GENE","name":"GNPTAB","canonical_id":"hgnc:HGNC:29670","description":"N-acetylglucosamine-1-phosphate transferase subunits alpha and beta","metadata":{"aliases":["KIAA1208","MGC4170","GNPTA"]}},{"id":"0d007dc7509e44e78bbffaf6108ddbc9","type":"GENE","name":"GNPTG","canonical_id":"hgnc:HGNC:23026","description":"N-acetylglucosamine-1-phosphate transferase subunit gamma","metadata":{"aliases":["CAB56184","c316G12.3","GNPTAG","C16orf27"]}},{"id":"4aa134764dd645fab185edf6181e149e","type":"GENE","name":"GNRH1","canonical_id":"hgnc:HGNC:4419","description":null,"metadata":null},{"id":"cf491a547687405d8c1679e437ae4df1","type":"GENE","name":"GNRH2","canonical_id":"hgnc:HGNC:4420","description":null,"metadata":null},{"id":"55a92744ce1143feb163e4cfef1dabe4","type":"GENE","name":"GNRHR","canonical_id":"hgnc:HGNC:4421","description":"gonadotropin releasing hormone receptor","metadata":{"aliases":["LHRHR","GRHR"]}},{"id":"32c608b5b98443fc94f5f902c9ed3914","type":"PROTEIN","name":"GNRHR","canonical_id":"uniprot:P30968","description":null,"metadata":null},{"id":"f6f58ecbb6e84d99a75d126f23369c62","type":"GENE","name":"GNRHR2","canonical_id":"hgnc:HGNC:16341","description":"gonadotropin releasing hormone receptor 2 (pseudogene)","metadata":{"aliases":["GNRHR2P"]}},{"id":"8d2483f339484ea794191bb1a1acfe44","type":"GENE","name":"GNRHR2P1","canonical_id":"hgnc:HGNC:39424","description":"GNRHR2 pseudogene 1","metadata":null},{"id":"1cdaeda6c10747839213d1a052a41882","type":"GENE","name":"GNS","canonical_id":"hgnc:HGNC:4422","description":"glucosamine (N-acetyl)-6-sulfatase","metadata":null},{"id":"da4c7b4e05834df687117c7843a5f99e","type":"TRIAL","name":"GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01360788","description":"Mild Chronic Obstructive Pulmonary Disease; Respiratory Symptoms; Physical Activity","metadata":null},{"id":"17e64619157942869c59bbc8cc77d92b","type":"GENE","name":"GOLGA1","canonical_id":"hgnc:HGNC:4424","description":"golgin A1","metadata":{"aliases":["golgin-97","MGC33154"]}},{"id":"89322e17ca4d41a79cbb39b49f993e5c","type":"GENE","name":"GOLGA2","canonical_id":"hgnc:HGNC:4425","description":"golgin A2","metadata":{"aliases":["GM130","golgin-95"]}},{"id":"53c6c9ceb08646b889383de2c8b99a43","type":"GENE","name":"GOLGA2P1","canonical_id":"hgnc:HGNC:31052","description":"GOLGA2 pseudogene 1","metadata":null},{"id":"d5b6d9ddb54346c69aa7c3820589e4a8","type":"GENE","name":"GOLGA2P10","canonical_id":"hgnc:HGNC:26229","description":"GOLGA2 pseudogene 10","metadata":{"aliases":["FLJ22795","AgSK1"]}},{"id":"2d36e9c822674a1fb8a9e97e209f24da","type":"GENE","name":"GOLGA2P11","canonical_id":"hgnc:HGNC:26788","description":"GOLGA2 pseudogene 11","metadata":{"aliases":["FLJ38723"]}},{"id":"9809f03382cb40cea65d33baedd68e3c","type":"GENE","name":"GOLGA2P2Y","canonical_id":"hgnc:HGNC:16479","description":"GOLGA2 pseudogene 2 Y-linked","metadata":{"aliases":["GOLGA2LY1","GOLGA2P2"]}},{"id":"6f16e5d921614dc79ba29a2f4f7d7b29","type":"GENE","name":"GOLGA2P3Y","canonical_id":"hgnc:HGNC:32426","description":"GOLGA2 pseudogene 3 Y-linked","metadata":{"aliases":["GOLGA2LY2","GOLGA2P3"]}},{"id":"847e8230425f47c2a088d7df6ad63195","type":"GENE","name":"GOLGA2P4","canonical_id":"hgnc:HGNC:38600","description":"GOLGA2 pseudogene 4","metadata":null},{"id":"b43bdbd8600447fea8c9281bde35b1b4","type":"GENE","name":"GOLGA2P5","canonical_id":"hgnc:HGNC:25315","description":"GOLGA2 pseudogene 5","metadata":{"aliases":["DKFZp434M0331","GOLGA2L1","GOLGA2B"]}},{"id":"fe2199394c1e4034956ab03fe25a5a14","type":"GENE","name":"GOLGA2P6","canonical_id":"hgnc:HGNC:44948","description":"GOLGA2 pseudogene 6","metadata":null},{"id":"2ed3fe2ff35a450ab9b9d5a11d1b7b75","type":"GENE","name":"GOLGA2P7","canonical_id":"hgnc:HGNC:49516","description":"GOLGA2 pseudogene 7","metadata":null},{"id":"f27baa4a841443fc9c8744305477997a","type":"GENE","name":"GOLGA2P8","canonical_id":"hgnc:HGNC:49922","description":"GOLGA2 pseudogene 8","metadata":null},{"id":"760d75ffb9fe4ee9b1895ccb6ae62801","type":"GENE","name":"GOLGA2P9","canonical_id":"hgnc:HGNC:49921","description":"GOLGA2 pseudogene 9","metadata":null},{"id":"5a0d59d3ddd94da781e8ef494b29ca1d","type":"GENE","name":"GOLGA3","canonical_id":"hgnc:HGNC:4426","description":"golgin A3","metadata":{"aliases":["golgin-160","GCP170","MEA-2"]}},{"id":"9320f9ae1b494faea7c1152303aa4b91","type":"GENE","name":"GOLGA4","canonical_id":"hgnc:HGNC:4427","description":"golgin A4","metadata":{"aliases":["golgin-245","GOLG","GCP2","p230","golgin-240"]}},{"id":"6a6f390bea644f8d966ad9be13c2d3d2","type":"GENE","name":"GOLGA4-AS1","canonical_id":"hgnc:HGNC:26469","description":"GOLGA4 antisense RNA 1","metadata":null},{"id":"923d0aecb2a8454c9d660aafd9079ac6","type":"GENE","name":"GOLGA4P1","canonical_id":"hgnc:HGNC:18660","description":"golgin A4 pseudogene 1","metadata":null},{"id":"5625c463c9214675a1ab5912b2424b42","type":"GENE","name":"GOLGA4P2","canonical_id":"hgnc:HGNC:20727","description":"golgin A4 pseudogene 2","metadata":null},{"id":"a845d865dfa74a4db03b0b69df5d50b5","type":"GENE","name":"GOLGA4P3","canonical_id":"hgnc:HGNC:43786","description":"golgin A4 pseudogene 3","metadata":null},{"id":"a4f1c3d2632d4b33b98e2b160cc169c0","type":"GENE","name":"GOLGA5","canonical_id":"hgnc:HGNC:4428","description":"golgin A5","metadata":{"aliases":["ret-II","golgin-84","rfg5","GOLIM5"]}},{"id":"c00ba38ba17549859e086298ec22ddaa","type":"GENE","name":"GOLGA5P1","canonical_id":"hgnc:HGNC:43925","description":"golgin A5 pseudogene 1","metadata":null},{"id":"ff755a96f9704640aef9de0c4f2afa80","type":"GENE","name":"GOLGA6A","canonical_id":"hgnc:HGNC:13567","description":"golgin A6 family member A","metadata":{"aliases":["GLP","GOLGA6"]}},{"id":"43fe63eb33224f7c8cf17206662d775d","type":"GENE","name":"GOLGA6B","canonical_id":"hgnc:HGNC:32205","description":"golgin A6 family member B","metadata":null},{"id":"3714d8c80eac4328a01550d852839a3d","type":"GENE","name":"GOLGA6C","canonical_id":"hgnc:HGNC:32206","description":"golgin A6 family member C","metadata":null},{"id":"3ba70bac770545f4b29a7d409113f8e8","type":"GENE","name":"GOLGA6D","canonical_id":"hgnc:HGNC:32204","description":"golgin A6 family member D","metadata":null},{"id":"bf6e8f4f50664481882cd898f1916f3b","type":"GENE","name":"GOLGA6EP","canonical_id":"hgnc:HGNC:55708","description":"golgin A6 family member E, pseudogene","metadata":null},{"id":"7f3a59eac83a4decb081234be0296f10","type":"GENE","name":"GOLGA6FP","canonical_id":"hgnc:HGNC:49206","description":"golgin A6 family member F, pseudogene","metadata":null},{"id":"bab0fbbea92b41db9effc4cc4e2ade57","type":"GENE","name":"GOLGA6GP","canonical_id":"hgnc:HGNC:55709","description":"golgin A6 family member G, pseudogene","metadata":null},{"id":"cb952e0012bd47e595536232b91f47d4","type":"GENE","name":"GOLGA6L1","canonical_id":"hgnc:HGNC:37444","description":"golgin A6 family like 1","metadata":null},{"id":"3c6196836ff54967b7cb46bcaed8ccb8","type":"GENE","name":"GOLGA6L10","canonical_id":"hgnc:HGNC:37228","description":"golgin A6 family like 10","metadata":{"aliases":["GOLGA6L18"]}},{"id":"562d178ad98f4d66aa618bc64990862d","type":"GENE","name":"GOLGA6L11P","canonical_id":"hgnc:HGNC:23958","description":"golgin A6 family like 11, pseudogene","metadata":{"aliases":["GOLGA6L15P"]}},{"id":"10dbb1468ce44702a089560ba2d20d71","type":"GENE","name":"GOLGA6L12P","canonical_id":"hgnc:HGNC:23959","description":"golgin A6 family like 12, pseudogene","metadata":null},{"id":"91a24201bb614ce0a44a72249296fefe","type":"GENE","name":"GOLGA6L13P","canonical_id":"hgnc:HGNC:23960","description":"golgin A6 family like 13, pseudogene","metadata":null},{"id":"37b58427bb804047b9535f5be2afba31","type":"GENE","name":"GOLGA6L14P","canonical_id":"hgnc:HGNC:23961","description":"golgin A6 family like 14, pseudogene","metadata":null},{"id":"967d238a95ed46ceb8c7693d217b9253","type":"GENE","name":"GOLGA6L16P","canonical_id":"hgnc:HGNC:38117","description":"golgin A6 family like 16, pseudogene","metadata":null},{"id":"858d417d613e45eb982c763bd60c769a","type":"GENE","name":"GOLGA6L17P","canonical_id":"hgnc:HGNC:49414","description":"golgin A6 family like 17, pseudogene","metadata":{"aliases":["GOLGA6L21P"]}},{"id":"6076905888bf405ca7819cc89a61398f","type":"GENE","name":"GOLGA6L19","canonical_id":"hgnc:HGNC:49416","description":"golgin A6 family like 19","metadata":null},{"id":"d7efbd32196f4f61a4da27554bfc7984","type":"GENE","name":"GOLGA6L2","canonical_id":"hgnc:HGNC:26695","description":"golgin A6 family like 2","metadata":{"aliases":["CT105","FLJ36144"]}},{"id":"2def66cd7502417fbaee4a791758d827","type":"GENE","name":"GOLGA6L22","canonical_id":"hgnc:HGNC:50289","description":"golgin A6 family like 22","metadata":null},{"id":"258aa865b718413c9ee7193ddbd83be0","type":"GENE","name":"GOLGA6L23P","canonical_id":"hgnc:HGNC:55697","description":"golgin A6 family like 23, pseudogene","metadata":null},{"id":"0337eebb5ae94d12a97ad66e3a07f2ef","type":"GENE","name":"GOLGA6L24","canonical_id":"hgnc:HGNC:55710","description":"golgin A6 family like 24","metadata":{"aliases":["GOLGA6L24P"]}},{"id":"733441b9311949cab9af50ae47433a4f","type":"GENE","name":"GOLGA6L25","canonical_id":"hgnc:HGNC:55711","description":"golgin A6 family like 25","metadata":{"aliases":["GOLGA6L25P"]}},{"id":"58baa4b0bd8f44af98106756a372359f","type":"GENE","name":"GOLGA6L26","canonical_id":"hgnc:HGNC:56306","description":"golgin A6 family like 26","metadata":null},{"id":"5f48ecd5ee0044178ac3eb484960a7c9","type":"GENE","name":"GOLGA6L3P","canonical_id":"hgnc:HGNC:37441","description":"golgin A6 family like 3, pseudogene","metadata":{"aliases":["GOLGA6L3"]}},{"id":"38165858d83c4f46b20bf94787d58206","type":"GENE","name":"GOLGA6L4","canonical_id":"hgnc:HGNC:27256","description":"golgin A6 family like 4","metadata":null},{"id":"10a74c86cc78470680eba76010b074e2","type":"GENE","name":"GOLGA6L5P","canonical_id":"hgnc:HGNC:30472","description":"golgin A6 family like 5, pseudogene","metadata":{"aliases":["FLJ35171","FLJ40113","GOLGA6L8","GOLGA6L5"]}},{"id":"3b28c823e1d842e281f056244b71b2e0","type":"GENE","name":"GOLGA6L6","canonical_id":"hgnc:HGNC:37225","description":"golgin A6 family like 6 (gene/pseudogene)","metadata":{"aliases":["FLJ36131"]}},{"id":"166856e8976c446baa615f2fdb54521b","type":"GENE","name":"GOLGA6L7","canonical_id":"hgnc:HGNC:37442","description":"golgin A6 family like 7","metadata":{"aliases":["GOLGA6L7P"]}},{"id":"70b00caf7b004274b76062626ea094d9","type":"GENE","name":"GOLGA6L9","canonical_id":"hgnc:HGNC:37229","description":"golgin A6 family like 9","metadata":{"aliases":["GOLGA6L20"]}},{"id":"e10a44e7391f47d9addd4936710dbe3d","type":"GENE","name":"GOLGA6L9-AS1","canonical_id":"hgnc:HGNC:56873","description":"GOLGA6L9 antisense RNA 1","metadata":null},{"id":"e5a09bce4eba40aaa6e19db50141b731","type":"GENE","name":"GOLGA7","canonical_id":"hgnc:HGNC:24876","description":"golgin A7","metadata":{"aliases":["GCP16","HSPC041","GOLGA3AP1","GOLGA7A"]}},{"id":"0c49e3d0dc624b56a612f09c88fe461d","type":"GENE","name":"GOLGA7B","canonical_id":"hgnc:HGNC:31668","description":"golgin A7 family member B","metadata":{"aliases":["bA459F3.4","bA451M19.3","C10orf133","C10orf132"]}},{"id":"67c794d4cb2c41c68b34a9cd82b99612","type":"GENE","name":"GOLGA7B-DT","canonical_id":"hgnc:HGNC:45232","description":"GOLGA7B divergent transcript","metadata":{"aliases":["LINC00866"]}},{"id":"76bb8eb7c6384de8b330a8a5abba2a1b","type":"GENE","name":"GOLGA8A","canonical_id":"hgnc:HGNC:31972","description":"golgin A8 family member A","metadata":{"aliases":["GM88","GOLGIN-67","FAP286","CFAP286"]}},{"id":"8897f6ba751045b4970af154864a8917","type":"GENE","name":"GOLGA8B","canonical_id":"hgnc:HGNC:31973","description":"golgin A8 family member B","metadata":null},{"id":"95b85702028a4312ba05bc8eee6e1f3c","type":"GENE","name":"GOLGA8CP","canonical_id":"hgnc:HGNC:32375","description":"golgin A8 family member C, pseudogene","metadata":{"aliases":["GOLGA8C"]}},{"id":"adbe966ea0e94731bf9d41e6907ac77c","type":"GENE","name":"GOLGA8DP","canonical_id":"hgnc:HGNC:32376","description":"golgin A8 family member D, pseudogene","metadata":{"aliases":["GOLGA8D"]}},{"id":"d9d4b6947c87471d99b23f17cedc56fb","type":"GENE","name":"GOLGA8EP","canonical_id":"hgnc:HGNC:32377","description":"golgin A8 family member E, pseudogene","metadata":{"aliases":["GOLGA8E"]}},{"id":"0fb212f35c7c4868a568bc9ce0d25b0c","type":"GENE","name":"GOLGA8F","canonical_id":"hgnc:HGNC:32378","description":"golgin A8 family member F","metadata":{"aliases":["DKFZp434P162"]}},{"id":"17c4acfb53d640b8830cb8cfa1dc3ff6","type":"GENE","name":"GOLGA8G","canonical_id":"hgnc:HGNC:25328","description":"golgin A8 family member G","metadata":{"aliases":["DKFZp434K052"]}},{"id":"aae4b899740b4229adfb19e91f38a11e","type":"GENE","name":"GOLGA8H","canonical_id":"hgnc:HGNC:37443","description":"golgin A8 family member H","metadata":{"aliases":["GOLGA6L11"]}},{"id":"098d937c77f34336891838da55da7b45","type":"GENE","name":"GOLGA8IP","canonical_id":"hgnc:HGNC:26660","description":"golgin A8 family member I, pseudogene","metadata":{"aliases":["FLJ35785","GOLGA9P","GOLGA8I"]}},{"id":"89789e6b4ffa4244804ea3af7c734c69","type":"GENE","name":"GOLGA8J","canonical_id":"hgnc:HGNC:38650","description":"golgin A8 family member J","metadata":null},{"id":"ffdcdb6b9a8f4f37b19c3c2e0c7a78aa","type":"GENE","name":"GOLGA8K","canonical_id":"hgnc:HGNC:38652","description":"golgin A8 family member K","metadata":null},{"id":"11bcb39e7af84dfca16babc1a3d0ea86","type":"GENE","name":"GOLGA8M","canonical_id":"hgnc:HGNC:44404","description":"golgin A8 family member M","metadata":null},{"id":"ca610c07215648119fc219f284b939cb","type":"GENE","name":"GOLGA8N","canonical_id":"hgnc:HGNC:44405","description":"golgin A8 family member N","metadata":null},{"id":"7a9c59dc0292496eafcc21869a6c5f44","type":"GENE","name":"GOLGA8O","canonical_id":"hgnc:HGNC:44406","description":"golgin A8 family member O","metadata":null},{"id":"e588a597f01141f8bf43212e8220d6d9","type":"GENE","name":"GOLGA8Q","canonical_id":"hgnc:HGNC:44408","description":"golgin A8 family member Q","metadata":null},{"id":"a9c8ca32a27b4ca2ad5065e0aa0c6845","type":"GENE","name":"GOLGA8R","canonical_id":"hgnc:HGNC:44407","description":"golgin A8 family member R","metadata":null},{"id":"b814587fa67148e19c5fe0d5644a9d1e","type":"GENE","name":"GOLGA8S","canonical_id":"hgnc:HGNC:44409","description":"golgin A8 family member S","metadata":null},{"id":"d90207b861f84b65b1aa00f68c146500","type":"GENE","name":"GOLGA8T","canonical_id":"hgnc:HGNC:44410","description":"golgin A8 family member T","metadata":null},{"id":"0e476a9aef224fc1acdd4619964bd5d6","type":"GENE","name":"GOLGA8UP","canonical_id":"hgnc:HGNC:44411","description":"golgin A8 family member U, pseudogene","metadata":null},{"id":"b9fa68b16c014fbcb8816c795574e5a5","type":"GENE","name":"GOLGA8VP","canonical_id":"hgnc:HGNC:49920","description":"golgin A8 family member V, pseudogene","metadata":null},{"id":"df47afc448404ba1a12a3baceba4900d","type":"GENE","name":"GOLGB1","canonical_id":"hgnc:HGNC:4429","description":"golgin B1","metadata":{"aliases":["GCP","GCP372","giantin","GOLIM1"]}},{"id":"fb77e510972b4009a499c533c636b0f8","type":"GENE","name":"GOLIM4","canonical_id":"hgnc:HGNC:15448","description":"golgi integral membrane protein 4","metadata":{"aliases":["GPP130","GIMPC","P138","GOLPH4"]}},{"id":"5361f82b1fc64178a60303a77289667f","type":"GENE","name":"GOLM1","canonical_id":"hgnc:HGNC:15451","description":"golgi membrane protein 1","metadata":{"aliases":["GP73","FLJ23608","bA379P1.3","GOLPH2","C9orf155"]}},{"id":"76afe8e01dcb483e846e0c07de77713f","type":"GENE","name":"GOLM2","canonical_id":"hgnc:HGNC:24892","description":"golgi membrane protein 2","metadata":{"aliases":["H63","DKFZp459F1927","CASC4"]}},{"id":"c6b62c0b4eb34f99bd8583ae0bdc3f8b","type":"GENE","name":"GOLM2P1","canonical_id":"hgnc:HGNC:39251","description":"GOLM2 pseudogene 1","metadata":{"aliases":["CASC4P1"]}},{"id":"8d00a9b15258417683305f7a5b0c7ef1","type":"GENE","name":"GOLPH3","canonical_id":"hgnc:HGNC:15452","description":"golgi phosphoprotein 3","metadata":{"aliases":["GPP34","GOPP1","MIDAS","Vps74"]}},{"id":"fa2eb5c05ab34c64a85380844c3eabc0","type":"GENE","name":"GOLPH3-DT","canonical_id":"hgnc:HGNC:55231","description":"GOLPH3 divergent transcript","metadata":null},{"id":"e65ae979c865442da9e3a8c911762969","type":"GENE","name":"GOLPH3L","canonical_id":"hgnc:HGNC:24882","description":"golgi phosphoprotein 3 like","metadata":{"aliases":["GPP34R"]}},{"id":"07c3be0a75924b57b8c0663d0bd57db0","type":"GENE","name":"GOLT1A","canonical_id":"hgnc:HGNC:24766","description":"golgi transport 1A","metadata":{"aliases":["FLJ42654","CGI-141","YMR292W","GOT1","MGC62027"]}},{"id":"4c961e4a45db425f9e458a5721c77c2a","type":"GENE","name":"GOLT1B","canonical_id":"hgnc:HGNC:20175","description":"golgi transport 1B","metadata":{"aliases":["CGI-141","YMR292W","GOT1"]}},{"id":"9c8142aadd8d40989a800d7726415f6a","type":"GENE","name":"GON4L","canonical_id":"hgnc:HGNC:25973","description":"gon-4 like","metadata":{"aliases":["FLJ20203","GON-4","YARP","GON4"]}},{"id":"866bfc6c669148b6acb721e66f80af30","type":"GENE","name":"GON7","canonical_id":"hgnc:HGNC:20356","description":"GON7 subunit of KEOPS complex","metadata":{"aliases":["C14orf142"]}},{"id":"ceba06cf56b44904ade274dc978c8882","type":"GENE","name":"GOPC","canonical_id":"hgnc:HGNC:17643","description":"golgi associated PDZ and coiled-coil motif containing","metadata":{"aliases":["dJ94G16.2","PIST","FIG","GOPC1","CAL"]}},{"id":"573cd4aa3360433db0770b52ab8b9369","type":"GENE","name":"GORAB","canonical_id":"hgnc:HGNC:25676","description":"golgin, RAB6 interacting","metadata":{"aliases":["FLJ11752","NTKL-BP1","GO","SCYL1BP1"]}},{"id":"9775ba6f1ac540eba1ff8296a3e37a24","type":"GENE","name":"GORAB-AS1","canonical_id":"hgnc:HGNC:54051","description":"GORAB antisense RNA 1","metadata":null},{"id":"6cf0c7fc3a614b4ab35c261d70acccae","type":"GENE","name":"GORASP1","canonical_id":"hgnc:HGNC:16769","description":"golgi reassembly stacking protein 1","metadata":{"aliases":["GRASP65","P65","FLJ23443","GOLPH5"]}},{"id":"64cea3e516394e4681dca9a2acc75b94","type":"GENE","name":"GORASP2","canonical_id":"hgnc:HGNC:17500","description":"golgi reassembly stacking protein 2","metadata":{"aliases":["GRASP55","GRS2","GOLPH6"]}},{"id":"a29489d329e94fe48c8f9d22b886da0c","type":"GENE","name":"GOSR1","canonical_id":"hgnc:HGNC:4430","description":"golgi SNAP receptor complex member 1","metadata":{"aliases":["GOS28","P28","GS28","GOS-28","GOLIM2"]}},{"id":"261696a3b2ae4834a00df9bac7c68872","type":"GENE","name":"GOSR2","canonical_id":"hgnc:HGNC:4431","description":"golgi SNAP receptor complex member 2","metadata":{"aliases":["GS27","Bos1"]}},{"id":"86a0f75d8ed940679be4d127ec8eaa51","type":"GENE","name":"GOSR2-DT","canonical_id":"hgnc:HGNC:55346","description":"GOSR2 divergent transcript","metadata":{"aliases":["LINC01974"]}},{"id":"92c12f2c23bd4d06a637a9f2d4a6f589","type":"GENE","name":"GOT1","canonical_id":"hgnc:HGNC:4432","description":"glutamic-oxaloacetic transaminase 1","metadata":{"aliases":["AST1","SGOT","AST"]}},{"id":"c3a1d31395a245fb84b5301c04fb1427","type":"GENE","name":"GOT1-DT","canonical_id":"hgnc:HGNC:55848","description":"GOT1 divergent transcript","metadata":null},{"id":"3c8f538a9e3b4fbfaea82e1f48b088c0","type":"GENE","name":"GOT1L1","canonical_id":"hgnc:HGNC:28487","description":"glutamic-oxaloacetic transaminase 1 like 1","metadata":{"aliases":["MGC33309"]}},{"id":"6c34cd58231a49bd8b6b8ce7c3e736c5","type":"GENE","name":"GOT2","canonical_id":"hgnc:HGNC:4433","description":"glutamic-oxaloacetic transaminase 2","metadata":{"aliases":["mitAAT","KATIV","KAT4","KYAT4","mAspAT"]}},{"id":"781c929c74a1481d9e619e009ceb3084","type":"GENE","name":"GOT2P1","canonical_id":"hgnc:HGNC:4434","description":"GOT2 pseudogene 1","metadata":{"aliases":["GOT2L1"]}},{"id":"35a327885e3341c19af611dcf6550232","type":"GENE","name":"GOT2P2","canonical_id":"hgnc:HGNC:4435","description":"GOT2 pseudogene 2","metadata":{"aliases":["GOT2L2"]}},{"id":"208cc9a2877c47b8a8876705d9603840","type":"GENE","name":"GOT2P3","canonical_id":"hgnc:HGNC:4436","description":"GOT2 pseudogene 3","metadata":{"aliases":["GOT2L3","GOT2L3P"]}},{"id":"82ca25e2f1c043018a4ecbf8e25490d6","type":"GENE","name":"GOT2P4","canonical_id":"hgnc:HGNC:22936","description":"GOT2 pseudogene 4","metadata":{"aliases":["GOT2L4"]}},{"id":"894e6ce8ad584b3fa7756bc37c9d2401","type":"GENE","name":"GOT2P5","canonical_id":"hgnc:HGNC:38439","description":"GOT2 pseudogene 5","metadata":{"aliases":["GOT2Y"]}},{"id":"9cd3a627b96f48b9b25652a7eea50445","type":"GENE","name":"GOT2P6","canonical_id":"hgnc:HGNC:54891","description":"GOT2 pseudogene 6","metadata":null},{"id":"317fcef8f3cf4d3d9146bba5e41df27b","type":"GENE","name":"GOT2P7","canonical_id":"hgnc:HGNC:54892","description":"GOT2 pseudogene 7","metadata":null},{"id":"2c3aaa4a70ba4b68a1a53dc7d28b34b5","type":"GENE","name":"GP1BA","canonical_id":"hgnc:HGNC:4439","description":null,"metadata":null},{"id":"8f07f9d9f2bf4beaa0771013b4aa95a5","type":"GENE","name":"GP1BB","canonical_id":"hgnc:HGNC:4440","description":null,"metadata":null},{"id":"fe54cfcc533942628b0ec2facead44bc","type":"GENE","name":"GP2","canonical_id":"hgnc:HGNC:4441","description":"glycoprotein 2","metadata":{"aliases":["ZAP75"]}},{"id":"d893e9793a1b4b259b10a8a56f4202c0","type":"GENE","name":"GP5","canonical_id":"hgnc:HGNC:4443","description":"glycoprotein V platelet","metadata":{"aliases":["CD42d"]}},{"id":"f27fce18a5994fdaa466cfe3961893ba","type":"GENE","name":"GP6","canonical_id":"hgnc:HGNC:14388","description":null,"metadata":null},{"id":"3611db347f29498a865d997bdd57b583","type":"GENE","name":"GP6-AS1","canonical_id":"hgnc:HGNC:55305","description":"GP6 antisense RNA 1","metadata":null},{"id":"ef441ffdc5144a48a64d8b85e8dfa98a","type":"GENE","name":"GP9","canonical_id":"hgnc:HGNC:4444","description":null,"metadata":null},{"id":"d8d6e5cb50c24490aa8c8ebace9a43d6","type":"GENE","name":"GPA33","canonical_id":"hgnc:HGNC:4445","description":null,"metadata":null},{"id":"fd8da92b0ea54b73b90a784b18b597e5","type":"GENE","name":"GPA33-AS1","canonical_id":"hgnc:HGNC:58358","description":"GPA33 antisense RNA 1","metadata":null},{"id":"79d46615d2e849b392c58fed0a680f0a","type":"GENE","name":"GPAA1","canonical_id":"hgnc:HGNC:4446","description":"glycosylphosphatidylinositol anchor attachment 1","metadata":{"aliases":["GAA1","hGAA1"]}},{"id":"921881380437427589b60aeba9955592","type":"GENE","name":"GPAA1P1","canonical_id":"hgnc:HGNC:4447","description":"glycosylphosphatidylinositol anchor attachment 1 pseudogene 1","metadata":null},{"id":"11d9d0ac746646f7922769ac2037ec2c","type":"GENE","name":"GPAA1P2","canonical_id":"hgnc:HGNC:51484","description":"glycosylphosphatidylinositol anchor attachment 1 pseudogene 2","metadata":null},{"id":"ffc547ec2e894dd19eb2265fda67f0ad","type":"GENE","name":"GPALPP1","canonical_id":"hgnc:HGNC:20298","description":"GPALPP motifs containing 1","metadata":{"aliases":["bA245H20.2","AD029","LSR7","KIAA1704"]}},{"id":"c4cc091096704ae2a867699865676510","type":"GENE","name":"GPAM","canonical_id":"hgnc:HGNC:24865","description":"glycerol-3-phosphate acyltransferase, mitochondrial","metadata":{"aliases":["KIAA1560","MGC26846","GPAT1"]}},{"id":"10e6c50abb944902b8a207f684b004f0","type":"GENE","name":"GPANK1","canonical_id":"hgnc:HGNC:13920","description":"G-patch domain and ankyrin repeats 1","metadata":{"aliases":["G5","D6S54E","GPATCH10","ANKRD59","BAT4"]}},{"id":"d403f2602ffb4d3ca3cf5b08a96e6b86","type":"GENE","name":"GPAT2","canonical_id":"hgnc:HGNC:27168","description":"glycerol-3-phosphate acyltransferase 2, mitochondrial","metadata":{"aliases":["CT123"]}},{"id":"0471f980d3d04da09f6bb05d2acabb74","type":"GENE","name":"GPAT2P1","canonical_id":"hgnc:HGNC:52330","description":"glycerol-3-phosphate acyltransferase 2 pseudogene 1","metadata":null},{"id":"c7c72b954e614371b2a1d4164d7ef679","type":"GENE","name":"GPAT2P2","canonical_id":"hgnc:HGNC:52331","description":"glycerol-3-phosphate acyltransferase 2 pseudogene 2","metadata":null},{"id":"8797d408a99443739afd29b6de98fd59","type":"GENE","name":"GPAT3","canonical_id":"hgnc:HGNC:28157","description":"glycerol-3-phosphate acyltransferase 3","metadata":{"aliases":["MGC11324","LPAAT-theta","MAG1","HMFN0839","AGPAT10","AGPAT9"]}},{"id":"ac1648ea071c410b87ec118f0685ec50","type":"GENE","name":"GPAT4","canonical_id":"hgnc:HGNC:20880","description":"glycerol-3-phosphate acyltransferase 4","metadata":{"aliases":["DKFZp586M1819","LPAAT-zeta","TSARG7","AGPAT6"]}},{"id":"fc5de78258c74beb89c2dc37a57b5a8b","type":"GENE","name":"GPAT4-AS1","canonical_id":"hgnc:HGNC:55539","description":"GPAT4 and GINS4 antisense RNA 1","metadata":{"aliases":["GIAT4RA"]}},{"id":"fd228ae90135412f8f591d33e502f56e","type":"GENE","name":"GPATCH1","canonical_id":"hgnc:HGNC:24658","description":"G-patch domain containing 1","metadata":{"aliases":["ECGP","FLJ10206","FLJ38686","GPATC1"]}},{"id":"b577c3c00b8f474d868b064357667e2e","type":"GENE","name":"GPATCH11","canonical_id":"hgnc:HGNC:26768","description":"G-patch domain containing 11","metadata":{"aliases":["FLJ38348","CENPY","CENP-Y","CCDC75"]}},{"id":"d5664989973b48a0b638a00d0e62592a","type":"GENE","name":"GPATCH11P1","canonical_id":"hgnc:HGNC:42659","description":"GPATCH11 pseudogene 1","metadata":{"aliases":["CCDC75P1"]}},{"id":"ee586abdce8941308d968d72705080d7","type":"GENE","name":"GPATCH2","canonical_id":"hgnc:HGNC:25499","description":"G-patch domain containing 2","metadata":{"aliases":["FLJ10252","CT110","PPP1R30","Pfa1","GPATC2"]}},{"id":"6301564fc78b4717942c7f88f72d944f","type":"GENE","name":"GPATCH2L","canonical_id":"hgnc:HGNC:20210","description":"G-patch domain containing 2 like","metadata":{"aliases":["FLJ20689","FLJ10033","C14orf118"]}},{"id":"fc9c3088f913491fbec93493b6a5cbd9","type":"GENE","name":"GPATCH3","canonical_id":"hgnc:HGNC:25720","description":"G-patch domain containing 3","metadata":{"aliases":["FLJ12455","GPATC3"]}},{"id":"8d131b3aab82495884ea08d9c7f8132a","type":"GENE","name":"GPATCH4","canonical_id":"hgnc:HGNC:25982","description":"G-patch domain containing 4 (gene/pseudogene)","metadata":{"aliases":["FLJ20249","DKFZP434F1735","GPATC4"]}},{"id":"2f3ab748ad524ad79719009712b7b12e","type":"GENE","name":"GPATCH8","canonical_id":"hgnc:HGNC:29066","description":"G-patch domain containing 8","metadata":{"aliases":["KIAA0553","GPATC8"]}},{"id":"acc1a925e81549c29d92929a4e4faced","type":"GENE","name":"GPBAR1","canonical_id":"hgnc:HGNC:19680","description":"G protein-coupled bile acid receptor 1","metadata":{"aliases":["BG37","GPCR","TGR5","M-BAR","GPCR19","GPR131","MGC40597"]}},{"id":"d38f57a49fd74c8e8b3ceb6d55f310b4","type":"GENE","name":"GPBP1","canonical_id":"hgnc:HGNC:29520","description":"GC-rich promoter binding protein 1","metadata":{"aliases":["DKFZp761C169"]}},{"id":"aadeb7fead1d474293607a1016ac2ebc","type":"GENE","name":"GPBP1-DT","canonical_id":"hgnc:HGNC:59056","description":"GPBP1 divergent transcript","metadata":null},{"id":"144abf98e75941d0b33e6d2eb53d7ddb","type":"GENE","name":"GPBP1L1","canonical_id":"hgnc:HGNC:28843","description":"GC-rich promoter binding protein 1 like 1","metadata":{"aliases":["SP192"]}},{"id":"1a0479a009074a5196b657652e7a4ebe","type":"GENE","name":"GPC1","canonical_id":"hgnc:HGNC:4449","description":"glypican 1","metadata":{"aliases":["glypican"]}},{"id":"fbdfbe0c1a06493ca61207837f30c9fb","type":"GENE","name":"GPC1-AS1","canonical_id":"hgnc:HGNC:56102","description":"GPC1 antisense RNA 1","metadata":null},{"id":"433d7e066bcc4061829e42f08b75d08e","type":"GENE","name":"GPC2","canonical_id":"hgnc:HGNC:4450","description":"glypican 2","metadata":{"aliases":["cerebroglycan","FLJ38962","DKFZp547M109"]}},{"id":"44d4fee113cf4f02ad49adf561f9853f","type":"GENE","name":"GPC3","canonical_id":"hgnc:HGNC:4451","description":"glypican 3","metadata":{"aliases":["OCI-5","SGBS","SGBS1","SGB","DGSX","SDYS"]}},{"id":"f8889b4bc921400baebcfddee8136053","type":"GENE","name":"GPC3-AS1","canonical_id":"hgnc:HGNC:52897","description":"GPC3 antisense RNA 1","metadata":null},{"id":"c43d91b840bd4810b5c0ec8b9bb11fa9","type":"GENE","name":"GPC4","canonical_id":"hgnc:HGNC:4452","description":"glypican 4","metadata":{"aliases":["K-glypican"]}},{"id":"be4509586f164569ac8f9b89d7ee3d31","type":"GENE","name":"GPC5","canonical_id":"hgnc:HGNC:4453","description":"glypican 5","metadata":null},{"id":"f22a9b2fdc094610b371af348e2f1582","type":"GENE","name":"GPC5-AS1","canonical_id":"hgnc:HGNC:39886","description":"GPC5 antisense RNA 1","metadata":null},{"id":"45939030893047b0b7d91b58ea391c4b","type":"GENE","name":"GPC5-AS2","canonical_id":"hgnc:HGNC:39887","description":"GPC5 antisense RNA 2","metadata":null},{"id":"b407b748325e405caa536474a2c63fa2","type":"GENE","name":"GPC5-IT1","canonical_id":"hgnc:HGNC:41340","description":"GPC5 intronic transcript 1","metadata":null},{"id":"0d9cd558882b433580c710ead98b98c7","type":"GENE","name":"GPC6","canonical_id":"hgnc:HGNC:4454","description":"glypican 6","metadata":null},{"id":"60de2d82cad74e1a8bc8ac0e590f0f92","type":"GENE","name":"GPC6-AS1","canonical_id":"hgnc:HGNC:39909","description":"GPC6 antisense RNA 1","metadata":null},{"id":"f66d299ab0a6411eae7a1cbccf1ce550","type":"GENE","name":"GPC6-AS2","canonical_id":"hgnc:HGNC:39910","description":"GPC6 antisense RNA 2","metadata":null},{"id":"da4e6c18775d498193e65adebc2cc828","type":"GENE","name":"GPCPD1","canonical_id":"hgnc:HGNC:26957","description":"glycerophosphocholine phosphodiesterase 1","metadata":{"aliases":["KIAA1434","GDE5","GDPD6"]}},{"id":"371600e48eee409aab52a9ba24626414","type":"GENE","name":"GPCPD1P1","canonical_id":"hgnc:HGNC:33851","description":"GPCPD1 pseudogene 1","metadata":null},{"id":"bf25ea63cfa24a488b86b71f936106e5","type":"GO_TERM","name":"GPCR bitter taste receptor activity","canonical_id":"go:GO:0090682","description":"\"A G protein-coupled receptor activity that is responsible for the sense of bitter taste.\" [GOC:hat, GOC:tb]","metadata":null},{"id":"5c64b08d95504c96971ec6fbaad5aed6","type":"GO_TERM","name":"GPCR sweet taste receptor activity","canonical_id":"go:GO:0090683","description":"\"A G protein-coupled receptor activity that is responsible for the sense of sweet taste.\" [GOC:hat, GOC:tb]","metadata":null},{"id":"12c79feb94a44ed793ca0fa208e0c951","type":"GO_TERM","name":"GPCR taste receptor activity","canonical_id":"go:GO:0090681","description":"\"A G protein-coupled receptor activity that is responsible for the sense of taste.\" [GOC:hat, GOC:tb]","metadata":null},{"id":"8c4fa66ff2e147ecb5a5932e2bf4fc33","type":"GENE","name":"GPD1","canonical_id":"hgnc:HGNC:4455","description":"glycerol-3-phosphate dehydrogenase 1","metadata":null},{"id":"dc89df21553746b199fc95d8dd9916a5","type":"GENE","name":"GPD1L","canonical_id":"hgnc:HGNC:28956","description":"glycerol-3-phosphate dehydrogenase 1 like","metadata":{"aliases":["KIAA0089"]}},{"id":"f0ee9545993f4d0c86e1b78fb86421ad","type":"GENE","name":"GPD2","canonical_id":"hgnc:HGNC:4456","description":"glycerol-3-phosphate dehydrogenase 2","metadata":null},{"id":"45caf3afe6da4b34b52d6752a64c8d51","type":"TRIAL","name":"GPED Regimen for Relapsed/Refractory or Advanced ENKTCL","canonical_id":"clinicaltrials.gov:NCT04405375","description":"Extranodal NK/T-cell Lymphoma, Nasal Type","metadata":null},{"id":"bc1cef9b7f03402f9c0049a521de65c1","type":"GENE","name":"GPER1","canonical_id":"hgnc:HGNC:4485","description":"G protein-coupled estrogen receptor 1","metadata":{"aliases":["FEG-1","GPCR-Br","LERGU","LERGU2","DRY12","LyGPR","CEPR","CMKRL2","GPR30","GPER"]}},{"id":"2663cb55775b4ee692ecba944e566bb2","type":"GENE","name":"GPHA2","canonical_id":"hgnc:HGNC:18054","description":"glycoprotein hormone subunit alpha 2","metadata":{"aliases":["GPA2","ZSIG51","A2","MGC126572"]}},{"id":"9263a13e4b3f4cf4811268008e932b97","type":"GENE","name":"GPHB5","canonical_id":"hgnc:HGNC:18055","description":"glycoprotein hormone subunit beta 5","metadata":{"aliases":["ZLUT1","GPB5"]}},{"id":"efc803aaf9ed4a4d94cfebfc66df0ad1","type":"GENE","name":"GPHN","canonical_id":"hgnc:HGNC:15465","description":"gephyrin","metadata":{"aliases":["KIAA1385","GEPH","GPH"]}},{"id":"1a80a143ffc44d44b4c34f03b9e9c571","type":"GENE","name":"GPHRA","canonical_id":"hgnc:HGNC:31984","description":"golgi pH regulator A","metadata":{"aliases":["GPHR","UNQ192","GPR89A"]}},{"id":"f01ba67ba7c2439f8adaaef24653b8ab","type":"GENE","name":"GPHRB","canonical_id":"hgnc:HGNC:13840","description":"golgi pH regulator B","metadata":{"aliases":["GPHRB","SH120","GPR89","GPR89C","LINC02804","GPR89B"]}},{"id":"5170cb86d9b64d129d232493902b9335","type":"GENE","name":"GPHRP1","canonical_id":"hgnc:HGNC:13951","description":"golgi pH regulator pseudogene 1","metadata":{"aliases":["C11H1.2-Lp","GPR89P"]}},{"id":"cc1cd2d053374e3d93e7d4cddaaaf6b4","type":"GENE","name":"GPI","canonical_id":"hgnc:HGNC:4458","description":"glucose-6-phosphate isomerase","metadata":{"aliases":["AMF","NLK"]}},{"id":"8bfb46c11cee48eeb630935ee7ce3dd7","type":"GO_TERM","name":"GPI anchor binding","canonical_id":"go:GO:0034235","description":"\"Binding to a glycosylphosphatidylinositol anchor. GPI anchors serve to attach membrane proteins to the lipid bilayer of cell membranes.\" [GOC:vw]","metadata":null},{"id":"b4233714796a4138b1779d11683141b7","type":"GO_TERM","name":"GPI anchor biosynthetic process","canonical_id":"go:GO:0006506","description":"\"The chemical reactions and pathways resulting in the formation of a glycosylphosphatidylinositol (GPI) anchor that attaches some membrane proteins to the lipid bilayer of the cell membrane. The phosphatidylinositol group is linked via the C-6 hydroxyl residue of inositol to a carbohydrate chain which is itself linked to the protein via an ethanolamine phosphate group, its amino group forming an amide linkage with the C-terminal carboxyl of the protein. Some GPI anchors have variants on this canonical linkage.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"b7318fe100614ae082faa02efee710f6","type":"GO_TERM","name":"GPI anchor metabolic process","canonical_id":"go:GO:0006505","description":"\"The chemical reactions and pathways involving glycosylphosphatidylinositol anchors, molecular mechanisms for attaching membrane proteins to the lipid bilayer of cell membranes. Structurally they consist of a molecule of phosphatidylinositol to which is linked, via the C-6 hydroxyl of the inositol, a carbohydrate chain. This chain is in turn linked to the protein through an ethanolamine phosphate group, the amino group of which is in amide linkage with the C-terminal carboxyl of the protein chain, the phosphate group being esterified to the C-6 hydroxyl of the terminal mannose of the core carbohydrate chain.\" [ISBN:0198506732]","metadata":null},{"id":"016b22d1632b4022b7b2b5880f38310a","type":"GO_TERM","name":"GPI anchor phospholipase C activity","canonical_id":"go:GO:0140335","description":"\"Catalysis of the reaction: glycoprotein phosphatidylinositol + H2O = phosphatidate + glycoprotein inositol, by cleavage of the  first phosphodiester bond between the phosphate and glycerol.\" [PMID:23329048]","metadata":null},{"id":"5f091e4e2449490c80cee1a89927ca13","type":"GO_TERM","name":"GPI anchor phospholipase D activity","canonical_id":"go:GO:0004621","description":"\"Catalysis of the reaction: glycoprotein phosphatidylinositol + H2O = phosphatidate + glycoprotein inositol, by cleavage of the second phosphodiester bond between the phosphate and phospholipid.\" [PMID:2760042, RHEA:86263]","metadata":null},{"id":"7a289187d56142bebbbb2de411a3b4c8","type":"GO_TERM","name":"GPI anchor remodelling","canonical_id":"go:GO:0120574","description":"\"Any process leading to the modification of the GPI-anchor after its transfer and attachment to a protein.\" [PMID:32156170]","metadata":null},{"id":"847f717d2e5b43df9736bcfd13cc9124","type":"GO_TERM","name":"GPI anchored protein biosynthesis","canonical_id":"go:GO:0180046","description":"\"Any process leading to the post-translational modification of a protein with a GPI anchor to achieve full functional capacity of the protein.\" [GOC:vw]","metadata":null},{"id":"a8c09ff1d1474f769d928ab19012c441","type":"GO_TERM","name":"GPI mannosyltransferase activity","canonical_id":"go:GO:0004376","description":"\"Catalysis of the transfer of an alpha-D-mannosyl residue from dolichol-P-mannose to GlcN-acyl-PI bearing 0-3 mannoses during formation of the GPI precursor.\" [GOC:curators]","metadata":null},{"id":"a8c0d944bd704b3eab482dea49017619","type":"GO_TERM","name":"GPI-anchor transamidase activity","canonical_id":"go:GO:0003923","description":"\"Catalysis of the formation of the linkage between a protein and a glycosylphosphatidylinositol anchor. The reaction probably occurs by subjecting a peptide bond to nucleophilic attack by the amino group of ethanolamine-GPI, transferring the protein from a signal peptide to the GPI anchor.\" [ISBN:0471331309]","metadata":null},{"id":"a899b359d59447b5a3f1639da2e2491b","type":"GO_TERM","name":"GPI-anchor transamidase complex","canonical_id":"go:GO:0042765","description":"\"An enzyme complex which in humans and yeast consists of at least five proteins; for example, the complex contains GAA1, GPI8, PIG-S, PIG-U, and PIG-T in human, and Gaa1p, Gab1p, Gpi8p, Gpi16p, and Gpi17p in yeast. Catalyzes the posttranslational attachment of the carboxy-terminus of a precursor protein to a GPI-anchor.\" [GOC:jl, GOC:rb, PMID:12802054]","metadata":null},{"id":"6966a44c3d92457497460b810ac0e471","type":"GO_TERM","name":"GPI-linked ephrin receptor activity","canonical_id":"go:GO:0005004","description":"\"Combining with a GPI-anchored ephrin to initiate a change in cell activity.\" [GOC:mah, PMID:9530499]","metadata":null},{"id":"bfdf7fdfcf1f44abb6cca0ad2135131d","type":"GO_TERM","name":"GPI-mannose ethanolamine phosphate phosphodiesterase activity","canonical_id":"go:GO:0062050","description":"\"A phosphoric diester hydrolase activity that removes the ethanolamine phosphate from mannose 2 of a GPI anchor.\" [PMID:19837036]","metadata":null},{"id":"43cb320a8cf847acb9c4fc6ad30f5a2c","type":"GENE","name":"GPIHBP1","canonical_id":"hgnc:HGNC:24945","description":"glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1","metadata":{"aliases":["LOC338328","GPI-HBP1"]}},{"id":"47dfbd4d5491482fad2ea1d803c85dd1","type":"TRIAL","name":"GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00538317","description":"Acute Myocardial Infarction","metadata":null},{"id":"ea59590f7e9c4e0a93339c455154a396","type":"GENE","name":"GPKOW","canonical_id":"hgnc:HGNC:30677","description":"G-patch domain and KOW motifs","metadata":{"aliases":["T54","GPATC5","GPATCH5","Spp2","Mos2"]}},{"id":"00102e813fa1480bb9a9f84bc45f0aad","type":"GENE","name":"GPLD1","canonical_id":"hgnc:HGNC:4459","description":"glycosylphosphatidylinositol specific phospholipase D1","metadata":null},{"id":"58cbae9a33e74b04b959037a337a9ff6","type":"GENE","name":"GPM6A","canonical_id":"hgnc:HGNC:4460","description":"glycoprotein M6A","metadata":{"aliases":["GPM6"]}},{"id":"af72bd14ebd54ab5914c1c56272401ab","type":"GENE","name":"GPM6A-AS1","canonical_id":"hgnc:HGNC:55577","description":"GPM6A antisense RNA 1","metadata":{"aliases":["GPM6A-DT"]}},{"id":"e760a6a75aa449d5883713523a938687","type":"GENE","name":"GPM6B","canonical_id":"hgnc:HGNC:4461","description":"glycoprotein M6B","metadata":{"aliases":["M6B","MGC17150","MGC54284"]}},{"id":"49776cc0cf00437cbb41924107cd84ea","type":"GENE","name":"GPM6BP1","canonical_id":"hgnc:HGNC:38782","description":"glycoprotein M6B pseudogene 1","metadata":null},{"id":"c83f2e02f1744e429a00f4dd1ffacbfe","type":"GENE","name":"GPM6BP2","canonical_id":"hgnc:HGNC:38781","description":"glycoprotein M6B pseudogene 2","metadata":null},{"id":"26dc9627846f41198d6fa4e817616ba5","type":"GENE","name":"GPM6BP3","canonical_id":"hgnc:HGNC:38783","description":"glycoprotein M6B pseudogene 3","metadata":null},{"id":"2c584e02da0040a381e9f3698c46c934","type":"GENE","name":"GPN1","canonical_id":"hgnc:HGNC:17030","description":"GPN-loop GTPase 1","metadata":{"aliases":["NTPBP","MBDIN","ATPBD1A","RPAP4","XAB1"]}},{"id":"ba58f4d4325e414cac948c5782b8ff38","type":"GENE","name":"GPN2","canonical_id":"hgnc:HGNC:25513","description":"GPN-loop GTPase 2","metadata":{"aliases":["FLJ10349","ATPBD1B"]}},{"id":"f6ea00df7cff4671b79b106e513c1125","type":"GENE","name":"GPN2-AS1","canonical_id":"hgnc:HGNC:58220","description":"GPN2 antisense RNA 1","metadata":null},{"id":"f5aec26e28cd4769b5bbe93d4c8f6f73","type":"GENE","name":"GPN3","canonical_id":"hgnc:HGNC:30186","description":"GPN-loop GTPase 3","metadata":{"aliases":["MGC14560","ATPBD1C"]}},{"id":"9d50364e84a1418fa3424400526026f0","type":"GENE","name":"GPN3P1","canonical_id":"hgnc:HGNC:44914","description":"GPN-loop GTPase 3 pseudogene 1","metadata":null},{"id":"b784abdb8a4f4bf095ae65664b583a8c","type":"GENE","name":"GPNMB","canonical_id":"hgnc:HGNC:4462","description":null,"metadata":null},{"id":"0dac636ee2f44f569fc844bff2d972ce","type":"GENE","name":"GPR101","canonical_id":"hgnc:HGNC:14963","description":"G protein-coupled receptor 101","metadata":null},{"id":"6977f9cca7d24a9d91f334f724ef6f73","type":"GENE","name":"GPR107","canonical_id":"hgnc:HGNC:17830","description":"G protein-coupled receptor 107","metadata":{"aliases":["KIAA1624","RP11-88G17","FLJ20998","LUSTR1"]}},{"id":"684b96c1d6f24f97856261efc7c32244","type":"GENE","name":"GPR108","canonical_id":"hgnc:HGNC:17829","description":"G protein-coupled receptor 108","metadata":{"aliases":["LUSTR2"]}},{"id":"f42e49a857e846f8b552f514e7d8245f","type":"GENE","name":"GPR119","canonical_id":"hgnc:HGNC:19060","description":"G protein-coupled receptor 119","metadata":{"aliases":["hGPCR2","GPCR2"]}},{"id":"af091de2e7604e6195b895dc73279d3a","type":"GENE","name":"GPR12","canonical_id":"hgnc:HGNC:4466","description":"G protein-coupled receptor 12","metadata":{"aliases":["GPCR21","PPP1R84"]}},{"id":"d3dd87d28fd7436a809f9603c23d717d","type":"GENE","name":"GPR132","canonical_id":"hgnc:HGNC:17482","description":"G protein-coupled receptor 132","metadata":{"aliases":["G2A"]}},{"id":"9d878bccac0041fda7a454f0b80de084","type":"GENE","name":"GPR135","canonical_id":"hgnc:HGNC:19991","description":"G protein-coupled receptor 135","metadata":{"aliases":["HUMNPIIY20","PAFR"]}},{"id":"52809b3709c1469c85aac42aedf19b7e","type":"GENE","name":"GPR137","canonical_id":"hgnc:HGNC:24300","description":"G protein-coupled receptor 137","metadata":{"aliases":["C11orf4","GPR137A","TM7SF1L1"]}},{"id":"56bb9f24d5c4416ab425e84a74a743ea","type":"GENE","name":"GPR137B","canonical_id":"hgnc:HGNC:11862","description":"G protein-coupled receptor 137B","metadata":{"aliases":["TM7SF1"]}},{"id":"d04fd039724d4d85ade00d3d9bd8890e","type":"GENE","name":"GPR137C","canonical_id":"hgnc:HGNC:25445","description":"G protein-coupled receptor 137C","metadata":{"aliases":["DKFZp762F0713","TM7SF1L2"]}},{"id":"fed3f87964784dbf8e5ec323b4e0d1cb","type":"GENE","name":"GPR139","canonical_id":"hgnc:HGNC:19995","description":"G protein-coupled receptor 139","metadata":{"aliases":["PGR3"]}},{"id":"9eaeddc08b1e4744997bfe183ad4cfbf","type":"GENE","name":"GPR141","canonical_id":"hgnc:HGNC:19997","description":"G protein-coupled receptor 141","metadata":{"aliases":["PGR13"]}},{"id":"69ec932fb0e64b98b46b4e3c951b19bd","type":"GENE","name":"GPR141BP","canonical_id":"hgnc:HGNC:53813","description":"G protein-coupled receptor 141B, pseudogene","metadata":null},{"id":"e527a293910844f3a8b599c111ee6639","type":"GENE","name":"GPR142","canonical_id":"hgnc:HGNC:20088","description":"G protein-coupled receptor 142","metadata":{"aliases":["PGR2"]}},{"id":"3f4d411145cc4cc19eec5e2305fa1c1f","type":"GENE","name":"GPR143","canonical_id":"hgnc:HGNC:20145","description":"G protein-coupled receptor 143","metadata":{"aliases":["OA1"]}},{"id":"290a8398cf7b4bd0a49d8843338ad1fa","type":"GENE","name":"GPR143YP","canonical_id":"hgnc:HGNC:18499","description":"G protein-coupled receptor 143 Y-linked pseudogene","metadata":{"aliases":["GPR143Y","OA1P","GPR143P"]}},{"id":"1e9add50746e435a9125b9030a976ecc","type":"GENE","name":"GPR146","canonical_id":"hgnc:HGNC:21718","description":"G protein-coupled receptor 146","metadata":{"aliases":["PGR8"]}},{"id":"b18847d5425f40d198fced49eb6b11ab","type":"GENE","name":"GPR148","canonical_id":"hgnc:HGNC:23623","description":"G protein-coupled receptor 148","metadata":{"aliases":["PGR6"]}},{"id":"67bfce836cf648fdae9e7614436400f0","type":"GENE","name":"GPR149","canonical_id":"hgnc:HGNC:23627","description":"G protein-coupled receptor 149","metadata":{"aliases":["PGR10","IEDA","R35"]}},{"id":"a4242993533740bb9bc26c435b5c1b70","type":"GENE","name":"GPR15","canonical_id":"hgnc:HGNC:4469","description":"G protein-coupled receptor 15","metadata":null},{"id":"14e0487c4e864612ae3c7af36626621e","type":"GENE","name":"GPR150","canonical_id":"hgnc:HGNC:23628","description":"G protein-coupled receptor 150","metadata":{"aliases":["PGR11"]}},{"id":"e379556f5dd04786ae595f007e51202a","type":"GENE","name":"GPR151","canonical_id":"hgnc:HGNC:23624","description":"G protein-coupled receptor 151","metadata":{"aliases":["PGR7","GALR4"]}},{"id":"745b7c9190534d54bf96d3cb123dc55b","type":"GENE","name":"GPR152","canonical_id":"hgnc:HGNC:23622","description":"G protein-coupled receptor 152","metadata":{"aliases":["PGR5"]}},{"id":"5655319f19f14d3aaf4fcbf921a961f5","type":"GENE","name":"GPR153","canonical_id":"hgnc:HGNC:23618","description":"G protein-coupled receptor 153","metadata":{"aliases":["PGR1"]}},{"id":"6e3157c48f1c439ca5f43e48980f4703","type":"GENE","name":"GPR155","canonical_id":"hgnc:HGNC:22951","description":"G protein-coupled receptor 155","metadata":{"aliases":["DEP.7","PGR22","DEPDC3","LYCHOS","FLJ31819"]}},{"id":"e6741e088d8441a68e0aaccb2f2c6e83","type":"GENE","name":"GPR155-DT","canonical_id":"hgnc:HGNC:55827","description":"GPR155 divergent transcript","metadata":null},{"id":"cdbf3bead1f14546a5067fbff2f68bc4","type":"GENE","name":"GPR156","canonical_id":"hgnc:HGNC:20844","description":"G protein-coupled receptor 156","metadata":{"aliases":["PGR28","GABABL"]}},{"id":"29d422a429004b5d9461f2c2a78f0d37","type":"GENE","name":"GPR157","canonical_id":"hgnc:HGNC:23687","description":"G protein-coupled receptor 157","metadata":{"aliases":["FLJ12132"]}},{"id":"0da929d5c26c4e4cb6f955aafe599d28","type":"GENE","name":"GPR158","canonical_id":"hgnc:HGNC:23689","description":"G protein-coupled receptor 158","metadata":{"aliases":["KIAA1136"]}},{"id":"22711f3d59ca4f588de2258831802503","type":"GENE","name":"GPR158-AS1","canonical_id":"hgnc:HGNC:44163","description":"GPR158 antisense RNA 1","metadata":null},{"id":"2475fe2f507443489492969844b38873","type":"GENE","name":"GPR15LG","canonical_id":"hgnc:HGNC:31428","description":"G protein-coupled receptor 15 ligand","metadata":{"aliases":["UNQ1833","RLLV1833","FLJ21763","CSBF","AP-57","GPR15L","C10orf99"]}},{"id":"38c5d5558f1e4e6e91361c5f7dfa38e1","type":"GENE","name":"GPR160","canonical_id":"hgnc:HGNC:23693","description":"G protein-coupled receptor 160","metadata":{"aliases":["GPCR150","GPCR1"]}},{"id":"fd3395b3214440aba4ea0dbe514b4150","type":"GENE","name":"GPR160P1","canonical_id":"hgnc:HGNC:54682","description":"GPR160 pseudogene 1","metadata":null},{"id":"7c5d8108f5d6425eb0531200c6046f92","type":"GENE","name":"GPR160P2","canonical_id":"hgnc:HGNC:54683","description":"GPR160 pseudogene 2","metadata":null},{"id":"3b3530ed0206474aad9f3e5ae294b5f9","type":"GENE","name":"GPR161","canonical_id":"hgnc:HGNC:23694","description":"G protein-coupled receptor 161","metadata":{"aliases":["RE2"]}},{"id":"8936de183f164a3881c20e3eb776a1ed","type":"GENE","name":"GPR162","canonical_id":"hgnc:HGNC:16693","description":"G protein-coupled receptor 162","metadata":{"aliases":["A-2","GRCA"]}},{"id":"9007d63519ff4c14accfe1235b6eeae2","type":"GENE","name":"GPR165P","canonical_id":"hgnc:HGNC:21462","description":"G protein-coupled receptor 165, pseudogene","metadata":{"aliases":["PGR15","6530406P05Rik"]}},{"id":"f3428ea4c4674682ac2f0d6fbd3d1adf","type":"GENE","name":"GPR166P","canonical_id":"hgnc:HGNC:23626","description":"G protein-coupled receptor 166, pseudogene","metadata":{"aliases":["PGR9"]}},{"id":"8c9e715c36494d429d97e4adea7e0fa0","type":"GENE","name":"GPR17","canonical_id":"hgnc:HGNC:4471","description":"G protein-coupled receptor 17","metadata":null},{"id":"c2020b65fbc442b99d9adc3baaa8ecff","type":"GENE","name":"GPR171","canonical_id":"hgnc:HGNC:30057","description":"G protein-coupled receptor 171","metadata":{"aliases":["H963"]}},{"id":"4b982062a5924cf7942a5ab45d96f5df","type":"GENE","name":"GPR173","canonical_id":"hgnc:HGNC:18186","description":"G protein-coupled receptor 173","metadata":{"aliases":["SREB3"]}},{"id":"c410fbdd23a84047ab711c9ae19e9663","type":"GENE","name":"GPR174","canonical_id":"hgnc:HGNC:30245","description":"G protein-coupled receptor 174","metadata":{"aliases":["FKSG79","LPS3"]}},{"id":"4876cd0f84674a089d580e2684f95c3d","type":"GENE","name":"GPR176","canonical_id":"hgnc:HGNC:32370","description":"G protein-coupled receptor 176","metadata":{"aliases":["Gm1012"]}},{"id":"7b51d448000f4dd29189f8ba1aaeb220","type":"GENE","name":"GPR176-DT","canonical_id":"hgnc:HGNC:54389","description":"GPR176 divergent transcript","metadata":null},{"id":"dfb9bd85e35d415c87ed7e7cacd2a9c4","type":"GENE","name":"GPR179","canonical_id":"hgnc:HGNC:31371","description":"G protein-coupled receptor 179","metadata":{"aliases":["CSNB1E","GPR158L1"]}},{"id":"7b78ef93811549f6b5d703dc6896c8ae","type":"GENE","name":"GPR18","canonical_id":"hgnc:HGNC:4472","description":"G protein-coupled receptor 18","metadata":{"aliases":["DRV2"]}},{"id":"090b5f7c5afc4726b214df3090c2cc02","type":"GENE","name":"GPR180","canonical_id":"hgnc:HGNC:28899","description":"G protein-coupled receptor 180","metadata":{"aliases":["ITR"]}},{"id":"a8581bcb42f74c28b12ecced1bfc55df","type":"GENE","name":"GPR183","canonical_id":"hgnc:HGNC:3128","description":"G protein-coupled receptor 183","metadata":{"aliases":["EBI2"]}},{"id":"035d068186ab4295accb33be9a9043cc","type":"GENE","name":"GPR19","canonical_id":"hgnc:HGNC:4473","description":"G protein-coupled receptor 19","metadata":null},{"id":"85196e8a49094beab550bfce9ec4f132","type":"GENE","name":"GPR199P","canonical_id":"hgnc:HGNC:55170","description":"G protein-coupled receptor 199, pseudogene","metadata":null},{"id":"f358cc2065e14a15bcbe68746b6eca59","type":"GENE","name":"GPR20","canonical_id":"hgnc:HGNC:4475","description":"G protein-coupled receptor 20","metadata":null},{"id":"09965d430623497fac49a4e205f90bac","type":"GENE","name":"GPR21","canonical_id":"hgnc:HGNC:4476","description":"G protein-coupled receptor 21","metadata":null},{"id":"29c35bbd3ac8424ab5f86b0660c3d8d2","type":"GENE","name":"GPR22","canonical_id":"hgnc:HGNC:4477","description":"G protein-coupled receptor 22","metadata":null},{"id":"89f34d78e4634efb81a309e2bf954b81","type":"GENE","name":"GPR25","canonical_id":"hgnc:HGNC:4480","description":"G protein-coupled receptor 25","metadata":null},{"id":"ced68eef10c34ded8c2c09b7963db136","type":"GENE","name":"GPR26","canonical_id":"hgnc:HGNC:4481","description":"G protein-coupled receptor 26","metadata":null},{"id":"f3cbf41a249541e7b0d01cf6b00e7d7f","type":"GENE","name":"GPR27","canonical_id":"hgnc:HGNC:4482","description":"G protein-coupled receptor 27","metadata":{"aliases":["SREB1"]}},{"id":"14bc320443454f7ea669e2bc530f941e","type":"GENE","name":"GPR3","canonical_id":"hgnc:HGNC:4484","description":"G protein-coupled receptor 3","metadata":{"aliases":["ACCA"]}},{"id":"9d01ff3f2f03419da2444bf70d34584f","type":"GENE","name":"GPR31","canonical_id":"hgnc:HGNC:4486","description":"G protein-coupled receptor 31","metadata":{"aliases":["HETER1","12-HETER"]}},{"id":"b4b0ba48715e4d998eea7cc1ab973776","type":"GENE","name":"GPR32","canonical_id":"hgnc:HGNC:4487","description":"G protein-coupled receptor 32","metadata":{"aliases":["RVDR1","DRV1"]}},{"id":"23d8de9593d84d8495fd1835ed43093a","type":"GENE","name":"GPR32P1","canonical_id":"hgnc:HGNC:4488","description":"GPR32 pseudogene 1","metadata":{"aliases":["GPR32P"]}},{"id":"726e34dc66914e4c853b459af272071f","type":"GENE","name":"GPR33","canonical_id":"hgnc:HGNC:4489","description":"G protein-coupled receptor 33","metadata":null},{"id":"f66739618b7244c28993cf5127f9b4ff","type":"GENE","name":"GPR34","canonical_id":"hgnc:HGNC:4490","description":"G protein-coupled receptor 34","metadata":{"aliases":["LPS1"]}},{"id":"78dbc0281f204046a3e0e1958d927b21","type":"GENE","name":"GPR35","canonical_id":"hgnc:HGNC:4492","description":"G protein-coupled receptor 35","metadata":null},{"id":"612905b37b0746d5bf8e42ffaa6c494a","type":"GENE","name":"GPR36","canonical_id":"hgnc:HGNC:4493","description":"G protein-coupled receptor 36","metadata":null},{"id":"7651ffe2b1934f0eba5859dff91fea79","type":"GENE","name":"GPR37","canonical_id":"hgnc:HGNC:4494","description":"G protein-coupled receptor 37","metadata":{"aliases":["EDNRBL","hET(B)R-LP","PAELR"]}},{"id":"944deac429d743eb9a0673951483b55f","type":"GENE","name":"GPR37L1","canonical_id":"hgnc:HGNC:14923","description":"G protein-coupled receptor 37 like 1","metadata":{"aliases":["ETBR-LP-2"]}},{"id":"3853036e7a97482a8d8e09be521631a5","type":"GENE","name":"GPR39","canonical_id":"hgnc:HGNC:4496","description":null,"metadata":null},{"id":"1ff6609710114dd7ae48c61adb4d6e87","type":"GENE","name":"GPR4","canonical_id":"hgnc:HGNC:4497","description":"G protein-coupled receptor 4","metadata":null},{"id":"d51457c3981640acb8f220a03df15e49","type":"GENE","name":"GPR42","canonical_id":"hgnc:HGNC:4500","description":"G protein-coupled receptor 42","metadata":{"aliases":["GPR41L","FFAR3L","GPR42P"]}},{"id":"e85ecc8949f54a25b3deba7d339d3aba","type":"GENE","name":"GPR45","canonical_id":"hgnc:HGNC:4503","description":"G protein-coupled receptor 45","metadata":{"aliases":["PSP24","PSP24A"]}},{"id":"488bbd36a524440cbfea8cc6cdd4c675","type":"GENE","name":"GPR50","canonical_id":"hgnc:HGNC:4506","description":"G protein-coupled receptor 50","metadata":{"aliases":["H9","Mel1c"]}},{"id":"f4bc5e26d6654af38047b6e241a0b03f","type":"GENE","name":"GPR50-AS1","canonical_id":"hgnc:HGNC:40259","description":"GPR50 antisense RNA 1","metadata":null},{"id":"b4f7423df50d46a199801ba1c46f09ca","type":"GENE","name":"GPR52","canonical_id":"hgnc:HGNC:4508","description":"G protein-coupled receptor 52","metadata":null},{"id":"7bd2f286bce843e680245fab60b2a354","type":"GENE","name":"GPR55","canonical_id":"hgnc:HGNC:4511","description":"G protein-coupled receptor 55","metadata":null},{"id":"472e69a112ba4398b4c71dd3d58a6afe","type":"GENE","name":"GPR55-AS1","canonical_id":"hgnc:HGNC:40260","description":"GPR55 antisense RNA 1","metadata":null},{"id":"17c8c6edd0124287a15ec26459883ee2","type":"GENE","name":"GPR6","canonical_id":"hgnc:HGNC:4515","description":"G protein-coupled receptor 6","metadata":null},{"id":"570658d41c0a4011b160c0495ee24f1e","type":"GENE","name":"GPR61","canonical_id":"hgnc:HGNC:13300","description":"G protein-coupled receptor 61","metadata":{"aliases":["BALGR"]}},{"id":"c97646df8c3a48fe8542eb0f450431f2","type":"GENE","name":"GPR62","canonical_id":"hgnc:HGNC:13301","description":"G protein-coupled receptor 62","metadata":null},{"id":"3aa634990cef405cbfa7bb8bd942c724","type":"GENE","name":"GPR63","canonical_id":"hgnc:HGNC:13302","description":"G protein-coupled receptor 63","metadata":{"aliases":["PSP24(beta)","PSP24B"]}},{"id":"c816acf5679f49908063d25970080835","type":"GENE","name":"GPR65","canonical_id":"hgnc:HGNC:4517","description":"G protein-coupled receptor 65","metadata":{"aliases":["hTDAG8","TDAG8"]}},{"id":"00d4d57eb3dd45b6b6ed9bed8a70a381","type":"GENE","name":"GPR68","canonical_id":"hgnc:HGNC:4519","description":"G protein-coupled receptor 68","metadata":{"aliases":["OGR1"]}},{"id":"d7584b23fe3c4bdb85285873b5a4dfee","type":"GENE","name":"GPR75","canonical_id":"hgnc:HGNC:4526","description":"G protein-coupled receptor 75","metadata":{"aliases":["WI-31133"]}},{"id":"c9d816ba52214815b17136005b54c52a","type":"GENE","name":"GPR75-ASB3","canonical_id":"hgnc:HGNC:40043","description":"GPR75-ASB3 readthrough","metadata":null},{"id":"9d422af37a6944de92c755f59cfaeea4","type":"GENE","name":"GPR78","canonical_id":"hgnc:HGNC:4528","description":"G protein-coupled receptor 78","metadata":null},{"id":"9d536761d9e54b68817d125a57445dc1","type":"GENE","name":"GPR79P","canonical_id":"hgnc:HGNC:4529","description":"G protein-coupled receptor 79, pseudogene","metadata":{"aliases":["GPR79"]}},{"id":"4cb42e4bccc747a3b3f81a5b3191bf3e","type":"GENE","name":"GPR82","canonical_id":"hgnc:HGNC:4533","description":"G protein-coupled receptor 82","metadata":null},{"id":"4a8970b7c637451ca5c566de780b2b4d","type":"GENE","name":"GPR83","canonical_id":"hgnc:HGNC:4523","description":"G protein-coupled receptor 83","metadata":{"aliases":["GPR72"]}},{"id":"b8a5b6029c2a45bf9ea84e5079e271c7","type":"GENE","name":"GPR84","canonical_id":"hgnc:HGNC:4535","description":"G protein-coupled receptor 84","metadata":{"aliases":["EX33"]}},{"id":"08683795ca5e485a940ab422e2def0e8","type":"GENE","name":"GPR84-AS1","canonical_id":"hgnc:HGNC:56187","description":"GPR84, ZNF385A, ITGA5 and GTSF1 antisense RNA 1","metadata":{"aliases":["LINC01154"]}},{"id":"1a19bfd92919406789d3f898e727e3e2","type":"GENE","name":"GPR85","canonical_id":"hgnc:HGNC:4536","description":"G protein-coupled receptor 85","metadata":{"aliases":["SREB2"]}},{"id":"8265b7afdf6143a9b09ef81ffa2231c7","type":"GENE","name":"GPR87","canonical_id":"hgnc:HGNC:4538","description":"G protein-coupled receptor 87","metadata":{"aliases":["GPR95"]}},{"id":"53dbfe0ef91743f8ae72a9906b5897d2","type":"GENE","name":"GPR88","canonical_id":"hgnc:HGNC:4539","description":"G protein-coupled receptor 88","metadata":null},{"id":"74aa2228e42f4edf807a9bd771b10862","type":"GENE","name":"GPRACR","canonical_id":"hgnc:HGNC:53957","description":"GPR107 adjacent cis regulating lncRNA","metadata":{"aliases":["LncGPR107"]}},{"id":"0d2a00e36f164779b51fdf69f127f8be","type":"GENE","name":"GPRASP1","canonical_id":"hgnc:HGNC:24834","description":"G protein-coupled receptor associated sorting protein 1","metadata":{"aliases":["GASP","GASP1"]}},{"id":"34a46dcded31454a8dd667103bf42aee","type":"GENE","name":"GPRASP2","canonical_id":"hgnc:HGNC:25169","description":"G protein-coupled receptor associated sorting protein 2","metadata":{"aliases":["GASP2","FLJ37327"]}},{"id":"94e0138086054d979dafc9190f9ba192","type":"GENE","name":"GPRASP3","canonical_id":"hgnc:HGNC:29353","description":"G protein-coupled receptor associated sorting protein family member 3","metadata":{"aliases":["p60TRP","KIAA1701","GASP3","BHLHB9"]}},{"id":"f1f61130a396457298945cb5cb8592d6","type":"GENE","name":"GPRASP3P1","canonical_id":"hgnc:HGNC:51373","description":"GPRASP3 pseudogene 1","metadata":{"aliases":["BHLHB9P1"]}},{"id":"0962c48cdfea4acd9e631160f8cd34cb","type":"GENE","name":"GPRC5A","canonical_id":"hgnc:HGNC:9836","description":"G protein-coupled receptor class C group 5 member A","metadata":{"aliases":["RAIG1","TIG1","PEIG-1","RAI3"]}},{"id":"244190b12dd44503b32c4d8337e8c992","type":"GENE","name":"GPRC5B","canonical_id":"hgnc:HGNC:13308","description":"G protein-coupled receptor class C group 5 member B","metadata":{"aliases":["RAIG-2"]}},{"id":"e773ae3e4a6c423aa146d19a32e6cac8","type":"GENE","name":"GPRC5C","canonical_id":"hgnc:HGNC:13309","description":"G protein-coupled receptor class C group 5 member C","metadata":{"aliases":["RAIG-3"]}},{"id":"e4b4004ca7e749c4a64e0fa4fa02526a","type":"GENE","name":"GPRC5D","canonical_id":"hgnc:HGNC:13310","description":"G protein-coupled receptor class C group 5 member D","metadata":null},{"id":"5b03df4671ce43e1b5bf22453f6c2954","type":"GENE","name":"GPRC5D-AS1","canonical_id":"hgnc:HGNC:53599","description":"GPRC5D and HEBP1 antisense RNA 1","metadata":{"aliases":["RP11-392P7.6"]}},{"id":"a2c7f7f3a9724e56b722720b9aee31c0","type":"GENE","name":"GPRC6A","canonical_id":"hgnc:HGNC:18510","description":"G protein-coupled receptor class C group 6 member A","metadata":{"aliases":["bA86F4.3"]}},{"id":"48275f8dcdbf4d25a30bcd7b76cfdb9a","type":"GENE","name":"GPRIN1","canonical_id":"hgnc:HGNC:24835","description":"G protein regulated inducer of neurite outgrowth 1","metadata":{"aliases":["GRIN1","KIAA1893"]}},{"id":"8135c5696a3b49aa88684a8a047cc2ae","type":"GENE","name":"GPRIN2","canonical_id":"hgnc:HGNC:23730","description":"G protein regulated inducer of neurite outgrowth 2","metadata":{"aliases":["MGC15171","KIAA0514"]}},{"id":"b59f7f87f6d449ceb5f146ef8fcabefe","type":"GENE","name":"GPRIN3","canonical_id":"hgnc:HGNC:27733","description":"GPRIN family member 3","metadata":{"aliases":["GRIN3","FLJ42625"]}},{"id":"1c164621586d460b8919a0ab5e9d9b41","type":"GENE","name":"GPRIN3-AS1","canonical_id":"hgnc:HGNC:58848","description":"GPRIN3 antisense RNA 1","metadata":null},{"id":"11749124a04e4b6ea8d0936a150145f7","type":"GENE","name":"GPS1","canonical_id":"hgnc:HGNC:4549","description":"G protein pathway suppressor 1","metadata":{"aliases":["COPS1","CSN1"]}},{"id":"60330a7fa5384cd8821819537bd2fcf7","type":"GENE","name":"GPS2","canonical_id":"hgnc:HGNC:4550","description":"G protein pathway suppressor 2","metadata":null},{"id":"dad87d8d7d83400d97a322490bbf4a30","type":"GENE","name":"GPS2P1","canonical_id":"hgnc:HGNC:49622","description":"G protein pathway suppressor 2 pseudogene 1","metadata":null},{"id":"90d6ba98d0a24ccdb6f86b2595e0cc95","type":"GENE","name":"GPS2P2","canonical_id":"hgnc:HGNC:49623","description":"G protein pathway suppressor 2 pseudogene 2","metadata":null},{"id":"22f5def7dae040afb23dee339835627e","type":"GENE","name":"GPSM1","canonical_id":"hgnc:HGNC:17858","description":"G protein signaling modulator 1","metadata":{"aliases":["AGS3","DKFZP727I051"]}},{"id":"81caec8cc4a0412e859a469a452fc4e9","type":"GENE","name":"GPSM2","canonical_id":"hgnc:HGNC:29501","description":"G protein signaling modulator 2","metadata":{"aliases":["LGN","Pins","DFNB82"]}},{"id":"279769d427564884897e0adb8ed61140","type":"GENE","name":"GPSM3","canonical_id":"hgnc:HGNC:13945","description":"G protein signaling modulator 3","metadata":{"aliases":["NG1","G18","G18.1a","G18.1b","G18.2","AGS4","C6orf9"]}},{"id":"272c7943e8544856b1fc266f6a49779a","type":"GENE","name":"GPT","canonical_id":"hgnc:HGNC:4552","description":"glutamic--pyruvic transaminase","metadata":{"aliases":["ALT1","ALT","GPT1","SGPT"]}},{"id":"02772892eb774f77b2abd8dd1ebab2d5","type":"GENE","name":"GPT2","canonical_id":"hgnc:HGNC:18062","description":"glutamic--pyruvic transaminase 2","metadata":{"aliases":["ALT2"]}},{"id":"2a80ae43117e4963ba9ae24eb1286339","type":"GENE","name":"GPX1","canonical_id":"hgnc:HGNC:4553","description":null,"metadata":null},{"id":"681a3668785741e0bef7f5a7b5e18568","type":"GENE","name":"GPX1P1","canonical_id":"hgnc:HGNC:4560","description":"glutathione peroxidase pseudogene 1","metadata":{"aliases":["GPXL2","GPXP1"]}},{"id":"d3198bcc4aed431d826cb271caa82cf5","type":"GENE","name":"GPX1P2","canonical_id":"hgnc:HGNC:4561","description":"glutathione peroxidase pseudogene 2","metadata":{"aliases":["GPXL2","GPXP2P","GPXL1","GPXP2"]}},{"id":"2921b874f4004adea9cc2e287bf3598e","type":"GENE","name":"GPX2","canonical_id":"hgnc:HGNC:4554","description":"glutathione peroxidase 2","metadata":{"aliases":["GSHPX-GI"]}},{"id":"375796bf3a9945c4b178134aa1b51508","type":"GENE","name":"GPX3","canonical_id":"hgnc:HGNC:4555","description":"glutathione peroxidase 3","metadata":null},{"id":"dbafd211a6c04ad68c6822c93ba7217d","type":"GENE","name":"GPX4","canonical_id":"hgnc:HGNC:4556","description":null,"metadata":null},{"id":"bda0f831586240d09b49c2bf079f927c","type":"GENE","name":"GPX5","canonical_id":"hgnc:HGNC:4557","description":"glutathione peroxidase 5","metadata":null},{"id":"1c4ca78d01024130a067898f9922d5d8","type":"GENE","name":"GPX6","canonical_id":"hgnc:HGNC:4558","description":"glutathione peroxidase 6","metadata":{"aliases":["GPXP3"]}},{"id":"d70db7b5977d47b6ac1ebd73eeb10d6e","type":"GENE","name":"GPX7","canonical_id":"hgnc:HGNC:4559","description":"glutathione peroxidase 7","metadata":{"aliases":["FLJ14777","GPX6","NPGPx"]}},{"id":"3e6dc7afff21426f9bd5d2ef47d0ee9a","type":"GENE","name":"GPX8","canonical_id":"hgnc:HGNC:33100","description":"glutathione peroxidase 8 (putative)","metadata":{"aliases":["UNQ847","EPLA847"]}},{"id":"809ac09113b54ce085bf80de033ca65e","type":"GENE","name":"GRAMD1A","canonical_id":"hgnc:HGNC:29305","description":"GRAM domain containing 1A","metadata":{"aliases":["LAMa","FLJ90346","KIAA1533"]}},{"id":"7fefecc2ed8b4851a22be96b72d58ff9","type":"GENE","name":"GRAMD1A-AS1","canonical_id":"hgnc:HGNC:55275","description":"GRAMD1A antisense RNA 1","metadata":null},{"id":"96099658195f423db68f775b9620d391","type":"GENE","name":"GRAMD1B","canonical_id":"hgnc:HGNC:29214","description":"GRAM domain containing 1B","metadata":{"aliases":["LAMb","KIAA1201","LINC01059"]}},{"id":"eece25fee22d418f9f5019076065fabb","type":"GENE","name":"GRAMD1C","canonical_id":"hgnc:HGNC:25252","description":"GRAM domain containing 1C","metadata":{"aliases":["LAMc","DKFZp434C0328"]}},{"id":"67b88ec538974beeafe4b6d513cfb288","type":"GENE","name":"GRAMD2A","canonical_id":"hgnc:HGNC:27287","description":"GRAM domain containing 2A","metadata":{"aliases":["GRAMD2"]}},{"id":"8d1e768844434ef289cb846c0745eed1","type":"GENE","name":"GRAMD2B","canonical_id":"hgnc:HGNC:24911","description":"GRAM domain containing 2B","metadata":{"aliases":["NS3TP2","FLJ21313","GRAMD3"]}},{"id":"43fb73bdffb4408ca4b4d32723891333","type":"GENE","name":"GRAMD2B-AS1","canonical_id":"hgnc:HGNC:41069","description":"GRAMD2B antisense RNA 1","metadata":null},{"id":"0479f72f1c7f42dfb1730282f9e0f37c","type":"GENE","name":"GRAMD4","canonical_id":"hgnc:HGNC:29113","description":"GRAM domain containing 4","metadata":{"aliases":["KIAA0767","DIP"]}},{"id":"dd587a906616447782ec7075513274bf","type":"GENE","name":"GRAMD4P1","canonical_id":"hgnc:HGNC:39653","description":"GRAM domain containing 4 pseudogene 1","metadata":null},{"id":"9e1526339e10446fb8cbe9fd3b7594d3","type":"GENE","name":"GRAMD4P2","canonical_id":"hgnc:HGNC:39654","description":"GRAM domain containing 4 pseudogene 2","metadata":null},{"id":"3f253c613cc2401cbbcf2ed95f76ecb6","type":"GENE","name":"GRAMD4P3","canonical_id":"hgnc:HGNC:49138","description":"GRAM domain containing 4 pseudogene 3","metadata":null},{"id":"f7ad5708536f4a25b59ed7eba9990d88","type":"GENE","name":"GRAMD4P4","canonical_id":"hgnc:HGNC:49139","description":"GRAM domain containing 4 pseudogene 4","metadata":null},{"id":"5d142023733d46dcadb0f3468718077a","type":"GENE","name":"GRAMD4P5","canonical_id":"hgnc:HGNC:49140","description":"GRAM domain containing 4 pseudogene 5","metadata":null},{"id":"b8df3af34d724b5b8d60d7744f826f66","type":"GENE","name":"GRAMD4P6","canonical_id":"hgnc:HGNC:49141","description":"GRAM domain containing 4 pseudogene 6","metadata":null},{"id":"ca72879be3834442b390119ca5fc4bb2","type":"GENE","name":"GRAMD4P7","canonical_id":"hgnc:HGNC:49142","description":"GRAM domain containing 4 pseudogene 7","metadata":null},{"id":"394e71f0f45b462fbe6c39f693651604","type":"GENE","name":"GRAMD4P8","canonical_id":"hgnc:HGNC:49143","description":"GRAM domain containing 4 pseudogene 8","metadata":null},{"id":"f6dfbf04e7cb4f95a517ea105f6484b7","type":"GENE","name":"GRAP","canonical_id":"hgnc:HGNC:4562","description":"GRB2 related adaptor protein","metadata":null},{"id":"bf039d2116964a6a9b5bbc33eb450e1d","type":"GENE","name":"GRAP2","canonical_id":"hgnc:HGNC:4563","description":"GRB2 related adaptor protein 2","metadata":{"aliases":["GRID","Grf40","GrbX","GRBLG","GADS","Mona"]}},{"id":"a121850cd60946debcc156f2c2d06d7c","type":"GENE","name":"GRAPL","canonical_id":"hgnc:HGNC:37240","description":"GRB2 related adaptor protein like","metadata":{"aliases":["GRAPLDR"]}},{"id":"fec15da716454f90a11fdbc2a5678730","type":"GENE","name":"GRAPL-AS1","canonical_id":"hgnc:HGNC:26214","description":"GRAPL antisense RNA 1","metadata":null},{"id":"3388472e6a4a4424a4b3ef1e5100cf36","type":"GENE","name":"GRASLND","canonical_id":"hgnc:HGNC:30963","description":"glycosaminoglycan regulatory associated long non-coding RNA","metadata":{"aliases":["RNF144A-AS1"]}},{"id":"c422ec07102541709c6a0db93ddedae3","type":"GENE","name":"GRB10","canonical_id":"hgnc:HGNC:4564","description":"growth factor receptor bound protein 10","metadata":null},{"id":"9e2beb1dd55b4e8aa7c0dfa45f199846","type":"GENE","name":"GRB14","canonical_id":"hgnc:HGNC:4565","description":"growth factor receptor bound protein 14","metadata":null},{"id":"ab81dbc7b05b4c9e99eede93c8fce829","type":"GENE","name":"GRB2","canonical_id":"hgnc:HGNC:4566","description":"growth factor receptor bound protein 2","metadata":{"aliases":["NCKAP2"]}},{"id":"94159bfd38384308a4b31ecc2bdd038d","type":"GENE","name":"GRB7","canonical_id":"hgnc:HGNC:4567","description":"growth factor receptor bound protein 7","metadata":null},{"id":"c4b2a017ffd2434f9629781a94a97b2d","type":"GENE","name":"GREB1","canonical_id":"hgnc:HGNC:24885","description":null,"metadata":null},{"id":"797fcc43d24b42349946129f9f72a157","type":"GENE","name":"GREB1L","canonical_id":"hgnc:HGNC:31042","description":"GREB1 like retinoic acid receptor coactivator","metadata":{"aliases":["FLJ13687","C18orf6","KIAA1772"]}},{"id":"60d44ba77b074e02be4877da400c668e","type":"GENE","name":"GREB1L-AS1","canonical_id":"hgnc:HGNC:58310","description":"GREB1L antisense RNA 1","metadata":null},{"id":"781f8ce3e2e6440fa12124d01b35ee6d","type":"GENE","name":"GREB1L-DT","canonical_id":"hgnc:HGNC:55323","description":"GREB1L divergent transcript","metadata":null},{"id":"c558c3cba932418fa14faf24a9f1d4db","type":"GENE","name":"GREM1","canonical_id":"hgnc:HGNC:2001","description":"gremlin 1, DAN family BMP antagonist","metadata":{"aliases":["DRM","gremlin","DAND2","HMPS","CKTSF1B1","CRAC1"]}},{"id":"157e742f970340f2a740da83f1247ff3","type":"GENE","name":"GREM1-AS1","canonical_id":"hgnc:HGNC:55411","description":"GREM1 antisense RNA 1","metadata":null},{"id":"db7a5e784e074d94913876b9deaeb4a0","type":"GENE","name":"GREM2","canonical_id":"hgnc:HGNC:17655","description":"gremlin 2, DAN family BMP antagonist","metadata":{"aliases":["Prdc","FLJ21195","CKTSF1B2","DAND3"]}},{"id":"cf950f4660064a0680d26e3c9289e91a","type":"GENE","name":"GREP1","canonical_id":"hgnc:HGNC:27549","description":"glycine rich extracellular protein 1","metadata":{"aliases":["G029442","LINC00514"]}},{"id":"4408886e1cef4fbca4f546dc341ac879","type":"GENE","name":"GRHL1","canonical_id":"hgnc:HGNC:17923","description":null,"metadata":null},{"id":"5c7abc4b50684a47bab541d3b744e1a8","type":"GENE","name":"GRHL2","canonical_id":"hgnc:HGNC:2799","description":null,"metadata":null},{"id":"d1ea5af60f3847e2ae3140bfa9e429fc","type":"GENE","name":"GRHL2-DT","canonical_id":"hgnc:HGNC:55466","description":"GRHL2 divergent transcript","metadata":{"aliases":["BX357664"]}},{"id":"8cbbf4f3be3d40759ead68832d379b3b","type":"GENE","name":"GRHL3","canonical_id":"hgnc:HGNC:25839","description":"grainyhead like transcription factor 3","metadata":{"aliases":["SOM","TFCP2L4"]}},{"id":"daf1df8948724c1c9acea0c3b6718a8b","type":"GENE","name":"GRHL3-AS1","canonical_id":"hgnc:HGNC:41119","description":"GRHL3 antisense RNA 1","metadata":null},{"id":"4908b7a4867e4d2781ccc1d8008e5e54","type":"GENE","name":"GRHPR","canonical_id":"hgnc:HGNC:4570","description":"glyoxylate and hydroxypyruvate reductase","metadata":{"aliases":["PH2","GLXR","GLYD"]}},{"id":"6f79d5d3687f4d70860be2a88dc21782","type":"GENE","name":"GRIA1","canonical_id":"hgnc:HGNC:4571","description":"glutamate ionotropic receptor AMPA type subunit 1","metadata":{"aliases":["GluA1","GLURA","GLUR1"]}},{"id":"bb6312efdebb4f83b0a3734cf7cc2f93","type":"GENE","name":"GRIA2","canonical_id":"hgnc:HGNC:4572","description":"glutamate ionotropic receptor AMPA type subunit 2","metadata":{"aliases":["GluA2","GLURB","GluR-K2","GluR-B","GluR-2","GLUR2"]}},{"id":"e450e2fb7b6c421bb54716f040138a19","type":"GENE","name":"GRIA3","canonical_id":"hgnc:HGNC:4573","description":"glutamate ionotropic receptor AMPA type subunit 3","metadata":{"aliases":["GluA3","GLURC","MRX94","GluR-3","GluR-C","GluR-K3","iGluR3","GLUR3"]}},{"id":"65f922d3078449b591e57d347026ad18","type":"GENE","name":"GRIA4","canonical_id":"hgnc:HGNC:4574","description":"glutamate ionotropic receptor AMPA type subunit 4","metadata":{"aliases":["GluA4","GLURD","GluR-4","GluR-D","GLUR4C","GLUR4"]}},{"id":"89986fd38dc24489a3b03518800eddc0","type":"GENE","name":"GRID1","canonical_id":"hgnc:HGNC:4575","description":"glutamate ionotropic receptor delta type subunit 1","metadata":{"aliases":["GluD1","KIAA1220"]}},{"id":"fc47077335ab46b385118550137e34d2","type":"GENE","name":"GRID1-AS1","canonical_id":"hgnc:HGNC:44131","description":"GRID1 antisense RNA 1","metadata":null},{"id":"87714f762ed949dfb6c3349bd9dd7ece","type":"GENE","name":"GRID1-AS2","canonical_id":"hgnc:HGNC:58334","description":"GRID1 antisense RNA 2","metadata":null},{"id":"a042012276704619b33a5da47e47e7e4","type":"GENE","name":"GRID2","canonical_id":"hgnc:HGNC:4576","description":"glutamate ionotropic receptor delta type subunit 2","metadata":{"aliases":["GluD2","GluR-delta-2"]}},{"id":"e944515de52d46fc96be5cdd6ca27ecf","type":"GENE","name":"GRID2-AS1","canonical_id":"hgnc:HGNC:58854","description":"GRID2 antisense RNA 1","metadata":null},{"id":"e411f1790a29460782cfaf0685c44ef5","type":"GENE","name":"GRID2IP","canonical_id":"hgnc:HGNC:18464","description":"Grid2 interacting protein","metadata":null},{"id":"4bed7f4517bc44608c371f3d58b4082b","type":"GENE","name":"GRIFIN","canonical_id":"hgnc:HGNC:4577","description":"galectin-related inter-fiber protein","metadata":null},{"id":"4b1ee0a0a5e64752bf69c8f49fe8302b","type":"GENE","name":"GRIK1","canonical_id":"hgnc:HGNC:4579","description":"glutamate ionotropic receptor kainate type subunit 1","metadata":{"aliases":["GluK1","GLUR5"]}},{"id":"dbbc13d54179490680f98c0f02ae81f7","type":"GENE","name":"GRIK1-AS1","canonical_id":"hgnc:HGNC:16458","description":"GRIK1 antisense RNA 1","metadata":{"aliases":["C21orf9","NCRNA00110","GRIK1AS","GRIK1-AS"]}},{"id":"f7fa31ff39e14e1a8264b67dd3609a5f","type":"GENE","name":"GRIK1-AS2","canonical_id":"hgnc:HGNC:1282","description":"GRIK1 antisense RNA 2","metadata":{"aliases":["C21orf41","NCRNA00258"]}},{"id":"d106c6199cf24b34b75163751e19c55e","type":"GENE","name":"GRIK1-AS3","canonical_id":"hgnc:HGNC:58345","description":"GRIK1 antisense RNA 3","metadata":null},{"id":"66bb8114106c482b85eeb93b296811f2","type":"GENE","name":"GRIK2","canonical_id":"hgnc:HGNC:4580","description":"glutamate ionotropic receptor kainate type subunit 2","metadata":{"aliases":["GluK2","MRT6","GluR-6","EAA4","GLUK6","GLUR6"]}},{"id":"32d81f05590b4e9e9f34c73328dc637c","type":"GENE","name":"GRIK3","canonical_id":"hgnc:HGNC:4581","description":"glutamate ionotropic receptor kainate type subunit 3","metadata":{"aliases":["GluK3","GLUR7"]}},{"id":"3c71e7d53f594a3980713b42c709bbf8","type":"GENE","name":"GRIK4","canonical_id":"hgnc:HGNC:4582","description":"glutamate ionotropic receptor kainate type subunit 4","metadata":{"aliases":["GluK4","KA1","GRIK"]}},{"id":"c09380c8761f47c4a31a9e0d1d5069e4","type":"GENE","name":"GRIK5","canonical_id":"hgnc:HGNC:4583","description":"glutamate ionotropic receptor kainate type subunit 5","metadata":{"aliases":["GluK5","KA2","GRIK2"]}},{"id":"d0c8a6f3a58b4f5cb083e4b527c89944","type":"GENE","name":"GRIN1","canonical_id":"hgnc:HGNC:4584","description":null,"metadata":null},{"id":"a217fb14e8fa495aad98c2d812a15aac","type":"GENE","name":"GRIN2A","canonical_id":"hgnc:HGNC:4585","description":"glutamate ionotropic receptor NMDA type subunit 2A","metadata":{"aliases":["GluN2A","NR2A","NMDAR2A"]}},{"id":"b959d6f123d64e36803e1eb15dfe8c16","type":"GENE","name":"GRIN2B","canonical_id":"hgnc:HGNC:4586","description":null,"metadata":null},{"id":"15e365abb208459f866717a56f330fd4","type":"GENE","name":"GRIN2C","canonical_id":"hgnc:HGNC:4587","description":"glutamate ionotropic receptor NMDA type subunit 2C","metadata":{"aliases":["GluN2C","NR2C","NMDAR2C"]}},{"id":"7423d784555a42b8a504d093fedf586b","type":"GENE","name":"GRIN2D","canonical_id":"hgnc:HGNC:4588","description":"glutamate ionotropic receptor NMDA type subunit 2D","metadata":{"aliases":["GluN2D","EB11","NR2D","NMDAR2D"]}},{"id":"a10a3e70623b462191f920cf596451a4","type":"GENE","name":"GRIN3A","canonical_id":"hgnc:HGNC:16767","description":"glutamate ionotropic receptor NMDA type subunit 3A","metadata":{"aliases":["GluN3A"]}},{"id":"2fe1ef5387c640d09299056e02ebc657","type":"GENE","name":"GRIN3B","canonical_id":"hgnc:HGNC:16768","description":"glutamate ionotropic receptor NMDA type subunit 3B","metadata":{"aliases":["GluN3B"]}},{"id":"84fe996870eb4b7da1fdf6f813664546","type":"GENE","name":"GRINA","canonical_id":"hgnc:HGNC:4589","description":"glutamate ionotropic receptor NMDA type subunit associated protein 1","metadata":{"aliases":["HNRGW","TMBIM3","LFG1","NMDARA1"]}},{"id":"472ed3b41b1445b7bbce9cfc9439c693","type":"GENE","name":"GRIP1","canonical_id":"hgnc:HGNC:18708","description":null,"metadata":null},{"id":"0b6f39f9754e415da099663c8ff50cd6","type":"GENE","name":"GRIP2","canonical_id":"hgnc:HGNC:23841","description":"glutamate receptor interacting protein 2","metadata":{"aliases":["KIAA1719"]}},{"id":"efd1c67ee8d9431e85a73772817b9934","type":"GENE","name":"GRIPAP1","canonical_id":"hgnc:HGNC:18706","description":"GRIP1 associated protein 1","metadata":{"aliases":["GRASP-1","GRASP1","KIAA1167","MPMGp800B12492Q3","DKFZp434P0630"]}},{"id":"9acf282175064c218a97b88a7eed9a10","type":"GENE","name":"GRK1","canonical_id":"hgnc:HGNC:10013","description":"G protein-coupled receptor kinase 1","metadata":{"aliases":["GPRK1","RK","RHOK"]}},{"id":"e0a22ca6b7664b8c9c8bc9c0b981a954","type":"GENE","name":"GRK2","canonical_id":"hgnc:HGNC:289","description":null,"metadata":null},{"id":"c533217b5ce444088f0dcb87cb5637b5","type":"GENE","name":"GRK3","canonical_id":"hgnc:HGNC:290","description":"G protein-coupled receptor kinase 3","metadata":{"aliases":["BARK2","ADRBK2"]}},{"id":"c5ef010d63b34ff08e5d8fc99216aaba","type":"GENE","name":"GRK3-AS1","canonical_id":"hgnc:HGNC:55679","description":"GRK3 antisense RNA 1","metadata":null},{"id":"994689a26d004200b2dff74d51540b6b","type":"GENE","name":"GRK4","canonical_id":"hgnc:HGNC:4543","description":"G protein-coupled receptor kinase 4","metadata":{"aliases":["GPRK4","GPRK2L"]}},{"id":"676cd665c09146aa811ce1e7ab8d98d9","type":"GENE","name":"GRK4-AS1","canonical_id":"hgnc:HGNC:58716","description":"GRK4 antisense RNA 1","metadata":null},{"id":"ed91560500644934afc1ff16af6961a6","type":"GENE","name":"GRK5","canonical_id":"hgnc:HGNC:4544","description":"G protein-coupled receptor kinase 5","metadata":{"aliases":["GPRK5"]}},{"id":"d67ffd11154e4dc9a790db0f7c3a01b6","type":"GENE","name":"GRK5-AS1","canonical_id":"hgnc:HGNC:58234","description":"GRK5 antisense RNA 1","metadata":null},{"id":"e4830c1a323a41f8be14daaa39dfb980","type":"GENE","name":"GRK5-IT1","canonical_id":"hgnc:HGNC:49478","description":"GRK5 intronic transcript 1","metadata":null},{"id":"695046316832498a8c63cac3d763e21f","type":"GENE","name":"GRK6","canonical_id":"hgnc:HGNC:4545","description":"G protein-coupled receptor kinase 6","metadata":{"aliases":["GPRK6"]}},{"id":"aeeb29c12de84e9589986b44fa46c257","type":"GENE","name":"GRK6P1","canonical_id":"hgnc:HGNC:4547","description":"G protein-coupled receptor kinase 6 pseudogene 1","metadata":{"aliases":["GPRK6L","GPRK6P","GRK6PS"]}},{"id":"e14e6a8fb017434393a082ec09149544","type":"GENE","name":"GRK7","canonical_id":"hgnc:HGNC:17031","description":"G protein-coupled receptor kinase 7","metadata":{"aliases":["GPRK7"]}},{"id":"fb25b80ec6b94a23858ae0d6a2813b06","type":"GENE","name":"GRM1","canonical_id":"hgnc:HGNC:4593","description":"glutamate metabotropic receptor 1","metadata":{"aliases":["GPRC1A","mGlu1","MGLUR1","PPP1R85"]}},{"id":"1a13f43f415840928b1a3581c587ca0f","type":"GENE","name":"GRM2","canonical_id":"hgnc:HGNC:4594","description":null,"metadata":null},{"id":"6839a5c3b1e94cb4918b47be4fe7a084","type":"GENE","name":"GRM3","canonical_id":"hgnc:HGNC:4595","description":"glutamate metabotropic receptor 3","metadata":{"aliases":["GPRC1C","mGlu3","MGLUR3"]}},{"id":"d1d7268c0fec48cabea92ae396d1d826","type":"GENE","name":"GRM3-AS1","canonical_id":"hgnc:HGNC:40264","description":"GRM3 antisense RNA 1","metadata":null},{"id":"95245b02f8704c0a9c6e14df10797df0","type":"GENE","name":"GRM4","canonical_id":"hgnc:HGNC:4596","description":"glutamate metabotropic receptor 4","metadata":{"aliases":["GPRC1D","mGlu4","MGLUR4"]}},{"id":"09be96bfc9c940959fdc7da15a983499","type":"GENE","name":"GRM5","canonical_id":"hgnc:HGNC:4597","description":"glutamate metabotropic receptor 5","metadata":{"aliases":["MGLUR5","GPRC1E","mGlu5","PPP1R86"]}},{"id":"7eedd8f99ced40ec8aa9c3614cb48610","type":"GENE","name":"GRM5-AS1","canonical_id":"hgnc:HGNC:40265","description":"GRM5 antisense RNA 1","metadata":null},{"id":"89a8c60808064dfd9567a4d9e50fe2e9","type":"GENE","name":"GRM5P1","canonical_id":"hgnc:HGNC:55419","description":"GRM5 pseudogene 1","metadata":null},{"id":"c8f23fb14fef48429001f80cb79ada16","type":"GENE","name":"GRM6","canonical_id":"hgnc:HGNC:4598","description":"glutamate metabotropic receptor 6","metadata":{"aliases":["GPRC1F","mGlu6","MGLUR6","CSNB1B"]}},{"id":"4a9e48e4863a4e40b572d09e0cacb41a","type":"GENE","name":"GRM7","canonical_id":"hgnc:HGNC:4599","description":"glutamate metabotropic receptor 7","metadata":{"aliases":["GLUR7","GPRC1G","mGlu7","MGLUR7","PPP1R87"]}},{"id":"fd73dbfb2d0d4d78a790acf2e4176839","type":"GENE","name":"GRM7-AS1","canonical_id":"hgnc:HGNC:40267","description":"GRM7 antisense RNA 1","metadata":null},{"id":"b47a0993275a47bf86524a4cf89b8723","type":"GENE","name":"GRM7-AS2","canonical_id":"hgnc:HGNC:40266","description":"GRM7 antisense RNA 2","metadata":null},{"id":"970caf6ca1f8412a90924313d2cdd4a5","type":"GENE","name":"GRM7-AS3","canonical_id":"hgnc:HGNC:42444","description":"GRM7 antisense RNA 3","metadata":null},{"id":"c45033aecea04067855dfc9f75ac9a18","type":"GENE","name":"GRM8","canonical_id":"hgnc:HGNC:4600","description":"glutamate metabotropic receptor 8","metadata":{"aliases":["GLUR8","GPRC1H","mGlu8","MGLUR8"]}},{"id":"9b30f2e7799b4227a58670005537b059","type":"GENE","name":"GRM8-AS1","canonical_id":"hgnc:HGNC:40268","description":"GRM8 antisense RNA 1","metadata":null},{"id":"69ffaf6632e342e4b71637aac1417ff4","type":"GENE","name":"GRN","canonical_id":"hgnc:HGNC:4601","description":"granulin precursor","metadata":{"aliases":["PCDGF","PGRN","CLN11"]}},{"id":"4e571f444fcd4f6cb4d458563bd9c707","type":"GENE","name":"GRP","canonical_id":"hgnc:HGNC:4605","description":"gastrin releasing peptide","metadata":null},{"id":"32165d6c02ed447d8acb9cd90583bf1c","type":"GENE","name":"GRPEL1","canonical_id":"hgnc:HGNC:19696","description":"GrpE like 1, mitochondrial","metadata":{"aliases":["FLJ25609","GrpE","hMGE"]}},{"id":"3c8c86712d264652a6abb053ba2e976c","type":"GENE","name":"GRPEL1P1","canonical_id":"hgnc:HGNC:58584","description":"GRPEL1 pseudogene 1","metadata":null},{"id":"31bab89f733141d9b8fea8b37c7bed43","type":"GENE","name":"GRPEL1P2","canonical_id":"hgnc:HGNC:58585","description":"GRPEL1 pseudogene 2","metadata":null},{"id":"76893445ab234661a5a147242b59cf35","type":"GENE","name":"GRPEL1P3","canonical_id":"hgnc:HGNC:58586","description":"GRPEL1 pseudogene 3","metadata":null},{"id":"8babdb92929e42b59be47a2da2564f5f","type":"GENE","name":"GRPEL2","canonical_id":"hgnc:HGNC:21060","description":"GrpE like 2, mitochondrial","metadata":{"aliases":["DKFZp451C205","Mt-GrpE#2","FLJ23713"]}},{"id":"98e1877f0b2d489a884c8e983ae92d6b","type":"GENE","name":"GRPEL2-AS1","canonical_id":"hgnc:HGNC:48999","description":"GRPEL2 antisense RNA 1","metadata":{"aliases":["RP11-394O4.4"]}},{"id":"3fd2e0506f7f4c58808e51b62e896a73","type":"GENE","name":"GRPEL2P1","canonical_id":"hgnc:HGNC:41969","description":"GRPEL2 pseudogene 1","metadata":null},{"id":"cfc29d3496ab4ab08c90a03af3ceb4b1","type":"GENE","name":"GRPEL2P2","canonical_id":"hgnc:HGNC:41970","description":"GRPEL2 pseudogene 2","metadata":null},{"id":"d3db2fabb4004994a029118714fedb62","type":"GENE","name":"GRPEL2P3","canonical_id":"hgnc:HGNC:41971","description":"GRPEL2 pseudogene 3","metadata":null},{"id":"e27e2cfc03984031bf818347b43be624","type":"GENE","name":"GRPR","canonical_id":"hgnc:HGNC:4609","description":null,"metadata":null},{"id":"b6c7e00a1a874c94b30f43396ee0747c","type":"GENE","name":"GRSF1","canonical_id":"hgnc:HGNC:4610","description":"G-rich RNA sequence binding factor 1","metadata":null},{"id":"67aa15a6850c498e923d04a04dd5b784","type":"GENE","name":"GRSF1-AS1","canonical_id":"hgnc:HGNC:58807","description":"GRSF1 antisense RNA 1","metadata":null},{"id":"5b2a5d5f4e274e2687de5de274bd7bba","type":"GENE","name":"GRTP1","canonical_id":"hgnc:HGNC:20310","description":"growth hormone regulated TBC protein 1","metadata":{"aliases":["FLJ22474","TBC1D6"]}},{"id":"bd1ba7b121d44dca82dd40a5c9d97689","type":"GENE","name":"GRTP1-AS1","canonical_id":"hgnc:HGNC:39917","description":"GRTP1 antisense RNA 1","metadata":null},{"id":"ba5c772a34914ebfa76a8baa7b9e1919","type":"GENE","name":"GRWD1","canonical_id":"hgnc:HGNC:21270","description":"glutamate rich WD repeat containing 1","metadata":{"aliases":["WDR28","GRWD","RRB1"]}},{"id":"64bc3d1ccfab452f9eb7099fc3e647b7","type":"GENE","name":"GRXCR1","canonical_id":"hgnc:HGNC:31673","description":"glutaredoxin and cysteine rich domain containing 1","metadata":{"aliases":["PPP1R88","DFNB25"]}},{"id":"4ad8bb2c95fd4023997fd36427e73dc8","type":"GENE","name":"GRXCR2","canonical_id":"hgnc:HGNC:33862","description":"glutaredoxin and cysteine rich domain containing 2","metadata":{"aliases":["DFNB101"]}},{"id":"3f1ff49d8cc746f9a7069ad05d0124c6","type":"TRIAL","name":"GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","canonical_id":"clinicaltrials.gov:NCT01356160","description":"Hepatitis C, Chronic","metadata":null},{"id":"4446d54dc47d40928ba07500d3ae439a","type":"GENE","name":"GSAP","canonical_id":"hgnc:HGNC:28042","description":"gamma-secretase activating protein","metadata":{"aliases":["LOC54103","PION"]}},{"id":"ae1740365fa4410eb2adacfc8a49ac71","type":"GENE","name":"GSC","canonical_id":"hgnc:HGNC:4612","description":null,"metadata":null},{"id":"de420251d6d742cf97616b91b24a306a","type":"GENE","name":"GSC-DT","canonical_id":"hgnc:HGNC:53074","description":"GSC divergent transcript","metadata":{"aliases":["DIGIT"]}},{"id":"864145ccc7534111a955763e2a5c0884","type":"GENE","name":"GSC2","canonical_id":"hgnc:HGNC:4613","description":null,"metadata":null},{"id":"ba6832c429d44fe18167b6dc839c846a","type":"GENE","name":"GSCAR","canonical_id":"hgnc:HGNC:56879","description":"glioma stem cell associated long noncoding RNA","metadata":null},{"id":"1d0f678fcd734fae9508fc9064e4bd51","type":"GENE","name":"GSDMA","canonical_id":"hgnc:HGNC:13311","description":"gasdermin A","metadata":{"aliases":["FLJ39120","GSDM","GSDM1"]}},{"id":"66680cbee44c4a3a83fd9bb526461b9c","type":"GENE","name":"GSDMB","canonical_id":"hgnc:HGNC:23690","description":"gasdermin B","metadata":{"aliases":["PRO2521","GSDML"]}},{"id":"f1b2876c8e4d44129a1eee9e509438ed","type":"GENE","name":"GSDMC","canonical_id":"hgnc:HGNC:7151","description":"gasdermin C","metadata":{"aliases":["MLZE"]}},{"id":"85c21fd0fd3a43b3a4f491c1e4aba543","type":"GENE","name":"GSDMD","canonical_id":"hgnc:HGNC:25697","description":"gasdermin D","metadata":{"aliases":["FLJ12150","DF5L","GSDMDC1"]}},{"id":"2399930fa5ca410cb8bd7a6b20e53c6d","type":"GENE","name":"GSDME","canonical_id":"hgnc:HGNC:2810","description":"gasdermin E","metadata":{"aliases":["ICERE-1","DFNA5"]}},{"id":"65fbe2a1709a4dd5935571549b103860","type":"GENE","name":"GSE1","canonical_id":"hgnc:HGNC:28979","description":"Gse1 coiled-coil protein","metadata":{"aliases":["KIAA0182"]}},{"id":"232bac2817314a5bb537ceb3d8f3a1b3","type":"GENE","name":"GSE1-AS1","canonical_id":"hgnc:HGNC:58141","description":"GSE1 antisense RNA 1","metadata":null},{"id":"0fa99853231749d584abdba84e7bd165","type":"GENE","name":"GSEC","canonical_id":"hgnc:HGNC:48645","description":"G-quadruplex forming sequence containing lncRNA","metadata":{"aliases":["GESP","DCPS-AS1","FLJ39051","ST3GAL4-AS1"]}},{"id":"1380e5142f354532804dc29b77429816","type":"GENE","name":"GSG1","canonical_id":"hgnc:HGNC:19716","description":"germ cell associated 1","metadata":{"aliases":["MGC3146"]}},{"id":"9594bc293dd94bcaa059865b6ebb7ae4","type":"GENE","name":"GSG1L","canonical_id":"hgnc:HGNC:28283","description":"GSG1 like","metadata":{"aliases":["MGC18079","PRO19651","KTSR5831"]}},{"id":"ae302973efe74ac3a56cd9ec8302f648","type":"GENE","name":"GSG1L2","canonical_id":"hgnc:HGNC:51826","description":"GSG1 like 2","metadata":null},{"id":"6677ee0f6eac4ecebd69077ca54404af","type":"TRIAL","name":"GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia","canonical_id":"clinicaltrials.gov:NCT01345253","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"841f748f26d2408fa556416f5c0904b5","type":"TRIAL","name":"GSK2251052 in Complicated Urinary Tract Infection","canonical_id":"clinicaltrials.gov:NCT01381549","description":"Infections, Urinary Tract","metadata":null},{"id":"117004115a7c4a1f8cc3e172e80c4420","type":"GENE","name":"GSK3A","canonical_id":"hgnc:HGNC:4616","description":null,"metadata":null},{"id":"9d036294ccfe4861bb26f500b2e3780a","type":"GENE","name":"GSK3B","canonical_id":"hgnc:HGNC:4617","description":null,"metadata":null},{"id":"14015f6644174b4790a43d06b06d7432","type":"GENE","name":"GSK3B-DT","canonical_id":"hgnc:HGNC:55635","description":"GSK3B divergent transcript","metadata":{"aliases":["GPNCA"]}},{"id":"c4fe1e241d6b45adaff8060ac984020f","type":"GENE","name":"GSKIP","canonical_id":"hgnc:HGNC:20343","description":"GSK3B interacting protein","metadata":{"aliases":["C14orf129"]}},{"id":"b1698bf0dacc4f8a9bc0815f8b551cb4","type":"GENE","name":"GSN","canonical_id":"hgnc:HGNC:4620","description":"gelsolin","metadata":{"aliases":["DKFZp313L0718"]}},{"id":"6b1b1e79fa854a7691dfbe08b825b5c2","type":"GENE","name":"GSN-AS1","canonical_id":"hgnc:HGNC:23372","description":"GSN antisense RNA 1","metadata":{"aliases":["MOST2","C9orf31"]}},{"id":"a8491ce9b3694131931ff4ef97839015","type":"GENE","name":"GSPT1","canonical_id":"hgnc:HGNC:4621","description":null,"metadata":null},{"id":"128d5aed038840dca86aa75732223f43","type":"GENE","name":"GSPT2","canonical_id":"hgnc:HGNC:4622","description":"G1 to S phase transition 2","metadata":{"aliases":["eRF3b","FLJ10441"]}},{"id":"6e32f36a6d3d4018950497145560fd87","type":"GENE","name":"GSR","canonical_id":"hgnc:HGNC:4623","description":"glutathione-disulfide reductase","metadata":{"aliases":["GRase"]}},{"id":"29f4325a075a4a8d80207a33a2e1cec7","type":"PROTEIN","name":"GSR","canonical_id":"uniprot:P00390","description":null,"metadata":null},{"id":"bb15f860648546e1b1e9c88e1503e8a1","type":"GENE","name":"GSS","canonical_id":"hgnc:HGNC:4624","description":null,"metadata":null},{"id":"d9136851e86a4b16a5f063b138a23a40","type":"GENE","name":"GSTA1","canonical_id":"hgnc:HGNC:4626","description":null,"metadata":null},{"id":"f02505ef2c1a4b47aa65b246e0ab4e16","type":"GENE","name":"GSTA10P","canonical_id":"hgnc:HGNC:49904","description":"glutathione S-transferase alpha 10, pseudogene","metadata":{"aliases":["GSTAP2"]}},{"id":"a17fa8f23dad42089ab05bb267631fea","type":"GENE","name":"GSTA11P","canonical_id":"hgnc:HGNC:49905","description":"glutathione S-transferase alpha 11, pseudogene","metadata":{"aliases":["GSTAP3"]}},{"id":"f2c83841e81346f18a5366ada6f2704f","type":"GENE","name":"GSTA12P","canonical_id":"hgnc:HGNC:49906","description":"glutathione S-transferase alpha 12, pseudogene","metadata":{"aliases":["GSTAP5"]}},{"id":"4de8ac8cc7d243538d1e3e99e52b7238","type":"GENE","name":"GSTA2","canonical_id":"hgnc:HGNC:4627","description":"glutathione S-transferase alpha 2","metadata":{"aliases":["GST2"]}},{"id":"56d1b76195414fda834a8e4932804288","type":"GENE","name":"GSTA3","canonical_id":"hgnc:HGNC:4628","description":"glutathione S-transferase alpha 3","metadata":null},{"id":"bd61e1e96ae54e6a857e8447968fbcdb","type":"GENE","name":"GSTA4","canonical_id":"hgnc:HGNC:4629","description":"glutathione S-transferase alpha 4","metadata":null},{"id":"d13cf251e2dc4d66aba9cd36b1c3c209","type":"GENE","name":"GSTA5","canonical_id":"hgnc:HGNC:19662","description":"glutathione S-transferase alpha 5","metadata":null},{"id":"5b7abf34707b4189bd392dfd5d3a7098","type":"GENE","name":"GSTA6P","canonical_id":"hgnc:HGNC:4630","description":"glutathione S-transferase alpha 6, pseudogene","metadata":{"aliases":["GSTAP1"]}},{"id":"2ac474c1af8f45e1b62e109150dd70b3","type":"GENE","name":"GSTA7P","canonical_id":"hgnc:HGNC:4631","description":"glutathione S-transferase alpha 7, pseudogene","metadata":{"aliases":["GSTAP6","GSTAP2"]}},{"id":"13c2f1bb6b4f4b63aaa5b27201892e47","type":"GENE","name":"GSTA8P","canonical_id":"hgnc:HGNC:49903","description":"glutathione S-transferase alpha 8, pseudogene","metadata":{"aliases":["GSTAP7"]}},{"id":"54ec6b6b56974252af01533030832d64","type":"GENE","name":"GSTA9P","canonical_id":"hgnc:HGNC:49902","description":"glutathione S-transferase alpha 9, pseudogene","metadata":{"aliases":["GSTAP4","GSTA4P"]}},{"id":"66f1056c6c9743f49335ed3d99fcfd00","type":"GENE","name":"GSTCD","canonical_id":"hgnc:HGNC:25806","description":"glutathione S-transferase C-terminal domain containing","metadata":{"aliases":["FLJ13273"]}},{"id":"b0cbf4d4982848bf8ff477c7d4d1e668","type":"GENE","name":"GSTCD-AS1","canonical_id":"hgnc:HGNC:41117","description":"GSTCD antisense RNA 1","metadata":null},{"id":"18afb129ccb74ea3862ccd9164b6e209","type":"GENE","name":"GSTK1","canonical_id":"hgnc:HGNC:16906","description":"glutathione S-transferase kappa 1","metadata":{"aliases":["GST13"]}},{"id":"7b23f0758d9f4cf7b30ed54e19465448","type":"GENE","name":"GSTM1","canonical_id":"hgnc:HGNC:4632","description":null,"metadata":null},{"id":"78fa96d0bda44010b356a21852d34601","type":"GENE","name":"GSTM2","canonical_id":"hgnc:HGNC:4634","description":"glutathione S-transferase mu 2","metadata":{"aliases":["GST4"]}},{"id":"55ed83ee51bc48a49a7cface45307937","type":"GENE","name":"GSTM2P1","canonical_id":"hgnc:HGNC:38009","description":"glutathione S-transferase mu 2 pseudogene 1","metadata":null},{"id":"10f99f3a1b5945a7aa72aef7988083b9","type":"GENE","name":"GSTM3","canonical_id":"hgnc:HGNC:4635","description":"glutathione S-transferase mu 3","metadata":{"aliases":["GST5","GSTM3TV2"]}},{"id":"4c394788967d4c48978bb3cd078e5f4a","type":"GENE","name":"GSTM3P1","canonical_id":"hgnc:HGNC:16606","description":"glutathione S-transferase mu 3 pseudogene 1","metadata":{"aliases":["dJ984P4.2","GSTM3P"]}},{"id":"6cd30f9a31054866902179b4d90a7bb0","type":"GENE","name":"GSTM3P2","canonical_id":"hgnc:HGNC:38006","description":"glutathione S-transferase mu 3 pseudogene 2","metadata":null},{"id":"2a14cbced3744feb8e0dfed29549cb4b","type":"GENE","name":"GSTM4","canonical_id":"hgnc:HGNC:4636","description":"glutathione S-transferase mu 4","metadata":null},{"id":"7fa3f8b471e74e7dad53521fab9752af","type":"GENE","name":"GSTM5","canonical_id":"hgnc:HGNC:4637","description":"glutathione S-transferase mu 5","metadata":null},{"id":"cd7c01d1903149868513d4218fce7d1e","type":"GENE","name":"GSTM5P1","canonical_id":"hgnc:HGNC:4633","description":"glutathione S-transferase mu 5 pseudogene 1","metadata":{"aliases":["GST1L","GSTM1L"]}},{"id":"2d60d35168ec46098d9650fc4bf30a6c","type":"GENE","name":"GSTO1","canonical_id":"hgnc:HGNC:13312","description":"glutathione S-transferase omega 1","metadata":{"aliases":["GSTTLp28","P28"]}},{"id":"6c4227962a1243be9040bf996bcebef7","type":"GENE","name":"GSTO2","canonical_id":"hgnc:HGNC:23064","description":"glutathione S-transferase omega 2","metadata":null},{"id":"d0bad72158064bf99f8469b14263488e","type":"GENE","name":"GSTO3P","canonical_id":"hgnc:HGNC:23065","description":"glutathione S-transferase omega 3, pseudogene","metadata":{"aliases":["GSTO3P1"]}},{"id":"a17c3b9ff61b403e8dc714eac2cfce32","type":"GENE","name":"GSTP1","canonical_id":"hgnc:HGNC:4638","description":null,"metadata":null},{"id":"e2a3aa9fc06c4ffda4a0de5ce301ec06","type":"GENE","name":"GSTP1P1","canonical_id":"hgnc:HGNC:4640","description":"glutathione S-transferase pi 1 pseudogene 1","metadata":{"aliases":["GSTP1P","Lnc712","GST3L","GSTPL","GSTPP"]}},{"id":"462dd1a67306481c877597e62193f4a0","type":"GENE","name":"GSTT1","canonical_id":"hgnc:HGNC:4641","description":"glutathione S-transferase theta 1","metadata":null},{"id":"5478ff7510ce4508931e86a144775715","type":"GENE","name":"GSTT1-AS1","canonical_id":"hgnc:HGNC:51839","description":"GSTT1 antisense RNA 1","metadata":{"aliases":["lncRNA-AS-GSTT1(1-72)","lncRNA-CD244","lncRNA-BC050410"]}},{"id":"8e1e626f18d94b778627a2381983810d","type":"GENE","name":"GSTT2","canonical_id":"hgnc:HGNC:4642","description":"glutathione S-transferase theta 2 (gene/pseudogene)","metadata":null},{"id":"229b742a58a143ac9efc46327a5d8ee7","type":"GENE","name":"GSTT2B","canonical_id":"hgnc:HGNC:33437","description":"glutathione S-transferase theta 2B","metadata":{"aliases":["GSTT2P"]}},{"id":"c25c5f0c913747ab9c7fe14f8bdb9525","type":"GENE","name":"GSTT3P","canonical_id":"hgnc:HGNC:55078","description":"glutathione S-transferase theta 3, pseudogene","metadata":null},{"id":"dd079411aad04ddf8776238439508a36","type":"GENE","name":"GSTT4","canonical_id":"hgnc:HGNC:26930","description":"glutathione S-transferase theta 4","metadata":{"aliases":["HS322B1A","GSTTP1"]}},{"id":"547f69dfab1f4c9aa043bc9204dc4c06","type":"GENE","name":"GSTTP2","canonical_id":"hgnc:HGNC:33606","description":"glutathione S-transferase theta pseudogene 2","metadata":null},{"id":"90ddbb88044d428dabf79feb9d6026bd","type":"GENE","name":"GSTZ1","canonical_id":"hgnc:HGNC:4643","description":"glutathione S-transferase zeta 1","metadata":{"aliases":["GSTZ1-1","MAAI","MAI"]}},{"id":"6219266b8076482da029a90c9d9eebc5","type":"GENE","name":"GSX1","canonical_id":"hgnc:HGNC:20374","description":"GS homeobox 1","metadata":{"aliases":["Gsh-1","GSH1"]}},{"id":"4b7d6547f43b476999b30304863f903a","type":"GENE","name":"GSX2","canonical_id":"hgnc:HGNC:24959","description":"GS homeobox 2","metadata":{"aliases":["Gsh2"]}},{"id":"af160bf88bae49628a586856422d867e","type":"GENE","name":"GTF2A1","canonical_id":"hgnc:HGNC:4646","description":null,"metadata":null},{"id":"a179a2ad643b485a94faf8394a0695b1","type":"GENE","name":"GTF2A1-AS1","canonical_id":"hgnc:HGNC:56195","description":"GTF2A1 antisense RNA 1","metadata":null},{"id":"451118ac5c5e419e9cd8e35b00739eac","type":"GENE","name":"GTF2A1L","canonical_id":"hgnc:HGNC:30727","description":"general transcription factor IIA subunit 1 like","metadata":{"aliases":["ALF"]}},{"id":"81d7d42227aa4d4ab33a639faaf405ee","type":"GENE","name":"GTF2A2","canonical_id":"hgnc:HGNC:4647","description":"general transcription factor IIA subunit 2","metadata":{"aliases":["TFIIA","HsT18745"]}},{"id":"2a4ec15b3c5c45ae8525d7ecaedafac7","type":"GENE","name":"GTF2A2P1","canonical_id":"hgnc:HGNC:58501","description":"GTF2A2 pseudogene 1","metadata":null},{"id":"92450aa8c8ea47d88c3bc5e0fcb0c33a","type":"GENE","name":"GTF2B","canonical_id":"hgnc:HGNC:4648","description":null,"metadata":null},{"id":"b58e023c39134e0c8d5dcf41eefbfa18","type":"GENE","name":"GTF2E1","canonical_id":"hgnc:HGNC:4650","description":"general transcription factor IIE subunit 1","metadata":{"aliases":["TFIIE-A","FE"]}},{"id":"92dff95a886546e0b507ff4d450b4228","type":"GENE","name":"GTF2E2","canonical_id":"hgnc:HGNC:4651","description":"general transcription factor IIE subunit 2","metadata":{"aliases":["TFIIE-B","FE","TF2E2"]}},{"id":"a2bcbc80a6554f1491557cc26923d786","type":"GENE","name":"GTF2F1","canonical_id":"hgnc:HGNC:4652","description":null,"metadata":null},{"id":"9a69dc78524c4aa69862fa0d3ecb2e20","type":"GENE","name":"GTF2F2","canonical_id":"hgnc:HGNC:4653","description":"general transcription factor IIF subunit 2","metadata":{"aliases":["TFIIF","BTF4","RAP30"]}},{"id":"71488264e27c4694a0088ac645ca2f88","type":"GENE","name":"GTF2F2P1","canonical_id":"hgnc:HGNC:4654","description":"general transcription factor IIF subunit 2 pseudogene 1","metadata":{"aliases":["TFIIF","GTF2F2L"]}},{"id":"225c868264d749b7b23a42aadc13cc15","type":"GENE","name":"GTF2F2P2","canonical_id":"hgnc:HGNC:39092","description":"general transcription factor IIF subunit 2 pseudogene 2","metadata":null},{"id":"4534154da2aa42f1bb1f8291fddaffcb","type":"GENE","name":"GTF2H1","canonical_id":"hgnc:HGNC:4655","description":"general transcription factor IIH subunit 1","metadata":{"aliases":["BTF2","P62","TFIIH"]}},{"id":"12c79238f9c24f0f91d69e7177b1679a","type":"GENE","name":"GTF2H2","canonical_id":"hgnc:HGNC:4656","description":"general transcription factor IIH subunit 2","metadata":{"aliases":["BTF2","TFIIH","BTF2P44","T-BTF2P44","p44"]}},{"id":"d69f403102c6423e9e4b68beb4840d84","type":"GENE","name":"GTF2H2B","canonical_id":"hgnc:HGNC:31393","description":"general transcription factor IIH subunit 2B (pseudogene)","metadata":{"aliases":["DKFZP686M0199"]}},{"id":"e899fa7e04484ead95a3aee26c914a5d","type":"GENE","name":"GTF2H2C","canonical_id":"hgnc:HGNC:31394","description":"GTF2H2 family member C","metadata":null},{"id":"bb8e2d1a66f1489aa735736e12b3a7ea","type":"GENE","name":"GTF2H2C_2","canonical_id":"hgnc:HGNC:35418","description":"GTF2H2 family member C, copy 2","metadata":{"aliases":["LOC730394","GTF2H2D"]}},{"id":"4e61c10abb63414e9df3c12554fccc6d","type":"GENE","name":"GTF2H3","canonical_id":"hgnc:HGNC:4657","description":"general transcription factor IIH subunit 3","metadata":{"aliases":["BTF2","TFIIH","P34"]}},{"id":"20b7814aadf9405bb2d844887c0737df","type":"GENE","name":"GTF2H4","canonical_id":"hgnc:HGNC:4658","description":"general transcription factor IIH subunit 4","metadata":{"aliases":["TFB2","TFIIH","P52"]}},{"id":"4c14c4b23dc54defa3ac9d383a0efa78","type":"GENE","name":"GTF2H5","canonical_id":"hgnc:HGNC:21157","description":"general transcription factor IIH subunit 5","metadata":{"aliases":["FLJ30544","bA120J8.2","TTD-A","TFB5","TFIIH","TTDA","C6orf175","TTD"]}},{"id":"dd95d55681e04ea88010c56e6e218c97","type":"GENE","name":"GTF2I","canonical_id":"hgnc:HGNC:4659","description":null,"metadata":null},{"id":"b118d8731f4b4e2fa41a762a9ddb138c","type":"GENE","name":"GTF2I-AS1","canonical_id":"hgnc:HGNC:55572","description":"GTF2I antisense RNA 1","metadata":null},{"id":"0873d2d9c8fe465285fd285c41b8019a","type":"GENE","name":"GTF2IP1","canonical_id":"hgnc:HGNC:4660","description":"general transcription factor IIi pseudogene 1","metadata":{"aliases":["WBSCR7"]}},{"id":"7f7e4debdab54f2d9669175ee86c8432","type":"GENE","name":"GTF2IP10","canonical_id":"hgnc:HGNC:51722","description":"general transcription factor IIi pseudogene 10","metadata":null},{"id":"3e00afdb08fd45a09d36eaf9fde2d172","type":"GENE","name":"GTF2IP11","canonical_id":"hgnc:HGNC:51724","description":"general transcription factor IIi pseudogene 11","metadata":null},{"id":"42346db08ea746418b9a18b0a2177d9a","type":"GENE","name":"GTF2IP12","canonical_id":"hgnc:HGNC:51723","description":"general transcription factor IIi pseudogene 12","metadata":null},{"id":"941543fcb7e24c969a2dceca763f3f45","type":"GENE","name":"GTF2IP13","canonical_id":"hgnc:HGNC:51725","description":"general transcription factor IIi pseudogene 13","metadata":null},{"id":"8d5e7af16bbe48749adb962f0547c7de","type":"GENE","name":"GTF2IP14","canonical_id":"hgnc:HGNC:51726","description":"general transcription factor IIi pseudogene 14","metadata":null},{"id":"9ec40549cacb40c58be7ba272dfaacb0","type":"GENE","name":"GTF2IP15","canonical_id":"hgnc:HGNC:51727","description":"general transcription factor IIi pseudogene 15","metadata":null},{"id":"91282353cf6149e599911993ebee3949","type":"GENE","name":"GTF2IP16","canonical_id":"hgnc:HGNC:51728","description":"general transcription factor IIi pseudogene 16","metadata":null},{"id":"8eedd381f4c149ac857eae6f5c1f02b1","type":"GENE","name":"GTF2IP17","canonical_id":"hgnc:HGNC:51729","description":"general transcription factor IIi pseudogene 17","metadata":null},{"id":"86ad6289a6e94a3f83fdfaace84ecad0","type":"GENE","name":"GTF2IP19","canonical_id":"hgnc:HGNC:51731","description":"general transcription factor IIi pseudogene 19","metadata":null},{"id":"010eac24e9314fcf8041c2abd73d209a","type":"GENE","name":"GTF2IP2","canonical_id":"hgnc:HGNC:16082","description":"general transcription factor IIi pseudogene 2","metadata":null},{"id":"7a686bea9260402eb3df1495a3af82d8","type":"GENE","name":"GTF2IP20","canonical_id":"hgnc:HGNC:51732","description":"general transcription factor IIi pseudogene 20","metadata":null},{"id":"8dc037fc4fbb4d7e97f78b753d92a595","type":"GENE","name":"GTF2IP21","canonical_id":"hgnc:HGNC:51733","description":"general transcription factor IIi pseudogene 21","metadata":null},{"id":"5741078c37d945bfa392807399955b98","type":"GENE","name":"GTF2IP22","canonical_id":"hgnc:HGNC:51734","description":"general transcription factor IIi pseudogene 22","metadata":null},{"id":"df26c8e03d9b4453a92e8094dce5fdc8","type":"GENE","name":"GTF2IP23","canonical_id":"hgnc:HGNC:51735","description":"general transcription factor IIi pseudogene 23","metadata":null},{"id":"4e68824752954ce78f6b62f18f5268de","type":"GENE","name":"GTF2IP3","canonical_id":"hgnc:HGNC:42640","description":"general transcription factor IIi pseudogene 3","metadata":null},{"id":"d216514defd44851b17fc023c08c08fc","type":"GENE","name":"GTF2IP4","canonical_id":"hgnc:HGNC:51716","description":"general transcription factor IIi pseudogene 4","metadata":null},{"id":"6092c4b136b341a497d1f8652dec7194","type":"GENE","name":"GTF2IP5","canonical_id":"hgnc:HGNC:51717","description":"general transcription factor IIi pseudogene 5","metadata":null},{"id":"1ac04e1d23f84a66b7596aa55cf437c4","type":"GENE","name":"GTF2IP6","canonical_id":"hgnc:HGNC:51718","description":"general transcription factor IIi pseudogene 6","metadata":null},{"id":"033b73cb8eee44eb8709bff5b9427406","type":"GENE","name":"GTF2IP7","canonical_id":"hgnc:HGNC:51720","description":"general transcription factor IIi pseudogene 7","metadata":null},{"id":"c3cd7917b8294c1a994e238d8633b45b","type":"GENE","name":"GTF2IP8","canonical_id":"hgnc:HGNC:51719","description":"general transcription factor IIi pseudogene 8","metadata":null},{"id":"29e6895af9b84bd78577d2169e3351e9","type":"GENE","name":"GTF2IP9","canonical_id":"hgnc:HGNC:51721","description":"general transcription factor IIi pseudogene 9","metadata":null},{"id":"ef6def6fa973446dadaa9251922e7702","type":"GENE","name":"GTF2IRD1","canonical_id":"hgnc:HGNC:4661","description":"GTF2I repeat domain containing 1","metadata":{"aliases":["MusTRD1","RBAP2","GTF3","WBSCR12","BEN","Cream1","WBSCR11"]}},{"id":"2c9f3adbe5bb413ca1d6282b51810b0a","type":"GENE","name":"GTF2IRD1P1","canonical_id":"hgnc:HGNC:44136","description":"GTF2I repeat domain containing 1 pseudogene 1","metadata":null},{"id":"744c98f8a14a431e8a2a96487db4e06f","type":"GENE","name":"GTF2IRD2","canonical_id":"hgnc:HGNC:30775","description":"GTF2I repeat domain containing 2","metadata":{"aliases":["FLJ37938","GTF2IRD2A"]}},{"id":"35ff233d8d4f4773a95efda58ffd4fb6","type":"GENE","name":"GTF2IRD2B","canonical_id":"hgnc:HGNC:33125","description":"GTF2I repeat domain containing 2B","metadata":null},{"id":"80b6a340e17f4681b0368bd3e07d6c17","type":"GENE","name":"GTF2IRD2P1","canonical_id":"hgnc:HGNC:33127","description":"GTF2I repeat domain containing 2 pseudogene 1","metadata":{"aliases":["GTF2IRD2P"]}},{"id":"2b87231b030f44fd8bbe31ab38b53396","type":"GENE","name":"GTF3A","canonical_id":"hgnc:HGNC:4662","description":null,"metadata":null},{"id":"f7640376ea6149b9815334757f61230f","type":"GENE","name":"GTF3AP1","canonical_id":"hgnc:HGNC:49744","description":"general transcription factor IIIA pseudogene 1","metadata":null},{"id":"797d677ef2a4430496060341a451f8e3","type":"GENE","name":"GTF3AP2","canonical_id":"hgnc:HGNC:49745","description":"general transcription factor IIIA pseudogene 2","metadata":null},{"id":"2a63e53ed17a4c3aae4971909a8507a7","type":"GENE","name":"GTF3AP3","canonical_id":"hgnc:HGNC:49746","description":"general transcription factor IIIA pseudogene 3","metadata":null},{"id":"2bdde76d8d9b4b0da189bd430a33d9b5","type":"GENE","name":"GTF3AP4","canonical_id":"hgnc:HGNC:49747","description":"general transcription factor IIIA pseudogene 4","metadata":null},{"id":"537b7367ea5944adb11e5b4d66978c71","type":"GENE","name":"GTF3AP5","canonical_id":"hgnc:HGNC:49748","description":"general transcription factor IIIA pseudogene 5","metadata":null},{"id":"d5cf694a61f24e2a9b1acd3ca664fa29","type":"GENE","name":"GTF3AP6","canonical_id":"hgnc:HGNC:49749","description":"general transcription factor IIIA pseudogene 6","metadata":null},{"id":"4955f873490548ad83866f8d097e1239","type":"GENE","name":"GTF3C1","canonical_id":"hgnc:HGNC:4664","description":null,"metadata":null},{"id":"7c0ead7477354ae5941f683d3b94fe5b","type":"GENE","name":"GTF3C2","canonical_id":"hgnc:HGNC:4665","description":null,"metadata":null},{"id":"96b3ea706b8b449a9c56952e63ac4c0c","type":"GENE","name":"GTF3C2-AS1","canonical_id":"hgnc:HGNC:40269","description":"GTF3C2 antisense RNA 1","metadata":null},{"id":"1855170e74ff41e68124b4a72a47c62e","type":"GENE","name":"GTF3C2-AS2","canonical_id":"hgnc:HGNC:55699","description":"GTF3C2 antisense RNA 2","metadata":{"aliases":["AC074117.10","AC074117.1"]}},{"id":"702167009c6846ec98ff8ae9b0d111a5","type":"GENE","name":"GTF3C3","canonical_id":"hgnc:HGNC:4666","description":"general transcription factor IIIC subunit 3","metadata":{"aliases":["TFiiiC2-102","TFIIIC102"]}},{"id":"98250a430a6243a88ec997067b3f84e6","type":"GENE","name":"GTF3C4","canonical_id":"hgnc:HGNC:4667","description":"general transcription factor IIIC subunit 4","metadata":{"aliases":["TFIIIC90","KAT12"]}},{"id":"ab7c20e402694b4485434dd991d629e0","type":"GENE","name":"GTF3C5","canonical_id":"hgnc:HGNC:4668","description":"general transcription factor IIIC subunit 5","metadata":{"aliases":["TFiiiC2-63","TFIIIC63","TFIIICepsilon"]}},{"id":"7bc9473efbe745f788d9b5adb077c181","type":"GENE","name":"GTF3C6","canonical_id":"hgnc:HGNC:20872","description":"general transcription factor IIIC subunit 6","metadata":{"aliases":["bA397G5.3","TFIIIC35","C6orf51"]}},{"id":"1bb5f9b544ba461ca0fb50ab29ea3a8f","type":"GENE","name":"GTF3C6P1","canonical_id":"hgnc:HGNC:55023","description":"GTF3C6 pseudogene 1","metadata":null},{"id":"2db3abc36a8246fa9dc04571c2d977b3","type":"GENE","name":"GTF3C6P2","canonical_id":"hgnc:HGNC:55024","description":"GTF3C6 pseudogene 2","metadata":null},{"id":"cdf0505a3c6049738c163ec166c8f5c8","type":"GENE","name":"GTF3C6P3","canonical_id":"hgnc:HGNC:55025","description":"GTF3C6 pseudogene 3","metadata":null},{"id":"b10d1e69d7d7471c86f54c63614ef7ba","type":"GO_TERM","name":"GTP 3',8'-cyclase activity","canonical_id":"go:GO:0061798","description":"\"Catalysis of the reaction: GTP=(8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate.\" [GOC:dph, GOC:ik, PMID:25896388]","metadata":null},{"id":"39f712da52734208993250ada098c0bc","type":"GO_TERM","name":"GTP binding","canonical_id":"go:GO:0005525","description":"\"Binding to GTP, guanosine triphosphate.\" [GOC:ai]","metadata":null},{"id":"c15a2a77ac2449058378a0fdf2c6a190","type":"GO_TERM","name":"GTP biosynthetic process","canonical_id":"go:GO:0006183","description":"\"The chemical reactions and pathways resulting in the formation of GTP, guanosine triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"7f8079e1a34d4c52848c9c2eaca41270","type":"GO_TERM","name":"GTP cyclohydrolase I activity","canonical_id":"go:GO:0003934","description":"\"Catalysis of the reaction: GTP + H2O = 7,8-dihydroneopterin 3'-triphosphate + formate + H+.\" [EC:3.5.4.16]","metadata":null},{"id":"d28832273baf45e0a1884fdced7db243","type":"GO_TERM","name":"GTP cyclohydrolase I regulator activity","canonical_id":"go:GO:0060308","description":"\"Binds to and modulates the activity of GTP cyclohydrolase I. GTP cyclohydrolase I activity catalyzes the reaction: GTP + 2 H2O = formate + 2-amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)-dihydropteridine triphosphate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ab049fda69844f07950001392255b49c","type":"GO_TERM","name":"GTP cyclohydrolase II activity","canonical_id":"go:GO:0003935","description":"\"Catalysis of the reaction: GTP + 4 H2O = 2,5-diamino-6-hydroxy-4-(5-phosphoribosylamino)-pyrimidine + formate + 3 H+ + 2 phosphate.\" [EC:3.5.4.25, RHEA:23704]","metadata":null},{"id":"10374812c0ea47af966fc78f20208102","type":"GO_TERM","name":"GTP cyclohydrolase IIa activity","canonical_id":"go:GO:0043740","description":"\"Catalysis of the reaction: GTP + 3 H2O = 2-amino-5-formylamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one + 2 H+ + 2 phosphate.\" [EC:3.5.4.29, RHEA:22468]","metadata":null},{"id":"ac3403f422d34d5ba06225f9d7b16f6d","type":"GO_TERM","name":"GTP cyclohydrolase IV activity","canonical_id":"go:GO:0044682","description":"\"Catalysis of the reaction: GTP + H2O = 7,8-dihydroneopterin 2',3'-cyclic phosphate + diphosphate + formate + H+. This activity is part of the biosynthesis of methanopterin in Archaea, and requires Fe2+.\" [GOC:mengo_curators, PMID:17497938, RHEA:25860]","metadata":null},{"id":"156ca6b013dd44feb5067c980fb8ddab","type":"GO_TERM","name":"GTP cyclohydrolase activity","canonical_id":"go:GO:0003933","description":"\"Catalysis of the hydrolysis of the imidazole ring of GTP, releasing formate. Two C-N bonds are hydrolyzed and the pentase unit is isomerized.\" [GOC:curators]","metadata":null},{"id":"8ae525abb9564fabae08aa5800150396","type":"GO_TERM","name":"GTP cyclohydrolase binding","canonical_id":"go:GO:0044549","description":"\"Binding to a GTP cyclohydrolase.\" [GOC:jl]","metadata":null},{"id":"19896197b8654604afc6ec36f8f79781","type":"GO_TERM","name":"GTP diphosphatase activity","canonical_id":"go:GO:0036219","description":"\"Catalysis of the reaction: GTP + H2O = GMP + H+ + diphosphate.\" [GOC:dgf, PMID:22531138, RHEA:29391]","metadata":null},{"id":"9998d5f1b75e474cb38288822c60356f","type":"GO_TERM","name":"GTP diphosphokinase activity","canonical_id":"go:GO:0008728","description":"\"Catalysis of the reaction: ATP + GTP = AMP + guanosine 3'-diphosphate 5'-triphosphate.\" [EC:2.7.6.5]","metadata":null},{"id":"be9fe674bbd94a5c99ef486f71b39238","type":"GO_TERM","name":"GTP guanylyltransferase activity","canonical_id":"go:GO:0047351","description":"\"Catalysis of the reaction: 2 GTP + H+ = P(1),P(4)-bis(5'-guanosyl) tetraphosphate + diphosphate + H+.\" [RHEA:18153]","metadata":null},{"id":"a99c595fbebf47caa2881d7714a87bcc","type":"GO_TERM","name":"GTP metabolic process","canonical_id":"go:GO:0046039","description":"\"The chemical reactions and pathways involving GTP, guanosine triphosphate.\" [GOC:curators]","metadata":null},{"id":"51e6a32cb3b641948a423bfdd4128fcc","type":"GO_TERM","name":"GTP synthesis coupled proton transport","canonical_id":"go:GO:0015987","description":"\"The transport of protons across a membrane to generate an electrochemical gradient (proton-motive force) that powers GTP synthesis.\" [ISBN:0716731363]","metadata":null},{"id":"7a92eecb7b804d5f84a9e070c48ab2b8","type":"GO_TERM","name":"GTP-dependent polydeoxyribonucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0051737","description":"\"Catalysis of the reaction: GTP + 5'-dephospho-DNA = GDP + 5'-phospho-DNA.\" [PMID:8428918]","metadata":null},{"id":"fd06b6bf38d94a4b98672fa9db7bf44a","type":"GO_TERM","name":"GTP-dependent polynucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0051735","description":"\"Catalysis of the reaction: GTP + 5'-dephosphopolynucleotide = GDP + 5'-phosphopolynucleotide. The polynucleotide may be DNA or RNA.\" [GOC:curators]","metadata":null},{"id":"3ff6823d21ef45d698ef816d2b9e13f1","type":"GO_TERM","name":"GTP-dependent polyribonucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0051730","description":"\"Catalysis of the reaction: GTP + 5'-dephospho-RNA = GDP + 5'-phospho-RNA.\" [PMID:8428918]","metadata":null},{"id":"be83c9022f614af1aaa01b4d96e90efc","type":"GO_TERM","name":"GTP-dependent protein binding","canonical_id":"go:GO:0030742","description":"\"Binding to a protein or protein complex when at least one of the interacting partners is in the GTP-bound state.\" [GOC:curators, GOC:krc]","metadata":null},{"id":"5ef6398541744b118452ee36c9cc0a41","type":"GO_TERM","name":"GTP-dependent protein kinase activity","canonical_id":"go:GO:0034211","description":"\"GTP dependent catalysis of the reaction: ATP + a protein serine/threonine = ADP + protein serine/threonine phosphate.\" [GOC:ecd, PMID:17200152]","metadata":null},{"id":"9a35c416e63548df9d3178a509b344c0","type":"GO_TERM","name":"GTP:GDP antiporter activity","canonical_id":"go:GO:0010292","description":"\"Catalysis of the reaction: GTP(out) + GDP(in) = GTP(in) + GDP(out).\" [PMID:10514379, PMID:12553910, PMID:16553903]","metadata":null},{"id":"fee3269e456e40afb2e607caf56f5405","type":"GENE","name":"GTPBP1","canonical_id":"hgnc:HGNC:4669","description":"GTP binding protein 1","metadata":{"aliases":["GP-1","HSPC018"]}},{"id":"0673a28c7b1242479688f9ce265bd0ff","type":"GENE","name":"GTPBP10","canonical_id":"hgnc:HGNC:25106","description":"GTP binding protein 10","metadata":{"aliases":["DKFZP686A10121","FLJ38242","OBGH2"]}},{"id":"fa02e8ddaedf4930b528a57a78f83514","type":"GENE","name":"GTPBP2","canonical_id":"hgnc:HGNC:4670","description":"GTP binding protein 2","metadata":null},{"id":"02e2b5dde3e74088b495f737a29bb803","type":"GENE","name":"GTPBP3","canonical_id":"hgnc:HGNC:14880","description":"GTP binding protein 3, mitochondrial","metadata":{"aliases":["MSS1","THDF1","GTPBG3","MTGP1","FLJ14700"]}},{"id":"23f5236bdd534201bbe5b0fde24821ed","type":"GO_TERM","name":"GTPBP3-MTO1 complex","canonical_id":"go:GO:7770010","description":"\"A protein complex consisting of GTP binding protein 3 (GTPBP3) and mitochondrial tRNA translation optimization 1 (MTO1). The complex catalyzes the formation of 5-taurinomethyluridine at wobble position U34 of mitochondrial tRNAs.\" [PMID:29390138, PMID:33619562]","metadata":null},{"id":"b09552eee9144fc385ec32263d9829c6","type":"GENE","name":"GTPBP4","canonical_id":"hgnc:HGNC:21535","description":"GTP binding protein 4","metadata":{"aliases":["CRFG","NGB","FLJ10690","FLJ10686","NOG1"]}},{"id":"f9766e5f848d41318d27d54e7fb0889c","type":"GENE","name":"GTPBP6","canonical_id":"hgnc:HGNC:30189","description":"GTP binding protein 6","metadata":{"aliases":["PGPL","FLJ20977"]}},{"id":"1727012109c84348b20225c72361c2b3","type":"GENE","name":"GTPBP8","canonical_id":"hgnc:HGNC:25007","description":"GTP binding protein 8","metadata":{"aliases":["HSPC135"]}},{"id":"d4b06a5856034be89e51a6149abdb460","type":"GO_TERM","name":"GTPase activating protein binding","canonical_id":"go:GO:0032794","description":"\"Binding to a GTPase activating protein.\" [GOC:nln]","metadata":null},{"id":"8cdbe5c1c0464fb8a5f4280bd579f2d6","type":"GO_TERM","name":"GTPase activator activity","canonical_id":"go:GO:0005096","description":"\"Binds to and increases the activity of a GTPase, an enzyme that catalyzes the hydrolysis of GTP.\" [GOC:mah]","metadata":null},{"id":"517fa1716b144ee8a322aa0508ccf968","type":"GO_TERM","name":"GTPase activator complex","canonical_id":"go:GO:1902773","description":"\"A protein complex which is capable of GTPase activator activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16449187]","metadata":null},{"id":"d08fe870ea6846ec90fb6258c3720714","type":"GO_TERM","name":"GTPase activity","canonical_id":"go:GO:0003924","description":"\"Catalysis of the reaction: GTP + H2O = GDP + H+ + phosphate.\" [PMID:26832457, PMID:27218782]","metadata":null},{"id":"afa6be9a9f6f4dbc8d7dc7d3ae84f516","type":"GO_TERM","name":"GTPase binding","canonical_id":"go:GO:0051020","description":"\"Binding to a GTPase, any enzyme that catalyzes the hydrolysis of GTP.\" [GOC:ai]","metadata":null},{"id":"602917c34dbb4527b4b907014f63a2ae","type":"GO_TERM","name":"GTPase complex","canonical_id":"go:GO:1905360","description":"\"A protein complex which is capable of GTPase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:9178006]","metadata":null},{"id":"8dfaccc3575f42f5b9a561f0572e8b3c","type":"GO_TERM","name":"GTPase inhibitor activity","canonical_id":"go:GO:0005095","description":"\"Stops, prevents or reduces the activity of any enzyme that catalyzes the hydrolysis of GTP to GDP and orthophosphate.\" [GOC:ai]","metadata":null},{"id":"bdafaf893218470bb658701d1651e769","type":"GO_TERM","name":"GTPase motor activity","canonical_id":"go:GO:0061791","description":"\"A motor activity driven by GTP hydrolysis.\" [GOC:dph, GOC:vw, PMID:11242086]","metadata":null},{"id":"5b12a65b8a1c4871a0d128f8b26e0d80","type":"GO_TERM","name":"GTPase regulator activity","canonical_id":"go:GO:0030695","description":"\"Binds to and modulates the activity of a GTPase.\" [GOC:mah]","metadata":null},{"id":"2e14cc46a8be4313b1f6e2b55adf8692","type":"GO_TERM","name":"GTPase-dependent fusogenic activity","canonical_id":"go:GO:0140523","description":"\"A GTPase activity that mediates the joining of two lipid bilayers to form a single membrane.\" [PMID:29663589]","metadata":null},{"id":"47b42273ef044cdc824df03efa1f7fd2","type":"GENE","name":"GTSCR1","canonical_id":"hgnc:HGNC:18406","description":"Gilles de la Tourette syndrome chromosome region, candidate 1","metadata":null},{"id":"5d44b246524e4e3fb40f50fbaeb85f1e","type":"GENE","name":"GTSE1","canonical_id":"hgnc:HGNC:13698","description":"G2 and S-phase expressed 1","metadata":{"aliases":["GTSE-1","B99","Lnc_bc060912"]}},{"id":"d3fbfb0f9ee4439fb576927e0c698de6","type":"GENE","name":"GTSE1-DT","canonical_id":"hgnc:HGNC:27163","description":"GTSE1 divergent transcript","metadata":{"aliases":["GTSE1-AS1"]}},{"id":"fb77718f7bbf4a75b0245740086ef496","type":"GENE","name":"GTSF1","canonical_id":"hgnc:HGNC:26565","description":"gametocyte specific factor 1","metadata":{"aliases":["FLJ32942","Cue110","FAM112B"]}},{"id":"76b714b5da784db480ae66586f6d2a09","type":"GENE","name":"GTSF1L","canonical_id":"hgnc:HGNC:16198","description":"gametocyte specific factor 1 like","metadata":{"aliases":["dJ1028D15.4","C20orf65","FAM112A"]}},{"id":"bab510a9f76348f9a02db20c6600d52b","type":"GENE","name":"GTSF2P","canonical_id":"hgnc:HGNC:54885","description":"gametocyte specific factor 2, pseudogene","metadata":{"aliases":["GTSF2"]}},{"id":"26756fc4442c490e8e3ff317c185e323","type":"GO_TERM","name":"GU repeat RNA binding","canonical_id":"go:GO:1990605","description":"\"Binding to an RNA molecule containing GU repeats.\" [PMID:20081200]","metadata":null},{"id":"0a864044ca964002b61940feadb330d7","type":"GO_TERM","name":"GUA codon-amino acid adaptor activity","canonical_id":"go:GO:0033451","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GUA codon.\" [GOC:mah]","metadata":null},{"id":"5469689e9a6740eaac304d9fa2a9f333","type":"GO_TERM","name":"GUC codon-amino acid adaptor activity","canonical_id":"go:GO:0033450","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GUC codon.\" [GOC:mah]","metadata":null},{"id":"8ce8c74462e54c4698239f031498f697","type":"GENE","name":"GUCA1A","canonical_id":"hgnc:HGNC:4678","description":"guanylate cyclase activator 1A","metadata":{"aliases":["GCAP","GCAP1","COD3","dJ139D8.6","CORD14","GCAP-I","GCAP-1","GUCA","GUCA1","C6orf131"]}},{"id":"b16f6d4b0e624acb96b88d6b9eb05d13","type":"GENE","name":"GUCA1ANB-GUCA1A","canonical_id":"hgnc:HGNC:56129","description":"GUCA1ANB-GUCA1A readthrough","metadata":null},{"id":"ef167b1dadd44bda8faf990fe100f3e9","type":"GENE","name":"GUCA1B","canonical_id":"hgnc:HGNC:4679","description":"guanylate cyclase activator 1B","metadata":{"aliases":["GCAP2","RP48","GCAP-2","GCAP-II"]}},{"id":"82a43f0c38424a0f980432e7e5792b3d","type":"GENE","name":"GUCA1C","canonical_id":"hgnc:HGNC:4680","description":"guanylate cyclase activator 1C","metadata":{"aliases":["GCAP3"]}},{"id":"ad7ff016ff914d4d95c1d77f15d96eb2","type":"GENE","name":"GUCA2A","canonical_id":"hgnc:HGNC:4682","description":"guanylate cyclase activator 2A","metadata":{"aliases":["STARA","GUCA2"]}},{"id":"e4a7ad7569bd42b98fec3693fd3b910b","type":"GENE","name":"GUCA2B","canonical_id":"hgnc:HGNC:4683","description":null,"metadata":null},{"id":"72ecd210cd5c481fbf13fe6272c88b23","type":"GENE","name":"GUCD1","canonical_id":"hgnc:HGNC:14237","description":"guanylyl cyclase domain containing 1","metadata":{"aliases":["MGC1842","LLN4","C22orf13"]}},{"id":"c7fd4fcb66de459bab5103808223560e","type":"GENE","name":"GUCY1A1","canonical_id":"hgnc:HGNC:4685","description":"guanylate cyclase 1 soluble subunit alpha 1","metadata":{"aliases":["GC-SA3","GUC1A3","GUCY1A3"]}},{"id":"a3d039dea88c43c6897eebec349d89ef","type":"GENE","name":"GUCY1A2","canonical_id":"hgnc:HGNC:4684","description":"guanylate cyclase 1 soluble subunit alpha 2","metadata":{"aliases":["GC-SA2","GUC1A2"]}},{"id":"169078e1c8444445aa0d545e3a9fa57f","type":"GENE","name":"GUCY1B1","canonical_id":"hgnc:HGNC:4687","description":null,"metadata":null},{"id":"69907e2363304f538227ddb5b43a8958","type":"GENE","name":"GUCY1B1-DT","canonical_id":"hgnc:HGNC:58902","description":"GUCY1B1 divergent transcript","metadata":null},{"id":"6a9df5781d8b4eb99bcb957533a72310","type":"GENE","name":"GUCY1B2","canonical_id":"hgnc:HGNC:4686","description":"guanylate cyclase 1 soluble subunit beta 2 (pseudogene)","metadata":{"aliases":["GUCY1B2P","GC-SB2"]}},{"id":"1a8df08e8ebf444883093f21a2335d31","type":"GENE","name":"GUCY2C","canonical_id":"hgnc:HGNC:4688","description":null,"metadata":null},{"id":"c375368a2da8426599ee0071b6e88a6b","type":"PROTEIN","name":"GUCY2C","canonical_id":"uniprot:P25092","description":null,"metadata":null},{"id":"db10ffb7fb2843d784c5aa45b8661018","type":"GENE","name":"GUCY2C-AS1","canonical_id":"hgnc:HGNC:56054","description":"GUCY2C antisense RNA 1","metadata":null},{"id":"31f6b27d6dce446ebaedc6f94ba7a30d","type":"GENE","name":"GUCY2D","canonical_id":"hgnc:HGNC:4689","description":"guanylate cyclase 2D, retinal","metadata":{"aliases":["retGC","RETGC-1","ROS-GC1","CYGD","LCA1","ROS-GC","CORD6","LCA","GUC2D","GUC1A4"]}},{"id":"19f335b83b6c4c33bb55c06244901f7c","type":"GENE","name":"GUCY2EP","canonical_id":"hgnc:HGNC:4690","description":"guanylate cyclase 2E, pseudogene","metadata":{"aliases":["GC-E","GUCY2E"]}},{"id":"6d20e50bcfb342ecbc591d4bddaaed88","type":"GENE","name":"GUCY2F","canonical_id":"hgnc:HGNC:4691","description":"guanylate cyclase 2F, retinal","metadata":{"aliases":["GUC2DL","GC-F","RetGC-2","ROS-GC2","CYGF"]}},{"id":"32af4adccd3340948e87e845f707bd7d","type":"GENE","name":"GUCY2GP","canonical_id":"hgnc:HGNC:31863","description":"guanylate cyclase 2G, pseudogene","metadata":{"aliases":["GUCY2G"]}},{"id":"c839f85f09bb4f5e8472cd7d08d27a41","type":"GENE","name":"GUF1","canonical_id":"hgnc:HGNC:25799","description":"GTP binding elongation factor GUF1","metadata":{"aliases":["FLJ13220"]}},{"id":"a3bd3f708cfd4315ad67e62bfb4617f8","type":"GO_TERM","name":"GUG codon-amino acid adaptor activity","canonical_id":"go:GO:0033452","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GUG codon.\" [GOC:mah]","metadata":null},{"id":"e3b70af7d7054a458217e2cc09ab69da","type":"GENE","name":"GUK1","canonical_id":"hgnc:HGNC:4693","description":"guanylate kinase 1","metadata":null},{"id":"3d9a5b9762434a7ba13c8834d5122bb9","type":"GENE","name":"GUK2","canonical_id":"hgnc:HGNC:4694","description":"guanylate kinase 2","metadata":null},{"id":"d78512361ffc4d2795acd03df40d0b76","type":"GENE","name":"GULOP","canonical_id":"hgnc:HGNC:4695","description":"gulonolactone (L-) oxidase, pseudogene","metadata":{"aliases":["GULO","scurvy"]}},{"id":"be63eafbb0a54708bac6a282d684794b","type":"GENE","name":"GULP1","canonical_id":"hgnc:HGNC:18649","description":"GULP PTB domain containing engulfment adaptor 1","metadata":{"aliases":["CED6","CED-6","GULP"]}},{"id":"c10ffa608cf6441b8da7748e224a413c","type":"GENE","name":"GUSB","canonical_id":"hgnc:HGNC:4696","description":null,"metadata":null},{"id":"2b5fb9e8c2284b67a491714d283b6de5","type":"GENE","name":"GUSBP1","canonical_id":"hgnc:HGNC:13670","description":"GUSB pseudogene 1","metadata":null},{"id":"83ef882856b1453eaff564d1bf499299","type":"GENE","name":"GUSBP10","canonical_id":"hgnc:HGNC:42324","description":"GUSB pseudogene 10","metadata":null},{"id":"20a1f1344e8442fe9882f54359d5a599","type":"GENE","name":"GUSBP11","canonical_id":"hgnc:HGNC:42325","description":"GUSB pseudogene 11","metadata":null},{"id":"251cb02369c44fc4bd3145bf7ebf04d0","type":"GENE","name":"GUSBP12","canonical_id":"hgnc:HGNC:42326","description":"GUSB pseudogene 12","metadata":null},{"id":"187a6d8e62ab43b69201c8692b5d69ac","type":"GENE","name":"GUSBP13","canonical_id":"hgnc:HGNC:54495","description":"GUSB pseudogene 13","metadata":null},{"id":"1cecb0ec6a024eee8e97c3efc6547f11","type":"GENE","name":"GUSBP14","canonical_id":"hgnc:HGNC:54496","description":"GUSB pseudogene 14","metadata":{"aliases":["SMA4","SMA3"]}},{"id":"51b7b822ecb7401baa8184d69e580b53","type":"GENE","name":"GUSBP15","canonical_id":"hgnc:HGNC:54497","description":"GUSB pseudogene 15","metadata":{"aliases":["SMA5"]}},{"id":"6c8fdfe3782d4737b62d38dda39d30c4","type":"GENE","name":"GUSBP16","canonical_id":"hgnc:HGNC:54498","description":"GUSB pseudogene 16","metadata":null},{"id":"4aed4455da3d4ff6af7def06000b5338","type":"GENE","name":"GUSBP17","canonical_id":"hgnc:HGNC:54970","description":"GUSB pseudogene 17","metadata":null},{"id":"0693cb491937431e9bed569e819c3e1a","type":"GENE","name":"GUSBP18","canonical_id":"hgnc:HGNC:55770","description":"GUSB pseudogene 18","metadata":null},{"id":"c39305c8c9e24b269602fdb75edcf921","type":"GENE","name":"GUSBP19","canonical_id":"hgnc:HGNC:55771","description":"GUSB pseudogene 19","metadata":null},{"id":"984225933f68472f84bd4be704d843bf","type":"GENE","name":"GUSBP2","canonical_id":"hgnc:HGNC:18792","description":"GUSB pseudogene 2","metadata":{"aliases":["bA239L20.5","bA239L20.1","SMA3-L","bGLU-Lp","SMAC3L","SMAC3L2","GUSBL1"]}},{"id":"b242011bfd8d4f948fa3c3d9546cacda","type":"GENE","name":"GUSBP3","canonical_id":"hgnc:HGNC:37301","description":"GUSB pseudogene 3","metadata":null},{"id":"6012d466bb4049b599277cb9faef95a7","type":"GENE","name":"GUSBP4","canonical_id":"hgnc:HGNC:18220","description":"GUSB pseudogene 4","metadata":{"aliases":["SMA3-L","FLJ13549","C6orf216","SMAC3L","GUSBL2"]}},{"id":"16d8435ab03e4e089e089dea7fd208f3","type":"GENE","name":"GUSBP5","canonical_id":"hgnc:HGNC:42319","description":"GUSB pseudogene 5","metadata":null},{"id":"453a40a39ffd456898190164cdf3d394","type":"GENE","name":"GUSBP6","canonical_id":"hgnc:HGNC:42320","description":"GUSB pseudogene 6","metadata":null},{"id":"57b155eefe1f43189d90a9432168f3eb","type":"GENE","name":"GUSBP7","canonical_id":"hgnc:HGNC:42321","description":"GUSB pseudogene 7","metadata":null},{"id":"9359b899095e4f67b99a2a9d00cb3112","type":"GENE","name":"GUSBP8","canonical_id":"hgnc:HGNC:42322","description":"GUSB pseudogene 8","metadata":null},{"id":"a1e1e8e307774cafa1e6f6474abaeb4d","type":"GENE","name":"GUSBP9","canonical_id":"hgnc:HGNC:42323","description":"GUSB pseudogene 9","metadata":null},{"id":"102a5c4b894642b3b965bf41af161cf6","type":"GO_TERM","name":"GUU codon-amino acid adaptor activity","canonical_id":"go:GO:0033449","description":"\"A triplet codon-amino acid adaptor activity that recognizes a GUU codon.\" [GOC:mah]","metadata":null},{"id":"b7e34ec7817440d392fbeb749154d09d","type":"GENE","name":"GVINP1","canonical_id":"hgnc:HGNC:25813","description":"GTPase, very large interferon inducible pseudogene 1","metadata":{"aliases":["VLIG-1","FLJ13373","VLIG1","GVIN1","GVIN1P"]}},{"id":"d8d9280a1d55456d93a5945e2babb06e","type":"GENE","name":"GVINP2","canonical_id":"hgnc:HGNC:38876","description":"GTPase, very large interferon inducible pseudogene 2","metadata":null},{"id":"b811d4c7316b4dba840e92ec2fbd3ef8","type":"GENE","name":"GVQW3","canonical_id":"hgnc:HGNC:51239","description":"GVQW motif containing 3","metadata":null},{"id":"6a9e28159d2b42c9b07bd7178495f54d","type":"GO_TERM","name":"GW body","canonical_id":"go:GO:0140364","description":"\"A ribonucleoprotein granule located in the cytoplasm and the nucleus. GW-bodies minimally contain the Argonaute2 (Ago2) and TNRC6B proteins, together with specific target RNAs.\" [PMID:16418578, PMID:26930655, PMID:29576456]","metadata":null},{"id":"376159e4194642598e241b381add3978","type":"TRIAL","name":"GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00320411","description":"Neoplasms, Breast","metadata":null},{"id":"5681db2be5bb40b28a19f44ad0304c20","type":"GENE","name":"GXYLT1","canonical_id":"hgnc:HGNC:27482","description":"glucoside xylosyltransferase 1","metadata":{"aliases":["FLJ43151","GLT8D3"]}},{"id":"8d465b938e5049b3a41c27c8b9b91087","type":"GENE","name":"GXYLT1P1","canonical_id":"hgnc:HGNC:39676","description":"GXYLT1 pseudogene 1","metadata":null},{"id":"253e9ffd2676440091d9c1f178397c42","type":"GENE","name":"GXYLT1P2","canonical_id":"hgnc:HGNC:39677","description":"GXYLT1 pseudogene 2","metadata":null},{"id":"6d96ab0f38b541989a8b62e03d1f25a3","type":"GENE","name":"GXYLT1P3","canonical_id":"hgnc:HGNC:50422","description":"GXYLT1 pseudogene 3","metadata":null},{"id":"0ffd6408e7614e98be34dd31817e9579","type":"GENE","name":"GXYLT1P4","canonical_id":"hgnc:HGNC:50423","description":"GXYLT1 pseudogene 4","metadata":null},{"id":"46ea4b3bf9344e2bb7184f18e1c168cc","type":"GENE","name":"GXYLT1P5","canonical_id":"hgnc:HGNC:50424","description":"GXYLT1 pseudogene 5","metadata":null},{"id":"f2dacf5df7a741809af838f3190b932b","type":"GENE","name":"GXYLT1P6","canonical_id":"hgnc:HGNC:50425","description":"GXYLT1 pseudogene 6","metadata":null},{"id":"b5aeac5850244cdb9417bf112f9df9db","type":"GENE","name":"GXYLT1P7","canonical_id":"hgnc:HGNC:54735","description":"GXYLT1 pseudogene 7","metadata":null},{"id":"f27cb136330f4b02996bf058b422e1b2","type":"GENE","name":"GXYLT2","canonical_id":"hgnc:HGNC:33383","description":"glucoside xylosyltransferase 2","metadata":{"aliases":["GLT8D4"]}},{"id":"520868791eea442cb3e0a01369870980","type":"GENE","name":"GYG1","canonical_id":"hgnc:HGNC:4699","description":"glycogenin 1","metadata":{"aliases":["GYG"]}},{"id":"0b5d19868ba64c1087f5f70ba82fde12","type":"GENE","name":"GYG1P1","canonical_id":"hgnc:HGNC:39712","description":"glycogenin 1 pseudogene 1","metadata":null},{"id":"68dd48bdf67a4728aed235e948a669d2","type":"GENE","name":"GYG1P2","canonical_id":"hgnc:HGNC:39710","description":"glycogenin 1 pseudogene 2","metadata":null},{"id":"de3ffb00eacc4de1b462388806fefd4b","type":"GENE","name":"GYG1P3","canonical_id":"hgnc:HGNC:39711","description":"glycogenin 1 pseudogene 3","metadata":null},{"id":"a61b6dbbc2b54270ab083d2f927b0f87","type":"GENE","name":"GYG2","canonical_id":"hgnc:HGNC:4700","description":"glycogenin 2","metadata":{"aliases":["GN-2"]}},{"id":"f3dfa1eb06ba4d2b833d712e3db83f40","type":"GENE","name":"GYG2-AS1","canonical_id":"hgnc:HGNC:40270","description":"GYG2 antisense RNA 1","metadata":null},{"id":"9b30747fafad400a9a6d89bea8d3b643","type":"GENE","name":"GYG2P1","canonical_id":"hgnc:HGNC:4701","description":"glycogenin 2 pseudogene 1","metadata":{"aliases":["GYG2P"]}},{"id":"468df297d15748bf8fe5ea7de13af354","type":"GENE","name":"GYG2P2","canonical_id":"hgnc:HGNC:39713","description":"glycogenin 2 pseudogene 2","metadata":null},{"id":"0108be406cfc423f84d7f95ea58b951f","type":"GENE","name":"GYPA","canonical_id":"hgnc:HGNC:4702","description":null,"metadata":null},{"id":"55bc9de36df248ddbd5725b1ed318387","type":"GENE","name":"GYPB","canonical_id":"hgnc:HGNC:4703","description":null,"metadata":null},{"id":"8ba1a7abbf5e4a5d837f3d4984bf967b","type":"GENE","name":"GYPC","canonical_id":"hgnc:HGNC:4704","description":"glycophorin C (Gerbich blood group)","metadata":{"aliases":["GPC","GYPD","Ge","CD236","CD236R","GPD"]}},{"id":"cb6b1c8f8c3a418ea79a94eea35af553","type":"GENE","name":"GYPE","canonical_id":"hgnc:HGNC:4705","description":"glycophorin E (MNS blood group)","metadata":{"aliases":["GPE","MNS"]}},{"id":"373c8a34ab194b6e98c11f23199e13ec","type":"GENE","name":"GYS1","canonical_id":"hgnc:HGNC:4706","description":"glycogen synthase 1","metadata":{"aliases":["GSY","GYS"]}},{"id":"44f44edf46ff42e88caa9cfe6bdc95c3","type":"GENE","name":"GYS2","canonical_id":"hgnc:HGNC:4707","description":"glycogen synthase 2","metadata":null},{"id":"0c347b02c7a745c6aae81c365c6c7735","type":"GENE","name":"GZF1","canonical_id":"hgnc:HGNC:15808","description":null,"metadata":null},{"id":"3b3725df91f3486c8ecba525204f4633","type":"GENE","name":"GZMA","canonical_id":"hgnc:HGNC:4708","description":"granzyme A","metadata":{"aliases":["HFSP","CTLA3"]}},{"id":"33a9e94f863149f4ab7f7ef38eecdff8","type":"GENE","name":"GZMB","canonical_id":"hgnc:HGNC:4709","description":null,"metadata":null},{"id":"bf63ffc0dfe54ee3b9ce44e57b79e8ae","type":"GENE","name":"GZMH","canonical_id":"hgnc:HGNC:4710","description":"granzyme H","metadata":{"aliases":["CGL-2","CCP-X","CTLA1","CSP-C","CTSGL2"]}},{"id":"8851bb2af6d54d6f83fede42cf7ffa80","type":"GENE","name":"GZMH-AS1","canonical_id":"hgnc:HGNC:58166","description":"GZMH and GMZB antisense RNA 1","metadata":{"aliases":["AL136018.1"]}},{"id":"1e71a33036a74f1eb67a752f36b2fad8","type":"GENE","name":"GZMK","canonical_id":"hgnc:HGNC:4711","description":"granzyme K","metadata":{"aliases":["TRYP2","PRSS"]}},{"id":"05514191d46a482a94d6e58b6d437589","type":"GENE","name":"GZMK-AS1","canonical_id":"hgnc:HGNC:59043","description":"GZMK antisense RNA 1","metadata":null},{"id":"42e172e0887544ba8403e0700738284f","type":"GENE","name":"GZMM","canonical_id":"hgnc:HGNC:4712","description":"granzyme M","metadata":{"aliases":["MET1","LMET1"]}},{"id":"888cc71b240c429aae81d54fa0ef1996","type":"GENE","name":"GZMOP","canonical_id":"hgnc:HGNC:44137","description":"granzyme O, pseudogene","metadata":{"aliases":["GZMAP1"]}},{"id":"872ce245dbb14ee785ebfb4eb29d1a25","type":"TRIAL","name":"GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy","canonical_id":"clinicaltrials.gov:NCT04129008","description":"Coronary Artery Disease; Gastroesophageal Reflux Disease","metadata":null},{"id":"84a18672de43429681e4df891b50a2c6","type":"DRUG","name":"Gabapentin","canonical_id":"mesh:D000077206","description":null,"metadata":null},{"id":"36934615d88d409393e8de937c26319f","type":"TRIAL","name":"Gabapentin Versus Loratadine in Uremic Pruritus","canonical_id":"clinicaltrials.gov:NCT05750875","description":"Pruritus; Uremia; Chronic Kidney Diseases","metadata":null},{"id":"ce309b17aae04c26b001e2ca8ee5d425","type":"DRUG","name":"Gabapentin enacarbil","canonical_id":"mesh:C493250","description":null,"metadata":null},{"id":"303ca6cd9ea245f895502bdf9891a950","type":"TRIAL","name":"Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT03080493","description":"Abortion, Induced; Cervical Preparation; Pain","metadata":null},{"id":"deb1034cd0e34daf84dd65b23caaa5ab","type":"TRIAL","name":"Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00880191","description":"Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"601026edd97042cfae8a7fc5d051c434","type":"TRIAL","name":"Galcanezumab for Vestibular Migraine","canonical_id":"clinicaltrials.gov:NCT04417361","description":"Vestibular Migraine","metadata":null},{"id":"6263ca7f31c24554bd38ff120a73a2d2","type":"DISEASE","name":"Gallbladder Diseases (Diagnostic)","canonical_id":"mesh:D005705","description":null,"metadata":null},{"id":"863bf32c459c4b1db94388f959e86e6f","type":"DRUG","name":"Galsulfase","canonical_id":"mesh:C508864","description":null,"metadata":null},{"id":"c2bd9734d0b048c8b855d9d859a80436","type":"TRIAL","name":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00975065","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"85769f9b8e2f4fdaaf03dab699686499","type":"TRIAL","name":"Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression","canonical_id":"clinicaltrials.gov:NCT06480201","description":"Healthy; Major Depressive Disorder; Treatment Resistant Depression","metadata":null},{"id":"4a8a81e8563f4b7ebe7b233350bbd9eb","type":"TRIAL","name":"Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01218620","description":"Adult Solid Neoplasm","metadata":null},{"id":"abd68a20cbc941e39da3979534542742","type":"PROTEIN","name":"Gamma-aminobutyric acid receptor subunit beta-like protein 1 (Sarcoptes scabiei)","canonical_id":"uniprot:A0A132A3X0","description":null,"metadata":null},{"id":"f4b59c37c86043ea98b0a8a47e58b1cf","type":"DRUG","name":"Ganciclovir","canonical_id":"mesh:D015774","description":null,"metadata":null},{"id":"927883d818ae40659a47896b681952d9","type":"DISEASE","name":"Ganglioglioma","canonical_id":"doid:5078","description":null,"metadata":null},{"id":"b6069f3c75b84537bd00f446d5416950","type":"TRIAL","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","canonical_id":"clinicaltrials.gov:NCT07294261","description":"Local Advanced or Metastatic NSCLC","metadata":null},{"id":"f4911ded5c064ade922ee965683e8e04","type":"DISEASE","name":"Gastric Adenocarcinoma","canonical_id":"doid:3717","description":null,"metadata":null},{"id":"2b305eca282f492cb49c9f8c3d0c88df","type":"TRIAL","name":"Gastric pH in Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT00590928","description":"Critically Ill Patients; Indication for Stress Ulcer Prophylaxis","metadata":null},{"id":"85377c02ca9d4af6bbc7a60852ebb03e","type":"DISEASE","name":"Gastritis","canonical_id":"mesh:D005756","description":null,"metadata":null},{"id":"ac99005654724710a8d9f661ba538b6b","type":"DISEASE","name":"Gastroesophageal Reflux","canonical_id":"mesh:D005764","description":null,"metadata":null},{"id":"4d6406b2731945059bd9dcf1246d2a90","type":"TRIAL","name":"Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance","canonical_id":"clinicaltrials.gov:NCT01079884","description":"GERD","metadata":null},{"id":"3531e018fdaf432fb34b44287e0ba26b","type":"TRIAL","name":"Gastroesophageal Reflux Treatment in Scleroderma","canonical_id":"clinicaltrials.gov:NCT01878526","description":"Gastroesophageal Reflux Disease; Systemic Sclerosis; Scleroderma","metadata":null},{"id":"6e45afc209f94b3c9f7c00fc0465be64","type":"TRIAL","name":"Gastrointestinal Dysmotility on Aspiration Risk","canonical_id":"clinicaltrials.gov:NCT05455359","description":"Esophageal Motility Disorders; Gastric Motor Dysfunction; Aspiration Pneumonia; Gastro Esophageal Reflux","metadata":null},{"id":"73b0cc549ece4f8eabafbe4817180b68","type":"TRIAL","name":"Gastrointestinal Motility Among Diabetes Patients","canonical_id":"clinicaltrials.gov:NCT02573519","description":"Diabetic Autonomic Neuropathy; Gastrointestinal Motility Disorder; Diabetes Mellitus; Change of Transit or Circulation","metadata":null},{"id":"d4a5485a1f324ee49a66efb6dd725b9c","type":"DISEASE","name":"Gastrointestinal Neuroendocrine Tumor","canonical_id":"doid:0050626","description":null,"metadata":null},{"id":"d90eb8914def4e3cbc7e16e412ac78b9","type":"DISEASE","name":"Gastrointestinal Stromal Tumor","canonical_id":"doid:9253","description":null,"metadata":null},{"id":"5bab7db3478544fd8692829c2e3917f4","type":"TRIAL","name":"Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair","canonical_id":"clinicaltrials.gov:NCT02379858","description":"Ventral Hernia","metadata":null},{"id":"a1f95e99da6e463495dca31d1c7ca6a6","type":"DISEASE","name":"Gastrointestinal anthrax","canonical_id":"mesh:C571911","description":null,"metadata":null},{"id":"3e9053d98ce1419d9ee3048eb1705987","type":"DISEASE","name":"Gastrointestinal stromal tumor","canonical_id":"mesh:D046152","description":null,"metadata":null},{"id":"b0db3c0c251844bda71a96479a1f6353","type":"DISEASE","name":"Gastroparesis","canonical_id":"mesh:D018589","description":null,"metadata":null},{"id":"72833037e73b40729883b31db42253e0","type":"DRUG","name":"Gatifloxacin","canonical_id":"mesh:C078049","description":null,"metadata":null},{"id":"251ca479221c490ca648dcc828a4e32b","type":"DISEASE","name":"Gaucher Disease","canonical_id":"mesh:D005776","description":null,"metadata":null},{"id":"47cd4f4527fc4d2d96fa699ba199cd31","type":"DISEASE","name":"Gaucher disease","canonical_id":"mondo:0018150","description":null,"metadata":null},{"id":"7e428583aefb444f97fc73ad164ca015","type":"DISEASE","name":"Gaucher disease type I","canonical_id":"mondo:0009265","description":null,"metadata":null},{"id":"2c4ed806abc347c79c31758f1fa98385","type":"TRIAL","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","canonical_id":"clinicaltrials.gov:NCT05501886","description":"Breast Cancer","metadata":null},{"id":"dca036d7fc0145779dcb1c9708e784cb","type":"TRIAL","name":"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers","canonical_id":"clinicaltrials.gov:NCT03911973","description":"TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"1a12b8cebba44e9d95566e05365110c7","type":"TRIAL","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06190899","description":"mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male; Urogenital Diseases, Male; Prostatic Disease; Prostatic Neoplasms, Castration-Resistant; Prostate Cancer","metadata":null},{"id":"18c7a2ccc08b4e369278ecbccef3e0e2","type":"TRIAL","name":"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")","canonical_id":"clinicaltrials.gov:NCT03400254","description":"Breast Cancer","metadata":null},{"id":"6ab4e2c0eff14157926f5284b25ba52d","type":"DRUG","name":"Gefitinib","canonical_id":"mesh:C419708","description":null,"metadata":null},{"id":"fb942f3a7f5c4a348e9eba0ed1b5c78b","type":"DRUG","name":"Gefitinib","canonical_id":"ncit:C1855","description":null,"metadata":null},{"id":"76195852c02246a597fedb4898856f63","type":"TRIAL","name":"Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00062062","description":"Lung Cancer","metadata":null},{"id":"808d20808a4a47f98e7636a897cf89f1","type":"TRIAL","name":"Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT03486496","description":"Lung Adenocarcinoma; EGFR Mutation","metadata":null},{"id":"109f9191ebf941a2b48c8d68a8d356fb","type":"TRIAL","name":"Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00096486","description":"Lung Cancer","metadata":null},{"id":"91cb03edf2e94550af0d1a67e3cc521a","type":"TRIAL","name":"Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00217698","description":"Lung Cancer","metadata":null},{"id":"eef47b739b00478397dd064eb9297690","type":"TRIAL","name":"Gefitinib in Treating Patients With Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT00025207","description":"Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma","metadata":null},{"id":"96cd3e98c40a455789458e501f9ac564","type":"TRIAL","name":"Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy","canonical_id":"clinicaltrials.gov:NCT00066339","description":"Breast Cancer","metadata":null},{"id":"f397c9778702428c915bd44b75831be7","type":"TRIAL","name":"Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00024089","description":"Head and Neck Cancer","metadata":null},{"id":"cbe0bf5c070743258b178d7f0d3ef8fd","type":"TRIAL","name":"Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00258297","description":"Esophageal Cancer","metadata":null},{"id":"e34fa7eeafa742c19c4576ad0e2c6b75","type":"TRIAL","name":"Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00049543","description":"Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer","metadata":null},{"id":"07b564c7bdec409dbae6a7f9466002a6","type":"TRIAL","name":"Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC","canonical_id":"clinicaltrials.gov:NCT01755923","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"ae6afb9e56814544ba03335a9a95c969","type":"TRIAL","name":"Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00086957","description":"Breast Cancer","metadata":null},{"id":"2b1fe23e7a47466aa5ecf89e6bcce13f","type":"TRIAL","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","canonical_id":"clinicaltrials.gov:NCT06963060","description":"Gallbladder Cancer; Cholangiocarcinoma","metadata":null},{"id":"c1f31200a618488d84af2a04b2a83a12","type":"DRUG","name":"Gemcitabine","canonical_id":"ncit:C66876","description":null,"metadata":null},{"id":"5027a7b742934285a2379765c478b581","type":"TRIAL","name":"Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01064622","description":"Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7","metadata":null},{"id":"06070b77d1354d0aae3109555e889dd7","type":"TRIAL","name":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01701986","description":"Hematopoietic Cell Transplantation Recipient; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"b79ccc1176fc4ee4b00e2a24eef78e0b","type":"TRIAL","name":"Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy","canonical_id":"clinicaltrials.gov:NCT01938716","description":"Pancreatic Cancer","metadata":null},{"id":"3bbe80ba64024ae19e8787690786a972","type":"TRIAL","name":"Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT00410982","description":"Leukemia; Lymphoma; Myeloma","metadata":null},{"id":"8f12ea4b563e40cbba6892a272335a14","type":"TRIAL","name":"Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00031837","description":"Pancreatic Cancer; Thromboembolism","metadata":null},{"id":"9742417a63d64e14bfc431156448b140","type":"TRIAL","name":"Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT07806110","description":"Pancreas Ductal Adenocarcinoma","metadata":null},{"id":"8a118a832db24f2ebd812b5b983e0a22","type":"TRIAL","name":"Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00660231","description":"Lymphoma","metadata":null},{"id":"9c5d63e75e9e4582b146a8c0f004702b","type":"TRIAL","name":"Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00326599","description":"Lung Cancer","metadata":null},{"id":"10fe903eff53430ca9770887265df9e9","type":"TRIAL","name":"Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT04088188","description":"Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma","metadata":null},{"id":"82f29cbe85b4419f820bde601687b0ce","type":"TRIAL","name":"Gemcitabine and Dasatinib in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00429234","description":"Advanced Cancer; Solid Tumors","metadata":null},{"id":"db22c3c6b083466ead79d4f62aff8343","type":"TRIAL","name":"Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00810719","description":"Pancreatic Cancer","metadata":null},{"id":"c7758935145d47e9ba1b7d85933fa8b9","type":"TRIAL","name":"Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF\u03b2i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06026657","description":"Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma","metadata":null},{"id":"8aabc4f58e3c4fc48c27da278e9c3703","type":"TRIAL","name":"Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease","canonical_id":"clinicaltrials.gov:NCT00388349","description":"Hodgkin Disease; Hodgkin's Lymphoma; Lymphoma","metadata":null},{"id":"65fafbb0661f49d994886640f88e93cf","type":"TRIAL","name":"Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT06454383","description":"Advanced Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"a03f2b57784a4a648fa26f9383ef7386","type":"TRIAL","name":"Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer","canonical_id":"clinicaltrials.gov:NCT07310069","description":"Gallbladder Cancer Unresectable","metadata":null},{"id":"db3c9c6504c1444e91c5b887c4ddfc7a","type":"TRIAL","name":"Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02879318","description":"Pancreatic Adenocarcinoma","metadata":null},{"id":"94850aeb604f4e308c9a12ba455c8240","type":"TRIAL","name":"Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02101021","description":"Metastatic Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"79ed89809b164cafb3cdcb79cd0e2aab","type":"TRIAL","name":"Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies","canonical_id":"clinicaltrials.gov:NCT01182168","description":"Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer","metadata":null},{"id":"884c47f33f6647ffb9a8f2574be9b095","type":"TRIAL","name":"Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00524069","description":"Pancreatic Cancer","metadata":null},{"id":"5d0c4d2e63d54cd4a42974ebcc9c6d47","type":"TRIAL","name":"Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00176813","description":"Pancreatic Cancer","metadata":null},{"id":"8ded9ead43bf412b94dd2f53fb6f08c8","type":"TRIAL","name":"Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04158635","description":"Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma","metadata":null},{"id":"92456966fdf34f43a869b42117d74e55","type":"DRUG","name":"Gemfibrozil","canonical_id":"mesh:D015248","description":null,"metadata":null},{"id":"9cad1560a74d426fa7aaad1d9800e956","type":"TRIAL","name":"Gemfibrozil for Nicotine Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT02638597","description":"Smoking Cessation","metadata":null},{"id":"ae51cc89256346f0bc9f2eb6b0b1e38b","type":"DRUG","name":"Gemifloxacin","canonical_id":"mesh:C103274","description":null,"metadata":null},{"id":"f9bd3cf90d774671ad89c7c97b1f0634","type":"GO_TERM","name":"Gemin3-Gemin4-Gemin5 complex","canonical_id":"go:GO:0034716","description":"\"A protein complex that contains Gemin3 (DDX20), Gemin4, and Gemin5, and can bind to snRNAs; may be an intermediate in SMN complex assembly.\" [GOC:mah, PMID:17640873]","metadata":null},{"id":"019477a884a846e89d3c93097a05b692","type":"GO_TERM","name":"Gemin6-Gemin7-unrip complex","canonical_id":"go:GO:0034717","description":"\"A protein complex that contains Gemin6, Gemin7, and unrip (STRAP), and can bind to snRNAs; may play a role in snRNP assembly.\" [GOC:mah, PMID:17640873]","metadata":null},{"id":"6d85c8b550284a89a62897cb82deac0a","type":"GO_TERM","name":"Gemini of Cajal bodies","canonical_id":"go:GO:0097504","description":"\"Nuclear bodies frequently found near or associated with Cajal bodies (also called coiled bodies or CBs). Gemini of coiled bodies, or 'gems', are similar in size and shape to CBs, and often indistinguishable under the microscope. Unlike CBs, gems do not contain small nuclear ribonucleoproteins (snRNPs); they contain a protein called survivor of motor neurons (SMN) whose function relates to snRNP biogenesis. Gems are believed to assist CBs in snRNP biogenesis, and to play a role in the etiology of spinal muscular atrophy (SMA).\" [GOC:pr, PMID:11031238, PMID:9683623, Wikipedia:Cell_nucleus#Cajal_bodies_and_gems]","metadata":null},{"id":"295eca9cb6854b278d3424cc9c922dcb","type":"TRIAL","name":"Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00460447","description":"Acute Myeloid Leukemia; Allogeneic Transplantation","metadata":null},{"id":"2347b94f317645b3bb2cfc0eaa3ea878","type":"TRIAL","name":"Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00089050","description":"Leukemia","metadata":null},{"id":"86c3f01bb67f421d81b3c059d390e972","type":"TRIAL","name":"Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)","canonical_id":"clinicaltrials.gov:NCT04093505","description":"Acute Myeloid Leukemia","metadata":null},{"id":"fb81371ea35648778bb82a8e444e695e","type":"TRIAL","name":"Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01548911","description":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia","metadata":null},{"id":"3c5b9f0e8f26461f95fc261ebf9b37d3","type":"TRIAL","name":"Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4","canonical_id":"clinicaltrials.gov:NCT02473146","description":"Acute Myeloid Leukemia","metadata":null},{"id":"d871f9207c764cb1a91a4a5bc7731a06","type":"TRIAL","name":"Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00008151","description":"Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"8759f3063ee1420091b71b733bf01157","type":"DRUG","name":"Gemtuzumab ozogamicin","canonical_id":"mesh:D000079982","description":null,"metadata":null},{"id":"70cb843f6ca8468da0392dcd6e111ff1","type":"TRIAL","name":"Gender Differences in Renal Functioning and Disease","canonical_id":"clinicaltrials.gov:NCT04085094","description":"Chronic Renal Failure; Healthy Controls","metadata":null},{"id":"a7352cfe670d47c4a105a851bbe00227","type":"TRIAL","name":"Gender Differences in the Metabolic Effects of Uric Acid","canonical_id":"clinicaltrials.gov:NCT03076684","description":"Hyperuricemia","metadata":null},{"id":"e60be8ebfa334cdd97b47247067e9f7b","type":"TRIAL","name":"Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma","canonical_id":"clinicaltrials.gov:NCT00569985","description":"Lymphoma","metadata":null},{"id":"e12d411e073e415b80f7f59d1ad8c869","type":"TRIAL","name":"Gene-by-Stress Interactions in Intervention Studies Significance","canonical_id":"clinicaltrials.gov:NCT03011645","description":"Cardiovascular Diseases","metadata":null},{"id":"f823d4d49920464a89f39e8e725a3ee5","type":"TRIAL","name":"General Anesthesia Emergence Induced by Methylphenidate","canonical_id":"clinicaltrials.gov:NCT02327195","description":"Delayed Emergence From Anesthesia","metadata":null},{"id":"459b04112dfe4b09880c2a6fa9e17edc","type":"TRIAL","name":"Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control","canonical_id":"clinicaltrials.gov:NCT04195867","description":"Healthy Volunteers","metadata":null},{"id":"cba3354526eb496c9473e57b5ce7651d","type":"TRIAL","name":"Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02160665","description":"Plaque Psoriasis","metadata":null},{"id":"ff64a42eae8c4af98d4c7799a91f8ae1","type":"TRIAL","name":"Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02160678","description":"Acne Vulgaris","metadata":null},{"id":"1a31ee09f9e44af0ac7a62fb11d5960b","type":"DISEASE","name":"Genetic 46,XY disorder of sex development","canonical_id":"orphanet:325706","description":null,"metadata":null},{"id":"030da16ab06c4163b2a7ca486c07e02e","type":"TRIAL","name":"Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain","canonical_id":"clinicaltrials.gov:NCT00115752","description":"Pain","metadata":null},{"id":"debe3da3780648f187d8930e1302ebd6","type":"TRIAL","name":"Genetic Determinant of Blood Pressure Sensitivity to Salt Intake","canonical_id":"clinicaltrials.gov:NCT01706887","description":"Hypertension","metadata":null},{"id":"03c9e78a75594661877755e17c3509e2","type":"TRIAL","name":"Genetic Determinants of ACEI Prodrug Activation","canonical_id":"clinicaltrials.gov:NCT03051282","description":"Healthy Volunteers","metadata":null},{"id":"ad5b59a3cdeb4d2887abe070fe1d6008","type":"TRIAL","name":"Genetic Determinants of Hemodynamic Response to Esmolol","canonical_id":"clinicaltrials.gov:NCT01388036","description":"Decrease in Heart Rate Below Baseline Value","metadata":null},{"id":"ed30660372954e8c91fc97b2ed8bbd99","type":"TRIAL","name":"Genetic Determinants of Response to Beta Blockade","canonical_id":"clinicaltrials.gov:NCT00837902","description":"Healthy","metadata":null},{"id":"747679ee43a14e709668c6eca38aa8aa","type":"TRIAL","name":"Genetic Epidemiology of Responses to Antihypertensives","canonical_id":"clinicaltrials.gov:NCT00005520","description":"Cardiovascular Diseases; Heart Diseases; Hypertension","metadata":null},{"id":"1c1e7404a6ec4ab9accae49921a9c1a7","type":"TRIAL","name":"Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation","canonical_id":"clinicaltrials.gov:NCT00773201","description":"Healthy Volunteers","metadata":null},{"id":"77b87410475840ea83e6a55fa9e54a32","type":"TRIAL","name":"Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT00885534","description":"Melanoma; Skin Cancer","metadata":null},{"id":"2eafbe63e1804ef4b238076a7894a7f1","type":"DISEASE","name":"Genetic central nervous system malformation","canonical_id":"orphanet:183506","description":null,"metadata":null},{"id":"f3b9bd4160674e348334b459a6bbb095","type":"DISEASE","name":"Genetic hypopigmentation of the skin","canonical_id":"orphanet:183469","description":null,"metadata":null},{"id":"68df6667fd98436cafa3844bde539e6e","type":"TRIAL","name":"Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate","canonical_id":"clinicaltrials.gov:NCT05542147","description":"Type 2 Diabetes; Cardiovascular Diseases; Pharmacogenomic Drug Interaction","metadata":null},{"id":"419e3d29f5f349f992796549e56f2f3c","type":"TRIAL","name":"Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT01719367","description":"Atrial Fibrillation","metadata":null},{"id":"1356ea1aee8c4a95b526352efe3b4407","type":"TRIAL","name":"Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (\u00b1 Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05864742","description":"Mantle Cell Lymphoma Refractory","metadata":null},{"id":"98ae432edb2447dc846318aec293e829","type":"TRIAL","name":"Genetics of Hypertension Associated Treatments (GenHAT)","canonical_id":"clinicaltrials.gov:NCT00006294","description":"Cardiovascular Diseases; Heart Diseases; Hypertension; Coronary Disease; Myocardial Infarction","metadata":null},{"id":"349a6dab1e7c479685b6fc1a0157b042","type":"TRIAL","name":"Genetics of QT Prolongation With Antiarrhythmics","canonical_id":"clinicaltrials.gov:NCT02439658","description":"Long QT Syndrome; Drug Toxicity","metadata":null},{"id":"0a336c13c4a6493493ed12d1537bf488","type":"TRIAL","name":"Genicular Nerve Block Versus Its Combination With Infiltration Between Popliteal Artery and Capsule of Posterior Knee","canonical_id":"clinicaltrials.gov:NCT05672784","description":"Postoperative Pain","metadata":null},{"id":"8b007a715efc4453a8126362d1ff88ad","type":"TRIAL","name":"Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00376948","description":"Pancreatic Cancer","metadata":null},{"id":"8ba8d1210f4848739622c17c5142d425","type":"DISEASE","name":"Genital herpes simplex","canonical_id":"mesh:D006558","description":null,"metadata":null},{"id":"b5299767e339481e8bd657a1c870118c","type":"TRIAL","name":"Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy","canonical_id":"clinicaltrials.gov:NCT01579630","description":"NSCLC","metadata":null},{"id":"84baba31ee11488ba7d4d783d39bc10c","type":"PROTEIN","name":"Genome polyprotein","canonical_id":"uniprot:P27958","description":null,"metadata":null},{"id":"fd93c99fb7cf4321b295800ad8864ab1","type":"PROTEIN","name":"Genome polyprotein","canonical_id":"uniprot:B0B3C9","description":null,"metadata":null},{"id":"00d5650cf10b4b7fac03dda87289a744","type":"PROTEIN","name":"Genome polyprotein","canonical_id":"uniprot:Q91RS4","description":null,"metadata":null},{"id":"2c010523652c430f873d64fc6f1678b8","type":"TRIAL","name":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04812366","description":"Prostate Cancer","metadata":null},{"id":"7cff597eb9c74a5992b690ee46810c00","type":"TRIAL","name":"Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00918385","description":"Prostate Cancer","metadata":null},{"id":"d35b0159f81e4c4d8b947dbf5d051473","type":"TRIAL","name":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","canonical_id":"clinicaltrials.gov:NCT05332561","description":"Early-stage Breast Cancer","metadata":null},{"id":"a072bd96f4734c9e9f11bad7bb0c2ad7","type":"TRIAL","name":"Genomics Study in CML Patients With Ponatinib Treatment","canonical_id":"clinicaltrials.gov:NCT06945146","description":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","metadata":null},{"id":"c415f96f14c14df0a188bd81199fd8be","type":"TRIAL","name":"Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy","canonical_id":"clinicaltrials.gov:NCT02638428","description":"Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML","metadata":null},{"id":"93f6fa6d76d9477bad249ae209796720","type":"TRIAL","name":"Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","canonical_id":"clinicaltrials.gov:NCT07010393","description":"Thyroid Neoplasms","metadata":null},{"id":"35a8480d4b194518a2927112abd8003c","type":"TRIAL","name":"Genotype-guided Treatment in Newly Diagnosed PTCL","canonical_id":"clinicaltrials.gov:NCT05675813","description":"Peripheral T Cell Lymphoma","metadata":null},{"id":"6d8be0ee55964428a780f35ea5d6eeab","type":"TRIAL","name":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03900949","description":"Acute Myeloid Leukemia","metadata":null},{"id":"b02a6ba85c924f74bcec8f001836c84b","type":"TRIAL","name":"Geodon (Ziprasidone) for Posttraumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT00208208","description":"Posttraumatic Stress Disorder; Post-Traumatic Stress Disorder; PTSD","metadata":null},{"id":"8ab214c0771544ca97e3beb172aaabc9","type":"TRIAL","name":"Geodon for the Treatment of Refractory Social Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00215150","description":"Social Anxiety Disorder","metadata":null},{"id":"e7defb3bee994f7a894ad43047cbcce3","type":"TRIAL","name":"Geodon in Weight Loss Study for Bipolar Disorders","canonical_id":"clinicaltrials.gov:NCT00472641","description":"Bipolar Disorder","metadata":null},{"id":"2ef07d20d2e84578aa51a626cd2cb4de","type":"TRIAL","name":"Gepant treAtments: EffectIveNess and tolERability (GAINER)","canonical_id":"clinicaltrials.gov:NCT05903027","description":"Migraine; Migraine With Aura; Migraine Without Aura; Chronic Migraine","metadata":null},{"id":"fe010fcc133a49c0871b0567d219f82a","type":"TRIAL","name":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03226418","description":"Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia","metadata":null},{"id":"1aeea8e483364c52ba72d50601e321be","type":"TRIAL","name":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)","canonical_id":"clinicaltrials.gov:NCT00199069","description":"Adult Acute Lymphocytic Leukemia","metadata":null},{"id":"e5bdb78e9410468591d60207128ca15e","type":"TRIAL","name":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)","canonical_id":"clinicaltrials.gov:NCT00199056","description":"Adult Acute Lymphocytic Leukemia","metadata":null},{"id":"e7c7af3e143a430588707a3c26e2ecb6","type":"TRIAL","name":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","canonical_id":"clinicaltrials.gov:NCT00198991","description":"Adult Acute Lymphocytic Leukemia","metadata":null},{"id":"3bb8c885702c4919b847bab80a9c18d1","type":"TRIAL","name":"German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults","canonical_id":"clinicaltrials.gov:NCT00199017","description":"Lymphoma, Lymphoblastic","metadata":null},{"id":"53da9f7830114bbcb1d809a51751295d","type":"TRIAL","name":"German Preoperative Adriamycin Docetaxel Study","canonical_id":"clinicaltrials.gov:NCT00543829","description":"Breast Neoplasms","metadata":null},{"id":"86a75d2285ff4436adca4f1fe7020a5b","type":"DISEASE","name":"Gestational trophoblastic neoplasia","canonical_id":"mesh:D031901","description":null,"metadata":null},{"id":"71719741019947688757cfaa64c13d26","type":"TRIAL","name":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","canonical_id":"clinicaltrials.gov:NCT03798626","description":"Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma","metadata":null},{"id":"d8bac5cff7d946a09fc94fdee314ca45","type":"GO_TERM","name":"Gi/o-coupled serotonin receptor activity","canonical_id":"go:GO:0001586","description":"\"Combining with serotonin and transmitting the signal across the membrane by activation of the Gi/o subunit of an associated cytoplasmic heterotrimeric G protein complex. The Gi/o subunit subsequently inhibits adenylate cyclase and results in a decrease in cyclic AMP (cAMP) levels.\" [GOC:mah, PMID:18571247]","metadata":null},{"id":"55a274ecc4014e40856f264a23a66ac0","type":"TRIAL","name":"Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab","canonical_id":"clinicaltrials.gov:NCT03745586","description":"Giant Cell Arteritis","metadata":null},{"id":"9ae84977c8c34985b7571b4aadc9d075","type":"DISEASE","name":"Giant Lymph Node Hyperplasia","canonical_id":"efo:1001332","description":null,"metadata":null},{"id":"f44ce0a80c0a438e95e3c9ad896be1ae","type":"DRUG","name":"Giant cell arteritis","canonical_id":"mesh:D013700","description":null,"metadata":null},{"id":"e69443493db44d2dad2a21ba4f46aa6c","type":"DISEASE","name":"Giardiasis","canonical_id":"mesh:D005873","description":null,"metadata":null},{"id":"179646b7999a4a5092a065403bc9cff8","type":"TRIAL","name":"Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment","canonical_id":"clinicaltrials.gov:NCT06696183","description":"AML - Acute Myeloid Leukemia","metadata":null},{"id":"43e041a3aaf94b7aac608e41f221a8e2","type":"TRIAL","name":"Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03836209","description":"Acute Myeloid Leukemia","metadata":null},{"id":"61bf1c0df5104f67b9d1fec9394b7071","type":"DRUG","name":"Gimeracil","canonical_id":"mesh:C104201","description":null,"metadata":null},{"id":"4abfb145eb124dd081861a6f1a2574f3","type":"GO_TERM","name":"Gin4 complex","canonical_id":"go:GO:1990317","description":"\"A protein complex involved in septin ring formation during mitosis. In Saccharomyces cerevisiae it consists of BNI5, CDC3, CDC10, CDC11, CDC12, GIN4, NAP1 and SHS1. At least 2 GIN4 molecules are involved.\" [GOC:bhm, PMID:12058072]","metadata":null},{"id":"9ee6c89d6e5e4bb69da355cf06f2b653","type":"TRIAL","name":"Ginger Capsules for the Acute Treatment of Migraine Attacks","canonical_id":"clinicaltrials.gov:NCT02568644","description":"Migraine","metadata":null},{"id":"2d101c401f21420cb2e9d3a77b17b5f3","type":"DISEASE","name":"Gingivitis","canonical_id":"mesh:D005891","description":null,"metadata":null},{"id":"29c111fd23a84bc997036a9f4e70a0cd","type":"DISEASE","name":"Gingivitis, Necrotizing Ulcerative","canonical_id":"mesh:D005892","description":null,"metadata":null},{"id":"c28a036dadaf444c8f9bfcbb309714f5","type":"DISEASE","name":"Gitelman syndrome","canonical_id":"mondo:0009904","description":null,"metadata":null},{"id":"1a5f24a07df548a581263e4a102d063c","type":"TRIAL","name":"Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy","canonical_id":"clinicaltrials.gov:NCT03249337","description":"Fuchs' Endothelial Dystrophy","metadata":null},{"id":"a5c611c42c414fb882f1eba24e6726a4","type":"DISEASE","name":"Glanzmann's thrombasthenia","canonical_id":"mesh:D013915","description":null,"metadata":null},{"id":"1f93cc4f71fe48fe89c5436fb1accfee","type":"TRIAL","name":"Glasdegib Absolute Bioavailability Study","canonical_id":"clinicaltrials.gov:NCT03270878","description":"Healthy Volunteer Study","metadata":null},{"id":"1760806ff4d9466f8bbb2c9da074c164","type":"TRIAL","name":"Glasdegib Renal Impairment Study","canonical_id":"clinicaltrials.gov:NCT03596567","description":"Renal Impairment","metadata":null},{"id":"276c06b446ab47c6934ca65f286a8296","type":"TRIAL","name":"Glasdegib for Chronic Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT04111497","description":"Chronic Graft Versus Host Disease; Fasciitis","metadata":null},{"id":"7b30ff22ea194998a3464cdedec98b24","type":"TRIAL","name":"Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT03415867","description":"Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)","metadata":null},{"id":"9c205134351440b5a2865bc9658da8cf","type":"TRIAL","name":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT04655391","description":"Recurrent Acute Myeloid Leukemia","metadata":null},{"id":"ba020a34ef8f47a58fa39f634d4905d6","type":"DRUG","name":"Glatiramer acetate","canonical_id":"mesh:D000068717","description":null,"metadata":null},{"id":"3a36ba8a290d423d90c505d76f95e127","type":"DISEASE","name":"Glaucoma","canonical_id":"mesh:D005901","description":null,"metadata":null},{"id":"deb3d243b5a04f4e80a72d820795ca1a","type":"DISEASE","name":"Glaucoma, Open-Angle","canonical_id":"mesh:D005902","description":null,"metadata":null},{"id":"7263589a4f5c41bca764c57147e5ecc5","type":"GO_TERM","name":"Glc2Man9GlcNAc2 oligosaccharide glucosidase activity","canonical_id":"go:GO:0106407","description":"\"Catalysis of the reaction: Glc(2)Man(9)GlcNAc(2)-[protein] + H2O = GlcMan(9)GlcNAc(2)-[protein] + beta-D-glucopyranose.\" [EC:3.2.1.207, PMID:30389790]","metadata":null},{"id":"462edac091c44ab88968fd4ea43b5fca","type":"GO_TERM","name":"Glc3Man9GlcNAc2 oligosaccharide glucosidase activity","canonical_id":"go:GO:0004573","description":"\"Catalysis of the exohydrolysis of the non-reducing terminal glucose residue in the mannosyl-oligosaccharide Glc(3)Man(9)GlcNAc(2).\" [EC:3.2.1.106]","metadata":null},{"id":"afbc0b308c54443c96fa9cecfe441884","type":"GO_TERM","name":"GlcNAc(2)-PP-Dol mannosyltransferase activity","canonical_id":"go:GO:0120562","description":"\"Catalysis of the transfer of a mannosyl residue to GlcNAc(2)-PP-Dol bearing 0-8 mannoses during synthesis of the N-glycan precursor.\" [GOC:curators]","metadata":null},{"id":"ecdba05d51914e9a99ecb1abc7dc62d0","type":"TRIAL","name":"Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage","canonical_id":"clinicaltrials.gov:NCT03741530","description":"Intracerebral Hemorrhage","metadata":null},{"id":"eee54412f72a4f2580ea9d13f1578ef1","type":"TRIAL","name":"Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT03569540","description":"Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"38b6c668df1546558b4b6c220491ddc9","type":"DRUG","name":"Glibornuride","canonical_id":"mesh:C073323","description":null,"metadata":null},{"id":"365f4378564c451c9766231e05cbdc5e","type":"DRUG","name":"Gliclazide","canonical_id":"mesh:D005907","description":null,"metadata":null},{"id":"398087177d9b4c35b542dc2bfa3b08ef","type":"TRIAL","name":"GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial","canonical_id":"clinicaltrials.gov:NCT04796428","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"f1bc21f95c894ab8a1b7746d8d0f7642","type":"TRIAL","name":"Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination","canonical_id":"clinicaltrials.gov:NCT04470310","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"885a638a2bd24f19aab4c94c45a8096d","type":"DISEASE","name":"Glioblastoma","canonical_id":"doid:3068","description":null,"metadata":null},{"id":"91a966919462407d946075ef8d912336","type":"DISEASE","name":"Glioblastoma multiforme","canonical_id":"mesh:D005909","description":null,"metadata":null},{"id":"4721a997acdf453282ec955160627f60","type":"DISEASE","name":"Glioma, malignant","canonical_id":"mesh:D005910","description":null,"metadata":null},{"id":"cc9947acc6c94c2499864dc0f5cb7bbb","type":"DRUG","name":"Glisoxepide","canonical_id":"mesh:C100171","description":null,"metadata":null},{"id":"acb60b479e2a43628166b7008db03648","type":"TRIAL","name":"Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)","canonical_id":"clinicaltrials.gov:NCT04950127","description":"Pruritus","metadata":null},{"id":"d36e99a532984c2c8a732399eeaa55c3","type":"TRIAL","name":"Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.","canonical_id":"clinicaltrials.gov:NCT01035229","description":"Carcinoma","metadata":null},{"id":"4bf855416a254c8991f4140ac6a4ec68","type":"TRIAL","name":"Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain","canonical_id":"clinicaltrials.gov:NCT02143713","description":"Endometriosis","metadata":null},{"id":"9e935f05d8d7484ebfbc93b4f145c5e4","type":"TRIAL","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy","canonical_id":"clinicaltrials.gov:NCT07718737","description":"NSCLC (Advanced Non-small Cell Lung Cancer)","metadata":null},{"id":"798816992a3e4398890f6e1e409d8747","type":"TRIAL","name":"Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07231250","description":"DLBCL - Diffuse Large B Cell Lymphoma; Chemo-free Therapy; Bispecific Antibody","metadata":null},{"id":"24767a50dcec41339654e86f9f8f18ca","type":"DISEASE","name":"Glossopharyngeal neuralgia","canonical_id":"mesh:D020435","description":null,"metadata":null},{"id":"e994cacf00d147e0b34d8c2c4a2d3310","type":"DRUG","name":"Glucagon","canonical_id":"mesh:D005934","description":null,"metadata":null},{"id":"d61e4f88aa5041dca96fbc542af9a8fd","type":"TRIAL","name":"Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses","canonical_id":"clinicaltrials.gov:NCT03490942","description":"Hypoglycemia Unawareness; Diabetes Mellitus, Type 1","metadata":null},{"id":"0aa0cc90a290423d99835488b92845d5","type":"TRIAL","name":"Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition","canonical_id":"clinicaltrials.gov:NCT03533179","description":"Drug Overdose; Overdose of Beta-adrenergic Blocking Drug","metadata":null},{"id":"ddb7b64dbe46498384d18256e164382c","type":"TRIAL","name":"Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)","canonical_id":"clinicaltrials.gov:NCT07537686","description":"Environmental Enteric Dysfunction","metadata":null},{"id":"d0d1d09e16ec440bb3fcc4805e501ae7","type":"TRIAL","name":"Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids","canonical_id":"clinicaltrials.gov:NCT03442972","description":"Hyperlipidemias","metadata":null},{"id":"4362c12a605c498ea41e4db2344d6f2f","type":"TRIAL","name":"Glucocorticoid Receptor Antagonism in Subclinical Cushings","canonical_id":"clinicaltrials.gov:NCT00721201","description":"Subclinical Cushing's","metadata":null},{"id":"0661feacda1145449f1f1673e743558a","type":"TRIAL","name":"Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)","canonical_id":"clinicaltrials.gov:NCT00032890","description":"Osteoarthritis","metadata":null},{"id":"87b4308b867448969e0c15d5ac382ff2","type":"DRUG","name":"Glucose","canonical_id":"mesh:D005947","description":null,"metadata":null},{"id":"4489018d5d4c4319b2d7e9faa11449bd","type":"TRIAL","name":"Glucose Absorption and Gut Hormone Secretion After Gastric Bypass","canonical_id":"clinicaltrials.gov:NCT03426956","description":"Overweight","metadata":null},{"id":"a8c55cc7dd804a37bacabe19e1a7a247","type":"TRIAL","name":"Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone","canonical_id":"clinicaltrials.gov:NCT00965406","description":"Acute Coronary Syndrome","metadata":null},{"id":"8b4dd0b09aa84830ad54eac84177b38f","type":"TRIAL","name":"Glucose Variability With DPP-4 Inhibition","canonical_id":"clinicaltrials.gov:NCT01751321","description":"Type 2 Diabetes","metadata":null},{"id":"0effded6fcdb4ccfab751ca29e61b394","type":"TRIAL","name":"Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","canonical_id":"clinicaltrials.gov:NCT04977674","description":"Depressive Disorder, Treatment-Resistant","metadata":null},{"id":"9bbe33bd9dcb4a1ab4797cfd87030fd0","type":"PROTEIN","name":"Glutamate receptor 1","canonical_id":"uniprot:P42261","description":null,"metadata":null},{"id":"fd6eec8710ec418eaa84a71a8860e8f2","type":"PROTEIN","name":"Glutamate receptor ionotropic, NMDA 2B","canonical_id":"uniprot:Q13224","description":null,"metadata":null},{"id":"98d4645351d44d2e9687bea95f94f1f1","type":"PROTEIN","name":"Glutamate receptor ionotropic, NMDA 2D","canonical_id":"uniprot:O15399","description":null,"metadata":null},{"id":"e1d99efee5a84d1f804b92fecd390a7e","type":"TRIAL","name":"Glutamate, Brain Connectivity and Duration of Untreated Psychosis","canonical_id":"clinicaltrials.gov:NCT02034253","description":"Schizophrenia; Psychosis; Schizoaffective Disorder","metadata":null},{"id":"9e8c8639e85a44ba9d809662d48422ff","type":"TRIAL","name":"Glutamatergic Modulation of Cocaine-related Deficits","canonical_id":"clinicaltrials.gov:NCT01790490","description":"Cocaine Dependence","metadata":null},{"id":"d89d6e0e3b3045f2b833b2d2001db62e","type":"TRIAL","name":"Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence","canonical_id":"clinicaltrials.gov:NCT02437344","description":"Opioid Dependence","metadata":null},{"id":"30f45ca7ccc149f08e953c97c195342b","type":"TRIAL","name":"Glutaminergic Agents for Cocaine Abuse - 5","canonical_id":"clinicaltrials.gov:NCT00000280","description":"Cocaine-Related Disorders","metadata":null},{"id":"8c6e29f7c1cd41c2bdbe057bf809f81c","type":"TRIAL","name":"Glutide for Ending Methamphetamine","canonical_id":"clinicaltrials.gov:NCT07204249","description":"Methamphetamine-dependence","metadata":null},{"id":"45047d56c4974d68814d13d6a16a32e1","type":"GO_TERM","name":"Gly-tRNA(Ala) deacylase activity","canonical_id":"go:GO:0106026","description":"\"Catalysis of the reaction: glycyl-tRNA(Ala) + H2O = tRNA(Ala) + glycine + H+.\" [PMID:28362257, RHEA:53744]","metadata":null},{"id":"148297fc261f4832bd073a6580f977e1","type":"TRIAL","name":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","canonical_id":"clinicaltrials.gov:NCT05688332","description":"Diabetes Mellitus Type 2 Without Complication","metadata":null},{"id":"c7d2afea13be4a23a879f707e4e27119","type":"TRIAL","name":"Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","canonical_id":"clinicaltrials.gov:NCT06862739","description":"Diabetes Mellitus; Type 2 DM","metadata":null},{"id":"c3466b696a9245e2959ba898bec2a3e6","type":"TRIAL","name":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","canonical_id":"clinicaltrials.gov:NCT00032487","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"335b584e142d42d2ad567106f8bcdab3","type":"TRIAL","name":"Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride","canonical_id":"clinicaltrials.gov:NCT02007278","description":"Type 2 Diabetes; Hypoglycemia","metadata":null},{"id":"2d19ad064d7043418570e9cd378ae081","type":"DRUG","name":"Glycine","canonical_id":"mesh:D005998","description":null,"metadata":null},{"id":"42cb7ce9db2d4b6c80b266f0a6d9cbc2","type":"TRIAL","name":"Glycine and D-Cycloserine in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00000372","description":"Schizophrenia","metadata":null},{"id":"d2e55b2c95e44cac8a13c825d9084a99","type":"DRUG","name":"Glycopyrronium bromide","canonical_id":"mesh:D006024","description":null,"metadata":null},{"id":"428f13c6d9d245cb94908ed4e5742460","type":"TRIAL","name":"Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)","canonical_id":"clinicaltrials.gov:NCT00194649","description":"Contraception","metadata":null},{"id":"b2d9446b386e48b8844aaeb8da4e6f02","type":"DISEASE","name":"Glycosuria","canonical_id":"hp:0003076","description":null,"metadata":null},{"id":"078d9043697743a891c55b32a25a3ff7","type":"DRUG","name":"Glymidine","canonical_id":"mesh:C073263","description":null,"metadata":null},{"id":"5aa8844ef95a49728ca14aa7a9a08a0f","type":"TRIAL","name":"GnRH Agonist and Antagonists in an Oocyte Donation Program","canonical_id":"clinicaltrials.gov:NCT00505817","description":"Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality","metadata":null},{"id":"b78fde97956c4b38a33cf72f2345875b","type":"TRIAL","name":"GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles","canonical_id":"clinicaltrials.gov:NCT02262416","description":"Infertility","metadata":null},{"id":"9f39985106994fa8883c0e96f31129d3","type":"TRIAL","name":"GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.","canonical_id":"clinicaltrials.gov:NCT01269125","description":"Endometriosis; Infertility","metadata":null},{"id":"aeb9bdc2eaf944f788df61632b74f354","type":"TRIAL","name":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","canonical_id":"clinicaltrials.gov:NCT01984424","description":"Hyperlipidemia","metadata":null},{"id":"e353077f6a4e4b27ba0b211e0c7934cb","type":"TRIAL","name":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","canonical_id":"clinicaltrials.gov:NCT02634580","description":"Hypercholesterolemia","metadata":null},{"id":"1e60a739a368497f9599d922c5b70227","type":"TRIAL","name":"Goal Oriented Strategy to Preserve Ejection Fraction Trial","canonical_id":"clinicaltrials.gov:NCT03236818","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"39b14191bae648e6a6f0d746600b6e27","type":"DISEASE","name":"Goiter","canonical_id":"mesh:D006042","description":null,"metadata":null},{"id":"1443a3d5eb004bc786fe5796625065a8","type":"GO_TERM","name":"Golgi apparatus","canonical_id":"go:GO:0005794","description":"\"A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways.\" [ISBN:0198506732, PMID:9695800]","metadata":null},{"id":"46dd3fc88658467f91eef51d04680b94","type":"GO_TERM","name":"Golgi apparatus N-glycan diversification","canonical_id":"go:GO:0016258","description":"\"The generation, in the Golgi apparatus, of side chain diversity from paucimannose mannose Man5GlcNAc2-Asn or Man3GlcNAc2-Asn N-glycans by specific glycosyltransferases and glycosidases.\" [PMID:30858582, PMID:35536965]","metadata":null},{"id":"8c73d8e1ffde41b59ae6064b6fd684ec","type":"GO_TERM","name":"Golgi apparatus N-glycan mannose trimming","canonical_id":"go:GO:1904381","description":"\"The trimming, in the Golgi apparatus, of the protein newly attached high-mannose-type N-glycans by mannosidases to produce paucimannose-type N-glycans.\" [PMID:10915796, PMID:30858582, PMID:35536965]","metadata":null},{"id":"27b47ed4f1d64202a4431f7deb4d3ab0","type":"GO_TERM","name":"Golgi apparatus subcompartment","canonical_id":"go:GO:0098791","description":"\"A compartment that consists of a lumen and an enclosing membrane, and is part of the Golgi apparatus.\" [GOC:dos]","metadata":null},{"id":"fca33bfe8ab443eebd286b34e56764c3","type":"GO_TERM","name":"Golgi calcium ion homeostasis","canonical_id":"go:GO:0032468","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions within the Golgi apparatus of a cell or between the Golgi and its surroundings.\" [GOC:mah]","metadata":null},{"id":"e52cf08cfe674c499381eb2ebee9469c","type":"GO_TERM","name":"Golgi calcium ion transmembrane transport","canonical_id":"go:GO:0061856","description":"\"A process in which a calcium ion is transported from one side of a Golgi membrane to the other by means of some agent such as a transporter or pore.\" [PMID:21811607]","metadata":null},{"id":"b8c3700c60744f4498e7ccbdb328e6ca","type":"GO_TERM","name":"Golgi calcium ion transport","canonical_id":"go:GO:0032472","description":"\"The directed movement of calcium ions (Ca2+) into, out of or within the Golgi apparatus.\" [GOC:mah]","metadata":null},{"id":"d58c1245df82478a96c4d15846e74b7b","type":"GO_TERM","name":"Golgi cell precursor proliferation","canonical_id":"go:GO:0021926","description":"\"The multiplication or reproduction of neuroblasts that will give rise to Golgi cells. A Golgi cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"32d1abae69854dd589efc98a9bf1d6dd","type":"GO_TERM","name":"Golgi cis cisterna","canonical_id":"go:GO:0000137","description":"\"The Golgi cisterna closest to the endoplasmic reticulum; the first processing compartment through which proteins pass after export from the ER.\" [ISBN:0815316194]","metadata":null},{"id":"6d34e44d07604a4695109a17ba27f3cf","type":"GO_TERM","name":"Golgi cis cisterna membrane","canonical_id":"go:GO:1990674","description":"\"The lipid bilayer surrounding any of the thin, flattened compartments that form the cis portion of the Golgi complex.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"54341565bffa40899d0f0f5d83606dc0","type":"GO_TERM","name":"Golgi cisterna","canonical_id":"go:GO:0031985","description":"\"Any of the thin, flattened membrane-bounded compartments that form the central portion of the Golgi complex.\" [GOC:mah]","metadata":null},{"id":"cca1af340a2943c891e7939e92adb8c8","type":"GO_TERM","name":"Golgi cisterna membrane","canonical_id":"go:GO:0032580","description":"\"The lipid bilayer surrounding any of the thin, flattened compartments that form the central portion of the Golgi complex.\" [GOC:ecd, GOC:mah]","metadata":null},{"id":"d83bce67afa84770963a6dbf1feae90a","type":"GO_TERM","name":"Golgi disassembly","canonical_id":"go:GO:0090166","description":"\"A cellular process that results in the breakdown of a Golgi apparatus that contributes to Golgi inheritance.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"c5ba09423c3242dfb4a2a6c4737a3a96","type":"GO_TERM","name":"Golgi distribution to daughter cells","canonical_id":"go:GO:0090167","description":"\"Any process in which disassembled Golgi vesicles are localized into daughter cells upon cell division.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"554d1bad8798400dabd5f926c1c91b61","type":"GO_TERM","name":"Golgi inheritance","canonical_id":"go:GO:0048313","description":"\"The partitioning of Golgi apparatus between daughter cells at cell division.\" [GOC:jid, PMID:12851069]","metadata":null},{"id":"cb58600758ed46e596b2622f2b52f6cb","type":"GO_TERM","name":"Golgi localization","canonical_id":"go:GO:0051645","description":"\"Any process in which the Golgi is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"a0d4ba403b394de1a7a8e1f1b52c8779","type":"GO_TERM","name":"Golgi lumen","canonical_id":"go:GO:0005796","description":"\"The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks.\" [GOC:mah]","metadata":null},{"id":"4e0d8ffb184b4adeb6f7ab2d1fd96ec7","type":"GO_TERM","name":"Golgi lumen acidification","canonical_id":"go:GO:0061795","description":"\"Any process that reduces the pH of the Golgi lumen, corresponding to an increase in hydrogen ion concentration.\" [GOC:dph, PMID:23447592]","metadata":null},{"id":"a7a60a50ba9c4e998233b4d96c93d357","type":"GO_TERM","name":"Golgi medial cisterna","canonical_id":"go:GO:0005797","description":"\"The middle Golgi cisterna (or cisternae).\" [ISBN:0815316194]","metadata":null},{"id":"0a04cd128c614c1b97f63f5ecad79085","type":"GO_TERM","name":"Golgi medial cisterna membrane","canonical_id":"go:GO:1990675","description":"\"The lipid bilayer surrounding any of the thin, flattened compartments that form the medial portion of the Golgi complex.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"a8ac822167b640018a87f72b6e7799c2","type":"GO_TERM","name":"Golgi medial cisterna-derived vesicle fusion with Golgi cis cisterna membrane","canonical_id":"go:GO:1990690","description":"\"The joining of the lipid bilayer membrane around a Golgi medial cisterna-derived vesicle to the lipid bilayer membrane around the Golgi cis cisterna. Such vesicles include COPI-coated transport vesicles involved in retrograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"9112bc0e48d746469d46f1b9a2cfadef","type":"GO_TERM","name":"Golgi membrane","canonical_id":"go:GO:0000139","description":"\"The lipid bilayer surrounding any of the compartments of the Golgi apparatus.\" [GOC:mah]","metadata":null},{"id":"0c66180efa544e3a91c806ab19ea1fba","type":"GO_TERM","name":"Golgi membrane coat protein complex assembly","canonical_id":"go:GO:0048197","description":"\"The aggregation, arrangement and bonding together of priming complexes to form a coat on a Golgi membrane. Priming complexes associate laterally and additional coat proteins are recruited from the cytosol to the forming coat. Cargo proteins diffuse into the budding site and become trapped by their interactions with the coat.\" [GOC:jid, GOC:mah, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"9a2c1467c5a14ee3a0a9f0e88d1b16ce","type":"GO_TERM","name":"Golgi membrane fusion","canonical_id":"go:GO:0036504","description":"\"The joining of two lipid bilayers that surround the Golgi apparatus to form a single Golgi membrane.\" [GOC:bf, GOC:PARL, PMID:12473691]","metadata":null},{"id":"826cafdc21db4f84a1899493bc3f868c","type":"GO_TERM","name":"Golgi membrane priming complex assembly","canonical_id":"go:GO:0048195","description":"\"The aggregation, arrangement and bonding together of a set of components to form a membrane priming complex. An incoming coat component recognizes both GTPase and a membrane protein to form the priming complex.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"84b8061709944fb69f8cb63446d889da","type":"GO_TERM","name":"Golgi organization","canonical_id":"go:GO:0007030","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the Golgi apparatus.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"3d40c212f77b4afc8cc71b10a36c9555","type":"GO_TERM","name":"Golgi reassembly","canonical_id":"go:GO:0090168","description":"\"The reformation of the Golgi following its breakdown and partitioning contributing to Golgi inheritance.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"59e253ab9b2e47b794645b2867b1250f","type":"GO_TERM","name":"Golgi ribbon formation","canonical_id":"go:GO:0090161","description":"\"The formation of a continuous ribbon of interconnected Golgi stacks of flat cisternae.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"7ecbd29de3f246ea992478d3afe44bfb","type":"GO_TERM","name":"Golgi stack","canonical_id":"go:GO:0005795","description":"\"The set of thin, flattened membrane-bounded compartments, called cisternae, that form the central portion of the Golgi complex. The stack usually comprises cis, medial, and trans cisternae; the cis- and trans-Golgi networks are not considered part of the stack.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"f3421787642e4721b118e97950cd1070","type":"GO_TERM","name":"Golgi stack lumen","canonical_id":"go:GO:0034469","description":"\"The volume enclosed by any of the membranes of the thin, flattened cisternae that form the central portion of the Golgi complex.\" [GOC:mah]","metadata":null},{"id":"5684d2168e4741acae91395d1517678c","type":"GO_TERM","name":"Golgi to ER transport vesicle membrane","canonical_id":"go:GO:0012508","description":"\"The lipid bilayer surrounding a vesicle transporting substances from the Golgi to the ER.\" [GOC:ai]","metadata":null},{"id":"d78447dd21ba4b0e9f7dce3535485317","type":"GO_TERM","name":"Golgi to endosome transport","canonical_id":"go:GO:0006895","description":"\"The directed movement of substances from the Golgi to early sorting endosomes. Clathrin vesicles transport substances from the trans-Golgi to endosomes.\" [GOC:jl, ISBN:0716731363, PMID:10873832]","metadata":null},{"id":"68ae3c562b604e0ea0b0ddf036b78d7a","type":"GO_TERM","name":"Golgi to lysosome transport","canonical_id":"go:GO:0090160","description":"\"The directed movement of substances from the Golgi to lysosomes.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"4d6b2fa2f7da447c8399f941e8117c65","type":"GO_TERM","name":"Golgi to plasma membrane protein transport","canonical_id":"go:GO:0043001","description":"\"The directed movement of proteins from the Golgi to the plasma membrane in transport vesicles that move from the trans-Golgi network to the plasma membrane. Golgi to plasma membrane transport precedes exocytosis.\" [ISBN:0716731363]","metadata":null},{"id":"f40a4a202e6c4c909c1d485f99739c9b","type":"GO_TERM","name":"Golgi to plasma membrane transport","canonical_id":"go:GO:0006893","description":"\"The directed movement of substances from the Golgi to the plasma membrane in transport vesicles that move from the trans-Golgi network to the plasma membrane. Golgi to plasma membrane transport precedes exocytosis.\" [ISBN:0716731363]","metadata":null},{"id":"dd2fb82f20c74f8fa61a62b6fa0a1263","type":"GO_TERM","name":"Golgi to plasma membrane transport vesicle","canonical_id":"go:GO:0070319","description":"\"A transport vesicle that mediates transport from the Golgi to the plasma membrane, and fuses with the plasma membrane to release various cargo molecules, such as proteins or hormones, by exocytosis.\" [GOC:kad, GOC:mah]","metadata":null},{"id":"9547dcc944e6480fb7eb693e935250ad","type":"GO_TERM","name":"Golgi to secretory granule transport","canonical_id":"go:GO:0055107","description":"\"The directed movement of proteins from the Golgi to a secretory granule. The secretory granule is a membrane-bounded particle, usually protein, formed in the granular endoplasmic reticulum and the Golgi complex.\" [GOC:curators]","metadata":null},{"id":"d95a16f070fe4f9ab5e28890a9c8a7ea","type":"GO_TERM","name":"Golgi to vacuole transport","canonical_id":"go:GO:0006896","description":"\"The directed movement of substances from the Golgi to the vacuole.\" [GOC:ai]","metadata":null},{"id":"9eb35df5ee5a41fc8ac141cc766b34ca","type":"GO_TERM","name":"Golgi trans cisterna","canonical_id":"go:GO:0000138","description":"\"The Golgi cisterna farthest from the endoplasmic reticulum; the final processing compartment through which proteins pass before exiting the Golgi apparatus; the compartment in which N-linked protein glycosylation is completed.\" [ISBN:0815316194]","metadata":null},{"id":"bafcf8ba7a3540c982779920a52ebf7c","type":"GO_TERM","name":"Golgi trans cisterna membrane","canonical_id":"go:GO:1990676","description":"\"The lipid bilayer surrounding any of the thin, flattened compartments that form the trans portion of the Golgi complex.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"4021c5696ad641669ea4a4f88cc1d911","type":"GO_TERM","name":"Golgi transport vesicle coating","canonical_id":"go:GO:0048200","description":"\"The addition of specific coat proteins to Golgi membranes during the formation of transport vesicles.\" [GOC:jid, GOC:mah, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"a7ff1ef0bb8b4b2b91a806c4e51eab0d","type":"GO_TERM","name":"Golgi vesicle bud deformation and release","canonical_id":"go:GO:0048198","description":"\"The process in which cytosolic coat proteins fit together in a basketlike convex framework to form a coated deformed region on the cytoplasmic surface of the membrane. The deformed region forms into a complete vesicle and is released.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"be1c437b23774bc381d58ed137b96733","type":"GO_TERM","name":"Golgi vesicle budding","canonical_id":"go:GO:0048194","description":"\"The evagination of the Golgi membrane, resulting in formation of a vesicle.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"c96124882ac74467943768a9b4fbf33e","type":"GO_TERM","name":"Golgi vesicle fusion to target membrane","canonical_id":"go:GO:0048210","description":"\"The joining of the lipid bilayer membrane around a Golgi transport vesicle to the target lipid bilayer membrane.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"630b5f8434a244d6b305b2805267d3f2","type":"GO_TERM","name":"Golgi vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane","canonical_id":"go:GO:1990688","description":"\"The joining of the lipid bilayer membrane around a Golgi vesicle to the lipid bilayer membrane of the ERGIC. Such vesicles include COPI-coated transport vesicles involved in retrograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"7911f61dfb854a89870ddc1f0bd13bb1","type":"GO_TERM","name":"Golgi vesicle transport","canonical_id":"go:GO:0048193","description":"\"The directed movement of substances into, out of or within the Golgi apparatus, mediated by vesicles.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"6c3742d75f7b4ff9b814a96db8e52b45","type":"GO_TERM","name":"Golgi vesicle uncoating","canonical_id":"go:GO:0048212","description":"\"The process in which Golgi vesicle coat proteins are depolymerized, and released for reuse.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"01d3b42144084d699befc0722cb2f2f8","type":"GO_TERM","name":"Golgi-associated vesicle","canonical_id":"go:GO:0005798","description":"\"Any vesicle associated with the Golgi complex and involved in mediating transport within the Golgi or between the Golgi and other parts of the cell.\" [GOC:mah]","metadata":null},{"id":"66e276d176b04a529cc06d7b166f54ab","type":"GO_TERM","name":"Golgi-associated vesicle lumen","canonical_id":"go:GO:0070931","description":"\"The volume enclosed by the membrane of a Golgi-associated vesicle.\" [GOC:mah]","metadata":null},{"id":"8616a57339f546b69bf75f0072228ae9","type":"GO_TERM","name":"Golgi-associated vesicle membrane","canonical_id":"go:GO:0030660","description":"\"The lipid bilayer surrounding a vesicle associated with the Golgi apparatus.\" [GOC:mah]","metadata":null},{"id":"cc2032cb35a440e0ba07fd6e22373f7d","type":"DRUG","name":"Golimumab","canonical_id":"mesh:C529000","description":null,"metadata":null},{"id":"e7982f268e01405f88f62788e2624f09","type":"TRIAL","name":"Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)","canonical_id":"clinicaltrials.gov:NCT03253796","description":"Spondyloarthritis","metadata":null},{"id":"5d3fc7109d4841d591cf8237e7eb3e09","type":"TRIAL","name":"Golimumab Safety and Surveillance Program Using the Ingenix NHI Database","canonical_id":"clinicaltrials.gov:NCT01081717","description":"Rheumatoid Arthritis; Arthritis, Psoriatic; Ankylosing Spondylitis","metadata":null},{"id":"cafb82b8a2f24810ba0ffcc8943eb93f","type":"TRIAL","name":"Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)","canonical_id":"clinicaltrials.gov:NCT02092285","description":"Ulcerative Colitis","metadata":null},{"id":"30ade125bad9422b934b5445c510fb5a","type":"TRIAL","name":"Golimumab for Adherence in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03729349","description":"Arthritis, Rheumatoid","metadata":null},{"id":"e88994cb99de4df4a9bb0ad5e04c9f0f","type":"TRIAL","name":"Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome","canonical_id":"clinicaltrials.gov:NCT02784457","description":"Assisted Reproduction","metadata":null},{"id":"09e5fe5d3bd244fba73bebc999c9010e","type":"DRUG","name":"Gonadotropin-Releasing Hormone","canonical_id":"mesh:D007987","description":null,"metadata":null},{"id":"4f599ce303bb48c1ab3a462029a79c05","type":"TRIAL","name":"Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00667758","description":"Rheumatoid Arthritis","metadata":null},{"id":"9176dccc2c56477a976a53b492bb7b33","type":"TRIAL","name":"Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02483767","description":"Breast Cancer","metadata":null},{"id":"3fc35ce4aab34c99b9fc8b83b92e9778","type":"TRIAL","name":"Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study","canonical_id":"clinicaltrials.gov:NCT00571870","description":"Infertility","metadata":null},{"id":"e3f9ab484a234ff8aed8259ffd00e150","type":"DISEASE","name":"Gonorrhea","canonical_id":"mesh:D006069","description":null,"metadata":null},{"id":"745cc2adf9b643238007c7f367bdbd21","type":"DISEASE","name":"Gorham-Stout disease","canonical_id":"mondo:0007414","description":null,"metadata":null},{"id":"1d49ddd71c76488b991d3405b054afff","type":"DRUG","name":"Goserelin","canonical_id":"mesh:D017273","description":null,"metadata":null},{"id":"26d323ba133f4218a3c6e915c94506fe","type":"TRIAL","name":"Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00767286","description":"Prostate Cancer","metadata":null},{"id":"20ce4f58f57d43fe893cecc292fe3061","type":"DISEASE","name":"Gout","canonical_id":"mesh:D006073","description":null,"metadata":null},{"id":"fe3bd17b16224c928a47b1a7333da343","type":"GO_TERM","name":"Gq/11-coupled serotonin receptor activity","canonical_id":"go:GO:0001587","description":"\"Combining with serotonin and transmitting the signal across the membrane by activation of the Gq/11 subunit of an associated cytoplasmic heterotrimeric G protein complex. The Gq/11 subunit subsequently activates phospholipase C and results in an increase in inositol triphosphate (IP3) levels.\" [GOC:bf, GOC:mah, PMID:18571247, PMID:18703043]","metadata":null},{"id":"390cb158823a44c89c2ba946fcaa1efe","type":"TRIAL","name":"Gradual Vs. Rapid Buprenorphine Detoxification - 2","canonical_id":"clinicaltrials.gov:NCT00000220","description":"Opioid-Related Disorders","metadata":null},{"id":"8d04847b4b0b418ba56a359f1eb7ecef","type":"GO_TERM","name":"Gram-negative-bacterium-type cell outer membrane assembly","canonical_id":"go:GO:0043165","description":"\"The assembly of an outer membrane of the type formed in Gram-negative bacteria. This membrane is enriched in polysaccharide and protein, and the outer leaflet of the membrane contains specific lipopolysaccharide structures.\" [GOC:jl, ISBN:0135712254]","metadata":null},{"id":"cfe4a37ac5924b73960cb0d6ff06e891","type":"GO_TERM","name":"Gram-negative-bacterium-type cell wall","canonical_id":"go:GO:0009276","description":"\"The peptidoglycan layer of the Gram-negative cell envelope. In Gram-negative cells the peptidoglycan is relatively thin (1-2nm) and is linked to the outer membrane by lipoproteins. In Gram-negative cells the peptidoglycan is too thin to retain the primary stain in the Gram staining procedure and therefore cells appear red after Gram stain.\" [GOC:mlg, ISBN:0815108893]","metadata":null},{"id":"c030727acc464ee794af3e89c3a34c23","type":"GO_TERM","name":"Gram-negative-bacterium-type cell wall biogenesis","canonical_id":"go:GO:0043164","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cell wall of the type found in Gram-negative bacteria. The cell wall is the rigid or semi-rigid envelope lying outside the cell membrane.\" [GOC:jl, GOC:mtg_sensu, ISBN:0815108893]","metadata":null},{"id":"573629b5456545f58757557767f9b9fe","type":"GO_TERM","name":"Gram-positive-bacterium-type cell wall","canonical_id":"go:GO:0009275","description":"\"A layer of peptidoglycan found outside of the cytoplasmic membrane. The peptidoglycan is relatively thick (20-80nm) and retains the primary stain of the Gram procedure, thus cells appear blue after Gram stain. The cell walls often contain teichoic acids (acidic anionic polysaccharides) bound to the peptidoglycan. Examples of this component are found in Gram-positive bacteria.\" [GOC:mlg, ISBN:0815108893]","metadata":null},{"id":"ae6fbd7e55eb4379b22058c084cf8bfb","type":"DRUG","name":"Gramicidin","canonical_id":"mesh:D006096","description":null,"metadata":null},{"id":"ed2bd150dc214ef880f1bd9f9b10e160","type":"TRIAL","name":"Granisetron 1 mg Tablets, Non-fasting","canonical_id":"clinicaltrials.gov:NCT00834522","description":"Healthy","metadata":null},{"id":"ed7a0056f5484719a12536387ace5c2e","type":"TRIAL","name":"Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT04085393","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"80a78d8e13da47dfbbbbde74ae6c0b48","type":"TRIAL","name":"Granisetron Transdermal Patch for Prophylaxis of Delayed CINV","canonical_id":"clinicaltrials.gov:NCT04912271","description":"Chemotherapy-induced Nausea and Vomiting (CINV)","metadata":null},{"id":"3b1e9c5301a2488e8f570d33b13481d1","type":"TRIAL","name":"Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents","canonical_id":"clinicaltrials.gov:NCT04472143","description":"Chemotherapy-induced Nausea and Vomiting (CINV)","metadata":null},{"id":"fdd1974f71ec4b79bce9eb5d1ec02d53","type":"TRIAL","name":"Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group","canonical_id":"clinicaltrials.gov:NCT06175806","description":"Nausea and Vomiting in Pediatric Age Group","metadata":null},{"id":"a5fc36bd541e45619caaa5b36a5fc678","type":"TRIAL","name":"Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc","canonical_id":"clinicaltrials.gov:NCT01352130","description":"Prolonged QTc Interval","metadata":null},{"id":"e9e9e90fb627457fb607c50c39194b20","type":"TRIAL","name":"Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections","canonical_id":"clinicaltrials.gov:NCT06513806","description":"Anesthesia; Adverse Effect, Spinal and Epidural","metadata":null},{"id":"4eeef12969a34f80b59de79160931a3a","type":"TRIAL","name":"Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT04570592","description":"PONV","metadata":null},{"id":"8a24942115324035a8c366dac2e60513","type":"TRIAL","name":"Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT01275664","description":"Nausea and Vomiting; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA P\u2026","metadata":null},{"id":"3b8e35f6c44941e3a87df465b70d54d8","type":"TRIAL","name":"Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT04899817","description":"Nausea and Vomiting, Postoperative","metadata":null},{"id":"cdad1f7c548f4d9c993996b60bcf857c","type":"DISEASE","name":"Granuloma Inguinale","canonical_id":"mesh:D006100","description":null,"metadata":null},{"id":"4b6de9f4437b4cedaa87ee4720db3bd9","type":"DISEASE","name":"Granuloma annulare","canonical_id":"mesh:D016460","description":null,"metadata":null},{"id":"288fb770bdd04948a0c11d0d26623c07","type":"DISEASE","name":"Graves disease","canonical_id":"mondo:0005364","description":null,"metadata":null},{"id":"999adf60f443494ab88ac87a8537f94e","type":"DISEASE","name":"Graves ophthalmopathy","canonical_id":"efo:1001466","description":null,"metadata":null},{"id":"bb079d753c024f46977742631e64ac3d","type":"TRIAL","name":"Graves' Disease Remission Study: MycoMeth Combo","canonical_id":"clinicaltrials.gov:NCT06068179","description":"Graves' Disease","metadata":null},{"id":"3a22bac0e3fb4d7599d1d4a2a3d6290c","type":"DISEASE","name":"Graves' disease","canonical_id":"mesh:D006111","description":null,"metadata":null},{"id":"b4b0c261519d4c89b0db9c14f21574ed","type":"TRIAL","name":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","canonical_id":"clinicaltrials.gov:NCT01440595","description":"Hepatitis C, Chronic","metadata":null},{"id":"3175e29dcc824fa294abd483371462f0","type":"GO_TERM","name":"Grb2-EGFR complex","canonical_id":"go:GO:0070436","description":"\"A protein complex that contains the epidermal growth factor receptor (EGFR) and Grb2, and is involved in linking EGFR activation to the p21-Ras pathway.\" [GOC:mah, PMID:7798267]","metadata":null},{"id":"89bfa0864ea846a7b3dd016f498d9bb5","type":"GO_TERM","name":"Grb2-SHP-2 complex","canonical_id":"go:GO:0070720","description":"\"A protein complex that contains the receptor adaptor proteins Grb2 and SHP-2, and is involved signaling via the PDGFR signaling pathway.\" [GOC:mah, PMID:8943348]","metadata":null},{"id":"e4cd097b7c054e2a96dfb1079ed465d9","type":"GO_TERM","name":"Grb2-Shc complex","canonical_id":"go:GO:0070437","description":"\"A protein complex that contains Grb2 and the adaptor protein Shc, and is involved in linking epidermal growth factor receptor (EGFR) activation to the p21-Ras pathway.\" [GOC:mah, PMID:7798267]","metadata":null},{"id":"4c470db2686f4ad696a84cc8bad3fd50","type":"GO_TERM","name":"Grb2-Sos complex","canonical_id":"go:GO:0070618","description":"\"A protein complex that contains Grb2 and the guanine nucleotide exchange factor Sos (or an ortholog thereof, such as mSos1), and is involved in linking EGFR activation to the p21-Ras pathway.\" [GOC:mah, PMID:7798267, PMID:8940013]","metadata":null},{"id":"736fe6564f8546189258bbafdfb604ad","type":"DRUG","name":"Grepafloxacin","canonical_id":"mesh:C075375","description":null,"metadata":null},{"id":"09d7d59f586b47a3bc932c0b46b33ca6","type":"DRUG","name":"Griseofulvin","canonical_id":"mesh:D006118","description":null,"metadata":null},{"id":"3a2f61159ac54b839fb8f264a006e41c","type":"GO_TERM","name":"GroEL-GroES complex","canonical_id":"go:GO:1990220","description":"\"Bacterial chaperonin complex consisting of a heptameric 10kDa chaperonin subunit GroES and a tetradecameric (2x7) 60kDa chaperonin subunit GroEL. The 60kDa subunit possesses ATPase activity while the holo-enzyme is responsible for the correct folding of proteins.\" [GOC:bhm, PMID:15313620]","metadata":null},{"id":"d4495ffacb18468187815e3a57ab6fac","type":"TRIAL","name":"Group Cognitive Behavioral Therapy (CBT I) Vs. Quetiapine for Residual Insomnia Impairing Recovery Among Elderly With Stable Major Affective Disorders","canonical_id":"clinicaltrials.gov:NCT00462618","description":"Insomnia","metadata":null},{"id":"a3cd17ecd6f44fa3bb8a665ab312e040","type":"GO_TERM","name":"Group I intron splicing","canonical_id":"go:GO:0000372","description":"\"The splicing of Group I introns. This occurs by a ribozymic mechanism where the intron sequence forms a distinct 3D structure, characteristic of Group I introns and involved in determining the locations of the splice sites (there do not appear to be consensus splice site sequences) as well as having a role in catalyzing the splicing reactions, though protein factors are also required in vivo. Splicing occurs by a series of two transesterification reactions, generally with exogenous guanosine as the initiating nucleophile. The intron is excised as a linear piece (though it may subsequently circularize).\" [GOC:krc, PMID:11377794]","metadata":null},{"id":"0d01c7ba44e24cf78e0033f851e13c56","type":"GO_TERM","name":"Group II intron splicing","canonical_id":"go:GO:0000373","description":"\"The splicing of Group II introns. This occurs by a ribozymic mechanism where the intron sequence forms a distinct 3D structure, characteristic of Group II introns and containing splice site consensus sequences, that is involved in catalyzing the splicing reactions, though protein factors are also required in vivo. Splicing occurs by a series of two transesterification reactions (mechanistically similar to those for splicing of nuclear mRNAs) initiated by a bulged adenosine residue within the intron sequence as the initiating nucleophile. The intron is excised as a lariat.\" [GOC:krc, PMID:11377794]","metadata":null},{"id":"350eee258f6b4020bd46b2f599d1821b","type":"GO_TERM","name":"Group III intron splicing","canonical_id":"go:GO:0000374","description":"\"The splicing of Group III introns. This occurs by a ribozymic mechanism where the intron sequence forms a distinct 3D structure, characteristic of Group III introns, that is involved in catalyzing the splicing reactions, though protein factors are also required in vivo. Splicing occurs by a series of two transesterification reactions begun by a bulged adenosine residue within the intron sequence as the initiating nucleophile. The intron is excised as a lariat. Though very similar in structure and mechanism to Group II introns, Group III introns are smaller and more streamlined and the splice site consensus sequences are not as well conserved.\" [GOC:krc, PMID:11377794]","metadata":null},{"id":"c094818d70854ef392eacc51f7eed15f","type":"TRIAL","name":"Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer","canonical_id":"clinicaltrials.gov:NCT00004132","description":"Drug/Agent Toxicity by Tissue/Organ; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Oral Complications; Radiation Toxicity","metadata":null},{"id":"ca8e3896ebd34a65abf034d3fab96030","type":"TRIAL","name":"Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content","canonical_id":"clinicaltrials.gov:NCT00476879","description":"Metabolism; Fatty Liver","metadata":null},{"id":"1b3356d642474af1a201e52a66155d59","type":"TRIAL","name":"Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk","canonical_id":"clinicaltrials.gov:NCT03375788","description":"Non-Alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Liver Fat; Fatty Liver","metadata":null},{"id":"349bf59a54614977ae897f8c05d540dd","type":"TRIAL","name":"Growth Hormone Signaling in Vivo in Humans","canonical_id":"clinicaltrials.gov:NCT00512473","description":"Intracellular Signaling Peptides and Proteins","metadata":null},{"id":"bf435d6fb5864a7b92efdba8b518eb73","type":"TRIAL","name":"Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis","canonical_id":"clinicaltrials.gov:NCT04998500","description":"Fibrosis","metadata":null},{"id":"d4bb95c9347c44879bd8af5572731acf","type":"DISEASE","name":"Growth delay","canonical_id":"hp:0001510","description":null,"metadata":null},{"id":"bfade351867147cdb4ed9dd06f417405","type":"GO_TERM","name":"Gtr1-Gtr2 GTPase complex","canonical_id":"go:GO:1990131","description":"\"A heterodimer GTPase complex. In S. cerevisiae, this complex contains Gtr1p and Gtr2p proteins.\" [GOC:rb, PMID:10388807, PMID:16143306]","metadata":null},{"id":"6e14d5b7715d4ecd8deb0d7f3d86b58e","type":"DRUG","name":"Guaifenesin","canonical_id":"mesh:D006140","description":null,"metadata":null},{"id":"302f192c069e4b08b0c5e9a077e96606","type":"DRUG","name":"Guanabenz","canonical_id":"mesh:D006143","description":null,"metadata":null},{"id":"a35883c9f0ad41e5805d682cae005cd5","type":"DRUG","name":"Guanadrel","canonical_id":"mesh:C004945","description":null,"metadata":null},{"id":"f7066649c35e4b4a84b2f992111a6730","type":"DRUG","name":"Guanethidine","canonical_id":"mesh:D006145","description":null,"metadata":null},{"id":"7d6e95dcbf244109a35a50ff0ae5cd58","type":"DRUG","name":"Guanfacine","canonical_id":"mesh:D016316","description":null,"metadata":null},{"id":"3d75fbf58dea414a8f183ba83aa4ff7f","type":"TRIAL","name":"Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00469664","description":"Schizophrenia; Schizoaffective Disorder; Cognitive Impairment","metadata":null},{"id":"f213ee6e11b441af9e6ffd2ca51bf5a0","type":"TRIAL","name":"Guanfacine Clinical Trial for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT02051309","description":"Smoking Cessation","metadata":null},{"id":"b753757ccf5a4847b4a5808b920e7fab","type":"TRIAL","name":"Guanfacine Extended-release for Adolescents With Cannabis Use","canonical_id":"clinicaltrials.gov:NCT05957848","description":"Cannabis Use Disorder","metadata":null},{"id":"d8c672632dfb4251ad9fb5b68c42aa02","type":"TRIAL","name":"Guanfacine Immediate-release Electrocardiogram Results (QTc) Study","canonical_id":"clinicaltrials.gov:NCT00672984","description":"Healthy Volunteers","metadata":null},{"id":"c3b60c44195a4c90b5a954c10ab7b2af","type":"TRIAL","name":"Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects","canonical_id":"clinicaltrials.gov:NCT00935493","description":"Cognitive Aging","metadata":null},{"id":"b2d5e403586942ca8d3394bf8c4c7961","type":"TRIAL","name":"Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial","canonical_id":"clinicaltrials.gov:NCT07757555","description":"Postural Orthostatic Tachycardia Syndrome (POTS); Dysautonomia; Orthostatic Intolerance; Autonomic Nervous System Diseases","metadata":null},{"id":"b8bbaa42540b49cc9100960f5f4fabcb","type":"TRIAL","name":"Guanfacine for Alcohol Use Disorder (AUD)","canonical_id":"clinicaltrials.gov:NCT06629259","description":"Alcohol Use Disorder","metadata":null},{"id":"49d44c3c96554f2db00a3fa252e882d8","type":"TRIAL","name":"Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)","canonical_id":"clinicaltrials.gov:NCT06042257","description":"Hyperactivity in Children With Down Syndrome; Impulsivity in Children With Down Syndrome","metadata":null},{"id":"f859c3ac3e3744cdacb76b18df7c5c35","type":"TRIAL","name":"Guanfacine for PONV and Pain After Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT02882854","description":"Postoperative Nausea and Vomiting; Pain, Postoperative","metadata":null},{"id":"26d78db08bfe4f54ae9e915613153b6e","type":"TRIAL","name":"Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder","canonical_id":"clinicaltrials.gov:NCT01238575","description":"Pervasive Development Disorders","metadata":null},{"id":"e6b5581261c2450ba2b0b6009c78cc25","type":"TRIAL","name":"Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)","canonical_id":"clinicaltrials.gov:NCT00018603","description":"Post-Traumatic Stress Disorder","metadata":null},{"id":"a641d429b0584b9fba7568faa465027a","type":"TRIAL","name":"Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance","canonical_id":"clinicaltrials.gov:NCT00955253","description":"Stroke; Hemispatial Neglect","metadata":null},{"id":"e504bb065d59423c867620c2959af7e3","type":"TRIAL","name":"Guanfacine in Children With Tic Disorders","canonical_id":"clinicaltrials.gov:NCT01547000","description":"Tourette Disorder; Tourette Syndrome","metadata":null},{"id":"ddb7ed9144e144d78c327b8e469cdd1a","type":"TRIAL","name":"Guanfacine to Improve Substance Use Outcomes in Women","canonical_id":"clinicaltrials.gov:NCT03980184","description":"Substance Use Disorders","metadata":null},{"id":"775c8fdba16e48eb9cde49e45887d928","type":"TRIAL","name":"Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)","canonical_id":"clinicaltrials.gov:NCT03137082","description":"Alcohol Abstinence","metadata":null},{"id":"ebb6a22288f14f57b16c5f4654993197","type":"TRIAL","name":"Guanfacine to Treat Borderline Personality Disorder","canonical_id":"clinicaltrials.gov:NCT00358969","description":"Borderline Personality Disorder","metadata":null},{"id":"25295208494a43229e8a15a9eda2e24f","type":"PROTEIN","name":"Guanylate cyclase soluble subunit alpha-2","canonical_id":"uniprot:P33402","description":null,"metadata":null},{"id":"83ecc84779da4255b118d7795e9b5abd","type":"TRIAL","name":"Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities","canonical_id":"clinicaltrials.gov:NCT04525300","description":"Obesity","metadata":null},{"id":"96be28d3d5d04f0ab4877f42ba0de67a","type":"TRIAL","name":"Gut Microbiota is Associated With Autoimmune Thyroid Disease","canonical_id":"clinicaltrials.gov:NCT03390582","description":"Gut Microbiota","metadata":null},{"id":"5bf996a24c204717a7ec29dd7dfe717e","type":"TRIAL","name":"Gut Transit Effect on Enterohepatic Circulation","canonical_id":"clinicaltrials.gov:NCT03501498","description":"Intestinal Transit","metadata":null},{"id":"067c21c57ea74adc9976f46220d60652","type":"GO_TERM","name":"H zone","canonical_id":"go:GO:0031673","description":"\"A relatively pale zone traversing the center of the A band of a sarcomere, visible in relaxed muscle fibers; consists of the central portion of thick (myosin) filaments that are not overlapped by thin (actin) filaments.\" [GOC:mtg_muscle, ISBN:0321204131]","metadata":null},{"id":"cd786a405da1472a8e8ff4e9411d4e27","type":"TRIAL","name":"H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)","canonical_id":"clinicaltrials.gov:NCT07484139","description":"Oral Cavity Squamous Cell Carcinoma; Head and Neck Cancer","metadata":null},{"id":"8c432ffe48af494b8787a4dd264ef156","type":"TRIAL","name":"H-36731: Finasteride in Management of Elevated Red Blood Cells","canonical_id":"clinicaltrials.gov:NCT02548117","description":"ERYTHROCYTOSIS","metadata":null},{"id":"6128c51d934a4341bca168a7f983bad6","type":"GO_TERM","name":"H-NS complex","canonical_id":"go:GO:1990121","description":"\"A multimer of H-NS proteins that is involved in bacterial nucleoid condensation and negative regulation of global gene expression by directly binding to promoter regions. Recognizes both structural and sequence-specific motifs in double-stranded DNA and has binding preference for bent DNA.\" [GOC:bhm, PMID:12592399]","metadata":null},{"id":"466885f665e14d969d1e3f66ca0073fd","type":"GO_TERM","name":"H-NS-Cnu complex","canonical_id":"go:GO:0036411","description":"\"A trimeric protein complex containing a H-NS homodimer and a Cnu monomer. In bacteria, this complex negatively regulates transcription of a range of genes.\" [GOC:bhm, PMID:18189420, PMID:22358512]","metadata":null},{"id":"978c0e811d324c7f94007799001a8367","type":"GO_TERM","name":"H-NS-Hha complex","canonical_id":"go:GO:0097495","description":"\"A trimeric protein complex made up of an H-NS homodimer and an Hha monomer. In Enterobacteriaceae, this complex negatively regulates transcription of a range of genes.\" [GOC:bhm, PMID:21600204]","metadata":null},{"id":"899392b5620f463da5e77e8f7ac1598a","type":"GO_TERM","name":"H-gal-GP complex","canonical_id":"go:GO:1990850","description":"\"A membrane glycoprotein complex with aspartyl proteinase and metalloproteinase activity which is expressed in the gut. An example of this is found in the nematode Haemonchus contortus.\" [PMID:11166393]","metadata":null},{"id":"d464c93397fc4163906ab74b46751c44","type":"GO_TERM","name":"H1 histamine receptor binding","canonical_id":"go:GO:0031807","description":"\"Binding to a H1 histamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"834b048d785e4c1ab0d0fd96f622cc1b","type":"GO_TERM","name":"H1 histone chaperone activity","canonical_id":"go:GO:0140890","description":"\"A histone chaperone that carries a H1 histone.\" [PMID:12509435]","metadata":null},{"id":"82e4dc6ab57b4fccad3d381d54b538e5","type":"GENE","name":"H1-0","canonical_id":"hgnc:HGNC:4714","description":"H1.0 linker histone","metadata":{"aliases":["H1.0","H1FV","H1F0"]}},{"id":"e0b4f75411bf48aaa53bee3e73a57189","type":"GENE","name":"H1-1","canonical_id":"hgnc:HGNC:4715","description":"H1.1 linker histone, cluster member","metadata":{"aliases":["H1.1","H1a","H1F1","HIST1H1A"]}},{"id":"be333ddc4284491b9292dc75adb5cf36","type":"GENE","name":"H1-10","canonical_id":"hgnc:HGNC:4722","description":"H1.10 linker histone","metadata":{"aliases":["MGC15959","MGC8350","H1X","H1FX"]}},{"id":"e34fe8a5bf9e4994b96d1166d530e991","type":"GENE","name":"H1-10-AS1","canonical_id":"hgnc:HGNC:27953","description":"H1-10 antisense RNA 1","metadata":{"aliases":["FLJ34151","C3orf47","H1FX-AS1"]}},{"id":"350c63925835479db0cb36b3e19c7904","type":"GENE","name":"H1-12P","canonical_id":"hgnc:HGNC:19163","description":"H1.12 linker histone, cluster member, pseudogene","metadata":{"aliases":["dJ34B20.16","FLJ39701","H1F6P","HIST1H1PS1"]}},{"id":"989949c7a25a4823b90bc834cf0dd112","type":"GENE","name":"H1-2","canonical_id":"hgnc:HGNC:4716","description":"H1.2 linker histone, cluster member","metadata":{"aliases":["H1.2","H1s-1","H1c","H1F2","HIST1H1C"]}},{"id":"560f598acdc748ac92b408c2f1bae0d0","type":"GENE","name":"H1-3","canonical_id":"hgnc:HGNC:4717","description":"H1.3 linker histone, cluster member","metadata":{"aliases":["H1.3","H1d","H1s-2","H1F3","HIST1H1D"]}},{"id":"cb76c65174394ec99e7f8ce83811f490","type":"GENE","name":"H1-4","canonical_id":"hgnc:HGNC:4718","description":"H1.4 linker histone, cluster member","metadata":{"aliases":["H1.4","H1e","H1s-4","H1F4","HIST1H1E"]}},{"id":"1ec321738ad04fa5aafebec6012dd9b1","type":"GO_TERM","name":"H1-4K26 methyltransferase activity","canonical_id":"go:GO:0140189","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H1-4 L-lysine (position 26) = S-adenosyl-L-homocysteine + histone H1-4 N6-methyl-L-lysine (position 26).\" [PMID:19144645]","metadata":null},{"id":"0789c9a5935f4d68a116f2fbb68536d3","type":"GENE","name":"H1-5","canonical_id":"hgnc:HGNC:4719","description":"H1.5 linker histone, cluster member","metadata":{"aliases":["H1b","H1s-3","H1F5","HIST1H1B"]}},{"id":"03666f26764c4859a1af62034137be8f","type":"GENE","name":"H1-6","canonical_id":"hgnc:HGNC:4720","description":"H1.6 linker histone, cluster member","metadata":{"aliases":["H1t","H1FT","HIST1H1T"]}},{"id":"ef8eb68f71a2469ab75bd23336bab9a6","type":"GENE","name":"H1-7","canonical_id":"hgnc:HGNC:24893","description":"H1.7 linker histone","metadata":{"aliases":["HANP1","H1T2","H1FNT"]}},{"id":"a031e970f3fd4a70b5e4fb1591378d5d","type":"GENE","name":"H1-8","canonical_id":"hgnc:HGNC:18463","description":"H1.8 linker histone","metadata":{"aliases":["H1FOO"]}},{"id":"32edb9d30bba4886a3dd8d0e86e604b7","type":"GENE","name":"H1-8P1","canonical_id":"hgnc:HGNC:56427","description":"H1-8 pseudogene 1","metadata":null},{"id":"7e0d82ddbe7d48ff84ea7600b8725844","type":"GENE","name":"H1-8P2","canonical_id":"hgnc:HGNC:56428","description":"H1-8 pseudogene 2","metadata":null},{"id":"3ad044d8e6944a17a9587d9e02dcd525","type":"GENE","name":"H1-9P","canonical_id":"hgnc:HGNC:30616","description":"H1.9 linker histone, pseudogene","metadata":{"aliases":["H1.9","HILS1","H1-9"]}},{"id":"13233b0d858844e29d3531e1d1328b4c","type":"GENE","name":"H19","canonical_id":"hgnc:HGNC:4713","description":null,"metadata":null},{"id":"c3be3c7735d74b02b02684f2011b6755","type":"GO_TERM","name":"H2 histamine receptor binding","canonical_id":"go:GO:0031808","description":"\"Binding to a H2 histamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"00f52baaa7d24e369d65e7b5be7cc6d7","type":"GO_TERM","name":"H2A-H2B histone complex chaperone activity","canonical_id":"go:GO:0000511","description":"\"A histone chaperone that carries a H2A-H2B histone complex.\" [PMID:28053344]","metadata":null},{"id":"a3899a540d4b461bad961820d38b2af1","type":"GENE","name":"H2AB1","canonical_id":"hgnc:HGNC:22516","description":"H2A.B variant histone 1","metadata":{"aliases":["H2A.B.2","H2AFB1"]}},{"id":"8f10a11c2435438286afc1a63583dccc","type":"GENE","name":"H2AB2","canonical_id":"hgnc:HGNC:18298","description":"H2A.B variant histone 2","metadata":{"aliases":["H2A.B.1","H2AFB2"]}},{"id":"b8c041e8abb346f9957edda48680998e","type":"GENE","name":"H2AB3","canonical_id":"hgnc:HGNC:14455","description":"H2A.B variant histone 3","metadata":{"aliases":["H2A.B.1","H2AFB","H2AFB3"]}},{"id":"897067d35dd847f48fcb8ed756a3e85d","type":"GENE","name":"H2AC1","canonical_id":"hgnc:HGNC:18729","description":"H2A clustered histone 1","metadata":{"aliases":["bA317E16.2","H2AFR","HIST1H2AA"]}},{"id":"e8f49b4a7a0844279d75784441fae629","type":"GENE","name":"H2AC10P","canonical_id":"hgnc:HGNC:4732","description":"H2A clustered histone 10, pseudogene","metadata":{"aliases":["pH2A/k","dJ34B20.2","H2AFK","H2AFKP","HIST1H2APS4"]}},{"id":"5e2a72e6934a4acbaccbce985d2068c5","type":"GENE","name":"H2AC11","canonical_id":"hgnc:HGNC:4737","description":"H2A clustered histone 11","metadata":{"aliases":["pH2A/f","H2A/p","H2A.1b","H2AFP","HIST1H2AG"]}},{"id":"b8e904a470404ad299e4506f7f6ef246","type":"GENE","name":"H2AC12","canonical_id":"hgnc:HGNC:13671","description":"H2A clustered histone 12","metadata":{"aliases":["H2AFALii","dJ86C11.1","H2A/S","HIST1H2AH"]}},{"id":"59b8af043c1249acb37e87cad3577505","type":"GENE","name":"H2AC13","canonical_id":"hgnc:HGNC:4725","description":"H2A clustered histone 13","metadata":{"aliases":["H2A/c","H2AFC","HIST1H2AI"]}},{"id":"cdaa304a343a4c2cad425096a8ea305f","type":"GENE","name":"H2AC14","canonical_id":"hgnc:HGNC:4727","description":"H2A clustered histone 14","metadata":{"aliases":["H2A/E","H2AFE","HIST1H2AJ"]}},{"id":"968bc9313b8f4103a546637a2fafa514","type":"GENE","name":"H2AC15","canonical_id":"hgnc:HGNC:4726","description":"H2A clustered histone 15","metadata":{"aliases":["H2A/d","H2AFD","HIST1H2AK"]}},{"id":"ac81dbfaec4e4d67b29c495f56894948","type":"GENE","name":"H2AC16","canonical_id":"hgnc:HGNC:4730","description":"H2A clustered histone 16","metadata":{"aliases":["H2A/i","dJ193B12.9","H2AFI","HIST1H2AL"]}},{"id":"ed25297088c34b7ca931acd69e5ee865","type":"GENE","name":"H2AC17","canonical_id":"hgnc:HGNC:4735","description":"H2A clustered histone 17","metadata":{"aliases":["H2A/n","H2A.1","H2AFN","HIST1H2AM"]}},{"id":"534557d6de4e41b7950097892c4b88b5","type":"GENE","name":"H2AC18","canonical_id":"hgnc:HGNC:4736","description":"H2A clustered histone 18","metadata":{"aliases":["H2A.2","H2A/q","H2AFO","HIST2H2AA","HIST2H2AA3"]}},{"id":"8cca0a6188374a289d72c9cf5872ec29","type":"GENE","name":"H2AC19","canonical_id":"hgnc:HGNC:29668","description":"H2A clustered histone 19","metadata":{"aliases":["H2A/r","HIST2H2AA4"]}},{"id":"2320d2640dff413f906222b79dcdd186","type":"GENE","name":"H2AC20","canonical_id":"hgnc:HGNC:4738","description":"H2A clustered histone 20","metadata":{"aliases":["H2A/q","H2A","H2AFQ","HIST2H2AC"]}},{"id":"48c8a76a9f864a86b0d599f1b0aeb548","type":"GENE","name":"H2AC21","canonical_id":"hgnc:HGNC:20508","description":"H2A clustered histone 21","metadata":{"aliases":["HIST2H2AB"]}},{"id":"7ae71446f1aa40f19968d1f5a0ba0915","type":"GENE","name":"H2AC25","canonical_id":"hgnc:HGNC:20507","description":"H2A clustered histone 25","metadata":{"aliases":["MGC3165","HIST3H2A","H2AW"]}},{"id":"53eccfdc65d54721a1cdef4274bf3671","type":"GENE","name":"H2AC2P","canonical_id":"hgnc:HGNC:18720","description":"H2A clustered histone 2, pseudogene","metadata":{"aliases":["bA317E16.5","H2AFSP","HIST1H2APS1"]}},{"id":"e091596e2f3f4bf9afd5a13e4d7feccb","type":"GENE","name":"H2AC3P","canonical_id":"hgnc:HGNC:18804","description":"H2A clustered histone 3, pseudogene","metadata":{"aliases":["dJ139G21.2","H2A/T","H2AFTP","HIST1H2APS2"]}},{"id":"fea47d38afce4a578278d8cd118823f8","type":"GENE","name":"H2AC4","canonical_id":"hgnc:HGNC:4734","description":"H2A clustered histone 4","metadata":{"aliases":["H2A/m","H2AFM","HIST1H2AB"]}},{"id":"835eb8ad1759408a84d09361a9b84e90","type":"GENE","name":"H2AC5P","canonical_id":"hgnc:HGNC:4728","description":"H2A clustered histone 5, pseudogene","metadata":{"aliases":["pH2A/f","H2AFFP","HIST1H2APS5"]}},{"id":"308b552d4f224ec9aa743d9339ac873a","type":"GENE","name":"H2AC6","canonical_id":"hgnc:HGNC:4733","description":"H2A clustered histone 6","metadata":{"aliases":["H2AFL","HIST1H2AC"]}},{"id":"53d8a0633bb346ee8c4ed3114eeb8846","type":"GENE","name":"H2AC7","canonical_id":"hgnc:HGNC:4729","description":"H2A clustered histone 7","metadata":{"aliases":["H2A/g","H2A.3","H2AFG","HIST1H2AD"]}},{"id":"71dd001913634d33909724c2f4612086","type":"GENE","name":"H2AC9P","canonical_id":"hgnc:HGNC:18805","description":"H2A clustered histone 9, pseudogene","metadata":{"aliases":["dJ34B20.8","H2AFUP","HIST1H2APS3"]}},{"id":"f37505e6bf7945998da4cc76a5655c37","type":"GENE","name":"H2ACP1","canonical_id":"hgnc:HGNC:42647","description":"H2AC histone family pseudogene 1","metadata":{"aliases":["HIST1H2APS6"]}},{"id":"49a5dcbb6d204e44b5380df386024e82","type":"GENE","name":"H2ACP2","canonical_id":"hgnc:HGNC:54439","description":"H2AC histone family pseudogene 2","metadata":null},{"id":"28f1e4ad98e8483183925c269789247c","type":"GENE","name":"H2AFX","canonical_id":"hgnc:HGNC:4739","description":null,"metadata":null},{"id":"19eca8dc3028444094759bd6792f9269","type":"GENE","name":"H2AJ","canonical_id":"hgnc:HGNC:14456","description":"H2A.J histone","metadata":{"aliases":["FLJ10903","MGC921","H2AFJ"]}},{"id":"7d085b00d1034a7babbfd96262698cbb","type":"GENE","name":"H2AL1MP","canonical_id":"hgnc:HGNC:53961","description":"H2A.L variant histone 1M, pseudogene","metadata":{"aliases":["H2AL1SP"]}},{"id":"2d6e209934cf42f7aa6bc67deeba6982","type":"GENE","name":"H2AL1Q","canonical_id":"hgnc:HGNC:53959","description":"H2A.L variant histone 1Q","metadata":{"aliases":["H2A.L.1","H2AL1QP"]}},{"id":"4809a6489b24400dbb18b9dceca7394b","type":"GENE","name":"H2AL3","canonical_id":"hgnc:HGNC:53960","description":"H2A.L variant histone 3","metadata":{"aliases":["H2A.L.3","H2AL1RP"]}},{"id":"bf0384c690af4ef2ae2308eb8ca9bb49","type":"GENE","name":"H2AP","canonical_id":"hgnc:HGNC:18417","description":"H2A.P histone","metadata":{"aliases":["HIP17","CXorf27","HYPM"]}},{"id":"7e98145484694e66bf6e7011a13c670c","type":"GENE","name":"H2AQ1P","canonical_id":"hgnc:HGNC:53962","description":"H2A.Q variant histone 1, pseudogene","metadata":null},{"id":"342c2d3b3b3a423582acf6d6e234fe26","type":"GENE","name":"H2AZ1","canonical_id":"hgnc:HGNC:4741","description":"H2A.Z variant histone 1","metadata":{"aliases":["H2A.Z","H2AZ","H2AFZ"]}},{"id":"32e06bf249cb4e40a9d788f1206f7cbf","type":"GENE","name":"H2AZ1-DT","canonical_id":"hgnc:HGNC:40271","description":"H2AZ1 divergent transcript","metadata":null},{"id":"a1124f43c66a43b49a6ca5d6e047ca6a","type":"GENE","name":"H2AZ2","canonical_id":"hgnc:HGNC:20664","description":"H2A.Z variant histone 2","metadata":{"aliases":["MGC10170","MGC10831","MGC1947","H2AV","H2AFV"]}},{"id":"40cea5df888b43cb8d84e3cb9748fe12","type":"GENE","name":"H2AZ2-DT","canonical_id":"hgnc:HGNC:52775","description":"H2AZ2 divergent transcript","metadata":{"aliases":["AC004854.4","LINC01952"]}},{"id":"3602ed351929496b8ca19820fec9f871","type":"GENE","name":"H2AZ2P1","canonical_id":"hgnc:HGNC:31026","description":"H2AZ2 pseudogene 1","metadata":{"aliases":["HsT19970","H2AFVP","H2AFVP1"]}},{"id":"a6ecbdea5d194ff5bc794215c407936b","type":"GENE","name":"H2AZP1","canonical_id":"hgnc:HGNC:4742","description":"H2A.Z histone pseudogene 1","metadata":{"aliases":["H2AFZP","H2AFZP1"]}},{"id":"b8fee2f205c04421afde18e2bea218c8","type":"GENE","name":"H2AZP2","canonical_id":"hgnc:HGNC:32279","description":"H2A.Z histone pseudogene 2","metadata":{"aliases":["H2AFZP2"]}},{"id":"5aaf6345c0cc46a9ba721235d035cbae","type":"GENE","name":"H2AZP3","canonical_id":"hgnc:HGNC:38013","description":"H2A.Z histone pseudogene 3","metadata":{"aliases":["H2AFZP3"]}},{"id":"9f9ada7152ad4f65a5e9753a0780adc5","type":"GENE","name":"H2AZP4","canonical_id":"hgnc:HGNC:38015","description":"H2A.Z histone pseudogene 4","metadata":{"aliases":["H2AFZP4"]}},{"id":"fa25e341d2aa4ebbbfb666440d0f09cf","type":"GENE","name":"H2AZP5","canonical_id":"hgnc:HGNC:38018","description":"H2A.Z histone pseudogene 5","metadata":{"aliases":["H2AFZP5"]}},{"id":"fc375c4e3fe94a94a2fcbfbff2f875f8","type":"GENE","name":"H2AZP6","canonical_id":"hgnc:HGNC:38019","description":"H2A.Z histone pseudogene 6","metadata":{"aliases":["H2AFZP6"]}},{"id":"5b7f9c012c7d477ca99bf7e9fe0ca613","type":"GENE","name":"H2AZP7","canonical_id":"hgnc:HGNC:54440","description":"H2A.Z histone pseudogene 7","metadata":null},{"id":"be67a906b0804edf81c475b6e14b213e","type":"GENE","name":"H2BC1","canonical_id":"hgnc:HGNC:18730","description":"H2B clustered histone 1","metadata":{"aliases":["bA317E16.3","STBP","TSH2B","H2BFU","HIST1H2BA"]}},{"id":"2229915a3cf64fb18a5f01b4f99a3ebe","type":"GENE","name":"H2BC10","canonical_id":"hgnc:HGNC:4756","description":"H2B clustered histone 10","metadata":{"aliases":["H2B/k","H2BFK","HIST1H2BI"]}},{"id":"77518c33d8874b7bb1447f0792f783b1","type":"GENE","name":"H2BC11","canonical_id":"hgnc:HGNC:4761","description":"H2B clustered histone 11","metadata":{"aliases":["H2B/r","H2BFR","HIST1H2BJ"]}},{"id":"f7bb6e4052e74dacb298b1f835e36ee6","type":"GENE","name":"H2BC12","canonical_id":"hgnc:HGNC:13954","description":"H2B clustered histone 12","metadata":{"aliases":["H2BFAiii","H2BFT","HIST1H2BK"]}},{"id":"9e91ca99a69a4f458f39b79efc8a7785","type":"GENE","name":"H2BC12L","canonical_id":"hgnc:HGNC:4762","description":"H2B clustered histone 12 like","metadata":{"aliases":["H2BFS","H2BS1"]}},{"id":"2b8276ab9ebc47d3a8640cb78a73e147","type":"GENE","name":"H2BC13","canonical_id":"hgnc:HGNC:4748","description":"H2B clustered histone 13","metadata":{"aliases":["H2B/c","dJ97D16.4","H2BFC","HIST1H2BL"]}},{"id":"e2c27c27d56e4b4fbf6b6b3d7f25d341","type":"GENE","name":"H2BC14","canonical_id":"hgnc:HGNC:4750","description":"H2B clustered histone 14","metadata":{"aliases":["H2B/e","dJ160A22.3","H2BFE","HIST1H2BM"]}},{"id":"39c0fb95116a4e049f44874b6930efb9","type":"GENE","name":"H2BC15","canonical_id":"hgnc:HGNC:4749","description":"H2B clustered histone 15","metadata":{"aliases":["H2B/d","H2BFD","HIST1H2BN"]}},{"id":"e2d31ebab0c244898089e49cec83e30b","type":"GENE","name":"H2BC16P","canonical_id":"hgnc:HGNC:4754","description":"H2B clustered histone 16, pseudogene","metadata":{"aliases":["pH2B/i","H2BFIP","HIST1H2BPS2"]}},{"id":"e93fc10295284ddf8c944ea5f604a78b","type":"GENE","name":"H2BC17","canonical_id":"hgnc:HGNC:4758","description":"H2B clustered histone 17","metadata":{"aliases":["H2B/n","H2B.2","H2BFN","HIST1H2BO"]}},{"id":"2d17ec580f2a464e9c6964375bb9b1b6","type":"GENE","name":"H2BC18","canonical_id":"hgnc:HGNC:24700","description":"H2B clustered histone 18","metadata":{"aliases":["HIST2H2BF"]}},{"id":"371b225ce5344376ab0a75139ab42204","type":"GENE","name":"H2BC19P","canonical_id":"hgnc:HGNC:20517","description":"H2B clustered histone 19, pseudogene","metadata":{"aliases":["H2B/s","H2B/o","H2BFO","HIST2H2BD"]}},{"id":"6e3ac84b8ae94b7f8e85e4f71f83769f","type":"GENE","name":"H2BC20P","canonical_id":"hgnc:HGNC:20516","description":"H2B clustered histone 20, pseudogene","metadata":{"aliases":["H2B/t","LETN","HIST2H2BC"]}},{"id":"637248db26b343078cb276d32d639b55","type":"GENE","name":"H2BC26","canonical_id":"hgnc:HGNC:20514","description":"H2B clustered histone 26","metadata":{"aliases":["HIST3H2BB","H2BU1"]}},{"id":"309a852be564440c8c9ff7ae52b0db19","type":"GENE","name":"H2BC27P","canonical_id":"hgnc:HGNC:20515","description":"H2B clustered histone 27, pseudogene","metadata":{"aliases":["HIST3H2BA","H2BU2P"]}},{"id":"c70529dbc0de42e1ad48ae6fbb88e287","type":"GENE","name":"H2BC2P","canonical_id":"hgnc:HGNC:18719","description":"H2B clustered histone 2, pseudogene","metadata":{"aliases":["bA317E16.4","H2BFVP","HIST1H2BPS1"]}},{"id":"a1f3515379144ef3a092bdca8aed6be6","type":"GENE","name":"H2BC3","canonical_id":"hgnc:HGNC:4751","description":"H2B clustered histone 3","metadata":{"aliases":["H2B/f","H2BFF","HIST1H2BB"]}},{"id":"5f4482f990f942c6ae2d3a599b4e3928","type":"GENE","name":"H2BC4","canonical_id":"hgnc:HGNC:4757","description":"H2B clustered histone 4","metadata":{"aliases":["H2B/l","H2B.1","H2BFL","HIST1H2BC"]}},{"id":"47fddc93a1034d52a9f89cc975807f1d","type":"GENE","name":"H2BC5","canonical_id":"hgnc:HGNC:4747","description":"H2B clustered histone 5","metadata":{"aliases":["H2B/b","H2BFB","HIST1H2BD"]}},{"id":"1124646491114b3fb96f3f3ed3dfe184","type":"GENE","name":"H2BC6","canonical_id":"hgnc:HGNC:4753","description":"H2B clustered histone 6","metadata":{"aliases":["H2B/h","H2B.h","H2BFH","HIST1H2BE"]}},{"id":"b66c78cc0fee452982f8658ed20edcfa","type":"GENE","name":"H2BC6-AS1","canonical_id":"hgnc:HGNC:56682","description":"H2BC6 antisense RNA 1","metadata":{"aliases":["AL353759.1"]}},{"id":"1fff0e0c7f4a4f80b2d04055c85d0375","type":"GENE","name":"H2BC7","canonical_id":"hgnc:HGNC:4752","description":"H2B clustered histone 7","metadata":{"aliases":["H2B/g","H2BFG","HIST1H2BF"]}},{"id":"f94f1b2122304af2934c4dfbe371a800","type":"GENE","name":"H2BC8","canonical_id":"hgnc:HGNC:4746","description":"H2B clustered histone 8","metadata":{"aliases":["H2B/a","H2B.1A","H2BFA","HIST1H2BG"]}},{"id":"e5b7675d84a9490699212bcdae5b25b9","type":"GENE","name":"H2BC9","canonical_id":"hgnc:HGNC:4755","description":"H2B clustered histone 9","metadata":{"aliases":["H2B/j","H2BFJ","HIST1H2BH"]}},{"id":"39fbe9c9035f40799f0cbe22420a86dc","type":"GENE","name":"H2BK1","canonical_id":"hgnc:HGNC:53833","description":"H2B.K variant histone 1","metadata":{"aliases":["H2BE1"]}},{"id":"f3979519f5be447b93786026c5138392","type":"GENE","name":"H2BL1P","canonical_id":"hgnc:HGNC:54442","description":"H2B.L histone variant 1, pseudogene","metadata":{"aliases":["1700024P04Rik","SubH2Bv","H2BP4"]}},{"id":"add5070363b54087b3025ea62545b375","type":"GENE","name":"H2BN1","canonical_id":"hgnc:HGNC:56200","description":"H2B.N variant histone 1","metadata":null},{"id":"6c87205e06cb401c9a47ee0570d6460a","type":"GENE","name":"H2BP1","canonical_id":"hgnc:HGNC:20560","description":"H2B histone pseudogene 1","metadata":{"aliases":["HIST2H2BA"]}},{"id":"96ab3433065b4865bd171a4333140a4d","type":"GENE","name":"H2BP2","canonical_id":"hgnc:HGNC:20654","description":"H2B histone pseudogene 2","metadata":{"aliases":["HIST2H2BB"]}},{"id":"48881b8aa50044fdaf394eaff3fafd33","type":"GENE","name":"H2BP3","canonical_id":"hgnc:HGNC:54441","description":"H2B histone pseudogene 3","metadata":null},{"id":"ae68326a48134cc2930006abd6e63b6b","type":"GENE","name":"H2BP5","canonical_id":"hgnc:HGNC:54443","description":"H2B histone pseudogene 5","metadata":null},{"id":"fb2c0269929c400589e268e893f7ff91","type":"GENE","name":"H2BP6","canonical_id":"hgnc:HGNC:42633","description":"H2B histone pseudogene 6","metadata":{"aliases":["HIST1H2BPS3"]}},{"id":"62328d4902724f07b8a9cee8b8561a39","type":"GENE","name":"H2BP7","canonical_id":"hgnc:HGNC:54444","description":"H2B histone pseudogene 7","metadata":null},{"id":"eb6703ce34584d18991556f4fc5894f6","type":"GENE","name":"H2BP8","canonical_id":"hgnc:HGNC:54445","description":"H2B histone pseudogene 8","metadata":null},{"id":"14cb6a324b0141a88d80b3ebe6b59f0a","type":"GENE","name":"H2BP9","canonical_id":"hgnc:HGNC:54446","description":"H2B histone pseudogene 9","metadata":null},{"id":"4e55388b9f2843b98dd000ffd970a0a0","type":"GENE","name":"H2BW1","canonical_id":"hgnc:HGNC:27252","description":"H2B.W histone 1","metadata":{"aliases":["TH2B-175","H2BFWT"]}},{"id":"9ff2821b8883418fa1efef6fbc1d21e2","type":"GENE","name":"H2BW2","canonical_id":"hgnc:HGNC:27867","description":"H2B.W histone 2","metadata":{"aliases":["H2BFM","H2BM"]}},{"id":"c346e6e486cd47fc991521082f930be4","type":"GENE","name":"H2BW3P","canonical_id":"hgnc:HGNC:44390","description":"H2B.W histone 3, pseudogene","metadata":null},{"id":"af26f064bf594e7bbd81f37e93ebb566","type":"GENE","name":"H2BW4P","canonical_id":"hgnc:HGNC:25757","description":"H2B.W histone 4, pseudogene","metadata":{"aliases":["H2BFXP"]}},{"id":"b3922417d21241dab64e79dfe6a23035","type":"GO_TERM","name":"H3 histamine receptor binding","canonical_id":"go:GO:0031809","description":"\"Binding to a H3 histamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c5f9462621944760ae99deb00dc0f9bf","type":"GO_TERM","name":"H3 histone acetyltransferase complex","canonical_id":"go:GO:0070775","description":"\"A multisubunit complex that catalyzes the acetylation of histone H3.\" [GOC:mah]","metadata":null},{"id":"fc492b2eca9d4e32bd6b8a9cc922bf04","type":"GENE","name":"H3-3A","canonical_id":"hgnc:HGNC:4764","description":"H3.3 histone A","metadata":{"aliases":["H3.3A","H3F3","H3F3A"]}},{"id":"81e057e0536b49eda187d1d11c79e0f7","type":"GENE","name":"H3-3A-DT","canonical_id":"hgnc:HGNC:55210","description":"H3-3A divergent transcript","metadata":null},{"id":"9e7dfaf92af3450ca263d159ea691aca","type":"GENE","name":"H3-3B","canonical_id":"hgnc:HGNC:4765","description":"H3.3 histone B","metadata":{"aliases":["H3.3B","H3F3B"]}},{"id":"c2019953aabf4e9aa4244f9b386e2158","type":"GENE","name":"H3-4","canonical_id":"hgnc:HGNC:4778","description":"H3.4 histone, cluster member","metadata":{"aliases":["H3t","H3/g","H3.4","H3C16","H3FT","HIST3H3"]}},{"id":"dd49978c60074e3789cde8f80859919d","type":"GENE","name":"H3-5","canonical_id":"hgnc:HGNC:33164","description":"H3.5 histone","metadata":{"aliases":["H3.5","H3.3C","H3F3C"]}},{"id":"55d7c345ce2e4639834658c7a9cbe5c5","type":"GENE","name":"H3-7","canonical_id":"hgnc:HGNC:32060","description":"H3.7 histone (putative)","metadata":{"aliases":["p06","H3.7","HIST2H3PS2","H3-2"]}},{"id":"b192804328874a35b9f32c45df224641","type":"GO_TERM","name":"H3-H4 histone complex chaperone activity","canonical_id":"go:GO:0000510","description":"\"A histone chaperone that carries a H3-H4 histone complex.\" [PMID:28053344]","metadata":null},{"id":"6ff00b97f63e4804af99a27d0c96c372","type":"GENE","name":"H3C1","canonical_id":"hgnc:HGNC:4766","description":"H3 clustered histone 1","metadata":{"aliases":["H3/A","H3FA","HIST1H3A"]}},{"id":"59aa7dcad4044e86ad43c02107ff4e0a","type":"GENE","name":"H3C10","canonical_id":"hgnc:HGNC:4775","description":"H3 clustered histone 10","metadata":{"aliases":["H3/k","H3F1K","H3FK","HIST1H3H"]}},{"id":"8098bdb47ef74684944f25e97b4e56ca","type":"GENE","name":"H3C11","canonical_id":"hgnc:HGNC:4771","description":"H3 clustered histone 11","metadata":{"aliases":["H3/f","H3.f","H3FF","HIST1H3I"]}},{"id":"9eb6dd53fd6f4c8ba51d4d7f014b90d4","type":"GENE","name":"H3C12","canonical_id":"hgnc:HGNC:4774","description":"H3 clustered histone 12","metadata":{"aliases":["H3/j","H3FJ","HIST1H3J"]}},{"id":"8f6d6ec69f98474ab5b0d5fc64ad4258","type":"GENE","name":"H3C13","canonical_id":"hgnc:HGNC:25311","description":"H3 clustered histone 13","metadata":{"aliases":["HIST2H3D"]}},{"id":"a686a9f3bb6f47a7ab8573dfda0ea6a6","type":"GENE","name":"H3C14","canonical_id":"hgnc:HGNC:20503","description":"H3 clustered histone 14","metadata":{"aliases":["MGC9629","H3/m","H3","H3.2","H3/M","H3F2","H3FM","HIST2H3C"]}},{"id":"113b96b54c334901884aca1faa67b259","type":"GENE","name":"H3C15","canonical_id":"hgnc:HGNC:20505","description":"H3 clustered histone 15","metadata":{"aliases":["H3/n","H3/o","HIST2H3A"]}},{"id":"b3b85c95151640689d1e2e5ae5c475e9","type":"GENE","name":"H3C2","canonical_id":"hgnc:HGNC:4776","description":"H3 clustered histone 2","metadata":{"aliases":["H3/l","H3FL","HIST1H3B"]}},{"id":"94d8d6924c8f49a4aa1e9446761942ee","type":"GENE","name":"H3C3","canonical_id":"hgnc:HGNC:4768","description":"H3 clustered histone 3","metadata":{"aliases":["H3/c","H3.1","H3FC","HIST1H3C"]}},{"id":"97db761d13914a1586b508dbe4c1c425","type":"GENE","name":"H3C4","canonical_id":"hgnc:HGNC:4767","description":"H3 clustered histone 4","metadata":{"aliases":["H3/b","H3FB","HIST1H3D"]}},{"id":"88be3c1f4458492d9559b8c899ff3ab2","type":"GENE","name":"H3C5P","canonical_id":"hgnc:HGNC:54427","description":"H3 clustered histone 5, pseudogene","metadata":null},{"id":"be5020df3c2d460ab86d0c20b9cba609","type":"GENE","name":"H3C6","canonical_id":"hgnc:HGNC:4769","description":"H3 clustered histone 6","metadata":{"aliases":["H3/d","H3.1","H3FD","HIST1H3E"]}},{"id":"0f50c405a09b400f84c522681ebb339d","type":"GENE","name":"H3C7","canonical_id":"hgnc:HGNC:4773","description":"H3 clustered histone 7","metadata":{"aliases":["H3/i","H3FI","HIST1H3F"]}},{"id":"783933d683c7430eb66c88764e07ca15","type":"GENE","name":"H3C8","canonical_id":"hgnc:HGNC:4772","description":"H3 clustered histone 8","metadata":{"aliases":["H3/h","H3FH","HIST1H3G"]}},{"id":"840a89840c2a4b17a3a361ed00bce622","type":"GENE","name":"H3C9P","canonical_id":"hgnc:HGNC:18982","description":"H3 clustered histone 9, pseudogene","metadata":{"aliases":["dJ45P21.6","H3F3AP1","p36","HIST1H3PS1"]}},{"id":"02322986181c47349b20fd8b8250c7dc","type":"GENE","name":"H3P1","canonical_id":"hgnc:HGNC:43794","description":"H3 histone pseudogene 1","metadata":{"aliases":["p02"]}},{"id":"30c48f66f0fb4d65a1b7a8e3b8e959f2","type":"GENE","name":"H3P10","canonical_id":"hgnc:HGNC:43802","description":"H3 histone pseudogene 10","metadata":{"aliases":["p16"]}},{"id":"92add31220c846ac8582fd955a582766","type":"GENE","name":"H3P11","canonical_id":"hgnc:HGNC:43803","description":"H3 histone pseudogene 11","metadata":{"aliases":["p17"]}},{"id":"a234e43b811c41fa853e07153c13b50a","type":"GENE","name":"H3P12","canonical_id":"hgnc:HGNC:42873","description":"H3 histone pseudogene 12","metadata":{"aliases":["p18","H3F3AP3"]}},{"id":"d27180125e7d4afbbb2cdeb443e9637f","type":"GENE","name":"H3P13","canonical_id":"hgnc:HGNC:43804","description":"H3 histone pseudogene 13","metadata":{"aliases":["p19"]}},{"id":"117b37a0be05489ea142f3829e09e051","type":"GENE","name":"H3P14","canonical_id":"hgnc:HGNC:43805","description":"H3 histone pseudogene 14","metadata":{"aliases":["p20"]}},{"id":"f3f8bc7fd295494dbe67ca3a2dc04673","type":"GENE","name":"H3P15","canonical_id":"hgnc:HGNC:54450","description":"H3 histone pseudogene 15","metadata":null},{"id":"4b7e12f843af4efe93354083b56edf04","type":"GENE","name":"H3P16","canonical_id":"hgnc:HGNC:42982","description":"H3 histone pseudogene 16","metadata":{"aliases":["p21","H3.6","H3F3AP6"]}},{"id":"3c76e70aa9f441ae9bbfbde7c9610494","type":"GENE","name":"H3P17","canonical_id":"hgnc:HGNC:54451","description":"H3 histone pseudogene 17","metadata":{"aliases":["p23"]}},{"id":"676511785bc149659edbee68a2f297ff","type":"GENE","name":"H3P18","canonical_id":"hgnc:HGNC:54452","description":"H3 histone pseudogene 18","metadata":null},{"id":"b678531835d7494392dd57103a214c7e","type":"GENE","name":"H3P19","canonical_id":"hgnc:HGNC:54453","description":"H3 histone pseudogene 19","metadata":{"aliases":["p24"]}},{"id":"55931921f65a4913b120de6a66463434","type":"GENE","name":"H3P2","canonical_id":"hgnc:HGNC:43795","description":"H3 histone pseudogene 2","metadata":{"aliases":["p03"]}},{"id":"ad3c72a9c09d4cb397c5f7a744011791","type":"GENE","name":"H3P20","canonical_id":"hgnc:HGNC:54454","description":"H3 histone pseudogene 20","metadata":{"aliases":["p58"]}},{"id":"5cb149851cf54c13adc9012b4a7bf207","type":"GENE","name":"H3P21","canonical_id":"hgnc:HGNC:54455","description":"H3 histone pseudogene 21","metadata":{"aliases":["p01"]}},{"id":"cd350f89e8514812a2b8e85402a7c9fd","type":"GENE","name":"H3P22","canonical_id":"hgnc:HGNC:54456","description":"H3 histone pseudogene 22","metadata":{"aliases":["p26"]}},{"id":"3c6c097827b84e6f857d6a59f52698df","type":"GENE","name":"H3P23","canonical_id":"hgnc:HGNC:54457","description":"H3 histone pseudogene 23","metadata":{"aliases":["p27"]}},{"id":"c4b529d97d384722bbf9c07030366131","type":"GENE","name":"H3P24","canonical_id":"hgnc:HGNC:54458","description":"H3 histone pseudogene 24","metadata":{"aliases":["p28"]}},{"id":"4a4f2ab0b9be4215bddcaffe60c5938b","type":"GENE","name":"H3P25","canonical_id":"hgnc:HGNC:54459","description":"H3 histone pseudogene 25","metadata":null},{"id":"a5e41af7128244e98e875750ecb9d913","type":"GENE","name":"H3P26","canonical_id":"hgnc:HGNC:4770","description":"H3 histone pseudogene 26","metadata":{"aliases":["pH3/e","H3FEP","HIST1H1PS2"]}},{"id":"79a8a6b82d054abe929dc66f522d2c5b","type":"GENE","name":"H3P27","canonical_id":"hgnc:HGNC:54460","description":"H3 histone pseudogene 27","metadata":{"aliases":["p59"]}},{"id":"3e4f314444144453a91fabee448d65a9","type":"GENE","name":"H3P28","canonical_id":"hgnc:HGNC:54461","description":"H3 histone pseudogene 28","metadata":{"aliases":["p40"]}},{"id":"ea0cb1d10b2a4fb5a76a33feb83941f8","type":"GENE","name":"H3P29","canonical_id":"hgnc:HGNC:54462","description":"H3 histone pseudogene 29","metadata":{"aliases":["p41"]}},{"id":"b42d59b5077f408d8c34bfc0a4ebcd94","type":"GENE","name":"H3P3","canonical_id":"hgnc:HGNC:43796","description":"H3 histone pseudogene 3","metadata":{"aliases":["p04"]}},{"id":"4f5847f184584c9b9e49a9992044ceae","type":"GENE","name":"H3P30","canonical_id":"hgnc:HGNC:54463","description":"H3 histone pseudogene 30","metadata":{"aliases":["p42"]}},{"id":"752ba4f93f114ee2be8d3ebb98e34261","type":"GENE","name":"H3P31","canonical_id":"hgnc:HGNC:54464","description":"H3 histone pseudogene 31","metadata":{"aliases":["p43"]}},{"id":"042cf304ed9c405b8fb913e59fef7df6","type":"GENE","name":"H3P32","canonical_id":"hgnc:HGNC:54465","description":"H3 histone pseudogene 32","metadata":null},{"id":"b8125fd61be04b0b8f815d9dd7e1b4ba","type":"GENE","name":"H3P33","canonical_id":"hgnc:HGNC:54466","description":"H3 histone pseudogene 33","metadata":{"aliases":["p44"]}},{"id":"0cc91c8f817146e5b98c826ed7ff86b1","type":"GENE","name":"H3P34","canonical_id":"hgnc:HGNC:54467","description":"H3 histone pseudogene 34","metadata":null},{"id":"eb1e0c6163a3424d8b9022b1b2626562","type":"GENE","name":"H3P35","canonical_id":"hgnc:HGNC:54468","description":"H3 histone pseudogene 35","metadata":null},{"id":"171e980fa16248339dba4392f33580c0","type":"GENE","name":"H3P36","canonical_id":"hgnc:HGNC:42030","description":"H3 histone pseudogene 36","metadata":{"aliases":["p46","H3F3BP1"]}},{"id":"97a854404d914b619bcc679fd8f5b098","type":"GENE","name":"H3P37","canonical_id":"hgnc:HGNC:19823","description":"H3 histone pseudogene 37","metadata":{"aliases":["H3F3CP","p47","H3F3AP2"]}},{"id":"bfd478a53acd465fbb18a83eaeb17e3c","type":"GENE","name":"H3P38","canonical_id":"hgnc:HGNC:31028","description":"H3 histone pseudogene 38","metadata":{"aliases":["HsT18159","p48","H3F3AP1"]}},{"id":"939d58f92605438dba32509de36e2f49","type":"GENE","name":"H3P39","canonical_id":"hgnc:HGNC:54469","description":"H3 histone pseudogene 39","metadata":{"aliases":["p49"]}},{"id":"ba1cc53ff920480c87bd0e49e2269cee","type":"GENE","name":"H3P4","canonical_id":"hgnc:HGNC:43797","description":"H3 histone pseudogene 4","metadata":{"aliases":["p05","HIST2H3DP1"]}},{"id":"2b18d3aba1c2409c84adc5be434d7c94","type":"GENE","name":"H3P40","canonical_id":"hgnc:HGNC:54470","description":"H3 histone pseudogene 40","metadata":{"aliases":["p50"]}},{"id":"df344f1a8b4847e39e13be3a58e9ab7a","type":"GENE","name":"H3P41","canonical_id":"hgnc:HGNC:42979","description":"H3 histone pseudogene 41","metadata":{"aliases":["p51","H3F3BP2"]}},{"id":"92d20ca0eba54628852893af575e8cbf","type":"GENE","name":"H3P42","canonical_id":"hgnc:HGNC:54471","description":"H3 histone pseudogene 42","metadata":{"aliases":["p52"]}},{"id":"a07859cca6d64c5d96b8660b91f3bfe5","type":"GENE","name":"H3P43","canonical_id":"hgnc:HGNC:54472","description":"H3 histone pseudogene 43","metadata":{"aliases":["p54"]}},{"id":"fec0b4e62a4345798bc186ae21b48bc3","type":"GENE","name":"H3P44","canonical_id":"hgnc:HGNC:42981","description":"H3 histone pseudogene 44","metadata":{"aliases":["p55","H3.8","H3F3AP5"]}},{"id":"a4fe51e1faba430381081729a07a7d4e","type":"GENE","name":"H3P45","canonical_id":"hgnc:HGNC:54473","description":"H3 histone pseudogene 45","metadata":{"aliases":["p56"]}},{"id":"9ab7a572a1bd4dd4a728218a2d83625d","type":"GENE","name":"H3P46","canonical_id":"hgnc:HGNC:54474","description":"H3 histone pseudogene 46","metadata":null},{"id":"99de40d851974292878781470667174e","type":"GENE","name":"H3P47","canonical_id":"hgnc:HGNC:54475","description":"H3 histone pseudogene 47","metadata":{"aliases":["p57"]}},{"id":"57a9001a827c4426962a93bf246cb03b","type":"GENE","name":"H3P5","canonical_id":"hgnc:HGNC:43798","description":"H3 histone pseudogene 5","metadata":{"aliases":["p12"]}},{"id":"78b8b6a51b3540c1b67dd6ddcafb9cdf","type":"GENE","name":"H3P6","canonical_id":"hgnc:HGNC:42980","description":"H3 histone pseudogene 6","metadata":{"aliases":["p13","H3F3AP4"]}},{"id":"78553ef895fc4b37ac768359f0cc353e","type":"GENE","name":"H3P7","canonical_id":"hgnc:HGNC:43799","description":"H3 histone pseudogene 7","metadata":{"aliases":["p60"]}},{"id":"2fc2e981bf0b43f2a19d79360ae84e48","type":"GENE","name":"H3P8","canonical_id":"hgnc:HGNC:54449","description":"H3 histone pseudogene 8","metadata":{"aliases":["p14"]}},{"id":"57f37cfad6314f179782129c9d13bfe3","type":"GENE","name":"H3P9","canonical_id":"hgnc:HGNC:43801","description":"H3 histone pseudogene 9","metadata":{"aliases":["p15"]}},{"id":"d4ea0d31fc9c4a49846c92acd2721478","type":"GENE","name":"H3Y1","canonical_id":"hgnc:HGNC:43735","description":"H3.Y histone 1","metadata":{"aliases":["H3.Y","H3.Y.1"]}},{"id":"a1c409158be04ed9ab09ce7390736485","type":"GENE","name":"H3Y2","canonical_id":"hgnc:HGNC:43734","description":"H3.Y histone 2","metadata":{"aliases":["H3.X","H3.Y.2"]}},{"id":"4ec3986c93904a08a20189d6df5f8cb3","type":"GENE","name":"H3Y2-AS1","canonical_id":"hgnc:HGNC:59008","description":"H3Y2 antisense RNA 1","metadata":null},{"id":"e94a2af673d34407a20de648e1529c5d","type":"GO_TERM","name":"H4 histamine receptor binding","canonical_id":"go:GO:0031810","description":"\"Binding to a H4 histamine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"784f64b217f1488ea5c8774d1fcf9319","type":"GO_TERM","name":"H4 histone acetyltransferase complex","canonical_id":"go:GO:1902562","description":"\"A protein complex which is capable of H4 histone acetyltransferase activity.\" [GOC:bhm, GOC:TermGenie, PMID:23775086]","metadata":null},{"id":"b02e6d66722243719df398785410f02f","type":"GO_TERM","name":"H4/H2A histone acetyltransferase complex","canonical_id":"go:GO:0043189","description":"\"A multisubunit complex that catalyzes the acetylation of histones H4 and H2A.\" [GOC:mah, GOC:rb]","metadata":null},{"id":"4f9d6844a1d14d8db5b668644a3dd0b2","type":"GENE","name":"H4C1","canonical_id":"hgnc:HGNC:4781","description":"H4 clustered histone 1","metadata":{"aliases":["H4FA","HIST1H4A"]}},{"id":"a66a53f2232c4e67a6d3e129cbfbd633","type":"GENE","name":"H4C10P","canonical_id":"hgnc:HGNC:4786","description":"H4 clustered histone 10, pseudogene","metadata":{"aliases":["pH4/f","dJ97D16.3","H4FFP","HIST1H4PS1"]}},{"id":"cf6424d6aa844487afc310da94e7bd9d","type":"GENE","name":"H4C11","canonical_id":"hgnc:HGNC:4785","description":"H4 clustered histone 11","metadata":{"aliases":["H4/e","H4F2iv","H4FE","HIST1H4J"]}},{"id":"42b5208716db4a2f8641765469868701","type":"GENE","name":"H4C12","canonical_id":"hgnc:HGNC:4784","description":"H4 clustered histone 12","metadata":{"aliases":["H4/d","H4F2iii","dJ160A22.1","H4FD","HIST1H4K"]}},{"id":"da3cb39f057d4116a716cd18cf85b60b","type":"GENE","name":"H4C15","canonical_id":"hgnc:HGNC:29607","description":"H4 clustered histone 15","metadata":{"aliases":["H4/o","HIST2H4B"]}},{"id":"1a8a758b31274a81a5b4127ceb3ab515","type":"GENE","name":"H4C16","canonical_id":"hgnc:HGNC:20510","description":"H4 histone 16","metadata":{"aliases":["MGC24116","HIST4H4","H4-16"]}},{"id":"0292099e17824ba8bb87f2009fb0ae0e","type":"GENE","name":"H4C2","canonical_id":"hgnc:HGNC:4789","description":"H4 clustered histone 2","metadata":{"aliases":["H4/I","H4FI","HIST1H4B"]}},{"id":"825f0d1cc1c3485697afd9c17bd1777c","type":"GENE","name":"H4C3","canonical_id":"hgnc:HGNC:4787","description":"H4 clustered histone 3","metadata":{"aliases":["H4/g","dJ221C16.1","H4FG","HIST1H4C"]}},{"id":"def066cf708f41a8888a83144dbd1849","type":"GENE","name":"H4C4","canonical_id":"hgnc:HGNC:4782","description":"H4 clustered histone 4","metadata":{"aliases":["H4/b","H4FB","HIST1H4D"]}},{"id":"255108945f954bb8a255a64e9b57d87b","type":"GENE","name":"H4C5","canonical_id":"hgnc:HGNC:4790","description":"H4 clustered histone 5","metadata":{"aliases":["H4/j","H4FJ","HIST1H4E"]}},{"id":"e818bf9eba2547aba28b3cb212a04291","type":"GENE","name":"H4C6","canonical_id":"hgnc:HGNC:4783","description":"H4 clustered histone 6","metadata":{"aliases":["H4/c","H4","H4FC","HIST1H4F"]}},{"id":"43a48fe4d96a4cd687f157fb5d83a918","type":"GENE","name":"H4C7","canonical_id":"hgnc:HGNC:4792","description":"H4 clustered histone 7","metadata":{"aliases":["H4/l","H4FL","HIST1H4G"]}},{"id":"23c08b5169dc438eb78048116844ea13","type":"GENE","name":"H4C8","canonical_id":"hgnc:HGNC:4788","description":"H4 clustered histone 8","metadata":{"aliases":["H4/h","H4FH","HIST1H4H"]}},{"id":"fcec37578c964043a3be6cb23b946c8a","type":"GENE","name":"H4C9","canonical_id":"hgnc:HGNC:4793","description":"H4 clustered histone 9","metadata":{"aliases":["H4/m","H4FM","HIST1H4I"]}},{"id":"bca687d8a84343cc90be13702451604e","type":"GENE","name":"H4P1","canonical_id":"hgnc:HGNC:54447","description":"H4 histone pseudogene 1","metadata":null},{"id":"6ac1dd334e48424cb36b09e518126b12","type":"GENE","name":"H6PD","canonical_id":"hgnc:HGNC:4795","description":"hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase","metadata":{"aliases":["H6PDH","GDH"]}},{"id":"8a88c664612a4b549a8d42789f4ab24c","type":"GO_TERM","name":"H9 melatonin receptor binding","canonical_id":"go:GO:0031787","description":"\"Binding to a H9 melatonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"0e40ae6cd7aa4b3b9b9e349be2f37bcc","type":"GENE","name":"HAAO","canonical_id":"hgnc:HGNC:4796","description":"3-hydroxyanthranilate 3,4-dioxygenase","metadata":{"aliases":["3-HAO","HAO"]}},{"id":"69bc66ef31244807bfa129beadd9e1a8","type":"GENE","name":"HABP2","canonical_id":"hgnc:HGNC:4798","description":"hyaluronan binding protein 2","metadata":{"aliases":["HABP","PHBP","HGFAL","FSAP"]}},{"id":"f8d88b3abca84ea096cc0559ffb0ef58","type":"GENE","name":"HABP4","canonical_id":"hgnc:HGNC:17062","description":"hyaluronan binding protein 4","metadata":{"aliases":["IHABP4","SERBP1L"]}},{"id":"d401faf6623249d0af71adb7e549a533","type":"GENE","name":"HACD1","canonical_id":"hgnc:HGNC:9639","description":"3-hydroxyacyl-CoA dehydratase 1","metadata":{"aliases":["CAP","PTPLA"]}},{"id":"7939e2f5ad3343a79c46f3ce010e6e34","type":"GENE","name":"HACD2","canonical_id":"hgnc:HGNC:9640","description":"3-hydroxyacyl-CoA dehydratase 2","metadata":{"aliases":["PTPLB"]}},{"id":"becf494efa4a45009e65d4195f1c24a0","type":"GENE","name":"HACD3","canonical_id":"hgnc:HGNC:24175","description":"3-hydroxyacyl-CoA dehydratase 3","metadata":{"aliases":["B-ind1","HSPC121","PTPLAD1"]}},{"id":"37a5655906e546c3960135b5710f66c1","type":"GENE","name":"HACD4","canonical_id":"hgnc:HGNC:20920","description":"3-hydroxyacyl-CoA dehydratase 4","metadata":{"aliases":["Em:AL662879.1","OTTHUMG00000021016","PTPLAD2"]}},{"id":"01eff11e5b944836afc7459f844e7e77","type":"GENE","name":"HACE1","canonical_id":"hgnc:HGNC:21033","description":"HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1","metadata":{"aliases":["KIAA1320"]}},{"id":"3ef59bd2b17648fc9d1f78f642faaf42","type":"GENE","name":"HACL1","canonical_id":"hgnc:HGNC:17856","description":"2-hydroxyacyl-CoA lyase 1","metadata":{"aliases":["2-HPCL","PHYH2","HPCL"]}},{"id":"de3adc8b520b4d368aec332233067a00","type":"GENE","name":"HACL2","canonical_id":"hgnc:HGNC:6041","description":"2-hydroxyacyl-CoA lyase 2","metadata":{"aliases":["209L8","AHAS","ILV2H","MGC1269","FLJ39061","MGC19535","HACL1L","HACL2","ILVBL"]}},{"id":"397539de4db54bbbb982da71ac3a5bcc","type":"GENE","name":"HADH","canonical_id":"hgnc:HGNC:4799","description":"hydroxyacyl-CoA dehydrogenase","metadata":{"aliases":["HADH1","SCHAD","HADHSC"]}},{"id":"433556dbe87842368ee0db06483dc697","type":"GENE","name":"HADHA","canonical_id":"hgnc:HGNC:4801","description":"hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha","metadata":{"aliases":["GBP","LCEH","LCHAD","MTPA"]}},{"id":"de9147520996483ba12fc875dadfedbe","type":"GENE","name":"HADHAP1","canonical_id":"hgnc:HGNC:4802","description":"HADHA pseudogene 1","metadata":{"aliases":["HADHAP"]}},{"id":"cb093d2a1fca465489a8c967f6c6b445","type":"GENE","name":"HADHAP2","canonical_id":"hgnc:HGNC:38585","description":"HADHA pseudogene 2","metadata":null},{"id":"24c111e01dcc470a94a0e52848722d65","type":"GENE","name":"HADHB","canonical_id":"hgnc:HGNC:4803","description":"hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta","metadata":{"aliases":["MTPB"]}},{"id":"e81843bac987452e9aa6183a087858b5","type":"GENE","name":"HADHBP1","canonical_id":"hgnc:HGNC:54887","description":"HADHB pseudogene 1","metadata":null},{"id":"61e894b4609f4f1fb97ccaa9f1cfbeb7","type":"GENE","name":"HAFML","canonical_id":"hgnc:HGNC:56694","description":"HuR (ELAVL1) associated fibroblast migratory lncRNA","metadata":{"aliases":["AC093801.1"]}},{"id":"8a5797b0f5de45fa998eb155ea085c37","type":"GENE","name":"HAGH","canonical_id":"hgnc:HGNC:4805","description":"hydroxyacylglutathione hydrolase","metadata":{"aliases":["GLO2","GLXII","HAGH1"]}},{"id":"cfd11d8eb0db450fa253306d224c1316","type":"GENE","name":"HAGHL","canonical_id":"hgnc:HGNC:14177","description":"hydroxyacylglutathione hydrolase like","metadata":{"aliases":["MGC2605"]}},{"id":"401b068ac7f0464e973ccdf5f49fbcc3","type":"GENE","name":"HAGLR","canonical_id":"hgnc:HGNC:43755","description":"HOXD antisense growth-associated long non-coding RNA","metadata":{"aliases":["Mdgt","MIR7704HG","STEEL","HOXD-AS1"]}},{"id":"ddb039f63f0c47c69bc728f30b4b69de","type":"GENE","name":"HAGLROS","canonical_id":"hgnc:HGNC:50646","description":"HAGLR opposite strand lncRNA","metadata":null},{"id":"4a232c39b0dd46c2894c55dd03934510","type":"TRIAL","name":"HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT","canonical_id":"clinicaltrials.gov:NCT05166239","description":"Hepatocellular Carcinoma; Portal Vein Thrombosis","metadata":null},{"id":"225cd9bb62764a5a87ef8511f12a7f90","type":"TRIAL","name":"HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC","canonical_id":"clinicaltrials.gov:NCT06335927","description":"Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"c446f3511aac40d39319357165409abf","type":"TRIAL","name":"HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT05400902","description":"Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"aa96712d30454e7894c4be7e90411b00","type":"TRIAL","name":"HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT06475287","description":"Hepatocellular Carcinoma","metadata":null},{"id":"c585c29d2c1241209f0d79692bab6517","type":"TRIAL","name":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","canonical_id":"clinicaltrials.gov:NCT05582278","description":"Unresectable Hepatocellular Carcinoma","metadata":null},{"id":"4760d6caa80149b994b480d5b0078463","type":"GENE","name":"HAL","canonical_id":"hgnc:HGNC:4806","description":"histidine ammonia-lyase","metadata":{"aliases":["HIS"]}},{"id":"8c9608963f4f440c83482358f9b6cf5c","type":"TRIAL","name":"HALT Progression of Polycystic Kidney Disease Study A","canonical_id":"clinicaltrials.gov:NCT00283686","description":"Kidney, Polycystic","metadata":null},{"id":"dfaca4906d3c46d1a8ef19436676abff","type":"TRIAL","name":"HALT Progression of Polycystic Kidney Disease Study B","canonical_id":"clinicaltrials.gov:NCT01885559","description":"Kidney, Polycystic","metadata":null},{"id":"d1079eaca37542d987df16506e969fb6","type":"GENE","name":"HAMP","canonical_id":"hgnc:HGNC:15598","description":null,"metadata":null},{"id":"af7688aaa2164b86a6ae67492f1b6a02","type":"GENE","name":"HAND1","canonical_id":"hgnc:HGNC:4807","description":"heart and neural crest derivatives expressed 1","metadata":{"aliases":["eHand","Thing1","Hxt","bHLHa27"]}},{"id":"eb88ada450564b378c8df12a7a1238b0","type":"GENE","name":"HAND1-AS1","canonical_id":"hgnc:HGNC:59287","description":"HAND1 antisense RNA 1","metadata":null},{"id":"d827902326f14d71b5d506d4c1e14b4c","type":"GENE","name":"HAND2","canonical_id":"hgnc:HGNC:4808","description":null,"metadata":null},{"id":"f2a09d584e3745118303fc9c0c3cf519","type":"GENE","name":"HAND2-AS1","canonical_id":"hgnc:HGNC:48872","description":"HAND2 antisense RNA 1","metadata":{"aliases":["DEIN","NBLA00301","FLJ11539"]}},{"id":"b80b286d162844b6bad53c14e34d0bed","type":"TRIAL","name":"HANDLE-a Real World Study on Satralizumab in NMOSD","canonical_id":"clinicaltrials.gov:NCT06829524","description":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","metadata":null},{"id":"c5190b3589c44fefbedafc14c6829c29","type":"GENE","name":"HAO1","canonical_id":"hgnc:HGNC:4809","description":"hydroxyacid oxidase 1","metadata":{"aliases":["GOX","GOX1"]}},{"id":"b0aa88969901467b9898c22bbad7edf3","type":"GENE","name":"HAO2","canonical_id":"hgnc:HGNC:4810","description":"hydroxyacid oxidase 2","metadata":{"aliases":["HAOX2","GIG16"]}},{"id":"90c444ef6cbf477bb7d24a22fb158e7b","type":"GENE","name":"HAO2-IT1","canonical_id":"hgnc:HGNC:41342","description":"HAO2 intronic transcript 1","metadata":null},{"id":"17a9e59d75c04a89aced665845ab592b","type":"GENE","name":"HAP1","canonical_id":"hgnc:HGNC:4812","description":null,"metadata":null},{"id":"4c73eea65b814b9ba2f399a29b1ec4f7","type":"GENE","name":"HAPLN1","canonical_id":"hgnc:HGNC:2380","description":"hyaluronan and proteoglycan link protein 1","metadata":{"aliases":["CRTL1"]}},{"id":"298af171ef4145ce9b356e53c178941d","type":"GENE","name":"HAPLN2","canonical_id":"hgnc:HGNC:17410","description":"hyaluronan and proteoglycan link protein 2","metadata":{"aliases":["BRAL1"]}},{"id":"270b205d775d4e75906fb964215f3701","type":"GENE","name":"HAPLN3","canonical_id":"hgnc:HGNC:21446","description":"hyaluronan and proteoglycan link protein 3","metadata":{"aliases":["HsT19883","EXLD1"]}},{"id":"66e969df67364ce69f70466bf6b5a554","type":"GENE","name":"HAPLN4","canonical_id":"hgnc:HGNC:31357","description":"hyaluronan and proteoglycan link protein 4","metadata":{"aliases":["BRAL2","KIAA1926"]}},{"id":"c1b5425ce4a246088936c5fc2579d26b","type":"GENE","name":"HAPSTR1","canonical_id":"hgnc:HGNC:30103","description":"HUWE1 associated protein modifying stress responses","metadata":{"aliases":["FLJ41272","PRO0149","TAPR1","C16orf72"]}},{"id":"57bac3e67fa74785867ffc8aef9ff613","type":"GENE","name":"HAPSTR2","canonical_id":"hgnc:HGNC:55138","description":"HUWE1 associated protein modifying stress responses 2","metadata":null},{"id":"821f0010176d48b3a31d058a2a64ff02","type":"GENE","name":"HAPSTR2-OT1","canonical_id":"hgnc:HGNC:58982","description":"HAPSTR2 overlapping transcript 1","metadata":{"aliases":["uc.482"]}},{"id":"2e39235279fa43aa99dadca90e163ae8","type":"GENE","name":"HAR1A","canonical_id":"hgnc:HGNC:33117","description":"highly accelerated region 1A","metadata":{"aliases":["HAR1F","NCRNA00064","LINC00064"]}},{"id":"3e07501cbb674e61b359689d35c5de8b","type":"GENE","name":"HAR1B","canonical_id":"hgnc:HGNC:33118","description":"highly accelerated region 1B","metadata":{"aliases":["HAR1R","NCRNA00065","LINC00065"]}},{"id":"280b005fcd014ccb8fae00a813f60c86","type":"GENE","name":"HARBI1","canonical_id":"hgnc:HGNC:26522","description":"harbinger transposase derived 1","metadata":{"aliases":["FLJ32675","C11orf77"]}},{"id":"eb995053b37f48349a4e89bab7afc1c6","type":"TRIAL","name":"HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt","canonical_id":"clinicaltrials.gov:NCT02073565","description":"Coronary Arteriosclerosis; Non ST Segment Elevation Acute Coronary Syndrome","metadata":null},{"id":"c653d72d6bdd460ba0f6b858dfce7cdf","type":"GENE","name":"HARS1","canonical_id":"hgnc:HGNC:4816","description":"histidyl-tRNA synthetase 1","metadata":{"aliases":["HisRS","USH3B","HARS"]}},{"id":"33b1e5308ab14af68b0392690d439530","type":"GENE","name":"HARS2","canonical_id":"hgnc:HGNC:4817","description":"histidyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["HO3","HARSR","HARSL"]}},{"id":"86670b2832ae450cb94536d3a0264154","type":"GENE","name":"HAS1","canonical_id":"hgnc:HGNC:4818","description":"hyaluronan synthase 1","metadata":{"aliases":["HAS"]}},{"id":"85a6e30344e841b69bf8a64ee18eaafc","type":"GENE","name":"HAS2","canonical_id":"hgnc:HGNC:4819","description":null,"metadata":null},{"id":"c912ec14e34e45d4a75e63d5bef7f673","type":"GENE","name":"HAS2-AS1","canonical_id":"hgnc:HGNC:34340","description":"HAS2 antisense RNA 1","metadata":{"aliases":["HASNT","NCRNA00077","HAS2AS","HAS2-AS"]}},{"id":"aabf81b7583a4bbd9fecf020bb3a3ce2","type":"GENE","name":"HAS3","canonical_id":"hgnc:HGNC:4820","description":"hyaluronan synthase 3","metadata":null},{"id":"99531a5649744779a12e1e4fbfe2c4c7","type":"GENE","name":"HASPIN","canonical_id":"hgnc:HGNC:19682","description":"histone H3 associated protein kinase","metadata":{"aliases":["GSG2"]}},{"id":"43e56ead03c844cbbb346ae3c1a8a198","type":"TRIAL","name":"HAT in Eye Complications of Behcet's Disease","canonical_id":"clinicaltrials.gov:NCT00001865","description":"Behcet's Syndrome; Retinal Disease; Uveitis","metadata":null},{"id":"771af26b2df745619510e6c79d2a2e7c","type":"GENE","name":"HAT1","canonical_id":"hgnc:HGNC:4821","description":"histone acetyltransferase 1","metadata":{"aliases":["KAT1"]}},{"id":"baad6531fbc846b7868a7d162bf6dbc7","type":"GO_TERM","name":"HAUS complex","canonical_id":"go:GO:0070652","description":"\"A protein complex that localizes to interphase centrosomes and to mitotic spindle tubules and regulates mitotic spindle assembly and centrosome integrity; in human, the complex consists of eight subunits, some of which are homologous to subunits of the Drosophila Augmin complex.\" [PMID:19427217]","metadata":null},{"id":"eb2e5f693ee8493fa5e6c39114e31e19","type":"GENE","name":"HAUS1","canonical_id":"hgnc:HGNC:25174","description":"HAUS augmin like complex subunit 1","metadata":{"aliases":["HEI-C","HsT1461","FLJ40084","CCDC5"]}},{"id":"c189ba5c477a468d8a224a86507535c0","type":"GENE","name":"HAUS1P1","canonical_id":"hgnc:HGNC:43760","description":"HAUS augmin like complex subunit 1 pseudogene 1","metadata":null},{"id":"a4e76b9c47254122a36247aa146cbeb4","type":"GENE","name":"HAUS1P2","canonical_id":"hgnc:HGNC:43761","description":"HAUS augmin like complex subunit 1 pseudogene 2","metadata":null},{"id":"b0942083f1074ef28594c0b9b28c6f24","type":"GENE","name":"HAUS1P3","canonical_id":"hgnc:HGNC:43762","description":"HAUS augmin like complex subunit 1 pseudogene 3","metadata":null},{"id":"a39054dc78454411a503e0d5fbc2ac75","type":"GENE","name":"HAUS2","canonical_id":"hgnc:HGNC:25530","description":"HAUS augmin like complex subunit 2","metadata":{"aliases":["FLJ10460","HsT17025","C15orf25","CEP27"]}},{"id":"f9d976e1bd0047b7a287825c2ee1a184","type":"GENE","name":"HAUS3","canonical_id":"hgnc:HGNC:28719","description":"HAUS augmin like complex subunit 3","metadata":{"aliases":["MGC4701","IT1","dgt3","C4orf15"]}},{"id":"4e8cd962b4b34568ac0d056187cf9b6f","type":"GENE","name":"HAUS4","canonical_id":"hgnc:HGNC:20163","description":"HAUS augmin like complex subunit 4","metadata":{"aliases":["FLJ20424","C14orf94"]}},{"id":"0d16fe001ec04852937338484c6896f7","type":"GENE","name":"HAUS4P1","canonical_id":"hgnc:HGNC:43763","description":"HAUS augmin like complex subunit 4 pseudogene 1","metadata":null},{"id":"3cac8b4e485242b7a40a0d51f7d37acc","type":"GENE","name":"HAUS5","canonical_id":"hgnc:HGNC:29130","description":"HAUS augmin like complex subunit 5","metadata":{"aliases":["dgt5","KIAA0841"]}},{"id":"5fe6ecd1e0be46df9a0994932e6d326b","type":"GENE","name":"HAUS5-DT","canonical_id":"hgnc:HGNC:55291","description":"HAUS5 divergent transcript","metadata":null},{"id":"05a40e43c86d48c381c77676b8fd6d9e","type":"GENE","name":"HAUS6","canonical_id":"hgnc:HGNC:25948","description":"HAUS augmin like complex subunit 6","metadata":{"aliases":["FLJ20060","KIAA1574","dgt6","FAM29A"]}},{"id":"7ba54299760d402c9d34d6d184864846","type":"GENE","name":"HAUS6P1","canonical_id":"hgnc:HGNC:43764","description":"HAUS augmin like complex subunit 6 pseudogene 1","metadata":null},{"id":"dfadea0129dd47d2b3e30da8157866c2","type":"GENE","name":"HAUS6P2","canonical_id":"hgnc:HGNC:43765","description":"HAUS augmin like complex subunit 6 pseudogene 2","metadata":null},{"id":"94ff4901001b42ac866e7f4a98f3256b","type":"GENE","name":"HAUS6P3","canonical_id":"hgnc:HGNC:50772","description":"HAUS augmin like complex subunit 6 pseudogene 3","metadata":null},{"id":"cadb0c435d7f48019ab4fd0973d59ea3","type":"GENE","name":"HAUS7","canonical_id":"hgnc:HGNC:32979","description":"HAUS augmin like complex subunit 7","metadata":{"aliases":["UIP1","UCHL5IP"]}},{"id":"c43b1bf7f1ff49549529adb29c335e64","type":"GENE","name":"HAUS8","canonical_id":"hgnc:HGNC:30532","description":"HAUS augmin like complex subunit 8","metadata":{"aliases":["MGC20533","NY-SAR-48","HICE1"]}},{"id":"f6b378c872f04a6bb573c122b5ea4a63","type":"GENE","name":"HAUS8P1","canonical_id":"hgnc:HGNC:43766","description":"HAUS augmin like complex subunit 8 pseudogene 1","metadata":null},{"id":"831cd08e3c1f4eed834f5b296b88c433","type":"GENE","name":"HAVCR1","canonical_id":"hgnc:HGNC:17866","description":"hepatitis A virus cellular receptor 1","metadata":{"aliases":["HAVCR-1","TIM-1","TIM1","HAVCR","TIMD1","CD365","KIM1"]}},{"id":"0808b2fd583949dd8ffe90d1351f36df","type":"GENE","name":"HAVCR1P1","canonical_id":"hgnc:HGNC:44033","description":"hepatitis A virus cellular receptor 1 pseudogene 1","metadata":null},{"id":"f25d9687d3c942c99d3447851725b381","type":"GENE","name":"HAVCR1P2","canonical_id":"hgnc:HGNC:44035","description":"hepatitis A virus cellular receptor 1 pseudogene 2","metadata":null},{"id":"7d7638b3e7cd4d29a0df35d8d18deec8","type":"GENE","name":"HAVCR2","canonical_id":"hgnc:HGNC:18437","description":"hepatitis A virus cellular receptor 2","metadata":{"aliases":["Tim-3","TIM3","FLJ14428","TIMD3","CD366"]}},{"id":"158466a450fd4ac493a106546a38bf18","type":"GENE","name":"HAVCR2-AS1","canonical_id":"hgnc:HGNC:40840","description":"HAVCR2 antisense RNA 1","metadata":null},{"id":"d41a14b252ea4f3595fd3719fda23210","type":"GENE","name":"HAX1","canonical_id":"hgnc:HGNC:16915","description":null,"metadata":null},{"id":"b1f51235318f42639d8bb5299a46c7ff","type":"GENE","name":"HAX1P1","canonical_id":"hgnc:HGNC:55151","description":"HAX1 pseudogene 1","metadata":null},{"id":"cb3729bae5f8446e889972e71cd0f93a","type":"GENE","name":"HBA1","canonical_id":"hgnc:HGNC:4823","description":null,"metadata":null},{"id":"6e528dbd679f459caaef67ec2b7ea28c","type":"GENE","name":"HBA2","canonical_id":"hgnc:HGNC:4824","description":null,"metadata":null},{"id":"83f2969785654b348dcb57b0f97b5f05","type":"GENE","name":"HBAP1","canonical_id":"hgnc:HGNC:4825","description":"hemoglobin subunit alpha pseudogene 1","metadata":{"aliases":["HBA-T1","HBA3","HBA3P","HBA-T1ps"]}},{"id":"6191bf9fbd4a4d6c8e5f98b3cdab913f","type":"GENE","name":"HBB","canonical_id":"hgnc:HGNC:4827","description":null,"metadata":null},{"id":"087d2e51138f45ba95f546c8a42635de","type":"GENE","name":"HBBP1","canonical_id":"hgnc:HGNC:4828","description":"hemoglobin subunit beta pseudogene 1","metadata":{"aliases":["HBH1","HBHP","HBHps"]}},{"id":"4e0c9ab57ef54835becc5e30ec258284","type":"GENE","name":"HBD","canonical_id":"hgnc:HGNC:4829","description":null,"metadata":null},{"id":"41135f246ae74d07aaf69dbec2198a44","type":"GENE","name":"HBE1","canonical_id":"hgnc:HGNC:4830","description":null,"metadata":null},{"id":"f02276eb54b34ed699983e231903f631","type":"GENE","name":"HBEGF","canonical_id":"hgnc:HGNC:3059","description":null,"metadata":null},{"id":"728f71b267e7446c97d22518c0efac6d","type":"GENE","name":"HBG1","canonical_id":"hgnc:HGNC:4831","description":null,"metadata":null},{"id":"6b99201877a8410f9706aa2814d05b2a","type":"GENE","name":"HBG2","canonical_id":"hgnc:HGNC:4832","description":"hemoglobin subunit gamma 2","metadata":{"aliases":["HBG-T1"]}},{"id":"5b81163d0d8a4fd7a8f13550bf9dd753","type":"GENE","name":"HBM","canonical_id":"hgnc:HGNC:4826","description":"hemoglobin subunit mu","metadata":{"aliases":["HBK","HBAP2"]}},{"id":"f5527bcb943c473192e553ab173a566c","type":"GENE","name":"HBP1","canonical_id":"hgnc:HGNC:23200","description":null,"metadata":null},{"id":"3b8b70aa6fdb4de5a6c6cacd85921829","type":"GENE","name":"HBQ1","canonical_id":"hgnc:HGNC:4833","description":"hemoglobin subunit theta 1","metadata":{"aliases":["HBQ"]}},{"id":"c9e5277415f14ad6b7d25abe5306a7fc","type":"GENE","name":"HBS1L","canonical_id":"hgnc:HGNC:4834","description":"HBS1 like translational GTPase","metadata":{"aliases":["ERFS","HBS1","HSPC276","KIAA1038","DKFZp434g247","EF-1a","eRF3c"]}},{"id":"ef0c365dcda14fed9732ee5f79a5de5c","type":"TRIAL","name":"HBV Vaccine in Renal Failure Patients","canonical_id":"clinicaltrials.gov:NCT02621112","description":"Renal Failure","metadata":null},{"id":"79b588482de24d35bb774a42cc0d5eab","type":"GENE","name":"HBZ","canonical_id":"hgnc:HGNC:4835","description":null,"metadata":null},{"id":"4e345392dd4e4a7ab32dc432b0897292","type":"GENE","name":"HBZP1","canonical_id":"hgnc:HGNC:4836","description":"hemoglobin subunit zeta pseudogene 1","metadata":{"aliases":["HBZ-T2","HBZ2","HBZ2P","HBZP"]}},{"id":"8681fadebf3f4c40aea19b2a895bb2d2","type":"GENE","name":"HCAR1","canonical_id":"hgnc:HGNC:4532","description":"hydroxycarboxylic acid receptor 1","metadata":{"aliases":["HCA1","FKSG80","TA-GPCR","LACR1","GPR104","GPR81"]}},{"id":"4b96c2ea4ec643d495b7ab5a3edac355","type":"GENE","name":"HCAR2","canonical_id":"hgnc:HGNC:24827","description":"hydroxycarboxylic acid receptor 2","metadata":{"aliases":["HCA2","HM74A","PUMAG","Puma-g","NIACR1","GPR109A"]}},{"id":"9722bbca23c140eebd3071119742cce4","type":"GENE","name":"HCAR3","canonical_id":"hgnc:HGNC:16824","description":"hydroxycarboxylic acid receptor 3","metadata":{"aliases":["HCA3","HM74","GPR109B"]}},{"id":"70a5e66ea6ea42588b3fba2c49145bde","type":"GENE","name":"HCCAT5","canonical_id":"hgnc:HGNC:48612","description":"hepatocellular carcinoma associated transcript 5","metadata":{"aliases":["HTA","FJ222407"]}},{"id":"c8a92daafc4c4add9ba52f825e841001","type":"GENE","name":"HCCS","canonical_id":"hgnc:HGNC:4837","description":"holocytochrome c synthase","metadata":{"aliases":["CCHL","MLS"]}},{"id":"b115142c9c774c54a1fc3f3249ea8357","type":"GENE","name":"HCCS-DT","canonical_id":"hgnc:HGNC:55698","description":"HCCS divergent transcript","metadata":null},{"id":"277319e11a0c46fabd34adce1a18f134","type":"GENE","name":"HCFC1","canonical_id":"hgnc:HGNC:4839","description":null,"metadata":null},{"id":"e3270fa2af3f4f6f9ce7d96358465949","type":"GENE","name":"HCFC1-AS1","canonical_id":"hgnc:HGNC:40273","description":"HCFC1 antisense RNA 1","metadata":null},{"id":"3b3b33ab320342388463c8899c341571","type":"GENE","name":"HCFC1R1","canonical_id":"hgnc:HGNC:21198","description":"host cell factor C1 regulator 1","metadata":{"aliases":["HPIP","FLJ20568"]}},{"id":"a9085c532775452ab8578ee57a5c5d6d","type":"GENE","name":"HCFC2","canonical_id":"hgnc:HGNC:24972","description":"host cell factor C2","metadata":{"aliases":["HCF-2"]}},{"id":"9d299d5e802c460aa912ade7ecfba59e","type":"GENE","name":"HCFC2P1","canonical_id":"hgnc:HGNC:39815","description":"host cell factor C2 pseudogene 1","metadata":null},{"id":"fb385c03afd24782a9ad8d20e6c56533","type":"GENE","name":"HCG11","canonical_id":"hgnc:HGNC:17707","description":"HLA complex group 11","metadata":{"aliases":["bK14H9.3","FLJ14049","FLJ30357"]}},{"id":"f043ca2aa2a6468882332a2489f72462","type":"GENE","name":"HCG13P","canonical_id":"hgnc:HGNC:17724","description":"HLA complex group 13 pseudogene","metadata":{"aliases":["dJ193B12.5"]}},{"id":"a90572c1d698452caf05797465752c04","type":"GENE","name":"HCG14","canonical_id":"hgnc:HGNC:18323","description":"HLA complex group 14","metadata":{"aliases":["dJ111M5.4"]}},{"id":"58c4df24f8154e62a8be49cae3a20e03","type":"GENE","name":"HCG15","canonical_id":"hgnc:HGNC:18361","description":"HLA complex group 15","metadata":{"aliases":["dJ25J6.6","dJ25J6.7","HCG16"]}},{"id":"676d84f0d72c40dcb618a37e8671d3ce","type":"GENE","name":"HCG18","canonical_id":"hgnc:HGNC:31337","description":"HLA complex group 18","metadata":{"aliases":["FLJ31598","FLJ25550","Em:AB014087.1","HCG17"]}},{"id":"69098ee1e71a4252ba29660a9f58dd1e","type":"GENE","name":"HCG19P","canonical_id":"hgnc:HGNC:31336","description":"HLA complex group 19 pseudogene","metadata":{"aliases":["AB014085.4"]}},{"id":"36a5117c51e94d2797634ce7c5cb1442","type":"GENE","name":"HCG20","canonical_id":"hgnc:HGNC:31334","description":"HLA complex group 20","metadata":{"aliases":["AB023051.1","NCRNA00149"]}},{"id":"71f7705fec6d49318edb7249f5012442","type":"GENE","name":"HCG21","canonical_id":"hgnc:HGNC:31335","description":"HLA complex group 21","metadata":{"aliases":["AB023048.2","NCRNA00150"]}},{"id":"1302bb24a4e143c98eae6fa0fe502e6b","type":"GENE","name":"HCG22","canonical_id":"hgnc:HGNC:27780","description":"HLA complex group 22","metadata":{"aliases":["FLJ37114","PBMUCL2"]}},{"id":"1794e83fcaed41ee9872dc5d60b763dd","type":"GENE","name":"HCG23","canonical_id":"hgnc:HGNC:19713","description":"HLA complex group 23","metadata":{"aliases":["dJ1077I5.3"]}},{"id":"7dbfc20d0e244f389ad24e05b0d382c0","type":"GENE","name":"HCG24","canonical_id":"hgnc:HGNC:23500","description":"HLA complex group 24","metadata":{"aliases":["dJ1033B10.15"]}},{"id":"5b486c1558c44f8e9d0a71dcc1b7696e","type":"GENE","name":"HCG25","canonical_id":"hgnc:HGNC:20196","description":"HLA complex group 25","metadata":{"aliases":["dJ1033B10.16"]}},{"id":"1f0e045d0edd40a48a1ddb630d431827","type":"GENE","name":"HCG26","canonical_id":"hgnc:HGNC:29671","description":"HLA complex group 26","metadata":{"aliases":["bPG181B23.4","bCX205D4.4","NCRNA00191"]}},{"id":"28bc7ff5dac34b808bd0d56b8cf2a64b","type":"GENE","name":"HCG26P1","canonical_id":"hgnc:HGNC:23995","description":"HLA complex group 26 pseudogene 1","metadata":{"aliases":["3.8-1.2"]}},{"id":"b6383b9ffe9b47e0a267bfa15f0e0bcd","type":"GENE","name":"HCG26P2","canonical_id":"hgnc:HGNC:23996","description":"HLA complex group 26 pseudogene 2","metadata":{"aliases":["3.8-1.3"]}},{"id":"f27b1f782e3b46b7b57ffb93bbc23a18","type":"GENE","name":"HCG26P3","canonical_id":"hgnc:HGNC:23997","description":"HLA complex group 26 pseudogene 3","metadata":{"aliases":["3.8-1.4"]}},{"id":"730f4cd38347482cb467cfd5ebace44b","type":"GENE","name":"HCG26P4","canonical_id":"hgnc:HGNC:23998","description":"HLA complex group 26 pseudogene 4","metadata":{"aliases":["3.8-1.5"]}},{"id":"0d6fe23c798e4f239e39603d0534ba7a","type":"GENE","name":"HCG27","canonical_id":"hgnc:HGNC:27366","description":"HLA complex group 27","metadata":{"aliases":["bPG299F13.9","bCX101P6.9","bQB115I13.2","FLJ40123"]}},{"id":"3e6b824a51514299aea0e95f7f02bfaf","type":"GENE","name":"HCG4","canonical_id":"hgnc:HGNC:21241","description":"HLA complex group 4","metadata":{"aliases":["HCGIV-10","HCGIV.9","HCG4P10"]}},{"id":"fcd13293a12a410d94aa92001d4a92ce","type":"GENE","name":"HCG4B","canonical_id":"hgnc:HGNC:22919","description":"HLA complex group 4B","metadata":{"aliases":["HCGIV-6","HCGIV.5","HCGIV-06","bCX67J3.3","Em:AB023056.16","bPG309N1.1","bQB90C11.3","HCG4P6"]}},{"id":"f49ce15dda264147bd1c42f6cfb316d6","type":"GENE","name":"HCG4P1","canonical_id":"hgnc:HGNC:30978","description":"HLA complex group 4 pseudogene 1","metadata":{"aliases":["HCGIV-01"]}},{"id":"60e78a15675e45278dfe2fa33adead3b","type":"GENE","name":"HCG4P11","canonical_id":"hgnc:HGNC:22930","description":"HLA complex group 4 pseudogene 11","metadata":{"aliases":["HCGIV-11","HCGIV.10"]}},{"id":"293117644c044c77b2d97be643da3fc2","type":"GENE","name":"HCG4P2","canonical_id":"hgnc:HGNC:30979","description":"HLA complex group 4 pseudogene 2","metadata":{"aliases":["HCGIV-02"]}},{"id":"44c1171cbf014c638027a4cc83f63c72","type":"GENE","name":"HCG4P3","canonical_id":"hgnc:HGNC:22922","description":"HLA complex group 4 pseudogene 3","metadata":{"aliases":["HCGIV-03","HCGIV.2","HCGIV-3"]}},{"id":"eabeede8f3324148a36533ce0fda3891","type":"GENE","name":"HCG4P4","canonical_id":"hgnc:HGNC:22924","description":"HLA complex group 4 pseudogene 4","metadata":{"aliases":["HCGIV-04","HCGIV.3","HCGIV-4"]}},{"id":"4fedbe29d029441fb97fe429e041f280","type":"GENE","name":"HCG4P5","canonical_id":"hgnc:HGNC:22925","description":"HLA complex group 4 pseudogene 5","metadata":{"aliases":["HCGIV-05","HCGIV.4","HCGIV-5"]}},{"id":"9b75b0271f384e32ba9117539e6172f0","type":"GENE","name":"HCG4P7","canonical_id":"hgnc:HGNC:22926","description":"HLA complex group 4 pseudogene 7","metadata":{"aliases":["HCGIV-07","HCGIV.C","HCGIV-7"]}},{"id":"45b414828c314f89bd70aacf390be577","type":"GENE","name":"HCG4P8","canonical_id":"hgnc:HGNC:22927","description":"HLA complex group 4 pseudogene 8","metadata":{"aliases":["HCGIV-08","HCGIV.7","HCGIV-8"]}},{"id":"5fb99b3886ae480f8f1e3b3cf0208fd0","type":"GENE","name":"HCG4P9","canonical_id":"hgnc:HGNC:22928","description":"HLA complex group 4 pseudogene 9","metadata":{"aliases":["HCGIV-09","HCGIV-9"]}},{"id":"68aff566349049b9b8b7ffe08e52c94e","type":"GENE","name":"HCG9","canonical_id":"hgnc:HGNC:21243","description":"HLA complex group 9","metadata":{"aliases":["PERB11","HCGIX","HCGIX4","HCGIX-4"]}},{"id":"461069c8624946a1bfae22445d31375e","type":"GENE","name":"HCG9P1","canonical_id":"hgnc:HGNC:30980","description":"HLA complex group 9 pseudogene 1","metadata":{"aliases":["HCGIX-1"]}},{"id":"52f18f8dc47b4864bbc507d57eeb3051","type":"GENE","name":"HCG9P2","canonical_id":"hgnc:HGNC:30981","description":"HLA complex group 9 pseudogene 2","metadata":{"aliases":["HCGIX-2"]}},{"id":"ddad9a6c63ad45c496d0352918f1871c","type":"GENE","name":"HCG9P3","canonical_id":"hgnc:HGNC:30982","description":"HLA complex group 9 pseudogene 3","metadata":{"aliases":["HCGIX-3.2"]}},{"id":"d20bc51a35d14214863d4fd4b18e3d34","type":"GENE","name":"HCG9P5","canonical_id":"hgnc:HGNC:30983","description":"HLA complex group 9 pseudogene 5","metadata":{"aliases":["HCGIX-5","dJ377H14.6"]}},{"id":"dcd69e64df3a4a7b9fe520e65f05a516","type":"GENE","name":"HCK","canonical_id":"hgnc:HGNC:4840","description":null,"metadata":null},{"id":"1456498af69f43a8a5853f0544ba649b","type":"PROTEIN","name":"HCK","canonical_id":"uniprot:P08631","description":null,"metadata":null},{"id":"5e393afc539d4ab3b423eafce7bac5ef","type":"GENE","name":"HCLS1","canonical_id":"hgnc:HGNC:4844","description":"hematopoietic cell-specific Lyn substrate 1","metadata":{"aliases":["HS1","CTTNL"]}},{"id":"32638e3191d9409da8ea7d2ed082c979","type":"GO_TERM","name":"HCN channel complex","canonical_id":"go:GO:0098855","description":"\"A cation ion channel with a preference for K+ over Na+ ions, which is activated by membrane hyperpolarization, and consists of a tetramer of HCN family members. Some members of this family (HCN1, HCN2 and HCN4) are also activated when cAMP binds to their cyclic nucleotide binding domain (CNBD). Channel complexes of this family play an important role in the control of pacemaker activity in the heart.\" [PMID:20829353]","metadata":null},{"id":"8eac597a41c24429ba99558a5a1f24a1","type":"GENE","name":"HCN1","canonical_id":"hgnc:HGNC:4845","description":"hyperpolarization activated cyclic nucleotide gated potassium channel 1","metadata":{"aliases":["BCNG-1","HAC-2","BCNG1"]}},{"id":"582879bddcfb4c30af835f0b263beb9c","type":"GENE","name":"HCN2","canonical_id":"hgnc:HGNC:4846","description":null,"metadata":null},{"id":"f76af1b33b6749cf9fa28725424c5705","type":"GENE","name":"HCN3","canonical_id":"hgnc:HGNC:19183","description":"hyperpolarization activated cyclic nucleotide gated potassium channel 3","metadata":{"aliases":["KIAA1535"]}},{"id":"d5c951dfa7e74135bb3966e20fc81528","type":"GENE","name":"HCN4","canonical_id":"hgnc:HGNC:16882","description":null,"metadata":null},{"id":"65e8fa2a765045dba381336f16752f09","type":"GENE","name":"HCN4-AS1","canonical_id":"hgnc:HGNC:58475","description":"HCN4 antisense RNA 1","metadata":null},{"id":"c1ab9d8734b04f2f838ea8e9c4cb5c76","type":"GENE","name":"HCP5","canonical_id":"hgnc:HGNC:21659","description":"HLA complex P5","metadata":{"aliases":["D6S2650E","P5-1"]}},{"id":"9cc71ad1a6694b3f8f424f4ef946af71","type":"GENE","name":"HCP5B","canonical_id":"hgnc:HGNC:30984","description":"HLA complex P5B","metadata":{"aliases":["P5-10","P5.9","HCP5P10"]}},{"id":"36188b0084544f7b882c6a95a75dbf7b","type":"GENE","name":"HCRT","canonical_id":"hgnc:HGNC:4847","description":"hypocretin neuropeptide precursor","metadata":{"aliases":["PPOX","OX"]}},{"id":"2d103794d1ca4a07b4d34fc130b1c649","type":"GENE","name":"HCRTR1","canonical_id":"hgnc:HGNC:4848","description":"hypocretin receptor 1","metadata":{"aliases":["OX1R","OXR1","ORXR1"]}},{"id":"7b1bacb2fdbf43ed9945f824402c0b64","type":"PROTEIN","name":"HCRTR1","canonical_id":"uniprot:O43613","description":null,"metadata":null},{"id":"a228e7ff53f14d549db1db6e35714347","type":"GENE","name":"HCRTR2","canonical_id":"hgnc:HGNC:4849","description":"hypocretin receptor 2","metadata":{"aliases":["OX2R","OXR2","ORXR2"]}},{"id":"5e63cb6755854d31bf159ce7d7be5d87","type":"PROTEIN","name":"HCRTR2","canonical_id":"uniprot:O43614","description":null,"metadata":null},{"id":"27d0565866c24d8f86e0434607137c7f","type":"GENE","name":"HCST","canonical_id":"hgnc:HGNC:16977","description":"hematopoietic cell signal transducer","metadata":{"aliases":["DAP10","DKFZP586C1522","KAP10","PIK3AP"]}},{"id":"d4b4f3fc393f49c09bdb815be92186c8","type":"TRIAL","name":"HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01683188","description":"Metastatic Melanoma","metadata":null},{"id":"2bdd5b3c557f4248b6cdb76a5292dfa7","type":"TRIAL","name":"HD11 for Intermediate Stages","canonical_id":"clinicaltrials.gov:NCT00264953","description":"Hodgkin\u00b4s Lymphoma","metadata":null},{"id":"f9240bc7b5a14552acb3436ce603095a","type":"TRIAL","name":"HD21 for Advanced Stages","canonical_id":"clinicaltrials.gov:NCT02661503","description":"Classical Hodgkin Lymphoma","metadata":null},{"id":"62037111f6624ff89d85917573a113f7","type":"GO_TERM","name":"HDA1 complex","canonical_id":"go:GO:0070823","description":"\"A tetrameric histone deacetylase complex that contains a Class II deacetylase catalytic subunit. In S. cerevisiae it is composed of two Hda1p subunits along with Hda2p and Hda3p.\" [GOC:dgf, GOC:mah, PMID:11287668, PMID:8663039]","metadata":null},{"id":"75b7d97229d443aca022503d9248430d","type":"GENE","name":"HDAC1","canonical_id":"hgnc:HGNC:4852","description":null,"metadata":null},{"id":"d388535618124c198c7525e0c805b061","type":"PROTEIN","name":"HDAC1","canonical_id":"uniprot:Q13547","description":null,"metadata":null},{"id":"f7cb32e12eb84bfaa949326431b4de7c","type":"GENE","name":"HDAC10","canonical_id":"hgnc:HGNC:18128","description":null,"metadata":null},{"id":"36e927274a944e8895887f386a2c1c9a","type":"GENE","name":"HDAC11","canonical_id":"hgnc:HGNC:19086","description":null,"metadata":null},{"id":"3cfc032f87ac47ad94c7a0f18afda237","type":"GENE","name":"HDAC11-AS1","canonical_id":"hgnc:HGNC:40868","description":"HDAC11 antisense RNA 1","metadata":null},{"id":"23036e67aeff424da8c076abc05b43de","type":"GENE","name":"HDAC1P1","canonical_id":"hgnc:HGNC:45190","description":"histone deacetylase 1 pseudogene 1","metadata":null},{"id":"7ffd518c63dd41869a8a036b7bf4c8ea","type":"GENE","name":"HDAC1P2","canonical_id":"hgnc:HGNC:45191","description":"histone deacetylase 1 pseudogene 2","metadata":null},{"id":"0dd1070a193b46069c47826567d64fd7","type":"GENE","name":"HDAC2","canonical_id":"hgnc:HGNC:4853","description":null,"metadata":null},{"id":"3f3540b6290c425bb9a864535660c7ab","type":"PROTEIN","name":"HDAC2","canonical_id":"uniprot:Q92769","description":null,"metadata":null},{"id":"65f9f118287b41a0917ea9456824e28f","type":"GENE","name":"HDAC2-AS2","canonical_id":"hgnc:HGNC:43590","description":"HDAC2 and HS3ST5 antisense RNA 2","metadata":{"aliases":["ENST00000421891"]}},{"id":"d4b7bcffe1544fdcb89152c97d6099be","type":"GENE","name":"HDAC3","canonical_id":"hgnc:HGNC:4854","description":null,"metadata":null},{"id":"c038fd3b562f4e669e2f27f9cbc99a40","type":"PROTEIN","name":"HDAC3","canonical_id":"uniprot:O15379","description":null,"metadata":null},{"id":"605ed76d7940414aa4f3be137e98f291","type":"GENE","name":"HDAC3-AS1","canonical_id":"hgnc:HGNC:40178","description":"HDAC3 antisense RNA 1","metadata":null},{"id":"f8f20ce99757432e8a13c2250dd0e09b","type":"GENE","name":"HDAC4","canonical_id":"hgnc:HGNC:14063","description":null,"metadata":null},{"id":"92a00eddaa8d41138883105f1900d4ba","type":"GENE","name":"HDAC4-AS1","canonical_id":"hgnc:HGNC:54064","description":"HDAC4 antisense RNA 1","metadata":null},{"id":"f413b78520d947a6abfec8e43893bdf2","type":"GENE","name":"HDAC4-AS2","canonical_id":"hgnc:HGNC:58134","description":"HDAC4 antisense RNA 2","metadata":{"aliases":["meloe"]}},{"id":"b0aa3d06766541798f8c365d891de3a6","type":"GENE","name":"HDAC4-AS3","canonical_id":"hgnc:HGNC:58397","description":"HDAC4 antisense RNA 3","metadata":null},{"id":"6b9d4bfc96024f36a2298978d45f09b7","type":"GENE","name":"HDAC5","canonical_id":"hgnc:HGNC:14068","description":null,"metadata":null},{"id":"89c60897bfcf4ca28c864b5ecec67ec8","type":"GENE","name":"HDAC6","canonical_id":"hgnc:HGNC:14064","description":"histone deacetylase 6","metadata":{"aliases":["KIAA0901","JM21","HD6","FLJ16239","PPP1R90","KDAC6"]}},{"id":"0543b4ca8d644bb2a9d1bfd17576cece","type":"PROTEIN","name":"HDAC6","canonical_id":"uniprot:Q9UBN7","description":null,"metadata":null},{"id":"0eaefeaaa6ae41d3b9f1d5bb38e1e335","type":"GENE","name":"HDAC7","canonical_id":"hgnc:HGNC:14067","description":null,"metadata":null},{"id":"3e939b746d364930bf3b332bcc17458c","type":"GENE","name":"HDAC8","canonical_id":"hgnc:HGNC:13315","description":null,"metadata":null},{"id":"ad99338fe6bf4f2aadff72308f6dc9ca","type":"GENE","name":"HDAC9","canonical_id":"hgnc:HGNC:14065","description":null,"metadata":null},{"id":"744e881d02544c978267e02e07e601dd","type":"GENE","name":"HDAC9-AS1","canonical_id":"hgnc:HGNC:40664","description":"HDAC9 antisense RNA 1","metadata":null},{"id":"7b7efb78944843fc96a8d823ae5e2200","type":"GENE","name":"HDC","canonical_id":"hgnc:HGNC:4855","description":null,"metadata":null},{"id":"4e55fa54bd06474caff0856b19871238","type":"GENE","name":"HDDC2","canonical_id":"hgnc:HGNC:21078","description":"HD domain containing 2","metadata":{"aliases":["CGI-130","dJ167O5.2","C6orf74"]}},{"id":"a025648da5df4136841935e2b49ec18e","type":"GENE","name":"HDDC3","canonical_id":"hgnc:HGNC:30522","description":"HD domain containing 3","metadata":{"aliases":["MGC45386","MESH1","MYNRL15"]}},{"id":"3e635c9e10714867a0a9d1a1edfed197","type":"TRIAL","name":"HDDO-1614 Bio Equivalence Study","canonical_id":"clinicaltrials.gov:NCT03382314","description":"Osteoporosis","metadata":null},{"id":"51503233b93f46bd95d987d2a240b050","type":"TRIAL","name":"HDDO-1614 Intervention Trial","canonical_id":"clinicaltrials.gov:NCT03234244","description":"Osteoporosis","metadata":null},{"id":"7b89a80133d044f39d490053fa1bb7c8","type":"GENE","name":"HDGF","canonical_id":"hgnc:HGNC:4856","description":null,"metadata":null},{"id":"cddf5b64bff34106a0dd336385a6b211","type":"GENE","name":"HDGFL1","canonical_id":"hgnc:HGNC:21095","description":"HDGF like 1","metadata":{"aliases":["dJ309H15.1","Hdgfrp1","HRP-1","PWWP1"]}},{"id":"86ab89e45e1b4424a9eff033c2e3aec1","type":"GENE","name":"HDGFL2","canonical_id":"hgnc:HGNC:14680","description":"HDGF like 2","metadata":{"aliases":["HRP2","Hdgfrp2"]}},{"id":"8565f722842e4b48810d15f179db8a5d","type":"GENE","name":"HDGFL3","canonical_id":"hgnc:HGNC:24937","description":"HDGF like 3","metadata":{"aliases":["HRP-3","Hdgfrp3"]}},{"id":"2690cb7df89245b08c182bd59cf641b2","type":"GENE","name":"HDGFL3P1","canonical_id":"hgnc:HGNC:54965","description":"HDGFL3 pseudogene 1","metadata":null},{"id":"d5968740a7654b7cb0851614c1073925","type":"GENE","name":"HDGFP1","canonical_id":"hgnc:HGNC:31836","description":"heparin binding growth factor pseudogene 1","metadata":{"aliases":["HDGFP"]}},{"id":"5e7264558ac84591b58ac8a656d05bcb","type":"GENE","name":"HDHD2","canonical_id":"hgnc:HGNC:25364","description":"haloacid dehalogenase like hydrolase domain containing 2","metadata":{"aliases":["DKFZP564D1378"]}},{"id":"7fc4c73c4119474097124ce6467cb16a","type":"GENE","name":"HDHD3","canonical_id":"hgnc:HGNC:28171","description":"haloacid dehalogenase like hydrolase domain containing 3","metadata":{"aliases":["MGC12904","C9orf158"]}},{"id":"62cfab4cee1f4130a4eaf3ec6a03b0dd","type":"GENE","name":"HDHD5","canonical_id":"hgnc:HGNC:1843","description":"haloacid dehalogenase like hydrolase domain containing 5","metadata":{"aliases":["CECR5"]}},{"id":"3fcb1a362c7a46f99c7f49818771ee12","type":"GENE","name":"HDHD5-AS1","canonical_id":"hgnc:HGNC:1842","description":"HDHD5 antisense RNA 1","metadata":{"aliases":["NCRNA00017","CECR4","CECR5-AS1"]}},{"id":"93129e7951d240d4bc0137b0074950a9","type":"GENE","name":"HDIP1","canonical_id":"hgnc:HGNC:33754","description":"HDAC and MIER1 interacting protein 1","metadata":{"aliases":["C16orf87"]}},{"id":"406d335341944ba080ff2fa6c86bbe8a","type":"GO_TERM","name":"HDL-containing protein-lipid-RNA complex","canonical_id":"go:GO:1990685","description":"\"A protein-lipid-RNA complex containing separate high-density lipoprotein (HDL), lipid and RNA molecules. Separate in this context means not covalently bound to each other.\" [GOC:vesicles, PMID:21423178, PMID:23559634]","metadata":null},{"id":"58483e8f3332428eaad97b29ef8da36c","type":"GENE","name":"HDLBP","canonical_id":"hgnc:HGNC:4857","description":"high density lipoprotein binding protein","metadata":{"aliases":["HBP","VGL"]}},{"id":"11f5842b8b594ff5ae408183b92efc9b","type":"GENE","name":"HDLBP-AS1","canonical_id":"hgnc:HGNC:56103","description":"HDLBP antisense RNA 1","metadata":null},{"id":"200e4050df3947cea3527f111d46ce28","type":"TRIAL","name":"HDM201 Added to CT in R/R or Newly Diagnosed AML","canonical_id":"clinicaltrials.gov:NCT03760445","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"2b45819d50a54218ad646da9a19b791f","type":"TRIAL","name":"HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.","canonical_id":"clinicaltrials.gov:NCT04496999","description":"AML, Adult","metadata":null},{"id":"5f60117f86034dd18da19ec7fc5cb0b1","type":"GENE","name":"HDX","canonical_id":"hgnc:HGNC:26411","description":"highly divergent homeobox","metadata":{"aliases":["FLJ30678","CXorf43"]}},{"id":"070c000622ca4c6385400a446bf341d5","type":"GENE","name":"HEATR1","canonical_id":"hgnc:HGNC:25517","description":"HEAT repeat containing 1","metadata":{"aliases":["FLJ10359","BAP28","UTP10"]}},{"id":"7655c882f1d240aeacf1d2f2f21c5245","type":"GENE","name":"HEATR3","canonical_id":"hgnc:HGNC:26087","description":"HEAT repeat containing 3","metadata":{"aliases":["FLJ20718"]}},{"id":"0e936dccbf5b4516a8a40ff00fcc78da","type":"GENE","name":"HEATR3-AS1","canonical_id":"hgnc:HGNC:55406","description":"HEATR3 antisense RNA 1","metadata":null},{"id":"d9507ab9660e4cc597efbe7973b5987c","type":"GENE","name":"HEATR4","canonical_id":"hgnc:HGNC:16761","description":"HEAT repeat containing 4","metadata":{"aliases":["MGC48595"]}},{"id":"a8a5b06cd7394ebab5d7efafbb608ff3","type":"GENE","name":"HEATR5A","canonical_id":"hgnc:HGNC:20276","description":"HEAT repeat containing 5A","metadata":{"aliases":["DKFZP434I1735","p200b","C14orf125"]}},{"id":"7c57940a4ea64c46933d7bf167727d05","type":"GENE","name":"HEATR5A-DT","canonical_id":"hgnc:HGNC:55552","description":"HEATR5A divergent transcript","metadata":null},{"id":"f4dcd308bf9e4edbad156b74ef63b667","type":"GENE","name":"HEATR5B","canonical_id":"hgnc:HGNC:29273","description":"HEAT repeat containing 5B","metadata":{"aliases":["KIAA1414","DKFZp686P15184","p200","p200a"]}},{"id":"a8548f7f90554ff6844a06faa93d989e","type":"GENE","name":"HEATR6","canonical_id":"hgnc:HGNC:24076","description":"HEAT repeat containing 6","metadata":{"aliases":["ABC1","FLJ22087"]}},{"id":"507f8904a9e74eceb93eb1dd207c5281","type":"GENE","name":"HEATR6-DT","canonical_id":"hgnc:HGNC:52929","description":"HEATR6 divergent transcript","metadata":{"aliases":["AC025048.4"]}},{"id":"04f497d8dfe3446db7b76907a79bc5cd","type":"GENE","name":"HEATR9","canonical_id":"hgnc:HGNC:26548","description":"HEAT repeat containing 9","metadata":{"aliases":["FLJ32830","C17orf66"]}},{"id":"468b180c59dc425b8930a1a97aa01ae2","type":"GENE","name":"HEBP1","canonical_id":"hgnc:HGNC:17176","description":"heme binding protein 1","metadata":{"aliases":["HEBP","HBP"]}},{"id":"db69b081ea684d50bf9949a18aa4b5ad","type":"GENE","name":"HEBP2","canonical_id":"hgnc:HGNC:15716","description":"heme binding protein 2","metadata":{"aliases":["SOUL","C6orf34"]}},{"id":"8efca351211e42c9a42bd91284eee192","type":"GENE","name":"HEBP2P1","canonical_id":"hgnc:HGNC:54784","description":"HEBP2 pseudogene 1","metadata":null},{"id":"883edd30ceb44e75b91667c3a7a9fb79","type":"GENE","name":"HECA","canonical_id":"hgnc:HGNC:21041","description":null,"metadata":null},{"id":"1056c147e3174135944f4cc72dd6c3da","type":"GO_TERM","name":"HECT domain binding","canonical_id":"go:GO:0032399","description":"\"Binding to a HECT, 'Homologous to the E6-AP Carboxy-Terminus', domain of a protein.\" [GOC:mah, Pfam:PF00632]","metadata":null},{"id":"b2c6824e59b0425ab9668d80f21b9a40","type":"GENE","name":"HECTD1","canonical_id":"hgnc:HGNC:20157","description":"HECT domain E3 ubiquitin protein ligase 1","metadata":{"aliases":["KIAA1131"]}},{"id":"6f2a4350da2445a988d1cbd9a6ef7d72","type":"GENE","name":"HECTD2","canonical_id":"hgnc:HGNC:26736","description":"HECT domain E3 ubiquitin protein ligase 2","metadata":{"aliases":["FLJ37306"]}},{"id":"7141cfddc0ba4c19a64a272ff982ac08","type":"GENE","name":"HECTD2-AS1","canonical_id":"hgnc:HGNC:48679","description":"HECTD2 antisense RNA 1","metadata":null},{"id":"841d3f88055647918697680317753ec7","type":"GENE","name":"HECTD3","canonical_id":"hgnc:HGNC:26117","description":"HECT domain E3 ubiquitin protein ligase 3","metadata":{"aliases":["FLJ21156"]}},{"id":"6b975e9870d0410d9a757636276bd810","type":"GENE","name":"HECTD4","canonical_id":"hgnc:HGNC:26611","description":"HECT domain E3 ubiquitin protein ligase 4","metadata":{"aliases":["FLJ34154","KIAA0614","C12orf51"]}},{"id":"831cdfd777344784990da28082d30edd","type":"GENE","name":"HECW1","canonical_id":"hgnc:HGNC:22195","description":"HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1","metadata":{"aliases":["KIAA0322","NEDL1"]}},{"id":"727022d3a49940509462a66b1ce2e2a7","type":"GENE","name":"HECW1-IT1","canonical_id":"hgnc:HGNC:41465","description":"HECW1 intronic transcript 1","metadata":null},{"id":"98f8e06d1ed644c18dad329280eba7d4","type":"GENE","name":"HECW2","canonical_id":"hgnc:HGNC:29853","description":"HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2","metadata":{"aliases":["KIAA1301","NEDL2"]}},{"id":"8c9f5515c1d3427686d62bddad532a89","type":"GENE","name":"HECW2-AS1","canonical_id":"hgnc:HGNC:54062","description":"HECW2 antisense RNA 1","metadata":null},{"id":"4aea0e5f76d64b4cb640f96ee051a424","type":"GENE","name":"HEG1","canonical_id":"hgnc:HGNC:29227","description":"heart development protein with EGF like domains 1","metadata":{"aliases":["KIAA1237","HEG"]}},{"id":"beae68ed36f1491084a0f9269af1eef4","type":"GENE","name":"HEIH","canonical_id":"hgnc:HGNC:45049","description":"hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA","metadata":{"aliases":["LINC-HEIH","lncRNA-HEIH","LINC00848","HCCAT2"]}},{"id":"a966fd4e3a27415fad70c56960520f21","type":"GENE","name":"HELB","canonical_id":"hgnc:HGNC:17196","description":"DNA helicase B","metadata":null},{"id":"c8365b3549474d27afb4f2e1ac320629","type":"GENE","name":"HELLPAR","canonical_id":"hgnc:HGNC:43984","description":"HELLP associated long non-coding RNA","metadata":{"aliases":["LINC-HELLP"]}},{"id":"f00a1d0dcdc44735b74d64f2e2e1626a","type":"GENE","name":"HELLS","canonical_id":"hgnc:HGNC:4861","description":"helicase, lymphoid specific","metadata":{"aliases":["PASG","SMARCA6","LSH","Nbla10143","SALNR"]}},{"id":"54dd2a13a1584b79bb16cdddfd6e98ea","type":"GENE","name":"HELQ","canonical_id":"hgnc:HGNC:18536","description":"helicase, POLQ like","metadata":{"aliases":["Hel308"]}},{"id":"f32575b7a8c146d699a731412c1d88f9","type":"GENE","name":"HELT","canonical_id":"hgnc:HGNC:33783","description":"helt bHLH transcription factor","metadata":{"aliases":["HESL","HCM1228","Mgn","bHLHb44","MEGANE"]}},{"id":"9999707ec03a4eb0b097a1a3e3417e63","type":"GENE","name":"HELZ","canonical_id":"hgnc:HGNC:16878","description":"helicase with zinc finger","metadata":{"aliases":["KIAA0054","HUMORF5","DHRC"]}},{"id":"2b611ca91c2d4b7b84af5c9daa4dde03","type":"GENE","name":"HELZ-AS1","canonical_id":"hgnc:HGNC:55319","description":"HELZ antisense RNA 1","metadata":null},{"id":"867dcf925cfc4ce083dab52df3138b6f","type":"GENE","name":"HELZ2","canonical_id":"hgnc:HGNC:30021","description":"helicase with zinc finger 2","metadata":{"aliases":["PDIP1","PRIC285","KIAA1769"]}},{"id":"19bdf426fba7457b8048750ad09c6299","type":"TRIAL","name":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","canonical_id":"clinicaltrials.gov:NCT05658640","description":"Acute Lymphoblastic Leukemia, in Relapse; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory","metadata":null},{"id":"f298bae57c8b4d29b12de96ae465866c","type":"TRIAL","name":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","canonical_id":"clinicaltrials.gov:NCT07175415","description":"Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory","metadata":null},{"id":"0af51fba470b4d05952b2df6c9354bcd","type":"GENE","name":"HEMGN","canonical_id":"hgnc:HGNC:17509","description":null,"metadata":null},{"id":"90748be9fe154a6bb44b779933b11db6","type":"GENE","name":"HEMK1","canonical_id":"hgnc:HGNC:24923","description":"HemK methyltransferase 1, mitochondrial release factors N(5)-glutamine","metadata":{"aliases":["MTQ1"]}},{"id":"40fc181178334d55989234ece6ae8534","type":"GENE","name":"HEMK2","canonical_id":"hgnc:HGNC:16021","description":"HemK methyltransferase 2, ETF1 glutamine and histone H4 lysine","metadata":{"aliases":["PRED28","N6AMT","MTQ2","KMT9","PrmC","N6AMT1","C21orf127"]}},{"id":"579f383dc99246558a8387dc68405cca","type":"GENE","name":"HENMT1","canonical_id":"hgnc:HGNC:26400","description":"HEN methyltransferase 1","metadata":{"aliases":["FLJ30525","HEN1","C1orf59"]}},{"id":"c80e4cf9323c4657a62cedd10f56ca9e","type":"GENE","name":"HEPACAM","canonical_id":"hgnc:HGNC:26361","description":"hepatic and glial cell adhesion molecule","metadata":{"aliases":["FLJ25530","GLIALCAM"]}},{"id":"999e23926642424e8c72ca06d7069c42","type":"GENE","name":"HEPACAM2","canonical_id":"hgnc:HGNC:27364","description":"HEPACAM family member 2","metadata":{"aliases":["FLJ38683"]}},{"id":"ccf9d95dbd5544ae940c607d32f092b9","type":"GENE","name":"HEPFAL","canonical_id":"hgnc:HGNC:56244","description":"hepatocellular carcinoma ferroptosis associative lncRNA","metadata":{"aliases":["KB-68A7.1","LINC03038"]}},{"id":"6120d82b255a4143bf2cd36bba0f700a","type":"GENE","name":"HEPH","canonical_id":"hgnc:HGNC:4866","description":null,"metadata":null},{"id":"acff4f08c6f945bb92add0ef57a9f19f","type":"GENE","name":"HEPHL1","canonical_id":"hgnc:HGNC:30477","description":"hephaestin like 1","metadata":{"aliases":["DKFZp686F22190","Zp"]}},{"id":"aac9703355984df08ba659a2cdb2fed5","type":"GENE","name":"HEPN1","canonical_id":"hgnc:HGNC:34400","description":"hepatocellular carcinoma, down-regulated 1","metadata":null},{"id":"dc147c45804e4643aea836b784e95e8b","type":"DISEASE","name":"HER2 Negative Breast Cancer","canonical_id":"doid:0060080","description":null,"metadata":null},{"id":"6edef48a1dff4cc4bcb47ac416289215","type":"DISEASE","name":"HER2 Positive Breast Cancer","canonical_id":"doid:0060079","description":null,"metadata":null},{"id":"79a3e33525eb430fa4af49b04eff90d7","type":"DISEASE","name":"HER2 positive breast carcinoma","canonical_id":"mondo:0006244","description":null,"metadata":null},{"id":"22a09472a06b45a7a7d73ea36b117a12","type":"TRIAL","name":"HER2-Peptide Vaccination of Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02276300","description":"Gastric Cancer; Breast Cancer","metadata":null},{"id":"6c43bfa5ec97468d8911a5a3108ca575","type":"TRIAL","name":"HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT07848633","description":"HER 2 Positive Advanced Breast Cancer","metadata":null},{"id":"84f6f4e509f54e4e851856d83347f5bb","type":"GENE","name":"HERC1","canonical_id":"hgnc:HGNC:4867","description":"HECT and RLD domain containing E3 ubiquitin protein ligase family member 1","metadata":{"aliases":["p532","p619"]}},{"id":"3c3e34e011b24c62917b9eae427424d7","type":"GENE","name":"HERC2","canonical_id":"hgnc:HGNC:4868","description":null,"metadata":null},{"id":"952e079dd9b349d79e56c51e29965568","type":"GENE","name":"HERC2P1","canonical_id":"hgnc:HGNC:4869","description":"HERC2 pseudogene 1","metadata":{"aliases":["D15F37S2"]}},{"id":"9556a6409bb048ac962a036b7fa3d053","type":"GENE","name":"HERC2P10","canonical_id":"hgnc:HGNC:39056","description":"HERC2 pseudogene 10","metadata":null},{"id":"42c4ee75dc074ede9aa1dbb8e82f2371","type":"GENE","name":"HERC2P11","canonical_id":"hgnc:HGNC:49882","description":"HERC2 pseudogene 11","metadata":null},{"id":"702caf2fe5624a30971aac4720fcb8a4","type":"GENE","name":"HERC2P2","canonical_id":"hgnc:HGNC:4870","description":"HERC2 pseudogene 2","metadata":{"aliases":["D15F37S3"]}},{"id":"8c333947c1fd487d852f1a6766eec141","type":"GENE","name":"HERC2P3","canonical_id":"hgnc:HGNC:4871","description":"HERC2 pseudogene 3","metadata":{"aliases":["D15F37S4","LOC283755"]}},{"id":"ef0a299a933c439da1391265f333c409","type":"GENE","name":"HERC2P4","canonical_id":"hgnc:HGNC:4872","description":"HERC2 pseudogene 4","metadata":{"aliases":["D16F37S5"]}},{"id":"1cd0d5c3f8ae4b4d9c0971d639adea70","type":"GENE","name":"HERC2P5","canonical_id":"hgnc:HGNC:4873","description":"HERC2 pseudogene 5","metadata":{"aliases":["D16F37S6"]}},{"id":"b585bb46e4fe4140b47a1ccedfc81b7b","type":"GENE","name":"HERC2P6","canonical_id":"hgnc:HGNC:4874","description":"HERC2 pseudogene 6","metadata":null},{"id":"69a709dbe8b14f86ae685de99e052eea","type":"GENE","name":"HERC2P7","canonical_id":"hgnc:HGNC:4875","description":"HERC2 pseudogene 7","metadata":null},{"id":"8c900b31b42343839023881dc8f787d1","type":"GENE","name":"HERC2P8","canonical_id":"hgnc:HGNC:38747","description":"HERC2 pseudogene 8","metadata":null},{"id":"4b7dc3cf2b084c38bdb74178c9f40fba","type":"GENE","name":"HERC2P9","canonical_id":"hgnc:HGNC:30495","description":"HERC2 pseudogene 9","metadata":{"aliases":["FLJ59185"]}},{"id":"3c511517fef745b184900c4f7ac9f02c","type":"GENE","name":"HERC3","canonical_id":"hgnc:HGNC:4876","description":"HECT and RLD domain containing E3 ubiquitin protein ligase 3","metadata":{"aliases":["KIAA0032"]}},{"id":"85a501516f194a169cc99a732192a69c","type":"GENE","name":"HERC4","canonical_id":"hgnc:HGNC:24521","description":"HECT and RLD domain containing E3 ubiquitin protein ligase 4","metadata":{"aliases":["DKFZP564G092","KIAA1593"]}},{"id":"898fe59793d44e819bf9e3d2f5bac10f","type":"GENE","name":"HERC5","canonical_id":"hgnc:HGNC:24368","description":"HECT and RLD domain containing E3 ubiquitin protein ligase 5","metadata":{"aliases":["CEB1"]}},{"id":"79c364b4b23447fa99b284d3e06a20ac","type":"GENE","name":"HERC5-AS1","canonical_id":"hgnc:HGNC:58846","description":"HERC5 and HERC6 antisense RNA 1","metadata":null},{"id":"f5afb7ba6d56452f821cc11a152b25e9","type":"GENE","name":"HERC6","canonical_id":"hgnc:HGNC:26072","description":"HECT and RLD domain containing E3 ubiquitin protein ligase family member 6","metadata":{"aliases":["FLJ20637"]}},{"id":"1e4f00319d3546fb86f06f840322ef5d","type":"GENE","name":"HERC6-AS1","canonical_id":"hgnc:HGNC:58845","description":"HERC6 antisense RNA 1","metadata":null},{"id":"0e6a19498b51469facbe81d7b832a0da","type":"TRIAL","name":"HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC","canonical_id":"clinicaltrials.gov:NCT07591805","description":"Upper Urinary Tract Urothelial Carcinoma","metadata":null},{"id":"70b1e4c2bd0847d194e907ff999dd352","type":"GENE","name":"HERPUD1","canonical_id":"hgnc:HGNC:13744","description":"homocysteine inducible ER protein with ubiquitin like domain 1","metadata":{"aliases":["KIAA0025","Mif1","HERP","SUP","HERPUD1-IT1"]}},{"id":"78f6a731b5644ba195bd1a6f42e7353b","type":"GENE","name":"HERPUD2","canonical_id":"hgnc:HGNC:21915","description":"HERPUD family member 2","metadata":{"aliases":["FLJ22313"]}},{"id":"40a35c64f8594a6b807e5203296f7b96","type":"GENE","name":"HERPUD2-AS1","canonical_id":"hgnc:HGNC:55258","description":"HERPUD2 antisense RNA 1","metadata":null},{"id":"9639b2499211424b853dd77f2cd93fce","type":"GENE","name":"HES1","canonical_id":"hgnc:HGNC:5192","description":null,"metadata":null},{"id":"76e2676b2a1c49b1bb448f78fcf23eab","type":"GENE","name":"HES2","canonical_id":"hgnc:HGNC:16005","description":"hes family bHLH transcription factor 2","metadata":{"aliases":["bHLHb40"]}},{"id":"af520fbb0fc44ebc8d83dad1564fa814","type":"GENE","name":"HES3","canonical_id":"hgnc:HGNC:26226","description":"hes family bHLH transcription factor 3","metadata":{"aliases":["bHLHb43"]}},{"id":"d2b82abfba5346da817cac1a18c4235a","type":"GENE","name":"HES4","canonical_id":"hgnc:HGNC:24149","description":"hes family bHLH transcription factor 4","metadata":{"aliases":["bHLHb42"]}},{"id":"c94129161c7e467daa85920d23cfb83e","type":"GENE","name":"HES5","canonical_id":"hgnc:HGNC:19764","description":"hes family bHLH transcription factor 5","metadata":{"aliases":["bHLHb38"]}},{"id":"2964664c5b50442a8480ac85faa5cdd8","type":"GENE","name":"HES6","canonical_id":"hgnc:HGNC:18254","description":null,"metadata":null},{"id":"2f642021bd8e4d5cbb72353ddbc0e4a7","type":"GENE","name":"HES7","canonical_id":"hgnc:HGNC:15977","description":"hes family bHLH transcription factor 7","metadata":{"aliases":["bHLHb37"]}},{"id":"bb3b3e50e7194bfea58fd2c653623f3b","type":"GENE","name":"HESX1","canonical_id":"hgnc:HGNC:4877","description":null,"metadata":null},{"id":"578de7730e34441090de479756b1a4fa","type":"GENE","name":"HEXA","canonical_id":"hgnc:HGNC:4878","description":"hexosaminidase subunit alpha","metadata":null},{"id":"bdd7c11b098b43c3a23db1589ded183f","type":"GENE","name":"HEXA-AS1","canonical_id":"hgnc:HGNC:25810","description":"HEXA antisense RNA 1","metadata":{"aliases":["FLJ13315","C15orf34"]}},{"id":"8965f41728d64778b615ae6541f5aad0","type":"GENE","name":"HEXB","canonical_id":"hgnc:HGNC:4879","description":"hexosaminidase subunit beta","metadata":null},{"id":"41c3d4ee5a884b249b458911941281b6","type":"GENE","name":"HEXB-AS1","canonical_id":"hgnc:HGNC:59069","description":"HEXB antisense RNA 1","metadata":null},{"id":"22a6fe38146a4215a6079032c58b2bef","type":"GENE","name":"HEXD","canonical_id":"hgnc:HGNC:26307","description":"hexosaminidase D","metadata":{"aliases":["FLJ23825","HEXDC"]}},{"id":"48028e78aab04b77933e2fea61576e43","type":"GENE","name":"HEXD-IT1","canonical_id":"hgnc:HGNC:43650","description":"HEXD intronic transcript 1","metadata":{"aliases":["HEXDC-IT1"]}},{"id":"a03c7f6f0e1749b08e1edc3a3a12d403","type":"GENE","name":"HEXIM1","canonical_id":"hgnc:HGNC:24953","description":null,"metadata":null},{"id":"f4621fe02a5b40e08cc6dc79a3a5766d","type":"GENE","name":"HEXIM2","canonical_id":"hgnc:HGNC:28591","description":"HEXIM P-TEFb complex subunit 2","metadata":{"aliases":["FLJ32384"]}},{"id":"f2e2b16b434947f4b6a63de571b02771","type":"GENE","name":"HEXIM2-AS1","canonical_id":"hgnc:HGNC:55857","description":"HEXIM2 antisense RNA 1","metadata":null},{"id":"3e950ee994064edb90798dbbffe3a6fd","type":"GENE","name":"HEXIM2-AS2","canonical_id":"hgnc:HGNC:56693","description":"HEXIM2 antisense RNA 2","metadata":{"aliases":["HSAL3","RP13-890H12.2"]}},{"id":"cc5dff3ca5344b92902d1c92add66a1a","type":"GENE","name":"HEY1","canonical_id":"hgnc:HGNC:4880","description":null,"metadata":null},{"id":"ed6356344446497a9603b34a80f4f3ef","type":"GENE","name":"HEY2","canonical_id":"hgnc:HGNC:4881","description":null,"metadata":null},{"id":"95bcaa92e4bd40da85c36bfe15dd8b05","type":"GENE","name":"HEY2-AS1","canonical_id":"hgnc:HGNC:55652","description":"HEY2 antisense RNA 1","metadata":null},{"id":"866245014a25442091740d976e97fd1b","type":"GENE","name":"HEYL","canonical_id":"hgnc:HGNC:4882","description":null,"metadata":null},{"id":"52480a93aa6647cbb39d9311a7a8053e","type":"GENE","name":"HFE","canonical_id":"hgnc:HGNC:4886","description":null,"metadata":null},{"id":"c009f9e0064b41b9b04a50712761ab49","type":"GENE","name":"HFE-AS1","canonical_id":"hgnc:HGNC:55168","description":"HFE antisense RNA 1","metadata":null},{"id":"085ce7eef0704f19a29f41fbf4dda1d2","type":"GO_TERM","name":"HFE-transferrin receptor complex","canonical_id":"go:GO:1990712","description":"\"A protein complex containing at least HFE and a transferrin receptor (either TFR1/TFRC or TFR2), proposed to play a role in the sensing of transferrin-bound Fe (Fe2-Tf) on the plasma membrane to regulate hepcidin transcription.\" [GOC:BHF, GOC:kom, PMID:25147378]","metadata":null},{"id":"3aaf2d9fad954183a8b12d2b27698e7a","type":"GENE","name":"HFM1","canonical_id":"hgnc:HGNC:20193","description":"helicase for meiosis 1","metadata":{"aliases":["MER3","FLJ39011","FLJ36760","SEC63D1"]}},{"id":"7cccdf9d2e5f4532aab18e7d7eccdc4b","type":"GENE","name":"HGD","canonical_id":"hgnc:HGNC:4892","description":"homogentisate 1,2-dioxygenase","metadata":{"aliases":["HGO","AKU"]}},{"id":"96cdd9c718c64c46a93f6b3b78e2e716","type":"GENE","name":"HGF","canonical_id":"hgnc:HGNC:4893","description":null,"metadata":null},{"id":"dd58252780b3402ba3a616a024ec9c9b","type":"GENE","name":"HGFAC","canonical_id":"hgnc:HGNC:4894","description":"HGF activator","metadata":{"aliases":["HGFAP","HGFA"]}},{"id":"73c0d25be1ba4529bea620087af06b76","type":"TRIAL","name":"HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)","canonical_id":"clinicaltrials.gov:NCT02239952","description":"Cancer; High-grade Glioma","metadata":null},{"id":"30495143d03d4bf3846a77bff69f68b1","type":"GENE","name":"HGH1","canonical_id":"hgnc:HGNC:24161","description":"HGH1 cochaperone","metadata":{"aliases":["FLJ40907","LOC51236","Brp16","C8orf30A","FAM203B","C8orf30B","FAM203A"]}},{"id":"54449aa498eb43ba81bed3e35f6d2915","type":"GENE","name":"HGS","canonical_id":"hgnc:HGNC:4897","description":"hepatocyte growth factor-regulated tyrosine kinase substrate","metadata":{"aliases":["Hrs","ZFYVE8","Vps27"]}},{"id":"cbd8ec61d164490e8ffc719aeea4b08f","type":"GENE","name":"HGSNAT","canonical_id":"hgnc:HGNC:26527","description":"heparan-alpha-glucosaminide N-acetyltransferase","metadata":{"aliases":["FLJ32731","HGNAT","TMEM76"]}},{"id":"50af8d1dabfa43e898b40f2b50e13e43","type":"GENE","name":"HHAT","canonical_id":"hgnc:HGNC:18270","description":"hedgehog acyltransferase","metadata":{"aliases":["FLJ10724","MART-2","MART2","Skn","ski","rasp","sit","GUP2"]}},{"id":"b0ce3964493b4e48bfa84cb56dcf0463","type":"GENE","name":"HHATL","canonical_id":"hgnc:HGNC:13242","description":"hedgehog acyltransferase like","metadata":{"aliases":["MG56","KIAA1173","OACT3","MSTP002","MBOAT3","C3orf3","GUP1"]}},{"id":"6753e69271e244f5a3f4ae9001825f09","type":"GENE","name":"HHATL-AS1","canonical_id":"hgnc:HGNC:42439","description":"HHATL antisense RNA 1","metadata":null},{"id":"8e5d61ee2e4d4a60bce5b872d984beb7","type":"GENE","name":"HHEX","canonical_id":"hgnc:HGNC:4901","description":null,"metadata":null},{"id":"e11d0acb980d4f77b17376fbbbbe7b84","type":"GENE","name":"HHIP","canonical_id":"hgnc:HGNC:14866","description":"hedgehog interacting protein","metadata":{"aliases":["HIP","FLJ20992"]}},{"id":"825d8e57c2fc4c4bab67d8b0fde0d8b8","type":"GENE","name":"HHIP-AS1","canonical_id":"hgnc:HGNC:44182","description":"HHIP antisense RNA 1","metadata":{"aliases":["HHAS1"]}},{"id":"46f251a5c1ac4ca999161627731b40ff","type":"GENE","name":"HHIPL1","canonical_id":"hgnc:HGNC:19710","description":"HHIP like 1","metadata":{"aliases":["KIAA1822"]}},{"id":"b75db673802042fe9ca5cc9bf08d72d5","type":"GENE","name":"HHIPL2","canonical_id":"hgnc:HGNC:25842","description":"HHIP like 2","metadata":{"aliases":["FLJ13840","KIAA1822L"]}},{"id":"841e00b909ab4253943abde06c42f3d7","type":"GENE","name":"HHLA1","canonical_id":"hgnc:HGNC:4904","description":"HHLA1 neighbor of OC90","metadata":{"aliases":["PLA2L"]}},{"id":"9d03c06742674e748ab4e011a48ea485","type":"GENE","name":"HHLA2","canonical_id":"hgnc:HGNC:4905","description":"HHLA2 member of B7 family","metadata":{"aliases":["B7H7","B7-H5","B7y","B7-H7"]}},{"id":"f3360f1c8e3f4111beba4225c3ca0e2c","type":"GENE","name":"HIBADH","canonical_id":"hgnc:HGNC:4907","description":"3-hydroxyisobutyrate dehydrogenase","metadata":{"aliases":["NS5ATP1"]}},{"id":"4285aa82748e47e9842426229cc0ede9","type":"GENE","name":"HIBCH","canonical_id":"hgnc:HGNC:4908","description":"3-hydroxyisobutyryl-CoA hydrolase","metadata":null},{"id":"f0032a99d436464083fa132e717629ef","type":"GENE","name":"HIC1","canonical_id":"hgnc:HGNC:4909","description":null,"metadata":null},{"id":"900de54d8fc64774a81b8b99d1b211e1","type":"GENE","name":"HIC2","canonical_id":"hgnc:HGNC:18595","description":"HIC ZBTB transcriptional repressor 2","metadata":{"aliases":["KIAA1020","HRG22","ZBTB30","ZNF907"]}},{"id":"dd2d06ee10894faebb5d09ecdc6474eb","type":"GO_TERM","name":"HICS complex","canonical_id":"go:GO:0044697","description":"\"A multisubunit complex involved in cytokinesis. In the yeast Saccharomyces cerevisiae this complex consists of Sho1p, Hof1p, Inn1p and Cyk3p proteins.\" [PMID:22623719]","metadata":null},{"id":"ddad867797224e499af8275b516e94b6","type":"GENE","name":"HID1","canonical_id":"hgnc:HGNC:15736","description":"HID1 domain containing","metadata":{"aliases":["DMC1","HID-1","C17orf28"]}},{"id":"106212e7daa14f90861a38c390644d22","type":"GENE","name":"HID1-AS1","canonical_id":"hgnc:HGNC:51181","description":"HID1 antisense RNA 1","metadata":null},{"id":"5fe3b4fb2da54e13a4267948f5acef01","type":"GENE","name":"HIF1A","canonical_id":"hgnc:HGNC:4910","description":null,"metadata":null},{"id":"f942b4c0d7734fb78056218a8a820f0b","type":"GENE","name":"HIF1A-AS1","canonical_id":"hgnc:HGNC:43014","description":"HIF1A antisense RNA 1","metadata":{"aliases":["HIFAL","5'aHIF-1A","HIF1A-AS3"]}},{"id":"26f6764f2c624eceb99a91009e9fe4f0","type":"GENE","name":"HIF1A-AS2","canonical_id":"hgnc:HGNC:43015","description":"HIF1A antisense RNA 2","metadata":{"aliases":["3'aHIF-1A","aHIF"]}},{"id":"1bc6f795e9bf4b0a855227f2a713577f","type":"GENE","name":"HIF1AN","canonical_id":"hgnc:HGNC:17113","description":"hypoxia inducible factor 1 subunit alpha inhibitor","metadata":{"aliases":["FLJ20615","DKFZp762F1811","FLJ22027","FIH1"]}},{"id":"9a983ee9368945fabc36f4945a06c29d","type":"GENE","name":"HIF1AP1","canonical_id":"hgnc:HGNC:43016","description":"HIF1AP pseudogene 1","metadata":null},{"id":"8f43729855f340828a7d76789f62edae","type":"GENE","name":"HIF3A","canonical_id":"hgnc:HGNC:15825","description":null,"metadata":null},{"id":"e6ae3a0075e64b2a9b4e36b163d94fef","type":"GENE","name":"HIGD1A","canonical_id":"hgnc:HGNC:29527","description":"HIG1 hypoxia inducible domain family member 1A","metadata":{"aliases":["HIG1","DKFZP564K247","RCF1A"]}},{"id":"f022ade7df974d2a9c822597eac20f8e","type":"GENE","name":"HIGD1AP1","canonical_id":"hgnc:HGNC:22804","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 1","metadata":{"aliases":["HIGD1D","HIGD1DP"]}},{"id":"c48316b8fe6149aebd7d61f87c419b1e","type":"GENE","name":"HIGD1AP10","canonical_id":"hgnc:HGNC:43005","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 10","metadata":null},{"id":"cfdef399c0054bddaeb09972a5156555","type":"GENE","name":"HIGD1AP11","canonical_id":"hgnc:HGNC:43006","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 11","metadata":null},{"id":"16b9423160624121bb13aef7d8bfa4dc","type":"GENE","name":"HIGD1AP12","canonical_id":"hgnc:HGNC:43007","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 12","metadata":null},{"id":"2f12c178a9814a8bbc1b14a41125861f","type":"GENE","name":"HIGD1AP13","canonical_id":"hgnc:HGNC:43008","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 13","metadata":null},{"id":"d6f7cc7b98e54a7881369a5fd1201c27","type":"GENE","name":"HIGD1AP14","canonical_id":"hgnc:HGNC:43009","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 14","metadata":null},{"id":"184e1dd2b56c473cafba80d3885371f0","type":"GENE","name":"HIGD1AP15","canonical_id":"hgnc:HGNC:43010","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 15","metadata":null},{"id":"44c3fdf42c744d7d9a3518825c416238","type":"GENE","name":"HIGD1AP16","canonical_id":"hgnc:HGNC:43011","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 16","metadata":null},{"id":"dcd13dfa782641a5a4b68b8e6ab25444","type":"GENE","name":"HIGD1AP17","canonical_id":"hgnc:HGNC:43012","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 17","metadata":null},{"id":"bb90833b8eec44c1bd0a9863aa864b25","type":"GENE","name":"HIGD1AP18","canonical_id":"hgnc:HGNC:43013","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 18","metadata":null},{"id":"7d96f6c9207e4b61a44835847266a960","type":"GENE","name":"HIGD1AP2","canonical_id":"hgnc:HGNC:42642","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 2","metadata":null},{"id":"c4ecbcf7ae124d5984c19b3f534343af","type":"GENE","name":"HIGD1AP3","canonical_id":"hgnc:HGNC:42998","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 3","metadata":null},{"id":"ec678c857f124feba003ba9dc58f1ca8","type":"GENE","name":"HIGD1AP4","canonical_id":"hgnc:HGNC:43000","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 4","metadata":null},{"id":"10da83ab5cef4a8a9193435a7bde52c5","type":"GENE","name":"HIGD1AP5","canonical_id":"hgnc:HGNC:42999","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 5","metadata":null},{"id":"e44c055ad95a43d9af32ddb1fc5dd3bc","type":"GENE","name":"HIGD1AP6","canonical_id":"hgnc:HGNC:43001","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 6","metadata":null},{"id":"c1b0e48a268947bb90edaeca990b1f7e","type":"GENE","name":"HIGD1AP7","canonical_id":"hgnc:HGNC:43002","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 7","metadata":null},{"id":"d0a95113440a44da8ede9a3236c30253","type":"GENE","name":"HIGD1AP8","canonical_id":"hgnc:HGNC:43003","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 8","metadata":null},{"id":"4e0b52d18b6c4c63b2c4b6b2ca70283c","type":"GENE","name":"HIGD1AP9","canonical_id":"hgnc:HGNC:43004","description":"HIG1 hypoxia inducible domain family member 1A pseudogene 9","metadata":null},{"id":"d1f820caf06747c4b2dbb2afadac8552","type":"GENE","name":"HIGD1B","canonical_id":"hgnc:HGNC:24318","description":"HIG1 hypoxia inducible domain family member 1B","metadata":{"aliases":["CLST11240","CLST11240-15"]}},{"id":"49969238ee1143b2a211262aa06ac8ab","type":"GENE","name":"HIGD1C","canonical_id":"hgnc:HGNC:28044","description":"HIG1 hypoxia inducible domain family member 1C","metadata":{"aliases":["Gm921"]}},{"id":"3b5972a305094e4580fefea5e816259a","type":"GENE","name":"HIGD2A","canonical_id":"hgnc:HGNC:28311","description":"HIG1 hypoxia inducible domain family member 2A","metadata":{"aliases":["MGC2198","RCF1B"]}},{"id":"aed4aa0dc83a4c5dbc2c21e4b335aef3","type":"GENE","name":"HIGD2AP1","canonical_id":"hgnc:HGNC:54793","description":"HIGD2A pseudogene 1","metadata":null},{"id":"08187284878e4c639bea7cd0fa4b8a7f","type":"GENE","name":"HIGD2AP2","canonical_id":"hgnc:HGNC:54794","description":"HIGD2A pseudogene 2","metadata":null},{"id":"04284363daf34bbc9378ac739a0f7575","type":"GENE","name":"HIGD2B","canonical_id":"hgnc:HGNC:26984","description":"HIG1 hypoxia inducible domain family member 2B","metadata":{"aliases":["HIGD2BP"]}},{"id":"63381126584347ac83c1ca73f2cb70b9","type":"GENE","name":"HIKESHI","canonical_id":"hgnc:HGNC:26938","description":"heat shock protein nuclear import factor hikeshi","metadata":{"aliases":["HSPC138","HSPC179","OPI10","C11orf73"]}},{"id":"5f265391b45a42a784b00f0557d92f25","type":"GENE","name":"HIKESHIP1","canonical_id":"hgnc:HGNC:54901","description":"HIKESHI pseudogene 1","metadata":null},{"id":"3b71115de0784f3f949a8506b7b8aa69","type":"GENE","name":"HIKESHIP2","canonical_id":"hgnc:HGNC:54902","description":"HIKESHI pseudogene 2","metadata":null},{"id":"9a5949b8ab634032bff882d08d92c34f","type":"GENE","name":"HIKESHIP3","canonical_id":"hgnc:HGNC:54904","description":"HIKESHI pseudogene 3","metadata":null},{"id":"8ade5c92a235463fa513635ee3841515","type":"GENE","name":"HILPDA","canonical_id":"hgnc:HGNC:28859","description":"hypoxia inducible lipid droplet associated","metadata":{"aliases":["FLJ21076","HIG-2","HIG2","C7orf68"]}},{"id":"00d411f8d55943459524dc8b8a803c5f","type":"GENE","name":"HILPDA-AS1","canonical_id":"hgnc:HGNC:55641","description":"HILPDA antisense RNA 1","metadata":null},{"id":"087250d1586541beaeb3493d1e86cf29","type":"GENE","name":"HINFP","canonical_id":"hgnc:HGNC:17850","description":null,"metadata":null},{"id":"34a2dece9f4644878e3859bd3640d3f3","type":"GENE","name":"HINT1","canonical_id":"hgnc:HGNC:4912","description":"histidine triad nucleotide binding protein 1","metadata":{"aliases":["PKCI-1","PRKCNH1","HINT"]}},{"id":"ffa9bdde85414d36a0575fa88a50c709","type":"GENE","name":"HINT1P1","canonical_id":"hgnc:HGNC:18467","description":"histidine triad nucleotide binding protein 1 pseudogene 1","metadata":{"aliases":["HINTP1"]}},{"id":"279e0db00e774cbc9209a21d5951493c","type":"GENE","name":"HINT1P2","canonical_id":"hgnc:HGNC:38049","description":"histidine triad nucleotide binding protein 1 pseudogene 2","metadata":null},{"id":"c65e75f529f44b12857acd496db327e3","type":"GENE","name":"HINT2","canonical_id":"hgnc:HGNC:18344","description":"histidine triad nucleotide binding protein 2","metadata":null},{"id":"e261ed26025040dc868a70db27e4d6f7","type":"GENE","name":"HINT2P1","canonical_id":"hgnc:HGNC:50311","description":"histidine triad nucleotide binding protein 2 pseudogene 1","metadata":null},{"id":"ea66f8c125504680b6c6a934d7091f7d","type":"GENE","name":"HINT3","canonical_id":"hgnc:HGNC:18468","description":"histidine triad nucleotide binding protein 3","metadata":{"aliases":["FLJ33126","HINT4"]}},{"id":"519ba069e0644c46a36722d2fbcb4ce4","type":"GENE","name":"HIP1","canonical_id":"hgnc:HGNC:4913","description":null,"metadata":null},{"id":"e3d6fa9011d84353a8bfbd46701404b5","type":"GENE","name":"HIP1R","canonical_id":"hgnc:HGNC:18415","description":null,"metadata":null},{"id":"fecc43f11593449a96987af1edeb957d","type":"TRIAL","name":"HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT07621484","description":"Locally Advanced Gastric Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"3e7e7f7ae4fe4afabfd5517ad625bd4d","type":"GENE","name":"HIPK1","canonical_id":"hgnc:HGNC:19006","description":"homeodomain interacting protein kinase 1","metadata":{"aliases":["KIAA0630","Myak","MGC26642","Nbak2","MGC33446","MGC33548"]}},{"id":"6dbcc78f7aa443d28f689397e962bdaa","type":"GENE","name":"HIPK1-AS1","canonical_id":"hgnc:HGNC:50576","description":"HIPK1 antisense RNA 1","metadata":null},{"id":"017f4d49d5d24016a43b5eef36cd7d09","type":"GENE","name":"HIPK2","canonical_id":"hgnc:HGNC:14402","description":null,"metadata":null},{"id":"b349ffd2dc664e51bc8d86d28e451d13","type":"GENE","name":"HIPK3","canonical_id":"hgnc:HGNC:4915","description":"homeodomain interacting protein kinase 3","metadata":{"aliases":["PKY","DYRK6","YAK1","FIST3"]}},{"id":"8118954ba8cc4106a1d0e9b6965fd61c","type":"GENE","name":"HIPK4","canonical_id":"hgnc:HGNC:19007","description":"homeodomain interacting protein kinase 4","metadata":{"aliases":["FLJ32818"]}},{"id":"551eeea8655c4f9da8abaab3aa6264a9","type":"GO_TERM","name":"HIR complex","canonical_id":"go:GO:0000417","description":"\"A protein complex proposed to be involved in replication-independent nucleosome assembly, by promoting histone deposition onto DNA. For example, in Saccharomyces, the complex contains Hir1p, Hir2p, Hir3p, and Hpc2p.\" [GOC:elh, GOC:mah, PMID:16303565, PMID:17180700]","metadata":null},{"id":"422cf5c6a7e446c58ac5c3cf2f8350db","type":"GENE","name":"HIRA","canonical_id":"hgnc:HGNC:4916","description":null,"metadata":null},{"id":"ee05f0d59ef64284b78380c23afaf9a2","type":"GENE","name":"HIRAP1","canonical_id":"hgnc:HGNC:44916","description":"histone cell cycle regulator pseudogene 1","metadata":null},{"id":"9829926c1d054f42a6fb42a970c9d130","type":"GENE","name":"HIRIP3","canonical_id":"hgnc:HGNC:4917","description":"HIRA interacting protein 3","metadata":null},{"id":"418760d40d384d579c95be6900b10400","type":"GENE","name":"HISLA","canonical_id":"hgnc:HGNC:49467","description":"HIF1A stabilizing long noncoding RNA","metadata":{"aliases":["LINC01146"]}},{"id":"f3df776732f64a7db94cc355ae42e53f","type":"GENE","name":"HIST1H2AE","canonical_id":"hgnc:HGNC:4724","description":null,"metadata":null},{"id":"facfd391769147c3b16c1c230572956f","type":"GENE","name":"HIST1H4L","canonical_id":"hgnc:HGNC:4791","description":null,"metadata":null},{"id":"b69f58f1d0d3471cb2183bb107bdd015","type":"GENE","name":"HIST2H2BE","canonical_id":"hgnc:HGNC:4760","description":null,"metadata":null},{"id":"d2f3e64d0045439c9b5fe3bf90fe1e19","type":"GENE","name":"HIST2H4A","canonical_id":"hgnc:HGNC:4794","description":null,"metadata":null},{"id":"7a91735583a44cc48e26aae654b36a69","type":"TRIAL","name":"HIV Risk Reduction and Drug Abuse Treatment in Iran","canonical_id":"clinicaltrials.gov:NCT00398008","description":"Opiate Dependence; HIV Infections","metadata":null},{"id":"e6356ec7b3de4bceab8abd5c01f85fb2","type":"DISEASE","name":"HIV infection","canonical_id":"mesh:D015658","description":null,"metadata":null},{"id":"04e6a48996f849c7a7b2d73175c81bba","type":"DISEASE","name":"HIV infectious disease","canonical_id":"mondo:0005109","description":null,"metadata":null},{"id":"9ebcbb73989244268a7938a8e664a03d","type":"DISEASE","name":"HIV-1 infection","canonical_id":"efo:0000180","description":null,"metadata":null},{"id":"3f30ee429703474b91e6bf2d589cbf56","type":"GENE","name":"HIVEP1","canonical_id":"hgnc:HGNC:4920","description":"HIVEP zinc finger 1","metadata":{"aliases":["CIRIP","MBP-1","CRYBP1","PRDII-BF1","ZAS1","Schnurri-1","ZNF40A","ZNF40"]}},{"id":"e4afc7eedca04dee9042b3857e05467e","type":"GENE","name":"HIVEP1-AS1","canonical_id":"hgnc:HGNC:59346","description":"HIVEP1 antisense RNA 1","metadata":null},{"id":"c806948d0be44646bc722983746cb80a","type":"GENE","name":"HIVEP2","canonical_id":"hgnc:HGNC:4921","description":null,"metadata":null},{"id":"79c71252818444e5ab70f14713a2a1af","type":"GENE","name":"HIVEP2-DT","canonical_id":"hgnc:HGNC:55724","description":"HIVEP2 divergent transcript","metadata":{"aliases":["PILA"]}},{"id":"b756b36d11b94c65aafeb36c303f71e9","type":"GENE","name":"HIVEP3","canonical_id":"hgnc:HGNC:13561","description":"HIVEP zinc finger 3","metadata":{"aliases":["KRC","KBP1","KBP-1","SHN3","FLJ16752","KIAA1555","ZAS3","Schnurri-3","ZNF40C"]}},{"id":"cb6a1ae9814e45e794c84fc5e2971a4d","type":"GENE","name":"HJURP","canonical_id":"hgnc:HGNC:25444","description":"Holliday junction recognition protein","metadata":{"aliases":["DKFZp762E1312","URLC9","hFLEG1","FAKTS"]}},{"id":"998a220a65a5407b90321630de3b7b29","type":"GENE","name":"HJV","canonical_id":"hgnc:HGNC:4887","description":"hemojuvelin BMP co-receptor","metadata":{"aliases":["JH","HFE2A","RGMC","hemojuvelin","haemojuvelin","HFE2"]}},{"id":"7e2aa2572beb44d1a2675cd420c04722","type":"GENE","name":"HK1","canonical_id":"hgnc:HGNC:4922","description":"hexokinase 1","metadata":{"aliases":["HKI"]}},{"id":"d73c3aa4faf04223a83c5b3beeed6358","type":"GENE","name":"HK2","canonical_id":"hgnc:HGNC:4923","description":null,"metadata":null},{"id":"d3d1947d56994666a3baf6ba87e27020","type":"GENE","name":"HK2-DT","canonical_id":"hgnc:HGNC:55204","description":"HK2 divergent transcript","metadata":null},{"id":"4d8db997bf8344129bb3ffc9cf24758b","type":"GENE","name":"HK2P1","canonical_id":"hgnc:HGNC:4924","description":"hexokinase 2 pseudogene 1","metadata":{"aliases":["HK2P"]}},{"id":"6b542c59a4994c3ba1d972ecdc40fb7d","type":"GENE","name":"HK3","canonical_id":"hgnc:HGNC:4925","description":null,"metadata":null},{"id":"81ce5eec9cd44162a5ca53679fe1305a","type":"GENE","name":"HK3-DT","canonical_id":"hgnc:HGNC:59312","description":"HK3 divergent transcript","metadata":null},{"id":"fa291d0b5cad4c13baf64670bdbd013e","type":"GENE","name":"HKDC1","canonical_id":"hgnc:HGNC:23302","description":"hexokinase domain containing 1","metadata":{"aliases":["FLJ37767","FLJ22761"]}},{"id":"06710af6591740159ded577672fc4dd1","type":"TRIAL","name":"HKI-272 Ketoconazole Drug Interaction Study","canonical_id":"clinicaltrials.gov:NCT00380328","description":"Healthy","metadata":null},{"id":"dd5f5901a79e42e7a48822b8d5fc3f8f","type":"TRIAL","name":"HKT-500 in Adult Patients With Ankle Sprain","canonical_id":"clinicaltrials.gov:NCT00680784","description":"Ankle Sprain","metadata":null},{"id":"8559d62599e4484cb00c3408726bd52d","type":"TRIAL","name":"HKT-500 in Adult Patients With Shoulder Pain","canonical_id":"clinicaltrials.gov:NCT00680472","description":"Pain","metadata":null},{"id":"efceb4a3c7a74bd1b98450f74e82c3c1","type":"GENE","name":"HLA-A","canonical_id":"hgnc:HGNC:4931","description":null,"metadata":null},{"id":"c6416fdca570494f967a764d8107c2e0","type":"GO_TERM","name":"HLA-A specific activating MHC class I receptor activity","canonical_id":"go:GO:0030108","description":"\"Combining with a MHC class I molecule of the HLA-A subclass to mediate signaling that activates a lymphocyte.\" [GOC:add, GOC:mah, PMID:11929129, PMID:9368779]","metadata":null},{"id":"34aa2569e81648aa86438af57a479b96","type":"GO_TERM","name":"HLA-A specific inhibitory MHC class I receptor activity","canonical_id":"go:GO:0030107","description":"\"Combining with a MHC class I molecule of the HLA-A subclass to mediate signaling that inhibits activation of a lymphocyte.\" [GOC:add, GOC:mah, PMID:11929129, PMID:9368779]","metadata":null},{"id":"a51e3c1f54c9424a8e52bab281ccd4c4","type":"GENE","name":"HLA-B","canonical_id":"hgnc:HGNC:4932","description":null,"metadata":null},{"id":"440d4e54ae204724ab40eaa412934cae","type":"GO_TERM","name":"HLA-B specific inhibitory MHC class I receptor activity","canonical_id":"go:GO:0030109","description":"\"Combining with a MHC class I molecule of the HLA-B subclass to mediate signaling that inhibits activation of a lymphocyte.\" [GOC:add, GOC:mah, PMID:11929129, PMID:9368779]","metadata":null},{"id":"b0c6fa1b6ca6451a8103ab4a54ad9b5f","type":"TRIAL","name":"HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness","canonical_id":"clinicaltrials.gov:NCT07369622","description":"Gout Initiating Urate-loweringUrate-lowering Therapy; Gout Arthritis; Gout and Hyperuricemia","metadata":null},{"id":"a5ca8d8ab9ae4cfe9187705a8ccbab8e","type":"GENE","name":"HLA-C","canonical_id":"hgnc:HGNC:4933","description":null,"metadata":null},{"id":"756c78b4f43e4d81a75ead436f703aea","type":"GO_TERM","name":"HLA-C specific inhibitory MHC class I receptor activity","canonical_id":"go:GO:0030110","description":"\"Combining with a MHC class I molecule of the HLA-C subclass to mediate signaling that inhibits activation of a lymphocyte.\" [GOC:add, GOC:mah, PMID:11929129, PMID:9368779]","metadata":null},{"id":"5ee34764cb544196aa32068f8109168b","type":"GENE","name":"HLA-DMA","canonical_id":"hgnc:HGNC:4934","description":null,"metadata":null},{"id":"73765982fb5e4cfdbddb883216e2d70a","type":"GENE","name":"HLA-DMB","canonical_id":"hgnc:HGNC:4935","description":null,"metadata":null},{"id":"c3cd78b75cd449bfb4c5f2ffab606f8f","type":"GENE","name":"HLA-DOA","canonical_id":"hgnc:HGNC:4936","description":null,"metadata":null},{"id":"e6c0e179609a4b739b6b2dfc449fef76","type":"GENE","name":"HLA-DOB","canonical_id":"hgnc:HGNC:4937","description":null,"metadata":null},{"id":"447a64c6b75442d09330f4578a8b05d8","type":"GENE","name":"HLA-DPA1","canonical_id":"hgnc:HGNC:4938","description":null,"metadata":null},{"id":"7287a39f7320401abdb0c9844aa8dc55","type":"GENE","name":"HLA-DPA2","canonical_id":"hgnc:HGNC:4939","description":"major histocompatibility complex, class II, DP alpha 2 (pseudogene)","metadata":{"aliases":["HLA-DP2A"]}},{"id":"4dfb4bf427f8405ab872f0ad160db08a","type":"GENE","name":"HLA-DPA3","canonical_id":"hgnc:HGNC:19393","description":"major histocompatibility complex, class II, DP alpha 3 (pseudogene)","metadata":null},{"id":"05f0ca402b164ca3a3f43cfb1c9ec957","type":"GENE","name":"HLA-DPB1","canonical_id":"hgnc:HGNC:4940","description":null,"metadata":null},{"id":"c3980889c6fe41ef9143c71191f547ad","type":"GENE","name":"HLA-DPB2","canonical_id":"hgnc:HGNC:4941","description":"major histocompatibility complex, class II, DP beta 2 (pseudogene)","metadata":{"aliases":["DP2B","DPB2","HLA-DP2B"]}},{"id":"ed35a4e4014f4477b6da0f6cafc946ef","type":"GENE","name":"HLA-DQA1","canonical_id":"hgnc:HGNC:4942","description":null,"metadata":null},{"id":"5ae2364e7dc640d2a7938f5fe6922f27","type":"GENE","name":"HLA-DQA1-AS1","canonical_id":"hgnc:HGNC:56667","description":"HLA-DQA1 antisense RNA 1","metadata":{"aliases":["TINA"]}},{"id":"aa68adbacc9c42d9bcf1ba022df7bd4e","type":"GENE","name":"HLA-DQA2","canonical_id":"hgnc:HGNC:4943","description":null,"metadata":null},{"id":"e32481ec2b154b09bf876efa39cfdfa9","type":"GENE","name":"HLA-DQB1","canonical_id":"hgnc:HGNC:4944","description":null,"metadata":null},{"id":"2ef919b5fd2646b4af727f3e86972339","type":"GENE","name":"HLA-DQB1-AS1","canonical_id":"hgnc:HGNC:39762","description":"HLA-DQB1 antisense RNA 1","metadata":null},{"id":"a35627c11c124ca2a18f826066a5572c","type":"GENE","name":"HLA-DQB2","canonical_id":"hgnc:HGNC:4945","description":null,"metadata":null},{"id":"803ab5737ced481aa628294dd76777e0","type":"GENE","name":"HLA-DQB3","canonical_id":"hgnc:HGNC:4946","description":"major histocompatibility complex, class II, DQ beta 3","metadata":{"aliases":["D6S205","D6S205E","DVB","DQB3","HLA-DVB"]}},{"id":"1a1b41efcc414040a9bec745135dee73","type":"GENE","name":"HLA-DRA","canonical_id":"hgnc:HGNC:4947","description":null,"metadata":null},{"id":"1a7439d773254887a638b585c0e7a78e","type":"GENE","name":"HLA-DRB1","canonical_id":"hgnc:HGNC:4948","description":null,"metadata":null},{"id":"d14f57ac0b454799888ec2384dc3d7a8","type":"GENE","name":"HLA-DRB2","canonical_id":"hgnc:HGNC:4950","description":"major histocompatibility complex, class II, DR beta 2 (pseudogene)","metadata":{"aliases":["HLA-DR2B"]}},{"id":"a9a65f76574b413db90ec41b3fb80c18","type":"GENE","name":"HLA-DRB3","canonical_id":"hgnc:HGNC:4951","description":null,"metadata":null},{"id":"16eed29f96ff4863a4659da908be8523","type":"GENE","name":"HLA-DRB4","canonical_id":"hgnc:HGNC:4952","description":null,"metadata":null},{"id":"042307c8cb074516bd1d32644980ad53","type":"GENE","name":"HLA-DRB5","canonical_id":"hgnc:HGNC:4953","description":null,"metadata":null},{"id":"01c637f55b57463da4845c6062a1b1f9","type":"GENE","name":"HLA-DRB6","canonical_id":"hgnc:HGNC:4954","description":"major histocompatibility complex, class II, DR beta 6 (pseudogene)","metadata":null},{"id":"96706118ac8e4928878c1b14f528c37a","type":"GENE","name":"HLA-DRB7","canonical_id":"hgnc:HGNC:4955","description":"major histocompatibility complex, class II, DR beta 7 (pseudogene)","metadata":null},{"id":"a5a1660887f341c0bb17ecfc1e4caaca","type":"GENE","name":"HLA-DRB8","canonical_id":"hgnc:HGNC:4956","description":"major histocompatibility complex, class II, DR beta 8 (pseudogene)","metadata":null},{"id":"cd5ae043a73448dfb59d1f440ab1cfbd","type":"GENE","name":"HLA-DRB9","canonical_id":"hgnc:HGNC:4957","description":"major histocompatibility complex, class II, DR beta 9 (pseudogene)","metadata":{"aliases":["D6S206","D6S206E","HLA-DRB1L","HLA-DR1BL"]}},{"id":"a0ce3b56db024ea68946a41b1bdfe092","type":"GENE","name":"HLA-E","canonical_id":"hgnc:HGNC:4962","description":null,"metadata":null},{"id":"62760dd8b784464baacec5361f534a49","type":"GO_TERM","name":"HLA-E specific inhibitory MHC class Ib receptor activity","canonical_id":"go:GO:0062082","description":"\"Combining with a MHC class Ib molecule of the HLA-A subclass to mediate signaling that inhibits activation of a lymphocyte.\" [DOI:10.1002/9780470015902.a0024246]","metadata":null},{"id":"b7af20212ed142908c6939c1421c863d","type":"GENE","name":"HLA-F","canonical_id":"hgnc:HGNC:4963","description":null,"metadata":null},{"id":"d3f6792637574e1281b792e733c563dc","type":"GENE","name":"HLA-F-AS1","canonical_id":"hgnc:HGNC:26645","description":"HLA-F antisense RNA 1","metadata":null},{"id":"11d66a3dc1a64f74bbb7b3c91c70d5fd","type":"GENE","name":"HLA-G","canonical_id":"hgnc:HGNC:4964","description":null,"metadata":null},{"id":"98061fd56b25445283152e70b0640e5c","type":"GO_TERM","name":"HLA-G specific inhibitory MHC class Ib receptor activity","canonical_id":"go:GO:0062083","description":"\"Combining with a MHC class Ib molecule of the HLA-G subclass to mediate signaling that inhibits activation of a lymphocyte.\" [DOI:10.1002/9780470015902.a0024246]","metadata":null},{"id":"be5e6818cf2845e28b2ecdd4307de9aa","type":"GENE","name":"HLA-H","canonical_id":"hgnc:HGNC:4965","description":"major histocompatibility complex, class I, H (pseudogene)","metadata":null},{"id":"574493ef0f03427bbb5ced650de727bf","type":"GENE","name":"HLA-J","canonical_id":"hgnc:HGNC:4967","description":"major histocompatibility complex, class I, J (pseudogene)","metadata":{"aliases":["CDA12","HLA-59","HLA-CDA12","D6S203"]}},{"id":"92bb935ab6564195a9b14ffd55d17574","type":"GENE","name":"HLA-K","canonical_id":"hgnc:HGNC:4969","description":"major histocompatibility complex, class I, K (pseudogene)","metadata":{"aliases":["HLA-70","HLAK","HLA70"]}},{"id":"631a21ff5d4644028d3be07b9674e77d","type":"GENE","name":"HLA-L","canonical_id":"hgnc:HGNC:4970","description":"major histocompatibility complex, class I, L (pseudogene)","metadata":{"aliases":["HLA-92","HLA92","HLAL"]}},{"id":"4bf08782eedf46af9abba7b06992801a","type":"TRIAL","name":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","canonical_id":"clinicaltrials.gov:NCT04904588","description":"Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Lymphoma","metadata":null},{"id":"cb8302acb9b0495c992cec516bcb6484","type":"GENE","name":"HLA-N","canonical_id":"hgnc:HGNC:19406","description":"major histocompatibility complex, class I, N (pseudogene)","metadata":{"aliases":["HLA-30"]}},{"id":"227635b1a72249c0a8658722f650a73a","type":"GENE","name":"HLA-P","canonical_id":"hgnc:HGNC:21196","description":"major histocompatibility complex, class I, P (pseudogene)","metadata":{"aliases":["dJ377H14.3","C6orf101","HLA-90"]}},{"id":"b79f9a1294d2415eb012220510fd0675","type":"GENE","name":"HLA-S","canonical_id":"hgnc:HGNC:19395","description":"major histocompatibility complex, class I, S (pseudogene)","metadata":{"aliases":["HLA-17"]}},{"id":"2c6dcff9f34642349b10d5d434e3e268","type":"GENE","name":"HLA-T","canonical_id":"hgnc:HGNC:23478","description":"major histocompatibility complex, class I, T (pseudogene)","metadata":{"aliases":["HLA-16"]}},{"id":"97dd2b63d82e4b439a241eda807b2dde","type":"GENE","name":"HLA-U","canonical_id":"hgnc:HGNC:23477","description":"major histocompatibility complex, class I, U (pseudogene)","metadata":{"aliases":["Em:AB023056.13","HLA-21"]}},{"id":"fff0c66eba1745aead62f97991a66e56","type":"GENE","name":"HLA-V","canonical_id":"hgnc:HGNC:23482","description":"major histocompatibility complex, class I, V (pseudogene)","metadata":{"aliases":["dJ377H14.4","HLA-75"]}},{"id":"7541a80ab2b540ad8fc8ba1575659f9b","type":"GENE","name":"HLA-W","canonical_id":"hgnc:HGNC:23425","description":"major histocompatibility complex, class I, W (pseudogene)","metadata":{"aliases":["HLA-80"]}},{"id":"d2ca7258e1ee4038ad52340c77e7d9c1","type":"GENE","name":"HLA-X","canonical_id":"hgnc:HGNC:19385","description":"major histocompatibility complex, class I, X (pseudogene)","metadata":null},{"id":"013cf97402a74e9e8cdb1f33e64bc9e2","type":"GENE","name":"HLA-Y","canonical_id":"hgnc:HGNC:33913","description":"major histocompatibility complex, class I, Y (pseudogene)","metadata":{"aliases":["HLA-BEL/COQ/DEL"]}},{"id":"96e85ca5da394575862da1bf3fee67ab","type":"GENE","name":"HLA-Z","canonical_id":"hgnc:HGNC:19394","description":"major histocompatibility complex, class I, Z (pseudogene)","metadata":{"aliases":["HLA-Z1"]}},{"id":"c2e1e80b5de34890bc53c7d286a92a40","type":"GENE","name":"HLCS","canonical_id":"hgnc:HGNC:4976","description":"holocarboxylase synthetase","metadata":{"aliases":["HCS"]}},{"id":"259de33ddcfe4edabe1b53e1d83d854a","type":"GENE","name":"HLCS-AS1","canonical_id":"hgnc:HGNC:55850","description":"HLCS antisense RNA 1","metadata":null},{"id":"b1594ba0469b4b97bad8991df62baf5b","type":"GENE","name":"HLCS-IT1","canonical_id":"hgnc:HGNC:41343","description":"HLCS intronic transcript 1","metadata":null},{"id":"80dda32fd8a3453b89fefb80e297ae1d","type":"GENE","name":"HLF","canonical_id":"hgnc:HGNC:4977","description":null,"metadata":null},{"id":"fa48461462614380b22fe8bdd8ef61f1","type":"GENE","name":"HLF-AS1","canonical_id":"hgnc:HGNC:58551","description":"HLF antisense RNA 1","metadata":null},{"id":"4b16c33d6afe4e57966b11cb76244b4c","type":"GENE","name":"HLFP1","canonical_id":"hgnc:HGNC:41922","description":"HLF pseudogene 1","metadata":null},{"id":"bf8737a336664464a94724875afeb800","type":"GO_TERM","name":"HLH domain binding","canonical_id":"go:GO:0043398","description":"\"Binding to a Helix Loop Helix domain, a domain of 40-50 residues that occurs in specific DNA-binding proteins that act as transcription factors. The domain is formed of two amphipathic helices joined by a variable length linker region that can form a loop and it mediates protein dimerization.\" [GOC:curators, Prosite:PDOC0038]","metadata":null},{"id":"a4c22f8fae3e4f789ffd7c4a62d0fdf4","type":"GENE","name":"HLMR1","canonical_id":"hgnc:HGNC:56713","description":"hepatic lncRNA metabolic regulator 1","metadata":null},{"id":"9de5728403e245bead53826a96999c8e","type":"GENE","name":"HLTF","canonical_id":"hgnc:HGNC:11099","description":null,"metadata":null},{"id":"c7d8e3d5d5764361a5f0f351efa2a0ee","type":"GENE","name":"HLTF-AS1","canonical_id":"hgnc:HGNC:40554","description":"HLTF antisense RNA 1","metadata":null},{"id":"e00060eefe5248669e384e03350526bb","type":"GENE","name":"HLX","canonical_id":"hgnc:HGNC:4978","description":null,"metadata":null},{"id":"6327eb3a8ffd44ce8e66210d23c9c456","type":"GENE","name":"HLX-AS1","canonical_id":"hgnc:HGNC:42509","description":"HLX antisense RNA 1","metadata":null},{"id":"2e6b7ee7fca64bdfb624e5721e2abffc","type":"GENE","name":"HM13","canonical_id":"hgnc:HGNC:16435","description":"histocompatibility minor 13","metadata":{"aliases":["H13","dJ324O17.1","SPP","PSL3","IMP1","IMPAS","PSENL3","SPPL1","HM13-IT1"]}},{"id":"fb933a2a9a8c4a2693ca2abab198111b","type":"GENE","name":"HM13-AS1","canonical_id":"hgnc:HGNC:41940","description":"HM13 antisense RNA 1","metadata":null},{"id":"a5d84d70d7aa482b8cacd98b875acc28","type":"TRIAL","name":"HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL","canonical_id":"clinicaltrials.gov:NCT06792825","description":"Follicular Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"5154f0b17c2646cc8181026f74d6d3d4","type":"GENE","name":"HMBOX1","canonical_id":"hgnc:HGNC:26137","description":"homeobox containing 1","metadata":{"aliases":["HNF1LA","PBHNF","FLJ21616","HOT1"]}},{"id":"2ac775424dd8479fb3dbe85c31b35486","type":"GENE","name":"HMBOX1-IT1","canonical_id":"hgnc:HGNC:43632","description":"HMBOX1 intronic transcript 1","metadata":null},{"id":"afd7fe6954e94e0a870d7aad826baec7","type":"GENE","name":"HMBS","canonical_id":"hgnc:HGNC:4982","description":"hydroxymethylbilane synthase","metadata":{"aliases":["PBGD","UPS","PORC"]}},{"id":"5795abeb2f064c0e8c0d1e6968358c41","type":"GENE","name":"HMCES","canonical_id":"hgnc:HGNC:24446","description":"5-hydroxymethylcytosine binding, ES cell specific","metadata":{"aliases":["DC12","SRAPD1","C3orf37"]}},{"id":"c821ce2d139f4e56a680acc200db3a2a","type":"GENE","name":"HMCN1","canonical_id":"hgnc:HGNC:19194","description":"hemicentin 1","metadata":{"aliases":["FBLN6","FIBL6","FIBL-6","ARMD1"]}},{"id":"23e876a66e4748c59decbe71c4c2d4e6","type":"GENE","name":"HMCN2","canonical_id":"hgnc:HGNC:21293","description":"hemicentin 2","metadata":{"aliases":["DKFZp434P0216","FLJ23816"]}},{"id":"d4501b1ef2154157bca2d28ca266f708","type":"GO_TERM","name":"HMG box domain binding","canonical_id":"go:GO:0071837","description":"\"Binding to an HMG box domain, a protein domain that consists of three helices in an irregular array. HMG-box domains are found in one or more copies in HMG-box proteins, which form a large, diverse family involved in the regulation of DNA-dependent processes such as transcription, replication, and strand repair, all of which require the bending and unwinding of chromatin.\" [GOC:yaf, InterPro:IPR009071, PMID:18445004]","metadata":null},{"id":"4648d700e9cb4ea38a6f5dff82bffc8a","type":"GENE","name":"HMG20A","canonical_id":"hgnc:HGNC:5001","description":"high mobility group 20A","metadata":{"aliases":["HMGX1","FLJ10739","HMGXB1"]}},{"id":"0b9d31491a6b4010b4418243c22e4528","type":"GENE","name":"HMG20B","canonical_id":"hgnc:HGNC:5002","description":null,"metadata":null},{"id":"4c1ecfb19bbd49da94ed76ad1d031003","type":"GENE","name":"HMGA1","canonical_id":"hgnc:HGNC:5010","description":null,"metadata":null},{"id":"0e724ad4f3494d9cb284aa3ee0a09f97","type":"GENE","name":"HMGA1P1","canonical_id":"hgnc:HGNC:13321","description":"high mobility group AT-hook 1 pseudogene 1","metadata":{"aliases":["HMGIYL1","HMGA1L1"]}},{"id":"bddf5a3c7b2249af92080a51f4a6745e","type":"GENE","name":"HMGA1P2","canonical_id":"hgnc:HGNC:13322","description":"high mobility group AT-hook 1 pseudogene 2","metadata":{"aliases":["HMGIYL2","HMGA1L2"]}},{"id":"cb32987e25424fe694dfe76b01061f00","type":"GENE","name":"HMGA1P3","canonical_id":"hgnc:HGNC:13323","description":"high mobility group AT-hook 1 pseudogene 3","metadata":{"aliases":["HMGIYL3","HMGA1L3"]}},{"id":"758a2b48e67d4dedbaed709df4833e13","type":"GENE","name":"HMGA1P4","canonical_id":"hgnc:HGNC:39093","description":"high mobility group AT-hook 1 pseudogene 4","metadata":null},{"id":"9d425172e3304059823a72e9437044db","type":"GENE","name":"HMGA1P5","canonical_id":"hgnc:HGNC:19120","description":"high mobility group AT-hook 1 pseudogene 5","metadata":{"aliases":["HMGA1L5"]}},{"id":"b7e4f4f2d53c4df086c1fc84e364e981","type":"GENE","name":"HMGA1P6","canonical_id":"hgnc:HGNC:19121","description":"high mobility group AT-hook 1 pseudogene 6","metadata":{"aliases":["HMGA1L6"]}},{"id":"4363c66e14b2489597575571ac32deb9","type":"GENE","name":"HMGA1P7","canonical_id":"hgnc:HGNC:19122","description":"high mobility group AT-hook 1 pseudogene 7","metadata":{"aliases":["HMGA1L7"]}},{"id":"3dc78c70b6f54388822f83e62214c93e","type":"GENE","name":"HMGA1P8","canonical_id":"hgnc:HGNC:39183","description":"high mobility group AT-hook 1 pseudogene 8","metadata":{"aliases":["HMGA1-p"]}},{"id":"8edbd6f65ade49b188bd2f8e75505e46","type":"GENE","name":"HMGA2","canonical_id":"hgnc:HGNC:5009","description":null,"metadata":null},{"id":"f5c10085731c4464b8105938d2897780","type":"GENE","name":"HMGA2-AS1","canonical_id":"hgnc:HGNC:53973","description":"HMGA2 antisense RNA 1","metadata":{"aliases":["RP11-366L20.2"]}},{"id":"bb72e4a4c3be4fe6a7a8bee59b94cd23","type":"GENE","name":"HMGA2-AS2","canonical_id":"hgnc:HGNC:58191","description":"HMGA2 antisense RNA 2","metadata":null},{"id":"527a5d506c024cea9e0a750aff0b26a5","type":"GENE","name":"HMGB1","canonical_id":"hgnc:HGNC:4983","description":null,"metadata":null},{"id":"1d7c71483e5449ed8c509884b145fe5d","type":"GENE","name":"HMGB1P1","canonical_id":"hgnc:HGNC:4993","description":"high mobility group box 1 pseudogene 1","metadata":{"aliases":["HMG1L7","HMG1L1","HMGB1L1"]}},{"id":"5886e3b203f742f5a5794ae4db3a8477","type":"GENE","name":"HMGB1P10","canonical_id":"hgnc:HGNC:4994","description":"high mobility group box 1 pseudogene 10","metadata":{"aliases":["HMG1L10","HMGB1L10"]}},{"id":"7443525f41174431bae829df9514b999","type":"GENE","name":"HMGB1P11","canonical_id":"hgnc:HGNC:13316","description":"high mobility group box 1 pseudogene 11","metadata":{"aliases":["HMGB1L11"]}},{"id":"8698c06cbaa44c92b84f527951a8f2e3","type":"GENE","name":"HMGB1P12","canonical_id":"hgnc:HGNC:13317","description":"high mobility group box 1 pseudogene 12","metadata":{"aliases":["HMGB1L12"]}},{"id":"791fe0af3eb14fcca7c42e68638b00d4","type":"GENE","name":"HMGB1P13","canonical_id":"hgnc:HGNC:13318","description":"high mobility group box 1 pseudogene 13","metadata":{"aliases":["HMGB1L13"]}},{"id":"8bb098f64f664cdba6964aebed17b225","type":"GENE","name":"HMGB1P14","canonical_id":"hgnc:HGNC:20014","description":"high mobility group box 1 pseudogene 14","metadata":{"aliases":["HMGB1P","HMGB1L14"]}},{"id":"89c42c507a99424db2f6035c0e1a2688","type":"GENE","name":"HMGB1P15","canonical_id":"hgnc:HGNC:39097","description":"high mobility group box 1 pseudogene 15","metadata":null},{"id":"436e6bd3ccc4406b96f20c138eab4449","type":"GENE","name":"HMGB1P16","canonical_id":"hgnc:HGNC:39098","description":"high mobility group box 1 pseudogene 16","metadata":null},{"id":"105cf329236746aca94abf7bd0f57398","type":"GENE","name":"HMGB1P17","canonical_id":"hgnc:HGNC:39099","description":"high mobility group box 1 pseudogene 17","metadata":null},{"id":"1f931b80005f4faa8977f46ab2119785","type":"GENE","name":"HMGB1P18","canonical_id":"hgnc:HGNC:39100","description":"high mobility group box 1 pseudogene 18","metadata":null},{"id":"00861c3adb844a3a89e08268f56ae753","type":"GENE","name":"HMGB1P19","canonical_id":"hgnc:HGNC:39101","description":"high mobility group box 1 pseudogene 19","metadata":null},{"id":"b64b894ce4924e998ca1b256e1711bc0","type":"GENE","name":"HMGB1P20","canonical_id":"hgnc:HGNC:39103","description":"high mobility group box 1 pseudogene 20","metadata":null},{"id":"7362a342ee994c5988d8aa0b83000ca2","type":"GENE","name":"HMGB1P21","canonical_id":"hgnc:HGNC:39106","description":"high mobility group box 1 pseudogene 21","metadata":null},{"id":"7c26d602f3d74b0b86ecf84389782f65","type":"GENE","name":"HMGB1P22","canonical_id":"hgnc:HGNC:39107","description":"high mobility group box 1 pseudogene 22","metadata":null},{"id":"6e543494ddfa4e3ab032758aa2fd7c76","type":"GENE","name":"HMGB1P23","canonical_id":"hgnc:HGNC:39114","description":"high mobility group box 1 pseudogene 23","metadata":null},{"id":"b323e7525e8e4facaeda6f32e3b211a8","type":"GENE","name":"HMGB1P24","canonical_id":"hgnc:HGNC:39115","description":"high mobility group box 1 pseudogene 24","metadata":null},{"id":"9efb38f0d8684592b0f1531c971f3e64","type":"GENE","name":"HMGB1P25","canonical_id":"hgnc:HGNC:39116","description":"high mobility group box 1 pseudogene 25","metadata":null},{"id":"93dd80a60dc84fd4a2047805f39e9f77","type":"GENE","name":"HMGB1P26","canonical_id":"hgnc:HGNC:39117","description":"high mobility group box 1 pseudogene 26","metadata":null},{"id":"1a4ef94491184ba3bb9a237a4d8080a2","type":"GENE","name":"HMGB1P27","canonical_id":"hgnc:HGNC:39118","description":"high mobility group box 1 pseudogene 27","metadata":null},{"id":"a58ab57509184e62b5994dcc3ec4b912","type":"GENE","name":"HMGB1P28","canonical_id":"hgnc:HGNC:39119","description":"high mobility group box 1 pseudogene 28","metadata":null},{"id":"a5424658356049859c1c4dcd38215815","type":"GENE","name":"HMGB1P29","canonical_id":"hgnc:HGNC:39120","description":"high mobility group box 1 pseudogene 29","metadata":null},{"id":"a3f150ebdf4b4e549fc5a93bea19c508","type":"GENE","name":"HMGB1P3","canonical_id":"hgnc:HGNC:4995","description":"high mobility group box 1 pseudogene 3","metadata":{"aliases":["HMG1L3","HMGB1L3"]}},{"id":"2be372efd78b4a41a927d358c291e5c0","type":"GENE","name":"HMGB1P30","canonical_id":"hgnc:HGNC:39121","description":"high mobility group box 1 pseudogene 30","metadata":null},{"id":"1c8c0b858088487dba3420dc5aa1f937","type":"GENE","name":"HMGB1P31","canonical_id":"hgnc:HGNC:39122","description":"high mobility group box 1 pseudogene 31","metadata":null},{"id":"7ff4cb83d22d42689c536ffef1ea158c","type":"GENE","name":"HMGB1P32","canonical_id":"hgnc:HGNC:39123","description":"high mobility group box 1 pseudogene 32","metadata":null},{"id":"ac6b7115cdf648b4828cd49c4e34490c","type":"GENE","name":"HMGB1P33","canonical_id":"hgnc:HGNC:39124","description":"high mobility group box 1 pseudogene 33","metadata":null},{"id":"d4c097e890e84b64855e307e349bbf13","type":"GENE","name":"HMGB1P34","canonical_id":"hgnc:HGNC:23342","description":"high mobility group box 1 pseudogene 34","metadata":null},{"id":"5a9c6267ce3b4549b606e87e6d48f10c","type":"GENE","name":"HMGB1P35","canonical_id":"hgnc:HGNC:39175","description":"high mobility group box 1 pseudogene 35","metadata":null},{"id":"27c5d6c72fb74c99963ce30c0e5a1437","type":"GENE","name":"HMGB1P36","canonical_id":"hgnc:HGNC:39176","description":"high mobility group box 1 pseudogene 36","metadata":null},{"id":"7e7b11c8177a4a73abfa4339a4280368","type":"GENE","name":"HMGB1P37","canonical_id":"hgnc:HGNC:39184","description":"high mobility group box 1 pseudogene 37","metadata":null},{"id":"76720ad0d848434b9ee23abb464e849b","type":"GENE","name":"HMGB1P38","canonical_id":"hgnc:HGNC:39185","description":"high mobility group box 1 pseudogene 38","metadata":null},{"id":"71aa0d044d6945ef89eb73613088330c","type":"GENE","name":"HMGB1P39","canonical_id":"hgnc:HGNC:39186","description":"high mobility group box 1 pseudogene 39","metadata":null},{"id":"0b9adb4bd66e41f590088b876175ae77","type":"GENE","name":"HMGB1P4","canonical_id":"hgnc:HGNC:4996","description":"high mobility group box 1 pseudogene 4","metadata":{"aliases":["HMG1L4","HMG1L4P","HMGB1L4"]}},{"id":"65626f9f7590483e9d93416298a02746","type":"GENE","name":"HMGB1P40","canonical_id":"hgnc:HGNC:39187","description":"high mobility group box 1 pseudogene 40","metadata":null},{"id":"4a96623f21dc4ba1b984d65a4dfcdcfa","type":"GENE","name":"HMGB1P41","canonical_id":"hgnc:HGNC:39188","description":"high mobility group box 1 pseudogene 41","metadata":null},{"id":"a7f522321e4e4fefa4bdcdb90aaf8a52","type":"GENE","name":"HMGB1P42","canonical_id":"hgnc:HGNC:39189","description":"high mobility group box 1 pseudogene 42","metadata":null},{"id":"5d9122393792418082923de16655f1da","type":"GENE","name":"HMGB1P43","canonical_id":"hgnc:HGNC:39191","description":"high mobility group box 1 pseudogene 43","metadata":null},{"id":"a6c08a74e30044768f2e535e81bb6079","type":"GENE","name":"HMGB1P44","canonical_id":"hgnc:HGNC:39275","description":"high mobility group box 1 pseudogene 44","metadata":null},{"id":"9e3bbec898154bb2899ef12454d442ab","type":"GENE","name":"HMGB1P45","canonical_id":"hgnc:HGNC:39277","description":"high mobility group box 1 pseudogene 45","metadata":null},{"id":"1831375cce5341c79296f8be67b19916","type":"GENE","name":"HMGB1P46","canonical_id":"hgnc:HGNC:39279","description":"high mobility group box 1 pseudogene 46","metadata":null},{"id":"b76c66f3763249bb967bcee5a9dd5361","type":"GENE","name":"HMGB1P47","canonical_id":"hgnc:HGNC:39280","description":"high mobility group box 1 pseudogene 47","metadata":null},{"id":"651ed27c873d4fedbc986ff311bd9beb","type":"GENE","name":"HMGB1P48","canonical_id":"hgnc:HGNC:39281","description":"high mobility group box 1 pseudogene 48","metadata":null},{"id":"87bdbc00bf9c46f9b2c48c19e1becf26","type":"GENE","name":"HMGB1P49","canonical_id":"hgnc:HGNC:39282","description":"high mobility group box 1 pseudogene 49","metadata":null},{"id":"6b20f68d5a0b4a549c4b0b00697ea407","type":"GENE","name":"HMGB1P5","canonical_id":"hgnc:HGNC:4997","description":"high mobility group box 1 pseudogene 5","metadata":{"aliases":["HMG1L5","HMGB1L15","HMGB1P2","HMGB1L5"]}},{"id":"80c67f4dc24d42078a343e10ba565a71","type":"GENE","name":"HMGB1P50","canonical_id":"hgnc:HGNC:52368","description":"high mobility group box 1 pseudogene 50","metadata":null},{"id":"f2db5bed0d984cfe81ee3090bd2065a6","type":"GENE","name":"HMGB1P51","canonical_id":"hgnc:HGNC:52369","description":"high mobility group box 1 pseudogene 51","metadata":null},{"id":"aff6ed87b8e44da2908705aa82f3fb3c","type":"GENE","name":"HMGB1P6","canonical_id":"hgnc:HGNC:4998","description":"high mobility group box 1 pseudogene 6","metadata":{"aliases":["HMG1L6","HMGB1L6"]}},{"id":"ebeee044690c470b8d1683c37965e650","type":"GENE","name":"HMGB1P7","canonical_id":"hgnc:HGNC:39096","description":"high mobility group box 1 pseudogene 7","metadata":null},{"id":"7009918e17d0414492434f5d180db6a9","type":"GENE","name":"HMGB1P8","canonical_id":"hgnc:HGNC:13319","description":"high mobility group box 1 pseudogene 8","metadata":{"aliases":["HMG1L8","HMGB1L8"]}},{"id":"db9b03e21b3c466d99f62ed15e3c128d","type":"GENE","name":"HMGB1P9","canonical_id":"hgnc:HGNC:13320","description":"high mobility group box 1 pseudogene 9","metadata":{"aliases":["HMG1L9","HMGB1L9"]}},{"id":"08457dfb57b844c397695866f9a0a5bf","type":"GENE","name":"HMGB2","canonical_id":"hgnc:HGNC:5000","description":null,"metadata":null},{"id":"2520e48746a84d098e888bf1cad48304","type":"GENE","name":"HMGB2P1","canonical_id":"hgnc:HGNC:39174","description":"high mobility group box 2 pseudogene 1","metadata":null},{"id":"4920febe64de4ecd87aeff0898f374b9","type":"GENE","name":"HMGB3","canonical_id":"hgnc:HGNC:5004","description":"high mobility group box 3","metadata":{"aliases":["HMG2A","MGC90319","HMG4"]}},{"id":"b565b8c649c44c34bd920f83f6dcbfbb","type":"GENE","name":"HMGB3P1","canonical_id":"hgnc:HGNC:16240","description":"high mobility group box 3 pseudogene 1","metadata":{"aliases":["dJ18C9.3","HMG4L","HMGB3L1"]}},{"id":"f930fec1f86f432fb090795acc6f0e59","type":"GENE","name":"HMGB3P10","canonical_id":"hgnc:HGNC:39302","description":"high mobility group box 3 pseudogene 10","metadata":null},{"id":"6822efa82e56464c871c0b8aa215d4a4","type":"GENE","name":"HMGB3P11","canonical_id":"hgnc:HGNC:39303","description":"high mobility group box 3 pseudogene 11","metadata":null},{"id":"ca69ba1fc45d4b169cedc8bc4e49dca2","type":"GENE","name":"HMGB3P12","canonical_id":"hgnc:HGNC:39304","description":"high mobility group box 3 pseudogene 12","metadata":null},{"id":"00a4a6c99b8e4a4788e43f1e1a864454","type":"GENE","name":"HMGB3P13","canonical_id":"hgnc:HGNC:39305","description":"high mobility group box 3 pseudogene 13","metadata":null},{"id":"f584694cbdbc448d9d3ddaa807bc5c59","type":"GENE","name":"HMGB3P14","canonical_id":"hgnc:HGNC:39306","description":"high mobility group box 3 pseudogene 14","metadata":null},{"id":"a9a59e2a5dc042799019dab48922720a","type":"GENE","name":"HMGB3P15","canonical_id":"hgnc:HGNC:39307","description":"high mobility group box 3 pseudogene 15","metadata":null},{"id":"a0cdd70b947b49bebf0a0b2900f4765b","type":"GENE","name":"HMGB3P16","canonical_id":"hgnc:HGNC:39308","description":"high mobility group box 3 pseudogene 16","metadata":null},{"id":"26f415106b824f58857f50aee41b76d8","type":"GENE","name":"HMGB3P17","canonical_id":"hgnc:HGNC:39309","description":"high mobility group box 3 pseudogene 17","metadata":null},{"id":"5d9371c6b3b048958c4626b0799727a7","type":"GENE","name":"HMGB3P18","canonical_id":"hgnc:HGNC:39310","description":"high mobility group box 3 pseudogene 18","metadata":null},{"id":"6071d04da3694e7c8c2a0e576deb564d","type":"GENE","name":"HMGB3P19","canonical_id":"hgnc:HGNC:39311","description":"high mobility group box 3 pseudogene 19","metadata":null},{"id":"4a97b4a491464432b5102d9df336df21","type":"GENE","name":"HMGB3P2","canonical_id":"hgnc:HGNC:16574","description":"high mobility group box 3 pseudogene 2","metadata":{"aliases":["dJ550H1.1","HMG4L2","HMGB3L2"]}},{"id":"c1100f6141bb477ab0750eb2adef2a68","type":"GENE","name":"HMGB3P20","canonical_id":"hgnc:HGNC:39312","description":"high mobility group box 3 pseudogene 20","metadata":null},{"id":"58f6ee172c9b4d56892a8fc1fd1ea68c","type":"GENE","name":"HMGB3P21","canonical_id":"hgnc:HGNC:39313","description":"high mobility group box 3 pseudogene 21","metadata":null},{"id":"205c1eb90dbf47678fa6b034fdb97c2b","type":"GENE","name":"HMGB3P22","canonical_id":"hgnc:HGNC:39314","description":"high mobility group box 3 pseudogene 22","metadata":null},{"id":"da51331b960f4acf9f95a9ad1ce9003b","type":"GENE","name":"HMGB3P23","canonical_id":"hgnc:HGNC:39315","description":"high mobility group box 3 pseudogene 23","metadata":null},{"id":"e7ca7b4cedb54a8f8ab253ec85d9d8f3","type":"GENE","name":"HMGB3P24","canonical_id":"hgnc:HGNC:39316","description":"high mobility group box 3 pseudogene 24","metadata":null},{"id":"ad02e815ed664cdd8953c07733f313a8","type":"GENE","name":"HMGB3P25","canonical_id":"hgnc:HGNC:39317","description":"high mobility group box 3 pseudogene 25","metadata":null},{"id":"10bfb71928c040b79893dee103b62b5e","type":"GENE","name":"HMGB3P26","canonical_id":"hgnc:HGNC:39318","description":"high mobility group box 3 pseudogene 26","metadata":null},{"id":"b8bb5e53ba1f449b95ada973c60e6abe","type":"GENE","name":"HMGB3P27","canonical_id":"hgnc:HGNC:39319","description":"high mobility group box 3 pseudogene 27","metadata":null},{"id":"93f2b29da0f14ed49f6da77dc3653c46","type":"GENE","name":"HMGB3P28","canonical_id":"hgnc:HGNC:39320","description":"high mobility group box 3 pseudogene 28","metadata":null},{"id":"d0700afc44644fc7887d253488337eac","type":"GENE","name":"HMGB3P29","canonical_id":"hgnc:HGNC:39321","description":"high mobility group box 3 pseudogene 29","metadata":null},{"id":"edac05736a41428f97461f9d5429055b","type":"GENE","name":"HMGB3P3","canonical_id":"hgnc:HGNC:39102","description":"high mobility group box 3 pseudogene 3","metadata":null},{"id":"6fb5e93041ae4471825c52967789c9ee","type":"GENE","name":"HMGB3P30","canonical_id":"hgnc:HGNC:39333","description":"high mobility group box 3 pseudogene 30","metadata":null},{"id":"79fddef36f204304b23e403135f9a041","type":"GENE","name":"HMGB3P31","canonical_id":"hgnc:HGNC:39334","description":"high mobility group box 3 pseudogene 31","metadata":null},{"id":"83f1f3b19df0492a826b15b7e9187df4","type":"GENE","name":"HMGB3P32","canonical_id":"hgnc:HGNC:39335","description":"high mobility group box 3 pseudogene 32","metadata":null},{"id":"91366326ec1e482ea55654a1845345fd","type":"GENE","name":"HMGB3P4","canonical_id":"hgnc:HGNC:39104","description":"high mobility group box 3 pseudogene 4","metadata":null},{"id":"a14bae0c9733433d9e28d801ad0cba7a","type":"GENE","name":"HMGB3P5","canonical_id":"hgnc:HGNC:39105","description":"high mobility group box 3 pseudogene 5","metadata":null},{"id":"8ff57c2e06784e24b1745413c01031af","type":"GENE","name":"HMGB3P6","canonical_id":"hgnc:HGNC:39283","description":"high mobility group box 3 pseudogene 6","metadata":null},{"id":"e4876d9e9aed45ccb5a591b8b21e1c28","type":"GENE","name":"HMGB3P7","canonical_id":"hgnc:HGNC:39299","description":"high mobility group box 3 pseudogene 7","metadata":null},{"id":"35fbe27aad7441a1b2149bc9228645ae","type":"GENE","name":"HMGB3P8","canonical_id":"hgnc:HGNC:39300","description":"high mobility group box 3 pseudogene 8","metadata":null},{"id":"ec9ba798f1d540d3a7d16b635d10dc0c","type":"GENE","name":"HMGB3P9","canonical_id":"hgnc:HGNC:39301","description":"high mobility group box 3 pseudogene 9","metadata":null},{"id":"b815889c08d84c7b9eb4808405d105ae","type":"GENE","name":"HMGB4","canonical_id":"hgnc:HGNC:24954","description":"high mobility group box 4","metadata":{"aliases":["FLJ40388"]}},{"id":"fb7fa914ff854378a34dcdc2eeeae55d","type":"GENE","name":"HMGCL","canonical_id":"hgnc:HGNC:5005","description":"3-hydroxy-3-methylglutaryl-CoA lyase","metadata":{"aliases":["HL","HMGCL1"]}},{"id":"e951fd45a6ea4b599c47da87accc0c17","type":"GENE","name":"HMGCLL1","canonical_id":"hgnc:HGNC:21359","description":"3-hydroxy-3-methylglutaryl-CoA lyase like 1","metadata":{"aliases":["DKFZP434G1411","bA418P12.1","er-cHL"]}},{"id":"b360f05cfeab4490a45e1cfc4f41374d","type":"GENE","name":"HMGCR","canonical_id":"hgnc:HGNC:5006","description":null,"metadata":null},{"id":"cdce18b2f63c47ed830cf19c76042f6e","type":"PROTEIN","name":"HMGCR","canonical_id":"uniprot:P04035","description":null,"metadata":null},{"id":"301ac0b238414c718afb74fffb8c10e8","type":"GENE","name":"HMGCS1","canonical_id":"hgnc:HGNC:5007","description":null,"metadata":null},{"id":"0992c0b225a94ef7bca5f59ddafc8a44","type":"GENE","name":"HMGCS1-DT","canonical_id":"hgnc:HGNC:59038","description":"HMGCS1 divergent transcript","metadata":null},{"id":"5bff3b80d0d84a7790d5827e4cdb4283","type":"GENE","name":"HMGCS2","canonical_id":"hgnc:HGNC:5008","description":"3-hydroxy-3-methylglutaryl-CoA synthase 2","metadata":null},{"id":"09884c1cfbba447985668bdeb1ebebf3","type":"GENE","name":"HMGN1","canonical_id":"hgnc:HGNC:4984","description":null,"metadata":null},{"id":"2a369bb27dde426d868af15e3c903cf4","type":"GENE","name":"HMGN1P1","canonical_id":"hgnc:HGNC:20015","description":"high mobility group nucleosome binding domain 1 pseudogene 1","metadata":{"aliases":["HMGN1L1"]}},{"id":"b946614788d2438d9ff5b5072c344d5a","type":"GENE","name":"HMGN1P10","canonical_id":"hgnc:HGNC:39353","description":"high mobility group nucleosome binding domain 1 pseudogene 10","metadata":null},{"id":"26523e5152a14b7ca06e309e5b4788a8","type":"GENE","name":"HMGN1P11","canonical_id":"hgnc:HGNC:39355","description":"high mobility group nucleosome binding domain 1 pseudogene 11","metadata":null},{"id":"24f330bee3c94b54bc4ba95ea44a0d84","type":"GENE","name":"HMGN1P12","canonical_id":"hgnc:HGNC:39356","description":"high mobility group nucleosome binding domain 1 pseudogene 12","metadata":null},{"id":"13a30afc4a51414eb9a52b0fa2fdb434","type":"GENE","name":"HMGN1P13","canonical_id":"hgnc:HGNC:39357","description":"high mobility group nucleosome binding domain 1 pseudogene 13","metadata":null},{"id":"7a88f341ba3c485cbacc0a4ccd5d1384","type":"GENE","name":"HMGN1P14","canonical_id":"hgnc:HGNC:39358","description":"high mobility group nucleosome binding domain 1 pseudogene 14","metadata":null},{"id":"c7c012570f9541919cccb5363a8573c4","type":"GENE","name":"HMGN1P15","canonical_id":"hgnc:HGNC:39359","description":"high mobility group nucleosome binding domain 1 pseudogene 15","metadata":null},{"id":"7180b93cefb44b07aef7df7b79bf1d7e","type":"GENE","name":"HMGN1P16","canonical_id":"hgnc:HGNC:39360","description":"high mobility group nucleosome binding domain 1 pseudogene 16","metadata":null},{"id":"c01e21c48d124678937bb535caae9428","type":"GENE","name":"HMGN1P17","canonical_id":"hgnc:HGNC:39361","description":"high mobility group nucleosome binding domain 1 pseudogene 17","metadata":null},{"id":"564305bd76f543a189efbc1df01052e1","type":"GENE","name":"HMGN1P18","canonical_id":"hgnc:HGNC:39362","description":"high mobility group nucleosome binding domain 1 pseudogene 18","metadata":null},{"id":"3196fd5277b2410ba8e4a11266fe8b6e","type":"GENE","name":"HMGN1P19","canonical_id":"hgnc:HGNC:39363","description":"high mobility group nucleosome binding domain 1 pseudogene 19","metadata":null},{"id":"84877ff6a4b74b41a8015d6eb22dc445","type":"GENE","name":"HMGN1P2","canonical_id":"hgnc:HGNC:4985","description":"high mobility group nucleosome binding domain 1 pseudogene 2","metadata":{"aliases":["HMG14P","HMGN1L2"]}},{"id":"5d326b554e20479b8139b65a408e1325","type":"GENE","name":"HMGN1P20","canonical_id":"hgnc:HGNC:39364","description":"high mobility group nucleosome binding domain 1 pseudogene 20","metadata":null},{"id":"e1b74f19d7ff4503877ff53077836466","type":"GENE","name":"HMGN1P21","canonical_id":"hgnc:HGNC:39365","description":"high mobility group nucleosome binding domain 1 pseudogene 21","metadata":null},{"id":"b76c44c53f7045f2b76a4a32cd75cd90","type":"GENE","name":"HMGN1P22","canonical_id":"hgnc:HGNC:39366","description":"high mobility group nucleosome binding domain 1 pseudogene 22","metadata":null},{"id":"0c24a3ddcfff4d239e5004fd135178be","type":"GENE","name":"HMGN1P23","canonical_id":"hgnc:HGNC:39367","description":"high mobility group nucleosome binding domain 1 pseudogene 23","metadata":null},{"id":"6e6f6c9ddae44f14807e0ba68dd4801f","type":"GENE","name":"HMGN1P24","canonical_id":"hgnc:HGNC:39368","description":"high mobility group nucleosome binding domain 1 pseudogene 24","metadata":null},{"id":"44b67b73174741d6b0fe6b1610072baa","type":"GENE","name":"HMGN1P25","canonical_id":"hgnc:HGNC:39369","description":"high mobility group nucleosome binding domain 1 pseudogene 25","metadata":null},{"id":"99781055f8f44c5aa63780a100666f4d","type":"GENE","name":"HMGN1P26","canonical_id":"hgnc:HGNC:39370","description":"high mobility group nucleosome binding domain 1 pseudogene 26","metadata":null},{"id":"76ac418dd6db4be78a0eae2f569cd7df","type":"GENE","name":"HMGN1P27","canonical_id":"hgnc:HGNC:39371","description":"high mobility group nucleosome binding domain 1 pseudogene 27","metadata":null},{"id":"5634773171204cd9a3d519669a8e3ca9","type":"GENE","name":"HMGN1P28","canonical_id":"hgnc:HGNC:39372","description":"high mobility group nucleosome binding domain 1 pseudogene 28","metadata":null},{"id":"1236f0653a0e41dfa4f9a8caba5d4045","type":"GENE","name":"HMGN1P29","canonical_id":"hgnc:HGNC:39373","description":"high mobility group nucleosome binding domain 1 pseudogene 29","metadata":null},{"id":"0f4c0672c03f433f965e81205bca0819","type":"GENE","name":"HMGN1P3","canonical_id":"hgnc:HGNC:23343","description":"high mobility group nucleosome binding domain 1 pseudogene 3","metadata":null},{"id":"9f99dae84d754d18bacd88a6c3876af1","type":"GENE","name":"HMGN1P30","canonical_id":"hgnc:HGNC:39374","description":"high mobility group nucleosome binding domain 1 pseudogene 30","metadata":null},{"id":"6d0c07ec5d1345b2bbdc11e8cc817aeb","type":"GENE","name":"HMGN1P31","canonical_id":"hgnc:HGNC:39375","description":"high mobility group nucleosome binding domain 1 pseudogene 31","metadata":null},{"id":"7b55570e15e948dab3e1790defa61777","type":"GENE","name":"HMGN1P32","canonical_id":"hgnc:HGNC:39376","description":"high mobility group nucleosome binding domain 1 pseudogene 32","metadata":null},{"id":"913a83cb75564e98a7a3bd472a39f9f5","type":"GENE","name":"HMGN1P33","canonical_id":"hgnc:HGNC:39377","description":"high mobility group nucleosome binding domain 1 pseudogene 33","metadata":null},{"id":"ed211b80457349e69e7d8abfc2298eb6","type":"GENE","name":"HMGN1P34","canonical_id":"hgnc:HGNC:39378","description":"high mobility group nucleosome binding domain 1 pseudogene 34","metadata":null},{"id":"11f2cb58923e4d268e9b42d748631432","type":"GENE","name":"HMGN1P35","canonical_id":"hgnc:HGNC:39379","description":"high mobility group nucleosome binding domain 1 pseudogene 35","metadata":null},{"id":"66a68a1b8bcc4157915b07e93885082a","type":"GENE","name":"HMGN1P36","canonical_id":"hgnc:HGNC:39380","description":"high mobility group nucleosome binding domain 1 pseudogene 36","metadata":null},{"id":"c577c1587a234ade9c5053762f01a147","type":"GENE","name":"HMGN1P37","canonical_id":"hgnc:HGNC:39421","description":"high mobility group nucleosome binding domain 1 pseudogene 37","metadata":null},{"id":"2372b653e13f4015b5a0fc3fbbf49f71","type":"GENE","name":"HMGN1P38","canonical_id":"hgnc:HGNC:39422","description":"high mobility group nucleosome binding domain 1 pseudogene 38","metadata":null},{"id":"6760c69516554c78a9fe71652a7d118f","type":"GENE","name":"HMGN1P4","canonical_id":"hgnc:HGNC:39336","description":"high mobility group nucleosome binding domain 1 pseudogene 4","metadata":null},{"id":"7286d53ffa5541be897f81efc2022363","type":"GENE","name":"HMGN1P5","canonical_id":"hgnc:HGNC:39348","description":"high mobility group nucleosome binding domain 1 pseudogene 5","metadata":null},{"id":"5741a97cef234c808f2f97fdb41c8fe0","type":"GENE","name":"HMGN1P6","canonical_id":"hgnc:HGNC:39349","description":"high mobility group nucleosome binding domain 1 pseudogene 6","metadata":null},{"id":"2f42b0c54f8b466693f81503104629e5","type":"GENE","name":"HMGN1P7","canonical_id":"hgnc:HGNC:39350","description":"high mobility group nucleosome binding domain 1 pseudogene 7","metadata":null},{"id":"aff613ec406f4d41a615d56a79e371b5","type":"GENE","name":"HMGN1P8","canonical_id":"hgnc:HGNC:39351","description":"high mobility group nucleosome binding domain 1 pseudogene 8","metadata":null},{"id":"9bf267a43b914b70962a3efd948c90c2","type":"GENE","name":"HMGN1P9","canonical_id":"hgnc:HGNC:39352","description":"high mobility group nucleosome binding domain 1 pseudogene","metadata":null},{"id":"f23d8b4a92d54a5b94c5e9fa4fe1ef53","type":"GENE","name":"HMGN2","canonical_id":"hgnc:HGNC:4986","description":"high mobility group nucleosomal binding domain 2","metadata":{"aliases":["HMG17"]}},{"id":"da835f7b83894cfba9d8c1aa81e293ec","type":"GENE","name":"HMGN2P1","canonical_id":"hgnc:HGNC:19930","description":"high mobility group nucleosomal binding domain 2 pseudogene 1","metadata":{"aliases":["HMGN2P","HMGN2L1"]}},{"id":"66d63ac48d4b4e14a05c04afab2e3f17","type":"GENE","name":"HMGN2P10","canonical_id":"hgnc:HGNC:4988","description":"high mobility group nucleosomal binding domain 2 pseudogene 10","metadata":{"aliases":["bK216E10","HMG17L2","HMGN2L10"]}},{"id":"0e6a848c1a21434487580b41c8c7fb09","type":"GENE","name":"HMGN2P11","canonical_id":"hgnc:HGNC:4990","description":"high mobility group nucleosomal binding domain 2 pseudogene 11","metadata":{"aliases":["28H","HMG17P1","HMGN2L11"]}},{"id":"62a67062f6e64c9ebfa1a64800f9be19","type":"GENE","name":"HMGN2P12","canonical_id":"hgnc:HGNC:4991","description":"high mobility group nucleosomal binding domain 2 pseudogene 12","metadata":{"aliases":["60H","HMG17P2","HMGN2L12"]}},{"id":"2827d1012e1741848eebd61f775af402","type":"GENE","name":"HMGN2P13","canonical_id":"hgnc:HGNC:33557","description":"high mobility group nucleosomal binding domain 2 pseudogene 13","metadata":null},{"id":"14aa58157ef74014abaadd16826e3659","type":"GENE","name":"HMGN2P14","canonical_id":"hgnc:HGNC:23341","description":"high mobility group nucleosomal binding domain 2 pseudogene 14","metadata":null},{"id":"a39b214ac65840358e20a6c6a265d0d7","type":"GENE","name":"HMGN2P15","canonical_id":"hgnc:HGNC:39020","description":"high mobility group nucleosomal binding domain 2 pseudogene 15","metadata":null},{"id":"4876530609d7413980cf5143e9d04492","type":"GENE","name":"HMGN2P16","canonical_id":"hgnc:HGNC:31330","description":"high mobility group nucleosomal binding domain 2 pseudogene 16","metadata":{"aliases":["Em:AL513423.2","HMGN2L"]}},{"id":"e2a296c33b3e49b1833745215219a22c","type":"GENE","name":"HMGN2P17","canonical_id":"hgnc:HGNC:39381","description":"high mobility group nucleosomal binding domain 2 pseudogene 17","metadata":null},{"id":"dcaf8745b54a4c89a5ce8480fb5d694e","type":"GENE","name":"HMGN2P18","canonical_id":"hgnc:HGNC:39382","description":"high mobility group nucleosomal binding domain 2 pseudogene 18","metadata":null},{"id":"57f638fdf4a54d289f95340d123487fe","type":"GENE","name":"HMGN2P19","canonical_id":"hgnc:HGNC:39383","description":"high mobility group nucleosomal binding domain 2 pseudogene 19","metadata":null},{"id":"95c066c928fa49afa5c07c40e664afd2","type":"GENE","name":"HMGN2P2","canonical_id":"hgnc:HGNC:20016","description":"high mobility group nucleosomal binding domain 2 pseudogene 2","metadata":{"aliases":["HMGN2L2"]}},{"id":"88a7e244077f485abafab14280ca8578","type":"GENE","name":"HMGN2P20","canonical_id":"hgnc:HGNC:39385","description":"high mobility group nucleosomal binding domain 2 pseudogene 20","metadata":null},{"id":"47c49f23a07844e2ad8cb0fe4f92c3a5","type":"GENE","name":"HMGN2P21","canonical_id":"hgnc:HGNC:39386","description":"high mobility group nucleosomal binding domain 2 pseudogene 21","metadata":null},{"id":"a0ab3a993cf449c9b071c2dfaa4a2f24","type":"GENE","name":"HMGN2P22","canonical_id":"hgnc:HGNC:39387","description":"high mobility group nucleosomal binding domain 2 pseudogene 22","metadata":null},{"id":"9be24d8d0e794b3cbcf6bd28f38cb38a","type":"GENE","name":"HMGN2P23","canonical_id":"hgnc:HGNC:39388","description":"high mobility group nucleosomal binding domain 2 pseudogene 23","metadata":null},{"id":"6b329bd2213542afa6028bc525ed43c2","type":"GENE","name":"HMGN2P24","canonical_id":"hgnc:HGNC:39389","description":"high mobility group nucleosomal binding domain 2 pseudogene 24","metadata":null},{"id":"d5e8a05d83e049e09c60eddbcddfbc44","type":"GENE","name":"HMGN2P25","canonical_id":"hgnc:HGNC:39392","description":"high mobility group nucleosomal binding domain 2 pseudogene 25","metadata":null},{"id":"a57dc5db30a249a6b53fa75189d59085","type":"GENE","name":"HMGN2P26","canonical_id":"hgnc:HGNC:39393","description":"high mobility group nucleosomal binding domain 2 pseudogene 26","metadata":null},{"id":"51f7282cdbc74999afc59d8c0b2d808e","type":"GENE","name":"HMGN2P27","canonical_id":"hgnc:HGNC:39394","description":"high mobility group nucleosomal binding domain 2 pseudogene 27","metadata":null},{"id":"3ed327351c2d46cd8fa4a401634daf1a","type":"GENE","name":"HMGN2P28","canonical_id":"hgnc:HGNC:39395","description":"high mobility group nucleosomal binding domain 2 pseudogene 28","metadata":null},{"id":"c114a1a9e7d745d08c9473ab71d1ebf0","type":"GENE","name":"HMGN2P29","canonical_id":"hgnc:HGNC:39396","description":"high mobility group nucleosomal binding domain 2 pseudogene 29","metadata":null},{"id":"87602d10b59245a4b30741fce91305dc","type":"GENE","name":"HMGN2P3","canonical_id":"hgnc:HGNC:33566","description":"high mobility group nucleosomal binding domain 2 pseudogene 3","metadata":{"aliases":["HMGN2L3"]}},{"id":"fcb7fcdec5e647a6a9f9879a0d94aebb","type":"GENE","name":"HMGN2P30","canonical_id":"hgnc:HGNC:39397","description":"high mobility group nucleosomal binding domain 2 pseudogene 30","metadata":null},{"id":"1b4aef633c3c418280965cdd66fef4c1","type":"GENE","name":"HMGN2P31","canonical_id":"hgnc:HGNC:39398","description":"high mobility group nucleosomal binding domain 2 pseudogene 31","metadata":null},{"id":"b47f2fc9eb45425eb2b07ee57e5aae93","type":"GENE","name":"HMGN2P32","canonical_id":"hgnc:HGNC:39403","description":"high mobility group nucleosomal binding domain 2 pseudogene 32","metadata":null},{"id":"baec6a9326d04e03be9fc3bfc132ea26","type":"GENE","name":"HMGN2P33","canonical_id":"hgnc:HGNC:39404","description":"high mobility group nucleosomal binding domain 2 pseudogene 33","metadata":null},{"id":"29a55e03caaa404bb42ce895cbda9e16","type":"GENE","name":"HMGN2P34","canonical_id":"hgnc:HGNC:39405","description":"high mobility group nucleosomal binding domain 2 pseudogene 34","metadata":null},{"id":"e5b4f28a66014ddeb98533bcbce6fa59","type":"GENE","name":"HMGN2P35","canonical_id":"hgnc:HGNC:39406","description":"high mobility group nucleosomal binding domain 2 pseudogene 35","metadata":null},{"id":"34cb879de5404095b73ee61c33bcd510","type":"GENE","name":"HMGN2P36","canonical_id":"hgnc:HGNC:39407","description":"high mobility group nucleosomal binding domain 2 pseudogene 36","metadata":null},{"id":"91da30466e164b528a57f942c9e6221b","type":"GENE","name":"HMGN2P37","canonical_id":"hgnc:HGNC:39408","description":"high mobility group nucleosomal binding domain 2 pseudogene 37","metadata":null},{"id":"02fb04e9e8254a1d826931298354af98","type":"GENE","name":"HMGN2P38","canonical_id":"hgnc:HGNC:39409","description":"high mobility group nucleosomal binding domain 2 pseudogene 38","metadata":null},{"id":"bd013649a58e48fea632b8b2d0580c0a","type":"GENE","name":"HMGN2P39","canonical_id":"hgnc:HGNC:39410","description":"high mobility group nucleosomal binding domain 2 pseudogene 39","metadata":null},{"id":"c80bf9dcb31347aa98a992f1da36eb2e","type":"GENE","name":"HMGN2P4","canonical_id":"hgnc:HGNC:33567","description":"high mobility group nucleosomal binding domain 2 pseudogene 4","metadata":{"aliases":["HMGN2L4"]}},{"id":"037dc51222c34cf8ac355f86f36c90b2","type":"GENE","name":"HMGN2P40","canonical_id":"hgnc:HGNC:39411","description":"high mobility group nucleosomal binding domain 2 pseudogene 40","metadata":null},{"id":"cef1941b064e4ff4a551ae0b77b64bb3","type":"GENE","name":"HMGN2P41","canonical_id":"hgnc:HGNC:39412","description":"high mobility group nucleosomal binding domain 2 pseudogene 41","metadata":null},{"id":"07b9e20f2bb84eb687cfa8e4d31e494d","type":"GENE","name":"HMGN2P42","canonical_id":"hgnc:HGNC:39413","description":"high mobility group nucleosomal binding domain 2 pseudogene 42","metadata":null},{"id":"2143d6496c814d0a8a133c8ff3929e7f","type":"GENE","name":"HMGN2P43","canonical_id":"hgnc:HGNC:39414","description":"high mobility group nucleosomal binding domain 2 pseudogene 43","metadata":null},{"id":"50336817905645f287b7ccc48d707b8a","type":"GENE","name":"HMGN2P44","canonical_id":"hgnc:HGNC:39415","description":"high mobility group nucleosomal binding domain 2 pseudogene 44","metadata":null},{"id":"123f45b16b3a4f5ea344c0e1109dfdfd","type":"GENE","name":"HMGN2P45","canonical_id":"hgnc:HGNC:39416","description":"high mobility group nucleosomal binding domain 2 pseudogene 45","metadata":null},{"id":"01017d639bee478c9b4bdbdca455ce2f","type":"GENE","name":"HMGN2P46","canonical_id":"hgnc:HGNC:26817","description":"high mobility group nucleosomal binding domain 2 pseudogene 46","metadata":{"aliases":["FLJ39426","D-PCa-2","C15orf21"]}},{"id":"241b0f296af04cae907eb25372f8a8e8","type":"GENE","name":"HMGN2P47","canonical_id":"hgnc:HGNC:44422","description":"high mobility group nucleosomal binding domain 2 pseudogene 47","metadata":null},{"id":"08105e87ce834579a655cbbc7113fb7f","type":"GENE","name":"HMGN2P48","canonical_id":"hgnc:HGNC:55157","description":"high mobility group nucleosomal binding domain 2 pseudogene 48","metadata":null},{"id":"5389e95932574b1794b5d3db642dd636","type":"GENE","name":"HMGN2P5","canonical_id":"hgnc:HGNC:33568","description":"high mobility group nucleosomal binding domain 2 pseudogene 5","metadata":{"aliases":["HMGN2L5"]}},{"id":"7a4000e011f84ae1951d345776c798ae","type":"GENE","name":"HMGN2P6","canonical_id":"hgnc:HGNC:33574","description":"high mobility group nucleosomal binding domain 2 pseudogene 6","metadata":{"aliases":["HMGN2L6"]}},{"id":"a34e04a56e084f9da77e70e8fd87da73","type":"GENE","name":"HMGN2P7","canonical_id":"hgnc:HGNC:33575","description":"high mobility group nucleosomal binding domain 2 pseudogene 7","metadata":{"aliases":["HMGN2L7"]}},{"id":"3b882dcaf1ed480aba052232bdc7c987","type":"GENE","name":"HMGN2P8","canonical_id":"hgnc:HGNC:31662","description":"high mobility group nucleosomal binding domain 2 pseudogene 8","metadata":{"aliases":["AC022394.1","HMGN2L8"]}},{"id":"f3bb6ab321d24cb684315ef2a7bf86b2","type":"GENE","name":"HMGN2P9","canonical_id":"hgnc:HGNC:4987","description":"high mobility group nucleosomal binding domain 2 pseudogene 9","metadata":{"aliases":["dJ388M5.2","HMG17L1","HMGN2L9"]}},{"id":"830f9f2cbf0f42c3b43c587671cfa680","type":"GENE","name":"HMGN3","canonical_id":"hgnc:HGNC:12312","description":"high mobility group nucleosomal binding domain 3","metadata":{"aliases":["TRIP7"]}},{"id":"2e4b2159407b4f0086c583347aa1a40d","type":"GENE","name":"HMGN3-AS1","canonical_id":"hgnc:HGNC:48984","description":"HMGN3 antisense RNA 1","metadata":null},{"id":"30adbd025be744bc82fb35983c43ca2e","type":"GENE","name":"HMGN3P1","canonical_id":"hgnc:HGNC:39206","description":"high mobility group nucleosomal binding domain 3 pseudogene 1","metadata":null},{"id":"ce3adf1e7a4b43c8be84b14e67ee7a27","type":"GENE","name":"HMGN4","canonical_id":"hgnc:HGNC:4989","description":"high mobility group nucleosomal binding domain 4","metadata":{"aliases":["NHC","HMG17L3"]}},{"id":"37f3c04c31854e0ab7581becdaa3f662","type":"GENE","name":"HMGN5","canonical_id":"hgnc:HGNC:8013","description":"high mobility group nucleosome binding domain 5","metadata":{"aliases":["NSBP1"]}},{"id":"92d691a5eab3460ca16b66c768ee3ca9","type":"GENE","name":"HMGXB3","canonical_id":"hgnc:HGNC:28982","description":"HMG-box containing 3","metadata":{"aliases":["SMF","KIAA0194","HMGX3"]}},{"id":"90da3af7b3f84662a34a9f11210a120a","type":"GENE","name":"HMGXB4","canonical_id":"hgnc:HGNC:5003","description":null,"metadata":null},{"id":"b77867cf56da4df09593b7d4c65c7ce3","type":"GENE","name":"HMHB1","canonical_id":"hgnc:HGNC:29677","description":"histocompatibility minor HB-1","metadata":{"aliases":["HB-1","HB-1Y"]}},{"id":"ac294672cf8f413480496bdc7a66e736","type":"GENE","name":"HMHB1-AS1","canonical_id":"hgnc:HGNC:59270","description":"HMHB1 antisense RNA 1","metadata":null},{"id":"0f09dd1baf3548b79ffa6629b80c0530","type":"GENE","name":"HMHB1-OT1","canonical_id":"hgnc:HGNC:59269","description":"HMHB1 overlapping transcript 1","metadata":null},{"id":"83ab815a7f7e4c53bddfb44d98631d4e","type":"GENE","name":"HMMR","canonical_id":"hgnc:HGNC:5012","description":null,"metadata":null},{"id":"e83335431b924ee8951ba781a02451f8","type":"GENE","name":"HMMR-AS1","canonical_id":"hgnc:HGNC:49149","description":"HMMR antisense RNA 1","metadata":null},{"id":"b4c1159ac96b4a68bf1d2635d82fe728","type":"GENE","name":"HMOX1","canonical_id":"hgnc:HGNC:5013","description":null,"metadata":null},{"id":"0c8019caebc243ff8d97b7284e617b83","type":"GENE","name":"HMOX2","canonical_id":"hgnc:HGNC:5014","description":"heme oxygenase 2","metadata":{"aliases":["HO-2"]}},{"id":"7e46b7c5bdf44cf2842a34cbb91e6c76","type":"GENE","name":"HMSD","canonical_id":"hgnc:HGNC:23037","description":"histocompatibility minor serpin domain containing","metadata":{"aliases":["ACC-6","ACC6","C18orf53"]}},{"id":"c443283557e84ba2ba48128d4de5be8d","type":"GENE","name":"HMX1","canonical_id":"hgnc:HGNC:5017","description":"H6 family homeobox 1","metadata":{"aliases":["H6","NKX5-3"]}},{"id":"91e8c1d7ae8844b890086b0d316b1cd5","type":"GENE","name":"HMX1-AS1","canonical_id":"hgnc:HGNC:58730","description":"HMX1 antisense RNA 1","metadata":null},{"id":"9828c840176144baab07c4cb18b16a8a","type":"GENE","name":"HMX2","canonical_id":"hgnc:HGNC:5018","description":"H6 family homeobox 2","metadata":{"aliases":["NKX5-2"]}},{"id":"774a26d1d7444ef8bf7297b6bb6a5325","type":"GENE","name":"HMX3","canonical_id":"hgnc:HGNC:5019","description":"H6 family homeobox 3","metadata":{"aliases":["NKX5-1"]}},{"id":"cb3a5de028d846bd96a66a5e3ee876ff","type":"GENE","name":"HNF1A","canonical_id":"hgnc:HGNC:11621","description":null,"metadata":null},{"id":"ff91403656c949e6a9f70057ac6fdb17","type":"GENE","name":"HNF1A-AS1","canonical_id":"hgnc:HGNC:26785","description":"HNF1A antisense RNA 1","metadata":{"aliases":["FLJ38690","HAS1","HASTER","C12orf27","NCRNA00262"]}},{"id":"5b2f839762bd4286a3efe847ee7910b6","type":"GENE","name":"HNF1B","canonical_id":"hgnc:HGNC:11630","description":null,"metadata":null},{"id":"24e3cdb68be24532a3f4e7e7a24a7020","type":"GENE","name":"HNF4A","canonical_id":"hgnc:HGNC:5024","description":null,"metadata":null},{"id":"1db3e13034cc4ba0b4055a40c47796d4","type":"GENE","name":"HNF4A-AS1","canonical_id":"hgnc:HGNC:49505","description":"HNF4A antisense RNA 1","metadata":{"aliases":["uc002xlx"]}},{"id":"8d984b4f29114de5ae5a0457dc0e7556","type":"GENE","name":"HNF4G","canonical_id":"hgnc:HGNC:5026","description":null,"metadata":null},{"id":"1d127c6e221a4929aa30f04d61597f09","type":"GENE","name":"HNF4GP1","canonical_id":"hgnc:HGNC:35417","description":"hepatocyte nuclear factor 4 gamma pseudogene 1","metadata":null},{"id":"c138ad55027142948b68a46910bd7f62","type":"GO_TERM","name":"HNK-1 sulfotransferase activity","canonical_id":"go:GO:0016232","description":"\"Catalysis of the synthesis of the HKK-1 carbohydrate epitope; adds a sulfate group to a precursor, GlcA-beta-(1->3)-Gal-beta-(1->4)-GlcNAc-beta-(1->R), forming sulfo-3GlcA-beta-(1->3)-Gal-beta-(1->4)-GlcNAc-beta-(1->R).\" [PMID:9478973]","metadata":null},{"id":"27c2daa9ac3942bb9575028906763623","type":"GENE","name":"HNMT","canonical_id":"hgnc:HGNC:5028","description":"histamine N-methyltransferase","metadata":{"aliases":["HMT"]}},{"id":"1804c2313a5e44cdb28790c3c487ae29","type":"GENE","name":"HNRNPA0","canonical_id":"hgnc:HGNC:5030","description":"heterogeneous nuclear ribonucleoprotein A0","metadata":{"aliases":["HNRPA0"]}},{"id":"d6f68d09503b447c80f79d35e5a5094a","type":"GENE","name":"HNRNPA1","canonical_id":"hgnc:HGNC:5031","description":null,"metadata":null},{"id":"c1c4f8514d144e59b3564d65312ee8a8","type":"GENE","name":"HNRNPA1L2","canonical_id":"hgnc:HGNC:27067","description":"heterogeneous nuclear ribonucleoprotein A1 like 2","metadata":{"aliases":["LOC144983"]}},{"id":"3bdbc217f4b74cdda7070c954c4256f5","type":"GENE","name":"HNRNPA1L3","canonical_id":"hgnc:HGNC:48778","description":"heterogeneous nuclear ribonucleoprotein A1 like 3","metadata":{"aliases":["HNRNPA1P48"]}},{"id":"9c9555efb2cb466db33c74491726f0ee","type":"GENE","name":"HNRNPA1P1","canonical_id":"hgnc:HGNC:13957","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 1","metadata":{"aliases":["hnRNPA1-Lp","b34I8.2","HNRPA1P1"]}},{"id":"551d33c7866544bd9fd17feebe3cd6b6","type":"GENE","name":"HNRNPA1P10","canonical_id":"hgnc:HGNC:39128","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 10","metadata":null},{"id":"ba7efe8d4b6b4afdabe3b24ab0b668e6","type":"GENE","name":"HNRNPA1P11","canonical_id":"hgnc:HGNC:39129","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 11","metadata":null},{"id":"aa83ce36a3d747f99dab941614c18c73","type":"GENE","name":"HNRNPA1P12","canonical_id":"hgnc:HGNC:39130","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 12","metadata":null},{"id":"3b436a6391594b2c934d8d71e226ffb3","type":"GENE","name":"HNRNPA1P13","canonical_id":"hgnc:HGNC:39131","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 13","metadata":null},{"id":"50b56112d7b244e5b3ffd3989e135d43","type":"GENE","name":"HNRNPA1P14","canonical_id":"hgnc:HGNC:39132","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 14","metadata":null},{"id":"4144da5a9a5748099f2b58a4cd1f0b70","type":"GENE","name":"HNRNPA1P15","canonical_id":"hgnc:HGNC:39133","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 15","metadata":null},{"id":"8904fe7e06aa4db4aac4969cd44a0621","type":"GENE","name":"HNRNPA1P16","canonical_id":"hgnc:HGNC:39134","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 16","metadata":null},{"id":"88c32690944f495caaf7d8721499d8cd","type":"GENE","name":"HNRNPA1P17","canonical_id":"hgnc:HGNC:39135","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 17","metadata":null},{"id":"3dfb331afc364f1ab4249a8d98a38b87","type":"GENE","name":"HNRNPA1P18","canonical_id":"hgnc:HGNC:39445","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 18","metadata":null},{"id":"647f9769e86a4127a96da683f8658e16","type":"GENE","name":"HNRNPA1P19","canonical_id":"hgnc:HGNC:39537","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 19","metadata":null},{"id":"76128e1f992943348d36c157574cf163","type":"GENE","name":"HNRNPA1P2","canonical_id":"hgnc:HGNC:13958","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 2","metadata":{"aliases":["dJ372B18.1","HNRPA1P2"]}},{"id":"14862955aa9e4f7ea5eb4ea1a5469b8f","type":"GENE","name":"HNRNPA1P20","canonical_id":"hgnc:HGNC:39538","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 20","metadata":null},{"id":"92f9b6bd621944a993fac78b0ce15d44","type":"GENE","name":"HNRNPA1P21","canonical_id":"hgnc:HGNC:39539","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 21","metadata":null},{"id":"f86402e5433040b8a379a0adfd3a5692","type":"GENE","name":"HNRNPA1P22","canonical_id":"hgnc:HGNC:39540","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 22","metadata":null},{"id":"214bc0a90f454e79b2df843c81108c9a","type":"GENE","name":"HNRNPA1P23","canonical_id":"hgnc:HGNC:39541","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 23","metadata":null},{"id":"c185d0af39a2412ba8334e6cca5fda2d","type":"GENE","name":"HNRNPA1P24","canonical_id":"hgnc:HGNC:39542","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 24","metadata":null},{"id":"2fa9ebf81aa54277bac72e8a52baeaac","type":"GENE","name":"HNRNPA1P25","canonical_id":"hgnc:HGNC:39543","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 25","metadata":null},{"id":"53164500d4b249388a36015c09b6473d","type":"GENE","name":"HNRNPA1P26","canonical_id":"hgnc:HGNC:39544","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 26","metadata":null},{"id":"94ae3cdf75fb489aafb72957b1a40078","type":"GENE","name":"HNRNPA1P27","canonical_id":"hgnc:HGNC:39545","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 27","metadata":null},{"id":"a2b56760f8a44912815aec2997895b9a","type":"GENE","name":"HNRNPA1P28","canonical_id":"hgnc:HGNC:39546","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 28","metadata":null},{"id":"cd01dce664e3446495d42ddcf47bb4a1","type":"GENE","name":"HNRNPA1P29","canonical_id":"hgnc:HGNC:39547","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 29","metadata":null},{"id":"a53d5a3b995440c2ba9a77fe0d611045","type":"GENE","name":"HNRNPA1P3","canonical_id":"hgnc:HGNC:16567","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 3","metadata":{"aliases":["dJ447F3.1","HNRPA1P3"]}},{"id":"73b3e99ac8394c77b56c1f020320d44f","type":"GENE","name":"HNRNPA1P30","canonical_id":"hgnc:HGNC:39548","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 30","metadata":null},{"id":"4d0d906a44c446e38abd7bc253012e68","type":"GENE","name":"HNRNPA1P31","canonical_id":"hgnc:HGNC:39549","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 31","metadata":null},{"id":"01e76f82d79e4e6080b4dab8bfad8b1a","type":"GENE","name":"HNRNPA1P32","canonical_id":"hgnc:HGNC:44958","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 32","metadata":null},{"id":"1605bae4e9e74b22a9856c27b670f647","type":"GENE","name":"HNRNPA1P33","canonical_id":"hgnc:HGNC:44990","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 33","metadata":null},{"id":"cb2a776058a8449d87861109d7041344","type":"GENE","name":"HNRNPA1P34","canonical_id":"hgnc:HGNC:48763","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 34","metadata":null},{"id":"a1c7ba8fe04d4a63b1000aebba86bd78","type":"GENE","name":"HNRNPA1P35","canonical_id":"hgnc:HGNC:48764","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 35","metadata":null},{"id":"e20aa64af81946318d8d770e1ab2b3c5","type":"GENE","name":"HNRNPA1P36","canonical_id":"hgnc:HGNC:48765","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 36","metadata":null},{"id":"287ef7046f3e4541a07394bdc63086ff","type":"GENE","name":"HNRNPA1P37","canonical_id":"hgnc:HGNC:48766","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 37","metadata":null},{"id":"a5b2fb6ae3474bfb8ef76c4b198f16b8","type":"GENE","name":"HNRNPA1P38","canonical_id":"hgnc:HGNC:48767","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 38","metadata":null},{"id":"6df9ed646c4a44088f2f8bcba011b578","type":"GENE","name":"HNRNPA1P39","canonical_id":"hgnc:HGNC:48768","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 39","metadata":null},{"id":"8883ac2be906426cb523a8e6ca099977","type":"GENE","name":"HNRNPA1P4","canonical_id":"hgnc:HGNC:32234","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 4","metadata":{"aliases":["HNRPA1P4"]}},{"id":"684630fad5a241da99a7f07cbd88d65b","type":"GENE","name":"HNRNPA1P40","canonical_id":"hgnc:HGNC:48769","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 40","metadata":null},{"id":"a99f89f69ddf4c4eaba34f49925dbabb","type":"GENE","name":"HNRNPA1P41","canonical_id":"hgnc:HGNC:48770","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 41","metadata":null},{"id":"af5c3e7c7de740c48611bc66aa3662ab","type":"GENE","name":"HNRNPA1P42","canonical_id":"hgnc:HGNC:48771","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 42","metadata":null},{"id":"209f572550c64de3acd69df9cbeeee31","type":"GENE","name":"HNRNPA1P43","canonical_id":"hgnc:HGNC:48772","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 43","metadata":null},{"id":"a08c8abed04848ef89abf95ee612dfa9","type":"GENE","name":"HNRNPA1P44","canonical_id":"hgnc:HGNC:48774","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 44","metadata":null},{"id":"91bca4fa6e074cf8afc0e7d83236fd6c","type":"GENE","name":"HNRNPA1P45","canonical_id":"hgnc:HGNC:48775","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 45","metadata":null},{"id":"d214f813816b4993a8467a73198600ec","type":"GENE","name":"HNRNPA1P46","canonical_id":"hgnc:HGNC:48776","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 46","metadata":null},{"id":"ab5e0946b40940e295d88651a7cdd9e1","type":"GENE","name":"HNRNPA1P47","canonical_id":"hgnc:HGNC:48777","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 47","metadata":null},{"id":"7f9e343fd66247e9a855fcf0eec84c6a","type":"GENE","name":"HNRNPA1P49","canonical_id":"hgnc:HGNC:48779","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 49","metadata":null},{"id":"bd76d145941a443e81f105b9061420ce","type":"GENE","name":"HNRNPA1P5","canonical_id":"hgnc:HGNC:15787","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 5","metadata":null},{"id":"4f20bd47a7b2435295765113897b9d0c","type":"GENE","name":"HNRNPA1P50","canonical_id":"hgnc:HGNC:48780","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 50","metadata":null},{"id":"2f21c887551e4a2a806853d1e9348b5d","type":"GENE","name":"HNRNPA1P51","canonical_id":"hgnc:HGNC:48781","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 51","metadata":null},{"id":"f396a5c75062491284c376a0a8e79b68","type":"GENE","name":"HNRNPA1P52","canonical_id":"hgnc:HGNC:48782","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 52","metadata":null},{"id":"9bc44676ce6848c1a55fe8f8d832737f","type":"GENE","name":"HNRNPA1P53","canonical_id":"hgnc:HGNC:48783","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 53","metadata":null},{"id":"eb90191fcbdd4dbd8555ca79253e683f","type":"GENE","name":"HNRNPA1P54","canonical_id":"hgnc:HGNC:48784","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 54","metadata":null},{"id":"03000cb438d04742836550215c36b5c9","type":"GENE","name":"HNRNPA1P55","canonical_id":"hgnc:HGNC:48785","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 55","metadata":null},{"id":"de58f30297284e10a7e9575401638aac","type":"GENE","name":"HNRNPA1P56","canonical_id":"hgnc:HGNC:48786","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 56","metadata":null},{"id":"851eae6f6a00480190a71e6f183152f3","type":"GENE","name":"HNRNPA1P57","canonical_id":"hgnc:HGNC:48787","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 57","metadata":null},{"id":"ef29ff3ec1b646b7b1f68fea4a92ea41","type":"GENE","name":"HNRNPA1P58","canonical_id":"hgnc:HGNC:48788","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 58","metadata":null},{"id":"d6913174b38b4feda4129c6e52a8fdb8","type":"GENE","name":"HNRNPA1P59","canonical_id":"hgnc:HGNC:48789","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 59","metadata":null},{"id":"21ba849696764598a25d0baa3c560f03","type":"GENE","name":"HNRNPA1P6","canonical_id":"hgnc:HGNC:5032","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 6","metadata":{"aliases":["HNRPA1L","HNRNPA1L","HNRNPA1L1"]}},{"id":"e07cedf42b754dd186c2c3913414872f","type":"GENE","name":"HNRNPA1P60","canonical_id":"hgnc:HGNC:48790","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 60","metadata":null},{"id":"a54450eaea7843d6b713b5fe2ae8b80f","type":"GENE","name":"HNRNPA1P61","canonical_id":"hgnc:HGNC:48791","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 61","metadata":null},{"id":"f222b809d2a64ce8937c58fa8559834d","type":"GENE","name":"HNRNPA1P62","canonical_id":"hgnc:HGNC:48792","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 62","metadata":null},{"id":"0e262663b498462e99b1096a017c0b61","type":"GENE","name":"HNRNPA1P63","canonical_id":"hgnc:HGNC:48793","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 63","metadata":null},{"id":"e2ec087fad3d4a3d8956eb6a937e31fd","type":"GENE","name":"HNRNPA1P64","canonical_id":"hgnc:HGNC:48794","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 64","metadata":null},{"id":"056ac318bbba48b09f19a5b473df55f3","type":"GENE","name":"HNRNPA1P65","canonical_id":"hgnc:HGNC:48795","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 65","metadata":null},{"id":"a27357bc22a046898f13012fd3740ad3","type":"GENE","name":"HNRNPA1P66","canonical_id":"hgnc:HGNC:48796","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 66","metadata":null},{"id":"2a97ee336361408f9e7ebd0fdad4c8f3","type":"GENE","name":"HNRNPA1P67","canonical_id":"hgnc:HGNC:48797","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 67","metadata":null},{"id":"e4e6e9c9b2b0435b9f2a4464a10ecc4e","type":"GENE","name":"HNRNPA1P68","canonical_id":"hgnc:HGNC:48798","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 68","metadata":null},{"id":"fb6e213cd9b64d9194356f4e350f556c","type":"GENE","name":"HNRNPA1P69","canonical_id":"hgnc:HGNC:48799","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 69","metadata":null},{"id":"663f4769e580410ead0473b0f6cb5cd8","type":"GENE","name":"HNRNPA1P7","canonical_id":"hgnc:HGNC:31015","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 7","metadata":{"aliases":["HNRPA1L3"]}},{"id":"ebc13a4828964fcba3c41a9f24d81119","type":"GENE","name":"HNRNPA1P70","canonical_id":"hgnc:HGNC:48800","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 70","metadata":null},{"id":"ee88e32f9d5843539572820a5fd6cd98","type":"GENE","name":"HNRNPA1P71","canonical_id":"hgnc:HGNC:48801","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 71","metadata":null},{"id":"6185cdbfd9ba4f0bb5a4c874abe75aff","type":"GENE","name":"HNRNPA1P72","canonical_id":"hgnc:HGNC:48802","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 72","metadata":null},{"id":"ba1d8c1d539d44fb9a6e8d084313a6b6","type":"GENE","name":"HNRNPA1P73","canonical_id":"hgnc:HGNC:48803","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 73","metadata":null},{"id":"4995fbe2c2974fcd9fb8f0a33361113f","type":"GENE","name":"HNRNPA1P74","canonical_id":"hgnc:HGNC:48804","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 74","metadata":null},{"id":"a698aca5b06d4f27ae2085635b7b01bd","type":"GENE","name":"HNRNPA1P75","canonical_id":"hgnc:HGNC:48805","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 75","metadata":null},{"id":"e80c5b663b424feb8a891073bc53c2ea","type":"GENE","name":"HNRNPA1P76","canonical_id":"hgnc:HGNC:48806","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 76","metadata":null},{"id":"981f6c5a59fe440c8a6a465f1b1c4294","type":"GENE","name":"HNRNPA1P77","canonical_id":"hgnc:HGNC:48807","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 77","metadata":null},{"id":"5fb76cc11fc74e2a9e46d2ad34299f6d","type":"GENE","name":"HNRNPA1P8","canonical_id":"hgnc:HGNC:39126","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 8","metadata":null},{"id":"494bc431af0b4f249531624b6135cbad","type":"GENE","name":"HNRNPA1P9","canonical_id":"hgnc:HGNC:39127","description":"heterogeneous nuclear ribonucleoprotein A1 pseudogene 9","metadata":null},{"id":"aac7f1b11192455e9d519d999874fb07","type":"GENE","name":"HNRNPA2B1","canonical_id":"hgnc:HGNC:5033","description":null,"metadata":null},{"id":"fe36038880f04726a58235e1ee2705ff","type":"GENE","name":"HNRNPA3","canonical_id":"hgnc:HGNC:24941","description":"heterogeneous nuclear ribonucleoprotein A3","metadata":{"aliases":["HNRPA3"]}},{"id":"473a760fd7ac4747889770f505158e0c","type":"GENE","name":"HNRNPA3P1","canonical_id":"hgnc:HGNC:13729","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 1","metadata":{"aliases":["FBRNP","D10S102","HNRPA3","HNRPA3P1"]}},{"id":"3c372fdf41cf440c8514f5d9e50d3ed0","type":"GENE","name":"HNRNPA3P10","canonical_id":"hgnc:HGNC:48756","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 10","metadata":null},{"id":"ef8176bcbda3425d97204d70690aa715","type":"GENE","name":"HNRNPA3P11","canonical_id":"hgnc:HGNC:48757","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 11","metadata":null},{"id":"78c4dbcaba2048a39d69b8a58a74195d","type":"GENE","name":"HNRNPA3P12","canonical_id":"hgnc:HGNC:48758","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 12","metadata":null},{"id":"edad26f0fc664e9baf46c31acf62cc16","type":"GENE","name":"HNRNPA3P13","canonical_id":"hgnc:HGNC:48759","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 13","metadata":null},{"id":"55a0bf5a753848b69d68a78915d4aaa5","type":"GENE","name":"HNRNPA3P14","canonical_id":"hgnc:HGNC:48760","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 14","metadata":null},{"id":"a5365929dac545768968153b6148e133","type":"GENE","name":"HNRNPA3P15","canonical_id":"hgnc:HGNC:48761","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 15","metadata":null},{"id":"b44ccbfefb04498e85fc29218f1e4d9a","type":"GENE","name":"HNRNPA3P16","canonical_id":"hgnc:HGNC:48762","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 16","metadata":null},{"id":"3135a3e3aed94818987f8dc81db6f2ef","type":"GENE","name":"HNRNPA3P17","canonical_id":"hgnc:HGNC:56917","description":"HNRNPA3 pseudogene 17","metadata":null},{"id":"33cc99f3eac54e1eb378cd68055bb822","type":"GENE","name":"HNRNPA3P2","canonical_id":"hgnc:HGNC:16605","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 2","metadata":{"aliases":["dJ977B1.2","HNRPA3P","HNRPA3P2"]}},{"id":"8fb707a6ab5144b8a4f82d873be923cf","type":"GENE","name":"HNRNPA3P3","canonical_id":"hgnc:HGNC:39772","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 3","metadata":null},{"id":"646ae8db68e94828bc46e01a487572ed","type":"GENE","name":"HNRNPA3P4","canonical_id":"hgnc:HGNC:39773","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 4","metadata":null},{"id":"ce4c92dd3e044a5da60945d0e26c6320","type":"GENE","name":"HNRNPA3P5","canonical_id":"hgnc:HGNC:39774","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 5","metadata":null},{"id":"fe4731bdfbb2495aabe717b1d62e3614","type":"GENE","name":"HNRNPA3P6","canonical_id":"hgnc:HGNC:48495","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 6","metadata":null},{"id":"42788dc25b3f4c1492ea41e8ce90ccc7","type":"GENE","name":"HNRNPA3P7","canonical_id":"hgnc:HGNC:48496","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 7","metadata":null},{"id":"84d1b3147a1d4dceb11a42e9cd2d5fbf","type":"GENE","name":"HNRNPA3P8","canonical_id":"hgnc:HGNC:48497","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 8","metadata":null},{"id":"cad888bf23af44ddbebdd08712c462ef","type":"GENE","name":"HNRNPA3P9","canonical_id":"hgnc:HGNC:48755","description":"heterogeneous nuclear ribonucleoprotein A3 pseudogene 9","metadata":null},{"id":"19ca23b740b04b019141a78aad3d16ed","type":"GENE","name":"HNRNPAB","canonical_id":"hgnc:HGNC:5034","description":"heterogeneous nuclear ribonucleoprotein A/B","metadata":{"aliases":["ABBP1","FLJ40338","HNRPAB"]}},{"id":"ba3d98f5e9264de2952cd6eabe61ac95","type":"GENE","name":"HNRNPABP1","canonical_id":"hgnc:HGNC:48744","description":"heterogeneous nuclear ribonucleoprotein A/B pseudogene 1","metadata":null},{"id":"f788f5995f0345a598e5ef9588a4b199","type":"GENE","name":"HNRNPC","canonical_id":"hgnc:HGNC:5035","description":"heterogeneous nuclear ribonucleoprotein C","metadata":{"aliases":["HNRPC"]}},{"id":"c79b8dc17b0740ee8294bb8f8546cdd4","type":"GENE","name":"HNRNPCL1","canonical_id":"hgnc:HGNC:29295","description":"heterogeneous nuclear ribonucleoprotein C like 1","metadata":{"aliases":["HNRPCL1"]}},{"id":"064669c9f0a046bdb68ab332c25e3f10","type":"GENE","name":"HNRNPCL2","canonical_id":"hgnc:HGNC:48813","description":"heterogeneous nuclear ribonucleoprotein C like 2","metadata":{"aliases":["HNRNPCP5"]}},{"id":"6934aae7b6094a288a5fa48df26f9257","type":"GENE","name":"HNRNPCL3","canonical_id":"hgnc:HGNC:51235","description":"heterogeneous nuclear ribonucleoprotein C like 3","metadata":null},{"id":"0d8831a42d3d4570b7b26dbda79e99d5","type":"GENE","name":"HNRNPCL4","canonical_id":"hgnc:HGNC:51333","description":"heterogeneous nuclear ribonucleoprotein C like 4","metadata":null},{"id":"c242af18a5764e7a8793b91d30b8557b","type":"GENE","name":"HNRNPCP1","canonical_id":"hgnc:HGNC:20017","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 1","metadata":{"aliases":["HNRPCP"]}},{"id":"cc5b1dc83357498d8230c7d57bdb318e","type":"GENE","name":"HNRNPCP10","canonical_id":"hgnc:HGNC:48821","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 10","metadata":null},{"id":"1cd2f2b54f1349a8a7a185ca9bb1c0cf","type":"GENE","name":"HNRNPCP2","canonical_id":"hgnc:HGNC:48814","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 2","metadata":null},{"id":"068a964b5de445849b6d1dfcb5ce5714","type":"GENE","name":"HNRNPCP3","canonical_id":"hgnc:HGNC:48815","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 3","metadata":null},{"id":"37fa1a2edacf4af6a8873174b3aaa398","type":"GENE","name":"HNRNPCP4","canonical_id":"hgnc:HGNC:48816","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 4","metadata":null},{"id":"e49779b12684427ea56a4f0548f38dc1","type":"GENE","name":"HNRNPCP6","canonical_id":"hgnc:HGNC:48817","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 6","metadata":null},{"id":"d5ab557a9082442f8097ec005b2bc1c7","type":"GENE","name":"HNRNPCP7","canonical_id":"hgnc:HGNC:48818","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 7","metadata":null},{"id":"3890dd2417f44be4a56f31230d33723e","type":"GENE","name":"HNRNPCP8","canonical_id":"hgnc:HGNC:48819","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 8","metadata":null},{"id":"a405e11e260b4639942533fcf13978e1","type":"GENE","name":"HNRNPCP9","canonical_id":"hgnc:HGNC:48820","description":"heterogeneous nuclear ribonucleoprotein C pseudogene 9","metadata":null},{"id":"4dcdc04de1f94b24bbb5bf2f97d9e8a2","type":"GENE","name":"HNRNPD","canonical_id":"hgnc:HGNC:5036","description":null,"metadata":null},{"id":"a6972f279c2a44a1b34161d586904e92","type":"GENE","name":"HNRNPD-DT","canonical_id":"hgnc:HGNC:55205","description":"HNRNPD divergent transcript","metadata":null},{"id":"9a846b14c86646778bb10f9bcc4aeff0","type":"GENE","name":"HNRNPDL","canonical_id":"hgnc:HGNC:5037","description":"heterogeneous nuclear ribonucleoprotein D like","metadata":{"aliases":["JKTBP","laAUF1","HNRPDL","LGMD1G"]}},{"id":"0879b447c06647059cc00d7f41a5ff6e","type":"GENE","name":"HNRNPDLP1","canonical_id":"hgnc:HGNC:48752","description":"HNRNPDL pseudogene 1","metadata":null},{"id":"d2d75369d5b14b429901848e142e6bb1","type":"GENE","name":"HNRNPDLP2","canonical_id":"hgnc:HGNC:48753","description":"HNRNPDL pseudogene 2","metadata":null},{"id":"7ed3adf170e34b06ad8270498367642f","type":"GENE","name":"HNRNPDLP3","canonical_id":"hgnc:HGNC:48754","description":"HNRNPDL pseudogene 3","metadata":null},{"id":"5edc319f26ab42b8a54df20d05eaf694","type":"GENE","name":"HNRNPDLP4","canonical_id":"hgnc:HGNC:48808","description":"HNRNPDL pseudogene 4","metadata":null},{"id":"830fab0938e247948d770d05dd7147e2","type":"GENE","name":"HNRNPDLP5","canonical_id":"hgnc:HGNC:48809","description":"HNRNPDL pseudogene 5","metadata":null},{"id":"7c441ea1c7cd4ce8a9003d2d453625bb","type":"GENE","name":"HNRNPDP1","canonical_id":"hgnc:HGNC:5038","description":"heterogeneous nuclear ribonucleoprotein D pseudogene 1","metadata":{"aliases":["AUF1B","AUF1P","HNRPDP","HNRNPDP"]}},{"id":"1e1fab28e96845a5b0d9d44961ba2f4e","type":"GENE","name":"HNRNPDP2","canonical_id":"hgnc:HGNC:48749","description":"heterogeneous nuclear ribonucleoprotein D pseudogene 2","metadata":null},{"id":"200cd2d72fc34a83aea41dfd32225e27","type":"GENE","name":"HNRNPF","canonical_id":"hgnc:HGNC:5039","description":"heterogeneous nuclear ribonucleoprotein F","metadata":{"aliases":["HNRPF"]}},{"id":"f16b40152030485c9391fb25978c9899","type":"GENE","name":"HNRNPFP1","canonical_id":"hgnc:HGNC:48812","description":"heterogeneous nuclear ribonucleoprotein F pseudogene 1","metadata":null},{"id":"db7331eda2874c4ab7f8bd4dcd0dae9c","type":"GENE","name":"HNRNPH1","canonical_id":"hgnc:HGNC:5041","description":"heterogeneous nuclear ribonucleoprotein H1","metadata":{"aliases":["hnRNPH","HNRPH1"]}},{"id":"c06a415d8224446a92b7ff8a86e8cb44","type":"GENE","name":"HNRNPH1P1","canonical_id":"hgnc:HGNC:48751","description":"heterogeneous nuclear ribonucleoprotein H1 pseudogene 1","metadata":null},{"id":"f988aecc1039425e93cfb7614fcd4461","type":"GENE","name":"HNRNPH1P2","canonical_id":"hgnc:HGNC:48810","description":"heterogeneous nuclear ribonucleoprotein H1 pseudogene 2","metadata":null},{"id":"a6394d0db5a844f1ba3ade262de6b73e","type":"GENE","name":"HNRNPH1P3","canonical_id":"hgnc:HGNC:48811","description":"heterogeneous nuclear ribonucleoprotein H1 pseudogene 3","metadata":null},{"id":"89ff3868635943c0bc9febb4a13e18c7","type":"GENE","name":"HNRNPH2","canonical_id":"hgnc:HGNC:5042","description":"heterogeneous nuclear ribonucleoprotein H2","metadata":{"aliases":["hnRNPH'","FTP3","HNRPH'","HNRPH2"]}},{"id":"4645148c1423404da9744367d2bf7500","type":"GENE","name":"HNRNPH3","canonical_id":"hgnc:HGNC:5043","description":"heterogeneous nuclear ribonucleoprotein H3","metadata":{"aliases":["2H9","HNRPH3"]}},{"id":"488b1c0472b84a2295f45e49d42e343f","type":"GENE","name":"HNRNPH3P1","canonical_id":"hgnc:HGNC:48750","description":"heterogeneous nuclear ribonucleoprotein H3 pseudogene 1","metadata":null},{"id":"3ebf8b40b9e6442ea0a3fe77428e3bac","type":"GENE","name":"HNRNPK","canonical_id":"hgnc:HGNC:5044","description":"heterogeneous nuclear ribonucleoprotein K","metadata":{"aliases":["CSBP","TUNP","HNRPK"]}},{"id":"e29b1eb0183942bf93353c1cf900d578","type":"GENE","name":"HNRNPK-AS1","canonical_id":"hgnc:HGNC:56061","description":"HNRNPK antisense RNA 1","metadata":null},{"id":"ccd98005e6e6401f800c8f0c0ffb898b","type":"GENE","name":"HNRNPKP1","canonical_id":"hgnc:HGNC:42374","description":"heterogeneous nuclear ribonucleoprotein K pseudogene 1","metadata":null},{"id":"6dcddcd4ebb24fbba8e0d718e9f13c04","type":"GENE","name":"HNRNPKP2","canonical_id":"hgnc:HGNC:42375","description":"heterogeneous nuclear ribonucleoprotein K pseudogene 2","metadata":null},{"id":"c3b2ebab2dc0425bbd11feb3528b6d2e","type":"GENE","name":"HNRNPKP3","canonical_id":"hgnc:HGNC:42376","description":"heterogeneous nuclear ribonucleoprotein K pseudogene 3","metadata":null},{"id":"f5244a440b5f4beab8e9bc5a95c0791b","type":"GENE","name":"HNRNPKP4","canonical_id":"hgnc:HGNC:42377","description":"heterogeneous nuclear ribonucleoprotein K pseudogene 4","metadata":null},{"id":"b4cb88beb03545748aa3a06a69b0686c","type":"GENE","name":"HNRNPKP5","canonical_id":"hgnc:HGNC:42378","description":"heterogeneous nuclear ribonucleoprotein K pseudogene 5","metadata":null},{"id":"ac9fbda474a14516af6b23f84e93ddb0","type":"GENE","name":"HNRNPL","canonical_id":"hgnc:HGNC:5045","description":"heterogeneous nuclear ribonucleoprotein L","metadata":{"aliases":["HNRPL"]}},{"id":"8be06c62f16a4c749c95feadfba92032","type":"GENE","name":"HNRNPLL","canonical_id":"hgnc:HGNC:25127","description":"heterogeneous nuclear ribonucleoprotein L like","metadata":{"aliases":["HNRPLL"]}},{"id":"b2f68f120bf946518a4e63314b59305e","type":"GENE","name":"HNRNPLL-AS1","canonical_id":"hgnc:HGNC:41083","description":"HNRPLL antisense RNA 1","metadata":null},{"id":"ab220e14aca34aab94185e734222efd8","type":"GENE","name":"HNRNPLP1","canonical_id":"hgnc:HGNC:48748","description":"heterogeneous nuclear ribonucleoprotein L pseudogene 1","metadata":null},{"id":"cf709f928d2f4b3ab453c1ddf2d5a5e3","type":"GENE","name":"HNRNPLP2","canonical_id":"hgnc:HGNC:48747","description":"heterogeneous nuclear ribonucleoprotein L pseudogene 2","metadata":null},{"id":"3d3f22d65fc3462899c0208ebc1fc64e","type":"GENE","name":"HNRNPM","canonical_id":"hgnc:HGNC:5046","description":"heterogeneous nuclear ribonucleoprotein M","metadata":{"aliases":["HTGR1","HNRNPM4","HNRPM4","CEAR","NAGR1","HNRPM"]}},{"id":"10a3cddcd9d04cc186f2ab46936496d9","type":"GENE","name":"HNRNPMP1","canonical_id":"hgnc:HGNC:48745","description":"heterogeneous nuclear ribonucleoprotein M pseudogene 1","metadata":null},{"id":"c2a9485b202647d08afaa2e51830b65c","type":"GENE","name":"HNRNPMP2","canonical_id":"hgnc:HGNC:48746","description":"heterogeneous nuclear ribonucleoprotein M pseudogene 2","metadata":null},{"id":"a284af93367044acb0331516e73ec912","type":"GENE","name":"HNRNPR","canonical_id":"hgnc:HGNC:5047","description":null,"metadata":null},{"id":"4be12fef22de40f39904151f7551d5ec","type":"GENE","name":"HNRNPRP1","canonical_id":"hgnc:HGNC:44907","description":"heterogeneous nuclear ribonucleoprotein R pseudogene 1","metadata":null},{"id":"c6acc6c5f62a4892b5a7c38afa8e594a","type":"GENE","name":"HNRNPRP2","canonical_id":"hgnc:HGNC:44908","description":"heterogeneous nuclear ribonucleoprotein R pseudogene 2","metadata":null},{"id":"35fc5e2f1d374612a78b759fcc01021e","type":"GENE","name":"HNRNPRP3","canonical_id":"hgnc:HGNC:44909","description":"heterogeneous nuclear ribonucleoprotein R pseudogene 3","metadata":null},{"id":"e310fd07ac8b40a799486015e75bac61","type":"GENE","name":"HNRNPU","canonical_id":"hgnc:HGNC:5048","description":"heterogeneous nuclear ribonucleoprotein U","metadata":{"aliases":["SAF-A","FLJ37978","FLJ30202","HNRPU","HNRNPU-AS1","C1orf199","NCRNA00201"]}},{"id":"0a2e936a12bb4d1f8708d6109886d46a","type":"GENE","name":"HNRNPUL1","canonical_id":"hgnc:HGNC:17011","description":"heterogeneous nuclear ribonucleoprotein U like 1","metadata":{"aliases":["E1B-AP5","E1BAP5","FLJ12944","HNRPUL1"]}},{"id":"12bc331674a54cf1bb4b5e184693118e","type":"GENE","name":"HNRNPUL2","canonical_id":"hgnc:HGNC:25451","description":"heterogeneous nuclear ribonucleoprotein U like 2","metadata":{"aliases":["DKFZp762N1910","HNRPUL2"]}},{"id":"bd518d45b8ea4627833297d92f8e7284","type":"GENE","name":"HNRNPUL2-BSCL2","canonical_id":"hgnc:HGNC:49189","description":"HNRNPUL2-BSCL2 readthrough (NMD candidate)","metadata":null},{"id":"9e6a2f7894274208a8dd89324ca3c9d7","type":"GENE","name":"HNRNPUP1","canonical_id":"hgnc:HGNC:19931","description":"heterogeneous nuclear ribonucleoprotein U pseudogene 1","metadata":{"aliases":["HNRPUP"]}},{"id":"ab0eb4799b9443edaf3d5caffa8aa47c","type":"GENE","name":"HOATZ","canonical_id":"hgnc:HGNC:25061","description":"HOATZ cilia and flagella associated protein","metadata":{"aliases":["FLJ46266","C11orf88"]}},{"id":"16b69e83dc994233a77322ac5a4ecb48","type":"GENE","name":"HOGA1","canonical_id":"hgnc:HGNC:25155","description":"4-hydroxy-2-oxoglutarate aldolase 1","metadata":{"aliases":["FLJ37472","DHDPS2","NPL2","C10orf65","DHDPSL"]}},{"id":"948bb1ef8faf426fa38db7a32c4db4f1","type":"GENE","name":"HOMER1","canonical_id":"hgnc:HGNC:17512","description":"homer scaffold protein 1","metadata":{"aliases":["Ves-1","SYN47","HOMER-1B"]}},{"id":"79de060a4c4242c29ba23c3cf883c773","type":"GENE","name":"HOMER1-DT","canonical_id":"hgnc:HGNC:59084","description":"HOMER1 divergent transcript","metadata":null},{"id":"2fba118a1b984b8ba694ef24a5c578bc","type":"GENE","name":"HOMER2","canonical_id":"hgnc:HGNC:17513","description":"homer scaffold protein 2","metadata":{"aliases":["CPD","Cupidin","Vesl-2","HOMER-2B","HOMER-2","HOMER-2A","DFNA68"]}},{"id":"795b599d4cfa4b7fa8c05650b42290ac","type":"GENE","name":"HOMER2P1","canonical_id":"hgnc:HGNC:20336","description":"HOMER2 pseudogene 1","metadata":null},{"id":"9d5ae245ba9442a5b7eec6d300eb8aee","type":"GENE","name":"HOMER2P2","canonical_id":"hgnc:HGNC:20334","description":"HOMER2 pseudogene 2","metadata":null},{"id":"bd2c76ae016e4ece8061dae864cca118","type":"GENE","name":"HOMER3","canonical_id":"hgnc:HGNC:17514","description":null,"metadata":null},{"id":"e809a57fab5c4af09395a3b45f759e3e","type":"GENE","name":"HOMER3-AS1","canonical_id":"hgnc:HGNC:53775","description":"HOMER3 antisense RNA 1","metadata":null},{"id":"9bfe2a576ce24c56ac3a8dcf27bd909d","type":"GENE","name":"HOMEZ","canonical_id":"hgnc:HGNC:20164","description":"homeobox and leucine zipper encoding","metadata":{"aliases":["KIAA1443"]}},{"id":"6b5663acde9f4823ac3bea23fd496b0a","type":"GENE","name":"HOOK1","canonical_id":"hgnc:HGNC:19884","description":"hook microtubule tethering protein 1","metadata":{"aliases":["HK1"]}},{"id":"0c6512c0a8e949529ac793a3a2fd35cb","type":"GENE","name":"HOOK2","canonical_id":"hgnc:HGNC:19885","description":"hook microtubule tethering protein 2","metadata":{"aliases":["HK2"]}},{"id":"756f417be5df442b9557dbc17925d7f0","type":"GENE","name":"HOOK3","canonical_id":"hgnc:HGNC:23576","description":"hook microtubule tethering protein 3","metadata":{"aliases":["HK3"]}},{"id":"aa9fe4e47cd340018521560cacfed553","type":"TRIAL","name":"HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC","canonical_id":"clinicaltrials.gov:NCT07608224","description":"Urinary Bladder Neoplasms","metadata":null},{"id":"c4490afb8f5a4622a44efec63af3366e","type":"GO_TERM","name":"HOPS complex","canonical_id":"go:GO:0030897","description":"\"A multimeric protein complex that associates with the vacuolar membrane, late endosomal (multivesicular body) and lysosomal membranes. HOPS is a tethering complex involved in vesicle fusion.\" [PMID:10944212, PMID:23645161]","metadata":null},{"id":"2f766726408b4125925d3a477ecfc0d6","type":"GENE","name":"HOPX","canonical_id":"hgnc:HGNC:24961","description":null,"metadata":null},{"id":"32d7fcf794d7425f8b2246477c96dce6","type":"GENE","name":"HOPX-AS1","canonical_id":"hgnc:HGNC:58797","description":"HOPX antisense RNA 1","metadata":null},{"id":"e641dd373ee64cfbbb7462d464ea7a58","type":"GENE","name":"HORMAD1","canonical_id":"hgnc:HGNC:25245","description":"HORMA domain containing 1","metadata":{"aliases":["DKFZP434A1315","CT46"]}},{"id":"f9b36ee979aa4674a8752d129f5b6545","type":"GENE","name":"HORMAD1P1","canonical_id":"hgnc:HGNC:58577","description":"HORMAD1 pseudogene 1","metadata":null},{"id":"60a9cc2bdf8c4dbd9dfcea1e128bb566","type":"GENE","name":"HORMAD2","canonical_id":"hgnc:HGNC:28383","description":"HORMA domain containing 2","metadata":{"aliases":["MGC26710","CT46.2"]}},{"id":"c0593926df6c4aa2b550d99f3ec93be1","type":"GENE","name":"HORMAD2-AS1","canonical_id":"hgnc:HGNC:50729","description":"HORMAD2 and MTMR3 antisense RNA 1","metadata":{"aliases":["MTMR3-AS1","NONHSAG033653"]}},{"id":"ce091f3dcf8c40458dceda628abd5181","type":"GENE","name":"HOTAIR","canonical_id":"hgnc:HGNC:33510","description":"HOX transcript antisense RNA","metadata":{"aliases":["HOXC-AS4","HOXC11-AS1","NCRNA00072"]}},{"id":"be691b4159bc45b593755278592fda57","type":"GENE","name":"HOTAIRM1","canonical_id":"hgnc:HGNC:37117","description":"HOXA transcript antisense RNA, myeloid-specific 1","metadata":{"aliases":["HOXA-AS1","NCRNA00179","HOXA1-AS1"]}},{"id":"0467ffe73a214f81baeef9624fb8e964","type":"GENE","name":"HOTTIP","canonical_id":"hgnc:HGNC:37461","description":"HOXA distal transcript antisense RNA","metadata":{"aliases":["HOXA-AS6","RP1-170O19.3","HOXA13-AS1","NCRNA00213"]}},{"id":"c3407c2303904dac802b8c6fa3d38d6e","type":"GENE","name":"HOXA-AS2","canonical_id":"hgnc:HGNC:43745","description":"HOXA cluster antisense RNA 2","metadata":{"aliases":["HOXA3as"]}},{"id":"1372c08119a7452ebe430f00d129a4bc","type":"GENE","name":"HOXA-AS3","canonical_id":"hgnc:HGNC:43748","description":"HOXA cluster antisense RNA 3","metadata":{"aliases":["HOXA6as"]}},{"id":"ccfe861f46f647de8f54c059d78ab6b7","type":"GENE","name":"HOXA1","canonical_id":"hgnc:HGNC:5099","description":null,"metadata":null},{"id":"3ba7ea24fc584a8792345590b4ded39f","type":"GENE","name":"HOXA10","canonical_id":"hgnc:HGNC:5100","description":null,"metadata":null},{"id":"268606d8659147acbe2fb4bcd3c51537","type":"GENE","name":"HOXA10-AS","canonical_id":"hgnc:HGNC:40281","description":"HOXA10 antisense RNA","metadata":{"aliases":["HOXA-AS4"]}},{"id":"ca33981e8e0e4fa7a850e32bbe441b70","type":"GENE","name":"HOXA10-HOXA9","canonical_id":"hgnc:HGNC:51908","description":"HOXA10-HOXA9 readthrough","metadata":{"aliases":["HDSP"]}},{"id":"16dd04cb40d545c7acf8e92bac779d71","type":"GENE","name":"HOXA11","canonical_id":"hgnc:HGNC:5101","description":null,"metadata":null},{"id":"49c112e70bc149aea3f557296044a765","type":"GENE","name":"HOXA11-AS","canonical_id":"hgnc:HGNC:24957","description":"HOXA11 antisense RNA","metadata":{"aliases":["HOXA11-AS1","HOXA11S","HOXA-AS5","NCRNA00076","LncHOXA11","HOXA11AS"]}},{"id":"c3301eee6ba84718a33d62dad5279feb","type":"GENE","name":"HOXA13","canonical_id":"hgnc:HGNC:5102","description":"homeobox A13","metadata":{"aliases":["HOX1J","HOX1"]}},{"id":"2a2956c09a7b48e188cb61674febc3b2","type":"GENE","name":"HOXA2","canonical_id":"hgnc:HGNC:5103","description":null,"metadata":null},{"id":"ec8abf14ca564307a5f98ce44a117cdc","type":"GENE","name":"HOXA3","canonical_id":"hgnc:HGNC:5104","description":"homeobox A3","metadata":{"aliases":["HOX1E","HOX1"]}},{"id":"15301c2b2af34488a065225d5bc95940","type":"GENE","name":"HOXA4","canonical_id":"hgnc:HGNC:5105","description":null,"metadata":null},{"id":"f6d13cc6ac314b3980195ce6abb7e8d7","type":"GENE","name":"HOXA5","canonical_id":"hgnc:HGNC:5106","description":null,"metadata":null},{"id":"8aedfa2ba410460eb0870a264de24885","type":"GENE","name":"HOXA6","canonical_id":"hgnc:HGNC:5107","description":"homeobox A6","metadata":{"aliases":["HOX1B","HOX1"]}},{"id":"2d0937f694164233b9b085c436caed1c","type":"GENE","name":"HOXA7","canonical_id":"hgnc:HGNC:5108","description":null,"metadata":null},{"id":"10d0395774b1430e93a83478771606d5","type":"GENE","name":"HOXA9","canonical_id":"hgnc:HGNC:5109","description":null,"metadata":null},{"id":"2bbd1852238b4868a44a9b54b5aeb785","type":"GENE","name":"HOXA@","canonical_id":"hgnc:HGNC:5098","description":"homeobox A cluster","metadata":{"aliases":["HOX1@"]}},{"id":"5eafe1a37abb4957948afebee8b4c0e7","type":"GENE","name":"HOXB-AS1","canonical_id":"hgnc:HGNC:43744","description":"HOXB cluster antisense RNA 1","metadata":null},{"id":"2110ac45d89e430498386a0e3debdeeb","type":"GENE","name":"HOXB-AS2","canonical_id":"hgnc:HGNC:40284","description":"HOXB cluster antisense RNA 2","metadata":null},{"id":"7119eb31170643b6b351c84e17971610","type":"GENE","name":"HOXB-AS3","canonical_id":"hgnc:HGNC:40283","description":"HOXB cluster antisense RNA 3","metadata":null},{"id":"b29ac79ff75940eb86ad2308ea478adc","type":"GENE","name":"HOXB-AS4","canonical_id":"hgnc:HGNC:40285","description":"HOXB cluster antisense RNA 4","metadata":null},{"id":"87cdbc07b3804379bd93b79fc30a531a","type":"GENE","name":"HOXB1","canonical_id":"hgnc:HGNC:5111","description":null,"metadata":null},{"id":"72278112200c4273a1328de444629c3d","type":"GENE","name":"HOXB13","canonical_id":"hgnc:HGNC:5112","description":null,"metadata":null},{"id":"c1522cd3256e4930b368df8bf761a180","type":"GENE","name":"HOXB2","canonical_id":"hgnc:HGNC:5113","description":"homeobox B2","metadata":{"aliases":["HOX2","HOX2H"]}},{"id":"3693a73499e84c8d93ed633b8e94e2fb","type":"GENE","name":"HOXB3","canonical_id":"hgnc:HGNC:5114","description":"homeobox B3","metadata":{"aliases":["HOX2","HOX2G"]}},{"id":"e9c13d6dfab546da837ce21bcd861bc2","type":"GENE","name":"HOXB4","canonical_id":"hgnc:HGNC:5115","description":null,"metadata":null},{"id":"8760db1e212349179fd89a115bd798e2","type":"GENE","name":"HOXB5","canonical_id":"hgnc:HGNC:5116","description":"homeobox B5","metadata":{"aliases":["HOX2","HOX2A"]}},{"id":"94b28cc8391b403a889903abf123e55b","type":"GENE","name":"HOXB6","canonical_id":"hgnc:HGNC:5117","description":"homeobox B6","metadata":{"aliases":["HOX2","HOX2B"]}},{"id":"e2979a33f0bb4145a26a36ebd3fbb902","type":"GENE","name":"HOXB7","canonical_id":"hgnc:HGNC:5118","description":null,"metadata":null},{"id":"583358ca93ad4e4a8ba1737b78de94c6","type":"GENE","name":"HOXB8","canonical_id":"hgnc:HGNC:5119","description":null,"metadata":null},{"id":"2f01063aa1a44606962c2bea14d8358c","type":"GENE","name":"HOXB9","canonical_id":"hgnc:HGNC:5120","description":"homeobox B9","metadata":{"aliases":["HOX2E","HOX2"]}},{"id":"bc498b1d550241edbc021dbb951e6f8f","type":"GENE","name":"HOXB@","canonical_id":"hgnc:HGNC:5110","description":"homeobox B cluster","metadata":{"aliases":["HOX2@"]}},{"id":"d7229f33e3c547b3bc8b667b4f748f80","type":"GENE","name":"HOXC-AS1","canonical_id":"hgnc:HGNC:43749","description":"HOXC cluster antisense RNA 1","metadata":null},{"id":"8a0e584d8967442e824b6df73546bbbe","type":"GENE","name":"HOXC-AS2","canonical_id":"hgnc:HGNC:43750","description":"HOXC cluster antisense RNA 2","metadata":null},{"id":"9e81b326a7ed4c8fa5d69a9060d12b59","type":"GENE","name":"HOXC-AS3","canonical_id":"hgnc:HGNC:43751","description":"HOXC cluster antisense RNA 3","metadata":null},{"id":"d3f01320744d4bdeb0125a1be0205789","type":"GENE","name":"HOXC10","canonical_id":"hgnc:HGNC:5122","description":null,"metadata":null},{"id":"e38a2d2207ed44ddb230016b54cfadc8","type":"GENE","name":"HOXC11","canonical_id":"hgnc:HGNC:5123","description":null,"metadata":null},{"id":"3c82b80926374defbced5bc371c69415","type":"GENE","name":"HOXC12","canonical_id":"hgnc:HGNC:5124","description":"homeobox C12","metadata":{"aliases":["HOX3","HOX3F","HOC3F"]}},{"id":"8687e316091a4d49866ba9f31156a825","type":"GENE","name":"HOXC13","canonical_id":"hgnc:HGNC:5125","description":null,"metadata":null},{"id":"8bac59c5fb134a1a92f9b1a6acbc4248","type":"GENE","name":"HOXC13-AS","canonical_id":"hgnc:HGNC:43753","description":"HOXC13 antisense RNA","metadata":{"aliases":["HOXC-AS5"]}},{"id":"f8d74ea020e645c7b9b7d2127f69984b","type":"GENE","name":"HOXC4","canonical_id":"hgnc:HGNC:5126","description":"homeobox C4","metadata":{"aliases":["HOX3","HOX3E"]}},{"id":"b706bd6527174fb4b5add118a451dade","type":"GENE","name":"HOXC5","canonical_id":"hgnc:HGNC:5127","description":"homeobox C5","metadata":{"aliases":["HOX3D","HOX3"]}},{"id":"7620a23185364eadbc08025b22ed4340","type":"GENE","name":"HOXC6","canonical_id":"hgnc:HGNC:5128","description":null,"metadata":null},{"id":"5039d801d8b646dcbdf13ebb21440360","type":"GENE","name":"HOXC8","canonical_id":"hgnc:HGNC:5129","description":null,"metadata":null},{"id":"b39804df64fa4e56b2331a2e65a89eb0","type":"GENE","name":"HOXC9","canonical_id":"hgnc:HGNC:5130","description":null,"metadata":null},{"id":"4ff3e2bc6199427f9f603a63e6bdb199","type":"GENE","name":"HOXC@","canonical_id":"hgnc:HGNC:5121","description":"homeobox C cluster","metadata":{"aliases":["HOX3@"]}},{"id":"0857b671ee164f8889caed1c9cfc19f4","type":"GENE","name":"HOXD-AS2","canonical_id":"hgnc:HGNC:43756","description":"HOXD cluster antisense RNA 2","metadata":null},{"id":"3c67a36a34f94d459c31992af17620b5","type":"GENE","name":"HOXD1","canonical_id":"hgnc:HGNC:5132","description":null,"metadata":null},{"id":"fd9df0f69b6c485bb3f05ff1f79b91cd","type":"GENE","name":"HOXD10","canonical_id":"hgnc:HGNC:5133","description":"homeobox D10","metadata":{"aliases":["HOX4","HOX4D"]}},{"id":"67edc2c40c4a4cf0b9e71c7524c1390d","type":"GENE","name":"HOXD11","canonical_id":"hgnc:HGNC:5134","description":"homeobox D11","metadata":{"aliases":["HOX4","HOX4F"]}},{"id":"915c95d4e1b748ab84f3323ddec70c3f","type":"GENE","name":"HOXD12","canonical_id":"hgnc:HGNC:5135","description":"homeobox D12","metadata":{"aliases":["HOX4H"]}},{"id":"0c33e512cf33481da946d16c9a092e81","type":"GENE","name":"HOXD13","canonical_id":"hgnc:HGNC:5136","description":null,"metadata":null},{"id":"bd41926a693745cb86c956b3b69eb4ae","type":"GENE","name":"HOXD3","canonical_id":"hgnc:HGNC:5137","description":null,"metadata":null},{"id":"ac2c870a539d4312a1a01449f88f0afa","type":"GENE","name":"HOXD4","canonical_id":"hgnc:HGNC:5138","description":"homeobox D4","metadata":{"aliases":["HOX4B","HOX4"]}},{"id":"650af97daa3c4ab1839cae8fa86ab2ef","type":"GENE","name":"HOXD8","canonical_id":"hgnc:HGNC:5139","description":"homeobox D8","metadata":{"aliases":["HOX4","HOX4E"]}},{"id":"2e41ba4302c54867a4ac336f72216bee","type":"GENE","name":"HOXD9","canonical_id":"hgnc:HGNC:5140","description":null,"metadata":null},{"id":"d7dd0bd278b94696bb9325bdda978d2f","type":"GENE","name":"HOXD@","canonical_id":"hgnc:HGNC:5131","description":"homeobox D cluster","metadata":{"aliases":["HOX4@"]}},{"id":"4f2c0bf653c84240bd42ad221adc87a0","type":"GENE","name":"HP","canonical_id":"hgnc:HGNC:5141","description":null,"metadata":null},{"id":"745320160f0547298b18a859bd8c2a10","type":"GENE","name":"HP1BP3","canonical_id":"hgnc:HGNC:24973","description":"heterochromatin protein 1 binding protein 3","metadata":{"aliases":["HP1-BP74"]}},{"id":"f57304fed6734274986dbfad4c9fcb4a","type":"GENE","name":"HPCA","canonical_id":"hgnc:HGNC:5144","description":"hippocalcin","metadata":{"aliases":["DYT2"]}},{"id":"20ec04c774f14534bfcafdc7c8f09ed4","type":"GENE","name":"HPCAL1","canonical_id":"hgnc:HGNC:5145","description":"hippocalcin like 1","metadata":{"aliases":["BDR1","HLP2","VILIP-3"]}},{"id":"ad3df2b11eb04733ac262ce6f1f75b13","type":"GENE","name":"HPCAL4","canonical_id":"hgnc:HGNC:18212","description":"hippocalcin like 4","metadata":{"aliases":["HLP4","DKFZp761G122"]}},{"id":"20546e3552d04d54a74aca024db183a6","type":"GENE","name":"HPD","canonical_id":"hgnc:HGNC:5147","description":"4-hydroxyphenylpyruvate dioxygenase","metadata":{"aliases":["4-HPPD","4HPPD","GLOD3","HPPD","PPD"]}},{"id":"b77cbdcb30e041be872db8245eed99b2","type":"PROTEIN","name":"HPD","canonical_id":"uniprot:P32754","description":null,"metadata":null},{"id":"340e17eb47274cc18b3ff6c943445e26","type":"GENE","name":"HPDL","canonical_id":"hgnc:HGNC:28242","description":"4-hydroxyphenylpyruvate dioxygenase like","metadata":{"aliases":["MGC15668","4-HPPD-L","GLOXD1"]}},{"id":"4d953c0ffc5141c0829f61a22665699c","type":"GENE","name":"HPF1","canonical_id":"hgnc:HGNC:26051","description":"histone PARylation factor 1","metadata":{"aliases":["FLJ20534","C4orf27"]}},{"id":"b7b4d5c5ca9e40499c1c1983df39dba8","type":"GENE","name":"HPF1-DT","canonical_id":"hgnc:HGNC:58908","description":"HPF1 divergent transcript","metadata":null},{"id":"aa825c00a48d4d07981a1cfea896bd90","type":"GENE","name":"HPF1P1","canonical_id":"hgnc:HGNC:49774","description":"HPF1 pseudogene 1","metadata":{"aliases":["C4orf27P1"]}},{"id":"a1a9f0cc6b9d4cdfb5924f374d8f254e","type":"GENE","name":"HPF1P2","canonical_id":"hgnc:HGNC:59152","description":"HPF1 pseudogene 2","metadata":null},{"id":"db1d9ff062b244c2b09ea0a25e412bc8","type":"GENE","name":"HPGD","canonical_id":"hgnc:HGNC:5154","description":null,"metadata":null},{"id":"ee82a537f6d3410c91f791b5566e3d75","type":"GENE","name":"HPGD-AS2","canonical_id":"hgnc:HGNC:58913","description":"HPGD antisense RNA 2","metadata":null},{"id":"1dd8c5333bac4d82966c897bcf20afc2","type":"GENE","name":"HPGDS","canonical_id":"hgnc:HGNC:17890","description":null,"metadata":null},{"id":"adc8b47263a34568bf5862b1ec78cea5","type":"TRIAL","name":"HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol","canonical_id":"clinicaltrials.gov:NCT00000799","description":"Cytomegalovirus Retinitis; HIV Infections","metadata":null},{"id":"705417f22a684dbf98b90d507cdde128","type":"GENE","name":"HPN","canonical_id":"hgnc:HGNC:5155","description":"hepsin","metadata":{"aliases":["TMPRSS1"]}},{"id":"c2bf874cbc6a45ee815a251c4308739b","type":"GENE","name":"HPN-AS1","canonical_id":"hgnc:HGNC:47041","description":"HPN antisense RNA 1","metadata":null},{"id":"ab360a6fa5be4be390eead542d070ba1","type":"GENE","name":"HPR","canonical_id":"hgnc:HGNC:5156","description":null,"metadata":null},{"id":"452873effebf4703a4c4d3161612cde0","type":"GENE","name":"HPRT1","canonical_id":"hgnc:HGNC:5157","description":"hypoxanthine phosphoribosyltransferase 1","metadata":{"aliases":["HGPRT","HPRT"]}},{"id":"e07c4c91c45147628daeb8cc5ca76e88","type":"GENE","name":"HPRT1P1","canonical_id":"hgnc:HGNC:51622","description":"hypoxanthine phosphoribosyltransferase 1 pseudogene 1","metadata":null},{"id":"2946dd422eb243cb9c8067ac0d79356c","type":"GENE","name":"HPRT1P2","canonical_id":"hgnc:HGNC:5160","description":"hypoxanthine phosphoribosyltransferase 1 pseudogene 2","metadata":{"aliases":["HPRTP2"]}},{"id":"a8f8217881704d7381f929936996905d","type":"GENE","name":"HPRT1P3","canonical_id":"hgnc:HGNC:5161","description":"hypoxanthine phosphoribosyltransferase 1 pseudogene 3","metadata":{"aliases":["HPRTP3","HPRTP4"]}},{"id":"80b653f0c3554ffea9dc1bac6adde9d6","type":"GENE","name":"HPS1","canonical_id":"hgnc:HGNC:5163","description":"HPS1 biogenesis of lysosomal organelles complex 3 subunit 1","metadata":{"aliases":["BLOC3S1","HPS"]}},{"id":"802649654c6b45dfb2830a2f21fb00f0","type":"GENE","name":"HPS1-AS1","canonical_id":"hgnc:HGNC:56166","description":"HPS1 antisense RNA 1","metadata":null},{"id":"69289ee0872a42acbf6b8530b9fb7538","type":"GENE","name":"HPS3","canonical_id":"hgnc:HGNC:15597","description":"HPS3 biogenesis of lysosomal organelles complex 2 subunit 1","metadata":{"aliases":["SUTAL","BLOC2S1"]}},{"id":"b7132130055a4c9e893d08cf65282590","type":"GENE","name":"HPS4","canonical_id":"hgnc:HGNC:15844","description":"HPS4 biogenesis of lysosomal organelles complex 3 subunit 2","metadata":{"aliases":["KIAA1667","LE","BLOC3S2"]}},{"id":"48314a03550e4d22a5edbbb61a74a040","type":"GENE","name":"HPS5","canonical_id":"hgnc:HGNC:17022","description":"HPS5 biogenesis of lysosomal organelles complex 2 subunit 2","metadata":{"aliases":["BLOC2S2","AIBP63","RU2"]}},{"id":"432d4b9e678b4570afbaebac9198f163","type":"GENE","name":"HPS6","canonical_id":"hgnc:HGNC:18817","description":"HPS6 biogenesis of lysosomal organelles complex 2 subunit 3","metadata":{"aliases":["FLJ22501","BLOC2S3"]}},{"id":"a21be0b597d5443499b1e69db1bf1e95","type":"GENE","name":"HPSE","canonical_id":"hgnc:HGNC:5164","description":null,"metadata":null},{"id":"572919906a8545b487fdf39f89287698","type":"GENE","name":"HPSE-AS1","canonical_id":"hgnc:HGNC:58838","description":"HPSE antisense RNA 1","metadata":null},{"id":"258d58617c454050abd04243659f6454","type":"GENE","name":"HPSE2","canonical_id":"hgnc:HGNC:18374","description":null,"metadata":null},{"id":"6b2367777b4c44d680aaf51d6b87b66b","type":"GENE","name":"HPV18I1","canonical_id":"hgnc:HGNC:5166","description":"human papillomavirus (type 18) integration site 1","metadata":{"aliases":["HPV18I","D8S37"]}},{"id":"55ad96f12f7241de8796dbe3c3fe6310","type":"GENE","name":"HPV18I2","canonical_id":"hgnc:HGNC:5167","description":"human papillomavirus (type 18) integration site 2","metadata":{"aliases":["PAL2"]}},{"id":"d0949bda858948d3ab5d890f3ec040cb","type":"GENE","name":"HPV6AI1","canonical_id":"hgnc:HGNC:5168","description":"human papillomavirus (type 6a) integration site 1","metadata":null},{"id":"156ca7fff6814729a3a6ac8ea6d38b00","type":"GENE","name":"HPX","canonical_id":"hgnc:HGNC:5171","description":"hemopexin","metadata":null},{"id":"c6cedd35532b4d7cbd49edbb404e5c4a","type":"GENE","name":"HPYR1","canonical_id":"hgnc:HGNC:16071","description":"Helicobacter pylori responsive 1","metadata":{"aliases":["HPRG1","NCRNA00027","LINC00027"]}},{"id":"b971a357414e4e5b9dc88549de199dfe","type":"GENE","name":"HR","canonical_id":"hgnc:HGNC:5172","description":null,"metadata":null},{"id":"c53f9800ba1f47d19d45ae6ec3460a22","type":"TRIAL","name":"HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan","canonical_id":"clinicaltrials.gov:NCT06236269","description":"Breast Cancer Stage IV","metadata":null},{"id":"46c0ee71cde3457f8ef69b7bf68c5411","type":"TRIAL","name":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","canonical_id":"clinicaltrials.gov:NCT07379190","description":"Stroke, Acute; Stroke, Ischemic; Cerebral Infarction","metadata":null},{"id":"278fa3f80b4147f69e28d5a292f4677d","type":"GENE","name":"HRAS","canonical_id":"hgnc:HGNC:5173","description":null,"metadata":null},{"id":"ec2b7b97e0284d8db6200bc4a273792e","type":"GENE","name":"HRC","canonical_id":"hgnc:HGNC:5178","description":"histidine rich calcium binding protein","metadata":{"aliases":["MGC133236"]}},{"id":"15ffc37d5c514143891cef9e883efa79","type":"GENE","name":"HRCT1","canonical_id":"hgnc:HGNC:33872","description":"histidine rich carboxyl terminus 1","metadata":{"aliases":["LGLL338","PRO537","UNQ338"]}},{"id":"c1b22028ba884d51885c9915fb517d15","type":"GENE","name":"HRDAL","canonical_id":"hgnc:HGNC:58851","description":"homologous recombination deficiency associated lncRNA","metadata":null},{"id":"a9f2540bf8d24094963ee7f5a3581003","type":"GENE","name":"HRES1","canonical_id":"hgnc:HGNC:5180","description":"HTLV-1 related endogenous sequence (pseudogene)","metadata":{"aliases":["HRES-1/p28","HRES-1"]}},{"id":"53772b2f880848c9bd7026c52879d4cf","type":"GENE","name":"HRG","canonical_id":"hgnc:HGNC:5181","description":"histidine rich glycoprotein","metadata":{"aliases":["HRGP","HPRG"]}},{"id":"e5dcbb92075d487c85ca57ef4e6a88b8","type":"GENE","name":"HRG-AS1","canonical_id":"hgnc:HGNC:55915","description":"HRG and FETUB antisense RNA 1","metadata":{"aliases":["RP11-573D15.8"]}},{"id":"60e6bd785f504ca28c00d792c8294dc8","type":"GENE","name":"HRGP1","canonical_id":"hgnc:HGNC:56613","description":"HRG pseudogene 1","metadata":null},{"id":"c2249b62561b4e8a9300394a37151674","type":"GENE","name":"HRGP2","canonical_id":"hgnc:HGNC:56614","description":"HRG pseudogene 2","metadata":null},{"id":"cd8f00d0c62b43aea2cf4e2e045ecd8a","type":"GENE","name":"HRH1","canonical_id":"hgnc:HGNC:5182","description":null,"metadata":null},{"id":"9325b52856e244d2b95af9deef6310a4","type":"PROTEIN","name":"HRH1","canonical_id":"uniprot:P35367","description":null,"metadata":null},{"id":"1d174f82ff154aebb56ce07bdbd59b85","type":"GENE","name":"HRH2","canonical_id":"hgnc:HGNC:5183","description":"histamine receptor H2","metadata":null},{"id":"efdf2307b7e246ec835225679239045b","type":"PROTEIN","name":"HRH2","canonical_id":"uniprot:P25021","description":null,"metadata":null},{"id":"324c08eb41ed43528c4cf9aa85eb6109","type":"GENE","name":"HRH2-AS1","canonical_id":"hgnc:HGNC:59309","description":"HRH2 antisense RNA 1","metadata":null},{"id":"dbc93d53a5c34407a7b06fd04c76e7e2","type":"GENE","name":"HRH3","canonical_id":"hgnc:HGNC:5184","description":"histamine receptor H3","metadata":{"aliases":["GPCR97"]}},{"id":"1d135305c444431998897426ee8b0725","type":"PROTEIN","name":"HRH3","canonical_id":"uniprot:Q9Y5N1","description":null,"metadata":null},{"id":"4020e90f68534a6fa6c4a9513fdd837e","type":"GENE","name":"HRH4","canonical_id":"hgnc:HGNC:17383","description":"histamine receptor H4","metadata":{"aliases":["H4R","HH4R","AXOR35","GPCR105","GPRv53"]}},{"id":"a9c6ab54247b46b59ae2bfbbea4e1158","type":"GO_TERM","name":"HRI-mediated signaling","canonical_id":"go:GO:0140468","description":"\"A series of reactions in which a signal is passed on to downstream proteins within the cell via HRI (also known as EIF2AK1), an intracellular protein kinase that is activated by stress signals, such as heme deficiency, oxidative stress, osmotic shock, mitochondrial dysfunction and heat shock.\" [PMID:27629041]","metadata":null},{"id":"5e1d527471e04fb492353a3c0fd8f9dd","type":"GENE","name":"HRK","canonical_id":"hgnc:HGNC:5185","description":null,"metadata":null},{"id":"82b495e3751b4005ae361068c519300b","type":"GENE","name":"HRNR","canonical_id":"hgnc:HGNC:20846","description":"hornerin","metadata":{"aliases":["S100a18","S100A16","FLG3"]}},{"id":"a8890993a43d47f49fcca8c0a2a9e121","type":"GENE","name":"HROB","canonical_id":"hgnc:HGNC:28460","description":"homologous recombination factor with OB-fold","metadata":{"aliases":["MGC3130","MCM8IP","C17orf53"]}},{"id":"9a91dccd907344659ade6221871f3169","type":"TRIAL","name":"HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients","canonical_id":"clinicaltrials.gov:NCT02330757","description":"Infertility","metadata":null},{"id":"73c8f20608ec4d6c94ea5ac58cc7feb4","type":"GENE","name":"HRURF","canonical_id":"hgnc:HGNC:55085","description":"HR upstream open reading frame","metadata":{"aliases":["U2HR"]}},{"id":"0c687355358f48fab751deb43ad83fc5","type":"GENE","name":"HS1BP3","canonical_id":"hgnc:HGNC:24979","description":"HCLS1 binding protein 3","metadata":{"aliases":["HS1-BP3","FLJ14249"]}},{"id":"d97153716fa74bc3b33123f972fbc554","type":"GENE","name":"HS1BP3-IT1","canonical_id":"hgnc:HGNC:41474","description":"HS1BP3 intronic transcript 1","metadata":null},{"id":"5b9acc76f3a148fcb1a07323f6604fa9","type":"GENE","name":"HS2ST1","canonical_id":"hgnc:HGNC:5193","description":"heparan sulfate 2-O-sulfotransferase 1","metadata":{"aliases":["KIAA0448"]}},{"id":"d9e3f52878fc4bfbab4858e402c5d2f0","type":"GENE","name":"HS3ST1","canonical_id":"hgnc:HGNC:5194","description":"heparan sulfate-glucosamine 3-sulfotransferase 1","metadata":{"aliases":["3OST1"]}},{"id":"761435b7b0cf4b1aa3bead1faf24ba57","type":"GENE","name":"HS3ST1-AS1","canonical_id":"hgnc:HGNC:58736","description":"HS3ST1 antisense RNA 1","metadata":null},{"id":"e8850b933ab647eaace496295c1b4feb","type":"GENE","name":"HS3ST2","canonical_id":"hgnc:HGNC:5195","description":"heparan sulfate-glucosamine 3-sulfotransferase 2","metadata":{"aliases":["3OST2"]}},{"id":"0defff8e902441678412080ba35ac356","type":"GENE","name":"HS3ST3A1","canonical_id":"hgnc:HGNC:5196","description":"heparan sulfate-glucosamine 3-sulfotransferase 3A1","metadata":{"aliases":["3OST3A1","30ST3A1"]}},{"id":"ca78af20a89b488f9dab128e70a69142","type":"GENE","name":"HS3ST3B1","canonical_id":"hgnc:HGNC:5198","description":"heparan sulfate-glucosamine 3-sulfotransferase 3B1","metadata":{"aliases":["3OST3B1","30ST3B1"]}},{"id":"dddc803ca628486c9e92829771065095","type":"GENE","name":"HS3ST4","canonical_id":"hgnc:HGNC:5200","description":"heparan sulfate-glucosamine 3-sulfotransferase 4","metadata":{"aliases":["3OST4"]}},{"id":"bc067d1b7b93421eadd1156da1084417","type":"GENE","name":"HS3ST5","canonical_id":"hgnc:HGNC:19419","description":"heparan sulfate-glucosamine 3-sulfotransferase 5","metadata":{"aliases":["3-OST-5"]}},{"id":"66615a95419449f2babeb6b756d3f9e8","type":"GENE","name":"HS3ST6","canonical_id":"hgnc:HGNC:14178","description":"heparan sulfate-glucosamine 3-sulfotransferase 6","metadata":{"aliases":["HS3ST5"]}},{"id":"dff8569daeb04a6194edb5b93650a01e","type":"GENE","name":"HS6ST1","canonical_id":"hgnc:HGNC:5201","description":"heparan sulfate 6-O-sulfotransferase 1","metadata":{"aliases":["HS6ST"]}},{"id":"8a2bb211af844f96aa2852a33bfd1239","type":"GENE","name":"HS6ST1P1","canonical_id":"hgnc:HGNC:31835","description":"heparan sulfate 6-O-sulfotransferase 1 pseudogene 1","metadata":{"aliases":["HS6ST1P"]}},{"id":"ec2fee2c3d2540f2adc063a4322755fa","type":"GENE","name":"HS6ST2","canonical_id":"hgnc:HGNC:19133","description":"heparan sulfate 6-O-sulfotransferase 2","metadata":{"aliases":["HS6ST-2"]}},{"id":"667d679d3f534be79abcc2b6a030a3be","type":"GENE","name":"HS6ST2-AS1","canonical_id":"hgnc:HGNC:40870","description":"HS6ST2 antisense RNA 1","metadata":null},{"id":"68a06a10cb4744819453c6a128b21c0d","type":"GENE","name":"HS6ST3","canonical_id":"hgnc:HGNC:19134","description":"heparan sulfate 6-O-sulfotransferase 3","metadata":null},{"id":"d86e6566c1fd4a16ba3177429a3036ea","type":"GENE","name":"HSALR1","canonical_id":"hgnc:HGNC:56095","description":"HSP90AB1 associated lncRNA 1","metadata":null},{"id":"7678c5eb2388415681e640a8fa57b113","type":"GENE","name":"HSBP1","canonical_id":"hgnc:HGNC:5203","description":"heat shock factor binding protein 1","metadata":null},{"id":"b5f1f193b7fe49b484d9b16d3d7d6eaa","type":"GENE","name":"HSBP1L1","canonical_id":"hgnc:HGNC:37243","description":"heat shock factor binding protein 1 like 1","metadata":{"aliases":["FLJ10967","MGC189743"]}},{"id":"533d7471251248ffbf52383f0e1fd1d5","type":"GENE","name":"HSBP1P1","canonical_id":"hgnc:HGNC:20053","description":"heat shock factor binding protein 1 pseudogene 1","metadata":null},{"id":"ba4c79241d13498f92bc20f20f8b75f1","type":"GENE","name":"HSBP1P2","canonical_id":"hgnc:HGNC:37300","description":"heat shock factor binding protein 1 pseudogene 2","metadata":null},{"id":"abea718c37cf48b5a627f350d11ca776","type":"GENE","name":"HSCB","canonical_id":"hgnc:HGNC:28913","description":"HscB mitochondrial iron-sulfur cluster cochaperone","metadata":{"aliases":["HSC20","DNAJC20","Jac1"]}},{"id":"d2512388c5f14f55932a32f03d6ef0ab","type":"TRIAL","name":"HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity","canonical_id":"clinicaltrials.gov:NCT02435901","description":"Sickle Cell Disease; Beta Thalassemia-Major","metadata":null},{"id":"7ed5274238d7415d880e2a730b41304e","type":"TRIAL","name":"HSCT for High Risk Inherited Inborn Errors","canonical_id":"clinicaltrials.gov:NCT00383448","description":"Adrenoleukodystrophy; Metachromatic Leukodystrophy; Globoid Cell Leukodystrophy; Tay Sachs Disease; Sandhoffs Disease; Wolman Disease; I-Cell Disease; Sanfilippo Syndrome; GM1 Gangliosidosis","metadata":null},{"id":"3a179a5fdf9b4e679577ac2002fd57ec","type":"GENE","name":"HSD11B1","canonical_id":"hgnc:HGNC:5208","description":"hydroxysteroid 11-beta dehydrogenase 1","metadata":{"aliases":["SDR26C1","HSD11B","HSD11"]}},{"id":"0a4cec8b46254a7a94bba760a4c977eb","type":"GENE","name":"HSD11B1-AS1","canonical_id":"hgnc:HGNC:54053","description":"HSD11B1 antisense RNA 1","metadata":null},{"id":"bf2fc5831a694db986529d50b8459ca6","type":"GENE","name":"HSD11B1L","canonical_id":"hgnc:HGNC:30419","description":"hydroxysteroid 11-beta dehydrogenase 1 like","metadata":{"aliases":["SCDR10","SDR26C2","HSD1L"]}},{"id":"8ef840950c4e43749b1ed19072ac100e","type":"GENE","name":"HSD11B2","canonical_id":"hgnc:HGNC:5209","description":null,"metadata":null},{"id":"4154e2fb2fe548db957d8da3e5e9acb1","type":"GENE","name":"HSD17B1","canonical_id":"hgnc:HGNC:5210","description":null,"metadata":null},{"id":"8c3204105ab7495babe2cdaa294f3a70","type":"GENE","name":"HSD17B1-AS1","canonical_id":"hgnc:HGNC:55314","description":"HSD17B1 antisense RNA 1","metadata":null},{"id":"e7f3683522b1474788607a5de421688c","type":"GENE","name":"HSD17B10","canonical_id":"hgnc:HGNC:4800","description":"hydroxysteroid 17-beta dehydrogenase 10","metadata":{"aliases":["ERAB","MHBD","17b-HSD10","ABAD","SDR5C1","MRPP2","CAMR","HADH2","MRXS10"]}},{"id":"49680e21c3984bf0896e556e3ec39849","type":"GENE","name":"HSD17B11","canonical_id":"hgnc:HGNC:22960","description":null,"metadata":null},{"id":"913678641aa746d7bc3159a9538572e0","type":"GENE","name":"HSD17B12","canonical_id":"hgnc:HGNC:18646","description":"hydroxysteroid 17-beta dehydrogenase 12","metadata":{"aliases":["KAR","SDR12C1"]}},{"id":"79f1bc3e86b24354886c0778aae7f811","type":"GENE","name":"HSD17B12P1","canonical_id":"hgnc:HGNC:58535","description":"HSD17B12 pseudogene 1","metadata":null},{"id":"8daec49c2d3843a8b57d1bf23d54ab0f","type":"GENE","name":"HSD17B12P2","canonical_id":"hgnc:HGNC:58536","description":"HSD17B12 pseudogene 2","metadata":null},{"id":"115f8c083ee64c4ba92d729938a1347a","type":"GENE","name":"HSD17B13","canonical_id":"hgnc:HGNC:18685","description":"hydroxysteroid 17-beta dehydrogenase 13","metadata":{"aliases":["SCDR9","SDR16C3"]}},{"id":"0444741ee1a9442ea6a81243301b1a1b","type":"GENE","name":"HSD17B14","canonical_id":"hgnc:HGNC:23238","description":"hydroxysteroid 17-beta dehydrogenase 14","metadata":{"aliases":["retSDR3","SDR47C1","DHRS10"]}},{"id":"0ae3962f87b34156943a102cdc79ba46","type":"GENE","name":"HSD17B1P1","canonical_id":"hgnc:HGNC:5216","description":"hydroxysteroid 17-beta dehydrogenase 1 pseudogene 1","metadata":{"aliases":["SDR28C1P1","EDHB17","EDH17B1","HSD17BP1"]}},{"id":"956bbe05b71f439dbf3ed1147d0ab048","type":"GENE","name":"HSD17B2","canonical_id":"hgnc:HGNC:5211","description":null,"metadata":null},{"id":"b507ba756564492b8b49c1374e9b414a","type":"GENE","name":"HSD17B2-AS1","canonical_id":"hgnc:HGNC:56281","description":"HSD17B2 antisense RNA 1","metadata":{"aliases":["RP11-510J16.5","AS-HSD17beta2"]}},{"id":"b310da0dedfb4d219de24b0857f45ea7","type":"GENE","name":"HSD17B3","canonical_id":"hgnc:HGNC:5212","description":"hydroxysteroid 17-beta dehydrogenase 3","metadata":{"aliases":["SDR12C2"]}},{"id":"aa5cab1c8e0c45f7af24c2673b8557b6","type":"GENE","name":"HSD17B3-AS1","canonical_id":"hgnc:HGNC:53136","description":"HSD17B3 antisense RNA 1","metadata":{"aliases":["ENST00000448857"]}},{"id":"aaf7fdb00b3e40ba95173c0c3ac915ce","type":"GENE","name":"HSD17B4","canonical_id":"hgnc:HGNC:5213","description":"hydroxysteroid 17-beta dehydrogenase 4","metadata":{"aliases":["MFE-2","DBP","SDR8C1"]}},{"id":"4f7a21fcdbfb4608bc8bfbb706be9b63","type":"GENE","name":"HSD17B6","canonical_id":"hgnc:HGNC:23316","description":null,"metadata":null},{"id":"f27ff6005ac84be6b944073072ca6024","type":"GENE","name":"HSD17B7","canonical_id":"hgnc:HGNC:5215","description":"hydroxysteroid 17-beta dehydrogenase 7","metadata":{"aliases":["PRAP","SDR37C1"]}},{"id":"5162caf908544d4fa0b136f63b3f36f8","type":"GENE","name":"HSD17B7P1","canonical_id":"hgnc:HGNC:18689","description":"hydroxysteroid 17-beta dehydrogenase 7 pseudogene 1","metadata":null},{"id":"8315b58abfbb4bc1b33db637c4dcf239","type":"GENE","name":"HSD17B7P2","canonical_id":"hgnc:HGNC:28120","description":"hydroxysteroid 17-beta dehydrogenase 7 pseudogene 2","metadata":{"aliases":["HSD17B7","bA291L22.1"]}},{"id":"5675c0e2e4ce45ca8053d3ddec57eb57","type":"GENE","name":"HSD17B8","canonical_id":"hgnc:HGNC:3554","description":"hydroxysteroid 17-beta dehydrogenase 8","metadata":{"aliases":["HKE6","D6S2245E","RING2","KE6","H2-KE6","SDR30C1","FABGL"]}},{"id":"dbf3ccfd841441709ea5f9784a16a92d","type":"GENE","name":"HSD3B1","canonical_id":"hgnc:HGNC:5217","description":null,"metadata":null},{"id":"88920615f29643768ab551afb2a4af9c","type":"GENE","name":"HSD3B2","canonical_id":"hgnc:HGNC:5218","description":null,"metadata":null},{"id":"bd4acabc37a14cf09ea213428d5933e3","type":"PROTEIN","name":"HSD3B2","canonical_id":"uniprot:P26439","description":null,"metadata":null},{"id":"5168d5fd9ba34effa187060ca0d0dcd4","type":"GENE","name":"HSD3B7","canonical_id":"hgnc:HGNC:18324","description":"hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7","metadata":{"aliases":["C(27)-3BETA-HSD","SDR11E3"]}},{"id":"f04aea5245bd4868b507c7adadea2cbc","type":"GENE","name":"HSD3BP1","canonical_id":"hgnc:HGNC:5219","description":"hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 1","metadata":null},{"id":"18c80d0847fc4f06910158d965e5cac7","type":"GENE","name":"HSD3BP2","canonical_id":"hgnc:HGNC:5220","description":"hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 2","metadata":null},{"id":"af8fe376e6c147aeb910ef6c14c62de6","type":"GENE","name":"HSD3BP3","canonical_id":"hgnc:HGNC:5221","description":"hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 3","metadata":null},{"id":"abdd4fc1e1254414a3fb1cc4df8a58e6","type":"GENE","name":"HSD3BP4","canonical_id":"hgnc:HGNC:5222","description":"hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 4","metadata":null},{"id":"041865583e50422db9b2f6a1eee6b81c","type":"GENE","name":"HSD3BP5","canonical_id":"hgnc:HGNC:5223","description":"hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 5","metadata":null},{"id":"c39bd558bfef4f55ab12c791e12c79a6","type":"GENE","name":"HSDL1","canonical_id":"hgnc:HGNC:16475","description":"hydroxysteroid dehydrogenase like 1","metadata":{"aliases":["SDR12C3"]}},{"id":"723817d004554679815e71991c5aa087","type":"GENE","name":"HSDL2","canonical_id":"hgnc:HGNC:18572","description":"hydroxysteroid dehydrogenase like 2","metadata":{"aliases":["SDR13C1","C9orf99"]}},{"id":"044158e7e856487297dd6f0392c25015","type":"GENE","name":"HSDL2-AS1","canonical_id":"hgnc:HGNC:31438","description":"HSDL2 antisense RNA 1","metadata":{"aliases":["bA32M23.3","C9orf147"]}},{"id":"a653ffaf2b5f4776a356267174742161","type":"GENE","name":"HSF1","canonical_id":"hgnc:HGNC:5224","description":null,"metadata":null},{"id":"011a42f1718e4043ac802c3165a481a6","type":"GENE","name":"HSF2","canonical_id":"hgnc:HGNC:5225","description":null,"metadata":null},{"id":"a4213879135a465888dc048015396ce5","type":"GENE","name":"HSF2BP","canonical_id":"hgnc:HGNC:5226","description":"heat shock transcription factor 2 binding protein","metadata":{"aliases":["MEILB2"]}},{"id":"36418d13c6cf49d188dde36b017da85a","type":"GENE","name":"HSF4","canonical_id":"hgnc:HGNC:5227","description":null,"metadata":null},{"id":"eda29e0d87184198847504aa4c1fdfa8","type":"GENE","name":"HSF5","canonical_id":"hgnc:HGNC:26862","description":"heat shock transcription factor 5","metadata":{"aliases":["FLJ40311"]}},{"id":"b2c4878e6e0b473cbbdb6016e8a6d7d7","type":"GENE","name":"HSFX1","canonical_id":"hgnc:HGNC:29603","description":"heat shock transcription factor family, X-linked 1","metadata":{"aliases":["LW-1"]}},{"id":"865b6fb5073a43bba5b00712bf156860","type":"GENE","name":"HSFX2","canonical_id":"hgnc:HGNC:32701","description":"heat shock transcription factor family, X-linked 2","metadata":null},{"id":"f5f738a464f84325bb8c71cac3ec4c8a","type":"GENE","name":"HSFX3","canonical_id":"hgnc:HGNC:52395","description":"heat shock transcription factor family, X-linked member 3","metadata":null},{"id":"185b528ea79c45d5906bbdb91c9d33dc","type":"GENE","name":"HSFX4","canonical_id":"hgnc:HGNC:52398","description":"heat shock transcription factor family, X-linked member 4","metadata":null},{"id":"2e630e9435a049ffb121b1b98456c51a","type":"GENE","name":"HSFY1","canonical_id":"hgnc:HGNC:18568","description":"heat shock transcription factor Y-linked 1","metadata":{"aliases":["HSF2L","HSFY"]}},{"id":"4383c0ebcad444e083959fdb5c16098b","type":"GENE","name":"HSFY1P1","canonical_id":"hgnc:HGNC:1846","description":"HSFY1 pseudogene 1","metadata":{"aliases":["HSFYP1","HSFYL1","CECR8"]}},{"id":"c84096426fec447f9b48d2bf6948faa1","type":"GENE","name":"HSFY2","canonical_id":"hgnc:HGNC:23950","description":"heat shock transcription factor Y-linked 2","metadata":{"aliases":["FLJ25453"]}},{"id":"211762b482b4438c80612e0d0bb51b0c","type":"GENE","name":"HSFY3P","canonical_id":"hgnc:HGNC:37119","description":"heat shock transcription factor Y-linked 3, pseudogene","metadata":{"aliases":["HSFYP2"]}},{"id":"aa8cf5ed471f4aacbda86656fc298f99","type":"GENE","name":"HSFY4P","canonical_id":"hgnc:HGNC:37721","description":"heat shock transcription factor Y-linked 4, pseudogene","metadata":null},{"id":"116f85a307d04dab97ee34a9aae6b0d9","type":"GENE","name":"HSFY5P","canonical_id":"hgnc:HGNC:38789","description":"heat shock transcription factor Y-linked 5, pseudogene","metadata":null},{"id":"290828ae0d044a5ba3f1835a3013ab63","type":"GENE","name":"HSFY6P","canonical_id":"hgnc:HGNC:38790","description":"heat shock transcription factor Y-linked 6, pseudogene","metadata":null},{"id":"5431924257c84c0daa7f78c15fbca065","type":"GENE","name":"HSFY7P","canonical_id":"hgnc:HGNC:38791","description":"heat shock transcription factor Y-linked 7, pseudogene","metadata":null},{"id":"24be73a9bc5b4d69a50b08c4405b07ed","type":"GENE","name":"HSFY8P","canonical_id":"hgnc:HGNC:38792","description":"heat shock transcription factor Y-linked 8, pseudogene","metadata":null},{"id":"e521b8c5e97d45068cac418343203341","type":"GENE","name":"HSH2D","canonical_id":"hgnc:HGNC:24920","description":"hematopoietic SH2 domain containing","metadata":{"aliases":["ALX","HSH2","FLJ14886"]}},{"id":"ec6c54c1539c48e98a61fa7a00569bed","type":"GENE","name":"HSH2D-AS1","canonical_id":"hgnc:HGNC:58332","description":"HSH2D and RAB8A antisense RNA 1","metadata":null},{"id":"89638ffa67e049e6a2a7b0984d15ee31","type":"GO_TERM","name":"HSP90-CDC37 chaperone complex","canonical_id":"go:GO:1990565","description":"\"A protein kinase chaperone complex required for the proper folding, maturation and stabilization of target proteins (mostly signaling protein kinases, some steroid hormone receptors), usually during or immediately after completion of translation. The highly conserved, phosphorylated CDC37-Ser13 (vertebrates) or cdc37-Ser14 (yeast) is essential for complex assembly and target protein binding. CDC37-Ser13 (Ser14) is phosphorylated by Casein kinase II (CK2), which in turn is a target of CDC37 creating a positive feedback loop. Complex binding also prevents rapid ubiquitin-dependent proteosomal degradation of target proteins.\" [GOC:bhm, GOC:pad, GOC:PARL, PMID:21855797, PMID:22939624]","metadata":null},{"id":"2301e069fcdf4a78a79e72043e80e35c","type":"GENE","name":"HSP90AA1","canonical_id":"hgnc:HGNC:5253","description":null,"metadata":null},{"id":"1c942d2af3cc4e9fb84d10a21b5b9435","type":"GENE","name":"HSP90AA2P","canonical_id":"hgnc:HGNC:5256","description":"heat shock protein 90 alpha family class A member 2, pseudogene","metadata":{"aliases":["HSPCA","HSP90ALPHA","HSPCAL3","HSP90AA2"]}},{"id":"8feed0c0f74d4e8087dcc17c27360f2c","type":"GENE","name":"HSP90AA3P","canonical_id":"hgnc:HGNC:5254","description":"heat shock protein 90 alpha family class A member 3, pseudogene","metadata":{"aliases":["HSPCAL1"]}},{"id":"f2c5a4fd143846139fdc8714fc5becb9","type":"GENE","name":"HSP90AA4P","canonical_id":"hgnc:HGNC:5255","description":"heat shock protein 90 alpha family class A member 4, pseudogene","metadata":{"aliases":["HSPCAL2"]}},{"id":"0e2b367c5abf4a32ab22519e9f708a67","type":"GENE","name":"HSP90AA5P","canonical_id":"hgnc:HGNC:32535","description":"heat shock protein 90 alpha family class A member 5, pseudogene","metadata":null},{"id":"7599d61ca2274e24912637048ca68154","type":"GENE","name":"HSP90AA6P","canonical_id":"hgnc:HGNC:32536","description":"heat shock protein 90 alpha family class A member 6, pseudogene","metadata":null},{"id":"e2cbfc0931614e0ea230e12265124187","type":"GENE","name":"HSP90AB1","canonical_id":"hgnc:HGNC:5258","description":null,"metadata":null},{"id":"6f6610af58924cc7a31aadb6c83fe1f6","type":"GENE","name":"HSP90AB1-AS1","canonical_id":"hgnc:HGNC:59415","description":"HSP90AB1 antisense RNA 1","metadata":null},{"id":"cf15ecdd78a6407594f66cfda8d9aa96","type":"GENE","name":"HSP90AB2P","canonical_id":"hgnc:HGNC:32537","description":"heat shock protein 90 alpha family class B member 2, pseudogene","metadata":{"aliases":["HSP90BB"]}},{"id":"586d4486bb1e4210aecd20f02194cd13","type":"GENE","name":"HSP90AB3P","canonical_id":"hgnc:HGNC:5259","description":"heat shock protein 90 alpha family class B member 3, pseudogene","metadata":{"aliases":["HSPCP1"]}},{"id":"debc0032da6c42d993383e1784cf5cb0","type":"GENE","name":"HSP90AB4P","canonical_id":"hgnc:HGNC:32538","description":"heat shock protein 90 alpha family class B member 4, pseudogene","metadata":null},{"id":"a235b79a97ba4d869e8d4296c7567f95","type":"GENE","name":"HSP90AB5P","canonical_id":"hgnc:HGNC:32539","description":"heat shock protein 90 alpha family class B member 5, pseudogene","metadata":null},{"id":"c96fea327a7645b3a973b995a1eea6a0","type":"GENE","name":"HSP90AB6P","canonical_id":"hgnc:HGNC:32540","description":"heat shock protein 90 alpha family class B member 6, pseudogene","metadata":null},{"id":"2a519d3b6aeb451baf019c91efe9f756","type":"GENE","name":"HSP90AB7P","canonical_id":"hgnc:HGNC:44701","description":"heat shock protein 90 alpha family class B member 7, pseudogene","metadata":null},{"id":"68395f58e4f948cc918e165a6adc9e81","type":"GENE","name":"HSP90B1","canonical_id":"hgnc:HGNC:12028","description":"heat shock protein 90 beta family member 1","metadata":{"aliases":["GP96","GRP94","TRA1"]}},{"id":"75d3eea5875b4c1198445a0ea4cddde7","type":"GENE","name":"HSP90B2P","canonical_id":"hgnc:HGNC:12099","description":null,"metadata":null},{"id":"00d5badaba684e279156f46ddebdc022","type":"GENE","name":"HSP90B3P","canonical_id":"hgnc:HGNC:12100","description":"heat shock protein 90 beta family member 3, pseudogene","metadata":{"aliases":["GRP94c","TRAP2","TRA1P2"]}},{"id":"add0908e38364bce86acb7fe87ce40fb","type":"GENE","name":"HSPA12A","canonical_id":"hgnc:HGNC:19022","description":"heat shock protein family A (Hsp70) member 12A","metadata":{"aliases":["FLJ13874","KIAA0417"]}},{"id":"af001b10d60342bdbf92f0a1d037a88c","type":"GENE","name":"HSPA12A-AS1","canonical_id":"hgnc:HGNC:55721","description":"HSPA12A antisense RNA 1","metadata":null},{"id":"fcf9586a18e44500834db90cb6bebaf6","type":"GENE","name":"HSPA12B","canonical_id":"hgnc:HGNC:16193","description":"heat shock protein family A (Hsp70) member 12B","metadata":{"aliases":["dJ1009E24.2","C20orf60"]}},{"id":"48fe0435ad38495b885d5ed3c680a9cf","type":"GENE","name":"HSPA13","canonical_id":"hgnc:HGNC:11375","description":"heat shock protein family A (Hsp70) member 13","metadata":{"aliases":["STCH"]}},{"id":"6004939cadca4de2bd8cda55255b5ade","type":"GENE","name":"HSPA14","canonical_id":"hgnc:HGNC:29526","description":"heat shock protein family A (Hsp70) member 14","metadata":{"aliases":["HSP70-4","HSP70L1"]}},{"id":"2221b8458e1249f280caeeaaaddebbe8","type":"GENE","name":"HSPA1A","canonical_id":"hgnc:HGNC:5232","description":null,"metadata":null},{"id":"fc0f4d62213143e6b8a3d89895ef5b08","type":"GENE","name":"HSPA1B","canonical_id":"hgnc:HGNC:5233","description":null,"metadata":null},{"id":"24c6dcbe2612436f8226470c855fd61e","type":"GENE","name":"HSPA1L","canonical_id":"hgnc:HGNC:5234","description":"heat shock protein family A (Hsp70) member 1 like","metadata":{"aliases":["HSP70-HOM","hum70t"]}},{"id":"47c2d46bdd044e2bad367a33f440f5a0","type":"GENE","name":"HSPA2","canonical_id":"hgnc:HGNC:5235","description":"heat shock protein family A (Hsp70) member 2","metadata":null},{"id":"5de71a1317534c759e06539ea003a7f8","type":"GENE","name":"HSPA2-AS1","canonical_id":"hgnc:HGNC:55433","description":"HSPA2 and ZBTB1 antisense RNA 1","metadata":null},{"id":"55e392df2264468fb23940f23f936979","type":"GENE","name":"HSPA4","canonical_id":"hgnc:HGNC:5237","description":null,"metadata":null},{"id":"9a515cc576af4d69b0c9a4057ad98b7d","type":"GENE","name":"HSPA4L","canonical_id":"hgnc:HGNC:17041","description":"heat shock protein family A (Hsp70) member 4 like","metadata":{"aliases":["APG-1","Osp94","HSPH3"]}},{"id":"3f87fcf3de4b422cb8b7cd775dfbb66c","type":"GENE","name":"HSPA5","canonical_id":"hgnc:HGNC:5238","description":null,"metadata":null},{"id":"1f0e65c3774440a898a1e154964cd3d7","type":"GENE","name":"HSPA5-DT","canonical_id":"hgnc:HGNC:55645","description":"HSPA5 divergent transcript","metadata":null},{"id":"f8830ee25aaa4f75a8100ad1a9ae0bed","type":"GENE","name":"HSPA5P1","canonical_id":"hgnc:HGNC:54532","description":"HSPA5 pseudogene 1","metadata":null},{"id":"b438e82e3f854f24b3660b472735b4a5","type":"GENE","name":"HSPA6","canonical_id":"hgnc:HGNC:5239","description":"heat shock protein family A (Hsp70) member 6","metadata":{"aliases":["HSP70B'"]}},{"id":"879c56dc732140eaa0c43a2eb0082a22","type":"GENE","name":"HSPA7","canonical_id":"hgnc:HGNC:5240","description":"heat shock protein family A (Hsp70) member 7 (pseudogene)","metadata":{"aliases":["HSP70B"]}},{"id":"6afa2ad09eaf428e8f499a8541b12b1d","type":"GENE","name":"HSPA8","canonical_id":"hgnc:HGNC:5241","description":null,"metadata":null},{"id":"451d52c8f88b444bbba32d6bc35d5384","type":"GENE","name":"HSPA8P1","canonical_id":"hgnc:HGNC:5245","description":"heat shock protein family A (Hsp70) member 8 pseudogene 1","metadata":{"aliases":["HSPAP1"]}},{"id":"516107e3d6814435bf18dc77e4b3fb13","type":"GENE","name":"HSPA8P10","canonical_id":"hgnc:HGNC:44925","description":"heat shock protein family A (Hsp70) member 8 pseudogene 10","metadata":null},{"id":"c6f07b537cc9451d8af5ce89ba8cdf14","type":"GENE","name":"HSPA8P11","canonical_id":"hgnc:HGNC:44926","description":"heat shock protein family A (Hsp70) member 8 pseudogene 11","metadata":null},{"id":"10f52adab73342ef909cded37aaffec7","type":"GENE","name":"HSPA8P12","canonical_id":"hgnc:HGNC:44927","description":"heat shock protein family A (Hsp70) member 8 pseudogene 12","metadata":null},{"id":"283df7cf701743bb9c7d4e15d94df3c4","type":"GENE","name":"HSPA8P13","canonical_id":"hgnc:HGNC:44928","description":"heat shock protein family A (Hsp70) member 8 pseudogene 13","metadata":null},{"id":"0e8dd10d9f094081989a438a1b083298","type":"GENE","name":"HSPA8P14","canonical_id":"hgnc:HGNC:44929","description":"heat shock protein family A (Hsp70) member 8 pseudogene 14","metadata":null},{"id":"ef834b1492e149ecb2991e6ca913e7b4","type":"GENE","name":"HSPA8P15","canonical_id":"hgnc:HGNC:44930","description":"heat shock protein family A (Hsp70) member 8 pseudogene 15","metadata":null},{"id":"babde7c4f03445cfb1f9156868074708","type":"GENE","name":"HSPA8P16","canonical_id":"hgnc:HGNC:44931","description":"heat shock protein family A (Hsp70) member 8 pseudogene 16","metadata":null},{"id":"54b0332b59a141739912cfdeb63d8c11","type":"GENE","name":"HSPA8P17","canonical_id":"hgnc:HGNC:44932","description":"heat shock protein family A (Hsp70) member 8 pseudogene 17","metadata":null},{"id":"ea7cd63ee56d44138bfc0c17effc4c53","type":"GENE","name":"HSPA8P18","canonical_id":"hgnc:HGNC:44933","description":"heat shock protein family A (Hsp70) member 8 pseudogene 18","metadata":null},{"id":"69cea422a6284924a6bf55a7d683a27b","type":"GENE","name":"HSPA8P19","canonical_id":"hgnc:HGNC:44935","description":"heat shock protein family A (Hsp70) member pseudogene 19","metadata":null},{"id":"8bb6f6dd19b2468ab79343d65e0645e2","type":"GENE","name":"HSPA8P2","canonical_id":"hgnc:HGNC:39806","description":"heat shock protein family A (Hsp70) member 8 pseudogene 2","metadata":null},{"id":"08fcc017b0e040ef885f43170588bffc","type":"GENE","name":"HSPA8P20","canonical_id":"hgnc:HGNC:44936","description":"heat shock protein family A (Hsp70) member 8 pseudogene 20","metadata":null},{"id":"6354a0b6b8714a7eba0d2b045f6aff92","type":"GENE","name":"HSPA8P3","canonical_id":"hgnc:HGNC:44918","description":"heat shock protein family A (Hsp70) member 8 pseudogene 3","metadata":null},{"id":"2ee40a112a6847af9815ddb5b971ead0","type":"GENE","name":"HSPA8P4","canonical_id":"hgnc:HGNC:44919","description":"heat shock protein family A (Hsp70) member 8 pseudogene 4","metadata":null},{"id":"c2e9fa80889141baa030d65fdcb9b6e4","type":"GENE","name":"HSPA8P5","canonical_id":"hgnc:HGNC:44920","description":"heat shock protein family A (Hsp70) member 8 pseudogene 5","metadata":null},{"id":"f1e7ad68e7e94353abdb5143a56965ee","type":"GENE","name":"HSPA8P6","canonical_id":"hgnc:HGNC:44921","description":"heat shock protein family A (Hsp70) member 8 pseudogene 6","metadata":null},{"id":"e3a3b1d60ef8412a9b61df7e36c2ea3f","type":"GENE","name":"HSPA8P7","canonical_id":"hgnc:HGNC:44922","description":"heat shock protein family A (Hsp70) member 8 pseudogene 7","metadata":null},{"id":"1a05d3c2262248c6944507d85239bad0","type":"GENE","name":"HSPA8P8","canonical_id":"hgnc:HGNC:44923","description":"heat shock protein family A (Hsp70) member 8 pseudogene 8","metadata":null},{"id":"42be750c7f1c4d4db2971eefec54ed0a","type":"GENE","name":"HSPA8P9","canonical_id":"hgnc:HGNC:44924","description":"heat shock protein family A (Hsp70) member 8 pseudogene 9","metadata":null},{"id":"96675c4c626242bba47cc3f8969ce2d2","type":"GENE","name":"HSPA9","canonical_id":"hgnc:HGNC:5244","description":"heat shock protein family A (Hsp70) member 9","metadata":{"aliases":["GRP75","PBP74","mot-2","mthsp75","HSPA9B"]}},{"id":"2e20b02aaf6c424b9bdb0e37ff2213f6","type":"GENE","name":"HSPA9-AS1","canonical_id":"hgnc:HGNC:59150","description":"HSPA9 antisense RNA 1","metadata":null},{"id":"6bb99ae7b54b4c368ff8a59a2683f730","type":"GENE","name":"HSPA9P1","canonical_id":"hgnc:HGNC:24915","description":"heat shock protein family A (Hsp70) member 9 pseudogene 1","metadata":{"aliases":["HSPA9BP","HSPA9P"]}},{"id":"a8b770c5040f466ebd5237197d0fb23a","type":"GENE","name":"HSPA9P2","canonical_id":"hgnc:HGNC:31733","description":"heat shock protein family A (Hsp70) member 9 pseudogene 2","metadata":null},{"id":"c594577094684c69889ba9d1410c15b6","type":"GENE","name":"HSPB1","canonical_id":"hgnc:HGNC:5246","description":null,"metadata":null},{"id":"7933a7c3d100496f979bbbb85c7e73ed","type":"GENE","name":"HSPB1P1","canonical_id":"hgnc:HGNC:5251","description":"heat shock protein family B (small) member 1 pseudogene 1","metadata":{"aliases":["HSPBL2"]}},{"id":"8bb01411036547bb8cd2bdd19eb15707","type":"GENE","name":"HSPB1P2","canonical_id":"hgnc:HGNC:5252","description":"heat shock protein family B (small) member 1 pseudogene 2","metadata":{"aliases":["HSPBL3"]}},{"id":"de44952f3eb54b838127a6c2e3a214bf","type":"GENE","name":"HSPB2","canonical_id":"hgnc:HGNC:5247","description":"heat shock protein family B (small) member 2","metadata":{"aliases":["Hs.78846","MKBP"]}},{"id":"e674649259a64ba4b33c9997c4a17f09","type":"GENE","name":"HSPB2-C11orf52","canonical_id":"hgnc:HGNC:41996","description":"HSPB2-C11orf52 readthrough (NMD candidate)","metadata":null},{"id":"efbcf8e6f6364a4fbfee97dab5412955","type":"GENE","name":"HSPB3","canonical_id":"hgnc:HGNC:5248","description":"heat shock protein family B (small) member 3","metadata":{"aliases":["HSPL27"]}},{"id":"565c4263fea949a38f50bf9ae8d4ae4e","type":"GENE","name":"HSPB6","canonical_id":"hgnc:HGNC:26511","description":"heat shock protein family B (small) member 6","metadata":{"aliases":["FLJ32389","Hsp20","PPP1R91"]}},{"id":"768ac9d3c1024815bc115870a6774dfd","type":"GENE","name":"HSPB7","canonical_id":"hgnc:HGNC:5249","description":"heat shock protein family B (small) member 7","metadata":{"aliases":["cvHSP"]}},{"id":"d5c3624be3c1446dbebfe523f830f31b","type":"GENE","name":"HSPB8","canonical_id":"hgnc:HGNC:30171","description":"heat shock protein family B (small) member 8","metadata":{"aliases":["H11","E2IG1","HSP22","CMT2L"]}},{"id":"5ed764f82b384ae4bac40fbb5464ba5e","type":"GENE","name":"HSPB8-AS1","canonical_id":"hgnc:HGNC:58274","description":"HSPB8 antisense RNA 1","metadata":null},{"id":"a4d2076593784dad989bb78a61e6d3ab","type":"GENE","name":"HSPB9","canonical_id":"hgnc:HGNC:30589","description":"heat shock protein family B (small) member 9","metadata":{"aliases":["CT51"]}},{"id":"ddc17029b6694404a0f27e3a3e34f734","type":"GENE","name":"HSPBAP1","canonical_id":"hgnc:HGNC:16389","description":"HSPB1 associated protein 1","metadata":{"aliases":["FLJ22623","PASS1"]}},{"id":"493c1990b39e466b9673070d87325466","type":"GENE","name":"HSPBAP1P1","canonical_id":"hgnc:HGNC:56946","description":"HSPBAP1 pseudogene 1","metadata":null},{"id":"3a70649c8d544a5f94093bf64f13c632","type":"GENE","name":"HSPBP1","canonical_id":"hgnc:HGNC:24989","description":"HSPA (Hsp70) binding protein 1","metadata":{"aliases":["FES1"]}},{"id":"d36309e0583747b994ef1f97f1b6bd55","type":"GENE","name":"HSPD1","canonical_id":"hgnc:HGNC:5261","description":null,"metadata":null},{"id":"6ef1e34d5b9f476fb8191d40ee9dd6da","type":"GENE","name":"HSPD1P1","canonical_id":"hgnc:HGNC:35133","description":"heat shock protein family D (Hsp60) member 1 pseudogene 1","metadata":{"aliases":["HSPD1-2P"]}},{"id":"5d99bbdf09d54080be513fa2b475c1a5","type":"GENE","name":"HSPD1P10","canonical_id":"hgnc:HGNC:35131","description":"heat shock protein family D (Hsp60) member 1 pseudogene 10","metadata":{"aliases":["HSPD1-4P"]}},{"id":"c4164768255c4059b58de5866e4cd6f8","type":"GENE","name":"HSPD1P11","canonical_id":"hgnc:HGNC:35142","description":"heat shock protein family D (Hsp60) member 1 pseudogene 11","metadata":null},{"id":"c55431174bee459d8cbce6244d705c4f","type":"GENE","name":"HSPD1P12","canonical_id":"hgnc:HGNC:35140","description":"heat shock protein family D (Hsp60) member 1 pseudogene 12","metadata":{"aliases":["HSPD1-10P"]}},{"id":"b28ce4a84ea84fcfa5f3213ba53bd0b3","type":"GENE","name":"HSPD1P13","canonical_id":"hgnc:HGNC:35138","description":"heat shock protein family D (Hsp60) member 1 pseudogene 13","metadata":{"aliases":["HSPD1-16P"]}},{"id":"20ac95c5605c410d95775eaaab9ad0ea","type":"GENE","name":"HSPD1P14","canonical_id":"hgnc:HGNC:35143","description":"heat shock protein family D (Hsp60) member 1 pseudogene 14","metadata":{"aliases":["HSPD1-17P"]}},{"id":"8fc46cc5e6b841f28ace3ade59666bf1","type":"GENE","name":"HSPD1P15","canonical_id":"hgnc:HGNC:35130","description":"heat shock protein family D (Hsp60) member 1 pseudogene 15","metadata":{"aliases":["HSPD1-15P"]}},{"id":"4db4c6ba17eb4d44a92bb7beb1dfdbeb","type":"GENE","name":"HSPD1P16","canonical_id":"hgnc:HGNC:35128","description":"heat shock protein family D (Hsp60) member 1 pseudogene 16","metadata":{"aliases":["HSPD1-13P"]}},{"id":"e3f7a3b13bc54dcda92c3f4370b57108","type":"GENE","name":"HSPD1P17","canonical_id":"hgnc:HGNC:35147","description":"heat shock protein family D (Hsp60) member 1 pseudogene 17","metadata":{"aliases":["HSPD1-19P"]}},{"id":"7419444422604a01a5194b01a57111cf","type":"GENE","name":"HSPD1P18","canonical_id":"hgnc:HGNC:35136","description":"heat shock protein family D (Hsp60) member 1 pseudogene 18","metadata":null},{"id":"f674ab4a8a5f41f09cfa0cf371452f94","type":"GENE","name":"HSPD1P19","canonical_id":"hgnc:HGNC:38590","description":"heat shock protein family D (Hsp60) member 1 pseudogene 19","metadata":{"aliases":["HSPD1-18P"]}},{"id":"838a7d97359f42df99050caf5e72d82b","type":"GENE","name":"HSPD1P2","canonical_id":"hgnc:HGNC:5263","description":"heat shock protein family D (Hsp60) member 1 pseudogene 2","metadata":{"aliases":["HSP60P2","HSPD-9P","HSPDP2"]}},{"id":"dd47f038d8a64261aaf7f598bf05d818","type":"GENE","name":"HSPD1P20","canonical_id":"hgnc:HGNC:38591","description":"heat shock protein family D (Hsp60) member 1 pseudogene 20","metadata":{"aliases":["HSPD1-20P"]}},{"id":"1e6c5a82672e46fd8e1aab99f49eaddd","type":"GENE","name":"HSPD1P21","canonical_id":"hgnc:HGNC:38592","description":"heat shock protein family D (Hsp60) member 1 pseudogene 21","metadata":{"aliases":["HSPD1-3P"]}},{"id":"7c34d8bff77040c98f5c5dfae0c864aa","type":"GENE","name":"HSPD1P22","canonical_id":"hgnc:HGNC:39502","description":"heat shock protein family D (Hsp60) member 1 pseudogene 22","metadata":{"aliases":["HSPD1-21P"]}},{"id":"b3e4fa39fac4400c9c2e64a10edd32e3","type":"GENE","name":"HSPD1P3","canonical_id":"hgnc:HGNC:5264","description":"heat shock protein family D (Hsp60) member 1 pseudogene 3","metadata":{"aliases":["HSP60P3","HSP60P1","HSP60P4","HSPD1-7P","HSPDP3","HSPDP1","HSPDP4"]}},{"id":"c734564be2504180a6ef213331d83a83","type":"GENE","name":"HSPD1P4","canonical_id":"hgnc:HGNC:35146","description":"heat shock protein family D (Hsp60) member 1 pseudogene 4","metadata":{"aliases":["HSPD1-5P"]}},{"id":"47747236dbf541ba84109600fe3da154","type":"GENE","name":"HSPD1P5","canonical_id":"hgnc:HGNC:5266","description":"heat shock protein family D (Hsp60) member 1 pseudogene 5","metadata":{"aliases":["HSPD1-8P","HSPDP5"]}},{"id":"7fc190143107428fb152f2680d0db5fe","type":"GENE","name":"HSPD1P6","canonical_id":"hgnc:HGNC:5267","description":"heat shock protein family D (Hsp60) member 1 pseudogene 6","metadata":{"aliases":["HSPD1-6P","HSPDP6"]}},{"id":"a54af5c3e62e48f6bacae684d17604e8","type":"GENE","name":"HSPD1P7","canonical_id":"hgnc:HGNC:5268","description":"heat shock protein family D (Hsp60) member 1 pseudogene 7","metadata":{"aliases":["HSPD1-22P","HSPDP7"]}},{"id":"f760b94781e641889c996de9af3a7af7","type":"GENE","name":"HSPD1P8","canonical_id":"hgnc:HGNC:35145","description":"heat shock protein family D (Hsp60) member 1 pseudogene 8","metadata":{"aliases":["HSPD1-12P"]}},{"id":"8f7cdb6521974d5a974830277709896b","type":"GENE","name":"HSPD1P9","canonical_id":"hgnc:HGNC:35132","description":"heat shock protein family D (Hsp60) member 1 pseudogene 9","metadata":{"aliases":["HSPD1-14P"]}},{"id":"a18b545391b9443d9c9d2597303fae06","type":"GENE","name":"HSPE1","canonical_id":"hgnc:HGNC:5269","description":"heat shock protein family E (Hsp10) member 1","metadata":{"aliases":["CPN10","GroES","HSP10","EPF"]}},{"id":"771c8683aab34a1c8bd82a721fbc837d","type":"GENE","name":"HSPE1-MOB4","canonical_id":"hgnc:HGNC:49184","description":"HSPE1-MOB4 readthrough","metadata":null},{"id":"5bbf0f44fe124be498c02b6b008ecc7b","type":"GENE","name":"HSPE1P1","canonical_id":"hgnc:HGNC:16530","description":"heat shock protein family E (Hsp10) member 1 pseudogene 1","metadata":{"aliases":["bA101E14.1","HSPEP1"]}},{"id":"52a84388c6034b34918328ab81b080b9","type":"GENE","name":"HSPE1P10","canonical_id":"hgnc:HGNC:49329","description":"heat shock protein family E (Hsp10) member 1 pseudogene 10","metadata":null},{"id":"2df2ca7683bf417a8f55a27f5772a475","type":"GENE","name":"HSPE1P11","canonical_id":"hgnc:HGNC:49330","description":"heat shock protein family E (Hsp10) member 1 pseudogene 11","metadata":null},{"id":"5976aca2f9b542c590a034912003e665","type":"GENE","name":"HSPE1P12","canonical_id":"hgnc:HGNC:49331","description":"heat shock protein family E (Hsp10) member 1 pseudogene 12","metadata":null},{"id":"03745364717349f0adc98919c4ceccc6","type":"GENE","name":"HSPE1P13","canonical_id":"hgnc:HGNC:49332","description":"heat shock protein family E (Hsp10) member 1 pseudogene 13","metadata":null},{"id":"1bbd92f67e4f4fb8a29bdd69438eef9e","type":"GENE","name":"HSPE1P14","canonical_id":"hgnc:HGNC:49333","description":"heat shock protein family E (Hsp10) member 1 pseudogene 14","metadata":null},{"id":"566abfe54efd48a68b00021444f21f88","type":"GENE","name":"HSPE1P15","canonical_id":"hgnc:HGNC:49335","description":"heat shock protein family E (Hsp10) member 1 pseudogene 15","metadata":null},{"id":"6fb383f4ee4441338edd8a521d1730a4","type":"GENE","name":"HSPE1P16","canonical_id":"hgnc:HGNC:49334","description":"heat shock protein family E (Hsp10) member 1 pseudogene 16","metadata":{"aliases":["EPF8"]}},{"id":"538ae1ae46ab4d9fbc68b0e82aee1687","type":"GENE","name":"HSPE1P17","canonical_id":"hgnc:HGNC:49336","description":"heat shock protein family E (Hsp10) member 1 pseudogene 17","metadata":null},{"id":"df8e51a5542248debd8ef3098f97bc9b","type":"GENE","name":"HSPE1P18","canonical_id":"hgnc:HGNC:49337","description":"heat shock protein family E (Hsp10) member 1 pseudogene 18","metadata":null},{"id":"babddd22de47441fbacdba7c44d91cab","type":"GENE","name":"HSPE1P19","canonical_id":"hgnc:HGNC:49338","description":"heat shock protein family E (Hsp10) member 1 pseudogene 19","metadata":null},{"id":"d30bbf11c2f44e9b9d71aa301c61d308","type":"GENE","name":"HSPE1P2","canonical_id":"hgnc:HGNC:20052","description":"heat shock protein family E (Hsp10) member 1 pseudogene 2","metadata":{"aliases":["HSPEP2"]}},{"id":"5c78eef28c4245dbbe557c0887fd2997","type":"GENE","name":"HSPE1P20","canonical_id":"hgnc:HGNC:49339","description":"heat shock protein family E (Hsp10) member 1 pseudogene 20","metadata":null},{"id":"fd4acb33e0e9404f96513455ab1b761b","type":"GENE","name":"HSPE1P21","canonical_id":"hgnc:HGNC:49340","description":"heat shock protein family E (Hsp10) member 1 pseudogene 21","metadata":null},{"id":"a5f5f066af4c4e578a34a7be21f017a5","type":"GENE","name":"HSPE1P22","canonical_id":"hgnc:HGNC:49341","description":"heat shock protein family E (Hsp10) member 1 pseudogene 22","metadata":null},{"id":"c8ed0ea14d35421d8f7886a5217e51c7","type":"GENE","name":"HSPE1P23","canonical_id":"hgnc:HGNC:49342","description":"heat shock protein family E (Hsp10) member 1 pseudogene 23","metadata":null},{"id":"2adfb4dc87dc465c91bbb4aeb593825b","type":"GENE","name":"HSPE1P24","canonical_id":"hgnc:HGNC:49343","description":"heat shock protein family E (Hsp10) member 1 pseudogene 24","metadata":null},{"id":"67d195bf0a0a4bb7885f80fb3f8d276f","type":"GENE","name":"HSPE1P25","canonical_id":"hgnc:HGNC:49344","description":"heat shock protein family E (Hsp10) member 1 pseudogene 25","metadata":null},{"id":"d147d1f3685d4c1bbd42e96debd1789d","type":"GENE","name":"HSPE1P26","canonical_id":"hgnc:HGNC:49345","description":"heat shock protein family E (Hsp10) member 1 pseudogene 26","metadata":null},{"id":"eaa513af0cb24493aaa7bded5cf94502","type":"GENE","name":"HSPE1P27","canonical_id":"hgnc:HGNC:49346","description":"heat shock protein family E (Hsp10) member 1 pseudogene 27","metadata":null},{"id":"c88e3ce1de5e4da8b5172dd6727ed802","type":"GENE","name":"HSPE1P28","canonical_id":"hgnc:HGNC:49347","description":"heat shock protein family E (Hsp10) member 1 pseudogene 28","metadata":null},{"id":"62ab2ea746814b98af669992576c3665","type":"GENE","name":"HSPE1P3","canonical_id":"hgnc:HGNC:49322","description":"heat shock protein family E (Hsp10) member 1 pseudogene 3","metadata":null},{"id":"3fbd4f537aa740b39f9886e90a2e1a62","type":"GENE","name":"HSPE1P4","canonical_id":"hgnc:HGNC:49323","description":"heat shock protein family E (Hsp10) member 1 pseudogene 4","metadata":null},{"id":"c5c19df3c1da44ab8b6e30b8ea04513f","type":"GENE","name":"HSPE1P5","canonical_id":"hgnc:HGNC:49324","description":"heat shock protein family E (Hsp10) member 1 pseudogene 5","metadata":null},{"id":"f4a8d1612da047308aae1035900b0cc7","type":"GENE","name":"HSPE1P6","canonical_id":"hgnc:HGNC:49325","description":"heat shock protein family E (Hsp10) member 1 pseudogene 6","metadata":null},{"id":"4989bd6007f1430893b134b8893962c9","type":"GENE","name":"HSPE1P7","canonical_id":"hgnc:HGNC:49327","description":"heat shock protein family E (Hsp10) member 1 pseudogene 7","metadata":null},{"id":"6759cc45b7234761bcaf5461a8a6f94e","type":"GENE","name":"HSPE1P8","canonical_id":"hgnc:HGNC:49326","description":"heat shock protein family E (Hsp10) member 1 pseudogene 8","metadata":null},{"id":"6773fdbdbb0344dc8173104c16edc164","type":"GENE","name":"HSPE1P9","canonical_id":"hgnc:HGNC:49328","description":"heat shock protein family E (Hsp10) member 1 pseudogene 9","metadata":null},{"id":"20e826a4290643daaaa134db6ac415ff","type":"GENE","name":"HSPG2","canonical_id":"hgnc:HGNC:5273","description":"heparan sulfate proteoglycan 2","metadata":{"aliases":["perlecan","PRCAN","SJS1"]}},{"id":"9475c0ae10cb4443bb500e88ff978c54","type":"GENE","name":"HSPH1","canonical_id":"hgnc:HGNC:16969","description":null,"metadata":null},{"id":"3cd3d791f753445a848d8da8832d7ebe","type":"GENE","name":"HTATIP2","canonical_id":"hgnc:HGNC:16637","description":null,"metadata":null},{"id":"f973477ef90847a5bb1793fb1907ec26","type":"GENE","name":"HTATSF1","canonical_id":"hgnc:HGNC:5276","description":"HIV-1 Tat specific factor 1","metadata":{"aliases":["TAT-SF1"]}},{"id":"905caf9220a24fe0be9005721c382503","type":"GENE","name":"HTATSF1P1","canonical_id":"hgnc:HGNC:13959","description":"HIV-1 Tat specific factor 1 pseudogene 1","metadata":{"aliases":["TAT-SF1-L","dJ1033B10.6","HTATSF1P"]}},{"id":"0796471a69a7459c8851906c551677c5","type":"GENE","name":"HTATSF1P2","canonical_id":"hgnc:HGNC:38586","description":"HIV-1 Tat specific factor 1 pseudogene 2","metadata":null},{"id":"c81985e6378e4348bafc8591d7026526","type":"GENE","name":"HTD2","canonical_id":"hgnc:HGNC:53111","description":"hydroxyacyl-thioester dehydratase type 2","metadata":null},{"id":"14c4bec9f12b4730ad6a39f656da0fb7","type":"GENE","name":"HTN1","canonical_id":"hgnc:HGNC:5283","description":"histatin 1","metadata":{"aliases":["HIS1"]}},{"id":"86aed6df25ac4dc3abc0ffe5cc669577","type":"GENE","name":"HTN3","canonical_id":"hgnc:HGNC:5284","description":"histatin 3","metadata":{"aliases":["HIS2"]}},{"id":"de1b4f7ef752438aab7df2fe3ffb83e5","type":"GENE","name":"HTOR","canonical_id":"hgnc:HGNC:5285","description":"5-hydroxytryptamine (serotonin) oxygenase regulator","metadata":null},{"id":"db72a3a1b1134ccea783c75a38a6e9a8","type":"GENE","name":"HTR1A","canonical_id":"hgnc:HGNC:5286","description":null,"metadata":null},{"id":"4a1632497b424f44a7e0952eb79468ec","type":"PROTEIN","name":"HTR1A","canonical_id":"uniprot:P08908","description":null,"metadata":null},{"id":"5747a4e37a354512a657c3729c8b10de","type":"GENE","name":"HTR1B","canonical_id":"hgnc:HGNC:5287","description":"5-hydroxytryptamine receptor 1B","metadata":{"aliases":["S12","5-HT1B","HTR1D2","5-HT1DB"]}},{"id":"bc5cec9ce2714f4bb9f33351a67e13f6","type":"PROTEIN","name":"HTR1B","canonical_id":"uniprot:P28222","description":null,"metadata":null},{"id":"83be7375b34343028a647413151d828d","type":"GENE","name":"HTR1D","canonical_id":"hgnc:HGNC:5289","description":"5-hydroxytryptamine receptor 1D","metadata":{"aliases":["RDC4","HT1DA","5-HT1D","HTRL"]}},{"id":"9d886c56c4234a9894c0f03f1b84f2db","type":"PROTEIN","name":"HTR1D","canonical_id":"uniprot:P28221","description":null,"metadata":null},{"id":"a1a7dee95d8e459285224d2a07e6ddda","type":"GENE","name":"HTR1DP1","canonical_id":"hgnc:HGNC:5290","description":"5-hydroxytryptamine receptor 1D pseudogene 1","metadata":null},{"id":"3de4418730be4cf38c27721691bd4688","type":"GENE","name":"HTR1E","canonical_id":"hgnc:HGNC:5291","description":"5-hydroxytryptamine receptor 1E","metadata":{"aliases":["5-HT1E"]}},{"id":"c10bb0808eca4bcba48bb72fb89d9778","type":"GENE","name":"HTR1F","canonical_id":"hgnc:HGNC:5292","description":"5-hydroxytryptamine receptor 1F","metadata":{"aliases":["HTR1EL","5-HT1F"]}},{"id":"3d3ca326daa64943bbe224e1aa561107","type":"PROTEIN","name":"HTR1F","canonical_id":"uniprot:P30939","description":null,"metadata":null},{"id":"192588d1de6a46a2b606dd84cc77972f","type":"GENE","name":"HTR2A","canonical_id":"hgnc:HGNC:5293","description":"5-hydroxytryptamine receptor 2A","metadata":{"aliases":["5-HT2A","HTR2"]}},{"id":"7cd933e4e7a741d798cd893ecd2f8044","type":"PROTEIN","name":"HTR2A","canonical_id":"uniprot:P28223","description":null,"metadata":null},{"id":"be50da7223b54bb6a2e43bc1069e6c88","type":"GENE","name":"HTR2A-AS1","canonical_id":"hgnc:HGNC:40289","description":"HTR2A antisense RNA 1","metadata":null},{"id":"4033619a0a344a4caeac2d1b06d1e561","type":"GENE","name":"HTR2B","canonical_id":"hgnc:HGNC:5294","description":"5-hydroxytryptamine receptor 2B","metadata":{"aliases":["5-HT(2B)","5-HT2B"]}},{"id":"473e34003eac4ef695f5a31014bc29b5","type":"GENE","name":"HTR2C","canonical_id":"hgnc:HGNC:5295","description":"5-hydroxytryptamine receptor 2C","metadata":{"aliases":["5-HT2C","5HTR2C","HTR1C"]}},{"id":"fed4582072164c9398655d69e2348fec","type":"PROTEIN","name":"HTR2C","canonical_id":"uniprot:P28335","description":null,"metadata":null},{"id":"56bdf18eb09a479cb8a51a52197707c1","type":"GENE","name":"HTR3A","canonical_id":"hgnc:HGNC:5297","description":"5-hydroxytryptamine receptor 3A","metadata":{"aliases":["5-HT3R","5-HT3A","HTR3"]}},{"id":"4cdc9d12f79947f0af0cd903ff73748f","type":"PROTEIN","name":"HTR3A","canonical_id":"uniprot:P46098","description":null,"metadata":null},{"id":"cf283181332a45708cc554f81b94b10d","type":"GENE","name":"HTR3B","canonical_id":"hgnc:HGNC:5298","description":"5-hydroxytryptamine receptor 3B","metadata":{"aliases":["5-HT3B"]}},{"id":"0a1e691bd14f4c298e88450fe273c5eb","type":"GENE","name":"HTR3C","canonical_id":"hgnc:HGNC:24003","description":"5-hydroxytryptamine receptor 3C","metadata":null},{"id":"35e1d97024074f2680845e3691ddaa3b","type":"GENE","name":"HTR3C2P","canonical_id":"hgnc:HGNC:53986","description":"5-hydroxytryptamine receptor 3C2, pseudogene","metadata":{"aliases":["5-HT3C2"]}},{"id":"f6d3ee16ba9044068bd981bbc6791762","type":"GENE","name":"HTR3D","canonical_id":"hgnc:HGNC:24004","description":"5-hydroxytryptamine receptor 3D","metadata":null},{"id":"858c1a19dbbb47e681edcdefe6f20ed3","type":"GENE","name":"HTR3E","canonical_id":"hgnc:HGNC:24005","description":"5-hydroxytryptamine receptor 3E","metadata":null},{"id":"174b74c428c54a6fb538ff63bd7e2a3e","type":"GENE","name":"HTR3E-AS1","canonical_id":"hgnc:HGNC:41032","description":"HTR3E antisense RNA 1","metadata":null},{"id":"6accf6dbefe44927a3d256868b91d7fe","type":"GENE","name":"HTR4","canonical_id":"hgnc:HGNC:5299","description":"5-hydroxytryptamine receptor 4","metadata":{"aliases":["5-HT4"]}},{"id":"ff748ab9592b4d29ade19cfa39d30613","type":"GENE","name":"HTR4-AS1","canonical_id":"hgnc:HGNC:59276","description":"HTR4 antisense RNA 1","metadata":null},{"id":"465945b4cbdc40ec9c6611edb24f90f8","type":"GENE","name":"HTR5A","canonical_id":"hgnc:HGNC:5300","description":"5-hydroxytryptamine receptor 5A","metadata":{"aliases":["5-HT5A"]}},{"id":"f8572e4639694c00826e188a1a21e94b","type":"GENE","name":"HTR5A-AS1","canonical_id":"hgnc:HGNC:48956","description":"HTR5A antisense RNA 1","metadata":{"aliases":["HTR5AOS"]}},{"id":"ebeed1d54d394a5dbaab8ed406001130","type":"GENE","name":"HTR5BP","canonical_id":"hgnc:HGNC:16291","description":"5-hydroxytryptamine receptor 5B, pseudogene","metadata":{"aliases":["5-HT5B","GPR134","HTR5B"]}},{"id":"e632c14668034dd7b61f0cc87a700831","type":"GENE","name":"HTR6","canonical_id":"hgnc:HGNC:5301","description":"5-hydroxytryptamine receptor 6","metadata":{"aliases":["5-HT6","5-HT6R"]}},{"id":"15b15467c4fa45bb9b77def1b32a9ed5","type":"GENE","name":"HTR7","canonical_id":"hgnc:HGNC:5302","description":"5-hydroxytryptamine receptor 7","metadata":{"aliases":["5-HT7"]}},{"id":"880b086ecd924ab183ff2cc4d5f2f0f0","type":"GENE","name":"HTR7P1","canonical_id":"hgnc:HGNC:30411","description":"5-hydroxytryptamine receptor 7 pseudogene 1","metadata":{"aliases":["HTR7P"]}},{"id":"c49d249d2bc8401b9ec2c9f1f45656f6","type":"GENE","name":"HTRA1","canonical_id":"hgnc:HGNC:9476","description":"HtrA serine peptidase 1","metadata":{"aliases":["HtrA","IGFBP5-protease","ARMD7","PRSS11"]}},{"id":"2552567461614473bd3236341574f243","type":"GENE","name":"HTRA1-AS1","canonical_id":"hgnc:HGNC:58122","description":"HTRA1 and ARMS2 antisense RNA 1","metadata":null},{"id":"8610cd77043c4f58bb045d8b3c50c389","type":"GENE","name":"HTRA2","canonical_id":"hgnc:HGNC:14348","description":null,"metadata":null},{"id":"93b88b57171343399e87ea46801047ad","type":"GENE","name":"HTRA3","canonical_id":"hgnc:HGNC:30406","description":"HtrA serine peptidase 3","metadata":{"aliases":["Tasp","Prsp"]}},{"id":"fa19e0618bc449d79b2fedf67a411fbb","type":"GENE","name":"HTRA3-AS1","canonical_id":"hgnc:HGNC:58728","description":"HTRA3 antisense RNA 1","metadata":null},{"id":"7b58620d1f044b0bbbf4d45f80844259","type":"GENE","name":"HTRA4","canonical_id":"hgnc:HGNC:26909","description":"HtrA serine peptidase 4","metadata":{"aliases":["FLJ90724"]}},{"id":"64fe9b8fd6f0435f9fd91ef814b73399","type":"GENE","name":"HTT","canonical_id":"hgnc:HGNC:4851","description":null,"metadata":null},{"id":"e4f930fc45dd4aedb228602b13af9124","type":"GENE","name":"HTT-AS","canonical_id":"hgnc:HGNC:37118","description":"HTT antisense RNA","metadata":{"aliases":["HTTAS","HTT-AS1"]}},{"id":"cb0f6a946d0c4c62b5cc1d1667cc747d","type":"GO_TERM","name":"HU-DNA complex","canonical_id":"go:GO:1990178","description":"\"A protein-DNA complex that consists of HU heterodimers (an alpha and a beta chain) assembled into octamers along DNA. HU binds to double-stranded DNA in a structure- and sequence-specific manner and bends the DNA into a nucleosome-like structure.\" [GOC:bhm, PMID:17360520]","metadata":null},{"id":"d4be6a4ee85c4ab4b91355c8df02c950","type":"GENE","name":"HULC","canonical_id":"hgnc:HGNC:34232","description":"hepatocellular carcinoma up-regulated long non-coding RNA","metadata":{"aliases":["NCRNA00078","LINC00078","HCCAT1"]}},{"id":"e7f07b54495a4fcbb810072b1120c3b3","type":"GO_TERM","name":"HULC complex","canonical_id":"go:GO:0033503","description":"\"A ubiquitin ligase complex that contains two RING finger proteins, which have ubiquitin ligase activity, in addition to a protein with ubiquitin-conjugating enzyme activity; catalyzes the ubiquitination of histone H2B at lysine 119 (or the equivalent residue). In Schizosaccharomyces the subunits are Rhp6, Shf1, Brl2/Rfp1 and Brl1/Rfp2.\" [GOC:mah, PMID:17363370, PMID:17374714]","metadata":null},{"id":"f009c4a7dd7b4c6e8dcd9f8119df0b8b","type":"GENE","name":"HUNK","canonical_id":"hgnc:HGNC:13326","description":"hormonally up-regulated Neu-associated kinase","metadata":null},{"id":"2bb6f791ecbc408387d961beca0c0ab3","type":"GENE","name":"HUNK-AS1","canonical_id":"hgnc:HGNC:40631","description":"HUNK antisense RNA 1","metadata":{"aliases":["TCONS_00028914"]}},{"id":"42f2c8cdf4ba4105b9e050457cfef137","type":"GENE","name":"HUPCOS","canonical_id":"hgnc:HGNC:58684","description":"hormone disturbance in PCOS associated regulator of RBPMS","metadata":{"aliases":["lnc-ZSCAN2-5:15"]}},{"id":"105ee34f68854365862e1a5d46223f2e","type":"GENE","name":"HUS1","canonical_id":"hgnc:HGNC:5309","description":"HUS1 checkpoint clamp component","metadata":null},{"id":"1aa729008fe54b608bcb005c2b77dfac","type":"GENE","name":"HUS1B","canonical_id":"hgnc:HGNC:16485","description":"HUS1 checkpoint clamp component B","metadata":null},{"id":"4f263305012c4ac7a31cd33d917f4b14","type":"GO_TERM","name":"HUSH complex","canonical_id":"go:GO:0140283","description":"\"A protein complex that mediates transcriptional silencing of mobile genetic elements, such as retroviruses and transposable elements. In human, it is composed of TASOR, PPHLN1 and MPHOSPH8.\" [PMID:39013473, PMID:39489739]","metadata":null},{"id":"945bd314ca4642ae9584e33de4f87dbf","type":"GO_TERM","name":"HUSH2 complex","canonical_id":"go:GO:0140286","description":"\"A protein complex that mediates transcriptional silencing of interferon-stimulated genes. In human, it is composed of TASOR2, PPHLN1 and MPHOSPH8.\" [PMID:26022416, PMID:39013473, PMID:39489739]","metadata":null},{"id":"00626bc91cd840a0992df05c6b1985ec","type":"GENE","name":"HUWE1","canonical_id":"hgnc:HGNC:30892","description":"HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1","metadata":{"aliases":["Ib772","KIAA0312","UREB1"]}},{"id":"2bb2e1ec7feb4e6f80c532f59b46228f","type":"GENE","name":"HVBS7","canonical_id":"hgnc:HGNC:5314","description":"hepatitis B virus integration site 7","metadata":null},{"id":"d1cd9514f30b4ced8f32f996a9dcc250","type":"GENE","name":"HVBS8","canonical_id":"hgnc:HGNC:5315","description":"hepatitis B virus integration site 8","metadata":null},{"id":"08d56e3e0c3142ae9e6302d7fffceb11","type":"GENE","name":"HVCN1","canonical_id":"hgnc:HGNC:28240","description":"hydrogen voltage gated channel 1","metadata":{"aliases":["MGC15619","Hv1","VSOP"]}},{"id":"15d9eecd9e944e6a8362b34056e1dca6","type":"TRIAL","name":"HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic Patients","canonical_id":"clinicaltrials.gov:NCT04254822","description":"Liver Cirrhoses; Variceal Hemorrhage; Esophageal Varices","metadata":null},{"id":"67581c2eda194bb6b31216ccb1253266","type":"GENE","name":"HYAL1","canonical_id":"hgnc:HGNC:5320","description":null,"metadata":null},{"id":"75a605181d084babb0ec72b394b522ff","type":"GENE","name":"HYAL2","canonical_id":"hgnc:HGNC:5321","description":"hyaluronidase 2","metadata":{"aliases":["LuCa-2","LUCA2"]}},{"id":"53d01e3eb8a943ff8653501e2fcd9ee9","type":"GENE","name":"HYAL3","canonical_id":"hgnc:HGNC:5322","description":"hyaluronidase 3","metadata":{"aliases":["LUCA-3","LUCA14","Minna14"]}},{"id":"a2ef73222f42475791a7140258443ad1","type":"GENE","name":"HYAL4","canonical_id":"hgnc:HGNC:5323","description":"hyaluronidase 4","metadata":null},{"id":"947fe330bda24125ad193c03ada401b5","type":"GENE","name":"HYAL6P","canonical_id":"hgnc:HGNC:5324","description":"hyaluronidase 6, pseudogene","metadata":{"aliases":["HYAL6","HYALP1"]}},{"id":"78c88933dc0a48f2a4c80524c407c357","type":"GENE","name":"HYCC1","canonical_id":"hgnc:HGNC:24587","description":"hyccin PI4KA lipid kinase complex subunit 1","metadata":{"aliases":["DRCTNNB1A","HCC","hyccin","FAM126A"]}},{"id":"faf955964a18429b8d537e470aebe316","type":"GENE","name":"HYCC2","canonical_id":"hgnc:HGNC:28593","description":"hyccin PI4KA lipid kinase complex subunit 2","metadata":{"aliases":["MGC39518","FAM126B"]}},{"id":"f34aa6ca877841a2afffdeb3822268ca","type":"GENE","name":"HYDIN","canonical_id":"hgnc:HGNC:19368","description":"HYDIN axonemal central pair apparatus protein","metadata":{"aliases":["DKFZp434D0513","KIAA1864","PPP1R31","CILD5"]}},{"id":"ac75d5f86f85482da5790a1852955802","type":"GENE","name":"HYDIN-AS1","canonical_id":"hgnc:HGNC:58478","description":"HYDIN antisense RNA 1","metadata":null},{"id":"b2535dd73dbb4b8d856aee1ebf43b54e","type":"GENE","name":"HYDIN2","canonical_id":"hgnc:HGNC:33129","description":"HYDIN axonemal central pair apparatus protein 2 (pseudogene)","metadata":{"aliases":["HYDINP1"]}},{"id":"a2d3cc51e2f542ed9d45c02eddacd78a","type":"GENE","name":"HYDINP1","canonical_id":"hgnc:HGNC:56452","description":"HYDIN pseudogene 1","metadata":null},{"id":"7b705792c9d54e90920b3741c4952ecc","type":"GENE","name":"HYI","canonical_id":"hgnc:HGNC:26948","description":"hydroxypyruvate isomerase (putative)","metadata":{"aliases":["HT036"]}},{"id":"bc8cac95bdf144c4a955217f6d1bac8e","type":"GENE","name":"HYI-AS1","canonical_id":"hgnc:HGNC:41173","description":"HYI antisense RNA 1","metadata":null},{"id":"3d62faf3d5bc4f01a5594632ff1c25f4","type":"GENE","name":"HYKK","canonical_id":"hgnc:HGNC:34403","description":"hydroxylysine kinase","metadata":{"aliases":["LOC123688","AGPHD1"]}},{"id":"46f753570db04a46957c0c24099b1ee0","type":"GENE","name":"HYLS1","canonical_id":"hgnc:HGNC:26558","description":"HYLS1 centriolar and ciliogenesis associated","metadata":{"aliases":["FLJ32915"]}},{"id":"392226aea5634fc9b679b96aa1b7f509","type":"GENE","name":"HYMAI","canonical_id":"hgnc:HGNC:5326","description":"hydatidiform mole associated and imprinted","metadata":{"aliases":["NCRNA00020"]}},{"id":"fa492891c2644f7c81c33b7dd4aa7104","type":"GENE","name":"HYOU1","canonical_id":"hgnc:HGNC:16931","description":null,"metadata":null},{"id":"db009943e53c4647a68c3079eda3c33a","type":"GENE","name":"HYOU1-AS1","canonical_id":"hgnc:HGNC:56704","description":"HYOU1 antisense RNA 1","metadata":{"aliases":["HYOU1-AS"]}},{"id":"86113856c2bd425a9a0159716237a489","type":"TRIAL","name":"HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications","canonical_id":"clinicaltrials.gov:NCT02775227","description":"Pancreatic Fistula; Pancreatic Neoplasms","metadata":null},{"id":"efa02594f5124246a16bbf0efa240f03","type":"GENE","name":"HYPK","canonical_id":"hgnc:HGNC:18418","description":"huntingtin interacting protein K","metadata":{"aliases":["HSPC136","FLJ20431","C15orf63"]}},{"id":"3bbdc81962dc4d7d8f433af50861fe89","type":"TRIAL","name":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00480805","description":"Type 2 Diabetes Mellitus; Hypertension","metadata":null},{"id":"a1a8c35126dc47b3a1b6f4dadbb3129e","type":"TRIAL","name":"HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents","canonical_id":"clinicaltrials.gov:NCT01147848","description":"Asthma","metadata":null},{"id":"8a2b666508e244f1b6570f7448c78f43","type":"TRIAL","name":"Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage","canonical_id":"clinicaltrials.gov:NCT00193674","description":"Recurrent Miscarriage","metadata":null},{"id":"a3fe94a1f9684db09ca874cbc50e634a","type":"DISEASE","name":"Haim-Munk syndrome","canonical_id":"mondo:0009491","description":null,"metadata":null},{"id":"53755c411518473b90401d56e4fb67d7","type":"DISEASE","name":"Hairy Cell Leukemia","canonical_id":"doid:285","description":null,"metadata":null},{"id":"e80b2afeed9c4b1f802ef7500f061b4a","type":"DISEASE","name":"Hairy cell leukemia","canonical_id":"mesh:D007943","description":null,"metadata":null},{"id":"fe7c673231ca488eaf27527926182407","type":"TRIAL","name":"Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen","canonical_id":"clinicaltrials.gov:NCT00320229","description":"Coronary Disease; Myocardial Infarction","metadata":null},{"id":"4e2e394c732f409e9ec069893dd1f12b","type":"TRIAL","name":"Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)","canonical_id":"clinicaltrials.gov:NCT03056482","description":"Cannabis Use Disorder","metadata":null},{"id":"c999e75097b6404d87188e78d82dd3b1","type":"TRIAL","name":"Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer","canonical_id":"clinicaltrials.gov:NCT03021486","description":"Advanced Malignant Neoplasm; Delirium; Locally Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm","metadata":null},{"id":"00f31f2fe38247ae975d67d35247d1d5","type":"TRIAL","name":"Haloperidol for Delirium in Adult Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT03628391","description":"Delirium; Critical Illness; Intensive Care Psychosis; Cognitive Impairment; Cognitive Decline","metadata":null},{"id":"cfd493d6b0b245f1af489408578c0793","type":"TRIAL","name":"Haloperidol vs Olanzapine for the Management of ICU Delirium","canonical_id":"clinicaltrials.gov:NCT00833300","description":"Delirium; Agitation","metadata":null},{"id":"1cdea8920f2542e9b25998d4d45ee022","type":"DRUG","name":"Haloprogin","canonical_id":"mesh:C100276","description":null,"metadata":null},{"id":"d13e7428af9e4c1abc68bb5ebc40a66c","type":"DISEASE","name":"Hamman-Rich Syndrome","canonical_id":"mesh:D000080203","description":null,"metadata":null},{"id":"56808e71a5054c7395800ee26314531e","type":"TRIAL","name":"HandiHaler\u00ae vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02172404","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"0d32d4b2492f4ab796281565f7d88b8f","type":"TRIAL","name":"Haplo Peripheral Blood Sct In GVHD Prevention","canonical_id":"clinicaltrials.gov:NCT04473911","description":"GVHD; AML; ALL; MDS; MPN; CMML; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Blood Stem Cell Transplant Failure; Graft Vs Host Disease; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorder; Chronic Myelomonocytic Leukemia; Chemosensitive Hodgkin Lymphoma","metadata":null},{"id":"1de7f2f3204c446fbe48630a999a1b14","type":"TRIAL","name":"Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT00824135","description":"Hematologic Malignancies","metadata":null},{"id":"0363eb238e1d4bc38052f35b7f361b4d","type":"TRIAL","name":"Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia","canonical_id":"clinicaltrials.gov:NCT00961142","description":"Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia","metadata":null},{"id":"ee9e10d188764752912f21698b64ce51","type":"GO_TERM","name":"Harderian gland development","canonical_id":"go:GO:0070384","description":"\"The process whose specific outcome is the progression of the Harderian gland over time, from its formation to the mature structure. The Harderian gland is an anterior orbital structure usually associated with the nictitating membrane, and produces and secretes a variety of substances to the eye, depending upon the species.\" [GOC:hjd, PMID:16856596, PMID:7559104]","metadata":null},{"id":"8965c40bd9ab48379aed525cdd266e91","type":"TRIAL","name":"Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00433966","description":"Myocardial Infarction","metadata":null},{"id":"95ad6e83d5a24f7f91259bc092c7d2e0","type":"DISEASE","name":"Hartsfield-Bixler-Demyer syndrome","canonical_id":"mondo:0014196","description":null,"metadata":null},{"id":"1d01c05217ef44a7bf1994a2c82db2c1","type":"TRIAL","name":"Harvard Atherosclerosis Reversibility Project (HARP)","canonical_id":"clinicaltrials.gov:NCT00000461","description":"Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Ischemia","metadata":null},{"id":"d161e592ee7644c297b7f907a3935a87","type":"DISEASE","name":"Hashimoto thyroiditis","canonical_id":"mondo:0007699","description":null,"metadata":null},{"id":"5c3375ede006425b994448f93e18f086","type":"DISEASE","name":"Hashimoto thyroiditis","canonical_id":"mesh:D050031","description":null,"metadata":null},{"id":"8a5f2a16653c4dd59f43ccf96454918b","type":"GO_TERM","name":"Hda-beta clamp complex","canonical_id":"go:GO:1990085","description":"\"A protein complex involved in inactivating the function of DnaA and thereby preventing multiple events of replication initiation. In E. coli, this complex is composed of the beta clamp (DnaN) and Hda.\" [GOC:bhm, PMID:15150238]","metadata":null},{"id":"b07a409e48814bd9ac45984ff349955b","type":"DISEASE","name":"Head And Neck Cancer","canonical_id":"doid:11934","description":null,"metadata":null},{"id":"eb63e7bf714f4d339e9a89c17ad996ca","type":"DISEASE","name":"Head And Neck Squamous Cell Carcinoma","canonical_id":"doid:5520","description":null,"metadata":null},{"id":"e3a0d379348c4f6b9d812e4188156902","type":"TRIAL","name":"Head and Neck Cancer Study Project in the Geriatric Population","canonical_id":"clinicaltrials.gov:NCT06998069","description":"Head and Neck Neoplasms","metadata":null},{"id":"994299f3ca734ba29eb62abff3a36b1f","type":"TRIAL","name":"Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT05361382","description":"Alzheimer Disease","metadata":null},{"id":"c873fde4b9474dcb9becf08ddf5fc66a","type":"DISEASE","name":"Headache","canonical_id":"hp:0002315","description":null,"metadata":null},{"id":"2d303e9b701d40ff8443756f67a06c53","type":"DISEASE","name":"Headache Disorders","canonical_id":"mesh:D006261","description":null,"metadata":null},{"id":"1fbfcf83860840f9917bb1fc024f3311","type":"DISEASE","name":"Headache disorder","canonical_id":"mesh:D020773","description":null,"metadata":null},{"id":"57a696c4632449d0a39f65e8468ecbc3","type":"TRIAL","name":"Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking","canonical_id":"clinicaltrials.gov:NCT00666978","description":"Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder","metadata":null},{"id":"3bb3bd9df91b49ac8acaa921a2382986","type":"TRIAL","name":"Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT05488613","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"82cc076094fd42a8b338a3b35a45db25","type":"TRIAL","name":"Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor","canonical_id":"clinicaltrials.gov:NCT01403896","description":"Malignant Lymphoma, Stem Cell Type","metadata":null},{"id":"0deb6e45f4c14864927b8f5e6e29157c","type":"TRIAL","name":"Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- \u0392 -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone","canonical_id":"clinicaltrials.gov:NCT01456507","description":"Healthy","metadata":null},{"id":"0cf0db8a47a840a688984985c5f605c9","type":"DISEASE","name":"Heart Arrest","canonical_id":"mesh:D006323","description":null,"metadata":null},{"id":"911655ef113347a5b8d21c09996fef21","type":"TISSUE","name":"Heart Atrial Appendage","canonical_id":"uberon:UBERON:0006631","description":null,"metadata":null},{"id":"55f5ecb0f3c9450b904eb3d02698d9dd","type":"TISSUE","name":"Heart Left Ventricle","canonical_id":"uberon:UBERON:0006566","description":null,"metadata":null},{"id":"a238555027954e7c90451d3d2dd51bbb","type":"TRIAL","name":"Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure","canonical_id":"clinicaltrials.gov:NCT00132886","description":"Heart Failure, Congestive","metadata":null},{"id":"e29624e7482a4c8d8401567e1bc9c18b","type":"TRIAL","name":"Heart Rate Control With Esmolol in Septic Shock","canonical_id":"clinicaltrials.gov:NCT01231698","description":"Septic Shock","metadata":null},{"id":"9279a269b6ae4c85a0c184fcca05a513","type":"TRIAL","name":"Heart Rate Controller in Computed Tomography Coronary Angiography","canonical_id":"clinicaltrials.gov:NCT05261464","description":"Heart Rate; Coronary Computed Tomography Angiography","metadata":null},{"id":"d5b66f986e73404caae324accfedefeb","type":"TRIAL","name":"Heart Rate Response to Regadenoson and Sudden Cardiac Death","canonical_id":"clinicaltrials.gov:NCT01842035","description":"Left Ventricular Systolic Dysfunction; Sudden Cardiac Death","metadata":null},{"id":"1996e2c12e354a678153e610b75b1d79","type":"TRIAL","name":"Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers","canonical_id":"clinicaltrials.gov:NCT01330654","description":"Cardiac Event Risk","metadata":null},{"id":"05ffd58a93084e89a8ed002dfd9fc55f","type":"TRIAL","name":"Heart Rhythm After Intravenous Methylprednisolone Administration","canonical_id":"clinicaltrials.gov:NCT04391439","description":"Graves Disease; Graves Ophthalmopathy; Heart Rhythm Disorder; Hypertension; Blood Pressure; Heart Failure","metadata":null},{"id":"5d90a6517f33419fb004b152ce615294","type":"DISEASE","name":"Heart block","canonical_id":"hp:0012722","description":null,"metadata":null},{"id":"360c57aaed0f4fb4b2e8518bf80f6b13","type":"DISEASE","name":"Heartburn","canonical_id":"mesh:D006356","description":null,"metadata":null},{"id":"01df1aefb12447b8908d711456212ef9","type":"TRIAL","name":"Heartland Osteoporosis Prevention Study","canonical_id":"clinicaltrials.gov:NCT02186600","description":"Osteopenia","metadata":null},{"id":"5bc743528a80426a9f79d96307638af8","type":"TRIAL","name":"Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study","canonical_id":"clinicaltrials.gov:NCT05916469","description":"Heavy Menstrual Bleeding; Bleeding Disorder; Von Willebrand Diseases","metadata":null},{"id":"0cae42fa6d454365ab037e90288c7ca2","type":"GO_TERM","name":"Hechtian strand","canonical_id":"go:GO:0120307","description":"\"An extended membranous thread which firmly connects the plasma membrane to the cell wall during plasmolysis such that the plasma membrane does not separate from the cell wall completely.\" [GOC:krc, PMID:32397402]","metadata":null},{"id":"8f3f863a4b954c569faf20ea83eacfa1","type":"GO_TERM","name":"Hedgehog signaling complex","canonical_id":"go:GO:0035301","description":"\"A multiprotein complex that binds microtubules in a Hedgehog-dependent manner, and is required for signal transduction by members of the Hedgehog family of proteins. The core components of the complex are the serine/threonine protein kinase Fused, the kinesin motor protein Costal2 (Cos2), and a zinc finger transcription factor (Gli family members in humans, and Cubitus interruptus (Ci) in Drosophila).\" [PMID:10825151, PMID:15057936]","metadata":null},{"id":"4bed4bb81c524d758b785408ae1955b8","type":"TRIAL","name":"Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy","canonical_id":"clinicaltrials.gov:NCT02296021","description":"Gastritis; Peptic Ulcer; Dyspepsia","metadata":null},{"id":"ebd3c2745ff341adaf4d51e83794d383","type":"TRIAL","name":"Helicobacter Pylori and Iron Deficiency: Prevalence of Association and Effect of Therapy","canonical_id":"clinicaltrials.gov:NCT00475527","description":"Anemia, Iron-Deficiency; Helicobacter Pylori","metadata":null},{"id":"b1ac15a687024e68b41c91216c58976e","type":"DISEASE","name":"Helicobacter pylori infectious disease","canonical_id":"mondo:0006781","description":null,"metadata":null},{"id":"36785f22d074451fbaf1f1e4375ac9dc","type":"TRIAL","name":"Helium-3 MRI Imaging Study in COPD","canonical_id":"clinicaltrials.gov:NCT02207452","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"ca5ef11097d1406a9bc2b35daa1bc72f","type":"DISEASE","name":"Hemangioma","canonical_id":"mesh:D006391","description":null,"metadata":null},{"id":"d228626dcdfe48cc8f05a17f37f45b1b","type":"TRIAL","name":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","canonical_id":"clinicaltrials.gov:NCT02015013","description":"Idiopathic CD4-Positive; T-Lymphocytopenia","metadata":null},{"id":"4a00e39a8a0c40178f27d977c03c0d71","type":"TRIAL","name":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT02162420","description":"Dyskeratosis Congenita; Aplastic Anemia","metadata":null},{"id":"e6da0667237b47ae93d4eb8952762ba0","type":"TRIAL","name":"Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim","canonical_id":"clinicaltrials.gov:NCT01182675","description":"Severe Combined Immunodeficiency","metadata":null},{"id":"731a6d7d75134ac7a5f0b8503ae7063c","type":"PROTEIN","name":"Heme ligase","canonical_id":"uniprot:Q8IL04","description":null,"metadata":null},{"id":"639c1bb7cf4541c0b60146c227cc9c7b","type":"TRIAL","name":"Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease","canonical_id":"clinicaltrials.gov:NCT05297786","description":"Hemodialysis Complication; Hypotension of Hemodialysis","metadata":null},{"id":"e65896655f2a46999e002118f38a3c1e","type":"TRIAL","name":"Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol","canonical_id":"clinicaltrials.gov:NCT01939509","description":"Hypertension; Metabolic Syndrome","metadata":null},{"id":"125a69f4bee74835b73a625d0d090888","type":"TRIAL","name":"Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)","canonical_id":"clinicaltrials.gov:NCT07263958","description":"Pulmnary Hypertension; COPD; Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","metadata":null},{"id":"f239790aa8cd499c8a93a37351ff9a2c","type":"TRIAL","name":"Hemodynamic Response to Intubation","canonical_id":"clinicaltrials.gov:NCT02844894","description":"Intubation","metadata":null},{"id":"711ca543566b475f9accfd885fb11ce1","type":"TRIAL","name":"Hemodynamic Study of Avanafil and Two \u03b1-Adrenergic Blockers,Doxazosin and Tamsulosin","canonical_id":"clinicaltrials.gov:NCT01100021","description":"Erectile Dysfunction","metadata":null},{"id":"94189193c51c451b94d7f3be13571b24","type":"TRIAL","name":"Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock","canonical_id":"clinicaltrials.gov:NCT00279214","description":"Sepsis; Septic Shock","metadata":null},{"id":"f43c9e5b2fc7484c9f0289cc479ad703","type":"TRIAL","name":"Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients","canonical_id":"clinicaltrials.gov:NCT05001854","description":"Septic Shock","metadata":null},{"id":"391ad964e44148f487aaf429fd4b7f09","type":"DISEASE","name":"Hemorrhage","canonical_id":"mesh:D006470","description":null,"metadata":null},{"id":"a3f4281aca364c89a0164836c7beef9a","type":"TRIAL","name":"Hemorrhage Risk Prescribed Arixtra","canonical_id":"clinicaltrials.gov:NCT01064362","description":"Thrombosis, Venous","metadata":null},{"id":"1529dda2d1594100a33743eae86d1ce3","type":"DISEASE","name":"Hemorrhagic disease of the newborn due to vitamin K deficiency","canonical_id":"mesh:D006475","description":null,"metadata":null},{"id":"d18e7453834246d5810ea6cde4e94568","type":"DISEASE","name":"Hemorrhoids","canonical_id":"mesh:D006484","description":null,"metadata":null},{"id":"24b79a2e030a4fd6b5ff5595e077584a","type":"DRUG","name":"Heparin","canonical_id":"mesh:D006493","description":null,"metadata":null},{"id":"7dd595d97d844554aac5b28da3eb8604","type":"TRIAL","name":"Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices","canonical_id":"clinicaltrials.gov:NCT00039767","description":"Thrombosis","metadata":null},{"id":"4b4e370b81c04d3c80dd7e8f3dcf39e8","type":"TRIAL","name":"Heparin for RAO Post-Transradial Angiography in AIS","canonical_id":"clinicaltrials.gov:NCT07162064","description":"Acute Ischemic Stroke","metadata":null},{"id":"cd181ed7a1654ffe8ec878add155d546","type":"TRIAL","name":"Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure","canonical_id":"clinicaltrials.gov:NCT01348412","description":"Colorectal Cancer; Liver Metastases","metadata":null},{"id":"20addc4caca44709b331d93d44379164","type":"TRIAL","name":"Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05003700","description":"Hepatocellular Carcinoma","metadata":null},{"id":"12c55092e8004ad8991da594b7654052","type":"TRIAL","name":"Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05231382","description":"Hepatocellular Carcinoma","metadata":null},{"id":"2f9c2256f43f45ae952e52f3e05edf5b","type":"TRIAL","name":"Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma","canonical_id":"clinicaltrials.gov:NCT04759846","description":"BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma; Hepatic Impairment","metadata":null},{"id":"d5f2e7e261c4433e803ff0d691c5ebd4","type":"TRIAL","name":"Hepatic Impairment Trial of Obeticholic Acid","canonical_id":"clinicaltrials.gov:NCT01904539","description":"Hepatic Impairment","metadata":null},{"id":"e21b1a77c2744b3ba6cf4a4195cca059","type":"TRIAL","name":"Hepatic Metabolic Changes in Response to Glucagon Infusion","canonical_id":"clinicaltrials.gov:NCT03526445","description":"Non-Alcoholic Fatty Liver Disease; Total Pancreatectomy; Diabetes Mellitus","metadata":null},{"id":"9ce03a1b3faf4fed82e60769f34b938d","type":"DISEASE","name":"Hepatic Veno-Occlusive Disease","canonical_id":"mesh:D006504","description":null,"metadata":null},{"id":"d6c8eb34c53c4e628d9fd22a948a3312","type":"DISEASE","name":"Hepatic encephalopathy","canonical_id":"mesh:D006501","description":null,"metadata":null},{"id":"00124680494941cbb6034a4c9d101d1e","type":"DISEASE","name":"Hepatitis B, Chronic","canonical_id":"mesh:D019694","description":null,"metadata":null},{"id":"f88d7da64bb74ce4a2eb756675bed434","type":"DISEASE","name":"Hepatocellular Carcinoma","canonical_id":"mesh:D006528","description":null,"metadata":null},{"id":"9df112d63312485cbfeaced0d8089f7b","type":"DISEASE","name":"Hepatocellular Carcinoma","canonical_id":"doid:684","description":null,"metadata":null},{"id":"b9d1644074334d1eb037bb63776baf6a","type":"TRIAL","name":"Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib","canonical_id":"clinicaltrials.gov:NCT01352728","description":"Hepatocellular Carcinoma","metadata":null},{"id":"02ba3c85203743dd827261731db65701","type":"DISEASE","name":"Hepatolenticular Degeneration","canonical_id":"mesh:D006527","description":null,"metadata":null},{"id":"c259fee33b20442ba624a300e1a941aa","type":"TRIAL","name":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","canonical_id":"clinicaltrials.gov:NCT07281924","description":"Metastatic Melanoma; Liver Metastases","metadata":null},{"id":"5915e42367354094871a0af0a37cecb8","type":"TRIAL","name":"Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs","canonical_id":"clinicaltrials.gov:NCT00923000","description":"Healthy","metadata":null},{"id":"fd42bc34854a47baa6801b67920da7d0","type":"DISEASE","name":"Hereditary combined deficiency of vitamin K-dependent clotting factors","canonical_id":"orphanet:98434","description":null,"metadata":null},{"id":"13d9af0e304343e1b944cfab1c3faac9","type":"DISEASE","name":"Hereditary factor IX deficiency disease","canonical_id":"mesh:D002836","description":null,"metadata":null},{"id":"a3bf5232631b45a9b4c893f071822d9e","type":"DISEASE","name":"Hereditary factor VIII deficiency disease","canonical_id":"mesh:D006467","description":null,"metadata":null},{"id":"7157e1e6c5d5427685aab2a33e165f5b","type":"DISEASE","name":"Hereditary factor XIII A subunit deficiency","canonical_id":"mesh:C567691","description":null,"metadata":null},{"id":"7781d69c9a2642a1a10744dd876e3c0d","type":"DISEASE","name":"Herpes Labialis","canonical_id":"mesh:D006560","description":null,"metadata":null},{"id":"62dfd967526b4d9c8028229d632f5d92","type":"DISEASE","name":"Herpes simplex","canonical_id":"mesh:D006561","description":null,"metadata":null},{"id":"882bf5f608be49e88f35e1d8ea7e07d7","type":"DISEASE","name":"Herpes simplex dendritic keratitis","canonical_id":"mesh:D007635","description":null,"metadata":null},{"id":"6abbf97208314c4da362877262f50dd6","type":"DISEASE","name":"Herpes zoster","canonical_id":"mesh:D006562","description":null,"metadata":null},{"id":"0d1c42452f954eecbbdae185224f209c","type":"GO_TERM","name":"Herring body","canonical_id":"go:GO:1990623","description":"\"The dilated terminal portions of neurosecretory axons constituting the hypothalamohypophyseal tract, found in close proximity to sinusoidal capillaries in the posterior pituitary. Herring bodies consist of aggregates of membrane-bound neurosecretory vesicles where oxytocin or antidiuretic hormone (ADH) are stored prior to release. Each Herring body also contains ATP and either neurophysin I or neurophysin II which bind to oxytocin and ADH, respectively.\" [ISBN:0199652473, Wikipedia:Herring_bodies]","metadata":null},{"id":"aa3ab337717a4ac995cafd552bcbff0f","type":"TRIAL","name":"Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06797622","description":"Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"edd3d150152044cdb7beaf0ade91c09e","type":"DISEASE","name":"Heterotopic ossification","canonical_id":"mesh:D009999","description":null,"metadata":null},{"id":"c714ba74f19f463291fdf04c92c3fd89","type":"TRIAL","name":"HiFIT Study : Hip Fracture: Iron and Tranexamic Acid","canonical_id":"clinicaltrials.gov:NCT02972294","description":"Hip Fractures Pathologic; Anemia","metadata":null},{"id":"ced70da3ef92444c9fe74fd9e91932fc","type":"DISEASE","name":"Hidradenitis suppurativa","canonical_id":"mesh:D017497","description":null,"metadata":null},{"id":"df9ef0d21e9a4510b74483b641574897","type":"TRIAL","name":"Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19","canonical_id":"clinicaltrials.gov:NCT04964583","description":"Covid19","metadata":null},{"id":"42b0be025e80440cb947a0301c0928c6","type":"TRIAL","name":"High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty","canonical_id":"clinicaltrials.gov:NCT00154050","description":"Arterial Occlusive Diseases","metadata":null},{"id":"c6a3c08b82244578915a2b2f8fb6163e","type":"TRIAL","name":"High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003578","description":"Lymphoma","metadata":null},{"id":"72bff0e716c34e28bced03a25ac9ea93","type":"TRIAL","name":"High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer","canonical_id":"clinicaltrials.gov:NCT01757275","description":"Bleeding Peptic Ulcer","metadata":null},{"id":"4796533049a74b35a78ed0c451c2b107","type":"TRIAL","name":"High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases","canonical_id":"clinicaltrials.gov:NCT02726568","description":"Non-small Cell Lung Cancer; Brain Metastases","metadata":null},{"id":"7bcf1672de81418c8cb9a4e07e506fab","type":"TRIAL","name":"High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation","canonical_id":"clinicaltrials.gov:NCT02404675","description":"NSCLC","metadata":null},{"id":"a8b71df496ef4c7bae95fa96d1a5c77a","type":"TRIAL","name":"High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01569659","description":"Schizophrenia","metadata":null},{"id":"fc31e1381eba45e4a860b302af299499","type":"TRIAL","name":"High Dose Risankizumab for Psoriasis","canonical_id":"clinicaltrials.gov:NCT05283135","description":"Psoriasis","metadata":null},{"id":"f01b299a460747ee9b16ff20fe66f8f9","type":"TRIAL","name":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","canonical_id":"clinicaltrials.gov:NCT06345495","description":"Splenomegaly; Myelofibrosis","metadata":null},{"id":"d5c49195c46c46a199d8a7143682ea5f","type":"TRIAL","name":"High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour","canonical_id":"clinicaltrials.gov:NCT01587625","description":"Birth; Delayed","metadata":null},{"id":"a97ad5b8846944b2a9d9eb306c118985","type":"DISEASE","name":"High Grade Glioma","canonical_id":"doid:3070","description":null,"metadata":null},{"id":"b24a95278070458d93668b6f8a42b700","type":"TRIAL","name":"High Intensity Focused Ultrasound (HIFU) Ablation System Study","canonical_id":"clinicaltrials.gov:NCT00392106","description":"Atrial Fibrillation","metadata":null},{"id":"7741c7e82faa4302ba817ac1efeb6ec9","type":"TRIAL","name":"High Potency Statins and the Risk of Diabetes","canonical_id":"clinicaltrials.gov:NCT02518503","description":"Diabetes Mellitus, Type 2; Cardiovascular Disease","metadata":null},{"id":"4bca0fc937484f2fbfff8887314120fb","type":"TRIAL","name":"High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)","canonical_id":"clinicaltrials.gov:NCT04247633","description":"Breast Cancer","metadata":null},{"id":"00496c975a744ea69c15e73f20ed8aea","type":"TRIAL","name":"High Risk Prostate Cancer Prevention Study","canonical_id":"clinicaltrials.gov:NCT01174953","description":"Prostate Cancer","metadata":null},{"id":"c705a3e929684a329335521f9019316c","type":"TRIAL","name":"High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients","canonical_id":"clinicaltrials.gov:NCT05912686","description":"Mechanical Thrombectomy; Acute Ischemic Stroke","metadata":null},{"id":"01f7cb43d73e45189dc6c5064e021bdb","type":"TRIAL","name":"High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00669812","description":"Lymphoma; Small Intestine Cancer","metadata":null},{"id":"55693563bef3484588268346e0cf093f","type":"TRIAL","name":"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00002784","description":"Breast Cancer","metadata":null},{"id":"bd3efe4238e144a7a866ec639ac94e18","type":"TRIAL","name":"High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma","canonical_id":"clinicaltrials.gov:NCT01237951","description":"Myeloma","metadata":null},{"id":"bb33daa5c4ec4369a215b505dfa7dc13","type":"TRIAL","name":"High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease","canonical_id":"clinicaltrials.gov:NCT01200329","description":"Lymphoma","metadata":null},{"id":"61872075be944d49b42532b06495fd65","type":"TRIAL","name":"High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study","canonical_id":"clinicaltrials.gov:NCT00288626","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"9c3b21dd64a24eb5aeb674a22633c954","type":"TRIAL","name":"High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD","canonical_id":"clinicaltrials.gov:NCT05895201","description":"Bone Marrow Transplant Complications; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia, Adult; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"94ecc2bab23b46fb90beea54f6195705","type":"TRIAL","name":"High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00349778","description":"Multiple Myeloma","metadata":null},{"id":"0a3c7b7affc043d390cdab1cedb34e1d","type":"TRIAL","name":"High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs","canonical_id":"clinicaltrials.gov:NCT01965275","description":"Self Efficacy; Drug Toxicity","metadata":null},{"id":"cf2ef2d4874d4710be8182ed8a49e6c1","type":"TRIAL","name":"High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study","canonical_id":"clinicaltrials.gov:NCT05585151","description":"Cerebral Atherosclerosis","metadata":null},{"id":"3e5988d93bba48eeb8287849b49a976e","type":"TRIAL","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","canonical_id":"clinicaltrials.gov:NCT04221035","description":"High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy","metadata":null},{"id":"9747069d522a400db36e7b6a273fceb0","type":"TRIAL","name":"High-dose Methylprednisolone and Rituximab in High Risk B-CLL","canonical_id":"clinicaltrials.gov:NCT00558181","description":"Chronic B-Lymphocytic Leukemia","metadata":null},{"id":"fd6bc5a94f0241eeb5459792323255a0","type":"TRIAL","name":"High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19","canonical_id":"clinicaltrials.gov:NCT05047874","description":"Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone","metadata":null},{"id":"90c478ddf4eb4f87950d452592c4daea","type":"TRIAL","name":"HighCycle Study: Acetazolamide, High Altitude and Plasma Volume","canonical_id":"clinicaltrials.gov:NCT07118462","description":"High Altitude Effects; High Altitude Hypoxia; Acute Mountain Sickness (AMS); Plasma Volume; Women","metadata":null},{"id":"9467cdc70112497db513f7312c7debf7","type":"TRIAL","name":"HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men","canonical_id":"clinicaltrials.gov:NCT06499727","description":"Acute Mountain Sickness","metadata":null},{"id":"5a911536498c41af9fddc31075a6790b","type":"TRIAL","name":"HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men","canonical_id":"clinicaltrials.gov:NCT06498505","description":"High Altitude","metadata":null},{"id":"10179672e6d14acc8a79a751686fca2e","type":"TRIAL","name":"Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes","canonical_id":"clinicaltrials.gov:NCT00208221","description":"Hypertension; Type 2 Diabetes; Albuminuria","metadata":null},{"id":"b5591a9187a64011ae25aae5515a03cd","type":"TRIAL","name":"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane","canonical_id":"clinicaltrials.gov:NCT05146739","description":"Acute Myeloid Leukemia Post Cytotoxic Therapy; Myelodysplastic Syndrome Post Cytotoxic Therapy; Myeloid Leukemia Associated With Down Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome","metadata":null},{"id":"f444e934102b4b5bb669148a6133c0c8","type":"TRIAL","name":"Hip Fracture Study of GSK576428 (Fondaparinux Sodium)","canonical_id":"clinicaltrials.gov:NCT00320424","description":"Thromboembolism","metadata":null},{"id":"70262207c5ee4a71a98074fa787d2cab","type":"TRIAL","name":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","canonical_id":"clinicaltrials.gov:NCT07228663","description":"Hip Fracture Surgery; Cardiovascular Prevention; Venous Thromboembolism (VTE)","metadata":null},{"id":"7f6d7e7eb1d2471bb45ffa2f02147e41","type":"TRIAL","name":"Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy","canonical_id":"clinicaltrials.gov:NCT00150839","description":"Depressive Disorder, Major","metadata":null},{"id":"39ab8a0ebede4632bc672d3c7632aa8f","type":"DISEASE","name":"Hirschsprung disease","canonical_id":"mondo:0018309","description":null,"metadata":null},{"id":"496745d8fac642e2aedc64e9addab79c","type":"DISEASE","name":"Hirsutism","canonical_id":"hp:0001007","description":null,"metadata":null},{"id":"20fe6667c54e4fe9bff97a9d8139be67","type":"GO_TERM","name":"His-Purkinje system cell development","canonical_id":"go:GO:0060933","description":"\"The process whose specific outcome is the progression of a His-Purkinje cell over time, from its formation to the mature state. These cells form the fibers that regulate cardiac muscle contraction in the ventricles.\" [GOC:mtg_heart]","metadata":null},{"id":"8e96ca6b2c174eb6a8a99024d5d0fb47","type":"GO_TERM","name":"His-Purkinje system cell differentiation","canonical_id":"go:GO:0060932","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a cell of the His-Purkinje system. These cells form the fibers regulate cardiac muscle contraction in the ventricles.\" [GOC:mtg_heart]","metadata":null},{"id":"f99111abfa5f4991b7bdb956dbd71030","type":"GO_TERM","name":"His-Purkinje system cell fate commitment","canonical_id":"go:GO:0060934","description":"\"The commitment of cells to His-Purkinje cell fates and their capacity to differentiate into His-Purkinje cells. These cells form the fibers that regulate cardiac muscle contraction in the ventricles.\" [GOC:mtg_heart]","metadata":null},{"id":"3941d633e2b04da2b2391c07d43e4acc","type":"GO_TERM","name":"His-Purkinje system development","canonical_id":"go:GO:0003164","description":"\"The process whose specific outcome is the progression of the His-Purkinje system over time, from its formation to the mature structure. The His-Purkinje system receives signals from the AV node and is composed of the fibers that regulate cardiac muscle contraction in the ventricles.\" [GOC:mtg_heart]","metadata":null},{"id":"4c31dc221d0d458390db00d796a8e1d1","type":"TRIAL","name":"Histamine H1/H2 Receptors and Training Adaptations","canonical_id":"clinicaltrials.gov:NCT04450134","description":"Exercise Training; Physical Activity","metadata":null},{"id":"0583b6a821fd483bb052732f7682e028","type":"TRIAL","name":"Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity","canonical_id":"clinicaltrials.gov:NCT03145012","description":"Cancer","metadata":null},{"id":"12d92b18c5e1406680589b4e310a0ef0","type":"DISEASE","name":"Histiocytic Sarcoma","canonical_id":"doid:0080915","description":null,"metadata":null},{"id":"3655d7ffea3a4e15bea2dc8588f9f188","type":"TRIAL","name":"Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%","canonical_id":"clinicaltrials.gov:NCT01892137","description":"Actinic Keratosis","metadata":null},{"id":"a7cf352326594cbeabc440ad89008c85","type":"DISEASE","name":"Histoplasmosis","canonical_id":"mesh:D006660","description":null,"metadata":null},{"id":"3104090180e941dc94e6632179130984","type":"DRUG","name":"Histrelin","canonical_id":"mesh:C029256","description":null,"metadata":null},{"id":"9daa1ceec5ee43eb855cbd285a299d5c","type":"DISEASE","name":"Hodgkin's disease","canonical_id":"mesh:D006689","description":null,"metadata":null},{"id":"8e1d63ac65074ae4b37a0b97e72e6bd8","type":"DISEASE","name":"Hodgkins lymphoma","canonical_id":"mondo:0004952","description":null,"metadata":null},{"id":"40c502e519104678b7a3c5b46a4f430c","type":"GO_TERM","name":"Holliday junction helicase complex","canonical_id":"go:GO:0009379","description":"\"A DNA helicase complex found at Holliday junctions where the helicase activity is involved in the migration of the junction branch point. The best-characterized example is the E. coli RuvAB complex, in which a hexamer of RuvB subunits possesses helicase activity that is modulated by association with RuvA.\" [PMID:16935884, PMID:9442895]","metadata":null},{"id":"01619ffc4dfc499b87771350337e13ab","type":"GO_TERM","name":"Holliday junction resolvase complex","canonical_id":"go:GO:0048476","description":"\"An endodeoxyribonuclease complex that resolves the 4-way DNA intermediates of a Holliday junction into two separate duplex DNA molecules. Can be branch-migration associated.\" [PMID:11207366, PMID:12374758]","metadata":null},{"id":"ca3be572f1874ba4ab0f638132e348e3","type":"TRIAL","name":"Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD","canonical_id":"clinicaltrials.gov:NCT05904028","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"60f227bdcb9a4f4e942f38a1612b3fd0","type":"DISEASE","name":"Homocystinuria","canonical_id":"mesh:D006712","description":null,"metadata":null},{"id":"eb3c136d211a43299d73569e95592abe","type":"TRIAL","name":"Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle","canonical_id":"clinicaltrials.gov:NCT04060992","description":"Ovulation; Failure or Lack of","metadata":null},{"id":"d974d3032bd145f18ab6bdbda7e1cc3a","type":"TRIAL","name":"Hormonal Mechanisms of Sleep Restriction - Axis Study","canonical_id":"clinicaltrials.gov:NCT03142893","description":"Sleep Restriction","metadata":null},{"id":"9534ce60708a4ebc9ed166b5d766edb7","type":"TRIAL","name":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT04037605","description":"Sleep Restriction","metadata":null},{"id":"0089bc790ee74c028a4e38d9749739bc","type":"TRIAL","name":"Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02494713","description":"Prostate Cancer","metadata":null},{"id":"9d166589d347423fbc4dc98988385194","type":"TRIAL","name":"Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide","canonical_id":"clinicaltrials.gov:NCT01375374","description":"Epilepsy, Partial","metadata":null},{"id":"62878fd05528471aaabc85c0ec15a255","type":"TRIAL","name":"Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding","canonical_id":"clinicaltrials.gov:NCT01004081","description":"Breast Cancer","metadata":null},{"id":"bab583343a904f769bbdb562389fb5bb","type":"TRIAL","name":"Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00044837","description":"HIV Infections","metadata":null},{"id":"02dc5cb8d77e44e0bcad3cd1f3b59fcc","type":"TRIAL","name":"Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00003437","description":"Leukemia","metadata":null},{"id":"c421636289a34ae2b2b9332d6c6b8ef3","type":"TRIAL","name":"Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00030654","description":"Prostate Cancer","metadata":null},{"id":"c716191f81e04ab095347ec0a2c08d9a","type":"TRIAL","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00002633","description":"Prostate Cancer","metadata":null},{"id":"9ba94a77e8c641a98b4b538c685e7c00","type":"TRIAL","name":"Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans","canonical_id":"clinicaltrials.gov:NCT05442463","description":"Hormone Therapy","metadata":null},{"id":"6b84ca1fb26e46c6868040e438732e4a","type":"TRIAL","name":"Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00170157","description":"Prostate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"eac35c4232d84c02867bc606fee74c68","type":"TRIAL","name":"Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00054106","description":"Prostate Cancer","metadata":null},{"id":"d4ba78b54bf54274ac9c929067e5b735","type":"TRIAL","name":"Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00512668","description":"Adenocarcinoma of the Prostate; Recurrent Prostate Cancer","metadata":null},{"id":"96d4b040f82a4c54a1db96b08b62d248","type":"TRIAL","name":"Hormone Therapy in Treating Patients With Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00003026","description":"Prostate Cancer","metadata":null},{"id":"d3e26fdf22674b08b7d931a5a2dd01c6","type":"TRIAL","name":"Hormone Therapy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00003323","description":"Prostate Cancer; Sexual Dysfunction and Infertility","metadata":null},{"id":"7e977ddffde245129860077cb653fa21","type":"TRIAL","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00003653","description":"Prostate Cancer","metadata":null},{"id":"b72612b616f7498db06ac8a2a34f129d","type":"TRIAL","name":"Hormones and Decision Making","canonical_id":"clinicaltrials.gov:NCT04865562","description":"Dyssocial Behavior","metadata":null},{"id":"1f418b6eeb41441faf3ad46d5840a982","type":"TRIAL","name":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","canonical_id":"clinicaltrials.gov:NCT04606563","description":"Covid19; SARS-CoV Infection","metadata":null},{"id":"06aae41fd45f4893b6bcd78f293144dd","type":"TRIAL","name":"Hot Flashes and Neurovascular Function in Women","canonical_id":"clinicaltrials.gov:NCT05193968","description":"Hot Flashes; Menopause; Vasomotor System; Labile","metadata":null},{"id":"e9ddcb1971ab49ca82a2233f64eb5a6f","type":"DISEASE","name":"Hot flashes","canonical_id":"hp:0031217","description":null,"metadata":null},{"id":"52df7fec0ef64ac6a1c8fccecf6e874b","type":"TRIAL","name":"How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany","canonical_id":"clinicaltrials.gov:NCT07395804","description":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","metadata":null},{"id":"389762ddbfce406c83b2bd817f6a2bbc","type":"TRIAL","name":"How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)","canonical_id":"clinicaltrials.gov:NCT00795158","description":"Urticaria","metadata":null},{"id":"1d39d303f3a44bffa2df018b00eacd96","type":"TRIAL","name":"How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT01519518","description":"Acute ST Elevation Myocardial Infarction","metadata":null},{"id":"32e3a27327de43f2babcc9db401bd225","type":"TRIAL","name":"How Well and Safely Does Lemborexant Work for People Who Wake up at Night to Urinate (LENS)","canonical_id":"clinicaltrials.gov:NCT07840638","description":"Nocturia","metadata":null},{"id":"12013a7cdc2a4279a4064d6609066926","type":"TRIAL","name":"How to Treat Opiate Withdrawal in Neonates","canonical_id":"clinicaltrials.gov:NCT02810782","description":"Neonatal Abstinence Syndrome","metadata":null},{"id":"ebf205990d044f86948070c798f2814f","type":"GO_TERM","name":"Hpa2 acetyltransferase complex","canonical_id":"go:GO:1990331","description":"\"A tetrameric protein complex capable of acetyltransferase activity. It can catalyze the transfer of an acetyl group from acetyl-CoA to an acceptor residue on histone H-3, histone H-4, or on polyamines. The complex is also capable of acetylating certain small basic proteins. The two Hpa2 dimers that make up the tetramer are held together by interactions between the bound acetyl-CoA molecules.\" [GOC:bhm, PMID:10600387]","metadata":null},{"id":"83083682b04144c4af686c586337c870","type":"GO_TERM","name":"Hrd1p ubiquitin ligase ERAD-L complex","canonical_id":"go:GO:0000839","description":"\"A multiprotein complex that recognizes and ubiquitinates proteins with misfolded luminal domains during ER-associated protein degradation (ERAD). In S. cerevisiae, this complex contains the ubiquitin ligase Hrd1p.\" [GOC:elh, PMID:16873065, PMID:16873066]","metadata":null},{"id":"c96e3f3df26a4996a692601b13b953b2","type":"GO_TERM","name":"Hrd1p ubiquitin ligase ERAD-M complex","canonical_id":"go:GO:0000838","description":"\"A multiprotein complex that recognizes and ubiquitinates proteins with misfolded membrane domains during ER-associated protein degradation (ERAD). In S. cerevisiae, this complex contains the ubiquitin ligase Hrd1p.\" [GOC:elh, PMID:16873066]","metadata":null},{"id":"6d163ff5f04d45fe91b5164fc2dfa7f2","type":"GO_TERM","name":"Hrd1p ubiquitin ligase complex","canonical_id":"go:GO:0000836","description":"\"A multiprotein complex that recognizes and ubiquitinates proteins with misfolded luminal and membrane domains during ER-associated protein degradation (ERAD). In S. cerevisiae, this complex contains the ubiquitin ligase Hrd1p. In mammals, this complex contains the ubiquitin ligase HRD1 (Synoviolin) or AMFR (gp78).\" [GOC:bf, GOC:elh, PMID:16619026, PMID:16873066, PMID:21454652]","metadata":null},{"id":"4a92bed86ced41fb9872cdc35e72bfc9","type":"GO_TERM","name":"HslUV protease complex","canonical_id":"go:GO:0009376","description":"\"A protein complex that possesses ATP-dependent protease activity; consists of an ATPase large subunit with homology to other ClpX family ATPases and a peptidase small subunit related to the proteasomal beta-subunits of eukaryotes. In the E. coli complex, a double ring-shaped homohexamer of HslV is capped on each side by a ring-shaped HslU homohexamer.\" [GOC:bhm, PMID:12670962, UniProt:P0A6H5]","metadata":null},{"id":"1a64a8a6f3b14a0792f152394f422639","type":"GO_TERM","name":"Hsp27 protein binding","canonical_id":"go:GO:0051008","description":"\"Binding to Hsp27 proteins, a lightweight heat shock protein.\" [GOC:ai]","metadata":null},{"id":"cfd928f1907841fdb2773ab5580fae43","type":"GO_TERM","name":"Hsp70 protein binding","canonical_id":"go:GO:0030544","description":"\"Binding to a Hsp70 protein, heat shock proteins around 70kDa in size.\" [ISBN:0198506732]","metadata":null},{"id":"c5a39eb3e42d4c48949af6c58a90e02e","type":"GO_TERM","name":"Hsp90 deacetylation","canonical_id":"go:GO:0070846","description":"\"The modification of an Hsp90 protein by removal of acetyl groups.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"88bba910311c4758bfe61b394578845a","type":"GO_TERM","name":"Hsp90 protein binding","canonical_id":"go:GO:0051879","description":"\"Binding to Hsp90 proteins, any of a group of heat shock proteins around 90kDa in size.\" [GOC:ai]","metadata":null},{"id":"5da6bba2062946899540c6491fafc8da","type":"GO_TERM","name":"Hub1 activating enzyme activity","canonical_id":"go:GO:0042293","description":"\"Catalysis of the activation of the small ubiquitin-related modifier Hub1, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:mah]","metadata":null},{"id":"1626e639b1cd49f78379f23df70db9b1","type":"GO_TERM","name":"Hulle cell development","canonical_id":"go:GO:0070792","description":"\"The process whose specific outcome is the progression of Hulle cells over time, from their formation to the mature structures. Hulle cells are specialized multinucleate cells that originate from a nest-like aggregation of hyphae during sexual development and serve as nurse cells to the developing cleistothecium, or fruiting body.\" [PMID:19210625]","metadata":null},{"id":"714dc9386fb24425919d2fe4cce54b4c","type":"TRIAL","name":"Humalog\u00ae Mix50/50(tm) as a Treatment for Gestational Diabetes","canonical_id":"clinicaltrials.gov:NCT01613807","description":"Gestational Diabetes Mellitus","metadata":null},{"id":"b21645f946e349c6832429a723704566","type":"TRIAL","name":"Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025","canonical_id":"clinicaltrials.gov:NCT03907540","description":"Autoimmune Diseases; Fibrosis","metadata":null},{"id":"7d741523d8e246aea0b4780a341982dc","type":"TRIAL","name":"Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis","canonical_id":"clinicaltrials.gov:NCT00130637","description":"Anterior Uveitis; Arthritis, Juvenile Idiopathic; Iritis; Immunosuppression","metadata":null},{"id":"90e08dfbc7944bad8b45deff1b1e4851","type":"TRIAL","name":"Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving","canonical_id":"clinicaltrials.gov:NCT01151813","description":"Alcohol Dependence; Cocaine Dependence","metadata":null},{"id":"18abf1ef2ec0401498ee85e8049d804b","type":"TRIAL","name":"Human Cytochrome P450 4F Enzymes and Drug Interactions","canonical_id":"clinicaltrials.gov:NCT01250535","description":"Healthy Volunteers; Drug Drug Interactions","metadata":null},{"id":"d9fc83c5bac9444cb4faa514a8a86266","type":"TRIAL","name":"Human Laboratory Study of Apremilast for Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT07325266","description":"Alcohol Use Disorder; Alcohol Misuse","metadata":null},{"id":"108b1c9e7cea49ba829b9d6dda92ca9c","type":"TRIAL","name":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT04177004","description":"Allogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm","metadata":null},{"id":"9609cdcdcde443e3a38833fd422ae7b0","type":"TRIAL","name":"Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT03531281","description":"Hematopoietic and Lymphoid Cell Neoplasm; Hematopoietic Cell Transplantation Recipient","metadata":null},{"id":"2c08e6848fc0458198521eb538eac4b5","type":"TRIAL","name":"Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma","canonical_id":"clinicaltrials.gov:NCT03240822","description":"Urologic Injuries; Genital Diseases, Male; Amputation","metadata":null},{"id":"3ed1bc8dbf1540639abe48ca8e29aeaf","type":"DISEASE","name":"Humoral Hypercalcemia Of Malignancy","canonical_id":"mesh:C562390","description":null,"metadata":null},{"id":"fe1c06195b8b46b8ba46cf073f9f9988","type":"DISEASE","name":"Huntington disease","canonical_id":"mondo:0007739","description":null,"metadata":null},{"id":"8f9f7ac647494f769637ebc13783184c","type":"DISEASE","name":"Huntington's chorea","canonical_id":"mesh:D006816","description":null,"metadata":null},{"id":"b21fa9353aef47d69a3b06f54592d109","type":"TRIAL","name":"Hyaluronic Acid and I-PRF Mixture for TMJ Disc Displacement Management","canonical_id":"clinicaltrials.gov:NCT07683650","description":"TMJ Disc Displacement With Reduction","metadata":null},{"id":"d6eae2b396fd4f6fb1a1ca73228a6bf8","type":"TRIAL","name":"Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT04233034","description":"Type1 Diabetes","metadata":null},{"id":"761813edec194197b42db765b8c5b7a9","type":"TRIAL","name":"Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy","canonical_id":"clinicaltrials.gov:NCT01538875","description":"Hypertension, Pregnancy Induced","metadata":null},{"id":"914845d3519041c9be49671d3271a5b8","type":"DRUG","name":"Hydrochlorothiazide","canonical_id":"mesh:D006852","description":null,"metadata":null},{"id":"60b117c0583548668d5bd36f911ae5d0","type":"TRIAL","name":"Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","canonical_id":"clinicaltrials.gov:NCT00902538","description":"Essential Hypertension","metadata":null},{"id":"c141ab78b62744c88af35e60ea6d122b","type":"TRIAL","name":"Hydrocodone For Pain Control in First Trimester Surgical Abortion","canonical_id":"clinicaltrials.gov:NCT01330459","description":"Pain","metadata":null},{"id":"456bafd5c6034befad82bbcfb99b5479","type":"TRIAL","name":"Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction","canonical_id":"clinicaltrials.gov:NCT00935311","description":"Pain","metadata":null},{"id":"cb4b71304e4b44df873ec3b6be6babf0","type":"TRIAL","name":"Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT07037043","description":"Inflammation in Cardiac Surgery","metadata":null},{"id":"47ce945ed8724029864e4eee4062750a","type":"TRIAL","name":"Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","canonical_id":"clinicaltrials.gov:NCT07383103","description":"Septic Shock","metadata":null},{"id":"b8bb0765ac9840f392d8aef128f99c89","type":"TRIAL","name":"Hydrogel Patch for the Treatment of Eczema","canonical_id":"clinicaltrials.gov:NCT00924508","description":"Eczema","metadata":null},{"id":"f2f2950716cc47788ed779e9f14d4f6f","type":"DRUG","name":"Hydromorphone","canonical_id":"mesh:D004091","description":null,"metadata":null},{"id":"f181e247b8c448569f120ea098542f20","type":"TRIAL","name":"Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine","canonical_id":"clinicaltrials.gov:NCT02389829","description":"Migraine","metadata":null},{"id":"a51048ee8ee248c5b147d5b907266efd","type":"TRIAL","name":"Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation","canonical_id":"clinicaltrials.gov:NCT04436224","description":"Hydromorphone; Analgesia; ICU","metadata":null},{"id":"01a31dee23fa47e28743dadd3034885c","type":"DRUG","name":"Hydroxyamfetamine","canonical_id":"mesh:D010136","description":null,"metadata":null},{"id":"da789fc9511340228469f5a2bc1a3955","type":"DRUG","name":"Hydroxycarbamide","canonical_id":"mesh:D006918","description":null,"metadata":null},{"id":"963bfd37ddfa4cf6974023775bf8afd2","type":"PROTEIN","name":"Hydroxycarboxylic acid receptor 2","canonical_id":"uniprot:Q8TDS4","description":null,"metadata":null},{"id":"7405b208f1e744b1830d20e2d367c0bf","type":"PROTEIN","name":"Hydroxycarboxylic acid receptor 3","canonical_id":"uniprot:P49019","description":null,"metadata":null},{"id":"9772f1105e2d43c8946bd8fa2b858a96","type":"TRIAL","name":"Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","canonical_id":"clinicaltrials.gov:NCT04365231","description":"COVID19","metadata":null},{"id":"9db5b252a3e6495a8ca098bfdaf25954","type":"TRIAL","name":"Hydroxychloroquine Efficacy in Chronic Urticaria","canonical_id":"clinicaltrials.gov:NCT01073852","description":"Chronic Urticaria","metadata":null},{"id":"8a54296cc6664e3f89674e83f7bf92e8","type":"TRIAL","name":"Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sj\u00f6gren's Syndrome","canonical_id":"clinicaltrials.gov:NCT01601028","description":"Autoimmune Diseases; Sjogren's Syndrome; Dry Eye","metadata":null},{"id":"542638afbc474ed38d6a67be9e53c07a","type":"TRIAL","name":"Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19","canonical_id":"clinicaltrials.gov:NCT04349592","description":"Covid19","metadata":null},{"id":"c9a0ef5185d64470b1a665d5a047ff8b","type":"TRIAL","name":"Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)","canonical_id":"clinicaltrials.gov:NCT04328961","description":"COVID-19; Corona Virus Infection; SARS (Severe Acute Respiratory Syndrome); SARS-CoV-2","metadata":null},{"id":"8e30c5cebf51494d901d66d7cccac365","type":"TRIAL","name":"Hydroxychloroquine in ANCA Vasculitis Evaluation","canonical_id":"clinicaltrials.gov:NCT04316494","description":"ANCA Associated Vasculitis; Microscopic Polyangiitis; Churg-Strauss Syndrome; Wegener Granulomatosis","metadata":null},{"id":"e5ac14a4da504131b1b5e8d01f8c512a","type":"TRIAL","name":"Hydroxychloroquine in Giant Cell Arteritis","canonical_id":"clinicaltrials.gov:NCT00430807","description":"Giant Cell Arteritis","metadata":null},{"id":"e082353b04054a3689004d61d5917cd1","type":"TRIAL","name":"Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients","canonical_id":"clinicaltrials.gov:NCT05084872","description":"Mastocytosis","metadata":null},{"id":"bd0fe6254bc24d13a10e5649127ebb5d","type":"TRIAL","name":"Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00962845","description":"Melanoma (Skin)","metadata":null},{"id":"b72975c80b8a4f03a6e7db84717414fa","type":"TRIAL","name":"Hydroxychloroquine in Prevention of Preeclampsia","canonical_id":"clinicaltrials.gov:NCT04755322","description":"Preeclampsia","metadata":null},{"id":"f3cdb04314b04be8a7c5290840f664b9","type":"TRIAL","name":"Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial","canonical_id":"clinicaltrials.gov:NCT04382625","description":"SARS-CoV-2 Pneumonia; COVID-19","metadata":null},{"id":"01ec157686474bb9bf1a8275f6727a57","type":"TRIAL","name":"Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00726596","description":"Prostate Cancer","metadata":null},{"id":"f0d54f884615436ba6d5cd84c96facd3","type":"TRIAL","name":"Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss","canonical_id":"clinicaltrials.gov:NCT05237843","description":"Recurrent Pregnancy Loss","metadata":null},{"id":"97b0b6aacbb54181a39d5060282cc93f","type":"TRIAL","name":"Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04011410","description":"Prostate Cancer Recurrent","metadata":null},{"id":"ff11c7913bad48b9a273da50d009390d","type":"TRIAL","name":"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04316169","description":"Solid Tumor; Advanced Breast Cancer","metadata":null},{"id":"9a582b518e7f449682a1b244a8c41cfc","type":"TRIAL","name":"Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00728845","description":"Lung Cancer","metadata":null},{"id":"9001fe24f9bb40cfb5abd2b0e3fedb9b","type":"TRIAL","name":"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","canonical_id":"clinicaltrials.gov:NCT04338698","description":"COVID 19","metadata":null},{"id":"84b1b12e9eb2417ea0a3bc3ba65f9df8","type":"TRIAL","name":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03774472","description":"Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8\u2026","metadata":null},{"id":"73b734e266db4e9589c758b178bb7328","type":"TRIAL","name":"Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00486603","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"219f64f7a6c346489a3bf7f6c9f05931","type":"TRIAL","name":"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","canonical_id":"clinicaltrials.gov:NCT04341727","description":"Coronavirus Infection","metadata":null},{"id":"4f5ee17dd31b4a16bca8540ba9e8abde","type":"TRIAL","name":"Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee","canonical_id":"clinicaltrials.gov:NCT01645176","description":"Osteoarthritis of the Knee","metadata":null},{"id":"3e8fd51c7eda4a0b91e2d07e977481d9","type":"TRIAL","name":"Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies","canonical_id":"clinicaltrials.gov:NCT03020615","description":"Sickle Cell Anemia","metadata":null},{"id":"d41d07668a334aa196558034e274674d","type":"TRIAL","name":"Hydroxyurea and EPO in Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT05451940","description":"Anemia, Sickle Cell; Sickle Cell Disease","metadata":null},{"id":"177c462047e549f2b976727dfe968bf0","type":"TRIAL","name":"Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia","canonical_id":"clinicaltrials.gov:NCT00001197","description":"Sickle Cell Anemia","metadata":null},{"id":"0b3808b442884d3d909010a9bdf5a1e7","type":"TRIAL","name":"Hydroxyurea in Primary Progressive Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01103583","description":"Multiple Sclerosis","metadata":null},{"id":"2cef5097b7a94a56871aa832a07d2764","type":"TRIAL","name":"Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma","canonical_id":"clinicaltrials.gov:NCT00006119","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"484070e968d046f0a2c9797bcf383884","type":"TRIAL","name":"Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)","canonical_id":"clinicaltrials.gov:NCT00001958","description":"Beta Thalassemia; Hemoglobinopathy","metadata":null},{"id":"d541d4e044464dd59f07f2516051dd6f","type":"DRUG","name":"Hydroxyzine","canonical_id":"mesh:D006919","description":null,"metadata":null},{"id":"8bbabe07d3e747489e09672ac9529e9b","type":"TRIAL","name":"Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients","canonical_id":"clinicaltrials.gov:NCT01055236","description":"Pruritus; Nausea; Vomiting","metadata":null},{"id":"eea7d8bd4e2145cab5e24160df6adc87","type":"TRIAL","name":"Hyoscine ButylBromide for Intrapartum Analgesia","canonical_id":"clinicaltrials.gov:NCT02557087","description":"Analgesia, Obstetrical","metadata":null},{"id":"9ff8dd615ea743f68b0160bf5c6ba372","type":"DRUG","name":"Hyoscyamine","canonical_id":"mesh:D064692","description":null,"metadata":null},{"id":"0113f403c9564bf093c3e4ce5a30c612","type":"DISEASE","name":"Hyperammonemia","canonical_id":"mesh:D022124","description":null,"metadata":null},{"id":"aa34b45556aa44328da66d35ed208594","type":"TRIAL","name":"Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers","canonical_id":"clinicaltrials.gov:NCT02682953","description":"Bone Marrow Transplantation; Hematopoietic Stem Cells; Multiple Myeloma; Lymphoma","metadata":null},{"id":"de3ebe9d1f3842418b78156dad81ce7c","type":"DISEASE","name":"Hypercalcemia","canonical_id":"mesh:D006934","description":null,"metadata":null},{"id":"9fbdfb884578404ea09409783e986f62","type":"DISEASE","name":"Hypercholesterolemia","canonical_id":"hp:0003124","description":null,"metadata":null},{"id":"c711080045724d2080552cbe61b94b04","type":"DISEASE","name":"Hypercholesterolemia","canonical_id":"mesh:D006937","description":null,"metadata":null},{"id":"33b906c1b92f4c8bbe67e317dfdc5cbd","type":"DISEASE","name":"Hypereosinophilic Syndrome","canonical_id":"mesh:D017681","description":null,"metadata":null},{"id":"39bd9947562e4b1fb3e8515b0fbd004b","type":"TRIAL","name":"Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT03722355","description":"Glioma; Glioblastoma Multiforme; Astrocytoma","metadata":null},{"id":"99f99e23ecb443558ad78816f712c7f4","type":"DISEASE","name":"Hyperglycemia","canonical_id":"hp:0003074","description":null,"metadata":null},{"id":"44dc99822d804cb8b249a886aaf87028","type":"DISEASE","name":"Hyperglycemia","canonical_id":"mesh:D006943","description":null,"metadata":null},{"id":"d2c00e6326794978bdc43f9c3e7596ba","type":"DISEASE","name":"Hyperhidrosis","canonical_id":"hp:0000975","description":null,"metadata":null},{"id":"b3466b8a7ef24cb48e98e7b4568b4357","type":"DISEASE","name":"Hyperinsulinism","canonical_id":"mesh:D006946","description":null,"metadata":null},{"id":"141d2b1cdc2e4e28ab55e23477f24645","type":"DISEASE","name":"Hyperkalemia","canonical_id":"mesh:D006947","description":null,"metadata":null},{"id":"46d4a96d97d645d9bce34ac5f04243eb","type":"DISEASE","name":"Hyperlipidemia","canonical_id":"mesh:D006949","description":null,"metadata":null},{"id":"46645a37986d4818a3b3bd8471ede465","type":"DISEASE","name":"Hyperlipidemia, Familial Combined","canonical_id":"mesh:D006950","description":null,"metadata":null},{"id":"0f98fcb0c6be483b8afe498fd5f19193","type":"DISEASE","name":"Hyperlipoproteinemia Type III","canonical_id":"mesh:D006952","description":null,"metadata":null},{"id":"cad1bde225bd48429acd7b0c6345ec8f","type":"DISEASE","name":"Hyperparathyroidism","canonical_id":"mesh:D006961","description":null,"metadata":null},{"id":"00a46ee6ece64568bd991ba1ce3b9e0f","type":"DISEASE","name":"Hyperphosphatemia","canonical_id":"mesh:D054559","description":null,"metadata":null},{"id":"579f4bb4d6714475b19e8b07ed846b7a","type":"DISEASE","name":"Hyperprolactinemia","canonical_id":"mesh:D006966","description":null,"metadata":null},{"id":"6987dda6b44b43c58a94241f906abb26","type":"DISEASE","name":"Hypertension","canonical_id":"mesh:D006973","description":null,"metadata":null},{"id":"97cb0f168aa74dd0b6ece89c69f65bdb","type":"TRIAL","name":"Hypertension Screening and Treatment Program","canonical_id":"clinicaltrials.gov:NCT00007592","description":"Hypertension","metadata":null},{"id":"47e110de14184c3287df4746a7c9d1b2","type":"TRIAL","name":"Hypertension Study of Ventavis\u00ae Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)","canonical_id":"clinicaltrials.gov:NCT01062282","description":"Pulmonary Hypertension","metadata":null},{"id":"76fcd633459b4a7ab6cc4c412d000ea7","type":"TRIAL","name":"Hypertension in Hemodialysis Patients (Aim 3)","canonical_id":"clinicaltrials.gov:NCT00582114","description":"Hemodialysis; Hypertension; Left Ventricular Hypertrophy","metadata":null},{"id":"3c5e1dfe37fc449bbf1b57d70f448f61","type":"DISEASE","name":"Hyperthyroidism","canonical_id":"mesh:D006980","description":null,"metadata":null},{"id":"65d78d6247084ff5862a83ddb611dd12","type":"TRIAL","name":"Hypertonic Saline to Reduce Hospital Admissions in Bronchiolitis","canonical_id":"clinicaltrials.gov:NCT00677729","description":"Viral Bronchiolitis","metadata":null},{"id":"de0eaeac6960469fa1245e85b75034d7","type":"DISEASE","name":"Hypertriglyceridemia","canonical_id":"mesh:D015228","description":null,"metadata":null},{"id":"be6e41bfbca44173bcaf901d858801d2","type":"DISEASE","name":"Hypertrophic scar","canonical_id":"mesh:D017439","description":null,"metadata":null},{"id":"393bd99d7a814d04be0903f7d59df2cb","type":"DISEASE","name":"Hyperuricemia","canonical_id":"mesh:D033461","description":null,"metadata":null},{"id":"b2adf6056f53471881d9e6858d15171c","type":"TRIAL","name":"Hypnotic Intake and Motor and Cognitive Performances at High Altitude","canonical_id":"clinicaltrials.gov:NCT02778659","description":"Physiology","metadata":null},{"id":"720ff04ffe394916b638b9f84f85fec8","type":"TRIAL","name":"Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?","canonical_id":"clinicaltrials.gov:NCT00811746","description":"Obstructive Sleep Apnea","metadata":null},{"id":"7b67f643f17c42dcb6f0b358f54c10bc","type":"TRIAL","name":"Hypoactive Sexual Desire Disorder in Males","canonical_id":"clinicaltrials.gov:NCT04002661","description":"Low Libido","metadata":null},{"id":"3d2d607a90f54ab985de73b74daaaa08","type":"DISEASE","name":"Hypoalphalipoproteinemia","canonical_id":"mesh:D052456","description":null,"metadata":null},{"id":"beae4063a54842d8a8e505dd555022f2","type":"DISEASE","name":"Hypocalcemia","canonical_id":"hp:0002901","description":null,"metadata":null},{"id":"3df871eed17b4237bc5525ca657a25e5","type":"TRIAL","name":"Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas","canonical_id":"clinicaltrials.gov:NCT07222735","description":"Sarcoma; Childhood Osteosarcoma; Childhood Rhabdomyosarcoma; Childhood Soft Tissue Sarcoma; Ewing Sarcoma","metadata":null},{"id":"2d2299aed2f14fcd9f549a1566e69360","type":"DISEASE","name":"Hypoglycemia","canonical_id":"hp:0001943","description":null,"metadata":null},{"id":"f1400ff93e164db59542eb9e8a0575eb","type":"TRIAL","name":"Hypoglycemia Associated Autonomic Failure in Type 1 DM","canonical_id":"clinicaltrials.gov:NCT00592670","description":"Type 1 Diabetes","metadata":null},{"id":"6dc6be886205479eae50f653b62fbba8","type":"TRIAL","name":"Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00608101","description":"Type 1 Diabetes","metadata":null},{"id":"eb392bce0eca41eba40e0d95e17cb11b","type":"TRIAL","name":"Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)","canonical_id":"clinicaltrials.gov:NCT01672255","description":"Type 1 Diabetes; Hypoglycemia Associated Autonomic Failure","metadata":null},{"id":"d2bf14b5c9404d28bd02f162d4ab5ac5","type":"TRIAL","name":"Hypoglycemia and the Mineralocorticoid Receptor","canonical_id":"clinicaltrials.gov:NCT01394627","description":"Hypoglycemia","metadata":null},{"id":"c1c0ddb055b4488c926d5681cef2c48b","type":"DISEASE","name":"Hypoglycemic disorder","canonical_id":"mesh:D007003","description":null,"metadata":null},{"id":"b1f2c35c3e4a46e185ef6356b690a03b","type":"TRIAL","name":"Hypogonadism in Young Men With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01155518","description":"Hypogonadotropic Hypogonadism; Type 2 Diabetes","metadata":null},{"id":"38851331ddd0434496024e1ca17e5536","type":"DISEASE","name":"Hypogonadotropic hypogonadism","canonical_id":"mesh:D007006","description":null,"metadata":null},{"id":"2f2efaeae4124b42a86f4f417a577e98","type":"DISEASE","name":"Hypokalemia","canonical_id":"mesh:D007008","description":null,"metadata":null},{"id":"d9ee78beb02a47599d5569d8de541fce","type":"DISEASE","name":"Hypomagnesemia","canonical_id":"hp:0002917","description":null,"metadata":null},{"id":"55061465761c4817888a4570f594b4b0","type":"TRIAL","name":"Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy","canonical_id":"clinicaltrials.gov:NCT04454580","description":"Acute Myeloid Leukemia, Adult; Hypomethylating Agents; Venetoclax","metadata":null},{"id":"be9cfc5073914984bafa85f7a0454538","type":"DISEASE","name":"Hyponatremia","canonical_id":"hp:0002902","description":null,"metadata":null},{"id":"1d112a0600b846a995da30afbedf0170","type":"DISEASE","name":"Hyponatremia","canonical_id":"mesh:D007010","description":null,"metadata":null},{"id":"ea688359ba1847ceb484e808f6562a45","type":"DISEASE","name":"Hypoparathyroidism","canonical_id":"mesh:D007011","description":null,"metadata":null},{"id":"a7d70767563f40279284a2aa95298b6d","type":"DISEASE","name":"Hypophosphatasia","canonical_id":"mesh:D007014","description":null,"metadata":null},{"id":"b2e00deb3228457f942f2be36a30df14","type":"DISEASE","name":"Hypophosphatemia","canonical_id":"mesh:D017674","description":null,"metadata":null},{"id":"fb720602d3904bc392aba00746103e48","type":"DISEASE","name":"Hypopituitarism","canonical_id":"mesh:D007018","description":null,"metadata":null},{"id":"96573fa871d24379a8980d79bd2f3df4","type":"TRIAL","name":"Hyporeactivity and Gulf War Illness","canonical_id":"clinicaltrials.gov:NCT00100412","description":"Gulf War Syndrome; Chronic Fatigue Syndrome; Post-Traumatic Stress Disorder","metadata":null},{"id":"8e303bd3eb234175be678c4a3e0fb407","type":"TRIAL","name":"Hypotensive Anesthesia for Orthognathic Surgery","canonical_id":"clinicaltrials.gov:NCT06093893","description":"Hypotensive Anesthesia; Orthognathic Surgery","metadata":null},{"id":"bab2d3e3c2fd4bb29d5997891c67400b","type":"DISEASE","name":"Hypothyroidism","canonical_id":"mesh:D007037","description":null,"metadata":null},{"id":"b5c71057973f48a8946bec83c8eb0612","type":"TRIAL","name":"Hypothyroidism Treated With Calcitonin","canonical_id":"clinicaltrials.gov:NCT03342001","description":"Hypothyroidism","metadata":null},{"id":"1e647a4cae6e4c2497d499e9bd793c7f","type":"DISEASE","name":"Hypovolemic shock","canonical_id":"mesh:D012769","description":null,"metadata":null},{"id":"f6132955c5044e808027666cc64839a9","type":"PROTEIN","name":"Hypoxanthine-guanine phosphoribosyltransferase","canonical_id":"uniprot:P00492","description":null,"metadata":null},{"id":"bb16a740486049e996a53dcf52d36a88","type":"TRIAL","name":"I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT00335673","description":"Hypertension","metadata":null},{"id":"9c7bf629a4c347ffabf924a283e97a7c","type":"GO_TERM","name":"I band","canonical_id":"go:GO:0031674","description":"\"A region of a sarcomere that appears as a light band on each side of the Z disc, comprising a region of the sarcomere where thin (actin) filaments are not overlapped by thick (myosin) filaments; contains actin, troponin, and tropomyosin; each sarcomere includes half of an I band at each end.\" [ISBN:0321204131]","metadata":null},{"id":"a6ae29e9dcb54735a181cb1101660221","type":"GO_TERM","name":"I(KACh) inward rectifier potassium channel complex","canonical_id":"go:GO:1990566","description":"\"An inward rectifier potassium channel complex expressed in cardiac muscle, specifically the sinoatrial node and atria, where it controls the heart rate, via regulation by G protein-coupled receptor signaling. In mammals it is composed of GIRK1 (or Kir3.1) and GIRK4 (or Kir3.4) subunits.\" [GOC:ame, PMID:9765280]","metadata":null},{"id":"d0dd7d11269e4f889cd1800bcefc1d94","type":"GO_TERM","name":"I-SMAD binding","canonical_id":"go:GO:0070411","description":"\"Binding to an inhibitory SMAD signaling protein.\" [GOC:BHF, GOC:vk, PMID:19114992]","metadata":null},{"id":"0b0bcd6a52b64d79a72d56e77e6b6885","type":"TRIAL","name":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT04488081","description":"COVID-19","metadata":null},{"id":"48a5e80f6357478a9c96f585a27cb956","type":"TRIAL","name":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01042379","description":"Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer","metadata":null},{"id":"f04173a347784178a526cfd38227b7aa","type":"GO_TERM","name":"I-kappaB phosphorylation","canonical_id":"go:GO:0007252","description":"\"The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.\" [GOC:bf, GOC:jl, PMID:21772278, PMID:7594468]","metadata":null},{"id":"b5030ad9e57e4124ac3e9ee464791a14","type":"GO_TERM","name":"I-kappaB/NF-kappaB complex","canonical_id":"go:GO:0033256","description":"\"A protein complex containing an inhibitory-kappaB (I-kappaB/IKB) protein and one or more copies of an NF-kappaB protein. In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm.\" [GOC:bf, GOC:mah, PMID:9407099]","metadata":null},{"id":"b75f3270a6244690bb69fcb0ce29a4ea","type":"GO_TERM","name":"IAA-Ala conjugate hydrolase activity","canonical_id":"go:GO:0010179","description":"\"Catalysis of the reaction: indole-3-acetyl-alanine + H2O = indole-3-acetate + L-alanine.\" [MetaCyc:RXN-2981]","metadata":null},{"id":"16c546d37d9d4fa684636751cab01835","type":"GO_TERM","name":"IAA-Leu conjugate hydrolase activity","canonical_id":"go:GO:0010211","description":"\"Catalysis of the reaction: indole-3-acetyl-leucine + H2O = indole-3-acetate + L-leucine.\" [MetaCyc:RXN-2982]","metadata":null},{"id":"aa3772a5342c4ad380f6c70a4b9f86fd","type":"GO_TERM","name":"IAA-Phe conjugate hydrolase activity","canonical_id":"go:GO:0010210","description":"\"Catalysis of the reaction: indole-3-acetyl-phenylalanine + H2O = indole-3-acetate + phenylalanine.\" [GOC:syr]","metadata":null},{"id":"21e24c531c384074b113e67658d9fe16","type":"GO_TERM","name":"IAA-amino acid conjugate hydrolase activity","canonical_id":"go:GO:0010178","description":"\"Catalysis of the cleavage of the amide bond between IAA (auxin) and the conjugated amino acid.\" [GOC:tb]","metadata":null},{"id":"9a4803afa74c49c2b0903c7e8ad0dfbb","type":"TRIAL","name":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05039801","description":"Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic St\u2026","metadata":null},{"id":"11b29c1753b041faa3992ddd2d632d7f","type":"GENE","name":"IADEN","canonical_id":"hgnc:HGNC:56877","description":"IGF2BP1 associated definitive endoderm lncRNA","metadata":{"aliases":["HIDEN"]}},{"id":"91766c14e951418b9b59713678bfcf3e","type":"GENE","name":"IAH1","canonical_id":"hgnc:HGNC:27696","description":"isoamyl acetate hydrolyzing esterase 1 (putative)","metadata":null},{"id":"8ab669c0d55a4a48bb2c751ef4497361","type":"GENE","name":"IAPP","canonical_id":"hgnc:HGNC:5329","description":null,"metadata":null},{"id":"9aaf311552644895b522b17001bca97d","type":"GENE","name":"IARS1","canonical_id":"hgnc:HGNC:5330","description":"isoleucyl-tRNA synthetase 1","metadata":{"aliases":["ILRS","IARS"]}},{"id":"e5c23c2bd26548a3a94e5de35ccfb554","type":"GENE","name":"IARS2","canonical_id":"hgnc:HGNC:29685","description":"isoleucyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["FLJ10326"]}},{"id":"2b282e621d6c43f18f71289e84f42ad8","type":"GENE","name":"IARS2P1","canonical_id":"hgnc:HGNC:50474","description":"IARS2 pseudogene 1","metadata":null},{"id":"abd6b35c574746b38b46cb402b8babee","type":"GENE","name":"IATPR","canonical_id":"hgnc:HGNC:53719","description":"ITGB1 adjacent tumor promoting lncRNA","metadata":{"aliases":["TCONS_00018476","linc-ITGB1"]}},{"id":"4225d626eb744be68fa9b5b80eec15f1","type":"GENE","name":"IBA57","canonical_id":"hgnc:HGNC:27302","description":"iron-sulfur cluster assembly factor IBA57","metadata":{"aliases":["FLJ12734","C1orf69"]}},{"id":"4ca06f6b1dff4aef9ba35683e6795abf","type":"GENE","name":"IBA57-DT","canonical_id":"hgnc:HGNC:32062","description":"IBA57 divergent transcript","metadata":{"aliases":["FLJ32878","C1orf148","IBA57-AS1"]}},{"id":"fecd798a8c5a42fbba7a72b016568236","type":"TRIAL","name":"IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease","canonical_id":"clinicaltrials.gov:NCT04849325","description":"Critical Limb Ischemia (CLI)","metadata":null},{"id":"3bb0488f216a4b24838bb2b7be9c3d65","type":"GENE","name":"IBSP","canonical_id":"hgnc:HGNC:5341","description":null,"metadata":null},{"id":"b6520442b637468582741f2d804951c7","type":"GENE","name":"IBTK","canonical_id":"hgnc:HGNC:17853","description":"inhibitor of Bruton tyrosine kinase","metadata":{"aliases":["DKFZP564B116","BTBD26","BTKI"]}},{"id":"5ba59cd50cb343cc91e1572a53d7497b","type":"GENE","name":"IBTKP1","canonical_id":"hgnc:HGNC:31672","description":"inhibitor of Bruton tyrosine kinase pseudogene 1","metadata":null},{"id":"35e7b8380c714228a1251697d0f34d7f","type":"GENE","name":"ICA1","canonical_id":"hgnc:HGNC:5343","description":"islet cell autoantigen 1","metadata":{"aliases":["ICAp69","ICA69"]}},{"id":"9ae0ba482b5b42c79de145cd155c53ab","type":"GENE","name":"ICA1-AS1","canonical_id":"hgnc:HGNC:55606","description":"ICA1 antisense RNA 1","metadata":null},{"id":"59e9a0a968a14eb39512fec167ccf0b8","type":"GENE","name":"ICA1L","canonical_id":"hgnc:HGNC:14442","description":"islet cell autoantigen 1 like","metadata":{"aliases":["ALS2CR15","ALS2CR14"]}},{"id":"ea9ec4d9fa7e425baa165720e24811b8","type":"GENE","name":"ICAM1","canonical_id":"hgnc:HGNC:5344","description":null,"metadata":null},{"id":"ec11e769723d4f82b995a4324b567580","type":"GENE","name":"ICAM2","canonical_id":"hgnc:HGNC:5345","description":null,"metadata":null},{"id":"63811992ec9b4d3b9ad2a540de0ec589","type":"GENE","name":"ICAM3","canonical_id":"hgnc:HGNC:5346","description":null,"metadata":null},{"id":"5c1556529a8347789b37ff6ce1573c84","type":"GENE","name":"ICAM4","canonical_id":"hgnc:HGNC:5347","description":"intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)","metadata":{"aliases":["CD242","LW"]}},{"id":"0f602f1022ef4a9fa371b414986a65cc","type":"GENE","name":"ICAM4-AS1","canonical_id":"hgnc:HGNC:55990","description":"ICAM4 antisense RNA 1","metadata":{"aliases":["LncRNA-ECM","ICR","AC011511.5"]}},{"id":"fc07eb8224504732afc85b1f0dea9752","type":"GENE","name":"ICAM5","canonical_id":"hgnc:HGNC:5348","description":"intercellular adhesion molecule 5","metadata":{"aliases":["TLN","TLCN"]}},{"id":"1f02073cf89c4e31baef2c4331882669","type":"TRIAL","name":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","canonical_id":"clinicaltrials.gov:NCT06321081","description":"RAS Mutation; Metastatic Colorectal Cancer; MSS","metadata":null},{"id":"829f52dc95284c8786e4605aa4d00e94","type":"GENE","name":"ICE1","canonical_id":"hgnc:HGNC:29154","description":"interactor of little elongation complex ELL subunit 1","metadata":{"aliases":["KIAA0947"]}},{"id":"e0db5e5d1fb84ac38a82a70a8100be9e","type":"GENE","name":"ICE1-DT","canonical_id":"hgnc:HGNC:58997","description":"ICE1 divergent transcript","metadata":null},{"id":"0af0b755a7234f7fbefe88092f8bde5b","type":"GENE","name":"ICE2","canonical_id":"hgnc:HGNC:29885","description":"interactor of little elongation complex ELL subunit 2","metadata":{"aliases":["FLJ11896","BRCC1","NARG2"]}},{"id":"3082f2ecbb0f40738e7dc27f364dadc3","type":"GENE","name":"ICE2P1","canonical_id":"hgnc:HGNC:48856","description":"interactor of little elongation complex ELL subunit 2 pseudogene 1","metadata":{"aliases":["NARG2P1"]}},{"id":"920700c9afac46bc923bc91984a235e3","type":"GENE","name":"ICE2P2","canonical_id":"hgnc:HGNC:48857","description":"interactor of little elongation complex ELL subunit 2 pseudogene 2","metadata":{"aliases":["NARG2P2"]}},{"id":"9b7b468d3cbc4da68d94fdaf078d4637","type":"TRIAL","name":"ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00010153","description":"Breast Cancer","metadata":null},{"id":"a33f6392b4c047f8aadbe5adb1ea08b0","type":"GENE","name":"ICMT","canonical_id":"hgnc:HGNC:5350","description":"isoprenylcysteine carboxyl methyltransferase","metadata":{"aliases":["PCCMT","HSTE14","PPMT"]}},{"id":"2c771a80b90345cf864aa692438268d6","type":"GENE","name":"ICMT-DT","canonical_id":"hgnc:HGNC:28620","description":"ICMT divergent transcript","metadata":{"aliases":["MGC40168","C1orf211","NCRNA00337","LINC00337"]}},{"id":"6d2da0c04f4a4cd2865ce362bddf92aa","type":"GENE","name":"ICOS","canonical_id":"hgnc:HGNC:5351","description":"inducible T cell costimulator","metadata":{"aliases":["AILIM","CD278"]}},{"id":"f68b92bec34b4d6493850769ef65f51d","type":"GENE","name":"ICOSLG","canonical_id":"hgnc:HGNC:17087","description":"inducible T cell costimulator ligand","metadata":{"aliases":["KIAA0653","GL50","B7-H2","B7RP-1","B7H2","B7RP1","ICOS-L","CD275","B7h","ICOSL"]}},{"id":"6b80760612304b138659c267ef77ceac","type":"GENE","name":"ID1","canonical_id":"hgnc:HGNC:5360","description":null,"metadata":null},{"id":"7d09f77dd6b1425c94d39903f40a0ab8","type":"GENE","name":"ID2","canonical_id":"hgnc:HGNC:5361","description":null,"metadata":null},{"id":"03f2316c1fc748c3a6207c435bf5d7b9","type":"GENE","name":"ID2-AS1","canonical_id":"hgnc:HGNC:51103","description":"ID2 antisense RNA 1","metadata":null},{"id":"2657db3059394971988be0d4bd2439ea","type":"GENE","name":"ID2B","canonical_id":"hgnc:HGNC:30656","description":"inhibitor of DNA binding 2B (pseudogene)","metadata":null},{"id":"183998a25a6b4db3b503da0409f5824e","type":"GENE","name":"ID3","canonical_id":"hgnc:HGNC:5362","description":null,"metadata":null},{"id":"99ebd480e9e54d70998935df1702c664","type":"GENE","name":"ID4","canonical_id":"hgnc:HGNC:5363","description":null,"metadata":null},{"id":"7da0a9ac201d435680a48ac720dd4dca","type":"GENE","name":"IDE","canonical_id":"hgnc:HGNC:5381","description":null,"metadata":null},{"id":"72aaad14d7f4423e961a11d18f785512","type":"TRIAL","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","canonical_id":"clinicaltrials.gov:NCT05987332","description":"Metastatic Uveal Melanoma","metadata":null},{"id":"76931463fa6b467580911b631abc3759","type":"TRIAL","name":"IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs","canonical_id":"clinicaltrials.gov:NCT00128518","description":"Hypertension","metadata":null},{"id":"d65b100f68524c61b567783ec5e0fc9a","type":"TRIAL","name":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","canonical_id":"clinicaltrials.gov:NCT05401097","description":"Acute Myeloid Leukemia","metadata":null},{"id":"4eb8ea89b8b0487da754f41dddba7ed9","type":"GENE","name":"IDH1","canonical_id":"hgnc:HGNC:5382","description":"isocitrate dehydrogenase (NADP(+)) 1","metadata":null},{"id":"89b49053c05f4b5e978c5d8532e1df7d","type":"GENE","name":"IDH1","canonical_id":"ensembl:ENSG00000138413","description":null,"metadata":null},{"id":"a2f495e07984445084f3fb44ef34ab73","type":"PROTEIN","name":"IDH1","canonical_id":"uniprot:O75874","description":null,"metadata":null},{"id":"1d6384eec5dc4d289fcb938f1d84040b","type":"TRIAL","name":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT03564821","description":"IDH1 Mutation Myeloid Neoplasms","metadata":null},{"id":"9ecede92e1654e20b912cf506b7cefe9","type":"GENE","name":"IDH1-AS1","canonical_id":"hgnc:HGNC:40292","description":"IDH1 antisense RNA 1","metadata":{"aliases":["IADMP"]}},{"id":"741b7b6b82bb495aab6f460d43a81c49","type":"GENE","name":"IDH1P1","canonical_id":"hgnc:HGNC:56900","description":"IDH1 pseudogene 1","metadata":null},{"id":"19f9b52b2ba14d56abfee1dc9c5148ce","type":"GENE","name":"IDH2","canonical_id":"hgnc:HGNC:5383","description":"isocitrate dehydrogenase (NADP(+)) 2","metadata":{"aliases":["IDH-2"]}},{"id":"768d95091d3440d39cb5a5e7170d223b","type":"GENE","name":"IDH2","canonical_id":"ensembl:ENSG00000182054","description":null,"metadata":null},{"id":"77a5e2d580904214a955396c426c941e","type":"GENE","name":"IDH2-DT","canonical_id":"hgnc:HGNC:53154","description":"IDH2 divergent transcript","metadata":null},{"id":"e22eecdf43ee4993869ecab09e770fc0","type":"GENE","name":"IDH3A","canonical_id":"hgnc:HGNC:5384","description":"isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha","metadata":null},{"id":"8e05dec3927c4db0822f23f859198795","type":"GENE","name":"IDH3B","canonical_id":"hgnc:HGNC:5385","description":"isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta","metadata":{"aliases":["RP46"]}},{"id":"10772ca677d04cee9a619994e157e6f0","type":"GENE","name":"IDH3B-DT","canonical_id":"hgnc:HGNC:55798","description":"IDH3B divergent transcript","metadata":null},{"id":"fc92510cf757440c8f6492e87dd75685","type":"GENE","name":"IDH3G","canonical_id":"hgnc:HGNC:5386","description":"isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma","metadata":null},{"id":"daee617ac9394a379081b9b90d1a92b9","type":"GENE","name":"IDI1","canonical_id":"hgnc:HGNC:5387","description":"isopentenyl-diphosphate delta isomerase 1","metadata":null},{"id":"d721a6e3a64e457f984917bdc0b50f40","type":"GENE","name":"IDI1P1","canonical_id":"hgnc:HGNC:54666","description":"IDI1 pseudogene 1","metadata":null},{"id":"6ef2100eb22b4c69ac7d67a87716901b","type":"GENE","name":"IDI1P2","canonical_id":"hgnc:HGNC:54667","description":"IDI1 pseudogene 2","metadata":null},{"id":"f58bce665d474766b620586f1420b7fc","type":"GENE","name":"IDI1P3","canonical_id":"hgnc:HGNC:54668","description":"IDI1 pseudogene 3","metadata":null},{"id":"634709bc1c714b10872fafb1e83ec29c","type":"GENE","name":"IDI2","canonical_id":"hgnc:HGNC:23487","description":"isopentenyl-diphosphate delta isomerase 2","metadata":{"aliases":["IPPI2"]}},{"id":"274c738e1e664f46a980774996afc27e","type":"GENE","name":"IDI2-AS1","canonical_id":"hgnc:HGNC:30885","description":"IDI2 antisense RNA 1","metadata":{"aliases":["HT009","Em:AC022536.4","C10orf110","IDI2-AS"]}},{"id":"f9ef000d482545fc86a1c46e7fb0c9b5","type":"GENE","name":"IDNK","canonical_id":"hgnc:HGNC:31367","description":"IDNK gluconokinase","metadata":{"aliases":["bA522I20.2","hGntK","C9orf103"]}},{"id":"d521d8ccdb204579b0240bb4cf876ba0","type":"GENE","name":"IDO1","canonical_id":"hgnc:HGNC:6059","description":null,"metadata":null},{"id":"d30cbadcfa8e4c5484231281d83d628d","type":"GENE","name":"IDO1-AS1","canonical_id":"hgnc:HGNC:59249","description":"IDO1 antisense RNA 1","metadata":{"aliases":["IDO1-AS","IDO1-AS6.4","hLinfRNA7"]}},{"id":"8e7ba8e93ddf49abb69bd89ba1237a1c","type":"GENE","name":"IDO2","canonical_id":"hgnc:HGNC:27269","description":null,"metadata":null},{"id":"8174dad45a434c34be1532e3cc1de20e","type":"GO_TERM","name":"IDP biosynthetic process","canonical_id":"go:GO:0046708","description":"\"The chemical reactions and pathways resulting in the formation of IDP, inosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"36eb9af9567741ceace391d6eb80ec6e","type":"GO_TERM","name":"IDP catabolic process","canonical_id":"go:GO:0046709","description":"\"The chemical reactions and pathways resulting in the breakdown of IDP, inosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"7fa6ec76ecf84a69ad13fc47f7b00f28","type":"GO_TERM","name":"IDP metabolic process","canonical_id":"go:GO:0046707","description":"\"The chemical reactions and pathways involving IDP, inosine 5'-diphosphate.\" [GOC:ai]","metadata":null},{"id":"d3cb2a095f4e4cff82424d87c95d54f9","type":"GO_TERM","name":"IDP phosphatase activity","canonical_id":"go:GO:1990003","description":"\"Catalysis of the reaction: IDP + H2O = IMP + H+ + phosphate.\" [PMID:20385596, PMID:22849572, RHEA:35207]","metadata":null},{"id":"1f3a8395c020474aabf5d747a7a6b9c6","type":"TRIAL","name":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT06677710","description":"Multiple Sclerosis; Primary Progressive Multiple Sclerosis (PPMS); Secondary Progressive Multiple Sclerosis (SPMS); Non-Active Secondary Progressive Multiple Sclerosis; Non-Active SPMS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Autoimmune Diseases; Demyelinating Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, Central Nervous System (CNS)","metadata":null},{"id":"0dc94bf3159a485ea34cd983dc847835","type":"GENE","name":"IDS","canonical_id":"hgnc:HGNC:5389","description":"iduronate 2-sulfatase","metadata":{"aliases":["ID2S","SIDS"]}},{"id":"9db6f6de3c03466995e23ce74d26e632","type":"GENE","name":"IDSP1","canonical_id":"hgnc:HGNC:5390","description":"iduronate 2-sulfatase pseudogene 1","metadata":{"aliases":["IDS2"]}},{"id":"38b7cef84af9438d92a08238595bf397","type":"GENE","name":"IDUA","canonical_id":"hgnc:HGNC:5391","description":"alpha-L-iduronidase","metadata":{"aliases":["MPS1","MPSI"]}},{"id":"93eff0d9bf134d8786da072aa6f7f607","type":"TRIAL","name":"IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03981900","description":"Arthritis, Rheumatoid","metadata":null},{"id":"2a67de75adb842b28726795fedbf8dcd","type":"GENE","name":"IER2","canonical_id":"hgnc:HGNC:28871","description":"immediate early response 2","metadata":{"aliases":["ETR101"]}},{"id":"17c6a46ebb50493abaa1e944a50039a1","type":"GENE","name":"IER2-AS1","canonical_id":"hgnc:HGNC:58207","description":"IER2 antisense RNA 1","metadata":null},{"id":"2b5e607977f04c2c8023790998c0e6b2","type":"GENE","name":"IER3","canonical_id":"hgnc:HGNC:5392","description":null,"metadata":null},{"id":"6801d214c4b548bf99841ffd7e96454b","type":"GENE","name":"IER3-AS1","canonical_id":"hgnc:HGNC:53629","description":"IER3 antisense RNA 1","metadata":null},{"id":"d2bb67fe9b6549148be2150961d95903","type":"GENE","name":"IER3IP1","canonical_id":"hgnc:HGNC:18550","description":"immediate early response 3 interacting protein 1","metadata":null},{"id":"d3473979f14c4a90afd1befbb169f47f","type":"GENE","name":"IER5","canonical_id":"hgnc:HGNC:5393","description":"immediate early response 5","metadata":null},{"id":"b7499cb620044dbfbbd66d361bbc034a","type":"GENE","name":"IER5L","canonical_id":"hgnc:HGNC:23679","description":"immediate early response 5 like","metadata":{"aliases":["bA247A12.2"]}},{"id":"5319997be58b4f97ad385ed3752a79cf","type":"GENE","name":"IER5L-AS1","canonical_id":"hgnc:HGNC:55825","description":"IER5L antisense RNA 1","metadata":null},{"id":"85e5f9a6cbcb41d18c981dd40cc6cd75","type":"GENE","name":"IFFO1","canonical_id":"hgnc:HGNC:24970","description":"intermediate filament family orphan 1","metadata":{"aliases":["HOM-TES-103","IFFO"]}},{"id":"c284ce8b20c8499695ab36d1620d8553","type":"GENE","name":"IFFO2","canonical_id":"hgnc:HGNC:27006","description":"intermediate filament family orphan 2","metadata":null},{"id":"1c0f7978452f46da93eafc50e1bbaeab","type":"GENE","name":"IFI16","canonical_id":"hgnc:HGNC:5395","description":null,"metadata":null},{"id":"0fe3439589ef4286989cab1c7842a806","type":"GENE","name":"IFI27","canonical_id":"hgnc:HGNC:5397","description":"interferon alpha inducible protein 27","metadata":{"aliases":["P27","FAM14D","ISG12"]}},{"id":"ed8c850dfe0f464fb3f9c957c4375b41","type":"GENE","name":"IFI27L1","canonical_id":"hgnc:HGNC:19754","description":"interferon alpha inducible protein 27 like 1","metadata":{"aliases":["FAM14B"]}},{"id":"1c0d97ad681742c2800791cd92d9e67e","type":"GENE","name":"IFI27L2","canonical_id":"hgnc:HGNC:19753","description":"interferon alpha inducible protein 27 like 2","metadata":{"aliases":["TLH29","FAM14A"]}},{"id":"0c25dc164fae4166ab9b6ae74dadac99","type":"GENE","name":"IFI30","canonical_id":"hgnc:HGNC:5398","description":"IFI30 lysosomal thiol reductase","metadata":{"aliases":["IFI-30","GILT","IP30","MGC32056","IP-30"]}},{"id":"6821763491d64140a9310a0e1951e6b6","type":"GENE","name":"IFI35","canonical_id":"hgnc:HGNC:5399","description":"interferon induced protein 35","metadata":{"aliases":["IFP35"]}},{"id":"b61256bdd2d745a0801a15aad08efe8d","type":"GENE","name":"IFI44","canonical_id":"hgnc:HGNC:16938","description":"interferon induced protein 44","metadata":{"aliases":["MTAP44","p44","TLDC5"]}},{"id":"f6ec3fae5633420289262e51220a4eda","type":"GENE","name":"IFI44L","canonical_id":"hgnc:HGNC:17817","description":"interferon induced protein 44 like","metadata":{"aliases":["GS3686","TLDC5B","C1orf29"]}},{"id":"a5e2dd0ec7234ca7891ee87aa2005b81","type":"GENE","name":"IFI6","canonical_id":"hgnc:HGNC:4054","description":"interferon alpha inducible protein 6","metadata":{"aliases":["IFI616","FAM14C","6-16","IFI-6-16","G1P3"]}},{"id":"c39164161f00480986ed9a6470a5adea","type":"GENE","name":"IFIH1","canonical_id":"hgnc:HGNC:18873","description":"interferon induced with helicase C domain 1","metadata":{"aliases":["MDA-5","Hlcd","MDA5","IDDM19"]}},{"id":"16e17f6fbf6741d2bcc1ba0955f26f1a","type":"GENE","name":"IFIT1","canonical_id":"hgnc:HGNC:5407","description":"interferon induced protein with tetratricopeptide repeats 1","metadata":{"aliases":["GARG-16","ISG56","G10P1","IFI56","IFNAI1"]}},{"id":"c1114ea3670d48e1bf4294da7e3aa584","type":"GENE","name":"IFIT1B","canonical_id":"hgnc:HGNC:23442","description":"interferon induced protein with tetratricopeptide repeats 1B","metadata":{"aliases":["bA149I23.6","IFIT1L"]}},{"id":"568f8fb7ef2c4d9abef3d9afd4ff69dd","type":"GENE","name":"IFIT1P1","canonical_id":"hgnc:HGNC:5408","description":"interferon induced protein with tetratricopeptide repeats 1 pseudogene 1","metadata":{"aliases":["II56P","G13P1","IFI56P","IFIT1P"]}},{"id":"4afd4fd1a1e24411a6272c33abf8f547","type":"GENE","name":"IFIT2","canonical_id":"hgnc:HGNC:5409","description":"interferon induced protein with tetratricopeptide repeats 2","metadata":{"aliases":["IFI-54","ISG-54K","ISG-54","cig42","GARG-39","IFI54","G10P2"]}},{"id":"441854ffbe8f4010a292384e2f521cc0","type":"GENE","name":"IFIT3","canonical_id":"hgnc:HGNC:5411","description":null,"metadata":null},{"id":"9448d58dda4b4dcea3262cf785bf93e6","type":"GENE","name":"IFIT5","canonical_id":"hgnc:HGNC:13328","description":"interferon induced protein with tetratricopeptide repeats 5","metadata":{"aliases":["RI58"]}},{"id":"1c9955de430142ab8089de5216310ccf","type":"GENE","name":"IFIT6P","canonical_id":"hgnc:HGNC:38020","description":"interferon induced protein with tetratricopeptide repeats 6, pseudogene","metadata":null},{"id":"bc4e8d6522df4021aab286c609511e14","type":"GENE","name":"IFITM1","canonical_id":"hgnc:HGNC:5412","description":"interferon induced transmembrane protein 1","metadata":{"aliases":["9-27","CD225","DSPA2a","IFI17"]}},{"id":"ff13ae68391643b1af3dcc2cca5475a8","type":"GENE","name":"IFITM10","canonical_id":"hgnc:HGNC:40022","description":"interferon induced transmembrane protein 10","metadata":{"aliases":["DSPA3"]}},{"id":"0488e42626694864962d307ad8a18f66","type":"GENE","name":"IFITM2","canonical_id":"hgnc:HGNC:5413","description":"interferon induced transmembrane protein 2","metadata":{"aliases":["1-8D","DSPA2c"]}},{"id":"4045bab6fe5149ca84292bf4722e52d3","type":"GENE","name":"IFITM3","canonical_id":"hgnc:HGNC:5414","description":null,"metadata":null},{"id":"6e956072748c4879a3dd2cc2595eee75","type":"GENE","name":"IFITM3-AS1","canonical_id":"hgnc:HGNC:58185","description":"IFITM3 antisense RNA 1","metadata":null},{"id":"9700a9fd328d48608000936be8009ef3","type":"GENE","name":"IFITM3P1","canonical_id":"hgnc:HGNC:54538","description":"IFITM3 pseudogene 1","metadata":null},{"id":"d8e81ecd74f04b728f691a375bd49915","type":"GENE","name":"IFITM3P2","canonical_id":"hgnc:HGNC:54539","description":"IFITM3 pseudogene 2","metadata":{"aliases":["DSPA2D"]}},{"id":"c9a2206e6ea84486b423cca9df3ea177","type":"GENE","name":"IFITM3P3","canonical_id":"hgnc:HGNC:54541","description":"IFITM3 pseudogene 3","metadata":null},{"id":"f491d8702e504f06be70e395f90ab1a2","type":"GENE","name":"IFITM3P4","canonical_id":"hgnc:HGNC:54542","description":"IFITM3 pseudogene 4","metadata":null},{"id":"5da9f08c441d4019878a7843b7eaf1ce","type":"GENE","name":"IFITM3P5","canonical_id":"hgnc:HGNC:54543","description":"IFITM3 pseudogene 5","metadata":null},{"id":"6aeb835b19d4433a97248f2ef74bdda6","type":"GENE","name":"IFITM3P6","canonical_id":"hgnc:HGNC:54545","description":"IFITM3P pseudogene 6","metadata":null},{"id":"bf1cfc0cbfaa4c0b87dd37ac5f94a074","type":"GENE","name":"IFITM3P7","canonical_id":"hgnc:HGNC:54546","description":"IFITM3 pseudogene 7","metadata":null},{"id":"3d6c83f8c31349c1ae14306d839fec0b","type":"GENE","name":"IFITM3P8","canonical_id":"hgnc:HGNC:54547","description":"IFITM3 pseudogene 8","metadata":null},{"id":"87d214e74f3440e0bff4f802ef0068b2","type":"GENE","name":"IFITM3P9","canonical_id":"hgnc:HGNC:54548","description":"IFITM3 pseudogene 9","metadata":null},{"id":"801b2f64c23e4946ae4a4c4c3126928a","type":"GENE","name":"IFITM4P","canonical_id":"hgnc:HGNC:21669","description":"interferon induced transmembrane protein 4 pseudogene","metadata":{"aliases":["dJ377H14.5"]}},{"id":"4085368ef9ae4cd3a5c44e7623485ed9","type":"GENE","name":"IFITM5","canonical_id":"hgnc:HGNC:16644","description":null,"metadata":null},{"id":"50e022e844c24578b12bcc98d019a107","type":"GENE","name":"IFITM8P","canonical_id":"hgnc:HGNC:32202","description":"interferon induced transmembrane protein 8 pseudogene","metadata":null},{"id":"717fa25c21114d67ac65efa0687f96de","type":"GENE","name":"IFITM9P","canonical_id":"hgnc:HGNC:33972","description":"interferon induced transmembrane protein 9 pseudogene","metadata":{"aliases":["lnc-MRGPRF-6"]}},{"id":"53e6aaa98a4a4736a7b2bb66c6d9095d","type":"GENE","name":"IFNA1","canonical_id":"hgnc:HGNC:5417","description":null,"metadata":null},{"id":"5b884476754f4a238ac86b3970023817","type":"GENE","name":"IFNA10","canonical_id":"hgnc:HGNC:5418","description":"interferon alpha 10","metadata":{"aliases":["IFN-alphaC"]}},{"id":"6be50fe4083a4ed1aa4ad3842b443aa5","type":"GENE","name":"IFNA11P","canonical_id":"hgnc:HGNC:5442","description":"interferon alpha 11, pseudogene","metadata":{"aliases":["IFNP11"]}},{"id":"0be992db6563495c8f44ae3cc80b60f2","type":"GENE","name":"IFNA12P","canonical_id":"hgnc:HGNC:5443","description":"interferon alpha 12, pseudogene","metadata":{"aliases":["IFNP12"]}},{"id":"d316c9799b39412483695c61404d87c2","type":"GENE","name":"IFNA13","canonical_id":"hgnc:HGNC:5419","description":null,"metadata":null},{"id":"e7a5d40d11cb4a9baa71828b1bb404cc","type":"GENE","name":"IFNA14","canonical_id":"hgnc:HGNC:5420","description":"interferon alpha 14","metadata":{"aliases":["LEIF2H","IFN-alphaH"]}},{"id":"b9e55a2924d04649b84ea2f0dc0b073b","type":"GENE","name":"IFNA16","canonical_id":"hgnc:HGNC:5421","description":"interferon alpha 16","metadata":{"aliases":["IFN-alphaO"]}},{"id":"4e19e7a4812d4c1cadbff481ced74c78","type":"GENE","name":"IFNA17","canonical_id":"hgnc:HGNC:5422","description":"interferon alpha 17","metadata":{"aliases":["LEIF2C1","IFN-alphaI"]}},{"id":"a95f40834b4e431bae9dce19031eec6c","type":"GENE","name":"IFNA2","canonical_id":"hgnc:HGNC:5423","description":null,"metadata":null},{"id":"61c882384a4648f38abe28d8a328dfb9","type":"GENE","name":"IFNA20P","canonical_id":"hgnc:HGNC:5444","description":"interferon alpha 20, pseudogene","metadata":{"aliases":["IFNP20"]}},{"id":"2bfe3767fb3c469aadc63e9c505086f4","type":"GENE","name":"IFNA21","canonical_id":"hgnc:HGNC:5424","description":"interferon alpha 21","metadata":{"aliases":["IFN-alphaI"]}},{"id":"cb2718c106294d998461746fcc2bbf6b","type":"GENE","name":"IFNA22P","canonical_id":"hgnc:HGNC:5431","description":"interferon alpha 22, pseudogene","metadata":{"aliases":["IFNAP22"]}},{"id":"0ae5c6a1e93d4b0dbe77be015b576177","type":"GENE","name":"IFNA4","canonical_id":"hgnc:HGNC:5425","description":"interferon alpha 4","metadata":{"aliases":["MGC142200","IFN-alpha4a"]}},{"id":"e532406242424e70b990bdd711c7d310","type":"GENE","name":"IFNA5","canonical_id":"hgnc:HGNC:5426","description":"interferon alpha 5","metadata":{"aliases":["IFN-alphaG"]}},{"id":"192076131c0d40e9984a4398caa8a200","type":"GENE","name":"IFNA6","canonical_id":"hgnc:HGNC:5427","description":"interferon alpha 6","metadata":{"aliases":["IFN-alphaK"]}},{"id":"ca9639a93cb54ccebbca46bb0cce113a","type":"GENE","name":"IFNA7","canonical_id":"hgnc:HGNC:5428","description":"interferon alpha 7","metadata":{"aliases":["IFNA-J","IFN-alphaJ"]}},{"id":"ce5574ff8c4f4d3386dfdbd1d59057a6","type":"GENE","name":"IFNA8","canonical_id":"hgnc:HGNC:5429","description":"interferon alpha 8","metadata":{"aliases":["IFN-alphaB"]}},{"id":"824063a86d7d4379a3bd2f36fe84336b","type":"GENE","name":"IFNAR1","canonical_id":"hgnc:HGNC:5432","description":null,"metadata":null},{"id":"aded490abb7246dd9871d76d6ce98e4f","type":"PROTEIN","name":"IFNAR1","canonical_id":"uniprot:P17181","description":null,"metadata":null},{"id":"e6dd26a2607045d79adb7384b7a45ff9","type":"GENE","name":"IFNAR2","canonical_id":"hgnc:HGNC:5433","description":"interferon alpha and beta receptor subunit 2","metadata":{"aliases":["IFNABR"]}},{"id":"99e90f95dcc64e739f41239b42fe04fa","type":"GENE","name":"IFNB1","canonical_id":"hgnc:HGNC:5434","description":null,"metadata":null},{"id":"08e8577f809f4df28886037ea082db33","type":"GENE","name":"IFNE","canonical_id":"hgnc:HGNC:18163","description":"interferon epsilon","metadata":{"aliases":["IFNE1"]}},{"id":"d16934362d854d56b5fde53874968a8e","type":"GENE","name":"IFNG","canonical_id":"hgnc:HGNC:5438","description":null,"metadata":null},{"id":"69f86e584cff43528ad842d32a3c184a","type":"PROTEIN","name":"IFNG","canonical_id":"uniprot:P01579","description":null,"metadata":null},{"id":"9b30c1e8c0474da3a5ee511c88dcd4dc","type":"GENE","name":"IFNG-AS1","canonical_id":"hgnc:HGNC:43910","description":"IFNG regulatory antisense RNA 1","metadata":{"aliases":["Tmevpg1","LincR-Ifng-3'AS","NEST"]}},{"id":"35e95679ce274ab7bd9be767cda0573e","type":"GENE","name":"IFNGR1","canonical_id":"hgnc:HGNC:5439","description":null,"metadata":null},{"id":"ad1b410821784142b2167bccdef6a7b1","type":"GENE","name":"IFNGR2","canonical_id":"hgnc:HGNC:5440","description":"interferon gamma receptor 2","metadata":{"aliases":["AF-1","IFNGT1"]}},{"id":"d5c0d1523c124b3f90f8143428943419","type":"GENE","name":"IFNK","canonical_id":"hgnc:HGNC:21714","description":"interferon kappa","metadata":null},{"id":"c40acc4d0244417ca8dc8ad38e7bae4b","type":"GENE","name":"IFNL1","canonical_id":"hgnc:HGNC:18363","description":null,"metadata":null},{"id":"ff8506e21c5a432f8fd744b4704bf818","type":"GENE","name":"IFNL2","canonical_id":"hgnc:HGNC:18364","description":null,"metadata":null},{"id":"bcd94122865b4d5dad8c9d5f8fbeed12","type":"GENE","name":"IFNL3","canonical_id":"hgnc:HGNC:18365","description":null,"metadata":null},{"id":"8ee4061c12c241b686ae6984c15bf069","type":"GENE","name":"IFNL3P1","canonical_id":"hgnc:HGNC:44483","description":"interferon lambda 3 pseudogene 1","metadata":{"aliases":["IL28BP1"]}},{"id":"6caa04aa90464850a41fd16e1b00a3df","type":"GENE","name":"IFNL4","canonical_id":"hgnc:HGNC:44480","description":"interferon lambda 4 (gene/pseudogene)","metadata":{"aliases":["IFNAN"]}},{"id":"5e62ebb8385640d2b637e373fd42e4d5","type":"GENE","name":"IFNL4P1","canonical_id":"hgnc:HGNC:45090","description":"interferon lambda 4 pseudogene 1","metadata":null},{"id":"68ad88bc3a38442eb382e785a35d0f7b","type":"GENE","name":"IFNLR1","canonical_id":"hgnc:HGNC:18584","description":null,"metadata":null},{"id":"f5dd94462ebc47ab92e77c552b118b00","type":"GENE","name":"IFNNP","canonical_id":"hgnc:HGNC:32009","description":"interferon nu, pseudogene","metadata":{"aliases":["IFNNP1"]}},{"id":"b258543130694005aa255246db40915f","type":"GENE","name":"IFNR","canonical_id":"hgnc:HGNC:5447","description":"interferon production regulator","metadata":null},{"id":"9536af9578614f18ab566dfaa7844546","type":"GENE","name":"IFNW1","canonical_id":"hgnc:HGNC:5448","description":"interferon omega 1","metadata":null},{"id":"dd677f77251941a9a690e7a86c0a997d","type":"GENE","name":"IFNWP15","canonical_id":"hgnc:HGNC:5449","description":"interferon omega 1 pseudogene 15","metadata":null},{"id":"0230f50fb390477a8821bd12b574a29c","type":"GENE","name":"IFNWP18","canonical_id":"hgnc:HGNC:5450","description":"interferon omega 1 pseudogene 18","metadata":{"aliases":["pseudo-IFN-alpha-m"]}},{"id":"871a8952875041dd8f41e17da304d10f","type":"GENE","name":"IFNWP19","canonical_id":"hgnc:HGNC:5451","description":"interferon omega 1 pseudogene 19","metadata":null},{"id":"a4f62614d36648f29a586766ffbf9921","type":"GENE","name":"IFNWP2","canonical_id":"hgnc:HGNC:5452","description":"interferon omega 1 pseudogene 2","metadata":null},{"id":"d5669a4f0c8642b78756f76de9b82a89","type":"GENE","name":"IFNWP4","canonical_id":"hgnc:HGNC:5453","description":"interferon omega 1 pseudogene 4","metadata":null},{"id":"3f35ed2e569e43cab3e311e8fb00721f","type":"GENE","name":"IFNWP5","canonical_id":"hgnc:HGNC:5454","description":"interferon omega 1 pseudogene 5","metadata":null},{"id":"9eefba1a7a1847b28f5c0f04c6f68750","type":"GENE","name":"IFNWP9","canonical_id":"hgnc:HGNC:5455","description":"interferon omega 1 pseudogene 9","metadata":null},{"id":"0e400ed3437d45b6a359e8fd7970b036","type":"GENE","name":"IFRD1","canonical_id":"hgnc:HGNC:5456","description":"interferon related developmental regulator 1","metadata":{"aliases":["PC4","TIS7"]}},{"id":"c023065fde404955af7561cb2127fcd8","type":"GENE","name":"IFRD2","canonical_id":"hgnc:HGNC:5457","description":"interferon related developmental regulator 2","metadata":{"aliases":["SKMc15","SM15","IFNRP"]}},{"id":"42c4fe6c65e846e494bad57a57f383e0","type":"GENE","name":"IFT122","canonical_id":"hgnc:HGNC:13556","description":"intraflagellar transport 122","metadata":{"aliases":["WDR140","WDR10p","SPG","FAP80","CFAP80","WDR10"]}},{"id":"bb6cf9ec07134419988f10fae19e69ab","type":"GENE","name":"IFT122P1","canonical_id":"hgnc:HGNC:56385","description":"IFT122 pseudogene 1","metadata":null},{"id":"63de6c302da240d1803506e2e173b604","type":"GENE","name":"IFT122P2","canonical_id":"hgnc:HGNC:56388","description":"IFT122 pseudogene 2","metadata":null},{"id":"7eff56ed84664be684cb51f30d77afd0","type":"GENE","name":"IFT122P3","canonical_id":"hgnc:HGNC:56389","description":"IFT122 pseudogene 3","metadata":null},{"id":"83541cbb11e549d29bdc9c68c3ec1339","type":"GENE","name":"IFT140","canonical_id":"hgnc:HGNC:29077","description":"intraflagellar transport 140","metadata":{"aliases":["gs114","KIAA0590","WDTC2"]}},{"id":"23353a3e0bee44999d4bf02743c54e6d","type":"GENE","name":"IFT172","canonical_id":"hgnc:HGNC:30391","description":"intraflagellar transport 172","metadata":{"aliases":["SLB","wim","osm-1","NPHP17","BBS20"]}},{"id":"6bdb8498fb5043dc9cb306061312e290","type":"GENE","name":"IFT20","canonical_id":"hgnc:HGNC:30989","description":"intraflagellar transport 20","metadata":null},{"id":"871440f9d7ee471980d8975e89f694c7","type":"GENE","name":"IFT22","canonical_id":"hgnc:HGNC:21895","description":"intraflagellar transport 22","metadata":{"aliases":["FLJ14117","FLJ13225","DKFZp761N0823","FAP9","CFAP9","RABL5"]}},{"id":"79cf30a5a19d438a9f72d2489524c9ee","type":"GENE","name":"IFT25","canonical_id":"hgnc:HGNC:25019","description":"intraflagellar transport 25","metadata":{"aliases":["HSPCO34","PP25","FAP232","CFAP232","C1orf41","HSPB11"]}},{"id":"9643a910e52c47f5ae0d955e6b21e3ee","type":"GENE","name":"IFT27","canonical_id":"hgnc:HGNC:18626","description":"intraflagellar transport 27","metadata":{"aliases":["RAYL","BBS19","FAP156","CFAP156","RABL4"]}},{"id":"090a8b62dc43479bbbbfd19296f1089a","type":"GENE","name":"IFT38","canonical_id":"hgnc:HGNC:19009","description":"intraflagellar transport 38","metadata":{"aliases":["FLJ13297","KIAA0643","FAP22","CFAP22","CLUAP1"]}},{"id":"8b7a9453e12e4e65a93afbfa38a0356a","type":"GENE","name":"IFT43","canonical_id":"hgnc:HGNC:29669","description":"intraflagellar transport 43","metadata":{"aliases":["FLJ32173","MGC16028","C14orf179"]}},{"id":"d15c2808bf4f44dd8d9f9b70d7461277","type":"GENE","name":"IFT46","canonical_id":"hgnc:HGNC:26146","description":"intraflagellar transport 46","metadata":{"aliases":["C11orf2","FLJ21827","FAP32","CFAP32","C11orf60"]}},{"id":"042b5475f8784f9d97bd880c4fb64def","type":"GENE","name":"IFT52","canonical_id":"hgnc:HGNC:15901","description":"intraflagellar transport 52","metadata":{"aliases":["CGI-53","NGD5","dJ1028D15.1","NGD2","C20orf9"]}},{"id":"4487852c45734ad8a63b83aba49558b5","type":"GENE","name":"IFT54","canonical_id":"hgnc:HGNC:17861","description":"intraflagellar transport 54","metadata":{"aliases":["MIP-T3","DKFZP434F124","MIPT3","FAP116","CFAP116","TRAF3IP1"]}},{"id":"6fbea57512124d0f895b6708022b51de","type":"GENE","name":"IFT56","canonical_id":"hgnc:HGNC:21882","description":"intraflagellar transport 56","metadata":{"aliases":["FLJ12571","dyf-13","DYF13","TTC26"]}},{"id":"801c28822ab6481196cb626bf757385c","type":"GENE","name":"IFT57","canonical_id":"hgnc:HGNC:17367","description":"intraflagellar transport 57","metadata":{"aliases":["FLJ10147","HIPPI","MHS4R2","ESRRBL1"]}},{"id":"cc3f2c9ee04148d3aacbb78a1c37abd5","type":"GENE","name":"IFT57P1","canonical_id":"hgnc:HGNC:56830","description":"IFT57 pseudogene 1","metadata":null},{"id":"0e9fa8724d954696a4aaab9301e6a36c","type":"GENE","name":"IFT70A","canonical_id":"hgnc:HGNC:25853","description":"intraflagellar transport 70A","metadata":{"aliases":["FLJ13946","FAP259","CFAP259","TTC30A"]}},{"id":"ac8c10b4fdc244a994c431c49163b92e","type":"GENE","name":"IFT70A-AS1","canonical_id":"hgnc:HGNC:58181","description":"IFT70A antisense RNA 1","metadata":null},{"id":"0e4b5902716848c3b120e60467bec5fc","type":"GENE","name":"IFT70B","canonical_id":"hgnc:HGNC:26425","description":"intraflagellar transport 70B","metadata":{"aliases":["FLJ30990","fleer","TTC30B"]}},{"id":"237c91a33d0d4c569c63450cf9fd97c4","type":"GENE","name":"IFT74","canonical_id":"hgnc:HGNC:21424","description":"intraflagellar transport 74","metadata":{"aliases":["CMG1","CMG-1","FLJ22621","CCDC2"]}},{"id":"ae0b4e918e5b419ea5f0558767229316","type":"GENE","name":"IFT74-AS1","canonical_id":"hgnc:HGNC:49806","description":"IFT74 antisense RNA 1","metadata":null},{"id":"cadfa0d07f6b4b95bffb7ec2fe29af44","type":"GENE","name":"IFT80","canonical_id":"hgnc:HGNC:29262","description":"intraflagellar transport 80","metadata":{"aliases":["KIAA1374","FAP167","CFAP167","WDR56"]}},{"id":"64b23d9769984fce8679fb017fe50f54","type":"GENE","name":"IFT81","canonical_id":"hgnc:HGNC:14313","description":"intraflagellar transport 81","metadata":{"aliases":["CDV-1R","MGC4027","CDV1"]}},{"id":"0d9d032170a44e52bbadad42cb834bab","type":"GENE","name":"IFT88","canonical_id":"hgnc:HGNC:20606","description":"intraflagellar transport 88","metadata":{"aliases":["hTg737","Tg737","D13S1056E","MGC26259","TTC10"]}},{"id":"903bc5d22c2b4b5ca79536bd26ea7dc1","type":"GENE","name":"IFTAP","canonical_id":"hgnc:HGNC:25142","description":"intraflagellar transport associated protein","metadata":{"aliases":["FLJ38678","HEPIS","NWC","C11orf74"]}},{"id":"a80b68c4105f41ecb3e946386990b05d","type":"GENE","name":"IFTAPP1","canonical_id":"hgnc:HGNC:59190","description":"IFTAP pseudogene 1","metadata":null},{"id":"16b53312e1834eb3b2be35be56c67368","type":"GENE","name":"IGBP1","canonical_id":"hgnc:HGNC:5461","description":"immunoglobulin binding protein 1","metadata":{"aliases":["\u03b14","IBP1"]}},{"id":"79aa830892b5467aa364bdd1b916cbcd","type":"GENE","name":"IGBP1-AS1","canonical_id":"hgnc:HGNC:40295","description":"IGBP1 antisense RNA 1","metadata":null},{"id":"7c685596834e4c489e5935008ec36577","type":"GENE","name":"IGBP1-AS2","canonical_id":"hgnc:HGNC:40294","description":"IGBP1 antisense RNA 2","metadata":null},{"id":"2550ef28521c4a4598d74176d7860ce2","type":"GENE","name":"IGBP1C","canonical_id":"hgnc:HGNC:43611","description":"IGBP1 family member C","metadata":{"aliases":["IGBP1P2"]}},{"id":"578da1763164473aaeced35040bfb43a","type":"GENE","name":"IGBP1P1","canonical_id":"hgnc:HGNC:19709","description":"IGBP1 pseudogene 1","metadata":{"aliases":["C14orf19"]}},{"id":"76a71188d20e4975b056ef95edfb94ae","type":"GENE","name":"IGBP1P3","canonical_id":"hgnc:HGNC:43612","description":"IGBP1 pseudogene 3","metadata":null},{"id":"7f72cc0b0a7b472a94d79204dbae2696","type":"GENE","name":"IGBP1P4","canonical_id":"hgnc:HGNC:43613","description":"IGBP1 pseudogene 4","metadata":null},{"id":"4f314bafefa749c696a1edc0d1ee4dd9","type":"GENE","name":"IGBP1P5","canonical_id":"hgnc:HGNC:43614","description":"IGBP1 pseudogene 5","metadata":null},{"id":"dcb7952e6a4d4d72a36192ccec8f9e98","type":"GENE","name":"IGDCC3","canonical_id":"hgnc:HGNC:9700","description":"immunoglobulin superfamily DCC subclass member 3","metadata":{"aliases":["HsT18880","PUNC"]}},{"id":"8c2782dbb91b4aee93156b3d2e04ca5f","type":"GENE","name":"IGDCC4","canonical_id":"hgnc:HGNC:13770","description":"immunoglobulin superfamily DCC subclass member 4","metadata":{"aliases":["NOPE","LOC57722"]}},{"id":"4c599124b07c4ffd9e9e7ba39ef1e364","type":"TRIAL","name":"IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus","canonical_id":"clinicaltrials.gov:NCT01234974","description":"Multiple Myeloma","metadata":null},{"id":"69c15d3df6d74f4bb4ba20ecbf7d38e3","type":"GENE","name":"IGF1","canonical_id":"hgnc:HGNC:5464","description":null,"metadata":null},{"id":"3bbd63f439dc4757bf7f97cf368faded","type":"GENE","name":"IGF1R","canonical_id":"hgnc:HGNC:5465","description":null,"metadata":null},{"id":"adf5194b3e96421eaaffb911da21f5b7","type":"PROTEIN","name":"IGF1R","canonical_id":"uniprot:P08069","description":null,"metadata":null},{"id":"12577748252a427e9aa723a351374cb4","type":"GENE","name":"IGF1R-AS2","canonical_id":"hgnc:HGNC:58474","description":"IGF1R antisense RNA 2","metadata":null},{"id":"9f12e35cd8ee4128b8b9bc00ad7a63f3","type":"GENE","name":"IGF2","canonical_id":"hgnc:HGNC:5466","description":null,"metadata":null},{"id":"21039d3cc05542ff8e53b46fb6bdee3f","type":"GENE","name":"IGF2-AS","canonical_id":"hgnc:HGNC:14062","description":"IGF2 antisense RNA","metadata":{"aliases":["PEG8","IGF2-AS1","IGF2AS"]}},{"id":"f0da3293db0f48d89ce423bffa2c5d68","type":"GENE","name":"IGF2BP1","canonical_id":"hgnc:HGNC:28866","description":null,"metadata":null},{"id":"0e3a0cfbd74e4f1e847b60f741066aba","type":"GENE","name":"IGF2BP2","canonical_id":"hgnc:HGNC:28867","description":null,"metadata":null},{"id":"160599e68c8d420281d567540cae39bc","type":"GENE","name":"IGF2BP2-AS1","canonical_id":"hgnc:HGNC:32674","description":"IGF2BP2 antisense RNA 1","metadata":{"aliases":["FLJ32900","C3orf65"]}},{"id":"a3df436ba13e4b26aa705f7f237a9f77","type":"GENE","name":"IGF2BP2P1","canonical_id":"hgnc:HGNC:58593","description":"IGF2BP2 pseudogene 1","metadata":null},{"id":"455401c122d64de48207f49cadfac7d1","type":"GENE","name":"IGF2BP2P2","canonical_id":"hgnc:HGNC:58594","description":"IGF2BP2 pseudogene 2","metadata":null},{"id":"1755a0fbe82e41afb6dd487c89889bfa","type":"GENE","name":"IGF2BP2P3","canonical_id":"hgnc:HGNC:58595","description":"IGF2BP2 pseudogene 3","metadata":null},{"id":"5b5fbf6dc9e648f5936c7ef48f458393","type":"GENE","name":"IGF2BP3","canonical_id":"hgnc:HGNC:28868","description":"insulin like growth factor 2 mRNA binding protein 3","metadata":{"aliases":["IMP-3","CT98","IMP3"]}},{"id":"76856ce6a987465bb42fe29b20434616","type":"GENE","name":"IGF2BP3P1","canonical_id":"hgnc:HGNC:58596","description":"IGF2BP3 pseudogene 1","metadata":null},{"id":"48600be671954a3cb82813ba547c059d","type":"GENE","name":"IGF2BP3P2","canonical_id":"hgnc:HGNC:58597","description":"IGF2BP3 pseudogene 2","metadata":null},{"id":"0ab3b87858fb4178b1eb82ea8dbd1fc4","type":"GENE","name":"IGF2R","canonical_id":"hgnc:HGNC:5467","description":null,"metadata":null},{"id":"caeead43a6344c649ba934e6f9506895","type":"GENE","name":"IGFALS","canonical_id":"hgnc:HGNC:5468","description":"insulin like growth factor binding protein acid labile subunit","metadata":{"aliases":["ALS"]}},{"id":"22d62129bd994dbf8a12bac41324527e","type":"GENE","name":"IGFBP-AS1","canonical_id":"hgnc:HGNC:55655","description":"IGFBP5 antisense RNA 1","metadata":null},{"id":"b18926abd0da41dd871ac3fe80cd9233","type":"GENE","name":"IGFBP1","canonical_id":"hgnc:HGNC:5469","description":null,"metadata":null},{"id":"5a1209c3eebf41e7a2abaf9df6c46569","type":"GENE","name":"IGFBP2","canonical_id":"hgnc:HGNC:5471","description":"insulin like growth factor binding protein 2","metadata":{"aliases":["IBP2"]}},{"id":"5cbe2a9135bd4fbb82962b1cdb2a6d95","type":"GENE","name":"IGFBP3","canonical_id":"hgnc:HGNC:5472","description":null,"metadata":null},{"id":"68ac844695944ae086fa1bda14c5dc6a","type":"GENE","name":"IGFBP4","canonical_id":"hgnc:HGNC:5473","description":null,"metadata":null},{"id":"36a9d2e46beb48fdb95f35d98a499849","type":"GENE","name":"IGFBP5","canonical_id":"hgnc:HGNC:5474","description":null,"metadata":null},{"id":"317f7773b5674e8d92103585dcd5ba6d","type":"GENE","name":"IGFBP6","canonical_id":"hgnc:HGNC:5475","description":"insulin like growth factor binding protein 6","metadata":null},{"id":"0eae1e31185a4fb3a3fc99e55812d3bd","type":"GENE","name":"IGFBP7","canonical_id":"hgnc:HGNC:5476","description":"insulin like growth factor binding protein 7","metadata":{"aliases":["MAC25","IGFBP-7","PSF","FSTL2"]}},{"id":"4ad04f8c1f9843b2bc6e652c59bb5015","type":"GENE","name":"IGFBP7-AS1","canonical_id":"hgnc:HGNC:40296","description":"IGFBP7 antisense RNA 1","metadata":null},{"id":"e73c8a4e124147768ac090e7914f1f99","type":"GENE","name":"IGFBPL1","canonical_id":"hgnc:HGNC:20081","description":"insulin like growth factor binding protein like 1","metadata":{"aliases":["bA113O24.1"]}},{"id":"1674c849b1ab46ceb0c2a358c9d99e95","type":"GENE","name":"IGFL1","canonical_id":"hgnc:HGNC:24093","description":"IGF like family member 1","metadata":{"aliases":["UNQ644"]}},{"id":"d5c596ff68484328942745a013ea00ff","type":"GENE","name":"IGFL1P1","canonical_id":"hgnc:HGNC:32956","description":"IGF like family member 1 pseudogene 1","metadata":{"aliases":["IGFL-5P"]}},{"id":"a62ba82821de474aaf45bc1b9237daca","type":"GENE","name":"IGFL1P2","canonical_id":"hgnc:HGNC:32957","description":"IGF like family member 1 pseudogene 2","metadata":{"aliases":["IGFL-6P"]}},{"id":"061a8ac2f73a4e7ea229f2f2bcdccdf1","type":"GENE","name":"IGFL2","canonical_id":"hgnc:HGNC:32929","description":"IGF like family member 2","metadata":{"aliases":["UNQ645"]}},{"id":"75cd62b35c5442558778e5285ed13cb8","type":"GENE","name":"IGFL2-AS1","canonical_id":"hgnc:HGNC:52559","description":"IGFL2 antisense RNA 1","metadata":{"aliases":["AC006262.5"]}},{"id":"7af07af473e7472aa3b153ee6f1df780","type":"GENE","name":"IGFL3","canonical_id":"hgnc:HGNC:32930","description":"IGF like family member 3","metadata":{"aliases":["UNQ483"]}},{"id":"482e460d0f654274b6eafc878df7d583","type":"GENE","name":"IGFL4","canonical_id":"hgnc:HGNC:32931","description":"IGF like family member 4","metadata":null},{"id":"4ca1ce701969465f8c207d5724469427","type":"GENE","name":"IGFLR1","canonical_id":"hgnc:HGNC:23620","description":"IGF like family receptor 1","metadata":{"aliases":["FLJ22573","U2AF1L4","TMEM149"]}},{"id":"1f2e2f419e4945feab068beb7b47204e","type":"GENE","name":"IGFN1","canonical_id":"hgnc:HGNC:24607","description":"immunoglobulin like and fibronectin type III domain containing 1","metadata":{"aliases":["DKFZp434B1231","EEF1A2BP1"]}},{"id":"36c0d937ff4449d7a84d5ff57fe903a4","type":"GENE","name":"IGH","canonical_id":"hgnc:HGNC:5477","description":null,"metadata":null},{"id":"7a2f20583aba48ca94f4ddd83528433b","type":"GENE","name":"IGHA1","canonical_id":"hgnc:HGNC:5478","description":"immunoglobulin heavy constant alpha 1","metadata":{"aliases":["AL928768.3"]}},{"id":"7b64adb33e61416cb94ec0170049ef37","type":"GENE","name":"IGHA2","canonical_id":"hgnc:HGNC:5479","description":"immunoglobulin heavy constant alpha 2 (A2m marker)","metadata":null},{"id":"d4284916b56641f88af1d25503b36835","type":"GENE","name":"IGHD","canonical_id":"hgnc:HGNC:5480","description":"immunoglobulin heavy constant delta","metadata":{"aliases":["FLJ00382","FLJ46727","MGC29633"]}},{"id":"485a4e971ef94792a12e2b5ce47e1458","type":"GENE","name":"IGHD1-1","canonical_id":"hgnc:HGNC:5482","description":"immunoglobulin heavy diversity 1-1","metadata":{"aliases":["IGHD11"]}},{"id":"ded2f3dc006a4357a9397937abbcf195","type":"GENE","name":"IGHD1-14","canonical_id":"hgnc:HGNC:5483","description":"immunoglobulin heavy diversity 1-14 (non-functional)","metadata":{"aliases":["IGHD114","DM2"]}},{"id":"0048fc1197364b9f850dc76140e8afc0","type":"GENE","name":"IGHD1-20","canonical_id":"hgnc:HGNC:5484","description":"immunoglobulin heavy diversity 1-20","metadata":{"aliases":["IGHD120"]}},{"id":"624d169aca414c64a82c21c052478869","type":"GENE","name":"IGHD1-26","canonical_id":"hgnc:HGNC:5485","description":"immunoglobulin heavy diversity 1-26","metadata":{"aliases":["IGHD126"]}},{"id":"b0f475f9b6684cfc893b52589d07993e","type":"GENE","name":"IGHD1-7","canonical_id":"hgnc:HGNC:5486","description":"immunoglobulin heavy diversity 1-7","metadata":{"aliases":["DM1","IGHD17"]}},{"id":"7fdbd815608d4a329fcaa12a98b5953e","type":"GENE","name":"IGHD1OR15-1A","canonical_id":"hgnc:HGNC:5487","description":"immunoglobulin heavy diversity 1/OR15-1A (non-functional)","metadata":{"aliases":["IGHD1/OR15-1A","IGHD1OR151A"]}},{"id":"09f78aa77625455cbfec2ba4a3bbed5a","type":"GENE","name":"IGHD1OR15-1B","canonical_id":"hgnc:HGNC:5488","description":"immunoglobulin heavy diversity 1/OR15-1B (non-functional)","metadata":{"aliases":["IGHD1/OR15-1B","IGHD1OR151B"]}},{"id":"edc4ad8679d74038bbc3400c77c53437","type":"GENE","name":"IGHD2-15","canonical_id":"hgnc:HGNC:5489","description":"immunoglobulin heavy diversity 2-15","metadata":{"aliases":["IGHD215","D2"]}},{"id":"1b1aaf575b264f139d7e5a3e80670fec","type":"GENE","name":"IGHD2-2","canonical_id":"hgnc:HGNC:5490","description":"immunoglobulin heavy diversity 2-2","metadata":{"aliases":["IGHD22"]}},{"id":"5cb6004415ea40efacb4877d02977e92","type":"GENE","name":"IGHD2-21","canonical_id":"hgnc:HGNC:5491","description":"immunoglobulin heavy diversity 2-21","metadata":{"aliases":["IGHD221"]}},{"id":"d7364586139344019bb7027f4cfe4d99","type":"GENE","name":"IGHD2-8","canonical_id":"hgnc:HGNC:5492","description":"immunoglobulin heavy diversity 2-8","metadata":{"aliases":["IGHD28","DLR1"]}},{"id":"7edf6c8ff1094cc08f55a07df50f54a9","type":"GENE","name":"IGHD2OR15-2A","canonical_id":"hgnc:HGNC:5493","description":"immunoglobulin heavy diversity 2/OR15-2A (non-functional)","metadata":{"aliases":["IGHD2/OR15-2A","IGHD2OR152A"]}},{"id":"1f36c09ea07e4685b9343257ff1eb1f7","type":"GENE","name":"IGHD2OR15-2B","canonical_id":"hgnc:HGNC:5494","description":"immunoglobulin heavy diversity 2/OR15-2B (non-functional)","metadata":{"aliases":["IGHD2/OR15-2B","IGHD2OR152B"]}},{"id":"471f5aedbe6b4813a5ca2837849dc1a7","type":"GENE","name":"IGHD3-10","canonical_id":"hgnc:HGNC:5495","description":"immunoglobulin heavy diversity 3-10","metadata":{"aliases":["IGHD310","DXP'1"]}},{"id":"1eb8d9a9e1f04d20a3deeb16c6480c8f","type":"GENE","name":"IGHD3-16","canonical_id":"hgnc:HGNC:5496","description":"immunoglobulin heavy diversity 3-16","metadata":{"aliases":["IGHD316"]}},{"id":"d17d559b5f344dfda7451eb475d32091","type":"GENE","name":"IGHD3-22","canonical_id":"hgnc:HGNC:5497","description":"immunoglobulin heavy diversity 3-22","metadata":{"aliases":["IGHD322"]}},{"id":"cfb37d3b9fe54c3ca70aa5fc056000dc","type":"GENE","name":"IGHD3-3","canonical_id":"hgnc:HGNC:5498","description":"immunoglobulin heavy diversity 3-3","metadata":{"aliases":["IGHD33","DXP4"]}},{"id":"e7e05af7047b4fba804358a8f453ea92","type":"GENE","name":"IGHD3-9","canonical_id":"hgnc:HGNC:5499","description":"immunoglobulin heavy diversity 3-9","metadata":{"aliases":["IGHD39","DXP1"]}},{"id":"db51884b429642caa3f5c5daea2accae","type":"GENE","name":"IGHD3OR15-3A","canonical_id":"hgnc:HGNC:5500","description":"immunoglobulin heavy diversity 3/OR15-3A (non-functional)","metadata":{"aliases":["IGHD3/OR15-3A","IGHD3OR153A"]}},{"id":"018874b5d49741dc8371ef748e7a9a1e","type":"GENE","name":"IGHD3OR15-3B","canonical_id":"hgnc:HGNC:5501","description":"immunoglobulin heavy diversity 3/OR15-3B (non-functional)","metadata":{"aliases":["IGHD3/OR15-3B","IGHD3OR153B"]}},{"id":"3764381cf5854febb4b08ceaaef78925","type":"GENE","name":"IGHD4-11","canonical_id":"hgnc:HGNC:5502","description":"immunoglobulin heavy diversity 4-11 (non-functional)","metadata":{"aliases":["IGHD411","DA1"]}},{"id":"d2685dae779e433e9119637cea78b362","type":"GENE","name":"IGHD4-17","canonical_id":"hgnc:HGNC:5503","description":"immunoglobulin heavy diversity 4-17","metadata":{"aliases":["IGHD417"]}},{"id":"393d79220b9240abb1806fdbef2edaff","type":"GENE","name":"IGHD4-23","canonical_id":"hgnc:HGNC:5504","description":"immunoglobulin heavy diversity 4-23 (non-functional)","metadata":{"aliases":["IGHD423"]}},{"id":"2d0db9ef30b649beb43e8f19538fd4b6","type":"GENE","name":"IGHD4-4","canonical_id":"hgnc:HGNC:5505","description":"immunoglobulin heavy diversity 4-4","metadata":{"aliases":["IGHD44","DA4"]}},{"id":"4d4ac2807af342f696e5ae1127ce28c8","type":"GENE","name":"IGHD4OR15-4A","canonical_id":"hgnc:HGNC:5506","description":"immunoglobulin heavy diversity 4/OR15-4A (non-functional)","metadata":{"aliases":["IGHD4/OR15-4A","IGHD4OR154A"]}},{"id":"a8f19b2dc4924cf380987b8b0b7baf5c","type":"GENE","name":"IGHD4OR15-4B","canonical_id":"hgnc:HGNC:5507","description":"immunoglobulin heavy diversity 4/OR15-4B (non-functional)","metadata":{"aliases":["IGHD4/OR15-4B","IGHD4OR154B"]}},{"id":"27aced54794b48a5a5649121158699b6","type":"GENE","name":"IGHD5-12","canonical_id":"hgnc:HGNC:5508","description":"immunoglobulin heavy diversity 5-12","metadata":{"aliases":["IGHD512","DK1"]}},{"id":"16a12b00a4bf45d0a79502dd231b1d87","type":"GENE","name":"IGHD5-18","canonical_id":"hgnc:HGNC:5509","description":"immunoglobulin heavy diversity 5-18","metadata":{"aliases":["IGHD518"]}},{"id":"f3f2afcb77f3413faca32d2ed5fed7a7","type":"GENE","name":"IGHD5-24","canonical_id":"hgnc:HGNC:5510","description":"immunoglobulin heavy diversity 5-24 (non-functional)","metadata":{"aliases":["IGHD524"]}},{"id":"3e250602b3a341e79d424d5ac9076333","type":"GENE","name":"IGHD5-5","canonical_id":"hgnc:HGNC:5511","description":"immunoglobulin heavy diversity 5-5","metadata":{"aliases":["IGHD55","DK4"]}},{"id":"89f17d2cf7ce4896b704374c66dd1541","type":"GENE","name":"IGHD5OR15-5A","canonical_id":"hgnc:HGNC:5512","description":"immunoglobulin heavy diversity 5/OR15-5A (non-functional)","metadata":{"aliases":["IGHD5/OR15-5A","IGHD5OR155A"]}},{"id":"335c44f88f7a4f649e1b5e2ee0da31f3","type":"GENE","name":"IGHD5OR15-5B","canonical_id":"hgnc:HGNC:5513","description":"immunoglobulin heavy diversity 5/OR15-5B (non-functional)","metadata":{"aliases":["IGHD5/OR15-5B","IGHD5OR155B"]}},{"id":"58bb3115a09e48bd9ff7e47ec6d9c371","type":"GENE","name":"IGHD6-13","canonical_id":"hgnc:HGNC:5514","description":"immunoglobulin heavy diversity 6-13","metadata":{"aliases":["IGHD613","DN1"]}},{"id":"09cc6bf4b5544ef0868435cec57bfe0a","type":"GENE","name":"IGHD6-19","canonical_id":"hgnc:HGNC:5515","description":"immunoglobulin heavy diversity 6-19","metadata":{"aliases":["IGHD619"]}},{"id":"c04482ee0ddc467c90dc87dbead4e1af","type":"GENE","name":"IGHD6-25","canonical_id":"hgnc:HGNC:5516","description":"immunoglobulin heavy diversity 6-25","metadata":{"aliases":["IGHD625"]}},{"id":"f75f4322d93d4e9697d49e11602f5a36","type":"GENE","name":"IGHD6-6","canonical_id":"hgnc:HGNC:5517","description":"immunoglobulin heavy diversity 6-6","metadata":{"aliases":["IGHD66","D(N4)"]}},{"id":"10266c619d2f4770b695ad11fc7951cc","type":"GENE","name":"IGHD7-27","canonical_id":"hgnc:HGNC:5518","description":"immunoglobulin heavy diversity 7-27","metadata":{"aliases":["IGHD727","DHQ52"]}},{"id":"0c484ff91e704264ab7fc14703c2dfe8","type":"GENE","name":"IGHE","canonical_id":"hgnc:HGNC:5522","description":"immunoglobulin heavy constant epsilon","metadata":null},{"id":"742c8dacc3e2412bbf1157d68f438e9b","type":"PROTEIN","name":"IGHE","canonical_id":"uniprot:P01854","description":null,"metadata":null},{"id":"e24a54c0e2ac4a418a934e53bc8ffa76","type":"GENE","name":"IGHEP1","canonical_id":"hgnc:HGNC:5523","description":"immunoglobulin heavy constant epsilon P1 (pseudogene)","metadata":null},{"id":"693df3abcdb4487886bb6add039139bc","type":"GENE","name":"IGHEP2","canonical_id":"hgnc:HGNC:5524","description":"immunoglobulin heavy constant epsilon P2 (pseudogene)","metadata":null},{"id":"ecb69358d5e44d0d8b2ecb8fb159b1b9","type":"GENE","name":"IGHG1","canonical_id":"hgnc:HGNC:5525","description":"immunoglobulin heavy constant gamma 1 (G1m marker)","metadata":null},{"id":"0a2a2c2151244eedbd7b9b33ec960bb7","type":"GENE","name":"IGHG2","canonical_id":"hgnc:HGNC:5526","description":"immunoglobulin heavy constant gamma 2 (G2m marker)","metadata":null},{"id":"af0085c7d81d458a92556fffda286b81","type":"GENE","name":"IGHG3","canonical_id":"hgnc:HGNC:5527","description":"immunoglobulin heavy constant gamma 3 (G3m marker)","metadata":null},{"id":"6b8c028162424e88ac79abb403ce2cb2","type":"GENE","name":"IGHG4","canonical_id":"hgnc:HGNC:5528","description":"immunoglobulin heavy constant gamma 4 (G4m marker)","metadata":null},{"id":"8d1a954d657045c0beb4b9e5d7eb45d0","type":"GENE","name":"IGHGP","canonical_id":"hgnc:HGNC:5529","description":"immunoglobulin heavy constant gamma P (non-functional)","metadata":{"aliases":["IGHGP1"]}},{"id":"8f92c9ff728442c8843d199e8f180485","type":"GENE","name":"IGHJ1","canonical_id":"hgnc:HGNC:5532","description":"immunoglobulin heavy joining 1","metadata":null},{"id":"d3377ee7c7334adb9a7532b4786e795f","type":"GENE","name":"IGHJ1P","canonical_id":"hgnc:HGNC:5533","description":"immunoglobulin heavy joining 1P (pseudogene)","metadata":{"aliases":["Jpsi1"]}},{"id":"3c20ac5e76c14cd99c59bf39724d5e9d","type":"GENE","name":"IGHJ2","canonical_id":"hgnc:HGNC:5534","description":"immunoglobulin heavy joining 2","metadata":null},{"id":"b1448ee747674768aea4e4f357540628","type":"GENE","name":"IGHJ2P","canonical_id":"hgnc:HGNC:5535","description":"immunoglobulin heavy joining 2P (pseudogene)","metadata":{"aliases":["Jpsi2"]}},{"id":"eee998a127a74d8995a5dabcde817843","type":"GENE","name":"IGHJ3","canonical_id":"hgnc:HGNC:5536","description":"immunoglobulin heavy joining 3","metadata":null},{"id":"3832993b74ec4c0fbebce5aa6edec1cc","type":"GENE","name":"IGHJ3P","canonical_id":"hgnc:HGNC:5537","description":"immunoglobulin heavy joining 3P (pseudogene)","metadata":{"aliases":["Jpsi3"]}},{"id":"73817241cfca48e599bac050d8a31118","type":"GENE","name":"IGHJ4","canonical_id":"hgnc:HGNC:5538","description":"immunoglobulin heavy joining 4","metadata":null},{"id":"07161fd291db47208e9369740aa725c2","type":"GENE","name":"IGHJ5","canonical_id":"hgnc:HGNC:5539","description":"immunoglobulin heavy joining 5","metadata":null},{"id":"09f63d66662d469faaa29620fd9179d5","type":"GENE","name":"IGHJ6","canonical_id":"hgnc:HGNC:5540","description":"immunoglobulin heavy joining 6","metadata":null},{"id":"63a26bdd30be44b1842ab292fbee25de","type":"GENE","name":"IGHM","canonical_id":"hgnc:HGNC:5541","description":"immunoglobulin heavy constant mu","metadata":null},{"id":"aaa6a080b99d42fb9d3b6f36b04cd32e","type":"GENE","name":"IGHMBP2","canonical_id":"hgnc:HGNC:5542","description":"immunoglobulin mu DNA binding protein 2","metadata":{"aliases":["ZFAND7","SMUBP2","CATF1","SMARD1","HCSA","HMN6","CMT2S"]}},{"id":"c0a0529ab86f482f86390dfdbead3ec4","type":"GENE","name":"IGHV1-12","canonical_id":"hgnc:HGNC:5546","description":"immunoglobulin heavy variable 1-12 (pseudogene)","metadata":null},{"id":"0a23752f20d8406d847a215ec83d2dff","type":"GENE","name":"IGHV1-14","canonical_id":"hgnc:HGNC:5547","description":"immunoglobulin heavy variable 1-14 (pseudogene)","metadata":null},{"id":"c47468b08faa41a3849b37ed8329e5f2","type":"GENE","name":"IGHV1-17","canonical_id":"hgnc:HGNC:5548","description":"immunoglobulin heavy variable 1-17 (pseudogene)","metadata":null},{"id":"95d0a330e806493986e0a044104447e8","type":"GENE","name":"IGHV1-18","canonical_id":"hgnc:HGNC:5549","description":"immunoglobulin heavy variable 1-18","metadata":null},{"id":"51c0d6824e59443c91d8d3dccce2b4aa","type":"GENE","name":"IGHV1-2","canonical_id":"hgnc:HGNC:5550","description":"immunoglobulin heavy variable 1-2","metadata":{"aliases":["V35"]}},{"id":"7656412a3b39441fbb85f20d33ab9725","type":"GENE","name":"IGHV1-24","canonical_id":"hgnc:HGNC:5551","description":"immunoglobulin heavy variable 1-24","metadata":null},{"id":"90a15e187bee43ccb57433a79d95fe1e","type":"GENE","name":"IGHV1-3","canonical_id":"hgnc:HGNC:5552","description":"immunoglobulin heavy variable 1-3","metadata":{"aliases":["VI-3B"]}},{"id":"4e842edcb51f462b9b9c9101d412d9c8","type":"GENE","name":"IGHV1-38-4","canonical_id":"hgnc:HGNC:5560","description":"immunoglobulin heavy variable 1-38-4 (non-functional)","metadata":{"aliases":["IGHV1-c","IGHV1-C"]}},{"id":"29c9ea25a7874a3788582236ce8b7a19","type":"GENE","name":"IGHV1-45","canonical_id":"hgnc:HGNC:5553","description":"immunoglobulin heavy variable 1-45","metadata":null},{"id":"3b1565486481464d92942528ee57cfc1","type":"GENE","name":"IGHV1-46","canonical_id":"hgnc:HGNC:5554","description":"immunoglobulin heavy variable 1-46","metadata":null},{"id":"05a4a758dd54410d9825df60ce05de59","type":"GENE","name":"IGHV1-58","canonical_id":"hgnc:HGNC:5555","description":"immunoglobulin heavy variable 1-58","metadata":null},{"id":"56ecbca7ebd045788885633dd975f483","type":"GENE","name":"IGHV1-67","canonical_id":"hgnc:HGNC:5556","description":"immunoglobulin heavy variable 1-67 (pseudogene)","metadata":null},{"id":"40a3a55571884e81bdb55363ca01aa3a","type":"GENE","name":"IGHV1-68","canonical_id":"hgnc:HGNC:5557","description":"immunoglobulin heavy variable 1-68 (pseudogene)","metadata":null},{"id":"cd165a2fa51d4d81b8dd025dfcb2f199","type":"GENE","name":"IGHV1-69","canonical_id":"hgnc:HGNC:5558","description":"immunoglobulin heavy variable 1-69","metadata":{"aliases":["IGHV1-E"]}},{"id":"82f67870ee4f4baf86d9e1f5f3c94425","type":"GENE","name":"IGHV1-69-2","canonical_id":"hgnc:HGNC:5562","description":"immunoglobulin heavy variable 1-69-2","metadata":{"aliases":["IGHV1-f","IGHV1-F"]}},{"id":"378b12190e3c4a378363837f7baf24f8","type":"GENE","name":"IGHV1-69D","canonical_id":"hgnc:HGNC:49601","description":"immunoglobulin heavy variable 1-69D","metadata":null},{"id":"e516191acae44150b987357fe5201419","type":"GENE","name":"IGHV1-8","canonical_id":"hgnc:HGNC:5559","description":"immunoglobulin heavy variable 1-8","metadata":null},{"id":"c7aec97586d54eba8faec60ac2009490","type":"GENE","name":"IGHV1OR15-1","canonical_id":"hgnc:HGNC:5563","description":"immunoglobulin heavy variable 1/OR15-1 (non-functional)","metadata":{"aliases":["IGHV1/OR15-1"]}},{"id":"56b5de3b896d4798898be0cc2f84b6b4","type":"GENE","name":"IGHV1OR15-2","canonical_id":"hgnc:HGNC:5564","description":"immunoglobulin heavy variable 1/OR15-2 (pseudogene)","metadata":{"aliases":["IGHV1/OR15-2"]}},{"id":"567fdf064ffd4f42b1940a0fa5bb508f","type":"GENE","name":"IGHV1OR15-3","canonical_id":"hgnc:HGNC:5565","description":"immunoglobulin heavy variable 1/OR15-3 (pseudogene)","metadata":{"aliases":["IGHV1/OR15-3"]}},{"id":"e7274658362545eda5c9d11871d8d1ff","type":"GENE","name":"IGHV1OR15-4","canonical_id":"hgnc:HGNC:5566","description":"immunoglobulin heavy variable 1/OR15-4 (pseudogene)","metadata":{"aliases":["IGHV1/OR15-4"]}},{"id":"8b121f1f611c418da8bc77af9668f9fe","type":"GENE","name":"IGHV1OR15-5","canonical_id":"hgnc:HGNC:5567","description":"immunoglobulin heavy variable 1/OR15-5 (non-functional)","metadata":{"aliases":["IGHV1/OR15-5"]}},{"id":"41859c11f24647dcac71bbfa82def5f4","type":"GENE","name":"IGHV1OR15-6","canonical_id":"hgnc:HGNC:5568","description":"immunoglobulin heavy variable 1/OR15-6 (pseudogene)","metadata":{"aliases":["IGHV1/OR15-6"]}},{"id":"2a2cb0c2c0984b01b1782815c5e57e37","type":"GENE","name":"IGHV1OR15-9","canonical_id":"hgnc:HGNC:5569","description":"immunoglobulin heavy variable 1/OR15-9 (non-functional)","metadata":{"aliases":["IGHV1/OR15-9","IGHV1OR159","VSIG7"]}},{"id":"b40e0daaefdb4d8f9ae4e5ee1c410045","type":"GENE","name":"IGHV1OR16-1","canonical_id":"hgnc:HGNC:5570","description":"immunoglobulin heavy variable 1/OR16-1 (pseudogene)","metadata":{"aliases":["IGHV1/OR16-1"]}},{"id":"1fe7204666ed409da203f3cbaecd1b8a","type":"GENE","name":"IGHV1OR16-2","canonical_id":"hgnc:HGNC:5571","description":"immunoglobulin heavy variable 1/OR16-2 (pseudogene)","metadata":{"aliases":["IGHV1/OR16-2"]}},{"id":"3dbed600a640474da6caccbadc30f4a7","type":"GENE","name":"IGHV1OR16-3","canonical_id":"hgnc:HGNC:5572","description":"immunoglobulin heavy variable 1/OR16-3 (pseudogene)","metadata":{"aliases":["IGHV1/OR16-3"]}},{"id":"a72ab97188624fc29ca8225fccb16be0","type":"GENE","name":"IGHV1OR16-4","canonical_id":"hgnc:HGNC:5573","description":"immunoglobulin heavy variable 1/OR16-4 (pseudogene)","metadata":{"aliases":["IGHV1/OR16-4"]}},{"id":"b4eeeb4287cb4912a682bbad3a7f5a78","type":"GENE","name":"IGHV1OR21-1","canonical_id":"hgnc:HGNC:38040","description":"immunoglobulin heavy variable 1/OR21-1 (non-functional)","metadata":{"aliases":["IGHV1/OR21-1"]}},{"id":"adbfad909fd84533824aab16d0e7015d","type":"GENE","name":"IGHV2-10","canonical_id":"hgnc:HGNC:5574","description":"immunoglobulin heavy variable 2-10 (pseudogene)","metadata":null},{"id":"c79368e44a1b4dda93408eecb60ea357","type":"GENE","name":"IGHV2-26","canonical_id":"hgnc:HGNC:5575","description":"immunoglobulin heavy variable 2-26","metadata":null},{"id":"508548e555414a34bc49238138df8b88","type":"GENE","name":"IGHV2-5","canonical_id":"hgnc:HGNC:5576","description":"immunoglobulin heavy variable 2-5","metadata":null},{"id":"afafdc0ef6e54997ab1fd66411a55b80","type":"GENE","name":"IGHV2-70","canonical_id":"hgnc:HGNC:5577","description":"immunoglobulin heavy variable 2-70","metadata":null},{"id":"3fb72fee67c443cf9abc408617f34c21","type":"GENE","name":"IGHV2-70D","canonical_id":"hgnc:HGNC:49602","description":"immunoglobulin heavy variable 2-70D","metadata":null},{"id":"6915a4064bfc44949c33bbfff0444d00","type":"GENE","name":"IGHV2OR16-5","canonical_id":"hgnc:HGNC:5579","description":"immunoglobulin heavy variable 2/OR16-5 (non-functional)","metadata":{"aliases":["IGHV2/OR16-5"]}},{"id":"e99846b3334849258424c14836b3f77f","type":"GENE","name":"IGHV3-11","canonical_id":"hgnc:HGNC:5580","description":"immunoglobulin heavy variable 3-11","metadata":null},{"id":"481a395b81a24027b76f7b103e6f6f21","type":"GENE","name":"IGHV3-13","canonical_id":"hgnc:HGNC:5581","description":"immunoglobulin heavy variable 3-13","metadata":null},{"id":"0d6887aff4c74095b301ee2b456dcf5d","type":"GENE","name":"IGHV3-15","canonical_id":"hgnc:HGNC:5582","description":"immunoglobulin heavy variable 3-15","metadata":null},{"id":"61efe77fa4c345f0b45091911c683b1d","type":"GENE","name":"IGHV3-16","canonical_id":"hgnc:HGNC:5583","description":"immunoglobulin heavy variable 3-16 (non-functional)","metadata":null},{"id":"627f3e16fa264aa3baee5382e47cd7a0","type":"GENE","name":"IGHV3-19","canonical_id":"hgnc:HGNC:5584","description":"immunoglobulin heavy variable 3-19 (pseudogene)","metadata":null},{"id":"ccb55ba7cbc5474589bd43f710d49bd8","type":"GENE","name":"IGHV3-20","canonical_id":"hgnc:HGNC:5585","description":"immunoglobulin heavy variable 3-20","metadata":null},{"id":"848635c1c111475db9831cb17ed5e83e","type":"GENE","name":"IGHV3-21","canonical_id":"hgnc:HGNC:5586","description":"immunoglobulin heavy variable 3-21","metadata":null},{"id":"ef2f8f3adf284059828a7badb75d0716","type":"GENE","name":"IGHV3-22","canonical_id":"hgnc:HGNC:5587","description":"immunoglobulin heavy variable 3-22 (pseudogene)","metadata":null},{"id":"f06c2f2ec15b4e1bb54b23caff7fec81","type":"GENE","name":"IGHV3-23","canonical_id":"hgnc:HGNC:5588","description":"immunoglobulin heavy variable 3-23","metadata":null},{"id":"a24d14744c25436e83a94d8d658aa53e","type":"GENE","name":"IGHV3-25","canonical_id":"hgnc:HGNC:5589","description":"immunoglobulin heavy variable 3-25 (pseudogene)","metadata":null},{"id":"45643476fd6f48b0af1f23b6b9ceac3a","type":"GENE","name":"IGHV3-29","canonical_id":"hgnc:HGNC:5590","description":"immunoglobulin heavy variable 3-29 (pseudogene)","metadata":null},{"id":"7412e302ca964f34a386ca293768b5ab","type":"GENE","name":"IGHV3-30","canonical_id":"hgnc:HGNC:5591","description":"immunoglobulin heavy variable 3-30","metadata":null},{"id":"e4a352f3dbcb477eaeedfa901f251935","type":"GENE","name":"IGHV3-30-2","canonical_id":"hgnc:HGNC:5592","description":"immunoglobulin heavy variable 3-30-2 (pseudogene)","metadata":null},{"id":"1a4aee5e485b4561a85f11b3ce973708","type":"GENE","name":"IGHV3-30-3","canonical_id":"hgnc:HGNC:5593","description":"immunoglobulin heavy variable 3-30-3","metadata":null},{"id":"c11303d76eda4521be720fd3d0b4013f","type":"GENE","name":"IGHV3-30-5","canonical_id":"hgnc:HGNC:5594","description":"immunoglobulin heavy variable 3-30-5","metadata":null},{"id":"c64077f4c2d648f589b66bda44fc8531","type":"GENE","name":"IGHV3-32","canonical_id":"hgnc:HGNC:5595","description":"immunoglobulin heavy variable 3-32 (pseudogene)","metadata":null},{"id":"17093c1ff2a94938bea5befe885f3b2e","type":"GENE","name":"IGHV3-33","canonical_id":"hgnc:HGNC:5596","description":"immunoglobulin heavy variable 3-33","metadata":null},{"id":"548f10a64c784a02a975e3df5e657b38","type":"GENE","name":"IGHV3-33-2","canonical_id":"hgnc:HGNC:5597","description":"immunoglobulin heavy variable 3-33-2 (pseudogene)","metadata":null},{"id":"c14e7adfb7bb440782adb77b2d118436","type":"GENE","name":"IGHV3-35","canonical_id":"hgnc:HGNC:5598","description":"immunoglobulin heavy variable 3-35 (non-functional)","metadata":null},{"id":"2e0f200c46384e23af8822ec78d028e2","type":"GENE","name":"IGHV3-36","canonical_id":"hgnc:HGNC:5599","description":"immunoglobulin heavy variable 3-36 (pseudogene)","metadata":null},{"id":"eeba268f57114fa6881ba2c6dfc63123","type":"GENE","name":"IGHV3-37","canonical_id":"hgnc:HGNC:5600","description":"immunoglobulin heavy variable 3-37 (pseudogene)","metadata":null},{"id":"2fbe5742b97d4e74992c01aa3750a2c8","type":"GENE","name":"IGHV3-38","canonical_id":"hgnc:HGNC:5601","description":"immunoglobulin heavy variable 3-38 (non-functional)","metadata":null},{"id":"76983ae96c884922b88d092ee3eb1e6f","type":"GENE","name":"IGHV3-38-3","canonical_id":"hgnc:HGNC:5629","description":"immunoglobulin heavy variable 3-38-3 (non-functional)","metadata":{"aliases":["IGHV3-d","IGHV3-D"]}},{"id":"e4dad81e9d1d4a4b98ac00a2d82f9618","type":"GENE","name":"IGHV3-41","canonical_id":"hgnc:HGNC:5602","description":"immunoglobulin heavy variable 3-41 (pseudogene)","metadata":null},{"id":"0b5c847ae4464e6aaea6a9a25843bd64","type":"GENE","name":"IGHV3-42","canonical_id":"hgnc:HGNC:5603","description":"immunoglobulin heavy variable 3-42 (pseudogene)","metadata":null},{"id":"2326fcba07e34daeacfd896363227e1e","type":"GENE","name":"IGHV3-43","canonical_id":"hgnc:HGNC:5604","description":"immunoglobulin heavy variable 3-43","metadata":null},{"id":"6ecff7ec70b24efd82cf3911fa708a17","type":"GENE","name":"IGHV3-43D","canonical_id":"hgnc:HGNC:50322","description":"immunoglobulin heavy variable 3-43D","metadata":null},{"id":"1e135ae98d89493198df970357eb9bf6","type":"GENE","name":"IGHV3-47","canonical_id":"hgnc:HGNC:5605","description":"immunoglobulin heavy variable 3-47 (pseudogene)","metadata":null},{"id":"e1bfca1cf3ed47939bc7bcf6289b36d0","type":"GENE","name":"IGHV3-48","canonical_id":"hgnc:HGNC:5606","description":"immunoglobulin heavy variable 3-48","metadata":null},{"id":"4347f8dbc57645789e799c59b0114130","type":"GENE","name":"IGHV3-49","canonical_id":"hgnc:HGNC:5607","description":"immunoglobulin heavy variable 3-49","metadata":null},{"id":"f6d4058ecbe54d6da77cc4d0336aef09","type":"GENE","name":"IGHV3-50","canonical_id":"hgnc:HGNC:5608","description":"immunoglobulin heavy variable 3-50 (pseudogene)","metadata":null},{"id":"e86644791de04ef3a4dd44fb064949cd","type":"GENE","name":"IGHV3-52","canonical_id":"hgnc:HGNC:5609","description":"immunoglobulin heavy variable 3-52 (pseudogene)","metadata":null},{"id":"00fa56e392de417085a8d2ae40c89145","type":"GENE","name":"IGHV3-53","canonical_id":"hgnc:HGNC:5610","description":"immunoglobulin heavy variable 3-53","metadata":null},{"id":"4ba5256fd6bd40709f599d4a8722779e","type":"GENE","name":"IGHV3-54","canonical_id":"hgnc:HGNC:5611","description":"immunoglobulin heavy variable 3-54 (pseudogene)","metadata":null},{"id":"4ec0cb78e991421c97f0c207b7b2e983","type":"GENE","name":"IGHV3-57","canonical_id":"hgnc:HGNC:5612","description":"immunoglobulin heavy variable 3-57 (pseudogene)","metadata":null},{"id":"5063290846684f69b19ad14f8b4e8473","type":"GENE","name":"IGHV3-6","canonical_id":"hgnc:HGNC:5613","description":"immunoglobulin heavy variable 3-6 (pseudogene)","metadata":null},{"id":"a3976c080e5c457f938aafa8dcefb767","type":"GENE","name":"IGHV3-60","canonical_id":"hgnc:HGNC:5614","description":"immunoglobulin heavy variable 3-60 (pseudogene)","metadata":null},{"id":"6d519f5762db40ffbed7d631a0ffc42b","type":"GENE","name":"IGHV3-62","canonical_id":"hgnc:HGNC:5615","description":"immunoglobulin heavy variable 3-62 (pseudogene)","metadata":null},{"id":"3db369fbf2db4fdb8bd9e892726731de","type":"GENE","name":"IGHV3-63","canonical_id":"hgnc:HGNC:5616","description":"immunoglobulin heavy variable 3-63 (pseudogene)","metadata":null},{"id":"234b9fa3fc2e4cda8c060e6354520bc7","type":"GENE","name":"IGHV3-64","canonical_id":"hgnc:HGNC:5617","description":"immunoglobulin heavy variable 3-64","metadata":null},{"id":"3d245f850dac4265bcccb9084c9ec3d2","type":"GENE","name":"IGHV3-64D","canonical_id":"hgnc:HGNC:49603","description":"immunoglobulin heavy variable 3-64D","metadata":null},{"id":"d4ccffa811ef4a6b9373bcfb041066d3","type":"GENE","name":"IGHV3-65","canonical_id":"hgnc:HGNC:5618","description":"immunoglobulin heavy variable 3-65 (pseudogene)","metadata":null},{"id":"abc3235cb6e341bc8c4a0fe7abbfb2c0","type":"GENE","name":"IGHV3-66","canonical_id":"hgnc:HGNC:5619","description":"immunoglobulin heavy variable 3-66","metadata":null},{"id":"460709668feb4b42859ecae19a0df4b7","type":"GENE","name":"IGHV3-69-1","canonical_id":"hgnc:HGNC:5631","description":"immunoglobulin heavy variable 3-69-1 (pseudogene)","metadata":{"aliases":["IGHV3-h","IGHV3-H"]}},{"id":"21fa4c9d8e40459f877070a6e7f27010","type":"GENE","name":"IGHV3-7","canonical_id":"hgnc:HGNC:5620","description":"immunoglobulin heavy variable 3-7","metadata":null},{"id":"7e719e78bfac4f718fd549135ebfe982","type":"GENE","name":"IGHV3-71","canonical_id":"hgnc:HGNC:5621","description":"immunoglobulin heavy variable 3-71 (pseudogene)","metadata":{"aliases":["IGHV3-g","IGHV3-G"]}},{"id":"9225889b08e04d7bbfcd3e11dbfc0416","type":"GENE","name":"IGHV3-72","canonical_id":"hgnc:HGNC:5622","description":"immunoglobulin heavy variable 3-72","metadata":null},{"id":"06ced00288f6480ca2f5c7b53a3b9faf","type":"GENE","name":"IGHV3-73","canonical_id":"hgnc:HGNC:5623","description":"immunoglobulin heavy variable 3-73","metadata":null},{"id":"b58a5be366bd494a9736904658ad0607","type":"GENE","name":"IGHV3-74","canonical_id":"hgnc:HGNC:5624","description":"immunoglobulin heavy variable 3-74","metadata":null},{"id":"59ee6c0e56cb478980d86ebe1f39115d","type":"GENE","name":"IGHV3-75","canonical_id":"hgnc:HGNC:5625","description":"immunoglobulin heavy variable 3-75 (pseudogene)","metadata":null},{"id":"d88b6e83ba3f41b48ce1141df92d567a","type":"GENE","name":"IGHV3-76","canonical_id":"hgnc:HGNC:5626","description":"immunoglobulin heavy variable 3-76 (pseudogene)","metadata":null},{"id":"18dcf9ad2db541aea05f2136212f3da2","type":"GENE","name":"IGHV3-79","canonical_id":"hgnc:HGNC:5627","description":"immunoglobulin heavy variable 3-79 (pseudogene)","metadata":null},{"id":"767bfc8671f642499856708e72f92e9f","type":"GENE","name":"IGHV3-9","canonical_id":"hgnc:HGNC:5628","description":"immunoglobulin heavy variable 3-9","metadata":null},{"id":"7bae22f210164105a2f2bacc6ff84da6","type":"GENE","name":"IGHV3OR15-7","canonical_id":"hgnc:HGNC:5633","description":"immunoglobulin heavy variable 3/OR15-7 (pseudogene)","metadata":{"aliases":["IGHV3/OR15-7"]}},{"id":"3216f65e5dd44cffb3284bac25780e82","type":"GENE","name":"IGHV3OR16-10","canonical_id":"hgnc:HGNC:5634","description":"immunoglobulin heavy variable 3/OR16-10 (non-functional)","metadata":{"aliases":["IGHV3/OR16-10"]}},{"id":"1520aab50db74684aabe8f23f1d76ce8","type":"GENE","name":"IGHV3OR16-11","canonical_id":"hgnc:HGNC:5635","description":"immunoglobulin heavy variable 3/OR16-11 (pseudogene)","metadata":{"aliases":["IGHV3/OR16-11"]}},{"id":"a1756eff0b364fd28b7c893fe41c8e08","type":"GENE","name":"IGHV3OR16-12","canonical_id":"hgnc:HGNC:5636","description":"immunoglobulin heavy variable 3/OR16-12 (non-functional)","metadata":{"aliases":["IGHV3/OR16-12"]}},{"id":"ef57285676d34797bfd57ff12673d034","type":"GENE","name":"IGHV3OR16-13","canonical_id":"hgnc:HGNC:5637","description":"immunoglobulin heavy variable 3/OR16-13 (non-functional)","metadata":{"aliases":["IGHV3/OR16-13"]}},{"id":"8527a353b72547e7886ff65b713971ff","type":"GENE","name":"IGHV3OR16-14","canonical_id":"hgnc:HGNC:5638","description":"immunoglobulin heavy variable 3/OR16-14 (pseudogene)","metadata":{"aliases":["IGHV3/OR16-14"]}},{"id":"0da0fdcf303e47cea475a9c59c776aca","type":"GENE","name":"IGHV3OR16-15","canonical_id":"hgnc:HGNC:5639","description":"immunoglobulin heavy variable 3/OR16-15 (pseudogene)","metadata":{"aliases":["IGHV3/OR16-15"]}},{"id":"d82eaed63fa041af8709efbe4431ed56","type":"GENE","name":"IGHV3OR16-16","canonical_id":"hgnc:HGNC:5640","description":"immunoglobulin heavy variable 3/OR16-16 (pseudogene)","metadata":{"aliases":["IGHV3/OR16-16"]}},{"id":"4ac2debe8be44aa484b62437d4ce2702","type":"GENE","name":"IGHV3OR16-17","canonical_id":"hgnc:HGNC:55105","description":"immunoglobulin heavy variable 3/OR16-17 (non-functional)","metadata":{"aliases":["IGHV3/OR16-17"]}},{"id":"a9a3bf75d11743cf98919c8a0bf326bf","type":"GENE","name":"IGHV3OR16-6","canonical_id":"hgnc:HGNC:5641","description":"immunoglobulin heavy variable 3/OR16-6 (pseudogene)","metadata":{"aliases":["IGHV3/OR16-6"]}},{"id":"bc0349bbd33e467e968fafc49b8b4d21","type":"GENE","name":"IGHV3OR16-7","canonical_id":"hgnc:HGNC:5642","description":"immunoglobulin heavy variable 3/OR16-7 (pseudogene)","metadata":{"aliases":["IGHV3/OR16-7"]}},{"id":"3f8c9ad2943748369940175050e68c40","type":"GENE","name":"IGHV3OR16-8","canonical_id":"hgnc:HGNC:5643","description":"immunoglobulin heavy variable 3/OR16-8 (non-functional)","metadata":{"aliases":["IGHV3/OR16-8"]}},{"id":"6a7519162a7a489e977d8c7435c7bbc0","type":"GENE","name":"IGHV3OR16-9","canonical_id":"hgnc:HGNC:5644","description":"immunoglobulin heavy variable 3/OR16-9 (non-functional)","metadata":{"aliases":["IGHV3/OR16-9"]}},{"id":"cb99fe1205534d9687712fb9bb13d3fc","type":"GENE","name":"IGHV4-28","canonical_id":"hgnc:HGNC:5645","description":"immunoglobulin heavy variable 4-28","metadata":null},{"id":"6ec070a253ec4e3eb3fb93b0d6449434","type":"GENE","name":"IGHV4-30-1","canonical_id":"hgnc:HGNC:5646","description":"immunoglobulin heavy variable 4-30-1","metadata":null},{"id":"4197a1adadb14e36abebc3d9aee400e9","type":"GENE","name":"IGHV4-30-2","canonical_id":"hgnc:HGNC:5647","description":"immunoglobulin heavy variable 4-30-2","metadata":{"aliases":["IGHV4-3","IGHV4302"]}},{"id":"6315774a85a744e492e3c866d9492a0d","type":"GENE","name":"IGHV4-30-4","canonical_id":"hgnc:HGNC:5648","description":"immunoglobulin heavy variable 4-30-4","metadata":{"aliases":["IGHV4-3","IGHV4304"]}},{"id":"74af70c8b837442596f61900f0e8a00b","type":"GENE","name":"IGHV4-31","canonical_id":"hgnc:HGNC:5649","description":"immunoglobulin heavy variable 4-31","metadata":null},{"id":"b1fe16abcbd345b5be1e43d1539b6e2e","type":"GENE","name":"IGHV4-34","canonical_id":"hgnc:HGNC:5650","description":"immunoglobulin heavy variable 4-34","metadata":null},{"id":"f38a23f066e344a297950bb2032c88ca","type":"GENE","name":"IGHV4-38-2","canonical_id":"hgnc:HGNC:5657","description":"immunoglobulin heavy variable 4-38-2","metadata":{"aliases":["IGHV4-B"]}},{"id":"6d44684edf844c15aa08feaf7ba4ef0e","type":"GENE","name":"IGHV4-39","canonical_id":"hgnc:HGNC:5651","description":"immunoglobulin heavy variable 4-39","metadata":null},{"id":"ccff4049cbe94c3083337604163e88fa","type":"GENE","name":"IGHV4-4","canonical_id":"hgnc:HGNC:5652","description":"immunoglobulin heavy variable 4-4","metadata":null},{"id":"14c7bce734b4497c80d3312c78f607cc","type":"GENE","name":"IGHV4-55","canonical_id":"hgnc:HGNC:5653","description":"immunoglobulin heavy variable 4-55 (pseudogene)","metadata":null},{"id":"ad5e9aa51b6d4e78ab59b90c6b7d4455","type":"GENE","name":"IGHV4-59","canonical_id":"hgnc:HGNC:5654","description":"immunoglobulin heavy variable 4-59","metadata":null},{"id":"2408a418d29448aeb2b03cafb3ab6bfa","type":"GENE","name":"IGHV4-61","canonical_id":"hgnc:HGNC:5655","description":"immunoglobulin heavy variable 4-61","metadata":null},{"id":"344542d594574eb29034a57c59c32739","type":"GENE","name":"IGHV4-80","canonical_id":"hgnc:HGNC:5656","description":"immunoglobulin heavy variable 4-80 (pseudogene)","metadata":null},{"id":"8599820ec5ba4e86807fd00a4b02fab7","type":"GENE","name":"IGHV4OR15-8","canonical_id":"hgnc:HGNC:5658","description":"immunoglobulin heavy variable 4/OR15-8 (non-functional)","metadata":{"aliases":["IGHV4/OR15-8","IGHV4OR158","VSIG6"]}},{"id":"0c8a6c3f7d1a412f88b34fde187ff76c","type":"GENE","name":"IGHV5-10-1","canonical_id":"hgnc:HGNC:5661","description":"immunoglobulin heavy variable 5-10-1","metadata":{"aliases":["IGHV5-a","IGHV5-A"]}},{"id":"1e817d891e9a45689db6e07805aff7cf","type":"GENE","name":"IGHV5-51","canonical_id":"hgnc:HGNC:5659","description":"immunoglobulin heavy variable 5-51","metadata":null},{"id":"e89ed4e6ab71453eb690e552f1f8899a","type":"GENE","name":"IGHV5-78","canonical_id":"hgnc:HGNC:5660","description":"immunoglobulin heavy variable 5-78 (pseudogene)","metadata":null},{"id":"ecb498370e54451abd1198934f597c18","type":"GENE","name":"IGHV6-1","canonical_id":"hgnc:HGNC:5662","description":"immunoglobulin heavy variable 6-1","metadata":null},{"id":"001123c262d24fa5a98d20b397bc6d36","type":"GENE","name":"IGHV7-27","canonical_id":"hgnc:HGNC:5663","description":"immunoglobulin heavy variable 7-27 (pseudogene)","metadata":null},{"id":"86c9aa33035d4deca6cbc10bcb480932","type":"GENE","name":"IGHV7-34-1","canonical_id":"hgnc:HGNC:5664","description":"immunoglobulin heavy variable 7-34-1 (pseudogene)","metadata":null},{"id":"33d24284b28b4234952c855bff621b97","type":"GENE","name":"IGHV7-4-1","canonical_id":"hgnc:HGNC:5665","description":"immunoglobulin heavy variable 7-4-1","metadata":null},{"id":"53d9480bf3c44936bdfebf446b705437","type":"GENE","name":"IGHV7-40","canonical_id":"hgnc:HGNC:5666","description":"immunoglobulin heavy variable 7-40 (pseudogene)","metadata":null},{"id":"dc87f9da4cec44c7a14c657948e525d3","type":"GENE","name":"IGHV7-56","canonical_id":"hgnc:HGNC:5667","description":"immunoglobulin heavy variable 7-56 (pseudogene)","metadata":null},{"id":"0c441a39f1744472b91958782fc80d64","type":"GENE","name":"IGHV7-81","canonical_id":"hgnc:HGNC:5669","description":"immunoglobulin heavy variable 7-81 (non-functional)","metadata":null},{"id":"b444fbf4716049118e01d4a1fc6082f9","type":"GENE","name":"IGHV8-51-1","canonical_id":"hgnc:HGNC:5704","description":"immunoglobulin heavy variable IGHV8-51-1 (non-functional)","metadata":{"aliases":["IGHV(III)-51-1","IGHVIII-51-1"]}},{"id":"2eaec8089af1478a86c733a7423bb028","type":"GENE","name":"IGHVII-1-1","canonical_id":"hgnc:HGNC:5670","description":"immunoglobulin heavy variable (II)-1-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-1-1"]}},{"id":"8f61b9cf804b412f8b6a8da6310552de","type":"GENE","name":"IGHVII-15-1","canonical_id":"hgnc:HGNC:5671","description":"immunoglobulin heavy variable (II)-15-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-15-1"]}},{"id":"e1be7d04804a4860a4ae005af9df22cb","type":"GENE","name":"IGHVII-20-1","canonical_id":"hgnc:HGNC:5672","description":"immunoglobulin heavy variable (II)-20-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-20-1"]}},{"id":"a66bad234cb44b779a74ab3575ee6adf","type":"GENE","name":"IGHVII-22-1","canonical_id":"hgnc:HGNC:5673","description":"immunoglobulin heavy variable (II)-22-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-22-1"]}},{"id":"b4e41a654a84483baca767af5c8bd6e6","type":"GENE","name":"IGHVII-26-2","canonical_id":"hgnc:HGNC:5674","description":"immunoglobulin heavy variable (II)-26-2 (pseudogene)","metadata":{"aliases":["IGHV(II)-26-2"]}},{"id":"60b43b87311543d59199cce3b389997a","type":"GENE","name":"IGHVII-28-1","canonical_id":"hgnc:HGNC:5675","description":"immunoglobulin heavy variable (II)-28-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-28-1"]}},{"id":"ad8a2454c1ca4834ba96b09b9a85c432","type":"GENE","name":"IGHVII-30-1","canonical_id":"hgnc:HGNC:5676","description":"immunoglobulin heavy variable (II)-30-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-30-1"]}},{"id":"13c00d7438554acb9b2479032099598a","type":"GENE","name":"IGHVII-30-21","canonical_id":"hgnc:HGNC:52400","description":"immunoglobulin heavy variable (II)-30-21 (pseudogene)","metadata":{"aliases":["IGHV(II)-30-21"]}},{"id":"4ab4d5a59f16438bbc32da851080336c","type":"GENE","name":"IGHVII-31-1","canonical_id":"hgnc:HGNC:5677","description":"immunoglobulin heavy variable (II)-31-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-31-1"]}},{"id":"8abee62cc799408786eb1857c7186d96","type":"GENE","name":"IGHVII-33-1","canonical_id":"hgnc:HGNC:5678","description":"immunoglobulin heavy variable (II)-33-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-33-1"]}},{"id":"6b0a6347e4a243b481313bb2af1ddfe7","type":"GENE","name":"IGHVII-40-1","canonical_id":"hgnc:HGNC:5679","description":"immunoglobulin heavy variable (II)-40-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-40-1"]}},{"id":"859736c2c8c6400c9cce89f48a9e9efd","type":"GENE","name":"IGHVII-43-1","canonical_id":"hgnc:HGNC:5680","description":"immunoglobulin heavy variable (II)-43-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-43-1"]}},{"id":"bb5c234a25f44d8d9fa71e10cd63eec2","type":"GENE","name":"IGHVII-44-2","canonical_id":"hgnc:HGNC:5681","description":"immunoglobulin heavy variable (II)-44-2 (pseudogene)","metadata":{"aliases":["IGHV(II)-44-2"]}},{"id":"ddb4d4422d444d999657f84b3cfc33ea","type":"GENE","name":"IGHVII-46-1","canonical_id":"hgnc:HGNC:5682","description":"immunoglobulin heavy variable (II)-46-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-46-1"]}},{"id":"490a6f065e004474baeda365ff4bc394","type":"GENE","name":"IGHVII-49-1","canonical_id":"hgnc:HGNC:5683","description":"immunoglobulin heavy variable (II)-49-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-49-1"]}},{"id":"220174e125eb4f0ea40c2fa742b53d66","type":"GENE","name":"IGHVII-51-2","canonical_id":"hgnc:HGNC:5684","description":"immunoglobulin heavy variable (II)-51-2 (pseudogene)","metadata":{"aliases":["IGHV(II)-51-2"]}},{"id":"0f6f112c00de4249af4560c77c713216","type":"GENE","name":"IGHVII-53-1","canonical_id":"hgnc:HGNC:5685","description":"immunoglobulin heavy variable (II)-53-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-53-1"]}},{"id":"9aa008eab8324186854ab8d40ec6f3f2","type":"GENE","name":"IGHVII-60-1","canonical_id":"hgnc:HGNC:5686","description":"immunoglobulin heavy variable (II)-60-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-60-1"]}},{"id":"7c53cde6b2e94f478a72ee1412dadded","type":"GENE","name":"IGHVII-62-1","canonical_id":"hgnc:HGNC:5687","description":"immunoglobulin heavy variable (II)-62-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-62-1"]}},{"id":"1b05cb5a82e54f9cbd1d45a1fddd30c4","type":"GENE","name":"IGHVII-65-1","canonical_id":"hgnc:HGNC:5688","description":"immunoglobulin heavy variable (II)-65-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-65-1"]}},{"id":"26f5e93205a44936b235122b850bf949","type":"GENE","name":"IGHVII-67-1","canonical_id":"hgnc:HGNC:5689","description":"immunoglobulin heavy variable (II)-67-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-67-1"]}},{"id":"3f84089414384b77871ac6a9f4527787","type":"GENE","name":"IGHVII-74-1","canonical_id":"hgnc:HGNC:5690","description":"immunoglobulin heavy variable (II)-74-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-74-1"]}},{"id":"89e794562cea401f8b407eed02f0dd95","type":"GENE","name":"IGHVII-78-1","canonical_id":"hgnc:HGNC:5691","description":"immunoglobulin heavy variable (II)-78-1 (pseudogene)","metadata":{"aliases":["IGHV(II)-78-1"]}},{"id":"2c493f5a3ed04a88b07f3ef4fb2238ee","type":"GENE","name":"IGHVIII-11-1","canonical_id":"hgnc:HGNC:5692","description":"immunoglobulin heavy variable (III)-11-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-11-1"]}},{"id":"f460662995df42568378a5f010be72eb","type":"GENE","name":"IGHVIII-13-1","canonical_id":"hgnc:HGNC:5693","description":"immunoglobulin heavy variable (III)-13-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-13-1"]}},{"id":"fa4ee8717e0a4b9e8c2ae1e73bde9b41","type":"GENE","name":"IGHVIII-16-1","canonical_id":"hgnc:HGNC:5694","description":"immunoglobulin heavy variable (III)-16-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-16-1"]}},{"id":"b0d697e934b049c88ad3926dd6cdc82d","type":"GENE","name":"IGHVIII-2-1","canonical_id":"hgnc:HGNC:5695","description":"immunoglobulin heavy variable (III)-2-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-2-1"]}},{"id":"8b714c9c9ee74b0eaf6e1b3e0deb8b56","type":"GENE","name":"IGHVIII-22-2","canonical_id":"hgnc:HGNC:5696","description":"immunoglobulin heavy variable (III)-22-2 (pseudogene)","metadata":{"aliases":["IGHV(III)-22-2"]}},{"id":"a3d32ecdca224195bd6ee779998aa0cb","type":"GENE","name":"IGHVIII-25-1","canonical_id":"hgnc:HGNC:5697","description":"immunoglobulin heavy variable (III)-25-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-25-1"]}},{"id":"69a9e3ee1dd54ea1ac15542ad1d1d50c","type":"GENE","name":"IGHVIII-26-1","canonical_id":"hgnc:HGNC:5698","description":"immunoglobulin heavy variable (III)-26-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-26-1"]}},{"id":"36f44c927a8a4216a635e5ad9b1d66e3","type":"GENE","name":"IGHVIII-38-1","canonical_id":"hgnc:HGNC:5699","description":"immunoglobulin heavy variable (III)-38-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-38-1"]}},{"id":"f1bc2d6eb93b48efbaddb004b411ac5f","type":"GENE","name":"IGHVIII-44","canonical_id":"hgnc:HGNC:5700","description":"immunoglobulin heavy variable (III)-44 (pseudogene)","metadata":{"aliases":["IGHV(III)-44"]}},{"id":"9daa6e82ccd142b28502db6114317d59","type":"GENE","name":"IGHVIII-47-1","canonical_id":"hgnc:HGNC:5701","description":"immunoglobulin heavy variable (III)-47-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-47-1"]}},{"id":"cf353827016b4b5ba15d1e473ae9a900","type":"GENE","name":"IGHVIII-5-1","canonical_id":"hgnc:HGNC:5702","description":"immunoglobulin heavy variable (III)-5-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-5-1"]}},{"id":"3538ea9511ec42a0bd69e4686453fbe2","type":"GENE","name":"IGHVIII-5-2","canonical_id":"hgnc:HGNC:5703","description":"immunoglobulin heavy variable (III)-5-2 (pseudogene)","metadata":{"aliases":["IGHV(III)-5-2"]}},{"id":"faf2a180ccf34c829f8c3ebbf9b8e1c1","type":"GENE","name":"IGHVIII-67-2","canonical_id":"hgnc:HGNC:5705","description":"immunoglobulin heavy variable (III)-67-2 (pseudogene)","metadata":{"aliases":["IGHV(III)-67-2"]}},{"id":"4bddd65d9fbe4285831fa54dd21cd1fd","type":"GENE","name":"IGHVIII-67-3","canonical_id":"hgnc:HGNC:5706","description":"immunoglobulin heavy variable (III)-67-3 (pseudogene)","metadata":{"aliases":["IGHV(III)-67-3"]}},{"id":"6ca9915510a34938ac49eb79be939bab","type":"GENE","name":"IGHVIII-67-4","canonical_id":"hgnc:HGNC:5707","description":"immunoglobulin heavy variable (III)-67-4 (pseudogene)","metadata":{"aliases":["IGHV(III)-67-4"]}},{"id":"7481db67a0d14e84a686663a4a2700b4","type":"GENE","name":"IGHVIII-76-1","canonical_id":"hgnc:HGNC:5708","description":"immunoglobulin heavy variable (III)-76-1 (pseudogene)","metadata":{"aliases":["IGHV(III)-76-1"]}},{"id":"c95ee0915de845b4aebb3cc0519c4c83","type":"GENE","name":"IGHVIII-82","canonical_id":"hgnc:HGNC:5709","description":"immunoglobulin heavy variable (III)-82 (pseudogene)","metadata":{"aliases":["IGHV(III)-82"]}},{"id":"bf3983ecb39b49999bbf962312123c78","type":"GENE","name":"IGHVIV-44-1","canonical_id":"hgnc:HGNC:5710","description":"immunoglobulin heavy variable (IV)-44-1 (pseudogene)","metadata":{"aliases":["IGHV(IV)-44-1"]}},{"id":"560465774324493a8104ee7114399067","type":"GENE","name":"IGIP","canonical_id":"hgnc:HGNC:33847","description":"IgA inducing protein","metadata":{"aliases":["LOC492311","C5orf53"]}},{"id":"abe30fef91b04351a6bf265e145e6acc","type":"GENE","name":"IGK","canonical_id":"hgnc:HGNC:5715","description":null,"metadata":null},{"id":"162d6b10dd7948348c2cf33f20faae74","type":"GENE","name":"IGKC","canonical_id":"hgnc:HGNC:5716","description":"immunoglobulin kappa constant","metadata":{"aliases":["HCAK1"]}},{"id":"613560c5ab0f48e2b6fc5beb117c3e80","type":"GENE","name":"IGKDEL","canonical_id":"hgnc:HGNC:5717","description":"immunoglobulin kappa deleting element or like","metadata":{"aliases":["IGKDE"]}},{"id":"1e5d0b60be6b4f19b7d877d68435656d","type":"GENE","name":"IGKJ1","canonical_id":"hgnc:HGNC:5719","description":"immunoglobulin kappa joining 1","metadata":{"aliases":["J1"]}},{"id":"f83b6d7a7af84f4b90bd40ce91069e10","type":"GENE","name":"IGKJ2","canonical_id":"hgnc:HGNC:5720","description":"immunoglobulin kappa joining 2","metadata":{"aliases":["J2"]}},{"id":"443edf46861b471093d608f16e3382c5","type":"GENE","name":"IGKJ3","canonical_id":"hgnc:HGNC:5721","description":"immunoglobulin kappa joining 3","metadata":null},{"id":"456e89c7b7e9446f9fee536f1c159508","type":"GENE","name":"IGKJ4","canonical_id":"hgnc:HGNC:5722","description":"immunoglobulin kappa joining 4","metadata":null},{"id":"9126f0b88463479bac548b5a59a5f06d","type":"GENE","name":"IGKJ5","canonical_id":"hgnc:HGNC:5723","description":"immunoglobulin kappa joining 5","metadata":null},{"id":"0eec0d4817c44d8b8de18cf02defbe83","type":"GENE","name":"IGKV1-12","canonical_id":"hgnc:HGNC:5730","description":"immunoglobulin kappa variable 1-12","metadata":{"aliases":["IGKV112","L19"]}},{"id":"6ed93749568d481f8d4eb7976ea70585","type":"GENE","name":"IGKV1-13","canonical_id":"hgnc:HGNC:5731","description":"immunoglobulin kappa variable 1-13","metadata":null},{"id":"24c3c9d2ec3a46688f66a47f84e90a48","type":"GENE","name":"IGKV1-16","canonical_id":"hgnc:HGNC:5732","description":"immunoglobulin kappa variable 1-16","metadata":{"aliases":["IGKV116","L1"]}},{"id":"c9f3844be78340edaf0b48982d3fea16","type":"GENE","name":"IGKV1-17","canonical_id":"hgnc:HGNC:5733","description":"immunoglobulin kappa variable 1-17","metadata":{"aliases":["IGKV117","A30"]}},{"id":"1cec0cc4ab8141faa6278f744efcda6c","type":"GENE","name":"IGKV1-22","canonical_id":"hgnc:HGNC:5734","description":"immunoglobulin kappa variable 1-22 (pseudogene)","metadata":null},{"id":"8709c7637e7944cda3be004c5715ad35","type":"GENE","name":"IGKV1-27","canonical_id":"hgnc:HGNC:5735","description":"immunoglobulin kappa variable 1-27","metadata":{"aliases":["IGKV127","A20"]}},{"id":"7a3b271f885b4ea1a27c3b8d92f5aad5","type":"GENE","name":"IGKV1-32","canonical_id":"hgnc:HGNC:5736","description":"immunoglobulin kappa variable 1-32 (pseudogene)","metadata":null},{"id":"310cbe99a72e4523809d7f8ddb7770aa","type":"GENE","name":"IGKV1-33","canonical_id":"hgnc:HGNC:5737","description":"immunoglobulin kappa variable 1-33","metadata":{"aliases":["IGKV133","O18"]}},{"id":"c3f17eab6553416880471a6c30821e09","type":"GENE","name":"IGKV1-35","canonical_id":"hgnc:HGNC:5738","description":"immunoglobulin kappa variable 1-35 (pseudogene)","metadata":null},{"id":"817d99dc9a4a44a9be9e7a0ddd7c21e5","type":"GENE","name":"IGKV1-37","canonical_id":"hgnc:HGNC:5739","description":"immunoglobulin kappa variable 1-37 (non-functional)","metadata":{"aliases":["IGKV137","O14"]}},{"id":"1727de0fd60040b59ab24325803d35f0","type":"GENE","name":"IGKV1-39","canonical_id":"hgnc:HGNC:5740","description":"immunoglobulin kappa variable 1-39","metadata":null},{"id":"60dca585a33048238e0370bb95733760","type":"GENE","name":"IGKV1-5","canonical_id":"hgnc:HGNC:5741","description":"immunoglobulin kappa variable 1-5","metadata":null},{"id":"a7683a1a52614aa68b503e318a6d7b80","type":"GENE","name":"IGKV1-6","canonical_id":"hgnc:HGNC:5742","description":"immunoglobulin kappa variable 1-6","metadata":null},{"id":"d511267ebc7b4cf08e57b0cfe763d0b3","type":"GENE","name":"IGKV1-8","canonical_id":"hgnc:HGNC:5743","description":"immunoglobulin kappa variable 1-8","metadata":{"aliases":["IGKV18","L9"]}},{"id":"13a47c4a1cd341feb810c408b74c3ba7","type":"GENE","name":"IGKV1-9","canonical_id":"hgnc:HGNC:5744","description":"immunoglobulin kappa variable 1-9","metadata":{"aliases":["IGKV19","L8"]}},{"id":"6ce449ea02844768be993f83b59bb1b4","type":"GENE","name":"IGKV1D-12","canonical_id":"hgnc:HGNC:5746","description":"immunoglobulin kappa variable 1D-12","metadata":null},{"id":"c46036279913453cadb0d50dcc7819a0","type":"GENE","name":"IGKV1D-13","canonical_id":"hgnc:HGNC:5747","description":"immunoglobulin kappa variable 1D-13","metadata":null},{"id":"5823471f521549eda99db503f017f737","type":"GENE","name":"IGKV1D-16","canonical_id":"hgnc:HGNC:5748","description":"immunoglobulin kappa variable 1D-16","metadata":null},{"id":"20131efab9a841968f37827993145f96","type":"GENE","name":"IGKV1D-17","canonical_id":"hgnc:HGNC:5749","description":"immunoglobulin kappa variable 1D-17","metadata":null},{"id":"56a97110d4c242a38ce190cec10a6b9f","type":"GENE","name":"IGKV1D-22","canonical_id":"hgnc:HGNC:5750","description":"immunoglobulin kappa variable 1D-22 (pseudogene)","metadata":null},{"id":"5a937db2cd2043e4a2177a3436603130","type":"GENE","name":"IGKV1D-27","canonical_id":"hgnc:HGNC:5751","description":"immunoglobulin kappa variable 1D-27 (pseudogene)","metadata":null},{"id":"e453a1e806f4460992998b91cd22e2a0","type":"GENE","name":"IGKV1D-32","canonical_id":"hgnc:HGNC:5752","description":"immunoglobulin kappa variable 1D-32 (pseudogene)","metadata":null},{"id":"f62f210ecb1f41ccb40c3b5576116c8b","type":"GENE","name":"IGKV1D-33","canonical_id":"hgnc:HGNC:5753","description":"immunoglobulin kappa variable 1D-33","metadata":null},{"id":"433d7631a0fc49efa10aad184c578396","type":"GENE","name":"IGKV1D-35","canonical_id":"hgnc:HGNC:5754","description":"immunoglobulin kappa variable 1D-35 (pseudogene)","metadata":null},{"id":"c871e99dab554022a9d2d699836e1a49","type":"GENE","name":"IGKV1D-37","canonical_id":"hgnc:HGNC:5755","description":"immunoglobulin kappa variable 1D-37 (non-functional)","metadata":{"aliases":["IGKV1D37","O4"]}},{"id":"f5711e09f1fb4d14afbd9a20d5e6f67f","type":"GENE","name":"IGKV1D-39","canonical_id":"hgnc:HGNC:5756","description":"immunoglobulin kappa variable 1D-39","metadata":null},{"id":"e7b665f6e13c40ea883ed0009a0cb20c","type":"GENE","name":"IGKV1D-42","canonical_id":"hgnc:HGNC:5757","description":"immunoglobulin kappa variable 1D-42 (non-functional)","metadata":null},{"id":"068e12ed5d744e60bb65f6fa26f1f21a","type":"GENE","name":"IGKV1D-43","canonical_id":"hgnc:HGNC:5758","description":"immunoglobulin kappa variable 1D-43","metadata":null},{"id":"5b2765e01aaa4b2dbe2267a34478c953","type":"GENE","name":"IGKV1D-8","canonical_id":"hgnc:HGNC:5759","description":"immunoglobulin kappa variable 1D-8","metadata":null},{"id":"4e32c32a2c9442ffba1f5d721ba6a76c","type":"GENE","name":"IGKV1OR-2","canonical_id":"hgnc:HGNC:5761","description":"immunoglobulin kappa variable 1/OR-2 (pseudogene)","metadata":{"aliases":["IGKV1/OR-2","IGKVPZ2"]}},{"id":"eb81004640dc45a19f1ddb9879234185","type":"GENE","name":"IGKV1OR-3","canonical_id":"hgnc:HGNC:5762","description":"immunoglobulin kappa variable 1/OR-3 (pseudogene)","metadata":{"aliases":["IGKV1/OR-3","IGKVPZ3"]}},{"id":"c98cb829921e4338ac7c384a8d2ed980","type":"GENE","name":"IGKV1OR-4","canonical_id":"hgnc:HGNC:5763","description":"immunoglobulin kappa variable 1/OR-4 (pseudogene)","metadata":{"aliases":["IGKV1/OR-4","IGKVPZ4"]}},{"id":"ffc90dc066ca46a7b7986965a6f55270","type":"GENE","name":"IGKV1OR1-1","canonical_id":"hgnc:HGNC:5764","description":"immunoglobulin kappa variable 1/OR1-1 (pseudogene)","metadata":{"aliases":["IGKV1/OR1-1","IGKVP1"]}},{"id":"255d0c630c484a42b0b81ad2a57dea48","type":"GENE","name":"IGKV1OR10-1","canonical_id":"hgnc:HGNC:44978","description":"immunoglobulin kappa variable 1/OR10-1 (pseudogene)","metadata":{"aliases":["IGKV1/OR10-1"]}},{"id":"6b789b0a985b4e5aa967ce362782bbcf","type":"GENE","name":"IGKV1OR15-118","canonical_id":"hgnc:HGNC:5765","description":"immunoglobulin kappa variable 1/OR15-118 (pseudogene)","metadata":{"aliases":["IGKV1/OR-118","IGKV1/OR15-118","IGKVP2"]}},{"id":"13774a8acb5f466e84827cb008966c98","type":"GENE","name":"IGKV1OR2-0","canonical_id":"hgnc:HGNC:5766","description":"immunoglobulin kappa variable 1/OR2-0 (non-functional)","metadata":{"aliases":["IGKV1/OR2-0"]}},{"id":"b6078a50db12402b9cd5212ef58fd794","type":"GENE","name":"IGKV1OR2-1","canonical_id":"hgnc:HGNC:5760","description":"immunoglobulin kappa variable 1/OR2-1 (pseudogene)","metadata":{"aliases":["IGKV1/OR-1","IGKV1/OR2-1","IGKVPZ1","IGKV1OR-1"]}},{"id":"44c178c3ac134dd0a5aa43fb85f36897","type":"GENE","name":"IGKV1OR2-108","canonical_id":"hgnc:HGNC:5767","description":"immunoglobulin kappa variable 1/OR2-108 (non-functional)","metadata":{"aliases":["IGKV1/OR2-108","IGKV1OR2108","IGO1"]}},{"id":"a1eed1d8f39d4021900893e8aad9e914","type":"GENE","name":"IGKV1OR2-11","canonical_id":"hgnc:HGNC:5768","description":"immunoglobulin kappa variable 1/OR2-11 (pseudogene)","metadata":{"aliases":["IGKV1/OR2-11"]}},{"id":"1d93b77cbc0f4389987fb49017b4c218","type":"GENE","name":"IGKV1OR2-118","canonical_id":"hgnc:HGNC:37488","description":"immunoglobulin kappa variable 1/OR2-118 (pseudogene)","metadata":{"aliases":["IGKV1/OR2-118"]}},{"id":"81cd6f811a74458e80ac2872c31c6b60","type":"GENE","name":"IGKV1OR2-2","canonical_id":"hgnc:HGNC:49465","description":"immunoglobulin kappa variable 1/OR2-2 (pseudogene)","metadata":{"aliases":["IGKV1/OR2-2"]}},{"id":"78b90a964b544192906ed889294b1112","type":"GENE","name":"IGKV1OR2-3","canonical_id":"hgnc:HGNC:5769","description":"immunoglobulin kappa variable 1/OR2-3 (pseudogene)","metadata":{"aliases":["IGKV1/OR2-3"]}},{"id":"8d01c8510ce34306b6f96e519efff14a","type":"GENE","name":"IGKV1OR2-6","canonical_id":"hgnc:HGNC:5770","description":"immunoglobulin kappa variable 1/OR2-6 (pseudogene)","metadata":{"aliases":["IGKV1/OR2-6"]}},{"id":"62078ceabcda4e6bb743ec1e604bf58e","type":"GENE","name":"IGKV1OR2-9","canonical_id":"hgnc:HGNC:5771","description":"immunoglobulin kappa variable 1/OR2-9 (pseudogene)","metadata":{"aliases":["IGKV1/OR2-9"]}},{"id":"69398a6e439140178c346de331f99735","type":"GENE","name":"IGKV1OR22-1","canonical_id":"hgnc:HGNC:5772","description":"immunoglobulin kappa variable 1/OR22-1 (pseudogene)","metadata":{"aliases":["IGKV1/OR22-1","IGKVP5"]}},{"id":"4f53d86d2d5f40d7a8b8770c83d50615","type":"GENE","name":"IGKV1OR22-5","canonical_id":"hgnc:HGNC:5773","description":"immunoglobulin kappa variable 1/OR22-5 (pseudogene)","metadata":{"aliases":["IGKV1/OR22-5","IGKV1/OR22-5A","IGKVP7","IGKV1OR22-5A"]}},{"id":"a2e61cd17d6848ff8244e3fbbea15144","type":"GENE","name":"IGKV1OR9-1","canonical_id":"hgnc:HGNC:49473","description":"immunoglobulin kappa variable 1/OR9-1 (pseudogene)","metadata":{"aliases":["IGKV1/OR9-1"]}},{"id":"7ccc03320af746089927002ba7cf8671","type":"GENE","name":"IGKV1OR9-2","canonical_id":"hgnc:HGNC:49466","description":"immunoglobulin kappa variable 1/OR9-2 (pseudogene)","metadata":{"aliases":["IGKV1/OR9-2"]}},{"id":"f83c66bcca4f402d91a7e587e6c29405","type":"GENE","name":"IGKV1ORY-1","canonical_id":"hgnc:HGNC:37729","description":"immunoglobulin kappa variable 1/ORY-1 (pseudogene)","metadata":{"aliases":["IGKV1/ORY-1"]}},{"id":"e2bd96c2823349f09961cbe4898ab07a","type":"GENE","name":"IGKV2-10","canonical_id":"hgnc:HGNC:5776","description":"immunoglobulin kappa variable 2-10 (pseudogene)","metadata":null},{"id":"ae3430b1fab54cad9d21b2c2f53c7975","type":"GENE","name":"IGKV2-14","canonical_id":"hgnc:HGNC:5777","description":"immunoglobulin kappa variable 2-14 (pseudogene)","metadata":null},{"id":"322226fd2d794c729fe1ffb34a8a865a","type":"GENE","name":"IGKV2-18","canonical_id":"hgnc:HGNC:5778","description":"immunoglobulin kappa variable 2-18 (pseudogene)","metadata":null},{"id":"9d2949025d064152b6b7a9dac0dfd514","type":"GENE","name":"IGKV2-19","canonical_id":"hgnc:HGNC:5779","description":"immunoglobulin kappa variable 2-19 (pseudogene)","metadata":null},{"id":"ca0f56532e0d4d0286a3cbc55b89010c","type":"GENE","name":"IGKV2-23","canonical_id":"hgnc:HGNC:5780","description":"immunoglobulin kappa variable 2-23 (pseudogene)","metadata":null},{"id":"4c51c64a83394d589ac2633d49d6964f","type":"GENE","name":"IGKV2-24","canonical_id":"hgnc:HGNC:5781","description":"immunoglobulin kappa variable 2-24","metadata":null},{"id":"30c675d11fd04d729cb3a3c101605fa7","type":"GENE","name":"IGKV2-26","canonical_id":"hgnc:HGNC:5782","description":"immunoglobulin kappa variable 2-26 (pseudogene)","metadata":null},{"id":"8de93228f97b4002ab6bff0f0afbe273","type":"GENE","name":"IGKV2-28","canonical_id":"hgnc:HGNC:5783","description":"immunoglobulin kappa variable 2-28","metadata":null},{"id":"a392f875d8df49dd80153eb09afda692","type":"GENE","name":"IGKV2-29","canonical_id":"hgnc:HGNC:5784","description":"immunoglobulin kappa variable 2-29","metadata":null},{"id":"6215688dbccf49a6b53d6da1a2946283","type":"GENE","name":"IGKV2-30","canonical_id":"hgnc:HGNC:5785","description":"immunoglobulin kappa variable 2-30","metadata":null},{"id":"2adb557ab5994a8d862ee2b2532ca937","type":"GENE","name":"IGKV2-36","canonical_id":"hgnc:HGNC:5786","description":"immunoglobulin kappa variable 2-36 (pseudogene)","metadata":null},{"id":"b31c86d99a734a889027959c6c99a4d9","type":"GENE","name":"IGKV2-38","canonical_id":"hgnc:HGNC:5787","description":"immunoglobulin kappa variable 2-38 (pseudogene)","metadata":null},{"id":"7c3a050f53a44baba3449fffc006128f","type":"GENE","name":"IGKV2-4","canonical_id":"hgnc:HGNC:5788","description":"immunoglobulin kappa variable 2-4 (pseudogene)","metadata":null},{"id":"a0ca9214abc740d6b00ca4360752bab2","type":"GENE","name":"IGKV2-40","canonical_id":"hgnc:HGNC:5789","description":"immunoglobulin kappa variable 2-40","metadata":null},{"id":"fdf9f4d0b02542b2af1236bebd3e46e6","type":"GENE","name":"IGKV2D-10","canonical_id":"hgnc:HGNC:5792","description":"immunoglobulin kappa variable 2D-10 (pseudogene)","metadata":null},{"id":"4ca43399fca140ff993159b708ee8863","type":"GENE","name":"IGKV2D-14","canonical_id":"hgnc:HGNC:5793","description":"immunoglobulin kappa variable 2D-14 (pseudogene)","metadata":null},{"id":"69b700eb3c784d8fb357dd8b88b434e2","type":"GENE","name":"IGKV2D-18","canonical_id":"hgnc:HGNC:5794","description":"immunoglobulin kappa variable 2D-18 (pseudogene)","metadata":null},{"id":"7feed7a7cb904e8791bd08a66050dd4c","type":"GENE","name":"IGKV2D-19","canonical_id":"hgnc:HGNC:5795","description":"immunoglobulin kappa variable 2D-19 (pseudogene)","metadata":null},{"id":"75cc76135243459ca2fb776535d6f2c6","type":"GENE","name":"IGKV2D-23","canonical_id":"hgnc:HGNC:5796","description":"immunoglobulin kappa variable 2D-23 (pseudogene)","metadata":null},{"id":"323a6aa08bfc4be6985b3b101833a10a","type":"GENE","name":"IGKV2D-24","canonical_id":"hgnc:HGNC:5797","description":"immunoglobulin kappa variable 2D-24 (non-functional)","metadata":null},{"id":"68450a7849c249768e2d71284e089350","type":"GENE","name":"IGKV2D-26","canonical_id":"hgnc:HGNC:5798","description":"immunoglobulin kappa variable 2D-26","metadata":null},{"id":"2d3f38795e824de0ace4997c41296726","type":"GENE","name":"IGKV2D-28","canonical_id":"hgnc:HGNC:5799","description":"immunoglobulin kappa variable 2D-28","metadata":null},{"id":"d32b38ec3803439baaf96e145f40bada","type":"GENE","name":"IGKV2D-29","canonical_id":"hgnc:HGNC:5800","description":"immunoglobulin kappa variable 2D-29","metadata":null},{"id":"303203d8018044ed942c7ae244d06899","type":"GENE","name":"IGKV2D-30","canonical_id":"hgnc:HGNC:5801","description":"immunoglobulin kappa variable 2D-30","metadata":null},{"id":"da9c47ca77254b99a03f2ee195d264d5","type":"GENE","name":"IGKV2D-36","canonical_id":"hgnc:HGNC:5802","description":"immunoglobulin kappa variable 2D-36 (pseudogene)","metadata":null},{"id":"b4c18ccc770e4883a86c2d0c44c4c1ea","type":"GENE","name":"IGKV2D-38","canonical_id":"hgnc:HGNC:5803","description":"immunoglobulin kappa variable 2D-38 (pseudogene)","metadata":null},{"id":"f93da5081800456ca30049e522f1aeda","type":"GENE","name":"IGKV2D-40","canonical_id":"hgnc:HGNC:5804","description":"immunoglobulin kappa variable 2D-40","metadata":null},{"id":"297cce6e48224a90a7c6799e74764c35","type":"GENE","name":"IGKV2OR2-1","canonical_id":"hgnc:HGNC:5805","description":"immunoglobulin kappa variable 2/OR2-1 (pseudogene)","metadata":{"aliases":["IGKV2/OR2-1","IGKV2/OR2-1A","IGKV2OR2-1A"]}},{"id":"656dc12d5465480ea417b620e4c83a0d","type":"GENE","name":"IGKV2OR2-10","canonical_id":"hgnc:HGNC:5806","description":"immunoglobulin kappa variable 2/OR2-10 (pseudogene)","metadata":{"aliases":["IGKV2/OR2-10"]}},{"id":"2f6925d43493415d8db554cd74471ebe","type":"GENE","name":"IGKV2OR2-2","canonical_id":"hgnc:HGNC:5808","description":"immunoglobulin kappa variable 2/OR2-2 (pseudogene)","metadata":{"aliases":["IGKV2/OR2-2"]}},{"id":"d06f0eb765fb45dd86a03e74664d7e96","type":"GENE","name":"IGKV2OR2-4","canonical_id":"hgnc:HGNC:5809","description":"immunoglobulin kappa variable 2/OR2-4 (pseudogene)","metadata":{"aliases":["IGKV2/OR2-4"]}},{"id":"0827d82662af46d080c65f2d69773dc8","type":"GENE","name":"IGKV2OR2-7","canonical_id":"hgnc:HGNC:5810","description":"immunoglobulin kappa variable 2/OR2-7 (pseudogene)","metadata":{"aliases":["IGKV2/OR2-7"]}},{"id":"e6b9a6b0030146a5a4d9dc18b3820c9b","type":"GENE","name":"IGKV2OR2-7D","canonical_id":"hgnc:HGNC:37489","description":"immunoglobulin kappa variable 2/OR2-7D (pseudogene)","metadata":{"aliases":["IGKV2/OR2-7D"]}},{"id":"c834c619358a4c378517eef41a026906","type":"GENE","name":"IGKV2OR2-8","canonical_id":"hgnc:HGNC:5811","description":"immunoglobulin kappa variable 2/OR2-8 (pseudogene)","metadata":{"aliases":["IGKV2/OR2-8"]}},{"id":"413f5e164bf343b38546bcd0f0eefb01","type":"GENE","name":"IGKV2OR22-3","canonical_id":"hgnc:HGNC:5812","description":"immunoglobulin kappa variable 2/OR22-3 (pseudogene)","metadata":{"aliases":["IGKV2/OR22-3","IGKVP4"]}},{"id":"ffecc6d9754845fa87b51fbe98f0301f","type":"GENE","name":"IGKV2OR22-4","canonical_id":"hgnc:HGNC:5813","description":"immunoglobulin kappa variable 2/OR22-4 (pseudogene)","metadata":{"aliases":["IGKV2/OR22-4","IGKVP6"]}},{"id":"fa3dda52db5b47c1bc60a36269c721cc","type":"GENE","name":"IGKV3-11","canonical_id":"hgnc:HGNC:5815","description":"immunoglobulin kappa variable 3-11","metadata":null},{"id":"4c25a7bd22914a97ba0303aa146a6867","type":"GENE","name":"IGKV3-15","canonical_id":"hgnc:HGNC:5816","description":"immunoglobulin kappa variable 3-15","metadata":null},{"id":"0309dcbb97d94b4b91a11207a1faf6ab","type":"GENE","name":"IGKV3-20","canonical_id":"hgnc:HGNC:5817","description":"immunoglobulin kappa variable 3-20","metadata":null},{"id":"d82c6511e821479a8d9660a078589e26","type":"GENE","name":"IGKV3-25","canonical_id":"hgnc:HGNC:5818","description":"immunoglobulin kappa variable 3-25 (pseudogene)","metadata":null},{"id":"0f249d6188444092b67cc961b0bdc780","type":"GENE","name":"IGKV3-31","canonical_id":"hgnc:HGNC:5819","description":"immunoglobulin kappa variable 3-31 (pseudogene)","metadata":null},{"id":"1cd88d8c8b054c5d90dfac9032f5868e","type":"GENE","name":"IGKV3-34","canonical_id":"hgnc:HGNC:5820","description":"immunoglobulin kappa variable 3-34 (pseudogene)","metadata":null},{"id":"e70cb9b4bf8b4ba59adde3c080fa1d99","type":"GENE","name":"IGKV3-7","canonical_id":"hgnc:HGNC:5821","description":"immunoglobulin kappa variable 3-7 (non-functional)","metadata":null},{"id":"70bcea51b71d466b97f1d05ab06fb21b","type":"GENE","name":"IGKV3D-11","canonical_id":"hgnc:HGNC:5823","description":"immunoglobulin kappa variable 3D-11","metadata":null},{"id":"06f01f4c29d34efa9b35eec2740294b3","type":"GENE","name":"IGKV3D-15","canonical_id":"hgnc:HGNC:5824","description":"immunoglobulin kappa variable 3D-15","metadata":null},{"id":"0799dacf13de4a6890d5ecaeee303cac","type":"GENE","name":"IGKV3D-20","canonical_id":"hgnc:HGNC:5825","description":"immunoglobulin kappa variable 3D-20","metadata":null},{"id":"5008bed4cbce4e5ca576e81b1f85a0de","type":"GENE","name":"IGKV3D-25","canonical_id":"hgnc:HGNC:5826","description":"immunoglobulin kappa variable 3D-25 (pseudogene)","metadata":null},{"id":"efee08c8b1524b648faf991c1689b70f","type":"GENE","name":"IGKV3D-31","canonical_id":"hgnc:HGNC:5827","description":"immunoglobulin kappa variable 3D-31 (pseudogene)","metadata":null},{"id":"9ae28141775a4b32b0361d1bdd1d9ca0","type":"GENE","name":"IGKV3D-34","canonical_id":"hgnc:HGNC:5828","description":"immunoglobulin kappa variable 3D-34 (pseudogene)","metadata":null},{"id":"e951f9b4cb2d434a8ec28210cbc702cc","type":"GENE","name":"IGKV3D-7","canonical_id":"hgnc:HGNC:5829","description":"immunoglobulin kappa variable 3D-7","metadata":null},{"id":"4c9cb3a23c7b4d0c8c1ab8041be3dae2","type":"GENE","name":"IGKV3OR2-268","canonical_id":"hgnc:HGNC:5830","description":"immunoglobulin kappa variable 3/OR2-268 (non-functional)","metadata":{"aliases":["IGKV3/OR2-268","IGKV3/OR2-268A","IGKV268","IGKV3OR2-268A"]}},{"id":"af55d3ab5cd642d7b998cda12d8984b8","type":"GENE","name":"IGKV3OR2-5","canonical_id":"hgnc:HGNC:5832","description":"immunoglobulin kappa variable 3/OR2-5 (pseudogene)","metadata":{"aliases":["IGKV3/OR2-5"]}},{"id":"4f342f6f2fdf4067842e75af33c85982","type":"GENE","name":"IGKV3OR22-2","canonical_id":"hgnc:HGNC:5833","description":"immunoglobulin kappa variable 3/OR22-2 (pseudogene)","metadata":{"aliases":["IGKV3/OR22-2","IGKVP3"]}},{"id":"0d8206ce7fed4a859d26540390a81579","type":"GENE","name":"IGKV4-1","canonical_id":"hgnc:HGNC:5834","description":"immunoglobulin kappa variable 4-1","metadata":{"aliases":["IGKV41","B3"]}},{"id":"ecd0a064cf294f1e967850809c669911","type":"GENE","name":"IGKV5-2","canonical_id":"hgnc:HGNC:5835","description":"immunoglobulin kappa variable 5-2","metadata":{"aliases":["IGKV52","B2"]}},{"id":"dec6cb80a6f648ac90fd38a7ac08129a","type":"GENE","name":"IGKV6-21","canonical_id":"hgnc:HGNC:5836","description":"immunoglobulin kappa variable 6-21 (non-functional)","metadata":{"aliases":["IGKV621","A26"]}},{"id":"3094bff6ee504485903a23d266dd58d0","type":"GENE","name":"IGKV6D-21","canonical_id":"hgnc:HGNC:5837","description":"immunoglobulin kappa variable 6D-21 (non-functional)","metadata":{"aliases":["IGKV6D21","A10"]}},{"id":"9cc4701d27e6489381895c1a75be7a77","type":"GENE","name":"IGKV6D-41","canonical_id":"hgnc:HGNC:5838","description":"immunoglobulin kappa variable 6D-41 (non-functional)","metadata":null},{"id":"b686f765f757401b8fd220cf5e13ab8d","type":"GENE","name":"IGKV7-3","canonical_id":"hgnc:HGNC:5839","description":"immunoglobulin kappa variable 7-3 (pseudogene)","metadata":null},{"id":"346a38e3f9ff461189ec17cd19084c23","type":"GENE","name":"IGL","canonical_id":"hgnc:HGNC:5853","description":"immunoglobulin lambda locus","metadata":{"aliases":["IGL@"]}},{"id":"e134085ba4d248be894f02a6aadaf526","type":"GENE","name":"IGLC1","canonical_id":"hgnc:HGNC:5855","description":"immunoglobulin lambda constant 1","metadata":{"aliases":["IGLC"]}},{"id":"034aa90e543c4cda872961502e8e628b","type":"GENE","name":"IGLC2","canonical_id":"hgnc:HGNC:5856","description":"immunoglobulin lambda constant 2","metadata":{"aliases":["IGLC"]}},{"id":"278a4f2a5a894b618626ca67e10f687d","type":"GENE","name":"IGLC3","canonical_id":"hgnc:HGNC:5857","description":"immunoglobulin lambda constant 3 (Kern-Oz+ marker)","metadata":{"aliases":["IGLC"]}},{"id":"b3c91a2575004c40b55a15639479f09c","type":"GENE","name":"IGLC4","canonical_id":"hgnc:HGNC:5858","description":"immunoglobulin lambda constant 4 (pseudogene)","metadata":{"aliases":["IGLC"]}},{"id":"2240bc61fe3a4946850f85e93faea1e2","type":"GENE","name":"IGLC5","canonical_id":"hgnc:HGNC:5859","description":"immunoglobulin lambda constant 5 (pseudogene)","metadata":{"aliases":["IGLC"]}},{"id":"a8766d2c4f4a4f8f84a7605978d703a9","type":"GENE","name":"IGLC6","canonical_id":"hgnc:HGNC:5860","description":"immunoglobulin lambda constant 6","metadata":{"aliases":["IGLC"]}},{"id":"1ef49b010d1d40dea830b264ce859f14","type":"GENE","name":"IGLC7","canonical_id":"hgnc:HGNC:5861","description":"immunoglobulin lambda constant 7","metadata":null},{"id":"d343410f80ec4a1eb31c198b80a03d9a","type":"GENE","name":"IGLCOR22-1","canonical_id":"hgnc:HGNC:15696","description":"immunoglobulin lambda constant/OR22-1 (pseudogene)","metadata":{"aliases":["IGLC/OR22-1"]}},{"id":"ef6f6b5323b6439a9799fb155d541267","type":"GENE","name":"IGLCOR22-2","canonical_id":"hgnc:HGNC:15697","description":"immunoglobulin lambda constant/OR22-2 (pseudogene)","metadata":{"aliases":["IGLC/OR22-2"]}},{"id":"dcf03279324c4315a0537d27409ca74a","type":"GENE","name":"IGLJ1","canonical_id":"hgnc:HGNC:5863","description":"immunoglobulin lambda joining 1","metadata":null},{"id":"4f1400ec7ab94d9c8f79ba1c27d97173","type":"GENE","name":"IGLJ2","canonical_id":"hgnc:HGNC:5864","description":"immunoglobulin lambda joining 2","metadata":null},{"id":"b1c7e806713047b48c38a2e471bfc018","type":"GENE","name":"IGLJ3","canonical_id":"hgnc:HGNC:5865","description":"immunoglobulin lambda joining 3","metadata":null},{"id":"94e46d074b454015bda3f0baa1c5ebd4","type":"GENE","name":"IGLJ4","canonical_id":"hgnc:HGNC:5866","description":"immunoglobulin lambda joining 4 (non-functional)","metadata":null},{"id":"c42f3864ca3d4a03b182bd78132fe227","type":"GENE","name":"IGLJ5","canonical_id":"hgnc:HGNC:5867","description":"immunoglobulin lambda joining 5 (non-functional)","metadata":null},{"id":"ef9705dce7314012b1815e384ee31e44","type":"GENE","name":"IGLJ6","canonical_id":"hgnc:HGNC:5868","description":"immunoglobulin lambda joining 6","metadata":null},{"id":"5deafdb7de38425d8bcd512c94eb80be","type":"GENE","name":"IGLJ7","canonical_id":"hgnc:HGNC:5869","description":"immunoglobulin lambda joining 7","metadata":null},{"id":"4ea6eb5f866a495183fbb0ee4fd9b75c","type":"GENE","name":"IGLJCOR18","canonical_id":"hgnc:HGNC:28614","description":"immunoglobulin lambda joining-constant/OR18 (pseudogene)","metadata":{"aliases":["IGLJ-COR18","IGLJ-C/OR18"]}},{"id":"912e034a707e4c0e91b43c00159942d5","type":"GENE","name":"IGLL1","canonical_id":"hgnc:HGNC:5870","description":"immunoglobulin lambda like polypeptide 1","metadata":{"aliases":["IGVPB","IGL5","14.1","CD179B","IGLL"]}},{"id":"da7fd42492f3407b8ae0625684dc9a1a","type":"GENE","name":"IGLL2P","canonical_id":"hgnc:HGNC:5871","description":"immunoglobulin lambda like polypeptide 2, pseudogene","metadata":{"aliases":["FLAMBDA1","16.2","IGLL1P","IGLL2"]}},{"id":"413d6370e8ff4710a7cccb574c846598","type":"GENE","name":"IGLL3P","canonical_id":"hgnc:HGNC:5872","description":"immunoglobulin lambda like polypeptide 3, pseudogene","metadata":{"aliases":["16.1","IGLL3"]}},{"id":"6260b64c7d5749ae88112c81b4027f8a","type":"GENE","name":"IGLL4P","canonical_id":"hgnc:HGNC:38475","description":"immunoglobulin lambda like polypeptide 4, pseudogene","metadata":{"aliases":["IGLL4"]}},{"id":"90c942e4fa1f481583111dc2c7c511fc","type":"GENE","name":"IGLL5","canonical_id":"hgnc:HGNC:38476","description":"immunoglobulin lambda like polypeptide 5","metadata":null},{"id":"474d4bd4ebe741899f35cc2bb8a8fbad","type":"GENE","name":"IGLON5","canonical_id":"hgnc:HGNC:34550","description":"IgLON family member 5","metadata":{"aliases":["LOC402665"]}},{"id":"1cbe335a2e19400ebe1fa7de88f28e7e","type":"GENE","name":"IGLV1-36","canonical_id":"hgnc:HGNC:5876","description":"immunoglobulin lambda variable 1-36","metadata":null},{"id":"fa92b1f5f4dd4d8497c02d23f33519e5","type":"GENE","name":"IGLV1-40","canonical_id":"hgnc:HGNC:5877","description":"immunoglobulin lambda variable 1-40","metadata":null},{"id":"a37002efcdf94d1e8c5b76780263eb84","type":"GENE","name":"IGLV1-41","canonical_id":"hgnc:HGNC:5878","description":"immunoglobulin lambda variable 1-41 (pseudogene)","metadata":null},{"id":"87003fdfc411466e983397bc2e5e0824","type":"GENE","name":"IGLV1-44","canonical_id":"hgnc:HGNC:5879","description":"immunoglobulin lambda variable 1-44","metadata":null},{"id":"80cdfa6e1d964eec96fc42b27965d7cd","type":"GENE","name":"IGLV1-47","canonical_id":"hgnc:HGNC:5880","description":"immunoglobulin lambda variable 1-47","metadata":null},{"id":"e7525c98a5ce4d3ebd8e88eb9046ad2f","type":"GENE","name":"IGLV1-50","canonical_id":"hgnc:HGNC:5881","description":"immunoglobulin lambda variable 1-50 (non-functional)","metadata":null},{"id":"ad5068d6310e4ca0a4bbf5242bfa5e9c","type":"GENE","name":"IGLV1-51","canonical_id":"hgnc:HGNC:5882","description":"immunoglobulin lambda variable 1-51","metadata":null},{"id":"23d3d1c197cb46bda0321245cb62d683","type":"GENE","name":"IGLV1-62","canonical_id":"hgnc:HGNC:5883","description":"immunoglobulin lambda variable 1-62 (pseudogene)","metadata":null},{"id":"4260a2fd17de496684cb3d45ca0988e1","type":"GENE","name":"IGLV10-54","canonical_id":"hgnc:HGNC:5884","description":"immunoglobulin lambda variable 10-54","metadata":null},{"id":"8ef6296c2276442c979419c2f4efe7ea","type":"GENE","name":"IGLV10-67","canonical_id":"hgnc:HGNC:5885","description":"immunoglobulin lambda variable 10-67 (pseudogene)","metadata":null},{"id":"6de5403fe9a24871a59f9a1dece3c0aa","type":"GENE","name":"IGLV11-55","canonical_id":"hgnc:HGNC:5886","description":"immunoglobulin lambda variable 11-55 (non-functional)","metadata":null},{"id":"d989ae13156c4015b87cab8e53c93df3","type":"GENE","name":"IGLV2-11","canonical_id":"hgnc:HGNC:5887","description":"immunoglobulin lambda variable 2-11","metadata":null},{"id":"af1ef29972334685a11f049fa3d774a6","type":"GENE","name":"IGLV2-14","canonical_id":"hgnc:HGNC:5888","description":"immunoglobulin lambda variable 2-14","metadata":null},{"id":"8bc5d58703074810b6c7afd225967cbb","type":"GENE","name":"IGLV2-18","canonical_id":"hgnc:HGNC:5889","description":"immunoglobulin lambda variable 2-18","metadata":null},{"id":"94d3aaa7fb334cf08182f2ac7dd1764f","type":"GENE","name":"IGLV2-23","canonical_id":"hgnc:HGNC:5890","description":"immunoglobulin lambda variable 2-23","metadata":null},{"id":"8dd5c85030974f3e8f4ec905e32cd092","type":"GENE","name":"IGLV2-28","canonical_id":"hgnc:HGNC:5891","description":"immunoglobulin lambda variable 2-28 (pseudogene)","metadata":null},{"id":"8e0c91c5c73e474691f2f3638a3937b1","type":"GENE","name":"IGLV2-33","canonical_id":"hgnc:HGNC:5892","description":"immunoglobulin lambda variable 2-33 (non-functional)","metadata":null},{"id":"de320f15e9004ce2807268587f00ab7e","type":"GENE","name":"IGLV2-34","canonical_id":"hgnc:HGNC:5893","description":"immunoglobulin lambda variable 2-34 (pseudogene)","metadata":null},{"id":"906f2f33d6964a5f9a23fc994f78444b","type":"GENE","name":"IGLV2-5","canonical_id":"hgnc:HGNC:5894","description":"immunoglobulin lambda variable 2-5 (pseudogene)","metadata":null},{"id":"969445d2fd164f0a870213d500d628af","type":"GENE","name":"IGLV2-8","canonical_id":"hgnc:HGNC:5895","description":"immunoglobulin lambda variable 2-8","metadata":null},{"id":"e69ed3acce3840eca5f0c051711dd0d2","type":"GENE","name":"IGLV3-1","canonical_id":"hgnc:HGNC:5896","description":"immunoglobulin lambda variable 3-1","metadata":null},{"id":"7896568146694b25a159d2efe121c6d1","type":"GENE","name":"IGLV3-10","canonical_id":"hgnc:HGNC:5897","description":"immunoglobulin lambda variable 3-10","metadata":null},{"id":"5de0f14504e9476e9cb9fc5013d8240b","type":"GENE","name":"IGLV3-12","canonical_id":"hgnc:HGNC:5898","description":"immunoglobulin lambda variable 3-12","metadata":null},{"id":"bb4d69eef80d44eb9efad83c3286a830","type":"GENE","name":"IGLV3-13","canonical_id":"hgnc:HGNC:5899","description":"immunoglobulin lambda variable 3-13 (pseudogene)","metadata":null},{"id":"b1922e1e163a4d7289a074854456fcc3","type":"GENE","name":"IGLV3-15","canonical_id":"hgnc:HGNC:5900","description":"immunoglobulin lambda variable 3-15 (pseudogene)","metadata":null},{"id":"903fbc45ff9a4f2d9b12d590b8d6de5b","type":"GENE","name":"IGLV3-16","canonical_id":"hgnc:HGNC:5901","description":"immunoglobulin lambda variable 3-16","metadata":null},{"id":"eef01b312b294bb2b3b22570023a224f","type":"GENE","name":"IGLV3-17","canonical_id":"hgnc:HGNC:5902","description":"immunoglobulin lambda variable 3-17 (pseudogene)","metadata":null},{"id":"c432b420948b4e548221ee5d0728d078","type":"GENE","name":"IGLV3-19","canonical_id":"hgnc:HGNC:5903","description":"immunoglobulin lambda variable 3-19","metadata":null},{"id":"4abac7156e644e058c5c29822ac6f706","type":"GENE","name":"IGLV3-2","canonical_id":"hgnc:HGNC:5904","description":"immunoglobulin lambda variable 3-2 (pseudogene)","metadata":null},{"id":"e19cafb7fa174eb4b497ed69a0aaf28f","type":"GENE","name":"IGLV3-21","canonical_id":"hgnc:HGNC:5905","description":"immunoglobulin lambda variable 3-21","metadata":null},{"id":"2396eb9ac4ac406b94c3e7f4281ffac4","type":"GENE","name":"IGLV3-22","canonical_id":"hgnc:HGNC:5906","description":"immunoglobulin lambda variable 3-22","metadata":null},{"id":"501bbddd49524be79d7b8365db4fef83","type":"GENE","name":"IGLV3-24","canonical_id":"hgnc:HGNC:5907","description":"immunoglobulin lambda variable 3-24 (pseudogene)","metadata":null},{"id":"a5a8ff6986aa4237a3d72f402f60d71b","type":"GENE","name":"IGLV3-25","canonical_id":"hgnc:HGNC:5908","description":"immunoglobulin lambda variable 3-25","metadata":null},{"id":"fa4837e317b3471989fcf60ca2cbc1c1","type":"GENE","name":"IGLV3-26","canonical_id":"hgnc:HGNC:5909","description":"immunoglobulin lambda variable 3-26 (pseudogene)","metadata":null},{"id":"e769915566754f298ece7cae7ee0f2ff","type":"GENE","name":"IGLV3-27","canonical_id":"hgnc:HGNC:5910","description":"immunoglobulin lambda variable 3-27","metadata":null},{"id":"6f6a9aaac15f4fccbb9d1f7ef80cb24f","type":"GENE","name":"IGLV3-29","canonical_id":"hgnc:HGNC:5911","description":"immunoglobulin lambda variable 3-29 (pseudogene)","metadata":null},{"id":"9e31dc8f7d6a4922bdcd80fb017d5a9d","type":"GENE","name":"IGLV3-30","canonical_id":"hgnc:HGNC:5912","description":"immunoglobulin lambda variable 3-30 (pseudogene)","metadata":null},{"id":"606d40a142804d2aa97b28711b02971e","type":"GENE","name":"IGLV3-31","canonical_id":"hgnc:HGNC:5913","description":"immunoglobulin lambda variable 3-31 (pseudogene)","metadata":null},{"id":"fe3b2ec3a6a74f20b21aca051203e52b","type":"GENE","name":"IGLV3-32","canonical_id":"hgnc:HGNC:5914","description":"immunoglobulin lambda variable 3-32 (non-functional)","metadata":null},{"id":"98dd4a2043024bf29bf1ae967ef5a27d","type":"GENE","name":"IGLV3-4","canonical_id":"hgnc:HGNC:5915","description":"immunoglobulin lambda variable 3-4 (pseudogene)","metadata":null},{"id":"96fd0c6759184393bca3ca40bcc263bd","type":"GENE","name":"IGLV3-6","canonical_id":"hgnc:HGNC:5916","description":"immunoglobulin lambda variable 3-6 (pseudogene)","metadata":null},{"id":"8a106174fec94060aa91f41211faec21","type":"GENE","name":"IGLV3-7","canonical_id":"hgnc:HGNC:5917","description":"immunoglobulin lambda variable 3-7 (pseudogene)","metadata":null},{"id":"c7eacd1669b446cabb4fb5e0b6b7b530","type":"GENE","name":"IGLV3-9","canonical_id":"hgnc:HGNC:5918","description":"immunoglobulin lambda variable 3-9","metadata":null},{"id":"1d3c362e35d34f3aa4e8326b0f3a19fd","type":"GENE","name":"IGLV4-3","canonical_id":"hgnc:HGNC:5919","description":"immunoglobulin lambda variable 4-3","metadata":null},{"id":"8cd19e25cfa64d0eacc2124c72e01924","type":"GENE","name":"IGLV4-60","canonical_id":"hgnc:HGNC:5920","description":"immunoglobulin lambda variable 4-60","metadata":null},{"id":"701f720d52f348e2b2a39e25caf8cd5d","type":"GENE","name":"IGLV4-69","canonical_id":"hgnc:HGNC:5921","description":"immunoglobulin lambda variable 4-69","metadata":null},{"id":"01a67d70992541fc9e676d8de3b64468","type":"GENE","name":"IGLV5-37","canonical_id":"hgnc:HGNC:5922","description":"immunoglobulin lambda variable 5-37","metadata":null},{"id":"db48283cc3d04281b943462d64f80e25","type":"GENE","name":"IGLV5-39","canonical_id":"hgnc:HGNC:5923","description":"immunoglobulin lambda variable 5-39","metadata":null},{"id":"73429054054c48b6ae957072008ceac9","type":"GENE","name":"IGLV5-45","canonical_id":"hgnc:HGNC:5924","description":"immunoglobulin lambda variable 5-45","metadata":null},{"id":"2aa069a44bbb462b9f02c3de5fa6ce2f","type":"GENE","name":"IGLV5-48","canonical_id":"hgnc:HGNC:5925","description":"immunoglobulin lambda variable 5-48 (non-functional)","metadata":null},{"id":"590eab857df7463abce8734db27e7020","type":"GENE","name":"IGLV5-52","canonical_id":"hgnc:HGNC:5926","description":"immunoglobulin lambda variable 5-52","metadata":null},{"id":"cd3d23a3947a40758d7fe8417c680791","type":"GENE","name":"IGLV6-57","canonical_id":"hgnc:HGNC:5927","description":"immunoglobulin lambda variable 6-57","metadata":null},{"id":"79d4ba875e054d2195ec9666a2a28342","type":"GENE","name":"IGLV7-35","canonical_id":"hgnc:HGNC:5928","description":"immunoglobulin lambda variable 7-35 (pseudogene)","metadata":null},{"id":"0db91e68ddf94b97a61c47742c91d32a","type":"GENE","name":"IGLV7-43","canonical_id":"hgnc:HGNC:5929","description":"immunoglobulin lambda variable 7-43","metadata":null},{"id":"3ec945757579437b9ee9e07bf2b604b7","type":"GENE","name":"IGLV7-46","canonical_id":"hgnc:HGNC:5930","description":"immunoglobulin lambda variable 7-46","metadata":null},{"id":"da95520df8734550a9d2fafc7f0211dc","type":"GENE","name":"IGLV8-61","canonical_id":"hgnc:HGNC:5931","description":"immunoglobulin lambda variable 8-61","metadata":null},{"id":"ce325f1bbaf149cfbfce36d2657c684b","type":"GENE","name":"IGLV8OR8-1","canonical_id":"hgnc:HGNC:5932","description":"immunoglobulin lambda variable 8/OR8-1 (pseudogene)","metadata":{"aliases":["IGLV8/OR8-1"]}},{"id":"586b0e0826de4fb68258a9eae2e386e3","type":"GENE","name":"IGLV9-49","canonical_id":"hgnc:HGNC:5933","description":"immunoglobulin lambda variable 9-49","metadata":null},{"id":"dc1a15b58ae4411ea82932342994e8f6","type":"GENE","name":"IGLVI-20","canonical_id":"hgnc:HGNC:5934","description":"immunoglobulin lambda variable (I)-20 (pseudogene)","metadata":{"aliases":["IGLV(I)-20"]}},{"id":"5a6d90df12834a028d4d7ffe22da968a","type":"GENE","name":"IGLVI-38","canonical_id":"hgnc:HGNC:5935","description":"immunoglobulin lambda variable (I)-38 (pseudogene)","metadata":{"aliases":["IGLV(I)-38"]}},{"id":"f02d651282324fb39bfa450876dcdfdf","type":"GENE","name":"IGLVI-42","canonical_id":"hgnc:HGNC:5936","description":"immunoglobulin lambda variable (I)-42 (pseudogene)","metadata":{"aliases":["IGLV(I)-42"]}},{"id":"896e7189c1f949879ea0c6f047a2691b","type":"GENE","name":"IGLVI-56","canonical_id":"hgnc:HGNC:5937","description":"immunoglobulin lambda variable (I)-56 (pseudogene)","metadata":{"aliases":["IGLV(I)-56"]}},{"id":"ed3ed8669eb740c099adae4cce0c7880","type":"GENE","name":"IGLVI-63","canonical_id":"hgnc:HGNC:5938","description":"immunoglobulin lambda variable (I)-63 (pseudogene)","metadata":{"aliases":["IGLV(I)-63"]}},{"id":"61a0cd87916c44e29bb97d47e4609d8e","type":"GENE","name":"IGLVI-68","canonical_id":"hgnc:HGNC:5939","description":"immunoglobulin lambda variable (I)-68 (pseudogene)","metadata":{"aliases":["IGLV(I)-68"]}},{"id":"1c4641dda759484eb697da2541e93ece","type":"GENE","name":"IGLVI-70","canonical_id":"hgnc:HGNC:5940","description":"immunoglobulin lambda variable (I)-70 (pseudogene)","metadata":{"aliases":["IGLV(I)-70"]}},{"id":"cf392089232542749fbe481efeffa22b","type":"GENE","name":"IGLVIV-53","canonical_id":"hgnc:HGNC:5941","description":"immunoglobulin lambda variable (IV)-53 (pseudogene)","metadata":{"aliases":["IGLV(IV)-53"]}},{"id":"5114a48c69d64129a18c1645f244971e","type":"GENE","name":"IGLVIV-59","canonical_id":"hgnc:HGNC:5942","description":"immunoglobulin lambda variable (IV)-59 (pseudogene)","metadata":{"aliases":["IGLV(IV)-59"]}},{"id":"3e3722191d264a168555448625406261","type":"GENE","name":"IGLVIV-64","canonical_id":"hgnc:HGNC:5943","description":"immunoglobulin lambda variable (IV)-64 (pseudogene)","metadata":{"aliases":["IGLV(IV)-64"]}},{"id":"d4f48c24bca0448893cabd7b537b5890","type":"GENE","name":"IGLVIV-65","canonical_id":"hgnc:HGNC:5944","description":"immunoglobulin lambda variable (IV)-65 (pseudogene)","metadata":{"aliases":["IGLV(IV)-65"]}},{"id":"826149f9ccc04aec80d72fd539719dc3","type":"GENE","name":"IGLVIV-66-1","canonical_id":"hgnc:HGNC:15692","description":"immunoglobulin lambda variable (IV)-66-1 (pseudogene)","metadata":{"aliases":["IGLV(IV)-66-1"]}},{"id":"0319cb23d5a74123a899aaf50f7e6ea5","type":"GENE","name":"IGLVIVOR22-1","canonical_id":"hgnc:HGNC:15694","description":"immunoglobulin lambda variable (IV)/OR22-1 (pseudogene)","metadata":{"aliases":["IGLV(IV)/OR22-1"]}},{"id":"1043c7db14fe4188b0a2827edb12d0ea","type":"GENE","name":"IGLVIVOR22-2","canonical_id":"hgnc:HGNC:15695","description":"immunoglobulin lambda variable (IV)/OR22-2 (pseudogene)","metadata":{"aliases":["IGLV(IV)/OR22-2"]}},{"id":"d802b4a594df4d04a69f9bf3c4cf007b","type":"GENE","name":"IGLVV-58","canonical_id":"hgnc:HGNC:5945","description":"immunoglobulin lambda variable (V)-58 (pseudogene)","metadata":{"aliases":["IGLV(V)-58"]}},{"id":"8862cde5f7f54f0f941e30e00912cc53","type":"GENE","name":"IGLVV-66","canonical_id":"hgnc:HGNC:5946","description":"immunoglobulin lambda variable (V)-66 (pseudogene)","metadata":{"aliases":["IGLV(V)-66"]}},{"id":"f919d752ca054daeb7087c696d2900fd","type":"GENE","name":"IGLVVI-22-1","canonical_id":"hgnc:HGNC:15689","description":"immunoglobulin lambda variable (VI)-22-1 (pseudogene)","metadata":{"aliases":["IGLV(VI)-22-1"]}},{"id":"cc59c582628f4db89290a0e81ce64aaf","type":"GENE","name":"IGLVVI-25-1","canonical_id":"hgnc:HGNC:15690","description":"immunoglobulin lambda variable (VI)-25-1 (pseudogene)","metadata":{"aliases":["IGLV(VI)-25-1"]}},{"id":"f9769845218a469ebd93c788e39c3d4c","type":"GENE","name":"IGLVVII-41-1","canonical_id":"hgnc:HGNC:15691","description":"immunoglobulin lambda variable (VII)-41-1 (pseudogene)","metadata":{"aliases":["IGLV(VII)-41-1"]}},{"id":"04445e23d5124cc28c431ffc84cf6816","type":"TRIAL","name":"IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)","canonical_id":"clinicaltrials.gov:NCT07104032","description":"Relapsed/Refractory Primary Central Nervous System Lymphoma","metadata":null},{"id":"1f787270824e4a048345df05b480a411","type":"GENE","name":"IGSF1","canonical_id":"hgnc:HGNC:5948","description":"immunoglobulin superfamily member 1","metadata":{"aliases":["KIAA0364","IGDC1","IGCD1","INHBP","MGC75490","PGSF2"]}},{"id":"a5211e23d4604dfa96db6c56d6d180b7","type":"GENE","name":"IGSF10","canonical_id":"hgnc:HGNC:26384","description":"immunoglobulin superfamily member 10","metadata":{"aliases":["FLJ25972","CMF608"]}},{"id":"436d19d4edd94bc9a29fe0b01e1d3343","type":"GENE","name":"IGSF11","canonical_id":"hgnc:HGNC:16669","description":"immunoglobulin superfamily member 11","metadata":{"aliases":["BT-IgSF","MGC35227","Igsf13","VSIG3","CT119"]}},{"id":"6cc244b7a7be4b85b92a909e6e57e2eb","type":"GENE","name":"IGSF11-AS1","canonical_id":"hgnc:HGNC:40777","description":"IGSF11 antisense RNA 1","metadata":null},{"id":"57b7b2ae5596492bb2a4a6a4536673c2","type":"GENE","name":"IGSF21","canonical_id":"hgnc:HGNC:28246","description":"immunoglobin superfamily member 21","metadata":{"aliases":["MGC15730","RP11-121A23.1"]}},{"id":"a16e1b6514c943d1b7d8f292b5b29334","type":"GENE","name":"IGSF21-AS1","canonical_id":"hgnc:HGNC:41190","description":"IGSF21 antisense RNA 1","metadata":null},{"id":"17a44783c99c4869a386e24f8f5a387c","type":"GENE","name":"IGSF22","canonical_id":"hgnc:HGNC:26750","description":"immunoglobulin superfamily member 22","metadata":{"aliases":["FLJ37794","IGFN2"]}},{"id":"8598911f80a24a0b90fc54e05ffa156d","type":"GENE","name":"IGSF22-AS1","canonical_id":"hgnc:HGNC:55511","description":"IGSF22 antisense RNA 1","metadata":null},{"id":"2d2ad1d8021d421b8ef458a86299dc49","type":"GENE","name":"IGSF23","canonical_id":"hgnc:HGNC:40040","description":"immunoglobulin superfamily member 23","metadata":null},{"id":"f1ef902c693f44f69a3db96acdaba49f","type":"GENE","name":"IGSF3","canonical_id":"hgnc:HGNC:5950","description":"immunoglobulin superfamily member 3","metadata":{"aliases":["V8","EWI-3","MGC117164"]}},{"id":"ee5848407da84129ac540200b51c9c57","type":"GENE","name":"IGSF3P1","canonical_id":"hgnc:HGNC:55895","description":"IGSF3 pseudogene 1","metadata":null},{"id":"79dd7391c3234bbd87b742b7da3b0782","type":"GENE","name":"IGSF3P2","canonical_id":"hgnc:HGNC:55896","description":"IGSF3 pseudogene 2","metadata":null},{"id":"284fb90a8b1d44da836b1113ebda62ed","type":"GENE","name":"IGSF5","canonical_id":"hgnc:HGNC:5952","description":"immunoglobulin superfamily member 5","metadata":{"aliases":["JAM4"]}},{"id":"90f4339cd531436aa3d87ae97ff2194f","type":"GENE","name":"IGSF6","canonical_id":"hgnc:HGNC:5953","description":"immunoglobulin superfamily member 6","metadata":{"aliases":["DORA"]}},{"id":"f52ee365ccb549faa47ef1fb8c6568c3","type":"GENE","name":"IGSF8","canonical_id":"hgnc:HGNC:17813","description":"immunoglobulin superfamily member 8","metadata":{"aliases":["CD81P3","EWI2","PGRL","CD316"]}},{"id":"e84a2be8693a4416aa85f22fe6d01062","type":"GENE","name":"IGSF9","canonical_id":"hgnc:HGNC:18132","description":"immunoglobulin superfamily member 9","metadata":{"aliases":["KIAA1355","Nrt1","IGSF9A"]}},{"id":"c4a78ab6b49840ec890efc75c040b985","type":"GENE","name":"IGSF9B","canonical_id":"hgnc:HGNC:32326","description":"immunoglobulin superfamily member 9B","metadata":{"aliases":["KIAA1030","LINC00947","LOC283174","MIR4697HG"]}},{"id":"f945c057fbb949ee9babec71c548d5c3","type":"GO_TERM","name":"IHF-DNA complex","canonical_id":"go:GO:1990177","description":"\"A protein-DNA complex containing IHF heterodimers (an alpha and a beta chain) bound to DNA. IHF binds to double-stranded DNA in a structure- and sequence-specific manner and bends the DNA into a nucleosome-like structure, the bacterial nucleoid.\" [GOC:bhm, PMID:17097674]","metadata":null},{"id":"9da735aa7e7b4851afd166289dfc847c","type":"GENE","name":"IHH","canonical_id":"hgnc:HGNC:5956","description":null,"metadata":null},{"id":"e08c9b3655a541d9abcc737a526fb5cd","type":"GENE","name":"IHO1","canonical_id":"hgnc:HGNC:27945","description":"interactor of HORMAD1 1","metadata":{"aliases":["FLJ25320","CT74","LELA1","CCDC36"]}},{"id":"9aff6b762cb1480ebd33b2da5175507a","type":"TRIAL","name":"IINB vs. QLB for Elective Open Inguinal Herniorrhaphy","canonical_id":"clinicaltrials.gov:NCT03007966","description":"Nerve Block; Herniorrhaphy; Regional Anesthesia","metadata":null},{"id":"9b8805c1f36d4bce9d7ba9758fb739bd","type":"TRIAL","name":"IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT01491841","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"9d9e88f749b448fca2060ad3c389249c","type":"GENE","name":"IK","canonical_id":"hgnc:HGNC:5958","description":"IK cytokine","metadata":{"aliases":["RED","RER"]}},{"id":"f5e8fc07b1b64be58577dedf7ca68383","type":"GENE","name":"IKBIP","canonical_id":"hgnc:HGNC:26430","description":"IKBKB interacting protein","metadata":{"aliases":["FLJ31051","IKIP"]}},{"id":"808cd124cdb94d75aea22cd66d47e3b1","type":"GENE","name":"IKBKB","canonical_id":"hgnc:HGNC:5960","description":null,"metadata":null},{"id":"4f9e704073bc425ea2f47d036eee78da","type":"GENE","name":"IKBKB-DT","canonical_id":"hgnc:HGNC:55254","description":"IKBKB divergent transcript","metadata":{"aliases":["RP11-231D20.2","ALAL-1","IKBKBAS"]}},{"id":"f4c3dcd9ceda4191bba21e4a2bc85a8e","type":"GENE","name":"IKBKE","canonical_id":"hgnc:HGNC:14552","description":null,"metadata":null},{"id":"a7e8b1b064de4186b161b27ca77e7b42","type":"GENE","name":"IKBKE-AS1","canonical_id":"hgnc:HGNC:32061","description":"IKBKE antisense RNA 1","metadata":{"aliases":["FLJ32597","C1orf147"]}},{"id":"0bc72afb2fd547109997ee21920507dd","type":"GENE","name":"IKBKG","canonical_id":"hgnc:HGNC:5961","description":"inhibitor of nuclear factor kappa B kinase regulatory subunit gamma","metadata":{"aliases":["IKK-gamma","NEMO","Fip3p","FIP-3","FIP3","IKKAP1","IKKG","IP2","IP1"]}},{"id":"7ea037719fa246eca77e2c520fabbc5b","type":"GENE","name":"IKBKGP1","canonical_id":"hgnc:HGNC:24455","description":"inhibitor of nuclear factor kappa B kinase subunit gamma pseudogene 1","metadata":{"aliases":["deltaNEMO","IKBKGP"]}},{"id":"793199b89a1f498e812770dfa2296bd3","type":"GO_TERM","name":"IKKalpha-IKKalpha complex","canonical_id":"go:GO:0038059","description":"\"A homodimeric protein complex containing two IkappaB kinase (IKK) alpha subunits.\" [GOC:bf, PMID:18626576, PMID:21173796]","metadata":null},{"id":"88baa81029fe496bb614242cb6f1a361","type":"GENE","name":"IKZF1","canonical_id":"hgnc:HGNC:13176","description":null,"metadata":null},{"id":"daf6d7e55b3f4a97b218d4e4d1fad9d4","type":"GENE","name":"IKZF2","canonical_id":"hgnc:HGNC:13177","description":"IKAROS family zinc finger 2","metadata":{"aliases":["Helios","ZNFN1A2"]}},{"id":"cbfb72f7b78a45d888a34d5b750ef0ec","type":"GENE","name":"IKZF3","canonical_id":"hgnc:HGNC:13178","description":"IKAROS family zinc finger 3","metadata":{"aliases":["Aiolos","ZNFN1A3"]}},{"id":"a882d58785944f4692289b98a6b95a4a","type":"GENE","name":"IKZF4","canonical_id":"hgnc:HGNC:13179","description":"IKAROS family zinc finger 4","metadata":{"aliases":["Eos","ZNFN1A4"]}},{"id":"c9f547d88d914a31a2c76f2f4fed8e47","type":"GENE","name":"IKZF5","canonical_id":"hgnc:HGNC:14283","description":"IKAROS family zinc finger 5","metadata":{"aliases":["Pegasus","FLJ22973","ZNFN1A5"]}},{"id":"e5864c877a8244b9bf3b0b7b983849e8","type":"TRIAL","name":"IL-11 in Adults With Von Willebrand Disease Undergoing Surgery","canonical_id":"clinicaltrials.gov:NCT00524225","description":"Von Willebrand Disease","metadata":null},{"id":"30f133c6941f4c8f9dffb8caf8d65af2","type":"TRIAL","name":"IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia","canonical_id":"clinicaltrials.gov:NCT00524342","description":"Von Willebrand Disease","metadata":null},{"id":"cc45ce963c194beb9c231c088ecb3549","type":"TRIAL","name":"IL-17 Blockade to Decrease irAEs (REPLAY)","canonical_id":"clinicaltrials.gov:NCT07237594","description":"Metastatic Melanoma","metadata":null},{"id":"edf8a34f0e0940879eadb729c8498163","type":"TRIAL","name":"IL-1RA, Acute Exercise, and Beta-cell Function","canonical_id":"clinicaltrials.gov:NCT02310009","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"dadbd3ecd49646648812e7ac2e757fd0","type":"TRIAL","name":"IL-1ra Dose-range Study for Moderate-to-severe TBI Patients","canonical_id":"clinicaltrials.gov:NCT02997371","description":"Traumatic Brain INjury","metadata":null},{"id":"ffc4e75e8cc649e3bacc5d0529a85ecb","type":"TRIAL","name":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","canonical_id":"clinicaltrials.gov:NCT02451748","description":"Rheumatoid Arthritis","metadata":null},{"id":"4bf863c94c4f465fa909ab6f31b63251","type":"TRIAL","name":"IL1-TRAP, Rilonacept, in Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT01538719","description":"Scleroderma; Systemic Sclerosis; Diffuse Scleroderma; Diffuse Systemic Sclerosis","metadata":null},{"id":"4e631843bb734938a4256b456fd92788","type":"GENE","name":"IL10","canonical_id":"hgnc:HGNC:5962","description":null,"metadata":null},{"id":"056a95a812234d54aea00038b9650724","type":"GENE","name":"IL10RA","canonical_id":"hgnc:HGNC:5964","description":"interleukin 10 receptor subunit alpha","metadata":{"aliases":["HIL-10R","CDW210A","CD210a","CD210","IL10R"]}},{"id":"8df73bb9b7474a71a0f0ce5ba406e4da","type":"GENE","name":"IL10RB","canonical_id":"hgnc:HGNC:5965","description":"interleukin 10 receptor subunit beta","metadata":{"aliases":["CRF2-4","CDW210B","IL-10R2","CRFB4","D21S58","D21S66"]}},{"id":"42d752903b894d62af7ba0f31bf67318","type":"GENE","name":"IL10RB-DT","canonical_id":"hgnc:HGNC:44303","description":"IL10RB divergent transcript","metadata":{"aliases":["IFNAR2-AS1","IL10RB-AS1"]}},{"id":"12af395df3d74dd6b822385ec0d8860f","type":"GENE","name":"IL11","canonical_id":"hgnc:HGNC:5966","description":null,"metadata":null},{"id":"3fe5a7c01bfc4afc849acfa9d5f5ac9b","type":"GENE","name":"IL11RA","canonical_id":"hgnc:HGNC:5967","description":"interleukin 11 receptor subunit alpha","metadata":null},{"id":"5a49eb9fc3e74293b2f018863d351487","type":"PROTEIN","name":"IL11RA","canonical_id":"uniprot:Q14626","description":null,"metadata":null},{"id":"6c715620a5be47409f3c6fd3608d04da","type":"GENE","name":"IL12A","canonical_id":"hgnc:HGNC:5969","description":null,"metadata":null},{"id":"7b12a64a659f4d438866b4f083268136","type":"GENE","name":"IL12A-AS1","canonical_id":"hgnc:HGNC:49094","description":"IL12A antisense RNA 1","metadata":{"aliases":["ILAS1-AS1"]}},{"id":"49230ff64d51469faae4bb9473a25e74","type":"GENE","name":"IL12B","canonical_id":"hgnc:HGNC:5970","description":null,"metadata":null},{"id":"a18c5188c03a4b6494d64c91a62f05fd","type":"PROTEIN","name":"IL12B","canonical_id":"uniprot:P29460","description":null,"metadata":null},{"id":"09c4ced94db34445b32977214aada67a","type":"GENE","name":"IL12B-AS1","canonical_id":"hgnc:HGNC:58156","description":"IL12B antisense RNA 1","metadata":{"aliases":["Uc003xsl.1"]}},{"id":"4cbef2d503664835aee3f9d28a6c7358","type":"GENE","name":"IL12RB1","canonical_id":"hgnc:HGNC:5971","description":"interleukin 12 receptor subunit beta 1","metadata":{"aliases":["CD212","IL12RB"]}},{"id":"2cd405d888c14256ba8b94ac4c7b032d","type":"GENE","name":"IL12RB2","canonical_id":"hgnc:HGNC:5972","description":null,"metadata":null},{"id":"27d50a697a054430abb70ab498209a60","type":"GENE","name":"IL13","canonical_id":"hgnc:HGNC:5973","description":null,"metadata":null},{"id":"d687b15b2daa4909a59898a55c40c6d5","type":"PROTEIN","name":"IL13","canonical_id":"uniprot:P35225","description":null,"metadata":null},{"id":"81e8e29e5a1e42c1b49b62db4becb974","type":"GENE","name":"IL13RA1","canonical_id":"hgnc:HGNC:5974","description":"interleukin 13 receptor subunit alpha 1","metadata":{"aliases":["IL-13Ra","NR4","CD213a1"]}},{"id":"d82e72d1387d40b7b7d2484158d40eae","type":"GENE","name":"IL13RA2","canonical_id":"hgnc:HGNC:5975","description":"interleukin 13 receptor subunit alpha 2","metadata":{"aliases":["IL-13R","IL13BP","CD213a2","CT19"]}},{"id":"998e91e9161249989a3c4e9378f73182","type":"GENE","name":"IL15","canonical_id":"hgnc:HGNC:5977","description":null,"metadata":null},{"id":"4efd24e4106644fdb197df619081a3e3","type":"GENE","name":"IL15RA","canonical_id":"hgnc:HGNC:5978","description":"interleukin 15 receptor subunit alpha","metadata":{"aliases":["CD215","IL-15RA"]}},{"id":"b57148f8a89845998911110aadafb1c5","type":"GENE","name":"IL16","canonical_id":"hgnc:HGNC:5980","description":"interleukin 16","metadata":{"aliases":["LCF","IL-16","prIL-16","HsT19289","FLJ42735","FLJ16806"]}},{"id":"850f0e98897749daa118d35727d115ec","type":"GENE","name":"IL17A","canonical_id":"hgnc:HGNC:5981","description":null,"metadata":null},{"id":"f40d7a319e0546bfb3f92c8671fbd0f0","type":"PROTEIN","name":"IL17A","canonical_id":"uniprot:Q16552","description":null,"metadata":null},{"id":"8bfc2b87da474e5e83eee9bf54b9d9db","type":"GENE","name":"IL17B","canonical_id":"hgnc:HGNC:5982","description":"interleukin 17B","metadata":{"aliases":["IL-17B","ZCYTO7","IL-20","MGC138900","MGC138901","NIRF"]}},{"id":"beb5d54e81fb4335b0f595a75aff41f8","type":"GENE","name":"IL17B-AS1","canonical_id":"hgnc:HGNC:40297","description":"IL17B antisense RNA 1","metadata":null},{"id":"7cdfdce8f82f444f92b21e36506dcdce","type":"GENE","name":"IL17C","canonical_id":"hgnc:HGNC:5983","description":null,"metadata":null},{"id":"7315d838ffd6434bb765195c5b5f23a9","type":"GENE","name":"IL17D","canonical_id":"hgnc:HGNC:5984","description":"interleukin 17D","metadata":{"aliases":["IL-27","IL-17D","IL27","FLJ30846"]}},{"id":"f2346b066f63488a93dbee0c9a266352","type":"GENE","name":"IL17F","canonical_id":"hgnc:HGNC:16404","description":"interleukin 17F","metadata":{"aliases":["IL-17F","ML-1","ML1"]}},{"id":"cabcc94c83a64088861862ec0e400460","type":"PROTEIN","name":"IL17F","canonical_id":"uniprot:Q96PD4","description":null,"metadata":null},{"id":"24d06ee495af41bbb34f1c9d6baa537e","type":"GENE","name":"IL17RA","canonical_id":"hgnc:HGNC:5985","description":"interleukin 17 receptor A","metadata":{"aliases":["hIL-17R","IL-17RA","CDw217","CD217","IL17R"]}},{"id":"37252fdc0627455e8cc4689ee817b386","type":"PROTEIN","name":"IL17RA","canonical_id":"uniprot:Q96F46","description":null,"metadata":null},{"id":"e5699e714e924951accc608333db2c70","type":"GENE","name":"IL17RB","canonical_id":"hgnc:HGNC:18015","description":null,"metadata":null},{"id":"36bbc4a1fa314530b714852f54d0cbe9","type":"GENE","name":"IL17RC","canonical_id":"hgnc:HGNC:18358","description":"interleukin 17 receptor C","metadata":{"aliases":["IL17-RL"]}},{"id":"fa4c551ba15a4c3a8691ac9d12f09cfc","type":"GENE","name":"IL17RD","canonical_id":"hgnc:HGNC:17616","description":"interleukin 17 receptor D","metadata":{"aliases":["SEF","IL17RLM","FLJ35755","IL-17RD"]}},{"id":"7e9b5a82dbca4f568951f5fc1eda2e7c","type":"GENE","name":"IL17RE","canonical_id":"hgnc:HGNC:18439","description":"interleukin 17 receptor E","metadata":{"aliases":["FLJ23658"]}},{"id":"005ff7874a2c491391ca2f615c5bb529","type":"GENE","name":"IL17REL","canonical_id":"hgnc:HGNC:33808","description":"interleukin 17 receptor E like","metadata":{"aliases":["FLJ41993"]}},{"id":"5f88f737c94b473fb0d4dffa4dc905ba","type":"GENE","name":"IL18","canonical_id":"hgnc:HGNC:5986","description":null,"metadata":null},{"id":"8d7d903f289b4147a7dc48e81ceb65fc","type":"GENE","name":"IL18BP","canonical_id":"hgnc:HGNC:5987","description":"interleukin 18 binding protein","metadata":{"aliases":["IL18BPa"]}},{"id":"2da6ab61c6ef4608b3e500412716e3c8","type":"GENE","name":"IL18R1","canonical_id":"hgnc:HGNC:5988","description":"interleukin 18 receptor 1","metadata":{"aliases":["IL-18R","IL1RRP","IL-1Rrp","CD218a"]}},{"id":"6ae2fbd0ff864c3b9cadb48f9824655e","type":"GENE","name":"IL18RAP","canonical_id":"hgnc:HGNC:5989","description":"interleukin 18 receptor accessory protein","metadata":{"aliases":["AcPL","CD218b"]}},{"id":"e35f5d8a994e4939a9e0e955d6cfe86a","type":"GENE","name":"IL19","canonical_id":"hgnc:HGNC:5990","description":"interleukin 19","metadata":{"aliases":["IL-19","MDA1","ZMDA1","IL-10C","NG.1"]}},{"id":"0b2c36e367e84d81aa6ff37d73e4f168","type":"GENE","name":"IL1A","canonical_id":"hgnc:HGNC:5991","description":null,"metadata":null},{"id":"b3dfe97f2e484cad9ca6caa9c032c9f6","type":"GENE","name":"IL1B","canonical_id":"hgnc:HGNC:5992","description":null,"metadata":null},{"id":"9c299fb93316415285383531eb74bf01","type":"PROTEIN","name":"IL1B","canonical_id":"uniprot:P01584","description":null,"metadata":null},{"id":"c1c898b281df428493afb1a831a343dc","type":"GENE","name":"IL1R1","canonical_id":"hgnc:HGNC:5993","description":null,"metadata":null},{"id":"fb746f6868ea49bcb56fbbbfffabf2cf","type":"PROTEIN","name":"IL1R1","canonical_id":"uniprot:P14778","description":null,"metadata":null},{"id":"5cbc54b348654d368855ed9b0a459b41","type":"GENE","name":"IL1R1-AS1","canonical_id":"hgnc:HGNC:53898","description":"IL1R1 antisense RNA 1","metadata":{"aliases":["AC007271.3"]}},{"id":"51064e1ca55848fdb9bc119b4a86f1eb","type":"GENE","name":"IL1R2","canonical_id":"hgnc:HGNC:5994","description":null,"metadata":null},{"id":"00bf0fb07c8c46aaa69ffc953b673950","type":"GENE","name":"IL1RAP","canonical_id":"hgnc:HGNC:5995","description":"interleukin 1 receptor accessory protein","metadata":{"aliases":["IL-1RAcP","IL1R3","C3orf13"]}},{"id":"7200a0f9175a4bee880e3dcc3b4f2b7a","type":"GENE","name":"IL1RAPL1","canonical_id":"hgnc:HGNC:5996","description":"interleukin 1 receptor accessory protein like 1","metadata":{"aliases":["OPHN4","TIGIRR-2","IL1R8","IL1RAPL-1","IL1RAPL","MRX34","MRX21","MRX10"]}},{"id":"5b43634c7d604768a488e9eaa029a9f6","type":"GENE","name":"IL1RAPL2","canonical_id":"hgnc:HGNC:5997","description":"interleukin 1 receptor accessory protein like 2","metadata":{"aliases":["IL-1R9","TIGIRR-1","IL1RAPL-2","IL1R9"]}},{"id":"852d8b47686e4554a25329abde752faa","type":"GENE","name":"IL1RL1","canonical_id":"hgnc:HGNC:5998","description":null,"metadata":null},{"id":"07ad137fa9a043b8bf8fbb5d80b961d4","type":"GENE","name":"IL1RN","canonical_id":"hgnc:HGNC:6000","description":null,"metadata":null},{"id":"9b7d714aef4e4a228bfc44c2d44b0046","type":"GENE","name":"IL2","canonical_id":"hgnc:HGNC:6001","description":null,"metadata":null},{"id":"1c035507127549fa8f83517b3182033c","type":"GENE","name":"IL20","canonical_id":"hgnc:HGNC:6002","description":"interleukin 20","metadata":{"aliases":["ZCYTO10","IL10D","IL-20"]}},{"id":"2ab3d2ac96914e2d89a51fd69768f8ba","type":"GENE","name":"IL20RA","canonical_id":"hgnc:HGNC:6003","description":"interleukin 20 receptor subunit alpha","metadata":{"aliases":["ZCYTOR7","IL-20R1"]}},{"id":"36cbcf859f1a4d5ebeefa6c7fa31dadf","type":"GENE","name":"IL20RB","canonical_id":"hgnc:HGNC:6004","description":"interleukin 20 receptor subunit beta","metadata":{"aliases":["DIRS1","IL-20R2","MGC34923","FNDC6"]}},{"id":"224837e1ece34e27b2b2e5f30a531e59","type":"GENE","name":"IL20RB-AS1","canonical_id":"hgnc:HGNC:40298","description":"IL20RB antisense RNA 1","metadata":null},{"id":"1a997418bd9744399803b56990f87153","type":"GENE","name":"IL21","canonical_id":"hgnc:HGNC:6005","description":null,"metadata":null},{"id":"5c8ab9bb34fb484e971d66a61f19d387","type":"GENE","name":"IL21-AS1","canonical_id":"hgnc:HGNC:40299","description":"IL21 antisense RNA 1","metadata":null},{"id":"89401faefe344cffbe9c1a761edc2d8a","type":"GENE","name":"IL21R","canonical_id":"hgnc:HGNC:6006","description":"interleukin 21 receptor","metadata":{"aliases":["CD360"]}},{"id":"f0a180cbdfbf45f2bc5935b68ac25177","type":"GENE","name":"IL21R-AS1","canonical_id":"hgnc:HGNC:27551","description":"IL21R antisense RNA 1","metadata":null},{"id":"d2782f7a2c344053b5200f9d82876940","type":"GENE","name":"IL22","canonical_id":"hgnc:HGNC:14900","description":null,"metadata":null},{"id":"90f8ee42411d4536a636ddc842ba6757","type":"GENE","name":"IL22RA1","canonical_id":"hgnc:HGNC:13700","description":"interleukin 22 receptor subunit alpha 1","metadata":{"aliases":["CRF2-9","IL22R"]}},{"id":"06d7991b017244e4be1e3ebca118facf","type":"GENE","name":"IL22RA2","canonical_id":"hgnc:HGNC:14901","description":"interleukin 22 receptor subunit alpha 2","metadata":{"aliases":["CRF2-S1","IL-22BP"]}},{"id":"eaabf8c24a674506aee22b02bbf1ef69","type":"GENE","name":"IL23A","canonical_id":"hgnc:HGNC:15488","description":null,"metadata":null},{"id":"ff389f1866334ddd966fa140d82a9b0c","type":"GENE","name":"IL23R","canonical_id":"hgnc:HGNC:19100","description":"interleukin 23 receptor","metadata":{"aliases":["IL-23R"]}},{"id":"99dae3e444eb4405848799b63b632898","type":"GENE","name":"IL24","canonical_id":"hgnc:HGNC:11346","description":null,"metadata":null},{"id":"8274ea0ff913491686e6ae329675ac47","type":"GENE","name":"IL25","canonical_id":"hgnc:HGNC:13765","description":"interleukin 25","metadata":{"aliases":["IL-25","IL-17E","IL17E"]}},{"id":"832968568e1845eea8033ce115f0a622","type":"GENE","name":"IL26","canonical_id":"hgnc:HGNC:17119","description":"interleukin 26","metadata":{"aliases":["AK155","IL-26"]}},{"id":"cf6633a86971435fa207058a828c21cd","type":"GENE","name":"IL27","canonical_id":"hgnc:HGNC:19157","description":null,"metadata":null},{"id":"344d3e2801f545b5b3338471e0b958aa","type":"GENE","name":"IL27RA","canonical_id":"hgnc:HGNC:17290","description":"interleukin 27 receptor subunit alpha","metadata":{"aliases":["WSX-1","TCCR","CRL1","WSX1","zcytor1","IL-27R"]}},{"id":"fe3f5dbc8460468584134dfc12a89fe7","type":"GENE","name":"IL2RA","canonical_id":"hgnc:HGNC:6008","description":null,"metadata":null},{"id":"7be11bded1ca4153b6f15af33477c5e3","type":"PROTEIN","name":"IL2RA","canonical_id":"uniprot:P01589","description":null,"metadata":null},{"id":"0a1420f635bc48a68d069edac23de76c","type":"GENE","name":"IL2RA-AS1","canonical_id":"hgnc:HGNC:58167","description":"IL2RA antisense RNA 1","metadata":null},{"id":"b44590a71f2a4aa7ac932fe6b4159d13","type":"GENE","name":"IL2RB","canonical_id":"hgnc:HGNC:6009","description":null,"metadata":null},{"id":"124582c914e645f8a2125cb5df9bb112","type":"GENE","name":"IL2RB-AS1","canonical_id":"hgnc:HGNC:40300","description":"IL2RB and C1QTNF6 antisense RNA 1","metadata":null},{"id":"c59d958b0ade46e0bd01644d3cc4313d","type":"GENE","name":"IL2RG","canonical_id":"hgnc:HGNC:6010","description":null,"metadata":null},{"id":"91115382ea7e4f87a496590fa6870a3f","type":"GENE","name":"IL3","canonical_id":"hgnc:HGNC:6011","description":null,"metadata":null},{"id":"ffdafa510f474d22a6507a9a845a5b31","type":"GENE","name":"IL3-AS1","canonical_id":"hgnc:HGNC:59130","description":"IL3 antisense RNA 1","metadata":null},{"id":"d13b0388b07b4566b236fcd4249e2ca2","type":"GENE","name":"IL31","canonical_id":"hgnc:HGNC:19372","description":"interleukin 31","metadata":{"aliases":["IL-31"]}},{"id":"638efc80099c40c8bd1320a8cae38f9a","type":"GENE","name":"IL31RA","canonical_id":"hgnc:HGNC:18969","description":"interleukin 31 receptor A","metadata":{"aliases":["CRL3","GLM-R","CRL","Glmr","IL-31RA"]}},{"id":"de7f3eb1fb0246c09ae5c30ea684daa4","type":"PROTEIN","name":"IL31RA","canonical_id":"uniprot:Q8NI17","description":null,"metadata":null},{"id":"545d622080c94229953da661f86ff7c0","type":"GENE","name":"IL32","canonical_id":"hgnc:HGNC:16830","description":null,"metadata":null},{"id":"cdd91f6c1e384e869cbd67dc4eabb88f","type":"GENE","name":"IL33","canonical_id":"hgnc:HGNC:16028","description":"interleukin 33","metadata":{"aliases":["DVS27","DKFZp586H0523","NF-HEV","IL1F11","C9orf26"]}},{"id":"66e6e86ee87f40a484be19cbfad582d2","type":"GENE","name":"IL34","canonical_id":"hgnc:HGNC:28529","description":"interleukin 34","metadata":{"aliases":["MGC34647","IL-34","C16orf77"]}},{"id":"4edb000b8d2c4d46be1bd758d48ed417","type":"GENE","name":"IL36A","canonical_id":"hgnc:HGNC:15562","description":"interleukin 36 alpha","metadata":{"aliases":["FIL1","FIL1E","IL-1F6","IL1(EPSILON)","MGC129553","MGC129552","IL1F6"]}},{"id":"4b1b6276f91e49afb82f0819001eff05","type":"GENE","name":"IL36B","canonical_id":"hgnc:HGNC:15564","description":"interleukin 36 beta","metadata":{"aliases":["FIL1","IL-1H2","IL-1F8","FILI-(ETA)","IL1-ETA","IL1H2","MGC126880","MGC126882","IL1F8"]}},{"id":"2c663e53abdc4aae9c61dc5b296e107e","type":"GENE","name":"IL36G","canonical_id":"hgnc:HGNC:15741","description":"interleukin 36 gamma","metadata":{"aliases":["IL-1H1","IL-1RP2","IL-1F9","IL1H1","IL1E","IL1F9"]}},{"id":"d0bbfafbe6084894ae3b7a3747578ec0","type":"GENE","name":"IL36R","canonical_id":"hgnc:HGNC:5999","description":"interleukin 36 receptor","metadata":{"aliases":["IL1R-rp2","IL1RRP2","IL-36R","IL1RL2"]}},{"id":"bc98bd9af8f241339bd8ed6c0f7fbb93","type":"GENE","name":"IL36RN","canonical_id":"hgnc:HGNC:15561","description":"interleukin 36 receptor antagonist","metadata":{"aliases":["FIL1","FIL1(DELTA)","FIL1D","IL1HY1","IL1RP3","IL1L1","IL-1F5","IL36RA","MGC29840","IL1F5"]}},{"id":"4dd28d44e0ff4cb18b78334dfeb121df","type":"GENE","name":"IL37","canonical_id":"hgnc:HGNC:15563","description":"interleukin 37","metadata":{"aliases":["FIL1","FIL1Z","FIL1(ZETA)","IL-1H4","IL-1RP1","IL-1F7","IL1F7"]}},{"id":"925a6f4081b345d9bfd81e466b0ae118","type":"GENE","name":"IL38","canonical_id":"hgnc:HGNC:15552","description":"interleukin 38","metadata":{"aliases":["IL-38","FKSG75","IL-1HY2","IL-1F10","IL1-theta","MGC11983","MGC119832","MGC119833","IL1F10"]}},{"id":"8551a87b5dbe4ceb8550f954c7b93f73","type":"GENE","name":"IL3RA","canonical_id":"hgnc:HGNC:6012","description":"interleukin 3 receptor subunit alpha","metadata":{"aliases":["CD123"]}},{"id":"9d0e3ef04457440d922f209b2ab21a18","type":"GENE","name":"IL4","canonical_id":"hgnc:HGNC:6014","description":null,"metadata":null},{"id":"f01b4eaa5aa342048b921ef0a67dcac0","type":"GENE","name":"IL4-AS1","canonical_id":"hgnc:HGNC:59131","description":"IL4 antisense RNA 1","metadata":null},{"id":"d15259c624a145f9a630b7d582656e7f","type":"GENE","name":"IL40","canonical_id":"hgnc:HGNC:34490","description":"interleukin 40","metadata":{"aliases":["GLPG464","UNQ464","IL-40","C17orf99"]}},{"id":"94e092b5e6104046a5335feb533f62c2","type":"GENE","name":"IL4I1","canonical_id":"hgnc:HGNC:19094","description":"interleukin 4 induced 1","metadata":{"aliases":["FIG1"]}},{"id":"46285e77d2f040d5b170013f943b8fcb","type":"GENE","name":"IL4R","canonical_id":"hgnc:HGNC:6015","description":"interleukin 4 receptor","metadata":{"aliases":["CD124"]}},{"id":"69e28223f95d4a418f18b26026f8bb89","type":"PROTEIN","name":"IL4R","canonical_id":"uniprot:P24394","description":null,"metadata":null},{"id":"6d1f804b7a5840ef8834d9fc68188b20","type":"GENE","name":"IL5","canonical_id":"hgnc:HGNC:6016","description":null,"metadata":null},{"id":"c931872aa28242bb80ed77865de0f5a9","type":"PROTEIN","name":"IL5","canonical_id":"uniprot:P05113","description":null,"metadata":null},{"id":"dbff10e0959846a882cb561316645bbc","type":"GENE","name":"IL5RA","canonical_id":"hgnc:HGNC:6017","description":null,"metadata":null},{"id":"31892b35a56c4e2caaa5581aaccb948d","type":"GENE","name":"IL6","canonical_id":"hgnc:HGNC:6018","description":null,"metadata":null},{"id":"5aff55deb800445d8a4229d25f1f6dc6","type":"PROTEIN","name":"IL6","canonical_id":"uniprot:P05231","description":null,"metadata":null},{"id":"688d49f51c464f668a923fe4a1fc86b9","type":"GENE","name":"IL6-AS1","canonical_id":"hgnc:HGNC:40301","description":"IL6 antisense RNA 1","metadata":null},{"id":"caf3c0e42ab741a98656e6970afa4b6e","type":"TRIAL","name":"IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD","canonical_id":"clinicaltrials.gov:NCT07484113","description":"cGVHD","metadata":null},{"id":"1d20dd65993e401fabaea986474c35b8","type":"GENE","name":"IL6R","canonical_id":"hgnc:HGNC:6019","description":null,"metadata":null},{"id":"3ae632591395466da1ec25e021786b62","type":"PROTEIN","name":"IL6R","canonical_id":"uniprot:P08887","description":null,"metadata":null},{"id":"53303c696eea412799acaf3647a676a2","type":"GENE","name":"IL6R-AS1","canonical_id":"hgnc:HGNC:53716","description":"IL6R antisense RNA 1","metadata":{"aliases":["RP11-350G8.5"]}},{"id":"0f8e107335e54c5e8e523f77182ad03b","type":"GENE","name":"IL6RP1","canonical_id":"hgnc:HGNC:6020","description":"interleukin 6 receptor pseudogene 1","metadata":{"aliases":["IL6RL1"]}},{"id":"e90d546511474ae3a5217ca8d7909e63","type":"GENE","name":"IL6ST","canonical_id":"hgnc:HGNC:6021","description":"interleukin 6 cytokine family signal transducer","metadata":{"aliases":["GP130","CD130","sGP130","IL-6RB"]}},{"id":"7c174265820644bbbb10a80502ceda1b","type":"GENE","name":"IL6ST-DT","canonical_id":"hgnc:HGNC:55804","description":"IL6ST divergent transcript","metadata":null},{"id":"65e8cd0d43784368b1d39e58470de0dd","type":"GENE","name":"IL6STP1","canonical_id":"hgnc:HGNC:6022","description":"interleukin 6 signal transducer pseudogene 1","metadata":{"aliases":["IL6STP"]}},{"id":"30f810771f8a4521885a4c41c0ad3c4e","type":"GENE","name":"IL7","canonical_id":"hgnc:HGNC:6023","description":null,"metadata":null},{"id":"6bccdd4600ad4771a0012bbc635929c8","type":"GENE","name":"IL7R","canonical_id":"hgnc:HGNC:6024","description":"interleukin 7 receptor","metadata":{"aliases":["CD127","IL7RA","lnc-IL7R","IL-7Ralpha","IL7Ralpha","sIL-7R","CDw127"]}},{"id":"79fb63ed83694f629e7bf55a36ab4179","type":"GENE","name":"IL7R-AS1","canonical_id":"hgnc:HGNC:59028","description":"IL7R and SPEF2 antisense RNA 1","metadata":null},{"id":"f7841ee17fa5449fbe7f23278edd8da3","type":"GENE","name":"IL9","canonical_id":"hgnc:HGNC:6029","description":"interleukin 9","metadata":{"aliases":["IL-9","HP40","P40"]}},{"id":"54c2cbff9e2746c2bfc1d16b08b05841","type":"GENE","name":"IL9R","canonical_id":"hgnc:HGNC:6030","description":"interleukin 9 receptor","metadata":{"aliases":["CD129"]}},{"id":"e1cf70f7f1024b9aae7ebb305825019d","type":"GENE","name":"IL9RP1","canonical_id":"hgnc:HGNC:6031","description":"IL9R pseudogene 1","metadata":null},{"id":"67e9044d338c434e91d2de2ab4f109b9","type":"GENE","name":"IL9RP2","canonical_id":"hgnc:HGNC:6032","description":"IL9R pseudogene 2","metadata":null},{"id":"7bf20c17ddc5400da68b65f206616105","type":"GENE","name":"IL9RP3","canonical_id":"hgnc:HGNC:6033","description":"IL9R pseudogene 3","metadata":null},{"id":"b93d11da21a84861af898c74d222ab74","type":"GENE","name":"IL9RP4","canonical_id":"hgnc:HGNC:6034","description":"IL9R pseudogene 4","metadata":null},{"id":"d438ee0fbc8f41c3ab6e17c2d2984d6b","type":"GENE","name":"IL9RP5","canonical_id":"hgnc:HGNC:56960","description":"IL9R pseudogene 5","metadata":null},{"id":"5e1fd0261e1b409ea42eb8321335a244","type":"GENE","name":"IL9RP6","canonical_id":"hgnc:HGNC:56970","description":"IL9R pseudogene 6","metadata":null},{"id":"aa5c3c6166c446b09a94441012344abc","type":"GENE","name":"ILDR1","canonical_id":"hgnc:HGNC:28741","description":"immunoglobulin like domain containing receptor 1","metadata":{"aliases":["MGC50831","DFNB42"]}},{"id":"389a9146dd784b36b6187c08d5a87b57","type":"GENE","name":"ILDR2","canonical_id":"hgnc:HGNC:18131","description":"immunoglobulin like domain containing receptor 2","metadata":{"aliases":["C1orf32"]}},{"id":"21dd9070fb00477a9572eb59977c8009","type":"GENE","name":"ILF2","canonical_id":"hgnc:HGNC:6037","description":null,"metadata":null},{"id":"b05f01386b174e99ac1dbcbddd41ee04","type":"GENE","name":"ILF2P1","canonical_id":"hgnc:HGNC:44695","description":"interleukin enhancer binding factor 2 pseudogene 1","metadata":null},{"id":"06a0691031b446ad86fb023cfbeefef3","type":"GENE","name":"ILF2P2","canonical_id":"hgnc:HGNC:44696","description":"interleukin enhancer binding factor 2 pseudogene 2","metadata":null},{"id":"7ae02eebf87740cda49ec80ec56fe0b0","type":"GENE","name":"ILF3","canonical_id":"hgnc:HGNC:6038","description":null,"metadata":null},{"id":"998e20476e774e28bf2c607d09208411","type":"GENE","name":"ILF3-DT","canonical_id":"hgnc:HGNC:27115","description":"ILF3 divergent transcript","metadata":{"aliases":["ILF3-AS1"]}},{"id":"9d3979d9c70d4d11bc2bf44edbb7041c","type":"GENE","name":"ILK","canonical_id":"hgnc:HGNC:6040","description":null,"metadata":null},{"id":"265d6265a865455b945723d7a2644ab6","type":"GENE","name":"ILKAP","canonical_id":"hgnc:HGNC:15566","description":"ILK associated serine/threonine phosphatase","metadata":{"aliases":["DKFZP434J2031","FLJ10181","PPM1O"]}},{"id":"5056b91e29054128b3577a2b5c58a021","type":"GENE","name":"ILRUN","canonical_id":"hgnc:HGNC:21215","description":"inflammation and lipid regulator with UBA-like and NBR1-like domains","metadata":{"aliases":["FLJ22195","dJ391O22.4","C6orf106"]}},{"id":"b56ea5995a104941abbd72895c5f4bec","type":"GENE","name":"ILRUN-AS1","canonical_id":"hgnc:HGNC:55216","description":"ILRUN antisense RNA 1","metadata":null},{"id":"ed92226f6c1b40d5b8e001be7a370d10","type":"GENE","name":"ILRUNP1","canonical_id":"hgnc:HGNC:54748","description":"ILRUN pseudogene 1","metadata":null},{"id":"d8bf321b6a874f6cbba22e107a13d857","type":"GENE","name":"ILVBL-AS1","canonical_id":"hgnc:HGNC:55279","description":"ILVBL antisense RNA 1","metadata":null},{"id":"92aec306228f451da8c520eadbf5455c","type":"TRIAL","name":"IM Olanzapine Versus Haloperidol or Midazolam","canonical_id":"clinicaltrials.gov:NCT02380118","description":"Acute Agitation, Behavioural Emergency","metadata":null},{"id":"3cdb70af0b29406c9c74df939de5b27b","type":"TRIAL","name":"IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02281682","description":"Keratosis, Actinic","metadata":null},{"id":"553838b9912844e98ec163232ac1c13d","type":"TRIAL","name":"IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)","canonical_id":"clinicaltrials.gov:NCT00136994","description":"Schizophrenia","metadata":null},{"id":"8c3332ac644f4993b9e80f07c300d5aa","type":"TRIAL","name":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","canonical_id":"clinicaltrials.gov:NCT06112314","description":"Advanced Melanoma","metadata":null},{"id":"296b6122bf654672a4ccca95ce6f2e77","type":"GENE","name":"IMMP1L","canonical_id":"hgnc:HGNC:26317","description":"inner mitochondrial membrane peptidase subunit 1","metadata":{"aliases":["FLJ25059","IMMP1"]}},{"id":"db0236dbd7d64346943c88c927b5b5dc","type":"GENE","name":"IMMP1LP1","canonical_id":"hgnc:HGNC:51131","description":"inner mitochondrial membrane peptidase subunit 1 pseudogene 1","metadata":null},{"id":"7006a68e0a8a431abea22985f469f38a","type":"GENE","name":"IMMP1LP2","canonical_id":"hgnc:HGNC:51132","description":"inner mitochondrial membrane peptidase subunit 1 pseudogene 2","metadata":null},{"id":"ac9e37e8df4e48238a3eb28bacecee2c","type":"GENE","name":"IMMP1LP3","canonical_id":"hgnc:HGNC:51134","description":"inner mitochondrial membrane peptidase subunit 1 pseudogene 3","metadata":null},{"id":"4a449c7fb2644e98ba5b71337e5064ac","type":"GENE","name":"IMMP2L","canonical_id":"hgnc:HGNC:14598","description":"inner mitochondrial membrane peptidase subunit 2","metadata":{"aliases":["IMP2","IMMP2L-IT1"]}},{"id":"4444ee380c9d4d6eac8855346a6bca43","type":"GENE","name":"IMMT","canonical_id":"hgnc:HGNC:6047","description":"inner membrane mitochondrial protein","metadata":{"aliases":["P87","P89","HMP","MINOS2","Mic60","MICOS60"]}},{"id":"6bf81f3f9a36474c98b9522d8ac17483","type":"GENE","name":"IMMTP1","canonical_id":"hgnc:HGNC:6048","description":"inner membrane mitochondrial protein pseudogene 1","metadata":{"aliases":["IMMTP"]}},{"id":"07aea971b4e14f3daf69e6161f78f3ce","type":"TRIAL","name":"IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT07674615","description":"Epithelial Ovarian Cancer; Fallopian Tube Cancers; Primary; Primary Peritoneal Carcinoma","metadata":null},{"id":"c2e66c2ca04046518fd52c7d5992d88a","type":"GO_TERM","name":"IMP binding","canonical_id":"go:GO:1902249","description":"\"Binding to IMP, inosine monophosphate.\" [GOC:mah, GOC:TermGenie, PMID:4314233]","metadata":null},{"id":"e47aa569c0f34f3ba4cfef068c536538","type":"GO_TERM","name":"IMP biosynthetic process","canonical_id":"go:GO:0006188","description":"\"The chemical reactions and pathways resulting in the formation of IMP, inosine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"fecbef30ea2947c5b6834062c5b032f6","type":"GO_TERM","name":"IMP catabolic process","canonical_id":"go:GO:0006204","description":"\"The chemical reactions and pathways resulting in the breakdown of IMP, inosine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"a10c41134a604a87ad03fd5e46ee4735","type":"GO_TERM","name":"IMP cyclohydrolase activity","canonical_id":"go:GO:0003937","description":"\"Catalysis of the reaction: IMP + H2O = 5-formamido-1-(5-phosphoribosyl)imidazole-4-carboxamide.\" [EC:3.5.4.10]","metadata":null},{"id":"d84128d99db34347b7ce0a4d69d4d0e2","type":"GO_TERM","name":"IMP dehydrogenase activity","canonical_id":"go:GO:0003938","description":"\"Catalysis of the reaction: inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+.\" [EC:1.1.1.205]","metadata":null},{"id":"448fefd1ec07484dab9ddc283ff17929","type":"GO_TERM","name":"IMP metabolic process","canonical_id":"go:GO:0046040","description":"\"The chemical reactions and pathways involving IMP, inosine monophosphate.\" [GOC:curators]","metadata":null},{"id":"632142d529a54cd78bb6b3c8d61b2362","type":"GO_TERM","name":"IMP salvage","canonical_id":"go:GO:0032264","description":"\"Any process which produces inosine monophosphate from derivatives of it, without de novo synthesis.\" [GOC:mah]","metadata":null},{"id":"bea50bb7b89d4ffca307112d998bc392","type":"GENE","name":"IMP3","canonical_id":"hgnc:HGNC:14497","description":"IMP U3 small nucleolar ribonucleoprotein 3","metadata":{"aliases":["FLJ10968","BRMS2","MRPS4","C15orf12"]}},{"id":"d9e9d422383340d4b4c4cc51739fdac1","type":"GENE","name":"IMP3P1","canonical_id":"hgnc:HGNC:49385","description":"IMP3 pseudogene 1","metadata":null},{"id":"fd8148f4bd6d43ff9f067d5f7677f69b","type":"GENE","name":"IMP3P2","canonical_id":"hgnc:HGNC:49386","description":"IMP3 pseudogene 2","metadata":null},{"id":"3725ee5e26fe4225ae5c10cde84c0db1","type":"GENE","name":"IMP4","canonical_id":"hgnc:HGNC:30856","description":"IMP U3 small nucleolar ribonucleoprotein 4","metadata":{"aliases":["MGC19606","BXDC4"]}},{"id":"b9100e77bd3e45e4acc650743930a3d4","type":"GENE","name":"IMPA1","canonical_id":"hgnc:HGNC:6050","description":"inositol monophosphatase 1","metadata":{"aliases":["IMPA"]}},{"id":"d5004e99967e480ca940eb5a4d4f8677","type":"GENE","name":"IMPA1P1","canonical_id":"hgnc:HGNC:33956","description":"inositol monophosphatase 1 pseudogene 1","metadata":{"aliases":["IMPA1P"]}},{"id":"30ee52bf38424c37944375a991394cc6","type":"GENE","name":"IMPA2","canonical_id":"hgnc:HGNC:6051","description":"inositol monophosphatase 2","metadata":null},{"id":"c5ad5f08b7e2458fa5a75764ed412d4a","type":"GENE","name":"IMPA2-AS1","canonical_id":"hgnc:HGNC:58565","description":"IMPA2 antisense RNA 1","metadata":null},{"id":"22e38454e01a454dbc252cefd659821e","type":"TRIAL","name":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","canonical_id":"clinicaltrials.gov:NCT00977756","description":"HIV Infections","metadata":null},{"id":"bee1e7bba0904ee38ea543d5563f8de7","type":"TRIAL","name":"IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia","canonical_id":"clinicaltrials.gov:NCT00663234","description":"HIV Infections; Hyperlipidemia","metadata":null},{"id":"6c571fb6806c46bab78e1953082b5062","type":"GENE","name":"IMPACT","canonical_id":"hgnc:HGNC:20387","description":"impact RWD domain protein","metadata":{"aliases":["RWDD5"]}},{"id":"4434782fadb344ef83fcc9d049510a64","type":"TRIAL","name":"IMPACT Study (Improving Measurements of Persistence on \"ACtonel\" Treatment)","canonical_id":"clinicaltrials.gov:NCT00268632","description":"Osteoporosis","metadata":null},{"id":"09b8929b6d224a248c718a05432f12fe","type":"TRIAL","name":"IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy","canonical_id":"clinicaltrials.gov:NCT03152058","description":"High Risk Pregnancy; Pregnancy Complications; Antiphospholipid Syndrome in Pregnancy; Lupus Anticoagulant Disorder","metadata":null},{"id":"c2f68e3d8fe94dcb948c8838b658237e","type":"GENE","name":"IMPDH1","canonical_id":"hgnc:HGNC:6052","description":"inosine monophosphate dehydrogenase 1","metadata":{"aliases":["sWSS2608","LCA11","RP10"]}},{"id":"2e02cde59556427faea12361b63df9f0","type":"PROTEIN","name":"IMPDH1","canonical_id":"uniprot:P20839","description":null,"metadata":null},{"id":"0edef9c386764ec8b65f6124c56e42d9","type":"GENE","name":"IMPDH1P1","canonical_id":"hgnc:HGNC:19912","description":"inosine monophosphate dehydrogenase 1 pseudogene 1","metadata":{"aliases":["bA537H15.4"]}},{"id":"412bbcab0d6247f5971196901e1379b0","type":"GENE","name":"IMPDH1P10","canonical_id":"hgnc:HGNC:33965","description":"inosine monophosphate dehydrogenase 1 pseudogene 10","metadata":null},{"id":"2022aaea492c48a4b5957d003e13bdc8","type":"GENE","name":"IMPDH1P11","canonical_id":"hgnc:HGNC:6054","description":"inosine monophosphate dehydrogenase 1 pseudogene 11","metadata":{"aliases":["IMPDHL1"]}},{"id":"e910ab1f29e646dd84e8b0c4aa05061c","type":"GENE","name":"IMPDH1P2","canonical_id":"hgnc:HGNC:33957","description":"inosine monophosphate dehydrogenase 1 pseudogene 2","metadata":null},{"id":"3d459a18aec04014a8c20f6c8afc9932","type":"GENE","name":"IMPDH1P3","canonical_id":"hgnc:HGNC:33958","description":"inosine monophosphate dehydrogenase 1 pseudogene 3","metadata":null},{"id":"d906039a0d124d7eaf6381ededab7c46","type":"GENE","name":"IMPDH1P4","canonical_id":"hgnc:HGNC:33959","description":"inosine monophosphate dehydrogenase 1 pseudogene 4","metadata":null},{"id":"4cad71d66b4e4cf895d25773ee8ad18e","type":"GENE","name":"IMPDH1P5","canonical_id":"hgnc:HGNC:33960","description":"inosine monophosphate dehydrogenase 1 pseudogene 5","metadata":null},{"id":"c507af19d2db40129dfe42834dc9dd73","type":"GENE","name":"IMPDH1P6","canonical_id":"hgnc:HGNC:33961","description":"inosine monophosphate dehydrogenase 1 pseudogene 6","metadata":null},{"id":"12ac2dbed33547a5ac8999fcfe06fb54","type":"GENE","name":"IMPDH1P7","canonical_id":"hgnc:HGNC:33962","description":"inosine monophosphate dehydrogenase 1 pseudogene 7","metadata":null},{"id":"29f09989cc764392b0a386d264840018","type":"GENE","name":"IMPDH1P8","canonical_id":"hgnc:HGNC:33963","description":"inosine monophosphate dehydrogenase 1 pseudogene 8","metadata":null},{"id":"cc8a5e21548a4ebe8402e1b809ac9acb","type":"GENE","name":"IMPDH1P9","canonical_id":"hgnc:HGNC:33964","description":"inosine monophosphate dehydrogenase 1 pseudogene 9","metadata":null},{"id":"9d43662c737e4ec7b5dbc6c906685a98","type":"GENE","name":"IMPDH2","canonical_id":"hgnc:HGNC:6053","description":null,"metadata":null},{"id":"9938fef5ada44decb7c1117cd54b35dc","type":"GENE","name":"IMPG1","canonical_id":"hgnc:HGNC:6055","description":"interphotoreceptor matrix proteoglycan 1","metadata":{"aliases":["IPM150","GP147","SPACR"]}},{"id":"3c8f8989b7dc4298833550f7d527b966","type":"GENE","name":"IMPG2","canonical_id":"hgnc:HGNC:18362","description":"interphotoreceptor matrix proteoglycan 2","metadata":{"aliases":["IPM200","RP56","SPACRCAN"]}},{"id":"db27eef4f89043abbe370bbda0835744","type":"TRIAL","name":"IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT04109456","description":"Metastatic Melanoma","metadata":null},{"id":"bd665bdf6de04f6596f842f147c462d2","type":"GENE","name":"INA","canonical_id":"hgnc:HGNC:6057","description":"internexin neuronal intermediate filament protein alpha","metadata":{"aliases":["NF-66","NEF5"]}},{"id":"5ffe411d73b64e8cb3d7bb41c938b0c5","type":"GO_TERM","name":"INA complex","canonical_id":"go:GO:1990524","description":"\"A protein complex located in the inner membrane of mitochondria that is involved in the assembly of the peripheral (or stator) stalk of the mitochondrial proton-transporting ATP synthase (also known as the F1F0 ATP synthase). In budding yeast, this complex includes Ina22p and Ina17p.\" [GOC:rn, PMID:24942160]","metadata":null},{"id":"54ef9b61159c4336ba551bcf6a987de9","type":"GENE","name":"INAFM1","canonical_id":"hgnc:HGNC:27406","description":"InaF motif containing 1","metadata":{"aliases":["PRR24"]}},{"id":"391c2cfe86384b89a75373ca001a385e","type":"GENE","name":"INAFM2","canonical_id":"hgnc:HGNC:35165","description":"InaF motif containing 2","metadata":{"aliases":["OGU1","LINC00984"]}},{"id":"3e354b9120024464b1f8b10a2efe7ca8","type":"GENE","name":"INAVA","canonical_id":"hgnc:HGNC:25599","description":"innate immunity activator","metadata":{"aliases":["FLJ10901","C1orf106"]}},{"id":"6f180f3ebd2f486ab7e8b14061049654","type":"GENE","name":"INAVAP1","canonical_id":"hgnc:HGNC:56475","description":"INAVA pseudogene 1","metadata":null},{"id":"968c079dd9284defb69141433de0dd0e","type":"GENE","name":"INCA1","canonical_id":"hgnc:HGNC:32224","description":"inhibitor of CDK, cyclin A1 interacting protein 1","metadata":null},{"id":"8ec0fb2949924c09ba84e871e75bf164","type":"TRIAL","name":"INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03837509","description":"Relapsed or Refractory Multiple Myeloma","metadata":null},{"id":"8abb369adada403696d2784c3661e44c","type":"TRIAL","name":"INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease","canonical_id":"clinicaltrials.gov:NCT01164163","description":"Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific","metadata":null},{"id":"4030e1e8643041339c228deda2690dcf","type":"GENE","name":"INCENP","canonical_id":"hgnc:HGNC:6058","description":"inner centromere protein","metadata":{"aliases":["FLJ31633"]}},{"id":"343a565d60564e898033398a8d2704d7","type":"TRIAL","name":"INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation","canonical_id":"clinicaltrials.gov:NCT05151640","description":"Lung Diseases, Interstitial","metadata":null},{"id":"01c526546b4b4a47ad5fc992988b7d7d","type":"GENE","name":"INCR1","canonical_id":"hgnc:HGNC:56906","description":"interferon stimulated noncoding RNA 1","metadata":null},{"id":"e5db95cd684d4f5d9e4594c4c021833e","type":"GENE","name":"INE1","canonical_id":"hgnc:HGNC:6060","description":"inactivation escape 1","metadata":{"aliases":["NCRNA00010"]}},{"id":"ac8eec28c9cc4977834bbfdea1f02d53","type":"GENE","name":"INE2","canonical_id":"hgnc:HGNC:6061","description":"inactivation escape 2","metadata":{"aliases":["NCRNA00011"]}},{"id":"8f3c869d21cd4e90a2000fdf00d67d94","type":"GENE","name":"INF2","canonical_id":"hgnc:HGNC:23791","description":"inverted formin 2","metadata":{"aliases":["MGC13251","C14orf151","C14orf173"]}},{"id":"3fb5ef22cd9240c39d7515aacb69910f","type":"GENE","name":"ING1","canonical_id":"hgnc:HGNC:6062","description":null,"metadata":null},{"id":"b8620a593ef54c37830797f8f9f5762b","type":"GENE","name":"ING2","canonical_id":"hgnc:HGNC:6063","description":null,"metadata":null},{"id":"731c765ec0b54389bab4b9a9d1f11300","type":"GENE","name":"ING2-DT","canonical_id":"hgnc:HGNC:55723","description":"ING2 divergent transcript","metadata":null},{"id":"bde084d63a414c1ebfdda779894a24af","type":"GENE","name":"ING3","canonical_id":"hgnc:HGNC:14587","description":"inhibitor of growth family member 3","metadata":{"aliases":["p47ING3","FLJ20089","Eaf4","MEAF4"]}},{"id":"5deee8cf1ed04353ae8e6b266a094ad6","type":"GENE","name":"ING4","canonical_id":"hgnc:HGNC:19423","description":null,"metadata":null},{"id":"9bdabc3d9d4645c78f10517cda2fa532","type":"GENE","name":"ING5","canonical_id":"hgnc:HGNC:19421","description":null,"metadata":null},{"id":"5d32d492d2b1411889afe7798e67c7f0","type":"GENE","name":"ING5-AS1","canonical_id":"hgnc:HGNC:40891","description":"ING5 antisense RNA 1","metadata":null},{"id":"75de70847881411884aba656f18c5528","type":"GENE","name":"INGX","canonical_id":"hgnc:HGNC:6064","description":"inhibitor of growth family, X-linked (pseudogene)","metadata":{"aliases":["ING1-like","ING2"]}},{"id":"4b748f52018e446382f758cd2086b78f","type":"GENE","name":"INHA","canonical_id":"hgnc:HGNC:6065","description":"inhibin subunit alpha","metadata":null},{"id":"0f6292a248c14d5297b3575e27f6edb9","type":"GENE","name":"INHBA","canonical_id":"hgnc:HGNC:6066","description":"inhibin subunit beta A","metadata":null},{"id":"c3764f0362b140feb654b80402f64679","type":"GENE","name":"INHBA-AS1","canonical_id":"hgnc:HGNC:40303","description":"INHBA antisense RNA 1","metadata":null},{"id":"26f80af5df244c3b80a96ebf6a4496c4","type":"GENE","name":"INHBB","canonical_id":"hgnc:HGNC:6067","description":"inhibin subunit beta B","metadata":null},{"id":"073e669d4e5c4c549e3267823d80aace","type":"GENE","name":"INHBC","canonical_id":"hgnc:HGNC:6068","description":"inhibin subunit beta C","metadata":null},{"id":"9e27dba82d4649d6852aa2ddbfdfcd97","type":"GENE","name":"INHBE","canonical_id":"hgnc:HGNC:24029","description":"inhibin subunit beta E","metadata":{"aliases":["activin","MGC4638"]}},{"id":"13053b3928a64b20a2666f8a8b6f641a","type":"GENE","name":"INHCAP","canonical_id":"hgnc:HGNC:11759","description":"inhibitor of carbonic anhydrase pseudogene","metadata":{"aliases":["TFP","TFP1"]}},{"id":"98d26f7998244f559af0163f69656cdb","type":"GENE","name":"INIP","canonical_id":"hgnc:HGNC:24994","description":"INTS3 and NABP interacting protein","metadata":{"aliases":["HSPC043","hSSBIP1","SOSS-C","MISE","C9orf80"]}},{"id":"7980a753550842e7b3a685b65d383c0d","type":"GENE","name":"INKA1","canonical_id":"hgnc:HGNC:32480","description":"inka box actin regulator 1","metadata":{"aliases":["C3orf54","FAM212A"]}},{"id":"87856b5be40448d796dbdc62d1884fe1","type":"GENE","name":"INKA2","canonical_id":"hgnc:HGNC:28045","description":"inka box actin regulator 2","metadata":{"aliases":["FLJ31105","C1orf183","FAM212B"]}},{"id":"b7e8482a549049c6b0afaa3edae9c32c","type":"GENE","name":"INKA2-AS1","canonical_id":"hgnc:HGNC:49446","description":"INKA2 antisense RNA 1","metadata":{"aliases":["FAM212B-AS1"]}},{"id":"73529b75a2ec4b62b9ac6740965e8d36","type":"GENE","name":"INKILN","canonical_id":"hgnc:HGNC:56260","description":"inflammatory MKL1 (MRTFA) interacting lncRNA","metadata":null},{"id":"14e6fabab63f4be4a5511fda3bbaf788","type":"GENE","name":"INMT","canonical_id":"hgnc:HGNC:6069","description":"indolethylamine N-methyltransferase","metadata":null},{"id":"e9d46f40ed6943f09e67f9738fa02874","type":"GENE","name":"INMT-MINDY4","canonical_id":"hgnc:HGNC:41995","description":"INMT-MINDY4 readthrough (NMD candidate)","metadata":{"aliases":["INMT-FAM188B"]}},{"id":"7d7d3891ea624ff9b49b010adc6bcddf","type":"GENE","name":"INO80","canonical_id":"hgnc:HGNC:26956","description":null,"metadata":null},{"id":"1b4aede56c08434198a17123c1de2f3e","type":"GENE","name":"INO80-AS1","canonical_id":"hgnc:HGNC:53138","description":"INO80 antisense RNA 1","metadata":{"aliases":["ENST00000560178"]}},{"id":"e016a24527344096ab2e3f0afa836578","type":"GO_TERM","name":"INO80-type complex","canonical_id":"go:GO:0097346","description":"\"A chromatin remodeling protein complex initially purified from S. cerevisiae and containing more than 10 subunits, including the SWR1-related complexes. INO80 (inositol requiring 80)-type complexes have diverse functions, including promoting transcriptional activation and DNA repair.\" [GOC:rb, PMID:19355820]","metadata":null},{"id":"631fdc98aa084538abf193fa971f6e24","type":"GENE","name":"INO80B","canonical_id":"hgnc:HGNC:13324","description":"INO80 complex subunit B","metadata":{"aliases":["HMGIYL4","PAPA-1","hIes2","PAP-1BP","IES2","HMGA1L4","ZNHIT4"]}},{"id":"086e24d9f6674ead849f167f9abec3fe","type":"GENE","name":"INO80B-WBP1","canonical_id":"hgnc:HGNC:49199","description":"INO80B-WBP1 readthrough (NMD candidate)","metadata":null},{"id":"d10a32ee73254146ad752ce88fee597e","type":"GENE","name":"INO80C","canonical_id":"hgnc:HGNC:26994","description":"INO80 complex subunit C","metadata":{"aliases":["FLJ38183","hIes6","IES6","C18orf37"]}},{"id":"5f01780a42df4ce1b0c64f953b35ca61","type":"GENE","name":"INO80D","canonical_id":"hgnc:HGNC:25997","description":"INO80 complex subunit D","metadata":{"aliases":["FLJ20309"]}},{"id":"d7020a8a179740568f7ce9ca7eca087e","type":"GENE","name":"INO80D-AS1","canonical_id":"hgnc:HGNC:55803","description":"INO80D antisense RNA 1","metadata":{"aliases":["AC007383.2","INO80D-AS2"]}},{"id":"96991dd7382746a5a33a71a124d69932","type":"GENE","name":"INO80E","canonical_id":"hgnc:HGNC:26905","description":"INO80 complex subunit E","metadata":{"aliases":["FLJ90652","CCDC95"]}},{"id":"6d38eebe252c4047929a88726a3a3bb3","type":"GENE","name":"INPP1","canonical_id":"hgnc:HGNC:6071","description":"inositol polyphosphate-1-phosphatase","metadata":null},{"id":"258f13bab124449394b09df0caee9550","type":"GENE","name":"INPP4A","canonical_id":"hgnc:HGNC:6074","description":"inositol polyphosphate-4-phosphatase type I A","metadata":{"aliases":["INPP4"]}},{"id":"41bb1646811c4935b8bb3863008cb55b","type":"GENE","name":"INPP4B","canonical_id":"hgnc:HGNC:6075","description":"inositol polyphosphate-4-phosphatase type II B","metadata":null},{"id":"2905257c628141819216ce428b2f751e","type":"GENE","name":"INPP4B-AS1","canonical_id":"hgnc:HGNC:53198","description":"INPP4B antisense RNA 1","metadata":null},{"id":"a60361e6bbd64475b4abe6e3d01d651d","type":"GENE","name":"INPP4B-AS2","canonical_id":"hgnc:HGNC:58887","description":"INPP4B antisense RNA 2","metadata":null},{"id":"01b9f4c092e745e5994a07856514b176","type":"GENE","name":"INPP5A","canonical_id":"hgnc:HGNC:6076","description":"inositol polyphosphate-5-phosphatase A","metadata":{"aliases":["5PTASE"]}},{"id":"25f52e2974154c47b69840d0d4255019","type":"GENE","name":"INPP5B","canonical_id":"hgnc:HGNC:6077","description":"inositol polyphosphate-5-phosphatase B","metadata":null},{"id":"7957e0bbf0454433aba6657c0cbd117f","type":"GENE","name":"INPP5B-AS1","canonical_id":"hgnc:HGNC:40304","description":"INPP5B antisense RNA 1","metadata":{"aliases":["AL929472.2"]}},{"id":"ba8f9b81bac741819a27e3a44b0f5174","type":"GENE","name":"INPP5D","canonical_id":"hgnc:HGNC:6079","description":"inositol polyphosphate-5-phosphatase D","metadata":{"aliases":["SHIP","hp51CN","SHIP1"]}},{"id":"f16bdf7a0c274372838ad665431b36f4","type":"GENE","name":"INPP5E","canonical_id":"hgnc:HGNC:21474","description":"inositol polyphosphate-5-phosphatase E","metadata":{"aliases":["PPI5PIV","CORS1","pharbin","JBTS1"]}},{"id":"b085263275ca47d28b8f1dc3991601c4","type":"GENE","name":"INPP5F","canonical_id":"hgnc:HGNC:17054","description":"inositol polyphosphate-5-phosphatase F","metadata":{"aliases":["SAC2","KIAA0966","hSac2"]}},{"id":"d9458e5fc1be4646817cd13881cd5ba7","type":"GENE","name":"INPP5J","canonical_id":"hgnc:HGNC:8956","description":null,"metadata":null},{"id":"5c2e5afb39884999b9146c91c6216b1b","type":"GENE","name":"INPP5K","canonical_id":"hgnc:HGNC:33882","description":"inositol polyphosphate-5-phosphatase K","metadata":{"aliases":["SKIP"]}},{"id":"d24328883f9a4288a88185620ac7c5fd","type":"GENE","name":"INPPL1","canonical_id":"hgnc:HGNC:6080","description":"inositol polyphosphate phosphatase like 1","metadata":{"aliases":["SHIP2"]}},{"id":"610ba78efa6145b6bbd9290c475d33fe","type":"GENE","name":"INS","canonical_id":"hgnc:HGNC:6081","description":null,"metadata":null},{"id":"74f45e3ae2754424ab52c8b08fee32e8","type":"GENE","name":"INS-IGF2","canonical_id":"hgnc:HGNC:33527","description":"INS-IGF2 readthrough","metadata":null},{"id":"5bfaae5d762044ff8a0772a7ae8201e2","type":"GENE","name":"INSC","canonical_id":"hgnc:HGNC:33116","description":"INSC spindle orientation adaptor protein","metadata":null},{"id":"f95673de97ac4142ab87e7e8aef0555a","type":"GENE","name":"INSIG1","canonical_id":"hgnc:HGNC:6083","description":"insulin induced gene 1","metadata":{"aliases":["CL-6","MGC1405"]}},{"id":"1019cdb9859d4cc897a7911246e4a2bf","type":"GENE","name":"INSIG1-DT","canonical_id":"hgnc:HGNC:55155","description":"INSIG1 divergent transcript","metadata":null},{"id":"b18c07d8bdce46b58e80c537a3038495","type":"GENE","name":"INSIG2","canonical_id":"hgnc:HGNC:20452","description":"insulin induced gene 2","metadata":null},{"id":"8b86b40ed2b84725a157eb7967a51686","type":"TRIAL","name":"INSIGHT-IBD Pragmatic Study","canonical_id":"clinicaltrials.gov:NCT07686757","description":"Ulcerative Colitis (UC); Crohn Disease (CD)","metadata":null},{"id":"f4c0ae899944453a9d7b4e41832a3a0a","type":"GENE","name":"INSL3","canonical_id":"hgnc:HGNC:6086","description":null,"metadata":null},{"id":"138a6890a3a944659b3dc9b81f4a2d5b","type":"GENE","name":"INSL4","canonical_id":"hgnc:HGNC:6087","description":"insulin like 4","metadata":{"aliases":["EPIL"]}},{"id":"25a74f1e58e64308b099f1634d812800","type":"GENE","name":"INSL5","canonical_id":"hgnc:HGNC:6088","description":"insulin like 5","metadata":null},{"id":"0c0b9108568b4930a950048a3bf51106","type":"GENE","name":"INSL6","canonical_id":"hgnc:HGNC:6089","description":"insulin like 6","metadata":{"aliases":["RIF1"]}},{"id":"74ebabe00cce4f5ba9fb96742429a6b6","type":"GENE","name":"INSM1","canonical_id":"hgnc:HGNC:6090","description":null,"metadata":null},{"id":"95d5598bdc7d4b92af81e342ddec587c","type":"GENE","name":"INSM2","canonical_id":"hgnc:HGNC:17539","description":"INSM transcriptional repressor 2","metadata":{"aliases":["IA-6","Mlt1"]}},{"id":"913653edc615425caede3b6e4a35df71","type":"TRIAL","name":"INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda\u00ae in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records","canonical_id":"clinicaltrials.gov:NCT05438186","description":"Obesity","metadata":null},{"id":"cba64f5d8d614864b7a58893c5d1be3e","type":"GENE","name":"INSR","canonical_id":"hgnc:HGNC:6091","description":null,"metadata":null},{"id":"38fd8493624d4cf4891bca62a232ff01","type":"PROTEIN","name":"INSR","canonical_id":"uniprot:P06213","description":null,"metadata":null},{"id":"93b793f654a34256a7bc0545d848f7b7","type":"GENE","name":"INSRR","canonical_id":"hgnc:HGNC:6093","description":"insulin receptor related receptor","metadata":{"aliases":["IRR"]}},{"id":"68e1782b4c914c229650cfdc2fc07935","type":"TRIAL","name":"INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial","canonical_id":"clinicaltrials.gov:NCT00638976","description":"Cardiovascular Disease","metadata":null},{"id":"c84a1fb40ee24774b1e91ec643ad4c3f","type":"GENE","name":"INSYN1","canonical_id":"hgnc:HGNC:33753","description":"inhibitory synaptic factor 1","metadata":{"aliases":["MGC131524","LOC388135","C15orf59"]}},{"id":"a980c92642864545b96e07d4e7a31e8e","type":"GENE","name":"INSYN1-AS1","canonical_id":"hgnc:HGNC:51422","description":"INSYN1 antisense RNA 1","metadata":{"aliases":["TCONS_00023459","C15orf59-AS1"]}},{"id":"bedd431288fb46969bbdda1d4bcae05b","type":"GENE","name":"INSYN2A","canonical_id":"hgnc:HGNC:33859","description":"inhibitory synaptic factor 2A","metadata":{"aliases":["FLJ45557","C10orf141","FAM196A","INSYN2"]}},{"id":"585f6847f316409eb3e9728c7bc8a88a","type":"GENE","name":"INSYN2B","canonical_id":"hgnc:HGNC:37271","description":"inhibitory synaptic factor family member 2B","metadata":{"aliases":["C5orf57","FAM196B"]}},{"id":"e0ec35a4c272426fb6d97de549af1dad","type":"GO_TERM","name":"INTAC complex","canonical_id":"go:GO:0160232","description":"\"A protein complex containing Integrator and protein phosphatase 2A core enzyme (PP2A-AC) that stably associates with the C-terminus of RNA polymerase II and promotes premature RNA polymerase II transcription termination.\" [PMID:33243860, PMID:38570683]","metadata":null},{"id":"6a94b4d58e8b467dbdb3c7ff78b9f9d1","type":"TRIAL","name":"INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION","canonical_id":"clinicaltrials.gov:NCT07415278","description":"Allergic Rhinitis","metadata":null},{"id":"888a3d7a983648af8d1be9b49e8b72e0","type":"GENE","name":"INTS1","canonical_id":"hgnc:HGNC:24555","description":"integrator complex subunit 1","metadata":{"aliases":["DKFZp586J0619","KIAA1440","INT1","NET28"]}},{"id":"ab9bc13e905a4b0fba9659170da202f8","type":"GENE","name":"INTS10","canonical_id":"hgnc:HGNC:25548","description":"integrator complex subunit 10","metadata":{"aliases":["FLJ10569","INT10","C8orf35"]}},{"id":"e11123455ab446ff95ff10b9032d453d","type":"GENE","name":"INTS11","canonical_id":"hgnc:HGNC:26052","description":"integrator complex subunit 11","metadata":{"aliases":["FLJ20542","RC-68","CPSF73L","INT11","CPSF3L"]}},{"id":"11525958a3704efeaa9e5d75ad487e88","type":"GENE","name":"INTS12","canonical_id":"hgnc:HGNC:25067","description":"integrator complex subunit 12","metadata":{"aliases":["SBBI22","INT12","PHF22"]}},{"id":"53726a1f5ce04ea2a0fa5a1020f802f4","type":"GENE","name":"INTS12-AS1","canonical_id":"hgnc:HGNC:58863","description":"INTS12 antisense RNA 1","metadata":null},{"id":"82ce2347c2974c90aa11795d24b87274","type":"GENE","name":"INTS13","canonical_id":"hgnc:HGNC:20174","description":"integrator complex subunit 13","metadata":{"aliases":["FLJ10637","NET48","Mat89Bb","SPATA30","C12orf11","ASUN"]}},{"id":"9215ccbd96644f86a207a505f94796d3","type":"GENE","name":"INTS14","canonical_id":"hgnc:HGNC:25372","description":"integrator complex subunit 14","metadata":{"aliases":["DKFZP564O1664","C15orf44","VWA9"]}},{"id":"2fba8c901d244cf999bb8eb5755d6185","type":"GENE","name":"INTS15","canonical_id":"hgnc:HGNC:21702","description":"integrator complex subunit 15","metadata":{"aliases":["MGC2718","C7orf26"]}},{"id":"c33c17b4f16b46158ecfdc83fd3f77ea","type":"GENE","name":"INTS2","canonical_id":"hgnc:HGNC:29241","description":"integrator complex subunit 2","metadata":{"aliases":["INT2","KIAA1287"]}},{"id":"5c2a126f8aec422f8bcf754fd949fce9","type":"GENE","name":"INTS3","canonical_id":"hgnc:HGNC:26153","description":"integrator complex subunit 3","metadata":{"aliases":["FLJ21919","INT3","SOSS-A","C1orf60"]}},{"id":"60f611ab21fb4a889d067dc5815c2d3a","type":"GENE","name":"INTS4","canonical_id":"hgnc:HGNC:25048","description":"integrator complex subunit 4","metadata":{"aliases":["INT4","MGC16733","MST093"]}},{"id":"273f526b25d64bb190b857172dd456a0","type":"GENE","name":"INTS4P1","canonical_id":"hgnc:HGNC:21925","description":"integrator complex subunit 4 pseudogene 1","metadata":{"aliases":["FLJ25037","INTS4L1"]}},{"id":"4ce160efeffc4b1b9e928b180bdac731","type":"GENE","name":"INTS4P2","canonical_id":"hgnc:HGNC:22351","description":"integrator complex subunit 4 pseudogene 2","metadata":{"aliases":["MGC133166","INTS4L2"]}},{"id":"8081bbd08aa340adab15e6639cee8dd6","type":"GENE","name":"INTS5","canonical_id":"hgnc:HGNC:29352","description":"integrator complex subunit 5","metadata":{"aliases":["INT5","KIAA1698"]}},{"id":"533e07b85f6e44469305af96adbab14f","type":"GENE","name":"INTS6","canonical_id":"hgnc:HGNC:14879","description":"integrator complex subunit 6","metadata":{"aliases":["DICE1","HDB","Notchl2","DBI-1","DDX26A","INT6","DDX26"]}},{"id":"6b510d0cb3bb4dad8dffc6412f96d397","type":"GENE","name":"INTS6-AS1","canonical_id":"hgnc:HGNC:42691","description":"INTS6 antisense RNA 1","metadata":null},{"id":"f07d3faf3f18458ca285f653a5fe681d","type":"GENE","name":"INTS6L","canonical_id":"hgnc:HGNC:27334","description":"integrator complex subunit 6 like","metadata":{"aliases":["FLJ41215","DDX26B"]}},{"id":"a6c01552a2f941bcb5ec51b79d907e54","type":"GENE","name":"INTS6L-AS1","canonical_id":"hgnc:HGNC:41180","description":"INTS6L antisense RNA 1","metadata":{"aliases":["DDX26B-AS1"]}},{"id":"24a3e8c4e48043829f368d94aa7b5934","type":"GENE","name":"INTS6P1","canonical_id":"hgnc:HGNC:43921","description":"integrator complex subunit 6 pseudogene 1","metadata":null},{"id":"0a8613f22d3e4d609b993969a73cb470","type":"GENE","name":"INTS7","canonical_id":"hgnc:HGNC:24484","description":"integrator complex subunit 7","metadata":{"aliases":["DKFZP434B168","INT7","C1orf73"]}},{"id":"efe051eb70b546f5a011e51fd3207931","type":"GENE","name":"INTS8","canonical_id":"hgnc:HGNC:26048","description":"integrator complex subunit 8","metadata":{"aliases":["FLJ20530","INT8","MGC131633","C8orf52"]}},{"id":"5ef9bcc7478d4fc9a9a83c936c295dcc","type":"GENE","name":"INTS9","canonical_id":"hgnc:HGNC:25592","description":"integrator complex subunit 9","metadata":{"aliases":["FLJ10871","CPSF2L","RC-74"]}},{"id":"4bb0650076ed4b249e2831bbc37dc59b","type":"GENE","name":"INTS9-AS1","canonical_id":"hgnc:HGNC:53139","description":"INTS9 antisense RNA 1","metadata":{"aliases":["ENST00000520055"]}},{"id":"08b8f5a64acd47c3b52d27def4793d79","type":"GENE","name":"INTU","canonical_id":"hgnc:HGNC:29239","description":"inturned planar cell polarity protein","metadata":{"aliases":["KIAA1284","CPLANE4","PDZK6","PDZD6"]}},{"id":"45f8bc038b2740fd9680aa497e341b74","type":"TRIAL","name":"INVEST: INternational VErapamil SR Trandolapril STudy","canonical_id":"clinicaltrials.gov:NCT00133692","description":"Hypertension; Coronary Artery Disease","metadata":null},{"id":"898bc1d5cf674bb6adbf88e3b40295aa","type":"GENE","name":"INVS","canonical_id":"hgnc:HGNC:17870","description":"inversin","metadata":{"aliases":["NPHP2"]}},{"id":"eff18a41f02f48a7b95fb7de5ad44d12","type":"TRIAL","name":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","canonical_id":"clinicaltrials.gov:NCT02977780","description":"Glioblastoma","metadata":null},{"id":"0bbaca3f72274937be4c4083497b878e","type":"TRIAL","name":"IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00527501","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"d1e4d08b381e47fb9f6bf6365443be2d","type":"GO_TERM","name":"IP-10 production","canonical_id":"go:GO:0071612","description":"\"The appearance of IP-10 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"d0cde3dd95144844a164475a916e7d9d","type":"GENE","name":"IP6K1","canonical_id":"hgnc:HGNC:18360","description":"inositol hexakisphosphate kinase 1","metadata":{"aliases":["KIAA0263","IHPK1"]}},{"id":"4856a13cb6d44dbdb5d16093cdafdda0","type":"GENE","name":"IP6K2","canonical_id":"hgnc:HGNC:17313","description":"inositol hexakisphosphate kinase 2","metadata":{"aliases":["IHPK2"]}},{"id":"18edaab23b294b43bbb9590f6ba0facb","type":"GENE","name":"IP6K3","canonical_id":"hgnc:HGNC:17269","description":"inositol hexakisphosphate kinase 3","metadata":{"aliases":["INSP6K3","IHPK3"]}},{"id":"d1b99646ff684b3c9f85d0c7318eda6b","type":"GO_TERM","name":"IPAF inflammasome complex","canonical_id":"go:GO:0072557","description":"\"An inflammasome complex that consists of three components, IPAF, NAIP and caspase-1, and includes among its functions the sensing of flagellin derived from Legionella pneumophila, Salmonella typhimurium, Pseudomonas aeruginosa and Shigella flexneri.\" [GOC:add, GOC:BHF, GOC:vp, PMID:20303873]","metadata":null},{"id":"8c51b329986043809e15f62234a33e4e","type":"GENE","name":"IPAN","canonical_id":"hgnc:HGNC:56706","description":"inhibitor of RIG-I/TRIM25 mediated viral protein degradation ncRNA","metadata":null},{"id":"0f492c3c6b6b41f0a96a45dd083a50ed","type":"GENE","name":"IPCEF1","canonical_id":"hgnc:HGNC:21204","description":"interaction protein for cytohesin exchange factors 1","metadata":{"aliases":["PIP3-E","KIAA0403"]}},{"id":"62f278f29eab40c5af23fd3867de3134","type":"GENE","name":"IPMK","canonical_id":"hgnc:HGNC:20739","description":"inositol polyphosphate multikinase","metadata":null},{"id":"3bdee593a2954dd09a7e3c39d419b221","type":"GENE","name":"IPMKP1","canonical_id":"hgnc:HGNC:39354","description":"inositol polyphosphate multikinase pseudogene 1","metadata":null},{"id":"d13fca1e028c43ceab3d9c054020a15a","type":"GENE","name":"IPO11","canonical_id":"hgnc:HGNC:20628","description":"importin 11","metadata":{"aliases":["RanBP11"]}},{"id":"b56cfa2d127046b28c651582598891c0","type":"GENE","name":"IPO13","canonical_id":"hgnc:HGNC:16853","description":null,"metadata":null},{"id":"6c4e41a105ab4b8d899c43d5382de27f","type":"GENE","name":"IPO4","canonical_id":"hgnc:HGNC:19426","description":"importin 4","metadata":{"aliases":["Imp4","FLJ23338"]}},{"id":"3dbcad1bb1f04897a482077b59bc8460","type":"GENE","name":"IPO5","canonical_id":"hgnc:HGNC:6402","description":"importin 5","metadata":{"aliases":["IMB3","MGC2068","PSE1","KPNB3","RANBP5"]}},{"id":"235ce3d38c7b4355acbc5b8939b1ee84","type":"GENE","name":"IPO5P1","canonical_id":"hgnc:HGNC:49687","description":"importin 5 pseudogene 1","metadata":null},{"id":"a38ce9ce87d74e93bb5db02c510bd7fc","type":"GENE","name":"IPO7","canonical_id":"hgnc:HGNC:9852","description":null,"metadata":null},{"id":"f147c8acfce64ce4860e006dc0c585c6","type":"GENE","name":"IPO7P1","canonical_id":"hgnc:HGNC:39837","description":"importin 7 pseudogene 1","metadata":null},{"id":"9692f9e0831b4470a55a815cc4a742c7","type":"GENE","name":"IPO7P2","canonical_id":"hgnc:HGNC:39838","description":"importin 7 pseudogene 2","metadata":null},{"id":"bd918e869d574dbd9177bc8ba904d6cd","type":"GENE","name":"IPO8","canonical_id":"hgnc:HGNC:9853","description":"importin 8","metadata":{"aliases":["IMP8","RANBP8"]}},{"id":"0da2bd053f034295961849f6db934f43","type":"GENE","name":"IPO8P1","canonical_id":"hgnc:HGNC:41955","description":"importin 8 pseudogene 1","metadata":null},{"id":"276c0d03e88e4c4aaad9462c41e8c5cd","type":"GENE","name":"IPO9","canonical_id":"hgnc:HGNC:19425","description":"importin 9","metadata":{"aliases":["Imp9","FLJ10402"]}},{"id":"84dbb9153b454a908a942b3ad0a310a4","type":"GENE","name":"IPO9-AS1","canonical_id":"hgnc:HGNC:40892","description":"IPO9 antisense RNA 1","metadata":null},{"id":"7af3e21c528a409a91f717908e1f2505","type":"GENE","name":"IPPK","canonical_id":"hgnc:HGNC:14645","description":"inositol-pentakisphosphate 2-kinase","metadata":{"aliases":["IP5-2K","INSP5K2","FLJ13163","IP5K","IPK1","C9orf12"]}},{"id":"4c1d6041a6254ac6b4bdaafb9dcffdd3","type":"GENE","name":"IPPKP1","canonical_id":"hgnc:HGNC:39390","description":"inositol 1,3,4,5,6-pentakisphosphate 2-kinase pseudogene 1","metadata":null},{"id":"2bc02c799b604c73841f6a410e1c89ca","type":"GENE","name":"IQANK1","canonical_id":"hgnc:HGNC:49576","description":"IQ motif and ankyrin repeat containing 1","metadata":{"aliases":["onco-lncRNA-3","CACClnc","FAM83H-AS1"]}},{"id":"d2f0e9557cae4536a4def91443fe4be2","type":"GENE","name":"IQCA1-AS1","canonical_id":"hgnc:HGNC:41137","description":"IQCA1 antisense RNA 1","metadata":null},{"id":"a4c8b31e88014971a205b9a280188df7","type":"GENE","name":"IQCB1","canonical_id":"hgnc:HGNC:28949","description":"IQ motif containing B1","metadata":{"aliases":["KIAA0036","NPHP5","SLSN5"]}},{"id":"4a9bf183f5354ebd8f7f8001401520af","type":"GENE","name":"IQCB2P","canonical_id":"hgnc:HGNC:17727","description":"IQ motif containing B2 pseudogene","metadata":{"aliases":["dJ313I6.1","IQCB1P1"]}},{"id":"ad937125a5d14a588f12a4ce443d0c02","type":"GENE","name":"IQCC","canonical_id":"hgnc:HGNC:25545","description":"IQ motif containing C","metadata":{"aliases":["FLJ10547"]}},{"id":"a636d56d36ce4c6fa1ce47cfe31bafd9","type":"GENE","name":"IQCC-AS1","canonical_id":"hgnc:HGNC:41107","description":"IQCC and CCDC28B antisense RNA 1","metadata":null},{"id":"3db37b68dd2f40a78b3e27ca3db908fb","type":"GENE","name":"IQCE","canonical_id":"hgnc:HGNC:29171","description":"IQ motif containing E","metadata":{"aliases":["KIAA1023"]}},{"id":"166d687f482c41e8b8df8ea6130f7d6f","type":"GENE","name":"IQCF1","canonical_id":"hgnc:HGNC:28607","description":"IQ motif containing F1","metadata":{"aliases":["MGC39725"]}},{"id":"cdfec2cea1b546f184e3787dfcd95432","type":"GENE","name":"IQCF2","canonical_id":"hgnc:HGNC:31815","description":"IQ motif containing F2","metadata":null},{"id":"bf12a62d31ce473f98cf190743696b11","type":"GENE","name":"IQCF3","canonical_id":"hgnc:HGNC:31816","description":"IQ motif containing F3","metadata":null},{"id":"118cf4250f424542842e1460533ab911","type":"GENE","name":"IQCF4P","canonical_id":"hgnc:HGNC:54720","description":"IQ motif containing F4, pseudogene","metadata":null},{"id":"059ce65f00a149e4943a5e24753b1a2e","type":"GENE","name":"IQCF5","canonical_id":"hgnc:HGNC:35159","description":"IQ motif containing F5","metadata":null},{"id":"dd8d846c6f04452f83b4077e6a561a23","type":"GENE","name":"IQCF5-AS1","canonical_id":"hgnc:HGNC:41297","description":"IQCF5 antisense RNA 1","metadata":null},{"id":"f23a01ba5df94ba283ac8d360ef9d3a0","type":"GENE","name":"IQCF6","canonical_id":"hgnc:HGNC:35158","description":"IQ motif containing F6","metadata":null},{"id":"7835953d1d9b4993bdd6abfe5b31e72a","type":"GENE","name":"IQCH","canonical_id":"hgnc:HGNC:25721","description":"IQ motif containing H","metadata":{"aliases":["FLJ12476"]}},{"id":"3509a11ec43f4c16990cf1eed20ea6a4","type":"GENE","name":"IQCH-AS1","canonical_id":"hgnc:HGNC:44104","description":"IQCH antisense RNA 1","metadata":null},{"id":"1002487f1c5346e3bd3b54a8c7d70711","type":"GENE","name":"IQCJ","canonical_id":"hgnc:HGNC:32406","description":"IQ motif containing J","metadata":null},{"id":"f5fef67026b44f2aba9b2fcd0978bc0c","type":"GENE","name":"IQCJ-SCHIP1","canonical_id":"hgnc:HGNC:38842","description":"IQCJ-SCHIP1 readthrough","metadata":null},{"id":"0a10affa418e48aa91f2bd8106c0ca44","type":"GENE","name":"IQCJ-SCHIP1-AS1","canonical_id":"hgnc:HGNC:41303","description":"IQCJ-SCHIP1 readthrough antisense RNA 1","metadata":null},{"id":"f735e8c3f14f4c169bc6b7e5e6d37538","type":"GENE","name":"IQCK","canonical_id":"hgnc:HGNC:28556","description":"IQ motif containing K","metadata":{"aliases":["MGC35048","FLJ36575"]}},{"id":"d8cfd71a1ec84cdf98f3c81764698521","type":"GENE","name":"IQCK-AS1","canonical_id":"hgnc:HGNC:58199","description":"IQCK antisense RNA 1","metadata":null},{"id":"49467e23025d472c9696b50fd584a596","type":"GENE","name":"IQCM","canonical_id":"hgnc:HGNC:53443","description":"IQ motif containing M","metadata":null},{"id":"64491a60e855442ab3e81bd26666ba10","type":"GENE","name":"IQCM-AS1","canonical_id":"hgnc:HGNC:58894","description":"IQCM antisense RNA 1","metadata":null},{"id":"fec7caa7523f484a91b10d5a6719ed19","type":"GENE","name":"IQCN","canonical_id":"hgnc:HGNC:29350","description":"IQ motif containing N","metadata":{"aliases":["KIAA1683"]}},{"id":"6dcbf9e3eac94d8d823a76544f237c55","type":"GENE","name":"IQGAP1","canonical_id":"hgnc:HGNC:6110","description":"IQ motif containing GTPase activating protein 1","metadata":{"aliases":["p195","KIAA0051","SAR1","HUMORFA01"]}},{"id":"be90866b28ee48109621a417796827e8","type":"GENE","name":"IQGAP2","canonical_id":"hgnc:HGNC:6111","description":"IQ motif containing GTPase activating protein 2","metadata":null},{"id":"d99c48675b764ced81e94e65a8e64972","type":"GENE","name":"IQGAP2-AS1","canonical_id":"hgnc:HGNC:59082","description":"IQGAP2 antisense RNA 1","metadata":null},{"id":"e9168526adc341fe8329dfad82cf769f","type":"GENE","name":"IQGAP3","canonical_id":"hgnc:HGNC:20669","description":"IQ motif containing GTPase activating protein 3","metadata":null},{"id":"12d907d0a5224f2099dafab079817eaa","type":"GENE","name":"IQSEC1","canonical_id":"hgnc:HGNC:29112","description":"IQ motif and Sec7 domain ArfGEF 1","metadata":{"aliases":["KIAA0763","GEP100","BRAG2","ARF-GEP100"]}},{"id":"c44083d87e6e41c6a44df565af741e26","type":"GENE","name":"IQSEC2","canonical_id":"hgnc:HGNC:29059","description":"IQ motif and Sec7 domain ArfGEF 2","metadata":{"aliases":["KIAA0522","BRAG1","IQ-ArfGEF","MRX1","MRX78","MRX18"]}},{"id":"615a4ad6a277400f993de663c0395240","type":"GENE","name":"IQSEC3","canonical_id":"hgnc:HGNC:29193","description":"IQ motif and Sec7 domain ArfGEF 3","metadata":{"aliases":["KIAA1110","MGC30156"]}},{"id":"60ed60e6634f4350b113529759037b2b","type":"GENE","name":"IQSEC3-AS1","canonical_id":"hgnc:HGNC:56002","description":"IQSEC3 antisense RNA 1","metadata":null},{"id":"6ed3dc1a86ad4c4a88eb259b136bd9c1","type":"GENE","name":"IQSEC3-AS2","canonical_id":"hgnc:HGNC:56741","description":"IQSEC3 antisense RNA 2","metadata":{"aliases":["AC026369.3"]}},{"id":"c06a664fdb1f49a39a45ef96f2571b91","type":"GENE","name":"IQSEC3-AS3","canonical_id":"hgnc:HGNC:58418","description":"IQSEC3 antisense RNA 3","metadata":null},{"id":"1e8ed11b964346788db9dfc9185cdc64","type":"GENE","name":"IQSEC3P1","canonical_id":"hgnc:HGNC:49848","description":"IQ motif and Sec7 domain 3 pseudogene 1","metadata":null},{"id":"564bbf0123d945f69d5bcf63058aa68f","type":"GENE","name":"IQSEC3P2","canonical_id":"hgnc:HGNC:49849","description":"IQ motif and Sec7 domain 3 pseudogene 2","metadata":null},{"id":"dba9953759c94f30a4a07a82b0f3fa33","type":"GENE","name":"IQSEC3P3","canonical_id":"hgnc:HGNC:49850","description":"IQ motif and Sec7 domain 3 pseudogene 3","metadata":null},{"id":"c2da5c12490d4a6bb3a6e9051ca39522","type":"GENE","name":"IQUB","canonical_id":"hgnc:HGNC:21995","description":"IQ motif and ubiquitin domain containing","metadata":{"aliases":["FLJ35834"]}},{"id":"2a881f432719439ab89d2d150314fd92","type":"GENE","name":"IRAG1-AS1","canonical_id":"hgnc:HGNC:43434","description":"IRAG1 antisense RNA 1","metadata":{"aliases":["MRVI1-AS1"]}},{"id":"1cb82a1f868f49f6a7d49da34171639d","type":"GENE","name":"IRAG2","canonical_id":"hgnc:HGNC:6690","description":"inositol 1,4,5-triphosphate receptor associated 2","metadata":{"aliases":["JAW1","LRMP"]}},{"id":"3fc299ecc4154066a5a430ecf527d7a3","type":"GENE","name":"IRAIN","canonical_id":"hgnc:HGNC:50365","description":"IGF1R antisense imprinted non-protein coding RNA","metadata":{"aliases":["IGF1R-AS","IGF1R-AS1"]}},{"id":"44ab186f470a42c29cb846ebf6d6e0b3","type":"GENE","name":"IRAK1","canonical_id":"hgnc:HGNC:6112","description":"interleukin 1 receptor associated kinase 1","metadata":{"aliases":["IRAK","pelle"]}},{"id":"2e0b36ffd3ea41c891f1e1c0353e4044","type":"GENE","name":"IRAK1BP1","canonical_id":"hgnc:HGNC:17368","description":"interleukin 1 receptor associated kinase 1 binding protein 1","metadata":{"aliases":["AIP70","SIMPL"]}},{"id":"628a8917c63a408f99d08e558966defc","type":"GENE","name":"IRAK2","canonical_id":"hgnc:HGNC:6113","description":null,"metadata":null},{"id":"fea2ba0ee3894e9dae0bc34dffbb4c93","type":"GENE","name":"IRAK3","canonical_id":"hgnc:HGNC:17020","description":"interleukin 1 receptor associated kinase 3","metadata":{"aliases":["IRAK-M"]}},{"id":"b18cbc175ac04c4a920ec74d7032eb89","type":"GENE","name":"IRAK4","canonical_id":"hgnc:HGNC:17967","description":"interleukin 1 receptor associated kinase 4","metadata":{"aliases":["NY-REN-64"]}},{"id":"7774b67ba47b4effbc97885ec13f8dea","type":"GO_TERM","name":"IRE1-RACK1-PP2A complex","canonical_id":"go:GO:1990630","description":"\"A protein complex consisting of IRE1 (Inositol-requiring enzyme-1), RACK1 (Receptor of activated protein kinase C 1, GNB2L1) and PP2A (protein phosphatase 2A). RACK1 acts as an adaptor to bridge an interaction between IRE1 and PP2A.\" [GOC:bf, GOC:PARL, PMID:20103773]","metadata":null},{"id":"47829911e89d441b80d1434b88995bb0","type":"GO_TERM","name":"IRE1-TRAF2-ASK1 complex","canonical_id":"go:GO:1990604","description":"\"A protein complex of the endoplasmic reticulum membrane that consists of IRE1 (Inositol-requiring enzyme-1), TRAF2 (TNF receptor-associated factor 2) and ASK1 (Apoptosis signal-regulating kinase 1, a MAP3K).\" [GOC:bf, GOC:PARL, PMID:12050113, PMID:23000344]","metadata":null},{"id":"f3bc4c2093b340679c83c51fa89c06e6","type":"GO_TERM","name":"IRE1-mediated unfolded protein response","canonical_id":"go:GO:0036498","description":"\"The series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB.\" [GOC:bf, GOC:PARL, PMID:22013210]","metadata":null},{"id":"576824cede2a4fc98b86bd70b6a25556","type":"GENE","name":"IREB2","canonical_id":"hgnc:HGNC:6115","description":"iron responsive element binding protein 2","metadata":{"aliases":["IRP2"]}},{"id":"72db4072f0684e64bf7d83b1b5e8bfe3","type":"GO_TERM","name":"IRES-dependent translational initiation of circular RNA","canonical_id":"go:GO:0110019","description":"\"The process where translation initiation recruits the 40S ribosomal subunits via an internal ribosome entry segment (IRES) before an AUG codon is encountered in an appropriate sequence context to initiate circular mRNA translation.\" [GOC:sp, PMID:28281539, PMID:28344080, PMID:28344082]","metadata":null},{"id":"9d35f88dd41c481fa35e1cd18762b707","type":"GO_TERM","name":"IRES-dependent translational initiation of linear mRNA","canonical_id":"go:GO:0002192","description":"\"The process where translation initiation recruits the 40S ribosomal subunits via an internal ribosome entry segment (IRES) before an AUG codon is encountered in an appropriate sequence context to initiate linear mRNA translation.\" [PMID:17284590]","metadata":null},{"id":"faddae5117d14f4f830d45bd5204792e","type":"GO_TERM","name":"IRES-dependent viral translational initiation","canonical_id":"go:GO:0075522","description":"\"Process by which viral mRNA translation is initiated, where a domain in the 5' untranslated region (UTR) of the viral mRNA called an internal ribosome entry site (IRES) binds the host 43S preinitiation complex, circumventing regular cap-dependent translation initiation.\" [GOC:bf, GOC:jl, PMID:19632368, VZ:867]","metadata":null},{"id":"5cf8872f00ce445488fe3f34fc2fec02","type":"GO_TERM","name":"IRES-mediated translation initiation factor activity","canonical_id":"go:GO:0160297","description":"\"A translation initiation factor activity that enables interaction with internal ribosome entry sites (IRESs) located within mRNA, promoting ribosome recruitment and assembly at internal initiation sites and translation initiation independent of the 5' cap structure.\" [PMID:21118130, PMID:31913484]","metadata":null},{"id":"e0a53a3c5a464a7ab387d59098c80ab3","type":"GENE","name":"IRF1","canonical_id":"hgnc:HGNC:6116","description":null,"metadata":null},{"id":"c072510df1a54778bab840c3f303ff83","type":"GENE","name":"IRF2","canonical_id":"hgnc:HGNC:6117","description":null,"metadata":null},{"id":"7205661ecbfc49028ffcc096447992d9","type":"GENE","name":"IRF2-DT","canonical_id":"hgnc:HGNC:54871","description":"IRF2 divergent transcript","metadata":null},{"id":"ee370d84a0ed4e1baa0d839f85b50b65","type":"GENE","name":"IRF2BP1","canonical_id":"hgnc:HGNC:21728","description":"interferon regulatory factor 2 binding protein 1","metadata":{"aliases":["DKFZP434M154","IRF-2BP1"]}},{"id":"0732e1b3d0f04f409989767e3d820158","type":"GENE","name":"IRF2BP2","canonical_id":"hgnc:HGNC:21729","description":null,"metadata":null},{"id":"9ee09258822b4252b27876a52ecb623f","type":"GENE","name":"IRF2BPL","canonical_id":"hgnc:HGNC:14282","description":"interferon regulatory factor 2 binding protein like","metadata":{"aliases":["EAP1","KIAA1865","C14orf4"]}},{"id":"d61ae67e83a4423ea67cf579584efead","type":"GENE","name":"IRF3","canonical_id":"hgnc:HGNC:6118","description":null,"metadata":null},{"id":"07ae5d1cfe4d47fa802d119bbddac71a","type":"GENE","name":"IRF4","canonical_id":"hgnc:HGNC:6119","description":null,"metadata":null},{"id":"c17f4abbf95b48d883fd97243e7df6fc","type":"GENE","name":"IRF4-AS1","canonical_id":"hgnc:HGNC:59324","description":"IRF4 antisense RNA 1","metadata":null},{"id":"2570b952f5c445ab9bd214ce6131198b","type":"GENE","name":"IRF5","canonical_id":"hgnc:HGNC:6120","description":null,"metadata":null},{"id":"053353f8b930435bb7ba01edde15f3c6","type":"GENE","name":"IRF5P1","canonical_id":"hgnc:HGNC:41981","description":"interferon regulatory factor 5 pseudogene 1","metadata":null},{"id":"c4cadb8e00a84c4c9fd8520e29df435b","type":"GENE","name":"IRF6","canonical_id":"hgnc:HGNC:6121","description":null,"metadata":null},{"id":"60bdab6850424377bdd036ebb3766c7b","type":"GENE","name":"IRF7","canonical_id":"hgnc:HGNC:6122","description":null,"metadata":null},{"id":"e7f78bb0cab24f50b2f91b8c93791514","type":"GENE","name":"IRF8","canonical_id":"hgnc:HGNC:5358","description":null,"metadata":null},{"id":"6184b79fbeee48e5bb1d8c88b4cb83f1","type":"GENE","name":"IRF9","canonical_id":"hgnc:HGNC:6131","description":null,"metadata":null},{"id":"e5327e0ad2c5405d843ba9660c50b9e3","type":"GENE","name":"IRGC","canonical_id":"hgnc:HGNC:28835","description":"immunity related GTPase cinema","metadata":{"aliases":["Iigp5","CINEMA","IRGC1"]}},{"id":"4f79237011154349a82771971a5c46d6","type":"GENE","name":"IRGM","canonical_id":"hgnc:HGNC:29597","description":"immunity related GTPase M","metadata":{"aliases":["LRG47","LRG-47","IFI1","IRGM1"]}},{"id":"535fbd8cffb7436997c08461e3b68e49","type":"GENE","name":"IRGQ","canonical_id":"hgnc:HGNC:24868","description":"immunity related GTPase Q","metadata":{"aliases":["FKSG27","IRGQ1"]}},{"id":"1b9cf0e8ebc442f48f97969b1258b396","type":"GENE","name":"IRS1","canonical_id":"hgnc:HGNC:6125","description":"insulin receptor substrate 1","metadata":{"aliases":["HIRS-1"]}},{"id":"ba10f54e06284b3789611d6b7243a1b2","type":"GENE","name":"IRS2","canonical_id":"hgnc:HGNC:6126","description":null,"metadata":null},{"id":"6f927cc8d99f4597bbaf2fe4c787358e","type":"GENE","name":"IRS3P","canonical_id":"hgnc:HGNC:6127","description":"insulin receptor substrate 3, pseudogene","metadata":{"aliases":["IRS3L"]}},{"id":"be820f80257c485ca4907e5186d89cc5","type":"GENE","name":"IRS4","canonical_id":"hgnc:HGNC:6128","description":"insulin receptor substrate 4","metadata":{"aliases":["PY160","IRS-4"]}},{"id":"cbba2e1ae9e04ea0aa0ba20de810b6d5","type":"GENE","name":"IRS4-AS1","canonical_id":"hgnc:HGNC:55650","description":"IRS4 antisense RNA 1","metadata":null},{"id":"02df3a03629641a1a6ce018fb364e101","type":"GENE","name":"IRX1","canonical_id":"hgnc:HGNC:14358","description":"iroquois homeobox 1","metadata":{"aliases":["IRX-5"]}},{"id":"3d66c809c70744d2b4b763f35fd2ed8f","type":"GENE","name":"IRX1-AS1","canonical_id":"hgnc:HGNC:58996","description":"IRX1 antisense RNA 1","metadata":null},{"id":"b75d3b3260de483991c7f00e7c0d87fd","type":"GENE","name":"IRX1P1","canonical_id":"hgnc:HGNC:33315","description":"iroquois homeobox 1 pseudogene 1","metadata":null},{"id":"5c10cd606f2248ba970af7106272e5c5","type":"GENE","name":"IRX2","canonical_id":"hgnc:HGNC:14359","description":"iroquois homeobox 2","metadata":null},{"id":"3c24a84df90a45de940397bf29c8da2b","type":"GENE","name":"IRX2-AS1","canonical_id":"hgnc:HGNC:58995","description":"IRX2 antisense RNA 1","metadata":null},{"id":"03ccbf2eaffc4e03940a35bf22e98d67","type":"GENE","name":"IRX2-DT","canonical_id":"hgnc:HGNC:24226","description":"IRX2 divergent transcript","metadata":{"aliases":["CEI","IRX2NB","C5orf38"]}},{"id":"ee6302ab1cb3407d84c20adb307f5ebf","type":"GENE","name":"IRX3","canonical_id":"hgnc:HGNC:14360","description":"iroquois homeobox 3","metadata":{"aliases":["IRX-1"]}},{"id":"473afa8913c440b08a1f9d30afe7537c","type":"GENE","name":"IRX3-AS1","canonical_id":"hgnc:HGNC:58975","description":"IRX3 antisense RNA 1","metadata":{"aliases":["uc.403"]}},{"id":"252aa5b9110b4668a56961e34697146a","type":"GENE","name":"IRX4","canonical_id":"hgnc:HGNC:6129","description":"iroquois homeobox 4","metadata":null},{"id":"66aa3729fff24ca28271eeb2093f6d1b","type":"GENE","name":"IRX4-AS1","canonical_id":"hgnc:HGNC:40305","description":"IRX4 antisense RNA 1","metadata":null},{"id":"884b7337c7e145f6ae1721add28c3a1a","type":"GENE","name":"IRX4-DT","canonical_id":"hgnc:HGNC:58994","description":"IRX4 divergent transcript","metadata":null},{"id":"6acd2e66fc9947dd946df9192db50af2","type":"GENE","name":"IRX4P1","canonical_id":"hgnc:HGNC:33316","description":"iroquois homeobox 4 pseudogene 1","metadata":null},{"id":"233bcd7321a34ee980f43c4b85df8fab","type":"GENE","name":"IRX5","canonical_id":"hgnc:HGNC:14361","description":"iroquois homeobox 5","metadata":{"aliases":["IRX-2a"]}},{"id":"5ebbb6fb88c649a2a828ce6508072ddf","type":"GENE","name":"IRX6","canonical_id":"hgnc:HGNC:14675","description":"iroquois homeobox 6","metadata":{"aliases":["IRX-3","IRX7"]}},{"id":"97265d74f95e46959b970abf345b1b00","type":"GENE","name":"ISCA1","canonical_id":"hgnc:HGNC:28660","description":"iron-sulfur cluster assembly 1","metadata":{"aliases":["MGC4276","ISA1","hIscA","hIscA1","HBLD2"]}},{"id":"ba7eb4519511461c8e76bcadbf674712","type":"GENE","name":"ISCA1P1","canonical_id":"hgnc:HGNC:33263","description":"iron-sulfur cluster assembly 1 pseudogene 1","metadata":{"aliases":["ISCA1L"]}},{"id":"daa374af5b7e43a0ae5ff722817489da","type":"GENE","name":"ISCA1P2","canonical_id":"hgnc:HGNC:38023","description":"iron-sulfur cluster assembly 1 pseudogene 2","metadata":null},{"id":"ffa4e6652097429f9b5c5c0a0cedd2f9","type":"GENE","name":"ISCA1P3","canonical_id":"hgnc:HGNC:38024","description":"iron-sulfur cluster assembly 1 pseudogene 3","metadata":null},{"id":"7e835e73b3a2487eb921e744316d1db6","type":"GENE","name":"ISCA1P4","canonical_id":"hgnc:HGNC:38025","description":"iron-sulfur cluster assembly 1 pseudogene 4","metadata":null},{"id":"090ca453027542c29f8a403f497e9a51","type":"GENE","name":"ISCA1P5","canonical_id":"hgnc:HGNC:38026","description":"iron-sulfur cluster assembly 1 pseudogene 5","metadata":null},{"id":"7d368d37e00e46188c2e1b2d44dca95c","type":"GENE","name":"ISCA1P6","canonical_id":"hgnc:HGNC:38027","description":"iron-sulfur cluster assembly 1 pseudogene 6","metadata":null},{"id":"1b2dec4c139b48b187a9738ac952255a","type":"GENE","name":"ISCA1P7","canonical_id":"hgnc:HGNC:57008","description":"iron-sulfur cluster assembly 1 pseudogene 7","metadata":null},{"id":"cd3dbf4838854b7e95b480b64252f597","type":"GENE","name":"ISCA2","canonical_id":"hgnc:HGNC:19857","description":"iron-sulfur cluster assembly 2","metadata":{"aliases":["ISA2","HBLD1"]}},{"id":"e7ae115a4e214ac7a4c8b6b71c9a13f3","type":"GENE","name":"ISCA2P1","canonical_id":"hgnc:HGNC:38022","description":"iron-sulfur cluster assembly 2 pseudogene 1","metadata":null},{"id":"8bb7bec96b504283b33bde3493e7a3a0","type":"GENE","name":"ISCU","canonical_id":"hgnc:HGNC:29882","description":"iron-sulfur cluster assembly enzyme","metadata":{"aliases":["ISU2","hnifU","NIFUN"]}},{"id":"f794f69c52474fd78028ad4c0d196bdd","type":"GENE","name":"ISCUP1","canonical_id":"hgnc:HGNC:38021","description":"iron-sulfur cluster assembly enzyme pseudogene 1","metadata":null},{"id":"f9fb03a36e614203a6eb5efc94920309","type":"GENE","name":"ISG15","canonical_id":"hgnc:HGNC:4053","description":"ISG15 ubiquitin like modifier","metadata":{"aliases":["IFI15","UCRP","G1P2"]}},{"id":"62f76935db61457dbf91837304e6f608","type":"GO_TERM","name":"ISG15 activating enzyme activity","canonical_id":"go:GO:0019782","description":"\"Catalysis of the activation of the small ubiquitin-related modifier ISG15, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:mah]","metadata":null},{"id":"37a61a4d74ee47cbb3dc16a9aaf0a440","type":"GO_TERM","name":"ISG15 conjugating enzyme activity","canonical_id":"go:GO:0061653","description":"\"Isoenergetic transfer of ISG15 from one protein to another via the reaction X-ISG15 + Y = Y-ISG15 + X, where both the X-ISG15 and Y-ISG15 linkages are thioester bonds between the C-terminal amino acid of ISG15 and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"5023e6d485514ab2a7530f591da5ebdb","type":"GO_TERM","name":"ISG15 ligase activity","canonical_id":"go:GO:0061662","description":"\"Catalysis of the transfer of a ISG15 to a substrate protein via the reaction X-ISG15 + S = X + S-ISG15, where X is either an E2 or E3 enzyme, the X-ISG15 linkage is a thioester bond, and the S-ISG15 linkage is an isopeptide bond between the C-terminal amino acid of ISG15 and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"479cc9f8b70342889aa114f70397d983","type":"GO_TERM","name":"ISG15 transferase activity","canonical_id":"go:GO:0042296","description":"\"Catalysis of the transfer of ISG15 from one protein to another via the reaction X-ISG15 + Y = Y-ISG15 + X, where both X-ISG15 and Y-ISG15 are covalent linkages.\" [GOC:mah, PMID:12826404]","metadata":null},{"id":"4a2ae3c525be4ac1b2a36a38ae8dc066","type":"GO_TERM","name":"ISG15-protein conjugation","canonical_id":"go:GO:0032020","description":"\"The covalent addition to a protein of ISG15, a ubiquitin-like protein.\" [GOC:mah]","metadata":null},{"id":"52a71f4898674424aa5e3fa38ac725ab","type":"GO_TERM","name":"ISG15-specific peptidase activity","canonical_id":"go:GO:0019785","description":"\"A thiol-dependent isopeptidase activity that cleaves ISG15 from a target protein to which it is conjugated.\" [GOC:mah, PMID:30213559]","metadata":null},{"id":"8d0a8bc3bf304ee68c18afb3376abf87","type":"GENE","name":"ISG20","canonical_id":"hgnc:HGNC:6130","description":null,"metadata":null},{"id":"dd6880b760c34840b4997bef53c4e1d1","type":"GENE","name":"ISG20L2","canonical_id":"hgnc:HGNC:25745","description":"interferon stimulated exonuclease gene 20 like 2","metadata":{"aliases":["FLJ12671"]}},{"id":"91655e3615dd43429a01a0fdd67b0612","type":"GENE","name":"ISG20L2P1","canonical_id":"hgnc:HGNC:56904","description":"ISG20L2 pseudogene 1","metadata":null},{"id":"5ffd0904689b4e20af29ef8f595fa049","type":"GENE","name":"ISG20L2P2","canonical_id":"hgnc:HGNC:56905","description":"ISG20L2 pseudogene 2","metadata":null},{"id":"3f580249580149f885fb37cf4c4f545c","type":"GO_TERM","name":"ISGF3 complex","canonical_id":"go:GO:0070721","description":"\"A transcription factor complex that consists of a Stat1-Stat2 heterodimer and the IRF9 protein.\" [GOC:mah, PMID:8943351]","metadata":null},{"id":"d4008ce6db16482f9caf68833d617f5f","type":"GENE","name":"ISL1","canonical_id":"hgnc:HGNC:6132","description":null,"metadata":null},{"id":"901dcbbd9aba40df8271738438dcacaa","type":"GENE","name":"ISL1-DT","canonical_id":"hgnc:HGNC:55414","description":"ISL1 divergent transcript","metadata":null},{"id":"ccbcc63606254915aad40adbaa922d0a","type":"GENE","name":"ISL2","canonical_id":"hgnc:HGNC:18524","description":"ISL LIM homeobox 2","metadata":{"aliases":["FLJ10160"]}},{"id":"c482c389288c469bbbbfeee0ab1f3f3d","type":"GENE","name":"ISLR","canonical_id":"hgnc:HGNC:6133","description":"immunoglobulin superfamily containing leucine rich repeat","metadata":{"aliases":["HsT17563"]}},{"id":"362c8cf42e674b429f2562cf180e9536","type":"GENE","name":"ISLR2","canonical_id":"hgnc:HGNC:29286","description":"immunoglobulin superfamily containing leucine rich repeat 2","metadata":{"aliases":["KIAA1465"]}},{"id":"7e56e04a431f4febb85a50eb40ed9233","type":"GENE","name":"ISLR2-AS1","canonical_id":"hgnc:HGNC:27530","description":"ISLR2 antisense RNA 1","metadata":null},{"id":"53e62aba677344ffa32ad7797a937fe8","type":"GENE","name":"ISM1","canonical_id":"hgnc:HGNC:16213","description":"isthmin 1","metadata":{"aliases":["bA149I18.1","C20orf82"]}},{"id":"f0beeefcbba04724a658a15beaa96f63","type":"GENE","name":"ISM1-AS1","canonical_id":"hgnc:HGNC:44313","description":"ISM1 antisense RNA 1","metadata":null},{"id":"7fb13e7f082f4e8f96b3bcb1453aff39","type":"GENE","name":"ISM2","canonical_id":"hgnc:HGNC:23176","description":"isthmin 2","metadata":{"aliases":["FLJ32147","TAIL1","THSD3"]}},{"id":"a6f3fd6eb7a34d0796cdf7af592c651c","type":"GENE","name":"ISOC1","canonical_id":"hgnc:HGNC:24254","description":"isochorismatase domain containing 1","metadata":{"aliases":["CGI-111"]}},{"id":"c9708d5c0d3a496699f621d859bdf9f0","type":"GENE","name":"ISOC1-AS1","canonical_id":"hgnc:HGNC:59129","description":"ISOC1 antisense RNA 1","metadata":null},{"id":"ef1b251f45464a7d91938ee996c432a1","type":"GENE","name":"ISOC2","canonical_id":"hgnc:HGNC:26278","description":"isochorismatase domain containing 2","metadata":{"aliases":["FLJ23469"]}},{"id":"115cb2f6d2fc4adaa14d7195d1fc8401","type":"GENE","name":"IST1","canonical_id":"hgnc:HGNC:28977","description":"IST1 factor associated with ESCRT-III","metadata":{"aliases":["CHMP8","KIAA0174"]}},{"id":"b040a76458e3484998f93e3fcfee5415","type":"GO_TERM","name":"ISWI-type complex","canonical_id":"go:GO:0031010","description":"\"Any nuclear protein complex that contains an ATPase subunit of the imitation switch (ISWI) family. ISWI ATPases are involved in assembling chromatin and in sliding and spacing nucleosomes to regulate transcription of nuclear RNA polymerases I, II, and III and also DNA replication, recombination and repair.\" [GOC:krc, GOC:mah, PMID:15020051, PMID:15284901, PMID:16568949, PMID:21810179]","metadata":null},{"id":"05490b0c58a84029ba905984e665e22f","type":"GENE","name":"ISX","canonical_id":"hgnc:HGNC:28084","description":"intestine specific homeobox","metadata":{"aliases":["RAXLX"]}},{"id":"05fe785e03c44616a1c022b9c325f28f","type":"GENE","name":"ISY1","canonical_id":"hgnc:HGNC:29201","description":"ISY1 spliceosome associated protein","metadata":{"aliases":["KIAA1160","fSAP33"]}},{"id":"0c5ad87615734b26b8055ac3fb5fc115","type":"GENE","name":"ISY1-RAB43","canonical_id":"hgnc:HGNC:42969","description":"ISY1-RAB43 readthrough","metadata":null},{"id":"47223065033744298f0b913f5f0db397","type":"GENE","name":"ISYNA1","canonical_id":"hgnc:HGNC:29821","description":null,"metadata":null},{"id":"6b5f205dafca460981eb882416c54341","type":"GENE","name":"ISYNA1P1","canonical_id":"hgnc:HGNC:58598","description":"ISYNA1 pseudogene 1","metadata":null},{"id":"677fa960d3a34421926eaa7b7f64bd4d","type":"TRIAL","name":"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma","canonical_id":"clinicaltrials.gov:NCT03958383","description":"Melanoma","metadata":null},{"id":"402fe377c4fd44448385b51af7eb68b4","type":"GENE","name":"ITCH","canonical_id":"hgnc:HGNC:13890","description":"itchy E3 ubiquitin protein ligase","metadata":{"aliases":["AIP4"]}},{"id":"248ed8553d8c447687e2521c4cecdb63","type":"GENE","name":"ITCH-AS1","canonical_id":"hgnc:HGNC:40659","description":"ITCH antisense RNA 1","metadata":null},{"id":"b716238c945b44bc872b38c94ab1568d","type":"GENE","name":"ITCH-IT1","canonical_id":"hgnc:HGNC:41397","description":"ITCH intronic transcript 1","metadata":null},{"id":"b78e0031901b444481b9c589b08c6b8a","type":"GENE","name":"ITFG1","canonical_id":"hgnc:HGNC:30697","description":"integrin alpha FG-GAP repeat containing 1","metadata":{"aliases":["CDA08","TIP","LNKN-1"]}},{"id":"05d00bb48b614401818714423d73e08d","type":"GENE","name":"ITFG1-AS1","canonical_id":"hgnc:HGNC:51383","description":"ITFG1 antisense RNA 1","metadata":null},{"id":"9b55a1e40fd941e4a40a94903d6bf589","type":"GENE","name":"ITFG1-AS2","canonical_id":"hgnc:HGNC:58303","description":"ITFG1 antisense RNA 2","metadata":null},{"id":"7db68dbc4a4c43feb324f40d95186998","type":"GENE","name":"ITFG2","canonical_id":"hgnc:HGNC:30879","description":"integrin alpha FG-GAP repeat containing 2","metadata":{"aliases":["MDS028","KICS3","FGGAP1"]}},{"id":"8b307ca030274622b40ae35e56043768","type":"GENE","name":"ITFG2-AS1","canonical_id":"hgnc:HGNC:53128","description":"ITFG2 antisense RNA 1","metadata":{"aliases":["CACNA1C-AS1","CACNA1C-AS2"]}},{"id":"5a194f72767241c98c33dbd41217c337","type":"GENE","name":"ITGA1","canonical_id":"hgnc:HGNC:6134","description":"integrin subunit alpha 1","metadata":{"aliases":["VLA1","CD49a"]}},{"id":"a14f8d0d57a948bda99916f5e7fd0b0e","type":"GENE","name":"ITGA1-AS1","canonical_id":"hgnc:HGNC:59041","description":"ITGA1 antisense RNA 1","metadata":null},{"id":"780de23bedda4e5aae870bd0b38635ad","type":"GENE","name":"ITGA10","canonical_id":"hgnc:HGNC:6135","description":"integrin subunit alpha 10","metadata":null},{"id":"a0691c3a06564b79a9fbfb313128ac8e","type":"GENE","name":"ITGA11","canonical_id":"hgnc:HGNC:6136","description":"integrin subunit alpha 11","metadata":{"aliases":["HsT18964"]}},{"id":"1b3d5fafed634621932de20223ae1f2d","type":"GENE","name":"ITGA2","canonical_id":"hgnc:HGNC:6137","description":null,"metadata":null},{"id":"6f28f3317f2b4fd89edafdb869a93994","type":"GENE","name":"ITGA2-AS1","canonical_id":"hgnc:HGNC:40306","description":"ITGA2 antisense RNA 1","metadata":{"aliases":["I2ALR"]}},{"id":"df09087eec7b4d10b22d5bdd96bc3437","type":"GENE","name":"ITGA2-AS2","canonical_id":"hgnc:HGNC:59042","description":"ITGA2 antisense RNA 2","metadata":null},{"id":"6a833861d07544eea12bc06e18abbad9","type":"GENE","name":"ITGA2B","canonical_id":"hgnc:HGNC:6138","description":null,"metadata":null},{"id":"fcc4ebc6c5584e338e4f76c1bc2c8a4d","type":"GENE","name":"ITGA3","canonical_id":"hgnc:HGNC:6139","description":"integrin subunit alpha 3","metadata":{"aliases":["CD49c","VLA3a","VCA-2","GAP-B3","MSK18"]}},{"id":"77cb9678aa834a20b925da22c270ba4e","type":"GENE","name":"ITGA4","canonical_id":"hgnc:HGNC:6140","description":"integrin subunit alpha 4","metadata":{"aliases":["CD49d","CD49D"]}},{"id":"cf6939da62ef4e3e91c0cc1dbdac5c5b","type":"PROTEIN","name":"ITGA4","canonical_id":"uniprot:P13612","description":null,"metadata":null},{"id":"6fffa58096184e548fb7391354c88ea5","type":"GENE","name":"ITGA5","canonical_id":"hgnc:HGNC:6141","description":null,"metadata":null},{"id":"d4d6f5895cd64526a7203237f1590093","type":"GENE","name":"ITGA6","canonical_id":"hgnc:HGNC:6142","description":null,"metadata":null},{"id":"2a8f29102b074ef1ba32bbdd49e673a3","type":"GENE","name":"ITGA6-AS1","canonical_id":"hgnc:HGNC:40308","description":"ITGA6 and PDK1 antisense RNA 1","metadata":{"aliases":["lncIHAT","AC078883.3","PDK1-AS1"]}},{"id":"3493475d85c14cd5b34aaa6ebb8b0c6d","type":"GENE","name":"ITGA7","canonical_id":"hgnc:HGNC:6143","description":"integrin subunit alpha 7","metadata":null},{"id":"ab63b60b0fc443159e348e6639c304f6","type":"GENE","name":"ITGA8","canonical_id":"hgnc:HGNC:6144","description":"integrin subunit alpha 8","metadata":null},{"id":"650a5f5fb4434f3f96be7d7a305739a8","type":"GENE","name":"ITGA9","canonical_id":"hgnc:HGNC:6145","description":null,"metadata":null},{"id":"2658cba8d6294c1bb3c43f58ee5cb019","type":"GENE","name":"ITGA9-AS1","canonical_id":"hgnc:HGNC:49668","description":"ITGA9 antisense RNA 1","metadata":null},{"id":"8a3a35a18332450995cb844afced9be8","type":"GENE","name":"ITGAD","canonical_id":"hgnc:HGNC:6146","description":null,"metadata":null},{"id":"fa538b6f938c48428f143b3a14de4ba1","type":"GENE","name":"ITGAE","canonical_id":"hgnc:HGNC:6147","description":"integrin subunit alpha E","metadata":{"aliases":["CD103","HUMINAE"]}},{"id":"42ddfa25a8d44ce692a91ca0a4e1ea1a","type":"GENE","name":"ITGAE-AS1","canonical_id":"hgnc:HGNC:59081","description":"ITGAE antisense RNA 1","metadata":{"aliases":["AC116914.2"]}},{"id":"a1eb3d9d5c0e4850a4cd3c9357dddcd5","type":"GENE","name":"ITGAEP1","canonical_id":"hgnc:HGNC:56927","description":"ITGAE pseudogene 1","metadata":null},{"id":"ad68df42266542deac1b1d58e8547527","type":"GENE","name":"ITGAL","canonical_id":"hgnc:HGNC:6148","description":null,"metadata":null},{"id":"cb64518f253b410dadad6f66e3dede48","type":"PROTEIN","name":"ITGAL","canonical_id":"uniprot:P20701","description":null,"metadata":null},{"id":"573cc245d3244f4f8da4ac57fbea3558","type":"GENE","name":"ITGAL-AS1","canonical_id":"hgnc:HGNC:56737","description":"ITGAL antisense RNA 1","metadata":{"aliases":["RP11-279C4.1"]}},{"id":"f66633205b884d48b7cbde75c28a049e","type":"GENE","name":"ITGAM","canonical_id":"hgnc:HGNC:6149","description":null,"metadata":null},{"id":"49dd4bc302ab4691b0ba680bc24e973b","type":"GENE","name":"ITGAV","canonical_id":"hgnc:HGNC:6150","description":null,"metadata":null},{"id":"0148075733f74e3982d0925993ef2995","type":"GENE","name":"ITGAX","canonical_id":"hgnc:HGNC:6152","description":null,"metadata":null},{"id":"93167133c84b4c309c8ecdef9cdc500c","type":"GENE","name":"ITGB1","canonical_id":"hgnc:HGNC:6153","description":null,"metadata":null},{"id":"bc46b7339d834213a0ee5914a8292735","type":"PROTEIN","name":"ITGB1","canonical_id":"uniprot:P05556","description":null,"metadata":null},{"id":"440b5f4013604597bca7d1056a61d44c","type":"GENE","name":"ITGB1-DT","canonical_id":"hgnc:HGNC:53718","description":"ITGB1 divergent transcript","metadata":{"aliases":["LincIN"]}},{"id":"89182c8e2201495690405af0aeb89978","type":"GENE","name":"ITGB1BP1","canonical_id":"hgnc:HGNC:23927","description":"integrin subunit beta 1 binding protein 1","metadata":{"aliases":["ICAP-1A","ICAP-1B","ICAP1","ICAP1A","ICAP1B","ICAP-1alpha"]}},{"id":"73e44c382cfd422b9da593cbdbfe9cfe","type":"GENE","name":"ITGB1BP2","canonical_id":"hgnc:HGNC:6154","description":"integrin subunit beta 1 binding protein 2","metadata":{"aliases":["CHORDC3"]}},{"id":"668a966fa5a443a692191a9f7623d486","type":"GENE","name":"ITGB1P1","canonical_id":"hgnc:HGNC:3781","description":"integrin subunit beta 1 pseudogene 1","metadata":{"aliases":["ITGB1L","FNRBL"]}},{"id":"bded4b90c02947f9bb74c8f3a6fba8cb","type":"GENE","name":"ITGB2","canonical_id":"hgnc:HGNC:6155","description":null,"metadata":null},{"id":"550f1105c1c0419abde4f49164b152a9","type":"GENE","name":"ITGB2-AS1","canonical_id":"hgnc:HGNC:44304","description":"ITGB2 antisense RNA 1","metadata":null},{"id":"3476cdb4d2dd413382dcf1f11c95e558","type":"GENE","name":"ITGB3","canonical_id":"hgnc:HGNC:6156","description":null,"metadata":null},{"id":"8a9b374434ea4d8295465fcaa8c3c703","type":"PROTEIN","name":"ITGB3","canonical_id":"uniprot:P05106","description":null,"metadata":null},{"id":"8b2fdf07991c4777961bce341ef8360e","type":"GENE","name":"ITGB3BP","canonical_id":"hgnc:HGNC:6157","description":null,"metadata":null},{"id":"edd1d1d602ab47b3bace3baaabf47886","type":"GENE","name":"ITGB4","canonical_id":"hgnc:HGNC:6158","description":null,"metadata":null},{"id":"f304f8b7af594751a9e9952394f79d63","type":"GENE","name":"ITGB5","canonical_id":"hgnc:HGNC:6160","description":"integrin subunit beta 5","metadata":null},{"id":"68cb02c69bf34780aacd78499eb58685","type":"GENE","name":"ITGB5-AS1","canonical_id":"hgnc:HGNC:40309","description":"ITGB5 antisense RNA 1","metadata":null},{"id":"f5a0fa68cd41448ca068ca7c91135ef9","type":"GENE","name":"ITGB6","canonical_id":"hgnc:HGNC:6161","description":"integrin subunit beta 6","metadata":null},{"id":"35630297aab7458fbb54f8cdbc9609e8","type":"GENE","name":"ITGB7","canonical_id":"hgnc:HGNC:6162","description":null,"metadata":null},{"id":"5b3fff98f0a14bf69f762d808bfb1c1b","type":"GENE","name":"ITGB8","canonical_id":"hgnc:HGNC:6163","description":null,"metadata":null},{"id":"08d68a7b19d64461a07aa4a1914483a8","type":"GENE","name":"ITGB8-AS1","canonical_id":"hgnc:HGNC:55257","description":"ITGB8 antisense RNA 1","metadata":null},{"id":"f4ffbb42aae04c36a776ce5ccfce35ea","type":"GENE","name":"ITGBL1","canonical_id":"hgnc:HGNC:6164","description":"integrin subunit beta like 1","metadata":{"aliases":["TIED","OSCP"]}},{"id":"580f783f38634b64b976359761ae5743","type":"GENE","name":"ITIH1","canonical_id":"hgnc:HGNC:6166","description":"inter-alpha-trypsin inhibitor heavy chain 1","metadata":{"aliases":["H1P","IATIH","ITIH"]}},{"id":"af1e636dfbd7448ab5a1670c312b7691","type":"GENE","name":"ITIH2","canonical_id":"hgnc:HGNC:6167","description":"inter-alpha-trypsin inhibitor heavy chain 2","metadata":{"aliases":["H2P"]}},{"id":"0f53f6ea83b04f169e685bc03e2243a2","type":"GENE","name":"ITIH3","canonical_id":"hgnc:HGNC:6168","description":"inter-alpha-trypsin inhibitor heavy chain 3","metadata":{"aliases":["H3P"]}},{"id":"ea33509fadcc4596a7fd747a88084219","type":"GENE","name":"ITIH4","canonical_id":"hgnc:HGNC:6169","description":"inter-alpha-trypsin inhibitor heavy chain 4","metadata":{"aliases":["IHRP","H4P","ITIHL1"]}},{"id":"eaac43e493d7442c8dead76657840e4e","type":"GENE","name":"ITIH4-AS1","canonical_id":"hgnc:HGNC:40310","description":"ITIH4 antisense RNA 1","metadata":null},{"id":"2524c9a9e12f48838532202e75be1e97","type":"GENE","name":"ITIH5","canonical_id":"hgnc:HGNC:21449","description":"inter-alpha-trypsin inhibitor heavy chain 5","metadata":{"aliases":["MGC10848"]}},{"id":"260abfd58d5f4b30803bd0da5175a79c","type":"GENE","name":"ITIH6","canonical_id":"hgnc:HGNC:28907","description":"inter-alpha-trypsin inhibitor heavy chain family member 6","metadata":{"aliases":["UNQ6369","ITIH5L"]}},{"id":"ddc44a1b51604086ba6af9c7d7933e38","type":"GENE","name":"ITK","canonical_id":"hgnc:HGNC:6171","description":"IL2 inducible T cell kinase","metadata":{"aliases":["EMT","PSCTK2","LYK"]}},{"id":"88e48fb5cb444cadb93fc0318169bfb3","type":"PROTEIN","name":"ITK","canonical_id":"uniprot:Q08881","description":null,"metadata":null},{"id":"cb11e87967944e9b9254ff5de9f4661e","type":"GENE","name":"ITK-AS1","canonical_id":"hgnc:HGNC:40311","description":"ITK antisense RNA 1","metadata":null},{"id":"582c3a39ca34400da89e079cefecfe6c","type":"GENE","name":"ITLN1","canonical_id":"hgnc:HGNC:18259","description":"intelectin 1","metadata":{"aliases":["ITLN","FLJ20022","LFR","HL-1","hIntL"]}},{"id":"16482bb9e7cd47b4a92f48652d4780dd","type":"GENE","name":"ITLN2","canonical_id":"hgnc:HGNC:20599","description":"intelectin 2","metadata":{"aliases":["HL-2"]}},{"id":"7b70288fb6d240199fa542f665a148f3","type":"GENE","name":"ITM2A","canonical_id":"hgnc:HGNC:6173","description":"integral membrane protein 2A","metadata":{"aliases":["BRICD2A","E25A"]}},{"id":"e89e876929cd4230ad0a3074234c3895","type":"GENE","name":"ITM2B","canonical_id":"hgnc:HGNC:6174","description":"integral membrane protein 2B","metadata":{"aliases":["BRI","E25B","E3-16","BRICD2B","BRI2"]}},{"id":"4cef145221134bcbaacbbb0c330301d2","type":"GENE","name":"ITM2BP1","canonical_id":"hgnc:HGNC:20919","description":"integral membrane protein 2B pseudogene 1","metadata":{"aliases":["HsT33912","ITM2BP"]}},{"id":"e8f2cc5cd0cb4d59ab3ea240f69493c8","type":"GENE","name":"ITM2C","canonical_id":"hgnc:HGNC:6175","description":"integral membrane protein 2C","metadata":{"aliases":["BRI3","E25","hRPC.1050_D_4","ITM3","BRICD2C"]}},{"id":"e542a45a0704401796c5d6f0bd65a2e6","type":"GO_TERM","name":"ITP binding","canonical_id":"go:GO:1901641","description":"\"Binding to ITP.\" [GOC:TermGenie]","metadata":null},{"id":"6b7ed49970174840a569186a64d898f7","type":"GO_TERM","name":"ITP biosynthetic process","canonical_id":"go:GO:0046042","description":"\"The chemical reactions and pathways resulting in the formation of ITP, inosine triphosphate.\" [GOC:curators]","metadata":null},{"id":"26a6429dd1ed40ad92020d8c6c84fdd7","type":"GO_TERM","name":"ITP catabolic process","canonical_id":"go:GO:0006193","description":"\"The chemical reactions and pathways resulting in the breakdown of ITP, inosine (5'-)triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"8c3182fea6d6465d910b11bf4ebd2557","type":"GO_TERM","name":"ITP diphosphatase activity","canonical_id":"go:GO:0036220","description":"\"Catalysis of the reaction: ITP + H2O = IMP + H+ + diphosphate.\" [GOC:dgf, PMID:17899088, PMID:22531138, RHEA:29399]","metadata":null},{"id":"ad54bcbfad5a44c1a3105198387cedef","type":"GO_TERM","name":"ITP metabolic process","canonical_id":"go:GO:0046041","description":"\"The chemical reactions and pathways involving ITP, inosine triphosphate.\" [GOC:curators]","metadata":null},{"id":"7e98b39cb1c24512834396cb2dc5f372","type":"GENE","name":"ITPA","canonical_id":"hgnc:HGNC:6176","description":"inosine triphosphatase","metadata":{"aliases":["HLC14-06-P","dJ794I6.3","C20orf37"]}},{"id":"e9d9b3d736da431d89d77ed8278104ff","type":"GENE","name":"ITPK1","canonical_id":"hgnc:HGNC:6177","description":"inositol-tetrakisphosphate 1-kinase","metadata":null},{"id":"0d8cbe4cf8454e4c89cf44d6c61156b6","type":"GENE","name":"ITPK1-AS1","canonical_id":"hgnc:HGNC:20132","description":"ITPK1 antisense RNA 1","metadata":{"aliases":["C14orf85","NCRNA00203","ITPK1AS","ITPK1-AS"]}},{"id":"bbcf50bb1a034da191857b9136f55cfd","type":"GENE","name":"ITPK1P1","canonical_id":"hgnc:HGNC:54951","description":"ITPK1 pseudogene 1","metadata":null},{"id":"4f0aa5d1ea434845a494a1ab2d592fb4","type":"GENE","name":"ITPKA","canonical_id":"hgnc:HGNC:6178","description":"inositol-trisphosphate 3-kinase A","metadata":{"aliases":["IP3KA","IP3-3KA"]}},{"id":"5152b8aa100f4808a7d9477a71ccf3c1","type":"GENE","name":"ITPKB","canonical_id":"hgnc:HGNC:6179","description":"inositol-trisphosphate 3-kinase B","metadata":{"aliases":["IP3KB","IP3-3KB"]}},{"id":"13879afa3d574bafaf514e54298aa94e","type":"GENE","name":"ITPKB-AS1","canonical_id":"hgnc:HGNC:40312","description":"ITPKB antisense RNA 1","metadata":null},{"id":"6907f7a0d5eb45f0b4523e9bf2afcef6","type":"GENE","name":"ITPKB-IT1","canonical_id":"hgnc:HGNC:41349","description":"ITPKB intronic transcript 1","metadata":null},{"id":"67ccd38b96a149f28cdffce4dfe3e9d6","type":"GENE","name":"ITPKC","canonical_id":"hgnc:HGNC:14897","description":"inositol-trisphosphate 3-kinase C","metadata":{"aliases":["IP3KC","IP3-3KC"]}},{"id":"cb18943860ee4b32a905a3a32dc4fc95","type":"GENE","name":"ITPR1","canonical_id":"hgnc:HGNC:6180","description":"inositol 1,4,5-trisphosphate receptor type 1","metadata":{"aliases":["Insp3r1","IP3R1","ACV","PPP1R94","SCA15","SCA16","SCA29"]}},{"id":"71a6bd58346d49ed9b43cc266b953a5d","type":"GENE","name":"ITPR1-DT","canonical_id":"hgnc:HGNC:44470","description":"ITPR1 divergent transcript","metadata":{"aliases":["ITPR1-AS1"]}},{"id":"3578215cd64042cfaae18408c5856dc9","type":"GENE","name":"ITPR2","canonical_id":"hgnc:HGNC:6181","description":"inositol 1,4,5-trisphosphate receptor type 2","metadata":{"aliases":["IP3R2","CFAP48"]}},{"id":"bfc17434ac244cebbad8f756355f5d10","type":"GENE","name":"ITPR2-AS2","canonical_id":"hgnc:HGNC:58268","description":"ITPR2 antisense RNA 2","metadata":null},{"id":"c1cae10b8b6143eb8cf4e7d753fad36f","type":"GENE","name":"ITPR3","canonical_id":"hgnc:HGNC:6182","description":"inositol 1,4,5-trisphosphate receptor type 3","metadata":{"aliases":["IP3R3"]}},{"id":"5fa88cb1e80042668a95c76c7a656b31","type":"GENE","name":"ITPR3-AS1","canonical_id":"hgnc:HGNC:56127","description":"ITPR3 antisense RNA 1","metadata":null},{"id":"655569277b82417599e633d0e821384f","type":"GENE","name":"ITPRID1","canonical_id":"hgnc:HGNC:27363","description":"ITPR interacting domain containing 1","metadata":{"aliases":["FLJ38344","CCDC129"]}},{"id":"fd72d12c1f3846f2bba9a8f8c9349669","type":"GENE","name":"ITPRID2","canonical_id":"hgnc:HGNC:11319","description":"ITPR interacting domain containing 2","metadata":{"aliases":["CS-1","SPAG13","KRAP","KIAA1927","SSFA2"]}},{"id":"108a4ca457f54586945026f421864155","type":"GENE","name":"ITPRID2-DT","canonical_id":"hgnc:HGNC:55386","description":"ITPRID2 divergent transcript","metadata":null},{"id":"5fde90fce940439ba1b0e45bc8984f31","type":"GENE","name":"ITPRIP","canonical_id":"hgnc:HGNC:29370","description":"inositol 1,4,5-trisphosphate receptor interacting protein","metadata":{"aliases":["bA127L20.2","DANGER","D1A","KIAA1754"]}},{"id":"bdebd77b300d439a9eaf17df711aec10","type":"GENE","name":"ITPRIP-AS1","canonical_id":"hgnc:HGNC:54100","description":"ITPRIP antisense RNA 1","metadata":null},{"id":"4101773e4f5e4db4aa844296c0731f78","type":"GENE","name":"ITPRIPL1","canonical_id":"hgnc:HGNC:29371","description":"ITPRIP like 1","metadata":{"aliases":["D1B","KIAA1754L"]}},{"id":"e47119f2a96b40239e4d9ea82efb7209","type":"GENE","name":"ITPRIPL2","canonical_id":"hgnc:HGNC:27257","description":"ITPRIP like 2","metadata":{"aliases":["FLJ22994","MGC126798","MGC126800","LOC162073","D1C"]}},{"id":"57e75d7a55974cf1a5b0365729f51439","type":"GENE","name":"ITPRIPL2-AS1","canonical_id":"hgnc:HGNC:58271","description":"ITPRIPL2 antisense RNA 1","metadata":{"aliases":["RP11-626G11.3"]}},{"id":"c25c6f18e37e4ee099dae15ea4c898ba","type":"GO_TERM","name":"ITPase activity","canonical_id":"go:GO:0103023","description":"\"Catalysis of the reaction: ITP + H2O = IDP + H+ + phosphate.\" [GOC:pz, PMID:16216582, RHEA:28330]","metadata":null},{"id":"0e2b994e251949e9964795d4449537b9","type":"GENE","name":"ITSN1","canonical_id":"hgnc:HGNC:6183","description":"intersectin 1","metadata":{"aliases":["SH3P17","MGC134948","MGC134949","SH3D1A","ITSN"]}},{"id":"55f746d86f4543bc93cedb80e8b2681d","type":"GENE","name":"ITSN1P1","canonical_id":"hgnc:HGNC:58581","description":"ITSN1 pseudogene 1","metadata":null},{"id":"1f10ebf930404523b9f27904eb7c8032","type":"GENE","name":"ITSN2","canonical_id":"hgnc:HGNC:6184","description":"intersectin 2","metadata":{"aliases":["KIAA1256","SWAP","SH3P18","SWA","PRO2015","SH3D1B"]}},{"id":"f1d99b3f04c342bb9b268d1faa1577a0","type":"TRIAL","name":"ITT4 Intratesticular Hormonal Milieu in Man (ITT4)","canonical_id":"clinicaltrials.gov:NCT01215292","description":"Healthy Males","metadata":null},{"id":"563182fb114d425f9b0634dfaa80956b","type":"TRIAL","name":"IUD Placement Without Sounding","canonical_id":"clinicaltrials.gov:NCT05700812","description":"IUD; IUD Insertion Complication; IUD; Complications","metadata":null},{"id":"7802393eaaec4affb11bf9919a3ebe51","type":"GENE","name":"IUR1","canonical_id":"hgnc:HGNC:56237","description":"imatinib upregulated ABL suppressing lncRNA 1","metadata":null},{"id":"dd62fdb9c597462ba80972796ba8e986","type":"TRIAL","name":"IV Acetaminophen as an Analgesic Adjunct","canonical_id":"clinicaltrials.gov:NCT02621619","description":"Acute Pain","metadata":null},{"id":"f6fac904c17645c0a3ef57aa0c1edaf4","type":"TRIAL","name":"IV Cocaine Abuse: A Laboratory Model - 1","canonical_id":"clinicaltrials.gov:NCT00000212","description":"Cocaine-Related Disorders","metadata":null},{"id":"cfd1636093b74b1e87bc5efff1b9fd80","type":"TRIAL","name":"IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures","canonical_id":"clinicaltrials.gov:NCT00510783","description":"Tonic-clonic Seizure","metadata":null},{"id":"ef49c5f18f424bee9086b2e03cc56e9c","type":"TRIAL","name":"IV Ketamine vs. IN Esketamine for MDD TRD","canonical_id":"clinicaltrials.gov:NCT06488586","description":"Treatment Resistant Depression","metadata":null},{"id":"df835cf61a9741688dae1b9005581017","type":"GENE","name":"IVD","canonical_id":"hgnc:HGNC:6186","description":"isovaleryl-CoA dehydrogenase","metadata":{"aliases":["ACAD2","IVDH"]}},{"id":"bbf1f2f6b1e448049cc85ccab2e594cb","type":"TRIAL","name":"IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure","canonical_id":"clinicaltrials.gov:NCT02601196","description":"Women With Leiomyoma After at Least One Unsuccessful IVF Treatment","metadata":null},{"id":"71ce9f7b16974b9980d9beabb4fd74ee","type":"GENE","name":"IVL","canonical_id":"hgnc:HGNC:6187","description":null,"metadata":null},{"id":"c243bc7bcf0a4401854919452be65a22","type":"GENE","name":"IVNS1ABP","canonical_id":"hgnc:HGNC:16951","description":"influenza virus NS1A binding protein","metadata":{"aliases":["NS1-BP","HSPC068","NS-1","KIAA0850","ND1","KLHL39","ARA3"]}},{"id":"a41546f43cd240308b97cdec52b9f437","type":"GENE","name":"IWS1","canonical_id":"hgnc:HGNC:25467","description":"interacts with SUPT6H, CTD assembly factor 1","metadata":{"aliases":["DKFZp761G0123","FLJ10006","FLJ14655","FLJ32319"]}},{"id":"aa26b85694c94951b30a51e8911eb1bb","type":"GENE","name":"IYD","canonical_id":"hgnc:HGNC:21071","description":"iodotyrosine deiodinase","metadata":{"aliases":["dJ422F24.1","DEHAL1","C6orf71"]}},{"id":"bce65db6630f4b8a8cd51ef39135cad1","type":"GENE","name":"IZUMO1","canonical_id":"hgnc:HGNC:28539","description":"izumo sperm-oocyte fusion 1","metadata":{"aliases":["IZUMO","MGC34799","OBF"]}},{"id":"18476c25ffd64a72809f6024d3e90b84","type":"GENE","name":"IZUMO1R","canonical_id":"hgnc:HGNC:32565","description":"IZUMO1 receptor, JUNO","metadata":{"aliases":["Folbp3","JUNO","FOLR4"]}},{"id":"4102e53b9b724d4f890a7c62e09f0bef","type":"GENE","name":"IZUMO2","canonical_id":"hgnc:HGNC:28518","description":"IZUMO family member 2","metadata":{"aliases":["MGC33947","SCRL","C19orf41"]}},{"id":"6faec695d44647d5884c08c96c685d52","type":"GENE","name":"IZUMO3","canonical_id":"hgnc:HGNC:31421","description":"IZUMO family member 3","metadata":{"aliases":["bA20A20.1","C9orf134"]}},{"id":"749987b9e4ad490cb8943a3a86172939","type":"GENE","name":"IZUMO4","canonical_id":"hgnc:HGNC:26950","description":"IZUMO family member 4","metadata":{"aliases":["C19orf36"]}},{"id":"17b4b94380db498f89809f12a92da0af","type":"TRIAL","name":"Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV","canonical_id":"clinicaltrials.gov:NCT02475629","description":"HIV","metadata":null},{"id":"a7d1074d9f834bb9869a793ef75d4193","type":"TRIAL","name":"Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1","canonical_id":"clinicaltrials.gov:NCT02707861","description":"HIV","metadata":null},{"id":"4a1d2a29f8cd4117aef25e48700872c8","type":"TRIAL","name":"Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06216158","description":"Multiple Myeloma","metadata":null},{"id":"e35c669ccc5e4c65a4b9e2cc6196bd1b","type":"TRIAL","name":"Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas","canonical_id":"clinicaltrials.gov:NCT00493454","description":"Lymphoma","metadata":null},{"id":"66b80813f9214dcd91901e4b658ee3f6","type":"TRIAL","name":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02443077","description":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","metadata":null},{"id":"2d8b119eb3fb40ab869c037f173f43ea","type":"TRIAL","name":"Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT06561243","description":"Chronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases","metadata":null},{"id":"f5ab079719d44fcd850f1b5ffd4a5995","type":"TRIAL","name":"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia","canonical_id":"clinicaltrials.gov:NCT03506373","description":"Recurrent Waldenstrom Macroglobulinemia; Refractory Waldenstrom Macroglobulinemia; Waldenstrom Macroglobulinemia","metadata":null},{"id":"87b6aa83a20547c58599a6ff03ef7896","type":"TRIAL","name":"Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03525925","description":"Metastatic Malignant Solid Neoplasm","metadata":null},{"id":"bc4cf864217c4fcd9da9627a398914e0","type":"TRIAL","name":"Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT03267186","description":"Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic Cell Transplantation Recipient","metadata":null},{"id":"3961300fe6ab4ae6b4728423cc02cc9f","type":"TRIAL","name":"Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression","canonical_id":"clinicaltrials.gov:NCT02863718","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"7449315b3ed54c34b7c6b0423b4333f2","type":"TRIAL","name":"Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT01841723","description":"Hairy Cell Leukemia; Hairy Cell Leukemia Variant; Recurrent Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia Variant","metadata":null},{"id":"3713b1f9bc914499a055000de3e24f35","type":"TRIAL","name":"Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT02129062","description":"Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Recurrent Adult Acute Lymphoblastic Leukemia","metadata":null},{"id":"c1f2e2c28c334c72b5ad95c9980ee684","type":"TRIAL","name":"Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT02662296","description":"Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma","metadata":null},{"id":"7683aac489c141dd83d4a004ab19252d","type":"TRIAL","name":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT02629809","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"9a7efa640d944d05b2ff4205233bdcaa","type":"TRIAL","name":"Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT03755947","description":"B-Cell Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)","metadata":null},{"id":"48757fdbe3c140ecbf23927faae6f2e0","type":"TRIAL","name":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03710772","description":"Mantle Cell Lymphoma","metadata":null},{"id":"1b7ded51b61a46229adb57c817264f18","type":"DRUG","name":"Ibudilast","canonical_id":"mesh:C038366","description":null,"metadata":null},{"id":"b5f3151ca9964fa9bd6b0eccef6d8588","type":"TRIAL","name":"Ibudilast and Withdrawal-Related Dysphoria","canonical_id":"clinicaltrials.gov:NCT03489850","description":"Alcohol Use Disorder","metadata":null},{"id":"ee818cf82d4949e9866f37df2bb47989","type":"TRIAL","name":"Ibudilast for Treating Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT05414240","description":"Alcohol Use Disorder (AUD); Alcoholism","metadata":null},{"id":"70583fecd55a4a15b9a7a373fb1c6474","type":"TRIAL","name":"Ibudilast for the Treatment of Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT03594435","description":"Alcohol Use Disorder","metadata":null},{"id":"f9d4bfaeb3e74ed2b51c6de939b66ebf","type":"TRIAL","name":"Ibudilast in the Treatment of Medication Overuse Headache","canonical_id":"clinicaltrials.gov:NCT01317992","description":"Medication Overuse Headache","metadata":null},{"id":"fd92e87cb796443cabeeddb86b1e684f","type":"TRIAL","name":"Ibudilast in the Treatment of Patients With Chronic Migraine.","canonical_id":"clinicaltrials.gov:NCT01389193","description":"Migraine Headache","metadata":null},{"id":"efd6bd4850934c63ae7a806fd93d3a59","type":"TRIAL","name":"Ibuprofen Extended-Release Dental Pain Study","canonical_id":"clinicaltrials.gov:NCT00707057","description":"Pain; Post-Operative Pain; Third Molar Extraction","metadata":null},{"id":"4cd23e2fd2f34d67b69297a43820b888","type":"TRIAL","name":"Ibuprofen Lozenge in Acute Sore Throat Pain","canonical_id":"clinicaltrials.gov:NCT01785862","description":"Acute Sore Throat Pain","metadata":null},{"id":"73ba5386f682489abdc026b6561d4f01","type":"TRIAL","name":"Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain","canonical_id":"clinicaltrials.gov:NCT03068897","description":"Low Back Pain","metadata":null},{"id":"16aedf6ff7f34dc288b52ceda24204b0","type":"TRIAL","name":"Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.","canonical_id":"clinicaltrials.gov:NCT05721027","description":"Radiculopathy, Lumbosacral Region; Back Pain With Radiation; Low Back Pain","metadata":null},{"id":"ab0b9ca047184793a640b6dc857d9cbb","type":"TRIAL","name":"Ibuprofen-PC Compared With Ibuprofen in a GI Safety Trial","canonical_id":"clinicaltrials.gov:NCT00219700","description":"Osteoarthritis","metadata":null},{"id":"52d15f1ede664c9e9e3b92b94685d74d","type":"TRIAL","name":"Ibutilide Administration During Pulmonary Vein Ablation","canonical_id":"clinicaltrials.gov:NCT00589992","description":"Atrial Fibrillation; Pulmonary Vein Ablation","metadata":null},{"id":"73c4fddb9c1f411b9fcb68a76e5e3603","type":"TRIAL","name":"Iclusig PMS in CML or Ph+ALL Patients","canonical_id":"clinicaltrials.gov:NCT03709017","description":"Chronic Myeloid Leukemia; Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","metadata":null},{"id":"ab00317981f74a7695a4d8c298075f8c","type":"DRUG","name":"Icotinib","canonical_id":"mesh:C531470","description":null,"metadata":null},{"id":"0886871f55034bd2960ecdb56194ee66","type":"TRIAL","name":"Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT03754530","description":"Non-Small Cell Lung Cancer; Brain Metastases","metadata":null},{"id":"2b00cfad99894ca79a6791dd38a2fcfb","type":"TRIAL","name":"Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT03153358","description":"Lung Cancer Stage IV","metadata":null},{"id":"bb3c4affb11147edb790a72f883acd60","type":"TRIAL","name":"Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT01516983","description":"Non-small Cell Lung Cancer; Brain Metastases","metadata":null},{"id":"1286850c8c0a484da530b19fb6504586","type":"TRIAL","name":"Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01514877","description":"Lung Cancer; Metastatic Cancer","metadata":null},{"id":"e9adfbb6591b4f5ab8648cc60570a0dd","type":"TRIAL","name":"Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT01996098","description":"Lung Cancer","metadata":null},{"id":"80f6d5572bb44e69a4149f090716763a","type":"TRIAL","name":"Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients","canonical_id":"clinicaltrials.gov:NCT02574091","description":"Psoriasis","metadata":null},{"id":"169a385ec7d14fe1ab7ed51dd40418ac","type":"TRIAL","name":"Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors","canonical_id":"clinicaltrials.gov:NCT02934256","description":"Vestibular Schwannoma; Neurofibromatosis Type 2","metadata":null},{"id":"c4ac211459a04458b802b93149e88fa6","type":"TRIAL","name":"Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients","canonical_id":"clinicaltrials.gov:NCT01719536","description":"NSCLC","metadata":null},{"id":"f437928b598d44a7a6988e9cd0ea8c21","type":"TRIAL","name":"Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02125240","description":"EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma","metadata":null},{"id":"76ffefacb5544367a27aeb13cf2e562f","type":"TRIAL","name":"Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02215356","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"e7a4e8dcff2342f387c63fbe9065391d","type":"TRIAL","name":"Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02407366","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"55103eadaa974ddd92f4f76f6f4c5bc8","type":"TRIAL","name":"Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT01929200","description":"Non-small-cell Lung Cancer","metadata":null},{"id":"4f566b2f49774ef780799e3a791d19c0","type":"TRIAL","name":"Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage \u2162A-N2 Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03749213","description":"EGF-R Positive Non-Small Cell Lung Cancer","metadata":null},{"id":"1bd36ee042fd439c92b7c6ef10e1b0a2","type":"TRIAL","name":"Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03349203","description":"EGF-R Positive Non-Small Cell Lung Cancer","metadata":null},{"id":"1d6d6cfc126c4641b76838dc83898162","type":"TRIAL","name":"Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation","canonical_id":"clinicaltrials.gov:NCT02283424","description":"Neoplasms, Therapy-Associated","metadata":null},{"id":"de200ba1044241bab204f5972642c88a","type":"TRIAL","name":"Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment","canonical_id":"clinicaltrials.gov:NCT01707329","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"9ed6b9a190854598ba7d4114e7ccb7f7","type":"TRIAL","name":"Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01724801","description":"Brain Metastasis; Non Small Cell Lung Cancer","metadata":null},{"id":"bab37ce14c814073bdd877cb9d0cd2c5","type":"TRIAL","name":"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02633059","description":"Loss of Chromosome 17p; Recurrent Plasma Cell Myeloma","metadata":null},{"id":"c48b71537678424291a9000cde1b1c81","type":"DRUG","name":"Idebenone","canonical_id":"mesh:C036619","description":null,"metadata":null},{"id":"878fcf1baabd4836af8f0b15b567aa6d","type":"DRUG","name":"Idelalisib","canonical_id":"mesh:C552946","description":null,"metadata":null},{"id":"a4801107f9a245a3abebdd1dc278c1cd","type":"DRUG","name":"Idelalisib","canonical_id":"ncit:C78825","description":null,"metadata":null},{"id":"1d45226136464577912b48cb087e7028","type":"TRIAL","name":"Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies","canonical_id":"clinicaltrials.gov:NCT03151057","description":"B Cells-Tumors; B Cell Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)","metadata":null},{"id":"08ea849753c046af81416166529f861d","type":"TRIAL","name":"Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT03349346","description":"Diffuse Large B-Cell Lymphoma; Mediastinal B-cell Lymphoma","metadata":null},{"id":"a03001c258ba401f887c8467dee863ba","type":"TRIAL","name":"Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis","canonical_id":"clinicaltrials.gov:NCT02590588","description":"Amyloidosis","metadata":null},{"id":"83335616e2654bb6bf19fab44cef9430","type":"TRIAL","name":"Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)","canonical_id":"clinicaltrials.gov:NCT05319301","description":"Oxytocin Deficiency; Hypopituitarism; Hypothalamic Obesity; Pituitary Dysfunction; Central Diabetes Insipidus; Social Isolation","metadata":null},{"id":"ca3caefdd4444af59698afb64a249f9c","type":"TRIAL","name":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","canonical_id":"clinicaltrials.gov:NCT03803553","description":"Metastatic Colon Cancer; Stage III Colon Cancer","metadata":null},{"id":"43c2fe00d0fd4c82af8b00bb0a599d1f","type":"TRIAL","name":"Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00956189","description":"Metabolic Syndrome X","metadata":null},{"id":"2ab25069007d41f2af69de3a8479119e","type":"TRIAL","name":"Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN","canonical_id":"clinicaltrials.gov:NCT01305772","description":"Squamous Cell Carcinoma of the Head and Neck","metadata":null},{"id":"fa6462895b714efcb4910856fbb9336e","type":"TRIAL","name":"Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","canonical_id":"clinicaltrials.gov:NCT07249216","description":"Age Related Macular Degeneration","metadata":null},{"id":"1d5d5568b0994769976762abdf095d31","type":"TRIAL","name":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT03885713","description":"Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis","metadata":null},{"id":"a9cadfb24b8a46b2b9d3885be08a7bc9","type":"TRIAL","name":"Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy","canonical_id":"clinicaltrials.gov:NCT05550246","description":"Obstructive Sleep Apnea","metadata":null},{"id":"353fc3e017e145d0a239e0c2b01731c1","type":"TRIAL","name":"Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus","canonical_id":"clinicaltrials.gov:NCT00003128","description":"Sarcoma","metadata":null},{"id":"94690f6f145144be93bc633087269447","type":"GO_TERM","name":"Ig heavy chain-bound endoplasmic reticulum chaperone complex","canonical_id":"go:GO:0034664","description":"\"A protein complex that is located in the endoplasmic reticulum (ER) and is formed by the association of an immunoglobulin heavy chain with the proteins of the ER chaperone complex; the latter include BiP, GRP94; CaBP1, protein disulfide isomerase (PDI), ERdj3, cyclophilin B, ERp72, GRP170, UDP-glucosyltransferase, and SDF2-L1.\" [PMID:12475965]","metadata":null},{"id":"f5ad006fcd2644dab41ddc8be4405de7","type":"GO_TERM","name":"IgA B cell receptor complex","canonical_id":"go:GO:0071747","description":"\"An IgA immunoglobulin complex that is present in the plasma membrane of B cells and is composed of two identical immunoglobulin heavy chains of an IgA isotype and two identical immunoglobulin light chains and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"38818f10bdc84cd19aad300eed5345f1","type":"GO_TERM","name":"IgA binding","canonical_id":"go:GO:0019862","description":"\"Binding to an immunoglobulin of an IgA isotype.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6911772286c842d4b562eb5ee2e95fdd","type":"DISEASE","name":"IgA glomerulonephritis","canonical_id":"mondo:0005342","description":null,"metadata":null},{"id":"477c7cc0ebae41399a14e82dc5a1db33","type":"GO_TERM","name":"IgA immunoglobulin complex","canonical_id":"go:GO:0071745","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and sometimes complexed with J chain or J chain and secretory component. An IgA immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"16a989ef4a7c45639da322c3490f41ab","type":"GO_TERM","name":"IgA immunoglobulin complex, circulating","canonical_id":"go:GO:0071746","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of an IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds, sometimes complexed with J chain or J chain and secretory component, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"4a822432919d4857b3102bcb0e64bdba","type":"GO_TERM","name":"IgA receptor activity","canonical_id":"go:GO:0019766","description":"\"Combining with an immunoglobulin of an IgA isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"3cb3e91ccad54d9aa4f54eba7294022c","type":"GO_TERM","name":"IgD B cell receptor complex","canonical_id":"go:GO:0071740","description":"\"An IgD immunoglobulin complex that is present in the plasma membrane of B cells and is composed of two identical immunoglobulin heavy chains of the IgD isotype and two identical immunoglobulin light chains and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781765196, PMID:11282392]","metadata":null},{"id":"996eba72fb5c4dc38fb979e5043789cc","type":"GO_TERM","name":"IgD binding","canonical_id":"go:GO:0043472","description":"\"Binding to an immunoglobulin of a D isotype.\" [PMID:12886015]","metadata":null},{"id":"eabac9c84582481686f9f80dd318df10","type":"GO_TERM","name":"IgD immunoglobulin complex","canonical_id":"go:GO:0071738","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgD isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgD immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:11282392]","metadata":null},{"id":"d290d6dc447d4f29a53ff96630a72b87","type":"GO_TERM","name":"IgD immunoglobulin complex, GPI-anchored","canonical_id":"go:GO:0071741","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgD isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and bound via a GPI-anchor to the plasma membrane of B cells.\" [GOC:add, ISBN:0781765196, PMID:11282392]","metadata":null},{"id":"5b3f6af66c2d4d0899fe3098d61f52b5","type":"GO_TERM","name":"IgD immunoglobulin complex, circulating","canonical_id":"go:GO:0071739","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgD isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:11282392]","metadata":null},{"id":"0350a2c96d9648c3afd9235f7feaae87","type":"GO_TERM","name":"IgE B cell receptor complex","canonical_id":"go:GO:0071744","description":"\"An IgE immunoglobulin complex that is present in the plasma membrane of B cells and is composed of two identical immunoglobulin heavy chains of the IgE isotype and two identical immunoglobulin light chains and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"76804415d7c549c384eb9d3afd9c2f9a","type":"GO_TERM","name":"IgE binding","canonical_id":"go:GO:0019863","description":"\"Binding to an immunoglobulin of the IgE isotype.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"90bc1ca447114637b549ff437b76d5ba","type":"GO_TERM","name":"IgE immunoglobulin complex","canonical_id":"go:GO:0071742","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgE isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgE immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"6353fb115ca0413d9ebf191f6ae1d5e6","type":"GO_TERM","name":"IgE immunoglobulin complex, circulating","canonical_id":"go:GO:0071743","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgE isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"3b298b57e6c24b6fae1c75d60a16dd22","type":"GO_TERM","name":"IgE receptor activity","canonical_id":"go:GO:0019767","description":"\"Combining with an immunoglobulin of the IgE isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"7ce48dd72ccb41cc8d058a7e068b4eec","type":"GO_TERM","name":"IgG B cell receptor complex","canonical_id":"go:GO:0071737","description":"\"An IgG immunoglobulin complex that is present in the plasma membrane of B cells and is composed of two identical immunoglobulin heavy chains of an IgG isotype and two identical immunoglobulin light chains and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"20cb0b887a344e3cb8c893c68feb5120","type":"GO_TERM","name":"IgG binding","canonical_id":"go:GO:0019864","description":"\"Binding to an immunoglobulin of an IgG isotype.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f9020ff195cd45ffa322a401c4930742","type":"GO_TERM","name":"IgG immunoglobulin complex","canonical_id":"go:GO:0071735","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of an IgG isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgG immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"9773fe7161874237a8855859fc3d3cfc","type":"GO_TERM","name":"IgG immunoglobulin complex, circulating","canonical_id":"go:GO:0071736","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of an IgG isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"6a02be3f04604429807d886b3b079dc3","type":"GO_TERM","name":"IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor","canonical_id":"go:GO:0002416","description":"\"The process of transporting IgG immunoglobulin, via transcytosis using the FcRn (also known as the neonatal Fc receptor; gene name FCGRT), from apical surface of an epithelial cell to the basolateral surface or vice versa depending on the location. This process is used for uptake of IgG from the milk in the gut in rodents, for transplacental transport of IgG from mother to embryo in humans, and for maintenance of a steady-state distribution of IgG across epithelial boundaries in general in adult mammals.\" [GOC:add, ISBN:0781735149, ISBN:081533642X]","metadata":null},{"id":"038eb808110d481ea352bced2c477cf5","type":"GO_TERM","name":"IgG receptor activity","canonical_id":"go:GO:0019770","description":"\"Combining with an immunoglobulin of an IgG isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"26cdb894ca8b47029522058ef3c7fc27","type":"GO_TERM","name":"IgM B cell receptor complex","canonical_id":"go:GO:0071755","description":"\"An IgM immunoglobulin complex that is present in the plasma membrane of B cells and is composed of two identical immunoglobulin heavy chains of the IgM isotype and two identical immunoglobulin light chains and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781765196, PMID:20176268]","metadata":null},{"id":"23e1b261a6d44490b58330ff36101801","type":"GO_TERM","name":"IgM binding","canonical_id":"go:GO:0001791","description":"\"Binding to an immunoglobulin of the IgM isotype.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"82f21cc46ed7463cab7b85c750bc88ff","type":"GO_TERM","name":"IgM immunoglobulin complex","canonical_id":"go:GO:0071753","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgM isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and in its circulating form complexed with J chain in polymeric forms. An IgM immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:20176268]","metadata":null},{"id":"1babeb5f0ab74a56b5f531e7980010ef","type":"GO_TERM","name":"IgM immunoglobulin complex, circulating","canonical_id":"go:GO:0071754","description":"\"A polymer of five or six IgM core units each composed of two identical immunoglobulin heavy chains of the IgM isotype and two identical immunoglobulin light chains, held together by disulfide bonds; the individual IgM core units are held together via disulfide bonds with a single J chain polypeptide acting as a bridge between two of the polymeric units. Circulating IgM is present in the extracellular space, in mucosal areas or other tissues, or in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:20176268]","metadata":null},{"id":"f0a66599675d40db8bd33b2ff1d54caa","type":"GO_TERM","name":"IgM receptor activity","canonical_id":"go:GO:0001793","description":"\"Combining with an immunoglobulin of the IgM isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"35533107f412402c81b5416a68347c39","type":"GO_TERM","name":"IgW immunoglobulin complex","canonical_id":"go:GO:0071758","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgW isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgW immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"f184beb2d2e24b4798c59b8e91e83476","type":"GO_TERM","name":"IgX immunoglobulin complex","canonical_id":"go:GO:0071759","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgX isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgX immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"53eb74ab14fe47a0a7cbbf2050971d43","type":"GO_TERM","name":"IgY immunoglobulin complex","canonical_id":"go:GO:0071760","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgY isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgY immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"371ed9df5b38476386772bd92071e4d1","type":"GO_TERM","name":"IgZ immunoglobulin complex","canonical_id":"go:GO:0071761","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgZ isotype and two identical immunoglobulin light chains, held together by disulfide bonds. The IgZ isotype is also known as the IgT isotype in certain species of fish.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"b6d2cd89296e4a8aa47550fc6d528e94","type":"GO_TERM","name":"IkappaB kinase activity","canonical_id":"go:GO:0008384","description":"\"Catalysis of the reaction: ATP + IkappaB protein = ADP + IkappaB phosphoprotein.\" [EC:2.7.11.10]","metadata":null},{"id":"0adab3fab5dc441085525f87cbdae3f1","type":"GO_TERM","name":"IkappaB kinase complex","canonical_id":"go:GO:0008385","description":"\"A trimeric protein complex that phosphorylates inhibitory-kappaB (I-kappaB) proteins. The complex is composed of two kinase subunits (alpha and beta) and a regulatory gamma subunit (also called NEMO). In a resting state, NF-kappaB dimers are bound to inhibitory IKB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.\" [GOC:bf, GOC:ma, PMID:12055104, PMID:20300203]","metadata":null},{"id":"6504e0f2bd2b4b64bb0c534e72cc8236","type":"GO_TERM","name":"IkappaB kinase complex binding","canonical_id":"go:GO:0106137","description":"\"Binding to a IkappaB kinase complex.\" [GOC:pga, PMID:12492477]","metadata":null},{"id":"bd4c558984e146d9b6e4c86c84cb553d","type":"TRIAL","name":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","canonical_id":"clinicaltrials.gov:NCT03362281","description":"Peptic Ulcer Hemorrhage","metadata":null},{"id":"c35a765472f34d6998bf42fb8e7940d5","type":"TRIAL","name":"Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients","canonical_id":"clinicaltrials.gov:NCT01107938","description":"Gastroesophageal Reflux Disease","metadata":null},{"id":"3dd7dae8690846138f5fcf67645a83bc","type":"TRIAL","name":"Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)","canonical_id":"clinicaltrials.gov:NCT02775994","description":"Periodic Fever","metadata":null},{"id":"7b1d312221864bd9a6d624cf052d5118","type":"TRIAL","name":"Ilaris\u00ae Effects in Schnitzler Syndrome (ILESCH)","canonical_id":"clinicaltrials.gov:NCT01390350","description":"Schnitzler Syndrome","metadata":null},{"id":"d849c628c7d44857b120b5988b7052eb","type":"TRIAL","name":"Ilaris\u00ae in Urticarial Vasculitis - Investigation of Treatment Responses","canonical_id":"clinicaltrials.gov:NCT01170936","description":"Urticaria; Vasculitis","metadata":null},{"id":"b9b98f7e4688456cbe14ef5e081ce7a5","type":"TRIAL","name":"Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging","canonical_id":"clinicaltrials.gov:NCT02494531","description":"Alzheimer Disease","metadata":null},{"id":"8f27a7e96bb1457085a8a0e7c336068e","type":"DRUG","name":"Iloperidone","canonical_id":"mesh:C081732","description":null,"metadata":null},{"id":"e00379d41da448afa9fddcd4914e2834","type":"TRIAL","name":"Iloprost Effects on Gas Exchange and Pulmonary Mechanics","canonical_id":"clinicaltrials.gov:NCT01274481","description":"Acute Respiratory Distress Syndrome; Acute Lung Injury; Pulmonary Hypertension","metadata":null},{"id":"9adde13906d04d1885dc102c41765414","type":"TRIAL","name":"Iloprost Power 15 in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00709956","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"25bf697899024110a5c2550fdcdcf94a","type":"TRIAL","name":"Iloprost Power Disc-15 in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00723554","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"52224510e5d443799e845b2820ad7b83","type":"TRIAL","name":"Iloprost Therapy in Patients With Critical Limb Ischemia","canonical_id":"clinicaltrials.gov:NCT01458041","description":"Peripheral Arterial Disease","metadata":null},{"id":"4610345e71ec47df9d7ca27a0335b118","type":"TRIAL","name":"Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention","canonical_id":"clinicaltrials.gov:NCT00345501","description":"Renal Insufficiency, Chronic; Coronary Angiography; Angioplasty, Transluminal, Percutaneous Coronary","metadata":null},{"id":"37c7738d6fc449349d27405a1d003138","type":"TRIAL","name":"Iloprost in Acute Respiratory Distress Syndrome","canonical_id":"clinicaltrials.gov:NCT03111212","description":"Respiratory Distress Syndrome, Adult","metadata":null},{"id":"8992e1ae0f9744459e36ae6044a2b455","type":"TRIAL","name":"Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00561223","description":"Chronic Obstructive Pulmonary Disease; Pulmonary Hypertension","metadata":null},{"id":"d09e99dd4b2c4f298bb353f0ca27d666","type":"TRIAL","name":"Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT00235521","description":"Pulmonary Hypertension","metadata":null},{"id":"0ef53fc3215c4bb6a1559e507877cd70","type":"TRIAL","name":"Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02117466","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"a18c93f46595487fa5f5a42839bacff6","type":"TRIAL","name":"Image Parkinson's Disease Progression Study","canonical_id":"clinicaltrials.gov:NCT02789020","description":"Parkinson's Disease","metadata":null},{"id":"fbd14ba979c1449ea7b7b9f74bac6dfa","type":"TRIAL","name":"Imaging Biomarkers of Pancreatic Function and Disease","canonical_id":"clinicaltrials.gov:NCT05659147","description":"Pancreatitis; Diabetes Mellitus","metadata":null},{"id":"f676101edcba41e9b5cbe0b50df6c56d","type":"TRIAL","name":"Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography","canonical_id":"clinicaltrials.gov:NCT01683825","description":"Cardiac Amyloidosis","metadata":null},{"id":"ddcf8d1c3c4a4129941c32864a5fe879","type":"TRIAL","name":"Imaging Characteristics of a Follow-up 18F-AV-1451 Scan","canonical_id":"clinicaltrials.gov:NCT02051764","description":"Alzheimer's Disease","metadata":null},{"id":"9ad787a694054fe39f03beb5815b3689","type":"TRIAL","name":"Imaging Inflammation in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02831283","description":"Alzheimer's Disease","metadata":null},{"id":"e7be1102a12e47a29ec87905cb8a3ee0","type":"TRIAL","name":"Imaging Inflammation in Alzheimer's Disease With 11C-ER176","canonical_id":"clinicaltrials.gov:NCT03744312","description":"Alzheimer Disease","metadata":null},{"id":"b20fd702a48c45c38dbd89432c2d3196","type":"TRIAL","name":"Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.","canonical_id":"clinicaltrials.gov:NCT03704519","description":"Cerebrovascular Circulation","metadata":null},{"id":"d3236ad2f0334c888833d310b835023e","type":"TRIAL","name":"Imaging of Cognition, Learning, and Memory in Aging","canonical_id":"clinicaltrials.gov:NCT01297114","description":"Alzheimer's Disease","metadata":null},{"id":"2c79bca46b3e44718c1033f1c27416a3","type":"TRIAL","name":"Imaging of Coronary Plaques in Participants Treated With Evolocumab","canonical_id":"clinicaltrials.gov:NCT03570697","description":"Coronary Artery Disease (CAD)","metadata":null},{"id":"526a4eb6b2ad42dd84ba009bb558f3de","type":"TRIAL","name":"Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant","canonical_id":"clinicaltrials.gov:NCT04340505","description":"Uveitis","metadata":null},{"id":"2b4739c57c434709974a95cea7f48805","type":"TRIAL","name":"Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children","canonical_id":"clinicaltrials.gov:NCT01521130","description":"Benign Childhood Epilepsy With Centro-Temporal Spikes","metadata":null},{"id":"4ebc06e4c4a14a75bef4b0ad091385b3","type":"TRIAL","name":"Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T","canonical_id":"clinicaltrials.gov:NCT01747590","description":"Psychotropic Drugs Effects","metadata":null},{"id":"12f1306b5d6243a29b25c1963218ac77","type":"TRIAL","name":"Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00403156","description":"Choroidal Neovascularization","metadata":null},{"id":"c9a727aa3ee944ada40f06d813a12178","type":"TRIAL","name":"Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00022490","description":"Leukemia","metadata":null},{"id":"fc9f186161bd4cd78a6cc80fcc9993d0","type":"TRIAL","name":"Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive","canonical_id":"clinicaltrials.gov:NCT00763763","description":"Leukemia, Lymphocytic, Acute; Philadelphia Chromosome; Blast Crisis; Leukemia, Myeloid, Chronic","metadata":null},{"id":"e6262fedc0cc4daeb9fe0262e3573f42","type":"TRIAL","name":"Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00066326","description":"Leukemia","metadata":null},{"id":"08534c5f25804c6c8e1cb306798ff3a9","type":"TRIAL","name":"Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT00354068","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"1861121ea9c549c6bbb31d309f02031a","type":"TRIAL","name":"Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes","canonical_id":"clinicaltrials.gov:NCT00171912","description":"Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma","metadata":null},{"id":"f1067d140cc2433b946f2c4829ed8f85","type":"TRIAL","name":"Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure","canonical_id":"clinicaltrials.gov:NCT00026169","description":"Malignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"309a95be94114041a7568eb437693c86","type":"TRIAL","name":"Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor","canonical_id":"clinicaltrials.gov:NCT00112632","description":"Gastrointestinal Stromal Tumor","metadata":null},{"id":"7182002d4033447d93ad0a558776c48a","type":"TRIAL","name":"Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor","canonical_id":"clinicaltrials.gov:NCT00049127","description":"Adult Anaplastic Oligodendroglioma; Adult Mixed Glioma; Adult Oligodendroglioma; Recurrent Adult Brain Neoplasm","metadata":null},{"id":"ac74fdced3454459bb1db52f4bc57c2a","type":"TRIAL","name":"Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients","canonical_id":"clinicaltrials.gov:NCT00499889","description":"Leukemia","metadata":null},{"id":"9110c72e822649ce9777e819afdf3bf8","type":"TRIAL","name":"Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT01568645","description":"Pulmonary Hypertension","metadata":null},{"id":"4290785e6f6c4419af385ad7ce7d28d7","type":"TRIAL","name":"Imatinib and Trametinib for KRAS-mutated Solid Tumor","canonical_id":"clinicaltrials.gov:NCT06962254","description":"Solid Tumor Cancer","metadata":null},{"id":"5dfdfff40dbb4d6a87e3e264c7cad97f","type":"TRIAL","name":"Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00644475","description":"Essential Hypertension","metadata":null},{"id":"6a74b9651612404d9baec558709d7954","type":"TRIAL","name":"Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)","canonical_id":"clinicaltrials.gov:NCT05204563","description":"Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia","metadata":null},{"id":"be00335472604bcfa3493ef7f1ef02e7","type":"TRIAL","name":"Imipenem/Cilastatin/Relebactam PK in ECMO","canonical_id":"clinicaltrials.gov:NCT04493151","description":"Sepsis","metadata":null},{"id":"7db5071b63c0434ab9164c9b3d91e687","type":"TRIAL","name":"Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)","canonical_id":"clinicaltrials.gov:NCT02493764","description":"Bacterial Pneumonia","metadata":null},{"id":"568ba8bece7a4dd59d7b4db82d5941e9","type":"DRUG","name":"Imipramine","canonical_id":"mesh:D007099","description":null,"metadata":null},{"id":"6a28e30badb447d595ebf49105b9ff6f","type":"TRIAL","name":"Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome","canonical_id":"clinicaltrials.gov:NCT01518634","description":"Somatisation Disorder; Somatoform Disorders","metadata":null},{"id":"03baebbfd4af4f97b987465c9af6a091","type":"TRIAL","name":"Imipramine and Pregabalin Combination in Painful Polyneuropathy","canonical_id":"clinicaltrials.gov:NCT01047488","description":"Polyneuropathy","metadata":null},{"id":"722740eec16c4d278ef7b9aed2ebd925","type":"TRIAL","name":"Imipramine on ER+ve and Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03122444","description":"Breast Cancer","metadata":null},{"id":"6cb08ab8ee5e44f0ac672c2b092f1d08","type":"TRIAL","name":"Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses","canonical_id":"clinicaltrials.gov:NCT01229319","description":"Actinic Keratosis","metadata":null},{"id":"562d99a8b026421db6843d6af3c30956","type":"TRIAL","name":"Imiquimod Treatment of CIN Lesions","canonical_id":"clinicaltrials.gov:NCT02329171","description":"Cervical Intraepithelial Neoplasia","metadata":null},{"id":"c045d9e541fc4e84a263f1722b9c3f6a","type":"TRIAL","name":"Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol","canonical_id":"clinicaltrials.gov:NCT02669459","description":"Cervical Intraepithelial Neoplasia","metadata":null},{"id":"823c2cf1b8044ac3bc2a227522103856","type":"TRIAL","name":"Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases","canonical_id":"clinicaltrials.gov:NCT00899574","description":"Breast Cancer; Breast Neoplasms","metadata":null},{"id":"91db802ab3ad4cf38e9727883dcd96dd","type":"TRIAL","name":"Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia","canonical_id":"clinicaltrials.gov:NCT00031759","description":"Cervical Cancer; Precancerous Condition","metadata":null},{"id":"071728f16abd4e27a3b119b04e9de6f4","type":"TRIAL","name":"Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions","canonical_id":"clinicaltrials.gov:NCT02059499","description":"Anal Intraepithelial Neoplasia; High-grade Squamous Intraepithelial Lesion; HIV Infection","metadata":null},{"id":"89aab8581058417ea3346604547841e4","type":"TRIAL","name":"Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma","canonical_id":"clinicaltrials.gov:NCT01400672","description":"Diffuse Intrinsic Pontine Glioma","metadata":null},{"id":"04c2c7626965470da0da65c85222501e","type":"TRIAL","name":"Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis","canonical_id":"clinicaltrials.gov:NCT06001112","description":"Acute Gout Arthritis; Acupuncture; Acute Pain","metadata":null},{"id":"95754bd16b9f492294a640a40ab7dc73","type":"TRIAL","name":"Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03964337","description":"Prostate Cancer; Prostate Cancer Adenocarcinoma; Non-Metastatic","metadata":null},{"id":"91a9bc56c96b4cf18bfc8594a6ee880c","type":"TRIAL","name":"Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy","canonical_id":"clinicaltrials.gov:NCT00439751","description":"Prostate Cancer","metadata":null},{"id":"12e41662b5474fa193db2ab107cbb1fa","type":"DRUG","name":"Immune Checkpoint Inhibitor","canonical_id":"ncit:C143250","description":null,"metadata":null},{"id":"6437b8a3d0ae4b0aa015be012fb0b704","type":"TRIAL","name":"Immune Effects of Vitamin D in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT00686751","description":"End Stage Renal Disease; Hemodialysis; Inflammatory Response; Cardiovascular Disease","metadata":null},{"id":"0cc28bddeddb48ab83216f6442fbab16","type":"TRIAL","name":"Immune Metabolic Associations in Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT03399708","description":"Psoriasis; Psoriatic Arthritis","metadata":null},{"id":"9dd5a13ba34b48368198974c5acc18f2","type":"TRIAL","name":"Immune-Pineal Axis Function in Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT02041455","description":"Fibromyalgia","metadata":null},{"id":"d0f63112d30748438ac10b80eb05f88c","type":"TRIAL","name":"Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT","canonical_id":"clinicaltrials.gov:NCT04150965","description":"Multiple Myeloma; Relapsed Refractory Multiple Myeloma","metadata":null},{"id":"6980ad1465b34bd0a65c73bdb1c29f49","type":"TRIAL","name":"Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial","canonical_id":"clinicaltrials.gov:NCT07643103","description":"Ph- Acute Lymphoblastic Leukemia (Ph-ALL)","metadata":null},{"id":"9e4dffb23b854acda4554e86fffa1b72","type":"TRIAL","name":"Immunoclassification of Psoriasis: a Strategy for Precision Medicine","canonical_id":"clinicaltrials.gov:NCT05503875","description":"Immunoclassification; Psoriasis","metadata":null},{"id":"7552be2dcbae424587e2ead7b052e966","type":"TRIAL","name":"Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03293030","description":"Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema; Atopic Dermatitis and Related Conditions","metadata":null},{"id":"5fb14647f8d340ef893dd6667cb91c2d","type":"TRIAL","name":"Immunologic Response to Secukinumab in Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02592018","description":"Psoriasis","metadata":null},{"id":"396ddebc2635488487a718fd583fb20b","type":"TRIAL","name":"Immunological Basis for Mepolizumab Activity in COPD","canonical_id":"clinicaltrials.gov:NCT05320939","description":"COPD","metadata":null},{"id":"1d19ab2ec80c4d48b73950cf489b452b","type":"TRIAL","name":"Immunological Tolerance in Patients With Mismatched Kidney Transplants","canonical_id":"clinicaltrials.gov:NCT05806749","description":"End Stage Kidney Disease; Immunological Tolerance; Kidney Transplant Failure and Rejection; Chronic Kidney Diseases","metadata":null},{"id":"4b687de9483b472f84b02c20f6d05e88","type":"TRIAL","name":"Immunomodulation With Eltrombopag in ITP","canonical_id":"clinicaltrials.gov:NCT04812483","description":"Primary Immune Thrombocytopenia (ITP)","metadata":null},{"id":"c6d61756221f4f6cb7a06c5a539a56fa","type":"TRIAL","name":"Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19","canonical_id":"clinicaltrials.gov:NCT04413864","description":"SARS-CoV 2","metadata":null},{"id":"ce553bc2c5074405a9390e36d788fafb","type":"TRIAL","name":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","canonical_id":"clinicaltrials.gov:NCT07138898","description":"Rheumatic Disease","metadata":null},{"id":"7f666824f02d48e1b3af885dcea8cd40","type":"TRIAL","name":"Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","canonical_id":"clinicaltrials.gov:NCT06925698","description":"Behcet Disease; Behcet Disease and Vascular Involvement; Deep Venous Thromboses; Post Thrombotic Syndrome","metadata":null},{"id":"c0edb73130a74a108f0953a47792f147","type":"TRIAL","name":"Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL","canonical_id":"clinicaltrials.gov:NCT07840976","description":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)","metadata":null},{"id":"f55a3634d54d4ab6abecd2984657c377","type":"TRIAL","name":"Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer","canonical_id":"clinicaltrials.gov:NCT07128680","description":"Advanced Clear Cell Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8","metadata":null},{"id":"0af91f43caed409c88560d6e3aaa380d","type":"TRIAL","name":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT03907488","description":"Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Ri\u2026","metadata":null},{"id":"7ede9fec77df494eb4ecb4377b3f3fea","type":"TRIAL","name":"Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04291885","description":"Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Merkel Cell Carcinoma, Stage III; Neuroendocrine Tumors; Carcinoma Neuroendocrine Skin","metadata":null},{"id":"1b7a290217424cc29a75e347741ef721","type":"TRIAL","name":"Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT04329221","description":"Cutaneous Squamous Cell Carcinoma; Actinic Keratoses; Skin Cancer; Organ Transplant Recipients; Immunotherapy","metadata":null},{"id":"1e9467c34f41415f8433501ce0f7fe02","type":"TRIAL","name":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","canonical_id":"clinicaltrials.gov:NCT07288034","description":"Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"5a7c4c7f5b484292a19f1ff8be0589f5","type":"TRIAL","name":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","canonical_id":"clinicaltrials.gov:NCT04238637","description":"Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"0353f76542c04eddb186f8a765ca8a91","type":"TRIAL","name":"Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT07793578","description":"Advanced Urothelial Carcinoma","metadata":null},{"id":"e822535c1f424cad9d945ebbd235ff8a","type":"TRIAL","name":"Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease","canonical_id":"clinicaltrials.gov:NCT05272371","description":"High-Risk Neuroblastoma","metadata":null},{"id":"76c67cd2256146cb837274bfd0268b11","type":"TRIAL","name":"Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04108481","description":"Colorectal Cancer Metastatic; Colon Cancer; Metastatic Colorectal Cancer; Rectal Cancer; Liver Metastasis Colon Cancer; Colo-rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms; Liver Metastases; Colorectal Carcinoma","metadata":null},{"id":"9f3a6d6112034ab9a5eeea8c9a8f0ce4","type":"TRIAL","name":"Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels","canonical_id":"clinicaltrials.gov:NCT07360743","description":"Non Small Cell Lung Cancer (Squamous or Non Squamous)","metadata":null},{"id":"d610e1062a8946b8ae35330534d6b3e9","type":"TRIAL","name":"Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT07369986","description":"Endometrial Cancer; Immunotherapy; Mismatch Repair Deficiency","metadata":null},{"id":"d1d728bacfc84cd9ada8ca8615da0d53","type":"TRIAL","name":"Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03568097","description":"Small Cell Lung Carcinoma","metadata":null},{"id":"ff2925be07324e2e906d9d15ff13c283","type":"TRIAL","name":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","canonical_id":"clinicaltrials.gov:NCT02573896","description":"Neuroblastoma","metadata":null},{"id":"280a9862cfe8409cb4d9e755365f463e","type":"TRIAL","name":"Imodium Syrup Versus Imodium Tablets for Faecal Incontinence","canonical_id":"clinicaltrials.gov:NCT00933465","description":"Fecal Incontinence","metadata":null},{"id":"b18d2dfa9f234ff3906cd639a56aa667","type":"TRIAL","name":"Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT07018206","description":"Axial Spondylarthritis (axSpA)","metadata":null},{"id":"83c32648848f4040b5f54b1575cc80ef","type":"TRIAL","name":"Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting","canonical_id":"clinicaltrials.gov:NCT02037737","description":"Rheumatoid Arthritis","metadata":null},{"id":"ecc0a608fcc346e3a994e23d3e672f0d","type":"TRIAL","name":"Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors","canonical_id":"clinicaltrials.gov:NCT06358703","description":"Immune Thrombotic Thrombocytopenia","metadata":null},{"id":"8990bdcc423b4e87965e65b9ae07c065","type":"TRIAL","name":"Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events","canonical_id":"clinicaltrials.gov:NCT07734753","description":"Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events","metadata":null},{"id":"b52e6d27782a4078b058182c73ebc60a","type":"TRIAL","name":"Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block","canonical_id":"clinicaltrials.gov:NCT01199237","description":"Airway Reflexes, Protective; Recovery After Neuromuscular Block; Anesthetic Recovery","metadata":null},{"id":"e58db51ea154497e92952c3923bf5e9e","type":"TRIAL","name":"Impact of Antiviral Therapy on Gastroesophageal Varices.","canonical_id":"clinicaltrials.gov:NCT02758509","description":"Chronic Hepatitis C; Cirrhosis","metadata":null},{"id":"3420ba3f44084f84ad0a4b1e2d4265ab","type":"TRIAL","name":"Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT06765265","description":"Acute Coronary Syndromes","metadata":null},{"id":"f74965a79e194645b040104d8984a60f","type":"TRIAL","name":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT05180773","description":"Peripartum Cardiomyopathy, Postpartum","metadata":null},{"id":"820d467566c644c691e70778aca4ef26","type":"TRIAL","name":"Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine","canonical_id":"clinicaltrials.gov:NCT01639157","description":"Cocaine Use Disorders","metadata":null},{"id":"da2edaedbb124f0d8cead8998b2bcbef","type":"TRIAL","name":"Impact of CES1 Genotype on Metabolism of Methylphenidate","canonical_id":"clinicaltrials.gov:NCT02147535","description":"Carboxylesterase 1 (CES1) Genotype; CES1 Activity","metadata":null},{"id":"c25e4ab46652427ca5c1932bcc95b667","type":"TRIAL","name":"Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT02019810","description":"Severe Traumatic Brain Injury With High Cerebral Pressure","metadata":null},{"id":"77e2538f80bb4fcea4486224a5c12b90","type":"TRIAL","name":"Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes","canonical_id":"clinicaltrials.gov:NCT02134717","description":"Sarcoidosis","metadata":null},{"id":"aaae43e5cbe0468fab391ec2fc0e309d","type":"TRIAL","name":"Impact of Chronic Statin Use During Surgery on Inflammation and Infection Rates","canonical_id":"clinicaltrials.gov:NCT00967252","description":"Inflammation; Infection; Endothelial Function","metadata":null},{"id":"67610efc5d4d48efa0582a970c7433c9","type":"TRIAL","name":"Impact of Colchicine in Hospitalized Colombian Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04539873","description":"Corona Virus Infection","metadata":null},{"id":"5e9d752482a94d1a92298e7ea229acad","type":"TRIAL","name":"Impact of Combined Hormonal Contraceptives on UPA","canonical_id":"clinicaltrials.gov:NCT02577601","description":"Contraception","metadata":null},{"id":"5befe58f9fb74015a3fcd62b522ccdf8","type":"TRIAL","name":"Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT01339819","description":"Atrial Fibrillation","metadata":null},{"id":"e70b1acb912241d081e8ab0e04c9de35","type":"TRIAL","name":"Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT01352702","description":"Coronary Heart Disease; Atrial Fibrillation; Acute Coronary Syndrome; Atherosclerosis","metadata":null},{"id":"8b528c4e5ce3429d97702bf2e41437ac","type":"TRIAL","name":"Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients","canonical_id":"clinicaltrials.gov:NCT05965440","description":"Chronic Kidney Diseases","metadata":null},{"id":"494eb6fe920640a290484ca830c6658d","type":"TRIAL","name":"Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease","canonical_id":"clinicaltrials.gov:NCT04713982","description":"Huntington Disease","metadata":null},{"id":"075fe36e6cb8449cbf01cf553f64ce67","type":"TRIAL","name":"Impact of Diabetes on Left Ventricular Remodeling","canonical_id":"clinicaltrials.gov:NCT01052272","description":"Diabetes","metadata":null},{"id":"08f6db519ef04c629d61efcfa89e1978","type":"TRIAL","name":"Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT05872789","description":"Burning Mouth Syndrome","metadata":null},{"id":"18b63460b16e4a76839a575764eace9a","type":"TRIAL","name":"Impact of Dietary Fiber as Prebiotics on Chemotherapy-related Diarrhea in Patients With Gastrointestinal Tumors","canonical_id":"clinicaltrials.gov:NCT04447443","description":"Chemotherapy-related Diarrhea","metadata":null},{"id":"0976636ef9904845b4d408d54bbc6957","type":"TRIAL","name":"Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction","canonical_id":"clinicaltrials.gov:NCT04731155","description":"Early PCSK9 Inhibitor on Ventricular Remodling","metadata":null},{"id":"22a7912387ff48429fb8463aa9b7e434","type":"TRIAL","name":"Impact of Endogenous E2 on SSI and GH Rebound","canonical_id":"clinicaltrials.gov:NCT02026973","description":"Normal Healthy Volunteers","metadata":null},{"id":"0a2b308f8b7f430fb7858698b0ff0070","type":"TRIAL","name":"Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques","canonical_id":"clinicaltrials.gov:NCT03349190","description":"Infertility, Female; Fibroid Uterus","metadata":null},{"id":"9bc5266fcc3245aa847e1ede8aa7a081","type":"TRIAL","name":"Impact of Estradiol Addback","canonical_id":"clinicaltrials.gov:NCT01862835","description":"Normal Healthy Volunteers","metadata":null},{"id":"5d7f4c6fe8dc47b79e65a5185e3e7d9f","type":"TRIAL","name":"Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT03981341","description":"Sleep Apnea; Post Menopausal; Oxidative Stress","metadata":null},{"id":"8fcc4f17e7ce4cabadc7ca5e79b41c7c","type":"TRIAL","name":"Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT04719221","description":"Clinical Trial; Acute Coronary Syndrome","metadata":null},{"id":"048342b0aa1948ebb48223a41f3a71b9","type":"TRIAL","name":"Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT05418166","description":"Acute Coronary Syndrome","metadata":null},{"id":"2ed7780f9303402183e37afae93a49d1","type":"TRIAL","name":"Impact of External Nasal Dilator on the Rhinogram","canonical_id":"clinicaltrials.gov:NCT01411969","description":"Nasal Obstruction","metadata":null},{"id":"f25263b0235648fd874481708deb1aa8","type":"TRIAL","name":"Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD","canonical_id":"clinicaltrials.gov:NCT02681172","description":"Alzheimer's Disease (AD)","metadata":null},{"id":"2f70dcf3a66b4016a95ac861877a8b60","type":"TRIAL","name":"Impact of Flumazenil on the Emergence Delirium","canonical_id":"clinicaltrials.gov:NCT05681377","description":"Anesthesia, General","metadata":null},{"id":"4092c4838d8c49a6baf2d94625462268","type":"TRIAL","name":"Impact of Fluocinonide 0,05% in Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT06135805","description":"Oral Lichen Planus","metadata":null},{"id":"3a73ca6930bc4b92a097788a27a187e9","type":"TRIAL","name":"Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers","canonical_id":"clinicaltrials.gov:NCT00908362","description":"Smoke-related Lung Diseases; Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"8c396115ed244267902c0d5b330d0471","type":"TRIAL","name":"Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Renal Stones","canonical_id":"clinicaltrials.gov:NCT07336485","description":"Kidney Stones","metadata":null},{"id":"c82d9a6d5843431fbddd7659006bc99b","type":"TRIAL","name":"Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia","canonical_id":"clinicaltrials.gov:NCT02931474","description":"Sleep Disorder; Traumatic Brain Injury","metadata":null},{"id":"978655c9d47045d4a88db950fcadc382","type":"TRIAL","name":"Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT06929507","description":"Renal Function Disorder; Diabetic Macular Edema (DME); Neovascular Age Related Macular Degeneration","metadata":null},{"id":"91e56c13978e4cf29957af6437f21793","type":"TRIAL","name":"Impact of KUVAN\u00ae on Gastric Relaxation in Women With Diabetic Gastroparesis.","canonical_id":"clinicaltrials.gov:NCT01135186","description":"Gastroparesis","metadata":null},{"id":"aa497a811d26452b884479d46e756bb4","type":"TRIAL","name":"Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens","canonical_id":"clinicaltrials.gov:NCT01049204","description":"HIV Infections","metadata":null},{"id":"9882fb40b7d848d2a2aece53f45c5b65","type":"TRIAL","name":"Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy","canonical_id":"clinicaltrials.gov:NCT05376579","description":"Active Secondary Progressive Multiple Sclerosis","metadata":null},{"id":"d13456615595436f80774de1f3ade35b","type":"TRIAL","name":"Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes","canonical_id":"clinicaltrials.gov:NCT07568574","description":"Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes","metadata":null},{"id":"87a87e4f0e534e189427c91962c85e43","type":"TRIAL","name":"Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition","canonical_id":"clinicaltrials.gov:NCT04640571","description":"Bile Salt Export Pump (BSEP) Transporter; Polysorbate 80","metadata":null},{"id":"616d5bec9cbb4cc2ab62c5fd18ed53a7","type":"TRIAL","name":"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02947893","description":"Alzheimer's Disease","metadata":null},{"id":"b6429265ba65432096188fef2006d526","type":"TRIAL","name":"Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel","canonical_id":"clinicaltrials.gov:NCT01269333","description":"Drug Interaction of Clopidogrel","metadata":null},{"id":"db7cfad477aa40b2a851a3d75c75ab25","type":"TRIAL","name":"Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19","canonical_id":"clinicaltrials.gov:NCT04941105","description":"Sars-CoV-2 Infection","metadata":null},{"id":"d7e926f0f8ec4dfe8cb0d3d1c15d77b2","type":"TRIAL","name":"Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography","canonical_id":"clinicaltrials.gov:NCT04338165","description":"Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"485e7b6a2adb40139204887690a995fc","type":"TRIAL","name":"Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections","canonical_id":"clinicaltrials.gov:NCT04281680","description":"Surgical Complications","metadata":null},{"id":"9f366c29b2194dc8858828392adac152","type":"TRIAL","name":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03571633","description":"HER2-positive Breast Cancer; Operable Breast Cancer","metadata":null},{"id":"7bff6ad4af2c4d2b82f5087a2366cd16","type":"TRIAL","name":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","canonical_id":"clinicaltrials.gov:NCT06851962","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"716e16fc561a43ac9da925347d1a5037","type":"TRIAL","name":"Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT02990312","description":"Hiv; Kidney Transplant; HIV Reservoir; CCR5","metadata":null},{"id":"a7f751956e034182b116d992a684b611","type":"TRIAL","name":"Impact of Smoking Cessation on Sleep - 5","canonical_id":"clinicaltrials.gov:NCT00132821","description":"Tobacco Use Cessation; Sleep Disorders","metadata":null},{"id":"fb7a765e302e4d4f8b8b0eb448b0b908","type":"TRIAL","name":"Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD","canonical_id":"clinicaltrials.gov:NCT00918567","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"e20106a40d3d4f2cbc75a5bdaf7dc41e","type":"TRIAL","name":"Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage","canonical_id":"clinicaltrials.gov:NCT01333878","description":"Rheumatoid Arthritis","metadata":null},{"id":"2569f93320504fdc948fccd0eacf04f5","type":"TRIAL","name":"Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer","canonical_id":"clinicaltrials.gov:NCT02383043","description":"Active Cocaine Users","metadata":null},{"id":"c61fb2ba6c6543ffab97772b1d4fa6c5","type":"TRIAL","name":"Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT03768713","description":"Chronic Insomnia","metadata":null},{"id":"520a81ebd70d4a09893de5acd4659f18","type":"TRIAL","name":"Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.","canonical_id":"clinicaltrials.gov:NCT00337623","description":"Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy","metadata":null},{"id":"ad4d5d3485ca4781a42c735953557005","type":"TRIAL","name":"Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach","canonical_id":"clinicaltrials.gov:NCT04344873","description":"Cardiovascular Diseases; Inflammation; Aging","metadata":null},{"id":"d6811cd6614e4959a45e8cc31c94aa39","type":"TRIAL","name":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT04610476","description":"Psoriatic Arthritis; Withdrawal; Reduction","metadata":null},{"id":"e00543d033ba4ed499ec35c8cb809859","type":"TRIAL","name":"Impact of Telehealth Warfarin Education on Patient Retention","canonical_id":"clinicaltrials.gov:NCT03650777","description":"Educational Problems; Medication Adherence","metadata":null},{"id":"b547875fb14343dbb7880341b2fc78b1","type":"TRIAL","name":"Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease","canonical_id":"clinicaltrials.gov:NCT07369063","description":"Graves Disease; Graves' Disease; Hyperthyroidism","metadata":null},{"id":"70279e735af74999b0dadac4f92037e9","type":"TRIAL","name":"Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse","canonical_id":"clinicaltrials.gov:NCT02242955","description":"Alcoholism","metadata":null},{"id":"9e361f9eb0394afaa2a7b6e2c0f6ea04","type":"TRIAL","name":"Impact of the Administration of Fludrocortisone in Very Premature Infants","canonical_id":"clinicaltrials.gov:NCT03001089","description":"Partial Mineralocorticoid Deficiency","metadata":null},{"id":"25efe9858cca4d59ad12573a212b32d2","type":"TRIAL","name":"Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis","canonical_id":"clinicaltrials.gov:NCT07821320","description":"Endometriosis; Endometriosis (Diagnosis); Endometriosis and Dysmenorrhea; Endometriosis Associated Pelvic Pain","metadata":null},{"id":"f426134103ea457fb254c970d9d17eaa","type":"TRIAL","name":"Impact of the Microbiota on the Likelihood of Renal Graft Rejection","canonical_id":"clinicaltrials.gov:NCT04736381","description":"Kidney Transplant Rejection","metadata":null},{"id":"934c99d354504d89b87ba287ae019ed7","type":"TRIAL","name":"Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer","canonical_id":"clinicaltrials.gov:NCT03263520","description":"Cachexia; Cancer","metadata":null},{"id":"7819676d28f2406aa152161fa3f1fac5","type":"TRIAL","name":"Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients","canonical_id":"clinicaltrials.gov:NCT01181388","description":"Myocardial Infarction","metadata":null},{"id":"b606d3e1cc0f4e0c826ae513b9a35568","type":"TRIAL","name":"Impedance Cardiography to Decrease the Risk of Preeclampsia","canonical_id":"clinicaltrials.gov:NCT03245970","description":"Chronic Hypertension Complicating Pregnancy (Diagnosis); Preeclampsia","metadata":null},{"id":"d43e57dc68a84ff2ac40cdbef31c6571","type":"DISEASE","name":"Impetigo","canonical_id":"mesh:D007169","description":null,"metadata":null},{"id":"006a205cd15a4b0296b80d20e43ee684","type":"TRIAL","name":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","canonical_id":"clinicaltrials.gov:NCT04199026","description":"Metastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma","metadata":null},{"id":"3f17c752dffd48b4a004064c0429d93f","type":"TRIAL","name":"Implantable System for Remodulin Post-Approval Study","canonical_id":"clinicaltrials.gov:NCT03833323","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"c862a313bc3a4315b08e2489a65d8695","type":"TRIAL","name":"Implications for Management of PET Amyloid Classification Technology","canonical_id":"clinicaltrials.gov:NCT02778971","description":"Mild Cognitive Impairment; Dementia; Alzheimer's Disease","metadata":null},{"id":"8c36dea86eee4bdaaf461b0adce7bdcd","type":"TRIAL","name":"Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease","canonical_id":"clinicaltrials.gov:NCT00865501","description":"Primary Hypertension","metadata":null},{"id":"9c1ce61ae4d0484eb86e0cc3393a3d6c","type":"TRIAL","name":"Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01269385","description":"B-cell Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia","metadata":null},{"id":"76a96fe671f4493bb61bae25a401e045","type":"TRIAL","name":"Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury","canonical_id":"clinicaltrials.gov:NCT07548736","description":"Acute Radiation Enteritis","metadata":null},{"id":"a57324a790c34238b5a78a39a277b5cd","type":"TRIAL","name":"Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients","canonical_id":"clinicaltrials.gov:NCT04128878","description":"Atrial Fibrillation","metadata":null},{"id":"01ed0cf673cf489f98c839e501a40b69","type":"TRIAL","name":"Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors","canonical_id":"clinicaltrials.gov:NCT00382161","description":"Impotence","metadata":null},{"id":"6e51ededf0ee4899977bb1e7699d4b10","type":"TRIAL","name":"Improvement of Myocardial Blood Flow by PhosphoDiesterase 5 Inhibition in Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT01406535","description":"Therapy Refractory Myocardial Ischemia; Coronary Artery Disease; Unsuitable for Surgical or Percutaneous Revascularisation","metadata":null},{"id":"c5247366c17940eeb084a73798dc67cd","type":"TRIAL","name":"Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium","canonical_id":"clinicaltrials.gov:NCT05343338","description":"Aortic Dissection; Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","metadata":null},{"id":"286c0285d1e24826b00e4079aa001d12","type":"TRIAL","name":"Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI)","canonical_id":"clinicaltrials.gov:NCT05903859","description":"Infertility, Male","metadata":null},{"id":"e019ba668dad4906a308387e5f34f007","type":"TRIAL","name":"Improving 24-hour Blood Pressure in Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT04021550","description":"Obstructive Sleep Apnea","metadata":null},{"id":"25f6d5d81ffc4ae3af17bba6d754559d","type":"TRIAL","name":"Improving Access to Abortion in the Republic of Georgia","canonical_id":"clinicaltrials.gov:NCT04458558","description":"Abortion Early; Pregnancy Related","metadata":null},{"id":"4ce1568fb6cf48029ab6eecdcc1dd01c","type":"TRIAL","name":"Improving Access to Naloxone to Prevent Opioid Overdose Deaths (SAIA-Naloxone)","canonical_id":"clinicaltrials.gov:NCT05886712","description":"Overdose; Implementation as Usual","metadata":null},{"id":"e295570d8a544fa7825bc58b3b4c96a6","type":"TRIAL","name":"Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02500784","description":"Alzheimer's Disease; Cognitive Dysfunction","metadata":null},{"id":"963a617409764516984a89e4aa073639","type":"TRIAL","name":"Improving Cognition With Neurodegradation Countermeasure","canonical_id":"clinicaltrials.gov:NCT05715073","description":"Hemodynamics; Caffeine; TeaCrine; Cognitive Change","metadata":null},{"id":"d7c751c64a28473d92eddb3bdc4887f4","type":"TRIAL","name":"Improving Driving in Young People With Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT03538431","description":"Autism Spectrum Disorder","metadata":null},{"id":"40e503158fe148e6b07fb25357807fb6","type":"TRIAL","name":"Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban","canonical_id":"clinicaltrials.gov:NCT07135089","description":"Stroke, Ischemic","metadata":null},{"id":"cdbe346146c2478f8b4f3c8c4c4eaf77","type":"TRIAL","name":"Improving Office Based Treatment of Opioid Use Disorder With Technology","canonical_id":"clinicaltrials.gov:NCT03586466","description":"Opioid-use Disorder","metadata":null},{"id":"4192b365e9424d678e6250432889d27e","type":"TRIAL","name":"Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction","canonical_id":"clinicaltrials.gov:NCT04676399","description":"Chronic Pain; Hypertension; Diuretics Drug Reactions; SCS","metadata":null},{"id":"15ae77b8983a45ca8d8615e2d6d6cc5d","type":"TRIAL","name":"Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility","canonical_id":"clinicaltrials.gov:NCT02432209","description":"Infertility, Female","metadata":null},{"id":"d4f06d5811764d63a27fa7d59084edda","type":"TRIAL","name":"Improving Sleep After TKA Using Mirtazapine and Quetiapine","canonical_id":"clinicaltrials.gov:NCT04728581","description":"Osteo Arthritis Knee; Insomnia","metadata":null},{"id":"50db74e23ee141ff9ff549da6c388143","type":"TRIAL","name":"Improving Sleep Quality in Heart Failure","canonical_id":"clinicaltrials.gov:NCT03307005","description":"Sleep Disturbance; Heart Failure","metadata":null},{"id":"77f329196b77423ebf6a2d75cddc0e0a","type":"TRIAL","name":"Improving Sleep and Psychological Functioning in People With Depression and Insomnia","canonical_id":"clinicaltrials.gov:NCT00247624","description":"Sleep Initiation and Maintenance Disorders; Depression","metadata":null},{"id":"fc4863141f45448599805c3e00f66a75","type":"TRIAL","name":"Improving Sleep in Nursing Homes","canonical_id":"clinicaltrials.gov:NCT00576927","description":"Sleep Deprivation","metadata":null},{"id":"3f7a56c6cfbc4a16a07a160bd19ad537","type":"TRIAL","name":"Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment","canonical_id":"clinicaltrials.gov:NCT05732272","description":"Smoking Cessation","metadata":null},{"id":"79aed31749b541e2a9309270f78be362","type":"TRIAL","name":"Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin","canonical_id":"clinicaltrials.gov:NCT00177580","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"6681f3ec35cd4d0984e2ce317d4104a3","type":"TRIAL","name":"Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic \" Patient Reported Outcome \") on Breast-related Quality of Life","canonical_id":"clinicaltrials.gov:NCT04356209","description":"Breast Cancer","metadata":null},{"id":"fd73f68734624dfc8852a066d26d5132","type":"TRIAL","name":"Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy","canonical_id":"clinicaltrials.gov:NCT07022743","description":"Chronic Myeloid Leukemia (CML)","metadata":null},{"id":"05b6aaa05a3141128bc39fff2b71f25a","type":"TRIAL","name":"Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00282828","description":"Social Phobia","metadata":null},{"id":"920573a94e5a434f976dc3a88ba9a1da","type":"TRIAL","name":"Improving Tumor Oxygenation in Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT00257829","description":"Cervical Cancer","metadata":null},{"id":"16c2dd92fde1401da6fe033b21e6f1c5","type":"TRIAL","name":"Improving Ventilatory Capacity in Those With Chronic High Level SCI","canonical_id":"clinicaltrials.gov:NCT05041322","description":"Spinal Cord Injuries","metadata":null},{"id":"f835bf0259b64f0c979a6d3bda9eff80","type":"TRIAL","name":"Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity","canonical_id":"clinicaltrials.gov:NCT07029126","description":"Migraine","metadata":null},{"id":"0486a3e6b0de4ce6836d8772df2adaff","type":"TRIAL","name":"Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation","canonical_id":"clinicaltrials.gov:NCT05147155","description":"Severe Asthma","metadata":null},{"id":"f5dc7c2664344b52a21df9faef01b4df","type":"DRUG","name":"Imrecoxib","canonical_id":"mesh:C488833","description":null,"metadata":null},{"id":"5124caff857c47d4984694ce9b39982f","type":"TRIAL","name":"In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?","canonical_id":"clinicaltrials.gov:NCT02700087","description":"Laryngomalacia; Acid Reflux; Stridor","metadata":null},{"id":"57e69722d0224575aba4afce6d5898e1","type":"TRIAL","name":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","canonical_id":"clinicaltrials.gov:NCT05974345","description":"Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"cfcc6dbbff1b43dd8f773e15abb5baef","type":"TRIAL","name":"In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline","canonical_id":"clinicaltrials.gov:NCT04468568","description":"Myelomeningocele; Terbutaline Adverse Reaction; Pregnancy; Malformation Central Nervous System","metadata":null},{"id":"f2c5c72517b842ff9fc8b848abf3c035","type":"TRIAL","name":"In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol","canonical_id":"clinicaltrials.gov:NCT03434444","description":"Postpartum Hemorrhage","metadata":null},{"id":"8e2abd5acd654a53a9fe75e1244ec396","type":"TRIAL","name":"In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer","canonical_id":"clinicaltrials.gov:NCT00086723","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"d7854e30b4dc4f50b66e342d7a0a88dc","type":"TRIAL","name":"In Vivo Efficacy of Salbutamol (Sandoz) Versus Salbutamol Ventolin (GSK) in Children With Asthma","canonical_id":"clinicaltrials.gov:NCT05884970","description":"Agents, Anti Asthmatic; Asthma in Children","metadata":null},{"id":"5946e19dfbdd4411a75418cf266a8795","type":"TRIAL","name":"In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects","canonical_id":"clinicaltrials.gov:NCT02521792","description":"Fibrodysplasia Ossificans Progressiva","metadata":null},{"id":"a55ae73e12c64082b8515ee1288ad6fd","type":"TRIAL","name":"In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)","canonical_id":"clinicaltrials.gov:NCT07119073","description":"Healthy Volunteers in Fed and Fasted State","metadata":null},{"id":"e7eeed7c18704586bc012f593ea4303f","type":"TRIAL","name":"In-hospital Cardiac Arrest - Dynamics and State Transitions","canonical_id":"clinicaltrials.gov:NCT00920244","description":"Heart Arrest; Death, Sudden, Cardiac","metadata":null},{"id":"82c6d025bb96415081b4f3a452dcb498","type":"TRIAL","name":"In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT05184530","description":"Coronary Disease","metadata":null},{"id":"5457880eda4e4073897e81fa6b8d52b7","type":"TRIAL","name":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT06059989","description":"Inflammatory Disease; Disease Crohn; Bowel Disease","metadata":null},{"id":"8fb9d40266f44977bed99f4db7befc19","type":"TRIAL","name":"InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics","canonical_id":"clinicaltrials.gov:NCT01026285","description":"Schizophrenia","metadata":null},{"id":"9581e072192548c49200745a19acadae","type":"DISEASE","name":"Inappropriate ADH Syndrome","canonical_id":"mesh:D007177","description":null,"metadata":null},{"id":"5613659b6bd04963ad2bd7cdb351c079","type":"DRUG","name":"Inavolisib","canonical_id":"ncit:C132166","description":null,"metadata":null},{"id":"dcac7e00210146598d024ab1f16b984d","type":"TRIAL","name":"Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4","canonical_id":"clinicaltrials.gov:NCT07522697","description":"Endometrial Cancer","metadata":null},{"id":"ad890c0df37042e0a831039ac19be334","type":"TRIAL","name":"Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib","canonical_id":"clinicaltrials.gov:NCT03094052","description":"HER2-positive Breast Cancer; Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7","metadata":null},{"id":"3d6c3d5bee784eb48a9fe41200e61c6a","type":"TRIAL","name":"Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)","canonical_id":"clinicaltrials.gov:NCT01381601","description":"Carcinoma, Renal Cell","metadata":null},{"id":"05e4bbc039fb46659c7e2781b7db7c54","type":"TRIAL","name":"Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)","canonical_id":"clinicaltrials.gov:NCT00892047","description":"Depression","metadata":null},{"id":"ee824dfc3f5a48cfb7fb461515bd36f1","type":"TRIAL","name":"Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT03036748","description":"Kidney Transplant; Complications","metadata":null},{"id":"32e56df7e6f042e9874b6f5ec926b426","type":"TRIAL","name":"Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition","canonical_id":"clinicaltrials.gov:NCT01545479","description":"Renal Disease","metadata":null},{"id":"7494d385705c4085bc6840a10a742ede","type":"TRIAL","name":"Incretin Effect in People With Impaired Fasting Glucose","canonical_id":"clinicaltrials.gov:NCT00795275","description":"Obesity","metadata":null},{"id":"35cda00e42e44d98a5c1068ad2b21f1c","type":"DRUG","name":"Indapamide","canonical_id":"mesh:D007190","description":null,"metadata":null},{"id":"1212d4f45fd345fa871f9ee2acafdb3d","type":"TRIAL","name":"Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading","canonical_id":"clinicaltrials.gov:NCT01491256","description":"Acute Coronary Syndrome","metadata":null},{"id":"e031df30fd6c4f0f82445fa26476b5cb","type":"TRIAL","name":"Indirect Comparison Between Eltrombopag & Romiplostim","canonical_id":"clinicaltrials.gov:NCT01236014","description":"Thrombocytopaenia","metadata":null},{"id":"dafdfed629094e35a4ee49be321ebb3c","type":"TRIAL","name":"Individual Patient Compassionate Use of Fedratinib","canonical_id":"clinicaltrials.gov:NCT03723148","description":"Myelofibrosis","metadata":null},{"id":"80b02a45251b4a438c841d6d563cf6b6","type":"TRIAL","name":"Individual Patient Compassionate Use of Mirdametinib","canonical_id":"clinicaltrials.gov:NCT05028166","description":"Neurofibromatosis Type 1-Associated Plexiform Neurofibromas; Histiocytic Neoplasm; Other MAP-K Pathway Driven Diseases","metadata":null},{"id":"f916931852c349c78b7cafc2de7c2ff9","type":"TRIAL","name":"Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C","canonical_id":"clinicaltrials.gov:NCT00910975","description":"Chronic Hepatitis C, Genotype 1","metadata":null},{"id":"046330631fbc4c899181747f71e6fb6a","type":"TRIAL","name":"Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT07213466","description":"Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1","metadata":null},{"id":"aac7fe4b9b394a3388c628d872392fcf","type":"TRIAL","name":"Individualized Therapy For Asthma in Toddlers","canonical_id":"clinicaltrials.gov:NCT01606306","description":"Asthma; Wheezing","metadata":null},{"id":"15b8360b24cc4f92b6e0564fb4165603","type":"TRIAL","name":"Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials","canonical_id":"clinicaltrials.gov:NCT04115098","description":"Axial Spondyloarthritis","metadata":null},{"id":"f56986770e4f482f8b9e720953f99694","type":"TRIAL","name":"Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry","canonical_id":"clinicaltrials.gov:NCT01515345","description":"Platelet Inhibition; Coronary Stent Implantation","metadata":null},{"id":"5c44fde9e68e4247866fbbb08147923b","type":"TRIAL","name":"Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)","canonical_id":"clinicaltrials.gov:NCT07493577","description":"Aneurysmal Subarachnoid Hemorrhage","metadata":null},{"id":"12cb8e7b27544be98e6dcdf0d6272f5d","type":"TRIAL","name":"Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)","canonical_id":"clinicaltrials.gov:NCT03691727","description":"Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"293d34b6779640d798530dfd08e7b9d2","type":"TRIAL","name":"Inducing Remission in Type 1 Diabetes With Alefacept","canonical_id":"clinicaltrials.gov:NCT00965458","description":"New-onset Type 1 Diabetes Mellitus","metadata":null},{"id":"5f6def0f174442c091014dfa309a9c2b","type":"TRIAL","name":"Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma","canonical_id":"clinicaltrials.gov:NCT05017610","description":"Recurrent Glioblastoma; Recurrent Gliosarcoma","metadata":null},{"id":"edebc1d8e8194b4999aaaf2d90f69c56","type":"TRIAL","name":"Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT06511726","description":"Cervical Cancer","metadata":null},{"id":"cb1217b6ba0545cbb0f53f2f4d143bf9","type":"TRIAL","name":"Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH","canonical_id":"clinicaltrials.gov:NCT05008666","description":"Safety and Efficacy","metadata":null},{"id":"8c92c8c704424979986dec279b67ff13","type":"TRIAL","name":"Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma","canonical_id":"clinicaltrials.gov:NCT05151588","description":"Sinonasal Carcinoma","metadata":null},{"id":"21c8e775fa8946cf8919c9d00f79a717","type":"TRIAL","name":"Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06281886","description":"Esophageal Squamous Cell Carcinoma; Efficacy; Toxicity","metadata":null},{"id":"7140797582264d19bb1ddd99e4d09ae8","type":"TRIAL","name":"Induction Optimization With Stelara for Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT04629196","description":"Crohn Disease","metadata":null},{"id":"242663ad798841b7a1487f3927e95063","type":"TRIAL","name":"Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01969032","description":"Triple Negative Breast Cancer","metadata":null},{"id":"018bba4fde694e249ba8501892ca76f9","type":"TRIAL","name":"Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03440372","description":"Crohn Disease","metadata":null},{"id":"27b0c5257cab4854bb8cbd91a848b040","type":"TRIAL","name":"Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03440385","description":"Crohn Disease","metadata":null},{"id":"7829c76d3c01408fa6653d5179729b52","type":"TRIAL","name":"Induction Therapy With Anti-TNF\u03b1 vs Cyclophosphamide in Severe Beh\u00e7et Disease","canonical_id":"clinicaltrials.gov:NCT03371095","description":"Behcet's Disease; Vasculitis","metadata":null},{"id":"7cb5a6009fb947d39805d29e923e0f51","type":"TRIAL","name":"Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy","canonical_id":"clinicaltrials.gov:NCT02968303","description":"Melanoma, Malignant, of Soft Parts","metadata":null},{"id":"c2f43e6183a04c23827534f8ccad7afe","type":"TRIAL","name":"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04982354","description":"Acute Myeloid Leukemia","metadata":null},{"id":"e06847a9334a4fe3bab6e6d621233bef","type":"TRIAL","name":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT07228273","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"2c7f1395871e4114a3a3d28312788f7f","type":"TRIAL","name":"Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment","canonical_id":"clinicaltrials.gov:NCT02261636","description":"Ulcerative Colitis","metadata":null},{"id":"2ddeeff0b35a42708188daaf96cea2f5","type":"TRIAL","name":"Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT00427700","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"03a73deaa69840778c526d079fe1fb54","type":"TRIAL","name":"Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 2 With and Without Suppression by Dienogest","canonical_id":"clinicaltrials.gov:NCT02575248","description":"Infertility","metadata":null},{"id":"92cc87131794434f97e2c472665698b8","type":"TRIAL","name":"Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT06068829","description":"Neuromyelitis Optica Spectrum Disorders","metadata":null},{"id":"a47ec6e24c9c4ac3a2f476b62f5e6718","type":"TRIAL","name":"Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis","canonical_id":"clinicaltrials.gov:NCT07862075","description":"Type 1 AIP","metadata":null},{"id":"c68d43f5012a4263a8be24e20dff799b","type":"TRIAL","name":"Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT05891379","description":"Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"73e31d248d3c491c9c61edcb7449ad34","type":"TRIAL","name":"Inectolizumab With Steroid Optimization in Newly Treated NMOSD","canonical_id":"clinicaltrials.gov:NCT07159893","description":"Neuromyelitis Optica; Autoimmune Diseases; Demyelinating Autoimmune Diseases, CNS","metadata":null},{"id":"c006a0f21ef94fd7985edd6fcb658b83","type":"DISEASE","name":"Infantile autism","canonical_id":"mesh:D001321","description":null,"metadata":null},{"id":"9e47f02127644e33a417534cee56dd96","type":"DISEASE","name":"Infection by Cryptosporidium","canonical_id":"mesh:D003457","description":null,"metadata":null},{"id":"4a554ffff9e54215a8e34605b9cf35ac","type":"DISEASE","name":"Infection by Loa loa","canonical_id":"mesh:D008118","description":null,"metadata":null},{"id":"db8a09f532f84b099021751311aa8ac7","type":"DISEASE","name":"Infection by Trichomonas","canonical_id":"mesh:D014245","description":null,"metadata":null},{"id":"4ea40d3195bf45b48556adef368abd69","type":"DISEASE","name":"Infection by Trypanosoma cruzi","canonical_id":"mesh:D014355","description":null,"metadata":null},{"id":"d30723b55753486a859689ae71e6fab3","type":"DISEASE","name":"Infection by larvae of Trichinella spiralis","canonical_id":"mesh:D014235","description":null,"metadata":null},{"id":"8234456fa0194ef392d872748d054fed","type":"DISEASE","name":"Infection due to Enterobacteriaceae","canonical_id":"mesh:D004756","description":null,"metadata":null},{"id":"e9751fe7846d44ca8e45a4ec4a68753b","type":"DISEASE","name":"Infection due to Escherichia coli","canonical_id":"mesh:D004927","description":null,"metadata":null},{"id":"db7e4c4ae37642f88196b76666df6ca3","type":"DISEASE","name":"Infection due to Staphylococcus aureus","canonical_id":"mesh:D013203","description":null,"metadata":null},{"id":"a091582c78f147e2b9551fd8bf7fe500","type":"DISEASE","name":"Infection due to Toxocara","canonical_id":"mesh:D014120","description":null,"metadata":null},{"id":"9de51967267d4ba3b97c3c8f2fd252b5","type":"DISEASE","name":"Infectious disease of abdomen","canonical_id":"mesh:D059413","description":null,"metadata":null},{"id":"68761320a1aa48e7a47e7ef51aaf0d22","type":"TRIAL","name":"Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin","canonical_id":"clinicaltrials.gov:NCT00456248","description":"Hepatitis C","metadata":null},{"id":"be75c4f6d2bd41e68e1378bbbf0cf86c","type":"DISEASE","name":"Infertility","canonical_id":"hp:0000789","description":null,"metadata":null},{"id":"6fa12c86880f40c0852ceb7f62304d80","type":"DISEASE","name":"Infestation by Sarcoptes scabiei var hominis","canonical_id":"mesh:D012532","description":null,"metadata":null},{"id":"0ffb157951384cb8b9902aed2e6d7913","type":"TRIAL","name":"Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT04228042","description":"Renal Pelvis and Ureter Urothelial Carcinoma","metadata":null},{"id":"2d1cc3a7add74352aaeed8d773fdccdf","type":"TRIAL","name":"Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations","canonical_id":"clinicaltrials.gov:NCT04233567","description":"Advanced Malignant Solid Neoplasm; Cholangiocarcinoma; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm","metadata":null},{"id":"6715b89c13684cae83edbd582f174f24","type":"TRIAL","name":"Infigratinib in Recurrent High-Grade Glioma Patients","canonical_id":"clinicaltrials.gov:NCT04424966","description":"Glioma; Glioblastoma; GBM","metadata":null},{"id":"509d61e4b8834ccba6314432b4b46484","type":"TRIAL","name":"Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations","canonical_id":"clinicaltrials.gov:NCT05019794","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Solid Tumor","metadata":null},{"id":"2f60db827dfc4342a2c813ff32277b12","type":"DISEASE","name":"Infiltrating duct carcinoma of breast","canonical_id":"mesh:D018270","description":null,"metadata":null},{"id":"bc65519e039d4344aaa4728a1d1186cb","type":"TRIAL","name":"Inflammation and Daily Life Study","canonical_id":"clinicaltrials.gov:NCT03771612","description":"Inflammation","metadata":null},{"id":"88c4aa59ee4c4a1b8ba10677e7d97714","type":"TRIAL","name":"Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)","canonical_id":"clinicaltrials.gov:NCT00897715","description":"Chronic Kidney Disease; Cardiovascular Disease","metadata":null},{"id":"69a2f0250c27407b92e229aca62c8ada","type":"DISEASE","name":"Inflammatory Bowel Diseases","canonical_id":"mesh:D015212","description":null,"metadata":null},{"id":"81790301825440a2bd74cda58e4b246b","type":"TRIAL","name":"Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT06217731","description":"Burning Mouth Syndrome","metadata":null},{"id":"f44db53df9f043e2ba229f229d120db9","type":"DISEASE","name":"Inflammatory Myofibroblastic Tumor","canonical_id":"doid:0050905","description":null,"metadata":null},{"id":"3559de5778484d3589b53b76d9becf60","type":"DRUG","name":"Infliximab","canonical_id":"mesh:D000069285","description":null,"metadata":null},{"id":"33cab5be2aa14ee1b3e179e8857a1cef","type":"TRIAL","name":"Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00269867","description":"Rheumatoid Arthritis","metadata":null},{"id":"afce17b840a34ba494c12a29a36bc012","type":"TRIAL","name":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","canonical_id":"clinicaltrials.gov:NCT04305145","description":"Melanoma Stage III; Melanoma Stage IV; Skin Cancer Stage III; Skin Cancer Stage IV; Drug-Induced Colitis; Drug Toxicity; Immune-related Adverse Event","metadata":null},{"id":"79b40d0a69e84e9f963d4d00fbb17466","type":"TRIAL","name":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00254982","description":"Psoriasis","metadata":null},{"id":"a3cbf5a47cdd468f9a0cb65564146f6b","type":"TRIAL","name":"Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00304954","description":"Age-Related Macular Degeneration; Choroidal Neovascularization","metadata":null},{"id":"3df345f5e80a452286a5a2b684262f74","type":"TRIAL","name":"Influence of Aliskiren on Albuminuria After Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT02446548","description":"Albuminuria","metadata":null},{"id":"30d009870d0542dd9516b77103147bbd","type":"TRIAL","name":"Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.","canonical_id":"clinicaltrials.gov:NCT04399148","description":"Pruritus","metadata":null},{"id":"7696f9f4528f4ae59be22f17d19c2719","type":"TRIAL","name":"Influence of CPB and Mini CPB to the Absorption of the Metoprolol","canonical_id":"clinicaltrials.gov:NCT01728272","description":"Drug Absorption","metadata":null},{"id":"abf543af1f5c43a584b88b146e9bc779","type":"TRIAL","name":"Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects","canonical_id":"clinicaltrials.gov:NCT02777489","description":"Obesity","metadata":null},{"id":"59a4cd4d7783444c81684bd2e3e0b3d3","type":"TRIAL","name":"Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects","canonical_id":"clinicaltrials.gov:NCT01599962","description":"Memory Functions","metadata":null},{"id":"4ccf951719824a69b3b8ae9e1debf227","type":"TRIAL","name":"Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS).","canonical_id":"clinicaltrials.gov:NCT03846765","description":"Nfuence of Vasoactive Medication on Spinal Oxygenation","metadata":null},{"id":"3d4489cf3f764eab848a06d52cd3c12c","type":"TRIAL","name":"Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography","canonical_id":"clinicaltrials.gov:NCT02448901","description":"Heart Failure","metadata":null},{"id":"4a7044c9c2a14c279ca767a5f700a042","type":"TRIAL","name":"Influence of Esmolol on a Closed-Loop Anesthesia System","canonical_id":"clinicaltrials.gov:NCT00922467","description":"Anesthesia","metadata":null},{"id":"82ed68e328c446d48a82e61387194272","type":"TRIAL","name":"Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment","canonical_id":"clinicaltrials.gov:NCT05274477","description":"Working Memory; Post-covid-19","metadata":null},{"id":"2bce31f05f3c4ef590b5ffa6659bbaba","type":"TRIAL","name":"Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin","canonical_id":"clinicaltrials.gov:NCT04231435","description":"Healthy Volunteers","metadata":null},{"id":"31b33b4e97cc47d3bf73ed9bfadc5767","type":"TRIAL","name":"Influence of Fluvoxamine on the Pharmacokinetics of BI 409306","canonical_id":"clinicaltrials.gov:NCT02853136","description":"Healthy","metadata":null},{"id":"0b1082dc2a354c9791eb45273f6502f4","type":"TRIAL","name":"Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02214966","description":"Healthy","metadata":null},{"id":"a2745a0852df4877bde4ea511f695437","type":"TRIAL","name":"Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02276378","description":"Healthy","metadata":null},{"id":"01a03276b13046bb915f76382a815334","type":"TRIAL","name":"Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery","canonical_id":"clinicaltrials.gov:NCT02450487","description":"Pain; Other Surgical Procedures; Impacted Third Molar Tooth; Cytochrome P450 CYP2C9 Enzyme Deficiency","metadata":null},{"id":"1aaa4cbadd1340d296c9cc5b568b901d","type":"TRIAL","name":"Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT01324310","description":"Hematologic Malignancy; Malignant Lymphoma","metadata":null},{"id":"ef8e091c15f34a5a94f36e1aee209ad0","type":"TRIAL","name":"Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene","canonical_id":"clinicaltrials.gov:NCT01289756","description":"Anovulation; Disorder Due Cytochrome P450 CYP2D6 Variant; Cytochrome P450 CYP3A Enzyme Deficiency","metadata":null},{"id":"85804ab9b4924789a7aacc8f5b85abb0","type":"TRIAL","name":"Influence of Piribedil (Clarium\u00ae) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists","canonical_id":"clinicaltrials.gov:NCT01007864","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"3723ab25a7d14c2b87d476271d03bfb5","type":"TRIAL","name":"Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis","canonical_id":"clinicaltrials.gov:NCT01690039","description":"Acidosis, Renal Tubular; Nephrolithiasis; Vacuolar Proton-Translocating ATPases","metadata":null},{"id":"9853c6a09d894fdb94be12b06f4c3a1d","type":"TRIAL","name":"Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine","canonical_id":"clinicaltrials.gov:NCT00000706","description":"HIV Infections","metadata":null},{"id":"9121c152e03b4ac1b7c2dcb801c2f1b6","type":"TRIAL","name":"Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening","canonical_id":"clinicaltrials.gov:NCT01929083","description":"Prolonged QT Interval in EKG and Sudden Death","metadata":null},{"id":"e92a51fbd7fa4773834586bb46531ce4","type":"TRIAL","name":"Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02264158","description":"Healthy","metadata":null},{"id":"3bac3675b42e48fa9faea9ee1047a5f1","type":"TRIAL","name":"Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes","canonical_id":"clinicaltrials.gov:NCT02513940","description":"Long QT Syndrome","metadata":null},{"id":"55345860c6894aad904cfea5f769247e","type":"TRIAL","name":"Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin","canonical_id":"clinicaltrials.gov:NCT05654298","description":"Migraine","metadata":null},{"id":"efaa38d60fb84b129eb1d7a7cbd60cf0","type":"TRIAL","name":"Influence of Varenicline on the Antiplatelet Action of Clopidogrel","canonical_id":"clinicaltrials.gov:NCT01308671","description":"Coronary Artery Disease","metadata":null},{"id":"0146c15e231a4aaba804e843dc10cf9c","type":"TRIAL","name":"Influence of the Noradrenergic System on the Formation of Intrusive Memories","canonical_id":"clinicaltrials.gov:NCT02541071","description":"Intrusive Memories","metadata":null},{"id":"f6fe3a9fa3d64564b618eb79cf43f05e","type":"DISEASE","name":"Influenza","canonical_id":"mesh:D007251","description":null,"metadata":null},{"id":"4dbd8a08907c43a389fc0529c5abc1c1","type":"TRIAL","name":"Infusion Laboratory: Protocol 1 - Selegeline - 2","canonical_id":"clinicaltrials.gov:NCT00000337","description":"Cocaine-Related Disorders","metadata":null},{"id":"43edd223dd89445ab64f2b61d1936d6b","type":"TRIAL","name":"Infusion of Apomorphine: Long-term Safety Study","canonical_id":"clinicaltrials.gov:NCT02339064","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"5e680ae6bd774aa0b3387f4e9451816d","type":"TRIAL","name":"Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure","canonical_id":"clinicaltrials.gov:NCT04123444","description":"Septic Shock","metadata":null},{"id":"19216182dab64d3fbe1159f73e2dabd6","type":"TRIAL","name":"Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure","canonical_id":"clinicaltrials.gov:NCT06319274","description":"Acute Respiratory Failure; Endothelial Dysfunction; Pulmonary Infection","metadata":null},{"id":"508c1be2721942148366c6bf82b29fcc","type":"TRIAL","name":"Ingenol Mebutate (Picato\u00ae) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02354391","description":"Actinic Keratosis","metadata":null},{"id":"34911e94582a401e985e9e329a2e5b34","type":"TRIAL","name":"Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp","canonical_id":"clinicaltrials.gov:NCT01836367","description":"Actinic Keratosis","metadata":null},{"id":"1f4e75d93d7e4224bc4e4f43f0f40106","type":"TRIAL","name":"Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions","canonical_id":"clinicaltrials.gov:NCT01735942","description":"Actinic Keratosis","metadata":null},{"id":"b12ba4f89c60404ca3ffa98921463877","type":"TRIAL","name":"Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses","canonical_id":"clinicaltrials.gov:NCT02473848","description":"Actinic Keratosis","metadata":null},{"id":"b119cf6e90c04263840ca292194e35f4","type":"TRIAL","name":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","canonical_id":"clinicaltrials.gov:NCT01600014","description":"Actinic Keratosis","metadata":null},{"id":"79c4c5d9b9ab4ce091efdf94fc19c5c2","type":"DRUG","name":"Ingenol mebutate","canonical_id":"mesh:C486592","description":null,"metadata":null},{"id":"dc0f51b5fa0d4453980128645a91b5e3","type":"DISEASE","name":"Inhalational anthrax","canonical_id":"mesh:C571912","description":null,"metadata":null},{"id":"ceaf463bcb194f0c98d7b0b41e1a4f31","type":"TRIAL","name":"Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide","canonical_id":"clinicaltrials.gov:NCT02170519","description":"Pulmonary Hypertension","metadata":null},{"id":"85da8570ebdb474c922fc2afc0f0fbbf","type":"TRIAL","name":"Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study","canonical_id":"clinicaltrials.gov:NCT01453023","description":"Asthma","metadata":null},{"id":"8ce1655e0b0a4bd5894a14d68dc27f36","type":"TRIAL","name":"Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.","canonical_id":"clinicaltrials.gov:NCT00409526","description":"Pulmonary Hypertension","metadata":null},{"id":"868a5f70634547edb4e1857a764d4948","type":"TRIAL","name":"Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT00109681","description":"Pulmonary Fibrosis; Pulmonary Hypertension","metadata":null},{"id":"39e86b2b41044081890fef3b6b87065a","type":"TRIAL","name":"Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years","canonical_id":"clinicaltrials.gov:NCT01389271","description":"Pulmonary Hypertension","metadata":null},{"id":"001f0be3c2bd423688e12e7126a94aa1","type":"TRIAL","name":"Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients","canonical_id":"clinicaltrials.gov:NCT01941225","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"f671bcab2b804bdbba41dad58362eb61","type":"TRIAL","name":"Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation","canonical_id":"clinicaltrials.gov:NCT03110900","description":"Agitation,Psychomotor; Haloperidol Causing Adverse Effects in Therapeutic Use; Lorazepam Causing Adverse Effects in Therapeutic Use; Loxapine Causing Adverse Effects in Therapeutic Use","metadata":null},{"id":"7ee74c6ac9694e0ead5416979cf507bb","type":"TRIAL","name":"Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01571037","description":"End Stage Heart Disease; Right Ventricular Dysfunction","metadata":null},{"id":"b18cc76ecec84813bd92cc5ad2844328","type":"TRIAL","name":"Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation","canonical_id":"clinicaltrials.gov:NCT05450328","description":"Right Heart Failure; Right Ventricular Dysfunction","metadata":null},{"id":"3bdc9b72435347b588c9ded27f60f7a5","type":"TRIAL","name":"Inhaled Milrinone in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01725776","description":"Pulmonary Hypertension","metadata":null},{"id":"1677adf6470b4ee4960ddcf7340977b3","type":"TRIAL","name":"Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT01881412","description":"Asthma","metadata":null},{"id":"5c116e2f7f3f49afac91ed4646b0c95a","type":"TRIAL","name":"Inhaled Steroids for Acute Pharyngitis.","canonical_id":"clinicaltrials.gov:NCT04027322","description":"Acute Pharyngitis","metadata":null},{"id":"a94e35ce14dd46c09c0c480b40bee509","type":"TRIAL","name":"Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma","canonical_id":"clinicaltrials.gov:NCT00327808","description":"Asthma","metadata":null},{"id":"1940d514e5664068afa56b09d924087f","type":"TRIAL","name":"Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia","canonical_id":"clinicaltrials.gov:NCT07037836","description":"COPD (Chronic Obstructive Pulmonary Disease); Hypoxemia","metadata":null},{"id":"df3059b930dc4b0b8d42c14a35f32026","type":"TRIAL","name":"Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT05572996","description":"Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema","metadata":null},{"id":"4ce607d3a168451f83af62a5e9c870ff","type":"TRIAL","name":"Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD","canonical_id":"clinicaltrials.gov:NCT06969573","description":"COPD (Chronic Obstructive Pulmonary Disease)","metadata":null},{"id":"dd8d57afa5fc4ca5ba1020d604ab16a7","type":"TRIAL","name":"Inhaled Treprostinil for PAH: Open-label Extension","canonical_id":"clinicaltrials.gov:NCT01557660","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"9478fe91dcdd4713b2123f08387f3d6f","type":"TRIAL","name":"Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT03814317","description":"Sarcoidosis; Precapillary Pulmonary Hypertension; Interstitial Lung Disease","metadata":null},{"id":"76f62722a57f4449803cfb84ad1a9e62","type":"TRIAL","name":"Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT05838846","description":"Mitral Valve Replacement; Pulmonary Hypertension; Inhaled Milrinone; Intravenous Milrinone","metadata":null},{"id":"2240d3dae5ff40a0ae101a53ef7b4a0c","type":"TRIAL","name":"Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01721291","description":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ASTHMA; HEALTHY SUBJECTS","metadata":null},{"id":"b1e64446863343ddafa7954a327f9548","type":"TRIAL","name":"Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression","canonical_id":"clinicaltrials.gov:NCT06839144","description":"Ovarian Cancer; Ovarian Cancer Metastatic Recurrent","metadata":null},{"id":"cf0435a0b4464d8abcc85475dd50ecdf","type":"TRIAL","name":"Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance","canonical_id":"clinicaltrials.gov:NCT04062890","description":"Hyperinsulinism; Insulin Resistance; Insulin Sensitivity; Glucose Intolerance; Hypertension","metadata":null},{"id":"2cd0528470734651aa04aa4a2cac3af4","type":"TRIAL","name":"Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)","canonical_id":"clinicaltrials.gov:NCT07481175","description":"HIV-1","metadata":null},{"id":"6a838bcb2ed6448d9acdd1441a07ba07","type":"TRIAL","name":"Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02764619","description":"Atrial Fibrillation","metadata":null},{"id":"762faf19b0af45abbb6c669910701b99","type":"TRIAL","name":"Inhibition of Anaphylaxis by Ibrutinib","canonical_id":"clinicaltrials.gov:NCT03149315","description":"Food Allergy; Anaphylaxis Food","metadata":null},{"id":"456d891cc20a444383fe7429c077f777","type":"TRIAL","name":"Inhibition of Bradykinin in COVID-19 Infection With Icatibant","canonical_id":"clinicaltrials.gov:NCT05407597","description":"SARS CoV 2 Infection","metadata":null},{"id":"a2aa0c32f3f2445ab6fafc705e91d083","type":"TRIAL","name":"Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury","canonical_id":"clinicaltrials.gov:NCT04848272","description":"Lung Injury","metadata":null},{"id":"bb46fcc554fd4850ae19ef5631e354fd","type":"TRIAL","name":"Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS","canonical_id":"clinicaltrials.gov:NCT03792490","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"9f05a203234144e09d06964477589b15","type":"TRIAL","name":"Inhibition of Sterile Inflammation by Digoxin","canonical_id":"clinicaltrials.gov:NCT03559868","description":"Inflammatory Response","metadata":null},{"id":"dfe33868e3eb43d2b170439448c4dbdc","type":"TRIAL","name":"Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT01447654","description":"Hypertrophic Cardiomyopathy","metadata":null},{"id":"625e209bb3ea46b89ed09d732e84b883","type":"PROTEIN","name":"Inhibitor of nuclear factor kappa-B kinase subunit beta","canonical_id":"uniprot:O14920","description":null,"metadata":null},{"id":"0cc8584f4cf345f29c03b53a91175787","type":"DRUG","name":"Iniparib","canonical_id":"ncit:C62526","description":null,"metadata":null},{"id":"0ad886ffe94d455da0728c0a94874896","type":"TRIAL","name":"Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT00307840","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"8d27ab6c53f14409b1c25850e9b956d5","type":"TRIAL","name":"Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT04780932","description":"Thromboembolic Pulmonary Hypertension; Chronic Disease; Inoperable Disease","metadata":null},{"id":"751f87e6d01a447d98653025956d03e2","type":"TRIAL","name":"Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction","canonical_id":"clinicaltrials.gov:NCT01876810","description":"Nicotine Dependence","metadata":null},{"id":"f5a7d5365b9744d9accf3e6866d069e7","type":"TRIAL","name":"Initial Study of Fenoterol as a Treatment for Heart Failure","canonical_id":"clinicaltrials.gov:NCT01440335","description":"Congestive Heart Failure","metadata":null},{"id":"38a7c4e26dc74dbd9662705cc75bf3fb","type":"TRIAL","name":"Initiating Early Control of Migraine Pain and Associated Symptoms","canonical_id":"clinicaltrials.gov:NCT04163185","description":"Migraine","metadata":null},{"id":"7cd534f11bd244e885eb70b5efdb3279","type":"TRIAL","name":"Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide","canonical_id":"clinicaltrials.gov:NCT01344564","description":"Prostate Cancer","metadata":null},{"id":"676b19d40629450cac029e6ad1d8ed8c","type":"TRIAL","name":"Injection Free IVF","canonical_id":"clinicaltrials.gov:NCT04850261","description":"Fertility Disorders","metadata":null},{"id":"64332709bf104b37849de7f4066c54e0","type":"TRIAL","name":"Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)","canonical_id":"clinicaltrials.gov:NCT01448239","description":"Hypercholesterolemia","metadata":null},{"id":"a14d76ff18ed4dac825bf4464085164e","type":"TRIAL","name":"Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).","canonical_id":"clinicaltrials.gov:NCT04750460","description":"Secondary Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder; Dialysis; Hypocalcemia; Hypoparathyroidism","metadata":null},{"id":"0f37e415a6ad45a0ae897143b499c634","type":"TRIAL","name":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","canonical_id":"clinicaltrials.gov:NCT04374305","description":"Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma","metadata":null},{"id":"63e50b74636340e48101df6728b59e67","type":"GO_TERM","name":"Ino80 complex","canonical_id":"go:GO:0031011","description":"\"A multisubunit protein complex that contains the Ino80p ATPase; exhibits chromatin remodeling activity.\" [GOC:jh, GOC:rb, PMID:19355820]","metadata":null},{"id":"a09e3993903a4b4fb4703cb5a398369d","type":"DRUG","name":"Inositol Niacinate","canonical_id":"mesh:C005193","description":null,"metadata":null},{"id":"6f1b726bd0f8417d9265fd537e6705b9","type":"PROTEIN","name":"Inositol monophosphatase 1","canonical_id":"uniprot:P29218","description":null,"metadata":null},{"id":"08799b3ab15c44828576580724c44ccc","type":"TRIAL","name":"Inotuzumab Ozogamicin - PF-05208773","canonical_id":"clinicaltrials.gov:NCT03127605","description":null,"metadata":null},{"id":"51999e72a95c43acbc36dff8cd8c6328","type":"TRIAL","name":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT03104491","description":"Acute Lymphocytic Leukemia","metadata":null},{"id":"b7da1c681a76483c9f51c45d8d904d88","type":"TRIAL","name":"Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03739814","description":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia","metadata":null},{"id":"2191845d4c4846c0a3ff84da1986f63f","type":"TRIAL","name":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03991884","description":"Recurrent B Acute Lymphoblastic Leukemia; Recurrent B Lymphoblastic Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory B Lymphoblastic Lymphoma","metadata":null},{"id":"7df28b656aa94f73a97dca2ce377ccc0","type":"TRIAL","name":"Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT01371630","description":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Burkitt-Like Lymphoma With 11q Aberration; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Burkitt Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory Burkitt Lymphoma","metadata":null},{"id":"fdc25a6993044fbeb5f56a13f80ae856","type":"TRIAL","name":"Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL","canonical_id":"clinicaltrials.gov:NCT03460522","description":"Precursor Cell Lymphoblastic Leukemia","metadata":null},{"id":"5c933d4f72884490bb4d4bada7311a9c","type":"TRIAL","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03150693","description":"B Acute Lymphoblastic Leukemia","metadata":null},{"id":"3b89adcc395947f89034865aa13d80fc","type":"TRIAL","name":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","canonical_id":"clinicaltrials.gov:NCT03959085","description":"B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia; Mixed Phenotype Acute Leukemia; Testicular Leukemia","metadata":null},{"id":"fba6723ac7da44f49094ef747e7d853a","type":"TRIAL","name":"Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03851081","description":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Blasts 5 Percent or More of Bone Marrow Nucleated Cells; Blasts 5 Percent or More of Peripheral Blood White Cells; CD22 Positive; Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells; Lymphoblasts 20 Percent or More of Peripheral Blood White Cells; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia","metadata":null},{"id":"8135f4e0964e4d15a27d40df7b36ad67","type":"TRIAL","name":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03913559","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"e29baf1301d043ab8e22f4dfa47acab6","type":"TRIAL","name":"Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease","canonical_id":"clinicaltrials.gov:NCT03441061","description":"Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia","metadata":null},{"id":"fca217abc9b9490da965bf6e2bd0eae2","type":"TRIAL","name":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT02981628","description":"Recurrent B Acute Lymphoblastic Leukemia; Recurrent B Lymphoblastic Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory B Lymphoblastic Lymphoma","metadata":null},{"id":"7ae47e3f41e048d39ea2c85cb69900eb","type":"TRIAL","name":"Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT07862946","description":"Acute Lymphobkastic Leukemia; Adult","metadata":null},{"id":"293f931e0c704d35af415e2d36168955","type":"DISEASE","name":"Insomnia","canonical_id":"mesh:D007319","description":null,"metadata":null},{"id":"48720583f6ce430c8daf88540c186980","type":"TRIAL","name":"Insomnia Prevalence and Treatment Impact on Systemic Hypertension","canonical_id":"clinicaltrials.gov:NCT05414864","description":"Insomnia; Hypertension","metadata":null},{"id":"bd1cb4a174a044bca407282e6a6293b7","type":"TRIAL","name":"Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes","canonical_id":"clinicaltrials.gov:NCT05908526","description":"Insomnia","metadata":null},{"id":"3945c061d6e34364b4b3fd78840b4be7","type":"TRIAL","name":"Insomnia and Drug Relapse Risk","canonical_id":"clinicaltrials.gov:NCT00253890","description":"Poor Quality Sleep; Opiate Addiction","metadata":null},{"id":"ef3c0d709df04c22ad38f5c88495e326","type":"DRUG","name":"Insulin Glargine","canonical_id":"mesh:D000069036","description":null,"metadata":null},{"id":"4c9d96b744074d318e51fa684c961fa1","type":"TRIAL","name":"Insulin Glargine in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT00347100","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"e6bbc61f546e4959ae1da8ae360606c3","type":"TRIAL","name":"Insulin Resistance in Patients With Mood Disorder","canonical_id":"clinicaltrials.gov:NCT00242619","description":"Depression; Bipolar Disorder; Insulin Resistance","metadata":null},{"id":"691c0b43f6e34f328f70c2573ffe2d66","type":"TRIAL","name":"Insulin Tolerance Test Study in Patients With Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT04026750","description":"Type 1 Diabetes; Hypoglycemia","metadata":null},{"id":"0687aa1693004ede8866a4cc627dcb51","type":"DRUG","name":"Insulin human","canonical_id":"mesh:D007328","description":null,"metadata":null},{"id":"61fc166482b743efbcbaf4e9af8a783a","type":"DISEASE","name":"Insulin resistance","canonical_id":"hp:0000855","description":null,"metadata":null},{"id":"b2c66e0ba63a4dac84ba2f0dd75d269e","type":"TRIAL","name":"Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma","canonical_id":"clinicaltrials.gov:NCT03041701","description":"Rhabdomyosarcoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal","metadata":null},{"id":"471dad700dbb44a4ac432b66a329e505","type":"PROTEIN","name":"Insulin-like growth factor I","canonical_id":"uniprot:P05019","description":null,"metadata":null},{"id":"120563758639450782305fd3f7c82ff5","type":"DISEASE","name":"Insulinoma","canonical_id":"mesh:D007340","description":null,"metadata":null},{"id":"392191226c784cb0b8ad45ea21761cc1","type":"PROTEIN","name":"Integrase","canonical_id":"uniprot:Q7ZJM1","description":null,"metadata":null},{"id":"cf91f5aadb5f45cdac1cbc7dba63f3c4","type":"PROTEIN","name":"Integrin alpha-IIb","canonical_id":"uniprot:P08514","description":null,"metadata":null},{"id":"7f6998ad60c24c87903100723ca082ed","type":"DISEASE","name":"Intellectual disability","canonical_id":"hp:0001249","description":null,"metadata":null},{"id":"fa507a5c5c044be4b47617ad81694250","type":"TRIAL","name":"Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)","canonical_id":"clinicaltrials.gov:NCT06060665","description":"Primary Biliary Cholangitis","metadata":null},{"id":"f9712a98bba8473295aa88a12e09b82c","type":"TRIAL","name":"Intensified Post Remission Therapy Containing PEG-Asparaginase","canonical_id":"clinicaltrials.gov:NCT00184041","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"4fdc7a6399834bc2a002a42b780bce48","type":"TRIAL","name":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00576979","description":"Leukemia","metadata":null},{"id":"c1c903e6b2bb477bb6f24848d7109733","type":"TRIAL","name":"Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage","canonical_id":"clinicaltrials.gov:NCT00226096","description":"CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages","metadata":null},{"id":"94624fecbe4a48159c65b6dfa5d9f53a","type":"TRIAL","name":"Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period","canonical_id":"clinicaltrials.gov:NCT07290699","description":"STEMI - ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","metadata":null},{"id":"d493eb7765874e8fa28c8dac59475a53","type":"TRIAL","name":"Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00005823","description":"Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms","metadata":null},{"id":"eeaea696d36c4dab90d578eeb76dda21","type":"TRIAL","name":"Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension","canonical_id":"clinicaltrials.gov:NCT00407680","description":"Type 2 Diabetes Mellitus; Hypertension","metadata":null},{"id":"bf1c61df989c4077906b606a9c4da4cb","type":"TRIAL","name":"Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)","canonical_id":"clinicaltrials.gov:NCT02029534","description":"Cardiothoracic Surgery; Post-operative Atrial Fibrillation","metadata":null},{"id":"02f9441af9614ad0ac9b32870234cc19","type":"TRIAL","name":"Intensive Statin Therapy in Patients With AMI","canonical_id":"clinicaltrials.gov:NCT01923077","description":"Acute Myocardial Infarction","metadata":null},{"id":"8aabf4c0f599426ab88c2ef0d166388e","type":"TRIAL","name":"Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT00909948","description":"Non Hodgkin's Lymphoma; Hodgkin Disease; Multiple Myeloma","metadata":null},{"id":"eba395d68aa64b8f9dc44941f761a720","type":"TRIAL","name":"Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)","canonical_id":"clinicaltrials.gov:NCT00631514","description":"Hypertension","metadata":null},{"id":"4b43de72a7c34769b9e7f03c11b9a5bc","type":"TRIAL","name":"Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size","canonical_id":"clinicaltrials.gov:NCT01501591","description":"Placebo Effect; Placebo Drug Interaction","metadata":null},{"id":"fd95fe0a1c05461b9ec0cce6e3429c85","type":"TRIAL","name":"Interaction Between Fluvoxamine and Sildenafil","canonical_id":"clinicaltrials.gov:NCT00175981","description":"Healthy","metadata":null},{"id":"e9adc8c4587141b9afdc510566ff5fcc","type":"TRIAL","name":"Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)","canonical_id":"clinicaltrials.gov:NCT00886886","description":"Mood Disorder; Substance-related Disorders; Amphetamine-related Disorders","metadata":null},{"id":"6b97199e452944368224ca27dd99f8f9","type":"TRIAL","name":"Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01129375","description":"Healthy","metadata":null},{"id":"51a4328c27e84b0eb4371d78337ef445","type":"TRIAL","name":"Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies","canonical_id":"clinicaltrials.gov:NCT04551963","description":"B-cell Malignancies","metadata":null},{"id":"aa564edcfe0942cbaca72803233c6968","type":"TRIAL","name":"Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT03070678","description":"Diabetes Mellitus","metadata":null},{"id":"981e1dcecd024db69b8b1f511a2892f3","type":"TRIAL","name":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","canonical_id":"clinicaltrials.gov:NCT02956044","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"7c80fc45154247a2ab6398048a617b89","type":"TRIAL","name":"Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK","canonical_id":"clinicaltrials.gov:NCT05789173","description":"Drug-Drug Interaction","metadata":null},{"id":"620639bed1764671ac8091c3508d64de","type":"TRIAL","name":"Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals","canonical_id":"clinicaltrials.gov:NCT01431690","description":"Hypertriglyceridemia","metadata":null},{"id":"2cb426a1e4da4ea3a1428e465d8f0d88","type":"TRIAL","name":"Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers","canonical_id":"clinicaltrials.gov:NCT00039975","description":"HIV Infections; Cardiovascular Diseases; Hypertension","metadata":null},{"id":"297e1ab7eb4d4b9f8415816a3fc7e652","type":"TRIAL","name":"Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway","canonical_id":"clinicaltrials.gov:NCT01231230","description":"Asthma","metadata":null},{"id":"03c6115532624016b8ba335f6d37d896","type":"TRIAL","name":"Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers","canonical_id":"clinicaltrials.gov:NCT01502202","description":"Non Small Cell Lung Cancer; Adenocarcinoma","metadata":null},{"id":"29e474722b404f94ae910b1052b47140","type":"TRIAL","name":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02031601","description":"Non-Small-Cell Lung Cancer","metadata":null},{"id":"7becb241030b4a88b0616606ef45869f","type":"TRIAL","name":"Interest of Audiovisual Distraction in the Management of Anxiety and Pain During Oocyte Retrieval","canonical_id":"clinicaltrials.gov:NCT04213781","description":"Fertilization in Vitro","metadata":null},{"id":"b36e5ef9f3ec40bca475ec00de3cbbab","type":"TRIAL","name":"Interest of Mycophenolate for CIDP Weaning","canonical_id":"clinicaltrials.gov:NCT02494505","description":"Chronic Inflammatory Demyelinating Polyradiculopathy","metadata":null},{"id":"c3387ee8430c4ab1b75d7e29bf6e426c","type":"TRIAL","name":"Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT03059173","description":"Polycystic Ovary Syndrome; Reproductive Medicine","metadata":null},{"id":"4c7e71fece8945ea98489087137fbdad","type":"TRIAL","name":"Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream","canonical_id":"clinicaltrials.gov:NCT01785693","description":"Peripheral Arterial Occlusive Disease","metadata":null},{"id":"8cd1950bc0c74653afcfac47e04d4cd9","type":"TRIAL","name":"Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00045422","description":"Leukemia","metadata":null},{"id":"7fe4c3ff7cc545a1900de68df71ebb88","type":"PROTEIN","name":"Interferon alpha/beta receptor 2","canonical_id":"uniprot:P48551","description":null,"metadata":null},{"id":"9e3d54481e564754b6adf63311aa3487","type":"DRUG","name":"Interferon beta-1a","canonical_id":"mesh:D000068556","description":null,"metadata":null},{"id":"6ab9b1ce91d64212a9f41c7455d48421","type":"DRUG","name":"Interferon beta-1b","canonical_id":"mesh:D000068576","description":null,"metadata":null},{"id":"df81eac5f42f4f828dbb889ef4eb0705","type":"TRIAL","name":"Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure","canonical_id":"clinicaltrials.gov:NCT05177822","description":"Heart Failure","metadata":null},{"id":"47085e11a1ae4898a7eaa416b979d78b","type":"TRIAL","name":"Interleukin-1 Blockade in HF With Preserved EF","canonical_id":"clinicaltrials.gov:NCT02173548","description":"Heart Failure With Normal Ejection Fraction","metadata":null},{"id":"3a164147e9e4481c9ea918ed8f94f11a","type":"TRIAL","name":"Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)","canonical_id":"clinicaltrials.gov:NCT01663103","description":"Renal Insufficiency, Chronic","metadata":null},{"id":"1b1f338058a14735b11d98cece8232d6","type":"TRIAL","name":"Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor \u03b1 (TNF\u03b1 )Inhibitor for the Treatment of Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT06833112","description":"Ankylosing Spondylitis","metadata":null},{"id":"55e5f63a4de24348b7fdf27e3317148f","type":"PROTEIN","name":"Interleukin-2","canonical_id":"uniprot:P60568","description":null,"metadata":null},{"id":"2c6d6c55bdab47a4a9161eb6f028538e","type":"PROTEIN","name":"Interleukin-2 receptor subunit beta","canonical_id":"uniprot:P14784","description":null,"metadata":null},{"id":"4c8101f19178441d80054a8cb0ddd379","type":"TRIAL","name":"Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT04842981","description":"Arthritis, Rheumatoid; Interaction","metadata":null},{"id":"23c45706efac474c9c98145f6aba665c","type":"TRIAL","name":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","canonical_id":"clinicaltrials.gov:NCT05428007","description":"Melanoma; Unresectable Melanoma","metadata":null},{"id":"746a2c051a484f86805b5963acd27471","type":"TRIAL","name":"Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial","canonical_id":"clinicaltrials.gov:NCT07506473","description":"Severe Trauma Patient; Venous Thromboembolism","metadata":null},{"id":"ca0e9566a71645c4a946c89641ad1d5c","type":"TRIAL","name":"Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin","canonical_id":"clinicaltrials.gov:NCT05031546","description":"Uremic Pruritus","metadata":null},{"id":"d4fa1aa4ca0d46e58afcfe9851d2a4cc","type":"TRIAL","name":"Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC","canonical_id":"clinicaltrials.gov:NCT06177015","description":"Metastatic Prostate Cancer; Intermitent Anti-androgen Therapy","metadata":null},{"id":"6f803bcefa724db198f85b44f8b29c7a","type":"TRIAL","name":"Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT03961672","description":"Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma","metadata":null},{"id":"e6f25e28d7ba491da963058242a217cd","type":"TRIAL","name":"Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in \u2162b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation","canonical_id":"clinicaltrials.gov:NCT03151161","description":"Lung, Carcinoma","metadata":null},{"id":"13d3cec81c1c434d8934e43c4144166f","type":"DISEASE","name":"Intermittent claudication","canonical_id":"mesh:D007383","description":null,"metadata":null},{"id":"4a16abf56d0b4ea49299405eea80b64e","type":"TRIAL","name":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06509126","description":"Colorectal Cancer Stage IV","metadata":null},{"id":"e1e41cf730484b3d8e167e59314a8c2c","type":"TRIAL","name":"Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04425239","description":"Colorectal Cancer Stage IV","metadata":null},{"id":"9bf6d9691d2748fb80e9e02db2aeb386","type":"TRIAL","name":"Intermittent vs Daily Tamsulosin for LUTS/BPH","canonical_id":"clinicaltrials.gov:NCT07308002","description":"Lower Urinary Tract Symptoms; Prostate Obstruction","metadata":null},{"id":"282f781a49484136b3b7305becc47e34","type":"TRIAL","name":"Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ","canonical_id":"clinicaltrials.gov:NCT00290654","description":"Breast Cancer","metadata":null},{"id":"ac2848a725844539bf018cd393459537","type":"TRIAL","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT01117441","description":"Leukemia","metadata":null},{"id":"626b3c6a138e4f81812108ae8222e7fc","type":"TRIAL","name":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT04043494","description":"Lymphoblastic Lymphoma, Childhood","metadata":null},{"id":"9f586eb000fe4a0b97ee19196001d717","type":"TRIAL","name":"International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma","canonical_id":"clinicaltrials.gov:NCT06839703","description":"High-risk GD2-Positive Ewing Sarcoma","metadata":null},{"id":"d3ade08182674178895bbe012b0cb7f8","type":"TRIAL","name":"International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia","canonical_id":"clinicaltrials.gov:NCT02724163","description":"Acute Myeloid Leukaemia","metadata":null},{"id":"f380590b2e984a69868ca232050dcefd","type":"TRIAL","name":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","canonical_id":"clinicaltrials.gov:NCT07476729","description":"B-Cell Acute Lymphoblastic Leukaemia","metadata":null},{"id":"97249bae7f0949ea8d93b23b328bd376","type":"TRIAL","name":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","canonical_id":"clinicaltrials.gov:NCT05669989","description":"Plasma Cell Myeloma","metadata":null},{"id":"577411638c054238b7f82e4be05f30e2","type":"TRIAL","name":"International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia","canonical_id":"clinicaltrials.gov:NCT02449044","description":"Hyponatremia","metadata":null},{"id":"0e7367b890104c7abab3d79630984323","type":"TRIAL","name":"Interpersonal Psychotherapy for Severely Depressed Inpatients","canonical_id":"clinicaltrials.gov:NCT00325000","description":"Major Depression","metadata":null},{"id":"8a838619e52e4d0b9b1d3e2ebfdbb3be","type":"TRIAL","name":"Interpersonal Psychotherapy for Treatment Resistant Depression","canonical_id":"clinicaltrials.gov:NCT01896349","description":"Treatment Resistant Depression","metadata":null},{"id":"e9e37c3db8984e6baa729535d9afcc90","type":"TRIAL","name":"Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males with Klinefelter Syndrome","canonical_id":"clinicaltrials.gov:NCT05498090","description":"Klinefelter Syndrome","metadata":null},{"id":"6cbea93bd3464ac4adc31ebfbeab4c9a","type":"TRIAL","name":"Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept","canonical_id":"clinicaltrials.gov:NCT04707027","description":"Polypoidal Choroidal Vasculopathy","metadata":null},{"id":"40cbe124bb2644b5be247bea10c992e3","type":"TRIAL","name":"Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet","canonical_id":"clinicaltrials.gov:NCT01324245","description":"Salt-sensitive Hypertension","metadata":null},{"id":"94572291585d4c37aa732a09a440a5c4","type":"TRIAL","name":"Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact","canonical_id":"clinicaltrials.gov:NCT07444801","description":"Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region","metadata":null},{"id":"e013deb910d14efd83139b27220477c4","type":"TRIAL","name":"Intervention to End Recurrent Unscheduled Bleeding Trial","canonical_id":"clinicaltrials.gov:NCT03118297","description":"Contraception; Bleeding","metadata":null},{"id":"c9cef8d047944b2790d1561f1428ffce","type":"TRIAL","name":"Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)","canonical_id":"clinicaltrials.gov:NCT07169279","description":"Achondroplasia","metadata":null},{"id":"11ae466a969c45ce87b3a80b75578ba8","type":"TRIAL","name":"Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)","canonical_id":"clinicaltrials.gov:NCT00927797","description":"Immunocytoma/Morbus Waldenstr\u00f6m; B-Cell Non-Hodgkin's Lymphoma; B-Cell Chronic Lymphocytic Leukemia","metadata":null},{"id":"b826c0d4aefd44dab9f54959f061e254","type":"TRIAL","name":"Interventions for Children With Attention and Reading Disorders","canonical_id":"clinicaltrials.gov:NCT01133847","description":"Attention Deficit Hyperactivity Disorder; Reading Disabilities","metadata":null},{"id":"0a7bf4b8bec641ab95ed3cfe9a1b0c1b","type":"TRIAL","name":"Intestinal Levodopa + Entacapone Therapy (Lecigon\u00ae) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT07151378","description":"PARKINSON DISEASE (Disorder)","metadata":null},{"id":"3acff8c0a4e8457f854bfb7e03f6d4b4","type":"TRIAL","name":"Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients","canonical_id":"clinicaltrials.gov:NCT05580887","description":"Breast Cancer; Pancreas Cancer","metadata":null},{"id":"a62b643b26034c9ebe0726a7dfcb7ed7","type":"TRIAL","name":"Intestinal Microbiota and Treatment of GD","canonical_id":"clinicaltrials.gov:NCT03433352","description":"Microbiota","metadata":null},{"id":"5e63ad275d9c42b88c610c5b9deb5541","type":"TRIAL","name":"Intestinal Microecology in Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT00934479","description":"Other Constipation; Irritable Bowel Syndrome","metadata":null},{"id":"a6c811538f0848049b17bf60a3860b54","type":"DISEASE","name":"Intestinal Pseudo-Obstruction","canonical_id":"mesh:D007418","description":null,"metadata":null},{"id":"f2346ff892854ee4be7038415f8d1c0c","type":"TRIAL","name":"Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting","canonical_id":"clinicaltrials.gov:NCT02095366","description":"Severe Traumatic Pain; Numeric Pain Rating Scale > 5 / 10","metadata":null},{"id":"9aae8cee9104447ba696c02ea32be082","type":"TRIAL","name":"Intra-Arterial Microdosing: Proof-of-Concept in Humans","canonical_id":"clinicaltrials.gov:NCT02304211","description":"Healthy","metadata":null},{"id":"9e131da9a2694bb1be3840d52e4c72c9","type":"TRIAL","name":"Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion","canonical_id":"clinicaltrials.gov:NCT07537933","description":"Acute Ischemic Stroke; Large-vessel Occlusion; Endovascular Treatment","metadata":null},{"id":"4bc6bdac345144c180c3d4bb79aa15b4","type":"TRIAL","name":"Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.","canonical_id":"clinicaltrials.gov:NCT03086759","description":"Knee Osteoarthritis","metadata":null},{"id":"df27634373824f068e9863019e880fcb","type":"TRIAL","name":"Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT01073189","description":"Kidney Failures, Acute","metadata":null},{"id":"b67002d3c2884826b61e84ffb0f04f01","type":"TRIAL","name":"Intra-operative Lidocaine Infusion in Preventing CPSP Post VATs","canonical_id":"clinicaltrials.gov:NCT02862769","description":"Chronic Pain; Acute Pain; Neuralgia","metadata":null},{"id":"343b494cce3d4640be237800e66de2a9","type":"TRIAL","name":"Intra-oral Treatment of OLP With Rivelin\u00ae-CLO Patches","canonical_id":"clinicaltrials.gov:NCT03592342","description":"Oral Lichen Planus","metadata":null},{"id":"d935282ce8af4c8e8cf3c8b345d3e8eb","type":"TRIAL","name":"Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis","canonical_id":"clinicaltrials.gov:NCT05305885","description":"Leptomeningeal Metastasis","metadata":null},{"id":"519f628713a84932adf4d24c1051b5b4","type":"TRIAL","name":"Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma","canonical_id":"clinicaltrials.gov:NCT06356883","description":"Glioblastoma Multiforme; Relapse","metadata":null},{"id":"e93311a48cbb4c0a8bedc61c0132ccf1","type":"TRIAL","name":"Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial","canonical_id":"clinicaltrials.gov:NCT00963976","description":"Intracerebral Hemorrhage","metadata":null},{"id":"9f720d71cdeb48c59e173cf3a587d13e","type":"TRIAL","name":"Intracoronary Abciximab With Clearway Catheter","canonical_id":"clinicaltrials.gov:NCT00894023","description":"Acute Myocardial Infarction","metadata":null},{"id":"3a50a9958f6c479494ab650e3f8dc3e0","type":"TRIAL","name":"Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.","canonical_id":"clinicaltrials.gov:NCT01080638","description":"Myocardial Infarction; Angioplasty","metadata":null},{"id":"5e46b92006a641ae9b1e48280dc183d4","type":"TRIAL","name":"Intracoronary Tirofiban on No-Reflow Phenomena","canonical_id":"clinicaltrials.gov:NCT02054000","description":"No-Reflow Phenomenon","metadata":null},{"id":"c620d2b5aab14f10ba429dd68424ec25","type":"TRIAL","name":"Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden","canonical_id":"clinicaltrials.gov:NCT06769256","description":"ST-segment Elevation Myocardial Infarction (STEMI)","metadata":null},{"id":"1990adf77d5e40f29179abe0ac495239","type":"DISEASE","name":"Intracranial Embolism","canonical_id":"mesh:D020766","description":null,"metadata":null},{"id":"a6b2a89049a54925ae9a4ee79b00e0ae","type":"TRIAL","name":"Intradermal Influenza Vaccine in the Young","canonical_id":"clinicaltrials.gov:NCT02103023","description":"Influenza Viral Infections","metadata":null},{"id":"bf5c7cc8883343cca1d8bdcc1d45be22","type":"TRIAL","name":"Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma","canonical_id":"clinicaltrials.gov:NCT04274816","description":"Cutaneous Melanoma","metadata":null},{"id":"de4788064c7d47d9a8374a9bb1f4be17","type":"TRIAL","name":"Intradermal LPS and Antibiotics","canonical_id":"clinicaltrials.gov:NCT03779360","description":"Inflammation; Skin","metadata":null},{"id":"60ec704e79794bf6bfb51e9ff0cd815a","type":"TRIAL","name":"Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?","canonical_id":"clinicaltrials.gov:NCT03263481","description":"Cholangiopancreatography, Endoscopic Retrograde","metadata":null},{"id":"6074972e4c7a4ff188fc676c2b968c4d","type":"DISEASE","name":"Intrahepatic Cholangiocarcinoma","canonical_id":"doid:4928","description":null,"metadata":null},{"id":"6d8b8d8d9aaa434580c4046afa5daf64","type":"TRIAL","name":"Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease","canonical_id":"clinicaltrials.gov:NCT05855070","description":"Peyronie's Disease; Hyaluronic Acid; Verapamil","metadata":null},{"id":"d30255a1a7ed41ef9cde67c1246a2a73","type":"TRIAL","name":"Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis","canonical_id":"clinicaltrials.gov:NCT05708625","description":"Leishmaniasis, Cutaneous","metadata":null},{"id":"d05198b23877454cbba65e269d0fc0e7","type":"TRIAL","name":"Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00797277","description":"Schizophrenia; Schizoaffective Disorder; Agitation","metadata":null},{"id":"eb30c4cbb11b4cdab9b1745e34e5487e","type":"TRIAL","name":"Intramuscular Midazolam Versus Intravenous Diazepam for Acute Seizure in Children","canonical_id":"clinicaltrials.gov:NCT06271096","description":"Seizures","metadata":null},{"id":"298a67a1af944096ac262976141a0faf","type":"TRIAL","name":"Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia","canonical_id":"clinicaltrials.gov:NCT05615727","description":"Insomnia","metadata":null},{"id":"d9bfaf7e33194572b996e4e10f8f31e0","type":"TRIAL","name":"Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT07479602","description":"Adenotonsillectomy; Children; Intranasal Administration; Dexmedetomidine; Esketamine; Postoperative Pain","metadata":null},{"id":"fd4fe6c74b674755984ed2e11b0d3d97","type":"TRIAL","name":"Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.","canonical_id":"clinicaltrials.gov:NCT02437669","description":"Pain","metadata":null},{"id":"5058cc2b8b9b46a1945474865b056a24","type":"TRIAL","name":"Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED)","canonical_id":"clinicaltrials.gov:NCT03525821","description":"Fractures, Closed","metadata":null},{"id":"6f6d2265d88445f382d27f7f8c89d2e6","type":"TRIAL","name":"Intranasal Ketorolac Trial","canonical_id":"clinicaltrials.gov:NCT06083571","description":"Headache, Migraine","metadata":null},{"id":"426e31a4e7864463ba5cb54aa211a2c1","type":"TRIAL","name":"Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain","canonical_id":"clinicaltrials.gov:NCT02000388","description":"Post Vasectomy Pain","metadata":null},{"id":"8a5167766c064aa0bf0cafcf3fb92bb4","type":"TRIAL","name":"Intranasal Nafarelin For Triggering Oocyte Maturation","canonical_id":"clinicaltrials.gov:NCT06763926","description":"Fertility Preservation","metadata":null},{"id":"278dcbd7770f4b4d97351af501fdfc72","type":"TRIAL","name":"Intranasal Oxytocin Treatment for Social Deficits in Children With Autism","canonical_id":"clinicaltrials.gov:NCT01624194","description":"Autism","metadata":null},{"id":"0c95eaaea1c6445e9a14d30b192e3e01","type":"TRIAL","name":"Intranasal Oxytocin in Youth With Autism","canonical_id":"clinicaltrials.gov:NCT05934812","description":"Autism Spectrum Disorder","metadata":null},{"id":"8726864b33d2410b9226ac6a08e40985","type":"TRIAL","name":"Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children","canonical_id":"clinicaltrials.gov:NCT05382494","description":"Sleep Disorder; Breathing-Related; Snoring; Obstructive Sleep Apnea of Child; Sleep Disorders in Children; Tonsillar Hypertrophy; Adenoidal Disorder","metadata":null},{"id":"9ebcbbbf9cbe46fa85160a33e0b5c2da","type":"TRIAL","name":"Intranasal Sufentanil Versus Intravenous Morphine for the Management of Acute Pain","canonical_id":"clinicaltrials.gov:NCT03224039","description":"Acute Pain","metadata":null},{"id":"7bbac4efffb64d4482efaa7acfd896c9","type":"TRIAL","name":"Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric","canonical_id":"clinicaltrials.gov:NCT06181695","description":"Vaso-occlusive Crisis","metadata":null},{"id":"fa4eed0b70554270bb4bb7c82e2d5e8c","type":"TRIAL","name":"Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade","canonical_id":"clinicaltrials.gov:NCT02215382","description":"Intraocular Pressure Changes During Tracheal Extubation","metadata":null},{"id":"4c7ebc75eebc4db0a7b37169582d6012","type":"TRIAL","name":"Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination","canonical_id":"clinicaltrials.gov:NCT00941096","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"29dda6240a404561ada7085913fa34a5","type":"TRIAL","name":"Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study","canonical_id":"clinicaltrials.gov:NCT01975714","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"ba0c51fd8ff2473cab5c9f9fa51058ff","type":"TRIAL","name":"Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT02327923","description":"Gall Stone Disease","metadata":null},{"id":"aad1faa044dd41409fa0f26decd40a3d","type":"TRIAL","name":"Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients","canonical_id":"clinicaltrials.gov:NCT02989597","description":"Pain, Postoperative","metadata":null},{"id":"49b4b43f5458460296aab325a298b842","type":"TRIAL","name":"Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia","canonical_id":"clinicaltrials.gov:NCT01430182","description":"Pain, Postoperative","metadata":null},{"id":"78b4923deef644a1bb26181c8c8107f6","type":"TRIAL","name":"Intraoperative Pectoral Block vs IV Analgesia for Pain After Modified Radical Mastectomy","canonical_id":"clinicaltrials.gov:NCT07257874","description":"Mastectomy, Modified Radical","metadata":null},{"id":"347cb617c2d8417ab811f90772a0a948","type":"TRIAL","name":"Intrapartum Oxytocin Administration Affects Primitive Neonatal Reflexes","canonical_id":"clinicaltrials.gov:NCT01891201","description":"Bonding; Oxytocin; Breastfeeding; Newborn; Perinatal","metadata":null},{"id":"7867f74acaf842bb8ed33d6a47908ac8","type":"TRIAL","name":"Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy","canonical_id":"clinicaltrials.gov:NCT03393572","description":"Anesthesia","metadata":null},{"id":"5734f808fbe342f4ad3b4fee361000be","type":"TRIAL","name":"Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites","canonical_id":"clinicaltrials.gov:NCT06759064","description":"Cancer of Stomach, Adenocarcinoma; Ascites, Malignant","metadata":null},{"id":"a1d62fb787914e0ea25de3943d7c6545","type":"TRIAL","name":"Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04802863","description":"Bacterial Infections","metadata":null},{"id":"7df7ea724552488e83992c17f47a89a2","type":"TRIAL","name":"Intrathecal (IT) Baclofen Drug Distribution","canonical_id":"clinicaltrials.gov:NCT02903823","description":"Muscle Spasticity","metadata":null},{"id":"5fe428058b5e42aaa37fb7627d378448","type":"TRIAL","name":"Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP). Preliminary Study.","canonical_id":"clinicaltrials.gov:NCT02705950","description":"Neuropathic Pain","metadata":null},{"id":"411c4edbcf09463c8be1967c7cc61bc9","type":"TRIAL","name":"Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","canonical_id":"clinicaltrials.gov:NCT06762080","description":"Leptomeningeal Metastasis","metadata":null},{"id":"32abb040ff5f4e138d6fb54ea2e4ba88","type":"TRIAL","name":"Intrathecal Midazolam, Fentanyl and Nalbuphine as Adjuvants to Bupivacaine in Spinal Anesthesia for Cesarean Section","canonical_id":"clinicaltrials.gov:NCT04932083","description":"Pain, Acute","metadata":null},{"id":"4c286aa26f83458bbf86942e65c434fb","type":"TRIAL","name":"Intrathecal Morphine for Unilateral Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT03232957","description":"Primary Osteoarthritis of Knee Nos","metadata":null},{"id":"e1d1c41150044e8b95f57d92f4852e02","type":"TRIAL","name":"Intrathecal Nalbuphine Versus Intrathecal Tramadol in Subarachnoid Block for Lower Limb Orthopaedic Surgeries","canonical_id":"clinicaltrials.gov:NCT07294352","description":"Adjuvants, Anesthesia; Subarachnoid Block","metadata":null},{"id":"0b0d4126bd7b41249d6e6f832aeea2b5","type":"TRIAL","name":"Intrathecal Pemetrexed for Leptomeningeal Metastasis","canonical_id":"clinicaltrials.gov:NCT05289908","description":"Leptomeningeal Metastases","metadata":null},{"id":"03ef2811fb9b4ceeab6b630f80c4ff03","type":"TRIAL","name":"Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.","canonical_id":"clinicaltrials.gov:NCT06296745","description":"Leptomeningeal Metastasis","metadata":null},{"id":"6da230b3acc54dec803e386218805c42","type":"TRIAL","name":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT04840615","description":"Mesothelioma","metadata":null},{"id":"cd80a8e03eb8408187452b4a5a025861","type":"TRIAL","name":"Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma","canonical_id":"clinicaltrials.gov:NCT05717153","description":"Diffuse Glioma; Malignant Glioma","metadata":null},{"id":"34eef40d95504b6d9c0ad1fd1ae5df2d","type":"TRIAL","name":"Intratumoral Microdosing of Motolimod in HNSCC","canonical_id":"clinicaltrials.gov:NCT04272333","description":"HNSCC","metadata":null},{"id":"778bd0b279d04f87b14c0d9d9a6c6bab","type":"TRIAL","name":"Intratympanic Injection for Autoimmune Inner Ear Disease","canonical_id":"clinicaltrials.gov:NCT01526174","description":"Autoimmune Inner Ear Disease","metadata":null},{"id":"42b0603ea433427786025a60a61d9562","type":"TRIAL","name":"Intratympanic Steroid for Bell's Palsy","canonical_id":"clinicaltrials.gov:NCT03508440","description":"Bell's Palsy; Facial Nerve Paresis","metadata":null},{"id":"41d022cf5704499c9198125f11d968a0","type":"TRIAL","name":"Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT01001143","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"63768029c59c46cb8260a336790e67a2","type":"TRIAL","name":"Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus","canonical_id":"clinicaltrials.gov:NCT01367548","description":"Postoperative Ileus","metadata":null},{"id":"23639140a1d84fbbba22864505e450ba","type":"TRIAL","name":"Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry","canonical_id":"clinicaltrials.gov:NCT05505591","description":"Bleeding; Coronary Artery Disease; Myocardial Infarction","metadata":null},{"id":"c21d54e7e30d4b75b5fe0683e4eafc3e","type":"TRIAL","name":"Intravenous Fluids in Benign Headaches Trial","canonical_id":"clinicaltrials.gov:NCT03185130","description":"Headache","metadata":null},{"id":"fd94008743214373a4a452c742ab4122","type":"TRIAL","name":"Intravenous Fluids in Pediatric Migraine","canonical_id":"clinicaltrials.gov:NCT06182098","description":"Migraine; Migraine in Children","metadata":null},{"id":"26357a6315984b2589dc953ad90db808","type":"TRIAL","name":"Intravenous Granisetron Vs Dexmedetomidine on Postspinal in the Cesarean Section.","canonical_id":"clinicaltrials.gov:NCT06762860","description":"Postspinal Shivering","metadata":null},{"id":"e799264816c3427d9dc3e13db65ac5a2","type":"TRIAL","name":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)","canonical_id":"clinicaltrials.gov:NCT03867097","description":"Raynaud Phenomenon Secondary to Systemic Sclerosis","metadata":null},{"id":"3efa8c64baf040119aee9e7e658f96d4","type":"TRIAL","name":"Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea","canonical_id":"clinicaltrials.gov:NCT00615797","description":"Sydenham Chorea; Post Streptococcal Movement Disorder","metadata":null},{"id":"8e101ba948784dabb5413b2a2e03afbc","type":"TRIAL","name":"Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)","canonical_id":"clinicaltrials.gov:NCT03888534","description":"Precursor Cell Lymphoblastic Leukemia-lymphoma","metadata":null},{"id":"9ea5d6f685b4406592e381c7519f315c","type":"TRIAL","name":"Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT01596166","description":"Probable Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"4af25d04ccb94140abc591c4994a0f3b","type":"TRIAL","name":"Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.","canonical_id":"clinicaltrials.gov:NCT06385600","description":"Severe Pre-eclampsia","metadata":null},{"id":"d8cec4fab75d447ea582d4793155b911","type":"TRIAL","name":"Intravenous Mepolizumab In Children With Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT00358449","description":"Oesophagitis, Eosinophilic","metadata":null},{"id":"906b0deb93d841d485737c652e544c5e","type":"TRIAL","name":"Intravenous Methadone in Perioperative Acute and Chronic Management in Chinese Adult Cardiac Surgical Patients","canonical_id":"clinicaltrials.gov:NCT05913284","description":"Pain, Postoperative; Pain, Acute; Pain, Chronic; Anesthesia","metadata":null},{"id":"23cdd168a7624a8a807e5384a94d7b5e","type":"TRIAL","name":"Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations","canonical_id":"clinicaltrials.gov:NCT01685658","description":"Renal Colic; Acute Renal Colic","metadata":null},{"id":"bdb7844485ba41efa6196b268182e3c1","type":"TRIAL","name":"Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery","canonical_id":"clinicaltrials.gov:NCT00569855","description":"Open-heart Surgery; Cardiopulmonary Bypass","metadata":null},{"id":"d117b1b88d9a4c86bc67766d27f97ba3","type":"TRIAL","name":"Intravenous Regadenoson Versus Intravenous Adenoscan\u00ae for Fractional Flow Reserve (FFR)","canonical_id":"clinicaltrials.gov:NCT01482169","description":"Coronary Artery Disease","metadata":null},{"id":"38063e68e2c64f3a989d5b59aa62c25b","type":"TRIAL","name":"Intravenous Remifentanil for Labor Analgesia","canonical_id":"clinicaltrials.gov:NCT00710086","description":"Labor Pain","metadata":null},{"id":"0752fa39d5be4492b88bb95035e56a9e","type":"TRIAL","name":"Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement","canonical_id":"clinicaltrials.gov:NCT01651962","description":"Labor Pain","metadata":null},{"id":"2c4610ef77ee4997a32a69b375029081","type":"TRIAL","name":"Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT07290751","description":"Acute Ischemic Stroke","metadata":null},{"id":"e976308c83f4491492f98cd78eabf568","type":"TRIAL","name":"Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion","canonical_id":"clinicaltrials.gov:NCT07335107","description":"Acute Ischemic Stroke","metadata":null},{"id":"65888a8679d74cf9bca2a1425aa5f153","type":"TRIAL","name":"Intravenous Tirofiban After Delayed Thrombolysis in Stroke","canonical_id":"clinicaltrials.gov:NCT07111806","description":"Acute Ischemic Stroke","metadata":null},{"id":"70c99afacb7f47ee9cd0889588b01d40","type":"TRIAL","name":"Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease","canonical_id":"clinicaltrials.gov:NCT04432233","description":"Helicobacter Pylori Infection; Intravenous Drug Usage","metadata":null},{"id":"3a52d83895db482e887e4b1e7a1d9764","type":"TRIAL","name":"Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00082823","description":"Cancer","metadata":null},{"id":"d35de6947ce94349affc1a1f055f142a","type":"TRIAL","name":"Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT02767024","description":"Acute Heart Failure","metadata":null},{"id":"b690b204e73b49a28160e324c75df958","type":"TRIAL","name":"Intravenous Versus Intracoronary Use of Abciximab","canonical_id":"clinicaltrials.gov:NCT00685464","description":"Atherosclerosis; Ischemic Heart Disease","metadata":null},{"id":"ba8c98a3e3e34b0995eb64e2f8aab968","type":"TRIAL","name":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06508463","description":"Peripheral T Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Relapsed Anaplastic Large Cell Lymphoma; Relapsed Mycosis Fungoides","metadata":null},{"id":"9c8316bb60fe4845a3b1ac68bfaba2f0","type":"TRIAL","name":"Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis","canonical_id":"clinicaltrials.gov:NCT05185947","description":"Gynecologic Cancer; Gynecologic Neoplasms; Peritoneal Carcinomatosis; Peritoneal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Colorectal Cancer; Colorectal Neoplasms; Appendiceal Cancer; Appendiceal Neoplasms; Cholangiocarcinoma; Breast Cancer","metadata":null},{"id":"6d2d89c3312a4ca7a5f4b0c08b6a4c0b","type":"TRIAL","name":"Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration","canonical_id":"clinicaltrials.gov:NCT04243954","description":"Cancer Pain","metadata":null},{"id":"6866706233f8496c8cbe685fdc17dcbf","type":"TRIAL","name":"Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder","canonical_id":"clinicaltrials.gov:NCT02202772","description":"Urothelial Carcinoma of the Urinary Bladder","metadata":null},{"id":"b98e2835c52f408390c92c42a13c16ac","type":"TRIAL","name":"Intravesical Cidofovir for Hemorrhagic Cystitis","canonical_id":"clinicaltrials.gov:NCT01816646","description":"Blood And Marrow Transplantation","metadata":null},{"id":"a154ad951a014b06a45b3b2aafd3d301","type":"TRIAL","name":"Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT02863354","description":"Proliferative Diabetic Retinopathy","metadata":null},{"id":"545aa93fedef482c8aedd6e98ad9776a","type":"TRIAL","name":"Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)","canonical_id":"clinicaltrials.gov:NCT02537054","description":"Pseudoxanthoma Elasticum","metadata":null},{"id":"3d8e81c859c441938c5d5764a4867fda","type":"TRIAL","name":"Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab","canonical_id":"clinicaltrials.gov:NCT02309281","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"a12c1064f41644488eb88e3979d0dfbd","type":"TRIAL","name":"Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis","canonical_id":"clinicaltrials.gov:NCT02641457","description":"Glaucoma; Rubeosis Iridis","metadata":null},{"id":"1dc331cdb4214d86829a5fb82a0d628b","type":"TRIAL","name":"Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept","canonical_id":"clinicaltrials.gov:NCT04287348","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"96bde2b1cede46da8bd56a4b807a8870","type":"TRIAL","name":"Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy","canonical_id":"clinicaltrials.gov:NCT05844982","description":"Radiation Retinopathy; Visual Impairment","metadata":null},{"id":"47b2c4e20bd84c21a70580f03ca48685","type":"TRIAL","name":"Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept","canonical_id":"clinicaltrials.gov:NCT05610488","description":"Diabetic Macular Edema","metadata":null},{"id":"548c6072e7b24883b41496c20eaca782","type":"TRIAL","name":"Intravitreal Faricimab in Patients With Refractory Macular Edema","canonical_id":"clinicaltrials.gov:NCT07093385","description":"Age-Related Macular Degeneration","metadata":null},{"id":"8c35f301b26e4c1099357decf6f7703d","type":"TRIAL","name":"Intravitreal Infliximab for Proliferative Vitreoretinopathy","canonical_id":"clinicaltrials.gov:NCT04891991","description":"Rhegmatogenous Retinal Detachment; Proliferative Vitreoretinopathy; Retinal Detachment","metadata":null},{"id":"f3fed86756ad476093b2d948638df12a","type":"TRIAL","name":"Intravitreal Injection Anesthesia - Comparison of Different Topical Agents","canonical_id":"clinicaltrials.gov:NCT01224847","description":"Age-Related Macular Degeneration (AMD)","metadata":null},{"id":"86ac4060573f42aabf4a97fd15353409","type":"TRIAL","name":"Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT02857491","description":"Proliferative Diabetic Retinopathy","metadata":null},{"id":"30384134334f407d89aea411868f5188","type":"TRIAL","name":"Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00056823","description":"Age-Related Maculopathy","metadata":null},{"id":"2bcf921a92a242dc8a728390ea403323","type":"TRIAL","name":"Intravitreal Macugen for Ischaemic Diabetic Macular Oedema","canonical_id":"clinicaltrials.gov:NCT01175070","description":"Diabetic Macular Oedema","metadata":null},{"id":"e77c904e89ab45b4847859caab699336","type":"TRIAL","name":"Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia","canonical_id":"clinicaltrials.gov:NCT01218230","description":"Myopic Choroidal Neovascular Membrane","metadata":null},{"id":"3a96d4e590a348809c07f210e81ed11b","type":"TRIAL","name":"Intravitreal Ranibizumab (Lucentis\u00ae) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy","canonical_id":"clinicaltrials.gov:NCT03763227","description":"Retinal Dystrophies","metadata":null},{"id":"79c8ff59a38f4f3aa279f44d88167c75","type":"TRIAL","name":"Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy","canonical_id":"clinicaltrials.gov:NCT00540930","description":"Uveal Melanoma; Radiation Retinopathy; Radiation Maculopathy","metadata":null},{"id":"ce1380eadeab4be6ac4e327791145d44","type":"TRIAL","name":"Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT00407849","description":"Diabetic Retinopathy","metadata":null},{"id":"e4a3b2c08c7c43159977174d6c96c848","type":"TRIAL","name":"Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00088192","description":"Macular Degeneration","metadata":null},{"id":"c17a7f75bbdc4ed4b614f32b02ba24b0","type":"TRIAL","name":"Intubation Time With Low Dose Rocuronium","canonical_id":"clinicaltrials.gov:NCT01464489","description":"Intubation; Difficult","metadata":null},{"id":"211435f6c9fb4351818924d4cac62f5a","type":"TRIAL","name":"Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial","canonical_id":"clinicaltrials.gov:NCT06866262","description":"Locally Advanced Clear Cell Renal Cell Carcinoma; Locally Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8","metadata":null},{"id":"f07c6898fd9844f58e78155d4feb4159","type":"DISEASE","name":"Invasive Pulmonary Aspergillosis","canonical_id":"mesh:D055744","description":null,"metadata":null},{"id":"1a9d13a40bc641c39d57c98595556b01","type":"TRIAL","name":"Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib","canonical_id":"clinicaltrials.gov:NCT02803762","description":"Healthy","metadata":null},{"id":"d02e1403a89544b2860a4b73db99c37c","type":"TRIAL","name":"Investigate a Pharmacokinetic Characteristics and the Safety of AG1502 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02614352","description":"Healthy Male Subjects","metadata":null},{"id":"c94cebc34c1348b9b93e68a999ea1bb4","type":"TRIAL","name":"Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients","canonical_id":"clinicaltrials.gov:NCT01103622","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f063f14582384597984388ebb4c6130a","type":"TRIAL","name":"Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01082120","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"5e46b2dc87c64093af4c75e11913c3e5","type":"TRIAL","name":"Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite","canonical_id":"clinicaltrials.gov:NCT03968848","description":"Hepatic Impairment; Hepatic Insufficiency; Healthy Subjects","metadata":null},{"id":"67c063163cf84d44833469fba02bbc97","type":"TRIAL","name":"Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases","canonical_id":"clinicaltrials.gov:NCT00807170","description":"Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"4576c444de814eada83aefbd55d168d1","type":"TRIAL","name":"Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)","canonical_id":"clinicaltrials.gov:NCT00665340","description":"Erectile Dysfunction","metadata":null},{"id":"747f73f5209847fda0f6c362c09911f1","type":"TRIAL","name":"Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01400828","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"33220fa3def44a629fd243044ed05b66","type":"TRIAL","name":"Investigating Cardiovascular Adverse Events Related to Cancer Treatment","canonical_id":"clinicaltrials.gov:NCT03199300","description":"Toxicity Due to Chemotherapy; Cardiovascular Morbidity; Cancer, Treatment-Related","metadata":null},{"id":"eb72ceb4707a4848a66d4e8a79771714","type":"TRIAL","name":"Investigating Dupilumab's Effect in Asthma by Genotype","canonical_id":"clinicaltrials.gov:NCT03694158","description":"Asthma","metadata":null},{"id":"3d6385ddd98640b2a2cb2c6d67225626","type":"TRIAL","name":"Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy","canonical_id":"clinicaltrials.gov:NCT00468286","description":"Prostate Cancer","metadata":null},{"id":"2bb7aed8436149d4bb4c7def98b88f92","type":"TRIAL","name":"Investigating Pre-Procedural Anxiety and Effect of Analgesia on Intrauterine Device Placement and Endometrial Biopsy","canonical_id":"clinicaltrials.gov:NCT07031206","description":"Anxiety; Pain","metadata":null},{"id":"69efa610f44f4d2f9713c85a64508f6a","type":"TRIAL","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT07745296","description":"Biliary Tract Cancer (BTC)","metadata":null},{"id":"6690e89ee645470f8d36c3475327d2b5","type":"TRIAL","name":"Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity","canonical_id":"clinicaltrials.gov:NCT02870231","description":"Metabolism and Nutrition Disorder; Obesity","metadata":null},{"id":"41b5682702604adaa96a1e7ff01c7740","type":"TRIAL","name":"Investigating the Clinical Consequences of Flutemetamol-PET-scanning","canonical_id":"clinicaltrials.gov:NCT02353949","description":"Mild Cognitive Impairment; Alzheimer's Disease; Dementia","metadata":null},{"id":"d0e06f1124a542639dd8d64c87154abe","type":"TRIAL","name":"Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics","canonical_id":"clinicaltrials.gov:NCT07625358","description":"Caffeine; Alcohol; Pupillary Response; Eye Movements; Optical Coherence Tomography; Optical Coherence Tomography Angiography; Physiological Responses","metadata":null},{"id":"0b64f47bcc3941b387d72f28f95efe31","type":"TRIAL","name":"Investigating the Effect of Vortioxetine in Adult ADHD Patients","canonical_id":"clinicaltrials.gov:NCT02327013","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"b8e72f0dbcfe4ffc947d24f35795f42a","type":"TRIAL","name":"Investigating the Effectiveness of E-CBTi Compared to Pharmaceutical Interventions in Treating Insomnia","canonical_id":"clinicaltrials.gov:NCT05125146","description":"Insomnia","metadata":null},{"id":"18ec168a054549bcb72ab6c091f983d6","type":"TRIAL","name":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","canonical_id":"clinicaltrials.gov:NCT03355027","description":"Atherosclerosis; Cardiovascular Diseases","metadata":null},{"id":"e88d25225f2242ddaa316100666f23ef","type":"TRIAL","name":"Investigating the Neuropsychological Effects of 5-HT2a Antagonism","canonical_id":"clinicaltrials.gov:NCT07022366","description":"Healthy","metadata":null},{"id":"624f2471733a4c1897ed2289d2b6fe2b","type":"TRIAL","name":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT05016349","description":"Breast Cancer Female","metadata":null},{"id":"b84256df1ee14732af0713824aa4e5cf","type":"TRIAL","name":"Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk","canonical_id":"clinicaltrials.gov:NCT06190483","description":"Prodromal Schizophrenia","metadata":null},{"id":"042a5fd541054c58ae487d714d8bd518","type":"TRIAL","name":"Investigating the Safety of Post-surgical Analgesics in Children With Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT01680939","description":"Pediatric Obstructive Sleep Apnea Syndrome","metadata":null},{"id":"3f9068eef71740af925c1fd635b31570","type":"TRIAL","name":"Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)","canonical_id":"clinicaltrials.gov:NCT00000174","description":"Alzheimer Disease; Cognition Disorders","metadata":null},{"id":"69ae90d76f63484090e6b33c2d6f33ea","type":"TRIAL","name":"Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers","canonical_id":"clinicaltrials.gov:NCT00436787","description":"Venous Thrombosis; Pulmonary Embolism","metadata":null},{"id":"9b40c188a596486681f76bad2fbbd290","type":"TRIAL","name":"Investigation Of A New Medication (GW642444) In Asthmatic Patients","canonical_id":"clinicaltrials.gov:NCT00354874","description":"Asthma","metadata":null},{"id":"ba5f38f9898947a6b02d6ba145f8873f","type":"TRIAL","name":"Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT02317484","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"9ca8f6d15718400f8b6119c3f7eb26a9","type":"TRIAL","name":"Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women","canonical_id":"clinicaltrials.gov:NCT01596010","description":"Menopause; Healthy","metadata":null},{"id":"eb07e75a97e8407897b813c72611bfdf","type":"TRIAL","name":"Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml","canonical_id":"clinicaltrials.gov:NCT02471105","description":"Ocular Hypertension; Glaucoma","metadata":null},{"id":"78a3d1ea4024460f8b16cdbe0f9f9517","type":"TRIAL","name":"Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass","canonical_id":"clinicaltrials.gov:NCT00131040","description":"Ischemic Heart Disease; Angina Pectoris","metadata":null},{"id":"2bb76d415cc14b04b143c8c69968a55e","type":"TRIAL","name":"Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients","canonical_id":"clinicaltrials.gov:NCT02078323","description":"Irritable Bowel Syndrome With Constipation (IBS-C)","metadata":null},{"id":"9c2b80ea1be248df96c97e14495a42e6","type":"TRIAL","name":"Investigation of Naltrexone for Pathological Gambling","canonical_id":"clinicaltrials.gov:NCT01057862","description":"Pathological Gambling","metadata":null},{"id":"e2081ac014854bddaa20e3d70aa5267a","type":"TRIAL","name":"Investigation of Nicotine Seeking Behavior in Current Smokers","canonical_id":"clinicaltrials.gov:NCT03670212","description":"Cigarette Smoking","metadata":null},{"id":"5384db97a4c44d0cb99ac641d194d0d8","type":"TRIAL","name":"Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis","canonical_id":"clinicaltrials.gov:NCT06626984","description":"Sepsis; Fluid Overload; Endothelial Dysfunction; Microcirculation","metadata":null},{"id":"2a4947a6b1a44cfd8c53aea378402e82","type":"TRIAL","name":"Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)","canonical_id":"clinicaltrials.gov:NCT00659048","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"b470d8f03d1a4fb2abc047de2d53e75d","type":"TRIAL","name":"Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab","canonical_id":"clinicaltrials.gov:NCT06648057","description":"Biliary Tract Cancer; Cholangiocarcinoma","metadata":null},{"id":"eadbdf9fec2f48bb96aa08f0f84f4c0d","type":"TRIAL","name":"Investigation of Psychedelic Effects in Psychoactive Substances","canonical_id":"clinicaltrials.gov:NCT06772753","description":"Psychedelic Effects in Healthy Volunteers","metadata":null},{"id":"d19d7b8873ab404f99c4655ad4afaa60","type":"TRIAL","name":"Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01426958","description":"Healthy","metadata":null},{"id":"701473b83be54450b2a8383e3dcde7ea","type":"TRIAL","name":"Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC","canonical_id":"clinicaltrials.gov:NCT04819399","description":"Urinary Bladder Neoplasms","metadata":null},{"id":"69867a4de109482eb67650cbc8011f2a","type":"TRIAL","name":"Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI","canonical_id":"clinicaltrials.gov:NCT02549898","description":"Migraine Headache; Migraine Without Aura","metadata":null},{"id":"25f606aa30d94c799a6a85c80f6db90a","type":"TRIAL","name":"Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks","canonical_id":"clinicaltrials.gov:NCT07816328","description":"Chronic Spontaneous Urticaria","metadata":null},{"id":"5ad94490c6db490baba70814c9913a53","type":"TRIAL","name":"Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01206647","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"073aa72591394b219ae7073ecb71ca00","type":"TRIAL","name":"Investigation of the Changes of Brain Structure and Function in Premature Ejaculation Patients and the Effects of Dapoxetine on Central Neural Activity in Premature Ejaculation Patients","canonical_id":"clinicaltrials.gov:NCT03583112","description":"Premature Ejaculation","metadata":null},{"id":"e17994fc050a4d16a6c4d384c5a74da8","type":"TRIAL","name":"Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.","canonical_id":"clinicaltrials.gov:NCT01451775","description":"Healthy","metadata":null},{"id":"52376d1ab1c3494b85e826258feb3f2d","type":"TRIAL","name":"Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02751385","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"cf4e5146239c41d196232fc5eef20d7f","type":"TRIAL","name":"Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)","canonical_id":"clinicaltrials.gov:NCT00806754","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"97b7d8d771894f58ad05a30b282cec98","type":"TRIAL","name":"Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis","canonical_id":"clinicaltrials.gov:NCT00049764","description":"Sepsis","metadata":null},{"id":"089611d2910c499a8a27a2b8963b8841","type":"TRIAL","name":"Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists","canonical_id":"clinicaltrials.gov:NCT06818292","description":"Healthy","metadata":null},{"id":"2e5519a6d16b420781034448e3b751a2","type":"TRIAL","name":"Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00223028","description":"Renal Transplantation","metadata":null},{"id":"bd7a4b28a13046668c9599d29b6284f0","type":"TRIAL","name":"Investigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00223015","description":"Renal Transplantation","metadata":null},{"id":"f9fe0ff7eeb749349557035fc6be2589","type":"TRIAL","name":"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT01272973","description":"Diabetes; Diabetes Mellitus, Type 2; Healthy","metadata":null},{"id":"178d011b839e4c7eb11997716ab85ab1","type":"TRIAL","name":"Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01349088","description":"Breast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"924eefcd043a457b911d3ecfb72eed21","type":"TRIAL","name":"Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092833","description":"Hypercholesterolemia, Familial; Lipid Metabolism, Inborn Errors","metadata":null},{"id":"5a53fffa1c7f4328a7c2227568c00f53","type":"TRIAL","name":"Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa","canonical_id":"clinicaltrials.gov:NCT00381472","description":"Parkinson Disease","metadata":null},{"id":"c72d7e90b4ca4cc59caaddb5db642e5e","type":"TRIAL","name":"Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain","canonical_id":"clinicaltrials.gov:NCT06411067","description":"Fibromyalgia","metadata":null},{"id":"96b59c48ea3d41e6804c14c7e7e9412e","type":"TRIAL","name":"Investigations of Mechanisms and Treatment in Post-traumatic Joint Contractures","canonical_id":"clinicaltrials.gov:NCT01902017","description":"Joint Contractures","metadata":null},{"id":"9bbfd12ae6084c2f92d4c73c4621af0d","type":"TRIAL","name":"Investigator Initiated Study - Asenapine Early Psychosis","canonical_id":"clinicaltrials.gov:NCT01968161","description":"Schizophrenia and Disorders With Psychotic Features; Disorders","metadata":null},{"id":"ac72bf40319a4fec9929672606eb3a71","type":"TRIAL","name":"Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT07323927","description":"Alzheimer Disease","metadata":null},{"id":"19031d3851cb415985152ea32b78090d","type":"TRIAL","name":"Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma","canonical_id":"clinicaltrials.gov:NCT04863950","description":"Glioblastoma","metadata":null},{"id":"8d7ee621223d4347a9bbabe9d3d115cb","type":"TRIAL","name":"Investigator-Sponsored Protocol - Continued Use of Ibalizumab","canonical_id":"clinicaltrials.gov:NCT01056393","description":"HIV Infections","metadata":null},{"id":"487a48c3489840378e6631ff30a6f097","type":"TRIAL","name":"Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00073931","description":"Lymphoma","metadata":null},{"id":"28c64d0f89c746d5ba33a45dbaa5cb28","type":"TRIAL","name":"Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00110071","description":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma\u2026","metadata":null},{"id":"a4faf9dec52649e2946d6b33b4a6e2bf","type":"TRIAL","name":"Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00073918","description":"Anaplastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recur\u2026","metadata":null},{"id":"684a87ca60774f4282a7a42240779a90","type":"TRIAL","name":"Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00996996","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"bc247ffa33e54b0f93219e4a88b92b7e","type":"TRIAL","name":"Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP","canonical_id":"clinicaltrials.gov:NCT01868035","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"3fae1c912c104dafa042010461473032","type":"DRUG","name":"Ionizing Radiotherapy","canonical_id":"ncit:C15846","description":null,"metadata":null},{"id":"4b6f29e65eed41a98fd4614ce197976d","type":"TRIAL","name":"Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers","canonical_id":"clinicaltrials.gov:NCT03654989","description":"Diabetic Foot Ulcer","metadata":null},{"id":"7d5077d837d04de2ba8c40a967a005a0","type":"TRIAL","name":"Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT07315854","description":"Gastric Cancer (GC); Gastroesophageal Junction Cancer; Advanced Gastric Cancer; Metastatic Gastric Cancer","metadata":null},{"id":"fca5429f175346a293aa96802a0738c7","type":"TRIAL","name":"Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma","canonical_id":"clinicaltrials.gov:NCT07738159","description":"Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); QL1706; Lenvatinib; Chemotherapy","metadata":null},{"id":"043ee96348fe455a8aeeaad49202288b","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07769853","description":"Locally Advanced Rectal Cancer (LARC); 5-12cm to Anal Verge","metadata":null},{"id":"eb1f1421e3434005bad7685acc1a8752","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC","canonical_id":"clinicaltrials.gov:NCT07152769","description":"Advanced Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"b7a676e3f3504b2c8d911a8341262618","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial","canonical_id":"clinicaltrials.gov:NCT07101744","description":"Nasopharyngeal Carcinoma (NPC); First-line Treatment Failure Nasopharyngeal Carcinoma","metadata":null},{"id":"91f02c575bf1449a881300e5a70744dd","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","canonical_id":"clinicaltrials.gov:NCT07041788","description":"Cancer","metadata":null},{"id":"0544c9a61bc74212b5cd5051a83b8ce8","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence","canonical_id":"clinicaltrials.gov:NCT06958484","description":"HCC - Hepatocellular Carcinoma; Adjuvant Treatment","metadata":null},{"id":"7ea2dcc23f814c8fab5b611515ec946b","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction","canonical_id":"clinicaltrials.gov:NCT07776639","description":"Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma","metadata":null},{"id":"60944eb2ec0440c385e59e43aeb7a41b","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07349225","description":"ES-SCLC","metadata":null},{"id":"30f4bced74234178aefd2968ea3dcbd4","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT07277972","description":"RCC, Renal Cell Cancer","metadata":null},{"id":"2023c0beac7e48678e51ee3d6a48a8ab","type":"TRIAL","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","canonical_id":"clinicaltrials.gov:NCT07447570","description":"Head and Neck Cancer; Radiotherapy; Anti-PD-1/CTLA-4 Antibody","metadata":null},{"id":"7358f36044124343956ed25d648e5db0","type":"TRIAL","name":"Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","canonical_id":"clinicaltrials.gov:NCT07776080","description":"HCC - Hepatocellular Carcinoma","metadata":null},{"id":"87a29f0f514a442ca99681620046df0b","type":"TRIAL","name":"Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma","canonical_id":"clinicaltrials.gov:NCT07347444","description":"Acral Melanoma; Mucosal Melanoma","metadata":null},{"id":"f785f1c608404376bd35dea5057008f4","type":"TRIAL","name":"Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC","canonical_id":"clinicaltrials.gov:NCT07801287","description":"HCC - Hepatocellular Carcinoma","metadata":null},{"id":"14369b3f324c42a6846af599ac15b3e0","type":"TRIAL","name":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","canonical_id":"clinicaltrials.gov:NCT07085234","description":"Locally Advanced Nasopharyngeal Carcinoma; Immunotherapy; Induction Therapy","metadata":null},{"id":"594b71daa5784f93929cdb9276197f98","type":"TRIAL","name":"Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer","canonical_id":"clinicaltrials.gov:NCT00060372","description":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Myelodysplastic Syndromes; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Disseminated Neuroblastoma; Malignant Neoplasm; Ovarian Choriocarcinoma; Ovarian Embryon\u2026","metadata":null},{"id":"3a4348cc174c4a86943ad9414d4b6c0a","type":"TRIAL","name":"Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma","canonical_id":"clinicaltrials.gov:NCT01740297","description":"Melanoma","metadata":null},{"id":"5939043935e34f7b8bab741320b1fedf","type":"TRIAL","name":"Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT01473940","description":"Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer","metadata":null},{"id":"93ddc65c9c3a4609ad7ee4f33857a4c4","type":"TRIAL","name":"Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT01693783","description":"Cervical Adenocarcinoma; Cervical Squamous Cell Carcinoma; Human Papillomavirus Infection; Recurrent Cervical Carcinoma; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVB Cervical Cancer AJCC v6 and v7","metadata":null},{"id":"ff15fa6b76ba475bae5f974cedea0baa","type":"TRIAL","name":"Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial","canonical_id":"clinicaltrials.gov:NCT04721301","description":"Colorectal Cancer Metastatic; Pancreatic Cancer Metastatic","metadata":null},{"id":"1436d51564ca41d49e2d0bbc660630f4","type":"TRIAL","name":"Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)","canonical_id":"clinicaltrials.gov:NCT02564211","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c9639fc66cb84aff8bc5ed2be0c4e8bb","type":"TRIAL","name":"Ipratropium Bromide/Salbutamol Delivered by the Respimat\u00ae Inhaler Compared to Ipratropium Bromide Respimat\u00ae, COMBIVENT\u00ae Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT02177253","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"316660c39f2449c8b658aafe17891b6c","type":"DRUG","name":"Iproclozide","canonical_id":"mesh:C010474","description":null,"metadata":null},{"id":"b8afef7b211949f0b0071e61d93ec528","type":"DRUG","name":"Iproniazid","canonical_id":"mesh:D007490","description":null,"metadata":null},{"id":"7fc03ffb32fa436c831bf73aa8d067a9","type":"DRUG","name":"Irbesartan","canonical_id":"mesh:C081309","description":null,"metadata":null},{"id":"5143ff2c7d494f988e6459d77cc29743","type":"TRIAL","name":"Irbesartan Versus Amlodipine: The OBI Study","canonical_id":"clinicaltrials.gov:NCT00987662","description":"Obesity; Hypertension","metadata":null},{"id":"f3a4b1ad3ac8439091222cb6033e89fd","type":"TRIAL","name":"Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria","canonical_id":"clinicaltrials.gov:NCT00095290","description":"Albuminuria","metadata":null},{"id":"a34fa309654449769bd0115bc8585ecb","type":"TRIAL","name":"Irbesartan and Atenolol in Hypertensive Heart Disease","canonical_id":"clinicaltrials.gov:NCT00389168","description":"Hypertension","metadata":null},{"id":"f01f14826fa8439b947dbc48d6148a21","type":"TRIAL","name":"Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions","canonical_id":"clinicaltrials.gov:NCT00350038","description":"Hypertension; Dyslipidemia","metadata":null},{"id":"850586522103489db79474141cb59b6e","type":"TRIAL","name":"Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population","canonical_id":"clinicaltrials.gov:NCT00847834","description":"Hypertension","metadata":null},{"id":"2290ef8a38e54587a0c9c29ff86fab1b","type":"TRIAL","name":"Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00095550","description":"Hypertension","metadata":null},{"id":"b62046a3e5f94b4696abf42c3b29245f","type":"GO_TERM","name":"Ire1 complex","canonical_id":"go:GO:1990332","description":"\"A type-I transmembrane protein complex located in the endoplasmic reticulum (ER) consisting of an IRE1-IRE1 dimer, which forms in response to the accumulation of unfolded protein in the ER. The dimeric complex has endoribonuclease (RNase) activity and evokes the unfolded protein response (UPR) by cleaving an intron of a mRNA coding for the transcription factor HAC1 in yeast or XBP1 in mammals; the complex cleaves a single phosphodiester bond in each of two RNA hairpins (with non-specific base paired stems and loops of consensus sequence CNCNNGN, where N is any base) to remove an intervening intron from the target transcript.\" [GOC:bf, GOC:bhm, PMID:18191223, PMID:25437541]","metadata":null},{"id":"98f6396ce4d94c7ea257cbba63729492","type":"TRIAL","name":"Ireland Natalizumab (TYSABRI) Observational Program","canonical_id":"clinicaltrials.gov:NCT01943526","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"a4f668b19e7b495094c0902cb185a0d1","type":"TRIAL","name":"Iressa Study in Patients With Salivary Gland Cancer","canonical_id":"clinicaltrials.gov:NCT00509002","description":"Salivary Gland Cancer","metadata":null},{"id":"917128125be041ad83fff96c3aae7b6a","type":"DISEASE","name":"Iridocyclitis","canonical_id":"mesh:D015863","description":null,"metadata":null},{"id":"3930598f1d194c20893f91e592b3fae3","type":"DRUG","name":"Irinotecan","canonical_id":"ncit:C62040","description":null,"metadata":null},{"id":"1257b38990344acaafd71db731057c6c","type":"TRIAL","name":"Irinotecan Hydrochloride Liposome Injection (\u2161) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06603376","description":"Colorectal Carcinoma","metadata":null},{"id":"d3bb6b441dc348c2b454772ad658b1e5","type":"TRIAL","name":"Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT01767194","description":"Ganglioneuroblastoma; Recurrent Neuroblastoma","metadata":null},{"id":"ae9f5ea106c24450b6f0782eb41ec721","type":"TRIAL","name":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT03794349","description":"High Risk Neuroblastoma; Recurrent Neuroblastoma; Refractory Neuroblastoma","metadata":null},{"id":"afc57c0294e84fe59fb71694f6f0d5d0","type":"TRIAL","name":"Irinotecan Liposome\uff0cAlbumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT06513455","description":"Pancreatic Cancer","metadata":null},{"id":"3bf5797237d04c529f5f999112cb6771","type":"TRIAL","name":"Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00002902","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"0ec0a2a72f264f4fa894785e64be121d","type":"TRIAL","name":"Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial","canonical_id":"clinicaltrials.gov:NCT02319187","description":"Esophageal Neoplasms","metadata":null},{"id":"651d5a78dba34b7ea608b39dbb39c59c","type":"TRIAL","name":"Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma","canonical_id":"clinicaltrials.gov:NCT00287976","description":"Liver Cancer","metadata":null},{"id":"6473867d3a234b12a24ba985ee4f54b7","type":"TRIAL","name":"Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC","canonical_id":"clinicaltrials.gov:NCT00755534","description":"Colorectal Cancer","metadata":null},{"id":"9ac1e6392b2042f4acb420edfcb0b1b3","type":"TRIAL","name":"Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients","canonical_id":"clinicaltrials.gov:NCT07743034","description":"Benign Prostatic Hyperplasia; Tamsulosin; Silodosin; Intraoperative Floppy Iris Syndrome; Tomography, Optical Coherence; Iris Diseases","metadata":null},{"id":"29a65c242c364ff5a296d61528218ba2","type":"DISEASE","name":"Iritis","canonical_id":"mesh:D007500","description":null,"metadata":null},{"id":"bbaba480def740ab84407b02c42e8ddd","type":"DISEASE","name":"Iron deficiency anemia","canonical_id":"hp:0001891","description":null,"metadata":null},{"id":"8e7ee1058b144720aba52d7e1cb7e5ce","type":"DISEASE","name":"Iron deficiency anemia","canonical_id":"mesh:D018798","description":null,"metadata":null},{"id":"adf0856e5c4c4514a8b3fe1c5045090e","type":"DISEASE","name":"Iron overload","canonical_id":"mesh:D019190","description":null,"metadata":null},{"id":"555f116bdbe34ea2bd9193bbb3ce81f4","type":"TRIAL","name":"Irradiation Stent Placement Plus TACE for HCC and PVTT","canonical_id":"clinicaltrials.gov:NCT03730675","description":"Hepatocellular Carcinoma; Portal Vein Tumor Thrombosis","metadata":null},{"id":"1422a04dffff4012ae00262393f209e9","type":"DISEASE","name":"Irritability","canonical_id":"hp:0000737","description":null,"metadata":null},{"id":"704bbe9c5e0248d1b3bbff9174570207","type":"TRIAL","name":"Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine","canonical_id":"clinicaltrials.gov:NCT00880594","description":"Irritable Bowel Syndrome","metadata":null},{"id":"3cf516332ecb43668fdfa6b56d5f4ed3","type":"DISEASE","name":"Irritable bowel syndrome","canonical_id":"mesh:D043183","description":null,"metadata":null},{"id":"2c3049e1e71d4299a74eeb4be0b9bdcc","type":"TRIAL","name":"Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch","canonical_id":"clinicaltrials.gov:NCT02727205","description":"Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch","metadata":null},{"id":"bea55b2f4f26436aa9de6084428085c1","type":"TRIAL","name":"Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?","canonical_id":"clinicaltrials.gov:NCT03368066","description":"Adrenal Insufficiency; Cirrhosis; Spur Cell Anemia; Lecithin Acyltransferase Deficiency","metadata":null},{"id":"c1c3726dd5aa47f785c2cca9be61d9b6","type":"TRIAL","name":"Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries?","canonical_id":"clinicaltrials.gov:NCT05368376","description":"Hypotension Drug-Induced","metadata":null},{"id":"d3a7060219a84c38b14c2f076fe73e96","type":"TRIAL","name":"Is Levocetirizine Less Sedating Than Cetirizine?","canonical_id":"clinicaltrials.gov:NCT00826943","description":"Allergic Rhinitis","metadata":null},{"id":"947c0f07cf3542738826a62f40b0d575","type":"TRIAL","name":"Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?","canonical_id":"clinicaltrials.gov:NCT01437371","description":"Heart Failure","metadata":null},{"id":"f0143c1ac0054824a2308f86e9b3c47a","type":"TRIAL","name":"Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy","canonical_id":"clinicaltrials.gov:NCT00377091","description":"Pulmonary Embolism","metadata":null},{"id":"81590db3ce67462a91432a17d85628ad","type":"TRIAL","name":"Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?","canonical_id":"clinicaltrials.gov:NCT02040350","description":"Deaths","metadata":null},{"id":"e146721bca1547ca866c49ef645c801d","type":"TRIAL","name":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)","canonical_id":"clinicaltrials.gov:NCT04483739","description":"Multiple Myeloma","metadata":null},{"id":"152dc5ec004e42148458ee9b298421cc","type":"TRIAL","name":"Isa-Pom-Dex in Elderly/Frail Subjects With RRMM","canonical_id":"clinicaltrials.gov:NCT05911321","description":"Multiple Myeloma; Relapse; Refractory; Aging; Co-morbidity","metadata":null},{"id":"12c9307198574452bb967c6b89995c81","type":"TRIAL","name":"Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05123131","description":"Multiple Myeloma","metadata":null},{"id":"4bb99eebe48647fca570bd916642bdc5","type":"TRIAL","name":"Isa-VRD in TIE HRMM","canonical_id":"clinicaltrials.gov:NCT07334535","description":"Multiple Myeloma","metadata":null},{"id":"a8cab376f7d444068bd3e44281607580","type":"TRIAL","name":"Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells","canonical_id":"clinicaltrials.gov:NCT07732712","description":"Multiple Myeloma","metadata":null},{"id":"e8cdf9f89ca443129f81a5ca9134f0e3","type":"TRIAL","name":"Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma","canonical_id":"clinicaltrials.gov:NCT05346809","description":"Lymphoma; Multiple Myeloma; Non-Hodgkin Lymphoma; Relapsed Hodgkin's Disease, Adult","metadata":null},{"id":"6a32b645631e4136a85c73b6195b71b7","type":"TRIAL","name":"Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)","canonical_id":"clinicaltrials.gov:NCT02960555","description":"Smoldering Plasma Cell Myeloma","metadata":null},{"id":"824225e77c11424f8e93b689c0069ffb","type":"TRIAL","name":"Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis","canonical_id":"clinicaltrials.gov:NCT04943302","description":"Amyloidosis; Light Chain (AL) Amyloidosis","metadata":null},{"id":"e5688b57f1634251be5f0d1e7e413d22","type":"TRIAL","name":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT04754945","description":"AL Amyloidosis","metadata":null},{"id":"12f0fb366c71493cbf0c63020e1aefe8","type":"TRIAL","name":"Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients","canonical_id":"clinicaltrials.gov:NCT03194867","description":"Plasma Cell Myeloma","metadata":null},{"id":"cf9c00c525b143bc9f6378c0f81ea9e4","type":"TRIAL","name":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03860844","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia","metadata":null},{"id":"79b3140581a84be386c5d71912592985","type":"TRIAL","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT04270409","description":"Plasma Cell Myeloma","metadata":null},{"id":"5c573f908e744d43828681a932da500a","type":"TRIAL","name":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","canonical_id":"clinicaltrials.gov:NCT04643002","description":"Plasma Cell Myeloma Refractory","metadata":null},{"id":"76d2f52872274a798001d07484460ff3","type":"TRIAL","name":"Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT03367819","description":"Prostate Cancer; Non-small Cell Lung Cancer","metadata":null},{"id":"b0747bf751bf40b58c42d7fd9ee8bb40","type":"TRIAL","name":"Isatuximab in Lung Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT05862766","description":"Antibody-mediated Rejection; Allosensitization","metadata":null},{"id":"c1fc5701222c4050914da5444eab770d","type":"TRIAL","name":"Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance","canonical_id":"clinicaltrials.gov:NCT04614558","description":"Monoclonal Gammopathy","metadata":null},{"id":"3732fb326c9e424e9dd86b7a02fe6e8c","type":"TRIAL","name":"Isatuximab in Type I Cryoglobulinemia","canonical_id":"clinicaltrials.gov:NCT05114109","description":"Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance; Cryoglobulinemic Vasculitis","metadata":null},{"id":"9d3d4c15115147a8a316b53552ec7ee2","type":"TRIAL","name":"Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05922501","description":"Relapsed Cancer; Refractory Multiple Myeloma; Multiple Myeloma","metadata":null},{"id":"465cf27eb3fb446cb10ed172d1a87858","type":"TRIAL","name":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT04883242","description":"Recurrent Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"62251263c3d841bd8d9548aa95e51c4f","type":"TRIAL","name":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","canonical_id":"clinicaltrials.gov:NCT04653246","description":"Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Autologous Stem Cell Transplant","metadata":null},{"id":"de57ccb009024bc88d40097ac956f203","type":"TRIAL","name":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT04835129","description":"Multiple Myeloma","metadata":null},{"id":"84a0bdbff11c4f02ad4d8f2d78bbb5ea","type":"TRIAL","name":"Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease","canonical_id":"clinicaltrials.gov:NCT04912427","description":"Multiple Myeloma","metadata":null},{"id":"acd25ac4cf8c4e55b72da159511d417a","type":"GO_TERM","name":"IscS-IscU complex","canonical_id":"go:GO:1990330","description":"\"A heterotetrameric protein complex involved in the sulfur transfer during iron-sulfur cluster assembly and in the modification of tRNA wobble positions. In E. coli it consists of a central IscS dimer with the IscU protomers attached to one of the IscS units each via a disulfide (-SSH) group.\" [GOC:bhm, PMID:20404999]","metadata":null},{"id":"fa298a7691f74e20818b4fb18967a2d0","type":"GO_TERM","name":"IscS-TusA complex","canonical_id":"go:GO:1990329","description":"\"A heterotetrameric protein complex involved in the sulfur-relay system required for 2-thiolation of 5-methylaminomethyl-2-thiouridine (mnm5s2U) at tRNA wobble positions. In E. coli it consists of a central IscS dimer with the two TusA protomers bound to one of the IscS units each via persulfide (-SSH) groups.\" [GOC:bhm, PMID:20404999]","metadata":null},{"id":"30bd4e96d71b4ffca6e2ee942b9a0a8e","type":"DISEASE","name":"Ischemic heart disease","canonical_id":"mesh:D017202","description":null,"metadata":null},{"id":"57a4c914009144c8bd68ba9b3accfbed","type":"TRIAL","name":"Islet Allotransplantation With Steroid Free Immunosuppression","canonical_id":"clinicaltrials.gov:NCT00446264","description":"Type 1 Diabetes; Hypoglycemia; Metabolic Diseases","metadata":null},{"id":"480d716bb7bb4816ad7d88e12814eaac","type":"TRIAL","name":"Islet Transplantation Using Abatacept","canonical_id":"clinicaltrials.gov:NCT00276250","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"770cada25ce24e2cb41de0a303de27ae","type":"DISEASE","name":"Islet cell hyperplasia","canonical_id":"mesh:D046768","description":null,"metadata":null},{"id":"006da3e546d849c5984f2107dd018b46","type":"TRIAL","name":"Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women","canonical_id":"clinicaltrials.gov:NCT00244907","description":"Osteoporosis; Osteopenia","metadata":null},{"id":"1916c1f103854e538f4bab80af9834e8","type":"TRIAL","name":"Isolated Systolic Hypertension in the Elderly and Very Elderly","canonical_id":"clinicaltrials.gov:NCT00751829","description":"Isolated Systolic Hypertension","metadata":null},{"id":"3fc96c8459e845bebaa97adb6332d16f","type":"PROTEIN","name":"Isoleucine--tRNA ligase","canonical_id":"uniprot:41972","description":null,"metadata":null},{"id":"fd83447bf44c410bac58fa2f1354f60f","type":"DRUG","name":"Isoniazid","canonical_id":"mesh:D007538","description":null,"metadata":null},{"id":"13402f432d9c48f7a003040089dcdd3f","type":"DRUG","name":"Isoprenaline","canonical_id":"mesh:D007545","description":null,"metadata":null},{"id":"36e524227d1843beae4facff3400559f","type":"DRUG","name":"Isopropamide","canonical_id":"mesh:C084831","description":null,"metadata":null},{"id":"6cc6e321ef714b3db8247790aad06bee","type":"DRUG","name":"Isosorbide Dinitrate","canonical_id":"mesh:D007548","description":null,"metadata":null},{"id":"0faf7eae101e4b0e9c7ed3d940bbc773","type":"DRUG","name":"Isotretinoin","canonical_id":"mesh:D015474","description":null,"metadata":null},{"id":"98d155a7cb6f4de8aca3640d3d4cbe9d","type":"TRIAL","name":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT00026312","description":"Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma","metadata":null},{"id":"734c6295376a4e11b1f5bf482bc51273","type":"DRUG","name":"Isoxsuprine","canonical_id":"mesh:D007556","description":null,"metadata":null},{"id":"1e1eb8de28da423abc4c6e4b281fdd94","type":"GO_TERM","name":"Isp3 layer of spore wall","canonical_id":"go:GO:1990916","description":"\"The outermost layers of the spore wall, as described in Schizosaccharomyces pombe.\" [PMID:24623719]","metadata":null},{"id":"71f96bcc2511457586735da1324ddefb","type":"DRUG","name":"Isradipine","canonical_id":"mesh:D017275","description":null,"metadata":null},{"id":"9dfc058a5bc04bdd943b4c09ac2a73de","type":"DRUG","name":"Istradefylline","canonical_id":"mesh:C111599","description":null,"metadata":null},{"id":"91643df893824b3bb4057effab990734","type":"GO_TERM","name":"Isw1 complex","canonical_id":"go:GO:0016587","description":"\"A protein complex that contains an Isw1 subunit from the ISWI-family of ATPases and acts to modify chromatin structure.\" [GOC:krc, GOC:mah, PMID:15020051, PMID:15284901, PMID:16568949, PMID:21810179]","metadata":null},{"id":"3f0f034a2a894896a8e4fc7e4cea9fa3","type":"GO_TERM","name":"Isw1a complex","canonical_id":"go:GO:0036436","description":"\"An Isw1 complex that binds DNA and has nucleosome-stimulated ATPase activity. In S. cerevisiae, contains an Isw1p ATPase subunit in complex with Ioc3p.\" [GOC:jd, PMID:12482963]","metadata":null},{"id":"c247b2f1338c4152b913f226a29c0ff7","type":"GO_TERM","name":"Isw1b complex","canonical_id":"go:GO:0036437","description":"\"An Isw1 complex that binds DNA and has nucleosome-stimulated ATPase activity. In S. cerevisiae, contains an Isw1p ATPase subunit in complex with Ioc2p and Ioc4p.\" [GOC:jd, PMID:12482963]","metadata":null},{"id":"c92c43dd84d94403b077b33d4bfa1fa0","type":"DISEASE","name":"Itching of skin","canonical_id":"mesh:D011537","description":null,"metadata":null},{"id":"65cd1b9cc8744b2aa6d77d6af0c865b8","type":"DRUG","name":"Itraconazole","canonical_id":"mesh:D017964","description":null,"metadata":null},{"id":"97862bbf311a42258e92daf781cb1d73","type":"TRIAL","name":"Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support","canonical_id":"clinicaltrials.gov:NCT05594342","description":"Heart Failure; Cardiogenic Shock; Ischemic Heart Disease","metadata":null},{"id":"136e9558ccad4d7e9fe04e2d9c468e44","type":"TRIAL","name":"Ivabradine Versus Propranolol for Induced Hypotension in Endoscopic Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT04580342","description":"Hypotension","metadata":null},{"id":"c902d73658cd4d879b9f9d00bd838e0a","type":"DRUG","name":"Ivacaftor","canonical_id":"mesh:C545203","description":null,"metadata":null},{"id":"0a600917d4294b61ab28c16fb75e03fb","type":"TRIAL","name":"Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors","canonical_id":"clinicaltrials.gov:NCT04056910","description":"Advanced Solid Tumor; IDH1 Mutation; Glioma","metadata":null},{"id":"514c3efe425c408a8bb2f14ef340b6a9","type":"TRIAL","name":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","canonical_id":"clinicaltrials.gov:NCT06465953","description":"Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS); Myelodysplastic Syndromes (MDS)","metadata":null},{"id":"5bd8a026df33443abfde26542bc1affd","type":"TRIAL","name":"Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation","canonical_id":"clinicaltrials.gov:NCT03245424","description":"Acute Myeloid Leukemia; Relapsed Adult AML; Relapsed Pediatric AML","metadata":null},{"id":"c987fd0dc2e94d358f30f0a3af64325f","type":"TRIAL","name":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","canonical_id":"clinicaltrials.gov:NCT06501625","description":"Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation","metadata":null},{"id":"acc631336ad5473686ff141f243d0803","type":"TRIAL","name":"Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation","canonical_id":"clinicaltrials.gov:NCT06291987","description":"Myeloproliferative Neoplasms","metadata":null},{"id":"31750e0efd394ef9a2da58d5cd7cfb69","type":"TRIAL","name":"Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT03471260","description":"Acute Myeloid Leukemia; Hematopoietic and Lymphoid System Neoplasm; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"23bcbd24917b40ddad3d4751bf3caebd","type":"TRIAL","name":"Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS","canonical_id":"clinicaltrials.gov:NCT07607418","description":"AML (Acute Myeloid Leukemia); MDS (Myelodysplastic Syndrome)","metadata":null},{"id":"434e53e840904d72968a581c5b9999a3","type":"TRIAL","name":"Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1","canonical_id":"clinicaltrials.gov:NCT05030441","description":"Clonal Cytopenia of Undetermined Significance","metadata":null},{"id":"4c12128442f045928595f8be4414b99b","type":"TRIAL","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","canonical_id":"clinicaltrials.gov:NCT06127407","description":"Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen","metadata":null},{"id":"fee5bf2c3e73477caf3c16743d71024a","type":"TRIAL","name":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT05921760","description":"IDH1-mutant Cholangiocarcinoma","metadata":null},{"id":"ed523f2b77574d2697f7fa1029f60e37","type":"TRIAL","name":"Ixabepilone Administered as an Enteric Coated Formulation.","canonical_id":"clinicaltrials.gov:NCT00309049","description":"Cancer","metadata":null},{"id":"c749f68e05164fc59fc37ac7047476c9","type":"TRIAL","name":"Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00866905","description":"Breast Cancer","metadata":null},{"id":"b35f578bddf74e61b59cb974bfdd91fa","type":"TRIAL","name":"Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00765765","description":"Breast Cancer","metadata":null},{"id":"ccc5b1872c8b4e5b9fb8bea9589941bf","type":"TRIAL","name":"Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00096317","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"327c827230f14486bf55238e566032a5","type":"TRIAL","name":"Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00182767","description":"Fallopian Tube Cancer; Female Reproductive Cancer; Recurrent Breast Cancer; Recurrent Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Breast Cancer; Stage IV Ovarian Epithelial Cancer","metadata":null},{"id":"fd5d2457bdda405a923627742c1eaa23","type":"TRIAL","name":"Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT01375829","description":"Adult Solid Neoplasm","metadata":null},{"id":"8108d3836be64bd19e8826988e7ac3f0","type":"TRIAL","name":"Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT00877500","description":"Bilateral Breast Carcinoma; HER2/Neu Negative; Invasive Breast Carcinoma","metadata":null},{"id":"9549d9866d0e4e48b357aee580f1a4a6","type":"TRIAL","name":"Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors","canonical_id":"clinicaltrials.gov:NCT00070096","description":"Brain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor","metadata":null},{"id":"1128c5221e574cec8f2eae1402c165a5","type":"TRIAL","name":"Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT00021099","description":"Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer","metadata":null},{"id":"63c3fb1f84af403c89798c97eee3ab7e","type":"TRIAL","name":"Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT00033618","description":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of \u2026","metadata":null},{"id":"e7efaf748386493e87a174b7a88e8339","type":"TRIAL","name":"Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00182702","description":"Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer","metadata":null},{"id":"600eb56868a848da9ea5761018ab303a","type":"TRIAL","name":"Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00025155","description":"Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer","metadata":null},{"id":"f4fdbd705fd94daf8c7f0998641e7f5a","type":"TRIAL","name":"Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT00095979","description":"Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Stage IV Endometrial Carcinoma","metadata":null},{"id":"e4871a21594a4985871846237cfe5a6d","type":"TRIAL","name":"Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00058019","description":"Anaplastic Large Cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma","metadata":null},{"id":"6a7b191fed534d3783bbb1176dc92ab2","type":"TRIAL","name":"Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders","canonical_id":"clinicaltrials.gov:NCT00052572","description":"Leukemia; Lymphoma","metadata":null},{"id":"d039a977261643aab87fddf593f846f2","type":"DRUG","name":"Ixazomib","canonical_id":"mesh:C548400","description":null,"metadata":null},{"id":"4815911ead7f4a93a317927bba0bea34","type":"DRUG","name":"Ixazomib","canonical_id":"ncit:C97940","description":null,"metadata":null},{"id":"ecbac28d4cb3428f9e472f866302383c","type":"TRIAL","name":"Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission","canonical_id":"clinicaltrials.gov:NCT02632396","description":"Mantle Cell Lymphoma","metadata":null},{"id":"2e145abaa02d431292b79676010915d7","type":"TRIAL","name":"Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02030405","description":"Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13\u2026","metadata":null},{"id":"676113aead72448090612718aed97adf","type":"TRIAL","name":"Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT02420847","description":"Metastatic Urothelial Carcinoma; Transitional Cell Carcinoma; Unresectable Transitional Cell Carcinoma","metadata":null},{"id":"9537ef0a83f345b2bcff4132a636bfe9","type":"TRIAL","name":"Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02339922","description":"Chronic Lymphocytic Leukemia; Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia","metadata":null},{"id":"fd4d4e44218343758c1fc0b2214ccffb","type":"TRIAL","name":"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03012880","description":"Plasma Cell Myeloma","metadata":null},{"id":"cc833e1c36d9495d9cdc10ab7d396067","type":"TRIAL","name":"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone","canonical_id":"clinicaltrials.gov:NCT02516423","description":"Solitary Osseous Plasmacytoma","metadata":null},{"id":"e5396c4e693b41eca35944aa72aab893","type":"TRIAL","name":"Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome","canonical_id":"clinicaltrials.gov:NCT02921893","description":"Plasmacytoma; POEMS Syndrome","metadata":null},{"id":"2a61bfa0aee94160b7cc6dffc712b74d","type":"TRIAL","name":"Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03202628","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"6890e402afbf4130bae6b0f68eb7a2b0","type":"TRIAL","name":"Ixazomib Maintenance Study in Patients With AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT03618537","description":"AL Amyloidosis","metadata":null},{"id":"b0ffcd13d9d34adfb0e5eb3fe3ef1385","type":"TRIAL","name":"Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)","canonical_id":"clinicaltrials.gov:NCT03616782","description":"Mantle Cell Lymphoma","metadata":null},{"id":"a3c306d5d4b14df392ebe2cf7a279d40","type":"TRIAL","name":"Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05722405","description":"Multiple Myeloma","metadata":null},{"id":"a0a752c4524d4726bad9fa285fb9b4b6","type":"TRIAL","name":"Ixazomib Rollover Study","canonical_id":"clinicaltrials.gov:NCT02924272","description":"Multiple Myeloma; Lymphoma; Amyloidosis","metadata":null},{"id":"d1560b49c6a2496d8eaa2f10c10ca911","type":"TRIAL","name":"Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement","canonical_id":"clinicaltrials.gov:NCT02765854","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"7adfbc0fd9324c03ba835a9b38958fba","type":"TRIAL","name":"Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03856112","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma; t(11;14) Negative","metadata":null},{"id":"726ae48998814c61a9d50bd16b808bdc","type":"TRIAL","name":"Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment","canonical_id":"clinicaltrials.gov:NCT03770260","description":"Recurrent Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"11b7826a245340b3b02cd62573d0f32b","type":"TRIAL","name":"Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02542657","description":"Myeloma","metadata":null},{"id":"9f276a43582e45e9970dd910381483f5","type":"TRIAL","name":"Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02070458","description":"Recurrent Adult Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"1ef17a1b3794406b976e58dba1e50403","type":"TRIAL","name":"Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight","canonical_id":"clinicaltrials.gov:NCT06588283","description":"Psoriasis; Obesity","metadata":null},{"id":"ef16b0989dfd44fd9cbc9352335a4bd5","type":"TRIAL","name":"Ixekizumab Diabetes Intervention Trial (I-DIT)","canonical_id":"clinicaltrials.gov:NCT04589325","description":"Type1 Diabetes Mellitus","metadata":null},{"id":"4657201629124aaf99966320d66952ac","type":"TRIAL","name":"Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis","canonical_id":"clinicaltrials.gov:NCT06811558","description":"Over 70-year-old Patients with Psoriasis","metadata":null},{"id":"593480655a40423c89de4c071d33ee8e","type":"TRIAL","name":"Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris","canonical_id":"clinicaltrials.gov:NCT05030415","description":"Lichen Planus Scalp; Lichen Planus; Lichen Planopilaris","metadata":null},{"id":"b709fbd4eacc4312af9e596051701170","type":"TRIAL","name":"Ixekizumab in the Treatment of Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT03099538","description":"Bullous Pemphigoid; Pemphigoid","metadata":null},{"id":"509d5026e2d54d3280ff1e6de24c425f","type":"TRIAL","name":"Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)","canonical_id":"clinicaltrials.gov:NCT03485976","description":"Pityriasis Rubra Pilaris","metadata":null},{"id":"ab57fb831e6f4b56b629bae07b02c2f5","type":"DRUG","name":"Izorlisib","canonical_id":"ncit:C158603","description":null,"metadata":null},{"id":"8b51c5e272f7418a843465fe26307acf","type":"TRIAL","name":"J-LINX: Japan LINerixibat eXtension Study","canonical_id":"clinicaltrials.gov:NCT07860710","description":"Pruritus","metadata":null},{"id":"89c133fc7003498f8db3e44ca262e0d9","type":"GENE","name":"JADE1","canonical_id":"hgnc:HGNC:30027","description":"jade family PHD finger 1","metadata":{"aliases":["JADE-1","PHF17"]}},{"id":"b849260e1dec4eeba0f5eaae03d24e1b","type":"GENE","name":"JADE2","canonical_id":"hgnc:HGNC:22984","description":"jade family PHD finger 2","metadata":{"aliases":["KIAA0239","JADE-2","PHF15"]}},{"id":"cc3db914f3bd4912933008a2192a0e6a","type":"GENE","name":"JADE2-AS1","canonical_id":"hgnc:HGNC:59136","description":"JADE2 antisense RNA 1","metadata":null},{"id":"f5b17c158cc143678970948990bc845f","type":"GENE","name":"JADE3","canonical_id":"hgnc:HGNC:22982","description":"jade family PHD finger 3","metadata":{"aliases":["KIAA0215","JADE-3","PHF16"]}},{"id":"84a04d2cb6c04df2be0edda8dd134061","type":"GENE","name":"JADRR","canonical_id":"hgnc:HGNC:48601","description":"JADE1 adjacent regulatory RNA","metadata":{"aliases":["lncRNA-JADE","LINC00915"]}},{"id":"dcdcf90f68ba406194f0d8bbb888a5f0","type":"GENE","name":"JAG1","canonical_id":"hgnc:HGNC:6188","description":null,"metadata":null},{"id":"22bc252d66d240e08d6ef6d1f60a68ad","type":"GENE","name":"JAG2","canonical_id":"hgnc:HGNC:6189","description":"jagged canonical Notch ligand 2","metadata":null},{"id":"1fb6790ab0414061acff7dbe58b9445e","type":"GENE","name":"JAGN1","canonical_id":"hgnc:HGNC:26926","description":"jagunal vesicle mediated transporter 1","metadata":{"aliases":["GL009","FLJ14602"]}},{"id":"a4fd03dd71a44c7ba0f0f7216b1d5d0f","type":"TRIAL","name":"JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM","canonical_id":"clinicaltrials.gov:NCT04208464","description":"Idiopathic Inflammatory Myopathies","metadata":null},{"id":"ca05fa8353c5462882fca0108592e67f","type":"TRIAL","name":"JAK Inhibitor Dose TAPering Strategy Study","canonical_id":"clinicaltrials.gov:NCT06687551","description":"Rheumatoid Arthritis (RA","metadata":null},{"id":"81afe2671a0544d1a40652f04d7d07bf","type":"TRIAL","name":"JAK Inhibitor Treatment in AGS","canonical_id":"clinicaltrials.gov:NCT03921554","description":"Aicardi Goutieres Syndrome","metadata":null},{"id":"35e7b54d00d64486abe1b68bd4d89009","type":"TRIAL","name":"JAK Signaling in Depression and Cognition in Male Football Players","canonical_id":"clinicaltrials.gov:NCT07608796","description":"Depressive Symptoms; Cognitive Symptom","metadata":null},{"id":"e15bbfb9cb2b42868edfc94492651bee","type":"GO_TERM","name":"JAK pathway signal transduction adaptor activity","canonical_id":"go:GO:0008269","description":"\"The binding activity of a molecule that brings together two molecules of the JAK signal transduction pathway, permitting them to function in a coordinated way.\" [GOC:mtg_MIT_16mar07]","metadata":null},{"id":"d7d9fb3f156443b1abdc8735690f8571","type":"GENE","name":"JAK1","canonical_id":"hgnc:HGNC:6190","description":null,"metadata":null},{"id":"4a922495770b49169a303f5ae64d68df","type":"PROTEIN","name":"JAK1","canonical_id":"uniprot:P23458","description":null,"metadata":null},{"id":"1f4ac9f413834eb1a41e56caae451c98","type":"GENE","name":"JAK2","canonical_id":"hgnc:HGNC:6192","description":null,"metadata":null},{"id":"61cdaf4c86044bc1bdfcbbdf6f0830f2","type":"PROTEIN","name":"JAK2","canonical_id":"uniprot:O60674","description":null,"metadata":null},{"id":"ed495bc55ad24123ba6ca55ae5e1a4c6","type":"GENE","name":"JAK2","canonical_id":"ensembl:ENSG00000096968","description":null,"metadata":null},{"id":"42f0e5842bad4aa4849a090274a88060","type":"GENE","name":"JAK3","canonical_id":"hgnc:HGNC:6193","description":"Janus kinase 3","metadata":{"aliases":["L-JAK","JAKL","LJAK","JAK3_HUMAN","JAK-3"]}},{"id":"98b420e6dcbc43d68349dc2eda98b7da","type":"PROTEIN","name":"JAK3","canonical_id":"uniprot:P52333","description":null,"metadata":null},{"id":"4bc9be675a5a4487b12fe2f8a3e85d9a","type":"GENE","name":"JAKMIP1","canonical_id":"hgnc:HGNC:26460","description":"janus kinase and microtubule interacting protein 1","metadata":{"aliases":["MARLIN1","JAMIP1","Gababrbp","FLJ31564"]}},{"id":"b8d3b1c64c5f471ebb6ff2308b2cc688","type":"GENE","name":"JAKMIP1-AS1","canonical_id":"hgnc:HGNC:58721","description":"JAKMIP1 antisense RNA 1","metadata":null},{"id":"e32bcb56ebe84ebb9dfde8e50b63f728","type":"GENE","name":"JAKMIP1-DT","canonical_id":"hgnc:HGNC:27728","description":"JAKMIP1 divergent transcript","metadata":{"aliases":["LINC02495"]}},{"id":"cf2cd857afdb4fa99d3b1737848bbfb3","type":"GENE","name":"JAKMIP2","canonical_id":"hgnc:HGNC:29067","description":"janus kinase and microtubule interacting protein 2","metadata":{"aliases":["JAMIP2","KIAA0555"]}},{"id":"457f31cfa49040d2818a633f9d744665","type":"GENE","name":"JAKMIP2-AS1","canonical_id":"hgnc:HGNC:27203","description":"JAKMIP2 antisense RNA 1","metadata":null},{"id":"0e3c28dbc3414bc0972f1b3be3f0af52","type":"GENE","name":"JAKMIP2-AS2","canonical_id":"hgnc:HGNC:59275","description":"JAKMIP2 antisense RNA 2","metadata":null},{"id":"6219955209cc4197bc26d02278c20b65","type":"GENE","name":"JAKMIP3","canonical_id":"hgnc:HGNC:23523","description":"Janus kinase and microtubule interacting protein 3","metadata":{"aliases":["FLJ37857","NECC2","KIAA4091","bA140A10.5","C10orf39","C10orf14"]}},{"id":"95b563ee40a24056a384cd7d62bde9ab","type":"GENE","name":"JAKMIP3-AS1","canonical_id":"hgnc:HGNC:55678","description":"JAKMIP3 antisense RNA 1","metadata":null},{"id":"1e1e1dba8bbc4b678006b0626c5144fa","type":"GENE","name":"JAM2","canonical_id":"hgnc:HGNC:14686","description":"junctional adhesion molecule 2","metadata":{"aliases":["VE-JAM","JAM-B","JAMB","CD322","JAM-2","C21orf43"]}},{"id":"d703e753c2564b36ac339eedf0bf4624","type":"GENE","name":"JAM3","canonical_id":"hgnc:HGNC:15532","description":"junctional adhesion molecule 3","metadata":{"aliases":["JAM-C","JAMC","JAM-3"]}},{"id":"eb24f4089cc74df78c255c9591a6b95b","type":"GENE","name":"JAML","canonical_id":"hgnc:HGNC:19084","description":"junction adhesion molecule like","metadata":{"aliases":["Gm638","AMICA","AMICA1"]}},{"id":"c229756d2fd24539b76abcbb1ff1a632","type":"GENE","name":"JARID2","canonical_id":"hgnc:HGNC:6196","description":null,"metadata":null},{"id":"75682a7472814d7c8c656784838bca41","type":"GENE","name":"JARID2-AS1","canonical_id":"hgnc:HGNC:40314","description":"JARID2 antisense RNA 1","metadata":null},{"id":"87e8f793a1c0489b9cce299a6b7888ac","type":"GENE","name":"JARID2-DT","canonical_id":"hgnc:HGNC:55240","description":"JARID2 divergent transcript","metadata":null},{"id":"04cc772829c846f7bf7d3179c9ea289b","type":"TRIAL","name":"JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study","canonical_id":"clinicaltrials.gov:NCT06412848","description":"Urothelial Carcinoma","metadata":null},{"id":"64b0c5c9d45e4c1ebf6bd2aa87b039ff","type":"GENE","name":"JAZF1","canonical_id":"hgnc:HGNC:28917","description":"JAZF zinc finger 1","metadata":{"aliases":["TIP27","DKFZp761K2222","ZNF802"]}},{"id":"53750ffb94764ae1b6a5ea2d0ee91882","type":"GENE","name":"JAZF1-AS1","canonical_id":"hgnc:HGNC:41218","description":"JAZF1 antisense RNA 1","metadata":null},{"id":"d0c4aaeee26e45268c807af047d93091","type":"GENE","name":"JCAD","canonical_id":"hgnc:HGNC:29283","description":"junctional cadherin 5 associated","metadata":{"aliases":["KIAA1462"]}},{"id":"3f0117931ec143229bbad3d27aa9a74d","type":"GENE","name":"JCADP1","canonical_id":"hgnc:HGNC:54491","description":"JCAD pseudogene 1","metadata":null},{"id":"d03b72a6083e42d3a8cfe828ee243ff6","type":"GENE","name":"JCHAIN","canonical_id":"hgnc:HGNC:5713","description":null,"metadata":null},{"id":"68a03255b32c4241a90c52b457e2676c","type":"GENE","name":"JCHAINP1","canonical_id":"hgnc:HGNC:5714","description":"joining chain of multimeric IgA and IgM pseudogene 1","metadata":{"aliases":["IGJP1"]}},{"id":"acfdd00d9ab143929d15e46939e12df0","type":"TRIAL","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","canonical_id":"clinicaltrials.gov:NCT07175389","description":"Refractory Pancreatic Ductal Adenocarcinoma; Refractory Pancreatic Adenocarcinoma","metadata":null},{"id":"08305a3e7f8147948314bb9cc916934e","type":"GENE","name":"JDP2","canonical_id":"hgnc:HGNC:17546","description":null,"metadata":null},{"id":"74a0efcc584344018e13191d5ea855a3","type":"GENE","name":"JDP2-AS1","canonical_id":"hgnc:HGNC:55424","description":"JDP2 antisense RNA 1","metadata":null},{"id":"8be6f8852e9444b4bc03c0af13aec23f","type":"GENE","name":"JHY","canonical_id":"hgnc:HGNC:26288","description":"junctional cadherin complex regulator","metadata":{"aliases":["FLJ23554","C11orf63"]}},{"id":"fce9cf13552a46b39f46b0c3303d55f4","type":"TRIAL","name":"JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure","canonical_id":"clinicaltrials.gov:NCT07798921","description":"Carcinoma; Non-Small-Cell Lung","metadata":null},{"id":"645ebe5ad6fb4526a741f63c15759791","type":"GENE","name":"JKAMP","canonical_id":"hgnc:HGNC:20184","description":"JNK1/MAPK8 associated membrane protein","metadata":{"aliases":["HSPC213","JAMP","HSPC327","CDA06","C14orf100"]}},{"id":"fe1664643f6247a8b1b40ca497d86250","type":"GENE","name":"JKAMPP1","canonical_id":"hgnc:HGNC:49759","description":"JNK1/MAPK8-associated membrane protein pseudogene 1","metadata":null},{"id":"9faabcd02fac43899641567308c57876","type":"GENE","name":"JMJD1C","canonical_id":"hgnc:HGNC:12313","description":"jumonji domain containing 1C","metadata":{"aliases":["DKFZp761F0118","KIAA1380","FLJ14374","KDM3C","TRIP8"]}},{"id":"e32834e46aaa40d3805a1af2ba2dace8","type":"GENE","name":"JMJD1C-AS1","canonical_id":"hgnc:HGNC:28222","description":"JMJD1C antisense RNA 1","metadata":null},{"id":"9ccb0de82c0d4357a8d612bfc045e212","type":"GENE","name":"JMJD1C-AS2","canonical_id":"hgnc:HGNC:56170","description":"JMJD1C antisense RNA 2","metadata":null},{"id":"1d3b7d43231f4c90ba48e17e4c2ae3bb","type":"GENE","name":"JMJD4","canonical_id":"hgnc:HGNC:25724","description":"jumonji domain containing 4","metadata":{"aliases":["FLJ12517"]}},{"id":"92ceb0bd939c4a38b06bd572352669b0","type":"GENE","name":"JMJD4P1","canonical_id":"hgnc:HGNC:56520","description":"JMJD4 pseudogene 1","metadata":null},{"id":"fa0166b5c8bb4b4f92ecac84f6348059","type":"GENE","name":"JMJD6","canonical_id":"hgnc:HGNC:19355","description":"jumonji domain containing 6, arginine demethylase and lysine hydroxylase","metadata":{"aliases":["PTDSR1","KIAA0585","PTDSR"]}},{"id":"2fd22c84c94148239536d22d24928230","type":"GENE","name":"JMJD7","canonical_id":"hgnc:HGNC:34397","description":"jumonji domain containing 7","metadata":null},{"id":"47925c2de14843019918e0940057d7ea","type":"GENE","name":"JMJD7-PLA2G4B","canonical_id":"hgnc:HGNC:34449","description":"JMJD7-PLA2G4B readthrough","metadata":null},{"id":"b47f563c36ba4a1eba19433f0ec956b4","type":"GENE","name":"JMJD8","canonical_id":"hgnc:HGNC:14148","description":"jumonji domain containing 8","metadata":{"aliases":["C16orf20"]}},{"id":"5d8cbf3b97dd4451b528469336db4047","type":"GENE","name":"JMY","canonical_id":"hgnc:HGNC:28916","description":"junction mediating and regulatory protein, p53 cofactor","metadata":{"aliases":["FLJ37870","WHAMM2"]}},{"id":"bf5b4534dd644e1ba81810334573e586","type":"GO_TERM","name":"JNK cascade","canonical_id":"go:GO:0007254","description":"\"A MAPK cascade containing at least the JNK (MAPK8) MAP kinase. It starts with the activation of JUN3K (a MAPK3K), which activates JNKK a MAP2K), which in turn activates JNK. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinases in the downstream tier. The JNK cascade is activated by stress signals, as well as by G protein-coupled receptors, growth factors, and cytokines, and results in cellular responses such as cell proliferation, cell differentiation, apoptosis and inflammation.\" [PMID:11790549, PMID:20811974, PMID:23125017]","metadata":null},{"id":"ec17efdd06194d5c9f37dcce89b71d36","type":"GENE","name":"JOSD1","canonical_id":"hgnc:HGNC:28953","description":"Josephin domain containing 1","metadata":{"aliases":["KIAA0063"]}},{"id":"523e609866ae47efb90fac8959ce9d8b","type":"GENE","name":"JOSD2","canonical_id":"hgnc:HGNC:28853","description":"Josephin domain containing 2","metadata":{"aliases":["SBBI54"]}},{"id":"d038119cdd4146f198982dd4413df4fa","type":"TRIAL","name":"JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis","canonical_id":"clinicaltrials.gov:NCT05443984","description":"Erosive Esophagitis","metadata":null},{"id":"0c4e83ceda9c49adb1b3a12afa69ee75","type":"TRIAL","name":"JP-1730 to Treat Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00040209","description":"Parkinson Disease","metadata":null},{"id":"fc7056d7e5af4a3b855a5f40f52eeeb4","type":"GENE","name":"JPH1","canonical_id":"hgnc:HGNC:14201","description":"junctophilin 1","metadata":{"aliases":["JP-1","JP1"]}},{"id":"9ad5a536c45b41dba565f5873ddf40d5","type":"GENE","name":"JPH2","canonical_id":"hgnc:HGNC:14202","description":"junctophilin 2","metadata":{"aliases":["JP-2","JP2"]}},{"id":"cd73f6ab74bd477dadacbb852071fa1e","type":"GENE","name":"JPH3","canonical_id":"hgnc:HGNC:14203","description":"junctophilin 3","metadata":{"aliases":["JP-3","CAGL237","HDL2","JP3","TNRC22"]}},{"id":"9dfc772db28b43c1b123aa8d3f4f0949","type":"GENE","name":"JPH4","canonical_id":"hgnc:HGNC:20156","description":"junctophilin 4","metadata":{"aliases":["KIAA1831","JP4","JPHL1"]}},{"id":"252e0c9e087640bba78d4882e8c66cd7","type":"GENE","name":"JPT1","canonical_id":"hgnc:HGNC:14569","description":"Jupiter microtubule associated homolog 1","metadata":{"aliases":["ARM2","HN1A","HN1"]}},{"id":"80f26cce40224d7e922f71edab0515fd","type":"GENE","name":"JPT1P1","canonical_id":"hgnc:HGNC:54768","description":"JPT1 pseudogene 1","metadata":null},{"id":"2d55f2a5a52b4203be2467a6d4642a90","type":"GENE","name":"JPT2","canonical_id":"hgnc:HGNC:14137","description":"Jupiter microtubule associated homolog 2","metadata":{"aliases":["FLJ13092","L11","KIAA1426","C16orf34","HN1L"]}},{"id":"55cdaa5084da42eda2cf629d3d7a2744","type":"GENE","name":"JPX","canonical_id":"hgnc:HGNC:37191","description":"JPX transcript, XIST activator","metadata":{"aliases":["ENOX","LINC00183","DCBALD06","NCRNA00183"]}},{"id":"f0d42904ee5c4703a65dc0303d22288c","type":"GENE","name":"JRK","canonical_id":"hgnc:HGNC:6199","description":"Jrk helix-turn-helix protein","metadata":{"aliases":["JH8","jerky"]}},{"id":"3434999ad2464bc09b82d01e066c2428","type":"GENE","name":"JRKL","canonical_id":"hgnc:HGNC:6200","description":"JRK like","metadata":{"aliases":["HHMJG"]}},{"id":"7b585d9188ab48d49b75a02eb2fb1779","type":"GENE","name":"JRKL-AS1","canonical_id":"hgnc:HGNC:43670","description":"JRKL antisense RNA 1","metadata":null},{"id":"b1fd8271aabc49018b396b283b500825","type":"TRIAL","name":"JSKN003 Combined Treatment of HER2-positive Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06998771","description":"HER2-positive Gastric Cancer","metadata":null},{"id":"dbdf0da49b95410291f6435cc5fc2b8d","type":"TRIAL","name":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan","canonical_id":"clinicaltrials.gov:NCT07384377","description":"HER2-positive Colorectal Cancer","metadata":null},{"id":"00ee461feb3b45108b06c7c5edff092c","type":"TRIAL","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06846437","description":"Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants","metadata":null},{"id":"da049470652b4455b9afae3bcd92b81f","type":"TRIAL","name":"JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT07797153","description":"Recurrent or Metastatic Cervical Cancer","metadata":null},{"id":"a4e9209d992f49e1909954f47ed0ad5d","type":"GENE","name":"JSRP1","canonical_id":"hgnc:HGNC:24963","description":"junctional sarcoplasmic reticulum protein 1","metadata":{"aliases":["JP-45","FLJ32416"]}},{"id":"884e4410f05445a19aacdd4448ff7d3e","type":"GENE","name":"JTB","canonical_id":"hgnc:HGNC:6201","description":"jumping translocation breakpoint","metadata":{"aliases":["hJT","PAR"]}},{"id":"52df890d5676406881c376e1c9d3bcd2","type":"GENE","name":"JTB-DT","canonical_id":"hgnc:HGNC:56047","description":"JTB divergent transcript","metadata":null},{"id":"631f845c95924402a197ec2fe1398a12","type":"GENE","name":"JTBP1","canonical_id":"hgnc:HGNC:39180","description":"jumping translocation breakpoint pseudogene 1","metadata":null},{"id":"7e175b9aa5894994a85fc6dd35d92581","type":"GENE","name":"JUN","canonical_id":"hgnc:HGNC:6204","description":null,"metadata":null},{"id":"f5ccf63587da4a6082c3452c604849aa","type":"GO_TERM","name":"JUN kinase activity","canonical_id":"go:GO:0004705","description":"\"Catalysis of the reaction: JUN + ATP = JUN phosphate + ADP. This reaction is the phosphorylation and activation of members of the JUN family, a gene family that encodes nuclear transcription factors.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"06d62b755a22423d8caf9fe9cf9ab26a","type":"GO_TERM","name":"JUN kinase binding","canonical_id":"go:GO:0008432","description":"\"Binding to JUN kinase, an enzyme that catalyzes the phosphorylation and activation of members of the JUN family.\" [GOC:jl]","metadata":null},{"id":"ecd0f0149d4a45d89ef02788164e4de7","type":"GO_TERM","name":"JUN kinase kinase activity","canonical_id":"go:GO:0008545","description":"\"Catalysis of the phosphorylation of tyrosine and threonine residues in a c-Jun NH2-terminal kinase (JNK), a member of a subgroup of mitogen-activated protein kinases (MAPKs), which signal in response to cytokines and exposure to environmental stress. JUN kinase kinase (JNKK) is a dual-specificity protein kinase kinase and requires activation by a serine/threonine kinase JUN kinase kinase kinase.\" [GOC:bf, PMID:11057897, PMID:11790549]","metadata":null},{"id":"48035b18d8cf4463af13ef6d6879a373","type":"GO_TERM","name":"JUN kinase kinase kinase activity","canonical_id":"go:GO:0004706","description":"\"Catalysis of the reaction: JNKK + ATP = JNKK phosphate + ADP. This reaction is the phosphorylation and activation of JUN kinase kinases (JNKKs).\" [GOC:bf]","metadata":null},{"id":"081905edf2164ee8bfd81cb62fdac0a9","type":"GO_TERM","name":"JUN kinase kinase kinase kinase activity","canonical_id":"go:GO:0042656","description":"\"Catalysis of the phosphorylation and activation of JUN kinase kinase kinases (JNKKKs).\" [GOC:bf]","metadata":null},{"id":"4e4f896130c6428daadaeef09b9b0224","type":"GO_TERM","name":"JUN kinase phosphatase activity","canonical_id":"go:GO:0008579","description":"\"Catalysis of the reaction: JUN kinase serine/threonine/tyrosine phosphate + H2O = JUN kinase serine/threonine/tyrosine + phosphate.\" [GOC:mah]","metadata":null},{"id":"b7b2c82bf2374dafa0c37609b126de3c","type":"GO_TERM","name":"JUN phosphorylation","canonical_id":"go:GO:0007258","description":"\"The process of introducing a phosphate group into a JUN protein.\" [GOC:jl]","metadata":null},{"id":"6d8f05a6ff7745b880b1666e97040574","type":"GENE","name":"JUN-DT","canonical_id":"hgnc:HGNC:49450","description":"JUN divergent transcript","metadata":{"aliases":["LINC01135","LINC01358"]}},{"id":"5c79b936c1ed47f7824b32e31f0dad3b","type":"GENE","name":"JUNB","canonical_id":"hgnc:HGNC:6205","description":null,"metadata":null},{"id":"8d525130e7f8469fae289e0644e60f03","type":"GENE","name":"JUND","canonical_id":"hgnc:HGNC:6206","description":null,"metadata":null},{"id":"5c887f09a0ee436ca6da90f1dc79be89","type":"GENE","name":"JUP","canonical_id":"hgnc:HGNC:6207","description":null,"metadata":null},{"id":"87b973670fb34fbf8ac5de72eb098c92","type":"DISEASE","name":"Jackson-Weiss syndrome","canonical_id":"mondo:0007400","description":null,"metadata":null},{"id":"ee7a417e43af431e8eaef49f2320cdc6","type":"TRIAL","name":"Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)","canonical_id":"clinicaltrials.gov:NCT05743244","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"20a236b6386a4cbbb9dfe02f0033722e","type":"TRIAL","name":"Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03071770","description":"Healthy","metadata":null},{"id":"169eeff17e8a477090ddf384ea5496cb","type":"DISEASE","name":"Joint pain","canonical_id":"mesh:D018771","description":null,"metadata":null},{"id":"58aef8640759409e830bbedf72870c85","type":"TRIAL","name":"Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT05110157","description":"Schizophrenia","metadata":null},{"id":"224b5f211ed048fc8b92e5ffad7c61df","type":"TRIAL","name":"Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)","canonical_id":"clinicaltrials.gov:NCT01636687","description":"Plaque-type Psoriasis","metadata":null},{"id":"0341cf6631224dcda0a4a52b9d077955","type":"TRIAL","name":"Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica","canonical_id":"clinicaltrials.gov:NCT07279688","description":"Polymyalgia Rheumatica (PMR)","metadata":null},{"id":"29a09563c88e47638dc7a7dfa48b8c77","type":"DISEASE","name":"Juvenile rheumatoid arthritis","canonical_id":"mesh:D001171","description":null,"metadata":null},{"id":"0c82df2f4e434a9389669820252f407e","type":"GO_TERM","name":"K antigen biosynthetic process","canonical_id":"go:GO:0009248","description":"\"The chemical reactions and pathways resulting in the formation of a K antigen, a capsular polysaccharide antigen carried on the surface of bacterial capsules that masks somatic (O) antigens.\" [ISBN:0198506732]","metadata":null},{"id":"eefd328ef79444abaf71a1e244e6ea36","type":"DRUG","name":"K-115","canonical_id":"mesh:C584679","description":null,"metadata":null},{"id":"d02dbf13cfa5494999581c9df83969fc","type":"GO_TERM","name":"K11-linked deubiquitinase activity","canonical_id":"go:GO:0180017","description":"\"Hydrolysis of a ubiquitin unit from a ubiquitinated protein linked via the Lys11 residue of ubiquitin.\" [PMID:26412298]","metadata":null},{"id":"525d04e689854d149b6c2139494d7134","type":"GO_TERM","name":"K11-linked polyubiquitin modification-dependent protein binding","canonical_id":"go:GO:0071795","description":"\"Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 11 in the target protein.\" [GOC:sp, PMID:18775313]","metadata":null},{"id":"1a64266a175d46fbbb135835af592ed3","type":"GO_TERM","name":"K48-linked deubiquitinase activity","canonical_id":"go:GO:1990380","description":"\"Hydrolysis of a ubiquitin unit from a ubiquitinated protein linked via the Lys48 residue of ubiquitin.\" [GOC:bf, GOC:PARL, PMID:22970133]","metadata":null},{"id":"a534dd0d745441b8aa8bd9921aaa7b39","type":"GO_TERM","name":"K48-linked polyubiquitin modification-dependent protein binding","canonical_id":"go:GO:0036435","description":"\"Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 48 in the target protein.\" [GOC:al, PMID:20739285]","metadata":null},{"id":"8efd66f4dc9243cb86c07fc95a94405b","type":"GO_TERM","name":"K6-linked polyubiquitin modification-dependent protein binding","canonical_id":"go:GO:0071796","description":"\"Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 6 in the target protein.\" [GOC:sp, PMID:17525341, PMID:20351172]","metadata":null},{"id":"61e00bedad6c4f81817642daa800ee76","type":"GO_TERM","name":"K63-linked deubiquitinase activity","canonical_id":"go:GO:0061578","description":"\"Hydrolysis of a ubiquitin unit from a ubiquitinated protein linked via the Lys63 residue of ubiquitin.\" [GOC:dph, GOC:pg, PMID:18313383]","metadata":null},{"id":"af02a86cbe1b4ffd8a8052deb56c524a","type":"GO_TERM","name":"K63-linked polyubiquitin modification-dependent protein binding","canonical_id":"go:GO:0070530","description":"\"Binding to a protein upon poly-ubiquitination formed by linkages between lysine residues at position 63 in the target protein.\" [GOC:mah, PMID:15556404, PMID:17525341]","metadata":null},{"id":"d4e5de49ae55444ba8152b7b51b2ec05","type":"GENE","name":"KAAG1","canonical_id":"hgnc:HGNC:21031","description":"kidney associated DCDC2 antisense RNA 1","metadata":{"aliases":["RU2","RU2AS"]}},{"id":"8a01aba05523432d9142b1ebda3ca453","type":"GENE","name":"KALRN","canonical_id":"hgnc:HGNC:4814","description":"kalirin RhoGEF kinase","metadata":{"aliases":["duo","Hs.8004","TRAD","DUET","Kalirin","ARHGEF24","KALNC2","HAPIP"]}},{"id":"6ba2d099b2cd4bceb212d405ad468bf6","type":"GENE","name":"KANGD1","canonical_id":"hgnc:HGNC:59231","description":"kanga transposable element derived 1","metadata":null},{"id":"6d560cac5cc04b3f852f7527e75888aa","type":"GENE","name":"KANK1","canonical_id":"hgnc:HGNC:19309","description":"KN motif and ankyrin repeat domains 1","metadata":{"aliases":["KIAA0172","KANK","ANKRD15"]}},{"id":"bf6fc5fd039b4abe98e207f580c1f098","type":"GENE","name":"KANK1-AS1","canonical_id":"hgnc:HGNC:58139","description":"KANK1 antisense RNA 1","metadata":null},{"id":"74df7a05d16c4ddf9c9fab8d7ceebc35","type":"GENE","name":"KANK1P1","canonical_id":"hgnc:HGNC:52337","description":"KN motif and ankyrin repeat domains 1 pseudogene 1","metadata":null},{"id":"f4161a9aa2e044279f817f7de0e74119","type":"GENE","name":"KANK2","canonical_id":"hgnc:HGNC:29300","description":"KN motif and ankyrin repeat domains 2","metadata":{"aliases":["KIAA1518","SIP","MXRA3","ANKRD25"]}},{"id":"7f93319a54aa49e89eb11849156522cb","type":"GENE","name":"KANK3","canonical_id":"hgnc:HGNC:24796","description":"KN motif and ankyrin repeat domains 3","metadata":{"aliases":["FLJ46061","ANKRD47"]}},{"id":"524697070049483c8a4c0c3a7c803921","type":"GENE","name":"KANK4","canonical_id":"hgnc:HGNC:27263","description":"KN motif and ankyrin repeat domains 4","metadata":{"aliases":["KIAA0172","ANKRD38"]}},{"id":"1d1c25215971403380b95276b7e14da1","type":"GENE","name":"KANSL1","canonical_id":"hgnc:HGNC:24565","description":"KAT8 regulatory NSL complex subunit 1","metadata":{"aliases":["DKFZP727C091","MSL1v1","CENP-36","NSL1","KIAA1267"]}},{"id":"6381442d29cd4209ae5b8df0a3766c40","type":"GENE","name":"KANSL1-AS1","canonical_id":"hgnc:HGNC:43740","description":"KANSL1 antisense RNA 1","metadata":null},{"id":"8a9f837d34574253aa3ec91915ae9857","type":"GENE","name":"KANSL1L","canonical_id":"hgnc:HGNC:26310","description":"KAT8 regulatory NSL complex subunit 1 like","metadata":{"aliases":["FLJ23861","FLJ32349","MSL1v2","KIAA1267L","C2orf67"]}},{"id":"43df9f160897469b972b9751e6442b4f","type":"GENE","name":"KANSL1L-AS1","canonical_id":"hgnc:HGNC:41139","description":"KANSL1L antisense RNA 1","metadata":null},{"id":"787123790c60492aa481f12219a9b007","type":"GENE","name":"KANSL2","canonical_id":"hgnc:HGNC:26024","description":"KAT8 regulatory NSL complex subunit 2","metadata":{"aliases":["FLJ20436","NSL2","C12orf41"]}},{"id":"057d6df1a80d4311a2ae74650ce0424a","type":"GENE","name":"KANSL3","canonical_id":"hgnc:HGNC:25473","description":"KAT8 regulatory NSL complex subunit 3","metadata":{"aliases":["FLJ10081","Rcd1","NSL3","KIAA1310"]}},{"id":"1b3524e5b5614f6d985de4fd88f1a07f","type":"GENE","name":"KANTR","canonical_id":"hgnc:HGNC:49510","description":"KANTR integral membrane protein","metadata":{"aliases":["Spasm","LINC01155"]}},{"id":"a7da1c76f3cb4abc8d93646ca21142f1","type":"GENE","name":"KARS1","canonical_id":"hgnc:HGNC:6215","description":"lysyl-tRNA synthetase 1","metadata":{"aliases":["KARS2","DFNB89","KARS"]}},{"id":"28180cefaf394dd39aa1eae6e01f11f8","type":"GENE","name":"KARS1P1","canonical_id":"hgnc:HGNC:39207","description":"lysyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["KARSP1"]}},{"id":"7566e9fec5ae41f3890bb6df253abd71","type":"GENE","name":"KARS1P2","canonical_id":"hgnc:HGNC:39208","description":"lysyl-tRNA synthetase 1 pseudogene 2","metadata":{"aliases":["KARSP2"]}},{"id":"f6c929eb6fae4c4d87281cda00f243ad","type":"GENE","name":"KARS1P3","canonical_id":"hgnc:HGNC:39209","description":"lysyl-tRNA synthetase 1 pseudogene 3","metadata":{"aliases":["KARSP3"]}},{"id":"6a1ddf3ffc5b4aeeb4a796cb00b812f9","type":"GENE","name":"KASH5","canonical_id":"hgnc:HGNC:26520","description":"KASH domain containing 5","metadata":{"aliases":["FLJ32658","CCDC155"]}},{"id":"3c71515109404328b9faa7c5c97902f1","type":"GENE","name":"KAT14","canonical_id":"hgnc:HGNC:15904","description":"lysine acetyltransferase 14","metadata":{"aliases":["CRP2BP","dJ717M23.1","PRO1194","ATAC2","CSRP2BP"]}},{"id":"2ee4c67ffb25449c8768314144e7d345","type":"GENE","name":"KAT2A","canonical_id":"hgnc:HGNC:4201","description":"lysine acetyltransferase 2A","metadata":{"aliases":["GCN5","PCAF-b","GCN5L2"]}},{"id":"6507f276e5e244b29d05998c51f04729","type":"GENE","name":"KAT2B","canonical_id":"hgnc:HGNC:8638","description":null,"metadata":null},{"id":"796eba87739247d0878c2f92e56d83e7","type":"GENE","name":"KAT5","canonical_id":"hgnc:HGNC:5275","description":null,"metadata":null},{"id":"91e84dd25c6b49f4bcec1e54714b4520","type":"GENE","name":"KAT6A","canonical_id":"hgnc:HGNC:13013","description":null,"metadata":null},{"id":"22323fe5af1e4d7a8efcd73f2d38a9d6","type":"GENE","name":"KAT6A-AS1","canonical_id":"hgnc:HGNC:56157","description":"KAT6A antisense RNA 1","metadata":null},{"id":"cef964e3f9cd42788a4d662faea7c5b0","type":"GENE","name":"KAT6B","canonical_id":"hgnc:HGNC:17582","description":"lysine acetyltransferase 6B","metadata":{"aliases":["querkopf","qkf","Morf","MOZ2","MYST4"]}},{"id":"2caa1121bbb14a6fb3f3889d2c4f5450","type":"GENE","name":"KAT7","canonical_id":"hgnc:HGNC:17016","description":"lysine acetyltransferase 7","metadata":{"aliases":["HBOA","HBO1","MYST2"]}},{"id":"b1aa6b49ea1a4afbae8faebbb3cec1a8","type":"GENE","name":"KAT7P1","canonical_id":"hgnc:HGNC:55026","description":"KAT7 pseudogene 1","metadata":null},{"id":"c5d7603d35414913a28267fb50c0e8f5","type":"GENE","name":"KAT8","canonical_id":"hgnc:HGNC:17933","description":"lysine acetyltransferase 8","metadata":{"aliases":["MOF","FLJ14040","hMOF","MYST1"]}},{"id":"826d913aed834b7caea2b75998007016","type":"GENE","name":"KATNA1","canonical_id":"hgnc:HGNC:6216","description":"katanin catalytic subunit A1","metadata":null},{"id":"870b889afc5642b6b1ac6fd9ff662159","type":"GENE","name":"KATNAL1","canonical_id":"hgnc:HGNC:28361","description":"katanin catalytic subunit A1 like 1","metadata":{"aliases":["MGC2599"]}},{"id":"c31a40e92c0c44689f3a473cf8df0b4b","type":"GENE","name":"KATNAL2","canonical_id":"hgnc:HGNC:25387","description":"katanin catalytic subunit A1 like 2","metadata":{"aliases":["MGC33211","DKFZP667C165"]}},{"id":"2ecafe37d51247fc8ab7a87867409d49","type":"GENE","name":"KATNB1","canonical_id":"hgnc:HGNC:6217","description":"katanin regulatory subunit B1","metadata":null},{"id":"8e8e42ba5f274b6faa2d074a0ab4750b","type":"GENE","name":"KATNBL1","canonical_id":"hgnc:HGNC:26199","description":"katanin regulatory subunit B1 like 1","metadata":{"aliases":["FLJ22557","C15orf29"]}},{"id":"df714c3ca65f47c3b6c2c80d7c97c46e","type":"GENE","name":"KATNBL1P1","canonical_id":"hgnc:HGNC:39724","description":"katanin regulatory subunit B1 like 1 pseudogene 1","metadata":null},{"id":"bf6b4f972690409c947eaee08897c6f1","type":"GENE","name":"KATNBL1P2","canonical_id":"hgnc:HGNC:49052","description":"katanin regulatory subunit B1 like 1 pseudogene 2","metadata":null},{"id":"29d0e22e60c54647a9f364a40a86127a","type":"GENE","name":"KATNBL1P3","canonical_id":"hgnc:HGNC:49053","description":"katanin regulatory subunit B1 like 1 pseudogene 3","metadata":null},{"id":"a02332bfe5d542b3bc679aca23196ca8","type":"GENE","name":"KATNBL1P4","canonical_id":"hgnc:HGNC:49054","description":"katanin regulatory subunit B1 like 1 pseudogene 4","metadata":null},{"id":"bf4a845a63bc4daba6dda4d8af19bb6d","type":"GENE","name":"KATNBL1P5","canonical_id":"hgnc:HGNC:49055","description":"katanin regulatory subunit B1 like 1 pseudogene 5","metadata":null},{"id":"577da286eabe4531813cf3c8866bd7f1","type":"GENE","name":"KATNBL1P6","canonical_id":"hgnc:HGNC:49056","description":"katanin regulatory subunit B1 like 1 pseudogene 6","metadata":null},{"id":"41f25214a00d4641a586495806155471","type":"GENE","name":"KATNIP","canonical_id":"hgnc:HGNC:29068","description":"katanin interacting protein","metadata":{"aliases":["JBTS26","KIAA0556"]}},{"id":"95d02442e81e449facfd9c71377488a3","type":"GENE","name":"KAZALD1","canonical_id":"hgnc:HGNC:25460","description":"Kazal type serine peptidase inhibitor domain 1","metadata":{"aliases":["FKSG40","FKSG28"]}},{"id":"c7c953034cd4449683ddcdba910afabb","type":"GENE","name":"KAZALD1-DT","canonical_id":"hgnc:HGNC:58985","description":"KAZALD1 divergent transcript","metadata":{"aliases":["Lnc-PDZD7-3"]}},{"id":"dd877ce8092447fcb715dd61c2358126","type":"GENE","name":"KAZN","canonical_id":"hgnc:HGNC:29173","description":"kazrin, periplakin interacting protein","metadata":{"aliases":["KIAA1026","KAZRIN","FLJ43806","C1orf196"]}},{"id":"db56f4d6ba32423f8dadffc1561d023d","type":"GENE","name":"KAZN-AS1","canonical_id":"hgnc:HGNC:53610","description":"KAZN antisense RNA 1","metadata":{"aliases":["ENST00000447908"]}},{"id":"36ff2a7d029f450884bae160e47c5deb","type":"GENE","name":"KBTBD11","canonical_id":"hgnc:HGNC:29104","description":"kelch repeat and BTB domain containing 11","metadata":{"aliases":["KIAA0711","KLHDC7C"]}},{"id":"4b5fdd6e9dc249be8f5af1505ca398fa","type":"GENE","name":"KBTBD11-AS1","canonical_id":"hgnc:HGNC:55530","description":"KBTBD11 antisense RNA 1","metadata":null},{"id":"19a9eccc87f44261a9f64fcb9aeaa6ed","type":"GENE","name":"KBTBD11-OT1","canonical_id":"hgnc:HGNC:49147","description":"KBTBD11 overlapping transcript 1","metadata":null},{"id":"57ab41bfb34e4fc3912bee42c26f6be1","type":"GENE","name":"KBTBD12","canonical_id":"hgnc:HGNC:25731","description":"kelch repeat and BTB domain containing 12","metadata":{"aliases":["FLJ46299","KLHDC6"]}},{"id":"2884b45b3c2d4d72874fb72511c2535f","type":"GENE","name":"KBTBD13","canonical_id":"hgnc:HGNC:37227","description":"kelch repeat and BTB domain containing 13","metadata":{"aliases":["hCG_1645727","NEM6"]}},{"id":"b5b71c060e8c457ba60573bc001895e9","type":"GENE","name":"KBTBD2","canonical_id":"hgnc:HGNC:21751","description":"kelch repeat and BTB domain containing 2","metadata":{"aliases":["DKFZP566C134","BKLHD1"]}},{"id":"edf96db955d040d299fd9465f536a3ad","type":"GENE","name":"KBTBD3","canonical_id":"hgnc:HGNC:22934","description":"kelch repeat and BTB domain containing 3","metadata":{"aliases":["BKLHD3"]}},{"id":"dd55111678334ab289dc2346511fc57c","type":"GENE","name":"KBTBD4","canonical_id":"hgnc:HGNC:23761","description":"kelch repeat and BTB domain containing 4","metadata":{"aliases":["FLJ10450","HSPC252","BKLHD4"]}},{"id":"e3b679299d0b447c8014cf5d9f1ded56","type":"GENE","name":"KBTBD6","canonical_id":"hgnc:HGNC:25340","description":"kelch repeat and BTB domain containing 6","metadata":{"aliases":["DKFZp547E1912"]}},{"id":"a528253b3bf84405b80ba454ff9d9b80","type":"GENE","name":"KBTBD6-DT","canonical_id":"hgnc:HGNC:56824","description":"KBTBD6 divergent transcript","metadata":{"aliases":["AL354696.2"]}},{"id":"cd3b37ad19d544e4b88d631c27b6298a","type":"GENE","name":"KBTBD7","canonical_id":"hgnc:HGNC:25266","description":"kelch repeat and BTB domain containing 7","metadata":{"aliases":["DKFZP434E2318"]}},{"id":"95a954f756534cce967b75c70c31afee","type":"GENE","name":"KBTBD8","canonical_id":"hgnc:HGNC:30691","description":"kelch repeat and BTB domain containing 8","metadata":{"aliases":["TA-KRP","KIAA1842"]}},{"id":"a3605c4d5a80403c93c344f92967099a","type":"GENE","name":"KCMF1","canonical_id":"hgnc:HGNC:20589","description":"potassium channel modulatory factor 1","metadata":{"aliases":["DEBT91","PCMF","DKFZP434L1021","ZZZ1"]}},{"id":"e5e3704173ef48119e7bdce058f1777f","type":"GENE","name":"KCNA1","canonical_id":"hgnc:HGNC:6218","description":"potassium voltage-gated channel subfamily A member 1","metadata":{"aliases":["Kv1.1","RBK1","HUK1","MBK1","AEMK"]}},{"id":"88c55ff888034d1793f676d4292a27d0","type":"GENE","name":"KCNA10","canonical_id":"hgnc:HGNC:6219","description":"potassium voltage-gated channel subfamily A member 10","metadata":{"aliases":["Kv1.8"]}},{"id":"72bb0f1dd90c4c058c94da120d2c9d8b","type":"GENE","name":"KCNA2","canonical_id":"hgnc:HGNC:6220","description":"potassium voltage-gated channel subfamily A member 2","metadata":{"aliases":["Kv1.2","HK4"]}},{"id":"2c8cb39e684343a3b1b1eba13f557204","type":"GENE","name":"KCNA3","canonical_id":"hgnc:HGNC:6221","description":"potassium voltage-gated channel subfamily A member 3","metadata":{"aliases":["Kv1.3","MK3","HLK3","HPCN3","RP11-284N8.3"]}},{"id":"d275f2a510a44bb78054c7387c981015","type":"GENE","name":"KCNA4","canonical_id":"hgnc:HGNC:6222","description":"potassium voltage-gated channel subfamily A member 4","metadata":{"aliases":["Kv1.4","HK1","HPCN2","PCN2","KCNA4L"]}},{"id":"1c9a9ccbf64746139b3d87adbc4589a4","type":"GENE","name":"KCNA5","canonical_id":"hgnc:HGNC:6224","description":"potassium voltage-gated channel subfamily A member 5","metadata":{"aliases":["Kv1.5","HK2","HPCN1"]}},{"id":"dbff5241d895487fa5aad0f05e9a911f","type":"GENE","name":"KCNA6","canonical_id":"hgnc:HGNC:6225","description":"potassium voltage-gated channel subfamily A member 6","metadata":{"aliases":["Kv1.6","HBK2","PPP1R96"]}},{"id":"5839492effa94922b49d5dcd4dfdb623","type":"GENE","name":"KCNA6-AS1","canonical_id":"hgnc:HGNC:58276","description":"KCNA6 antisense RNA 1","metadata":null},{"id":"cd28abe9d1d24539b1d1275603c2d8fd","type":"GENE","name":"KCNA7","canonical_id":"hgnc:HGNC:6226","description":"potassium voltage-gated channel subfamily A member 7","metadata":{"aliases":["Kv1.7","HAK6"]}},{"id":"f58a7295bada4b13af868ef8cfd7f61b","type":"GENE","name":"KCNAB1","canonical_id":"hgnc:HGNC:6228","description":"potassium voltage-gated channel subfamily A regulatory beta subunit 1","metadata":{"aliases":["AKR6A3","KCNA1B","hKvBeta3","Kvb1.3","hKvb3"]}},{"id":"2b4cf01da9da4c51b52c7b80228722e0","type":"GENE","name":"KCNAB1-AS1","canonical_id":"hgnc:HGNC:40316","description":"KCNAB1 antisense RNA 1","metadata":null},{"id":"a9e2b584cd0f465ca5fa040ab66ac817","type":"GENE","name":"KCNAB1-AS2","canonical_id":"hgnc:HGNC:40315","description":"KCNAB1 antisense RNA 2","metadata":null},{"id":"2be9accb83764bf9a31ae628bd2f415d","type":"GENE","name":"KCNAB2","canonical_id":"hgnc:HGNC:6229","description":"potassium voltage-gated channel subfamily A regulatory beta subunit 2","metadata":{"aliases":["AKR6A5","KCNA2B","HKvbeta2.1","HKvbeta2.2"]}},{"id":"8baaf109e96441eab42cd1562cbfe5cb","type":"GENE","name":"KCNAB3","canonical_id":"hgnc:HGNC:6230","description":"potassium voltage-gated channel subfamily A regulatory beta subunit 3","metadata":{"aliases":["AKR6A9","KCNA3B"]}},{"id":"cbde038ab60b4a78b7e8aabdf5e2b675","type":"GENE","name":"KCNB1","canonical_id":"hgnc:HGNC:6231","description":"potassium voltage-gated channel subfamily B member 1","metadata":{"aliases":["Kv2.1"]}},{"id":"498d4c04b39a4d9ea1a1fe710610d09b","type":"GENE","name":"KCNB2","canonical_id":"hgnc:HGNC:6232","description":"potassium voltage-gated channel subfamily B member 2","metadata":{"aliases":["Kv2.2"]}},{"id":"913884ab2a8f483f88ab02027ad6e9b9","type":"GENE","name":"KCNB2-AS1","canonical_id":"hgnc:HGNC:58256","description":"KCNB2 antisense RNA 1","metadata":null},{"id":"447003f1dde74a34abe316adb6cd7150","type":"GENE","name":"KCNC1","canonical_id":"hgnc:HGNC:6233","description":"potassium voltage-gated channel subfamily C member 1","metadata":{"aliases":["Kv3.1"]}},{"id":"cb898b0d54e54b7fb2fd1cabee06319c","type":"GENE","name":"KCNC2","canonical_id":"hgnc:HGNC:6234","description":"potassium voltage-gated channel subfamily C member 2","metadata":{"aliases":["Kv3.2"]}},{"id":"87c39b53ad9a479a8215556a07021bfb","type":"GENE","name":"KCNC3","canonical_id":"hgnc:HGNC:6235","description":"potassium voltage-gated channel subfamily C member 3","metadata":{"aliases":["Kv3.3","SCA13"]}},{"id":"2bacc09a709448f7bce53624eff6c123","type":"GENE","name":"KCNC4","canonical_id":"hgnc:HGNC:6236","description":"potassium voltage-gated channel subfamily C member 4","metadata":{"aliases":["Kv3.4","HKSHIIIC","C1orf30"]}},{"id":"9e0b52f90b4f40aea18b28e378f4b2b7","type":"GENE","name":"KCNC4-DT","canonical_id":"hgnc:HGNC:39958","description":"KCNC4 divergent transcript","metadata":{"aliases":["KCNC4-AS1","LINC02586"]}},{"id":"3398c3f76e374877ac4d826fbe1f9e99","type":"GENE","name":"KCND1","canonical_id":"hgnc:HGNC:6237","description":"potassium voltage-gated channel subfamily D member 1","metadata":{"aliases":["Kv4.1"]}},{"id":"19c3338ffa6548b0be316eee2f2fc64d","type":"GENE","name":"KCND2","canonical_id":"hgnc:HGNC:6238","description":"potassium voltage-gated channel subfamily D member 2","metadata":{"aliases":["Kv4.2","RK5","KIAA1044"]}},{"id":"87a816657f2f49f381a29b98b3266d70","type":"GENE","name":"KCND3","canonical_id":"hgnc:HGNC:6239","description":"potassium voltage-gated channel subfamily D member 3","metadata":{"aliases":["Kv4.3","KSHIVB","SCA22","SCA19"]}},{"id":"c3935caf2f9c461281f49a8bf455ccbe","type":"GENE","name":"KCND3-AS1","canonical_id":"hgnc:HGNC:40317","description":"KCND3 antisense RNA 1","metadata":null},{"id":"281c0858159844f6b628778a46921506","type":"GENE","name":"KCND3-IT1","canonical_id":"hgnc:HGNC:41350","description":"KCND3 intronic transcript 1","metadata":null},{"id":"ad944ba9d7d444558edd4c4f15cc33c0","type":"GENE","name":"KCNE1","canonical_id":"hgnc:HGNC:6240","description":"potassium voltage-gated channel subfamily E regulatory subunit 1","metadata":{"aliases":["minK","IsK","JLNS2","LQT5"]}},{"id":"16cbff17287243b29c73f11c8e9a01cf","type":"GENE","name":"KCNE2","canonical_id":"hgnc:HGNC:6242","description":"potassium voltage-gated channel subfamily E regulatory subunit 2","metadata":{"aliases":["MiRP1","LQT6"]}},{"id":"532e6efc1cc4491a81976bde90001d07","type":"GENE","name":"KCNE3","canonical_id":"hgnc:HGNC:6243","description":"potassium voltage-gated channel subfamily E regulatory subunit 3","metadata":{"aliases":["MiRP2","HOKPP"]}},{"id":"27348121e31d47289793d6b032ba0f25","type":"GENE","name":"KCNE4","canonical_id":"hgnc:HGNC:6244","description":"potassium voltage-gated channel subfamily E regulatory subunit 4","metadata":{"aliases":["MiRP3"]}},{"id":"d6b2884308de41f7a3c5e322a12dcd11","type":"GENE","name":"KCNE5","canonical_id":"hgnc:HGNC:6241","description":"potassium voltage-gated channel subfamily E regulatory subunit 5","metadata":{"aliases":["KCNE1L"]}},{"id":"d828e1661dba47839846bc8699c1418f","type":"GENE","name":"KCNF1","canonical_id":"hgnc:HGNC:6246","description":"potassium voltage-gated channel modifier subfamily F member 1","metadata":{"aliases":["Kv5.1","kH1","IK8","KCNF"]}},{"id":"3f268cd99b364ebd8ca6172999d5cd06","type":"GENE","name":"KCNG1","canonical_id":"hgnc:HGNC:6248","description":"potassium voltage-gated channel modifier subfamily G member 1","metadata":{"aliases":["Kv6.1","kH2","K13","KCNG"]}},{"id":"2383ee5968c64ea69cfe37b654ca73da","type":"GENE","name":"KCNG2","canonical_id":"hgnc:HGNC:6249","description":"potassium voltage-gated channel modifier subfamily G member 2","metadata":{"aliases":["Kv6.2","KCNF2"]}},{"id":"9cd756e778074631bb6739718b817424","type":"GENE","name":"KCNG3","canonical_id":"hgnc:HGNC:18306","description":"potassium voltage-gated channel modifier subfamily G member 3","metadata":{"aliases":["Kv6.3"]}},{"id":"aa70818794a940ad81203c48a8c98004","type":"GENE","name":"KCNG4","canonical_id":"hgnc:HGNC:19697","description":"potassium voltage-gated channel modifier subfamily G member 4","metadata":{"aliases":["Kv6.4"]}},{"id":"aacd34b316c8409897e1d6795e85bbc1","type":"GENE","name":"KCNH1","canonical_id":"hgnc:HGNC:6250","description":"potassium voltage-gated channel subfamily H member 1","metadata":{"aliases":["Kv10.1","eag","h-eag","eag1","hEAG","K(V)10.1"]}},{"id":"cf11b69ff7e04641908b1f0b947a1134","type":"GENE","name":"KCNH1-IT1","canonical_id":"hgnc:HGNC:41351","description":"KCNH1 intronic transcript 1","metadata":null},{"id":"86079f3782644c419ef7bd7b51a46966","type":"GENE","name":"KCNH2","canonical_id":"hgnc:HGNC:6251","description":null,"metadata":null},{"id":"6e1d4ae8f04b4b948aaa805163518a11","type":"PROTEIN","name":"KCNH2","canonical_id":"uniprot:Q12809","description":null,"metadata":null},{"id":"0110ad2fd8fc49cbb001251b77fca608","type":"GENE","name":"KCNH3","canonical_id":"hgnc:HGNC:6252","description":"potassium voltage-gated channel subfamily H member 3","metadata":{"aliases":["Kv12.2","BEC1","elk2"]}},{"id":"4445d133c9944468a4d44517eb884f29","type":"GENE","name":"KCNH4","canonical_id":"hgnc:HGNC:6253","description":"potassium voltage-gated channel subfamily H member 4","metadata":{"aliases":["Kv12.3","elk1"]}},{"id":"5bf6da22efdd4677b7fcb372343d7038","type":"GENE","name":"KCNH5","canonical_id":"hgnc:HGNC:6254","description":"potassium voltage-gated channel subfamily H member 5","metadata":{"aliases":["Kv10.2","H-EAG2","eag2","hEAG2"]}},{"id":"e29910f5f43f47648e12b573282e6877","type":"GENE","name":"KCNH6","canonical_id":"hgnc:HGNC:18862","description":"potassium voltage-gated channel subfamily H member 6","metadata":{"aliases":["Kv11.2","erg2","HERG2"]}},{"id":"ace2d8f6c37e462ab86d34e7a6ea32b6","type":"GENE","name":"KCNH7","canonical_id":"hgnc:HGNC:18863","description":"potassium voltage-gated channel subfamily H member 7","metadata":{"aliases":["Kv11.3","HERG3","erg3"]}},{"id":"b5eca5f62d4a4194b2093c4e8b9bde48","type":"GENE","name":"KCNH7-AS1","canonical_id":"hgnc:HGNC:40858","description":"KCNH7 antisense RNA 1","metadata":null},{"id":"b6fa1428390a42cd96a49205d427c489","type":"GENE","name":"KCNH8","canonical_id":"hgnc:HGNC:18864","description":"potassium voltage-gated channel subfamily H member 8","metadata":{"aliases":["Kv12.1","elk3"]}},{"id":"4ca079c8c9844b6a82d2379f6ccdd397","type":"GENE","name":"KCNIP1","canonical_id":"hgnc:HGNC:15521","description":"potassium voltage-gated channel interacting protein 1","metadata":{"aliases":["KCHIP1"]}},{"id":"c203788b62b1485baa441b78106bec92","type":"GENE","name":"KCNIP1-AS1","canonical_id":"hgnc:HGNC:40710","description":"KCNIP1 antisense RNA 1","metadata":null},{"id":"6171636f85f544058f9f0eb721998259","type":"GENE","name":"KCNIP1-AS2","canonical_id":"hgnc:HGNC:40709","description":"KCNIP1 antisense RNA 2","metadata":null},{"id":"a87a3512ecb643f3b1cbdd2ea1a361e3","type":"GENE","name":"KCNIP1-OT1","canonical_id":"hgnc:HGNC:40320","description":"KCNIP1 overlapping transcript 1","metadata":null},{"id":"7022f1d0fd1549c5be50cfa801bc5871","type":"GENE","name":"KCNIP2","canonical_id":"hgnc:HGNC:15522","description":"potassium voltage-gated channel interacting protein 2","metadata":{"aliases":["KCHIP2"]}},{"id":"75cd06a455b24ee194cda859feedcde3","type":"GENE","name":"KCNIP2-AS1","canonical_id":"hgnc:HGNC:48680","description":"KCNIP2 antisense RNA 1","metadata":null},{"id":"b1ffd36f6ad649b68511c191320292b5","type":"GENE","name":"KCNIP3","canonical_id":"hgnc:HGNC:15523","description":null,"metadata":null},{"id":"1b225f6f56aa48afbefa7ce80884a819","type":"GENE","name":"KCNIP4","canonical_id":"hgnc:HGNC:30083","description":"potassium voltage-gated channel interacting protein 4","metadata":{"aliases":["CALP","KCHIP4","MGC44947"]}},{"id":"8da857a0487c4e9a8a708df9e3665bed","type":"GENE","name":"KCNIP4-AS1","canonical_id":"hgnc:HGNC:41256","description":"KCNIP4 antisense RNA 1","metadata":null},{"id":"50e491e0b5e746c49faecb51db1da307","type":"GENE","name":"KCNIP4-AS2","canonical_id":"hgnc:HGNC:41255","description":"KCNIP4 antisense RNA 2","metadata":null},{"id":"07f9a5bb5bcc4bcd9679e2e04efbff6e","type":"GENE","name":"KCNIP4-AS3","canonical_id":"hgnc:HGNC:41254","description":"KCNIP4 antisense RNA 3","metadata":null},{"id":"600a1dfb4d1d41fa89e52cc527eba8d4","type":"GENE","name":"KCNIP4-DT","canonical_id":"hgnc:HGNC:58742","description":"KCNIP4 divergent transcript","metadata":null},{"id":"a1b6938fff9546c887d96bdc9baff69b","type":"GENE","name":"KCNIP4-IT1","canonical_id":"hgnc:HGNC:29895","description":"KCNIP4 intronic transcript 1","metadata":{"aliases":["UM9-5","NCRNA00099"]}},{"id":"1c3074a1cc8a484d8260bc5db6dcada6","type":"GENE","name":"KCNJ1","canonical_id":"hgnc:HGNC:6255","description":"potassium inwardly rectifying channel subfamily J member 1","metadata":{"aliases":["Kir1.1","ROMK1"]}},{"id":"5ee8997fd848402da4c43c093784290c","type":"GENE","name":"KCNJ10","canonical_id":"hgnc:HGNC:6256","description":"potassium inwardly rectifying channel subfamily J member 10","metadata":{"aliases":["Kir4.1","Kir1.2"]}},{"id":"b417ede11410411fb46d2dccb62e5244","type":"GENE","name":"KCNJ11","canonical_id":"hgnc:HGNC:6257","description":null,"metadata":null},{"id":"b70c88069ba24e93b56ae80014e66234","type":"PROTEIN","name":"KCNJ11","canonical_id":"uniprot:Q14654","description":null,"metadata":null},{"id":"c74c166511a04808a507306272c59e30","type":"GENE","name":"KCNJ12","canonical_id":"hgnc:HGNC:6258","description":"potassium inwardly rectifying channel subfamily J member 12","metadata":{"aliases":["Kir2.2","Kir2.2v","IRK2","hIRK1","KCNJN1"]}},{"id":"0afb47dc67804e5bb0689e4a9c550f8c","type":"GENE","name":"KCNJ13","canonical_id":"hgnc:HGNC:6259","description":"potassium inwardly rectifying channel subfamily J member 13","metadata":{"aliases":["Kir7.1","Kir1.4","LCA16"]}},{"id":"4a6a0decf8dc4b60b589b25a25e16455","type":"GENE","name":"KCNJ14","canonical_id":"hgnc:HGNC:6260","description":"potassium inwardly rectifying channel subfamily J member 14","metadata":{"aliases":["Kir2.4","IRK4"]}},{"id":"06d9a4e05fc14db5b63181c8a2078d3b","type":"GENE","name":"KCNJ15","canonical_id":"hgnc:HGNC:6261","description":"potassium inwardly rectifying channel subfamily J member 15","metadata":{"aliases":["Kir4.2","Kir1.3","IRKK"]}},{"id":"e1ff7121bb0145329910b87b62b6b86c","type":"GENE","name":"KCNJ16","canonical_id":"hgnc:HGNC:6262","description":"potassium inwardly rectifying channel subfamily J member 16","metadata":{"aliases":["Kir5.1","BIR9"]}},{"id":"132b26dea00a436c8acefb5809d09754","type":"GENE","name":"KCNJ18","canonical_id":"hgnc:HGNC:39080","description":"potassium inwardly rectifying channel subfamily J member 18","metadata":{"aliases":["KIR2.6","TTPP2"]}},{"id":"1393bc7df80c4a36a011627c7ac85cd5","type":"GENE","name":"KCNJ2","canonical_id":"hgnc:HGNC:6263","description":"potassium inwardly rectifying channel subfamily J member 2","metadata":{"aliases":["Kir2.1","IRK1","LQT7"]}},{"id":"343e07b4e9ed44728cd16083f302d831","type":"GENE","name":"KCNJ2-AS1","canonical_id":"hgnc:HGNC:43720","description":"KCNJ2 antisense RNA 1","metadata":{"aliases":["FLJ36644"]}},{"id":"3317a969ffcf407cba4cc4db61a1fafa","type":"GENE","name":"KCNJ3","canonical_id":"hgnc:HGNC:6264","description":"potassium inwardly rectifying channel subfamily J member 3","metadata":{"aliases":["Kir3.1","GIRK1","KGA"]}},{"id":"d7f42ed6745f49dfa389bbae986e88b7","type":"GENE","name":"KCNJ4","canonical_id":"hgnc:HGNC:6265","description":"potassium inwardly rectifying channel subfamily J member 4","metadata":{"aliases":["Kir2.3","HIR","HRK1","hIRK2","IRK3"]}},{"id":"9cdb7690b0f647f8947f19d7bd08b1ed","type":"GENE","name":"KCNJ5","canonical_id":"hgnc:HGNC:6266","description":"potassium inwardly rectifying channel subfamily J member 5","metadata":{"aliases":["Kir3.4","CIR","KATP1","GIRK4","LQT13"]}},{"id":"6f8d7d236b7744c9baa0c4b4169952d9","type":"GENE","name":"KCNJ5-AS1","canonical_id":"hgnc:HGNC:28584","description":"KCNJ5 antisense RNA 1","metadata":{"aliases":["MGC35558","FLJ43646","C11orf45"]}},{"id":"70a4b44b91f64d7899afe647ed65e0c0","type":"GENE","name":"KCNJ6","canonical_id":"hgnc:HGNC:6267","description":"potassium inwardly rectifying channel subfamily J member 6","metadata":{"aliases":["Kir3.2","GIRK2","KATP2","BIR1","hiGIRK2","KCNJ7"]}},{"id":"8b900c7760d14e5ba87029a31b3d4cd1","type":"GENE","name":"KCNJ6-AS1","canonical_id":"hgnc:HGNC:41352","description":"KCNJ6 antisense RNA 1","metadata":{"aliases":["KCNJ6-IT1"]}},{"id":"d391c66af95547edb3c4c7dbcc496a96","type":"GENE","name":"KCNJ8","canonical_id":"hgnc:HGNC:6269","description":"potassium inwardly rectifying channel subfamily J member 8","metadata":{"aliases":["Kir6.1"]}},{"id":"736a44f6ba234a49a5f8736123488f7a","type":"GENE","name":"KCNJ8-AS1","canonical_id":"hgnc:HGNC:58193","description":"KCNJ8 antisense RNA 1","metadata":null},{"id":"330e26e34b184fd4b4178956889b8803","type":"GENE","name":"KCNJ9","canonical_id":"hgnc:HGNC:6270","description":"potassium inwardly rectifying channel subfamily J member 9","metadata":{"aliases":["Kir3.3","GIRK3"]}},{"id":"fbaad25791e14c10a1474bd3ae03a1a3","type":"GENE","name":"KCNK1","canonical_id":"hgnc:HGNC:6272","description":"potassium two pore domain channel subfamily K member 1","metadata":{"aliases":["K2p1.1","DPK","TWIK-1"]}},{"id":"b653dd5d20514e6eb9033fa576f3a840","type":"GENE","name":"KCNK10","canonical_id":"hgnc:HGNC:6273","description":"potassium two pore domain channel subfamily K member 10","metadata":{"aliases":["K2p10.1","TREK-2","TREK2","PPP1R97"]}},{"id":"9eb4369b5e474792b0a59116abd78a7e","type":"PROTEIN","name":"KCNK10","canonical_id":"uniprot:P57789","description":null,"metadata":null},{"id":"ccaddf4b4d064cee85ba4aa9706da2be","type":"GENE","name":"KCNK10-AS1","canonical_id":"hgnc:HGNC:58074","description":"KCNK10 antisense RNA 1","metadata":{"aliases":["AL133279.1"]}},{"id":"55760ec197e84be0b05a059d1bc0118f","type":"GENE","name":"KCNK12","canonical_id":"hgnc:HGNC:6274","description":"potassium two pore domain channel subfamily K member 12","metadata":{"aliases":["THIK-2","THIK2","K2p12.1"]}},{"id":"c4a7a3efd16e4cd09555883dcb07c7a9","type":"GENE","name":"KCNK13","canonical_id":"hgnc:HGNC:6275","description":"potassium two pore domain channel subfamily K member 13","metadata":{"aliases":["K2p13.1","THIK-1","THIK1"]}},{"id":"eb1c233f462443d997ba0eb09c510d1f","type":"GENE","name":"KCNK15","canonical_id":"hgnc:HGNC:13814","description":"potassium two pore domain channel subfamily K member 15","metadata":{"aliases":["K2p15.1","dJ781B1.1","KT3.3","KIAA0237","TASK5","TASK-5","KCNK11","KCNK14"]}},{"id":"97791961173b4c31bc0c29f7b59d190c","type":"GENE","name":"KCNK15-AS1","canonical_id":"hgnc:HGNC:49901","description":"KCNK15 and WISP2 antisense RNA 1","metadata":{"aliases":["RP11-445H22.4","LINC01260"]}},{"id":"89d54a58e05144e08df407214b81f751","type":"GENE","name":"KCNK16","canonical_id":"hgnc:HGNC:14464","description":"potassium two pore domain channel subfamily K member 16","metadata":{"aliases":["K2p16.1","TALK-1","TALK1"]}},{"id":"ba7f251d29934d329e029dd987a90576","type":"GENE","name":"KCNK17","canonical_id":"hgnc:HGNC:14465","description":"potassium two pore domain channel subfamily K member 17","metadata":{"aliases":["K2p17.1","TALK-2","TALK2","TASK4","TASK-4"]}},{"id":"625102b94e974cafa1c96774a8fb9fbd","type":"GENE","name":"KCNK18","canonical_id":"hgnc:HGNC:19439","description":"potassium two pore domain channel subfamily K member 18","metadata":{"aliases":["K2p18.1","TRESK-2","TRESK2","TRESK","TRIK"]}},{"id":"80d4f233976f4a779c2e890c5762fe04","type":"PROTEIN","name":"KCNK18","canonical_id":"uniprot:Q7Z418","description":null,"metadata":null},{"id":"331b6ea26cc94e65bc41737bf92b89f1","type":"GENE","name":"KCNK2","canonical_id":"hgnc:HGNC:6277","description":"potassium two pore domain channel subfamily K member 2","metadata":{"aliases":["K2p2.1","TREK-1"]}},{"id":"f6b37a155c56462392f2a1ca4f2fd91e","type":"PROTEIN","name":"KCNK2","canonical_id":"uniprot:O95069","description":null,"metadata":null},{"id":"b0dddeb7d9eb4660848de20d5572d3d8","type":"GENE","name":"KCNK3","canonical_id":"hgnc:HGNC:6278","description":"potassium two pore domain channel subfamily K member 3","metadata":{"aliases":["K2p3.1","TASK","TASK-1","TASK1"]}},{"id":"020bd53cf0cb45f8a23a3dbb298b0b7a","type":"PROTEIN","name":"KCNK3","canonical_id":"uniprot:O14649","description":null,"metadata":null},{"id":"f3ef89a209d64427a6d630b0635291c5","type":"GENE","name":"KCNK4","canonical_id":"hgnc:HGNC:6279","description":"potassium two pore domain channel subfamily K member 4","metadata":{"aliases":["K2p4.1","TRAAK"]}},{"id":"e8fcdc6240fb47eb9a0a08fdf3a021bc","type":"GENE","name":"KCNK4-CATSPERZ","canonical_id":"hgnc:HGNC:56753","description":"KCNK4-CATSPERZ readthrough (NMD candidate)","metadata":null},{"id":"5bc811b5ebd4432682f19d5d730d1378","type":"GENE","name":"KCNK5","canonical_id":"hgnc:HGNC:6280","description":"potassium two pore domain channel subfamily K member 5","metadata":{"aliases":["K2p5.1","TASK-2","TASK2"]}},{"id":"3fdda2fcb8b5430bb4d89d7adf79a6eb","type":"GENE","name":"KCNK6","canonical_id":"hgnc:HGNC:6281","description":"potassium two pore domain channel subfamily K member 6","metadata":{"aliases":["K2p6.1","TWIK-2"]}},{"id":"b6ac6a54de904ae1bfe45ad969f3b774","type":"GENE","name":"KCNK7","canonical_id":"hgnc:HGNC:6282","description":"potassium two pore domain channel subfamily K member 7","metadata":{"aliases":["K2p7.1"]}},{"id":"28fc16f6cd4243cc96aaa0a2f5809738","type":"GENE","name":"KCNK9","canonical_id":"hgnc:HGNC:6283","description":"potassium two pore domain channel subfamily K member 9","metadata":{"aliases":["K2p9.1","TASK3","TASK-3"]}},{"id":"66803a734a22442b9c093089e9ad5d10","type":"PROTEIN","name":"KCNK9","canonical_id":"uniprot:Q9NPC2","description":null,"metadata":null},{"id":"cf5353e7e0e14b6799dc6462ee19f858","type":"GENE","name":"KCNMA1","canonical_id":"hgnc:HGNC:6284","description":null,"metadata":null},{"id":"2caed73811cd4d409f102de704272278","type":"GENE","name":"KCNMA1-AS1","canonical_id":"hgnc:HGNC:51213","description":"KCNMA1 antisense RNA 1","metadata":null},{"id":"237c9d1897cc45f2b4e4488b2deab3e9","type":"GENE","name":"KCNMA1-AS2","canonical_id":"hgnc:HGNC:51214","description":"KCNMA1 antisense RNA 2","metadata":null},{"id":"d0ab40ece8f14920be8028e194af14de","type":"GENE","name":"KCNMA1-AS3","canonical_id":"hgnc:HGNC:51215","description":"KCNMA1 antisense RNA 3","metadata":null},{"id":"2e3ffe10d74c4db28e203aa0ccc40f11","type":"GENE","name":"KCNMB1","canonical_id":"hgnc:HGNC:6285","description":"potassium calcium-activated channel subfamily M regulatory beta subunit 1","metadata":{"aliases":["hslo-beta"]}},{"id":"437e73eba309451c80b33bd2a753e7a6","type":"GENE","name":"KCNMB2","canonical_id":"hgnc:HGNC:6286","description":"potassium calcium-activated channel subfamily M regulatory beta subunit 2","metadata":null},{"id":"cad9c52c52984c4881b1ffe7604f2a75","type":"GENE","name":"KCNMB2-AS1","canonical_id":"hgnc:HGNC:51409","description":"KCNMB2 antisense RNA 1","metadata":{"aliases":["RP11-385J1.2"]}},{"id":"f825945c335d4f6c8baa021d4704fdbd","type":"GENE","name":"KCNMB3","canonical_id":"hgnc:HGNC:6287","description":"potassium calcium-activated channel subfamily M regulatory beta subunit 3","metadata":{"aliases":["KCNMB2","KCNMBL"]}},{"id":"2968f00a6f0349dfa97c4f88926b6cb5","type":"GENE","name":"KCNMB3P1","canonical_id":"hgnc:HGNC:6288","description":"KCNMB3 pseudogene 1","metadata":{"aliases":["KCNMB3L1","KCNMB2L","KCNMBLP","KCNMB3L"]}},{"id":"8a2d8814b5f8409682cdcabf3a1e8c23","type":"GENE","name":"KCNMB4","canonical_id":"hgnc:HGNC:6289","description":"potassium calcium-activated channel subfamily M regulatory beta subunit 4","metadata":null},{"id":"bbd69a45305748deb9772890d6f1d202","type":"GENE","name":"KCNN1","canonical_id":"hgnc:HGNC:6290","description":"potassium calcium-activated channel subfamily N member 1","metadata":{"aliases":["KCa2.1","hSK1"]}},{"id":"a6c3e044f3314d8b9ce41d6651a85f47","type":"GENE","name":"KCNN2","canonical_id":"hgnc:HGNC:6291","description":null,"metadata":null},{"id":"9fdb5bf1fd1d46febc6a7a58f8a5b57f","type":"GENE","name":"KCNN2-AS1","canonical_id":"hgnc:HGNC:59115","description":"KCNN2 antisense RNA 1","metadata":null},{"id":"55cfd9a045d446efbff2b2964635c31a","type":"GENE","name":"KCNN3","canonical_id":"hgnc:HGNC:6292","description":"potassium calcium-activated channel subfamily N member 3","metadata":{"aliases":["KCa2.3","hSK3","SKCA3"]}},{"id":"ff8f09727cf146d69f69e09c30b90805","type":"GENE","name":"KCNN4","canonical_id":"hgnc:HGNC:6293","description":null,"metadata":null},{"id":"559be7c5edf746d6ad5a2619d0c42d8b","type":"GENE","name":"KCNQ1","canonical_id":"hgnc:HGNC:6294","description":"potassium voltage-gated channel subfamily Q member 1","metadata":{"aliases":["Kv7.1","KCNA8","KVLQT1","JLNS1","LQT1","LQT","KCNA9"]}},{"id":"33600845a6af4f3daec710dea7cecfed","type":"PROTEIN","name":"KCNQ1","canonical_id":"uniprot:P51787","description":null,"metadata":null},{"id":"e75be2ee95374e16bc0ae29b29b6277d","type":"GENE","name":"KCNQ1-AS1","canonical_id":"hgnc:HGNC:42790","description":"KCNQ1 antisense RNA 1","metadata":null},{"id":"1c561e4e29af41598bc2cbfb6bc138c8","type":"GENE","name":"KCNQ1DN","canonical_id":"hgnc:HGNC:13335","description":"KCNQ1 downstream neighbor","metadata":{"aliases":["BWRT","HSA404617"]}},{"id":"ddb576b9db2646519790e93e6cd525d3","type":"GENE","name":"KCNQ1OT1","canonical_id":"hgnc:HGNC:6295","description":"KCNQ1 opposite strand/antisense transcript 1","metadata":{"aliases":["KvDMR1","KCNQ1-AS2","KvLQT1-AS","LIT1","NCRNA00012"]}},{"id":"80a3afb60e6a497ca3a0d9b6200cac2c","type":"GENE","name":"KCNQ2","canonical_id":"hgnc:HGNC:6296","description":null,"metadata":null},{"id":"571a3946e54f46d4ab7e1cc8e4a83493","type":"GENE","name":"KCNQ2-AS1","canonical_id":"hgnc:HGNC:40321","description":"KCNQ2 antisense RNA 1","metadata":null},{"id":"efa8c0ea9fa640cf9156b0d2ef9c9490","type":"GENE","name":"KCNQ3","canonical_id":"hgnc:HGNC:6297","description":null,"metadata":null},{"id":"1f20c8df78c64ec7810788c5f0238a11","type":"GENE","name":"KCNQ4","canonical_id":"hgnc:HGNC:6298","description":"potassium voltage-gated channel subfamily Q member 4","metadata":{"aliases":["Kv7.4","DFNA2"]}},{"id":"f42447c3d9114ffa93e4f4bd0d9f12eb","type":"GENE","name":"KCNQ5","canonical_id":"hgnc:HGNC:6299","description":"potassium voltage-gated channel subfamily Q member 5","metadata":{"aliases":["Kv7.5"]}},{"id":"f65996273ca54a5ea1d9a59372a56d1e","type":"GENE","name":"KCNQ5-AS1","canonical_id":"hgnc:HGNC:40323","description":"KCNQ5 antisense RNA 1","metadata":null},{"id":"20e629a9c20143fdb803695d5b534b3d","type":"GENE","name":"KCNQ5-DT","canonical_id":"hgnc:HGNC:55469","description":"KCNQ5 divergent transcript","metadata":{"aliases":["CATG00000088862.1"]}},{"id":"0aa3afad80094e218be627266ef8017c","type":"GENE","name":"KCNQ5-IT1","canonical_id":"hgnc:HGNC:41354","description":"KCNQ5 intronic transcript 1","metadata":null},{"id":"0ad11eb5118d4ca2a91a5ec9c9d6b503","type":"GENE","name":"KCNRG","canonical_id":"hgnc:HGNC:18893","description":"potassium channel regulator","metadata":null},{"id":"669578b650704b279c83df6c60ba7978","type":"GENE","name":"KCNS1","canonical_id":"hgnc:HGNC:6300","description":"potassium voltage-gated channel modifier subfamily S member 1","metadata":{"aliases":["Kv9.1"]}},{"id":"14f9d4034eb5430b98a46323ace989bd","type":"GENE","name":"KCNS2","canonical_id":"hgnc:HGNC:6301","description":"potassium voltage-gated channel modifier subfamily S member 2","metadata":{"aliases":["Kv9.2"]}},{"id":"5014f5d4ed1547f88e2794b9e3630fb4","type":"GENE","name":"KCNS3","canonical_id":"hgnc:HGNC:6302","description":"potassium voltage-gated channel modifier subfamily S member 3","metadata":{"aliases":["Kv9.3"]}},{"id":"86600fab0af1443289c00cbdae5e6cfc","type":"GENE","name":"KCNT1","canonical_id":"hgnc:HGNC:18865","description":"potassium sodium-activated channel subfamily T member 1","metadata":{"aliases":["KCa4.1","KIAA1422","SLACK","Slo2.2"]}},{"id":"c49031a014ac4eef94102cc8108cb572","type":"GENE","name":"KCNT2","canonical_id":"hgnc:HGNC:18866","description":"potassium sodium-activated channel subfamily T member 2","metadata":{"aliases":["KCa4.2","SLICK","SLO2.1"]}},{"id":"c74704716e054469b4c0a18273a9ee30","type":"GENE","name":"KCNU1","canonical_id":"hgnc:HGNC:18867","description":"potassium calcium-activated channel subfamily U member 1","metadata":{"aliases":["KCa5.1","Slo3","KCNMC1","Kcnma3"]}},{"id":"bb9e99644ecb48ff84b91e9254712b13","type":"GENE","name":"KCNV1","canonical_id":"hgnc:HGNC:18861","description":"potassium voltage-gated channel modifier subfamily V member 1","metadata":{"aliases":["Kv8.1"]}},{"id":"1a4ab958572b46afb380f4fec83142a6","type":"GENE","name":"KCNV2","canonical_id":"hgnc:HGNC:19698","description":"potassium voltage-gated channel modifier subfamily V member 2","metadata":{"aliases":["Kv8.2"]}},{"id":"9c21679b13454eda955727b35140efed","type":"GENE","name":"KCP","canonical_id":"hgnc:HGNC:17585","description":"kielin cysteine rich BMP regulator","metadata":{"aliases":["FLJ33365","NET67","CRIM2"]}},{"id":"1d38b39bd0c74579ab1110ca9af301c5","type":"GENE","name":"KCTD1","canonical_id":"hgnc:HGNC:18249","description":"potassium channel tetramerization domain containing 1","metadata":{"aliases":["C18orf5"]}},{"id":"4caebaf066484d8c9c62e93ab5b9e10e","type":"GENE","name":"KCTD10","canonical_id":"hgnc:HGNC:23236","description":"potassium channel tetramerization domain containing 10","metadata":{"aliases":["MSTP028","BTBD28"]}},{"id":"3ae102088e6b4bcf9a95e0aebd122931","type":"GENE","name":"KCTD10P1","canonical_id":"hgnc:HGNC:49807","description":"potassium channel tetramerization domain containing 10 pseudogene 1","metadata":null},{"id":"b7fb4dfffb8048aeb4e7b97d01d79077","type":"GENE","name":"KCTD11","canonical_id":"hgnc:HGNC:21302","description":null,"metadata":null},{"id":"0d80580d2f554477bd9e46b1848a9175","type":"GENE","name":"KCTD12","canonical_id":"hgnc:HGNC:14678","description":"potassium channel tetramerization domain containing 12","metadata":{"aliases":["KIAA1778","PFET1","C13orf2"]}},{"id":"46950e7fb58340b69701e3afa1eac75c","type":"GENE","name":"KCTD13","canonical_id":"hgnc:HGNC:22234","description":"potassium channel tetramerization domain containing 13","metadata":{"aliases":["PDIP1","FKSG86","POLDIP1"]}},{"id":"1d135b09641f4d28be0be4dc07a231d9","type":"GENE","name":"KCTD13-DT","canonical_id":"hgnc:HGNC:55585","description":"KCTD13 divergent transcript","metadata":null},{"id":"59d2dea802ef490699697478539aa073","type":"GENE","name":"KCTD14","canonical_id":"hgnc:HGNC:23295","description":"potassium channel tetramerization domain containing 14","metadata":{"aliases":["MGC2376"]}},{"id":"b5b417db37af45769e690abe62c5dd32","type":"GENE","name":"KCTD14-AS2","canonical_id":"hgnc:HGNC:41020","description":"KCTD14 antisense RNA 2","metadata":null},{"id":"12e4a862d6e745f39bffe76cfe09ae93","type":"GENE","name":"KCTD15","canonical_id":"hgnc:HGNC:23297","description":"potassium channel tetramerization domain containing 15","metadata":{"aliases":["MGC25497"]}},{"id":"7471589ac0c24bb1801be0637f264492","type":"GENE","name":"KCTD16","canonical_id":"hgnc:HGNC:29244","description":"potassium channel tetramerization domain containing 16","metadata":{"aliases":["KIAA1317"]}},{"id":"c3ad823c338f40b8b658c4045f099c8c","type":"GENE","name":"KCTD16-AS1","canonical_id":"hgnc:HGNC:59271","description":"KCTD16 antisense RNA 1","metadata":null},{"id":"c85a14dbb71846739ce3775846737ccd","type":"GENE","name":"KCTD17","canonical_id":"hgnc:HGNC:25705","description":"potassium channel tetramerization domain containing 17","metadata":{"aliases":["FLJ12242"]}},{"id":"a7ce079f7a3442eb832deb5cdbd893dc","type":"GENE","name":"KCTD18","canonical_id":"hgnc:HGNC:26446","description":"potassium channel tetramerization domain containing 18","metadata":{"aliases":["FLJ31322","6530404F10Rik","FLJ37818"]}},{"id":"15043b957d4c4085bc135b911b792495","type":"GENE","name":"KCTD19","canonical_id":"hgnc:HGNC:24753","description":"potassium channel tetramerization domain containing 19","metadata":{"aliases":["FLJ40162"]}},{"id":"f3afe059d16c499a865941677b41cc80","type":"GENE","name":"KCTD2","canonical_id":"hgnc:HGNC:21294","description":"potassium channel tetramerization domain containing 2","metadata":{"aliases":["KIAA0176"]}},{"id":"cf9ed369d80947fabaeb7b0051698a3e","type":"GENE","name":"KCTD20","canonical_id":"hgnc:HGNC:21052","description":"potassium channel tetramerization domain containing 20","metadata":{"aliases":["dJ108K11.3","MGC14254","C6orf69"]}},{"id":"2800b2307c3547a6bb687417b9c60dd0","type":"GENE","name":"KCTD21","canonical_id":"hgnc:HGNC:27452","description":"potassium channel tetramerization domain containing 21","metadata":{"aliases":["KCASH2"]}},{"id":"b8ea79b9d29a46529773673b4676ac0c","type":"GENE","name":"KCTD21-AS1","canonical_id":"hgnc:HGNC:48674","description":"KCTD21 antisense RNA 1","metadata":null},{"id":"6c8fc5d311d2433aa34a86ca555307e1","type":"GENE","name":"KCTD3","canonical_id":"hgnc:HGNC:21305","description":"potassium channel tetramerization domain containing 3","metadata":{"aliases":["NY-REN-45"]}},{"id":"ada93f97cf1a41139c5bb90291281d89","type":"GENE","name":"KCTD4","canonical_id":"hgnc:HGNC:23227","description":"potassium channel tetramerization domain containing 4","metadata":{"aliases":["bA321C24.3"]}},{"id":"479deee425494494a309c095b62e2f02","type":"GENE","name":"KCTD5","canonical_id":"hgnc:HGNC:21423","description":"potassium channel tetramerization domain containing 5","metadata":{"aliases":["FLJ20040"]}},{"id":"9b42dd65b7ac4ebba51a8a9ae3ff2d22","type":"GENE","name":"KCTD5P1","canonical_id":"hgnc:HGNC:54736","description":"KCTD5 pseudogene 1","metadata":null},{"id":"138ed5941ca44f41ad4180ea2ea40318","type":"GENE","name":"KCTD6","canonical_id":"hgnc:HGNC:22235","description":"potassium channel tetramerization domain containing 6","metadata":{"aliases":["MGC27385","KCASH3"]}},{"id":"e2ac27eaad97466c8145735c3ae6eed9","type":"GENE","name":"KCTD7","canonical_id":"hgnc:HGNC:21957","description":"potassium channel tetramerization domain containing 7","metadata":{"aliases":["FLJ32069","EPM3","CLN14"]}},{"id":"f1b6bdb5769d4f66a816bbf5b69604b3","type":"GENE","name":"KCTD8","canonical_id":"hgnc:HGNC:22394","description":"potassium channel tetramerization domain containing 8","metadata":null},{"id":"2a15bef813ed43c7a0233b9e1fe36e40","type":"GENE","name":"KCTD9","canonical_id":"hgnc:HGNC:22401","description":"potassium channel tetramerization domain containing 9","metadata":{"aliases":["FLJ20038","BTBD27"]}},{"id":"e93ec364e319444ba4933726acac2fe4","type":"GENE","name":"KCTD9P1","canonical_id":"hgnc:HGNC:21428","description":"potassium channel tetramerization domain containing 9 pseudogene 1","metadata":{"aliases":["HsT38306"]}},{"id":"d89aecc1541547f7904c82012931d8ee","type":"GENE","name":"KCTD9P2","canonical_id":"hgnc:HGNC:29274","description":"potassium channel tetramerization domain containing 9 pseudogene 2","metadata":{"aliases":["KCTD9L"]}},{"id":"88539e8c0239430695ded7ad898c0db9","type":"GENE","name":"KCTD9P3","canonical_id":"hgnc:HGNC:49912","description":"potassium channel tetramerization domain containing 9 pseudogene 3","metadata":null},{"id":"4e29d647602646589828b3d54d57cad6","type":"GENE","name":"KCTD9P4","canonical_id":"hgnc:HGNC:49913","description":"potassium channel tetramerization domain containing 9 pseudogene 4","metadata":null},{"id":"41c9886191b34d71b826918a9b3c6536","type":"GENE","name":"KCTD9P5","canonical_id":"hgnc:HGNC:49914","description":"potassium channel tetramerization domain containing 9 pseudogene 5","metadata":null},{"id":"7da9f84e43cc48b99adecbf5845a6b0a","type":"GENE","name":"KCTD9P6","canonical_id":"hgnc:HGNC:49915","description":"potassium channel tetramerization domain containing 9 pseudogene 6","metadata":null},{"id":"19a9e6f4e86e47198c6f6cfc8b2dc007","type":"TRIAL","name":"KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT03919799","description":"System; Sclerosis; Diffuse Cutaneous Systemic Sclerosis","metadata":null},{"id":"a36514f4f22243fb845983eb902444f1","type":"GENE","name":"KDELR1","canonical_id":"hgnc:HGNC:6304","description":"KDEL endoplasmic reticulum protein retention receptor 1","metadata":{"aliases":["ERD2.1","ERD2","HDEL"]}},{"id":"0bf264d667f043e097a4213b5fba92d6","type":"GENE","name":"KDELR2","canonical_id":"hgnc:HGNC:6305","description":"KDEL endoplasmic reticulum protein retention receptor 2","metadata":{"aliases":["ELP-1","ERD2.2"]}},{"id":"e4d755ed2a6244fa946b0b210f8c08f7","type":"GENE","name":"KDELR3","canonical_id":"hgnc:HGNC:6306","description":"KDEL endoplasmic reticulum protein retention receptor 3","metadata":null},{"id":"a9d622adf821464184c1d5a4f39bb78c","type":"GENE","name":"KDF1","canonical_id":"hgnc:HGNC:26624","description":"keratinocyte differentiation factor 1","metadata":{"aliases":["FLJ34633","RP11-344H11.3","C1orf172"]}},{"id":"a79b2408b9d640ed96ff388d78741493","type":"GENE","name":"KDM1A","canonical_id":"hgnc:HGNC:29079","description":"lysine demethylase 1A","metadata":{"aliases":["KIAA0601","BHC110","LSD1","AOF2","KDM1"]}},{"id":"5106a1ef443a4cbc8bbc4de3352d2a5f","type":"GENE","name":"KDM1B","canonical_id":"hgnc:HGNC:21577","description":"lysine demethylase 1B","metadata":{"aliases":["FLJ34109","FLJ33898","dJ298J15.2","bA204B7.3","FLJ43328","LSD2","C6orf193","AOF1"]}},{"id":"30e39826528b42bda97d2aa4b42fe4a2","type":"GENE","name":"KDM2A","canonical_id":"hgnc:HGNC:13606","description":null,"metadata":null},{"id":"20ddded118964ac2be4af33f08992d1c","type":"GENE","name":"KDM2B","canonical_id":"hgnc:HGNC:13610","description":"lysine demethylase 2B","metadata":{"aliases":["PCCX2","CXXC2","Fbl10","JHDM1B","FBXL10"]}},{"id":"71c732296fa94cc6bfee2373d1f62c22","type":"GENE","name":"KDM2B-DT","canonical_id":"hgnc:HGNC:53287","description":"KDM2B divergent transcript","metadata":null},{"id":"418bb1095aa74251bd773dd50d4e0581","type":"GENE","name":"KDM3A","canonical_id":"hgnc:HGNC:20815","description":"lysine demethylase 3A","metadata":{"aliases":["TSGA","KIAA0742","JHMD2A","JMJD1","JMJD1A"]}},{"id":"f1690d1b43aa4847801fcaf0eef51ece","type":"GENE","name":"KDM3AP1","canonical_id":"hgnc:HGNC:54795","description":"KDM3A pseudogene 1","metadata":null},{"id":"dadf99ae2027487b84a58f83ba22d650","type":"GENE","name":"KDM3B","canonical_id":"hgnc:HGNC:1337","description":"lysine demethylase 3B","metadata":{"aliases":["KIAA1082","NET22","C5orf7","JMJD1B"]}},{"id":"d1eefd4439c44816b8fc303589bbab60","type":"GENE","name":"KDM4A","canonical_id":"hgnc:HGNC:22978","description":"lysine demethylase 4A","metadata":{"aliases":["KIAA0677","JHDM3A","TDRD14A","JMJD2","JMJD2A"]}},{"id":"399c1bf5a56f401e80e5e99157bd2414","type":"GENE","name":"KDM4A-AS1","canonical_id":"hgnc:HGNC:40528","description":"KDM4A antisense RNA 1","metadata":null},{"id":"a0b31148ee77473c9ca1a5d550aed722","type":"GENE","name":"KDM4B","canonical_id":"hgnc:HGNC:29136","description":null,"metadata":null},{"id":"4007444fdd234335a914a20a5676e18a","type":"GENE","name":"KDM4C","canonical_id":"hgnc:HGNC:17071","description":null,"metadata":null},{"id":"9c8e192a90aa479f825826a6f299c8df","type":"GENE","name":"KDM4D","canonical_id":"hgnc:HGNC:25498","description":"lysine demethylase 4D","metadata":{"aliases":["FLJ10251","JMJD2D"]}},{"id":"6fdeb8d1238c4e8fa9a8abdec98a0c3b","type":"GENE","name":"KDM4E","canonical_id":"hgnc:HGNC:37098","description":"lysine demethylase 4E","metadata":{"aliases":["JMJD2E","KDM5E","KDM4DL"]}},{"id":"3bb9d75bcb4649b7837d26087847ce0c","type":"GENE","name":"KDM4F","canonical_id":"hgnc:HGNC:52413","description":"lysine demethylase 4F (putative)","metadata":{"aliases":["JMJD2F"]}},{"id":"9a231af737614768a3f93eb588f1c93b","type":"GENE","name":"KDM5A","canonical_id":"hgnc:HGNC:9886","description":"lysine demethylase 5A","metadata":{"aliases":["RBBP2","JARID1A"]}},{"id":"0c52a13adcf042748f98c6c4ec2c326a","type":"GENE","name":"KDM5B","canonical_id":"hgnc:HGNC:18039","description":"lysine demethylase 5B","metadata":{"aliases":["RBBP2H1A","PLU-1","CT31","PPP1R98","JARID1B"]}},{"id":"30bf90bbd3fb462d8b6fa31b08c5e1ad","type":"GENE","name":"KDM5C","canonical_id":"hgnc:HGNC:11114","description":null,"metadata":null},{"id":"1210ce3783d94e6aa46dc71e841b4578","type":"GENE","name":"KDM5C-IT1","canonical_id":"hgnc:HGNC:41384","description":"KDM5C intronic transcript 1","metadata":null},{"id":"29c7c225939d4ef0be00e1ad2ba4ee06","type":"GENE","name":"KDM5D","canonical_id":"hgnc:HGNC:11115","description":"lysine demethylase 5D","metadata":{"aliases":["KIAA0234","HYA","HY","SMCY","JARID1D"]}},{"id":"082131fbebab41b1805b42bef762f9e0","type":"GENE","name":"KDM5D-DT","canonical_id":"hgnc:HGNC:58352","description":"KDM5D divergent transcript","metadata":null},{"id":"7f544d93d5f04d0aba3cbf535b41d1dd","type":"GENE","name":"KDM5DP1","canonical_id":"hgnc:HGNC:23976","description":"lysine demethylase 5D pseudogene 1","metadata":{"aliases":["SMCYP"]}},{"id":"9d965b11f1eb4420b5c9b388f22467ba","type":"GENE","name":"KDM6A","canonical_id":"hgnc:HGNC:12637","description":"lysine demethylase 6A","metadata":{"aliases":["UTX"]}},{"id":"2d33031d65ed4a4d99fcaad5e64ee577","type":"GENE","name":"KDM6B","canonical_id":"hgnc:HGNC:29012","description":"lysine demethylase 6B","metadata":{"aliases":["KIAA0346","JMJD3"]}},{"id":"1a194de8d41b4119a7f5c8141c5523dd","type":"GENE","name":"KDM7A","canonical_id":"hgnc:HGNC:22224","description":"lysine demethylase 7A","metadata":{"aliases":["KIAA1718","JHDM1D"]}},{"id":"f9935a1b818442868bac26742ca3fd17","type":"GENE","name":"KDM7A-DT","canonical_id":"hgnc:HGNC:48959","description":"KDM7A divergent transcript","metadata":{"aliases":["JHDM1D-AS1"]}},{"id":"0781733b4ce14965a542821a44cc4e63","type":"GENE","name":"KDM8","canonical_id":"hgnc:HGNC:25840","description":"lysine demethylase 8 (putative)","metadata":{"aliases":["FLJ13798","JMJD5"]}},{"id":"52c4d7345d624621be718e00d2685d88","type":"GENE","name":"KDNBY","canonical_id":"hgnc:HGNC:58375","description":"KDM5D neighbour, Y-linked","metadata":{"aliases":["RP11-424G14.1"]}},{"id":"82fd9b5731864251a17b70af78360778","type":"GENE","name":"KDR","canonical_id":"hgnc:HGNC:6307","description":null,"metadata":null},{"id":"f104a9b989504fefac231aaaa979189f","type":"PROTEIN","name":"KDR","canonical_id":"uniprot:P35968","description":null,"metadata":null},{"id":"b3b43719dda7463db1ebceb63b9927e5","type":"GENE","name":"KDR","canonical_id":"ensembl:ENSG00000128052","description":null,"metadata":null},{"id":"b207b79c37b244909b2310756302e28b","type":"GENE","name":"KDR-AS1","canonical_id":"hgnc:HGNC:58789","description":"KDR antisense RNA 1","metadata":null},{"id":"ddcdb6119832407f8fd555549c1b167b","type":"GENE","name":"KDSR","canonical_id":"hgnc:HGNC:4021","description":"3-ketodihydrosphingosine reductase","metadata":{"aliases":["DHSR","SDR35C1","FVT1"]}},{"id":"bcc97b836dba40e89636d5097ac9a078","type":"GENE","name":"KDSR-DT","canonical_id":"hgnc:HGNC:55299","description":"KDSR divergent transcript","metadata":null},{"id":"c7388cf6b8b54456865b11bbef831292","type":"GENE","name":"KEAP1","canonical_id":"hgnc:HGNC:23177","description":"kelch like ECH associated protein 1","metadata":{"aliases":["KIAA0132","MGC10630","MGC1114","MGC20887","MGC4407","MGC9454","INrf2","KLHL19"]}},{"id":"2ad3ba5c77ee458282e1ee9661ad54f4","type":"GENE","name":"KEL","canonical_id":"hgnc:HGNC:6308","description":"Kell metallo-endopeptidase (Kell blood group)","metadata":{"aliases":["ECE3","CD238"]}},{"id":"bc6841f727e14fb88529d19fbce11613","type":"GENE","name":"KERA","canonical_id":"hgnc:HGNC:6309","description":"keratocan","metadata":{"aliases":["SLRR2B","CNA2"]}},{"id":"7f6546c3108c4648a831c61e92ff7835","type":"TRIAL","name":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","canonical_id":"clinicaltrials.gov:NCT06566794","description":"Drug Interaction","metadata":null},{"id":"76dc72dcfc6a4a558353a9501638b281","type":"GENE","name":"KGD4","canonical_id":"hgnc:HGNC:16631","description":"alpha-ketoglutarate dehydrogenase subunit 4","metadata":{"aliases":["DC47","MRP-S36","MRPS36"]}},{"id":"bab05810c7d74ecf969ca1b0c129b2dc","type":"GENE","name":"KHDC1","canonical_id":"hgnc:HGNC:21366","description":"KH domain containing 1","metadata":{"aliases":["MGC10818","bA257K9.4","NDG1","Em:AC019205.8","C6orf148","C6orf147"]}},{"id":"c5fec888ad734531b6bf44b6e707f25e","type":"GENE","name":"KHDC1-AS1","canonical_id":"hgnc:HGNC:55468","description":"KHDC1 antisense RNA 1","metadata":{"aliases":["lnc-KHDC3L-2"]}},{"id":"2c7922148c024ad1994b636aae975ca3","type":"GENE","name":"KHDC1L","canonical_id":"hgnc:HGNC:37274","description":"KH domain containing 1 like","metadata":{"aliases":["RP11-257K9.7"]}},{"id":"5f1b61e086e34238b6858503ad2377d5","type":"GENE","name":"KHDC1P1","canonical_id":"hgnc:HGNC:43757","description":"KH domain containing 1 pseudogene 1","metadata":null},{"id":"4e7a0f26ab6f4126a2ad6e7bb0fff922","type":"GENE","name":"KHDC3L","canonical_id":"hgnc:HGNC:33699","description":"KH domain containing 3 like, subcortical maternal complex member","metadata":{"aliases":["ECAT1","C6orf221"]}},{"id":"44ca0808d4f24368a9405dd961366c6f","type":"GENE","name":"KHDC4","canonical_id":"hgnc:HGNC:29145","description":"KH domain containing 4, pre-mRNA splicing factor","metadata":{"aliases":["BLOM7","SNORA80EHG","KIAA0907"]}},{"id":"69c806497f794e59857c3693a8c26bbf","type":"GENE","name":"KHDRBS1","canonical_id":"hgnc:HGNC:18116","description":null,"metadata":null},{"id":"ac57d1dbc1134ea68c590aff8be1f8b0","type":"GENE","name":"KHDRBS2","canonical_id":"hgnc:HGNC:18114","description":"KH RNA binding domain containing, signal transduction associated 2","metadata":{"aliases":["SLM1","SLM-1","MGC26664","KHDRBS2-OT1","KHDRBS2-OT"]}},{"id":"c0c0c6a9e5344944b984db863c759206","type":"GENE","name":"KHDRBS3","canonical_id":"hgnc:HGNC:18117","description":"KH RNA binding domain containing, signal transduction associated 3","metadata":{"aliases":["T-STAR","Etle","etoile","SALP","SLM2","SLM-2"]}},{"id":"ddfa9c95e9a34709bd0f1e8e680b4ae7","type":"GENE","name":"KHK","canonical_id":"hgnc:HGNC:6315","description":"ketohexokinase","metadata":null},{"id":"1efc7ea9fd924e209bdeec3c498ddc2b","type":"TRIAL","name":"KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02867007","description":"Solid Tumor; Cancer; Carcinoma","metadata":null},{"id":"d7bcaed08c7a42b58323655022a1b1a0","type":"GENE","name":"KHNYN","canonical_id":"hgnc:HGNC:20166","description":"KH and NYN domain containing","metadata":{"aliases":["KIAA0323"]}},{"id":"4aa04cbf29fa4706abd46f8b1f1bc8c9","type":"GENE","name":"KHSRP","canonical_id":"hgnc:HGNC:6316","description":null,"metadata":null},{"id":"c6f9dafbd3dd4b6894f627ccbd59e5db","type":"GENE","name":"KHSRPP1","canonical_id":"hgnc:HGNC:39198","description":"KH-type splicing regulatory protein pseudogene 1","metadata":null},{"id":"0be7784a15ac497e8a9049ba30f7144b","type":"GENE","name":"KIAA0040","canonical_id":"hgnc:HGNC:28950","description":"KIAA0040","metadata":{"aliases":["IAMP"]}},{"id":"2fd50dbeb5484e8a9de25aed11bb37b7","type":"GENE","name":"KIAA0087","canonical_id":"hgnc:HGNC:22191","description":"KIAA0087 lncRNA","metadata":null},{"id":"8c06da45d84442798911d9099c91abab","type":"GENE","name":"KIAA0232","canonical_id":"hgnc:HGNC:28992","description":"KIAA0232","metadata":null},{"id":"a1c9d35872e94b63a2e694c8effe423f","type":"GENE","name":"KIAA0319","canonical_id":"hgnc:HGNC:21580","description":"KIAA0319","metadata":{"aliases":["NMIG"]}},{"id":"775578db0eef4564adef2b9038459881","type":"GENE","name":"KIAA0319L","canonical_id":"hgnc:HGNC:30071","description":"KIAA0319 like","metadata":{"aliases":["KIAA1837","AAVR"]}},{"id":"aff355a42962478e8867537996169d30","type":"GENE","name":"KIAA0408","canonical_id":"hgnc:HGNC:21636","description":"KIAA0408","metadata":null},{"id":"d9860d6c4f714c2c9fda3007b7a5c868","type":"GENE","name":"KIAA0513","canonical_id":"hgnc:HGNC:29058","description":"KIAA0513","metadata":null},{"id":"f5e9d5e6370c45f4829fb964c8fff8ae","type":"GENE","name":"KIAA0586","canonical_id":"hgnc:HGNC:19960","description":"KIAA0586","metadata":{"aliases":["Talpid3","JBTS23"]}},{"id":"50ee537a06784af8adac3c794af9dacd","type":"GENE","name":"KIAA0753","canonical_id":"hgnc:HGNC:29110","description":"KIAA0753","metadata":{"aliases":["OFIP","MNR"]}},{"id":"649ad2e985be4c74ba7e517d6d522fa2","type":"GENE","name":"KIAA0825","canonical_id":"hgnc:HGNC:28532","description":"KIAA0825","metadata":{"aliases":["DKFZp686F0372","MGC34713","C5orf36"]}},{"id":"4a56261fee734637aa8526fff88c80b6","type":"GENE","name":"KIAA0930","canonical_id":"hgnc:HGNC:1314","description":"KIAA0930","metadata":{"aliases":["bK268H5.C22.1","C22orf9"]}},{"id":"c182bde2a07d40e38e86f38e3b9282c7","type":"GENE","name":"KIAA1143","canonical_id":"hgnc:HGNC:29198","description":"KIAA1143","metadata":null},{"id":"c238aeb5eac04c37b5169e5dc1bdd505","type":"GENE","name":"KIAA1143P1","canonical_id":"hgnc:HGNC:54591","description":"KIAA1143 pseudogene 1","metadata":null},{"id":"141af184a4cf4c6e91d44c19be9bdf8f","type":"GENE","name":"KIAA1143P2","canonical_id":"hgnc:HGNC:54594","description":"KIAA1143 pseudogene 2","metadata":null},{"id":"0b0fe63663a04fbcac2e2d1f988d5c0b","type":"GENE","name":"KIAA1191","canonical_id":"hgnc:HGNC:29209","description":"KIAA1191","metadata":{"aliases":["FLJ21022","p33MONOX","p60MONOX"]}},{"id":"db20abcf6973418d89756ae402107629","type":"GENE","name":"KIAA1191-AS1","canonical_id":"hgnc:HGNC:41234","description":"KIAA1191 antisense RNA 1","metadata":null},{"id":"414dd45a34794ff6a5518776b4192e1e","type":"GENE","name":"KIAA1191P1","canonical_id":"hgnc:HGNC:56785","description":"KIAA1191 pseudogene 1","metadata":null},{"id":"86799ec21cb548ba9f9a54aada67ae0e","type":"GENE","name":"KIAA1191P2","canonical_id":"hgnc:HGNC:56786","description":"KIAA1191 pseudogene 2","metadata":null},{"id":"91811445caaf4a7780407a912095817b","type":"GENE","name":"KIAA1191P3","canonical_id":"hgnc:HGNC:56787","description":"KIAA1191 pseudogene 3","metadata":null},{"id":"c339907f46f04312bbd6d0bbc67b2577","type":"GENE","name":"KIAA1210","canonical_id":"hgnc:HGNC:29218","description":"KIAA1210","metadata":null},{"id":"bd279cf2d5a8436f9f6303d340e564bf","type":"GENE","name":"KIAA1217","canonical_id":"hgnc:HGNC:25428","description":"KIAA1217","metadata":{"aliases":["DKFZP761L0424","SKT","ETL4"]}},{"id":"fe9e2d73a1c64ba49562b186cb40330c","type":"GENE","name":"KIAA1328","canonical_id":"hgnc:HGNC:29248","description":"KIAA1328","metadata":null},{"id":"8b4198f007f34fd7a3c33e16bd1ede8d","type":"GENE","name":"KIAA1328P1","canonical_id":"hgnc:HGNC:56561","description":"KIAA1328 pseudogene 1","metadata":null},{"id":"f18e3be3b22046ab93f669f1915460e4","type":"GENE","name":"KIAA1549","canonical_id":"hgnc:HGNC:22219","description":"KIAA1549","metadata":null},{"id":"391226760a7a4c0dacd5d776639fc9d9","type":"GENE","name":"KIAA1549L","canonical_id":"hgnc:HGNC:24836","description":"KIAA1549 like","metadata":{"aliases":["G2","MGC34830","C11orf69","C11orf41"]}},{"id":"7321de488bed4ef08cb5938953d46216","type":"GENE","name":"KIAA1586","canonical_id":"hgnc:HGNC:21360","description":"KIAA1586","metadata":null},{"id":"feb2c7b6bbea40b3938382f4acb2a854","type":"GENE","name":"KIAA1586P1","canonical_id":"hgnc:HGNC:58920","description":"KIAA1586 pseudogene 1","metadata":null},{"id":"e22983e155c247708eca6b054d618a77","type":"GENE","name":"KIAA1614","canonical_id":"hgnc:HGNC:29327","description":"KIAA1614","metadata":null},{"id":"d710f6bcc72f49288e2b4c694776d57d","type":"GENE","name":"KIAA1614-AS1","canonical_id":"hgnc:HGNC:50644","description":"KIAA1614 antisense RNA 1","metadata":{"aliases":["RP11-46A10.4"]}},{"id":"e0c3a33dd9124ce7b989d84d89f3e0da","type":"GENE","name":"KIAA1671","canonical_id":"hgnc:HGNC:29345","description":"KIAA1671","metadata":null},{"id":"ae19ebaba09e4515840fffadbcfee191","type":"GENE","name":"KIAA1671-AS1","canonical_id":"hgnc:HGNC:41238","description":"KIAA1671 antisense RNA 1","metadata":null},{"id":"721bdbe214194712879284c4098fb339","type":"GENE","name":"KIAA1755","canonical_id":"hgnc:HGNC:29372","description":"KIAA1755","metadata":{"aliases":["RP5-1054A22.3","quo"]}},{"id":"9b2cca1496af412da156af5d4caf683c","type":"GENE","name":"KIAA1958","canonical_id":"hgnc:HGNC:23427","description":"KIAA1958","metadata":{"aliases":["FLJ39294"]}},{"id":"dc5e81b5f67142d092b775abb96ba6d9","type":"GENE","name":"KIAA2012","canonical_id":"hgnc:HGNC:51250","description":"KIAA2012","metadata":null},{"id":"1515f6e0c7d64c1780855c2eadc4f7b0","type":"GENE","name":"KIAA2012-AS1","canonical_id":"hgnc:HGNC:41164","description":"KIAA2012 antisense RNA 1","metadata":null},{"id":"5bfbbadcbcff48588ec67f30f2760035","type":"GENE","name":"KIAA2013","canonical_id":"hgnc:HGNC:28513","description":"KIAA2013","metadata":{"aliases":["MGC33867","RP5-1077B9.1"]}},{"id":"098e7817596545a4964f812e17bd9f3f","type":"GENE","name":"KIAA2013P1","canonical_id":"hgnc:HGNC:58919","description":"KIAA2031 pseudogene 1","metadata":null},{"id":"a9927ae77dfa40048279a6f01779ed8f","type":"GENE","name":"KICS2","canonical_id":"hgnc:HGNC:26517","description":"KICSTOR subunit 2","metadata":{"aliases":["FLJ32549","C12orf66"]}},{"id":"a0a3520700e14f9798e7435429a049b2","type":"GO_TERM","name":"KICSTOR complex","canonical_id":"go:GO:0140007","description":"\"A protein complex that regulates the TORC1 signaling pathway in response to nutrients. The KICSTOR complex is composed of KPTN, ITFG2, C12orf66 and SZT2.\" [PMID:28199306]","metadata":null},{"id":"bd2f10be46d94fada3aa58731110fd23","type":"GENE","name":"KIDINS220","canonical_id":"hgnc:HGNC:29508","description":"kinase D interacting substrate 220","metadata":{"aliases":["ARMS"]}},{"id":"1753d093c8574db2828e3b6545b703f2","type":"GENE","name":"KIF11","canonical_id":"hgnc:HGNC:6388","description":"kinesin family member 11","metadata":{"aliases":["Eg5","HKSP","TRIP5","KNSL1"]}},{"id":"062ba4dd51324691a77fe835fa34c9a3","type":"GENE","name":"KIF12","canonical_id":"hgnc:HGNC:21495","description":"kinesin family member 12","metadata":null},{"id":"36e3d52f446c444093b4e6aaa2acbb5b","type":"GENE","name":"KIF13A","canonical_id":"hgnc:HGNC:14566","description":"kinesin family member 13A","metadata":{"aliases":["bA500C11.2","RBKIN"]}},{"id":"68c840c935c34a35a07b356c548db379","type":"GENE","name":"KIF13A-AS1","canonical_id":"hgnc:HGNC:59365","description":"KIF13A antisense RNA 1","metadata":null},{"id":"31d6f01fb1eb4a0ab9337ebd3fabf87e","type":"GENE","name":"KIF13B","canonical_id":"hgnc:HGNC:14405","description":"kinesin family member 13B","metadata":{"aliases":["GAKIN","KIAA0639"]}},{"id":"6a5bb5a12c524a10801400835414876d","type":"GENE","name":"KIF14","canonical_id":"hgnc:HGNC:19181","description":"kinesin family member 14","metadata":{"aliases":["KIAA0042"]}},{"id":"f815a5c8996044579f3fae28d9c8f2da","type":"GENE","name":"KIF15","canonical_id":"hgnc:HGNC:17273","description":"kinesin family member 15","metadata":{"aliases":["HKLP2","NY-BR-62","KNSL7"]}},{"id":"a3a0f4100cfd4a10984d98d5158ba337","type":"GENE","name":"KIF16B","canonical_id":"hgnc:HGNC:15869","description":"kinesin family member 16B","metadata":{"aliases":["FLJ20135","dJ971B4.1","SNX23","C20orf23"]}},{"id":"accd954b7f2640cb83bbe885f9f1fcfc","type":"GENE","name":"KIF17","canonical_id":"hgnc:HGNC:19167","description":"kinesin family member 17","metadata":{"aliases":["KIAA1405","KIF3X","KIF17B","OSM-3","KLP-2"]}},{"id":"c08d8c9bf05f405f876603719f7ed431","type":"GENE","name":"KIF18A","canonical_id":"hgnc:HGNC:29441","description":"kinesin family member 18A","metadata":{"aliases":["DKFZP434G2226","PPP1R99"]}},{"id":"83d6d4c35a2340648e318e032420d484","type":"GENE","name":"KIF18B","canonical_id":"hgnc:HGNC:27102","description":"kinesin family member 18B","metadata":null},{"id":"286c2c1b158c4f41a40eb6a8bbadfe82","type":"GENE","name":"KIF18B-DT","canonical_id":"hgnc:HGNC:55300","description":"KIF18B divergent transcript","metadata":null},{"id":"8f56bd3c176140899c5ce10dfa629f2a","type":"GENE","name":"KIF18BP1","canonical_id":"hgnc:HGNC:51808","description":"kinesin family member 18B pseudogene 1","metadata":null},{"id":"f0a47a7b41c643d19e2dd5ac639103cb","type":"GENE","name":"KIF19","canonical_id":"hgnc:HGNC:26735","description":"kinesin family member 19","metadata":{"aliases":["FLJ37300","KIF19A"]}},{"id":"5f09ac3bde62450ca0d41c0722a500e6","type":"GENE","name":"KIF19BP","canonical_id":"hgnc:HGNC:55167","description":"kinesin family member 19B, pseudogene","metadata":null},{"id":"2a9a03d956c445538088f27af8227f09","type":"GENE","name":"KIF1A","canonical_id":"hgnc:HGNC:888","description":"kinesin family member 1A","metadata":{"aliases":["UNC104","ATSV","C2orf20","SPG30"]}},{"id":"14a042b10747420a9a7a7dab30ff5503","type":"GENE","name":"KIF1B","canonical_id":"hgnc:HGNC:16636","description":"kinesin family member 1B","metadata":{"aliases":["KIAA0591","KLP","HMSNII","CMT2A","CMT2"]}},{"id":"052f00e0e45847be86079e91720fa5cd","type":"GENE","name":"KIF1C","canonical_id":"hgnc:HGNC:6317","description":"kinesin family member 1C","metadata":{"aliases":["SPAX2","SPG58","SAX2"]}},{"id":"6bb07d5bc154494fbf55592995980f1f","type":"GENE","name":"KIF1C-AS1","canonical_id":"hgnc:HGNC:40324","description":"KIF1C antisense RNA 1","metadata":null},{"id":"cc8b7d50866a458a8c368e23a78a7900","type":"GENE","name":"KIF20A","canonical_id":"hgnc:HGNC:9787","description":"kinesin family member 20A","metadata":{"aliases":["MKLP2","RAB6KIFL"]}},{"id":"d8103ec2c6b94a179e7cc221002e4f08","type":"GENE","name":"KIF20B","canonical_id":"hgnc:HGNC:7212","description":"kinesin family member 20B","metadata":{"aliases":["MPP1","KRMP1","CT90","MPHOSPH1"]}},{"id":"854b1309404a4e2c871aa064b3bd2441","type":"GENE","name":"KIF21A","canonical_id":"hgnc:HGNC:19349","description":"kinesin family member 21A","metadata":{"aliases":["FLJ20052","FEOM1"]}},{"id":"bce82c787e2046c0a75e151028ce7841","type":"GENE","name":"KIF21B","canonical_id":"hgnc:HGNC:29442","description":"kinesin family member 21B","metadata":{"aliases":["DKFZP434J212","KIAA0449"]}},{"id":"1feb816f09a84da0a23fcf129ed45bde","type":"GENE","name":"KIF22","canonical_id":"hgnc:HGNC:6391","description":"kinesin family member 22","metadata":{"aliases":["Kid","OBP-1","OBP-2","KNSL4"]}},{"id":"212237c3631848dfb79265583ade5d6d","type":"GENE","name":"KIF23","canonical_id":"hgnc:HGNC:6392","description":"kinesin family member 23","metadata":{"aliases":["MKLP1","MKLP-1","KNSL5"]}},{"id":"bff73da5e1034607b4518a73c71d6b93","type":"GENE","name":"KIF23-AS1","canonical_id":"hgnc:HGNC:27075","description":"KIF23 and PAQR5 antisense RNA 1","metadata":null},{"id":"6c8d889e7f06439e9246a3eef0d60f63","type":"GENE","name":"KIF24","canonical_id":"hgnc:HGNC:19916","description":"kinesin family member 24","metadata":{"aliases":["bA571F15.4","FLJ10933","FLJ43884","C9orf48"]}},{"id":"c5f3ee5ded0b46b6b24ebcb75bda7465","type":"GENE","name":"KIF25","canonical_id":"hgnc:HGNC:6390","description":"kinesin family member 25","metadata":{"aliases":["KNSL3"]}},{"id":"8e18fd8c937d4561812310fdc3b77e1f","type":"GENE","name":"KIF25-AS1","canonical_id":"hgnc:HGNC:20953","description":"KIF25 antisense RNA 1","metadata":{"aliases":["HGC6.1.1","C6orf54","NCRNA00300"]}},{"id":"03461fdd1c8c4021a7f85fb605112297","type":"GENE","name":"KIF26A","canonical_id":"hgnc:HGNC:20226","description":"kinesin family member 26A","metadata":{"aliases":["KIAA1236","DKFZP434N178"]}},{"id":"8b6a9402d3a44a86addca83d2244b66a","type":"GENE","name":"KIF26A-DT","canonical_id":"hgnc:HGNC:55439","description":"KIF26A divergent transcript","metadata":null},{"id":"7045bdc2e1b6499892a615427b64f9d5","type":"GENE","name":"KIF26B","canonical_id":"hgnc:HGNC:25484","description":"kinesin family member 26B","metadata":{"aliases":["FLJ10157"]}},{"id":"233e6a2f886840a4aa217ffacf72183c","type":"GENE","name":"KIF26B-AS1","canonical_id":"hgnc:HGNC:41098","description":"KIF26B antisense RNA 1","metadata":{"aliases":["RP11-62I21.1"]}},{"id":"28fcfc89a66543b48de8f18fff5e6a1a","type":"GENE","name":"KIF26B-AS2","canonical_id":"hgnc:HGNC:41099","description":"KIF26B antisense RNA 2","metadata":null},{"id":"547aca0f29e04b889dbd8e9d7248dac4","type":"GENE","name":"KIF26B-AS3","canonical_id":"hgnc:HGNC:41100","description":"KIF26B antisense RNA 3","metadata":null},{"id":"d9b816fea41747b5ac34e62244f3a64f","type":"GENE","name":"KIF27","canonical_id":"hgnc:HGNC:18632","description":"kinesin family member 27","metadata":{"aliases":["DKFZp434D0917"]}},{"id":"9d7f7b8d8c7e4ddc9aaccb042031b2fd","type":"GENE","name":"KIF27P1","canonical_id":"hgnc:HGNC:56291","description":"KIF27 pseudogene 1","metadata":{"aliases":["KIF27BCP"]}},{"id":"f56ff0b64df74b599788bad460a4b290","type":"GENE","name":"KIF27P2","canonical_id":"hgnc:HGNC:56290","description":"KIF27 pseudogene 2","metadata":{"aliases":["KIF27BNP"]}},{"id":"6bc4d328349244bbbecef5bd5b26abc8","type":"GENE","name":"KIF28P","canonical_id":"hgnc:HGNC:49205","description":"kinesin family member 28, pseudogene","metadata":{"aliases":["KLP-6"]}},{"id":"6301e7c88be6444d861dd3aabb2d88b6","type":"GENE","name":"KIF2A","canonical_id":"hgnc:HGNC:6318","description":"kinesin family member 2A","metadata":{"aliases":["HK2","KIF2"]}},{"id":"ee0ec734433d4a78bf6b995af08d4928","type":"GENE","name":"KIF2B","canonical_id":"hgnc:HGNC:29443","description":"kinesin family member 2B","metadata":null},{"id":"b1a7f227dfb84f38affba94bcc602c35","type":"GENE","name":"KIF2C","canonical_id":"hgnc:HGNC:6393","description":null,"metadata":null},{"id":"af7817447a964969a2ec4fdf145bba55","type":"GENE","name":"KIF3A","canonical_id":"hgnc:HGNC:6319","description":"kinesin family member 3A","metadata":{"aliases":["FLA10","KLP-20"]}},{"id":"fc1dc86b240441948f6e3d7afd94d8ae","type":"GENE","name":"KIF3A-AS1","canonical_id":"hgnc:HGNC:59132","description":"KIF3A antisense RNA 1","metadata":null},{"id":"5a3eb0387f19497f838a0f60c7a572df","type":"GENE","name":"KIF3AP1","canonical_id":"hgnc:HGNC:52811","description":"kinesin family member 3A pseudogene 1","metadata":null},{"id":"c7449647e2b7431696d984bca01dee41","type":"GENE","name":"KIF3B","canonical_id":"hgnc:HGNC:6320","description":"kinesin family member 3B","metadata":{"aliases":["KIAA0359","FLA8","KLP-11"]}},{"id":"bbce242d45f049a2a8b20579bb3d56a6","type":"GENE","name":"KIF3C","canonical_id":"hgnc:HGNC:6321","description":"kinesin family member 3C","metadata":null},{"id":"29e922591c234b7786fbd7339b88ff7d","type":"GENE","name":"KIF4A","canonical_id":"hgnc:HGNC:13339","description":"kinesin family member 4A","metadata":{"aliases":["KIF4-G1","KIF4","HSA271784","FLJ12530","FLJ12655","FLJ14204","FLJ20631","MRX100"]}},{"id":"b0d7ade459aa470484b09fccc589ff63","type":"GENE","name":"KIF4B","canonical_id":"hgnc:HGNC:6322","description":"kinesin family member 4B","metadata":null},{"id":"8e4defe4a124422fbc8122a2be04d3f7","type":"GENE","name":"KIF4CP","canonical_id":"hgnc:HGNC:13340","description":"kinesin family member 4C, pseudogene","metadata":{"aliases":["KIF4P1"]}},{"id":"bacb08d9cb94420c9c6527371ccde5d8","type":"GENE","name":"KIF5A","canonical_id":"hgnc:HGNC:6323","description":"kinesin family member 5A","metadata":{"aliases":["D12S1889","NKHC","MY050","SPG10"]}},{"id":"6ca82509bc1746be85fb2103bf86ea49","type":"GENE","name":"KIF5B","canonical_id":"hgnc:HGNC:6324","description":"kinesin family member 5B","metadata":{"aliases":["KNS","uKHC","KNS1"]}},{"id":"49b480bf0d3c4a4dabc48c8496452497","type":"GENE","name":"KIF5C","canonical_id":"hgnc:HGNC:6325","description":"kinesin family member 5C","metadata":{"aliases":["NKHC2"]}},{"id":"a026acbb1e7d443a8c3f2aa3cd1153e9","type":"GENE","name":"KIF5C-AS1","canonical_id":"hgnc:HGNC:40325","description":"KIF5C antisense RNA 1","metadata":null},{"id":"5c145eb657c745fea0985ebd64c2fa8d","type":"GENE","name":"KIF6","canonical_id":"hgnc:HGNC:21202","description":"kinesin family member 6","metadata":{"aliases":["dJ1043E3.1","MGC33317","dJ137F1.4","dJ188D3.1","DKFZp451I2418","C6orf102"]}},{"id":"4757c7f7a1164d968eb60f1e22329ce5","type":"GENE","name":"KIF7","canonical_id":"hgnc:HGNC:30497","description":"kinesin family member 7","metadata":{"aliases":["JBTS12"]}},{"id":"6dcb2d0eca5341f3828e8323c916ac3c","type":"GENE","name":"KIF9","canonical_id":"hgnc:HGNC:16666","description":"kinesin family member 9","metadata":{"aliases":["MGC104186"]}},{"id":"33bf9ebbcdb445ee95385098a91626ee","type":"GENE","name":"KIF9-AS1","canonical_id":"hgnc:HGNC:26822","description":"KIF9 antisense RNA 1","metadata":{"aliases":["FLJ39534"]}},{"id":"3b538dc1459342909974152755bdab03","type":"GENE","name":"KIFAP3","canonical_id":"hgnc:HGNC:17060","description":"kinesin associated protein 3","metadata":{"aliases":["SMAP","KAP3","FLA3","KAP-1"]}},{"id":"6bef6326d143485fb7f723ba633bae34","type":"GENE","name":"KIFAP3-AS1","canonical_id":"hgnc:HGNC:40788","description":"KIFAP3 antisense RNA 1","metadata":null},{"id":"3faf811075fc40babf68840c36279a41","type":"GENE","name":"KIFBP","canonical_id":"hgnc:HGNC:23419","description":"kinesin family binding protein","metadata":{"aliases":["DKFZP586B0923","TTC20","KBP","KIAA1279","KIF1BP"]}},{"id":"98ef9104e0514dd9a09828f254ac450b","type":"GENE","name":"KIFC1","canonical_id":"hgnc:HGNC:6389","description":"kinesin family member C1","metadata":{"aliases":["HSET","KNSL2"]}},{"id":"436be33d50cd4c6f9813e89b2f0ecd73","type":"GENE","name":"KIFC2","canonical_id":"hgnc:HGNC:29530","description":"kinesin family member C2","metadata":null},{"id":"4b53d5f894714ac8945a89b4345ab55e","type":"GENE","name":"KIFC3","canonical_id":"hgnc:HGNC:6326","description":"kinesin family member C3","metadata":null},{"id":"9dff51ba894040aeaa399085e5495f47","type":"GENE","name":"KILH","canonical_id":"hgnc:HGNC:56729","description":"KRT19 interacting long noncoding RNA in hepatocellular carcinoma","metadata":{"aliases":["linc-KILH","lnc-GCLC-1"]}},{"id":"1e1e5a0b4f3444a4a2444091d16aef7e","type":"GENE","name":"KIN","canonical_id":"hgnc:HGNC:6327","description":null,"metadata":null},{"id":"aefe28f1978448a99153783c97fe67ca","type":"GENE","name":"KIR2DL1","canonical_id":"hgnc:HGNC:6329","description":"killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1","metadata":{"aliases":["cl-42","nkat1","47.11","p58.1","CD158A"]}},{"id":"178320e403a74ee99521f7e03a843532","type":"GENE","name":"KIR2DL2","canonical_id":"hgnc:HGNC:6330","description":"killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2","metadata":{"aliases":["cl-43","nkat6","CD158B1","CD158k"]}},{"id":"da2d31d5d95045b3b31fc858fb51bef9","type":"GENE","name":"KIR2DL3","canonical_id":"hgnc:HGNC:6331","description":null,"metadata":null},{"id":"3379299bb8204faaba86b95a62e0e597","type":"GENE","name":"KIR2DL4","canonical_id":"hgnc:HGNC:6332","description":"killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4","metadata":{"aliases":["103AS","15.212","CD158D"]}},{"id":"d85306a5531f4c76a02fad1703941011","type":"GENE","name":"KIR2DL5A","canonical_id":"hgnc:HGNC:16345","description":"killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5A","metadata":{"aliases":["KIR2DL5.1","KIR2DL5","CD158F"]}},{"id":"ce706fe7bbea4dd4affc28737031fb44","type":"GENE","name":"KIR2DL5B","canonical_id":"hgnc:HGNC:16346","description":"killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5B","metadata":{"aliases":["KIR2DL5.2","KIR2DL5","KIR2DL5.3","KIR2DL5.4"]}},{"id":"4ef50f18fa54479d9d8d80b47e0c5fa1","type":"GENE","name":"KIR2DP1","canonical_id":"hgnc:HGNC:16344","description":"killer cell immunoglobulin like receptor, two Ig domains pseudogene 1","metadata":{"aliases":["KIRZ","KIRY","KIR15","KIR2DL6"]}},{"id":"b070644d93454e36a46439620ff47f91","type":"GENE","name":"KIR2DS1","canonical_id":"hgnc:HGNC:6333","description":"killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 1","metadata":{"aliases":["EB6ActI","EB6ActII","CD158H"]}},{"id":"d64413bd5b224ebc8598a2cfc2ef62cb","type":"GENE","name":"KIR2DS2","canonical_id":"hgnc:HGNC:6334","description":"killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 2","metadata":{"aliases":["cl-49","nkat5","183ActI","CD158J"]}},{"id":"0d5d4363a831417e871ab8225daed7dc","type":"GENE","name":"KIR2DS3","canonical_id":"hgnc:HGNC:6335","description":"killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 3","metadata":{"aliases":["nkat7"]}},{"id":"992b2ec6569742d79a9f3d40028a594e","type":"GENE","name":"KIR2DS4","canonical_id":"hgnc:HGNC:6336","description":"killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4 (gene/pseudogene)","metadata":{"aliases":["cl-39","KKA3","nkat8","CD158I"]}},{"id":"9e37c2a67f694ec899abe423c8a89c26","type":"GENE","name":"KIR2DS5","canonical_id":"hgnc:HGNC:6337","description":"killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 5","metadata":{"aliases":["nkat9","CD158G"]}},{"id":"15f29b3a143b47d3aa4bfb6ac9ab71f5","type":"GENE","name":"KIR3DL1","canonical_id":"hgnc:HGNC:6338","description":null,"metadata":null},{"id":"0860399ca8204cd6be0950e2a30bb698","type":"GENE","name":"KIR3DL2","canonical_id":"hgnc:HGNC:6339","description":"killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2","metadata":{"aliases":["cl-5","nkat4","nkat4a","nkat4b","CD158K"]}},{"id":"6687f3b275fe4ecbb95e68b0ad3b6cd4","type":"GENE","name":"KIR3DL3","canonical_id":"hgnc:HGNC:16312","description":"killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3","metadata":{"aliases":["KIRC1","KIR3DL7","KIR44","CD158Z"]}},{"id":"512321e0d75d429dac440d8d4f1b3829","type":"GENE","name":"KIR3DP1","canonical_id":"hgnc:HGNC:16343","description":"killer cell immunoglobulin like receptor, three Ig domains pseudogene 1","metadata":{"aliases":["KIRX","KIR48","KIR2DS6","KIR3DS2P","CD158C"]}},{"id":"e542d1c795864375a262b0ec3ff491fc","type":"GENE","name":"KIR3DS1","canonical_id":"hgnc:HGNC:6340","description":"killer cell immunoglobulin like receptor, three Ig domains and short cytoplasmic tail 1","metadata":{"aliases":["nkat10"]}},{"id":"ae80d024829848128d3337b6b3e04329","type":"GENE","name":"KIR3DX1","canonical_id":"hgnc:HGNC:25043","description":"killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene)","metadata":{"aliases":["FLJ00060","LENG12"]}},{"id":"f70fc127722042e2a31f4d5ca8a696e6","type":"GENE","name":"KIRREL1","canonical_id":"hgnc:HGNC:15734","description":"kirre like nephrin family adhesion molecule 1","metadata":{"aliases":["NEPH1","KIRREL"]}},{"id":"e631313ba89a47e09fc7c609325df2e8","type":"GENE","name":"KIRREL1-IT1","canonical_id":"hgnc:HGNC:41412","description":"KIRREL1 intronic transcript 1","metadata":{"aliases":["KIRREL-IT1"]}},{"id":"12f11876366a43b9bde447e37594ead2","type":"GENE","name":"KIRREL2","canonical_id":"hgnc:HGNC:18816","description":"kirre like nephrin family adhesion molecule 2","metadata":{"aliases":["NLG1","NEPH3","FILTRIN","DKFZp564A1164","MGC15718"]}},{"id":"da9cf7e98c67432fa0ade49d34bbddca","type":"GENE","name":"KIRREL3","canonical_id":"hgnc:HGNC:23204","description":"kirre like nephrin family adhesion molecule 3","metadata":{"aliases":["NEPH2","KIAA1867","KIRRE"]}},{"id":"3f97c3ade04149478d4988ad655af8b0","type":"GENE","name":"KIRREL3-AS1","canonical_id":"hgnc:HGNC:42655","description":"KIRREL3 antisense RNA 1","metadata":null},{"id":"02ea29470c8b49a38315428836558585","type":"GENE","name":"KIRREL3-AS2","canonical_id":"hgnc:HGNC:42656","description":"KIRREL3 antisense RNA 2","metadata":null},{"id":"8e19955229a543fe90c710f6a8eab721","type":"GENE","name":"KIRREL3-AS3","canonical_id":"hgnc:HGNC:26855","description":"KIRREL3 antisense RNA 3","metadata":{"aliases":["FLJ40224","PRR10","NCRNA00288"]}},{"id":"f2a01644c6e24765bb19a01b03864606","type":"GENE","name":"KIRREL3-AS4","canonical_id":"hgnc:HGNC:58263","description":"KIRREL3 antisense RNA 4","metadata":null},{"id":"b6dd62ac788f4408ae0875d2a1f2263d","type":"GENE","name":"KISS1","canonical_id":"hgnc:HGNC:6341","description":null,"metadata":null},{"id":"c78378e5e7374814abe07166426117c7","type":"GENE","name":"KISS1R","canonical_id":"hgnc:HGNC:4510","description":null,"metadata":null},{"id":"41d73c39c88148e489484be6ca10d7af","type":"GENE","name":"KIT","canonical_id":"hgnc:HGNC:6342","description":null,"metadata":null},{"id":"bfa3de30be894908b974e4563aec632a","type":"PROTEIN","name":"KIT","canonical_id":"uniprot:P10721","description":null,"metadata":null},{"id":"fa37d18d63704f64ab5fbbee0b1bf4b9","type":"GENE","name":"KIT","canonical_id":"ensembl:ENSG00000157404","description":null,"metadata":null},{"id":"f982009da76548038c927b1eae610019","type":"GENE","name":"KITLG","canonical_id":"hgnc:HGNC:6343","description":"KIT ligand","metadata":{"aliases":["SCF","SF","Kitl","KL-1","FPH2","SLF","DFNA69","MGF"]}},{"id":"f0c4ade7bbc84defaf1caa29a26a0d12","type":"GENE","name":"KIZ","canonical_id":"hgnc:HGNC:15865","description":"kizuna centrosomal protein","metadata":{"aliases":["HT013","NCRNA00153","C20orf19","PLK1S1"]}},{"id":"0c24a6791530431ab36ce553dfcf05a0","type":"GENE","name":"KIZ-AS1","canonical_id":"hgnc:HGNC:51231","description":"KIZ antisense RNA 1","metadata":null},{"id":"2f434653fbff42d0aba5cf58e78ba942","type":"GENE","name":"KL","canonical_id":"hgnc:HGNC:6344","description":null,"metadata":null},{"id":"e113e596e38f4cc2919e8fc25fe9f96a","type":"GENE","name":"KLB","canonical_id":"hgnc:HGNC:15527","description":"klotho beta","metadata":null},{"id":"1004b126dd9441eba7dd0400898ba357","type":"GENE","name":"KLC1","canonical_id":"hgnc:HGNC:6387","description":"kinesin light chain 1","metadata":{"aliases":["KNS2A","KLC","hKLC1S","hKLC1N","hKLC1P","hKLC1G","hKLC1R","hKLC1J","hKLC1B","KNS2"]}},{"id":"c3d83cca4b4b423cabc3b19033f3ecb9","type":"GENE","name":"KLC1-AS1","canonical_id":"hgnc:HGNC:56065","description":"KLC1 antisense RNA 1","metadata":null},{"id":"f745784c70204c639a6b70ee9bd5c826","type":"GENE","name":"KLC2","canonical_id":"hgnc:HGNC:20716","description":"kinesin light chain 2","metadata":{"aliases":["FLJ12387"]}},{"id":"325abd7113ad4d91a1c2c829fde588eb","type":"GENE","name":"KLC2-AS1","canonical_id":"hgnc:HGNC:40934","description":"KLC2 antisense RNA 1","metadata":null},{"id":"9e2b4a4c790b467194b4bff1a76b5bf3","type":"GENE","name":"KLC2-AS2","canonical_id":"hgnc:HGNC:55515","description":"KLC2 antisense RNA 2","metadata":null},{"id":"e2f918f6a478472b8b25ddae176896da","type":"GENE","name":"KLC3","canonical_id":"hgnc:HGNC:20717","description":"kinesin light chain 3","metadata":{"aliases":["KLC2L","KNS2B","KLCt"]}},{"id":"c337851a70eb492c9432a01880f9a2e4","type":"GENE","name":"KLC4","canonical_id":"hgnc:HGNC:21624","description":"kinesin light chain 4","metadata":{"aliases":["bA387M24.3","KNSL8"]}},{"id":"d4ad785fc9ff450cbf12e73e31ea4ef6","type":"GENE","name":"KLC4-AS1","canonical_id":"hgnc:HGNC:55228","description":"KLC4 antisense RNA 1","metadata":null},{"id":"4bb70fce4e3643f5a48ddf3554043939","type":"GENE","name":"KLF1","canonical_id":"hgnc:HGNC:6345","description":null,"metadata":null},{"id":"de844fa8215042b2a1a30742bc9d9011","type":"GENE","name":"KLF10","canonical_id":"hgnc:HGNC:11810","description":null,"metadata":null},{"id":"8416983e5c5646d1a162551aac313918","type":"GENE","name":"KLF11","canonical_id":"hgnc:HGNC:11811","description":null,"metadata":null},{"id":"6f2619de87364618a36ce72f60f984f6","type":"GENE","name":"KLF11-DT","canonical_id":"hgnc:HGNC:56037","description":"KLF11 divergent transcript","metadata":null},{"id":"70b99da094d44faab3af5edb204834d5","type":"GENE","name":"KLF12","canonical_id":"hgnc:HGNC:6346","description":null,"metadata":null},{"id":"3c59300faba94b6d9fb6a8ea0c4eebe3","type":"GENE","name":"KLF13","canonical_id":"hgnc:HGNC:13672","description":null,"metadata":null},{"id":"8a61370f51d24040ba3966f5f6450b5a","type":"GENE","name":"KLF14","canonical_id":"hgnc:HGNC:23025","description":null,"metadata":null},{"id":"9061ae994092455582ab41cc052ef698","type":"GENE","name":"KLF15","canonical_id":"hgnc:HGNC:14536","description":null,"metadata":null},{"id":"bcca3a31db974a5bb1c7fd9198b2e2e6","type":"GENE","name":"KLF16","canonical_id":"hgnc:HGNC:16857","description":null,"metadata":null},{"id":"43c25df8e7e54872ae540a2bf842cf03","type":"GENE","name":"KLF16-AS1","canonical_id":"hgnc:HGNC:58318","description":"KLF16 antisense RNA 1","metadata":null},{"id":"256416323eac4ad4987d345336ddb88a","type":"GENE","name":"KLF17","canonical_id":"hgnc:HGNC:18830","description":null,"metadata":null},{"id":"1d00f2fa317d48e3b3c1c89f0ea8046f","type":"GENE","name":"KLF17P1","canonical_id":"hgnc:HGNC:41521","description":"KLF17 pseudogene 1","metadata":null},{"id":"df6e1187abe4401989e6dbeb0578dff1","type":"GENE","name":"KLF17P2","canonical_id":"hgnc:HGNC:49135","description":"KLF17 pseudogene 2","metadata":null},{"id":"13994cb7ee9e4259b13e1a356b622398","type":"GENE","name":"KLF18","canonical_id":"hgnc:HGNC:51793","description":"KLF transcription factor 18","metadata":null},{"id":"7610f79b2f12429785e8b0244f43f790","type":"GENE","name":"KLF2","canonical_id":"hgnc:HGNC:6347","description":null,"metadata":null},{"id":"c2151a38379d4ac392f77647a2d764fe","type":"GENE","name":"KLF2-DT","canonical_id":"hgnc:HGNC:55304","description":"KLF2 divergent transcript","metadata":null},{"id":"c1a3efa0534f4ca19f730604d333f85e","type":"GENE","name":"KLF2P1","canonical_id":"hgnc:HGNC:49280","description":"KLF2 pseudogene 1","metadata":null},{"id":"7ccbb80fd5354b6abbf40a03325b3d85","type":"GENE","name":"KLF2P2","canonical_id":"hgnc:HGNC:49281","description":"KLF2 pseudogene 2","metadata":null},{"id":"8d722e4c60564df197914d4ecc09f3a5","type":"GENE","name":"KLF2P3","canonical_id":"hgnc:HGNC:49282","description":"KLF2 pseudogene 3","metadata":null},{"id":"477103cffeb84af4acb45efcd617eed8","type":"GENE","name":"KLF2P4","canonical_id":"hgnc:HGNC:49283","description":"KLF2 pseudogene 4","metadata":null},{"id":"5c023ebb718b4ee9887dc34b19d85b60","type":"GENE","name":"KLF3","canonical_id":"hgnc:HGNC:16516","description":null,"metadata":null},{"id":"b3ac6559cb524cff8b2d2d1052a37e93","type":"GENE","name":"KLF3-AS1","canonical_id":"hgnc:HGNC:25796","description":"KLF3 antisense RNA 1","metadata":{"aliases":["FLJ13197"]}},{"id":"b576abe47a1d42258df2a1e136572b9f","type":"GENE","name":"KLF3-AS2","canonical_id":"hgnc:HGNC:58760","description":"KLF3 antisense RNA 2","metadata":null},{"id":"072bbdd8f1534521869af54d4cb2dbab","type":"GENE","name":"KLF3P1","canonical_id":"hgnc:HGNC:41518","description":"KLF3 pseudogene 1","metadata":null},{"id":"09270d425a504bf7a11cb2bb8c853e18","type":"GENE","name":"KLF3P2","canonical_id":"hgnc:HGNC:41519","description":"KLF3 pseudogene 2","metadata":null},{"id":"09812b72f40841c8b90ee6868beba9e2","type":"GENE","name":"KLF4","canonical_id":"hgnc:HGNC:6348","description":null,"metadata":null},{"id":"9a02bfcc743b4cc9b5dbdeb3427a45b3","type":"GENE","name":"KLF4P1","canonical_id":"hgnc:HGNC:49738","description":"KLF4 pseudogene 1","metadata":null},{"id":"2ae5fef99bbf437680c6e366293e71e6","type":"GENE","name":"KLF5","canonical_id":"hgnc:HGNC:6349","description":null,"metadata":null},{"id":"dd723fdd1cd64d81b08871812e335420","type":"GENE","name":"KLF6","canonical_id":"hgnc:HGNC:2235","description":null,"metadata":null},{"id":"ac9f31ef5e3c4f348d8ee09a6461387a","type":"GENE","name":"KLF7","canonical_id":"hgnc:HGNC:6350","description":null,"metadata":null},{"id":"c69149227a9442b6899dcbb991a08667","type":"GENE","name":"KLF7-IT1","canonical_id":"hgnc:HGNC:41355","description":"KLF7 intronic transcript 1","metadata":null},{"id":"1ab4f20aeb1843f2b71dcccbd79db2c6","type":"GENE","name":"KLF7P1","canonical_id":"hgnc:HGNC:17207","description":"KLF7 pseudogene 1","metadata":{"aliases":["KLF7P"]}},{"id":"976ca4b6e8a145c1bcc8b6ec2ae6a2ba","type":"GENE","name":"KLF8","canonical_id":"hgnc:HGNC:6351","description":null,"metadata":null},{"id":"76b5ffb9d64a42a68c8d5ce4cd26faf9","type":"GENE","name":"KLF8P1","canonical_id":"hgnc:HGNC:41520","description":"KLF8 pseudogene 1","metadata":null},{"id":"d86c33c624b14719812a2ecb921c68cd","type":"GENE","name":"KLF9","canonical_id":"hgnc:HGNC:1123","description":null,"metadata":null},{"id":"69b7658b9e6d40d18bb0d0c5d636c9cc","type":"GENE","name":"KLF9-DT","canonical_id":"hgnc:HGNC:54815","description":"KLF9 divergent transcript","metadata":null},{"id":"bf3a1d762c674c00ae1778b97db2602c","type":"GENE","name":"KLHDC1","canonical_id":"hgnc:HGNC:19836","description":"kelch domain containing 1","metadata":{"aliases":["MST025"]}},{"id":"04736ce03c704e01a3cb8769ef465340","type":"GENE","name":"KLHDC10","canonical_id":"hgnc:HGNC:22194","description":"kelch domain containing 10","metadata":{"aliases":["KIAA0265","slim"]}},{"id":"1a8c213d9d8f47cc8c7952e83de22a28","type":"GENE","name":"KLHDC2","canonical_id":"hgnc:HGNC:20231","description":"kelch domain containing 2","metadata":{"aliases":["HCLP-1","LCP"]}},{"id":"f1738786ca514814a6114ee5e3304d9d","type":"GENE","name":"KLHDC3","canonical_id":"hgnc:HGNC:20704","description":"kelch domain containing 3","metadata":{"aliases":["PEAS","hPeas","dJ20C7.3"]}},{"id":"78bee88948ef4530aaa09b89543a4abe","type":"GENE","name":"KLHDC4","canonical_id":"hgnc:HGNC:25272","description":"kelch domain containing 4","metadata":{"aliases":["DKFZp434G0522"]}},{"id":"c2f4269289744b348f83f9c6bec8b27b","type":"GENE","name":"KLHDC7A","canonical_id":"hgnc:HGNC:26791","description":"kelch domain containing 7A","metadata":{"aliases":["FLJ38753"]}},{"id":"3ab5176f79ee401ba027c01c52252375","type":"GENE","name":"KLHDC7B","canonical_id":"hgnc:HGNC:25145","description":"kelch domain containing 7B","metadata":{"aliases":["MGC16635"]}},{"id":"da1094c05d034da7857be62fd345071e","type":"GENE","name":"KLHDC7B-DT","canonical_id":"hgnc:HGNC:53791","description":"KLHDC7B divergent transcript","metadata":null},{"id":"3b1ec30f81bd439a919035e41b6fd7ae","type":"GENE","name":"KLHDC8A","canonical_id":"hgnc:HGNC:25573","description":"kelch domain containing 8A","metadata":{"aliases":["FLJ10748"]}},{"id":"83aebaa3a51f4eea98da355021fee34b","type":"GENE","name":"KLHDC8B","canonical_id":"hgnc:HGNC:28557","description":"kelch domain containing 8B","metadata":{"aliases":["MGC35097"]}},{"id":"2674281c2af54a5b88d5fe02015288c6","type":"GENE","name":"KLHDC9","canonical_id":"hgnc:HGNC:28489","description":"kelch domain containing 9","metadata":{"aliases":["KARCA1"]}},{"id":"9fb6cc561a9844a289bee4741513022e","type":"GENE","name":"KLHL1","canonical_id":"hgnc:HGNC:6352","description":"kelch like family member 1","metadata":{"aliases":["KIAA1490","MRP2","FLJ30047"]}},{"id":"bb4d52faba9a4d44a20c512f047704c7","type":"GENE","name":"KLHL10","canonical_id":"hgnc:HGNC:18829","description":"kelch like family member 10","metadata":{"aliases":["FLJ32662"]}},{"id":"1af014928d66486096046da60feace52","type":"GENE","name":"KLHL11","canonical_id":"hgnc:HGNC:19008","description":"kelch like family member 11","metadata":{"aliases":["FLJ10572"]}},{"id":"14c18283ccc24cd0bb82a9bfe1c6092a","type":"GENE","name":"KLHL12","canonical_id":"hgnc:HGNC:19360","description":"kelch like family member 12","metadata":{"aliases":["C3IP1"]}},{"id":"a0003f55fd45497fa4f6a4a81f89e354","type":"GENE","name":"KLHL12P1","canonical_id":"hgnc:HGNC:56971","description":"KLHL12 pseudogene 1","metadata":null},{"id":"d72f1e3538c14485a2d77631275ca68f","type":"GENE","name":"KLHL13","canonical_id":"hgnc:HGNC:22931","description":"kelch like family member 13","metadata":{"aliases":["FLJ10262","BKLHD2","KIAA1309"]}},{"id":"01a691f5cc6940338f8e5999bd6f9bac","type":"GENE","name":"KLHL14","canonical_id":"hgnc:HGNC:29266","description":"kelch like family member 14","metadata":{"aliases":["KIAA1384"]}},{"id":"4599340a57894bdb9f2e7f0764583103","type":"GENE","name":"KLHL14-AS1","canonical_id":"hgnc:HGNC:58976","description":"KLHL14 antisense RNA 1","metadata":{"aliases":["uc.428"]}},{"id":"b3ad95def071485c9c859ef1cc9d31a6","type":"GENE","name":"KLHL15","canonical_id":"hgnc:HGNC:29347","description":"kelch like family member 15","metadata":{"aliases":["KIAA1677"]}},{"id":"da02affbd1c040c88f7bb03b502e8fd3","type":"GENE","name":"KLHL17","canonical_id":"hgnc:HGNC:24023","description":"kelch like family member 17","metadata":null},{"id":"ad2b08cb38f6480b8b600e56c38d0ea2","type":"GENE","name":"KLHL18","canonical_id":"hgnc:HGNC:29120","description":"kelch like family member 18","metadata":{"aliases":["KIAA0795","FLJ13703"]}},{"id":"7182a88f1a8e4ef5847a8449ba0d6487","type":"GENE","name":"KLHL2","canonical_id":"hgnc:HGNC:6353","description":"kelch like family member 2","metadata":{"aliases":["MAV"]}},{"id":"686f0257ee8c48bf8bd8dd386f301c99","type":"GENE","name":"KLHL20","canonical_id":"hgnc:HGNC:25056","description":"kelch like family member 20","metadata":{"aliases":["KLEIP","KHLHX"]}},{"id":"6f3757739c50408aab00298e04f2a01e","type":"GENE","name":"KLHL21","canonical_id":"hgnc:HGNC:29041","description":"kelch like family member 21","metadata":{"aliases":["KIAA0469"]}},{"id":"3b6393e806a6431c871992b3cee7d4da","type":"GENE","name":"KLHL22","canonical_id":"hgnc:HGNC:25888","description":"kelch like family member 22","metadata":{"aliases":["FLJ14360","KELCHL"]}},{"id":"a623eb2aeb424377994aeb1affe0f453","type":"GENE","name":"KLHL23","canonical_id":"hgnc:HGNC:27506","description":"kelch like family member 23","metadata":{"aliases":["MGC2610","FLJ37812","MGC22679"]}},{"id":"c1dea36e6e994346ab6da32e4a2bfd5c","type":"GENE","name":"KLHL24","canonical_id":"hgnc:HGNC:25947","description":"kelch like family member 24","metadata":{"aliases":["DRE1","FLJ20059","KRIP6"]}},{"id":"01dacb9b0836447eb6a8f64e6025aefe","type":"GENE","name":"KLHL25","canonical_id":"hgnc:HGNC:25732","description":"kelch like family member 25","metadata":{"aliases":["FLJ12587","ENC2","ENC-2"]}},{"id":"1f545fdee2e04677821b2f3d7efb96f0","type":"GENE","name":"KLHL25P1","canonical_id":"hgnc:HGNC:56403","description":"KLHL25 pseudogene 1","metadata":null},{"id":"b126811e52174debb45424aee9308de0","type":"GENE","name":"KLHL26","canonical_id":"hgnc:HGNC:25623","description":"kelch like family member 26","metadata":null},{"id":"d6be911450864fbc859266ee01d0bbaa","type":"GENE","name":"KLHL27","canonical_id":"hgnc:HGNC:6108","description":"kelch like family member 27","metadata":{"aliases":["IPP"]}},{"id":"aea0a02066de4a699d2b62927f597029","type":"GENE","name":"KLHL28","canonical_id":"hgnc:HGNC:19741","description":"kelch like family member 28","metadata":{"aliases":["FLJ20081","BTBD5"]}},{"id":"4319934f00b548bc932e5e052b2d57c9","type":"GENE","name":"KLHL29","canonical_id":"hgnc:HGNC:29404","description":"kelch like family member 29","metadata":{"aliases":["KIAA1921","KBTBD9"]}},{"id":"4d91b9e1660446759f6d441faf430c63","type":"GENE","name":"KLHL2P1","canonical_id":"hgnc:HGNC:44046","description":"kelch like family member 2 pseudogene 1","metadata":{"aliases":["MAVP1"]}},{"id":"49a3e14d1fb8432a8a079cc567ab6528","type":"GENE","name":"KLHL3","canonical_id":"hgnc:HGNC:6354","description":"kelch like family member 3","metadata":{"aliases":["KIAA1129"]}},{"id":"9fe715871d4048e3a3ba82542f83a0b5","type":"GENE","name":"KLHL30","canonical_id":"hgnc:HGNC:24770","description":"kelch like family member 30","metadata":{"aliases":["FLJ43374"]}},{"id":"900b82f1d76344419608bbaab35cec53","type":"GENE","name":"KLHL30-AS1","canonical_id":"hgnc:HGNC:31018","description":"KLHL30 antisense RNA 1","metadata":{"aliases":["C2orf19"]}},{"id":"a807730a637f4c59a2af808002d6f54f","type":"GENE","name":"KLHL31","canonical_id":"hgnc:HGNC:21353","description":"kelch like family member 31","metadata":{"aliases":["bA345L23.2","BKLHD6","KBTBD1"]}},{"id":"1046a602d5484e60ac71827f045a06d3","type":"GENE","name":"KLHL32","canonical_id":"hgnc:HGNC:21221","description":"kelch like family member 32","metadata":{"aliases":["BKLHD5","KIAA1900"]}},{"id":"fdd5e92a07e54c98aec086023df64ab9","type":"GENE","name":"KLHL33","canonical_id":"hgnc:HGNC:31952","description":"kelch like family member 33","metadata":null},{"id":"eab4320cdd1344aaaf415a47c92484c5","type":"GENE","name":"KLHL34","canonical_id":"hgnc:HGNC:26634","description":"kelch like family member 34","metadata":{"aliases":["FLJ34960","RP11-450P7.3"]}},{"id":"c9105c0d2f844e6a96f3553d4d153317","type":"GENE","name":"KLHL35","canonical_id":"hgnc:HGNC:26597","description":"kelch like family member 35","metadata":{"aliases":["FLJ33790"]}},{"id":"1b4f6bf7370c4b9a802a05d3396854e6","type":"GENE","name":"KLHL36","canonical_id":"hgnc:HGNC:17844","description":"kelch like family member 36","metadata":{"aliases":["FLJ12543","C16orf44"]}},{"id":"77ff0c9f66ea42a8a88f6c6903cd06ad","type":"GENE","name":"KLHL38","canonical_id":"hgnc:HGNC:34435","description":"kelch like family member 38","metadata":{"aliases":["C8ORFK36"]}},{"id":"1034ec2ffcb24e83b5e23772338a4f8b","type":"GENE","name":"KLHL4","canonical_id":"hgnc:HGNC:6355","description":"kelch like family member 4","metadata":{"aliases":["KIAA1687","DKELCHL","KHL4"]}},{"id":"92e29f8d55f94c0eaadacf5000442441","type":"GENE","name":"KLHL40","canonical_id":"hgnc:HGNC:30372","description":"kelch like family member 40","metadata":{"aliases":["SRYP","NEM8","KBTBD5"]}},{"id":"753d2cdfcaf84d7f8a8003bf052e3275","type":"GENE","name":"KLHL41","canonical_id":"hgnc:HGNC:16905","description":"kelch like family member 41","metadata":{"aliases":["SARCOSIN","Krp1","KBTBD10"]}},{"id":"6632f8c1e616454e96cb428ebe71eec0","type":"GENE","name":"KLHL42","canonical_id":"hgnc:HGNC:29252","description":"kelch like family member 42","metadata":{"aliases":["KIAA1340","Ctb9","KLHDC5"]}},{"id":"c4cde579ee364496b244c3f3112a4f05","type":"GENE","name":"KLHL5","canonical_id":"hgnc:HGNC:6356","description":"kelch like family member 5","metadata":null},{"id":"c07cdf146118430d884acab0c3c89c9d","type":"GENE","name":"KLHL5P1","canonical_id":"hgnc:HGNC:56977","description":"KLHL5 pseudogene 1","metadata":null},{"id":"bcf3247e9eba4b0f9e3b83e108b04936","type":"GENE","name":"KLHL6","canonical_id":"hgnc:HGNC:18653","description":"kelch like family member 6","metadata":{"aliases":["FLJ00029"]}},{"id":"b650d41f04e64efda98ba0cfabc9c157","type":"GENE","name":"KLHL6-AS1","canonical_id":"hgnc:HGNC:40850","description":"KLHL6 antisense RNA 1","metadata":null},{"id":"0744951911ec4e8599bec341aa1d2d6d","type":"GENE","name":"KLHL7","canonical_id":"hgnc:HGNC:15646","description":"kelch like family member 7","metadata":{"aliases":["KLHL6","SBBI26","RP42"]}},{"id":"343920277a3c4adda544df51c5fd8c21","type":"GENE","name":"KLHL7-DT","canonical_id":"hgnc:HGNC:43431","description":"KLHL7 divergent transcript","metadata":{"aliases":["PLATAK","KLHL7-AS1"]}},{"id":"6b19c2f6bfec478c9b0e3a20244e615a","type":"GENE","name":"KLHL8","canonical_id":"hgnc:HGNC:18644","description":"kelch like family member 8","metadata":{"aliases":["KIAA1378"]}},{"id":"62163442d8934fc2afce32a6b47c1aeb","type":"GENE","name":"KLHL9","canonical_id":"hgnc:HGNC:18732","description":"kelch like family member 9","metadata":{"aliases":["KIAA1354","FLJ13568"]}},{"id":"1f5dc52d993f47ab9e323185c88533b6","type":"GENE","name":"KLK1","canonical_id":"hgnc:HGNC:6357","description":null,"metadata":null},{"id":"743c0f05f64345fe90c2c5d7ed221010","type":"GENE","name":"KLK10","canonical_id":"hgnc:HGNC:6358","description":null,"metadata":null},{"id":"7c70c730cc8149d8b9b40576525e0b32","type":"GENE","name":"KLK11","canonical_id":"hgnc:HGNC:6359","description":"kallikrein related peptidase 11","metadata":{"aliases":["TLSP","PRSS20"]}},{"id":"b6a73b378e9744519bebe64790513656","type":"GENE","name":"KLK12","canonical_id":"hgnc:HGNC:6360","description":"kallikrein related peptidase 12","metadata":{"aliases":["KLK-L5"]}},{"id":"fb5d74a05a9542158910ade37f02c668","type":"GENE","name":"KLK13","canonical_id":"hgnc:HGNC:6361","description":"kallikrein related peptidase 13","metadata":{"aliases":["KLK-L4"]}},{"id":"0b2043794a1942d58e2bf67c8b009504","type":"GENE","name":"KLK14","canonical_id":"hgnc:HGNC:6362","description":"kallikrein related peptidase 14","metadata":{"aliases":["KLK-L6"]}},{"id":"f7309a40b68b4010ab3678a03c0f12cb","type":"GENE","name":"KLK15","canonical_id":"hgnc:HGNC:20453","description":"kallikrein related peptidase 15","metadata":{"aliases":["HSRNASPH","ACO","prostinogen"]}},{"id":"f802fe3ed355462db037e08113774243","type":"GENE","name":"KLK2","canonical_id":"hgnc:HGNC:6363","description":null,"metadata":null},{"id":"e98839942f0e4450a86f94a2619587b8","type":"GENE","name":"KLK3","canonical_id":"hgnc:HGNC:6364","description":null,"metadata":null},{"id":"56f13b75f6da442a9f0f83cb88bb0207","type":"GENE","name":"KLK4","canonical_id":"hgnc:HGNC:6365","description":null,"metadata":null},{"id":"1ea8cf8080044eb8af7a65119e7e5f14","type":"GENE","name":"KLK5","canonical_id":"hgnc:HGNC:6366","description":"kallikrein related peptidase 5","metadata":{"aliases":["SCTE","KLK-L2"]}},{"id":"ea5d49ff9b724062865e37df43f3e2dd","type":"GENE","name":"KLK6","canonical_id":"hgnc:HGNC:6367","description":"kallikrein related peptidase 6","metadata":{"aliases":["Bssp","Klk7","neurosin","PRSS9","PRSS18"]}},{"id":"1ae020da2a2b415c828c06e4f9751777","type":"GENE","name":"KLK7","canonical_id":"hgnc:HGNC:6368","description":"kallikrein related peptidase 7","metadata":{"aliases":["SCCE","PRSS6"]}},{"id":"439f8185a39d47e3abfd0d4e00be63c9","type":"GENE","name":"KLK8","canonical_id":"hgnc:HGNC:6369","description":"kallikrein related peptidase 8","metadata":{"aliases":["HNP","TADG14","neuropsin","ovasin","PRSS19"]}},{"id":"f088a5c2ba764115a06a11e7d1a55945","type":"GENE","name":"KLK9","canonical_id":"hgnc:HGNC:6370","description":"kallikrein related peptidase 9","metadata":{"aliases":["KLK-L3"]}},{"id":"49f215ead7394dfab4e42298c2d7611e","type":"GENE","name":"KLKB1","canonical_id":"hgnc:HGNC:6371","description":"kallikrein B1","metadata":{"aliases":["KLK3"]}},{"id":"2022943dec764d608adf47595f035475","type":"PROTEIN","name":"KLKB1","canonical_id":"uniprot:P03952","description":null,"metadata":null},{"id":"a8bc0241b472453f881e3d61cdc3f1c4","type":"GENE","name":"KLKP1","canonical_id":"hgnc:HGNC:21260","description":"kallikrein pseudogene 1","metadata":{"aliases":["YKLK1","PsiKLK1","KLK31P"]}},{"id":"df9a184913b6470c8fb24e7e92e683c8","type":"GENE","name":"KLLN","canonical_id":"hgnc:HGNC:37212","description":"killin, p53 regulated DNA replication inhibitor","metadata":{"aliases":["killin"]}},{"id":"e5037ad9f7bf487a990038fe48e41c8d","type":"GENE","name":"KLRA1P","canonical_id":"hgnc:HGNC:6372","description":"killer cell lectin like receptor A1, pseudogene","metadata":{"aliases":["Ly49","LY49L","KLRA1","KLRAP1"]}},{"id":"e6b21bb1870b41ffb7afc355acd3d1d7","type":"GENE","name":"KLRB1","canonical_id":"hgnc:HGNC:6373","description":"killer cell lectin like receptor B1","metadata":{"aliases":["CD161","NKR-P1","NKR-P1A","hNKR-P1A","CLEC5B","NKR"]}},{"id":"bf60a821d22a45ccacc6d6716241779f","type":"GENE","name":"KLRC1","canonical_id":"hgnc:HGNC:6374","description":"killer cell lectin like receptor C1","metadata":{"aliases":["NKG2-A","NKG2-B","CD159a","NKG2"]}},{"id":"5bab16013e894b76a37e351cb6b7b879","type":"GENE","name":"KLRC2","canonical_id":"hgnc:HGNC:6375","description":"killer cell lectin like receptor C2","metadata":{"aliases":["NKG2-C","CD159c","NKG2C"]}},{"id":"0742b073e33e42bdad8810276c9d7922","type":"GENE","name":"KLRC3","canonical_id":"hgnc:HGNC:6376","description":"killer cell lectin like receptor C3","metadata":{"aliases":["NKG2-E"]}},{"id":"bc3aedcf7560407c8c48494692537809","type":"GENE","name":"KLRC4","canonical_id":"hgnc:HGNC:6377","description":"killer cell lectin like receptor C4","metadata":{"aliases":["NKG2-F"]}},{"id":"3573fece86934910bd90b50f697cbc9b","type":"GENE","name":"KLRC4-KLRK1","canonical_id":"hgnc:HGNC:48357","description":"KLRC4-KLRK1 readthrough","metadata":null},{"id":"f26626447467454fa72c18902722d8ae","type":"GENE","name":"KLRD1","canonical_id":"hgnc:HGNC:6378","description":"killer cell lectin like receptor D1","metadata":{"aliases":["CD94"]}},{"id":"d6d5f526f55d427db6da6af346ca22ae","type":"GENE","name":"KLRF1","canonical_id":"hgnc:HGNC:13342","description":"killer cell lectin like receptor F1","metadata":{"aliases":["CLEC5C","NKp80"]}},{"id":"badff8651cac4b01aef227a924d5442d","type":"GENE","name":"KLRF2","canonical_id":"hgnc:HGNC:37646","description":"killer cell lectin like receptor F2","metadata":{"aliases":["NKp65"]}},{"id":"1d1da08991d74ac586b961fc1c2d0d4d","type":"GENE","name":"KLRG1","canonical_id":"hgnc:HGNC:6380","description":"killer cell lectin like receptor G1","metadata":{"aliases":["MAFA","2F1","MAFA-L","CLEC15A"]}},{"id":"229788c365b346eea030c293aabbf376","type":"GENE","name":"KLRG2","canonical_id":"hgnc:HGNC:24778","description":"killer cell lectin like receptor G2","metadata":{"aliases":["FLJ44186","CLEC15B"]}},{"id":"421b5d29728c4a6cb11f0d42f2da9bc3","type":"GENE","name":"KLRK1","canonical_id":"hgnc:HGNC:18788","description":null,"metadata":null},{"id":"2b9b266814c84623ab733342cb9acde0","type":"GENE","name":"KLRK1-AS1","canonical_id":"hgnc:HGNC:54868","description":"KLRK1 antisense RNA 1","metadata":{"aliases":["LOC101928100","TP53LC04"]}},{"id":"fd8da4eb5cb949cf871b28a1a5c9bee9","type":"GENE","name":"KMO","canonical_id":"hgnc:HGNC:6381","description":"kynurenine 3-monooxygenase","metadata":null},{"id":"83b55996f5ad4a92ae948003b5954494","type":"GENE","name":"KMT2A","canonical_id":"hgnc:HGNC:7132","description":null,"metadata":null},{"id":"e573434af908422e91a3a62477d691ae","type":"GENE","name":"KMT2CP1","canonical_id":"hgnc:HGNC:56179","description":"lysine methyltransferase 2C pseudogene 1","metadata":null},{"id":"81f23e02a8aa4d31b03799d01a55e918","type":"GENE","name":"KMT2CP2","canonical_id":"hgnc:HGNC:56180","description":"lysine methyltransferase 2C pseudogene 2","metadata":null},{"id":"d0db13d3825d43b3ac16da8d919d8995","type":"GENE","name":"KMT2CP3","canonical_id":"hgnc:HGNC:56181","description":"lysine methyltransferase 2C pseudogene 3","metadata":null},{"id":"759a42c4983b462c8822e2775843303e","type":"GENE","name":"KMT2CP4","canonical_id":"hgnc:HGNC:56182","description":"lysine methyltransferase 2C pseudogene 4","metadata":null},{"id":"8e1d2b9402914818b86e644a08c018de","type":"GENE","name":"KMT2CP5","canonical_id":"hgnc:HGNC:56183","description":"lysine methyltransferase 2C pseudogene 5","metadata":null},{"id":"f9a5bf4f0ce44213b48fdb616a3fcfc0","type":"GENE","name":"KMT2D","canonical_id":"hgnc:HGNC:7133","description":"lysine methyltransferase 2D","metadata":{"aliases":["ALR","MLL4","CAGL114","TNRC21","MLL2"]}},{"id":"577e1d8d7ee94749b60de53afc91e9c8","type":"GENE","name":"KMT2E","canonical_id":"hgnc:HGNC:18541","description":"lysine methyltransferase 2E (inactive)","metadata":{"aliases":["HDCMC04P","SETD5B","MLL5"]}},{"id":"ae5e43d65457462ab6acc6a2d44b7e4b","type":"GENE","name":"KMT2E-AS1","canonical_id":"hgnc:HGNC:40845","description":"KMT2E antisense RNA 1","metadata":{"aliases":["lncPENG","LOC100216545","RP11-325F22.5.1","LINC01004","LHFPL3-AS2"]}},{"id":"1d47b99f3c684b2a95253cfb03370ea7","type":"GENE","name":"KMT5A","canonical_id":"hgnc:HGNC:29489","description":null,"metadata":null},{"id":"c51245fb55af46f5a6f4c2a8c53db0ca","type":"GENE","name":"KMT5AP1","canonical_id":"hgnc:HGNC:30088","description":"KMT5A pseudogene 1","metadata":{"aliases":["SET07p","SETD8P1"]}},{"id":"55aa5a69afba4797a479a011a22923d9","type":"GENE","name":"KMT5AP2","canonical_id":"hgnc:HGNC:54727","description":"KMT5A pseudogene 2","metadata":null},{"id":"ee2724cff19848cc9b094f51b44dccc3","type":"GENE","name":"KMT5AP3","canonical_id":"hgnc:HGNC:54728","description":"KMT5A pseudogene 3","metadata":null},{"id":"10ba7367e89048138a72f0a42794a86b","type":"GENE","name":"KMT5B","canonical_id":"hgnc:HGNC:24283","description":"lysine methyltransferase 5B","metadata":{"aliases":["CGI-85","SUV420H1"]}},{"id":"92d4f82600d9402c87eb0115a3339317","type":"GENE","name":"KMT5C","canonical_id":"hgnc:HGNC:28405","description":"lysine methyltransferase 5C","metadata":{"aliases":["MGC2705","SUV420H2"]}},{"id":"26bf2faaf5d84687b6a226de22c361ab","type":"GENE","name":"KNCN","canonical_id":"hgnc:HGNC:26488","description":"kinocilin","metadata":{"aliases":["FLJ32011","KINO","L5"]}},{"id":"087dec835fb34de5aba919061bc279c5","type":"GENE","name":"KNDC1","canonical_id":"hgnc:HGNC:29374","description":"kinase non-catalytic C-lobe domain containing 1","metadata":{"aliases":["KIAA1768","bB439H18.3","FLJ25027","Very-KIND","v-KIND","RASGEF2","C10orf23"]}},{"id":"539b8ca221794b4aaf30205cb84a2f4b","type":"GENE","name":"KNG1","canonical_id":"hgnc:HGNC:6383","description":"kininogen 1","metadata":{"aliases":["BK","HMWK","KNG","BDK","HK"]}},{"id":"b6ae847ec3d647f9b38ad572e0c86928","type":"GENE","name":"KNL1","canonical_id":"hgnc:HGNC:24054","description":"kinetochore scaffold 1","metadata":{"aliases":["D40","AF15Q14","CT29","KIAA1570","hKNL-1","hSpc105","PPP1R55","Spc7","MCPH4","CASC5"]}},{"id":"df5a4a10b44344dbbe3fd8cba7e4a39c","type":"GENE","name":"KNOP1","canonical_id":"hgnc:HGNC:34404","description":"lysine rich nucleolar protein 1","metadata":{"aliases":["101F10.1","FAM191A","TSG118","C16orf88"]}},{"id":"29c5b30bbeed48cf801ef2551f9ea8d3","type":"GENE","name":"KNOP1P1","canonical_id":"hgnc:HGNC:48919","description":"lysine rich nucleolar protein 1 pseudogene 1","metadata":null},{"id":"111ed6e1e90f4c5db9e48d469552a918","type":"GENE","name":"KNOP1P2","canonical_id":"hgnc:HGNC:48920","description":"lysine rich nucleolar protein 1 pseudogene 2","metadata":null},{"id":"42c15c3696fb49a3b9833c10c7227976","type":"GENE","name":"KNOP1P3","canonical_id":"hgnc:HGNC:48921","description":"lysine rich nucleolar protein 1 pseudogene 3","metadata":null},{"id":"1ccf794c37cc4b81af78b3e0e717a9ba","type":"GENE","name":"KNOP1P4","canonical_id":"hgnc:HGNC:48922","description":"lysine rich nucleolar protein 1 pseudogene 4","metadata":null},{"id":"a4ae5f47e8474cd1add25d2f612b4751","type":"GENE","name":"KNOP1P5","canonical_id":"hgnc:HGNC:48923","description":"lysine rich nucleolar protein 1 pseudogene 5","metadata":null},{"id":"0bdfa9f12967435cbd062b4626dcd330","type":"GENE","name":"KNSTRN","canonical_id":"hgnc:HGNC:30767","description":"kinetochore localized astrin (SPAG5) binding protein","metadata":{"aliases":["FLJ14502","SKAP","kinastrin","TRAF4AF1","C15orf23"]}},{"id":"8cde9f00a76c457f8ccd7692f4fed661","type":"GENE","name":"KNTC1","canonical_id":"hgnc:HGNC:17255","description":"kinetochore associated 1","metadata":{"aliases":["KIAA0166","ROD"]}},{"id":"3ea8dd74f88647b2b7272f593467ba85","type":"GENE","name":"KPLCE","canonical_id":"hgnc:HGNC:29468","description":"KPRP N-terminal and LCE C-terminal like protein","metadata":{"aliases":["LEP7","XP32","C1orf68"]}},{"id":"f852860c6a9a4f80931de7ac654ab41e","type":"TRIAL","name":"KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","canonical_id":"clinicaltrials.gov:NCT05525858","description":"Solid Tumor; Advanced Solid Tumor; Metastatic Cancer","metadata":null},{"id":"18162a0123734bfeb975df93cdc8b24c","type":"GENE","name":"KPNA1","canonical_id":"hgnc:HGNC:6394","description":null,"metadata":null},{"id":"e5b1a16a4c2e47338fcf19c604544f87","type":"GENE","name":"KPNA2","canonical_id":"hgnc:HGNC:6395","description":null,"metadata":null},{"id":"67af296a1af84fd8a17c77cd6afcd967","type":"GENE","name":"KPNA2P1","canonical_id":"hgnc:HGNC:52871","description":"karyopherin subunit alpha 2 pseudogene 1","metadata":null},{"id":"2e2c052c10754f23b03df02137d8ecbe","type":"GENE","name":"KPNA2P2","canonical_id":"hgnc:HGNC:52872","description":"karyopherin subunit alpha 2 pseudogene 2","metadata":null},{"id":"02b757a3db7247369047ca6377f98ce7","type":"GENE","name":"KPNA2P3","canonical_id":"hgnc:HGNC:52870","description":"karyopherin subunit alpha 2 pseudogene 3","metadata":null},{"id":"3cf834d0499c4799bdbbb7a5f2933a5f","type":"GENE","name":"KPNA3","canonical_id":"hgnc:HGNC:6396","description":"karyopherin subunit alpha 3","metadata":{"aliases":["SRP1gamma","SRP4","hSRP1","IPOA4"]}},{"id":"61d39ae7c7ab4bab9d49fa863ae625bb","type":"GENE","name":"KPNA4","canonical_id":"hgnc:HGNC:6397","description":"karyopherin subunit alpha 4","metadata":{"aliases":["QIP1","SRP3","IPOA3","MGC12217","MGC26703"]}},{"id":"6869562613634fb08e733fa16aef6992","type":"GENE","name":"KPNA4P1","canonical_id":"hgnc:HGNC:54976","description":"KPNA4 pseudogene 1","metadata":null},{"id":"8bb1887d8f8e42c29b5f6066a2719c5a","type":"GENE","name":"KPNA5","canonical_id":"hgnc:HGNC:6398","description":"karyopherin subunit alpha 5","metadata":{"aliases":["SRP6","IPOA6"]}},{"id":"a6fe160847024a4fb1d35358087606f5","type":"GENE","name":"KPNA6","canonical_id":"hgnc:HGNC:6399","description":"karyopherin subunit alpha 6","metadata":{"aliases":["IPOA7","KPNA7","MGC17918","FLJ11249"]}},{"id":"3584dc1443d544cbb05f381f41412bd1","type":"GENE","name":"KPNA7","canonical_id":"hgnc:HGNC:21839","description":"karyopherin subunit alpha 7","metadata":{"aliases":["IPOA8"]}},{"id":"b7e1bcb17de54c0b96465e178a45223f","type":"GENE","name":"KPNB1","canonical_id":"hgnc:HGNC:6400","description":null,"metadata":null},{"id":"c05a8d82d5e943caba60f7c8547847df","type":"GENE","name":"KPNB1-DT","canonical_id":"hgnc:HGNC:55336","description":"KPNB1 divergent transcript","metadata":null},{"id":"af9e312149ff4007ac6cea73b5d649a9","type":"GENE","name":"KPNB1P1","canonical_id":"hgnc:HGNC:55029","description":"KPNB1 pseudogene 1","metadata":null},{"id":"165dcc5c40dc44568400b84bcd16271e","type":"GENE","name":"KPRP","canonical_id":"hgnc:HGNC:31823","description":"keratinocyte proline rich protein","metadata":{"aliases":["C1orf45"]}},{"id":"716573b54d2f443d9ad7c5840c626131","type":"GENE","name":"KPTN","canonical_id":"hgnc:HGNC:6404","description":"kaptin, actin binding protein","metadata":{"aliases":["2E4","KICS4"]}},{"id":"d4dc1c5ecfdc415ebd271bc40d03f837","type":"GENE","name":"KRABD1","canonical_id":"hgnc:HGNC:38708","description":"KRAB domain containing 1","metadata":{"aliases":["KRBOX1"]}},{"id":"3ae35a3e0af44c23bc57d93151a04f17","type":"GENE","name":"KRABD1-AS1","canonical_id":"hgnc:HGNC:42942","description":"KRABD1 antisense RNA 1","metadata":{"aliases":["FLJ32776","KRBOX1-AS1"]}},{"id":"912196d5285f43ddac684c388e7fdcf8","type":"GENE","name":"KRABD2","canonical_id":"hgnc:HGNC:26989","description":"KRAB domain containing 2","metadata":{"aliases":["KRBA2"]}},{"id":"c38d349ebd434d1a90cc99e1f13dd44b","type":"GENE","name":"KRABD3","canonical_id":"hgnc:HGNC:22228","description":"KRAB domain containing 3","metadata":{"aliases":["KIAA1862","KRBA1"]}},{"id":"de3827b515ba4ea2b2d87d9febd4b3f2","type":"GENE","name":"KRABD4","canonical_id":"hgnc:HGNC:26007","description":"KRAB domain containing 4","metadata":{"aliases":["FLJ20344","ZNF673","KRBOX4"]}},{"id":"67d70fd85ae941dca8610c13259e01a0","type":"GENE","name":"KRABD5","canonical_id":"hgnc:HGNC:26987","description":"KRAB domain containing 5","metadata":{"aliases":["ZNF720","KRBOX5"]}},{"id":"1d5d6d6373df4416a73d83e043515eaf","type":"GENE","name":"KRABD5P1","canonical_id":"hgnc:HGNC:34505","description":"KRABD5 pseudogene 1","metadata":{"aliases":["ZNF720P1","KRBOX5P1"]}},{"id":"ef80b18deb614086b3578d1ec848e06e","type":"GENE","name":"KRAS","canonical_id":"hgnc:HGNC:6407","description":null,"metadata":null},{"id":"31d9d0df3c2548519e40014eda9ebb1b","type":"GENE","name":"KRAS","canonical_id":"ensembl:ENSG00000133703","description":null,"metadata":null},{"id":"7c413acca1a04d6fb653938fb20912ff","type":"BIOMARKER","name":"KRAS A11_G12insGA","canonical_id":"civic:3210","description":null,"metadata":null},{"id":"1d2186dbd6f04c009b488b34f751af61","type":"BIOMARKER","name":"KRAS A146","canonical_id":"civic:2848","description":null,"metadata":null},{"id":"3f5e2258b1b749ea88654ffaa5c433b7","type":"BIOMARKER","name":"KRAS A146P","canonical_id":"civic:879","description":null,"metadata":null},{"id":"73b2c34de4a44ae9a7b4eba462646555","type":"BIOMARKER","name":"KRAS A146T","canonical_id":"civic:880","description":null,"metadata":null},{"id":"5fcf3c82595041648e9b4ff213d219ff","type":"BIOMARKER","name":"KRAS A146V","canonical_id":"civic:318","description":null,"metadata":null},{"id":"d16944f0089744f2aba306bb72ceaf96","type":"BIOMARKER","name":"KRAS Amplification","canonical_id":"civic:588","description":null,"metadata":null},{"id":"a6a2e0caec994f9aabf306dfae1c687e","type":"BIOMARKER","name":"KRAS Exon 2 Mutation","canonical_id":"civic:75","description":null,"metadata":null},{"id":"9131bcad3f364912bb00c0bcfc838ea2","type":"BIOMARKER","name":"KRAS G10_A11insG","canonical_id":"civic:3209","description":null,"metadata":null},{"id":"c788b37a3c8149de850c3d0fb46e6321","type":"BIOMARKER","name":"KRAS G12","canonical_id":"civic:76","description":null,"metadata":null},{"id":"30f178cb743d421fabbcf547de7bbe7b","type":"BIOMARKER","name":"KRAS G12 OR KRAS G13","canonical_id":"civic:5162","description":null,"metadata":null},{"id":"f8d08132f6b443ada0c5fa75635e196f","type":"BIOMARKER","name":"KRAS G12 OR KRAS G13D","canonical_id":"civic:5665","description":null,"metadata":null},{"id":"e14212e98b3d4dc9b0aeb4bde8ff18ce","type":"BIOMARKER","name":"KRAS G12/G13","canonical_id":"civic:77","description":null,"metadata":null},{"id":"70c5f8f2def84fb69b997f39c7260552","type":"BIOMARKER","name":"KRAS G12A","canonical_id":"civic:148","description":null,"metadata":null},{"id":"df9dbbee3b664d1c8dbc493448f0154a","type":"BIOMARKER","name":"KRAS G12C","canonical_id":"civic:78","description":null,"metadata":null},{"id":"872530bfc03a4e4ba710ea437e30a9ed","type":"BIOMARKER","name":"KRAS G12D","canonical_id":"civic:79","description":null,"metadata":null},{"id":"92695b1e37e5491b9236d7d63a2aeb13","type":"BIOMARKER","name":"KRAS G12D AND TSC1 Loss-of-function","canonical_id":"civic:6021","description":null,"metadata":null},{"id":"81f7d65763de427bbd9a8f6eeaa47702","type":"BIOMARKER","name":"KRAS G12R","canonical_id":"civic:526","description":null,"metadata":null},{"id":"9e57f429097046e2a74507541cb3f5c3","type":"BIOMARKER","name":"KRAS G12S","canonical_id":"civic:887","description":null,"metadata":null},{"id":"8743875950bb4b0ca93cd91a5dd0c37a","type":"BIOMARKER","name":"KRAS G12V","canonical_id":"civic:421","description":null,"metadata":null},{"id":"1e3662f906a8427c9819ff921ac4ab49","type":"BIOMARKER","name":"KRAS G13","canonical_id":"civic:80","description":null,"metadata":null},{"id":"95241556cbdc4689913c14aa72954327","type":"BIOMARKER","name":"KRAS G13D","canonical_id":"civic:81","description":null,"metadata":null},{"id":"d394e0bc252e46ae92e5ef4b6fde789a","type":"BIOMARKER","name":"KRAS G13V","canonical_id":"civic:1425","description":null,"metadata":null},{"id":"9e5819072b944de98e6f795b2bf44cdd","type":"BIOMARKER","name":"KRAS Mutation","canonical_id":"civic:332","description":null,"metadata":null},{"id":"d92c05507d2142f895ddafc7ab2ac81c","type":"BIOMARKER","name":"KRAS Q22*","canonical_id":"civic:475","description":null,"metadata":null},{"id":"b537010e65454c4986f44d2f8b774890","type":"BIOMARKER","name":"KRAS Q61","canonical_id":"civic:203","description":null,"metadata":null},{"id":"75e1b1780fb44ecfad7a840fb6b0b125","type":"BIOMARKER","name":"KRAS Q61H","canonical_id":"civic:881","description":null,"metadata":null},{"id":"9282d8479938478f95f8bfdc7302fc8a","type":"BIOMARKER","name":"KRAS Q61K","canonical_id":"civic:884","description":null,"metadata":null},{"id":"27303fee12d3436f8664890ec250ecbb","type":"BIOMARKER","name":"KRAS Q61L","canonical_id":"civic:882","description":null,"metadata":null},{"id":"a09fddefb86a44cf8783bf8b27f3dd39","type":"BIOMARKER","name":"KRAS Q61R","canonical_id":"civic:883","description":null,"metadata":null},{"id":"a4f1923ae6324e5985a932359bdaa6ff","type":"BIOMARKER","name":"KRAS R164Q (exon 5b)","canonical_id":"civic:1181","description":null,"metadata":null},{"id":"1f8160f0eb544b9a8e65f68a665ec6ac","type":"BIOMARKER","name":"KRAS RS61764370","canonical_id":"civic:250","description":null,"metadata":null},{"id":"3b32e89333f641b69d4be7b0c818c439","type":"BIOMARKER","name":"KRAS Wildtype","canonical_id":"civic:3069","description":null,"metadata":null},{"id":"73de4617ed6f4729983fa74817fd6539","type":"GENE","name":"KRASP1","canonical_id":"hgnc:HGNC:6406","description":"KRas proto-oncogene, GTPase pseudogene 1","metadata":{"aliases":["KRAS1P"]}},{"id":"efcc1e2777434e5e9e52213b954fdfb6","type":"GENE","name":"KRCC1","canonical_id":"hgnc:HGNC:28039","description":"lysine rich coiled-coil 1","metadata":{"aliases":["FLJ22333"]}},{"id":"fc61f00ddf83417381d6577f719dec5c","type":"TRIAL","name":"KRDI in Transplant-Eligible MM","canonical_id":"clinicaltrials.gov:NCT04430894","description":"Multiple Myeloma","metadata":null},{"id":"af6740d0de8a4936bd7e533fb7f53d1d","type":"GENE","name":"KREMEN1","canonical_id":"hgnc:HGNC:17550","description":"kringle containing transmembrane protein 1","metadata":{"aliases":["KRM1","KREMEN"]}},{"id":"3da648e00793449caf781bc1e8f2b295","type":"GENE","name":"KREMEN2","canonical_id":"hgnc:HGNC:18797","description":"kringle containing transmembrane protein 2","metadata":{"aliases":["MGC10791","KRM2"]}},{"id":"489855d4a7194a4b83a3f7ac38da9449","type":"GENE","name":"KRI1","canonical_id":"hgnc:HGNC:25769","description":"KRI1 homolog","metadata":{"aliases":["FLJ12949"]}},{"id":"9ddeddd215bb4d84b36da93da11f0fb1","type":"GENE","name":"KRIT1","canonical_id":"hgnc:HGNC:1573","description":"KRIT1 ankyrin repeat containing","metadata":{"aliases":["CAM","CCM1"]}},{"id":"60f3de59aafe48a18465d80c404bfc7d","type":"GENE","name":"KRR1","canonical_id":"hgnc:HGNC:5176","description":"KRR1 small subunit processome component","metadata":{"aliases":["RIP-1","HRB2"]}},{"id":"87c9be7ee7ba42debb18c6f6cd7cc499","type":"GENE","name":"KRR1P1","canonical_id":"hgnc:HGNC:39580","description":"KRR1 pseudogene 1","metadata":null},{"id":"39b1e9d7febb4d8c8a164564d1f67f10","type":"TRIAL","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","canonical_id":"clinicaltrials.gov:NCT03669965","description":"Polycythemia Vera","metadata":null},{"id":"e32d35ba89434e018b8835382774e6e0","type":"GENE","name":"KRT1","canonical_id":"hgnc:HGNC:6412","description":"keratin 1","metadata":{"aliases":["KRT1A","EHK1"]}},{"id":"43722e4dea914e909665e2c71a5d0848","type":"GENE","name":"KRT10","canonical_id":"hgnc:HGNC:6413","description":null,"metadata":null},{"id":"b91512d57d3e4818a0580d54d7cc458b","type":"GENE","name":"KRT10-AS1","canonical_id":"hgnc:HGNC:28305","description":"KRT10 antisense RNA 1","metadata":{"aliases":["MGC21518","TMEM99"]}},{"id":"99488e8ec6f646d8bf75a5b48d560133","type":"GENE","name":"KRT12","canonical_id":"hgnc:HGNC:6414","description":null,"metadata":null},{"id":"48bfc07ec189431faab250cf097380d4","type":"GENE","name":"KRT125P","canonical_id":"hgnc:HGNC:48875","description":"keratin 125, pseudogene","metadata":null},{"id":"11b5d4724cf74cb89db5da2c161e4206","type":"GENE","name":"KRT126P","canonical_id":"hgnc:HGNC:32970","description":"keratin 126, pseudogene","metadata":null},{"id":"de24958706f1485c9de1b960cddcc090","type":"GENE","name":"KRT127P","canonical_id":"hgnc:HGNC:40019","description":"keratin 127, pseudogene","metadata":{"aliases":["KRT3P1"]}},{"id":"618e0a4a35f54eda8904c4ebb7a1fc1f","type":"GENE","name":"KRT128P","canonical_id":"hgnc:HGNC:48882","description":"keratin 128, pseudogene","metadata":null},{"id":"1dc7d09faae742209b30b875e379c79c","type":"GENE","name":"KRT13","canonical_id":"hgnc:HGNC:6415","description":null,"metadata":null},{"id":"fababab4830b4a7894ce0b673e31b330","type":"GENE","name":"KRT14","canonical_id":"hgnc:HGNC:6416","description":null,"metadata":null},{"id":"b2ec214372ad471daf0bb23fb27c6717","type":"GENE","name":"KRT15","canonical_id":"hgnc:HGNC:6421","description":null,"metadata":null},{"id":"a4797ed033a9407c91cbbf3334ff7bba","type":"GENE","name":"KRT16","canonical_id":"hgnc:HGNC:6423","description":null,"metadata":null},{"id":"509f9667e4f940b08cf36fc6d730bb42","type":"GENE","name":"KRT16P1","canonical_id":"hgnc:HGNC:6420","description":"keratin 16 pseudogene 1","metadata":{"aliases":["KRT14P"]}},{"id":"8cfe47e1c4d54c92811402167fe06067","type":"GENE","name":"KRT16P2","canonical_id":"hgnc:HGNC:37807","description":"keratin 16 pseudogene 2","metadata":null},{"id":"14fd680d8c7c4f88a2b9c177c9dff3a2","type":"GENE","name":"KRT16P3","canonical_id":"hgnc:HGNC:37808","description":"keratin 16 pseudogene 3","metadata":{"aliases":["MGC102966","KERSMCR"]}},{"id":"20e9f6fff33e4fa2ba21111b9e6e73c2","type":"GENE","name":"KRT16P4","canonical_id":"hgnc:HGNC:37809","description":"keratin 16 pseudogene 4","metadata":null},{"id":"23eb2bbd155c4bcc947d894dc7185bc2","type":"GENE","name":"KRT16P5","canonical_id":"hgnc:HGNC:37810","description":"keratin 16 pseudogene 5","metadata":null},{"id":"49b09f4f13454e439af413d5dcabfdbb","type":"GENE","name":"KRT16P6","canonical_id":"hgnc:HGNC:50719","description":"keratin 16 pseudogene 6","metadata":{"aliases":["lncKRT16P6"]}},{"id":"501e8fc28d424b408e656cbdc7bd34c3","type":"GENE","name":"KRT17","canonical_id":"hgnc:HGNC:6427","description":null,"metadata":null},{"id":"629d6fc4d68f49869f1fd6ec8250ce5d","type":"GENE","name":"KRT17P1","canonical_id":"hgnc:HGNC:6428","description":"keratin 17 pseudogene 1","metadata":null},{"id":"f6e140c8bf844f6fa3b3b008bead7553","type":"GENE","name":"KRT17P2","canonical_id":"hgnc:HGNC:6429","description":"keratin 17 pseudogene 2","metadata":null},{"id":"91e4b1bd3b994785b084002b80d7e401","type":"GENE","name":"KRT17P3","canonical_id":"hgnc:HGNC:33697","description":"keratin 17 pseudogene 3","metadata":null},{"id":"e47fa9fd82c34949b13c8cca44d9fc9a","type":"GENE","name":"KRT17P4","canonical_id":"hgnc:HGNC:50722","description":"keratin 17 pseudogene 4","metadata":null},{"id":"f5971ea60dde4cf8b13dbc8734b5190b","type":"GENE","name":"KRT17P5","canonical_id":"hgnc:HGNC:50723","description":"keratin 17 pseudogene 5","metadata":null},{"id":"8d91a6953a5b4aa49720fcc84c129dd4","type":"GENE","name":"KRT17P6","canonical_id":"hgnc:HGNC:50724","description":"keratin 17 pseudogene 6","metadata":null},{"id":"3b00872061bd43f38b8d666f56a9de1d","type":"GENE","name":"KRT17P7","canonical_id":"hgnc:HGNC:50725","description":"keratin 17 pseudogene 7","metadata":null},{"id":"6b7480b7feab4519a571080b37294068","type":"GENE","name":"KRT17P8","canonical_id":"hgnc:HGNC:50726","description":"keratin 17 pseudogene 8","metadata":null},{"id":"76d4eca5105d4eab8cf1bf1faf9bbe62","type":"GENE","name":"KRT18","canonical_id":"hgnc:HGNC:6430","description":null,"metadata":null},{"id":"ab33bb5e0dc84245a7f10e8566659f7f","type":"GENE","name":"KRT18P1","canonical_id":"hgnc:HGNC:6434","description":"keratin 18 pseudogene 1","metadata":{"aliases":["dJ25J6.3"]}},{"id":"f13246f1f2174273988b7c781f32ed24","type":"GENE","name":"KRT18P10","canonical_id":"hgnc:HGNC:23962","description":"keratin 18 pseudogene 10","metadata":null},{"id":"6baea94616ae4dcc9c1b4767bfc93ca4","type":"GENE","name":"KRT18P11","canonical_id":"hgnc:HGNC:6431","description":"keratin 18 pseudogene 11","metadata":{"aliases":["KRT18L1"]}},{"id":"9c4b8debb8334c8fb5010cd185037c65","type":"GENE","name":"KRT18P12","canonical_id":"hgnc:HGNC:33410","description":"keratin 18 pseudogene 12","metadata":null},{"id":"d7d5bd1df1fb4fb68598a00c659af24e","type":"GENE","name":"KRT18P13","canonical_id":"hgnc:HGNC:6432","description":"keratin 18 pseudogene 13","metadata":{"aliases":["KRT18L3"]}},{"id":"342f52768ab24dcb94ee1144a14bda7b","type":"GENE","name":"KRT18P14","canonical_id":"hgnc:HGNC:6433","description":"keratin 18 pseudogene 14","metadata":{"aliases":["KRT18L4"]}},{"id":"8884ae4521464447bfc74f7e22c7292a","type":"GENE","name":"KRT18P15","canonical_id":"hgnc:HGNC:32449","description":"keratin 18 pseudogene 15","metadata":{"aliases":["KRT18L5"]}},{"id":"7dd3aeb72add4747b2fc53f77435058b","type":"GENE","name":"KRT18P16","canonical_id":"hgnc:HGNC:33384","description":"keratin 18 pseudogene 16","metadata":null},{"id":"000e1c50cd0943d280b022273f09c8a1","type":"GENE","name":"KRT18P17","canonical_id":"hgnc:HGNC:33385","description":"keratin 18 pseudogene 17","metadata":null},{"id":"1458c77ebcc041439c1ea8f190bb1602","type":"GENE","name":"KRT18P18","canonical_id":"hgnc:HGNC:33386","description":"keratin 18 pseudogene 18","metadata":null},{"id":"097d902c76204213a45a2371cf33afdd","type":"GENE","name":"KRT18P19","canonical_id":"hgnc:HGNC:33387","description":"keratin 18 pseudogene 19","metadata":null},{"id":"7144e50d7c754d0d981106846e7af95f","type":"GENE","name":"KRT18P2","canonical_id":"hgnc:HGNC:6435","description":"keratin 18 pseudogene 2","metadata":{"aliases":["OTTHUMG00000078062"]}},{"id":"507c72eff95b49afa820a00b983ac9e6","type":"GENE","name":"KRT18P20","canonical_id":"hgnc:HGNC:33388","description":"keratin 18 pseudogene 20","metadata":null},{"id":"124637d2b48044488c38a2965b4c0448","type":"GENE","name":"KRT18P21","canonical_id":"hgnc:HGNC:33389","description":"keratin 18 pseudogene 21","metadata":null},{"id":"1c178f95e4404aec81bb390cfe6667cf","type":"GENE","name":"KRT18P22","canonical_id":"hgnc:HGNC:33390","description":"keratin 18 pseudogene 22","metadata":null},{"id":"bd15dc5976924306b114c2a1c7b58670","type":"GENE","name":"KRT18P23","canonical_id":"hgnc:HGNC:33392","description":"keratin 18 pseudogene 23","metadata":null},{"id":"04ecd4b11cfb436681cb8ad9adc71dba","type":"GENE","name":"KRT18P24","canonical_id":"hgnc:HGNC:33393","description":"keratin 18 pseudogene 24","metadata":null},{"id":"6e353427686a4161afbe74c52f93264b","type":"GENE","name":"KRT18P25","canonical_id":"hgnc:HGNC:33394","description":"keratin 18 pseudogene 25","metadata":null},{"id":"e0578c69f0d14053ad79662f20de1bee","type":"GENE","name":"KRT18P26","canonical_id":"hgnc:HGNC:33395","description":"keratin 18 pseudogene 26","metadata":null},{"id":"fe7d9654127040e0b32e19eff38c56bd","type":"GENE","name":"KRT18P27","canonical_id":"hgnc:HGNC:33396","description":"keratin 18 pseudogene 27","metadata":null},{"id":"3ed4bc41f98547cdb20e82f09c5d92f3","type":"GENE","name":"KRT18P28","canonical_id":"hgnc:HGNC:33397","description":"keratin 18 pseudogene 28","metadata":null},{"id":"d4ba3f4d658545228402d25b9356a31a","type":"GENE","name":"KRT18P29","canonical_id":"hgnc:HGNC:33398","description":"keratin 18 pseudogene 29","metadata":null},{"id":"b2a29cc1fb614f2d8b00d937c7e64592","type":"GENE","name":"KRT18P3","canonical_id":"hgnc:HGNC:16540","description":"keratin 18 pseudogene 3","metadata":{"aliases":["bA359G22.1","OTTHUMG00000032046"]}},{"id":"64c2b27e44384e7dbc093738a3386f36","type":"GENE","name":"KRT18P30","canonical_id":"hgnc:HGNC:33399","description":"keratin 18 pseudogene 30","metadata":null},{"id":"3fef445b944c4f8fa6782c5fde6f6f9d","type":"GENE","name":"KRT18P31","canonical_id":"hgnc:HGNC:33400","description":"keratin 18 pseudogene 31","metadata":null},{"id":"323f405ab30f4786971d8e24674cffdc","type":"GENE","name":"KRT18P32","canonical_id":"hgnc:HGNC:33401","description":"keratin 18 pseudogene 32","metadata":null},{"id":"03cd8d06ec604762af032c9e23dfdf0e","type":"GENE","name":"KRT18P33","canonical_id":"hgnc:HGNC:33402","description":"keratin 18 pseudogene 33","metadata":null},{"id":"3460e44285c8414ab1b5b423ef0b31fa","type":"GENE","name":"KRT18P34","canonical_id":"hgnc:HGNC:33403","description":"keratin 18 pseudogene 34","metadata":null},{"id":"02a012c92ec6455aa29a0a118050fc34","type":"GENE","name":"KRT18P35","canonical_id":"hgnc:HGNC:33404","description":"keratin 18 pseudogene 35","metadata":null},{"id":"5ad264f8d3354c2d9c5fb9aa4e4c45c6","type":"GENE","name":"KRT18P36","canonical_id":"hgnc:HGNC:33405","description":"keratin 18 pseudogene 36","metadata":null},{"id":"0643a52d0da44f31adbfc905ef0a484c","type":"GENE","name":"KRT18P37","canonical_id":"hgnc:HGNC:33406","description":"keratin 18 pseudogene 37","metadata":null},{"id":"efb3bf4a0d5d4ad980c74c93b11dfd72","type":"GENE","name":"KRT18P38","canonical_id":"hgnc:HGNC:33407","description":"keratin 18 pseudogene 38","metadata":null},{"id":"d29efe0f9d194f7da6778a661a97ccc2","type":"GENE","name":"KRT18P39","canonical_id":"hgnc:HGNC:33408","description":"keratin 18 pseudogene 39","metadata":null},{"id":"3eecb53cf7314c428fabef93fb8f3838","type":"GENE","name":"KRT18P4","canonical_id":"hgnc:HGNC:16604","description":"keratin 18 pseudogene 4","metadata":{"aliases":["dJ963K23.1","OTTHUMG00000032705"]}},{"id":"34c2071dfb724d8e9bedd475ece93132","type":"GENE","name":"KRT18P40","canonical_id":"hgnc:HGNC:33409","description":"keratin 18 pseudogene 40","metadata":null},{"id":"44232b37c50d48cbada54106ec085ef5","type":"GENE","name":"KRT18P41","canonical_id":"hgnc:HGNC:33411","description":"keratin 18 pseudogene 41","metadata":null},{"id":"482bac0ae17c4e9586ecdc7ff2762f5d","type":"GENE","name":"KRT18P42","canonical_id":"hgnc:HGNC:33412","description":"keratin 18 pseudogene 42","metadata":null},{"id":"53357351e9ac4825917242910e709da1","type":"GENE","name":"KRT18P43","canonical_id":"hgnc:HGNC:33413","description":"keratin 18 pseudogene 43","metadata":null},{"id":"318fad1005854566a2628748c34c9bfa","type":"GENE","name":"KRT18P44","canonical_id":"hgnc:HGNC:33414","description":"keratin 18 pseudogene 44","metadata":null},{"id":"d261d4ac10e5405a8bfe169e24803bf4","type":"GENE","name":"KRT18P45","canonical_id":"hgnc:HGNC:33415","description":"keratin 18 pseudogene 45","metadata":null},{"id":"8ab4870f5ee9441fa240282684cf4a7b","type":"GENE","name":"KRT18P46","canonical_id":"hgnc:HGNC:33416","description":"keratin 18 pseudogene 46","metadata":null},{"id":"0693af9ce62f400db618614a6c05ae2d","type":"GENE","name":"KRT18P47","canonical_id":"hgnc:HGNC:33417","description":"keratin 18 pseudogene 47","metadata":null},{"id":"4ea743089c604ae1884a7f4e24bf7cd5","type":"GENE","name":"KRT18P48","canonical_id":"hgnc:HGNC:33418","description":"keratin 18 pseudogene 48","metadata":null},{"id":"05ad953e5e4646fe88d5e8ba93447518","type":"GENE","name":"KRT18P49","canonical_id":"hgnc:HGNC:33419","description":"keratin 18 pseudogene 49","metadata":null},{"id":"1e809120a66847288d65d5c0cca045dd","type":"GENE","name":"KRT18P5","canonical_id":"hgnc:HGNC:19259","description":"keratin 18 pseudogene 5","metadata":null},{"id":"bcfedc8d12af4c79916b8813ac13e8a1","type":"GENE","name":"KRT18P50","canonical_id":"hgnc:HGNC:33420","description":"keratin 18 pseudogene 50","metadata":null},{"id":"5fea810508d940c6ac089c0a1ba62c2c","type":"GENE","name":"KRT18P51","canonical_id":"hgnc:HGNC:33421","description":"keratin 18 pseudogene 51","metadata":null},{"id":"66425ca3867047a6a9489c4c60aa6faa","type":"GENE","name":"KRT18P52","canonical_id":"hgnc:HGNC:37888","description":"keratin 18 pseudogene 52","metadata":null},{"id":"531817c0619e4087887a44b19b190aa2","type":"GENE","name":"KRT18P53","canonical_id":"hgnc:HGNC:38714","description":"keratin 18 pseudogene 53","metadata":null},{"id":"dfdaae14c56f430fb1efa90e2f3759e5","type":"GENE","name":"KRT18P54","canonical_id":"hgnc:HGNC:39425","description":"keratin 18 pseudogene 54","metadata":null},{"id":"f842c0e255e147a89973dc830df9ae05","type":"GENE","name":"KRT18P55","canonical_id":"hgnc:HGNC:26874","description":"keratin 18 pseudogene 55","metadata":null},{"id":"0c7676897b804530a346f7b8707eae01","type":"GENE","name":"KRT18P56","canonical_id":"hgnc:HGNC:43923","description":"keratin 18 pseudogene 56","metadata":null},{"id":"dfaf5b96dc004fa7804b68462b863272","type":"GENE","name":"KRT18P57","canonical_id":"hgnc:HGNC:48884","description":"keratin 18 pseudogene 57","metadata":null},{"id":"f57c87b080af4d838997ce48d8c5ba0d","type":"GENE","name":"KRT18P58","canonical_id":"hgnc:HGNC:48885","description":"keratin 18 pseudogene 58","metadata":null},{"id":"e3a8d321b7854f0abd308962752e6a41","type":"GENE","name":"KRT18P59","canonical_id":"hgnc:HGNC:48886","description":"keratin 18 pseudogene 59","metadata":null},{"id":"b0bcd79c6acc442da0537710c2ee6c05","type":"GENE","name":"KRT18P6","canonical_id":"hgnc:HGNC:20280","description":"keratin 18 pseudogene 6","metadata":null},{"id":"cba3d7cddc2d4bbfae47ac692a98e5a2","type":"GENE","name":"KRT18P60","canonical_id":"hgnc:HGNC:48887","description":"keratin 18 pseudogene 60","metadata":null},{"id":"60232f15cdf34248a138d3566f9c3b5c","type":"GENE","name":"KRT18P61","canonical_id":"hgnc:HGNC:48888","description":"keratin 18 pseudogene 61","metadata":null},{"id":"144282b61c0843cc971d51026a81cd6b","type":"GENE","name":"KRT18P62","canonical_id":"hgnc:HGNC:48889","description":"keratin 18 pseudogene 62","metadata":null},{"id":"29d1e1faaae24d479d01425513c2f05a","type":"GENE","name":"KRT18P63","canonical_id":"hgnc:HGNC:48890","description":"keratin 18 pseudogene 63","metadata":null},{"id":"ec3afab7ad5b47698a528dcf4131bb49","type":"GENE","name":"KRT18P64","canonical_id":"hgnc:HGNC:48891","description":"keratin 18 pseudogene 64","metadata":null},{"id":"2e3adbd80a46450b98cc0e722b5e21c3","type":"GENE","name":"KRT18P65","canonical_id":"hgnc:HGNC:48892","description":"keratin 18 pseudogene 65","metadata":null},{"id":"fd55e5a279c04a8f9fe21f8c1020a525","type":"GENE","name":"KRT18P66","canonical_id":"hgnc:HGNC:48893","description":"keratin 18 pseudogene 66","metadata":null},{"id":"40a9c5369a1b4ec6b150a1a614a2135b","type":"GENE","name":"KRT18P67","canonical_id":"hgnc:HGNC:48894","description":"keratin 18 pseudogene 67","metadata":null},{"id":"66da52eb19794d2f81b36900a5637907","type":"GENE","name":"KRT18P68","canonical_id":"hgnc:HGNC:48895","description":"keratin 18 pseudogene 68","metadata":null},{"id":"ba55552c1827463fa9184bddec14053a","type":"GENE","name":"KRT18P7","canonical_id":"hgnc:HGNC:20283","description":"keratin 18 pseudogene 7","metadata":null},{"id":"f8912ed6156942dd95f5a54e4fb67d2f","type":"GENE","name":"KRT18P8","canonical_id":"hgnc:HGNC:31093","description":"keratin 18 pseudogene 8","metadata":null},{"id":"39fd84f639874b3e8693ed149e09387d","type":"GENE","name":"KRT18P9","canonical_id":"hgnc:HGNC:17767","description":"keratin 18 pseudogene 9","metadata":{"aliases":["bA513I15.2"]}},{"id":"1a5104405a544322ac58ef0b9bc9e5cd","type":"GENE","name":"KRT19","canonical_id":"hgnc:HGNC:6436","description":null,"metadata":null},{"id":"fdb11134b9ae4a39ac68522dc66b15e8","type":"GENE","name":"KRT19P1","canonical_id":"hgnc:HGNC:33422","description":"keratin 19 pseudogene 1","metadata":null},{"id":"753498c576254dcba34c20c8045d37a3","type":"GENE","name":"KRT19P2","canonical_id":"hgnc:HGNC:33423","description":"keratin 19 pseudogene 2","metadata":{"aliases":["KRT19P5"]}},{"id":"c92be08a52634ea59bafefb75185d3eb","type":"GENE","name":"KRT19P3","canonical_id":"hgnc:HGNC:33424","description":"keratin 19 pseudogene 3","metadata":null},{"id":"5095d6ad9f424e72b89bb1daec3489d4","type":"GENE","name":"KRT19P4","canonical_id":"hgnc:HGNC:45073","description":"keratin 19 pseudogene 4","metadata":null},{"id":"7f37bc524b58483c9d1146b670be9de6","type":"GENE","name":"KRT19P6","canonical_id":"hgnc:HGNC:45076","description":"keratin 19 pseudogene 6","metadata":null},{"id":"a846c25e2b924ed69f19ae818eabff68","type":"GENE","name":"KRT2","canonical_id":"hgnc:HGNC:6439","description":"keratin 2","metadata":{"aliases":["KRTE","KRT2A"]}},{"id":"dd89604bd69b442ebae6f085b4144e2c","type":"GENE","name":"KRT20","canonical_id":"hgnc:HGNC:20412","description":null,"metadata":null},{"id":"bbb883866bb643c08b4c95312398e531","type":"GENE","name":"KRT222","canonical_id":"hgnc:HGNC:28695","description":"keratin 222","metadata":{"aliases":["KA21","MGC45562","KRT222P"]}},{"id":"61f144ea236a440896b1e170021afb3f","type":"GENE","name":"KRT223P","canonical_id":"hgnc:HGNC:32968","description":"keratin 223, pseudogene","metadata":null},{"id":"0ede1fb4f9fd4283aa1a647252b0c51b","type":"GENE","name":"KRT224P","canonical_id":"hgnc:HGNC:55253","description":"keratin 224, pseudogene","metadata":null},{"id":"8b177583f0354c65a38c787304a02b9b","type":"GENE","name":"KRT23","canonical_id":"hgnc:HGNC:6438","description":"keratin 23","metadata":{"aliases":["K23","DKFZP434G032","HAIK1","CK23","MGC26158"]}},{"id":"b68ddaa030a147518729484bebcdfc0c","type":"GENE","name":"KRT24","canonical_id":"hgnc:HGNC:18527","description":"keratin 24","metadata":{"aliases":["FLJ20261","MGC138169","MGC138173"]}},{"id":"35a011223d134e678a306d12dedda69d","type":"GENE","name":"KRT25","canonical_id":"hgnc:HGNC:30839","description":"keratin 25","metadata":{"aliases":["KRT25A"]}},{"id":"eaf9819c72024fcbb1ddffba6a18c1c1","type":"GENE","name":"KRT26","canonical_id":"hgnc:HGNC:30840","description":"keratin 26","metadata":{"aliases":["KRT25B"]}},{"id":"8ff85f26b4724eff92d6dc22dd8dcaac","type":"GENE","name":"KRT27","canonical_id":"hgnc:HGNC:30841","description":"keratin 27","metadata":{"aliases":["KRT25C"]}},{"id":"0888af5dd6dd423482d9baeb192bafcc","type":"GENE","name":"KRT28","canonical_id":"hgnc:HGNC:30842","description":"keratin 28","metadata":{"aliases":["KRT25D"]}},{"id":"f6912394fd354add8d0ea52d46f8835f","type":"GENE","name":"KRT3","canonical_id":"hgnc:HGNC:6440","description":"keratin 3","metadata":{"aliases":["CK3","K3"]}},{"id":"ca1840ec42374d5faf4520dd74418489","type":"GENE","name":"KRT31","canonical_id":"hgnc:HGNC:6448","description":"keratin 31","metadata":{"aliases":["Ha-1","KRTHA1"]}},{"id":"7a73990234d847b4aebb2560a13f60f9","type":"GENE","name":"KRT32","canonical_id":"hgnc:HGNC:6449","description":"keratin 32","metadata":{"aliases":["Ha-2","KRTHA2"]}},{"id":"7619cb9805cb43df82ecd58733eedfae","type":"GENE","name":"KRT33A","canonical_id":"hgnc:HGNC:6450","description":"keratin 33A","metadata":{"aliases":["Ha-3I","Krt1-3","KRTHA3A"]}},{"id":"cac77c6f5e60479d99bd006195b925fd","type":"GENE","name":"KRT33B","canonical_id":"hgnc:HGNC:6451","description":"keratin 33B","metadata":{"aliases":["Ha-3II","KRTHA3B"]}},{"id":"a1d2e50d7d61451f999c9787cc1c2a24","type":"GENE","name":"KRT34","canonical_id":"hgnc:HGNC:6452","description":"keratin 34","metadata":{"aliases":["Ha-4","KRTHA4"]}},{"id":"1c09397d30ea4035b2105f3a7a92c312","type":"GENE","name":"KRT35","canonical_id":"hgnc:HGNC:6453","description":"keratin 35","metadata":{"aliases":["Ha-5","KRTHA5"]}},{"id":"fc8567357b1e4976b5e9d9feb8b1f284","type":"GENE","name":"KRT36","canonical_id":"hgnc:HGNC:6454","description":"keratin 36","metadata":{"aliases":["KRTHA6"]}},{"id":"59bf620016494ec4b037a18c87e367a7","type":"GENE","name":"KRT37","canonical_id":"hgnc:HGNC:6455","description":"keratin 37","metadata":{"aliases":["KRTHA7"]}},{"id":"cb9ec3f3c2c64286ad06827104f8691a","type":"GENE","name":"KRT38","canonical_id":"hgnc:HGNC:6456","description":"keratin 38","metadata":{"aliases":["KRTHA8"]}},{"id":"5bdff6cff7cd4fae964afe354494ec32","type":"GENE","name":"KRT39","canonical_id":"hgnc:HGNC:32971","description":"keratin 39","metadata":{"aliases":["KA35"]}},{"id":"b542ccc280b748b5917d54969143821f","type":"GENE","name":"KRT4","canonical_id":"hgnc:HGNC:6441","description":null,"metadata":null},{"id":"aeea9abed124487e96fa862be60ddb17","type":"GENE","name":"KRT40","canonical_id":"hgnc:HGNC:26707","description":"keratin 40","metadata":{"aliases":["FLJ36600","KA36"]}},{"id":"e1f5212177be4152b97e57c52ea6f1dc","type":"GENE","name":"KRT41P","canonical_id":"hgnc:HGNC:6457","description":"keratin 41, pseudogene","metadata":{"aliases":["phihHaA","HHaA","KRTHAP1"]}},{"id":"0d0b6cced07949798c08233aca124a7e","type":"GENE","name":"KRT42P","canonical_id":"hgnc:HGNC:27581","description":"keratin 42, pseudogene","metadata":null},{"id":"49ebe6034f3443dbaa88d2c68b4fd3eb","type":"GENE","name":"KRT43P","canonical_id":"hgnc:HGNC:48870","description":"keratin 43, pseudogene","metadata":null},{"id":"b9f0d6676a4e45e5aa687f462463da1c","type":"GENE","name":"KRT5","canonical_id":"hgnc:HGNC:6442","description":null,"metadata":null},{"id":"3d80292751ae416b88784ade45e7a093","type":"GENE","name":"KRT6A","canonical_id":"hgnc:HGNC:6443","description":"keratin 6A","metadata":{"aliases":["CK6C","K6C","CK6D","K6D","KRT6C","KRT6D"]}},{"id":"378e260610d040fa850bd08cb1181fe2","type":"GENE","name":"KRT6B","canonical_id":"hgnc:HGNC:6444","description":"keratin 6B","metadata":{"aliases":["KRTL1"]}},{"id":"ee2cddb8115b49428979b01ef030c470","type":"GENE","name":"KRT6C","canonical_id":"hgnc:HGNC:20406","description":"keratin 6C","metadata":{"aliases":["KRT6E"]}},{"id":"c485f494dbed4b13aa962d680d519469","type":"GENE","name":"KRT7","canonical_id":"hgnc:HGNC:6445","description":null,"metadata":null},{"id":"be13773407ec47009cb654a6c4acc140","type":"GENE","name":"KRT7-AS","canonical_id":"hgnc:HGNC:52643","description":"KRT7 antisense RNA 1","metadata":null},{"id":"fa92dfd2dc564ec7bd31c5b2f204cf08","type":"GENE","name":"KRT71","canonical_id":"hgnc:HGNC:28927","description":"keratin 71","metadata":{"aliases":["KRT6IRS","KRT6IRS1","K6IRS1"]}},{"id":"4c09c9d07f094ff49271f33d0e518433","type":"GENE","name":"KRT72","canonical_id":"hgnc:HGNC:28932","description":"keratin 72","metadata":{"aliases":["K6IRS2","KRT6IRS2","KRT6","K6irs"]}},{"id":"3fe0cb2fd00940d19e7c9d8d0da5becd","type":"GENE","name":"KRT73","canonical_id":"hgnc:HGNC:28928","description":"keratin 73","metadata":{"aliases":["KRT6IRS3","K6IRS3"]}},{"id":"5fc86d9fc9c1478599a6eb2e346d1c46","type":"GENE","name":"KRT73-AS1","canonical_id":"hgnc:HGNC:49607","description":"KRT73 antisense RNA 1","metadata":null},{"id":"35d5c5247f99489e90986207645d7dec","type":"GENE","name":"KRT74","canonical_id":"hgnc:HGNC:28929","description":"keratin 74","metadata":{"aliases":["K6IRS4","KRT5C","KRT6IRS4"]}},{"id":"4d84688a9cd5409c8b7047d8c9fb7526","type":"GENE","name":"KRT75","canonical_id":"hgnc:HGNC:24431","description":"keratin 75","metadata":{"aliases":["K6HF"]}},{"id":"3f150efd76d54437b59da26f927fb909","type":"GENE","name":"KRT76","canonical_id":"hgnc:HGNC:24430","description":"keratin 76","metadata":{"aliases":["HUMCYT2A","KRT2B","KRT2P"]}},{"id":"2b879f025ba9494a8d96f7aa5a4fe096","type":"GENE","name":"KRT77","canonical_id":"hgnc:HGNC:20411","description":"keratin 77","metadata":{"aliases":["KRT1B"]}},{"id":"0542f3c24e004f13bedc856fe77cc47b","type":"GENE","name":"KRT78","canonical_id":"hgnc:HGNC:28926","description":"keratin 78","metadata":{"aliases":["K5B"]}},{"id":"7d06617f43cc45a795e3840241696e58","type":"GENE","name":"KRT79","canonical_id":"hgnc:HGNC:28930","description":"keratin 79","metadata":{"aliases":["K6L","KRT6L"]}},{"id":"79ddcece64174ab6acb71c6b0dd36cbb","type":"GENE","name":"KRT8","canonical_id":"hgnc:HGNC:6446","description":"keratin 8","metadata":{"aliases":["CARD2","K8","CK8","CK-8","CYK8","K2C8","KO"]}},{"id":"c9ad4747dc8442d5a4ac35fc839c273b","type":"GENE","name":"KRT80","canonical_id":"hgnc:HGNC:27056","description":"keratin 80","metadata":{"aliases":["KB20"]}},{"id":"f95daeed0a724cb1a9b62de00d5a7044","type":"GENE","name":"KRT81","canonical_id":"hgnc:HGNC:6458","description":"keratin 81","metadata":{"aliases":["Hb-1","KRTHB1"]}},{"id":"297fdcc83c4b4cf68d38dbcbffd82ec4","type":"GENE","name":"KRT82","canonical_id":"hgnc:HGNC:6459","description":"keratin 82","metadata":{"aliases":["Hb-2","KRTHB2"]}},{"id":"ddce555e2a3b43de96950ad98f074cbb","type":"GENE","name":"KRT83","canonical_id":"hgnc:HGNC:6460","description":"keratin 83","metadata":{"aliases":["Hb-3","KRTHB3"]}},{"id":"84062e6c4baf42de949fc3bd12d5037c","type":"GENE","name":"KRT83-AS1","canonical_id":"hgnc:HGNC:58282","description":"KRT83 antisense RNA 1","metadata":null},{"id":"0fc54adf33d1490a982385faeb1618af","type":"GENE","name":"KRT84","canonical_id":"hgnc:HGNC:6461","description":"keratin 84","metadata":{"aliases":["Hb-4","KRTHB4"]}},{"id":"d1a6d11affcd4be78cb528dda27d04d7","type":"GENE","name":"KRT84-AS1","canonical_id":"hgnc:HGNC:58283","description":"KRT84 and KRT82 antisense RNA 1","metadata":null},{"id":"18b9edec25cf4c43a4da8985d9ed602e","type":"GENE","name":"KRT85","canonical_id":"hgnc:HGNC:6462","description":"keratin 85","metadata":{"aliases":["Hb-5","KRTHB5"]}},{"id":"79d3eff21d6e41c28411c43db626d157","type":"GENE","name":"KRT86","canonical_id":"hgnc:HGNC:6463","description":"keratin 86","metadata":{"aliases":["MNX","Hb6","KRTHB6"]}},{"id":"11dc85d95c28460284f27cd190944f3c","type":"GENE","name":"KRT86-AS1","canonical_id":"hgnc:HGNC:58281","description":"KRT86 antisense RNA 1","metadata":null},{"id":"d298aa90bf8644d7be5c236f3a9891df","type":"GENE","name":"KRT86-AS2","canonical_id":"hgnc:HGNC:58284","description":"KRT86 antisense RNA 2","metadata":null},{"id":"a74a694eec5548e8835f50d7bdafe4e2","type":"GENE","name":"KRT87P","canonical_id":"hgnc:HGNC:30198","description":"keratin 87, pseudogene","metadata":{"aliases":["psihHbD","KRTHBP4","KRT121P"]}},{"id":"fd6ef1a36bb240858a869135403b8c63","type":"GENE","name":"KRT88P","canonical_id":"hgnc:HGNC:30197","description":"keratin 88, pseudogene","metadata":{"aliases":["HBC","KRTHBP3","KRT122P"]}},{"id":"de606435cdd6426a80e87bce2c6d3519","type":"GENE","name":"KRT89P","canonical_id":"hgnc:HGNC:30196","description":"keratin 89, pseudogene","metadata":{"aliases":["psihHbB","KRTHBP2","KRT123P"]}},{"id":"270a59136dc34ff2ba215b758fc74732","type":"GENE","name":"KRT8P1","canonical_id":"hgnc:HGNC:20281","description":"keratin 8 pseudogene 1","metadata":null},{"id":"c4c718f0fdf34b26a72b2789d468ca16","type":"GENE","name":"KRT8P10","canonical_id":"hgnc:HGNC:33364","description":"keratin 8 pseudogene 10","metadata":null},{"id":"a7bacd2ff5bb45988f9272937d682deb","type":"GENE","name":"KRT8P11","canonical_id":"hgnc:HGNC:31058","description":"keratin 8 pseudogene 11","metadata":{"aliases":["RP11-13B9.3","KRT8L1"]}},{"id":"39fa2f0808e84926a07cbe512fd03771","type":"GENE","name":"KRT8P12","canonical_id":"hgnc:HGNC:28057","description":"keratin 8 pseudogene 12","metadata":{"aliases":["KRT8L2"]}},{"id":"a2aa72a2ab094c89870aa385a9954e8d","type":"GENE","name":"KRT8P13","canonical_id":"hgnc:HGNC:33365","description":"keratin 8 pseudogene 13","metadata":null},{"id":"90d839696d754f838b019e2b24018d86","type":"GENE","name":"KRT8P14","canonical_id":"hgnc:HGNC:33366","description":"keratin 8 pseudogene 14","metadata":null},{"id":"c0d02fa347fc422ba84163e986780ed2","type":"GENE","name":"KRT8P15","canonical_id":"hgnc:HGNC:33367","description":"keratin 8 pseudogene 15","metadata":null},{"id":"1981c736053c4a4d834fbd312b9e2073","type":"GENE","name":"KRT8P16","canonical_id":"hgnc:HGNC:33368","description":"keratin 8 pseudogene 16","metadata":null},{"id":"862d545c8a5441fc8b0ba96fb6569ae8","type":"GENE","name":"KRT8P17","canonical_id":"hgnc:HGNC:33369","description":"keratin 8 pseudogene 17","metadata":null},{"id":"deef3a28d0a3412c84e4f494ffce2f1e","type":"GENE","name":"KRT8P18","canonical_id":"hgnc:HGNC:33370","description":"keratin 8 pseudogene 18","metadata":null},{"id":"cbb995583e054caa8c607dc3e504bd21","type":"GENE","name":"KRT8P19","canonical_id":"hgnc:HGNC:33371","description":"keratin 8 pseudogene 19","metadata":null},{"id":"a61a84df012244a79e3a89527da3944a","type":"GENE","name":"KRT8P2","canonical_id":"hgnc:HGNC:20282","description":"keratin 8 pseudogene 2","metadata":{"aliases":["OTTHUMG00000135122"]}},{"id":"7329c1dd39df41af8a7cb3a65d235117","type":"GENE","name":"KRT8P20","canonical_id":"hgnc:HGNC:33372","description":"keratin 8 pseudogene 20","metadata":null},{"id":"a6d1dad4cf334b80a9793c1d619bc7f3","type":"GENE","name":"KRT8P21","canonical_id":"hgnc:HGNC:33373","description":"keratin 8 pseudogene 21","metadata":null},{"id":"46b83387526a45dd989e2e89473a21c0","type":"GENE","name":"KRT8P22","canonical_id":"hgnc:HGNC:33374","description":"keratin 8 pseudogene 22","metadata":null},{"id":"dbb1333b3807476eba1c8ee9295ca582","type":"GENE","name":"KRT8P23","canonical_id":"hgnc:HGNC:33375","description":"keratin 8 pseudogene 23","metadata":null},{"id":"5cdb96086318443ba4001f5250b58593","type":"GENE","name":"KRT8P24","canonical_id":"hgnc:HGNC:33376","description":"keratin 8 pseudogene 24","metadata":null},{"id":"c8880020e89243d59186486a2d90811c","type":"GENE","name":"KRT8P25","canonical_id":"hgnc:HGNC:33377","description":"keratin 8 pseudogene 25","metadata":null},{"id":"e3aa810019364becbc4120abac263438","type":"GENE","name":"KRT8P26","canonical_id":"hgnc:HGNC:33378","description":"keratin 8 pseudogene 26","metadata":null},{"id":"8eeb536643814b22a0dd6f516a7d711f","type":"GENE","name":"KRT8P27","canonical_id":"hgnc:HGNC:33379","description":"keratin 8 pseudogene 27","metadata":null},{"id":"d636ce6d92d946eb842bbf09f800783a","type":"GENE","name":"KRT8P28","canonical_id":"hgnc:HGNC:33380","description":"keratin 8 pseudogene 28","metadata":null},{"id":"5058df4486014bbe8a7993fcba8610cb","type":"GENE","name":"KRT8P29","canonical_id":"hgnc:HGNC:33381","description":"keratin 8 pseudogene 29","metadata":null},{"id":"f53360fb005143159c77cf7f865a731b","type":"GENE","name":"KRT8P3","canonical_id":"hgnc:HGNC:31056","description":"keratin 8 pseudogene 3","metadata":null},{"id":"87e73799cf4049a492820a7d8b210289","type":"GENE","name":"KRT8P30","canonical_id":"hgnc:HGNC:33382","description":"keratin 8 pseudogene 30","metadata":null},{"id":"d1c879d0cc9941cd88b5da34084e1715","type":"GENE","name":"KRT8P31","canonical_id":"hgnc:HGNC:39865","description":"keratin 8 pseudogene 31","metadata":null},{"id":"5a031a51cb9f4f7f9a13807f32e82f24","type":"GENE","name":"KRT8P32","canonical_id":"hgnc:HGNC:39866","description":"keratin 8 pseudogene 32","metadata":null},{"id":"275a9b4295b0438590638f1b773e1a19","type":"GENE","name":"KRT8P33","canonical_id":"hgnc:HGNC:39867","description":"keratin 8 pseudogene 33","metadata":null},{"id":"16d38b0f13054f7a8a22e1e5a46ad8f4","type":"GENE","name":"KRT8P34","canonical_id":"hgnc:HGNC:39868","description":"keratin 8 pseudogene 34","metadata":null},{"id":"cb5a9711da734b5492e8310427ab49f8","type":"GENE","name":"KRT8P35","canonical_id":"hgnc:HGNC:39869","description":"keratin 8 pseudogene 35","metadata":null},{"id":"ca636f249ce240e98fdb5e7d27e99157","type":"GENE","name":"KRT8P36","canonical_id":"hgnc:HGNC:39870","description":"keratin 8 pseudogene 36","metadata":null},{"id":"a76566d0e05f43469dbaee56cd242213","type":"GENE","name":"KRT8P37","canonical_id":"hgnc:HGNC:39871","description":"keratin 8 pseudogene 37","metadata":null},{"id":"fb94085d78a24fcaacbb9a459ee4cfa9","type":"GENE","name":"KRT8P38","canonical_id":"hgnc:HGNC:39872","description":"keratin 8 pseudogene 38","metadata":null},{"id":"7e0a5f85299f4932921a6c11c2400e29","type":"GENE","name":"KRT8P39","canonical_id":"hgnc:HGNC:39873","description":"keratin 8 pseudogene 39","metadata":null},{"id":"7009d59dd9f647d68171b24d0adaad81","type":"GENE","name":"KRT8P4","canonical_id":"hgnc:HGNC:31057","description":"keratin 8 pseudogene 4","metadata":null},{"id":"74fc417e9b8d4fceb9cb70361e4aa9c9","type":"GENE","name":"KRT8P40","canonical_id":"hgnc:HGNC:39874","description":"keratin 8 pseudogene 40","metadata":null},{"id":"a8f655db1b164da6af36553a0cf60e5f","type":"GENE","name":"KRT8P41","canonical_id":"hgnc:HGNC:39875","description":"keratin 8 pseudogene 41","metadata":null},{"id":"531fe21f90b6443383a50ea4d25d8529","type":"GENE","name":"KRT8P42","canonical_id":"hgnc:HGNC:39876","description":"keratin 8 pseudogene 42","metadata":null},{"id":"8a027b694887413fb7791de62dec9f72","type":"GENE","name":"KRT8P43","canonical_id":"hgnc:HGNC:39877","description":"keratin 8 pseudogene 43","metadata":null},{"id":"2d205ebe834b415e8c51518d5896d1cd","type":"GENE","name":"KRT8P44","canonical_id":"hgnc:HGNC:39878","description":"keratin 8 pseudogene 44","metadata":null},{"id":"c6b16cea79994e0f9714f3dfe4d18b0a","type":"GENE","name":"KRT8P45","canonical_id":"hgnc:HGNC:39879","description":"keratin 8 pseudogene 45","metadata":null},{"id":"5ce2c0064e314fc086143cba5a40f5a5","type":"GENE","name":"KRT8P46","canonical_id":"hgnc:HGNC:39880","description":"keratin 8 pseudogene 46","metadata":null},{"id":"81f5d95648a540ebbc57205dd39fe2c1","type":"GENE","name":"KRT8P47","canonical_id":"hgnc:HGNC:44461","description":"keratin 8 pseudogene 47","metadata":null},{"id":"0f040b9a07974d13a1199d14bd521897","type":"GENE","name":"KRT8P48","canonical_id":"hgnc:HGNC:48344","description":"keratin 8 pseudogene 48","metadata":null},{"id":"ab26d3bbe9ce45bf8d5ab5a04eaa37a8","type":"GENE","name":"KRT8P49","canonical_id":"hgnc:HGNC:48345","description":"keratin 8 pseudogene 49","metadata":null},{"id":"6c5c8070f53440ceaa40469c70ad746c","type":"GENE","name":"KRT8P5","canonical_id":"hgnc:HGNC:31094","description":"keratin 8 pseudogene 5","metadata":null},{"id":"c4c5c18e89b941c5895d2098647676f1","type":"GENE","name":"KRT8P50","canonical_id":"hgnc:HGNC:48346","description":"keratin 8 pseudogene 50","metadata":null},{"id":"00e6af56e92241b08bb634c47c62d008","type":"GENE","name":"KRT8P51","canonical_id":"hgnc:HGNC:48883","description":"keratin 8 pseudogene 51","metadata":null},{"id":"df188174a63a43fd993596e07d65edd3","type":"GENE","name":"KRT8P52","canonical_id":"hgnc:HGNC:54654","description":"keratin 8 pseudogene 52","metadata":null},{"id":"992879e361c24434a697af45b7b4cd42","type":"GENE","name":"KRT8P6","canonical_id":"hgnc:HGNC:33360","description":"keratin 8 pseudogene 6","metadata":null},{"id":"0d111714c72549909abe02a81253b981","type":"GENE","name":"KRT8P7","canonical_id":"hgnc:HGNC:33361","description":"keratin 8 pseudogene 7","metadata":null},{"id":"6cb748c814164cc1a757dfe7d539e2ca","type":"GENE","name":"KRT8P8","canonical_id":"hgnc:HGNC:33362","description":"keratin 8 pseudogene 8","metadata":null},{"id":"856deb6fe4a449fbab13e23cadfbbdcf","type":"GENE","name":"KRT8P9","canonical_id":"hgnc:HGNC:33363","description":"keratin 8 pseudogene 9","metadata":null},{"id":"7c9184cc94e04299940f5666c56cee64","type":"GENE","name":"KRT9","canonical_id":"hgnc:HGNC:6447","description":"keratin 9","metadata":{"aliases":["EPPK","K9","CK-9"]}},{"id":"e3a585dcb65d428285acd65e75e64d8b","type":"GENE","name":"KRT90P","canonical_id":"hgnc:HGNC:30195","description":"keratin 90, pseudogene","metadata":{"aliases":["HBA","KRTHBP1","KRT124P"]}},{"id":"f1f0d1bfe05a4abe961d8c46f31fe464","type":"GENE","name":"KRTAP1-1","canonical_id":"hgnc:HGNC:16772","description":"keratin associated protein 1-1","metadata":{"aliases":["KAP1.1B","HB2A","KAP1.1","KAP1.1A"]}},{"id":"857470e3d45c411e9f6a2cd1c305ae13","type":"GENE","name":"KRTAP1-3","canonical_id":"hgnc:HGNC:16771","description":"keratin associated protein 1-3","metadata":{"aliases":["KAP1.3"]}},{"id":"1bbe442ac59e434983c82d195d48591e","type":"GENE","name":"KRTAP1-4","canonical_id":"hgnc:HGNC:18904","description":"keratin associated protein 1-4","metadata":{"aliases":["KAP1.4"]}},{"id":"0e31cb719a714966bbe87292d68788b9","type":"GENE","name":"KRTAP1-5","canonical_id":"hgnc:HGNC:16777","description":"keratin associated protein 1-5","metadata":{"aliases":["KAP1.5"]}},{"id":"a7f3fdf22ebb4477a7f82680d51bb741","type":"GENE","name":"KRTAP10-1","canonical_id":"hgnc:HGNC:22966","description":"keratin associated protein 10-1","metadata":{"aliases":["KAP10.1","KAP18.1","KRTAP18-1"]}},{"id":"91ad5e5f6ff04a61b80eef9e7b00cda0","type":"GENE","name":"KRTAP10-10","canonical_id":"hgnc:HGNC:22972","description":"keratin associated protein 10-10","metadata":{"aliases":["KAP10.10","KAP18.10","KRTAP18-10"]}},{"id":"29c6cd1f8fa246a9982aca4d8b6f1d2f","type":"GENE","name":"KRTAP10-11","canonical_id":"hgnc:HGNC:20528","description":"keratin associated protein 10-11","metadata":{"aliases":["KRTAP18.11","KAP18.11","KAP10.11","KRTAP18-11"]}},{"id":"edcbd904212b4d75be06c479e0eec086","type":"GENE","name":"KRTAP10-12","canonical_id":"hgnc:HGNC:20533","description":"keratin associated protein 10-12","metadata":{"aliases":["KRTAP18.12","KAP10.12","KRTAP18-12"]}},{"id":"7c199f7a0c624a0d971747b59abe2c21","type":"GENE","name":"KRTAP10-13P","canonical_id":"hgnc:HGNC:34213","description":"keratin associated protein 10-13, pseudogene","metadata":null},{"id":"36c449a1813944b584afe32560e899fd","type":"GENE","name":"KRTAP10-2","canonical_id":"hgnc:HGNC:22967","description":"keratin associated protein 10-2","metadata":{"aliases":["KAP10.2","KAP18.2","KRTAP18-2"]}},{"id":"f7f29dd699b641fe97c3ee834dbc1301","type":"GENE","name":"KRTAP10-3","canonical_id":"hgnc:HGNC:22968","description":"keratin associated protein 10-3","metadata":{"aliases":["KAP10.3","KAP18.3","KRTAP18-3"]}},{"id":"42ab3536b2fa4b30b674302db7500812","type":"GENE","name":"KRTAP10-4","canonical_id":"hgnc:HGNC:20521","description":"keratin associated protein 10-4","metadata":{"aliases":["KRTAP18.4","KAP10.4","KRTAP18-4"]}},{"id":"e3c6fb7d62e3457db80f52ae4618f9ff","type":"GENE","name":"KRTAP10-5","canonical_id":"hgnc:HGNC:22969","description":"keratin associated protein 10-5","metadata":{"aliases":["KAP10.5","KAP18.5","KRTAP18-5"]}},{"id":"2cb2b2c27e524c32a71851a4b7024dc5","type":"GENE","name":"KRTAP10-6","canonical_id":"hgnc:HGNC:20523","description":"keratin associated protein 10-6","metadata":{"aliases":["KRTAP18.6","KAP18.6","KAP10.6","KRTAP18-6"]}},{"id":"65e8bd735a3446cc97e35ea6464f85e7","type":"GENE","name":"KRTAP10-7","canonical_id":"hgnc:HGNC:22970","description":"keratin associated protein 10-7","metadata":{"aliases":["KAP10.7","KAP18.7","KRTAP18-7"]}},{"id":"57e83db6403c4dd0bcad68e8651d4f3c","type":"GENE","name":"KRTAP10-8","canonical_id":"hgnc:HGNC:20525","description":"keratin associated protein 10-8","metadata":{"aliases":["KRTAP18.8","KAP10.8","KRTAP18-8"]}},{"id":"3df4f4cc555346d493f79dcd4390f70e","type":"GENE","name":"KRTAP10-9","canonical_id":"hgnc:HGNC:22971","description":"keratin associated protein 10-9","metadata":{"aliases":["KAP10.9","KAP18.9","KRTAP18-9"]}},{"id":"f2d6822d75c04f5886ab0cbd310a9280","type":"GENE","name":"KRTAP11-1","canonical_id":"hgnc:HGNC:18922","description":"keratin associated protein 11-1","metadata":{"aliases":["KAP11.1"]}},{"id":"6861b0c238e2443d8cf559917869ecb6","type":"GENE","name":"KRTAP12-1","canonical_id":"hgnc:HGNC:20529","description":"keratin associated protein 12-1","metadata":{"aliases":["KRTAP12.1","KAP12.1"]}},{"id":"b4a36d2a0c3f42959969b1dd335eb1a7","type":"GENE","name":"KRTAP12-2","canonical_id":"hgnc:HGNC:20530","description":"keratin associated protein 12-2","metadata":{"aliases":["KRTAP12.2","KAP12.2"]}},{"id":"314de43c75fa4927a68ac30911411671","type":"GENE","name":"KRTAP12-3","canonical_id":"hgnc:HGNC:20531","description":"keratin associated protein 12-3","metadata":{"aliases":["KRTAP12.3"]}},{"id":"49686354ddb84e79833b44f65482fe60","type":"GENE","name":"KRTAP12-4","canonical_id":"hgnc:HGNC:20532","description":"keratin associated protein 12-4","metadata":{"aliases":["KRTAP12.4"]}},{"id":"f978cb6016ec4cda936ced2838d2d987","type":"GENE","name":"KRTAP12-5P","canonical_id":"hgnc:HGNC:34212","description":"keratin associated protein 12-5, pseudogene","metadata":{"aliases":["KRTAP12p1","KRTAP12-6P"]}},{"id":"13b9d255a3dc45199cd90774b8ba046b","type":"GENE","name":"KRTAP13-1","canonical_id":"hgnc:HGNC:18924","description":"keratin associated protein 13-1","metadata":{"aliases":["KAP13.1"]}},{"id":"643e828c174b4196a33b40a50de72027","type":"GENE","name":"KRTAP13-2","canonical_id":"hgnc:HGNC:18923","description":"keratin associated protein 13-2","metadata":{"aliases":["KAP13-2"]}},{"id":"8c6854478ac44607a39688a0bd158568","type":"GENE","name":"KRTAP13-3","canonical_id":"hgnc:HGNC:18925","description":"keratin associated protein 13-3","metadata":{"aliases":["KAP13.3"]}},{"id":"195928be1c5e49a896d31d927cbcbd88","type":"GENE","name":"KRTAP13-4","canonical_id":"hgnc:HGNC:18926","description":"keratin associated protein 13-4","metadata":{"aliases":["KAP13.4"]}},{"id":"3f6da25f9b874303afbf39e3002bb227","type":"GENE","name":"KRTAP13-5P","canonical_id":"hgnc:HGNC:18929","description":"keratin associated protein 13-5, pseudogene","metadata":{"aliases":["KAP13A","KRTAP13P1"]}},{"id":"4d171972f7324f50abcbf0005c3c711a","type":"GENE","name":"KRTAP13-6P","canonical_id":"hgnc:HGNC:18930","description":"keratin associated protein 13-6, pseudogene","metadata":{"aliases":["KAP13B","KRTAP13P2"]}},{"id":"a63d6517c422493592c05016e9b0e6ff","type":"GENE","name":"KRTAP15-1","canonical_id":"hgnc:HGNC:18927","description":"keratin associated protein 15-1","metadata":{"aliases":["KAP15.1"]}},{"id":"5773d18f687e44b8aa23f3e917959869","type":"GENE","name":"KRTAP16-1","canonical_id":"hgnc:HGNC:18916","description":"keratin associated protein 16-1","metadata":{"aliases":["KAP16.1"]}},{"id":"e7e7743775a3422e8787634ebcae2c40","type":"GENE","name":"KRTAP17-1","canonical_id":"hgnc:HGNC:18917","description":"keratin associated protein 17-1","metadata":{"aliases":["KAP17.1"]}},{"id":"66d6eb36cc394b96b19fa45ac206e026","type":"GENE","name":"KRTAP19-1","canonical_id":"hgnc:HGNC:18936","description":"keratin associated protein 19-1","metadata":{"aliases":["KAP19.1"]}},{"id":"774d048a645b41aea44adb36cf70f736","type":"GENE","name":"KRTAP19-10P","canonical_id":"hgnc:HGNC:18951","description":"keratin associated protein 19-10, pseudogene","metadata":{"aliases":["KAP19B","KRTAP19P2"]}},{"id":"aba0134827a641d48a207c3833c161b6","type":"GENE","name":"KRTAP19-11P","canonical_id":"hgnc:HGNC:18952","description":"keratin associated protein 19-11, pseudogene","metadata":{"aliases":["KAP19C","KRTAP19P3"]}},{"id":"65dfff3987d84d85b199ffb03e94164a","type":"GENE","name":"KRTAP19-2","canonical_id":"hgnc:HGNC:18937","description":"keratin associated protein 19-2","metadata":{"aliases":["KAP19.2"]}},{"id":"40510140cfdf4bc7a66827befdba3f5e","type":"GENE","name":"KRTAP19-3","canonical_id":"hgnc:HGNC:18938","description":"keratin associated protein 19-3","metadata":{"aliases":["KAP19.3"]}},{"id":"3887b2ef054e4e5f8b42eb5d59cde8d0","type":"GENE","name":"KRTAP19-4","canonical_id":"hgnc:HGNC:18939","description":"keratin associated protein 19-4","metadata":{"aliases":["KAP19.4"]}},{"id":"70900e6f739f40a1ad9e994fededae87","type":"GENE","name":"KRTAP19-5","canonical_id":"hgnc:HGNC:18940","description":"keratin associated protein 19-5","metadata":{"aliases":["KAP19.5"]}},{"id":"afc92612a26e48679d295f0d69dcb5e7","type":"GENE","name":"KRTAP19-6","canonical_id":"hgnc:HGNC:18941","description":"keratin associated protein 19-6","metadata":{"aliases":["KAP19.6"]}},{"id":"3622b2587d414e59bdb601e8dbef6c3e","type":"GENE","name":"KRTAP19-7","canonical_id":"hgnc:HGNC:18942","description":"keratin associated protein 19-7","metadata":{"aliases":["KAP19.7"]}},{"id":"d206e2af14514795b1f7b01766c6d712","type":"GENE","name":"KRTAP19-8","canonical_id":"hgnc:HGNC:33898","description":"keratin associated protein 19-8","metadata":null},{"id":"482ebbd801d94ab093fb3001eaeaa38b","type":"GENE","name":"KRTAP19-9P","canonical_id":"hgnc:HGNC:18950","description":"keratin associated protein 19-9, pseudogene","metadata":{"aliases":["KAP19A","KRTAP19P1"]}},{"id":"26e5f0eb901f4d33a530b7b6b1098f49","type":"GENE","name":"KRTAP2-1","canonical_id":"hgnc:HGNC:16775","description":"keratin associated protein 2-1","metadata":{"aliases":["KAP2.1A"]}},{"id":"d45a266f0d264018bedadea2dff089b5","type":"GENE","name":"KRTAP2-2","canonical_id":"hgnc:HGNC:18905","description":"keratin associated protein 2-2","metadata":{"aliases":["KAP2.2"]}},{"id":"d8464782cddd437fa489a74918a9ab94","type":"GENE","name":"KRTAP2-3","canonical_id":"hgnc:HGNC:18906","description":"keratin associated protein 2-3","metadata":{"aliases":["KAP2.3"]}},{"id":"fce76243f1084f52909cfe27796df7d4","type":"GENE","name":"KRTAP2-4","canonical_id":"hgnc:HGNC:18891","description":"keratin associated protein 2-4","metadata":{"aliases":["KAP2.4"]}},{"id":"fffc72b400bc4e5f9c337179ea17933f","type":"GENE","name":"KRTAP2-5P","canonical_id":"hgnc:HGNC:18920","description":"keratin associated protein 2-5, pseudogene","metadata":{"aliases":["KAP2A","KRTAP2P1"]}},{"id":"e9c17be2ab5a49b99ff7c8012cdf55be","type":"GENE","name":"KRTAP20-1","canonical_id":"hgnc:HGNC:18943","description":"keratin associated protein 20-1","metadata":{"aliases":["KAP20.1"]}},{"id":"0575c3d147b347b380b79fedfe28e876","type":"GENE","name":"KRTAP20-2","canonical_id":"hgnc:HGNC:18944","description":"keratin associated protein 20-2","metadata":{"aliases":["KAP20.2"]}},{"id":"3f34e9cb24534c6fbe135144e0e17c48","type":"GENE","name":"KRTAP20-3","canonical_id":"hgnc:HGNC:34001","description":"keratin associated protein 20-3","metadata":{"aliases":["KAP20.3","KAP19D","KRTAP19P4"]}},{"id":"b3c38b895f274d57ace5e2ef75ef61eb","type":"GENE","name":"KRTAP20-4","canonical_id":"hgnc:HGNC:34002","description":"keratin associated protein 20-4","metadata":{"aliases":["KAP20.4"]}},{"id":"ac19d45ec4ff4c36ad5af8b52765cd1f","type":"GENE","name":"KRTAP21-1","canonical_id":"hgnc:HGNC:18945","description":"keratin associated protein 21-1","metadata":{"aliases":["KAP21.1"]}},{"id":"4a29e32ab2614eacaab4fad496d07732","type":"GENE","name":"KRTAP21-2","canonical_id":"hgnc:HGNC:18946","description":"keratin associated protein 21-2","metadata":{"aliases":["KAP21.2"]}},{"id":"12439961e5ae401990f9b8b7d8967be9","type":"GENE","name":"KRTAP21-3","canonical_id":"hgnc:HGNC:34216","description":"keratin associated protein 21-3","metadata":null},{"id":"3f07b19f0dc04c3eba5c59bd66f35e4c","type":"GENE","name":"KRTAP21-4P","canonical_id":"hgnc:HGNC:18954","description":"keratin associated protein 21-4, pseudogene","metadata":{"aliases":["KAP21A","KRTAP21P1"]}},{"id":"fd7f06a2f80d4827883253e211a01c4b","type":"GENE","name":"KRTAP22-1","canonical_id":"hgnc:HGNC:18947","description":"keratin associated protein 22-1","metadata":{"aliases":["KAP22.1"]}},{"id":"1d2a72b54f274a749a225b49d564753b","type":"GENE","name":"KRTAP22-2","canonical_id":"hgnc:HGNC:37091","description":"keratin associated protein 22-2","metadata":{"aliases":["KAP22.2"]}},{"id":"f5d884368e57434c84092136c72b4bfe","type":"GENE","name":"KRTAP23-1","canonical_id":"hgnc:HGNC:18928","description":"keratin associated protein 23-1","metadata":{"aliases":["KAP23.1"]}},{"id":"058543896ec1422da212c87b37510698","type":"GENE","name":"KRTAP24-1","canonical_id":"hgnc:HGNC:33902","description":"keratin associated protein 24-1","metadata":{"aliases":["KAP24.1"]}},{"id":"02a9e3b149254f9cb9fea9b0d32fafe3","type":"GENE","name":"KRTAP25-1","canonical_id":"hgnc:HGNC:34003","description":"keratin associated protein 25-1","metadata":{"aliases":["KAP25.1"]}},{"id":"601c71a513df4cb5bc28744ae480e728","type":"GENE","name":"KRTAP26-1","canonical_id":"hgnc:HGNC:33760","description":"keratin associated protein 26-1","metadata":null},{"id":"dd663416142a45f88b51ba485cadc3eb","type":"GENE","name":"KRTAP27-1","canonical_id":"hgnc:HGNC:33864","description":"keratin associated protein 27-1","metadata":null},{"id":"618b3284723148d48cb1b86fcf52886e","type":"GENE","name":"KRTAP29-1","canonical_id":"hgnc:HGNC:34211","description":"keratin associated like protein 29-1","metadata":{"aliases":["KAP29.2"]}},{"id":"26c7f4a88bcd41c3b3477e37ecdb3c4b","type":"GENE","name":"KRTAP3-1","canonical_id":"hgnc:HGNC:16778","description":"keratin associated protein 3-1","metadata":{"aliases":["KAP3.1"]}},{"id":"8240f34fc88d4e9e9150e94f53fbd3a3","type":"GENE","name":"KRTAP3-2","canonical_id":"hgnc:HGNC:16779","description":"keratin associated protein 3-2","metadata":{"aliases":["KAP3.2"]}},{"id":"f272ffc6edc64031a85d488dcacd66ab","type":"GENE","name":"KRTAP3-3","canonical_id":"hgnc:HGNC:18890","description":"keratin associated protein 3-3","metadata":{"aliases":["KAP3.3"]}},{"id":"c1d21e8f629346b282e9e435502af9cb","type":"GENE","name":"KRTAP3-4P","canonical_id":"hgnc:HGNC:18919","description":"keratin associated protein 3-4, pseudogene","metadata":{"aliases":["KAP3A","KRTAP3P1"]}},{"id":"7a549e36a14941208991c3ae07c51a52","type":"GENE","name":"KRTAP4-1","canonical_id":"hgnc:HGNC:18907","description":"keratin associated protein 4-1","metadata":{"aliases":["KAP4.1","KAP4.10","KRTAP4-10"]}},{"id":"789d67b47f5d48b6831101dd859ee94e","type":"GENE","name":"KRTAP4-11","canonical_id":"hgnc:HGNC:18911","description":"keratin associated protein 4-11","metadata":{"aliases":["KAP4.11","KAP4.14","KRTAP4-14"]}},{"id":"eb4dbeac8dad4350b005d044b585fb0a","type":"GENE","name":"KRTAP4-12","canonical_id":"hgnc:HGNC:16776","description":"keratin associated protein 4-12","metadata":{"aliases":["KAP4.12"]}},{"id":"6ed26bbb389d45ecab22eae981d03357","type":"GENE","name":"KRTAP4-16","canonical_id":"hgnc:HGNC:18921","description":"keratin associated protein 4-16","metadata":{"aliases":["KAP4A","KRTAP4P1","KRTAP4-16P"]}},{"id":"2c22a9eb8b384e9dab76e9ee14ed27e1","type":"GENE","name":"KRTAP4-17P","canonical_id":"hgnc:HGNC:53814","description":"keratin associated protein 4-17, pseudogene","metadata":{"aliases":["KRTAP4p3"]}},{"id":"81ee375f0bfb4bdea3b6039f5dd1ceee","type":"GENE","name":"KRTAP4-2","canonical_id":"hgnc:HGNC:18900","description":"keratin associated protein 4-2","metadata":{"aliases":["KAP4.2"]}},{"id":"7e8cc6dd9c234e80a02a5a6d5c23a801","type":"GENE","name":"KRTAP4-3","canonical_id":"hgnc:HGNC:18908","description":"keratin associated protein 4-3","metadata":{"aliases":["KAP4.3"]}},{"id":"5baeb8d41c8e4db082c5839791fbb11c","type":"GENE","name":"KRTAP4-4","canonical_id":"hgnc:HGNC:16928","description":"keratin associated protein 4-4","metadata":{"aliases":["KAP4.4","KAP4.13","KRTAP4-13"]}},{"id":"af81408c34764267b29363276e5dc4b0","type":"GENE","name":"KRTAP4-5","canonical_id":"hgnc:HGNC:18899","description":"keratin associated protein 4-5","metadata":{"aliases":["KAP4.5"]}},{"id":"8c7c698a9ddd452196e77e0810222745","type":"GENE","name":"KRTAP4-6","canonical_id":"hgnc:HGNC:18909","description":"keratin associated protein 4-6","metadata":{"aliases":["KAP4.6","KAP4.15","KRTAP4-15"]}},{"id":"7e2874015f3242128b0166ec165e203b","type":"GENE","name":"KRTAP4-7","canonical_id":"hgnc:HGNC:18898","description":"keratin associated protein 4-7","metadata":{"aliases":["KAP4.7"]}},{"id":"a4dd7e6263074fe1bbf57d6a0aab9382","type":"GENE","name":"KRTAP4-8","canonical_id":"hgnc:HGNC:17230","description":"keratin associated protein 4-8","metadata":{"aliases":["KAP4.8"]}},{"id":"82c4da9a65964fb38fb3ec2494caef32","type":"GENE","name":"KRTAP4-9","canonical_id":"hgnc:HGNC:18910","description":"keratin associated protein 4-9","metadata":{"aliases":["KAP4.9"]}},{"id":"7819bb08c4c04262956d9188fbe287e3","type":"GENE","name":"KRTAP5-1","canonical_id":"hgnc:HGNC:23596","description":"keratin associated protein 5-1","metadata":{"aliases":["KRTAP5.1","KRN1L"]}},{"id":"77795529f477479da507990eeac7be1a","type":"GENE","name":"KRTAP5-10","canonical_id":"hgnc:HGNC:23605","description":"keratin associated protein 5-10","metadata":{"aliases":["KRTAP5.10"]}},{"id":"ad7862960020444d81148d98ae7ec34a","type":"GENE","name":"KRTAP5-11","canonical_id":"hgnc:HGNC:23606","description":"keratin associated protein 5-11","metadata":{"aliases":["KRTAP5.11","KRTAP5-6"]}},{"id":"c888f5c1754c4a8399cf8e50e039350f","type":"GENE","name":"KRTAP5-13P","canonical_id":"hgnc:HGNC:23607","description":"keratin associated protein 5-13, pseudogene","metadata":{"aliases":["KRTAP5.P1","KRTAP5P1"]}},{"id":"7f5b0814534d4a5cb6ea6f2e6b3bf1ac","type":"GENE","name":"KRTAP5-14P","canonical_id":"hgnc:HGNC:23608","description":"keratin associated protein 5-14, pseudogene","metadata":{"aliases":["KRTAP5.P2","KRTAP5-12","KRTAP5P2"]}},{"id":"b911290391ce4579a12c10ef2821fc80","type":"GENE","name":"KRTAP5-2","canonical_id":"hgnc:HGNC:23597","description":"keratin associated protein 5-2","metadata":{"aliases":["KRTAP5.2","KRTAP5-8"]}},{"id":"e65686f43fba4138a0f2b48ab795cf51","type":"GENE","name":"KRTAP5-3","canonical_id":"hgnc:HGNC:23598","description":"keratin associated protein 5-3","metadata":{"aliases":["KRTAP5.3","KRTAP5-9"]}},{"id":"19d8332734e14ca08dc07d5a155e5144","type":"GENE","name":"KRTAP5-4","canonical_id":"hgnc:HGNC:23599","description":"keratin associated protein 5-4","metadata":{"aliases":["KRTAP5.4"]}},{"id":"4a09a9961bd945e89f54321c9cc75401","type":"GENE","name":"KRTAP5-5","canonical_id":"hgnc:HGNC:23601","description":"keratin associated protein 5-5","metadata":{"aliases":["KRTAP5.5","KRTAP5-11"]}},{"id":"ebdabbafd6eb4895a740d3932c94ed04","type":"GENE","name":"KRTAP5-6","canonical_id":"hgnc:HGNC:23600","description":"keratin associated protein 5-6","metadata":{"aliases":["KRTAP5.6"]}},{"id":"75bdf3905ef94178bbe46eda896a7f1f","type":"GENE","name":"KRTAP5-7","canonical_id":"hgnc:HGNC:23602","description":"keratin associated protein 5-7","metadata":{"aliases":["KRTAP5.7","KRTAP5-3"]}},{"id":"176f59c36cf5486987a37fb9f7adfb98","type":"GENE","name":"KRTAP5-8","canonical_id":"hgnc:HGNC:23603","description":"keratin associated protein 5-8","metadata":{"aliases":["KRTAP5.8","UHSKerB","KRTAP5-2"]}},{"id":"c3f2e0096dd24a6fb820697b8fb20ebf","type":"GENE","name":"KRTAP5-9","canonical_id":"hgnc:HGNC:23604","description":"keratin associated protein 5-9","metadata":{"aliases":["KRTAP5.9","KRTAP5-1","KRN1"]}},{"id":"f8c9481880c44a0292c42e7d4bfa6f09","type":"GENE","name":"KRTAP5-AS1","canonical_id":"hgnc:HGNC:27877","description":"KRTAP5-1/KRTAP5-2 antisense RNA 1","metadata":null},{"id":"6e28922300354fbaa1e74e62fa23b7a5","type":"GENE","name":"KRTAP6-1","canonical_id":"hgnc:HGNC:18931","description":"keratin associated protein 6-1","metadata":{"aliases":["KAP6.1","C21orf103"]}},{"id":"7084705609ec47ec847f0d17100b07d8","type":"GENE","name":"KRTAP6-2","canonical_id":"hgnc:HGNC:18932","description":"keratin associated protein 6-2","metadata":{"aliases":["KAP6.2"]}},{"id":"01766a5b93074c3d9012948a2c08871c","type":"GENE","name":"KRTAP6-3","canonical_id":"hgnc:HGNC:18933","description":"keratin associated protein 6-3","metadata":{"aliases":["KAP6.3"]}},{"id":"d47b80507c134e4dbcf40cbfe625617e","type":"GENE","name":"KRTAP7-1","canonical_id":"hgnc:HGNC:18934","description":"keratin associated protein 7-1","metadata":{"aliases":["KAP7.1"]}},{"id":"8efb8b58614b4973945eb167e9c54cc4","type":"GENE","name":"KRTAP8-1","canonical_id":"hgnc:HGNC:18935","description":"keratin associated protein 8-1","metadata":{"aliases":["KAP8.1"]}},{"id":"af83f336c5c9409c9ead11b2695e96df","type":"GENE","name":"KRTAP8-2P","canonical_id":"hgnc:HGNC:18948","description":"keratin associated protein 8-2, pseudogene","metadata":{"aliases":["KAP8A","KRTAP8P1"]}},{"id":"5e6e995d7f2d46419a9396353026fe24","type":"GENE","name":"KRTAP8-3P","canonical_id":"hgnc:HGNC:18949","description":"keratin associated protein 8-3, pseudogene","metadata":{"aliases":["KAP8B","KRTAP8P2"]}},{"id":"c8584fc828f84db59f83aa9df09ed4c3","type":"GENE","name":"KRTAP9-1","canonical_id":"hgnc:HGNC:18912","description":"keratin associated protein 9-1","metadata":{"aliases":["KAP9.1","KRTAP9L3"]}},{"id":"805054656c7d4a10941705d9a518c7fe","type":"GENE","name":"KRTAP9-10P","canonical_id":"hgnc:HGNC:34210","description":"keratin associated protein 9-10, pseudogene","metadata":null},{"id":"3a77f654cd4d47c78b9d5341f3bbadd7","type":"GENE","name":"KRTAP9-11P","canonical_id":"hgnc:HGNC:18918","description":"keratin associated protein 9-11, pseudogene","metadata":{"aliases":["KAP9A","KRTAP9P1"]}},{"id":"1139a6e9854a45a2ba2c9c701e188156","type":"GENE","name":"KRTAP9-12P","canonical_id":"hgnc:HGNC:48873","description":"keratin associated protein 9-12, pseudogene","metadata":null},{"id":"996149ccab474bcb9615e818e3576411","type":"GENE","name":"KRTAP9-2","canonical_id":"hgnc:HGNC:16926","description":"keratin associated protein 9-2","metadata":{"aliases":["KAP9.2"]}},{"id":"7812d9f4c1034fcfb90365d0e7af9c02","type":"GENE","name":"KRTAP9-3","canonical_id":"hgnc:HGNC:16927","description":"keratin associated protein 9-3","metadata":{"aliases":["KAP9.3"]}},{"id":"178f6d10c86d4562b79fa0350f49caa7","type":"GENE","name":"KRTAP9-4","canonical_id":"hgnc:HGNC:18902","description":"keratin associated protein 9-4","metadata":{"aliases":["KAP9.4"]}},{"id":"1e08e05be1374c17814fd1881452849f","type":"GENE","name":"KRTAP9-6","canonical_id":"hgnc:HGNC:18914","description":"keratin associated protein 9-6","metadata":{"aliases":["KAP9.6","KRTAP9L2"]}},{"id":"c12f0f5653374940ab4a63fbf1085908","type":"GENE","name":"KRTAP9-7","canonical_id":"hgnc:HGNC:18915","description":"keratin associated protein 9-7","metadata":{"aliases":["KAP9.7","KRTAP9L1"]}},{"id":"1c60b01d591d4736af5c4e274bca7d4e","type":"GENE","name":"KRTAP9-8","canonical_id":"hgnc:HGNC:17231","description":"keratin associated protein 9-8","metadata":{"aliases":["KAP9.8"]}},{"id":"4a1bcfdec3374eb7891439ecdae0a670","type":"GENE","name":"KRTAP9-9","canonical_id":"hgnc:HGNC:16773","description":"keratin associated protein 9-9","metadata":{"aliases":["KAP9.9","KAP9.5","KRTAP9-5"]}},{"id":"fdc22ea0319c4ff2abaa362ee268a19f","type":"GENE","name":"KRTCAP2","canonical_id":"hgnc:HGNC:28942","description":"keratinocyte associated protein 2","metadata":{"aliases":["KCP2"]}},{"id":"93662633b0b44321989436fea20bd8b5","type":"GENE","name":"KRTCAP2P1","canonical_id":"hgnc:HGNC:54589","description":"KRTCAP2 pseudogene 1","metadata":null},{"id":"ef0c5af8468643c085ece33db24b6f48","type":"GENE","name":"KRTCAP3","canonical_id":"hgnc:HGNC:28943","description":"keratinocyte associated protein 3","metadata":{"aliases":["KCP3"]}},{"id":"acf1db07a2ad42bcb40be125d4f89365","type":"GENE","name":"KRTDAP","canonical_id":"hgnc:HGNC:16313","description":"keratinocyte differentiation associated protein","metadata":{"aliases":["KDAP","UNQ467"]}},{"id":"00dddfb8c04b48cda841c6df96a93a32","type":"TRIAL","name":"KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges","canonical_id":"clinicaltrials.gov:NCT00929877","description":"Pain","metadata":null},{"id":"cdec6939ea27472791d64759e444320c","type":"GENE","name":"KSR1","canonical_id":"hgnc:HGNC:6465","description":"kinase suppressor of ras 1","metadata":{"aliases":["RSU2","KSR"]}},{"id":"030c399d71be49668f4b2a7d788beac8","type":"GENE","name":"KSR1P1","canonical_id":"hgnc:HGNC:44977","description":"kinase suppressor of ras 1 pseudogene 1","metadata":null},{"id":"2b9f96d944454019a8abd40eb30f2907","type":"GENE","name":"KSR2","canonical_id":"hgnc:HGNC:18610","description":"kinase suppressor of ras 2","metadata":{"aliases":["FLJ25965"]}},{"id":"0df89d6c40a74b878cd41d6ceabe7541","type":"GENE","name":"KTI12","canonical_id":"hgnc:HGNC:25160","description":"KTI12 chromatin associated homolog","metadata":{"aliases":["TOT4","MGC20419","SBBI81"]}},{"id":"7d5bc2801c03488bb139f23292d0c9ef","type":"GENE","name":"KTN1","canonical_id":"hgnc:HGNC:6467","description":"kinectin 1","metadata":{"aliases":["KIAA0004","CG1","KNT"]}},{"id":"dbbdf79e91c840dcb3468e20db19c838","type":"GENE","name":"KTN1-AS1","canonical_id":"hgnc:HGNC:19842","description":"KTN1 antisense RNA 1","metadata":{"aliases":["MYCLo-3","C14orf33"]}},{"id":"2168630a9417454a9bad6deed8eaf27e","type":"TRIAL","name":"KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)","canonical_id":"clinicaltrials.gov:NCT01626664","description":"Adult T-cell Leukemia-Lymphoma","metadata":null},{"id":"ae7c215b4c8848c684b1b53e9011e755","type":"GENE","name":"KXD1","canonical_id":"hgnc:HGNC:28420","description":"KxDL motif containing 1","metadata":{"aliases":["FLJ25480","MGC2749","KXDL","BORCS4","C19orf50"]}},{"id":"5055bf7cfc1743148ee79ad0e519c846","type":"GENE","name":"KXD1-AS1","canonical_id":"hgnc:HGNC:56662","description":"KXD1 antisense RNA 1","metadata":{"aliases":["AC005253.1"]}},{"id":"c53f322f773e4dcfaa88c6ac5cabde80","type":"GENE","name":"KY","canonical_id":"hgnc:HGNC:26576","description":"kyphoscoliosis peptidase","metadata":{"aliases":["FLJ33207"]}},{"id":"63ccbffa7405425c85bd00459b7b70c7","type":"GENE","name":"KYAT1","canonical_id":"hgnc:HGNC:1564","description":"kynurenine aminotransferase 1","metadata":{"aliases":["KATI","GTK","CCBL1"]}},{"id":"4e5ccd7f90a54df4820fde7ff419db46","type":"GENE","name":"KYAT3","canonical_id":"hgnc:HGNC:33238","description":"kynurenine aminotransferase 3","metadata":{"aliases":["RBM1","RP11-82K18.3","KAT3","KATIII","CCBL2"]}},{"id":"dbea2d8e356c4891b84364670fb6eaaa","type":"GENE","name":"KYNU","canonical_id":"hgnc:HGNC:6469","description":"kynureninase","metadata":null},{"id":"0d7f5f5abc1c4860b70efc8c9be6c028","type":"GENE","name":"KYNUP1","canonical_id":"hgnc:HGNC:39199","description":"kynureninase pseudogene 1","metadata":null},{"id":"c4dff967714843d2a55a46b5d3aedbd6","type":"GENE","name":"KYNUP2","canonical_id":"hgnc:HGNC:39200","description":"kynureninase pseudogene 2","metadata":null},{"id":"29856b4f8f2343f283e8e4032e2d0651","type":"GENE","name":"KYNUP3","canonical_id":"hgnc:HGNC:39201","description":"kynureninase pseudogene 3","metadata":null},{"id":"d01eb63082544d23b3f08489dbdf16af","type":"TRIAL","name":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","canonical_id":"clinicaltrials.gov:NCT05388149","description":"Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"586a2276b5ae481b84452ded483eb67a","type":"TRIAL","name":"Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism","canonical_id":"clinicaltrials.gov:NCT00155064","description":"Hyperaldosteronism","metadata":null},{"id":"d5784acd4a6e42ed986562aa5982616f","type":"DISEASE","name":"Kallmann syndrome","canonical_id":"mondo:0018800","description":null,"metadata":null},{"id":"585e769887354c128a109b3b1fbbe25c","type":"DISEASE","name":"Kaposi's sarcoma","canonical_id":"mondo:0005055","description":null,"metadata":null},{"id":"9742f3fa068c41b79adb527416374bdd","type":"DISEASE","name":"Kaposi's sarcoma","canonical_id":"mesh:D012514","description":null,"metadata":null},{"id":"ad9d8149fa134342b35857f2424b96a3","type":"DISEASE","name":"Kaposi's sarcoma associated with AIDS","canonical_id":"mesh:C554498","description":null,"metadata":null},{"id":"e1cd5ad85d544746b4d6c3b3f1be81b4","type":"GO_TERM","name":"Kdo transferase activity","canonical_id":"go:GO:0043842","description":"\"Catalysis of the reactions: (KDO)-lipid IVA + CMP-3-deoxy-D-manno-octulosonate = KDO2-lipid IVA + CMP, and lipid IVA + CMP-3-deoxy-D-manno-octulosonate = (KDO)-lipid IVA + CMP.\" [PMID:1577828, PMID:2033061, PMID:9195966]","metadata":null},{"id":"dd16ea188db4448284d7b0bdf6d34f66","type":"GO_TERM","name":"Kdo2-lipid A biosynthetic process","canonical_id":"go:GO:0036104","description":"\"The chemical reactions and pathways resulting in the formation of Kdo2-lipid A, a lipopolysaccharide (LPS) component.\" [GOC:yaf, PMID:21106097]","metadata":null},{"id":"fb00ac03b030495c84b48367b536fd96","type":"GO_TERM","name":"Kdo2-lipid IVA acyltransferase activity","canonical_id":"go:GO:0008913","description":"\"Catalysis of the reaction: a fatty acyl-[ACP] + an alpha-Kdo-(2->4)-alpha-Kdo-(2->6)-lipid IVA = an alpha-Kdo-(2->4)-alpha-Kdo-(2->6)-(acyl)-lipid IVA + holo-[ACP].\" [EC:2.3.1.241, PMID:18656959]","metadata":null},{"id":"f680459fe0134c17acd8b7888309f7ab","type":"GO_TERM","name":"Kelch-containing formin regulatory complex","canonical_id":"go:GO:1990615","description":"\"A protein complex that regulates actin cable formation, polarized cell growth, and cytokinesis in a formin-dependent manner. In S. cerevisiae the complex is composed of Bud14p and two Kelch family proteins, Kel1p and Kel2p.\" [PMID:24828508]","metadata":null},{"id":"b8d66342ad214f9b9f57fabe17e37090","type":"PROTEIN","name":"Kelch-like ECH-associated protein 1","canonical_id":"uniprot:Q14145","description":null,"metadata":null},{"id":"70c5d3a904ba41168f77e1886b743ed0","type":"DISEASE","name":"Keloid scar","canonical_id":"mesh:D007627","description":null,"metadata":null},{"id":"842f3cf097784a4cb8be6957cef322e5","type":"DISEASE","name":"Kennedy disease","canonical_id":"mondo:0010735","description":null,"metadata":null},{"id":"bd8dbc4bbcf84da98a05ac62dde8df2b","type":"TRIAL","name":"Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01712945","description":"Multiple Sclerosis","metadata":null},{"id":"4d7c01965879400a9dd187fbc5208c69","type":"DISEASE","name":"Keratitis","canonical_id":"mesh:D007634","description":null,"metadata":null},{"id":"b1bff98d6c7f4275957c9c73f078782a","type":"DISEASE","name":"Keratitis, Herpetic","canonical_id":"mesh:D016849","description":null,"metadata":null},{"id":"152750192fc44222b456340048c3bd01","type":"DISEASE","name":"Keratoconjunctivitis","canonical_id":"mesh:D007637","description":null,"metadata":null},{"id":"19faa1f143504f5b921b53cd87884fe1","type":"DISEASE","name":"Keratoconjunctivitis sicca","canonical_id":"mesh:D007638","description":null,"metadata":null},{"id":"52a2eb7c64fc41e0b64f63551482642d","type":"TRIAL","name":"Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study","canonical_id":"clinicaltrials.gov:NCT06486779","description":"Relapsing Multiple Sclerosis (RMS)","metadata":null},{"id":"b892dfb01b69494eaa254ba0bd474026","type":"TRIAL","name":"Ketamine + Cognitive Training for Suicidality in the Medical Setting","canonical_id":"clinicaltrials.gov:NCT04578938","description":"Suicide, Attempted","metadata":null},{"id":"58f156a238ca4a2da490389c4388aec5","type":"TRIAL","name":"Ketamine Analgesia in Third Molar Surgery","canonical_id":"clinicaltrials.gov:NCT04459377","description":"Pain; Postoperative","metadata":null},{"id":"c53972593ca1424999205f07c8eab106","type":"TRIAL","name":"Ketamine In Thoracic Surgery (KITS) Trial","canonical_id":"clinicaltrials.gov:NCT00504725","description":"Lung Cancer","metadata":null},{"id":"cd54e6198e6b4a70b0ccfb6c53cdb5cc","type":"TRIAL","name":"Ketamine Versus Fentanyl for Induction of Anesthesia in Septic Shock","canonical_id":"clinicaltrials.gov:NCT03251170","description":"Septic Shock","metadata":null},{"id":"daf30e4699684d5fa6ca5ef96053d394","type":"TRIAL","name":"Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital","canonical_id":"clinicaltrials.gov:NCT02103881","description":"Agitation","metadata":null},{"id":"feed28135baf4f058b470786a0779917","type":"TRIAL","name":"Ketamine and fMRI for Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT02373449","description":"Neuralgia","metadata":null},{"id":"0854f0c438d9453eb190d6a8ec4bea29","type":"TRIAL","name":"Ketamine for Treatment Resistant MDD","canonical_id":"clinicaltrials.gov:NCT04021433","description":"Depressive Disorder, Major","metadata":null},{"id":"694ad0c6d8b8469697c3ac1043ba5146","type":"TRIAL","name":"Ketamine in Colorectal Surgery","canonical_id":"clinicaltrials.gov:NCT02785003","description":"Acute Pain; Pain, Postoperative; Colorectal Surgery","metadata":null},{"id":"a35b6055932d4d9f8ad656658cfba031","type":"TRIAL","name":"Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress","canonical_id":"clinicaltrials.gov:NCT05344625","description":"Cancer-related Problem/Condition; Depressive Symptoms; Anxiety Disorders","metadata":null},{"id":"af9af4def27d41e3b324022b483a3ce5","type":"TRIAL","name":"Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy","canonical_id":"clinicaltrials.gov:NCT03649334","description":"Hematological Malignancy (Leukemia- Lymphoma)","metadata":null},{"id":"9ada4650df774bfaa8e999e97c3420e0","type":"TRIAL","name":"Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM)","canonical_id":"clinicaltrials.gov:NCT00970567","description":"Type 1 Diabetes","metadata":null},{"id":"83fe3647160148a38a938cb1170c523b","type":"TRIAL","name":"Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT02069197","description":"Obesity; Diabetes; Obstructive Sleep Apnea","metadata":null},{"id":"06b4eba706ef4c728f33748aec0db3ce","type":"TRIAL","name":"Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors","canonical_id":"clinicaltrials.gov:NCT07421518","description":"Type 1 Diabetes; Type 2 Diabetes","metadata":null},{"id":"18d81da9deb64e8995db0a489aa40b44","type":"TRIAL","name":"Ketoprofen Gel vs Placebo in Children With Ankle Sprain","canonical_id":"clinicaltrials.gov:NCT02491736","description":"Ankle Sprain","metadata":null},{"id":"30c5c9da8280466bb901a453d50836ec","type":"TRIAL","name":"Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis","canonical_id":"clinicaltrials.gov:NCT00352625","description":"Tendonitis; Bursitis","metadata":null},{"id":"e595cdd9f69a43559274680066debbcc","type":"TRIAL","name":"Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee","canonical_id":"clinicaltrials.gov:NCT00365586","description":"Osteoarthritis","metadata":null},{"id":"20b12df0f3154c548c1a2bc219cdd38f","type":"TRIAL","name":"Ketorol Gel in Gonarthrosis and Low Back Pain","canonical_id":"clinicaltrials.gov:NCT02638831","description":"Gonarthrosis; Low Back Pain","metadata":null},{"id":"83c016fb85b54534b0e16e8a816af59c","type":"TRIAL","name":"Ketorolac Premedication for Anesthetic Efficiency of IANB & Postendodontic Pain in Teeth With Irreversible Pulpitis","canonical_id":"clinicaltrials.gov:NCT02940405","description":"Irreversible Pulpitis","metadata":null},{"id":"981f2e1768f84fe0baf55effd0c96f52","type":"DRUG","name":"Ketotifen","canonical_id":"mesh:D007665","description":null,"metadata":null},{"id":"f686926b50c24f4f989eb17dcf61f07a","type":"TRIAL","name":"Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis","canonical_id":"clinicaltrials.gov:NCT00133627","description":"Seasonal Allergic Conjunctivitis","metadata":null},{"id":"630bfa79359c45928915415ca15a87a5","type":"TRIAL","name":"Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19","canonical_id":"clinicaltrials.gov:NCT05007522","description":"COVID-19 Respiratory Infection","metadata":null},{"id":"920a63ece6e24651a92adf00976f13d6","type":"TRIAL","name":"Ketotifen as a Treatment for Vascular Leakage During Dengue Fever","canonical_id":"clinicaltrials.gov:NCT02673840","description":"Dengue Fever; Pleural Effusion","metadata":null},{"id":"bb225032d8eb46bcabef89ec4542d1f5","type":"TRIAL","name":"Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia","canonical_id":"clinicaltrials.gov:NCT02484248","description":"Functional Dyspepsia","metadata":null},{"id":"28f53980db004ec1930f4149bb7d4dce","type":"TRIAL","name":"Ketotifen in Non-Alcoholic Fatty Liver Disease Patients","canonical_id":"clinicaltrials.gov:NCT05616442","description":"Hepatic Disease","metadata":null},{"id":"88fa4d7b406c40d7838a73eecb131e22","type":"TRIAL","name":"Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.","canonical_id":"clinicaltrials.gov:NCT00770133","description":"Allergic Conjunctivitis","metadata":null},{"id":"728247b2d02c48ec8912b659ab3c7adf","type":"TRIAL","name":"Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.","canonical_id":"clinicaltrials.gov:NCT00769886","description":"Allergic Conjunctivitis","metadata":null},{"id":"3b178274acb64d6e9d59c1c740e7a979","type":"TRIAL","name":"Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy","canonical_id":"clinicaltrials.gov:NCT04435028","description":"Breast Cancer; Iron Chelation","metadata":null},{"id":"19d5b7b74f7a4b13865c822921637c9c","type":"GO_TERM","name":"Kibra-Ex-Mer complex","canonical_id":"go:GO:0036375","description":"\"An apical protein complex that contains the proteins Kibra, Expanded and Merlin (Mer), or orthologs thereof. In humans, the complex contains KIBRA, FDM6 and NF2.\" [PMID:20159598]","metadata":null},{"id":"9c1abb45144140b2834e6e69da060e00","type":"TISSUE","name":"Kidney Cortex","canonical_id":"uberon:UBERON:0001225","description":null,"metadata":null},{"id":"36b8ac6e087749c1bfa841de0dd50f33","type":"TRIAL","name":"Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00993135","description":"Leukemia; Renal Toxicity","metadata":null},{"id":"c6427fcfae1c4f07859eccb72078474c","type":"TISSUE","name":"Kidney Medulla","canonical_id":"uberon:UBERON:0001293","description":null,"metadata":null},{"id":"0b932ac020434fe49c2b90970fcbb434","type":"TRIAL","name":"Kineret CAPS Post Authorisation Study","canonical_id":"clinicaltrials.gov:NCT02326376","description":"Cryopyrin-Associated Periodic Syndromes","metadata":null},{"id":"414a0e33e3dd4bd381cccba066eba5fe","type":"TRIAL","name":"Kineret in the Treatment of Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02915094","description":"Rheumatoid Arthritis","metadata":null},{"id":"f135226647194f5b849ed5410ab727ae","type":"TRIAL","name":"Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes","canonical_id":"clinicaltrials.gov:NCT01704638","description":"Depression","metadata":null},{"id":"b02393eeeb0248a2885032a843c68a6f","type":"TRIAL","name":"Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions","canonical_id":"clinicaltrials.gov:NCT06939608","description":"Pharmacokinetic Study in Healthy Volunteers","metadata":null},{"id":"55867554038848f4a46f410d7d4e0882","type":"TRIAL","name":"Kinetics of the Finasteride Prostate Induced Apoptosis","canonical_id":"clinicaltrials.gov:NCT00130767","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"0dfd4152c9d5461eb76f80cc5e0fdc96","type":"DISEASE","name":"King-Denborough syndrome","canonical_id":"mondo:0020485","description":null,"metadata":null},{"id":"b4387472cb1b4a1f8f3e06abed6950dd","type":"GO_TERM","name":"Kir2 inward rectifier potassium channel complex","canonical_id":"go:GO:1990374","description":"\"A inward rectifier potassium channel complex. Homo- or heterotetramer composed of subunits of the eukaryotic Kir2 protein family. Plays a key role in maintaining the correct resting potential in eukaryotic cells.\" [GOC:bhm, PMID:16834334]","metadata":null},{"id":"332dc6bee83247e1812582357b1a6ad2","type":"GO_TERM","name":"Kit signaling pathway","canonical_id":"go:GO:0038109","description":"\"The series of molecular signals initiated by the binding of stem cell factor to the tyrosine kinase receptor KIT on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription. Stem cell factor (KIT ligand) binding to the receptor Kit mediates receptor dimerization, activation of its intrinsic tyrosine kinase activity and autophosphorylation. The activated receptor then phosphorylates various substrates, thereby activating distinct signaling cascades within the cell that trigger a change in state or activity of the cell.\" [GOC:nhn, GOC:signaling, PMID:16129412]","metadata":null},{"id":"34fb37913e794e838fe2ec87c82cbd7e","type":"DISEASE","name":"Klebsiella cystitis","canonical_id":"mesh:D007710","description":null,"metadata":null},{"id":"1b4f7a0360614104a1f0d085976264ea","type":"DISEASE","name":"Klinefelter syndrome","canonical_id":"mondo:0006823","description":null,"metadata":null},{"id":"2c5a9903910547e28035e31d1fa7d9c8","type":"DISEASE","name":"Klinefelter's syndrome, XXY","canonical_id":"mesh:D007713","description":null,"metadata":null},{"id":"fb2302740ac7432caf7bcbfd5d0dbdab","type":"TRIAL","name":"Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.","canonical_id":"clinicaltrials.gov:NCT02063139","description":"Mild Persistent Asthma","metadata":null},{"id":"f0734e387f8b4c1dbb83273d249fa55d","type":"GO_TERM","name":"Knl1/Spc105 complex","canonical_id":"go:GO:0180019","description":"\"A kinetochore subcomplex that binds to centromeric chromatin and forms part of the outer kinetochore. It is involved in kinetochore-microtubule binding, recruiting microtubule binding outer kinetochore subunits. It is essential for kinetochore binding by components of the spindle assembly checkpoint. In humans, budding and fission yeast, it consists of KNL1/ZWINT, Spc105p/Kre28p and Spc7/Sos1, members of the Panther PTHR28260 and PTHR37329 families, respectively.\" [PMID:14565975, PMID:19893618]","metadata":null},{"id":"ea3950ae518c4d37bc6ac8eac4c85690","type":"DISEASE","name":"Korsakoff Syndrome","canonical_id":"mesh:D020915","description":null,"metadata":null},{"id":"cff25b4d53514fdfabeb0a6db6096c13","type":"GO_TERM","name":"Krueppel-associated box domain binding","canonical_id":"go:GO:0035851","description":"\"Binding to a Krueppel-associated box (KRAB) domain of a protein. The approximately 75 amino acid KRAB domain is enriched in charged amino acids, and is found in the N-terminal regions of many zinc finger-containing transcription factors.\" [InterPro:IPR001909]","metadata":null},{"id":"a181471e112745f4b0516a2dc6cb1361","type":"GO_TERM","name":"Ku-DNA ligase complex","canonical_id":"go:GO:0070420","description":"\"A nonhomologous end joining complex that contains one or more Ku monomers and one or more DNA ligase molecules from the LigC or LigD family, and mediates nonhomologous end joining in bacteria.\" [GOC:mah, PMID:17938628]","metadata":null},{"id":"5cfd5e5da9094918b11c1df02481e8a2","type":"GO_TERM","name":"Ku70:Ku80 complex","canonical_id":"go:GO:0043564","description":"\"Heterodimeric protein complex composed of a 70 kDa and a 80 kDa subunit, binds DNA through a channel formed by the heterodimer. Functions in DNA double stranded break repair, chromosome maintenance, transcription regulation, V(D)J recombination, and activation of DNA-PK.\" [PMID:12518983]","metadata":null},{"id":"3615b09b2b94480daa9604c585517184","type":"TRIAL","name":"Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07691333","description":"HR+/HER2- Breast Cancer; Breast Neoplasms","metadata":null},{"id":"f4b42ec750644e1cbb099ea9d2a2fc2b","type":"GO_TERM","name":"Kupffer's vesicle development","canonical_id":"go:GO:0070121","description":"\"The progression of the Kupffer's vesicle over time from its initial formation until its mature state. The Kupffer's vesicle is a small but distinctive epithelial sac containing fluid, located midventrally posterior to the yolk cell or its extension, and transiently present during most of the segmentation period.\" [GOC:dgh]","metadata":null},{"id":"88e50fbd2d58458fb37d1fd8c9ac31c3","type":"GO_TERM","name":"Kv4.1-DPP10 channel complex","canonical_id":"go:GO:0071199","description":"\"A voltage-gated potassium channel complex that contains the peptidase-related protein DPP10 associated with the channel via interaction with the Kv alpha subunit 4.1.\" [PMID:15911355]","metadata":null},{"id":"57f7b005c7fe4239902460d5630ca903","type":"GO_TERM","name":"Kv4.1-DPP6 channel complex","canonical_id":"go:GO:0071198","description":"\"A voltage-gated potassium channel complex that contains the peptidase-related protein DPP6 associated with the channel via interaction with the Kv alpha subunit 4.1.\" [PMID:15911355]","metadata":null},{"id":"24806d6e5c8148fa8e64be484bf0a2f0","type":"GO_TERM","name":"Kv4.2-DPP6 channel complex","canonical_id":"go:GO:0071200","description":"\"A voltage-gated potassium channel complex that contains the peptidase-related protein DPP6 associated with the channel via interaction with the Kv alpha subunit 4.2.\" [PMID:12575952, PMID:15911355]","metadata":null},{"id":"20dd0d02b6b845f6bf5fa9f96a9547e3","type":"GO_TERM","name":"Kv4.2-KChIP1 channel complex","canonical_id":"go:GO:0071192","description":"\"A voltage-gated potassium channel complex that contains the Kv channel interacting protein KChIP1 associated with the channel via interaction with the Kv alpha subunit 4.2.\" [PMID:15356203]","metadata":null},{"id":"18ee95438b264f10a92de9da57cd3f93","type":"GO_TERM","name":"Kv4.2-KChIP2 channel complex","canonical_id":"go:GO:0071193","description":"\"A voltage-gated potassium channel complex that contains the Kv channel interacting protein KChIP2 associated with the channel via interaction with the Kv alpha subunit 4.2.\" [PMID:15356203]","metadata":null},{"id":"4a7e5b44f7784b66931d9e9530cbaff8","type":"GO_TERM","name":"Kv4.2-KChIP3 channel complex","canonical_id":"go:GO:0071194","description":"\"A voltage-gated potassium channel complex that contains the Kv channel interacting protein KChIP3 associated with the channel via interaction with the Kv alpha subunit 4.2.\" [PMID:15356203]","metadata":null},{"id":"3a701b440ce14fdeb9f8e4736564ad09","type":"GO_TERM","name":"Kv4.2-KChIP4 channel complex","canonical_id":"go:GO:0071195","description":"\"A voltage-gated potassium channel complex that contains the Kv channel interacting protein KChIP4 associated with the channel via interaction with the Kv alpha subunit 4.2.\" [PMID:15356203]","metadata":null},{"id":"86d276e1a432467385a882132f78031f","type":"GO_TERM","name":"Kv4.2-Kv4.3 channel complex","canonical_id":"go:GO:0071197","description":"\"A voltage-gated potassium channel complex that contains the Kv alpha subunits 4.2 and 4.3.\" [PMID:15356203]","metadata":null},{"id":"732784eecc434dd98b72500896f05141","type":"GO_TERM","name":"Kv4.3-DPP10 channel complex","canonical_id":"go:GO:0071202","description":"\"A voltage-gated potassium channel complex that contains the peptidase-related protein DPP10 associated with the channel via interaction with the Kv alpha subunit 4.3.\" [PMID:15911355]","metadata":null},{"id":"5f182d8fca3642a5a7abbf324d684c02","type":"GO_TERM","name":"Kv4.3-DPP6 channel complex","canonical_id":"go:GO:0071201","description":"\"A voltage-gated potassium channel complex that contains the peptidase-related protein DPP6 associated with the channel via interaction with the Kv alpha subunit 4.3.\" [PMID:12575952, PMID:15911355]","metadata":null},{"id":"da049b39bc324ae5ba93a50618b33673","type":"GO_TERM","name":"Kv4.3-KChIP1 channel complex","canonical_id":"go:GO:0071196","description":"\"A voltage-gated potassium channel complex that contains the Kv channel interacting protein KChIP1 associated with the channel via interaction with the Kv alpha subunit 4.3.\" [PMID:15356203]","metadata":null},{"id":"c49559e9fed546ff970a2ca483902e2f","type":"GO_TERM","name":"L(+)-tartrate dehydratase activity","canonical_id":"go:GO:0008730","description":"\"Catalysis of the reaction: L-tartrate = H2O + oxaloacetate.\" [EC:4.2.1.32, RHEA:15413]","metadata":null},{"id":"b6a5dc8de3b94a9f8fae9bff3ac1089f","type":"GO_TERM","name":"L,L-diaminopimelate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0010285","description":"\"Catalysis of the reaction: 2-oxoglutarate + LL-2,6-diaminopimelate = (S)-2,3,4,5-tetrahydrodipicolinate + L-glutamate + H2O + H+.\" [RHEA:23988]","metadata":null},{"id":"d09b43a318e8462eae54e0e2b36991fd","type":"GO_TERM","name":"L-2,4-diaminobutyrate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0045303","description":"\"Catalysis of the reaction: L-2,4-diaminobutanoate + 2-oxoglutarate = L-aspartate 4-semialdehyde + L-glutamate.\" [RHEA:11160]","metadata":null},{"id":"11ad6d68a4534f419d2e37a47c9c1216","type":"GO_TERM","name":"L-2,4-diaminobutyrate:pyruvate transaminase activity","canonical_id":"go:GO:0047307","description":"\"Catalysis of the reaction: L-2,4-diaminobutyrate + pyruvate = L-alanine + L-aspartate 4-semialdehyde.\" [RHEA:12380]","metadata":null},{"id":"2230596d9d8b4762b506c675f8d5bd13","type":"GO_TERM","name":"L-2-amino-4-chloropent-4-enoate dehydrochlorinase activity","canonical_id":"go:GO:0047460","description":"\"Catalysis of the reaction: L-2-amino-4-chloropent-4-enoate + H2O = 2-oxopent-4-enoate + chloride + H+ + NH4.\" [EC:4.5.1.4, RHEA:11620]","metadata":null},{"id":"53599e33767243dbaac2fc93d9f89dc5","type":"GO_TERM","name":"L-2-aminoadipate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047536","description":"\"Catalysis of the reaction: L-2-aminoadipate + 2-oxoglutarate = 2-oxoadipate + L-glutamate.\" [RHEA:12601]","metadata":null},{"id":"1ef8c3d4dc5242bc83f88123bd87877d","type":"GO_TERM","name":"L-2-aminohexanoate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047537","description":"\"Catalysis of the reaction: L-2-aminohexanoate + 2-oxoglutarate = 2-oxohexanoate + L-glutamate.\" [RHEA:23600]","metadata":null},{"id":"3541fd7b6307413d90ecd3fd8deb00af","type":"GO_TERM","name":"L-2-hydroxycarboxylate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0102443","description":"\"Catalysis of the reaction: a (2S)-2-hydroxycarboxylate + NAD+ = a 2-oxocarboxylate + NADH + H+.\" [RHEA:34555]","metadata":null},{"id":"dd1e41056cab4f42aa10354a4211cf90","type":"GO_TERM","name":"L-3-cyanoalanine synthase activity","canonical_id":"go:GO:0050017","description":"\"Catalysis of the reaction: L-cysteine + HCN = sulfide + L-3-cyanoalanine.\" [EC:4.4.1.9, MetaCyc:L-3-CYANOALANINE-SYNTHASE-RXN]","metadata":null},{"id":"5ca909cf33104b81a6e180116996d35f","type":"GO_TERM","name":"L-Ala-D/L-Glu epimerase activity","canonical_id":"go:GO:0103031","description":"\"Catalysis of the reaction:L-alanyl-L-glutamate = L-alanyl-D-glutamate.\" [RHEA:28394]","metadata":null},{"id":"c988e78a979642af8682af8cab8a1373","type":"TRIAL","name":"L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT03476356","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"7954f6750d87453ea17317b4e8a7b208","type":"GO_TERM","name":"L-DOPA binding","canonical_id":"go:GO:0072544","description":"\"Binding to L-DOPA, the modified amino acid (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"384c685671d74db4af711634d6bc330e","type":"GO_TERM","name":"L-DOPA receptor activity","canonical_id":"go:GO:0035643","description":"\"Combining with L-DOPA to initiate a change in cell activity. L-DOPA is the modified amino acid (2S)-2-amino-3-(3,4-dihydroxyphenyl) propanoic acid, and is the precursor to dopamine, norepinephrine (noradrenaline) and epinephrine.\" [PMID:18828673, Wikipedia:L-DOPA]","metadata":null},{"id":"5c99762602e64c75b0ab8793115554ab","type":"TRIAL","name":"L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release","canonical_id":"clinicaltrials.gov:NCT03534661","description":"Hyperlipidemias","metadata":null},{"id":"7330f93bdff54fd89f89c70c8c088950","type":"GO_TERM","name":"L-alanine biosynthetic process","canonical_id":"go:GO:0042852","description":"\"The chemical reactions and pathways resulting in the formation of L-alanine, the L-enantiomer of 2-aminopropanoic acid, i.e. (2S)-2-aminopropanoic acid.\" [GOC:jl, GOC:jsg, GOC:mah]","metadata":null},{"id":"944553d739494755b6bde4fe22c4cecf","type":"GO_TERM","name":"L-alanine catabolic process","canonical_id":"go:GO:0042853","description":"\"The chemical reactions and pathways resulting in the breakdown of L-alanine.\" [GOC:curators]","metadata":null},{"id":"4e203b33f51b48418688f983f4882804","type":"GO_TERM","name":"L-alanine conjugated cholate hydrolase activity","canonical_id":"go:GO:7770005","description":"\"Catalysis of the reaction: cholate + L-alanine = L-alanocholate + H2O.\" [PMID:38326609, RHEA:79131]","metadata":null},{"id":"cccd5223e8ae43fabd9b25a82f1c1255","type":"GO_TERM","name":"L-alanine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0000286","description":"\"Catalysis of the reaction: L-alanine + NAD+ + H2O = pyruvate + NH4+ + NADH + H+.\" [RHEA:18405]","metadata":null},{"id":"9e89f7a87bba41b4b6e526e7d1c6f3f9","type":"GO_TERM","name":"L-alanine export across the plasma membrane","canonical_id":"go:GO:0140406","description":"\"The directed movement of L-alanine from inside of a cell, across the plasma membrane and into the extracellular region.\" [PMID:26073055, PMID:31591285]","metadata":null},{"id":"9ceb56583d7d4f688dd0369f04c964a9","type":"GO_TERM","name":"L-alanine fermentation","canonical_id":"go:GO:0019667","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of L-alanine, yielding acetylCoA. AcetylCoA can be further converted to ATP.\" [GOC:jl, PMID:38821505]","metadata":null},{"id":"fd6560e6a673411483c539467def0ccd","type":"GO_TERM","name":"L-alanine import across plasma membrane","canonical_id":"go:GO:1904273","description":"\"The directed import of L-alanine from the extracellular region across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:kmv, GOC:TermGenie, PMID:21097500]","metadata":null},{"id":"13eff4b34ae84b3c8db7eec658d3e08f","type":"GO_TERM","name":"L-alanine transmembrane transport","canonical_id":"go:GO:1904557","description":"\"The directed movement of L-alanine across a membrane by means of some agent such as a transporter or a pore.\" [GO_REF:0000069, GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"0534b39e0cf3463fba82052f569d66d8","type":"GO_TERM","name":"L-alanine transmembrane transporter activity","canonical_id":"go:GO:0015180","description":"\"Enables the transfer of L-alanine from one side of a membrane to the other. L-alanine is the L-enantiomer of 2-aminopropanoic acid.\" [GOC:curators, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"654fb3a23f9a49f985bb64c26f18ed45","type":"GO_TERM","name":"L-alanine transport","canonical_id":"go:GO:0015808","description":"\"The directed movement of L-alanine, the L-enantiomer of 2-aminopropanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"bf50d0b5c1f343f788bb53351455f008","type":"GO_TERM","name":"L-alanine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0004021","description":"\"Catalysis of the reaction: L-alanine + 2-oxoglutarate = pyruvate + L-glutamate.\" [RHEA:19453]","metadata":null},{"id":"60a3483296d0473197ba9cdc2a2c438c","type":"GO_TERM","name":"L-alanine:glyoxylate transaminase activity","canonical_id":"go:GO:0008453","description":"\"Catalysis of the reaction: L-alanine + glyoxylate = pyruvate + glycine.\" [RHEA:24248]","metadata":null},{"id":"59e1b31eaacc4110a93de61b7a33a683","type":"GO_TERM","name":"L-alanine:oxo-acid transaminase activity","canonical_id":"go:GO:0047635","description":"\"Catalysis of the reaction: L-alanine + a 2-oxocarboxylate = an L-alpha-amino acid + pyruvate.\" [RHEA:19953]","metadata":null},{"id":"f1bfb364de914e459a5d55bba5bfd16c","type":"GO_TERM","name":"L-alanine:oxomalonate transaminase activity","canonical_id":"go:GO:0047308","description":"\"Catalysis of the reaction: L-alanine + oxomalonate = aminomalonate + pyruvate.\" [RHEA:18809]","metadata":null},{"id":"4d1e5237f967499cb12c3f167aa566bf","type":"GO_TERM","name":"L-alanine:proton antiporter activity","canonical_id":"go:GO:0140407","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + L-alanine(in) = H+(in) + L-alanine(out).\" [PMID:26073055, PMID:31591285]","metadata":null},{"id":"82e967472abb493fb32a206bca7499f5","type":"GO_TERM","name":"L-allo-threonine aldolase activity","canonical_id":"go:GO:0008732","description":"\"Catalysis of the reaction: L-allo-threonine = glycine + acetaldehyde.\" [PMID:9228760, RHEA:26209]","metadata":null},{"id":"8cb8224fea8644849fbb00c34067e259","type":"GO_TERM","name":"L-alpha-amino acid transmembrane transport","canonical_id":"go:GO:1902475","description":"\"The directed movement of L-alpha-amino acid across a membrane by means of some agent such as a transporter or a pore.\" [GOC:kmv, GOC:TermGenie, PMID:14668347]","metadata":null},{"id":"91a60020cafa4232ae6e0c1505dc68c9","type":"GO_TERM","name":"L-altrarate catabolic process","canonical_id":"go:GO:1903663","description":"\"The chemical reactions and pathways resulting in the breakdown of L-altrarate.\" [GO_REF:0000068, GOC:TermGenie, PMID:17649980]","metadata":null},{"id":"654ac5e3f7564722b9953c0e9804fde1","type":"GO_TERM","name":"L-altrarate dehydratase activity","canonical_id":"go:GO:1990594","description":"\"Catalysis of the reaction: L-altrarate = 5-dehydro-4-deoxy-D-glucarate + H2O.\" [PMID:17649980]","metadata":null},{"id":"94b184de02c54dceab0d869506a1d441","type":"GO_TERM","name":"L-amino acid efflux transmembrane transporter activity","canonical_id":"go:GO:0034639","description":"\"Enables the transfer of an L-amino acid from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mah]","metadata":null},{"id":"8a7f7b9c748d4092a7881eb3582a5af3","type":"GO_TERM","name":"L-amino acid transmembrane transporter activity","canonical_id":"go:GO:0015179","description":"\"Enables the transfer of an L-amino acid from one side of a membrane to the other. L-amino acids are the L-enantiomers of amino acids.\" [GOC:ai, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"3e9671b3a17248f2a874a28ebd21f6e8","type":"GO_TERM","name":"L-amino acid transport","canonical_id":"go:GO:0015807","description":"\"The directed movement of L-enantiomer amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"a353c744653b40a7a61ea4ee1e7c5811","type":"GO_TERM","name":"L-amino-acid N-acetyltransferase activity","canonical_id":"go:GO:0140085","description":"\"Catalysis of the reaction: acetyl-CoA + a L-amino acid = CoA + an N-acetyl-L-amino-acid. In some cases other acetyl containing molecules can be used as donor.\" [GOC:pg, RHEA:83863]","metadata":null},{"id":"c2a56f8cda22412fb76061d7afc3c324","type":"GO_TERM","name":"L-amino-acid alpha-ligase activity","canonical_id":"go:GO:0034026","description":"\"Catalysis of the reaction: ATP + an L-amino acid + an L-amino acid = ADP + phosphate + L-aminoacyl-L-amino acid.\" [EC:6.3.2.49]","metadata":null},{"id":"0bd5739722ef413d978f97fc717c6283","type":"GO_TERM","name":"L-amino-acid oxidase activity","canonical_id":"go:GO:0001716","description":"\"Catalysis of the reaction: an L-alpha-amino acid + H2O + O2 = a 2-oxocarboxylate + H2O2 + NH4+.\" [RHEA:13781]","metadata":null},{"id":"e605bebb307f4e58b1248531f21011a4","type":"GO_TERM","name":"L-aminoadipate-semialdehyde dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0004043","description":"\"Catalysis of the reaction: (S)-2-amino-6-oxohexanoate + NAD(P)+ + H2O = L-2-aminoadipate + NAD(P)H + 2 H+.\" [EC:1.2.1.31]","metadata":null},{"id":"39681d6a2a614fe88de6ee790516f891","type":"GO_TERM","name":"L-arabinitol 2-dehydrogenase activity","canonical_id":"go:GO:0047002","description":"\"Catalysis of the reaction: L-arabinitol + NAD+ = L-ribulose + H+ + NADH.\" [EC:1.1.1.13, RHEA:21356]","metadata":null},{"id":"0b014c74e79048c89893ed1f26fe25d2","type":"GO_TERM","name":"L-arabinitol 4-dehydrogenase activity","canonical_id":"go:GO:0050019","description":"\"Catalysis of the reaction: L-arabinitol + NAD+ = L-xylulose + H+ + NADH.\" [EC:1.1.1.12, RHEA:16381]","metadata":null},{"id":"79a9908912614aec93d41db847dd3e39","type":"GO_TERM","name":"L-arabinofuranose binding","canonical_id":"go:GO:2001084","description":"\"Binding to L-arabinofuranose.\" [GOC:mengo_curators]","metadata":null},{"id":"d9c43ab0bc16435284913477b4771553","type":"GO_TERM","name":"L-arabinokinase activity","canonical_id":"go:GO:0009702","description":"\"Catalysis of the reaction: L-arabinose + ATP = beta-L-arabinose 1-phosphate + ADP + 2 H+.\" [EC:2.7.1.46, RHEA:20153]","metadata":null},{"id":"24833aff189e4345b57b17c62ebe0bbf","type":"GO_TERM","name":"L-arabinonate dehydratase activity","canonical_id":"go:GO:0050020","description":"\"Catalysis of the reaction: L-arabinonate = 2-dehydro-3-deoxy-L-arabinonate + H2O.\" [EC:4.2.1.25, RHEA:20968]","metadata":null},{"id":"471c81f22f804229a65750698a241b3e","type":"GO_TERM","name":"L-arabinonolactonase activity","canonical_id":"go:GO:0050021","description":"\"Catalysis of the reaction: L-arabinono-1,4-lactone + H2O = L-arabinonate + H+.\" [EC:3.1.1.15, RHEA:16217]","metadata":null},{"id":"50ccd31ba12d45d69a8f197ff1cdb88f","type":"GO_TERM","name":"L-arabinose 1-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050022","description":"\"Catalysis of the reaction: L-arabinose + NAD+ = L-arabinono-1,4-lactone + NADH.\" [EC:1.1.1.46, MetaCyc:L-ARABINOSE-1-DEHYDROGENASE-RXN]","metadata":null},{"id":"aee5aa02bae7450880b82943a37ce82c","type":"GO_TERM","name":"L-arabinose 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0044103","description":"\"Catalysis of the reaction: L-arabinose + NADP+ = L-arabinono-1,4-lactone + NADPH + H+.\" [GOC:jl, PMID:16326697]","metadata":null},{"id":"7cebb1de55d24092b9b0167f6017f70b","type":"GO_TERM","name":"L-arabinose biosynthetic process","canonical_id":"go:GO:0033357","description":"\"The chemical reactions and pathways resulting in the formation of L-arabinose, arabino-pentose.\" [GOC:mah]","metadata":null},{"id":"4d936072e9f3486085500358954e617f","type":"GO_TERM","name":"L-arabinose catabolic process","canonical_id":"go:GO:0019572","description":"\"The chemical reactions and pathways resulting in the breakdown of L-arabinose, the L-enantiomer of arabino-pentose.\" [GOC:jsg, GOC:mah]","metadata":null},{"id":"f3572579dd014567b24254e49ff54eb4","type":"GO_TERM","name":"L-arabinose isomerase activity","canonical_id":"go:GO:0008733","description":"\"Catalysis of the reaction: L-arabinose = L-ribulose.\" [EC:5.3.1.4, RHEA:14821]","metadata":null},{"id":"3303528cbe2049beb0f9ba9f7a6c9981","type":"GO_TERM","name":"L-arabinose metabolic process","canonical_id":"go:GO:0046373","description":"\"The chemical reactions and pathways involving L-arabinose, the D-enantiomer of arabino-pentose. L-arabinose occurs free, e.g. in the heartwood of many conifers, and in the combined state, in both furanose and pyranose forms, as a constituent of various plant hemicelluloses, bacterial polysaccharides etc.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"6c74c20160574f56922329a2e6c3ae8f","type":"GO_TERM","name":"L-arabinose reductase (NADPH) activity","canonical_id":"go:GO:0032867","description":"\"Catalysis of the reaction: L-arabitol + NADP+ = L-arabinose + NADPH + H+.\" [PMID:12724380, PMID:15184173, RHEA:25229]","metadata":null},{"id":"98c8a9e5958f4dec96a11b1837cd76ad","type":"GO_TERM","name":"L-arabinose transmembrane transport","canonical_id":"go:GO:0042882","description":"\"The process in which L-arabinose, the L-enantiomer of arabinose, is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl, GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"16e68d9e3c0d4125ba7a9f504f9147ef","type":"GO_TERM","name":"L-arabinose transmembrane transporter activity","canonical_id":"go:GO:0015147","description":"\"Enables the transfer of L-arabinose from one side of a membrane to the other. Arabinose occurs free, for example in the heartwood of many conifers and in the combined states, in both furanose and pyranose forms, as a constituent of various plant hemicelluloses, bacterial polysaccharides, etc.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"b2e26271e9ed442da4f9274509e2f95a","type":"GO_TERM","name":"L-arabitol catabolic process","canonical_id":"go:GO:0051158","description":"\"The chemical reactions and pathways resulting in the breakdown of L-arabitol, the pentitol derived from arabinose or lyxose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"04e45680b299484cbba04d231e16b162","type":"GO_TERM","name":"L-arginine N-succinyltransferase activity","canonical_id":"go:GO:0008791","description":"\"Catalysis of the reaction: succinyl-CoA + L-arginine = N2-succinyl-L-arginine + CoA + H+.\" [RHEA:15185]","metadata":null},{"id":"ff1cc7df4b9742d3ab52a3e220a2dffc","type":"TRIAL","name":"L-arginine Study for Persistent Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT04054973","description":"Schizo Affective Disorder; Schizophrenia","metadata":null},{"id":"c7e15bbe4a4c4fbe8530c476357dec50","type":"GO_TERM","name":"L-arginine biosynthetic process","canonical_id":"go:GO:0006526","description":"\"The chemical reactions and pathways resulting in the formation of arginine, 2-amino-5-(carbamimidamido)pentanoic acid.\" [ISBN:0198506732]","metadata":null},{"id":"1409ea63bffa452ab2fbc8163f455508","type":"GO_TERM","name":"L-arginine catabolic process","canonical_id":"go:GO:0006527","description":"\"The chemical reactions and pathways resulting in the breakdown of L-arginine.\" [GOC:curators]","metadata":null},{"id":"5804e09c38cf494780db2ba139328dca","type":"GO_TERM","name":"L-arginine conjugated cholate hydrolase activity","canonical_id":"go:GO:7770007","description":"\"Catalysis of the reaction: cholate + L-arginine = L-arginocholate + H2O.\" [PMID:38326608, RHEA:79111]","metadata":null},{"id":"1755642e6446457bba89b384a7f6ecb0","type":"GO_TERM","name":"L-arginine import across plasma membrane","canonical_id":"go:GO:0097638","description":"\"The directed movement of L-arginine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:krc, PMID:8195186]","metadata":null},{"id":"886a71eb92d84690a9fc4ef58caa4eb0","type":"GO_TERM","name":"L-arginine transmembrane export from vacuole","canonical_id":"go:GO:1990818","description":"\"The directed movement of L-arginine out of the vacuole, across the vacuolar membrane.\" [PMID:26083598]","metadata":null},{"id":"b303cda02842432fbd30d368886a1288","type":"GO_TERM","name":"L-arginine transmembrane import into vacuole","canonical_id":"go:GO:0090518","description":"\"The directed movement of L-arginine into the vacuole across the vacuolar membrane.\" [GOC:al]","metadata":null},{"id":"b4190445ada44473b8c54be87c0e09c6","type":"GO_TERM","name":"L-arginine transmembrane transport","canonical_id":"go:GO:1903826","description":"\"The directed movement of L-arginine across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:18357653, PMID:22822152, PMID:8195186]","metadata":null},{"id":"effcbec8148f4e169d2db9fd8aa47275","type":"GO_TERM","name":"L-arginine transmembrane transport from lysosomal lumen to cytosol","canonical_id":"go:GO:1904917","description":"\"The directed movement of L-arginine across a membrane from lysosomal lumen to cytosol.\" [GO_REF:0000078, GOC:kmv, GOC:TermGenie, PMID:22822152]","metadata":null},{"id":"fd0484d5f3e343c2a7722625135e8ef6","type":"GO_TERM","name":"L-arginine transmembrane transporter activity","canonical_id":"go:GO:0061459","description":"\"Enables the transfer of L-arginine from one side of a membrane to the other.\" [GOC:dph]","metadata":null},{"id":"20343bdb31314f0ea3a91aa0abcdc722","type":"GO_TERM","name":"L-ascorbate 6-phosphate lactonase activity","canonical_id":"go:GO:0035460","description":"\"Catalysis of the reaction: L-ascorbate 6-phosphate + H2O = 3-keto-L-gulonate 6-phosphate.\" [PMID:18097099, PMID:20359483]","metadata":null},{"id":"d0782087f6414a4c88c1656547008500","type":"GO_TERM","name":"L-ascorbate oxidase activity","canonical_id":"go:GO:0008447","description":"\"Catalysis of the reaction: 4 L-ascorbate + O2 = 4 monodehydroascorbate + 2 H2O.\" [RHEA:30243]","metadata":null},{"id":"f8c0328c51254bde9f06905f226edc21","type":"GO_TERM","name":"L-ascorbate peroxidase activity","canonical_id":"go:GO:0016688","description":"\"Catalysis of the reaction: L-ascorbate + H2O2 = dehydroascorbate + 2 H2O.\" [EC:1.11.1.11]","metadata":null},{"id":"78ddd9684d314dd8846d026fd83a65d7","type":"GO_TERM","name":"L-ascorbate:sodium symporter activity","canonical_id":"go:GO:0008520","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-ascorbate(out) + Na+(out) = L-ascorbate(in) + Na+(in).\" [GOC:mah, GOC:yaf, PMID:18094143]","metadata":null},{"id":"d05e0323157c4cd7884592adba03bd8c","type":"GO_TERM","name":"L-ascorbic acid binding","canonical_id":"go:GO:0031418","description":"\"Binding to L-ascorbic acid, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate; L-ascorbic acid is vitamin C and has co-factor and anti-oxidant activities in many species.\" [GOC:mah]","metadata":null},{"id":"76bef594b6be4bce91975253d6b48fc6","type":"GO_TERM","name":"L-ascorbic acid biosynthetic process","canonical_id":"go:GO:0019853","description":"\"The chemical reactions and pathways resulting in the formation of L-ascorbic acid; L-ascorbic acid ionizes to give L-ascorbate, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate, which is required as a cofactor in the oxidation of prolyl residues to hydroxyprolyl, and other reactions.\" [GOC:ma, ISBN:0198547684]","metadata":null},{"id":"9ee45e030b184d16babb1d05e31e055d","type":"GO_TERM","name":"L-ascorbic acid catabolic process","canonical_id":"go:GO:0019854","description":"\"The chemical reactions and pathways resulting in the breakdown of L-ascorbic acid; L-ascorbic acid ionizes to give L-ascorbate, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate, which is required as a cofactor in the oxidation of prolyl residues to hydroxyprolyl, and other reactions.\" [GOC:curators]","metadata":null},{"id":"8d84fed0f8df4d83931239c009cc6f7f","type":"GO_TERM","name":"L-ascorbic acid metabolic process","canonical_id":"go:GO:0019852","description":"\"The chemical reactions and pathways involving L-ascorbic acid, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate; L-ascorbic acid is vitamin C and has co-factor and anti-oxidant activities in many species.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"132bbfc504294f38b04fc9bca69a2e7a","type":"GO_TERM","name":"L-ascorbic acid transmembrane transport","canonical_id":"go:GO:0015882","description":"\"The process in which L-ascorbic acid is transported across a lipid bilayer, from one side of a membrane to the other. L-ascorbate, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate, is vitamin C and has co-factor and anti-oxidant activities in many species.\" [GOC:ai]","metadata":null},{"id":"e4131928fb934ee19135ca99d7653bd5","type":"GO_TERM","name":"L-ascorbic acid transmembrane transporter activity","canonical_id":"go:GO:0015229","description":"\"Enables the transfer of L-ascorbate from one side of a membrane to the other. L-ascorbate, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate, is vitamin C and has co-factor and anti-oxidant activities in many species.\" [ISBN:0198506732]","metadata":null},{"id":"556d494751714d78911e868a8ebf9850","type":"GO_TERM","name":"L-asparagine biosynthetic process","canonical_id":"go:GO:0070981","description":"\"The chemical reactions and pathways resulting in the formation of asparagine, (2S)-2-amino-3-carbamoylpropanoic acid.\" [GOC:mah]","metadata":null},{"id":"79a25f9ba41b4de8baf8d40b1464b103","type":"GO_TERM","name":"L-asparagine catabolic process","canonical_id":"go:GO:0006530","description":"\"The chemical reactions and pathways resulting in the breakdown of L-asparagine.\" [GOC:curators]","metadata":null},{"id":"fb0b780dd8ee45f7922e611b948e3101","type":"GO_TERM","name":"L-asparagine import across plasma membrane","canonical_id":"go:GO:1903811","description":"\"The directed movement of L-asparagine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"d7d8b98be2c4418ea94731fe16ef1e3c","type":"GO_TERM","name":"L-asparagine transmembrane transporter activity","canonical_id":"go:GO:0015182","description":"\"Enables the transfer of L-asparagine from one side of a membrane to the other. L-asparagine is the L-enantiomer of alpha-aminosuccinamic acid.\" [GOC:curators, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"bdbec61298004d099d1d7766fad47bae","type":"GO_TERM","name":"L-asparagine, sodium:proton antiporter activity","canonical_id":"go:GO:0140831","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(in) + L-asparagine(out) + Na+(out) = H+(out) + L-asparagine(in) + Na+(in).\" [PMID:10619430, PMID:11742981]","metadata":null},{"id":"da88f1c170af414ca6223ff25398e4ab","type":"GO_TERM","name":"L-asparagine:oxo-acid transaminase activity","canonical_id":"go:GO:0047297","description":"\"Catalysis of the reaction: L-asparagine + a 2-oxocarboxylate = 2-oxosuccinamate + an L-alpha-amino acid.\" [RHEA:19813]","metadata":null},{"id":"8130e2ff475c4842bc09e238f963e9e6","type":"GO_TERM","name":"L-asparagine:sodium symporter activity","canonical_id":"go:GO:0140901","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-asparagine(out) + Na+(out) = L-asparagine(in) + Na+(in).\" [PMID:21511949, PMID:28416685]","metadata":null},{"id":"72e6bc15a02a4a6b8b59a104c9210a6b","type":"GO_TERM","name":"L-aspartate N-acetyltransferase activity","canonical_id":"go:GO:0017188","description":"\"Catalysis of the reaction: L-aspartate + acetyl-CoA = N-acetyl-L-aspartate + CoA + H+.\" [RHEA:14165]","metadata":null},{"id":"3fb2f9b1671a429cb5cc80e5e2ee8a72","type":"GO_TERM","name":"L-aspartate biosynthetic process","canonical_id":"go:GO:0006532","description":"\"The chemical reactions and pathways resulting in the formation of aspartate, the anion derived from aspartic acid, 2-aminobutanedioic acid.\" [GOC:curators, ISBN:0198506732, MetaCyc:ASPARTATESYN-PWY]","metadata":null},{"id":"bd642c6526894b88a7d0a960bb5052d6","type":"GO_TERM","name":"L-aspartate catabolic process","canonical_id":"go:GO:0006533","description":"\"The chemical reactions and pathways resulting in the breakdown of L-aspartate.\" [GOC:curators]","metadata":null},{"id":"781bbf03c2f546b7b6e5a54c8f2074fd","type":"GO_TERM","name":"L-aspartate dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0033735","description":"\"Catalysis of the reaction: Catalysis of the reaction: L-aspartate + NAD(P)+ + H2O = oxaloacetate + NH4+ + NADPH + H+.\" [EC:1.4.1.21]","metadata":null},{"id":"c31b4d5c4c6944c9b0bd60eb99f3ad30","type":"GO_TERM","name":"L-aspartate import across plasma membrane","canonical_id":"go:GO:0140009","description":"\"The directed movement of L-aspartate from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000069, PMID:7914198]","metadata":null},{"id":"7f9daae624c24a0ab286f7875585ed8a","type":"GO_TERM","name":"L-aspartate oxidase activity","canonical_id":"go:GO:0008734","description":"\"Catalysis of the reaction: L-aspartate + O2 = iminosuccinate + H2O2. Can also use fumatate as electron acceptor under anaerobic conditions, yielding succinate.\" [EC:1.4.3.16]","metadata":null},{"id":"a5a89e4f0116408faa8a3c2082079f92","type":"GO_TERM","name":"L-aspartate transmembrane export from vacuole","canonical_id":"go:GO:0089703","description":"\"The directed movement of L-aspartate out of the vacuole, across the vacuolar membrane.\" [PMID:21307582]","metadata":null},{"id":"eecb8300b0af4e12a7b048cd7a321bcb","type":"GO_TERM","name":"L-aspartate transmembrane transport","canonical_id":"go:GO:0070778","description":"\"The directed movement of L-aspartate across a membrane by means of some agent such as a transporter or a pore.\" [PMID:21307582]","metadata":null},{"id":"d0fcc1c8cb1e4075a57c5ec4c56649d3","type":"GO_TERM","name":"L-aspartate transmembrane transporter activity","canonical_id":"go:GO:0015183","description":"\"Enables the transfer of L-aspartate from one side of a membrane to the other. L-aspartate is the anion derived from aspartic acid.\" [GOC:curators, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"724dee08c63f4e54b42d7b56277f6a7e","type":"GO_TERM","name":"L-aspartate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0004069","description":"\"Catalysis of the reaction: L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate.\" [RHEA:21824]","metadata":null},{"id":"467642d1139f4c879d30b49a44c3280e","type":"GO_TERM","name":"L-aspartate:fumarate antiporter activity","canonical_id":"go:GO:0062057","description":"\"Enables the transport of L-aspartate and fumarate across a membrane according to the reaction L-aspartate (out) + fumarate (in) = L-aspartate (in) + fumarate (out).\" [PMID:29995997]","metadata":null},{"id":"078e301305864a1a82c7f2e221655298","type":"GO_TERM","name":"L-aspartate:phenylpyruvate transaminase activity","canonical_id":"go:GO:0047319","description":"\"Catalysis of the reaction: L-aspartate + 3-phenylpyruvate = oxaloacetate + L-phenylalanine.\" [RHEA:14097]","metadata":null},{"id":"c301b6e1a14c47fab9f65df8af8d0b3f","type":"GO_TERM","name":"L-aspartate:prephenate transaminase activity","canonical_id":"go:GO:0033853","description":"\"Catalysis of the reaction: L-arogenate + oxaloacetate = prephenate + L-aspartate.\" [RHEA:20445]","metadata":null},{"id":"9e214d9cba784750a6d1620274c30a10","type":"GO_TERM","name":"L-beta-ethynylserine biosynthetic process","canonical_id":"go:GO:0062142","description":"\"The chemical reactions and pathways resulting in the formation of L-beta-ethynylserine. L-beta-ethynylserine is an antibiotic produced by Streptomyces bacteria.\" [PMID:3082841, PMID:30867596]","metadata":null},{"id":"7f82e215f11a4c90b6236c9aab3cca10","type":"GO_TERM","name":"L-carnitine CoA-transferase activity","canonical_id":"go:GO:0008735","description":"\"Catalysis of the reactions: (E)-4-(trimethylammonio)but-2-enoyl-CoA + L-carnitine = (E)-4-(trimethylammonio)but-2-enoate + L-carnitinyl-CoA and 4-trimethylammoniobutanoyl-CoA + L-carnitine = 4-trimethylammoniobutanoate + L-carnitinyl-CoA.\" [EC:2.8.3.21, PMID:7815937, PMID:8188598]","metadata":null},{"id":"c06a5d74c72f4b4fa74500fddc583125","type":"GO_TERM","name":"L-citrulline biosynthetic process","canonical_id":"go:GO:0019240","description":"\"The chemical reactions and pathways resulting in the formation of L-citrulline, N5-carbamoyl-L-ornithine, an alpha amino acid not found in proteins.\" [ISBN:0198506732]","metadata":null},{"id":"0332173a5d20479aaea104de86002830","type":"GO_TERM","name":"L-citrulline catabolic process","canonical_id":"go:GO:0019241","description":"\"The chemical reactions and pathways resulting in the breakdown of L-citrulline.\" [GOC:curators]","metadata":null},{"id":"c980728e48bb4691bd8dabcb683d38d7","type":"GO_TERM","name":"L-cysteate sulfo-lyase activity","canonical_id":"go:GO:0034011","description":"\"Catalysis of the reaction: L-cysteate + H2O = NH4 + pyruvate + sulfite.\" [EC:4.4.1.25, RHEA:13441]","metadata":null},{"id":"a99ed7baf0ed403bbc5aa83982dd5522","type":"GO_TERM","name":"L-cysteine binding","canonical_id":"go:GO:1902485","description":"\"Binding to L-cysteine.\" [GOC:bhm, GOC:TermGenie, PMID:12941942]","metadata":null},{"id":"ffa98b8d7e5b476b991a88bdef830cf2","type":"GO_TERM","name":"L-cysteine biosynthetic process","canonical_id":"go:GO:0019344","description":"\"The chemical reactions and pathways resulting in the formation of L-cysteine, 2-amino-3-mercaptopropanoic acid.\" [GOC:curators]","metadata":null},{"id":"541962eabf6f4f02b18cf47e463fb639","type":"GO_TERM","name":"L-cysteine catabolic process","canonical_id":"go:GO:0019448","description":"\"The chemical reactions and pathways resulting in the breakdown of L-cysteine.\" [GOC:curators]","metadata":null},{"id":"c4b6d4de66b0408a8f4fed4b22c50cd2","type":"GO_TERM","name":"L-cysteine desulfhydrase activity","canonical_id":"go:GO:0080146","description":"\"Catalysis of the reaction: L-cysteine + H2O = hydrogen sulfide + pyruvate + NH4+ + H+.\" [PMID:19955263, RHEA:24931]","metadata":null},{"id":"7e3c4dada90142d6b2a56502c7c07355","type":"GO_TERM","name":"L-cysteine desulfurase complex","canonical_id":"go:GO:1990221","description":"\"A protein complex capable of cysteine desulfurase activity decomposing L-cysteine to L-alanine and sulfur. It belongs to a ubiquitous family of pyridoxal 5-phosphate (PLP)-dependent enzymes.\" [GOC:bhm, PMID:11827487]","metadata":null},{"id":"3907a286a16e4b5591685493f6f6e345","type":"GO_TERM","name":"L-cysteine export across plasma membrane","canonical_id":"go:GO:0033228","description":"\"The directed movement of L-cysteine from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:mlg]","metadata":null},{"id":"43d0a85cb6e24490a3cf5ee63427982f","type":"GO_TERM","name":"L-cysteine transmembrane transport","canonical_id":"go:GO:1903712","description":"\"The directed movement of L-cysteine across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:17435223]","metadata":null},{"id":"cae9597dfba14051bccc0c552a526544","type":"GO_TERM","name":"L-cysteine transmembrane transporter activity","canonical_id":"go:GO:0033229","description":"\"Enables the transfer of L-cysteine from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"94aafea714a74dca8f09bc9573c9a077","type":"GO_TERM","name":"L-cysteine transport","canonical_id":"go:GO:0042883","description":"\"The directed movement of L-cysteine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a7431530115a402381344a3de7f89184","type":"GO_TERM","name":"L-cysteine-S-conjugate N-acetyltransferase activity","canonical_id":"go:GO:0047198","description":"\"Catalysis of the reaction: S-substituted L-cysteine + acetyl-CoA = S-substituted N-acetyl-L-cysteine + CoA + H+.\" [RHEA:19213]","metadata":null},{"id":"d01c116407e54cb8a0f9a0b31126bf48","type":"GO_TERM","name":"L-cysteine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047801","description":"\"Catalysis of the reaction: L-cysteine + 2-oxoglutarate = 2-oxo-3-sulfanylpropanoate + L-glutamate.\" [RHEA:17441]","metadata":null},{"id":"e1e431095b8f49f7a70863012b222eb8","type":"GO_TERM","name":"L-cystine L-cysteine-lyase (deaminating) activity","canonical_id":"go:GO:0044540","description":"\"Catalysis of the reaction: L-cystine + H2O = S-sulfanyl-L-cysteine + pyruvate + NH4+.\" [RHEA:24927]","metadata":null},{"id":"a9075e08f68d40a3a261efc5f021b4b5","type":"GO_TERM","name":"L-cystine reductase (NADH) activity","canonical_id":"go:GO:0050456","description":"\"Catalysis of the reaction: 2 L-cysteine + NAD+ = L-cystine + H+ + NADH.\" [EC:1.8.1.6, RHEA:20597]","metadata":null},{"id":"425b22b03e1c49848ad997bd9556e542","type":"GO_TERM","name":"L-cystine transmembrane transport from lysosomal lumen to cytosol","canonical_id":"go:GO:1904919","description":"\"The directed movement of L-cystine from the lysosomal lumen across the lysosomal membrane and into the cytosol.\" [GO_REF:0000078, GOC:kmv, GOC:TermGenie, PMID:22822152]","metadata":null},{"id":"1455cee0cc38449687f4d5a78c617095","type":"GO_TERM","name":"L-cystine transmembrane transporter activity","canonical_id":"go:GO:0015184","description":"\"Enables the transfer of L-cystine from one side of a membrane to the other.\" [GOC:curators, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"7645e90f219448938e9125adea44a515","type":"GO_TERM","name":"L-cystine transport","canonical_id":"go:GO:0015811","description":"\"The directed movement of L-cystine (also known as dicysteine) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"8a84b91651e64d70a6fc7de28f7d7a36","type":"GO_TERM","name":"L-diaminopimelate transmembrane transporter activity","canonical_id":"go:GO:0015626","description":"\"Enables the transfer of L-diaminopimelate from one side of a membrane to the other. L-diaminopimelate is the L-enantiomer anion of 2,6-diaminoheptanedioic acid.\" [GOC:curators, GOC:jsg, GOC:mah, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"d91afb93523141298400262e0dcf95ad","type":"GO_TERM","name":"L-dopa catabolic process","canonical_id":"go:GO:0120575","description":"\"The chemical reactions and pathways resulting in the breakdown of L-dopa.\" [MetaCyc:PWY-6334, MetaCyc:PWY-8110]","metadata":null},{"id":"466cef06293c4a3fa9d425f1f06849d5","type":"GO_TERM","name":"L-dopa decarboxylase activator activity","canonical_id":"go:GO:0036478","description":"\"Interacts with and increases L-dopa decarboxylase activity.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"e6ebe225e0e74057a7001caa552d0e2d","type":"GO_TERM","name":"L-dopa decarboxylase activity","canonical_id":"go:GO:0036468","description":"\"Catalysis of the reaction: L-dopa + H+ = CO2 + dopamine.\" [GOC:bf, GOC:PARL, RHEA:12272]","metadata":null},{"id":"a7756da7d16e454e9a34fedc6f534649","type":"GO_TERM","name":"L-erythro-3,5-diaminohexanoate dehydrogenase activity","canonical_id":"go:GO:0047124","description":"\"Catalysis of the reaction: (3S,5S)-3,5-diaminohexanoate + H2O + NAD+ = (S)-5-amino-3-oxo-hexanoate + H+ + NADH + NH4.\" [EC:1.4.1.11, RHEA:19633]","metadata":null},{"id":"d65b72079ccd479a8882d993f25d4c4b","type":"GO_TERM","name":"L-erythro-3-methylmalyl-CoA lyase activity","canonical_id":"go:GO:0043959","description":"\"Catalysis of the reaction: (2R,3S)-beta-methylmalyl-CoA = glyoxylate + propanoyl-CoA.\" [RHEA:38259]","metadata":null},{"id":"e66db99e8cca48ae80a102748d183ccf","type":"GO_TERM","name":"L-fuconate dehydratase activity","canonical_id":"go:GO:0050023","description":"\"Catalysis of the reaction: L-fuconate = 2-dehydro-3-deoxy-L-fuconate + H2O.\" [EC:4.2.1.68, RHEA:22772]","metadata":null},{"id":"2803d5766f4e47778b9d9533a4818ebb","type":"GO_TERM","name":"L-fucose biosynthetic process","canonical_id":"go:GO:0006005","description":"\"The chemical reactions and pathways resulting in the formation of L-fucose (6-deoxy-L-galactose).\" [GOC:jl]","metadata":null},{"id":"a6e8b05babae477cac6751f707202e90","type":"GO_TERM","name":"L-fucose catabolic process","canonical_id":"go:GO:0042355","description":"\"The chemical reactions and pathways resulting in the breakdown of L-fucose (6-deoxy-Lgalactose).\" [GOC:jl]","metadata":null},{"id":"33870f49b1594b509270d2624cfc0a15","type":"GO_TERM","name":"L-fucose isomerase activity","canonical_id":"go:GO:0008736","description":"\"Catalysis of the reaction: L-fucose = L-fuculose.\" [RHEA:17233]","metadata":null},{"id":"ee9a5d80221c437fa8abd98ad34095b2","type":"GO_TERM","name":"L-fucose metabolic process","canonical_id":"go:GO:0042354","description":"\"The chemical reactions and pathways involving L-fucose, 6-deoxy-L-galactose, a sugar that occurs in fucans, a class of polysaccharides in seaweeds, especially Fucus species, and in the cell wall matrix of higher plants.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"e8ba2e15eab64315ba9a535a6acb8a4c","type":"GO_TERM","name":"L-fucose mutarotase activity","canonical_id":"go:GO:0036373","description":"\"Catalysis of the reaction: alpha-L-fucose = beta-L-fucose.\" [GOC:crds, PMID:15060078, RHEA:25580]","metadata":null},{"id":"f24621fb3d3c4c3aaebd42ab47a294a9","type":"GO_TERM","name":"L-fuculokinase activity","canonical_id":"go:GO:0008737","description":"\"Catalysis of the reaction: L-fuculose + ATP = L-fuculose 1-phosphate + ADP + 2 H+.\" [EC:2.7.1.51, RHEA:12376]","metadata":null},{"id":"6a54bc664d1940f4b3d98ed2b606e90e","type":"GO_TERM","name":"L-fuculose-phosphate aldolase activity","canonical_id":"go:GO:0008738","description":"\"Catalysis of the reaction: L-fuculose 1-phosphate = (S)-lactaldehyde + glycerone phosphate.\" [EC:4.1.2.17, RHEA:12933]","metadata":null},{"id":"238544bfae0f4a60b27f04d80c26b20f","type":"GO_TERM","name":"L-galactonate catabolic process","canonical_id":"go:GO:0034195","description":"\"The chemical reactions and pathways resulting in the breakdown of L-galactonate, the anion of L-galactonic acid.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"d3c71144745b41aa823ae02bb5b9f2b4","type":"GO_TERM","name":"L-galactonolactone oxidase activity","canonical_id":"go:GO:0050024","description":"\"Catalysis of the reaction: L-galactono-1,4-lactone + O2 = L-ascorbate + H2O2 + H+.\" [EC:1.3.3.12, RHEA:20617]","metadata":null},{"id":"40a0077219cc444f9af3f0c2d584458f","type":"GO_TERM","name":"L-galactose dehydrogenase activity","canonical_id":"go:GO:0010349","description":"\"Catalysis of the reaction: L-galactose + NAD+ = L-galactono-1,4-lactone + NADH + H+.\" [PMID:12047629, RHEA:31559]","metadata":null},{"id":"95c1a3e51bc3432687112f70c6aa3e2e","type":"GO_TERM","name":"L-galactose-1-phosphate phosphatase activity","canonical_id":"go:GO:0010347","description":"\"Catalysis of the reaction: L-galactose-1-phosphate + H2O = L-galactose + phosphate.\" [PMID:15550539, PMID:16595667]","metadata":null},{"id":"f282b94a7bed45008f80483e4fd83acd","type":"GO_TERM","name":"L-gamma-glutamyl-L-propargylglycine hydroxylase activity","canonical_id":"go:GO:0062148","description":"\"Catalysis of the reaction: 2-oxoglutarate + L-gamma-glutamyl-L-propargylglycine + O2 = CO2 + L-gamma-glutamyl-(3R)-L-beta-ethynylserine + succinate.\" [PMID:30867596, RHEA:59900]","metadata":null},{"id":"61c6059a8ceb4ed19bfd660b9da77b11","type":"GO_TERM","name":"L-glucuronate reductase activity","canonical_id":"go:GO:0047939","description":"\"Catalysis of the reaction: L-gulonate + NADP+ = D-glucuronate + H+ + NADPH.\" [EC:1.1.1.19, RHEA:14909]","metadata":null},{"id":"e51514cd8d2246afb1f13a2e64842971","type":"GO_TERM","name":"L-glutamate N-acetyltransferase activity, acting on acetyl-CoA as donor","canonical_id":"go:GO:0004042","description":"\"Catalysis of the reaction: L-glutamate + acetyl-CoA = N-acetyl-L-glutamate + CoA + H+.\" [RHEA:24292]","metadata":null},{"id":"16b8869a95fc4cb39bd5d0d5466fa3a1","type":"GO_TERM","name":"L-glutamate N-acetyltransferase activity, acting on acetyl-L-ornithine as donor","canonical_id":"go:GO:0004358","description":"\"Catalysis of the reaction: N2-acetyl-L-ornithine + L-glutamate = N-acetyl-L-glutamate + L-ornithine.\" [RHEA:15349]","metadata":null},{"id":"8c36eb6132bd459380f6bda80e2d4a22","type":"GO_TERM","name":"L-glutamate biosynthetic process","canonical_id":"go:GO:0097054","description":"\"The chemical reactions and pathways resulting in the formation of L-glutamate, the L enantiomer anion of 2-aminopentanedioic acid.\" [GOC:yaf]","metadata":null},{"id":"9bed9a5f17554e30969f619cfb8b1424","type":"GO_TERM","name":"L-glutamate catabolic process","canonical_id":"go:GO:0006538","description":"\"The chemical reactions and pathways resulting in the breakdown of L-glutamate.\" [GOC:curators]","metadata":null},{"id":"cbda473d9a2f4de7996b241b74d7e7fc","type":"GO_TERM","name":"L-glutamate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004352","description":"\"Catalysis of the reaction: L-glutamate + NAD+ + H2O = 2-oxoglutarate + NH4+ + NADH + H+.\" [RHEA:15133]","metadata":null},{"id":"d689f718fc134589ab6eb926c058f9bf","type":"GO_TERM","name":"L-glutamate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004354","description":"\"Catalysis of the reaction: L-glutamate + NADP+ + H2O = 2-oxoglutarate + NH4+ + NADPH + H+.\" [RHEA:11612]","metadata":null},{"id":"c17b57f72df94b9ea1f67029420ccf1b","type":"GO_TERM","name":"L-glutamate dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0004353","description":"\"Catalysis of the reaction: L-glutamate + NAD(P)+ + H2O = 2-oxoglutarate + NH4+ + NAD(P)H + H+.\" [EC:1.4.1.3]","metadata":null},{"id":"821029dd89ef4290a02be0220e604097","type":"GO_TERM","name":"L-glutamate fermentation","canonical_id":"go:GO:0033508","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of L-glutamate, yielding energy in the form of ATP.\" [PMID:38821505]","metadata":null},{"id":"9ffb34587aa0466683f36fe9443e288b","type":"GO_TERM","name":"L-glutamate gamma-semialdehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0003842","description":"\"L-glutamate 5-semialdehyde + NAD+ + H2O = L-glutamate + NADH + 2 H+.\" [RHEA:30235]","metadata":null},{"id":"3c547f8ddb694ccca7860b9b012f180f","type":"GO_TERM","name":"L-glutamate import","canonical_id":"go:GO:0051938","description":"\"The directed movement of L-glutamate, the L-enantiomer of the anion of 2-aminopentanedioic acid, into a cell or organelle.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"8e7450147ed640ceadf6bf4e9006a924","type":"GO_TERM","name":"L-glutamate import across plasma membrane","canonical_id":"go:GO:0098712","description":"\"The directed movement of L-glutamate from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"60ea43a729bf412db8250ee38a6f9e54","type":"GO_TERM","name":"L-glutamate import into mitochondrion","canonical_id":"go:GO:0110141","description":"\"The process in which L-glutamate is transported from the cytosol into the mitochondrial matrix.\" [GOC:vw, PMID:30297026]","metadata":null},{"id":"00bad736b3a14997bbc504978487315c","type":"GO_TERM","name":"L-glutamate oxidase activity","canonical_id":"go:GO:0050025","description":"\"Catalysis of the reaction: L-glutamate + O2 + H2O = 2-oxoglutarate + H2O2 + NH4+.\" [RHEA:20728]","metadata":null},{"id":"6b85cfdd7b45445588fc55818b3c0b8a","type":"GO_TERM","name":"L-glutamate transmembrane export from vacuole","canonical_id":"go:GO:0089704","description":"\"The directed movement of L-glutamate out of the vacuole, across the vacuolar membrane.\" [PMID:21307582]","metadata":null},{"id":"65151b003ab947dfb89ae7a173146f41","type":"GO_TERM","name":"L-glutamate transmembrane import into vacuole","canonical_id":"go:GO:0090515","description":"\"The directed movement of L-glutamate into the vacuole across the vacuolar membrane.\" [GOC:al]","metadata":null},{"id":"31ca771af5af4be3901321ff1f9e43ae","type":"GO_TERM","name":"L-glutamate transmembrane transport","canonical_id":"go:GO:0015813","description":"\"The directed movement of L-glutamate across a membrane by means of some agent such as a transporter or a pore.\" [PMID:21307582]","metadata":null},{"id":"68df837ea23d4323914e0d4e66a7cb51","type":"GO_TERM","name":"L-glutamate transmembrane transporter activity","canonical_id":"go:GO:0005313","description":"\"Enables the transfer of L-glutamate from one side of a membrane to the other. L-glutamate is the anion of 2-aminopentanedioic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"371eb2d3c21740109da23f2eae0d081e","type":"GO_TERM","name":"L-glutamate uniporter activity","canonical_id":"go:GO:0140788","description":"\"Catalysis of the active transport of a L-glutamate across a membrane by a mechanism involving conformational change, where energy for active transport is derived from membrane potential if the solute is charged.\" [PMID:27133463, PMID:29642010]","metadata":null},{"id":"35cee2ccb39f470e8ee3bd2715d9ca1e","type":"GO_TERM","name":"L-glutamate:prephenate transaminase activity","canonical_id":"go:GO:0033854","description":"\"Catalysis of the reaction: 2-oxoglutarate + L-arogenate = L-glutamate + prephenate.\" [RHEA:22880]","metadata":null},{"id":"56b285c279df4e798f45cc83132d75b3","type":"GO_TERM","name":"L-glutamate:proton antiporter activity","canonical_id":"go:GO:0106421","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-glutamate(out) + H+(in) = L-glutamate(in) + H+(out).\" [PMID:29273736]","metadata":null},{"id":"e79ac05da54f4cbea2792bb2bd0b8d34","type":"GO_TERM","name":"L-glutamine N-acyltransferase activity","canonical_id":"go:GO:0047946","description":"\"Catalysis of the reaction: acyl-CoA + L-glutamine = CoA + N-acyl-L-glutamine.\" [RHEA:18469]","metadata":null},{"id":"825470e35472404297b0f85aa69bf5b8","type":"GO_TERM","name":"L-glutamine binding","canonical_id":"go:GO:0070406","description":"\"Binding to L-glutamine, 2,5-diamino-5-oxopentanoic acid.\" [GOC:ecd]","metadata":null},{"id":"7af0949d08364b6799415800cdb5bc73","type":"GO_TERM","name":"L-glutamine biosynthetic process","canonical_id":"go:GO:1901704","description":"\"The chemical reactions and pathways resulting in the formation of L-glutamine.\" [GOC:TermGenie]","metadata":null},{"id":"2b238fc7c7aa45efb810afbae213f3da","type":"GO_TERM","name":"L-glutamine catabolic process","canonical_id":"go:GO:0006543","description":"\"The chemical reactions and pathways resulting in the breakdown of L-glutamine.\" [GOC:curators]","metadata":null},{"id":"ef56ece36be14510b021549be77f3140","type":"GO_TERM","name":"L-glutamine import across plasma membrane","canonical_id":"go:GO:1903803","description":"\"The directed movement of L-glutamine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"8357541bbf6a4c2f9f2a564b947a95e0","type":"GO_TERM","name":"L-glutamine metabolic process","canonical_id":"go:GO:0006541","description":"\"The chemical reactions and pathways involving glutamine, 2-amino-4-carbamoylbutanoic acid.\" [GOC:ai]","metadata":null},{"id":"2f06b64e76214768b9cc279ff8767cd4","type":"GO_TERM","name":"L-glutamine secretion","canonical_id":"go:GO:0010585","description":"\"The controlled release of glutamine by a cell.\" [PMID:15208395]","metadata":null},{"id":"bfb8afa7254a473081f79092fb41efe1","type":"GO_TERM","name":"L-glutamine transmembrane transporter activity","canonical_id":"go:GO:0015186","description":"\"Enables the transfer of L-glutamine from one side of a membrane to the other. L-glutamine is 2-amino-4-carbamoylbutanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"6eb2ebe7977e4c95944aea56c29f3553","type":"GO_TERM","name":"L-glutamine transport","canonical_id":"go:GO:0006868","description":"\"The directed movement of glutamine, 2-amino-4-carbamoylbutanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"c43de54e892f40c5b9f1d65b82defda8","type":"GO_TERM","name":"L-glutamine, sodium:proton antiporter activity","canonical_id":"go:GO:0140830","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(in) + L-glutamine(out) + Na+(out) = H+(out) + L-glutamine(in) + Na+(in).\" [PMID:10619430, PMID:11742981, PMID:11850497]","metadata":null},{"id":"38a22d189d234597961a052827d86727","type":"GO_TERM","name":"L-glutamine:D-fructose-6-phosphate transaminase (isomerizing) activity","canonical_id":"go:GO:0004360","description":"\"Catalysis of the reaction: D-fructose 6-phosphate + L-glutamine = D-glucosamine 6-phosphate + L-glutamate.\" [RHEA:13237]","metadata":null},{"id":"32ad16bac96a4c1ab5ef9c94725ab9ff","type":"GO_TERM","name":"L-glutamine:phenylpyruvate transaminase activity","canonical_id":"go:GO:0047316","description":"\"Catalysis of the reaction: 3-phenylpyruvate + L-glutamine = 2-oxoglutaramate + L-phenylalanine.\" [RHEA:17593]","metadata":null},{"id":"a1124e3c339c4b1683321c66cdaba0fa","type":"GO_TERM","name":"L-glutamine:pyruvate transaminase activity","canonical_id":"go:GO:0047945","description":"\"Catalysis of the reaction: L-glutamine + pyruvate = 2-oxoglutaramate + L-alanine.\" [RHEA:10400]","metadata":null},{"id":"3a396fe9215449769da2c13eef6626cc","type":"GO_TERM","name":"L-glutamine:scyllo-inositol transaminase activity","canonical_id":"go:GO:0047310","description":"\"Catalysis of the reaction: scyllo-inosose + L-glutamine = 1-amino-1-deoxy-scyllo-inositol + 2-oxoglutaramate.\" [RHEA:22920]","metadata":null},{"id":"079e623e904f4ec5875a71c465fca4da","type":"GO_TERM","name":"L-glutamine:sodium symporter activity","canonical_id":"go:GO:0140902","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-glutamine(out) + Na+(out) = L-glutamine(in) + Na+(in).\" [PMID:28416685]","metadata":null},{"id":"44a66cee36c54e7792a1f98fe87a36c0","type":"GO_TERM","name":"L-glyceraldehyde 3-phosphate reductase activity","canonical_id":"go:GO:0103037","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + NADP = H+ + L-glyceraldehyde 3-phosphate + NADPH.\" [GOC:pz, PMID:18620424]","metadata":null},{"id":"8ae62703dfb7459c882c7a6b49dd28dd","type":"GO_TERM","name":"L-glycol dehydrogenase activity","canonical_id":"go:GO:0050026","description":"\"Catalysis of the reaction: an L-glycol + NAD(P)+ = a 2-hydroxycarbonyl compound + NAD(P)H + H+.\" [EC:1.1.1.185, MetaCyc:L-GLYCOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"5493dc6558a44514815ca511a3401b10","type":"GO_TERM","name":"L-gulonate 3-dehydrogenase activity","canonical_id":"go:GO:0050104","description":"\"Catalysis of the reaction: L-gulonate + NAD+ = 3-dehydro-L-gulonate + H+ + NADH.\" [EC:1.1.1.45, RHEA:12889]","metadata":null},{"id":"469b990347c04e7db717908a8757cf61","type":"GO_TERM","name":"L-gulono-1,4-lactone dehydrogenase activity","canonical_id":"go:GO:0080049","description":"\"Catalysis of the reaction: L-gulono-1,4-lactone + 2 ferricytochrome c = L-ascorbate + 2 ferrocytochrome c.\" [PMID:18190525, PMID:30112455, RHEA:47248]","metadata":null},{"id":"75f36f4ad473482d852dda2c6e5e95cb","type":"GO_TERM","name":"L-gulonolactone oxidase activity","canonical_id":"go:GO:0050105","description":"\"Catalysis of the reaction: L-gulono-1,4-lactone + O2 = L-xylo-hex-3-ulonolactone + H2O2.\" [EC:1.1.3.8, MetaCyc:L-GULONOLACTONE-OXIDASE-RXN, RHEA:32363]","metadata":null},{"id":"0a7fabb660fc4bf6b5588258d2be28bd","type":"GO_TERM","name":"L-histidine N(alpha)-methyltransferase activity","canonical_id":"go:GO:0052706","description":"\"Catalysis of the reaction: L-histidine + 3 S-adenosyl-L-methionine <=> 3 H(+) + hercynine + 3 S-adenosyl-L-homocysteine. This reaction is the addition of three methyl groups to L-histidine to form N-alpha,N-alpha,N-alpha-trimethyl-L-histidine (also known as hercynine).\" [RHEA:38471]","metadata":null},{"id":"f1d74407ade641dfa962f59679805c95","type":"GO_TERM","name":"L-histidine N-acetyltransferase activity","canonical_id":"go:GO:0047981","description":"\"Catalysis of the reaction: L-histidine + acetyl-CoA = N(alpha)-acetyl-L-histidine + CoA + H+.\" [RHEA:24596]","metadata":null},{"id":"ef8c8d03d8634894a52521453c83a929","type":"GO_TERM","name":"L-histidine biosynthetic process","canonical_id":"go:GO:0000105","description":"\"The chemical reactions and pathways resulting in the formation of L-histidine, 2-amino-3-(1H-imidazol-4-yl)propanoic acid.\" [GOC:curators]","metadata":null},{"id":"4b99867cb2f145d18e17ace6278520dd","type":"GO_TERM","name":"L-histidine catabolic process","canonical_id":"go:GO:0006548","description":"\"The chemical reactions and pathways resulting in the breakdown of L-histidine.\" [GOC:curators]","metadata":null},{"id":"78c7132f31014f3ba0e93670be8597ed","type":"GO_TERM","name":"L-histidine conjugated cholate hydrolase activity","canonical_id":"go:GO:7770008","description":"\"Catalysis of the reaction: cholate + L-histidine = L-histidocholate + H2O.\" [PMID:38326608, RHEA:79099]","metadata":null},{"id":"9b96f26d49b742eebb1a922b94103d9f","type":"GO_TERM","name":"L-histidine import across plasma membrane","canonical_id":"go:GO:1903810","description":"\"The directed movement of L-histidine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"c19e6631d48246a18a84b5000b2e9833","type":"GO_TERM","name":"L-histidine transmembrane export from vacuole","canonical_id":"go:GO:0089708","description":"\"The directed movement of L-histidine out of the vacuole, across the vacuolar membrane.\" [PMID:21307582]","metadata":null},{"id":"db2af42556404859b005a5b743ded812","type":"GO_TERM","name":"L-histidine transmembrane import into vacuole","canonical_id":"go:GO:0090513","description":"\"The directed movement of L-histidine into the vacuole across the vacuolar membrane.\" [GOC:al]","metadata":null},{"id":"f6cbb5d708804a8ab521f770bb9ff1f5","type":"GO_TERM","name":"L-histidine transmembrane transport","canonical_id":"go:GO:0089709","description":"\"The directed movement of L-histidine across a membrane.\" [PMID:21307582]","metadata":null},{"id":"e2efc8eadd9a4fa0acbdb77f8716f1bd","type":"GO_TERM","name":"L-histidine transmembrane transport from lysosomal lumen to cytosol","canonical_id":"go:GO:1904918","description":"\"The directed movement of L-histidine from the lysosomal lumen across the lysosomal membrane and into the cytosol.\" [GO_REF:0000078, GOC:kmv, GOC:TermGenie, PMID:22822152]","metadata":null},{"id":"95e3063b297c43dab03530d7cedd7526","type":"GO_TERM","name":"L-histidine transmembrane transporter activity","canonical_id":"go:GO:0005290","description":"\"Enables the transfer of L-histidine from one side of a membrane to the other. L-histidine is 2-amino-3-(1H-imidazol-4-yl)propanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"76ca373848424ebcae41027f2af4dd08","type":"GO_TERM","name":"L-histidine transport","canonical_id":"go:GO:1902024","description":"\"The directed movement of a L-histidine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:kmv, GOC:TermGenie, PMID:22822152]","metadata":null},{"id":"b87a853e70014051a32bc96e44cbe54d","type":"GO_TERM","name":"L-histidine, sodium:proton antiporter activity","canonical_id":"go:GO:0140832","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(in) + L-histidine(out) + Na+(out) = H+(out) + L-histidine(in) + Na+(in).\" [PMID:10619430, PMID:11742981]","metadata":null},{"id":"0d2d1a083a1a499693b66d8af8589bfd","type":"GO_TERM","name":"L-histidine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0008110","description":"\"Catalysis of the reaction: L-histidine + 2-oxoglutarate = 3-(imidazol-5-yl)pyruvate + L-glutamate.\" [RHEA:16565]","metadata":null},{"id":"131bc6949edc4cdbba104bf4339baa60","type":"GO_TERM","name":"L-histidine:histamine antiporter activity","canonical_id":"go:GO:0070907","description":"\"Catalysis of the reaction: L-histidine(out) + histamine(in) = L-histidine(in) + histamine(out).\" [GOC:dh]","metadata":null},{"id":"d3b6caaf66a94f0c9d9c6186d2f744f9","type":"GO_TERM","name":"L-histidinol-phosphate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0004400","description":"\"Catalysis of the reaction: L-histidinol-phosphate + 2-oxoglutarate = 3-(imidazol-4-yl)-2-oxopropyl phosphate + L-glutamate.\" [RHEA:23744]","metadata":null},{"id":"7fde1f058f8c441084a97b8659546a4c","type":"GO_TERM","name":"L-homocysteine biosynthetic process","canonical_id":"go:GO:0071269","description":"\"The chemical reactions and pathways resulting in the formation of L-homocysteine.\" [GOC:curators]","metadata":null},{"id":"40ccd76a33b0424485082e81ca11b82f","type":"GO_TERM","name":"L-homocysteine catabolic process","canonical_id":"go:GO:0043418","description":"\"The chemical reactions and pathways resulting in the breakdown of L-homocysteine, the amino acid alpha-amino-gamma-mercaptobutanoic acid.\" [GOC:jl]","metadata":null},{"id":"3a8e534ec78246ff92e08c52c05e703c","type":"GO_TERM","name":"L-homomethionine biosynthetic process","canonical_id":"go:GO:0033322","description":"\"The chemical reactions and pathways resulting in the formation of L-homomethionine, a non-protein amino acid synthesized from L-methionine via chain elongation.\" [GOC:mah, MetaCyc:PWY-1186]","metadata":null},{"id":"2d19bcc613f94b9ba87d04e8fdce72c6","type":"GO_TERM","name":"L-homoserine biosynthetic process","canonical_id":"go:GO:0009090","description":"\"The chemical reactions and pathways resulting in the formation of homoserine, alpha-amino-gamma-hydroxybutyric acid.\" [GOC:curators, ISBN:0198506732, MetaCyc:HOMOSERSYN-PWY]","metadata":null},{"id":"6b2536ce103745e19dd9b250cac6f5db","type":"GO_TERM","name":"L-homoserine metabolic process","canonical_id":"go:GO:0009092","description":"\"The chemical reactions and pathways involving homoserine, alpha-amino-gamma-hydroxybutyric acid, an intermediate in the biosynthesis of cystathionine, threonine and methionine.\" [ISBN:0198506732]","metadata":null},{"id":"e061cf3921cb4a6ea37a766c65ecf15d","type":"GO_TERM","name":"L-homoserine transmembrane transport","canonical_id":"go:GO:0042968","description":"\"The directed movement of homoserine, alpha-amino-gamma-hydroxybutyric acid, an intermediate in the biosynthesis of cystathionine, threonine and methionine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [PMID:10386596]","metadata":null},{"id":"707cb1606b084939aa17751b6826b924","type":"GO_TERM","name":"L-homoserine transmembrane transporter activity","canonical_id":"go:GO:0042970","description":"\"Enables the transfer of homoserine from one side of a membrane to the other. Homoserine is alpha-amino-gamma-hydroxybutyric acid, an intermediate in the biosynthesis of cystathionine, threonine and methionine.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"41d0cb96d6b345c6a577538e90c3456b","type":"GO_TERM","name":"L-hydroxyproline transmembrane transporter activity","canonical_id":"go:GO:0034590","description":"\"Enables the transfer of L-hydroxyproline from one side of a membrane to the other.\" [GOC:mah, PMID:14502423]","metadata":null},{"id":"84f5ea0cc0684b76a530adc1ca7d92e8","type":"GO_TERM","name":"L-iditol 2-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0003939","description":"\"Catalysis of the reaction: L-iditol + NAD+ = L-sorbose + NADH + H+. Acts on a number of sugar alcohols, including (but not limited to) L-iditol, D-glucitol, D-xylitol, and D-galactitol.\" [EC:1.1.1.14, PMID:13373783]","metadata":null},{"id":"dccf6a7f3ed94e11a199a502d56799fa","type":"GO_TERM","name":"L-idonate 5-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0102198","description":"\"Catalysis of the reaction: L-idonate + NAD+ = 5-dehydro-D-gluconate + NADH + H+.\" [RHEA:21172]","metadata":null},{"id":"e55edf816eb64739aa17f98c4575b81d","type":"GO_TERM","name":"L-idonate 5-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0050572","description":"\"Catalysis of the reaction: L-idonate + NAD(P)+ = 5-dehydrogluconate + NAD(P)H + H+.\" [EC:1.1.1.264]","metadata":null},{"id":"1ce19d4afbe64b8ca99395469b977815","type":"GO_TERM","name":"L-idonate biosynthetic process","canonical_id":"go:GO:0046182","description":"\"The chemical reactions and pathways resulting in the formation of L-idonate, the anion of idonic acid, an aldonic acid derived from L-idose, an aldohexose which is epimeric with D-glucose.\" [GOC:curators]","metadata":null},{"id":"36df2088b80d4c39b2f39bace3850667","type":"GO_TERM","name":"L-idonate catabolic process","canonical_id":"go:GO:0046183","description":"\"The chemical reactions and pathways resulting in the breakdown of L-idonate, the anion of idonic acid, an aldonic acid derived from L-idose, an aldohexose which is epimeric with D-glucose.\" [GOC:curators]","metadata":null},{"id":"28840a07ceab4bbd83146ccc2c4f673a","type":"GO_TERM","name":"L-idonate transmembrane transport","canonical_id":"go:GO:0015726","description":"\"The process in which L-idonate is transported across a lipid bilayer, from one side of a membrane to the other. L-idonate is an aldonic acid derived from L-idose, an aldohexose which is epimeric with D-glucose.\" [GOC:krc]","metadata":null},{"id":"daad93f90da84999a8ad11fd6146874a","type":"GO_TERM","name":"L-idonate transmembrane transporter activity","canonical_id":"go:GO:0015568","description":"\"Enables the transfer of L-idonate from one side of a membrane to the other. L-idonate is an aldonic acid derived from L-idose, an aldohexose which is epimeric with D-glucose.\" [GOC:ai]","metadata":null},{"id":"1d76acde21ba4266b0991cf67f5c4c9d","type":"GO_TERM","name":"L-iduronidase activity","canonical_id":"go:GO:0003940","description":"\"Catalysis of the hydrolysis of alpha-L-iduronosidic linkages in dermatan sulfate. Can also hydrolyze alpha-L-iduronosidic linkages in heparan sulfate.\" [EC:3.2.1.76, PMID:35011691]","metadata":null},{"id":"e6afc2071b144d3e99ce43d1802c4ed9","type":"GO_TERM","name":"L-isoleucine 4-hydroxylase activity","canonical_id":"go:GO:0102394","description":"\"Catalysis of the reaction: L-isoleucine + 2-oxoglutarate + O2 = (4S)-4-hydroxy-L-isoleucine + succinate + CO2.\" [PMID:21069315, RHEA:41448]","metadata":null},{"id":"f7f45806190445c4993ffdaecc106e8c","type":"GO_TERM","name":"L-isoleucine biosynthetic process","canonical_id":"go:GO:1901705","description":"\"The chemical reactions and pathways resulting in the formation of L-isoleucine.\" [GOC:TermGenie]","metadata":null},{"id":"b95a1bf9183a48608bad0ef99a3c6f50","type":"GO_TERM","name":"L-isoleucine catabolic process","canonical_id":"go:GO:0006550","description":"\"The chemical reactions and pathways resulting in the breakdown of L-isoleucine.\" [GOC:curators]","metadata":null},{"id":"6ec52e5fc35849f1a9213d2b877eeade","type":"GO_TERM","name":"L-isoleucine import across plasma membrane","canonical_id":"go:GO:1903806","description":"\"The directed movement of L-isoleucine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"36056e473221444c929eb9c8d3ec0a4a","type":"GO_TERM","name":"L-isoleucine transmembrane transporter activity","canonical_id":"go:GO:0015188","description":"\"Enables the transfer of L-isoleucine from one side of a membrane to the other. L-isoleucine is (2R*,3R*)-2-amino-3-methylpentanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"3f6fafbff4d2497aba84742422c8a797","type":"GO_TERM","name":"L-isoleucine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0052656","description":"\"Catalysis of the reaction: L-isoleucine + 2-oxoglutarate = (S)-3-methyl-2-oxopentanoate + L-glutamate.\" [RHEA:24801]","metadata":null},{"id":"1e8772d986484c32b721f3fe00ff5a16","type":"GO_TERM","name":"L-kynurenine transmembrane transport","canonical_id":"go:GO:0140924","description":"\"The directed movement of L-kynurenine across a membrane.\" [PMID:35245456]","metadata":null},{"id":"dcfe7054bc8d4cf49514d1160a444619","type":"GO_TERM","name":"L-kynurenine transmembrane transporter activity","canonical_id":"go:GO:0140926","description":"\"Enables the transfer of L-kynurenine from one side of a membrane to the other.\" [PMID:35245456]","metadata":null},{"id":"f0ce11c52ffc447dbb2db6a4a96f82a4","type":"GO_TERM","name":"L-kynurenine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0016212","description":"\"Catalysis of the reaction: 2-oxoglutarate + L-kynurenine = H2O + kynurenate + L-glutamate. The product 4-(2-aminophenyl)-2,4-dioxobutanoate is converted into kynurenate by a spontaneous reaction. Also acts on 3-hydroxykynurenine to form xanthurenate.\" [EC:2.6.1.7]","metadata":null},{"id":"d0661fcc4e2543b7bbc331c980faa111","type":"GO_TERM","name":"L-kynurenine:glyoxylate transaminase activity","canonical_id":"go:GO:0047315","description":"\"Catalysis of the reaction: L-kynurenine + glyoxylate = 4-(2-aminophenyl)-2,4-dioxobutanoate + glycine.\" [RHEA:19249]","metadata":null},{"id":"cb030e0bea444fa9bcbd33e2dcf5c72b","type":"GO_TERM","name":"L-lactate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004459","description":"\"Catalysis of the reaction: (S)-lactate + NAD+ = pyruvate + NADH + H+.\" [RHEA:23444]","metadata":null},{"id":"00c9100b3b9b41158eda2a13785d91d6","type":"GO_TERM","name":"L-lactate dehydrogenase (cytochrome) activity","canonical_id":"go:GO:0004460","description":"\"Catalysis of the reaction: (S)-lactate + 2 [Fe(III)cytochrome c] = 2 [Fe(II)cytochrome c] + 2 H+ + pyruvate.\" [RHEA:19909]","metadata":null},{"id":"f8b1f49e96c546a1a7f443782585fe75","type":"PROTEIN","name":"L-lactate dehydrogenase A chain","canonical_id":"uniprot:P00338","description":null,"metadata":null},{"id":"9d2c9ebff1434ff5a7b8f2f61b029a22","type":"GO_TERM","name":"L-lactate dehydrogenase activity","canonical_id":"go:GO:0140171","description":"\"Catalysis of the reaction: (S)-lactate + A = AH(2) + pyruvate.\" [GOC:pg]","metadata":null},{"id":"f7da42cb10a1466797b9dabfdbb1b6fe","type":"GO_TERM","name":"L-lactate dehydrogenase inhibitor activity","canonical_id":"go:GO:0160193","description":"\"Binds to and stops, prevents or reduces the activity of L-lactate dehydrogenase.\" [PMID:33406399]","metadata":null},{"id":"34815911caf94839a370f824b9c62241","type":"GO_TERM","name":"L-lactate oxidase activity","canonical_id":"go:GO:0120572","description":"\"Catalysis of the reaction: (S)-lactate + O2 = pyruvate + H2O2.\" [PMID:34555022, PMID:8589073, RHEA:55868]","metadata":null},{"id":"81a55656c6044576af63f90aadd07317","type":"GO_TERM","name":"L-leucine 2,3-aminomutase activity","canonical_id":"go:GO:0050047","description":"\"Catalysis of the reaction: L-leucine = (3R)-beta-leucine.\" [RHEA:10284]","metadata":null},{"id":"363e362259844485ac3d9e4f9b976619","type":"GO_TERM","name":"L-leucine N-acetyltransferase activity","canonical_id":"go:GO:0050050","description":"\"Catalysis of the reaction: L-leucine + acetyl-CoA = N-acetyl-L-leucine + CoA + H+.\" [RHEA:20089]","metadata":null},{"id":"59ba1db1955340f3b6c8b511e151b23a","type":"GO_TERM","name":"L-leucine binding","canonical_id":"go:GO:0070728","description":"\"Binding to L-leucine, 2-amino-4-methylpentanoic acid.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"500d659cbcd84db196c50f89889d95a8","type":"GO_TERM","name":"L-leucine biosynthetic process","canonical_id":"go:GO:0009098","description":"\"The chemical reactions and pathways resulting in the formation of L-leucine, 2-amino-4-methylpentanoic acid.\" [GOC:ai, MetaCyc:LEUSYN-PWY]","metadata":null},{"id":"0ae637021e4f47ff95f54c0cc5ef28ca","type":"GO_TERM","name":"L-leucine catabolic process","canonical_id":"go:GO:0006552","description":"\"The chemical reactions and pathways resulting in the breakdown of L-leucine.\" [GOC:curators]","metadata":null},{"id":"9e012981d4744805b61e65e0e38793e1","type":"GO_TERM","name":"L-leucine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050049","description":"\"Catalysis of the reaction: L-leucine + NAD+ + H2O = 4-methyl-2-oxopentanoate + NH4+ + NADH + H+.\" [RHEA:12220]","metadata":null},{"id":"c75017e39a5446039f4ca904755d18da","type":"GO_TERM","name":"L-leucine import across plasma membrane","canonical_id":"go:GO:1903801","description":"\"The directed movement of L-leucine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"c2ef4a08659340b5862c82151af77ab7","type":"GO_TERM","name":"L-leucine metabolic process","canonical_id":"go:GO:0006551","description":"\"The chemical reactions and pathways involving L-leucine, 2-amino-4-methylpentanoic acid.\" [GOC:ai]","metadata":null},{"id":"fd79fd0e1393477eaee0d8e68953c629","type":"GO_TERM","name":"L-leucine transmembrane transporter activity","canonical_id":"go:GO:0015190","description":"\"Enables the transfer of L-leucine from one side of a membrane to the other. L-leucine is 2-amino-4-methylpentanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"6fadd8a1775a4357b93d13743968e9cc","type":"GO_TERM","name":"L-leucine transport","canonical_id":"go:GO:0015820","description":"\"The directed movement of L-leucine, 2-amino-4-methylpentanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"8100d025058f4f2c9c7ce76a6cd3fe87","type":"GO_TERM","name":"L-leucine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0052654","description":"\"Catalysis of the reaction:L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate.\" [RHEA:18321]","metadata":null},{"id":"aa057bef9ba64dcfad9d343e34d79296","type":"GO_TERM","name":"L-lysine 2,3-aminomutase activity","canonical_id":"go:GO:0050066","description":"\"Catalysis of the reaction: L-lysine = (3S)-3,6-diaminohexanoate.\" [RHEA:19177]","metadata":null},{"id":"835f9e24d8254f0a9c0ae46718112791","type":"GO_TERM","name":"L-lysine 2-monooxygenase activity","canonical_id":"go:GO:0050067","description":"\"Catalysis of the reaction: L-lysine + O2 = 5-aminopentanamide + CO2 + H2O.\" [EC:1.13.12.2, RHEA:14601]","metadata":null},{"id":"1e69b7e377d34b4dbb9486dc099cafc6","type":"GO_TERM","name":"L-lysine 4-chlorinase activity","canonical_id":"go:GO:0062147","description":"\"Catalysis of the reaction: 2-oxoglutarate + chloride + H+ + L-lysine + O2 = 4-chloro-L-lysine + CO2 + H2O + succinate.\" [PMID:30867596, RHEA:59884]","metadata":null},{"id":"4a8ba9cbf7da415db551ba3887c192f7","type":"GO_TERM","name":"L-lysine 6-dehydrogenase activity","canonical_id":"go:GO:0050303","description":"\"Catalysis of the reaction: L-lysine + NAD+ = L-1-piperideine-6-carboxylate + NH4+ + NADH + 2 H+. (S)-(2-aminoethyl)-L-cysteine can act as a substrate, and NADP+ can act as the acceptor.\" [EC:1.4.1.18]","metadata":null},{"id":"659652a52d0049c4bc43de5d9d5e319f","type":"GO_TERM","name":"L-lysine 6-monooxygenase (NADPH) activity","canonical_id":"go:GO:0047091","description":"\"Catalysis of the reaction: L-lysine + NADPH + O2 = N(6)-hydroxy-L-lysine + H2O + NADP+.\" [EC:1.14.13.59, RHEA:23228]","metadata":null},{"id":"0d1c704181a54df19ed4962ce702276a","type":"GO_TERM","name":"L-lysine 6-oxidase activity","canonical_id":"go:GO:0033736","description":"\"Catalysis of the reaction: H2O + L-lysine + O2 = (S)-2-amino-6-oxohexanoate + H2O2 + NH4+.\" [RHEA:22548]","metadata":null},{"id":"bf94e7d0264844c1af6401f14c77fa45","type":"GO_TERM","name":"L-lysine N6-acetyltransferase activity","canonical_id":"go:GO:0090595","description":"\"Catalysis of the reaction: acetyl-CoA + L-lysine = CoA + H+ + N6-acetyl-L-lysine.\" [RHEA:69476]","metadata":null},{"id":"d7fbbd329b9b4e218ef2b85204d111c3","type":"GO_TERM","name":"L-lysine N6-acetyltransferase activity, acting on acetyl phosphate as donor","canonical_id":"go:GO:0004468","description":"\"Catalysis of the reaction: acetyl phosphate + L-lysine = phosphate + N6-acetyl-L-lysine.\" [RHEA:14417]","metadata":null},{"id":"125c6cf24cdf4f978309334d59d34b2e","type":"GO_TERM","name":"L-lysine biosynthetic process","canonical_id":"go:GO:0009085","description":"\"The chemical reactions and pathways resulting in the formation of L-lysine, 2,6-diaminohexanoic acid.\" [GOC:curators]","metadata":null},{"id":"f83e891ac44947a1a1ab6a5a55c1fe97","type":"GO_TERM","name":"L-lysine catabolic process","canonical_id":"go:GO:0019477","description":"\"The chemical reactions and pathways resulting in the breakdown of L-lysine.\" [GOC:curators]","metadata":null},{"id":"4943ecb2c82d4000ac4aba350d2460de","type":"GO_TERM","name":"L-lysine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050069","description":"\"Catalysis of the reaction: L-lysine + NAD+ = delta1-piperideine-2-carboxylate + NH4+ + NADH + H+.\" [RHEA:18505]","metadata":null},{"id":"6824e326e11f46c193e9a97f9f889faa","type":"GO_TERM","name":"L-lysine efflux transmembrane transporter activity","canonical_id":"go:GO:0015661","description":"\"Enables the transfer of L-lysine from the inside of the cell to the outside of the cell across a membrane.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"29588cc57afd493e9924cdcc81d076c4","type":"GO_TERM","name":"L-lysine fermentation","canonical_id":"go:GO:0019475","description":"\"The chemical reactions and pathways resulting in the breakdown of L-lysine into acetyl-CoA and butanoate. Acetyl-CoA can be further converted into acetate, releasing one ATP molecule.\" [MetaCyc:P163-PWY, PMID:17166837]","metadata":null},{"id":"63dee527e9e040b1af1da4f25b24f034","type":"GO_TERM","name":"L-lysine import across plasma membrane","canonical_id":"go:GO:0097639","description":"\"The directed movement of L-lysine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:krc, PMID:8195186]","metadata":null},{"id":"31d2f79c210b4e23b6993aa61c233abb","type":"GO_TERM","name":"L-lysine oxidase activity","canonical_id":"go:GO:0050029","description":"\"Catalysis of the reaction: H2O + L-lysine + O2 = 6-amino-2-oxohexanoate + H2O2 + NH4+.\" [RHEA:14437]","metadata":null},{"id":"b681dad36bd6485eadad925e88e5872a","type":"GO_TERM","name":"L-lysine transmembrane export from vacuole","canonical_id":"go:GO:0089707","description":"\"The directed movement of L-lysine out of the vacuole, across the vacuolar membrane.\" [PMID:21307582]","metadata":null},{"id":"8ac6c78ab5574545864b7d127bb3f942","type":"GO_TERM","name":"L-lysine transmembrane import into the mitochondrion","canonical_id":"go:GO:0160256","description":"\"The process in which L-lysine is transported from the cytosol into the mitochondrial matrix.\" [PMID:24652292]","metadata":null},{"id":"c8ad7bd13b344222b6bebaee8ef31cd0","type":"GO_TERM","name":"L-lysine transmembrane import into vacuole","canonical_id":"go:GO:0090517","description":"\"The directed movement of L-lysine into the vacuole across the vacuolar membrane.\" [GOC:al]","metadata":null},{"id":"785ae9df0ffa459da85b40f185b32e34","type":"GO_TERM","name":"L-lysine transmembrane transport","canonical_id":"go:GO:1903401","description":"\"The directed movement of L-lysine across a membrane.\" [GO_REF:0000069, GOC:krc, GOC:TermGenie, PMID:8195186]","metadata":null},{"id":"2214796a19404a41930c550947e089a5","type":"GO_TERM","name":"L-lysine transmembrane transport from lysosomal lumen to cytosol","canonical_id":"go:GO:1904916","description":"\"The directed movement of L-lysine from the lysosomal lumen across the lysosomal membrane and into the cytosol.\" [GO_REF:0000078, GOC:kmv, GOC:TermGenie, PMID:22822152]","metadata":null},{"id":"f3b43071f575471b9a0ad13fe3ccedf7","type":"GO_TERM","name":"L-lysine transmembrane transporter activity","canonical_id":"go:GO:0015189","description":"\"Enables the transfer of L-lysine from one side of a membrane to the other. L-lysine is 2,6-diaminohexanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"20442054287e434482fe5bb193593d7b","type":"GO_TERM","name":"L-lysine transport","canonical_id":"go:GO:1902022","description":"\"The directed movement of a L-lysine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:kmv, GOC:TermGenie, PMID:22822152]","metadata":null},{"id":"b97e4777eca14168bc0354d93247f571","type":"GO_TERM","name":"L-lysine-lactamase activity","canonical_id":"go:GO:0050028","description":"\"Catalysis of the reaction: L-2-aminohexano-6-lactam + H2O = L-lysine.\" [EC:3.5.2.11, RHEA:21388]","metadata":null},{"id":"fbbebd9680b541cda0c2267b3162168c","type":"GO_TERM","name":"L-lysine:2-oxoglutarate 6-transaminase activity","canonical_id":"go:GO:0045484","description":"\"Catalysis of the reaction: 2-oxoglutarate + L-lysine = L-glutamate + allysine.\" [RHEA:21200]","metadata":null},{"id":"609842cf0db84dd7a13486848e51d6b4","type":"GO_TERM","name":"L-lysine:L-arginine antiporter activity","canonical_id":"go:GO:0106439","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: L-lysine(out) + L-arginine(in) = L-lysine(in) + L-arginine(out).\" [PMID:10903140, RHEA:70827]","metadata":null},{"id":"41426fa225b54905bb13500e1dfa6419","type":"GO_TERM","name":"L-lysine:pyruvate 6-transaminase activity","canonical_id":"go:GO:0050065","description":"\"Catalysis of the reaction: L-lysine + pyruvate = (S)-2-amino-6-oxohexanoate + L-alanine.\" [RHEA:19393]","metadata":null},{"id":"e27ea6b41bb84a36b812292dc3e65891","type":"GO_TERM","name":"L-lysine:pyruvate alpha-transaminase activity","canonical_id":"go:GO:0062045","description":"\"Catalysis of the reaction: L-lysine + pyruvate= epsilon-amino-alpha-ketocaproic acid (KAC) + alanine.\" [PMID:27758894, PMID:28330936]","metadata":null},{"id":"d6d8a22499fb41f885b0e7805c55645b","type":"GO_TERM","name":"L-lyxonate dehydratase activity","canonical_id":"go:GO:0140356","description":"\"Catalysis of the reaction: L-lyxonate =2-dehydro-3-deoxy-L-arabinonate + H2O.\" [RHEA:62436]","metadata":null},{"id":"30061f8e371845749f35e35fd173fb13","type":"GO_TERM","name":"L-lyxose metabolic process","canonical_id":"go:GO:0019324","description":"\"The chemical reactions and pathways involving L-lyxose, the L-enantiomer of aldopentose lyxo-pentose, the C-2 epimer of xylose.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"e6aa1a8c12d1438b80b22dcebd52869c","type":"GO_TERM","name":"L-malate catabolic process","canonical_id":"go:GO:0043464","description":"\"The chemical reactions and pathways resulting in the breakdown of L-malate.\" [PMID:10427020, PMID:8808948]","metadata":null},{"id":"61e560e0387149e8adfc4dfe7c5b6cfd","type":"GO_TERM","name":"L-malate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0030060","description":"\"Catalysis of the reaction: (S)-malate + NAD+ = oxaloacetate + NADH + H+.\" [RHEA:21432]","metadata":null},{"id":"d29b7601676d43e8b1472640ddaef1fa","type":"GO_TERM","name":"L-malate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0046554","description":"\"Catalysis of the reaction: (S)-malate + NADP+ = oxaloacetate + NADPH + H+.\" [RHEA:10824]","metadata":null},{"id":"251ad40059f6485aaa4fc8fd402699d8","type":"GO_TERM","name":"L-malate dehydrogenase (quinone) activity","canonical_id":"go:GO:0008924","description":"\"Catalysis of the reaction: (S)-malate + a quinone = oxaloacetate + a quinol. Vitamin K (menaquinone) and several other quinones can act as acceptors.\" [PMID:234747, RHEA:46012]","metadata":null},{"id":"3b804b6803eb448094944325e51cd21e","type":"GO_TERM","name":"L-methionine (R)-S-oxide reductase activity","canonical_id":"go:GO:0033745","description":"\"Catalysis of the reaction: [thioredoxin]-disulfide + L-methionine + H2O = L-methionine (R)-S-oxide + [thioredoxin]-dithiol.\" [RHEA:21260]","metadata":null},{"id":"110eb0b256484663b1fb7787592ae13f","type":"GO_TERM","name":"L-methionine (S)-S-oxide reductase activity","canonical_id":"go:GO:0033744","description":"\"Catalysis of the reaction: [thioredoxin]-disulfide + L-methionine + H2O = L-methionine (S)-S-oxide + [thioredoxin]-dithiol.\" [RHEA:19993]","metadata":null},{"id":"7c6ad65259454477a4070f94c7c27f9e","type":"GO_TERM","name":"L-methionine N-acyltransferase activity","canonical_id":"go:GO:0103045","description":"\"Catalysis of the reaction: L-methionine + acetyl-CoA = N-acetyl-L-methionine + coenzyme A + H+.\" [RHEA:44144]","metadata":null},{"id":"86430c9b54c6475b9361a5244ebbafdc","type":"GO_TERM","name":"L-methionine biosynthetic process","canonical_id":"go:GO:0071265","description":"\"The chemical reactions and pathways resulting in the formation of L-methionine, the L-enantiomer of (2S)-2-amino-4-(methylsulfanyl)butanoic acid.\" [GOC:ecd, MetaCyc:Methionine-De-novo-Biosynthesis]","metadata":null},{"id":"9da8ed4ffa2248f28a57b5eebfaf042b","type":"GO_TERM","name":"L-methionine catabolic process","canonical_id":"go:GO:0009087","description":"\"The chemical reactions and pathways resulting in the breakdown of L-methionine.\" [GOC:curators]","metadata":null},{"id":"2a0d833af42a4a90bd644059d9800afe","type":"GO_TERM","name":"L-methionine cycle","canonical_id":"go:GO:0033353","description":"\"A cyclic series of interconversions involving S-adenosyl-L-homocysteine, L-homocysteine, L-methionine and S-adenosyl-L-methionine (SAM). Couples utilization of the methyl group of SAM with recycling of the homocysteinyl group and regeneration of L-methionine.\" [PMID:31950558, PMID:39394448]","metadata":null},{"id":"547bddaed8434837befde9fea03d95e5","type":"GO_TERM","name":"L-methionine import across plasma membrane","canonical_id":"go:GO:1905544","description":"\"The directed movement of L-methionine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:17556368]","metadata":null},{"id":"2c6bad97ce244aad9fdd8aea9e0cf236","type":"GO_TERM","name":"L-methionine metabolic process","canonical_id":"go:GO:0006555","description":"\"The chemical reactions and pathways involving L-methionine (2-amino-4-(methylthio)butanoic acid), a sulfur-containing, essential amino acid found in peptide linkage in proteins.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"5ccf6cdf0613443c97c4ccc0b2df72ac","type":"GO_TERM","name":"L-methionine salvage","canonical_id":"go:GO:0071267","description":"\"Any process that generates L-methionine from derivatives of it, without de novo synthesis.\" [GOC:ecd]","metadata":null},{"id":"733f35b9bc0c47dd885188ab2c2191b9","type":"GO_TERM","name":"L-methionine secondary active transmembrane transporter activity","canonical_id":"go:GO:0000102","description":"\"Enables the transfer of L-methionine from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport]","metadata":null},{"id":"f2c705d0120f4e45baf742f6877949bd","type":"GO_TERM","name":"L-methionine transmembrane transporter activity","canonical_id":"go:GO:0015191","description":"\"Enables the transfer of L-methionine from one side of a membrane to the other. L-methionine is 2-amino-4-(methylthio)butanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"653003be8f144ce9af86bb4e35ff33ef","type":"GO_TERM","name":"L-methionine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0080099","description":"\"Catalysis of the reaction: L-methionine + 2-oxoglutarate = 4-methylsulfanyl-2-oxobutanoate + L-glutamate.\" [PMID:18394996, RHEA:25796]","metadata":null},{"id":"ea8f0ac9fd62463f8742404c1052faf8","type":"GO_TERM","name":"L-methionine:glyoxylate transaminase activity","canonical_id":"go:GO:0050094","description":"\"Catalysis of the reaction: glyoxylate + L-methionine = 4-methylsulfanyl-2-oxobutanoate + glycine.\" [RHEA:22884]","metadata":null},{"id":"25fb095ae5c14d82a534a8b16f3eccc4","type":"GO_TERM","name":"L-methionine:oxo-acid transaminase activity","canonical_id":"go:GO:0010326","description":"\"Catalysis of the reaction: a 2-oxocarboxylate + L-methionine = 4-methylsulfanyl-2-oxobutanoate + an L-alpha-amino acid.\" [PMID:17056707, RHEA:31763]","metadata":null},{"id":"a13c89f8c8af405dad20c824c19b6c20","type":"GO_TERM","name":"L-methylmalonyl-CoA biosynthetic process","canonical_id":"go:GO:0019680","description":"\"The chemical reactions and pathways resulting in the formation of L-methylmalonyl-CoA, the L-enantiomer of 2-carboxypropanoyl-CoA.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"9672ee8283694ac8b58fcae0cb9a0fa4","type":"GO_TERM","name":"L-methylmalonyl-CoA metabolic process","canonical_id":"go:GO:0046491","description":"\"The chemical reactions and pathways involving L-methylmalonyl-CoA, the L-enantiomer of 2-carboxypropanoyl-CoA. S-methylmalonyl-CoA is an intermediate in the beta oxidation of odd-numbered fatty acids in animals.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"58056c370f6b4eaaa28f9d3fd703d678","type":"GO_TERM","name":"L-mimosine synthase activity","canonical_id":"go:GO:0050461","description":"\"Catalysis of the reaction: 3,4-dihydroxypyridine + O-acetyl-L-serine = 3-(3,4-dihydroxypyridinium-1-yl)-L-alanine + acetate.\" [RHEA:12693]","metadata":null},{"id":"c6b86b85bc2f4d5db330072c16b74806","type":"GO_TERM","name":"L-ornithine biosynthetic process","canonical_id":"go:GO:0006592","description":"\"The chemical reactions and pathways resulting in the formation of ornithine, an amino acid only rarely found in proteins, but which is important in living organisms as an intermediate in the reactions of the urea cycle and in arginine biosynthesis.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"951af19623ce4eb8a6f6dedf68cb6237","type":"GO_TERM","name":"L-ornithine catabolic process","canonical_id":"go:GO:0006593","description":"\"The chemical reactions and pathways resulting in the breakdown of L-ornithine.\" [GOC:curators]","metadata":null},{"id":"f53ae2867b0f44a08c045a7ae68fbdc7","type":"GO_TERM","name":"L-ornithine import across plasma membrane","canonical_id":"go:GO:0097640","description":"\"The directed movement of L-ornithine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:krc, PMID:8195186]","metadata":null},{"id":"467028b45c26446b8b37b8482e1c0054","type":"GO_TERM","name":"L-ornithine transaminase activity","canonical_id":"go:GO:0004587","description":"\"Catalysis of the reaction: a 2-oxocarboxylate + L-ornithine = L-glutamate 5-semialdehyde + an L-alpha-amino acid.\" [RHEA:13877]","metadata":null},{"id":"79cef772f41c4ba8a2051da5ebe7d61a","type":"GO_TERM","name":"L-ornithine transmembrane export from vacuole","canonical_id":"go:GO:0089706","description":"\"The directed movement of L-ornithine out of the vacuole, across the vacuolar membrane.\" [PMID:21307582]","metadata":null},{"id":"9f60376ab9684fed9e9b4d19edd46d59","type":"GO_TERM","name":"L-ornithine transmembrane transport","canonical_id":"go:GO:1903352","description":"\"The directed movement of L-ornithine across a membrane.\" [GO_REF:0000069, GOC:krc, GOC:TermGenie, PMID:8195186]","metadata":null},{"id":"3668184e6bfe486d919849d97d4e2053","type":"GO_TERM","name":"L-ornithine transmembrane transporter activity","canonical_id":"go:GO:0000064","description":"\"Enables the transfer of L-ornithine from one side of a membrane to the other. L-ornithine is 2,5-diaminopentanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e6f3e1c2a3a64e7cbbf95bdd0a0ec215","type":"GO_TERM","name":"L-phenylalaine oxidase activity","canonical_id":"go:GO:0106329","description":"\"Catalysis of the reaction: H2O + L-phenylalanine + O2 = 3-phenylpyruvate + H2O2 + NH4+.\" [RHEA:61240]","metadata":null},{"id":"e28980c53ec84e88926d801e0915f142","type":"GO_TERM","name":"L-phenylalanine N-acetyltransferase activity","canonical_id":"go:GO:0050176","description":"\"Catalysis of the reaction: L-phenylalanine + acetyl-CoA = N-acetyl-L-phenylalanine + CoA + H+.\" [RHEA:17801]","metadata":null},{"id":"88ae8e37edd647229e59130f7b63b5d1","type":"GO_TERM","name":"L-phenylalanine N-monooxygenase activity","canonical_id":"go:GO:0102684","description":"\"Catalysis of the reaction: L-phenylalanine + 2 NADPH + 2 O2 + 2 H+ = (E)-phenylacetaldehyde oxime + 2 NADP + 3 H2O + carbon dioxide.\" [EC:1.14.14.40, GOC:pz]","metadata":null},{"id":"ce77b11d14944fb780a4c02da609f51c","type":"GO_TERM","name":"L-phenylalanine biosynthetic process","canonical_id":"go:GO:0009094","description":"\"The chemical reactions and pathways resulting in the formation of L-phenylalanine, the L-enantiomer of 2-amino-3-phenylpropanoic acid, i.e. (2S)-2-amino-3-phenylpropanoic acid.\" [GOC:jsg, GOC:mah]","metadata":null},{"id":"6284fcc3608f4f08af3f6526fd0bed18","type":"GO_TERM","name":"L-phenylalanine catabolic process","canonical_id":"go:GO:0006559","description":"\"The chemical reactions and pathways resulting in the breakdown of L-phenylalanine.\" [GOC:curators]","metadata":null},{"id":"69b0aee2491d447e95f26f3d561be771","type":"GO_TERM","name":"L-phenylalanine conjugated cholate hydrolase activity","canonical_id":"go:GO:7770006","description":"\"Catalysis of the reaction: cholate + L-phenylalanine = L-phenylalanocholate + H2O.\" [PMID:38326608, RHEA:79123]","metadata":null},{"id":"632452a325d54cb5b9e0f7e937001e5a","type":"GO_TERM","name":"L-phenylalanine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050175","description":"\"Catalysis of the reaction: L-phenylalanine + NAD+ + H2O = 3-phenylpyruvate + NH4+ + NADH + H+.\" [RHEA:21408]","metadata":null},{"id":"0c201e8429d24eadb03a7d863cc61099","type":"GO_TERM","name":"L-phenylalanine import across plasma membrane","canonical_id":"go:GO:0140925","description":"\"The directed movement of L-phenylalanine from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:11069779]","metadata":null},{"id":"145c8af52a954248a2a8828d5eaa0144","type":"GO_TERM","name":"L-phenylalanine transmembrane transporter activity","canonical_id":"go:GO:0015192","description":"\"Enables the transfer of L-phenylalanine from one side of a membrane to the other. L-phenylalanine is 2-amino-3-phenylpropanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"f18e75620df54fed8409d48cc3c0bfea","type":"GO_TERM","name":"L-phenylalanine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0080130","description":"\"Catalysis of the reaction: L-phenylalanine + 2-oxoglutarate = 3-phenylpyruvate + L-glutamate.\" [PMID:18394996, RHEA:25152]","metadata":null},{"id":"6f4ff7a1de9b4fdab893673ffba6c048","type":"GO_TERM","name":"L-phenylalanine:pyruvate transaminase activity","canonical_id":"go:GO:0047312","description":"\"Catalysis of the reaction: L-phenylalanine + pyruvate = 3-phenylpyruvate + L-alanine.\" [RHEA:13053]","metadata":null},{"id":"43c492c3e9854d518df018f34d4e78ee","type":"GO_TERM","name":"L-phosphinothricin biosynthetic process","canonical_id":"go:GO:1901766","description":"\"The chemical reactions and pathways resulting in the formation of phosphinothricin.\" [GOC:TermGenie, MetaCyc:PWY-6322, PMID:7938785]","metadata":null},{"id":"eff0c82cc3a643148e23790df4a9c811","type":"GO_TERM","name":"L-phosphoserine phosphatase activity","canonical_id":"go:GO:0036424","description":"\"Catalysis of the reaction: O-phospho-L-serine + H2O = L-serine + phosphate, on a free amino acid.\" [PMID:25037224, PMID:9188776, RHEA:21208]","metadata":null},{"id":"10600b4bfe814c1795775ad770c04095","type":"GO_TERM","name":"L-pipecolate dehydrogenase activity","canonical_id":"go:GO:0050030","description":"\"Catalysis of the reaction: L-pipecolate + acceptor = delta1-piperideine-6-carboxylate + reduced acceptor. Delta1-piperideine-6-carboxylate is also known as 2,3,4,5-tetrahydropyridine-2-carboxylate.\" [EC:1.5.99.3, MetaCyc:L-PIPECOLATE-DEHYDROGENASE-RXN]","metadata":null},{"id":"5ed8bb8222c746fa83ff0509356600eb","type":"GO_TERM","name":"L-pipecolate oxidase activity","canonical_id":"go:GO:0050031","description":"\"Catalysis of the reaction: L-pipecolate + O2 = 2,3,4,5-tetrahydropyridine-2-carboxylate + H2O2 + H+. Delta1-piperideine-6-carboxylate is also known as 2,3,4,5-tetrahydropyridine-2-carboxylate.\" [EC:1.5.3.7, RHEA:11992]","metadata":null},{"id":"6a2e9b594b5e47bfadf990b0c7a82dad","type":"GO_TERM","name":"L-pipecolic acid biosynthetic process","canonical_id":"go:GO:0062034","description":"\"The chemical reactions and pathways resulting in the formation of L-pipecolic acid, a metabolite of lysine.\" [PMID:27758894, PMID:28330936]","metadata":null},{"id":"e8b544fce2e84307ac49ed1b05a01f38","type":"GO_TERM","name":"L-proline betaine catabolic process","canonical_id":"go:GO:0019504","description":"\"The chemical reactions and pathways resulting in the breakdown of L-proline betaine (stachydrine).\" [PMID:10689197, PMID:1804402, PMID:24520058]","metadata":null},{"id":"6675083f6cc843b6b7f05b86d77d4ac3","type":"GO_TERM","name":"L-proline biosynthetic process","canonical_id":"go:GO:0055129","description":"\"The chemical reactions and pathways resulting in the formation of L-proline, an L-enantiomer of a chiral, cyclic, nonessential alpha-amino acid found in peptide linkage in proteins.\" [GOC:ecd]","metadata":null},{"id":"10878b5ee4bb47e6b89b9b54953dd55b","type":"GO_TERM","name":"L-proline catabolic process","canonical_id":"go:GO:0006562","description":"\"The chemical reactions and pathways resulting in the breakdown of L-proline.\" [GOC:curators]","metadata":null},{"id":"32adb7adaae2413cb79d41d9f2a20011","type":"GO_TERM","name":"L-proline import across plasma membrane","canonical_id":"go:GO:1904271","description":"\"The directed movement of L-proline from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:kmv, GOC:TermGenie, PMID:21097500]","metadata":null},{"id":"621e1fcb824e41508cc315cc3e7b93c9","type":"GO_TERM","name":"L-proline metabolic process","canonical_id":"go:GO:0006560","description":"\"The chemical reactions and pathways involving proline (pyrrolidine-2-carboxylic acid), a chiral, cyclic, nonessential alpha-amino acid found in peptide linkage in proteins.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"9904c738fe6c4942b0b3ecc54a657034","type":"GO_TERM","name":"L-proline transmembrane transport","canonical_id":"go:GO:1904555","description":"\"The directed movement of L-proline across a membrane.\" [GO_REF:0000069, GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"4b5179d06f664998a9386c7f99b94679","type":"GO_TERM","name":"L-proline transmembrane transporter activity","canonical_id":"go:GO:0015193","description":"\"Enables the transfer of L-proline from one side of a membrane to the other. L-proline is pyrrolidine-2-carboxylic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"4d03ab9672c3472685d1aed9b5b472a5","type":"GO_TERM","name":"L-propargylglycine biosynthetic process","canonical_id":"go:GO:0062143","description":"\"The chemical reactions and pathways resulting in the formation of L-propargylglycine (Pra). L-propargylglycine is an antibiotic produced by Streptomyces bacteria.\" [PMID:30867596]","metadata":null},{"id":"dab70eace3a64ed39df5640e8f7c7e65","type":"GO_TERM","name":"L-propargylglycine synthase activity","canonical_id":"go:GO:0062144","description":"\"Catalysis of the reaction: L-2-amino-4-chloropent-4-enoate = chloride + H+ + L-propargylglycine.\" [PMID:30867596, RHEA:59892]","metadata":null},{"id":"e80b8fdf995e4dfb8119a78920eb3508","type":"GO_TERM","name":"L-propargylglycine--L-glutamate ligase activity","canonical_id":"go:GO:0062145","description":"\"Catalysis of the reaction: ATP + L-glutamate + L-propargylglycine = ADP + H+ + L-gamma-glutamyl-L-propargylglycine + phosphate.\" [PMID:30867596, RHEA:59896]","metadata":null},{"id":"70e0014613f742ecbb65066258e97224","type":"GO_TERM","name":"L-rhamnonate dehydratase activity","canonical_id":"go:GO:0050032","description":"\"Catalysis of the reaction: L-rhamnonate = 2-dehydro-3-deoxy-L-rhamnonate + H2O.\" [EC:4.2.1.90, RHEA:23080]","metadata":null},{"id":"94402ff33b2a4d04a6b8693140d3d117","type":"GO_TERM","name":"L-rhamnono-1,4-lactonase activity","canonical_id":"go:GO:0050033","description":"\"Catalysis of the reaction: L-rhamnono-1,4-lactone + H2O = L-rhamnonate + H+.\" [EC:3.1.1.65, RHEA:10288]","metadata":null},{"id":"7bb806b25daa417495bdb68964a1d500","type":"GO_TERM","name":"L-rhamnose 1-dehydrogenase activity","canonical_id":"go:GO:0050034","description":"\"Catalysis of the reaction: L-rhamnofuranose + NAD+ = L-rhamnono-1,4-lactone + H+ + NADH.\" [EC:1.1.1.173, RHEA:12649]","metadata":null},{"id":"5a7d665bd44b494c8041da0b939519f9","type":"GO_TERM","name":"L-rhamnose isomerase activity","canonical_id":"go:GO:0008740","description":"\"Catalysis of the reaction: L-rhamnose = L-rhamnulose.\" [RHEA:23160]","metadata":null},{"id":"2fbff21d7cb4401b84526f0aeb748d6a","type":"GO_TERM","name":"L-rhamnose mutarotase activity","canonical_id":"go:GO:0062192","description":"\"Catalysis of the reaction: alpha-L-rhamnose = beta-L-rhamnose.\" [RHEA:25584]","metadata":null},{"id":"8e0994bdc0e645cf8427eb9232c49715","type":"GO_TERM","name":"L-ribulose-5-phosphate 3-epimerase activity","canonical_id":"go:GO:0034015","description":"\"Catalysis of the reaction: L-ribulose 5-phosphate = L-xylulose 5-phosphate.\" [EC:5.1.3.22, RHEA:18497]","metadata":null},{"id":"e962616d17664d1386e5bebf232362a1","type":"GO_TERM","name":"L-ribulose-phosphate 4-epimerase activity","canonical_id":"go:GO:0008742","description":"\"Catalysis of the reaction: L-ribulose 5-phosphate = D-xylulose 5-phosphate.\" [EC:5.1.3.4, RHEA:22368]","metadata":null},{"id":"3cce50811f864525ac6e88e2a5c290ca","type":"GO_TERM","name":"L-selenocysteine biosynthetic process","canonical_id":"go:GO:0016260","description":"\"The chemical reactions and pathways resulting in the formation of L-selenocysteine, an essential component of glutathione peroxidase and some other proteins.\" [PMID:17880704]","metadata":null},{"id":"e38793f653f842468a311030e09bb246","type":"GO_TERM","name":"L-selenocysteine catabolic process","canonical_id":"go:GO:0016261","description":"\"The chemical reactions and pathways resulting in the breakdown of selenocysteine, an essential component of glutathione peroxidase and some other proteins.\" [PMID:12382038]","metadata":null},{"id":"747d94d4e8f9460ca1b6e609134a2cac","type":"GO_TERM","name":"L-serine 2-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050282","description":"\"Catalysis of the reaction: L-serine + NAD+ + H2O = 3-hydroxypyruvate + NH4+ + NADH + H+.\" [RHEA:20884]","metadata":null},{"id":"119768cd78944d62b2dc7b38e7c191e0","type":"GO_TERM","name":"L-serine O-acetyltransferase activity","canonical_id":"go:GO:0009001","description":"\"Catalysis of the reaction: L-serine + acetyl-CoA = O-acetyl-L-serine + CoA.\" [RHEA:24560]","metadata":null},{"id":"3880625c427d465ba3c3760f50e81074","type":"GO_TERM","name":"L-serine O-succinyltransferase activity","canonical_id":"go:GO:0160210","description":"\"Catalysis of the reaction: L-serine + succinyl-CoA = CoA + O-succinyl-L-serine.\" [PMID:28581482, RHEA:52820]","metadata":null},{"id":"a283e5f0bfc747339f153ca1ebdf9e7a","type":"GO_TERM","name":"L-serine ammonia-lyase activity","canonical_id":"go:GO:0003941","description":"\"Catalysis of the reaction: L-serine = pyruvate + NH4+.\" [RHEA:19169]","metadata":null},{"id":"ba0776ef85374f5db6a7a816d7816f08","type":"GO_TERM","name":"L-serine biosynthetic process","canonical_id":"go:GO:0006564","description":"\"The chemical reactions and pathways resulting in the formation of L-serine.\" [MetaCyc:SERSYN-PWY]","metadata":null},{"id":"e0af60375a9f46a9b581df08e9b6e817","type":"GO_TERM","name":"L-serine catabolic process","canonical_id":"go:GO:0006565","description":"\"The chemical reactions and pathways resulting in the breakdown of L-serine.\" [GOC:curators]","metadata":null},{"id":"5a54ed50b875446184de7adcb529cc2c","type":"GO_TERM","name":"L-serine conjugated cholate hydrolase activity","canonical_id":"go:GO:7770004","description":"\"Catalysis of the reaction: cholate + L-serine = L-serocholate + H2O.\" [PMID:38326609, RHEA:79139]","metadata":null},{"id":"cd37b360979f4a48bd9ade5c14553007","type":"GO_TERM","name":"L-serine hydro-lyase (adding indole, L-tryptophan-forming) activity","canonical_id":"go:GO:0052684","description":"\"Catalysis of the reaction: indole + L-serine = L-tryptophan + H2O.\" [MetaCyc:RXN0-2382]","metadata":null},{"id":"9c32308efa4d44168dc9ead3f2bdf579","type":"GO_TERM","name":"L-serine import across plasma membrane","canonical_id":"go:GO:1903812","description":"\"The directed movement of L-serine into a cell.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"39913f15195949e0913781b5dd26b2a2","type":"GO_TERM","name":"L-serine metabolic process","canonical_id":"go:GO:0006563","description":"\"The chemical reactions and pathways involving L-serine, the L-enantiomer of serine, i.e. (2S)-2-amino-3-hydroxypropanoic acid.\" [GOC:ai, GOC:jsg]","metadata":null},{"id":"1451ca413d8548b0b94c918c5117b348","type":"GO_TERM","name":"L-serine transmembrane import into vacuole","canonical_id":"go:GO:0090516","description":"\"The directed movement of L-serine into the vacuole across the vacuolar membrane.\" [GOC:al]","metadata":null},{"id":"dca452ad4902441ba6e393952526368a","type":"GO_TERM","name":"L-serine transmembrane transporter activity","canonical_id":"go:GO:0015194","description":"\"Enables the transfer of L-serine from one side of a membrane to the other. L-serine is the L-enantiomer of 2-amino-3-hydroxypropanoic acid.\" [GOC:ai, GOC:jsg, GOC:mah, GOC:mtg_transport]","metadata":null},{"id":"45bc13d622f740be8a41dc36b2964e0c","type":"GO_TERM","name":"L-serine transport","canonical_id":"go:GO:0015825","description":"\"The directed movement of L-serine, the L-enantiomer of 2-amino-3-hydroxypropanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai, GOC:jsg, GOC:mah]","metadata":null},{"id":"7b75848e2aa74a0aae13e204c4997403","type":"GO_TERM","name":"L-serine-phosphatidylcholine phosphatidyltransferase activity","canonical_id":"go:GO:0106258","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phosphocholine + L-serine = 1,2-diacyl-sn-glycero-3-phospho-L-serine + choline.\" [PMID:19014349, RHEA:45088]","metadata":null},{"id":"4ff76247bbe749df81268aa13de85887","type":"GO_TERM","name":"L-serine-phosphatidylethanolamine phosphatidyltransferase activity","canonical_id":"go:GO:0106245","description":"\"Catalysis of the reaction: L-1-phosphatidylethanolamine + L-serine = L-1-phosphatidylserine + ethanolamine.\" [PMID:19014349, PMID:31869331, RHEA:27606]","metadata":null},{"id":"83cb7b14a77c420a934ae533e5de0bce","type":"GO_TERM","name":"L-serine:glyoxylate transaminase activity","canonical_id":"go:GO:0050281","description":"\"Catalysis of the reaction: L-serine + glyoxylate = 3-hydroxypyruvate + glycine.\" [RHEA:19125]","metadata":null},{"id":"3b5d6ed91add4a0ab8c2a49670e865cf","type":"GO_TERM","name":"L-serine:pyruvate transaminase activity","canonical_id":"go:GO:0004760","description":"\"Catalysis of the reaction: L-serine + pyruvate = 3-hydroxypyruvate + L-alanine.\" [RHEA:22852]","metadata":null},{"id":"a1ec1a8bc88842b2b75626347a984154","type":"GO_TERM","name":"L-seryl-tRNA(Sec) kinase activity","canonical_id":"go:GO:0043915","description":"\"Catalysis of the reaction: ATP + L-seryl-tRNA(Sec) = ADP + O-phospho-L-seryl-tRNA(Sec).\" [GOC:jl, PMID:16201757, RHEA:25037]","metadata":null},{"id":"5b122617818c4209b27624052063b148","type":"GO_TERM","name":"L-seryl-tRNA(Sec) selenium transferase activity","canonical_id":"go:GO:0004125","description":"\"Catalysis of the reaction: L-seryl-tRNA(Sec) + selenophosphate = L-selenocysteinyl-tRNA(Sec) + H2O + phosphate.\" [RHEA:22728]","metadata":null},{"id":"5c14642d5eaa4d45970836d6604ca96a","type":"GO_TERM","name":"L-seryl-tRNA(Thr) hydrolase activity","canonical_id":"go:GO:0043905","description":"\"Catalysis of the hydrolysis of misacylated Ser-tRNA(Thr).\" [GOC:jl, PMID:15240874]","metadata":null},{"id":"07696bba8f7143a18a74eb2ad9020634","type":"GO_TERM","name":"L-sorbose biosynthetic process","canonical_id":"go:GO:0042849","description":"\"The chemical reactions and pathways resulting in the formation of L-sorbose, the L-enantiomer of the ketohexose xylo-2-hexulose. L-sorbose is formed by bacterial oxidation of sorbitol.\" [ISBN:0198506732]","metadata":null},{"id":"80d4a5a6d2964721be916b6717615adc","type":"GO_TERM","name":"L-sorbose catabolic process","canonical_id":"go:GO:0042850","description":"\"The chemical reactions and pathways resulting in the breakdown of L-sorbose, the L-enantiomer of the ketohexose xylo-2-hexulose.\" [GOC:jsg, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"922d0b558f844de68221299189d4bf50","type":"GO_TERM","name":"L-sorbose oxidase activity","canonical_id":"go:GO:0050035","description":"\"Catalysis of the reaction: L-sorbose + O2 = 5-dehydro-D-fructose + H2O2.\" [EC:1.1.3.11, RHEA:17853]","metadata":null},{"id":"784d5ea87d5440c2bea65cd8362055b5","type":"GO_TERM","name":"L-threonate 3-dehydrogenase activity","canonical_id":"go:GO:0050036","description":"\"Catalysis of the reaction: L-threonate + NAD+ = 3-dehydro-L-threonate + H+ + NADH.\" [EC:1.1.1.129, RHEA:23376]","metadata":null},{"id":"99e9dae9eb3347529d53088c5c91a345","type":"GO_TERM","name":"L-threonine 3-dehydrogenase activity","canonical_id":"go:GO:0008743","description":"\"Catalysis of the reaction: L-threonine + NAD+ = (2S)-2-amino-3-oxobutanoate + NADH + H+.\" [RHEA:13161]","metadata":null},{"id":"911d3882e9f84cfd9616565c76ea21ea","type":"GO_TERM","name":"L-threonine biosynthetic process","canonical_id":"go:GO:0009088","description":"\"The chemical reactions and pathways resulting in the formation of L-threonine (2-amino-3-hydroxybutyric acid), a polar, uncharged, essential amino acid found in peptide linkage in proteins.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"7a8fe8aa958440debe175306a8a807f6","type":"GO_TERM","name":"L-threonine catabolic process","canonical_id":"go:GO:0006567","description":"\"The chemical reactions and pathways resulting in the breakdown of L-threonine.\" [GOC:curators]","metadata":null},{"id":"6359b1432783449bbcfa27be23a1f096","type":"GO_TERM","name":"L-threonine import across plasma membrane","canonical_id":"go:GO:1903807","description":"\"The directed movement of L-threonine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"d556551a795045069839d131a1887d5e","type":"GO_TERM","name":"L-threonine metabolic process","canonical_id":"go:GO:0006566","description":"\"The chemical reactions and pathways involving threonine (2-amino-3-hydroxybutyric acid), a polar, uncharged, essential amino acid found in peptide linkage in proteins.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"05a831bc56ee4958b1be84d630dc3144","type":"GO_TERM","name":"L-threonine transmembrane transporter activity","canonical_id":"go:GO:0015195","description":"\"Enables the transfer of L-threonine from one side of a membrane to the other. L-threonine is (2R*,3S*)-2-amino-3-hydroxybutanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"59e9658cb0b846d1b41b6d6ddef328f9","type":"GO_TERM","name":"L-threonylcarbamoyladenylate synthase activity","canonical_id":"go:GO:0061710","description":"\"Catalysis of the reaction: L-threonine + hydrogencarbonate + ATP = L-threonylcarbamoyladenylate + diphosphate + H2O.\" [RHEA:36407]","metadata":null},{"id":"5d986c42024542519764f48b3d7a91b4","type":"GO_TERM","name":"L-tryptophan 2,3-dioxygenase activity","canonical_id":"go:GO:0004833","description":"\"Catalysis of the reaction: L-tryptophan + O2 = N-formyl-L-kynurenine.\" [EC:1.13.11.11]","metadata":null},{"id":"6763ee21d2fa4e27ba7634ddd8dcc133","type":"GO_TERM","name":"L-tryptophan biosynthetic process","canonical_id":"go:GO:0000162","description":"\"The chemical reactions and pathways resulting in the formation of L-tryptophan, the chiral amino acid 2-amino-3-(1H-indol-3-yl)propanoic acid; L-tryptophan is synthesized from chorismate via anthranilate.\" [GOC:mah, ISBN:0471331309, MetaCyc:TRPSYN-PWY]","metadata":null},{"id":"fcd43eed976a42a3a8f7c9b46abc7d7b","type":"GO_TERM","name":"L-tryptophan catabolic process","canonical_id":"go:GO:0006569","description":"\"The chemical reactions and pathways resulting in the breakdown of L-tryptophan.\" [GOC:curators]","metadata":null},{"id":"2227134b56314a6ba5ab07420dfd7b0f","type":"GO_TERM","name":"L-tryptophan conjugated cholate hydrolase activity","canonical_id":"go:GO:7770009","description":"\"Catalysis of the reaction: cholate + L-tryptophan = L-tryptophocholate + H2O.\" [PMID:40446798, RHEA:85423]","metadata":null},{"id":"9583fa07e82c48f2bac6100dad5f040f","type":"GO_TERM","name":"L-tryptophan decarboxylase activity","canonical_id":"go:GO:0036469","description":"\"Catalysis of the reaction: L-tryptophan + H+ = CO2 + tryptamine.\" [GOC:bf, GOC:PARL, RHEA:30339]","metadata":null},{"id":"3ea325cd19034b0daa4aaf075585c8a0","type":"GO_TERM","name":"L-tryptophan dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0050363","description":"\"Catalysis of the reaction: L-tryptophan + NAD(P)+ + H2O = indole-3-pyruvate + NH4+ + NAD(P)H + H+.\" [EC:1.4.1.19]","metadata":null},{"id":"9de8af7372174ff389c6197e80e3c43f","type":"GO_TERM","name":"L-tryptophan import across plasma membrane","canonical_id":"go:GO:1904272","description":"\"The directed movement of L-tryptophan from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:kmv, GOC:TermGenie, PMID:21097500]","metadata":null},{"id":"baff41da548b45ef903db8aed9d0ec73","type":"GO_TERM","name":"L-tryptophan transmembrane transport","canonical_id":"go:GO:1904556","description":"\"The directed movement of L-tryptophan across a membrane.\" [GO_REF:0000069, GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"5e5b4821dd814f6db894fd3b3c132109","type":"GO_TERM","name":"L-tryptophan transmembrane transporter activity","canonical_id":"go:GO:0015196","description":"\"Enables the transfer of L-tryptophan from one side of a membrane to the other. Tryptophan is 2-amino-3-(1H-indol-3-yl)propanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"721550616050448db38df79fc4ee5af8","type":"GO_TERM","name":"L-tryptophan:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0050362","description":"\"Catalysis of the reaction: L-tryptophan + 2-oxoglutarate = indole-3-pyruvate + L-glutamate.\" [RHEA:14093]","metadata":null},{"id":"4c4334e707014f5ba4bf12aca40ccb34","type":"GO_TERM","name":"L-tryptophan:phenylpyruvate transaminase activity","canonical_id":"go:GO:0047299","description":"\"Catalysis of the reaction: 3-phenylpyruvate + L-tryptophan = indole-3-pyruvate + L-phenylalanine.\" [RHEA:13741]","metadata":null},{"id":"e09535a4f0ab4181984a78a35912e6dc","type":"GO_TERM","name":"L-tryptophan:pyruvate transaminase activity","canonical_id":"go:GO:0080097","description":"\"Catalysis of the reaction: L-tryptophan + pyruvate = indole-3-pyruvate + L-alanine.\" [RHEA:27586]","metadata":null},{"id":"c78aa562f31d430887ebf62a6fec46f5","type":"GO_TERM","name":"L-type voltage-gated calcium channel complex","canonical_id":"go:GO:1990454","description":"\"A type of voltage-dependent calcium channel responsible for excitation-contraction coupling of skeletal, smooth, and cardiac muscle. 'L' stands for 'long-lasting' referring to the length of activation.\" [GOC:ame, PMID:12946355]","metadata":null},{"id":"183cd6fff7ab445f8cf82eb5abd7c99c","type":"GO_TERM","name":"L-tyrosine 2,3-aminomutase activity","canonical_id":"go:GO:0050368","description":"\"Catalysis of the reaction: L-tyrosine = 3-amino-3-(4-hydroxyphenyl)propanoate.\" [RHEA:15781]","metadata":null},{"id":"2afcf59bc52f47c7890ee9ad991b2f89","type":"GO_TERM","name":"L-tyrosine binding","canonical_id":"go:GO:0072545","description":"\"Binding to L-tyrosine, 2-amino-3-(4-hydroxyphenyl)propanoic acid.\" [GOC:mah]","metadata":null},{"id":"2bd9d17a64b146fd9ca9c34093bc52f3","type":"GO_TERM","name":"L-tyrosine biosynthetic process","canonical_id":"go:GO:0006571","description":"\"The chemical reactions and pathways resulting in the formation of tyrosine, an aromatic amino acid, 2-amino-3-(4-hydroxyphenyl)propanoic acid.\" [GOC:sm]","metadata":null},{"id":"6ce6ddd4f55c4e0daf78150e8788d211","type":"GO_TERM","name":"L-tyrosine catabolic process","canonical_id":"go:GO:0006572","description":"\"The chemical reactions and pathways resulting in the breakdown of L-tyrosine.\" [GOC:curators]","metadata":null},{"id":"83ea0fcbf7a4420ea9dfb9b3ffec1839","type":"GO_TERM","name":"L-tyrosine import across plasma membrane","canonical_id":"go:GO:1903808","description":"\"The directed movement of L-tyrosine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"2ab1d0ebcf9542eb8dc795e05a48a994","type":"GO_TERM","name":"L-tyrosine transmembrane import into vacuole","canonical_id":"go:GO:0090514","description":"\"The directed movement of L-tyrosine into the vacuole across the vacuolar membrane.\" [GOC:al]","metadata":null},{"id":"8d914693b7674d23a8711cd82f11f11c","type":"GO_TERM","name":"L-tyrosine transmembrane transporter activity","canonical_id":"go:GO:0005302","description":"\"Enables the transfer of L-tyrosine from one side of a membrane to the other. L-tyrosine is 2-amino-3-(4-hydroxyphenyl)propanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"1b995c879deb43baad7ad2406de76ecd","type":"GO_TERM","name":"L-tyrosine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0004838","description":"\"Catalysis of the reaction: L-tyrosine + 2-oxoglutarate = 3-(4-hydroxyphenyl)pyruvate + L-glutamate.\" [RHEA:15093]","metadata":null},{"id":"4b028513383140c68a506a88f9013f0c","type":"GO_TERM","name":"L-tyrosine:pyruvate transaminase activity","canonical_id":"go:GO:0080098","description":"\"Catalysis of the reaction: L-tyrosine + pyruvate = 3-(4-hydroxyphenyl)pyruvate + L-alanine.\" [MetaCyc:RXN3O-4157]","metadata":null},{"id":"365f6e9617d546e3ab7d0da3fdf936d0","type":"GO_TERM","name":"L-valine biosynthetic process","canonical_id":"go:GO:0009099","description":"\"The chemical reactions and pathways resulting in the formation of valine, 2-amino-3-methylbutanoic acid.\" [GOC:ai, MetaCyc:VALSYN-PWY]","metadata":null},{"id":"21f96cccc05346d8a74b60c8f0abd05e","type":"GO_TERM","name":"L-valine catabolic process","canonical_id":"go:GO:0006574","description":"\"The chemical reactions and pathways resulting in the breakdown of L-valine.\" [GOC:curators]","metadata":null},{"id":"1c09ef46feb74f369b6019398d394685","type":"GO_TERM","name":"L-valine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0043837","description":"\"Catalysis of the reaction: L-valine + NAD+ + H2O = 3-methyl-2-oxobutanoate + NH4+ + NADH + H+.\" [PMID:10612726, PMID:2803248, RHEA:30763]","metadata":null},{"id":"c283eb278d134d5099f7788273d315b3","type":"GO_TERM","name":"L-valine dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050391","description":"\"Catalysis of the reaction: L-valine + NADP+ + H2O = 3-methyl-2-oxobutanoate + NH4+ + NADPH + H+.\" [RHEA:11156]","metadata":null},{"id":"8577d34f2b774c26b2468f325b14ad6d","type":"GO_TERM","name":"L-valine import across plasma membrane","canonical_id":"go:GO:1903805","description":"\"The directed movement of L-valine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"786a30dddca84c718221d256c8d86dea","type":"GO_TERM","name":"L-valine transmembrane import into vacuole","canonical_id":"go:GO:0110101","description":"\"The directed movement of L-valine into the vacuole across the vacuolar membrane.\" [GOC:al, PMID:20944394]","metadata":null},{"id":"889312eab2204d628a92a922ba7b4a39","type":"GO_TERM","name":"L-valine transmembrane transport","canonical_id":"go:GO:1903785","description":"\"The directed movement of L-valine across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:20944394]","metadata":null},{"id":"d196cab306fa4a299238bd1cbc487415","type":"GO_TERM","name":"L-valine transmembrane transporter activity","canonical_id":"go:GO:0005304","description":"\"Enables the transfer of L-valine from one side of a membrane to the other. L-valine is 2-amino-3-methylbutanoic acid.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"665aa1ad8a48453d889a282a6cfdc32c","type":"GO_TERM","name":"L-valine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0052655","description":"\"Catalysis of the reaction: L-valine + 2-oxoglutarate = 3-methyl-2-oxobutanoate + L-glutamate.\" [RHEA:24813]","metadata":null},{"id":"5ce7dd787956469a9c9873170414f0ac","type":"GO_TERM","name":"L-valine:3-methyl-2-oxovalerate transaminase activity","canonical_id":"go:GO:0047301","description":"\"Catalysis of the reaction: (S)-3-methyl-2-oxopentanoate + L-valine = 3-methyl-2-oxobutanoate + L-isoleucine.\" [RHEA:11468]","metadata":null},{"id":"4dbdf0365d514389bd7ebc5a28c69435","type":"GO_TERM","name":"L-valine:pyruvate transaminase activity","canonical_id":"go:GO:0009042","description":"\"Catalysis of the reaction: L-valine + pyruvate = 3-methyl-2-oxobutanoate + L-alanine.\" [RHEA:22912]","metadata":null},{"id":"ecbcc0a3aae14b5690b059f89d53f954","type":"GO_TERM","name":"L-xylose 1-dehydrogenase activity","canonical_id":"go:GO:0050037","description":"\"Catalysis of the reaction: L-xylose + NADP+ = H+ + L-xylono-1,4-lactone + NADPH.\" [RHEA:15789]","metadata":null},{"id":"fb89ad2a3e6c4a77aaf5d4876b932977","type":"GO_TERM","name":"L-xylulokinase activity","canonical_id":"go:GO:0008744","description":"\"Catalysis of the reaction: ATP + L-xylulose = ADP + L-xylulose 5-phosphate.\" [EC:2.7.1.53]","metadata":null},{"id":"9c40cca40ed4450297c559dd1cfed1ad","type":"GO_TERM","name":"L-xylulose reductase (NADH) activity","canonical_id":"go:GO:0044105","description":"\"Catalysis of the reaction: xylitol + NAD+ = L-xylulose + NADH + H+.\" [PMID:14736891, RHEA:68100]","metadata":null},{"id":"09f949f6686a4fd084f3a5bc4b19d059","type":"GO_TERM","name":"L-xylulose reductase (NADPH) activity","canonical_id":"go:GO:0050038","description":"\"Catalysis of the reaction: NADP+ + xylitol = L-xylulose + H+ + NADPH.\" [RHEA:17025]","metadata":null},{"id":"5362075ba3c44ce99dbd6d22a5e5fac9","type":"GENE","name":"L1CAM","canonical_id":"hgnc:HGNC:6470","description":null,"metadata":null},{"id":"9b4629cbeb1042fe82ba5d801d74818a","type":"GENE","name":"L1CAM-AS1","canonical_id":"hgnc:HGNC:55247","description":"L1CAM antisense RNA 1","metadata":{"aliases":["LCA10"]}},{"id":"379afa6207ba44f295f1c4d6109963e7","type":"GENE","name":"L1TD1","canonical_id":"hgnc:HGNC:25595","description":null,"metadata":null},{"id":"137b08f15c8140919d87f91993335151","type":"GENE","name":"L1TD1P1","canonical_id":"hgnc:HGNC:49127","description":"LINE-1 type transposase domain containing 1 pseudogene 1","metadata":null},{"id":"dd61ee58791b44038a93dc3bafad52b1","type":"GO_TERM","name":"L27 domain binding","canonical_id":"go:GO:0097016","description":"\"Binding to a L27 domain of a protein. L27 is composed of conserved negatively charged amino acids and a conserved aromatic amino acid. L27 domains can assemble proteins involved in signaling and establishment and maintenance of cell polarity into complexes by interacting in a heterodimeric manner.\" [GOC:BHF, PMID:15241471, PMID:17237226, Prosite:PDOC51022]","metadata":null},{"id":"86d4778de1da41638db71306cfdcf7ee","type":"GENE","name":"L2HGDH","canonical_id":"hgnc:HGNC:20499","description":"L-2-hydroxyglutarate dehydrogenase","metadata":{"aliases":["FLJ12618","C14orf160"]}},{"id":"1c745b03591147b6954ceb6bf4135c6b","type":"GENE","name":"L3HYPDH","canonical_id":"hgnc:HGNC:20488","description":"trans-L-3-hydroxyproline dehydratase","metadata":{"aliases":["FLJ25436","C14orf149"]}},{"id":"889543bcf7864e8daf09e79586b3a91a","type":"GENE","name":"L3MBTL1","canonical_id":"hgnc:HGNC:15905","description":null,"metadata":null},{"id":"c7d2ca98cc274a7bb275cc33a57dea43","type":"GENE","name":"L3MBTL2","canonical_id":"hgnc:HGNC:18594","description":"L3MBTL histone methyl-lysine binding protein 2","metadata":{"aliases":["H-l(3)mbt-l","DKFZP761I141","dJ756G23.3"]}},{"id":"b11aafb2c44c472d9bddecfcd1497b1a","type":"GENE","name":"L3MBTL2-AS1","canonical_id":"hgnc:HGNC:40847","description":"L3MBTL2 antisense RNA 1","metadata":null},{"id":"a4bbf222a43a428e9fa53e66fcea1e15","type":"GENE","name":"L3MBTL3","canonical_id":"hgnc:HGNC:23035","description":"L3MBTL histone methyl-lysine binding protein 3","metadata":{"aliases":["KIAA1798"]}},{"id":"11d6762bd4414742af507f15f0709cd2","type":"GENE","name":"L3MBTL4","canonical_id":"hgnc:HGNC:26677","description":"L3MBTL histone methyl-lysine binding protein 4","metadata":{"aliases":["FLJ35936","HsT1031"]}},{"id":"b0b813bcb058433191f88c51e0da5b26","type":"GENE","name":"L3MBTL4-AS1","canonical_id":"hgnc:HGNC:51320","description":"L3MBTL4 antisense RNA 1","metadata":null},{"id":"7e3628fc42664eaa859186f80b071c6b","type":"GENE","name":"LACC1","canonical_id":"hgnc:HGNC:26789","description":"laccase domain multifunctional purine nucleosidase 1","metadata":{"aliases":["FLJ38725","FAMIN","C13orf31"]}},{"id":"0807eccc1dc141afbf1af3c715078325","type":"GENE","name":"LACRT","canonical_id":"hgnc:HGNC:16430","description":"lacritin","metadata":{"aliases":["LACRITIN"]}},{"id":"a5fd3ef480344d0b9e021341483d4e5a","type":"GENE","name":"LACTB","canonical_id":"hgnc:HGNC:16468","description":"lactamase beta","metadata":{"aliases":["FLJ14902","MRPL56"]}},{"id":"0a7a05f5a98c4727bd33e220f3a610fc","type":"GENE","name":"LACTB2","canonical_id":"hgnc:HGNC:18512","description":"lactamase beta 2","metadata":{"aliases":["CGI-83"]}},{"id":"a9fea3595a854302a968bf23fc1256a2","type":"GENE","name":"LACTB2-AS1","canonical_id":"hgnc:HGNC:27841","description":"LACTB2 antisense RNA 1","metadata":null},{"id":"bf340dea69644148a10ad6c6ff3299e2","type":"GENE","name":"LACTBL1","canonical_id":"hgnc:HGNC:35445","description":"lactamase beta like 1","metadata":null},{"id":"40f23cb7b5954aa1accc7bf1c716a371","type":"GENE","name":"LAD1","canonical_id":"hgnc:HGNC:6472","description":"ladinin 1","metadata":null},{"id":"a550cf695e7543dc88d23a5225ad2027","type":"DISEASE","name":"LADD syndrome","canonical_id":"mondo:0007872","description":null,"metadata":null},{"id":"291ee1e557b04d4c90e87c99b0c27a2d","type":"DISEASE","name":"LADD syndrome 1","canonical_id":"mondo:0100302","description":null,"metadata":null},{"id":"414ffde10aa04f44846bc79704f1f64e","type":"GENE","name":"LAG3","canonical_id":"hgnc:HGNC:6476","description":"lymphocyte activating 3","metadata":{"aliases":["CD223"]}},{"id":"c4c820a9ff924d4fa2e8d8d99208a998","type":"PROTEIN","name":"LAG3","canonical_id":"uniprot:P18627","description":null,"metadata":null},{"id":"ea188c63c4984f428cf482a07affb5e7","type":"GENE","name":"LAGE3","canonical_id":"hgnc:HGNC:26058","description":"L antigen family member 3","metadata":{"aliases":["ITBA2","CVG5","DXS9951E","DXS9879E","ESO3","Pcc1"]}},{"id":"0f731647563547e98b50f7a71330831f","type":"GENE","name":"LAGE3P1","canonical_id":"hgnc:HGNC:49909","description":"L antigen family member 3 pseudogene 1","metadata":null},{"id":"d834de1e3a74471aab02ce2b17ddff3b","type":"GENE","name":"LAIR1","canonical_id":"hgnc:HGNC:6477","description":"leukocyte associated immunoglobulin like receptor 1","metadata":{"aliases":["CD305","LAIR-1"]}},{"id":"c5e713d3c7474a79a5f2f41642048d60","type":"GENE","name":"LAIR2","canonical_id":"hgnc:HGNC:6478","description":"leukocyte associated immunoglobulin like receptor 2","metadata":{"aliases":["CD306","LAIR-2"]}},{"id":"d8494409363543278022c53bc9478324","type":"GENE","name":"LALBA","canonical_id":"hgnc:HGNC:6480","description":"lactalbumin alpha","metadata":{"aliases":["LYZL7","LYZG","HAMLET"]}},{"id":"73be924656904be7b1b1d9cdf8e606c1","type":"GENE","name":"LALTOP","canonical_id":"hgnc:HGNC:58132","description":"lung cancer associated lncRNA targeting TOP2A","metadata":null},{"id":"7e7c9f6cc0824843b9d9d1260bb21fd8","type":"GENE","name":"LAMA1","canonical_id":"hgnc:HGNC:6481","description":null,"metadata":null},{"id":"f74a6bb335474f74bbd0960d64e85ece","type":"GENE","name":"LAMA2","canonical_id":"hgnc:HGNC:6482","description":"laminin subunit alpha 2","metadata":{"aliases":["LAMM"]}},{"id":"447754dbf988498796b553c3100972f7","type":"GENE","name":"LAMA3","canonical_id":"hgnc:HGNC:6483","description":null,"metadata":null},{"id":"b44f60f8f82e4e77b80b5997e8d18990","type":"GENE","name":"LAMA4","canonical_id":"hgnc:HGNC:6484","description":"laminin subunit alpha 4","metadata":{"aliases":["LAMA3"]}},{"id":"243010614dfe44d8889229b1fb0592ca","type":"GENE","name":"LAMA4-AS1","canonical_id":"hgnc:HGNC:40333","description":"LAMA4 antisense RNA 1","metadata":null},{"id":"42645fe8edf24a57ae1f38f4ef219b3d","type":"GENE","name":"LAMA5","canonical_id":"hgnc:HGNC:6485","description":"laminin subunit alpha 5","metadata":null},{"id":"e339e6f5ce904c339ef2f2e82bb53420","type":"GENE","name":"LAMA5-AS1","canonical_id":"hgnc:HGNC:40334","description":"LAMA5 antisense RNA 1","metadata":null},{"id":"79caf27761d84dd898a7c3865f2b50a0","type":"GENE","name":"LAMB1","canonical_id":"hgnc:HGNC:6486","description":null,"metadata":null},{"id":"f23a0d516bde43f3ac01f8e5da584a26","type":"GENE","name":"LAMB2","canonical_id":"hgnc:HGNC:6487","description":"laminin subunit beta 2","metadata":{"aliases":["NPHS5","LAMS"]}},{"id":"720ef2237de447de9af101637ef3a546","type":"GENE","name":"LAMB2P1","canonical_id":"hgnc:HGNC:6488","description":"laminin subunit beta 2 pseudogene 1","metadata":{"aliases":["LAMB2L"]}},{"id":"e13a4029073e47618867e383411fcab0","type":"GENE","name":"LAMB3","canonical_id":"hgnc:HGNC:6490","description":"laminin subunit beta 3","metadata":{"aliases":["nicein-125kDa","kalinin-140kDa","BM600-125kDa","LAMNB1"]}},{"id":"d725816ccd844af39942379213d101eb","type":"GENE","name":"LAMB4","canonical_id":"hgnc:HGNC:6491","description":"laminin subunit beta 4","metadata":null},{"id":"cedf61d0422e41778b0514b2bd060651","type":"GENE","name":"LAMC1","canonical_id":"hgnc:HGNC:6492","description":"laminin subunit gamma 1","metadata":{"aliases":["LAMB2"]}},{"id":"ab060fac0bf44bfd884d2525f354bf1b","type":"GENE","name":"LAMC1-AS1","canonical_id":"hgnc:HGNC:52645","description":"LAMC1 antisense RNA 1","metadata":{"aliases":["lnc-LAMC2-1:1"]}},{"id":"fd44870e92314137aa717a2cd1842bb6","type":"GENE","name":"LAMC2","canonical_id":"hgnc:HGNC:6493","description":null,"metadata":null},{"id":"8135f8d964034b089e4b0553b88bffe2","type":"GENE","name":"LAMC3","canonical_id":"hgnc:HGNC:6494","description":"laminin subunit gamma 3","metadata":{"aliases":["DKFZp434E202"]}},{"id":"c8ff4728e3704812a66d703f82be685d","type":"GENE","name":"LAMP1","canonical_id":"hgnc:HGNC:6499","description":"lysosome associated membrane protein 1","metadata":{"aliases":["CD107a"]}},{"id":"5704faab331942c0bf318146535a8b29","type":"GENE","name":"LAMP1P1","canonical_id":"hgnc:HGNC:6500","description":"LAMP1 pseudogene 1","metadata":{"aliases":["LAMP1L1"]}},{"id":"1f5fc3d7954146689ae6d7257e042c80","type":"GENE","name":"LAMP2","canonical_id":"hgnc:HGNC:6501","description":"lysosome associated membrane protein 2","metadata":{"aliases":["CD107b"]}},{"id":"5eda726671d243ec8ea8145f5646eca5","type":"GENE","name":"LAMP3","canonical_id":"hgnc:HGNC:14582","description":"lysosome associated membrane protein 3","metadata":{"aliases":["LAMP","TSC403","DC-LAMP","DCLAMP","CD208"]}},{"id":"27762b2fbfa04f4383b68679a04bc800","type":"GENE","name":"LAMP5","canonical_id":"hgnc:HGNC:16097","description":"lysosome associated membrane protein 5","metadata":{"aliases":["dJ1119D9.3","BAD-LAMP","UNC-46","C20orf103"]}},{"id":"8437cde5ab094f0097af64d178b8ee3c","type":"GENE","name":"LAMP5-AS1","canonical_id":"hgnc:HGNC:40754","description":"LAMP5 antisense RNA 1","metadata":null},{"id":"d5bdde9382e24d4c987f0ed8e2a1d97f","type":"GENE","name":"LAMTOR1","canonical_id":"hgnc:HGNC:26068","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 1","metadata":{"aliases":["FLJ20625","p18","p27RF-Rho","Pdro","Ragulator1","C11orf59"]}},{"id":"6a95562268ed48e6bed2c6bb27644993","type":"GENE","name":"LAMTOR2","canonical_id":"hgnc:HGNC:29796","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 2","metadata":{"aliases":["MAPBPIP","MAPKSP1AP","p14","ENDAP","Ragulator2","ROBLD3"]}},{"id":"7cf0217fe50c4835a22c46841a05390e","type":"GENE","name":"LAMTOR3","canonical_id":"hgnc:HGNC:15606","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 3","metadata":{"aliases":["MP1","MAPBP","Ragulator3","MAP2K1IP1","MAPKSP1"]}},{"id":"32a0932e5fe64843a07881ef2cdc7788","type":"GENE","name":"LAMTOR3P1","canonical_id":"hgnc:HGNC:39726","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 pseudogene 1","metadata":null},{"id":"99b4ece08d074acc83b1b0fe9f3aa4b2","type":"GENE","name":"LAMTOR3P2","canonical_id":"hgnc:HGNC:39727","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 pseudogene 2","metadata":null},{"id":"4bf80a540369496fb928ab54fa00b363","type":"GENE","name":"LAMTOR4","canonical_id":"hgnc:HGNC:33772","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 4","metadata":{"aliases":["C7orf59"]}},{"id":"84e7f1b0934c40d3834588b63261e4a8","type":"GENE","name":"LAMTOR5","canonical_id":"hgnc:HGNC:17955","description":null,"metadata":null},{"id":"7c7b1acd097041ed85f84c45604ec134","type":"GENE","name":"LAMTOR5-AS1","canonical_id":"hgnc:HGNC:40823","description":"LAMTOR5 and SLC16A4 antisense RNA 1","metadata":{"aliases":["SLC16A4-AS1"]}},{"id":"eb69a355f22146fc91aef77a4b915cb3","type":"GENE","name":"LAMTOR5P1","canonical_id":"hgnc:HGNC:31854","description":"late endosomal/lysosomal adaptor, MAPK and MTOR activator 5 pseudogene 1","metadata":{"aliases":["HBXIPL","HBXIPP1"]}},{"id":"2d402ddff6b543bb9dd14433f6dad4cf","type":"GENE","name":"LANCL1","canonical_id":"hgnc:HGNC:6508","description":"LanC like glutathione S-transferase 1","metadata":{"aliases":["p40","GPR69A"]}},{"id":"0bc1b741e0214395b70a7586e2e29809","type":"GENE","name":"LANCL1-AS1","canonical_id":"hgnc:HGNC:50727","description":"LANCL1 antisense RNA 1","metadata":{"aliases":["LANCLOT"]}},{"id":"4addf52eaeab486bb613b9a1c06328c5","type":"GENE","name":"LANCL2","canonical_id":"hgnc:HGNC:6509","description":"LanC like glutathione S-transferase 2","metadata":{"aliases":["TASP","GPR69B"]}},{"id":"89e293e9f98d48ca8f4dc573d1012632","type":"GENE","name":"LANCL3","canonical_id":"hgnc:HGNC:24767","description":"LanC like family member 3","metadata":{"aliases":["FLJ42925"]}},{"id":"a3832ec48ff54f6b93033a4f6332a585","type":"GENE","name":"LAP3","canonical_id":"hgnc:HGNC:18449","description":"leucine aminopeptidase 3","metadata":{"aliases":["LAPEP","LAP","PEPS"]}},{"id":"4267a2eaf6094e2d94b30f4bb7e703f0","type":"GENE","name":"LAP3P1","canonical_id":"hgnc:HGNC:42364","description":"leucine aminopeptidase 3 pseudogene 1","metadata":null},{"id":"2515ef3a0b3145129920249232490567","type":"GENE","name":"LAP3P2","canonical_id":"hgnc:HGNC:42365","description":"leucine aminopeptidase 3 pseudogene 2","metadata":null},{"id":"c66f459086564f7e99e7a5b68f34b7e7","type":"GENE","name":"LAPTM4A","canonical_id":"hgnc:HGNC:6924","description":"lysosomal protein transmembrane 4 alpha","metadata":{"aliases":["HUMORF13","KIAA0108","Mtrp","LAPTM4","MBNT"]}},{"id":"6653d47299e1458d9329277028abed85","type":"GENE","name":"LAPTM4A-DT","canonical_id":"hgnc:HGNC:54382","description":"LAPTM4A divergent transcript","metadata":null},{"id":"ac03c47e3e3e4cf59d4ee17ac4f5b2b0","type":"GENE","name":"LAPTM4B","canonical_id":"hgnc:HGNC:13646","description":null,"metadata":null},{"id":"8ed63ca09e4b4d5c8ed7bc3cc938b91c","type":"GENE","name":"LAPTM4BP1","canonical_id":"hgnc:HGNC:51934","description":"lysosomal protein transmembrane 4 beta pseudogene 1","metadata":null},{"id":"da903af7c01249739b840f292511ecef","type":"GENE","name":"LAPTM4BP2","canonical_id":"hgnc:HGNC:51935","description":"lysosomal protein transmembrane 4 beta pseudogene 2","metadata":null},{"id":"2f2684fb13ef485f87668aae1148b891","type":"GENE","name":"LAPTM5","canonical_id":"hgnc:HGNC:29612","description":"lysosomal protein transmembrane 5","metadata":null},{"id":"fc11b4b877dd4127bdcb29b6459cc6a4","type":"GENE","name":"LARGE-AS1","canonical_id":"hgnc:HGNC:40336","description":"LARGE antisense RNA 1","metadata":null},{"id":"fde41ae656084b0085348d861e31bef2","type":"GENE","name":"LARGE-IT1","canonical_id":"hgnc:HGNC:41357","description":"LARGE intronic transcript 1","metadata":null},{"id":"425e5cb24f604ee8b7cf872f4da0f425","type":"GENE","name":"LARGE1","canonical_id":"hgnc:HGNC:6511","description":"LARGE xylosyl- and glucuronyltransferase 1","metadata":{"aliases":["KIAA0609","LARGE"]}},{"id":"d88976a684b54082b5a0ad16d81728d9","type":"GENE","name":"LARGE1-AS1","canonical_id":"hgnc:HGNC:55162","description":"LARGE1 antisense RNA 1","metadata":null},{"id":"4e7cb322df674aa4a1603d92c98c98cf","type":"GENE","name":"LARGE1-AS2","canonical_id":"hgnc:HGNC:58379","description":"LARGE1 antisense RNA 2","metadata":null},{"id":"1ade7fa81b3547459474018adebd3ae9","type":"GENE","name":"LARGE2","canonical_id":"hgnc:HGNC:16522","description":"LARGE xylosyl- and glucuronyltransferase 2","metadata":{"aliases":["PP5656","FLJ35207","GYLTL1B"]}},{"id":"305ac95d53b44245a0e687496c687bd5","type":"GENE","name":"LARP1","canonical_id":"hgnc:HGNC:29531","description":"La ribonucleoprotein 1, translational regulator","metadata":{"aliases":["LARP","KIAA0731","MGC19556","Lar1","Lhp1"]}},{"id":"6f7fe198b17b472ebffe33ebbed2ddc2","type":"GENE","name":"LARP1B","canonical_id":"hgnc:HGNC:24704","description":"La ribonucleoprotein 1B","metadata":{"aliases":["FLJ10378","DKFZp434K245","DKFZp686E0316","LARP2"]}},{"id":"96050fde48594b7c8b29e3b2c807c614","type":"GENE","name":"LARP1BP1","canonical_id":"hgnc:HGNC:37097","description":"LARP1B pseudogene 1","metadata":null},{"id":"06c8b76a9f764b528f2398d4406520f1","type":"GENE","name":"LARP1BP2","canonical_id":"hgnc:HGNC:44084","description":"LARP1B pseudogene 2","metadata":null},{"id":"fe560c0a93a84c409d90218c6ce4548f","type":"GENE","name":"LARP1BP3","canonical_id":"hgnc:HGNC:44085","description":"LARP1B pseudogene 3","metadata":null},{"id":"fd3220f37df24d76a61a3f01b0070257","type":"GENE","name":"LARP1P1","canonical_id":"hgnc:HGNC:23183","description":"LARP1 pseudogene 1","metadata":{"aliases":["dJ221C16.7","HCG10P"]}},{"id":"fcc74f82aa3647028888a86b20043cd9","type":"GENE","name":"LARP4","canonical_id":"hgnc:HGNC:24320","description":"La ribonucleoprotein 4","metadata":{"aliases":["PP13296"]}},{"id":"0c7acbb740404bd9bb61e11100f76362","type":"GENE","name":"LARP4B","canonical_id":"hgnc:HGNC:28987","description":"La ribonucleoprotein 4B","metadata":{"aliases":["KIAA0217","LARP5"]}},{"id":"f487b38bf22e47dbbe9b0594d34eb4a6","type":"GENE","name":"LARP4B-DT","canonical_id":"hgnc:HGNC:55786","description":"LARP4B divergent transcript","metadata":null},{"id":"d18f9c43569a4d27b2cf960412749584","type":"GENE","name":"LARP4P","canonical_id":"hgnc:HGNC:21438","description":"LARP4 pseudogene","metadata":null},{"id":"a3fee35ca81345bead9499b976aa42c7","type":"GENE","name":"LARP6","canonical_id":"hgnc:HGNC:24012","description":"La ribonucleoprotein 6, translational regulator","metadata":{"aliases":["acheron","FLJ11196"]}},{"id":"a1fa89854206481cb0465e9fd576ed8d","type":"GENE","name":"LARP7","canonical_id":"hgnc:HGNC:24912","description":"La ribonucleoprotein 7, transcriptional regulator","metadata":{"aliases":["HDCMA18P","PIP7S","DKFZP564K112"]}},{"id":"778da72eb53b4913896b60dac6017e19","type":"GENE","name":"LARP7P1","canonical_id":"hgnc:HGNC:49763","description":"LARP7 pseudogene 1","metadata":null},{"id":"6948f9031ee24af1a3e97ac4bc733aae","type":"GENE","name":"LARP7P2","canonical_id":"hgnc:HGNC:49764","description":"LARP7 pseudogene 2","metadata":null},{"id":"a6bda84ae9b843759ef16484c313e8dc","type":"GENE","name":"LARP7P3","canonical_id":"hgnc:HGNC:49765","description":"LARP7 pseudogene 3","metadata":null},{"id":"bbec6759a6ed4582a40b0303fe839408","type":"GENE","name":"LARP7P4","canonical_id":"hgnc:HGNC:49766","description":"LARP7 pseudogene 4","metadata":null},{"id":"145d40a426d647c6b056b666a5c5fdd0","type":"GENE","name":"LARRPM","canonical_id":"hgnc:HGNC:56664","description":"LINC00240 antisense RNA regulating promoter methylation","metadata":null},{"id":"2c2aac1def25499a9b4d79cd55989c83","type":"GENE","name":"LARS1","canonical_id":"hgnc:HGNC:6512","description":"leucyl-tRNA synthetase 1","metadata":{"aliases":["HSPC192","FLJ10595","FLJ21788","LEUS","RNTLS","LARS"]}},{"id":"875c73a6ec3246f1ac4d1a023a33ff55","type":"GENE","name":"LARS2","canonical_id":"hgnc:HGNC:17095","description":"leucyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["KIAA0028","LEURS","MGC26121","mtLeuRS"]}},{"id":"3553b23332444df9b3f617badcadc39f","type":"GENE","name":"LARS2-AS1","canonical_id":"hgnc:HGNC:40796","description":"LARS2 antisense RNA 1","metadata":null},{"id":"96e6c9b414704c8699f9174c99cbb5af","type":"GENE","name":"LAS1L","canonical_id":"hgnc:HGNC:25726","description":"LAS1 like ribosome biogenesis factor","metadata":{"aliases":["FLJ12525","Las1"]}},{"id":"01c884a192f946f786e49f08923f2ae8","type":"TRIAL","name":"LASER and Radiofrequency and Genitourinary Syndrome of Menopause","canonical_id":"clinicaltrials.gov:NCT04045379","description":"Postmenopausal Atrophic Vaginitis; Postmenopausal Symptoms; Genitourinary Symptoms","metadata":null},{"id":"526ff0c4addf471dad4c409942f9ef61","type":"GENE","name":"LASP1","canonical_id":"hgnc:HGNC:6513","description":"LIM and SH3 protein 1","metadata":{"aliases":["MLN50","Lasp-1"]}},{"id":"e7c844315ef044b39f26aa38a11e95f6","type":"GENE","name":"LASP1NB","canonical_id":"hgnc:HGNC:44353","description":"LASP1 neighbor","metadata":{"aliases":["LINC00672"]}},{"id":"a6d85ecc626f4e50861bf5c5827acc71","type":"GENE","name":"LASTR","canonical_id":"hgnc:HGNC:54143","description":"lncRNA associated with SART3 regulation of splicing","metadata":{"aliases":["LINC02657"]}},{"id":"fb510297a6234e9ab3a2a48aa420823f","type":"GENE","name":"LAT","canonical_id":"hgnc:HGNC:18874","description":"linker for activation of T cells","metadata":{"aliases":["LAT1"]}},{"id":"7a1d3524b7ff47a7b1c0fc8ade833cc1","type":"GENE","name":"LAT2","canonical_id":"hgnc:HGNC:12749","description":"linker for activation of T cells family member 2","metadata":{"aliases":["WSCR5","HSPC046","LAB","NTAL","WBSCR15","WBSCR5"]}},{"id":"beb095e62f7f42648607c4f70184ef1f","type":"GENE","name":"LATS1","canonical_id":"hgnc:HGNC:6514","description":"large tumor suppressor kinase 1","metadata":{"aliases":["WARTS"]}},{"id":"c3bab45fda4046b2940576f3b7a68279","type":"GENE","name":"LATS2","canonical_id":"hgnc:HGNC:6515","description":null,"metadata":null},{"id":"3497693b13664ef9bd70efa262997306","type":"GENE","name":"LATS2-AS1","canonical_id":"hgnc:HGNC:39912","description":"LATS2 antisense RNA 1","metadata":null},{"id":"fec8e2abda134064ab6fbcec5d0d7a0a","type":"GENE","name":"LAX1","canonical_id":"hgnc:HGNC:26005","description":"lymphocyte transmembrane adaptor 1","metadata":{"aliases":["LAX","FLJ20340"]}},{"id":"dd8c2c24feed496e9ce5f0928de71b2d","type":"GENE","name":"LAYN","canonical_id":"hgnc:HGNC:29471","description":"layilin","metadata":{"aliases":["FLJ30977","FLJ31092"]}},{"id":"07416448ca334f88a1773c66de0e8b44","type":"TRIAL","name":"LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04560972","description":"Extensive Stage Lung Small Cell Carcinoma","metadata":null},{"id":"a448b77c4c58426eb6e7ce038be03b59","type":"GO_TERM","name":"LBD domain binding","canonical_id":"go:GO:0050693","description":"\"Binding to a protein's ligand binding domain (LBD) domain, found in nuclear receptors. In general, the LBDs consist of three layers comprised of twelve alpha-helices and several beta-strands that are organized around a lipophilic ligand-binding pocket.\" [PMID:9682036]","metadata":null},{"id":"9516392bccca4b8887d0a0cfeb777607","type":"GENE","name":"LBH","canonical_id":"hgnc:HGNC:29532","description":"LBH regulator of Wnt signaling pathway","metadata":null},{"id":"6895ae4623a640619cba3bd1f8f62ad4","type":"GENE","name":"LBHD1","canonical_id":"hgnc:HGNC:28351","description":"LBH domain containing 1","metadata":{"aliases":["MGC2477","C11orf48"]}},{"id":"7800e2333a684a5ca96bb113e5b14d1e","type":"GENE","name":"LBHD2","canonical_id":"hgnc:HGNC:52384","description":"LBH domain containing 2","metadata":null},{"id":"cdfd4c20b6a6441fa870d0f17d8085a5","type":"GENE","name":"LBP","canonical_id":"hgnc:HGNC:6517","description":null,"metadata":null},{"id":"44db0c772afe4b9a93373b5acbe89291","type":"GENE","name":"LBR","canonical_id":"hgnc:HGNC:6518","description":"lamin B receptor","metadata":{"aliases":["DHCR14B","TDRD18"]}},{"id":"65d314ab313b4351bc5b560e26645a2e","type":"GENE","name":"LBX1","canonical_id":"hgnc:HGNC:16960","description":"ladybird homeobox 1","metadata":{"aliases":["LBX1H","HPX6"]}},{"id":"2a286314cbc147eaad740cf493920d50","type":"GENE","name":"LBX1-AS1","canonical_id":"hgnc:HGNC:48678","description":"LBX1 antisense RNA 1","metadata":{"aliases":["FLJ41350"]}},{"id":"35ea07804b6e48a0a4b0242ea860347e","type":"GENE","name":"LBX2","canonical_id":"hgnc:HGNC:15525","description":"ladybird homeobox 2","metadata":null},{"id":"c97294fff8634353b00b12ef86f821c1","type":"GENE","name":"LBX2-AS1","canonical_id":"hgnc:HGNC:25136","description":"LBX2 antisense RNA 1","metadata":null},{"id":"d328b28f7f2c4f87ae1e4d0660dcdf2d","type":"GENE","name":"LCA5","canonical_id":"hgnc:HGNC:31923","description":"lebercilin LCA5","metadata":{"aliases":["C6orf152"]}},{"id":"b0ff24385f7a4cbbb6cdb05292cbce2b","type":"GENE","name":"LCA5L","canonical_id":"hgnc:HGNC:1255","description":"lebercilin LCA5 like","metadata":{"aliases":["MGC33295","C21orf13"]}},{"id":"57a2e782f5b4409ba10624eb4a403d1d","type":"GENE","name":"LCAL1","canonical_id":"hgnc:HGNC:25837","description":"lung cancer associated lncRNA 1","metadata":{"aliases":["onco-lncRNA-27"]}},{"id":"5fe53845b54f48d0b15591df54d2005a","type":"GENE","name":"LCAT","canonical_id":"hgnc:HGNC:6522","description":null,"metadata":null},{"id":"1e1f9f1848a54b27b4db02f3b8f1f027","type":"TRIAL","name":"LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations","canonical_id":"clinicaltrials.gov:NCT01726738","description":"Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma","metadata":null},{"id":"8fbaddc37e5840aeaec06e7259344ad5","type":"GENE","name":"LCDR","canonical_id":"hgnc:HGNC:44308","description":"lysosome cell death regulator","metadata":{"aliases":["LINC00653"]}},{"id":"242679cf5b314f5e88f71c39cd81cfbe","type":"GENE","name":"LCE1A","canonical_id":"hgnc:HGNC:29459","description":"late cornified envelope 1A","metadata":{"aliases":["LEP1"]}},{"id":"aade259365ec4bd1b359659ff1c94ed8","type":"GENE","name":"LCE1B","canonical_id":"hgnc:HGNC:16611","description":"late cornified envelope 1B","metadata":{"aliases":["LEP2","SPRL2A"]}},{"id":"14e77090657d437699d9ba003ca93eb9","type":"GENE","name":"LCE1C","canonical_id":"hgnc:HGNC:29464","description":"late cornified envelope 1C","metadata":{"aliases":["LEP3"]}},{"id":"6c408cde979f43d9903a9728c7a3b6bb","type":"GENE","name":"LCE1D","canonical_id":"hgnc:HGNC:29465","description":"late cornified envelope 1D","metadata":{"aliases":["LEP4"]}},{"id":"7e6fc0d3a3df457888e568e537e5946f","type":"GENE","name":"LCE1E","canonical_id":"hgnc:HGNC:29466","description":"late cornified envelope 1E","metadata":{"aliases":["LEP5"]}},{"id":"870afaf64b494f3db1af3cea3c7b41e9","type":"GENE","name":"LCE1F","canonical_id":"hgnc:HGNC:29467","description":"late cornified envelope 1F","metadata":{"aliases":["LEP6"]}},{"id":"3908178c11fd4e2085144fe20dda58b4","type":"GENE","name":"LCE2A","canonical_id":"hgnc:HGNC:29469","description":"late cornified envelope 2A","metadata":{"aliases":["LEP9"]}},{"id":"f8582d35b98343ff9f5eda80a65d0738","type":"GENE","name":"LCE2B","canonical_id":"hgnc:HGNC:16610","description":"late cornified envelope 2B","metadata":{"aliases":["LEP10","XP5","SPRL1B"]}},{"id":"c975ec0af85a42f78cddb1eee0a5183a","type":"GENE","name":"LCE2C","canonical_id":"hgnc:HGNC:29460","description":"late cornified envelope 2C","metadata":{"aliases":["LEP11"]}},{"id":"20001765721a4450a7f6930b9d42c6d2","type":"GENE","name":"LCE2D","canonical_id":"hgnc:HGNC:16518","description":"late cornified envelope 2D","metadata":{"aliases":["LEP12","SPRL1A"]}},{"id":"2be07624687c48d1b22a975d5c82b379","type":"GENE","name":"LCE3A","canonical_id":"hgnc:HGNC:29461","description":"late cornified envelope 3A","metadata":{"aliases":["LEP13"]}},{"id":"467ed62ace0d4738b48c0e3ad7bd5e27","type":"GENE","name":"LCE3B","canonical_id":"hgnc:HGNC:29462","description":"late cornified envelope 3B","metadata":{"aliases":["LEP14"]}},{"id":"9ce4e138a3644cf2ba9dcb000aa50b61","type":"GENE","name":"LCE3C","canonical_id":"hgnc:HGNC:16612","description":"late cornified envelope 3C","metadata":{"aliases":["LEP15","SPRL3A"]}},{"id":"9455238863c5422f9280cc26de56572f","type":"GENE","name":"LCE3D","canonical_id":"hgnc:HGNC:16615","description":"late cornified envelope 3D","metadata":{"aliases":["LEP16","SPRL6B","SPRL6A"]}},{"id":"43bbb29ae04540768af47c7a9202a7f6","type":"GENE","name":"LCE3E","canonical_id":"hgnc:HGNC:29463","description":"late cornified envelope 3E","metadata":{"aliases":["LEP17"]}},{"id":"6456a51a6beb421ba58167c41393dedb","type":"GENE","name":"LCE4A","canonical_id":"hgnc:HGNC:16613","description":"late cornified envelope 4A","metadata":{"aliases":["LEP8","SPRL4A"]}},{"id":"098f9393668c48859660bc3af1c7bf19","type":"GENE","name":"LCE5A","canonical_id":"hgnc:HGNC:16614","description":"late cornified envelope 5A","metadata":{"aliases":["LEP18","SPRL5A"]}},{"id":"b06166909e2a436a96d5f92cc19afa4a","type":"GENE","name":"LCE6A","canonical_id":"hgnc:HGNC:31824","description":"late cornified envelope 6A","metadata":{"aliases":["C1orf44"]}},{"id":"f020173ca0574564866b5f16deac71b0","type":"GENE","name":"LCE7A","canonical_id":"hgnc:HGNC:55921","description":"late cornified envelope 7A","metadata":null},{"id":"2751b9fadd2d4a0aa12a5e6f2391ee4e","type":"GENE","name":"LCEP1","canonical_id":"hgnc:HGNC:31806","description":"late cornified envelope pseudogene 1","metadata":null},{"id":"a7fe1e5c99174fe0a2962e045eaaf40d","type":"GENE","name":"LCEP2","canonical_id":"hgnc:HGNC:31807","description":"late cornified envelope pseudogene 2","metadata":null},{"id":"9851149a99fe4d05b8acdb76e1aa5cc0","type":"GENE","name":"LCEP3","canonical_id":"hgnc:HGNC:31809","description":"late cornified envelope pseudogene 3","metadata":null},{"id":"e747ed50977d4a618366b6f0d39b9a0d","type":"GENE","name":"LCEP4","canonical_id":"hgnc:HGNC:31808","description":"late cornified envelope pseudogene 4","metadata":null},{"id":"60e8c82b326147309459d25548bfa89b","type":"TRIAL","name":"LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03773107","description":"Multiple Myeloma","metadata":null},{"id":"0b8da3ccc67c474e97835676649f7b98","type":"GENE","name":"LCIIAR","canonical_id":"hgnc:HGNC:56346","description":"lung cancer immune cell infiltration associated lncRNA","metadata":{"aliases":["GSLR"]}},{"id":"7339437946f04245880721fda760749a","type":"GENE","name":"LCK","canonical_id":"hgnc:HGNC:6524","description":null,"metadata":null},{"id":"cc0aaf32e27044a9bc6bf9e847aeadde","type":"GENE","name":"LCLAT1","canonical_id":"hgnc:HGNC:26756","description":"lysocardiolipin acyltransferase 1","metadata":{"aliases":["FLJ37965","ALCAT1","AGPAT8","LPLAT6","LYCAT"]}},{"id":"eb897dc5f0904d12b859b7af677acf54","type":"GENE","name":"LCMT1","canonical_id":"hgnc:HGNC:17557","description":"leucine carboxyl methyltransferase 1","metadata":{"aliases":["CGI-68","PPMT1"]}},{"id":"7581a0f343e24ed68511caccec00b405","type":"GENE","name":"LCMT1-AS1","canonical_id":"hgnc:HGNC:51177","description":"LCMT1 antisense RNA 1","metadata":null},{"id":"80dd945cc55e4e2cbf86c98c6e1cfeef","type":"GENE","name":"LCMT1-AS2","canonical_id":"hgnc:HGNC:51178","description":"LCMT1 antisense RNA 2","metadata":null},{"id":"394f72a4d00d4e349d239dee6d6b5c91","type":"GENE","name":"LCMT1P1","canonical_id":"hgnc:HGNC:58368","description":"LCMT1 pseudogene 1","metadata":{"aliases":["AC133552.2"]}},{"id":"bd0ca2297bc7409e85f68e186fb1aa5b","type":"GENE","name":"LCMT2","canonical_id":"hgnc:HGNC:17558","description":"leucine carboxyl methyltransferase 2","metadata":{"aliases":["KIAA0547","MGC9534","TYW4","PPM2"]}},{"id":"ce6c141d4a194102a951f00be73b8286","type":"GENE","name":"LCN1","canonical_id":"hgnc:HGNC:6525","description":"lipocalin 1","metadata":{"aliases":["VEGP","TP","PMFA","MGC71975","TLC"]}},{"id":"c2cc93ccbc8742578266cf98393593ff","type":"GENE","name":"LCN10","canonical_id":"hgnc:HGNC:20892","description":"lipocalin 10","metadata":null},{"id":"5b05aa67418b4d97816e94cca2843a55","type":"GENE","name":"LCN12","canonical_id":"hgnc:HGNC:28733","description":"lipocalin 12","metadata":{"aliases":["MGC48935"]}},{"id":"a8b617f17b4a40edba1e02bdd8bc79b5","type":"GENE","name":"LCN15","canonical_id":"hgnc:HGNC:33777","description":"lipocalin 15","metadata":{"aliases":["UNQ2541","PRO6093"]}},{"id":"f119bf0b101e4f5da878d8f50a5887d9","type":"GENE","name":"LCN1P1","canonical_id":"hgnc:HGNC:23412","description":"lipocalin 1 pseudogene 1","metadata":{"aliases":["bA430N14.2","LCN1L1"]}},{"id":"ba5f72c7465c498da18acac93bc0fa99","type":"GENE","name":"LCN1P2","canonical_id":"hgnc:HGNC:23680","description":"lipocalin 1 pseudogene 2","metadata":{"aliases":["bA244N20.11","LCN1L2"]}},{"id":"92d3cc3555df48eeaf4a15e0b30d4640","type":"GENE","name":"LCN2","canonical_id":"hgnc:HGNC:6526","description":null,"metadata":null},{"id":"820e877eda114889b143746fc409487e","type":"GENE","name":"LCN6","canonical_id":"hgnc:HGNC:17337","description":"lipocalin 6","metadata":null},{"id":"48d76444d4cc4d0f968d275a9bbdf555","type":"GENE","name":"LCN8","canonical_id":"hgnc:HGNC:27038","description":"lipocalin 8","metadata":{"aliases":["LCN5"]}},{"id":"000d8ef1a54f49ec92b32bd70ec17b94","type":"GENE","name":"LCN9","canonical_id":"hgnc:HGNC:17442","description":"lipocalin 9","metadata":null},{"id":"488e58d80fae4b158bc5b11a464de579","type":"GENE","name":"LCNL1","canonical_id":"hgnc:HGNC:34436","description":"lipocalin like 1","metadata":{"aliases":["FLJ45224"]}},{"id":"76e4ba6da4d0410fb112a379cd0cec13","type":"GENE","name":"LCOR","canonical_id":"hgnc:HGNC:29503","description":null,"metadata":null},{"id":"00946b3dc6394cc1985f949bc05868d7","type":"GENE","name":"LCORL","canonical_id":"hgnc:HGNC:30776","description":"ligand dependent nuclear receptor corepressor like","metadata":{"aliases":["MLR1","FLJ30696"]}},{"id":"6be7f0ed757a4370a372646b77a6dbd3","type":"GENE","name":"LCORLP1","canonical_id":"hgnc:HGNC:56426","description":"LCORL pseudogene 1","metadata":null},{"id":"9b950d3d42f74f56bdc8342d997f7f96","type":"GENE","name":"LCP1","canonical_id":"hgnc:HGNC:6528","description":"lymphocyte cytosolic protein 1","metadata":{"aliases":["PLS2","CP64","L-PLASTIN","LC64P"]}},{"id":"7e828d7e721f4bbdad9e549a810edef7","type":"GENE","name":"LCP2","canonical_id":"hgnc:HGNC:6529","description":"lymphocyte cytosolic protein 2","metadata":{"aliases":["SLP-76","SLP76"]}},{"id":"48ee24f1bb4a4f128cbe3e2039be87bd","type":"GENE","name":"LCP2-AS1","canonical_id":"hgnc:HGNC:59301","description":"LCP2 antisense RNA 1","metadata":null},{"id":"55d6b4cfd16f4ab1bb5b8e470082e96b","type":"GENE","name":"LCT","canonical_id":"hgnc:HGNC:6530","description":null,"metadata":null},{"id":"3a482d39494b405d936d31eac16b2a2e","type":"GENE","name":"LCT-AS1","canonical_id":"hgnc:HGNC:40337","description":"LCT antisense RNA 1","metadata":null},{"id":"6743d3134a6e4d2d93b25048ad437f7e","type":"GENE","name":"LCTL","canonical_id":"hgnc:HGNC:15583","description":"lactase like","metadata":{"aliases":["KLPH","FLJ33279","KLG"]}},{"id":"ff732878329044bf87947fcae8cc9d12","type":"GENE","name":"LDAF1","canonical_id":"hgnc:HGNC:30136","description":"lipid droplet assembly factor 1","metadata":{"aliases":["promethin","TMEM159"]}},{"id":"328c24a811ab4ef9bb52be98db677aa3","type":"GENE","name":"LDAH","canonical_id":"hgnc:HGNC:26145","description":"lipid droplet associated hydrolase","metadata":{"aliases":["FLJ21820","C2orf43"]}},{"id":"e36cd6cfe41c4a469d177060e2c6c942","type":"GENE","name":"LDB1","canonical_id":"hgnc:HGNC:6532","description":null,"metadata":null},{"id":"a4a0ea4bbfa04ab2b2d5eaf70d39e1a9","type":"GENE","name":"LDB2","canonical_id":"hgnc:HGNC:6533","description":"LIM domain binding 2","metadata":{"aliases":["CLIM1","LDB1"]}},{"id":"8668cbbf1d2f490dae285df330ecfc2d","type":"GENE","name":"LDB2-AS1","canonical_id":"hgnc:HGNC:58741","description":"LDB2 antisense RNA 1","metadata":null},{"id":"6e6dfcbc1756471b83f649134070a898","type":"GENE","name":"LDB3","canonical_id":"hgnc:HGNC:15710","description":"LIM domain binding 3","metadata":{"aliases":["PDLIM6","KIAA0613","ZASP","CMD1C"]}},{"id":"2e61b8ec80ec44b2a7d8da222f1c7293","type":"GENE","name":"LDC1P","canonical_id":"hgnc:HGNC:49677","description":"leucine decarboxylase 1, pseudogene","metadata":{"aliases":["SEELA1","LINC01225"]}},{"id":"a21cee2104414104ad78fbd25ac3a9f6","type":"GENE","name":"LDHA","canonical_id":"hgnc:HGNC:6535","description":null,"metadata":null},{"id":"cc4f45edb56548c0aa57916d4b5d7d55","type":"GENE","name":"LDHAL6A","canonical_id":"hgnc:HGNC:28335","description":"lactate dehydrogenase A like 6A","metadata":{"aliases":["MGC23940","LDH6A"]}},{"id":"3f266e4ba1f64597980a897c8acd1bac","type":"GENE","name":"LDHAL6B","canonical_id":"hgnc:HGNC:21481","description":"lactate dehydrogenase A like 6B","metadata":{"aliases":["LDHL","LDH6B","LDHAL6"]}},{"id":"40b4487f709c45e2a12a90846a07dff4","type":"GENE","name":"LDHAL6CP","canonical_id":"hgnc:HGNC:39423","description":"lactate dehydrogenase A like 6C, pseudogene","metadata":{"aliases":["LDH6C"]}},{"id":"a01c42ab4f3a464c9434256c840c0c66","type":"GENE","name":"LDHAL6DP","canonical_id":"hgnc:HGNC:44239","description":"lactate dehydrogenase A like 6D, pseudogene","metadata":null},{"id":"9fdac444a6e444e3882f2da0e59c7f0b","type":"GENE","name":"LDHAL6EP","canonical_id":"hgnc:HGNC:44241","description":"lactate dehydrogenase A like 6E, pseudogene","metadata":null},{"id":"ab5e408873dd40529a92c68c52dfcbd7","type":"GENE","name":"LDHAL6FP","canonical_id":"hgnc:HGNC:44240","description":"lactate dehydrogenase A like 6F, pseudogene","metadata":null},{"id":"62b45201bc364ac29db5c4869e75e6c0","type":"GENE","name":"LDHAP1","canonical_id":"hgnc:HGNC:6536","description":"lactate dehydrogenase A pseudogene 1","metadata":{"aliases":["LDHAL1"]}},{"id":"bee75d3e4f2d42b6ade64bbbc58ada8c","type":"GENE","name":"LDHAP2","canonical_id":"hgnc:HGNC:6537","description":"lactate dehydrogenase A pseudogene 2","metadata":{"aliases":["LDHAL2"]}},{"id":"8c5b6267df3e42d6afae8986cc58595f","type":"GENE","name":"LDHAP3","canonical_id":"hgnc:HGNC:6538","description":"lactate dehydrogenase A pseudogene 3","metadata":{"aliases":["LDHAL3"]}},{"id":"979cbf2406834f3e9764c8c4afedc61f","type":"GENE","name":"LDHAP4","canonical_id":"hgnc:HGNC:6539","description":"lactate dehydrogenase A pseudogene 4","metadata":{"aliases":["LDHAL4"]}},{"id":"69d50ee4f9f348f4b4d2753b78b3590d","type":"GENE","name":"LDHAP5","canonical_id":"hgnc:HGNC:6540","description":"lactate dehydrogenase A pseudogene 5","metadata":{"aliases":["LDHAL5"]}},{"id":"20f0a88d120a44e9ad8005b9b8e09413","type":"GENE","name":"LDHAP7","canonical_id":"hgnc:HGNC:23144","description":"lactate dehydrogenase A pseudogene 7","metadata":{"aliases":["LDHAL7"]}},{"id":"3a69df4a7a11496d8850d5c69583faa0","type":"GENE","name":"LDHB","canonical_id":"hgnc:HGNC:6541","description":"lactate dehydrogenase B","metadata":null},{"id":"f21a6c73c9124076bbe15a2b59f09179","type":"GENE","name":"LDHBP1","canonical_id":"hgnc:HGNC:6542","description":"lactate dehydrogenase B pseudogene 1","metadata":{"aliases":["LDHBL1"]}},{"id":"e393206ca33446178189f2a56377e2ce","type":"GENE","name":"LDHBP2","canonical_id":"hgnc:HGNC:6543","description":"lactate dehydrogenase B pseudogene 2","metadata":{"aliases":["LDHBP","LDHBL2"]}},{"id":"9ca9d4a02f774976aa6652a82e0618be","type":"GENE","name":"LDHBP3","canonical_id":"hgnc:HGNC:39136","description":"lactate dehydrogenase B pseudogene 3","metadata":null},{"id":"05d3877c19354c2faf52d9f6dbbb3f09","type":"GENE","name":"LDHC","canonical_id":"hgnc:HGNC:6544","description":null,"metadata":null},{"id":"079c90b4f09c42f9a07808f3a322f743","type":"GENE","name":"LDHD","canonical_id":"hgnc:HGNC:19708","description":"lactate dehydrogenase D","metadata":null},{"id":"057f793d28cb4480bc302e732afde276","type":"TRIAL","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","canonical_id":"clinicaltrials.gov:NCT01828112","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"bd54b2c7be4840a4bbf4b47588456249","type":"TRIAL","name":"LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01828099","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"f9884d574f304f888aa9e557ae2c3def","type":"GO_TERM","name":"LDL-containing protein-lipid-RNA complex","canonical_id":"go:GO:1990686","description":"\"A protein-lipid-RNA complex containing separate low-density lipoprotein (LDL), lipid and RNA molecules. Separate in this context means not covalently bound to each other.\" [GOC:vesicles, PMID:23559634]","metadata":null},{"id":"0d69c16e9bb14e47b4d5780f40d7b375","type":"GENE","name":"LDLR","canonical_id":"hgnc:HGNC:6547","description":null,"metadata":null},{"id":"d2d8a3bb43c140ef803d21320958cbf0","type":"GENE","name":"LDLR-AS1","canonical_id":"hgnc:HGNC:54407","description":"LDLR antisense RNA 1","metadata":{"aliases":["BM450697"]}},{"id":"08836325c9044f18a5e315eb0515b527","type":"GENE","name":"LDLRAD1","canonical_id":"hgnc:HGNC:32069","description":"low density lipoprotein receptor class A domain containing 1","metadata":null},{"id":"0838eb450bc641dc8c6d9b1728d95f44","type":"GENE","name":"LDLRAD2","canonical_id":"hgnc:HGNC:32071","description":"low density lipoprotein receptor class A domain containing 2","metadata":null},{"id":"a506b051664946b492753622244c3c9d","type":"GENE","name":"LDLRAD3","canonical_id":"hgnc:HGNC:27046","description":"low density lipoprotein receptor class A domain containing 3","metadata":{"aliases":["LRAD3"]}},{"id":"6642ef42beb84fe2b53765b035983dd9","type":"GENE","name":"LDLRAD4","canonical_id":"hgnc:HGNC:1224","description":"low density lipoprotein receptor class A domain containing 4","metadata":{"aliases":["C18orf1"]}},{"id":"ace49348f49845fa96d0a3cb20275a87","type":"GENE","name":"LDLRAD4-AS1","canonical_id":"hgnc:HGNC:48592","description":"LDLRAD4 antisense RNA 1","metadata":null},{"id":"dbf1ffbd82f340938a8986ee0be1512e","type":"GENE","name":"LDLRAD4-AS2","canonical_id":"hgnc:HGNC:58069","description":"LDLRAD4 antisense RNA 2","metadata":{"aliases":["RP11-701H16.4"]}},{"id":"1fe7552cd29e48dd9815a169769fa161","type":"GENE","name":"LDLRAD4-AS3","canonical_id":"hgnc:HGNC:58589","description":"LDLRAD4 antisense RNA 3","metadata":null},{"id":"c74918b9186d4c76b76fbf5b2dc21ec1","type":"GENE","name":"LDLRAP1","canonical_id":"hgnc:HGNC:18640","description":"low density lipoprotein receptor adaptor protein 1","metadata":{"aliases":["ARH","ARH2","FHCB1","FHCB2","MGC34705","DKFZp586D0624"]}},{"id":"071daa2e1bd345ebb9023bba36f74243","type":"GENE","name":"LDOC1","canonical_id":"hgnc:HGNC:6548","description":"LDOC1 regulator of NFKB signaling","metadata":{"aliases":["Mar7","Mart7","SIRH7","RTL7","BCUR1"]}},{"id":"903eaa163c3a4c9da2a15205e81181cf","type":"TRIAL","name":"LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis","canonical_id":"clinicaltrials.gov:NCT06848465","description":"Colorectal Cancer; Liver Metastasis; LDRT","metadata":null},{"id":"83dea13906404b0c92664c5ac14680c0","type":"TRIAL","name":"LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy","canonical_id":"clinicaltrials.gov:NCT01986777","description":"Cognitive Impairments; RRSO","metadata":null},{"id":"02a098be6a5543ecb4e236487436f38c","type":"TRIAL","name":"LEA29Y (Belatacept) Emory Edmonton Protocol","canonical_id":"clinicaltrials.gov:NCT00468403","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"4a8ec460f8fe4e4c9fdae62dd75ac907","type":"GENE","name":"LEAP2","canonical_id":"hgnc:HGNC:29571","description":"liver enriched antimicrobial peptide 2","metadata":{"aliases":["LEAP-2"]}},{"id":"4faf2146c7a14b148176664f57f3ab4b","type":"GENE","name":"LECT2","canonical_id":"hgnc:HGNC:6550","description":"leukocyte cell derived chemotaxin 2","metadata":{"aliases":["chm-II","chm2"]}},{"id":"3c60de8fb6794aa498c3e69f980de6a4","type":"GENE","name":"LEF1","canonical_id":"hgnc:HGNC:6551","description":null,"metadata":null},{"id":"fc20fc0d0b454c0395c291bf05462894","type":"GENE","name":"LEF1-AS1","canonical_id":"hgnc:HGNC:40339","description":"LEF1 antisense RNA 1","metadata":null},{"id":"41223f9416f44666a8d434d11595e5f4","type":"GENE","name":"LEFTY1","canonical_id":"hgnc:HGNC:6552","description":null,"metadata":null},{"id":"d9bf38b61c7149d4a3f1ae2200de4b52","type":"GENE","name":"LEFTY2","canonical_id":"hgnc:HGNC:3122","description":"left-right determination factor 2","metadata":{"aliases":["LEFTA","LEFTYA","TGFB4","EBAF"]}},{"id":"1b5767b5dead4cb4912e28ea707a26b1","type":"GENE","name":"LEFTY3P","canonical_id":"hgnc:HGNC:55878","description":"left-right determination factor 3, pseudogene","metadata":{"aliases":["LEFTY3"]}},{"id":"493e9c4fcf49498d9a41b356a1da3c0c","type":"GENE","name":"LEISA1","canonical_id":"hgnc:HGNC:55264","description":"lncRNA enhancing IL-6/STAT3 signaling activation 1","metadata":{"aliases":["LEISA","NAV2-AS6"]}},{"id":"97e43a3d928a41318a3c837f7f507019","type":"GENE","name":"LEKR1","canonical_id":"hgnc:HGNC:33765","description":"leucine, glutamate and lysine rich 1","metadata":{"aliases":["FLJ16641"]}},{"id":"6666d17e858e446eb963b350605c5e2b","type":"GENE","name":"LELP1","canonical_id":"hgnc:HGNC:32046","description":"late cornified envelope like proline rich 1","metadata":null},{"id":"e02e49756e614ed99c59fd385ffe9bb8","type":"GO_TERM","name":"LEM domain binding","canonical_id":"go:GO:0097726","description":"\"Binding to a LEM domain. The LEM domain (for lamina-associated polypeptide, emerin, MAN1 domain) is present in a group of nuclear proteins that bind chromatin through interaction of the LEM motif with the conserved DNA crosslinking protein, barrier-to-autointegration factor (BAF).\" [GOC:rz, InterPro:IPR003887, PMID:22399800]","metadata":null},{"id":"26c6914d78264e73be91ee3a593c90e0","type":"GENE","name":"LEMD1","canonical_id":"hgnc:HGNC:18725","description":"LEM domain containing 1","metadata":{"aliases":["LEMP-1","CT50"]}},{"id":"dc6433a05fd14b088702ee2d8772f924","type":"GENE","name":"LEMD1-AS1","canonical_id":"hgnc:HGNC:44132","description":"LEMD1 antisense RNA 1","metadata":null},{"id":"736fabb0c72c423e9c3d780dd37a7676","type":"GENE","name":"LEMD1-DT","canonical_id":"hgnc:HGNC:27631","description":"LEMD1 divergent transcript","metadata":null},{"id":"73f913170cd947f2ace2197db8dd1b9a","type":"GENE","name":"LEMD2","canonical_id":"hgnc:HGNC:21244","description":"LEM domain nuclear envelope protein 2","metadata":{"aliases":["dJ482C21.1","NET25","LEM2"]}},{"id":"1c47ff3ff04048ea82ff286075c46e14","type":"GENE","name":"LEMD3","canonical_id":"hgnc:HGNC:28887","description":"LEM domain containing 3","metadata":{"aliases":["MAN1"]}},{"id":"56799dc366d74ee3885025963e3b3832","type":"TRIAL","name":"LEMTRADA Pregnancy Registry in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03774914","description":"Multiple Sclerosis","metadata":null},{"id":"61f7b304576b4728b7d3a4d7f6768729","type":"GENE","name":"LENEP","canonical_id":"hgnc:HGNC:14429","description":"lens epithelial protein","metadata":{"aliases":["LEP503"]}},{"id":"b8dd4f38b5614fa2b012057a905fbd85","type":"GENE","name":"LENG1","canonical_id":"hgnc:HGNC:15502","description":"leukocyte receptor cluster member 1","metadata":null},{"id":"89c78c7270d247608b7923ae888dfa5a","type":"GENE","name":"LENG8","canonical_id":"hgnc:HGNC:15500","description":"leukocyte receptor cluster member 8","metadata":{"aliases":["KIAA1932","MGC40108","pp13842"]}},{"id":"c5c6abb3a5e441e7bceff0d28a49f827","type":"GENE","name":"LENG8-AS1","canonical_id":"hgnc:HGNC:40705","description":"LENG8 antisense RNA 1","metadata":null},{"id":"1e3415e199144e25bc6c59b35f5898ec","type":"GENE","name":"LENG9","canonical_id":"hgnc:HGNC:16306","description":"leukocyte receptor cluster member 9","metadata":null},{"id":"eb3957603d5f46148d849eac11c90f61","type":"TRIAL","name":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT01536886","description":"Psoriasis Vulgaris","metadata":null},{"id":"9d2cf0a76e0a478d85ed77042a7edd4b","type":"TRIAL","name":"LEO 90105 Ointment in Japanese Subjects With Psoriasis","canonical_id":"clinicaltrials.gov:NCT01422434","description":"Psoriasis","metadata":null},{"id":"3dd2584a57b6423ca133bfe359fd0af6","type":"GENE","name":"LEO1","canonical_id":"hgnc:HGNC:30401","description":"LEO1 component of Paf1/RNA polymerase II complex","metadata":null},{"id":"242de38cefc1487d9759cfded29249fb","type":"GENE","name":"LEO1P1","canonical_id":"hgnc:HGNC:59183","description":"LEO1 pseudogene 1","metadata":null},{"id":"a3041251e6834d899eafb4273e9cdaab","type":"DISEASE","name":"LEOPARD syndrome 3","canonical_id":"mondo:0013380","description":null,"metadata":null},{"id":"351db0db9ddf45bc9c5a505060e6b4a3","type":"GENE","name":"LEP","canonical_id":"hgnc:HGNC:6553","description":null,"metadata":null},{"id":"0ce19badb261415bb266f709007c4562","type":"GENE","name":"LEPR","canonical_id":"hgnc:HGNC:6554","description":"leptin receptor","metadata":{"aliases":["OBR","CD295","LEP-R","OB-R"]}},{"id":"0a05fdc806ff4574a430df68a19b4472","type":"GENE","name":"LEPROT","canonical_id":"hgnc:HGNC:29477","description":"leptin receptor overlapping transcript","metadata":{"aliases":["OBRGRP","OB-RGRP","VPS55","FLJ90360"]}},{"id":"64eb0f182bfe478c839d99c3b5d56001","type":"GENE","name":"LEPROTL1","canonical_id":"hgnc:HGNC:6555","description":"leptin receptor overlapping transcript like 1","metadata":{"aliases":["my047","Vps55"]}},{"id":"4b6ed05ea040453897484da9e6297de2","type":"GENE","name":"LERFS","canonical_id":"hgnc:HGNC:51182","description":"lncRNA negative regulator of fibroblast-like synoviocyte migration, SYNCRIP interacting","metadata":null},{"id":"63e2bbdffa0840c4a7c839ff913e17b1","type":"GENE","name":"LETM1","canonical_id":"hgnc:HGNC:6556","description":"leucine zipper and EF-hand containing transmembrane protein 1","metadata":{"aliases":["SLC55A1","Mdm38"]}},{"id":"81fcf50fa1364e5c932b09c6f32672b7","type":"GENE","name":"LETM1-DT","canonical_id":"hgnc:HGNC:58710","description":"LETM1 divergent transcript","metadata":null},{"id":"d33fc0402136441ca96a26d9b84faacf","type":"GENE","name":"LETM1P1","canonical_id":"hgnc:HGNC:14649","description":"leucine zipper and EF-hand containing transmembrane protein 1 pseudogene 1","metadata":null},{"id":"660c9e10b56a45249ed9cd9ba4d48d40","type":"GENE","name":"LETM1P2","canonical_id":"hgnc:HGNC:33985","description":"leucine zipper and EF-hand containing transmembrane protein 1 pseudogene 2","metadata":null},{"id":"297f2abf39504b9eb27babc6458ebad6","type":"GENE","name":"LETM1P3","canonical_id":"hgnc:HGNC:33986","description":"leucine zipper and EF-hand containing transmembrane protein 1 pseudogene 3","metadata":null},{"id":"8dc5817582ad44828bce2b19a77cc1fc","type":"GENE","name":"LETM2","canonical_id":"hgnc:HGNC:14648","description":"leucine zipper and EF-hand containing transmembrane protein 2","metadata":{"aliases":["FLJ25409","SLC55A2"]}},{"id":"abc7a195499143ff9efd9b9be0f3a40b","type":"GENE","name":"LETMD1","canonical_id":"hgnc:HGNC:24241","description":"LETM1 domain containing 1","metadata":{"aliases":["HCCR1","HCCR","HCCR-2","HCCR-1","HCCR2","SLC55A3"]}},{"id":"ac1dab1bc49a44239e1135f03d6c666a","type":"GENE","name":"LETR1","canonical_id":"hgnc:HGNC:49597","description":"lymphatic endothelial transcriptional regulator lncRNA 1","metadata":{"aliases":["LINC01197"]}},{"id":"4dc027af90124b7babdd34911b61e4d6","type":"GENE","name":"LEUTX","canonical_id":"hgnc:HGNC:31953","description":"leucine twenty homeobox","metadata":null},{"id":"f4b4785e4b6845e694a658d353a51c9f","type":"TRIAL","name":"LEVITRA\u00ae 20mg Special Drug Use Investigation (Long-term)","canonical_id":"clinicaltrials.gov:NCT00909233","description":"Erectile Dysfunction","metadata":null},{"id":"079f9f61567d480e9e2b302908955b71","type":"GENE","name":"LFNG","canonical_id":"hgnc:HGNC:6560","description":"LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase","metadata":{"aliases":["SCDO3"]}},{"id":"32c847032ff04e5a81404b2a5c1d7485","type":"GENE","name":"LGALS1","canonical_id":"hgnc:HGNC:6561","description":null,"metadata":null},{"id":"280960d480fe4095bb1ce08a83d3f8fc","type":"GENE","name":"LGALS12","canonical_id":"hgnc:HGNC:15788","description":"galectin 12","metadata":{"aliases":["GRIP1"]}},{"id":"c478a6c5a7fd43ad8650e6c9cd986dce","type":"GENE","name":"LGALS13","canonical_id":"hgnc:HGNC:15449","description":"galectin 13","metadata":{"aliases":["PP13","PLAC8"]}},{"id":"578b6a21f762450fbeaf8e0e197e5c36","type":"GENE","name":"LGALS14","canonical_id":"hgnc:HGNC:30054","description":"galectin 14","metadata":{"aliases":["PPL13","CLC2"]}},{"id":"1a25d8a723b24455a5b526b9a46cd0a1","type":"GENE","name":"LGALS16","canonical_id":"hgnc:HGNC:40039","description":"galectin 16","metadata":null},{"id":"1d257a3f791248e49bdf50a50222bf19","type":"GENE","name":"LGALS2","canonical_id":"hgnc:HGNC:6562","description":"galectin 2","metadata":{"aliases":["HL14"]}},{"id":"6790c66ff167459ebd601b55ae0fea3b","type":"GENE","name":"LGALS3","canonical_id":"hgnc:HGNC:6563","description":null,"metadata":null},{"id":"acaa5c7d88824be4b98901200bd4f058","type":"GENE","name":"LGALS3BP","canonical_id":"hgnc:HGNC:6564","description":null,"metadata":null},{"id":"324d9507bd7545fe82d07b9310700f8a","type":"GENE","name":"LGALS4","canonical_id":"hgnc:HGNC:6565","description":null,"metadata":null},{"id":"e1c6da94244d45b1869c9a3659c44e37","type":"GENE","name":"LGALS7","canonical_id":"hgnc:HGNC:6568","description":"galectin 7","metadata":{"aliases":["GAL7","PIG1","TP53I1","LGALS7A"]}},{"id":"8ec2d0bf7ed244d796757bed3cff3fb7","type":"GENE","name":"LGALS7B","canonical_id":"hgnc:HGNC:34447","description":"galectin 7B","metadata":{"aliases":["GAL7"]}},{"id":"3231b243705243188a33e299d83f4fe5","type":"GENE","name":"LGALS8","canonical_id":"hgnc:HGNC:6569","description":"galectin 8","metadata":{"aliases":["PCTA-1"]}},{"id":"4657c9673b844cf79db403d7ea653d03","type":"GENE","name":"LGALS8-AS1","canonical_id":"hgnc:HGNC:40340","description":"LGALS8 antisense RNA 1","metadata":null},{"id":"3c4ee3924a2c4991a7fcdb0b728b226c","type":"GENE","name":"LGALS9","canonical_id":"hgnc:HGNC:6570","description":null,"metadata":null},{"id":"6e6a5f4e776d4b55a41eea1369c8cb59","type":"GENE","name":"LGALS9B","canonical_id":"hgnc:HGNC:24842","description":"galectin 9B","metadata":null},{"id":"07a42e22aa4c4eda90be5a82937aeb53","type":"GENE","name":"LGALS9C","canonical_id":"hgnc:HGNC:33874","description":"galectin 9C","metadata":null},{"id":"75b8fc1f915141869e01e12aad1bc49a","type":"GENE","name":"LGALS9DP","canonical_id":"hgnc:HGNC:49896","description":"galectin 9D, pseudogene","metadata":null},{"id":"686bca67d1594f6e84190726b0541637","type":"GENE","name":"LGALSL","canonical_id":"hgnc:HGNC:25012","description":"galectin like","metadata":{"aliases":["HSPC159","GRP"]}},{"id":"722fe90ea47d43afa2b6a5adbfe77243","type":"GENE","name":"LGALSL-DT","canonical_id":"hgnc:HGNC:53951","description":"LGALSL divergent transcript","metadata":{"aliases":["LOC105374771"]}},{"id":"dfcc4dbe94e74e52b8692f3c102a2595","type":"GENE","name":"LGI1","canonical_id":"hgnc:HGNC:6572","description":"leucine rich glioma inactivated 1","metadata":{"aliases":["IB1099","ETL1","EPITEMPIN","EPT"]}},{"id":"ab44c96314e44118923aa6b5ea568d38","type":"GENE","name":"LGI2","canonical_id":"hgnc:HGNC:18710","description":"leucine rich repeat LGI family member 2","metadata":{"aliases":["KIAA1916","FLJ10675"]}},{"id":"980c20680a7145d58945296a451d8561","type":"GENE","name":"LGI2-AS1","canonical_id":"hgnc:HGNC:58746","description":"LGI2 antisense RNA 1","metadata":null},{"id":"698bc50cd63d45c8bffda35e22954781","type":"GENE","name":"LGI3","canonical_id":"hgnc:HGNC:18711","description":"leucine rich repeat LGI family member 3","metadata":null},{"id":"84d4a893f5b14a979f511e63e349e011","type":"GENE","name":"LGI4","canonical_id":"hgnc:HGNC:18712","description":"leucine rich repeat LGI family member 4","metadata":null},{"id":"74f7bde1c81a4b12b49af057125b3e76","type":"GENE","name":"LGMN","canonical_id":"hgnc:HGNC:9472","description":"legumain","metadata":{"aliases":["LGMN1","PRSC1"]}},{"id":"a09059b7b4ea48588ab898c9602e969f","type":"GENE","name":"LGMNP1","canonical_id":"hgnc:HGNC:23079","description":"legumain pseudogene 1","metadata":{"aliases":["LGMN2P"]}},{"id":"f86fab00a1ea4630a1ae7e0374478d2b","type":"GENE","name":"LGR4","canonical_id":"hgnc:HGNC:13299","description":"leucine rich repeat containing G protein-coupled receptor 4","metadata":{"aliases":["GPR48"]}},{"id":"6a6ff831ae414ba899f2951d80aa028c","type":"GENE","name":"LGR4-AS1","canonical_id":"hgnc:HGNC:40629","description":"LGR4 antisense RNA 1","metadata":null},{"id":"4a9c2458ef844d8e8e4e835fa2871dd3","type":"GENE","name":"LGR5","canonical_id":"hgnc:HGNC:4504","description":null,"metadata":null},{"id":"e0cea9aff1c54927a917298146168d48","type":"GENE","name":"LGR6","canonical_id":"hgnc:HGNC:19719","description":"leucine rich repeat containing G protein-coupled receptor 6","metadata":{"aliases":["FLJ14471"]}},{"id":"79816c938ec3457e8a254ec17ee523bd","type":"GENE","name":"LGSN","canonical_id":"hgnc:HGNC:21016","description":"lengsin, lens protein with glutamine synthetase domain","metadata":{"aliases":["LGS","GLULD1"]}},{"id":"dcb801bdb7554ae0b9613d7fcf2ac897","type":"GENE","name":"LGTN","canonical_id":"hgnc:HGNC:39494","description":"ligatin","metadata":null},{"id":"41868b43293b4cd48e9432d6fe8aa86e","type":"DRUG","name":"LH","canonical_id":"gtopdb:1159","description":null,"metadata":null},{"id":"28b07122d3f0465d83da50d1136d2fca","type":"GENE","name":"LHB","canonical_id":"hgnc:HGNC:6584","description":null,"metadata":null},{"id":"96aa4c89ad89415baeb4534da06f5bed","type":"GENE","name":"LHCGR","canonical_id":"hgnc:HGNC:6585","description":null,"metadata":null},{"id":"c7f22309888044de9e2ac21df8838e28","type":"PROTEIN","name":"LHCGR","canonical_id":"uniprot:P22888","description":null,"metadata":null},{"id":"1e7959ba0e234ddbba3b456f01a42097","type":"GENE","name":"LHFPL1","canonical_id":"hgnc:HGNC:6587","description":"LHFPL tetraspan subfamily member 1","metadata":null},{"id":"c43f29b6ab25489780b416aeff0dcf7b","type":"GENE","name":"LHFPL2","canonical_id":"hgnc:HGNC:6588","description":"LHFPL tetraspan subfamily member 2","metadata":{"aliases":["KIAA0206"]}},{"id":"37c17bb8d9764561ae4ce6797c45c249","type":"GENE","name":"LHFPL3","canonical_id":"hgnc:HGNC:6589","description":"LHFPL tetraspan subfamily member 3","metadata":{"aliases":["LHFPL4"]}},{"id":"9dc36b92d60f43bd936773cc352924af","type":"GENE","name":"LHFPL3-AS1","canonical_id":"hgnc:HGNC:40341","description":"LHFPL3 antisense RNA 1","metadata":null},{"id":"1925fadfc1054b4ab93812d6708c1058","type":"GENE","name":"LHFPL4","canonical_id":"hgnc:HGNC:29568","description":"LHFPL tetraspan subfamily member 4","metadata":{"aliases":["GARLH4"]}},{"id":"e191ebb19c334cd88c6d9a92f96e5ab0","type":"GENE","name":"LHFPL5","canonical_id":"hgnc:HGNC:21253","description":"LHFPL tetraspan subfamily member 5","metadata":{"aliases":["MGC33835","dJ510O8.8","Tmhs","DFNB67"]}},{"id":"2f94c38723d34a5e9ed6f9e858cadf9b","type":"GENE","name":"LHFPL6","canonical_id":"hgnc:HGNC:6586","description":"LHFPL tetraspan subfamily member 6","metadata":{"aliases":["MGC22429","LHFP"]}},{"id":"d8ac5fd1dd294ede8868287acd1b5870","type":"GENE","name":"LHFPL7","canonical_id":"hgnc:HGNC:33725","description":"LHFPL tetraspan subfamily member 7","metadata":{"aliases":["bA9F11.1","TMEM211"]}},{"id":"ac4fcdbf94724e11bebfe61d86a270a1","type":"GENE","name":"LHPP","canonical_id":"hgnc:HGNC:30042","description":"phospholysine phosphohistidine inorganic pyrophosphate phosphatase","metadata":{"aliases":["HDHD2B"]}},{"id":"99201a8c2d264583957fb943875a2b54","type":"GENE","name":"LHX1","canonical_id":"hgnc:HGNC:6593","description":"LIM homeobox 1","metadata":{"aliases":["LIM-1","LIM1"]}},{"id":"06178914c4c14e429a3446aff6d81988","type":"GENE","name":"LHX1-DT","canonical_id":"hgnc:HGNC:53778","description":"LHX1 divergent transcript","metadata":{"aliases":["lnc-ACACA-1"]}},{"id":"d1f1b5fa5d0443cf9e632307aedfc530","type":"GENE","name":"LHX2","canonical_id":"hgnc:HGNC:6594","description":null,"metadata":null},{"id":"05f18faf00e941af93d00442c6fc9922","type":"GENE","name":"LHX2-AS1","canonical_id":"hgnc:HGNC:56163","description":"LHX2 antisense RNA 1","metadata":null},{"id":"6f5ed267ba8f4fb3bc0f96715ccf3e36","type":"GENE","name":"LHX3","canonical_id":"hgnc:HGNC:6595","description":null,"metadata":null},{"id":"c9ae2ff250934d0d9ac3ede3d4f0b50a","type":"GENE","name":"LHX4","canonical_id":"hgnc:HGNC:21734","description":null,"metadata":null},{"id":"2cd7c8e37fd94e6e9d01bbc010bd5137","type":"GENE","name":"LHX4-AS1","canonical_id":"hgnc:HGNC:40982","description":"LHX4 antisense RNA 1","metadata":null},{"id":"cc24df1ee883494fab5e6eee2f950094","type":"GENE","name":"LHX5","canonical_id":"hgnc:HGNC:14216","description":"LIM homeobox 5","metadata":null},{"id":"372de283829441b6a8ed7e96fa6e32b6","type":"GENE","name":"LHX5-AS1","canonical_id":"hgnc:HGNC:49570","description":"LHX5 antisense RNA 1","metadata":{"aliases":["locus4010"]}},{"id":"100e3a49c4794faeb31aa9dbe56d3c8d","type":"GENE","name":"LHX6","canonical_id":"hgnc:HGNC:21735","description":null,"metadata":null},{"id":"0893f7cbfb4c4ab6a53ee00a9a8c2454","type":"GENE","name":"LHX8","canonical_id":"hgnc:HGNC:28838","description":"LIM homeobox 8","metadata":{"aliases":["Lhx7"]}},{"id":"89cc58cfc2d14a87a2f15e9158046ea2","type":"GENE","name":"LHX8-AS1","canonical_id":"hgnc:HGNC:41213","description":"LHX8 antisense RNA 1","metadata":null},{"id":"bce7b23a0dc14b6ca06b42a4c8ec358e","type":"GENE","name":"LHX9","canonical_id":"hgnc:HGNC:14222","description":"LIM homeobox 9","metadata":null},{"id":"268aa21b4fcc432e9d1fb6d2096e785e","type":"GENE","name":"LIAS","canonical_id":"hgnc:HGNC:16429","description":"lipoic acid synthetase","metadata":{"aliases":["LAS"]}},{"id":"031a1f5c260d40f4be57fddc9119d6c0","type":"GENE","name":"LIAT1","canonical_id":"hgnc:HGNC:33800","description":"ligand of ATE1","metadata":{"aliases":["LOC400566","C17orf97"]}},{"id":"89631529d2e14cd1bca00d8048ddea5a","type":"GENE","name":"LIF","canonical_id":"hgnc:HGNC:6596","description":null,"metadata":null},{"id":"b3f616fa5ec54a9eb8e96f3ad6293c50","type":"GENE","name":"LIF-AS1","canonical_id":"hgnc:HGNC:53473","description":"LIF antisense RNA 1","metadata":{"aliases":["Lnc-LIF-AS","RP1-102K2.6"]}},{"id":"0b54beb9cf8445ef90c3dfb7db89bdf4","type":"GENE","name":"LIF-AS2","canonical_id":"hgnc:HGNC:28298","description":"LIF antisense RNA 2","metadata":{"aliases":["TP53LC08"]}},{"id":"eaee294d28a547aba30b64037218dbce","type":"GENE","name":"LIFR","canonical_id":"hgnc:HGNC:6597","description":"LIF receptor subunit alpha","metadata":{"aliases":["CD118"]}},{"id":"2a5fa18973ee4a7e8b6004ac31e74684","type":"GENE","name":"LIFR-AS1","canonical_id":"hgnc:HGNC:43600","description":"LIFR antisense RNA 1","metadata":null},{"id":"8d32c045930e402cb7a714e2401b7c41","type":"GENE","name":"LIG1","canonical_id":"hgnc:HGNC:6598","description":"DNA ligase 1","metadata":{"aliases":["LIGI","hLig1"]}},{"id":"623c777810d14356ad81f3b1a5984149","type":"GENE","name":"LIG1-AS1","canonical_id":"hgnc:HGNC:58602","description":"LIG1 antisense RNA 1","metadata":null},{"id":"49aa315739eb48cfa1db40a0abacd2de","type":"GENE","name":"LIG3","canonical_id":"hgnc:HGNC:6600","description":"DNA ligase 3","metadata":{"aliases":["LIG3alpha","LIG2"]}},{"id":"8835795c0b3e4d26970a12b7c156fbcd","type":"GENE","name":"LIG4","canonical_id":"hgnc:HGNC:6601","description":"DNA ligase 4","metadata":null},{"id":"1e31fea0f6c0459288961927bb793a18","type":"TRIAL","name":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT05313529","description":"Type 2 Diabetes Mellitus; Mild Cognitive Impairment","metadata":null},{"id":"6f6c88efef864cfca87f249fdbd87bc9","type":"GENE","name":"LILRA1","canonical_id":"hgnc:HGNC:6602","description":"leukocyte immunoglobulin like receptor A1","metadata":{"aliases":["LIR-6","CD85i","LIR6"]}},{"id":"d130481c1ade4296951d1dc7d66c21b5","type":"GENE","name":"LILRA2","canonical_id":"hgnc:HGNC:6603","description":"leukocyte immunoglobulin like receptor A2","metadata":{"aliases":["LIR-7","ILT1","CD85h","LIR7"]}},{"id":"fd51baaa9f6f4e1390b4db9130723652","type":"GENE","name":"LILRA2P1","canonical_id":"hgnc:HGNC:56565","description":"LILRA2 pseudogene 1","metadata":null},{"id":"4f4169da94f14c2b945eedfc5a119fea","type":"GENE","name":"LILRA3","canonical_id":"hgnc:HGNC:6604","description":"leukocyte immunoglobulin like receptor A3","metadata":{"aliases":["LIR-4","HM43","ILT6","HM31","LIR4","CD85e"]}},{"id":"b1d05cdbde3f47bc9c938b2d99ab1177","type":"GENE","name":"LILRA4","canonical_id":"hgnc:HGNC:15503","description":"leukocyte immunoglobulin like receptor A4","metadata":{"aliases":["ILT7","CD85g"]}},{"id":"54a9df1af6d743fdb072e25f2389f51d","type":"GENE","name":"LILRA5","canonical_id":"hgnc:HGNC:16309","description":"leukocyte immunoglobulin like receptor A5","metadata":{"aliases":["ILT11","LIR9","CD85","CD85f","LILRB7"]}},{"id":"a542396f12bb48afa88e9884bdd7f894","type":"GENE","name":"LILRA6","canonical_id":"hgnc:HGNC:15495","description":"leukocyte immunoglobulin like receptor A6","metadata":{"aliases":["ILT8","CD85b","LILRB6"]}},{"id":"4098a39ad510479a8e8a0d6aafcb1094","type":"GENE","name":"LILRB1","canonical_id":"hgnc:HGNC:6605","description":null,"metadata":null},{"id":"fe1438aba19447ed9e6e221d3b24621a","type":"GENE","name":"LILRB1-AS1","canonical_id":"hgnc:HGNC:53114","description":"LILRB1 antisense RNA 1","metadata":{"aliases":["AC009892.10"]}},{"id":"556334949e5b43a49180722c9713bfe5","type":"GENE","name":"LILRB2","canonical_id":"hgnc:HGNC:6606","description":null,"metadata":null},{"id":"79f5150bff4b44f1aaaa80a1d2bad9c9","type":"GENE","name":"LILRB3","canonical_id":"hgnc:HGNC:6607","description":"leukocyte immunoglobulin like receptor B3","metadata":{"aliases":["LIR-3","HL9","ILT5","LIR3","CD85a","PIRB","PIR-B"]}},{"id":"e3a406019bfd43fab7ec8adaf83ebe33","type":"GENE","name":"LILRB4","canonical_id":"hgnc:HGNC:6608","description":null,"metadata":null},{"id":"163e5fcb5ed443988f11758660b4638b","type":"GENE","name":"LILRB5","canonical_id":"hgnc:HGNC:6609","description":"leukocyte immunoglobulin like receptor B5","metadata":{"aliases":["LIR-8","LIR8","CD85c"]}},{"id":"c864ae0c7e2a491bad5df62288cb7b1b","type":"GENE","name":"LILRP1","canonical_id":"hgnc:HGNC:15496","description":"leukocyte immunoglobulin-like receptor pseudogene 1","metadata":{"aliases":["ILT9","CD85l","LILRA6P"]}},{"id":"7d204b1062f4411c992e9cbb2bebee57","type":"GENE","name":"LILRP2","canonical_id":"hgnc:HGNC:15497","description":"leukocyte immunoglobulin-like receptor pseudogene 2","metadata":{"aliases":["ILT10","CD85m"]}},{"id":"00353f3242a64ed2b9e759e6674667eb","type":"GO_TERM","name":"LIM domain binding","canonical_id":"go:GO:0030274","description":"\"Binding to a LIM domain (for Lin-11 Isl-1 Mec-3) of a protein, a domain with seven conserved cysteine residues and a histidine, that binds two zinc ions and acts as an interface for protein-protein interactions.\" [GOC:curators, Pfam:PF00412]","metadata":null},{"id":"2df92d9a889d4d7e90c58db69d77c88f","type":"GENE","name":"LIM2","canonical_id":"hgnc:HGNC:6610","description":"lens intrinsic membrane protein 2","metadata":{"aliases":["MP19","MP17"]}},{"id":"99f9a04c77174fccabd58dafa2756306","type":"GENE","name":"LIM2-AS1","canonical_id":"hgnc:HGNC:56004","description":"LIM2 and SIGLEC10 antisense RNA 1","metadata":null},{"id":"71109c02d1cb4fde8058a9a6161e4c5e","type":"GENE","name":"LIMA1","canonical_id":"hgnc:HGNC:24636","description":"LIM domain and actin binding 1","metadata":{"aliases":["EPLIN"]}},{"id":"c34a5228da234364947bc748203e647e","type":"GENE","name":"LIMA1-DT","canonical_id":"hgnc:HGNC:59210","description":"LIMA1 divergent transcript","metadata":null},{"id":"eca281fab0944713b595d9ced2828b1c","type":"GENE","name":"LIMASI","canonical_id":"hgnc:HGNC:56357","description":"lncRNA inflammatory and mucous response associated, antisense to ICAM1","metadata":{"aliases":["LASI","AC011511.2"]}},{"id":"6a982351337d495e98acf64b8e47e23b","type":"GENE","name":"LIMCH1","canonical_id":"hgnc:HGNC:29191","description":"LIM and calponin homology domains 1","metadata":{"aliases":["DKFZP686A01247","LIMCH1A","LMO7B"]}},{"id":"d1dbf4abe2a24be68cc90239acffb8e7","type":"GENE","name":"LIMCH1-AS1","canonical_id":"hgnc:HGNC:58416","description":"LIMCH1 antisense RNA 1","metadata":null},{"id":"10a66e0e8dab4e4f837dd68d1a85ff49","type":"GENE","name":"LIMCH1-AS2","canonical_id":"hgnc:HGNC:58778","description":"LIMCH1 antisense RNA 2","metadata":null},{"id":"914649048b9b4c568350d803dd19db4a","type":"GENE","name":"LIMD1","canonical_id":"hgnc:HGNC:6612","description":null,"metadata":null},{"id":"8319808e99c74c088faf659869a5b58e","type":"GENE","name":"LIMD1-AS1","canonical_id":"hgnc:HGNC:44107","description":"LIMD1 antisense RNA 1","metadata":null},{"id":"3e14ed560ddb4361b18afbbce0de3d34","type":"GENE","name":"LIMD2","canonical_id":"hgnc:HGNC:28142","description":"LIM domain containing 2","metadata":{"aliases":["MGC10986"]}},{"id":"4daebb1cb885411b99ba2e214a9764e0","type":"GENE","name":"LIME1","canonical_id":"hgnc:HGNC:26016","description":"Lck interacting transmembrane adaptor 1","metadata":{"aliases":["FLJ20406","dJ583P15.4","LIME"]}},{"id":"9bcd68e9a5fb40a1aa56fcbfdcde1ded","type":"GENE","name":"LIMK1","canonical_id":"hgnc:HGNC:6613","description":"LIM domain kinase 1","metadata":{"aliases":["LIMK"]}},{"id":"2ef5d2ecf96842fd896613baee46d3cc","type":"GENE","name":"LIMK2","canonical_id":"hgnc:HGNC:6614","description":"LIM domain kinase 2","metadata":null},{"id":"ba7bf5445dd44141bc2db039703c0078","type":"GENE","name":"LIMK2P1","canonical_id":"hgnc:HGNC:54893","description":"LIMK2 pseudogene 1","metadata":null},{"id":"c88cf671c9fc4ef8b0efa49c17892465","type":"GENE","name":"LIMS1","canonical_id":"hgnc:HGNC:6616","description":"LIM zinc finger domain containing 1","metadata":{"aliases":["PINCH","PINCH1"]}},{"id":"8991e15462cd483195fe141a67957be6","type":"GENE","name":"LIMS1-AS1","canonical_id":"hgnc:HGNC:40342","description":"LIMS1 antisense RNA 1","metadata":null},{"id":"b7f68435f89442b28edff9dcf54c5579","type":"GENE","name":"LIMS2","canonical_id":"hgnc:HGNC:16084","description":"LIM zinc finger domain containing 2","metadata":{"aliases":["PINCH2","PINCH-2"]}},{"id":"2be92231bad74c2aa7c4ad39527fe78d","type":"GENE","name":"LIMS3","canonical_id":"hgnc:HGNC:30047","description":"LIM zinc finger domain containing 3","metadata":null},{"id":"66d6c65b5f2f45a98fe49919820299e8","type":"GENE","name":"LIMS4","canonical_id":"hgnc:HGNC:39941","description":"LIM zinc finger domain containing 4","metadata":{"aliases":["LIMS3L"]}},{"id":"6a0fcb4b340544a18a5840dc48b4f6ad","type":"GENE","name":"LIN28A","canonical_id":"hgnc:HGNC:15986","description":null,"metadata":null},{"id":"d67847cff60144d5a500a4947c0134fd","type":"GENE","name":"LIN28AP1","canonical_id":"hgnc:HGNC:38055","description":"LIN28A pseudogene 1","metadata":null},{"id":"efe5030dea1e4ad883a9d93dabaedd44","type":"GENE","name":"LIN28AP2","canonical_id":"hgnc:HGNC:38056","description":"LIN28A pseudogene 2","metadata":null},{"id":"8502c9b6fd084640bf79e1fd7bc08093","type":"GENE","name":"LIN28AP3","canonical_id":"hgnc:HGNC:38057","description":"LIN28A pseudogene 3","metadata":null},{"id":"907a0951b0774caa921205bda586d744","type":"GENE","name":"LIN28B","canonical_id":"hgnc:HGNC:32207","description":null,"metadata":null},{"id":"79f7f37e38364e17b3a910dc3282951e","type":"GENE","name":"LIN28B-AS1","canonical_id":"hgnc:HGNC:21553","description":"LIN28B antisense RNA 1","metadata":{"aliases":["dJ439I14.1","C6orf220","LINC00577"]}},{"id":"18c032495a7b44d88a46fc80641d25ab","type":"GENE","name":"LIN37","canonical_id":"hgnc:HGNC:33234","description":"lin-37 DREAM MuvB core complex component","metadata":{"aliases":["ZK418.4","F25965","lin-37"]}},{"id":"d473c8a980bb4bc89f155cc517196a96","type":"GENE","name":"LIN52","canonical_id":"hgnc:HGNC:19856","description":"lin-52 DREAM MuvB core complex component","metadata":{"aliases":["C14orf46"]}},{"id":"ad5a83e98ee6481fbf069adedaf422fa","type":"GENE","name":"LIN54","canonical_id":"hgnc:HGNC:25397","description":null,"metadata":null},{"id":"4746b02fc8c14394b44827311df46f85","type":"GENE","name":"LIN7A","canonical_id":"hgnc:HGNC:17787","description":"lin-7 cell polarity scaffold A","metadata":{"aliases":["MALS-1","TIP-33","LIN-7A","VELI1"]}},{"id":"56ab6f533a6b42208813e8e33556d5d3","type":"GENE","name":"LIN7B","canonical_id":"hgnc:HGNC:17788","description":"lin-7 cell polarity scaffold B","metadata":{"aliases":["MALS-2","LIN-7B","VELI2"]}},{"id":"9223f8315f6e44eeb4c834ecab9943ae","type":"GENE","name":"LIN7C","canonical_id":"hgnc:HGNC:17789","description":"lin-7 cell polarity scaffold C","metadata":{"aliases":["MALS-3","LIN-7C","LIN-7-C","VELI3","FLJ11215"]}},{"id":"e7146ef0a71e4fbb9942f2d2b40b764f","type":"GENE","name":"LIN9","canonical_id":"hgnc:HGNC:30830","description":"lin-9 DREAM MuvB core complex component","metadata":{"aliases":["TGS"]}},{"id":"a4a39c3b21b742feaa460d1f65b8e410","type":"GENE","name":"LINC-ADAIN","canonical_id":"hgnc:HGNC:49686","description":"long intergenic non-coding adipose anti-inflammatory","metadata":{"aliases":["linc-DMRT2","lnc-DRMT2","TCONS_00015639","LINC01230"]}},{"id":"2face4e40abf40b7b549bf78c33ae133","type":"GENE","name":"LINC-PINT","canonical_id":"hgnc:HGNC:26885","description":"long independently transcribed non-coding RNA, p53 induced transcript","metadata":{"aliases":["PINT","TISPL","FLJ43663","PINT87aa","LOC646329","LincRNA-Pint","MKLN1-AS1"]}},{"id":"27f1dfb29f3b407fa4057f4579d9f69d","type":"GENE","name":"LINC-ROR","canonical_id":"hgnc:HGNC:43773","description":"long independently transcribed non-coding RNA, regulator of reprogramming","metadata":{"aliases":["lincRNA-RoR","lincRNA-ST8SIA3","ROR"]}},{"id":"db8e15c3fff647dcba503a859cc5291b","type":"GENE","name":"LINC00028","canonical_id":"hgnc:HGNC:16224","description":"long independently transcribed non-coding RNA 28","metadata":{"aliases":["dJ1093G12.6","C20orf93","NCRNA00028"]}},{"id":"4f68e0f1832a42e9b2a242b72e0a31b3","type":"GENE","name":"LINC00029","canonical_id":"hgnc:HGNC:16184","description":"long independently transcribed non-coding RNA 29","metadata":{"aliases":["bA305P22.4","C20orf51","NCRNA00029"]}},{"id":"812d7f4adce0444a93d18618a17f3f4b","type":"GENE","name":"LINC00051","canonical_id":"hgnc:HGNC:32028","description":"long independently transcribed non-coding RNA 51","metadata":{"aliases":["C8orf43","NCRNA00051"]}},{"id":"4029f3a20f8949b48ab4469ae08e9d6e","type":"GENE","name":"LINC00052","canonical_id":"hgnc:HGNC:26455","description":"long independently transcribed non-coding RNA 52","metadata":{"aliases":["FLJ31461","TMEM83","NCRNA00052"]}},{"id":"16488b12fcdb4b7380e371bd5967b27b","type":"GENE","name":"LINC00092","canonical_id":"hgnc:HGNC:31408","description":"long independently transcribed non-coding RNA 92","metadata":{"aliases":["bA346B7.1","NCRNA00092"]}},{"id":"aec28420246147fab7eae16438acda0f","type":"GENE","name":"LINC00102","canonical_id":"hgnc:HGNC:30470","description":"long independently transcribed non-coding RNA 102","metadata":{"aliases":["OTTHUMT00000055623","NCRNA00102"]}},{"id":"7bf15b09cb784a5691ba345032a770dd","type":"GENE","name":"LINC00106","canonical_id":"hgnc:HGNC:31843","description":"long independently transcribed non-coding RNA 106","metadata":{"aliases":["OTTHUMG00000021061","CXYorf8","NCRNA00106"]}},{"id":"2f0fd05a70e346deb425349cfb151422","type":"GENE","name":"LINC00111","canonical_id":"hgnc:HGNC:1262","description":"long independently transcribed non-coding RNA 111","metadata":{"aliases":["C21orf21","NCRNA00111"]}},{"id":"1be083fbd4d44378a3d46087fc18ca38","type":"GENE","name":"LINC00112","canonical_id":"hgnc:HGNC:1263","description":"long independently transcribed non-coding RNA 112","metadata":{"aliases":["C21orf22","NCRNA00112"]}},{"id":"f11ee6a427b3422db3a759e6c6f0e743","type":"GENE","name":"LINC00113","canonical_id":"hgnc:HGNC:1264","description":"long independently transcribed non-coding RNA 113","metadata":{"aliases":["SLERCC","C21orf23","NCRNA00113"]}},{"id":"21740abcf3374c1fbc5e96e30ae36b18","type":"GENE","name":"LINC00114","canonical_id":"hgnc:HGNC:1265","description":"long independently transcribed non-coding RNA 114","metadata":{"aliases":["C21orf24","NCRNA00114"]}},{"id":"03bf25730fe34b42b53f8d33678a07a3","type":"GENE","name":"LINC00115","canonical_id":"hgnc:HGNC:26211","description":"long independently transcribed non-coding RNA 115","metadata":{"aliases":["FLJ22639","NCRNA00115"]}},{"id":"f4445ed57d2d4846bdad4954fc31dbbb","type":"GENE","name":"LINC00158","canonical_id":"hgnc:HGNC:1283","description":"long independently transcribed non-coding RNA 158","metadata":{"aliases":["C21orf42","NCRNA00158"]}},{"id":"e1c1a6f475d04015b4f1c5af2795a903","type":"GENE","name":"LINC00159","canonical_id":"hgnc:HGNC:1285","description":"long independently transcribed non-coding RNA 159","metadata":{"aliases":["C21orf44","NCRNA00159"]}},{"id":"ce0163cc6d8f4c8fa15f67a6ba54ff7a","type":"GENE","name":"LINC00160","canonical_id":"hgnc:HGNC:1294","description":"long independently transcribed non-coding RNA 160","metadata":{"aliases":["C21orf52","NCRNA00160"]}},{"id":"6a9f50194c3d49c59999a74956e5d304","type":"GENE","name":"LINC00161","canonical_id":"hgnc:HGNC:17138","description":"long independently transcribed non-coding RNA 161","metadata":{"aliases":["HORAS5","C21orf100","NCRNA00161"]}},{"id":"8ac8faa9515b4444968cbba54f2c0d8b","type":"GENE","name":"LINC00163","canonical_id":"hgnc:HGNC:33165","description":"long independently transcribed non-coding RNA 163","metadata":{"aliases":["NLC1-A","NLC1A","C21orf134","NCRNA00163"]}},{"id":"ddec68ac42194093b7cb7f67e5062a00","type":"GENE","name":"LINC00165","canonical_id":"hgnc:HGNC:33166","description":"long independently transcribed non-coding RNA 165","metadata":{"aliases":["NLC1-B","AP001505.9","C21orf135","NCRNA00165"]}},{"id":"ce60bdb7dd2b475083276c3f3bcb9ced","type":"GENE","name":"LINC00173","canonical_id":"hgnc:HGNC:33791","description":"long independently transcribed non-coding RNA 173","metadata":{"aliases":["FLJ42957","NCRNA00173"]}},{"id":"eee748443bff4d9882ee37dc5dec2354","type":"GENE","name":"LINC00174","canonical_id":"hgnc:HGNC:27788","description":"long independently transcribed non-coding RNA 174","metadata":{"aliases":["NCRNA00174"]}},{"id":"8c682e0791c546cfa3a8c3542c532196","type":"GENE","name":"LINC00184","canonical_id":"hgnc:HGNC:37192","description":"long independently transcribed non-coding RNA 184","metadata":{"aliases":["HANC","lnc-beta-Catm","NCRNA00184"]}},{"id":"8375a5d12f2e4536893a226120a08ad6","type":"GENE","name":"LINC00189","canonical_id":"hgnc:HGNC:18461","description":"long independently transcribed non-coding RNA 189","metadata":{"aliases":["C21orf109","NCRNA00189"]}},{"id":"2d9f827b92484491bfb060fd91163591","type":"GENE","name":"LINC00200","canonical_id":"hgnc:HGNC:30974","description":"long independently transcribed non-coding RNA 200","metadata":{"aliases":["FLJ40354","C10orf139","NCRNA00200"]}},{"id":"a496c2c9b193439d9e568c24057b6049","type":"GENE","name":"LINC00205","canonical_id":"hgnc:HGNC:16420","description":"long independently transcribed non-coding RNA 205","metadata":{"aliases":["LVBU","NCRNA00205"]}},{"id":"d1326af45b0b49daa9891d9f45ce2f2a","type":"GENE","name":"LINC00207","canonical_id":"hgnc:HGNC:37255","description":"long independently transcribed non-coding RNA 207","metadata":{"aliases":["NCRNA00207"]}},{"id":"e50bd2ce391e47cfa252f9ec55565738","type":"GENE","name":"LINC00208","canonical_id":"hgnc:HGNC:15535","description":"long independently transcribed non-coding RNA 208","metadata":{"aliases":["C8orf14","NCRNA00208"]}},{"id":"ba362fa8db5e4ef5a5f59106a79bb3ec","type":"GENE","name":"LINC00210","canonical_id":"hgnc:HGNC:37458","description":"long independently transcribed non-coding RNA 210","metadata":{"aliases":["RP11-72L13.1","NCRNA00210"]}},{"id":"77315346453c4400a152d0eb249bbee8","type":"GENE","name":"LINC00216","canonical_id":"hgnc:HGNC:20191","description":"long independently transcribed non-coding RNA 216","metadata":{"aliases":["PRO1617","C14orf107","NCRNA00216"]}},{"id":"1d1291531fc842429b10d74a254bc634","type":"GENE","name":"LINC00221","canonical_id":"hgnc:HGNC:20169","description":"long independently transcribed non-coding RNA 221","metadata":{"aliases":["C14orf98","NCRNA00221"]}},{"id":"932bfab0d6f9476fb7e565d0acffa200","type":"GENE","name":"LINC00222","canonical_id":"hgnc:HGNC:21560","description":"long independently transcribed non-coding RNA 222","metadata":{"aliases":["dJ354J5.2","C6orf181","NCRNA00222"]}},{"id":"4862fd8951cd4baab2184b9b2b8c2948","type":"GENE","name":"LINC00226","canonical_id":"hgnc:HGNC:20168","description":"long independently transcribed non-coding RNA 226","metadata":{"aliases":["C14orf97","NCRNA00226"]}},{"id":"2846bc87655846ffa40104477ad5f7ef","type":"GENE","name":"LINC00229","canonical_id":"hgnc:HGNC:13240","description":"long independently transcribed non-coding RNA 229","metadata":{"aliases":["dJ474I12.C22.2","C22orf10","NCRNA00229"]}},{"id":"ec88d9d53303464ea96966043aae9312","type":"GENE","name":"LINC00235","canonical_id":"hgnc:HGNC:14138","description":"long independently transcribed non-coding RNA 235","metadata":{"aliases":["C16orf10","NCRNA00235"]}},{"id":"a2523eeab6af4143a9c7eebd0eeebf2d","type":"GENE","name":"LINC00237","canonical_id":"hgnc:HGNC:38166","description":"long independently transcribed non-coding RNA 237","metadata":{"aliases":["NCRNA00237"]}},{"id":"d2ec6c69cb594292ad78eceebe34cccd","type":"GENE","name":"LINC00239","canonical_id":"hgnc:HGNC:20119","description":"long independently transcribed non-coding RNA 239","metadata":{"aliases":["C14orf72","NCRNA00239"]}},{"id":"bed5928c7b7f4ab8b5501ffba06bb2e0","type":"GENE","name":"LINC00240","canonical_id":"hgnc:HGNC:18772","description":"long independently transcribed non-coding RNA 240","metadata":{"aliases":["bA373D17.1","C6orf41","NCRNA00240"]}},{"id":"50be1f30dec84f51b6ee261f08075050","type":"GENE","name":"LINC00242","canonical_id":"hgnc:HGNC:21249","description":"long independently transcribed non-coding RNA 242","metadata":{"aliases":["FLJ31451","dJ266L20.5","C6orf122","NCRNA00242"]}},{"id":"4e4007e45fe94c00bb932a9d01085034","type":"GENE","name":"LINC00243","canonical_id":"hgnc:HGNC:30956","description":"long independently transcribed non-coding RNA 243","metadata":{"aliases":["bQB230F21.2","FLJ40693","bQB10J12.2","C6orf214","NCRNA00243"]}},{"id":"d2e004f4d65b4a499b75cf2a217b5f5b","type":"GENE","name":"LINC00244","canonical_id":"hgnc:HGNC:13245","description":"long independently transcribed non-coding RNA 244","metadata":{"aliases":["C7orf4","NCRNA00244"]}},{"id":"ed2b3547e4b941b2a1edfa072ac8ad50","type":"GENE","name":"LINC00251","canonical_id":"hgnc:HGNC:31950","description":"long independently transcribed non-coding RNA 251","metadata":{"aliases":["C8orf25","NCRNA00251"]}},{"id":"0aa6525960604a92be74ecdfa649071c","type":"GENE","name":"LINC00254","canonical_id":"hgnc:HGNC:14160","description":"long independently transcribed non-coding RNA 254","metadata":{"aliases":["C16orf32","NCRNA00254"]}},{"id":"6fd1bd53075a499a9e3c3003c89d5350","type":"GENE","name":"LINC00260","canonical_id":"hgnc:HGNC:28770","description":"long independently transcribed non-coding RNA 260","metadata":{"aliases":["MGC5457","C1orf217","NCRNA00260"]}},{"id":"a51f7b1db7bc4cb4937f98f8df78b809","type":"GENE","name":"LINC00261","canonical_id":"hgnc:HGNC:16189","description":"long independently transcribed non-coding RNA 261","metadata":{"aliases":["bA216C10.1","HCCDR1","TCONS_00027846","ALIEN","DEANR1","onco-lncRNA-17","FALCOR","LCAL62","C20orf56","NCRNA00261"]}},{"id":"9e085e2e15134318b2f007d8bf88ee42","type":"GENE","name":"LINC00265","canonical_id":"hgnc:HGNC:28019","description":"long independently transcribed non-coding RNA 265","metadata":{"aliases":["NCRNA00265-1","NCRNA00265"]}},{"id":"71d69e14af9b4c7ea15019330dfddfae","type":"GENE","name":"LINC00265-2P","canonical_id":"hgnc:HGNC:38523","description":"long independently transcribed non-coding RNA 265-2, pseudogene","metadata":{"aliases":["NCRNA00265B","NCRNA00265-2P"]}},{"id":"d9b02529a3a7423991dee25a3d352291","type":"GENE","name":"LINC00265-3P","canonical_id":"hgnc:HGNC:38536","description":"long independently transcribed non-coding RNA 265-3, pseudogene","metadata":{"aliases":["NCRNA00265C","NCRNA00265-3P"]}},{"id":"e80a1042f3044012937dd7c1db4a889d","type":"GENE","name":"LINC00268-2P","canonical_id":"hgnc:HGNC:37771","description":"long independently transcribed non-coding RNA 268-2, pseudogene","metadata":{"aliases":["NCRNA00268B","NCRNA00268-2P"]}},{"id":"eeef486e97474be49997773739a44d24","type":"GENE","name":"LINC00269","canonical_id":"hgnc:HGNC:26586","description":"long independently transcribed non-coding RNA 269","metadata":{"aliases":["FLJ33610","CXorf62","NCRNA00269"]}},{"id":"24d876b3879b405da843eb8c4b39f8a2","type":"GENE","name":"LINC00272","canonical_id":"hgnc:HGNC:26898","description":"long independently transcribed non-coding RNA 272","metadata":{"aliases":["RP1-223H12.3","C1orf120","NCRNA00272"]}},{"id":"9663d375cbfa434d9b986e6c072417a6","type":"GENE","name":"LINC00273","canonical_id":"hgnc:HGNC:38595","description":"long independently transcribed non-coding RNA 273","metadata":{"aliases":["TOP","NCRNA00273-1","NCRNA00273"]}},{"id":"4a7104c014fd4bcfa68cc8d1bc6af7bc","type":"GENE","name":"LINC00276","canonical_id":"hgnc:HGNC:38663","description":"long independently transcribed non-coding RNA 276","metadata":{"aliases":["NCRNA00276"]}},{"id":"c75a1cfa0d9f47c0ae07021c9789e2d3","type":"GENE","name":"LINC00278","canonical_id":"hgnc:HGNC:38712","description":"long independently transcribed non-coding RNA 278","metadata":{"aliases":["YY1BM","NCRNA00278"]}},{"id":"a9ab13dd837345849a376a5f23cf9d92","type":"GENE","name":"LINC00279","canonical_id":"hgnc:HGNC:38724","description":"long independently transcribed non-coding RNA 279","metadata":{"aliases":["NCRNA00279"]}},{"id":"968de71dee674d4fb3da941d1134ae58","type":"GENE","name":"LINC00280","canonical_id":"hgnc:HGNC:38803","description":"long independently transcribed non-coding RNA 280","metadata":{"aliases":["NCRNA00280"]}},{"id":"9a1fbf8a3ff64566882075ff6894dbc1","type":"GENE","name":"LINC00290","canonical_id":"hgnc:HGNC:38515","description":"long independently transcribed non-coding RNA 290","metadata":{"aliases":["NCRNA00290"]}},{"id":"e500558857b041659e7742e9ae0529eb","type":"GENE","name":"LINC00293","canonical_id":"hgnc:HGNC:39078","description":"long independently transcribed non-coding RNA 293","metadata":{"aliases":["BEYLA","NCRNA00293"]}},{"id":"46d3e0609c7e4a29b3343ab566012662","type":"GENE","name":"LINC00294","canonical_id":"hgnc:HGNC:27456","description":"long independently transcribed non-coding RNA 294","metadata":{"aliases":["NCRNA00294"]}},{"id":"de6dc5a8dba844869575dd02534887ac","type":"GENE","name":"LINC00297","canonical_id":"hgnc:HGNC:39210","description":"long independently transcribed non-coding RNA 297","metadata":{"aliases":["NCRNA00297"]}},{"id":"3f8f59511aa844da8285e3a030546306","type":"GENE","name":"LINC00299","canonical_id":"hgnc:HGNC:27940","description":"long independently transcribed non-coding RNA 299","metadata":{"aliases":["FLJ45673","C2orf46","LINC00298","LINC01814","NCRNA00299"]}},{"id":"45608604aade4ad399b8519fb884153f","type":"GENE","name":"LINC00301","canonical_id":"hgnc:HGNC:28603","description":"long independently transcribed non-coding RNA 301","metadata":{"aliases":["MGC39681","C11orf64","NCRNA00301"]}},{"id":"72f83fbfed7844f18f99afceee0ca1fd","type":"GENE","name":"LINC00303","canonical_id":"hgnc:HGNC:26865","description":"long independently transcribed non-coding RNA 303","metadata":{"aliases":["FLJ40343","C1orf157","NCRNA00303"]}},{"id":"9c4f9b31f72b45d19c06cd60df6f8720","type":"GENE","name":"LINC00304","canonical_id":"hgnc:HGNC:26713","description":"long independently transcribed non-coding RNA 304","metadata":{"aliases":["FLJ36701","C16orf81","NCRNA00304"]}},{"id":"80cafbc709234626ad3fc77501417c2a","type":"GENE","name":"LINC00305","canonical_id":"hgnc:HGNC:28597","description":"long independently transcribed non-coding RNA 305","metadata":{"aliases":["MGC39571","HsT1235","C18orf20","NCRNA00305"]}},{"id":"625aa2f09ccb43a995526f154e21f309","type":"GENE","name":"LINC00307","canonical_id":"hgnc:HGNC:16727","description":"long independently transcribed non-coding RNA 307","metadata":{"aliases":["D21S2091E","NCRNA00307"]}},{"id":"3aeaccdffa4e48898c5de56b1629e142","type":"GENE","name":"LINC00308","canonical_id":"hgnc:HGNC:16023","description":"long independently transcribed non-coding RNA 308","metadata":{"aliases":["PRED16","C21orf74","NCRNA00308"]}},{"id":"4d5ea5fd0b9d427da1d6fbcc9331789e","type":"GENE","name":"LINC00309","canonical_id":"hgnc:HGNC:25279","description":"long independently transcribed non-coding RNA 309","metadata":{"aliases":["NCRNA00309"]}},{"id":"3c84c54017314e55a18a461f5e62765b","type":"GENE","name":"LINC00310","canonical_id":"hgnc:HGNC:16414","description":"long independently transcribed non-coding RNA 310","metadata":{"aliases":["C21orf82","NCRNA00310"]}},{"id":"6c5699deab754ac8a7dbde9624d47116","type":"GENE","name":"LINC00311","canonical_id":"hgnc:HGNC:28312","description":"long independently transcribed non-coding RNA 311","metadata":{"aliases":["MGC22001","TMEM148","NCRNA00311"]}},{"id":"8b4ab3d8a49e4b11a84fbd3d13793881","type":"GENE","name":"LINC00312","canonical_id":"hgnc:HGNC:6662","description":"long independently transcribed non-coding RNA 312","metadata":{"aliases":["NAG7","NAG-7","ERR10","ERR-10","LMCD1DN","LOH3CR2A","NCRNA00312"]}},{"id":"5d68a24257d94715b7f53d9c3cf0a7f4","type":"GENE","name":"LINC00313","canonical_id":"hgnc:HGNC:16416","description":"long independently transcribed non-coding RNA 313","metadata":{"aliases":["C21orf84","NCRNA00313"]}},{"id":"189243149624482f95e73626189d17ab","type":"GENE","name":"LINC00314","canonical_id":"hgnc:HGNC:16622","description":"long independently transcribed non-coding RNA 314","metadata":{"aliases":["C21orf94","NCRNA00314"]}},{"id":"49b7de4db92d4eac8081db60ae6965e2","type":"GENE","name":"LINC00315","canonical_id":"hgnc:HGNC:16621","description":"long independently transcribed non-coding RNA 315","metadata":{"aliases":["C21orf93","NCRNA00315"]}},{"id":"b6ce7f1748c349b48df9d5c81c8a3f76","type":"GENE","name":"LINC00316","canonical_id":"hgnc:HGNC:19723","description":"long independently transcribed non-coding RNA 316","metadata":{"aliases":["PRED59","C21orf111","NCRNA00316"]}},{"id":"fdb4d68759b8405fb7c40e6d3026b7e2","type":"GENE","name":"LINC00317","canonical_id":"hgnc:HGNC:23126","description":"long independently transcribed non-coding RNA 317","metadata":{"aliases":["PRED89","C21orf117","NCRNA00317"]}},{"id":"dcb61962a3424b3c90a3297f19d8cf9e","type":"GENE","name":"LINC00319","canonical_id":"hgnc:HGNC:19730","description":"long independently transcribed non-coding RNA 319","metadata":{"aliases":["PRED49","FLJ38036","C21orf125","NCRNA00319"]}},{"id":"76d29f4f132f42c09346eac176bac857","type":"GENE","name":"LINC00320","canonical_id":"hgnc:HGNC:19690","description":"long independently transcribed non-coding RNA 320","metadata":{"aliases":["PRED14","FLJ37539","C21orf131","NCRNA00320"]}},{"id":"36418d542ca742f79e7b6a30f354a1c8","type":"GENE","name":"LINC00322","canonical_id":"hgnc:HGNC:33698","description":"long independently transcribed non-coding RNA 322","metadata":{"aliases":["FLJ16545","C21orf136","NCRNA00322"]}},{"id":"3b0a5bea1f2f4b7ca33f05a236d879de","type":"GENE","name":"LINC00323","canonical_id":"hgnc:HGNC:19720","description":"long independently transcribed non-coding RNA 323","metadata":{"aliases":["PRED42","FLJ37173","C21orf130","NCRNA00323"]}},{"id":"f5f2fea2f6494fa3a3c2ba8eea6e2c9a","type":"GENE","name":"LINC00324","canonical_id":"hgnc:HGNC:26628","description":"long independently transcribed non-coding RNA 324","metadata":{"aliases":["FLJ34790","MGC104931","TP53LC03","RNA00324","C17orf44","NCRNA00324"]}},{"id":"8d7d1e18d30e4fb3b50f509b112ec117","type":"GENE","name":"LINC00326","canonical_id":"hgnc:HGNC:41926","description":"long independently transcribed non-coding RNA 326","metadata":{"aliases":["NCRNA00326"]}},{"id":"f4efdb61e6464f9fa72e3a89aa380422","type":"GENE","name":"LINC00327","canonical_id":"hgnc:HGNC:42009","description":"long independently transcribed non-coding RNA 327","metadata":{"aliases":["NCRNA00327"]}},{"id":"ee67d835a9ad4ab492e8e12951ffbd18","type":"GENE","name":"LINC00328","canonical_id":"hgnc:HGNC:42028","description":"long independently transcribed non-coding RNA 328","metadata":{"aliases":["NCRNA00328-1","NCRNA00328A","NCRNA00328"]}},{"id":"a28428447e564d328589a5c060bc32b0","type":"GENE","name":"LINC00328-2P","canonical_id":"hgnc:HGNC:42027","description":"long independently transcribed non-coding RNA 328-2, pseudogene","metadata":{"aliases":["NCRNA00328B","NCRNA00328-2P"]}},{"id":"81ca390875c14227a5bed19d4fd1a1a3","type":"GENE","name":"LINC00330","canonical_id":"hgnc:HGNC:42047","description":"long independently transcribed non-coding RNA 330","metadata":{"aliases":["NCRNA00330"]}},{"id":"333c03ccdb0a473b8bb8be64e6a18006","type":"GENE","name":"LINC00331","canonical_id":"hgnc:HGNC:42048","description":"long independently transcribed non-coding RNA 331","metadata":{"aliases":["NCRNA00331"]}},{"id":"773a8633d233469fb39ef4826f78db9a","type":"GENE","name":"LINC00332","canonical_id":"hgnc:HGNC:42049","description":"long independently transcribed non-coding RNA 332","metadata":{"aliases":["NCRNA00332"]}},{"id":"787d9f37aa6648c8b3a7b1d266bd8bf1","type":"GENE","name":"LINC00333","canonical_id":"hgnc:HGNC:42050","description":"long independently transcribed non-coding RNA 333","metadata":{"aliases":["NCRNA00333"]}},{"id":"77d308526dbd4744ad46b402ec8ea7dd","type":"GENE","name":"LINC00334","canonical_id":"hgnc:HGNC:16425","description":"long independently transcribed non-coding RNA 334","metadata":{"aliases":["C21orf89","NCRNA00334"]}},{"id":"ad8bf87d2e1d4ec2b06e41fe670fe0ab","type":"GENE","name":"LINC00336","canonical_id":"hgnc:HGNC:33813","description":"long independently transcribed non-coding RNA 336","metadata":{"aliases":["FLJ43752","C6orf227","NCRNA00336"]}},{"id":"7d28941d4b424494beea3374b5d2a857","type":"GENE","name":"LINC00339","canonical_id":"hgnc:HGNC:25011","description":"long independently transcribed non-coding RNA 339","metadata":{"aliases":["HSPC157","NCRNA00339"]}},{"id":"5daba05bd0ab4bea85df71e825e464f3","type":"GENE","name":"LINC00342","canonical_id":"hgnc:HGNC:42470","description":"long independently transcribed non-coding RNA 342","metadata":{"aliases":["NCRNA00342"]}},{"id":"fffdbc173bc24d25b286dbac6a2bf5dc","type":"GENE","name":"LINC00343","canonical_id":"hgnc:HGNC:42500","description":"long independently transcribed non-coding RNA 343","metadata":{"aliases":["NCRNA00343","LINC00344","NCRNA00344"]}},{"id":"69116d45d97c4578aab6e1ce98d9267e","type":"GENE","name":"LINC00345","canonical_id":"hgnc:HGNC:42503","description":"long independently transcribed non-coding RNA 345","metadata":null},{"id":"d7da11cfae6240149f0b60ca833ecc71","type":"GENE","name":"LINC00347","canonical_id":"hgnc:HGNC:27890","description":"long independently transcribed non-coding RNA 347","metadata":null},{"id":"6549a900a6294277bed0915050e7f290","type":"GENE","name":"LINC00348","canonical_id":"hgnc:HGNC:42658","description":"long independently transcribed non-coding RNA 348","metadata":null},{"id":"6e23676e135540cb90a360f0815ad325","type":"GENE","name":"LINC00349","canonical_id":"hgnc:HGNC:42667","description":"long independently transcribed non-coding RNA 349","metadata":null},{"id":"54abcce9e95e4339a9d0808b05876d2b","type":"GENE","name":"LINC00351","canonical_id":"hgnc:HGNC:42669","description":"long independently transcribed non-coding RNA 351","metadata":null},{"id":"fa5e4294d53e4668b127a8cdd9a75a22","type":"GENE","name":"LINC00352","canonical_id":"hgnc:HGNC:42670","description":"long independently transcribed non-coding RNA 352","metadata":null},{"id":"5631aaaa699a4b9898fbd0abf9979d81","type":"GENE","name":"LINC00353","canonical_id":"hgnc:HGNC:42671","description":"long independently transcribed non-coding RNA 353","metadata":null},{"id":"c30d37ee0bba47779c1a9e90eee09323","type":"GENE","name":"LINC00354","canonical_id":"hgnc:HGNC:42672","description":"long independently transcribed non-coding RNA 354","metadata":null},{"id":"4cf8fd3ff4f940a7adf8717af1de4d22","type":"GENE","name":"LINC00355","canonical_id":"hgnc:HGNC:27061","description":"long independently transcribed non-coding RNA 355","metadata":null},{"id":"7309b5345756412a8d35ee66a35e9d0b","type":"GENE","name":"LINC00358","canonical_id":"hgnc:HGNC:42678","description":"long independently transcribed non-coding RNA 358","metadata":null},{"id":"d21a3a6da2014d28970b985bed9fbb62","type":"GENE","name":"LINC00359","canonical_id":"hgnc:HGNC:42679","description":"long independently transcribed non-coding RNA 359","metadata":null},{"id":"f85816cb15444cc5800ba3e860c4a2c1","type":"GENE","name":"LINC00362","canonical_id":"hgnc:HGNC:42682","description":"long independently transcribed non-coding RNA 362","metadata":null},{"id":"0c00d32237ba4d4b97d02bace3b498c4","type":"GENE","name":"LINC00363","canonical_id":"hgnc:HGNC:42684","description":"long independently transcribed non-coding RNA 363","metadata":{"aliases":["TCONS_00021586"]}},{"id":"542bf6a5d2744e0bb0fd661b185b1f20","type":"GENE","name":"LINC00364","canonical_id":"hgnc:HGNC:42686","description":"long independently transcribed non-coding RNA 364","metadata":{"aliases":["LncRNA00364"]}},{"id":"f8dbd796c493431e9ade0e4656fccc59","type":"GENE","name":"LINC00365","canonical_id":"hgnc:HGNC:42687","description":"long independently transcribed non-coding RNA 365","metadata":null},{"id":"ea37094f4d854eb6a64c73ccae1f81ee","type":"GENE","name":"LINC00366","canonical_id":"hgnc:HGNC:42688","description":"long independently transcribed non-coding RNA 366","metadata":null},{"id":"046b0b494a7b4f8fa203888c77396b3b","type":"GENE","name":"LINC00367","canonical_id":"hgnc:HGNC:42689","description":"long independently transcribed non-coding RNA 367","metadata":{"aliases":["TCONS_l2_00007488"]}},{"id":"0f4fb643acb14808ada2a9f96bb19f1d","type":"GENE","name":"LINC00368","canonical_id":"hgnc:HGNC:42690","description":"long independently transcribed non-coding RNA 368","metadata":null},{"id":"45f769799bda4f279e43b65538b9d790","type":"GENE","name":"LINC00370","canonical_id":"hgnc:HGNC:42692","description":"long independently transcribed non-coding RNA 370","metadata":{"aliases":["AL161431.1","RP11-54H7.4","LINC03061"]}},{"id":"00c2588cf0cb4b11b8c0e051cc4bec15","type":"GENE","name":"LINC00373","canonical_id":"hgnc:HGNC:42695","description":"long independently transcribed non-coding RNA 373","metadata":null},{"id":"9d2705568b1d4905b12ac5c61a8ec549","type":"GENE","name":"LINC00374","canonical_id":"hgnc:HGNC:42698","description":"long independently transcribed non-coding RNA 374","metadata":null},{"id":"598af13a32d34df28beee43ab2817301","type":"GENE","name":"LINC00375","canonical_id":"hgnc:HGNC:42699","description":"long independently transcribed non-coding RNA 375","metadata":null},{"id":"c6b8b0135936471b9753d937a897b4bf","type":"GENE","name":"LINC00376","canonical_id":"hgnc:HGNC:42701","description":"long independently transcribed non-coding RNA 376","metadata":{"aliases":["RP11-527N12.1"]}},{"id":"1266ab455f6f4118ae21864c64793a78","type":"GENE","name":"LINC00377","canonical_id":"hgnc:HGNC:42703","description":"long independently transcribed non-coding RNA 377","metadata":{"aliases":["TCONS_00021861"]}},{"id":"e9d27758d7d948fa9773d9d90ca3dcf6","type":"GENE","name":"LINC00378","canonical_id":"hgnc:HGNC:42704","description":"long independently transcribed non-coding RNA 378","metadata":null},{"id":"eae4d75ab627445f836b800e1f9bc59c","type":"GENE","name":"LINC00379","canonical_id":"hgnc:HGNC:42705","description":"long independently transcribed non-coding RNA 379","metadata":null},{"id":"29bc874374434c4a88bbf715e3621f85","type":"GENE","name":"LINC00380","canonical_id":"hgnc:HGNC:42706","description":"long independently transcribed non-coding RNA 380","metadata":{"aliases":["TCONS_00021685"]}},{"id":"742b82d36a254f7bbf71da7a53a3179e","type":"GENE","name":"LINC00382","canonical_id":"hgnc:HGNC:42709","description":"long independently transcribed non-coding RNA 382","metadata":{"aliases":["TCONS_00021500"]}},{"id":"e4d5fd15c9ce4f22b91a0be2a75d78eb","type":"GENE","name":"LINC00383","canonical_id":"hgnc:HGNC:42710","description":"long independently transcribed non-coding RNA 383","metadata":{"aliases":["LINC00401"]}},{"id":"995fa8cf3ede433599fd31a2db2a3784","type":"GENE","name":"LINC00384","canonical_id":"hgnc:HGNC:42711","description":"long independently transcribed non-coding RNA 384","metadata":null},{"id":"1ae52f5331394b8fbe3074dd92ce86af","type":"GENE","name":"LINC00385","canonical_id":"hgnc:HGNC:42713","description":"long independently transcribed non-coding RNA 385","metadata":null},{"id":"9d1d5edf517e4ff4b4645025437602d0","type":"GENE","name":"LINC00387","canonical_id":"hgnc:HGNC:42715","description":"long independently transcribed non-coding RNA 387","metadata":null},{"id":"91eb0d8db90c4b68ab3f38827cc9c361","type":"GENE","name":"LINC00388","canonical_id":"hgnc:HGNC:42716","description":"long independently transcribed non-coding RNA 388","metadata":null},{"id":"314cf1970acc4670b65bbca395d4fdc9","type":"GENE","name":"LINC00390","canonical_id":"hgnc:HGNC:42718","description":"long independently transcribed non-coding RNA 390","metadata":{"aliases":["TCONS_00021641"]}},{"id":"ab5d398ff02744768244150c9190d30a","type":"GENE","name":"LINC00391","canonical_id":"hgnc:HGNC:42719","description":"long independently transcribed non-coding RNA 391","metadata":null},{"id":"a79ef495ec18464ea92459f38701eaaa","type":"GENE","name":"LINC00392","canonical_id":"hgnc:HGNC:42720","description":"long independently transcribed non-coding RNA 392","metadata":null},{"id":"885dd15b41f24e548b3004019ff87dba","type":"GENE","name":"LINC00393","canonical_id":"hgnc:HGNC:42721","description":"long independently transcribed non-coding RNA 393","metadata":null},{"id":"76a9f1a7403a4264ab6d4f85e3ad2adb","type":"GENE","name":"LINC00395","canonical_id":"hgnc:HGNC:42723","description":"long independently transcribed non-coding RNA 395","metadata":null},{"id":"59b46e0eb24a40ef8ee48e6932d0ecfc","type":"GENE","name":"LINC00396","canonical_id":"hgnc:HGNC:42724","description":"long independently transcribed non-coding RNA 396","metadata":null},{"id":"5674808c9cef42cfbb79214809e89e03","type":"GENE","name":"LINC00397","canonical_id":"hgnc:HGNC:42725","description":"long independently transcribed non-coding RNA 397","metadata":{"aliases":["TCONS_00021582"]}},{"id":"2de2866d233a4d0ab3b2539830adb710","type":"GENE","name":"LINC00398","canonical_id":"hgnc:HGNC:42727","description":"long independently transcribed non-coding RNA 398","metadata":{"aliases":["LINC00545"]}},{"id":"2119b10664974d12bd7576a95852f56c","type":"GENE","name":"LINC00399","canonical_id":"hgnc:HGNC:42728","description":"long independently transcribed non-coding RNA 399","metadata":{"aliases":["TCONS_00021596"]}},{"id":"4224072d0b144e14b70238bfef90581d","type":"GENE","name":"LINC00400","canonical_id":"hgnc:HGNC:42729","description":"long independently transcribed non-coding RNA 400","metadata":null},{"id":"cbb11f1d19a84a889fec4ff1ef392838","type":"GENE","name":"LINC00402","canonical_id":"hgnc:HGNC:42732","description":"long independently transcribed non-coding RNA 402","metadata":{"aliases":["LINC00381"]}},{"id":"ce66e308a94a419ca0a672bf7e662eb4","type":"GENE","name":"LINC00404","canonical_id":"hgnc:HGNC:42734","description":"long independently transcribed non-coding RNA 404","metadata":null},{"id":"9c5bbd3a3a804de4bbf2c63fb4304aba","type":"GENE","name":"LINC00408","canonical_id":"hgnc:HGNC:42740","description":"long independently transcribed non-coding RNA 408","metadata":null},{"id":"1a0cba4010884a4ca41ace2f1799632c","type":"GENE","name":"LINC00410","canonical_id":"hgnc:HGNC:42742","description":"long independently transcribed non-coding RNA 410","metadata":null},{"id":"f01592a65ec84d3abcc93d05ebb5a7d8","type":"GENE","name":"LINC00411","canonical_id":"hgnc:HGNC:42744","description":"long independently transcribed non-coding RNA 411","metadata":null},{"id":"4e96dfebc29c455189e8db032705f403","type":"GENE","name":"LINC00412","canonical_id":"hgnc:HGNC:42745","description":"long independently transcribed non-coding RNA 412","metadata":{"aliases":["LINC02340"]}},{"id":"39d2ee8fca794a618a176ac4a93fbb2d","type":"GENE","name":"LINC00415","canonical_id":"hgnc:HGNC:42748","description":"long independently transcribed non-coding RNA 415","metadata":null},{"id":"8c58303a114544cea9228330fed47c18","type":"GENE","name":"LINC00421","canonical_id":"hgnc:HGNC:42755","description":"long independently transcribed non-coding RNA 421","metadata":null},{"id":"9ce64744fefc4369a6320e9a6bdaf875","type":"GENE","name":"LINC00423","canonical_id":"hgnc:HGNC:42758","description":"long independently transcribed non-coding RNA 423","metadata":null},{"id":"3bec6a8f334e478f8d86859c6d148b0d","type":"GENE","name":"LINC00424","canonical_id":"hgnc:HGNC:42815","description":"long independently transcribed non-coding RNA 424","metadata":null},{"id":"1e7bc96ef60342e1b023d55ee4bb349b","type":"GENE","name":"LINC00426","canonical_id":"hgnc:HGNC:42761","description":"long independently transcribed non-coding RNA 426","metadata":null},{"id":"cb791c066fda40ccab6247f049090f2d","type":"GENE","name":"LINC00427","canonical_id":"hgnc:HGNC:42762","description":"long independently transcribed non-coding RNA 427","metadata":null},{"id":"c09dc29a580c4b75aef9bddb6e99ecf5","type":"GENE","name":"LINC00428","canonical_id":"hgnc:HGNC:42763","description":"long independently transcribed non-coding RNA 428","metadata":null},{"id":"05138c7cda3449a4941298bdb173e948","type":"GENE","name":"LINC00430","canonical_id":"hgnc:HGNC:42765","description":"long independently transcribed non-coding RNA 430","metadata":{"aliases":["TCONS_00021581"]}},{"id":"af57222298534b749ef13168320fbb29","type":"GENE","name":"LINC00431","canonical_id":"hgnc:HGNC:42766","description":"long independently transcribed non-coding RNA 431","metadata":null},{"id":"8c54b58625b84c23af27453bf2109df7","type":"GENE","name":"LINC00433","canonical_id":"hgnc:HGNC:42768","description":"long independently transcribed non-coding RNA 433","metadata":{"aliases":["LINC00560"]}},{"id":"5d373c8b1e9e4de69e48b8638a85109d","type":"GENE","name":"LINC00434","canonical_id":"hgnc:HGNC:42769","description":"long independently transcribed non-coding RNA 434","metadata":null},{"id":"f17fb6ee18794bd6ad4b1c7dd406cc8b","type":"GENE","name":"LINC00437","canonical_id":"hgnc:HGNC:42772","description":"long independently transcribed non-coding RNA 437","metadata":{"aliases":["TCONS_00021639"]}},{"id":"6b3ea76fea954fe29b4ac6f0572ade5b","type":"GENE","name":"LINC00440","canonical_id":"hgnc:HGNC:42777","description":"long independently transcribed non-coding RNA 440","metadata":null},{"id":"7624574c76dd48a28163387193cc56f3","type":"GENE","name":"LINC00442","canonical_id":"hgnc:HGNC:42779","description":"long independently transcribed non-coding RNA 442","metadata":null},{"id":"29f875fd46704bd6977851c7bb38d10b","type":"GENE","name":"LINC00445","canonical_id":"hgnc:HGNC:42782","description":"long independently transcribed non-coding RNA 445","metadata":null},{"id":"23bdab85733f42ebabf826898d696ad3","type":"GENE","name":"LINC00446","canonical_id":"hgnc:HGNC:42783","description":"long independently transcribed non-coding RNA 446","metadata":null},{"id":"d7ee35f1bd934481a43539637a58cb72","type":"GENE","name":"LINC00448","canonical_id":"hgnc:HGNC:42785","description":"long independently transcribed non-coding RNA 448","metadata":null},{"id":"c4dff43493aa41dc858294201544c5b3","type":"GENE","name":"LINC00452","canonical_id":"hgnc:HGNC:42800","description":"long independently transcribed non-coding RNA 452","metadata":{"aliases":["LINC00453"]}},{"id":"323a4d84e3c545fd8d738a508b70f9ab","type":"GENE","name":"LINC00454","canonical_id":"hgnc:HGNC:42802","description":"long independently transcribed non-coding RNA 454","metadata":null},{"id":"c043f60bd4c14b01a68369b10a498beb","type":"GENE","name":"LINC00456","canonical_id":"hgnc:HGNC:42804","description":"long independently transcribed non-coding RNA 456","metadata":null},{"id":"4e527bebcdb94c9d8d0f318a75ec16a5","type":"GENE","name":"LINC00457","canonical_id":"hgnc:HGNC:42805","description":"long independently transcribed non-coding RNA 457","metadata":null},{"id":"0724295fbced4ae89c5d868d9b04889b","type":"GENE","name":"LINC00458","canonical_id":"hgnc:HGNC:42807","description":"long independently transcribed non-coding RNA 458","metadata":{"aliases":["ES3","HBL1","LncRNA-ES3"]}},{"id":"5542b55120af49018cf1d82049482d40","type":"GENE","name":"LINC00459","canonical_id":"hgnc:HGNC:42808","description":"long independently transcribed non-coding RNA 459","metadata":null},{"id":"3b9fdbc7177b41e4b3e028ca1cb4840a","type":"GENE","name":"LINC00460","canonical_id":"hgnc:HGNC:42809","description":"long independently transcribed non-coding RNA 460","metadata":null},{"id":"1a2be10f2f4840338af1afe2b288a065","type":"GENE","name":"LINC00462","canonical_id":"hgnc:HGNC:42811","description":"long independently transcribed non-coding RNA 462","metadata":null},{"id":"66314fbe5d604ff6abc0c1e1b6080686","type":"GENE","name":"LINC00463","canonical_id":"hgnc:HGNC:42813","description":"long independently transcribed non-coding RNA 463","metadata":{"aliases":["TCONS_l2_00007499","AMER2-AS1"]}},{"id":"dbdf3e597e7f40fbb98155fdc3dfd06b","type":"GENE","name":"LINC00466","canonical_id":"hgnc:HGNC:27294","description":"long independently transcribed non-coding RNA 466","metadata":null},{"id":"69ad80034d8640ffbda1d8f8a651ab29","type":"GENE","name":"LINC00467","canonical_id":"hgnc:HGNC:28227","description":"long independently transcribed non-coding RNA 467","metadata":{"aliases":["MGC14801","ASAP","C1orf97"]}},{"id":"cf26180b608142eb801c61063745e71d","type":"GENE","name":"LINC00469","canonical_id":"hgnc:HGNC:26863","description":"long independently transcribed non-coding RNA 469","metadata":{"aliases":["FLJ40319","C17orf54"]}},{"id":"02b21707a9844112a58d6a41d9a63c27","type":"GENE","name":"LINC00470","canonical_id":"hgnc:HGNC:1225","description":"long independently transcribed non-coding RNA 470","metadata":{"aliases":["C18orf2"]}},{"id":"67fb103399314980b5230effac403530","type":"GENE","name":"LINC00471","canonical_id":"hgnc:HGNC:28668","description":"long independently transcribed non-coding RNA 471","metadata":{"aliases":["MGC43122","C2orf52"]}},{"id":"0566cc792351400aaa85bfce34abd516","type":"GENE","name":"LINC00472","canonical_id":"hgnc:HGNC:21380","description":"long independently transcribed non-coding RNA 472","metadata":{"aliases":["PEXF","P53RRA","FLJ13189","dJ288M22.3","C6orf155"]}},{"id":"0a561262cb9b4629a6ed12e9bf165757","type":"GENE","name":"LINC00473","canonical_id":"hgnc:HGNC:21160","description":"long independently transcribed non-coding RNA 473","metadata":{"aliases":["bA142J11.1","LNC473","C6orf176"]}},{"id":"8bf737fa13d045f0b0d07c0012b37e0e","type":"GENE","name":"LINC00474","canonical_id":"hgnc:HGNC:23367","description":"long independently transcribed non-coding RNA 474","metadata":{"aliases":["EST-YD1","C9orf27"]}},{"id":"87c2d4e62cb54574ba804b0e5013b0d3","type":"GENE","name":"LINC00475","canonical_id":"hgnc:HGNC:23569","description":"long independently transcribed non-coding RNA 475","metadata":{"aliases":["C9orf44"]}},{"id":"d75430d6ade847879bf247e9bc05c5b3","type":"GENE","name":"LINC00477","canonical_id":"hgnc:HGNC:26557","description":"long independently transcribed non-coding RNA 477","metadata":{"aliases":["FLJ32894","FAM191B","C12orf67"]}},{"id":"ebe77d6b13a645c79c69d259795be0c4","type":"GENE","name":"LINC00479","canonical_id":"hgnc:HGNC:19727","description":"long independently transcribed non-coding RNA 479","metadata":{"aliases":["PRED76","FLJ32835","C21orf129"]}},{"id":"d911e3b0b3694553a53d1efa8979daa1","type":"GENE","name":"LINC00482","canonical_id":"hgnc:HGNC:26816","description":"long independently transcribed non-coding RNA 482","metadata":{"aliases":["FLJ39421","C17orf55"]}},{"id":"c413f2b02a9e429cb90ae4c6b0d82fdd","type":"GENE","name":"LINC00484","canonical_id":"hgnc:HGNC:27862","description":"long independently transcribed non-coding RNA 484","metadata":{"aliases":["C9orf73"]}},{"id":"efa91c868f1241c3a54a1cb873e333b2","type":"GENE","name":"LINC00485","canonical_id":"hgnc:HGNC:27476","description":"long independently transcribed non-coding RNA 485","metadata":null},{"id":"3d9ae43224d0424d9cbca157934b82bf","type":"GENE","name":"LINC00486","canonical_id":"hgnc:HGNC:42946","description":"long independently transcribed non-coding RNA 486","metadata":null},{"id":"92be5d616f504ceeb8a8cb3d680654de","type":"GENE","name":"LINC00487","canonical_id":"hgnc:HGNC:42947","description":"long independently transcribed non-coding RNA 487","metadata":{"aliases":["FLJ42418"]}},{"id":"94b8f5d6173343e5b0e67389461a14f1","type":"GENE","name":"LINC00488","canonical_id":"hgnc:HGNC:32675","description":"long independently transcribed non-coding RNA 488","metadata":{"aliases":["FLJ41232","C3orf66"]}},{"id":"b1102ce1f6ce4d669ad0e6c181432a86","type":"GENE","name":"LINC00489","canonical_id":"hgnc:HGNC:43426","description":"long independently transcribed non-coding RNA 489","metadata":null},{"id":"577a06c38d6a47a8855e69ac71273eed","type":"GENE","name":"LINC00491","canonical_id":"hgnc:HGNC:43428","description":"long independently transcribed non-coding RNA 491","metadata":{"aliases":["BC008363"]}},{"id":"a23979fd0dcd4edf82148c5512f728b3","type":"GENE","name":"LINC00492","canonical_id":"hgnc:HGNC:43429","description":"long independently transcribed non-coding RNA 492","metadata":null},{"id":"b727266a77334507907615b9be6e303c","type":"GENE","name":"LINC00494","canonical_id":"hgnc:HGNC:27657","description":"long independently transcribed non-coding RNA 494","metadata":null},{"id":"355b7496ede2417e85ff9a89aec9e771","type":"GENE","name":"LINC00498","canonical_id":"hgnc:HGNC:43435","description":"long independently transcribed non-coding RNA 498","metadata":null},{"id":"0ba1663340ef4c44a3b728479e9b81e6","type":"GENE","name":"LINC00499","canonical_id":"hgnc:HGNC:43436","description":"long independently transcribed non-coding RNA 499","metadata":{"aliases":["LINC00500"]}},{"id":"773b9ca1b59a4e27b50ac0ae2e3ecefe","type":"GENE","name":"LINC00501","canonical_id":"hgnc:HGNC:43439","description":"long independently transcribed non-coding RNA 501","metadata":null},{"id":"917965f2e0a74f579dc402795e35210b","type":"GENE","name":"LINC00502","canonical_id":"hgnc:HGNC:43442","description":"long independently transcribed non-coding RNA 502","metadata":null},{"id":"a1fa699492654df697fbd76155afb858","type":"GENE","name":"LINC00504","canonical_id":"hgnc:HGNC:43555","description":"long independently transcribed non-coding RNA 504","metadata":null},{"id":"1a6448365e8548f6b38d00c725b149b8","type":"GENE","name":"LINC00506","canonical_id":"hgnc:HGNC:43557","description":"long independently transcribed non-coding RNA 506","metadata":null},{"id":"580d86c25c024f9f9a595971ff4d417e","type":"GENE","name":"LINC00507","canonical_id":"hgnc:HGNC:43558","description":"long independently transcribed non-coding RNA 507","metadata":null},{"id":"bfded31418ea4932844139931de14452","type":"GENE","name":"LINC00508","canonical_id":"hgnc:HGNC:43559","description":"long independently transcribed non-coding RNA 508","metadata":null},{"id":"cfe053a3a43a4eeda644b3e4231da064","type":"GENE","name":"LINC00511","canonical_id":"hgnc:HGNC:43564","description":"long independently transcribed non-coding RNA 511","metadata":{"aliases":["onco-lncRNA-12"]}},{"id":"5bf52cd5b3e142e4a9989b0e2b8c0ab8","type":"GENE","name":"LINC00513","canonical_id":"hgnc:HGNC:43566","description":"long independently transcribed non-coding RNA 513","metadata":{"aliases":["AC016831.7"]}},{"id":"e186f15f567142bfb4aa143571fafb97","type":"GENE","name":"LINC00515","canonical_id":"hgnc:HGNC:16019","description":"long independently transcribed non-coding RNA 515","metadata":{"aliases":["PRED21","C21orf71"]}},{"id":"52bba858c84c4e46a92384da7e2e2e31","type":"GENE","name":"LINC00517","canonical_id":"hgnc:HGNC:19831","description":"long independently transcribed non-coding RNA 517","metadata":{"aliases":["C14orf26"]}},{"id":"8d6e6ec8b2074cbda22999aa7a83d3c6","type":"GENE","name":"LINC00518","canonical_id":"hgnc:HGNC:28626","description":"long independently transcribed non-coding RNA 518","metadata":{"aliases":["MGC40222","LENOX","C6orf218"]}},{"id":"ca835773fd9f4afbaad4d4d3bfbcd734","type":"GENE","name":"LINC00519","canonical_id":"hgnc:HGNC:19838","description":"long independently transcribed non-coding RNA 519","metadata":{"aliases":["C14orf30"]}},{"id":"7582a39ba7ec4a3399be6cf0a9e899b3","type":"GENE","name":"LINC00520","canonical_id":"hgnc:HGNC:19843","description":"long independently transcribed non-coding RNA 520","metadata":{"aliases":["LENT","LASSIE","LEENE","LncRNA00520","C14orf34"]}},{"id":"dadb39ba00f14cd4900a265f5fba69d0","type":"GENE","name":"LINC00523","canonical_id":"hgnc:HGNC:20117","description":"long independently transcribed non-coding RNA 523","metadata":{"aliases":["C14orf70"]}},{"id":"5e5859e786b645a1ad0b4b408101108d","type":"GENE","name":"LINC00524","canonical_id":"hgnc:HGNC:20118","description":"long independently transcribed non-coding RNA 524","metadata":{"aliases":["C14orf71"]}},{"id":"d2d04f2994364d7ea2ef8fba495306c5","type":"GENE","name":"LINC00525","canonical_id":"hgnc:HGNC:40290","description":"long independently transcribed non-coding RNA 525","metadata":null},{"id":"bf734ef8e73c439fb9921443ac600ff4","type":"GENE","name":"LINC00526","canonical_id":"hgnc:HGNC:28278","description":"long independently transcribed non-coding RNA 526","metadata":{"aliases":["MGC17515","HsT959","TP53LC13","C18orf18"]}},{"id":"b500cbe3cf4d432f9c469492767b17a1","type":"GENE","name":"LINC00528","canonical_id":"hgnc:HGNC:26875","description":"long independently transcribed non-coding RNA 528","metadata":{"aliases":["ATHENA","FLJ40542","C22orf37"]}},{"id":"813847e331b34da2b11e118e0b07d47e","type":"GENE","name":"LINC00529","canonical_id":"hgnc:HGNC:15544","description":"long independently transcribed non-coding RNA 529","metadata":{"aliases":["C8orf8"]}},{"id":"8f28c069f901459d97b4b0914ff771ee","type":"GENE","name":"LINC00533","canonical_id":"hgnc:HGNC:18690","description":"long independently transcribed non-coding RNA 533","metadata":{"aliases":["bA373N24.1","C6orf39","C6orf38"]}},{"id":"2b77d3cbb24840f7810ec21d605e7dd8","type":"GENE","name":"LINC00534","canonical_id":"hgnc:HGNC:43643","description":"long independently transcribed non-coding RNA 534","metadata":null},{"id":"53530b8e75134586853d2bb4c61cff86","type":"GENE","name":"LINC00536","canonical_id":"hgnc:HGNC:43645","description":"long independently transcribed non-coding RNA 536","metadata":null},{"id":"5380ed40173c4d6aa0aef3e1dbfb3fbe","type":"GENE","name":"LINC00537","canonical_id":"hgnc:HGNC:43654","description":"long independently transcribed non-coding RNA 537","metadata":null},{"id":"902d40df9e7f4404a2fee855fa791492","type":"GENE","name":"LINC00538","canonical_id":"hgnc:HGNC:43655","description":"long independently transcribed non-coding RNA 538","metadata":{"aliases":["Yiya","PROX1UT"]}},{"id":"b55ef058533f43de91aef9d6214e347c","type":"GENE","name":"LINC00539","canonical_id":"hgnc:HGNC:43672","description":"long independently transcribed non-coding RNA 539","metadata":{"aliases":["LINC00422"]}},{"id":"c74507e858d54e798b45157e0e266ef7","type":"GENE","name":"LINC00540","canonical_id":"hgnc:HGNC:43673","description":"long independently transcribed non-coding RNA 540","metadata":null},{"id":"b74a1759f9074eb5a3864a330c8aa27d","type":"GENE","name":"LINC00543","canonical_id":"hgnc:HGNC:43678","description":"long independently transcribed non-coding RNA 543","metadata":null},{"id":"bfdc376c4a61447c9bd6d23ad19ae6ce","type":"GENE","name":"LINC00544","canonical_id":"hgnc:HGNC:43679","description":"long independently transcribed non-coding RNA 544","metadata":null},{"id":"4e50d381da3d42f78bcf77ba4d1cf0ec","type":"GENE","name":"LINC00547","canonical_id":"hgnc:HGNC:43682","description":"long independently transcribed non-coding RNA 547","metadata":{"aliases":["FLJ34747"]}},{"id":"083c4e87da774ed1821204b80ba17631","type":"GENE","name":"LINC00548","canonical_id":"hgnc:HGNC:43683","description":"long independently transcribed non-coding RNA 548","metadata":{"aliases":["FLJ42392"]}},{"id":"af2fbc6e194347d68c230b30ae5d0dce","type":"GENE","name":"LINC00550","canonical_id":"hgnc:HGNC:43688","description":"long independently transcribed non-coding RNA 550","metadata":null},{"id":"f87bc52d84f5493ab3b4ed739df2f813","type":"GENE","name":"LINC00552","canonical_id":"hgnc:HGNC:43692","description":"long independently transcribed non-coding RNA 552","metadata":null},{"id":"33b12d305eb942728a2613327afc138b","type":"GENE","name":"LINC00554","canonical_id":"hgnc:HGNC:43697","description":"long independently transcribed non-coding RNA 554","metadata":{"aliases":["lncZic2"]}},{"id":"cd08ee9cbdb94292951d81f82e86b3ea","type":"GENE","name":"LINC00555","canonical_id":"hgnc:HGNC:43699","description":"long independently transcribed non-coding RNA 555","metadata":null},{"id":"a342f1bcadc2444a99a2e1a13e70f77c","type":"GENE","name":"LINC00556","canonical_id":"hgnc:HGNC:43700","description":"long independently transcribed non-coding RNA 556","metadata":null},{"id":"1160301ee52c4a05ab78daf34f5ae604","type":"GENE","name":"LINC00557","canonical_id":"hgnc:HGNC:43701","description":"long independently transcribed non-coding RNA 557","metadata":null},{"id":"5a584402cf90493d9f37cce914be4443","type":"GENE","name":"LINC00558","canonical_id":"hgnc:HGNC:43702","description":"long independently transcribed non-coding RNA 558","metadata":null},{"id":"1288387b96ec4757b33710bd652740bc","type":"GENE","name":"LINC00559","canonical_id":"hgnc:HGNC:43703","description":"long independently transcribed non-coding RNA 559","metadata":null},{"id":"eb3b6c5aa6d048db97590a1569a990d5","type":"GENE","name":"LINC00561","canonical_id":"hgnc:HGNC:43705","description":"long independently transcribed non-coding RNA 561","metadata":null},{"id":"ab1c6d5d0e71426f86c05b263ae5cefc","type":"GENE","name":"LINC00562","canonical_id":"hgnc:HGNC:43706","description":"long independently transcribed non-coding RNA 562","metadata":null},{"id":"c216f2c7c81d4721b40c98fa495d5c6d","type":"GENE","name":"LINC00563","canonical_id":"hgnc:HGNC:43707","description":"long independently transcribed non-coding RNA 563","metadata":null},{"id":"4b5475167fb9467ab0576d97fca40e1f","type":"GENE","name":"LINC00564","canonical_id":"hgnc:HGNC:43708","description":"long independently transcribed non-coding RNA 564","metadata":null},{"id":"23f736d92da94a5ab7c4c362dbc8e1b5","type":"GENE","name":"LINC00566","canonical_id":"hgnc:HGNC:43710","description":"long independently transcribed non-coding RNA 566","metadata":null},{"id":"1b23ff09ac9a49ac90c589db2853ca1d","type":"GENE","name":"LINC00567","canonical_id":"hgnc:HGNC:43711","description":"long independently transcribed non-coding RNA 567","metadata":null},{"id":"799de80a5ab848c799f64e4a4b1c50f6","type":"GENE","name":"LINC00570","canonical_id":"hgnc:HGNC:43717","description":"long independently transcribed non-coding RNA 570","metadata":{"aliases":["ncRNA-a5"]}},{"id":"7bd249fbe9934b30b274e11e262e9b43","type":"GENE","name":"LINC00571","canonical_id":"hgnc:HGNC:43721","description":"long independently transcribed non-coding RNA 571","metadata":null},{"id":"dd2ecfae3a2542029843b61c6f4476c7","type":"GENE","name":"LINC00572","canonical_id":"hgnc:HGNC:43722","description":"long independently transcribed non-coding RNA 572","metadata":null},{"id":"28c23d9888f1495b8234d943f3aba653","type":"GENE","name":"LINC00574","canonical_id":"hgnc:HGNC:21598","description":"long independently transcribed non-coding RNA 574","metadata":{"aliases":["FLJ13162","dJ182D15.1","CRALA","C6orf208"]}},{"id":"82184130b2054198a3578249da465946","type":"GENE","name":"LINC00575","canonical_id":"hgnc:HGNC:21342","description":"long independently transcribed non-coding RNA 575","metadata":{"aliases":["C4orf11"]}},{"id":"10bf6c69b3cb4a3383ec2af167151e51","type":"GENE","name":"LINC00578","canonical_id":"hgnc:HGNC:43807","description":"long independently transcribed non-coding RNA 578","metadata":{"aliases":["AC026355.2"]}},{"id":"1b89793875cc46e0915a106d768d4264","type":"GENE","name":"LINC00581","canonical_id":"hgnc:HGNC:43840","description":"long independently transcribed non-coding RNA 581","metadata":null},{"id":"776f651aad134335b18c3d74e7aefe38","type":"GENE","name":"LINC00582","canonical_id":"hgnc:HGNC:43842","description":"long independently transcribed non-coding RNA 582","metadata":{"aliases":["SMILO"]}},{"id":"e298e89006084517b5ab508f1ebaff52","type":"GENE","name":"LINC00583","canonical_id":"hgnc:HGNC:31437","description":"long independently transcribed non-coding RNA 583","metadata":{"aliases":["uc.250","C9orf146"]}},{"id":"d6ba98da28ed4cf9bf99bc7c1427da32","type":"GENE","name":"LINC00587","canonical_id":"hgnc:HGNC:31372","description":"long independently transcribed non-coding RNA 587","metadata":{"aliases":["bA785H23.1","C9orf107"]}},{"id":"399a8c46d6d344e790e5710017a8b681","type":"GENE","name":"LINC00588","canonical_id":"hgnc:HGNC:24494","description":"long independently transcribed non-coding RNA 588","metadata":{"aliases":["DKFZP434F122","C8orf71"]}},{"id":"a7d7fad14b6047ec8787c69e74050695","type":"GENE","name":"LINC00589","canonical_id":"hgnc:HGNC:32299","description":"long independently transcribed non-coding RNA 589","metadata":{"aliases":["TSLNC8","C8orf75"]}},{"id":"9a0c0f1b791a46c89632e90d7d98f8c6","type":"GENE","name":"LINC00592","canonical_id":"hgnc:HGNC:27474","description":"long independently transcribed non-coding RNA 592","metadata":null},{"id":"b3877defb92846bd9c3fd931ca6c65a4","type":"GENE","name":"LINC00593","canonical_id":"hgnc:HGNC:32382","description":"long independently transcribed non-coding RNA 593","metadata":{"aliases":["MGC42951","C15orf50"]}},{"id":"8c44e935bda04b16957e9d31afa3cf80","type":"GENE","name":"LINC00595","canonical_id":"hgnc:HGNC:31430","description":"long independently transcribed non-coding RNA 595","metadata":{"aliases":["C10orf101"]}},{"id":"96bcf0e8e79a4d7a8487c4348980aec3","type":"GENE","name":"LINC00596","canonical_id":"hgnc:HGNC:23167","description":"long independently transcribed non-coding RNA 596","metadata":{"aliases":["CNSLT1I7G","C14orf165"]}},{"id":"d6b1ba415d88434b8fbfa6ec8925cdb1","type":"GENE","name":"LINC00597","canonical_id":"hgnc:HGNC:1193","description":"long independently transcribed non-coding RNA 597","metadata":{"aliases":["C15orf5"]}},{"id":"29c732c36b1c477b8ee1e78e2c1aa5ff","type":"GENE","name":"LINC00598","canonical_id":"hgnc:HGNC:42770","description":"long independently transcribed non-coding RNA 598","metadata":{"aliases":["TTL","lncFOXO1"]}},{"id":"76cdc68e769249ffb3566f8768bfbc45","type":"GENE","name":"LINC00601","canonical_id":"hgnc:HGNC:43916","description":"long independently transcribed non-coding RNA 601","metadata":null},{"id":"ef0ae6ebd4be4ced9db7199378ea4332","type":"GENE","name":"LINC00602","canonical_id":"hgnc:HGNC:43917","description":"long independently transcribed non-coding RNA 602","metadata":{"aliases":["LncRNA00602"]}},{"id":"d0fe0fe7618f4c05ae9d19ed64d30429","type":"GENE","name":"LINC00603","canonical_id":"hgnc:HGNC:43918","description":"long independently transcribed non-coding RNA 603","metadata":null},{"id":"37fde33bcba84b578c7d55b2a522133e","type":"GENE","name":"LINC00604","canonical_id":"hgnc:HGNC:43924","description":"long independently transcribed non-coding RNA 604","metadata":null},{"id":"a9c596fd60b246a6933805607cafc2e3","type":"GENE","name":"LINC00605","canonical_id":"hgnc:HGNC:43928","description":"long independently transcribed non-coding RNA 605","metadata":null},{"id":"d0b406400a3f4049aeb99eb9614318d5","type":"GENE","name":"LINC00606","canonical_id":"hgnc:HGNC:43931","description":"long independently transcribed non-coding RNA 606","metadata":null},{"id":"bddb0e93a8f34c1ebaa5d5cb05e18966","type":"GENE","name":"LINC00607","canonical_id":"hgnc:HGNC:43944","description":"long independently transcribed non-coding RNA 607","metadata":null},{"id":"d3ede9dc025346e9b7743be530ded76e","type":"GENE","name":"LINC00608","canonical_id":"hgnc:HGNC:27179","description":"long independently transcribed non-coding RNA 608","metadata":null},{"id":"b8381a6b8c26430283925309715a747f","type":"GENE","name":"LINC00609","canonical_id":"hgnc:HGNC:43960","description":"long independently transcribed non-coding RNA 609","metadata":{"aliases":["uc.373"]}},{"id":"a641587ab1cd4c10bd905662f24a87e0","type":"GENE","name":"LINC00612","canonical_id":"hgnc:HGNC:28621","description":"long independently transcribed non-coding RNA 612","metadata":{"aliases":["MGC40170","FLJ41814","C12orf33"]}},{"id":"609228daaa814c82a05c7b415fed8a46","type":"GENE","name":"LINC00613","canonical_id":"hgnc:HGNC:44060","description":"long independently transcribed non-coding RNA 613","metadata":null},{"id":"db67233842b849f1b864b602828fec9b","type":"GENE","name":"LINC00615","canonical_id":"hgnc:HGNC:26343","description":"long independently transcribed non-coding RNA 615","metadata":{"aliases":["FLJ25378","C12orf37"]}},{"id":"44f724794ae245aca8f8fd87d2d956ef","type":"GENE","name":"LINC00616","canonical_id":"hgnc:HGNC:44065","description":"long independently transcribed non-coding RNA 616","metadata":null},{"id":"046c98b281b14cc0837d319ce01488dd","type":"GENE","name":"LINC00618","canonical_id":"hgnc:HGNC:20110","description":"long independently transcribed non-coding RNA 618","metadata":{"aliases":["C14orf63"]}},{"id":"de974e37550e45228d25d9f1a0a758b0","type":"GENE","name":"LINC00619","canonical_id":"hgnc:HGNC:31657","description":"long independently transcribed non-coding RNA 619","metadata":{"aliases":["bA168P8.1","C10orf136"]}},{"id":"7687ceb277604b958b824c0c4efff940","type":"GENE","name":"LINC00620","canonical_id":"hgnc:HGNC:44223","description":"long independently transcribed non-coding RNA 620","metadata":null},{"id":"25228a7320c24edc9b8d4ad25ff4a68d","type":"GENE","name":"LINC00621","canonical_id":"hgnc:HGNC:44227","description":"long independently transcribed non-coding RNA 621","metadata":null},{"id":"b3f1b54a46cf448e83fc7225faada728","type":"GENE","name":"LINC00622","canonical_id":"hgnc:HGNC:44251","description":"long independently transcribed non-coding RNA 622","metadata":null},{"id":"8c8b80f6becc48cd8186e7c72d94b3ce","type":"GENE","name":"LINC00623","canonical_id":"hgnc:HGNC:44252","description":"long independently transcribed non-coding RNA 623","metadata":null},{"id":"6b30b99f4ea44c2c9515c5a6dd678a6a","type":"GENE","name":"LINC00624","canonical_id":"hgnc:HGNC:44254","description":"long independently transcribed non-coding RNA 624","metadata":null},{"id":"de64b716656f4d7bb06cae2901db7bbe","type":"GENE","name":"LINC00626","canonical_id":"hgnc:HGNC:44257","description":"long independently transcribed non-coding RNA 626","metadata":{"aliases":["LISS","MGC4473"]}},{"id":"eddf6627c6a0478baa874cd1e847b8a6","type":"GENE","name":"LINC00628","canonical_id":"hgnc:HGNC:27008","description":"long independently transcribed non-coding RNA 628","metadata":null},{"id":"3dc5eb33561d428d989b93357726f709","type":"GENE","name":"LINC00629","canonical_id":"hgnc:HGNC:44262","description":"long independently transcribed non-coding RNA 629","metadata":null},{"id":"efec7e92c0c446a399963f53a8f0a545","type":"GENE","name":"LINC00630","canonical_id":"hgnc:HGNC:44263","description":"long independently transcribed non-coding RNA 630","metadata":null},{"id":"df4508c58b53423398a6264c571ec2f7","type":"GENE","name":"LINC00632","canonical_id":"hgnc:HGNC:27865","description":"long independently transcribed non-coding RNA 632","metadata":{"aliases":["ASINC","ARST","CDR1NAT","ciRS-7","CDR1as","MDHDH","CDR1-AS"]}},{"id":"4d90d26fd0a74763bbcbe0f7f892ca0b","type":"GENE","name":"LINC00635","canonical_id":"hgnc:HGNC:27184","description":"long independently transcribed non-coding RNA 635","metadata":null},{"id":"0c660cf0e1544f7c9a3454f2e77a4a6e","type":"GENE","name":"LINC00636","canonical_id":"hgnc:HGNC:27702","description":"long independently transcribed non-coding RNA 636","metadata":null},{"id":"b9540868beb04e0c98c40c31eae914ec","type":"GENE","name":"LINC00639","canonical_id":"hgnc:HGNC:27502","description":"long independently transcribed non-coding RNA 639","metadata":null},{"id":"1d29cc916cb14768bde5b12764f53d1a","type":"GENE","name":"LINC00640","canonical_id":"hgnc:HGNC:44291","description":"long independently transcribed non-coding RNA 640","metadata":null},{"id":"8fff2b8fe48748aea683f9c92830624e","type":"GENE","name":"LINC00641","canonical_id":"hgnc:HGNC:27511","description":"long independently transcribed non-coding RNA 641","metadata":null},{"id":"c9399e307077470cbe99f0d965c7b24c","type":"GENE","name":"LINC00642","canonical_id":"hgnc:HGNC:44293","description":"long independently transcribed non-coding RNA 642","metadata":null},{"id":"76b810354993484c871c015c1be1d831","type":"GENE","name":"LINC00644","canonical_id":"hgnc:HGNC:44297","description":"long independently transcribed non-coding RNA 644","metadata":null},{"id":"034f4a86229b49c4b866332c75ad8cb1","type":"GENE","name":"LINC00645","canonical_id":"hgnc:HGNC:44299","description":"long independently transcribed non-coding RNA 645","metadata":null},{"id":"444110343b774a339077b03f4d7970dd","type":"GENE","name":"LINC00648","canonical_id":"hgnc:HGNC:44302","description":"long independently transcribed non-coding RNA 648","metadata":null},{"id":"4547479a4d6c4fc6bfba1120c112aa72","type":"GENE","name":"LINC00649","canonical_id":"hgnc:HGNC:44305","description":"long independently transcribed non-coding RNA 649","metadata":{"aliases":["TCONS_00028768","lnc-ITSN1-2"]}},{"id":"961ff7e2c05a4d04b6fda410a9cb4399","type":"GENE","name":"LINC00652","canonical_id":"hgnc:HGNC:25003","description":"long independently transcribed non-coding RNA 652","metadata":{"aliases":["HSPC072"]}},{"id":"56af39c2defb48e5b0476eec155b3ef6","type":"GENE","name":"LINC00654","canonical_id":"hgnc:HGNC:27154","description":"long independently transcribed non-coding RNA 654","metadata":{"aliases":["LINC01729"]}},{"id":"9f6f7a018274499b95344b2b85f4f436","type":"GENE","name":"LINC00656","canonical_id":"hgnc:HGNC:27304","description":"long independently transcribed non-coding RNA 656","metadata":null},{"id":"de9dd2db1ee74df8980684503d188b12","type":"GENE","name":"LINC00658","canonical_id":"hgnc:HGNC:44315","description":"long independently transcribed non-coding RNA 658","metadata":null},{"id":"4cbbbc30f6824c7ea7a5b8f702069151","type":"GENE","name":"LINC00659","canonical_id":"hgnc:HGNC:44316","description":"long independently transcribed non-coding RNA 659","metadata":null},{"id":"da45c96f45f64fb6a8748d8375994fdf","type":"GENE","name":"LINC00661","canonical_id":"hgnc:HGNC:27002","description":"long independently transcribed non-coding RNA 661","metadata":null},{"id":"387d3eb0e8d9468bbce1da2c9f734685","type":"GENE","name":"LINC00662","canonical_id":"hgnc:HGNC:27122","description":"long independently transcribed non-coding RNA 662","metadata":null},{"id":"efca1a570ef54e47a37fb20bc2de1258","type":"GENE","name":"LINC00663","canonical_id":"hgnc:HGNC:28609","description":"long independently transcribed non-coding RNA 663","metadata":{"aliases":["MGC39821"]}},{"id":"e4fdc1cc53f1404e9e9a183cee1a01d1","type":"GENE","name":"LINC00664","canonical_id":"hgnc:HGNC:44319","description":"long independently transcribed non-coding RNA 664","metadata":null},{"id":"63a19bc8633647b6879cfe45c7c64b13","type":"GENE","name":"LINC00665","canonical_id":"hgnc:HGNC:44323","description":"long independently transcribed non-coding RNA 665","metadata":{"aliases":["CIP2A-BP"]}},{"id":"0a1bc1ebe1124fd786f83b5e2b6f7254","type":"GENE","name":"LINC00667","canonical_id":"hgnc:HGNC:27906","description":"long independently transcribed non-coding RNA 667","metadata":{"aliases":["lncOCMRL1"]}},{"id":"284397867f0f4cf59b7a2b5f455d76ef","type":"GENE","name":"LINC00668","canonical_id":"hgnc:HGNC:44328","description":"long independently transcribed non-coding RNA 668","metadata":null},{"id":"59590ead2cbf41739d6983c2b600e327","type":"GENE","name":"LINC00670","canonical_id":"hgnc:HGNC:44338","description":"long independently transcribed non-coding RNA 670","metadata":{"aliases":["FLJ34690","CARDINAL"]}},{"id":"7391cb0e2f944edd8f554599b3cf83b6","type":"GENE","name":"LINC00671","canonical_id":"hgnc:HGNC:44339","description":"long independently transcribed non-coding RNA 671","metadata":null},{"id":"fd8de9219b224bdc8f55abb7f981c874","type":"GENE","name":"LINC00673","canonical_id":"hgnc:HGNC:44354","description":"long independently transcribed non-coding RNA 673","metadata":{"aliases":["HI-LNC75","SLNCR1","ERRLR01","LUCAIR1","RASON","SLNCR"]}},{"id":"234c2be817ce4798945649eb418cf1e2","type":"GENE","name":"LINC00674","canonical_id":"hgnc:HGNC:44355","description":"long independently transcribed non-coding RNA 674","metadata":{"aliases":["CALA"]}},{"id":"f394edc5795a4c09902238203153b0ff","type":"GENE","name":"LINC00676","canonical_id":"hgnc:HGNC:44394","description":"long independently transcribed non-coding RNA 676","metadata":null},{"id":"50670c30f74e4398a92730a3d1d4ac73","type":"GENE","name":"LINC00677","canonical_id":"hgnc:HGNC:20121","description":"long independently transcribed non-coding RNA 677","metadata":{"aliases":["C14orf74"]}},{"id":"fd890380f911413bbfc411150ae091e7","type":"GENE","name":"LINC00678","canonical_id":"hgnc:HGNC:44413","description":"long independently transcribed non-coding RNA 678","metadata":null},{"id":"998403f8519e40bf8a8f2903c8b632f2","type":"GENE","name":"LINC00680","canonical_id":"hgnc:HGNC:44417","description":"long independently transcribed non-coding RNA 680","metadata":null},{"id":"ee95f486f4d84cac87ccaba21c857718","type":"GENE","name":"LINC00680-GUSBP4","canonical_id":"hgnc:HGNC:56755","description":"LINC00680-GUSBP4 readthrough, transcribed pseudogene","metadata":null},{"id":"b24156cca13c4c0786c72ac4011107f5","type":"GENE","name":"LINC00681","canonical_id":"hgnc:HGNC:44423","description":"long independently transcribed non-coding RNA 681","metadata":null},{"id":"f01fc5acbc3c41e09a06b4f1fcbbb3a1","type":"GENE","name":"LINC00682","canonical_id":"hgnc:HGNC:44466","description":"long independently transcribed non-coding RNA 682","metadata":null},{"id":"b0dc3061adeb44489fb19acfffd8e67b","type":"GENE","name":"LINC00685","canonical_id":"hgnc:HGNC:27560","description":"long independently transcribed non-coding RNA 685","metadata":{"aliases":["OTTHUMT00000055574","CXYorf10","NCRNA00107","PPP2R3B-AS1"]}},{"id":"c2a85d3ea23e493d870cdbe42e63907f","type":"GENE","name":"LINC00686","canonical_id":"hgnc:HGNC:16221","description":"long independently transcribed non-coding RNA 686","metadata":{"aliases":["bA93B14.2","C20orf90"]}},{"id":"cb23b3e80acd4ccf91598ed586850f57","type":"GENE","name":"LINC00687","canonical_id":"hgnc:HGNC:16194","description":"long independently transcribed non-coding RNA 687","metadata":{"aliases":["dJ1012F16.1","C20orf61"]}},{"id":"9bf4167f12764a88b07b172061965b6a","type":"GENE","name":"LINC00689","canonical_id":"hgnc:HGNC:27217","description":"long independently transcribed non-coding RNA 689","metadata":{"aliases":["STORM"]}},{"id":"8ef09fff443d4fd7a7f5a9dba90acaed","type":"GENE","name":"LINC00690","canonical_id":"hgnc:HGNC:44503","description":"long independently transcribed non-coding RNA 690","metadata":null},{"id":"e9a37d0fd71644c2bd5f0c4a011e679d","type":"GENE","name":"LINC00691","canonical_id":"hgnc:HGNC:44514","description":"long independently transcribed non-coding RNA 691","metadata":null},{"id":"55b2a6fab6004de088283296a5fcfd96","type":"GENE","name":"LINC00692","canonical_id":"hgnc:HGNC:27708","description":"long independently transcribed non-coding RNA 692","metadata":null},{"id":"f8e6277f53fd405bba232678b4f99f81","type":"GENE","name":"LINC00693","canonical_id":"hgnc:HGNC:44526","description":"long independently transcribed non-coding RNA 693","metadata":null},{"id":"900e1b81616543d6b98ba6fac84ed074","type":"GENE","name":"LINC00696","canonical_id":"hgnc:HGNC:34426","description":"long independently transcribed non-coding RNA 696","metadata":{"aliases":["C3orf74"]}},{"id":"d2093ba6c05941528335b0c0b337c0e8","type":"GENE","name":"LINC00698","canonical_id":"hgnc:HGNC:27720","description":"long independently transcribed non-coding RNA 698","metadata":null},{"id":"eb1d8cf4d04c4281b147e992fd87dee4","type":"GENE","name":"LINC00700","canonical_id":"hgnc:HGNC:27422","description":"long independently transcribed non-coding RNA 700","metadata":null},{"id":"ef31d877af66476ca45620f5fc708a32","type":"GENE","name":"LINC00701","canonical_id":"hgnc:HGNC:44674","description":"long independently transcribed non-coding RNA 701","metadata":null},{"id":"da3348a685044c57b1b821d7bb3c39cc","type":"GENE","name":"LINC00702","canonical_id":"hgnc:HGNC:44676","description":"long independently transcribed non-coding RNA 702","metadata":null},{"id":"240c022bd20a4df1a8031144164b340d","type":"GENE","name":"LINC00703","canonical_id":"hgnc:HGNC:44677","description":"long independently transcribed non-coding RNA 703","metadata":null},{"id":"f97496f572494ad6946e323a361777d6","type":"GENE","name":"LINC00705","canonical_id":"hgnc:HGNC:27874","description":"long independently transcribed non-coding RNA 705","metadata":null},{"id":"10ddbe9cd998433a94ab2be20ab3bc20","type":"GENE","name":"LINC00706","canonical_id":"hgnc:HGNC:44690","description":"long independently transcribed non-coding RNA 706","metadata":null},{"id":"0b8e4b817faf4574baa20aaefaea947b","type":"GENE","name":"LINC00708","canonical_id":"hgnc:HGNC:44694","description":"long independently transcribed non-coding RNA 708","metadata":null},{"id":"13f4dae579724a44abf531fb5a7af2f0","type":"GENE","name":"LINC00709","canonical_id":"hgnc:HGNC:44700","description":"long independently transcribed non-coding RNA 709","metadata":null},{"id":"a38bfc0b7adf4ea292ce5725a0259cde","type":"GENE","name":"LINC00710","canonical_id":"hgnc:HGNC:27386","description":"long independently transcribed non-coding RNA 710","metadata":null},{"id":"e43dc29e8ec742cb811bc2ea753dc716","type":"GENE","name":"LINC00824","canonical_id":"hgnc:HGNC:50281","description":"long independently transcribed non-coding RNA 824","metadata":{"aliases":["LINC01263"]}},{"id":"ea171485702143d2a05ce2444209733e","type":"GENE","name":"LINC00836","canonical_id":"hgnc:HGNC:44915","description":"long independently transcribed non-coding RNA 836","metadata":null},{"id":"df8640d959974ef8b3e4b948824abb9a","type":"GENE","name":"LINC00837","canonical_id":"hgnc:HGNC:27436","description":"long independently transcribed non-coding RNA 837","metadata":null},{"id":"61aaeaf143834269949cf8294bb8bacf","type":"GENE","name":"LINC00838","canonical_id":"hgnc:HGNC:44963","description":"long independently transcribed non-coding RNA 838","metadata":null},{"id":"0a91f7f4157d435390845f581525a352","type":"GENE","name":"LINC00839","canonical_id":"hgnc:HGNC:28269","description":"long independently transcribed non-coding RNA 839","metadata":null},{"id":"fc4de069a04c4c01bcdc10393f223a94","type":"GENE","name":"LINC00840","canonical_id":"hgnc:HGNC:44987","description":"long independently transcribed non-coding RNA 840","metadata":null},{"id":"59309662390543078447fefa4368e86a","type":"GENE","name":"LINC00841","canonical_id":"hgnc:HGNC:27430","description":"long independently transcribed non-coding RNA 841","metadata":null},{"id":"620bac3f243a43fa8c283d45e8652877","type":"GENE","name":"LINC00842","canonical_id":"hgnc:HGNC:44989","description":"long independently transcribed non-coding RNA 842","metadata":null},{"id":"edde1b1ed0434f65abc43bdd39a58c01","type":"GENE","name":"LINC00844","canonical_id":"hgnc:HGNC:45031","description":"long independently transcribed non-coding RNA 844","metadata":null},{"id":"6c2b233a5d194c3aa2ea2272c9ee4270","type":"GENE","name":"LINC00845","canonical_id":"hgnc:HGNC:45033","description":"long independently transcribed non-coding RNA 845","metadata":null},{"id":"170be2e9a3e141d983879abbddede68f","type":"GENE","name":"LINC00847","canonical_id":"hgnc:HGNC:45050","description":"long independently transcribed non-coding RNA 847","metadata":null},{"id":"6c2c9333b93d484b9dc82b4a627a3c1e","type":"GENE","name":"LINC00850","canonical_id":"hgnc:HGNC:45092","description":"long independently transcribed non-coding RNA 850","metadata":{"aliases":["KUCG1"]}},{"id":"bd9358678e0e48549d5c07387832e9d6","type":"GENE","name":"LINC00851","canonical_id":"hgnc:HGNC:43424","description":"long independently transcribed non-coding RNA 851","metadata":{"aliases":["DZANK1-AS1"]}},{"id":"9add05ab1a5a40bb9a5264ed1e84c0fc","type":"GENE","name":"LINC00852","canonical_id":"hgnc:HGNC:29904","description":"long independently transcribed non-coding RNA 852","metadata":{"aliases":["NAG73","GHRL-AS2","C3orf42","GHRLOS2"]}},{"id":"fb081bcf120e4bdfbfd0509d44be2906","type":"GENE","name":"LINC00853","canonical_id":"hgnc:HGNC:43716","description":"long independently transcribed non-coding RNA 853","metadata":{"aliases":["ncRNA-a4","PDZK1IP1-AS1"]}},{"id":"7bf4103a2ad449939489adfd30fe2ec8","type":"GENE","name":"LINC00856","canonical_id":"hgnc:HGNC:45111","description":"long independently transcribed non-coding RNA 856","metadata":null},{"id":"d5d61cefd95e49dc8b7daa1eed9a0f11","type":"GENE","name":"LINC00857","canonical_id":"hgnc:HGNC:45114","description":"long independently transcribed non-coding RNA 857","metadata":{"aliases":["HUMT"]}},{"id":"d01478e367834f4ba206b6e01cccd395","type":"GENE","name":"LINC00858","canonical_id":"hgnc:HGNC:27276","description":"long independently transcribed non-coding RNA 858","metadata":{"aliases":["CRCAL-2","LNMAT2"]}},{"id":"c2c4bc62aa384a3b886286170dc15eac","type":"GENE","name":"LINC00861","canonical_id":"hgnc:HGNC:45133","description":"long independently transcribed non-coding RNA 861","metadata":null},{"id":"3fc83349847e4ccea8930def0671a702","type":"GENE","name":"LINC00862","canonical_id":"hgnc:HGNC:21901","description":"long independently transcribed non-coding RNA 862","metadata":{"aliases":["C1orf98","SMIM16"]}},{"id":"82445691a1774a1eaccd310869883251","type":"GENE","name":"LINC00863","canonical_id":"hgnc:HGNC:45162","description":"long independently transcribed non-coding RNA 863","metadata":null},{"id":"ce51198f059146678704295e35977581","type":"GENE","name":"LINC00865","canonical_id":"hgnc:HGNC:45170","description":"long independently transcribed non-coding RNA 865","metadata":{"aliases":["LINC01374"]}},{"id":"c48ce58e8a5344cd8ad03eb9333bf7c7","type":"GENE","name":"LINC00867","canonical_id":"hgnc:HGNC:45265","description":"long independently transcribed non-coding RNA 867","metadata":null},{"id":"71402db70ca648d99af114207d1064ef","type":"GENE","name":"LINC00868","canonical_id":"hgnc:HGNC:27562","description":"long independently transcribed non-coding RNA 868","metadata":{"aliases":["C17orf52"]}},{"id":"bd70e6e6fcac4cdc9a2f100aa09f90ef","type":"GENE","name":"LINC00869","canonical_id":"hgnc:HGNC:29050","description":"long independently transcribed non-coding RNA 869","metadata":{"aliases":["KIAA0493"]}},{"id":"96afedafe8ad468fbe1e4000851eae86","type":"GENE","name":"LINC00870","canonical_id":"hgnc:HGNC:27319","description":"long independently transcribed non-coding RNA 870","metadata":null},{"id":"b55d213d106c4a2cb209f8a619ecfdb9","type":"GENE","name":"LINC00871","canonical_id":"hgnc:HGNC:47038","description":"long independently transcribed non-coding RNA 871","metadata":{"aliases":["RP11-1A16.1"]}},{"id":"45fd2fa3fdd0463bb7bf9682b73f9abb","type":"GENE","name":"LINC00877","canonical_id":"hgnc:HGNC:27706","description":"long independently transcribed non-coding RNA 877","metadata":null},{"id":"3a2fd116754f4671b3bed60cf3a6ed00","type":"GENE","name":"LINC00879","canonical_id":"hgnc:HGNC:48566","description":"long independently transcribed non-coding RNA 879","metadata":null},{"id":"4113e26776a441d7a46acbc5e62c2a63","type":"GENE","name":"LINC00880","canonical_id":"hgnc:HGNC:27948","description":"long independently transcribed non-coding RNA 880","metadata":null},{"id":"f1711826d12847658b0559fc11351bc3","type":"GENE","name":"LINC00881","canonical_id":"hgnc:HGNC:48567","description":"long independently transcribed non-coding RNA 881","metadata":{"aliases":["LIPTER"]}},{"id":"2703ecec095d4ee9a651c2fffa2b257e","type":"GENE","name":"LINC00882","canonical_id":"hgnc:HGNC:48568","description":"long independently transcribed non-coding RNA 882","metadata":null},{"id":"9213f6b192ab4b2c8abdc6f2c5c72160","type":"GENE","name":"LINC00885","canonical_id":"hgnc:HGNC:48571","description":"long independently transcribed non-coding RNA 885","metadata":{"aliases":["PARylator"]}},{"id":"3463dc54c17d4ef5bf6d812426aacf36","type":"GENE","name":"LINC00886","canonical_id":"hgnc:HGNC:48572","description":"long independently transcribed non-coding RNA 886","metadata":null},{"id":"77f46e91cab24bbc9ba0f64603a0b0ca","type":"GENE","name":"LINC00887","canonical_id":"hgnc:HGNC:48574","description":"long independently transcribed non-coding RNA 887","metadata":{"aliases":["linc-ATP13A4-8","HEIRCC","ACLY-BP","LINC02036"]}},{"id":"f29c37c9913c412aabc168a3002b372b","type":"GENE","name":"LINC00891","canonical_id":"hgnc:HGNC:48577","description":"long independently transcribed non-coding RNA 891","metadata":{"aliases":["FLJ46446"]}},{"id":"18cc1a70ed9a4cac84c2d8c7d93c91f1","type":"GENE","name":"LINC00892","canonical_id":"hgnc:HGNC:48578","description":"long independently transcribed non-coding RNA 892","metadata":null},{"id":"b282122f6df147489aa25339945cf3cf","type":"GENE","name":"LINC00895","canonical_id":"hgnc:HGNC:48580","description":"long independently transcribed non-coding RNA 895","metadata":null},{"id":"7f567330acb242f3af66dcb0e043d818","type":"GENE","name":"LINC00896","canonical_id":"hgnc:HGNC:26519","description":"long independently transcribed non-coding RNA 896","metadata":{"aliases":["FLJ32575"]}},{"id":"4c3ca270ab8a4bba83b4dbd731f2b518","type":"GENE","name":"LINC00898","canonical_id":"hgnc:HGNC:48581","description":"long independently transcribed non-coding RNA 898","metadata":null},{"id":"a52a8d4611b94b1aa512f18571a04497","type":"GENE","name":"LINC00899","canonical_id":"hgnc:HGNC:48583","description":"long independently transcribed non-coding RNA 899","metadata":null},{"id":"ac765cfd77ae46a2b5a5b4e77831117f","type":"GENE","name":"LINC00900","canonical_id":"hgnc:HGNC:27444","description":"long independently transcribed non-coding RNA 900","metadata":null},{"id":"49a1f407e7c64ec88646e32b13daaf8b","type":"GENE","name":"LINC00901","canonical_id":"hgnc:HGNC:40352","description":"long independently transcribed non-coding RNA 901","metadata":{"aliases":["TCONS_00005428","BC040587","LSAMP-AS4"]}},{"id":"b1f24d3e71914cc8aa372eaf2ecf0a67","type":"GENE","name":"LINC00903","canonical_id":"hgnc:HGNC:40351","description":"long independently transcribed non-coding RNA 903","metadata":{"aliases":["LSAMP-AS2"]}},{"id":"d661d8dbd9a14d9ca4c5afdfaa11903e","type":"GENE","name":"LINC00904","canonical_id":"hgnc:HGNC:44325","description":"long independently transcribed non-coding RNA 904","metadata":null},{"id":"9c9ec0a0ef074a4a8baa4585ab369152","type":"GENE","name":"LINC00905","canonical_id":"hgnc:HGNC:26334","description":"long independently transcribed non-coding RNA 905","metadata":{"aliases":["FLJ25328","LINC01855"]}},{"id":"cb971899b15c42438ace30c4145feacb","type":"GENE","name":"LINC00906","canonical_id":"hgnc:HGNC:27121","description":"long independently transcribed non-coding RNA 906","metadata":null},{"id":"0854558987074101b06f090e40cd7742","type":"GENE","name":"LINC00907","canonical_id":"hgnc:HGNC:44327","description":"long independently transcribed non-coding RNA 907","metadata":null},{"id":"3aacb1016e3f4748afd83bdd0724aa84","type":"GENE","name":"LINC00908","canonical_id":"hgnc:HGNC:27599","description":"long independently transcribed non-coding RNA 908","metadata":{"aliases":["ASRPS","LINC00683","LINC01879"]}},{"id":"aee76801f28049adb261e50e834d7b3b","type":"GENE","name":"LINC00910","canonical_id":"hgnc:HGNC:44361","description":"long independently transcribed non-coding RNA 910","metadata":null},{"id":"1fa0a96b15f2443caa61627b781d6f3d","type":"GENE","name":"LINC00911","canonical_id":"hgnc:HGNC:48596","description":"long independently transcribed non-coding RNA 911","metadata":null},{"id":"bf4934976282405fbce4d24d98757cbf","type":"GENE","name":"LINC00917","canonical_id":"hgnc:HGNC:48607","description":"long independently transcribed non-coding RNA 917","metadata":null},{"id":"c5e309ad21054d20b605060eb29dfc89","type":"GENE","name":"LINC00919","canonical_id":"hgnc:HGNC:48610","description":"long independently transcribed non-coding RNA 919","metadata":null},{"id":"91153337d74f49c0b1ba6f49894e49b0","type":"GENE","name":"LINC00920","canonical_id":"hgnc:HGNC:48611","description":"long independently transcribed non-coding RNA 920","metadata":{"aliases":["CALIC","LINRIS"]}},{"id":"782e4ece215c47ed8b8aa23724c590a0","type":"GENE","name":"LINC00921","canonical_id":"hgnc:HGNC:26830","description":"long independently transcribed non-coding RNA 921","metadata":{"aliases":["FLJ39639"]}},{"id":"b9b2fd339ddb43cb8cec6facf62452eb","type":"GENE","name":"LINC00922","canonical_id":"hgnc:HGNC:27545","description":"long independently transcribed non-coding RNA 922","metadata":{"aliases":["Lnc-LALC"]}},{"id":"db6d2b95af834a5ba5ae7d19acd3b0d1","type":"GENE","name":"LINC00923","canonical_id":"hgnc:HGNC:28088","description":"long independently transcribed non-coding RNA 923","metadata":{"aliases":["LINC02254"]}},{"id":"50647a5026864ba482344c3283088c18","type":"GENE","name":"LINC00924","canonical_id":"hgnc:HGNC:27081","description":"long independently transcribed non-coding RNA 924","metadata":null},{"id":"69d636728f944f8ca287c0edc84d40b6","type":"GENE","name":"LINC00926","canonical_id":"hgnc:HGNC:27514","description":"long independently transcribed non-coding RNA 926","metadata":null},{"id":"e2289e8414a74d468850a13d11afcd5d","type":"GENE","name":"LINC00927","canonical_id":"hgnc:HGNC:27522","description":"long independently transcribed non-coding RNA 927","metadata":null},{"id":"0ad2de946cad446ab26f47b351c95abc","type":"GENE","name":"LINC00928","canonical_id":"hgnc:HGNC:27535","description":"long independently transcribed non-coding RNA 928","metadata":null},{"id":"7312d1c7b21141d6b417104d4fb76bf3","type":"GENE","name":"LINC00929","canonical_id":"hgnc:HGNC:48615","description":"long independently transcribed non-coding RNA 929","metadata":null},{"id":"e79f394684e94b14bc40476a5eefc535","type":"GENE","name":"LINC00930","canonical_id":"hgnc:HGNC:48620","description":"long independently transcribed non-coding RNA 930","metadata":null},{"id":"9d1526301d794dab9ae883d723db7331","type":"GENE","name":"LINC00933","canonical_id":"hgnc:HGNC:48625","description":"long independently transcribed non-coding RNA 933","metadata":null},{"id":"688c7f1efc334943812b893f00a3d538","type":"GENE","name":"LINC00934","canonical_id":"hgnc:HGNC:27059","description":"long independently transcribed non-coding RNA 934","metadata":null},{"id":"b45f2f8691d549258b6ea2b2003944be","type":"GENE","name":"LINC00937","canonical_id":"hgnc:HGNC:48629","description":"long independently transcribed non-coding RNA 937","metadata":null},{"id":"3e150b39e7d648f1864e386500f864cd","type":"GENE","name":"LINC00938","canonical_id":"hgnc:HGNC:48630","description":"long independently transcribed non-coding RNA 938","metadata":null},{"id":"784a1f841855473390d92c66f5767883","type":"GENE","name":"LINC00939","canonical_id":"hgnc:HGNC:48631","description":"long independently transcribed non-coding RNA 939","metadata":null},{"id":"4eef6eeaf580480c843ee85c114127c5","type":"GENE","name":"LINC00940","canonical_id":"hgnc:HGNC:48634","description":"long independently transcribed non-coding RNA 940","metadata":null},{"id":"3f4c8c018bd34e9b8b222eaaab9c9d64","type":"GENE","name":"LINC00941","canonical_id":"hgnc:HGNC:48635","description":"long independently transcribed non-coding RNA 941","metadata":{"aliases":["LISRR","lncRNA-MUF","lncIAPF"]}},{"id":"96349c30a6004cd197ab1b402f38e0c0","type":"GENE","name":"LINC00942","canonical_id":"hgnc:HGNC:48636","description":"long independently transcribed non-coding RNA 942","metadata":null},{"id":"70714676cc9340b88422bd00c06a2956","type":"GENE","name":"LINC00943","canonical_id":"hgnc:HGNC:48639","description":"long independently transcribed non-coding RNA 943","metadata":null},{"id":"578c067ba7c541aa86806b6f8e252930","type":"GENE","name":"LINC00944","canonical_id":"hgnc:HGNC:48640","description":"long independently transcribed non-coding RNA 944","metadata":{"aliases":["DMDRMR"]}},{"id":"89b6a67bcf6347fa8991eb455751b6e6","type":"GENE","name":"LINC00945","canonical_id":"hgnc:HGNC:48643","description":"long independently transcribed non-coding RNA 945","metadata":{"aliases":["TCONS_00028834"]}},{"id":"84edadfd7e0f4da3982d280b1d7aa79e","type":"GENE","name":"LINC00951","canonical_id":"hgnc:HGNC:48662","description":"long independently transcribed non-coding RNA 951","metadata":{"aliases":["lincRNA-uc003opf.1","FLJ41649"]}},{"id":"a8c2f6fb1c6e4b9586e96e4642894478","type":"GENE","name":"LINC00954","canonical_id":"hgnc:HGNC:48668","description":"long independently transcribed non-coding RNA 954","metadata":{"aliases":["FLJ12334"]}},{"id":"f6c895a7517b4614a2b4fa6eb42e804c","type":"GENE","name":"LINC00955","canonical_id":"hgnc:HGNC:26644","description":"long independently transcribed non-coding RNA 955","metadata":{"aliases":["FLJ35424"]}},{"id":"711b667b0807452ca0781ff0ba9f98f4","type":"GENE","name":"LINC00957","canonical_id":"hgnc:HGNC:22332","description":"long independently transcribed non-coding RNA 957","metadata":null},{"id":"311857606e764a48904f43521b788f75","type":"GENE","name":"LINC00958","canonical_id":"hgnc:HGNC:48671","description":"long independently transcribed non-coding RNA 958","metadata":null},{"id":"57551e21880741f18d789b97f90a156e","type":"GENE","name":"LINC00960","canonical_id":"hgnc:HGNC:48710","description":"long independently transcribed non-coding RNA 960","metadata":null},{"id":"ef075c1779f446b7ae18743b569d08c0","type":"GENE","name":"LINC00963","canonical_id":"hgnc:HGNC:48716","description":"long independently transcribed non-coding RNA 963","metadata":{"aliases":["MetaLnc9"]}},{"id":"215f8bc65c6d41e5a0908af155d704bd","type":"GENE","name":"LINC00964","canonical_id":"hgnc:HGNC:27226","description":"long independently transcribed non-coding RNA 964","metadata":null},{"id":"4e0bb997f4994b4a85ac8f4c84a9a71e","type":"GENE","name":"LINC00965","canonical_id":"hgnc:HGNC:28022","description":"long independently transcribed non-coding RNA 965","metadata":null},{"id":"58b02e3647dc4333adc31c7430201813","type":"GENE","name":"LINC00967","canonical_id":"hgnc:HGNC:48725","description":"long independently transcribed non-coding RNA 967","metadata":null},{"id":"f460a6b968cb46fb9fe65a9cb0f427db","type":"GENE","name":"LINC00968","canonical_id":"hgnc:HGNC:48727","description":"long independently transcribed non-coding RNA 968","metadata":null},{"id":"ec0d6358710f4b10beb7b69edf383801","type":"GENE","name":"LINC00970","canonical_id":"hgnc:HGNC:48730","description":"long independently transcribed non-coding RNA 970","metadata":null},{"id":"f4dd7a5c98e946c6acea027af9b0687f","type":"GENE","name":"LINC00971","canonical_id":"hgnc:HGNC:48737","description":"long independently transcribed non-coding RNA 971","metadata":null},{"id":"646e0fab5c6c4cb880bd2c060aea0e6d","type":"GENE","name":"LINC00972","canonical_id":"hgnc:HGNC:48826","description":"long independently transcribed non-coding RNA 972","metadata":{"aliases":["PLADE"]}},{"id":"d045b7153af24c10801520ea3d154993","type":"GENE","name":"LINC00973","canonical_id":"hgnc:HGNC:48868","description":"long independently transcribed non-coding RNA 973","metadata":{"aliases":["L3EMP","CTD-2021J15.2"]}},{"id":"bb19a1a4c93c4deaa1641331bd61c73c","type":"GENE","name":"LINC00974","canonical_id":"hgnc:HGNC:27105","description":"long independently transcribed non-coding RNA 974","metadata":null},{"id":"303b43f27e5746c09b69b950f80b0d09","type":"GENE","name":"LINC00976","canonical_id":"hgnc:HGNC:50610","description":"long independently transcribed non-coding RNA 976","metadata":null},{"id":"f2ce323319bb4e6c9b879450dc94085a","type":"GENE","name":"LINC00977","canonical_id":"hgnc:HGNC:48902","description":"long independently transcribed non-coding RNA 977","metadata":null},{"id":"062bd1966aa440b29cf3ca6462b99ebc","type":"GENE","name":"LINC00987","canonical_id":"hgnc:HGNC:48911","description":"long independently transcribed non-coding RNA 987","metadata":null},{"id":"6207cf670d5a40278b784587c556e766","type":"GENE","name":"LINC00989","canonical_id":"hgnc:HGNC:48918","description":"long independently transcribed non-coding RNA 989","metadata":null},{"id":"d5c2456fb2164b4ebb4787d55a162c98","type":"GENE","name":"LINC00992","canonical_id":"hgnc:HGNC:48943","description":"long independently transcribed non-coding RNA 992","metadata":{"aliases":["GT3-INCP","ERINA"]}},{"id":"6f811469e30f4d62b1b6177c51df8419","type":"GENE","name":"LINC00993","canonical_id":"hgnc:HGNC:48948","description":"long independently transcribed non-coding RNA 993","metadata":{"aliases":["TCONS_l2_00002973"]}},{"id":"bf9a868493d242c7a7f1c38aa2a069df","type":"GENE","name":"LINC00994","canonical_id":"hgnc:HGNC:48949","description":"long independently transcribed non-coding RNA 994","metadata":null},{"id":"f7da1458a94d4450bcc37edc1b5e6263","type":"GENE","name":"LINC00996","canonical_id":"hgnc:HGNC:27800","description":"long independently transcribed non-coding RNA 996","metadata":null},{"id":"e93bdabe03e94feeb547f034e3e194e2","type":"GENE","name":"LINC00997","canonical_id":"hgnc:HGNC:48952","description":"long independently transcribed non-coding RNA 997","metadata":null},{"id":"7a37281807fc4aa2a76f39af3b77aa1e","type":"GENE","name":"LINC00999","canonical_id":"hgnc:HGNC:38537","description":"long independently transcribed non-coding RNA 999","metadata":{"aliases":["FLJ44672"]}},{"id":"f09f3adf389440c19ebc3195715a403e","type":"GENE","name":"LINC01000","canonical_id":"hgnc:HGNC:38541","description":"long independently transcribed non-coding RNA 1000","metadata":{"aliases":["FLJ45340"]}},{"id":"5458174764284b2c8085af0121a7641a","type":"GENE","name":"LINC01001","canonical_id":"hgnc:HGNC:38540","description":"long independently transcribed non-coding RNA 1001","metadata":null},{"id":"061aaafb210943969eb4de069f8b982c","type":"GENE","name":"LINC01002","canonical_id":"hgnc:HGNC:38538","description":"long independently transcribed non-coding RNA 1002","metadata":null},{"id":"03e983ebca8c46acb6eb159718cc4cce","type":"GENE","name":"LINC01003","canonical_id":"hgnc:HGNC:48957","description":"long independently transcribed non-coding RNA 1003","metadata":null},{"id":"61f90d1c95154990a1cf8c5fb62eb124","type":"GENE","name":"LINC01005","canonical_id":"hgnc:HGNC:48963","description":"long independently transcribed non-coding RNA 1005","metadata":null},{"id":"2fd1ffbc3fd6481baa481cbc60449bc2","type":"GENE","name":"LINC01007","canonical_id":"hgnc:HGNC:48973","description":"long independently transcribed non-coding RNA 1007","metadata":null},{"id":"f7d2508dec08473bb7ad3e0624262c1e","type":"GENE","name":"LINC01010","canonical_id":"hgnc:HGNC:48978","description":"long independently transcribed non-coding RNA 1010","metadata":null},{"id":"8fd39c93d6854d1990dc5070fb56f45c","type":"GENE","name":"LINC01011","canonical_id":"hgnc:HGNC:33812","description":"long independently transcribed non-coding RNA 1011","metadata":{"aliases":["CISAL","DKFZp686I15217"]}},{"id":"739481b16dc84de78fe49bb81bffb8ff","type":"GENE","name":"LINC01012","canonical_id":"hgnc:HGNC:48986","description":"long independently transcribed non-coding RNA 1012","metadata":null},{"id":"9a1c8c36114c4156a21674fb97a72690","type":"GENE","name":"LINC01013","canonical_id":"hgnc:HGNC:48987","description":"long independently transcribed non-coding RNA 1013","metadata":{"aliases":["AERRIE","LINC01013ORF","LINC02921"]}},{"id":"675d5c53f3634d4480f6cc33c6fd6efc","type":"GENE","name":"LINC01014","canonical_id":"hgnc:HGNC:41353","description":"long independently transcribed non-coding RNA 1014","metadata":{"aliases":["KCNMB2-IT1"]}},{"id":"0d4c75eeeffb4012b45239c81e06347d","type":"GENE","name":"LINC01015","canonical_id":"hgnc:HGNC:48988","description":"long independently transcribed non-coding RNA 1015","metadata":null},{"id":"e025f06ddbe1478c90d6e0f3e79ad0f7","type":"GENE","name":"LINC01016","canonical_id":"hgnc:HGNC:48991","description":"long independently transcribed non-coding RNA 1016","metadata":null},{"id":"4a0131df0efb4661ab7261636bd33cf3","type":"GENE","name":"LINC01018","canonical_id":"hgnc:HGNC:27394","description":"long independently transcribed non-coding RNA 1018","metadata":{"aliases":["SRHC"]}},{"id":"2a076106a47944fea9ba5d0be4e768fd","type":"GENE","name":"LINC01019","canonical_id":"hgnc:HGNC:27742","description":"long independently transcribed non-coding RNA 1019","metadata":{"aliases":["uc.150","LINC01017"]}},{"id":"ef35d6f7fd68481fbee7dc9ba1a49abb","type":"GENE","name":"LINC01020","canonical_id":"hgnc:HGNC:27968","description":"long independently transcribed non-coding RNA 1020","metadata":null},{"id":"b8d1a4afba2742658592b94f0e071c2c","type":"GENE","name":"LINC01022","canonical_id":"hgnc:HGNC:48998","description":"long independently transcribed non-coding RNA 1022","metadata":{"aliases":["TCONS_00013107"]}},{"id":"b5ab5b2f51d443599ae19951ff523ad6","type":"GENE","name":"LINC01023","canonical_id":"hgnc:HGNC:49004","description":"long independently transcribed non-coding RNA 1023","metadata":null},{"id":"c73d3df250104deea87fd16486830c67","type":"GENE","name":"LINC01028","canonical_id":"hgnc:HGNC:49014","description":"long independently transcribed non-coding RNA 1028","metadata":{"aliases":["TCONS_00025127"]}},{"id":"1b590fc431414c0fb32e8c6491ef7dc5","type":"GENE","name":"LINC01029","canonical_id":"hgnc:HGNC:49015","description":"long independently transcribed non-coding RNA 1029","metadata":null},{"id":"84f776691fa944498886563ec61369fd","type":"GENE","name":"LINC01030","canonical_id":"hgnc:HGNC:49016","description":"long independently transcribed non-coding RNA 1030","metadata":{"aliases":["TCONS_00015085"]}},{"id":"a2dba2282b374887a46edf0b77b5c0ad","type":"GENE","name":"LINC01031","canonical_id":"hgnc:HGNC:49017","description":"long independently transcribed non-coding RNA 1031","metadata":{"aliases":["TCONS_00000361"]}},{"id":"9730e4f2b15c41d880a608c7d72b03cb","type":"GENE","name":"LINC01033","canonical_id":"hgnc:HGNC:49019","description":"long independently transcribed non-coding RNA 1033","metadata":null},{"id":"a5fd9712107a43a0811ef56672f30d29","type":"GENE","name":"LINC01034","canonical_id":"hgnc:HGNC:49021","description":"long independently transcribed non-coding RNA 1034","metadata":{"aliases":["TCONS_00021570"]}},{"id":"b35692bcc9a14a7dbfd45ca1dcf2a875","type":"GENE","name":"LINC01035","canonical_id":"hgnc:HGNC:49022","description":"long independently transcribed non-coding RNA 1035","metadata":null},{"id":"b4b170b5e5a143dd8cdaebec5f0cde04","type":"GENE","name":"LINC01036","canonical_id":"hgnc:HGNC:49024","description":"long independently transcribed non-coding RNA 1036","metadata":null},{"id":"204aad8978184241895937c8d526de78","type":"GENE","name":"LINC01037","canonical_id":"hgnc:HGNC:49025","description":"long independently transcribed non-coding RNA 1037","metadata":null},{"id":"95091dcb5a1e4beab2dbea4d03ac21fc","type":"GENE","name":"LINC01038","canonical_id":"hgnc:HGNC:49026","description":"long independently transcribed non-coding RNA 1038","metadata":null},{"id":"79938b9829944d8b86279de537393643","type":"GENE","name":"LINC01039","canonical_id":"hgnc:HGNC:49027","description":"long independently transcribed non-coding RNA 1039","metadata":null},{"id":"e6438211e05e41b7aa6b73ef4480b017","type":"GENE","name":"LINC01040","canonical_id":"hgnc:HGNC:49028","description":"long independently transcribed non-coding RNA 1040","metadata":{"aliases":["TCONS_00021682"]}},{"id":"2c1ea8d2adbc4f4a8165ae3e05206c87","type":"GENE","name":"LINC01043","canonical_id":"hgnc:HGNC:49031","description":"long independently transcribed non-coding RNA 1043","metadata":null},{"id":"d0d1b1df78fb4f0eb3e846b49ddbfcb5","type":"GENE","name":"LINC01044","canonical_id":"hgnc:HGNC:49032","description":"long independently transcribed non-coding RNA 1044","metadata":null},{"id":"f797bbe8b6c846a0a1ef5c4235f217ed","type":"GENE","name":"LINC01046","canonical_id":"hgnc:HGNC:49040","description":"long independently transcribed non-coding RNA 1046","metadata":null},{"id":"49347e39188d4c76bbcdb277ca6f59bf","type":"GENE","name":"LINC01047","canonical_id":"hgnc:HGNC:49041","description":"long independently transcribed non-coding RNA 1047","metadata":null},{"id":"13430c70ca1b4287a12769b35a421827","type":"GENE","name":"LINC01048","canonical_id":"hgnc:HGNC:49042","description":"long independently transcribed non-coding RNA 1048","metadata":null},{"id":"87a80c7101b44ea1b5889673083e736e","type":"GENE","name":"LINC01049","canonical_id":"hgnc:HGNC:49043","description":"long independently transcribed non-coding RNA 1049","metadata":null},{"id":"4c9a21caefaa45968f275ab73f32aac0","type":"GENE","name":"LINC01050","canonical_id":"hgnc:HGNC:49044","description":"long independently transcribed non-coding RNA 1050","metadata":null},{"id":"4ced5183297749f28f800c5f68e3321b","type":"GENE","name":"LINC01052","canonical_id":"hgnc:HGNC:49046","description":"long independently transcribed non-coding RNA 1052","metadata":null},{"id":"56c4b71c03bb42159f3a83abacfb9297","type":"GENE","name":"LINC01053","canonical_id":"hgnc:HGNC:49047","description":"long independently transcribed non-coding RNA 1053","metadata":null},{"id":"880377cc045a42b7ae7ab1e893868e8e","type":"GENE","name":"LINC01054","canonical_id":"hgnc:HGNC:49048","description":"long independently transcribed non-coding RNA 1054","metadata":null},{"id":"4339376453304af6877bcbe946cb27e7","type":"GENE","name":"LINC01055","canonical_id":"hgnc:HGNC:49049","description":"long independently transcribed non-coding RNA 1055","metadata":null},{"id":"63ae8ec8080242e0961b8bf1f6ed4023","type":"GENE","name":"LINC01056","canonical_id":"hgnc:HGNC:49050","description":"long independently transcribed non-coding RNA 1056","metadata":null},{"id":"9dd5902088d94e2ca44bb066c6505f4a","type":"GENE","name":"LINC01058","canonical_id":"hgnc:HGNC:49061","description":"long independently transcribed non-coding RNA 1058","metadata":null},{"id":"ab6724dcc4aa41e7b9bb17833d7a0563","type":"GENE","name":"LINC01060","canonical_id":"hgnc:HGNC:49081","description":"long independently transcribed non-coding RNA 1060","metadata":null},{"id":"c14c35f0794b4a3e8f7464cef48d6887","type":"GENE","name":"LINC01061","canonical_id":"hgnc:HGNC:49084","description":"long independently transcribed non-coding RNA 1061","metadata":{"aliases":["FLJ14186","KIKAT"]}},{"id":"94c73c017b484753917fb764f28ed76e","type":"GENE","name":"LINC01063","canonical_id":"hgnc:HGNC:49092","description":"long independently transcribed non-coding RNA 1063","metadata":null},{"id":"aec88fa728ff41af855288dea69156c8","type":"GENE","name":"LINC01065","canonical_id":"hgnc:HGNC:49103","description":"long independently transcribed non-coding RNA 1065","metadata":null},{"id":"2b57905b320147b7a7e19752a628f8c7","type":"GENE","name":"LINC01066","canonical_id":"hgnc:HGNC:49104","description":"long independently transcribed non-coding RNA 1066","metadata":null},{"id":"e221fc425d1d45639bd9483baff7e768","type":"GENE","name":"LINC01067","canonical_id":"hgnc:HGNC:49105","description":"long independently transcribed non-coding RNA 1067","metadata":null},{"id":"e0839cde76004a4ea3f5847c4aa3064c","type":"GENE","name":"LINC01068","canonical_id":"hgnc:HGNC:49106","description":"long independently transcribed non-coding RNA 1068","metadata":null},{"id":"899ea03e11614308bb9e54a90b6df76f","type":"GENE","name":"LINC01069","canonical_id":"hgnc:HGNC:49109","description":"long independently transcribed non-coding RNA 1069","metadata":null},{"id":"d437c86ca9fc42db82ced1fbe8bc0feb","type":"GENE","name":"LINC01070","canonical_id":"hgnc:HGNC:49110","description":"long independently transcribed non-coding RNA 1070","metadata":null},{"id":"778fd301967943009c46d148d1ca8c14","type":"GENE","name":"LINC01072","canonical_id":"hgnc:HGNC:49112","description":"long independently transcribed non-coding RNA 1072","metadata":null},{"id":"a2c2cccb52f04a73a1b3b05f606611fb","type":"GENE","name":"LINC01074","canonical_id":"hgnc:HGNC:49117","description":"long independently transcribed non-coding RNA 1074","metadata":null},{"id":"624b9f0cee064c1bb7b85503991a62ae","type":"GENE","name":"LINC01075","canonical_id":"hgnc:HGNC:49118","description":"long independently transcribed non-coding RNA 1075","metadata":null},{"id":"6b7d5d53d39c421c9b26a878d93aebc6","type":"GENE","name":"LINC01076","canonical_id":"hgnc:HGNC:49119","description":"long independently transcribed non-coding RNA 1076","metadata":null},{"id":"df3dee47a95640c78d341f52d1daf6c4","type":"GENE","name":"LINC01077","canonical_id":"hgnc:HGNC:49120","description":"long independently transcribed non-coding RNA 1077","metadata":null},{"id":"e55f1e0fd9d6442890813627ecd5e0f5","type":"GENE","name":"LINC01078","canonical_id":"hgnc:HGNC:49121","description":"long independently transcribed non-coding RNA 1078","metadata":null},{"id":"6d2beb4f3c8b4133b4acac3dd9bed1b7","type":"GENE","name":"LINC01079","canonical_id":"hgnc:HGNC:49122","description":"long independently transcribed non-coding RNA 1079","metadata":null},{"id":"1cd2d131fee14696bbff1f30cf7ed180","type":"GENE","name":"LINC01080","canonical_id":"hgnc:HGNC:49123","description":"long independently transcribed non-coding RNA 1080","metadata":{"aliases":["TCONS_00021856"]}},{"id":"5d5ac7b3b673490aa96e66636c3361a8","type":"GENE","name":"LINC01081","canonical_id":"hgnc:HGNC:49124","description":"long independently transcribed non-coding RNA 1081","metadata":{"aliases":["TCONS_00024764"]}},{"id":"25b74afd21f647d7a2930012e29f3a10","type":"GENE","name":"LINC01082","canonical_id":"hgnc:HGNC:49125","description":"long independently transcribed non-coding RNA 1082","metadata":{"aliases":["TCONS_00024492"]}},{"id":"da4c68b115954581b955b048f746ccad","type":"GENE","name":"LINC01085","canonical_id":"hgnc:HGNC:27198","description":"long independently transcribed non-coding RNA 1085","metadata":null},{"id":"7bf0c2b072814b8d8061585221bb10aa","type":"GENE","name":"LINC01087","canonical_id":"hgnc:HGNC:49144","description":"long independently transcribed non-coding RNA 1087","metadata":{"aliases":["ERLC1"]}},{"id":"4ce1f9c6a1da4b33905b9eec7e6b8eef","type":"GENE","name":"LINC01088","canonical_id":"hgnc:HGNC:49148","description":"long independently transcribed non-coding RNA 1088","metadata":null},{"id":"d7d6b8e8184b484e97e0cc2962492d1a","type":"GENE","name":"LINC01089","canonical_id":"hgnc:HGNC:27886","description":"long independently transcribed non-coding RNA 1089","metadata":{"aliases":["LIMT","AK096174"]}},{"id":"47f8c4a83c5e4014982d850b0b0bda36","type":"GENE","name":"LINC01090","canonical_id":"hgnc:HGNC:49201","description":"long independently transcribed non-coding RNA 1090","metadata":null},{"id":"8c2576784eb348ccaad7c054e75025cc","type":"GENE","name":"LINC01091","canonical_id":"hgnc:HGNC:27721","description":"long independently transcribed non-coding RNA 1091","metadata":null},{"id":"e0ab21fb02ff45349d3e78e9e964279a","type":"GENE","name":"LINC01093","canonical_id":"hgnc:HGNC:49218","description":"long independently transcribed non-coding RNA 1093","metadata":null},{"id":"7082334d49ad4b88a7b3ddb6e8bf581a","type":"GENE","name":"LINC01094","canonical_id":"hgnc:HGNC:49219","description":"long independently transcribed non-coding RNA 1094","metadata":{"aliases":["CTEPHA1","lincRNA-ANXA3"]}},{"id":"3196192a95bd46d7a497781a3e1a0e4f","type":"GENE","name":"LINC01095","canonical_id":"hgnc:HGNC:49220","description":"long independently transcribed non-coding RNA 1095","metadata":null},{"id":"3a47d0a76e4a4e76b94aff5e2708a992","type":"GENE","name":"LINC01096","canonical_id":"hgnc:HGNC:27739","description":"long independently transcribed non-coding RNA 1096","metadata":null},{"id":"0b8fde3e816846df9904dbe63988d5b1","type":"GENE","name":"LINC01097","canonical_id":"hgnc:HGNC:27738","description":"long independently transcribed non-coding RNA 1097","metadata":null},{"id":"a3fb7e58476a41e4acdab4f7bd3bb2d9","type":"GENE","name":"LINC01098","canonical_id":"hgnc:HGNC:27731","description":"long independently transcribed non-coding RNA 1098","metadata":null},{"id":"0fa9dd3c52ae4516ae11ead439439cbe","type":"GENE","name":"LINC01099","canonical_id":"hgnc:HGNC:49222","description":"long independently transcribed non-coding RNA 1099","metadata":null},{"id":"bb09ddfefba546dd9a92a5fd3a0dc18f","type":"GENE","name":"LINC01100","canonical_id":"hgnc:HGNC:49224","description":"long independently transcribed non-coding RNA 1100","metadata":null},{"id":"ca0f26650a494f7ab9e81be90bf08d54","type":"GENE","name":"LINC01101","canonical_id":"hgnc:HGNC:25923","description":"long independently transcribed non-coding RNA 1101","metadata":{"aliases":["FLJ14816"]}},{"id":"2da1d249f2c0405fab6bc98605a768bf","type":"GENE","name":"LINC01102","canonical_id":"hgnc:HGNC:27165","description":"long independently transcribed non-coding RNA 1102","metadata":null},{"id":"65a747e35bd74df791d7acc1b04fb383","type":"GENE","name":"LINC01103","canonical_id":"hgnc:HGNC:49225","description":"long independently transcribed non-coding RNA 1103","metadata":null},{"id":"27c23b45bd224b1c80c71c68ea782a6f","type":"GENE","name":"LINC01104","canonical_id":"hgnc:HGNC:49226","description":"long independently transcribed non-coding RNA 1104","metadata":null},{"id":"d27f4cd8fbf149678945dccf627a47dd","type":"GENE","name":"LINC01106","canonical_id":"hgnc:HGNC:26769","description":"long independently transcribed non-coding RNA 1106","metadata":{"aliases":["FLJ38359"]}},{"id":"5239675e1dde4712bb8330c6cb3fcee2","type":"GENE","name":"LINC01107","canonical_id":"hgnc:HGNC:49229","description":"long independently transcribed non-coding RNA 1107","metadata":null},{"id":"ad756398ecd3476d940e50b3e78413dd","type":"GENE","name":"LINC01108","canonical_id":"hgnc:HGNC:49234","description":"long independently transcribed non-coding RNA 1108","metadata":{"aliases":["LncRNA-ES1"]}},{"id":"cfb13b769c254156b3a761b62b3988e1","type":"GENE","name":"LINC01109","canonical_id":"hgnc:HGNC:49235","description":"long independently transcribed non-coding RNA 1109","metadata":{"aliases":["lncRNA-N1"]}},{"id":"8c760d1b6e334a66bf03e28b1b324768","type":"GENE","name":"LINC01111","canonical_id":"hgnc:HGNC:49237","description":"long independently transcribed non-coding RNA 1111","metadata":null},{"id":"54c13ffb198647949c713323d58f6983","type":"GENE","name":"LINC01115","canonical_id":"hgnc:HGNC:49258","description":"long independently transcribed non-coding RNA 1115","metadata":null},{"id":"8348201c7381462aaa2a82d33cabfbf0","type":"GENE","name":"LINC01116","canonical_id":"hgnc:HGNC:49259","description":"long independently transcribed non-coding RNA 1116","metadata":{"aliases":["TALNEC2"]}},{"id":"b55f112e345b471080c66459d2b7ba7b","type":"GENE","name":"LINC01117","canonical_id":"hgnc:HGNC:49260","description":"long independently transcribed non-coding RNA 1117","metadata":{"aliases":["uc.109"]}},{"id":"7a9458a0e2a142b5a869151e6c101f5a","type":"GENE","name":"LINC01118","canonical_id":"hgnc:HGNC:49261","description":"long independently transcribed non-coding RNA 1118","metadata":null},{"id":"3a5f842088544a37bbdf3d201a469420","type":"GENE","name":"LINC01119","canonical_id":"hgnc:HGNC:49262","description":"long independently transcribed non-coding RNA 1119","metadata":null},{"id":"7c2669782fe44207a94603f503d88c03","type":"GENE","name":"LINC01120","canonical_id":"hgnc:HGNC:49265","description":"long independently transcribed non-coding RNA 1120","metadata":null},{"id":"6bbe70a5170d4d27b05f7e137ca80229","type":"GENE","name":"LINC01121","canonical_id":"hgnc:HGNC:49266","description":"long independently transcribed non-coding RNA 1121","metadata":{"aliases":["UNQ6975"]}},{"id":"2974be431ce44cdaa7d1049fb6535dc9","type":"GENE","name":"LINC01122","canonical_id":"hgnc:HGNC:49267","description":"long independently transcribed non-coding RNA 1122","metadata":{"aliases":["uc.54","uc.53","uc.52","FLJ30838","AC007092.1","LINC01793"]}},{"id":"ed52d786933c4a29afe156d2e85abd1c","type":"GENE","name":"LINC01123","canonical_id":"hgnc:HGNC:49269","description":"long independently transcribed non-coding RNA 1123","metadata":{"aliases":["YG-6"]}},{"id":"2c676fd591fc4395b582548abdaf4920","type":"GENE","name":"LINC01124","canonical_id":"hgnc:HGNC:49270","description":"long independently transcribed non-coding RNA 1124","metadata":null},{"id":"4ce8cfc971ad49ff8f6a24c3eb21c7f0","type":"GENE","name":"LINC01126","canonical_id":"hgnc:HGNC:49275","description":"long independently transcribed non-coding RNA 1126","metadata":null},{"id":"d1fe79e01cef40aa95aeeab4dd0c91db","type":"GENE","name":"LINC01127","canonical_id":"hgnc:HGNC:49292","description":"long independently transcribed non-coding RNA 1127","metadata":null},{"id":"3a086a2418424350a9e3c3f6061490be","type":"GENE","name":"LINC01128","canonical_id":"hgnc:HGNC:49377","description":"long independently transcribed non-coding RNA 1128","metadata":{"aliases":["RP11-206L10.11"]}},{"id":"9f4a875dd45c4c859148e0b83a6f6153","type":"GENE","name":"LINC01132","canonical_id":"hgnc:HGNC:49444","description":"long independently transcribed non-coding RNA 1132","metadata":null},{"id":"8450264c53094de4adc6a5ece8d9443e","type":"GENE","name":"LINC01133","canonical_id":"hgnc:HGNC:49447","description":"long independently transcribed non-coding RNA 1133","metadata":{"aliases":["lncRNA-PAGBC"]}},{"id":"1cf4122b291b45938a215609e84a53d8","type":"GENE","name":"LINC01134","canonical_id":"hgnc:HGNC:49449","description":"long independently transcribed non-coding RNA 1134","metadata":{"aliases":["TLNC1"]}},{"id":"5ad136eea2044f03a15f9b3f1dcba2f9","type":"GENE","name":"LINC01138","canonical_id":"hgnc:HGNC:49454","description":"long independently transcribed non-coding RNA 1138","metadata":{"aliases":["FLJ39739","MP60","LINC00875","LINC01731"]}},{"id":"1d41302aba57459e8877d109fa0300f3","type":"GENE","name":"LINC01139","canonical_id":"hgnc:HGNC:27924","description":"long independently transcribed non-coding RNA 1139","metadata":{"aliases":["LINK-A","TCONS_00000027"]}},{"id":"39744a4e41fe49aa9e5ee427e9b6acd0","type":"GENE","name":"LINC01140","canonical_id":"hgnc:HGNC:27922","description":"long independently transcribed non-coding RNA 1140","metadata":{"aliases":["FLJ41676"]}},{"id":"661b5a8be85d4475b7fe1f40aa3c14ec","type":"GENE","name":"LINC01141","canonical_id":"hgnc:HGNC:49455","description":"long independently transcribed non-coding RNA 1141","metadata":null},{"id":"dedd2ce2eb1f456195fd94b737be56e7","type":"GENE","name":"LINC01142","canonical_id":"hgnc:HGNC:49456","description":"long independently transcribed non-coding RNA 1142","metadata":null},{"id":"2512d8356d144c4991d8eb6425839c5e","type":"GENE","name":"LINC01143","canonical_id":"hgnc:HGNC:49458","description":"long independently transcribed non-coding RNA 1143","metadata":null},{"id":"80f4078a3fa8483b9e34f66ac82ad36a","type":"GENE","name":"LINC01144","canonical_id":"hgnc:HGNC:49460","description":"long independently transcribed non-coding RNA 1144","metadata":{"aliases":["TCONS_00000513"]}},{"id":"a4661c8e376a4e5da29af04cdb5d3a86","type":"GENE","name":"LINC01145","canonical_id":"hgnc:HGNC:49462","description":"long independently transcribed non-coding RNA 1145","metadata":null},{"id":"f4b49f94b98442589c3660813a3b1059","type":"GENE","name":"LINC01147","canonical_id":"hgnc:HGNC:49468","description":"long independently transcribed non-coding RNA 1147","metadata":null},{"id":"53598764e20946f885e604c9050ca42f","type":"GENE","name":"LINC01148","canonical_id":"hgnc:HGNC:27507","description":"long independently transcribed non-coding RNA 1148","metadata":{"aliases":["LOC283585"]}},{"id":"87e6b349fb1640a7ba0d56d00f900d85","type":"GENE","name":"LINC01149","canonical_id":"hgnc:HGNC:39757","description":"long independently transcribed non-coding RNA 1149","metadata":{"aliases":["XXbac-BPG181B23.4"]}},{"id":"5e66945de1b24169976f0cdbdd501ff3","type":"GENE","name":"LINC01150","canonical_id":"hgnc:HGNC:49469","description":"long independently transcribed non-coding RNA 1150","metadata":{"aliases":["2G7","TCONS_00019134"]}},{"id":"5ccd5ebbe3184dd989608c7e2d39eda9","type":"GENE","name":"LINC01151","canonical_id":"hgnc:HGNC:49471","description":"long independently transcribed non-coding RNA 1151","metadata":null},{"id":"5e68f0cb133a4d579c816f55eed941ac","type":"GENE","name":"LINC01152","canonical_id":"hgnc:HGNC:16752","description":"long independently transcribed non-coding RNA 1152","metadata":{"aliases":["TCONS_00025128","CMPD","RP11-84E24.3"]}},{"id":"1e120866fc3445af8c083e0c7df29b38","type":"GENE","name":"LINC01153","canonical_id":"hgnc:HGNC:49495","description":"long independently transcribed non-coding RNA 1153","metadata":null},{"id":"bb96d432dcc14169b64a0f10a6c5ca33","type":"GENE","name":"LINC01157","canonical_id":"hgnc:HGNC:49512","description":"long independently transcribed non-coding RNA 1157","metadata":{"aliases":["TCONS_00010378","linc-Enc1","Lncenc1"]}},{"id":"f75acfc97ca8477983bdd63a0ba69e70","type":"GENE","name":"LINC01159","canonical_id":"hgnc:HGNC:49514","description":"long independently transcribed non-coding RNA 1159","metadata":{"aliases":["linc-Brn1b"]}},{"id":"c386cd92e80648508c9466303479d181","type":"GENE","name":"LINC01160","canonical_id":"hgnc:HGNC:49525","description":"long independently transcribed non-coding RNA 1160","metadata":null},{"id":"72406133997a4919b044a385787b44e8","type":"GENE","name":"LINC01162","canonical_id":"hgnc:HGNC:49528","description":"long independently transcribed non-coding RNA 1162","metadata":{"aliases":["uc.206"]}},{"id":"fab0799b05b4472ca4a0abd955d30865","type":"GENE","name":"LINC01163","canonical_id":"hgnc:HGNC:49530","description":"long independently transcribed non-coding RNA 1163","metadata":{"aliases":["TCONS_00017722"]}},{"id":"2555e40161394b9dbaf74ec38f6b7070","type":"GENE","name":"LINC01164","canonical_id":"hgnc:HGNC:49533","description":"long independently transcribed non-coding RNA 1164","metadata":null},{"id":"dd0c73d966594a62a75f560dd6d51fac","type":"GENE","name":"LINC01165","canonical_id":"hgnc:HGNC:49534","description":"long independently transcribed non-coding RNA 1165","metadata":null},{"id":"3805849719a24e3a9648b77b956e22f0","type":"GENE","name":"LINC01166","canonical_id":"hgnc:HGNC:49535","description":"long independently transcribed non-coding RNA 1166","metadata":{"aliases":["LINC01167"]}},{"id":"9567a323f51b4cb194d916121fba0e56","type":"GENE","name":"LINC01168","canonical_id":"hgnc:HGNC:49537","description":"long independently transcribed non-coding RNA 1168","metadata":null},{"id":"950be708aa744166a0146859bf59ba99","type":"GENE","name":"LINC01169","canonical_id":"hgnc:HGNC:49541","description":"long independently transcribed non-coding RNA 1169","metadata":null},{"id":"d516140a8e204185ab86d02b7dd27c73","type":"GENE","name":"LINC01170","canonical_id":"hgnc:HGNC:49542","description":"long independently transcribed non-coding RNA 1170","metadata":null},{"id":"0629eeb20eac4ef6b08a385c23e1971a","type":"GENE","name":"LINC01173","canonical_id":"hgnc:HGNC:49545","description":"long independently transcribed non-coding RNA 1173","metadata":{"aliases":["TCONS_00004057"]}},{"id":"98b9141c9acd4412baad2065ceb7aeeb","type":"GENE","name":"LINC01176","canonical_id":"hgnc:HGNC:49548","description":"long independently transcribed non-coding RNA 1176","metadata":null},{"id":"d59cd985001842679f94ac419764f59a","type":"GENE","name":"LINC01177","canonical_id":"hgnc:HGNC:49549","description":"long independently transcribed non-coding RNA 1177","metadata":null},{"id":"b178311a35934817b61dabeb44045e75","type":"GENE","name":"LINC01179","canonical_id":"hgnc:HGNC:49556","description":"long independently transcribed non-coding RNA 1179","metadata":null},{"id":"bc122f0a8508494e9a20d1a9f41e4b01","type":"GENE","name":"LINC01180","canonical_id":"hgnc:HGNC:49558","description":"long independently transcribed non-coding RNA 1180","metadata":null},{"id":"1b6a70c229b54e1e859f05991614511c","type":"GENE","name":"LINC01181","canonical_id":"hgnc:HGNC:25533","description":"long independently transcribed non-coding RNA 1181","metadata":{"aliases":["FLJ10489"]}},{"id":"7e248632059648448ba210347f2ec6df","type":"GENE","name":"LINC01182","canonical_id":"hgnc:HGNC:49564","description":"long independently transcribed non-coding RNA 1182","metadata":null},{"id":"03720cbd5cfe44f793e55be7a7c6ac7e","type":"GENE","name":"LINC01186","canonical_id":"hgnc:HGNC:49573","description":"long independently transcribed non-coding RNA 1186","metadata":{"aliases":["ZNF674-1"]}},{"id":"482449f166994228a8f811e863b392c8","type":"GENE","name":"LINC01187","canonical_id":"hgnc:HGNC:49575","description":"long independently transcribed non-coding RNA 1187","metadata":{"aliases":["KIDR"]}},{"id":"89e59d00463b42c2bc4206ad34c1dd02","type":"GENE","name":"LINC01189","canonical_id":"hgnc:HGNC:49592","description":"long independently transcribed non-coding RNA 1189","metadata":null},{"id":"575dde5ccade4dbd8fb1cb9b72b8c6c5","type":"GENE","name":"LINC01191","canonical_id":"hgnc:HGNC:49595","description":"long independently transcribed non-coding RNA 1191","metadata":{"aliases":["VIN","lnc-ACTR3"]}},{"id":"11e0373478ea43d2b115c6a44c56930d","type":"GENE","name":"LINC01192","canonical_id":"hgnc:HGNC:37197","description":"long independently transcribed non-coding RNA 1192","metadata":{"aliases":["CT64"]}},{"id":"1b01492401e048918f5fa506cc556893","type":"GENE","name":"LINC01193","canonical_id":"hgnc:HGNC:28003","description":"long independently transcribed non-coding RNA 1193","metadata":{"aliases":["LOC348120","CT60"]}},{"id":"3375e7da284f4a61a504cabb19224821","type":"GENE","name":"LINC01194","canonical_id":"hgnc:HGNC:37171","description":"long independently transcribed non-coding RNA 1194","metadata":{"aliases":["TAG","CT49"]}},{"id":"a7e29f0bfd05455ab9d4cd861199df93","type":"GENE","name":"LINC01195","canonical_id":"hgnc:HGNC:49550","description":"long independently transcribed non-coding RNA 1195","metadata":null},{"id":"3cbed29afbfd448ba076d5354a81ba80","type":"GENE","name":"LINC01198","canonical_id":"hgnc:HGNC:49598","description":"long independently transcribed non-coding RNA 1198","metadata":null},{"id":"ad2d2a5c662745f8b458d166d4030129","type":"GENE","name":"LINC01201","canonical_id":"hgnc:HGNC:49632","description":"long independently transcribed non-coding RNA 1201","metadata":{"aliases":["TCONS_00017091"]}},{"id":"4358a271fe5d4410bdf72151ee4f8d23","type":"GENE","name":"LINC01202","canonical_id":"hgnc:HGNC:49633","description":"long independently transcribed non-coding RNA 1202","metadata":null},{"id":"37fec57fcd104866b6e1f87e4b0d8e11","type":"GENE","name":"LINC01203","canonical_id":"hgnc:HGNC:49634","description":"long independently transcribed non-coding RNA 1203","metadata":null},{"id":"24aeab31430942edb8bb8523723b125b","type":"GENE","name":"LINC01204","canonical_id":"hgnc:HGNC:49635","description":"long independently transcribed non-coding RNA 1204","metadata":null},{"id":"04a4b063480f40dd9fe60752e3ed5d12","type":"GENE","name":"LINC01205","canonical_id":"hgnc:HGNC:49636","description":"long independently transcribed non-coding RNA 1205","metadata":null},{"id":"10b2b1f2107047c9a82efc7971fd1fac","type":"GENE","name":"LINC01206","canonical_id":"hgnc:HGNC:49637","description":"long independently transcribed non-coding RNA 1206","metadata":null},{"id":"c22e756945af448b9417bb314c5f4aac","type":"GENE","name":"LINC01208","canonical_id":"hgnc:HGNC:49639","description":"long independently transcribed non-coding RNA 1208","metadata":null},{"id":"83055d40d4d8405ca61d2e4cd4021296","type":"GENE","name":"LINC01209","canonical_id":"hgnc:HGNC:49640","description":"long independently transcribed non-coding RNA 1209","metadata":null},{"id":"c7f0437d95ba46a9a032e91b091b40ff","type":"GENE","name":"LINC01210","canonical_id":"hgnc:HGNC:49642","description":"long independently transcribed non-coding RNA 1210","metadata":null},{"id":"d6d6a2fa37774cd9b91d7dea34bc729c","type":"GENE","name":"LINC01213","canonical_id":"hgnc:HGNC:49648","description":"long independently transcribed non-coding RNA 1213","metadata":null},{"id":"e75c32e45a6b4d489eff3e59e6584eef","type":"GENE","name":"LINC01214","canonical_id":"hgnc:HGNC:49650","description":"long independently transcribed non-coding RNA 1214","metadata":null},{"id":"c4880728c3304dc38c90e321cb5fc26c","type":"GENE","name":"LINC01215","canonical_id":"hgnc:HGNC:49651","description":"long independently transcribed non-coding RNA 1215","metadata":null},{"id":"e2b85f7652e94fa698f22465b3600aa5","type":"GENE","name":"LINC01216","canonical_id":"hgnc:HGNC:41418","description":"long independently transcribed non-coding RNA 1216","metadata":{"aliases":["EMCN-IT3"]}},{"id":"711b50fbd35947c0bd55a3823536970d","type":"GENE","name":"LINC01217","canonical_id":"hgnc:HGNC:41419","description":"long independently transcribed non-coding RNA 1217","metadata":{"aliases":["EMCN-IT2"]}},{"id":"ab2af3ee4e5c46408dc18f9cfe952d55","type":"GENE","name":"LINC01218","canonical_id":"hgnc:HGNC:41420","description":"long independently transcribed non-coding RNA 1218","metadata":{"aliases":["EMCN-IT1"]}},{"id":"34df43eec1304a4287cf729c629132ba","type":"GENE","name":"LINC01219","canonical_id":"hgnc:HGNC:49653","description":"long independently transcribed non-coding RNA 1219","metadata":null},{"id":"e8cec8cd747e4546ba8803ec93db3057","type":"GENE","name":"LINC01220","canonical_id":"hgnc:HGNC:49664","description":"long independently transcribed non-coding RNA 1220","metadata":null},{"id":"49ec8b36de9a437c948a3b5522e0f4cc","type":"GENE","name":"LINC01221","canonical_id":"hgnc:HGNC:49671","description":"long independently transcribed non-coding RNA 1221","metadata":{"aliases":["TCONS_00000366"]}},{"id":"cc48c8313c6446eab5497c6b6615ca1c","type":"GENE","name":"LINC01222","canonical_id":"hgnc:HGNC:49672","description":"long independently transcribed non-coding RNA 1222","metadata":{"aliases":["TCONS_00000112"]}},{"id":"665bfd02622f4c2682d3e135c67ca876","type":"GENE","name":"LINC01224","canonical_id":"hgnc:HGNC:49676","description":"long independently transcribed non-coding RNA 1224","metadata":null},{"id":"6a89a619dd884c7f8b36ab852199dcf7","type":"GENE","name":"LINC01226","canonical_id":"hgnc:HGNC:49678","description":"long independently transcribed non-coding RNA 1226","metadata":{"aliases":["SEELA2"]}},{"id":"429f1e576f4c4894b0bfd648a39d22fb","type":"GENE","name":"LINC01227","canonical_id":"hgnc:HGNC:49680","description":"long independently transcribed non-coding RNA 1227","metadata":null},{"id":"f12832350f784fc7b7002360f107e247","type":"GENE","name":"LINC01228","canonical_id":"hgnc:HGNC:49681","description":"long independently transcribed non-coding RNA 1228","metadata":{"aliases":["lincRNA-DYNLRB2-2"]}},{"id":"62d83b0f6cf54637808fac179a52fa82","type":"GENE","name":"LINC01229","canonical_id":"hgnc:HGNC:49682","description":"long independently transcribed non-coding RNA 1229","metadata":{"aliases":["TCONS_00024480"]}},{"id":"15cee2fc1a514b1ba0cc6b8750c222f1","type":"GENE","name":"LINC01231","canonical_id":"hgnc:HGNC:49688","description":"long independently transcribed non-coding RNA 1231","metadata":null},{"id":"14f1ee45c19c4096a8a1a9e8d6d8038f","type":"GENE","name":"LINC01232","canonical_id":"hgnc:HGNC:49755","description":"long independently transcribed non-coding RNA 1232","metadata":{"aliases":["FLJ41590","TCONS_00021520","LINC00449"]}},{"id":"931f82b4f2984537a1039aa9f0b5bcf4","type":"GENE","name":"LINC01233","canonical_id":"hgnc:HGNC:49756","description":"long independently transcribed non-coding RNA 1233","metadata":{"aliases":["XLOC_013014"]}},{"id":"7d4c711b9f1342d9aad316c57978c96b","type":"GENE","name":"LINC01234","canonical_id":"hgnc:HGNC:49757","description":"long independently transcribed non-coding RNA 1234","metadata":{"aliases":["onco-lncRNA-32","MBOP"]}},{"id":"7ed3d16fa37c47cf8f6ef737c3c12cee","type":"GENE","name":"LINC01235","canonical_id":"hgnc:HGNC:49769","description":"long independently transcribed non-coding RNA 1235","metadata":{"aliases":["FLJ41200"]}},{"id":"658ad63565b74f41959f12dfab5a3b94","type":"GENE","name":"LINC01237","canonical_id":"hgnc:HGNC:49793","description":"long independently transcribed non-coding RNA 1237","metadata":{"aliases":["LINC01238"]}},{"id":"f87bf99f60cc4160be429bdc0b82a9b1","type":"GENE","name":"LINC01239","canonical_id":"hgnc:HGNC:49796","description":"long independently transcribed non-coding RNA 1239","metadata":null},{"id":"4521d293594b4c749f2b788f320f2f41","type":"GENE","name":"LINC01241","canonical_id":"hgnc:HGNC:49804","description":"long independently transcribed non-coding RNA 1241","metadata":null},{"id":"04ac09f9127d484f8bf867fdb4e5e637","type":"GENE","name":"LINC01242","canonical_id":"hgnc:HGNC:49810","description":"long independently transcribed non-coding RNA 1242","metadata":null},{"id":"6dc2fc99f06c41bfa14a95d84d253277","type":"GENE","name":"LINC01243","canonical_id":"hgnc:HGNC:49814","description":"long independently transcribed non-coding RNA 1243","metadata":null},{"id":"c84fc69a026b4d93b927e389788bad2e","type":"GENE","name":"LINC01246","canonical_id":"hgnc:HGNC:49840","description":"long independently transcribed non-coding RNA 1246","metadata":null},{"id":"d0604dfcc5cc4e39adb19fd27a7bf5f6","type":"GENE","name":"LINC01247","canonical_id":"hgnc:HGNC:49841","description":"long independently transcribed non-coding RNA 1247","metadata":null},{"id":"d5a020de9fec4cb191c60437847b1c8e","type":"GENE","name":"LINC01248","canonical_id":"hgnc:HGNC:49842","description":"long independently transcribed non-coding RNA 1248","metadata":null},{"id":"3084ed2a5def46f8a3f1c64852889a47","type":"GENE","name":"LINC01249","canonical_id":"hgnc:HGNC:49843","description":"long independently transcribed non-coding RNA 1249","metadata":null},{"id":"19926add3e664d738315db04554c9d2c","type":"GENE","name":"LINC01250","canonical_id":"hgnc:HGNC:49844","description":"long independently transcribed non-coding RNA 1250","metadata":{"aliases":["FLJ37991"]}},{"id":"80dc96c028f84c5397d8b3976907777f","type":"GENE","name":"LINC01252","canonical_id":"hgnc:HGNC:27888","description":"long independently transcribed non-coding RNA 1252","metadata":null},{"id":"cfa08482883f43cfafc655f8509e41c1","type":"GENE","name":"LINC01254","canonical_id":"hgnc:HGNC:49870","description":"long independently transcribed non-coding RNA 1254","metadata":null},{"id":"f7b029511a8d4cdca7d0945739f7f183","type":"GENE","name":"LINC01255","canonical_id":"hgnc:HGNC:49871","description":"long independently transcribed non-coding RNA 1255","metadata":null},{"id":"29f5fcec6e49415b9216c109b2d8f349","type":"GENE","name":"LINC01256","canonical_id":"hgnc:HGNC:49895","description":"long independently transcribed non-coding RNA 1256","metadata":{"aliases":["TCONS_l2_00021715"]}},{"id":"dd21609b2b7c4e0690acd1d69637620e","type":"GENE","name":"LINC01257","canonical_id":"hgnc:HGNC:26972","description":"long independently transcribed non-coding RNA 1257","metadata":null},{"id":"8caf0f1e4f7149dfafb507c6d4cc59f5","type":"GENE","name":"LINC01258","canonical_id":"hgnc:HGNC:49898","description":"long independently transcribed non-coding RNA 1258","metadata":null},{"id":"5d52d16684fc4ed8962222978be5cd40","type":"GENE","name":"LINC01259","canonical_id":"hgnc:HGNC:49899","description":"long independently transcribed non-coding RNA 1259","metadata":{"aliases":["TCONS_00007515"]}},{"id":"32bd56b2db0a4619a1500a6d30d1c89d","type":"GENE","name":"LINC01262","canonical_id":"hgnc:HGNC:50275","description":"long independently transcribed non-coding RNA 1262","metadata":{"aliases":["TCONS_l2_00021807","RP11-462G22.1"]}},{"id":"6e874cbf11e9409e8cc8b7cb10683fed","type":"GENE","name":"LINC01264","canonical_id":"hgnc:HGNC:50282","description":"long independently transcribed non-coding RNA 1264","metadata":{"aliases":["RP11-124O11.2"]}},{"id":"1d2e786e8bdb4a06bc4804c06c2d87a7","type":"GENE","name":"LINC01265","canonical_id":"hgnc:HGNC:50297","description":"long independently transcribed non-coding RNA 1265","metadata":null},{"id":"25076cf8a6e14158abe1d0b9e13e6bd1","type":"GENE","name":"LINC01266","canonical_id":"hgnc:HGNC:50309","description":"long independently transcribed non-coding RNA 1266","metadata":null},{"id":"4b6ada1492f84812912cb2d469255c09","type":"GENE","name":"LINC01267","canonical_id":"hgnc:HGNC:50320","description":"long independently transcribed non-coding RNA 1267","metadata":null},{"id":"8241e2c91f574affb52139459d4baa50","type":"GENE","name":"LINC01269","canonical_id":"hgnc:HGNC:50325","description":"long independently transcribed non-coding RNA 1269","metadata":{"aliases":["HNSCAT1","PARLncRNA-1","lncRNA-RP6-65G23.1"]}},{"id":"ea8da3b88b654ab9b5ccd386f8fb15e0","type":"GENE","name":"LINC01270","canonical_id":"hgnc:HGNC:27658","description":"long independently transcribed non-coding RNA 1270","metadata":null},{"id":"6de7963e60f54599bd0b6854ad3fa6b1","type":"GENE","name":"LINC01271","canonical_id":"hgnc:HGNC:50327","description":"long independently transcribed non-coding RNA 1271","metadata":null},{"id":"3cf0636a1c9a474e96157c02e7470633","type":"GENE","name":"LINC01273","canonical_id":"hgnc:HGNC:50329","description":"long independently transcribed non-coding RNA 1273","metadata":null},{"id":"da20c5e1384941b1b8c71e123df473e2","type":"GENE","name":"LINC01275","canonical_id":"hgnc:HGNC:50331","description":"long independently transcribed non-coding RNA 1275","metadata":null},{"id":"b526a5209d1545cc8e31bb1d136a0104","type":"GENE","name":"LINC01276","canonical_id":"hgnc:HGNC:50333","description":"long independently transcribed non-coding RNA 1276","metadata":null},{"id":"f313dea287f44c129d25da6407d32e3a","type":"GENE","name":"LINC01277","canonical_id":"hgnc:HGNC:50334","description":"long independently transcribed non-coding RNA 1277","metadata":null},{"id":"2f297f300f3c4c188b8ee6c52b26e576","type":"GENE","name":"LINC01278","canonical_id":"hgnc:HGNC:28090","description":"long independently transcribed non-coding RNA 1278","metadata":null},{"id":"4a9d07bb9f644c8b98fbd440818ddbcc","type":"GENE","name":"LINC01280","canonical_id":"hgnc:HGNC:50336","description":"long independently transcribed non-coding RNA 1280","metadata":null},{"id":"6fc2a6f6ab284ed29df95e433b28ea71","type":"GENE","name":"LINC01281","canonical_id":"hgnc:HGNC:50337","description":"long independently transcribed non-coding RNA 1281","metadata":null},{"id":"915f19ca8d8f4348975e30e206a5da9e","type":"GENE","name":"LINC01282","canonical_id":"hgnc:HGNC:50338","description":"long independently transcribed non-coding RNA 1282","metadata":null},{"id":"ab8c2627967848cb9a53b5f27b10d581","type":"GENE","name":"LINC01283","canonical_id":"hgnc:HGNC:50339","description":"long independently transcribed non-coding RNA 1283","metadata":null},{"id":"7bc3656b9ed9403d920e9a34e4bf8870","type":"GENE","name":"LINC01284","canonical_id":"hgnc:HGNC:50342","description":"long independently transcribed non-coding RNA 1284","metadata":null},{"id":"33643ce19d7a4c768fa84a2da0371b5b","type":"GENE","name":"LINC01285","canonical_id":"hgnc:HGNC:50344","description":"long independently transcribed non-coding RNA 1285","metadata":null},{"id":"8cf2d44c41ac42bca6b14ed66f126737","type":"GENE","name":"LINC01287","canonical_id":"hgnc:HGNC:50351","description":"long independently transcribed non-coding RNA 1287","metadata":{"aliases":["TCONS_l2_00027522"]}},{"id":"a2e77a2419484f42a2aea4b108be3cb3","type":"GENE","name":"LINC01288","canonical_id":"hgnc:HGNC:50353","description":"long independently transcribed non-coding RNA 1288","metadata":{"aliases":["TCONS_00014671"]}},{"id":"ec2f9513f6994952b5b40066077298cb","type":"GENE","name":"LINC01289","canonical_id":"hgnc:HGNC:50354","description":"long independently transcribed non-coding RNA 1289","metadata":null},{"id":"28aa5b07e304498491d1a4ac30ba6d2e","type":"GENE","name":"LINC01290","canonical_id":"hgnc:HGNC:50356","description":"long independently transcribed non-coding RNA 1290","metadata":null},{"id":"9f48c8955dfc470db6c99f037496717c","type":"GENE","name":"LINC01291","canonical_id":"hgnc:HGNC:50358","description":"long independently transcribed non-coding RNA 1291","metadata":{"aliases":["TCONS_00002938","AC104135.4","LINC01293"]}},{"id":"a386f5ca51af4ae1aa23abf97111e38c","type":"GENE","name":"LINC01297","canonical_id":"hgnc:HGNC:50443","description":"long independently transcribed non-coding RNA 1297","metadata":null},{"id":"e3e9fe112b03439d95f030a12c11c00d","type":"GENE","name":"LINC01298","canonical_id":"hgnc:HGNC:32292","description":"long independently transcribed non-coding RNA 1298","metadata":{"aliases":["C8orf69"]}},{"id":"5c124d6c577144cabb065cb4848121c9","type":"GENE","name":"LINC01299","canonical_id":"hgnc:HGNC:27839","description":"long independently transcribed non-coding RNA 1299","metadata":null},{"id":"f3c295ee7f574693912b2dae9a2b5ede","type":"GENE","name":"LINC01300","canonical_id":"hgnc:HGNC:50460","description":"long independently transcribed non-coding RNA 1300","metadata":null},{"id":"775ab4e348f249879698419d83434f7e","type":"GENE","name":"LINC01301","canonical_id":"hgnc:HGNC:50464","description":"long independently transcribed non-coding RNA 1301","metadata":null},{"id":"b3967b95fe6e42b7b89d560d59ddcdc5","type":"GENE","name":"LINC01303","canonical_id":"hgnc:HGNC:50470","description":"long independently transcribed non-coding RNA 1303","metadata":null},{"id":"ec9cb3a1bbf64494a0862d13fd48c93b","type":"GENE","name":"LINC01304","canonical_id":"hgnc:HGNC:50472","description":"long independently transcribed non-coding RNA 1304","metadata":null},{"id":"6393eec85f5d4910aa57ed0374d67e41","type":"GENE","name":"LINC01305","canonical_id":"hgnc:HGNC:27690","description":"long independently transcribed non-coding RNA 1305","metadata":null},{"id":"dacbb7d1880d458c8d5fd88fef6e1557","type":"GENE","name":"LINC01307","canonical_id":"hgnc:HGNC:50494","description":"long independently transcribed non-coding RNA 1307","metadata":{"aliases":["RP11-157N3.1"]}},{"id":"f79d0a44d99540bab99acd14ae610f63","type":"GENE","name":"LINC01309","canonical_id":"hgnc:HGNC:50497","description":"long independently transcribed non-coding RNA 1309","metadata":{"aliases":["TCONS_l2_00007459"]}},{"id":"58908761094648f39005a735e3599b20","type":"GENE","name":"LINC01310","canonical_id":"hgnc:HGNC:50501","description":"long independently transcribed non-coding RNA 1310","metadata":{"aliases":["WI2-81516E3.1"]}},{"id":"9bcfe07d184642fb9397785f19d17cb5","type":"GENE","name":"LINC01311","canonical_id":"hgnc:HGNC:50503","description":"long independently transcribed non-coding RNA 1311","metadata":null},{"id":"5185262c61ba450dad9251bb7471bb94","type":"GENE","name":"LINC01312","canonical_id":"hgnc:HGNC:28525","description":"long independently transcribed non-coding RNA 1312","metadata":{"aliases":["MGC34034"]}},{"id":"ea6fad7e59004d058c0ef538d9b3b0e3","type":"GENE","name":"LINC01315","canonical_id":"hgnc:HGNC:50513","description":"long independently transcribed non-coding RNA 1315","metadata":{"aliases":["lnc-C22orf32-1","C22orf32-1"]}},{"id":"8d96760125174cbdaf7b38b3e726bcd0","type":"GENE","name":"LINC01317","canonical_id":"hgnc:HGNC:50523","description":"long independently transcribed non-coding RNA 1317","metadata":null},{"id":"d63c007639d24aa3bc29516ecc6c33ef","type":"GENE","name":"LINC01318","canonical_id":"hgnc:HGNC:50524","description":"long independently transcribed non-coding RNA 1318","metadata":null},{"id":"5a7b49c9b5d34c029ee651a71eb40d3f","type":"GENE","name":"LINC01320","canonical_id":"hgnc:HGNC:50526","description":"long independently transcribed non-coding RNA 1320","metadata":null},{"id":"64aa015ebc07459ba7a33df65508ede2","type":"GENE","name":"LINC01322","canonical_id":"hgnc:HGNC:50528","description":"long independently transcribed non-coding RNA 1322","metadata":{"aliases":["RUS"]}},{"id":"e699dbb439644e7dbf31de6706de4891","type":"GENE","name":"LINC01324","canonical_id":"hgnc:HGNC:50530","description":"long independently transcribed non-coding RNA 1324","metadata":{"aliases":["LINC01323"]}},{"id":"6e3b39aa97e54b6387727abcbe94bbc6","type":"GENE","name":"LINC01326","canonical_id":"hgnc:HGNC:50532","description":"long independently transcribed non-coding RNA 1326","metadata":{"aliases":["TCONS_00005878"]}},{"id":"9d2a05bdec0647d69604a3d17ca92eac","type":"GENE","name":"LINC01327","canonical_id":"hgnc:HGNC:50533","description":"long independently transcribed non-coding RNA 1327","metadata":{"aliases":["TCONS_00005644"]}},{"id":"d0c3092db5d7477990bbc68b805885d1","type":"GENE","name":"LINC01331","canonical_id":"hgnc:HGNC:50538","description":"long independently transcribed non-coding RNA 1331","metadata":{"aliases":["LINC01332","LINC01335"]}},{"id":"2a7b4b3935a4499aa13bd85822251054","type":"GENE","name":"LINC01333","canonical_id":"hgnc:HGNC:50539","description":"long independently transcribed non-coding RNA 1333","metadata":null},{"id":"9ec05920ab0c4f5181fe499e8a16a5fe","type":"GENE","name":"LINC01337","canonical_id":"hgnc:HGNC:50546","description":"long independently transcribed non-coding RNA 1337","metadata":{"aliases":["TCONS_00009713"]}},{"id":"9ade27dd100d4a1898280096b3dd85ce","type":"GENE","name":"LINC01338","canonical_id":"hgnc:HGNC:50547","description":"long independently transcribed non-coding RNA 1338","metadata":null},{"id":"4af3b64e92ed43b5b08aaa92becc72b6","type":"GENE","name":"LINC01339","canonical_id":"hgnc:HGNC:50549","description":"long independently transcribed non-coding RNA 1339","metadata":null},{"id":"8b48bd12a38948eab70f7f597d059a49","type":"GENE","name":"LINC01340","canonical_id":"hgnc:HGNC:50550","description":"long independently transcribed non-coding RNA 1340","metadata":{"aliases":["LINC02234"]}},{"id":"9af74cd4ad55473ea106b12480e13fff","type":"GENE","name":"LINC01341","canonical_id":"hgnc:HGNC:49457","description":"long independently transcribed non-coding RNA 1341","metadata":{"aliases":["CRL"]}},{"id":"72d99aa2d4594e399ec800a8b6689089","type":"GENE","name":"LINC01342","canonical_id":"hgnc:HGNC:50551","description":"long independently transcribed non-coding RNA 1342","metadata":null},{"id":"e2f40ede41204dc483a343dce5c285a1","type":"GENE","name":"LINC01343","canonical_id":"hgnc:HGNC:50553","description":"long independently transcribed non-coding RNA 1343","metadata":null},{"id":"578960ce15e6414ea7746387d07389a0","type":"GENE","name":"LINC01344","canonical_id":"hgnc:HGNC:50554","description":"long independently transcribed non-coding RNA 1344","metadata":null},{"id":"003e48797d624605a8e20a442f46223c","type":"GENE","name":"LINC01345","canonical_id":"hgnc:HGNC:50564","description":"long independently transcribed non-coding RNA 1345","metadata":null},{"id":"8a59b15c4997460dbbe53f58dda7d7cb","type":"GENE","name":"LINC01346","canonical_id":"hgnc:HGNC:50563","description":"long independently transcribed non-coding RNA 1346","metadata":null},{"id":"4d00a662604040e686a8ea4ca96f95d8","type":"GENE","name":"LINC01347","canonical_id":"hgnc:HGNC:50566","description":"long independently transcribed non-coding RNA 1347","metadata":null},{"id":"4b872675c2ae40d9ab9007af37190c81","type":"GENE","name":"LINC01348","canonical_id":"hgnc:HGNC:50567","description":"long independently transcribed non-coding RNA 1348","metadata":null},{"id":"f7c417d431674d72981619c80c7c1325","type":"GENE","name":"LINC01349","canonical_id":"hgnc:HGNC:50568","description":"long independently transcribed non-coding RNA 1349","metadata":null},{"id":"0628b4acef024153b454f9fd5cfbc4b7","type":"GENE","name":"LINC01350","canonical_id":"hgnc:HGNC:50575","description":"long independently transcribed non-coding RNA 1350","metadata":null},{"id":"cf71bf7e1ce74ce99755a5c2699beb18","type":"GENE","name":"LINC01352","canonical_id":"hgnc:HGNC:50578","description":"long independently transcribed non-coding RNA 1352","metadata":null},{"id":"8caff89f9f60430cb566ae0650df3150","type":"GENE","name":"LINC01353","canonical_id":"hgnc:HGNC:50580","description":"long independently transcribed non-coding RNA 1353","metadata":null},{"id":"d1e6e68bf1554de3ade7773c118df8de","type":"GENE","name":"LINC01354","canonical_id":"hgnc:HGNC:50581","description":"long independently transcribed non-coding RNA 1354","metadata":null},{"id":"a11f78f8cd05419ba7be99d66dc1d19a","type":"GENE","name":"LINC01355","canonical_id":"hgnc:HGNC:50584","description":"long independently transcribed non-coding RNA 1355","metadata":{"aliases":["HYPAL"]}},{"id":"b3eefdf1ee104500a186d6f71937c23f","type":"GENE","name":"LINC01356","canonical_id":"hgnc:HGNC:50587","description":"long independently transcribed non-coding RNA 1356","metadata":{"aliases":["LIMp27"]}},{"id":"ccc5ef77c9f348ffad4fbf78ae8198d4","type":"GENE","name":"LINC01359","canonical_id":"hgnc:HGNC:50591","description":"long independently transcribed non-coding RNA 1359","metadata":null},{"id":"f62a0f6b3abf4091a7f09c5c0398605b","type":"GENE","name":"LINC01360","canonical_id":"hgnc:HGNC:50593","description":"long independently transcribed non-coding RNA 1360","metadata":null},{"id":"7ebcb1f4b32c4d14a00795071edba4a2","type":"GENE","name":"LINC01361","canonical_id":"hgnc:HGNC:50595","description":"long independently transcribed non-coding RNA 1361","metadata":null},{"id":"3420e063f33e491fb85a4adbf660a070","type":"GENE","name":"LINC01362","canonical_id":"hgnc:HGNC:50596","description":"long independently transcribed non-coding RNA 1362","metadata":null},{"id":"1bf02ed9ff314700bfef9db2527e8df5","type":"GENE","name":"LINC01363","canonical_id":"hgnc:HGNC:50598","description":"long independently transcribed non-coding RNA 1363","metadata":{"aliases":["RBSG4"]}},{"id":"e31fb162e7d447d1a6d635cbbf1a5a34","type":"GENE","name":"LINC01364","canonical_id":"hgnc:HGNC:50599","description":"long independently transcribed non-coding RNA 1364","metadata":{"aliases":["uc.29"]}},{"id":"c8ab6330743f43be81ede5b2791b4351","type":"GENE","name":"LINC01365","canonical_id":"hgnc:HGNC:50603","description":"long independently transcribed non-coding RNA 1365","metadata":null},{"id":"f2a34c5ec390467387d55e7b31477d83","type":"GENE","name":"LINC01366","canonical_id":"hgnc:HGNC:27416","description":"long independently transcribed non-coding RNA 1366","metadata":null},{"id":"3af7c229c3f14480819c42b284cbe4e6","type":"GENE","name":"LINC01370","canonical_id":"hgnc:HGNC:50608","description":"long independently transcribed non-coding RNA 1370","metadata":{"aliases":["HI-LNC25"]}},{"id":"2037c86b39d94792a0f0936edf9c6982","type":"GENE","name":"LINC01372","canonical_id":"hgnc:HGNC:50623","description":"long independently transcribed non-coding RNA 1372","metadata":null},{"id":"0f2da0afeaf7407aaed876bc78f3ed7e","type":"GENE","name":"LINC01375","canonical_id":"hgnc:HGNC:50632","description":"long independently transcribed non-coding RNA 1375","metadata":null},{"id":"ed9ca358a542456aa798b59f03a6fe30","type":"GENE","name":"LINC01376","canonical_id":"hgnc:HGNC:50637","description":"long independently transcribed non-coding RNA 1376","metadata":null},{"id":"512b5de5205745fcb6741610e3892947","type":"GENE","name":"LINC01377","canonical_id":"hgnc:HGNC:50642","description":"long independently transcribed non-coding RNA 1377","metadata":null},{"id":"82a45a4b75c54d6f9c9843c725def4f4","type":"GENE","name":"LINC01378","canonical_id":"hgnc:HGNC:50645","description":"long independently transcribed non-coding RNA 1378","metadata":null},{"id":"b63f209126b7458cb0ffdcfc2fb86de0","type":"GENE","name":"LINC01381","canonical_id":"hgnc:HGNC:50653","description":"long independently transcribed non-coding RNA 1381","metadata":{"aliases":["TCONS_00002860","DADOT"]}},{"id":"e97970c59fee4283a021fd1086f7ec65","type":"GENE","name":"LINC01385","canonical_id":"hgnc:HGNC:50657","description":"long independently transcribed non-coding RNA 1385","metadata":{"aliases":["TCONS_00009424"]}},{"id":"ec17d448024f41f8b518ddeedc4d93bb","type":"GENE","name":"LINC01386","canonical_id":"hgnc:HGNC:50659","description":"long independently transcribed non-coding RNA 1386","metadata":null},{"id":"c98e23ca6fd6457787cf7847c54c12b1","type":"GENE","name":"LINC01387","canonical_id":"hgnc:HGNC:44660","description":"long independently transcribed non-coding RNA 1387","metadata":{"aliases":["C18orf64"]}},{"id":"e4449d6a95a04d1e85a0a58aee8d553e","type":"GENE","name":"LINC01388","canonical_id":"hgnc:HGNC:50660","description":"long independently transcribed non-coding RNA 1388","metadata":{"aliases":["TCONS_l2_00029888"]}},{"id":"f9393ff38d374e24aef92675901b6ee4","type":"GENE","name":"LINC01389","canonical_id":"hgnc:HGNC:50661","description":"long independently transcribed non-coding RNA 1389","metadata":null},{"id":"479e0e2bfdce4f04835f27dbf85b903e","type":"GENE","name":"LINC01391","canonical_id":"hgnc:HGNC:50666","description":"long independently transcribed non-coding RNA 1391","metadata":null},{"id":"4dc749fee8c4440092573ea8bc16927a","type":"GENE","name":"LINC01392","canonical_id":"hgnc:HGNC:50668","description":"long independently transcribed non-coding RNA 1392","metadata":null},{"id":"c9644b3a248543b881024082a76e97d3","type":"GENE","name":"LINC01393","canonical_id":"hgnc:HGNC:50669","description":"long independently transcribed non-coding RNA 1393","metadata":null},{"id":"0f79da5c3b8a458b90d4f321260bb4e7","type":"GENE","name":"LINC01395","canonical_id":"hgnc:HGNC:50674","description":"long independently transcribed non-coding RNA 1395","metadata":{"aliases":["TCONS_00019178"]}},{"id":"9debfc4a4112415b9fc667836b56727e","type":"GENE","name":"LINC01396","canonical_id":"hgnc:HGNC:50675","description":"long independently transcribed non-coding RNA 1396","metadata":null},{"id":"b5952e1e4bdb403082b046f583fc492f","type":"GENE","name":"LINC01397","canonical_id":"hgnc:HGNC:50677","description":"long independently transcribed non-coding RNA 1397","metadata":null},{"id":"22bc8f2b45f24e8b9607ae6381a34c9a","type":"GENE","name":"LINC01398","canonical_id":"hgnc:HGNC:50678","description":"long independently transcribed non-coding RNA 1398","metadata":null},{"id":"fb7f228569804440a710c2ec72364796","type":"GENE","name":"LINC01399","canonical_id":"hgnc:HGNC:50680","description":"long independently transcribed non-coding RNA 1399","metadata":null},{"id":"43d4b32347524f14864ad97dfaf6596f","type":"GENE","name":"LINC01400","canonical_id":"hgnc:HGNC:50681","description":"long independently transcribed non-coding RNA 1400","metadata":{"aliases":["TCONS_00015805"]}},{"id":"dc837f7373444e44bb8739994e6885a7","type":"GENE","name":"LINC01402","canonical_id":"hgnc:HGNC:50685","description":"long independently transcribed non-coding RNA 1402","metadata":{"aliases":["TCONS_00017087"]}},{"id":"be4a8a3713ee44b58c4aa3aa61cb9782","type":"GENE","name":"LINC01404","canonical_id":"hgnc:HGNC:50689","description":"long independently transcribed non-coding RNA 1404","metadata":null},{"id":"008948ace4e44f2d903d462233d176e6","type":"GENE","name":"LINC01409","canonical_id":"hgnc:HGNC:50701","description":"long independently transcribed non-coding RNA 1409","metadata":null},{"id":"95549936d14045cbb00a9effccf9f472","type":"GENE","name":"LINC01410","canonical_id":"hgnc:HGNC:50702","description":"long independently transcribed non-coding RNA 1410","metadata":null},{"id":"a6b71b4f553743889a303814172bf065","type":"GENE","name":"LINC01411","canonical_id":"hgnc:HGNC:50703","description":"long independently transcribed non-coding RNA 1411","metadata":{"aliases":["RP11-267A15.1"]}},{"id":"d75e0dda49a24011979d52a2e211f28f","type":"GENE","name":"LINC01412","canonical_id":"hgnc:HGNC:50704","description":"long independently transcribed non-coding RNA 1412","metadata":null},{"id":"5a4e265b005940c485ab99901fddf260","type":"GENE","name":"LINC01413","canonical_id":"hgnc:HGNC:50705","description":"long independently transcribed non-coding RNA 1413","metadata":null},{"id":"ae034faa8ad843a5b370b84aacccbf5e","type":"GENE","name":"LINC01414","canonical_id":"hgnc:HGNC:50707","description":"long independently transcribed non-coding RNA 1414","metadata":null},{"id":"b79b4f4a53334cbaa8ac7bd6f751f91c","type":"GENE","name":"LINC01415","canonical_id":"hgnc:HGNC:50709","description":"long independently transcribed non-coding RNA 1415","metadata":{"aliases":["TCONS_00026208"]}},{"id":"8f399bbf3bf14c47b525e91f20236ee3","type":"GENE","name":"LINC01416","canonical_id":"hgnc:HGNC:51645","description":"long independently transcribed non-coding RNA 1416","metadata":null},{"id":"2bd54617409a45b8a98aefa6b75db68b","type":"GENE","name":"LINC01418","canonical_id":"hgnc:HGNC:50711","description":"long independently transcribed non-coding RNA 1418","metadata":{"aliases":["AC104041.1"]}},{"id":"f226ede73ee4422ca43245d719f90760","type":"GENE","name":"LINC01419","canonical_id":"hgnc:HGNC:50712","description":"long independently transcribed non-coding RNA 1419","metadata":{"aliases":["TCONS_00014497","PRLH1"]}},{"id":"587ca8d9648e40d1a8ae6da2d76a0774","type":"GENE","name":"LINC01422","canonical_id":"hgnc:HGNC:50728","description":"long independently transcribed non-coding RNA 1422","metadata":null},{"id":"ab11982121294098b072034364f13e0c","type":"GENE","name":"LINC01423","canonical_id":"hgnc:HGNC:50732","description":"long independently transcribed non-coding RNA 1423","metadata":null},{"id":"aa2f8e4cf24445e3acb53cb0c4e0df01","type":"GENE","name":"LINC01424","canonical_id":"hgnc:HGNC:40558","description":"long independently transcribed non-coding RNA 1424","metadata":null},{"id":"748dee30d31a4162a8bb6e8bbb50118e","type":"GENE","name":"LINC01425","canonical_id":"hgnc:HGNC:50733","description":"long independently transcribed non-coding RNA 1425","metadata":null},{"id":"8b3785bc5701474f9394b3704d3eabaa","type":"GENE","name":"LINC01426","canonical_id":"hgnc:HGNC:50734","description":"long independently transcribed non-coding RNA 1426","metadata":null},{"id":"0cbee7961fe94cb1996e13d988414895","type":"GENE","name":"LINC01427","canonical_id":"hgnc:HGNC:50737","description":"long independently transcribed non-coding RNA 1427","metadata":null},{"id":"ad0c6e1bc9fe41b2ab669dd1afb36c0b","type":"GENE","name":"LINC01428","canonical_id":"hgnc:HGNC:50738","description":"long independently transcribed non-coding RNA 1428","metadata":null},{"id":"0cb5dcf5864946ed9e43d06530f6b521","type":"GENE","name":"LINC01429","canonical_id":"hgnc:HGNC:50741","description":"long independently transcribed non-coding RNA 1429","metadata":null},{"id":"728c33ad42194acfa130c1a6f5213296","type":"GENE","name":"LINC01430","canonical_id":"hgnc:HGNC:50742","description":"long independently transcribed non-coding RNA 1430","metadata":{"aliases":["lncRNA-DAW"]}},{"id":"263d8977ef3c4fdcb3a961a8fcbf35e1","type":"GENE","name":"LINC01431","canonical_id":"hgnc:HGNC:50744","description":"long independently transcribed non-coding RNA 1431","metadata":null},{"id":"5d9fbdaf90db4a6995375539540f9112","type":"GENE","name":"LINC01432","canonical_id":"hgnc:HGNC:50745","description":"long independently transcribed non-coding RNA 1432","metadata":null},{"id":"838adb0dfc4b46c6977eb56befff87d3","type":"GENE","name":"LINC01433","canonical_id":"hgnc:HGNC:50746","description":"long independently transcribed non-coding RNA 1433","metadata":{"aliases":["LOC728228"]}},{"id":"216b457d9a85450db2855e1a33d82211","type":"GENE","name":"LINC01435","canonical_id":"hgnc:HGNC:50753","description":"long independently transcribed non-coding RNA 1435","metadata":{"aliases":["RP11-215N21.1","TCONS_00018040"]}},{"id":"61f8fc1dfa7b476b86870ea7617d36ee","type":"GENE","name":"LINC01436","canonical_id":"hgnc:HGNC:50754","description":"long independently transcribed non-coding RNA 1436","metadata":{"aliases":["AP000688.8"]}},{"id":"691c80570a254779bb4795fd5fe0c49f","type":"GENE","name":"LINC01438","canonical_id":"hgnc:HGNC:50757","description":"long independently transcribed non-coding RNA 1438","metadata":{"aliases":["TCONS_00007593"]}},{"id":"0cf75c31dd204cb083fd06de9ea922a8","type":"GENE","name":"LINC01440","canonical_id":"hgnc:HGNC:50762","description":"long independently transcribed non-coding RNA 1440","metadata":null},{"id":"8e5ed43a08d44cce9a435af5224fe46e","type":"GENE","name":"LINC01441","canonical_id":"hgnc:HGNC:50763","description":"long independently transcribed non-coding RNA 1441","metadata":null},{"id":"680ada243d6a4ee690cc22f57421609b","type":"GENE","name":"LINC01442","canonical_id":"hgnc:HGNC:50764","description":"long independently transcribed non-coding RNA 1442","metadata":null},{"id":"5f1fa269aa9745c796336e5e3dfbd370","type":"GENE","name":"LINC01443","canonical_id":"hgnc:HGNC:50768","description":"long independently transcribed non-coding RNA 1443","metadata":null},{"id":"b5acfe80a5004c99b36ab4ecf61457d1","type":"GENE","name":"LINC01444","canonical_id":"hgnc:HGNC:50769","description":"long independently transcribed non-coding RNA 1444","metadata":null},{"id":"e0c2995300cc4007b57f76907e15331e","type":"GENE","name":"LINC01445","canonical_id":"hgnc:HGNC:50771","description":"long independently transcribed non-coding RNA 1445","metadata":null},{"id":"71befa75536f441f828b06f3c82df61d","type":"GENE","name":"LINC01446","canonical_id":"hgnc:HGNC:50773","description":"long independently transcribed non-coding RNA 1446","metadata":{"aliases":["FLJ45974"]}},{"id":"09d0810cc7ec4c0ca55ab60ebc2db084","type":"GENE","name":"LINC01447","canonical_id":"hgnc:HGNC:50783","description":"long independently transcribed non-coding RNA 1447","metadata":null},{"id":"9a82671bc76940608b699deb8bdf9212","type":"GENE","name":"LINC01448","canonical_id":"hgnc:HGNC:50790","description":"long independently transcribed non-coding RNA 1448","metadata":null},{"id":"27048d41c0b7459dbe5c322a3a6f85a6","type":"GENE","name":"LINC01449","canonical_id":"hgnc:HGNC:50791","description":"long independently transcribed non-coding RNA 1449","metadata":null},{"id":"2bd9e41c87b14721b2f80620ac40033d","type":"GENE","name":"LINC01450","canonical_id":"hgnc:HGNC:50792","description":"long independently transcribed non-coding RNA 1450","metadata":null},{"id":"4d5e4318c53f4aff9d307f7798babb1a","type":"GENE","name":"LINC01451","canonical_id":"hgnc:HGNC:48599","description":"long independently transcribed non-coding RNA 1451","metadata":{"aliases":["HCCAT4"]}},{"id":"6038b21830434d9992e22435a9017d63","type":"GENE","name":"LINC01455","canonical_id":"hgnc:HGNC:50545","description":"long independently transcribed non-coding RNA 1455","metadata":{"aliases":["TCONS_00009433","MDONA"]}},{"id":"05142ef3e4034ab7aac496666cfb2597","type":"GENE","name":"LINC01456","canonical_id":"hgnc:HGNC:50846","description":"long independently transcribed non-coding RNA 1456","metadata":null},{"id":"6402e28a714d4af786c63b26bfc73560","type":"GENE","name":"LINC01460","canonical_id":"hgnc:HGNC:50858","description":"long independently transcribed non-coding RNA 1460","metadata":null},{"id":"c51af0d9ed9a4c1aaa7f745cb1723587","type":"GENE","name":"LINC01461","canonical_id":"hgnc:HGNC:50859","description":"long independently transcribed non-coding RNA 1461","metadata":{"aliases":["TCONS_00001552"]}},{"id":"14d75d48f7a94a449eb6f55b5ca74722","type":"GENE","name":"LINC01465","canonical_id":"hgnc:HGNC:26364","description":"long independently transcribed non-coding RNA 1465","metadata":{"aliases":["FLJ25590","C12orf61"]}},{"id":"7d70810bc5294368bbddf0df8fbfffd8","type":"GENE","name":"LINC01467","canonical_id":"hgnc:HGNC:50911","description":"long independently transcribed non-coding RNA 1467","metadata":null},{"id":"709ad52fd1aa44cdb15cd518b3e33ed1","type":"GENE","name":"LINC01470","canonical_id":"hgnc:HGNC:51105","description":"long independently transcribed non-coding RNA 1470","metadata":null},{"id":"78bd24979dfd43fa8caec1b597cb7146","type":"GENE","name":"LINC01471","canonical_id":"hgnc:HGNC:51106","description":"long independently transcribed non-coding RNA 1471","metadata":null},{"id":"6c21d68277c84d29b68839af4abc69f9","type":"GENE","name":"LINC01472","canonical_id":"hgnc:HGNC:51107","description":"long independently transcribed non-coding RNA 1472","metadata":{"aliases":["RP11-59J16.2"]}},{"id":"c05af068aeda4db08e11e99317fefc14","type":"GENE","name":"LINC01473","canonical_id":"hgnc:HGNC:51109","description":"long independently transcribed non-coding RNA 1473","metadata":null},{"id":"770c4a737fa34546b12f5dffc7536125","type":"GENE","name":"LINC01474","canonical_id":"hgnc:HGNC:51111","description":"long independently transcribed non-coding RNA 1474","metadata":null},{"id":"6756ffe0d39044bf8851d8f5d2dab7cc","type":"GENE","name":"LINC01475","canonical_id":"hgnc:HGNC:51113","description":"long independently transcribed non-coding RNA 1475","metadata":null},{"id":"a101d8684481454bbbb433942eb97728","type":"GENE","name":"LINC01476","canonical_id":"hgnc:HGNC:51117","description":"long independently transcribed non-coding RNA 1476","metadata":null},{"id":"4ae76e96b54e4cd49acc662669ec019b","type":"GENE","name":"LINC01477","canonical_id":"hgnc:HGNC:51119","description":"long independently transcribed non-coding RNA 1477","metadata":null},{"id":"bc590c43cfc04f9eb78a929b07cbbe5d","type":"GENE","name":"LINC01478","canonical_id":"hgnc:HGNC:51121","description":"long independently transcribed non-coding RNA 1478","metadata":null},{"id":"8c7555095a3546be9490d9d8c4039cf5","type":"GENE","name":"LINC01479","canonical_id":"hgnc:HGNC:51123","description":"long independently transcribed non-coding RNA 1479","metadata":null},{"id":"6095fb5aeb764456930b1fae8fe0c7ea","type":"GENE","name":"LINC01480","canonical_id":"hgnc:HGNC:51124","description":"long independently transcribed non-coding RNA 1480","metadata":null},{"id":"1a01251fde2d45b89061b1346ed91a71","type":"GENE","name":"LINC01482","canonical_id":"hgnc:HGNC:51128","description":"long independently transcribed non-coding RNA 1482","metadata":null},{"id":"16f78fcfc8ec464a92a15d27ef567f73","type":"GENE","name":"LINC01483","canonical_id":"hgnc:HGNC:51130","description":"long independently transcribed non-coding RNA 1483","metadata":null},{"id":"65d4d38a86bc467abfd1b0ab259ddd5d","type":"GENE","name":"LINC01484","canonical_id":"hgnc:HGNC:51136","description":"long independently transcribed non-coding RNA 1484","metadata":null},{"id":"39dda3a02fc34db58eaeae1a7c103937","type":"GENE","name":"LINC01485","canonical_id":"hgnc:HGNC:51138","description":"long independently transcribed non-coding RNA 1485","metadata":null},{"id":"beab3e18c2a84419a8aa09ede521f862","type":"GENE","name":"LINC01486","canonical_id":"hgnc:HGNC:51137","description":"long independently transcribed non-coding RNA 1486","metadata":{"aliases":["TCONS_00021407"]}},{"id":"c6b795948942449ba0c3a63434814ef7","type":"GENE","name":"LINC01487","canonical_id":"hgnc:HGNC:51139","description":"long independently transcribed non-coding RNA 1487","metadata":null},{"id":"431964c618764fb7bd986faa5e206dac","type":"GENE","name":"LINC01488","canonical_id":"hgnc:HGNC:51144","description":"long independently transcribed non-coding RNA 1488","metadata":{"aliases":["CUPID1"]}},{"id":"7be9e7912def478a80ac60577b3d2d28","type":"GENE","name":"LINC01489","canonical_id":"hgnc:HGNC:51145","description":"long independently transcribed non-coding RNA 1489","metadata":null},{"id":"9b2d9dfed9514733bacd5be28e846703","type":"GENE","name":"LINC01490","canonical_id":"hgnc:HGNC:51146","description":"long independently transcribed non-coding RNA 1490","metadata":null},{"id":"0c138e8f9b4646a1b263f04bc093c997","type":"GENE","name":"LINC01491","canonical_id":"hgnc:HGNC:51148","description":"long independently transcribed non-coding RNA 1491","metadata":null},{"id":"cd81ae47ce0d47a6ace159cc56655caa","type":"GENE","name":"LINC01492","canonical_id":"hgnc:HGNC:51149","description":"long independently transcribed non-coding RNA 1492","metadata":null},{"id":"c3f1b009717145ada1599cc2e5eafa6a","type":"GENE","name":"LINC01493","canonical_id":"hgnc:HGNC:51150","description":"long independently transcribed non-coding RNA 1493","metadata":null},{"id":"f4d988db91ae4279a8c14123ca3cbbcc","type":"GENE","name":"LINC01495","canonical_id":"hgnc:HGNC:51161","description":"long independently transcribed non-coding RNA 1495","metadata":null},{"id":"2dce20573b414a6fb7f45660d002933b","type":"GENE","name":"LINC01496","canonical_id":"hgnc:HGNC:51162","description":"long independently transcribed non-coding RNA 1496","metadata":null},{"id":"55ed3c22d2d84e4aad5df8843b486701","type":"GENE","name":"LINC01497","canonical_id":"hgnc:HGNC:51163","description":"long independently transcribed non-coding RNA 1497","metadata":null},{"id":"5db8f96135754c229f67003b6d770df3","type":"GENE","name":"LINC01498","canonical_id":"hgnc:HGNC:51164","description":"long independently transcribed non-coding RNA 1498","metadata":null},{"id":"d7de4d8c854f4a14a5c47556b1b0916c","type":"GENE","name":"LINC01499","canonical_id":"hgnc:HGNC:51165","description":"long independently transcribed non-coding RNA 1499","metadata":null},{"id":"7e4114773c0444978c038ba178c4db35","type":"GENE","name":"LINC01500","canonical_id":"hgnc:HGNC:51166","description":"long independently transcribed non-coding RNA 1500","metadata":null},{"id":"08fcea82a1684f70b2760ed99a03728e","type":"GENE","name":"LINC01501","canonical_id":"hgnc:HGNC:27988","description":"long independently transcribed non-coding RNA 1501","metadata":null},{"id":"2c1182c85536440aba59b6e0b120ec2b","type":"GENE","name":"LINC01502","canonical_id":"hgnc:HGNC:51183","description":"long independently transcribed non-coding RNA 1502","metadata":null},{"id":"54e82bb39c604f05a91b7ee5f3437c90","type":"GENE","name":"LINC01503","canonical_id":"hgnc:HGNC:51184","description":"long independently transcribed non-coding RNA 1503","metadata":{"aliases":["lnc-PPP2R4-5","RP11-65J3.1"]}},{"id":"d10468cebbcd4b4fab1d0ff1f68e4ea1","type":"GENE","name":"LINC01504","canonical_id":"hgnc:HGNC:51185","description":"long independently transcribed non-coding RNA 1504","metadata":null},{"id":"1fdb7da57d174717ab175ea65515ed11","type":"GENE","name":"LINC01505","canonical_id":"hgnc:HGNC:51186","description":"long independently transcribed non-coding RNA 1505","metadata":{"aliases":["uc.266","RP11-308N19.1"]}},{"id":"04b0e52ba0204c6a858d32e8ee001d8a","type":"GENE","name":"LINC01506","canonical_id":"hgnc:HGNC:51187","description":"long independently transcribed non-coding RNA 1506","metadata":null},{"id":"d37bf6025a6e49e7bc1c02ddb3a4571d","type":"GENE","name":"LINC01507","canonical_id":"hgnc:HGNC:51189","description":"long independently transcribed non-coding RNA 1507","metadata":{"aliases":["XLOC_000303"]}},{"id":"df61ab7ac4c24270bdb0df371f7f9063","type":"GENE","name":"LINC01508","canonical_id":"hgnc:HGNC:51190","description":"long independently transcribed non-coding RNA 1508","metadata":null},{"id":"13087b4e178f441b9eceadd057571b20","type":"GENE","name":"LINC01509","canonical_id":"hgnc:HGNC:51193","description":"long independently transcribed non-coding RNA 1509","metadata":null},{"id":"d21ff260f83b45699d7ed35a66d2162b","type":"GENE","name":"LINC01511","canonical_id":"hgnc:HGNC:51200","description":"long independently transcribed non-coding RNA 1511","metadata":{"aliases":["RP11-325I22.2"]}},{"id":"e5db720d74934a5ea241d3e974beb116","type":"GENE","name":"LINC01512","canonical_id":"hgnc:HGNC:51201","description":"long independently transcribed non-coding RNA 1512","metadata":{"aliases":["LOC100132354","TCONS_00011120","HI-LNC77"]}},{"id":"3b700c4e86ad49aca4423c1f0687efeb","type":"GENE","name":"LINC01514","canonical_id":"hgnc:HGNC:51207","description":"long independently transcribed non-coding RNA 1514","metadata":null},{"id":"aa8f6ea4692140eea73da096fcd30409","type":"GENE","name":"LINC01515","canonical_id":"hgnc:HGNC:51210","description":"long independently transcribed non-coding RNA 1515","metadata":null},{"id":"8c6236d4a9a3468c841b768e7ab00a47","type":"GENE","name":"LINC01516","canonical_id":"hgnc:HGNC:51211","description":"long independently transcribed non-coding RNA 1516","metadata":null},{"id":"d1b258c10912443f93333a9937f942f9","type":"GENE","name":"LINC01517","canonical_id":"hgnc:HGNC:51212","description":"long independently transcribed non-coding RNA 1517","metadata":null},{"id":"d73acca25bb6490a8506bb5578593011","type":"GENE","name":"LINC01518","canonical_id":"hgnc:HGNC:51216","description":"long independently transcribed non-coding RNA 1518","metadata":{"aliases":["JINR1"]}},{"id":"858cd615b4644ad3b6f04d01b50a37c1","type":"GENE","name":"LINC01519","canonical_id":"hgnc:HGNC:51217","description":"long independently transcribed non-coding RNA 1519","metadata":null},{"id":"a6c3bb3f420d4666a17035b43a9a7894","type":"GENE","name":"LINC01520","canonical_id":"hgnc:HGNC:51218","description":"long independently transcribed non-coding RNA 1520","metadata":null},{"id":"28b8f101d85c446689e0829e2e6ce0e5","type":"GENE","name":"LINC01521","canonical_id":"hgnc:HGNC:26029","description":"long independently transcribed non-coding RNA 1521","metadata":null},{"id":"b6f49d4296ab46039b9ffc86bb97bf10","type":"GENE","name":"LINC01522","canonical_id":"hgnc:HGNC:51224","description":"long independently transcribed non-coding RNA 1522","metadata":null},{"id":"d00f5617e00441298ac36bb971560b99","type":"GENE","name":"LINC01523","canonical_id":"hgnc:HGNC:51225","description":"long independently transcribed non-coding RNA 1523","metadata":null},{"id":"ff104e4776d5487696a1d2e875145a88","type":"GENE","name":"LINC01524","canonical_id":"hgnc:HGNC:51228","description":"long independently transcribed non-coding RNA 1524","metadata":null},{"id":"d97bfd06c0ba489da597bf186bff83ac","type":"GENE","name":"LINC01525","canonical_id":"hgnc:HGNC:51264","description":"long independently transcribed non-coding RNA 1525","metadata":{"aliases":["lnc-MAN1A2-1"]}},{"id":"dec078a472ee496fb8d08823cc971932","type":"GENE","name":"LINC01526","canonical_id":"hgnc:HGNC:51265","description":"long independently transcribed non-coding RNA 1526","metadata":{"aliases":["Lnc-FAM46A-1"]}},{"id":"aac9a772734240ceb2604e72e13bf54f","type":"GENE","name":"LINC01527","canonical_id":"hgnc:HGNC:51266","description":"long independently transcribed non-coding RNA 1527","metadata":{"aliases":["lnc-SPRR2D-1","RP1-13P20.6"]}},{"id":"93f652c7c3e54a12960d386d299c9ecc","type":"GENE","name":"LINC01530","canonical_id":"hgnc:HGNC:44320","description":"long independently transcribed non-coding RNA 1530","metadata":{"aliases":["FLJ30403"]}},{"id":"2191dc226c76452296f91f9bff02d046","type":"GENE","name":"LINC01531","canonical_id":"hgnc:HGNC:51270","description":"long independently transcribed non-coding RNA 1531","metadata":null},{"id":"c1f13a7d74934ef2b5c3bdede8ce19e0","type":"GENE","name":"LINC01532","canonical_id":"hgnc:HGNC:51272","description":"long independently transcribed non-coding RNA 1532","metadata":null},{"id":"eac846df838645779294e0c031bd7d53","type":"GENE","name":"LINC01533","canonical_id":"hgnc:HGNC:51274","description":"long independently transcribed non-coding RNA 1533","metadata":null},{"id":"82eea0762338419cb04f5829ac889125","type":"GENE","name":"LINC01535","canonical_id":"hgnc:HGNC:51282","description":"long independently transcribed non-coding RNA 1535","metadata":null},{"id":"b452728ddb994d1bac8341629fb6d48d","type":"GENE","name":"LINC01537","canonical_id":"hgnc:HGNC:51301","description":"long independently transcribed non-coding RNA 1537","metadata":{"aliases":["h-Hilnc","RP11-169D4.1-001"]}},{"id":"c795a34014a345448ca888a9fd7af7e3","type":"GENE","name":"LINC01538","canonical_id":"hgnc:HGNC:51306","description":"long independently transcribed non-coding RNA 1538","metadata":{"aliases":["TCONS_00026184","RP11-909B2.1"]}},{"id":"7585fd7490e14aeb96ff05099564180f","type":"GENE","name":"LINC01539","canonical_id":"hgnc:HGNC:51307","description":"long independently transcribed non-coding RNA 1539","metadata":{"aliases":["LINC03069"]}},{"id":"ff3494e32b3b4f3283bfe36caf70d8a8","type":"GENE","name":"LINC01541","canonical_id":"hgnc:HGNC:51309","description":"long independently transcribed non-coding RNA 1541","metadata":null},{"id":"b36f1f9474074a3ea828e9950ef634c4","type":"GENE","name":"LINC01543","canonical_id":"hgnc:HGNC:51310","description":"long independently transcribed non-coding RNA 1543","metadata":{"aliases":["TCONS_00026302"]}},{"id":"d634dad238db4c828466b50f7650c1e3","type":"GENE","name":"LINC01544","canonical_id":"hgnc:HGNC:51312","description":"long independently transcribed non-coding RNA 1544","metadata":{"aliases":["TCONS_00026194"]}},{"id":"c5ba630ff41d4fcb84c9ec9026e2fc9f","type":"GENE","name":"LINC01545","canonical_id":"hgnc:HGNC:17986","description":"long independently transcribed non-coding RNA 1545","metadata":{"aliases":["OTTHUMG00000021429","CXorf31"]}},{"id":"b914139aaad0410b9af0cff34f32a25f","type":"GENE","name":"LINC01546","canonical_id":"hgnc:HGNC:27336","description":"long independently transcribed non-coding RNA 1546","metadata":{"aliases":["VAL","CXorf28"]}},{"id":"a7297b18e8ff456787861719e6815bff","type":"GENE","name":"LINC01547","canonical_id":"hgnc:HGNC:15707","description":"long independently transcribed non-coding RNA 1547","metadata":{"aliases":["C21orf69","C21orf67"]}},{"id":"fe5058725b5748e1987542b72c559522","type":"GENE","name":"LINC01548","canonical_id":"hgnc:HGNC:1296","description":"long independently transcribed non-coding RNA 1548","metadata":{"aliases":["C21orf54"]}},{"id":"de92d65fbb8f42d984c48639f849da6b","type":"GENE","name":"LINC01549","canonical_id":"hgnc:HGNC:1277","description":"long independently transcribed non-coding RNA 1549","metadata":{"aliases":["C21orf37"]}},{"id":"bb1b6b07dd7040b19f201414caf4dae7","type":"GENE","name":"LINC01550","canonical_id":"hgnc:HGNC:20111","description":"long independently transcribed non-coding RNA 1550","metadata":{"aliases":["C14orf64"]}},{"id":"70f96ae6251c42e39e108a751027f929","type":"GENE","name":"LINC01551","canonical_id":"hgnc:HGNC:19828","description":"long independently transcribed non-coding RNA 1551","metadata":{"aliases":["C14orf23"]}},{"id":"86f0442ec8aa40a49beccbdbc107b83a","type":"GENE","name":"LINC01553","canonical_id":"hgnc:HGNC:23524","description":"long independently transcribed non-coding RNA 1553","metadata":{"aliases":["AC023904.2","C10orf40"]}},{"id":"f0ba5da7fcd84f35a6c6d81a99b5de5d","type":"GENE","name":"LINC01554","canonical_id":"hgnc:HGNC:24687","description":"long independently transcribed non-coding RNA 1554","metadata":{"aliases":["FLJ38821","FIS","C5orf27"]}},{"id":"c0b53e3b9cd44d1eb520e6e7e49d65b0","type":"GENE","name":"LINC01555","canonical_id":"hgnc:HGNC:26647","description":"long independently transcribed non-coding RNA 1555","metadata":{"aliases":["FLJ35487","C1orf180"]}},{"id":"45683971312f4218bf2f8265b9a0eda7","type":"GENE","name":"LINC01556","canonical_id":"hgnc:HGNC:21195","description":"long independently transcribed non-coding RNA 1556","metadata":{"aliases":["dJ25J6.5","C6orf100"]}},{"id":"1e8a3fde318748929601e720bdd7baca","type":"GENE","name":"LINC01559","canonical_id":"hgnc:HGNC:26598","description":"long independently transcribed non-coding RNA 1559","metadata":{"aliases":["FLJ33810","C12orf36"]}},{"id":"7d46ab5ba8bb418194c345b328ed1968","type":"GENE","name":"LINC01560","canonical_id":"hgnc:HGNC:27333","description":"long independently transcribed non-coding RNA 1560","metadata":{"aliases":["CXorf24"]}},{"id":"657d1042e84d40c6b501275552fb428a","type":"GENE","name":"LINC01561","canonical_id":"hgnc:HGNC:31365","description":"long independently transcribed non-coding RNA 1561","metadata":{"aliases":["FLJ37402","Em:AC023282.2","C10orf85"]}},{"id":"229e0dcbf0654f6cb907f396f358d127","type":"GENE","name":"LINC01562","canonical_id":"hgnc:HGNC:51335","description":"long independently transcribed non-coding RNA 1562","metadata":{"aliases":["RP11-296A18.3"]}},{"id":"788d217c3cce47b89d0c2b4b42b7d406","type":"GENE","name":"LINC01563","canonical_id":"hgnc:HGNC:51343","description":"long independently transcribed non-coding RNA 1563","metadata":null},{"id":"07a4ac3aba6d462cb91c88950d1a7055","type":"GENE","name":"LINC01564","canonical_id":"hgnc:HGNC:51361","description":"long independently transcribed non-coding RNA 1564","metadata":{"aliases":["TCONS_00011314","RAMS11"]}},{"id":"36f035d7fab04131bf5662bd6de5a29a","type":"GENE","name":"LINC01565","canonical_id":"hgnc:HGNC:17099","description":"long independently transcribed non-coding RNA 1565","metadata":{"aliases":["GR6","C3orf27"]}},{"id":"f974fc5f6a574fb38722a726d2fc7621","type":"GENE","name":"LINC01566","canonical_id":"hgnc:HGNC:27555","description":"long independently transcribed non-coding RNA 1566","metadata":null},{"id":"ca30e7e07f454bbaafc84fb9cfff5edf","type":"GENE","name":"LINC01567","canonical_id":"hgnc:HGNC:51367","description":"long independently transcribed non-coding RNA 1567","metadata":{"aliases":["LOCCS"]}},{"id":"f6d9ea6f7f214a00ba719efb63635031","type":"GENE","name":"LINC01569","canonical_id":"hgnc:HGNC:51380","description":"long independently transcribed non-coding RNA 1569","metadata":{"aliases":["TCONS_00024567"]}},{"id":"5569cffd1a564942a59df85aa43fddbf","type":"GENE","name":"LINC01570","canonical_id":"hgnc:HGNC:51382","description":"long independently transcribed non-coding RNA 1570","metadata":null},{"id":"0041e3a8fd534105a8fe01d70b8f8680","type":"GENE","name":"LINC01571","canonical_id":"hgnc:HGNC:51384","description":"long independently transcribed non-coding RNA 1571","metadata":{"aliases":["TCONS_00024399"]}},{"id":"9095f48a5c8142f8b485ca9a28c786bc","type":"GENE","name":"LINC01572","canonical_id":"hgnc:HGNC:51385","description":"long independently transcribed non-coding RNA 1572","metadata":null},{"id":"0f644fbce375418ab7c1b1f23d1a0f28","type":"GENE","name":"LINC01574","canonical_id":"hgnc:HGNC:51388","description":"long independently transcribed non-coding RNA 1574","metadata":{"aliases":["HI-LNC12","TCONS_00009551"]}},{"id":"8ca2c935097d4dfda85aaf8944b9f7fc","type":"GENE","name":"LINC01579","canonical_id":"hgnc:HGNC:27519","description":"long independently transcribed non-coding RNA 1579","metadata":null},{"id":"4930b3d6f1534db29c66d68ef8487fe6","type":"GENE","name":"LINC01580","canonical_id":"hgnc:HGNC:51414","description":"long independently transcribed non-coding RNA 1580","metadata":null},{"id":"f70d1ef94a0042be8a986b6dfb6045f7","type":"GENE","name":"LINC01581","canonical_id":"hgnc:HGNC:51415","description":"long independently transcribed non-coding RNA 1581","metadata":null},{"id":"e6ab5b262af940ca9ecec535646db935","type":"GENE","name":"LINC01582","canonical_id":"hgnc:HGNC:51416","description":"long independently transcribed non-coding RNA 1582","metadata":{"aliases":["TCONS_00023827"]}},{"id":"29fb89bde62d4c74a2386e9ae0d56ad5","type":"GENE","name":"LINC01583","canonical_id":"hgnc:HGNC:51425","description":"long independently transcribed non-coding RNA 1583","metadata":null},{"id":"ee22ea77fd5a47f8a69a9c61afbc11a5","type":"GENE","name":"LINC01584","canonical_id":"hgnc:HGNC:51426","description":"long independently transcribed non-coding RNA 1584","metadata":{"aliases":["TCONS_00024001"]}},{"id":"1ab762bc55ed4838be8d15e13e309133","type":"GENE","name":"LINC01585","canonical_id":"hgnc:HGNC:51432","description":"long independently transcribed non-coding RNA 1585","metadata":null},{"id":"56e97d3e60964f76afbaca1c13cd7d01","type":"GENE","name":"LINC01586","canonical_id":"hgnc:HGNC:51434","description":"long independently transcribed non-coding RNA 1586","metadata":{"aliases":["TCONS_00023252"]}},{"id":"5649117b33494aaebb9d4d9fc94c6f05","type":"GENE","name":"LINC01587","canonical_id":"hgnc:HGNC:13716","description":"long independently transcribed non-coding RNA 1587","metadata":{"aliases":["aC1","C4orf6"]}},{"id":"94a3a4ebab85425f9344a786e26fdd57","type":"GENE","name":"LINC01588","canonical_id":"hgnc:HGNC:27503","description":"long independently transcribed non-coding RNA 1588","metadata":{"aliases":["C14orf182"]}},{"id":"fa4bdd0b35ee4055b09b2a4d4959cfc8","type":"GENE","name":"LINC01589","canonical_id":"hgnc:HGNC:51520","description":"long independently transcribed non-coding RNA 1589","metadata":{"aliases":["CTA-941F9.9","TCONS_00029353"]}},{"id":"14249df565594107a2ff6c89f16c771d","type":"GENE","name":"LINC01590","canonical_id":"hgnc:HGNC:21404","description":"long independently transcribed non-coding RNA 1590","metadata":{"aliases":["dJ102H19.4","C6orf164"]}},{"id":"b8879eb8c88441ccbe6ef5b1f7564490","type":"GENE","name":"LINC01591","canonical_id":"hgnc:HGNC:27819","description":"long independently transcribed non-coding RNA 1591","metadata":null},{"id":"4825e8282b7b4ca58a6439e49aaefe8c","type":"GENE","name":"LINC01592","canonical_id":"hgnc:HGNC:51557","description":"long independently transcribed non-coding RNA 1592","metadata":null},{"id":"653d3a7808904bc7ba618f09752ad02a","type":"GENE","name":"LINC01593","canonical_id":"hgnc:HGNC:51583","description":"long independently transcribed non-coding RNA 1593","metadata":{"aliases":["TCONS_00003364"]}},{"id":"1371af0304114a9f8ac830b691d7e508","type":"GENE","name":"LINC01594","canonical_id":"hgnc:HGNC:51584","description":"long independently transcribed non-coding RNA 1594","metadata":{"aliases":["TCONS_l2_00015893"]}},{"id":"514b2685cd7d4325a9a3d969d9a72dd3","type":"GENE","name":"LINC01595","canonical_id":"hgnc:HGNC:51586","description":"long independently transcribed non-coding RNA 1595","metadata":null},{"id":"9871866fe848408088fc8b0cb3e9bf26","type":"GENE","name":"LINC01596","canonical_id":"hgnc:HGNC:51591","description":"long independently transcribed non-coding RNA 1596","metadata":{"aliases":["TCONS_00007705"]}},{"id":"8c85f81a85d9430d986b130dfc4b4419","type":"GENE","name":"LINC01597","canonical_id":"hgnc:HGNC:51594","description":"long independently transcribed non-coding RNA 1597","metadata":null},{"id":"3aaa2f96706a4779b48bb2f327229835","type":"GENE","name":"LINC01599","canonical_id":"hgnc:HGNC:27285","description":"long independently transcribed non-coding RNA 1599","metadata":{"aliases":["C14orf183"]}},{"id":"3f61ad9ed56a4f01bc4a4b11005fc096","type":"GENE","name":"LINC01600","canonical_id":"hgnc:HGNC:21600","description":"long independently transcribed non-coding RNA 1600","metadata":{"aliases":["FLJ31934","bA145H9.2","C6orf195"]}},{"id":"bb4bd5cace13472e93e38d757c503232","type":"GENE","name":"LINC01601","canonical_id":"hgnc:HGNC:51651","description":"long independently transcribed non-coding RNA 1601","metadata":null},{"id":"5384d687d06b4f299a336643a639ae02","type":"GENE","name":"LINC01602","canonical_id":"hgnc:HGNC:51634","description":"long independently transcribed non-coding RNA 1602","metadata":{"aliases":["T1560"]}},{"id":"d21ae4c3fc95419aae971b1a79e446bb","type":"GENE","name":"LINC01603","canonical_id":"hgnc:HGNC:51652","description":"long independently transcribed non-coding RNA 1603","metadata":null},{"id":"491615beda7946a4a3f9c77852780592","type":"GENE","name":"LINC01605","canonical_id":"hgnc:HGNC:51654","description":"long independently transcribed non-coding RNA 1605","metadata":{"aliases":["ODIR1","lncGALM","LincDUSP","RP11-527N22.2","TCONS_00014973"]}},{"id":"600218e7dddd4dceabd9f2919f6a98a7","type":"GENE","name":"LINC01606","canonical_id":"hgnc:HGNC:51656","description":"long independently transcribed non-coding RNA 1606","metadata":{"aliases":["TCONS_l2_00027778"]}},{"id":"bfdd0b6b3d4c40a9af73ea4459349d17","type":"GENE","name":"LINC01607","canonical_id":"hgnc:HGNC:51660","description":"long independently transcribed non-coding RNA 1607","metadata":null},{"id":"4e92edb30ab14f34a47dd04f93213828","type":"GENE","name":"LINC01608","canonical_id":"hgnc:HGNC:51662","description":"long independently transcribed non-coding RNA 1608","metadata":{"aliases":["TCONS_00015136"]}},{"id":"6e1da0c0340c43bbab90815fa176194e","type":"GENE","name":"LINC01609","canonical_id":"hgnc:HGNC:51663","description":"long independently transcribed non-coding RNA 1609","metadata":null},{"id":"7c711020912042c9bad08c0623de33e5","type":"GENE","name":"LINC01610","canonical_id":"hgnc:HGNC:51676","description":"long independently transcribed non-coding RNA 1610","metadata":{"aliases":["EVADR"]}},{"id":"c6c793f8a76945e1afef6522e0e12e33","type":"GENE","name":"LINC01611","canonical_id":"hgnc:HGNC:51791","description":"long independently transcribed non-coding RNA 1611","metadata":{"aliases":["RP1-90L14.1","TCONS_l2_00025430"]}},{"id":"41ee8304121344c3807744138a66f3de","type":"GENE","name":"LINC01612","canonical_id":"hgnc:HGNC:51837","description":"long independently transcribed non-coding RNA 1612","metadata":{"aliases":["RP11-789C1.1","TCONS_00008319","linc-GALNTL6-4"]}},{"id":"9b3862b4bd334d8abadd7e442803ee9c","type":"GENE","name":"LINC01613","canonical_id":"hgnc:HGNC:51842","description":"long independently transcribed non-coding RNA 1613","metadata":{"aliases":["n341773"]}},{"id":"d0decb50ec834d64a869720d9abdc342","type":"GENE","name":"LINC01614","canonical_id":"hgnc:HGNC:51847","description":"long independently transcribed non-coding RNA 1614","metadata":{"aliases":["LCAL4","TCONS_00003105"]}},{"id":"a54232e9281443b696da31fec626f408","type":"GENE","name":"LINC01615","canonical_id":"hgnc:HGNC:51898","description":"long independently transcribed non-coding RNA 1615","metadata":{"aliases":["RP11-417E7.1","LINC02544"]}},{"id":"f344279fbe5c4c6e8ff551c79aa36990","type":"GENE","name":"LINC01616","canonical_id":"hgnc:HGNC:51900","description":"long independently transcribed non-coding RNA 1616","metadata":{"aliases":["n341006"]}},{"id":"9a81654180d24733b78204395c6bf1b9","type":"GENE","name":"LINC01617","canonical_id":"hgnc:HGNC:30442","description":"long independently transcribed non-coding RNA 1617","metadata":{"aliases":["XLOC_006844","C8orf23","NCRNA00249"]}},{"id":"ceb4b87c2edc44819522a097a31202e6","type":"GENE","name":"LINC01618","canonical_id":"hgnc:HGNC:27195","description":"long independently transcribed non-coding RNA 1618","metadata":{"aliases":["LOC152578"]}},{"id":"1af92bee00bb425b9305b31a0cf54825","type":"GENE","name":"LINC01619","canonical_id":"hgnc:HGNC:27409","description":"long independently transcribed non-coding RNA 1619","metadata":{"aliases":["C12orf79"]}},{"id":"3476884e7cf64912b33dd7475cf6caca","type":"GENE","name":"LINC01620","canonical_id":"hgnc:HGNC:16195","description":"long independently transcribed non-coding RNA 1620","metadata":{"aliases":["dJ1013A22.3","C20orf62"]}},{"id":"4995d821449547a5b4cc3ec8d57b4396","type":"GENE","name":"LINC01621","canonical_id":"hgnc:HGNC:14109","description":"long independently transcribed non-coding RNA 1621","metadata":{"aliases":["C6orf7"]}},{"id":"fdc87952a22d42a4b34a34f85a4c36bd","type":"GENE","name":"LINC01622","canonical_id":"hgnc:HGNC:27768","description":"long independently transcribed non-coding RNA 1622","metadata":{"aliases":["TCONS_00011202"]}},{"id":"4bd10b73cdaa48949b373d6c96817107","type":"GENE","name":"LINC01623","canonical_id":"hgnc:HGNC:52050","description":"long independently transcribed non-coding RNA 1623","metadata":null},{"id":"f6da39d697d641788cc203ac2091d69f","type":"GENE","name":"LINC01624","canonical_id":"hgnc:HGNC:52051","description":"long independently transcribed non-coding RNA 1624","metadata":{"aliases":["TCONS_00011425"]}},{"id":"04326f32270d4580857c3c40a9af4c4e","type":"GENE","name":"LINC01625","canonical_id":"hgnc:HGNC:52052","description":"long independently transcribed non-coding RNA 1625","metadata":{"aliases":["TCONS_00011139"]}},{"id":"6e7d738c76654c3185133de31487d88e","type":"GENE","name":"LINC01626","canonical_id":"hgnc:HGNC:52257","description":"long independently transcribed non-coding RNA 1626","metadata":null},{"id":"875e33d518d8462c90879db6b93a33e4","type":"GENE","name":"LINC01627","canonical_id":"hgnc:HGNC:52258","description":"long independently transcribed non-coding RNA 1627","metadata":{"aliases":["RP11-397D12.4"]}},{"id":"359fdb4b54dc4c7dbb8022dfae2f13e6","type":"GENE","name":"LINC01628","canonical_id":"hgnc:HGNC:52259","description":"long independently transcribed non-coding RNA 1628","metadata":{"aliases":["AC007403.1"]}},{"id":"a0a8de43a69f40cbb2094a163a87e578","type":"GENE","name":"LINC01629","canonical_id":"hgnc:HGNC:52260","description":"long independently transcribed non-coding RNA 1629","metadata":{"aliases":["linc-KIAA1737-2"]}},{"id":"62806ab7a7f0456185fb9ed8b2c5bba4","type":"GENE","name":"LINC01630","canonical_id":"hgnc:HGNC:52295","description":"long independently transcribed non-coding RNA 1630","metadata":{"aliases":["LOC100287225"]}},{"id":"c7186546fd7c4597b503af8af46f6f60","type":"GENE","name":"LINC01632","canonical_id":"hgnc:HGNC:52419","description":"long independently transcribed non-coding RNA 1632","metadata":null},{"id":"c9d96cc277c84e3898ec1afc303a0793","type":"GENE","name":"LINC01633","canonical_id":"hgnc:HGNC:52420","description":"long independently transcribed non-coding RNA 1633","metadata":null},{"id":"da46628485bc42aeb6b48f329b660351","type":"GENE","name":"LINC01634","canonical_id":"hgnc:HGNC:52421","description":"long independently transcribed non-coding RNA 1634","metadata":null},{"id":"328b3037554d45b9aef6931ad282b0c9","type":"GENE","name":"LINC01635","canonical_id":"hgnc:HGNC:52422","description":"long independently transcribed non-coding RNA 1635","metadata":null},{"id":"dc88891c87cf41e59dd15faf94908352","type":"GENE","name":"LINC01637","canonical_id":"hgnc:HGNC:52424","description":"long independently transcribed non-coding RNA 1637","metadata":null},{"id":"cb992e1ffd6b4b76b08fe1742418559a","type":"GENE","name":"LINC01638","canonical_id":"hgnc:HGNC:52425","description":"long independently transcribed non-coding RNA 1638","metadata":{"aliases":["lncRNA4114"]}},{"id":"541f61e0fba042fe893f36d9b73944f8","type":"GENE","name":"LINC01639","canonical_id":"hgnc:HGNC:52426","description":"long independently transcribed non-coding RNA 1639","metadata":null},{"id":"79bdaf9983b340c9b0d9fb3f67d312ba","type":"GENE","name":"LINC01640","canonical_id":"hgnc:HGNC:52427","description":"long independently transcribed non-coding RNA 1640","metadata":null},{"id":"ea2ba5d80cf34b279a10c6925c74f13c","type":"GENE","name":"LINC01641","canonical_id":"hgnc:HGNC:52428","description":"long independently transcribed non-coding RNA 1641","metadata":null},{"id":"692b834a3096445dbc970b72cec38299","type":"GENE","name":"LINC01643","canonical_id":"hgnc:HGNC:52430","description":"long independently transcribed non-coding RNA 1643","metadata":null},{"id":"af10b15e6b1241cf9bca9053c86fbfc3","type":"GENE","name":"LINC01644","canonical_id":"hgnc:HGNC:52431","description":"long independently transcribed non-coding RNA 1644","metadata":null},{"id":"87a5ec5bd68f4c82a2f50d8bd6a73d02","type":"GENE","name":"LINC01645","canonical_id":"hgnc:HGNC:52432","description":"long independently transcribed non-coding RNA 1645","metadata":null},{"id":"7c887788d1264490bcc49a5e2455ed49","type":"GENE","name":"LINC01646","canonical_id":"hgnc:HGNC:52433","description":"long independently transcribed non-coding RNA 1646","metadata":null},{"id":"87789fbeea924cf098090801f01fdb28","type":"GENE","name":"LINC01647","canonical_id":"hgnc:HGNC:52434","description":"long independently transcribed non-coding RNA 1647","metadata":null},{"id":"d6019267d54e4915824f2ac4b8949b3a","type":"GENE","name":"LINC01648","canonical_id":"hgnc:HGNC:52435","description":"long independently transcribed non-coding RNA 1648","metadata":null},{"id":"ef4104ee44f24e2cbee785a805ef33e8","type":"GENE","name":"LINC01649","canonical_id":"hgnc:HGNC:52436","description":"long independently transcribed non-coding RNA 1649","metadata":null},{"id":"4549adfa6f0c400fb4d38fd14b1fadcf","type":"GENE","name":"LINC01650","canonical_id":"hgnc:HGNC:52437","description":"long independently transcribed non-coding RNA 1650","metadata":null},{"id":"c4901b6531c2419e9551ea61c6ddee85","type":"GENE","name":"LINC01651","canonical_id":"hgnc:HGNC:52439","description":"long independently transcribed non-coding RNA 1651","metadata":null},{"id":"1c30b2f9bed44f23ad9a22f39a9076a9","type":"GENE","name":"LINC01653","canonical_id":"hgnc:HGNC:52441","description":"long independently transcribed non-coding RNA 1653","metadata":null},{"id":"4de2fa31c7dd4f7ea70c148c3da8404f","type":"GENE","name":"LINC01654","canonical_id":"hgnc:HGNC:52442","description":"long independently transcribed non-coding RNA 1654","metadata":null},{"id":"8cc840552c7f4f7ea312cdf7d5d95659","type":"GENE","name":"LINC01656","canonical_id":"hgnc:HGNC:52444","description":"long independently transcribed non-coding RNA 1656","metadata":null},{"id":"1d2c34b1dd4643d182d564d6f2d2a48b","type":"GENE","name":"LINC01657","canonical_id":"hgnc:HGNC:52445","description":"long independently transcribed non-coding RNA 1657","metadata":null},{"id":"2902fd1a19f740279556d3d7e82f37fd","type":"GENE","name":"LINC01659","canonical_id":"hgnc:HGNC:52447","description":"long independently transcribed non-coding RNA 1659","metadata":null},{"id":"3c46f187a17c4f00922feb7db169cac4","type":"GENE","name":"LINC01661","canonical_id":"hgnc:HGNC:52449","description":"long independently transcribed non-coding RNA 1661","metadata":null},{"id":"15754a0feeb54089975b09e712b3dc85","type":"GENE","name":"LINC01664","canonical_id":"hgnc:HGNC:52452","description":"long independently transcribed non-coding RNA 1664","metadata":null},{"id":"841eeed4f4d543d5939ba56c869eafbb","type":"GENE","name":"LINC01665","canonical_id":"hgnc:HGNC:52453","description":"long independently transcribed non-coding RNA 1665","metadata":null},{"id":"c250295bce024ffbbf6796d9af6af993","type":"GENE","name":"LINC01666","canonical_id":"hgnc:HGNC:52454","description":"long independently transcribed non-coding RNA 1666","metadata":null},{"id":"19b7ee3a909b45e9bf1af5794a39a36e","type":"GENE","name":"LINC01667","canonical_id":"hgnc:HGNC:52455","description":"long independently transcribed non-coding RNA 1667","metadata":null},{"id":"57c4d1241b2a4e84bbf3e6dcb6818dd0","type":"GENE","name":"LINC01668","canonical_id":"hgnc:HGNC:52456","description":"long independently transcribed non-coding RNA 1668","metadata":null},{"id":"f68cbf5760db4979a2b53e873188b4cd","type":"GENE","name":"LINC01670","canonical_id":"hgnc:HGNC:52458","description":"long independently transcribed non-coding RNA 1670","metadata":null},{"id":"971b0f1461f94db3aad0169828763cb1","type":"GENE","name":"LINC01671","canonical_id":"hgnc:HGNC:52459","description":"long independently transcribed non-coding RNA 1671","metadata":{"aliases":["BC041455","AP001626.1"]}},{"id":"97d69bb5c7664908a376996ac6577263","type":"GENE","name":"LINC01672","canonical_id":"hgnc:HGNC:52460","description":"long independently transcribed non-coding RNA 1672","metadata":{"aliases":["NMR"]}},{"id":"cd2786b0ca3945b4afeaa91d85ce9190","type":"GENE","name":"LINC01673","canonical_id":"hgnc:HGNC:52461","description":"long independently transcribed non-coding RNA 1673","metadata":null},{"id":"db1a93fea4d84e598feffa2c25a1e7d2","type":"GENE","name":"LINC01674","canonical_id":"hgnc:HGNC:52462","description":"long independently transcribed non-coding RNA 1674","metadata":null},{"id":"d7f297e9514747d7a1b78d8fa102ee7a","type":"GENE","name":"LINC01675","canonical_id":"hgnc:HGNC:52463","description":"long independently transcribed non-coding RNA 1675","metadata":null},{"id":"1f5e9b1ee14c48b08c67c56e2c753682","type":"GENE","name":"LINC01676","canonical_id":"hgnc:HGNC:52464","description":"long independently transcribed non-coding RNA 1676","metadata":null},{"id":"d6e82f692d344a3abe71f105efaada9b","type":"GENE","name":"LINC01677","canonical_id":"hgnc:HGNC:52465","description":"long independently transcribed non-coding RNA 1677","metadata":null},{"id":"e2fb3453aac14d19b9da48defb24c24f","type":"GENE","name":"LINC01678","canonical_id":"hgnc:HGNC:52466","description":"long independently transcribed non-coding RNA 1678","metadata":null},{"id":"ea1d5be3dd8a4d05943ad827ca1d67bc","type":"GENE","name":"LINC01679","canonical_id":"hgnc:HGNC:52469","description":"long independently transcribed non-coding RNA 1679","metadata":null},{"id":"c089310559c9429e855bfbcde6c39949","type":"GENE","name":"LINC01680","canonical_id":"hgnc:HGNC:52467","description":"long independently transcribed non-coding RNA 1680","metadata":null},{"id":"86157c04cb174c4da5bf7a6323392a36","type":"GENE","name":"LINC01681","canonical_id":"hgnc:HGNC:52468","description":"long independently transcribed non-coding RNA 1681","metadata":null},{"id":"4c01cbad614b4efaa0d8ff449d03f7b3","type":"GENE","name":"LINC01682","canonical_id":"hgnc:HGNC:52470","description":"long independently transcribed non-coding RNA 1682","metadata":null},{"id":"3b2bbe3ef14c48a48d06c760414b9a58","type":"GENE","name":"LINC01683","canonical_id":"hgnc:HGNC:52471","description":"long independently transcribed non-coding RNA 1683","metadata":null},{"id":"a76544758ac84ead80b7729fad53a335","type":"GENE","name":"LINC01684","canonical_id":"hgnc:HGNC:52472","description":"long independently transcribed non-coding RNA 1684","metadata":{"aliases":["lnc-JAM2-6"]}},{"id":"28d128782753499985c283e3d0419c2b","type":"GENE","name":"LINC01685","canonical_id":"hgnc:HGNC:52473","description":"long independently transcribed non-coding RNA 1685","metadata":null},{"id":"bb2f309270184f90a19050506f699646","type":"GENE","name":"LINC01686","canonical_id":"hgnc:HGNC:27643","description":"long independently transcribed non-coding RNA 1686","metadata":null},{"id":"fe968610902e45f2b38f96435253de60","type":"GENE","name":"LINC01687","canonical_id":"hgnc:HGNC:52474","description":"long independently transcribed non-coding RNA 1687","metadata":null},{"id":"342f86915dbd47fa900e9d5a76575465","type":"GENE","name":"LINC01688","canonical_id":"hgnc:HGNC:52475","description":"long independently transcribed non-coding RNA 1688","metadata":null},{"id":"ce2f8972bfdb490b83b5546a647393be","type":"GENE","name":"LINC01689","canonical_id":"hgnc:HGNC:52476","description":"long independently transcribed non-coding RNA 1689","metadata":{"aliases":["AP000469.2"]}},{"id":"658731988f02478aaa618d5b19b155b6","type":"GENE","name":"LINC01690","canonical_id":"hgnc:HGNC:52477","description":"long independently transcribed non-coding RNA 1690","metadata":null},{"id":"07231cb3dac94764aebc4db363567d89","type":"GENE","name":"LINC01691","canonical_id":"hgnc:HGNC:52479","description":"long independently transcribed non-coding RNA 1691","metadata":null},{"id":"829cc37dd049494590fadb95ba539299","type":"GENE","name":"LINC01692","canonical_id":"hgnc:HGNC:52480","description":"long independently transcribed non-coding RNA 1692","metadata":null},{"id":"814fde40233d408fa5d9a04dc4d2a32b","type":"GENE","name":"LINC01694","canonical_id":"hgnc:HGNC:52481","description":"long independently transcribed non-coding RNA 1694","metadata":null},{"id":"60a495f5075a4d9dac56dd6a8c9e8000","type":"GENE","name":"LINC01695","canonical_id":"hgnc:HGNC:52483","description":"long independently transcribed non-coding RNA 1695","metadata":null},{"id":"9ba468ef88024075958bbaa4ed7acaf1","type":"GENE","name":"LINC01696","canonical_id":"hgnc:HGNC:52484","description":"long independently transcribed non-coding RNA 1696","metadata":null},{"id":"db1000578a3c4bd68d1d4851320aed1d","type":"GENE","name":"LINC01697","canonical_id":"hgnc:HGNC:52485","description":"long independently transcribed non-coding RNA 1697","metadata":null},{"id":"0fb27274054248418b8f5f86cf381134","type":"GENE","name":"LINC01698","canonical_id":"hgnc:HGNC:52486","description":"long independently transcribed non-coding RNA 1698","metadata":null},{"id":"62570df788a0475a8192689a9744f158","type":"GENE","name":"LINC01699","canonical_id":"hgnc:HGNC:52487","description":"long independently transcribed non-coding RNA 1699","metadata":{"aliases":["GM140"]}},{"id":"660aca67d09645bc857677bb20b2d317","type":"GENE","name":"LINC01700","canonical_id":"hgnc:HGNC:52488","description":"long independently transcribed non-coding RNA 1700","metadata":null},{"id":"d1242f059bf24687803887f586fdb01d","type":"GENE","name":"LINC01701","canonical_id":"hgnc:HGNC:52489","description":"long independently transcribed non-coding RNA 1701","metadata":null},{"id":"a7b788bb3ded494e9a4454645e4cf295","type":"GENE","name":"LINC01702","canonical_id":"hgnc:HGNC:52490","description":"long independently transcribed non-coding RNA 1702","metadata":null},{"id":"06dff8bf6ad8456ca27390d67bc8c8e2","type":"GENE","name":"LINC01703","canonical_id":"hgnc:HGNC:52491","description":"long independently transcribed non-coding RNA 1703","metadata":{"aliases":["lncPARP1"]}},{"id":"1f4f751b717140f29cd6c8dd6ae93f15","type":"GENE","name":"LINC01704","canonical_id":"hgnc:HGNC:52492","description":"long independently transcribed non-coding RNA 1704","metadata":null},{"id":"91203d384c8c4f5d88cdb011b7b7c35a","type":"GENE","name":"LINC01705","canonical_id":"hgnc:HGNC:52493","description":"long independently transcribed non-coding RNA 1705","metadata":{"aliases":["ERLR","TBUR1","RP11-400N13.3","LINC01655","LINC02257"]}},{"id":"9d128b61fe7849ddb83753a33041f351","type":"GENE","name":"LINC01706","canonical_id":"hgnc:HGNC:52494","description":"long independently transcribed non-coding RNA 1706","metadata":null},{"id":"a7bd3819580e4d9e950307006b48c2dc","type":"GENE","name":"LINC01707","canonical_id":"hgnc:HGNC:52495","description":"long independently transcribed non-coding RNA 1707","metadata":null},{"id":"ec14e56686024f92acea188022455e82","type":"GENE","name":"LINC01708","canonical_id":"hgnc:HGNC:52496","description":"long independently transcribed non-coding RNA 1708","metadata":null},{"id":"165f9f274cbe469f90f60eacb58b5ef7","type":"GENE","name":"LINC01709","canonical_id":"hgnc:HGNC:52497","description":"long independently transcribed non-coding RNA 1709","metadata":null},{"id":"687f8f9117914fe99889785bf64d3bf9","type":"GENE","name":"LINC01710","canonical_id":"hgnc:HGNC:52498","description":"long independently transcribed non-coding RNA 1710","metadata":null},{"id":"02c5e11a2c444dcab76ee74ba070911a","type":"GENE","name":"LINC01711","canonical_id":"hgnc:HGNC:28663","description":"long independently transcribed non-coding RNA 1711","metadata":{"aliases":["MGC4294"]}},{"id":"489cd9410b314e4aacb5782973c75078","type":"GENE","name":"LINC01712","canonical_id":"hgnc:HGNC:52499","description":"long independently transcribed non-coding RNA 1712","metadata":null},{"id":"ed32ff23c4b2484bae2914f3b048678c","type":"GENE","name":"LINC01713","canonical_id":"hgnc:HGNC:52500","description":"long independently transcribed non-coding RNA 1713","metadata":null},{"id":"3c85e94c56784daf8fe049978421a4bd","type":"GENE","name":"LINC01714","canonical_id":"hgnc:HGNC:52501","description":"long independently transcribed non-coding RNA 1714","metadata":null},{"id":"b4f3c8b69656428b83abf83e95938903","type":"GENE","name":"LINC01716","canonical_id":"hgnc:HGNC:52503","description":"long independently transcribed non-coding RNA 1716","metadata":null},{"id":"518e4ddafe2043deb6404a84f446c3f3","type":"GENE","name":"LINC01717","canonical_id":"hgnc:HGNC:52504","description":"long independently transcribed non-coding RNA 1717","metadata":null},{"id":"6fbdc940e655474f9b7995f4ffbb6fdc","type":"GENE","name":"LINC01718","canonical_id":"hgnc:HGNC:52505","description":"long independently transcribed non-coding RNA 1718","metadata":null},{"id":"72d0557533874265a8eeb10474941d27","type":"GENE","name":"LINC01719","canonical_id":"hgnc:HGNC:52506","description":"long independently transcribed non-coding RNA 1719","metadata":null},{"id":"beec97fde061478e8ff15b0d0bbc75c4","type":"GENE","name":"LINC01720","canonical_id":"hgnc:HGNC:52507","description":"long independently transcribed non-coding RNA 1720","metadata":null},{"id":"295d901c0cd24b5a86535d6693db581c","type":"GENE","name":"LINC01721","canonical_id":"hgnc:HGNC:52508","description":"long independently transcribed non-coding RNA 1721","metadata":null},{"id":"bf2f7d2e32d54a30944abbc50a16c65f","type":"GENE","name":"LINC01722","canonical_id":"hgnc:HGNC:52510","description":"long independently transcribed non-coding RNA 1722","metadata":null},{"id":"fe12c56b9ffa46dab1fa31b4f6512e20","type":"GENE","name":"LINC01723","canonical_id":"hgnc:HGNC:52511","description":"long independently transcribed non-coding RNA 1723","metadata":null},{"id":"950b3d8870f14ec997f4c5f87cd9ea9f","type":"GENE","name":"LINC01724","canonical_id":"hgnc:HGNC:52512","description":"long independently transcribed non-coding RNA 1724","metadata":null},{"id":"a45cb28cee4b4688adea3f23f8452a9b","type":"GENE","name":"LINC01725","canonical_id":"hgnc:HGNC:52513","description":"long independently transcribed non-coding RNA 1725","metadata":null},{"id":"7810ffba28804362b7444cd4c4e07fb7","type":"GENE","name":"LINC01726","canonical_id":"hgnc:HGNC:52514","description":"long independently transcribed non-coding RNA 1726","metadata":null},{"id":"f4adbee0562043c9be7e42253ee8b014","type":"GENE","name":"LINC01727","canonical_id":"hgnc:HGNC:52515","description":"long independently transcribed non-coding RNA 1727","metadata":{"aliases":["IRENA"]}},{"id":"5198535a6f224234b3ab51985e140b02","type":"GENE","name":"LINC01728","canonical_id":"hgnc:HGNC:52516","description":"long independently transcribed non-coding RNA 1728","metadata":null},{"id":"34b641be5acc4e759fb63be66c23fe16","type":"GENE","name":"LINC01730","canonical_id":"hgnc:HGNC:52518","description":"long independently transcribed non-coding RNA 1730","metadata":null},{"id":"da1f74fb3a79404a834dcec6c3b85793","type":"GENE","name":"LINC01732","canonical_id":"hgnc:HGNC:52520","description":"long independently transcribed non-coding RNA 1732","metadata":null},{"id":"184a3c9eeac14842a3c4bbabcf029e08","type":"GENE","name":"LINC01733","canonical_id":"hgnc:HGNC:52521","description":"long independently transcribed non-coding RNA 1733","metadata":null},{"id":"b7abf2b2d1024d9ab650dd6bfb89d2d5","type":"GENE","name":"LINC01734","canonical_id":"hgnc:HGNC:52522","description":"long independently transcribed non-coding RNA 1734","metadata":null},{"id":"8a196de5fe924c5eb151137fafe60ef5","type":"GENE","name":"LINC01735","canonical_id":"hgnc:HGNC:52523","description":"long independently transcribed non-coding RNA 1735","metadata":null},{"id":"a736c8b9a751473c8c903db7c75b2fa5","type":"GENE","name":"LINC01736","canonical_id":"hgnc:HGNC:52524","description":"long independently transcribed non-coding RNA 1736","metadata":{"aliases":["RP11-552D4.1"]}},{"id":"ff22cfc58a8d485eb20f7691bdd2fccb","type":"GENE","name":"LINC01737","canonical_id":"hgnc:HGNC:52525","description":"long independently transcribed non-coding RNA 1737","metadata":null},{"id":"ef0e2c7e48d94869955768c447db086d","type":"GENE","name":"LINC01738","canonical_id":"hgnc:HGNC:52526","description":"long independently transcribed non-coding RNA 1738","metadata":null},{"id":"47ca29e5fa214759a1135c9b0ae6219d","type":"GENE","name":"LINC01739","canonical_id":"hgnc:HGNC:52527","description":"long independently transcribed non-coding RNA 1739","metadata":null},{"id":"0257f2460ede4378b0cd39cd89e04d6c","type":"GENE","name":"LINC01740","canonical_id":"hgnc:HGNC:52528","description":"long independently transcribed non-coding RNA 1740","metadata":null},{"id":"4a2af50fbb53458a98dd38dc58d26d17","type":"GENE","name":"LINC01741","canonical_id":"hgnc:HGNC:52529","description":"long independently transcribed non-coding RNA 1741","metadata":null},{"id":"348e97566a5e42879f8d6abd6608b0e6","type":"GENE","name":"LINC01742","canonical_id":"hgnc:HGNC:52530","description":"long independently transcribed non-coding RNA 1742","metadata":null},{"id":"7305cbd705854a00bc7a2be0cb90d057","type":"GENE","name":"LINC01743","canonical_id":"hgnc:HGNC:52531","description":"long independently transcribed non-coding RNA 1743","metadata":null},{"id":"151fa331af714e32806d535a4f3a4f31","type":"GENE","name":"LINC01744","canonical_id":"hgnc:HGNC:52532","description":"long independently transcribed non-coding RNA 1744","metadata":null},{"id":"f23bab48374e4466a9e67e072f931d16","type":"GENE","name":"LINC01745","canonical_id":"hgnc:HGNC:52533","description":"long independently transcribed non-coding RNA 1745","metadata":null},{"id":"ffc98b0af100464ea7d366411dacba9e","type":"GENE","name":"LINC01746","canonical_id":"hgnc:HGNC:52534","description":"long independently transcribed non-coding RNA 1746","metadata":null},{"id":"bf6087a6eb8c463ebaa4fa959f5d6259","type":"GENE","name":"LINC01747","canonical_id":"hgnc:HGNC:52536","description":"long independently transcribed non-coding RNA 1747","metadata":null},{"id":"25256535a32640ea83c64b191ebc130d","type":"GENE","name":"LINC01748","canonical_id":"hgnc:HGNC:52535","description":"long independently transcribed non-coding RNA 1748","metadata":null},{"id":"7756d56de2d240eca879898a4e0be85f","type":"GENE","name":"LINC01749","canonical_id":"hgnc:HGNC:52537","description":"long independently transcribed non-coding RNA 1749","metadata":null},{"id":"b26127e48fcf469eaed34adb74511aac","type":"GENE","name":"LINC01750","canonical_id":"hgnc:HGNC:52538","description":"long independently transcribed non-coding RNA 1750","metadata":null},{"id":"f368cc203b4a4e0e82b8411b6f9d2a73","type":"GENE","name":"LINC01751","canonical_id":"hgnc:HGNC:52539","description":"long independently transcribed non-coding RNA 1751","metadata":null},{"id":"64f9cf9496de4593b13dafbb990e5f49","type":"GENE","name":"LINC01752","canonical_id":"hgnc:HGNC:52540","description":"long independently transcribed non-coding RNA 1752","metadata":null},{"id":"e45ddd38b4f642488322111c18cc671d","type":"GENE","name":"LINC01753","canonical_id":"hgnc:HGNC:52541","description":"long independently transcribed non-coding RNA 1753","metadata":null},{"id":"d5283c600b654a3eb92c19833449d310","type":"GENE","name":"LINC01754","canonical_id":"hgnc:HGNC:52542","description":"long independently transcribed non-coding RNA 1754","metadata":null},{"id":"ff074320449e4f5b9f2349c45ea7647e","type":"GENE","name":"LINC01755","canonical_id":"hgnc:HGNC:52543","description":"long independently transcribed non-coding RNA 1755","metadata":null},{"id":"e0347f9d15ec4754b52d750ade0bdbc9","type":"GENE","name":"LINC01756","canonical_id":"hgnc:HGNC:52545","description":"long independently transcribed non-coding RNA 1756","metadata":null},{"id":"9ba5397e3c154a859aebc596929ae632","type":"GENE","name":"LINC01757","canonical_id":"hgnc:HGNC:52546","description":"long independently transcribed non-coding RNA 1757","metadata":null},{"id":"d4688eefe7f14479bfca1d75d1db3d84","type":"GENE","name":"LINC01758","canonical_id":"hgnc:HGNC:52547","description":"long independently transcribed non-coding RNA 1758","metadata":null},{"id":"6fddb147b5c84604b7227e91a5140fca","type":"GENE","name":"LINC01760","canonical_id":"hgnc:HGNC:52549","description":"long independently transcribed non-coding RNA 1760","metadata":null},{"id":"7ddcc1a4ee9f4611940e956e86b99df0","type":"GENE","name":"LINC01761","canonical_id":"hgnc:HGNC:52551","description":"long independently transcribed non-coding RNA 1761","metadata":null},{"id":"fae522a7ca92481fbc1458753f13391a","type":"GENE","name":"LINC01762","canonical_id":"hgnc:HGNC:52552","description":"long independently transcribed non-coding RNA 1762","metadata":null},{"id":"65cc56113afa486887f3973ce758ee81","type":"GENE","name":"LINC01763","canonical_id":"hgnc:HGNC:52554","description":"long independently transcribed non-coding RNA 1763","metadata":null},{"id":"fe3bfbc439914be195551a61d5190140","type":"GENE","name":"LINC01765","canonical_id":"hgnc:HGNC:52555","description":"long independently transcribed non-coding RNA 1765","metadata":null},{"id":"26c5e5c94a0f4b7a95e9a68df921cdb7","type":"GENE","name":"LINC01766","canonical_id":"hgnc:HGNC:52556","description":"long independently transcribed non-coding RNA 1766","metadata":null},{"id":"3caef39670e24076885541b375302c77","type":"GENE","name":"LINC01767","canonical_id":"hgnc:HGNC:52557","description":"long independently transcribed non-coding RNA 1767","metadata":{"aliases":["CRLM1"]}},{"id":"0953f96acdc94ca081dd98ec84d4784b","type":"GENE","name":"LINC01768","canonical_id":"hgnc:HGNC:52558","description":"long independently transcribed non-coding RNA 1768","metadata":null},{"id":"2a0e29eced8d45d1b188bc04ebf57cef","type":"GENE","name":"LINC01770","canonical_id":"hgnc:HGNC:52560","description":"long independently transcribed non-coding RNA 1770","metadata":{"aliases":["RRFERV"]}},{"id":"00cc7bf0b9d84ccaaa87e208a5d0d4ac","type":"GENE","name":"LINC01772","canonical_id":"hgnc:HGNC:52562","description":"long independently transcribed non-coding RNA 1772","metadata":{"aliases":["ENSG00000226029"]}},{"id":"a8510706e31b4a469cdaf066fa43c6e1","type":"GENE","name":"LINC01773","canonical_id":"hgnc:HGNC:52563","description":"long independently transcribed non-coding RNA 1773","metadata":null},{"id":"21ded3a8f7be4ed284c7e45e7ebc5e37","type":"GENE","name":"LINC01774","canonical_id":"hgnc:HGNC:52564","description":"long independently transcribed non-coding RNA 1774","metadata":null},{"id":"cd1a0ff1b99c4721a1f2f1988933fc23","type":"GENE","name":"LINC01775","canonical_id":"hgnc:HGNC:52565","description":"long independently transcribed non-coding RNA 1775","metadata":null},{"id":"1a16ca213d524504b854f04d9bbbdad2","type":"GENE","name":"LINC01776","canonical_id":"hgnc:HGNC:52566","description":"long independently transcribed non-coding RNA 1776","metadata":null},{"id":"e17a0d08bf9b42918bb591c60679c479","type":"GENE","name":"LINC01777","canonical_id":"hgnc:HGNC:52567","description":"long independently transcribed non-coding RNA 1777","metadata":null},{"id":"132c846d0d094545b1633cf15ade9298","type":"GENE","name":"LINC01778","canonical_id":"hgnc:HGNC:52568","description":"long independently transcribed non-coding RNA 1778","metadata":null},{"id":"52cc7de5c7da46b49ba16a8455230f97","type":"GENE","name":"LINC01779","canonical_id":"hgnc:HGNC:52569","description":"long independently transcribed non-coding RNA 1779","metadata":null},{"id":"f02189fbef4f47198303e53ef6ad9ecb","type":"GENE","name":"LINC01780","canonical_id":"hgnc:HGNC:52570","description":"long independently transcribed non-coding RNA 1780","metadata":null},{"id":"0e35d818c7e145ef84c3827441a60d8a","type":"GENE","name":"LINC01781","canonical_id":"hgnc:HGNC:52571","description":"long independently transcribed non-coding RNA 1781","metadata":null},{"id":"77534fdd6ee94da782a4c70d710797e9","type":"GENE","name":"LINC01782","canonical_id":"hgnc:HGNC:52572","description":"long independently transcribed non-coding RNA 1782","metadata":null},{"id":"f4c69264dff0413ca09fba8b6418ec5a","type":"GENE","name":"LINC01783","canonical_id":"hgnc:HGNC:52573","description":"long independently transcribed non-coding RNA 1783","metadata":null},{"id":"d9a8b6aca17e49ea97b21535249b3b0f","type":"GENE","name":"LINC01784","canonical_id":"hgnc:HGNC:52574","description":"long independently transcribed non-coding RNA 1784","metadata":null},{"id":"1f32352f74c34466a1fe74485dbcbaee","type":"GENE","name":"LINC01785","canonical_id":"hgnc:HGNC:25060","description":"long independently transcribed non-coding RNA 1785","metadata":null},{"id":"a700f8e4921742a4ac2deeac48625f92","type":"GENE","name":"LINC01786","canonical_id":"hgnc:HGNC:52575","description":"long independently transcribed non-coding RNA 1786","metadata":null},{"id":"221a6059ad4044f1afd843120f3362c2","type":"GENE","name":"LINC01787","canonical_id":"hgnc:HGNC:52576","description":"long independently transcribed non-coding RNA 1787","metadata":null},{"id":"e369b9550b444240b6355b2408c16a42","type":"GENE","name":"LINC01788","canonical_id":"hgnc:HGNC:52577","description":"long independently transcribed non-coding RNA 1788","metadata":null},{"id":"c5c0e99b1618450c89bdc70203b5b606","type":"GENE","name":"LINC01789","canonical_id":"hgnc:HGNC:52578","description":"long independently transcribed non-coding RNA 1789","metadata":null},{"id":"d7c003331fb94b118aa5e8e5c050eb59","type":"GENE","name":"LINC01790","canonical_id":"hgnc:HGNC:52579","description":"long independently transcribed non-coding RNA 1790","metadata":null},{"id":"728b4d530d504dfd879f093a5f944fcf","type":"GENE","name":"LINC01791","canonical_id":"hgnc:HGNC:52581","description":"long independently transcribed non-coding RNA 1791","metadata":null},{"id":"772e8381a57346d1878d4a0e28352a59","type":"GENE","name":"LINC01792","canonical_id":"hgnc:HGNC:52582","description":"long independently transcribed non-coding RNA 1792","metadata":null},{"id":"43b3cf9100df43849c43788e07c0cdcb","type":"GENE","name":"LINC01794","canonical_id":"hgnc:HGNC:52584","description":"long independently transcribed non-coding RNA 1794","metadata":null},{"id":"9bb76bbc30724f0b982e16ce8042a460","type":"GENE","name":"LINC01795","canonical_id":"hgnc:HGNC:52585","description":"long independently transcribed non-coding RNA 1795","metadata":null},{"id":"7120e8ddfa0d4faa95ec9f9efc4698a6","type":"GENE","name":"LINC01796","canonical_id":"hgnc:HGNC:52586","description":"long independently transcribed non-coding RNA 1796","metadata":null},{"id":"4c5a1358222a48f3ab8a355183bb4138","type":"GENE","name":"LINC01797","canonical_id":"hgnc:HGNC:52587","description":"long independently transcribed non-coding RNA 1797","metadata":null},{"id":"9555e675aa174f45b7fbf9723161eb00","type":"GENE","name":"LINC01798","canonical_id":"hgnc:HGNC:52588","description":"long independently transcribed non-coding RNA 1798","metadata":{"aliases":["LINC01799"]}},{"id":"eb5745a87d724fd8b987c3a113669a1f","type":"GENE","name":"LINC01800","canonical_id":"hgnc:HGNC:52590","description":"long independently transcribed non-coding RNA 1800","metadata":null},{"id":"fd298ea088b54fc99ac5238e1aac83dc","type":"GENE","name":"LINC01801","canonical_id":"hgnc:HGNC:52592","description":"long independently transcribed non-coding RNA 1801","metadata":{"aliases":["LINC03049"]}},{"id":"eac71ad2d12f4dc69fd1d5777b0a8e59","type":"GENE","name":"LINC01802","canonical_id":"hgnc:HGNC:52591","description":"long independently transcribed non-coding RNA 1802","metadata":null},{"id":"acfc174ea3e44d0d807497ca20ec3daa","type":"GENE","name":"LINC01803","canonical_id":"hgnc:HGNC:52595","description":"long independently transcribed non-coding RNA 1803","metadata":null},{"id":"724362d423a1462faab2fa83b35b04b4","type":"GENE","name":"LINC01804","canonical_id":"hgnc:HGNC:52596","description":"long independently transcribed non-coding RNA 1804","metadata":null},{"id":"53a99260d5f44f2aa44b94a0926d3601","type":"GENE","name":"LINC01805","canonical_id":"hgnc:HGNC:52597","description":"long independently transcribed non-coding RNA 1805","metadata":null},{"id":"45cea569033048df9a204570dd76709e","type":"GENE","name":"LINC01806","canonical_id":"hgnc:HGNC:52599","description":"long independently transcribed non-coding RNA 1806","metadata":null},{"id":"f7cb8f6b17fa4f30982b80b86b2c6f5c","type":"GENE","name":"LINC01807","canonical_id":"hgnc:HGNC:52610","description":"long independently transcribed non-coding RNA 1807","metadata":null},{"id":"ee6c3389a0354a969bfcadc38b3c0df4","type":"GENE","name":"LINC01808","canonical_id":"hgnc:HGNC:52611","description":"long independently transcribed non-coding RNA 1808","metadata":null},{"id":"e510e4c51cba425f86f309ae20ec6e4e","type":"GENE","name":"LINC01809","canonical_id":"hgnc:HGNC:52612","description":"long independently transcribed non-coding RNA 1809","metadata":null},{"id":"2ce28fcd22c24722a5c121186bd49472","type":"GENE","name":"LINC01810","canonical_id":"hgnc:HGNC:52613","description":"long independently transcribed non-coding RNA 1810","metadata":null},{"id":"62db3248e5fd42c6b46923f3e92f8f18","type":"GENE","name":"LINC01811","canonical_id":"hgnc:HGNC:52615","description":"long independently transcribed non-coding RNA 1811","metadata":null},{"id":"422c69d882544ba0936b98d417b437d3","type":"GENE","name":"LINC01812","canonical_id":"hgnc:HGNC:52616","description":"long independently transcribed non-coding RNA 1812","metadata":null},{"id":"9c4f823b3e4b45f287d99cc13e2b7fc1","type":"GENE","name":"LINC01813","canonical_id":"hgnc:HGNC:52617","description":"long independently transcribed non-coding RNA 1813","metadata":null},{"id":"7ad3d9c3207b42678656f9a1c774011a","type":"GENE","name":"LINC01815","canonical_id":"hgnc:HGNC:52619","description":"long independently transcribed non-coding RNA 1815","metadata":null},{"id":"fbc86cc7deed49bdb94d74425b924c8a","type":"GENE","name":"LINC01816","canonical_id":"hgnc:HGNC:52621","description":"long independently transcribed non-coding RNA 1816","metadata":{"aliases":["LOC100133985"]}},{"id":"b22a99f4db4146dcb83edc683bf68d12","type":"GENE","name":"LINC01817","canonical_id":"hgnc:HGNC:52622","description":"long independently transcribed non-coding RNA 1817","metadata":null},{"id":"d833b1d5d6614e469bc15fdcc33b81cc","type":"GENE","name":"LINC01818","canonical_id":"hgnc:HGNC:52623","description":"long independently transcribed non-coding RNA 1818","metadata":null},{"id":"17d80a71bbcd4b03afb1cf7d833fd3f7","type":"GENE","name":"LINC01819","canonical_id":"hgnc:HGNC:52624","description":"long independently transcribed non-coding RNA 1819","metadata":{"aliases":["AC016735.2","KPRT4","LINC02590"]}},{"id":"37b26c9db3274e74a753a4b4894c8cb3","type":"GENE","name":"LINC01820","canonical_id":"hgnc:HGNC:52625","description":"long independently transcribed non-coding RNA 1820","metadata":null},{"id":"b61143f0fc8d49ef93c2ef1534a968cd","type":"GENE","name":"LINC01821","canonical_id":"hgnc:HGNC:52626","description":"long independently transcribed non-coding RNA 1821","metadata":null},{"id":"444729fa45154509ad44afcbc37a59a0","type":"GENE","name":"LINC01822","canonical_id":"hgnc:HGNC:52627","description":"long independently transcribed non-coding RNA 1822","metadata":null},{"id":"6ae5667afe36434bbe1a03128129e8aa","type":"GENE","name":"LINC01823","canonical_id":"hgnc:HGNC:52628","description":"long independently transcribed non-coding RNA 1823","metadata":null},{"id":"74ffc7dbdc544ba199a63d546e1c2257","type":"GENE","name":"LINC01824","canonical_id":"hgnc:HGNC:52630","description":"long independently transcribed non-coding RNA 1824","metadata":null},{"id":"5df6f4f428e348518e50c3274c1e1077","type":"GENE","name":"LINC01825","canonical_id":"hgnc:HGNC:52631","description":"long independently transcribed non-coding RNA 1825","metadata":null},{"id":"8085ad98cb6a4bf8bba9bad0f57ddd86","type":"GENE","name":"LINC01826","canonical_id":"hgnc:HGNC:52632","description":"long independently transcribed non-coding RNA 1826","metadata":{"aliases":["lnc-MKI67IP-3"]}},{"id":"853bbcd877c7477c964ad40255d12064","type":"GENE","name":"LINC01827","canonical_id":"hgnc:HGNC:52633","description":"long independently transcribed non-coding RNA 1827","metadata":null},{"id":"10c981cae5c04a9a8969ee5433bb04c9","type":"GENE","name":"LINC01828","canonical_id":"hgnc:HGNC:52634","description":"long independently transcribed non-coding RNA 1828","metadata":null},{"id":"c4958f38188e460c8353dc85c3b2e7aa","type":"GENE","name":"LINC01829","canonical_id":"hgnc:HGNC:52635","description":"long independently transcribed non-coding RNA 1829","metadata":null},{"id":"8c59e8c0241741719259f4a91f1e3f43","type":"GENE","name":"LINC01830","canonical_id":"hgnc:HGNC:52636","description":"long independently transcribed non-coding RNA 1830","metadata":null},{"id":"89f0e189d5934ea6be1adc39075f526c","type":"GENE","name":"LINC01831","canonical_id":"hgnc:HGNC:52637","description":"long independently transcribed non-coding RNA 1831","metadata":null},{"id":"e75c7b5c297948c7880567bc2a76b206","type":"GENE","name":"LINC01832","canonical_id":"hgnc:HGNC:52638","description":"long independently transcribed non-coding RNA 1832","metadata":null},{"id":"41d84c8e5bb746e6a926cd0eed1e4be4","type":"GENE","name":"LINC01833","canonical_id":"hgnc:HGNC:52644","description":"long independently transcribed non-coding RNA 1833","metadata":{"aliases":["RP11-89-K21.1"]}},{"id":"e466ea4529a74091becc67982fea3d6b","type":"GENE","name":"LINC01834","canonical_id":"hgnc:HGNC:52648","description":"long independently transcribed non-coding RNA 1834","metadata":null},{"id":"4fdf30bd948041e3a2b1b04c4a939bcd","type":"GENE","name":"LINC01836","canonical_id":"hgnc:HGNC:52652","description":"long independently transcribed non-coding RNA 1836","metadata":null},{"id":"cd4397ccb9204791bfcff51c6408c226","type":"GENE","name":"LINC01837","canonical_id":"hgnc:HGNC:52653","description":"long independently transcribed non-coding RNA 1837","metadata":null},{"id":"0c39cb8980374b488065c2d4f2d65da6","type":"GENE","name":"LINC01838","canonical_id":"hgnc:HGNC:52654","description":"long independently transcribed non-coding RNA 1838","metadata":null},{"id":"92ccf2f539394a66aacb2107af82265d","type":"GENE","name":"LINC01839","canonical_id":"hgnc:HGNC:41330","description":"long independently transcribed non-coding RNA 1839","metadata":{"aliases":["EIF2B5-IT1"]}},{"id":"10c5c58881d8493984ca92415ae15491","type":"GENE","name":"LINC01840","canonical_id":"hgnc:HGNC:40209","description":"long independently transcribed non-coding RNA 1840","metadata":{"aliases":["EIF2B5-AS1"]}},{"id":"9a33619b03fa4758a870e5f37f604545","type":"GENE","name":"LINC01841","canonical_id":"hgnc:HGNC:52655","description":"long independently transcribed non-coding RNA 1841","metadata":null},{"id":"6edae4f589ae4f10878a62de33454940","type":"GENE","name":"LINC01842","canonical_id":"hgnc:HGNC:52656","description":"long independently transcribed non-coding RNA 1842","metadata":null},{"id":"a8f870a8b73c45c9a42f3376b02eec5d","type":"GENE","name":"LINC01843","canonical_id":"hgnc:HGNC:52659","description":"long independently transcribed non-coding RNA 1843","metadata":{"aliases":["Lnc-APUE"]}},{"id":"48e62a34c38149ada40bf2c6591425e5","type":"GENE","name":"LINC01845","canonical_id":"hgnc:HGNC:27747","description":"long independently transcribed non-coding RNA 1845","metadata":null},{"id":"ac9ebd3976d24ec99c13b1bff037945e","type":"GENE","name":"LINC01846","canonical_id":"hgnc:HGNC:52661","description":"long independently transcribed non-coding RNA 1846","metadata":null},{"id":"d9d4dbfaa9fd45c6b18e16802a619077","type":"GENE","name":"LINC01847","canonical_id":"hgnc:HGNC:52662","description":"long independently transcribed non-coding RNA 1847","metadata":null},{"id":"f186990c417e4885a6ef9d6a7c39af24","type":"GENE","name":"LINC01848","canonical_id":"hgnc:HGNC:52663","description":"long independently transcribed non-coding RNA 1848","metadata":null},{"id":"68c489611e8f406586124b8aa37b9bd1","type":"GENE","name":"LINC01849","canonical_id":"hgnc:HGNC:52665","description":"long independently transcribed non-coding RNA 1849","metadata":null},{"id":"13c02de53c0a435ba65393e3f89c7096","type":"GENE","name":"LINC01850","canonical_id":"hgnc:HGNC:52666","description":"long independently transcribed non-coding RNA 1850","metadata":null},{"id":"8889b78655ec4073bea0f3bea5f1fce7","type":"GENE","name":"LINC01851","canonical_id":"hgnc:HGNC:52667","description":"long independently transcribed non-coding RNA 1851","metadata":null},{"id":"b70f6e0d7446448ea90570c0dfad054b","type":"GENE","name":"LINC01852","canonical_id":"hgnc:HGNC:52668","description":"long independently transcribed non-coding RNA 1852","metadata":{"aliases":["ENST00000434223"]}},{"id":"5c77973d138e4290ba8a3b9dbfc507ac","type":"GENE","name":"LINC01853","canonical_id":"hgnc:HGNC:52669","description":"long independently transcribed non-coding RNA 1853","metadata":null},{"id":"78b5002b6234440aa56865b943d4b8e4","type":"GENE","name":"LINC01854","canonical_id":"hgnc:HGNC:52670","description":"long independently transcribed non-coding RNA 1854","metadata":null},{"id":"e63447b291ac4c248def4d22c9f533ad","type":"GENE","name":"LINC01856","canonical_id":"hgnc:HGNC:52672","description":"long independently transcribed non-coding RNA 1856","metadata":null},{"id":"822240e3241d4061abdd456958750480","type":"GENE","name":"LINC01858","canonical_id":"hgnc:HGNC:52676","description":"long independently transcribed non-coding RNA 1858","metadata":null},{"id":"a39067c5c9d14d1e8635114e657d683a","type":"GENE","name":"LINC01859","canonical_id":"hgnc:HGNC:52677","description":"long independently transcribed non-coding RNA 1859","metadata":null},{"id":"87715b4139e6422c971a3c1e8fd53511","type":"GENE","name":"LINC01861","canonical_id":"hgnc:HGNC:52680","description":"long independently transcribed non-coding RNA 1861","metadata":null},{"id":"d24b567e71784dee979b65f6a1d2c7e6","type":"GENE","name":"LINC01863","canonical_id":"hgnc:HGNC:52682","description":"long independently transcribed non-coding RNA 1863","metadata":null},{"id":"c08bba9278c44d3fb551e5690a8a3048","type":"GENE","name":"LINC01864","canonical_id":"hgnc:HGNC:52683","description":"long independently transcribed non-coding RNA 1864","metadata":null},{"id":"5dbe62624efb4ad2a49f47ff25f8e657","type":"GENE","name":"LINC01865","canonical_id":"hgnc:HGNC:52684","description":"long independently transcribed non-coding RNA 1865","metadata":null},{"id":"00f76100055c4e9db7c7b4450251e2d8","type":"GENE","name":"LINC01866","canonical_id":"hgnc:HGNC:52685","description":"long independently transcribed non-coding RNA 1866","metadata":null},{"id":"176c8a5063624ab8976b14db75cd5229","type":"GENE","name":"LINC01867","canonical_id":"hgnc:HGNC:52687","description":"long independently transcribed non-coding RNA 1867","metadata":null},{"id":"cbdfd6084b174e228474b3c68317af2b","type":"GENE","name":"LINC01868","canonical_id":"hgnc:HGNC:52688","description":"long independently transcribed non-coding RNA 1868","metadata":null},{"id":"4c6f3a55fa6f44dc9008c7ea4fdb59a1","type":"GENE","name":"LINC01870","canonical_id":"hgnc:HGNC:52689","description":"long independently transcribed non-coding RNA 1870","metadata":null},{"id":"d85e8aa3e0554d13b6878cf74cb2fe8a","type":"GENE","name":"LINC01871","canonical_id":"hgnc:HGNC:52690","description":"long independently transcribed non-coding RNA 1871","metadata":null},{"id":"a7b50e4e8aee40d9827a8c32d41fdc18","type":"GENE","name":"LINC01872","canonical_id":"hgnc:HGNC:52691","description":"long independently transcribed non-coding RNA 1872","metadata":null},{"id":"045001a6f58c44c6ae0c2619409ebbf9","type":"GENE","name":"LINC01873","canonical_id":"hgnc:HGNC:52692","description":"long independently transcribed non-coding RNA 1873","metadata":null},{"id":"a05c5abeb126436e9299f475853b817f","type":"GENE","name":"LINC01874","canonical_id":"hgnc:HGNC:52693","description":"long independently transcribed non-coding RNA 1874","metadata":null},{"id":"fd510a06991b48418a4d70a557317104","type":"GENE","name":"LINC01875","canonical_id":"hgnc:HGNC:52694","description":"long independently transcribed non-coding RNA 1875","metadata":null},{"id":"c68f337cd00b496bae8d8ca1281e31d5","type":"GENE","name":"LINC01876","canonical_id":"hgnc:HGNC:52695","description":"long independently transcribed non-coding RNA 1876","metadata":{"aliases":["uc.83"]}},{"id":"1d834431e79749b885bd9be2a2d640e0","type":"GENE","name":"LINC01877","canonical_id":"hgnc:HGNC:52696","description":"long independently transcribed non-coding RNA 1877","metadata":null},{"id":"c98892b0d528465d9b535fe9c26a19bd","type":"GENE","name":"LINC01878","canonical_id":"hgnc:HGNC:52697","description":"long independently transcribed non-coding RNA 1878","metadata":null},{"id":"2076b6fde22d4c3c9daa1f316ce3ad38","type":"GENE","name":"LINC01880","canonical_id":"hgnc:HGNC:52699","description":"long independently transcribed non-coding RNA 1880","metadata":null},{"id":"5b402a3282b04c738ec74ff653dbeae5","type":"GENE","name":"LINC01881","canonical_id":"hgnc:HGNC:52700","description":"long independently transcribed non-coding RNA 1881","metadata":null},{"id":"4210c050eca14cdc9679a0a5a7ba329a","type":"GENE","name":"LINC01882","canonical_id":"hgnc:HGNC:52701","description":"long independently transcribed non-coding RNA 1882","metadata":null},{"id":"421d8391ca9b476aa9b0f7916a0eb87a","type":"GENE","name":"LINC01883","canonical_id":"hgnc:HGNC:52702","description":"long independently transcribed non-coding RNA 1883","metadata":null},{"id":"70e7c3b94af344e7abbf32e80f952738","type":"GENE","name":"LINC01884","canonical_id":"hgnc:HGNC:52703","description":"long independently transcribed non-coding RNA 1884","metadata":null},{"id":"8fed6d58f3a046e2b1808ba80626ba01","type":"GENE","name":"LINC01885","canonical_id":"hgnc:HGNC:52704","description":"long independently transcribed non-coding RNA 1885","metadata":null},{"id":"0bf7a09ee6b449a38b0d90250e41fe52","type":"GENE","name":"LINC01886","canonical_id":"hgnc:HGNC:52705","description":"long independently transcribed non-coding RNA 1886","metadata":null},{"id":"30ef0253d260456db838792e382349d4","type":"GENE","name":"LINC01887","canonical_id":"hgnc:HGNC:52706","description":"long independently transcribed non-coding RNA 1887","metadata":null},{"id":"df9edd6b9dd348ea9ad02a80f5d0ac18","type":"GENE","name":"LINC01888","canonical_id":"hgnc:HGNC:52707","description":"long independently transcribed non-coding RNA 1888","metadata":null},{"id":"95172c623eab4c8787c17aba87742efc","type":"GENE","name":"LINC01889","canonical_id":"hgnc:HGNC:52708","description":"long independently transcribed non-coding RNA 1889","metadata":null},{"id":"0ece87f6ebdb4c96945dee1e98f75101","type":"GENE","name":"LINC01890","canonical_id":"hgnc:HGNC:52709","description":"long independently transcribed non-coding RNA 1890","metadata":null},{"id":"ce99ffc5fb8a4084b79ec2479c0a3fd7","type":"GENE","name":"LINC01891","canonical_id":"hgnc:HGNC:52710","description":"long independently transcribed non-coding RNA 1891","metadata":null},{"id":"2de83f89ac2d46ad8987d1bbcb0f8191","type":"GENE","name":"LINC01892","canonical_id":"hgnc:HGNC:52711","description":"long independently transcribed non-coding RNA 1892","metadata":null},{"id":"51a5cad035aa4ae3bfba65394b6b40db","type":"GENE","name":"LINC01893","canonical_id":"hgnc:HGNC:52712","description":"long independently transcribed non-coding RNA 1893","metadata":null},{"id":"18cc100cd2ab4a438c23858488dc812f","type":"GENE","name":"LINC01894","canonical_id":"hgnc:HGNC:52713","description":"long independently transcribed non-coding RNA 1894","metadata":null},{"id":"589dac66ffb84c418903ed2a502cebf1","type":"GENE","name":"LINC01895","canonical_id":"hgnc:HGNC:52714","description":"long independently transcribed non-coding RNA 1895","metadata":null},{"id":"702bde2c828b401ebf805e0cdf14b953","type":"GENE","name":"LINC01896","canonical_id":"hgnc:HGNC:52715","description":"long independently transcribed non-coding RNA 1896","metadata":null},{"id":"ac1f378afc644111a6a81f907fce8bfe","type":"GENE","name":"LINC01897","canonical_id":"hgnc:HGNC:52716","description":"long independently transcribed non-coding RNA 1897","metadata":null},{"id":"34331cd3b55040c6b37aa627ba54456e","type":"GENE","name":"LINC01898","canonical_id":"hgnc:HGNC:52717","description":"long independently transcribed non-coding RNA 1898","metadata":null},{"id":"a42274044fb54a3c9508bdf1629d183e","type":"GENE","name":"LINC01899","canonical_id":"hgnc:HGNC:52718","description":"long independently transcribed non-coding RNA 1899","metadata":null},{"id":"cb66d04645d64b2dbbca7c1315992248","type":"GENE","name":"LINC01900","canonical_id":"hgnc:HGNC:52719","description":"long independently transcribed non-coding RNA 1900","metadata":null},{"id":"a51069fa62a44dc4a055d3b30e52c347","type":"GENE","name":"LINC01901","canonical_id":"hgnc:HGNC:52720","description":"long independently transcribed non-coding RNA 1901","metadata":null},{"id":"c272554f14114a0090feaac36727d9b6","type":"GENE","name":"LINC01902","canonical_id":"hgnc:HGNC:52721","description":"long independently transcribed non-coding RNA 1902","metadata":null},{"id":"bece7f41b88a4947ac6c935a2f6a8af6","type":"GENE","name":"LINC01903","canonical_id":"hgnc:HGNC:52722","description":"long independently transcribed non-coding RNA 1903","metadata":null},{"id":"d63c084aac774979b219275a3f716b87","type":"GENE","name":"LINC01904","canonical_id":"hgnc:HGNC:52723","description":"long independently transcribed non-coding RNA 1904","metadata":null},{"id":"69c3d65a9ca84392ab29a3e7eaf8424d","type":"GENE","name":"LINC01905","canonical_id":"hgnc:HGNC:52724","description":"long independently transcribed non-coding RNA 1905","metadata":null},{"id":"b17ceb50a4654bf29c2431430f877cf3","type":"GENE","name":"LINC01906","canonical_id":"hgnc:HGNC:52725","description":"long independently transcribed non-coding RNA 1906","metadata":null},{"id":"9f8715b7e0a04447bc6f8cac92a9bd47","type":"GENE","name":"LINC01907","canonical_id":"hgnc:HGNC:52726","description":"long independently transcribed non-coding RNA 1907","metadata":null},{"id":"ab65865b46964c96aa01fcfa93125583","type":"GENE","name":"LINC01908","canonical_id":"hgnc:HGNC:52727","description":"long independently transcribed non-coding RNA 1908","metadata":null},{"id":"c4fb98da5a874ef3aca44f51068839c2","type":"GENE","name":"LINC01909","canonical_id":"hgnc:HGNC:52728","description":"long independently transcribed non-coding RNA 1909","metadata":null},{"id":"40562115a197437da5e4523e1ea8a338","type":"GENE","name":"LINC01910","canonical_id":"hgnc:HGNC:52729","description":"long independently transcribed non-coding RNA 1910","metadata":null},{"id":"64a0d9e87cac4d47a84d64a6113ce295","type":"GENE","name":"LINC01911","canonical_id":"hgnc:HGNC:52730","description":"long independently transcribed non-coding RNA 1911","metadata":null},{"id":"a378c526c1534714aaad68eeba6c281e","type":"GENE","name":"LINC01912","canonical_id":"hgnc:HGNC:52731","description":"long independently transcribed non-coding RNA 1912","metadata":null},{"id":"5417e16751244dd3921a9617be77d3ba","type":"GENE","name":"LINC01913","canonical_id":"hgnc:HGNC:52732","description":"long independently transcribed non-coding RNA 1913","metadata":null},{"id":"ff958535b67b409996e0601e6d1102ea","type":"GENE","name":"LINC01914","canonical_id":"hgnc:HGNC:52733","description":"long independently transcribed non-coding RNA 1914","metadata":null},{"id":"7e71897cc5634eaa91dcd5a81750d6a8","type":"GENE","name":"LINC01915","canonical_id":"hgnc:HGNC:52734","description":"long independently transcribed non-coding RNA 1915","metadata":null},{"id":"1b73bc4f4f1f4f6b829b7224cb7b1627","type":"GENE","name":"LINC01916","canonical_id":"hgnc:HGNC:52735","description":"long independently transcribed non-coding RNA 1916","metadata":null},{"id":"aa0c562bcbac4825ab8681ac96cc98f3","type":"GENE","name":"LINC01917","canonical_id":"hgnc:HGNC:52736","description":"long independently transcribed non-coding RNA 1917","metadata":null},{"id":"c9bd6897073740f7968f32bf95c2019d","type":"GENE","name":"LINC01919","canonical_id":"hgnc:HGNC:52739","description":"long independently transcribed non-coding RNA 1919","metadata":null},{"id":"ca3cac08e0cc418eb2642612c47873d2","type":"GENE","name":"LINC01920","canonical_id":"hgnc:HGNC:52738","description":"long independently transcribed non-coding RNA 1920","metadata":null},{"id":"f61e79a5ecbf45d0b0e03000ecb875e7","type":"GENE","name":"LINC01922","canonical_id":"hgnc:HGNC:52741","description":"long independently transcribed non-coding RNA 1922","metadata":null},{"id":"ff6df7f2764d4cb8a2638187b7fd1c4c","type":"GENE","name":"LINC01923","canonical_id":"hgnc:HGNC:52742","description":"long independently transcribed non-coding RNA 1923","metadata":null},{"id":"f3bd2bf5457849a8912f2227dcc6daa2","type":"GENE","name":"LINC01924","canonical_id":"hgnc:HGNC:27600","description":"long independently transcribed non-coding RNA 1924","metadata":null},{"id":"13dfb8a49d2d4650b8b5811378d2b545","type":"GENE","name":"LINC01925","canonical_id":"hgnc:HGNC:52745","description":"long independently transcribed non-coding RNA 1925","metadata":null},{"id":"ce21a93851d34612b9e1efcfe16368f7","type":"GENE","name":"LINC01926","canonical_id":"hgnc:HGNC:52748","description":"long independently transcribed non-coding RNA 1926","metadata":null},{"id":"e470d8faf01f490f931de6e1f897a8c0","type":"GENE","name":"LINC01927","canonical_id":"hgnc:HGNC:52749","description":"long independently transcribed non-coding RNA 1927","metadata":null},{"id":"60b9986606e54c69ad7a8e1c5c6f4ae0","type":"GENE","name":"LINC01928","canonical_id":"hgnc:HGNC:52750","description":"long independently transcribed non-coding RNA 1928","metadata":null},{"id":"fd3eb02f1d9443e2a686e7ab60b6b03d","type":"GENE","name":"LINC01929","canonical_id":"hgnc:HGNC:52751","description":"long independently transcribed non-coding RNA 1929","metadata":{"aliases":["CTD-2171N6.1"]}},{"id":"1a608b98f0ca487580118f32c6ab9047","type":"GENE","name":"LINC01930","canonical_id":"hgnc:HGNC:52744","description":"long independently transcribed non-coding RNA 1930","metadata":{"aliases":["EU358092"]}},{"id":"a2402193b3974379a99549e52997ad09","type":"GENE","name":"LINC01931","canonical_id":"hgnc:HGNC:52743","description":"long independently transcribed non-coding RNA 1931","metadata":null},{"id":"cedb54f4fe7d4f679b0b976e45a37cd9","type":"GENE","name":"LINC01932","canonical_id":"hgnc:HGNC:52755","description":"long independently transcribed non-coding RNA 1932","metadata":null},{"id":"41657e780b59407992acec8d11530272","type":"GENE","name":"LINC01933","canonical_id":"hgnc:HGNC:52756","description":"long independently transcribed non-coding RNA 1933","metadata":null},{"id":"0df0a16d6c9c4227a5bee2aee698ef0f","type":"GENE","name":"LINC01934","canonical_id":"hgnc:HGNC:52757","description":"long independently transcribed non-coding RNA 1934","metadata":null},{"id":"9d2553dbface4594ab9cb85c2d17643a","type":"GENE","name":"LINC01935","canonical_id":"hgnc:HGNC:52758","description":"long independently transcribed non-coding RNA 1935","metadata":null},{"id":"1fd56e60e6834dab9b57d674dc4b7ff8","type":"GENE","name":"LINC01936","canonical_id":"hgnc:HGNC:52759","description":"long independently transcribed non-coding RNA 1936","metadata":null},{"id":"af54c498fef847dd8b70500e1864f892","type":"GENE","name":"LINC01937","canonical_id":"hgnc:HGNC:52760","description":"long independently transcribed non-coding RNA 1937","metadata":null},{"id":"43cb076c1a3543cc9dd351ab6e73dd50","type":"GENE","name":"LINC01938","canonical_id":"hgnc:HGNC:52761","description":"long independently transcribed non-coding RNA 1938","metadata":null},{"id":"7ff2a04526644a6689162be29cfc05f8","type":"GENE","name":"LINC01939","canonical_id":"hgnc:HGNC:52762","description":"long independently transcribed non-coding RNA 1939","metadata":null},{"id":"c0f910a870ef40038da4fe71294053bb","type":"GENE","name":"LINC01940","canonical_id":"hgnc:HGNC:52763","description":"long independently transcribed non-coding RNA 1940","metadata":null},{"id":"438ccb8c1aa142e984d7ca5bf106555d","type":"GENE","name":"LINC01941","canonical_id":"hgnc:HGNC:52764","description":"long independently transcribed non-coding RNA 1941","metadata":null},{"id":"9daa466cf3c54aa1a09ffe63f9ee5400","type":"GENE","name":"LINC01942","canonical_id":"hgnc:HGNC:52766","description":"long independently transcribed non-coding RNA 1942","metadata":null},{"id":"48263c2db97045b89a99d0244ef64672","type":"GENE","name":"LINC01943","canonical_id":"hgnc:HGNC:52767","description":"long independently transcribed non-coding RNA 1943","metadata":null},{"id":"efc4e665bc9c43c297072f2633cc4597","type":"GENE","name":"LINC01944","canonical_id":"hgnc:HGNC:52768","description":"long independently transcribed non-coding RNA 1944","metadata":null},{"id":"23c0164265574a2f85e386229b6443cf","type":"GENE","name":"LINC01945","canonical_id":"hgnc:HGNC:52769","description":"long independently transcribed non-coding RNA 1945","metadata":null},{"id":"11e4ec9df784403aa7a6e18d48ed4165","type":"GENE","name":"LINC01946","canonical_id":"hgnc:HGNC:52770","description":"long independently transcribed non-coding RNA 1946","metadata":null},{"id":"251b1b7046f644e2aae44b001c075185","type":"GENE","name":"LINC01947","canonical_id":"hgnc:HGNC:52771","description":"long independently transcribed non-coding RNA 1947","metadata":null},{"id":"439d580f2baf47afb451b501b9fa786d","type":"GENE","name":"LINC01948","canonical_id":"hgnc:HGNC:52772","description":"long independently transcribed non-coding RNA 1948","metadata":null},{"id":"f0e7589d1bd540c8beb4c4b8328744df","type":"GENE","name":"LINC01949","canonical_id":"hgnc:HGNC:25650","description":"long independently transcribed non-coding RNA 1949","metadata":null},{"id":"e493930f0ae94e11ab5001513f67d995","type":"GENE","name":"LINC01950","canonical_id":"hgnc:HGNC:52773","description":"long independently transcribed non-coding RNA 1950","metadata":null},{"id":"709516ee54db4574b0bf999775357fed","type":"GENE","name":"LINC01951","canonical_id":"hgnc:HGNC:52774","description":"long independently transcribed non-coding RNA 1951","metadata":null},{"id":"f8947e82054b433bb8acd69b2280b8fd","type":"GENE","name":"LINC01953","canonical_id":"hgnc:HGNC:52776","description":"long independently transcribed non-coding RNA 1953","metadata":null},{"id":"8174a356207740e780b8cf4261129bf3","type":"GENE","name":"LINC01954","canonical_id":"hgnc:HGNC:52779","description":"long independently transcribed non-coding RNA 1954","metadata":null},{"id":"099d6a11af574204bb99a35b25cb3bff","type":"GENE","name":"LINC01955","canonical_id":"hgnc:HGNC:52780","description":"long independently transcribed non-coding RNA 1955","metadata":null},{"id":"531a39151f6b44f5b02190a2f222fa6c","type":"GENE","name":"LINC01956","canonical_id":"hgnc:HGNC:52777","description":"long independently transcribed non-coding RNA 1956","metadata":{"aliases":["RP11-19E11.1"]}},{"id":"3334bf232e4145bbb721e5981cbb9f60","type":"GENE","name":"LINC01957","canonical_id":"hgnc:HGNC:52783","description":"long independently transcribed non-coding RNA 1957","metadata":null},{"id":"8bdf1bce71754768967f1b00fc1ad30a","type":"GENE","name":"LINC01958","canonical_id":"hgnc:HGNC:52784","description":"long independently transcribed non-coding RNA 1958","metadata":{"aliases":["uc.85"]}},{"id":"96a6aaa6f24b49b49bf69fb927b11031","type":"GENE","name":"LINC01960","canonical_id":"hgnc:HGNC:52785","description":"long independently transcribed non-coding RNA 1960","metadata":null},{"id":"fe0205c112be4de988ec458b2a0cfb7b","type":"GENE","name":"LINC01961","canonical_id":"hgnc:HGNC:52786","description":"long independently transcribed non-coding RNA 1961","metadata":null},{"id":"a2828d4f33e24dbe80ec59229f09d2f9","type":"GENE","name":"LINC01962","canonical_id":"hgnc:HGNC:52787","description":"long independently transcribed non-coding RNA 1962","metadata":null},{"id":"f19c4e1860804345be957d00ce639971","type":"GENE","name":"LINC01963","canonical_id":"hgnc:HGNC:25283","description":"long independently transcribed non-coding RNA 1963","metadata":{"aliases":["DKFZp434H1419"]}},{"id":"f7cd592e74db4afe8dbc75918c111231","type":"GENE","name":"LINC01964","canonical_id":"hgnc:HGNC:52789","description":"long independently transcribed non-coding RNA 1964","metadata":null},{"id":"019aaafd3cd743b89e6138b04e60cb1f","type":"GENE","name":"LINC01965","canonical_id":"hgnc:HGNC:52790","description":"long independently transcribed non-coding RNA 1965","metadata":null},{"id":"7b41552f199d4882b6abe7ab33f85189","type":"GENE","name":"LINC01966","canonical_id":"hgnc:HGNC:52792","description":"long independently transcribed non-coding RNA 1966","metadata":null},{"id":"9a247f89cb0c43768b6d391492ae8d97","type":"GENE","name":"LINC01967","canonical_id":"hgnc:HGNC:52793","description":"long independently transcribed non-coding RNA 1967","metadata":null},{"id":"9d6d61070aa64d8ea2af83c5d36dd0ee","type":"GENE","name":"LINC01968","canonical_id":"hgnc:HGNC:52794","description":"long independently transcribed non-coding RNA 1968","metadata":null},{"id":"d3ec3717142e48e0a137d8f32c23cdef","type":"GENE","name":"LINC01970","canonical_id":"hgnc:HGNC:52796","description":"long independently transcribed non-coding RNA 1970","metadata":null},{"id":"a0677f37a7b84a57bcf3e7e16e23599c","type":"GENE","name":"LINC01971","canonical_id":"hgnc:HGNC:52797","description":"long independently transcribed non-coding RNA 1971","metadata":null},{"id":"5aacfb4ff3e54a129e27581c22800f08","type":"GENE","name":"LINC01972","canonical_id":"hgnc:HGNC:52798","description":"long independently transcribed non-coding RNA 1972","metadata":null},{"id":"d0d1cb2c8bb94873988c657835a5674b","type":"GENE","name":"LINC01973","canonical_id":"hgnc:HGNC:52800","description":"long independently transcribed non-coding RNA 1973","metadata":null},{"id":"8a5819792ddf4ec3b7f3207fc44a0f74","type":"GENE","name":"LINC01975","canonical_id":"hgnc:HGNC:52802","description":"long independently transcribed non-coding RNA 1975","metadata":null},{"id":"ac3ba9cd16a34642a5437b77f24a528c","type":"GENE","name":"LINC01976","canonical_id":"hgnc:HGNC:52803","description":"long independently transcribed non-coding RNA 1976","metadata":null},{"id":"f20512fdeeef419ca5f1195e00b1fbc1","type":"GENE","name":"LINC01977","canonical_id":"hgnc:HGNC:52804","description":"long independently transcribed non-coding RNA 1977","metadata":null},{"id":"82e560801fca4db89496fb2d4e6c87a2","type":"GENE","name":"LINC01978","canonical_id":"hgnc:HGNC:52806","description":"long independently transcribed non-coding RNA 1978","metadata":null},{"id":"db3c721c37534eeb902fd3518613e7ec","type":"GENE","name":"LINC01979","canonical_id":"hgnc:HGNC:52807","description":"long independently transcribed non-coding RNA 1979","metadata":null},{"id":"155d12689f64483f9d2def731432982f","type":"GENE","name":"LINC01980","canonical_id":"hgnc:HGNC:52808","description":"long independently transcribed non-coding RNA 1980","metadata":null},{"id":"0a79a64ccfa54293b5902d2bd105102b","type":"GENE","name":"LINC01981","canonical_id":"hgnc:HGNC:52809","description":"long independently transcribed non-coding RNA 1981","metadata":null},{"id":"814777e0008c4b99af9f732955e94603","type":"GENE","name":"LINC01982","canonical_id":"hgnc:HGNC:52812","description":"long independently transcribed non-coding RNA 1982","metadata":null},{"id":"4c7b58235c184f0a846b8ecc821f1788","type":"GENE","name":"LINC01983","canonical_id":"hgnc:HGNC:52813","description":"long independently transcribed non-coding RNA 1983","metadata":null},{"id":"1fe1ac0cb423459fbf0668a5aa133d56","type":"GENE","name":"LINC01985","canonical_id":"hgnc:HGNC:52816","description":"long independently transcribed non-coding RNA 1985","metadata":null},{"id":"a6d4bc7250564349ba4f8d3bcd8f13be","type":"GENE","name":"LINC01986","canonical_id":"hgnc:HGNC:52817","description":"long independently transcribed non-coding RNA 1986","metadata":null},{"id":"32de1c9994fa475d8efbdfde87774ca5","type":"GENE","name":"LINC01987","canonical_id":"hgnc:HGNC:52819","description":"long independently transcribed non-coding RNA 1987","metadata":null},{"id":"1e61daf63b3c43739226ac2add57b5f7","type":"GENE","name":"LINC01988","canonical_id":"hgnc:HGNC:52820","description":"long independently transcribed non-coding RNA 1988","metadata":{"aliases":["PAAN"]}},{"id":"43e09836f6cc48b582a04305b6f95925","type":"GENE","name":"LINC01989","canonical_id":"hgnc:HGNC:52821","description":"long independently transcribed non-coding RNA 1989","metadata":null},{"id":"b0ed5375cbee4d1cb3f5c8d976fa591a","type":"GENE","name":"LINC01990","canonical_id":"hgnc:HGNC:52822","description":"long independently transcribed non-coding RNA 1990","metadata":null},{"id":"05b1ad8e714b43d8a32461a36d9072a2","type":"GENE","name":"LINC01991","canonical_id":"hgnc:HGNC:52823","description":"long independently transcribed non-coding RNA 1991","metadata":null},{"id":"2ee0623069774928b8bbab766dad24c0","type":"GENE","name":"LINC01992","canonical_id":"hgnc:HGNC:52824","description":"long independently transcribed non-coding RNA 1992","metadata":null},{"id":"e5aef7060c774587a07828fcb79e71f5","type":"GENE","name":"LINC01993","canonical_id":"hgnc:HGNC:52826","description":"long independently transcribed non-coding RNA 1993","metadata":null},{"id":"43f6f9ebcb3b45559d264d7ee37a4e2f","type":"GENE","name":"LINC01994","canonical_id":"hgnc:HGNC:52827","description":"long independently transcribed non-coding RNA 1994","metadata":{"aliases":["CASCADES","LINC01995"]}},{"id":"6204648f5b5a41fdbdb7fe8f50835ab2","type":"GENE","name":"LINC01996","canonical_id":"hgnc:HGNC:52830","description":"long independently transcribed non-coding RNA 1996","metadata":null},{"id":"19908e4bee7e44228debae2bdb6f4482","type":"GENE","name":"LINC01997","canonical_id":"hgnc:HGNC:52831","description":"long independently transcribed non-coding RNA 1997","metadata":null},{"id":"00ba1755cb614902aa2c98612b889613","type":"GENE","name":"LINC01998","canonical_id":"hgnc:HGNC:52832","description":"long independently transcribed non-coding RNA 1998","metadata":null},{"id":"afe9fe65e2e740e2a7d1189eeb34c04e","type":"GENE","name":"LINC01999","canonical_id":"hgnc:HGNC:52834","description":"long independently transcribed non-coding RNA 1999","metadata":null},{"id":"5f51165b3699421097bfa9c6bc3e7645","type":"GENE","name":"LINC02000","canonical_id":"hgnc:HGNC:52835","description":"long independently transcribed non-coding RNA 2000","metadata":null},{"id":"f9ca567cf824499aa30d20905bec85bb","type":"GENE","name":"LINC02002","canonical_id":"hgnc:HGNC:52837","description":"long independently transcribed non-coding RNA 2002","metadata":null},{"id":"8fc6514caf0f462ca97acd5de63fc752","type":"GENE","name":"LINC02003","canonical_id":"hgnc:HGNC:27099","description":"long independently transcribed non-coding RNA 2003","metadata":null},{"id":"11035267626143479ced9598ecd56a0f","type":"GENE","name":"LINC02004","canonical_id":"hgnc:HGNC:52838","description":"long independently transcribed non-coding RNA 2004","metadata":null},{"id":"9836bc2da205447d9c56fdc7e8268123","type":"GENE","name":"LINC02005","canonical_id":"hgnc:HGNC:52839","description":"long independently transcribed non-coding RNA 2005","metadata":null},{"id":"90c8d3ea1de9404782e8cd986ebf347a","type":"GENE","name":"LINC02006","canonical_id":"hgnc:HGNC:52842","description":"long independently transcribed non-coding RNA 2006","metadata":null},{"id":"6f6df8ca06ea4d7a807d6b27f3de1a7c","type":"GENE","name":"LINC02008","canonical_id":"hgnc:HGNC:52844","description":"long independently transcribed non-coding RNA 2008","metadata":null},{"id":"72c69a5a537742f6abc6823fb513bae2","type":"GENE","name":"LINC02009","canonical_id":"hgnc:HGNC:52845","description":"long independently transcribed non-coding RNA 2009","metadata":null},{"id":"1293f9b0278b46a498578ee6a6867f9a","type":"GENE","name":"LINC02010","canonical_id":"hgnc:HGNC:52846","description":"long independently transcribed non-coding RNA 2010","metadata":null},{"id":"0cb6f8922510429aa0b26ba3c9c22365","type":"GENE","name":"LINC02011","canonical_id":"hgnc:HGNC:27191","description":"long independently transcribed non-coding RNA 2011","metadata":{"aliases":["FLJ31836"]}},{"id":"fa677ea0fb3848fca498ebf3e8bb1084","type":"GENE","name":"LINC02012","canonical_id":"hgnc:HGNC:52847","description":"long independently transcribed non-coding RNA 2012","metadata":null},{"id":"aa16b7ad114e4ddaa38169ecf8354f54","type":"GENE","name":"LINC02013","canonical_id":"hgnc:HGNC:52848","description":"long independently transcribed non-coding RNA 2013","metadata":null},{"id":"b534990114cf4a41a93ea219f0e77ae9","type":"GENE","name":"LINC02014","canonical_id":"hgnc:HGNC:52849","description":"long independently transcribed non-coding RNA 2014","metadata":null},{"id":"5c9e5ab8c4b44094970ec3f9e1439cbe","type":"GENE","name":"LINC02015","canonical_id":"hgnc:HGNC:52850","description":"long independently transcribed non-coding RNA 2015","metadata":null},{"id":"4e258b091d184bcd850e347103d04d29","type":"GENE","name":"LINC02016","canonical_id":"hgnc:HGNC:52851","description":"long independently transcribed non-coding RNA 2016","metadata":null},{"id":"389eca1a07e44cbfabf316822d29f6b4","type":"GENE","name":"LINC02017","canonical_id":"hgnc:HGNC:52852","description":"long independently transcribed non-coding RNA 2017","metadata":null},{"id":"39f6902a7c83465baeb454f57c783732","type":"GENE","name":"LINC02018","canonical_id":"hgnc:HGNC:52853","description":"long independently transcribed non-coding RNA 2018","metadata":null},{"id":"c26c18f1606946df866526a0ec024b82","type":"GENE","name":"LINC02019","canonical_id":"hgnc:HGNC:52854","description":"long independently transcribed non-coding RNA 2019","metadata":null},{"id":"293a7ff406f44ec39adbfea039197f64","type":"GENE","name":"LINC02020","canonical_id":"hgnc:HGNC:52855","description":"long independently transcribed non-coding RNA 2020","metadata":null},{"id":"6bfa22d70ece4c6a966b2da4f23f969e","type":"GENE","name":"LINC02021","canonical_id":"hgnc:HGNC:52856","description":"long independently transcribed non-coding RNA 2021","metadata":null},{"id":"bab18efec0c0463f9e3d3c6bdee88ba2","type":"GENE","name":"LINC02022","canonical_id":"hgnc:HGNC:52857","description":"long independently transcribed non-coding RNA 2022","metadata":null},{"id":"b1c1033634124934933d3cd1ab541639","type":"GENE","name":"LINC02023","canonical_id":"hgnc:HGNC:52858","description":"long independently transcribed non-coding RNA 2023","metadata":null},{"id":"aa14ef9841db40b989acc10a377e39ff","type":"GENE","name":"LINC02024","canonical_id":"hgnc:HGNC:52859","description":"long independently transcribed non-coding RNA 2024","metadata":null},{"id":"2e6ea249a9ef46a58b2ca103377fec31","type":"GENE","name":"LINC02025","canonical_id":"hgnc:HGNC:52860","description":"long independently transcribed non-coding RNA 2025","metadata":null},{"id":"80453b0eb94044f794545dfc8098dc4f","type":"GENE","name":"LINC02026","canonical_id":"hgnc:HGNC:52861","description":"long independently transcribed non-coding RNA 2026","metadata":null},{"id":"98fb89be1892449db5a379dd47d49489","type":"GENE","name":"LINC02027","canonical_id":"hgnc:HGNC:52862","description":"long independently transcribed non-coding RNA 2027","metadata":{"aliases":["LOC728290"]}},{"id":"2d8f2be703764d529d122c9ef54d0080","type":"GENE","name":"LINC02028","canonical_id":"hgnc:HGNC:27718","description":"long independently transcribed non-coding RNA 2028","metadata":null},{"id":"44b949ce3732461cb344a56236787271","type":"GENE","name":"LINC02029","canonical_id":"hgnc:HGNC:52863","description":"long independently transcribed non-coding RNA 2029","metadata":null},{"id":"ef89bb687f1c46c0a18d584cba69e11b","type":"GENE","name":"LINC02030","canonical_id":"hgnc:HGNC:52864","description":"long independently transcribed non-coding RNA 2030","metadata":null},{"id":"53852f8c9f1e4fe48a19913d416e62e3","type":"GENE","name":"LINC02031","canonical_id":"hgnc:HGNC:52865","description":"long independently transcribed non-coding RNA 2031","metadata":null},{"id":"9e01a79db87942398a070680ca8b12bd","type":"GENE","name":"LINC02032","canonical_id":"hgnc:HGNC:52866","description":"long independently transcribed non-coding RNA 2032","metadata":null},{"id":"b4a04a98a7ff4c68b72997de3db158e3","type":"GENE","name":"LINC02033","canonical_id":"hgnc:HGNC:52867","description":"long independently transcribed non-coding RNA 2033","metadata":null},{"id":"43accdfaa42749dd999e0400093f586f","type":"GENE","name":"LINC02034","canonical_id":"hgnc:HGNC:52868","description":"long independently transcribed non-coding RNA 2034","metadata":null},{"id":"9c5c7695bfd94a15ab46e118a1cb876c","type":"GENE","name":"LINC02035","canonical_id":"hgnc:HGNC:52875","description":"long independently transcribed non-coding RNA 2035","metadata":null},{"id":"c90fd20f94ad463daa4d0e0ebd0eb800","type":"GENE","name":"LINC02037","canonical_id":"hgnc:HGNC:52877","description":"long independently transcribed non-coding RNA 2037","metadata":null},{"id":"71d1267c7a8e42f2840412a124d085d2","type":"GENE","name":"LINC02038","canonical_id":"hgnc:HGNC:52878","description":"long independently transcribed non-coding RNA 2038","metadata":null},{"id":"7f92bbd2f9314790b88f8d59223f2df2","type":"GENE","name":"LINC02039","canonical_id":"hgnc:HGNC:52879","description":"long independently transcribed non-coding RNA 2039","metadata":null},{"id":"bb2402bb7cb54fb48cfbc1078db91a81","type":"GENE","name":"LINC02040","canonical_id":"hgnc:HGNC:52880","description":"long independently transcribed non-coding RNA 2040","metadata":null},{"id":"03ebfc2245c847ada6ef8d2b5a4b8def","type":"GENE","name":"LINC02041","canonical_id":"hgnc:HGNC:52881","description":"long independently transcribed non-coding RNA 2041","metadata":{"aliases":["RP11-567G11.1"]}},{"id":"ff6e5389a8474c7db9f7195b94dc3241","type":"GENE","name":"LINC02042","canonical_id":"hgnc:HGNC:52882","description":"long independently transcribed non-coding RNA 2042","metadata":null},{"id":"a83c73c1b5944993a32013743ff76a7a","type":"GENE","name":"LINC02043","canonical_id":"hgnc:HGNC:52883","description":"long independently transcribed non-coding RNA 2043","metadata":null},{"id":"1b41c022cb4f4b32b81394dca394f716","type":"GENE","name":"LINC02044","canonical_id":"hgnc:HGNC:52884","description":"long independently transcribed non-coding RNA 2044","metadata":null},{"id":"c9cf34f7a7cb47fd9b154bdcd4624af2","type":"GENE","name":"LINC02045","canonical_id":"hgnc:HGNC:52885","description":"long independently transcribed non-coding RNA 2045","metadata":null},{"id":"3128ae004be94bf1ad79ea71f1f8470e","type":"GENE","name":"LINC02046","canonical_id":"hgnc:HGNC:52886","description":"long independently transcribed non-coding RNA 2046","metadata":null},{"id":"eeff86f56de6486fa7389a7750e04416","type":"GENE","name":"LINC02047","canonical_id":"hgnc:HGNC:52887","description":"long independently transcribed non-coding RNA 2047","metadata":null},{"id":"e88c6216dd3f4b949e387310a40f4e7a","type":"GENE","name":"LINC02048","canonical_id":"hgnc:HGNC:52888","description":"long independently transcribed non-coding RNA 2048","metadata":null},{"id":"6e12fe4ce56d41e6a14653da17f1fba9","type":"GENE","name":"LINC02049","canonical_id":"hgnc:HGNC:52889","description":"long independently transcribed non-coding RNA 2049","metadata":null},{"id":"1a7e0d0d2ed043ffbdd9a97854ad8360","type":"GENE","name":"LINC02050","canonical_id":"hgnc:HGNC:52890","description":"long independently transcribed non-coding RNA 2050","metadata":null},{"id":"6a84f3298cb24234984fa05e22eaadb4","type":"GENE","name":"LINC02051","canonical_id":"hgnc:HGNC:52891","description":"long independently transcribed non-coding RNA 2051","metadata":null},{"id":"713e8c05608449238389c9f8f771aa26","type":"GENE","name":"LINC02052","canonical_id":"hgnc:HGNC:27372","description":"long independently transcribed non-coding RNA 2052","metadata":null},{"id":"f936633431ec432796149445aff305ce","type":"GENE","name":"LINC02053","canonical_id":"hgnc:HGNC:52893","description":"long independently transcribed non-coding RNA 2053","metadata":null},{"id":"f3f989fbc4064ee6a588cff18f865fce","type":"GENE","name":"LINC02054","canonical_id":"hgnc:HGNC:52894","description":"long independently transcribed non-coding RNA 2054","metadata":null},{"id":"3159b81b033144a0aa68aa951a60176b","type":"GENE","name":"LINC02055","canonical_id":"hgnc:HGNC:52895","description":"long independently transcribed non-coding RNA 2055","metadata":{"aliases":["RP1130-1"]}},{"id":"dd4b1c6ea8934bc482de65b9df3bddf9","type":"GENE","name":"LINC02057","canonical_id":"hgnc:HGNC:52900","description":"long independently transcribed non-coding RNA 2057","metadata":null},{"id":"8c01260d714740ab941ce7d96cfebe39","type":"GENE","name":"LINC02058","canonical_id":"hgnc:HGNC:52901","description":"long independently transcribed non-coding RNA 2058","metadata":null},{"id":"e01bd5d5d8d84a6e978b87ba0e7e7f20","type":"GENE","name":"LINC02059","canonical_id":"hgnc:HGNC:52902","description":"long independently transcribed non-coding RNA 2059","metadata":null},{"id":"9646b3d5227a4cc2a68ad4ce8fd771c4","type":"GENE","name":"LINC02061","canonical_id":"hgnc:HGNC:52906","description":"long independently transcribed non-coding RNA 2061","metadata":null},{"id":"57f1028c465f4352a46c378c5b134d93","type":"GENE","name":"LINC02063","canonical_id":"hgnc:HGNC:52908","description":"long independently transcribed non-coding RNA 2063","metadata":{"aliases":["CTD-2008N3.1"]}},{"id":"c4657d239cc34e59b1bbdd8b6001f5c1","type":"GENE","name":"LINC02064","canonical_id":"hgnc:HGNC:52909","description":"long independently transcribed non-coding RNA 2064","metadata":null},{"id":"4e3b10d49a3241fb99e51a8c50cf9e15","type":"GENE","name":"LINC02065","canonical_id":"hgnc:HGNC:52910","description":"long independently transcribed non-coding RNA 2065","metadata":null},{"id":"c71099d22f104553be9e5011530f9b97","type":"GENE","name":"LINC02066","canonical_id":"hgnc:HGNC:52911","description":"long independently transcribed non-coding RNA 2066","metadata":null},{"id":"a245c54e40a5400d8af618db263372a2","type":"GENE","name":"LINC02067","canonical_id":"hgnc:HGNC:52913","description":"long independently transcribed non-coding RNA 2067","metadata":null},{"id":"e411920673d14aee92515de2f151ae06","type":"GENE","name":"LINC02068","canonical_id":"hgnc:HGNC:52914","description":"long independently transcribed non-coding RNA 2068","metadata":null},{"id":"9df9ef85112249a994eb8c3b3d1d0e53","type":"GENE","name":"LINC02069","canonical_id":"hgnc:HGNC:52915","description":"long independently transcribed non-coding RNA 2069","metadata":null},{"id":"94b9111951d648cdae2c59c8c5c9b54f","type":"GENE","name":"LINC02070","canonical_id":"hgnc:HGNC:52916","description":"long independently transcribed non-coding RNA 2070","metadata":null},{"id":"568332dfa4db47bf99698507ff2d6f3f","type":"GENE","name":"LINC02071","canonical_id":"hgnc:HGNC:52917","description":"long independently transcribed non-coding RNA 2071","metadata":null},{"id":"9b1d778c41b945b38a083a1c4fbe35e8","type":"GENE","name":"LINC02072","canonical_id":"hgnc:HGNC:52918","description":"long independently transcribed non-coding RNA 2072","metadata":null},{"id":"c559ff723f5146c3ac809471d114416a","type":"GENE","name":"LINC02073","canonical_id":"hgnc:HGNC:52919","description":"long independently transcribed non-coding RNA 2073","metadata":null},{"id":"6f1faefa440c42da8fde2162951dfbdb","type":"GENE","name":"LINC02074","canonical_id":"hgnc:HGNC:52920","description":"long independently transcribed non-coding RNA 2074","metadata":null},{"id":"edb1e2b995ce4ad89c7343933df9c3ac","type":"GENE","name":"LINC02075","canonical_id":"hgnc:HGNC:52921","description":"long independently transcribed non-coding RNA 2075","metadata":null},{"id":"53012bf37bdf4984801f44f394d9c8e1","type":"GENE","name":"LINC02076","canonical_id":"hgnc:HGNC:52924","description":"long independently transcribed non-coding RNA 2076","metadata":{"aliases":["FLJ35934"]}},{"id":"686fca96a03e45b7aa2a8bdfd9fa9982","type":"GENE","name":"LINC02077","canonical_id":"hgnc:HGNC:52925","description":"long independently transcribed non-coding RNA 2077","metadata":null},{"id":"2b78b8c352c74039811313c4bc108136","type":"GENE","name":"LINC02078","canonical_id":"hgnc:HGNC:52926","description":"long independently transcribed non-coding RNA 2078","metadata":{"aliases":["HP09025"]}},{"id":"851631d8f438424e9e9e8ac15fe709fe","type":"GENE","name":"LINC02079","canonical_id":"hgnc:HGNC:52927","description":"long independently transcribed non-coding RNA 2079","metadata":null},{"id":"341dc2124c05405aa0bbbc973ea4d271","type":"GENE","name":"LINC02080","canonical_id":"hgnc:HGNC:52928","description":"long independently transcribed non-coding RNA 2080","metadata":{"aliases":["FLJ30938","CTD-2246P4.1"]}},{"id":"91ca288ae7c548a0b479dbab7d020fc7","type":"GENE","name":"LINC02082","canonical_id":"hgnc:HGNC:52931","description":"long independently transcribed non-coding RNA 2082","metadata":null},{"id":"5a70573a0b684a30b3025ddde5a4da27","type":"GENE","name":"LINC02083","canonical_id":"hgnc:HGNC:52933","description":"long independently transcribed non-coding RNA 2083","metadata":null},{"id":"b61c0786be7d43e18b459f2898046635","type":"GENE","name":"LINC02084","canonical_id":"hgnc:HGNC:52934","description":"long independently transcribed non-coding RNA 2084","metadata":null},{"id":"e8a2b9050cf04cc0a277f8a2736386b8","type":"GENE","name":"LINC02086","canonical_id":"hgnc:HGNC:52936","description":"long independently transcribed non-coding RNA 2086","metadata":null},{"id":"1f48b318e38b4eec8b848fe454ca4df5","type":"GENE","name":"LINC02087","canonical_id":"hgnc:HGNC:52938","description":"long independently transcribed non-coding RNA 2087","metadata":null},{"id":"e9f68e5ab24e4fc4a17ba90c8dbb2174","type":"GENE","name":"LINC02088","canonical_id":"hgnc:HGNC:52939","description":"long independently transcribed non-coding RNA 2088","metadata":null},{"id":"c98f5646397f4aa49a4a5cf822911b13","type":"GENE","name":"LINC02089","canonical_id":"hgnc:HGNC:52940","description":"long independently transcribed non-coding RNA 2089","metadata":{"aliases":["C17orf112","LINC02876"]}},{"id":"1d844cb006d64628a8ae03f6503423a9","type":"GENE","name":"LINC02090","canonical_id":"hgnc:HGNC:52941","description":"long independently transcribed non-coding RNA 2090","metadata":null},{"id":"d5d03ba6bae04acd9afaa28ab8a25a71","type":"GENE","name":"LINC02091","canonical_id":"hgnc:HGNC:52942","description":"long independently transcribed non-coding RNA 2091","metadata":null},{"id":"d0182fa0f4674cdda742578c6f4167ba","type":"GENE","name":"LINC02092","canonical_id":"hgnc:HGNC:52943","description":"long independently transcribed non-coding RNA 2092","metadata":null},{"id":"7c0b3a698cb94430baacf334863b353a","type":"GENE","name":"LINC02093","canonical_id":"hgnc:HGNC:52944","description":"long independently transcribed non-coding RNA 2093","metadata":null},{"id":"b3ec0dedb5614cf49a0b076c83a9a32e","type":"GENE","name":"LINC02094","canonical_id":"hgnc:HGNC:52945","description":"long independently transcribed non-coding RNA 2094","metadata":null},{"id":"76a34ecceb1848b8b78bc1041111e198","type":"GENE","name":"LINC02096","canonical_id":"hgnc:HGNC:52947","description":"long independently transcribed non-coding RNA 2096","metadata":null},{"id":"db9126a054fc49d39ff51bae04b58a21","type":"GENE","name":"LINC02097","canonical_id":"hgnc:HGNC:52948","description":"long independently transcribed non-coding RNA 2097","metadata":null},{"id":"819a4bca45f1447d9c7084739f0c70ca","type":"GENE","name":"LINC02098","canonical_id":"hgnc:HGNC:52950","description":"long independently transcribed non-coding RNA 2098","metadata":{"aliases":["RP11-702B10.1"]}},{"id":"498be60866a34bdb96078fd16b7226ae","type":"GENE","name":"LINC02099","canonical_id":"hgnc:HGNC:52953","description":"long independently transcribed non-coding RNA 2099","metadata":{"aliases":["Slt","AC145110.1"]}},{"id":"69476f72465140d5bb273b2dd671f108","type":"GENE","name":"LINC02100","canonical_id":"hgnc:HGNC:52955","description":"long independently transcribed non-coding RNA 2100","metadata":null},{"id":"72b50d85db934868ae35641a9be80e17","type":"GENE","name":"LINC02101","canonical_id":"hgnc:HGNC:52956","description":"long independently transcribed non-coding RNA 2101","metadata":null},{"id":"7e3c618188784a47b4a78c1d6a8bb452","type":"GENE","name":"LINC02102","canonical_id":"hgnc:HGNC:52957","description":"long independently transcribed non-coding RNA 2102","metadata":null},{"id":"1354a650a2ec44f9a5c794e3594ba7d9","type":"GENE","name":"LINC02103","canonical_id":"hgnc:HGNC:52958","description":"long independently transcribed non-coding RNA 2103","metadata":null},{"id":"352767af950247599e7ad405394c90fe","type":"GENE","name":"LINC02104","canonical_id":"hgnc:HGNC:52959","description":"long independently transcribed non-coding RNA 2104","metadata":null},{"id":"0ac3df45fcca4d4e97b21a1fa2b016f7","type":"GENE","name":"LINC02105","canonical_id":"hgnc:HGNC:52960","description":"long independently transcribed non-coding RNA 2105","metadata":null},{"id":"7adb0091af66457a8ae84df760e9ecdb","type":"GENE","name":"LINC02106","canonical_id":"hgnc:HGNC:52961","description":"long independently transcribed non-coding RNA 2106","metadata":null},{"id":"decccc65ae0d451e899029bbd54ab6ae","type":"GENE","name":"LINC02107","canonical_id":"hgnc:HGNC:52962","description":"long independently transcribed non-coding RNA 2107","metadata":null},{"id":"5820940ef8bc4ac7898265ef337f3dc7","type":"GENE","name":"LINC02108","canonical_id":"hgnc:HGNC:52963","description":"long independently transcribed non-coding RNA 2108","metadata":null},{"id":"b10dd0e4d32f4d90ab93e3bbbdba6253","type":"GENE","name":"LINC02109","canonical_id":"hgnc:HGNC:52964","description":"long independently transcribed non-coding RNA 2109","metadata":null},{"id":"2004ea42e34f4c03843d39ce0db566b0","type":"GENE","name":"LINC02111","canonical_id":"hgnc:HGNC:52966","description":"long independently transcribed non-coding RNA 2111","metadata":null},{"id":"fa28428724e3474b8cea1fcff3840e0f","type":"GENE","name":"LINC02112","canonical_id":"hgnc:HGNC:27756","description":"long independently transcribed non-coding RNA 2112","metadata":null},{"id":"a4b12c9acd6044d3ab9d7348a0de5d12","type":"GENE","name":"LINC02113","canonical_id":"hgnc:HGNC:52967","description":"long independently transcribed non-coding RNA 2113","metadata":null},{"id":"bc1d5c042fc24aad9d9414a8fd78f776","type":"GENE","name":"LINC02114","canonical_id":"hgnc:HGNC:52968","description":"long independently transcribed non-coding RNA 2114","metadata":null},{"id":"8c07c901786544c09f39a1f0b772cf33","type":"GENE","name":"LINC02115","canonical_id":"hgnc:HGNC:52970","description":"long independently transcribed non-coding RNA 2115","metadata":null},{"id":"e00fd450a6ce4b89a4173327b249f9fb","type":"GENE","name":"LINC02116","canonical_id":"hgnc:HGNC:52971","description":"long independently transcribed non-coding RNA 2116","metadata":null},{"id":"9b7fd5cdfa3240b5a604dd1484fb5a6a","type":"GENE","name":"LINC02117","canonical_id":"hgnc:HGNC:52972","description":"long independently transcribed non-coding RNA 2117","metadata":null},{"id":"1c6ced05cfb44940b9e7cd41c8a2f912","type":"GENE","name":"LINC02118","canonical_id":"hgnc:HGNC:52974","description":"long independently transcribed non-coding RNA 2118","metadata":null},{"id":"8714d6577caf48f49af9efc29010a2d9","type":"GENE","name":"LINC02119","canonical_id":"hgnc:HGNC:52975","description":"long independently transcribed non-coding RNA 2119","metadata":null},{"id":"871e863eb0064f3badfec2c9cfc5f349","type":"GENE","name":"LINC02120","canonical_id":"hgnc:HGNC:27971","description":"long independently transcribed non-coding RNA 2120","metadata":null},{"id":"aca73b398a3d4a59babc79757a86d180","type":"GENE","name":"LINC02121","canonical_id":"hgnc:HGNC:52977","description":"long independently transcribed non-coding RNA 2121","metadata":null},{"id":"365dc7a8bcfd4506971c96cd41c2c92c","type":"GENE","name":"LINC02122","canonical_id":"hgnc:HGNC:52979","description":"long independently transcribed non-coding RNA 2122","metadata":null},{"id":"30fc75263e8a4ebe84c5bb456c705c0b","type":"GENE","name":"LINC02123","canonical_id":"hgnc:HGNC:52980","description":"long independently transcribed non-coding RNA 2123","metadata":null},{"id":"88ceb177012b4b75a2259670c7a855fa","type":"GENE","name":"LINC02124","canonical_id":"hgnc:HGNC:52981","description":"long independently transcribed non-coding RNA 2124","metadata":null},{"id":"f97236e3fd7d4566a69c6bf1363a7d2e","type":"GENE","name":"LINC02125","canonical_id":"hgnc:HGNC:52982","description":"long independently transcribed non-coding RNA 2125","metadata":null},{"id":"5ed5c44cbe61406abf2b093e28616e4d","type":"GENE","name":"LINC02126","canonical_id":"hgnc:HGNC:52983","description":"long independently transcribed non-coding RNA 2126","metadata":null},{"id":"40e47b1cbf044b6ab03219146ea4a9da","type":"GENE","name":"LINC02127","canonical_id":"hgnc:HGNC:52985","description":"long independently transcribed non-coding RNA 2127","metadata":null},{"id":"311fc04aec99452a875eadbb3450fdc8","type":"GENE","name":"LINC02128","canonical_id":"hgnc:HGNC:52986","description":"long independently transcribed non-coding RNA 2128","metadata":{"aliases":["LINC02187"]}},{"id":"5a9270c4feaf44a599a4a675eb1a26a0","type":"GENE","name":"LINC02129","canonical_id":"hgnc:HGNC:52988","description":"long independently transcribed non-coding RNA 2129","metadata":null},{"id":"66b0fffc5c66438d8499bdda54ca887d","type":"GENE","name":"LINC02130","canonical_id":"hgnc:HGNC:52989","description":"long independently transcribed non-coding RNA 2130","metadata":null},{"id":"02328d35e6e54111992f51342851aad4","type":"GENE","name":"LINC02131","canonical_id":"hgnc:HGNC:52991","description":"long independently transcribed non-coding RNA 2131","metadata":null},{"id":"1a80e2ea66c24f7baa733e09e8eea61c","type":"GENE","name":"LINC02132","canonical_id":"hgnc:HGNC:52992","description":"long independently transcribed non-coding RNA 2132","metadata":null},{"id":"5d414b69df5f4eda8bc4c441898a3dc8","type":"GENE","name":"LINC02133","canonical_id":"hgnc:HGNC:52993","description":"long independently transcribed non-coding RNA 2133","metadata":null},{"id":"deefb80b134b4ec8894f71ca49b50f52","type":"GENE","name":"LINC02134","canonical_id":"hgnc:HGNC:52994","description":"long independently transcribed non-coding RNA 2134","metadata":null},{"id":"193cba74a1f047bf805887d5bdd5d241","type":"GENE","name":"LINC02135","canonical_id":"hgnc:HGNC:27094","description":"long independently transcribed non-coding RNA 2135","metadata":null},{"id":"a999520533974e1bae2b72f63362fed7","type":"GENE","name":"LINC02136","canonical_id":"hgnc:HGNC:52995","description":"long independently transcribed non-coding RNA 2136","metadata":null},{"id":"03155139ad3e4b2fb019d2f24d8c1788","type":"GENE","name":"LINC02137","canonical_id":"hgnc:HGNC:52997","description":"long independently transcribed non-coding RNA 2137","metadata":null},{"id":"32115597fa0c482089e98c9c9943abf8","type":"GENE","name":"LINC02138","canonical_id":"hgnc:HGNC:52998","description":"long independently transcribed non-coding RNA 2138","metadata":null},{"id":"23fb8b9e0c74420d870bc5cbcfa5a43a","type":"GENE","name":"LINC02139","canonical_id":"hgnc:HGNC:52999","description":"long independently transcribed non-coding RNA 2139","metadata":null},{"id":"ad67191d4d174756a520a8e0d225b600","type":"GENE","name":"LINC02140","canonical_id":"hgnc:HGNC:53000","description":"long independently transcribed non-coding RNA 2140","metadata":null},{"id":"849bb6fd7aee49c19f0f640f1c523cb7","type":"GENE","name":"LINC02141","canonical_id":"hgnc:HGNC:53001","description":"long independently transcribed non-coding RNA 2141","metadata":null},{"id":"41c3541871e2463dbcbc50983772ec4c","type":"GENE","name":"LINC02142","canonical_id":"hgnc:HGNC:53002","description":"long independently transcribed non-coding RNA 2142","metadata":null},{"id":"c16b3c4312124368aea5fed55287059d","type":"GENE","name":"LINC02143","canonical_id":"hgnc:HGNC:53003","description":"long independently transcribed non-coding RNA 2143","metadata":null},{"id":"58914a882f52445eb170f81512d928e7","type":"GENE","name":"LINC02144","canonical_id":"hgnc:HGNC:53004","description":"long independently transcribed non-coding RNA 2144","metadata":null},{"id":"ba156c2bcecb43cfa2380c7cfeee104e","type":"GENE","name":"LINC02145","canonical_id":"hgnc:HGNC:53005","description":"long independently transcribed non-coding RNA 2145","metadata":{"aliases":["CTC","FLJ33360"]}},{"id":"822252b4262c4681bbe327d2b7562d4e","type":"GENE","name":"LINC02146","canonical_id":"hgnc:HGNC:53006","description":"long independently transcribed non-coding RNA 2146","metadata":null},{"id":"4ab38eb344364761ab7472fd21e56b46","type":"GENE","name":"LINC02147","canonical_id":"hgnc:HGNC:53007","description":"long independently transcribed non-coding RNA 2147","metadata":null},{"id":"e364ca9af9334309b1eac4d57108cfde","type":"GENE","name":"LINC02148","canonical_id":"hgnc:HGNC:53008","description":"long independently transcribed non-coding RNA 2148","metadata":null},{"id":"9ee3814860f747f2acba41d21358ceb2","type":"GENE","name":"LINC02149","canonical_id":"hgnc:HGNC:53010","description":"long independently transcribed non-coding RNA 2149","metadata":null},{"id":"fefa2b1f5b904a6c93c156a7b84d79c9","type":"GENE","name":"LINC02150","canonical_id":"hgnc:HGNC:53012","description":"long independently transcribed non-coding RNA 2150","metadata":null},{"id":"a5cbc05f608c406e9e6b8ffb84bc4eb7","type":"GENE","name":"LINC02151","canonical_id":"hgnc:HGNC:53013","description":"long independently transcribed non-coding RNA 2151","metadata":{"aliases":["uc.332","TCONS_00019174"]}},{"id":"b4517a9a100e432fa408d72133b05667","type":"GENE","name":"LINC02152","canonical_id":"hgnc:HGNC:53014","description":"long independently transcribed non-coding RNA 2152","metadata":{"aliases":["ENST00000566208"]}},{"id":"b80d85750cca47fca15b086d5aa679c4","type":"GENE","name":"LINC02153","canonical_id":"hgnc:HGNC:27823","description":"long independently transcribed non-coding RNA 2153","metadata":{"aliases":["ENST00000517573"]}},{"id":"ef17cde714fd42b994d9f182654f0d5e","type":"GENE","name":"LINC02154","canonical_id":"hgnc:HGNC:53015","description":"long independently transcribed non-coding RNA 2154","metadata":{"aliases":["GS1-600G8.5","MALR"]}},{"id":"6a9d08db2d43470d9fe641b66fe15835","type":"GENE","name":"LINC02156","canonical_id":"hgnc:HGNC:53017","description":"long independently transcribed non-coding RNA 2156","metadata":{"aliases":["RP1-90J4.1"]}},{"id":"331ffdb6bf2e4914a580ca929e971ffd","type":"GENE","name":"LINC02157","canonical_id":"hgnc:HGNC:53018","description":"long independently transcribed non-coding RNA 2157","metadata":{"aliases":["RP11-327J17.1"]}},{"id":"3266ffd10cec420394b9a28db31a02b1","type":"GENE","name":"LINC02159","canonical_id":"hgnc:HGNC:27749","description":"long independently transcribed non-coding RNA 2159","metadata":null},{"id":"89469659d49748af99bf76db1f5242fc","type":"GENE","name":"LINC02160","canonical_id":"hgnc:HGNC:53021","description":"long independently transcribed non-coding RNA 2160","metadata":null},{"id":"5b8d226e316b4937ae0e13ac23f9462b","type":"GENE","name":"LINC02161","canonical_id":"hgnc:HGNC:53022","description":"long independently transcribed non-coding RNA 2161","metadata":null},{"id":"7b3dcab9148347bb85a33bb6ed280663","type":"GENE","name":"LINC02162","canonical_id":"hgnc:HGNC:53023","description":"long independently transcribed non-coding RNA 2162","metadata":null},{"id":"eaa11c8a6faa4d78b0192742d67e86d3","type":"GENE","name":"LINC02164","canonical_id":"hgnc:HGNC:53025","description":"long independently transcribed non-coding RNA 2164","metadata":null},{"id":"d29769730b2c4a67b3335e25bdf24184","type":"GENE","name":"LINC02165","canonical_id":"hgnc:HGNC:53026","description":"long independently transcribed non-coding RNA 2165","metadata":null},{"id":"64617854046e4be9afe3531f5625e149","type":"GENE","name":"LINC02166","canonical_id":"hgnc:HGNC:53027","description":"long independently transcribed non-coding RNA 2166","metadata":null},{"id":"26072365c22546db9bbe1641553cd914","type":"GENE","name":"LINC02167","canonical_id":"hgnc:HGNC:53028","description":"long independently transcribed non-coding RNA 2167","metadata":{"aliases":["FLJ26245"]}},{"id":"61c0a90d121b435c9e8a9e6d36304527","type":"GENE","name":"LINC02168","canonical_id":"hgnc:HGNC:53030","description":"long independently transcribed non-coding RNA 2168","metadata":null},{"id":"843365f7cc59499ba7dcaff65ba4fc13","type":"GENE","name":"LINC02169","canonical_id":"hgnc:HGNC:53031","description":"long independently transcribed non-coding RNA 2169","metadata":null},{"id":"8b35ff10eec84a42b043009bee2af640","type":"GENE","name":"LINC02171","canonical_id":"hgnc:HGNC:53033","description":"long independently transcribed non-coding RNA 2171","metadata":null},{"id":"aa99ec591ced4da28a07eae4655ae80f","type":"GENE","name":"LINC02172","canonical_id":"hgnc:HGNC:53034","description":"long independently transcribed non-coding RNA 2172","metadata":null},{"id":"db20b28d407346a4b6b3af6cc9530510","type":"GENE","name":"LINC02173","canonical_id":"hgnc:HGNC:53035","description":"long independently transcribed non-coding RNA 2173","metadata":null},{"id":"f2bfe8b89fea458c9195b4e03459d56b","type":"GENE","name":"LINC02174","canonical_id":"hgnc:HGNC:53037","description":"long independently transcribed non-coding RNA 2174","metadata":null},{"id":"b123192d934d4b6a8d96b368417eeee1","type":"GENE","name":"LINC02175","canonical_id":"hgnc:HGNC:27550","description":"long independently transcribed non-coding RNA 2175","metadata":null},{"id":"6466824f60944f179253fd1481b6ae02","type":"GENE","name":"LINC02176","canonical_id":"hgnc:HGNC:53038","description":"long independently transcribed non-coding RNA 2176","metadata":null},{"id":"b01d4ffc514642acaa307c45fe223a46","type":"GENE","name":"LINC02177","canonical_id":"hgnc:HGNC:53039","description":"long independently transcribed non-coding RNA 2177","metadata":null},{"id":"6eb47d7d8dac4399b4e31381e75c9020","type":"GENE","name":"LINC02178","canonical_id":"hgnc:HGNC:53040","description":"long independently transcribed non-coding RNA 2178","metadata":null},{"id":"537df07b79d44fe6a767f741aa9f2215","type":"GENE","name":"LINC02179","canonical_id":"hgnc:HGNC:53041","description":"long independently transcribed non-coding RNA 2179","metadata":{"aliases":["RP11-189E14.4"]}},{"id":"cec39a44ad364ce9a74c549cd759e85b","type":"GENE","name":"LINC02180","canonical_id":"hgnc:HGNC:53042","description":"long independently transcribed non-coding RNA 2180","metadata":null},{"id":"5b2135e7ddd54036ad0df0c58e6185b6","type":"GENE","name":"LINC02181","canonical_id":"hgnc:HGNC:53043","description":"long independently transcribed non-coding RNA 2181","metadata":null},{"id":"bb1db0b99dfa47379a2f02a8cb3f056b","type":"GENE","name":"LINC02182","canonical_id":"hgnc:HGNC:53044","description":"long independently transcribed non-coding RNA 2182","metadata":null},{"id":"810ca0cb189c479dbe330458c95fed2a","type":"GENE","name":"LINC02183","canonical_id":"hgnc:HGNC:53045","description":"long independently transcribed non-coding RNA 2183","metadata":null},{"id":"629a4e1cef5f439dac862ef83410c254","type":"GENE","name":"LINC02184","canonical_id":"hgnc:HGNC:53046","description":"long independently transcribed non-coding RNA 2184","metadata":null},{"id":"2ecd24c3f9e7452a8f64dbec136c35d1","type":"GENE","name":"LINC02185","canonical_id":"hgnc:HGNC:53047","description":"long independently transcribed non-coding RNA 2185","metadata":null},{"id":"e65f508f570342fcb7031f79d9197e8b","type":"GENE","name":"LINC02186","canonical_id":"hgnc:HGNC:53048","description":"long independently transcribed non-coding RNA 2186","metadata":null},{"id":"e4026de7a8634843969d37667cbc8dcd","type":"GENE","name":"LINC02188","canonical_id":"hgnc:HGNC:53050","description":"long independently transcribed non-coding RNA 2188","metadata":null},{"id":"912f9f61f3c44fc1a324dac2b72cd4a5","type":"GENE","name":"LINC02189","canonical_id":"hgnc:HGNC:53051","description":"long independently transcribed non-coding RNA 2189","metadata":null},{"id":"84788988c69b412e8fe30f52b19d249e","type":"GENE","name":"LINC02190","canonical_id":"hgnc:HGNC:53052","description":"long independently transcribed non-coding RNA 2190","metadata":null},{"id":"df145d73d2614ad2aa53f86a67d480c7","type":"GENE","name":"LINC02191","canonical_id":"hgnc:HGNC:53053","description":"long independently transcribed non-coding RNA 2191","metadata":null},{"id":"61e94b676b73406484252b5fb766a16f","type":"GENE","name":"LINC02192","canonical_id":"hgnc:HGNC:53054","description":"long independently transcribed non-coding RNA 2192","metadata":null},{"id":"42db5bca2c3e47e193076f2c128d40d7","type":"GENE","name":"LINC02194","canonical_id":"hgnc:HGNC:53057","description":"long independently transcribed non-coding RNA 2194","metadata":{"aliases":["LINC2194"]}},{"id":"2be853b916df4ab9b7fb376c9a56e0cc","type":"GENE","name":"LINC02195","canonical_id":"hgnc:HGNC:53058","description":"long independently transcribed non-coding RNA 2195","metadata":null},{"id":"4297a2f3b8f545218e56065a90734f13","type":"GENE","name":"LINC02196","canonical_id":"hgnc:HGNC:53062","description":"long independently transcribed non-coding RNA 2196","metadata":null},{"id":"738685048a62425591b343b5099f5b66","type":"GENE","name":"LINC02197","canonical_id":"hgnc:HGNC:53063","description":"long independently transcribed non-coding RNA 2197","metadata":null},{"id":"9bee550c2f2542758ed39ef34b73aba5","type":"GENE","name":"LINC02198","canonical_id":"hgnc:HGNC:53064","description":"long independently transcribed non-coding RNA 2198","metadata":null},{"id":"afebe5cb185a4542aeec88a5b1e1d5cc","type":"GENE","name":"LINC02199","canonical_id":"hgnc:HGNC:53065","description":"long independently transcribed non-coding RNA 2199","metadata":null},{"id":"81183f2848c64a6483235d36790b675b","type":"GENE","name":"LINC02200","canonical_id":"hgnc:HGNC:53066","description":"long independently transcribed non-coding RNA 2200","metadata":{"aliases":["RP11-159K7.2"]}},{"id":"6bb00b9f5a5141aa9b5cd04c53cc3d05","type":"GENE","name":"LINC02201","canonical_id":"hgnc:HGNC:53067","description":"long independently transcribed non-coding RNA 2201","metadata":null},{"id":"cab871abbc7a481abca656d00fd831ba","type":"GENE","name":"LINC02202","canonical_id":"hgnc:HGNC:53068","description":"long independently transcribed non-coding RNA 2202","metadata":null},{"id":"e50a97190c6d4dab851f3d17b37cef55","type":"GENE","name":"LINC02203","canonical_id":"hgnc:HGNC:53069","description":"long independently transcribed non-coding RNA 2203","metadata":null},{"id":"6c400b5fdfac409eae077b9c2d67e4e8","type":"GENE","name":"LINC02204","canonical_id":"hgnc:HGNC:53070","description":"long independently transcribed non-coding RNA 2204","metadata":null},{"id":"e3f0acf184cf4d859c77402252d1ff5d","type":"GENE","name":"LINC02205","canonical_id":"hgnc:HGNC:53071","description":"long independently transcribed non-coding RNA 2205","metadata":null},{"id":"15d142934a8843279eeebc2713d077b9","type":"GENE","name":"LINC02207","canonical_id":"hgnc:HGNC:53073","description":"long independently transcribed non-coding RNA 2207","metadata":null},{"id":"e6e6299b4e7743b8a4c7fe8c37e611df","type":"GENE","name":"LINC02208","canonical_id":"hgnc:HGNC:52978","description":"long independently transcribed non-coding RNA 2208","metadata":{"aliases":["HRAT56"]}},{"id":"23b318b557fe46db806c0241c8c243f2","type":"GENE","name":"LINC02209","canonical_id":"hgnc:HGNC:27827","description":"long independently transcribed non-coding RNA 2209","metadata":{"aliases":["FAM183CP"]}},{"id":"efaeb98e7e114e02a489646554e37eaa","type":"GENE","name":"LINC02210","canonical_id":"hgnc:HGNC:26327","description":"long independently transcribed non-coding RNA 2210","metadata":{"aliases":["FLJ25168","C17orf69","CRHR1-IT1"]}},{"id":"3ae7f0a9d8d941eb8b9b45682a6a8e26","type":"GENE","name":"LINC02210-CRHR1","canonical_id":"hgnc:HGNC:51483","description":"LINC02210-CRHR1 readthrough","metadata":null},{"id":"4692482edafb498ea5d69e71a915a94d","type":"GENE","name":"LINC02211","canonical_id":"hgnc:HGNC:53078","description":"long independently transcribed non-coding RNA 2211","metadata":null},{"id":"c1056d417b9a4b21b13f749e45d7321c","type":"GENE","name":"LINC02212","canonical_id":"hgnc:HGNC:53079","description":"long independently transcribed non-coding RNA 2212","metadata":null},{"id":"8e77ae54628c48dbbd0d8ee323c4e246","type":"GENE","name":"LINC02213","canonical_id":"hgnc:HGNC:53080","description":"long independently transcribed non-coding RNA 2213","metadata":null},{"id":"ccb7467f29be483b98f46a378a76f8c8","type":"GENE","name":"LINC02214","canonical_id":"hgnc:HGNC:53081","description":"long independently transcribed non-coding RNA 2214","metadata":null},{"id":"284b159b994d4f73b11ff88e158e4084","type":"GENE","name":"LINC02215","canonical_id":"hgnc:HGNC:53082","description":"long independently transcribed non-coding RNA 2215","metadata":null},{"id":"627e41db449041b29c289eb46fdc5d79","type":"GENE","name":"LINC02216","canonical_id":"hgnc:HGNC:53083","description":"long independently transcribed non-coding RNA 2216","metadata":null},{"id":"d9b5b56abd8f4fd6befb2f07df7b8d0f","type":"GENE","name":"LINC02217","canonical_id":"hgnc:HGNC:53084","description":"long independently transcribed non-coding RNA 2217","metadata":null},{"id":"4689c519b1ce4d0aa4063c3854b51b83","type":"GENE","name":"LINC02218","canonical_id":"hgnc:HGNC:53085","description":"long independently transcribed non-coding RNA 2218","metadata":null},{"id":"1351c8f2906642a0a5e4fae47502df69","type":"GENE","name":"LINC02219","canonical_id":"hgnc:HGNC:53086","description":"long independently transcribed non-coding RNA 2219","metadata":null},{"id":"5e28156724e34438b9c15362b14283f3","type":"GENE","name":"LINC02220","canonical_id":"hgnc:HGNC:53087","description":"long independently transcribed non-coding RNA 2220","metadata":null},{"id":"09b0f98ec3694091be001150c5b73465","type":"GENE","name":"LINC02221","canonical_id":"hgnc:HGNC:53090","description":"long independently transcribed non-coding RNA 2221","metadata":null},{"id":"6d6780754fad42c4a791c1dba3fdab1f","type":"GENE","name":"LINC02222","canonical_id":"hgnc:HGNC:53091","description":"long independently transcribed non-coding RNA 2222","metadata":null},{"id":"27b08582f3ab4b4b8d31535ec4ab2dee","type":"GENE","name":"LINC02223","canonical_id":"hgnc:HGNC:53092","description":"long independently transcribed non-coding RNA 2223","metadata":null},{"id":"73146e20b95d4cb5b7b08665194f5d5b","type":"GENE","name":"LINC02225","canonical_id":"hgnc:HGNC:53094","description":"long independently transcribed non-coding RNA 2225","metadata":null},{"id":"12192c19b4ad404f96ef7027d24a192d","type":"GENE","name":"LINC02226","canonical_id":"hgnc:HGNC:53095","description":"long independently transcribed non-coding RNA 2226","metadata":null},{"id":"da029c8f27c445d884d9765627070616","type":"GENE","name":"LINC02227","canonical_id":"hgnc:HGNC:53096","description":"long independently transcribed non-coding RNA 2227","metadata":null},{"id":"d05cb2ae62244967a1fe3a1896f228d5","type":"GENE","name":"LINC02228","canonical_id":"hgnc:HGNC:53097","description":"long independently transcribed non-coding RNA 2228","metadata":{"aliases":["HIKER"]}},{"id":"5b95b445e1ab4b3cac11a9f2a59f167b","type":"GENE","name":"LINC02229","canonical_id":"hgnc:HGNC:53098","description":"long independently transcribed non-coding RNA 2229","metadata":null},{"id":"d457d2d138ca4574bec21ff10e8d9923","type":"GENE","name":"LINC02230","canonical_id":"hgnc:HGNC:53099","description":"long independently transcribed non-coding RNA 2230","metadata":null},{"id":"a48d6aaf84e64ef4830f7424141a3df5","type":"GENE","name":"LINC02231","canonical_id":"hgnc:HGNC:53100","description":"long independently transcribed non-coding RNA 2231","metadata":{"aliases":["RP11-766N7.4"]}},{"id":"29634dd6c2544a7abc60cafebfcbe5ac","type":"GENE","name":"LINC02232","canonical_id":"hgnc:HGNC:53103","description":"long independently transcribed non-coding RNA 2232","metadata":{"aliases":["RP11-707A18.1"]}},{"id":"b987a54d4943437f98d7d00142e7c280","type":"GENE","name":"LINC02233","canonical_id":"hgnc:HGNC:53104","description":"long independently transcribed non-coding RNA 2233","metadata":{"aliases":["RP11-6C14.1"]}},{"id":"d278836f20f64b569d85a54495b95e8e","type":"GENE","name":"LINC02235","canonical_id":"hgnc:HGNC:53106","description":"long independently transcribed non-coding RNA 2235","metadata":{"aliases":["RP11-354A14.1"]}},{"id":"7806bbe1519143468a4015025961a64f","type":"GENE","name":"LINC02236","canonical_id":"hgnc:HGNC:53107","description":"long independently transcribed non-coding RNA 2236","metadata":{"aliases":["RP11-332J15.1"]}},{"id":"84c5d142698e4b37a1681dcf042aae15","type":"GENE","name":"LINC02237","canonical_id":"hgnc:HGNC:53108","description":"long independently transcribed non-coding RNA 2237","metadata":{"aliases":["RP11-1101K5.1"]}},{"id":"4adf4b2b025a4c3caf2c631ccd503e71","type":"GENE","name":"LINC02238","canonical_id":"hgnc:HGNC:53116","description":"long independently transcribed non-coding RNA 2238","metadata":{"aliases":["RP4-788P17.1"]}},{"id":"8fca1816281049a8aeebc2b56225da02","type":"GENE","name":"LINC02239","canonical_id":"hgnc:HGNC:27969","description":"long independently transcribed non-coding RNA 2239","metadata":null},{"id":"b70fd774da864cb697fae5828c111613","type":"GENE","name":"LINC02240","canonical_id":"hgnc:HGNC:53118","description":"long independently transcribed non-coding RNA 2240","metadata":null},{"id":"ec5f124791c7424faa07d2f9ff4de3b5","type":"GENE","name":"LINC02241","canonical_id":"hgnc:HGNC:53126","description":"long independently transcribed non-coding RNA 2241","metadata":null},{"id":"67fb91c377fc448e9772f841eecd8696","type":"GENE","name":"LINC02242","canonical_id":"hgnc:HGNC:53127","description":"long independently transcribed non-coding RNA 2242","metadata":null},{"id":"972e05e5e4f54722a5ebf7433c04821d","type":"GENE","name":"LINC02243","canonical_id":"hgnc:HGNC:53129","description":"long independently transcribed non-coding RNA 2243","metadata":{"aliases":["ENST00000441841"]}},{"id":"4cf1f7f8bdbc4f74b745ee4055c35ce8","type":"GENE","name":"LINC02244","canonical_id":"hgnc:HGNC:53929","description":"long independently transcribed non-coding RNA 2244","metadata":{"aliases":["RP11-20G13.3"]}},{"id":"fc1707ea3e1f4b56911746b9a637d241","type":"GENE","name":"LINC02245","canonical_id":"hgnc:HGNC:53134","description":"long independently transcribed non-coding RNA 2245","metadata":{"aliases":["lnc-SERTAD2-3","AC007386.2"]}},{"id":"8202763e8e5643e4af9794560e1fe2dd","type":"GENE","name":"LINC02247","canonical_id":"hgnc:HGNC:53140","description":"long independently transcribed non-coding RNA 2247","metadata":{"aliases":["ENST00000417135"]}},{"id":"3552848d50f64e3ea1f1e79f06bbd295","type":"GENE","name":"LINC02248","canonical_id":"hgnc:HGNC:53147","description":"long independently transcribed non-coding RNA 2248","metadata":null},{"id":"df2f748c10144a0699a96f82b68a2d00","type":"GENE","name":"LINC02249","canonical_id":"hgnc:HGNC:32351","description":"long independently transcribed non-coding RNA 2249","metadata":{"aliases":["DKFZp434L187"]}},{"id":"65b111caca6245c6a7652591d3bfe758","type":"GENE","name":"LINC02250","canonical_id":"hgnc:HGNC:53148","description":"long independently transcribed non-coding RNA 2250","metadata":{"aliases":["TCONS_00023273"]}},{"id":"6f6c556d50854eca97986d9bbd021d98","type":"GENE","name":"LINC02251","canonical_id":"hgnc:HGNC:53149","description":"long independently transcribed non-coding RNA 2251","metadata":null},{"id":"ab74274141734a1f8ca4d3cf6fd5662e","type":"GENE","name":"LINC02252","canonical_id":"hgnc:HGNC:53150","description":"long independently transcribed non-coding RNA 2252","metadata":null},{"id":"44cde9b2fc8e4f7aad38df18c6d75e53","type":"GENE","name":"LINC02253","canonical_id":"hgnc:HGNC:53151","description":"long independently transcribed non-coding RNA 2253","metadata":null},{"id":"943e44a998ee47d38636e9f628d24a31","type":"GENE","name":"LINC02255","canonical_id":"hgnc:HGNC:53153","description":"long independently transcribed non-coding RNA 2255","metadata":null},{"id":"d017238ad02d48f68b306e323b55322f","type":"GENE","name":"LINC02256","canonical_id":"hgnc:HGNC:53157","description":"long independently transcribed non-coding RNA 2256","metadata":null},{"id":"3d191e3a28fd49edb7a510afd90928ce","type":"GENE","name":"LINC02258","canonical_id":"hgnc:HGNC:53165","description":"long independently transcribed non-coding RNA 2258","metadata":{"aliases":["RP11-248E9.5"]}},{"id":"536bdeb31acd4058a310f5a01803a245","type":"GENE","name":"LINC02259","canonical_id":"hgnc:HGNC:53172","description":"long independently transcribed non-coding RNA 2259","metadata":null},{"id":"eb05f26278a24021b97eabd7c4e702d8","type":"GENE","name":"LINC02260","canonical_id":"hgnc:HGNC:27956","description":"long independently transcribed non-coding RNA 2260","metadata":null},{"id":"7c3259eee03e42d586ee54697d2d7cae","type":"GENE","name":"LINC02261","canonical_id":"hgnc:HGNC:53173","description":"long independently transcribed non-coding RNA 2261","metadata":null},{"id":"ee30dde7cdd14114956d89a094d288ce","type":"GENE","name":"LINC02262","canonical_id":"hgnc:HGNC:53174","description":"long independently transcribed non-coding RNA 2262","metadata":null},{"id":"79ebad9d70934e17a9d9222f7ce4cea8","type":"GENE","name":"LINC02263","canonical_id":"hgnc:HGNC:53175","description":"long independently transcribed non-coding RNA 2263","metadata":null},{"id":"01af825812784d30ae4670998fb243a6","type":"GENE","name":"LINC02264","canonical_id":"hgnc:HGNC:53176","description":"long independently transcribed non-coding RNA 2264","metadata":null},{"id":"383749c794d64df6a07fe8afe1944831","type":"GENE","name":"LINC02265","canonical_id":"hgnc:HGNC:53179","description":"long independently transcribed non-coding RNA 2265","metadata":null},{"id":"b1cf5eee246248b5a584d91218728826","type":"GENE","name":"LINC02266","canonical_id":"hgnc:HGNC:53180","description":"long independently transcribed non-coding RNA 2266","metadata":{"aliases":["RP11-142A22.4"]}},{"id":"cf8ccc13058a430a90bdb2ea875219c5","type":"GENE","name":"LINC02267","canonical_id":"hgnc:HGNC:53181","description":"long independently transcribed non-coding RNA 2267","metadata":null},{"id":"1523d4eed5dc4197a1d03589e49c249b","type":"GENE","name":"LINC02268","canonical_id":"hgnc:HGNC:53183","description":"long independently transcribed non-coding RNA 2268","metadata":null},{"id":"0fe539c1481e4beebf4df995ada66e4e","type":"GENE","name":"LINC02269","canonical_id":"hgnc:HGNC:53184","description":"long independently transcribed non-coding RNA 2269","metadata":null},{"id":"10ecaadc208547cc8e9b43366d6e0ee4","type":"GENE","name":"LINC02270","canonical_id":"hgnc:HGNC:53185","description":"long independently transcribed non-coding RNA 2270","metadata":null},{"id":"70d760c9ab0d458faf5f594279f1355d","type":"GENE","name":"LINC02271","canonical_id":"hgnc:HGNC:53186","description":"long independently transcribed non-coding RNA 2271","metadata":null},{"id":"6d62c417ac0f4544acfeef7bb5e7c9b6","type":"GENE","name":"LINC02272","canonical_id":"hgnc:HGNC:53187","description":"long independently transcribed non-coding RNA 2272","metadata":null},{"id":"c792afd4b6cd408ea065cb35a915de20","type":"GENE","name":"LINC02273","canonical_id":"hgnc:HGNC:53188","description":"long independently transcribed non-coding RNA 2273","metadata":null},{"id":"c8d4ce62a2b94bdfae93cfb6ddaddefd","type":"GENE","name":"LINC02274","canonical_id":"hgnc:HGNC:53190","description":"long independently transcribed non-coding RNA 2274","metadata":null},{"id":"1c6c7bb79d3647f2abf946f385c56c8a","type":"GENE","name":"LINC02275","canonical_id":"hgnc:HGNC:53191","description":"long independently transcribed non-coding RNA 2275","metadata":null},{"id":"e27673c6de3c4cc093e61ccaa7c86fcc","type":"GENE","name":"LINC02276","canonical_id":"hgnc:HGNC:53192","description":"long independently transcribed non-coding RNA 2276","metadata":null},{"id":"bab0f07ce43a48a6986de1c5f8079431","type":"GENE","name":"LINC02277","canonical_id":"hgnc:HGNC:53193","description":"long independently transcribed non-coding RNA 2277","metadata":null},{"id":"2d98a72490794a9b86afa649df024a0f","type":"GENE","name":"LINC02278","canonical_id":"hgnc:HGNC:53194","description":"long independently transcribed non-coding RNA 2278","metadata":null},{"id":"85d9cc2dd73b427caee51a06c037aa74","type":"GENE","name":"LINC02279","canonical_id":"hgnc:HGNC:53195","description":"long independently transcribed non-coding RNA 2279","metadata":null},{"id":"e8683f9cbaa544c89442856c8fba4226","type":"GENE","name":"LINC02280","canonical_id":"hgnc:HGNC:53196","description":"long independently transcribed non-coding RNA 2280","metadata":null},{"id":"30fb66002d6f4969b8097dbed039c0a6","type":"GENE","name":"LINC02281","canonical_id":"hgnc:HGNC:53197","description":"long independently transcribed non-coding RNA 2281","metadata":null},{"id":"b4f3df2ea10b44b9b43c53b5ee41700b","type":"GENE","name":"LINC02282","canonical_id":"hgnc:HGNC:53199","description":"long independently transcribed non-coding RNA 2282","metadata":null},{"id":"66b569cd4b3e43a7ab534d5d9d875954","type":"GENE","name":"LINC02283","canonical_id":"hgnc:HGNC:53200","description":"long independently transcribed non-coding RNA 2283","metadata":null},{"id":"cb327da9c4134d5787babf1d306e933c","type":"GENE","name":"LINC02284","canonical_id":"hgnc:HGNC:53201","description":"long independently transcribed non-coding RNA 2284","metadata":null},{"id":"b07861e2ebcc402dbbecdeb90c8af94e","type":"GENE","name":"LINC02285","canonical_id":"hgnc:HGNC:53202","description":"long independently transcribed non-coding RNA 2285","metadata":null},{"id":"b7a4c5eada1746aa88d574ffc5a19d23","type":"GENE","name":"LINC02286","canonical_id":"hgnc:HGNC:53203","description":"long independently transcribed non-coding RNA 2286","metadata":null},{"id":"41f850f761ba45f5850ab0ab8446a80c","type":"GENE","name":"LINC02287","canonical_id":"hgnc:HGNC:53204","description":"long independently transcribed non-coding RNA 2287","metadata":null},{"id":"a15191b5fd6d4705b2812cbb953fafba","type":"GENE","name":"LINC02288","canonical_id":"hgnc:HGNC:27505","description":"long independently transcribed non-coding RNA 2288","metadata":null},{"id":"4ed60c725f494a539ab4f1394ab6034f","type":"GENE","name":"LINC02289","canonical_id":"hgnc:HGNC:53205","description":"long independently transcribed non-coding RNA 2289","metadata":null},{"id":"4e64b27feddc4a4d8cbf1e3c581cf5c3","type":"GENE","name":"LINC02290","canonical_id":"hgnc:HGNC:53206","description":"long independently transcribed non-coding RNA 2290","metadata":null},{"id":"c810f336b0b84d13989e3bc9de1dc655","type":"GENE","name":"LINC02291","canonical_id":"hgnc:HGNC:53207","description":"long independently transcribed non-coding RNA 2291","metadata":null},{"id":"13a7606d8ff44dbcb0cec82a68adf0bf","type":"GENE","name":"LINC02292","canonical_id":"hgnc:HGNC:53208","description":"long independently transcribed non-coding RNA 2292","metadata":null},{"id":"ea9dadaba496410ebdef188e58e48b3c","type":"GENE","name":"LINC02293","canonical_id":"hgnc:HGNC:53209","description":"long independently transcribed non-coding RNA 2293","metadata":null},{"id":"3503d287d18d47a1b515d3daab81894f","type":"GENE","name":"LINC02294","canonical_id":"hgnc:HGNC:53210","description":"long independently transcribed non-coding RNA 2294","metadata":null},{"id":"0d9cc4e0686b42c7b30ce15e8eec357c","type":"GENE","name":"LINC02295","canonical_id":"hgnc:HGNC:53211","description":"long independently transcribed non-coding RNA 2295","metadata":null},{"id":"bb77dbf1fded4a4ab6420b3d05a42277","type":"GENE","name":"LINC02296","canonical_id":"hgnc:HGNC:53212","description":"long independently transcribed non-coding RNA 2296","metadata":null},{"id":"dee5ebcfc62c4d05ae4bb45d37125b87","type":"GENE","name":"LINC02297","canonical_id":"hgnc:HGNC:53214","description":"long independently transcribed non-coding RNA 2297","metadata":null},{"id":"3be2768511624267a02d1c7bab65cc13","type":"GENE","name":"LINC02298","canonical_id":"hgnc:HGNC:53216","description":"long independently transcribed non-coding RNA 2298","metadata":null},{"id":"8629410873d842b2b590f6cd8b762016","type":"GENE","name":"LINC02299","canonical_id":"hgnc:HGNC:53218","description":"long independently transcribed non-coding RNA 2299","metadata":null},{"id":"d1ffba31bb3d4cec863776d0410d17e3","type":"GENE","name":"LINC02300","canonical_id":"hgnc:HGNC:53219","description":"long independently transcribed non-coding RNA 2300","metadata":null},{"id":"4ae5dbb297494854a1ae6e1e44aca11e","type":"GENE","name":"LINC02301","canonical_id":"hgnc:HGNC:53220","description":"long independently transcribed non-coding RNA 2301","metadata":null},{"id":"8582055ecc2c44a595b9d52f7153d868","type":"GENE","name":"LINC02303","canonical_id":"hgnc:HGNC:53222","description":"long independently transcribed non-coding RNA 2303","metadata":{"aliases":["TRMP"]}},{"id":"32b9e39b644f4c4490f73c124455fa94","type":"GENE","name":"LINC02304","canonical_id":"hgnc:HGNC:53223","description":"long independently transcribed non-coding RNA 2304","metadata":null},{"id":"40181995b97947dc9f6cab018b2f81bd","type":"GENE","name":"LINC02305","canonical_id":"hgnc:HGNC:53224","description":"long independently transcribed non-coding RNA 2305","metadata":null},{"id":"5b0db34c4856450e800e7ae6d0b0ae3e","type":"GENE","name":"LINC02306","canonical_id":"hgnc:HGNC:53225","description":"long independently transcribed non-coding RNA 2306","metadata":{"aliases":["uc.358"]}},{"id":"94d4e3390cd7414e99afc4975a993467","type":"GENE","name":"LINC02307","canonical_id":"hgnc:HGNC:53226","description":"long independently transcribed non-coding RNA 2307","metadata":null},{"id":"eeef3603b0564252814b497e89b175c4","type":"GENE","name":"LINC02308","canonical_id":"hgnc:HGNC:53227","description":"long independently transcribed non-coding RNA 2308","metadata":null},{"id":"c52e78d8c8d64ec4a1a1cd30b301dd69","type":"GENE","name":"LINC02309","canonical_id":"hgnc:HGNC:53228","description":"long independently transcribed non-coding RNA 2309","metadata":null},{"id":"0c91ee8c7a15492f8b59913f35b4a57a","type":"GENE","name":"LINC02310","canonical_id":"hgnc:HGNC:53229","description":"long independently transcribed non-coding RNA 2310","metadata":null},{"id":"f5fcb7b278ea41c4a95d95104654d10c","type":"GENE","name":"LINC02311","canonical_id":"hgnc:HGNC:53230","description":"long independently transcribed non-coding RNA 2311","metadata":null},{"id":"0d86710c4f1b4aa38029313143f8a1c2","type":"GENE","name":"LINC02312","canonical_id":"hgnc:HGNC:53231","description":"long independently transcribed non-coding RNA 2312","metadata":null},{"id":"abf3d9da7a1f48c993bc7e5b859e4586","type":"GENE","name":"LINC02313","canonical_id":"hgnc:HGNC:53232","description":"long independently transcribed non-coding RNA 2313","metadata":null},{"id":"e92a9a642b494857843d30567b49c5a3","type":"GENE","name":"LINC02314","canonical_id":"hgnc:HGNC:53233","description":"long independently transcribed non-coding RNA 2314","metadata":null},{"id":"5d39d19072c047e68f0cbb4db1f37e24","type":"GENE","name":"LINC02315","canonical_id":"hgnc:HGNC:53234","description":"long independently transcribed non-coding RNA 2315","metadata":null},{"id":"b0865167d56f4d2185f3a8709d539d15","type":"GENE","name":"LINC02316","canonical_id":"hgnc:HGNC:53235","description":"long independently transcribed non-coding RNA 2316","metadata":null},{"id":"eae839379ce749e1b0c9ba755487b9c4","type":"GENE","name":"LINC02317","canonical_id":"hgnc:HGNC:53236","description":"long independently transcribed non-coding RNA 2317","metadata":null},{"id":"e30d4e73a64a49e3a6207bf1252fd504","type":"GENE","name":"LINC02318","canonical_id":"hgnc:HGNC:53237","description":"long independently transcribed non-coding RNA 2318","metadata":null},{"id":"4b9fa0a0a53946a2820b24e31e653de6","type":"GENE","name":"LINC02319","canonical_id":"hgnc:HGNC:53238","description":"long independently transcribed non-coding RNA 2319","metadata":null},{"id":"8102a3c3049e4847b00cdae1b65ef9b3","type":"GENE","name":"LINC02320","canonical_id":"hgnc:HGNC:53239","description":"long independently transcribed non-coding RNA 2320","metadata":null},{"id":"a6ff76e43e7f4383adf854eb23e51956","type":"GENE","name":"LINC02321","canonical_id":"hgnc:HGNC:53240","description":"long independently transcribed non-coding RNA 2321","metadata":null},{"id":"81b281ed425744fda0a1903fcba2407a","type":"GENE","name":"LINC02322","canonical_id":"hgnc:HGNC:53241","description":"long independently transcribed non-coding RNA 2322","metadata":null},{"id":"49a7264d2a7e464988178707e5607850","type":"GENE","name":"LINC02323","canonical_id":"hgnc:HGNC:53242","description":"long independently transcribed non-coding RNA 2323","metadata":null},{"id":"8aeced8e6b014e9694e045a35336f567","type":"GENE","name":"LINC02324","canonical_id":"hgnc:HGNC:53244","description":"long independently transcribed non-coding RNA 2324","metadata":null},{"id":"ea93655f4aca45e4b90c16c6eca14c5e","type":"GENE","name":"LINC02325","canonical_id":"hgnc:HGNC:53245","description":"long independently transcribed non-coding RNA 2325","metadata":null},{"id":"5ad95c470e7a414396a393c69143446c","type":"GENE","name":"LINC02326","canonical_id":"hgnc:HGNC:53246","description":"long independently transcribed non-coding RNA 2326","metadata":{"aliases":["uc.362"]}},{"id":"d5a97b3a07004afeb1586fa989e245d4","type":"GENE","name":"LINC02327","canonical_id":"hgnc:HGNC:53247","description":"long independently transcribed non-coding RNA 2327","metadata":{"aliases":["uc.362"]}},{"id":"1b964f5198b84ef88c2a9ffef7300b9d","type":"GENE","name":"LINC02328","canonical_id":"hgnc:HGNC:53248","description":"long independently transcribed non-coding RNA 2328","metadata":null},{"id":"d409b8284a8b4b2dad7ffe403ca4dcbf","type":"GENE","name":"LINC02329","canonical_id":"hgnc:HGNC:53249","description":"long independently transcribed non-coding RNA 2329","metadata":null},{"id":"6b5d97281a784e45b8fa0f516a6debc2","type":"GENE","name":"LINC02330","canonical_id":"hgnc:HGNC:53250","description":"long independently transcribed non-coding RNA 2330","metadata":null},{"id":"dcc01c615ded482c91efb3481fbb163e","type":"GENE","name":"LINC02331","canonical_id":"hgnc:HGNC:53251","description":"long independently transcribed non-coding RNA 2331","metadata":null},{"id":"bb04dfbf3d694de6b4538d148bf9f36e","type":"GENE","name":"LINC02332","canonical_id":"hgnc:HGNC:53252","description":"long independently transcribed non-coding RNA 2332","metadata":null},{"id":"12c182ef018e414b9f25ce639825896b","type":"GENE","name":"LINC02333","canonical_id":"hgnc:HGNC:53253","description":"long independently transcribed non-coding RNA 2333","metadata":null},{"id":"e847c12bf6344a16a1a831ca93386276","type":"GENE","name":"LINC02334","canonical_id":"hgnc:HGNC:53254","description":"long independently transcribed non-coding RNA 2334","metadata":null},{"id":"07e10639e4964634b0c373842037842a","type":"GENE","name":"LINC02335","canonical_id":"hgnc:HGNC:53255","description":"long independently transcribed non-coding RNA 2335","metadata":null},{"id":"ac2e3086f46847aa9fc27983416f6500","type":"GENE","name":"LINC02336","canonical_id":"hgnc:HGNC:53256","description":"long independently transcribed non-coding RNA 2336","metadata":null},{"id":"b9f1c26a8f0e4eafa4d4a496559f25aa","type":"GENE","name":"LINC02337","canonical_id":"hgnc:HGNC:53257","description":"long independently transcribed non-coding RNA 2337","metadata":null},{"id":"049b97fa916c47c8abaf41019e0bde3e","type":"GENE","name":"LINC02338","canonical_id":"hgnc:HGNC:53258","description":"long independently transcribed non-coding RNA 2338","metadata":null},{"id":"fac69de208e04709a4f44a355f8429ba","type":"GENE","name":"LINC02339","canonical_id":"hgnc:HGNC:53259","description":"long independently transcribed non-coding RNA 2339","metadata":null},{"id":"571d8d3d9d764e9a908d6fb1a1df3e78","type":"GENE","name":"LINC02341","canonical_id":"hgnc:HGNC:53261","description":"long independently transcribed non-coding RNA 2341","metadata":null},{"id":"bf3fe93ee15a4f36bc46b918255290fa","type":"GENE","name":"LINC02342","canonical_id":"hgnc:HGNC:53262","description":"long independently transcribed non-coding RNA 2342","metadata":null},{"id":"471c8c05e34e456ab9790fde5c524be5","type":"GENE","name":"LINC02343","canonical_id":"hgnc:HGNC:53263","description":"long independently transcribed non-coding RNA 2343","metadata":null},{"id":"b17805b05dc44145aff49f6c78714d24","type":"GENE","name":"LINC02344","canonical_id":"hgnc:HGNC:53264","description":"long independently transcribed non-coding RNA 2344","metadata":null},{"id":"d28059fb81d64856971b39c106a8c425","type":"GENE","name":"LINC02345","canonical_id":"hgnc:HGNC:53267","description":"long independently transcribed non-coding RNA 2345","metadata":null},{"id":"799de88b350b4c578f444e66ef1e6f5a","type":"GENE","name":"LINC02346","canonical_id":"hgnc:HGNC:53268","description":"long independently transcribed non-coding RNA 2346","metadata":null},{"id":"375517f138114bffa15fa2aaf900a4ea","type":"GENE","name":"LINC02347","canonical_id":"hgnc:HGNC:53269","description":"long independently transcribed non-coding RNA 2347","metadata":null},{"id":"31ccccbf27794d04936dcc4ca5a59c94","type":"GENE","name":"LINC02348","canonical_id":"hgnc:HGNC:53270","description":"long independently transcribed non-coding RNA 2348","metadata":null},{"id":"e4261e299c3648f78fe3e6d099521a1c","type":"GENE","name":"LINC02349","canonical_id":"hgnc:HGNC:53271","description":"long independently transcribed non-coding RNA 2349","metadata":null},{"id":"2b43fa721ac04c56a883634b70fc52c5","type":"GENE","name":"LINC02350","canonical_id":"hgnc:HGNC:53272","description":"long independently transcribed non-coding RNA 2350","metadata":null},{"id":"cee5614186244a7da878b4cd3aca8b79","type":"GENE","name":"LINC02351","canonical_id":"hgnc:HGNC:53273","description":"long independently transcribed non-coding RNA 2351","metadata":null},{"id":"5ffd8f43d29348cdac17c6a733656f23","type":"GENE","name":"LINC02352","canonical_id":"hgnc:HGNC:53274","description":"long independently transcribed non-coding RNA 2352","metadata":null},{"id":"4fde3946d43f48f0a994d131bb1d5fd2","type":"GENE","name":"LINC02353","canonical_id":"hgnc:HGNC:53275","description":"long independently transcribed non-coding RNA 2353","metadata":null},{"id":"0101382e3e184b53b3650adfb12ff868","type":"GENE","name":"LINC02354","canonical_id":"hgnc:HGNC:53276","description":"long independently transcribed non-coding RNA 2354","metadata":null},{"id":"b0a2e8f080cb4f5dabfdabfef58f032f","type":"GENE","name":"LINC02355","canonical_id":"hgnc:HGNC:53277","description":"long independently transcribed non-coding RNA 2355","metadata":null},{"id":"2fb0d92140a2443492884e7a05c4082e","type":"GENE","name":"LINC02356","canonical_id":"hgnc:HGNC:53278","description":"long independently transcribed non-coding RNA 2356","metadata":null},{"id":"87b0f07dce7e43499304fb8bd059895b","type":"GENE","name":"LINC02357","canonical_id":"hgnc:HGNC:53279","description":"long independently transcribed non-coding RNA 2357","metadata":null},{"id":"29f5a109385148428b77a23b9a566c43","type":"GENE","name":"LINC02358","canonical_id":"hgnc:HGNC:53281","description":"long independently transcribed non-coding RNA 2358","metadata":null},{"id":"fd6fb37bd18c427e86bb1acb929ccd4f","type":"GENE","name":"LINC02359","canonical_id":"hgnc:HGNC:53280","description":"long independently transcribed non-coding RNA 2359","metadata":{"aliases":["LINC02467"]}},{"id":"420fed4d9b6543b5a87e6ad9a60e9dee","type":"GENE","name":"LINC02360","canonical_id":"hgnc:HGNC:53282","description":"long independently transcribed non-coding RNA 2360","metadata":null},{"id":"a56344d77cf44c3a907a2e0b26db56f8","type":"GENE","name":"LINC02361","canonical_id":"hgnc:HGNC:53283","description":"long independently transcribed non-coding RNA 2361","metadata":null},{"id":"5227bc9c741844e5ad17eeeb59269e16","type":"GENE","name":"LINC02362","canonical_id":"hgnc:HGNC:53284","description":"long independently transcribed non-coding RNA 2362","metadata":{"aliases":["PLUM"]}},{"id":"07b925774e684e728c2c8d71f913d883","type":"GENE","name":"LINC02363","canonical_id":"hgnc:HGNC:53286","description":"long independently transcribed non-coding RNA 2363","metadata":null},{"id":"c9cadb708dd7485a948d0a22df9590dc","type":"GENE","name":"LINC02364","canonical_id":"hgnc:HGNC:53288","description":"long independently transcribed non-coding RNA 2364","metadata":null},{"id":"a369f8385ad0478bbe0aa2c4d66e7cf9","type":"GENE","name":"LINC02365","canonical_id":"hgnc:HGNC:53285","description":"long independently transcribed non-coding RNA 2365","metadata":{"aliases":["LVCAT8"]}},{"id":"fecd671410f745149f375ca76c099c97","type":"GENE","name":"LINC02366","canonical_id":"hgnc:HGNC:53289","description":"long independently transcribed non-coding RNA 2366","metadata":null},{"id":"53b206fa26f640059b2505236a6c05b1","type":"GENE","name":"LINC02367","canonical_id":"hgnc:HGNC:53290","description":"long independently transcribed non-coding RNA 2367","metadata":null},{"id":"93ec13c671c34c61bd6e071b872f0790","type":"GENE","name":"LINC02368","canonical_id":"hgnc:HGNC:53291","description":"long independently transcribed non-coding RNA 2368","metadata":null},{"id":"85dfbf1ad2a8489db30f004be9627351","type":"GENE","name":"LINC02369","canonical_id":"hgnc:HGNC:53292","description":"long independently transcribed non-coding RNA 2369","metadata":null},{"id":"4d5d890e4c6142938901d4f5e21a492f","type":"GENE","name":"LINC02370","canonical_id":"hgnc:HGNC:27885","description":"long independently transcribed non-coding RNA 2370","metadata":null},{"id":"25f483841e544bf9ba73b68f327b1a81","type":"GENE","name":"LINC02371","canonical_id":"hgnc:HGNC:53293","description":"long independently transcribed non-coding RNA 2371","metadata":null},{"id":"584dbc61e50f4657a6d48f0253de1d05","type":"GENE","name":"LINC02372","canonical_id":"hgnc:HGNC:53294","description":"long independently transcribed non-coding RNA 2372","metadata":null},{"id":"5c821bb6ffa348ee9f5fe036d0b05f56","type":"GENE","name":"LINC02373","canonical_id":"hgnc:HGNC:53295","description":"long independently transcribed non-coding RNA 2373","metadata":null},{"id":"49315a71611b44bab118d680aaa88d71","type":"GENE","name":"LINC02374","canonical_id":"hgnc:HGNC:53296","description":"long independently transcribed non-coding RNA 2374","metadata":null},{"id":"ef80db67b3a046e2a33f3fb5afc8dce1","type":"GENE","name":"LINC02375","canonical_id":"hgnc:HGNC:53297","description":"long independently transcribed non-coding RNA 2375","metadata":null},{"id":"eccb52f4cd0e4247bde325aa7739769d","type":"GENE","name":"LINC02376","canonical_id":"hgnc:HGNC:53298","description":"long independently transcribed non-coding RNA 2376","metadata":null},{"id":"c1e6badbbfbd4d7a8bfc175ab790867b","type":"GENE","name":"LINC02377","canonical_id":"hgnc:HGNC:53300","description":"long independently transcribed non-coding RNA 2377","metadata":null},{"id":"fc64a1fc6b3b4ca393b8740df80671ca","type":"GENE","name":"LINC02378","canonical_id":"hgnc:HGNC:53301","description":"long independently transcribed non-coding RNA 2378","metadata":null},{"id":"91f6dfcc2b80402cb86352dca2d95c2f","type":"GENE","name":"LINC02379","canonical_id":"hgnc:HGNC:53302","description":"long independently transcribed non-coding RNA 2379","metadata":null},{"id":"646093c24e2f4191b09df3471d9e5284","type":"GENE","name":"LINC02380","canonical_id":"hgnc:HGNC:53303","description":"long independently transcribed non-coding RNA 2380","metadata":null},{"id":"a34db42895eb451e8d496b2cd9b74cf1","type":"GENE","name":"LINC02381","canonical_id":"hgnc:HGNC:53304","description":"long independently transcribed non-coding RNA 2381","metadata":{"aliases":["LOC400043","HMS","lncEPAT"]}},{"id":"6619e5bc7fd44d8b821f0a6244dc0516","type":"GENE","name":"LINC02382","canonical_id":"hgnc:HGNC:53305","description":"long independently transcribed non-coding RNA 2382","metadata":null},{"id":"f316831b9ff1445eafb214522f7a87c7","type":"GENE","name":"LINC02383","canonical_id":"hgnc:HGNC:53306","description":"long independently transcribed non-coding RNA 2383","metadata":null},{"id":"b4156fa19c3d479baee76f086cf682ea","type":"GENE","name":"LINC02384","canonical_id":"hgnc:HGNC:53308","description":"long independently transcribed non-coding RNA 2384","metadata":null},{"id":"327c7776ab8f49e1a1c478bc0dc3a733","type":"GENE","name":"LINC02385","canonical_id":"hgnc:HGNC:53309","description":"long independently transcribed non-coding RNA 2385","metadata":null},{"id":"9d19df7167174e6a84a0d357c091d444","type":"GENE","name":"LINC02386","canonical_id":"hgnc:HGNC:53312","description":"long independently transcribed non-coding RNA 2386","metadata":null},{"id":"2224f144b14544fd8bf4ab4a08a082aa","type":"GENE","name":"LINC02387","canonical_id":"hgnc:HGNC:53313","description":"long independently transcribed non-coding RNA 2387","metadata":null},{"id":"cbec5b2196454a218c2e218e19aa0c32","type":"GENE","name":"LINC02388","canonical_id":"hgnc:HGNC:53315","description":"long independently transcribed non-coding RNA 2388","metadata":null},{"id":"e35c9a3a3194472bb0ae035b406e893b","type":"GENE","name":"LINC02389","canonical_id":"hgnc:HGNC:53316","description":"long independently transcribed non-coding RNA 2389","metadata":{"aliases":["FLJ41278"]}},{"id":"88a51c421d874932a061e083ba233917","type":"GENE","name":"LINC02390","canonical_id":"hgnc:HGNC:53317","description":"long independently transcribed non-coding RNA 2390","metadata":null},{"id":"3413b5ad7f7d4a6b8d0d2449242f73c5","type":"GENE","name":"LINC02391","canonical_id":"hgnc:HGNC:53318","description":"long independently transcribed non-coding RNA 2391","metadata":null},{"id":"ef99a4b49a514ebc8f809756c766774a","type":"GENE","name":"LINC02392","canonical_id":"hgnc:HGNC:53319","description":"long independently transcribed non-coding RNA 2392","metadata":{"aliases":["lncRNA-ECVSR"]}},{"id":"927b59e4e4fa4f7bb18b16a563cdfb65","type":"GENE","name":"LINC02393","canonical_id":"hgnc:HGNC:53320","description":"long independently transcribed non-coding RNA 2393","metadata":{"aliases":["FLJ37505"]}},{"id":"dd7e7e5d2304447ea3aaf5c69a9a319e","type":"GENE","name":"LINC02394","canonical_id":"hgnc:HGNC:53321","description":"long independently transcribed non-coding RNA 2394","metadata":null},{"id":"839fcda4a3d24d03be933b7bb57d3ebe","type":"GENE","name":"LINC02395","canonical_id":"hgnc:HGNC:53322","description":"long independently transcribed non-coding RNA 2395","metadata":null},{"id":"65e869b0339942b5ab8b7a8455e89aa4","type":"GENE","name":"LINC02396","canonical_id":"hgnc:HGNC:27463","description":"long independently transcribed non-coding RNA 2396","metadata":null},{"id":"1605adf0e6c2464e8702d1308a08ca5e","type":"GENE","name":"LINC02397","canonical_id":"hgnc:HGNC:53323","description":"long independently transcribed non-coding RNA 2397","metadata":null},{"id":"11f55e2182544aa5b405767d0dcfcbd5","type":"GENE","name":"LINC02398","canonical_id":"hgnc:HGNC:53325","description":"long independently transcribed non-coding RNA 2398","metadata":null},{"id":"be3b9cdb1137422b817a8952daf949dc","type":"GENE","name":"LINC02399","canonical_id":"hgnc:HGNC:53326","description":"long independently transcribed non-coding RNA 2399","metadata":null},{"id":"153c1b61b56841f8aeb3c588fcee8522","type":"GENE","name":"LINC02400","canonical_id":"hgnc:HGNC:53327","description":"long independently transcribed non-coding RNA 2400","metadata":null},{"id":"8bcdde55861f409b9e30733d43b06008","type":"GENE","name":"LINC02401","canonical_id":"hgnc:HGNC:53328","description":"long independently transcribed non-coding RNA 2401","metadata":null},{"id":"cc9b7f9a558c457ca203a0b81f05d0bd","type":"GENE","name":"LINC02402","canonical_id":"hgnc:HGNC:53329","description":"long independently transcribed non-coding RNA 2402","metadata":{"aliases":["ENST00000550337.1"]}},{"id":"a73ac453c6c4429588d9061b74b09b63","type":"GENE","name":"LINC02403","canonical_id":"hgnc:HGNC:53330","description":"long independently transcribed non-coding RNA 2403","metadata":null},{"id":"3a0de9d6d9014b1b80c0035fb9a8aa14","type":"GENE","name":"LINC02404","canonical_id":"hgnc:HGNC:53331","description":"long independently transcribed non-coding RNA 2404","metadata":null},{"id":"bcc73a1bff6b43f588909e77b096f705","type":"GENE","name":"LINC02405","canonical_id":"hgnc:HGNC:53333","description":"long independently transcribed non-coding RNA 2405","metadata":null},{"id":"c4ee802d37a249359b5999cc885c1825","type":"GENE","name":"LINC02406","canonical_id":"hgnc:HGNC:53334","description":"long independently transcribed non-coding RNA 2406","metadata":null},{"id":"ac0361e6045f4a7594fdc25b5cde801d","type":"GENE","name":"LINC02408","canonical_id":"hgnc:HGNC:53337","description":"long independently transcribed non-coding RNA 2408","metadata":null},{"id":"ffe7a3641e7c41cd9a19afb6ab895785","type":"GENE","name":"LINC02409","canonical_id":"hgnc:HGNC:53338","description":"long independently transcribed non-coding RNA 2409","metadata":null},{"id":"d96486ecf4cc481cbd06468489ce06ee","type":"GENE","name":"LINC02410","canonical_id":"hgnc:HGNC:53339","description":"long independently transcribed non-coding RNA 2410","metadata":null},{"id":"6076475fc993492aa8425cb53ea32633","type":"GENE","name":"LINC02411","canonical_id":"hgnc:HGNC:53340","description":"long independently transcribed non-coding RNA 2411","metadata":null},{"id":"bde5d3a0a1f444408233ea1819dd775b","type":"GENE","name":"LINC02412","canonical_id":"hgnc:HGNC:53341","description":"long independently transcribed non-coding RNA 2412","metadata":null},{"id":"b94eb7acea1f45a39f41a7812454c4f4","type":"GENE","name":"LINC02413","canonical_id":"hgnc:HGNC:53342","description":"long independently transcribed non-coding RNA 2413","metadata":null},{"id":"06f5e4e5b7194b42af1f4e2c0ee7615e","type":"GENE","name":"LINC02414","canonical_id":"hgnc:HGNC:53343","description":"long independently transcribed non-coding RNA 2414","metadata":null},{"id":"1a73e6bb5ea341e8b2f0afa74aec872e","type":"GENE","name":"LINC02415","canonical_id":"hgnc:HGNC:53344","description":"long independently transcribed non-coding RNA 2415","metadata":null},{"id":"6d990dc84a5345d19e8653c294c11dd8","type":"GENE","name":"LINC02416","canonical_id":"hgnc:HGNC:53345","description":"long independently transcribed non-coding RNA 2416","metadata":null},{"id":"ce7de6fc7ef7440ca9eac08b98587ed9","type":"GENE","name":"LINC02417","canonical_id":"hgnc:HGNC:53347","description":"long independently transcribed non-coding RNA 2417","metadata":null},{"id":"b8ac6b5821a248a1a445bf2321e2ed35","type":"GENE","name":"LINC02418","canonical_id":"hgnc:HGNC:53348","description":"long independently transcribed non-coding RNA 2418","metadata":null},{"id":"c6f197f2514a424f91180d1754807f5a","type":"GENE","name":"LINC02419","canonical_id":"hgnc:HGNC:53349","description":"long independently transcribed non-coding RNA 2419","metadata":null},{"id":"3c7ee778c7ed44049919283a5f45ff43","type":"GENE","name":"LINC02420","canonical_id":"hgnc:HGNC:53350","description":"long independently transcribed non-coding RNA 2420","metadata":null},{"id":"1e1ffe47144b4532bbb7286bbfd709b5","type":"GENE","name":"LINC02421","canonical_id":"hgnc:HGNC:53351","description":"long independently transcribed non-coding RNA 2421","metadata":null},{"id":"d6e6b72b777d4e64a8cb9ad1bdd41e67","type":"GENE","name":"LINC02422","canonical_id":"hgnc:HGNC:53352","description":"long independently transcribed non-coding RNA 2422","metadata":null},{"id":"a49631ff6cb9481ca70b2815346adb32","type":"GENE","name":"LINC02423","canonical_id":"hgnc:HGNC:53353","description":"long independently transcribed non-coding RNA 2423","metadata":null},{"id":"a3507dff56154abfabd527fcf3491b9b","type":"GENE","name":"LINC02424","canonical_id":"hgnc:HGNC:53354","description":"long independently transcribed non-coding RNA 2424","metadata":null},{"id":"6a1a2acf827e4acbb790f2ee361d525a","type":"GENE","name":"LINC02425","canonical_id":"hgnc:HGNC:53356","description":"long independently transcribed non-coding RNA 2425","metadata":null},{"id":"c5a275ac087c4a0a8ec120dc4c4864d7","type":"GENE","name":"LINC02426","canonical_id":"hgnc:HGNC:53357","description":"long independently transcribed non-coding RNA 2426","metadata":null},{"id":"8c22af33281a4c8491d7861ec3a6f603","type":"GENE","name":"LINC02427","canonical_id":"hgnc:HGNC:53358","description":"long independently transcribed non-coding RNA 2427","metadata":null},{"id":"4af1f53ebb99425fb7b3976884ebb734","type":"GENE","name":"LINC02428","canonical_id":"hgnc:HGNC:53359","description":"long independently transcribed non-coding RNA 2428","metadata":null},{"id":"dc4351c4e4bb4956b3cbb7d4d7de7032","type":"GENE","name":"LINC02429","canonical_id":"hgnc:HGNC:53360","description":"long independently transcribed non-coding RNA 2429","metadata":null},{"id":"2070bc21e2e54bc6a943361d1935593f","type":"GENE","name":"LINC02430","canonical_id":"hgnc:HGNC:53361","description":"long independently transcribed non-coding RNA 2430","metadata":null},{"id":"96ef1a5867894138bd3760d505c7dd35","type":"GENE","name":"LINC02431","canonical_id":"hgnc:HGNC:53362","description":"long independently transcribed non-coding RNA 2431","metadata":null},{"id":"9f4a0d036e65412fb430abd8d39066f1","type":"GENE","name":"LINC02432","canonical_id":"hgnc:HGNC:53363","description":"long independently transcribed non-coding RNA 2432","metadata":null},{"id":"8154282524354cb0abcdc1fbb432288c","type":"GENE","name":"LINC02433","canonical_id":"hgnc:HGNC:27959","description":"long independently transcribed non-coding RNA 2433","metadata":null},{"id":"f3f9d6f3de774eac96a796ff36c4ac28","type":"GENE","name":"LINC02434","canonical_id":"hgnc:HGNC:53365","description":"long independently transcribed non-coding RNA 2434","metadata":null},{"id":"ff981e2204814462911fe789f7c66b9a","type":"GENE","name":"LINC02435","canonical_id":"hgnc:HGNC:53366","description":"long independently transcribed non-coding RNA 2435","metadata":null},{"id":"17c45ff8d16241d6bb7ba32663ee990a","type":"GENE","name":"LINC02436","canonical_id":"hgnc:HGNC:53368","description":"long independently transcribed non-coding RNA 2436","metadata":null},{"id":"ce9e6148c13a47c9bc152f1dadb8e056","type":"GENE","name":"LINC02437","canonical_id":"hgnc:HGNC:53369","description":"long independently transcribed non-coding RNA 2437","metadata":null},{"id":"954e910e829f4fb39b65f438d575b066","type":"GENE","name":"LINC02438","canonical_id":"hgnc:HGNC:53370","description":"long independently transcribed non-coding RNA 2438","metadata":null},{"id":"b5340fdf0c0f40d7b5865bb5d7046066","type":"GENE","name":"LINC02439","canonical_id":"hgnc:HGNC:53371","description":"long independently transcribed non-coding RNA 2439","metadata":null},{"id":"f657a04a7c0241c9921d3fbe73fb56e1","type":"GENE","name":"LINC02440","canonical_id":"hgnc:HGNC:53372","description":"long independently transcribed non-coding RNA 2440","metadata":null},{"id":"332ded1a689b48aab7042adda88613d7","type":"GENE","name":"LINC02441","canonical_id":"hgnc:HGNC:53373","description":"long independently transcribed non-coding RNA 2441","metadata":{"aliases":["CRAT8"]}},{"id":"178c388856b44382896d04d1d4ff1fcc","type":"GENE","name":"LINC02442","canonical_id":"hgnc:HGNC:53374","description":"long independently transcribed non-coding RNA 2442","metadata":null},{"id":"a80809bde9e4423b88f96b211028c4f8","type":"GENE","name":"LINC02443","canonical_id":"hgnc:HGNC:53375","description":"long independently transcribed non-coding RNA 2443","metadata":null},{"id":"70c97094fd1f42939c2afb3971264ca5","type":"GENE","name":"LINC02444","canonical_id":"hgnc:HGNC:53376","description":"long independently transcribed non-coding RNA 2444","metadata":null},{"id":"7e5333fb5ff54b73ad0549a9d094c098","type":"GENE","name":"LINC02445","canonical_id":"hgnc:HGNC:53377","description":"long independently transcribed non-coding RNA 2445","metadata":null},{"id":"ddcd015bb7474d73a9a802b7b99298c0","type":"GENE","name":"LINC02446","canonical_id":"hgnc:HGNC:53378","description":"long independently transcribed non-coding RNA 2446","metadata":null},{"id":"b74aef34ed4c4d0599a0b17f168636e6","type":"GENE","name":"LINC02447","canonical_id":"hgnc:HGNC:53379","description":"long independently transcribed non-coding RNA 2447","metadata":null},{"id":"9bb8b3cbe45d4b6582ac9d83a88cc39e","type":"GENE","name":"LINC02448","canonical_id":"hgnc:HGNC:53380","description":"long independently transcribed non-coding RNA 2448","metadata":null},{"id":"9d8c5c99cbf7406eb3cec1f3f693ab82","type":"GENE","name":"LINC02449","canonical_id":"hgnc:HGNC:53381","description":"long independently transcribed non-coding RNA 2449","metadata":null},{"id":"0cf4e263c44244e0bce200914b1083c2","type":"GENE","name":"LINC02450","canonical_id":"hgnc:HGNC:53382","description":"long independently transcribed non-coding RNA 2450","metadata":{"aliases":["LINC02451"]}},{"id":"088dbb21042544b58652f2bca3dd1be2","type":"GENE","name":"LINC02452","canonical_id":"hgnc:HGNC:53384","description":"long independently transcribed non-coding RNA 2452","metadata":null},{"id":"8285af5b5b9a4df1b097970ae1cf987b","type":"GENE","name":"LINC02453","canonical_id":"hgnc:HGNC:53392","description":"long independently transcribed non-coding RNA 2453","metadata":null},{"id":"48f93faf23df40fa86bed79565bcec37","type":"GENE","name":"LINC02454","canonical_id":"hgnc:HGNC:53387","description":"long independently transcribed non-coding RNA 2454","metadata":null},{"id":"c6a3031865e3435a8d24d1f4b867c7bb","type":"GENE","name":"LINC02455","canonical_id":"hgnc:HGNC:53388","description":"long independently transcribed non-coding RNA 2455","metadata":null},{"id":"3b462e102ef844f388d4f01ee9bb348f","type":"GENE","name":"LINC02456","canonical_id":"hgnc:HGNC:53389","description":"long independently transcribed non-coding RNA 2456","metadata":null},{"id":"7e544b19eb474e3a9190aa3413c0bb46","type":"GENE","name":"LINC02457","canonical_id":"hgnc:HGNC:53393","description":"long independently transcribed non-coding RNA 2457","metadata":null},{"id":"14c75b9436804f3382fe9735008d6e2d","type":"GENE","name":"LINC02458","canonical_id":"hgnc:HGNC:53394","description":"long independently transcribed non-coding RNA 2458","metadata":null},{"id":"3488484e22a840c3ae4cc68fc0ec237e","type":"GENE","name":"LINC02459","canonical_id":"hgnc:HGNC:53395","description":"long independently transcribed non-coding RNA 2459","metadata":null},{"id":"faaea039fa0541eabebfaf4fc88359ea","type":"GENE","name":"LINC02460","canonical_id":"hgnc:HGNC:53396","description":"long independently transcribed non-coding RNA 2460","metadata":null},{"id":"bd9e2960d8aa424dbd8ea32073c7db45","type":"GENE","name":"LINC02461","canonical_id":"hgnc:HGNC:53398","description":"long independently transcribed non-coding RNA 2461","metadata":null},{"id":"6066f52a6d494945b8b51b4240de4036","type":"GENE","name":"LINC02462","canonical_id":"hgnc:HGNC:53399","description":"long independently transcribed non-coding RNA 2462","metadata":null},{"id":"778d266ac01244c1944f2612337ce804","type":"GENE","name":"LINC02463","canonical_id":"hgnc:HGNC:53400","description":"long independently transcribed non-coding RNA 2463","metadata":null},{"id":"64797c8500314b9587333dd554548ae2","type":"GENE","name":"LINC02464","canonical_id":"hgnc:HGNC:53401","description":"long independently transcribed non-coding RNA 2464","metadata":null},{"id":"fd9a3c6c90974640ab5d419ba33123b8","type":"GENE","name":"LINC02465","canonical_id":"hgnc:HGNC:53403","description":"long independently transcribed non-coding RNA 2465","metadata":null},{"id":"be8adde2723348e1b6277d18e1c74c34","type":"GENE","name":"LINC02466","canonical_id":"hgnc:HGNC:53405","description":"long independently transcribed non-coding RNA 2466","metadata":null},{"id":"503e2d113f7f48e0b8bb05535f6316bb","type":"GENE","name":"LINC02468","canonical_id":"hgnc:HGNC:53406","description":"long independently transcribed non-coding RNA 2468","metadata":null},{"id":"c64e155c69e946849a115a6c213c162a","type":"GENE","name":"LINC02469","canonical_id":"hgnc:HGNC:53408","description":"long independently transcribed non-coding RNA 2469","metadata":null},{"id":"8fb00efc58294518be4bb07b86397b81","type":"GENE","name":"LINC02470","canonical_id":"hgnc:HGNC:53409","description":"long independently transcribed non-coding RNA 2470","metadata":{"aliases":["AC091814.2"]}},{"id":"51ae4dc26cbd442488e602c6f94e8825","type":"GENE","name":"LINC02471","canonical_id":"hgnc:HGNC:53410","description":"long independently transcribed non-coding RNA 2471","metadata":{"aliases":["AC079630.2"]}},{"id":"bd1d0c8192fc4688a9e41e7f25512d13","type":"GENE","name":"LINC02472","canonical_id":"hgnc:HGNC:53411","description":"long independently transcribed non-coding RNA 2472","metadata":null},{"id":"9f8c03783f664b7e8c12d39e3b6fdb69","type":"GENE","name":"LINC02473","canonical_id":"hgnc:HGNC:53412","description":"long independently transcribed non-coding RNA 2473","metadata":null},{"id":"23e2f806399e47308cbe32aff8ba819b","type":"GENE","name":"LINC02474","canonical_id":"hgnc:HGNC:53417","description":"long independently transcribed non-coding RNA 2474","metadata":{"aliases":["RP11-400N13.2","lncSLCC1"]}},{"id":"8c2445f2b1d64cacb716fbf59d4ff29d","type":"GENE","name":"LINC02475","canonical_id":"hgnc:HGNC:53418","description":"long independently transcribed non-coding RNA 2475","metadata":{"aliases":["LVCAT1"]}},{"id":"cda78a96a41d4b48b184ac6e633acc45","type":"GENE","name":"LINC02476","canonical_id":"hgnc:HGNC:53419","description":"long independently transcribed non-coding RNA 2476","metadata":{"aliases":["LVCAT5","lnc-TSPAN12"]}},{"id":"68585fd92cfd4dc3867414dbdcca1acc","type":"GENE","name":"LINC02477","canonical_id":"hgnc:HGNC:53425","description":"long independently transcribed non-coding RNA 2477","metadata":null},{"id":"038c0dd66b1045b2921e59f0daa2a073","type":"GENE","name":"LINC02478","canonical_id":"hgnc:HGNC:53446","description":"long independently transcribed non-coding RNA 2478","metadata":null},{"id":"9fee23b93641439eb03908d5bbe16216","type":"GENE","name":"LINC02479","canonical_id":"hgnc:HGNC:53453","description":"long independently transcribed non-coding RNA 2479","metadata":null},{"id":"81b6c8a84f544825bc8c6c4584ca9d25","type":"GENE","name":"LINC02480","canonical_id":"hgnc:HGNC:53454","description":"long independently transcribed non-coding RNA 2480","metadata":null},{"id":"8a885357ceb1444ab81104c668eaa1f8","type":"GENE","name":"LINC02481","canonical_id":"hgnc:HGNC:27958","description":"long independently transcribed non-coding RNA 2481","metadata":{"aliases":["LINC002481"]}},{"id":"91adc72993ca4924a0a2c74cb0ca4cf6","type":"GENE","name":"LINC02482","canonical_id":"hgnc:HGNC:53458","description":"long independently transcribed non-coding RNA 2482","metadata":null},{"id":"8a39b6d8e7e642f1ac5a71acba8f201a","type":"GENE","name":"LINC02483","canonical_id":"hgnc:HGNC:53457","description":"long independently transcribed non-coding RNA 2483","metadata":null},{"id":"1bf5405430354aeca5e4d1f3018c08f6","type":"GENE","name":"LINC02484","canonical_id":"hgnc:HGNC:53459","description":"long independently transcribed non-coding RNA 2484","metadata":null},{"id":"29ff11720cf34b14994595368e23b042","type":"GENE","name":"LINC02485","canonical_id":"hgnc:HGNC:53460","description":"long independently transcribed non-coding RNA 2485","metadata":null},{"id":"ad7c36c37283463c80028dc5d3925715","type":"GENE","name":"LINC02487","canonical_id":"hgnc:HGNC:53466","description":"long independently transcribed non-coding RNA 2487","metadata":null},{"id":"4a17d3c95a114db0879482f4a1074bab","type":"GENE","name":"LINC02489","canonical_id":"hgnc:HGNC:53470","description":"long independently transcribed non-coding RNA 2489","metadata":{"aliases":["CTD-2589M5.4"]}},{"id":"5e83f6c390ee4b9daed53f4c35296afc","type":"GENE","name":"LINC02490","canonical_id":"hgnc:HGNC:53471","description":"long independently transcribed non-coding RNA 2490","metadata":{"aliases":["RP11-209E8"]}},{"id":"35af322e1253489190127af8f7ec5ad6","type":"GENE","name":"LINC02491","canonical_id":"hgnc:HGNC:53475","description":"long independently transcribed non-coding RNA 2491","metadata":null},{"id":"59de933c9fb040749c433352aa5edd03","type":"GENE","name":"LINC02492","canonical_id":"hgnc:HGNC:53476","description":"long independently transcribed non-coding RNA 2492","metadata":null},{"id":"f708db5c99ef4611b336c77927b5b9e8","type":"GENE","name":"LINC02493","canonical_id":"hgnc:HGNC:53477","description":"long independently transcribed non-coding RNA 2493","metadata":null},{"id":"910fe4e667f24c55888853b518c71bb5","type":"GENE","name":"LINC02494","canonical_id":"hgnc:HGNC:53479","description":"long independently transcribed non-coding RNA 2494","metadata":null},{"id":"2e635868320f43a78c014f7754909d43","type":"GENE","name":"LINC02496","canonical_id":"hgnc:HGNC:53480","description":"long independently transcribed non-coding RNA 2496","metadata":null},{"id":"54cdcd85bb754268abef4a6a4b98b920","type":"GENE","name":"LINC02497","canonical_id":"hgnc:HGNC:53482","description":"long independently transcribed non-coding RNA 2497","metadata":null},{"id":"fc5db9f458ee467bbf6d893bf08e8334","type":"GENE","name":"LINC02498","canonical_id":"hgnc:HGNC:53483","description":"long independently transcribed non-coding RNA 2498","metadata":null},{"id":"0b74c1a927e74d99b062e2475aa877ba","type":"GENE","name":"LINC02499","canonical_id":"hgnc:HGNC:53484","description":"long independently transcribed non-coding RNA 2499","metadata":null},{"id":"44569dbb0ea14623abcfd89ab19fe95b","type":"GENE","name":"LINC02500","canonical_id":"hgnc:HGNC:53488","description":"long independently transcribed non-coding RNA 2500","metadata":null},{"id":"f25c2fec2c65436b8ae6757d4ac8725a","type":"GENE","name":"LINC02501","canonical_id":"hgnc:HGNC:53489","description":"long independently transcribed non-coding RNA 2501","metadata":null},{"id":"83cdbcc806114892a150e05856131fee","type":"GENE","name":"LINC02502","canonical_id":"hgnc:HGNC:53491","description":"long independently transcribed non-coding RNA 2502","metadata":null},{"id":"b19729fdadda4258ac8e99739f8a11ef","type":"GENE","name":"LINC02503","canonical_id":"hgnc:HGNC:53492","description":"long independently transcribed non-coding RNA 2503","metadata":null},{"id":"f391d77ba9be4b15a38bc6174d36015d","type":"GENE","name":"LINC02504","canonical_id":"hgnc:HGNC:53493","description":"long independently transcribed non-coding RNA 2504","metadata":null},{"id":"92692933425f4cd1877adfeddbc87851","type":"GENE","name":"LINC02505","canonical_id":"hgnc:HGNC:53494","description":"long independently transcribed non-coding RNA 2505","metadata":null},{"id":"48a419895d2f4ef3a10c7308de53c897","type":"GENE","name":"LINC02506","canonical_id":"hgnc:HGNC:53495","description":"long independently transcribed non-coding RNA 2506","metadata":null},{"id":"b38ccbbf97d14ce99713dd50dfb889ba","type":"GENE","name":"LINC02507","canonical_id":"hgnc:HGNC:53496","description":"long independently transcribed non-coding RNA 2507","metadata":null},{"id":"518fa1d2fddf441a956562ac9e05be3a","type":"GENE","name":"LINC02508","canonical_id":"hgnc:HGNC:53497","description":"long independently transcribed non-coding RNA 2508","metadata":null},{"id":"54cd78c5e7c140e3a2bb1cdc9645589f","type":"GENE","name":"LINC02509","canonical_id":"hgnc:HGNC:53498","description":"long independently transcribed non-coding RNA 2509","metadata":null},{"id":"ac48ef6d795e45c1b6b5dba01f9bbfac","type":"GENE","name":"LINC02510","canonical_id":"hgnc:HGNC:53499","description":"long independently transcribed non-coding RNA 2510","metadata":null},{"id":"c0211f31016748a998c548f36d0fcdde","type":"GENE","name":"LINC02511","canonical_id":"hgnc:HGNC:53500","description":"long independently transcribed non-coding RNA 2511","metadata":null},{"id":"cd4fd66f17754cb7a30a87dd3ae3eb1d","type":"GENE","name":"LINC02512","canonical_id":"hgnc:HGNC:53501","description":"long independently transcribed non-coding RNA 2512","metadata":null},{"id":"86118cfee0304282bd6e9ebdb1166745","type":"GENE","name":"LINC02513","canonical_id":"hgnc:HGNC:53502","description":"long independently transcribed non-coding RNA 2513","metadata":null},{"id":"e53f72df2ee9429d8c473db807b3238d","type":"GENE","name":"LINC02514","canonical_id":"hgnc:HGNC:53503","description":"long independently transcribed non-coding RNA 2514","metadata":null},{"id":"4b3907f13d3d4e82966c43e647c78985","type":"GENE","name":"LINC02515","canonical_id":"hgnc:HGNC:53504","description":"long independently transcribed non-coding RNA 2515","metadata":null},{"id":"ec60344c9d1746a995876582a388bb08","type":"GENE","name":"LINC02516","canonical_id":"hgnc:HGNC:53505","description":"long independently transcribed non-coding RNA 2516","metadata":null},{"id":"7a42a57a91484c1787449477da1894ad","type":"GENE","name":"LINC02517","canonical_id":"hgnc:HGNC:53506","description":"long independently transcribed non-coding RNA 2517","metadata":null},{"id":"c55e442e85414d25bd444b415bb934f2","type":"GENE","name":"LINC02518","canonical_id":"hgnc:HGNC:53509","description":"long independently transcribed non-coding RNA 2518","metadata":null},{"id":"a0a542e5a65e48e3ab582f61b4a84282","type":"GENE","name":"LINC02519","canonical_id":"hgnc:HGNC:53510","description":"long independently transcribed non-coding RNA 2519","metadata":null},{"id":"c514a4af841440e8a7f20c7b0fe44739","type":"GENE","name":"LINC02520","canonical_id":"hgnc:HGNC:53511","description":"long independently transcribed non-coding RNA 2520","metadata":null},{"id":"a22fc47349894b91ba4a1f62104c022d","type":"GENE","name":"LINC02521","canonical_id":"hgnc:HGNC:53560","description":"long independently transcribed non-coding RNA 2521","metadata":null},{"id":"49094f944b94464faed82b489e60fbd3","type":"GENE","name":"LINC02522","canonical_id":"hgnc:HGNC:53541","description":"long independently transcribed non-coding RNA 2522","metadata":null},{"id":"ffedfe135e0442a8b4fe716e1b28d9eb","type":"GENE","name":"LINC02523","canonical_id":"hgnc:HGNC:53542","description":"long independently transcribed non-coding RNA 2523","metadata":null},{"id":"3d7b68bda07341719d42231521cc09e0","type":"GENE","name":"LINC02524","canonical_id":"hgnc:HGNC:53544","description":"long independently transcribed non-coding RNA 2524","metadata":null},{"id":"d461938cd2da48e4a81d0de589657f62","type":"GENE","name":"LINC02525","canonical_id":"hgnc:HGNC:53545","description":"long independently transcribed non-coding RNA 2525","metadata":{"aliases":["TP53LC14","lncNB1","RP1-40E16.9"]}},{"id":"679b1a9e78834698b706af6cbd117920","type":"GENE","name":"LINC02526","canonical_id":"hgnc:HGNC:53550","description":"long independently transcribed non-coding RNA 2526","metadata":null},{"id":"8d81916856a34461b8c3764652d19c8d","type":"GENE","name":"LINC02527","canonical_id":"hgnc:HGNC:53553","description":"long independently transcribed non-coding RNA 2527","metadata":null},{"id":"5e8034d054054cafa319841ac39c1853","type":"GENE","name":"LINC02529","canonical_id":"hgnc:HGNC:53555","description":"long independently transcribed non-coding RNA 2529","metadata":null},{"id":"f05f39d21f744442b733b6fb56d8703c","type":"GENE","name":"LINC02530","canonical_id":"hgnc:HGNC:53556","description":"long independently transcribed non-coding RNA 2530","metadata":null},{"id":"25b590d33b4e4b848af91d97e136ae0f","type":"GENE","name":"LINC02531","canonical_id":"hgnc:HGNC:53557","description":"long independently transcribed non-coding RNA 2531","metadata":null},{"id":"4d2fc4e5dd2349429f6cafa523b08201","type":"GENE","name":"LINC02532","canonical_id":"hgnc:HGNC:53549","description":"long independently transcribed non-coding RNA 2532","metadata":null},{"id":"35a7d3d1c6e74929bdb65366f896b4dd","type":"GENE","name":"LINC02533","canonical_id":"hgnc:HGNC:53566","description":"long independently transcribed non-coding RNA 2533","metadata":null},{"id":"9f553d3fc46b45e993e0b88e3ba04726","type":"GENE","name":"LINC02534","canonical_id":"hgnc:HGNC:53567","description":"long independently transcribed non-coding RNA 2534","metadata":null},{"id":"052f30821f3741e182167c4cc6afd47f","type":"GENE","name":"LINC02535","canonical_id":"hgnc:HGNC:53569","description":"long independently transcribed non-coding RNA 2535","metadata":null},{"id":"416c0835a1e44faf9d9894b95f6471fd","type":"GENE","name":"LINC02536","canonical_id":"hgnc:HGNC:53570","description":"long independently transcribed non-coding RNA 2536","metadata":null},{"id":"168a1a4429f849d28030a917ac18f158","type":"GENE","name":"LINC02537","canonical_id":"hgnc:HGNC:27784","description":"long independently transcribed non-coding RNA 2537","metadata":null},{"id":"5b51bce0b6274e98aed03ca9ff0bbdeb","type":"GENE","name":"LINC02538","canonical_id":"hgnc:HGNC:53571","description":"long independently transcribed non-coding RNA 2538","metadata":null},{"id":"92e6a13a8ba54b79a0f6c1dd1f46b937","type":"GENE","name":"LINC02539","canonical_id":"hgnc:HGNC:53572","description":"long independently transcribed non-coding RNA 2539","metadata":{"aliases":["RP11-356I2.2"]}},{"id":"fb53b4f0f09b476c9b356b2f733f46ae","type":"GENE","name":"LINC02540","canonical_id":"hgnc:HGNC:53573","description":"long independently transcribed non-coding RNA 2540","metadata":null},{"id":"c92c3bb8681c4e3bb5d095cd3bb2068c","type":"GENE","name":"LINC02541","canonical_id":"hgnc:HGNC:53574","description":"long independently transcribed non-coding RNA 2541","metadata":{"aliases":["RP11-367G18.1"]}},{"id":"69e1b3c7e3d042ceaca252ae21a56e94","type":"GENE","name":"LINC02542","canonical_id":"hgnc:HGNC:53576","description":"long independently transcribed non-coding RNA 2542","metadata":null},{"id":"dbc2fd5eecda43c0bf87876bd66655f6","type":"GENE","name":"LINC02543","canonical_id":"hgnc:HGNC:53577","description":"long independently transcribed non-coding RNA 2543","metadata":null},{"id":"4d58418ac1214a26ac93155d1c006b88","type":"GENE","name":"LINC02545","canonical_id":"hgnc:HGNC:53580","description":"long independently transcribed non-coding RNA 2545","metadata":null},{"id":"c3b3014741f14a22bcf4f058a452ea9f","type":"GENE","name":"LINC02546","canonical_id":"hgnc:HGNC:53581","description":"long independently transcribed non-coding RNA 2546","metadata":null},{"id":"babe25c18c624e2c99ea48abb611db14","type":"GENE","name":"LINC02547","canonical_id":"hgnc:HGNC:53582","description":"long independently transcribed non-coding RNA 2547","metadata":null},{"id":"7ff0caab704b406eaa1fe593a220573c","type":"GENE","name":"LINC02548","canonical_id":"hgnc:HGNC:53583","description":"long independently transcribed non-coding RNA 2548","metadata":null},{"id":"f60e1c6e6ca54b3ba922b622fda3d84e","type":"GENE","name":"LINC02549","canonical_id":"hgnc:HGNC:53584","description":"long independently transcribed non-coding RNA 2549","metadata":null},{"id":"f50185d053474c33b37d63e7d72dee41","type":"GENE","name":"LINC02550","canonical_id":"hgnc:HGNC:53585","description":"long independently transcribed non-coding RNA 2550","metadata":null},{"id":"326e79b13f894ab398e7868db5979e68","type":"GENE","name":"LINC02551","canonical_id":"hgnc:HGNC:53586","description":"long independently transcribed non-coding RNA 2551","metadata":{"aliases":["JunBP","RP11-890B15.2"]}},{"id":"7837b9a004e247c9a496a30e16e7825d","type":"GENE","name":"LINC02552","canonical_id":"hgnc:HGNC:53587","description":"long independently transcribed non-coding RNA 2552","metadata":null},{"id":"0887c748c0744ab39bcd4fe76b216aa9","type":"GENE","name":"LINC02553","canonical_id":"hgnc:HGNC:53588","description":"long independently transcribed non-coding RNA 2553","metadata":null},{"id":"2c44e7b910d84b0a81e1f5ff7b370301","type":"GENE","name":"LINC02554","canonical_id":"hgnc:HGNC:53594","description":"long independently transcribed non-coding RNA 2554","metadata":null},{"id":"6400d4f681f441918ceee9fcccead5e0","type":"GENE","name":"LINC02555","canonical_id":"hgnc:HGNC:53593","description":"long independently transcribed non-coding RNA 2555","metadata":{"aliases":["AC079630.2"]}},{"id":"83c6b52987a9429eb491dd5782f4c6ff","type":"GENE","name":"LINC02556","canonical_id":"hgnc:HGNC:53595","description":"long independently transcribed non-coding RNA 2556","metadata":null},{"id":"2f9c9f65cc164d9f8d02e98e9a4d15bf","type":"GENE","name":"LINC02557","canonical_id":"hgnc:HGNC:53596","description":"long independently transcribed non-coding RNA 2557","metadata":null},{"id":"3aba82068cbc46d2a0abb886e1b6e611","type":"GENE","name":"LINC02558","canonical_id":"hgnc:HGNC:53597","description":"long independently transcribed non-coding RNA 2558","metadata":null},{"id":"0f1d8c8ab0b14f1788b3b25bdbea6c68","type":"GENE","name":"LINC02559","canonical_id":"hgnc:HGNC:53598","description":"long independently transcribed non-coding RNA 2559","metadata":null},{"id":"179277babf174cf794958c6212d4d4d6","type":"GENE","name":"LINC02560","canonical_id":"hgnc:HGNC:53600","description":"long independently transcribed non-coding RNA 2560","metadata":{"aliases":["CTD-2619J13.13"]}},{"id":"0374df750f7b42f79c3b35ffaa96ba4b","type":"GENE","name":"LINC02561","canonical_id":"hgnc:HGNC:53601","description":"long independently transcribed non-coding RNA 2561","metadata":{"aliases":["RP11-445P17.8"]}},{"id":"01446473e28f48f9821fd60afc81aad3","type":"GENE","name":"LINC02562","canonical_id":"hgnc:HGNC:53602","description":"long independently transcribed non-coding RNA 2562","metadata":{"aliases":["RP11-44F21.5"]}},{"id":"56a1886c6899402ebe5182b0d4c359ca","type":"GENE","name":"LINC02563","canonical_id":"hgnc:HGNC:52923","description":"long independently transcribed non-coding RNA 2563","metadata":{"aliases":["CRAT40"]}},{"id":"31b537925f0f4799b34146a430dc4b1a","type":"GENE","name":"LINC02564","canonical_id":"hgnc:HGNC:53604","description":"long independently transcribed non-coding RNA 2564","metadata":null},{"id":"db6ccbbd664c4bbab07b563fadc78307","type":"GENE","name":"LINC02565","canonical_id":"hgnc:HGNC:53605","description":"long independently transcribed non-coding RNA 2565","metadata":null},{"id":"4819498b3c0a4c1dab3949ea574776e0","type":"GENE","name":"LINC02566","canonical_id":"hgnc:HGNC:53606","description":"long independently transcribed non-coding RNA 2566","metadata":{"aliases":["LNC-Sox5"]}},{"id":"ce9792b3cac14eb49dab646620e090d7","type":"GENE","name":"LINC02567","canonical_id":"hgnc:HGNC:53609","description":"long independently transcribed non-coding RNA 2567","metadata":{"aliases":["ENST00000427806"]}},{"id":"bf6123ecc55e4a3abf06221738c26c93","type":"GENE","name":"LINC02568","canonical_id":"hgnc:HGNC:51430","description":"long independently transcribed non-coding RNA 2568","metadata":null},{"id":"2430f454e04b44b2a26a4e480fa52e81","type":"GENE","name":"LINC02569","canonical_id":"hgnc:HGNC:39760","description":"long independently transcribed non-coding RNA 2569","metadata":{"aliases":["TCONS_00011283"]}},{"id":"13475a60048c4b46bfafce11d8ff2c1d","type":"GENE","name":"LINC02570","canonical_id":"hgnc:HGNC:39766","description":"long independently transcribed non-coding RNA 2570","metadata":{"aliases":["XXbac-BPG27H4.8"]}},{"id":"7255024044fc408fbbf5bd038638762c","type":"GENE","name":"LINC02571","canonical_id":"hgnc:HGNC:53630","description":"long independently transcribed non-coding RNA 2571","metadata":null},{"id":"87897794d027431e988c102960fddb8c","type":"GENE","name":"LINC02572","canonical_id":"hgnc:HGNC:53634","description":"long independently transcribed non-coding RNA 2572","metadata":{"aliases":["AC079776.2"]}},{"id":"bf8ab8a08b9546a5b1b57bcd94e5b1ba","type":"GENE","name":"LINC02573","canonical_id":"hgnc:HGNC:53730","description":"long independently transcribed non-coding RNA 2573","metadata":null},{"id":"c698b73ccbd047ea8e053ce41722cb0b","type":"GENE","name":"LINC02574","canonical_id":"hgnc:HGNC:53746","description":"long independently transcribed non-coding RNA 2574","metadata":{"aliases":["RP11-288L9.1","HEAL"]}},{"id":"bd1b2dcf09e041898efec84bc8d3729b","type":"GENE","name":"LINC02575","canonical_id":"hgnc:HGNC:53747","description":"long independently transcribed non-coding RNA 2575","metadata":{"aliases":["AP001065.15"]}},{"id":"29252c45656e47f7b61c24e4c0a2a0ab","type":"GENE","name":"LINC02576","canonical_id":"hgnc:HGNC:53748","description":"long independently transcribed non-coding RNA 2576","metadata":null},{"id":"73ee9c05afd34fa8aa5b4531fac87faa","type":"GENE","name":"LINC02577","canonical_id":"hgnc:HGNC:53749","description":"long independently transcribed non-coding RNA 2577","metadata":{"aliases":["AC002384.1","SLINKY","CLAN"]}},{"id":"7154bd9542274f40b4a4e911009e8697","type":"GENE","name":"LINC02578","canonical_id":"hgnc:HGNC:53750","description":"long independently transcribed non-coding RNA 2578","metadata":{"aliases":["RP11-127L21.1"]}},{"id":"10f5126839ef4720bba09db22d6b676a","type":"GENE","name":"LINC02579","canonical_id":"hgnc:HGNC:27942","description":"long independently transcribed non-coding RNA 2579","metadata":{"aliases":["AC007365.1"]}},{"id":"7d34628d74974af9a477e755a60bc158","type":"GENE","name":"LINC02580","canonical_id":"hgnc:HGNC:53751","description":"long independently transcribed non-coding RNA 2580","metadata":{"aliases":["AC093609.1"]}},{"id":"45685782433c4f5aa7e91660b91f5f32","type":"GENE","name":"LINC02582","canonical_id":"hgnc:HGNC:53792","description":"long independently transcribed non-coding RNA 2582","metadata":{"aliases":["CTD-2354A18.1"]}},{"id":"7ebfc31d707e47078f6285140f43aca8","type":"GENE","name":"LINC02583","canonical_id":"hgnc:HGNC:53812","description":"long independently transcribed non-coding RNA 2583","metadata":null},{"id":"e1fd2afaa7d649c3b38b18925652de4c","type":"GENE","name":"LINC02584","canonical_id":"hgnc:HGNC:33275","description":"long independently transcribed non-coding RNA 2584","metadata":{"aliases":["C11orf78","NCRNA00224","ANO1-AS2"]}},{"id":"82b8f0b1bf8a4f3f92589d535cf0a025","type":"GENE","name":"LINC02585","canonical_id":"hgnc:HGNC:50302","description":"long independently transcribed non-coding RNA 2585","metadata":{"aliases":["CELSR3-AS1"]}},{"id":"fa4801a0f2fb46bc982a7dacee7c211f","type":"GENE","name":"LINC02587","canonical_id":"hgnc:HGNC:50672","description":"long independently transcribed non-coding RNA 2587","metadata":{"aliases":["MEOX2-AS1"]}},{"id":"f99accb80f13480583ea7aa4b7c2e4c3","type":"GENE","name":"LINC02589","canonical_id":"hgnc:HGNC:53859","description":"long independently transcribed non-coding RNA 2589","metadata":null},{"id":"7702456d8c5e48cf8bbb9e6b49545974","type":"GENE","name":"LINC02591","canonical_id":"hgnc:HGNC:53901","description":"long independently transcribed non-coding RNA 2591","metadata":null},{"id":"42d1d56ef9e1470eb9bfebfb5d79fac9","type":"GENE","name":"LINC02593","canonical_id":"hgnc:HGNC:53933","description":"long independently transcribed non-coding RNA 2593","metadata":{"aliases":["AL645608.1"]}},{"id":"9cce946e313b4cb3892a1bc6f012ec29","type":"GENE","name":"LINC02594","canonical_id":"hgnc:HGNC:53935","description":"long independently transcribed non-coding RNA 2594","metadata":null},{"id":"f7281c62b8264d959aa7b13d99ce5b2a","type":"GENE","name":"LINC02596","canonical_id":"hgnc:HGNC:53948","description":"long independently transcribed non-coding RNA 2596","metadata":{"aliases":["LOC105376834"]}},{"id":"48157bed86e64187a7fa9698c1955994","type":"GENE","name":"LINC02597","canonical_id":"hgnc:HGNC:53950","description":"long independently transcribed non-coding RNA 2597","metadata":{"aliases":["LOC101929866"]}},{"id":"a417ecb2c2504f80bcacdf08d7a090d4","type":"GENE","name":"LINC02598","canonical_id":"hgnc:HGNC:53954","description":"long independently transcribed non-coding RNA 2598","metadata":{"aliases":["RP11","277P12.9"]}},{"id":"c4c6e3cefba1437fb14057b354255188","type":"GENE","name":"LINC02599","canonical_id":"hgnc:HGNC:53931","description":"long independently transcribed non-coding RNA 2599","metadata":{"aliases":["AC026904.1"]}},{"id":"a7c15ef19f02490a8a77c753cd844dfc","type":"GENE","name":"LINC02600","canonical_id":"hgnc:HGNC:53177","description":"long independently transcribed non-coding RNA 2600","metadata":{"aliases":["AC141928.1"]}},{"id":"3a7fc3433e9c40fa8036d1dd5b4b98f6","type":"GENE","name":"LINC02601","canonical_id":"hgnc:HGNC:53966","description":"long independently transcribed non-coding RNA 2601","metadata":null},{"id":"3bbda87ffd4445bf8efd2568cd0d51dc","type":"GENE","name":"LINC02602","canonical_id":"hgnc:HGNC:53968","description":"long independently transcribed non-coding RNA 2602","metadata":{"aliases":["TCONS_00001798"]}},{"id":"dc723f2ccc4442d18c6dfd25c01c1d94","type":"GENE","name":"LINC02603","canonical_id":"hgnc:HGNC:37186","description":"long independently transcribed non-coding RNA 2603","metadata":{"aliases":["MIRLET7DHG"]}},{"id":"4707b96ef4ec41a7b75b24e73df49a14","type":"GENE","name":"LINC02604","canonical_id":"hgnc:HGNC:53972","description":"long independently transcribed non-coding RNA 2604","metadata":{"aliases":["lncHERG"]}},{"id":"d6f4cc3c2dcc4a1eb520b7eac22000bc","type":"GENE","name":"LINC02605","canonical_id":"hgnc:HGNC:53974","description":"long independently transcribed non-coding RNA 2605","metadata":{"aliases":["RP11-79H23.3","IL-7-AS","AC083837.1"]}},{"id":"00a78cb1c7084d02af73212ac3259909","type":"GENE","name":"LINC02606","canonical_id":"hgnc:HGNC:54047","description":"long independently transcribed non-coding RNA 2606","metadata":null},{"id":"bcd8f102960d4d6bbb7efe5f35df226e","type":"GENE","name":"LINC02607","canonical_id":"hgnc:HGNC:54049","description":"long independently transcribed non-coding RNA 2607","metadata":null},{"id":"be281a9754034805b2393b15baa18afb","type":"GENE","name":"LINC02608","canonical_id":"hgnc:HGNC:54052","description":"long independently transcribed non-coding RNA 2608","metadata":null},{"id":"3163634ab5104a19b653425250fc9e37","type":"GENE","name":"LINC02609","canonical_id":"hgnc:HGNC:27140","description":"long independently transcribed non-coding RNA 2609","metadata":null},{"id":"99ac5a35c92040dd8093c5e1a9e5eb40","type":"GENE","name":"LINC02610","canonical_id":"hgnc:HGNC:27177","description":"long independently transcribed non-coding RNA 2610","metadata":null},{"id":"fc6d0d860efa46c4ae6961163d235d00","type":"GENE","name":"LINC02611","canonical_id":"hgnc:HGNC:54060","description":"long independently transcribed non-coding RNA 2611","metadata":null},{"id":"25289d14a4f24fafb8f2d0156cdc3568","type":"GENE","name":"LINC02612","canonical_id":"hgnc:HGNC:54067","description":"long independently transcribed non-coding RNA 2612","metadata":null},{"id":"34f53066ba5641ef9ca1d8cc2d5582ca","type":"GENE","name":"LINC02613","canonical_id":"hgnc:HGNC:54068","description":"long independently transcribed non-coding RNA 2613","metadata":null},{"id":"d281799eb40e444390845e72fdc217ef","type":"GENE","name":"LINC02614","canonical_id":"hgnc:HGNC:54072","description":"long independently transcribed non-coding RNA 2614","metadata":null},{"id":"9a8f4c0386714e03a19d2c144617f395","type":"GENE","name":"LINC02615","canonical_id":"hgnc:HGNC:53402","description":"long independently transcribed non-coding RNA 2615","metadata":null},{"id":"912bc5553f8049bcab74d6ff77ee667a","type":"GENE","name":"LINC02616","canonical_id":"hgnc:HGNC:54078","description":"long independently transcribed non-coding RNA 2616","metadata":null},{"id":"195d3b60628b4da1a81eda2e7ce19759","type":"GENE","name":"LINC02617","canonical_id":"hgnc:HGNC:54089","description":"long independently transcribed non-coding RNA 2617","metadata":{"aliases":["ENST00000539009"]}},{"id":"ee6d0e041cfe49ad8c0da5585e098ae6","type":"GENE","name":"LINC02619","canonical_id":"hgnc:HGNC:54094","description":"long independently transcribed non-coding RNA 2619","metadata":null},{"id":"12a24b37195b47fb942081b7b3ed1730","type":"GENE","name":"LINC02620","canonical_id":"hgnc:HGNC:54097","description":"long independently transcribed non-coding RNA 2620","metadata":{"aliases":["BCRT1"]}},{"id":"183f0f2908d14a559664a2723fe00115","type":"GENE","name":"LINC02621","canonical_id":"hgnc:HGNC:54098","description":"long independently transcribed non-coding RNA 2621","metadata":null},{"id":"0c7a45253c1e48a7a0b6ac2f6d00f530","type":"GENE","name":"LINC02622","canonical_id":"hgnc:HGNC:54099","description":"long independently transcribed non-coding RNA 2622","metadata":null},{"id":"32d993a5947c43bf9fc8b2ffadb8b362","type":"GENE","name":"LINC02623","canonical_id":"hgnc:HGNC:54101","description":"long independently transcribed non-coding RNA 2623","metadata":null},{"id":"c92e1dbb282b46139830a5189835b1c1","type":"GENE","name":"LINC02624","canonical_id":"hgnc:HGNC:54103","description":"long independently transcribed non-coding RNA 2624","metadata":null},{"id":"8b7a1352103e43169ade240e5479fd3b","type":"GENE","name":"LINC02625","canonical_id":"hgnc:HGNC:54104","description":"long independently transcribed non-coding RNA 2625","metadata":null},{"id":"2f469e4f07e64b60aee81dcd42f8dfa6","type":"GENE","name":"LINC02626","canonical_id":"hgnc:HGNC:54105","description":"long independently transcribed non-coding RNA 2626","metadata":null},{"id":"73711970c636490cb16b2c5b6f0cbadc","type":"GENE","name":"LINC02627","canonical_id":"hgnc:HGNC:54106","description":"long independently transcribed non-coding RNA 2627","metadata":null},{"id":"f0d719de06ed4004b5aeeeadc92a1638","type":"GENE","name":"LINC02628","canonical_id":"hgnc:HGNC:54107","description":"long independently transcribed non-coding RNA 2628","metadata":null},{"id":"242cf4d175ff430ea46c5dd37f8c3219","type":"GENE","name":"LINC02629","canonical_id":"hgnc:HGNC:54108","description":"long independently transcribed non-coding RNA 2629","metadata":{"aliases":["TCONS_00017811"]}},{"id":"8846da50bd954ed89b092be7c478e3ff","type":"GENE","name":"LINC02630","canonical_id":"hgnc:HGNC:54110","description":"long independently transcribed non-coding RNA 2630","metadata":null},{"id":"eabc7a348c3547a3a1bb1c8b8a711dd6","type":"GENE","name":"LINC02631","canonical_id":"hgnc:HGNC:54112","description":"long independently transcribed non-coding RNA 2631","metadata":{"aliases":["AC092620.3"]}},{"id":"a4053ea28e394a0d8d46bf3e9a66c7bd","type":"GENE","name":"LINC02632","canonical_id":"hgnc:HGNC:54114","description":"long independently transcribed non-coding RNA 2632","metadata":null},{"id":"7e7ccfbd3e3e4f67a2d1da3241e715cf","type":"GENE","name":"LINC02633","canonical_id":"hgnc:HGNC:54116","description":"long independently transcribed non-coding RNA 2633","metadata":{"aliases":["TCONS_00018174","XLOC_008466"]}},{"id":"435edfda268b41389da11aa6c8371b6b","type":"GENE","name":"LINC02635","canonical_id":"hgnc:HGNC:54118","description":"long independently transcribed non-coding RNA 2635","metadata":null},{"id":"7a22f00303ec4418a51c422dd84afdff","type":"GENE","name":"LINC02636","canonical_id":"hgnc:HGNC:54119","description":"long independently transcribed non-coding RNA 2636","metadata":null},{"id":"4e98a3083f014500a50bcde11a3b5525","type":"GENE","name":"LINC02637","canonical_id":"hgnc:HGNC:54120","description":"long independently transcribed non-coding RNA 2637","metadata":null},{"id":"27a781b4c1d8439a9c8ba197f04582c8","type":"GENE","name":"LINC02639","canonical_id":"hgnc:HGNC:54122","description":"long independently transcribed non-coding RNA 2639","metadata":null},{"id":"6306daf22cda4989a67e8e2906999848","type":"GENE","name":"LINC02640","canonical_id":"hgnc:HGNC:54123","description":"long independently transcribed non-coding RNA 2640","metadata":null},{"id":"441f716eeace43268fed98d4af81eac5","type":"GENE","name":"LINC02641","canonical_id":"hgnc:HGNC:54125","description":"long independently transcribed non-coding RNA 2641","metadata":null},{"id":"21e5fdbcc484473d908efc205be3a18d","type":"GENE","name":"LINC02642","canonical_id":"hgnc:HGNC:54124","description":"long independently transcribed non-coding RNA 2642","metadata":null},{"id":"4cf0643426e340fa83ab3fc14d176235","type":"GENE","name":"LINC02643","canonical_id":"hgnc:HGNC:54126","description":"long independently transcribed non-coding RNA 2643","metadata":null},{"id":"97f137a4101644c38636a418fd5bd30b","type":"GENE","name":"LINC02644","canonical_id":"hgnc:HGNC:54127","description":"long independently transcribed non-coding RNA 2644","metadata":null},{"id":"87925ef8637849f1b9bb2cc83a48b83a","type":"GENE","name":"LINC02645","canonical_id":"hgnc:HGNC:54129","description":"long independently transcribed non-coding RNA 2645","metadata":null},{"id":"e95c3c17b32a475fa6e2dcbb39f5a4d5","type":"GENE","name":"LINC02646","canonical_id":"hgnc:HGNC:54130","description":"long independently transcribed non-coding RNA 2646","metadata":null},{"id":"fb8ad856444d47109de89892e70efa7f","type":"GENE","name":"LINC02647","canonical_id":"hgnc:HGNC:54131","description":"long independently transcribed non-coding RNA 2647","metadata":null},{"id":"5ec24eee0458488fbc668151a05994fb","type":"GENE","name":"LINC02648","canonical_id":"hgnc:HGNC:54132","description":"long independently transcribed non-coding RNA 2648","metadata":null},{"id":"6bc46d25552e4064815eb7293ac10731","type":"GENE","name":"LINC02649","canonical_id":"hgnc:HGNC:54134","description":"long independently transcribed non-coding RNA 2649","metadata":null},{"id":"9c98c3e7bb574b53a117c85bb520d93b","type":"GENE","name":"LINC02650","canonical_id":"hgnc:HGNC:54135","description":"long independently transcribed non-coding RNA 2650","metadata":null},{"id":"ffabd9fdee134465bf6c73c9c97984af","type":"GENE","name":"LINC02651","canonical_id":"hgnc:HGNC:54136","description":"long independently transcribed non-coding RNA 2651","metadata":null},{"id":"11c7673f39e844d5ae28170f40cd49b5","type":"GENE","name":"LINC02652","canonical_id":"hgnc:HGNC:54137","description":"long independently transcribed non-coding RNA 2652","metadata":null},{"id":"cc0cde1660e04bc4bb99d887ab376736","type":"GENE","name":"LINC02653","canonical_id":"hgnc:HGNC:54138","description":"long independently transcribed non-coding RNA 2653","metadata":null},{"id":"f4b3e2901f9c4581aa47fd3c5dfe5510","type":"GENE","name":"LINC02654","canonical_id":"hgnc:HGNC:54140","description":"long independently transcribed non-coding RNA 2654","metadata":null},{"id":"a40bf0971c1f421993d8a5945792f5a0","type":"GENE","name":"LINC02655","canonical_id":"hgnc:HGNC:54141","description":"long independently transcribed non-coding RNA 2655","metadata":null},{"id":"517abc36a3bf4c27a0878889a2837329","type":"GENE","name":"LINC02656","canonical_id":"hgnc:HGNC:54142","description":"long independently transcribed non-coding RNA 2656","metadata":null},{"id":"c217a69844264cb0be08b668b3c2f7ea","type":"GENE","name":"LINC02658","canonical_id":"hgnc:HGNC:54144","description":"long independently transcribed non-coding RNA 2658","metadata":null},{"id":"8a87af7e4a174b4a90eebe530dcf1ac9","type":"GENE","name":"LINC02659","canonical_id":"hgnc:HGNC:54145","description":"long independently transcribed non-coding RNA 2659","metadata":null},{"id":"30f42df3592f472b914b10a1237c335d","type":"GENE","name":"LINC02660","canonical_id":"hgnc:HGNC:54146","description":"long independently transcribed non-coding RNA 2660","metadata":null},{"id":"0dd1d71db089468fb9580816368f5869","type":"GENE","name":"LINC02661","canonical_id":"hgnc:HGNC:54147","description":"long independently transcribed non-coding RNA 2661","metadata":null},{"id":"57bd6b3cadbb442fb6590ee76d5dac2f","type":"GENE","name":"LINC02662","canonical_id":"hgnc:HGNC:54148","description":"long independently transcribed non-coding RNA 2662","metadata":null},{"id":"6e76435f8c654bd7bb3bbe50499da63c","type":"GENE","name":"LINC02663","canonical_id":"hgnc:HGNC:54149","description":"long independently transcribed non-coding RNA 2663","metadata":null},{"id":"a9f3dd1c369b4454a9ab56d641a41af0","type":"GENE","name":"LINC02664","canonical_id":"hgnc:HGNC:54150","description":"long independently transcribed non-coding RNA 2664","metadata":null},{"id":"c3a61f7681594a258144d6172b03219d","type":"GENE","name":"LINC02665","canonical_id":"hgnc:HGNC:54151","description":"long independently transcribed non-coding RNA 2665","metadata":null},{"id":"2f07a415dc404497a36d804c6f765166","type":"GENE","name":"LINC02666","canonical_id":"hgnc:HGNC:54152","description":"long independently transcribed non-coding RNA 2666","metadata":null},{"id":"6c741da6845b4d13af5b46f6e878d0e0","type":"GENE","name":"LINC02667","canonical_id":"hgnc:HGNC:54153","description":"long independently transcribed non-coding RNA 2667","metadata":null},{"id":"1a00945ee89d4d6b90fa0c7e6b12a596","type":"GENE","name":"LINC02668","canonical_id":"hgnc:HGNC:54154","description":"long independently transcribed non-coding RNA 2668","metadata":null},{"id":"884f3d013b39402781baae60d7ec0b15","type":"GENE","name":"LINC02669","canonical_id":"hgnc:HGNC:54155","description":"long independently transcribed non-coding RNA 2669","metadata":null},{"id":"42b91a0e353c461089450c9ff9682972","type":"GENE","name":"LINC02670","canonical_id":"hgnc:HGNC:54156","description":"long independently transcribed non-coding RNA 2670","metadata":null},{"id":"62d8aead216d4220a15b6fa127bd3347","type":"GENE","name":"LINC02671","canonical_id":"hgnc:HGNC:54158","description":"long independently transcribed non-coding RNA 2671","metadata":null},{"id":"c0e8853201664c77bf8f193f42ff14dd","type":"GENE","name":"LINC02672","canonical_id":"hgnc:HGNC:54159","description":"long independently transcribed non-coding RNA 2672","metadata":{"aliases":["OIN1"]}},{"id":"095c1c57f8c64c0485928d7c51f0558a","type":"GENE","name":"LINC02673","canonical_id":"hgnc:HGNC:54167","description":"long independently transcribed non-coding RNA 2673","metadata":null},{"id":"7598d9c758a445c8a4df2e5725d48612","type":"GENE","name":"LINC02674","canonical_id":"hgnc:HGNC:54168","description":"long independently transcribed non-coding RNA 2674","metadata":null},{"id":"79189dd4dd72475e940f43f8825de967","type":"GENE","name":"LINC02675","canonical_id":"hgnc:HGNC:54169","description":"long independently transcribed non-coding RNA 2675","metadata":null},{"id":"d2467c0e2a1948aa919b07e0466c217d","type":"GENE","name":"LINC02676","canonical_id":"hgnc:HGNC:54170","description":"long independently transcribed non-coding RNA 2676","metadata":null},{"id":"bbd49b581d0f412fa8bc7033bbad8371","type":"GENE","name":"LINC02677","canonical_id":"hgnc:HGNC:54171","description":"long independently transcribed non-coding RNA 2677","metadata":null},{"id":"40d4655b632447d0b438a8b586d0d3d5","type":"GENE","name":"LINC02678","canonical_id":"hgnc:HGNC:54172","description":"long independently transcribed non-coding RNA 2678","metadata":null},{"id":"efc98e6da85c47e788839d5d39b735fd","type":"GENE","name":"LINC02679","canonical_id":"hgnc:HGNC:54173","description":"long independently transcribed non-coding RNA 2679","metadata":null},{"id":"aeeb113ab31a42fea93c61e1a22f2066","type":"GENE","name":"LINC02680","canonical_id":"hgnc:HGNC:54174","description":"long independently transcribed non-coding RNA 2680","metadata":null},{"id":"d5591ea8298041c98e82fd7b6cb77c66","type":"GENE","name":"LINC02681","canonical_id":"hgnc:HGNC:54175","description":"long independently transcribed non-coding RNA 2681","metadata":{"aliases":["uc.303"]}},{"id":"6bdcd654f5564909a8e67be22bb89b0a","type":"GENE","name":"LINC02682","canonical_id":"hgnc:HGNC:54177","description":"long independently transcribed non-coding RNA 2682","metadata":{"aliases":["TCONS_00019584","lnc-SOX6-1"]}},{"id":"ed684f287dca49debb65e8026728a1e3","type":"GENE","name":"LINC02683","canonical_id":"hgnc:HGNC:54179","description":"long independently transcribed non-coding RNA 2683","metadata":null},{"id":"8c8382d9479a432382afc4c8396bad78","type":"GENE","name":"LINC02684","canonical_id":"hgnc:HGNC:54180","description":"long independently transcribed non-coding RNA 2684","metadata":null},{"id":"34d0a885107e49daa97b8c1300cb9e68","type":"GENE","name":"LINC02685","canonical_id":"hgnc:HGNC:27350","description":"long independently transcribed non-coding RNA 2685","metadata":null},{"id":"f4f01f11f89a4d7983a802c5529e76a7","type":"GENE","name":"LINC02686","canonical_id":"hgnc:HGNC:54186","description":"long independently transcribed non-coding RNA 2686","metadata":null},{"id":"7ced47fb66da412ea698985a572ebe29","type":"GENE","name":"LINC02687","canonical_id":"hgnc:HGNC:54187","description":"long independently transcribed non-coding RNA 2687","metadata":{"aliases":["LINC02696"]}},{"id":"313ec83f918745b0a377687e3b3b817d","type":"GENE","name":"LINC02688","canonical_id":"hgnc:HGNC:54184","description":"long independently transcribed non-coding RNA 2688","metadata":null},{"id":"8a2f3ff9bca9475ab86eb441d716ecf4","type":"GENE","name":"LINC02689","canonical_id":"hgnc:HGNC:54192","description":"long independently transcribed non-coding RNA 2689","metadata":null},{"id":"56d19e5bf26e4fe3966b1bc2361689a1","type":"GENE","name":"LINC02690","canonical_id":"hgnc:HGNC:54194","description":"long independently transcribed non-coding RNA 2690","metadata":null},{"id":"49f2d11aae08472e8463fb150f46d2ee","type":"GENE","name":"LINC02691","canonical_id":"hgnc:HGNC:20358","description":"long independently transcribed non-coding RNA 2691","metadata":{"aliases":["C14orf144"]}},{"id":"40e6ff9e639a43fe861161bfda9a3942","type":"GENE","name":"LINC02692","canonical_id":"hgnc:HGNC:18147","description":"long independently transcribed non-coding RNA 2692","metadata":{"aliases":["C9orf141","PRR31"]}},{"id":"d3ed798ce9a74872931814847c39133d","type":"GENE","name":"LINC02693","canonical_id":"hgnc:HGNC:27904","description":"long independently transcribed non-coding RNA 2693","metadata":{"aliases":["FLJ12977","FLJ31874","FLJ33618","C17orf51"]}},{"id":"9821815e7a3145f8bd3265f9b91181ef","type":"GENE","name":"LINC02694","canonical_id":"hgnc:HGNC:33796","description":"long independently transcribed non-coding RNA 2694","metadata":{"aliases":["FLJ35695","C15orf53"]}},{"id":"1a5bf55cd2ab40c483bdac8d68a3b1a0","type":"GENE","name":"LINC02695","canonical_id":"hgnc:HGNC:54209","description":"long independently transcribed non-coding RNA 2695","metadata":null},{"id":"a4eeeef55d5f4670a862d0822f4f514b","type":"GENE","name":"LINC02697","canonical_id":"hgnc:HGNC:54211","description":"long independently transcribed non-coding RNA 2697","metadata":null},{"id":"708d9a42e49e4ed8ae26fa5946b5a730","type":"GENE","name":"LINC02698","canonical_id":"hgnc:HGNC:54212","description":"long independently transcribed non-coding RNA 2698","metadata":null},{"id":"4d4d9f68ebce4f4dbf4c44a21f7a3b02","type":"GENE","name":"LINC02699","canonical_id":"hgnc:HGNC:54213","description":"long independently transcribed non-coding RNA 2699","metadata":null},{"id":"1088df41dbe34b22bc4c45565835e156","type":"GENE","name":"LINC02700","canonical_id":"hgnc:HGNC:54214","description":"long independently transcribed non-coding RNA 2700","metadata":null},{"id":"47ec3468d0134810bdac650bd8d8054a","type":"GENE","name":"LINC02701","canonical_id":"hgnc:HGNC:54216","description":"long independently transcribed non-coding RNA 2701","metadata":null},{"id":"b873c14f73ac41eabf677689be443e7b","type":"GENE","name":"LINC02702","canonical_id":"hgnc:HGNC:54217","description":"long independently transcribed non-coding RNA 2702","metadata":{"aliases":["LASER"]}},{"id":"a429d782ebbe4795b2706407c134de9b","type":"GENE","name":"LINC02703","canonical_id":"hgnc:HGNC:54218","description":"long independently transcribed non-coding RNA 2703","metadata":null},{"id":"9d59bfc6484f4380bdc58ce7a9446805","type":"GENE","name":"LINC02704","canonical_id":"hgnc:HGNC:54220","description":"long independently transcribed non-coding RNA 2704","metadata":null},{"id":"7390e0670df64a82b410cf238697031a","type":"GENE","name":"LINC02705","canonical_id":"hgnc:HGNC:54222","description":"long independently transcribed non-coding RNA 2705","metadata":null},{"id":"792be74018bc4c7e9c04c37f65b6cb1c","type":"GENE","name":"LINC02706","canonical_id":"hgnc:HGNC:54223","description":"long independently transcribed non-coding RNA 2706","metadata":null},{"id":"8096ce0dd023426cb6abb0dfbca43284","type":"GENE","name":"LINC02707","canonical_id":"hgnc:HGNC:54224","description":"long independently transcribed non-coding RNA 2707","metadata":null},{"id":"14bad1beb51641fba78fc2e7c624294a","type":"GENE","name":"LINC02708","canonical_id":"hgnc:HGNC:54225","description":"long independently transcribed non-coding RNA 2708","metadata":null},{"id":"fa49c515975a42a1b97b514feed90b75","type":"GENE","name":"LINC02709","canonical_id":"hgnc:HGNC:54226","description":"long independently transcribed non-coding RNA 2709","metadata":null},{"id":"16e494d0fca14bbea8d3f0a138c44209","type":"GENE","name":"LINC02710","canonical_id":"hgnc:HGNC:54227","description":"long independently transcribed non-coding RNA 2710","metadata":null},{"id":"cffccb0888b343ea9e104e97e901e92d","type":"GENE","name":"LINC02711","canonical_id":"hgnc:HGNC:54228","description":"long independently transcribed non-coding RNA 2711","metadata":null},{"id":"1dbc73adc8fa4b818ac96074845c3505","type":"GENE","name":"LINC02712","canonical_id":"hgnc:HGNC:54229","description":"long independently transcribed non-coding RNA 2712","metadata":null},{"id":"5d2c42f9a67144e587062d0b94c63134","type":"GENE","name":"LINC02713","canonical_id":"hgnc:HGNC:54230","description":"long independently transcribed non-coding RNA 2713","metadata":null},{"id":"a0d4761a9ff14227ab1bce4a58d18888","type":"GENE","name":"LINC02714","canonical_id":"hgnc:HGNC:54231","description":"long independently transcribed non-coding RNA 2714","metadata":null},{"id":"d76a2b84562b4d4aae1df6f3298c12f9","type":"GENE","name":"LINC02715","canonical_id":"hgnc:HGNC:54232","description":"long independently transcribed non-coding RNA 2715","metadata":null},{"id":"befd94cb9fca4272bf63d324d319d9af","type":"GENE","name":"LINC02716","canonical_id":"hgnc:HGNC:25454","description":"long independently transcribed non-coding RNA 2716","metadata":null},{"id":"cb0b99842e5f46eda499847202095c14","type":"GENE","name":"LINC02717","canonical_id":"hgnc:HGNC:54234","description":"long independently transcribed non-coding RNA 2717","metadata":null},{"id":"8057571efae0450f986a6c13a3a7590e","type":"GENE","name":"LINC02718","canonical_id":"hgnc:HGNC:54235","description":"long independently transcribed non-coding RNA 2718","metadata":null},{"id":"7da50ce2aec343d7926c625bfcd9264b","type":"GENE","name":"LINC02719","canonical_id":"hgnc:HGNC:54236","description":"long independently transcribed non-coding RNA 2719","metadata":null},{"id":"29d6a445bfcb4ba7bf1eda3c0644f290","type":"GENE","name":"LINC02720","canonical_id":"hgnc:HGNC:54237","description":"long independently transcribed non-coding RNA 2720","metadata":null},{"id":"ff6ff84ba3e541d3b9f75a661f59ab13","type":"GENE","name":"LINC02721","canonical_id":"hgnc:HGNC:54238","description":"long independently transcribed non-coding RNA 2721","metadata":null},{"id":"8fd3defd207240ab88fcd454d958ec91","type":"GENE","name":"LINC02722","canonical_id":"hgnc:HGNC:54239","description":"long independently transcribed non-coding RNA 2722","metadata":null},{"id":"a8fff9baef25471a986e81491e203be0","type":"GENE","name":"LINC02723","canonical_id":"hgnc:HGNC:54240","description":"long independently transcribed non-coding RNA 2723","metadata":null},{"id":"d65aa37c1b3e49048b7fe92e17537b96","type":"GENE","name":"LINC02724","canonical_id":"hgnc:HGNC:54241","description":"long independently transcribed non-coding RNA 2724","metadata":null},{"id":"22ea0f6806eb43618e32be904a682139","type":"GENE","name":"LINC02725","canonical_id":"hgnc:HGNC:54242","description":"long independently transcribed non-coding RNA 2725","metadata":null},{"id":"6e25d346bc674ea0afd445804596d95b","type":"GENE","name":"LINC02726","canonical_id":"hgnc:HGNC:54243","description":"long independently transcribed non-coding RNA 2726","metadata":null},{"id":"d40dfc48f4b040cfba387450035874e2","type":"GENE","name":"LINC02727","canonical_id":"hgnc:HGNC:54244","description":"long independently transcribed non-coding RNA 2727","metadata":null},{"id":"a5bbd1ba6d2a496ab0cfa4b665320d85","type":"GENE","name":"LINC02728","canonical_id":"hgnc:HGNC:54245","description":"long independently transcribed non-coding RNA 2728","metadata":null},{"id":"f3614f52f4484d1bb2139bbf5b99a843","type":"GENE","name":"LINC02729","canonical_id":"hgnc:HGNC:54246","description":"long independently transcribed non-coding RNA 2729","metadata":null},{"id":"ddc56887765c4b33a6918f9418553ec5","type":"GENE","name":"LINC02730","canonical_id":"hgnc:HGNC:54247","description":"long independently transcribed non-coding RNA 2730","metadata":null},{"id":"bc449a157cc84440909f68c4af6c99d0","type":"GENE","name":"LINC02731","canonical_id":"hgnc:HGNC:54248","description":"long independently transcribed non-coding RNA 2731","metadata":null},{"id":"98f96d922cbc43abb8964b25571cf235","type":"GENE","name":"LINC02732","canonical_id":"hgnc:HGNC:54249","description":"long independently transcribed non-coding RNA 2732","metadata":null},{"id":"80f050d06b824cf7a3db3d30b26be5aa","type":"GENE","name":"LINC02733","canonical_id":"hgnc:HGNC:54250","description":"long independently transcribed non-coding RNA 2733","metadata":null},{"id":"eaa96a8d3cff464eb208bb9a7df6d000","type":"GENE","name":"LINC02734","canonical_id":"hgnc:HGNC:54251","description":"long independently transcribed non-coding RNA 2734","metadata":null},{"id":"4611a5432e59489aab7658147d85ecfc","type":"GENE","name":"LINC02735","canonical_id":"hgnc:HGNC:54252","description":"long independently transcribed non-coding RNA 2735","metadata":null},{"id":"1df666f9e7354505887386273e5efed7","type":"GENE","name":"LINC02736","canonical_id":"hgnc:HGNC:54253","description":"long independently transcribed non-coding RNA 2736","metadata":null},{"id":"1a07a7f837aa489b918a39ab7f73169f","type":"GENE","name":"LINC02737","canonical_id":"hgnc:HGNC:54254","description":"long independently transcribed non-coding RNA 2737","metadata":null},{"id":"dbf8fac896564e30a3d9c4bb55a76501","type":"GENE","name":"LINC02739","canonical_id":"hgnc:HGNC:54256","description":"long independently transcribed non-coding RNA 2739","metadata":null},{"id":"8d79333f4a6143fbba952fac4f2d34de","type":"GENE","name":"LINC02740","canonical_id":"hgnc:HGNC:54257","description":"long independently transcribed non-coding RNA 2740","metadata":null},{"id":"d7662dbabe2a4584a07734dd84feea70","type":"GENE","name":"LINC02741","canonical_id":"hgnc:HGNC:54258","description":"long independently transcribed non-coding RNA 2741","metadata":null},{"id":"54e633e43bfb417496503116a5746257","type":"GENE","name":"LINC02742","canonical_id":"hgnc:HGNC:54259","description":"long independently transcribed non-coding RNA 2742","metadata":null},{"id":"5cc1e225a4b042be82dee9dc7af6b8e6","type":"GENE","name":"LINC02743","canonical_id":"hgnc:HGNC:54261","description":"long independently transcribed non-coding RNA 2743","metadata":null},{"id":"f5d9d2ae67454cc9ac6ad5644b53e85a","type":"GENE","name":"LINC02744","canonical_id":"hgnc:HGNC:54262","description":"long independently transcribed non-coding RNA 2744","metadata":null},{"id":"44bd0b631ac8431bac592bfe26264b6b","type":"GENE","name":"LINC02745","canonical_id":"hgnc:HGNC:54263","description":"long independently transcribed non-coding RNA 2745","metadata":null},{"id":"90a00c343973464aaa3ded9aab492c61","type":"GENE","name":"LINC02746","canonical_id":"hgnc:HGNC:54264","description":"long independently transcribed non-coding RNA 2746","metadata":null},{"id":"9eb8672647fb464ebbe77546205d8a35","type":"GENE","name":"LINC02747","canonical_id":"hgnc:HGNC:54266","description":"long independently transcribed non-coding RNA 2747","metadata":{"aliases":["AP000439.3","CUPID2","AP000439.2"]}},{"id":"12dfca41b78e4530ac7ae33610275c9b","type":"GENE","name":"LINC02748","canonical_id":"hgnc:HGNC:54267","description":"long independently transcribed non-coding RNA 2748","metadata":null},{"id":"13f85357e52342448feddc2d0e6ee57e","type":"GENE","name":"LINC02749","canonical_id":"hgnc:HGNC:54268","description":"long independently transcribed non-coding RNA 2749","metadata":null},{"id":"8fd9420c41944e2ebb212b79b6e687ed","type":"GENE","name":"LINC02750","canonical_id":"hgnc:HGNC:54269","description":"long independently transcribed non-coding RNA 2750","metadata":null},{"id":"9d225d1c3e7e4148a49956ff19272feb","type":"GENE","name":"LINC02751","canonical_id":"hgnc:HGNC:54271","description":"long independently transcribed non-coding RNA 2751","metadata":{"aliases":["uc.321"]}},{"id":"6a301f96d1a842a49b8afa3d4fd122df","type":"GENE","name":"LINC02752","canonical_id":"hgnc:HGNC:54272","description":"long independently transcribed non-coding RNA 2752","metadata":null},{"id":"80159700efcc4f35bc493e26c2d14432","type":"GENE","name":"LINC02753","canonical_id":"hgnc:HGNC:54273","description":"long independently transcribed non-coding RNA 2753","metadata":{"aliases":["AP003555.1","onclncRNA-626"]}},{"id":"1e47229286864c888383cd65cfc399e3","type":"GENE","name":"LINC02754","canonical_id":"hgnc:HGNC:54274","description":"long independently transcribed non-coding RNA 2754","metadata":null},{"id":"085995af3abd4049990263c2d017293d","type":"GENE","name":"LINC02755","canonical_id":"hgnc:HGNC:54275","description":"long independently transcribed non-coding RNA 2755","metadata":null},{"id":"f127a200725f4ad49dfe4b066511f9f6","type":"GENE","name":"LINC02756","canonical_id":"hgnc:HGNC:54276","description":"long independently transcribed non-coding RNA 2756","metadata":null},{"id":"9616a3303c564674a994b69aa39044e4","type":"GENE","name":"LINC02757","canonical_id":"hgnc:HGNC:54277","description":"long independently transcribed non-coding RNA 2757","metadata":null},{"id":"2801b1e25672429187caa52bfbd996b4","type":"GENE","name":"LINC02758","canonical_id":"hgnc:HGNC:54278","description":"long independently transcribed non-coding RNA 2758","metadata":null},{"id":"cd3c89a8d80946cab7a4b7fe432142ce","type":"GENE","name":"LINC02759","canonical_id":"hgnc:HGNC:54279","description":"long independently transcribed non-coding RNA 2759","metadata":null},{"id":"5cebdff69d87496f9c55cc90f5bb6bc6","type":"GENE","name":"LINC02760","canonical_id":"hgnc:HGNC:54280","description":"long independently transcribed non-coding RNA 2760","metadata":null},{"id":"a051b499ab7241b18e0f3c22124d7682","type":"GENE","name":"LINC02761","canonical_id":"hgnc:HGNC:54281","description":"long independently transcribed non-coding RNA 2761","metadata":null},{"id":"883cf81e08874b53907ef158537bfee2","type":"GENE","name":"LINC02762","canonical_id":"hgnc:HGNC:27443","description":"long independently transcribed non-coding RNA 2762","metadata":{"aliases":["lnc-PTS-1"]}},{"id":"600a2bc927ac4a2fbab3c371fd9c76e1","type":"GENE","name":"LINC02763","canonical_id":"hgnc:HGNC:54282","description":"long independently transcribed non-coding RNA 2763","metadata":{"aliases":["RP11-65M17.3"]}},{"id":"94ae7cac87e4488ea0efea1e3815e180","type":"GENE","name":"LINC02764","canonical_id":"hgnc:HGNC:54283","description":"long independently transcribed non-coding RNA 2764","metadata":null},{"id":"4d5ff279c2984aa99d4fd8dbf9e855a2","type":"GENE","name":"LINC02765","canonical_id":"hgnc:HGNC:54285","description":"long independently transcribed non-coding RNA 2765","metadata":null},{"id":"02c0e4ddea034af2bc44f982ee6a184d","type":"GENE","name":"LINC02766","canonical_id":"hgnc:HGNC:54286","description":"long independently transcribed non-coding RNA 2766","metadata":null},{"id":"b84e2d7552ed451aaded52ed3a73405b","type":"GENE","name":"LINC02767","canonical_id":"hgnc:HGNC:54287","description":"long independently transcribed non-coding RNA 2767","metadata":null},{"id":"876404894c5f43dda783198af9e46b9c","type":"GENE","name":"LINC02768","canonical_id":"hgnc:HGNC:54288","description":"long independently transcribed non-coding RNA 2768","metadata":{"aliases":["LINC03081"]}},{"id":"b334382863914fedae52cbf4ace25b33","type":"GENE","name":"LINC02769","canonical_id":"hgnc:HGNC:54289","description":"long independently transcribed non-coding RNA 2769","metadata":null},{"id":"ab1ba6229edd42018ef7e48dfebb4df5","type":"GENE","name":"LINC02770","canonical_id":"hgnc:HGNC:54290","description":"long independently transcribed non-coding RNA 2770","metadata":null},{"id":"c469ec2520424e90b84347e4a34afbcd","type":"GENE","name":"LINC02771","canonical_id":"hgnc:HGNC:54291","description":"long independently transcribed non-coding RNA 2771","metadata":null},{"id":"60a5107b8bc643b0bc6b85d59a03819d","type":"GENE","name":"LINC02772","canonical_id":"hgnc:HGNC:54292","description":"long independently transcribed non-coding RNA 2772","metadata":null},{"id":"15a42277583342fd81302ba28e4f651c","type":"GENE","name":"LINC02773","canonical_id":"hgnc:HGNC:54293","description":"long independently transcribed non-coding RNA 2773","metadata":null},{"id":"0d556280d92c412cad046d235f4784c6","type":"GENE","name":"LINC02774","canonical_id":"hgnc:HGNC:27923","description":"long independently transcribed non-coding RNA 2774","metadata":null},{"id":"3b20f6ceac2f476285aaa773ca3bc117","type":"GENE","name":"LINC02775","canonical_id":"hgnc:HGNC:54294","description":"long independently transcribed non-coding RNA 2775","metadata":null},{"id":"0acae0f7cb7244cdb9384887a7cbfb67","type":"GENE","name":"LINC02777","canonical_id":"hgnc:HGNC:54297","description":"long independently transcribed non-coding RNA 2777","metadata":null},{"id":"98423b8089014971bb0d1029e3daae09","type":"GENE","name":"LINC02778","canonical_id":"hgnc:HGNC:54298","description":"long independently transcribed non-coding RNA 2778","metadata":null},{"id":"17c83ee7bccb447790ab6f7b1152ee61","type":"GENE","name":"LINC02779","canonical_id":"hgnc:HGNC:54299","description":"long independently transcribed non-coding RNA 2779","metadata":null},{"id":"b0e938dc1d824886b76a0e66b8edafd8","type":"GENE","name":"LINC02780","canonical_id":"hgnc:HGNC:54300","description":"long independently transcribed non-coding RNA 2780","metadata":null},{"id":"8371d913f2134f87b6c6bf27d977e154","type":"GENE","name":"LINC02781","canonical_id":"hgnc:HGNC:54301","description":"long independently transcribed non-coding RNA 2781","metadata":null},{"id":"a424806e5a9f41ac98b0a124d8596bb4","type":"GENE","name":"LINC02782","canonical_id":"hgnc:HGNC:54302","description":"long independently transcribed non-coding RNA 2782","metadata":null},{"id":"00108db460f74de9b797e4dec168b0ae","type":"GENE","name":"LINC02783","canonical_id":"hgnc:HGNC:54303","description":"long independently transcribed non-coding RNA 2783","metadata":null},{"id":"f8e0b598af8543268786c658c7e9ac1c","type":"GENE","name":"LINC02784","canonical_id":"hgnc:HGNC:54304","description":"long independently transcribed non-coding RNA 2784","metadata":null},{"id":"b6c0b43f9a8d4ebb8ccb7527ccc416d3","type":"GENE","name":"LINC02786","canonical_id":"hgnc:HGNC:54307","description":"long independently transcribed non-coding RNA 2786","metadata":null},{"id":"95a1795117cc489bbf0c29d93f4537ae","type":"GENE","name":"LINC02787","canonical_id":"hgnc:HGNC:54308","description":"long independently transcribed non-coding RNA 2787","metadata":null},{"id":"19897820491c483580e28090efbaec61","type":"GENE","name":"LINC02788","canonical_id":"hgnc:HGNC:54309","description":"long independently transcribed non-coding RNA 2788","metadata":null},{"id":"b0e7631dd12f4e34bef29fb92548695e","type":"GENE","name":"LINC02789","canonical_id":"hgnc:HGNC:54310","description":"long independently transcribed non-coding RNA 2789","metadata":null},{"id":"eb0677479ca74445a84622cb0d82fe5b","type":"GENE","name":"LINC02790","canonical_id":"hgnc:HGNC:54313","description":"long independently transcribed non-coding RNA 2790","metadata":null},{"id":"aa12c5ce0ba6427ba479ff1585efe848","type":"GENE","name":"LINC02791","canonical_id":"hgnc:HGNC:54315","description":"long independently transcribed non-coding RNA 2791","metadata":null},{"id":"7aa6adf4481941faaa6c7f6540d10363","type":"GENE","name":"LINC02792","canonical_id":"hgnc:HGNC:54316","description":"long independently transcribed non-coding RNA 2792","metadata":null},{"id":"b8b612cf64884772a439342f463c59b4","type":"GENE","name":"LINC02793","canonical_id":"hgnc:HGNC:54317","description":"long independently transcribed non-coding RNA 2793","metadata":null},{"id":"849134ddc1684fb0a312d7b3a12beafc","type":"GENE","name":"LINC02794","canonical_id":"hgnc:HGNC:54318","description":"long independently transcribed non-coding RNA 2794","metadata":null},{"id":"97a0179ec8e44059ba4e49ddd7115edc","type":"GENE","name":"LINC02795","canonical_id":"hgnc:HGNC:54319","description":"long independently transcribed non-coding RNA 2795","metadata":null},{"id":"3fc30fc43f0844e09e256a94516d004d","type":"GENE","name":"LINC02796","canonical_id":"hgnc:HGNC:27918","description":"long independently transcribed non-coding RNA 2796","metadata":{"aliases":["LINC02797"]}},{"id":"1cf225b74dcc4a8c8a86e8f9901a0088","type":"GENE","name":"LINC02798","canonical_id":"hgnc:HGNC:54323","description":"long independently transcribed non-coding RNA 2798","metadata":null},{"id":"cd8e50e53cfd48bd92d4774cff8a60d5","type":"GENE","name":"LINC02799","canonical_id":"hgnc:HGNC:54324","description":"long independently transcribed non-coding RNA 2799","metadata":null},{"id":"837c13e01ef149feb48c8fbf999ada80","type":"GENE","name":"LINC02800","canonical_id":"hgnc:HGNC:27642","description":"long independently transcribed non-coding RNA 2800","metadata":null},{"id":"83107d9ae69d4689b01d9a7cb04f7d51","type":"GENE","name":"LINC02801","canonical_id":"hgnc:HGNC:54325","description":"long independently transcribed non-coding RNA 2801","metadata":null},{"id":"539e1f414af447c99763b1e44b8e21e3","type":"GENE","name":"LINC02802","canonical_id":"hgnc:HGNC:54326","description":"long independently transcribed non-coding RNA 2802","metadata":null},{"id":"0acd61df2b8b4890844523e7b327dd1b","type":"GENE","name":"LINC02803","canonical_id":"hgnc:HGNC:54328","description":"long independently transcribed non-coding RNA 2803","metadata":null},{"id":"c8655f6a63074ca7867eae8d43a69efd","type":"GENE","name":"LINC02805","canonical_id":"hgnc:HGNC:54339","description":"long independently transcribed non-coding RNA 2805","metadata":null},{"id":"d4945a84147549c49912bc3866d973ba","type":"GENE","name":"LINC02806","canonical_id":"hgnc:HGNC:27628","description":"long independently transcribed non-coding RNA 2806","metadata":null},{"id":"8fbd72ec20f54baabd508d24751760df","type":"GENE","name":"LINC02808","canonical_id":"hgnc:HGNC:54340","description":"long independently transcribed non-coding RNA 2808","metadata":null},{"id":"87a2fac0f3bb476ba979dd36472076e2","type":"GENE","name":"LINC02809","canonical_id":"hgnc:HGNC:54341","description":"long independently transcribed non-coding RNA 2809","metadata":null},{"id":"0d861c8eb3fd48488d6f345dbd3213fc","type":"GENE","name":"LINC02810","canonical_id":"hgnc:HGNC:54342","description":"long independently transcribed non-coding RNA 2810","metadata":null},{"id":"6a1094aac0ea4b6d80ad2b7b794b1ce4","type":"GENE","name":"LINC02811","canonical_id":"hgnc:HGNC:54343","description":"long independently transcribed non-coding RNA 2811","metadata":null},{"id":"7a45297e51ee4aee87912551e32c13af","type":"GENE","name":"LINC02812","canonical_id":"hgnc:HGNC:54344","description":"long independently transcribed non-coding RNA 2812","metadata":null},{"id":"49af84f6117348c989bee39ced7ac8ef","type":"GENE","name":"LINC02813","canonical_id":"hgnc:HGNC:54345","description":"long independently transcribed non-coding RNA 2813","metadata":null},{"id":"c1f685be9485498d879ea8b118520ec5","type":"GENE","name":"LINC02814","canonical_id":"hgnc:HGNC:54346","description":"long independently transcribed non-coding RNA 2814","metadata":{"aliases":["LINC02815"]}},{"id":"74baf6ee5fc14e888e9aef21a047b71d","type":"GENE","name":"LINC02816","canonical_id":"hgnc:HGNC:54348","description":"long independently transcribed non-coding RNA 2816","metadata":null},{"id":"e55b5ac884bc4b8aadc7856cccb6a234","type":"GENE","name":"LINC02817","canonical_id":"hgnc:HGNC:32042","description":"long independently transcribed non-coding RNA 2817","metadata":{"aliases":["FLJ46636","C1orf140"]}},{"id":"0831002b02024f4d8a881a7309a73515","type":"GENE","name":"LINC02818","canonical_id":"hgnc:HGNC:54349","description":"long independently transcribed non-coding RNA 2818","metadata":null},{"id":"e845fb5b64be4575bd978658fb331cc3","type":"GENE","name":"LINC02819","canonical_id":"hgnc:HGNC:54350","description":"long independently transcribed non-coding RNA 2819","metadata":null},{"id":"50f71eb7877441d8a88884ba0ac60559","type":"GENE","name":"LINC02820","canonical_id":"hgnc:HGNC:54351","description":"long independently transcribed non-coding RNA 2820","metadata":{"aliases":["lnc-ALX1-2"]}},{"id":"d6e1bc1a5a9544d6b9b433f1f4e6a5ac","type":"GENE","name":"LINC02821","canonical_id":"hgnc:HGNC:54352","description":"long independently transcribed non-coding RNA 2821","metadata":null},{"id":"8c72ce48ef4d4d44b36a0abf62e11758","type":"GENE","name":"LINC02822","canonical_id":"hgnc:HGNC:54353","description":"long independently transcribed non-coding RNA 2822","metadata":null},{"id":"9f55f298cdd84772a0ad73d6e07d3128","type":"GENE","name":"LINC02823","canonical_id":"hgnc:HGNC:54354","description":"long independently transcribed non-coding RNA 2823","metadata":null},{"id":"87db72e3b856472ebc41ce442f984cd7","type":"GENE","name":"LINC02824","canonical_id":"hgnc:HGNC:54356","description":"long independently transcribed non-coding RNA 2824","metadata":null},{"id":"b26c3796797e4e398a8a17cc3c192c57","type":"GENE","name":"LINC02825","canonical_id":"hgnc:HGNC:27477","description":"long independently transcribed non-coding RNA 2825","metadata":null},{"id":"c6d867f200f44eb5aa781d0a01336554","type":"GENE","name":"LINC02826","canonical_id":"hgnc:HGNC:54357","description":"long independently transcribed non-coding RNA 2826","metadata":null},{"id":"8ec0e5c7e33d4e6aa1d3445f13874df3","type":"GENE","name":"LINC02827","canonical_id":"hgnc:HGNC:54358","description":"long independently transcribed non-coding RNA 2827","metadata":null},{"id":"f80154b6720e4b2994c57a9abcaf4aa0","type":"GENE","name":"LINC02828","canonical_id":"hgnc:HGNC:54359","description":"long independently transcribed non-coding RNA 2828","metadata":null},{"id":"7f3d720e28314626a30c1110ba28892d","type":"GENE","name":"LINC02829","canonical_id":"hgnc:HGNC:54362","description":"long independently transcribed non-coding RNA 2829","metadata":null},{"id":"63ea34c26ac54be58cf5c063a0582a63","type":"GENE","name":"LINC02830","canonical_id":"hgnc:HGNC:54363","description":"long independently transcribed non-coding RNA 2830","metadata":null},{"id":"be9d99f9bc3d4fbb8bcc2f81400dd738","type":"GENE","name":"LINC02831","canonical_id":"hgnc:HGNC:54365","description":"long independently transcribed non-coding RNA 2831","metadata":null},{"id":"da19092cb6d9432f9ebfe087c60a598c","type":"GENE","name":"LINC02832","canonical_id":"hgnc:HGNC:54366","description":"long independently transcribed non-coding RNA 2832","metadata":null},{"id":"d561a8d53b96402cab51122acfad5685","type":"GENE","name":"LINC02833","canonical_id":"hgnc:HGNC:54367","description":"long independently transcribed non-coding RNA 2833","metadata":null},{"id":"b4e7eed82f0a47d28b4ca6c8e09fff16","type":"GENE","name":"LINC02834","canonical_id":"hgnc:HGNC:54368","description":"long independently transcribed non-coding RNA 2834","metadata":null},{"id":"d38ba5c741d6497587c5a5a3722fa6db","type":"GENE","name":"LINC02835","canonical_id":"hgnc:HGNC:54369","description":"long independently transcribed non-coding RNA 2835","metadata":{"aliases":["lncMER52A"]}},{"id":"a7c168678acd4952894d2c0e732e9e45","type":"GENE","name":"LINC02836","canonical_id":"hgnc:HGNC:54370","description":"long independently transcribed non-coding RNA 2836","metadata":null},{"id":"f0d8986db0824c00908f17a3ee16168b","type":"GENE","name":"LINC02837","canonical_id":"hgnc:HGNC:54371","description":"long independently transcribed non-coding RNA 2837","metadata":null},{"id":"5650d80bc76f4cdbaa527425163487df","type":"GENE","name":"LINC02838","canonical_id":"hgnc:HGNC:54372","description":"long independently transcribed non-coding RNA 2838","metadata":null},{"id":"5c6ab855150b44358a109cb9bfb628ac","type":"GENE","name":"LINC02839","canonical_id":"hgnc:HGNC:54373","description":"long independently transcribed non-coding RNA 2839","metadata":null},{"id":"29ff4c19a6be4cd1ba7521d03eef9ce0","type":"GENE","name":"LINC02840","canonical_id":"hgnc:HGNC:54374","description":"long independently transcribed non-coding RNA 2840","metadata":null},{"id":"9e61c53757024988be4c67f36a236b73","type":"GENE","name":"LINC02841","canonical_id":"hgnc:HGNC:54376","description":"long independently transcribed non-coding RNA 2841","metadata":null},{"id":"0a7eb3e16184400f850fc8d6930317f1","type":"GENE","name":"LINC02842","canonical_id":"hgnc:HGNC:54378","description":"long independently transcribed non-coding RNA 2842","metadata":{"aliases":["RP11-705O24.1","LINC02155"]}},{"id":"afdd781c456e41879df1355ba361eeef","type":"GENE","name":"LINC02843","canonical_id":"hgnc:HGNC:27847","description":"long independently transcribed non-coding RNA 2843","metadata":null},{"id":"c411a621df184bcebc1129d6a784b8b5","type":"GENE","name":"LINC02844","canonical_id":"hgnc:HGNC:54379","description":"long independently transcribed non-coding RNA 2844","metadata":null},{"id":"93430b47c4874e4cb426b9801c0b7a65","type":"GENE","name":"LINC02845","canonical_id":"hgnc:HGNC:54380","description":"long independently transcribed non-coding RNA 2845","metadata":null},{"id":"04bdf4f7594540b2b3b0085d1bde9936","type":"GENE","name":"LINC02846","canonical_id":"hgnc:HGNC:54381","description":"long independently transcribed non-coding RNA 2846","metadata":null},{"id":"6e91eb0162e9452aa0f4e6e28adcd916","type":"GENE","name":"LINC02847","canonical_id":"hgnc:HGNC:54383","description":"long independently transcribed non-coding RNA 2847","metadata":null},{"id":"2eef2de823d2489994cbed08f4ea21e1","type":"GENE","name":"LINC02848","canonical_id":"hgnc:HGNC:54384","description":"long independently transcribed non-coding RNA 2848","metadata":null},{"id":"c76fe09057d841adbfed11000cee8938","type":"GENE","name":"LINC02849","canonical_id":"hgnc:HGNC:54385","description":"long independently transcribed non-coding RNA 2849","metadata":null},{"id":"2e76e07317b243339417089d8b570031","type":"GENE","name":"LINC02850","canonical_id":"hgnc:HGNC:54386","description":"long independently transcribed non-coding RNA 2850","metadata":null},{"id":"d4646ebdf1ee4a21978e768c14ca93de","type":"GENE","name":"LINC02852","canonical_id":"hgnc:HGNC:54388","description":"long independently transcribed non-coding RNA 2852","metadata":null},{"id":"35755305e56d42db8c88e6ccf141845f","type":"GENE","name":"LINC02853","canonical_id":"hgnc:HGNC:54390","description":"long independently transcribed non-coding RNA 2853","metadata":null},{"id":"0f6d9984ea734efc9d4e9d3690eb6e95","type":"GENE","name":"LINC02854","canonical_id":"hgnc:HGNC:54391","description":"long independently transcribed non-coding RNA 2854","metadata":null},{"id":"7d27fb675982498c8ef7e2c8fe3417e2","type":"GENE","name":"LINC02855","canonical_id":"hgnc:HGNC:54392","description":"long independently transcribed non-coding RNA 2855","metadata":null},{"id":"b575cba766054fd5b777c6536a7acd79","type":"GENE","name":"LINC02856","canonical_id":"hgnc:HGNC:54393","description":"long independently transcribed non-coding RNA 2856","metadata":null},{"id":"15dccedb81db4c0480becdf8ae815b14","type":"GENE","name":"LINC02857","canonical_id":"hgnc:HGNC:54394","description":"long independently transcribed non-coding RNA 2857","metadata":null},{"id":"81bf1e34735f46c2add568758d57c396","type":"GENE","name":"LINC02858","canonical_id":"hgnc:HGNC:54395","description":"long independently transcribed non-coding RNA 2858","metadata":null},{"id":"78dfa35ad7e14cde80a70624a180f0ac","type":"GENE","name":"LINC02859","canonical_id":"hgnc:HGNC:54399","description":"long independently transcribed non-coding RNA 2859","metadata":{"aliases":["LncRNA-LOC101928316"]}},{"id":"27f43449443940b48af3f63be74c04d3","type":"GENE","name":"LINC02860","canonical_id":"hgnc:HGNC:22364","description":"long independently transcribed non-coding RNA 2860","metadata":{"aliases":["C7orf71"]}},{"id":"b0b2469670d44286b98642eaf12b1761","type":"GENE","name":"LINC02862","canonical_id":"hgnc:HGNC:54419","description":"long independently transcribed non-coding RNA 2862","metadata":{"aliases":["AC073284.4"]}},{"id":"a67ae2f0caf14818bb9ac0adf1639cec","type":"GENE","name":"LINC02863","canonical_id":"hgnc:HGNC:41290","description":"long independently transcribed non-coding RNA 2863","metadata":null},{"id":"d6d4b9be9ee349e99b7d1414dd59f8f9","type":"GENE","name":"LINC02864","canonical_id":"hgnc:HGNC:54480","description":"long independently transcribed non-coding RNA 2864","metadata":{"aliases":["RP11-169F17.1"]}},{"id":"402036c232a14b648b31379869017641","type":"GENE","name":"LINC02865","canonical_id":"hgnc:HGNC:54516","description":"long independently transcribed non-coding RNA 2865","metadata":null},{"id":"968bd3e4e03341308a09210a4d0d2527","type":"GENE","name":"LINC02866","canonical_id":"hgnc:HGNC:54518","description":"long independently transcribed non-coding RNA 2866","metadata":{"aliases":["RP11-359E19.2"]}},{"id":"f9832342b67041ed80b85f999a970175","type":"GENE","name":"LINC02868","canonical_id":"hgnc:HGNC:32040","description":"long independently transcribed non-coding RNA 2868","metadata":{"aliases":["C1orf137"]}},{"id":"08952889a6db4b61a88f3e66796e6fe4","type":"GENE","name":"LINC02869","canonical_id":"hgnc:HGNC:32045","description":"long independently transcribed non-coding RNA 2869","metadata":{"aliases":["C1orf143"]}},{"id":"693a69d591c44359bb8ca9d4e220649c","type":"GENE","name":"LINC02870","canonical_id":"hgnc:HGNC:27275","description":"long independently transcribed non-coding RNA 2870","metadata":{"aliases":["bA432J24.4","C10orf91"]}},{"id":"286fbae195aa4e6fb559c6505a8dff37","type":"GENE","name":"LINC02871","canonical_id":"hgnc:HGNC:16180","description":"long independently transcribed non-coding RNA 2871","metadata":{"aliases":["dJ727I10.1","C20orf187"]}},{"id":"1ab972ad53bf4d0ca8baa6aed7816f72","type":"GENE","name":"LINC02872","canonical_id":"hgnc:HGNC:33817","description":"long independently transcribed non-coding RNA 2872","metadata":{"aliases":["FLJ45537","C9orf170"]}},{"id":"4a8a1b6312824fc497f11df142ddcd7a","type":"GENE","name":"LINC02873","canonical_id":"hgnc:HGNC:26805","description":"long independently transcribed non-coding RNA 2873","metadata":{"aliases":["FLJ39058","C11orf44"]}},{"id":"7347f144b0bb40db84c9a94266ce1cdb","type":"GENE","name":"LINC02874","canonical_id":"hgnc:HGNC:27473","description":"long independently transcribed non-coding RNA 2874","metadata":{"aliases":["C12orf80"]}},{"id":"339fbf00314a4ecda2d0a510ab34b3e9","type":"GENE","name":"LINC02875","canonical_id":"hgnc:HGNC:32699","description":"long independently transcribed non-coding RNA 2875","metadata":{"aliases":["C17orf82"]}},{"id":"2666d0a7d379457f889ddac7d8306b4f","type":"GENE","name":"LINC02877","canonical_id":"hgnc:HGNC:37259","description":"long independently transcribed non-coding RNA 2877","metadata":{"aliases":["C3orf79"]}},{"id":"ba90b900396e4fd58574ca07e5637d83","type":"GENE","name":"LINC02878","canonical_id":"hgnc:HGNC:54524","description":"long independently transcribed non-coding RNA 2878","metadata":{"aliases":["BREA2"]}},{"id":"898431373f234cfb8002cf5005f7c321","type":"GENE","name":"LINC02879","canonical_id":"hgnc:HGNC:54551","description":"long independently transcribed non-coding RNA 2879","metadata":{"aliases":["USFM"]}},{"id":"fd55c5090be44f99acd463da4efe9098","type":"GENE","name":"LINC02880","canonical_id":"hgnc:HGNC:54660","description":"long independently transcribed non-coding RNA 2880","metadata":{"aliases":["FLJ34503"]}},{"id":"015a286417c0473cbdac236c611cd02b","type":"GENE","name":"LINC02881","canonical_id":"hgnc:HGNC:51236","description":"long independently transcribed non-coding RNA 2881","metadata":{"aliases":["C10orf142"]}},{"id":"f7a9035c9dc040bb8e4ba4f79db1759b","type":"GENE","name":"LINC02882","canonical_id":"hgnc:HGNC:54802","description":"long independently transcribed non-coding RNA 2882","metadata":{"aliases":["RP11-81H3.2"]}},{"id":"3648ebb7019c408590cbc1c1d053d990","type":"GENE","name":"LINC02883","canonical_id":"hgnc:HGNC:54806","description":"long independently transcribed non-coding RNA 2883","metadata":{"aliases":["KMU15"]}},{"id":"0db9fd1a7f534b57b8e040ab615cd542","type":"GENE","name":"LINC02884","canonical_id":"hgnc:HGNC:54808","description":"long independently transcribed non-coding RNA 2884","metadata":null},{"id":"82eb92775f2d44f094bcb8ba65776167","type":"GENE","name":"LINC02885","canonical_id":"hgnc:HGNC:41188","description":"long independently transcribed non-coding RNA 2885","metadata":{"aliases":["ISX-AS1"]}},{"id":"184842fe2a2445329a51ebaca27f19e1","type":"GENE","name":"LINC02886","canonical_id":"hgnc:HGNC:54867","description":"long independently transcribed non-coding RNA 2886","metadata":{"aliases":["RP11-697M17.1"]}},{"id":"c3bad63d377142ac991115b8757e875e","type":"GENE","name":"LINC02887","canonical_id":"hgnc:HGNC:55047","description":"long independently transcribed non-coding RNA 2887","metadata":null},{"id":"26ed7a90e7634760a08653d036d6cd58","type":"GENE","name":"LINC02888","canonical_id":"hgnc:HGNC:53765","description":"long independently transcribed non-coding RNA 2888","metadata":{"aliases":["KCCAT333"]}},{"id":"d8f957cb25e046ec96259b39a179d305","type":"GENE","name":"LINC02889","canonical_id":"hgnc:HGNC:55071","description":"long independently transcribed non-coding RNA 2889","metadata":null},{"id":"edf0b00e2805400ab84c6868b6ff879a","type":"GENE","name":"LINC02890","canonical_id":"hgnc:HGNC:55220","description":"long independently transcribed non-coding RNA 2890","metadata":null},{"id":"7859578c73ba48c4b2cb078ac6318d49","type":"GENE","name":"LINC02891","canonical_id":"hgnc:HGNC:55221","description":"long independently transcribed non-coding RNA 2891","metadata":{"aliases":["lnc-RTN4R-1"]}},{"id":"ded3f49c50a642b395b3cde43633ec85","type":"GENE","name":"LINC02893","canonical_id":"hgnc:HGNC:55359","description":"long independently transcribed non-coding RNA 2893","metadata":{"aliases":["AL513318.2"]}},{"id":"e94dfbf79416432cb1a34eecef224891","type":"GENE","name":"LINC02894","canonical_id":"hgnc:HGNC:55364","description":"long independently transcribed non-coding RNA 2894","metadata":null},{"id":"5df1639920764bcb8bfc663da72cae0b","type":"GENE","name":"LINC02895","canonical_id":"hgnc:HGNC:55422","description":"long independently transcribed non-coding RNA 2895","metadata":null},{"id":"63a7a2428ddd455fb237393bf1cb9b9e","type":"GENE","name":"LINC02896","canonical_id":"hgnc:HGNC:55427","description":"long independently transcribed non-coding RNA 2896","metadata":null},{"id":"7e50cc3860f649b2a4e58f36e9d16e40","type":"GENE","name":"LINC02897","canonical_id":"hgnc:HGNC:33759","description":"long independently transcribed non-coding RNA 2897","metadata":{"aliases":["FLJ45717","C1orf229"]}},{"id":"461e7a0620fd437ea86cccefd1256692","type":"GENE","name":"LINC02898","canonical_id":"hgnc:HGNC:42966","description":"long independently transcribed non-coding RNA 2898","metadata":{"aliases":["C2orf91"]}},{"id":"91332b22835a4fd1bd9a73e00e702d8d","type":"GENE","name":"LINC02899","canonical_id":"hgnc:HGNC:26630","description":"long independently transcribed non-coding RNA 2899","metadata":{"aliases":["FLJ34836","C5orf17"]}},{"id":"afe45e4d06c041e19d353ae844391514","type":"GENE","name":"LINC02900","canonical_id":"hgnc:HGNC:27964","description":"long independently transcribed non-coding RNA 2900","metadata":{"aliases":["C5orf66-AS2"]}},{"id":"2e7bb375fe29458db0518c59f346dac1","type":"GENE","name":"LINC02901","canonical_id":"hgnc:HGNC:21179","description":"long independently transcribed non-coding RNA 2901","metadata":{"aliases":["yR211F11.1","C6orf99"]}},{"id":"4bee6a648030444b92d81e7155cbe903","type":"GENE","name":"LINC02902","canonical_id":"hgnc:HGNC:34432","description":"long independently transcribed non-coding RNA 2902","metadata":{"aliases":["FLJ44108","C7orf65"]}},{"id":"4ecfcebffbce42cea04f73576ec267c7","type":"GENE","name":"LINC02903","canonical_id":"hgnc:HGNC:33712","description":"long independently transcribed non-coding RNA 2903","metadata":{"aliases":["C7orf66"]}},{"id":"608e8be8be704bc983025b818e03396d","type":"GENE","name":"LINC02905","canonical_id":"hgnc:HGNC:32200","description":"long independently transcribed non-coding RNA 2905","metadata":{"aliases":["FLJ30972","G4DM","C8orf49"]}},{"id":"05423cd63e71462388ecd7a38951cf96","type":"GENE","name":"LINC02906","canonical_id":"hgnc:HGNC:42974","description":"long independently transcribed non-coding RNA 2906","metadata":{"aliases":["C8orf87"]}},{"id":"2b8897c985ee48fca23e176a7ea3ccff","type":"GENE","name":"LINC02907","canonical_id":"hgnc:HGNC:28581","description":"long independently transcribed non-coding RNA 2907","metadata":{"aliases":["MGC35463","C9orf62"]}},{"id":"e5e15f3caf934040a45cef1466b82983","type":"GENE","name":"LINC02908","canonical_id":"hgnc:HGNC:31426","description":"long independently transcribed non-coding RNA 2908","metadata":{"aliases":["FLJ36268","FLJ42909","C9orf139"]}},{"id":"2de282d4aea945229dc64f19f2d56898","type":"GENE","name":"LINC02909","canonical_id":"hgnc:HGNC:27282","description":"long independently transcribed non-coding RNA 2909","metadata":{"aliases":["C12orf77"]}},{"id":"d917882b04b24006a740f0632529e281","type":"GENE","name":"LINC02911","canonical_id":"hgnc:HGNC:44658","description":"long independently transcribed non-coding RNA 2911","metadata":{"aliases":["C16orf97"]}},{"id":"48f3b2ef7fec4aceb05f7de72bb00fbc","type":"GENE","name":"LINC02912","canonical_id":"hgnc:HGNC:32295","description":"long independently transcribed non-coding RNA 2912","metadata":{"aliases":["FLJ36105","TMEM75"]}},{"id":"b70a5d15504c47b7ad8b922d24029d60","type":"GENE","name":"LINC02913","canonical_id":"hgnc:HGNC:31370","description":"long independently transcribed non-coding RNA 2913","metadata":{"aliases":["bA65J3.5","C9orf106"]}},{"id":"d1bbeb8aaca748c38a191ac71d9edb76","type":"GENE","name":"LINC02914","canonical_id":"hgnc:HGNC:26375","description":"long independently transcribed non-coding RNA 2914","metadata":{"aliases":["FLJ25773","C14orf177"]}},{"id":"ad6be8525d2c410988bcbdb3cdba3602","type":"GENE","name":"LINC02915","canonical_id":"hgnc:HGNC:33797","description":"long independently transcribed non-coding RNA 2915","metadata":{"aliases":["FLJ39531","C15orf54"]}},{"id":"03bb9245d18040aa9bd2544e158c371b","type":"GENE","name":"LINC02916","canonical_id":"hgnc:HGNC:55574","description":"long independently transcribed non-coding RNA 2916","metadata":{"aliases":["TCONS_00018175"]}},{"id":"ff34a755412749f583d2edc81f03dcca","type":"GENE","name":"LINC02917","canonical_id":"hgnc:HGNC:55643","description":"long independently transcribed non-coding RNA 2917","metadata":null},{"id":"cf5a26eec61c4dcc8afda6474f837387","type":"GENE","name":"LINC02918","canonical_id":"hgnc:HGNC:55649","description":"long independently transcribed non-coding RNA 2918","metadata":{"aliases":["AL357079.1"]}},{"id":"1b3100a028b043abb1d72e04375e502e","type":"GENE","name":"LINC02919","canonical_id":"hgnc:HGNC:55653","description":"long independently transcribed non-coding RNA 2919","metadata":null},{"id":"131b99f6da904f2b834bf16efdac6b81","type":"GENE","name":"LINC02920","canonical_id":"hgnc:HGNC:55660","description":"long independently transcribed non-coding RNA 2920","metadata":null},{"id":"3b939adf1eeb43a2841c0fe17a417c20","type":"GENE","name":"LINC02922","canonical_id":"hgnc:HGNC:55667","description":"long independently transcribed non-coding RNA 2922","metadata":null},{"id":"07786b4c45184097ad41cc906bbeba9e","type":"GENE","name":"LINC02923","canonical_id":"hgnc:HGNC:55672","description":"long independently transcribed non-coding RNA 2923","metadata":null},{"id":"04d87cfe796f49d6a9e565c184205531","type":"GENE","name":"LINC02924","canonical_id":"hgnc:HGNC:55719","description":"long independently transcribed non-coding RNA 2924","metadata":null},{"id":"aa6fe182d74a4dbe9c7869dddae766c9","type":"GENE","name":"LINC02925","canonical_id":"hgnc:HGNC:55756","description":"long independently transcribed non-coding RNA 2925","metadata":{"aliases":["RP3-439F8.1"]}},{"id":"20e645e462dc47bda2e6f40ffae90aa1","type":"GENE","name":"LINC02926","canonical_id":"hgnc:HGNC:55776","description":"long independently transcribed non-coding RNA 2926","metadata":null},{"id":"997a48b9e9424346b3febeb414730b86","type":"GENE","name":"LINC02927","canonical_id":"hgnc:HGNC:55778","description":"long independently transcribed non-coding RNA 2927","metadata":null},{"id":"4772da13fc65404cade3ed0b45f20861","type":"GENE","name":"LINC02928","canonical_id":"hgnc:HGNC:55799","description":"long independently transcribed non-coding RNA 2928","metadata":null},{"id":"eea6a1fd27d249e3b48bde2f602ff420","type":"GENE","name":"LINC02929","canonical_id":"hgnc:HGNC:55812","description":"long independently transcribed non-coding RNA 2929","metadata":null},{"id":"8f6c2e10fa954d2ab919f2bb5812fb07","type":"GENE","name":"LINC02930","canonical_id":"hgnc:HGNC:55821","description":"long independently transcribed non-coding RNA 2930","metadata":null},{"id":"b7b3746b92df47288a5e1d59076d4d01","type":"GENE","name":"LINC02931","canonical_id":"hgnc:HGNC:55853","description":"long independently transcribed non-coding RNA 2931","metadata":null},{"id":"a87521a6a1aa43d382c0e8d224468d36","type":"GENE","name":"LINC02932","canonical_id":"hgnc:HGNC:55875","description":"long independently transcribed non-coding RNA 2932","metadata":{"aliases":["RP11-115N4.1"]}},{"id":"140f59d91b5b43c0b47cb01a560ad15c","type":"GENE","name":"LINC02933","canonical_id":"hgnc:HGNC:55908","description":"long independently transcribed non-coding RNA 2933","metadata":{"aliases":["AC012213.3"]}},{"id":"8bcd7d0e614b427086dc12c2b7ea4bf0","type":"GENE","name":"LINC02934","canonical_id":"hgnc:HGNC:55913","description":"long independently transcribed non-coding RNA 2934","metadata":{"aliases":["uc.65"]}},{"id":"1ddf0557446b423893790b0dfbc1593b","type":"GENE","name":"LINC02935","canonical_id":"hgnc:HGNC:55939","description":"long independently transcribed non-coding RNA 2935","metadata":{"aliases":["AL158212.1"]}},{"id":"ac1f30025dde483687be38d0982081ca","type":"GENE","name":"LINC02936","canonical_id":"hgnc:HGNC:55940","description":"long independently transcribed non-coding RNA 2936","metadata":{"aliases":["AC017074.1"]}},{"id":"7a6c959feeb4409f9c8c6ef236093ffb","type":"GENE","name":"LINC02937","canonical_id":"hgnc:HGNC:55942","description":"long independently transcribed non-coding RNA 2937","metadata":null},{"id":"4b80a1418cbb4590ba28663a5b9f9b94","type":"GENE","name":"LINC02938","canonical_id":"hgnc:HGNC:55952","description":"long independently transcribed non-coding RNA 2938","metadata":null},{"id":"3ee8d78c187f430792c5fff1451e674d","type":"GENE","name":"LINC02939","canonical_id":"hgnc:HGNC:55954","description":"long independently transcribed non-coding RNA 2939","metadata":null},{"id":"8b51bc73dae64c53b50f69fdc4c32a9a","type":"GENE","name":"LINC02940","canonical_id":"hgnc:HGNC:55955","description":"long independently transcribed non-coding RNA 2940","metadata":{"aliases":["CCMAlnc"]}},{"id":"582b58c6acd44ae086a3d23b2a8d0ad1","type":"GENE","name":"LINC02941","canonical_id":"hgnc:HGNC:55956","description":"long independently transcribed non-coding RNA 2941","metadata":null},{"id":"bd1735e8570e4c1c85864c1ebb434025","type":"GENE","name":"LINC02942","canonical_id":"hgnc:HGNC:55957","description":"long independently transcribed non-coding RNA 2942","metadata":null},{"id":"3de6ea24a4ef425ca71a3fc06bc9c3f6","type":"GENE","name":"LINC02943","canonical_id":"hgnc:HGNC:55958","description":"long independently transcribed non-coding RNA 2943","metadata":null},{"id":"3748c84f05e149439e4086290d9e6a6c","type":"GENE","name":"LINC02944","canonical_id":"hgnc:HGNC:55959","description":"long independently transcribed non-coding RNA 2944","metadata":null},{"id":"1c2fa3c651cb4509918c54762f09408f","type":"GENE","name":"LINC02945","canonical_id":"hgnc:HGNC:55960","description":"long independently transcribed non-coding RNA 2945","metadata":{"aliases":["AC004704.1"]}},{"id":"df34c74e5f9944fc88e5d92060261633","type":"GENE","name":"LINC02946","canonical_id":"hgnc:HGNC:27680","description":"long independently transcribed non-coding RNA 2946","metadata":{"aliases":["RMEL1"]}},{"id":"43f78585169f48a4ac9d02d50303c02f","type":"GENE","name":"LINC02947","canonical_id":"hgnc:HGNC:55962","description":"long independently transcribed non-coding RNA 2947","metadata":null},{"id":"81b788cd447442e49286552b5c41575a","type":"GENE","name":"LINC02948","canonical_id":"hgnc:HGNC:55963","description":"long independently transcribed non-coding RNA 2948","metadata":null},{"id":"4d98fe47be0a44c0b597e6e7594b546b","type":"GENE","name":"LINC02949","canonical_id":"hgnc:HGNC:55964","description":"long independently transcribed non-coding RNA 2949","metadata":null},{"id":"ed3de9e564f34836bd877007f43b3164","type":"GENE","name":"LINC02950","canonical_id":"hgnc:HGNC:55965","description":"long independently transcribed non-coding RNA 2950","metadata":null},{"id":"b34800d758204f04ac7e970a284a17d6","type":"GENE","name":"LINC02951","canonical_id":"hgnc:HGNC:55967","description":"long independently transcribed non-coding RNA 2951","metadata":null},{"id":"957d6509ee3c40a8aeb68bcc76d7a137","type":"GENE","name":"LINC02952","canonical_id":"hgnc:HGNC:55968","description":"long independently transcribed non-coding RNA 2952","metadata":null},{"id":"452faf3c084b4a3fbe807f3312800338","type":"GENE","name":"LINC02953","canonical_id":"hgnc:HGNC:55970","description":"long independently transcribed non-coding RNA 2953","metadata":null},{"id":"96956761f3074ae6a97d71069d7274ff","type":"GENE","name":"LINC02954","canonical_id":"hgnc:HGNC:55972","description":"long independently transcribed non-coding RNA 2954","metadata":null},{"id":"5d5d345a32ac4c5eb0527da5dee72649","type":"GENE","name":"LINC02955","canonical_id":"hgnc:HGNC:55973","description":"long independently transcribed non-coding RNA 2955","metadata":null},{"id":"09b2c4e14566463ea8dbd0bd3f510bc4","type":"GENE","name":"LINC02956","canonical_id":"hgnc:HGNC:55976","description":"long independently transcribed non-coding RNA 2956","metadata":null},{"id":"8e7335b3d4b443c0b7d3b9b5389067b5","type":"GENE","name":"LINC02957","canonical_id":"hgnc:HGNC:55977","description":"long independently transcribed non-coding RNA 2957","metadata":null},{"id":"c6f35c5e05e942e7905f47c4456ba094","type":"GENE","name":"LINC02958","canonical_id":"hgnc:HGNC:55981","description":"long independently transcribed non-coding RNA 2958","metadata":null},{"id":"eca1d5fc0cab424a89bb9391f78d4460","type":"GENE","name":"LINC02959","canonical_id":"hgnc:HGNC:55982","description":"long independently transcribed non-coding RNA 2959","metadata":null},{"id":"41f1abb6ec154725924a8ec15194ae62","type":"GENE","name":"LINC02960","canonical_id":"hgnc:HGNC:55985","description":"long independently transcribed non-coding RNA 2960","metadata":null},{"id":"01e71ca067d944dbb1005989f6c2edc7","type":"GENE","name":"LINC02961","canonical_id":"hgnc:HGNC:55986","description":"long independently transcribed non-coding RNA 2961","metadata":{"aliases":["PP2672"]}},{"id":"df57f8d4d92f45bc9067a80142191ecb","type":"GENE","name":"LINC02963","canonical_id":"hgnc:HGNC:53945","description":"long independently transcribed non-coding RNA 2963","metadata":{"aliases":["lncRNA-p3134"]}},{"id":"aef81481441e4678a63d751a22d393ea","type":"GENE","name":"LINC02964","canonical_id":"hgnc:HGNC:53487","description":"long independently transcribed non-coding RNA 2964","metadata":null},{"id":"d566877071874481ae363dd1854fea15","type":"GENE","name":"LINC02965","canonical_id":"hgnc:HGNC:56003","description":"long independently transcribed non-coding RNA 2965","metadata":{"aliases":["CTC-523E23.5","lnc-ZNF30-3"]}},{"id":"64ee23d3463f47dc80a5aea74656bdd7","type":"GENE","name":"LINC02966","canonical_id":"hgnc:HGNC:56006","description":"long independently transcribed non-coding RNA 2966","metadata":{"aliases":["AC016745.3"]}},{"id":"0074cee75d58415abe285c7c72ca64ec","type":"GENE","name":"LINC02967","canonical_id":"hgnc:HGNC:56007","description":"long independently transcribed non-coding RNA 2967","metadata":{"aliases":["AL035661.1"]}},{"id":"6c7cb15420d34be196d28b2585f78b3d","type":"GENE","name":"LINC02968","canonical_id":"hgnc:HGNC:56008","description":"long independently transcribed non-coding RNA 2968","metadata":{"aliases":["AL683807.1"]}},{"id":"88d74a956b2e4013b627a236c864f199","type":"GENE","name":"LINC02970","canonical_id":"hgnc:HGNC:56010","description":"long independently transcribed non-coding RNA 2970","metadata":null},{"id":"80e2551976de4fa7be3d086b6f24b625","type":"GENE","name":"LINC02971","canonical_id":"hgnc:HGNC:56012","description":"long independently transcribed non-coding RNA 2971","metadata":{"aliases":["AL391832.1"]}},{"id":"b64343218fee4ff68575efe17143b016","type":"GENE","name":"LINC02972","canonical_id":"hgnc:HGNC:56013","description":"long independently transcribed non-coding RNA 2972","metadata":{"aliases":["AC092490.1"]}},{"id":"0e1ad1a82a924d998297b9894e06c535","type":"GENE","name":"LINC02973","canonical_id":"hgnc:HGNC:56015","description":"long independently transcribed non-coding RNA 2973","metadata":{"aliases":["AC010904.2"]}},{"id":"f9c9b2e52cdc410a8c4a57a73a11b134","type":"GENE","name":"LINC02974","canonical_id":"hgnc:HGNC:56017","description":"long independently transcribed non-coding RNA 2974","metadata":{"aliases":["AP005671.1"]}},{"id":"b6aca00f41e04903a32d1968956a5fee","type":"GENE","name":"LINC02975","canonical_id":"hgnc:HGNC:56025","description":"long independently transcribed non-coding RNA 2975","metadata":{"aliases":["AL161785.1"]}},{"id":"a5f05a6463894fe4b4c5f4f91e3efe1e","type":"GENE","name":"LINC02976","canonical_id":"hgnc:HGNC:56026","description":"long independently transcribed non-coding RNA 2976","metadata":{"aliases":["RP3-475N16.1"]}},{"id":"b7006a6814bf4849b8c3e153af2907e9","type":"GENE","name":"LINC02977","canonical_id":"hgnc:HGNC:56036","description":"long independently transcribed non-coding RNA 2977","metadata":{"aliases":["RP11-4O1.2"]}},{"id":"143334be78c547cba04470b0bea4df7d","type":"GENE","name":"LINC02978","canonical_id":"hgnc:HGNC:56041","description":"long independently transcribed non-coding RNA 2978","metadata":null},{"id":"972d88a321dc49c19b1cba361a72e393","type":"GENE","name":"LINC02979","canonical_id":"hgnc:HGNC:56043","description":"long independently transcribed non-coding RNA 2979","metadata":{"aliases":["RP11-703I16.1"]}},{"id":"6615021cf458411da562477cd774b4ac","type":"GENE","name":"LINC02980","canonical_id":"hgnc:HGNC:56046","description":"long independently transcribed non-coding RNA 2980","metadata":null},{"id":"89d4197059144cc7a5f8973877d7d440","type":"GENE","name":"LINC02981","canonical_id":"hgnc:HGNC:56055","description":"long independently transcribed non-coding RNA 2981","metadata":null},{"id":"8cab09cb7ef94f29a593efb740dc2348","type":"GENE","name":"LINC02982","canonical_id":"hgnc:HGNC:56056","description":"long independently transcribed non-coding RNA 2982","metadata":null},{"id":"a950c188f5ac43a28cfd94cbe23c9b5c","type":"GENE","name":"LINC02983","canonical_id":"hgnc:HGNC:56060","description":"long independently transcribed non-coding RNA 2983","metadata":null},{"id":"c0a4b0fa84324dc4a44ad38a9d898967","type":"GENE","name":"LINC02984","canonical_id":"hgnc:HGNC:56063","description":"long independently transcribed non-coding RNA 2984","metadata":{"aliases":["PROCA11","lnc-OPRK1-3","RP11-400K9.4"]}},{"id":"6f4b2dc119fb44ffb13590cde96c3286","type":"GENE","name":"LINC02985","canonical_id":"hgnc:HGNC:56073","description":"long independently transcribed non-coding RNA 2985","metadata":{"aliases":["AC156455.1"]}},{"id":"0ccacd112454441d9e94ca51753cb007","type":"GENE","name":"LINC02986","canonical_id":"hgnc:HGNC:56083","description":"long independently transcribed non-coding RNA 2986","metadata":null},{"id":"370c9e7ac4d945ed91dc36a50098d749","type":"GENE","name":"LINC02987","canonical_id":"hgnc:HGNC:56093","description":"long independently transcribed non-coding RNA 2987","metadata":null},{"id":"0bbaaf26aa244bdb88f7fdd0938da09f","type":"GENE","name":"LINC02988","canonical_id":"hgnc:HGNC:56098","description":"long independently transcribed non-coding RNA 2988","metadata":null},{"id":"bb12c39e20d946b5bacc5e757ac08b20","type":"GENE","name":"LINC02989","canonical_id":"hgnc:HGNC:56100","description":"long independently transcribed non-coding RNA 2989","metadata":{"aliases":["lnc-MICAL2-1"]}},{"id":"658d70466c364a37b03463567c372c6f","type":"GENE","name":"LINC02991","canonical_id":"hgnc:HGNC:33810","description":"long independently transcribed non-coding RNA 2991","metadata":null},{"id":"ba212b3520c94d7fbb215a1a2eb3f78c","type":"GENE","name":"LINC02992","canonical_id":"hgnc:HGNC:49287","description":"long independently transcribed non-coding RNA 2992","metadata":null},{"id":"62682684d9534e958b698f408674baae","type":"GENE","name":"LINC02993","canonical_id":"hgnc:HGNC:56105","description":"long independently transcribed non-coding RNA 2993","metadata":null},{"id":"c74c618265cc450d9cbd15e54c250375","type":"GENE","name":"LINC02994","canonical_id":"hgnc:HGNC:56109","description":"long independently transcribed non-coding RNA 2994","metadata":null},{"id":"0ae7854ed0a04b4d96207997253f41eb","type":"GENE","name":"LINC02995","canonical_id":"hgnc:HGNC:27744","description":"long independently transcribed non-coding RNA 2995","metadata":null},{"id":"e82591dd86e84476a4feaa28c88b5132","type":"GENE","name":"LINC02996","canonical_id":"hgnc:HGNC:56112","description":"long independently transcribed non-coding RNA 2996","metadata":{"aliases":["TCONS_00010315"]}},{"id":"9909ad4cbe81480889398cb769cd400d","type":"GENE","name":"LINC02997","canonical_id":"hgnc:HGNC:56113","description":"long independently transcribed non-coding RNA 2997","metadata":null},{"id":"e8800dbb1c9e4651ad2fa835fa317571","type":"GENE","name":"LINC02998","canonical_id":"hgnc:HGNC:56114","description":"long independently transcribed non-coding RNA 2998","metadata":{"aliases":["TCONS_00010334"]}},{"id":"16096d2b623642ce8bc8952669fbb924","type":"GENE","name":"LINC02999","canonical_id":"hgnc:HGNC:56115","description":"long independently transcribed non-coding RNA 2999","metadata":null},{"id":"d8db5ca868ec443482c09d7eb491064d","type":"GENE","name":"LINC03000","canonical_id":"hgnc:HGNC:56116","description":"long independently transcribed non-coding RNA 3000","metadata":null},{"id":"c664ddb00f5346bc9b0bda3e48839557","type":"GENE","name":"LINC03001","canonical_id":"hgnc:HGNC:56118","description":"long independently transcribed non-coding RNA 3001","metadata":{"aliases":["TCONS_00011222"]}},{"id":"41318798bc944449982a1b0958dc8767","type":"GENE","name":"LINC03002","canonical_id":"hgnc:HGNC:56123","description":"long independently transcribed non-coding RNA 3002","metadata":null},{"id":"1432ab355b244d4089753bcc81728ff8","type":"GENE","name":"LINC03003","canonical_id":"hgnc:HGNC:56126","description":"long independently transcribed non-coding RNA 3003","metadata":null},{"id":"84527dbc7db44410a2bf527b3f552ff5","type":"GENE","name":"LINC03004","canonical_id":"hgnc:HGNC:56128","description":"long independently transcribed non-coding RNA 3004","metadata":null},{"id":"8d2ac5e58ca148f4bf0dfa67e10edf8e","type":"GENE","name":"LINC03005","canonical_id":"hgnc:HGNC:56130","description":"long independently transcribed non-coding RNA 3005","metadata":null},{"id":"e515f1c8c6554d1e9409704213b6cf24","type":"GENE","name":"LINC03006","canonical_id":"hgnc:HGNC:56131","description":"long independently transcribed non-coding RNA 3006","metadata":null},{"id":"41b913870ace4ce5af05738f9960d4c4","type":"GENE","name":"LINC03007","canonical_id":"hgnc:HGNC:56132","description":"long independently transcribed non-coding RNA 3007","metadata":{"aliases":["AC005165.1","AC003090.1"]}},{"id":"d2f42980dfcb4a3581d19e5a97a5874d","type":"GENE","name":"LINC03008","canonical_id":"hgnc:HGNC:56133","description":"long independently transcribed non-coding RNA 3008","metadata":null},{"id":"d25acc84c53e4e20b0f04a1647cfc86d","type":"GENE","name":"LINC03009","canonical_id":"hgnc:HGNC:56134","description":"long independently transcribed non-coding RNA 3009","metadata":null},{"id":"c7f06c4c44974fbfbcd3ef561fa9c52a","type":"GENE","name":"LINC03010","canonical_id":"hgnc:HGNC:56135","description":"long independently transcribed non-coding RNA 3010","metadata":null},{"id":"44036991da1245559ef25391a7fd0483","type":"GENE","name":"LINC03011","canonical_id":"hgnc:HGNC:56136","description":"long independently transcribed non-coding RNA 3011","metadata":null},{"id":"270e94eae77b482882e321d47336660f","type":"GENE","name":"LINC03012","canonical_id":"hgnc:HGNC:56139","description":"long independently transcribed non-coding RNA 3012","metadata":{"aliases":["REIR-5"]}},{"id":"38d8741862e24e26ad144e522fb04825","type":"GENE","name":"LINC03013","canonical_id":"hgnc:HGNC:56140","description":"long independently transcribed non-coding RNA 3013","metadata":null},{"id":"d3b4e206d7ee45398b0ae52fe9650367","type":"GENE","name":"LINC03014","canonical_id":"hgnc:HGNC:56142","description":"long independently transcribed non-coding RNA 3014","metadata":null},{"id":"52c611a0485c42a8b4522e3dad7862f6","type":"GENE","name":"LINC03015","canonical_id":"hgnc:HGNC:56143","description":"long independently transcribed non-coding RNA 3015","metadata":null},{"id":"4c05ee67a9564c03800dc775243e7e1a","type":"GENE","name":"LINC03016","canonical_id":"hgnc:HGNC:56145","description":"long independently transcribed non-coding RNA 3016","metadata":null},{"id":"880f0e0ce98b4b2b9098ef455b1b9d7a","type":"GENE","name":"LINC03017","canonical_id":"hgnc:HGNC:56146","description":"long independently transcribed non-coding RNA 3017","metadata":null},{"id":"e8c4348cb2834cd1b809664c869a440d","type":"GENE","name":"LINC03018","canonical_id":"hgnc:HGNC:27837","description":"long independently transcribed non-coding RNA 3018","metadata":null},{"id":"562c590bca4746a187785a22cb3456cd","type":"GENE","name":"LINC03019","canonical_id":"hgnc:HGNC:27982","description":"long independently transcribed non-coding RNA 3019","metadata":{"aliases":["RP11-252C15.1"]}},{"id":"4a7937a0b8e14e39b856ca5acd620ed6","type":"GENE","name":"LINC03020","canonical_id":"hgnc:HGNC:56148","description":"long independently transcribed non-coding RNA 3020","metadata":null},{"id":"7e17db7051f14dd28837b929f9431d86","type":"GENE","name":"LINC03021","canonical_id":"hgnc:HGNC:56149","description":"long independently transcribed non-coding RNA 3021","metadata":null},{"id":"fa21b71c7ebb4bd6a2c2755244c8fe8d","type":"GENE","name":"LINC03022","canonical_id":"hgnc:HGNC:56151","description":"long independently transcribed non-coding RNA 3022","metadata":{"aliases":["LINCR-0001"]}},{"id":"8aa2bc77909447a2b28102733ca4fe1d","type":"GENE","name":"LINC03023","canonical_id":"hgnc:HGNC:56154","description":"long independently transcribed non-coding RNA 3023","metadata":null},{"id":"21dd650f638f4ded931554311334ef2f","type":"GENE","name":"LINC03024","canonical_id":"hgnc:HGNC:56155","description":"long independently transcribed non-coding RNA 3024","metadata":null},{"id":"9c93721965a54d15be7856d41fa0896f","type":"GENE","name":"LINC03025","canonical_id":"hgnc:HGNC:56158","description":"long independently transcribed non-coding RNA 3025","metadata":null},{"id":"950c97d408d24463aaf23e46ed7713a2","type":"GENE","name":"LINC03026","canonical_id":"hgnc:HGNC:56164","description":"long independently transcribed non-coding RNA 3026","metadata":null},{"id":"429d707407d740848a19968da7361577","type":"GENE","name":"LINC03027","canonical_id":"hgnc:HGNC:48681","description":"long independently transcribed non-coding RNA 3027","metadata":null},{"id":"a5ac9b03dda64ca8841234f70057b277","type":"GENE","name":"LINC03028","canonical_id":"hgnc:HGNC:56168","description":"long independently transcribed non-coding RNA 3028","metadata":null},{"id":"6c7fbb0436e24650b0407c839bee6dba","type":"GENE","name":"LINC03029","canonical_id":"hgnc:HGNC:56169","description":"long independently transcribed non-coding RNA 3029","metadata":null},{"id":"023421d697dc4cd8b0831f72b79d527b","type":"GENE","name":"LINC03030","canonical_id":"hgnc:HGNC:56171","description":"long independently transcribed non-coding RNA 3030","metadata":null},{"id":"5a612692899d4f48bf85ba82f767e845","type":"GENE","name":"LINC03031","canonical_id":"hgnc:HGNC:56174","description":"long independently transcribed non-coding RNA 3031","metadata":null},{"id":"cf3d4673065b42a5b1f984a07a4f8edb","type":"GENE","name":"LINC03032","canonical_id":"hgnc:HGNC:56192","description":"long independently transcribed non-coding RNA 3032","metadata":null},{"id":"ffb2c4db320045f6b9759044bdd2118a","type":"GENE","name":"LINC03033","canonical_id":"hgnc:HGNC:44292","description":"long independently transcribed non-coding RNA 3033","metadata":{"aliases":["LncRNA-CAF","FLJ22447"]}},{"id":"3f830f52626b4c59a20631302891854f","type":"GENE","name":"LINC03034","canonical_id":"hgnc:HGNC:54360","description":"long independently transcribed non-coding RNA 3034","metadata":null},{"id":"0cc2b024c268482caa9418631ce04df4","type":"GENE","name":"LINC03035","canonical_id":"hgnc:HGNC:56211","description":"long independently transcribed non-coding RNA 3035","metadata":null},{"id":"e1fa0a87baee4b6faec73daed9d7cdc6","type":"GENE","name":"LINC03036","canonical_id":"hgnc:HGNC:56220","description":"long independently transcribed non-coding RNA 3036","metadata":{"aliases":["TP53LC01"]}},{"id":"60fb58f649a7422daa6f4662db2b05af","type":"GENE","name":"LINC03037","canonical_id":"hgnc:HGNC:56227","description":"long independently transcribed non-coding RNA 3037","metadata":{"aliases":["TP53LC17"]}},{"id":"c49de6c21dd145c2bac5107c345b593a","type":"GENE","name":"LINC03039","canonical_id":"hgnc:HGNC:56234","description":"long independently transcribed non-coding RNA 3039","metadata":{"aliases":["lncSIK1"]}},{"id":"80a705f9d0304c59a5af3f02353a2957","type":"GENE","name":"LINC03040","canonical_id":"hgnc:HGNC:28692","description":"long independently transcribed non-coding RNA 3040","metadata":{"aliases":["MGC45491","C6orf223"]}},{"id":"3fcbc0fdd9e44fe78d403b388f23db50","type":"GENE","name":"LINC03041","canonical_id":"hgnc:HGNC:19054","description":"long independently transcribed non-coding RNA 3041","metadata":{"aliases":["Em:AL513424.1","C9orf92"]}},{"id":"78305a3beb4c4cda8aee27b042bab402","type":"GENE","name":"LINC03042","canonical_id":"hgnc:HGNC:33774","description":"long independently transcribed non-coding RNA 3042","metadata":{"aliases":["FLJ43582","C8orf86"]}},{"id":"b038809067f74ff2b5dbaa7b6d0a3eb8","type":"GENE","name":"LINC03043","canonical_id":"hgnc:HGNC:51256","description":"long independently transcribed non-coding RNA 3043","metadata":{"aliases":["C7orf77"]}},{"id":"cf6ab3d329f44a84b44137fd97c66496","type":"GENE","name":"LINC03044","canonical_id":"hgnc:HGNC:56250","description":"long independently transcribed non-coding RNA 3044","metadata":{"aliases":["Lnc524369"]}},{"id":"5e0f017ceaf5480994eef01a91bbcb60","type":"GENE","name":"LINC03046","canonical_id":"hgnc:HGNC:56262","description":"long independently transcribed non-coding RNA 3046","metadata":{"aliases":["AC010789.1"]}},{"id":"21a456b4e1c6473da6f83a5241d3a104","type":"GENE","name":"LINC03047","canonical_id":"hgnc:HGNC:56265","description":"long independently transcribed non-coding RNA 3047","metadata":{"aliases":["KB-1980E6.3"]}},{"id":"900711725e5b406cbb422f10a44f3d84","type":"GENE","name":"LINC03048","canonical_id":"hgnc:HGNC:56272","description":"long independently transcribed non-coding RNA 3048","metadata":null},{"id":"4701a89984e9472483061941fa13958b","type":"GENE","name":"LINC03050","canonical_id":"hgnc:HGNC:56283","description":"long independently transcribed non-coding RNA 3050","metadata":{"aliases":["AC007389.3"]}},{"id":"e0efbbbc03fa463fa9ce994fdef6263b","type":"GENE","name":"LINC03051","canonical_id":"hgnc:HGNC:56330","description":"long independently transcribed non-coding RNA 3051","metadata":{"aliases":["Lnc-LSAMP-1"]}},{"id":"e09282b24e9e4fe6980b17400bb2bc5a","type":"GENE","name":"LINC03052","canonical_id":"hgnc:HGNC:56335","description":"long independently transcribed non-coding RNA 3052","metadata":{"aliases":["AC009237.14","lncRNA799"]}},{"id":"92717a4bd6ef432e825134fcbf79656a","type":"GENE","name":"LINC03053","canonical_id":"hgnc:HGNC:56342","description":"long independently transcribed non-coding RNA 3053","metadata":{"aliases":["AC092198.1"]}},{"id":"8bcf4974be5a401283b3db93db4383cb","type":"GENE","name":"LINC03054","canonical_id":"hgnc:HGNC:56349","description":"long independently transcribed non-coding RNA 3054","metadata":{"aliases":["AC022915.1"]}},{"id":"cdb9fabd9ffe48f6bd798cc4f207e7ad","type":"GENE","name":"LINC03055","canonical_id":"hgnc:HGNC:56352","description":"long independently transcribed non-coding RNA 3055","metadata":null},{"id":"9de67808aecb4986bac80d65b35a3b2c","type":"GENE","name":"LINC03056","canonical_id":"hgnc:HGNC:56354","description":"long independently transcribed non-coding RNA 3056","metadata":null},{"id":"d3d84de7d3f84afc8a64d67f7bdd495d","type":"GENE","name":"LINC03057","canonical_id":"hgnc:HGNC:56359","description":"long independently transcribed non-coding RNA 3057","metadata":{"aliases":["lnc-HOXB8-1:2","RP11-357H14.17"]}},{"id":"c0c5cdef469946a08e5907ce3ff82083","type":"GENE","name":"LINC03058","canonical_id":"hgnc:HGNC:56363","description":"long independently transcribed non-coding RNA 3058","metadata":{"aliases":["RP11-219E7.1","AL133371.2"]}},{"id":"744930353ba54fd2a8ee0f77a23d3977","type":"GENE","name":"LINC03059","canonical_id":"hgnc:HGNC:56366","description":"long independently transcribed non-coding RNA 3059","metadata":{"aliases":["RP11-108M12.3"]}},{"id":"1038d213c400409897010048baa28460","type":"GENE","name":"LINC03060","canonical_id":"hgnc:HGNC:56367","description":"long independently transcribed non-coding RNA 3060","metadata":{"aliases":["RP11-38M8.1"]}},{"id":"4dd78e86fe04487a9d9d5539c25985a9","type":"GENE","name":"LINC03062","canonical_id":"hgnc:HGNC:56369","description":"long independently transcribed non-coding RNA 3062","metadata":null},{"id":"e92a1d94765b4a18a4fa25fe3134b53d","type":"GENE","name":"LINC03064","canonical_id":"hgnc:HGNC:56372","description":"long independently transcribed non-coding RNA 3064","metadata":{"aliases":["AC026462.3"]}},{"id":"1ed9ae8d49ba482195cb6543df6a68c7","type":"GENE","name":"LINC03065","canonical_id":"hgnc:HGNC:56373","description":"long independently transcribed non-coding RNA 3065","metadata":{"aliases":["AC010999.2"]}},{"id":"31f0a448c48040e6a87ee7346ed0fddd","type":"GENE","name":"LINC03066","canonical_id":"hgnc:HGNC:27767","description":"long independently transcribed non-coding RNA 3066","metadata":null},{"id":"8ea90e09741c4ff29620ed1606f5d302","type":"GENE","name":"LINC03067","canonical_id":"hgnc:HGNC:56639","description":"long independently transcribed non-coding RNA 3067","metadata":{"aliases":["AC026412.3"]}},{"id":"77035a590c4e44389a522d3719f83679","type":"GENE","name":"LINC03068","canonical_id":"hgnc:HGNC:56640","description":"long independently transcribed non-coding RNA 3068","metadata":{"aliases":["AL451069.3"]}},{"id":"2672f270b85a44458352deb45e66b2c8","type":"GENE","name":"LINC03070","canonical_id":"hgnc:HGNC:56642","description":"long independently transcribed non-coding RNA 3070","metadata":{"aliases":["AC110995.1"]}},{"id":"98778f32a0514df499923b0defaecb57","type":"GENE","name":"LINC03071","canonical_id":"hgnc:HGNC:56645","description":"long independently transcribed non-coding RNA 3071","metadata":{"aliases":["AC115837.2"]}},{"id":"54b25d81b39c485bbe1955329e485126","type":"GENE","name":"LINC03072","canonical_id":"hgnc:HGNC:56650","description":"long independently transcribed non-coding RNA 3072","metadata":{"aliases":["AC090114.2"]}},{"id":"3c5e8c28d07448dea3bdadd199b6cfe7","type":"GENE","name":"LINC03073","canonical_id":"hgnc:HGNC:56651","description":"long independently transcribed non-coding RNA 3073","metadata":{"aliases":["AC092171.5"]}},{"id":"6cb7d6799fe34cf3b5fd65aaeebe79e6","type":"GENE","name":"LINC03074","canonical_id":"hgnc:HGNC:56654","description":"long independently transcribed non-coding RNA 3074","metadata":null},{"id":"54cfe572c9fd43f08c45af847d2cac86","type":"GENE","name":"LINC03075","canonical_id":"hgnc:HGNC:56655","description":"long independently transcribed non-coding RNA 3075","metadata":null},{"id":"c6ff2eb17829406a84f0f6b22e0de21c","type":"GENE","name":"LINC03076","canonical_id":"hgnc:HGNC:56656","description":"long independently transcribed non-coding RNA 3076","metadata":null},{"id":"a1be919e5c1c471c9441c52d5136ee05","type":"GENE","name":"LINC03077","canonical_id":"hgnc:HGNC:56657","description":"long independently transcribed non-coding RNA 3077","metadata":{"aliases":["RP11-485F13.1"]}},{"id":"18564ac511024870b3037d80d8d95386","type":"GENE","name":"LINC03078","canonical_id":"hgnc:HGNC:56665","description":"long independently transcribed non-coding RNA 3078","metadata":{"aliases":["AC005392.2","CTC-490G23.2"]}},{"id":"8e38a4b2f0554e63bed40ad86c27677f","type":"GENE","name":"LINC03079","canonical_id":"hgnc:HGNC:56669","description":"long independently transcribed non-coding RNA 3079","metadata":{"aliases":["AL139351.1"]}},{"id":"5b9567a28351468daedd82f0e688c5b0","type":"GENE","name":"LINC03080","canonical_id":"hgnc:HGNC:56670","description":"long independently transcribed non-coding RNA 3080","metadata":{"aliases":["AC015660.1"]}},{"id":"6da43d904dca449ba08f13b139548fdc","type":"GENE","name":"LINC03082","canonical_id":"hgnc:HGNC:56676","description":"long independently transcribed non-coding RNA 3082","metadata":null},{"id":"5acb3f8d660e40d4a88f564b061faae3","type":"GENE","name":"LINC03083","canonical_id":"hgnc:HGNC:56677","description":"long independently transcribed non-coding RNA 3083","metadata":{"aliases":["AL133465.1"]}},{"id":"dfe8c3ce53594028ab8d631e388f9c5b","type":"GENE","name":"LINC03084","canonical_id":"hgnc:HGNC:56686","description":"long independently transcribed non-coding RNA 3084","metadata":null},{"id":"13469ed5a3124bd798e6361c5255d14e","type":"GENE","name":"LINC03085","canonical_id":"hgnc:HGNC:56691","description":"long independently transcribed non-coding RNA 3085","metadata":{"aliases":["AC073534.2"]}},{"id":"b6bdfaf4186e4386a07b3e861e64e79d","type":"GENE","name":"LINC03086","canonical_id":"hgnc:HGNC:56701","description":"long independently transcribed non-coding RNA 3086","metadata":null},{"id":"857f1899dffc4a048686523062801658","type":"GENE","name":"LINC03088","canonical_id":"hgnc:HGNC:56710","description":"long independently transcribed non-coding RNA 3088","metadata":{"aliases":["AC125603.2"]}},{"id":"c09947dc62ca460d882097f32ed84090","type":"GENE","name":"LINC03089","canonical_id":"hgnc:HGNC:56717","description":"long independently transcribed non-coding RNA 3089","metadata":{"aliases":["RP11-20J15.2"]}},{"id":"4fa9d16e6c524d5282e1efeace64b6ef","type":"GENE","name":"LINC03090","canonical_id":"hgnc:HGNC:56719","description":"long independently transcribed non-coding RNA 3090","metadata":null},{"id":"34d28777e509446cb09678eb2b294aa6","type":"GENE","name":"LINC03091","canonical_id":"hgnc:HGNC:56720","description":"long independently transcribed non-coding RNA 3091","metadata":null},{"id":"b4623f7bec2e4d0f8449d70032081945","type":"GENE","name":"LINC03092","canonical_id":"hgnc:HGNC:56721","description":"long independently transcribed non-coding RNA 3092","metadata":null},{"id":"74569e750e35473788798e8c8a9b149a","type":"GENE","name":"LINC03093","canonical_id":"hgnc:HGNC:56723","description":"long independently transcribed non-coding RNA 3093","metadata":null},{"id":"3fe02223efbe4a86b0bd0a08c91a89b3","type":"GENE","name":"LINC03094","canonical_id":"hgnc:HGNC:56725","description":"long independently transcribed non-coding RNA 3094","metadata":{"aliases":["lnc-SMC2-1"]}},{"id":"e09ac7523b844d88823a4c0afa05d60f","type":"GENE","name":"LINC03095","canonical_id":"hgnc:HGNC:56738","description":"long independently transcribed non-coding RNA 3095","metadata":{"aliases":["lnc-SNX10-87"]}},{"id":"2180ce73358f4236bde9f2c745c2a651","type":"GENE","name":"LINC03096","canonical_id":"hgnc:HGNC:56743","description":"long independently transcribed non-coding RNA 3096","metadata":null},{"id":"0beb54c73dca4ec2b0b76ecb6ef38bad","type":"GENE","name":"LINC03097","canonical_id":"hgnc:HGNC:56744","description":"long independently transcribed non-coding RNA 3097","metadata":null},{"id":"eb76874d08b5417eb1748f9327673d28","type":"GENE","name":"LINC03098","canonical_id":"hgnc:HGNC:56745","description":"long independently transcribed non-coding RNA 3098","metadata":null},{"id":"5aad65d4a45540d49d6d54162a75e488","type":"GENE","name":"LINC03099","canonical_id":"hgnc:HGNC:56750","description":"long independently transcribed non-coding RNA 3099","metadata":null},{"id":"5c8a875b01db4501809d655407c85992","type":"GENE","name":"LINC03100","canonical_id":"hgnc:HGNC:56763","description":"long independently transcribed non-coding RNA 3100","metadata":null},{"id":"0493321987ed444ca442e351bb99d0ca","type":"GENE","name":"LINC03101","canonical_id":"hgnc:HGNC:56823","description":"long independently transcribed non-coding RNA 3101","metadata":{"aliases":["AC018445.6"]}},{"id":"ed26d18b10ad43248e712f5a07c99fde","type":"GENE","name":"LINC03102","canonical_id":"hgnc:HGNC:40277","description":"long independently transcribed non-coding RNA 3102","metadata":{"aliases":["HHLA3-AS1"]}},{"id":"89f362ee90944c208b9670ff4f722980","type":"GENE","name":"LINC03103","canonical_id":"hgnc:HGNC:48330","description":"long independently transcribed non-coding RNA 3103","metadata":{"aliases":["THEG5"]}},{"id":"b2c63ad003c54306a25d0e5e6f07a7e2","type":"GENE","name":"LINC03104","canonical_id":"hgnc:HGNC:56834","description":"long independently transcribed non-coding RNA 3104","metadata":null},{"id":"8eef4377ceb34022ad06d5d8e69159a5","type":"GENE","name":"LINC03105","canonical_id":"hgnc:HGNC:56835","description":"long independently transcribed non-coding RNA 3105","metadata":null},{"id":"dac3d72204f34b64a7a8c6a6eadcc81e","type":"GENE","name":"LINC03106","canonical_id":"hgnc:HGNC:56836","description":"long independently transcribed non-coding RNA 3106","metadata":null},{"id":"d17cdcb039fd4baaadf3d54138c99525","type":"GENE","name":"LINC03107","canonical_id":"hgnc:HGNC:56841","description":"long independently transcribed non-coding RNA 3107","metadata":null},{"id":"363e9398281a4c769bce7ac3d9efb6fd","type":"GENE","name":"LINC03108","canonical_id":"hgnc:HGNC:56844","description":"long independently transcribed non-coding RNA 3108","metadata":{"aliases":["AL391832.3"]}},{"id":"ec1d976616e942aa8a840ea524a552f9","type":"GENE","name":"LINC03109","canonical_id":"hgnc:HGNC:56845","description":"long independently transcribed non-coding RNA 3109","metadata":{"aliases":["AC078788.1"]}},{"id":"788dfa28ee2b4357958dd0e6f4dbf305","type":"GENE","name":"LINC03110","canonical_id":"hgnc:HGNC:56846","description":"long independently transcribed non-coding RNA 3110","metadata":null},{"id":"93b09471b36c4ea1b0f22ee40eabf420","type":"GENE","name":"LINC03111","canonical_id":"hgnc:HGNC:56850","description":"long independently transcribed non-coding RNA 3111","metadata":{"aliases":["AC090771.2"]}},{"id":"544532a60536449ba334fe249096736d","type":"GENE","name":"LINC03112","canonical_id":"hgnc:HGNC:56853","description":"long independently transcribed non-coding RNA 3112","metadata":null},{"id":"7604f9d9cd2d42c1b5f9109240741bc7","type":"GENE","name":"LINC03113","canonical_id":"hgnc:HGNC:56854","description":"long independently transcribed non-coding RNA 3113","metadata":null},{"id":"2c8d7417994d45398a6074a41335d952","type":"GENE","name":"LINC03114","canonical_id":"hgnc:HGNC:56855","description":"long independently transcribed non-coding RNA 3114","metadata":null},{"id":"6b9f1f0f695a405b94e8e03662d7292c","type":"GENE","name":"LINC03116","canonical_id":"hgnc:HGNC:56881","description":"long independently transcribed non-coding RNA 3116","metadata":null},{"id":"af6c18547c4d4f579c8487f7833d5733","type":"GENE","name":"LINC03117","canonical_id":"hgnc:HGNC:56883","description":"long independently transcribed non-coding RNA 3117","metadata":{"aliases":["lincRTL"]}},{"id":"f7a2c5ce511a4e15ae98b4b030913ff9","type":"GENE","name":"LINC03121","canonical_id":"hgnc:HGNC:56937","description":"long independently transcribed non-coding RNA 3121","metadata":{"aliases":["Lnc-PAL2G4A-4"]}},{"id":"329b59173d45427d970a1a34d4a8ea84","type":"GENE","name":"LINC03122","canonical_id":"hgnc:HGNC:26744","description":"long independently transcribed non-coding RNA 3122","metadata":{"aliases":["FLJ37543","C5orf64","LINC03119"]}},{"id":"edcaa210ae9647c38fb1af1860da2b10","type":"GENE","name":"LINC03123","canonical_id":"hgnc:HGNC:52969","description":"long independently transcribed non-coding RNA 3123","metadata":{"aliases":["C5orf64-AS1"]}},{"id":"f09ce6af84f842a0b1eb69698ff3611b","type":"GENE","name":"LINC03124","canonical_id":"hgnc:HGNC:25077","description":"long independently transcribed non-coding RNA 3124","metadata":{"aliases":["C2orf27","C2orf27A"]}},{"id":"67906519a7e845679e49d6174399c9ca","type":"GENE","name":"LINC03125","canonical_id":"hgnc:HGNC:57012","description":"long independently transcribed non-coding RNA 3125","metadata":{"aliases":["InSETG-4"]}},{"id":"2aeddc95f3d64dc5a090eddba5d474af","type":"GENE","name":"LINC03126","canonical_id":"hgnc:HGNC:57013","description":"long independently transcribed non-coding RNA 3126","metadata":null},{"id":"7e2fd5a7cb4c41c2ba95e9fa4909bc02","type":"GENE","name":"LINC03127","canonical_id":"hgnc:HGNC:58077","description":"long independently transcribed non-coding RNA 3127","metadata":{"aliases":["REIR-2"]}},{"id":"6e3e9c27eeeb4f38962179cd3fd933cb","type":"GENE","name":"LINC03128","canonical_id":"hgnc:HGNC:58079","description":"long independently transcribed non-coding RNA 3128","metadata":{"aliases":["REIR-4"]}},{"id":"fdff50b1e79d45e28731eab453fb5517","type":"GENE","name":"LINC03129","canonical_id":"hgnc:HGNC:57044","description":"long independently transcribed non-coding RNA 3129","metadata":null},{"id":"340df514bda747a484e1b3025c4f5834","type":"GENE","name":"LINC03130","canonical_id":"hgnc:HGNC:58087","description":"long independently transcribed non-coding RNA 3130","metadata":{"aliases":["AC025254.1"]}},{"id":"f982468a38ec40d19ff5b670df6cea13","type":"GENE","name":"LINC03131","canonical_id":"hgnc:HGNC:58088","description":"long independently transcribed non-coding RNA 3131","metadata":{"aliases":["AL162413.1"]}},{"id":"e92874dd56d947c396d6e11b4ba43ce3","type":"GENE","name":"LINC03133","canonical_id":"hgnc:HGNC:58095","description":"long independently transcribed non-coding RNA 3133","metadata":{"aliases":["Lnc-CYP7A1-1"]}},{"id":"58c15dd3e72a4376a3bc30132188b30e","type":"GENE","name":"LINC03134","canonical_id":"hgnc:HGNC:58096","description":"long independently transcribed non-coding RNA 3134","metadata":{"aliases":["CTC-537E7.3","CTC-537E7.2"]}},{"id":"34b823b2ad7e4ab187a73b0279c8fe30","type":"GENE","name":"LINC03135","canonical_id":"hgnc:HGNC:58100","description":"long independently transcribed non-coding RNA 3135","metadata":{"aliases":["AL033519.3","RP3-340B19.3"]}},{"id":"a81fd4fc8981477d912ef724dd472f5f","type":"GENE","name":"LINC03136","canonical_id":"hgnc:HGNC:58102","description":"long independently transcribed non-coding RNA 3136","metadata":{"aliases":["AP000842.3"]}},{"id":"1204af73b7c94b9eb3fa992d55000c75","type":"GENE","name":"LINC03137","canonical_id":"hgnc:HGNC:58103","description":"long independently transcribed non-coding RNA 3137","metadata":{"aliases":["OLBC15","AC100826.1"]}},{"id":"e70eea241cc84e6183c45430cecf4452","type":"GENE","name":"LINC03138","canonical_id":"hgnc:HGNC:58104","description":"long independently transcribed non-coding RNA 3138","metadata":{"aliases":["AF131217.1"]}},{"id":"08012f2229aa4c45aacd9bf869b38cf8","type":"GENE","name":"LINC03139","canonical_id":"hgnc:HGNC:58111","description":"long independently transcribed non-coding RNA 3139","metadata":{"aliases":["RP11-472G21.2"]}},{"id":"a6a4e4d3f1ba45918c728da9eab3ac29","type":"GENE","name":"LINC03140","canonical_id":"hgnc:HGNC:58127","description":"long independently transcribed non-coding RNA 3140","metadata":{"aliases":["lincRNA-JADE1"]}},{"id":"e1b198e59ffd4f83babbc0714a05cba5","type":"GENE","name":"LINC03141","canonical_id":"hgnc:HGNC:58143","description":"long independently transcribed non-coding RNA 3141","metadata":{"aliases":["AC007207.2"]}},{"id":"07b013a519714913b574bd929fc16e2d","type":"GENE","name":"LINC03142","canonical_id":"hgnc:HGNC:58153","description":"long independently transcribed non-coding RNA 3142","metadata":null},{"id":"c3e2016abab5447e9c160d39bb8bb6f1","type":"GENE","name":"LINC03143","canonical_id":"hgnc:HGNC:58162","description":"long independently transcribed non-coding RNA 3143","metadata":{"aliases":["U73166"]}},{"id":"5cf7b2e330a942418f682bf4c33287c7","type":"GENE","name":"LINC03144","canonical_id":"hgnc:HGNC:58272","description":"long independently transcribed non-coding RNA 3144","metadata":{"aliases":["AP002754.2"]}},{"id":"b6e0e92d47504e2f85680136e6ff7a4e","type":"GENE","name":"LINC03145","canonical_id":"hgnc:HGNC:56020","description":"long independently transcribed non-coding RNA 3145","metadata":{"aliases":["CRART16"]}},{"id":"e3e8564e0c044dc8b29e20e86ed93f1d","type":"GENE","name":"LINC03146","canonical_id":"hgnc:HGNC:58312","description":"long independently transcribed non-coding RNA 3146","metadata":null},{"id":"551e0ea13e7d4cc389e6e9b6a6a4702b","type":"GENE","name":"LINC03147","canonical_id":"hgnc:HGNC:1279","description":"long independently transcribed non-coding RNA 3147","metadata":{"aliases":["C21orf39","NCRNA00157","CHODL-AS1"]}},{"id":"dae3243cceed4caeb13be15f75455fa7","type":"GENE","name":"LINC03148","canonical_id":"hgnc:HGNC:58365","description":"long independently transcribed non-coding RNA 3148","metadata":null},{"id":"156e162882fb40ed83e755380d2518bf","type":"GENE","name":"LINC03149","canonical_id":"hgnc:HGNC:58369","description":"long independently transcribed non-coding RNA 3149","metadata":{"aliases":["AC145207.5"]}},{"id":"c4bfb78482c8471888f34decc1feca5c","type":"GENE","name":"LINC03150","canonical_id":"hgnc:HGNC:58374","description":"long independently transcribed non-coding RNA 3150","metadata":null},{"id":"8960eda631f0463cbe8e1875d0d6f22d","type":"GENE","name":"LINC03151","canonical_id":"hgnc:HGNC:58391","description":"long independently transcribed non-coding RNA 3151","metadata":null},{"id":"471ace10d2c74c6eafd7233ac3f5cc52","type":"GENE","name":"LINC03152","canonical_id":"hgnc:HGNC:58412","description":"long independently transcribed non-coding RNA 3152","metadata":null},{"id":"adda273986f545dca0586d2b4ce394af","type":"GENE","name":"LINC03153","canonical_id":"hgnc:HGNC:58484","description":"long independently transcribed non-coding RNA 3153","metadata":null},{"id":"ed949fa449af436fbf648df708ec6359","type":"GENE","name":"LINC03154","canonical_id":"hgnc:HGNC:58485","description":"long independently transcribed non-coding RNA 3154","metadata":null},{"id":"eb1a18f9d2f14b32ad31ae35915a1355","type":"GENE","name":"LINC03155","canonical_id":"hgnc:HGNC:58489","description":"long independently transcribed non-coding RNA 3155","metadata":null},{"id":"341038a0413c413494ea03f18d3b9173","type":"GENE","name":"LINC03156","canonical_id":"hgnc:HGNC:49838","description":"long independently transcribed non-coding RNA 3156","metadata":{"aliases":["MIR7515HG"]}},{"id":"bd3ff169d69040c39d203c8fc27fa470","type":"GENE","name":"LINC03157","canonical_id":"hgnc:HGNC:58697","description":"long independently transcribed non-coding RNA 3157","metadata":{"aliases":["lncRNA-ACOD1"]}},{"id":"be2a871802f3495780b0044b9b3d362e","type":"GENE","name":"LINC03158","canonical_id":"hgnc:HGNC:58698","description":"long independently transcribed non-coding RNA 3158","metadata":null},{"id":"a5d2b4b6526f415ca818c8c092262eb4","type":"GENE","name":"LINC03159","canonical_id":"hgnc:HGNC:58713","description":"long independently transcribed non-coding RNA 3159","metadata":null},{"id":"0ac509e7fa7d4a89a1d06106ee8f10f6","type":"GENE","name":"LINC03160","canonical_id":"hgnc:HGNC:58770","description":"long independently transcribed non-coding RNA 3160","metadata":{"aliases":["lncRNA-6195"]}},{"id":"c536aa63a87f4ecc9fab2a59d21fa799","type":"GENE","name":"LINC03161","canonical_id":"hgnc:HGNC:58772","description":"long independently transcribed non-coding RNA 3161","metadata":{"aliases":["AC021683.2"]}},{"id":"223d410257d246f280d2e0e2e8ccc735","type":"GENE","name":"LINC03162","canonical_id":"hgnc:HGNC:58849","description":"long independently transcribed non-coding RNA 3162","metadata":{"aliases":["CTD-2555A7.2"]}},{"id":"744cea21eff4490caa4610eb384f673a","type":"GENE","name":"LINC03163","canonical_id":"hgnc:HGNC:27927","description":"long independently transcribed non-coding RNA 3163","metadata":null},{"id":"a8c55aa155074a76b3e651465acfdbec","type":"GENE","name":"LINC03164","canonical_id":"hgnc:HGNC:58927","description":"long independently transcribed non-coding RNA 3164","metadata":{"aliases":["uc.9"]}},{"id":"32f848510a1a49bbb1c853fc3ca634c5","type":"GENE","name":"LINC03165","canonical_id":"hgnc:HGNC:58928","description":"long independently transcribed non-coding RNA 3165","metadata":{"aliases":["uc.16"]}},{"id":"959c720642944669b2ed577f97ba5620","type":"GENE","name":"LINC03166","canonical_id":"hgnc:HGNC:58929","description":"long independently transcribed non-coding RNA 3166","metadata":{"aliases":["uc.17"]}},{"id":"7cac9bee19a443898841b02111cd86c3","type":"GENE","name":"LINC03167","canonical_id":"hgnc:HGNC:58930","description":"long independently transcribed non-coding RNA 3167","metadata":{"aliases":["uc.17"]}},{"id":"2cad3469196f41db866c18eaf5739bdb","type":"GENE","name":"LINC03168","canonical_id":"hgnc:HGNC:58932","description":"long independently transcribed non-coding RNA 3168","metadata":{"aliases":["uc.30"]}},{"id":"28dcdc55b90d4e3394221cbf21577793","type":"GENE","name":"LINC03169","canonical_id":"hgnc:HGNC:58933","description":"long independently transcribed non-coding RNA 3169","metadata":{"aliases":["uc.38"]}},{"id":"595ab42b3b5244e1904d30f71a3ee601","type":"GENE","name":"LINC03170","canonical_id":"hgnc:HGNC:58934","description":"long independently transcribed non-coding RNA 3170","metadata":{"aliases":["uc.47"]}},{"id":"26a71fd0a33b45a99977aadc9301526d","type":"GENE","name":"LINC03171","canonical_id":"hgnc:HGNC:58935","description":"long independently transcribed non-coding RNA 3171","metadata":{"aliases":["uc.51"]}},{"id":"9b6abf4f1e3d4cf380d8a519dd9f4bc3","type":"GENE","name":"LINC03172","canonical_id":"hgnc:HGNC:58936","description":"long independently transcribed non-coding RNA 3172","metadata":{"aliases":["uc.57","uc.56","uc.55"]}},{"id":"7c341e9326964194baaa20f27cb5bbb4","type":"GENE","name":"LINC03173","canonical_id":"hgnc:HGNC:58937","description":"long independently transcribed non-coding RNA 3173","metadata":{"aliases":["uc.58"]}},{"id":"fdac95614d514ff3832c251f24d4c642","type":"GENE","name":"LINC03174","canonical_id":"hgnc:HGNC:58938","description":"long independently transcribed non-coding RNA 3174","metadata":{"aliases":["uc.81"]}},{"id":"4c36650d1948488d9c315bcd6757dfc5","type":"GENE","name":"LINC03175","canonical_id":"hgnc:HGNC:58939","description":"long independently transcribed non-coding RNA 3175","metadata":{"aliases":["uc.82"]}},{"id":"fb709987efae482a91968087a2b5865f","type":"GENE","name":"LINC03176","canonical_id":"hgnc:HGNC:58940","description":"long independently transcribed non-coding RNA 3176","metadata":{"aliases":["uc.86"]}},{"id":"fcc1a3a9e4d64c7ca47cee02ee32a5f9","type":"GENE","name":"LINC03177","canonical_id":"hgnc:HGNC:58941","description":"long independently transcribed non-coding RNA 3177","metadata":{"aliases":["uc.87"]}},{"id":"533581ed4bc44929aa55a37de00c3207","type":"GENE","name":"LINC03178","canonical_id":"hgnc:HGNC:58942","description":"long independently transcribed non-coding RNA 3178","metadata":{"aliases":["uc.94","uc.93"]}},{"id":"8906738c25724b36ab7b8610ecee44b1","type":"GENE","name":"LINC03179","canonical_id":"hgnc:HGNC:58944","description":"long independently transcribed non-coding RNA 3179","metadata":{"aliases":["uc.115"]}},{"id":"622d65259d3d4269a89c2d1cc5d63ecb","type":"GENE","name":"LINC03180","canonical_id":"hgnc:HGNC:58945","description":"long independently transcribed non-coding RNA 3180","metadata":{"aliases":["uc.115"]}},{"id":"f80adebbfece4593a5072c23db2db317","type":"GENE","name":"LINC03181","canonical_id":"hgnc:HGNC:58946","description":"long independently transcribed non-coding RNA 3181","metadata":{"aliases":["uc.124"]}},{"id":"5941eca914f046ceb7fbf8983cf71c3a","type":"GENE","name":"LINC03182","canonical_id":"hgnc:HGNC:58947","description":"long independently transcribed non-coding RNA 3182","metadata":{"aliases":["uc.128","uc.127"]}},{"id":"a7cdb3c605fc440992b8b94550af7e39","type":"GENE","name":"LINC03183","canonical_id":"hgnc:HGNC:58948","description":"long independently transcribed non-coding RNA 3183","metadata":{"aliases":["uc.130"]}},{"id":"2b49d1ffe4ca46b5860b714397009067","type":"GENE","name":"LINC03184","canonical_id":"hgnc:HGNC:58949","description":"long independently transcribed non-coding RNA 3184","metadata":{"aliases":["uc.137"]}},{"id":"03c3d0b7d47841b8b573352c52357350","type":"GENE","name":"LINC03185","canonical_id":"hgnc:HGNC:58950","description":"long independently transcribed non-coding RNA 3185","metadata":{"aliases":["uc.146"]}},{"id":"2070e25cc34147c6ae5ab7787b1b2e82","type":"GENE","name":"LINC03187","canonical_id":"hgnc:HGNC:58952","description":"long independently transcribed non-coding RNA 3187","metadata":{"aliases":["uc.205"]}},{"id":"f3e803f3818a415a8cd969cc32337a71","type":"GENE","name":"LINC03188","canonical_id":"hgnc:HGNC:58953","description":"long independently transcribed non-coding RNA 3188","metadata":{"aliases":["uc.206"]}},{"id":"4a6cdab17c0049b79c4b78645ae63f01","type":"GENE","name":"LINC03189","canonical_id":"hgnc:HGNC:58955","description":"long independently transcribed non-coding RNA 3189","metadata":{"aliases":["uc.230"]}},{"id":"eea849c602c2483fa02225588b45e58b","type":"GENE","name":"LINC03190","canonical_id":"hgnc:HGNC:58956","description":"long independently transcribed non-coding RNA 3190","metadata":{"aliases":["uc.250"]}},{"id":"6d3f32c4b9f14db090f27753197dd051","type":"GENE","name":"LINC03191","canonical_id":"hgnc:HGNC:58957","description":"long independently transcribed non-coding RNA 3191","metadata":{"aliases":["uc.303"]}},{"id":"ba4786ed36644d6db358fb558f9a8440","type":"GENE","name":"LINC03193","canonical_id":"hgnc:HGNC:58961","description":"long independently transcribed non-coding RNA 3193","metadata":{"aliases":["uc.152"]}},{"id":"6b3e802118574816b714f23e3ed61d49","type":"GENE","name":"LINC03194","canonical_id":"hgnc:HGNC:58962","description":"long independently transcribed non-coding RNA 3194","metadata":{"aliases":["uc.162"]}},{"id":"8f02673247ff4564b39cd2422df34668","type":"GENE","name":"LINC03195","canonical_id":"hgnc:HGNC:58963","description":"long independently transcribed non-coding RNA 3195","metadata":{"aliases":["uc.162"]}},{"id":"5f528eceaca348e8a001cc894b795bc6","type":"GENE","name":"LINC03196","canonical_id":"hgnc:HGNC:58965","description":"long independently transcribed non-coding RNA 3196","metadata":{"aliases":["uc.321"]}},{"id":"8b782d3b20224cb1ac9091255543575f","type":"GENE","name":"LINC03197","canonical_id":"hgnc:HGNC:58966","description":"long independently transcribed non-coding RNA 3197","metadata":{"aliases":["uc.340"]}},{"id":"99550225437143e98686173fb2e13f2b","type":"GENE","name":"LINC03198","canonical_id":"hgnc:HGNC:58969","description":"long independently transcribed non-coding RNA 3198","metadata":{"aliases":["uc.355"]}},{"id":"114e8069567a44dfb669e6ad85cca40b","type":"GENE","name":"LINC03199","canonical_id":"hgnc:HGNC:58970","description":"long independently transcribed non-coding RNA 3199","metadata":{"aliases":["uc.362"]}},{"id":"2223a6331adb45a4931b1c5a4d950fb6","type":"GENE","name":"LINC03200","canonical_id":"hgnc:HGNC:58971","description":"long independently transcribed non-coding RNA 3200","metadata":{"aliases":["uc.363"]}},{"id":"7899dd7c4b194204bca2684bc2ad7d0c","type":"GENE","name":"LINC03201","canonical_id":"hgnc:HGNC:58972","description":"long independently transcribed non-coding RNA 3201","metadata":{"aliases":["uc.381"]}},{"id":"8b6ce25484fb42dd915fc2be8b826456","type":"GENE","name":"LINC03202","canonical_id":"hgnc:HGNC:58973","description":"long independently transcribed non-coding RNA 3202","metadata":{"aliases":["uc.383"]}},{"id":"f59599097936462ca4777a80ff8ef025","type":"GENE","name":"LINC03203","canonical_id":"hgnc:HGNC:58974","description":"long independently transcribed non-coding RNA 3203","metadata":{"aliases":["uc.392"]}},{"id":"1310ae1d32f44eefa3b91ece16f5b4be","type":"GENE","name":"LINC03204","canonical_id":"hgnc:HGNC:58977","description":"long independently transcribed non-coding RNA 3204","metadata":{"aliases":["uc.431"]}},{"id":"9455baff2a08460f9020a4c0fe597ea1","type":"GENE","name":"LINC03205","canonical_id":"hgnc:HGNC:58978","description":"long independently transcribed non-coding RNA 3205","metadata":{"aliases":["uc.432"]}},{"id":"5c298b04d5074e7cb2c3953985559bd3","type":"GENE","name":"LINC03206","canonical_id":"hgnc:HGNC:58979","description":"long independently transcribed non-coding RNA 3206","metadata":{"aliases":["uc.433"]}},{"id":"4177ac8e59894c92be32b36125a27886","type":"GENE","name":"LINC03207","canonical_id":"hgnc:HGNC:58981","description":"long independently transcribed non-coding RNA 3207","metadata":{"aliases":["uc.470"]}},{"id":"bb408eb2d6e142798e0ea385a08ccc13","type":"GENE","name":"LINC03208","canonical_id":"hgnc:HGNC:58983","description":"long independently transcribed non-coding RNA 3208","metadata":null},{"id":"161aa58aa944415f8fa8fed14a9e479d","type":"GENE","name":"LINC03209","canonical_id":"hgnc:HGNC:59050","description":"long independently transcribed non-coding RNA 3209","metadata":null},{"id":"3acab644e03947d691493d48cb32ffd4","type":"GENE","name":"LINC03210","canonical_id":"hgnc:HGNC:59051","description":"long independently transcribed non-coding RNA 3210","metadata":null},{"id":"885ee43c5cdc491a8ec9b4c080d0730a","type":"GENE","name":"LINC03211","canonical_id":"hgnc:HGNC:59052","description":"long independently transcribed non-coding RNA 3211","metadata":null},{"id":"894bf95ebb864fe1a9edec3d3f127901","type":"GENE","name":"LINC03212","canonical_id":"hgnc:HGNC:59053","description":"long independently transcribed non-coding RNA 3212","metadata":null},{"id":"dda068e611f24238bd84cdd1b941007a","type":"GENE","name":"LINC03213","canonical_id":"hgnc:HGNC:59054","description":"long independently transcribed non-coding RNA 3213","metadata":null},{"id":"2869a591ef4349088b0b42987ca1a364","type":"GENE","name":"LINC03214","canonical_id":"hgnc:HGNC:59055","description":"long independently transcribed non-coding RNA 3214","metadata":null},{"id":"408b7162a74a444880881f0ea3dba5e3","type":"GENE","name":"LINC03215","canonical_id":"hgnc:HGNC:59078","description":"long independently transcribed non-coding RNA 3215","metadata":null},{"id":"28543aff523c4caebdff5fa087667d91","type":"GENE","name":"LINC03216","canonical_id":"hgnc:HGNC:59079","description":"long independently transcribed non-coding RNA 3216","metadata":null},{"id":"6687870e48cd44e3ba58546a686d286e","type":"GENE","name":"LINC03217","canonical_id":"hgnc:HGNC:59080","description":"long independently transcribed non-coding RNA 3217","metadata":null},{"id":"0a9e474cf48a4791b7b36bca6c2c0e51","type":"GENE","name":"LINC03218","canonical_id":"hgnc:HGNC:39763","description":"long independently transcribed non-coding RNA 3218","metadata":{"aliases":["XXbac-BPG254F23.7"]}},{"id":"1dfa4364f1074fd3ad08dd978c3fb788","type":"GENE","name":"LINC03219","canonical_id":"hgnc:HGNC:59162","description":"long independently transcribed non-coding RNA 3219","metadata":null},{"id":"34ed28b79cf14199adafec33de57cd8b","type":"GENE","name":"LINC03220","canonical_id":"hgnc:HGNC:59163","description":"long independently transcribed non-coding RNA 3220","metadata":null},{"id":"1b8d6c1ab59243fd9fe319cf221be42d","type":"GENE","name":"LINC03221","canonical_id":"hgnc:HGNC:59164","description":"long independently transcribed non-coding RNA 3221","metadata":null},{"id":"66c6e636075b48a4a31914d81a4e6834","type":"GENE","name":"LINC03222","canonical_id":"hgnc:HGNC:59165","description":"long independently transcribed non-coding RNA 3222","metadata":null},{"id":"baba8b6172cc43a5bc64fd159937ee3e","type":"GENE","name":"LINC03223","canonical_id":"hgnc:HGNC:59166","description":"long independently transcribed non-coding RNA 3223","metadata":null},{"id":"4ecf32b841c649ce9bdc49ff416e728e","type":"GENE","name":"LINC03224","canonical_id":"hgnc:HGNC:59167","description":"long independently transcribed non-coding RNA 3224","metadata":null},{"id":"63eca782a1c94f6d98c657dc0455a17b","type":"GENE","name":"LINC03225","canonical_id":"hgnc:HGNC:59168","description":"long independently transcribed non-coding RNA 3225","metadata":null},{"id":"676203f084bd430399a9d3ea76f4b11f","type":"GENE","name":"LINC03226","canonical_id":"hgnc:HGNC:59178","description":"long independently transcribed non-coding RNA 3226","metadata":null},{"id":"c5bafdf540a544c79a336384a12e5291","type":"GENE","name":"LINC03227","canonical_id":"hgnc:HGNC:27583","description":"long independently transcribed non-coding RNA 3227","metadata":null},{"id":"48848daa9d9f4fb08765962628e49e4a","type":"GENE","name":"LINC03228","canonical_id":"hgnc:HGNC:59193","description":"long independently transcribed non-coding RNA 3228","metadata":null},{"id":"5b4b386451654b35a8293bb06ea41be5","type":"GENE","name":"LINC03229","canonical_id":"hgnc:HGNC:59200","description":"long independently transcribed non-coding RNA 3229","metadata":null},{"id":"ec5378405fb84c04ab15b523d0286c00","type":"GENE","name":"LINC03230","canonical_id":"hgnc:HGNC:59201","description":"long independently transcribed non-coding RNA 3230","metadata":null},{"id":"429c020811c84a048bbbeeae735a0087","type":"GENE","name":"LINC03232","canonical_id":"hgnc:HGNC:59204","description":"long independently transcribed non-coding RNA 3232","metadata":{"aliases":["CTA-384D8.34","U62317.4"]}},{"id":"b871be0b9b8f4e029a612fb11a6563e5","type":"GENE","name":"LINC03233","canonical_id":"hgnc:HGNC:59214","description":"long independently transcribed non-coding RNA 3233","metadata":null},{"id":"cda33f7fd7034000ba2c1666a0f750f0","type":"GENE","name":"LINC03234","canonical_id":"hgnc:HGNC:59215","description":"long independently transcribed non-coding RNA 3234","metadata":null},{"id":"79f99d7b919a47b484b2980c6a0895e0","type":"GENE","name":"LINC03235","canonical_id":"hgnc:HGNC:27470","description":"long independently transcribed non-coding RNA 3235","metadata":null},{"id":"b38b1d151e104a4fa2266653cd159197","type":"GENE","name":"LINC03236","canonical_id":"hgnc:HGNC:59218","description":"long independently transcribed non-coding RNA 3236","metadata":null},{"id":"4fc6529e21394983aea6abebf9a09fb4","type":"GENE","name":"LINC03237","canonical_id":"hgnc:HGNC:59219","description":"long independently transcribed non-coding RNA 3237","metadata":null},{"id":"59d0c933b182475197968322db5d1bee","type":"GENE","name":"LINC03238","canonical_id":"hgnc:HGNC:59220","description":"long independently transcribed non-coding RNA 3238","metadata":null},{"id":"376d97b27d7d477da529a960a2404377","type":"GENE","name":"LINC03239","canonical_id":"hgnc:HGNC:59223","description":"long independently transcribed non-coding RNA 3239","metadata":null},{"id":"5d44c96024444871baeb0b5979cc7daf","type":"GENE","name":"LINC03240","canonical_id":"hgnc:HGNC:59224","description":"long independently transcribed non-coding RNA 3240","metadata":null},{"id":"c3b01c895dc244f9981c1a33a6f05a4b","type":"GENE","name":"LINC03241","canonical_id":"hgnc:HGNC:59226","description":"long independently transcribed non-coding RNA 3241","metadata":null},{"id":"5dcbdf736a1e4d8ebfa8e675c1a1c097","type":"GENE","name":"LINC03242","canonical_id":"hgnc:HGNC:59228","description":"long independently transcribed non-coding RNA 3242","metadata":null},{"id":"b350c140d6074c6b9e68a840c63d74de","type":"GENE","name":"LINC03243","canonical_id":"hgnc:HGNC:59229","description":"long independently transcribed non-coding RNA 3243","metadata":null},{"id":"b3b842b4270643c099514ba18f0967e4","type":"GENE","name":"LINC03244","canonical_id":"hgnc:HGNC:59253","description":"long independently transcribed non-coding RNA 3244","metadata":{"aliases":["RP3-340N1.2"]}},{"id":"7862fb57340147eabbaa2ee59bddec69","type":"GENE","name":"LINCADL","canonical_id":"hgnc:HGNC:53956","description":"lincRNA adipogenesis and lipogenesis associated","metadata":{"aliases":["linc-ADAL"]}},{"id":"bb942b5b3aef4c24866e9d35bcdcd730","type":"GENE","name":"LINCMD1","canonical_id":"hgnc:HGNC:49089","description":"long independently transcribed non-coding RNA, muscle differentiation 1","metadata":{"aliases":["MIR133BHG","LINC-MD1"]}},{"id":"22969f053e9d46cfabf1474cef8b6336","type":"GENE","name":"LINGO1","canonical_id":"hgnc:HGNC:21205","description":"leucine rich repeat and Ig domain containing 1","metadata":{"aliases":["FLJ14594","LERN1","LRRN6A"]}},{"id":"bfe4d3105b4641698ec0d78894b62c5a","type":"GENE","name":"LINGO1-AS1","canonical_id":"hgnc:HGNC:27368","description":"LINGO1 antisense RNA 1","metadata":null},{"id":"e923ca7de12e4e299d27544812c2a048","type":"GENE","name":"LINGO1-AS2","canonical_id":"hgnc:HGNC:51423","description":"LINGO1 antisense RNA 2","metadata":null},{"id":"9bf02226c21e44c0b43b4db3d7f175ee","type":"GENE","name":"LINGO2","canonical_id":"hgnc:HGNC:21207","description":"leucine rich repeat and Ig domain containing 2","metadata":{"aliases":["LERN3","LRRN6C"]}},{"id":"26a874f9f0784b5985d5ba733a9187fa","type":"GENE","name":"LINGO3","canonical_id":"hgnc:HGNC:21206","description":"leucine rich repeat and Ig domain containing 3","metadata":{"aliases":["LERN2","LRRN6B"]}},{"id":"4ecb582da9c84feaa3ea646b9d1fdb3d","type":"GENE","name":"LINGO4","canonical_id":"hgnc:HGNC:31814","description":"leucine rich repeat and Ig domain containing 4","metadata":{"aliases":["LRRN6D"]}},{"id":"c7ebbc1164d54c01a257e90c30bf6fb9","type":"GENE","name":"LINP1","canonical_id":"hgnc:HGNC:53170","description":"lncRNA in non-homologous end joining pathway 1","metadata":{"aliases":["PARROT","LINC00707"]}},{"id":"a3f7f0e3445c4cbabeac9e8486add308","type":"GENE","name":"LINS1","canonical_id":"hgnc:HGNC:30922","description":"lines homolog 1","metadata":{"aliases":["WINS1","LINS","MRT27"]}},{"id":"1b50958098eb420f9fa9e320170cdf45","type":"GENE","name":"LIPA","canonical_id":"hgnc:HGNC:6617","description":"lipase A, lysosomal acid type","metadata":{"aliases":["LAL","CESD"]}},{"id":"0d188613d64c4376b55541222cdbac7c","type":"GENE","name":"LIPB","canonical_id":"hgnc:HGNC:6618","description":"lipase B, lysosomal acid type","metadata":null},{"id":"1cb92af00bd14099858ebdd381315794","type":"GENE","name":"LIPC","canonical_id":"hgnc:HGNC:6619","description":null,"metadata":null},{"id":"a17a5d5b99fa45faa68fc45072b013b6","type":"GENE","name":"LIPC-AS1","canonical_id":"hgnc:HGNC:52294","description":"LIPC antisense RNA 1","metadata":null},{"id":"9955c5c5d99f434fa9b586a67c0ef92f","type":"GENE","name":"LIPE","canonical_id":"hgnc:HGNC:6621","description":null,"metadata":null},{"id":"a7680c2c4a4e487bb9c99d210d218667","type":"GENE","name":"LIPE-AS1","canonical_id":"hgnc:HGNC:48589","description":"LIPE antisense RNA 1","metadata":null},{"id":"d13dd126b5ac4ec9b893ad8a78fdb49c","type":"GENE","name":"LIPF","canonical_id":"hgnc:HGNC:6622","description":"lipase F, gastric type","metadata":{"aliases":["HGL","HLAL"]}},{"id":"5c40a7ec00654065a29248761faf54d5","type":"PROTEIN","name":"LIPF","canonical_id":"uniprot:P07098","description":null,"metadata":null},{"id":"d3507a141d9944f8977ede86b172ee57","type":"GENE","name":"LIPG","canonical_id":"hgnc:HGNC:6623","description":"lipase G, endothelial type","metadata":{"aliases":["EDL"]}},{"id":"d0a5f6112d9743e2b62d23baa35df77c","type":"GENE","name":"LIPH","canonical_id":"hgnc:HGNC:18483","description":"lipase H","metadata":{"aliases":["mPA-PLA1","PLA1B","mPA-PLA1alpha","LPDLR"]}},{"id":"757a0886b2214b8db5b93595ad3a1f0f","type":"GENE","name":"LIPI","canonical_id":"hgnc:HGNC:18821","description":"lipase I","metadata":{"aliases":["PRED5","LPDL","CT17","mPA-PLA1beta","PLA1C"]}},{"id":"198c0b97822041edae21554f5b787393","type":"GENE","name":"LIPJ","canonical_id":"hgnc:HGNC:21773","description":"lipase family member J","metadata":{"aliases":["bA425M17.2","LIPL1"]}},{"id":"fa65bc85229b47aba4df1fcedc2b8df3","type":"GENE","name":"LIPK","canonical_id":"hgnc:HGNC:23444","description":"lipase family member K","metadata":{"aliases":["bA186O14.2","LIPL2"]}},{"id":"20dc7ea63aae427d8ed8e368332ee856","type":"GENE","name":"LIPM","canonical_id":"hgnc:HGNC:23455","description":"lipase family member M","metadata":{"aliases":["bA304I5.1","LIPL3"]}},{"id":"93147f9e72854c0fa72a5b8af0c630cd","type":"GENE","name":"LIPN","canonical_id":"hgnc:HGNC:23452","description":"lipase family member N","metadata":{"aliases":["bA186O14.3","LIPL4"]}},{"id":"2baf2893cb43464e8f9d7dffb298137f","type":"GENE","name":"LIPT1","canonical_id":"hgnc:HGNC:29569","description":"lipoyltransferase 1","metadata":{"aliases":["MGC12290","MGC13378"]}},{"id":"2d7c0aa104c54834a4a843353dcfc9b2","type":"GENE","name":"LIPT1P1","canonical_id":"hgnc:HGNC:39278","description":"lipoyltransferase 1 pseudogene 1","metadata":null},{"id":"cbf025ccb3e74c5099036b09a5645acf","type":"GENE","name":"LIPT2","canonical_id":"hgnc:HGNC:37216","description":"lipoyl(octanoyl) transferase 2","metadata":null},{"id":"181eeafc4dbc4c268d87b50c1ba586c5","type":"GENE","name":"LIPT2-AS1","canonical_id":"hgnc:HGNC:56172","description":"LIPT2 antisense RNA 1","metadata":null},{"id":"43aa8e6fe9dd41c8b28afe521baebf47","type":"TRIAL","name":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.","canonical_id":"clinicaltrials.gov:NCT02964247","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"0513df05aa0945e18a8f63cf6f7f2241","type":"GENE","name":"LIRIL2R","canonical_id":"hgnc:HGNC:56638","description":"lincRNA regulator of IL2RA","metadata":null},{"id":"36e4cb2ae5bf4f15b35a4958050ed8bf","type":"GENE","name":"LITAF","canonical_id":"hgnc:HGNC:16841","description":null,"metadata":null},{"id":"7ac70a33251d4bb78e239c8b86f0514b","type":"GENE","name":"LITAFD","canonical_id":"hgnc:HGNC:53927","description":"LITAF domain containing","metadata":null},{"id":"7eeb96e4fccc436c88d7a758275324c9","type":"GENE","name":"LITATS1","canonical_id":"hgnc:HGNC:49453","description":"lncRNA induced by TGF-beta and antagonizes TGF-beta signaling 1","metadata":{"aliases":["LOC728431","LINC01137","ZC3H12A-DT"]}},{"id":"78561da5661c4f5d8f1e07ec68b6c923","type":"GENE","name":"LIVAR","canonical_id":"hgnc:HGNC:53130","description":"liver cell viability associated lncRNA","metadata":{"aliases":["lnc18q22.2"]}},{"id":"55d80dab5d444feca24f79c1fc6ed982","type":"TRIAL","name":"LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT02631772","description":"Hepatitis C","metadata":null},{"id":"dcc7ba051b1f4ed59733003b886c6296","type":"GENE","name":"LIX1","canonical_id":"hgnc:HGNC:18581","description":"limb and CNS expressed 1","metadata":{"aliases":["Lft","C5orf11"]}},{"id":"d355cf763da04f0dba6a138f3b96a94c","type":"GENE","name":"LIX1-AS1","canonical_id":"hgnc:HGNC:52976","description":"LIX1 and RIOK2 antisense RNA 1","metadata":null},{"id":"a351ae0fb24641c8ac48696d753a149e","type":"GENE","name":"LIX1L","canonical_id":"hgnc:HGNC:28715","description":"limb and CNS expressed 1 like","metadata":{"aliases":["MGC46719"]}},{"id":"1a0a537274eb4681ac05995ae14f6373","type":"GENE","name":"LIX1L-AS1","canonical_id":"hgnc:HGNC:41210","description":"LIX1L antisense RNA 1","metadata":null},{"id":"67bc36981368443591e41b69890ad86a","type":"GENE","name":"LKAAEAR1","canonical_id":"hgnc:HGNC:33718","description":"LKAAEAR motif containing 1","metadata":{"aliases":["C20orf201"]}},{"id":"02d5d5ee13fc48fdba1846b5f51ce016","type":"GENE","name":"LLGL1","canonical_id":"hgnc:HGNC:6628","description":"LLGL scribble cell polarity complex component 1","metadata":{"aliases":["Lgl1","Mgl1","DLG4","LLGL","HUGL","HUGL-1"]}},{"id":"87b8b66f0d154596b8753665b6af9cdd","type":"GENE","name":"LLGL2","canonical_id":"hgnc:HGNC:6629","description":"LLGL scribble cell polarity complex component 2","metadata":{"aliases":["HGL","Hugl-2"]}},{"id":"0a39622f5706493dab9de8cc67dbf140","type":"GENE","name":"LLPH","canonical_id":"hgnc:HGNC:28229","description":"LLP homolog, long-term synaptic facilitation factor","metadata":{"aliases":["MGC14817","hLLP","C12orf31"]}},{"id":"adc89137126946129e894a0a51a59a2f","type":"GENE","name":"LLPH-DT","canonical_id":"hgnc:HGNC:50493","description":"LLPH divergent transcript","metadata":{"aliases":["LLPH-AS1"]}},{"id":"33fccccf2a8c4c52ae2529bc5b195c6f","type":"GENE","name":"LLPHP1","canonical_id":"hgnc:HGNC:50491","description":"LLPH pseudogene 1","metadata":null},{"id":"ee531d60868245058f3f8d1b829eff8b","type":"GENE","name":"LLPHP2","canonical_id":"hgnc:HGNC:50492","description":"LLPH pseudogene 2","metadata":null},{"id":"b0663c15430d42e7a3c08cec0f25f71f","type":"GENE","name":"LLPHP3","canonical_id":"hgnc:HGNC:54775","description":"LLPH pseudogene 3","metadata":null},{"id":"caf4bed1766c4757afcd72ea008186b8","type":"GENE","name":"LMAN1","canonical_id":"hgnc:HGNC:6631","description":"lectin, mannose binding 1","metadata":{"aliases":["MR60","ERGIC-53","ERGIC53","gp58","MCFD1","FMFD1","F5F8D"]}},{"id":"b6d5297222a8433ba19643c48c01b0a5","type":"GENE","name":"LMAN1L","canonical_id":"hgnc:HGNC:6632","description":"lectin, mannose binding 1 like","metadata":{"aliases":["ERGL","ERGIC-53L"]}},{"id":"bf0a110e679d4ecf9fc7f800d3dfa9c7","type":"GENE","name":"LMAN2","canonical_id":"hgnc:HGNC:16986","description":"lectin, mannose binding 2","metadata":{"aliases":["GP36B","VIP36","C5orf8"]}},{"id":"3ab6e167023047adbca2e769fc09a6b1","type":"GENE","name":"LMAN2L","canonical_id":"hgnc:HGNC:19263","description":"lectin, mannose binding 2 like","metadata":{"aliases":["DKFZp564L2423","VIPL"]}},{"id":"2667a8aac5a2498f9cca9d90a8b14a18","type":"GENE","name":"LMBR1","canonical_id":"hgnc:HGNC:13243","description":"limb development membrane protein 1","metadata":{"aliases":["ACHP","FLJ11665","ZRS","C7orf2"]}},{"id":"3c90aa7a53e7463db9b074872b7aa815","type":"GENE","name":"LMBR1L","canonical_id":"hgnc:HGNC:18268","description":"limb development membrane protein 1 like","metadata":{"aliases":["LIMR","FLJ10494","KIAA1174"]}},{"id":"a7c7d8acd0eb4194bc19242d3344b093","type":"GENE","name":"LMBRD1","canonical_id":"hgnc:HGNC:23038","description":"LMBR1 domain containing 1","metadata":{"aliases":["FLJ11240","bA810I22.1","cblF","C6orf209"]}},{"id":"5a4c50ef0fb3411f825d188bcf90969e","type":"GENE","name":"LMBRD2","canonical_id":"hgnc:HGNC:25287","description":"LMBR1 domain containing 2","metadata":{"aliases":["DKFZp434H2226"]}},{"id":"ca878b46968246f4bb9d8e93a717634a","type":"GENE","name":"LMCD1","canonical_id":"hgnc:HGNC:6633","description":"LIM and cysteine rich domains 1","metadata":null},{"id":"b23b3e5c415344619c3f69970656ead0","type":"GENE","name":"LMCD1-AS1","canonical_id":"hgnc:HGNC:44477","description":"LMCD1 antisense RNA 1","metadata":null},{"id":"15900702d6c6492699319cc07d6349d9","type":"GENE","name":"LMF1","canonical_id":"hgnc:HGNC:14154","description":"lipase maturation factor 1","metadata":{"aliases":["FLJ12681","JFP11","FLJ22302","TMEM112A","C16orf26","TMEM112"]}},{"id":"ba7c47284bd34c9f8280901b7fc95dfa","type":"GENE","name":"LMF1-AS1","canonical_id":"hgnc:HGNC:50469","description":"LMF1 antisense RNA 1","metadata":null},{"id":"38f6d4d1ae9541c9a6ed608fb5fef7f9","type":"GENE","name":"LMF2","canonical_id":"hgnc:HGNC:25096","description":"lipase maturation factor 2","metadata":{"aliases":["TMEM153","TMEM112B"]}},{"id":"37e0872d083e4a9db4f0d91d87c93309","type":"GENE","name":"LMLN","canonical_id":"hgnc:HGNC:15991","description":"leishmanolysin like peptidase","metadata":{"aliases":["Gp63","Msp","LMNL1"]}},{"id":"f17a282cbb7a4f429c8a11a693cb4695","type":"GENE","name":"LMLN-AS1","canonical_id":"hgnc:HGNC:40738","description":"LMLN antisense RNA 1","metadata":null},{"id":"d61ccbe51cbe47d6a867f4a1da347c9f","type":"GENE","name":"LMNA","canonical_id":"hgnc:HGNC:6636","description":"lamin A/C","metadata":{"aliases":["HGPS","MADA","LMN1","CMD1A","LGMD1B","PRO1","LMNL1"]}},{"id":"6d8f2a6e8e2c44eca3ddafb090ab91ad","type":"GENE","name":"LMNB1","canonical_id":"hgnc:HGNC:6637","description":"lamin B1","metadata":null},{"id":"e379ccd49ad548ce9e119f774d4f0f95","type":"GENE","name":"LMNB1-DT","canonical_id":"hgnc:HGNC:53089","description":"LMNB1 divergent transcript","metadata":null},{"id":"ddf3dad3b0224bd4a65c34cb84586042","type":"GENE","name":"LMNB2","canonical_id":"hgnc:HGNC:6638","description":"lamin B2","metadata":{"aliases":["LMN2"]}},{"id":"07c676d7c59d44f4bc69401a1fb45215","type":"GENE","name":"LMNTD1","canonical_id":"hgnc:HGNC:26683","description":"lamin tail domain containing 1","metadata":{"aliases":["FLJ36004","Pas1c1","IFLTD1"]}},{"id":"8dc32d5207374387888a597d5ab9b8fb","type":"GENE","name":"LMNTD2","canonical_id":"hgnc:HGNC:28561","description":"lamin tail domain containing 2","metadata":{"aliases":["MGC35138","C11orf35"]}},{"id":"c3b455f7ee7641a9ac59d6a877c99229","type":"GENE","name":"LMNTD2-AS1","canonical_id":"hgnc:HGNC:41204","description":"LMNTD2 antisense RNA 1","metadata":null},{"id":"c494460b28f04d379000d1aaca5250da","type":"GENE","name":"LMO1","canonical_id":"hgnc:HGNC:6641","description":null,"metadata":null},{"id":"2c1cd2db79dd44538a9da95c818517f8","type":"GENE","name":"LMO2","canonical_id":"hgnc:HGNC:6642","description":null,"metadata":null},{"id":"7ef5c108b49e44d5a3ba03c943f5b900","type":"GENE","name":"LMO3","canonical_id":"hgnc:HGNC:6643","description":null,"metadata":null},{"id":"b158d0ff4d2148c6a976f52b055306d0","type":"GENE","name":"LMO4","canonical_id":"hgnc:HGNC:6644","description":null,"metadata":null},{"id":"5941bddbeef24fb78d495c73233f3f9e","type":"GENE","name":"LMO7","canonical_id":"hgnc:HGNC:6646","description":null,"metadata":null},{"id":"df88538021f24333af07964c5d1ea38c","type":"GENE","name":"LMO7-AS1","canonical_id":"hgnc:HGNC:50277","description":"LMO7 antisense RNA 1","metadata":{"aliases":["UCHL3-AS1"]}},{"id":"6cfeeb9002484ffa91fcc53cefde98c7","type":"GENE","name":"LMO7DN","canonical_id":"hgnc:HGNC:44370","description":"LMO7 downstream neighbor","metadata":{"aliases":["C13orf45","LMO7DN-IT1"]}},{"id":"cf8dfe0da0a0451da5c0d606c77125a9","type":"GENE","name":"LMOD1","canonical_id":"hgnc:HGNC:6647","description":"leiomodin 1","metadata":{"aliases":["64kD","D1","1D","SM-LMOD","SMLMOD"]}},{"id":"45aaeb4f2bbc47ea9a13ead2bbe35bad","type":"GENE","name":"LMOD1-AS1","canonical_id":"hgnc:HGNC:58701","description":"LMOD2 antisense RNA 1","metadata":{"aliases":["lnc458"]}},{"id":"4f77eea9b82f43f2b3be0d13046ea609","type":"GENE","name":"LMOD2","canonical_id":"hgnc:HGNC:6648","description":"leiomodin 2","metadata":{"aliases":["C-Lmod"]}},{"id":"cc3c9753a9b0425bbe2394641dc9c63c","type":"GENE","name":"LMOD3","canonical_id":"hgnc:HGNC:6649","description":"leiomodin 3","metadata":null},{"id":"9d095003ea12443b8fe8e06385f8d5d2","type":"GENE","name":"LMTK1","canonical_id":"hgnc:HGNC:21","description":"lemur tail kinase 1","metadata":{"aliases":["AATYK","KIAA0641","LMR1","AATYK1","PPP1R77","AATK"]}},{"id":"24bed2ce1031488086e791fa7b604de1","type":"GENE","name":"LMTK2","canonical_id":"hgnc:HGNC:17880","description":null,"metadata":null},{"id":"be736610efef4d6f9eccb87a85efffce","type":"GENE","name":"LMTK3","canonical_id":"hgnc:HGNC:19295","description":"lemur tail kinase 3","metadata":{"aliases":["KIAA1883","LMR3","AATYK3","TYKLM3","PPP1R101"]}},{"id":"848b05b3fed0462c92fffa3c4252758b","type":"GENE","name":"LMX1A","canonical_id":"hgnc:HGNC:6653","description":"LIM homeobox transcription factor 1 alpha","metadata":{"aliases":["LMX1.1","LMX1"]}},{"id":"cc9851b179154efa8c1baa05f2f325e1","type":"GENE","name":"LMX1A-AS1","canonical_id":"hgnc:HGNC:40344","description":"LMX1A antisense RNA 1","metadata":null},{"id":"b87d198f1070467e9c4f45f45453c741","type":"GENE","name":"LMX1A-AS2","canonical_id":"hgnc:HGNC:40343","description":"LMX1A antisense RNA 2","metadata":null},{"id":"74eb50f991e248889d45b35e3e787882","type":"GENE","name":"LMX1B","canonical_id":"hgnc:HGNC:6654","description":null,"metadata":null},{"id":"bb4043f7105343abbc329d8346152fcd","type":"GENE","name":"LMX1B-DT","canonical_id":"hgnc:HGNC:55849","description":"LMX1B divergent transcript","metadata":null},{"id":"bbf24751d30c4d8eaa14b72c025bcdd7","type":"GENE","name":"LNC-LBCS","canonical_id":"hgnc:HGNC:54418","description":"lncRNA bladder and prostate cancer suppressor, hnRNPK interacting","metadata":{"aliases":["LBCS"]}},{"id":"fdee8dacc1ce4eeb8688a6abf3f8553d","type":"GENE","name":"LNC-RHL1","canonical_id":"hgnc:HGNC:56708","description":"lncRNA regulator of hepatic lineages 1","metadata":{"aliases":["lnc-RHL"]}},{"id":"0925d15df27d4be8a3bb122f172d3953","type":"GENE","name":"LNC-WAL","canonical_id":"hgnc:HGNC:58120","description":"lncRNA Wnt/beta-catenin associated regulator","metadata":null},{"id":"d652c2eae2ce473db6f09a0780322def","type":"GENE","name":"LNCARGI","canonical_id":"hgnc:HGNC:56890","description":"lncRNA antiviral response interferon signaling inducer","metadata":{"aliases":["ARGI"]}},{"id":"eecdb441852a4387bbde90a7b1faaa07","type":"GENE","name":"LNCAROD","canonical_id":"hgnc:HGNC:50913","description":"lncRNA activating regulator of DKK1","metadata":{"aliases":["lnc-MBL2-4","A-ROD","LINC01468"]}},{"id":"e9a5b057fc6b47ffabb098e617936c74","type":"GENE","name":"LNCARSR","canonical_id":"hgnc:HGNC:53864","description":"lncRNA regulator of Akt signaling associated with HCC and RCC","metadata":{"aliases":["lnc-TALC"]}},{"id":"c97a065cd6604a848710eedd4bb0077d","type":"GENE","name":"LNCATV","canonical_id":"hgnc:HGNC:54478","description":"lncRNA negative regulator of antiviral signaling","metadata":null},{"id":"2be83d057d6b43938ed85429f6c42284","type":"GENE","name":"LNCBRM","canonical_id":"hgnc:HGNC:52752","description":"lncRNA SMARCA2 (BRM) associated","metadata":{"aliases":["LINCR-0003","lncBRM"]}},{"id":"749275f47be14156bce4d9935d9b09b4","type":"GENE","name":"LNCDAT","canonical_id":"hgnc:HGNC:54855","description":"lncRNA divergent activator of TBXT","metadata":{"aliases":["YYLNCT"]}},{"id":"a1be0d926f40432fb1c6754428121092","type":"GENE","name":"LNCEGFL7OS","canonical_id":"hgnc:HGNC:58066","description":"lncRNA EGFL7 opposite strand","metadata":{"aliases":["HSPC324","LncEGFL7OS"]}},{"id":"57228fa0547c4205a1699638a4423964","type":"GENE","name":"LNCHR1","canonical_id":"hgnc:HGNC:56254","description":"lncRNA induced by HCV, regulator of SREBF1","metadata":{"aliases":["lncHR1"]}},{"id":"152e5d9fb3ed44e181001dcfa786ab75","type":"GENE","name":"LNCMB1","canonical_id":"hgnc:HGNC:58924","description":"lncRNA MYC regulated medulloblastoma associated 1","metadata":null},{"id":"797a370ad4944bcd95b0904134d25e25","type":"GENE","name":"LNCMB2","canonical_id":"hgnc:HGNC:58925","description":"lncRNA MYC regulated medulloblastoma associated 2","metadata":null},{"id":"7d7cf8e982f04c35971f9482d2799032","type":"GENE","name":"LNCMB3","canonical_id":"hgnc:HGNC:58926","description":"lncRNA MYC regulated medulloblastoma associated 3","metadata":null},{"id":"9cd67618d2a1405ebecb6bd410376b3d","type":"GENE","name":"LNCNEF","canonical_id":"hgnc:HGNC:50656","description":"lncRNA neighboring enhancer of FOXA2","metadata":{"aliases":["lncRNA-NEF","LINC01384"]}},{"id":"31039ea8503f45bca39d936000051eea","type":"GENE","name":"LNCOB1","canonical_id":"hgnc:HGNC:56209","description":"lncRNA osteoblastogenesis associated 1","metadata":{"aliases":["lnc-OB1"]}},{"id":"2dc62e0f66184eb584f4265658ce9682","type":"GENE","name":"LNCOC1","canonical_id":"hgnc:HGNC:53947","description":"lncRNA associated with ovarian cancer 1","metadata":{"aliases":["Lnc-OC1"]}},{"id":"9e6471f19a364aa98a84c025e9381bef","type":"GENE","name":"LNCOG","canonical_id":"hgnc:HGNC:53336","description":"lncRNA osteogenesis associated","metadata":{"aliases":["RP11-54A9.1","lncRNA-OG","LINC02407"]}},{"id":"9f012befa83b4e77bc52f59b98c3d27b","type":"GENE","name":"LNCPNKY","canonical_id":"hgnc:HGNC:51638","description":"lncRNA POU3F2 adjacent neural key regulator","metadata":{"aliases":["pinky","PNKY"]}},{"id":"79613cceb12f4975b394610e217cb8e1","type":"GENE","name":"LNCPOIR","canonical_id":"hgnc:HGNC:54521","description":"lncRNA periodontal mesenchymal stem cell osteogenesis related","metadata":{"aliases":["POIR","lncRNA-POIR"]}},{"id":"c597327e3395411a9653bd448bebded9","type":"GENE","name":"LNCPRESS1","canonical_id":"hgnc:HGNC:52746","description":"lncRNA p53 regulated and ESC associated 1","metadata":null},{"id":"b2575d62859e43b69c18a1724dbe536e","type":"GENE","name":"LNCPRESS2","canonical_id":"hgnc:HGNC:52747","description":"lncRNA p53 regulated and ESC associated 2","metadata":null},{"id":"72beffa6e1eb44289b27e245fc1dd51b","type":"GENE","name":"LNCPTCTS","canonical_id":"hgnc:HGNC:56876","description":"lncRNA papillary thyroid carcinoma tumor suppressor","metadata":{"aliases":["RP11-616M22.2"]}},{"id":"7888e93f65774137995c28469db86322","type":"GENE","name":"LNCR-SMAL","canonical_id":"hgnc:HGNC:58119","description":"lncRNA senescence and mitophagy associated regulator of PRKN","metadata":null},{"id":"68e819f5e3de4c3e8c8d42a7b0883e2b","type":"GENE","name":"LNCRI","canonical_id":"hgnc:HGNC:53790","description":"lncRNA radiation induced regulator of PLK1 and RAD51","metadata":{"aliases":["lnc-RI"]}},{"id":"3f0d2c6cc7044394a7466401f27b5423","type":"GENE","name":"LNCRMP","canonical_id":"hgnc:HGNC:58164","description":"long non-coding RNA regulator of monocyte proliferation","metadata":null},{"id":"c9cc78136f6e4d8387164b93b0cedbcb","type":"GENE","name":"LNCRNA-ATB","canonical_id":"hgnc:HGNC:52657","description":"lncRNA activated by TGF-beta","metadata":null},{"id":"1e6fbbb2372f4c8c8866eb9729e82637","type":"GENE","name":"LNCRNA-IUR","canonical_id":"hgnc:HGNC:55755","description":"lncRNA imatinib upregulated","metadata":null},{"id":"c8e6608ed9dc49368d758bc24c99c4f2","type":"GENE","name":"LNCROPM","canonical_id":"hgnc:HGNC:58146","description":"lncRNA regulator of PLAAT3 mediated phospholipid metabolism","metadata":null},{"id":"41c04fadfebc4821be35662a6b908b2c","type":"GENE","name":"LNCSRLR","canonical_id":"hgnc:HGNC:52753","description":"lncRNA sorafenib resistance in renal cell carcinoma associated","metadata":{"aliases":["lncRNA-SRLR"]}},{"id":"4f369da73a0045379982dd4d28835843","type":"GENE","name":"LNCTAM34A","canonical_id":"hgnc:HGNC:52548","description":"long non coding transcriptional activator of miR34a","metadata":{"aliases":["GUARDIN","TP53LC18","LINC01759"]}},{"id":"8bbb3b14e38941e6876abbb2e19d1b46","type":"GENE","name":"LNCTSI","canonical_id":"hgnc:HGNC:56660","description":"lncRNA TGF-beta/SMAD3 pathway interacting","metadata":{"aliases":["AP000695.1","PTAR","lnc-TSI","lnc-UTGF","AP000695.4","lnc-CHAF1B-2","lnc-CHAF1B-3","AP000695.2","CLDN14-AS1"]}},{"id":"c3d1b24c34444e5eb6f4a6e33906aaae","type":"GENE","name":"LNMICC","canonical_id":"hgnc:HGNC:56001","description":"lncRNA associated with lymph node metastasis in cervical cancer","metadata":null},{"id":"5a48f0c4be1441f7a30eb6008dd2863f","type":"GENE","name":"LNP1","canonical_id":"hgnc:HGNC:28014","description":"leukemia NUP98 fusion partner 1","metadata":{"aliases":["NP3"]}},{"id":"4d99b28539e2477ba0d1e49e58278d9c","type":"GENE","name":"LNPEP","canonical_id":"hgnc:HGNC:6656","description":null,"metadata":null},{"id":"da162863bc4543cebb908ca2d2dc0d3d","type":"GENE","name":"LNPK","canonical_id":"hgnc:HGNC:21610","description":"lunapark, ER junction formation factor","metadata":{"aliases":["Ul","LNP1","LNP","KIAA1715"]}},{"id":"12300dab8a0b4100b700a215c2295eab","type":"GENE","name":"LNPPS","canonical_id":"hgnc:HGNC:51665","description":"lncRNA PDCD5 and p53 scaffold","metadata":null},{"id":"c9c4723d5cc84d9ca43c7f9aa3a6f899","type":"GENE","name":"LNROP","canonical_id":"hgnc:HGNC:55512","description":"long non-coding regulator of POU2F2","metadata":{"aliases":["POU2F2-AS1","POU2F2-AS2"]}},{"id":"ed6824e0019f44fcac7bd0860175c7c1","type":"GENE","name":"LNX1","canonical_id":"hgnc:HGNC:6657","description":"ligand of numb-protein X 1","metadata":{"aliases":["MPDZ","PDZRN2","LNX"]}},{"id":"c1e3f2032aa647b1a88519406c82a92b","type":"GENE","name":"LNX1-AS1","canonical_id":"hgnc:HGNC:40345","description":"LNX1 antisense RNA 1","metadata":null},{"id":"a912393bca2b4472b3117032e2cf31ca","type":"GENE","name":"LNX1-AS2","canonical_id":"hgnc:HGNC:41450","description":"LNX1 antisense RNA 2","metadata":null},{"id":"89eb9b65799349b2b906a5ff527b4abe","type":"GENE","name":"LNX2","canonical_id":"hgnc:HGNC:20421","description":"ligand of numb-protein X 2","metadata":{"aliases":["MGC46315","PDZRN1"]}},{"id":"bb8aaf7b27334d009f234e1e7eeff7f2","type":"GENE","name":"LNX2BP","canonical_id":"hgnc:HGNC:56859","description":"ligand of numb-protein X 2B, pseudogene","metadata":null},{"id":"5fdd16ce79794ece80ad7987f213afc1","type":"TRIAL","name":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","canonical_id":"clinicaltrials.gov:NCT00680901","description":"Neoplasms, Gastrointestinal Tract","metadata":null},{"id":"602717c935ed4e41bea59519b4100147","type":"GENE","name":"LOH12CR2","canonical_id":"hgnc:HGNC:26524","description":"loss of heterozygosity on chromosome 12, region 2","metadata":{"aliases":["LOH2CR12"]}},{"id":"b89bd56d8e89494489eb32f418c5852c","type":"GENE","name":"LOH1CR1","canonical_id":"hgnc:HGNC:6661","description":"loss of heterozygosity on chromosome 1, region 1","metadata":null},{"id":"2048a2a1a45b47669071412856c99bbc","type":"GENE","name":"LOHAN2","canonical_id":"hgnc:HGNC:51371","description":"lncRNA oncogene in head and neck cancer 2","metadata":{"aliases":["LINC01568"]}},{"id":"706a92746d8947f6bf5b4e2dbf4bcb94","type":"GENE","name":"LOLI1","canonical_id":"hgnc:HGNC:56775","description":"lncRNA oncogene in liver cancer 1","metadata":null},{"id":"8e59ee4354e64e51801243659eb54276","type":"GENE","name":"LONP1","canonical_id":"hgnc:HGNC:9479","description":"lon peptidase 1, mitochondrial","metadata":{"aliases":["LonHS","hLON","PIM1","PRSS15"]}},{"id":"5241c2e0d711462da0d03b6982363ae8","type":"GENE","name":"LONP2","canonical_id":"hgnc:HGNC:20598","description":"lon peptidase 2, peroxisomal","metadata":{"aliases":["MGC4840","LONP","LONPL"]}},{"id":"dcae3cccb2a14d94afedd03721e7d234","type":"GENE","name":"LONRF1","canonical_id":"hgnc:HGNC:26302","description":"LON peptidase N-terminal domain and ring finger 1","metadata":{"aliases":["FLJ23749","RNF191"]}},{"id":"2c4276129e2248da8a268c3eb41480c8","type":"GENE","name":"LONRF2","canonical_id":"hgnc:HGNC:24788","description":"LON peptidase N-terminal domain and ring finger 2","metadata":{"aliases":["FLJ45273","RNF192"]}},{"id":"c9d9df32a4b4442abc1b7ff31b922da3","type":"GENE","name":"LONRF2P1","canonical_id":"hgnc:HGNC:39828","description":"LONRF2 pseudogene 1","metadata":null},{"id":"a3faaeefbada47a28df997c98e9d6713","type":"GENE","name":"LONRF2P2","canonical_id":"hgnc:HGNC:39829","description":"LONRF2 pseudogene 2","metadata":null},{"id":"dac969845b7f42258ccad46d5f9c3b56","type":"GENE","name":"LONRF2P3","canonical_id":"hgnc:HGNC:54499","description":"LONRF2 pseudogene 3","metadata":null},{"id":"3df42f47f46b405f9d3a834ced257964","type":"GENE","name":"LONRF2P4","canonical_id":"hgnc:HGNC:54500","description":"LONRF2 pseudogene 4","metadata":null},{"id":"ce81ae02d1b84b248d68d308a2754b0e","type":"GENE","name":"LONRF2P5","canonical_id":"hgnc:HGNC:54501","description":"LONRF2 pseudogene 5","metadata":null},{"id":"ec710ce402284723aacc2582e35e5392","type":"GENE","name":"LONRF3","canonical_id":"hgnc:HGNC:21152","description":"LON peptidase N-terminal domain and ring finger 3","metadata":{"aliases":["FLJ22612","RNF127"]}},{"id":"89d029d75a7e4c19abb07e0b2e3b54af","type":"GENE","name":"LOR","canonical_id":"hgnc:HGNC:6663","description":null,"metadata":null},{"id":"08caa54a18bd4ac296cf161c6970e0ce","type":"TRIAL","name":"LOSS- Louisiana Obese Subjects Study","canonical_id":"clinicaltrials.gov:NCT00115063","description":"Obesity","metadata":null},{"id":"a673f0631d864f0ba0d83b7dc91f6a0f","type":"GENE","name":"LOX","canonical_id":"hgnc:HGNC:6664","description":null,"metadata":null},{"id":"242b061e49e049729b4ec93a6a29504e","type":"GENE","name":"LOXHD1","canonical_id":"hgnc:HGNC:26521","description":"lipoxygenase homology PLAT domains 1","metadata":{"aliases":["FLJ32670","LH2D1","DFNB77"]}},{"id":"88a2b62a3fc54b228d1830739f834130","type":"GENE","name":"LOXL1","canonical_id":"hgnc:HGNC:6665","description":"lysyl oxidase like 1","metadata":{"aliases":["LOXL","LOL"]}},{"id":"7f47b763c8464afcb786de0c803069b0","type":"GENE","name":"LOXL1-AS1","canonical_id":"hgnc:HGNC:44169","description":"LOXL1 antisense RNA 1","metadata":null},{"id":"62c45291489f4e2f9510fd373e59d5c2","type":"GENE","name":"LOXL2","canonical_id":"hgnc:HGNC:6666","description":null,"metadata":null},{"id":"eab79ffe8f724b249adc3821fa8ec35b","type":"GENE","name":"LOXL2-AS1","canonical_id":"hgnc:HGNC:56648","description":"LOXL2 antisense RNA 1","metadata":{"aliases":["AC090197.1"]}},{"id":"ff8d4a716ba246dfbb7bb0450e0099ab","type":"GENE","name":"LOXL3","canonical_id":"hgnc:HGNC:13869","description":"lysyl oxidase like 3","metadata":null},{"id":"1d72366ac9d44cdcb763dcb9b46d1010","type":"GENE","name":"LOXL4","canonical_id":"hgnc:HGNC:17171","description":null,"metadata":null},{"id":"3b5ad81ddcea4276b8cb6de6496a0ce6","type":"TRIAL","name":"LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC","canonical_id":"clinicaltrials.gov:NCT05537402","description":"Hepatocellular Carcinoma","metadata":null},{"id":"84b3f7e5f216455aa8f1405752c70a0d","type":"TRIAL","name":"LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This","canonical_id":"clinicaltrials.gov:NCT06978088","description":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma; CLL/SLL; Chronic Lymphocytic Leukemia","metadata":null},{"id":"7d3f6408621d46c5af12d9988ba769ed","type":"GENE","name":"LPA","canonical_id":"hgnc:HGNC:6667","description":"lipoprotein(a)","metadata":{"aliases":["Lp(a)","LP"]}},{"id":"b188af9c7557487bb2be28139f3ab918","type":"GENE","name":"LPAL1","canonical_id":"hgnc:HGNC:6668","description":"lipoprotein(a) like 1","metadata":null},{"id":"980fa0648cd24a678bdd364bf0ea227e","type":"GENE","name":"LPAL2","canonical_id":"hgnc:HGNC:21210","description":"lipoprotein(a) like 2 (pseudogene)","metadata":{"aliases":["APOARGC","APOAL"]}},{"id":"dc4b532f4e6946b598f19968ff069b9f","type":"GENE","name":"LPAR1","canonical_id":"hgnc:HGNC:3166","description":"lysophosphatidic acid receptor 1","metadata":{"aliases":["edg-2","rec.1.3","vzg-1","Gpcr26","Mrec1.3","LPA1","EDG2"]}},{"id":"f0c181526de64c769ba51ac8f8fac477","type":"GENE","name":"LPAR2","canonical_id":"hgnc:HGNC:3168","description":null,"metadata":null},{"id":"fcef9e1cbb8e46c7b69eb995289bf1c6","type":"GENE","name":"LPAR3","canonical_id":"hgnc:HGNC:14298","description":"lysophosphatidic acid receptor 3","metadata":{"aliases":["LP-A3","Edg-7","RP4-678I3","HOFNH30","LPA3","EDG7"]}},{"id":"b72b28eab4cb4bdd91544e4bfcfbc562","type":"GENE","name":"LPAR4","canonical_id":"hgnc:HGNC:4478","description":"lysophosphatidic acid receptor 4","metadata":{"aliases":["P2Y9","P2Y5-LIKE","P2RY9","LPA4","GPR23"]}},{"id":"d42e58d64bf84838aae4f12e45414894","type":"GENE","name":"LPAR5","canonical_id":"hgnc:HGNC:13307","description":"lysophosphatidic acid receptor 5","metadata":{"aliases":["KPG_010","LPA5","GPR93","GPR92"]}},{"id":"13c14bccb85f458a9e1ae3b22e946492","type":"GENE","name":"LPAR6","canonical_id":"hgnc:HGNC:15520","description":"lysophosphatidic acid receptor 6","metadata":{"aliases":["P2Y5","P2RY5"]}},{"id":"394f3db6005548298e4aab8fae7f3ca9","type":"GENE","name":"LPCAT1","canonical_id":"hgnc:HGNC:25718","description":"lysophosphatidylcholine acyltransferase 1","metadata":{"aliases":["FLJ12443","AGPAT9","AGPAT10","LPLAT8","AYTL2"]}},{"id":"f7a89936af514498a725ce32741979cf","type":"GENE","name":"LPCAT1-AS1","canonical_id":"hgnc:HGNC:58992","description":"LPCAT1 antisense RNA 1","metadata":null},{"id":"ebbab4a4a18145ab8473b7fff23affe4","type":"GENE","name":"LPCAT2","canonical_id":"hgnc:HGNC:26032","description":"lysophosphatidylcholine acyltransferase 2","metadata":{"aliases":["FLJ20481","AGPAT11","LysoPAFAT","LPLAT9","AYTL1"]}},{"id":"bce48dcd5f324a0797c454208c6db483","type":"GENE","name":"LPCAT2BP","canonical_id":"hgnc:HGNC:38003","description":"lysophosphatidylcholine acyltransferase 2b, pseudogene","metadata":null},{"id":"9034e7d8e9e448f0b60a554833b8f23f","type":"GENE","name":"LPCAT3","canonical_id":"hgnc:HGNC:30244","description":"lysophosphatidylcholine acyltransferase 3","metadata":{"aliases":["C3F","nessy","LPLAT12","OACT5","MBOAT5"]}},{"id":"8cd5d378a2d5493480df62eae7518c36","type":"GENE","name":"LPCAT4","canonical_id":"hgnc:HGNC:30059","description":"lysophosphatidylcholine acyltransferase 4","metadata":{"aliases":["FLJ10257","LPAAT-eta","LPEAT2","LPLAT10","AYTL3","AGPAT7"]}},{"id":"51e76ce088004dbaaded6a94cd66584e","type":"GENE","name":"LPGAT1","canonical_id":"hgnc:HGNC:28985","description":"lysophosphatidylglycerol acyltransferase 1","metadata":{"aliases":["KIAA0205","FAM34A1","NET8","LPLAT7","FAM34A"]}},{"id":"3497a30d7dbd44bdb6fb768f3527f1a1","type":"GENE","name":"LPGAT1-AS1","canonical_id":"hgnc:HGNC:41221","description":"LPGAT1 antisense RNA 1","metadata":null},{"id":"0e5c387ef2df4596b5b762922f974fd0","type":"GENE","name":"LPGAT1P1","canonical_id":"hgnc:HGNC:31402","description":"lysophosphatidylglycerol acyltransferase 1 pseudogene 1","metadata":{"aliases":["FAM34BP","FAM34A2P"]}},{"id":"286c66fc41f145918bb12fea02184ee9","type":"GENE","name":"LPIN1","canonical_id":"hgnc:HGNC:13345","description":null,"metadata":null},{"id":"e07970e44632416a8e5ea1f4ee0a3f20","type":"GENE","name":"LPIN2","canonical_id":"hgnc:HGNC:14450","description":"lipin 2","metadata":{"aliases":["KIAA0249"]}},{"id":"f21287569f6c48fc8fdf06def594aed5","type":"GENE","name":"LPIN2-AS1","canonical_id":"hgnc:HGNC:58311","description":"LPIN2 antisense RNA 1","metadata":null},{"id":"63a4469ca26845ceb63592e564c62728","type":"GENE","name":"LPIN2-AS2","canonical_id":"hgnc:HGNC:58313","description":"LPIN2 antisense RNA 2","metadata":null},{"id":"a31efbaeb9294461bc2bded6c9428ff0","type":"GENE","name":"LPIN3","canonical_id":"hgnc:HGNC:14451","description":"lipin 3","metadata":{"aliases":["SMP2","LIPN3L"]}},{"id":"2ca1d80afa464001bdb3ce478bfa57a3","type":"GENE","name":"LPL","canonical_id":"hgnc:HGNC:6677","description":null,"metadata":null},{"id":"8348072593b44194be5e30b048c6166e","type":"GENE","name":"LPO","canonical_id":"hgnc:HGNC:6678","description":"lactoperoxidase","metadata":{"aliases":["SPO"]}},{"id":"5f82abecf80b4b95a624b79303bd5e6a","type":"GENE","name":"LPP","canonical_id":"hgnc:HGNC:6679","description":"LIM domain containing preferred translocation partner in lipoma","metadata":null},{"id":"7e673cdcdd9a4618a555e373bb3e7062","type":"GENE","name":"LPP-AS1","canonical_id":"hgnc:HGNC:40346","description":"LPP antisense RNA 1","metadata":null},{"id":"f06c5c28fd79402d9ee027cffd2577f0","type":"GENE","name":"LPP-AS2","canonical_id":"hgnc:HGNC:27952","description":"LPP antisense RNA 2","metadata":{"aliases":["MYCLo-5","MYCLo-6"]}},{"id":"8b202ed2f81b4f149f799f4eb1e6cd80","type":"GO_TERM","name":"LPPG:FO 2-phospho-L-lactate transferase activity","canonical_id":"go:GO:0043743","description":"\"Catalysis of the reaction: 7,8-didemethyl-8-hydroxy-5-deazariboflavin + lactyl-2-diphospho-5'-guanosine = coenzyme F420-0 + GMP.\" [PMID:11888293]","metadata":null},{"id":"e4759eb3d3a54d48bf49ab2ae4fa51f9","type":"GENE","name":"LPXN","canonical_id":"hgnc:HGNC:14061","description":"leupaxin","metadata":{"aliases":["LDPL"]}},{"id":"3fcea70f72f84d50ad258f73865b62f1","type":"GENE","name":"LRAT","canonical_id":"hgnc:HGNC:6685","description":"lecithin retinol acyltransferase","metadata":{"aliases":["LCA14"]}},{"id":"e167bb44e36a48b7a3df08a66aa79173","type":"GENE","name":"LRATD1","canonical_id":"hgnc:HGNC:20743","description":"LRAT domain containing 1","metadata":{"aliases":["NSE1","FLJ35392","FAM84A"]}},{"id":"37c294de4bc640b1829dc8a55d04e09f","type":"GENE","name":"LRATD2","canonical_id":"hgnc:HGNC:24166","description":"LRAT domain containing 2","metadata":{"aliases":["BCMP101","NSE2","FAM84B"]}},{"id":"77456992d9764e9284fa536c33284e7e","type":"GENE","name":"LRBA","canonical_id":"hgnc:HGNC:1742","description":null,"metadata":null},{"id":"24daeffbdcf54fbfae520d2bc2073457","type":"GENE","name":"LRBA-AS1","canonical_id":"hgnc:HGNC:58247","description":"LRBA antisense RNA 1","metadata":null},{"id":"f0cff30e08df45e981ec1a846fc35a76","type":"GENE","name":"LRCH1","canonical_id":"hgnc:HGNC:20309","description":"leucine rich repeats and calponin homology domain containing 1","metadata":{"aliases":["KIAA1016","CHDC1"]}},{"id":"971de9e50fdd486aae93c78f6ba764c0","type":"GENE","name":"LRCH2","canonical_id":"hgnc:HGNC:29292","description":"leucine rich repeats and calponin homology domain containing 2","metadata":{"aliases":["KIAA1495"]}},{"id":"34dd6298413547ea86978b163571cd89","type":"GENE","name":"LRCH3","canonical_id":"hgnc:HGNC:28637","description":"leucine rich repeats and calponin homology domain containing 3","metadata":{"aliases":["MGC4126"]}},{"id":"000598e5323245eca5073d4489bae932","type":"GENE","name":"LRCH4","canonical_id":"hgnc:HGNC:6691","description":"leucine rich repeats and calponin homology domain containing 4","metadata":{"aliases":["LRN","LRRN1"]}},{"id":"bb82f43ecbd840d09afac53bea360bf6","type":"GENE","name":"LRCOL1","canonical_id":"hgnc:HGNC:44160","description":"leucine rich colipase like 1","metadata":null},{"id":"fc144ced430543168e74525f8d2cbe21","type":"GENE","name":"LRF","canonical_id":"hgnc:HGNC:18078","description":null,"metadata":null},{"id":"9241493452764b67896b7ded16a0023a","type":"GENE","name":"LRFN1","canonical_id":"hgnc:HGNC:29290","description":"leucine rich repeat and fibronectin type III domain containing 1","metadata":{"aliases":["KIAA1484","SALM2"]}},{"id":"9ecbc0c995a7403e9347e87058e6770d","type":"GENE","name":"LRFN2","canonical_id":"hgnc:HGNC:21226","description":"leucine rich repeat and fibronectin type III domain containing 2","metadata":{"aliases":["FIGLER2","KIAA1246","SALM1"]}},{"id":"2bc72e69e9074f4698bd0355afbed8e4","type":"GENE","name":"LRFN2-AS1","canonical_id":"hgnc:HGNC:59399","description":"LRFN2 antisense RNA 1","metadata":null},{"id":"f125f77fcaf2436fb9d56ac4f5f3ae98","type":"GENE","name":"LRFN3","canonical_id":"hgnc:HGNC:28370","description":"leucine rich repeat and fibronectin type III domain containing 3","metadata":{"aliases":["MGC2656","SALM4","FIGLER1"]}},{"id":"9f1d20da6f5443c2b66b863921ae4106","type":"GENE","name":"LRFN4","canonical_id":"hgnc:HGNC:28456","description":"leucine rich repeat and fibronectin type III domain containing 4","metadata":{"aliases":["MGC3103","SALM3.","FIGLER6"]}},{"id":"043128729d5a4f91adf29a80240f133e","type":"GENE","name":"LRFN5","canonical_id":"hgnc:HGNC:20360","description":"leucine rich repeat and fibronectin type III domain containing 5","metadata":{"aliases":["FIGLER8","SALM5","C14orf146"]}},{"id":"9d12088c4e46479599122d4a942ba369","type":"GENE","name":"LRFN5-DT","canonical_id":"hgnc:HGNC:55444","description":"LRFN5 divergent transcript","metadata":null},{"id":"97f456394d864893907476530198e7fc","type":"GENE","name":"LRG1","canonical_id":"hgnc:HGNC:29480","description":"leucine rich alpha-2-glycoprotein 1","metadata":{"aliases":["LRG"]}},{"id":"dfaa901b77e1466887c586698a54c146","type":"GENE","name":"LRGUK","canonical_id":"hgnc:HGNC:21964","description":"leucine rich repeats and guanylate kinase domain containing","metadata":{"aliases":["FLJ32786","CFAP246"]}},{"id":"d0d991d89990463cbae8f38590732d02","type":"GENE","name":"LRIF1","canonical_id":"hgnc:HGNC:30299","description":"ligand dependent nuclear receptor interacting factor 1","metadata":{"aliases":["RIF1","FLJ11269","C1orf103"]}},{"id":"f790501474ef449ea46ba4de0e1d5cd6","type":"GENE","name":"LRIG1","canonical_id":"hgnc:HGNC:17360","description":"leucine rich repeats and immunoglobulin like domains 1","metadata":{"aliases":["LIG-1","DKFZP586O1624","LIG1"]}},{"id":"f024744bfbc34095a2f7fa09d70ceb4d","type":"GENE","name":"LRIG2","canonical_id":"hgnc:HGNC:20889","description":null,"metadata":null},{"id":"efd08f48859d43d6a4585a4256bf08b6","type":"GENE","name":"LRIG2-DT","canonical_id":"hgnc:HGNC:54312","description":"LRIG2 divergent transcript","metadata":null},{"id":"539ba1a03975421180e39aab35df169e","type":"GENE","name":"LRIG3","canonical_id":"hgnc:HGNC:30991","description":"leucine rich repeats and immunoglobulin like domains 3","metadata":{"aliases":["FLJ90440","KIAA3016"]}},{"id":"d648d18a3ba345d080438df0014328a2","type":"GENE","name":"LRIG3-DT","canonical_id":"hgnc:HGNC:55476","description":"LRIG3 divergent transcript","metadata":null},{"id":"bd432baf687441048d0e4bbebcbddf2b","type":"GENE","name":"LRIT1","canonical_id":"hgnc:HGNC:23404","description":"leucine rich repeat, Ig-like and transmembrane domains 1","metadata":{"aliases":["PAL","DKFZP434K091","FIGLER9","LRRC21"]}},{"id":"65ce32c288f943e5b22576383d1400be","type":"GENE","name":"LRIT2","canonical_id":"hgnc:HGNC:23443","description":"leucine rich repeat, Ig-like and transmembrane domains 2","metadata":{"aliases":["AC022389.4","LRRC22"]}},{"id":"433a153944d340c1bff76e1e06984c80","type":"GENE","name":"LRIT3","canonical_id":"hgnc:HGNC:24783","description":"leucine rich repeat, Ig-like and transmembrane domains 3","metadata":{"aliases":["FLJ44691","FIGLER4","CSNB1F"]}},{"id":"665795c18aee432684047a7d9c696568","type":"GENE","name":"LRMDA","canonical_id":"hgnc:HGNC:23405","description":"leucine rich melanocyte differentiation associated","metadata":{"aliases":["CDA017","OCA7","C10orf11"]}},{"id":"122d8ffe4ae14c8585320b96d900e683","type":"GENE","name":"LROMI1","canonical_id":"hgnc:HGNC:58488","description":"lncRNA regulator of macrophage immunity 1","metadata":{"aliases":["AC022816.1"]}},{"id":"2b1807ff9b3a42f8a9850391b3f3dacc","type":"GENE","name":"LRP1","canonical_id":"hgnc:HGNC:6692","description":null,"metadata":null},{"id":"e36050f0dcca4631b4aa0c2c54c07c24","type":"GENE","name":"LRP1-AS","canonical_id":"hgnc:HGNC:51694","description":"LRP1 antisense RNA","metadata":null},{"id":"6b7e6a202da54b56839e15b882a42ca6","type":"GENE","name":"LRP10","canonical_id":"hgnc:HGNC:14553","description":"LDL receptor related protein 10","metadata":{"aliases":["DKFZP564C1940","MGC8675","LRP9","MST087","MSTP087"]}},{"id":"59b6b7aae4544dcd9ec32aae7ca6ca51","type":"GENE","name":"LRP11","canonical_id":"hgnc:HGNC:16936","description":"LDL receptor related protein 11","metadata":{"aliases":["bA350J20.3","MANSC3"]}},{"id":"11a43697fd304888bd34279c4f98dbe9","type":"GENE","name":"LRP11-AS1","canonical_id":"hgnc:HGNC:58689","description":"LRP11 antisense RNA 1","metadata":null},{"id":"d9535c3245cf4190b90d969d43f388be","type":"GENE","name":"LRP12","canonical_id":"hgnc:HGNC:31708","description":"LDL receptor related protein 12","metadata":{"aliases":["ST7","FLJ12929"]}},{"id":"844d5d74505a4c8aab978feda47b50e0","type":"GENE","name":"LRP13P","canonical_id":"hgnc:HGNC:55094","description":"LDL receptor related protein family member 13, pseudogene","metadata":null},{"id":"00e9114608fe400fa83cad432f3d6ee4","type":"GENE","name":"LRP1B","canonical_id":"hgnc:HGNC:6693","description":"LDL receptor related protein 1B","metadata":{"aliases":["LRP-DIT","LRPDIT"]}},{"id":"9dac407ea8754c54ad77395098089048","type":"GENE","name":"LRP2","canonical_id":"hgnc:HGNC:6694","description":"LDL receptor related protein 2","metadata":{"aliases":["gp330","DBS"]}},{"id":"6427da2f93b94017945eb2210b763f32","type":"GENE","name":"LRP2BP","canonical_id":"hgnc:HGNC:25434","description":"LRP2 binding protein","metadata":{"aliases":["DKFZp761O0113"]}},{"id":"420b46ec71844dfcb330e43e0b74c524","type":"GENE","name":"LRP3","canonical_id":"hgnc:HGNC:6695","description":"LDL receptor related protein 3","metadata":{"aliases":["LRP-3","hLRp105"]}},{"id":"058b7a43132e4bd7ae0ea578fc489f32","type":"GENE","name":"LRP4","canonical_id":"hgnc:HGNC:6696","description":"LDL receptor related protein 4","metadata":{"aliases":["MEGF7","CLSS","LRP-4","SOST2"]}},{"id":"1d7bdc29781b43a8881156ef65d20208","type":"GENE","name":"LRP4-AS1","canonical_id":"hgnc:HGNC:44128","description":"LRP4 antisense RNA 1","metadata":null},{"id":"f2363bfc4cbd4fbe803686fbaf79ad07","type":"GENE","name":"LRP5","canonical_id":"hgnc:HGNC:6697","description":null,"metadata":null},{"id":"5fddf7e5a81e4a358818e6911529e8f0","type":"GENE","name":"LRP5L","canonical_id":"hgnc:HGNC:25323","description":"LDL receptor related protein 5 like (pseudogene)","metadata":{"aliases":["DKFZp434O0213"]}},{"id":"bb5d62e0871d4810b9fb308705483a7e","type":"GENE","name":"LRP6","canonical_id":"hgnc:HGNC:6698","description":"LDL receptor related protein 6","metadata":{"aliases":["ADCAD2"]}},{"id":"bc28252581314aa487d7c0eced8cc7d2","type":"GENE","name":"LRP8","canonical_id":"hgnc:HGNC:6700","description":null,"metadata":null},{"id":"94a6d5f7ed2945bbadec4fbb13fc651b","type":"GENE","name":"LRP8-DT","canonical_id":"hgnc:HGNC:52561","description":"LRP8 divergent transcript","metadata":{"aliases":["LINC01771"]}},{"id":"9c4cf40a842b45d292ce2b32271467d7","type":"GENE","name":"LRPAP1","canonical_id":"hgnc:HGNC:6701","description":"LDL receptor related protein associated protein 1","metadata":{"aliases":["HBP44","Alpha-2-MRAP","A2MRAP","RAP"]}},{"id":"92719346319c4a73866dafea5531a2e6","type":"GENE","name":"LRPPRC","canonical_id":"hgnc:HGNC:15714","description":"leucine rich pentatricopeptide repeat containing","metadata":{"aliases":["GP130","LRP130","LSFC"]}},{"id":"8c50934f3d014552b2c228a173311f32","type":"GO_TERM","name":"LRR domain binding","canonical_id":"go:GO:0030275","description":"\"Binding to a LRR domain (leucine rich repeats) of a protein.\" [GOC:curators, Pfam:PF00560]","metadata":null},{"id":"bc199204232d4d9c97df63ec623b62a0","type":"GENE","name":"LRR1","canonical_id":"hgnc:HGNC:19742","description":"leucine rich repeat protein 1","metadata":{"aliases":["4-1BBLRR","MGC20689","LRR-1","PPIL5"]}},{"id":"ead6ec7ff5ba44699a62d28b57655028","type":"GENE","name":"LRRC1","canonical_id":"hgnc:HGNC:14307","description":"leucine rich repeat containing 1","metadata":{"aliases":["dJ523E19.1","LANO","FLJ10775","FLJ11834"]}},{"id":"c645e638320c423eb297bae8642ff0b7","type":"GENE","name":"LRRC10","canonical_id":"hgnc:HGNC:20264","description":"leucine rich repeat containing 10","metadata":{"aliases":["HRLRRP","LRRC10A"]}},{"id":"3f1958d4b9d24c64b9ce202cc6ce4b6b","type":"GENE","name":"LRRC10B","canonical_id":"hgnc:HGNC:37215","description":"leucine rich repeat containing 10B","metadata":null},{"id":"70ec943c2f864f41a1f7bde6b226edbc","type":"GENE","name":"LRRC14","canonical_id":"hgnc:HGNC:20419","description":"leucine rich repeat containing 14","metadata":{"aliases":["KIAA0014","LRRC14A"]}},{"id":"f7c43990b11145fe99bd346223ac4695","type":"GENE","name":"LRRC14B","canonical_id":"hgnc:HGNC:37268","description":"leucine rich repeat containing 14B","metadata":null},{"id":"d9a73aa1528f4fea81d916362e5c0c3e","type":"GENE","name":"LRRC14B-AS1","canonical_id":"hgnc:HGNC:58986","description":"LRRC14B antisense RNA 1","metadata":null},{"id":"ed0f388c758a488294c5f313ac0cae98","type":"GENE","name":"LRRC15","canonical_id":"hgnc:HGNC:20818","description":"leucine rich repeat containing 15","metadata":{"aliases":["LIB"]}},{"id":"19d3468925e743d9bd6b002fa2daefd4","type":"GENE","name":"LRRC17","canonical_id":"hgnc:HGNC:16895","description":"leucine rich repeat containing 17","metadata":{"aliases":["P37NB","H_RG318M05.3"]}},{"id":"db045996279e4a7ebee79b54de84130c","type":"GENE","name":"LRRC18","canonical_id":"hgnc:HGNC:23199","description":"leucine rich repeat containing 18","metadata":{"aliases":["UNQ933","MGC34773","UNQ9338","VKGE9338"]}},{"id":"975fb07b26774cc7bb563a4ad8c8ef40","type":"GENE","name":"LRRC19","canonical_id":"hgnc:HGNC:23379","description":"leucine rich repeat containing 19","metadata":{"aliases":["FLJ21302"]}},{"id":"ed6a70e0352747719bc64bd0642eaa67","type":"GENE","name":"LRRC2","canonical_id":"hgnc:HGNC:14676","description":"leucine rich repeat containing 2","metadata":null},{"id":"af77c2afc6724295b7014721eb215925","type":"GENE","name":"LRRC2-AS1","canonical_id":"hgnc:HGNC:15571","description":"LRRC2 antisense RNA 1","metadata":{"aliases":["NONHSAT089447.2","LUZP3","LUZPP1","LUZP3P"]}},{"id":"14c6f28422cc47d0b1a4d69a33c3adaa","type":"GENE","name":"LRRC20","canonical_id":"hgnc:HGNC:23421","description":"leucine rich repeat containing 20","metadata":{"aliases":["FLJ10751","FLJ10844"]}},{"id":"1b12997b6a0440b98ec0d6127f0b305a","type":"GENE","name":"LRRC23","canonical_id":"hgnc:HGNC:19138","description":"leucine rich repeat containing 23","metadata":{"aliases":["B7","LRPB7"]}},{"id":"301678bf22ed479595db1e2497d016ee","type":"GENE","name":"LRRC24","canonical_id":"hgnc:HGNC:28947","description":"leucine rich repeat containing 24","metadata":{"aliases":["LRRC14OS"]}},{"id":"2485a3fd35ca426ab935b22c9266dfd5","type":"GENE","name":"LRRC25","canonical_id":"hgnc:HGNC:29806","description":"leucine rich repeat containing 25","metadata":{"aliases":["MAPA","FLJ38116"]}},{"id":"fbd432ef5464437fa47e70f107054e27","type":"GENE","name":"LRRC26","canonical_id":"hgnc:HGNC:31409","description":"leucine rich repeat containing 26","metadata":{"aliases":["bA350O14.10","OTTHUMG00000020980"]}},{"id":"32716818f7244807a828c8a6d532e776","type":"GENE","name":"LRRC27","canonical_id":"hgnc:HGNC:29346","description":"leucine rich repeat containing 27","metadata":{"aliases":["KIAA1674"]}},{"id":"e555862c03984b78b5216d51dc5cfdcb","type":"GENE","name":"LRRC28","canonical_id":"hgnc:HGNC:28355","description":"leucine rich repeat containing 28","metadata":{"aliases":["MGC24976","FLJ34269","FLJ45242"]}},{"id":"90f6555ed29241a6b6ae3190c718b4f1","type":"GENE","name":"LRRC2P1","canonical_id":"hgnc:HGNC:54785","description":"LRRC2 pseudogene 1","metadata":null},{"id":"97b8801ffdb749d285958a04f91e0706","type":"GENE","name":"LRRC3","canonical_id":"hgnc:HGNC:14965","description":"leucine rich repeat containing 3","metadata":{"aliases":["DKFZP434C128","C21orf102","LRRC3DN","C21orf30"]}},{"id":"0f7e65650cd446eea69cce1e2859d960","type":"GENE","name":"LRRC3-DT","canonical_id":"hgnc:HGNC:43636","description":"LRRC3 divergent transcript","metadata":{"aliases":["LRRC3-AS1"]}},{"id":"a53e3637444a429c9de70a5e60a0fe74","type":"GENE","name":"LRRC30","canonical_id":"hgnc:HGNC:30219","description":"leucine rich repeat containing 30","metadata":null},{"id":"420e0b3b6e8d4a66b7808fa2bdf6ce60","type":"GENE","name":"LRRC31","canonical_id":"hgnc:HGNC:26261","description":"leucine rich repeat containing 31","metadata":{"aliases":["FLJ23259"]}},{"id":"ee45741dd0b54a35ac05f4e2182f59d8","type":"GENE","name":"LRRC32","canonical_id":"hgnc:HGNC:4161","description":"leucine rich repeat containing 32","metadata":{"aliases":["D11S833E","GARP"]}},{"id":"4a40c1a76f5d4ba9882e3957efdb16d4","type":"GENE","name":"LRRC32-AS1","canonical_id":"hgnc:HGNC:58233","description":"LRRC32 antisense RNA 1","metadata":null},{"id":"41c982107d1446ddadac8b5ebe8b8de5","type":"GENE","name":"LRRC34","canonical_id":"hgnc:HGNC:28408","description":"leucine rich repeat containing 34","metadata":{"aliases":["MGC27085"]}},{"id":"a9fbe3fb29dc477087fa1daf05932579","type":"GENE","name":"LRRC34P1","canonical_id":"hgnc:HGNC:49887","description":"leucine rich repeat containing 34 pseudogene 1","metadata":null},{"id":"445d5ded9853453b8cb928315202bc47","type":"GENE","name":"LRRC34P2","canonical_id":"hgnc:HGNC:49888","description":"leucine rich repeat containing 34 pseudogene 2","metadata":null},{"id":"e4eb4a6292d148a38f92530aa7d6ba17","type":"GENE","name":"LRRC36","canonical_id":"hgnc:HGNC:25615","description":"leucine rich repeat containing 36","metadata":{"aliases":["FLJ11004"]}},{"id":"a3bae98b00324110b58f00248e0c261f","type":"GENE","name":"LRRC37A","canonical_id":"hgnc:HGNC:29069","description":"leucine rich repeat containing 37A","metadata":{"aliases":["KIAA0563","LRRC37A1"]}},{"id":"09c52f5f1de34c3ea5ab04583154db90","type":"GENE","name":"LRRC37A10P","canonical_id":"hgnc:HGNC:43814","description":"leucine rich repeat containing 37 member A10, pseudogene","metadata":null},{"id":"404ecf4e737b4b30a1d6317f75d8b3a3","type":"GENE","name":"LRRC37A11P","canonical_id":"hgnc:HGNC:43815","description":"leucine rich repeat containing 37 member A11, pseudogene","metadata":{"aliases":["LRRC37F"]}},{"id":"94524d6a9f5342009ed5563e102ca7cf","type":"GENE","name":"LRRC37A12P","canonical_id":"hgnc:HGNC:43816","description":"leucine rich repeat containing 37 member A12, pseudogene","metadata":null},{"id":"3d9ed39b0c274ae0957a15ff25139299","type":"GENE","name":"LRRC37A13P","canonical_id":"hgnc:HGNC:43817","description":"leucine rich repeat containing 37 member A13, pseudogene","metadata":null},{"id":"77eeb4260efa4fec87cd07b587ee298b","type":"GENE","name":"LRRC37A14P","canonical_id":"hgnc:HGNC:43818","description":"leucine rich repeat containing 37 member A14, pseudogene","metadata":null},{"id":"32f997e142b340d5a273b17f11be91f2","type":"GENE","name":"LRRC37A15P","canonical_id":"hgnc:HGNC:43819","description":"leucine rich repeat containing 37 member A15, pseudogene","metadata":null},{"id":"65f7a06298ee4e2cac3d511803ab6b95","type":"GENE","name":"LRRC37A16P","canonical_id":"hgnc:HGNC:43820","description":"leucine rich repeat containing 37 member A16, pseudogene","metadata":{"aliases":["LRRC37C"]}},{"id":"92b6f9c311ee4646bf9ac74c9fa8d09c","type":"GENE","name":"LRRC37A17P","canonical_id":"hgnc:HGNC:48365","description":"leucine rich repeat containing 37 member A17, pseudogene","metadata":{"aliases":["LRRC37A5"]}},{"id":"2c6aaeb7da934d05b360cc670f0d0c7f","type":"GENE","name":"LRRC37A2","canonical_id":"hgnc:HGNC:32404","description":"leucine rich repeat containing 37 member A2","metadata":{"aliases":["FLJ45049"]}},{"id":"5cff6ce121384c10926eb410e3b46938","type":"GENE","name":"LRRC37A2-AS1","canonical_id":"hgnc:HGNC:58690","description":"LRRC37A2 antisense RNA 1","metadata":null},{"id":"270531407b6c442aaf4b3c980f6f94a2","type":"GENE","name":"LRRC37A3","canonical_id":"hgnc:HGNC:32427","description":"leucine rich repeat containing 37 member A3","metadata":{"aliases":["FLJ34306","KIAA0563"]}},{"id":"ef17f2ef9e9b45f7b570c8d549742bec","type":"GENE","name":"LRRC37A4P","canonical_id":"hgnc:HGNC:25479","description":"leucine rich repeat containing 37 member A4, pseudogene","metadata":{"aliases":["FLJ10120","LRRC37A4"]}},{"id":"5a6974e3a8be4697a01b768bd8927e1f","type":"GENE","name":"LRRC37A5P","canonical_id":"hgnc:HGNC:23369","description":"leucine rich repeat containing 37 member A5, pseudogene","metadata":{"aliases":["C9orf29"]}},{"id":"d78b5eff9c1843bf96661a88733212e9","type":"GENE","name":"LRRC37A6P","canonical_id":"hgnc:HGNC:33746","description":"leucine rich repeat containing 37 member A6, pseudogene","metadata":{"aliases":["LRRC37E"]}},{"id":"25231c4fc870495cbd155429d6b969df","type":"GENE","name":"LRRC37A7P","canonical_id":"hgnc:HGNC:43792","description":"leucine rich repeat containing 37 member A7, pseudogene","metadata":null},{"id":"26f63cbd62094f82a58b5b50d024a065","type":"GENE","name":"LRRC37A8P","canonical_id":"hgnc:HGNC:43793","description":"leucine rich repeat containing 37 member A8, pseudogene","metadata":null},{"id":"9c17fb8098d74ac3b921b0b7fce25880","type":"GENE","name":"LRRC37A9P","canonical_id":"hgnc:HGNC:43813","description":"leucine rich repeat containing 37 member A9, pseudogene","metadata":null},{"id":"f029b745f66740ce97352e31c0e9d816","type":"GENE","name":"LRRC37B","canonical_id":"hgnc:HGNC:29070","description":"leucine rich repeat containing 37B","metadata":null},{"id":"affca0e57be34558b5c3b94dcfa578d5","type":"GENE","name":"LRRC37BP1","canonical_id":"hgnc:HGNC:25390","description":"leucine rich repeat containing 37B pseudogene 1","metadata":{"aliases":["DKFZp667M2411","LRRC37B2"]}},{"id":"2502fe91afc9446eb091d584b9bb0cf4","type":"GENE","name":"LRRC38","canonical_id":"hgnc:HGNC:27005","description":"leucine rich repeat containing 38","metadata":null},{"id":"e8f6a63497ef4c69adcce5e8220cef78","type":"GENE","name":"LRRC39","canonical_id":"hgnc:HGNC:28228","description":"leucine rich repeat containing 39","metadata":{"aliases":["MGC14816","myomasp"]}},{"id":"1b4585ce961f4ba1892b7e6aa8fe8cb9","type":"GENE","name":"LRRC3B","canonical_id":"hgnc:HGNC:28105","description":"leucine rich repeat containing 3B","metadata":{"aliases":["LRP15"]}},{"id":"27576932c8ca4e9cbc80a8cf8a13097f","type":"GENE","name":"LRRC3B-AS1","canonical_id":"hgnc:HGNC:55847","description":"LRRC3B antisense RNA 1","metadata":null},{"id":"a7407a92d89e4d0489245b0fa2c202c3","type":"GENE","name":"LRRC3C","canonical_id":"hgnc:HGNC:40034","description":"leucine rich repeat containing 3C","metadata":null},{"id":"f1861470c96a4db3b623e6216750e4a0","type":"GENE","name":"LRRC4","canonical_id":"hgnc:HGNC:15586","description":"leucine rich repeat containing 4","metadata":{"aliases":["NAG14","NGL-2"]}},{"id":"ae33d14c42884e1f9445cea25d03fa08","type":"GENE","name":"LRRC40","canonical_id":"hgnc:HGNC:26004","description":"leucine rich repeat containing 40","metadata":{"aliases":["FLJ20331"]}},{"id":"4886084d866f43cfb83435066594db50","type":"GENE","name":"LRRC41","canonical_id":"hgnc:HGNC:16917","description":"leucine rich repeat containing 41","metadata":{"aliases":["MUF1"]}},{"id":"3139165898484405ac23bc5c53b02440","type":"GENE","name":"LRRC42","canonical_id":"hgnc:HGNC:28792","description":"leucine rich repeat containing 42","metadata":{"aliases":["MGC8974"]}},{"id":"81d85a3bcc1f45deb741aa4f34b4dc4f","type":"GENE","name":"LRRC43","canonical_id":"hgnc:HGNC:28562","description":"leucine rich repeat containing 43","metadata":{"aliases":["MGC35140"]}},{"id":"0e6b4bd371754be38397ff989d4a7f02","type":"GENE","name":"LRRC45","canonical_id":"hgnc:HGNC:28302","description":"leucine rich repeat containing 45","metadata":{"aliases":["MGC20806"]}},{"id":"d9a7428f680c4d7e90c55117f5418438","type":"GENE","name":"LRRC46","canonical_id":"hgnc:HGNC:25047","description":"leucine rich repeat containing 46","metadata":{"aliases":["MGC16309"]}},{"id":"25c56f2c55a947909a7ec50700d119a7","type":"GENE","name":"LRRC47","canonical_id":"hgnc:HGNC:29207","description":"leucine rich repeat containing 47","metadata":{"aliases":["KIAA1185","RP1-286D6.3"]}},{"id":"a7ea184bc1b94a82a7c05f6f4882d62d","type":"GENE","name":"LRRC49","canonical_id":"hgnc:HGNC:25965","description":"leucine rich repeat containing 49","metadata":{"aliases":["FLJ20156","CSTPP2","PGs4"]}},{"id":"7af64df882064d99add6dd5962b3b3f1","type":"GENE","name":"LRRC4B","canonical_id":"hgnc:HGNC:25042","description":"leucine rich repeat containing 4B","metadata":{"aliases":["DKFZp761A179","HSM","NGL-3","LRIG4"]}},{"id":"6fcd59a11e754b79be2cd6bd16b3cb62","type":"GENE","name":"LRRC4C","canonical_id":"hgnc:HGNC:29317","description":"leucine rich repeat containing 4C","metadata":{"aliases":["KIAA1580","NGL-1"]}},{"id":"df90492e3a2c4c3098e8e78c4e8972ca","type":"GENE","name":"LRRC51","canonical_id":"hgnc:HGNC:55526","description":"leucine rich repeat containing 51","metadata":null},{"id":"b31641c510b441998695714a2e0769fd","type":"GENE","name":"LRRC52","canonical_id":"hgnc:HGNC:32156","description":"leucine rich repeat containing 52","metadata":{"aliases":["FLJ25811"]}},{"id":"905ecb5d405c4b98996a85385c5e874b","type":"GENE","name":"LRRC52-AS1","canonical_id":"hgnc:HGNC:54044","description":"LRRC52 antisense RNA 1","metadata":null},{"id":"6b61669703e849aeb543d70416b36f1f","type":"GENE","name":"LRRC53","canonical_id":"hgnc:HGNC:25255","description":"leucine rich repeat containing 53","metadata":null},{"id":"42736e1050db4a568f30565802d00a93","type":"GENE","name":"LRRC55","canonical_id":"hgnc:HGNC:32324","description":"leucine rich repeat containing 55","metadata":{"aliases":["FLJ45686"]}},{"id":"455a4098a79f4f46b067eb07dfca9311","type":"GENE","name":"LRRC56","canonical_id":"hgnc:HGNC:25430","description":"leucine rich repeat containing 56","metadata":{"aliases":["FLJ00101","oda8","DKFZp761L1518","DNAAF12"]}},{"id":"30f947d61958409599c47741a9625db7","type":"GENE","name":"LRRC57","canonical_id":"hgnc:HGNC:26719","description":"leucine rich repeat containing 57","metadata":{"aliases":["FLJ36812"]}},{"id":"e62d9f9ddeda4af79283efb9fa55ac42","type":"GENE","name":"LRRC57P1","canonical_id":"hgnc:HGNC:54680","description":"LRRC57 pseudogene 1","metadata":null},{"id":"e661c68cb01b45c188d3ca652cbc230d","type":"GENE","name":"LRRC58","canonical_id":"hgnc:HGNC:26968","description":"leucine rich repeat containing 58","metadata":null},{"id":"9d8cf913ffaf41a8b24a13f0d2f1d14b","type":"GENE","name":"LRRC59","canonical_id":"hgnc:HGNC:28817","description":"leucine rich repeat containing 59","metadata":{"aliases":["PRO1855","FLJ21675"]}},{"id":"5605b1913cc340369e6e844d5181d393","type":"GENE","name":"LRRC59-AS1","canonical_id":"hgnc:HGNC:58254","description":"LRRC59 antisense RNA 1","metadata":null},{"id":"0d758a26c1294536be505e319416f6ff","type":"GENE","name":"LRRC61","canonical_id":"hgnc:HGNC:21704","description":"leucine rich repeat containing 61","metadata":{"aliases":["MGC3036","FLJ31392","HSPC295"]}},{"id":"73b2b71768f14b1a943e35629b810f66","type":"GENE","name":"LRRC63","canonical_id":"hgnc:HGNC:34296","description":"leucine rich repeat containing 63","metadata":{"aliases":["RP11-139H14.4"]}},{"id":"bc064017550e47c6b2a648d1d64a3a8e","type":"GENE","name":"LRRC66","canonical_id":"hgnc:HGNC:34299","description":"leucine rich repeat containing 66","metadata":null},{"id":"b61948842d694235964a3269fc91ecd0","type":"GENE","name":"LRRC69","canonical_id":"hgnc:HGNC:34303","description":"leucine rich repeat containing 69","metadata":null},{"id":"ed9a2d4e36f84555a781208ba7c3c2b0","type":"GENE","name":"LRRC7","canonical_id":"hgnc:HGNC:18531","description":"leucine rich repeat containing 7","metadata":{"aliases":["KIAA1365","densin-180"]}},{"id":"cc26924447a14fb981ef9a1daed0a24d","type":"GENE","name":"LRRC7-AS1","canonical_id":"hgnc:HGNC:40843","description":"LRRC7 antisense RNA 1","metadata":null},{"id":"3847b4bff8ca4c65b4cc2a6ff355130e","type":"GENE","name":"LRRC70","canonical_id":"hgnc:HGNC:35155","description":"leucine rich repeat containing 70","metadata":{"aliases":["SLRN","LOC100130733"]}},{"id":"3f15396050f14722952e2c34dacf1905","type":"GENE","name":"LRRC71","canonical_id":"hgnc:HGNC:26556","description":"leucine rich repeat containing 71","metadata":{"aliases":["FLJ32884","C1orf92"]}},{"id":"2416bc3bac434e2d87a25605072f2d58","type":"GENE","name":"LRRC72","canonical_id":"hgnc:HGNC:42972","description":"leucine rich repeat containing 72","metadata":{"aliases":["CFAP279","FAP279"]}},{"id":"aea3efd321114adbae9e867beb4a1149","type":"GENE","name":"LRRC73","canonical_id":"hgnc:HGNC:21375","description":"leucine rich repeat containing 73","metadata":{"aliases":["dJ337H4.2","C6orf154"]}},{"id":"d64db7dd54f24f5ba2b44bef6908f025","type":"GENE","name":"LRRC74A","canonical_id":"hgnc:HGNC:23346","description":"leucine rich repeat containing 74A","metadata":{"aliases":["C14orf166B","LRRC74"]}},{"id":"6ed0069cbe474de1bd07f635657fb23c","type":"GENE","name":"LRRC74B","canonical_id":"hgnc:HGNC:34301","description":"leucine rich repeat containing 74B","metadata":null},{"id":"4016e43a24e94b5bb9229538f2233afc","type":"GENE","name":"LRRC74BNL","canonical_id":"hgnc:HGNC:24067","description":"LRRC74B N-terminal like","metadata":{"aliases":["TUBA3FP"]}},{"id":"650f26371b3349e89d977fb321386032","type":"GENE","name":"LRRC75A","canonical_id":"hgnc:HGNC:32403","description":"leucine rich repeat containing 75A","metadata":{"aliases":["FLJ35696","C17orf76","FAM211A"]}},{"id":"6b891dba7ce44ad68542f3af4be0e8ea","type":"GENE","name":"LRRC75B","canonical_id":"hgnc:HGNC:33155","description":"leucine rich repeat containing 75B","metadata":{"aliases":["MGC131773","C22orf36","FAM211B"]}},{"id":"2c58b205922e436ba7caf3eff4f54499","type":"GENE","name":"LRRC77P","canonical_id":"hgnc:HGNC:50536","description":"leucine rich repeat containing 77, pseudogene","metadata":{"aliases":["LINC01330"]}},{"id":"64b92dbec1d047f6becf0d71b139f64c","type":"GENE","name":"LRRC78P","canonical_id":"hgnc:HGNC:54091","description":"leucine rich repeat containing 78, pseudogene","metadata":{"aliases":["LINC02618"]}},{"id":"b62ad9ebe1a24f35b5f3065429153813","type":"GENE","name":"LRRC8A","canonical_id":"hgnc:HGNC:19027","description":"leucine rich repeat containing 8 VRAC subunit A","metadata":{"aliases":["KIAA1437","FLJ10337","SWELL1","LRRC8"]}},{"id":"a664d618af4743a6bc2d4911c929066d","type":"GENE","name":"LRRC8B","canonical_id":"hgnc:HGNC:30692","description":"leucine rich repeat containing 8 VRAC subunit B","metadata":{"aliases":["TA-LRRP","KIAA0231"]}},{"id":"8e276b27ab7e4df1bef4f41de47ee2f0","type":"GENE","name":"LRRC8C","canonical_id":"hgnc:HGNC:25075","description":"leucine rich repeat containing 8 VRAC subunit C","metadata":{"aliases":["AD158"]}},{"id":"02e3f2ce1fb742d5a9a2288c56b6234d","type":"GENE","name":"LRRC8C-DT","canonical_id":"hgnc:HGNC:53731","description":"LRRC8C divergent transcript","metadata":{"aliases":["FLJ27354"]}},{"id":"5970a1e498004f5fbd631265927ad9de","type":"GENE","name":"LRRC8D","canonical_id":"hgnc:HGNC:16992","description":"leucine rich repeat containing 8 VRAC subunit D","metadata":{"aliases":["FLJ10470","LRRC5"]}},{"id":"80a9863edee84f6698f70543ee81f748","type":"GENE","name":"LRRC8D-DT","canonical_id":"hgnc:HGNC:55186","description":"LRRC8D divergent transcript","metadata":null},{"id":"bb1d8903f1fe44b5aad8d2cbf90e3e38","type":"GENE","name":"LRRC8E","canonical_id":"hgnc:HGNC:26272","description":"leucine rich repeat containing 8 VRAC subunit E","metadata":{"aliases":["FLJ23420"]}},{"id":"6d90d5ef05e645d0b69cda3d7766f9bb","type":"GENE","name":"LRRC9","canonical_id":"hgnc:HGNC:19848","description":"leucine rich repeat containing 9","metadata":{"aliases":["FLJ46156"]}},{"id":"435b519bdffc4afea16274e60fcfd57e","type":"GENE","name":"LRRCC1","canonical_id":"hgnc:HGNC:29373","description":"leucine rich repeat and coiled-coil centrosomal protein 1","metadata":{"aliases":["KIAA1764","CLERC","VFL1"]}},{"id":"f66b4f0293ec45d5ba66083a07f18786","type":"GENE","name":"LRRD1","canonical_id":"hgnc:HGNC:34300","description":"leucine rich repeats and death domain containing 1","metadata":{"aliases":["IMAGE:4798971"]}},{"id":"74a21fed544a473fa9d52ee11db45159","type":"GENE","name":"LRRFIP1","canonical_id":"hgnc:HGNC:6702","description":null,"metadata":null},{"id":"8d1f2e4dd8a243f28111f1ea70609fbb","type":"GENE","name":"LRRFIP1P1","canonical_id":"hgnc:HGNC:32937","description":"LRR binding FLII interacting protein 1 pseudogene 1","metadata":null},{"id":"ef773d854b054c0192b689c775518648","type":"GENE","name":"LRRFIP2","canonical_id":"hgnc:HGNC:6703","description":"LRR binding FLII interacting protein 2","metadata":{"aliases":["HUFI-2"]}},{"id":"a1cbeed35b1c4b1199ba719a7f1d490f","type":"GENE","name":"LRRFIP2P1","canonical_id":"hgnc:HGNC:54992","description":"LRRFIP2 pseudogene 1","metadata":null},{"id":"9f088154f60c40968f9cfd9c1d08e4e0","type":"GENE","name":"LRRIQ1","canonical_id":"hgnc:HGNC:25708","description":"leucine rich repeats and IQ motif containing 1","metadata":{"aliases":["FLJ12303","KIAA1801"]}},{"id":"683cc4ea0c014a3c920af3fa033d60f1","type":"GENE","name":"LRRIQ3","canonical_id":"hgnc:HGNC:28318","description":"leucine rich repeats and IQ motif containing 3","metadata":{"aliases":["MGC22773","LRRC44"]}},{"id":"861e6112ff6440479e41db83fc31bc06","type":"GENE","name":"LRRIQ4","canonical_id":"hgnc:HGNC:34298","description":"leucine rich repeats and IQ motif containing 4","metadata":{"aliases":["LRRC64"]}},{"id":"53e9a7d38e5b43e49e41a2b1fed9238c","type":"GENE","name":"LRRK1","canonical_id":"hgnc:HGNC:18608","description":"leucine rich repeat kinase 1","metadata":{"aliases":["FLJ23119","KIAA1790","ROCO1","RIPK6"]}},{"id":"a10ececb75874c11b270c484584d28e6","type":"GENE","name":"LRRK1-AS1","canonical_id":"hgnc:HGNC:58299","description":"LRRK1 antisense RNA 1","metadata":null},{"id":"670b7c6f5c85413e92907298b4e906e9","type":"GENE","name":"LRRK2","canonical_id":"hgnc:HGNC:18618","description":"leucine rich repeat kinase 2","metadata":{"aliases":["ROCO2","DKFZp434H2111","FLJ45829","RIPK7","PARK8"]}},{"id":"c41bcc12b21f4e8ebebfd68ddbff52b6","type":"GENE","name":"LRRK2-DT","canonical_id":"hgnc:HGNC:40848","description":"LRRK2 divergent transcript","metadata":null},{"id":"4165419506cf4c85b638c03ab59c8361","type":"GENE","name":"LRRN1","canonical_id":"hgnc:HGNC:20980","description":"leucine rich repeat neuronal 1","metadata":{"aliases":["FIGLER3"]}},{"id":"428ba1ea06a74b16b0b7fa46441b2369","type":"GENE","name":"LRRN2","canonical_id":"hgnc:HGNC:16914","description":"leucine rich repeat neuronal 2","metadata":{"aliases":["GAC1","LRANK1","FIGLER7","LRRN5"]}},{"id":"e664c69e438d4be2acfb1781a630ae40","type":"GENE","name":"LRRN2-AS1","canonical_id":"hgnc:HGNC:58404","description":"LRRN2 antisense RNA 1","metadata":null},{"id":"6e7833ab5d034716a34a1a47a9ef2881","type":"GENE","name":"LRRN3","canonical_id":"hgnc:HGNC:17200","description":null,"metadata":null},{"id":"de57daa58f1b482b9f36b2cf3351c266","type":"GENE","name":"LRRN4","canonical_id":"hgnc:HGNC:16208","description":"leucine rich repeat neuronal 4","metadata":{"aliases":["dJ1056H1.1","NLRR4","C20orf75"]}},{"id":"a77b4fd000f24e5bbb0b8a0288c436cf","type":"GENE","name":"LRRN4CL","canonical_id":"hgnc:HGNC:33724","description":"LRRN4 C-terminal like","metadata":null},{"id":"fccc38da1f5d4f959d56f31d3965961a","type":"GENE","name":"LRRTM1","canonical_id":"hgnc:HGNC:19408","description":"leucine rich repeat transmembrane neuronal 1","metadata":{"aliases":["FLJ32082"]}},{"id":"0cc95d0031284110983864a6817101b8","type":"GENE","name":"LRRTM2","canonical_id":"hgnc:HGNC:19409","description":"leucine rich repeat transmembrane neuronal 2","metadata":{"aliases":["KIAA0416"]}},{"id":"c72ab6fce0474ed89e159acd2801cdd9","type":"GENE","name":"LRRTM3","canonical_id":"hgnc:HGNC:19410","description":"leucine rich repeat transmembrane neuronal 3","metadata":null},{"id":"bb911674e27d42429ea019ea4c5e80e4","type":"GENE","name":"LRRTM4","canonical_id":"hgnc:HGNC:19411","description":"leucine rich repeat transmembrane neuronal 4","metadata":{"aliases":["FLJ12568"]}},{"id":"2b4d296b6cd74f278c2b116d5048550d","type":"GENE","name":"LRRTM4-AS1","canonical_id":"hgnc:HGNC:40889","description":"LRRTM4 antisense RNA 1","metadata":null},{"id":"8f42364e34af4fd88ca22ca9d24da220","type":"GENE","name":"LRSAM1","canonical_id":"hgnc:HGNC:25135","description":"leucine rich repeat and sterile alpha motif containing 1","metadata":{"aliases":["FLJ31641","CMT2P","RIFLE","TAL"]}},{"id":"45ef98e204b64344acd5f3b22b2318a2","type":"GENE","name":"LRTM1","canonical_id":"hgnc:HGNC:25023","description":"leucine rich repeat transmembrane protein 1","metadata":{"aliases":["HT017"]}},{"id":"856db007beda4ee9b6d97ca7737b607b","type":"GENE","name":"LRTM2","canonical_id":"hgnc:HGNC:32443","description":"leucine rich repeat transmembrane protein 2","metadata":null},{"id":"2fafc889a64e4097bf3f81c128557084","type":"GENE","name":"LRTM3","canonical_id":"hgnc:HGNC:26851","description":"leucine rich repeat transmembrane protein 3","metadata":{"aliases":["FLJ40176","C13orf40","CCDC168"]}},{"id":"568ad947f627440786730db4d41aeb44","type":"GENE","name":"LRTOMT","canonical_id":"hgnc:HGNC:25033","description":"leucine rich transmembrane and O-methyltransferase domain containing","metadata":{"aliases":["COMT2","CFAP111","LRTOMT1","LRTOMT2","LRRC51","DFNB63"]}},{"id":"c44fe6f540104c409ee9743247154b55","type":"GENE","name":"LRWD1","canonical_id":"hgnc:HGNC:21769","description":"leucine rich repeats and WD repeat domain containing 1","metadata":{"aliases":["DKFZp434K1815","ORCA","CENP-33"]}},{"id":"3d0f366e2699417aad79afce09add105","type":"GENE","name":"LSAMP","canonical_id":"hgnc:HGNC:6705","description":"limbic system associated membrane protein","metadata":{"aliases":["LAMP","IGLON3"]}},{"id":"d4050e4c914840eaa3fb20674f1e1a9e","type":"GENE","name":"LSAMP-AS1","canonical_id":"hgnc:HGNC:40350","description":"LSAMP antisense RNA 1","metadata":null},{"id":"eeaa28422d2c42218a559f7449aa8995","type":"GENE","name":"LSG1","canonical_id":"hgnc:HGNC:25652","description":"large 60S subunit nuclear export GTPase 1","metadata":{"aliases":["FLJ11301"]}},{"id":"55f7241e311940b29d0947b51a7b8b2b","type":"GENE","name":"LSINCT5","canonical_id":"hgnc:HGNC:37824","description":"long stress-induced non-coding transcript 5","metadata":null},{"id":"ad8e9c4c99b24da68b8389f2fe2cb06e","type":"GENE","name":"LSM1","canonical_id":"hgnc:HGNC:20472","description":"LSM1 homolog, mRNA degradation associated","metadata":{"aliases":["CASM","YJL124C"]}},{"id":"fa2c677361144a20b4ce53ccbc5eac52","type":"GENE","name":"LSM10","canonical_id":"hgnc:HGNC:17562","description":"LSM10, U7 small nuclear RNA associated","metadata":{"aliases":["MGC15749"]}},{"id":"03015df474464d759e0f0c4020dd39ba","type":"GENE","name":"LSM11","canonical_id":"hgnc:HGNC:30860","description":"LSM11, U7 small nuclear RNA associated","metadata":{"aliases":["FLJ38273"]}},{"id":"e58d1fd7b75849ed8e16f2ed9e635cd7","type":"GENE","name":"LSM12","canonical_id":"hgnc:HGNC:26407","description":"LSM12 homolog","metadata":{"aliases":["FLJ30656"]}},{"id":"16ad9374991c498ba8fc5d7fd212ab24","type":"GENE","name":"LSM12P1","canonical_id":"hgnc:HGNC:32453","description":"LSM12 pseudogene 1","metadata":{"aliases":["LSM12P"]}},{"id":"683040623ec9473fb3dce30d424a01f2","type":"GENE","name":"LSM14A","canonical_id":"hgnc:HGNC:24489","description":"LSM14A mRNA processing body assembly factor","metadata":{"aliases":["DKFZP434D1335","RAP55A","RAP55","C19orf13","FAM61A"]}},{"id":"1431472dbc7846fab1d1c955c93093b1","type":"GENE","name":"LSM14B","canonical_id":"hgnc:HGNC:15887","description":"LSM family member 14B","metadata":{"aliases":["FT005","bA11M20.3","FLJ25473","LSM13","RAP55B","C20orf40","FAM61B"]}},{"id":"9d2a19a1c0b141579e3f931c97a75e67","type":"GENE","name":"LSM1P1","canonical_id":"hgnc:HGNC:49776","description":"LSM1 pseudogene 1","metadata":null},{"id":"21678970b8eb476cbf135a96997a083b","type":"GENE","name":"LSM1P2","canonical_id":"hgnc:HGNC:49777","description":"LSM1 pseudogene 2","metadata":null},{"id":"61a8757d64a5444da8a1f2bf75a0ee14","type":"GENE","name":"LSM2","canonical_id":"hgnc:HGNC:13940","description":"LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated","metadata":{"aliases":["G7b","YBL026W","C6orf28"]}},{"id":"d4d0a6ef58184b159a7342135a95c9d2","type":"GENE","name":"LSM2P1","canonical_id":"hgnc:HGNC:57002","description":"LSM2 pseudogene 1","metadata":null},{"id":"bb4f5f00d9054773aac5856aa4fd0cf7","type":"GENE","name":"LSM2P2","canonical_id":"hgnc:HGNC:57003","description":"LSM2 pseudogene 2","metadata":null},{"id":"812002bec93e4bd695580a371bf3e882","type":"GENE","name":"LSM3","canonical_id":"hgnc:HGNC:17874","description":"LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated","metadata":{"aliases":["YLR438C","SMX4","USS2"]}},{"id":"e14916d2bc174a4ab32c328264c875b8","type":"GENE","name":"LSM3P1","canonical_id":"hgnc:HGNC:44346","description":"LSM3 pseudogene 1","metadata":null},{"id":"638a4118313f420797dcc75df275a4d1","type":"GENE","name":"LSM3P2","canonical_id":"hgnc:HGNC:44347","description":"LSM3 pseudogene 2","metadata":null},{"id":"1ac92e2ff2d24eb5ad9d4c07a40f3dd4","type":"GENE","name":"LSM3P3","canonical_id":"hgnc:HGNC:44348","description":"LSM3 pseudogene 3","metadata":null},{"id":"48165cd9352a4c2da89563ab9cab033d","type":"GENE","name":"LSM3P4","canonical_id":"hgnc:HGNC:44349","description":"LSM3 pseudogene 4","metadata":null},{"id":"4071dfe5b49a411eac43df6513fbece0","type":"GENE","name":"LSM3P5","canonical_id":"hgnc:HGNC:44350","description":"LSM3 pseudogene 5","metadata":null},{"id":"7b34199424ca4bb4ae04b45a09dce534","type":"GENE","name":"LSM3P6","canonical_id":"hgnc:HGNC:59191","description":"LSM3 pseudogene 6","metadata":null},{"id":"6883b99568ab4fc7a833cdec4ea7ecf5","type":"GENE","name":"LSM4","canonical_id":"hgnc:HGNC:17259","description":"LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated","metadata":{"aliases":["YER112W"]}},{"id":"80435700fef54d73aa47e2ba9b63ddec","type":"GENE","name":"LSM5","canonical_id":"hgnc:HGNC:17162","description":"LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated","metadata":{"aliases":["YER146W"]}},{"id":"2050410bcca2428a85db3d39c1a00e4c","type":"GENE","name":"LSM6","canonical_id":"hgnc:HGNC:17017","description":"LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated","metadata":{"aliases":["YDR378C"]}},{"id":"eb74f4f8718846999a0ce4f82499b3d0","type":"GENE","name":"LSM6P1","canonical_id":"hgnc:HGNC:31738","description":"LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated pseudogene 1","metadata":{"aliases":["HsT818","LSM6P"]}},{"id":"11174b6df7e74184b636991cdc47b3f7","type":"GENE","name":"LSM6P2","canonical_id":"hgnc:HGNC:37811","description":"LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated pseudogene 2","metadata":null},{"id":"03b3e1eb16cc4151a64593b93ede0289","type":"GENE","name":"LSM7","canonical_id":"hgnc:HGNC:20470","description":"LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated","metadata":{"aliases":["YNL147W"]}},{"id":"0d449a9ad9224b10b75d580b9caba696","type":"GENE","name":"LSM8","canonical_id":"hgnc:HGNC:20471","description":"LSM8 homolog, U6 small nuclear RNA associated","metadata":{"aliases":["YJR022W"]}},{"id":"feee96f8a03c4c308c0f13818d410cb8","type":"GENE","name":"LSMEM1","canonical_id":"hgnc:HGNC:22036","description":"leucine rich single-pass membrane protein 1","metadata":{"aliases":["FLJ39575","C7orf53"]}},{"id":"e3f525b55f454d1dbfbc4f1a5b6217f1","type":"GENE","name":"LSMEM2","canonical_id":"hgnc:HGNC:26781","description":"leucine rich single-pass membrane protein 2","metadata":{"aliases":["FLJ38608","C3orf45"]}},{"id":"10a3b8d9c7b245d1809315a5f861d970","type":"GENE","name":"LSP1","canonical_id":"hgnc:HGNC:6707","description":null,"metadata":null},{"id":"79dbba70e19e4d63bc3d36db30862286","type":"GENE","name":"LSP1P1","canonical_id":"hgnc:HGNC:39716","description":"LSP1 pseudogene 1","metadata":null},{"id":"752cb5df6c38464a9c7dc03741bcfae0","type":"GENE","name":"LSP1P2","canonical_id":"hgnc:HGNC:39717","description":"LSP1 pseudogene 2","metadata":null},{"id":"2b6e1ac5f3474b038c322ff7e533c176","type":"GENE","name":"LSP1P3","canonical_id":"hgnc:HGNC:39718","description":"LSP1 pseudogene 3","metadata":null},{"id":"5513cca8230f49c297431f327e14fa41","type":"GENE","name":"LSP1P4","canonical_id":"hgnc:HGNC:53915","description":"LSP1 pseudogene 4","metadata":null},{"id":"eedeb5803e5349238eb8f330eda0d699","type":"GENE","name":"LSP1P5","canonical_id":"hgnc:HGNC:50697","description":"LSP1 pseudogene 5","metadata":null},{"id":"467f97798cf74868bf01180f99d6fe82","type":"GENE","name":"LSR","canonical_id":"hgnc:HGNC:29572","description":"lipolysis stimulated lipoprotein receptor","metadata":{"aliases":["LISCH7","ILDR3"]}},{"id":"b28dc06f227d4a94a3b5442ddceb7747","type":"GENE","name":"LSS","canonical_id":"hgnc:HGNC:6708","description":null,"metadata":null},{"id":"2406c3febb0b4e7cb871d077d2bd6d72","type":"GENE","name":"LST1","canonical_id":"hgnc:HGNC:14189","description":"leukocyte specific transcript 1","metadata":{"aliases":["LST-1","B144","D6S49E"]}},{"id":"2d58e359754749a3a3f57cd64983d279","type":"GENE","name":"LTA","canonical_id":"hgnc:HGNC:6709","description":null,"metadata":null},{"id":"6ab9babbde81493883064b570a68749e","type":"GENE","name":"LTA4H","canonical_id":"hgnc:HGNC:6710","description":"leukotriene A4 hydrolase","metadata":null},{"id":"d112f480665c40789827f3856979b525","type":"GENE","name":"LTAP1","canonical_id":"hgnc:HGNC:29876","description":"lipid transport auxiliary protein 1","metadata":{"aliases":["NICE-3","DKFZp586G1722","C1orf43"]}},{"id":"97b63c4922c748a9aacbe29f657854b9","type":"GENE","name":"LTB","canonical_id":"hgnc:HGNC:6711","description":null,"metadata":null},{"id":"3b16e3d6a050485b85619733f0e63131","type":"GENE","name":"LTB4R","canonical_id":"hgnc:HGNC:6713","description":"leukotriene B4 receptor","metadata":{"aliases":["BLTR","P2Y7","LTB4R1","P2RY7","GPR16","CMKRL1"]}},{"id":"49170455936842aeab21f19f684bf07f","type":"GENE","name":"LTB4R2","canonical_id":"hgnc:HGNC:19260","description":"leukotriene B4 receptor 2","metadata":{"aliases":["BLTR2","BLT2","JULF2","NOP9"]}},{"id":"fc70abed6d474202b6988866872df357","type":"GENE","name":"LTBP1","canonical_id":"hgnc:HGNC:6714","description":null,"metadata":null},{"id":"bda8034358a0446b8ca004cbe9abad65","type":"GENE","name":"LTBP2","canonical_id":"hgnc:HGNC:6715","description":"latent transforming growth factor beta binding protein 2","metadata":{"aliases":["LTBP3","C14orf141"]}},{"id":"ee783e8be771426d95b2fd4b289b8122","type":"GENE","name":"LTBP3","canonical_id":"hgnc:HGNC:6716","description":"latent transforming growth factor beta binding protein 3","metadata":{"aliases":["LTBP2"]}},{"id":"7f41da26c1be4937b19848f82f2dfb9a","type":"GENE","name":"LTBP4","canonical_id":"hgnc:HGNC:6717","description":null,"metadata":null},{"id":"4885f93224f447b986f18f4b5a96df74","type":"GENE","name":"LTBR","canonical_id":"hgnc:HGNC:6718","description":null,"metadata":null},{"id":"cfde72ca6eee40fb8c2eb4db02fbbfe1","type":"GENE","name":"LTC4S","canonical_id":"hgnc:HGNC:6719","description":null,"metadata":null},{"id":"3f250c70e83042b7b9234f2fc0ebde83","type":"GENE","name":"LTF","canonical_id":"hgnc:HGNC:6720","description":null,"metadata":null},{"id":"9d8dec9e0feb4bcd94c30f50b4c201b4","type":"GENE","name":"LTK","canonical_id":"hgnc:HGNC:6721","description":"leukocyte receptor tyrosine kinase","metadata":{"aliases":["TYK1"]}},{"id":"25dea7b2b0d5433b878123a98c00589b","type":"GENE","name":"LTN1","canonical_id":"hgnc:HGNC:13082","description":"listerin E3 ubiquitin protein ligase 1","metadata":{"aliases":["KIAA0714","FLJ11053","LISTERIN","C21orf98","C21orf10","ZNF294","RNF160"]}},{"id":"450ce26b4ecb4471a962f82cdb288b11","type":"GENE","name":"LTO1","canonical_id":"hgnc:HGNC:17589","description":"LTO1 maturation factor of ABCE1","metadata":{"aliases":["TAOS1","CIAB1","ORAOV1"]}},{"id":"ff58b876000042258858aa96e0887ff3","type":"GENE","name":"LTO1P1","canonical_id":"hgnc:HGNC:39203","description":"LTO1 pseudogene 1","metadata":{"aliases":["ORAOV1P1"]}},{"id":"12fd2c1fd6e543e8acc15011395fdd59","type":"TRIAL","name":"LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT03254667","description":"Psoriasis","metadata":null},{"id":"20448f438fc44c7fbaade5596f869900","type":"GENE","name":"LTV1","canonical_id":"hgnc:HGNC:21173","description":"LTV1 ribosome biogenesis factor","metadata":{"aliases":["FLJ14909","dJ468K18.4","C6orf93"]}},{"id":"07b3d52c54834da69ec21eaae02b7697","type":"GENE","name":"LTV1P1","canonical_id":"hgnc:HGNC:44049","description":"LTV1 ribosome biogenesis factor pseudogene 1","metadata":null},{"id":"18d102a4d8d042648ca8fd8013e247ee","type":"GENE","name":"LUADT1","canonical_id":"hgnc:HGNC:51845","description":"lung adenocarcinoma associated transcript 1","metadata":null},{"id":"53e38ccb0ccb4c87899349ae6d4023bd","type":"GENE","name":"LUARIS","canonical_id":"hgnc:HGNC:40992","description":"lncRNA upregulator of antiviral response interferon signaling","metadata":{"aliases":["lncRNA#32","SCAT6"]}},{"id":"452e17e7d0db49d7b8846407ed3f43e6","type":"GO_TERM","name":"LUBAC complex","canonical_id":"go:GO:0071797","description":"\"A ubiquitin ligase complex that catalyzes linear head-to-tail polyubiquitin conjugation on its targets. In human the complex consists of RBCK1, RNF31 and SHARPIN, and has an MW of approximately 600 kDa, suggesting a heteromultimeric assembly of its subunits. LUBAC stands for Linear Ubiquitin Chain Assembly Complex.\" [GOC:sp, PMID:17006537, PMID:19136968, PMID:21455180]","metadata":null},{"id":"944854d1afc7405faaa169704362a8db","type":"GENE","name":"LUC7L","canonical_id":"hgnc:HGNC:6723","description":"LUC7 like","metadata":{"aliases":["LUC7B1","hLuc7B1","Luc7"]}},{"id":"482ba443003947fa87c3e91aec416f58","type":"GENE","name":"LUC7L2","canonical_id":"hgnc:HGNC:21608","description":"LUC7 like 2, pre-mRNA splicing factor","metadata":{"aliases":["CGI-74","CGI-59","H_NH0792N18.3","FLJ10657","LUC7B2","hLuc7B2"]}},{"id":"88a5a4884f15425ea455acc402bf5c4d","type":"GENE","name":"LUC7L3","canonical_id":"hgnc:HGNC:24309","description":"LUC7 like 3 pre-mRNA splicing factor","metadata":{"aliases":["LUC7A","CROP","OA48-18","CREAP-1","FLJ11063","CRA","hLuc7A"]}},{"id":"59340360f8a9482b9684b67a6afd94bf","type":"GENE","name":"LUC7L3P1","canonical_id":"hgnc:HGNC:39790","description":"LUC7 like 3 pre-mRNA splicing factor pseudogene 1","metadata":null},{"id":"ad93f364cbb045b9af6fa22c2e7c58da","type":"GENE","name":"LUCAT1","canonical_id":"hgnc:HGNC:48498","description":"lung cancer associated transcript 1","metadata":{"aliases":["SCAL1","SCAT5"]}},{"id":"85f9a533653a4ab9a289b72d7f5249b9","type":"GENE","name":"LUM","canonical_id":"hgnc:HGNC:6724","description":"lumican","metadata":{"aliases":["SLRR2D","LDC"]}},{"id":"0ff10eadd4104f5795c4761dc26d0b7a","type":"TRIAL","name":"LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research","canonical_id":"clinicaltrials.gov:NCT02231164","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"c99a415f999b46d4879f17d593880769","type":"TRIAL","name":"LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06558799","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"0f185700557f418b8ae6090c50694df8","type":"GENE","name":"LUNAR1","canonical_id":"hgnc:HGNC:51199","description":"leukemia-associated non-coding IGF1R activator RNA 1","metadata":null},{"id":"b2b06c39ed4a460a9df265bd0ac2792a","type":"TRIAL","name":"LUPKYNIS Drug-use Results Survey","canonical_id":"clinicaltrials.gov:NCT07053891","description":"Lupus Nephritis","metadata":null},{"id":"8dfb8f88f10f4e4886034161d8a61303","type":"GENE","name":"LURAP1","canonical_id":"hgnc:HGNC:32327","description":"leucine rich adaptor protein 1","metadata":{"aliases":["FLJ25163","LRAP35a","C1orf190"]}},{"id":"470733f4fada42fb9aa2e08da35e9d91","type":"GENE","name":"LURAP1L","canonical_id":"hgnc:HGNC:31452","description":"leucine rich adaptor protein 1 like","metadata":{"aliases":["MGC46502","FLJ38505","bA3L8.2","LRAP35b","C9orf150"]}},{"id":"10ed2e62c6894d839182b63ea0befd08","type":"GENE","name":"LURAP1L-AS1","canonical_id":"hgnc:HGNC:49761","description":"LURAP1L antisense RNA 1","metadata":null},{"id":"51ea5cfc62924f3abde2ad3fdc607c57","type":"TRIAL","name":"LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01345682","description":"Head and Neck Neoplasms; Carcinoma, Squamous Cell","metadata":null},{"id":"53fa4a759b42403abc7a2488d2d05e6d","type":"GENE","name":"LUZP1","canonical_id":"hgnc:HGNC:14985","description":"leucine zipper protein 1","metadata":{"aliases":["LUZP"]}},{"id":"aa3495d5c5e9475d922297bf2af94f12","type":"GENE","name":"LUZP2","canonical_id":"hgnc:HGNC:23206","description":"leucine zipper protein 2","metadata":null},{"id":"8ba5af70c848448b8b74a402e72dc3db","type":"GENE","name":"LUZP4","canonical_id":"hgnc:HGNC:24971","description":"leucine zipper protein 4","metadata":{"aliases":["HOM-TES-85","CT-8","CT28"]}},{"id":"73bd8ec2a4e04eefa87c0dc05ca85b61","type":"GENE","name":"LUZP4P1","canonical_id":"hgnc:HGNC:44904","description":"leucine zipper protein 4 pseudogene 1","metadata":null},{"id":"5648343e57dc42d0b70153a7ed7ff1a8","type":"GENE","name":"LUZP6","canonical_id":"hgnc:HGNC:33955","description":"leucine zipper protein 6","metadata":{"aliases":["MTPNUT","MPD6"]}},{"id":"5d3a5f86eafd4472a18826c6b23cfcc3","type":"GENE","name":"LVRN","canonical_id":"hgnc:HGNC:26904","description":"laeverin","metadata":{"aliases":["APQ","FLJ90650","AQPEP","TAQPEP"]}},{"id":"159d1c26345f4684ac1c943cdbf12911","type":"GENE","name":"LXN","canonical_id":"hgnc:HGNC:13347","description":null,"metadata":null},{"id":"a313c86f99804036929c1a183fa98a02","type":"TRIAL","name":"LXRA Gene Polymorphisms and Response to Fenofibrate","canonical_id":"clinicaltrials.gov:NCT00644592","description":"Healthy","metadata":null},{"id":"637a753bd5794c82bdfcb8b220c46d13","type":"TRIAL","name":"LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma","canonical_id":"clinicaltrials.gov:NCT03101254","description":"Melanoma","metadata":null},{"id":"161aecd6436143649f526cab34b02279","type":"TRIAL","name":"LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:","canonical_id":"clinicaltrials.gov:NCT07186101","description":"Ulcerative Colitis","metadata":null},{"id":"1c63054171984faea51a7c1c60c651de","type":"GENE","name":"LY6D","canonical_id":"hgnc:HGNC:13348","description":"lymphocyte antigen 6 family member D","metadata":{"aliases":["E48"]}},{"id":"994e12d134ff44d887be8053159de0a7","type":"GENE","name":"LY6E","canonical_id":"hgnc:HGNC:6727","description":"lymphocyte antigen 6 family member E","metadata":{"aliases":["TSA-1","RIG-E","SCA-2"]}},{"id":"289506c183c04cfebaecb5b4148812fe","type":"GENE","name":"LY6E-DT","canonical_id":"hgnc:HGNC:53728","description":"LY6E divergent transcript","metadata":{"aliases":["LOC100133669"]}},{"id":"b6e1ee1bea0f4e51ad6cfaaad7ccd10c","type":"GENE","name":"LY6G5B","canonical_id":"hgnc:HGNC:13931","description":"lymphocyte antigen 6 family member G5B","metadata":{"aliases":["G5b","C6orf19"]}},{"id":"57845a1c9c4d4c84a93aca8d75842199","type":"GENE","name":"LY6G5C","canonical_id":"hgnc:HGNC:13932","description":"lymphocyte antigen 6 family member G5C","metadata":{"aliases":["G5c","NG33","C6orf20"]}},{"id":"744cf675982944abbaf649a1587ede6c","type":"GENE","name":"LY6G5C-AS1","canonical_id":"hgnc:HGNC:59160","description":"LY6G5C antisense RNA 1","metadata":null},{"id":"b8eac73b2cc347e09d6e3b8028876c89","type":"GENE","name":"LY6G6C","canonical_id":"hgnc:HGNC:13936","description":"lymphocyte antigen 6 family member G6C","metadata":{"aliases":["G6c","NG24","C6orf24"]}},{"id":"7649440905e04bd1a03a7b4624583af4","type":"GENE","name":"LY6G6D","canonical_id":"hgnc:HGNC:13935","description":"lymphocyte antigen 6 family member G6D","metadata":{"aliases":["MEGT1","Ly6-D","G6D","LY6-D","NG25","C6orf23"]}},{"id":"5761fbaeab4a48e097f19e0ca27bc48a","type":"GENE","name":"LY6G6E","canonical_id":"hgnc:HGNC:13934","description":"lymphocyte antigen 6 family member G6E (pseudogene)","metadata":{"aliases":["LY6G6EP","G6e","C6orf22"]}},{"id":"e366317934164dea98446918ba1959ff","type":"GENE","name":"LY6G6F","canonical_id":"hgnc:HGNC:13933","description":"lymphocyte antigen 6 family member G6F","metadata":{"aliases":["G6f","NG32","LY6G6D","C6orf21"]}},{"id":"6dff21fc684741749b90c674a6abcdb5","type":"GENE","name":"LY6G6F-LY6G6D","canonical_id":"hgnc:HGNC:38821","description":"LY6G6F-LY6G6D readthrough","metadata":{"aliases":["MEGT1","MEGT-1","G6F-LY6G6D"]}},{"id":"2815ececbe6648e2be963226be96f18a","type":"GENE","name":"LY6H","canonical_id":"hgnc:HGNC:6728","description":"lymphocyte antigen 6 family member H","metadata":{"aliases":["NMLY6"]}},{"id":"04362d00a2994a009041c38daa7e4484","type":"GENE","name":"LY6K","canonical_id":"hgnc:HGNC:24225","description":"lymphocyte antigen 6 family member K","metadata":{"aliases":["HSJ001348","FLJ35226","CT97"]}},{"id":"c40cf34a99dd4d0b9aa48a19e7069ec9","type":"GENE","name":"LY6L","canonical_id":"hgnc:HGNC:52284","description":"lymphocyte antigen 6 family member L","metadata":null},{"id":"ff0ab77b6b6845cfb8f2db7be1473b93","type":"GENE","name":"LY6S","canonical_id":"hgnc:HGNC:54397","description":"lymphocyte antigen 6 family member S","metadata":{"aliases":["LY6A"]}},{"id":"6b954860742746c39ab1f91971b26094","type":"GENE","name":"LY6S-AS1","canonical_id":"hgnc:HGNC:26731","description":"LY6S antisense RNA 1","metadata":{"aliases":["FLJ37131","C8orf31","LINC02904"]}},{"id":"69c7392c55204672868661d1ad1107f9","type":"GENE","name":"LY75","canonical_id":"hgnc:HGNC:6729","description":"lymphocyte antigen 75","metadata":{"aliases":["DEC-205","CLEC13B","CD205"]}},{"id":"57e9aa240ca14a57aac165d09f8d4d33","type":"GENE","name":"LY75-CD302","canonical_id":"hgnc:HGNC:38828","description":"LY75-CD302 readthrough","metadata":null},{"id":"99068c3ae1e3443cbaa371b179ff164f","type":"GENE","name":"LY86","canonical_id":"hgnc:HGNC:16837","description":"lymphocyte antigen 86","metadata":{"aliases":["MD-1","dJ80N2.1"]}},{"id":"92c8055e53334766af928ae78391daf9","type":"GENE","name":"LY86-AS1","canonical_id":"hgnc:HGNC:26593","description":"LY86 antisense RNA 1","metadata":{"aliases":["FLJ33708","LY86AS","LY86-AS"]}},{"id":"25f0dd7f790d487091731483fe9e6a0f","type":"GENE","name":"LY9","canonical_id":"hgnc:HGNC:6730","description":"lymphocyte antigen 9","metadata":{"aliases":["CD229","mLY9","SLAMF3","hly9"]}},{"id":"20c3bd37ac924ade9714f45f75f0efb1","type":"GENE","name":"LY96","canonical_id":"hgnc:HGNC:17156","description":null,"metadata":null},{"id":"8c67dc775ce9474c818e9310226f2f70","type":"GENE","name":"LYAR","canonical_id":"hgnc:HGNC:26021","description":"Ly1 antibody reactive","metadata":{"aliases":["ZLYAR"]}},{"id":"42da126ac5104c189b290bd93306ba64","type":"GENE","name":"LYARP1","canonical_id":"hgnc:HGNC:50747","description":"Ly1 antibody reactive pseudogene 1","metadata":null},{"id":"7fc7710dff894fdca8bbfef580110a4f","type":"GENE","name":"LYG1","canonical_id":"hgnc:HGNC:27014","description":"lysozyme g1","metadata":{"aliases":["SALW1939","LYGA1"]}},{"id":"e7402af64ecb439e8a2a737f65a5cb9f","type":"GENE","name":"LYG2","canonical_id":"hgnc:HGNC:29615","description":"lysozyme g2","metadata":{"aliases":["LYGH","LYGA2"]}},{"id":"e832692469e840dc8c7f28176108ce01","type":"GENE","name":"LYL1","canonical_id":"hgnc:HGNC:6734","description":null,"metadata":null},{"id":"d6843538ce7c4fac8441f261fd8b19a4","type":"GENE","name":"LYLDT1","canonical_id":"hgnc:HGNC:28553","description":"lysosomal-lipid droplet tether 1","metadata":{"aliases":["MGC35033","C12orf54"]}},{"id":"f887d7db5002425bbfa4db32c3acbab4","type":"GENE","name":"LYN","canonical_id":"hgnc:HGNC:6735","description":"LYN proto-oncogene, Src family tyrosine kinase","metadata":{"aliases":["JTK8"]}},{"id":"a5f1ebf5625a4c4ba9d00a7167bf018b","type":"PROTEIN","name":"LYN","canonical_id":"uniprot:P07948","description":null,"metadata":null},{"id":"0d9fb56e39af4dacbc3f61475b8038e2","type":"GENE","name":"LYNX1","canonical_id":"hgnc:HGNC:29604","description":"Ly6/neurotoxin 1","metadata":{"aliases":["SLURP2"]}},{"id":"dc48b04d9f10496a85f4f79cc5ae71d7","type":"GENE","name":"LYNX1-SLURP2","canonical_id":"hgnc:HGNC:52291","description":"LYNX1-SLURP2 readthrough","metadata":null},{"id":"35c33e0003c14ae9a5a7cdc2e9d0cdb6","type":"GENE","name":"LYPD1","canonical_id":"hgnc:HGNC:28431","description":"LY6/PLAUR domain containing 1","metadata":{"aliases":["MGC29643","PHTS","LYPDC1"]}},{"id":"629536b9136b4276b799389b2a6aa593","type":"GENE","name":"LYPD2","canonical_id":"hgnc:HGNC:25215","description":"LY6/PLAUR domain containing 2","metadata":{"aliases":["RGTR430","UNQ430","LYPDC2"]}},{"id":"f3f51279ac7e453596e711533189c959","type":"GENE","name":"LYPD3","canonical_id":"hgnc:HGNC:24880","description":"LY6/PLAUR domain containing 3","metadata":{"aliases":["C4.4A"]}},{"id":"9587dac70a1d4c61a2f3e7b6038a7381","type":"GENE","name":"LYPD4","canonical_id":"hgnc:HGNC:28659","description":"LY6/PLAUR domain containing 4","metadata":{"aliases":["MGC42718"]}},{"id":"06c4de0d5987406190b752a7c9c11e78","type":"GENE","name":"LYPD5","canonical_id":"hgnc:HGNC:26397","description":"LY6/PLAUR domain containing 5","metadata":{"aliases":["FLJ30469","Haldisin"]}},{"id":"8820d02fb28c43c08818d711754d467f","type":"GENE","name":"LYPD6","canonical_id":"hgnc:HGNC:28751","description":"LY6/PLAUR domain containing 6","metadata":{"aliases":["MGC52057"]}},{"id":"ff3ce7b88a564d96928fd410975efa8b","type":"GENE","name":"LYPD6B","canonical_id":"hgnc:HGNC:27018","description":"LY6/PLAUR domain containing 6B","metadata":{"aliases":["CT116","LYPD7"]}},{"id":"4502a5c97a6c4bcd9d5c41fe59204d6e","type":"GENE","name":"LYPD8","canonical_id":"hgnc:HGNC:44208","description":"LY6/PLAUR domain containing 8","metadata":null},{"id":"abef6447542c464791073e3fec9a328e","type":"GENE","name":"LYPD9P","canonical_id":"hgnc:HGNC:53735","description":"LY6/PLAUR domain containing 9, pseudogene","metadata":null},{"id":"76a647dee1424c55b686dac73a167802","type":"GENE","name":"LYPLA1","canonical_id":"hgnc:HGNC:6737","description":"lysophospholipase 1","metadata":{"aliases":["LPL1","APT-1","APT1"]}},{"id":"5ad5113f5f0d4e50b3c0fe7be030f1ae","type":"GENE","name":"LYPLA1P1","canonical_id":"hgnc:HGNC:44005","description":"LYPLA1 pseudogene 1","metadata":null},{"id":"abcf687c39d641f78e04f4db10547367","type":"GENE","name":"LYPLA1P2","canonical_id":"hgnc:HGNC:44006","description":"LYPLA1 pseudogene 2","metadata":null},{"id":"29e2703d245e43db9bb027ebcf5a34a1","type":"GENE","name":"LYPLA1P3","canonical_id":"hgnc:HGNC:44007","description":"LYPLA1 pseudogene 3","metadata":null},{"id":"77d96c4dfc8e440f8a72b77b783aaaa3","type":"GENE","name":"LYPLA2","canonical_id":"hgnc:HGNC:6738","description":"lysophospholipase 2","metadata":{"aliases":["APT-2","APT2"]}},{"id":"0e6e7c0651fb4ff3a0e3d0c500c71a0c","type":"GENE","name":"LYPLA2P1","canonical_id":"hgnc:HGNC:21069","description":"LYPLA2 pseudogene 1","metadata":{"aliases":["dJ570F3.6","APT","LYPLA2L"]}},{"id":"ac0966337d6c40359d2878043823e2aa","type":"GENE","name":"LYPLA2P2","canonical_id":"hgnc:HGNC:50445","description":"LYPLA2 pseudogene 2","metadata":null},{"id":"63a2e07a7feb44e7a61cbec8b7ea24ce","type":"GENE","name":"LYPLA2P3","canonical_id":"hgnc:HGNC:50446","description":"LYPLA2 pseudogene 3","metadata":null},{"id":"f5521603bda94081aea96f3afac80755","type":"GENE","name":"LYPLAL1","canonical_id":"hgnc:HGNC:20440","description":"lysophospholipase like 1","metadata":{"aliases":["Q96AV0"]}},{"id":"0f98e7413ae947119216c84bb0ae9579","type":"GENE","name":"LYPLAL1-AS1","canonical_id":"hgnc:HGNC:54054","description":"LYPLAL1 antisense RNA 1","metadata":null},{"id":"3b8f10c3b7d440529d7fe066099e4ffe","type":"GENE","name":"LYPLAL1-DT","canonical_id":"hgnc:HGNC:50560","description":"LYPLAL1 divergent transcript","metadata":{"aliases":["LYPLAL1-AS1"]}},{"id":"0a9be2e16cfb4c27957dba68aec06362","type":"GENE","name":"LYRM1","canonical_id":"hgnc:HGNC:25074","description":"LYR motif containing 1","metadata":{"aliases":["A211C6.1"]}},{"id":"58429deca01648fcbd53b02802013c0d","type":"GENE","name":"LYRM2","canonical_id":"hgnc:HGNC:25229","description":"LYR motif containing 2","metadata":{"aliases":["DJ122O8.2"]}},{"id":"f012dfdcdf694b99a256932be8b74bc7","type":"GENE","name":"LYRM4","canonical_id":"hgnc:HGNC:21365","description":"LYR motif containing 4","metadata":{"aliases":["CGI-203","ISD11","C6orf149"]}},{"id":"3c04417d0cd84cd890b1b7f573dcf519","type":"GENE","name":"LYRM4-AS1","canonical_id":"hgnc:HGNC:52055","description":"LYRM4 antisense RNA 1","metadata":null},{"id":"29f9b0a43b38476d80751566761fe978","type":"GENE","name":"LYRM7","canonical_id":"hgnc:HGNC:28072","description":"LYR motif containing 7","metadata":{"aliases":["FLJ20796","MZM1L","C5orf31"]}},{"id":"871cb586065f43438d71aed112827119","type":"GENE","name":"LYRM9","canonical_id":"hgnc:HGNC:27314","description":"LYR motif containing 9","metadata":{"aliases":["HSD24","C17orf108"]}},{"id":"4cdfd5fd7605479ea6444feed8b9d4f1","type":"GENE","name":"LYRM9-AS1","canonical_id":"hgnc:HGNC:58314","description":"LYRM9 antisense RNA 1","metadata":null},{"id":"e14712a516da45f09bd6400598200d96","type":"GENE","name":"LYSET","canonical_id":"hgnc:HGNC:20218","description":"lysosomal enzyme trafficking factor","metadata":{"aliases":["DKFZP564F1123","GCAF","C14orf109","TMEM251"]}},{"id":"c66333b0f25d4d2a90a31a940117afe0","type":"GENE","name":"LYSETP1","canonical_id":"hgnc:HGNC:52396","description":"LYSET pseudogene 1","metadata":{"aliases":["TMEM251P1"]}},{"id":"b0ced2cfd5ff448fa4a11df14130fc79","type":"GENE","name":"LYSMD1","canonical_id":"hgnc:HGNC:32070","description":"LysM domain containing 1","metadata":{"aliases":["SB145","MGC35223","RP11-68I18.5"]}},{"id":"9c0fa0f33b444e28b52f0d3079c7f03b","type":"GENE","name":"LYSMD2","canonical_id":"hgnc:HGNC:28571","description":"LysM domain containing 2","metadata":{"aliases":["MGC35274"]}},{"id":"049aafbfdf3b4fd9980df3c978b58871","type":"GENE","name":"LYSMD3","canonical_id":"hgnc:HGNC:26969","description":"LysM domain containing 3","metadata":{"aliases":["FLJ13542"]}},{"id":"ed9d3f69c101489a8ca3f89e9d8f3375","type":"GENE","name":"LYSMD4","canonical_id":"hgnc:HGNC:26571","description":"LysM domain containing 4","metadata":{"aliases":["FLJ33008"]}},{"id":"4f33936d85eb4133ba71b56b3a4ba523","type":"GO_TERM","name":"LYSP100-associated nuclear domain","canonical_id":"go:GO:0016606","description":"\"A nuclear body that is enriched in the lymphoid cell-specific protein LYSp100B; LANDs are globular, electron-dense structures and are morphologically distinct from the annular structures characteristic of PML bodies.\" [PMID:10921892, PMID:8695863]","metadata":null},{"id":"493451abffc24f6883958e0a947a353d","type":"GENE","name":"LYST","canonical_id":"hgnc:HGNC:1968","description":"lysosomal trafficking regulator","metadata":{"aliases":["CHS","Mauve","CHS1"]}},{"id":"79f7fb641efe473aae98cd2af3c42af7","type":"GENE","name":"LYVE1","canonical_id":"hgnc:HGNC:14687","description":"lymphatic vessel endothelial hyaluronan receptor 1","metadata":{"aliases":["LYVE-1","XLKD1"]}},{"id":"46fce26ab1ee4d54a76fd05c511ebf24","type":"GENE","name":"LYZ","canonical_id":"hgnc:HGNC:6740","description":null,"metadata":null},{"id":"1d5be1ce079a47e3a563eb68dd8123fa","type":"GENE","name":"LYZL1","canonical_id":"hgnc:HGNC:30502","description":"lysozyme like 1","metadata":{"aliases":["MGC33408","LYC2"]}},{"id":"2f69fffeff134290ba718f498b069ac0","type":"GENE","name":"LYZL2","canonical_id":"hgnc:HGNC:29613","description":"lysozyme like 2","metadata":null},{"id":"2e29a355c57a4cefab7a6b4242ccbb43","type":"GENE","name":"LYZL4","canonical_id":"hgnc:HGNC:28387","description":"lysozyme like 4","metadata":{"aliases":["MGC26768","LYC4"]}},{"id":"223c973d3f6b43f9a54f92a8fae9f3bb","type":"GENE","name":"LYZL6","canonical_id":"hgnc:HGNC:29614","description":"lysozyme like 6","metadata":{"aliases":["LYC1","PRO1485","TKAL754"]}},{"id":"8a6337cd995a498692b32ec24e45cc99","type":"GENE","name":"LZIC","canonical_id":"hgnc:HGNC:17497","description":"leucine zipper and CTNNBIP1 domain containing","metadata":{"aliases":["MGC15436"]}},{"id":"68846da6e0394e549828e4e8a7e10d20","type":"GENE","name":"LZTFL1","canonical_id":"hgnc:HGNC:6741","description":"leucine zipper transcription factor like 1","metadata":{"aliases":["BBS17"]}},{"id":"63337ff6198042ebb7e56c3993f96f13","type":"GENE","name":"LZTR1","canonical_id":"hgnc:HGNC:6742","description":"leucine zipper like post translational regulator 1","metadata":{"aliases":["LZTR-1","BTBD29"]}},{"id":"f87f0e77019f419b977c2e2fc69b3e21","type":"GENE","name":"LZTS1","canonical_id":"hgnc:HGNC:13861","description":"leucine zipper tumor suppressor 1","metadata":{"aliases":["FEZ1"]}},{"id":"e066635b2b384dd99a156be31b2afe3a","type":"GENE","name":"LZTS1-AS1","canonical_id":"hgnc:HGNC:43630","description":"LZTS1 antisense RNA 1","metadata":null},{"id":"6422e333127144feb81d319bcb8990c5","type":"GENE","name":"LZTS2","canonical_id":"hgnc:HGNC:29381","description":"leucine zipper tumor suppressor 2","metadata":{"aliases":["KIAA1813","LAPSER1"]}},{"id":"57e86a5b0665450e8cd0c8bd777ac06b","type":"GENE","name":"LZTS3","canonical_id":"hgnc:HGNC:30139","description":"leucine zipper tumor suppressor family member 3","metadata":{"aliases":["ProSAPiP1","KIAA0552"]}},{"id":"7df281c8cc8b48be9c37ed109c1b1aaa","type":"GO_TERM","name":"Labd-13(16),14-diene-9-ol synthase activity","canonical_id":"go:GO:0062202","description":"\"Catalysis of the reaction: peregrinol diphosphate = diphosphate + labd-13(16),14-diene-9-ol.\" [PMID:29315936, RHEA:62184]","metadata":null},{"id":"edcf306705564ee590b4623ad3d236c1","type":"TRIAL","name":"Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial","canonical_id":"clinicaltrials.gov:NCT00293735","description":"Preeclampsia; Pregnancy Induced Hypertension; Gestational Hypertension; Chronic Hypertension; Superimposed Preeclampsia","metadata":null},{"id":"63f71f9455ae4de88373a9566cfa1373","type":"TRIAL","name":"Labetalol and Esmolol: Vital Signs and Post Operative Pain Management","canonical_id":"clinicaltrials.gov:NCT01114971","description":"Laparoscopic Surgery","metadata":null},{"id":"c3f317244b574342aae885ca3952c573","type":"TRIAL","name":"Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy","canonical_id":"clinicaltrials.gov:NCT00394537","description":"Bronchoscopy","metadata":null},{"id":"8262b17f36a44ae3a34958891ba860b2","type":"TRIAL","name":"Labor Scale Versus WHO Partograph in the Management of Labor","canonical_id":"clinicaltrials.gov:NCT02486822","description":"Dystocia","metadata":null},{"id":"5a7dea0cc7be414ba3239aa9ff7a944d","type":"DISEASE","name":"Labor pain","canonical_id":"mesh:D048949","description":null,"metadata":null},{"id":"6b6b9196096d45ae983c7b0da797d653","type":"TRIAL","name":"Laboratory Screening of Lorcaserin for Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT04396847","description":"Alcohol Use Disorder; Tobacco Smoking","metadata":null},{"id":"e63162c3eb4744a9b91f358b9643c724","type":"TRIAL","name":"Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT00871481","description":"Recurrent Melanoma; Stage IV Melanoma","metadata":null},{"id":"895e79553a374f658e9c7782aee2cd75","type":"TRIAL","name":"Lacosamid-i.v.-Register","canonical_id":"clinicaltrials.gov:NCT01620840","description":"Epilepsy With Partial Onset Seizures With or Without Secondary Generalization","metadata":null},{"id":"bc23fda80bfc428fb56db88ec588896e","type":"TRIAL","name":"Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT06966830","description":"Epilepsy; Status Epilepticus","metadata":null},{"id":"fc76e457954e497f9450ed0513e0beee","type":"TRIAL","name":"Lacosamide Versus Propranolol in Migraine","canonical_id":"clinicaltrials.gov:NCT05851781","description":"Migraine Disorders","metadata":null},{"id":"02a86845b26a405683cfd987034424c6","type":"TRIAL","name":"Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline","canonical_id":"clinicaltrials.gov:NCT05024422","description":"Lactation Suppressed","metadata":null},{"id":"0c1fb2d3043242e5979e71e2036599c6","type":"TRIAL","name":"Lactoferrin or Progesterone for Prevention of Preterm Delivery","canonical_id":"clinicaltrials.gov:NCT02372942","description":"Preterm Delivery","metadata":null},{"id":"2e6579c3f81a4231946aa9ddcede48a6","type":"DISEASE","name":"Lactose intolerance","canonical_id":"mesh:D007787","description":null,"metadata":null},{"id":"e80aa4774b9f45268d954828d152bbff","type":"DISEASE","name":"Lambert-Eaton myasthenic syndrome","canonical_id":"efo:0020094","description":null,"metadata":null},{"id":"a380e32fed6640c689aee14fa126aa96","type":"TRIAL","name":"Lanadelumab for Treatment of COVID-19 Disease","canonical_id":"clinicaltrials.gov:NCT04422509","description":"COVID-19","metadata":null},{"id":"479d9e67785949a489d632b51e407dd4","type":"TRIAL","name":"Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)","canonical_id":"clinicaltrials.gov:NCT04278885","description":"Hereditary Autoinflammatory Disease","metadata":null},{"id":"b381b43828ca48b6946128496714bc82","type":"TRIAL","name":"Lanadelumab in Long-term Prophylaxis of Acquired Angioedema","canonical_id":"clinicaltrials.gov:NCT06818474","description":"Angioedema","metadata":null},{"id":"0c7c4d6104754a48a5a5f98db746882a","type":"TRIAL","name":"Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04460105","description":"COVID-19 Pneumonia","metadata":null},{"id":"e2b5239d2a584c1faa0ec437f0ca0019","type":"DISEASE","name":"Landau-Kleffner syndrome","canonical_id":"mondo:0009509","description":null,"metadata":null},{"id":"2e875478293c4c53b4a91c0770af1322","type":"GO_TERM","name":"Lands organization","canonical_id":"go:GO:0030577","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of Lands, a class of nuclear body that react against SP140 auto-antibodies.\" [GOC:mah, PMID:10921892, PMID:8695863]","metadata":null},{"id":"2c08d875dc6b4ec9a05fe280a15f0e9e","type":"GO_TERM","name":"Langerhans cell chemotaxis","canonical_id":"go:GO:0002409","description":"\"The movement of a Langerhans cell in response to an external stimulus.\" [GOC:add, PMID:16056255, PMID:16387601]","metadata":null},{"id":"4e89cb49206b4c2e9104308b372c8696","type":"GO_TERM","name":"Langerhans cell differentiation","canonical_id":"go:GO:0061520","description":"\"The process in which a precursor cell type acquires the specialized features of a Langerhans cell.\" [GOC:dph, PMID:22729249]","metadata":null},{"id":"a4e0323ba2b740689398624c45c16a58","type":"DISEASE","name":"Langerhans cell histiocytosis","canonical_id":"mondo:0018310","description":null,"metadata":null},{"id":"cf0a5699bc8d469ebaddf326f5008671","type":"DISEASE","name":"Langerhans cell histiocytosis, disseminated","canonical_id":"mesh:C538636","description":null,"metadata":null},{"id":"54022669e5084793a0a8ec8b2e2c71eb","type":"DISEASE","name":"Langerhans-cell Histiocytosis","canonical_id":"doid:2571","description":null,"metadata":null},{"id":"83a6f79c482d4a2083a90cbd7a3f5e5c","type":"TRIAL","name":"Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine","canonical_id":"clinicaltrials.gov:NCT01146002","description":"Attention-deficit/Hyperactivity Disorder","metadata":null},{"id":"30205a91b89648289e001ee667544f51","type":"DRUG","name":"Laninamivir octanoate hydrate","canonical_id":"mesh:C546918","description":null,"metadata":null},{"id":"475f19365ccf435097e1dcdd69778d90","type":"PROTEIN","name":"Lanosterol 14-alpha demethylase (Coccidioides immitis)","canonical_id":"uniprot:A0A6C1LUF2","description":null,"metadata":null},{"id":"63738938bb274161b860906ce40ef423","type":"PROTEIN","name":"Lanosterol 14-alpha-demethylase","canonical_id":"uniprot:Q68HC5","description":null,"metadata":null},{"id":"a9a28874a627432cbee458714c010f5a","type":"PROTEIN","name":"Lanosterol 14-alpha-demethylase","canonical_id":"uniprot:P50859","description":null,"metadata":null},{"id":"86d7bd5f7483406cb1d92eaf7e3b52b6","type":"TRIAL","name":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","canonical_id":"clinicaltrials.gov:NCT01070758","description":"Congenital Hyperinsulinism","metadata":null},{"id":"84627a8a65de4909b77055602ae78461","type":"TRIAL","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT00383708","description":"Acromegaly","metadata":null},{"id":"015ccae8d4af41499aecf4bd8aee57f1","type":"TRIAL","name":"Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR","canonical_id":"clinicaltrials.gov:NCT00216398","description":"Acromegaly","metadata":null},{"id":"7f70b8ac49844052a171cd7b84fc832f","type":"TRIAL","name":"Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea","canonical_id":"clinicaltrials.gov:NCT00891371","description":"Diarrhea","metadata":null},{"id":"0ceed20bdaac4367bf6f10d10907c444","type":"TRIAL","name":"Lanreotide In Polycystic Kidney Disease Study","canonical_id":"clinicaltrials.gov:NCT02127437","description":"Autosomal Dominant Polycystic Kidney Disease (ADPKD","metadata":null},{"id":"5061e171c8cb49c6825f1dba41463fc8","type":"TRIAL","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","canonical_id":"clinicaltrials.gov:NCT06807437","description":"Pancreatic Carcinoma; Pancreatic Neoplasm","metadata":null},{"id":"87a9f25ab87146e2a0e9c8f3511ef162","type":"TRIAL","name":"Lanreotide in the Treatment of Small Bowel Motility Disorders","canonical_id":"clinicaltrials.gov:NCT03012594","description":"Gastrointestinal Motility Disorder; Intestinal Disease","metadata":null},{"id":"60f7aaf5237f464186a675539ca27c6e","type":"TRIAL","name":"Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients","canonical_id":"clinicaltrials.gov:NCT04325581","description":"Weight Loss","metadata":null},{"id":"6da3af7de8d348969780f90151f58843","type":"TRIAL","name":"Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia","canonical_id":"clinicaltrials.gov:NCT02953210","description":"Pain, Postoperative; Anesthesia Complication; Nausea; Vomiting; Ileus Paralytic; Hemodynamic Instability","metadata":null},{"id":"e2bab0b89de04037a68dfe7e7814fc22","type":"DRUG","name":"Lapatinib","canonical_id":"ncit:C26653","description":null,"metadata":null},{"id":"e1ba7fcd736647a099c20d6f0d302766","type":"TRIAL","name":"Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China","canonical_id":"clinicaltrials.gov:NCT00508274","description":"Neoplasms, Breast","metadata":null},{"id":"d0850fd9df69420dab60f5a91806aee6","type":"TRIAL","name":"Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00962312","description":"Pancreatic Cancer","metadata":null},{"id":"6b4028392ca641568ceffdf7eafde10d","type":"TRIAL","name":"Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy","canonical_id":"clinicaltrials.gov:NCT00903656","description":"Metastatic Breast Cancer","metadata":null},{"id":"cae9165dfdef42ff987ee2025f43e04e","type":"TRIAL","name":"Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT01591577","description":"Newly Diagnosed Glioblastoma Multiforme","metadata":null},{"id":"7d5934040360481096c30d88018518ee","type":"TRIAL","name":"Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01283789","description":"Metastatic Breast Cancer","metadata":null},{"id":"bb95ec35734d4efba94a3e66b6f7109e","type":"TRIAL","name":"Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors","canonical_id":"clinicaltrials.gov:NCT01218529","description":"Brain Metastases; Lung Tumors; Breast Tumors","metadata":null},{"id":"0b198c5f28d9472597a0d329649ebb60","type":"TRIAL","name":"Lapatinib in Combination With Vinorelbine","canonical_id":"clinicaltrials.gov:NCT01013740","description":"Cancer","metadata":null},{"id":"76b958a255694222bb54bcf0684883b9","type":"TRIAL","name":"Lapatinib in Combination With Vinorelbine","canonical_id":"clinicaltrials.gov:NCT01128543","description":"Cancer","metadata":null},{"id":"62af75c673be45d0af3fcf136116a9a1","type":"TRIAL","name":"Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2","canonical_id":"clinicaltrials.gov:NCT00544804","description":"Breast Cancer; Metastatic Cancer","metadata":null},{"id":"24d6cab3f33c41b9ba0fd56f07bb1fb9","type":"TRIAL","name":"Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00095667","description":"Recurrent Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"196949c037d7406d8b8ec2c6e6c787a2","type":"TRIAL","name":"Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00316407","description":"Ovarian Epithelial Cancer Stage III; Stage IV Ovarian Cancer; Stage IV Breast Cancer","metadata":null},{"id":"b399805ce66249f29dc74fe9ce163f87","type":"TRIAL","name":"Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)","canonical_id":"clinicaltrials.gov:NCT00418171","description":"Schizophrenia","metadata":null},{"id":"d076c9de27bd4990b60e8fc75aef61fc","type":"TRIAL","name":"Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)","canonical_id":"clinicaltrials.gov:NCT01645124","description":"Polycythemia Vera","metadata":null},{"id":"a578464793914f3f9c51f7905f68cb80","type":"TRIAL","name":"Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT00125437","description":"Heart Failure, Congestive","metadata":null},{"id":"bc3ef809efb8472a98c7ff1ff01a953d","type":"DISEASE","name":"Laron syndrome","canonical_id":"mondo:0009877","description":null,"metadata":null},{"id":"0ce480eccf11406194bac351ca47cb09","type":"DISEASE","name":"Laron-type isolated somatotropin defect","canonical_id":"mesh:D046150","description":null,"metadata":null},{"id":"f33580451b9a48d4ad62f92352ee3655","type":"DISEASE","name":"Laryngeal Edema","canonical_id":"mesh:D007819","description":null,"metadata":null},{"id":"e852320c3b2e462f8025676331e5d4f2","type":"GO_TERM","name":"Las1 complex","canonical_id":"go:GO:0090730","description":"\"A four subunit complex, that comprises all the necessary RNA processing enzymes (endonuclease, polynucleotide kinase, and exonuclease) to mediate 'cistronic rRNA transcript ITS2 (internal transcribed spacer) cleavage' (GO:0000448).\" [GOC:vw, PMID:26638174]","metadata":null},{"id":"3ce3a04d321346bc92c937c564f3dec1","type":"TRIAL","name":"Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure","canonical_id":"clinicaltrials.gov:NCT02613013","description":"Glaucoma, Angle-Closure","metadata":null},{"id":"72181ff84fd64ce697e0a8566007b2db","type":"DRUG","name":"Latanoprost","canonical_id":"mesh:C072042","description":null,"metadata":null},{"id":"bd2c1df46d0948388493f7e74083d29e","type":"TRIAL","name":"Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)","canonical_id":"clinicaltrials.gov:NCT01162603","description":"Primary Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"5ebaddc24f8f46c195e89f45c6c7a90c","type":"TRIAL","name":"Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH","canonical_id":"clinicaltrials.gov:NCT01721707","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"10b51330283a4cceb36a4080e6a3b34a","type":"TRIAL","name":"Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation","canonical_id":"clinicaltrials.gov:NCT03513458","description":"Asthma","metadata":null},{"id":"7810e94d4061488b8c0e76c049a65da1","type":"DISEASE","name":"Late-infantile neuronal ceroid lipofuscinosis","canonical_id":"mesh:D009472","description":null,"metadata":null},{"id":"7197c114d0304c5bab4bd1bc72da4002","type":"GO_TERM","name":"Latia-luciferin monooxygenase (demethylating) activity","canonical_id":"go:GO:0047098","description":"\"Catalysis of the reaction: 2 O2 + donor-H2 + Latia luciferin = light + H2O + acceptor + formate + CO2 + oxidized Latia luciferin.\" [EC:1.14.99.21]","metadata":null},{"id":"ddd918ff66504a18af56e070ad31ddc0","type":"TRIAL","name":"Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo","canonical_id":"clinicaltrials.gov:NCT01387906","description":"Hypotrichosis","metadata":null},{"id":"a07943180817435684c627be9d301301","type":"TRIAL","name":"Lavender vs Zolpidem Sleep Quality During Diagnostic PSG","canonical_id":"clinicaltrials.gov:NCT04102345","description":"Sleep","metadata":null},{"id":"6df71be878974825b04f8b0777bc85b5","type":"DRUG","name":"Lazertinib","canonical_id":"ncit:C148147","description":null,"metadata":null},{"id":"ccff15fad42949fca6e78ec5913511a9","type":"TRIAL","name":"Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment","canonical_id":"clinicaltrials.gov:NCT06106802","description":"Non-Small Cell Lung Cancer Metastatic","metadata":null},{"id":"550e12a0ef934b6aa758b6c2574e5b72","type":"DISEASE","name":"Leber congenital amaurosis","canonical_id":"mondo:0018998","description":null,"metadata":null},{"id":"f7cff1c3c58646738da180c484ad7517","type":"DISEASE","name":"Leber congenital amaurosis 11","canonical_id":"mondo:0013454","description":null,"metadata":null},{"id":"7a40095072e8483c9d0f369e2a6f6c30","type":"DISEASE","name":"Leber's optic atrophy","canonical_id":"mesh:D029242","description":null,"metadata":null},{"id":"9a8bf57a064f4f129ad25d837b6fccd2","type":"DRUG","name":"Leflunomide","canonical_id":"mesh:C045463","description":null,"metadata":null},{"id":"69026e2d769341d4af29565101d5a579","type":"TRIAL","name":"Leflunomide 20 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00834418","description":"Healthy","metadata":null},{"id":"39f22701e8ee4d9886f32ac22eb0ffaa","type":"TRIAL","name":"Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT04020328","description":"Glomerulonephritis, IGA; Renal Insufficiency, Chronic","metadata":null},{"id":"d6d1e8a0aeee4b0ebde2e269efe6179b","type":"TRIAL","name":"Leflunomide for Maintenance of Remission in IgG4 Related Disease","canonical_id":"clinicaltrials.gov:NCT02703194","description":"Immunoglobulin G4 Related Sclerosing Disease","metadata":null},{"id":"7cac430cf88a482a99ffabbfc0d43a8d","type":"TRIAL","name":"Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT04932564","description":"Musculoskeletal Disease Other; GVHD, Chronic","metadata":null},{"id":"b25065b731e645fc80d3bd7bde2ec908","type":"TRIAL","name":"Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients","canonical_id":"clinicaltrials.gov:NCT05014646","description":"Smoldering Plasma Cell Myeloma","metadata":null},{"id":"5f858745a6554cc6bf5c18b2fc55e1ea","type":"TRIAL","name":"Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy","canonical_id":"clinicaltrials.gov:NCT04532372","description":"Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed","metadata":null},{"id":"72f7a6d7d6864718b9d847a0f80378ae","type":"TRIAL","name":"Leflunomide in Mild COVID-19 Patients","canonical_id":"clinicaltrials.gov:NCT04361214","description":"COVID-19","metadata":null},{"id":"2c64ff44e35e41e697f309ec6f6d4941","type":"TRIAL","name":"Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03952832","description":"Smoldering Plasma Cell Myeloma","metadata":null},{"id":"0029e0562e1748b09d8267c5e1058998","type":"TRIAL","name":"Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT04212416","description":"Chronic Graft Versus Host Disease; Steroid Refractory Graft Versus Host Disease","metadata":null},{"id":"58f9e60654f848a4bc03c179f5fd2db0","type":"TRIAL","name":"Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients","canonical_id":"clinicaltrials.gov:NCT07709013","description":"Hematologic Malignancies","metadata":null},{"id":"34fb63c793c645bb9a20ea101b08d6a2","type":"TRIAL","name":"Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT04508790","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"0d5bfa4627974e77b8a32d4c65421e38","type":"TRIAL","name":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","canonical_id":"clinicaltrials.gov:NCT03463317","description":"Atrial Fibrillation","metadata":null},{"id":"15542fe31f704703aafd86b2531d9459","type":"TRIAL","name":"Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan","canonical_id":"clinicaltrials.gov:NCT00517322","description":"Left Atrial Volume; Hypertensive Heart Disease; Antihypertensive Drugs; Diastolic Function; Renin Angiotensin System","metadata":null},{"id":"d488ca48f9b14dc6802650e315c78af7","type":"TRIAL","name":"Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon","canonical_id":"clinicaltrials.gov:NCT02591225","description":"Atrial Fibrillation; Left Atrial Thrombosis","metadata":null},{"id":"250c1827cfa247baa94866f1e3077e0b","type":"DISEASE","name":"Leiomyosarcoma","canonical_id":"mesh:D007890","description":null,"metadata":null},{"id":"fca3969cd8264abcb6b00e2b2d7c5bff","type":"DISEASE","name":"Leishmaniasis","canonical_id":"mesh:D007896","description":null,"metadata":null},{"id":"cc1d194904544eb0991817d2d7b8f06a","type":"TRIAL","name":"Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep","canonical_id":"clinicaltrials.gov:NCT05458609","description":"Alcohol Use Disorder","metadata":null},{"id":"7ac2046f9b454023a65ee08caf73b91f","type":"TRIAL","name":"Lemborexant Shift Work Treatment Study","canonical_id":"clinicaltrials.gov:NCT05344443","description":"Shift-Work Related Sleep Disturbance","metadata":null},{"id":"0e21087b90594fa696417bfb26986fea","type":"TRIAL","name":"Lemborexant Treatment of Insomnia Linked to Epilepsy","canonical_id":"clinicaltrials.gov:NCT06262594","description":"Epilepsy; Sleep","metadata":null},{"id":"70ab6491c8ca4226a7aa0a78115b87eb","type":"TRIAL","name":"Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT07695285","description":"Postoperative Delirium","metadata":null},{"id":"87581d437be74d8899cb7961170b7139","type":"TRIAL","name":"Lemborexant for Cannabis Use Disorder","canonical_id":"clinicaltrials.gov:NCT07802990","description":"Cannabis Use Disorder","metadata":null},{"id":"ece7a4f974a64f1aa88f37eb17249d10","type":"TRIAL","name":"Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial","canonical_id":"clinicaltrials.gov:NCT06093126","description":"Insomnia; Dementia; Frontotemporal Dementia","metadata":null},{"id":"b0f284dc424648ce8ba7b06a287f6732","type":"TRIAL","name":"Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients","canonical_id":"clinicaltrials.gov:NCT07407400","description":"Sleep Disturbance; Delirium; Critical Illness","metadata":null},{"id":"d84f15aa4b7046198a8448e2428c1c43","type":"TRIAL","name":"Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT06843187","description":"Major Depressive Disorder(MDD); Insomnia Comorbid to Psychiatric Disorder","metadata":null},{"id":"7f049fe8458b431e8b5ce4fcf507c37e","type":"TRIAL","name":"Lemborexant in Delayed Sleep Phase Syndrome","canonical_id":"clinicaltrials.gov:NCT06874855","description":"Delayed Sleep Phase Syndrome","metadata":null},{"id":"48b6a734fef0447989f7142644c617c4","type":"TRIAL","name":"Lemborexant in Delayed Sleep Phase Syndrome","canonical_id":"clinicaltrials.gov:NCT05463861","description":"Delayed Sleep Phase Syndrome","metadata":null},{"id":"f5aa39ffeddf4c26a27f365c48dfa958","type":"TRIAL","name":"Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers","canonical_id":"clinicaltrials.gov:NCT06496282","description":"Sleep","metadata":null},{"id":"6a14d94590b14b50aef9846e3825837f","type":"TRIAL","name":"Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT07811401","description":"Postoperative Sleep Disturbance; Thoracoscopic Surgery","metadata":null},{"id":"d95376b69a1346998be8f2b277d670d8","type":"TRIAL","name":"Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients","canonical_id":"clinicaltrials.gov:NCT06648681","description":"Delirium - Postoperative; Cardiac Surgery; Cardiac Surgery Subjects; Orexin Antagonist; Feasibility Studies; Sleep; In-hospital Mortality","metadata":null},{"id":"ec3ece12d7a14ff2a2d63ddba914d727","type":"TRIAL","name":"Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients","canonical_id":"clinicaltrials.gov:NCT05618002","description":"Chronic Insomnia; Chronic Pain","metadata":null},{"id":"cade365e3faf40f9821e74c0a9e47761","type":"DRUG","name":"Lenalidomide","canonical_id":"mesh:C467567","description":null,"metadata":null},{"id":"a857b2405bd749abb7ab57b9f4af6ae6","type":"TRIAL","name":"Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT01373229","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"e6e7897a310b408889412f1437568629","type":"TRIAL","name":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","canonical_id":"clinicaltrials.gov:NCT02589145","description":"Lymphoma","metadata":null},{"id":"7b3f8d74cc5b42a09e9bbf189dcb5dec","type":"TRIAL","name":"Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01838434","description":"Relapsed/Refractory Mantle Cell Lymphoma","metadata":null},{"id":"926ac97db7174f5487f6958a64faccba","type":"TRIAL","name":"Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT02389517","description":"Plasma Cell Myeloma; Residual Disease","metadata":null},{"id":"5327fdf7959144d0a49e72dbdbabaf5b","type":"TRIAL","name":"Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01126450","description":"Colon Cancer; Rectal Cancer","metadata":null},{"id":"3a4d1fe6434548da9615854528e503f7","type":"TRIAL","name":"Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT01711554","description":"Recurrent Neuroblastoma; Refractory Neuroblastoma","metadata":null},{"id":"a847ae42b1ca4412b4e5325b0a50807b","type":"TRIAL","name":"Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT01644799","description":"Recurrent Follicular Lymphoma","metadata":null},{"id":"bc4eef4bc24041bba12f1155619d7720","type":"TRIAL","name":"Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)","canonical_id":"clinicaltrials.gov:NCT01183663","description":"Advanced Cancers","metadata":null},{"id":"fbbd58f17d8e49f7949040f957dddc62","type":"TRIAL","name":"Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05804032","description":"Multiple Myeloma","metadata":null},{"id":"b8e03ee0ec9547e3aefd1dd04642a82a","type":"TRIAL","name":"Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis","canonical_id":"clinicaltrials.gov:NCT03252600","description":"Recurrent Primary Amyloidosis","metadata":null},{"id":"683beeb3b3ae4a6b81ae1752f3a07737","type":"TRIAL","name":"Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02898259","description":"B Cell Lymphoma; Lymphoma","metadata":null},{"id":"31198a5b4ef24cf08a5c61a2a6f5a730","type":"TRIAL","name":"Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL","canonical_id":"clinicaltrials.gov:NCT03795571","description":"Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory","metadata":null},{"id":"e9dc44a7f7ce4529bc36ee74f5d6b440","type":"TRIAL","name":"Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04635683","description":"Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Follicular Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Re\u2026","metadata":null},{"id":"9bf52aff1aa6428db0a58344e381bbcc","type":"TRIAL","name":"Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)","canonical_id":"clinicaltrials.gov:NCT01531998","description":"Myeloma","metadata":null},{"id":"a4168e753a6442a0b6cb2256f5de9e93","type":"TRIAL","name":"Leniolisib for Immune Dysregulation in CVID","canonical_id":"clinicaltrials.gov:NCT06897358","description":"Common Variable Immunodeficiency (CVID)","metadata":null},{"id":"439d8cc5dbbe44e4b3b74a95099d11cc","type":"TRIAL","name":"Leniolisib for Immune Dysregulation in PIDs","canonical_id":"clinicaltrials.gov:NCT06549114","description":"Primary Immunodeficiency Disorders (PIDs)","metadata":null},{"id":"431331530f4f4068b5dcc61c41f4d8da","type":"DISEASE","name":"Lennox-Gastaut syndrome","canonical_id":"mondo:0016532","description":null,"metadata":null},{"id":"d9c00f71ca244dc5bdb84b09039e04f2","type":"DISEASE","name":"Lennox-Gastaut syndrome","canonical_id":"mesh:D065768","description":null,"metadata":null},{"id":"30a9a5e0b0584e9f816aa74d21c8ebb5","type":"TRIAL","name":"Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency","canonical_id":"clinicaltrials.gov:NCT03315078","description":"X-Linked Combined Immunodeficiency Diseases","metadata":null},{"id":"9b2be2a1cedf4527bf0aac2485dcfeb4","type":"TRIAL","name":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","canonical_id":"clinicaltrials.gov:NCT01306019","description":"X-linked Severe Combined Immunodeficiency (XSCID)","metadata":null},{"id":"17858084c2614b878b18bbe11d38a229","type":"TRIAL","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","canonical_id":"clinicaltrials.gov:NCT05170438","description":"Advanced Biliary Tract Cancer","metadata":null},{"id":"28a11dbf216044dbbbac6a04c69b5f5f","type":"TRIAL","name":"Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer","canonical_id":"clinicaltrials.gov:NCT05010681","description":"Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"c9efda17fd5540d8b90980e439c79aed","type":"TRIAL","name":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","canonical_id":"clinicaltrials.gov:NCT04127396","description":"Carcinoma, Hepatocellular; Portal Vein Tumor Thrombus","metadata":null},{"id":"27c0ab560fab45a6a60f9363c21e7d77","type":"TRIAL","name":"Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore","canonical_id":"clinicaltrials.gov:NCT06157996","description":"Gastric Cancer","metadata":null},{"id":"c97d869652034cd4a14cd813226446f7","type":"TRIAL","name":"Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT06241105","description":"Recurrent Ovarian Carcinoma","metadata":null},{"id":"97e5cbcc49334c4dbe0396890d2f30cd","type":"TRIAL","name":"Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT04171622","description":"Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Squamous Cell Carcinoma; Unresectable Thyroid Gland Carcinoma","metadata":null},{"id":"e95a81e86b154b9f9795a5679a6d576d","type":"TRIAL","name":"Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant","canonical_id":"clinicaltrials.gov:NCT05103904","description":"Recurrent Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma","metadata":null},{"id":"03c15b4bbd9a43698ca07ab8f50a1b87","type":"TRIAL","name":"Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations","canonical_id":"clinicaltrials.gov:NCT05258279","description":"Non-squamous Non-small-cell Lung Cancer; EGFR Activating Mutation","metadata":null},{"id":"70617e1740074b3d9c2d538801388d12","type":"TRIAL","name":"Lenvatinib in Second Line Endometrial Carcinoma","canonical_id":"clinicaltrials.gov:NCT03005015","description":"Endometrial Neoplasms","metadata":null},{"id":"56d0d1c0b2614668b0c51a0751c678a8","type":"TRIAL","name":"Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05954897","description":"Hepatocellular Carcinoma","metadata":null},{"id":"750a5af4b48c4aa6862015eaf7c714fc","type":"TRIAL","name":"Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00003726","description":"Lung Cancer","metadata":null},{"id":"172c8269fd71457a847719913af40071","type":"DISEASE","name":"Leprosy","canonical_id":"mesh:D007918","description":null,"metadata":null},{"id":"4f7f91f78882404983c30f6bf8ade342","type":"DRUG","name":"Lesinurad","canonical_id":"mesh:C000593471","description":null,"metadata":null},{"id":"00cea6a3cb2e48c89766a28edca3bf2e","type":"TRIAL","name":"Lesinurad Interaction Study With Ranitidine","canonical_id":"clinicaltrials.gov:NCT01908257","description":"Healthy","metadata":null},{"id":"50a6050f174b43e8a7799d86a9985d5c","type":"TRIAL","name":"Lesinurad and Febuxostat Combination Extension Study in Gout","canonical_id":"clinicaltrials.gov:NCT01808144","description":"Gout","metadata":null},{"id":"5258d30d7bd4466ca905190861ac01fe","type":"TRIAL","name":"Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability","canonical_id":"clinicaltrials.gov:NCT02581553","description":"Healthy","metadata":null},{"id":"a166b842fcc64399aaf145c86b417874","type":"TRIAL","name":"Letrozole vs Danazol for Endometriosis-Related Pain: Randomized Trial","canonical_id":"clinicaltrials.gov:NCT07183787","description":"Endometriosis","metadata":null},{"id":"1da69d17e20746d2985376ab2c5755d3","type":"TRIAL","name":"Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility","canonical_id":"clinicaltrials.gov:NCT00610077","description":"Infertility","metadata":null},{"id":"7f031ddcd6904cd6881fd16108aa55b6","type":"DRUG","name":"Leucovorin","canonical_id":"ncit:C71631","description":null,"metadata":null},{"id":"297842daed2e47099080205103d3c7d6","type":"DISEASE","name":"Leukemia","canonical_id":"doid:1240","description":null,"metadata":null},{"id":"5ac0d0ff6b1848cbb626df2ca5853004","type":"DISEASE","name":"Leukemia, Lymphocytic, Chronic, B-Cell","canonical_id":"mesh:D015451","description":null,"metadata":null},{"id":"a04854719ff94b57b78a5e27895dfeb2","type":"DISEASE","name":"Leukemia, Myeloid, Acute","canonical_id":"mesh:D015470","description":null,"metadata":null},{"id":"39be48987e1c4eac803c28e3dfda91dc","type":"TRIAL","name":"Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT00937768","description":"Prostate Adenocarcinoma; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"6c3a7623a8ba49d2bc3dd053b0fc4157","type":"TRIAL","name":"Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01163084","description":"Prostate Adenocarcinoma; Stage IIA Prostate Cancer AJCC v7; Stage IIB Prostate Cancer AJCC v7","metadata":null},{"id":"d398aab33551498b934e35512f41f25d","type":"TRIAL","name":"Leuprolide in Determining the Cause of Gonadotropin Deficiency","canonical_id":"clinicaltrials.gov:NCT00004426","description":"Hypogonadism","metadata":null},{"id":"24d914f774cd44f7a31bee521bc2d9c7","type":"TRIAL","name":"Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01122121","description":"Prostatic Neoplasms, Locally Advanced","metadata":null},{"id":"c6df577957c6486096910abeda581739","type":"DRUG","name":"Levamisole","canonical_id":"mesh:D007978","description":null,"metadata":null},{"id":"62527facff8946cc91afd122000299c4","type":"TRIAL","name":"Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial","canonical_id":"clinicaltrials.gov:NCT04383717","description":"Respiratory Tract Infections","metadata":null},{"id":"b1a9d7a7b7714ca39bd80e969d28d4fa","type":"TRIAL","name":"Levetiracetam 750 mg Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00849485","description":"Healthy","metadata":null},{"id":"4710d6f5efbc48678838938baa22c0f6","type":"TRIAL","name":"Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA)","canonical_id":"clinicaltrials.gov:NCT00393614","description":"Subclinical Sleep-Activated Epileptiform Activity; CSWS","metadata":null},{"id":"52fe5c19a01d45bdb0863d2583427327","type":"TRIAL","name":"Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks","canonical_id":"clinicaltrials.gov:NCT00279617","description":"Panic Disorder","metadata":null},{"id":"ba930dc04b934e718a695522cd6862d4","type":"TRIAL","name":"Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures","canonical_id":"clinicaltrials.gov:NCT03940326","description":"Epilepsy, Idiopathic Generalized","metadata":null},{"id":"a34c6c05879e49319a8309efa345d20a","type":"TRIAL","name":"Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)","canonical_id":"clinicaltrials.gov:NCT01044758","description":"Mild Cognitive Impairment (MCI)","metadata":null},{"id":"2f457667b3934f6aa6c5590f2759202e","type":"TRIAL","name":"Levetiracetam for Benign Rolandic Epilepsy","canonical_id":"clinicaltrials.gov:NCT00181116","description":"Epilepsy","metadata":null},{"id":"1a22683f7ec04900a4c49ec1389a117e","type":"TRIAL","name":"Levetiracetam for Seizure Prevention After Brain Tumor Surgery","canonical_id":"clinicaltrials.gov:NCT07239115","description":"Postoperative Seizures After Brain Tumor Surgery","metadata":null},{"id":"06f5fe9acb2e4ba5990cdf4288d69e39","type":"TRIAL","name":"Levetiracetam in the Management of Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT00566150","description":"Bipolar Depression","metadata":null},{"id":"16b02faa689c42a5ab0a2791426bd49f","type":"TRIAL","name":"Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II","canonical_id":"clinicaltrials.gov:NCT00377793","description":"Sexual Dysfunction; Male Erectile Dysfunction","metadata":null},{"id":"f4febd93b28a4ff7bcb862e11c3db1f6","type":"TRIAL","name":"Levitra\u00ae - Real Life Safety and Efficacy of Levitra","canonical_id":"clinicaltrials.gov:NCT00663598","description":"Erectile Dysfunction","metadata":null},{"id":"00f7c49dfe7c4f699da8d29e5f868460","type":"TRIAL","name":"Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT02617459","description":"Primary Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"54d93bd31d4b45719d3faaeb83f92f29","type":"DRUG","name":"Levobunolol","canonical_id":"mesh:D002040","description":null,"metadata":null},{"id":"f23fe4d2f321447eb5c990c5785bd6b3","type":"DRUG","name":"Levocetirizine","canonical_id":"mesh:C472067","description":null,"metadata":null},{"id":"e4ec26a3f9d5486e9f50e73fbc5e2466","type":"TRIAL","name":"Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00335153","description":"Advanced Parkinson's Disease","metadata":null},{"id":"c4c5c80bd91749749986a7c16326a4d7","type":"TRIAL","name":"Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection","canonical_id":"clinicaltrials.gov:NCT02978157","description":"Helicobacter Pylori Infection","metadata":null},{"id":"3819784635824e12ba4071e3862fa105","type":"DRUG","name":"Levomenthol","canonical_id":"mesh:D008610","description":null,"metadata":null},{"id":"fcbabea1b0fe4e9d90a9e141884d4bb9","type":"TRIAL","name":"Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD","canonical_id":"clinicaltrials.gov:NCT02720198","description":"Major Depressive Disorder","metadata":null},{"id":"4c26127b2bf841d78bf91d7c8417877e","type":"TRIAL","name":"Levomilnacipran in Healthy Males","canonical_id":"clinicaltrials.gov:NCT03249311","description":"None (i.e. Healthy Volunteers)","metadata":null},{"id":"aec0d630969143c6b02b25cb7c96fd49","type":"TRIAL","name":"Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period","canonical_id":"clinicaltrials.gov:NCT01088178","description":"Contraception","metadata":null},{"id":"246457089fcb4fa582b1a0c7bb2ea16d","type":"TRIAL","name":"Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception","canonical_id":"clinicaltrials.gov:NCT06727734","description":"Contraception","metadata":null},{"id":"8232ec5a3d8b4bb2821bf0fd302f6eb2","type":"TRIAL","name":"Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT03579446","description":"Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm","metadata":null},{"id":"fef9f0e0ce534421aa4465e4235b749f","type":"DRUG","name":"Levosimendan","canonical_id":"mesh:C076731","description":null,"metadata":null},{"id":"3981b8f6407f4336b153e57ee8ddb93c","type":"TRIAL","name":"Levosimendan Versus Dobutamine for Renal Function in Heart Failure","canonical_id":"clinicaltrials.gov:NCT02133105","description":"Cardiorenal Syndrome","metadata":null},{"id":"3c02b5a029f4486f8356a190d829a61d","type":"TRIAL","name":"Levosimendan Versus Dobutamine in Shock Patients","canonical_id":"clinicaltrials.gov:NCT00093301","description":"Cardiogenic Shock; Septic Shock","metadata":null},{"id":"f8d9aaefb24144f78660821bb960fa5b","type":"DRUG","name":"Levothyroxine","canonical_id":"mesh:D013974","description":null,"metadata":null},{"id":"319c4bf4f01d4792bfdb3ffb07de9933","type":"GO_TERM","name":"Lewis a epitope biosynthetic process","canonical_id":"go:GO:0010493","description":"\"The chemical reactions and pathways resulting in the formation of a Lewis a epitope, a trisaccharide (Fuc-alpha-(1->4)[Gal-beta-(1->3)]GlcNAc) characteristic of plant protein N-linked oligosaccharides.\" [PMID:17630273]","metadata":null},{"id":"75e4b91b65174d7fa64df3b28b947d64","type":"GO_TERM","name":"Lewis x epitope biosynthetic process","canonical_id":"go:GO:0106402","description":"\"The chemical reactions and pathways resulting in the formation of a Lewis x epitope, a trisaccharide (beta-D-galactosyl-(1,4)-[alpha-L-fucosyl-(1,3)]-N-acetyl-beta-D-glucosamine) expressed on several glycolipids, glycoproteins, and proteoglycans of the nervous system. The related Lewis x epitope is formed by alpha(1,3) fucosylation of the N-acetylglucosaminyl residue of a type 2 histo-blood group antigen precursor disaccharide.\" [PMID:16973732, PMID:23000574]","metadata":null},{"id":"334a9943203a4fb7bfaa29c576154058","type":"GO_TERM","name":"Lewy body","canonical_id":"go:GO:0097413","description":"\"Cytoplasmic, spherical inclusion commonly found in damaged neurons, and composed of abnormally phosphorylated, neurofilament proteins aggregated with ubiquitin and alpha-synuclein.\" [NIF_Subcellular:sao4933778419]","metadata":null},{"id":"10e6f04afd5f4897b74b474c759734cb","type":"GO_TERM","name":"Lewy body core","canonical_id":"go:GO:1990037","description":"\"The center portion of a Lewy body. In Parkinson's disease, it contains a matted meshwork of filaments.\" [NIF_Subcellular:sao6587439252]","metadata":null},{"id":"dbb52db977b44f1e9fbbdf7675d7bad5","type":"GO_TERM","name":"Lewy body corona","canonical_id":"go:GO:1990038","description":"\"The periphery of a Lewy body. In Parkinson's disease, it contains spherical accumulations of filaments arranged in a loose, radiating array.\" [NIF_Subcellular:sao5764355747]","metadata":null},{"id":"96d03b8c94d54c1eba1dfc098bb9cf59","type":"GO_TERM","name":"Lewy body formation","canonical_id":"go:GO:0140121","description":"\"The aggregation, arrangement and bonding together of a set of components to form a Lewy body.\" [PMID:15158159]","metadata":null},{"id":"2048847f2dac4a1b940242cf35d07bc2","type":"GO_TERM","name":"Lewy body-like hyaline inclusion","canonical_id":"go:GO:0097416","description":"\"Cytoplasmic inclusion found in neurons. It consists of filaments and granular materials, exhibits a dense core with a rough peripheral halo and lacks a limiting membrane. The filaments of these inclusions are composed of approximately 15-25 nm granule-coated fibrils in association with normal 10-nm neurofilaments.\" [NIF_Subcellular:nlx_subcell_20090105, PMID:18026741]","metadata":null},{"id":"7a1a0a0a828748eea267f69593265999","type":"GO_TERM","name":"Lewy neurite","canonical_id":"go:GO:0097462","description":"\"Elongated neuronal process, often with side branches and more than one branching point, described in brains of patients with Parkinson's disease. Lewy neurites stain positively for ubiquitin in brainstem and forebrain regions affected in Parkinson's disease.\" [NIF_Subcellular:sao601362597]","metadata":null},{"id":"fe48a06a1521437aa3eeae49a067a27e","type":"TRIAL","name":"Lexapro\u00ae's Efficacy After Dose Escalation in Remission Study","canonical_id":"clinicaltrials.gov:NCT01594866","description":"Major Depressive Disorder","metadata":null},{"id":"ad8dccce1ff14659af8ba617a9d22484","type":"GO_TERM","name":"Leydig cell differentiation","canonical_id":"go:GO:0033327","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a Leydig cell. A Leydig cell is a testosterone-secreting cell in the interstitial area, between the seminiferous tubules, in the testis.\" [GOC:ln, PMID:12050120]","metadata":null},{"id":"dee10b7b153343b6a69aeb4744df667a","type":"DISEASE","name":"Leydig cell hypoplasia, type 1","canonical_id":"mondo:0009384","description":null,"metadata":null},{"id":"53db9d5726b242afb4798221cba59279","type":"GO_TERM","name":"Leydig cell proliferation","canonical_id":"go:GO:0160024","description":"\"The multiplication or reproduction of Leydig cells, resulting in the expansion of a cell population. Leydig cells are interstitial cells located adjacent to the seminiferous tubules in the testis which produce testosterone.\" [PMID:29632025]","metadata":null},{"id":"0a6dfaebc5184e07aba210bc43e0fbe9","type":"DRUG","name":"Li+","canonical_id":"gtopdb:5212","description":null,"metadata":null},{"id":"484b572ab51d48b6849149c30120a505","type":"DISEASE","name":"Lichen Planus","canonical_id":"mesh:D008010","description":null,"metadata":null},{"id":"898c6e37ea7b4dc985dff2b3ca7e55be","type":"TRIAL","name":"Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin","canonical_id":"clinicaltrials.gov:NCT01538732","description":"Lichen Planus (LP)","metadata":null},{"id":"b2827184bb0e4addb059d3233558b3c7","type":"DISEASE","name":"Lichen simplex chronicus","canonical_id":"mesh:D009450","description":null,"metadata":null},{"id":"f139991f7b904473a970ca09a6af9a45","type":"TRIAL","name":"Licorice Botanical Dietary Supplements - Metabolism and Safety in Women","canonical_id":"clinicaltrials.gov:NCT03948243","description":"Food-drug Interaction","metadata":null},{"id":"a755a79c2a874432965dce4b37ace85e","type":"GO_TERM","name":"Lid2 complex","canonical_id":"go:GO:0048189","description":"\"A protein complex involved in regulation of chromatin remodeling. In Schizosaccharomyces the complex contains Lid2, Ash2, Jmj3, Snt2, and Sdc1.\" [PMID:12488447]","metadata":null},{"id":"bac0872fa5814ae4bfc270a06efe9d1f","type":"TRIAL","name":"Lidocaine 10% Spray Reduces Pain During Intrauterine Device Insertion","canonical_id":"clinicaltrials.gov:NCT02020551","description":"Pain","metadata":null},{"id":"b8c14e2b0782470a983c8720b882652f","type":"TRIAL","name":"Lidocaine Infusion in Hystroscopy","canonical_id":"clinicaltrials.gov:NCT03825016","description":"Pain","metadata":null},{"id":"23710b5092164f4aa8906044e462c643","type":"TRIAL","name":"Lidocaine Versus Esmolol for Optimizing Surgical Field Visibility","canonical_id":"clinicaltrials.gov:NCT04260685","description":"Lumbar Disc Herniation","metadata":null},{"id":"8f8a43cbf4c14372a48caa87cd783365","type":"TRIAL","name":"Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain","canonical_id":"clinicaltrials.gov:NCT04356352","description":"Injection Site Irritation; Pain","metadata":null},{"id":"12deda3d24ba446fa96691bef2baf761","type":"TRIAL","name":"Lifestyle Modification and Lorcaserin for Weight Loss Maintenance","canonical_id":"clinicaltrials.gov:NCT02388568","description":"Obesity","metadata":null},{"id":"3927cc95734748cd8b05f4781e757506","type":"DRUG","name":"Lifitegrast","canonical_id":"mesh:C575157","description":null,"metadata":null},{"id":"81804e8b4a3a49dca64c291ea79284be","type":"TRIAL","name":"Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness","canonical_id":"clinicaltrials.gov:NCT03686878","description":"Contact Lens; Contact Lens Discomfort; Contact Lens Dryness","metadata":null},{"id":"7aed1cc6de1b43a7bd4a3ee88c406a0d","type":"TRIAL","name":"Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers","canonical_id":"clinicaltrials.gov:NCT05505292","description":"Dry Eye","metadata":null},{"id":"bc0b6d33e0f140f08caf4afaad46bae0","type":"TRIAL","name":"Lifitegrast Eye Drops in Healthy Subjects\uff1aPhase I Study","canonical_id":"clinicaltrials.gov:NCT07040826","description":"Dry Eye Syndromes","metadata":null},{"id":"7c16e392e7ef448e9e5ab065f7184af2","type":"TRIAL","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","canonical_id":"clinicaltrials.gov:NCT06789848","description":"Advanced Hepatocellular Carcinoma; Refractory Hepatocellular Carcinoma; Biliary Tract Cancer","metadata":null},{"id":"ca55dc30af9c457698c53b58a43885b2","type":"DISEASE","name":"Limb pain","canonical_id":"hp:0009763","description":null,"metadata":null},{"id":"b02306520d874f19989f11066777d287","type":"GO_TERM","name":"LinE complex","canonical_id":"go:GO:0062119","description":"\"A protein complex that associates with chromatin to form linear elements in fission yeast. In S. pombe, the LinE complex contains four main structural components (Rec10, Rec25, Rec27, and Mug20) and other associated proteins.\" [PMID:30640914]","metadata":null},{"id":"cbd734ae117942ea92e819cdc9f08cf5","type":"GO_TERM","name":"LinE complex assembly","canonical_id":"go:GO:0062120","description":"\"The aggregation, arrangement and bonding together of a set of components during meiotic prophase to form a LinE complex, the protein complex that associates with chromatin to form linear elements in fission yeast. In S. pombe, the LinE complex contains four main structural components (Rec10, Rec25, Rec27, and Mug20) and other associated proteins.\" [PMID:30640914]","metadata":null},{"id":"85fd9ae56d324b55ba00a5d0b13c9a31","type":"TRIAL","name":"Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01950403","description":"Colorectal Cancer; Healthy, no Evidence of Disease","metadata":null},{"id":"4863ef07ae834121a703f0cb04727045","type":"TRIAL","name":"Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation","canonical_id":"clinicaltrials.gov:NCT04110145","description":"Functional Constipation","metadata":null},{"id":"696b8e6b8ba940ff8fd57dfaed7abf3c","type":"TRIAL","name":"Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)","canonical_id":"clinicaltrials.gov:NCT04026113","description":"Functional Constipation; Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"a6e94ca8e0ee493bb2047c1e86de5ee5","type":"TRIAL","name":"Linaclotide for Colonoscopy Bowel Prep","canonical_id":"clinicaltrials.gov:NCT06692673","description":"Patients Scheduled for Colonoscopy","metadata":null},{"id":"078e2db1f4044f9c9f040b092aec75ac","type":"TRIAL","name":"Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03796884","description":"Colorectal Adenoma; Stage 0 Colorectal Cancer AJCC v8; Stage I Colorectal Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage IIA Colorectal Cancer AJCC v8; Stage IIB Colorectal Cancer AJCC v8; Stage IIC Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8","metadata":null},{"id":"e1d63e27fa7e433183ab425f6acb9b13","type":"DRUG","name":"Linagliptin","canonical_id":"mesh:D000069476","description":null,"metadata":null},{"id":"dd87ea4983414921b6459223c9b84d7f","type":"TRIAL","name":"Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone","canonical_id":"clinicaltrials.gov:NCT00996658","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"edecf61b3d5f4b73882df168af044f80","type":"TRIAL","name":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02489968","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"d9ea393bc37e464c9ba335f18c2b4801","type":"TRIAL","name":"Linagliptin as Add on to Basal Insulin in the Elderly","canonical_id":"clinicaltrials.gov:NCT02240680","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"9dd8385b775f4adfb3c13921927a501b","type":"DRUG","name":"Lindane","canonical_id":"mesh:D001556","description":null,"metadata":null},{"id":"1c0d4dfa93c44ff587fb95da85d57769","type":"TRIAL","name":"Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)","canonical_id":"clinicaltrials.gov:NCT05448170","description":"Pruritus","metadata":null},{"id":"c38ec4937ab64ff6af485843e377bf77","type":"TRIAL","name":"Linerixibat Long-term Safety, and Tolerability Study","canonical_id":"clinicaltrials.gov:NCT04167358","description":"Cholestasis","metadata":null},{"id":"6185138c5b944691bc5e8dd16d097c8e","type":"TRIAL","name":"Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT05133830","description":"Pruritus","metadata":null},{"id":"d446926d45e24c809ccb300fd2d0f2d5","type":"TRIAL","name":"Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT04053023","description":"Cholestasis","metadata":null},{"id":"9baa3535102d40278d35dd00dd076cb1","type":"DRUG","name":"Linezolid","canonical_id":"mesh:D000069349","description":null,"metadata":null},{"id":"017c81ca7f26492689627a41c9f317dd","type":"TRIAL","name":"Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia","canonical_id":"clinicaltrials.gov:NCT01356472","description":"Methicillin-resistant Staphylococcus Aureus; Pneumonia, Ventilator-Associated","metadata":null},{"id":"c6a59a20c46a44a59bde912dd207dfc0","type":"TRIAL","name":"Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)","canonical_id":"clinicaltrials.gov:NCT01179828","description":"Low Back Pain","metadata":null},{"id":"c8b2826755124daebdf16ce4836bc7d1","type":"DRUG","name":"Liothyronine","canonical_id":"mesh:D014284","description":null,"metadata":null},{"id":"3bbfc6131b44448d9b6f58c125749438","type":"TRIAL","name":"Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00935259","description":"Hypercholesterolemia, Dyslipidemia","metadata":null},{"id":"88833cb446f142528ecd2e6023937d94","type":"TRIAL","name":"Lipid Management in Renal Transplant Recipients Using Evolocumab.","canonical_id":"clinicaltrials.gov:NCT04608474","description":"Hyperlipidemias","metadata":null},{"id":"de7bb57b95db4f1e92f99bf92fe971fd","type":"PROTEIN","name":"Lipoprotein lipase","canonical_id":"uniprot:P06858","description":null,"metadata":null},{"id":"c68d4a814b36427faab15d710fe55c99","type":"TRIAL","name":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","canonical_id":"clinicaltrials.gov:NCT06858332","description":"Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"688b13a2012b4bd1a4a33735a6c1c2af","type":"DISEASE","name":"Liposarcoma","canonical_id":"mesh:D008080","description":null,"metadata":null},{"id":"a5d318ba52214a42bc4ccd241325a9a5","type":"TRIAL","name":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT04128748","description":"Acute Myeloid Leukemia; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome","metadata":null},{"id":"4db6d5a60dca4481a26ec2324f2b1366","type":"TRIAL","name":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04915612","description":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia","metadata":null},{"id":"92e705a461614e37b633cf285c74f761","type":"TRIAL","name":"Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00255801","description":"Lymphoma","metadata":null},{"id":"b481ae5bb00a424e80c89077664420f4","type":"TRIAL","name":"Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy","canonical_id":"clinicaltrials.gov:NCT03883919","description":"Pancreatic Cancer; Pancreas Cancer; Cancer of the Pancreas","metadata":null},{"id":"f86db39c500f4ceaad03f9265081d84d","type":"TRIAL","name":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","canonical_id":"clinicaltrials.gov:NCT03337087","description":"Metastatic Biliary Tract Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Digestive System Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7","metadata":null},{"id":"153cdb13cdb04a77954d326eb6d2bc29","type":"TRIAL","name":"Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05601440","description":"Breast Cancer","metadata":null},{"id":"441db4d372354f89be2dea1aa2707398","type":"DRUG","name":"Liraglutide","canonical_id":"mesh:D000069450","description":null,"metadata":null},{"id":"569da027f2b3499a901abc3179ced8ae","type":"TRIAL","name":"Liraglutide and Peripheral Artery Disease","canonical_id":"clinicaltrials.gov:NCT04881110","description":"Type 2 Diabetes; Peripheral Arterial Disease","metadata":null},{"id":"405d7bf369c84109ba82741b82e0182d","type":"TRIAL","name":"Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.","canonical_id":"clinicaltrials.gov:NCT01784965","description":"Pre-diabetes; Older Adults","metadata":null},{"id":"03267c748cfb431d8c656c1c77278321","type":"TRIAL","name":"Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01299012","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"f6628a5d31a74318833d5d5aafaabfcc","type":"TRIAL","name":"Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2","canonical_id":"clinicaltrials.gov:NCT01484262","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"0f9abd2b580f4fbd8cf5048d561d7a0e","type":"TRIAL","name":"Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT01010750","description":"Attention-Deficit Hyperactivity Disorder","metadata":null},{"id":"15f481a0bdb34f1cb015ea881752187e","type":"TRIAL","name":"Lisdexamfetamine for Adults With Bulimia Nervosa","canonical_id":"clinicaltrials.gov:NCT03397446","description":"Bulimia Nervosa","metadata":null},{"id":"658902ef63284b028979acddef642c0e","type":"TRIAL","name":"Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects","canonical_id":"clinicaltrials.gov:NCT02659488","description":"Binge Eating Disorder","metadata":null},{"id":"e384df5a60b746aea7f94025f93f4e88","type":"TRIAL","name":"Lisdexamfetamine's Effect In ADHD in the Brain and Cognition","canonical_id":"clinicaltrials.gov:NCT02170298","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"2880c12084624e04add7df844a9cf8ab","type":"TRIAL","name":"Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01880528","description":"Dyspnea; Non-small Cell Lung Cancer; Small Cell Lung Cancer","metadata":null},{"id":"7d5889b656f44cc0975532bee8499ed3","type":"DISEASE","name":"Listeriosis","canonical_id":"mesh:D008088","description":null,"metadata":null},{"id":"3fd09ec3911343c58dcf8210c55bdee5","type":"DRUG","name":"Lisuride","canonical_id":"mesh:D008090","description":null,"metadata":null},{"id":"86e9cc8f3b054e68a505bbb63d339fae","type":"TRIAL","name":"Lithium Drug-Drug Interaction Study With Lurasidone HCl","canonical_id":"clinicaltrials.gov:NCT01074073","description":"Schizophrenia","metadata":null},{"id":"c25893a51e944ce59ba14df858ab5197","type":"DRUG","name":"Lithium carbonate","canonical_id":"mesh:D016651","description":null,"metadata":null},{"id":"d963be165453428981e349471af01767","type":"TRIAL","name":"Little Lungs Study","canonical_id":"clinicaltrials.gov:NCT06855043","description":"Invasive Mechanical Ventilation; Severe Respiratory Distress Syndrome","metadata":null},{"id":"21ed00442e634acd9a80c0b17f71e2da","type":"TRIAL","name":"Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT07626840","description":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","metadata":null},{"id":"bcde228dfd7442cda627a76af9d59ca1","type":"TISSUE","name":"Liver","canonical_id":"uberon:UBERON:0001114","description":null,"metadata":null},{"id":"2de9746caa5b4900871a07aa997a8e49","type":"DISEASE","name":"Liver Abscess","canonical_id":"mesh:D008100","description":null,"metadata":null},{"id":"34412196d56a41a58bc1de1d125666e1","type":"DISEASE","name":"Liver Cirrhosis, Biliary","canonical_id":"mesh:D008105","description":null,"metadata":null},{"id":"95cbef3df9694b88aea856b06f56526d","type":"DISEASE","name":"Liver Neoplasms","canonical_id":"mesh:D008113","description":null,"metadata":null},{"id":"2fea8efc877047fbb7e1621bf372921f","type":"TRIAL","name":"Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)","canonical_id":"clinicaltrials.gov:NCT04004884","description":"Leiomyoma, Uterine; Liver Injury; Treatment Side Effects","metadata":null},{"id":"a86213c3aa054964852cfbe498d7e360","type":"TRIAL","name":"Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2","canonical_id":"clinicaltrials.gov:NCT00931372","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"8338dbcd7920440b913b1222dabb1b24","type":"TRIAL","name":"Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer","canonical_id":"clinicaltrials.gov:NCT07537946","description":"Hepatocellular Carcinoma (HCC); Metastases","metadata":null},{"id":"a8b5288533e143e985176693be8f31ac","type":"TRIAL","name":"Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03707938","description":"Advanced Lung Carcinoma; ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"0d8b2b167ec146e0a72b6450d543354e","type":"TRIAL","name":"Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction","canonical_id":"clinicaltrials.gov:NCT00001724","description":"Pain","metadata":null},{"id":"b5fabe762ab8453b9d3f3543aa0fa658","type":"TRIAL","name":"Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis","canonical_id":"clinicaltrials.gov:NCT03204097","description":"Chronic Periodontitis","metadata":null},{"id":"c4a957551ea047fca464d2691ea4ff34","type":"TRIAL","name":"Local Injection and Systemic Therapy in the Treatment of NSCLC.","canonical_id":"clinicaltrials.gov:NCT06618391","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"88886e9f3f084fbbb45ae68f660a9c5d","type":"TRIAL","name":"Local Pilocarpine for Relieving Dry Mouth","canonical_id":"clinicaltrials.gov:NCT04195100","description":"Patients of Advanced Age (\u2265 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth","metadata":null},{"id":"7b9ced5cedd44dd8974740fedb5fb1a9","type":"TRIAL","name":"Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment","canonical_id":"clinicaltrials.gov:NCT03348735","description":"Neuropathic Pain","metadata":null},{"id":"59e4bf6b6a544d21bdc01ee2e7af7e4f","type":"TRIAL","name":"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03870919","description":"Breast Cancer Stage IV; Radiotherapy; Surgery","metadata":null},{"id":"bc87931295d04a1b95ccace80cabf38a","type":"TRIAL","name":"Lofexidine for Inpatient Opiate Detox in Singapore","canonical_id":"clinicaltrials.gov:NCT01675648","description":"Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore","metadata":null},{"id":"d5911407984c49e78750736e0cbb0fdd","type":"DRUG","name":"Lomefloxacin","canonical_id":"mesh:C053091","description":null,"metadata":null},{"id":"0a0374bfc2d248c0bcdc49ead765eeec","type":"DRUG","name":"Lomustine","canonical_id":"mesh:D008130","description":null,"metadata":null},{"id":"948514a231094b40944b0e397bfeb01a","type":"TRIAL","name":"Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)","canonical_id":"clinicaltrials.gov:NCT02363478","description":"Systemic Sclerosis","metadata":null},{"id":"0e0e4a8d15794e1ab3a04895db6fbb0c","type":"TRIAL","name":"Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia","canonical_id":"clinicaltrials.gov:NCT05816343","description":"Type 1 Hyperlipoprotenemia","metadata":null},{"id":"ca16c8d2f83445c385f2bf4a79528766","type":"TRIAL","name":"Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases","canonical_id":"clinicaltrials.gov:NCT00434447","description":"Bone Neoplasms","metadata":null},{"id":"526eb49cfb5a4aada90a4b5fb831fafb","type":"TRIAL","name":"Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","canonical_id":"clinicaltrials.gov:NCT07187804","description":"Age-related Macular Degeneration (ARMD); Choroidal Neovascularization; Anti-vascular Endothelial Growth Factor","metadata":null},{"id":"2bf4a293fdf3479bacf054881e725950","type":"TRIAL","name":"Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05142774","description":"Atopic Dermatitis","metadata":null},{"id":"adbf4c295953439382a4b904990271a7","type":"TRIAL","name":"Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)","canonical_id":"clinicaltrials.gov:NCT04053387","description":"Plaque Psoriasis","metadata":null},{"id":"0e2dab46b6c649f28f9be842be563d5c","type":"TRIAL","name":"Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03025308","description":"Rheumatoid Arthritis","metadata":null},{"id":"217f84f33ab04b42ab5e33693a2bbce3","type":"TRIAL","name":"Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy","canonical_id":"clinicaltrials.gov:NCT00150748","description":"Generalized Epilepsy","metadata":null},{"id":"b1b28e172c064d5181ba255063011329","type":"TRIAL","name":"Long Term Safety Observation of Crizotinib in Chinese NSCLC Population","canonical_id":"clinicaltrials.gov:NCT03672643","description":"ALK or ROS1-positive NSCLC","metadata":null},{"id":"b0bc467b8b6f42ff850b9338235221dc","type":"TRIAL","name":"Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)","canonical_id":"clinicaltrials.gov:NCT03579966","description":"Myasthenia Gravis, MuSK; AChR Myasthenia Gravis","metadata":null},{"id":"eb0aa1754ad54462a27ec8bfeea2bb99","type":"TRIAL","name":"Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care","canonical_id":"clinicaltrials.gov:NCT02320084","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"5dea272f134b4cfeac39e0ef1313d012","type":"TRIAL","name":"Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease","canonical_id":"clinicaltrials.gov:NCT02310269","description":"Cushings Disease","metadata":null},{"id":"548307b1dc4e403bbff8217992868d62","type":"TRIAL","name":"Long Term Safety and Efficacy of SC Apomorphine in Treatment of \"Off\" Episodes in Late-Stage Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00142545","description":"Parkinson Disease","metadata":null},{"id":"189455b7c18c42a69399d81d8a25070e","type":"TRIAL","name":"Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses","canonical_id":"clinicaltrials.gov:NCT00228163","description":"Multiple Sclerosis","metadata":null},{"id":"215e9a55d8e24e6896f58614e39e8981","type":"TRIAL","name":"Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain","canonical_id":"clinicaltrials.gov:NCT00195728","description":"Moderate to Severe Chronic, Non-malignant Pain","metadata":null},{"id":"6819a64e2d644bd2937a0ac55eb7ebc4","type":"TRIAL","name":"Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00219037","description":"Hypertension","metadata":null},{"id":"a345717ef85d4b5c82b91eb6a7916fb9","type":"TRIAL","name":"Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT02794285","description":"Active Systemic Lupus Erythematosus","metadata":null},{"id":"11ac33262fa74dd498a8ef89ed6d325f","type":"TRIAL","name":"Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02251275","description":"Polycystic Kidney, Autosomal Dominant","metadata":null},{"id":"9c4274105c1649a69439883460443ca8","type":"TRIAL","name":"Long Term Safety of Naldemedine","canonical_id":"clinicaltrials.gov:NCT01965652","description":"Opioid-induced Constipation","metadata":null},{"id":"b5f8c977351e49b995c9bc467eac6115","type":"TRIAL","name":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00811395","description":"Multiple Sclerosis","metadata":null},{"id":"02906c98d33a42598ff637ddc3d7952b","type":"TRIAL","name":"Long Term Study With B2036-PEG","canonical_id":"clinicaltrials.gov:NCT00143416","description":"Acromegaly","metadata":null},{"id":"c6a22cf6bc084849950dd1cf0cb97b6d","type":"TRIAL","name":"Long Term Study of Canakinumab (ACZ885) in Patients With Gout","canonical_id":"clinicaltrials.gov:NCT00927810","description":"Gouty Arthritis","metadata":null},{"id":"558a7b4d942c42fb94fd073f0b4c656a","type":"TRIAL","name":"Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program","canonical_id":"clinicaltrials.gov:NCT01281657","description":"Multiple Sclerosis","metadata":null},{"id":"d543afaa675544a2a53adfa6e5815172","type":"TRIAL","name":"Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","canonical_id":"clinicaltrials.gov:NCT01021332","description":"Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia","metadata":null},{"id":"677d6a8198954b1f897f8cb83a528f3a","type":"TRIAL","name":"Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)","canonical_id":"clinicaltrials.gov:NCT00338936","description":"Hypertension","metadata":null},{"id":"e33ba86815bc484da0f35ea04926d11a","type":"TRIAL","name":"Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing","canonical_id":"clinicaltrials.gov:NCT00156533","description":"Insomnia; Primary Insomnia; Psychophysiologic Insomnia","metadata":null},{"id":"82d1a70dedc44b7496eee7e1075567ca","type":"TRIAL","name":"Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine","canonical_id":"clinicaltrials.gov:NCT02852577","description":"Panic Disorder; Agoraphobia","metadata":null},{"id":"ae482e608311471b980803e026627129","type":"TRIAL","name":"Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan","canonical_id":"clinicaltrials.gov:NCT00658879","description":"Acromegaly","metadata":null},{"id":"ed543de2dee245acb93aac5871b300a4","type":"TRIAL","name":"Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial","canonical_id":"clinicaltrials.gov:NCT00461890","description":"Alcohol Dependence; Veterans","metadata":null},{"id":"18211217eb5f4b56bea79b94be46d662","type":"TRIAL","name":"Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT02734407","description":"Clinically Significant Diabetic Macular Edema","metadata":null},{"id":"2bc682f3197d4c6abe5eb10af10e87cb","type":"TRIAL","name":"Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)","canonical_id":"clinicaltrials.gov:NCT00156065","description":"Schizophrenia","metadata":null},{"id":"dfa46f733874403bb91007e198a3d19c","type":"TRIAL","name":"Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)","canonical_id":"clinicaltrials.gov:NCT00156091","description":"Schizophrenia","metadata":null},{"id":"6535655c965847309b57b011206dc022","type":"TRIAL","name":"Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial","canonical_id":"clinicaltrials.gov:NCT04708145","description":"Diabetic Retinopathy","metadata":null},{"id":"286a11c1e2b041f9813f52ad40c14987","type":"TRIAL","name":"Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.","canonical_id":"clinicaltrials.gov:NCT00247390","description":"Chronic Insomnia","metadata":null},{"id":"75fee03f47534116b8791852f366748a","type":"TRIAL","name":"Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)","canonical_id":"clinicaltrials.gov:NCT01286207","description":"Migraine Disorders","metadata":null},{"id":"509f03fbfc164177a2657358f51fd52a","type":"TRIAL","name":"Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan","canonical_id":"clinicaltrials.gov:NCT05064371","description":"Migraine","metadata":null},{"id":"00b45817e7694c4aa572215b4839b6a5","type":"TRIAL","name":"Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019","canonical_id":"clinicaltrials.gov:NCT01797965","description":"Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis","metadata":null},{"id":"afc6b3edb3c649bc8e32327e52ba9453","type":"TRIAL","name":"Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris","canonical_id":"clinicaltrials.gov:NCT02613910","description":"Pemphigus","metadata":null},{"id":"25cc835216854cb98a401c6578929717","type":"TRIAL","name":"Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.","canonical_id":"clinicaltrials.gov:NCT03552276","description":"Psoriatic Arthritis","metadata":null},{"id":"4a00b4bb769d4716be1cd50260162d00","type":"TRIAL","name":"Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT01498120","description":"Restless Legs Syndrome","metadata":null},{"id":"7cd0e0995d12428ba03520342c82c6b8","type":"TRIAL","name":"Long-Term One Year Use of Alefacept (Amevive\u00ae) in Moderate to Severe Chronic Plaque Type Psoriasis","canonical_id":"clinicaltrials.gov:NCT00655564","description":"Psoriasis","metadata":null},{"id":"ee55f8d07c4e49fa947671d8a0e03c48","type":"TRIAL","name":"Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT00338091","description":"Renal Insufficiency,Chronic; Disease Progression; Proteinuria; Dose-Response Relationship,Drug; ACE Inhibitor; Angiotensin II Type 1 Receptor Blockers","metadata":null},{"id":"53e63aafe1a94510b1c4f291cdeaa07d","type":"TRIAL","name":"Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain","canonical_id":"clinicaltrials.gov:NCT00241722","description":"Bowel Dysfunction; Constipation","metadata":null},{"id":"b4e69dc17a6a4981ba0802a524f8c496","type":"TRIAL","name":"Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)","canonical_id":"clinicaltrials.gov:NCT01395992","description":"Bipolar I Disorder","metadata":null},{"id":"35a2f3a829434cb8a37665d242f4bce5","type":"TRIAL","name":"Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)","canonical_id":"clinicaltrials.gov:NCT01617200","description":"Schizophrenia","metadata":null},{"id":"1ab0bf593cbe4c4c9657f8e853168261","type":"TRIAL","name":"Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01309542","description":"Major Depressive Disorder","metadata":null},{"id":"9c375ec40a624c59bda5426b4e22c1a2","type":"TRIAL","name":"Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00355641","description":"Restless Legs Syndrome","metadata":null},{"id":"7a3e357408614bcea4d0a033d98ca1e5","type":"TRIAL","name":"Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","canonical_id":"clinicaltrials.gov:NCT07116967","description":"Plaque Psoriasis","metadata":null},{"id":"fdbe2c23f8df43a4a472ce0629a758e4","type":"TRIAL","name":"Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","canonical_id":"clinicaltrials.gov:NCT03271489","description":"Heavy Menstrual Bleeding; Uterine Fibroids","metadata":null},{"id":"7d80c590ca37418fbd0aed5509ad3aa9","type":"TRIAL","name":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02220907","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a22b76be10ee4a9d9d94d9a74af37742","type":"TRIAL","name":"Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)","canonical_id":"clinicaltrials.gov:NCT01336621","description":"Epilepsy","metadata":null},{"id":"2d7d074f664f429d8de931af35cb1d4b","type":"TRIAL","name":"Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01331109","description":"Primary Fibromyalgia","metadata":null},{"id":"72bbd1620c404df1a35e4d91632199d1","type":"TRIAL","name":"Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients","canonical_id":"clinicaltrials.gov:NCT01431638","description":"Acute Gouty Arthritis","metadata":null},{"id":"95888231af544016b33db4c84d8e0db4","type":"TRIAL","name":"Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus","canonical_id":"clinicaltrials.gov:NCT01585558","description":"Atrophy; Vaginal Diseases","metadata":null},{"id":"54573839ecb14529a39549be532cdf2c","type":"TRIAL","name":"Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03764475","description":"Plaque Psoriasis","metadata":null},{"id":"9c6cada1276a493a911dc2cf8b528bbe","type":"TRIAL","name":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","canonical_id":"clinicaltrials.gov:NCT01309828","description":"Safety","metadata":null},{"id":"2dc2e7aeb2b94ee29966af361e6d612d","type":"TRIAL","name":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01298700","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"df228b66d31f4ee7bac687cf24135e09","type":"TRIAL","name":"Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus","canonical_id":"clinicaltrials.gov:NCT01586364","description":"Atrophy; Vaginal Diseases","metadata":null},{"id":"807e1b7bd29346d3933625ae252ac1c9","type":"TRIAL","name":"Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT02784496","description":"Myelofibrosis","metadata":null},{"id":"db3bade81e014cdcafb9bf973e772fd0","type":"TRIAL","name":"Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.","canonical_id":"clinicaltrials.gov:NCT00219323","description":"Asthma","metadata":null},{"id":"8ab97e3c374c4cc380575513668fae0d","type":"TRIAL","name":"Long-Term Study of MP-214 in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01626872","description":"Schizophrenia","metadata":null},{"id":"3ab4ac4b2f4648d8b769b85e17f3f3d3","type":"TRIAL","name":"Long-Term Study of Nitisinone to Treat Alkaptonuria","canonical_id":"clinicaltrials.gov:NCT00107783","description":"Alkaptonuria","metadata":null},{"id":"41eeb9cb7238492db36731e26f1ac34f","type":"TRIAL","name":"Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04339595","description":"Plaque Psoriasis","metadata":null},{"id":"ce4c5687cbc7443d8e58849b8dda57e3","type":"TRIAL","name":"Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00845273","description":"Macular Degeneration","metadata":null},{"id":"c6d91f17c25944cea4b9f46c55f6c1d2","type":"TRIAL","name":"Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT05962788","description":"Adolescent Lupus Nephritis; Pediatric Lupus Nephritis","metadata":null},{"id":"e612df0dd493450cb300d0d3887cf609","type":"TRIAL","name":"Long-acting Beta Agonist Step Down Study","canonical_id":"clinicaltrials.gov:NCT01437995","description":"Asthma","metadata":null},{"id":"91dc6c2fa7ca40ecb111a82c0c99705e","type":"TRIAL","name":"Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02918825","description":"Schizophrenia","metadata":null},{"id":"bab0089459b543cd9c97b7e2a90c3ced","type":"TRIAL","name":"Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921","canonical_id":"clinicaltrials.gov:NCT03298061","description":"Churg-Strauss Syndrome; Eosinophilic Granulomatosis With Polyangiitis","metadata":null},{"id":"5672328c16ff4759a52151ef128d3828","type":"TRIAL","name":"Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529","canonical_id":"clinicaltrials.gov:NCT01342952","description":"Hypertension, Pulmonary","metadata":null},{"id":"eccb3ab6432f4d8689c93c5a41c589bd","type":"TRIAL","name":"Long-term Antipsychotic Pediatric Safety Trial","canonical_id":"clinicaltrials.gov:NCT03522168","description":"Weight, Body","metadata":null},{"id":"017c6e86db9e4431b9e6fcb0c0353b9f","type":"TRIAL","name":"Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy","canonical_id":"clinicaltrials.gov:NCT03181113","description":"Hepatitis B","metadata":null},{"id":"0ef471ffcf7a4ec9800c8fa1d37b831c","type":"TRIAL","name":"Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination","canonical_id":"clinicaltrials.gov:NCT01462942","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"78fd4dec41d244e2a33e2dac7149306d","type":"TRIAL","name":"Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)","canonical_id":"clinicaltrials.gov:NCT00472199","description":"Restless Legs Syndrome","metadata":null},{"id":"111a4def666241b2bc3e3f5e2383698c","type":"TRIAL","name":"Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164","canonical_id":"clinicaltrials.gov:NCT00650104","description":"Parkinson Disease","metadata":null},{"id":"fd4d27f570ab4b799924ab42a191196e","type":"TRIAL","name":"Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)","canonical_id":"clinicaltrials.gov:NCT00970268","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"17aadda26ebb412180a0fb4e41f72ede","type":"TRIAL","name":"Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)","canonical_id":"clinicaltrials.gov:NCT03038399","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"1da0796ec38f486a9e0675984dc350a3","type":"TRIAL","name":"Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND","canonical_id":"clinicaltrials.gov:NCT03587805","description":"Atopic Dermatitis","metadata":null},{"id":"d6554bea4cdc47adbcb4a9635a74f110","type":"TRIAL","name":"Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)","canonical_id":"clinicaltrials.gov:NCT01142596","description":"Schizophrenia","metadata":null},{"id":"d390b49522814dd088f8b75df8ad9379","type":"TRIAL","name":"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03232073","description":"Multiple Sclerosis","metadata":null},{"id":"85b4ec4f558f442485640a56ac6efbf9","type":"TRIAL","name":"Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants","canonical_id":"clinicaltrials.gov:NCT02065700","description":"Rheumatoid Arthritis","metadata":null},{"id":"9df2448451ad40caaf76fa8eb67855a5","type":"TRIAL","name":"Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00607256","description":"Fibromyalgia","metadata":null},{"id":"fdc83c66c28848d8af2c3c456376bc3e","type":"TRIAL","name":"Long-term Observational Study in HIV Subjects Exposed to EGRIFTA\u00ae","canonical_id":"clinicaltrials.gov:NCT01579695","description":"HIV","metadata":null},{"id":"f0bb4f793a174226a02ee625ccd6ece2","type":"TRIAL","name":"Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)","canonical_id":"clinicaltrials.gov:NCT00498186","description":"Restless Legs Syndrome","metadata":null},{"id":"b8e15cfa172a4e20b26714bd31bcb6fa","type":"TRIAL","name":"Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan","canonical_id":"clinicaltrials.gov:NCT01318135","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c9f923cc2e2e4f1e991b7639c284ecdc","type":"TRIAL","name":"Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","canonical_id":"clinicaltrials.gov:NCT01318122","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"dde902c53d42484b8e7cc3ba6b25f622","type":"TRIAL","name":"Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan","canonical_id":"clinicaltrials.gov:NCT01263496","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e414eb411334472abb91fe25c349645a","type":"TRIAL","name":"Long-term Safety Study of Brodalumab in Adults With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT01199302","description":"Crohn's Disease","metadata":null},{"id":"82a6c55d1ed34bffa995c72f529a4a5e","type":"TRIAL","name":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT02314637","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e9295cfdfab84ce4a758ad084dced672","type":"TRIAL","name":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01301833","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a55edb09ccce4c3e8a573381bab26f5e","type":"TRIAL","name":"Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD","canonical_id":"clinicaltrials.gov:NCT00577460","description":"Parkinson Disease","metadata":null},{"id":"eae884ef459c41218bd685473e791db6","type":"TRIAL","name":"Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson\u00b4s Disease (PD).","canonical_id":"clinicaltrials.gov:NCT00601523","description":"Parkinson Disease","metadata":null},{"id":"675173082a8540c39276b542caa0361d","type":"TRIAL","name":"Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)","canonical_id":"clinicaltrials.gov:NCT00701805","description":"Secondary Hyperparathyroidism; Hemodialysis","metadata":null},{"id":"91e408740fb84fbdafe35e0fd13f2d0b","type":"TRIAL","name":"Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT04743141","description":"Acute Treatment of Migraine","metadata":null},{"id":"5a8c0a15b96e4a50949c0a8a83ddfdb7","type":"TRIAL","name":"Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy","canonical_id":"clinicaltrials.gov:NCT07563634","description":"Epilepsy, Focal","metadata":null},{"id":"746d5a6252814315b678679adc6ce1b4","type":"TRIAL","name":"Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation","canonical_id":"clinicaltrials.gov:NCT06990529","description":"PIDs Linked to PI3K","metadata":null},{"id":"5fa676a49226447c9df9f692e3941a84","type":"TRIAL","name":"Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia","canonical_id":"clinicaltrials.gov:NCT02124746","description":"Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis; Polycythemia Vera; Essential Thrombocythemia","metadata":null},{"id":"027474dd541a4744b954e8b89f111252","type":"TRIAL","name":"Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03989206","description":"Moderate-to-Severe Atopic Dermatitis","metadata":null},{"id":"0324c392e480488980bf988c7e1b9177","type":"TRIAL","name":"Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01201356","description":"Relapsing Forms of Multiple Sclerosis","metadata":null},{"id":"8ed71a73df3f48aea9b31bbb160814d7","type":"TRIAL","name":"Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia","canonical_id":"clinicaltrials.gov:NCT01467661","description":"Essential Thrombocythemia (ET)","metadata":null},{"id":"f38a183584e144edbdf1e98136b6b123","type":"TRIAL","name":"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)","canonical_id":"clinicaltrials.gov:NCT01044459","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"40cbbeeadd51481ca04f419779c26f17","type":"TRIAL","name":"Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children","canonical_id":"clinicaltrials.gov:NCT01328886","description":"Allergic Asthma","metadata":null},{"id":"e3a9272af08e4032a05f32328ffa1741","type":"TRIAL","name":"Long-term Study Of Ropinirole In Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00329602","description":"Restless Legs Syndrome","metadata":null},{"id":"6c6469c24e1a43feb709accad6cdeaae","type":"TRIAL","name":"Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01456130","description":"Diabetes Mellitus","metadata":null},{"id":"c330f2fba18a44b98a5f630804d00fdf","type":"TRIAL","name":"Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)","canonical_id":"clinicaltrials.gov:NCT01244828","description":"Schizophrenia","metadata":null},{"id":"138188a8c2fc4ace8fcb0502a789fb98","type":"TRIAL","name":"Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact","canonical_id":"clinicaltrials.gov:NCT00141518","description":"Advanced Idiopathic Parkinson's Disease","metadata":null},{"id":"c15d86d1f1ac4d9fa16e8abaa682624a","type":"TRIAL","name":"Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)","canonical_id":"clinicaltrials.gov:NCT02952820","description":"Insomnia Disorder","metadata":null},{"id":"1486c430c513448da111fe96d80b6b4f","type":"TRIAL","name":"Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT02279173","description":"Immune Thrombocytopenia","metadata":null},{"id":"fb9d8b2babec4907ab70773c03f82465","type":"TRIAL","name":"Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study","canonical_id":"clinicaltrials.gov:NCT02949362","description":"Short Bowel Syndrome","metadata":null},{"id":"be1e9824e8f943118701b6554444b8c5","type":"TRIAL","name":"Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada","canonical_id":"clinicaltrials.gov:NCT06312189","description":"Chorea, Huntington","metadata":null},{"id":"57a4564f6db941ceac2ee4549fcd89eb","type":"TRIAL","name":"Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients","canonical_id":"clinicaltrials.gov:NCT00850343","description":"Rheumatoid Arthritis","metadata":null},{"id":"f838c3c3ef904430ba290f0aec4dc4e7","type":"TRIAL","name":"Long-term Use of Mifepristone in the Treatment of Adenomyosis","canonical_id":"clinicaltrials.gov:NCT05151016","description":"Adenomyosis; Mifepristone","metadata":null},{"id":"3240c3cc291a41fe81c4f98466c5d93c","type":"TRIAL","name":"Long-term Use of Romidepsin in Patients With CTCL","canonical_id":"clinicaltrials.gov:NCT02296398","description":"Cutaneous T-cell Lymphoma","metadata":null},{"id":"906240671ebc4ded94d4b2e39e5a9aff","type":"TRIAL","name":"Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS","canonical_id":"clinicaltrials.gov:NCT01668654","description":"Epilepsy","metadata":null},{"id":"9a7fb517a9dc4afc9798ee63087a6416","type":"TRIAL","name":"Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)","canonical_id":"clinicaltrials.gov:NCT06180278","description":"Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"38ef4f254b1546ad808bd17b983a1786","type":"TRIAL","name":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","canonical_id":"clinicaltrials.gov:NCT02893371","description":"Bipolar Disorder","metadata":null},{"id":"e2d21a64571c45d486f6a950f0caf1dc","type":"TRIAL","name":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","canonical_id":"clinicaltrials.gov:NCT03507257","description":"Early Onset Alzheimer Disease; Alzheimer Disease; Mild Cognitive Impairment","metadata":null},{"id":"1c21fd2b57ec4fc4b1536760fdf6bf77","type":"TRIAL","name":"Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT04576793","description":"Alzheimer Disease","metadata":null},{"id":"7e015bbc7832413da247c8c2dec33f4b","type":"TRIAL","name":"Longitudinal Study of Brain Amyloid imaGing in MEMENTO","canonical_id":"clinicaltrials.gov:NCT02164643","description":"Alzheimer's Disease (AD) and Related Disorders","metadata":null},{"id":"45ee695de5e44fd49a841b805c622a29","type":"TRIAL","name":"Longjohn Amgen Study - Effect of Denosumab...","canonical_id":"clinicaltrials.gov:NCT02444585","description":"Arthroplasty, Replacement, Hip","metadata":null},{"id":"0b937e2fb82f4c90b1af420a2914771b","type":"TRIAL","name":"Loop Diuretics in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00478543","description":"Chronic Kidney Disease","metadata":null},{"id":"2dc34b3f1a8c4f809a329ae0eceed411","type":"DRUG","name":"Loperamide","canonical_id":"mesh:D008139","description":null,"metadata":null},{"id":"92294c73684948efa92c707f37e58414","type":"TRIAL","name":"Loperamide Grapefruit Juice Interaction PK Trial","canonical_id":"clinicaltrials.gov:NCT00806299","description":"Drug Interaction","metadata":null},{"id":"693539501b58460a9d3d605b1e5c4b0b","type":"TRIAL","name":"Loratadine for the Prevention of G-CSF-related Bone Pain","canonical_id":"clinicaltrials.gov:NCT05421416","description":"Stem Cell Transplant Complications","metadata":null},{"id":"857cd37dc1944539b646590eb4a90774","type":"TRIAL","name":"Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization","canonical_id":"clinicaltrials.gov:NCT04211259","description":"Plasma Cell Myeloma","metadata":null},{"id":"afcebfe1c9444796927f85e9d1052263","type":"DRUG","name":"Lorazepam","canonical_id":"mesh:D008140","description":null,"metadata":null},{"id":"3d40e967d8174de598ed0e3015626c93","type":"DRUG","name":"Lorcaserin","canonical_id":"mesh:C506658","description":null,"metadata":null},{"id":"0a9020942eae49c3bae2a8abd602e6e3","type":"TRIAL","name":"Lorcaserin Intra Venous Cocaine Effects","canonical_id":"clinicaltrials.gov:NCT02680288","description":"Cocaine Use Disorders","metadata":null},{"id":"f71b81096a1a4d83968514739d2ce749","type":"TRIAL","name":"Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients","canonical_id":"clinicaltrials.gov:NCT03720574","description":"Obesity","metadata":null},{"id":"ce8dfd86f0e5456ebcfc1db003b1b168","type":"TRIAL","name":"Lorcaserin for Cannabis Use Disorder","canonical_id":"clinicaltrials.gov:NCT03637842","description":"Cannabis Use Disorder","metadata":null},{"id":"3fa26d8801484ccfa158e3fda22e1a83","type":"TRIAL","name":"Lorcaserin for Preventing Weight Gain Among Smokers","canonical_id":"clinicaltrials.gov:NCT02393547","description":"Tobacco Use Disorder; Weight Gain","metadata":null},{"id":"208f01db4f68469c9ad432a08fbd7d50","type":"TRIAL","name":"Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01962402","description":"Weight Gain","metadata":null},{"id":"def30cfd55614419bfa42cd0254dbb9e","type":"TRIAL","name":"Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder","canonical_id":"clinicaltrials.gov:NCT03169816","description":"Opioid-use Disorder","metadata":null},{"id":"e08c4cf82da54cf28dcdcce159b9325e","type":"TRIAL","name":"Lorcaserin in Obesity: Identification of CNS Targets Using fMRI","canonical_id":"clinicaltrials.gov:NCT02400359","description":"Obesity; Weight Loss","metadata":null},{"id":"0d070690c4fa4d95b7c20c73144390a0","type":"TRIAL","name":"Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04205071","description":"Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Chemotherapy-Induced Peripheral Neuropat\u2026","metadata":null},{"id":"67b9f9b5a9b54ce5952b8a6352df2125","type":"TRIAL","name":"Lorcaserin in the Treatment of Cocaine Use Disorder","canonical_id":"clinicaltrials.gov:NCT03007394","description":"Cocaine-Related Disorders","metadata":null},{"id":"46992c3c30d64db7bd14ad1da002f626","type":"TRIAL","name":"Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic","canonical_id":"clinicaltrials.gov:NCT03552107","description":"Obesity; Weight Loss; Overweight","metadata":null},{"id":"e25f99367667482e8cf26331bf9cc4d3","type":"DRUG","name":"Lorlatinib","canonical_id":"ncit:C113655","description":null,"metadata":null},{"id":"14b2d27ce4624ce6ac532289b4181e2e","type":"TRIAL","name":"Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04111705","description":"Non Small Cell Lung Cancer Metastatic","metadata":null},{"id":"db13634c5c784c6d81011a56364724db","type":"TRIAL","name":"Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)","canonical_id":"clinicaltrials.gov:NCT04621188","description":"Non Small Cell Lung Cancer Metastatic","metadata":null},{"id":"ed3aac0f391b4b0f9a8cb175f954a153","type":"TRIAL","name":"Lorlatinib Continuation Study","canonical_id":"clinicaltrials.gov:NCT05144997","description":"Non-Small-Cell Lung Cancer; NSCLC","metadata":null},{"id":"908428d4ee2c4386b013983d475bf624","type":"TRIAL","name":"Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT07750704","description":"ALK Positive Non-small Cell Lung Cancer","metadata":null},{"id":"296c2a3efd4345d8bf02221ec8cb0a73","type":"TRIAL","name":"Lorlatinib Renal Impairment Study","canonical_id":"clinicaltrials.gov:NCT03542305","description":"Renal Impairment","metadata":null},{"id":"ac07d2055f574f4fbee70e9efdecc4dc","type":"TRIAL","name":"Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06682884","description":"Neoadjuvant Non-Small Cell Lung Cancer","metadata":null},{"id":"125b5742907449439e62a176dc77e45b","type":"TRIAL","name":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","canonical_id":"clinicaltrials.gov:NCT06333899","description":"High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Infant Type Hemispheric Glioma; Glioblastoma; Glioblastoma Multiforme; WHO Grade III Glioma; WHO Grade IV Glioma; Diffuse Midline Glioma, H3K27-altered","metadata":null},{"id":"f3746fe1b96d4c89b8500d5479a84dfe","type":"TRIAL","name":"Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India","canonical_id":"clinicaltrials.gov:NCT04541706","description":"Advanced Non-Small Cell Lung Cancer","metadata":null},{"id":"d981b6b1d7de4439a4b720cb1777ad78","type":"TRIAL","name":"Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib","canonical_id":"clinicaltrials.gov:NCT05948462","description":"Lung Cancer; Non-small Cell Lung Cancer","metadata":null},{"id":"c848373cc9f84653af0001b83db1a5d1","type":"TRIAL","name":"Lorlatinib in ROS1+ NSCLC With Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT07083687","description":"Lung Cancer (NSCLC)","metadata":null},{"id":"345498ab41364cefb2133ba366978783","type":"DRUG","name":"Losartan","canonical_id":"mesh:D019808","description":null,"metadata":null},{"id":"8fc1cee279c04d5990b0b2acbf2bc5f3","type":"TRIAL","name":"Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01124175","description":"Healthy","metadata":null},{"id":"0a393e62783748999494ce9e5194eb11","type":"TRIAL","name":"Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)","canonical_id":"clinicaltrials.gov:NCT00338260","description":"Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)","metadata":null},{"id":"273f870fabc64ff799c1aa507214d242","type":"TRIAL","name":"Losartan Therapy in Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT00519870","description":"Pulmonary Hypertension","metadata":null},{"id":"805d2ce1b9554d20819839fb769c8387","type":"TRIAL","name":"Losartan and Emotion Processing","canonical_id":"clinicaltrials.gov:NCT03396523","description":"Healthy","metadata":null},{"id":"2d2cdf331c1e4e4aa26e94722cb4320b","type":"TRIAL","name":"Losartan and Emotional Learning","canonical_id":"clinicaltrials.gov:NCT06628154","description":"Emotional Processing","metadata":null},{"id":"174269f6a3fb4a3ca6c2668971da53ac","type":"TRIAL","name":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03563248","description":"Pancreatic Cancer","metadata":null},{"id":"9daee30a6592489985c8e5d79c1d0ad4","type":"TRIAL","name":"Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT05012631","description":"Sickle Cell Disease; Diffuse Myocardial Fibrosis","metadata":null},{"id":"4f38cd88b9f34b198d29fc39cdc78560","type":"TRIAL","name":"Loss of RESponse to Ustekinumab Treated by Dose Escalation","canonical_id":"clinicaltrials.gov:NCT04245215","description":"Crohn Disease","metadata":null},{"id":"67ac054f8bbc4a8a853b51acdc2a4c77","type":"DRUG","name":"Loteprednol etabonate","canonical_id":"mesh:D000069559","description":null,"metadata":null},{"id":"eb9caa28367f49e49e69df29523e2fcb","type":"TRIAL","name":"Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression","canonical_id":"clinicaltrials.gov:NCT04876521","description":"Post-Schizophrenic Depression","metadata":null},{"id":"5b3db1a12d28486c8e68f517a4a383c4","type":"TRIAL","name":"Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19","canonical_id":"clinicaltrials.gov:NCT04380818","description":"Pneumonia, Viral","metadata":null},{"id":"cd6087f4a86a4c948e140a93e372de68","type":"TRIAL","name":"Low Dose Apomorphine and Parkinsonism","canonical_id":"clinicaltrials.gov:NCT00472355","description":"Parkinson's Disease","metadata":null},{"id":"fb27dd996b2a4dcdbf354cd7d7318e61","type":"TRIAL","name":"Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00900653","description":"Urinary Tract Infections","metadata":null},{"id":"e3d75d3f313e49019302e1b52df273bf","type":"TRIAL","name":"Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT06364267","description":"Breast Cancer","metadata":null},{"id":"745532692b0f43458e64c246aab8eb17","type":"TRIAL","name":"Low Dose Magnesium Sulphate","canonical_id":"clinicaltrials.gov:NCT06621004","description":"Mean Arterial Pressure","metadata":null},{"id":"a8b38d21a7da4653aa450fb64cc7b3a7","type":"TRIAL","name":"Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy","canonical_id":"clinicaltrials.gov:NCT01966484","description":"Intubating Conditions; Performance With Respiratory Exercise Device; Postoperative Myalgia","metadata":null},{"id":"7010cc9004fd42b2ab242d4c99503d63","type":"TRIAL","name":"Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation","canonical_id":"clinicaltrials.gov:NCT03244930","description":"Lymphoma, Non-Hodgkin; Lymphoma, Hodgkin; Myeloma; Stem Cell Transplant Complications","metadata":null},{"id":"3612f4383dbb4736aa00c3d7bd3e7175","type":"TRIAL","name":"Low Dose Statins, Ezetimibe and Nutraceuticals","canonical_id":"clinicaltrials.gov:NCT03277079","description":"Coronary Artery Disease","metadata":null},{"id":"7f19b53e48504f01bfc9ac98962b1b5a","type":"TRIAL","name":"Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.","canonical_id":"clinicaltrials.gov:NCT04500860","description":"Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence","metadata":null},{"id":"e1a38e87ecc64af596bdf2a6cff9c623","type":"TRIAL","name":"Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT05388123","description":"Hairy Cell Leukemia","metadata":null},{"id":"106aa417e26f472daea3b707e34a5900","type":"TRIAL","name":"Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT00907374","description":"Microalbuminuria","metadata":null},{"id":"c44e98161ad145c5a1c40161603926e7","type":"TRIAL","name":"Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01004601","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"cfc40fdf55c04ee0b356d3ef100b8fff","type":"TRIAL","name":"Low Dose of Diltiazem for Rate Control of Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT00834925","description":"Atrial Fibrillation","metadata":null},{"id":"5d119c63001b4f3892acefa72e38cebd","type":"DISEASE","name":"Low Grade Glioma","canonical_id":"doid:0080829","description":null,"metadata":null},{"id":"224e50c13b0149858b27b76e2aca42fb","type":"TRIAL","name":"Low Level Laser Therapy Plus Topical Clonazepam Treatment to Burning Mouth Symdrome","canonical_id":"clinicaltrials.gov:NCT04313907","description":"Burning Mouth Syndrome","metadata":null},{"id":"b640fefe72e6403b96443080e82a8ca6","type":"TRIAL","name":"Low Level Laser Therapy in the Treatment of Temporomandibular Joint Disorders (TMJDs) Related Pain","canonical_id":"clinicaltrials.gov:NCT03119324","description":"Temporomandibular Joint Disorders","metadata":null},{"id":"22ba62677c72404a944859274afebe33","type":"TRIAL","name":"Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management","canonical_id":"clinicaltrials.gov:NCT02129608","description":"Overweight; Obese","metadata":null},{"id":"88e41a990317407188e66193e190542d","type":"TRIAL","name":"Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy","canonical_id":"clinicaltrials.gov:NCT07561060","description":"Rectal Cancer","metadata":null},{"id":"5f16e102337a4d99859731552d9198d2","type":"DISEASE","name":"Low back pain","canonical_id":"hp:0003419","description":null,"metadata":null},{"id":"cfe676217ac94581bf4813766cb546ee","type":"DISEASE","name":"Low blood pressure","canonical_id":"mesh:D007022","description":null,"metadata":null},{"id":"11397c639e1545569bb8037087bad8c0","type":"DISEASE","name":"Low cardiac output syndrome","canonical_id":"mesh:D002303","description":null,"metadata":null},{"id":"cbfe63ab65174a419dd152c3b03c6167","type":"TRIAL","name":"Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice","canonical_id":"clinicaltrials.gov:NCT07615166","description":"Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"4bb8ab5cc76d4220819ba14a27e923e8","type":"TRIAL","name":"Low-Dose Danazol for the Treatment of Telomere Related Diseases","canonical_id":"clinicaltrials.gov:NCT03312400","description":"Telomere Disease","metadata":null},{"id":"b9fc05290b4e4aed8bc39980c8cf0c99","type":"TRIAL","name":"Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)","canonical_id":"clinicaltrials.gov:NCT03201393","description":"Chronic Low Back Pain; Lumbar Radiculopathy","metadata":null},{"id":"efaa9a7bf5d24880862080cb12fe898b","type":"TRIAL","name":"Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder","canonical_id":"clinicaltrials.gov:NCT07844694","description":"Familial Platelet Disorder With Associated Myeloid Malignancy","metadata":null},{"id":"db88fd04210b4be080960cf51edd00f7","type":"TRIAL","name":"Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor","canonical_id":"clinicaltrials.gov:NCT05782816","description":"Labor Long","metadata":null},{"id":"8aaf8cfad0da450db5077c72b7d1935d","type":"TRIAL","name":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03147612","description":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia With BCR-ABL1; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia","metadata":null},{"id":"af0e89759edd4ac092d53b7a84b7a5d6","type":"TRIAL","name":"Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00923845","description":"Renal Cell Carcinoma; Graft-Versus-Host Disease; Engraftment Syndrome","metadata":null},{"id":"43d41cc06e904221847afbef7462564f","type":"PROTEIN","name":"Low-density lipoprotein receptor","canonical_id":"uniprot:P01130","description":null,"metadata":null},{"id":"5b6fd1acc98c4eabbbaf6518e762a074","type":"TRIAL","name":"Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05852847","description":"Immune Thrombocytopenia","metadata":null},{"id":"0e313c81d7434ff9993d2e67da6df4ac","type":"TRIAL","name":"Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT02035891","description":"Diabetic Nephropathy","metadata":null},{"id":"882661bf691749598fdbe6055daed50f","type":"TRIAL","name":"Low-dose Combination of Three Antihypertensive Drugs","canonical_id":"clinicaltrials.gov:NCT02710552","description":"Arterial Hypertension","metadata":null},{"id":"348efa682f9042778888e66d7799be00","type":"TRIAL","name":"Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial","canonical_id":"clinicaltrials.gov:NCT06756945","description":"ST-elevation Myocardial Infarction (STEMI)","metadata":null},{"id":"d5c630bd60134a3a96507e9526cc38fe","type":"TRIAL","name":"Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","canonical_id":"clinicaltrials.gov:NCT04340349","description":"Hydroxychloroquine; Antimalarials; Enzyme Inhibitors; Antirheumatic Agents","metadata":null},{"id":"72fec2c84c13404e9f995e2bd982bf91","type":"TRIAL","name":"Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00708721","description":"Cancer; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"f436b2f74cfe40a58dc848214e73ebf3","type":"TRIAL","name":"Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma","canonical_id":"clinicaltrials.gov:NCT06494189","description":"Head and Neck Cancer","metadata":null},{"id":"4957fa2b7950472186034df484e53ea0","type":"TRIAL","name":"Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children","canonical_id":"clinicaltrials.gov:NCT06763315","description":"Plexiform Neurofibromas (PN)","metadata":null},{"id":"40d6af3717c044c7a20f35cc62699808","type":"TRIAL","name":"Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT01599871","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"d97c838b33b2467eaf433cbc607e6f56","type":"TRIAL","name":"Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women","canonical_id":"clinicaltrials.gov:NCT07473310","description":"Overactive Bladder (OAB); Urge Incontinence","metadata":null},{"id":"13ddb09dbb544e638ea6ebc46b792dd8","type":"TRIAL","name":"Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization","canonical_id":"clinicaltrials.gov:NCT02479555","description":"Chronic Limb Ischemia","metadata":null},{"id":"f3e06accfbd1449ab286ee9c666a79ec","type":"TRIAL","name":"Lowering Uric Acid in Live Kidney Donors","canonical_id":"clinicaltrials.gov:NCT03353298","description":"Renal Transplant Donor of Left Kidney; Renal Transplant Donor of Right Kidney","metadata":null},{"id":"c592bd898d4943ff94e760f5fdce1757","type":"TRIAL","name":"Loxapine and Weaning From Ventilator","canonical_id":"clinicaltrials.gov:NCT00122733","description":"Respiratory Insufficiency; Psychomotor Agitation","metadata":null},{"id":"4d5488ecdb084c73b12cd92693711a9a","type":"TRIAL","name":"Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning","canonical_id":"clinicaltrials.gov:NCT01193816","description":"Restlessness","metadata":null},{"id":"fb9c1dead5114155ad60d2bb75db17a4","type":"TRIAL","name":"Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT07099274","description":"HCC","metadata":null},{"id":"8750e22b31234b7ea619c4a68c1e49cb","type":"GO_TERM","name":"Lsd1/2 complex","canonical_id":"go:GO:0033193","description":"\"A nucleosome-binding protein complex that comprises two SWIRM domain histone demethylases and two PHD finger proteins. The complex is involved in transcriptional regulation via heterochromatic silencing and the regulation of chromatin boundary formation, and was first identified in fission yeast.\" [GOC:vw, PMID:17371846, PMID:17434129, PMID:17440621]","metadata":null},{"id":"639b39c443e34b80b6d4da10782658f2","type":"GO_TERM","name":"Lsm-containing SMN-Sm protein complex","canonical_id":"go:GO:0034731","description":"\"An SMN-Sm protein complex formed by the association of the methylated Sm proteins B/B', D3, E, F, and G, and Lsm10 and Lsm11, with the SMN complex. This complex forms Sm cores on U7 snRNA.\" [PMID:12975319, PMID:17401408]","metadata":null},{"id":"c6b11ab5969a4a4f9d181b65113953ca","type":"GO_TERM","name":"Lsm1-7-Pat1 complex","canonical_id":"go:GO:1990726","description":"\"A conserved, heteroheptameric, cytoplasmic protein complex composed of Lsm1, Lsm2, Lsm3, Lsm4, Lsm5, Lsm6, Lsm7, and Pat1, or orthologs thereof, that shows a strong binding preference for oligoadenylated RNAs over polyadenylated RNAs. May bind further associated proteins. Facilitates the deadenylation-dependent decapping of mRNA in the P-body thereby regulating mRNA decay and subsequent degradation by the 5' to 3' pathway.\" [GOC:bhm, GOC:krc, PMID:19121818, PMID:23620288, PMID:24139796, PMID:27627834, PMID:28768202]","metadata":null},{"id":"a45e036c908b4ab381ffae19fd37cdfe","type":"GO_TERM","name":"Lsm2-8 complex","canonical_id":"go:GO:0120115","description":"\"A heteroheptameric, nuclear protein complex composed of Lsm2, Lsm3, Lsm4, Lsm5, Lsm6, Lsm7, and Lsm8, or orthologs thereof, that selectively binds to snRNAs, in particular U6 or U6atac snRNAs, and also to unspliced transcripts localized within the nucleus.\" [GOC:bhm, GOC:krc, PMID:19121818, PMID:23221597, PMID:27627834, PMID:28768202]","metadata":null},{"id":"62d89456eb9b4cf9a8d97aab651d59b0","type":"TRIAL","name":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","canonical_id":"clinicaltrials.gov:NCT04086485","description":"Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms","metadata":null},{"id":"2cf3d1a60fcc4b0ab318e8e76f4bfa31","type":"TRIAL","name":"Lubiprostone (Amitiza\u00ae) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation","canonical_id":"clinicaltrials.gov:NCT00662363","description":"Constipation","metadata":null},{"id":"3309cfabc9f54f25bd1c0c48d03c8b95","type":"TRIAL","name":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07405736","description":"Colorectal Cancer Metastatic; Peritoneal (Metastatic) Cancer; Peritoneal Metastasis; Colorectal Cancer (CRC); MSS Metastatic Colorectal Cancer","metadata":null},{"id":"f44554f76f244f95bdc1e3881ac34186","type":"TRIAL","name":"Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT01469819","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"8f8eaeb2bba0423db8441051df54f53e","type":"TRIAL","name":"Lubiprostone Effects on Visceral Pain Sensitivity","canonical_id":"clinicaltrials.gov:NCT01166789","description":"Irritable Bowel Syndrome","metadata":null},{"id":"b7d8170eb74f47fa91a69e1add6be0ec","type":"TRIAL","name":"Lubiprostone and Mucus Secretion in Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT01447849","description":"Constipation","metadata":null},{"id":"e294e2c0708f495c813e11a28507c375","type":"TRIAL","name":"Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy","canonical_id":"clinicaltrials.gov:NCT01839734","description":"HIV","metadata":null},{"id":"8fcd210d96d4456ca1b04bad84d7192f","type":"TRIAL","name":"Lubiprostone as a Treatment for Constipation in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00669461","description":"Constipation; Parkinson's Disease","metadata":null},{"id":"12e9da47a3b44c08ac693d0cbd71a300","type":"TRIAL","name":"Lubiprostone for Children With Constipation","canonical_id":"clinicaltrials.gov:NCT02138136","description":"Constipation - Functional","metadata":null},{"id":"9e3049fd5249454cb824d508000eb153","type":"TRIAL","name":"Lubiprostone for Chronic Idiopathic Constipation Treatment","canonical_id":"clinicaltrials.gov:NCT02729909","description":"Constipation","metadata":null},{"id":"bbbbb84217f749cfb36a331325e0a5d4","type":"TRIAL","name":"Lubiprostone for Functional Constipation in the Under 18 Years Patients","canonical_id":"clinicaltrials.gov:NCT05144295","description":"Clinical Efficacy; Treatment Efficacy; Drug Side Effect","metadata":null},{"id":"5d7c5deb15d14994b307c9568895e063","type":"TRIAL","name":"Lubiprostone for Treatment of Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT02695719","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"95bde8f4e05d48d2904ec0af5e2fb176","type":"TRIAL","name":"Lubiprostone for the Treatment of Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT02651155","description":"Constipation","metadata":null},{"id":"413e9140c7fb4f3dba0031e1540cbc51","type":"TRIAL","name":"Lubiprostone in Children With Functional Constipation","canonical_id":"clinicaltrials.gov:NCT02042183","description":"Constipation - Functional","metadata":null},{"id":"89bdf992c70848959c03b217c7876a0d","type":"TRIAL","name":"Lubiprostone in Patients With Multiple Sclerosis Associated Constipation","canonical_id":"clinicaltrials.gov:NCT01236534","description":"Multiple Sclerosis; Constipation","metadata":null},{"id":"931143a5f1b34cfda61dc8d164237390","type":"TRIAL","name":"Lubiprostone, Colonic Motility and Sensation","canonical_id":"clinicaltrials.gov:NCT00953043","description":"Healthy","metadata":null},{"id":"cddfd9e4a31d4e8b8b28eff8477cdb9c","type":"TRIAL","name":"Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation","canonical_id":"clinicaltrials.gov:NCT01223612","description":"Diabetic Retinopathy","metadata":null},{"id":"218a63e4c6ef4fbdb003e7ad98c30fde","type":"TRIAL","name":"Lucentis Versus Mitomycin C During Glaucoma Surgery","canonical_id":"clinicaltrials.gov:NCT00626782","description":"Glaucoma","metadata":null},{"id":"7111d934fc6a4b8688c90ab7367210ea","type":"GO_TERM","name":"Lugaro cell differentiation","canonical_id":"go:GO:0021708","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature Lugaro cell. Differentiation includes the processes involved in commitment of a neuroblast to a Lugaro cell fate. A Lugaro cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"cf249c763a9d438aaf8d0f5fbdc9f7ed","type":"DRUG","name":"Lumacaftor","canonical_id":"mesh:C569105","description":null,"metadata":null},{"id":"75f5b54e04304d85baebefc2b7cf4cf3","type":"TRIAL","name":"Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT04866355","description":"Women With Primary Dysmenorrhea","metadata":null},{"id":"5ca5ae34e5ed42459037f861b8d8daa3","type":"TRIAL","name":"Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC","canonical_id":"clinicaltrials.gov:NCT00806819","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"e6d44ecf4fde418191f3230f0f26dec9","type":"TRIAL","name":"Lumigan Versus Cosopt","canonical_id":"clinicaltrials.gov:NCT00273455","description":"Open-Angle Glaucoma","metadata":null},{"id":"6177c0b60c7a424584ae6a9d864231eb","type":"TRIAL","name":"Lumigan\u00ae in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","canonical_id":"clinicaltrials.gov:NCT01628588","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"b15f46b80a2445f0a13a964d731b5dcf","type":"DRUG","name":"Luminespib","canonical_id":"ncit:C71467","description":null,"metadata":null},{"id":"e22026ac9e7f44e1baf9f59acf933e56","type":"TISSUE","name":"Lung","canonical_id":"uberon:UBERON:0008952","description":null,"metadata":null},{"id":"fd6387c893d64bd3a412674343a61ad9","type":"DISEASE","name":"Lung Abscess","canonical_id":"mesh:D008169","description":null,"metadata":null},{"id":"c9aa17270c354bfe8507cd3e9e617ac0","type":"DISEASE","name":"Lung Adenocarcinoma","canonical_id":"doid:3910","description":null,"metadata":null},{"id":"039255f718e84084ba2085ef4560bdf8","type":"DISEASE","name":"Lung Cancer","canonical_id":"doid:1324","description":null,"metadata":null},{"id":"302c83f44c12474e9175f7bfbee1c138","type":"DISEASE","name":"Lung Carcinoma","canonical_id":"doid:3905","description":null,"metadata":null},{"id":"7938a65a92014a85a63434e81e18d7c6","type":"TRIAL","name":"Lung Deposition of TRIMBOW\u00ae pMDI in Healthy Volunteers, Asthmatic and COPD Patients","canonical_id":"clinicaltrials.gov:NCT03795350","description":"Chronic Obstructive Pulmonary Disease; Asthma","metadata":null},{"id":"30528cb29ee6490ab422e8fa8349175d","type":"DISEASE","name":"Lung Diseases","canonical_id":"mesh:D008171","description":null,"metadata":null},{"id":"774016b67d0447c997beb431de9ec884","type":"DISEASE","name":"Lung Neoplasms","canonical_id":"mesh:D008175","description":null,"metadata":null},{"id":"2ebfa39581054b91bcb08bf8053229cd","type":"DISEASE","name":"Lung Non-small Cell Carcinoma","canonical_id":"doid:3908","description":null,"metadata":null},{"id":"8f825ff84b5a40c5810effcb8b0758a6","type":"DISEASE","name":"Lung Small Cell Carcinoma","canonical_id":"doid:5409","description":null,"metadata":null},{"id":"8e526eff142645eb8893a9c6f0252231","type":"TRIAL","name":"Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization","canonical_id":"clinicaltrials.gov:NCT03805178","description":"Lung Transplant Rejection; Antibody-mediated Rejection","metadata":null},{"id":"bc26caf662384e298e532cc218635c15","type":"TRIAL","name":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02154490","description":"Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7","metadata":null},{"id":"899b927b42a1422789367ee5ce0f017d","type":"TRIAL","name":"Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03377556","description":"ATM Gene Mutation; ATR Gene Mutation; BARD1 Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; FANCC Gene Mutation; FANCD2 Gene Mutation; FANCF Gene Mutation; FANCM Gene Mutation; NBN Gene Mutation; PALB2 Gene Mutation; RAD51 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation; Recurrent Squamous Cell Lung Carcinoma; RPA1 Gene Mutation; Stage IV Squamous Cell Lung Carcinoma AJCC v7","metadata":null},{"id":"5e708bddc82a4dc0b43802ab891985b1","type":"TRIAL","name":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","canonical_id":"clinicaltrials.gov:NCT00868452","description":"Bipolar Depression","metadata":null},{"id":"8dcc657c31a249ceb500268820000f25","type":"TRIAL","name":"Lurasidone Effects on Tissue Glutamate in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02199743","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"245d73f1c72941028a88516a0ad60e9e","type":"TRIAL","name":"Lurasidone Extended Use Study","canonical_id":"clinicaltrials.gov:NCT01485640","description":"Schizophrenia; Bipolar Disorder","metadata":null},{"id":"f4b5f7c60ff44d0d815b0e4b412d2d80","type":"TRIAL","name":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","canonical_id":"clinicaltrials.gov:NCT00790192","description":"Schizophrenia","metadata":null},{"id":"0213fcb95d424d4ab331eaf817096de8","type":"TRIAL","name":"Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00641745","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"47d8db31869c4727939d713ab1221ec9","type":"TRIAL","name":"Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00615433","description":"Schizophrenia","metadata":null},{"id":"35295d22c4404d6394bc008e6befa253","type":"TRIAL","name":"Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00549718","description":"Schizophrenia","metadata":null},{"id":"7c446786cbb342e88147cb67011368c9","type":"TRIAL","name":"Lurasidone Low-Dose - High-Dose Study Study","canonical_id":"clinicaltrials.gov:NCT01821378","description":"Schizophrenia","metadata":null},{"id":"deaad50be8ce4feeb15fb856bd024bd8","type":"TRIAL","name":"Lurasidone Non-Interventional Study in Schizophrenia Patients","canonical_id":"clinicaltrials.gov:NCT06527885","description":"Schizophrenia","metadata":null},{"id":"b7bb0c73779045c69833814c75eb0499","type":"TRIAL","name":"Lurasidone Pediatric Bipolar Study","canonical_id":"clinicaltrials.gov:NCT02046369","description":"Bipolar I Depression","metadata":null},{"id":"d5eaffa3f02249a092bcb9c2b2e9ea09","type":"TRIAL","name":"Lurasidone Pediatric Pharmacokinetics Study","canonical_id":"clinicaltrials.gov:NCT01620060","description":"Schizophrenia; Autism","metadata":null},{"id":"bfb99a3a647b46858e6709df99acd35c","type":"TRIAL","name":"Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03304457","description":"Schizophrenia","metadata":null},{"id":"4861d5fb62714d3b9a738da962484ea9","type":"TRIAL","name":"Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma","canonical_id":"clinicaltrials.gov:NCT05042934","description":"Metastatic Ewing Sarcoma; Recurrent Ewing Sarcoma","metadata":null},{"id":"e4a3f1cfdbd340ab93ef0b0b67704e7c","type":"TRIAL","name":"Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery","canonical_id":"clinicaltrials.gov:NCT06673498","description":"Thrombocytopenia","metadata":null},{"id":"358bb8e757594e07990339e463736e05","type":"TRIAL","name":"Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT06287567","description":"Idiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia","metadata":null},{"id":"efe9a02629804acfb831270a912f2372","type":"TRIAL","name":"Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)","canonical_id":"clinicaltrials.gov:NCT02392520","description":"Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"dbf40619c35d425e9a9d000ca44ed774","type":"TRIAL","name":"Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles","canonical_id":"clinicaltrials.gov:NCT06150703","description":"In Vitro Fertilization; ICSI Intracytoplasmic Spermatozoid Injection","metadata":null},{"id":"79382413826d4bbf9bcb384c5325eae6","type":"TRIAL","name":"Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT02024984","description":"PCOS","metadata":null},{"id":"8c1fda5b3a474fc4bf3e071d12f8344a","type":"TRIAL","name":"Luteal Support in Frozen-Thawed Embryo Transfer Cycles","canonical_id":"clinicaltrials.gov:NCT03948022","description":"Implantation; Placenta; Pregnancy Loss; Frozen Embryo; Luteal Support; Luteal Phase Defect; Assisted Reproduction","metadata":null},{"id":"c259a7a763c0433fa7e3db67ff899df6","type":"TRIAL","name":"Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00293540","description":"Breast Cancer","metadata":null},{"id":"06e2c9ea4e454791bf39800f9f66b66e","type":"TRIAL","name":"Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03336983","description":"Prostate Cancer; Bone Metastases","metadata":null},{"id":"f1479c55814c4a56aab64eca62c31d78","type":"TRIAL","name":"Luvometinib in Combination With Serplulimab for NF2-Related Tumors","canonical_id":"clinicaltrials.gov:NCT07708285","description":"NF2-related Schwannomatosis; NF2; Neurofibromatosis Type 2; Vestibular Schwannoma; Meningioma","metadata":null},{"id":"a9990066a9d94b438140af6cdf48f987","type":"TRIAL","name":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06593548","description":"CRC; MSS; Metastatic Cancer","metadata":null},{"id":"c62f0265655f414e83d257f252f4751f","type":"TRIAL","name":"Lybrido for Female Sexual Dysfunction","canonical_id":"clinicaltrials.gov:NCT01432665","description":"Hypoactive Sexual Desire Disorder","metadata":null},{"id":"83723ba46fab4717bdb92c2fff6691c1","type":"TRIAL","name":"Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems","canonical_id":"clinicaltrials.gov:NCT01743235","description":"Hypoactive Sexual Desire Disorder","metadata":null},{"id":"285d4788f6da4b0691dfdeef0b8d8526","type":"TRIAL","name":"Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder","canonical_id":"clinicaltrials.gov:NCT02101203","description":"Hypoactive Sexual Desire Disorder","metadata":null},{"id":"075d5aa6729c492ea31d17f2690b17dd","type":"DISEASE","name":"Lyme Disease","canonical_id":"mesh:D008193","description":null,"metadata":null},{"id":"cdf98b22274c4446bc4055ac4152786b","type":"DISEASE","name":"Lymphatic filariasis","canonical_id":"mesh:D004604","description":null,"metadata":null},{"id":"38ed896b01d64aaf9cb27233dcffb46f","type":"TRIAL","name":"Lymphedema Treatment Registry","canonical_id":"clinicaltrials.gov:NCT04272372","description":"Breast Cancer Lymphedema","metadata":null},{"id":"2b870a2c41c04c6f8d171ffcb5a39124","type":"TRIAL","name":"Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT00001832","description":"Melanoma; Neoplasm Metastasis","metadata":null},{"id":"d2e78014a9254c419735c755b65b2b4b","type":"TRIAL","name":"Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT01541072","description":"Non Hodgkin Lymphoma","metadata":null},{"id":"0ee7f92b08d24b16b19e136a08c17b02","type":"DISEASE","name":"Lymphogranuloma venereum","canonical_id":"mesh:D008219","description":null,"metadata":null},{"id":"92aabc7a34bf494e8a89eee3b87da2ff","type":"PROTEIN","name":"Lysosomal acid glucosylceramidase","canonical_id":"uniprot:P04062","description":null,"metadata":null},{"id":"a492420be56549d49b1208532d2e4741","type":"DISEASE","name":"Lysosomal alpha-1,4-glucosidase deficiency - infantile onset","canonical_id":"mesh:D006009","description":null,"metadata":null},{"id":"17d8ea3ddf954bf59b6de9139e8979e9","type":"TRIAL","name":"Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding","canonical_id":"clinicaltrials.gov:NCT01190150","description":"Menorrhagia","metadata":null},{"id":"4dabcb37d5f2440a902e6079c03ce820","type":"GO_TERM","name":"M band","canonical_id":"go:GO:0031430","description":"\"The midline of aligned thick filaments in a sarcomere; location of specific proteins that link thick filaments. Depending on muscle type the M band consists of different numbers of M lines.\" [GOC:mtg_muscle, ISBN:0198506732, ISBN:0815316194]","metadata":null},{"id":"fa7dba8c4e2e4d44a63dfb36d796abac","type":"GO_TERM","name":"M phase","canonical_id":"go:GO:0000279","description":"\"A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"6af47561d50449afa80aa68d9d6974a9","type":"GO_TERM","name":"M/G1 phase-specific MADS box-forkhead transcription factor complex","canonical_id":"go:GO:0097221","description":"\"A protein complex that contains a MADS-box protein and two forkhead domain proteins, and binds to and regulates transcription from promoters of genes transcribed during the M/G1 transition of the cell cycle. In Schizosaccharomyces pombe, the complex contains the MADS-box protein Mbx1 and two forkhead proteins, Sep1 and Fkh2.\" [GOC:mah, PMID:18057023]","metadata":null},{"id":"ba8e4bd6813c49cab448e686c12dbcdf","type":"GENE","name":"M1AP","canonical_id":"hgnc:HGNC:25183","description":"meiosis 1 associated protein","metadata":{"aliases":["D6Mm5e","SPATA37","C2orf65"]}},{"id":"05bfa7fbbec346a7ad27c85dd3ba51e7","type":"GENE","name":"M6PR","canonical_id":"hgnc:HGNC:6752","description":"mannose-6-phosphate receptor, cation dependent","metadata":{"aliases":["CD-MPR","CD-M6PR"]}},{"id":"ef94cdcb51f34afeb160f760961f6048","type":"GENE","name":"M6PRP1","canonical_id":"hgnc:HGNC:55051","description":"M6PR pseudogene 1","metadata":null},{"id":"633befebe7ff46ba8cbd6cf1af0d1837","type":"TRIAL","name":"MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen","canonical_id":"clinicaltrials.gov:NCT00531336","description":"Macular Degeneration","metadata":null},{"id":"ff1fd5ddf5a1490588f9c314c21d2445","type":"GENE","name":"MAB21L1","canonical_id":"hgnc:HGNC:6757","description":"mab-21 like 1","metadata":{"aliases":["CAGR1"]}},{"id":"176132759ba748fbab12ce4c48a82021","type":"GENE","name":"MAB21L2","canonical_id":"hgnc:HGNC:6758","description":"mab-21 like 2","metadata":null},{"id":"78414a489c22404c847c2577f70abce3","type":"GENE","name":"MAB21L3","canonical_id":"hgnc:HGNC:26787","description":"mab-21 like 3","metadata":{"aliases":["FLJ38716","D5","C1orf161"]}},{"id":"aeed93d7cc0a487f863a23ca47479438","type":"GENE","name":"MAB21L4","canonical_id":"hgnc:HGNC:26216","description":"mab-21 like 4","metadata":{"aliases":["FLJ22671","C2orf54"]}},{"id":"c8898abd7016402da8aa6758be1a3e86","type":"GENE","name":"MACC1","canonical_id":"hgnc:HGNC:30215","description":null,"metadata":null},{"id":"8f13bddd0c1742e4adc1fc03ba67c061","type":"GENE","name":"MACC1-AS1","canonical_id":"hgnc:HGNC:41257","description":"MACC1 antisense RNA 1","metadata":null},{"id":"dea35ae039d94f3cb271249bf0960874","type":"GENE","name":"MACC1-OT1","canonical_id":"hgnc:HGNC:58196","description":"MACC1 3' UTR overlapping transcript 1","metadata":null},{"id":"a3fa94de46ed474387c140b56b254509","type":"GENE","name":"MACF1","canonical_id":"hgnc:HGNC:13664","description":"microtubule actin crosslinking factor 1","metadata":{"aliases":["KIAA0465","ACF7","ABP620","KIAA1251","MACF","FLJ45612","FLJ46776","Lnc-PMIF","KIAA0754"]}},{"id":"b7594433c76e4cb5a8171c8fd30a35cf","type":"GENE","name":"MACIR","canonical_id":"hgnc:HGNC:25052","description":"macrophage immunometabolism regulator","metadata":{"aliases":["FLJ25291","C5orf30"]}},{"id":"bd74813450d7459cb89e3c68cbe02e6c","type":"GENE","name":"MACO1","canonical_id":"hgnc:HGNC:25572","description":"macoilin 1","metadata":{"aliases":["FLJ10747","TMEM57"]}},{"id":"895b12dba9db4cac9ddbb11754f4a276","type":"GENE","name":"MACORIS","canonical_id":"hgnc:HGNC:53963","description":"macrophage enriched lincRNA repressor of IFN-gamma signaling","metadata":null},{"id":"6b6e3fbfd6ba408a8ef3ad7716733f69","type":"GENE","name":"MACROD1","canonical_id":"hgnc:HGNC:29598","description":null,"metadata":null},{"id":"7bcb8a9754324a72a2b730d8e7e43c6b","type":"GENE","name":"MACROD2","canonical_id":"hgnc:HGNC:16126","description":"mono-ADP ribosylhydrolase 2","metadata":{"aliases":["dJ631M13.5","C20orf133"]}},{"id":"5d8eeec97ae8486fb039bd505cf86b2b","type":"GENE","name":"MACROD2-AS1","canonical_id":"hgnc:HGNC:37193","description":"MACROD2 antisense RNA 1","metadata":{"aliases":["BA318C17.1","NCRNA00186"]}},{"id":"64937cbcfaea40ffa52ed3c7ef872cd9","type":"GENE","name":"MACROD2-IT1","canonical_id":"hgnc:HGNC:16201","description":"MACROD2 intronic transcript 1","metadata":{"aliases":["bA467D7.4","C20orf68","NCRNA00227"]}},{"id":"db711a5cf402410e81f609b0f95802e4","type":"GENE","name":"MACROH2A1","canonical_id":"hgnc:HGNC:4740","description":"macroH2A.1 histone","metadata":{"aliases":["macroH2A1.2","H2AFY"]}},{"id":"50754e99ffd4413c898a4c4eda2b1e61","type":"GENE","name":"MACROH2A2","canonical_id":"hgnc:HGNC:14453","description":"macroH2A.2 histone","metadata":{"aliases":["H2AFY2"]}},{"id":"c4a4d90f34644d888ee28e8d77c4ca56","type":"TRIAL","name":"MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study","canonical_id":"clinicaltrials.gov:NCT06543082","description":"Acute Coronary Syndrome","metadata":null},{"id":"62ba07003c4e4bf8b8db77aee59bad34","type":"GO_TERM","name":"MAD1 complex","canonical_id":"go:GO:1990706","description":"\"A protein complex involved in the assembly of the mitotic checkpoint complex that in turn inhibits the anaphase promoting complex/cyclosome (APC/C).\" [GOC:bhm, intAct:EBI-10691224, PMID:22493223, PMID:22898774]","metadata":null},{"id":"d56685c757844908af410b36c23685fe","type":"GENE","name":"MAD1L1","canonical_id":"hgnc:HGNC:6762","description":null,"metadata":null},{"id":"1833e483f2664f3b82c0848ec826af4b","type":"GENE","name":"MAD2L1","canonical_id":"hgnc:HGNC:6763","description":null,"metadata":null},{"id":"0fc4d58010df40d69ae7fcd8a437d51b","type":"GENE","name":"MAD2L1-DT","canonical_id":"hgnc:HGNC:55546","description":"MAD2L1 divergent transcript","metadata":null},{"id":"c00baae8ebe4446ca8400b85830043f4","type":"GENE","name":"MAD2L1BP","canonical_id":"hgnc:HGNC:21059","description":"MAD2L1 binding protein","metadata":{"aliases":["CMT2","KIAA0110","dJ261G23.1","p31comet"]}},{"id":"ca5ee7cf9a504249b01cf668489c2e3f","type":"GENE","name":"MAD2L1P1","canonical_id":"hgnc:HGNC:20019","description":"mitotic arrest deficient 2 like 1 pseudogene 1","metadata":{"aliases":["MAD2L1P"]}},{"id":"c76b38ef0de94a32b766fb80bc803701","type":"GENE","name":"MAD2L2","canonical_id":"hgnc:HGNC:6764","description":"mitotic arrest deficient 2 like 2","metadata":{"aliases":["MAD2B","REV7","POLZ2","FANCV"]}},{"id":"059db5da30c14f8d833f53058d55c99b","type":"GENE","name":"MADCAM1","canonical_id":"hgnc:HGNC:6765","description":null,"metadata":null},{"id":"4fd92c825d2546039874d4660d2496bc","type":"GENE","name":"MADCAM1-AS1","canonical_id":"hgnc:HGNC:55315","description":"MADCAM1 antisense RNA 1","metadata":null},{"id":"d35e03746ed1458a9336847eb2025471","type":"GENE","name":"MADD","canonical_id":"hgnc:HGNC:6766","description":"MAP kinase activating death domain","metadata":{"aliases":["DENN","KIAA0358","RAB3GEP","IG20"]}},{"id":"88f0cc61e80a48a5b81f6526c62dba66","type":"GENE","name":"MADD-AS1","canonical_id":"hgnc:HGNC:40354","description":"MADD antisense RNA 1","metadata":null},{"id":"bc4c2af35b1c4a4cb6989cf21d6a0566","type":"GO_TERM","name":"MADS box domain binding","canonical_id":"go:GO:0097162","description":"\"Binding to a MADS box domain, a protein domain that encodes the DNA-binding MADS domain. The MADS domain binds to DNA sequences of high similarity to the motif CC[A/T]6GG termed the CArG-box. MADS-domain proteins are generally transcription factors. The length of the MADS-box is in the range of 168 to 180 base pairs.\" [GOC:yaf, InterPro:IPR002100, PMID:18296735, Wikipedia:MADS-box]","metadata":null},{"id":"810775daf96d49099b845a3755ee6ea3","type":"GENE","name":"MAEA","canonical_id":"hgnc:HGNC:13731","description":"macrophage erythroblast attacher, E3 ubiquitin ligase","metadata":{"aliases":["EMP","GID9","p44EMLP","HLC-10"]}},{"id":"c4779ea853fd47e99b601c493317ddb8","type":"GENE","name":"MAEA-DT","canonical_id":"hgnc:HGNC:58709","description":"MAEA divergent transcript","metadata":null},{"id":"968fa525b2794df6845553e51775af39","type":"GENE","name":"MAEL","canonical_id":"hgnc:HGNC:25929","description":"maelstrom spermatogenic transposon silencer","metadata":{"aliases":["FLJ14904","CT128","SPATA35"]}},{"id":"2b748107cf2442c7ae89767874397a23","type":"GENE","name":"MAF","canonical_id":"hgnc:HGNC:6776","description":null,"metadata":null},{"id":"64ec53025aa3410f8ff7a9e70bb636db","type":"GENE","name":"MAF1","canonical_id":"hgnc:HGNC:24966","description":"MAF1 negative regulator of RNA polymerase III","metadata":{"aliases":["DKFZp586G1123"]}},{"id":"caa80ae29a01416099d671c2c01db8f9","type":"GENE","name":"MAF1P1","canonical_id":"hgnc:HGNC:56527","description":"MAF1 pseudogene 1","metadata":null},{"id":"497ae799b8c54182a39c9ac6a529d951","type":"GENE","name":"MAFA","canonical_id":"hgnc:HGNC:23145","description":null,"metadata":null},{"id":"44e3e2a1846d408ebfd9022a4e474591","type":"GENE","name":"MAFA-AS1","canonical_id":"hgnc:HGNC:51203","description":"MAFA antisense RNA 1","metadata":{"aliases":["RP11-909N17.2","RP11-909N17.3","TCONS_00014882","LINC02990"]}},{"id":"e43a1cdf64414a728f0dce15b10ddf89","type":"GENE","name":"MAFB","canonical_id":"hgnc:HGNC:6408","description":null,"metadata":null},{"id":"ca5b33408d3d479f98ab4a05c5e07c4d","type":"GENE","name":"MAFF","canonical_id":"hgnc:HGNC:6780","description":null,"metadata":null},{"id":"0f9e465cc98d47ebab7c258899723dd4","type":"GENE","name":"MAFG","canonical_id":"hgnc:HGNC:6781","description":null,"metadata":null},{"id":"2e631393c94a48529806bd1ade5dba97","type":"GENE","name":"MAFG-AS1","canonical_id":"hgnc:HGNC:56705","description":"MAFG antisense RNA 1","metadata":null},{"id":"8d3916f2cf074f85a68dd29557fd9cec","type":"GENE","name":"MAFIP","canonical_id":"hgnc:HGNC:31102","description":"MAFF interacting protein","metadata":{"aliases":["FLJ35473","FLJ00219","FLJ39633","MIP","pp5644","TEKT4P4"]}},{"id":"9aed6f3a9b3246b792166a533394a802","type":"GENE","name":"MAFK","canonical_id":"hgnc:HGNC:6782","description":null,"metadata":null},{"id":"d14ed654eda14ac2b400899838047408","type":"GENE","name":"MAFTRR","canonical_id":"hgnc:HGNC:51525","description":"MAF transcriptional regulator RNA","metadata":{"aliases":["linc-MAF-4"]}},{"id":"4ac927c1367142dd99620fa6ce5d9a08","type":"GENE","name":"MAG","canonical_id":"hgnc:HGNC:6783","description":"myelin associated glycoprotein","metadata":{"aliases":["SIGLEC4A","SIGLEC-4A","S-MAG","SIGLEC4","GMA"]}},{"id":"d71fcce4c6fb4ee386e57382af96bb55","type":"GENE","name":"MAGEA1","canonical_id":"hgnc:HGNC:6796","description":"MAGE family member A1","metadata":{"aliases":["MGC9326","CT1.1","MAGE1"]}},{"id":"b21b8897a2724c90ac20452142898a42","type":"GENE","name":"MAGEA10","canonical_id":"hgnc:HGNC:6797","description":"MAGE family member A10","metadata":{"aliases":["MGC10599","CT1.10","MAGE10"]}},{"id":"db360bc690f24495ae740de7406ffeaa","type":"GENE","name":"MAGEA11","canonical_id":"hgnc:HGNC:6798","description":"MAGE family member A11","metadata":{"aliases":["MAGE-11","MAGEA-11","MGC10511","CT1.11","MAGE11"]}},{"id":"165a4fe7abbf455b9d2e0ea36ab74450","type":"GENE","name":"MAGEA12","canonical_id":"hgnc:HGNC:6799","description":"MAGE family member A12","metadata":{"aliases":["CT1.12","MAGE12"]}},{"id":"17cb30faa41f45089a421bcc9c62a36f","type":"GENE","name":"MAGEA13P","canonical_id":"hgnc:HGNC:35154","description":"MAGE family member A13, pseudogene","metadata":{"aliases":["LOC139363"]}},{"id":"df644a11f13e4cfba745881a6d440b52","type":"GENE","name":"MAGEA2","canonical_id":"hgnc:HGNC:6800","description":"MAGE family member A2","metadata":{"aliases":["MAGEA2A","CT1.2","MAGE2"]}},{"id":"e9e7ad2c254044aabfd7ce9226ecb676","type":"GENE","name":"MAGEA2B","canonical_id":"hgnc:HGNC:19340","description":"MAGE family member A2B","metadata":{"aliases":["MAGE2","MGC16973","MAGEA2"]}},{"id":"54ddc9d417c14ae4b05ee8e51b285479","type":"GENE","name":"MAGEA3","canonical_id":"hgnc:HGNC:6801","description":"MAGE family member A3","metadata":{"aliases":["HYPD","HIP8","MGC14613","CT1.3","MAGE3"]}},{"id":"9f29402d8f864cfdb090191d38741bd5","type":"GENE","name":"MAGEA3-DT","canonical_id":"hgnc:HGNC:56247","description":"MAGEA3 divergent transcript","metadata":null},{"id":"b4550ffbbfc94e84a522a9d3fa9647ed","type":"GENE","name":"MAGEA4","canonical_id":"hgnc:HGNC:6802","description":"MAGE family member A4","metadata":{"aliases":["MAGE4A","MAGE4B","MAGE-41","MAGE-X2","MGC21336","CT1.4","MAGE4"]}},{"id":"2594ce97cc3842788c83d8346217b82d","type":"GENE","name":"MAGEA4-AS1","canonical_id":"hgnc:HGNC:53860","description":"MAGEA4 antisense RNA 1","metadata":null},{"id":"6f6ceff965f740b599a7df8bd07627f0","type":"GENE","name":"MAGEA5P","canonical_id":"hgnc:HGNC:6803","description":"MAGE family member A5, pseudogene","metadata":{"aliases":["MGC129526","CT1.5","MAGE5","MAGEA5"]}},{"id":"f9c89ee53a25455f87ea5c728bc13137","type":"GENE","name":"MAGEA6","canonical_id":"hgnc:HGNC:6804","description":"MAGE family member A6","metadata":{"aliases":["CT1.6","MAGE3B","MAGE-3b","MAGE6"]}},{"id":"657261fd41b14500b84ba5b2843a19fb","type":"GENE","name":"MAGEA6-DT","canonical_id":"hgnc:HGNC:55139","description":"MAGEA6 divergent transcript","metadata":null},{"id":"ce72f0cf4b0f45a0962231dd6bda4142","type":"GENE","name":"MAGEA7P","canonical_id":"hgnc:HGNC:6805","description":"MAGE family member A7, pseudogene","metadata":{"aliases":["MAGE7","MAGEA7"]}},{"id":"202e45004b6945f9b3939337be3c75c1","type":"GENE","name":"MAGEA8","canonical_id":"hgnc:HGNC:6806","description":"MAGE family member A8","metadata":{"aliases":["MGC2182","CT1.8","MAGE8"]}},{"id":"1f89a4680ca3460b9a0c7dd35ce5f0d4","type":"GENE","name":"MAGEA8-AS1","canonical_id":"hgnc:HGNC:45093","description":"MAGEA8 antisense RNA 1","metadata":{"aliases":["RP5-869M20.2"]}},{"id":"384fbcb004c54d2182095b01ee0ee03c","type":"GENE","name":"MAGEA9","canonical_id":"hgnc:HGNC:6807","description":"MAGE family member A9","metadata":{"aliases":["MGC8421","CT1.9","MAGE9"]}},{"id":"b9cf093bb7854bc7998739ba855243d7","type":"GENE","name":"MAGEA9B","canonical_id":"hgnc:HGNC:31909","description":"MAGE family member A9B","metadata":null},{"id":"4c1cd9ee5803490282e33c811ba3e50d","type":"GENE","name":"MAGEB1","canonical_id":"hgnc:HGNC:6808","description":"MAGE family member B1","metadata":{"aliases":["MAGEL1","MAGE-Xp","DAM10","MGC9322","CT3.1"]}},{"id":"428b494a9da440d4845b72f65b2cddaa","type":"GENE","name":"MAGEB10","canonical_id":"hgnc:HGNC:25377","description":"MAGE family member B10","metadata":{"aliases":["FLJ32965"]}},{"id":"37c5bb52f3d94c169a4f05cfc20fa9f0","type":"GENE","name":"MAGEB16","canonical_id":"hgnc:HGNC:21188","description":"MAGE family member B16","metadata":null},{"id":"849aeb1fd7a84e8582ef20d4e0924733","type":"GENE","name":"MAGEB17","canonical_id":"hgnc:HGNC:17418","description":"MAGE family member B17","metadata":null},{"id":"e3373d35eee74c3b92d1d01a45d2dc3c","type":"GENE","name":"MAGEB17-AS1","canonical_id":"hgnc:HGNC:56739","description":"MAGEB17 antisense RNA 1","metadata":{"aliases":["lnc-AP1S2-2"]}},{"id":"7e7128c09bd449a9a76d021fe4a361b6","type":"GENE","name":"MAGEB18","canonical_id":"hgnc:HGNC:28515","description":"MAGE family member B18","metadata":{"aliases":["MGC33889"]}},{"id":"4df63fda301448108405aa4aadd03a94","type":"GENE","name":"MAGEB2","canonical_id":"hgnc:HGNC:6809","description":"MAGE family member B2","metadata":{"aliases":["DAM6","MAGE-XP-2","MGC26438","CT3.2"]}},{"id":"ba81cf3c68eb48c8867b9bae93c07e54","type":"GENE","name":"MAGEB3","canonical_id":"hgnc:HGNC:6810","description":"MAGE family member B3","metadata":{"aliases":["CT3.5"]}},{"id":"dad0642905f540a7b00b02c25a587369","type":"GENE","name":"MAGEB4","canonical_id":"hgnc:HGNC:6811","description":"MAGE family member B4","metadata":{"aliases":["MGC33144","CT3.6"]}},{"id":"dcf514e32456491cbc192147cf094970","type":"GENE","name":"MAGEB5","canonical_id":"hgnc:HGNC:23795","description":"MAGE family member B5","metadata":{"aliases":["MAGE-B5","CT3.3"]}},{"id":"ed410727a6ab43cfb9eee44310cb2e2b","type":"GENE","name":"MAGEB6","canonical_id":"hgnc:HGNC:23796","description":"MAGE family member B6","metadata":{"aliases":["FLJ40242","MAGE-B6","MAGEB6A","CT3.4"]}},{"id":"fea82350cd704e5fa94aad6a017e55de","type":"GENE","name":"MAGEB6B","canonical_id":"hgnc:HGNC:28824","description":"MAGE family member B6B","metadata":{"aliases":["MAGEB6P1"]}},{"id":"a51535671c314e0fba02be8d50181257","type":"GENE","name":"MAGEC1","canonical_id":"hgnc:HGNC:6812","description":"MAGE family member C1","metadata":{"aliases":["MAGE-C1","CT7","MGC39366","CT7.1"]}},{"id":"3262e10b0d554fa2aea6e78a6b0d30cd","type":"GENE","name":"MAGEC2","canonical_id":"hgnc:HGNC:13574","description":"MAGE family member C2","metadata":{"aliases":["CT10","MAGE-C2","HCA587","MAGEE1"]}},{"id":"e928408cfee84073993b7ae5a75b09ac","type":"GENE","name":"MAGEC3","canonical_id":"hgnc:HGNC:23798","description":"MAGE family member C3","metadata":{"aliases":["HCA2","MAGE-C3","CT7.2"]}},{"id":"2e92f83b287445fa96706336538236f6","type":"GENE","name":"MAGED1","canonical_id":"hgnc:HGNC:6813","description":"MAGE family member D1","metadata":{"aliases":["NRAGE","DLXIN-1"]}},{"id":"b4caeefd3946405484565e9c94d1addc","type":"GENE","name":"MAGED2","canonical_id":"hgnc:HGNC:16353","description":"MAGE family member D2","metadata":{"aliases":["JCL-1","BCG1","11B6","MAGE-D2","HCA10","MAGED","MGC8386"]}},{"id":"740a77a9b7e145edb5289d175f8e4b9a","type":"GENE","name":"MAGED4","canonical_id":"hgnc:HGNC:23793","description":"MAGE family member D4","metadata":{"aliases":["MAGE1","MGC3210","KIAA1859","MAGE-E1"]}},{"id":"b2eb14b567834028b52c85d0b8d1de41","type":"GENE","name":"MAGED4B","canonical_id":"hgnc:HGNC:22880","description":"MAGE family member D4B","metadata":null},{"id":"287775ffb64d46beb17bc1dfe0ec4539","type":"GENE","name":"MAGEE1","canonical_id":"hgnc:HGNC:24934","description":"MAGE family member E1","metadata":{"aliases":["KIAA1587","DAMAGE"]}},{"id":"707d77070d7648e394e57ec7ec13097e","type":"GENE","name":"MAGEE2","canonical_id":"hgnc:HGNC:24935","description":"MAGE family member E2","metadata":{"aliases":["HCA3"]}},{"id":"86837c8516fd4404a63311fb152d87f6","type":"GENE","name":"MAGEF1","canonical_id":"hgnc:HGNC:29639","description":"MAGE family member F1","metadata":null},{"id":"591ae1adf08b452aa4a35fb61276017e","type":"GENE","name":"MAGEH1","canonical_id":"hgnc:HGNC:24092","description":"MAGE family member H1","metadata":{"aliases":["APR1"]}},{"id":"bd809de903104c2aa5a0b852da53d7cf","type":"GENE","name":"MAGEL2","canonical_id":"hgnc:HGNC:6814","description":"MAGE family member L2","metadata":{"aliases":["nM15","NDNL1"]}},{"id":"fa968f6004094f5bbc8ece2713048bed","type":"GENE","name":"MAGI1","canonical_id":"hgnc:HGNC:946","description":"membrane associated guanylate kinase, WW and PDZ domain containing 1","metadata":{"aliases":["BAP1","MAGI-1","TNRC19","AIP3","WWP3","BAIAP1"]}},{"id":"a4963d303d6b400ba4f26fff8be4a95b","type":"GENE","name":"MAGI1-AS1","canonical_id":"hgnc:HGNC:40091","description":"MAGI1 antisense RNA 1","metadata":null},{"id":"1542c786694c4685843e04a670ca74f0","type":"GENE","name":"MAGI1-IT1","canonical_id":"hgnc:HGNC:42436","description":"MAGI1 intronic transcript 1","metadata":null},{"id":"e10cb25b693b4a15a5413c27e8b58e42","type":"GENE","name":"MAGI2","canonical_id":"hgnc:HGNC:18957","description":"membrane associated guanylate kinase, WW and PDZ domain containing 2","metadata":{"aliases":["AIP1","ARIP1","KIAA0705","ACVRIP1","MAGI-2"]}},{"id":"03e7d7347f2f4d249ab25c1cef0bb251","type":"GENE","name":"MAGI2-AS1","canonical_id":"hgnc:HGNC:40860","description":"MAGI2 antisense RNA 1","metadata":null},{"id":"fbb721b2b7e54ad9b6ee9b20a4de00b8","type":"GENE","name":"MAGI2-AS2","canonical_id":"hgnc:HGNC:40861","description":"MAGI2 antisense RNA 2","metadata":null},{"id":"5f9bafd5dcee4656a5ae6e7d49f5fe2a","type":"GENE","name":"MAGI2-AS3","canonical_id":"hgnc:HGNC:40862","description":"MAGI2 antisense RNA 3","metadata":{"aliases":["ENST00000414797"]}},{"id":"4432332daeac45a1b1cf0cdc2395f03b","type":"GENE","name":"MAGI3","canonical_id":"hgnc:HGNC:29647","description":"membrane associated guanylate kinase, WW and PDZ domain containing 3","metadata":{"aliases":["MAGI-3"]}},{"id":"7a25c2f0c0eb432594f66f1ece8a961e","type":"GENE","name":"MAGIX","canonical_id":"hgnc:HGNC:30006","description":"MAGI family member, X-linked","metadata":{"aliases":["PDZX","JM10","FLJ21687"]}},{"id":"f6603ed2b9c24cc8a1d1b23e38b98d8d","type":"GENE","name":"MAGOH","canonical_id":"hgnc:HGNC:6815","description":"mago homolog, exon junction complex subunit","metadata":{"aliases":["MAGOHA","MAGOH1"]}},{"id":"7ea965088f4f4c128a15e1577483fadc","type":"GENE","name":"MAGOH-DT","canonical_id":"hgnc:HGNC:49539","description":"MAGOH divergent transcript","metadata":null},{"id":"a9de17a1aa9241098634b9b64bbc58b5","type":"GENE","name":"MAGOH2P","canonical_id":"hgnc:HGNC:30148","description":"mago homolog 2, pseudogene","metadata":{"aliases":["MAGOH2"]}},{"id":"78dcc8c20ab743bbbc3b83cb3e719578","type":"GENE","name":"MAGOH3P","canonical_id":"hgnc:HGNC:20020","description":"mago homolog 3, pseudogene","metadata":{"aliases":["MAGOHP1","MAGOHP"]}},{"id":"0b39a73da5544cbaaf3f1cbfd705388d","type":"GENE","name":"MAGOHB","canonical_id":"hgnc:HGNC:25504","description":"mago homolog B, exon junction complex subunit","metadata":{"aliases":["FLJ10292","MGN2"]}},{"id":"fb960f340786491981113aa209dee805","type":"GENE","name":"MAGT1","canonical_id":"hgnc:HGNC:28880","description":"magnesium transporter 1","metadata":{"aliases":["DKFZp564K142","IAP","OST3B","MRX95","SLC58A1"]}},{"id":"0018de24a13a43c7ab448035d68c7b97","type":"GENE","name":"MAHAC","canonical_id":"hgnc:HGNC:54387","description":"maintenance of histone H4K5 acetylation associated lncRNA","metadata":{"aliases":["LINC02851"]}},{"id":"544705959e9449b085002aef2d59d6ef","type":"GENE","name":"MAILR","canonical_id":"hgnc:HGNC:51558","description":"macrophage interferon regulatory lncRNA","metadata":{"aliases":["MAIL1","H22954","AZIN1-AS1"]}},{"id":"7e9d5b3eeac243a5938bcfa24b12ef75","type":"TRIAL","name":"MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV","canonical_id":"clinicaltrials.gov:NCT01970410","description":"Multiple Sclerosis","metadata":null},{"id":"bd4da27251c643f68dfd15219ae0fef3","type":"GENE","name":"MAIP1","canonical_id":"hgnc:HGNC:26198","description":"matrix AAA peptidase interacting protein 1","metadata":{"aliases":["DKFZp666A212","FLJ22555","C2orf47"]}},{"id":"f3d99b0fc43e436084870f2b48ebd4b9","type":"GENE","name":"MAJIN","canonical_id":"hgnc:HGNC:27441","description":"membrane anchored junction protein","metadata":{"aliases":["C11orf85"]}},{"id":"1d0bf32bbabc44fe9f48b7f88c56dc81","type":"GENE","name":"MAK","canonical_id":"hgnc:HGNC:6816","description":"male germ cell associated kinase","metadata":{"aliases":["dJ417M14.2","RP62"]}},{"id":"70584298d3e24f77a21e7cbfbca81112","type":"GENE","name":"MAK16","canonical_id":"hgnc:HGNC:13703","description":"MAK16 homolog","metadata":{"aliases":["MAK16L","RBM13"]}},{"id":"a188a1fc611849d1b0978ebca438d9bd","type":"GENE","name":"MAL","canonical_id":"hgnc:HGNC:6817","description":null,"metadata":null},{"id":"b947e800c148498c8fe1ec23a36517b3","type":"GENE","name":"MAL-AS1","canonical_id":"hgnc:HGNC:40355","description":"MAL antisense RNA 1","metadata":{"aliases":["AC103563.8"]}},{"id":"86786bfcc66e4746a603da28d1acd7dd","type":"GENE","name":"MAL2","canonical_id":"hgnc:HGNC:13634","description":"mal, T cell differentiation protein 2","metadata":null},{"id":"8407f3f1b3ec4aa49846b2ef42db54d9","type":"GENE","name":"MAL2-AS1","canonical_id":"hgnc:HGNC:53626","description":"MAL2 antisense RNA 1","metadata":null},{"id":"767e6f5f99ca4abaa67cc54401d5a90f","type":"GENE","name":"MALAT1","canonical_id":"hgnc:HGNC:29665","description":"metastasis associated lung adenocarcinoma transcript 1","metadata":{"aliases":["miPEP-52","PRO1073","MALAT-1","NCRNA00047","HCN","NEAT2","LINC00047","mascRNA"]}},{"id":"ab1d7ee873b344778ddb473075eaf738","type":"GENE","name":"MALINC1","canonical_id":"hgnc:HGNC:49009","description":"mitosis associated long intergenic non-coding RNA 1","metadata":{"aliases":["MA-linc1","LINC01024"]}},{"id":"3e6dc0d03dcc4ce7ae02ba7e94e8599a","type":"GENE","name":"MALL","canonical_id":"hgnc:HGNC:6818","description":"mal, T cell differentiation protein like","metadata":{"aliases":["BENE"]}},{"id":"fe8ad7020bfe44d0b0d69654761fb2d2","type":"GENE","name":"MALLP1","canonical_id":"hgnc:HGNC:55038","description":"MALL pseudogene 1","metadata":null},{"id":"b1c84b794f324e1c88a70a94f9b90c37","type":"GENE","name":"MALLP2","canonical_id":"hgnc:HGNC:55039","description":"MALL pseudogene 2","metadata":null},{"id":"5a4b504fb1bb4135832a41493c11cf9c","type":"GENE","name":"MALNC","canonical_id":"hgnc:HGNC:56208","description":"myeloid and AML associated intergenic long non-coding RNA","metadata":null},{"id":"b83d4caecdcf42e5b0d62f48fd7978dd","type":"GENE","name":"MALRD1","canonical_id":"hgnc:HGNC:24331","description":"MAM and LDL receptor class A domain containing 1","metadata":{"aliases":["bA265G8.2","Diet1","C10orf112"]}},{"id":"2ea3542c7cfb438387c07eb5d08ba069","type":"GENE","name":"MALRD1-AS1","canonical_id":"hgnc:HGNC:58180","description":"MALRD1 antisense RNA 1","metadata":null},{"id":"eee0a5abba944d26b310c8c05ccbf5c7","type":"GENE","name":"MALSU1","canonical_id":"hgnc:HGNC:21721","description":"mitochondrial assembly of ribosomal large subunit 1","metadata":{"aliases":["mtRsfA","C7orf30"]}},{"id":"88879fd9fc87415694ea3fc5423283ae","type":"GENE","name":"MALT1","canonical_id":"hgnc:HGNC:6819","description":"MALT1 paracaspase","metadata":{"aliases":["PCASP1","MLT"]}},{"id":"c033ebc55470421c9e4a6f056159d210","type":"GENE","name":"MALT1-AS1","canonical_id":"hgnc:HGNC:55306","description":"MALT1 antisense RNA 1","metadata":null},{"id":"f06c97a948f1442bb8ca5a2a159bdb8e","type":"GENE","name":"MAMDC2","canonical_id":"hgnc:HGNC:23673","description":"MAM domain containing 2","metadata":{"aliases":["MGC21981"]}},{"id":"9ccea3ccb0dd438c9e1a31d4a360bfbd","type":"GENE","name":"MAMDC2-AS1","canonical_id":"hgnc:HGNC:48719","description":"MAMDC2 antisense RNA 1","metadata":{"aliases":["SMC5-DT"]}},{"id":"db7f332c356d43c78c2fd582c9b99c7e","type":"GENE","name":"MAMDC4","canonical_id":"hgnc:HGNC:24083","description":"MAM domain containing 4","metadata":{"aliases":["AEGP","DKFZp434M1411","EDTB"]}},{"id":"ecef171305474580b2860962f46179cf","type":"GENE","name":"MAML1","canonical_id":"hgnc:HGNC:13632","description":null,"metadata":null},{"id":"e6e8de0e53034099a67d86dd08a563bf","type":"GO_TERM","name":"MAML1-RBP-Jkappa- ICN1 complex","canonical_id":"go:GO:0002193","description":"\"A protein complex that consists of the intracellular domain of Notch1 (ICN1), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-1 (MAML1); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [CORUM:2949, PMID:16510869]","metadata":null},{"id":"e8126afd0fd94e22bbc317171c78e52f","type":"GENE","name":"MAML2","canonical_id":"hgnc:HGNC:16259","description":"mastermind like transcriptional coactivator 2","metadata":{"aliases":["KIAA1819","MAM3"]}},{"id":"8f79fd4a79b94870994de8e31933f9cf","type":"GO_TERM","name":"MAML2-RBP-Jkappa-ICN1 complex","canonical_id":"go:GO:0071175","description":"\"A protein complex that consists of the intracellular domain of Notch1 (ICN1), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-2 (MAML2); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"a2df3549ca924b388c9152a400865433","type":"GO_TERM","name":"MAML2-RBP-Jkappa-ICN2 complex","canonical_id":"go:GO:0071176","description":"\"A protein complex that consists of the intracellular domain of Notch2 (ICN2), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-2 (MAML2); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"99e7efc04a78423a91a4306aab0b80cc","type":"GO_TERM","name":"MAML2-RBP-Jkappa-ICN3 complex","canonical_id":"go:GO:0071177","description":"\"A protein complex that consists of the intracellular domain of Notch3 (ICN3), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-2 (MAML2); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"0f1a141c457e41c18c077fc430356715","type":"GO_TERM","name":"MAML2-RBP-Jkappa-ICN4 complex","canonical_id":"go:GO:0071178","description":"\"A protein complex that consists of the intracellular domain of Notch4 (ICN4), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-2 (MAML2); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"4b7ff629f18c42999a697342c0b71d93","type":"GENE","name":"MAML3","canonical_id":"hgnc:HGNC:16272","description":"mastermind like transcriptional coactivator 3","metadata":{"aliases":["KIAA1816","MAM2","CAGH3","GDN","TNRC3"]}},{"id":"512814adc6cc42b9a2ed763130a07e4f","type":"GENE","name":"MAML3-AS1","canonical_id":"hgnc:HGNC:58423","description":"MAML3 antisense RNA 1","metadata":null},{"id":"0b3e30613dc24d65a7b3a41da8f2622c","type":"GENE","name":"MAML3-AS2","canonical_id":"hgnc:HGNC:58886","description":"MAML3 antisense RNA 2","metadata":null},{"id":"7e54e5127d994b8681be889f995b168b","type":"GO_TERM","name":"MAML3-RBP-Jkappa-ICN1 complex","canonical_id":"go:GO:0071179","description":"\"A protein complex that consists of the intracellular domain of Notch1 (ICN1), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-3 (MAML3); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"29ddd31185ad4936ba3f470c2418812e","type":"GO_TERM","name":"MAML3-RBP-Jkappa-ICN2 complex","canonical_id":"go:GO:0071180","description":"\"A protein complex that consists of the intracellular domain of Notch2 (ICN2), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-3 (MAML3); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"8101e4d2eef541de8a58d827da171a62","type":"GO_TERM","name":"MAML3-RBP-Jkappa-ICN3 complex","canonical_id":"go:GO:0071181","description":"\"A protein complex that consists of the intracellular domain of Notch3 (ICN3), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-3 (MAML3); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"274717fc4b464c0dacbd30ff53121779","type":"GO_TERM","name":"MAML3-RBP-Jkappa-ICN4 complex","canonical_id":"go:GO:0071182","description":"\"A protein complex that consists of the intracellular domain of Notch4 (ICN4), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-3 (MAML3); the complex is involved in transcriptional activation in response to Notch-mediated signaling.\" [PMID:12370315]","metadata":null},{"id":"4d05d18d03aa449280be113207b42ce6","type":"GENE","name":"MAMLD1","canonical_id":"hgnc:HGNC:2568","description":"mastermind like domain containing 1","metadata":{"aliases":["CG1","F18","CXorf6"]}},{"id":"bdf281b361fd45e58294582126bfbadd","type":"GENE","name":"MAMSTR","canonical_id":"hgnc:HGNC:26689","description":"MEF2 activating motif and SAP domain containing transcriptional regulator","metadata":{"aliases":["MASTR","FLJ36070"]}},{"id":"019d1c618b46448f8cf28833ec8e85fd","type":"GENE","name":"MAN1A1","canonical_id":"hgnc:HGNC:6821","description":"mannosidase alpha class 1A member 1","metadata":null},{"id":"617c2f257c3045fcaaedd32af18d7084","type":"GENE","name":"MAN1A2","canonical_id":"hgnc:HGNC:6822","description":"mannosidase alpha class 1A member 2","metadata":{"aliases":["MAN1B"]}},{"id":"2855c50d9602431d8dcdfc8893503850","type":"GENE","name":"MAN1A2P1","canonical_id":"hgnc:HGNC:50488","description":"mannosidase alpha class 1A member 2 pseudogene 1","metadata":null},{"id":"ef2a812170fc4205bef938a08fc58416","type":"GENE","name":"MAN1B1","canonical_id":"hgnc:HGNC:6823","description":"mannosidase alpha class 1B member 1","metadata":{"aliases":["MANA-ER","MRT15","ERManI","ERMan1"]}},{"id":"860888a03b704377a9300f74a9e9b76f","type":"GENE","name":"MAN1B1-DT","canonical_id":"hgnc:HGNC:48715","description":"MAN1B1 divergent transcript","metadata":{"aliases":["MAN1B1-AS1"]}},{"id":"dd85d1b8be584a30a0bdfe036ce13acc","type":"GENE","name":"MAN1C1","canonical_id":"hgnc:HGNC:19080","description":"mannosidase alpha class 1C member 1","metadata":{"aliases":["HMIC"]}},{"id":"e241daac20474dd19e9a5160c6386070","type":"GENE","name":"MAN2A1","canonical_id":"hgnc:HGNC:6824","description":"mannosidase alpha class 2A member 1","metadata":{"aliases":["GOLIM7","MANII","MANA2"]}},{"id":"cfff1b52f72141379516e1b643c80a77","type":"GENE","name":"MAN2A1-DT","canonical_id":"hgnc:HGNC:54821","description":"MAN2A1 divergent transcript","metadata":null},{"id":"c479f1e1d699409aa99d0b9e92e4845c","type":"GENE","name":"MAN2A2","canonical_id":"hgnc:HGNC:6825","description":"mannosidase alpha class 2A member 2","metadata":{"aliases":["MANA2X","HsT19662","alpha-MIIx"]}},{"id":"cfe803499af1482bafa302edd5a99fb9","type":"GENE","name":"MAN2A2-AS1","canonical_id":"hgnc:HGNC:58476","description":"MAN2A2 antisense RNA 1","metadata":null},{"id":"8814b8078fec468eb2ead96b26ff97b6","type":"GENE","name":"MAN2B1","canonical_id":"hgnc:HGNC:6826","description":"mannosidase alpha class 2B member 1","metadata":{"aliases":["LAMAN","MANB"]}},{"id":"86c0e8ddf28742cdabb3bd413acd07ab","type":"GENE","name":"MAN2B2","canonical_id":"hgnc:HGNC:29623","description":"mannosidase alpha class 2B member 2","metadata":{"aliases":["KIAA0935","EpMAN"]}},{"id":"6b4244492c054fd0b249d24c8bc18ce8","type":"GENE","name":"MAN2C1","canonical_id":"hgnc:HGNC:6827","description":"mannosidase alpha class 2C member 1","metadata":{"aliases":["MANA1","MANA"]}},{"id":"0811edca37af4ef0b4c35916b1df77f0","type":"GENE","name":"MANBA","canonical_id":"hgnc:HGNC:6831","description":"mannosidase beta","metadata":null},{"id":"97ec1f522eea43738aca05f31abac3a0","type":"GENE","name":"MANBAL","canonical_id":"hgnc:HGNC:15799","description":"mannosidase beta like","metadata":{"aliases":["dJ1141E15.2"]}},{"id":"0e9dcd0fc65946678d3299386c5b4edc","type":"GENE","name":"MANCR","canonical_id":"hgnc:HGNC:44678","description":"mitotically associated long non coding RNA","metadata":{"aliases":["CR749391","LINC00704"]}},{"id":"a65b982919be4b988e20ff6b810ef393","type":"GENE","name":"MANEA","canonical_id":"hgnc:HGNC:21072","description":"mannosidase endo-alpha","metadata":{"aliases":["FLJ12838","mandaselin"]}},{"id":"f311933d34d94c1db16d7085c951a176","type":"GENE","name":"MANEA-DT","canonical_id":"hgnc:HGNC:43732","description":"MANEA divergent transcript","metadata":{"aliases":["MANEA-AS1"]}},{"id":"1cdc814666074eeab12f47c0890df129","type":"GENE","name":"MANEAL","canonical_id":"hgnc:HGNC:26452","description":"mannosidase endo-alpha like","metadata":{"aliases":["FLJ31434"]}},{"id":"acb326a5517a457ebbb68cefe40d6085","type":"GENE","name":"MANEALP1","canonical_id":"hgnc:HGNC:54641","description":"MANEAL pseudogene 1","metadata":null},{"id":"cb0b2a65f1e748d49e68f1b933b6d97f","type":"GENE","name":"MANF","canonical_id":"hgnc:HGNC:15461","description":"mesencephalic astrocyte derived neurotrophic factor","metadata":{"aliases":["ARP","ARMET"]}},{"id":"bd10e2afe1b94f1998ca7b2d6c100d81","type":"GENE","name":"MANSC1","canonical_id":"hgnc:HGNC:25505","description":"MANSC domain containing 1","metadata":{"aliases":["FLJ10298","LOH12CR3"]}},{"id":"15984a5da03f42259357cb38a6f1795f","type":"GENE","name":"MANSC4","canonical_id":"hgnc:HGNC:40023","description":"MANSC domain containing 4","metadata":null},{"id":"43bb485d26c749f9aebff3dd0fbfb31b","type":"GENE","name":"MAOA","canonical_id":"hgnc:HGNC:6833","description":null,"metadata":null},{"id":"49860ed9ca6f473982e25755a1b8e1cb","type":"PROTEIN","name":"MAOA","canonical_id":"uniprot:P21397","description":null,"metadata":null},{"id":"f39337c3dbb94a04bf6e3497ada8949d","type":"GENE","name":"MAOB","canonical_id":"hgnc:HGNC:6834","description":null,"metadata":null},{"id":"5923c58a1cf740ffb241f1a8734ca0b4","type":"PROTEIN","name":"MAOB","canonical_id":"uniprot:P27338","description":null,"metadata":null},{"id":"065e8aed4d544d4d9adf3f889a4488e1","type":"GO_TERM","name":"MAP kinase activity","canonical_id":"go:GO:0004707","description":"\"Catalysis of the reaction: protein + ATP = protein phosphate + ADP. This reaction is the phosphorylation of proteins. Mitogen-activated protein kinase; a family of protein kinases that perform a crucial step in relaying signals from the plasma membrane to the nucleus. They are activated by a wide range of proliferation- or differentiation-inducing signals; activation is strong with agonists such as polypeptide growth factors and tumor-promoting phorbol esters, but weak (in most cell backgrounds) by stress stimuli.\" [GOC:ma, ISBN:0198547684]","metadata":null},{"id":"3839a381913c4fcdb87425913a7b5914","type":"GO_TERM","name":"MAP kinase kinase activity","canonical_id":"go:GO:0004708","description":"\"Catalysis of the concomitant phosphorylation of threonine (T) and tyrosine (Y) residues in a T-X-Y motif in the activation loop of a MAP kinase (MAPK) substrate.\" [PMID:12623839, PMID:38270553]","metadata":null},{"id":"7385e454f8f44a379a6da2b93809fed1","type":"GO_TERM","name":"MAP kinase kinase kinase activity","canonical_id":"go:GO:0004709","description":"\"Catalysis of the phosphorylation and activation of a MAP kinase kinase; each MAP kinase kinase can be phosphorylated by any of several MAP kinase kinase kinases.\" [PMID:9561267]","metadata":null},{"id":"120f7d01112445bcae4cd89a5171657c","type":"GO_TERM","name":"MAP kinase kinase kinase kinase activity","canonical_id":"go:GO:0008349","description":"\"Catalysis of the phosphorylation of serine and threonine residues in a mitogen-activated protein kinase kinase kinase (MAPKKK), resulting in activation of MAPKKK. MAPKKK signaling pathways relay, amplify and integrate signals from the plasma membrane to the nucleus in response to a diverse range of extracellular stimuli.\" [GOC:bf, PMID:11790549]","metadata":null},{"id":"20935d652e2743f3b8e65adc8935386b","type":"GO_TERM","name":"MAP kinase phosphatase activity","canonical_id":"go:GO:0033549","description":"\"Catalysis of the reaction: a phosphorylated MAP kinase + H2O = a MAP kinase + phosphate.\" [GOC:mah, PMID:12184814, PMID:17208316]","metadata":null},{"id":"927c8c41d3194588b79097137b75de37","type":"GO_TERM","name":"MAP kinase scaffold activity","canonical_id":"go:GO:0005078","description":"\"The binding activity of a molecule that functions as a physical support for the assembly of a multiprotein mitogen-activated protein kinase (MAPK) complex. Binds multiple kinases of the MAPKKK cascade, and also upstream signaling proteins, permitting those molecules to function in a coordinated way. Bringing together multiple enzymes and their substrates enables the signal to be transduced quickly and efficiently.\" [PMID:12511654, PMID:15213240, PMID:9405336]","metadata":null},{"id":"b6a9c1657e294fe5926022073817aa3c","type":"GO_TERM","name":"MAP kinase serine/threonine phosphatase activity","canonical_id":"go:GO:1990439","description":"\"Catalysis of the reaction: MAP kinase threonine phosphate + H2O = MAP kinase threonine + phosphate and MAP kinase serine phosphate + H2O = MAP kinase serine + phosphate.\" [PMID:10398679]","metadata":null},{"id":"6dac99a2e5c04191910c79f424319751","type":"GO_TERM","name":"MAP kinase tyrosine phosphatase activity","canonical_id":"go:GO:0033550","description":"\"Catalysis of the reaction: MAP kinase tyrosine phosphate + H2O = MAP kinase tyrosine + phosphate.\" [GOC:mah]","metadata":null},{"id":"60dbd63a58e140a5831fe66a4ee802b6","type":"GO_TERM","name":"MAP kinase tyrosine/serine/threonine phosphatase activity","canonical_id":"go:GO:0017017","description":"\"Catalysis of the reaction: MAP kinase serine/threonine/tyrosine phosphate + H2O = MAP kinase serine/threonine/tyrosine + phosphate.\" [GOC:mah, PMID:12184814]","metadata":null},{"id":"90059a175c834449847532cf86e79c48","type":"GENE","name":"MAP10","canonical_id":"hgnc:HGNC:29265","description":"microtubule associated protein 10","metadata":{"aliases":["MTR120","KIAA1383"]}},{"id":"773faf59f9504364a6c690e55328ea01","type":"GENE","name":"MAP1A","canonical_id":"hgnc:HGNC:6835","description":null,"metadata":null},{"id":"7ea9a6b0446f487196945015ffe5eea2","type":"GENE","name":"MAP1B","canonical_id":"hgnc:HGNC:6836","description":"microtubule associated protein 1B","metadata":{"aliases":["MAP5","PPP1R102"]}},{"id":"898a7b25055347cb9f4522e66fe397cd","type":"GENE","name":"MAP1B-AS1","canonical_id":"hgnc:HGNC:59065","description":"MAP1B antisense RNA 1","metadata":null},{"id":"66dbcd0343d3477d8c88a758285f356a","type":"GENE","name":"MAP1LC3A","canonical_id":"hgnc:HGNC:6838","description":null,"metadata":null},{"id":"0283dcea41f24868a319908105021ccf","type":"GENE","name":"MAP1LC3B","canonical_id":"hgnc:HGNC:13352","description":null,"metadata":null},{"id":"6c2b297fd1a645c0865d5b7188ea258a","type":"GENE","name":"MAP1LC3B2","canonical_id":"hgnc:HGNC:34390","description":"microtubule associated protein 1 light chain 3 beta 2","metadata":{"aliases":["ATG8G"]}},{"id":"81544dccd69a485eabe5c765a7d43dd5","type":"GENE","name":"MAP1LC3BP1","canonical_id":"hgnc:HGNC:49783","description":"microtubule associated protein 1 light chain 3 beta pseudogene 1","metadata":null},{"id":"dcbbf1f9cd994f43a7e75792fd835793","type":"GENE","name":"MAP1LC3C","canonical_id":"hgnc:HGNC:13353","description":"microtubule associated protein 1 light chain 3 gamma","metadata":{"aliases":["ATG8J"]}},{"id":"b68b66a106264998a3d34e88efebab6c","type":"GENE","name":"MAP1LC3P","canonical_id":"hgnc:HGNC:31004","description":"microtubule associated protein 1 light chain 3 pseudogene","metadata":{"aliases":["HsT312"]}},{"id":"3433056b47f9439ca8dc832859ce8791","type":"GENE","name":"MAP1S","canonical_id":"hgnc:HGNC:15715","description":"microtubule associated protein 1S","metadata":{"aliases":["FLJ10669","MAP8","C19orf5","VCY2IP1","BPY2IP1"]}},{"id":"409e29ff3b2f459aafda0474ec849eb2","type":"GENE","name":"MAP2","canonical_id":"hgnc:HGNC:6839","description":null,"metadata":null},{"id":"b796a184972b47dab0d41f454beab014","type":"GENE","name":"MAP2K1","canonical_id":"hgnc:HGNC:6840","description":"mitogen-activated protein kinase kinase 1","metadata":{"aliases":["MEK1","MAPKK1","MKK1","PRKMK1"]}},{"id":"0461d7923f7a4172bf358b5ef659381b","type":"PROTEIN","name":"MAP2K1","canonical_id":"uniprot:Q02750","description":null,"metadata":null},{"id":"95f6b33271c84d2cb49a2778ddda9815","type":"GENE","name":"MAP2K1P1","canonical_id":"hgnc:HGNC:6841","description":"MAP2K1 pseudogene 1","metadata":null},{"id":"054c07f0020d450687593e206d2b7b85","type":"GENE","name":"MAP2K1P2","canonical_id":"hgnc:HGNC:53881","description":"MAP2K1 pseudogene 2","metadata":{"aliases":["MAP2K2L"]}},{"id":"171a496497d145938d7cb8190ea017b0","type":"GENE","name":"MAP2K2","canonical_id":"hgnc:HGNC:6842","description":"mitogen-activated protein kinase kinase 2","metadata":{"aliases":["MEK2","MKK2","PRKMK2"]}},{"id":"24a54c3ead41466d9ac9d6208b9fc4ce","type":"PROTEIN","name":"MAP2K2","canonical_id":"uniprot:P36507","description":null,"metadata":null},{"id":"650cce61aa8e4fd988410e0409309e74","type":"GENE","name":"MAP2K3","canonical_id":"hgnc:HGNC:6843","description":"mitogen-activated protein kinase kinase 3","metadata":{"aliases":["MEK3","MKK3","MAPKK3","SAPKK2","PRKMK3"]}},{"id":"559365ee66df4f62b5613ea85242ee60","type":"GENE","name":"MAP2K4","canonical_id":"hgnc:HGNC:6844","description":null,"metadata":null},{"id":"6dafcf4501ad451c87a16a6625caaf13","type":"GENE","name":"MAP2K4P1","canonical_id":"hgnc:HGNC:43837","description":"mitogen-activated protein kinase kinase 4 pseudogene 1","metadata":null},{"id":"de86b302be1040c9b597a4c0f3ef8d0f","type":"GENE","name":"MAP2K5","canonical_id":"hgnc:HGNC:6845","description":"mitogen-activated protein kinase kinase 5","metadata":{"aliases":["MEK5","MAPKK5","HsT17454","PRKMK5"]}},{"id":"7921a9395c894451ae726fbac4dfe1f5","type":"GENE","name":"MAP2K5-DT","canonical_id":"hgnc:HGNC:55261","description":"MAP2K5 divergent transcript","metadata":null},{"id":"35090198270b4304bdfbe2818e6773a6","type":"GENE","name":"MAP2K6","canonical_id":"hgnc:HGNC:6846","description":"mitogen-activated protein kinase kinase 6","metadata":{"aliases":["MEK6","MKK6","SAPKK3","MAPKK6","CRCMSL","PRKMK6"]}},{"id":"ab5e20c2f0ee44a5b0b4222ffb7a43c2","type":"GENE","name":"MAP2K6-AS1","canonical_id":"hgnc:HGNC:58588","description":"MAP2K6 antisense RNA 1","metadata":null},{"id":"b213e2dfdead41cf981865da552d8fd0","type":"GENE","name":"MAP2K7","canonical_id":"hgnc:HGNC:6847","description":"mitogen-activated protein kinase kinase 7","metadata":{"aliases":["MKK7","Jnkk2","SAPKK4","PRKMK7"]}},{"id":"e059c5d39699405d8cc2d9c113c7826e","type":"GENE","name":"MAP2K7-AS1","canonical_id":"hgnc:HGNC:58326","description":"MAP2K7 antisense RNA 1","metadata":null},{"id":"59185d09363549feaff3a0984f3eee40","type":"GENE","name":"MAP3K1","canonical_id":"hgnc:HGNC:6848","description":null,"metadata":null},{"id":"1762827b59344c65aba8831a0f1cd18a","type":"GENE","name":"MAP3K1-AS1","canonical_id":"hgnc:HGNC:40357","description":"MAP3K1 antisense RNA 1","metadata":null},{"id":"61627ad86cf444c09a3e83b27c68b90e","type":"GENE","name":"MAP3K1-DT","canonical_id":"hgnc:HGNC:59049","description":"MAP3K1 divergent transcript","metadata":null},{"id":"9f3ac270a8114acba1fbde18234d1fe2","type":"GENE","name":"MAP3K10","canonical_id":"hgnc:HGNC:6849","description":"mitogen-activated protein kinase kinase kinase 10","metadata":{"aliases":["MST","MEKK10","MLK2"]}},{"id":"576dab9ee0cd4d5bac43ff2893ca865d","type":"GENE","name":"MAP3K11","canonical_id":"hgnc:HGNC:6850","description":"mitogen-activated protein kinase kinase kinase 11","metadata":{"aliases":["SPRK","MEKK11","MLK3","PTK1"]}},{"id":"3e42f00e1d9a4d1b9cbf0fa573a4f1fe","type":"GENE","name":"MAP3K12","canonical_id":"hgnc:HGNC:6851","description":"mitogen-activated protein kinase kinase kinase 12","metadata":{"aliases":["MUK","DLK","ZPKP1","MEKK12","ZPK"]}},{"id":"103437dca4714ab5bdb22c9172f77d89","type":"GENE","name":"MAP3K13","canonical_id":"hgnc:HGNC:6852","description":"mitogen-activated protein kinase kinase kinase 13","metadata":{"aliases":["LZK","MEKK13"]}},{"id":"0ab6ede21564460faae363e07ce946c1","type":"GENE","name":"MAP3K14","canonical_id":"hgnc:HGNC:6853","description":null,"metadata":null},{"id":"722cae8de8f04795bbe9c5563aee5ebd","type":"GENE","name":"MAP3K14-AS1","canonical_id":"hgnc:HGNC:44359","description":"MAP3K14 antisense RNA 1","metadata":null},{"id":"f492b5de50c047049ec188386b346048","type":"GENE","name":"MAP3K15","canonical_id":"hgnc:HGNC:31689","description":"mitogen-activated protein kinase kinase kinase 15","metadata":{"aliases":["bA723P2.3","FLJ16518","ASK3"]}},{"id":"ee699b0de524411190dcc65bcfe733c6","type":"GENE","name":"MAP3K19","canonical_id":"hgnc:HGNC:26249","description":"mitogen-activated protein kinase kinase kinase 19","metadata":{"aliases":["FLJ23074","RCK","YSK4"]}},{"id":"bd5953f8d4c94ef4829ecfda330e6d1d","type":"GENE","name":"MAP3K2","canonical_id":"hgnc:HGNC:6854","description":"mitogen-activated protein kinase kinase kinase 2","metadata":{"aliases":["MEKK2B","MEKK2"]}},{"id":"db006503a0894a5fb8e191804554c982","type":"GENE","name":"MAP3K2-DT","canonical_id":"hgnc:HGNC:54088","description":"MAP3K2 divergent transcript","metadata":{"aliases":["ENST00000433673"]}},{"id":"52681641c516419cad6d93b7b5283b45","type":"GENE","name":"MAP3K20","canonical_id":"hgnc:HGNC:17797","description":"mitogen-activated protein kinase kinase kinase 20","metadata":{"aliases":["MLTKalpha","MLTKbeta","ZAK","MLTK","MLK7","MRK"]}},{"id":"f50bdbfef3ab4cb0bdd6fe2777a3fa8e","type":"GENE","name":"MAP3K20-AS1","canonical_id":"hgnc:HGNC:27935","description":"MAP3K20 antisense RNA 1","metadata":{"aliases":["MLK7-AS1"]}},{"id":"95c3ae9582e0427aba154d176db9be27","type":"GENE","name":"MAP3K21","canonical_id":"hgnc:HGNC:29798","description":"mitogen-activated protein kinase kinase kinase 21","metadata":{"aliases":["KIAA1804","MLK4"]}},{"id":"366c0269dc17404d8120c8ccbe1457ea","type":"GENE","name":"MAP3K3","canonical_id":"hgnc:HGNC:6855","description":"mitogen-activated protein kinase kinase kinase 3","metadata":{"aliases":["MAPKKK3","MEKK3"]}},{"id":"e29abceffae4455ea9a322852d33e794","type":"GENE","name":"MAP3K4","canonical_id":"hgnc:HGNC:6856","description":"mitogen-activated protein kinase kinase kinase 4","metadata":{"aliases":["MTK1","MAPKKK4","KIAA0213","MEKK4"]}},{"id":"c43f3c952f7e490288345188a3ef256b","type":"GENE","name":"MAP3K4-AS1","canonical_id":"hgnc:HGNC:55048","description":"MAP3K4 antisense RNA 1","metadata":null},{"id":"ba6f7a8369464de7b24c8b574a9284bb","type":"GENE","name":"MAP3K5","canonical_id":"hgnc:HGNC:6857","description":null,"metadata":null},{"id":"8e35f3d2b3b14c6eb1815d93f58c7243","type":"GENE","name":"MAP3K5-AS1","canonical_id":"hgnc:HGNC:40358","description":"MAP3K5 antisense RNA 1","metadata":null},{"id":"ca779138b8aa4bad8c95a940e45bad70","type":"GENE","name":"MAP3K5-AS2","canonical_id":"hgnc:HGNC:56125","description":"MAP3K5 antisense RNA 2","metadata":null},{"id":"654bc592e35f455fb665c0401f9054fb","type":"GENE","name":"MAP3K6","canonical_id":"hgnc:HGNC:6858","description":"mitogen-activated protein kinase kinase kinase 6","metadata":{"aliases":["MAPKKK6","ASK2","MEKK6"]}},{"id":"76db727183dd44e2b67609a048813642","type":"GENE","name":"MAP3K7","canonical_id":"hgnc:HGNC:6859","description":"mitogen-activated protein kinase kinase kinase 7","metadata":{"aliases":["MEKK7","TAK1"]}},{"id":"3d0c1098d1da49ffb06bf2f2b81a1b20","type":"GENE","name":"MAP3K7CL","canonical_id":"hgnc:HGNC:16457","description":"MAP3K7 C-terminal like","metadata":{"aliases":["TAKL","TAK1L","TAKL-1","TAKL-2","TAKL-4","C21orf7"]}},{"id":"7b5fa6552114464994986e1fc4b42572","type":"GENE","name":"MAP3K8","canonical_id":"hgnc:HGNC:6860","description":"mitogen-activated protein kinase kinase kinase 8","metadata":{"aliases":["Tpl-2","EST","c-COT","MEKK8","COT","ESTF"]}},{"id":"7ef8cd8e02614055bd9482c553d02dc7","type":"GENE","name":"MAP3K9","canonical_id":"hgnc:HGNC:6861","description":"mitogen-activated protein kinase kinase kinase 9","metadata":{"aliases":["PRKE1","MEKK9","MLK1"]}},{"id":"89434e7c79994766b12772cdcb7b2b85","type":"GENE","name":"MAP3K9-DT","canonical_id":"hgnc:HGNC:53189","description":"MAP3K9 divergent transcript","metadata":{"aliases":["lincNMR"]}},{"id":"58de198d96c742e6aa6edce9e3dcf979","type":"GENE","name":"MAP4","canonical_id":"hgnc:HGNC:6862","description":null,"metadata":null},{"id":"27a183c6faa943c8a532e94b332d3726","type":"GENE","name":"MAP4K1","canonical_id":"hgnc:HGNC:6863","description":"mitogen-activated protein kinase kinase kinase kinase 1","metadata":{"aliases":["HPK1"]}},{"id":"f4c17cc3d8e9457890fdfc3fe9656c43","type":"GENE","name":"MAP4K1-AS1","canonical_id":"hgnc:HGNC:55302","description":"MAP4K1 antisense RNA 1","metadata":null},{"id":"7ea3a526a3fc4560a009ae2cabacf08d","type":"GENE","name":"MAP4K2","canonical_id":"hgnc:HGNC:6864","description":"mitogen-activated protein kinase kinase kinase kinase 2","metadata":{"aliases":["GCK","BL44","RAB8IP"]}},{"id":"f05da71ee31b4e18b5e36a8ebb0ad6b8","type":"GENE","name":"MAP4K3","canonical_id":"hgnc:HGNC:6865","description":"mitogen-activated protein kinase kinase kinase kinase 3","metadata":{"aliases":["GLK","MAPKKKK3","RAB8IPL1"]}},{"id":"df5f352e9db749188a6cd43366e40b52","type":"GENE","name":"MAP4K3-DT","canonical_id":"hgnc:HGNC:54056","description":"MAP4K3 divergent transcript","metadata":null},{"id":"e5aaaa1cd0c24b2d861a8f360b62b012","type":"GENE","name":"MAP4K4","canonical_id":"hgnc:HGNC:6866","description":"mitogen-activated protein kinase kinase kinase kinase 4","metadata":{"aliases":["HGK","NIK","FLH21957"]}},{"id":"76b955f1c949416fb55b157176660e91","type":"GENE","name":"MAP4K5","canonical_id":"hgnc:HGNC:6867","description":"mitogen-activated protein kinase kinase kinase kinase 5","metadata":{"aliases":["KHS1","GCKR","KHS"]}},{"id":"eff3f1e9644a43aea50513875f797465","type":"GENE","name":"MAP6","canonical_id":"hgnc:HGNC:6868","description":"microtubule associated protein 6","metadata":{"aliases":["KIAA1878","STOP","FLJ41346","MAP6-N"]}},{"id":"fd8d691306ef49a887375c314b21574a","type":"GENE","name":"MAP6-AS1","canonical_id":"hgnc:HGNC:58170","description":"MAP6 antisense RNA 1","metadata":null},{"id":"8bf2da0a2e6042c896ad1e118760b3c1","type":"GENE","name":"MAP6D1","canonical_id":"hgnc:HGNC:25753","description":"MAP6 domain containing 1","metadata":{"aliases":["FLJ12748","SL21"]}},{"id":"f56e0aa40b3e4d43a290c07e81924974","type":"GENE","name":"MAP7","canonical_id":"hgnc:HGNC:6869","description":"microtubule associated protein 7","metadata":{"aliases":["E-MAP-115"]}},{"id":"7b1f0b881558400c8249f820226e6b13","type":"GENE","name":"MAP7-AS1","canonical_id":"hgnc:HGNC:56045","description":"MAP7 antisense RNA 1","metadata":null},{"id":"4e3e494c2baa4249a99374bfa9e8b9d2","type":"GENE","name":"MAP7D1","canonical_id":"hgnc:HGNC:25514","description":"MAP7 domain containing 1","metadata":{"aliases":["FLJ10350","FLJ39022","PARCC1","RPRC1"]}},{"id":"152f544366514045a872721b68999c8e","type":"GENE","name":"MAP7D2","canonical_id":"hgnc:HGNC:25899","description":"MAP7 domain containing 2","metadata":{"aliases":["FLJ14503"]}},{"id":"8efb08725f674973ac7e65401660959b","type":"GENE","name":"MAP7D3","canonical_id":"hgnc:HGNC:25742","description":"MAP7 domain containing 3","metadata":{"aliases":["FLJ12649"]}},{"id":"7abe2c36da7747aeaca4e1f1032a3915","type":"GENE","name":"MAP9","canonical_id":"hgnc:HGNC:26118","description":"microtubule associated protein 9","metadata":{"aliases":["ASAP","FLJ21159"]}},{"id":"cbdd5088a7a1459ab0c9707b13da9251","type":"GENE","name":"MAP9-AS1","canonical_id":"hgnc:HGNC:56110","description":"MAP9 antisense RNA 1","metadata":null},{"id":"76fd897083aa481cbebfcc2afe8bd70c","type":"GENE","name":"MAPDA","canonical_id":"hgnc:HGNC:31853","description":"N6-Methyl-AMP deaminase","metadata":{"aliases":["ADAL"]}},{"id":"1cb6afab956f4d809fc8ed37a32745a3","type":"TRIAL","name":"MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas","canonical_id":"clinicaltrials.gov:NCT06712875","description":"Low Grade Glioma; High Grade Glioma","metadata":null},{"id":"75f93b4a33bc4cb49fcd9e6f6c0ccc2a","type":"GO_TERM","name":"MAPK cascade","canonical_id":"go:GO:0000165","description":"\"An intracellular protein kinase cascade containing at least a MAP kinase (MAPK). It starts with the activation of a MAP3K, and the consecutive activation of a MPK2K and a MAPK. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinase in the downstream tier to transmit a signal within a cell.\" [PMID:20811974, PMID:9561267]","metadata":null},{"id":"3a25dee0a84b41568543ed02ebe2dc4d","type":"GO_TERM","name":"MAPK-activating adrenergic receptor signaling pathway","canonical_id":"go:GO:0071883","description":"\"The series of molecular signals generated as a consequence of an adrenergic receptor binding to its physiological ligand and leading to the activation of a MAP kinase cascade.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"68dbfc068813402f93809f8a9d34adb1","type":"GENE","name":"MAPK1","canonical_id":"hgnc:HGNC:6871","description":null,"metadata":null},{"id":"e68f5bf5914a4cd586c1827e61bac7f2","type":"GENE","name":"MAPK10","canonical_id":"hgnc:HGNC:6872","description":"mitogen-activated protein kinase 10","metadata":{"aliases":["JNK3","p493F12","p54bSAPK","PRKM10"]}},{"id":"ae7edbfe07904087a0fb94f99d7a26ee","type":"GENE","name":"MAPK10-AS1","canonical_id":"hgnc:HGNC:40359","description":"MAPK10 antisense RNA 1","metadata":null},{"id":"7ce7e390ee8c448aab5a7f94d88d4eb5","type":"GENE","name":"MAPK11","canonical_id":"hgnc:HGNC:6873","description":"mitogen-activated protein kinase 11","metadata":{"aliases":["p38-2","p38Beta","SAPK2","PRKM11"]}},{"id":"ce9a82c60edf4abd95c38581b5b4ba59","type":"PROTEIN","name":"MAPK11","canonical_id":"uniprot:Q15759","description":null,"metadata":null},{"id":"b724a294c9ad4961be419fdbe7092e4e","type":"GENE","name":"MAPK12","canonical_id":"hgnc:HGNC:6874","description":"mitogen-activated protein kinase 12","metadata":{"aliases":["ERK6","PRKM12","p38gamma","SAPK-3","SAPK3"]}},{"id":"84ee215fe1414a81b97b4381b586cbfd","type":"GENE","name":"MAPK13","canonical_id":"hgnc:HGNC:6875","description":"mitogen-activated protein kinase 13","metadata":{"aliases":["SAPK4","p38delta","PRKM13"]}},{"id":"181b7996c4794244b6edce0cd4e27974","type":"GENE","name":"MAPK14","canonical_id":"hgnc:HGNC:6876","description":null,"metadata":null},{"id":"b5ada13b542c4c5dad9b2b914a670902","type":"GENE","name":"MAPK15","canonical_id":"hgnc:HGNC:24667","description":"mitogen-activated protein kinase 15","metadata":{"aliases":["ERK8","ERK7"]}},{"id":"b5666571024449959c82cc2e4851ac1a","type":"GENE","name":"MAPK1IP1L","canonical_id":"hgnc:HGNC:19840","description":"mitogen-activated protein kinase 1 interacting protein 1 like","metadata":{"aliases":["C14orf32"]}},{"id":"b5aa3487a4b74e3385ff8b6d39224299","type":"GENE","name":"MAPK3","canonical_id":"hgnc:HGNC:6877","description":null,"metadata":null},{"id":"bb26522b682347a681a000865b3b42d5","type":"GENE","name":"MAPK4","canonical_id":"hgnc:HGNC:6878","description":"mitogen-activated protein kinase 4","metadata":{"aliases":["Erk3-related","Erk4","PRKM4"]}},{"id":"55a7e49f6b044327a977ec872d7fbcd3","type":"GENE","name":"MAPK6","canonical_id":"hgnc:HGNC:6879","description":"mitogen-activated protein kinase 6","metadata":{"aliases":["ERK3","p97MAPK","HsT17250","PRKM6"]}},{"id":"694e9e06588b451e89ee8c11a398a716","type":"GENE","name":"MAPK6-DT","canonical_id":"hgnc:HGNC:53900","description":"MAPK6 divergent transcript","metadata":{"aliases":["lncMAPK6"]}},{"id":"c704ed73356a46c18b45e2ede80ddbeb","type":"GENE","name":"MAPK6P1","canonical_id":"hgnc:HGNC:18980","description":"mitogen-activated protein kinase 6 pseudogene 1","metadata":{"aliases":["Erk3ps1","MAPK6PS1"]}},{"id":"8525ff4d4fdb407e887b8c41fdf0d026","type":"GENE","name":"MAPK6P2","canonical_id":"hgnc:HGNC:16756","description":"mitogen-activated protein kinase 6 pseudogene 2","metadata":{"aliases":["MAPK6PS2"]}},{"id":"ba91b3aaea3b49b994f4265f96aa7cc9","type":"GENE","name":"MAPK6P3","canonical_id":"hgnc:HGNC:18977","description":"mitogen-activated protein kinase 6 pseudogene 3","metadata":{"aliases":["MAPK6PS3"]}},{"id":"982e6a6b09db4287be398fe04d33209e","type":"GENE","name":"MAPK6P4","canonical_id":"hgnc:HGNC:18456","description":"mitogen-activated protein kinase 6 pseudogene 4","metadata":{"aliases":["Erk3ps4","MAPK6PS4"]}},{"id":"2e1096fc725a4fd69d02f56cde6b2571","type":"GENE","name":"MAPK6P5","canonical_id":"hgnc:HGNC:18979","description":"mitogen-activated protein kinase 6 pseudogene 5","metadata":{"aliases":["MAPK6PS5"]}},{"id":"43d2eeab3f6346598d9c3462715a2c01","type":"GENE","name":"MAPK6P6","canonical_id":"hgnc:HGNC:18978","description":"mitogen-activated protein kinase 6 pseudogene 6","metadata":{"aliases":["MAPK6PS6"]}},{"id":"09dadb6e1cfe47eb9d50667c8ffc9c71","type":"GENE","name":"MAPK7","canonical_id":"hgnc:HGNC:6880","description":null,"metadata":null},{"id":"eaad0de5da5644cf8ca476b39a0a8612","type":"GENE","name":"MAPK8","canonical_id":"hgnc:HGNC:6881","description":null,"metadata":null},{"id":"38458ad3287b4082a2c2d4b9ec10a1a2","type":"GENE","name":"MAPK8IP1","canonical_id":"hgnc:HGNC:6882","description":"mitogen-activated protein kinase 8 interacting protein 1","metadata":{"aliases":["IB1","JIP-1","JIP1","PRKM8IP"]}},{"id":"1a402af3c8e04692b87d35f8265304e4","type":"GENE","name":"MAPK8IP1P1","canonical_id":"hgnc:HGNC:6885","description":"mitogen-activated protein kinase 8 interacting protein 1 pseudogene 1","metadata":{"aliases":["PRKM8IPP","MAPK8IPP"]}},{"id":"f0c888e20e5c43cfa2119570f2af04fc","type":"GENE","name":"MAPK8IP1P2","canonical_id":"hgnc:HGNC:52402","description":"mitogen-activated protein kinase 8 interacting protein 1 pseudogene 2","metadata":null},{"id":"abd382477db84ac5bc00b7e46f1e5aab","type":"GENE","name":"MAPK8IP2","canonical_id":"hgnc:HGNC:6883","description":"mitogen-activated protein kinase 8 interacting protein 2","metadata":{"aliases":["IB2","JIP2","PRKM8IPL"]}},{"id":"cea76a242854403c870c9a1f2904f6ea","type":"GENE","name":"MAPK8IP3","canonical_id":"hgnc:HGNC:6884","description":"mitogen-activated protein kinase 8 interacting protein 3","metadata":{"aliases":["KIAA1066","JSAP1","JIP3","syd"]}},{"id":"6a9fbe934f8e4a20ab119a344a3f2eb0","type":"GENE","name":"MAPK8IP3-AS1","canonical_id":"hgnc:HGNC:56087","description":"MAPK8IP3 antisense RNA 1","metadata":null},{"id":"6b00abfa2538498692574a9a9de6e3a7","type":"GENE","name":"MAPK9","canonical_id":"hgnc:HGNC:6886","description":"mitogen-activated protein kinase 9","metadata":{"aliases":["JNK2","p54a","SAPK","PRKM9"]}},{"id":"374870fb10da4dea9873bbdc9ee419ce","type":"GENE","name":"MAPK9-DT","canonical_id":"hgnc:HGNC:59319","description":"MAPK9 divergent transcript","metadata":null},{"id":"6e46f0ab8bae4af8a1cb0b9ac50ddaef","type":"GENE","name":"MAPKAP1","canonical_id":"hgnc:HGNC:18752","description":"MAPK associated protein 1","metadata":{"aliases":["MGC2745","SIN1","MIP1"]}},{"id":"e3aa04b23d7549948033ffea1ace8766","type":"GENE","name":"MAPKAPK2","canonical_id":"hgnc:HGNC:6887","description":"MAPK activated protein kinase 2","metadata":{"aliases":["MK2"]}},{"id":"5c0d528f30234d71ad50c6fa3ef9d8e3","type":"GENE","name":"MAPKAPK3","canonical_id":"hgnc:HGNC:6888","description":null,"metadata":null},{"id":"b213593669684dbf833fbcae36997c89","type":"GENE","name":"MAPKAPK5","canonical_id":"hgnc:HGNC:6889","description":"MAPK activated protein kinase 5","metadata":{"aliases":["PRAK","MK5"]}},{"id":"02addfc653104d4d890bd0b5bd70b020","type":"GENE","name":"MAPKAPK5-AS1","canonical_id":"hgnc:HGNC:24091","description":"MAPKAPK5 antisense RNA 1","metadata":{"aliases":["FLJ39616","MAAS","lncRNA-cCSC1","C12orf47"]}},{"id":"74458c265b9f4a1a9d6913cb91cb380b","type":"GENE","name":"MAPKAPK5P1","canonical_id":"hgnc:HGNC:45246","description":"MAPKAPK5 pseudogene 1","metadata":null},{"id":"75bd130eeb544d57ac4a6ddcfed4e561","type":"GENE","name":"MAPKBP1","canonical_id":"hgnc:HGNC:29536","description":"mitogen-activated protein kinase binding protein 1","metadata":{"aliases":["KIAA0596","NPHP20"]}},{"id":"da38ec315ae8445098cb7e8c7f8e6189","type":"GENE","name":"MAPRE1","canonical_id":"hgnc:HGNC:6890","description":"microtubule associated protein RP/EB family member 1","metadata":{"aliases":["EB1"]}},{"id":"e366db694f8f44b0a070012bef076b28","type":"GENE","name":"MAPRE1P1","canonical_id":"hgnc:HGNC:29624","description":"MAPRE1 pseudogene 1","metadata":{"aliases":["MAPRE1P"]}},{"id":"1bd83148a7d8489e956ee205f532fb25","type":"GENE","name":"MAPRE1P2","canonical_id":"hgnc:HGNC:37761","description":"MAPRE1 pseudogene 2","metadata":null},{"id":"96e0dbdc29f14359b08a5762502b58de","type":"GENE","name":"MAPRE1P3","canonical_id":"hgnc:HGNC:37762","description":"MAPRE1 pseudogene 3","metadata":null},{"id":"8ba98046f8be466592bf334232f75cdd","type":"GENE","name":"MAPRE2","canonical_id":"hgnc:HGNC:6891","description":"microtubule associated protein RP/EB family member 2","metadata":{"aliases":["RP1","EB1","EB2"]}},{"id":"89ad6adaad0243bb82238c6380c4e2bc","type":"GENE","name":"MAPRE3","canonical_id":"hgnc:HGNC:6892","description":"microtubule associated protein RP/EB family member 3","metadata":{"aliases":["RP3","EB3"]}},{"id":"dc3a755a821d4d23a3b2653d5b1a463c","type":"GENE","name":"MAPRE3-AS1","canonical_id":"hgnc:HGNC:40362","description":"MAPRE3 antisense RNA 1","metadata":null},{"id":"bca152a43d5847a4947a117fb5b2936d","type":"GENE","name":"MAPT","canonical_id":"hgnc:HGNC:6893","description":"microtubule associated protein tau","metadata":{"aliases":["MTBT1","tau","PPND","FTDP-17","TAU","MSTD","MTBT2","FLJ31424","MGC138549","PPP1R103","tau-40","Tau-PHF6","DDPAC","MAPTL"]}},{"id":"d11ffe29a61d4c4dae04491306578a1e","type":"GENE","name":"MAPT-AS1","canonical_id":"hgnc:HGNC:43738","description":"MAPT antisense RNA 1","metadata":{"aliases":["MAPT-AS"]}},{"id":"93b17a120af6417f96750e1658a85351","type":"GENE","name":"MAPT-IT1","canonical_id":"hgnc:HGNC:43741","description":"MAPT intronic transcript 1","metadata":null},{"id":"68eca4fc29e747778a506dbaf74a2288","type":"GENE","name":"MARCHF1","canonical_id":"hgnc:HGNC:26077","description":"membrane associated ring-CH-type finger 1","metadata":{"aliases":["FLJ20668","MARCH-I","RNF171","MARCH1"]}},{"id":"781561ac703244e2aa1940973743ea1a","type":"GENE","name":"MARCHF1-AS1","canonical_id":"hgnc:HGNC:58905","description":"MARCHF1 antisense RNA 1","metadata":null},{"id":"b1dcad7667a04d81b6e4a6fee5ea72bb","type":"GENE","name":"MARCHF10","canonical_id":"hgnc:HGNC:26655","description":"membrane associated ring-CH-type finger 10","metadata":{"aliases":["FLJ35757","MARCH-X","RNF190","MARCH10"]}},{"id":"abe6ec97fd6746bf9d4c85bc30eb39fe","type":"GENE","name":"MARCHF10-AS1","canonical_id":"hgnc:HGNC:58173","description":"MARCHF10 antisense RNA 1","metadata":null},{"id":"490b47ecf6234e9eb25aec8a0ed4076f","type":"GENE","name":"MARCHF10-DT","canonical_id":"hgnc:HGNC:52815","description":"MARCHF10 divergent transcript","metadata":{"aliases":["MARCH10-DT"]}},{"id":"babb89468b7a46a2a84a19eb94849e31","type":"GENE","name":"MARCHF11","canonical_id":"hgnc:HGNC:33609","description":"membrane associated ring-CH-type finger 11","metadata":{"aliases":["MARCH-XI","RNF226","MARCH11"]}},{"id":"e55a6d8df26149db855d266a8ad7fc63","type":"GENE","name":"MARCHF11-AS1","canonical_id":"hgnc:HGNC:41287","description":"MARCHF11 antisense RNA 1","metadata":{"aliases":["MARCH11-AS1"]}},{"id":"e360c26eb8784f7f826e47bc03332494","type":"GENE","name":"MARCHF11-DT","canonical_id":"hgnc:HGNC:55550","description":"MARCHF11 divergent transcript","metadata":null},{"id":"617a4c1d7fbe4f0f9fcd18237a5a4c16","type":"GENE","name":"MARCHF2","canonical_id":"hgnc:HGNC:28038","description":"membrane associated ring-CH-type finger 2","metadata":{"aliases":["HSPC240","MARCH-II","RNF172","MARCH2"]}},{"id":"903e168deef54f29b48bc264686d00e9","type":"GENE","name":"MARCHF3","canonical_id":"hgnc:HGNC:28728","description":"membrane associated ring-CH-type finger 3","metadata":{"aliases":["MGC48332","MARCH-III","RNF173","MARCH3"]}},{"id":"12c437395aca413cb00751754ef37f23","type":"GENE","name":"MARCHF3-DT","canonical_id":"hgnc:HGNC:59125","description":"MARCHF3 divergent transcript","metadata":null},{"id":"29198343cbb447a09b15091d972c0a0b","type":"GENE","name":"MARCHF4","canonical_id":"hgnc:HGNC:29269","description":"membrane associated ring-CH-type finger 4","metadata":{"aliases":["KIAA1399","MARCH-IV","RNF174","MARCH4"]}},{"id":"d90d1f575fc54193be58872719243394","type":"GENE","name":"MARCHF4-AS1","canonical_id":"hgnc:HGNC:58229","description":"MARCHF4 antisense RNA 1","metadata":null},{"id":"eed911a2f6084a1483efd2f98ddda4e4","type":"GENE","name":"MARCHF5","canonical_id":"hgnc:HGNC:26025","description":"membrane associated ring-CH-type finger 5","metadata":{"aliases":["FLJ20445","MARCH-V","MITOL","RNF153","MARCH5"]}},{"id":"92fa25e4a97847b19d3fad370a912a95","type":"GENE","name":"MARCHF6","canonical_id":"hgnc:HGNC:30550","description":"membrane associated ring-CH-type finger 6","metadata":{"aliases":["TEB4","MARCH-VI","RNF176","MARCH6"]}},{"id":"d8998a234fac404bb5d8df218f93fd10","type":"GENE","name":"MARCHF6-DT","canonical_id":"hgnc:HGNC:56238","description":"MARCHF6 divergent transcript","metadata":{"aliases":["CTD-2256P15.2","PACMP"]}},{"id":"a14a48d38cc54e7ca2db5fba91b67939","type":"GENE","name":"MARCHF7","canonical_id":"hgnc:HGNC:17393","description":"membrane associated ring-CH-type finger 7","metadata":{"aliases":["MARCH-VII","RNF177","AXOT","MARCH7"]}},{"id":"ae6ec479b91d48d9983fc3ee9c472638","type":"GENE","name":"MARCHF8","canonical_id":"hgnc:HGNC:23356","description":"membrane associated ring-CH-type finger 8","metadata":{"aliases":["c-MIR","CMIR","MARCH-VIII","RNF178","MIR","MARCH8"]}},{"id":"3fca76a678c64d14baac0d9b2b5cefdd","type":"GENE","name":"MARCHF9","canonical_id":"hgnc:HGNC:25139","description":"membrane associated ring-CH-type finger 9","metadata":{"aliases":["RNF179","FLJ36578","MARCH9"]}},{"id":"3264dcb4562b4d489b170cc6366b3451","type":"GENE","name":"MARCKS","canonical_id":"hgnc:HGNC:6759","description":"myristoylated alanine rich protein kinase C substrate","metadata":{"aliases":["PKCSL","80K-L","MACS"]}},{"id":"310fb22aeb2e4ce5b967b703d69b8b63","type":"GENE","name":"MARCKSL1","canonical_id":"hgnc:HGNC:7142","description":"MARCKS like 1","metadata":{"aliases":["F52","MacMARCKS","MLP1","MLP"]}},{"id":"40bb1c0936924f8d99bb1b49e25fe03e","type":"GENE","name":"MARCKSL1P1","canonical_id":"hgnc:HGNC:45239","description":"MARCKS like 1 pseudogene 1","metadata":null},{"id":"2f241091064e4d9b875cd099647d54dd","type":"GENE","name":"MARCKSL1P2","canonical_id":"hgnc:HGNC:45240","description":"MARCKS like 1 pseudogene 2","metadata":null},{"id":"c9ea28567b60448a87491c22434b4b9c","type":"GENE","name":"MARCKSP1","canonical_id":"hgnc:HGNC:6760","description":"myristoylated alanine rich protein kinase C substrate pseudogene 1","metadata":{"aliases":["MACSL1"]}},{"id":"b5d462fd567f4f369538c8bee9210c38","type":"GENE","name":"MARCO","canonical_id":"hgnc:HGNC:6895","description":"macrophage receptor with collagenous structure","metadata":{"aliases":["SCARA2","SR-A6"]}},{"id":"84c12924a6d942aa815d4a6cc87bbe6d","type":"GENE","name":"MARCO-AS1","canonical_id":"hgnc:HGNC:58466","description":"MARCO antisense RNA 1","metadata":null},{"id":"9571633e01db4ecdbdb22968ab496a06","type":"GENE","name":"MARCOL","canonical_id":"hgnc:HGNC:53644","description":"MARCO like","metadata":null},{"id":"2feb6b6c604c4fe593c092b5970ca031","type":"GENE","name":"MARF1","canonical_id":"hgnc:HGNC:29562","description":"meiosis regulator and mRNA stability factor 1","metadata":{"aliases":["LKAP","PPP1R34","LMKB","KIAA0430"]}},{"id":"6b2080392167462598c859f5ce235c02","type":"TRIAL","name":"MARGetuximab Or Trastuzumab (MARGOT)","canonical_id":"clinicaltrials.gov:NCT04425018","description":"Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"09a31791c01b449ebcddd0864a722ef2","type":"GENE","name":"MARK1","canonical_id":"hgnc:HGNC:6896","description":"microtubule affinity regulating kinase 1","metadata":{"aliases":["MARK","PAR-1C"]}},{"id":"197f862462924d7ea872cb34aa138ca4","type":"GENE","name":"MARK2","canonical_id":"hgnc:HGNC:3332","description":"microtubule affinity regulating kinase 2","metadata":{"aliases":["PAR-1","Par1b","PAR-1B","EMK1"]}},{"id":"61111975b194442abfe60a780009a6cc","type":"GENE","name":"MARK2P1","canonical_id":"hgnc:HGNC:39792","description":"MARK2 pseudogene 1","metadata":null},{"id":"35def9438e2f4066845741d2d2e15916","type":"GENE","name":"MARK2P10","canonical_id":"hgnc:HGNC:39801","description":"MARK2 pseudogene 10","metadata":null},{"id":"3087eacbd954452cbe347cd5f5100e41","type":"GENE","name":"MARK2P11","canonical_id":"hgnc:HGNC:39802","description":"MARK2 pseudogene 11","metadata":null},{"id":"378a1004d411499abf221e50472ad8d3","type":"GENE","name":"MARK2P12","canonical_id":"hgnc:HGNC:39803","description":"MARK2 pseudogene 12","metadata":null},{"id":"004d427783ce4eeeb91bc6268e84d283","type":"GENE","name":"MARK2P13","canonical_id":"hgnc:HGNC:39804","description":"MARK2 pseudogene 13","metadata":null},{"id":"26d44e11f62b4999bf204646985a5eae","type":"GENE","name":"MARK2P14","canonical_id":"hgnc:HGNC:44495","description":"MARK2 pseudogene 14","metadata":null},{"id":"9caf8a724d0240648428a333712d1f1a","type":"GENE","name":"MARK2P15","canonical_id":"hgnc:HGNC:45119","description":"MARK2 pseudogene 15","metadata":null},{"id":"f2f750485aca41a3bf969182659960ea","type":"GENE","name":"MARK2P16","canonical_id":"hgnc:HGNC:45171","description":"MARK2 pseudogene 16","metadata":null},{"id":"483ad702472d4c06ac54433c73dc2b4a","type":"GENE","name":"MARK2P17","canonical_id":"hgnc:HGNC:50318","description":"MARK2 pseudogene 17","metadata":null},{"id":"8dda102f5f0d465abbf2906026dc9613","type":"GENE","name":"MARK2P18","canonical_id":"hgnc:HGNC:56405","description":"MARK2 pseudogene 18","metadata":null},{"id":"9b7ccd8c79934c03bb5a47e234976375","type":"GENE","name":"MARK2P19","canonical_id":"hgnc:HGNC:56521","description":"MARK2 pseudogene 19","metadata":null},{"id":"351fd5b387624c8ebcc8f80fa003ddbe","type":"GENE","name":"MARK2P2","canonical_id":"hgnc:HGNC:39793","description":"MARK2 pseudogene 2","metadata":null},{"id":"20ad7b3b7f0f46aba935d3f07e7db26b","type":"GENE","name":"MARK2P20","canonical_id":"hgnc:HGNC:44494","description":"MARK2 pseudogene 20","metadata":null},{"id":"3631d932285548dda3546a3462a18716","type":"GENE","name":"MARK2P21","canonical_id":"hgnc:HGNC:57000","description":"MARK2 pseudogene 21","metadata":null},{"id":"44894937d25b49fab28fc15d2f0f02cf","type":"GENE","name":"MARK2P3","canonical_id":"hgnc:HGNC:39794","description":"MARK2 pseudogene 3","metadata":null},{"id":"1f4d630526a840fe8bf989f594062f37","type":"GENE","name":"MARK2P4","canonical_id":"hgnc:HGNC:39795","description":"MARK2 pseudogene 4","metadata":null},{"id":"c1baba1be9b64292849999189825b897","type":"GENE","name":"MARK2P5","canonical_id":"hgnc:HGNC:39796","description":"MARK2 pseudogene 5","metadata":null},{"id":"3e38122e1bf54065843d0b0aaab5860b","type":"GENE","name":"MARK2P6","canonical_id":"hgnc:HGNC:39797","description":"MARK2 pseudogene 6","metadata":null},{"id":"eeaad6f24b7444698eca9b6a76e6a65c","type":"GENE","name":"MARK2P7","canonical_id":"hgnc:HGNC:39798","description":"MARK2 pseudogene 7","metadata":null},{"id":"a59b2f4c61024393a37e0245f93c9e91","type":"GENE","name":"MARK2P8","canonical_id":"hgnc:HGNC:39799","description":"MARK2 pseudogene 8","metadata":null},{"id":"5dd0eb108ec4433e97819092d3cee537","type":"GENE","name":"MARK2P9","canonical_id":"hgnc:HGNC:39800","description":"MARK2 pseudogene 9","metadata":null},{"id":"516d605be56348348957304ef9079847","type":"GENE","name":"MARK3","canonical_id":"hgnc:HGNC:6897","description":"microtubule affinity regulating kinase 3","metadata":{"aliases":["CTAK1","KP78","PAR-1A"]}},{"id":"67fea950316141e3ae191ee3d7b8a776","type":"GENE","name":"MARK3P1","canonical_id":"hgnc:HGNC:50312","description":"microtubule affinity regulating kinase 3 pseudogene 1","metadata":null},{"id":"5b4fec79d07a4cf1bce953c8582b905d","type":"GENE","name":"MARK3P2","canonical_id":"hgnc:HGNC:50313","description":"microtubule affinity regulating kinase 3 pseudogene 2","metadata":null},{"id":"05890ba5ea0842c9838006275e2c9d3f","type":"GENE","name":"MARK3P3","canonical_id":"hgnc:HGNC:50314","description":"microtubule affinity regulating kinase 3 pseudogene 3","metadata":null},{"id":"a4aff0a7a3b24fe1b9359d30f47adb24","type":"GENE","name":"MARK4","canonical_id":"hgnc:HGNC:13538","description":"microtubule affinity regulating kinase 4","metadata":{"aliases":["Nbla00650","FLJ90097","KIAA1860","PAR-1D","MARKL1"]}},{"id":"d23cf6df31534507afb3ce5e682f8297","type":"GENE","name":"MARS1","canonical_id":"hgnc:HGNC:6898","description":"methionyl-tRNA synthetase 1","metadata":{"aliases":["MetRS","SPG70","CMT2U","MARS"]}},{"id":"bbbfe0eefe724dcbb99c9411d9a30cbe","type":"GENE","name":"MARS2","canonical_id":"hgnc:HGNC:25133","description":"methionyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["mtMetRS","SPAX3"]}},{"id":"2755a0bf8c954cf38865149c0409186e","type":"GENE","name":"MARVELD1","canonical_id":"hgnc:HGNC:28674","description":"MARVEL domain containing 1","metadata":{"aliases":["MGC4415","GB14","FLJ23440","FLJ22343","bA548K23.8","MRVLDC1"]}},{"id":"fd66fa2cc752479198c68cb95d277ffd","type":"GENE","name":"MARVELD2","canonical_id":"hgnc:HGNC:26401","description":"MARVEL domain containing 2","metadata":{"aliases":["FLJ30532","TRIC","MRVLDC2","DFNB49"]}},{"id":"8ab64c61076944f6b7336b318e3aefb0","type":"GENE","name":"MARVELD3","canonical_id":"hgnc:HGNC:30525","description":"MARVEL domain containing 3","metadata":{"aliases":["MRVLDC3"]}},{"id":"a040bdfa80974e3fbfb6923888f5e487","type":"GENE","name":"MAS1","canonical_id":"hgnc:HGNC:6899","description":"MAS1 proto-oncogene, G protein-coupled receptor","metadata":null},{"id":"1b22c7c7057042d1b4c72131a7a9bb65","type":"GENE","name":"MAS1L","canonical_id":"hgnc:HGNC:13961","description":"MAS1 proto-oncogene like, G protein-coupled receptor","metadata":{"aliases":["MAS-L","MRG","dJ994E9.2"]}},{"id":"9a1bdb5265cd4525aab4ef26878bf7f8","type":"GENE","name":"MAS1LP1","canonical_id":"hgnc:HGNC:33448","description":"MAS1L pseudogene 1","metadata":{"aliases":["OTTHUMG00000086553","MAS1LP"]}},{"id":"98009d6fcb964087935d538e2c953c33","type":"GENE","name":"MAS1LP2","canonical_id":"hgnc:HGNC:4509","description":"MAS1L pseudogene 2","metadata":{"aliases":["PsiGPR53","dJ271M21.8","GPR53P"]}},{"id":"96f01db1ff2f4a2e847e851098df7bdf","type":"GENE","name":"MASP1","canonical_id":"hgnc:HGNC:6901","description":"MBL associated serine protease 1","metadata":{"aliases":["MASP","Map44","MASP-3","MAP-1","CRARF","PRSS5"]}},{"id":"2790a7c8218d41ec9e565960dae46d36","type":"GENE","name":"MASP2","canonical_id":"hgnc:HGNC:6902","description":"MBL associated serine protease 2","metadata":{"aliases":["Map19","sMAP","MAP-2","MASP1P1"]}},{"id":"ddd37b9744ed4ae7aed1ec1adcdd13fb","type":"PROTEIN","name":"MASP2","canonical_id":"uniprot:O00187","description":null,"metadata":null},{"id":"ac5c36f85ddf4a328d5e67aa9c5280d4","type":"GENE","name":"MAST1","canonical_id":"hgnc:HGNC:19034","description":"microtubule associated serine/threonine kinase 1","metadata":{"aliases":["SAST","KIAA0973"]}},{"id":"bb57d30011d24b2e896b110799d9eaab","type":"GENE","name":"MAST2","canonical_id":"hgnc:HGNC:19035","description":"microtubule associated serine/threonine kinase 2","metadata":{"aliases":["MAST205","KIAA0807"]}},{"id":"f27c9cec78ae4bbd96d199bd375b845c","type":"GENE","name":"MAST3","canonical_id":"hgnc:HGNC:19036","description":"microtubule associated serine/threonine kinase 3","metadata":{"aliases":["KIAA0561"]}},{"id":"593475eed0a343c28b3e43df8236fd9d","type":"GENE","name":"MAST3-AS1","canonical_id":"hgnc:HGNC:55276","description":"MAST3 antisense RNA 1","metadata":null},{"id":"7463ecb2b20a4df5b57b2d0907539c03","type":"GENE","name":"MAST4","canonical_id":"hgnc:HGNC:19037","description":"microtubule associated serine/threonine kinase family member 4","metadata":{"aliases":["KIAA0303"]}},{"id":"a1d176263f5b4b81be4c9c95a4d45b5a","type":"GENE","name":"MAST4-AS1","canonical_id":"hgnc:HGNC:40865","description":"MAST4 antisense RNA 1","metadata":null},{"id":"50f8a99a94a043289fc3c5970225f8dc","type":"GENE","name":"MAST4-IT1","canonical_id":"hgnc:HGNC:41448","description":"MAST4 intronic transcript 1","metadata":null},{"id":"40c1dc16bfa742ba84a08d901f5e949d","type":"GENE","name":"MASTL","canonical_id":"hgnc:HGNC:19042","description":"microtubule associated serine/threonine kinase like","metadata":{"aliases":["FLJ14813","THC2","Gwl"]}},{"id":"ae19681637a2440baa4a30b77eac0de7","type":"GENE","name":"MAT1A","canonical_id":"hgnc:HGNC:6903","description":"methionine adenosyltransferase 1A","metadata":{"aliases":["MAT","SAMS","MATA1","SAMS1","MAT-I/III"]}},{"id":"cafd60adb8a24b4a913f979f9bd6f52f","type":"GENE","name":"MAT2A","canonical_id":"hgnc:HGNC:6904","description":null,"metadata":null},{"id":"5ef53b87a07a456c902476549ab8ee80","type":"GENE","name":"MAT2AP1","canonical_id":"hgnc:HGNC:56476","description":"MAT2A pseudogene 1","metadata":null},{"id":"50ec8c95058744e3ae1225db8db6a56f","type":"GENE","name":"MAT2B","canonical_id":"hgnc:HGNC:6905","description":null,"metadata":null},{"id":"420efee8b00440bb8fed1b0d4211a2d5","type":"GENE","name":"MATCAP1","canonical_id":"hgnc:HGNC:34408","description":"microtubule associated tyrosine carboxypeptidase 1","metadata":{"aliases":["LOC653319","TMCP1","KIAA0895L"]}},{"id":"be036928534c44c5b962b6b749e457c3","type":"GENE","name":"MATCAP1P1","canonical_id":"hgnc:HGNC:53865","description":"MATCAP1 pseudogene 1","metadata":{"aliases":["KIAA0895LP1"]}},{"id":"f48287cf252c4e7db595309de92437f2","type":"GENE","name":"MATCAP2","canonical_id":"hgnc:HGNC:22206","description":"microtubule associated tyrosine carboxypeptidase 2","metadata":{"aliases":["TMCP2","KIAA0895"]}},{"id":"fc3a605ac1ca429fa96c7c63e5815fe0","type":"GO_TERM","name":"MATH domain binding","canonical_id":"go:GO:0090736","description":"\"Binding to a meprin and TRAF homology (MATH) domain.\" [InterPro:IPR002083, PMID:22621901]","metadata":null},{"id":"9433598ddad2453cb77159aaa8b2f19d","type":"GENE","name":"MATK","canonical_id":"hgnc:HGNC:6906","description":"megakaryocyte-associated tyrosine kinase","metadata":{"aliases":["HYLTK","CTK","HYL","Lsk","CHK","HHYLTK","DKFZp434N1212","MGC1708","MGC2101"]}},{"id":"c2244c8e1dcb472abbe1f61e2b6b97e5","type":"GENE","name":"MATN1","canonical_id":"hgnc:HGNC:6907","description":null,"metadata":null},{"id":"789ff8beb1474e40b17ef6c0d2cfe47c","type":"GENE","name":"MATN1-AS1","canonical_id":"hgnc:HGNC:40364","description":"MATN1 antisense RNA 1","metadata":null},{"id":"be527d7642b04f75b191904f6c99735f","type":"GENE","name":"MATN2","canonical_id":"hgnc:HGNC:6908","description":"matrilin 2","metadata":null},{"id":"fdb4f130ae4c45fead1838800d73c83f","type":"GENE","name":"MATN3","canonical_id":"hgnc:HGNC:6909","description":"matrilin 3","metadata":{"aliases":["EDM5","HOA"]}},{"id":"afac07b7bf8a4dc6b50e8b236a69c776","type":"GENE","name":"MATN4","canonical_id":"hgnc:HGNC:6910","description":"matrilin 4","metadata":null},{"id":"2fb2974a3e074e24bf284e3b8375de2c","type":"GENE","name":"MATR3","canonical_id":"hgnc:HGNC:6912","description":"matrin 3","metadata":{"aliases":["KIAA0723","MGC9105","VCPDM","MPD2"]}},{"id":"ea9521a57309467ba3c5baeb13569dd1","type":"GENE","name":"MATR3P1","canonical_id":"hgnc:HGNC:54991","description":"MATR3 pseudogene 1","metadata":null},{"id":"afd231f3355c4fe893bec957fd04d922","type":"GENE","name":"MATR3P2","canonical_id":"hgnc:HGNC:56591","description":"MATR3 pseudogene 2","metadata":null},{"id":"39ba201cc4d34f53953a7c043fcbcfea","type":"GENE","name":"MATR3P3","canonical_id":"hgnc:HGNC:56592","description":"MATR3 pseudogene 3","metadata":null},{"id":"50b06166c44847109790660761037559","type":"GENE","name":"MAU2","canonical_id":"hgnc:HGNC:29140","description":"MAU2 sister chromatid cohesion factor","metadata":{"aliases":["MGC75361","mau-2","MAU2L","SCC4","KIAA0892"]}},{"id":"342f8ca19d4046799787029219ede8ba","type":"GENE","name":"MAVS","canonical_id":"hgnc:HGNC:29233","description":null,"metadata":null},{"id":"f02b8969005445e69bb7aab2a5554e72","type":"GENE","name":"MAX","canonical_id":"hgnc:HGNC:6913","description":null,"metadata":null},{"id":"d4ed7c9431c14799a547b0c0e5b2e2d5","type":"GENE","name":"MAX-AS1","canonical_id":"hgnc:HGNC:58293","description":"MAX antisense RNA 1","metadata":null},{"id":"9c0e136187314703b54caa4465ef0722","type":"GENE","name":"MAZ","canonical_id":"hgnc:HGNC:6914","description":null,"metadata":null},{"id":"5cbd8fd19b7b49da9b22873f884543da","type":"GENE","name":"MB","canonical_id":"hgnc:HGNC:6915","description":"myoglobin","metadata":{"aliases":["PVALB"]}},{"id":"ca24b41f8c784e559836ce4df1c311bb","type":"GENE","name":"MB21D2","canonical_id":"hgnc:HGNC:30438","description":"Mab-21 domain containing 2","metadata":{"aliases":["D2A","C3orf59"]}},{"id":"da4aaa4d21f547e2890f42b4abee684d","type":"GENE","name":"MBD1","canonical_id":"hgnc:HGNC:6916","description":null,"metadata":null},{"id":"8a0834851ac14079a63977e0f88029d8","type":"GENE","name":"MBD2","canonical_id":"hgnc:HGNC:6917","description":null,"metadata":null},{"id":"b9dadc609dfe47d7bf6b6fc6c8659151","type":"GENE","name":"MBD3","canonical_id":"hgnc:HGNC:6918","description":"methyl-CpG binding domain protein 3","metadata":null},{"id":"a07ae22515624ff58b5c181260364870","type":"GENE","name":"MBD3L1","canonical_id":"hgnc:HGNC:15774","description":"methyl-CpG binding domain protein 3 like 1","metadata":{"aliases":["MBD3L"]}},{"id":"86859631c0734b0fa39abd93f241e38e","type":"GENE","name":"MBD3L2","canonical_id":"hgnc:HGNC:18532","description":"methyl-CpG binding domain protein 3 like 2","metadata":null},{"id":"e796da57b95c48748ae49549dcd1589e","type":"GENE","name":"MBD3L2B","canonical_id":"hgnc:HGNC:53435","description":"methyl-CpG binding domain protein 3 like 2B","metadata":null},{"id":"d85feb0d0d9c48b2bc700e0cb210fc20","type":"GENE","name":"MBD3L3","canonical_id":"hgnc:HGNC:37205","description":"methyl-CpG binding domain protein 3 like 3","metadata":null},{"id":"761484b87c0a4028882ea7d510885755","type":"GENE","name":"MBD3L4","canonical_id":"hgnc:HGNC:37206","description":"methyl-CpG binding domain protein 3 like 4","metadata":null},{"id":"6e655c2930a145aca55733dfa6a3d223","type":"GENE","name":"MBD3L5","canonical_id":"hgnc:HGNC:37204","description":"methyl-CpG binding domain protein 3 like 5","metadata":null},{"id":"b9e1f457f6dd4d21b13616833c55e16c","type":"GENE","name":"MBD4","canonical_id":"hgnc:HGNC:6919","description":"methyl-CpG binding domain 4, DNA glycosylase","metadata":{"aliases":["MED1"]}},{"id":"4641bffd09e64205b291fedae0893b6e","type":"GENE","name":"MBD5","canonical_id":"hgnc:HGNC:20444","description":"methyl-CpG binding domain protein 5","metadata":{"aliases":["FLJ11113","KIAA1461"]}},{"id":"1b3b379cca804926af78ddffec3bc2fc","type":"GENE","name":"MBD6","canonical_id":"hgnc:HGNC:20445","description":"methyl-CpG binding domain protein 6","metadata":{"aliases":["KIAA1887"]}},{"id":"3dca51af51174597ac9431e7d1e91663","type":"GO_TERM","name":"MBF transcription complex","canonical_id":"go:GO:0030907","description":"\"A protein complex that binds to the Mlu1 cell cycle box (MCB) promoter element, consensus sequence ACGCGN, and is involved in regulation of transcription during the G1/S transition of the cell cycle. In Saccharomyces, the complex contains a heterodimer of the DNA binding protein Mbp1p and the activator Swi6p, and is associated with additional proteins known as Nrm1p, Msa1p, and Msa2p; in Schizosaccharomyces the complex contains Res1p, Res2p, and Cdc10p.\" [GOC:mah, PMID:11206552, PMID:15838511, PMID:18160399, PMID:9343385]","metadata":null},{"id":"088bff98c5fe4680a37d4a27d4ee3ae6","type":"GO_TERM","name":"MBF transcription complex assembly","canonical_id":"go:GO:0120185","description":"\"The aggregation, arrangement and bonding together of a set of components to form an MBF transcription complex.\" [PMID:9303312]","metadata":null},{"id":"1ad653fc43cf417599b39192c5edf9f8","type":"GENE","name":"MBIP","canonical_id":"hgnc:HGNC:20427","description":"MAP3K12 binding inhibitory protein 1","metadata":null},{"id":"5c60e761b9ea44f491c5132cd0fd7122","type":"GENE","name":"MBL1P","canonical_id":"hgnc:HGNC:6921","description":"mannose binding lectin 1, pseudogene","metadata":{"aliases":["COLEC3P","MBL1P1"]}},{"id":"0bf0514cd66149bb8ac6be2c48604436","type":"GENE","name":"MBL2","canonical_id":"hgnc:HGNC:6922","description":"mannose binding lectin 2","metadata":{"aliases":["COLEC1","MBP-C","MBP1","MBP","MBL"]}},{"id":"40e8fca66447452eb4cab6d7c0015e4b","type":"GENE","name":"MBL3P","canonical_id":"hgnc:HGNC:2221","description":"mannose-binding lectin family member 3, pseudogene","metadata":{"aliases":["COLEC2"]}},{"id":"7c1501603ad949d7a0277e0b8d7d0c8d","type":"GENE","name":"MBLAC1","canonical_id":"hgnc:HGNC:22180","description":"metallo-beta-lactamase domain containing 1","metadata":{"aliases":["MGC49416"]}},{"id":"a6a397564d6549cd8c04599c9095c6f7","type":"GENE","name":"MBLAC2","canonical_id":"hgnc:HGNC:33711","description":"metallo-beta-lactamase domain containing 2","metadata":{"aliases":["DKFZp686P15118","MGC46734"]}},{"id":"e0744e8cb8524c9ca2b26ee3483a5775","type":"GENE","name":"MBNL1","canonical_id":"hgnc:HGNC:6923","description":"muscleblind like splicing regulator 1","metadata":{"aliases":["KIAA0428","EXP42","EXP40","EXP35","EXP","MBNL"]}},{"id":"2d1a4a9652bc4d55b5146e578dc87158","type":"GENE","name":"MBNL1-AS1","canonical_id":"hgnc:HGNC:44584","description":"MBNL1 antisense RNA 1","metadata":{"aliases":["LOC401093"]}},{"id":"1efe0bf3a07743fbba17538835ac1182","type":"GENE","name":"MBNL2","canonical_id":"hgnc:HGNC:16746","description":"muscleblind like splicing regulator 2","metadata":{"aliases":["MBLL","MBLL39"]}},{"id":"6d19c580256944569b2a404e997a2c89","type":"GENE","name":"MBNL3","canonical_id":"hgnc:HGNC:20564","description":"muscleblind like splicing regulator 3","metadata":{"aliases":["CHCR","FLJ11316","MBLX39","MBXL"]}},{"id":"23e22e211eae4cc280b9e3a3ee8d6f70","type":"GENE","name":"MBOAT1","canonical_id":"hgnc:HGNC:21579","description":"membrane bound glycerophospholipid O-acyltransferase 1","metadata":{"aliases":["MGC44669","dJ434O11.1","LPEAT1","LPLAT14","OACT1"]}},{"id":"ff0a8e2fcd0f4df3b8d38904ed3849c8","type":"GENE","name":"MBOAT1-AS1","canonical_id":"hgnc:HGNC:59369","description":"MBOAT1 antisense RNA 1","metadata":null},{"id":"2c9550ed18714b19b690449944814d60","type":"GENE","name":"MBOAT2","canonical_id":"hgnc:HGNC:25193","description":"membrane bound glycerophospholipid O-acyltransferase 2","metadata":{"aliases":["FLJ14415","FLJ90298","LPLAT13","OACT2"]}},{"id":"33da40b372f54dc296f7569430893cc9","type":"GENE","name":"MBOAT4","canonical_id":"hgnc:HGNC:32311","description":"membrane bound ghrelin O-acyltransferase MBOAT4","metadata":{"aliases":["FKSG89","GOAT","OACT4"]}},{"id":"208d4757853c4fba892f1cac648b2c2a","type":"GENE","name":"MBOAT7","canonical_id":"hgnc:HGNC:15505","description":"membrane bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7","metadata":{"aliases":["BB1","hMBOA-7","LPLAT","LPIAT1","LPLAT11","LENG4"]}},{"id":"1bc705045b15495aafb0089ed0f8fa4c","type":"GENE","name":"MBP","canonical_id":"hgnc:HGNC:6925","description":null,"metadata":null},{"id":"ed2bb0b8081548ba8bf2c32ee5e2a2b9","type":"GENE","name":"MBP-AS1","canonical_id":"hgnc:HGNC:58315","description":"MBP antisense RNA 1","metadata":null},{"id":"e3bcbce17c9f497383e0c1b1806f0807","type":"GENE","name":"MBP-AS2","canonical_id":"hgnc:HGNC:58393","description":"MBP antisense RNA 2","metadata":null},{"id":"2edbd889a6bc403aa1290ca1baa6ddab","type":"GENE","name":"MBTD1","canonical_id":"hgnc:HGNC:19866","description":"mbt domain containing 1","metadata":{"aliases":["SA49P01","FLJ20055"]}},{"id":"1eee3948c90b4f2a9952fd2624cdf40b","type":"GENE","name":"MBTPS1","canonical_id":"hgnc:HGNC:15456","description":"membrane bound transcription factor peptidase, site 1","metadata":{"aliases":["S1P","KIAA0091","SKI-1","PCSK8"]}},{"id":"c241695931e8495d911c2bf77b0f039a","type":"GENE","name":"MBTPS1-DT","canonical_id":"hgnc:HGNC:55401","description":"MBTPS1 divergent transcript","metadata":{"aliases":["AC040169.1"]}},{"id":"80c86a2d454f4945a4164056e69d7c17","type":"GENE","name":"MBTPS2","canonical_id":"hgnc:HGNC:15455","description":"membrane bound transcription factor peptidase, site 2","metadata":{"aliases":["S2P","KFSD"]}},{"id":"970fc1107a634a32b4dd611955037fb7","type":"TRIAL","name":"MC RCT - BPO vs Adapalene","canonical_id":"clinicaltrials.gov:NCT05536882","description":"Molluscum Contagiosum","metadata":null},{"id":"8209be6df6844bdeb226672ee922809f","type":"GENE","name":"MC1R","canonical_id":"hgnc:HGNC:6929","description":null,"metadata":null},{"id":"1542922fc666475dac6be738a37055fa","type":"GENE","name":"MC2R","canonical_id":"hgnc:HGNC:6930","description":null,"metadata":null},{"id":"f5a174ea64394da3a9cc87c64d9562b5","type":"PROTEIN","name":"MC2R","canonical_id":"uniprot:Q01718","description":null,"metadata":null},{"id":"6c4953a20ec442c8aaa7c00b8de73e47","type":"GENE","name":"MC3R","canonical_id":"hgnc:HGNC:6931","description":"melanocortin 3 receptor","metadata":{"aliases":["MC3"]}},{"id":"e6d38acd917a4244afb9acb0e62694f8","type":"GENE","name":"MC4R","canonical_id":"hgnc:HGNC:6932","description":"melanocortin 4 receptor","metadata":null},{"id":"b73dc6d2a2c74ca3a1ea7af7db1c196b","type":"GENE","name":"MC5R","canonical_id":"hgnc:HGNC:6933","description":"melanocortin 5 receptor","metadata":null},{"id":"779817ed1555411e9c07774c09ec84f5","type":"GENE","name":"MCAM","canonical_id":"hgnc:HGNC:6934","description":null,"metadata":null},{"id":"b2e809d06f284cb88b5774c078822e91","type":"GENE","name":"MCAT","canonical_id":"hgnc:HGNC:29622","description":null,"metadata":null},{"id":"d8de68c74de14879bebb28282371611a","type":"GENE","name":"MCC","canonical_id":"hgnc:HGNC:6935","description":"MCC regulator of Wnt signaling pathway","metadata":null},{"id":"0ff6cd5442db412ea9e6eec517a619c6","type":"GENE","name":"MCC-AS1","canonical_id":"hgnc:HGNC:40365","description":"MCC and TSSK1B antisense RNA 1","metadata":null},{"id":"82522b2112ee45c6b66fa41c4760d082","type":"GENE","name":"MCC-AS2","canonical_id":"hgnc:HGNC:59113","description":"MCC antisense RNA 2","metadata":null},{"id":"f110c9f60db447b0800fbbc8a367c6a4","type":"GENE","name":"MCCC1","canonical_id":"hgnc:HGNC:6936","description":"methylcrotonyl-CoA carboxylase subunit 1","metadata":{"aliases":["MCCA","MCCC\u03b1"]}},{"id":"9f25f14a64d642888724b854ded1a7cc","type":"GENE","name":"MCCC1-AS1","canonical_id":"hgnc:HGNC:40366","description":"MCCC1 antisense RNA 1","metadata":null},{"id":"0f3d7c3922cb41fc9a18c7817a8b9cb7","type":"GENE","name":"MCCC2","canonical_id":"hgnc:HGNC:6937","description":"methylcrotonyl-CoA carboxylase subunit 2","metadata":{"aliases":["MCCB","MCCC\u03b2"]}},{"id":"da304694a418476eb45905e4a7ca6085","type":"GENE","name":"MCCD1","canonical_id":"hgnc:HGNC:20668","description":"mitochondrial coiled-coil domain 1","metadata":null},{"id":"87263ba7d7734a7587ff7511757e6a14","type":"GENE","name":"MCCD1P1","canonical_id":"hgnc:HGNC:33449","description":"mitochondrial coiled-coil domain 1 pseudogene 1","metadata":{"aliases":["OTTHUMG00000130506"]}},{"id":"93b6b2d8d2804cf88d99b21593b7e588","type":"GENE","name":"MCCD1P2","canonical_id":"hgnc:HGNC:33462","description":"mitochondrial coiled-coil domain 1 pseudogene 2","metadata":{"aliases":["BPG309N1.16"]}},{"id":"8bcc9526224c4ccab60151a194e06e4e","type":"GENE","name":"MCEE","canonical_id":"hgnc:HGNC:16732","description":"methylmalonyl-CoA epimerase","metadata":{"aliases":["GLOD2","MCE","MMCE"]}},{"id":"d2061dec6bbc4529b1e118055b9861a2","type":"GENE","name":"MCEMP1","canonical_id":"hgnc:HGNC:27291","description":"mast cell expressed membrane protein 1","metadata":{"aliases":["MGC132456","C19orf59"]}},{"id":"e98cac33adf349ecb8f465e81fc170d8","type":"GENE","name":"MCF2","canonical_id":"hgnc:HGNC:6940","description":"MCF.2 cell line derived transforming sequence","metadata":{"aliases":["DBL","ARHGEF21"]}},{"id":"cdacd7d26ddf4ee1acb714711213937b","type":"GENE","name":"MCF2L","canonical_id":"hgnc:HGNC:14576","description":"MCF.2 cell line derived transforming sequence like","metadata":{"aliases":["KIAA0362","DBS","OST","ARHGEF14"]}},{"id":"1228cecf178848f2b41db268e11b921c","type":"GENE","name":"MCF2L-AS1","canonical_id":"hgnc:HGNC:39825","description":"MCF2L antisense RNA 1","metadata":null},{"id":"b30f5c46273748bd963ac0fc667d773b","type":"GENE","name":"MCF2L2","canonical_id":"hgnc:HGNC:30319","description":"MCF.2 cell line derived transforming sequence-like 2","metadata":{"aliases":["KIAA0861","ARHGEF22"]}},{"id":"eecebd5285d442c4ac86ccd2d172ccdb","type":"GENE","name":"MCF2L2P1","canonical_id":"hgnc:HGNC:56615","description":"MCF2L2 pseudogene 1","metadata":null},{"id":"d0888c125a694948a419b28cfca0d3d0","type":"GENE","name":"MCFD2","canonical_id":"hgnc:HGNC:18451","description":"multiple coagulation factor deficiency 2, ER cargo receptor complex subunit","metadata":{"aliases":["F5F8D","LMAN1IP","SDNSF"]}},{"id":"e54e2eee3e604a28a64615867e889f76","type":"GENE","name":"MCFD2-AS1","canonical_id":"hgnc:HGNC:58223","description":"MCFD2 antisense RNA 1","metadata":null},{"id":"e10cac0783914cfdbd48edb61f096575","type":"GENE","name":"MCFD2P1","canonical_id":"hgnc:HGNC:21582","description":"multiple coagulation factor deficiency 2 pseudogene 1","metadata":{"aliases":["dJ153G14.2","NUCB2-L","C6orf44","MCFD2L"]}},{"id":"ac7984f9c08543d790644cc1b9128483","type":"GENE","name":"MCHR1","canonical_id":"hgnc:HGNC:4479","description":"melanin concentrating hormone receptor 1","metadata":{"aliases":["SLC1","MCH1R","GPR24"]}},{"id":"21d0439096ff489f849729a48c8f0a4a","type":"GENE","name":"MCHR2","canonical_id":"hgnc:HGNC:20867","description":"melanin concentrating hormone receptor 2","metadata":{"aliases":["SLT","MCH2","MCH2R","GPR145"]}},{"id":"6f27251b722a4b7cb304bcef79bb9270","type":"GENE","name":"MCHR2-AS1","canonical_id":"hgnc:HGNC:48980","description":"MCHR2 antisense RNA 1","metadata":null},{"id":"e0a27b0d758c4beb82b9d87fad72f440","type":"GENE","name":"MCIDAS","canonical_id":"hgnc:HGNC:40050","description":"multiciliate differentiation and DNA synthesis associated cell cycle protein","metadata":{"aliases":["MCI","IDAS","MCIN"]}},{"id":"6cd90dbedf824cd4aeb7c8498edce9df","type":"GENE","name":"MCIDAS-AS1","canonical_id":"hgnc:HGNC:59044","description":"MCIDAS antisense RNA 1","metadata":null},{"id":"7ca799747d9443468810d0ddfcfc179c","type":"GENE","name":"MCL1","canonical_id":"hgnc:HGNC:6943","description":null,"metadata":null},{"id":"4ce81fe71a574ce48cc12aa92ad599fa","type":"GO_TERM","name":"MCM complex","canonical_id":"go:GO:0042555","description":"\"A hexameric protein complex required for the initiation and regulation of DNA replication.\" [GOC:jl, PMID:11282021]","metadata":null},{"id":"f5e17f7cdbe44a6cba4be353e42e37b1","type":"GO_TERM","name":"MCM complex assembly","canonical_id":"go:GO:0072689","description":"\"The aggregation, arrangement and bonding together of a set of components to form an MCM complex, a hexameric protein complex required for the initiation and regulation of DNA replication.\" [GOC:mah, PMID:21813639]","metadata":null},{"id":"021ca55977f147da9d5492593629c266","type":"GO_TERM","name":"MCM complex binding","canonical_id":"go:GO:1904931","description":"\"Binding to an MCM complex.\" [GOC:TermGenie, PMID:12604790]","metadata":null},{"id":"8c2edf7a77ec4387a198fcf7691c0585","type":"GO_TERM","name":"MCM complex loading","canonical_id":"go:GO:0140530","description":"\"The protein localization process in which two MCM complexes become associated with chromatin at replication origins. MCM loading begins when origin-bound ORC and Cdc6 (Cdc18 in fission yeast) recruit one MCM2-7/Cdt1 complex to the origin, includes formation of a succession of intermediate complexes and ATP hydrolysis-dependent Mcm2-7 ring closure, and ends when two MCM hexamers fully encircle DNA, and are oriented head-to-head. The double hexamer is inactive for DNA unwinding. MCM loading takes place during G1 phase, and precedes CMG complex assembly.\" [PMID:23603117, PMID:28191893, PMID:28191894, PMID:28501329]","metadata":null},{"id":"ab4fbe65620449f087a7731245e42a32","type":"GO_TERM","name":"MCM core complex","canonical_id":"go:GO:0097373","description":"\"A protein complex that contains Mcm4, Mcm6, and Mcm7 proteins, and possesses DNA helicase activity. In the heterohexameric MCM complex, the Mcm4/6/7 proteins form a stable core, and Mcm2, Mcm3, and Mcm5 are more peripherally associated.\" [GOC:mah, PMID:10770926, PMID:15007098, PMID:9305914]","metadata":null},{"id":"ac3d60ae9ab74b5493d879cbe98b310c","type":"GENE","name":"MCM10","canonical_id":"hgnc:HGNC:18043","description":null,"metadata":null},{"id":"e00daa8a1ead4c29b132f7cf5fff85b6","type":"GENE","name":"MCM2","canonical_id":"hgnc:HGNC:6944","description":null,"metadata":null},{"id":"b7546b1a85a2439a92bc897cad65337c","type":"GENE","name":"MCM3","canonical_id":"hgnc:HGNC:6945","description":null,"metadata":null},{"id":"40b327c0b7ab42a6984d24e4ede4da23","type":"GENE","name":"MCM3AP","canonical_id":"hgnc:HGNC:6946","description":"minichromosome maintenance complex component 3 associated protein","metadata":{"aliases":["Map80","KIAA0572","GANP","SAC3"]}},{"id":"0cfdf6c7c7744c49ab5fc5c0b8f17c06","type":"GENE","name":"MCM3AP-AS1","canonical_id":"hgnc:HGNC:16417","description":"MCM3AP antisense RNA 1","metadata":{"aliases":["FLJ10508","NCRNA00031","C21orf85","MCM3APAS","MCM3AP-AS"]}},{"id":"fffa934aaca44a75b953dab7d85a405e","type":"GENE","name":"MCM4","canonical_id":"hgnc:HGNC:6947","description":null,"metadata":null},{"id":"1c7e739d6bfc4fc2b50c87cc27381c37","type":"GENE","name":"MCM5","canonical_id":"hgnc:HGNC:6948","description":null,"metadata":null},{"id":"76111eb0e751409c947dcde148355ce4","type":"GENE","name":"MCM6","canonical_id":"hgnc:HGNC:6949","description":null,"metadata":null},{"id":"f943338781374a24994f216c1ab8c91c","type":"GENE","name":"MCM7","canonical_id":"hgnc:HGNC:6950","description":null,"metadata":null},{"id":"8acaf11e42e144cf88205feea3d212cd","type":"GENE","name":"MCM8","canonical_id":"hgnc:HGNC:16147","description":null,"metadata":null},{"id":"dd60999d8a304acfafc62671cb01ded0","type":"GENE","name":"MCM8-AS1","canonical_id":"hgnc:HGNC:51230","description":"MCM8 antisense RNA 1","metadata":null},{"id":"9fba8557732741779e54a4da37573876","type":"GO_TERM","name":"MCM8-MCM9 complex","canonical_id":"go:GO:0097362","description":"\"A hexameric protein complex composed of MCM8 and MCM9 and involved in homologous recombination repair following DNA interstrand cross-links.\" [GOC:sp, PMID:22771115, PMID:22771120]","metadata":null},{"id":"8eed3e829f694d6288a5ee088c5f3dec","type":"GENE","name":"MCM9","canonical_id":"hgnc:HGNC:21484","description":"minichromosome maintenance 9 homologous recombination repair factor","metadata":{"aliases":["MGC35304","dJ329L24.3","FLJ20170","MCMDC1","C6orf61"]}},{"id":"a4c3d2deeabb4dbb965b41ad05e97bce","type":"GENE","name":"MCMBP","canonical_id":"hgnc:HGNC:25782","description":"minichromosome maintenance complex binding protein","metadata":{"aliases":["FLJ13081","MCM-BP","C10orf119"]}},{"id":"c5351488f49741ee83080d6649f06358","type":"GENE","name":"MCMDC2","canonical_id":"hgnc:HGNC:26368","description":"minichromosome maintenance domain containing 2","metadata":{"aliases":["FLJ25692","C8orf45"]}},{"id":"8584a544e7bb432e8c009a07c42d61a0","type":"GENE","name":"MCOLN1","canonical_id":"hgnc:HGNC:13356","description":"mucolipin TRP cation channel 1","metadata":{"aliases":["TRPML1","ML4","MLIV","MST080","MSTP080","TRPM-L1"]}},{"id":"601ed4118899485ba4d0459387eb20de","type":"GENE","name":"MCOLN2","canonical_id":"hgnc:HGNC:13357","description":"mucolipin TRP cation channel 2","metadata":{"aliases":["TRPML2","FLJ36691","TRP-ML2"]}},{"id":"a88776b3cf984f07988235308bbfd426","type":"GENE","name":"MCOLN3","canonical_id":"hgnc:HGNC:13358","description":"mucolipin TRP cation channel 3","metadata":{"aliases":["TRPML3","FLJ11006","TRP-ML3"]}},{"id":"484ce3b722f0404291501b505e93d222","type":"GENE","name":"MCPH1","canonical_id":"hgnc:HGNC:6954","description":null,"metadata":null},{"id":"f3ee798e2aad44cd892af37bbbb5a9e8","type":"GENE","name":"MCPH1-AS1","canonical_id":"hgnc:HGNC:51655","description":"MCPH1 antisense RNA 1","metadata":null},{"id":"149c76a37e554b85a7330393904cf4a8","type":"GENE","name":"MCPH1-DT","canonical_id":"hgnc:HGNC:55599","description":"MCPH1 divergent transcript","metadata":null},{"id":"c86f8d70b96848dc93b11d9ccc45d1ea","type":"GENE","name":"MCRIP1","canonical_id":"hgnc:HGNC:28007","description":"MAPK regulated corepressor interacting protein 1","metadata":{"aliases":["GRAN2","MCRIP","FAM195B"]}},{"id":"262cf122d0954ae39141e7d668097fb0","type":"GENE","name":"MCRIP2","canonical_id":"hgnc:HGNC:14142","description":"MAPK regulated corepressor interacting protein 2","metadata":{"aliases":["MGC15416","C16orf14","FAM195A"]}},{"id":"bb44d4267b514d90a1afc57f10391126","type":"GENE","name":"MCRIP2P1","canonical_id":"hgnc:HGNC:49629","description":"MAPK regulated corepressor interacting protein 2 pseudogene 1","metadata":{"aliases":["FAM195CP"]}},{"id":"0aa7cde7104a486ab366b92888a8d027","type":"GENE","name":"MCRIP2P2","canonical_id":"hgnc:HGNC:49631","description":"MAPK regulated corepressor interacting protein 2 pseudogene 2","metadata":{"aliases":["FAM195DP","MCRIP2P1"]}},{"id":"22a5fe578b1149049eed5f69493b2b8a","type":"GENE","name":"MCRS1","canonical_id":"hgnc:HGNC:6960","description":"microspherule protein 1","metadata":{"aliases":["ICP22BP","MSP58","P78","MCRS2","INO80Q"]}},{"id":"8449a780803b49aca219e2988d1b634e","type":"TRIAL","name":"MCS110 With BRAF/MEK Inhibition in Patients With Melanoma","canonical_id":"clinicaltrials.gov:NCT03455764","description":"Melanoma","metadata":null},{"id":"1189c4ebc3da48879e46415f82a33e07","type":"GENE","name":"MCTP1","canonical_id":"hgnc:HGNC:26183","description":"multiple C2 and transmembrane domain containing 1","metadata":{"aliases":["FLJ22344"]}},{"id":"5e2b08732e3d44adbadcf4ea1c15dbc0","type":"GENE","name":"MCTP1-AS1","canonical_id":"hgnc:HGNC:54085","description":"MCTP1 antisense RNA 1","metadata":{"aliases":["ENST00000503710"]}},{"id":"6896073e425b4798b0b87a02bc191e4b","type":"GENE","name":"MCTP1-AS2","canonical_id":"hgnc:HGNC:59098","description":"MCTP1 antisense RNA 2","metadata":null},{"id":"d94ab0290223470586e091857f4b8e46","type":"GENE","name":"MCTP1-AS3","canonical_id":"hgnc:HGNC:59099","description":"MCTP1 antisense RNA 3","metadata":null},{"id":"68f8ddfcbddd4ca78b5850eab2171708","type":"GENE","name":"MCTP2","canonical_id":"hgnc:HGNC:25636","description":"multiple C2 and transmembrane domain containing 2","metadata":{"aliases":["FLJ11175","FLJ33303"]}},{"id":"3138385494904f4ea8f8cd58c4c242af","type":"GENE","name":"MCTS1","canonical_id":"hgnc:HGNC:23357","description":null,"metadata":null},{"id":"8c5da81ff5864c7a869c7842013d1ef3","type":"GENE","name":"MCTS2","canonical_id":"hgnc:HGNC:49760","description":"MCTS family member 2","metadata":{"aliases":["psiMCT-1","MCTS2P"]}},{"id":"89c2ea6a9948400b826e125b9d7fbcff","type":"GENE","name":"MCU","canonical_id":"hgnc:HGNC:23526","description":"mitochondrial calcium uniporter","metadata":{"aliases":["FLJ46135","C10orf42","CCDC109A"]}},{"id":"83fa1cf132b549ffb4a909c8f7fe0d4f","type":"GENE","name":"MCUB","canonical_id":"hgnc:HGNC:26076","description":"mitochondrial calcium uniporter dominant negative subunit beta","metadata":{"aliases":["FLJ20647","CCDC109B"]}},{"id":"51e24394d77c45aba3596f2b7b35338c","type":"GENE","name":"MCUB-AS1","canonical_id":"hgnc:HGNC:58893","description":"MCUB antisense RNA 1","metadata":null},{"id":"701e03a7a33a48ee852cca3c0cc11ca3","type":"GENE","name":"MCUR1","canonical_id":"hgnc:HGNC:21097","description":"mitochondrial calcium uniporter regulator 1","metadata":{"aliases":["FLJ20958","C6orf79","CCDC90A"]}},{"id":"d80bdc3cea96449789fa45b2b197eb1c","type":"GENE","name":"MCUR1-AS1","canonical_id":"hgnc:HGNC:59358","description":"MCUR1 antisense RNA 1","metadata":null},{"id":"55d0061c17214ded9de943fa13021bf0","type":"GENE","name":"MCUR1P1","canonical_id":"hgnc:HGNC:1217","description":"MCUR1 pseudogene 1","metadata":{"aliases":["C17orf23","CCDC90AP1"]}},{"id":"7d404919baab4f34ab24be676802ecb3","type":"GENE","name":"MCUR1P2","canonical_id":"hgnc:HGNC:53756","description":"MCUR1 pseudogene 2","metadata":null},{"id":"b56ce44207a144bf9a624b08ce2a85e7","type":"GO_TERM","name":"MDA-5 binding","canonical_id":"go:GO:0039556","description":"\"Binding to MDA-5, a cytoplasmic pattern recognition receptor that initiates an antiviral signaling pathway upon binding to viral dsRNA.\" [PMID:19019954]","metadata":null},{"id":"61f6d7ec95a74fe5ade8b7e8424aef7b","type":"GO_TERM","name":"MDA-5 signaling pathway","canonical_id":"go:GO:0039530","description":"\"The series of molecular signals initiated by the binding of dsRNA from another organism to the cytoplasmic pattern recognition receptor (PRR) MDA-5 (also known as IFIH1). MDA-5 detects RNA synthesized during viral replication or shed by non-viral pathogens, and triggers a signaling pathway to protect the host against infection, for example by inducing the expression of cytokines.\" [GOC:bf, PMID:19620789, PMID:33087405]","metadata":null},{"id":"8346ef59ff8e42788e5b89b99aa4906c","type":"GENE","name":"MDC1","canonical_id":"hgnc:HGNC:21163","description":null,"metadata":null},{"id":"7c6dc06d5e064f53bc03bd269d7cb992","type":"GENE","name":"MDC1-AS1","canonical_id":"hgnc:HGNC:39764","description":"MDC1 antisense RNA 1","metadata":{"aliases":["MDC1-AS"]}},{"id":"f1c6525413be4397bf62b82d8636074f","type":"GENE","name":"MDFI","canonical_id":"hgnc:HGNC:6967","description":"MyoD family inhibitor","metadata":{"aliases":["I-mfa"]}},{"id":"cec796309e7c40a5ae89ba459ae6f461","type":"GENE","name":"MDFIC","canonical_id":"hgnc:HGNC:28870","description":"MyoD family inhibitor domain containing","metadata":{"aliases":["HIC","MDFIC1"]}},{"id":"a7b2855ef1cf4842acb7f61d8c43361a","type":"GENE","name":"MDFIC2","canonical_id":"hgnc:HGNC:53442","description":"MyoD family inhibitor domain containing 2","metadata":null},{"id":"2909b0ce46674529afa3d288aa5c173e","type":"GENE","name":"MDGA1","canonical_id":"hgnc:HGNC:19267","description":"MAM domain containing glycosylphosphatidylinositol anchor 1","metadata":{"aliases":["GPIM","MAMDC3"]}},{"id":"90472f6f9b0d4ebabf49cdee9de7c910","type":"GENE","name":"MDGA2","canonical_id":"hgnc:HGNC:19835","description":"MAM domain containing glycosylphosphatidylinositol anchor 2","metadata":{"aliases":["MAMDC1"]}},{"id":"38c8129655b3484686bbfb0d03617463","type":"GENE","name":"MDH1","canonical_id":"hgnc:HGNC:6970","description":"malate dehydrogenase 1","metadata":null},{"id":"c8c9b1a3441646029bdd53c9962e3d22","type":"GENE","name":"MDH1B","canonical_id":"hgnc:HGNC:17836","description":"malate dehydrogenase 1B","metadata":{"aliases":["FLJ25341","RP11-95H11"]}},{"id":"24ee7a231c73406f8295fa6ab25ddcc8","type":"GENE","name":"MDH1P1","canonical_id":"hgnc:HGNC:54968","description":"MDH1 pseudogene 1","metadata":null},{"id":"e52707cc92504061901aeabaebdc4ba5","type":"GENE","name":"MDH1P2","canonical_id":"hgnc:HGNC:54969","description":"MDH1 pseudogene 2","metadata":null},{"id":"914aa18901e84de78147dc7e7db3cf7f","type":"GENE","name":"MDH2","canonical_id":"hgnc:HGNC:6971","description":"malate dehydrogenase 2","metadata":null},{"id":"2da4394fc3ed4e6c834553b8001a6dab","type":"GENE","name":"MDK","canonical_id":"hgnc:HGNC:6972","description":"midkine","metadata":{"aliases":["MK","FLJ27379","NEGF2"]}},{"id":"ff9997f710f04570b2a1a9113d2753a7","type":"GENE","name":"MDM2","canonical_id":"hgnc:HGNC:6973","description":null,"metadata":null},{"id":"54bb4db022b94dec8fed855aad9c88ad","type":"GENE","name":"MDM2","canonical_id":"ensembl:ENSG00000135679","description":null,"metadata":null},{"id":"f0017fc1bcf9414f9e168f8f851c018d","type":"DRUG","name":"MDM2 Inhibitor AMGMDS3","canonical_id":"ncit:C171616","description":null,"metadata":null},{"id":"c904a345b6084f829fecdf3cfff0c124","type":"GO_TERM","name":"MDM2/MDM4 family protein binding","canonical_id":"go:GO:0097371","description":"\"Binding to a member of the MDM2/MDM4 protein family, comprising negative regulators of p53.\" [InterPro:IPR016495]","metadata":null},{"id":"54ff46a09c004871ac2059184b0567ea","type":"GENE","name":"MDM4","canonical_id":"hgnc:HGNC:6974","description":null,"metadata":null},{"id":"74cf00e20a04468b8922b077b0569e80","type":"GENE","name":"MDM4P1","canonical_id":"hgnc:HGNC:54898","description":"MDM4 pseudogene 1","metadata":null},{"id":"d4e19d0cce5a4d80bc18bccc0cf8b20b","type":"GENE","name":"MDN1","canonical_id":"hgnc:HGNC:18302","description":"midasin AAA ATPase 1","metadata":{"aliases":["KIAA0301","Rea1"]}},{"id":"16c5ceba5f4b42388e9e53256a28b08e","type":"GENE","name":"MDN1-AS1","canonical_id":"hgnc:HGNC:40837","description":"MDN1 antisense RNA 1","metadata":null},{"id":"c60c809d13854b5490e7ad0e87b02b4a","type":"GENE","name":"MDP1","canonical_id":"hgnc:HGNC:28781","description":"magnesium dependent phosphatase 1","metadata":{"aliases":["MGC5987","FN6Pase"]}},{"id":"425091490e30485ab72fc1af0a3b1b69","type":"GENE","name":"MDS2","canonical_id":"hgnc:HGNC:29633","description":"myelodysplastic syndrome 2 translocation associated","metadata":null},{"id":"1f52bb4a1c034fa7a0c514c185d178b2","type":"GENE","name":"ME1","canonical_id":"hgnc:HGNC:6983","description":null,"metadata":null},{"id":"3309b208546c4c2994080dbd5a49c5fa","type":"GENE","name":"ME2","canonical_id":"hgnc:HGNC:6984","description":"malic enzyme 2","metadata":null},{"id":"5cb0a61e61ff4474933fdc985edb6c35","type":"GENE","name":"ME2P1","canonical_id":"hgnc:HGNC:49809","description":"malic enzyme 2 pseudogene 1","metadata":null},{"id":"abf750018131467fa0d7d3dfa816b8f2","type":"GENE","name":"ME3","canonical_id":"hgnc:HGNC:6985","description":"malic enzyme 3","metadata":null},{"id":"483a3eb8233b4ebaa7f22ebbe13133c7","type":"GENE","name":"ME3-AS1","canonical_id":"hgnc:HGNC:58438","description":"Me3 antisense RNA 1","metadata":null},{"id":"7124cda21a5f4a9699a6a14398588882","type":"GENE","name":"ME3-DT","canonical_id":"hgnc:HGNC:54182","description":"ME3 divergent transcript","metadata":null},{"id":"b317e270be7542938845c8fe09d0f4fb","type":"GENE","name":"MEA1","canonical_id":"hgnc:HGNC:6986","description":"male-enhanced antigen 1","metadata":{"aliases":["MEA"]}},{"id":"a4bdcdf6d451454abe1cf20fdf313960","type":"TRIAL","name":"MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects","canonical_id":"clinicaltrials.gov:NCT01691859","description":"Asthma","metadata":null},{"id":"39261551b3794e9baffb5ed4ae0f7a53","type":"GENE","name":"MEAF6","canonical_id":"hgnc:HGNC:25674","description":null,"metadata":null},{"id":"4f149a3624f4450ba32bdd6d7ead5bcf","type":"GENE","name":"MEAF6P1","canonical_id":"hgnc:HGNC:42660","description":"MYST/Esa1-associated factor 6 pseudogene 1","metadata":null},{"id":"640c573adc3d4f52b2a73a43df278dab","type":"GENE","name":"MEAK7","canonical_id":"hgnc:HGNC:29325","description":"MTOR associated protein MEAK7","metadata":{"aliases":["mEAK-7","KIAA1609","TLDC1"]}},{"id":"4cde3af4f3f046cca2e2818efad0dbff","type":"GO_TERM","name":"MECO complex","canonical_id":"go:GO:0002929","description":"\"A highly stable complex composed of the ATAC complex and the mediator complex (also called TRAP or MED). MECO binds and regulates the transcription of a subset of non-coding RNAs transcribed by RNA polymerase II.\" [GOC:hjd, PMID:20508642]","metadata":null},{"id":"9e1aac323a5241339bdadfc931612c3f","type":"GENE","name":"MECOM","canonical_id":"hgnc:HGNC:3498","description":null,"metadata":null},{"id":"a641aad7f5a74cfa8923252bb3d9ff9d","type":"GENE","name":"MECOM-AS1","canonical_id":"hgnc:HGNC:40368","description":"MECOM antisense RNA 1","metadata":null},{"id":"4d03f5170b01442c9cf2f8c127e331c8","type":"GENE","name":"MECP2","canonical_id":"hgnc:HGNC:6990","description":null,"metadata":null},{"id":"7091090ff01748fd9fe44ec594708fba","type":"GENE","name":"MECR","canonical_id":"hgnc:HGNC:19691","description":"mitochondrial trans-2-enoyl-CoA reductase","metadata":{"aliases":["CGI-63","NRBF1","FASN2B","ETR1"]}},{"id":"b08533bff6bb4cf58ccdc5b575a5e3b5","type":"GENE","name":"MED1","canonical_id":"hgnc:HGNC:9234","description":null,"metadata":null},{"id":"6d81b3148d01401cbcd0065e32e72140","type":"GENE","name":"MED10","canonical_id":"hgnc:HGNC:28760","description":"mediator complex subunit 10","metadata":{"aliases":["TRG20","L6","MGC5309","NUT2"]}},{"id":"c33a08c275594f93b557cf87ed13ba03","type":"GENE","name":"MED10-DT","canonical_id":"hgnc:HGNC:58998","description":"MED10 divergent transcript","metadata":null},{"id":"f9b949e787434c45afd0428e515935b4","type":"GENE","name":"MED11","canonical_id":"hgnc:HGNC:32687","description":"mediator complex subunit 11","metadata":{"aliases":["HSPC296","MGC88387"]}},{"id":"095464728a7e451d8fa6d2b51adde657","type":"GENE","name":"MED12","canonical_id":"hgnc:HGNC:11957","description":"mediator complex subunit 12","metadata":{"aliases":["CAGH45","HOPA","OPA1","TRAP230","KIAA0192","OKS","ARC240","Kto","TNRC11","FGS1"]}},{"id":"fd4d73e128674e79ad6c5db31c106727","type":"GENE","name":"MED12L","canonical_id":"hgnc:HGNC:16050","description":"mediator complex subunit 12L","metadata":{"aliases":["KIAA1635","TNRC11L","TRALPUSH","TRALP"]}},{"id":"fb74f454d56a4c61b635e857edd75401","type":"GENE","name":"MED13","canonical_id":"hgnc:HGNC:22474","description":"mediator complex subunit 13","metadata":{"aliases":["KIAA0593","TRAP240","THRAP1"]}},{"id":"d1c269ca5d3c4515974f3f12468b48fc","type":"GENE","name":"MED13L","canonical_id":"hgnc:HGNC:22962","description":"mediator complex subunit 13L","metadata":{"aliases":["KIAA1025","TRAP240L","THRAP2"]}},{"id":"ec958f39d5b549698bc1961ef1654cfc","type":"GENE","name":"MED13P1","canonical_id":"hgnc:HGNC:38733","description":"mediator complex subunit 13 pseudogene 1","metadata":null},{"id":"3b663493ffa6406793087659402103d8","type":"GENE","name":"MED14","canonical_id":"hgnc:HGNC:2370","description":"mediator complex subunit 14","metadata":{"aliases":["EXLM1","CRSP150","TRAP170","RGR1","CSRP","CXorf4","CRSP2"]}},{"id":"76c9f504f71c4aef96a88739379f8c02","type":"GENE","name":"MED14OS","canonical_id":"hgnc:HGNC:40162","description":"MED14 opposite strand","metadata":{"aliases":["MED14-AS1"]}},{"id":"796631a959974a5981c5628a19b5f7a0","type":"GENE","name":"MED14P1","canonical_id":"hgnc:HGNC:2371","description":"mediator complex subunit 14 pseudogene 1","metadata":{"aliases":["CXorf4P","CRSP2P","MED14P"]}},{"id":"f7fcf222d74f410aa1ade21573b5b2dd","type":"GENE","name":"MED15","canonical_id":"hgnc:HGNC:14248","description":null,"metadata":null},{"id":"0cd1989fb1bb45208fdf137c189b12ad","type":"GENE","name":"MED15P1","canonical_id":"hgnc:HGNC:19271","description":"mediator complex subunit 15 pseudogene 1","metadata":{"aliases":["PCQAPP","MED15P"]}},{"id":"cb96489c784f413c98eb2fd1779f2015","type":"GENE","name":"MED15P3","canonical_id":"hgnc:HGNC:48652","description":"mediator complex subunit 15 pseudogene 3","metadata":null},{"id":"7bb0bb8b76834fa79c93133cb06aaf0f","type":"GENE","name":"MED15P4","canonical_id":"hgnc:HGNC:48653","description":"mediator complex subunit 15 pseudogene 4","metadata":null},{"id":"f4b94dde1e02461da7846774b590bce8","type":"GENE","name":"MED15P5","canonical_id":"hgnc:HGNC:48654","description":"mediator complex subunit 15 pseudogene 5","metadata":null},{"id":"01cac26beec5454395dbdfaefcc95390","type":"GENE","name":"MED15P6","canonical_id":"hgnc:HGNC:48655","description":"mediator complex subunit 15 pseudogene 6","metadata":null},{"id":"65bb39ad6bd744d0822248a8be50ca8c","type":"GENE","name":"MED15P7","canonical_id":"hgnc:HGNC:48656","description":"mediator complex subunit 15 pseudogene 7","metadata":null},{"id":"6c0a4d18ffed4abeafaadef67b0887f6","type":"GENE","name":"MED15P8","canonical_id":"hgnc:HGNC:48657","description":"mediator complex subunit 15 pseudogene 8","metadata":null},{"id":"ee32e6737ffc46b1921cd6d2049952c6","type":"GENE","name":"MED15P9","canonical_id":"hgnc:HGNC:44130","description":"mediator complex subunit 15 pseudogene 9","metadata":{"aliases":["CCDC74B-AS1","MED15P2"]}},{"id":"e8cb3a14746242269252af9dd8149dd6","type":"GENE","name":"MED16","canonical_id":"hgnc:HGNC:17556","description":"mediator complex subunit 16","metadata":{"aliases":["DRIP92","TRAP95","THRAP5"]}},{"id":"1db54a36bc984ba4aee935bbd9807808","type":"GENE","name":"MED17","canonical_id":"hgnc:HGNC:2375","description":"mediator complex subunit 17","metadata":{"aliases":["CRSP77","TRAP80","DRIP80","SRB4","CRSP6"]}},{"id":"6313d2fdf5664ddbb9ac9f37a821c0d2","type":"GENE","name":"MED18","canonical_id":"hgnc:HGNC:25944","description":"mediator complex subunit 18","metadata":{"aliases":["FLJ20045","p28b","SRB5"]}},{"id":"2c0e981d74e2425f956b3221abaad395","type":"GENE","name":"MED19","canonical_id":"hgnc:HGNC:29600","description":"mediator complex subunit 19","metadata":{"aliases":["LCMR1"]}},{"id":"d85034253f9e46e492c88b30a235ff96","type":"GENE","name":"MED20","canonical_id":"hgnc:HGNC:16840","description":"mediator complex subunit 20","metadata":{"aliases":["DKFZp586D2223","PRO0213","SRB2","TRFP"]}},{"id":"50149d4accee4c8daf9d9c72b6d4ca20","type":"GENE","name":"MED21","canonical_id":"hgnc:HGNC:11473","description":"mediator complex subunit 21","metadata":{"aliases":["SRB7","SURB7"]}},{"id":"0230c80edde244f59d618ff4e7cd5be7","type":"GENE","name":"MED22","canonical_id":"hgnc:HGNC:11477","description":"mediator complex subunit 22","metadata":{"aliases":["Med24","SRB6","SURF5"]}},{"id":"f9efa0c7d428412fbc1c03238b0c1fcc","type":"GENE","name":"MED23","canonical_id":"hgnc:HGNC:2372","description":null,"metadata":null},{"id":"f9352a6f7e8a46dfb8a53f623e52b795","type":"GENE","name":"MED24","canonical_id":"hgnc:HGNC:22963","description":"mediator complex subunit 24","metadata":{"aliases":["TRAP100","KIAA0130","DRIP100","CRSP100","MED5","THRAP4","CRSP4"]}},{"id":"abaa3c53d5854883bdcc4870bdb0eecf","type":"GENE","name":"MED25","canonical_id":"hgnc:HGNC:28845","description":"mediator complex subunit 25","metadata":{"aliases":["ARC92","ACID1","TCBAP0758","DKFZp434K0512"]}},{"id":"7dcb95a4223444819ce216216caf492d","type":"GENE","name":"MED26","canonical_id":"hgnc:HGNC:2376","description":"mediator complex subunit 26","metadata":{"aliases":["CRSP70","CRSP7"]}},{"id":"7a973e87d62a4edba5bea6d522c20c9e","type":"GENE","name":"MED27","canonical_id":"hgnc:HGNC:2377","description":"mediator complex subunit 27","metadata":{"aliases":["TRAP37","CRSP34","MED3","CRSP8"]}},{"id":"3d3eb874616a4f0ca2f8916691683da7","type":"GENE","name":"MED28","canonical_id":"hgnc:HGNC:24628","description":"mediator complex subunit 28","metadata":{"aliases":["EG1","DKFZP434N185","magicin"]}},{"id":"201b7c93e28b47f79da6236c78d6b268","type":"GENE","name":"MED28-DT","canonical_id":"hgnc:HGNC:55567","description":"MED28 divergent transcript","metadata":{"aliases":["LAP3-AS1","AC006160.1"]}},{"id":"e9195b25d77a4914a1841fde1c63d64e","type":"GENE","name":"MED28P1","canonical_id":"hgnc:HGNC:45078","description":"mediator complex subunit 28 pseudogene 1","metadata":null},{"id":"27d7c6986bb7418093a2fde725747ae7","type":"GENE","name":"MED28P2","canonical_id":"hgnc:HGNC:45079","description":"mediator complex subunit 28 pseudogene 2","metadata":null},{"id":"888d8375d02b4ac59e2b806ab93b7be9","type":"GENE","name":"MED28P3","canonical_id":"hgnc:HGNC:45080","description":"mediator complex subunit 28 pseudogene 3","metadata":null},{"id":"fec51cd9ca8d406bb0cea573792534fa","type":"GENE","name":"MED28P4","canonical_id":"hgnc:HGNC:45081","description":"mediator complex subunit 28 pseudogene 4","metadata":null},{"id":"3cdbd6885f4b46f0ae257f8884006b45","type":"GENE","name":"MED28P5","canonical_id":"hgnc:HGNC:45082","description":"mediator complex subunit 28 pseudogene 5","metadata":null},{"id":"ef2ffab881a6438d87c04067d8030024","type":"GENE","name":"MED28P6","canonical_id":"hgnc:HGNC:45083","description":"mediator complex subunit 28 pseudogene 6","metadata":null},{"id":"5683afb4b2ed47c68218a7cf85bf4cd6","type":"GENE","name":"MED28P7","canonical_id":"hgnc:HGNC:45084","description":"mediator complex subunit 28 pseudogene 7","metadata":null},{"id":"e3a6fde1b72741c7bfa70aa59a9a191c","type":"GENE","name":"MED28P8","canonical_id":"hgnc:HGNC:45085","description":"mediator complex subunit 28 pseudogene 8","metadata":null},{"id":"55fe348b6be345209e7a3a1a591b7636","type":"GENE","name":"MED29","canonical_id":"hgnc:HGNC:23074","description":"mediator complex subunit 29","metadata":{"aliases":["DKFZp434H247","MED2","IXL"]}},{"id":"c120bbe8ad9448e59e5975ce8fb2d0e3","type":"GENE","name":"MED30","canonical_id":"hgnc:HGNC:23032","description":"mediator complex subunit 30","metadata":{"aliases":["TRAP25","THRAP6"]}},{"id":"8ffedae962c7422da8a8131d8c41fdde","type":"GENE","name":"MED31","canonical_id":"hgnc:HGNC:24260","description":"mediator complex subunit 31","metadata":{"aliases":["CGI-125","Soh1"]}},{"id":"c93fbae2ee2548f987b7d6a4ae8a03e1","type":"GENE","name":"MED4","canonical_id":"hgnc:HGNC:17903","description":"mediator complex subunit 4","metadata":{"aliases":["HSPC126","DRIP36","TRAP36","VDRIP"]}},{"id":"1f1e5bd1594b4561924bf23a2a3d2149","type":"GENE","name":"MED4-AS1","canonical_id":"hgnc:HGNC:39213","description":"MED4 antisense RNA 1","metadata":{"aliases":["MED4-AS"]}},{"id":"897cc0a0c6ba4d1885f06d432750a3ec","type":"GENE","name":"MED6","canonical_id":"hgnc:HGNC:19970","description":"mediator complex subunit 6","metadata":{"aliases":["NY-REN-28"]}},{"id":"c3e2a75331a3410cb888e9da24ab628e","type":"GENE","name":"MED6P1","canonical_id":"hgnc:HGNC:45164","description":"mediator complex subunit 6 pseudogene 1","metadata":null},{"id":"a0dde3f5d6e94e6e808f9d515c61ccd7","type":"GENE","name":"MED7","canonical_id":"hgnc:HGNC:2378","description":"mediator complex subunit 7","metadata":{"aliases":["CRSP33","CRSP9"]}},{"id":"7c3e2536a33a49b1a93a4046ecd9b87f","type":"GENE","name":"MED8","canonical_id":"hgnc:HGNC:19971","description":"mediator complex subunit 8","metadata":{"aliases":["MGC17544","MGC19641","ARC32"]}},{"id":"933fb439ef1542adb168d1185202bcba","type":"GENE","name":"MED8-AS1","canonical_id":"hgnc:HGNC:40908","description":"MED8 antisense RNA 1","metadata":null},{"id":"ca7a9ef033a34bf7ac6c5aa5cd7fe36e","type":"GENE","name":"MED9","canonical_id":"hgnc:HGNC:25487","description":"mediator complex subunit 9","metadata":{"aliases":["FLJ10193","MED25"]}},{"id":"ceb28c708cc64a9b823404741646ba94","type":"GENE","name":"MEDAG","canonical_id":"hgnc:HGNC:25926","description":"mesenteric estrogen dependent adipogenesis","metadata":{"aliases":["FLJ14834","AWMS3","MEDA-4","C13orf33"]}},{"id":"7fb7f6c828884a59b562c292827046bb","type":"TRIAL","name":"MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).","canonical_id":"clinicaltrials.gov:NCT02088112","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"3e0390543b13462db340c0b67f4c40aa","type":"GENE","name":"MEF2A","canonical_id":"hgnc:HGNC:6993","description":null,"metadata":null},{"id":"3c4e638284c249d9864887648574c2cc","type":"GENE","name":"MEF2AP1","canonical_id":"hgnc:HGNC:6994","description":"myocyte enhancer factor 2A pseudogene 1","metadata":{"aliases":["MEF2AP"]}},{"id":"896d0636f7d54cbca20503787619e283","type":"GENE","name":"MEF2B","canonical_id":"hgnc:HGNC:6995","description":null,"metadata":null},{"id":"42f6b158518a4de4a007bda85558f1d8","type":"GENE","name":"MEF2C","canonical_id":"hgnc:HGNC:6996","description":null,"metadata":null},{"id":"9c5a56499b554935a8b32c0e7409328b","type":"GENE","name":"MEF2C-AS1","canonical_id":"hgnc:HGNC:48908","description":"MEF2C antisense RNA 1","metadata":null},{"id":"3bc2e6545cc14164b3efc8a15f7c7c0b","type":"GENE","name":"MEF2C-AS2","canonical_id":"hgnc:HGNC:53115","description":"MEF2C antisense RNA 2","metadata":{"aliases":["CTC-467M3.1"]}},{"id":"22a193c9693b422ca2ad874738ee8df6","type":"GENE","name":"MEF2D","canonical_id":"hgnc:HGNC:6997","description":null,"metadata":null},{"id":"4beeba4694254790b6490866bcb7e62e","type":"GENE","name":"MEFV","canonical_id":"hgnc:HGNC:6998","description":null,"metadata":null},{"id":"45fa8b9336ed4404a44c260d603b1293","type":"GENE","name":"MEG3","canonical_id":"hgnc:HGNC:14575","description":null,"metadata":null},{"id":"81331f026e3749ea85bf6df59fb6ece6","type":"GENE","name":"MEG8","canonical_id":"hgnc:HGNC:14574","description":"maternally expressed 8, small nucleolar RNA host gene","metadata":{"aliases":["NCRNA00024","Irm","Rian","Bsr","LINC00024","AL132709.8","lnc-MGC","SNHG23","SNHG24"]}},{"id":"b0b0b9c6fffd4937a0fae9775a397b95","type":"GENE","name":"MEG9","canonical_id":"hgnc:HGNC:43874","description":"maternally expressed 9","metadata":{"aliases":["LINC00584"]}},{"id":"0978293ef3cd4375b0cce75b105edf6d","type":"GENE","name":"MEGF10","canonical_id":"hgnc:HGNC:29634","description":"multiple EGF like domains 10","metadata":{"aliases":["KIAA1780","SR-F3"]}},{"id":"b29d9c65745d4809829ccf248b37c048","type":"GENE","name":"MEGF10-DT","canonical_id":"hgnc:HGNC:59126","description":"MEGF10 divergent transcript","metadata":null},{"id":"dab78ed6d83549f482ef6e8fc7dbe503","type":"GENE","name":"MEGF11","canonical_id":"hgnc:HGNC:29635","description":"multiple EGF like domains 11","metadata":{"aliases":["KIAA1781","DKFZp434L121"]}},{"id":"052cf3a31fff4d7585d9eb609e93204c","type":"GENE","name":"MEGF6","canonical_id":"hgnc:HGNC:3232","description":"multiple EGF like domains 6","metadata":{"aliases":["EGFL3"]}},{"id":"123f96efd3434946bc1d02d28e98f391","type":"GENE","name":"MEGF8","canonical_id":"hgnc:HGNC:3233","description":"multiple EGF like domains 8","metadata":{"aliases":["SBP1","FLJ22365","EGFL4","C19orf49"]}},{"id":"61163cac810949a98e6a9484fc42346c","type":"GENE","name":"MEGF9","canonical_id":"hgnc:HGNC:3234","description":"multiple EGF like domains 9","metadata":{"aliases":["EGFL5"]}},{"id":"c9849fe37f02470d90c7f75a07d7745d","type":"GENE","name":"MEI1","canonical_id":"hgnc:HGNC:28613","description":"meiotic double-stranded break formation protein 1","metadata":{"aliases":["MGC40042","SPATA38"]}},{"id":"3254025a4e9945c18ad8e8d9e0f00e4d","type":"GENE","name":"MEI4","canonical_id":"hgnc:HGNC:43638","description":"meiotic double-stranded break formation protein 4","metadata":null},{"id":"acb5e56db9284eefaf0f93a4d10bf37a","type":"GENE","name":"MEIG1","canonical_id":"hgnc:HGNC:23429","description":"meiosis/spermiogenesis associated 1","metadata":{"aliases":["bA2K17.3","SPATA39"]}},{"id":"c9c8afa4cc694cddb4d08350b3fd9fdc","type":"GENE","name":"MEIKIN","canonical_id":"hgnc:HGNC:51253","description":"meiotic kinetochore factor","metadata":{"aliases":["SPO13"]}},{"id":"28a2df372dec4dd987b5104370230f1d","type":"GENE","name":"MEIKIN-AS1","canonical_id":"hgnc:HGNC:40771","description":"MEIKIN and ACSL6 antisense RNA 1","metadata":null},{"id":"7a138450b071453e95e34118b2a93d02","type":"GENE","name":"MEIOB","canonical_id":"hgnc:HGNC:28569","description":"meiosis specific with OB-fold","metadata":{"aliases":["MGC35212","C16orf73"]}},{"id":"982a8306d513499599e50d832b9a931b","type":"GENE","name":"MEIOC","canonical_id":"hgnc:HGNC:26670","description":"meiosis specific with coiled-coil domain","metadata":{"aliases":["FLJ35848","C17orf104"]}},{"id":"98af1012d3e448758599bb0338aff0e7","type":"GENE","name":"MEIOSIN","canonical_id":"hgnc:HGNC:44318","description":"meiosis initiator","metadata":{"aliases":["HMGDC","BHMG1"]}},{"id":"27430f9625ed42849fc55b6c7f1082d9","type":"GENE","name":"MEIS1","canonical_id":"hgnc:HGNC:7000","description":null,"metadata":null},{"id":"384d8db8971f4bb28d29e85e42d1533d","type":"GENE","name":"MEIS1-AS2","canonical_id":"hgnc:HGNC:40370","description":"MEIS1 antisense RNA 2","metadata":{"aliases":["MEIS1-AS1"]}},{"id":"5bc3d5bebb5049a19da8b91f77004bc1","type":"GENE","name":"MEIS1-AS3","canonical_id":"hgnc:HGNC:40369","description":"MEIS1 antisense RNA 3","metadata":{"aliases":["MEIS1-AS"]}},{"id":"dcf3c3a6febf441794b8fb7e7a151a11","type":"GENE","name":"MEIS2","canonical_id":"hgnc:HGNC:7001","description":null,"metadata":null},{"id":"e44c8c5054634f95a2678e739c48df7f","type":"GENE","name":"MEIS3","canonical_id":"hgnc:HGNC:29537","description":"Meis homeobox 3","metadata":{"aliases":["MRG2","DKFZp547H236"]}},{"id":"9aa377f5f4ae4dfab01992593616f91b","type":"GENE","name":"MEIS3P1","canonical_id":"hgnc:HGNC:7002","description":"Meis homeobox 3 pseudogene 1","metadata":{"aliases":["MRG2","MEIS3","MEIS4"]}},{"id":"8ebb1d62d73d4342b67beebd221454ff","type":"GENE","name":"MEIS3P2","canonical_id":"hgnc:HGNC:17638","description":"Meis homeobox 3 pseudogene 2","metadata":null},{"id":"91aca05850a543f0b0fcedeacca08378","type":"TRIAL","name":"MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma","canonical_id":"clinicaltrials.gov:NCT00866177","description":"Recurrent Melanoma; Stage III Skin Melanoma; Stage IV Skin Melanoma","metadata":null},{"id":"42775f9afb0b4c10ba94ec560c624ffa","type":"DRUG","name":"MEK Inhibitor GDC-0623","canonical_id":"ncit:C95738","description":null,"metadata":null},{"id":"d9c5a918e5914db48b5b6c33be3c0277","type":"TRIAL","name":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","canonical_id":"clinicaltrials.gov:NCT03962543","description":"Plexiform Neurofibroma; Neurofibromatosis Type 1 (NF1)","metadata":null},{"id":"46e8a66d959645f3bfd415b08e691360","type":"DRUG","name":"MEK Inhibitor REC-4881","canonical_id":"ncit:C84858","description":null,"metadata":null},{"id":"81436f88bb664f609b1044d73e666c28","type":"DRUG","name":"MEK Inhibitor RO4987655","canonical_id":"ncit:C82696","description":null,"metadata":null},{"id":"d75fb42fd9db46748261380ee5961e1b","type":"TRIAL","name":"MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT04216953","description":"Sarcoma,Soft Tissue","metadata":null},{"id":"195616ecf66d4a6e95adbc6b75a14cc6","type":"TRIAL","name":"MEK and MET Inhibition in Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02510001","description":"Solid Tumor; Colorectal Cancer","metadata":null},{"id":"d961acd95b914d23959d2e714743c385","type":"GENE","name":"MELK","canonical_id":"hgnc:HGNC:16870","description":"maternal embryonic leucine zipper kinase","metadata":{"aliases":["KIAA0175"]}},{"id":"a5644de27e784091ae631bfdcd5009d2","type":"GENE","name":"MELTF","canonical_id":"hgnc:HGNC:7037","description":null,"metadata":null},{"id":"bd16de899f2743138a6421b98a09363b","type":"GENE","name":"MELTF-AS1","canonical_id":"hgnc:HGNC:40373","description":"MELTF antisense RNA 1","metadata":{"aliases":["AC068302.3","PLANE","MFI2-AS1"]}},{"id":"784c1fefe5f844dcbf93f3b1fccca216","type":"GENE","name":"MEMO1","canonical_id":"hgnc:HGNC:14014","description":"mediator of cell motility 1","metadata":{"aliases":["CGI-27","MEMO","C2orf4"]}},{"id":"fdb86d8853e848309caef8ebcc055ee6","type":"GENE","name":"MEMO1P1","canonical_id":"hgnc:HGNC:23274","description":"MEMO1 pseudogene 1","metadata":{"aliases":["MEMO1P","C21orf19"]}},{"id":"d58a46075fe14a35905989511f28bede","type":"GENE","name":"MEMO1P2","canonical_id":"hgnc:HGNC:38502","description":"MEMO1 pseudogene 2","metadata":null},{"id":"980140e035844a6bb0adc5edec66155d","type":"GENE","name":"MEMO1P3","canonical_id":"hgnc:HGNC:38503","description":"MEMO1 pseudogene 3","metadata":null},{"id":"03e3f402f48441eb875574a040dfbc18","type":"GENE","name":"MEMO1P4","canonical_id":"hgnc:HGNC:38504","description":"MEMO1 pseudogene 4","metadata":null},{"id":"a1460a1a2e2f4bdaad2c9e364173ae90","type":"GENE","name":"MEMO1P5","canonical_id":"hgnc:HGNC:49102","description":"MEMO1 pseudogene 5","metadata":null},{"id":"ae4841c2aab84313b8d78a1c576b7fe0","type":"GENE","name":"MEMO1P6","canonical_id":"hgnc:HGNC:56633","description":"MEMO1 pseudogene 6","metadata":null},{"id":"806de15c605841ef952ba580c4ac990c","type":"GENE","name":"MEN1","canonical_id":"hgnc:HGNC:7010","description":null,"metadata":null},{"id":"2dbceb5cf47a45bda0401f4511a659fb","type":"GENE","name":"MEOX1","canonical_id":"hgnc:HGNC:7013","description":"mesenchyme homeobox 1","metadata":{"aliases":["MOX1"]}},{"id":"4e5a0f4f27484c39b46837cef6617a13","type":"GENE","name":"MEOX2","canonical_id":"hgnc:HGNC:7014","description":null,"metadata":null},{"id":"ada567c0634648a9983eb4122523dc05","type":"GENE","name":"MEOX2-AS2","canonical_id":"hgnc:HGNC:58080","description":"MEOX2 antisense RNA 2","metadata":{"aliases":["REIR-6"]}},{"id":"ed87607c1c594326b1ecbda34091f21b","type":"GENE","name":"MEP1A","canonical_id":"hgnc:HGNC:7015","description":null,"metadata":null},{"id":"8cd76e80ca914b049a804b7a64ed5878","type":"GENE","name":"MEP1AP1","canonical_id":"hgnc:HGNC:7016","description":"meprin A subunit alpha pseudogene 1","metadata":{"aliases":["MEP1AL1"]}},{"id":"e42d3830431b4f9595f255086531bddb","type":"GENE","name":"MEP1AP2","canonical_id":"hgnc:HGNC:7017","description":"meprin A subunit alpha pseudogene 2","metadata":{"aliases":["MEP1AL2"]}},{"id":"e43c6d4bda414383ae372ef6ecdd4fa3","type":"GENE","name":"MEP1AP3","canonical_id":"hgnc:HGNC:39137","description":"meprin A subunit alpha pseudogene 3","metadata":null},{"id":"35b742c6ca5045a38f3ea0632ff7e2f5","type":"GENE","name":"MEP1AP4","canonical_id":"hgnc:HGNC:39138","description":"meprin A subunit alpha pseudogene 4","metadata":null},{"id":"368f78b003b64078aae8a8034ee66bb7","type":"GENE","name":"MEP1B","canonical_id":"hgnc:HGNC:7020","description":"meprin A subunit beta","metadata":null},{"id":"a3df528a3c8b4e9299ef5f441a374168","type":"GENE","name":"MEPCE","canonical_id":"hgnc:HGNC:20247","description":"methylphosphate capping enzyme","metadata":{"aliases":["FLJ20257","BCDIN3"]}},{"id":"a01e355936464ba3a86641b5a83eaa2a","type":"GENE","name":"MEPE","canonical_id":"hgnc:HGNC:13361","description":"matrix extracellular phosphoglycoprotein","metadata":null},{"id":"bf368fa55e7648cd8a4d39e781c02b39","type":"GENE","name":"MEPE-AS1","canonical_id":"hgnc:HGNC:58843","description":"MEPE and IBSP antisense RNA 1","metadata":null},{"id":"f18e9284f7dd4984ade5b4f8c6ba8036","type":"GENE","name":"MERTK","canonical_id":"hgnc:HGNC:7027","description":"MER proto-oncogene, tyrosine kinase","metadata":{"aliases":["mer","RP38","c-Eyk","Tyro12"]}},{"id":"4a9bb87422d348c081c167a95833566f","type":"GENE","name":"MESD","canonical_id":"hgnc:HGNC:13520","description":"mesoderm development LRP chaperone","metadata":{"aliases":["KIAA0081","BOCA","MESDC2"]}},{"id":"ac403d80f55c4e0a9bcaf0473e031420","type":"GENE","name":"MESDP1","canonical_id":"hgnc:HGNC:27324","description":"MESD pseudogene 1","metadata":null},{"id":"e9e064a1a58e4a539604571583ed7007","type":"DISEASE","name":"MESH:D053159","canonical_id":"mesh:D053159","description":null,"metadata":null},{"id":"8120beada4ab45beafab9eb9ad2a051f","type":"GENE","name":"MESP1","canonical_id":"hgnc:HGNC:29658","description":"mesoderm posterior bHLH transcription factor 1","metadata":{"aliases":["MGC10676","bHLHc5"]}},{"id":"60ec4c02fa734ac88a1c24fcb27a3e43","type":"GENE","name":"MESP2","canonical_id":"hgnc:HGNC:29659","description":"mesoderm posterior bHLH transcription factor 2","metadata":{"aliases":["SCDO2","bHLHc6"]}},{"id":"3d805692477b40fabca018b480a2e064","type":"GENE","name":"MEST","canonical_id":"hgnc:HGNC:7028","description":"mesoderm specific transcript","metadata":{"aliases":["PEG1"]}},{"id":"aa8b79fbcf2b49db8a5803fff96f0819","type":"GENE","name":"MESTIT1","canonical_id":"hgnc:HGNC:17991","description":"MEST intronic transcript 1, antisense RNA","metadata":{"aliases":["NCRNA00040","MEST-AS1","MEST-IT1"]}},{"id":"72b1c8bf471f4afeb23138cc415d49ae","type":"GENE","name":"MESTP1","canonical_id":"hgnc:HGNC:29660","description":"mesoderm specific transcript pseudogene 1","metadata":null},{"id":"b3616dfe714645d0bfa879e8a85197a1","type":"GENE","name":"MESTP2","canonical_id":"hgnc:HGNC:18208","description":"mesoderm specific transcript pseudogene 2","metadata":null},{"id":"8b0e1da6053f44db88f032afa2cc036f","type":"GENE","name":"MESTP3","canonical_id":"hgnc:HGNC:38553","description":"mesoderm specific transcript pseudogene 3","metadata":null},{"id":"f87babcc70e345f79ec51b43bc594b20","type":"GENE","name":"MESTP4","canonical_id":"hgnc:HGNC:38554","description":"mesoderm specific transcript pseudogene 4","metadata":null},{"id":"3656020497f1402780980681aeeea85b","type":"GENE","name":"MET","canonical_id":"hgnc:HGNC:7029","description":null,"metadata":null},{"id":"9818c1a6a88d4d0793303adedf37b22a","type":"PROTEIN","name":"MET","canonical_id":"uniprot:P08581","description":null,"metadata":null},{"id":"a845b3d6e7914c1aa48ef4e8d36c7bd3","type":"GENE","name":"MET","canonical_id":"ensembl:ENSG00000105976","description":null,"metadata":null},{"id":"4e453df65deb41d8b4b9eab1646e2a94","type":"BIOMARKER","name":"MET Amplification AND NOT KRAS Mutation","canonical_id":"civic:5696","description":null,"metadata":null},{"id":"43559ca20a9f4140bed4013599e4f125","type":"GENE","name":"METAP1","canonical_id":"hgnc:HGNC:15789","description":"methionyl aminopeptidase 1","metadata":{"aliases":["KIAA0094","MetAP1A","MAP1A"]}},{"id":"40d9b1b3bdf44fd895d57850c860944a","type":"GENE","name":"METAP1-DT","canonical_id":"hgnc:HGNC:58857","description":"METAP1 divergent transcript","metadata":null},{"id":"275289b93bd7480ea900fbe6a7fb1d7a","type":"GENE","name":"METAP1D","canonical_id":"hgnc:HGNC:32583","description":"methionyl aminopeptidase type 1D, mitochondrial","metadata":{"aliases":["MAP1D","Metap1l"]}},{"id":"25e7979ef42d4608b373b4cd0efebc9a","type":"GENE","name":"METAP1P1","canonical_id":"hgnc:HGNC:59242","description":"METAP1 pseudogene 1","metadata":null},{"id":"bf82bccbc4734f6f9f9cf3c4b934b9f0","type":"GENE","name":"METAP2","canonical_id":"hgnc:HGNC:16672","description":null,"metadata":null},{"id":"1d1b2f5d449c4921ae9a2d4ea4b92fcb","type":"GENE","name":"METAP2P1","canonical_id":"hgnc:HGNC:54558","description":"METAP2 pseudogene 1","metadata":{"aliases":["Lnc-ZEB2-19"]}},{"id":"6681ab1d60dc4ec79f0d6ea2224b5c27","type":"GENE","name":"METRN","canonical_id":"hgnc:HGNC:14151","description":"meteorin, glial cell differentiation regulator","metadata":{"aliases":["MGC2601","C16orf23"]}},{"id":"0d366470a782468fa006f9029e541153","type":"GENE","name":"METRNL","canonical_id":"hgnc:HGNC:27584","description":"meteorin like, glial cell differentiation regulator","metadata":null},{"id":"8054b16834f04c50be61845447ad8146","type":"GENE","name":"METTL1","canonical_id":"hgnc:HGNC:7030","description":"methyltransferase 1, tRNA methylguanosine","metadata":{"aliases":["TRM8","TRMT8","C12orf1"]}},{"id":"12d1d362ec8a4949ade9581bb7c78268","type":"GENE","name":"METTL13","canonical_id":"hgnc:HGNC:24248","description":"methyltransferase 13, eEF1A N-terminus and K55","metadata":{"aliases":["CGI-01","FEAT","KIAA0859","DFNM1","EEF1AKNMT"]}},{"id":"3462d926086840d18af77fed4e88854b","type":"GENE","name":"METTL14","canonical_id":"hgnc:HGNC:29330","description":"methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit","metadata":{"aliases":["KIAA1627"]}},{"id":"f5c76ed4545c4a15a74ace57135ccde6","type":"GENE","name":"METTL14-DT","canonical_id":"hgnc:HGNC:53367","description":"METTL14 divergent transcript","metadata":null},{"id":"e934da82976e47d6b868ae359f8abdcb","type":"GENE","name":"METTL15","canonical_id":"hgnc:HGNC:26606","description":"methyltransferase 15, mitochondrial 12S rRNA N4-cytidine","metadata":{"aliases":["FLJ33979","METT5D1"]}},{"id":"3f55510d08b24948a2c71b25af1c046b","type":"GENE","name":"METTL15P1","canonical_id":"hgnc:HGNC:31926","description":"methyltransferase like 15 pseudogene 1","metadata":{"aliases":["METT5D2"]}},{"id":"289e449a3aae4857ab7fe12419404e49","type":"GENE","name":"METTL15P2","canonical_id":"hgnc:HGNC:39559","description":"methyltransferase like 15 pseudogene 2","metadata":null},{"id":"a72b0e42173843aba61c05f5d3ad02b0","type":"GENE","name":"METTL15P3","canonical_id":"hgnc:HGNC:39558","description":"methyltransferase like 15 pseudogene 3","metadata":null},{"id":"ecc42a591846466e91ccc657cafff595","type":"GENE","name":"METTL16","canonical_id":"hgnc:HGNC:28484","description":"methyltransferase 16, RNA N6-adenosine","metadata":{"aliases":["MGC3329","METT10D"]}},{"id":"0d40d43bb8f441a89a888fb333774fa5","type":"GENE","name":"METTL17","canonical_id":"hgnc:HGNC:19280","description":"methyltransferase like 17","metadata":{"aliases":["FLJ20859","METT11D1"]}},{"id":"9f9e76275d8b4fb0a155cda77f706e1e","type":"GENE","name":"METTL18","canonical_id":"hgnc:HGNC:28793","description":"methyltransferase 18, RPL3 N3(tau)-histidine","metadata":{"aliases":["MGC9084","AsTP2","HPM1","C1orf156"]}},{"id":"e8210fced1414651a535675d16cd7881","type":"GENE","name":"METTL1P1","canonical_id":"hgnc:HGNC:54907","description":"METTL1 pseudogene 1","metadata":null},{"id":"1c26941b835f49888469891b9e7c3cda","type":"GENE","name":"METTL21A","canonical_id":"hgnc:HGNC:30476","description":"methyltransferase 21A, HSPA lysine","metadata":{"aliases":["LOC151194","HCA557b","HSPA-KMT","FAM119A"]}},{"id":"9e9dff9906c1481bb3b1f4349b4bb3fa","type":"GENE","name":"METTL21AP1","canonical_id":"hgnc:HGNC:41921","description":"methyltransferase like 21A pseudogene 1","metadata":null},{"id":"8a821d951be5478dbd76217d8e20db92","type":"GENE","name":"METTL21C","canonical_id":"hgnc:HGNC:33717","description":"methyltransferase 21C, AARS1 lysine","metadata":{"aliases":["LOC196541","C13orf39"]}},{"id":"3826049732bb4d15b23fb6dd107c00d9","type":"GENE","name":"METTL21EP","canonical_id":"hgnc:HGNC:41948","description":"methyltransferase like 21E, pseudogene","metadata":{"aliases":["METTL21CP1"]}},{"id":"65163d4fb002412e833494aa5328f7d9","type":"GENE","name":"METTL22","canonical_id":"hgnc:HGNC:28368","description":"methyltransferase 22, Kin17 lysine","metadata":{"aliases":["FLJ12433","MGC2654","C16orf68"]}},{"id":"47045c7bec90458f9f56dc4056269139","type":"GENE","name":"METTL23","canonical_id":"hgnc:HGNC:26988","description":"methyltransferase 23, arginine","metadata":{"aliases":["LOC124512","C17orf95"]}},{"id":"d7328d64559f4b41af7326940175e452","type":"GENE","name":"METTL24","canonical_id":"hgnc:HGNC:21566","description":"methyltransferase like 24","metadata":{"aliases":["dJ71D21.2","C6orf186"]}},{"id":"7b372a2fc1de44cba9d55cf3aeb26d4f","type":"GENE","name":"METTL25","canonical_id":"hgnc:HGNC:26228","description":"methyltransferase like 25","metadata":{"aliases":["FLJ22789","C12orf26"]}},{"id":"9b7d8f425e534df6af4ccff48bf550c0","type":"GENE","name":"METTL25B","canonical_id":"hgnc:HGNC:24273","description":"methyltransferase like 25B","metadata":{"aliases":["CGI-41","C1orf66","RRNAD1"]}},{"id":"6b1c275dc72447da83e2c69a04c224ac","type":"GENE","name":"METTL26","canonical_id":"hgnc:HGNC:14141","description":"methyltransferase like 26","metadata":{"aliases":["MGC13114","C16orf13"]}},{"id":"10359d2955eb4ac6aa74499687e8a11f","type":"GENE","name":"METTL27","canonical_id":"hgnc:HGNC:19068","description":"methyltransferase like 27","metadata":{"aliases":["WBSCR27"]}},{"id":"9ae33c7c20db42dfb20df66fa6da7926","type":"GENE","name":"METTL28P","canonical_id":"hgnc:HGNC:55198","description":"methyltransferase like 28, pseudogene","metadata":null},{"id":"94a5ecf29701485dbc4844319eb27a53","type":"GENE","name":"METTL2A","canonical_id":"hgnc:HGNC:25755","description":"methyltransferase 2A, tRNA N3-cytidine","metadata":{"aliases":["FLJ12760","METTL2"]}},{"id":"acf7ce4f9a4a4adeac5481558c8ac96c","type":"GENE","name":"METTL2B","canonical_id":"hgnc:HGNC:18272","description":"methyltransferase 2B, tRNA N3-cytidine","metadata":{"aliases":["METL","FLJ11350","METTL2"]}},{"id":"df3688e167764cb9867f6e1b026f5fa8","type":"GENE","name":"METTL3","canonical_id":"hgnc:HGNC:17563","description":"methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit","metadata":{"aliases":["Spo8","M6A","MT-A70"]}},{"id":"c82ef33385bf43d1afb9b75baccf5697","type":"GENE","name":"METTL4","canonical_id":"hgnc:HGNC:24726","description":"methyltransferase 4, N6-adenosine","metadata":{"aliases":["FLJ23017","HsT661"]}},{"id":"beb8d3094a1444b884ffcbd92c49b6ca","type":"GENE","name":"METTL5","canonical_id":"hgnc:HGNC:25006","description":"methyltransferase 5, N6-adenosine","metadata":{"aliases":["HSPC133"]}},{"id":"1ac0789376fe469e957615b9c5504acd","type":"GENE","name":"METTL5P1","canonical_id":"hgnc:HGNC:56501","description":"METTL5 pseudogene 1","metadata":null},{"id":"1b5e91cb460042d49047a74692eecfc9","type":"GENE","name":"METTL5P2","canonical_id":"hgnc:HGNC:56502","description":"METTL5 pseudogene 2","metadata":null},{"id":"1e4d5bc753414fe082c92c210c31ece2","type":"GENE","name":"METTL5P3","canonical_id":"hgnc:HGNC:56503","description":"METTL5 pseudogene 3","metadata":null},{"id":"8d99bcd29d5743ba9f51e3435f2f374b","type":"GENE","name":"METTL5P4","canonical_id":"hgnc:HGNC:56504","description":"METTL5 pseudogene 4","metadata":null},{"id":"4c27256897504fcf813685986e8aa264","type":"GENE","name":"METTL6","canonical_id":"hgnc:HGNC:28343","description":"methyltransferase 6, tRNA N3-cytidine","metadata":{"aliases":["MGC24132"]}},{"id":"c12a2ee77d184cab946a7f9c220937f6","type":"GENE","name":"METTL8","canonical_id":"hgnc:HGNC:25856","description":"methyltransferase 8, tRNA N3-cytidine","metadata":{"aliases":["FLJ13984","TIP"]}},{"id":"67593206352f49eb9964deef083e8f0f","type":"GENE","name":"METTL8P1","canonical_id":"hgnc:HGNC:49856","description":"methyltransferase like 8 pseudogene 1","metadata":null},{"id":"f957747f8cda4e949fa2143631ae198a","type":"GENE","name":"METTL9","canonical_id":"hgnc:HGNC:24586","description":"methyltransferase 9, His-X-His N1(pi)-histidine","metadata":{"aliases":["DREV1"]}},{"id":"172a5f49242a4667ab477b7bd2503dbc","type":"GENE","name":"MEX3A","canonical_id":"hgnc:HGNC:33482","description":"mex-3 RNA binding family member A","metadata":{"aliases":["RNF162","RKHD4"]}},{"id":"0ad7c4dc171f41b38161506700c57b2a","type":"GENE","name":"MEX3B","canonical_id":"hgnc:HGNC:25297","description":"mex-3 RNA binding family member B","metadata":{"aliases":["DKFZp434J0617","RNF195","RKHD3"]}},{"id":"bed169214c464acf819f808682a9d108","type":"GENE","name":"MEX3C","canonical_id":"hgnc:HGNC:28040","description":"mex-3 RNA binding family member C","metadata":{"aliases":["FLJ38871","RNF194","RKHD2"]}},{"id":"9b8d6bf3e0204241a0f1a5662eba58db","type":"GENE","name":"MEX3D","canonical_id":"hgnc:HGNC:16734","description":"mex-3 RNA binding family member D","metadata":{"aliases":["Tino","KIAA2031","OK/SW-cl.4","RNF193","RKHD1"]}},{"id":"d53b106ad8d54fb8baca390e26991647","type":"TRIAL","name":"MEdical Versus SUrgical Treatments of Rectal Endometriosis","canonical_id":"clinicaltrials.gov:NCT01973816","description":"Endometriosis","metadata":null},{"id":"67affda6f1b849cf892e6298f14c3f55","type":"TRIAL","name":"MEtformin and Lorcaserin for WeighT Loss in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02796144","description":"Schizophrenia; Schizoaffective Disorder; Overweight","metadata":null},{"id":"0097be83301144b4baa65984b6a117a8","type":"TRIAL","name":"MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias","canonical_id":"clinicaltrials.gov:NCT05017155","description":"Non-Dystrophic Myotonia","metadata":null},{"id":"3be7ee001d2a4577b38dc6c57e9845a7","type":"GENE","name":"MFAP1","canonical_id":"hgnc:HGNC:7032","description":"microfibril associated protein 1","metadata":{"aliases":["AMP"]}},{"id":"906c0837bed243fc888077d940743763","type":"GENE","name":"MFAP1P1","canonical_id":"hgnc:HGNC:39694","description":"microfibril associated protein 1 pseudogene 1","metadata":null},{"id":"d5005dc62e8249e98717e0a7a0ace138","type":"GENE","name":"MFAP2","canonical_id":"hgnc:HGNC:7033","description":"microfibril associated protein 2","metadata":{"aliases":["MAGP","MAGP-1"]}},{"id":"e6775d1a2b7d43e799ee33380c0b7795","type":"GENE","name":"MFAP3","canonical_id":"hgnc:HGNC:7034","description":"microfibril associated protein 3","metadata":null},{"id":"fc1daee9e9204a029705d5ec7d5469d8","type":"GENE","name":"MFAP3L","canonical_id":"hgnc:HGNC:29083","description":"microfibril associated protein 3 like","metadata":{"aliases":["KIAA0626","NYD-sp9"]}},{"id":"b6cc06619db54870b34738d5850b88cb","type":"GENE","name":"MFAP3L-AS1","canonical_id":"hgnc:HGNC:58419","description":"MFAP3L antisense RNA 1","metadata":null},{"id":"7ad7f23acf594e48bd39421b5a9974e1","type":"GENE","name":"MFAP4","canonical_id":"hgnc:HGNC:7035","description":"microfibril associated protein 4","metadata":null},{"id":"e5d6ae80a0094f04a48d0a9e7ce06d29","type":"GENE","name":"MFAP5","canonical_id":"hgnc:HGNC:29673","description":"microfibril associated protein 5","metadata":{"aliases":["MAGP2","MP25"]}},{"id":"6426d60454504b2db073537d30736ec9","type":"GENE","name":"MFF","canonical_id":"hgnc:HGNC:24858","description":"mitochondrial fission factor","metadata":{"aliases":["GL004","C2orf33"]}},{"id":"cdc1dd2af2174a27a6c1bd411788990d","type":"GENE","name":"MFF-DT","canonical_id":"hgnc:HGNC:41067","description":"MFF divergent transcript","metadata":null},{"id":"cef53b10e06e463494c39247fae499f2","type":"GENE","name":"MFFP1","canonical_id":"hgnc:HGNC:54537","description":"MFF pseudogene 1","metadata":null},{"id":"f9a1f9c16d4e4b5c981bd5ebb890727d","type":"GENE","name":"MFFP2","canonical_id":"hgnc:HGNC:54540","description":"MFF pseudogene 2","metadata":null},{"id":"aa255248400d442784aab4cb68c146d5","type":"GENE","name":"MFFP3","canonical_id":"hgnc:HGNC:54944","description":"MFF pseudogene 3","metadata":null},{"id":"510e40ac2c12455a8ce8143388fcdffe","type":"GENE","name":"MFGE8","canonical_id":"hgnc:HGNC:7036","description":"milk fat globule EGF and factor V/VIII domain containing","metadata":{"aliases":["SED1","EDIL1","BA46","OAcGD3S","HsT19888","MFG-E8","hP47","SPAG10"]}},{"id":"38bf959734794caca12840d25ab423e3","type":"GENE","name":"MFHAS1","canonical_id":"hgnc:HGNC:16982","description":"multifunctional ROCO family signaling regulator 1","metadata":{"aliases":["MASL1","LRRC65"]}},{"id":"073129b7662d475a9143a8f0443f28bb","type":"GENE","name":"MFN1","canonical_id":"hgnc:HGNC:18262","description":"mitofusin 1","metadata":{"aliases":["FLJ20693"]}},{"id":"03499c7fd9f5494095b8b3353b98c373","type":"GENE","name":"MFN1P1","canonical_id":"hgnc:HGNC:55050","description":"MFN1 pseudogene 1","metadata":null},{"id":"41219ac93969497c8c3e05284bcf0cf3","type":"GENE","name":"MFN2","canonical_id":"hgnc:HGNC:16877","description":null,"metadata":null},{"id":"f5b21359f6ce46779c6a50f71e541e31","type":"GENE","name":"MFNG","canonical_id":"hgnc:HGNC:7038","description":"MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase","metadata":null},{"id":"cfbc2ab5d9d541f5b8c15ff91881dabe","type":"GENE","name":"MFRP","canonical_id":"hgnc:HGNC:18121","description":"membrane frizzled-related protein","metadata":{"aliases":["FLJ30570","rd6","NNO2","C1QTNF5"]}},{"id":"fea4cdc5bfb54cff9be736c1ce3e7c2b","type":"GENE","name":"MFSD1","canonical_id":"hgnc:HGNC:25874","description":"major facilitator superfamily domain containing 1","metadata":{"aliases":["Minerva","SLC72A1","FLJ14153","UG0581B09"]}},{"id":"d11d3d13f2f04fe1866508813327e41d","type":"GENE","name":"MFSD11","canonical_id":"hgnc:HGNC:25458","description":"major facilitator superfamily domain containing 11","metadata":{"aliases":["FLJ22196","FLJ20226"]}},{"id":"a5cc8fd1813a42b4a16e5297a58af9a6","type":"GENE","name":"MFSD12","canonical_id":"hgnc:HGNC:28299","description":"major facilitator superfamily domain containing 12","metadata":{"aliases":["MGC20700","PP3501","SLC59B1","C19orf28"]}},{"id":"dc0adc2c2e2348058048b4bd835a87a5","type":"GENE","name":"MFSD12-AS1","canonical_id":"hgnc:HGNC:56727","description":"MFSD12 antisense RNA 1","metadata":null},{"id":"c57d9315eb714b8cb20b13e998daa9f7","type":"GENE","name":"MFSD1P1","canonical_id":"hgnc:HGNC:50625","description":"major facilitator superfamily domain containing 1 pseudogene 1","metadata":null},{"id":"b1ebb5cfd1a443d3a993b0a0acc2b3c9","type":"GENE","name":"MFSD2A","canonical_id":"hgnc:HGNC:25897","description":null,"metadata":null},{"id":"dda4dbf8576f46268f957fe5151556c3","type":"GENE","name":"MFSD2B","canonical_id":"hgnc:HGNC:37207","description":"MFSD2 lysolipid transporter B, sphingolipid","metadata":{"aliases":["SLC59A2"]}},{"id":"a9fd6d7571504d27a7e119774172c403","type":"GENE","name":"MFSD6","canonical_id":"hgnc:HGNC:24711","description":"major facilitator superfamily domain containing 6","metadata":{"aliases":["SLC73A1","FLJ20160"]}},{"id":"db0239e2056e48c5955db6cd847ba56a","type":"GENE","name":"MFSD6L","canonical_id":"hgnc:HGNC:26656","description":"major facilitator superfamily domain containing 6 like","metadata":{"aliases":["SLC73A2","FLJ35773"]}},{"id":"807a65f09c724a2fa9919b948ee00252","type":"GENE","name":"MFSD8","canonical_id":"hgnc:HGNC:28486","description":"major facilitator superfamily domain containing 8","metadata":{"aliases":["SLC74A1","MGC33302","CLN7"]}},{"id":"2463b05f3b3c40c4b488efe8a5a5fab5","type":"GENE","name":"MGA","canonical_id":"hgnc:HGNC:14010","description":"MAX dimerization protein MGA","metadata":{"aliases":["KIAA0518","MAD5","MXD5","FLJ12634"]}},{"id":"a4009c7f57544edb9f839784fec91b8f","type":"GENE","name":"MGAM","canonical_id":"hgnc:HGNC:7043","description":"maltase-glucoamylase","metadata":{"aliases":["MGA"]}},{"id":"2bc10723ab3649a4b8878df6c22b6668","type":"PROTEIN","name":"MGAM","canonical_id":"uniprot:O43451","description":null,"metadata":null},{"id":"2b5f93dab7874bc6ac0847e2b8dc4dd1","type":"GENE","name":"MGAM2","canonical_id":"hgnc:HGNC:28101","description":"maltase-glucoamylase 2 (putative)","metadata":null},{"id":"6deb40bfbd9641f69a8adb707fe6001d","type":"GENE","name":"MGARP","canonical_id":"hgnc:HGNC:29969","description":"mitochondria localized glutamic acid rich protein","metadata":{"aliases":["OSAP","CESP-1","HUMMR","C4orf49"]}},{"id":"042971090554407f9faf93e18758953f","type":"GENE","name":"MGAT1","canonical_id":"hgnc:HGNC:7044","description":"alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase","metadata":{"aliases":["GNT-1","GLCNAC-TI","GnTI","MGAT","GLYT1"]}},{"id":"e1b24c237e7d40a9a792704b2bccb682","type":"GENE","name":"MGAT1-AS1","canonical_id":"hgnc:HGNC:59321","description":"MGAT1 antisense RNA 1","metadata":null},{"id":"1e5abaaa690f4537b30331b03c9a8aec","type":"GENE","name":"MGAT2","canonical_id":"hgnc:HGNC:7045","description":"alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase","metadata":{"aliases":["GNT-II"]}},{"id":"9c85abacbd194939af0c0518b183c0a8","type":"GENE","name":"MGAT2P1","canonical_id":"hgnc:HGNC:51244","description":"MGAT2 pseudogene 1","metadata":null},{"id":"c36ed403f8b34c5f9fb456299bae28c9","type":"GENE","name":"MGAT2P2","canonical_id":"hgnc:HGNC:51243","description":"MGAT2 pseudogene 2","metadata":null},{"id":"8495aa084d3f4d7a954d0cf9a0a5fe9f","type":"GENE","name":"MGAT3","canonical_id":"hgnc:HGNC:7046","description":"beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase","metadata":{"aliases":["GNT-III"]}},{"id":"335a72cc2d224a42b55c1e92dc85487c","type":"GENE","name":"MGAT3-AS1","canonical_id":"hgnc:HGNC:51356","description":"MGAT3 antisense RNA 1","metadata":{"aliases":["TapSAKI"]}},{"id":"529f84217270445eaf62f432753cb0da","type":"GENE","name":"MGAT4A","canonical_id":"hgnc:HGNC:7047","description":"alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A","metadata":{"aliases":["GnT-Iva","GnT-4a"]}},{"id":"39c3bb6cd086490088cdac9b906ef6a1","type":"GENE","name":"MGAT4B","canonical_id":"hgnc:HGNC:7048","description":"alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B","metadata":{"aliases":["GnT-Ivb"]}},{"id":"95d881932d024896a575c7fa4ce774f6","type":"GENE","name":"MGAT4C","canonical_id":"hgnc:HGNC:30871","description":"MGAT4 family member C","metadata":{"aliases":["HGNT-IV-H"]}},{"id":"11984ba58cdf41a9826e8c18f9042c50","type":"GENE","name":"MGAT4D","canonical_id":"hgnc:HGNC:43619","description":"MGAT4 family member D","metadata":{"aliases":["GnT1IP"]}},{"id":"1cd403ddee4c4843bad859aaea93b498","type":"GENE","name":"MGAT4EP","canonical_id":"hgnc:HGNC:49418","description":"MGAT4 family member E, pseudogene","metadata":null},{"id":"ba680f6e1de0415c98ae0c49bfe93735","type":"GENE","name":"MGAT4FP","canonical_id":"hgnc:HGNC:49419","description":"MGAT4 family member F, pseudogene","metadata":null},{"id":"1ab8c2e9a60a4d1aaf81dba1ad684ff5","type":"GENE","name":"MGAT5","canonical_id":"hgnc:HGNC:7049","description":null,"metadata":null},{"id":"765b0d8e714443498fd947eb6394efd8","type":"GENE","name":"MGAT5B","canonical_id":"hgnc:HGNC:24140","description":"alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B","metadata":{"aliases":["GnT-IX","FLJ25132","GnT-VB"]}},{"id":"123086acf23b4434b9f909b45c2bc58d","type":"GENE","name":"MGLL","canonical_id":"hgnc:HGNC:17038","description":"monoglyceride lipase","metadata":{"aliases":["HU-K5","MGL","MAGL"]}},{"id":"f235f8973c7347c7b477ee52d5b4609c","type":"GENE","name":"MGME1","canonical_id":"hgnc:HGNC:16205","description":"mitochondrial genome maintenance exonuclease 1","metadata":{"aliases":["bA504H3.4","DDK1","C20orf72"]}},{"id":"dbb283a5895a46738e34fa3a0c5cbcdb","type":"GENE","name":"MGMT","canonical_id":"hgnc:HGNC:7059","description":null,"metadata":null},{"id":"602a15c221fb4c76962fef43a0268009","type":"GENE","name":"MGP","canonical_id":"hgnc:HGNC:7060","description":null,"metadata":null},{"id":"62f03075da704fd3a807f17ef77fe2e4","type":"GENE","name":"MGRN1","canonical_id":"hgnc:HGNC:20254","description":"mahogunin ring finger 1","metadata":{"aliases":["KIAA0544","RNF156"]}},{"id":"3ee51a89fc9d4b73a33b639b096f3215","type":"GENE","name":"MGRN1-AS1","canonical_id":"hgnc:HGNC:58541","description":"MGRN1 antisense RNA 1","metadata":null},{"id":"200bab1a4eef4bc9b3366785a0e53bfa","type":"GENE","name":"MGST1","canonical_id":"hgnc:HGNC:7061","description":"microsomal glutathione S-transferase 1","metadata":{"aliases":["MGST-I","PMAN","GST12"]}},{"id":"fb9eb906da2d4fc29902d0c81a1aa8e7","type":"GENE","name":"MGST2","canonical_id":"hgnc:HGNC:7063","description":"microsomal glutathione S-transferase 2","metadata":{"aliases":["MGST-II"]}},{"id":"efc00dce599a49018188aad593e80957","type":"GENE","name":"MGST3","canonical_id":"hgnc:HGNC:7064","description":"microsomal glutathione S-transferase 3","metadata":{"aliases":["GST-III"]}},{"id":"344dd11dfd9f49fbaddba891521e72e1","type":"GO_TERM","name":"MH1 domain binding","canonical_id":"go:GO:0035501","description":"\"Binding to a MH1 (MAD homology 1) protein domain. The MH1 domain is found at the amino terminus of MAD related proteins such as Smads and can mediate DNA binding in some proteins. Smads also use the MH1 domain to interact with some transcription factors.\" [Pfam:PF03165]","metadata":null},{"id":"739763ff294e4b6f83ff67dc5f572791","type":"GO_TERM","name":"MH2 domain binding","canonical_id":"go:GO:0035500","description":"\"Binding to a MH2 (MAD homology 2) protein domain. The MH2 domain is found at the carboxy-terminus of MAD related proteins such as Smads. The MH2 domain mediates interaction with a wide variety of proteins and provides specificity and selectivity to Smad function and also is critical for mediating interactions in Smad oligomers.\" [GOC:curators]","metadata":null},{"id":"3d168b2d84e74febb39b30704498d4d2","type":"GO_TERM","name":"MHC class I biosynthetic process","canonical_id":"go:GO:0045341","description":"\"The chemical reactions and pathways resulting in the formation of major histocompatibility protein class I.\" [GOC:curators]","metadata":null},{"id":"374c2c8242ec4fdd9a00c268e9d89d20","type":"GO_TERM","name":"MHC class I peptide loading complex","canonical_id":"go:GO:0042824","description":"\"A large, multisubunit complex which consists of the MHC class I-beta 2 microglobulin dimer, the transporter associated with antigen presentation (TAP), tapasin (an MHC-encoded membrane protein), the chaperone calreticulin and the thiol oxidoreductase ERp57. Functions in the assembly of peptides with newly synthesized MHC class I molecules.\" [GOC:jl, PMID:10631934]","metadata":null},{"id":"5006c7d439b44baeba2a52bb609b6d26","type":"GO_TERM","name":"MHC class I protein binding","canonical_id":"go:GO:0042288","description":"\"Binding to a major histocompatibility complex class I molecule; a set of molecules displayed on cell surfaces that are responsible for lymphocyte recognition and antigen presentation.\" [GOC:jl]","metadata":null},{"id":"6b34907040314201acce40ef6fa3b85a","type":"GO_TERM","name":"MHC class I protein binding, via antigen binding groove","canonical_id":"go:GO:0023027","description":"\"Binding to a major histocompatibility complex class I molecules via the antigen binding groove.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"93a44bdeab8e4574afcd5e4528410cfa","type":"GO_TERM","name":"MHC class I protein binding, via lateral surface","canonical_id":"go:GO:0023028","description":"\"Binding to a major histocompatibility complex class I molecules via the lateral surface.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"d75e412d89284db785cb3ff3b07ca11e","type":"GO_TERM","name":"MHC class I protein complex","canonical_id":"go:GO:0042612","description":"\"A transmembrane protein complex composed of a MHC class I alpha chain and an invariant beta2-microglobin chain, and with or without a bound peptide antigen. Class I here refers to classical class I molecules.\" [GOC:add, GOC:jl, ISBN:0120781859, ISBN:0781735149]","metadata":null},{"id":"28a9ed4a46ff4073a1dbc3149750936e","type":"GO_TERM","name":"MHC class I protein complex assembly","canonical_id":"go:GO:0002397","description":"\"The aggregation, arrangement and bonding together of a set of components to form an MHC class I protein complex. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"54ad8225336c4c8cb450ca385d65c6a9","type":"GO_TERM","name":"MHC class I protein complex binding","canonical_id":"go:GO:0023024","description":"\"Binding to a class I major histocompatibility complex.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"e1884dc7aff6480981baa63b4c064263","type":"GO_TERM","name":"MHC class I receptor activity","canonical_id":"go:GO:0032393","description":"\"Combining with an MHC class I protein complex to initiate a change in cellular activity. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"556023d79c0d450183b77735bebc2674","type":"GO_TERM","name":"MHC class II biosynthetic process","canonical_id":"go:GO:0045342","description":"\"The chemical reactions and pathways resulting in the formation of major histocompatibility protein class II.\" [GOC:curators]","metadata":null},{"id":"0423206ef4924cf8b3f05be654c50a35","type":"GO_TERM","name":"MHC class II protein binding","canonical_id":"go:GO:0042289","description":"\"Binding to a major histocompatibility complex class II molecule; a set of molecules displayed on cell surfaces that are responsible for lymphocyte recognition and antigen presentation.\" [GOC:jl]","metadata":null},{"id":"11950428e05f4942bbce3f76ce1306a1","type":"GO_TERM","name":"MHC class II protein binding, via antigen binding groove","canonical_id":"go:GO:0042658","description":"\"Binding to the antigen binding groove of major histocompatibility complex class II molecules.\" [GOC:jl]","metadata":null},{"id":"a86d0d68bf054fd692211def10993950","type":"GO_TERM","name":"MHC class II protein binding, via lateral surface","canonical_id":"go:GO:0042657","description":"\"Binding to the lateral surface of major histocompatibility complex class II molecules.\" [GOC:jl]","metadata":null},{"id":"6f2900d9e32d49b0ac48677acbef1684","type":"GO_TERM","name":"MHC class II protein complex","canonical_id":"go:GO:0042613","description":"\"A transmembrane protein complex composed of an MHC class II alpha and MHC class II beta chain, and with or without a bound peptide or polysaccharide antigen.\" [GOC:add, GOC:jl, ISBN:0120781859, PMID:15928678]","metadata":null},{"id":"47d1a5a6e6e641349a86c13511bce845","type":"GO_TERM","name":"MHC class II protein complex assembly","canonical_id":"go:GO:0002399","description":"\"The aggregation, arrangement and bonding together of a set of components to form an MHC class II protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"fcfc7c1a3676465ca3c2588f5fe2f1b7","type":"GO_TERM","name":"MHC class II protein complex binding","canonical_id":"go:GO:0023026","description":"\"Binding to a class II major histocompatibility complex.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"35585ed3110749cfb1482019b6e2161c","type":"GO_TERM","name":"MHC class II receptor activity","canonical_id":"go:GO:0032395","description":"\"Combining with an MHC class II protein complex and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"3a09a1b4253f493a925e69d56a8095be","type":"GO_TERM","name":"MHC class Ib protein binding","canonical_id":"go:GO:0023029","description":"\"Binding to a major histocompatibility complex class Ib molecules.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"40d0b560c18a4734b3acda8d20da3a3b","type":"GO_TERM","name":"MHC class Ib protein binding, via antigen binding groove","canonical_id":"go:GO:0023030","description":"\"Binding to a major histocompatibility complex class Ib molecules via the antigen binding groove.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"5506f8d2fcca433dabe9e1ea191e74d9","type":"GO_TERM","name":"MHC class Ib protein binding, via lateral surface","canonical_id":"go:GO:0023031","description":"\"Binding to a major histocompatibility complex class Ib molecules via the lateral surface.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"8ceb49235b19425889eb486685769982","type":"GO_TERM","name":"MHC class Ib protein complex","canonical_id":"go:GO:0032398","description":"\"A transmembrane protein complex composed of a MHC class Ib alpha chain and, in most cases, an invariant beta2-microglobin chain, and with or without a bound peptide or lipid antigen. Class Ib here refers to non-classical class I molecules, such as those of the CD1 or HLA-E gene families.\" [GOC:add, ISBN:0781735149, PMID:15928678]","metadata":null},{"id":"664c921cc051409ebf62d0f2bf68fcad","type":"GO_TERM","name":"MHC class Ib protein complex assembly","canonical_id":"go:GO:0002398","description":"\"The aggregation, arrangement and bonding together of a set of components to form an MHC class Ib protein complex. Class Ib here refers to non-classical class I molecules.\" [GOC:add, PMID:15928678, PMID:15928680]","metadata":null},{"id":"2abd8fae58484db8b01abee737b459a9","type":"GO_TERM","name":"MHC class Ib protein complex binding","canonical_id":"go:GO:0023025","description":"\"Binding to a class Ib major histocompatibility complex.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"fcddc290793841eaa76352bc15f40143","type":"GO_TERM","name":"MHC class Ib receptor activity","canonical_id":"go:GO:0032394","description":"\"Combining with an MHC class Ib protein complex and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Class Ib here refers to non-classical class I molecules, such as those of the CD1 or HLA-E gene families.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"e2d28298967b49cf9d2997d4286d55d4","type":"GO_TERM","name":"MHC protein binding","canonical_id":"go:GO:0042287","description":"\"Binding to a major histocompatibility complex molecule; a set of molecules displayed on cell surfaces that are responsible for lymphocyte recognition and antigen presentation.\" [GOC:jl]","metadata":null},{"id":"ba2bb9d8849c4e3d9be61139e162c19b","type":"GO_TERM","name":"MHC protein complex","canonical_id":"go:GO:0042611","description":"\"A transmembrane protein complex composed of an MHC alpha chain and, in most cases, either an MHC class II beta chain or an invariant beta2-microglobin chain, and with or without a bound peptide, lipid, or polysaccharide antigen.\" [GOC:add, GOC:jl, ISBN:0781735149, PMID:15928678, PMID:16153240]","metadata":null},{"id":"c21e3f5189b140caa4add0523279526d","type":"GO_TERM","name":"MHC protein complex assembly","canonical_id":"go:GO:0002396","description":"\"The aggregation, arrangement and bonding together of a set of components to form an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591, PMID:15928678]","metadata":null},{"id":"91a015c95a294e6a95624fbb310c2238","type":"GO_TERM","name":"MHC protein complex binding","canonical_id":"go:GO:0023023","description":"\"Binding to a major histocompatibility complex.\" [GOC:mtg_signal, GOC:vw]","metadata":null},{"id":"ee4b6c5d7c764d93a66f13f68d558857","type":"GENE","name":"MHENCR","canonical_id":"hgnc:HGNC:53110","description":"melanoma highly expressed competing endogenous lncRNA for miR-425 and miR-489","metadata":null},{"id":"68dcf417b44c4db29caa015648e1dbaf","type":"GENE","name":"MHRT","canonical_id":"hgnc:HGNC:51291","description":"myosin heavy chain associated RNA transcript","metadata":{"aliases":["Myheart"]}},{"id":"350f485afda941d891a24798f5650982","type":"GENE","name":"MIA","canonical_id":"hgnc:HGNC:7076","description":null,"metadata":null},{"id":"b054793c88dc464db49da8cd255b801e","type":"GENE","name":"MIA-RAB4B","canonical_id":"hgnc:HGNC:48352","description":"MIA-RAB4B readthrough (NMD candidate)","metadata":null},{"id":"c35c36cfc1e242bfbb3e3137d381794e","type":"GENE","name":"MIA2","canonical_id":"hgnc:HGNC:18432","description":"MIA SH3 domain ER export factor 2","metadata":{"aliases":["FLJ22404","TALI","MEA6","cTAGE-5A","cTAGE-5B","cTAGE-5C","cTAGE-5D","MGEA11","CTAGE5","MGEA","MGEA6"]}},{"id":"6fb09c621ecb4cde92c3447e7b02a981","type":"GENE","name":"MIA2-AS1","canonical_id":"hgnc:HGNC:55436","description":"MIA2 antisense RNA 1","metadata":null},{"id":"727480904b214e719b926225ccedab32","type":"GENE","name":"MIA3","canonical_id":"hgnc:HGNC:24008","description":"MIA SH3 domain ER export factor 3","metadata":{"aliases":["UNQ6077","FLJ39207","KIAA0268","TANGO","TANGO1"]}},{"id":"a1cd4f2c9db6498e97fcb8374b4aa2c6","type":"GENE","name":"MIAT","canonical_id":"hgnc:HGNC:33425","description":"myocardial infarction associated transcript","metadata":{"aliases":["FLJ25967","Rncr2","gomafu","NCRNA00066","LINC00066","lncRNA-MIAT","C22orf35"]}},{"id":"f9bd5a11e0014b939b151c58a92ff347","type":"GENE","name":"MIATNB","canonical_id":"hgnc:HGNC:50731","description":"MIAT neighbor","metadata":null},{"id":"180efd52ea77483b96975f674b1c8694","type":"GO_TERM","name":"MIB complex","canonical_id":"go:GO:0140275","description":"\"A mitochondrial intermembrane space bridging complex consisting of components of the MICOS complex in the inner mitochondrial membrane, the SAM complex in the outer membrane, a conserved DNAJ protein (human DNAJC11) and Metaxin 1.\" [PMID:26477565]","metadata":null},{"id":"85d66d8c6777487faa7d45c5db296b57","type":"GENE","name":"MIB1","canonical_id":"hgnc:HGNC:21086","description":"MIB E3 ubiquitin protein ligase 1","metadata":{"aliases":["DIP-1","MIB","KIAA1323","ZZANK2","ZZZ6"]}},{"id":"af4e746664484d0d83c26899bda3ea58","type":"GENE","name":"MIB2","canonical_id":"hgnc:HGNC:30577","description":"MIB E3 ubiquitin protein ligase 2","metadata":{"aliases":["skeletrophin","ZZZ5","FLJ39787","ZZANK1"]}},{"id":"82dd1f4be9eb44a09471ef615d833ff6","type":"TRIAL","name":"MIBG With Dinutuximab +/- Vorinostat","canonical_id":"clinicaltrials.gov:NCT03332667","description":"Neuroblastoma","metadata":null},{"id":"7f3586c625604842bc6a7011c7840ae2","type":"GENE","name":"MICA","canonical_id":"hgnc:HGNC:7090","description":null,"metadata":null},{"id":"aa2f346f9b1e486f91a0a5222fd0fa69","type":"GENE","name":"MICA-AS1","canonical_id":"hgnc:HGNC:53631","description":"MICA antisense RNA 1","metadata":null},{"id":"ea9e601244b245cd9465b49eeaa5448d","type":"GENE","name":"MICAL1","canonical_id":"hgnc:HGNC:20619","description":"microtubule associated monooxygenase, calponin and LIM domain containing 1","metadata":{"aliases":["MICAL","FLJ11937","DKFZp434B1517","FLJ21739","NICAL"]}},{"id":"2680e5d01bb04254aa2443fd7b87fbb9","type":"GENE","name":"MICAL2","canonical_id":"hgnc:HGNC:24693","description":"microtubule associated monooxygenase, calponin and LIM domain containing 2","metadata":{"aliases":["KIAA0750","FLJ14966","MICALCL"]}},{"id":"4249efa170ec4a7995104ff8c2d75fe8","type":"GENE","name":"MICAL2-AS1","canonical_id":"hgnc:HGNC:58437","description":"MICAL2 antisense RNA 1","metadata":null},{"id":"d2bd72f04ed24536991f89da5ee865b9","type":"GENE","name":"MICAL3","canonical_id":"hgnc:HGNC:24694","description":"microtubule associated monooxygenase, calponin and LIM domain containing 3","metadata":{"aliases":["KIAA0819"]}},{"id":"9d4f3cad1a3d4104adb1373ec10138de","type":"GENE","name":"MICALL1","canonical_id":"hgnc:HGNC:29804","description":"MICAL like 1","metadata":{"aliases":["MIRAB13","KIAA1668","MICAL-L1"]}},{"id":"0d5ceec2a21744469fdc065bac90cf46","type":"GENE","name":"MICALL2","canonical_id":"hgnc:HGNC:29672","description":"MICAL like 2","metadata":{"aliases":["MGC46023","FLJ23471","MICAL-L2","JRAB"]}},{"id":"3ae6be38f3d54282bf26b8547e80b83c","type":"GENE","name":"MICALL2-DT","canonical_id":"hgnc:HGNC:56050","description":"MICALL2 divergent transcript","metadata":null},{"id":"8ee799931dc44a9fbc1db282ce6beecb","type":"GENE","name":"MICB","canonical_id":"hgnc:HGNC:7091","description":null,"metadata":null},{"id":"2fa3069e4b3b4c5d99b8bd46b83a96c0","type":"GENE","name":"MICB-DT","canonical_id":"hgnc:HGNC:53632","description":"MICB divergent transcript","metadata":{"aliases":["TCONS_00012692"]}},{"id":"332fbc748148457ab34908640b3619f3","type":"GENE","name":"MICC","canonical_id":"hgnc:HGNC:7092","description":"MHC class I polypeptide-related sequence C (pseudogene)","metadata":{"aliases":["PERB11.3"]}},{"id":"19c7ff0c487b4bc69b19735078876f9a","type":"GENE","name":"MICD","canonical_id":"hgnc:HGNC:7093","description":"MHC class I polypeptide-related sequence D (pseudogene)","metadata":{"aliases":["PERB11.4"]}},{"id":"f774e063787d4a828b6c261c90940dd2","type":"GENE","name":"MICE","canonical_id":"hgnc:HGNC:7094","description":"MHC class I polypeptide-related sequence E (pseudogene)","metadata":{"aliases":["dJ377H14.7","PERB11.5"]}},{"id":"b9a6946ac2484091adaeb9b5783aeafb","type":"GENE","name":"MICF","canonical_id":"hgnc:HGNC:16801","description":"MHC class I polypeptide-related sequence F (pseudogene)","metadata":null},{"id":"3c7ca659192a4364af63cdbe7cb7674f","type":"GENE","name":"MICG","canonical_id":"hgnc:HGNC:16802","description":"MHC class I polypeptide-related sequence G (pseudogene)","metadata":null},{"id":"95fd5eb706ca452d876a38ba373e8ee5","type":"GO_TERM","name":"MICOS complex","canonical_id":"go:GO:0061617","description":"\"Mitochondrial inner membrane complex involved in maintenance of crista junctions, inner membrane architecture, and formation of contact sites to the outer membrane. In Saccharomyces cerevisiae the complex has six subunits: MIC10, MIC12, MIC19, MIC26, MIC27, and MIC60.\" [GOC:dph, PMID:21944719, PMID:21987634, PMID:22009199, PMID:24687277]","metadata":null},{"id":"d55c21e1b7ed42c39f72b81fa1544d72","type":"GENE","name":"MICOS10","canonical_id":"hgnc:HGNC:32068","description":"mitochondrial contact site and cristae organizing system subunit 10","metadata":{"aliases":["RP5-1056L3.2","FLJ36999","MIO10","Mic10","C1orf151","MINOS1"]}},{"id":"c7b64adc24664bb886f75f50c19130c1","type":"GENE","name":"MICOS10-DT","canonical_id":"hgnc:HGNC:55676","description":"MICOS10 divergent transcript","metadata":null},{"id":"1d2a4052fb1340a4a3a9fde560e5cf52","type":"GENE","name":"MICOS10-NBL1","canonical_id":"hgnc:HGNC:48338","description":"MICOS10-NBL1 readthrough","metadata":{"aliases":["MINOS1-NBL1"]}},{"id":"705affe4d286446c84f50e4e219bc583","type":"GENE","name":"MICOS10P1","canonical_id":"hgnc:HGNC:25036","description":"MICOS10 pseudogene 1","metadata":{"aliases":["CG012","N4BP2L2IT1","N4BP2L2-IT1","MINOS1P1"]}},{"id":"6c6c24291fd64490be986188643b07c6","type":"GENE","name":"MICOS10P2","canonical_id":"hgnc:HGNC:44092","description":"MICOS10 pseudogene 2","metadata":{"aliases":["MINOS1P2"]}},{"id":"7845354602934c008224764177913324","type":"GENE","name":"MICOS10P3","canonical_id":"hgnc:HGNC:44093","description":"MICOS10 pseudogene 3","metadata":{"aliases":["MINOS1P3"]}},{"id":"c99b84785a7d4a94bcee6e00e38d46f8","type":"GENE","name":"MICOS10P4","canonical_id":"hgnc:HGNC:44094","description":"MICOS10 pseudogene 4","metadata":{"aliases":["MINOS1P4"]}},{"id":"ebec50c8bee041f9a4510291ed6ffb0b","type":"GENE","name":"MICOS13","canonical_id":"hgnc:HGNC:33702","description":"mitochondrial contact site and cristae organizing system subunit 13","metadata":{"aliases":["QIL1","P117","MIC13","MIC12","C19orf70"]}},{"id":"f6d09d562c2a43da979a50d732d710df","type":"GENE","name":"MICU1","canonical_id":"hgnc:HGNC:1530","description":"mitochondrial calcium uptake 1","metadata":{"aliases":["CALC","EFHA3","FLJ12684","CBARA1"]}},{"id":"f083cc6a0eb3494ba0fb0d52af0600bc","type":"GENE","name":"MICU2","canonical_id":"hgnc:HGNC:31830","description":"mitochondrial calcium uptake 2","metadata":{"aliases":["EFHA1"]}},{"id":"c2573647c9504f5fa38105c40e96bfc2","type":"GENE","name":"MICU3","canonical_id":"hgnc:HGNC:27820","description":"mitochondrial calcium uptake 3","metadata":{"aliases":["DKFZp313A0139","EFHA2"]}},{"id":"cdfc7a5eda0d43c8901d7d48dfb1f925","type":"GENE","name":"MID1","canonical_id":"hgnc:HGNC:7095","description":null,"metadata":null},{"id":"b2b8010451e54e058c386e4e0567939a","type":"GENE","name":"MID1IP1","canonical_id":"hgnc:HGNC:20715","description":"MID1 interacting protein 1","metadata":{"aliases":["STRAIT11499","FLJ10386","MIG12","THRSPL","G12-like"]}},{"id":"920500db855346fbad106c118f7be2a6","type":"GENE","name":"MID1IP1-AS1","canonical_id":"hgnc:HGNC:40932","description":"MID1IP1 antisense RNA 1","metadata":null},{"id":"3ed8e5719e674c00a141fbd186758020","type":"GENE","name":"MID2","canonical_id":"hgnc:HGNC:7096","description":"midline 2","metadata":{"aliases":["FXY2","TRIM1","RNF60","MRX101"]}},{"id":"d1fc6888a9164ac589f9d452d96334f1","type":"GENE","name":"MIDEAS","canonical_id":"hgnc:HGNC:19853","description":"mitotic deacetylase associated SANT domain protein","metadata":{"aliases":["LSR68","C14orf117","C14orf43","ELMSAN1"]}},{"id":"e15ec7a2611e40d4b13d3a9b33452b34","type":"GENE","name":"MIDEAS-AS1","canonical_id":"hgnc:HGNC:56194","description":"MIDEAS antisense RNA 1","metadata":null},{"id":"49a3416b7adf4e42bc33a9da2c9b950c","type":"GENE","name":"MIDN","canonical_id":"hgnc:HGNC:16298","description":"midnolin","metadata":{"aliases":["Stx"]}},{"id":"c63fbc2b53ef4260b3508db25a6e8a95","type":"GENE","name":"MIEF1","canonical_id":"hgnc:HGNC:25979","description":"mitochondrial elongation factor 1","metadata":{"aliases":["FLJ20232","MiD51","L0R8F8","D3A","SMCR7L"]}},{"id":"a1ee8a5e13c44d52856f2dafc888e30c","type":"GENE","name":"MIEF2","canonical_id":"hgnc:HGNC:17920","description":"mitochondrial elongation factor 2","metadata":{"aliases":["MGC23130","MiD49","D3B","SMCR7"]}},{"id":"32280cf941e14b23abd56c7ee79f84e3","type":"GENE","name":"MIEN1","canonical_id":"hgnc:HGNC:28230","description":"migration and invasion enhancer 1","metadata":{"aliases":["MGC14832","ORB3","XTP4","C35","Rdx12","C17orf37"]}},{"id":"e2518936c63d45419a59d20e6c0dcf24","type":"GENE","name":"MIER1","canonical_id":"hgnc:HGNC:29657","description":"MIER1 transcriptional regulator","metadata":{"aliases":["hMI-ER1","MI-ER1","KIAA1610"]}},{"id":"d500504b2cd84a84948728e629149342","type":"GENE","name":"MIER2","canonical_id":"hgnc:HGNC:29210","description":"MIER family member 2","metadata":{"aliases":["KIAA1193"]}},{"id":"285472dbe54c4eb38249cae782073e3f","type":"GENE","name":"MIER3","canonical_id":"hgnc:HGNC:26678","description":"MIER family member 3","metadata":{"aliases":["FLJ35954","DKFZp686L09111","DKFZp781I1119"]}},{"id":"45d1dd82dbc94b59a977958d62377ae9","type":"GENE","name":"MIER3-AS1","canonical_id":"hgnc:HGNC:41157","description":"MIER3 antisense RNA 1","metadata":null},{"id":"b44c8b4c5f3144f1a375719639260ec0","type":"GENE","name":"MIF","canonical_id":"hgnc:HGNC:7097","description":null,"metadata":null},{"id":"7f976374fbe74e3c9db3709ea6cff9b7","type":"GENE","name":"MIF-AS1","canonical_id":"hgnc:HGNC:27669","description":"MIF antisense RNA 1","metadata":{"aliases":["LOC284889","MIF-AS"]}},{"id":"b038ebb196d9495eaed233eabf1fcca0","type":"GENE","name":"MIF4GD","canonical_id":"hgnc:HGNC:24030","description":"MIF4G domain containing","metadata":{"aliases":["AD023","MGC45027","SLIP1","MIFD"]}},{"id":"d22675073859484da4d964a8a3db30ec","type":"GENE","name":"MIF4GD-DT","canonical_id":"hgnc:HGNC:55335","description":"MIF4GD divergent transcript","metadata":{"aliases":["AC022211.2"]}},{"id":"6401cd33cf03489694fcd4cfb4568cf7","type":"GENE","name":"MIGA1","canonical_id":"hgnc:HGNC:24741","description":"mitoguardin 1","metadata":{"aliases":["FLJ35093","FAM73A"]}},{"id":"93939715c21746539941bcee06d7642d","type":"GENE","name":"MIGA2","canonical_id":"hgnc:HGNC:23621","description":"mitoguardin 2","metadata":{"aliases":["FLJ14596","FLJ00199","C9orf54","FAM73B"]}},{"id":"7ae6c51b895b49a1ba7a7a1f76cebc32","type":"GO_TERM","name":"MIH complex","canonical_id":"go:GO:0120155","description":"\"A trimeric complex involved in cytokinesis. Proposed to bridge actomyosin ring contraction and septum synthesis in yeast, resulting in the coordination of these processes, and leading to plasma membrane ingression and fusion. In the yeast Saccharomyces cerevisiae this complex consists of Mlc1p, Iqg1p and Hof1p proteins.\" [GOC:rn, PMID:24413167, PMID:24895401]","metadata":null},{"id":"61d501a191754787984f53a525d56f7f","type":"GENE","name":"MIIP","canonical_id":"hgnc:HGNC:25715","description":"migration and invasion inhibitory protein","metadata":{"aliases":["FLJ12438","IIp45"]}},{"id":"abf9607ac93b492897e768b7afb33be4","type":"GENE","name":"MILIP","canonical_id":"hgnc:HGNC:43649","description":"MYC inducible lncRNA inactivating p53","metadata":{"aliases":["MAFG-AS1","MAFG-DT"]}},{"id":"6c96d68d386d4dd7a1c00f3d9f686151","type":"GENE","name":"MILR1","canonical_id":"hgnc:HGNC:27570","description":"mast cell immunoglobulin like receptor 1","metadata":{"aliases":["Allergin-1","MCA-32","C17orf60"]}},{"id":"1ecc513161bd499592a5adf988176923","type":"GO_TERM","name":"MIM complex","canonical_id":"go:GO:0140595","description":"\"A protein complex located in the mitochondrial outer membrane that functions as an insertase, mediating the insertion of alpha-helical proteins from the cytosol into the outer membrane. Client proteins are usually single- and multi-span proteins that include components of the TOM complex.\" [GOC:vw]","metadata":null},{"id":"987906d662134b35af3e24ecf4b35623","type":"GENE","name":"MIMS1","canonical_id":"hgnc:HGNC:28346","description":"mitochondrial inner membrane structural 1","metadata":{"aliases":["MGC24180","HsT2329","C18orf19","FAM210A"]}},{"id":"e1ad95ac9e1e40b2859288bc52c35cbe","type":"GENE","name":"MIMS2","canonical_id":"hgnc:HGNC:16102","description":"mitochondrial inner membrane structural 2","metadata":{"aliases":["dJ1167H4.1","DKFZP434A1114","C20orf108","FAM210B"]}},{"id":"7364ff823cf8467aa4b538f68a2658e6","type":"GENE","name":"MIMS3P","canonical_id":"hgnc:HGNC:44938","description":"MIMS family member 3, pseudogene","metadata":{"aliases":["FAM210CP"]}},{"id":"5fd5c3d6694b46acb2885f69299124b3","type":"GENE","name":"MIMT1","canonical_id":"hgnc:HGNC:33464","description":"MER1 repeat containing imprinted transcript 1","metadata":{"aliases":["MIM1","NCRNA00067","LINC00067"]}},{"id":"26815d1d975f4a9695b9a8c18f163089","type":"GENE","name":"MINAR1","canonical_id":"hgnc:HGNC:29172","description":"membrane integral NOTCH2 associated receptor 1","metadata":{"aliases":["UBTOR","KIAA1024"]}},{"id":"9c367a30cadc4459a98dacb99b6b35e2","type":"GENE","name":"MINAR2","canonical_id":"hgnc:HGNC:33914","description":"membrane integral NOTCH2 associated receptor 2","metadata":{"aliases":["KIAA1024L"]}},{"id":"91d505696f5c4c269f82e611c3be07e7","type":"GENE","name":"MINCR","canonical_id":"hgnc:HGNC:51653","description":"MYC-induced long non-coding RNA","metadata":{"aliases":["TCONS_00015189","LINC01604"]}},{"id":"ace57920a0354f2fbf48cbcd7b556fa9","type":"GENE","name":"MINDY1","canonical_id":"hgnc:HGNC:25648","description":"MINDY lysine 48 deubiquitinase 1","metadata":{"aliases":["FLJ11280","MINDY-1","FAM63A"]}},{"id":"f990ab6692af49bdbc3bfea8510eaab1","type":"GENE","name":"MINDY2","canonical_id":"hgnc:HGNC:26954","description":"MINDY lysine 48 deubiquitinase 2","metadata":{"aliases":["KIAA1164","FAM63B"]}},{"id":"fa155e48c15c48b9b819d9e46fd5d5a4","type":"GENE","name":"MINDY2-DT","canonical_id":"hgnc:HGNC:55889","description":"MINDY2 divergent transcript","metadata":null},{"id":"cdb2acba0f524ebea888f432bd121519","type":"GENE","name":"MINDY3","canonical_id":"hgnc:HGNC:23578","description":"MINDY lysine 48 deubiquitinase 3","metadata":{"aliases":["FLJ13397","CARP","my042","DERP5","C10orf97","FAM188A"]}},{"id":"fc752e7fb9cc4a5684e0d47f6593e6a8","type":"GENE","name":"MINDY4","canonical_id":"hgnc:HGNC:21916","description":"MINDY lysine 48 deubiquitinase 4","metadata":{"aliases":["FLJ22374","C7orf67","FAM188B"]}},{"id":"d81b03a1b05642239c83fa6393a471c3","type":"GENE","name":"MINDY4B","canonical_id":"hgnc:HGNC:35475","description":"MINDY family member 4B","metadata":{"aliases":["C3orf76","FAM188B2"]}},{"id":"5c3c99c2998b431a8b709196165c1b9d","type":"GENE","name":"MINK1","canonical_id":"hgnc:HGNC:17565","description":"misshapen like kinase 1","metadata":{"aliases":["B55","MINK","ZC3","MAP4K6","YSK2"]}},{"id":"0e054478af3f47fa9bf310410087f1ae","type":"GENE","name":"MINPP1","canonical_id":"hgnc:HGNC:7102","description":"multiple inositol-polyphosphate phosphatase 1","metadata":{"aliases":["MIPP"]}},{"id":"32480ac36d654b62995a2745ee5720f5","type":"TRIAL","name":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","canonical_id":"clinicaltrials.gov:NCT01501487","description":"Breast Cancer","metadata":null},{"id":"f27a74501ea243199c835faa01dc9125","type":"GENE","name":"MIOS","canonical_id":"hgnc:HGNC:21905","description":"meiosis regulator for oocyte development","metadata":{"aliases":["FLJ20323","MIO","Sea4","Yulink"]}},{"id":"ee33297e01974c538b852e67cf672317","type":"GENE","name":"MIOS-DT","canonical_id":"hgnc:HGNC:55187","description":"MIOS divergent transcript","metadata":null},{"id":"20dc281839ba48e694f019ac447e41c5","type":"GENE","name":"MIOX","canonical_id":"hgnc:HGNC:14522","description":"myo-inositol oxygenase","metadata":{"aliases":["ALDRL6"]}},{"id":"2adadcdaf6ff453bb9f6499a31cff908","type":"GENE","name":"MIOXP1","canonical_id":"hgnc:HGNC:50748","description":"myo-inositol oxygenase pseudogene 1","metadata":null},{"id":"2ee984e354b14a54b3617ebfcc053d98","type":"GENE","name":"MIP","canonical_id":"hgnc:HGNC:7103","description":null,"metadata":null},{"id":"64651f7bf6ac478ca8973b27a6615fb9","type":"GENE","name":"MIPEP","canonical_id":"hgnc:HGNC:7104","description":"mitochondrial intermediate peptidase","metadata":{"aliases":["MIP"]}},{"id":"05815d555592493695c3b9c61c543fd6","type":"GENE","name":"MIPEPP1","canonical_id":"hgnc:HGNC:39456","description":"mitochondrial intermediate peptidase pseudogene 1","metadata":null},{"id":"0a757e7f215d4b299b7e7804c1ff7bc4","type":"GENE","name":"MIPEPP2","canonical_id":"hgnc:HGNC:39457","description":"mitochondrial intermediate peptidase pseudogene 2","metadata":null},{"id":"f9c2344c1cfe4ba1a81c5c525a67d41c","type":"GENE","name":"MIPEPP3","canonical_id":"hgnc:HGNC:39458","description":"mitochondrial intermediate peptidase pseudogene 3","metadata":null},{"id":"81f245a1256642de8ef35857abfc6c0c","type":"GENE","name":"MIPOL1","canonical_id":"hgnc:HGNC:21460","description":"mirror-image polydactyly 1","metadata":{"aliases":["CCDC193"]}},{"id":"e36c6056dc974bbb8b0fe532f6910cba","type":"GENE","name":"MIR1-1","canonical_id":"hgnc:HGNC:31499","description":"microRNA 1-1","metadata":{"aliases":["hsa-mir-1-1","MIRN1-1"]}},{"id":"87a8b8f0b82d4384a8ff17f05ffe297a","type":"GENE","name":"MIR1-1HG","canonical_id":"hgnc:HGNC:16159","description":"MIR1-1 host gene","metadata":{"aliases":["dJ353C17.1","MIR133A2HG","C20orf166"]}},{"id":"d61de6a3b1564c31a94b052482b32643","type":"GENE","name":"MIR1-2","canonical_id":"hgnc:HGNC:31500","description":"microRNA 1-2","metadata":{"aliases":["hsa-mir-1-2","MIRN1-2"]}},{"id":"48d299677c064c4dae1be13f29dd89a6","type":"GENE","name":"MIR100","canonical_id":"hgnc:HGNC:31487","description":"microRNA 100","metadata":{"aliases":["hsa-mir-100","MIRN100"]}},{"id":"e02fa37d8e484280a4e25f4cc44e6f94","type":"GENE","name":"MIR100HG","canonical_id":"hgnc:HGNC:39522","description":"mir-100-let-7a-2-mir-125b-1 cluster host gene","metadata":{"aliases":["AGD1","lncRNA-N2","linc-NeD125"]}},{"id":"8fea1a73c7bc47e8a8a403dc5dbd0088","type":"GENE","name":"MIR101-1","canonical_id":"hgnc:HGNC:31488","description":"microRNA 101-1","metadata":{"aliases":["hsa-mir-101-1","MIRN101-1"]}},{"id":"3a47b3b30e89425e8d62dff868d8df1a","type":"GENE","name":"MIR101-2","canonical_id":"hgnc:HGNC:31489","description":"microRNA 101-2","metadata":{"aliases":["hsa-mir-101-2","MIRN101-2"]}},{"id":"7613d1f7d18240c6860448a1e4366532","type":"GENE","name":"MIR10226","canonical_id":"hgnc:HGNC:54000","description":"microRNA 10226","metadata":{"aliases":["hsa-mir-10226"]}},{"id":"f94d594e6a93436caa838702709122d2","type":"GENE","name":"MIR10392","canonical_id":"hgnc:HGNC:54001","description":"microRNA 10392","metadata":{"aliases":["hsa-mir-10392"]}},{"id":"6974af7499864eb3a349daac5d604fb0","type":"GENE","name":"MIR10393","canonical_id":"hgnc:HGNC:54002","description":"microRNA 10393","metadata":{"aliases":["hsa-mir-10393"]}},{"id":"7c8bd57cc7b143e99708c921d14e91be","type":"GENE","name":"MIR10394","canonical_id":"hgnc:HGNC:54003","description":"microRNA 10394","metadata":{"aliases":["hsa-mir-10394"]}},{"id":"753dd78b51d04343ba1284099e892992","type":"GENE","name":"MIR10396A","canonical_id":"hgnc:HGNC:54005","description":"microRNA 10396a","metadata":{"aliases":["hsa-mir-10396a"]}},{"id":"ce87db5300c04840bc69986bd9485fab","type":"GENE","name":"MIR10396B","canonical_id":"hgnc:HGNC:54006","description":"microRNA 10396b","metadata":{"aliases":["hsa-mir-10396b"]}},{"id":"a0b480067aac47f9aed119083a420e5d","type":"GENE","name":"MIR10397","canonical_id":"hgnc:HGNC:54007","description":"microRNA 10397","metadata":{"aliases":["hsa-mir-10397"]}},{"id":"bc6e93a46f2e48508407af3e26b3a96d","type":"GENE","name":"MIR10398","canonical_id":"hgnc:HGNC:54008","description":"microRNA 10398","metadata":{"aliases":["hsa-mir-10398"]}},{"id":"5105f447ad624bf6a312252526e0a839","type":"GENE","name":"MIR10399","canonical_id":"hgnc:HGNC:54009","description":"microRNA 10399","metadata":{"aliases":["hsa-mir-10399"]}},{"id":"6f667c8a02734b7f880f2df5b5a1047b","type":"GENE","name":"MIR103A1","canonical_id":"hgnc:HGNC:31490","description":"microRNA 103a-1","metadata":{"aliases":["hsa-mir-103-1","hsa-mir-103a-1","MIRN103-1","MIR103-1"]}},{"id":"073e949b0b3a42a29eca451281696f32","type":"GENE","name":"MIR103A2","canonical_id":"hgnc:HGNC:31491","description":"microRNA 103a-2","metadata":{"aliases":["hsa-mir-103-2","hsa-mir-103a-2","MIRN103-2","MIR103-2"]}},{"id":"8c1733d7494349088bd552b206595275","type":"GENE","name":"MIR103B1","canonical_id":"hgnc:HGNC:35384","description":"microRNA 103b-1","metadata":{"aliases":["hsa-mir-103-1-as","hsa-mir-103b-1","MIRN103-1AS","MIR103-1AS"]}},{"id":"da91a67c4d1c415e80526491b68ff7d0","type":"GENE","name":"MIR103B2","canonical_id":"hgnc:HGNC:35385","description":"microRNA 103b-2","metadata":{"aliases":["hsa-mir-103-2-as","hsa-mir-103b-2","MIRN103-2AS","MIR103-2AS"]}},{"id":"fbea7b3656cb4b738bcf468009a595fe","type":"GENE","name":"MIR10400","canonical_id":"hgnc:HGNC:54010","description":"microRNA 10400","metadata":{"aliases":["hsa-mir-10400"]}},{"id":"9784b62d9ca8468c85ece42df9768941","type":"GENE","name":"MIR105-1","canonical_id":"hgnc:HGNC:31492","description":"microRNA 105-1","metadata":{"aliases":["hsa-mir-105-1","MIRN105-1"]}},{"id":"6a52085594a94fee840ed5978385735f","type":"GENE","name":"MIR105-2","canonical_id":"hgnc:HGNC:31493","description":"microRNA 105-2","metadata":{"aliases":["hsa-mir-105-2","MIRN105-2"]}},{"id":"7c917da39ffa4451a062d73004a1e3f6","type":"GENE","name":"MIR10522","canonical_id":"hgnc:HGNC:54012","description":"microRNA 10522","metadata":{"aliases":["hsa-mir-10522"]}},{"id":"5da5b34b949d43ec9a502a0536e743e0","type":"GENE","name":"MIR10523","canonical_id":"hgnc:HGNC:54013","description":"microRNA 10523","metadata":{"aliases":["hsa-mir-10523"]}},{"id":"a6f34019415c44c3a7252cec4656ccbd","type":"GENE","name":"MIR10524","canonical_id":"hgnc:HGNC:54014","description":"microRNA 10524","metadata":{"aliases":["hsa-mir-10524"]}},{"id":"5868be02ddde4382a6aa7ffcb458d1dd","type":"GENE","name":"MIR10525","canonical_id":"hgnc:HGNC:54015","description":"microRNA 10525","metadata":{"aliases":["hsa-mir-10525"]}},{"id":"2f800ef54b134e788fb91c4f06b4b503","type":"GENE","name":"MIR10526","canonical_id":"hgnc:HGNC:54016","description":"microRNA 10526","metadata":{"aliases":["hsa-mir-10526"]}},{"id":"94e4ada0744d424a8c005401b8f68d58","type":"GENE","name":"MIR10527","canonical_id":"hgnc:HGNC:54017","description":"microRNA 10527","metadata":{"aliases":["hsa-mir-10527"]}},{"id":"1ca1dab9dc854c9b99478bc37729e1a0","type":"GENE","name":"MIR106A","canonical_id":"hgnc:HGNC:31494","description":"microRNA 106a","metadata":{"aliases":["hsa-mir-106a","MIRN106A"]}},{"id":"db139451d0444cc3b3b5b9ab247d9cb5","type":"GENE","name":"MIR106AHG","canonical_id":"hgnc:HGNC:56862","description":"miR-106a-363 cluster host gene","metadata":null},{"id":"4fc9c763008349b1b456c3ceef1c5d71","type":"GENE","name":"MIR106B","canonical_id":"hgnc:HGNC:31495","description":"microRNA 106b","metadata":{"aliases":["hsa-mir-106b","MIRN106B"]}},{"id":"5c65b6836d3e4f72a7157f81634eba80","type":"GENE","name":"MIR107","canonical_id":"hgnc:HGNC:31496","description":"microRNA 107","metadata":{"aliases":["hsa-mir-107","MIRN107"]}},{"id":"1673b4be7b684f3f99dbc92640295fa1","type":"GENE","name":"MIR10A","canonical_id":"hgnc:HGNC:31497","description":"microRNA 10a","metadata":{"aliases":["hsa-mir-10a","MIRN10A"]}},{"id":"09d30ecfa10d421292a8e9f33362a132","type":"GENE","name":"MIR10B","canonical_id":"hgnc:HGNC:31498","description":"microRNA 10b","metadata":{"aliases":["hsa-mir-10b","MIRN10B"]}},{"id":"0fa3b573ba5141679bc377fbd53aa627","type":"GENE","name":"MIR11181","canonical_id":"hgnc:HGNC:54018","description":"microRNA 11181","metadata":{"aliases":["hsa-mir-11181"]}},{"id":"c004dc14a0c84a6b97d01ade203899d7","type":"GENE","name":"MIR11399","canonical_id":"hgnc:HGNC:54019","description":"microRNA 11399","metadata":{"aliases":["hsa-mir-11399"]}},{"id":"119468c85b2f4646bb0a8b13602db97d","type":"GENE","name":"MIR11400","canonical_id":"hgnc:HGNC:54160","description":"microRNA 11400","metadata":{"aliases":["hsa-mir-11400"]}},{"id":"7c54020b4355444f806da7de8e80e507","type":"GENE","name":"MIR11401","canonical_id":"hgnc:HGNC:54020","description":"microRNA 11401","metadata":{"aliases":["hsa-mir-11401"]}},{"id":"11dddc7640fb4cde8ffb99a22c82d04a","type":"GENE","name":"MIR1178","canonical_id":"hgnc:HGNC:35259","description":"microRNA 1178","metadata":{"aliases":["hsa-mir-1178","MIRN1178"]}},{"id":"1677f82a334949b5b73f238c07b47471","type":"GENE","name":"MIR1179","canonical_id":"hgnc:HGNC:35260","description":"microRNA 1179","metadata":{"aliases":["hsa-mir-1179","MIRN1179"]}},{"id":"6ad2a377d9204effa8f9f6a5ac4dbab2","type":"GENE","name":"MIR1180","canonical_id":"hgnc:HGNC:35261","description":"microRNA 1180","metadata":{"aliases":["hsa-mir-1180","MIRN1180"]}},{"id":"cef6bf4dcbcc42e690525c48c76ca69a","type":"GENE","name":"MIR1181","canonical_id":"hgnc:HGNC:35262","description":"microRNA 1181","metadata":{"aliases":["hsa-mir-1181","MIRN1181"]}},{"id":"8197634cda4c4335ad1866c2e6111ce0","type":"GENE","name":"MIR1182","canonical_id":"hgnc:HGNC:35263","description":"microRNA 1182","metadata":{"aliases":["hsa-mir-1182","MIRN1182"]}},{"id":"a0a5f900b94f4a32a9e18de5e51c8fe1","type":"GENE","name":"MIR1183","canonical_id":"hgnc:HGNC:35264","description":"microRNA 1183","metadata":{"aliases":["hsa-mir-1183","MIRN1183"]}},{"id":"8c595faf0b9f489d9a9def4b1cc9ce32","type":"GENE","name":"MIR1184-1","canonical_id":"hgnc:HGNC:35265","description":"microRNA 1184-1","metadata":{"aliases":["hsa-mir-1184","MIRN1184","MIR1184"]}},{"id":"46dbad2dc76b414b9d5df81a1dab90cc","type":"GENE","name":"MIR1184-2","canonical_id":"hgnc:HGNC:38211","description":"microRNA 1184-2","metadata":{"aliases":["hsa-mir-1184-2"]}},{"id":"5919a13b458f43f19fbde5a5743986e2","type":"GENE","name":"MIR1184-3","canonical_id":"hgnc:HGNC:38389","description":"microRNA 1184-3","metadata":{"aliases":["hsa-mir-1184-3"]}},{"id":"9279d8ddb9714e9dbe3d128bbab85b11","type":"GENE","name":"MIR1185-1","canonical_id":"hgnc:HGNC:35257","description":"microRNA 1185-1","metadata":{"aliases":["hsa-mir-1185-1","MIRN1185-1"]}},{"id":"2e80aa20001c4e91ad09244a113565a4","type":"GENE","name":"MIR1185-2","canonical_id":"hgnc:HGNC:35254","description":"microRNA 1185-2","metadata":{"aliases":["hsa-mir-1185-2","MIRN1185-2"]}},{"id":"fc1eb009d3bc45449483c15c1a3e50dd","type":"GENE","name":"MIR1193","canonical_id":"hgnc:HGNC:38247","description":"microRNA 1193","metadata":{"aliases":["hsa-mir-1193"]}},{"id":"24edc6ad74224651a3726dc78d32bf85","type":"GENE","name":"MIR1197","canonical_id":"hgnc:HGNC:35376","description":"microRNA 1197","metadata":{"aliases":["hsa-mir-1197","MIRN1197"]}},{"id":"d12f47d3ae8040538baf82de5f272c6e","type":"GENE","name":"MIR1199","canonical_id":"hgnc:HGNC:50081","description":"microRNA 1199","metadata":{"aliases":["hsa-mir-1199"]}},{"id":"50b3d9dbc9154e39b2fa840f52dba3c4","type":"GENE","name":"MIR1200","canonical_id":"hgnc:HGNC:35266","description":"microRNA 1200","metadata":{"aliases":["hsa-mir-1200","MIRN1200"]}},{"id":"2a1a114526844dbd9a7d2766ffb7156e","type":"GENE","name":"MIR1202","canonical_id":"hgnc:HGNC:35268","description":"microRNA 1202","metadata":{"aliases":["hsa-mir-1202","MIRN1202"]}},{"id":"6a2bd2705cfe4e03a4c521c12751c3b9","type":"GENE","name":"MIR1203","canonical_id":"hgnc:HGNC:35269","description":"microRNA 1203","metadata":{"aliases":["hsa-mir-1203","MIRN1203"]}},{"id":"d4ba5275d46a4010b11051b33a86ca2d","type":"GENE","name":"MIR1204","canonical_id":"hgnc:HGNC:37059","description":"microRNA 1204","metadata":{"aliases":["hsa-mir-1204"]}},{"id":"8772c9a656ae447fbe666f08f5b817cf","type":"GENE","name":"MIR1205","canonical_id":"hgnc:HGNC:35271","description":"microRNA 1205","metadata":{"aliases":["hsa-mir-1205","MIRN1205"]}},{"id":"25493aa5bd33433cafa011354739cf75","type":"GENE","name":"MIR1206","canonical_id":"hgnc:HGNC:35272","description":"microRNA 1206","metadata":{"aliases":["hsa-mir-1206","MIRN1206"]}},{"id":"feef62a45d5a41b295e235dc86f81baa","type":"GENE","name":"MIR1207","canonical_id":"hgnc:HGNC:35273","description":"microRNA 1207","metadata":{"aliases":["hsa-mir-1207","MIRN1207"]}},{"id":"0d191a33281e489db543baa7c68a2fb5","type":"GENE","name":"MIR1208","canonical_id":"hgnc:HGNC:35274","description":"microRNA 1208","metadata":{"aliases":["hsa-mir-1208","MIRN1208"]}},{"id":"f8f8069565ac40b08fedf47f38e30045","type":"GENE","name":"MIR12113","canonical_id":"hgnc:HGNC:54021","description":"microRNA 12113","metadata":{"aliases":["hsa-mir-12113"]}},{"id":"54daf24849d74eb396df6d37b2486e9a","type":"GENE","name":"MIR12114","canonical_id":"hgnc:HGNC:54022","description":"microRNA 12114","metadata":{"aliases":["hsa-mir-12114"]}},{"id":"4b478eca588143a2bf002aa891a5c3a3","type":"GENE","name":"MIR12115","canonical_id":"hgnc:HGNC:54023","description":"microRNA 12115","metadata":{"aliases":["hsa-mir-12115"]}},{"id":"8ffeefd3e1464e098c4cc3b0e9a8a61b","type":"GENE","name":"MIR12116","canonical_id":"hgnc:HGNC:54024","description":"microRNA 12116","metadata":{"aliases":["hsa-mir-12116"]}},{"id":"6072312a4e2644519b4d717d295f63be","type":"GENE","name":"MIR12117","canonical_id":"hgnc:HGNC:54025","description":"microRNA 12117","metadata":{"aliases":["hsa-mir-12117"]}},{"id":"7f40bbb9ab794ddb89d8b40da5ef50be","type":"GENE","name":"MIR12118","canonical_id":"hgnc:HGNC:54026","description":"microRNA 12118","metadata":{"aliases":["hsa-mir-12118"]}},{"id":"330afa3ebd174a7aa449539b0e04cca4","type":"GENE","name":"MIR12119","canonical_id":"hgnc:HGNC:54027","description":"microRNA 12119","metadata":{"aliases":["hsa-mir-12119"]}},{"id":"ad3b283d6bfe4662af228e6de544411b","type":"GENE","name":"MIR12120","canonical_id":"hgnc:HGNC:54028","description":"microRNA 12120","metadata":{"aliases":["hsa-mir-12120"]}},{"id":"f1ac3a124e4d49a8b152411e9e4a2bc4","type":"GENE","name":"MIR12121","canonical_id":"hgnc:HGNC:54029","description":"microRNA 12121","metadata":{"aliases":["hsa-mir-12121"]}},{"id":"fb0e9e814bee4055b27c54739b660e5f","type":"GENE","name":"MIR12122","canonical_id":"hgnc:HGNC:54030","description":"microRNA 12122","metadata":{"aliases":["hsa-mir-12122"]}},{"id":"85c0b4ad50b643269007b87e5fb36ffb","type":"GENE","name":"MIR12123","canonical_id":"hgnc:HGNC:54031","description":"microRNA 12123","metadata":{"aliases":["hsa-mir-12123"]}},{"id":"b7d8d6a625fa4466a5f351f0e024817e","type":"GENE","name":"MIR12124","canonical_id":"hgnc:HGNC:54032","description":"microRNA 12124","metadata":{"aliases":["hsa-mir-12124"]}},{"id":"549392243b634b9e92dbcfceeaa13607","type":"GENE","name":"MIR12125","canonical_id":"hgnc:HGNC:54033","description":"microRNA 12125","metadata":{"aliases":["hsa-mir-12125"]}},{"id":"6ca28c8adcaa44c7bd96921d69ea02a3","type":"GENE","name":"MIR12126","canonical_id":"hgnc:HGNC:54034","description":"microRNA 12126","metadata":{"aliases":["hsa-mir-12126"]}},{"id":"b591f0661ee44667b56f9fcf385a3150","type":"GENE","name":"MIR12127","canonical_id":"hgnc:HGNC:54035","description":"microRNA 12127","metadata":{"aliases":["hsa-mir-12127"]}},{"id":"ba50081e739a4fada6125f2ee484a187","type":"GENE","name":"MIR12128","canonical_id":"hgnc:HGNC:54036","description":"microRNA 12128","metadata":{"aliases":["hsa-mir-12128"]}},{"id":"e5dfbc651f4a49dd91ce1b834a3105d8","type":"GENE","name":"MIR12129","canonical_id":"hgnc:HGNC:54037","description":"microRNA 12129","metadata":{"aliases":["hsa-mir-12129"]}},{"id":"807be791653d47fe8f2c2e7b29b98045","type":"GENE","name":"MIR12130","canonical_id":"hgnc:HGNC:54038","description":"microRNA 12130","metadata":{"aliases":["hsa-mir-12130"]}},{"id":"6f975cb9b6a24dbab0b8aa51964819bd","type":"GENE","name":"MIR12131","canonical_id":"hgnc:HGNC:54039","description":"microRNA 12131","metadata":{"aliases":["hsa-mir-12131"]}},{"id":"bb2b0f4585b243bfbb56c64cbb1c813e","type":"GENE","name":"MIR12132","canonical_id":"hgnc:HGNC:54040","description":"microRNA 12132","metadata":{"aliases":["hsa-mir-12132"]}},{"id":"de4eab64035245188e145541c63061e4","type":"GENE","name":"MIR12133","canonical_id":"hgnc:HGNC:54041","description":"microRNA 12133","metadata":{"aliases":["hsa-mir-12133"]}},{"id":"2615a205802e461d91cb3b01e6e21d62","type":"GENE","name":"MIR12135","canonical_id":"hgnc:HGNC:54042","description":"microRNA 12135","metadata":{"aliases":["hsa-mir-12135"]}},{"id":"6846e817cba7487fa734b6422e79efe6","type":"GENE","name":"MIR12136","canonical_id":"hgnc:HGNC:54043","description":"microRNA 12136","metadata":{"aliases":["hsa-mir-12136"]}},{"id":"c1e1183818d240399c99356edd2107e7","type":"GENE","name":"MIR122","canonical_id":"hgnc:HGNC:31501","description":"microRNA 122","metadata":{"aliases":["hsa-mir-122a","hsa-mir-122","miR-122","MIRN122A","MIRN122"]}},{"id":"00744cb1fff64b2a8867f7a6b040141c","type":"GENE","name":"MIR1224","canonical_id":"hgnc:HGNC:33923","description":"microRNA 1224","metadata":{"aliases":["hsa-mir-1224","MIRN1224"]}},{"id":"f925d8bc0f1843d68755bffb267fdb58","type":"GENE","name":"MIR1225","canonical_id":"hgnc:HGNC:33931","description":"microRNA 1225","metadata":{"aliases":["hsa-mir-1225","MIRN1225"]}},{"id":"20872df3e9cc488a8198538ebcf14d62","type":"GENE","name":"MIR1226","canonical_id":"hgnc:HGNC:33922","description":"microRNA 1226","metadata":{"aliases":["hsa-mir-1226","MIRN1226"]}},{"id":"b3cf1db9ff504450a5cc915554840cff","type":"GENE","name":"MIR1227","canonical_id":"hgnc:HGNC:33932","description":"microRNA 1227","metadata":{"aliases":["hsa-mir-1227","MIRN1227"]}},{"id":"f79ad0d293c642e5a3da063566579f93","type":"GENE","name":"MIR1228","canonical_id":"hgnc:HGNC:33928","description":"microRNA 1228","metadata":{"aliases":["hsa-mir-1228","MIRN1228"]}},{"id":"babbbed1e8b94211a558582c6396ef67","type":"GENE","name":"MIR1229","canonical_id":"hgnc:HGNC:33924","description":"microRNA 1229","metadata":{"aliases":["hsa-mir-1229","MIRN1229"]}},{"id":"dfdb187ea56049e6aa29e62962158417","type":"GENE","name":"MIR122HG","canonical_id":"hgnc:HGNC:53821","description":"MIR122 host gene","metadata":{"aliases":["lnc122","lnc-pri-miR-122"]}},{"id":"1b9819bbd9a9499e802ad03df6573e63","type":"GENE","name":"MIR1231","canonical_id":"hgnc:HGNC:33921","description":"microRNA 1231","metadata":{"aliases":["hsa-mir-1231","MIRN1231"]}},{"id":"dce02864eff04f4fa3da124cdc6d9651","type":"GENE","name":"MIR1233-1","canonical_id":"hgnc:HGNC:33929","description":"microRNA 1233-1","metadata":{"aliases":["hsa-mir-1233","MIRN1233","MIR1233"]}},{"id":"0f3fb79fe1d3470a954d1428b84c909e","type":"GENE","name":"MIR1233-2","canonical_id":"hgnc:HGNC:38277","description":"microRNA 1233-2","metadata":{"aliases":["hsa-mir-1233-2"]}},{"id":"b5f4acd5dc594bb88455b7d0d0cca2a7","type":"GENE","name":"MIR1234","canonical_id":"hgnc:HGNC:33926","description":"microRNA 1234","metadata":{"aliases":["hsa-mir-1234","MIRN1234"]}},{"id":"1dc7f0a6c4ea489d987be5c1d5e9b1a4","type":"GENE","name":"MIR1236","canonical_id":"hgnc:HGNC:33925","description":"microRNA 1236","metadata":{"aliases":["hsa-mir-1236","MIRN1236"]}},{"id":"e03d189291a843ffacad678498e2f1e1","type":"GENE","name":"MIR1237","canonical_id":"hgnc:HGNC:33927","description":"microRNA 1237","metadata":{"aliases":["hsa-mir-1237","MIRN1237"]}},{"id":"6a622b03bd3049668339d3e9bc831952","type":"GENE","name":"MIR1238","canonical_id":"hgnc:HGNC:33933","description":"microRNA 1238","metadata":{"aliases":["hsa-mir-1238","MIRN1238"]}},{"id":"855f8123e0a346d8ada42a4398edd49a","type":"GENE","name":"MIR124-1","canonical_id":"hgnc:HGNC:31502","description":"microRNA 124-1","metadata":{"aliases":["hsa-mir-124a-1","hsa-mir-124-1","MIRN124A1","MIRN124-1"]}},{"id":"ff029c65480842e186b7d23fbf1b6bfd","type":"GENE","name":"MIR124-1HG","canonical_id":"hgnc:HGNC:27231","description":"MIR124-1 host gene","metadata":{"aliases":["Rncr3","neuroLNC","LINC00599"]}},{"id":"efa8967b54eb445fb9f2da0cfe6d8a05","type":"GENE","name":"MIR124-2","canonical_id":"hgnc:HGNC:31503","description":"microRNA 124-2","metadata":{"aliases":["hsa-mir-124a-2","hsa-mir-124-2","MIRN124A2","MIRN124-2"]}},{"id":"6b6781912ec44da3891aef8b9515e7ce","type":"GENE","name":"MIR124-2HG","canonical_id":"hgnc:HGNC:48723","description":"MIR124-2 host gene","metadata":{"aliases":["LINC00966"]}},{"id":"6842ac8701f74f4ba5a425fc26e4ce26","type":"GENE","name":"MIR124-3","canonical_id":"hgnc:HGNC:31504","description":"microRNA 124-3","metadata":{"aliases":["hsa-mir-124a-3","hsa-mir-124-3","MIRN124A3","MIRN124-3"]}},{"id":"3bfd7a90dabd49ccb49d8ba5633b078e","type":"GENE","name":"MIR1243","canonical_id":"hgnc:HGNC:35304","description":"microRNA 1243","metadata":{"aliases":["hsa-mir-1243","MIRN1243"]}},{"id":"f4f4264c2e534c7098cbcd9716a08f90","type":"GENE","name":"MIR1244-1","canonical_id":"hgnc:HGNC:35310","description":"microRNA 1244-1","metadata":{"aliases":["hsa-mir-1244","MIRN1244","MIR1244"]}},{"id":"0ade57255f6f42b994ff5cfea9f60860","type":"GENE","name":"MIR1244-2","canonical_id":"hgnc:HGNC:38321","description":"microRNA 1244-2","metadata":{"aliases":["hsa-mir-1244-2"]}},{"id":"d946efb1496148bca7b9b700a2ae9e84","type":"GENE","name":"MIR1244-3","canonical_id":"hgnc:HGNC:38390","description":"microRNA 1244-3","metadata":{"aliases":["hsa-mir-1244-3"]}},{"id":"256ef0527c724b68b517e258c39ee00c","type":"GENE","name":"MIR1244-4","canonical_id":"hgnc:HGNC:50831","description":"microRNA 1244-4","metadata":null},{"id":"c356e54f262e48969a6bdabaec87030a","type":"GENE","name":"MIR1245A","canonical_id":"hgnc:HGNC:35311","description":"microRNA 1245a","metadata":{"aliases":["hsa-mir-1245","MIRN1245","MIR1245"]}},{"id":"2464186ea1d74e51a80937d907364235","type":"GENE","name":"MIR1245B","canonical_id":"hgnc:HGNC:41794","description":"microRNA 1245b","metadata":{"aliases":["hsa-mir-1245b"]}},{"id":"507895f4bf60488e90e3813a33bf75cc","type":"GENE","name":"MIR1246","canonical_id":"hgnc:HGNC:35312","description":"microRNA 1246","metadata":{"aliases":["hsa-mir-1246","MIRN1246"]}},{"id":"45a52690a800480b822a71fd3fceadef","type":"GENE","name":"MIR1247","canonical_id":"hgnc:HGNC:35313","description":"microRNA 1247","metadata":{"aliases":["hsa-mir-1247","MIRN1247"]}},{"id":"5517851df2b64148928cbba687520af3","type":"GENE","name":"MIR1248","canonical_id":"hgnc:HGNC:35314","description":"microRNA 1248","metadata":{"aliases":["hsa-mir-1248","MIRN1248"]}},{"id":"609a8d46965f4d6281370ec9a3c39291","type":"GENE","name":"MIR1249","canonical_id":"hgnc:HGNC:35315","description":"microRNA 1249","metadata":{"aliases":["hsa-mir-1249","MIRN1249"]}},{"id":"ee918cb65f2e44dd816804bccad247b5","type":"GENE","name":"MIR1250","canonical_id":"hgnc:HGNC:35316","description":"microRNA 1250","metadata":{"aliases":["hsa-mir-1250","MIRN1250"]}},{"id":"b9b08ec85c0442b7a18df01bc2217ccf","type":"GENE","name":"MIR1251","canonical_id":"hgnc:HGNC:35317","description":"microRNA 1251","metadata":{"aliases":["hsa-mir-1251","MIRN1251"]}},{"id":"4310e6eb87d3408f8b2068b281e35c33","type":"GENE","name":"MIR1252","canonical_id":"hgnc:HGNC:35365","description":"microRNA 1252","metadata":{"aliases":["hsa-mir-1252","MIRN1252"]}},{"id":"c68b29e9416b48dc8655638e8ec00b6b","type":"GENE","name":"MIR1253","canonical_id":"hgnc:HGNC:35318","description":"microRNA 1253","metadata":{"aliases":["hsa-mir-1253","MIRN1253"]}},{"id":"6671521ae99d42aabd510f0e3d51ddc7","type":"GENE","name":"MIR1255A","canonical_id":"hgnc:HGNC:35320","description":"microRNA 1255a","metadata":{"aliases":["hsa-mir-1255a","MIRN1255A"]}},{"id":"3505cba24d424d0bac8ec01987a4860c","type":"GENE","name":"MIR1255B1","canonical_id":"hgnc:HGNC:35366","description":"microRNA 1255b-1","metadata":{"aliases":["hsa-mir-1255b-1","MIRN1255B1"]}},{"id":"0ac3f5df1b304470bf4a8e8addbc36da","type":"GENE","name":"MIR1255B2","canonical_id":"hgnc:HGNC:35367","description":"microRNA 1255b-2","metadata":{"aliases":["hsa-mir-1255b-2","MIRN1255B2"]}},{"id":"5e87996c6c2d439fa97c145cf8750879","type":"GENE","name":"MIR1256","canonical_id":"hgnc:HGNC:35321","description":"microRNA 1256","metadata":{"aliases":["hsa-mir-1256","MIRN1256"]}},{"id":"c2ea211592c04435839799a83a21ab94","type":"GENE","name":"MIR1257","canonical_id":"hgnc:HGNC:35322","description":"microRNA 1257","metadata":{"aliases":["hsa-mir-1257","MIRN1257"]}},{"id":"05a900974c7748e2a4f7ba755092efd4","type":"GENE","name":"MIR1258","canonical_id":"hgnc:HGNC:35323","description":"microRNA 1258","metadata":{"aliases":["hsa-mir-1258","MIRN1258"]}},{"id":"dfb51148ee404d2a9f31562115bd4c88","type":"GENE","name":"MIR125A","canonical_id":"hgnc:HGNC:31505","description":"microRNA 125a","metadata":{"aliases":["hsa-mir-125a","MIRN125A"]}},{"id":"705ee940ac5749afbbd199e98f206953","type":"GENE","name":"MIR125B1","canonical_id":"hgnc:HGNC:31506","description":"microRNA 125b-1","metadata":{"aliases":["hsa-mir-125b-1","MIRN125B1"]}},{"id":"f3f8be7a0399449dbdfe2339c6d83921","type":"GENE","name":"MIR125B2","canonical_id":"hgnc:HGNC:31507","description":"microRNA 125b-2","metadata":{"aliases":["hsa-mir-125b-2","MIRN125B2"]}},{"id":"5ffa90f05d2e4987a14bccaafed8ca49","type":"GENE","name":"MIR126","canonical_id":"hgnc:HGNC:31508","description":"microRNA 126","metadata":{"aliases":["hsa-mir-126","MIRN126"]}},{"id":"726f3240e78a410cbed7b6ae26df346a","type":"GENE","name":"MIR1260A","canonical_id":"hgnc:HGNC:35325","description":"microRNA 1260a","metadata":{"aliases":["hsa-mir-1260","MIRN1260","MIR1260"]}},{"id":"0de99afecb6f43b791f7186f4e5b8b87","type":"GENE","name":"MIR1260B","canonical_id":"hgnc:HGNC:38258","description":"microRNA 1260b","metadata":{"aliases":["hsa-mir-1260b"]}},{"id":"cb4aec6922024e55b43e7d55d7edc486","type":"GENE","name":"MIR1261","canonical_id":"hgnc:HGNC:35327","description":"microRNA 1261","metadata":{"aliases":["hsa-mir-1261","MIRN1261"]}},{"id":"a9e87fdd0b3f418babd0614608cd5e41","type":"GENE","name":"MIR1262","canonical_id":"hgnc:HGNC:35328","description":"microRNA 1262","metadata":{"aliases":["hsa-mir-1262","MIRN1262"]}},{"id":"a516931b9dce4af0826d88b25befdc1b","type":"GENE","name":"MIR1263","canonical_id":"hgnc:HGNC:35329","description":"microRNA 1263","metadata":{"aliases":["hsa-mir-1263","MIRN1263"]}},{"id":"94ceaf14abb047e5bcd890e3f37c85ae","type":"GENE","name":"MIR1264","canonical_id":"hgnc:HGNC:35246","description":"microRNA 1264","metadata":{"aliases":["hsa-mir-1264","MIRN1264"]}},{"id":"e5b4acb0080e4931b1ede8e6bd3f92e2","type":"GENE","name":"MIR1265","canonical_id":"hgnc:HGNC:35332","description":"microRNA 1265","metadata":{"aliases":["hsa-mir-1265","MIRN1265"]}},{"id":"b9b9edee71b54d129ac0965852f8f288","type":"GENE","name":"MIR1266","canonical_id":"hgnc:HGNC:35334","description":"microRNA 1266","metadata":{"aliases":["hsa-mir-1266","MIRN1266"]}},{"id":"158aa7fca5c54cadaafad30664808cef","type":"GENE","name":"MIR1267","canonical_id":"hgnc:HGNC:35335","description":"microRNA 1267","metadata":{"aliases":["hsa-mir-1267","MIRN1267"]}},{"id":"9cd254f5223b44778a579fce4ad3ea09","type":"GENE","name":"MIR1268A","canonical_id":"hgnc:HGNC:35336","description":"microRNA 1268a","metadata":{"aliases":["hsa-mir-1268","MIRN1268","MIR1268"]}},{"id":"6c06af70b803491186ca634136e0725f","type":"GENE","name":"MIR1268B","canonical_id":"hgnc:HGNC:41581","description":"microRNA 1268b","metadata":{"aliases":["hsa-mir-1268b"]}},{"id":"a038264b59f348df834a42721adfcce9","type":"GENE","name":"MIR1269A","canonical_id":"hgnc:HGNC:35337","description":"microRNA 1269a","metadata":{"aliases":["hsa-mir-1269","MIRN1269","MIR1269"]}},{"id":"6076ba9e8efe4445b7bdf13907cc7699","type":"GENE","name":"MIR1269B","canonical_id":"hgnc:HGNC:41787","description":"microRNA 1269b","metadata":{"aliases":["hsa-mir-1269b"]}},{"id":"37b14fc712c5489595b0dd24cdb63d56","type":"GENE","name":"MIR127","canonical_id":"hgnc:HGNC:31509","description":"microRNA 127","metadata":{"aliases":["hsa-mir-127","MIRN127"]}},{"id":"af0ed94ba26e4d71be38ad9f719ba971","type":"GENE","name":"MIR1270","canonical_id":"hgnc:HGNC:35338","description":"microRNA 1270","metadata":{"aliases":["hsa-mir-1270","hsa-mir-1270-2","MIRN1270","MIR1270-2","MIR1270-1"]}},{"id":"97df0888a05c46dda816df0d46ec81da","type":"GENE","name":"MIR1271","canonical_id":"hgnc:HGNC:35252","description":"microRNA 1271","metadata":{"aliases":["hsa-mir-1271","MIRN1271"]}},{"id":"d3ca514a7f9443e3b193a43ae2bf9660","type":"GENE","name":"MIR1272","canonical_id":"hgnc:HGNC:35339","description":"microRNA 1272","metadata":{"aliases":["hsa-mir-1272","MIRN1272"]}},{"id":"167d6f5cd635472e99242b404eb15ff7","type":"GENE","name":"MIR1273C","canonical_id":"hgnc:HGNC:38173","description":"microRNA 1273c","metadata":{"aliases":["hsa-mir-1273c"]}},{"id":"b854e894cc3940b28c44663bf2275a08","type":"GENE","name":"MIR1273H","canonical_id":"hgnc:HGNC:49973","description":"microRNA 1273h","metadata":{"aliases":["hsa-mir-1273h"]}},{"id":"18b9eeb604f64c8aa746d0e11b456547","type":"GENE","name":"MIR1275","canonical_id":"hgnc:HGNC:35346","description":"microRNA 1275","metadata":{"aliases":["hsa-mir-1275","MIRN1275"]}},{"id":"219a6e41d4a5429aa115fe72b82be73e","type":"GENE","name":"MIR1276","canonical_id":"hgnc:HGNC:35347","description":"microRNA 1276","metadata":{"aliases":["hsa-mir-1276","MIRN1276"]}},{"id":"e33f25f2c09542d4ac420b7ba3e1cd7f","type":"GENE","name":"MIR1277","canonical_id":"hgnc:HGNC:35350","description":"microRNA 1277","metadata":{"aliases":["hsa-mir-1277","MIRN1277"]}},{"id":"ab06aee8cd4343a99758794e6b69e4fd","type":"GENE","name":"MIR1278","canonical_id":"hgnc:HGNC:35356","description":"microRNA 1278","metadata":{"aliases":["hsa-mir-1278","MIRN1278"]}},{"id":"8cd1fd6d08174c10ae078629cf556877","type":"GENE","name":"MIR1279","canonical_id":"hgnc:HGNC:35357","description":"microRNA 1279","metadata":{"aliases":["hsa-mir-1279","MIRN1279"]}},{"id":"41cf3597f9874f67b88eb331c90252c1","type":"GENE","name":"MIR128-1","canonical_id":"hgnc:HGNC:31510","description":"microRNA 128-1","metadata":{"aliases":["hsa-mir-128a","hsa-mir-128-1","mir-128-1","MIRN128A","MIRN128-1"]}},{"id":"e359895a19b841ccb021814e86f43e37","type":"GENE","name":"MIR128-2","canonical_id":"hgnc:HGNC:31511","description":"microRNA 128-2","metadata":{"aliases":["hsa-mir-128b","hsa-mir-128-2","MIRN128B","MIRN128-2"]}},{"id":"620757346d3746bf8b412dea1e952c29","type":"GENE","name":"MIR1281","canonical_id":"hgnc:HGNC:35359","description":"microRNA 1281","metadata":{"aliases":["hsa-mir-1281","MIRN1281"]}},{"id":"4ee7d60b357d48b0877c0acfb0086923","type":"GENE","name":"MIR1282","canonical_id":"hgnc:HGNC:35360","description":"microRNA 1282","metadata":{"aliases":["hsa-mir-1282","MIRN1282"]}},{"id":"edea14a4891a40448903c1ccc873c0d6","type":"GENE","name":"MIR1283-1","canonical_id":"hgnc:HGNC:35255","description":"microRNA 1283-1","metadata":{"aliases":["hsa-mir-1283-1","MIRN1283-1"]}},{"id":"691572a61aad40c7bedddaf9be0bd58b","type":"GENE","name":"MIR1283-2","canonical_id":"hgnc:HGNC:35361","description":"microRNA 1283-2","metadata":{"aliases":["hsa-mir-1283-2","MIRN1283-2"]}},{"id":"4aee7bd76bed454288f7ef478fa06e7e","type":"GENE","name":"MIR1284","canonical_id":"hgnc:HGNC:35362","description":"microRNA 1284","metadata":{"aliases":["hsa-mir-1284","MIRN1284"]}},{"id":"c2f6e61297524e2dafb8b69a470b2b1a","type":"GENE","name":"MIR1285-1","canonical_id":"hgnc:HGNC:35277","description":"microRNA 1285-1","metadata":{"aliases":["hsa-mir-1285-1","MIRN1285-1"]}},{"id":"6511272aee30436db2e88607abadb453","type":"GENE","name":"MIR1285-2","canonical_id":"hgnc:HGNC:35278","description":"microRNA 1285-2","metadata":{"aliases":["hsa-mir-1285-2","MIRN1285-2"]}},{"id":"448c0dfda1fe4ee8bb59161a3450702c","type":"GENE","name":"MIR1286","canonical_id":"hgnc:HGNC:35279","description":"microRNA 1286","metadata":{"aliases":["hsa-mir-1286","MIRN1286"]}},{"id":"3110329b3a374fe5ab746e349e0ac410","type":"GENE","name":"MIR1287","canonical_id":"hgnc:HGNC:35280","description":"microRNA 1287","metadata":{"aliases":["hsa-mir-1287","MIRN1287"]}},{"id":"b91d9006a96b4e918e577e8446884839","type":"GENE","name":"MIR1288","canonical_id":"hgnc:HGNC:35363","description":"microRNA 1288","metadata":{"aliases":["hsa-mir-1288","MIRN1288"]}},{"id":"7cec2d7cdc7f4933a3bc37bc46f489ce","type":"GENE","name":"MIR1289-1","canonical_id":"hgnc:HGNC:35281","description":"microRNA 1289-1","metadata":{"aliases":["hsa-mir-1289-1","MIRN1289-1"]}},{"id":"11a5648ec2b84d4492b60cad0e32c0fd","type":"GENE","name":"MIR1289-2","canonical_id":"hgnc:HGNC:35282","description":"microRNA 1289-2","metadata":{"aliases":["hsa-mir-1289-2","MIRN1289-2"]}},{"id":"85412bd59f3041a5bbbbcacb9949be4b","type":"GENE","name":"MIR129-1","canonical_id":"hgnc:HGNC:31512","description":"microRNA 129-1","metadata":{"aliases":["hsa-mir-129-1","MIRN129-1"]}},{"id":"d2d82429cbb348899c4540d2189573fd","type":"GENE","name":"MIR129-2","canonical_id":"hgnc:HGNC:31513","description":"microRNA 129-2","metadata":{"aliases":["hsa-mir-129-2","MIRN129-2"]}},{"id":"cebbcc55bd7846c38936cf2d640d7820","type":"GENE","name":"MIR1290","canonical_id":"hgnc:HGNC:35283","description":"microRNA 1290","metadata":{"aliases":["hsa-mir-1290","MIRN1290"]}},{"id":"c73b0c45268b4de5938eaf476d310f5c","type":"GENE","name":"MIR1291","canonical_id":"hgnc:HGNC:35284","description":"microRNA 1291","metadata":{"aliases":["hsa-mir-1291","MIRN1291"]}},{"id":"119c6dc623a74292840f384d6c655cea","type":"GENE","name":"MIR1292","canonical_id":"hgnc:HGNC:35364","description":"microRNA 1292","metadata":{"aliases":["hsa-mir-1292","MIRN1292"]}},{"id":"3658580f5ff14fd29d7cfac90fda6856","type":"GENE","name":"MIR1293","canonical_id":"hgnc:HGNC:35286","description":"microRNA 1293","metadata":{"aliases":["hsa-mir-1293","MIRN1293"]}},{"id":"be37e6ab766749a7a0a03afeed0b95c3","type":"GENE","name":"MIR1294","canonical_id":"hgnc:HGNC:35287","description":"microRNA 1294","metadata":{"aliases":["hsa-mir-1294","MIRN1294"]}},{"id":"c3287d92582142328b70cc19751d4857","type":"GENE","name":"MIR1295A","canonical_id":"hgnc:HGNC:35288","description":"microRNA 1295a","metadata":{"aliases":["hsa-mir-1295","MIRN1295","MIR1295"]}},{"id":"5916d7d84503477e918a5734b531557f","type":"GENE","name":"MIR1295B","canonical_id":"hgnc:HGNC:43524","description":"microRNA 1295b","metadata":{"aliases":["hsa-mir-1295b"]}},{"id":"1b2ae2ae45f04c47bd6a745278af7539","type":"GENE","name":"MIR1296","canonical_id":"hgnc:HGNC:35249","description":"microRNA 1296","metadata":{"aliases":["hsa-mir-1296","MIRN1296"]}},{"id":"3e13d7c5d97d47c9bdbd3319d6730d7a","type":"GENE","name":"MIR1297","canonical_id":"hgnc:HGNC:35289","description":"microRNA 1297","metadata":{"aliases":["hsa-mir-1297","MIRN1297"]}},{"id":"6fe4836175ba47689d532889adc37b8c","type":"GENE","name":"MIR1298","canonical_id":"hgnc:HGNC:35258","description":"microRNA 1298","metadata":{"aliases":["hsa-mir-1298","MIRN1298"]}},{"id":"fa26880457294b2f8a86e2e3155e2390","type":"GENE","name":"MIR1299","canonical_id":"hgnc:HGNC:35290","description":"microRNA 1299","metadata":{"aliases":["hsa-mir-1299","MIRN1299"]}},{"id":"73a969a1cbf743afacd06e1a47189e73","type":"GENE","name":"MIR1301","canonical_id":"hgnc:HGNC:35253","description":"microRNA 1301","metadata":{"aliases":["hsa-mir-1301","MIRN1301"]}},{"id":"8f330be399ca43ba88c94cf513580513","type":"GENE","name":"MIR1302-1","canonical_id":"hgnc:HGNC:35293","description":"microRNA 1302-1","metadata":{"aliases":["hsa-mir-1302-1","MIRN1302-1"]}},{"id":"822ff1d54be4413daadab2dc83fbd5dd","type":"GENE","name":"MIR1302-10","canonical_id":"hgnc:HGNC:38233","description":"microRNA 1302-10","metadata":{"aliases":["hsa-mir-1302-10"]}},{"id":"ce601bb3592742449ba2a702883dfc2d","type":"GENE","name":"MIR1302-11","canonical_id":"hgnc:HGNC:38246","description":"microRNA 1302-11","metadata":{"aliases":["hsa-mir-1302-11"]}},{"id":"46caa4fc1ec14e9982f7286dd2ed8cad","type":"GENE","name":"MIR1302-2","canonical_id":"hgnc:HGNC:35294","description":"microRNA 1302-2","metadata":{"aliases":["hsa-mir-1302-2","MIRN1302-2"]}},{"id":"1638c863ffa54189985f017097cb3f86","type":"GENE","name":"MIR1302-2HG","canonical_id":"hgnc:HGNC:52482","description":"MIR1302-2 host gene","metadata":null},{"id":"06689462bff545c7a14a39c16eddc7aa","type":"GENE","name":"MIR1302-3","canonical_id":"hgnc:HGNC:35295","description":"microRNA 1302-3","metadata":{"aliases":["hsa-mir-1302-3","MIRN1302-3"]}},{"id":"26ed2a8643f94ae484b7a9a83fb9557d","type":"GENE","name":"MIR1302-4","canonical_id":"hgnc:HGNC:35296","description":"microRNA 1302-4","metadata":{"aliases":["hsa-mir-1302-4","MIRN1302-4"]}},{"id":"ee38cb1572734bd7afe1f192ec22a1f6","type":"GENE","name":"MIR1302-5","canonical_id":"hgnc:HGNC:35297","description":"microRNA 1302-5","metadata":{"aliases":["hsa-mir-1302-5","MIRN1302-5"]}},{"id":"1deb27fc3b094ec586dd3d9c5dba9652","type":"GENE","name":"MIR1302-6","canonical_id":"hgnc:HGNC:35298","description":"microRNA 1302-6","metadata":{"aliases":["hsa-mir-1302-6","MIRN1302-6"]}},{"id":"403417d65eea44eda98d8744dfce8387","type":"GENE","name":"MIR1302-7","canonical_id":"hgnc:HGNC:35299","description":"microRNA 1302-7","metadata":{"aliases":["hsa-mir-1302-7","MIRN1302-7"]}},{"id":"3d817124987e4b0a9396e3f3ea848cb7","type":"GENE","name":"MIR1302-8","canonical_id":"hgnc:HGNC:35300","description":"microRNA 1302-8","metadata":{"aliases":["hsa-mir-1302-8","MIRN1302-8"]}},{"id":"fbae2012240749e7b894a007f0faa1b8","type":"GENE","name":"MIR1302-9","canonical_id":"hgnc:HGNC:38218","description":"microRNA 1302-9","metadata":{"aliases":["hsa-mir-1302-9"]}},{"id":"1be1139d758444fcbf88d0905cc32914","type":"GENE","name":"MIR1302-9HG","canonical_id":"hgnc:HGNC:55045","description":"MIR1302-9 host gene","metadata":null},{"id":"bca1d7e3d9fb4dd5b19241737f0cc70a","type":"GENE","name":"MIR1303","canonical_id":"hgnc:HGNC:35301","description":"microRNA 1303","metadata":{"aliases":["hsa-mir-1303","MIRN1303"]}},{"id":"84eade83771b4973b6c4db85de617281","type":"GENE","name":"MIR1304","canonical_id":"hgnc:HGNC:35302","description":"microRNA 1304","metadata":{"aliases":["hsa-mir-1304","MIRN1304"]}},{"id":"d579da58582d49458a811743788ba0b9","type":"GENE","name":"MIR1305","canonical_id":"hgnc:HGNC:35303","description":"microRNA 1305","metadata":{"aliases":["hsa-mir-1305","MIRN1305"]}},{"id":"c13ce2c3b616477da6531db988b72b8b","type":"GENE","name":"MIR1306","canonical_id":"hgnc:HGNC:35371","description":"microRNA 1306","metadata":{"aliases":["hsa-mir-1306","MIRN1306"]}},{"id":"2821daa961424af0bc31c33789cefd6d","type":"GENE","name":"MIR1307","canonical_id":"hgnc:HGNC:35372","description":"microRNA 1307","metadata":{"aliases":["hsa-mir-1307","MIRN1307"]}},{"id":"89d05baddea44653a99b0411a8f84d3e","type":"GENE","name":"MIR130A","canonical_id":"hgnc:HGNC:31514","description":"microRNA 130a","metadata":{"aliases":["hsa-mir-130a","MIRN130A"]}},{"id":"9ab3c850bb824e0697f991126d79b89b","type":"GENE","name":"MIR130AHG","canonical_id":"hgnc:HGNC:55966","description":"MIR130A host gene","metadata":null},{"id":"b8f83486207a415a923102206e1a7a7d","type":"GENE","name":"MIR130B","canonical_id":"hgnc:HGNC:31515","description":"microRNA 130b","metadata":{"aliases":["hsa-mir-130b","MIRN130B"]}},{"id":"b1501fe092f0494d858c32851dbc2c6c","type":"GENE","name":"MIR132","canonical_id":"hgnc:HGNC:31516","description":"microRNA 132","metadata":{"aliases":["hsa-mir-132","MIRN132"]}},{"id":"5868e9a87c5b46a7969f14d00db7424f","type":"GENE","name":"MIR1321","canonical_id":"hgnc:HGNC:35373","description":"microRNA 1321","metadata":{"aliases":["hsa-mir-1321","MIRN1321"]}},{"id":"6b4f12bf2fc747839438b5a97040beed","type":"GENE","name":"MIR1322","canonical_id":"hgnc:HGNC:35374","description":"microRNA 1322","metadata":{"aliases":["hsa-mir-1322","MIRN1322"]}},{"id":"c09b3a32a93b4bb5ae5e8e107d7ab451","type":"GENE","name":"MIR1323","canonical_id":"hgnc:HGNC:35251","description":"microRNA 1323","metadata":{"aliases":["hsa-mir-1323","MIRN1323"]}},{"id":"062ff1045a6e4e9a938e8ed0eca07915","type":"GENE","name":"MIR1324","canonical_id":"hgnc:HGNC:35377","description":"microRNA 1324","metadata":{"aliases":["hsa-mir-1324","MIRN1324"]}},{"id":"5dbf13a92c2e47f699de0a7e253e6c71","type":"GENE","name":"MIR133A1","canonical_id":"hgnc:HGNC:31517","description":"microRNA 133a-1","metadata":{"aliases":["hsa-mir-133a-1","MIRN133A1"]}},{"id":"fadc2540a4094a8aa9b3379663e9e47f","type":"GENE","name":"MIR133A1HG","canonical_id":"hgnc:HGNC:49594","description":"MIR133A1 host gene","metadata":{"aliases":["LPCRL","MIR1-2HG"]}},{"id":"b9d7a1356de64cb9bdf7f10cffadf3b4","type":"GENE","name":"MIR133A2","canonical_id":"hgnc:HGNC:31518","description":"microRNA 133a-2","metadata":{"aliases":["hsa-mir-133a-2","MIRN133A2"]}},{"id":"9a17a7341aa7418b88088f0cbdffb3d1","type":"GENE","name":"MIR133B","canonical_id":"hgnc:HGNC:31759","description":"microRNA 133b","metadata":{"aliases":["hsa-mir-133b","MIRN133B"]}},{"id":"803ab412ed13435198b937317406d5db","type":"GENE","name":"MIR134","canonical_id":"hgnc:HGNC:31519","description":"microRNA 134","metadata":{"aliases":["hsa-mir-134","MIRN134"]}},{"id":"7e15adad3797468695ca2c081629d51e","type":"GENE","name":"MIR1343","canonical_id":"hgnc:HGNC:41902","description":"microRNA 1343","metadata":{"aliases":["hsa-mir-1343"]}},{"id":"9ef1fbcc04024c22bb7aa26729a801ca","type":"GENE","name":"MIR135A1","canonical_id":"hgnc:HGNC:31520","description":"microRNA 135a-1","metadata":{"aliases":["hsa-mir-135-1","hsa-mir-135a-1","MIRN135-1","MIRN135A1"]}},{"id":"b7509a30149e4fd3840cab8a924f4c35","type":"GENE","name":"MIR135A2","canonical_id":"hgnc:HGNC:31521","description":"microRNA 135a-2","metadata":{"aliases":["hsa-mir-135-2","hsa-mir-135a-2","MIRN135-2","MIRN135A2"]}},{"id":"eebdff1e92664abfbfd6a34347441e0c","type":"GENE","name":"MIR135B","canonical_id":"hgnc:HGNC:31760","description":"microRNA 135b","metadata":{"aliases":["hsa-mir-135b","MIRN135B"]}},{"id":"ca202b9ced794f218f87eca3df2381b7","type":"GENE","name":"MIR136","canonical_id":"hgnc:HGNC:31522","description":"microRNA 136","metadata":{"aliases":["hsa-mir-136","MIRN136"]}},{"id":"d9ff5457dd3b42688f2d68f861c6a148","type":"GENE","name":"MIR137","canonical_id":"hgnc:HGNC:31523","description":"microRNA 137","metadata":{"aliases":["hsa-mir-137","miR-137","MIRN137"]}},{"id":"b76ce250886f47b0b7ce9d44376fac2f","type":"GENE","name":"MIR137HG","canonical_id":"hgnc:HGNC:42871","description":"MIR137 host gene","metadata":null},{"id":"c829d4d382754c9ab0b8bca352547b53","type":"GENE","name":"MIR138-1","canonical_id":"hgnc:HGNC:31524","description":"microRNA 138-1","metadata":{"aliases":["hsa-mir-138-1","MIRN138-1"]}},{"id":"226516e9d9c64e19b5cc6dcd41431e3f","type":"GENE","name":"MIR138-2","canonical_id":"hgnc:HGNC:31525","description":"microRNA 138-2","metadata":{"aliases":["hsa-mir-138-2","MIRN138-2"]}},{"id":"663bc3a4fbc546b38a0255f9ea762c3c","type":"GENE","name":"MIR139","canonical_id":"hgnc:HGNC:31526","description":"microRNA 139","metadata":{"aliases":["hsa-mir-139","MIRN139"]}},{"id":"a5d146e7eace49b6929d29f26971a359","type":"GENE","name":"MIR140","canonical_id":"hgnc:HGNC:31527","description":"microRNA 140","metadata":{"aliases":["hsa-mir-140","MIR-140","MIRN140"]}},{"id":"5a93c93227904b738b8c10774119b78a","type":"GENE","name":"MIR141","canonical_id":"hgnc:HGNC:31528","description":"microRNA 141","metadata":{"aliases":["hsa-mir-141","MIRN141"]}},{"id":"9485c1dfe08941a1925a6af3360e10fc","type":"GENE","name":"MIR142","canonical_id":"hgnc:HGNC:31529","description":"microRNA 142","metadata":{"aliases":["hsa-mir-142","MIRN142"]}},{"id":"ed1dd7f28ec1495f98c4968487c3522d","type":"GENE","name":"MIR142HG","canonical_id":"hgnc:HGNC:55980","description":"MIR142 host genes","metadata":null},{"id":"d85d9d38dffc4ba1a3575b59cce1a9b0","type":"GENE","name":"MIR143","canonical_id":"hgnc:HGNC:31530","description":"microRNA 143","metadata":{"aliases":["hsa-mir-143","MIRN143"]}},{"id":"b79fe9cd6dd341c588ddb8f49c14712e","type":"GENE","name":"MIR144","canonical_id":"hgnc:HGNC:31531","description":"microRNA 144","metadata":{"aliases":["hsa-mir-144","MIRN144"]}},{"id":"f9b4ba7ea5b9418a873157a7b2ea4473","type":"GENE","name":"MIR145","canonical_id":"hgnc:HGNC:31532","description":"microRNA 145","metadata":{"aliases":["hsa-mir-145","MIR-145","MIRN145"]}},{"id":"b327444a123046bc92e98f37a728ef12","type":"GENE","name":"MIR1468","canonical_id":"hgnc:HGNC:35250","description":"microRNA 1468","metadata":{"aliases":["hsa-mir-1468","MIRN1468"]}},{"id":"80054eb3bcd240f2bc0d2c68c6ac070f","type":"GENE","name":"MIR1469","canonical_id":"hgnc:HGNC:35378","description":"microRNA 1469","metadata":{"aliases":["hsa-mir-1469","MIRN1469"]}},{"id":"39a3a631b30e4b00a8a78337036f1905","type":"GENE","name":"MIR146A","canonical_id":"hgnc:HGNC:31533","description":"microRNA 146a","metadata":{"aliases":["hsa-mir-146","hsa-mir-146a","MIRN146","MIRN146A"]}},{"id":"573b7b8198d9419c8211d0f9ad376f5b","type":"GENE","name":"MIR146B","canonical_id":"hgnc:HGNC:32079","description":"microRNA 146b","metadata":{"aliases":["hsa-mir-146b","MIRN146B"]}},{"id":"fe4b706b9afd4fc5866f3766bae437e3","type":"GENE","name":"MIR1470","canonical_id":"hgnc:HGNC:35379","description":"microRNA 1470","metadata":{"aliases":["hsa-mir-1470","MIRN1470"]}},{"id":"e4a467dcb1224c11aed941f96de78254","type":"GENE","name":"MIR1471","canonical_id":"hgnc:HGNC:35380","description":"microRNA 1471","metadata":{"aliases":["hsa-mir-1471","MIRN1471"]}},{"id":"10ea89411dc248f591fb4d88fe60a280","type":"GENE","name":"MIR147A","canonical_id":"hgnc:HGNC:31534","description":"microRNA 147a","metadata":{"aliases":["hsa-mir-147","MIRN147","MIR147"]}},{"id":"cd94bb114fb34928bea2ee11de4d8218","type":"GENE","name":"MIR147B","canonical_id":"hgnc:HGNC:33655","description":"microRNA 147b","metadata":{"aliases":["hsa-mir-147b","MIRN147B"]}},{"id":"465fb6f89b56449c9a395961a11b6be5","type":"GENE","name":"MIR148A","canonical_id":"hgnc:HGNC:31535","description":"microRNA 148a","metadata":{"aliases":["hsa-mir-148","hsa-mir-148a","MIRN148","MIRN148A"]}},{"id":"8106c2b523b64fb984227449d6b615bc","type":"GENE","name":"MIR148B","canonical_id":"hgnc:HGNC:31761","description":"microRNA 148b","metadata":{"aliases":["hsa-mir-148b","MIRN148B"]}},{"id":"2a3e1206415340838c4c3edc1840dcde","type":"GENE","name":"MIR149","canonical_id":"hgnc:HGNC:31536","description":"microRNA 149","metadata":{"aliases":["hsa-mir-149","MIRN149"]}},{"id":"35687bfb896e44e698e8c73e3d4cb7c3","type":"GENE","name":"MIR150","canonical_id":"hgnc:HGNC:31537","description":"microRNA 150","metadata":{"aliases":["hsa-mir-150","MIRN150"]}},{"id":"17089366c5d04e898e045a7524955710","type":"GENE","name":"MIR151A","canonical_id":"hgnc:HGNC:31762","description":"microRNA 151a","metadata":{"aliases":["hsa-mir-151","MIRN151","MIR151"]}},{"id":"8ea8e44e017f4dcfa1765c3913ecd732","type":"GENE","name":"MIR151B","canonical_id":"hgnc:HGNC:41588","description":"microRNA 151b","metadata":{"aliases":["hsa-mir-151b"]}},{"id":"d6d91bc1b661480aaf53a3e39755fa71","type":"GENE","name":"MIR152","canonical_id":"hgnc:HGNC:31538","description":"microRNA 152","metadata":{"aliases":["hsa-mir-152","MIRN152"]}},{"id":"0d4f157167b74f439a7a1904720a8126","type":"GENE","name":"MIR153-1","canonical_id":"hgnc:HGNC:31539","description":"microRNA 153-1","metadata":{"aliases":["hsa-mir-153-1","MIRN153-1"]}},{"id":"370adcc23ce843c8b7f93c5a714fb1af","type":"GENE","name":"MIR153-2","canonical_id":"hgnc:HGNC:31540","description":"microRNA 153-2","metadata":{"aliases":["hsa-mir-153-2","MIRN153-2"]}},{"id":"2e888ed48a7e402baae2162cdf5bf542","type":"GENE","name":"MIR1537","canonical_id":"hgnc:HGNC:35381","description":"microRNA 1537","metadata":{"aliases":["hsa-mir-1537","MIRN1537"]}},{"id":"766a675830da48dba1d5d9f13aa140eb","type":"GENE","name":"MIR1538","canonical_id":"hgnc:HGNC:35382","description":"microRNA 1538","metadata":{"aliases":["hsa-mir-1538","MIRN1538"]}},{"id":"7d48eb11ebe34f0497619da48cd81090","type":"GENE","name":"MIR1539","canonical_id":"hgnc:HGNC:35383","description":"microRNA 1539","metadata":{"aliases":["hsa-mir-1539","MIRN1539"]}},{"id":"1bd12c02d865459b8a5182505dcfe472","type":"GENE","name":"MIR154","canonical_id":"hgnc:HGNC:31541","description":"microRNA 154","metadata":{"aliases":["hsa-mir-154","MIRN154"]}},{"id":"578031deb2cc4ba6b713dfc9ac38f0ae","type":"GENE","name":"MIR155","canonical_id":"hgnc:HGNC:31542","description":"microRNA 155","metadata":{"aliases":["hsa-mir-155","MIRN155"]}},{"id":"5b9a4ac5d6474cf4b954564e384302ac","type":"GENE","name":"MIR155HG","canonical_id":"hgnc:HGNC:35460","description":"MIR155 host gene","metadata":{"aliases":["BIC","BIC-155","miPEP155","NCRNA00172","LncRNA-SERB","MIRHG2"]}},{"id":"464c00a4622a4249aed547198c811505","type":"GENE","name":"MIR1587","canonical_id":"hgnc:HGNC:41596","description":"microRNA 1587","metadata":{"aliases":["hsa-mir-1587"]}},{"id":"5f160d33321d47f3a5793a88b9e19d8e","type":"GENE","name":"MIR15A","canonical_id":"hgnc:HGNC:31543","description":"microRNA 15a","metadata":{"aliases":["hsa-mir-15a","MIRN15A"]}},{"id":"7d2efa7c02f24351862d7a0beb13cb2d","type":"GENE","name":"MIR15B","canonical_id":"hgnc:HGNC:31544","description":"microRNA 15b","metadata":{"aliases":["hsa-mir-15b","MIRN15B"]}},{"id":"0306a40b105348b888c3e45ac02917c5","type":"GENE","name":"MIR16-1","canonical_id":"hgnc:HGNC:31545","description":"microRNA 16-1","metadata":{"aliases":["hsa-mir-16-1","MIRN16-1"]}},{"id":"c34e198747904b4bb027fe05ac6f12ed","type":"GENE","name":"MIR16-2","canonical_id":"hgnc:HGNC:31546","description":"microRNA 16-2","metadata":{"aliases":["hsa-mir-16-2","MIRN16-2"]}},{"id":"02ddc79bf77640ddb34b540b29f4ab28","type":"GENE","name":"MIR17","canonical_id":"hgnc:HGNC:31547","description":"microRNA 17","metadata":{"aliases":["hsa-mir-17","MIRN17"]}},{"id":"4ba9daaf511f4c07b33ac7329aabb485","type":"GENE","name":"MIR17HG","canonical_id":"hgnc:HGNC:23564","description":"miR-17-92a-1 cluster host gene","metadata":{"aliases":["FLJ14178","MIRH1","MIHG1","NCRNA00048","miR-17-92","LINC00048","C13orf25","MIRHG1"]}},{"id":"20ff3bbc78ba4897b3590e6e44b7a504","type":"GENE","name":"MIR181A1","canonical_id":"hgnc:HGNC:31590","description":"microRNA 181a-1","metadata":{"aliases":["hsa-mir-213","MIRN213","MIRN181A1"]}},{"id":"9bd5d3a9ac184c2b8ecc2edf40765f53","type":"GENE","name":"MIR181A1HG","canonical_id":"hgnc:HGNC:48659","description":"MIR181A1 host gene","metadata":null},{"id":"b4d79fdac0504f1cb9f1e479abf5f4d6","type":"GENE","name":"MIR181A2","canonical_id":"hgnc:HGNC:31549","description":"microRNA 181a-2","metadata":{"aliases":["hsa-mir-181a","MIRN181A","MIRN181A2"]}},{"id":"bece7d465af64ab7bda8f9b8cbd9a3f0","type":"GENE","name":"MIR181A2HG","canonical_id":"hgnc:HGNC:37188","description":"MIR181A2 host gene","metadata":null},{"id":"d8572f46c7b54f69bcd2de7e33e9ff9f","type":"GENE","name":"MIR181B1","canonical_id":"hgnc:HGNC:31550","description":"microRNA 181b-1","metadata":{"aliases":["hsa-mir-181b-1","MIRN181B1"]}},{"id":"66323460a83c4270b1bf24fa11e93c86","type":"GENE","name":"MIR181B2","canonical_id":"hgnc:HGNC:31551","description":"microRNA 181b-2","metadata":{"aliases":["hsa-mir-181b-2","MIRN181B2"]}},{"id":"6be18f54ecfe4e2186eaf40a32da55d1","type":"GENE","name":"MIR181C","canonical_id":"hgnc:HGNC:31552","description":"microRNA 181c","metadata":{"aliases":["hsa-mir-181c","MIRN181C"]}},{"id":"95e9feff5ea94c848ab442b8665cfac0","type":"GENE","name":"MIR181D","canonical_id":"hgnc:HGNC:32089","description":"microRNA 181d","metadata":{"aliases":["hsa-mir-181d","MIRN181D"]}},{"id":"7cde7b90db064966bee465f375a56ce0","type":"GENE","name":"MIR182","canonical_id":"hgnc:HGNC:31553","description":"microRNA 182","metadata":{"aliases":["hsa-mir-182","miR-182","MIRN182"]}},{"id":"26161cf270b84c9094e98460f2e9a5d2","type":"GENE","name":"MIR1825","canonical_id":"hgnc:HGNC:35389","description":"microRNA 1825","metadata":{"aliases":["hsa-mir-1825","MIRN1825"]}},{"id":"903f5e9c10284dd88f1d5ffbbfc7655f","type":"GENE","name":"MIR1827","canonical_id":"hgnc:HGNC:35391","description":"microRNA 1827","metadata":{"aliases":["hsa-mir-1827","MIRN1827"]}},{"id":"d77ca9a2b32c45ca8fc33c62ba66ec7d","type":"GENE","name":"MIR183","canonical_id":"hgnc:HGNC:31554","description":"microRNA 183","metadata":{"aliases":["hsa-mir-183","MIRN183"]}},{"id":"a8c0529130af41c29648ae9bd3436fcc","type":"GENE","name":"MIR184","canonical_id":"hgnc:HGNC:31555","description":"microRNA 184","metadata":{"aliases":["hsa-mir-184","MIRN184"]}},{"id":"1df618122e904c2cb59580ac6997ac11","type":"GENE","name":"MIR1843","canonical_id":"hgnc:HGNC:54161","description":"microRNA 1843","metadata":{"aliases":["hsa-mir-1843"]}},{"id":"105e7d18af524c9393a19c2cf9662fde","type":"GENE","name":"MIR185","canonical_id":"hgnc:HGNC:31556","description":"microRNA 185","metadata":{"aliases":["hsa-mir-185","MIRN185"]}},{"id":"9cfb7e564e2f470eb07c0b400d580b44","type":"GENE","name":"MIR186","canonical_id":"hgnc:HGNC:31557","description":"microRNA 186","metadata":{"aliases":["hsa-mir-186","MIRN186"]}},{"id":"bae0a8c037ad4b7f9ab13fa0ce0791c0","type":"GENE","name":"MIR187","canonical_id":"hgnc:HGNC:31558","description":"microRNA 187","metadata":{"aliases":["hsa-mir-187","MIRN187"]}},{"id":"0cefa518af314ac4a16b0f38151d57bc","type":"GENE","name":"MIR188","canonical_id":"hgnc:HGNC:31559","description":"microRNA 188","metadata":{"aliases":["hsa-mir-188","MIRN188"]}},{"id":"ea936d954398449da4a4877c8c84fabd","type":"GENE","name":"MIR18A","canonical_id":"hgnc:HGNC:31548","description":"microRNA 18a","metadata":{"aliases":["hsa-mir-18","hsa-mir-18a","MIRN18","MIRN18A"]}},{"id":"8367f12d0f554819b689b10b4c2a0129","type":"GENE","name":"MIR18B","canonical_id":"hgnc:HGNC:32025","description":"microRNA 18b","metadata":{"aliases":["hsa-mir-18b","MIRN18B"]}},{"id":"8dcc3898cd4f4b24a7689dac21745c0f","type":"GENE","name":"MIR1908","canonical_id":"hgnc:HGNC:35392","description":"microRNA 1908","metadata":{"aliases":["hsa-mir-1908","MIRN1908"]}},{"id":"b1c219bb528a4ca49694b9bdbc2ea540","type":"GENE","name":"MIR1909","canonical_id":"hgnc:HGNC:35393","description":"microRNA 1909","metadata":{"aliases":["hsa-mir-1909","MIRN1909"]}},{"id":"3ec64789af6d47ea9a9ac94b095ac580","type":"GENE","name":"MIR190A","canonical_id":"hgnc:HGNC:31560","description":"microRNA 190a","metadata":{"aliases":["hsa-mir-190","MIRN190","MIR190"]}},{"id":"4f975123fd9f4609b17ecb031780e444","type":"GENE","name":"MIR190B","canonical_id":"hgnc:HGNC:33656","description":"microRNA 190b","metadata":{"aliases":["hsa-mir-190b","MIRN190B"]}},{"id":"e518d0b20e384e5780193cb4e23a5956","type":"GENE","name":"MIR191","canonical_id":"hgnc:HGNC:31561","description":"microRNA 191","metadata":{"aliases":["hsa-mir-191","MIRN191"]}},{"id":"24982f2fdbda4627a10c2942a604ab4c","type":"GENE","name":"MIR1910","canonical_id":"hgnc:HGNC:35394","description":"microRNA 1910","metadata":{"aliases":["hsa-mir-1910","MIRN1910"]}},{"id":"a498ce4f759142fbbc7b19d995be1d7e","type":"GENE","name":"MIR1911","canonical_id":"hgnc:HGNC:35395","description":"microRNA 1911","metadata":{"aliases":["hsa-mir-1911","MIRN1911"]}},{"id":"42403fe9d8064a6b807a4aaefecf380b","type":"GENE","name":"MIR1912","canonical_id":"hgnc:HGNC:35396","description":"microRNA 1912","metadata":{"aliases":["hsa-mir-1912","MIRN1912"]}},{"id":"b98fe5e5d8b44d23b59d39a0b979dd20","type":"GENE","name":"MIR1913","canonical_id":"hgnc:HGNC:35397","description":"microRNA 1913","metadata":{"aliases":["hsa-mir-1913","MIRN1913"]}},{"id":"71f5656bd31042839c4cb5462b69b9e9","type":"GENE","name":"MIR1914","canonical_id":"hgnc:HGNC:35398","description":"microRNA 1914","metadata":{"aliases":["hsa-mir-1914","MIRN1914"]}},{"id":"d2870280649845709733a7cdbfe93a4d","type":"GENE","name":"MIR1915","canonical_id":"hgnc:HGNC:35399","description":"microRNA 1915","metadata":{"aliases":["hsa-mir-1915","MIRN1915"]}},{"id":"b327cd6d00534ade9a44c0cf14726fb8","type":"GENE","name":"MIR1915HG","canonical_id":"hgnc:HGNC:31448","description":"MIR1915 host gene","metadata":{"aliases":["bA418C1.3","C10orf114","CASC10"]}},{"id":"54a66f4f44ce42d9853ca8d6a7d9591d","type":"GENE","name":"MIR192","canonical_id":"hgnc:HGNC:31562","description":"microRNA 192","metadata":{"aliases":["hsa-mir-192","MIRN192"]}},{"id":"8c1807b7eb9c4aef9700ff376cd899a1","type":"GENE","name":"MIR193A","canonical_id":"hgnc:HGNC:31563","description":"microRNA 193a","metadata":{"aliases":["hsa-mir-193","hsa-mir-193a","MIRN193","MIRN193A"]}},{"id":"346acae4c2764212b913bbe1e255c7ae","type":"GENE","name":"MIR193B","canonical_id":"hgnc:HGNC:32087","description":"microRNA 193b","metadata":{"aliases":["hsa-mir-193b","MIRN193B"]}},{"id":"ab006fe8aa0b40c9bd2359eb40f90e2a","type":"GENE","name":"MIR193BHG","canonical_id":"hgnc:HGNC:51945","description":"MIR193b-365a host gene","metadata":{"aliases":["lincNORS","HypERlnc"]}},{"id":"0af246703f284b1085964c276b234857","type":"GENE","name":"MIR194-1","canonical_id":"hgnc:HGNC:31564","description":"microRNA 194-1","metadata":{"aliases":["hsa-mir-194-1","MIRN194-1"]}},{"id":"b1bfcc71ebbd45faa2ea68a34e687523","type":"GENE","name":"MIR194-2","canonical_id":"hgnc:HGNC:31565","description":"microRNA 194-2","metadata":{"aliases":["hsa-mir-194-2","MIRN194-2"]}},{"id":"f61de42f17d0427bad3e7bb9828c8bb0","type":"GENE","name":"MIR194-2HG","canonical_id":"hgnc:HGNC:51946","description":"MIR194-2 host gene","metadata":null},{"id":"daf85d8b062b4d9aadba975d378ebda7","type":"GENE","name":"MIR195","canonical_id":"hgnc:HGNC:31566","description":"microRNA 195","metadata":{"aliases":["hsa-mir-195","MIRN195"]}},{"id":"985bcae5f1244f97a53bfa3810553252","type":"GENE","name":"MIR196A1","canonical_id":"hgnc:HGNC:31567","description":"microRNA 196a-1","metadata":{"aliases":["hsa-mir-196-1","hsa-mir-196a-1","MIRN196-1","MIRN196A1"]}},{"id":"5a699b30de5f4ddc90b0c501214ed899","type":"GENE","name":"MIR196A2","canonical_id":"hgnc:HGNC:31568","description":"microRNA 196a-2","metadata":{"aliases":["hsa-mir-196-2","hsa-mir-196a-2","MIRN196-2","MIRN196A2"]}},{"id":"a4996bd7aa9d4723a5c4d7f3c22902d7","type":"GENE","name":"MIR196B","canonical_id":"hgnc:HGNC:31790","description":"microRNA 196b","metadata":{"aliases":["hsa-mir-196b","MIRN196B"]}},{"id":"27372439149043f3ad88e2bd0ff37287","type":"GENE","name":"MIR197","canonical_id":"hgnc:HGNC:31569","description":"microRNA 197","metadata":{"aliases":["hsa-mir-197","MIRN197"]}},{"id":"1e5d116389874abe95432baf0cb157e5","type":"GENE","name":"MIR1972-1","canonical_id":"hgnc:HGNC:37060","description":"microRNA 1972-1","metadata":{"aliases":["hsa-mir-1972","MIR1972"]}},{"id":"6193cc4b081945c8b181cef7f79a81f1","type":"GENE","name":"MIR1972-2","canonical_id":"hgnc:HGNC:38252","description":"microRNA 1972-2","metadata":{"aliases":["hsa-mir-1972-2"]}},{"id":"f5432b699c4843aa8887d05e75217dab","type":"GENE","name":"MIR1973","canonical_id":"hgnc:HGNC:37061","description":"microRNA 1973","metadata":{"aliases":["hsa-mir-1973"]}},{"id":"dec03614c35646f39eace87f04edbac3","type":"GENE","name":"MIR1976","canonical_id":"hgnc:HGNC:37064","description":"microRNA 1976","metadata":{"aliases":["hsa-mir-1976"]}},{"id":"b2b1b6b49ab74b47aec24a1313da6e8a","type":"GENE","name":"MIR198","canonical_id":"hgnc:HGNC:31570","description":"microRNA 198","metadata":{"aliases":["hsa-mir-198","MIRN198"]}},{"id":"d19d94d983be48d6a99d4686c71548aa","type":"GENE","name":"MIR199A1","canonical_id":"hgnc:HGNC:31571","description":"microRNA 199a-1","metadata":{"aliases":["hsa-mir-199a-1","MIRN199A1"]}},{"id":"ef5f6b62a19c4f7281effac023a6e940","type":"GENE","name":"MIR199A2","canonical_id":"hgnc:HGNC:31572","description":"microRNA 199a-2","metadata":{"aliases":["hsa-mir-199a-2","MIRN199A2"]}},{"id":"28cbd539e9044e8ea085c2de84f53bff","type":"GENE","name":"MIR199B","canonical_id":"hgnc:HGNC:31573","description":"microRNA 199b","metadata":{"aliases":["hsa-mir-199b","MIRN199B"]}},{"id":"9c2020c5ae9a4ec9990968b7de049a90","type":"GENE","name":"MIR19A","canonical_id":"hgnc:HGNC:31574","description":"microRNA 19a","metadata":{"aliases":["hsa-mir-19a","MIRN19A"]}},{"id":"1a5d29e44f2940deaeb2cec046c36482","type":"GENE","name":"MIR19B1","canonical_id":"hgnc:HGNC:31575","description":"microRNA 19b-1","metadata":{"aliases":["hsa-mir-19b-1","MIRN19B1"]}},{"id":"636d73dcf1144aa8a270334cf19c2656","type":"GENE","name":"MIR19B2","canonical_id":"hgnc:HGNC:31576","description":"microRNA 19b-2","metadata":{"aliases":["hsa-mir-19b-2","MIRN19B2"]}},{"id":"7c34a53b676c4070a71c796a3c5bd554","type":"GENE","name":"MIR200A","canonical_id":"hgnc:HGNC:31578","description":"microRNA 200a","metadata":{"aliases":["hsa-mir-200a","MIRN200A"]}},{"id":"dad7a08912d84f04a3de7e5baaa06b04","type":"GENE","name":"MIR200B","canonical_id":"hgnc:HGNC:31579","description":"microRNA 200b","metadata":{"aliases":["hsa-mir-200b","MIRN200B"]}},{"id":"43659af6dd0e43c3bcb335f0093881cc","type":"GENE","name":"MIR200BHG","canonical_id":"hgnc:HGNC:58145","description":"MIR200B, MIR200A and MIR429 host gene","metadata":null},{"id":"75042d67b9dd42ea83c2c15d685415e8","type":"GENE","name":"MIR200C","canonical_id":"hgnc:HGNC:31580","description":"microRNA 200c","metadata":{"aliases":["hsa-mir-200c","MIRN200C"]}},{"id":"2d372fe909514bfab878cfb7ed57a221","type":"GENE","name":"MIR200CHG","canonical_id":"hgnc:HGNC:53161","description":"MIR200C and MIR141 host gene","metadata":{"aliases":["U47924.27"]}},{"id":"ec9c90fc12c141acafa164b46855f739","type":"GENE","name":"MIR202","canonical_id":"hgnc:HGNC:32080","description":null,"metadata":null},{"id":"6fc5b5c680ce47438b302445e23132b0","type":"GENE","name":"MIR202HG","canonical_id":"hgnc:HGNC:49402","description":"MIR202 host gene","metadata":null},{"id":"81b5bc26d7334aef9ea53beb15a8770b","type":"GENE","name":"MIR203A","canonical_id":"hgnc:HGNC:31581","description":"microRNA 203a","metadata":{"aliases":["hsa-mir-203","MIRN203","MIR203"]}},{"id":"3af82391a618437e87492788da0ea066","type":"GENE","name":"MIR203B","canonical_id":"hgnc:HGNC:41811","description":"microRNA 203b","metadata":{"aliases":["hsa-mir-3545","MIR3545"]}},{"id":"20752e9602594874a5ca65175992adf1","type":"GENE","name":"MIR204","canonical_id":"hgnc:HGNC:31582","description":"microRNA 204","metadata":{"aliases":["hsa-mir-204","MIRN204"]}},{"id":"f1982927a23743278dd30509805840e0","type":"GENE","name":"MIR205","canonical_id":"hgnc:HGNC:31583","description":"microRNA 205","metadata":{"aliases":["hsa-mir-205","MIRN205"]}},{"id":"5a6e2ad35a984b90900b69bcfc55968f","type":"GENE","name":"MIR2052","canonical_id":"hgnc:HGNC:37068","description":"microRNA 2052","metadata":{"aliases":["hsa-mir-2052"]}},{"id":"8d136d18b77c4f8182c8d47883047601","type":"GENE","name":"MIR2052HG","canonical_id":"hgnc:HGNC:51555","description":"MIR2052 host gene","metadata":null},{"id":"0e0d1f00678948cd8a9987078677f3a0","type":"GENE","name":"MIR2053","canonical_id":"hgnc:HGNC:37069","description":"microRNA 2053","metadata":{"aliases":["hsa-mir-2053"]}},{"id":"f833c3ba2a8d40d29b57e0c80186b684","type":"GENE","name":"MIR2054","canonical_id":"hgnc:HGNC:37070","description":"microRNA 2054","metadata":{"aliases":["hsa-mir-2054"]}},{"id":"3602e2e5243b4252b758ef5bd517c140","type":"GENE","name":"MIR205HG","canonical_id":"hgnc:HGNC:43562","description":"MIR205 host gene","metadata":{"aliases":["LEADR","miPEP205","LINC00510"]}},{"id":"8604694ad6824b7ab94ec4752164a0ea","type":"GENE","name":"MIR206","canonical_id":"hgnc:HGNC:31584","description":"microRNA 206","metadata":{"aliases":["hsa-mir-206","MIRN206"]}},{"id":"f9805ffe30e0469e81e624cf063e387d","type":"GENE","name":"MIR208A","canonical_id":"hgnc:HGNC:31585","description":"microRNA 208a","metadata":{"aliases":["hsa-mir-208","hsa-mir-208a","MIRN208","MIRN208A"]}},{"id":"abf8b50b19f148b4814a97502edb539c","type":"GENE","name":"MIR208B","canonical_id":"hgnc:HGNC:33669","description":"microRNA 208b","metadata":{"aliases":["hsa-mir-208b","MIRN208B"]}},{"id":"976412a14389475ca74aa682a309540c","type":"GENE","name":"MIR20A","canonical_id":"hgnc:HGNC:31577","description":"microRNA 20a","metadata":{"aliases":["hsa-mir-20","hsa-mir-20a","MIRN20","MIRN20A"]}},{"id":"8861d9d0ca4d4173810308170f66d54a","type":"GENE","name":"MIR20B","canonical_id":"hgnc:HGNC:32024","description":"microRNA 20b","metadata":{"aliases":["hsa-mir-20b","MIRN20B"]}},{"id":"b42375e9c45c4b55806737a21ce9fb82","type":"GENE","name":"MIR21","canonical_id":"hgnc:HGNC:31586","description":"microRNA 21","metadata":{"aliases":["hsa-mir-21","MIR-21","MIRN21"]}},{"id":"e12f4cb86acc43e7b15a30aa85171086","type":"GENE","name":"MIR210","canonical_id":"hgnc:HGNC:31587","description":"microRNA 210","metadata":{"aliases":["hsa-mir-210","MIRN210"]}},{"id":"72585e5f37524780b4c74dc2d69bd898","type":"GENE","name":"MIR210HG","canonical_id":"hgnc:HGNC:39524","description":"MIR210 host gene","metadata":null},{"id":"f5a31d80fa1448ba9bbc3d5ec3de27bb","type":"GENE","name":"MIR211","canonical_id":"hgnc:HGNC:31588","description":"microRNA 211","metadata":{"aliases":["hsa-mir-211","MIRN211"]}},{"id":"98401acbfa2b4969a9e9d00b3d790b5f","type":"GENE","name":"MIR2110","canonical_id":"hgnc:HGNC:37071","description":"microRNA 2110","metadata":{"aliases":["hsa-mir-2110"]}},{"id":"d639ae602e5e4e14a9ff429915a15281","type":"GENE","name":"MIR2113","canonical_id":"hgnc:HGNC:37058","description":"microRNA 2113","metadata":{"aliases":["hsa-mir-2113"]}},{"id":"ee9ad64e297a4d949eb427eb00addece","type":"GENE","name":"MIR2113HG","canonical_id":"hgnc:HGNC:58964","description":"MIR2113 host gene","metadata":{"aliases":["uc.199","uc.198","uc.197","uc.196"]}},{"id":"b96d6e4cf0b6477aa5653aef1bc624da","type":"GENE","name":"MIR2114","canonical_id":"hgnc:HGNC:37308","description":"microRNA 2114","metadata":{"aliases":["hsa-mir-2114"]}},{"id":"9a2bc4531f4b4e1d847497640dcdc1e6","type":"GENE","name":"MIR2115","canonical_id":"hgnc:HGNC:37309","description":"microRNA 2115","metadata":{"aliases":["hsa-mir-2115"]}},{"id":"9aab3c1d70524c92a2229fadbc41b1f9","type":"GENE","name":"MIR2116","canonical_id":"hgnc:HGNC:37310","description":"microRNA 2116","metadata":{"aliases":["hsa-mir-2116"]}},{"id":"958c0c66ed6545f1a30151e0b57580eb","type":"GENE","name":"MIR2117","canonical_id":"hgnc:HGNC:37311","description":"microRNA 2117","metadata":{"aliases":["hsa-mir-2117"]}},{"id":"3585ab259fc24a51b395051016b99fa2","type":"GENE","name":"MIR2117HG","canonical_id":"hgnc:HGNC:51999","description":"MIR2117 host gene","metadata":null},{"id":"9f68842ffbb246e6bb33b1657cdbe6be","type":"GENE","name":"MIR212","canonical_id":"hgnc:HGNC:31589","description":"microRNA 212","metadata":{"aliases":["hsa-mir-212","MIRN212"]}},{"id":"7b55cce8e8994419bf32228a97d6140b","type":"GENE","name":"MIR214","canonical_id":"hgnc:HGNC:31591","description":"microRNA 214","metadata":{"aliases":["hsa-mir-214","MIRN214"]}},{"id":"935196bcbd0b418cb41311c7654218fe","type":"GENE","name":"MIR215","canonical_id":"hgnc:HGNC:31592","description":"microRNA 215","metadata":{"aliases":["hsa-mir-215","MIRN215"]}},{"id":"ec90c83b11954e19823f51d4920208d5","type":"GENE","name":"MIR216A","canonical_id":"hgnc:HGNC:31593","description":"microRNA 216a","metadata":{"aliases":["hsa-mir-216","hsa-mir-216a","MIRN216","MIRN216A"]}},{"id":"e3429320d094427ab497e625d1de1ec3","type":"GENE","name":"MIR216B","canonical_id":"hgnc:HGNC:33668","description":"microRNA 216b","metadata":{"aliases":["hsa-mir-216b","MIRN216B"]}},{"id":"30429d80fa8445c0b63ff09bc0bd4981","type":"GENE","name":"MIR217","canonical_id":"hgnc:HGNC:31594","description":"microRNA 217","metadata":{"aliases":["hsa-mir-217","miR-217","MIRN217"]}},{"id":"ed95f2d995db4d39a898af167c17be90","type":"GENE","name":"MIR217HG","canonical_id":"hgnc:HGNC:50537","description":"MIR217 host gene","metadata":{"aliases":["MIR216AHG","MIR216BHG"]}},{"id":"ab6b8e987da64b428415cc2cfdddad5b","type":"GENE","name":"MIR218-1","canonical_id":"hgnc:HGNC:31595","description":"microRNA 218-1","metadata":{"aliases":["hsa-mir-218-1","MIRN218-1"]}},{"id":"e80248411afa42fd8df640b86e1f20d6","type":"GENE","name":"MIR218-2","canonical_id":"hgnc:HGNC:31596","description":"microRNA 218-2","metadata":{"aliases":["hsa-mir-218-2","MIRN218-2"]}},{"id":"dca1021253ea43359d2db8b0fbd4b571","type":"GENE","name":"MIR219A1","canonical_id":"hgnc:HGNC:31597","description":"microRNA 219a-1","metadata":{"aliases":["hsa-mir-219-1","MIRN219-1","MIR219-1"]}},{"id":"6113a776c8ad4e26bc2764297c40fb1f","type":"GENE","name":"MIR219A2","canonical_id":"hgnc:HGNC:31598","description":"microRNA 219a-2","metadata":{"aliases":["hsa-mir-219-2","MIRN219-2","MIR219-2"]}},{"id":"e8ad99bdbe344405b68c52341c97722a","type":"GENE","name":"MIR219A2HG","canonical_id":"hgnc:HGNC:55938","description":"MIR219A2 host gene","metadata":null},{"id":"40810bb7087c405e97cfc1aec0be5e26","type":"GENE","name":"MIR219B","canonical_id":"hgnc:HGNC:41823","description":"microRNA 219b","metadata":{"aliases":["hsa-mir-2964a","MIR2964A"]}},{"id":"c8393582478a4e8d9a2cdc1f7c2695ea","type":"GENE","name":"MIR22","canonical_id":"hgnc:HGNC:31599","description":"microRNA 22","metadata":{"aliases":["hsa-mir-22","MIRN22"]}},{"id":"e6b79c0979014e1c95532811ebae280e","type":"GENE","name":"MIR221","canonical_id":"hgnc:HGNC:31601","description":"microRNA 221","metadata":{"aliases":["hsa-mir-221","MIRN221"]}},{"id":"b85f1b204f1e4b62a7180550083e85ec","type":"GENE","name":"MIR222","canonical_id":"hgnc:HGNC:31602","description":"microRNA 222","metadata":{"aliases":["hsa-mir-222","MIRN222"]}},{"id":"fc4f06e97fc044a2bcf8b61a4187b6c7","type":"GENE","name":"MIR222HG","canonical_id":"hgnc:HGNC:49555","description":"miR222/221 cluster host gene","metadata":{"aliases":["Lnc-Ang362","LINC02595"]}},{"id":"17f860d5a9cc458dab6741f8bec14725","type":"GENE","name":"MIR223","canonical_id":"hgnc:HGNC:31603","description":"microRNA 223","metadata":{"aliases":["hsa-mir-223","MIRN223"]}},{"id":"97b5d79f4e364973b23eead32bbdf986","type":"GENE","name":"MIR223HG","canonical_id":"hgnc:HGNC:54520","description":"MIR223 host gene","metadata":{"aliases":["linc-223"]}},{"id":"1a2caeb489b74145bce37eec009f0177","type":"GENE","name":"MIR224","canonical_id":"hgnc:HGNC:31604","description":"microRNA 224","metadata":{"aliases":["hsa-mir-224","MIRN224"]}},{"id":"a3b54f5c016f401398be1f4a27112251","type":"GENE","name":"MIR2276","canonical_id":"hgnc:HGNC:37313","description":"microRNA 2276","metadata":{"aliases":["hsa-mir-2276"]}},{"id":"9317b703dc15446ea60f8e989fe0ae54","type":"GENE","name":"MIR2277","canonical_id":"hgnc:HGNC:37314","description":"microRNA 2277","metadata":{"aliases":["hsa-mir-2277"]}},{"id":"c2334f8ca52f4da087fb9bbea3feeaa4","type":"GENE","name":"MIR2278","canonical_id":"hgnc:HGNC:37315","description":"microRNA 2278","metadata":{"aliases":["hsa-mir-2278"]}},{"id":"fc464478a4a24caeb9a49a9f56e57fdf","type":"GENE","name":"MIR22HG","canonical_id":"hgnc:HGNC:28219","description":"MIR22 host gene","metadata":{"aliases":["MGC14376","DKFZp686O06159","C17orf91"]}},{"id":"e81bb621c05548288d21e12bf3b12b39","type":"GENE","name":"MIR2355","canonical_id":"hgnc:HGNC:38328","description":"microRNA 2355","metadata":{"aliases":["hsa-mir-2355"]}},{"id":"bb81ff72c2434e7d99dad8404788af26","type":"GENE","name":"MIR2392","canonical_id":"hgnc:HGNC:41843","description":"microRNA 2392","metadata":{"aliases":["hsa-mir-2392"]}},{"id":"7c72e9bdb0ff4a77be4c2821cb58a0a4","type":"GENE","name":"MIR23A","canonical_id":"hgnc:HGNC:31605","description":"microRNA 23a","metadata":{"aliases":["hsa-mir-23a","MIRN23A"]}},{"id":"ed7c81d5f5d34af7b562f46c08b27538","type":"GENE","name":"MIR23AHG","canonical_id":"hgnc:HGNC:27620","description":"miR-23a/27a/24-2 cluster host gene","metadata":{"aliases":["LOC284454","Smyca"]}},{"id":"8cfdd399a4484700a4574bf03eccf10b","type":"GENE","name":"MIR23B","canonical_id":"hgnc:HGNC:31606","description":"microRNA 23b","metadata":{"aliases":["hsa-mir-23b","MIRN23B"]}},{"id":"5a888086e47742f39ef463e989173389","type":"GENE","name":"MIR23C","canonical_id":"hgnc:HGNC:38913","description":"microRNA 23c","metadata":{"aliases":["hsa-mir-23c"]}},{"id":"a3806f3ee3cd471fa9f435b696885192","type":"GENE","name":"MIR24-1","canonical_id":"hgnc:HGNC:31607","description":"microRNA 24-1","metadata":{"aliases":["hsa-mir-24-1","MIRN24-1"]}},{"id":"7210278e9ac845c3a1fad992d780a15e","type":"GENE","name":"MIR24-2","canonical_id":"hgnc:HGNC:31608","description":"microRNA 24-2","metadata":{"aliases":["hsa-mir-24-2","MIRN24-2"]}},{"id":"3903e18de2a94f3bb52280c7e7d526f1","type":"GENE","name":"MIR2467","canonical_id":"hgnc:HGNC:41881","description":"microRNA 2467","metadata":{"aliases":["hsa-mir-2467"]}},{"id":"f64719540fbd44b5961d9879a9c3c990","type":"GENE","name":"MIR25","canonical_id":"hgnc:HGNC:31609","description":"microRNA 25","metadata":{"aliases":["hsa-mir-25","MIRN25"]}},{"id":"345b60cb63db4edab601ce10ae47bd0d","type":"GENE","name":"MIR2681","canonical_id":"hgnc:HGNC:41532","description":"microRNA 2681","metadata":{"aliases":["hsa-mir-2681"]}},{"id":"7af02575d978431f937e37cd3a6d162e","type":"GENE","name":"MIR2682","canonical_id":"hgnc:HGNC:41688","description":"microRNA 2682","metadata":{"aliases":["hsa-mir-2682"]}},{"id":"03bd428f3ce04262b3eaf9824c800f04","type":"GENE","name":"MIR26A1","canonical_id":"hgnc:HGNC:31610","description":"microRNA 26a-1","metadata":{"aliases":["hsa-mir-26a-1","MIRN26A1"]}},{"id":"6bc83ea606dd45f7ad7e927d6a437313","type":"GENE","name":"MIR26A2","canonical_id":"hgnc:HGNC:31611","description":"microRNA 26a-2","metadata":{"aliases":["hsa-mir-26a-2","MIRN26A2"]}},{"id":"9b662ed8deff4431b4e4565320090ef0","type":"GENE","name":"MIR26B","canonical_id":"hgnc:HGNC:31612","description":"microRNA 26b","metadata":{"aliases":["hsa-mir-26b","MIRN26B"]}},{"id":"dcb3a0bb8c86417aaa9d8650f117cca9","type":"GENE","name":"MIR27A","canonical_id":"hgnc:HGNC:31613","description":null,"metadata":null},{"id":"89084a58ed5043b7ad646c50a996f25f","type":"GENE","name":"MIR27B","canonical_id":"hgnc:HGNC:31614","description":"microRNA 27b","metadata":{"aliases":["hsa-mir-27b","MIR-27b","MIRN27B"]}},{"id":"6edb875be0fc48bf83e649f2fba944b1","type":"GENE","name":"MIR28","canonical_id":"hgnc:HGNC:31615","description":"microRNA 28","metadata":{"aliases":["hsa-mir-28","MIRN28"]}},{"id":"1bd036037a9545f789aa98990840229b","type":"GENE","name":"MIR2861","canonical_id":"hgnc:HGNC:38221","description":"microRNA 2861","metadata":{"aliases":["hsa-mir-2861"]}},{"id":"ef8c8f160a2944fd90060a1067475390","type":"GENE","name":"MIR2909","canonical_id":"hgnc:HGNC:38372","description":"microRNA 2909","metadata":{"aliases":["hsa-mir-2909"]}},{"id":"5290b19d0f7b43b395527013cd6fc2b4","type":"GENE","name":"MIR296","canonical_id":"hgnc:HGNC:31617","description":"microRNA 296","metadata":{"aliases":["hsa-mir-296","MIRN296"]}},{"id":"66a625e9007c4b528b964004ac7a76c3","type":"GENE","name":"MIR297","canonical_id":"hgnc:HGNC:33691","description":"microRNA 297","metadata":{"aliases":["hsa-mir-297","MIRN297"]}},{"id":"cbf485dba0324edb9a0d4dc227084f72","type":"GENE","name":"MIR298","canonical_id":"hgnc:HGNC:33634","description":"microRNA 298","metadata":{"aliases":["hsa-mir-298","MIRN298"]}},{"id":"5a45b6c0b0654f33ad13ab4265d166a2","type":"GENE","name":"MIR299","canonical_id":"hgnc:HGNC:31618","description":"microRNA 299","metadata":{"aliases":["hsa-mir-299","MIRN299"]}},{"id":"bfdb3b079b214c39bcac2ca9b794b1b4","type":"GENE","name":"MIR29A","canonical_id":"hgnc:HGNC:31616","description":"microRNA 29a","metadata":{"aliases":["hsa-mir-29","hsa-mir-29a","MIRN29","MIRN29A"]}},{"id":"6256a43e77774d0b87c848038ca7e361","type":"GENE","name":"MIR29B1","canonical_id":"hgnc:HGNC:31619","description":"microRNA 29b-1","metadata":{"aliases":["hsa-mir-29b-1","MIRN29B1"]}},{"id":"525f5ec08dda44e1a29c330c0f51dd2a","type":"GENE","name":"MIR29B2","canonical_id":"hgnc:HGNC:31620","description":"microRNA 29b-2","metadata":{"aliases":["hsa-mir-29b-2","MIRN29B2"]}},{"id":"d698704dc68b4cbb9101ecffc5062a7f","type":"GENE","name":"MIR29B2CHG","canonical_id":"hgnc:HGNC:32018","description":"MIR29B2 and MIR29C host gene","metadata":{"aliases":["FLJ35650","C1orf132"]}},{"id":"2c28c902080645459b17e86cdd06e644","type":"GENE","name":"MIR29C","canonical_id":"hgnc:HGNC:31621","description":"microRNA 29c","metadata":{"aliases":["hsa-mir-29c","MIRN29C"]}},{"id":"e30b1c47a2f24b9fb4a7186c1ec03740","type":"GENE","name":"MIR300","canonical_id":"hgnc:HGNC:33636","description":"microRNA 300","metadata":{"aliases":["hsa-mir-300","MIRN300"]}},{"id":"5a24e9377c32477d93c42095dcd60502","type":"GENE","name":"MIR301A","canonical_id":"hgnc:HGNC:31622","description":"microRNA 301a","metadata":{"aliases":["hsa-mir-301","hsa-mir-301a","MIRN301","MIRN301A"]}},{"id":"29ee5d05931842fa9a5a300b730a8170","type":"GENE","name":"MIR301B","canonical_id":"hgnc:HGNC:33667","description":"microRNA 301b","metadata":{"aliases":["hsa-mir-301b","MIRN301B"]}},{"id":"d242fcf6880b461cb58317503ade6b34","type":"GENE","name":"MIR302A","canonical_id":"hgnc:HGNC:31623","description":"microRNA 302a","metadata":{"aliases":["hsa-mir-302","hsa-mir-302a","MIRN302","MIRN302A"]}},{"id":"9c936f8f90454064a34f4625aa538e00","type":"GENE","name":"MIR302B","canonical_id":"hgnc:HGNC:31763","description":"microRNA 302b","metadata":{"aliases":["hsa-mir-302b","MIRN302B"]}},{"id":"9d54d2c0f1e9435ea6316b50f794acac","type":"GENE","name":"MIR302C","canonical_id":"hgnc:HGNC:31764","description":"microRNA 302c","metadata":{"aliases":["hsa-mir-302c","MIRN302C"]}},{"id":"6eaf1fef439548ff86efbe3ee6b0c767","type":"GENE","name":"MIR302CHG","canonical_id":"hgnc:HGNC:41070","description":"miR-302/367 cluster host gene","metadata":null},{"id":"fef4d15315234da89f1c0111a139cd0a","type":"GENE","name":"MIR302D","canonical_id":"hgnc:HGNC:31765","description":"microRNA 302d","metadata":{"aliases":["hsa-mir-302d","MIRN302D"]}},{"id":"6e66d7c37a6449e89be41ac7c69bf1fc","type":"GENE","name":"MIR302E","canonical_id":"hgnc:HGNC:35348","description":"microRNA 302e","metadata":{"aliases":["hsa-mir-302e","MIRN302E"]}},{"id":"dccd713980b44b98870e761fa8f33324","type":"GENE","name":"MIR302F","canonical_id":"hgnc:HGNC:35349","description":"microRNA 302f","metadata":{"aliases":["hsa-mir-302f","MIRN302F"]}},{"id":"8efb2e947d0a4c83bd85cf088685554f","type":"GENE","name":"MIR3059","canonical_id":"hgnc:HGNC:54162","description":"microRNA 3059","metadata":{"aliases":["hsa-mir-3059"]}},{"id":"31edbb7d63644764bbf778f2f35f75ba","type":"GENE","name":"MIR3064","canonical_id":"hgnc:HGNC:41652","description":"microRNA 3064","metadata":{"aliases":["hsa-mir-3064"]}},{"id":"eadee53e93544a05b7566b817702f59f","type":"GENE","name":"MIR3065","canonical_id":"hgnc:HGNC:38234","description":"microRNA 3065","metadata":{"aliases":["hsa-mir-3065"]}},{"id":"7539aad927254431b9e37e2b07ef4a16","type":"GENE","name":"MIR3074","canonical_id":"hgnc:HGNC:38268","description":"microRNA 3074","metadata":{"aliases":["hsa-mir-3074"]}},{"id":"933796b0c57c4ff8b7b38eb52842e33c","type":"GENE","name":"MIR3085","canonical_id":"hgnc:HGNC:54163","description":"microRNA 3085","metadata":{"aliases":["hsa-mir-3085"]}},{"id":"0ba343f1106c4ae0b1df8d3c8325efc8","type":"GENE","name":"MIR30A","canonical_id":"hgnc:HGNC:31624","description":"microRNA 30a","metadata":{"aliases":["hsa-mir-30a","MIRN30A"]}},{"id":"5d3ee7dc74eb410095b7b6552d408756","type":"GENE","name":"MIR30B","canonical_id":"hgnc:HGNC:31625","description":"microRNA 30b","metadata":{"aliases":["hsa-mir-30b","MIRN30B"]}},{"id":"cb58f3eb3adb4285b2c903ce65d1efda","type":"GENE","name":"MIR30C1","canonical_id":"hgnc:HGNC:31626","description":"microRNA 30c-1","metadata":{"aliases":["hsa-mir-30c-1","MIRN30C1"]}},{"id":"753e2b9a34784111b215d69023ae8035","type":"GENE","name":"MIR30C2","canonical_id":"hgnc:HGNC:31627","description":"microRNA 30c-2","metadata":{"aliases":["hsa-mir-30c-2","MIRN30C2"]}},{"id":"e9aff52c32b9452c8f4bd90fda8dfc85","type":"GENE","name":"MIR30D","canonical_id":"hgnc:HGNC:31628","description":"microRNA 30d","metadata":{"aliases":["hsa-mir-30d","MIRN30D"]}},{"id":"893247217b384136b95c849dd3d7e199","type":"GENE","name":"MIR30DHG","canonical_id":"hgnc:HGNC:56081","description":"MIR30D and MIR30B host gene","metadata":null},{"id":"7854941ea7f84c08bb8b171352e5327e","type":"GENE","name":"MIR30E","canonical_id":"hgnc:HGNC:31629","description":"microRNA 30e","metadata":{"aliases":["hsa-mir-30e","MIRN30E"]}},{"id":"0bdb39a6abda493c95503401fe39708e","type":"GENE","name":"MIR31","canonical_id":"hgnc:HGNC:31630","description":"microRNA 31","metadata":{"aliases":["hsa-mir-31","MIRN31"]}},{"id":"c528f90896814dbb8aee23d7692f6516","type":"GENE","name":"MIR3115","canonical_id":"hgnc:HGNC:38371","description":"microRNA 3115","metadata":{"aliases":["hsa-mir-3115"]}},{"id":"b045b2f261214f2e800a2295afb4c929","type":"GENE","name":"MIR3116-1","canonical_id":"hgnc:HGNC:38200","description":"microRNA 3116-1","metadata":{"aliases":["hsa-mir-3116-1"]}},{"id":"893059f38a2a4bc49a82b2c241adf06d","type":"GENE","name":"MIR3116-2","canonical_id":"hgnc:HGNC:38318","description":"microRNA 3116-2","metadata":{"aliases":["hsa-mir-3116-2"]}},{"id":"34b72270cebd4d36a75bc6946e110cbb","type":"GENE","name":"MIR3117","canonical_id":"hgnc:HGNC:38385","description":"microRNA 3117","metadata":{"aliases":["hsa-mir-3117"]}},{"id":"868c3113244f4af2bde310aeca5b0538","type":"GENE","name":"MIR3118-1","canonical_id":"hgnc:HGNC:38265","description":"microRNA 3118-1","metadata":{"aliases":["hsa-mir-3118-1"]}},{"id":"123566d7fca74ef69c2b76e955af621b","type":"GENE","name":"MIR3118-2","canonical_id":"hgnc:HGNC:38324","description":"microRNA 3118-2","metadata":{"aliases":["hsa-mir-3118-2"]}},{"id":"4920b917d4a04a9186a35bf8353d0704","type":"GENE","name":"MIR3118-3","canonical_id":"hgnc:HGNC:38274","description":"microRNA 3118-3","metadata":{"aliases":["hsa-mir-3118-3"]}},{"id":"a2f2ddd8c8924b2ab5c1e2ad06245ffe","type":"GENE","name":"MIR3118-4","canonical_id":"hgnc:HGNC:38287","description":"microRNA 3118-4","metadata":{"aliases":["hsa-mir-3118-4"]}},{"id":"7bd4d87079144297bbbf6c8d1d75256e","type":"GENE","name":"MIR3119-1","canonical_id":"hgnc:HGNC:38253","description":"microRNA 3119-1","metadata":{"aliases":["hsa-mir-3119-1"]}},{"id":"51d10a0060a34a598522cd5fee1456b2","type":"GENE","name":"MIR3119-2","canonical_id":"hgnc:HGNC:38315","description":"microRNA 3119-2","metadata":{"aliases":["hsa-mir-3119-2"]}},{"id":"c0b45ed9f1ad4c4a9e6c5f50bdaba3c9","type":"GENE","name":"MIR3120","canonical_id":"hgnc:HGNC:38295","description":"microRNA 3120","metadata":{"aliases":["hsa-mir-3120"]}},{"id":"c31bf95dc30f4040a2dcb50b50438d41","type":"GENE","name":"MIR3121","canonical_id":"hgnc:HGNC:38259","description":"microRNA 3121","metadata":{"aliases":["hsa-mir-3121"]}},{"id":"1393faf0e8da493caad95d8a5fce5ec9","type":"GENE","name":"MIR3122","canonical_id":"hgnc:HGNC:38320","description":"microRNA 3122","metadata":{"aliases":["hsa-mir-3122"]}},{"id":"784fcaf50f0e4897ab24aaa40a773aa8","type":"GENE","name":"MIR3123","canonical_id":"hgnc:HGNC:38330","description":"microRNA 3123","metadata":{"aliases":["hsa-mir-3123"]}},{"id":"3453a6a6648b429b8909a11c862e3c0d","type":"GENE","name":"MIR3124","canonical_id":"hgnc:HGNC:38262","description":"microRNA 3124","metadata":{"aliases":["hsa-mir-3124"]}},{"id":"b71e950b0a1f4e378bfb803ee363c322","type":"GENE","name":"MIR3125","canonical_id":"hgnc:HGNC:38219","description":"microRNA 3125","metadata":{"aliases":["hsa-mir-3125"]}},{"id":"dc08785c43a2467fbd831a24d96ac12f","type":"GENE","name":"MIR3126","canonical_id":"hgnc:HGNC:38225","description":"microRNA 3126","metadata":{"aliases":["hsa-mir-3126"]}},{"id":"b693d1ddea794c8cbf16de88d07da7b4","type":"GENE","name":"MIR3127","canonical_id":"hgnc:HGNC:38269","description":"microRNA 3127","metadata":{"aliases":["hsa-mir-3127"]}},{"id":"dc0b72e9036c4da5a41c0b7925748609","type":"GENE","name":"MIR3128","canonical_id":"hgnc:HGNC:38188","description":"microRNA 3128","metadata":{"aliases":["hsa-mir-3128"]}},{"id":"506f0f39452e4ccdaa7e28be3d61236c","type":"GENE","name":"MIR3129","canonical_id":"hgnc:HGNC:38217","description":"microRNA 3129","metadata":{"aliases":["hsa-mir-3129"]}},{"id":"47c5fcdb59aa40919103a5917ee81cba","type":"GENE","name":"MIR3130-1","canonical_id":"hgnc:HGNC:38275","description":"microRNA 3130-1","metadata":{"aliases":["hsa-mir-3130-1","hsa-mir-3130-3","MIR3130-3"]}},{"id":"9ced670c59344890bf793c26b547b5ca","type":"GENE","name":"MIR3130-2","canonical_id":"hgnc:HGNC:38363","description":"microRNA 3130-2","metadata":{"aliases":["hsa-mir-3130-2","hsa-mir-3130-4","MIR3130-4"]}},{"id":"6cc1384ea67049fea654ad8dac8a7f81","type":"GENE","name":"MIR3131","canonical_id":"hgnc:HGNC:38347","description":"microRNA 3131","metadata":{"aliases":["hsa-mir-3131"]}},{"id":"32b21e5a8ae740ca9e9f153c9a925138","type":"GENE","name":"MIR3132","canonical_id":"hgnc:HGNC:38373","description":"microRNA 3132","metadata":{"aliases":["hsa-mir-3132"]}},{"id":"ffa0accf71df45c5adf5415a888ad88d","type":"GENE","name":"MIR3133","canonical_id":"hgnc:HGNC:38305","description":"microRNA 3133","metadata":{"aliases":["hsa-mir-3133"]}},{"id":"cbf5f33c58714710a4469883d632b6dc","type":"GENE","name":"MIR3134","canonical_id":"hgnc:HGNC:38254","description":"microRNA 3134","metadata":{"aliases":["hsa-mir-3134"]}},{"id":"c8399ae5c9114fc8a4794f7748f3645d","type":"GENE","name":"MIR3135A","canonical_id":"hgnc:HGNC:38199","description":"microRNA 3135a","metadata":{"aliases":["hsa-mir-3135","MIR3135"]}},{"id":"72e3e8cd2f844f9098c5b3db0d7fae50","type":"GENE","name":"MIR3135B","canonical_id":"hgnc:HGNC:41783","description":"microRNA 3135b","metadata":{"aliases":["hsa-mir-3135b"]}},{"id":"6cf95c354dfb43b1b282c2f7744f6d38","type":"GENE","name":"MIR3136","canonical_id":"hgnc:HGNC:38340","description":"microRNA 3136","metadata":{"aliases":["hsa-mir-3136"]}},{"id":"d9ed70ffdc644712a12afbd8dda95413","type":"GENE","name":"MIR3137","canonical_id":"hgnc:HGNC:38263","description":"microRNA 3137","metadata":{"aliases":["hsa-mir-3137"]}},{"id":"baa055bba82547cb89aa888f258e5f07","type":"GENE","name":"MIR3138","canonical_id":"hgnc:HGNC:38341","description":"microRNA 3138","metadata":{"aliases":["hsa-mir-3138"]}},{"id":"e4b04dad777b4fb8a89dfd82f88b9df5","type":"GENE","name":"MIR3139","canonical_id":"hgnc:HGNC:38201","description":"microRNA 3139","metadata":{"aliases":["hsa-mir-3139"]}},{"id":"85cdada2087643d09278675fec45c9b6","type":"GENE","name":"MIR3140","canonical_id":"hgnc:HGNC:38183","description":"microRNA 3140","metadata":{"aliases":["hsa-mir-3140"]}},{"id":"d9668cee45af48dcab6c825537a8a755","type":"GENE","name":"MIR3141","canonical_id":"hgnc:HGNC:38326","description":"microRNA 3141","metadata":{"aliases":["hsa-mir-3141"]}},{"id":"a9d4fc5ac0a745d29cf22b1d7cc92187","type":"GENE","name":"MIR3142","canonical_id":"hgnc:HGNC:38297","description":"microRNA 3142","metadata":{"aliases":["hsa-mir-3142"]}},{"id":"29bc3ae2bd7f4d7fad9ddb2f3c8337a7","type":"GENE","name":"MIR3142HG","canonical_id":"hgnc:HGNC:51944","description":"MIR3142 host gene","metadata":null},{"id":"ee44f5511bc64094acd85b7620379b36","type":"GENE","name":"MIR3143","canonical_id":"hgnc:HGNC:38284","description":"microRNA 3143","metadata":{"aliases":["hsa-mir-3143"]}},{"id":"09bbc09e201f43ff866851736d46c0e7","type":"GENE","name":"MIR3144","canonical_id":"hgnc:HGNC:38331","description":"microRNA 3144","metadata":{"aliases":["hsa-mir-3144"]}},{"id":"b880f929f3d143448d4c4b4aba132fe2","type":"GENE","name":"MIR3145","canonical_id":"hgnc:HGNC:38327","description":"microRNA 3145","metadata":{"aliases":["hsa-mir-3145"]}},{"id":"66d96fe734884acd8e9e41f4aac5964f","type":"GENE","name":"MIR3146","canonical_id":"hgnc:HGNC:38368","description":"microRNA 3146","metadata":{"aliases":["hsa-mir-3146"]}},{"id":"2dfd29fae3894d5b9c7c9c073a9547cf","type":"GENE","name":"MIR3147","canonical_id":"hgnc:HGNC:38300","description":"microRNA 3147","metadata":{"aliases":["hsa-mir-3147"]}},{"id":"81ad60d385204c8f8498287ba726eb43","type":"GENE","name":"MIR3147HG","canonical_id":"hgnc:HGNC:56144","description":"MIR3147 host gene","metadata":null},{"id":"0c8851e99f394aeb8cf74beb2f7484bc","type":"GENE","name":"MIR3148","canonical_id":"hgnc:HGNC:38215","description":"microRNA 3148","metadata":{"aliases":["hsa-mir-3148"]}},{"id":"7a454bd9c78f447cb7b5b828e17b9db2","type":"GENE","name":"MIR3149","canonical_id":"hgnc:HGNC:38251","description":"microRNA 3149","metadata":{"aliases":["hsa-mir-3149"]}},{"id":"045e54cda6b54b40bc8976ac491c0488","type":"GENE","name":"MIR3150A","canonical_id":"hgnc:HGNC:38362","description":"microRNA 3150a","metadata":{"aliases":["hsa-mir-3150","hsa-mir-3150a","MIR3150"]}},{"id":"33060fd0852149aa99dfbf682fc517ab","type":"GENE","name":"MIR3150B","canonical_id":"hgnc:HGNC:38938","description":"microRNA 3150b","metadata":{"aliases":["hsa-mir-3150b"]}},{"id":"4dc2ce55678b48de8f61fa74d107f76d","type":"GENE","name":"MIR3150BHG","canonical_id":"hgnc:HGNC:52000","description":"MIR3150B host gene","metadata":null},{"id":"514b7310f15a42c99f017944c6a6ad4f","type":"GENE","name":"MIR3151","canonical_id":"hgnc:HGNC:38266","description":"microRNA 3151","metadata":{"aliases":["hsa-mir-3151"]}},{"id":"d03ae87624d54d94b0e98a296b3c48d2","type":"GENE","name":"MIR3152","canonical_id":"hgnc:HGNC:38379","description":"microRNA 3152","metadata":{"aliases":["hsa-mir-3152"]}},{"id":"1cec2a9016b249f7af9d3d08dae6412f","type":"GENE","name":"MIR3153","canonical_id":"hgnc:HGNC:38289","description":"microRNA 3153","metadata":{"aliases":["hsa-mir-3153"]}},{"id":"5198cf1d02684a14979b46b813795297","type":"GENE","name":"MIR3154","canonical_id":"hgnc:HGNC:38176","description":"microRNA 3154","metadata":{"aliases":["hsa-mir-3154"]}},{"id":"d561512574b1466cb490e2e01efaedb0","type":"GENE","name":"MIR3155A","canonical_id":"hgnc:HGNC:38245","description":"microRNA 3155a","metadata":{"aliases":["hsa-mir-3155","MIR3155"]}},{"id":"26e045b9c28a4251b8ba7511af6a4762","type":"GENE","name":"MIR3155B","canonical_id":"hgnc:HGNC:50003","description":"microRNA 3155b","metadata":{"aliases":["hsa-mir-3155b"]}},{"id":"b7440aa420924f7faa6a9562ca6b7d48","type":"GENE","name":"MIR3156-1","canonical_id":"hgnc:HGNC:38241","description":"microRNA 3156-1","metadata":{"aliases":["hsa-mir-3156-1"]}},{"id":"f76755e110854d8cb81f9bc57815fa9a","type":"GENE","name":"MIR3156-2","canonical_id":"hgnc:HGNC:38213","description":"microRNA 3156-2","metadata":{"aliases":["hsa-mir-3156-2"]}},{"id":"1c45cff8147e4742a9ffa0f4ed5d3f7a","type":"GENE","name":"MIR3156-3","canonical_id":"hgnc:HGNC:38229","description":"microRNA 3156-3","metadata":{"aliases":["hsa-mir-3156-3"]}},{"id":"fdc211931078436388c9c97a68740b18","type":"GENE","name":"MIR3157","canonical_id":"hgnc:HGNC:38172","description":"microRNA 3157","metadata":{"aliases":["hsa-mir-3157"]}},{"id":"a42b391f5ecf4e818ce132d4f7fea390","type":"GENE","name":"MIR3158-1","canonical_id":"hgnc:HGNC:38196","description":"microRNA 3158-1","metadata":{"aliases":["hsa-mir-3158-1"]}},{"id":"88256cd705334bef8c42bdd690248a06","type":"GENE","name":"MIR3158-2","canonical_id":"hgnc:HGNC:38279","description":"microRNA 3158-2","metadata":{"aliases":["hsa-mir-3158-2"]}},{"id":"0c378e1d162e4bd8874d09302310c158","type":"GENE","name":"MIR3159","canonical_id":"hgnc:HGNC:38181","description":"microRNA 3159","metadata":{"aliases":["hsa-mir-3159"]}},{"id":"3421fe68aece4eacb9e93f024fdc73b1","type":"GENE","name":"MIR3160-1","canonical_id":"hgnc:HGNC:38197","description":"microRNA 3160-1","metadata":{"aliases":["hsa-mir-3160-1"]}},{"id":"ea03e8d9a1f842c294ecc3ed37f57241","type":"GENE","name":"MIR3160-2","canonical_id":"hgnc:HGNC:38192","description":"microRNA 3160-2","metadata":{"aliases":["hsa-mir-3160-2"]}},{"id":"cc641f3c6ea9472ea6cb900a168bec27","type":"GENE","name":"MIR3161","canonical_id":"hgnc:HGNC:38285","description":"microRNA 3161","metadata":{"aliases":["hsa-mir-3161"]}},{"id":"b28df070b94e4bcdb2dafe5a5198ae8a","type":"GENE","name":"MIR3162","canonical_id":"hgnc:HGNC:38271","description":"microRNA 3162","metadata":{"aliases":["hsa-mir-3162"]}},{"id":"a61d6fea2e28476fac55359279f90799","type":"GENE","name":"MIR3163","canonical_id":"hgnc:HGNC:38209","description":"microRNA 3163","metadata":{"aliases":["hsa-mir-3163"]}},{"id":"8dc2ebb1d7f5457e8d084825510eb133","type":"GENE","name":"MIR3164","canonical_id":"hgnc:HGNC:38288","description":"microRNA 3164","metadata":{"aliases":["hsa-mir-3164"]}},{"id":"6696caf4ead04769a91ad039b31c1075","type":"GENE","name":"MIR3165","canonical_id":"hgnc:HGNC:38335","description":"microRNA 3165","metadata":{"aliases":["hsa-mir-3165"]}},{"id":"e1362a8085c6404093960322e10af700","type":"GENE","name":"MIR3166","canonical_id":"hgnc:HGNC:38386","description":"microRNA 3166","metadata":{"aliases":["hsa-mir-3166"]}},{"id":"ce65964359724a31b31d712d22370e05","type":"GENE","name":"MIR3167","canonical_id":"hgnc:HGNC:38242","description":"microRNA 3167","metadata":{"aliases":["hsa-mir-3167"]}},{"id":"0e1ceed1608a4d53a4f11e379db493c4","type":"GENE","name":"MIR3168","canonical_id":"hgnc:HGNC:38249","description":"microRNA 3168","metadata":{"aliases":["hsa-mir-3168"]}},{"id":"217b6d9e559145268887bb11ea1f119b","type":"GENE","name":"MIR3169","canonical_id":"hgnc:HGNC:38380","description":"microRNA 3169","metadata":{"aliases":["hsa-mir-3169"]}},{"id":"597c0b6488444f5da1ae49108c0d0ede","type":"GENE","name":"MIR3170","canonical_id":"hgnc:HGNC:38282","description":"microRNA 3170","metadata":{"aliases":["hsa-mir-3170"]}},{"id":"548c2a13eb9846a686618d5619825226","type":"GENE","name":"MIR3171","canonical_id":"hgnc:HGNC:38216","description":"microRNA 3171","metadata":{"aliases":["hsa-mir-3171"]}},{"id":"fae579406e3142a0b32a5613113ca837","type":"GENE","name":"MIR3171HG","canonical_id":"hgnc:HGNC:56193","description":"MIR3171 host gene","metadata":null},{"id":"01513dad155243d5846146457da3a57f","type":"GENE","name":"MIR3173","canonical_id":"hgnc:HGNC:38174","description":"microRNA 3173","metadata":{"aliases":["hsa-mir-3173"]}},{"id":"a94b3e506f084d609947dd88c495183b","type":"GENE","name":"MIR3174","canonical_id":"hgnc:HGNC:38264","description":"microRNA 3174","metadata":{"aliases":["hsa-mir-3174"]}},{"id":"2bbe3a2bc6d44b73a2debcf16d847975","type":"GENE","name":"MIR3175","canonical_id":"hgnc:HGNC:38299","description":"microRNA 3175","metadata":{"aliases":["hsa-mir-3175"]}},{"id":"0212d499c8194ffc9907c2c628fc7809","type":"GENE","name":"MIR3176","canonical_id":"hgnc:HGNC:38345","description":"microRNA 3176","metadata":{"aliases":["hsa-mir-3176"]}},{"id":"821f9ae4a6b540c4994a43e562cab260","type":"GENE","name":"MIR3177","canonical_id":"hgnc:HGNC:38364","description":"microRNA 3177","metadata":{"aliases":["hsa-mir-3177"]}},{"id":"0529fef974594726bcfd9fab0ffb83a1","type":"GENE","name":"MIR3178","canonical_id":"hgnc:HGNC:38381","description":"microRNA 3178","metadata":{"aliases":["hsa-mir-3178"]}},{"id":"85c2669aff8747a3a92ac32665389282","type":"GENE","name":"MIR3179-1","canonical_id":"hgnc:HGNC:38353","description":"microRNA 3179-1","metadata":{"aliases":["hsa-mir-3179-1"]}},{"id":"2458af09b0d44c15af853f5eb5aa695c","type":"GENE","name":"MIR3179-2","canonical_id":"hgnc:HGNC:38325","description":"microRNA 3179-2","metadata":{"aliases":["hsa-mir-3179-2"]}},{"id":"957a080a0315443281c8ff8ea811f41c","type":"GENE","name":"MIR3179-3","canonical_id":"hgnc:HGNC:38214","description":"microRNA 3179-3","metadata":{"aliases":["hsa-mir-3179-3"]}},{"id":"2ef306232fd14d559126c7645ecbca4f","type":"GENE","name":"MIR3179-4","canonical_id":"hgnc:HGNC:50838","description":"microRNA 3179-4","metadata":null},{"id":"a5523833e7a247749a4952354612dff4","type":"GENE","name":"MIR3180-1","canonical_id":"hgnc:HGNC:38382","description":"microRNA 3180-1","metadata":{"aliases":["hsa-mir-3180-1"]}},{"id":"e7ac79354ad54e18bb9c6ffb7d97bdea","type":"GENE","name":"MIR3180-2","canonical_id":"hgnc:HGNC:38343","description":"microRNA 3180-2","metadata":{"aliases":["hsa-mir-3180-2"]}},{"id":"7f777a492eb44cd087d9c530420f204e","type":"GENE","name":"MIR3180-3","canonical_id":"hgnc:HGNC:38239","description":"microRNA 3180-3","metadata":{"aliases":["hsa-mir-3180-3"]}},{"id":"8fbd11a194aa4ff2aeac8c372cb4d7da","type":"GENE","name":"MIR3180-4","canonical_id":"hgnc:HGNC:38920","description":"microRNA 3180-4","metadata":{"aliases":["hsa-mir-3180-4"]}},{"id":"a26f63d3da1f4f2191143ad52c44145b","type":"GENE","name":"MIR3180-5","canonical_id":"hgnc:HGNC:38969","description":"microRNA 3180-5","metadata":{"aliases":["hsa-mir-3180-5"]}},{"id":"0a890361c9d44350b2b07ba2b8b2ea37","type":"GENE","name":"MIR3181","canonical_id":"hgnc:HGNC:38378","description":"microRNA 3181","metadata":{"aliases":["hsa-mir-3181"]}},{"id":"3007be1c69234d81b2e9784e24fc932e","type":"GENE","name":"MIR3182","canonical_id":"hgnc:HGNC:38317","description":"microRNA 3182","metadata":{"aliases":["hsa-mir-3182"]}},{"id":"28c01b1d93c64018947890e33e527538","type":"GENE","name":"MIR3183","canonical_id":"hgnc:HGNC:38237","description":"microRNA 3183","metadata":{"aliases":["hsa-mir-3183"]}},{"id":"b4fc7a741db346dbb92314133864cb31","type":"GENE","name":"MIR3184","canonical_id":"hgnc:HGNC:38182","description":"microRNA 3184","metadata":{"aliases":["hsa-mir-3184"]}},{"id":"459b2d144efe4fefbeec3e0d03a927fc","type":"GENE","name":"MIR3185","canonical_id":"hgnc:HGNC:38391","description":"microRNA 3185","metadata":{"aliases":["hsa-mir-3185"]}},{"id":"b2d1262330fa49c3ac40ec6226dee2bb","type":"GENE","name":"MIR3186","canonical_id":"hgnc:HGNC:38311","description":"microRNA 3186","metadata":{"aliases":["hsa-mir-3186"]}},{"id":"26a78ff68c2548b683df9c2c2554658c","type":"GENE","name":"MIR3187","canonical_id":"hgnc:HGNC:38319","description":"microRNA 3187","metadata":{"aliases":["hsa-mir-3187"]}},{"id":"51ae914729c04710a99b55fd5777b236","type":"GENE","name":"MIR3188","canonical_id":"hgnc:HGNC:38226","description":"microRNA 3188","metadata":{"aliases":["hsa-mir-3188"]}},{"id":"5237e2ff77164e6e9fd135a9f115a75b","type":"GENE","name":"MIR3189","canonical_id":"hgnc:HGNC:38307","description":"microRNA 3189","metadata":{"aliases":["hsa-mir-3189"]}},{"id":"caa0b09ed84a40baa125c3bba90f8b8d","type":"GENE","name":"MIR3190","canonical_id":"hgnc:HGNC:38190","description":"microRNA 3190","metadata":{"aliases":["hsa-mir-3190"]}},{"id":"41c442783ac04b3d9498a6feaa4d3364","type":"GENE","name":"MIR3191","canonical_id":"hgnc:HGNC:38222","description":"microRNA 3191","metadata":{"aliases":["hsa-mir-3191"]}},{"id":"888abfc2776041d2900b4eff1f5b75c8","type":"GENE","name":"MIR3192","canonical_id":"hgnc:HGNC:38202","description":"microRNA 3192","metadata":{"aliases":["hsa-mir-3192"]}},{"id":"a972b2831a654abd804141b72919d5cd","type":"GENE","name":"MIR3193","canonical_id":"hgnc:HGNC:38204","description":"microRNA 3193","metadata":{"aliases":["hsa-mir-3193"]}},{"id":"e0a92bf997c24c85ad8c62ce1453cabb","type":"GENE","name":"MIR3194","canonical_id":"hgnc:HGNC:38346","description":"microRNA 3194","metadata":{"aliases":["hsa-mir-3194"]}},{"id":"1da5323f299e46aea867fc84b394b6cc","type":"GENE","name":"MIR3195","canonical_id":"hgnc:HGNC:38250","description":"microRNA 3195","metadata":{"aliases":["hsa-mir-3195"]}},{"id":"1c093a74f5514bb3b4dc08a88dabe375","type":"GENE","name":"MIR3196","canonical_id":"hgnc:HGNC:38198","description":"microRNA 3196","metadata":{"aliases":["hsa-mir-3196"]}},{"id":"0c0690a821204f4e8ac8036d5f56272d","type":"GENE","name":"MIR3197","canonical_id":"hgnc:HGNC:38366","description":"microRNA 3197","metadata":{"aliases":["hsa-mir-3197"]}},{"id":"702fc154f8774dcfa55b06d0b16d9f05","type":"GENE","name":"MIR3198-1","canonical_id":"hgnc:HGNC:38236","description":"microRNA 3198-1","metadata":{"aliases":["hsa-mir-3198-1","MIR3198"]}},{"id":"b8f8d442c96d45258d59cace918ff4eb","type":"GENE","name":"MIR3198-2","canonical_id":"hgnc:HGNC:41766","description":"microRNA 3198-2","metadata":{"aliases":["hsa-mir-3198-2"]}},{"id":"e089fb495b5a41ba8f4d46a9bc0ea3a5","type":"GENE","name":"MIR3199-1","canonical_id":"hgnc:HGNC:38294","description":"microRNA 3199-1","metadata":{"aliases":["hsa-mir-3199-1"]}},{"id":"45a9c38d23d040389cdc31a5acc94781","type":"GENE","name":"MIR3199-2","canonical_id":"hgnc:HGNC:38205","description":"microRNA 3199-2","metadata":{"aliases":["hsa-mir-3199-2"]}},{"id":"f5244c3c49f944c3b3baabe31bb4bc6b","type":"GENE","name":"MIR31HG","canonical_id":"hgnc:HGNC:37187","description":"MIR31 host gene","metadata":{"aliases":["LOC554202","hsa-lnc-31","LncHIFCAR"]}},{"id":"3b08deabae5c4b1e8b2657daa9c1fce5","type":"GENE","name":"MIR32","canonical_id":"hgnc:HGNC:31631","description":"microRNA 32","metadata":{"aliases":["hsa-mir-32","MIRN32"]}},{"id":"70c3c29699dc4b15a3c5940b65897c09","type":"GENE","name":"MIR3200","canonical_id":"hgnc:HGNC:38227","description":"microRNA 3200","metadata":{"aliases":["hsa-mir-3200"]}},{"id":"74fa2fc8b4d44203aad792f53eb45279","type":"GENE","name":"MIR3201","canonical_id":"hgnc:HGNC:38235","description":"microRNA 3201","metadata":{"aliases":["hsa-mir-3201"]}},{"id":"84201cd83a684539b922cf83ee02dfb9","type":"GENE","name":"MIR3202-1","canonical_id":"hgnc:HGNC:38224","description":"microRNA 3202-1","metadata":{"aliases":["hsa-mir-3202-1"]}},{"id":"ab70946119db47e4847139933b9506d2","type":"GENE","name":"MIR3202-2","canonical_id":"hgnc:HGNC:38228","description":"microRNA 3202-2","metadata":{"aliases":["hsa-mir-3202-2"]}},{"id":"14d83cfbe8df4945b531f57bda910f92","type":"GENE","name":"MIR320A","canonical_id":"hgnc:HGNC:31632","description":"microRNA 320a","metadata":{"aliases":["hsa-mir-320","MIRN320","MIRN320A"]}},{"id":"543dc78de369487cbebd4580e88b42c4","type":"GENE","name":"MIR320B1","canonical_id":"hgnc:HGNC:35247","description":"microRNA 320b-1","metadata":{"aliases":["hsa-mir-320b-1","MIRN320B1"]}},{"id":"98a8d6e76c0c40949d825b4c18f615cc","type":"GENE","name":"MIR320B2","canonical_id":"hgnc:HGNC:35256","description":"microRNA 320b-2","metadata":{"aliases":["hsa-mir-320b-2","MIRN320B2"]}},{"id":"7c33942cae9c4fcf8812849d26a8b2e5","type":"GENE","name":"MIR320C1","canonical_id":"hgnc:HGNC:35248","description":"microRNA 320c-1","metadata":{"aliases":["hsa-mir-320c-1","MIRN320C1"]}},{"id":"d09acbeeb33f4ba49b2037a4d9ccc211","type":"GENE","name":"MIR320C2","canonical_id":"hgnc:HGNC:35387","description":"microRNA 320c-2","metadata":{"aliases":["hsa-mir-320c-2","MIRN320C2"]}},{"id":"ac8b84af52414958964c0a409f7c0b40","type":"GENE","name":"MIR320D1","canonical_id":"hgnc:HGNC:35386","description":"microRNA 320d-1","metadata":{"aliases":["hsa-mir-320d-1","MIRN320D1"]}},{"id":"94437a83f69f4508b2f4dfd08bb124b4","type":"GENE","name":"MIR320D2","canonical_id":"hgnc:HGNC:35388","description":"microRNA 320d-2","metadata":{"aliases":["hsa-mir-320d-2","MIRN320D2"]}},{"id":"4968f70622be4ceb80454698826bcd8c","type":"GENE","name":"MIR320E","canonical_id":"hgnc:HGNC:38230","description":"microRNA 320e","metadata":{"aliases":["hsa-mir-320e"]}},{"id":"ebc70e97a2b749bf88cb314d9b51ec1e","type":"GENE","name":"MIR323A","canonical_id":"hgnc:HGNC:31766","description":"microRNA 323a","metadata":{"aliases":["hsa-mir-323","MIRN323","MIR323"]}},{"id":"778bb25acd564ae0a7094e7f582e2866","type":"GENE","name":"MIR323B","canonical_id":"hgnc:HGNC:38349","description":"microRNA 323b","metadata":{"aliases":["hsa-mir-323b","hsa-mir-453","MIR453","MIRN453"]}},{"id":"6af97f3dc4894e8eb0045b473ae048e1","type":"GENE","name":"MIR324","canonical_id":"hgnc:HGNC:31767","description":"microRNA 324","metadata":{"aliases":["hsa-mir-324","MIRN324"]}},{"id":"4c3dd1bfaaa14fe698b5cfb7ca1bc12b","type":"GENE","name":"MIR325","canonical_id":"hgnc:HGNC:31768","description":"microRNA 325","metadata":{"aliases":["hsa-mir-325","MIRN325"]}},{"id":"9dae0fc0923e4e1a8f1f8bf800dfebe2","type":"GENE","name":"MIR325HG","canonical_id":"hgnc:HGNC:50346","description":"MIR325 host gene","metadata":{"aliases":["MIR384HG"]}},{"id":"20c9ed949ece4a77865644798959398f","type":"GENE","name":"MIR326","canonical_id":"hgnc:HGNC:31769","description":"microRNA 326","metadata":{"aliases":["hsa-mir-326","MIRN326"]}},{"id":"a8aca2d27ab04de695c8baa5b6816974","type":"GENE","name":"MIR328","canonical_id":"hgnc:HGNC:31770","description":"microRNA 328","metadata":{"aliases":["hsa-mir-328","MIRN328"]}},{"id":"2f602e0841914b52abc434e10246e957","type":"GENE","name":"MIR329-1","canonical_id":"hgnc:HGNC:32050","description":"microRNA 329-1","metadata":{"aliases":["hsa-mir-329-1","MIRN329-1"]}},{"id":"9300850a1759442caecb6cfe3e807941","type":"GENE","name":"MIR329-2","canonical_id":"hgnc:HGNC:32051","description":"microRNA 329-2","metadata":{"aliases":["hsa-mir-329-2","MIRN329-2"]}},{"id":"8ab5dcbbc93a4232b587905ce40b48e4","type":"GENE","name":"MIR330","canonical_id":"hgnc:HGNC:31771","description":"microRNA 330","metadata":{"aliases":["hsa-mir-330","MIRN330"]}},{"id":"555baa2b6a894491b691a3187dd1c023","type":"GENE","name":"MIR331","canonical_id":"hgnc:HGNC:31772","description":"microRNA 331","metadata":{"aliases":["hsa-mir-331","MIRN331"]}},{"id":"86fb150938924ce593170f15ab0ffb91","type":"GENE","name":"MIR335","canonical_id":"hgnc:HGNC:31773","description":"microRNA 335","metadata":{"aliases":["hsa-mir-335","MIRN335"]}},{"id":"6fd1d20dc2244a9ba04505d4f070b3eb","type":"GENE","name":"MIR337","canonical_id":"hgnc:HGNC:31774","description":"microRNA 337","metadata":{"aliases":["hsa-mir-337","MIRN337"]}},{"id":"2e3e872727eb41cbad903658dbd14255","type":"GENE","name":"MIR338","canonical_id":"hgnc:HGNC:31775","description":"microRNA 338","metadata":{"aliases":["hsa-mir-338","MIRN338"]}},{"id":"f46ca2529775406dbe06d2f6e97a1f39","type":"GENE","name":"MIR339","canonical_id":"hgnc:HGNC:31776","description":"microRNA 339","metadata":{"aliases":["hsa-mir-339","MIRN339"]}},{"id":"8e99c413b78a41f7b0ea40aaca2edeae","type":"GENE","name":"MIR33A","canonical_id":"hgnc:HGNC:31634","description":"microRNA 33a","metadata":{"aliases":["hsa-mir-33","hsa-mir-33a","MIRN33","MIRN33A"]}},{"id":"387504da830648808860dd042b86c9c6","type":"GENE","name":"MIR33B","canonical_id":"hgnc:HGNC:32791","description":"microRNA 33b","metadata":{"aliases":["hsa-mir-33b","MIRN33B"]}},{"id":"a4e2bd8977ac4c7d95baa94803bdeff4","type":"GENE","name":"MIR340","canonical_id":"hgnc:HGNC:31777","description":"microRNA 340","metadata":{"aliases":["hsa-mir-340","MIRN340"]}},{"id":"98ad8756e1194e53b3ac52bc4886dc05","type":"GENE","name":"MIR342","canonical_id":"hgnc:HGNC:31778","description":"microRNA 342","metadata":{"aliases":["hsa-mir-342","MIRN342"]}},{"id":"e2a2ac0840f24115855b4c46cc502eb1","type":"GENE","name":"MIR345","canonical_id":"hgnc:HGNC:31779","description":"microRNA 345","metadata":{"aliases":["hsa-mir-345","MIRN345"]}},{"id":"38969b85e96a49dd964a8ab2c57f1c65","type":"GENE","name":"MIR346","canonical_id":"hgnc:HGNC:31780","description":"microRNA 346","metadata":{"aliases":["hsa-mir-346","MIRN346"]}},{"id":"0462a08699124fb78d3e3e41be6f5fd3","type":"GENE","name":"MIR34A","canonical_id":"hgnc:HGNC:31635","description":"microRNA 34a","metadata":{"aliases":["hsa-mir-34a","MIRN34A"]}},{"id":"291eb2c7e9744709a3e8cef99d2f8299","type":"GENE","name":"MIR34AHG","canonical_id":"hgnc:HGNC:51913","description":"MIR34A host gene","metadata":{"aliases":["lnc34a"]}},{"id":"c7002a874ed040a893036afb94d70b74","type":"GENE","name":"MIR34B","canonical_id":"hgnc:HGNC:31636","description":"microRNA 34b","metadata":{"aliases":["hsa-mir-34b","MIRN34B"]}},{"id":"c51cdec952a9460d920a4d1338c6de14","type":"GENE","name":"MIR34BHG","canonical_id":"hgnc:HGNC:55987","description":"MIR34B and MIR34C host gene","metadata":{"aliases":["SPARCLE"]}},{"id":"84c759ca103549999b7a79f2facdfb27","type":"GENE","name":"MIR34C","canonical_id":"hgnc:HGNC:31637","description":"microRNA 34c","metadata":{"aliases":["hsa-mir-34c","MIRN34C"]}},{"id":"0463e29906a44f369330885bfb49f17a","type":"GENE","name":"MIR3529","canonical_id":"hgnc:HGNC:41564","description":"microRNA 3529","metadata":{"aliases":["hsa-mir-3529"]}},{"id":"539599507f6c4238ab2086970ebf8332","type":"GENE","name":"MIR3591","canonical_id":"hgnc:HGNC:41875","description":"microRNA 3591","metadata":{"aliases":["hsa-mir-3591","hsa-mir-122b"]}},{"id":"fc473f180cbc44a8b3817bf6820af746","type":"GENE","name":"MIR3605","canonical_id":"hgnc:HGNC:38922","description":"microRNA 3605","metadata":{"aliases":["hsa-mir-3605"]}},{"id":"b13832e15df94ec4b84921f7ccb3104f","type":"GENE","name":"MIR3606","canonical_id":"hgnc:HGNC:38881","description":"microRNA 3606","metadata":{"aliases":["hsa-mir-3606"]}},{"id":"b436205124714e9f8bd10b54f852c2c3","type":"GENE","name":"MIR3609","canonical_id":"hgnc:HGNC:38956","description":"microRNA 3609","metadata":{"aliases":["hsa-mir-3609"]}},{"id":"e326282c46e44d5d8008f833c9e0917e","type":"GENE","name":"MIR361","canonical_id":"hgnc:HGNC:31867","description":"microRNA 361","metadata":{"aliases":["hsa-mir-361","MIRN361"]}},{"id":"9db08b2ed0aa46c6b85ad137b4b16652","type":"GENE","name":"MIR3610","canonical_id":"hgnc:HGNC:38942","description":"microRNA 3610","metadata":{"aliases":["hsa-mir-3610"]}},{"id":"f2603a40af1b498db72279429381ab5b","type":"GENE","name":"MIR3611","canonical_id":"hgnc:HGNC:38914","description":"microRNA 3611","metadata":{"aliases":["hsa-mir-3611"]}},{"id":"59928e1085ac4bbeaff23f33a9b8089f","type":"GENE","name":"MIR3612","canonical_id":"hgnc:HGNC:38951","description":"microRNA 3612","metadata":{"aliases":["hsa-mir-3612"]}},{"id":"3249fed2adc2467b838475478a16d89a","type":"GENE","name":"MIR3613","canonical_id":"hgnc:HGNC:38964","description":"microRNA 3613","metadata":{"aliases":["hsa-mir-3613"]}},{"id":"646c7e36e17642b1a2c228e2902f44e1","type":"GENE","name":"MIR3614","canonical_id":"hgnc:HGNC:38995","description":"microRNA 3614","metadata":{"aliases":["hsa-mir-3614"]}},{"id":"b15a576a2d404f72afc958486ef576a4","type":"GENE","name":"MIR3615","canonical_id":"hgnc:HGNC:38905","description":"microRNA 3615","metadata":{"aliases":["hsa-mir-3615"]}},{"id":"0600e629e9514d398bda15d799dfe584","type":"GENE","name":"MIR3616","canonical_id":"hgnc:HGNC:38943","description":"microRNA 3616","metadata":{"aliases":["hsa-mir-3616"]}},{"id":"b0c1a27984634a14890e5b1bc9b98fd7","type":"GENE","name":"MIR3617","canonical_id":"hgnc:HGNC:38977","description":"microRNA 3617","metadata":{"aliases":["hsa-mir-3617"]}},{"id":"b9025792ff084ab7a6450520bfc33394","type":"GENE","name":"MIR3618","canonical_id":"hgnc:HGNC:38937","description":"microRNA 3618","metadata":{"aliases":["hsa-mir-3618"]}},{"id":"f24d3523acee41c4bc7fc30c6a35a62c","type":"GENE","name":"MIR3619","canonical_id":"hgnc:HGNC:38998","description":"microRNA 3619","metadata":{"aliases":["hsa-mir-3619"]}},{"id":"74a56f3b59374e568a5bcd95647117df","type":"GENE","name":"MIR362","canonical_id":"hgnc:HGNC:32022","description":"microRNA 362","metadata":{"aliases":["hsa-mir-362","MIRN362"]}},{"id":"6dabaf55b0184b038949c9a534d2bc04","type":"GENE","name":"MIR3620","canonical_id":"hgnc:HGNC:38917","description":"microRNA 3620","metadata":{"aliases":["hsa-mir-3620"]}},{"id":"04dca1ada79d42f68c206132d0a2d162","type":"GENE","name":"MIR3621","canonical_id":"hgnc:HGNC:38930","description":"microRNA 3621","metadata":{"aliases":["hsa-mir-3621"]}},{"id":"be43d45c00f54312aa02635680cdcbe6","type":"GENE","name":"MIR3622A","canonical_id":"hgnc:HGNC:38934","description":"microRNA 3622a","metadata":{"aliases":["hsa-mir-3622a"]}},{"id":"32eff6ab300a41b7a21d35d91b714a85","type":"GENE","name":"MIR3622B","canonical_id":"hgnc:HGNC:38961","description":"microRNA 3622b","metadata":{"aliases":["hsa-mir-3622b"]}},{"id":"2022b85ae11a4e13a731064c814aa07d","type":"GENE","name":"MIR363","canonical_id":"hgnc:HGNC:32023","description":"microRNA 363","metadata":{"aliases":["hsa-mir-363","MIR-363","MIRN363"]}},{"id":"88a4d68d1e2b4e2a8d1a4fdb4024cdf9","type":"GENE","name":"MIR3646","canonical_id":"hgnc:HGNC:38935","description":"microRNA 3646","metadata":{"aliases":["hsa-mir-3646"]}},{"id":"2623b3ae02e34229a754edbc621b64a2","type":"GENE","name":"MIR3648-1","canonical_id":"hgnc:HGNC:38941","description":"microRNA 3648-1","metadata":{"aliases":["hsa-mir-3648","MIR3648"]}},{"id":"fb39099ca8574471bcbbad42f11802bf","type":"GENE","name":"MIR3648-2","canonical_id":"hgnc:HGNC:50843","description":"microRNA 3648-2","metadata":null},{"id":"e0753ded0f794e788e5ae6111f230abb","type":"GENE","name":"MIR3649","canonical_id":"hgnc:HGNC:38948","description":"microRNA 3649","metadata":{"aliases":["hsa-mir-3649"]}},{"id":"b04e498b5a944ad9b7a609c67b6f31b4","type":"GENE","name":"MIR3650","canonical_id":"hgnc:HGNC:38981","description":"microRNA 3650","metadata":{"aliases":["hsa-mir-3650"]}},{"id":"c7b7840524b34c6187f01e8c5d39baae","type":"GENE","name":"MIR3651","canonical_id":"hgnc:HGNC:38897","description":"microRNA 3651","metadata":{"aliases":["hsa-mir-3651"]}},{"id":"21c2bc340deb41aa8aaf0165fdb559eb","type":"GENE","name":"MIR3652","canonical_id":"hgnc:HGNC:38894","description":"microRNA 3652","metadata":{"aliases":["hsa-mir-3652"]}},{"id":"276161a0e35f4638a65738f961525c57","type":"GENE","name":"MIR3654","canonical_id":"hgnc:HGNC:38896","description":"microRNA 3654","metadata":{"aliases":["hsa-mir-3654"]}},{"id":"95326633ff604be68283f413bf98dfea","type":"GENE","name":"MIR3655","canonical_id":"hgnc:HGNC:38960","description":"microRNA 3655","metadata":{"aliases":["hsa-mir-3655"]}},{"id":"d3c293d3bb684b7098822d3ea79ff2bb","type":"GENE","name":"MIR3657","canonical_id":"hgnc:HGNC:38906","description":"microRNA 3657","metadata":{"aliases":["hsa-mir-3657"]}},{"id":"514db668dd7344cbb4771cb71b16db2d","type":"GENE","name":"MIR3658","canonical_id":"hgnc:HGNC:38963","description":"microRNA 3658","metadata":{"aliases":["hsa-mir-3658"]}},{"id":"d6c6f45d72b34f439c33a7be7a8064dc","type":"GENE","name":"MIR3659","canonical_id":"hgnc:HGNC:38882","description":"microRNA 3659","metadata":{"aliases":["hsa-mir-3659"]}},{"id":"fe0aa4e9986247a2b2742ad794427f6f","type":"GENE","name":"MIR3659HG","canonical_id":"hgnc:HGNC:54306","description":"MIR3659 host gene","metadata":{"aliases":["uc.15"]}},{"id":"5b88ab61489540e1830565222a5f5021","type":"GENE","name":"MIR365A","canonical_id":"hgnc:HGNC:33692","description":"microRNA 365a","metadata":{"aliases":["hsa-mir-365-1","MIRN365-1","MIR365-1"]}},{"id":"874dd0af1bbc4b44a3eb2cdf7b85df93","type":"GENE","name":"MIR365B","canonical_id":"hgnc:HGNC:33693","description":"microRNA 365b","metadata":{"aliases":["hsa-mir-365-2","MIRN365-2","MIR365-2"]}},{"id":"bcc7d46797ce4737a5a41b2e7b4c9e00","type":"GENE","name":"MIR365BHG","canonical_id":"hgnc:HGNC:55941","description":"MIR365B and MIR4725 host gene","metadata":null},{"id":"6ce402e7d6bb47978a3d78abadfc82fb","type":"GENE","name":"MIR3660","canonical_id":"hgnc:HGNC:38985","description":"microRNA 3660","metadata":{"aliases":["hsa-mir-3660"]}},{"id":"6da26bfa8d5245b0805414b23578a9ba","type":"GENE","name":"MIR3660HG","canonical_id":"hgnc:HGNC:59092","description":"MIR3660 host gene","metadata":null},{"id":"8b978f60d6af4ccea22d8732039a03c5","type":"GENE","name":"MIR3661","canonical_id":"hgnc:HGNC:38892","description":"microRNA 3661","metadata":{"aliases":["hsa-mir-3661"]}},{"id":"8591c5d6032a4d6b9ad96d51bbbafc80","type":"GENE","name":"MIR3662","canonical_id":"hgnc:HGNC:38983","description":"microRNA 3662","metadata":{"aliases":["hsa-mir-3662"]}},{"id":"6e30044914c64ce9b2ad166b1ea1ea73","type":"GENE","name":"MIR3663","canonical_id":"hgnc:HGNC:38958","description":"microRNA 3663","metadata":{"aliases":["hsa-mir-3663"]}},{"id":"258c1cd5bf0b40dabcf9119073a28233","type":"GENE","name":"MIR3663HG","canonical_id":"hgnc:HGNC:50676","description":"MIR3663 host gene","metadata":null},{"id":"1edd5e01cf9d412da02b6e08bbd5dcf2","type":"GENE","name":"MIR3664","canonical_id":"hgnc:HGNC:38899","description":"microRNA 3664","metadata":{"aliases":["hsa-mir-3664"]}},{"id":"5be2928b39bf483ba99dc5cb0ae5280d","type":"GENE","name":"MIR3665","canonical_id":"hgnc:HGNC:38939","description":"microRNA 3665","metadata":{"aliases":["hsa-mir-3665"]}},{"id":"d5f82d395269455badb1f35a5ebe1f6e","type":"GENE","name":"MIR3666","canonical_id":"hgnc:HGNC:38940","description":"microRNA 3666","metadata":{"aliases":["hsa-mir-3666"]}},{"id":"37e7b43b9b394285870b3f77e7783c4b","type":"GENE","name":"MIR3667","canonical_id":"hgnc:HGNC:38990","description":"microRNA 3667","metadata":{"aliases":["hsa-mir-3667"]}},{"id":"527ff79e5e5246e69f1e53b708a91593","type":"GENE","name":"MIR3667HG","canonical_id":"hgnc:HGNC:28010","description":"MIR3667 host gene","metadata":{"aliases":["C22orf34"]}},{"id":"eea13987abd94b32b2102c7e2653ebcf","type":"GENE","name":"MIR3668","canonical_id":"hgnc:HGNC:38982","description":"microRNA 3668","metadata":{"aliases":["hsa-mir-3668"]}},{"id":"363d5f4263ae4d4db6540148ecf576d9","type":"GENE","name":"MIR367","canonical_id":"hgnc:HGNC:31781","description":"microRNA 367","metadata":{"aliases":["hsa-mir-367","MIRN367"]}},{"id":"c4cdd5187f3f489f9409a2f0847d51b6","type":"GENE","name":"MIR3670-1","canonical_id":"hgnc:HGNC:38997","description":"microRNA 3670-1","metadata":{"aliases":["hsa-mir-3670","MIR3670"]}},{"id":"15844e2d47bd4b1d880040cd2359c20e","type":"GENE","name":"MIR3670-2","canonical_id":"hgnc:HGNC:43460","description":"microRNA 3670-2","metadata":{"aliases":["hsa-mir-3670-2"]}},{"id":"c952890a98a243d6b84f5af66340e25f","type":"GENE","name":"MIR3670-3","canonical_id":"hgnc:HGNC:50829","description":"microRNA 3670-3","metadata":null},{"id":"55d55f65bd614b259e4b224a9a213492","type":"GENE","name":"MIR3670-4","canonical_id":"hgnc:HGNC:50828","description":"microRNA 3670-4","metadata":null},{"id":"a57e2c5643514f038b904180dbfe85eb","type":"GENE","name":"MIR3671","canonical_id":"hgnc:HGNC:38925","description":"microRNA 3671","metadata":{"aliases":["hsa-mir-3671"]}},{"id":"26641047fa4e42f781fccbabac22e15a","type":"GENE","name":"MIR3672","canonical_id":"hgnc:HGNC:38957","description":"microRNA 3672","metadata":{"aliases":["hsa-mir-3672"]}},{"id":"400fbae2aafd42bfbde18e29ae98b868","type":"GENE","name":"MIR3674","canonical_id":"hgnc:HGNC:38915","description":"microRNA 3674","metadata":{"aliases":["hsa-mir-3674"]}},{"id":"ab8e5e8585f840a7bc83e081dea1daea","type":"GENE","name":"MIR3675","canonical_id":"hgnc:HGNC:38973","description":"microRNA 3675","metadata":{"aliases":["hsa-mir-3675"]}},{"id":"43998964f7a54c1e9d1086cfa1023605","type":"GENE","name":"MIR3677","canonical_id":"hgnc:HGNC:38932","description":"microRNA 3677","metadata":{"aliases":["hsa-mir-3677"]}},{"id":"b6631838f92a462684ea44a42ff361fd","type":"GENE","name":"MIR3677HG","canonical_id":"hgnc:HGNC:55382","description":"MIR3677 and MIR940 host gene","metadata":null},{"id":"8c4a579bbef54a38acbd8fab62737721","type":"GENE","name":"MIR3678","canonical_id":"hgnc:HGNC:38891","description":"microRNA 3678","metadata":{"aliases":["hsa-mir-3678"]}},{"id":"04941dd3f3ba4140a3d0593e0b1d68cb","type":"GENE","name":"MIR3679","canonical_id":"hgnc:HGNC:38979","description":"microRNA 3679","metadata":{"aliases":["hsa-mir-3679"]}},{"id":"e6cea98848b549948f1d018035ddc122","type":"GENE","name":"MIR3680-1","canonical_id":"hgnc:HGNC:38989","description":"microRNA 3680-1","metadata":{"aliases":["hsa-mir-3680","MIR3680"]}},{"id":"dc42dbe122c04cef8e270ff718a7503b","type":"GENE","name":"MIR3680-2","canonical_id":"hgnc:HGNC:43472","description":"microRNA 3680-2","metadata":{"aliases":["hsa-mir-3680-2"]}},{"id":"b67aa3fdfc14466989925e71c40448e5","type":"GENE","name":"MIR3681","canonical_id":"hgnc:HGNC:38994","description":"microRNA 3681","metadata":{"aliases":["hsa-mir-3681"]}},{"id":"d87b88308e374c9b9ed9e4b071fc5ae0","type":"GENE","name":"MIR3681HG","canonical_id":"hgnc:HGNC:52001","description":"MIR3681 host gene","metadata":null},{"id":"203cd2e4ced6449d9d3915d9393e56fb","type":"GENE","name":"MIR3682","canonical_id":"hgnc:HGNC:38916","description":"microRNA 3682","metadata":{"aliases":["hsa-mir-3682"]}},{"id":"ee288f0ccb964e4d8088374f900064a8","type":"GENE","name":"MIR3683","canonical_id":"hgnc:HGNC:38999","description":"microRNA 3683","metadata":{"aliases":["hsa-mir-3683"]}},{"id":"f9a830d7c2534ebd8b562c7484c9a94b","type":"GENE","name":"MIR3684","canonical_id":"hgnc:HGNC:38950","description":"microRNA 3684","metadata":{"aliases":["hsa-mir-3684"]}},{"id":"4f082ff8a6c443d78d72472e4b345c54","type":"GENE","name":"MIR3685","canonical_id":"hgnc:HGNC:38886","description":"microRNA 3685","metadata":{"aliases":["hsa-mir-3685"]}},{"id":"6eebff318b854ef983d9b198a59ab329","type":"GENE","name":"MIR3686","canonical_id":"hgnc:HGNC:38887","description":"microRNA 3686","metadata":{"aliases":["hsa-mir-3686"]}},{"id":"3a918cc0e41245b2a01d9ac0a994b083","type":"GENE","name":"MIR3688-1","canonical_id":"hgnc:HGNC:38986","description":"microRNA 3688-1","metadata":{"aliases":["hsa-mir-3688","hsa-mir-3688-1","MIR3688"]}},{"id":"ebac405680a54264b80dbe7384a3b0f4","type":"GENE","name":"MIR3688-2","canonical_id":"hgnc:HGNC:41735","description":"microRNA 3688-2","metadata":{"aliases":["hsa-mir-3688-2"]}},{"id":"027d6c0789904570b9ca0f220d390437","type":"GENE","name":"MIR3689A","canonical_id":"hgnc:HGNC:38904","description":"microRNA 3689a","metadata":{"aliases":["hsa-mir-3689a"]}},{"id":"b7606c793ecd4499ab6c6b12c8ea57bc","type":"GENE","name":"MIR3689B","canonical_id":"hgnc:HGNC:38924","description":"microRNA 3689b","metadata":{"aliases":["hsa-mir-3689b"]}},{"id":"ef67f56834f9418cab37f5c17d22cdd5","type":"GENE","name":"MIR3689C","canonical_id":"hgnc:HGNC:41816","description":"microRNA 3689c","metadata":{"aliases":["hsa-mir-3689c"]}},{"id":"16826117ea2c4148b2752c944c3b505b","type":"GENE","name":"MIR3689D1","canonical_id":"hgnc:HGNC:41621","description":"microRNA 3689d-1","metadata":{"aliases":["hsa-mir-3689d-1"]}},{"id":"30b2cab544f7450da6fd85f1ebddcb07","type":"GENE","name":"MIR3689D2","canonical_id":"hgnc:HGNC:41846","description":"microRNA 3689d-2","metadata":{"aliases":["hsa-mir-3689d-2"]}},{"id":"2f5715e5d1554cde965cc06821a3a28f","type":"GENE","name":"MIR3689E","canonical_id":"hgnc:HGNC:41887","description":"microRNA 3689e","metadata":{"aliases":["hsa-mir-3689e"]}},{"id":"6b97d8445b074763ace1424b7959e82d","type":"GENE","name":"MIR3689F","canonical_id":"hgnc:HGNC:41702","description":"microRNA 3689f","metadata":{"aliases":["hsa-mir-3689f"]}},{"id":"11a544512e4640849ddd9257d7d07769","type":"GENE","name":"MIR369","canonical_id":"hgnc:HGNC:31783","description":"microRNA 369","metadata":{"aliases":["hsa-mir-369","MIRN369"]}},{"id":"9372549a6fc44c4d952ea47095dd3191","type":"GENE","name":"MIR3690","canonical_id":"hgnc:HGNC:38967","description":"microRNA 3690","metadata":{"aliases":["hsa-mir-3690","hsa-mir-3690-2","MIR3690-2","MIR3690-1"]}},{"id":"dce4b11244a3462dbd874c56f922a299","type":"GENE","name":"MIR3691","canonical_id":"hgnc:HGNC:38909","description":"microRNA 3691","metadata":{"aliases":["hsa-mir-3691"]}},{"id":"d626a6bcad6d4ef68c661b7cf40d4693","type":"GENE","name":"MIR3692","canonical_id":"hgnc:HGNC:38885","description":"microRNA 3692","metadata":{"aliases":["hsa-mir-3692"]}},{"id":"fcd54fec757d4e1d92865f2483cfafe6","type":"GENE","name":"MIR370","canonical_id":"hgnc:HGNC:31784","description":"microRNA 370","metadata":{"aliases":["hsa-mir-370","MIRN370"]}},{"id":"846c289e12e848e2b9924239c445e4bf","type":"GENE","name":"MIR3713","canonical_id":"hgnc:HGNC:38926","description":"microRNA 3713","metadata":{"aliases":["hsa-mir-3713"]}},{"id":"e9fff47b462f46e78b345d564b4afaf8","type":"GENE","name":"MIR3714","canonical_id":"hgnc:HGNC:38928","description":"microRNA 3714","metadata":{"aliases":["hsa-mir-3714"]}},{"id":"6d01734c22ce4c4482f531705aa64a99","type":"GENE","name":"MIR371A","canonical_id":"hgnc:HGNC:31785","description":"microRNA 371a","metadata":{"aliases":["hsa-mir-371","MIRN371","MIR371"]}},{"id":"21e8d80700b54f1fbeb8a5c3fcbc59bb","type":"GENE","name":"MIR371B","canonical_id":"hgnc:HGNC:41863","description":"microRNA 371b","metadata":{"aliases":["hsa-mir-371b"]}},{"id":"ebe2718a572047a8875242fc78c94c53","type":"GENE","name":"MIR372","canonical_id":"hgnc:HGNC:31786","description":"microRNA 372","metadata":{"aliases":["hsa-mir-372","MIRN372"]}},{"id":"1791e984b40741b6a96599ea2084bef1","type":"GENE","name":"MIR373","canonical_id":"hgnc:HGNC:31787","description":"microRNA 373","metadata":{"aliases":["hsa-mir-373","MIRN373"]}},{"id":"fc151e6914b44df28d1ba555aa806130","type":"GENE","name":"MIR374A","canonical_id":"hgnc:HGNC:31788","description":"microRNA 374a","metadata":{"aliases":["hsa-mir-374","hsa-mir-374a","MIRN374","MIRN374A"]}},{"id":"0cd8c72b578b4c218bab09468ea1b130","type":"GENE","name":"MIR374B","canonical_id":"hgnc:HGNC:33665","description":"microRNA 374b","metadata":{"aliases":["hsa-mir-374b","MIRN374B"]}},{"id":"d63e011697004c4d8b1e1d9bbc35cc82","type":"GENE","name":"MIR374C","canonical_id":"hgnc:HGNC:38907","description":"microRNA 374c","metadata":{"aliases":["hsa-mir-374c"]}},{"id":"b87a3fd9fb174f81b5c7ef1538751294","type":"GENE","name":"MIR375","canonical_id":"hgnc:HGNC:31868","description":"microRNA 375","metadata":{"aliases":["hsa-mir-375","MIRN375"]}},{"id":"89cfc83846f44151bff1793469160993","type":"GENE","name":"MIR376A1","canonical_id":"hgnc:HGNC:31869","description":"microRNA 376a-1","metadata":{"aliases":["hsa-mir-376a","hsa-mir-376a-1","MIRN376A","MIRN376A1"]}},{"id":"8aac23651afe4557b5c34f9c5d798081","type":"GENE","name":"MIR376A2","canonical_id":"hgnc:HGNC:32532","description":"microRNA 376a-2","metadata":{"aliases":["hsa-mir-376a-2","MIRN376A2"]}},{"id":"b0b7729f28084b68a83d44260439c54c","type":"GENE","name":"MIR376B","canonical_id":"hgnc:HGNC:32066","description":"microRNA 376b","metadata":{"aliases":["hsa-mir-376b","MIRN376B"]}},{"id":"02e78279b8a746a6822fb9f56c592d39","type":"GENE","name":"MIR376C","canonical_id":"hgnc:HGNC:31782","description":"microRNA 376c","metadata":{"aliases":["hsa-mir-368","hsa-mir-376c","MIRN368","MIRN376C"]}},{"id":"2a89cf844960457ab3013da2c08f5713","type":"GENE","name":"MIR377","canonical_id":"hgnc:HGNC:31870","description":"microRNA 377","metadata":{"aliases":["hsa-mir-377","MIRN377"]}},{"id":"e74db526f10f434ea2bda455e9825de0","type":"GENE","name":"MIR378A","canonical_id":"hgnc:HGNC:31871","description":"microRNA 378a","metadata":{"aliases":["hsa-mir-378","MIRN378","MIR378"]}},{"id":"57a4aada18c04ff28d76d5857053bbc6","type":"GENE","name":"MIR378B","canonical_id":"hgnc:HGNC:38283","description":"microRNA 378b","metadata":{"aliases":["hsa-mir-378b"]}},{"id":"18afd9b631f74920b5d1dfa86144a7ee","type":"GENE","name":"MIR378C","canonical_id":"hgnc:HGNC:38374","description":"microRNA 378c","metadata":{"aliases":["hsa-mir-378c"]}},{"id":"ad82e1bda33f43f8b087b4dfb18b4c81","type":"GENE","name":"MIR378D1","canonical_id":"hgnc:HGNC:41550","description":"microRNA 378d-1","metadata":{"aliases":["hsa-mir-378d-1"]}},{"id":"64b2224b0e9140f1831cbb7ccdf74d93","type":"GENE","name":"MIR378D2","canonical_id":"hgnc:HGNC:41797","description":"microRNA 378d-2","metadata":{"aliases":["hsa-mir-378d-2"]}},{"id":"fc46bf68109548c79ff98bd064df25bc","type":"GENE","name":"MIR378D2HG","canonical_id":"hgnc:HGNC:54166","description":"MIR378D2 host gene","metadata":null},{"id":"977f637f123b41cbac3657e7ee401b48","type":"GENE","name":"MIR378E","canonical_id":"hgnc:HGNC:41671","description":"microRNA 378e","metadata":{"aliases":["hsa-mir-378e"]}},{"id":"3a36950bbe904bde9bb977f0c142024a","type":"GENE","name":"MIR378F","canonical_id":"hgnc:HGNC:41686","description":"microRNA 378f","metadata":{"aliases":["hsa-mir-378f"]}},{"id":"cd3042116f524ea48c198de48dbb333b","type":"GENE","name":"MIR378G","canonical_id":"hgnc:HGNC:41785","description":"microRNA 378g","metadata":{"aliases":["hsa-mir-378g"]}},{"id":"295f9e69204d4ebbb8bcd480dd4d0191","type":"GENE","name":"MIR378H","canonical_id":"hgnc:HGNC:41744","description":"microRNA 378h","metadata":{"aliases":["hsa-mir-378h"]}},{"id":"8e5044ec011e4f928c50c443b631b19f","type":"GENE","name":"MIR378I","canonical_id":"hgnc:HGNC:41620","description":"microRNA 378i","metadata":{"aliases":["hsa-mir-378i"]}},{"id":"7fe367fa151348179281393cfa0442e2","type":"GENE","name":"MIR378J","canonical_id":"hgnc:HGNC:49979","description":"microRNA 378j","metadata":{"aliases":["hsa-mir-378j"]}},{"id":"54bebf2d67154fcd9fe2d27ec955b09f","type":"GENE","name":"MIR379","canonical_id":"hgnc:HGNC:31872","description":"microRNA 379","metadata":{"aliases":["hsa-mir-379","MIRN379"]}},{"id":"3033b575fb4342f4a1882e111147aaff","type":"GENE","name":"MIR380","canonical_id":"hgnc:HGNC:31873","description":"microRNA 380","metadata":{"aliases":["hsa-mir-380","MIRN380"]}},{"id":"ed19fac110444c3cb2e08b4df70b305e","type":"GENE","name":"MIR381","canonical_id":"hgnc:HGNC:31874","description":"microRNA 381","metadata":{"aliases":["hsa-mir-381","MIRN381"]}},{"id":"1bea3fe6ab8a4ee8b261c1ed8170d27d","type":"GENE","name":"MIR381HG","canonical_id":"hgnc:HGNC:20136","description":"MIR381 host gene","metadata":{"aliases":["NCRNA00225","C14orf89"]}},{"id":"8f275e01c02840fdaeac44bf7bc1543f","type":"GENE","name":"MIR382","canonical_id":"hgnc:HGNC:31875","description":"microRNA 382","metadata":{"aliases":["hsa-mir-382","MIRN382"]}},{"id":"b82136bd634b4fcbbacc445e8dc6c6fd","type":"GENE","name":"MIR383","canonical_id":"hgnc:HGNC:31876","description":"microRNA 383","metadata":{"aliases":["hsa-mir-383","MIRN383"]}},{"id":"4168b990d1ce4657b638471ec3a81db9","type":"GENE","name":"MIR384","canonical_id":"hgnc:HGNC:31878","description":"microRNA 384","metadata":{"aliases":["hsa-mir-384","MIRN384"]}},{"id":"16e6181365af4069a083a95729e4bb42","type":"GENE","name":"MIR3907","canonical_id":"hgnc:HGNC:38988","description":"microRNA 3907","metadata":{"aliases":["hsa-mir-3907"]}},{"id":"fb3db383a79b44048b0df17378f9937c","type":"GENE","name":"MIR3908","canonical_id":"hgnc:HGNC:38991","description":"microRNA 3908","metadata":{"aliases":["hsa-mir-3908"]}},{"id":"b2bec6c1b4c3495387b5cc88359355dd","type":"GENE","name":"MIR3909","canonical_id":"hgnc:HGNC:38987","description":"microRNA 3909","metadata":{"aliases":["hsa-mir-3909"]}},{"id":"0a9aa964517f4ed4b9e610b307cdcd59","type":"GENE","name":"MIR3910-1","canonical_id":"hgnc:HGNC:38966","description":"microRNA 3910-1","metadata":{"aliases":["hsa-mir-3910-1"]}},{"id":"ed7d428af01b422b800c99d83cdd40b2","type":"GENE","name":"MIR3910-2","canonical_id":"hgnc:HGNC:38952","description":"microRNA 3910-2","metadata":{"aliases":["hsa-mir-3910-2"]}},{"id":"0a394ded3860433b8f1c479daa0bc84d","type":"GENE","name":"MIR3911","canonical_id":"hgnc:HGNC:38962","description":"microRNA 3911","metadata":{"aliases":["hsa-mir-3911"]}},{"id":"86317458fd454db7880847c95ad06ea9","type":"GENE","name":"MIR3912","canonical_id":"hgnc:HGNC:38923","description":"microRNA 3912","metadata":{"aliases":["hsa-mir-3912"]}},{"id":"0aae6b78e4ed4b529a2a1192d26bf839","type":"GENE","name":"MIR3913-1","canonical_id":"hgnc:HGNC:38884","description":"microRNA 3913-1","metadata":{"aliases":["hsa-mir-3913-1"]}},{"id":"1d82f94389024c6ba1cb95c1d2b61d5f","type":"GENE","name":"MIR3913-2","canonical_id":"hgnc:HGNC:38953","description":"microRNA 3913-2","metadata":{"aliases":["hsa-mir-3913-2"]}},{"id":"18bd6d7e009f44c0b108f4083bd52e38","type":"GENE","name":"MIR3914-1","canonical_id":"hgnc:HGNC:38993","description":"microRNA 3914-1","metadata":{"aliases":["hsa-mir-3914-1"]}},{"id":"6df2044a9d4f424f891b584778e7557b","type":"GENE","name":"MIR3914-2","canonical_id":"hgnc:HGNC:38975","description":"microRNA 3914-2","metadata":{"aliases":["hsa-mir-3914-2"]}},{"id":"b0800f1646974bf1aa137f6518e74070","type":"GENE","name":"MIR3915","canonical_id":"hgnc:HGNC:38955","description":"microRNA 3915","metadata":{"aliases":["hsa-mir-3915"]}},{"id":"2f3e41a00a2546c48556ff1e9038ff22","type":"GENE","name":"MIR3916","canonical_id":"hgnc:HGNC:38912","description":"microRNA 3916","metadata":{"aliases":["hsa-mir-3916"]}},{"id":"67ef35e7d7564d74abddae384a8a1e72","type":"GENE","name":"MIR3917","canonical_id":"hgnc:HGNC:38911","description":"microRNA 3917","metadata":{"aliases":["hsa-mir-3917"]}},{"id":"be2d28ea91214eb2a8428d1bbeaab9f3","type":"GENE","name":"MIR3918","canonical_id":"hgnc:HGNC:38919","description":"microRNA 3918","metadata":{"aliases":["hsa-mir-3918"]}},{"id":"2b3977f5104544bb8b7d5213bee633f5","type":"GENE","name":"MIR3919","canonical_id":"hgnc:HGNC:38890","description":"microRNA 3919","metadata":{"aliases":["hsa-mir-3919"]}},{"id":"814e4fa8e8794f17b67b5c83666fbcdd","type":"GENE","name":"MIR3920","canonical_id":"hgnc:HGNC:38974","description":"microRNA 3920","metadata":{"aliases":["hsa-mir-3920"]}},{"id":"9279be6c41934a528a6086bdf023c541","type":"GENE","name":"MIR3921","canonical_id":"hgnc:HGNC:38936","description":"microRNA 3921","metadata":{"aliases":["hsa-mir-3921"]}},{"id":"d602435a822b45e7ad0d3cec80436a96","type":"GENE","name":"MIR3922","canonical_id":"hgnc:HGNC:38895","description":"microRNA 3922","metadata":{"aliases":["hsa-mir-3922"]}},{"id":"094b2d059861413f8c4dce7ae04b3892","type":"GENE","name":"MIR3923","canonical_id":"hgnc:HGNC:38978","description":"microRNA 3923","metadata":{"aliases":["hsa-mir-3923"]}},{"id":"4feaee5f48514718a5e598e4d948b4f3","type":"GENE","name":"MIR3924","canonical_id":"hgnc:HGNC:38984","description":"microRNA 3924","metadata":{"aliases":["hsa-mir-3924"]}},{"id":"8f4b398fe3214f88a529c421f3c868ba","type":"GENE","name":"MIR3925","canonical_id":"hgnc:HGNC:38996","description":"microRNA 3925","metadata":{"aliases":["hsa-mir-3925"]}},{"id":"d33a9adacce04e9f8403f48d37d19951","type":"GENE","name":"MIR3926-1","canonical_id":"hgnc:HGNC:38959","description":"microRNA 3926-1","metadata":{"aliases":["hsa-mir-3926-1"]}},{"id":"629afba424fc48219dc49583584e9490","type":"GENE","name":"MIR3926-2","canonical_id":"hgnc:HGNC:38883","description":"microRNA 3926-2","metadata":{"aliases":["hsa-mir-3926-2"]}},{"id":"eb7e76ab124f47209e1a1bb30238a3ba","type":"GENE","name":"MIR3927","canonical_id":"hgnc:HGNC:38901","description":"microRNA 3927","metadata":{"aliases":["hsa-mir-3927"]}},{"id":"45d15d40292049fa8c24c6cd56865116","type":"GENE","name":"MIR3928","canonical_id":"hgnc:HGNC:38933","description":"microRNA 3928","metadata":{"aliases":["hsa-mir-3928"]}},{"id":"6a49ebd544c847619c6e578b089da262","type":"GENE","name":"MIR3929","canonical_id":"hgnc:HGNC:38945","description":"microRNA 3929","metadata":{"aliases":["hsa-mir-3929"]}},{"id":"bdda1c7c772a49fc934187526e7560fb","type":"GENE","name":"MIR3934","canonical_id":"hgnc:HGNC:38965","description":"microRNA 3934","metadata":{"aliases":["hsa-mir-3934"]}},{"id":"ddfc6542581e4f6db192439d0e6f372d","type":"GENE","name":"MIR3935","canonical_id":"hgnc:HGNC:38918","description":"microRNA 3935","metadata":{"aliases":["hsa-mir-3935"]}},{"id":"79eb2609bea1488aa0f22a9c802991c2","type":"GENE","name":"MIR3936","canonical_id":"hgnc:HGNC:38947","description":"microRNA 3936","metadata":{"aliases":["hsa-mir-3936"]}},{"id":"d569646fc1f64c8f997444f432807d6d","type":"GENE","name":"MIR3936HG","canonical_id":"hgnc:HGNC:40538","description":"MIR3936 host gene","metadata":{"aliases":["LOC553103","SLC22A5-AS1"]}},{"id":"b4a84b3788ec4517a1b4aba696c70fd2","type":"GENE","name":"MIR3937","canonical_id":"hgnc:HGNC:38970","description":"microRNA 3937","metadata":{"aliases":["hsa-mir-3937"]}},{"id":"8b51a8d221a14965ad7ccf5341d885db","type":"GENE","name":"MIR3938","canonical_id":"hgnc:HGNC:38972","description":"microRNA 3938","metadata":{"aliases":["hsa-mir-3938"]}},{"id":"9a679c4f98b242b7a0f3c52b697b7327","type":"GENE","name":"MIR3939","canonical_id":"hgnc:HGNC:38931","description":"microRNA 3939","metadata":{"aliases":["hsa-mir-3939"]}},{"id":"7fcf708a883c44dc9eb9034af5f55786","type":"GENE","name":"MIR3940","canonical_id":"hgnc:HGNC:38893","description":"microRNA 3940","metadata":{"aliases":["hsa-mir-3940"]}},{"id":"1f7cccaa1f874ffdb9472aa94adc0128","type":"GENE","name":"MIR3941","canonical_id":"hgnc:HGNC:38949","description":"microRNA 3941","metadata":{"aliases":["hsa-mir-3941"]}},{"id":"d85f1bff42914a62a57aea31c8d111d4","type":"GENE","name":"MIR3942","canonical_id":"hgnc:HGNC:38976","description":"microRNA 3942","metadata":{"aliases":["hsa-mir-3942"]}},{"id":"18638d40c78240a3ac0ae51bddc8f74b","type":"GENE","name":"MIR3943","canonical_id":"hgnc:HGNC:38888","description":"microRNA 3943","metadata":{"aliases":["hsa-mir-3943"]}},{"id":"37de3c1ba282458db4fd990302cd39b1","type":"GENE","name":"MIR3944","canonical_id":"hgnc:HGNC:38898","description":"microRNA 3944","metadata":{"aliases":["hsa-mir-3944"]}},{"id":"f4b470ed079b4b71880d5c9ff8182cf8","type":"GENE","name":"MIR3945","canonical_id":"hgnc:HGNC:38954","description":"microRNA 3945","metadata":{"aliases":["hsa-mir-3945"]}},{"id":"6623f2ecc9e14d03bedc629f7691584a","type":"GENE","name":"MIR3945HG","canonical_id":"hgnc:HGNC:52002","description":"MIR3945 host gene","metadata":null},{"id":"4af3b67f04c44d4eb67e9137f8b36657","type":"GENE","name":"MIR3960","canonical_id":"hgnc:HGNC:41595","description":"microRNA 3960","metadata":{"aliases":["hsa-mir-3960"]}},{"id":"3a04f71ec58947fdb9a12b72834e0a3e","type":"GENE","name":"MIR3972","canonical_id":"hgnc:HGNC:41876","description":"microRNA 3972","metadata":{"aliases":["hsa-mir-3972"]}},{"id":"c01526f5016844fc9daa2b3643439f56","type":"GENE","name":"MIR3973","canonical_id":"hgnc:HGNC:41756","description":"microRNA 3973","metadata":{"aliases":["hsa-mir-3973"]}},{"id":"dc0e4fbca2244b4cb77b5a6e37f459bd","type":"GENE","name":"MIR3974","canonical_id":"hgnc:HGNC:41672","description":"microRNA 3974","metadata":{"aliases":["hsa-mir-3974"]}},{"id":"9fe2e73def564a77bf2aea0b72f9fc08","type":"GENE","name":"MIR3975","canonical_id":"hgnc:HGNC:41613","description":"microRNA 3975","metadata":{"aliases":["hsa-mir-3975"]}},{"id":"fd2ff6a62c514e118320f8de7c889121","type":"GENE","name":"MIR3976","canonical_id":"hgnc:HGNC:41578","description":"microRNA 3976","metadata":{"aliases":["hsa-mir-3976"]}},{"id":"b2d0997a2fb341e1b1a921592f177deb","type":"GENE","name":"MIR3976HG","canonical_id":"hgnc:HGNC:51104","description":"MIR3976 host gene","metadata":{"aliases":["LINC01469"]}},{"id":"3608648debe144fcb69c53eb01bdc3d3","type":"GENE","name":"MIR3977","canonical_id":"hgnc:HGNC:41721","description":"microRNA 3977","metadata":{"aliases":["hsa-mir-3977"]}},{"id":"65bffd633426482fb39ebb30015b2e54","type":"GENE","name":"MIR3978","canonical_id":"hgnc:HGNC:41630","description":"microRNA 3978","metadata":{"aliases":["hsa-mir-3978"]}},{"id":"db027c2d1c41425ebe2cfad228ba1018","type":"GENE","name":"MIR409","canonical_id":"hgnc:HGNC:32055","description":"microRNA 409","metadata":{"aliases":["hsa-mir-409","MIRN409"]}},{"id":"f0cc550fe10c4005947c74fbfaa35786","type":"GENE","name":"MIR410","canonical_id":"hgnc:HGNC:32065","description":"microRNA 410","metadata":{"aliases":["hsa-mir-410","MIRN410"]}},{"id":"5e854e42b94e445cbeadbd916d72994a","type":"GENE","name":"MIR411","canonical_id":"hgnc:HGNC:32792","description":"microRNA 411","metadata":{"aliases":["hsa-mir-411","MIRN411"]}},{"id":"3cc3b1e92d8b44f6a186144a0c4642de","type":"GENE","name":"MIR412","canonical_id":"hgnc:HGNC:32064","description":"microRNA 412","metadata":{"aliases":["hsa-mir-412","MIRN412"]}},{"id":"509d7ca4906c49e4be8ba7710d92f483","type":"GENE","name":"MIR421","canonical_id":"hgnc:HGNC:32793","description":"microRNA 421","metadata":{"aliases":["hsa-mir-421","MIRN421"]}},{"id":"40bf7e7427db41c28df0c039c845eca3","type":"GENE","name":"MIR422A","canonical_id":"hgnc:HGNC:31879","description":"microRNA 422a","metadata":{"aliases":["hsa-mir-422a","MIRN422A"]}},{"id":"6cf9f08c5ec24aa0be060bdb5e8da35d","type":"GENE","name":"MIR423","canonical_id":"hgnc:HGNC:31880","description":"microRNA 423","metadata":{"aliases":["hsa-mir-423","MIRN423"]}},{"id":"c3adea14c2df453aa0b6cad4c03770bd","type":"GENE","name":"MIR424","canonical_id":"hgnc:HGNC:31881","description":"microRNA 424","metadata":{"aliases":["hsa-mir-424","MIRN424"]}},{"id":"4caa37b9969743abaaac9a08097a815e","type":"GENE","name":"MIR425","canonical_id":"hgnc:HGNC:31882","description":"microRNA 425","metadata":{"aliases":["hsa-mir-425","MIRN425"]}},{"id":"b19d21307487482dbfbe30b7b4492433","type":"GENE","name":"MIR4251","canonical_id":"hgnc:HGNC:38370","description":"microRNA 4251","metadata":{"aliases":["hsa-mir-4251"]}},{"id":"91067aa2aa6b4274abee8ddd0b40e644","type":"GENE","name":"MIR4252","canonical_id":"hgnc:HGNC:38384","description":"microRNA 4252","metadata":{"aliases":["hsa-mir-4252"]}},{"id":"6ce65ee860e149e5ab01758cf4513802","type":"GENE","name":"MIR4253","canonical_id":"hgnc:HGNC:38231","description":"microRNA 4253","metadata":{"aliases":["hsa-mir-4253"]}},{"id":"276c4c7dae81420d8bf9197a2ab39e47","type":"GENE","name":"MIR4254","canonical_id":"hgnc:HGNC:38193","description":"microRNA 4254","metadata":{"aliases":["hsa-mir-4254"]}},{"id":"ee9e859c38064a9a8b80ce7795b1936a","type":"GENE","name":"MIR4255","canonical_id":"hgnc:HGNC:38187","description":"microRNA 4255","metadata":{"aliases":["hsa-mir-4255"]}},{"id":"f8a793d8c9e942bbaf3114c6db91bec8","type":"GENE","name":"MIR4256","canonical_id":"hgnc:HGNC:38388","description":"microRNA 4256","metadata":{"aliases":["hsa-mir-4256"]}},{"id":"c024e62b6220436c9e4725e85b6ca3c6","type":"GENE","name":"MIR4257","canonical_id":"hgnc:HGNC:38312","description":"microRNA 4257","metadata":{"aliases":["hsa-mir-4257"]}},{"id":"81321d7e991a4f0d9e7bb3dccba93b73","type":"GENE","name":"MIR4258","canonical_id":"hgnc:HGNC:38281","description":"microRNA 4258","metadata":{"aliases":["hsa-mir-4258"]}},{"id":"de2f4f7d56f541a3bcbfc158600eecd4","type":"GENE","name":"MIR4259","canonical_id":"hgnc:HGNC:38309","description":"microRNA 4259","metadata":{"aliases":["hsa-mir-4259"]}},{"id":"112f23e5a8d64430811b311c8bc25a5c","type":"GENE","name":"MIR4260","canonical_id":"hgnc:HGNC:38179","description":"microRNA 4260","metadata":{"aliases":["hsa-mir-4260"]}},{"id":"1ed22fcdb26d45eba9c6c5e63aa7695e","type":"GENE","name":"MIR4261","canonical_id":"hgnc:HGNC:38272","description":"microRNA 4261","metadata":{"aliases":["hsa-mir-4261"]}},{"id":"2116585e2c8547788e18ecca8c04b3e8","type":"GENE","name":"MIR4262","canonical_id":"hgnc:HGNC:38308","description":"microRNA 4262","metadata":{"aliases":["hsa-mir-4262"]}},{"id":"ac7864d8f6da4a638c61e9f84c39ded4","type":"GENE","name":"MIR4263","canonical_id":"hgnc:HGNC:38365","description":"microRNA 4263","metadata":{"aliases":["hsa-mir-4263"]}},{"id":"e373940c11ba4c0885f0a132114fe16d","type":"GENE","name":"MIR4264","canonical_id":"hgnc:HGNC:38338","description":"microRNA 4264","metadata":{"aliases":["hsa-mir-4264"]}},{"id":"21bcd6dccb2d4bfba0c707511c1abf3a","type":"GENE","name":"MIR4265","canonical_id":"hgnc:HGNC:38358","description":"microRNA 4265","metadata":{"aliases":["hsa-mir-4265"]}},{"id":"ec235944a411463da1df3512384e247b","type":"GENE","name":"MIR4266","canonical_id":"hgnc:HGNC:38175","description":"microRNA 4266","metadata":{"aliases":["hsa-mir-4266"]}},{"id":"8177ea2f309e4190ac1286863469f5a3","type":"GENE","name":"MIR4267","canonical_id":"hgnc:HGNC:38286","description":"microRNA 4267","metadata":{"aliases":["hsa-mir-4267"]}},{"id":"440a61a65ff1418baa2c9609ab860f01","type":"GENE","name":"MIR4268","canonical_id":"hgnc:HGNC:38352","description":"microRNA 4268","metadata":{"aliases":["hsa-mir-4268"]}},{"id":"fe37bb35ba874a1bae61087cc2b6dde5","type":"GENE","name":"MIR4269","canonical_id":"hgnc:HGNC:38291","description":"microRNA 4269","metadata":{"aliases":["hsa-mir-4269"]}},{"id":"932e883cb0cf434c97489814a3bf3833","type":"GENE","name":"MIR4270","canonical_id":"hgnc:HGNC:38377","description":"microRNA 4270","metadata":{"aliases":["hsa-mir-4270"]}},{"id":"40fb70fa298d4c5d9af05c2a320b3048","type":"GENE","name":"MIR4271","canonical_id":"hgnc:HGNC:38332","description":"microRNA 4271","metadata":{"aliases":["hsa-mir-4271"]}},{"id":"99f452e8e15a497e9fe715b69cb864d1","type":"GENE","name":"MIR4272","canonical_id":"hgnc:HGNC:38303","description":"microRNA 4272","metadata":{"aliases":["hsa-mir-4272"]}},{"id":"d7fef630005b4c4c935b993290e78251","type":"GENE","name":"MIR4273","canonical_id":"hgnc:HGNC:38339","description":"microRNA 4273","metadata":{"aliases":["hsa-mir-4273"]}},{"id":"d68603e66eaf45f88f2e7daeca444fee","type":"GENE","name":"MIR4274","canonical_id":"hgnc:HGNC:38194","description":"microRNA 4274","metadata":{"aliases":["hsa-mir-4274"]}},{"id":"01ea42549be047e1873c364cf009b9d9","type":"GENE","name":"MIR4275","canonical_id":"hgnc:HGNC:38293","description":"microRNA 4275","metadata":{"aliases":["hsa-mir-4275"]}},{"id":"61a262ad839f42fe9c658a36732dfb71","type":"GENE","name":"MIR4276","canonical_id":"hgnc:HGNC:38232","description":"microRNA 4276","metadata":{"aliases":["hsa-mir-4276"]}},{"id":"80e6765b520d42029191f15fb0cb859a","type":"GENE","name":"MIR4277","canonical_id":"hgnc:HGNC:38367","description":"microRNA 4277","metadata":{"aliases":["hsa-mir-4277"]}},{"id":"c580e760e25541a7a9cee2c313bcc449","type":"GENE","name":"MIR4277HG","canonical_id":"hgnc:HGNC:58993","description":"MIR4277 host gene","metadata":null},{"id":"f27d8c4a4ae84022bb0d7200906a4c1b","type":"GENE","name":"MIR4278","canonical_id":"hgnc:HGNC:38243","description":"microRNA 4278","metadata":{"aliases":["hsa-mir-4278"]}},{"id":"cb12661add64487c91e5a05671072f80","type":"GENE","name":"MIR4279","canonical_id":"hgnc:HGNC:38195","description":"microRNA 4279","metadata":{"aliases":["hsa-mir-4279"]}},{"id":"91d8c37752624d8195f96962a89cf456","type":"GENE","name":"MIR4280","canonical_id":"hgnc:HGNC:38334","description":"microRNA 4280","metadata":{"aliases":["hsa-mir-4280"]}},{"id":"f860d8e298234a4dbfc0783e2eb519cb","type":"GENE","name":"MIR4280HG","canonical_id":"hgnc:HGNC:54975","description":"MIR4280 host gene","metadata":null},{"id":"8bf8cd9fd29c4b3a81864cc7a88ce733","type":"GENE","name":"MIR4281","canonical_id":"hgnc:HGNC:38357","description":"microRNA 4281","metadata":{"aliases":["hsa-mir-4281"]}},{"id":"bf2538d0579741d1933db7332f4f9484","type":"GENE","name":"MIR4282","canonical_id":"hgnc:HGNC:38189","description":"microRNA 4282","metadata":{"aliases":["hsa-mir-4282"]}},{"id":"60adf903a5154a308e21ddb9f58686ea","type":"GENE","name":"MIR4283-1","canonical_id":"hgnc:HGNC:38238","description":"microRNA 4283-1","metadata":{"aliases":["hsa-mir-4283-1"]}},{"id":"6cdc7de3cfba4568920cd1e4424b8a10","type":"GENE","name":"MIR4283-2","canonical_id":"hgnc:HGNC:38296","description":"microRNA 4283-2","metadata":{"aliases":["hsa-mir-4283-2"]}},{"id":"51770bb494a04d908411ca83515f81f7","type":"GENE","name":"MIR4284","canonical_id":"hgnc:HGNC:38322","description":"microRNA 4284","metadata":{"aliases":["hsa-mir-4284"]}},{"id":"5718dc4bbed34ab5ba0de1b161a5d550","type":"GENE","name":"MIR4285","canonical_id":"hgnc:HGNC:38337","description":"microRNA 4285","metadata":{"aliases":["hsa-mir-4285"]}},{"id":"177927bb295e4a5a871e5eaef85ea1b9","type":"GENE","name":"MIR4286","canonical_id":"hgnc:HGNC:38186","description":"microRNA 4286","metadata":{"aliases":["hsa-mir-4286"]}},{"id":"a572e1dc4b23416aab397d0f3725ede9","type":"GENE","name":"MIR4287","canonical_id":"hgnc:HGNC:38208","description":"microRNA 4287","metadata":{"aliases":["hsa-mir-4287"]}},{"id":"e3f34f2cca2f47648cf83e3491808d87","type":"GENE","name":"MIR4288","canonical_id":"hgnc:HGNC:38203","description":"microRNA 4288","metadata":{"aliases":["hsa-mir-4288"]}},{"id":"30fd92235e444878b1d4fc34058ba80f","type":"GENE","name":"MIR4289","canonical_id":"hgnc:HGNC:38278","description":"microRNA 4289","metadata":{"aliases":["hsa-mir-4289"]}},{"id":"261888fcb17c41808e4224c517ce8bec","type":"GENE","name":"MIR429","canonical_id":"hgnc:HGNC:13784","description":"microRNA 429","metadata":{"aliases":["hsa-mir-429","MIRN429"]}},{"id":"7e12618b55aa4731869616164ead8a09","type":"GENE","name":"MIR4290","canonical_id":"hgnc:HGNC:38360","description":"microRNA 4290","metadata":{"aliases":["hsa-mir-4290"]}},{"id":"9d1a14ec610249e58311568c92df7f41","type":"GENE","name":"MIR4290HG","canonical_id":"hgnc:HGNC:27861","description":"MIR4290 host gene","metadata":null},{"id":"a3ed2d20309c4db6901fafee594c00d3","type":"GENE","name":"MIR4291","canonical_id":"hgnc:HGNC:38267","description":"microRNA 4291","metadata":{"aliases":["hsa-mir-4291"]}},{"id":"baf6a4e8ea20490c931fd4102943cb92","type":"GENE","name":"MIR4292","canonical_id":"hgnc:HGNC:38348","description":"microRNA 4292","metadata":{"aliases":["hsa-mir-4292"]}},{"id":"714433b312754cfbbb6d559d64a93cc5","type":"GENE","name":"MIR4293","canonical_id":"hgnc:HGNC:38270","description":"microRNA 4293","metadata":{"aliases":["hsa-mir-4293"]}},{"id":"04ccefc7db37428f8d39727be130596f","type":"GENE","name":"MIR4294","canonical_id":"hgnc:HGNC:38180","description":"microRNA 4294","metadata":{"aliases":["hsa-mir-4294"]}},{"id":"f81fa6314bb84cc9a1e7df824703b11b","type":"GENE","name":"MIR4295","canonical_id":"hgnc:HGNC:38220","description":"microRNA 4295","metadata":{"aliases":["hsa-mir-4295"]}},{"id":"af300984d6cd49e382253e2e2d04c809","type":"GENE","name":"MIR4296","canonical_id":"hgnc:HGNC:38178","description":"microRNA 4296","metadata":{"aliases":["hsa-mir-4296"]}},{"id":"c0eb95e3724d4edbabbebefcbf5fd063","type":"GENE","name":"MIR4297","canonical_id":"hgnc:HGNC:38393","description":"microRNA 4297","metadata":{"aliases":["hsa-mir-4297"]}},{"id":"040c9b24db544ac6a5f714cc2ae7fe72","type":"GENE","name":"MIR4298","canonical_id":"hgnc:HGNC:38313","description":"microRNA 4298","metadata":{"aliases":["hsa-mir-4298"]}},{"id":"efdfb47a5eef447fa7e084449fa30c1d","type":"GENE","name":"MIR4299","canonical_id":"hgnc:HGNC:38329","description":"microRNA 4299","metadata":{"aliases":["hsa-mir-4299"]}},{"id":"d872ceaaf50741cc937867929000f238","type":"GENE","name":"MIR4300","canonical_id":"hgnc:HGNC:38184","description":"microRNA 4300","metadata":{"aliases":["hsa-mir-4300"]}},{"id":"c0081ad837424116956c7da53ec7a969","type":"GENE","name":"MIR4300HG","canonical_id":"hgnc:HGNC:52003","description":"MIR4300 host gene","metadata":null},{"id":"fbd4be0e33a74baa876e2fa99684fa79","type":"GENE","name":"MIR4301","canonical_id":"hgnc:HGNC:38323","description":"microRNA 4301","metadata":{"aliases":["hsa-mir-4301"]}},{"id":"980416712615470f81ac20b9e57d151d","type":"GENE","name":"MIR4302","canonical_id":"hgnc:HGNC:38185","description":"microRNA 4302","metadata":{"aliases":["hsa-mir-4302"]}},{"id":"eba8347fd9d84e73a58b6b9f3f89522d","type":"GENE","name":"MIR4303","canonical_id":"hgnc:HGNC:38256","description":"microRNA 4303","metadata":{"aliases":["hsa-mir-4303"]}},{"id":"3e1821f8601f42758c3a1bfc95880fbf","type":"GENE","name":"MIR4304","canonical_id":"hgnc:HGNC:38276","description":"microRNA 4304","metadata":{"aliases":["hsa-mir-4304"]}},{"id":"b90e36cf514842fe8e265ebf1c8d1bda","type":"GENE","name":"MIR4305","canonical_id":"hgnc:HGNC:38301","description":"microRNA 4305","metadata":{"aliases":["hsa-mir-4305"]}},{"id":"865e14da23c14b75baf682ba249e7ea6","type":"GENE","name":"MIR4306","canonical_id":"hgnc:HGNC:38350","description":"microRNA 4306","metadata":{"aliases":["hsa-mir-4306"]}},{"id":"c1993ba6811c4b948b25e11a560e0609","type":"GENE","name":"MIR4307","canonical_id":"hgnc:HGNC:38257","description":"microRNA 4307","metadata":{"aliases":["hsa-mir-4307"]}},{"id":"6118a705c829493e9d0123c66064d285","type":"GENE","name":"MIR4307HG","canonical_id":"hgnc:HGNC:52004","description":"MIR4307 host gene","metadata":null},{"id":"2b4f45dc6a454a29836589177386b091","type":"GENE","name":"MIR4308","canonical_id":"hgnc:HGNC:38206","description":"microRNA 4308","metadata":{"aliases":["hsa-mir-4308"]}},{"id":"2d56c5c704cb4044b6b25fc6b9747b56","type":"GENE","name":"MIR4309","canonical_id":"hgnc:HGNC:38336","description":"microRNA 4309","metadata":{"aliases":["hsa-mir-4309"]}},{"id":"172545251bb443bd96c2075f298a01ca","type":"GENE","name":"MIR431","canonical_id":"hgnc:HGNC:32027","description":"microRNA 431","metadata":{"aliases":["hsa-mir-431","MIRN431"]}},{"id":"2fc8ffcb800741289422b1b12b64f7db","type":"GENE","name":"MIR4310","canonical_id":"hgnc:HGNC:38383","description":"microRNA 4310","metadata":{"aliases":["hsa-mir-4310"]}},{"id":"8b0ae1d4eb4b4804a6022a0cf0a5df10","type":"GENE","name":"MIR4311","canonical_id":"hgnc:HGNC:38207","description":"microRNA 4311","metadata":{"aliases":["hsa-mir-4311"]}},{"id":"f88dbc91d5324bc5a2dbddb133c50a28","type":"GENE","name":"MIR4312","canonical_id":"hgnc:HGNC:38376","description":"microRNA 4312","metadata":{"aliases":["hsa-mir-4312"]}},{"id":"451fb429c3524b1b87d9fe6396980174","type":"GENE","name":"MIR4313","canonical_id":"hgnc:HGNC:38310","description":"microRNA 4313","metadata":{"aliases":["hsa-mir-4313"]}},{"id":"79ba49a0ba34464aaf6bea5103a5e301","type":"GENE","name":"MIR4314","canonical_id":"hgnc:HGNC:38191","description":"microRNA 4314","metadata":{"aliases":["hsa-mir-4314"]}},{"id":"1cfb5675ab5642e0989eab1af1226edb","type":"GENE","name":"MIR4315-1","canonical_id":"hgnc:HGNC:38342","description":"microRNA 4315-1","metadata":{"aliases":["hsa-mir-4315-1"]}},{"id":"a9c2f5c8e20149578599236e63e56458","type":"GENE","name":"MIR4315-2","canonical_id":"hgnc:HGNC:38356","description":"microRNA 4315-2","metadata":{"aliases":["hsa-mir-4315-2"]}},{"id":"18d7309a22c142fb8a2ec255422bfe41","type":"GENE","name":"MIR4316","canonical_id":"hgnc:HGNC:38306","description":"microRNA 4316","metadata":{"aliases":["hsa-mir-4316"]}},{"id":"ac39c814bf584c76af7fed851fb08b40","type":"GENE","name":"MIR4317","canonical_id":"hgnc:HGNC:38260","description":"microRNA 4317","metadata":{"aliases":["hsa-mir-4317"]}},{"id":"2749b81dff49481ab1e1e50b4590c381","type":"GENE","name":"MIR4318","canonical_id":"hgnc:HGNC:38333","description":"microRNA 4318","metadata":{"aliases":["hsa-mir-4318"]}},{"id":"f5b1a98a291f46f387f5f062041a3302","type":"GENE","name":"MIR4319","canonical_id":"hgnc:HGNC:38212","description":"microRNA 4319","metadata":{"aliases":["hsa-mir-4319"]}},{"id":"84f8e1433c89483e9bbbe70686486be4","type":"GENE","name":"MIR432","canonical_id":"hgnc:HGNC:32083","description":"microRNA 432","metadata":{"aliases":["hsa-mir-432","MIRN432"]}},{"id":"cad9ca5cffff444794133f3711caf9ed","type":"GENE","name":"MIR4320","canonical_id":"hgnc:HGNC:38369","description":"microRNA 4320","metadata":{"aliases":["hsa-mir-4320"]}},{"id":"c6f24b743d4d4a6599d9a08a4c164261","type":"GENE","name":"MIR4321","canonical_id":"hgnc:HGNC:38244","description":"microRNA 4321","metadata":{"aliases":["hsa-mir-4321"]}},{"id":"441bf577c34a442aadc3264a26eade1d","type":"GENE","name":"MIR4322","canonical_id":"hgnc:HGNC:38261","description":"microRNA 4322","metadata":{"aliases":["hsa-mir-4322"]}},{"id":"d40d05362e024c45ae98b742e0b5cc37","type":"GENE","name":"MIR4323","canonical_id":"hgnc:HGNC:38394","description":"microRNA 4323","metadata":{"aliases":["hsa-mir-4323"]}},{"id":"1f1539799cae4571983a80f4b7641e6a","type":"GENE","name":"MIR4324","canonical_id":"hgnc:HGNC:38392","description":"microRNA 4324","metadata":{"aliases":["hsa-mir-4324"]}},{"id":"2a90d065cf544a478d1dbf152d359213","type":"GENE","name":"MIR4325","canonical_id":"hgnc:HGNC:38304","description":"microRNA 4325","metadata":{"aliases":["hsa-mir-4325"]}},{"id":"bda5163a2bc84dac9beb019bfb086d92","type":"GENE","name":"MIR4326","canonical_id":"hgnc:HGNC:38314","description":"microRNA 4326","metadata":{"aliases":["hsa-mir-4326"]}},{"id":"0493cb5aff364666825a53da9710dfff","type":"GENE","name":"MIR4327","canonical_id":"hgnc:HGNC:38355","description":"microRNA 4327","metadata":{"aliases":["hsa-mir-4327"]}},{"id":"46b364e757a84be08a6f0c6a0254aba3","type":"GENE","name":"MIR4328","canonical_id":"hgnc:HGNC:38280","description":"microRNA 4328","metadata":{"aliases":["hsa-mir-4328"]}},{"id":"76027ab13622437180e16d293ed7d7a9","type":"GENE","name":"MIR4329","canonical_id":"hgnc:HGNC:38290","description":"microRNA 4329","metadata":{"aliases":["hsa-mir-4329"]}},{"id":"76c452be8b594a4786cdbada16b21fcd","type":"GENE","name":"MIR433","canonical_id":"hgnc:HGNC:32026","description":"microRNA 433","metadata":{"aliases":["hsa-mir-433","MIRN433"]}},{"id":"123fbd46a04142af9998a5c2fb836ccc","type":"GENE","name":"MIR4330","canonical_id":"hgnc:HGNC:38273","description":"microRNA 4330","metadata":{"aliases":["hsa-mir-4330"]}},{"id":"1940522387e24f0ebcf973583bd3f09e","type":"GENE","name":"MIR4418","canonical_id":"hgnc:HGNC:41789","description":"microRNA 4418","metadata":{"aliases":["hsa-mir-4418"]}},{"id":"224414ac37db4e86b036e137ab16be01","type":"GENE","name":"MIR4420","canonical_id":"hgnc:HGNC:41772","description":"microRNA 4420","metadata":{"aliases":["hsa-mir-4420"]}},{"id":"0694229ec4f7428f93316e2ce9c3ba4b","type":"GENE","name":"MIR4421","canonical_id":"hgnc:HGNC:41879","description":"microRNA 4421","metadata":{"aliases":["hsa-mir-4421"]}},{"id":"4f52c48728dd4e05b21231e83692f899","type":"GENE","name":"MIR4422","canonical_id":"hgnc:HGNC:41654","description":"microRNA 4422","metadata":{"aliases":["hsa-mir-4422"]}},{"id":"0c033e993ae4462cbc6a6e1947cb3311","type":"GENE","name":"MIR4422HG","canonical_id":"hgnc:HGNC:53113","description":"MIR4422 host gene","metadata":{"aliases":["RP11-101C11.1"]}},{"id":"4f347e2fba254cceafbd0a935e243836","type":"GENE","name":"MIR4423","canonical_id":"hgnc:HGNC:41784","description":"microRNA 4423","metadata":{"aliases":["hsa-mir-4423"]}},{"id":"4573f9e2e2094b69a515448ba4130714","type":"GENE","name":"MIR4424","canonical_id":"hgnc:HGNC:41805","description":"microRNA 4424","metadata":{"aliases":["hsa-mir-4424"]}},{"id":"79ccb6c38eba4cdbaa48fd4f51dfeb0e","type":"GENE","name":"MIR4425","canonical_id":"hgnc:HGNC:41891","description":"microRNA 4425","metadata":{"aliases":["hsa-mir-4425"]}},{"id":"69037e0950924355b2f7ec75ac77f487","type":"GENE","name":"MIR4426","canonical_id":"hgnc:HGNC:41848","description":"microRNA 4426","metadata":{"aliases":["hsa-mir-4426"]}},{"id":"f11c0e7408a14f289e54b83f95c399fd","type":"GENE","name":"MIR4427","canonical_id":"hgnc:HGNC:41678","description":"microRNA 4427","metadata":{"aliases":["hsa-mir-4427"]}},{"id":"0253437c7d264cc4a59af9eb7647846e","type":"GENE","name":"MIR4428","canonical_id":"hgnc:HGNC:41667","description":"microRNA 4428","metadata":{"aliases":["hsa-mir-4428"]}},{"id":"fe5a3623249c4adc9ff9ee2452c392b1","type":"GENE","name":"MIR4429","canonical_id":"hgnc:HGNC:41579","description":"microRNA 4429","metadata":{"aliases":["hsa-mir-4429"]}},{"id":"391a35e26af64650a42e479ff1c9cbc9","type":"GENE","name":"MIR4430","canonical_id":"hgnc:HGNC:41646","description":"microRNA 4430","metadata":{"aliases":["hsa-mir-4430"]}},{"id":"e889e050eb4f4c4e8590a1b565653245","type":"GENE","name":"MIR4431","canonical_id":"hgnc:HGNC:41738","description":"microRNA 4431","metadata":{"aliases":["hsa-mir-4431"]}},{"id":"beb8e4747f76444e81529b7b36c70099","type":"GENE","name":"MIR4432","canonical_id":"hgnc:HGNC:41649","description":"microRNA 4432","metadata":{"aliases":["hsa-mir-4432"]}},{"id":"c0d0ce936f6c4d19ab13f82b0cb37bd6","type":"GENE","name":"MIR4432HG","canonical_id":"hgnc:HGNC:52005","description":"MIR4432 host gene","metadata":null},{"id":"e39c01a7594042769995f9ddce102ce3","type":"GENE","name":"MIR4433A","canonical_id":"hgnc:HGNC:41634","description":"microRNA 4433a","metadata":{"aliases":["hsa-mir-4433","MIR4433"]}},{"id":"6c8144f6e8c04c18b4a89f9b902ee003","type":"GENE","name":"MIR4433B","canonical_id":"hgnc:HGNC:50258","description":"microRNA 4433b","metadata":{"aliases":["hsa-mir-4433b"]}},{"id":"24aeac5c566646cfa7de34658d0fc262","type":"GENE","name":"MIR4434","canonical_id":"hgnc:HGNC:41832","description":"microRNA 4434","metadata":{"aliases":["hsa-mir-4434"]}},{"id":"d90ff95ccfda41f69dea79fbb1647d4f","type":"GENE","name":"MIR4435-1","canonical_id":"hgnc:HGNC:41713","description":"microRNA 4435-1","metadata":{"aliases":["hsa-mir-4435-1"]}},{"id":"e512af1df79c4aac81b6404da775d0df","type":"GENE","name":"MIR4435-2","canonical_id":"hgnc:HGNC:41837","description":"microRNA 4435-2","metadata":{"aliases":["hsa-mir-4435-2"]}},{"id":"c11ee97bafac470db9d9cdb67f2efdd1","type":"GENE","name":"MIR4435-2HG","canonical_id":"hgnc:HGNC:35163","description":"MIR4435-2 host gene","metadata":{"aliases":["LINC00978","AGD2","AK001796","lncRNA-AWPPH","MORRBID","MIR4435-1HG"]}},{"id":"5d4de58bcae742e1ac579c9f3f7ae2c9","type":"GENE","name":"MIR4436A","canonical_id":"hgnc:HGNC:41762","description":"microRNA 4436a","metadata":{"aliases":["hsa-mir-4436a"]}},{"id":"36a9621aff914721bc7fdeef4d142d67","type":"GENE","name":"MIR4436B1","canonical_id":"hgnc:HGNC:41587","description":"microRNA 4436b-1","metadata":{"aliases":["hsa-mir-4436b","MIR4436B"]}},{"id":"286cb686d5e64016bed0f6187b1c59fb","type":"GENE","name":"MIR4436B2","canonical_id":"hgnc:HGNC:43451","description":"microRNA 4436b-2","metadata":{"aliases":["hsa-mir-4436b-2"]}},{"id":"2af22be02fbc4c0fb26a0f82740e7380","type":"GENE","name":"MIR4437","canonical_id":"hgnc:HGNC:41715","description":"microRNA 4437","metadata":{"aliases":["hsa-mir-4437"]}},{"id":"6b569b30ec064a198509a2147ef8080a","type":"GENE","name":"MIR4438","canonical_id":"hgnc:HGNC:41555","description":"microRNA 4438","metadata":{"aliases":["hsa-mir-4438"]}},{"id":"6a3d7297ca7b4b3e80ba856144044339","type":"GENE","name":"MIR4439","canonical_id":"hgnc:HGNC:41622","description":"microRNA 4439","metadata":{"aliases":["hsa-mir-4439"]}},{"id":"970eb20adebe413bb3e889d53180063a","type":"GENE","name":"MIR4440","canonical_id":"hgnc:HGNC:41740","description":"microRNA 4440","metadata":{"aliases":["hsa-mir-4440"]}},{"id":"61e26b16910c41bf858ded3e8a1d6bd2","type":"GENE","name":"MIR4441","canonical_id":"hgnc:HGNC:41728","description":"microRNA 4441","metadata":{"aliases":["hsa-mir-4441"]}},{"id":"740d1ef1eaba4ab7ab524b16f345aeab","type":"GENE","name":"MIR4442","canonical_id":"hgnc:HGNC:41718","description":"microRNA 4442","metadata":{"aliases":["hsa-mir-4442"]}},{"id":"7d3511eb403e478f8dbabaf0c2fa17b7","type":"GENE","name":"MIR4443","canonical_id":"hgnc:HGNC:41830","description":"microRNA 4443","metadata":{"aliases":["hsa-mir-4443"]}},{"id":"5fd657c364874207a2c0cfb8c81e9282","type":"GENE","name":"MIR4444-1","canonical_id":"hgnc:HGNC:41710","description":"microRNA 4444-1","metadata":{"aliases":["hsa-mir-4444","miR-4444-1","MIR4444"]}},{"id":"6d3965ae129745a2bc94e894de1a266c","type":"GENE","name":"MIR4444-2","canonical_id":"hgnc:HGNC:43481","description":"microRNA 4444-2","metadata":{"aliases":["hsa-mir-4444-2"]}},{"id":"0b3e3ab8c3544310a636fab3ca592d3a","type":"GENE","name":"MIR4445","canonical_id":"hgnc:HGNC:41614","description":"microRNA 4445","metadata":{"aliases":["hsa-mir-4445"]}},{"id":"1d2188a9d2e641e893b971cb5e3bf90a","type":"GENE","name":"MIR4446","canonical_id":"hgnc:HGNC:41700","description":"microRNA 4446","metadata":{"aliases":["hsa-mir-4446"]}},{"id":"bf614ee3ae4a43b795cedbd7707bd8f4","type":"GENE","name":"MIR4447","canonical_id":"hgnc:HGNC:41850","description":"microRNA 4447","metadata":{"aliases":["hsa-mir-4447"]}},{"id":"fa44c558fd36440e962929982d1a7ffd","type":"GENE","name":"MIR4448","canonical_id":"hgnc:HGNC:41604","description":"microRNA 4448","metadata":{"aliases":["hsa-mir-4448"]}},{"id":"548f13d0cda245c1a9eacfac7b530d64","type":"GENE","name":"MIR4449","canonical_id":"hgnc:HGNC:41864","description":"microRNA 4449","metadata":{"aliases":["hsa-mir-4449"]}},{"id":"785fe93db88c4ab1a048bcef3394dac4","type":"GENE","name":"MIR4450","canonical_id":"hgnc:HGNC:41725","description":"microRNA 4450","metadata":{"aliases":["hsa-mir-4450"]}},{"id":"2a3f124b780048789e2babb892ca617d","type":"GENE","name":"MIR4451","canonical_id":"hgnc:HGNC:41858","description":"microRNA 4451","metadata":{"aliases":["hsa-mir-4451"]}},{"id":"3291047da0be490f9231cc363e1391e9","type":"GENE","name":"MIR4452","canonical_id":"hgnc:HGNC:41539","description":"microRNA 4452","metadata":{"aliases":["hsa-mir-4452"]}},{"id":"1498db3b27194aa2a3a8ad838359a9d9","type":"GENE","name":"MIR4453","canonical_id":"hgnc:HGNC:41892","description":"microRNA 4453","metadata":{"aliases":["hsa-mir-4453"]}},{"id":"94a8b280280c48fb9efd5a4817b0fe27","type":"GENE","name":"MIR4453HG","canonical_id":"hgnc:HGNC:25288","description":"MIR4453 host gene","metadata":{"aliases":["DKFZP434I0714","LINC02486"]}},{"id":"2991526c80c0428ca54c1fa7d08fe9bd","type":"GENE","name":"MIR4454","canonical_id":"hgnc:HGNC:41553","description":"microRNA 4454","metadata":{"aliases":["hsa-mir-4454"]}},{"id":"5f39867ecd4f4bad94c28460bb3c9ac0","type":"GENE","name":"MIR4455","canonical_id":"hgnc:HGNC:41536","description":"microRNA 4455","metadata":{"aliases":["hsa-mir-4455"]}},{"id":"368d6cebb49f47d9bb5b0848a7f5c10b","type":"GENE","name":"MIR4456","canonical_id":"hgnc:HGNC:41606","description":"microRNA 4456","metadata":{"aliases":["hsa-mir-4456"]}},{"id":"141e4beb62af40afbaa71d3c6d9d3372","type":"GENE","name":"MIR4457","canonical_id":"hgnc:HGNC:41554","description":"microRNA 4457","metadata":{"aliases":["hsa-mir-4457"]}},{"id":"0821eeee59cb401eab4b42649dd625a6","type":"GENE","name":"MIR4458","canonical_id":"hgnc:HGNC:41674","description":"microRNA 4458","metadata":{"aliases":["hsa-mir-4458"]}},{"id":"c67019175b2a433d8a3bd694ad621355","type":"GENE","name":"MIR4458HG","canonical_id":"hgnc:HGNC:49008","description":"MIR4458 host gene","metadata":null},{"id":"4bd8212c66b34f53920930d0152b4ddd","type":"GENE","name":"MIR4460","canonical_id":"hgnc:HGNC:41795","description":"microRNA 4460","metadata":{"aliases":["hsa-mir-4460"]}},{"id":"78b202fcb83240239fc528431a87ac77","type":"GENE","name":"MIR4462","canonical_id":"hgnc:HGNC:41549","description":"microRNA 4462","metadata":{"aliases":["hsa-mir-4462"]}},{"id":"4e788fba2d854e52bdb3d53f4ee2f4f3","type":"GENE","name":"MIR4463","canonical_id":"hgnc:HGNC:41665","description":"microRNA 4463","metadata":{"aliases":["hsa-mir-4463"]}},{"id":"f927cd526de243f7a5fd1702212c4fd8","type":"GENE","name":"MIR4464","canonical_id":"hgnc:HGNC:41528","description":"microRNA 4464","metadata":{"aliases":["hsa-mir-4464"]}},{"id":"5dc684c4e81b482097ba284e7f2ce495","type":"GENE","name":"MIR4465","canonical_id":"hgnc:HGNC:41842","description":"microRNA 4465","metadata":{"aliases":["hsa-mir-4465"]}},{"id":"2a0e3378923640a8badc1be805d1805b","type":"GENE","name":"MIR4466","canonical_id":"hgnc:HGNC:41726","description":"microRNA 4466","metadata":{"aliases":["hsa-mir-4466"]}},{"id":"ff5b3e1ea06048dea9ff39f04afd6d87","type":"GENE","name":"MIR4467","canonical_id":"hgnc:HGNC:41896","description":"microRNA 4467","metadata":{"aliases":["hsa-mir-4467"]}},{"id":"ab268fb3f0dc4254b410df28df910b6e","type":"GENE","name":"MIR4468","canonical_id":"hgnc:HGNC:41533","description":"microRNA 4468","metadata":{"aliases":["hsa-mir-4468"]}},{"id":"a1cf4970123c437db80696762df2cb93","type":"GENE","name":"MIR4469","canonical_id":"hgnc:HGNC:41556","description":"microRNA 4469","metadata":{"aliases":["hsa-mir-4469"]}},{"id":"a3e478c93abb4c2da6f703f91a151109","type":"GENE","name":"MIR4470","canonical_id":"hgnc:HGNC:41833","description":"microRNA 4470","metadata":{"aliases":["hsa-mir-4470"]}},{"id":"f567aaf2ad69491b80135a2af7247159","type":"GENE","name":"MIR4471","canonical_id":"hgnc:HGNC:41657","description":"microRNA 4471","metadata":{"aliases":["hsa-mir-4471"]}},{"id":"b7fd68b65fe04757915afdf57e9137f8","type":"GENE","name":"MIR4472-1","canonical_id":"hgnc:HGNC:41644","description":"microRNA 4472-1","metadata":{"aliases":["hsa-mir-4472-1"]}},{"id":"4b6eb9982abe4daf80dfcd184a315a92","type":"GENE","name":"MIR4472-2","canonical_id":"hgnc:HGNC:41752","description":"microRNA 4472-2","metadata":{"aliases":["hsa-mir-4472-2"]}},{"id":"cca6b8f7dfc24701a89e31632a2ee75b","type":"GENE","name":"MIR4473","canonical_id":"hgnc:HGNC:41540","description":"microRNA 4473","metadata":{"aliases":["hsa-mir-4473"]}},{"id":"b2c6ae33cb19486abf3f375b42fe076b","type":"GENE","name":"MIR4474","canonical_id":"hgnc:HGNC:41821","description":"microRNA 4474","metadata":{"aliases":["hsa-mir-4474"]}},{"id":"2ceb3ce6f7ce463c9ab8492b75779d58","type":"GENE","name":"MIR4475","canonical_id":"hgnc:HGNC:41697","description":"microRNA 4475","metadata":{"aliases":["hsa-mir-4475"]}},{"id":"3c2220d63c3b4f3f8a5db4771f43d296","type":"GENE","name":"MIR4476","canonical_id":"hgnc:HGNC:41793","description":"microRNA 4476","metadata":{"aliases":["hsa-mir-4476"]}},{"id":"4b7dced2ba204f4e97f4894890835e16","type":"GENE","name":"MIR4477A","canonical_id":"hgnc:HGNC:41859","description":"microRNA 4477a","metadata":{"aliases":["hsa-mir-4477a"]}},{"id":"be2ae93144eb4453aef6bd1432da69d3","type":"GENE","name":"MIR4477B","canonical_id":"hgnc:HGNC:41898","description":"microRNA 4477b","metadata":{"aliases":["hsa-mir-4477b"]}},{"id":"3a033661b06c436a8279054502200768","type":"GENE","name":"MIR4478","canonical_id":"hgnc:HGNC:41759","description":"microRNA 4478","metadata":{"aliases":["hsa-mir-4478"]}},{"id":"62f21a1db46145df99f6fb36dca3df67","type":"GENE","name":"MIR4479","canonical_id":"hgnc:HGNC:41767","description":"microRNA 4479","metadata":{"aliases":["hsa-mir-4479"]}},{"id":"5328b033f6e64ba2bee518f5a41a516c","type":"GENE","name":"MIR448","canonical_id":"hgnc:HGNC:26069","description":"microRNA 448","metadata":{"aliases":["hsa-mir-448","MIRN448"]}},{"id":"a584f0a79009415da29176bc7a354067","type":"GENE","name":"MIR4480","canonical_id":"hgnc:HGNC:41716","description":"microRNA 4480","metadata":{"aliases":["hsa-mir-4480"]}},{"id":"3cd862a459a040948cb80440954dbeba","type":"GENE","name":"MIR4481","canonical_id":"hgnc:HGNC:41781","description":"microRNA 4481","metadata":{"aliases":["hsa-mir-4481"]}},{"id":"244a6e1bf1614b6085d0435b127eb43f","type":"GENE","name":"MIR4482","canonical_id":"hgnc:HGNC:41792","description":"microRNA 4482","metadata":{"aliases":["hsa-mir-4482","MIR4482-1"]}},{"id":"b783c7532ac1486a9a9bc7cface44908","type":"GENE","name":"MIR4483","canonical_id":"hgnc:HGNC:41761","description":"microRNA 4483","metadata":{"aliases":["hsa-mir-4483"]}},{"id":"9aafd53566c846c3befd622a360ad618","type":"GENE","name":"MIR4484","canonical_id":"hgnc:HGNC:41799","description":"microRNA 4484","metadata":{"aliases":["hsa-mir-4484"]}},{"id":"7f741049a58e40bd902faea2751395b8","type":"GENE","name":"MIR4485","canonical_id":"hgnc:HGNC:41628","description":"microRNA 4485","metadata":{"aliases":["hsa-mir-4485"]}},{"id":"821a590a2f964680af509b57355c3b70","type":"GENE","name":"MIR4486","canonical_id":"hgnc:HGNC:41566","description":"microRNA 4486","metadata":{"aliases":["hsa-mir-4486"]}},{"id":"2ca46e4cc275478484ec335140c17ccb","type":"GENE","name":"MIR4487","canonical_id":"hgnc:HGNC:41851","description":"microRNA 4487","metadata":{"aliases":["hsa-mir-4487"]}},{"id":"8c7ac4b7340743b5b076da5dc09f13e0","type":"GENE","name":"MIR4488","canonical_id":"hgnc:HGNC:41599","description":"microRNA 4488","metadata":{"aliases":["hsa-mir-4488"]}},{"id":"ec2e8631d1e24f8c88818579f722c023","type":"GENE","name":"MIR4489","canonical_id":"hgnc:HGNC:41685","description":"microRNA 4489","metadata":{"aliases":["hsa-mir-4489"]}},{"id":"8e73736cd69d48b4914b3d95171f3623","type":"GENE","name":"MIR4490","canonical_id":"hgnc:HGNC:41871","description":"microRNA 4490","metadata":{"aliases":["hsa-mir-4490"]}},{"id":"d2e0dbe3b704487da5b3533308e3c5eb","type":"GENE","name":"MIR4491","canonical_id":"hgnc:HGNC:41808","description":"microRNA 4491","metadata":{"aliases":["hsa-mir-4491"]}},{"id":"8f06cdbf8bb443478064b5e499c75e86","type":"GENE","name":"MIR4492","canonical_id":"hgnc:HGNC:41563","description":"microRNA 4492","metadata":{"aliases":["hsa-mir-4492"]}},{"id":"9d96b8dd844d4bd6a30be92b9c749c32","type":"GENE","name":"MIR4493","canonical_id":"hgnc:HGNC:41778","description":"microRNA 4493","metadata":{"aliases":["hsa-mir-4493"]}},{"id":"3dd642566cf74853a3931418c43939b8","type":"GENE","name":"MIR4494","canonical_id":"hgnc:HGNC:41731","description":"microRNA 4494","metadata":{"aliases":["hsa-mir-4494"]}},{"id":"6ac8c4cdfa8c4b4c9d8cbb20cfcc96fa","type":"GENE","name":"MIR4495","canonical_id":"hgnc:HGNC:41693","description":"microRNA 4495","metadata":{"aliases":["hsa-mir-4495"]}},{"id":"84053a8232a9434b8d381fb2221eb95d","type":"GENE","name":"MIR4496","canonical_id":"hgnc:HGNC:41569","description":"microRNA 4496","metadata":{"aliases":["hsa-mir-4496"]}},{"id":"912787b9b02b443eb12db841850f8929","type":"GENE","name":"MIR4497","canonical_id":"hgnc:HGNC:41737","description":"microRNA 4497","metadata":{"aliases":["hsa-mir-4497"]}},{"id":"5b5ee1a9ad9f4b57bbc7f2e215b932db","type":"GENE","name":"MIR4498","canonical_id":"hgnc:HGNC:41838","description":"microRNA 4498","metadata":{"aliases":["hsa-mir-4498"]}},{"id":"40573c062d3642f88b43ac3a56e78235","type":"GENE","name":"MIR4499","canonical_id":"hgnc:HGNC:41739","description":"microRNA 4499","metadata":{"aliases":["hsa-mir-4499"]}},{"id":"00192afdccbd42aeb25f89682567460b","type":"GENE","name":"MIR449A","canonical_id":"hgnc:HGNC:27645","description":"microRNA 449a","metadata":{"aliases":["hsa-mir-449","hsa-mir-449a","MIRN449","MIRN449A"]}},{"id":"8c99744151a24d35bfb4c195f3f924b7","type":"GENE","name":"MIR449B","canonical_id":"hgnc:HGNC:32794","description":"microRNA 449b","metadata":{"aliases":["hsa-mir-449b","MIRN449B"]}},{"id":"db07c435cef74b6293795dff81bd1420","type":"GENE","name":"MIR449C","canonical_id":"hgnc:HGNC:37302","description":"microRNA 449c","metadata":{"aliases":["hsa-mir-449c"]}},{"id":"5c54c2ba94f242a2bd9ca94dc02816a3","type":"GENE","name":"MIR4500","canonical_id":"hgnc:HGNC:41853","description":"microRNA 4500","metadata":{"aliases":["hsa-mir-4500"]}},{"id":"ea4fb6a238e447bb973934780da303a2","type":"GENE","name":"MIR4500HG","canonical_id":"hgnc:HGNC:42773","description":"MIR4500 host gene","metadata":null},{"id":"1c207fad790445a1813ed4092e55693c","type":"GENE","name":"MIR4501","canonical_id":"hgnc:HGNC:41650","description":"microRNA 4501","metadata":{"aliases":["hsa-mir-4501"]}},{"id":"a6c46db7f66c435db65fdd7e131fd9b9","type":"GENE","name":"MIR4502","canonical_id":"hgnc:HGNC:41534","description":"microRNA 4502","metadata":{"aliases":["hsa-mir-4502"]}},{"id":"3b6cb6eed8004ae0b6193fe8a7c90506","type":"GENE","name":"MIR4503","canonical_id":"hgnc:HGNC:41675","description":"microRNA 4503","metadata":{"aliases":["hsa-mir-4503"]}},{"id":"f01479e59261416fbe7351b41f413269","type":"GENE","name":"MIR4504","canonical_id":"hgnc:HGNC:41624","description":"microRNA 4504","metadata":{"aliases":["hsa-mir-4504"]}},{"id":"0311bd4fd4f24b0580c86f4bcfe3ef5d","type":"GENE","name":"MIR4505","canonical_id":"hgnc:HGNC:41743","description":"microRNA 4505","metadata":{"aliases":["hsa-mir-4505"]}},{"id":"33fc48bc03714279a40ff2acf4707a01","type":"GENE","name":"MIR4506","canonical_id":"hgnc:HGNC:41663","description":"microRNA 4506","metadata":{"aliases":["hsa-mir-4506"]}},{"id":"9aee1c1ebd0f4f21ae9a3f0639596574","type":"GENE","name":"MIR4507","canonical_id":"hgnc:HGNC:41642","description":"microRNA 4507","metadata":{"aliases":["hsa-mir-4507"]}},{"id":"8297c1f86188465ba57b24e5d70f4e37","type":"GENE","name":"MIR4508","canonical_id":"hgnc:HGNC:41659","description":"microRNA 4508","metadata":{"aliases":["hsa-mir-4508"]}},{"id":"8b2263cd4b0a4f0584299d1ea1d73209","type":"GENE","name":"MIR4509-1","canonical_id":"hgnc:HGNC:41860","description":"microRNA 4509-1","metadata":{"aliases":["hsa-mir-4509-1"]}},{"id":"e35b256cb9d843408500c39fd7c4e380","type":"GENE","name":"MIR4509-2","canonical_id":"hgnc:HGNC:41537","description":"microRNA 4509-2","metadata":{"aliases":["hsa-mir-4509-2"]}},{"id":"cd0e56336cd74cb69f106d043d91d098","type":"GENE","name":"MIR4509-3","canonical_id":"hgnc:HGNC:41610","description":"microRNA 4509-3","metadata":{"aliases":["hsa-mir-4509-3"]}},{"id":"a958ad13cda745529450cedc39535ccc","type":"GENE","name":"MIR450A1","canonical_id":"hgnc:HGNC:28008","description":"microRNA 450a-1","metadata":{"aliases":["hsa-mir-450","hsa-mir-450-1","hsa-mir-450a-1","MIRN450","MIRN450-1","MIRN450A1"]}},{"id":"140208fb2f714749800b3ad5a341f6b0","type":"GENE","name":"MIR450A2","canonical_id":"hgnc:HGNC:32137","description":"microRNA 450a-2","metadata":{"aliases":["hsa-mir-450-2","hsa-mir-450a-2","MIRN450-2","MIRN450A2"]}},{"id":"f9da817ac36947b69240d53cdbca64f5","type":"GENE","name":"MIR450B","canonical_id":"hgnc:HGNC:33642","description":"microRNA 450b","metadata":{"aliases":["hsa-mir-450b","MIRN450B"]}},{"id":"ddeee4a014974c9587cc90a17c9eb4e2","type":"GENE","name":"MIR4510","canonical_id":"hgnc:HGNC:41708","description":"microRNA 4510","metadata":{"aliases":["hsa-mir-4510"]}},{"id":"de8b48ff16814e84ad83bdd5e2a1373d","type":"GENE","name":"MIR4511","canonical_id":"hgnc:HGNC:41589","description":"microRNA 4511","metadata":{"aliases":["hsa-mir-4511"]}},{"id":"148ff23464144c20b0d9eee04500a518","type":"GENE","name":"MIR4512","canonical_id":"hgnc:HGNC:41701","description":"microRNA 4512","metadata":{"aliases":["hsa-mir-4512"]}},{"id":"05111557ce5d4406b10cd7f8da2069d3","type":"GENE","name":"MIR4513","canonical_id":"hgnc:HGNC:41855","description":"microRNA 4513","metadata":{"aliases":["hsa-mir-4513"]}},{"id":"354b82e110934412bd53a006a1f0796f","type":"GENE","name":"MIR4514","canonical_id":"hgnc:HGNC:41845","description":"microRNA 4514","metadata":{"aliases":["hsa-mir-4514"]}},{"id":"82de30e3b6824728b86ebce844595e80","type":"GENE","name":"MIR4515","canonical_id":"hgnc:HGNC:41800","description":"microRNA 4515","metadata":{"aliases":["hsa-mir-4515"]}},{"id":"58d5b57543544967a3c1a82dd5a9984c","type":"GENE","name":"MIR4516","canonical_id":"hgnc:HGNC:41617","description":"microRNA 4516","metadata":{"aliases":["hsa-mir-4516"]}},{"id":"61cfae6102a04e62a665498f8dc96a6c","type":"GENE","name":"MIR4517","canonical_id":"hgnc:HGNC:41878","description":"microRNA 4517","metadata":{"aliases":["hsa-mir-4517"]}},{"id":"9d9e05551220426699c594330a4003b6","type":"GENE","name":"MIR4518","canonical_id":"hgnc:HGNC:41809","description":"microRNA 4518","metadata":{"aliases":["hsa-mir-4518"]}},{"id":"0385a1ffade343538e71a0f7d0185207","type":"GENE","name":"MIR4519","canonical_id":"hgnc:HGNC:41544","description":"microRNA 4519","metadata":{"aliases":["hsa-mir-4519"]}},{"id":"1e14e31537ad4f5a9ab5027decd1c49d","type":"GENE","name":"MIR451A","canonical_id":"hgnc:HGNC:32053","description":"microRNA 451a","metadata":{"aliases":["hsa-mir-451","MIRN451","MIR451"]}},{"id":"9282d0e36fd948b580bac8ed6c92a2c1","type":"GENE","name":"MIR451B","canonical_id":"hgnc:HGNC:41655","description":"microRNA 451b","metadata":{"aliases":["hsa-mir-451b"]}},{"id":"988f757093bc48b1bbeccc5f79979844","type":"GENE","name":"MIR452","canonical_id":"hgnc:HGNC:32054","description":"microRNA 452","metadata":{"aliases":["hsa-mir-452","MIRN452"]}},{"id":"e1cbe479eea94a89aff85470cb4fa355","type":"GENE","name":"MIR4520-1","canonical_id":"hgnc:HGNC:41775","description":"microRNA 4520-1","metadata":{"aliases":["hsa-mir-4520a","MIR4520A"]}},{"id":"b0007a44f00246dca3ac76258e46c10b","type":"GENE","name":"MIR4520-2","canonical_id":"hgnc:HGNC:41839","description":"microRNA 4520-2","metadata":{"aliases":["hsa-mir-4520b","MIR4520B"]}},{"id":"1b8abfab2cd440d18fc75801b05ce838","type":"GENE","name":"MIR4521","canonical_id":"hgnc:HGNC:41813","description":"microRNA 4521","metadata":{"aliases":["hsa-mir-4521"]}},{"id":"f1087f979a0c42fdb30e8d00ff666735","type":"GENE","name":"MIR4522","canonical_id":"hgnc:HGNC:41668","description":"microRNA 4522","metadata":{"aliases":["hsa-mir-4522"]}},{"id":"7680882ab46b4ed199db22695e62d3a4","type":"GENE","name":"MIR4523","canonical_id":"hgnc:HGNC:41583","description":"microRNA 4523","metadata":{"aliases":["hsa-mir-4523"]}},{"id":"84bee998022f416cabbadab5ff043fca","type":"GENE","name":"MIR4524A","canonical_id":"hgnc:HGNC:41771","description":"microRNA 4524a","metadata":{"aliases":["hsa-mir-4524","MIR4524"]}},{"id":"6b244c771750450a8000517f0d11f976","type":"GENE","name":"MIR4524B","canonical_id":"hgnc:HGNC:43520","description":"microRNA 4524b","metadata":{"aliases":["hsa-mir-4524b"]}},{"id":"823a072bd1d34a9e9da74500f374edeb","type":"GENE","name":"MIR4525","canonical_id":"hgnc:HGNC:41903","description":"microRNA 4525","metadata":{"aliases":["hsa-mir-4525"]}},{"id":"445435e336c24c9a9f0b5187c1882265","type":"GENE","name":"MIR4526","canonical_id":"hgnc:HGNC:41618","description":"microRNA 4526","metadata":{"aliases":["hsa-mir-4526"]}},{"id":"0e6e66a3c1294057bf880940667930fa","type":"GENE","name":"MIR4527","canonical_id":"hgnc:HGNC:41633","description":"microRNA 4527","metadata":{"aliases":["hsa-mir-4527"]}},{"id":"06f334f492ac40d3a4d92cee5dd443a8","type":"GENE","name":"MIR4527HG","canonical_id":"hgnc:HGNC:31724","description":"MIR4527 host gene","metadata":null},{"id":"025ae30f5525449083de5969a9f84641","type":"GENE","name":"MIR4528","canonical_id":"hgnc:HGNC:41547","description":"microRNA 4528","metadata":{"aliases":["hsa-mir-4528"]}},{"id":"4382efcbee0143bdbf17069fe23beb04","type":"GENE","name":"MIR4529","canonical_id":"hgnc:HGNC:41703","description":"microRNA 4529","metadata":{"aliases":["hsa-mir-4529"]}},{"id":"4a3e95e9b15744f2ae3f064acc5ffc3c","type":"GENE","name":"MIR4530","canonical_id":"hgnc:HGNC:41764","description":"microRNA 4530","metadata":{"aliases":["hsa-mir-4530"]}},{"id":"9de72a529dcd40d59770fc378fa2b6d2","type":"GENE","name":"MIR4531","canonical_id":"hgnc:HGNC:41872","description":"microRNA 4531","metadata":{"aliases":["hsa-mir-4531"]}},{"id":"819f7f4115f846b691f843f834084182","type":"GENE","name":"MIR4533","canonical_id":"hgnc:HGNC:41886","description":"microRNA 4533","metadata":{"aliases":["hsa-mir-4533"]}},{"id":"88115001dc95483dbff6fc7f7d199bb4","type":"GENE","name":"MIR4534","canonical_id":"hgnc:HGNC:41692","description":"microRNA 4534","metadata":{"aliases":["hsa-mir-4534"]}},{"id":"8eccfb44f8114094a2abc876c06c9e5a","type":"GENE","name":"MIR4535","canonical_id":"hgnc:HGNC:41629","description":"microRNA 4535","metadata":{"aliases":["hsa-mir-4535"]}},{"id":"061c2f2e07714e0191674c9f3189b3fe","type":"GENE","name":"MIR4536-1","canonical_id":"hgnc:HGNC:41730","description":"microRNA 4536-1","metadata":{"aliases":["hsa-mir-4536","MIR4536"]}},{"id":"a6817c7b30e04624951da347ba650a6e","type":"GENE","name":"MIR4536-2","canonical_id":"hgnc:HGNC:43525","description":"microRNA 4536-2","metadata":{"aliases":["hsa-mir-4536-2"]}},{"id":"00373e4a30a94988af52b101c5340e43","type":"GENE","name":"MIR4537","canonical_id":"hgnc:HGNC:41682","description":"microRNA 4537","metadata":{"aliases":["hsa-mir-4537"]}},{"id":"8bc2c655f89a41438486cf2f4402f685","type":"GENE","name":"MIR4538","canonical_id":"hgnc:HGNC:41664","description":"microRNA 4538","metadata":{"aliases":["hsa-mir-4538"]}},{"id":"7335dab09c594da0a362069f66f1906a","type":"GENE","name":"MIR4539","canonical_id":"hgnc:HGNC:41546","description":"microRNA 4539","metadata":{"aliases":["hsa-mir-4539"]}},{"id":"da335a4b2ead408f9898d835be4f64a3","type":"GENE","name":"MIR454","canonical_id":"hgnc:HGNC:33137","description":"microRNA 454","metadata":{"aliases":["hsa-mir-454","MIRN454"]}},{"id":"b11921f37a9f4d41ad38eedcf3b84b50","type":"GENE","name":"MIR4540","canonical_id":"hgnc:HGNC:41670","description":"microRNA 4540","metadata":{"aliases":["hsa-mir-4540"]}},{"id":"f2f8fd34023a4706baf32b2c7313666b","type":"GENE","name":"MIR455","canonical_id":"hgnc:HGNC:32344","description":"microRNA 455","metadata":{"aliases":["hsa-mir-455","MIRN455"]}},{"id":"3fc521b51c8c4b2f9183bc1927a9b812","type":"GENE","name":"MIR4632","canonical_id":"hgnc:HGNC:41593","description":"microRNA 4632","metadata":{"aliases":["hsa-mir-4632"]}},{"id":"7276ef4ec3764a8682556856b5fac548","type":"GENE","name":"MIR4633","canonical_id":"hgnc:HGNC:41822","description":"microRNA 4633","metadata":{"aliases":["hsa-mir-4633"]}},{"id":"ddaae3b7b62748c7b1af1c41c0a73227","type":"GENE","name":"MIR4634","canonical_id":"hgnc:HGNC:41559","description":"microRNA 4634","metadata":{"aliases":["hsa-mir-4634"]}},{"id":"0add6a376a74427dbc3a5bc41799d86d","type":"GENE","name":"MIR4635","canonical_id":"hgnc:HGNC:41748","description":"microRNA 4635","metadata":{"aliases":["hsa-mir-4635"]}},{"id":"ef07be808c5149759459df8a8231dc53","type":"GENE","name":"MIR4636","canonical_id":"hgnc:HGNC:41798","description":"microRNA 4636","metadata":{"aliases":["hsa-mir-4636"]}},{"id":"c18337747eaa4bf8821ffe2e77a768ba","type":"GENE","name":"MIR4637","canonical_id":"hgnc:HGNC:41651","description":"microRNA 4637","metadata":{"aliases":["hsa-mir-4637"]}},{"id":"dc1e00cd368a40c6bab2afc64f4944cf","type":"GENE","name":"MIR4638","canonical_id":"hgnc:HGNC:41841","description":"microRNA 4638","metadata":{"aliases":["hsa-mir-4638"]}},{"id":"70e6bf92ef4844bdbd3744e8d8c3715d","type":"GENE","name":"MIR4639","canonical_id":"hgnc:HGNC:41645","description":"microRNA 4639","metadata":{"aliases":["hsa-mir-4639"]}},{"id":"166e2a2a29654c36801ad10bdfb22a1c","type":"GENE","name":"MIR4640","canonical_id":"hgnc:HGNC:41561","description":"microRNA 4640","metadata":{"aliases":["hsa-mir-4640"]}},{"id":"8329f3744b58449b979f888f68f06383","type":"GENE","name":"MIR4641","canonical_id":"hgnc:HGNC:41835","description":"microRNA 4641","metadata":{"aliases":["hsa-mir-4641"]}},{"id":"b4e6fe6d00b64d8f8f88d47c07d677d3","type":"GENE","name":"MIR4642","canonical_id":"hgnc:HGNC:41865","description":"microRNA 4642","metadata":{"aliases":["hsa-mir-4642"]}},{"id":"ccf0e0e717b048e7b658f9f096869cf8","type":"GENE","name":"MIR4643","canonical_id":"hgnc:HGNC:41814","description":"microRNA 4643","metadata":{"aliases":["hsa-mir-4643"]}},{"id":"2c85b87a8fc24204ac84d3caa5551fe5","type":"GENE","name":"MIR4644","canonical_id":"hgnc:HGNC:41687","description":"microRNA 4644","metadata":{"aliases":["hsa-mir-4644"]}},{"id":"c95c25a8de5642859c695ad31b02a1c6","type":"GENE","name":"MIR4645","canonical_id":"hgnc:HGNC:41689","description":"microRNA 4645","metadata":{"aliases":["hsa-mir-4645"]}},{"id":"23802223a717476498a97ea8b20cf9d8","type":"GENE","name":"MIR4646","canonical_id":"hgnc:HGNC:41543","description":"microRNA 4646","metadata":{"aliases":["hsa-mir-4646"]}},{"id":"67cf903ce8a34468a7e1347224061cea","type":"GENE","name":"MIR4647","canonical_id":"hgnc:HGNC:41594","description":"microRNA 4647","metadata":{"aliases":["hsa-mir-4647"]}},{"id":"538f63a43bca49ccb675b52f9e43eaea","type":"GENE","name":"MIR4648","canonical_id":"hgnc:HGNC:41560","description":"microRNA 4648","metadata":{"aliases":["hsa-mir-4648"]}},{"id":"118cb9f27f5c44b3a49f1d9ea86d815f","type":"GENE","name":"MIR4649","canonical_id":"hgnc:HGNC:41852","description":"microRNA 4649","metadata":{"aliases":["hsa-mir-4649"]}},{"id":"2dd8fefc4b2447bd90022cc57997b624","type":"GENE","name":"MIR4650-1","canonical_id":"hgnc:HGNC:41755","description":"microRNA 4650-1","metadata":{"aliases":["hsa-mir-4650-1"]}},{"id":"1aeec369bfaa45238d641399d9fbf029","type":"GENE","name":"MIR4650-2","canonical_id":"hgnc:HGNC:41810","description":"microRNA 4650-2","metadata":{"aliases":["hsa-mir-4650-2"]}},{"id":"bd99d97e827c417e857f79b476e79848","type":"GENE","name":"MIR4651","canonical_id":"hgnc:HGNC:41647","description":"microRNA 4651","metadata":{"aliases":["hsa-mir-4651"]}},{"id":"a24571e5bf374de28d9221255ccaface","type":"GENE","name":"MIR4652","canonical_id":"hgnc:HGNC:41615","description":"microRNA 4652","metadata":{"aliases":["hsa-mir-4652"]}},{"id":"d426410074ea4dc2bf65e3fe52e5045e","type":"GENE","name":"MIR4653","canonical_id":"hgnc:HGNC:41562","description":"microRNA 4653","metadata":{"aliases":["hsa-mir-4653"]}},{"id":"71aba69ea23048df9b49ecc95370f319","type":"GENE","name":"MIR4654","canonical_id":"hgnc:HGNC:41643","description":"microRNA 4654","metadata":{"aliases":["hsa-mir-4654"]}},{"id":"491f4ecb0f1240849aee8c75a9b79355","type":"GENE","name":"MIR4655","canonical_id":"hgnc:HGNC:41754","description":"microRNA 4655","metadata":{"aliases":["hsa-mir-4655"]}},{"id":"f9ecf15342b64549a92193855c4736ec","type":"GENE","name":"MIR4656","canonical_id":"hgnc:HGNC:41749","description":"microRNA 4656","metadata":{"aliases":["hsa-mir-4656"]}},{"id":"fd9e17a90c15437fbac90f972fd1ba5b","type":"GENE","name":"MIR4657","canonical_id":"hgnc:HGNC:41706","description":"microRNA 4657","metadata":{"aliases":["hsa-mir-4657"]}},{"id":"7ef02afe388043c2aa30bc4743c863fe","type":"GENE","name":"MIR4658","canonical_id":"hgnc:HGNC:41673","description":"microRNA 4658","metadata":{"aliases":["hsa-mir-4658"]}},{"id":"00e078f82de84f94b82fd6571ae8025b","type":"GENE","name":"MIR4659A","canonical_id":"hgnc:HGNC:41857","description":"microRNA 4659a","metadata":{"aliases":["hsa-mir-4659a"]}},{"id":"05720779f7e84d62921f97b1246ba0d2","type":"GENE","name":"MIR4659B","canonical_id":"hgnc:HGNC:41530","description":"microRNA 4659b","metadata":{"aliases":["hsa-mir-4659b"]}},{"id":"4d355cc8e87c44eabff5aaa388352d84","type":"GENE","name":"MIR466","canonical_id":"hgnc:HGNC:38359","description":"microRNA 466","metadata":{"aliases":["hsa-mir-466"]}},{"id":"7747b26ba2514e979e4e9e7e517c4a58","type":"GENE","name":"MIR4660","canonical_id":"hgnc:HGNC:41861","description":"microRNA 4660","metadata":{"aliases":["hsa-mir-4660"]}},{"id":"1b5dc7d2136f410287aca1629f31fa66","type":"GENE","name":"MIR4661","canonical_id":"hgnc:HGNC:41582","description":"microRNA 4661","metadata":{"aliases":["hsa-mir-4661"]}},{"id":"c933ad1fbafb450d9464e52fa89e2d95","type":"GENE","name":"MIR4662A","canonical_id":"hgnc:HGNC:41826","description":"microRNA 4662a","metadata":{"aliases":["hsa-mir-4662a"]}},{"id":"72aa4680769a48988ca8b9caf6c20aae","type":"GENE","name":"MIR4662B","canonical_id":"hgnc:HGNC:41607","description":"microRNA 4662b","metadata":{"aliases":["hsa-mir-4662b"]}},{"id":"050e9764a3f34302955e0d0fd75b22a4","type":"GENE","name":"MIR4663","canonical_id":"hgnc:HGNC:41623","description":"microRNA 4663","metadata":{"aliases":["hsa-mir-4663"]}},{"id":"5d14598cd74c4b0d8776290ad1b95791","type":"GENE","name":"MIR4664","canonical_id":"hgnc:HGNC:41777","description":"microRNA 4664","metadata":{"aliases":["hsa-mir-4664"]}},{"id":"98c8e22eae94465899e7af2515bcb904","type":"GENE","name":"MIR4665","canonical_id":"hgnc:HGNC:41696","description":"microRNA 4665","metadata":{"aliases":["hsa-mir-4665"]}},{"id":"841b410a7d3f4d96ad447d748e9818c0","type":"GENE","name":"MIR4666A","canonical_id":"hgnc:HGNC:41750","description":"microRNA 4666a","metadata":{"aliases":["hsa-mir-4666","MIR4666"]}},{"id":"cc5c80a19423473fa8fb19ebf7cb1a4e","type":"GENE","name":"MIR4666B","canonical_id":"hgnc:HGNC:43486","description":"microRNA 4666b","metadata":{"aliases":["hsa-mir-4666b"]}},{"id":"70dfd20c930c45b481435cf58a75b3d9","type":"GENE","name":"MIR4667","canonical_id":"hgnc:HGNC:41723","description":"microRNA 4667","metadata":{"aliases":["hsa-mir-4667"]}},{"id":"03a582d8871748449868e00a395edd49","type":"GENE","name":"MIR4668","canonical_id":"hgnc:HGNC:41545","description":"microRNA 4668","metadata":{"aliases":["hsa-mir-4668"]}},{"id":"fbc23e45d79b48f082ffa4ce464db9ab","type":"GENE","name":"MIR4669","canonical_id":"hgnc:HGNC:41558","description":"microRNA 4669","metadata":{"aliases":["hsa-mir-4669"]}},{"id":"8b7b52e8b94d4b43a376411c0b919fe6","type":"GENE","name":"MIR4670","canonical_id":"hgnc:HGNC:41862","description":"microRNA 4670","metadata":{"aliases":["hsa-mir-4670"]}},{"id":"1f081b5d241249c48acf4f91cef1e625","type":"GENE","name":"MIR4671","canonical_id":"hgnc:HGNC:41598","description":"microRNA 4671","metadata":{"aliases":["hsa-mir-4671"]}},{"id":"d2debbb91a804519a8b18d1ac388c2ab","type":"GENE","name":"MIR4672","canonical_id":"hgnc:HGNC:41662","description":"microRNA 4672","metadata":{"aliases":["hsa-mir-4672"]}},{"id":"bda6c10c20cd4d67a7c235770e3cf2ac","type":"GENE","name":"MIR4673","canonical_id":"hgnc:HGNC:41574","description":"microRNA 4673","metadata":{"aliases":["hsa-mir-4673"]}},{"id":"a5008d1116524db6b6b85a5e8f455944","type":"GENE","name":"MIR4674","canonical_id":"hgnc:HGNC:41729","description":"microRNA 4674","metadata":{"aliases":["hsa-mir-4674"]}},{"id":"813306e0f91941259afd7b9d85e78a91","type":"GENE","name":"MIR4675","canonical_id":"hgnc:HGNC:41619","description":"microRNA 4675","metadata":{"aliases":["hsa-mir-4675"]}},{"id":"b47042db816943a48be936dd776b3d2a","type":"GENE","name":"MIR4676","canonical_id":"hgnc:HGNC:41691","description":"microRNA 4676","metadata":{"aliases":["hsa-mir-4676"]}},{"id":"ea41991f22e6459aa5ba189d0f1efe39","type":"GENE","name":"MIR4677","canonical_id":"hgnc:HGNC:41844","description":"microRNA 4677","metadata":{"aliases":["hsa-mir-4677"]}},{"id":"97e3c3717273490a9d59db7e581544d5","type":"GENE","name":"MIR4678","canonical_id":"hgnc:HGNC:41717","description":"microRNA 4678","metadata":{"aliases":["hsa-mir-4678"]}},{"id":"147c59c00978455f93facef64acff977","type":"GENE","name":"MIR4679-1","canonical_id":"hgnc:HGNC:41612","description":"microRNA 4679-1","metadata":{"aliases":["hsa-mir-4679-1"]}},{"id":"7abd4951621f4095abeaf9a72b1e275d","type":"GENE","name":"MIR4679-2","canonical_id":"hgnc:HGNC:41890","description":"microRNA 4679-2","metadata":{"aliases":["hsa-mir-4679-2"]}},{"id":"6fe35a69876f4e2d9085e7ddedaa1f65","type":"GENE","name":"MIR4680","canonical_id":"hgnc:HGNC:41541","description":"microRNA 4680","metadata":{"aliases":["hsa-mir-4680"]}},{"id":"90e7ee581b83459b93dc725ad2a28242","type":"GENE","name":"MIR4681","canonical_id":"hgnc:HGNC:41753","description":"microRNA 4681","metadata":{"aliases":["hsa-mir-4681"]}},{"id":"ac167243b6c042628d3df58af81bfb33","type":"GENE","name":"MIR4682","canonical_id":"hgnc:HGNC:41788","description":"microRNA 4682","metadata":{"aliases":["hsa-mir-4682"]}},{"id":"9d8c616786db454b9c3dc97845354adf","type":"GENE","name":"MIR4683","canonical_id":"hgnc:HGNC:41883","description":"microRNA 4683","metadata":{"aliases":["hsa-mir-4683"]}},{"id":"795dd83b07834cf3acf3d9dd2b2898e4","type":"GENE","name":"MIR4684","canonical_id":"hgnc:HGNC:41695","description":"microRNA 4684","metadata":{"aliases":["hsa-mir-4684"]}},{"id":"7d2a7aa2c1c84838a3010de80223b805","type":"GENE","name":"MIR4685","canonical_id":"hgnc:HGNC:41802","description":"microRNA 4685","metadata":{"aliases":["hsa-mir-4685"]}},{"id":"1bc133ad0fa74b08ab9a19e9ff4752f7","type":"GENE","name":"MIR4686","canonical_id":"hgnc:HGNC:41601","description":"microRNA 4686","metadata":{"aliases":["hsa-mir-4686"]}},{"id":"200b23f5c5b3420dba39b575ee0d8860","type":"GENE","name":"MIR4687","canonical_id":"hgnc:HGNC:41712","description":"microRNA 4687","metadata":{"aliases":["hsa-mir-4687"]}},{"id":"6b41e9b07aac4e19a9fe1200b8c6c098","type":"GENE","name":"MIR4688","canonical_id":"hgnc:HGNC:41897","description":"microRNA 4688","metadata":{"aliases":["hsa-mir-4688"]}},{"id":"3cea993536324a56867c37a1cde4562e","type":"GENE","name":"MIR4689","canonical_id":"hgnc:HGNC:41895","description":"microRNA 4689","metadata":{"aliases":["hsa-mir-4689"]}},{"id":"7500bec9be6a4d98981c497c7a46cf1b","type":"GENE","name":"MIR4690","canonical_id":"hgnc:HGNC:41707","description":"microRNA 4690","metadata":{"aliases":["hsa-mir-4690"]}},{"id":"4fed173b68854efaaa112ceded4b6998","type":"GENE","name":"MIR4691","canonical_id":"hgnc:HGNC:41796","description":"microRNA 4691","metadata":{"aliases":["hsa-mir-4691"]}},{"id":"153d0ea9d6df49e6bb988319d0c00a07","type":"GENE","name":"MIR4692","canonical_id":"hgnc:HGNC:41856","description":"microRNA 4692","metadata":{"aliases":["hsa-mir-4692"]}},{"id":"82398a6ac34a4bde96ee82038924c772","type":"GENE","name":"MIR4693","canonical_id":"hgnc:HGNC:41818","description":"microRNA 4693","metadata":{"aliases":["hsa-mir-4693"]}},{"id":"0ea6e86f8f884297b97b9d39224ebc0b","type":"GENE","name":"MIR4694","canonical_id":"hgnc:HGNC:41586","description":"microRNA 4694","metadata":{"aliases":["hsa-mir-4694"]}},{"id":"2563db90fe3a45b3945245dbe00212de","type":"GENE","name":"MIR4695","canonical_id":"hgnc:HGNC:41573","description":"microRNA 4695","metadata":{"aliases":["hsa-mir-4695"]}},{"id":"427d562e7d154d5ea4983f944b6919b5","type":"GENE","name":"MIR4696","canonical_id":"hgnc:HGNC:41780","description":"microRNA 4696","metadata":{"aliases":["hsa-mir-4696"]}},{"id":"01691e6c25c74d77ad89e0fc1a76099f","type":"GENE","name":"MIR4697","canonical_id":"hgnc:HGNC:41570","description":"microRNA 4697","metadata":{"aliases":["hsa-mir-4697"]}},{"id":"70f3985688934d5ca8c8aa15bfd1905e","type":"GENE","name":"MIR4698","canonical_id":"hgnc:HGNC:41867","description":"microRNA 4698","metadata":{"aliases":["hsa-mir-4698"]}},{"id":"a5dc8b1690484bbcae2e2094a81f3be3","type":"GENE","name":"MIR4699","canonical_id":"hgnc:HGNC:41636","description":"microRNA 4699","metadata":{"aliases":["hsa-mir-4699"]}},{"id":"d59d6b951881475abe262b34ced80b78","type":"GENE","name":"MIR4700","canonical_id":"hgnc:HGNC:41806","description":"microRNA 4700","metadata":{"aliases":["hsa-mir-4700"]}},{"id":"a7867fdee06645faa5bee5ef96c81c0d","type":"GENE","name":"MIR4701","canonical_id":"hgnc:HGNC:41627","description":"microRNA 4701","metadata":{"aliases":["hsa-mir-4701"]}},{"id":"ad3046d643ea44c5814e7211c7c43e73","type":"GENE","name":"MIR4703","canonical_id":"hgnc:HGNC:41817","description":"microRNA 4703","metadata":{"aliases":["hsa-mir-4703"]}},{"id":"d011cf2a48f04420a60ad7a5fce5214f","type":"GENE","name":"MIR4704","canonical_id":"hgnc:HGNC:41602","description":"microRNA 4704","metadata":{"aliases":["hsa-mir-4704"]}},{"id":"d1c33985141b42068a82e65f17a9710e","type":"GENE","name":"MIR4705","canonical_id":"hgnc:HGNC:41567","description":"microRNA 4705","metadata":{"aliases":["hsa-mir-4705"]}},{"id":"7ae8df4474f8495bbf2008f0b6922107","type":"GENE","name":"MIR4706","canonical_id":"hgnc:HGNC:41576","description":"microRNA 4706","metadata":{"aliases":["hsa-mir-4706"]}},{"id":"81be3740b7094c46965957975b64a22e","type":"GENE","name":"MIR4707","canonical_id":"hgnc:HGNC:41531","description":"microRNA 4707","metadata":{"aliases":["hsa-mir-4707"]}},{"id":"57c4b2ab3a73478ba81f34b317974a99","type":"GENE","name":"MIR4708","canonical_id":"hgnc:HGNC:41824","description":"microRNA 4708","metadata":{"aliases":["hsa-mir-4708"]}},{"id":"ea9e30b08df24aaababa131ebb0f6d5c","type":"GENE","name":"MIR4709","canonical_id":"hgnc:HGNC:41690","description":"microRNA 4709","metadata":{"aliases":["hsa-mir-4709"]}},{"id":"e70149b3cdfe4a43865a2762ed1e59a0","type":"GENE","name":"MIR4710","canonical_id":"hgnc:HGNC:41727","description":"microRNA 4710","metadata":{"aliases":["hsa-mir-4710"]}},{"id":"e860c8d982bd4d198f1790da11058542","type":"GENE","name":"MIR4711","canonical_id":"hgnc:HGNC:41847","description":"microRNA 4711","metadata":{"aliases":["hsa-mir-4711"]}},{"id":"d96c669b592d4ea283122a6cd5e2ea3f","type":"GENE","name":"MIR4712","canonical_id":"hgnc:HGNC:41732","description":"microRNA 4712","metadata":{"aliases":["hsa-mir-4712"]}},{"id":"a7eb4ba96e954ed1b101b5840723579e","type":"GENE","name":"MIR4713","canonical_id":"hgnc:HGNC:41899","description":"microRNA 4713","metadata":{"aliases":["hsa-mir-4713"]}},{"id":"6dbbef62c29d433da6bce94070b57e17","type":"GENE","name":"MIR4713HG","canonical_id":"hgnc:HGNC:53124","description":"MIR4713 host gene","metadata":{"aliases":["RP11-108K3.1"]}},{"id":"9e63820b8860470292b30c04983af3df","type":"GENE","name":"MIR4714","canonical_id":"hgnc:HGNC:41763","description":"microRNA 4714","metadata":{"aliases":["hsa-mir-4714"]}},{"id":"7bdb7cd2b460495ba75e7dabe5c556e9","type":"GENE","name":"MIR4715","canonical_id":"hgnc:HGNC:41666","description":"microRNA 4715","metadata":{"aliases":["hsa-mir-4715"]}},{"id":"b4cdd423fa7e4c4d8d4826d98a8219a9","type":"GENE","name":"MIR4716","canonical_id":"hgnc:HGNC:41812","description":"microRNA 4716","metadata":{"aliases":["hsa-mir-4716"]}},{"id":"b88b871b508249ff83048b91088d07a2","type":"GENE","name":"MIR4717","canonical_id":"hgnc:HGNC:41571","description":"microRNA 4717","metadata":{"aliases":["hsa-mir-4717"]}},{"id":"5b9c940830f6461192a39bbf6b9a7515","type":"GENE","name":"MIR4718","canonical_id":"hgnc:HGNC:41900","description":"microRNA 4718","metadata":{"aliases":["hsa-mir-4718"]}},{"id":"f5a24beb36144328981dd0f9c70e378c","type":"GENE","name":"MIR4719","canonical_id":"hgnc:HGNC:41807","description":"microRNA 4719","metadata":{"aliases":["hsa-mir-4719"]}},{"id":"5ca8a61f010740778108775eb5375998","type":"GENE","name":"MIR4720","canonical_id":"hgnc:HGNC:41705","description":"microRNA 4720","metadata":{"aliases":["hsa-mir-4720"]}},{"id":"9c00d235d705449ca5ba11ef5e245b68","type":"GENE","name":"MIR4721","canonical_id":"hgnc:HGNC:41609","description":"microRNA 4721","metadata":{"aliases":["hsa-mir-4721"]}},{"id":"ac213622f22744c69917038ac20130ab","type":"GENE","name":"MIR4722","canonical_id":"hgnc:HGNC:41782","description":"microRNA 4722","metadata":{"aliases":["hsa-mir-4722"]}},{"id":"a3245e6017044bc4adf8a24e6447ba03","type":"GENE","name":"MIR4723","canonical_id":"hgnc:HGNC:41660","description":"microRNA 4723","metadata":{"aliases":["hsa-mir-4723"]}},{"id":"2ef6e582587d4abeb8f69a6b17f5ad9c","type":"GENE","name":"MIR4724","canonical_id":"hgnc:HGNC:41590","description":"microRNA 4724","metadata":{"aliases":["hsa-mir-4724"]}},{"id":"c50cd1214a3c4759a33b34b7d45a3700","type":"GENE","name":"MIR4725","canonical_id":"hgnc:HGNC:41608","description":"microRNA 4725","metadata":{"aliases":["hsa-mir-4725"]}},{"id":"b5033e756ed045a19fcdc35afcc60912","type":"GENE","name":"MIR4726","canonical_id":"hgnc:HGNC:41722","description":"microRNA 4726","metadata":{"aliases":["hsa-mir-4726"]}},{"id":"f10a256b968a4aee9f86c4f593924fc1","type":"GENE","name":"MIR4727","canonical_id":"hgnc:HGNC:41709","description":"microRNA 4727","metadata":{"aliases":["hsa-mir-4727"]}},{"id":"2c428549d7d6419bbc6b67dab3779e05","type":"GENE","name":"MIR4728","canonical_id":"hgnc:HGNC:41632","description":"microRNA 4728","metadata":{"aliases":["hsa-mir-4728"]}},{"id":"c94568deaedd4ff3b0f145956bb7ec28","type":"GENE","name":"MIR4729","canonical_id":"hgnc:HGNC:41585","description":"microRNA 4729","metadata":{"aliases":["hsa-mir-4729"]}},{"id":"6952f0a2abfe4807b0692c2832d98067","type":"GENE","name":"MIR4730","canonical_id":"hgnc:HGNC:41880","description":"microRNA 4730","metadata":{"aliases":["hsa-mir-4730"]}},{"id":"df9ddf547e1b412b8dc180a4f387a99d","type":"GENE","name":"MIR4731","canonical_id":"hgnc:HGNC:41597","description":"microRNA 4731","metadata":{"aliases":["hsa-mir-4731"]}},{"id":"6b305f1a707044e29d291f06cd7211b2","type":"GENE","name":"MIR4732","canonical_id":"hgnc:HGNC:41639","description":"microRNA 4732","metadata":{"aliases":["hsa-mir-4732"]}},{"id":"aad9585796c64e449e0d4b6ea99b6aed","type":"GENE","name":"MIR4733","canonical_id":"hgnc:HGNC:41638","description":"microRNA 4733","metadata":{"aliases":["hsa-mir-4733"]}},{"id":"92a485a6f6b745368d1d0d1425234f26","type":"GENE","name":"MIR4733HG","canonical_id":"hgnc:HGNC:55332","description":"MIR4733 host gene","metadata":null},{"id":"2a346f9c3ff04cf4830cf0b662e14e27","type":"GENE","name":"MIR4734","canonical_id":"hgnc:HGNC:41572","description":"microRNA 4734","metadata":{"aliases":["hsa-mir-4734"]}},{"id":"7cd154dd51f74691ae27986ee538be98","type":"GENE","name":"MIR4735","canonical_id":"hgnc:HGNC:41888","description":"microRNA 4735","metadata":{"aliases":["hsa-mir-4735"]}},{"id":"24e8fb4fa73f4fac863d5cadabea5573","type":"GENE","name":"MIR4736","canonical_id":"hgnc:HGNC:41804","description":"microRNA 4736","metadata":{"aliases":["hsa-mir-4736"]}},{"id":"dc22dbd0bed744d79c9a35ec4dbf2df3","type":"GENE","name":"MIR4737","canonical_id":"hgnc:HGNC:41669","description":"microRNA 4737","metadata":{"aliases":["hsa-mir-4737"]}},{"id":"818eb24b1ae443199d719ac625242887","type":"GENE","name":"MIR4738","canonical_id":"hgnc:HGNC:41679","description":"microRNA 4738","metadata":{"aliases":["hsa-mir-4738"]}},{"id":"e58d35a81cc54ad4922d39a11c1f2ef4","type":"GENE","name":"MIR4739","canonical_id":"hgnc:HGNC:41801","description":"microRNA 4739","metadata":{"aliases":["hsa-mir-4739"]}},{"id":"d00f16061ba640718950774c1d60fa33","type":"GENE","name":"MIR4740","canonical_id":"hgnc:HGNC:41711","description":"microRNA 4740","metadata":{"aliases":["hsa-mir-4740"]}},{"id":"5d153740bddc4f4dba9f37be82107d3a","type":"GENE","name":"MIR4741","canonical_id":"hgnc:HGNC:41661","description":"microRNA 4741","metadata":{"aliases":["hsa-mir-4741"]}},{"id":"baea9b54386a4f82b909dfbbb1741436","type":"GENE","name":"MIR4742","canonical_id":"hgnc:HGNC:41565","description":"microRNA 4742","metadata":{"aliases":["hsa-mir-4742"]}},{"id":"a5ed784153ab43ee9b37b91f43fbe841","type":"GENE","name":"MIR4743","canonical_id":"hgnc:HGNC:41894","description":"microRNA 4743","metadata":{"aliases":["hsa-mir-4743"]}},{"id":"25a2e68f629d426aad04ddb1e62a4546","type":"GENE","name":"MIR4744","canonical_id":"hgnc:HGNC:41866","description":"microRNA 4744","metadata":{"aliases":["hsa-mir-4744"]}},{"id":"47d84c604ea0483582b843064373a767","type":"GENE","name":"MIR4745","canonical_id":"hgnc:HGNC:41868","description":"microRNA 4745","metadata":{"aliases":["hsa-mir-4745"]}},{"id":"167da8781bee435a95331f833f16a57c","type":"GENE","name":"MIR4746","canonical_id":"hgnc:HGNC:41904","description":"microRNA 4746","metadata":{"aliases":["hsa-mir-4746"]}},{"id":"c24f2d185a1a4c78b1aeab08e8e4aa8e","type":"GENE","name":"MIR4747","canonical_id":"hgnc:HGNC:41827","description":"microRNA 4747","metadata":{"aliases":["hsa-mir-4747"]}},{"id":"d44c1c4a7fca427bb066653de4f19624","type":"GENE","name":"MIR4748","canonical_id":"hgnc:HGNC:41557","description":"microRNA 4748","metadata":{"aliases":["hsa-mir-4748"]}},{"id":"87dc716a4c514acc90a07dd487f132b8","type":"GENE","name":"MIR4749","canonical_id":"hgnc:HGNC:41760","description":"microRNA 4749","metadata":{"aliases":["hsa-mir-4749"]}},{"id":"8f1667d95c154448809564f771cab8ba","type":"GENE","name":"MIR4750","canonical_id":"hgnc:HGNC:41765","description":"microRNA 4750","metadata":{"aliases":["hsa-mir-4750"]}},{"id":"f791f445e2494dfba2154dec15f6e2ad","type":"GENE","name":"MIR4751","canonical_id":"hgnc:HGNC:41819","description":"microRNA 4751","metadata":{"aliases":["hsa-mir-4751"]}},{"id":"5e782b108a8a4c2e991088d91eb1a339","type":"GENE","name":"MIR4752","canonical_id":"hgnc:HGNC:41803","description":"microRNA 4752","metadata":{"aliases":["hsa-mir-4752"]}},{"id":"782311027fae41148d587d6a6d86caa6","type":"GENE","name":"MIR4753","canonical_id":"hgnc:HGNC:41527","description":"microRNA 4753","metadata":{"aliases":["hsa-mir-4753"]}},{"id":"507c6eafb4034eb3a7eef9c4209aa5c4","type":"GENE","name":"MIR4754","canonical_id":"hgnc:HGNC:41786","description":"microRNA 4754","metadata":{"aliases":["hsa-mir-4754"]}},{"id":"23e07ace40544f5cad7137665accb8ac","type":"GENE","name":"MIR4755","canonical_id":"hgnc:HGNC:41815","description":"microRNA 4755","metadata":{"aliases":["hsa-mir-4755"]}},{"id":"35ee83ce55b74ff1b2c81de17471a854","type":"GENE","name":"MIR4756","canonical_id":"hgnc:HGNC:41529","description":"microRNA 4756","metadata":{"aliases":["hsa-mir-4756"]}},{"id":"3d641cac209346b19344365e876776bc","type":"GENE","name":"MIR4757","canonical_id":"hgnc:HGNC:41746","description":"microRNA 4757","metadata":{"aliases":["hsa-mir-4757"]}},{"id":"ba286674bb744c6b983b912e96555935","type":"GENE","name":"MIR4758","canonical_id":"hgnc:HGNC:41836","description":"microRNA 4758","metadata":{"aliases":["hsa-mir-4758"]}},{"id":"704d9b7f67ff4d4fa5aa99691da1c4a3","type":"GENE","name":"MIR4759","canonical_id":"hgnc:HGNC:41575","description":"microRNA 4759","metadata":{"aliases":["hsa-mir-4759"]}},{"id":"24ca39975215497aa840222bae5860c5","type":"GENE","name":"MIR4760","canonical_id":"hgnc:HGNC:41698","description":"microRNA 4760","metadata":{"aliases":["hsa-mir-4760"]}},{"id":"f5a3e331a80d414fb4c4f10a935f4dc0","type":"GENE","name":"MIR4761","canonical_id":"hgnc:HGNC:41591","description":"microRNA 4761","metadata":{"aliases":["hsa-mir-4761"]}},{"id":"38111e54a49244f0a2a9fe4fe3777606","type":"GENE","name":"MIR4762","canonical_id":"hgnc:HGNC:41603","description":"microRNA 4762","metadata":{"aliases":["hsa-mir-4762"]}},{"id":"2a9cc42017594e18bf9d6532a44b0dec","type":"GENE","name":"MIR4763","canonical_id":"hgnc:HGNC:41677","description":"microRNA 4763","metadata":{"aliases":["hsa-mir-4763"]}},{"id":"5382e7232866427fbf08c56c6831fdb7","type":"GENE","name":"MIR4764","canonical_id":"hgnc:HGNC:41714","description":"microRNA 4764","metadata":{"aliases":["hsa-mir-4764"]}},{"id":"08ae9eb35acf41dc9a6fe5a10140dd52","type":"GENE","name":"MIR4765","canonical_id":"hgnc:HGNC:41791","description":"microRNA 4765","metadata":{"aliases":["hsa-mir-4765"]}},{"id":"5c768915dc234ecc9c53d013d5b4836f","type":"GENE","name":"MIR4766","canonical_id":"hgnc:HGNC:41680","description":"microRNA 4766","metadata":{"aliases":["hsa-mir-4766"]}},{"id":"45be85e3560a483c8de64a6d63271dcc","type":"GENE","name":"MIR4767","canonical_id":"hgnc:HGNC:41548","description":"microRNA 4767","metadata":{"aliases":["hsa-mir-4767"]}},{"id":"332fdaab94ea4f8d820f114907770a83","type":"GENE","name":"MIR4768","canonical_id":"hgnc:HGNC:41592","description":"microRNA 4768","metadata":{"aliases":["hsa-mir-4768"]}},{"id":"2693d617346b4371a7a7aa53ad7e72b9","type":"GENE","name":"MIR4769","canonical_id":"hgnc:HGNC:41694","description":"microRNA 4769","metadata":{"aliases":["hsa-mir-4769"]}},{"id":"65c06506f21747afbcb29dd20826531f","type":"GENE","name":"MIR4770","canonical_id":"hgnc:HGNC:41542","description":"microRNA 4770","metadata":{"aliases":["hsa-mir-4770"]}},{"id":"649b745ae6bd45c9b2a82d91535c6d79","type":"GENE","name":"MIR4771-1","canonical_id":"hgnc:HGNC:41901","description":"microRNA 4771-1","metadata":{"aliases":["hsa-mir-4771-1"]}},{"id":"d07f4c4351074c638aeb6ff2f895c971","type":"GENE","name":"MIR4771-2","canonical_id":"hgnc:HGNC:41774","description":"microRNA 4771-2","metadata":{"aliases":["hsa-mir-4771-2"]}},{"id":"4199df1e65fe41dc8cae143ec9a3fca8","type":"GENE","name":"MIR4772","canonical_id":"hgnc:HGNC:41741","description":"microRNA 4772","metadata":{"aliases":["hsa-mir-4772"]}},{"id":"39b3e4d1881a43369506260d170231a7","type":"GENE","name":"MIR4773-1","canonical_id":"hgnc:HGNC:41699","description":"microRNA 4773-1","metadata":{"aliases":["hsa-mir-4773-1"]}},{"id":"0d2b8a236c7c4135b62fe8422a62ce59","type":"GENE","name":"MIR4773-2","canonical_id":"hgnc:HGNC:41790","description":"microRNA 4773-2","metadata":{"aliases":["hsa-mir-4773-2"]}},{"id":"519031d662314dfc835f7450c41d4423","type":"GENE","name":"MIR4774","canonical_id":"hgnc:HGNC:41873","description":"microRNA 4774","metadata":{"aliases":["hsa-mir-4774"]}},{"id":"34fc98fafb074dbba3cac714d5c8a171","type":"GENE","name":"MIR4775","canonical_id":"hgnc:HGNC:41885","description":"microRNA 4775","metadata":{"aliases":["hsa-mir-4775"]}},{"id":"62b97a6d46034d3d8fbbe43e95b579ae","type":"GENE","name":"MIR4776-1","canonical_id":"hgnc:HGNC:41641","description":"microRNA 4776-1","metadata":{"aliases":["hsa-mir-4776-1"]}},{"id":"dd0147c135bf48dfab24aa2a081c1a08","type":"GENE","name":"MIR4776-2","canonical_id":"hgnc:HGNC:41631","description":"microRNA 4776-2","metadata":{"aliases":["hsa-mir-4776-2"]}},{"id":"770ff47132a64a0cb68aa709059fd057","type":"GENE","name":"MIR4777","canonical_id":"hgnc:HGNC:41773","description":"microRNA 4777","metadata":{"aliases":["hsa-mir-4777"]}},{"id":"d2626d5880d44bda923723054fd3d723","type":"GENE","name":"MIR4778","canonical_id":"hgnc:HGNC:41648","description":"microRNA 4778","metadata":{"aliases":["hsa-mir-4778"]}},{"id":"fd7ca2374afc407c99fc712319b8ef40","type":"GENE","name":"MIR4779","canonical_id":"hgnc:HGNC:41747","description":"microRNA 4779","metadata":{"aliases":["hsa-mir-4779"]}},{"id":"4e329a85283c44c68706313dfb9d1389","type":"GENE","name":"MIR4780","canonical_id":"hgnc:HGNC:41552","description":"microRNA 4780","metadata":{"aliases":["hsa-mir-4780"]}},{"id":"29bd7305d5a141cf90514f6d4d54235e","type":"GENE","name":"MIR4781","canonical_id":"hgnc:HGNC:41769","description":"microRNA 4781","metadata":{"aliases":["hsa-mir-4781"]}},{"id":"a1844df76c974e71bdc4c81d65b1b147","type":"GENE","name":"MIR4782","canonical_id":"hgnc:HGNC:41635","description":"microRNA 4782","metadata":{"aliases":["hsa-mir-4782"]}},{"id":"597395cb74c2434a9d975c5359f04a33","type":"GENE","name":"MIR4783","canonical_id":"hgnc:HGNC:41874","description":"microRNA 4783","metadata":{"aliases":["hsa-mir-4783"]}},{"id":"b5f694f0c6cf471696e02f1db4e6973f","type":"GENE","name":"MIR4784","canonical_id":"hgnc:HGNC:41580","description":"microRNA 4784","metadata":{"aliases":["hsa-mir-4784"]}},{"id":"6da02f8473f84343bd2757d96f8d3485","type":"GENE","name":"MIR4785","canonical_id":"hgnc:HGNC:41889","description":"microRNA 4785","metadata":{"aliases":["hsa-mir-4785"]}},{"id":"f9ad4084e3744790be3113f6943292a1","type":"GENE","name":"MIR4786","canonical_id":"hgnc:HGNC:41751","description":"microRNA 4786","metadata":{"aliases":["hsa-mir-4786"]}},{"id":"b625922613a44f978c119b3477bf94ac","type":"GENE","name":"MIR4787","canonical_id":"hgnc:HGNC:41653","description":"microRNA 4787","metadata":{"aliases":["hsa-mir-4787"]}},{"id":"35430f7d4f014cefb7c88f6bae7751f8","type":"GENE","name":"MIR4788","canonical_id":"hgnc:HGNC:41676","description":"microRNA 4788","metadata":{"aliases":["hsa-mir-4788"]}},{"id":"391258af35fe4218ad362f7676f30ead","type":"GENE","name":"MIR4789","canonical_id":"hgnc:HGNC:41719","description":"microRNA 4789","metadata":{"aliases":["hsa-mir-4789"]}},{"id":"dab9c2fa94564042801c45192ec2c2a4","type":"GENE","name":"MIR4790","canonical_id":"hgnc:HGNC:41820","description":"microRNA 4790","metadata":{"aliases":["hsa-mir-4790"]}},{"id":"53676a42182844e185836301fce28450","type":"GENE","name":"MIR4791","canonical_id":"hgnc:HGNC:41704","description":"microRNA 4791","metadata":{"aliases":["hsa-mir-4791"]}},{"id":"db775d7cfddb4089b9739efe226c0c82","type":"GENE","name":"MIR4793","canonical_id":"hgnc:HGNC:41538","description":"microRNA 4793","metadata":{"aliases":["hsa-mir-4793"]}},{"id":"8570daeb60a54657978175e61382ba2f","type":"GENE","name":"MIR4794","canonical_id":"hgnc:HGNC:41829","description":"microRNA 4794","metadata":{"aliases":["hsa-mir-4794"]}},{"id":"d317898c10bb4883bcdfadc251bc56e3","type":"GENE","name":"MIR4795","canonical_id":"hgnc:HGNC:41757","description":"microRNA 4795","metadata":{"aliases":["hsa-mir-4795"]}},{"id":"0dcd1189f0464ec8959423a4f8e1d25d","type":"GENE","name":"MIR4796","canonical_id":"hgnc:HGNC:41779","description":"microRNA 4796","metadata":{"aliases":["hsa-mir-4796"]}},{"id":"4109af31de074900899f2785904a4c7d","type":"GENE","name":"MIR4797","canonical_id":"hgnc:HGNC:41758","description":"microRNA 4797","metadata":{"aliases":["hsa-mir-4797"]}},{"id":"49094bf95bbb4c45b5d0124b5dbc7073","type":"GENE","name":"MIR4798","canonical_id":"hgnc:HGNC:41616","description":"microRNA 4798","metadata":{"aliases":["hsa-mir-4798"]}},{"id":"00e85f6247484a1d9c0c0bdcbbd736d8","type":"GENE","name":"MIR4799","canonical_id":"hgnc:HGNC:41584","description":"microRNA 4799","metadata":{"aliases":["hsa-mir-4799"]}},{"id":"6907bd95d09e4fe28a74f53e10ad4f61","type":"GENE","name":"MIR4800","canonical_id":"hgnc:HGNC:41877","description":"microRNA 4800","metadata":{"aliases":["hsa-mir-4800"]}},{"id":"87b63b782bc948468e0b29a69861df01","type":"GENE","name":"MIR4801","canonical_id":"hgnc:HGNC:41840","description":"microRNA 4801","metadata":{"aliases":["hsa-mir-4801"]}},{"id":"c62da60b844842cfbd362867807e77be","type":"GENE","name":"MIR4802","canonical_id":"hgnc:HGNC:41658","description":"microRNA 4802","metadata":{"aliases":["hsa-mir-4802"]}},{"id":"d230bcf700da4672908f3bdb956c8dca","type":"GENE","name":"MIR4803","canonical_id":"hgnc:HGNC:41568","description":"microRNA 4803","metadata":{"aliases":["hsa-mir-4803"]}},{"id":"8621621432d7408fb9f90544b7e5c14c","type":"GENE","name":"MIR4804","canonical_id":"hgnc:HGNC:41720","description":"microRNA 4804","metadata":{"aliases":["hsa-mir-4804"]}},{"id":"777b564cfab04064bd29ffeb69b3844c","type":"GENE","name":"MIR483","canonical_id":"hgnc:HGNC:32340","description":"microRNA 483","metadata":{"aliases":["hsa-mir-483","MIRN483"]}},{"id":"3294f29f1f4744329d1505d5ab0a7e70","type":"GENE","name":"MIR484","canonical_id":"hgnc:HGNC:32341","description":"microRNA 484","metadata":{"aliases":["hsa-mir-484","MIRN484"]}},{"id":"df7fafa4918245668f8f74a3c455a79b","type":"GENE","name":"MIR485","canonical_id":"hgnc:HGNC:32067","description":"microRNA 485","metadata":{"aliases":["hsa-mir-485","MIRN485"]}},{"id":"ef499f551fd343b2a8d1c565e83e95c7","type":"GENE","name":"MIR486-1","canonical_id":"hgnc:HGNC:32342","description":"microRNA 486-1","metadata":{"aliases":["hsa-mir-486","MIRN486","MIR486"]}},{"id":"3ac566b2ceee45abb926a93cbd70fc9b","type":"GENE","name":"MIR486-2","canonical_id":"hgnc:HGNC:50213","description":"microRNA 486-2","metadata":{"aliases":["hsa-mir-486-2"]}},{"id":"182b12f6772a477993d442427fb475aa","type":"GENE","name":"MIR487A","canonical_id":"hgnc:HGNC:32343","description":"microRNA 487a","metadata":{"aliases":["hsa-mir-487","hsa-mir-487a","MIRN487","MIRN487A"]}},{"id":"230a1f7fb934463ca244080c707f8fe2","type":"GENE","name":"MIR487B","canonical_id":"hgnc:HGNC:32533","description":"microRNA 487b","metadata":{"aliases":["hsa-mir-487b","MIRN487B"]}},{"id":"188e425dc7374f6682a25af3faab6088","type":"GENE","name":"MIR488","canonical_id":"hgnc:HGNC:32073","description":"microRNA 488","metadata":{"aliases":["hsa-mir-488","MIRN488"]}},{"id":"239d1722e2bd4dc6a103b1c7ede2b693","type":"GENE","name":"MIR489","canonical_id":"hgnc:HGNC:32074","description":"microRNA 489","metadata":{"aliases":["hsa-mir-489","MIRN489"]}},{"id":"ad0e4c1425714c02bfc9310a7c45f942","type":"GENE","name":"MIR490","canonical_id":"hgnc:HGNC:32075","description":"microRNA 490","metadata":{"aliases":["hsa-mir-490","miR-490","MIRN490"]}},{"id":"c311e166d88e41c9bdb39aa5407dee11","type":"GENE","name":"MIR491","canonical_id":"hgnc:HGNC:32076","description":"microRNA 491","metadata":{"aliases":["hsa-mir-491","MIRN491"]}},{"id":"db16898ef64047c0bb69918f86b934bb","type":"GENE","name":"MIR492","canonical_id":"hgnc:HGNC:32081","description":"microRNA 492","metadata":{"aliases":["hsa-mir-492","MIRN492"]}},{"id":"c2a0e3b0f9e346d4963241b4c7b23cc6","type":"GENE","name":"MIR493","canonical_id":"hgnc:HGNC:32082","description":"microRNA 493","metadata":{"aliases":["hsa-mir-493","MIRN493"]}},{"id":"8ad056be0af64d7c958e1e84fe6e6313","type":"GENE","name":"MIR493HG","canonical_id":"hgnc:HGNC:55978","description":"MIR493 cluster host gene","metadata":null},{"id":"5df23d05bcc54506ae2e6f5b735af454","type":"GENE","name":"MIR494","canonical_id":"hgnc:HGNC:32084","description":"microRNA 494","metadata":{"aliases":["hsa-mir-494","MIRN494"]}},{"id":"85c2f80c2f6843c3abb388386daafb03","type":"GENE","name":"MIR495","canonical_id":"hgnc:HGNC:32085","description":"microRNA 495","metadata":{"aliases":["hsa-mir-495","MIRN495"]}},{"id":"3bc804d203c94f6a9b349a64ff9edb98","type":"GENE","name":"MIR496","canonical_id":"hgnc:HGNC:32086","description":"microRNA 496","metadata":{"aliases":["hsa-mir-496","MIRN496"]}},{"id":"622d3c69cd0948c69f0a5b0a2e2037f5","type":"GENE","name":"MIR497","canonical_id":"hgnc:HGNC:32088","description":"microRNA 497","metadata":{"aliases":["hsa-mir-497","MIRN497"]}},{"id":"3b7a47a0305d48da9ab35a4fdf7f7128","type":"GENE","name":"MIR497HG","canonical_id":"hgnc:HGNC:39523","description":"mir-497-195 cluster host gene","metadata":{"aliases":["MIR195HG","ALOX12-AS1"]}},{"id":"620074ced18043699c58852ba4cb6286","type":"GENE","name":"MIR498","canonical_id":"hgnc:HGNC:32092","description":"microRNA 498","metadata":{"aliases":["hsa-mir-498","MIRN498"]}},{"id":"91fcabff96bc4ada8114e2b680036fcc","type":"GENE","name":"MIR4999","canonical_id":"hgnc:HGNC:43494","description":"microRNA 4999","metadata":{"aliases":["hsa-mir-4999"]}},{"id":"1f2fd3cf1d1c4f64be7d33f99d8b738c","type":"GENE","name":"MIR499A","canonical_id":"hgnc:HGNC:32133","description":"microRNA 499a","metadata":{"aliases":["hsa-mir-499","MIRN499","MIR499"]}},{"id":"a93093101ed34f7eb758ce2106328377","type":"GENE","name":"MIR499B","canonical_id":"hgnc:HGNC:41640","description":"microRNA 499b","metadata":{"aliases":["hsa-mir-499a","MIR499A"]}},{"id":"ebda014731b2421f97356b1fbc1de777","type":"GENE","name":"MIR5000","canonical_id":"hgnc:HGNC:43464","description":"microRNA 5000","metadata":{"aliases":["hsa-mir-5000"]}},{"id":"e966c8098bf64f12a2747044c5ca9475","type":"GENE","name":"MIR5001","canonical_id":"hgnc:HGNC:43462","description":"microRNA 5001","metadata":{"aliases":["hsa-mir-5001"]}},{"id":"8d68bd29bfa64fbea49f5e08e81cc701","type":"GENE","name":"MIR5002","canonical_id":"hgnc:HGNC:43470","description":"microRNA 5002","metadata":{"aliases":["hsa-mir-5002"]}},{"id":"dc277ad904db4c8fa5400459d50bcb75","type":"GENE","name":"MIR5003","canonical_id":"hgnc:HGNC:43512","description":"microRNA 5003","metadata":{"aliases":["hsa-mir-5003"]}},{"id":"93a58d52a6b34651a75833d5981233c1","type":"GENE","name":"MIR5004","canonical_id":"hgnc:HGNC:43532","description":"microRNA 5004","metadata":{"aliases":["hsa-mir-5004"]}},{"id":"ec2a0f6e94004b939009e775299e7c7c","type":"GENE","name":"MIR5006","canonical_id":"hgnc:HGNC:43495","description":"microRNA 5006","metadata":{"aliases":["hsa-mir-5006"]}},{"id":"3f9a056db3d14b2a9136d7892de86196","type":"GENE","name":"MIR5007","canonical_id":"hgnc:HGNC:43468","description":"microRNA 5007","metadata":{"aliases":["hsa-mir-5007"]}},{"id":"dab1132d35c844e49ea9a32adc50745e","type":"GENE","name":"MIR5008","canonical_id":"hgnc:HGNC:43546","description":"microRNA 5008","metadata":{"aliases":["hsa-mir-5008"]}},{"id":"6b113ebc776f4b1a9c9ad85ab74c0f86","type":"GENE","name":"MIR5009","canonical_id":"hgnc:HGNC:43458","description":"microRNA 5009","metadata":{"aliases":["hsa-mir-5009"]}},{"id":"e487f90b6313404bb2606ca27358b137","type":"GENE","name":"MIR500A","canonical_id":"hgnc:HGNC:32134","description":"microRNA 500a","metadata":{"aliases":["hsa-mir-500","MIRN500","MIR500"]}},{"id":"1f66982406e8419ba145d21069857921","type":"GENE","name":"MIR500B","canonical_id":"hgnc:HGNC:38223","description":"microRNA 500b","metadata":{"aliases":["hsa-mir-500b"]}},{"id":"3c5f68b596b6415a907e30b2e6847f7a","type":"GENE","name":"MIR501","canonical_id":"hgnc:HGNC:32135","description":"microRNA 501","metadata":{"aliases":["hsa-mir-501","MIRN501"]}},{"id":"507a245d7ef24791bc4f9e168bde594e","type":"GENE","name":"MIR5010","canonical_id":"hgnc:HGNC:43484","description":"microRNA 5010","metadata":{"aliases":["hsa-mir-5010"]}},{"id":"04cbd762457a4c5b9fe145b918748114","type":"GENE","name":"MIR5011","canonical_id":"hgnc:HGNC:43496","description":"microRNA 5011","metadata":{"aliases":["hsa-mir-5011"]}},{"id":"6cf811aa6ac842dab082dea7ded0be9e","type":"GENE","name":"MIR502","canonical_id":"hgnc:HGNC:32136","description":"microRNA 502","metadata":{"aliases":["hsa-mir-502","MIRN502"]}},{"id":"92279cf75b924ffe90bc70a6eee971f0","type":"GENE","name":"MIR503","canonical_id":"hgnc:HGNC:32138","description":"microRNA 503","metadata":{"aliases":["hsa-mir-503","MIRN503"]}},{"id":"45cbf71089f74690b717fd8f562edf0d","type":"GENE","name":"MIR503HG","canonical_id":"hgnc:HGNC:28258","description":"MIR503 host gene","metadata":{"aliases":["MGC16121","H19X"]}},{"id":"61e474e8d7734bd0a854407d495000ae","type":"GENE","name":"MIR504","canonical_id":"hgnc:HGNC:32139","description":"microRNA 504","metadata":{"aliases":["hsa-mir-504","MIRN504"]}},{"id":"8b64a97cd8e545ef8e16faad6a68ef8b","type":"GENE","name":"MIR5047","canonical_id":"hgnc:HGNC:41834","description":"microRNA 5047","metadata":{"aliases":["hsa-mir-5047"]}},{"id":"2e648a1239c64ae28efae74d2965711b","type":"GENE","name":"MIR505","canonical_id":"hgnc:HGNC:32140","description":"microRNA 505","metadata":{"aliases":["hsa-mir-505","MIRN505"]}},{"id":"fa68cf33c4c34108bfd220ed54d9dcf3","type":"GENE","name":"MIR506","canonical_id":"hgnc:HGNC:32143","description":"microRNA 506","metadata":{"aliases":["hsa-mir-506","MIRN506"]}},{"id":"74361464734b47b7bd3e654a0e2d9cd8","type":"GENE","name":"MIR507","canonical_id":"hgnc:HGNC:32144","description":"microRNA 507","metadata":{"aliases":["hsa-mir-507","MIRN507"]}},{"id":"1949d4b22c1744c2811662a523806a32","type":"GENE","name":"MIR508","canonical_id":"hgnc:HGNC:32145","description":"microRNA 508","metadata":{"aliases":["hsa-mir-508","MIRN508"]}},{"id":"e42f16d827184494a00bb86961a59408","type":"GENE","name":"MIR5087","canonical_id":"hgnc:HGNC:43480","description":"microRNA 5087","metadata":{"aliases":["hsa-mir-5087"]}},{"id":"6c8f970145524149a303be0c817f6712","type":"GENE","name":"MIR5088","canonical_id":"hgnc:HGNC:43489","description":"microRNA 5088","metadata":{"aliases":["hsa-mir-5088"]}},{"id":"4d5b757e2f044b239fb1773b7d658d45","type":"GENE","name":"MIR5089","canonical_id":"hgnc:HGNC:43536","description":"microRNA 5089","metadata":{"aliases":["hsa-mir-5089"]}},{"id":"d260c4ff285648c8aa0c8d7c85d93f91","type":"GENE","name":"MIR509-1","canonical_id":"hgnc:HGNC:32146","description":"microRNA 509-1","metadata":{"aliases":["hsa-mir-509","hsa-mir-509-1","MIRN509","MIRN509-1"]}},{"id":"48019aaef4ee4dd38df7b8b4579ed4bf","type":"GENE","name":"MIR509-2","canonical_id":"hgnc:HGNC:33641","description":"microRNA 509-2","metadata":{"aliases":["hsa-mir-509-2","MIRN509-2"]}},{"id":"075cd7cbcb634fc9baaf1ec831d2a96c","type":"GENE","name":"MIR509-3","canonical_id":"hgnc:HGNC:33675","description":"microRNA 509-3","metadata":{"aliases":["hsa-mir-509-3","MIRN509-3"]}},{"id":"6d977f297b7a428d9619f9160af182b9","type":"GENE","name":"MIR5090","canonical_id":"hgnc:HGNC:43547","description":"microRNA 5090","metadata":{"aliases":["hsa-mir-5090"]}},{"id":"95c2dbe2cd2e474dabaac5574eb6dc70","type":"GENE","name":"MIR5091","canonical_id":"hgnc:HGNC:43478","description":"microRNA 5091","metadata":{"aliases":["hsa-mir-5091"]}},{"id":"d336075b2363448ba0c800a6f2d5a7c8","type":"GENE","name":"MIR5092","canonical_id":"hgnc:HGNC:43467","description":"microRNA 5092","metadata":{"aliases":["hsa-mir-5092"]}},{"id":"6e1a3db0408f43fbb475e906bf172d28","type":"GENE","name":"MIR5093","canonical_id":"hgnc:HGNC:43474","description":"microRNA 5093","metadata":{"aliases":["hsa-mir-5093"]}},{"id":"d1ba289ac3ef47f3b0dd32d8648c6c58","type":"GENE","name":"MIR5094","canonical_id":"hgnc:HGNC:43519","description":"microRNA 5094","metadata":{"aliases":["hsa-mir-5094"]}},{"id":"3f0c1d1486784016a9f132dd6c107d11","type":"GENE","name":"MIR510","canonical_id":"hgnc:HGNC:32147","description":"microRNA 510","metadata":{"aliases":["hsa-mir-510","MIRN510"]}},{"id":"8a3a7fa303324331b03b140dffc8a8cb","type":"GENE","name":"MIR5100","canonical_id":"hgnc:HGNC:43540","description":"microRNA 5100","metadata":{"aliases":["hsa-mir-5100"]}},{"id":"2815d3f6d4ce4f5b8bacc4486d2f6769","type":"GENE","name":"MIR511","canonical_id":"hgnc:HGNC:32077","description":"microRNA 511","metadata":{"aliases":["hsa-mir-511-1","hsa-mir-511-2","MIRN511-1","MIR511-2","MIRN511-2","MIR511-1"]}},{"id":"90babf2654e343558110a4ea98f27399","type":"GENE","name":"MIR512-1","canonical_id":"hgnc:HGNC:32090","description":"microRNA 512-1","metadata":{"aliases":["hsa-mir-512-1","MIRN512-1"]}},{"id":"cf65521b0acf42dd8c098b057d0987ed","type":"GENE","name":"MIR512-2","canonical_id":"hgnc:HGNC:32091","description":"microRNA 512-2","metadata":{"aliases":["hsa-mir-512-2","MIRN512-2"]}},{"id":"55e3e33121854e1899d83bd188899048","type":"GENE","name":"MIR513A1","canonical_id":"hgnc:HGNC:32141","description":"microRNA 513a-1","metadata":{"aliases":["hsa-mir-513-1","hsa-mir-513a-1","MIRN513-1","MIRN513A1"]}},{"id":"041065bdee6a44cc8ea7f60261ff25d7","type":"GENE","name":"MIR513A2","canonical_id":"hgnc:HGNC:32142","description":"microRNA 513a-2","metadata":{"aliases":["hsa-mir-513-2","MIRN513-2","MIRN513A-2","MIRN513A2"]}},{"id":"516efb24deff4ad5a2b652324d41d823","type":"GENE","name":"MIR513B","canonical_id":"hgnc:HGNC:33935","description":"microRNA 513b","metadata":{"aliases":["hsa-mir-513b","MIRN513B"]}},{"id":"838680b4a5fe45e1a54fbdaad4db502d","type":"GENE","name":"MIR513C","canonical_id":"hgnc:HGNC:33934","description":"microRNA 513c","metadata":{"aliases":["hsa-mir-513c","MIRN513C"]}},{"id":"a0c5f558e16840b9a29a909a04182998","type":"GENE","name":"MIR514A1","canonical_id":"hgnc:HGNC:32148","description":"microRNA 514a-1","metadata":{"aliases":["hsa-mir-514-1","MIRN514-1","MIR514-1"]}},{"id":"4bd17cb1624649628533dcef268e0ecb","type":"GENE","name":"MIR514A2","canonical_id":"hgnc:HGNC:32149","description":"microRNA 514a-2","metadata":{"aliases":["hsa-mir-514-2","MIRN514-2","MIR514-2"]}},{"id":"6780b9979545477a8648a802a8a7cd53","type":"GENE","name":"MIR514A3","canonical_id":"hgnc:HGNC:32150","description":"microRNA 514a-3","metadata":{"aliases":["hsa-mir-514-3","MIRN514-3","MIR514-3"]}},{"id":"9a3f8e05eba3443897dda28a49a32a81","type":"GENE","name":"MIR514B","canonical_id":"hgnc:HGNC:38292","description":"microRNA 514b","metadata":{"aliases":["hsa-mir-514b"]}},{"id":"9c24aa238f3d441d92ced17293e53377","type":"GENE","name":"MIR515-1","canonical_id":"hgnc:HGNC:32094","description":"microRNA 515-1","metadata":{"aliases":["hsa-mir-515-1","MIRN515-1"]}},{"id":"75e67abb84704a9a8ca2ba5fc14e23f1","type":"GENE","name":"MIR515-2","canonical_id":"hgnc:HGNC:32097","description":"microRNA 515-2","metadata":{"aliases":["hsa-mir-515-2","MIRN515-2"]}},{"id":"8d4149f449a4453aaeb9d2188c296ca6","type":"GENE","name":"MIR516A1","canonical_id":"hgnc:HGNC:32130","description":"microRNA 516a-1","metadata":{"aliases":["hsa-mir-516-1","hsa-mir-516a-1","MIRN516-1","MIRN516A1"]}},{"id":"0418ce38ee1943bdba26131bae32a0b3","type":"GENE","name":"MIR516A2","canonical_id":"hgnc:HGNC:32131","description":"microRNA 516a-2","metadata":{"aliases":["hsa-mir-516-2","hsa-mir-516a-2","MIRN516-2","MIRN516A2"]}},{"id":"d5d19d7f96f849b8a033c3fafbe2fddc","type":"GENE","name":"MIR516B1","canonical_id":"hgnc:HGNC:32122","description":"microRNA 516b-1","metadata":{"aliases":["hsa-mir-516-4","hsa-mir-516b-1","MIRN516-4","MIRN516B1"]}},{"id":"5cfc472f02764c1fbb3630f920b0f750","type":"GENE","name":"MIR516B2","canonical_id":"hgnc:HGNC:32117","description":"microRNA 516b-2","metadata":{"aliases":["hsa-mir-516-3","hsa-mir-516b-2","MIRN516-3","MIRN516B2"]}},{"id":"5b992e8eb73943c597bb694ef54a6560","type":"GENE","name":"MIR517A","canonical_id":"hgnc:HGNC:32111","description":"microRNA 517a","metadata":{"aliases":["hsa-mir-517a","MIRN517A"]}},{"id":"66cfae836d224f729e1b46ed585bb3d0","type":"GENE","name":"MIR517B","canonical_id":"hgnc:HGNC:32115","description":"microRNA 517b","metadata":{"aliases":["hsa-mir-517b","MIRN517B"]}},{"id":"4e7bd7f84dcb46228ea0b41e5625706d","type":"GENE","name":"MIR517C","canonical_id":"hgnc:HGNC:32124","description":"microRNA 517c","metadata":{"aliases":["hsa-mir-517c","MIRN517C"]}},{"id":"8e9dd8a00bbf4f85aaf314c07903591d","type":"GENE","name":"MIR5186","canonical_id":"hgnc:HGNC:43459","description":"microRNA 5186","metadata":{"aliases":["hsa-mir-5186"]}},{"id":"5742fab0bad944988a342e345b03b6df","type":"GENE","name":"MIR5187","canonical_id":"hgnc:HGNC:43523","description":"microRNA 5187","metadata":{"aliases":["hsa-mir-5187"]}},{"id":"aaa1a15ba7404d51bc02550149a25779","type":"GENE","name":"MIR5188","canonical_id":"hgnc:HGNC:43502","description":"microRNA 5188","metadata":{"aliases":["hsa-mir-5188"]}},{"id":"fa524283d876442fa160fe8eafb79359","type":"GENE","name":"MIR5189","canonical_id":"hgnc:HGNC:43515","description":"microRNA 5189","metadata":{"aliases":["hsa-mir-5189"]}},{"id":"70a559e8712a4cd1be63c58f604be9c2","type":"GENE","name":"MIR518A1","canonical_id":"hgnc:HGNC:32120","description":"microRNA 518a-1","metadata":{"aliases":["hsa-mir-518a-1","MIRN518A-1","MIRN518A1"]}},{"id":"56b9e56eb23a4ecabfcbc1cc649f24ef","type":"GENE","name":"MIR518A2","canonical_id":"hgnc:HGNC:32123","description":"microRNA 518a-2","metadata":{"aliases":["hsa-mir-518a-2","MIRN518A-2","MIRN518A2"]}},{"id":"ecdb0d5629c04d52bb5c812262894ab5","type":"GENE","name":"MIR518B","canonical_id":"hgnc:HGNC:32106","description":"microRNA 518b","metadata":{"aliases":["hsa-mir-518b","MIRN518B"]}},{"id":"0f7185add5f047b893aa6c7e7374c728","type":"GENE","name":"MIR518C","canonical_id":"hgnc:HGNC:32109","description":"microRNA 518c","metadata":{"aliases":["hsa-mir-518c","MIRN518C"]}},{"id":"aa860326671f42fea9e260ad98a21f06","type":"GENE","name":"MIR518D","canonical_id":"hgnc:HGNC:32121","description":"microRNA 518d","metadata":{"aliases":["hsa-mir-518d","MIRN518D"]}},{"id":"a0ebb5b25ea7482d86e38039ecddecc8","type":"GENE","name":"MIR518E","canonical_id":"hgnc:HGNC:32119","description":"microRNA 518e","metadata":{"aliases":["hsa-mir-518e","MIRN518E"]}},{"id":"99353472783341f286dc974c6947243f","type":"GENE","name":"MIR518F","canonical_id":"hgnc:HGNC:32104","description":"microRNA 518f","metadata":{"aliases":["hsa-mir-518f","MIRN518F"]}},{"id":"498cce96202e4392b5a724dcfdbf5d2a","type":"GENE","name":"MIR5190","canonical_id":"hgnc:HGNC:43549","description":"microRNA 5190","metadata":{"aliases":["hsa-mir-5190"]}},{"id":"e04374055ee947dc83476ca3891b1516","type":"GENE","name":"MIR5191","canonical_id":"hgnc:HGNC:43497","description":"microRNA 5191","metadata":{"aliases":["hsa-mir-5191"]}},{"id":"aa847ed972c84e1382ec5a118e25ed90","type":"GENE","name":"MIR5192","canonical_id":"hgnc:HGNC:43473","description":"microRNA 5192","metadata":{"aliases":["hsa-mir-5192"]}},{"id":"bd8f641795a440d88fcf997f029760e6","type":"GENE","name":"MIR5193","canonical_id":"hgnc:HGNC:43534","description":"microRNA 5193","metadata":{"aliases":["hsa-mir-5193"]}},{"id":"c44b754a34f343f8a3c0d097e44d6b8e","type":"GENE","name":"MIR5194","canonical_id":"hgnc:HGNC:43498","description":"microRNA 5194","metadata":{"aliases":["hsa-mir-5194"]}},{"id":"a10183afdb8d4c7c959e264fa4d42618","type":"GENE","name":"MIR5195","canonical_id":"hgnc:HGNC:43526","description":"microRNA 5195","metadata":{"aliases":["hsa-mir-5195"]}},{"id":"44ab803b0cc94c26aee81c673e7dc2b1","type":"GENE","name":"MIR5196","canonical_id":"hgnc:HGNC:43542","description":"microRNA 5196","metadata":{"aliases":["hsa-mir-5196"]}},{"id":"a5a02cd4a0484dbeb424ef84c6a6c2ca","type":"GENE","name":"MIR5197","canonical_id":"hgnc:HGNC:43450","description":"microRNA 5197","metadata":{"aliases":["hsa-mir-5197"]}},{"id":"58317364d1e4407fa3c98a4d9e386619","type":"GENE","name":"MIR519A1","canonical_id":"hgnc:HGNC:32128","description":"microRNA 519a-1","metadata":{"aliases":["hsa-mir-519a-1","MIRN519A-1","MIRN519A1"]}},{"id":"10fdcab513c54947a26bb8e58790c527","type":"GENE","name":"MIR519A2","canonical_id":"hgnc:HGNC:32132","description":"microRNA 519a-2","metadata":{"aliases":["hsa-mir-519a-2","MIRN519A-2","MIRN519A2"]}},{"id":"06bea5c53097453a9d314844cd1dbd54","type":"GENE","name":"MIR519B","canonical_id":"hgnc:HGNC:32101","description":"microRNA 519b","metadata":{"aliases":["hsa-mir-519b","MIRN519B"]}},{"id":"10d1234f8e0a4d69865e5b412a071197","type":"GENE","name":"MIR519C","canonical_id":"hgnc:HGNC:32098","description":"microRNA 519c","metadata":{"aliases":["hsa-mir-519c","MIRN519C"]}},{"id":"34d2d964cb754157aded6576c6463779","type":"GENE","name":"MIR519D","canonical_id":"hgnc:HGNC:32112","description":"microRNA 519d","metadata":{"aliases":["hsa-mir-519d","MIRN519D"]}},{"id":"e91c518045ad41bbb6664d6474a27049","type":"GENE","name":"MIR519E","canonical_id":"hgnc:HGNC:32095","description":"microRNA 519e","metadata":{"aliases":["hsa-mir-519e","MIRN519E"]}},{"id":"b2784e77d7cb462786c3cba2a0f42b48","type":"GENE","name":"MIR520A","canonical_id":"hgnc:HGNC:32099","description":"microRNA 520a","metadata":{"aliases":["hsa-mir-520a","MIRN520A"]}},{"id":"9c95de890f1844669f9edc33bce7a362","type":"GENE","name":"MIR520B","canonical_id":"hgnc:HGNC:32105","description":"microRNA 520b","metadata":{"aliases":["hsa-mir-520b","MIRN520B"]}},{"id":"879cb84285f64ccfb6dc7ea16c7ea0f4","type":"GENE","name":"MIR520C","canonical_id":"hgnc:HGNC:32108","description":"microRNA 520c","metadata":{"aliases":["hsa-mir-520c","MIRN520C"]}},{"id":"d8b18000686c43b0acd28a437c714b79","type":"GENE","name":"MIR520D","canonical_id":"hgnc:HGNC:32114","description":"microRNA 520d","metadata":{"aliases":["hsa-mir-520d","MIRN520D"]}},{"id":"b7f53c654f0645e4a650a4948ee235d3","type":"GENE","name":"MIR520E","canonical_id":"hgnc:HGNC:32093","description":"microRNA 520e","metadata":{"aliases":["hsa-mir-520e","MIRN520E"]}},{"id":"a0ee043a73be4fd39cd4c12cb06a8c12","type":"GENE","name":"MIR520F","canonical_id":"hgnc:HGNC:32096","description":"microRNA 520f","metadata":{"aliases":["hsa-mir-520f","MIRN520F"]}},{"id":"1e310912c98d458f851fe4f70e0f8c95","type":"GENE","name":"MIR520G","canonical_id":"hgnc:HGNC:32116","description":"microRNA 520g","metadata":{"aliases":["hsa-mir-520g","MIRN520G"]}},{"id":"7086caebed074514830192187cdfb328","type":"GENE","name":"MIR520H","canonical_id":"hgnc:HGNC:32125","description":"microRNA 520h","metadata":{"aliases":["hsa-mir-520h","MIRN520H"]}},{"id":"b71018bcfd3142f6a52b4fb635987a9c","type":"GENE","name":"MIR521-1","canonical_id":"hgnc:HGNC:32126","description":"microRNA 521-1","metadata":{"aliases":["hsa-mir-521-1","MIRN521-1"]}},{"id":"f8f746aaa8a549ef90ee8a4369bfeeab","type":"GENE","name":"MIR521-2","canonical_id":"hgnc:HGNC:32113","description":"microRNA 521-2","metadata":{"aliases":["hsa-mir-521-2","MIRN521-2"]}},{"id":"f00fe66459c447039186b7e9c28c1e66","type":"GENE","name":"MIR522","canonical_id":"hgnc:HGNC:32127","description":"microRNA 522","metadata":{"aliases":["hsa-mir-522","MIRN522"]}},{"id":"ed5f4160be914efe8cbb7cc3689e8035","type":"GENE","name":"MIR523","canonical_id":"hgnc:HGNC:32103","description":"microRNA 523","metadata":{"aliases":["hsa-mir-523","MIRN523"]}},{"id":"ec1bb0d7e2ee4ac8950c2deae9f78f8c","type":"GENE","name":"MIR524","canonical_id":"hgnc:HGNC:32110","description":"microRNA 524","metadata":{"aliases":["hsa-mir-524","MIRN524"]}},{"id":"c786aff2894b4f4085839ab2bd50b71e","type":"GENE","name":"MIR525","canonical_id":"hgnc:HGNC:32102","description":"microRNA 525","metadata":{"aliases":["hsa-mir-525","MIRN525"]}},{"id":"01748bdc6e0c4549ada42ec4181e9fdc","type":"GENE","name":"MIR526A1","canonical_id":"hgnc:HGNC:32107","description":"microRNA 526a-1","metadata":{"aliases":["hsa-mir-526a-1","MIRN526A-1","MIRN526A1"]}},{"id":"9398da47ef7c414a87ce0f4f81a1203d","type":"GENE","name":"MIR526A2","canonical_id":"hgnc:HGNC:32118","description":"microRNA 526a-2","metadata":{"aliases":["hsa-mir-526a-2","MIRN526A-2","MIRN526A2"]}},{"id":"21f9101da0384d8e9a44f329f2e165ba","type":"GENE","name":"MIR526B","canonical_id":"hgnc:HGNC:32100","description":"microRNA 526b","metadata":{"aliases":["hsa-mir-526b","MIRN526B"]}},{"id":"389bb3e2462d4ecbb2db43e683d39d88","type":"GENE","name":"MIR527","canonical_id":"hgnc:HGNC:32129","description":"microRNA 527","metadata":{"aliases":["hsa-mir-527","MIRN527"]}},{"id":"eb92cd4e5c8a4048bd76fec23f9e01b6","type":"GENE","name":"MIR532","canonical_id":"hgnc:HGNC:32795","description":"microRNA 532","metadata":{"aliases":["hsa-mir-532","MIRN532"]}},{"id":"1f6fefc966564b318802a33422c18ba1","type":"GENE","name":"MIR539","canonical_id":"hgnc:HGNC:32529","description":"microRNA 539","metadata":{"aliases":["hsa-mir-539","MIRN539"]}},{"id":"e648116497294e09bedef144c9fe938f","type":"GENE","name":"MIR541","canonical_id":"hgnc:HGNC:33650","description":"microRNA 541","metadata":{"aliases":["hsa-mir-541","MIRN541"]}},{"id":"42db08bf35a64d1290ed3573467b1e68","type":"GENE","name":"MIR542","canonical_id":"hgnc:HGNC:32534","description":"microRNA 542","metadata":{"aliases":["hsa-mir-542","MIRN542"]}},{"id":"0f4ffa59dd30411eb0479e82ca5c357f","type":"GENE","name":"MIR543","canonical_id":"hgnc:HGNC:33664","description":"microRNA 543","metadata":{"aliases":["hsa-mir-543","MIRN543"]}},{"id":"818627081eb84ab19c3fbca80a87a733","type":"GENE","name":"MIR544A","canonical_id":"hgnc:HGNC:32530","description":"microRNA 544a","metadata":{"aliases":["hsa-mir-544","MIRN544","MIR544"]}},{"id":"eab40193244f4af083eaad830ae8bc28","type":"GENE","name":"MIR544B","canonical_id":"hgnc:HGNC:38361","description":"microRNA 544b","metadata":{"aliases":["hsa-mir-544b"]}},{"id":"8c414ecdb67b4f66b2bc40c30d01f8ad","type":"GENE","name":"MIR545","canonical_id":"hgnc:HGNC:32531","description":"microRNA 545","metadata":{"aliases":["hsa-mir-545","MIRN545"]}},{"id":"e4b8dbb7ada64c9cafe7a3ce50fab2db","type":"GENE","name":"MIR548A1","canonical_id":"hgnc:HGNC:32796","description":"microRNA 548a-1","metadata":{"aliases":["hsa-mir-548a-1","MIRN548A1"]}},{"id":"b88d3bf422334932a0015667fd7e10e3","type":"GENE","name":"MIR548A1HG","canonical_id":"hgnc:HGNC:53539","description":"MIR548A1 host gene","metadata":null},{"id":"692ea062814d4556a0f0030fe3243676","type":"GENE","name":"MIR548A2","canonical_id":"hgnc:HGNC:32797","description":"microRNA 548a-2","metadata":{"aliases":["hsa-mir-548a-2","MIRN548A2"]}},{"id":"eca78d12cc534c43b5147583e7f5c969","type":"GENE","name":"MIR548A3","canonical_id":"hgnc:HGNC:32798","description":"microRNA 548a-3","metadata":{"aliases":["hsa-mir-548a-3","MIRN548A3"]}},{"id":"300b5d6fa7944a099f3405dc5b3e39e7","type":"GENE","name":"MIR548AA1","canonical_id":"hgnc:HGNC:38944","description":"microRNA 548aa-1","metadata":{"aliases":["hsa-mir-548aa-1"]}},{"id":"37a34467d1cf41428f913c9dab9f1ce4","type":"GENE","name":"MIR548AA2","canonical_id":"hgnc:HGNC:38921","description":"microRNA 548aa-2","metadata":{"aliases":["hsa-mir-548aa-2"]}},{"id":"d3a48b1002664640a9ac4022bb9bc930","type":"GENE","name":"MIR548AB","canonical_id":"hgnc:HGNC:41825","description":"microRNA 548ab","metadata":{"aliases":["hsa-mir-548ab"]}},{"id":"2038623a6ed742d7b23d826158969a7f","type":"GENE","name":"MIR548AC","canonical_id":"hgnc:HGNC:41626","description":"microRNA 548ac","metadata":{"aliases":["hsa-mir-548ac"]}},{"id":"0191fae035d548ea8c3483babfff3a43","type":"GENE","name":"MIR548AD","canonical_id":"hgnc:HGNC:41683","description":"microRNA 548ad","metadata":{"aliases":["hsa-mir-548ad"]}},{"id":"2ee9608f82c545468636d14fa8aa2fdd","type":"GENE","name":"MIR548AE1","canonical_id":"hgnc:HGNC:41742","description":"microRNA 548ae-1","metadata":{"aliases":["hsa-mir-548ae-1"]}},{"id":"3c43825421214bae87002ca34d676488","type":"GENE","name":"MIR548AE2","canonical_id":"hgnc:HGNC:41831","description":"microRNA 548ae-2","metadata":{"aliases":["hsa-mir-548ae-2"]}},{"id":"d8a3ec66154a4a7093fd0e4d15b9fdb2","type":"GENE","name":"MIR548AG1","canonical_id":"hgnc:HGNC:41625","description":"microRNA 548ag-1","metadata":{"aliases":["hsa-mir-548ag-1"]}},{"id":"b16bdf80bc204d0789269d18662dd503","type":"GENE","name":"MIR548AG2","canonical_id":"hgnc:HGNC:41745","description":"microRNA 548ag-2","metadata":{"aliases":["hsa-mir-548ag-2"]}},{"id":"8420990950044aa098802517e5376117","type":"GENE","name":"MIR548AH","canonical_id":"hgnc:HGNC:41605","description":"microRNA 548ah","metadata":{"aliases":["hsa-mir-548ah"]}},{"id":"464fae8fa0ad4639b1ebece0f22a77b0","type":"GENE","name":"MIR548AI","canonical_id":"hgnc:HGNC:41854","description":"microRNA 548ai","metadata":{"aliases":["hsa-mir-548ai"]}},{"id":"95f32599ce12499192edcb439ef63893","type":"GENE","name":"MIR548AJ1","canonical_id":"hgnc:HGNC:41884","description":"microRNA 548aj-1","metadata":{"aliases":["hsa-mir-548aj-1"]}},{"id":"82499cc2210f479abf9d6b9425403538","type":"GENE","name":"MIR548AJ2","canonical_id":"hgnc:HGNC:41600","description":"microRNA 548aj-2","metadata":{"aliases":["hsa-mir-548aj-2"]}},{"id":"a28265d3daea4bb5ad31daf2c6e53620","type":"GENE","name":"MIR548AK","canonical_id":"hgnc:HGNC:41893","description":"microRNA 548ak","metadata":{"aliases":["hsa-mir-548ak"]}},{"id":"4bc0c31554854416ab9ddd1bebbef133","type":"GENE","name":"MIR548AL","canonical_id":"hgnc:HGNC:41736","description":"microRNA 548al","metadata":{"aliases":["hsa-mir-548al"]}},{"id":"fb28d379c19a487398cb61bdd5b8a278","type":"GENE","name":"MIR548AM","canonical_id":"hgnc:HGNC:41637","description":"microRNA 548am","metadata":{"aliases":["hsa-mir-548am"]}},{"id":"24bf495fb0554f79a896725f23cf74b9","type":"GENE","name":"MIR548AN","canonical_id":"hgnc:HGNC:41681","description":"microRNA 548an","metadata":{"aliases":["hsa-mir-548an"]}},{"id":"d121a8cd973d403d87c5582d23e776eb","type":"GENE","name":"MIR548AO","canonical_id":"hgnc:HGNC:43539","description":"microRNA 548ao","metadata":{"aliases":["hsa-mir-548ao"]}},{"id":"92e679e8b30947b192a2eed060ebf7d3","type":"GENE","name":"MIR548AP","canonical_id":"hgnc:HGNC:43465","description":"microRNA 548ap","metadata":{"aliases":["hsa-mir-548ap"]}},{"id":"8ac0d827f2764219b04d7302d7f6caa3","type":"GENE","name":"MIR548AQ","canonical_id":"hgnc:HGNC:43488","description":"microRNA 548aq","metadata":{"aliases":["hsa-mir-548aq"]}},{"id":"f2e680745da94e5980d2a3ade856ce4b","type":"GENE","name":"MIR548AR","canonical_id":"hgnc:HGNC:43455","description":"microRNA 548ar","metadata":{"aliases":["hsa-mir-548ar"]}},{"id":"38e4af3be6cc45368c3954978e3f19bb","type":"GENE","name":"MIR548AS","canonical_id":"hgnc:HGNC:43550","description":"microRNA 548as","metadata":{"aliases":["hsa-mir-548as"]}},{"id":"f3f6113119694598802f00da55ccf6da","type":"GENE","name":"MIR548AT","canonical_id":"hgnc:HGNC:43517","description":"microRNA 548at","metadata":{"aliases":["hsa-mir-548at"]}},{"id":"0e43589f52fc44b58bab768246109571","type":"GENE","name":"MIR548AU","canonical_id":"hgnc:HGNC:43483","description":"microRNA 548au","metadata":{"aliases":["hsa-mir-548au"]}},{"id":"943785955743450d982188047f44a71c","type":"GENE","name":"MIR548AV","canonical_id":"hgnc:HGNC:43537","description":"microRNA 548av","metadata":{"aliases":["hsa-mir-548av"]}},{"id":"b154ac26270c4fa38498a368604fa5be","type":"GENE","name":"MIR548AW","canonical_id":"hgnc:HGNC:43454","description":"microRNA 548aw","metadata":{"aliases":["hsa-mir-548aw"]}},{"id":"5e364ef8cc704892b98ca441b4b9df52","type":"GENE","name":"MIR548AX","canonical_id":"hgnc:HGNC:43528","description":"microRNA 548ax","metadata":{"aliases":["hsa-mir-548ax"]}},{"id":"9fce2b96146e4d85ae5c8e1944bb35d1","type":"GENE","name":"MIR548AY","canonical_id":"hgnc:HGNC:49943","description":"microRNA 548ay","metadata":{"aliases":["hsa-mir-548ay"]}},{"id":"5136efe2d3a745a580d359295a22c8e4","type":"GENE","name":"MIR548AZ","canonical_id":"hgnc:HGNC:49981","description":"microRNA 548az","metadata":{"aliases":["hsa-mir-548az"]}},{"id":"0a30bb6cdcea4b43a6251df690218eb5","type":"GENE","name":"MIR548B","canonical_id":"hgnc:HGNC:32799","description":"microRNA 548b","metadata":{"aliases":["hsa-mir-548b","MIRN548B"]}},{"id":"cc0af7784eea4b2f96184a258d85832c","type":"GENE","name":"MIR548BA","canonical_id":"hgnc:HGNC:50260","description":"microRNA 548ba","metadata":{"aliases":["hsa-mir-548ba"]}},{"id":"50f212a228394c3d948e3a12ffff9476","type":"GENE","name":"MIR548BAHG","canonical_id":"hgnc:HGNC:58158","description":"MIR548BA host gene","metadata":{"aliases":["AC009975.1"]}},{"id":"5356c7b896b24ee8bbec1d9609fe781e","type":"GENE","name":"MIR548BB","canonical_id":"hgnc:HGNC:50834","description":"microRNA 548bb","metadata":{"aliases":["MI0029321"]}},{"id":"b696eb8be6a049f2b9b7dd7f4a9d5c29","type":"GENE","name":"MIR548BC","canonical_id":"hgnc:HGNC:54164","description":"microRNA 548BC","metadata":{"aliases":["hsa-mir-548bc"]}},{"id":"804d2f8be8a64aaf8d9c3239ac1e7f7f","type":"GENE","name":"MIR548C","canonical_id":"hgnc:HGNC:32800","description":"microRNA 548c","metadata":{"aliases":["hsa-mir-548c","MIRN548C"]}},{"id":"b442613afd1248958e9ccfef34d4317e","type":"GENE","name":"MIR548D1","canonical_id":"hgnc:HGNC:32801","description":"microRNA 548d-1","metadata":{"aliases":["hsa-mir-548d-1","MIRN548D1"]}},{"id":"1acbd7e713a140488a6f3132d7183332","type":"GENE","name":"MIR548D2","canonical_id":"hgnc:HGNC:32802","description":"microRNA 548d-2","metadata":{"aliases":["hsa-mir-548d-2","MIRN548D2"]}},{"id":"9f6e9d1c832249efb4c67ff388e60836","type":"GENE","name":"MIR548E","canonical_id":"hgnc:HGNC:35275","description":"microRNA 548e","metadata":{"aliases":["hsa-mir-548e","MIRN548E"]}},{"id":"b600999511fd413a83f4aaff35b447f9","type":"GENE","name":"MIR548F1","canonical_id":"hgnc:HGNC:35305","description":"microRNA 548f-1","metadata":{"aliases":["hsa-mir-548f-1","MIRN548F1"]}},{"id":"ef5d2fcd912b455898b5c218307d3ced","type":"GENE","name":"MIR548F2","canonical_id":"hgnc:HGNC:35306","description":"microRNA 548f-2","metadata":{"aliases":["hsa-mir-548f-2","MIRN548F2"]}},{"id":"6ce998684ecf4d2b9e300d652d67017e","type":"GENE","name":"MIR548F3","canonical_id":"hgnc:HGNC:35307","description":"microRNA 548f-3","metadata":{"aliases":["hsa-mir-548f-3","MIRN548F3"]}},{"id":"e4f7e75ca9a54cf7a2e9485138324f18","type":"GENE","name":"MIR548F4","canonical_id":"hgnc:HGNC:35308","description":"microRNA 548f-4","metadata":{"aliases":["hsa-mir-548f-4","MIRN548F4"]}},{"id":"e8fe17f4c20b42f8b6c618b447c1f39e","type":"GENE","name":"MIR548F5","canonical_id":"hgnc:HGNC:35309","description":"microRNA 548f-5","metadata":{"aliases":["hsa-mir-548f-5","MIRN548F5"]}},{"id":"d2c7dddd94764a6a8f3837f180d2c5b1","type":"GENE","name":"MIR548G","canonical_id":"hgnc:HGNC:35326","description":"microRNA 548g","metadata":{"aliases":["hsa-mir-548g","MIRN548G"]}},{"id":"83ead37ff31541f7aec4711e83ca747c","type":"GENE","name":"MIR548H1","canonical_id":"hgnc:HGNC:35342","description":"microRNA 548h-1","metadata":{"aliases":["hsa-mir-548h-1","MIRN548H1"]}},{"id":"f3707059cd7a47ac9986fe9c8b8b4eb1","type":"GENE","name":"MIR548H2","canonical_id":"hgnc:HGNC:35343","description":"microRNA 548h-2","metadata":{"aliases":["hsa-mir-548h-2","MIRN548H2"]}},{"id":"f3107cd618664d4db60d2e49d8f02dcb","type":"GENE","name":"MIR548H3","canonical_id":"hgnc:HGNC:35344","description":"microRNA 548h-3","metadata":{"aliases":["hsa-mir-548h-3","MIRN548H3"]}},{"id":"2ed654b98aac4eae998874ec95a7cb0e","type":"GENE","name":"MIR548H4","canonical_id":"hgnc:HGNC:35345","description":"microRNA 548h-4","metadata":{"aliases":["hsa-mir-548h-4","MIRN548H4"]}},{"id":"aa8e8723e71040ffa39c890d3f60c23c","type":"GENE","name":"MIR548H5","canonical_id":"hgnc:HGNC:41768","description":"microRNA 548h-5","metadata":{"aliases":["hsa-mir-548h-5"]}},{"id":"402fb7ef4efd4728b6f5ad99100e0f69","type":"GENE","name":"MIR548I1","canonical_id":"hgnc:HGNC:35352","description":"microRNA 548i-1","metadata":{"aliases":["hsa-mir-548i-1","MIRN548I1"]}},{"id":"51f33be4b027441481ad8012cd4d8287","type":"GENE","name":"MIR548I2","canonical_id":"hgnc:HGNC:35353","description":"microRNA 548i-2","metadata":{"aliases":["hsa-mir-548i-2","MIRN548I2"]}},{"id":"ae43f6eae62c4d88acefda42fe541577","type":"GENE","name":"MIR548I3","canonical_id":"hgnc:HGNC:35354","description":"microRNA 548i-3","metadata":{"aliases":["hsa-mir-548i-3","MIRN548I3"]}},{"id":"ebe661f5aefe4762bd3a6efacecd206b","type":"GENE","name":"MIR548I4","canonical_id":"hgnc:HGNC:35355","description":"microRNA 548i-4","metadata":{"aliases":["hsa-mir-548i-4","MIRN548I4"]}},{"id":"3cd81c76b00b4006af61b2c37ee927af","type":"GENE","name":"MIR548J","canonical_id":"hgnc:HGNC:35276","description":"microRNA 548j","metadata":{"aliases":["hsa-mir-548j","MIRN548J"]}},{"id":"66a9f6d70f38455096a6683af9947a6a","type":"GENE","name":"MIR548K","canonical_id":"hgnc:HGNC:35285","description":"microRNA 548k","metadata":{"aliases":["hsa-mir-548k","MIRN548K"]}},{"id":"dc4233cf992046bba71e2997f54e33a6","type":"GENE","name":"MIR548L","canonical_id":"hgnc:HGNC:35292","description":"microRNA 548l","metadata":{"aliases":["hsa-mir-548l","MIRN548L"]}},{"id":"c14c436bbb74476cbd3463979633017b","type":"GENE","name":"MIR548M","canonical_id":"hgnc:HGNC:35331","description":"microRNA 548m","metadata":{"aliases":["hsa-mir-548m","MIRN548M"]}},{"id":"6870fee64bb8420c8ee9e3ecf47417af","type":"GENE","name":"MIR548N","canonical_id":"hgnc:HGNC:35330","description":"microRNA 548n","metadata":{"aliases":["hsa-mir-548n","MIRN548N"]}},{"id":"74d12a3b7519445a8ace097e3606ac73","type":"GENE","name":"MIR548O","canonical_id":"hgnc:HGNC:35333","description":"microRNA 548o","metadata":{"aliases":["hsa-mir-548o","MIRN548O"]}},{"id":"12a9d6559db943eb9f8c59206f43ec39","type":"GENE","name":"MIR548O2","canonical_id":"hgnc:HGNC:41882","description":"microRNA 548o-2","metadata":{"aliases":["hsa-mir-548o-2"]}},{"id":"8fb5e8aa29474c2cac221b8dd3e2fa65","type":"GENE","name":"MIR548P","canonical_id":"hgnc:HGNC:35351","description":"microRNA 548p","metadata":{"aliases":["hsa-mir-548p","MIRN548P"]}},{"id":"1dc4f69952b44f6da2a1032e951d4aad","type":"GENE","name":"MIR548Q","canonical_id":"hgnc:HGNC:37312","description":"microRNA 548q","metadata":{"aliases":["hsa-mir-548q"]}},{"id":"29e210fb23294f59aa31cf5d6817c96a","type":"GENE","name":"MIR548S","canonical_id":"hgnc:HGNC:38354","description":"microRNA 548s","metadata":{"aliases":["hsa-mir-548s"]}},{"id":"cc1e1c9e21ba483f8277dbf3618064b0","type":"GENE","name":"MIR548T","canonical_id":"hgnc:HGNC:38298","description":"microRNA 548t","metadata":{"aliases":["hsa-mir-548t"]}},{"id":"380c372774ce4824b1616d48345fdc40","type":"GENE","name":"MIR548U","canonical_id":"hgnc:HGNC:38316","description":"microRNA 548u","metadata":{"aliases":["hsa-mir-548u"]}},{"id":"2fb809e6aadd4bd5b6cd0aa32f64df02","type":"GENE","name":"MIR548V","canonical_id":"hgnc:HGNC:38302","description":"microRNA 548v","metadata":{"aliases":["hsa-mir-548v"]}},{"id":"96088b5d3c394f3f9a9084819a7fb4bd","type":"GENE","name":"MIR548W","canonical_id":"hgnc:HGNC:38255","description":"microRNA 548w","metadata":{"aliases":["hsa-mir-548w"]}},{"id":"c0865529382f4761bb9d3db5b594e86e","type":"GENE","name":"MIR548X","canonical_id":"hgnc:HGNC:38248","description":"microRNA 548x","metadata":{"aliases":["hsa-mir-548x"]}},{"id":"a97a6d3a8f3b42fd8a62b206346881c6","type":"GENE","name":"MIR548X2","canonical_id":"hgnc:HGNC:41734","description":"microRNA 548x-2","metadata":{"aliases":["hsa-mir-548x-2"]}},{"id":"fb1b47f256df419abdfb775c4dd9872a","type":"GENE","name":"MIR548XHG","canonical_id":"hgnc:HGNC:52006","description":"MIR548X host gene","metadata":null},{"id":"101c19b44f2a4f308d93e9c6906be648","type":"GENE","name":"MIR548Y","canonical_id":"hgnc:HGNC:38980","description":"microRNA 548y","metadata":{"aliases":["hsa-mir-548y"]}},{"id":"82b7e22ac2004e4da185bd037f309dd6","type":"GENE","name":"MIR548Z","canonical_id":"hgnc:HGNC:38929","description":"microRNA 548z","metadata":{"aliases":["hsa-mir-548z"]}},{"id":"b3ab2dc358ea4ac1b1fa7c3d6b364f37","type":"GENE","name":"MIR549A","canonical_id":"hgnc:HGNC:32803","description":"microRNA 549a","metadata":{"aliases":["hsa-mir-549","MIRN549","MIR549"]}},{"id":"136f8d10f55f463182853635dc753dbb","type":"GENE","name":"MIR550A1","canonical_id":"hgnc:HGNC:32804","description":"microRNA 550a-1","metadata":{"aliases":["hsa-mir-550-1","MIRN550-1","MIR550-1"]}},{"id":"19484ada0ce4428ebf2f09325d9181a2","type":"GENE","name":"MIR550A2","canonical_id":"hgnc:HGNC:32805","description":"microRNA 550a-2","metadata":{"aliases":["hsa-mir-550-2","hsa-mir-550a-2","MIRN550-2","MIR550-2"]}},{"id":"f23e07af0b9c432ab2aa266d6f620205","type":"GENE","name":"MIR550A3","canonical_id":"hgnc:HGNC:41870","description":"microRNA 550a-3","metadata":{"aliases":["hsa-mir-550a-3"]}},{"id":"8ad8506dd7b746d1bba999046651de2f","type":"GENE","name":"MIR550A3HG","canonical_id":"hgnc:HGNC:58072","description":"MIR550A3 host gene","metadata":null},{"id":"f8c4a2c49a244a918daeec8303b84dd1","type":"GENE","name":"MIR550B1","canonical_id":"hgnc:HGNC:38992","description":"microRNA 550b-1","metadata":{"aliases":["hsa-mir-550b-1"]}},{"id":"83b8909ae3c44a35a16ad9d4a62a84e7","type":"GENE","name":"MIR550B2","canonical_id":"hgnc:HGNC:38910","description":"microRNA 550b-2","metadata":{"aliases":["hsa-mir-550b-2"]}},{"id":"aa2afd9a5390454ea3cc51e4e24bfa00","type":"GENE","name":"MIR551A","canonical_id":"hgnc:HGNC:32806","description":"microRNA 551a","metadata":{"aliases":["hsa-mir-551a","MIRN551A"]}},{"id":"e9387679be344f22929bd626f07974b1","type":"GENE","name":"MIR551B","canonical_id":"hgnc:HGNC:32807","description":"microRNA 551b","metadata":{"aliases":["hsa-mir-551b","MIRN551B"]}},{"id":"f9e378c479f545928c4a620c08209162","type":"GENE","name":"MIR552","canonical_id":"hgnc:HGNC:32808","description":"microRNA 552","metadata":{"aliases":["hsa-mir-552","MIRN552"]}},{"id":"7d5d9c69bdf14da792dfe9878f1b0902","type":"GENE","name":"MIR553","canonical_id":"hgnc:HGNC:32809","description":"microRNA 553","metadata":{"aliases":["hsa-mir-553","MIRN553"]}},{"id":"880478b8e6d3475fa7a4491750ed3b73","type":"GENE","name":"MIR554","canonical_id":"hgnc:HGNC:32810","description":"microRNA 554","metadata":{"aliases":["hsa-mir-554","MIRN554"]}},{"id":"47f382495c5343598cdc41303ac15f5c","type":"GENE","name":"MIR555","canonical_id":"hgnc:HGNC:32811","description":"microRNA 555","metadata":{"aliases":["hsa-mir-555","MIRN555"]}},{"id":"d2efe119cf7b4755a5580478ed8e8537","type":"GENE","name":"MIR556","canonical_id":"hgnc:HGNC:32812","description":"microRNA 556","metadata":{"aliases":["hsa-mir-556","MIRN556"]}},{"id":"11e843e2895b449b995670ee01c9c4ae","type":"GENE","name":"MIR557","canonical_id":"hgnc:HGNC:32813","description":"microRNA 557","metadata":{"aliases":["hsa-mir-557","MIRN557"]}},{"id":"d4a936ea76984c768f45e795e33fa064","type":"GENE","name":"MIR5571","canonical_id":"hgnc:HGNC:43513","description":"microRNA 5571","metadata":{"aliases":["hsa-mir-5571"]}},{"id":"8c4e392e835b45e291201cf60c4d506f","type":"GENE","name":"MIR5572","canonical_id":"hgnc:HGNC:43476","description":"microRNA 5572","metadata":{"aliases":["hsa-mir-5572"]}},{"id":"03711b7ab8b24ee6bf6544d10c790a1d","type":"GENE","name":"MIR5579","canonical_id":"hgnc:HGNC:43485","description":"microRNA 5579","metadata":{"aliases":["hsa-mir-5579"]}},{"id":"8c6de04443ec4bf58c662563228c0091","type":"GENE","name":"MIR558","canonical_id":"hgnc:HGNC:32814","description":"microRNA 558","metadata":{"aliases":["hsa-mir-558","MIRN558"]}},{"id":"fadb2bd573064c42aafa46d3721e814a","type":"GENE","name":"MIR5580","canonical_id":"hgnc:HGNC:43482","description":"microRNA 5580","metadata":{"aliases":["hsa-mir-5580"]}},{"id":"ec65a8aec75a4be6b6c276049cfd13b9","type":"GENE","name":"MIR5581","canonical_id":"hgnc:HGNC:43527","description":"microRNA 5581","metadata":{"aliases":["hsa-mir-5581"]}},{"id":"842078dfbf9b49c8bd0bb611518f50bc","type":"GENE","name":"MIR5582","canonical_id":"hgnc:HGNC:43461","description":"microRNA 5582","metadata":{"aliases":["hsa-mir-5582"]}},{"id":"7d0b916f88994524b5853eeab13491f6","type":"GENE","name":"MIR5583-1","canonical_id":"hgnc:HGNC:43491","description":"microRNA 5583-1","metadata":{"aliases":["hsa-mir-5583-1"]}},{"id":"2dce73994aa144c698a021c3e95b1a27","type":"GENE","name":"MIR5583-2","canonical_id":"hgnc:HGNC:43471","description":"microRNA 5583-2","metadata":{"aliases":["hsa-mir-5583-2"]}},{"id":"86090e5555644141be48f2bd88b50e99","type":"GENE","name":"MIR5584","canonical_id":"hgnc:HGNC:43507","description":"microRNA 5584","metadata":{"aliases":["hsa-mir-5584"]}},{"id":"518c872704274e6b85b1703552a29f04","type":"GENE","name":"MIR5585","canonical_id":"hgnc:HGNC:43452","description":"microRNA 5585","metadata":{"aliases":["hsa-mir-5585"]}},{"id":"2aa65f0c458146d39bfa0dba3d377720","type":"GENE","name":"MIR5586","canonical_id":"hgnc:HGNC:43493","description":"microRNA 5586","metadata":{"aliases":["hsa-mir-5586"]}},{"id":"e15e7bbeb2b6442eb5a151348b9ee8dd","type":"GENE","name":"MIR5587","canonical_id":"hgnc:HGNC:43508","description":"microRNA 5587","metadata":{"aliases":["hsa-mir-5587"]}},{"id":"1abafff6087e466886b324a4bc12b3f8","type":"GENE","name":"MIR5588","canonical_id":"hgnc:HGNC:43505","description":"microRNA 5588","metadata":{"aliases":["hsa-mir-5588"]}},{"id":"0b75d1bbcc954eb88a6db43d0ad59542","type":"GENE","name":"MIR5589","canonical_id":"hgnc:HGNC:43514","description":"microRNA 5589","metadata":{"aliases":["hsa-mir-5589"]}},{"id":"f53cc75907314d8bae92833c0871b185","type":"GENE","name":"MIR559","canonical_id":"hgnc:HGNC:32815","description":"microRNA 559","metadata":{"aliases":["hsa-mir-559","MIRN559"]}},{"id":"49a10426e2e542b691169f81be2fcfb4","type":"GENE","name":"MIR5590","canonical_id":"hgnc:HGNC:43541","description":"microRNA 5590","metadata":{"aliases":["hsa-mir-5590"]}},{"id":"8dadfb8b38194597854b7dc3989f16b7","type":"GENE","name":"MIR5591","canonical_id":"hgnc:HGNC:43531","description":"microRNA 5591","metadata":{"aliases":["hsa-mir-5591"]}},{"id":"e13c1cdb1a5547d187b9373d951f26df","type":"GENE","name":"MIR561","canonical_id":"hgnc:HGNC:32817","description":"microRNA 561","metadata":{"aliases":["hsa-mir-561","MIRN561"]}},{"id":"b892efa60d8b42c8a8a283828ffd68fc","type":"GENE","name":"MIR562","canonical_id":"hgnc:HGNC:32818","description":"microRNA 562","metadata":{"aliases":["hsa-mir-562","MIRN562"]}},{"id":"804d044e84e148fdbe309176c5622ec3","type":"GENE","name":"MIR563","canonical_id":"hgnc:HGNC:32819","description":"microRNA 563","metadata":{"aliases":["hsa-mir-563","MIRN563"]}},{"id":"25231dd9dbbf4f7fbc93355b4dc4ffae","type":"GENE","name":"MIR564","canonical_id":"hgnc:HGNC:32820","description":"microRNA 564","metadata":{"aliases":["hsa-mir-564","MIRN564"]}},{"id":"ac7de48be7e44e0caa59d25deafa9ae3","type":"GENE","name":"MIR567","canonical_id":"hgnc:HGNC:32823","description":"microRNA 567","metadata":{"aliases":["hsa-mir-567","MIRN567"]}},{"id":"452567b4c0a54ec8bed33888a588ffa8","type":"GENE","name":"MIR568","canonical_id":"hgnc:HGNC:32824","description":"microRNA 568","metadata":{"aliases":["hsa-mir-568","MIRN568"]}},{"id":"e94dea86de564062995dfaa63bd4ea87","type":"GENE","name":"MIR5680","canonical_id":"hgnc:HGNC:43492","description":"microRNA 5680","metadata":{"aliases":["hsa-mir-5680"]}},{"id":"23eb4acad8b149eaa0f7e97c180f1ee5","type":"GENE","name":"MIR5681A","canonical_id":"hgnc:HGNC:43518","description":"microRNA 5681a","metadata":{"aliases":["hsa-mir-5681a"]}},{"id":"647bad27a2a94314bb41c65857982ff4","type":"GENE","name":"MIR5681B","canonical_id":"hgnc:HGNC:43538","description":"microRNA 5681b","metadata":{"aliases":["hsa-mir-5681b"]}},{"id":"3f5bcb06b8a44fd5b0c65143efd3db17","type":"GENE","name":"MIR5682","canonical_id":"hgnc:HGNC:43477","description":"microRNA 5682","metadata":{"aliases":["hsa-mir-5682"]}},{"id":"afd36fd89df1448581f03003af6f8426","type":"GENE","name":"MIR5683","canonical_id":"hgnc:HGNC:43453","description":"microRNA 5683","metadata":{"aliases":["hsa-mir-5683"]}},{"id":"544b255dbd2444e2a6805e3b37220421","type":"GENE","name":"MIR5684","canonical_id":"hgnc:HGNC:43544","description":"microRNA 5684","metadata":{"aliases":["hsa-mir-5684"]}},{"id":"91b6c898cbdf436386624c791b9d5e36","type":"GENE","name":"MIR5685","canonical_id":"hgnc:HGNC:43543","description":"microRNA 5685","metadata":{"aliases":["hsa-mir-5685"]}},{"id":"648a3b37d5364ac6aa8c9e7417dc3a7b","type":"GENE","name":"MIR5687","canonical_id":"hgnc:HGNC:43457","description":"microRNA 5687","metadata":{"aliases":["hsa-mir-5687"]}},{"id":"7c8ed0da4f6042c3b518be95891b1aa2","type":"GENE","name":"MIR5688","canonical_id":"hgnc:HGNC:43463","description":"microRNA 5688","metadata":{"aliases":["hsa-mir-5688"]}},{"id":"d0ddd1188f4e48f898296a46786719de","type":"GENE","name":"MIR5689","canonical_id":"hgnc:HGNC:43479","description":"microRNA 5689","metadata":{"aliases":["hsa-mir-5689"]}},{"id":"a6d3a002d5534ac3ab92a5efc6dbaaba","type":"GENE","name":"MIR5689HG","canonical_id":"hgnc:HGNC:52007","description":"MIR5689 host gene","metadata":null},{"id":"a8b951efe3c24a0db40c2cae501e5bce","type":"GENE","name":"MIR569","canonical_id":"hgnc:HGNC:32825","description":"microRNA 569","metadata":{"aliases":["hsa-mir-569","MIRN569"]}},{"id":"76145784f41944c7aaabb25867057923","type":"GENE","name":"MIR5690","canonical_id":"hgnc:HGNC:43490","description":"microRNA 5690","metadata":{"aliases":["hsa-mir-5690"]}},{"id":"c030d914da2d4e59bd8fdd1f4427e034","type":"GENE","name":"MIR5691","canonical_id":"hgnc:HGNC:43545","description":"microRNA 5691","metadata":{"aliases":["hsa-mir-5691"]}},{"id":"4799f6b9acb140a48c574919a4622057","type":"GENE","name":"MIR5692A1","canonical_id":"hgnc:HGNC:43533","description":"microRNA 5692a-1","metadata":{"aliases":["hsa-mir-5692a-1"]}},{"id":"6d9829d595d54258bd8a27d459aec0d9","type":"GENE","name":"MIR5692A2","canonical_id":"hgnc:HGNC:43466","description":"microRNA 5692a-2","metadata":{"aliases":["hsa-mir-5692a-2"]}},{"id":"cf7b87fc84b2447d876223cb0f11ee2a","type":"GENE","name":"MIR5692B","canonical_id":"hgnc:HGNC:43535","description":"microRNA 5692b","metadata":{"aliases":["hsa-mir-5692b"]}},{"id":"d9c06c36c809429aba5d24ed18d617fe","type":"GENE","name":"MIR5692C1","canonical_id":"hgnc:HGNC:43506","description":"microRNA 5692c-1","metadata":{"aliases":["hsa-mir-5692c-1"]}},{"id":"b9773139ee1f4db9898cd8f84c1e4a77","type":"GENE","name":"MIR5692C2","canonical_id":"hgnc:HGNC:43448","description":"microRNA 5692c-2","metadata":{"aliases":["hsa-mir-5692c-2"]}},{"id":"952c05ad76394deb9c81b957e92e31f1","type":"GENE","name":"MIR5693","canonical_id":"hgnc:HGNC:43499","description":"microRNA 5693","metadata":{"aliases":["hsa-mir-5693"]}},{"id":"b0074f76d84248dabe337991c8a6ebe9","type":"GENE","name":"MIR5694","canonical_id":"hgnc:HGNC:43530","description":"microRNA 5694","metadata":{"aliases":["hsa-mir-5694"]}},{"id":"d782fc8872114747b9d3acaa7d6e6633","type":"GENE","name":"MIR5695","canonical_id":"hgnc:HGNC:43548","description":"microRNA 5695","metadata":{"aliases":["hsa-mir-5695"]}},{"id":"0d0e9f3699364af79b0ca8063b6af01d","type":"GENE","name":"MIR5696","canonical_id":"hgnc:HGNC:43516","description":"microRNA 5696","metadata":{"aliases":["hsa-mir-5696"]}},{"id":"c001cf8e7a8245ac86cbb9566758ee77","type":"GENE","name":"MIR5697","canonical_id":"hgnc:HGNC:43509","description":"microRNA 5697","metadata":{"aliases":["hsa-mir-5697"]}},{"id":"60c0427f7d4d4f3a83f118b0fcdd0d89","type":"GENE","name":"MIR5698","canonical_id":"hgnc:HGNC:43487","description":"microRNA 5698","metadata":{"aliases":["hsa-mir-5698"]}},{"id":"52f3154bb7394d99b9c7632a8fdb55a8","type":"GENE","name":"MIR5699","canonical_id":"hgnc:HGNC:43456","description":"microRNA 5699","metadata":{"aliases":["hsa-mir-5699"]}},{"id":"c4c9da5c09334871aadcfecad1b54325","type":"GENE","name":"MIR570","canonical_id":"hgnc:HGNC:32826","description":"microRNA 570","metadata":{"aliases":["hsa-mir-570","MIRN570"]}},{"id":"e36e02c366db4fd8bf901c784a7f4b6b","type":"GENE","name":"MIR5700","canonical_id":"hgnc:HGNC:43521","description":"microRNA 5700","metadata":{"aliases":["hsa-mir-5700"]}},{"id":"b3214b5636bf457bbc70b74280cff0a5","type":"GENE","name":"MIR5701-1","canonical_id":"hgnc:HGNC:43522","description":"microRNA 5701-1","metadata":{"aliases":["hsa-mir-5701-1"]}},{"id":"230bcae7d4ae4128be5fcc557b072b92","type":"GENE","name":"MIR5701-2","canonical_id":"hgnc:HGNC:43510","description":"microRNA 5701-2","metadata":{"aliases":["hsa-mir-5701-2"]}},{"id":"b9bc6a459f884cd6b611cf5e0bd80896","type":"GENE","name":"MIR5701-3","canonical_id":"hgnc:HGNC:50844","description":"microRNA 5701-3","metadata":null},{"id":"de97e91ea5da49aaa3f9e55b8ba7a9e1","type":"GENE","name":"MIR5702","canonical_id":"hgnc:HGNC:43503","description":"microRNA 5702","metadata":{"aliases":["hsa-mir-5702"]}},{"id":"674af7cbbf0b4380a372c5b3084c0c68","type":"GENE","name":"MIR5703","canonical_id":"hgnc:HGNC:43475","description":"microRNA 5703","metadata":{"aliases":["hsa-mir-5703"]}},{"id":"dbd4c1a9e258472a9a80295f698f0a4b","type":"GENE","name":"MIR5704","canonical_id":"hgnc:HGNC:43469","description":"microRNA 5704","metadata":{"aliases":["hsa-mir-5704"]}},{"id":"370f63f634c14db99234a083a051056f","type":"GENE","name":"MIR5705","canonical_id":"hgnc:HGNC:43504","description":"microRNA 5705","metadata":{"aliases":["hsa-mir-5705"]}},{"id":"c6111bebf13248d781a5223e5273dc59","type":"GENE","name":"MIR5706","canonical_id":"hgnc:HGNC:43500","description":"microRNA 5706","metadata":{"aliases":["hsa-mir-5706"]}},{"id":"9360ef6df31f4e9a96d0ddbf283e4cd8","type":"GENE","name":"MIR5707","canonical_id":"hgnc:HGNC:43449","description":"microRNA 5707","metadata":{"aliases":["hsa-mir-5707"]}},{"id":"2c640d923ddb4fb7895551bee30fb0f7","type":"GENE","name":"MIR5708","canonical_id":"hgnc:HGNC:43511","description":"microRNA 5708","metadata":{"aliases":["hsa-mir-5708"]}},{"id":"15d1405feb524ae1bf186aa6e3d21949","type":"GENE","name":"MIR570HG","canonical_id":"hgnc:HGNC:53743","description":"MIR570 host gene","metadata":{"aliases":["ENST00000453324","LINC00969"]}},{"id":"a273aa2265a942e6912a630a26913988","type":"GENE","name":"MIR571","canonical_id":"hgnc:HGNC:32827","description":"microRNA 571","metadata":{"aliases":["hsa-mir-571","MIRN571"]}},{"id":"4c719d5040914a9d8b1cd780417bc1bf","type":"GENE","name":"MIR572","canonical_id":"hgnc:HGNC:32828","description":"microRNA 572","metadata":{"aliases":["hsa-mir-572","MIRN572"]}},{"id":"b3be351ac97641dc8b85126dbac2fd0e","type":"GENE","name":"MIR573","canonical_id":"hgnc:HGNC:32829","description":"microRNA 573","metadata":{"aliases":["hsa-mir-573","MIRN573"]}},{"id":"39f74b066ac34811b575b28566e8ff21","type":"GENE","name":"MIR5739","canonical_id":"hgnc:HGNC:49977","description":"microRNA 5739","metadata":{"aliases":["hsa-mir-5739"]}},{"id":"38918803510b47c997e8b4f77996933b","type":"GENE","name":"MIR574","canonical_id":"hgnc:HGNC:32830","description":"microRNA 574","metadata":{"aliases":["hsa-mir-574","MIRN574"]}},{"id":"ab86d01ac822438e95569830c0228b4e","type":"GENE","name":"MIR575","canonical_id":"hgnc:HGNC:32831","description":"microRNA 575","metadata":{"aliases":["hsa-mir-575","MIRN575"]}},{"id":"9adbdac7b133495fb353f940a5a3c359","type":"GENE","name":"MIR576","canonical_id":"hgnc:HGNC:32832","description":"microRNA 576","metadata":{"aliases":["hsa-mir-576","MIRN576"]}},{"id":"c0bbd16c9906416a9a17d4590b7c1576","type":"GENE","name":"MIR577","canonical_id":"hgnc:HGNC:32833","description":"microRNA 577","metadata":{"aliases":["hsa-mir-577","MIRN577"]}},{"id":"86149ae041a647fcb89f72399c06c257","type":"GENE","name":"MIR578","canonical_id":"hgnc:HGNC:32834","description":"microRNA 578","metadata":{"aliases":["hsa-mir-578","MIRN578"]}},{"id":"227cf3ebd66945ca832c9d4a16cafd2f","type":"GENE","name":"MIR5787","canonical_id":"hgnc:HGNC:49930","description":"microRNA 5787","metadata":{"aliases":["hsa-mir-5787"]}},{"id":"f31076c8740d4e4285564dbf15cc2dd6","type":"GENE","name":"MIR579","canonical_id":"hgnc:HGNC:32835","description":"microRNA 579","metadata":{"aliases":["hsa-mir-579","MIRN579"]}},{"id":"835b4f86393d409388e2c801e2f0ca2b","type":"GENE","name":"MIR580","canonical_id":"hgnc:HGNC:32836","description":"microRNA 580","metadata":{"aliases":["hsa-mir-580","MIRN580"]}},{"id":"fd2d813eb63c458d81ae06003335ce80","type":"GENE","name":"MIR581","canonical_id":"hgnc:HGNC:32837","description":"microRNA 581","metadata":{"aliases":["hsa-mir-581","MIRN581"]}},{"id":"085de2b669104c7cac5808f2c3a02e11","type":"GENE","name":"MIR582","canonical_id":"hgnc:HGNC:32838","description":"microRNA 582","metadata":{"aliases":["hsa-mir-582","MIRN582"]}},{"id":"94cb036edcc447dbaa9f8d098ec34b84","type":"GENE","name":"MIR583","canonical_id":"hgnc:HGNC:32839","description":"microRNA 583","metadata":{"aliases":["hsa-mir-583","MIRN583"]}},{"id":"af604ccdeecc4cb48496f4488c909c24","type":"GENE","name":"MIR584","canonical_id":"hgnc:HGNC:32840","description":"microRNA 584","metadata":{"aliases":["hsa-mir-584","MIRN584"]}},{"id":"a0f94bfa6ecd4643aefc5c6f995452f7","type":"GENE","name":"MIR585","canonical_id":"hgnc:HGNC:32841","description":"microRNA 585","metadata":{"aliases":["hsa-mir-585","MIRN585"]}},{"id":"d111321e71a84eeba2b3eea1bf622829","type":"GENE","name":"MIR586","canonical_id":"hgnc:HGNC:32842","description":"microRNA 586","metadata":{"aliases":["hsa-mir-586","MIRN586"]}},{"id":"73a1e568306d48619f0c26adb5d65a96","type":"GENE","name":"MIR587","canonical_id":"hgnc:HGNC:32843","description":"microRNA 587","metadata":{"aliases":["hsa-mir-587","MIRN587"]}},{"id":"f76087d2ae65499b934159fa6c8b68f4","type":"GENE","name":"MIR588","canonical_id":"hgnc:HGNC:32844","description":"microRNA 588","metadata":{"aliases":["hsa-mir-588","MIRN588"]}},{"id":"010cc90bf17c414d9caa0a96ab0d3f7b","type":"GENE","name":"MIR589","canonical_id":"hgnc:HGNC:32845","description":"microRNA 589","metadata":{"aliases":["hsa-mir-589","MIRN589"]}},{"id":"f85f57a5c24e4c9f9885b6f1e4b469d7","type":"GENE","name":"MIR590","canonical_id":"hgnc:HGNC:32846","description":"microRNA 590","metadata":{"aliases":["hsa-mir-590","MIRN590"]}},{"id":"58f6b721ac33485792fa0f46e5f51fe2","type":"GENE","name":"MIR591","canonical_id":"hgnc:HGNC:32847","description":"microRNA 591","metadata":{"aliases":["hsa-mir-591","MIRN591"]}},{"id":"baae043b6d1744e9a4fce99267ce02f8","type":"GENE","name":"MIR592","canonical_id":"hgnc:HGNC:32848","description":"microRNA 592","metadata":{"aliases":["hsa-mir-592","MIRN592"]}},{"id":"85f8bb16697e46b695c69087d316ae66","type":"GENE","name":"MIR593","canonical_id":"hgnc:HGNC:32849","description":"microRNA 593","metadata":{"aliases":["hsa-mir-593","MIRN593"]}},{"id":"c9ba784e2605433aab3f20e364049315","type":"GENE","name":"MIR595","canonical_id":"hgnc:HGNC:32851","description":"microRNA 595","metadata":{"aliases":["hsa-mir-595","MIRN595"]}},{"id":"01fedf2c799a45179cf551d433b82d4a","type":"GENE","name":"MIR596","canonical_id":"hgnc:HGNC:32852","description":"microRNA 596","metadata":{"aliases":["hsa-mir-596","MIRN596"]}},{"id":"67ab3d08dd714a85b3d9950fc6d5d314","type":"GENE","name":"MIR597","canonical_id":"hgnc:HGNC:32853","description":"microRNA 597","metadata":{"aliases":["hsa-mir-597","MIRN597"]}},{"id":"7dfc695f59104b629926b81dd9488fba","type":"GENE","name":"MIR598","canonical_id":"hgnc:HGNC:32854","description":"microRNA 598","metadata":{"aliases":["hsa-mir-598","MIRN598"]}},{"id":"6383697fcbab42cda2703bb27006cbac","type":"GENE","name":"MIR599","canonical_id":"hgnc:HGNC:32855","description":"microRNA 599","metadata":{"aliases":["hsa-mir-599","MIRN599"]}},{"id":"fb212fd86d65485e9a55c72add69ec63","type":"GENE","name":"MIR600","canonical_id":"hgnc:HGNC:32856","description":"microRNA 600","metadata":{"aliases":["hsa-mir-600","MIRN600"]}},{"id":"ad03cb66928448b4bb6caf71a6d73953","type":"GENE","name":"MIR600HG","canonical_id":"hgnc:HGNC:23642","description":"MIR600 host gene","metadata":{"aliases":["GL012","FLJ22161","C9orf45","NCRNA00287"]}},{"id":"48f7aef6c35f41879fdfbab9a89299be","type":"GENE","name":"MIR601","canonical_id":"hgnc:HGNC:32857","description":"microRNA 601","metadata":{"aliases":["hsa-mir-601","MIRN601"]}},{"id":"355024435c81470b97c62d61f9c82590","type":"GENE","name":"MIR602","canonical_id":"hgnc:HGNC:32858","description":"microRNA 602","metadata":{"aliases":["hsa-mir-602","MIRN602"]}},{"id":"2c6fe2458b2f4f82a337a4aef9f21e4f","type":"GENE","name":"MIR603","canonical_id":"hgnc:HGNC:32859","description":"microRNA 603","metadata":{"aliases":["hsa-mir-603","MIRN603"]}},{"id":"bd929cf99aab4ff3a32688a43f0c7cba","type":"GENE","name":"MIR604","canonical_id":"hgnc:HGNC:32860","description":"microRNA 604","metadata":{"aliases":["hsa-mir-604","MIRN604"]}},{"id":"e5ea793bbf9a42918e3cf40116f0eee2","type":"GENE","name":"MIR605","canonical_id":"hgnc:HGNC:32861","description":"microRNA 605","metadata":{"aliases":["hsa-mir-605","MIRN605"]}},{"id":"6fc4ed44b4864b6eab87d2a64d79c4e8","type":"GENE","name":"MIR606","canonical_id":"hgnc:HGNC:32862","description":"microRNA 606","metadata":{"aliases":["hsa-mir-606","MIRN606"]}},{"id":"c82d530b29b14e059809855eb437081b","type":"GENE","name":"MIR6068","canonical_id":"hgnc:HGNC:50261","description":"microRNA 6068","metadata":{"aliases":["hsa-mir-6068"]}},{"id":"71d2c7df8da9410aa444bb20a79cbf0b","type":"GENE","name":"MIR6069","canonical_id":"hgnc:HGNC:50124","description":"microRNA 6069","metadata":{"aliases":["hsa-mir-6069"]}},{"id":"2a6f0323956d4f028509cc069ede98d7","type":"GENE","name":"MIR607","canonical_id":"hgnc:HGNC:32863","description":"microRNA 607","metadata":{"aliases":["hsa-mir-607","MIRN607"]}},{"id":"5e45fd5f21b245d9ad91acc03dc317b7","type":"GENE","name":"MIR6070","canonical_id":"hgnc:HGNC:49950","description":"microRNA 6070","metadata":{"aliases":["hsa-mir-6070"]}},{"id":"a6dcb0733d724a5d981ecd6153ae2405","type":"GENE","name":"MIR6071","canonical_id":"hgnc:HGNC:50229","description":"microRNA 6071","metadata":{"aliases":["hsa-mir-6071"]}},{"id":"d515443cc81e45df9da8ca14eb8b6f46","type":"GENE","name":"MIR6072","canonical_id":"hgnc:HGNC:50144","description":"microRNA 6072","metadata":{"aliases":["hsa-mir-6072"]}},{"id":"7a1f7614df97445f910572d117e422d6","type":"GENE","name":"MIR6073","canonical_id":"hgnc:HGNC:50128","description":"microRNA 6073","metadata":{"aliases":["hsa-mir-6073"]}},{"id":"14092d5a19e745f787b9939ae96fad85","type":"GENE","name":"MIR6074","canonical_id":"hgnc:HGNC:50060","description":"microRNA 6074","metadata":{"aliases":["hsa-mir-6074"]}},{"id":"7a2a571584bd470c9f003ef3ff626256","type":"GENE","name":"MIR6075","canonical_id":"hgnc:HGNC:50198","description":"microRNA 6075","metadata":{"aliases":["hsa-mir-6075"]}},{"id":"dc0edbd6e38d439d94f60c7418f3fefb","type":"GENE","name":"MIR6076","canonical_id":"hgnc:HGNC:50232","description":"microRNA 6076","metadata":{"aliases":["hsa-mir-6076"]}},{"id":"62a3fd01552c456f8ccbae7a8ad84570","type":"GENE","name":"MIR6077","canonical_id":"hgnc:HGNC:50025","description":"microRNA 6077","metadata":{"aliases":["hsa-mir-6077-1","hsa-mir-6077-2","MIR6077-2","MIR6077-1"]}},{"id":"646e92bab8a542e5aab0c637b93b784c","type":"GENE","name":"MIR6078","canonical_id":"hgnc:HGNC:50136","description":"microRNA 6078","metadata":{"aliases":["hsa-mir-6078"]}},{"id":"41bb97c27099479c87e8a9a3d41938d6","type":"GENE","name":"MIR6079","canonical_id":"hgnc:HGNC:50114","description":"microRNA 6079","metadata":{"aliases":["hsa-mir-6079"]}},{"id":"d48503750e684f0ea232d2ccd40b296b","type":"GENE","name":"MIR608","canonical_id":"hgnc:HGNC:32864","description":"microRNA 608","metadata":{"aliases":["hsa-mir-608","MIRN608"]}},{"id":"f74c15fcfa754be8b6e815016707b406","type":"GENE","name":"MIR6080","canonical_id":"hgnc:HGNC:50142","description":"microRNA 6080","metadata":{"aliases":["hsa-mir-6080"]}},{"id":"64b3dc8bd0c8460799146a457ee05b51","type":"GENE","name":"MIR6081","canonical_id":"hgnc:HGNC:50151","description":"microRNA 6081","metadata":{"aliases":["hsa-mir-6081"]}},{"id":"683147736df649d9919017ff9f2b4962","type":"GENE","name":"MIR6082","canonical_id":"hgnc:HGNC:49984","description":"microRNA 6082","metadata":{"aliases":["hsa-mir-6082"]}},{"id":"a6bce6e548a241a5bc4c8b75b726e2f3","type":"GENE","name":"MIR6083","canonical_id":"hgnc:HGNC:50076","description":"microRNA 6083","metadata":{"aliases":["hsa-mir-6083"]}},{"id":"02a345b0cf614a348dec4e98018c2b36","type":"GENE","name":"MIR6084","canonical_id":"hgnc:HGNC:50235","description":"microRNA 6084","metadata":{"aliases":["hsa-mir-6084"]}},{"id":"fa443e30c94147e6bff4e5c58310c83d","type":"GENE","name":"MIR6085","canonical_id":"hgnc:HGNC:50002","description":"microRNA 6085","metadata":{"aliases":["hsa-mir-6085"]}},{"id":"ff05cdb3fbc1437daf87573c839f373c","type":"GENE","name":"MIR6086","canonical_id":"hgnc:HGNC:49986","description":"microRNA 6086","metadata":{"aliases":["hsa-mir-6086"]}},{"id":"c70177abcb374f349ff6efb4f03ea220","type":"GENE","name":"MIR6088","canonical_id":"hgnc:HGNC:50164","description":"microRNA 6088","metadata":{"aliases":["hsa-mir-6088"]}},{"id":"593d9e5f4e1b4d12a453b688f84fd824","type":"GENE","name":"MIR6089","canonical_id":"hgnc:HGNC:50179","description":"microRNA 6089","metadata":{"aliases":["hsa-mir-6089-1","MIR6089-1","MIR6089-2"]}},{"id":"1ae1f5e5347d4c34ad076a131db77261","type":"GENE","name":"MIR609","canonical_id":"hgnc:HGNC:32865","description":"microRNA 609","metadata":{"aliases":["hsa-mir-609","MIRN609"]}},{"id":"8c272b608f484823881f87628e6df86c","type":"GENE","name":"MIR6090","canonical_id":"hgnc:HGNC:50204","description":"microRNA 6090","metadata":{"aliases":["hsa-mir-6090"]}},{"id":"7c222fcaace245aaa06cbf37a5938a5a","type":"GENE","name":"MIR610","canonical_id":"hgnc:HGNC:32866","description":"microRNA 610","metadata":{"aliases":["hsa-mir-610","MIRN610"]}},{"id":"c6c32cc72c04442bbff7bed3c456c3be","type":"GENE","name":"MIR611","canonical_id":"hgnc:HGNC:32867","description":"microRNA 611","metadata":{"aliases":["hsa-mir-611","MIRN611"]}},{"id":"d7e73bb7ec034356b6c488a1d2794cfb","type":"GENE","name":"MIR612","canonical_id":"hgnc:HGNC:32868","description":"microRNA 612","metadata":{"aliases":["hsa-mir-612","MIRN612"]}},{"id":"22c726753c324017a57dc8858843fa32","type":"GENE","name":"MIR6124","canonical_id":"hgnc:HGNC:50200","description":"microRNA 6124","metadata":{"aliases":["hsa-mir-6124"]}},{"id":"818015c7064040ebb42b43b89236071b","type":"GENE","name":"MIR6125","canonical_id":"hgnc:HGNC:49931","description":"microRNA 6125","metadata":{"aliases":["hsa-mir-6125"]}},{"id":"60786335bc914cfa96e46f534ddd72f1","type":"GENE","name":"MIR6126","canonical_id":"hgnc:HGNC:50099","description":"microRNA 6126","metadata":{"aliases":["hsa-mir-6126"]}},{"id":"3e995a5a2ce8405783a8ebfe3f94e14d","type":"GENE","name":"MIR6127","canonical_id":"hgnc:HGNC:50163","description":"microRNA 6127","metadata":{"aliases":["hsa-mir-6127"]}},{"id":"55292902eaaa403a9a32a3de15c70e6f","type":"GENE","name":"MIR6128","canonical_id":"hgnc:HGNC:50109","description":"microRNA 6128","metadata":{"aliases":["hsa-mir-6128"]}},{"id":"874ec315ba8e46eb99293a224c2d43d6","type":"GENE","name":"MIR6129","canonical_id":"hgnc:HGNC:50220","description":"microRNA 6129","metadata":{"aliases":["hsa-mir-6129"]}},{"id":"112cad5d2b68442cb7e5d2d135631907","type":"GENE","name":"MIR613","canonical_id":"hgnc:HGNC:32869","description":"microRNA 613","metadata":{"aliases":["hsa-mir-613","MIRN613"]}},{"id":"dcf5bf64c5324e2b971ce44ca93cb587","type":"GENE","name":"MIR6130","canonical_id":"hgnc:HGNC:50156","description":"microRNA 6130","metadata":{"aliases":["hsa-mir-6130"]}},{"id":"f1f81cc1b249491a8d7eaf9eb2bce891","type":"GENE","name":"MIR6131","canonical_id":"hgnc:HGNC:49929","description":"microRNA 6131","metadata":{"aliases":["hsa-mir-6131"]}},{"id":"944874f3aa434e56ba88cedfbb56ddf9","type":"GENE","name":"MIR6132","canonical_id":"hgnc:HGNC:50272","description":"microRNA 6132","metadata":{"aliases":["hsa-mir-6132"]}},{"id":"2db8797078474788afd147f80ef5ac26","type":"GENE","name":"MIR6133","canonical_id":"hgnc:HGNC:50007","description":"microRNA 6133","metadata":{"aliases":["hsa-mir-6133"]}},{"id":"854c54ac2652446b8e912da2326de611","type":"GENE","name":"MIR6134","canonical_id":"hgnc:HGNC:49951","description":"microRNA 6134","metadata":{"aliases":["hsa-mir-6134"]}},{"id":"97f8c33beed5492e965e31a779a78f38","type":"GENE","name":"MIR614","canonical_id":"hgnc:HGNC:32870","description":"microRNA 614","metadata":{"aliases":["hsa-mir-614","MIRN614"]}},{"id":"c0896d3e55944d2897ca018eb5871995","type":"GENE","name":"MIR615","canonical_id":"hgnc:HGNC:32871","description":"microRNA 615","metadata":{"aliases":["hsa-mir-615","MIRN615"]}},{"id":"d03ef6694e55484084561c4e84c8a46e","type":"GENE","name":"MIR616","canonical_id":"hgnc:HGNC:32872","description":"microRNA 616","metadata":{"aliases":["hsa-mir-616","MIRN616"]}},{"id":"b75f189db05743abaccc1090aa6fe6dd","type":"GENE","name":"MIR6165","canonical_id":"hgnc:HGNC:50197","description":"microRNA 6165","metadata":{"aliases":["hsa-mir-6165"]}},{"id":"747daeb14b6f446a8bb00bde39a8f1a2","type":"GENE","name":"MIR617","canonical_id":"hgnc:HGNC:32873","description":"microRNA 617","metadata":{"aliases":["hsa-mir-617","MIRN617"]}},{"id":"747a00cdce634df39757a6247f14a931","type":"GENE","name":"MIR618","canonical_id":"hgnc:HGNC:32874","description":"microRNA 618","metadata":{"aliases":["hsa-mir-618","MIRN618"]}},{"id":"5f147c5410354c788f946824e5436483","type":"GENE","name":"MIR619","canonical_id":"hgnc:HGNC:32875","description":"microRNA 619","metadata":{"aliases":["hsa-mir-619","MIRN619"]}},{"id":"6848fb3fcaa24b029e3480f573ee49fb","type":"GENE","name":"MIR620","canonical_id":"hgnc:HGNC:32876","description":"microRNA 620","metadata":{"aliases":["hsa-mir-620","MIRN620"]}},{"id":"cb5b16e2e2d944448c78ec150b55022b","type":"GENE","name":"MIR621","canonical_id":"hgnc:HGNC:32877","description":"microRNA 621","metadata":{"aliases":["hsa-mir-621","MIRN621"]}},{"id":"b5e5b3904c36438c8985e81e88f669f0","type":"GENE","name":"MIR622","canonical_id":"hgnc:HGNC:32878","description":"microRNA 622","metadata":{"aliases":["hsa-mir-622","MIRN622"]}},{"id":"87155a2b60134502a922ebb2fdedf957","type":"GENE","name":"MIR623","canonical_id":"hgnc:HGNC:32879","description":"microRNA 623","metadata":{"aliases":["hsa-mir-623","MIRN623"]}},{"id":"e5ad316eeed243d7b04e7a49300287fc","type":"GENE","name":"MIR624","canonical_id":"hgnc:HGNC:32880","description":"microRNA 624","metadata":{"aliases":["hsa-mir-624","MIRN624"]}},{"id":"e5be14d64e0841a599307d463ad0f41e","type":"GENE","name":"MIR625","canonical_id":"hgnc:HGNC:32881","description":"microRNA 625","metadata":{"aliases":["hsa-mir-625","MIRN625"]}},{"id":"4fdd57c3368240228ae937adbfd62cd9","type":"GENE","name":"MIR626","canonical_id":"hgnc:HGNC:32882","description":"microRNA 626","metadata":{"aliases":["hsa-mir-626","MIRN626"]}},{"id":"f7ccc327b02d4ae780bebc38bdda2c6c","type":"GENE","name":"MIR627","canonical_id":"hgnc:HGNC:32883","description":"microRNA 627","metadata":{"aliases":["hsa-mir-627","MIRN627"]}},{"id":"0de13098ae864c63aee07818a8b560b4","type":"GENE","name":"MIR628","canonical_id":"hgnc:HGNC:32884","description":"microRNA 628","metadata":{"aliases":["hsa-mir-628","MIRN628"]}},{"id":"9a057971ecc6418ca23eeab83be2640f","type":"GENE","name":"MIR629","canonical_id":"hgnc:HGNC:32885","description":"microRNA 629","metadata":{"aliases":["hsa-mir-629","MIRN629"]}},{"id":"49a97bea35d344da8d32fbfc1f3d2287","type":"GENE","name":"MIR630","canonical_id":"hgnc:HGNC:32886","description":"microRNA 630","metadata":{"aliases":["hsa-mir-630","MIRN630"]}},{"id":"f5ac1a06e26440da9344f1bf730bcf7b","type":"GENE","name":"MIR631","canonical_id":"hgnc:HGNC:32887","description":"microRNA 631","metadata":{"aliases":["hsa-mir-631","MIRN631"]}},{"id":"9484caae5de54b658095e657e18df1f1","type":"GENE","name":"MIR632","canonical_id":"hgnc:HGNC:32888","description":"microRNA 632","metadata":{"aliases":["hsa-mir-632","MIRN632"]}},{"id":"0a809705b65f456d9c984142728a10de","type":"GENE","name":"MIR633","canonical_id":"hgnc:HGNC:32889","description":"microRNA 633","metadata":{"aliases":["hsa-mir-633","MIRN633"]}},{"id":"910a0de32a254b1fa1a89cc6bfbfe1c7","type":"GENE","name":"MIR634","canonical_id":"hgnc:HGNC:32890","description":"microRNA 634","metadata":{"aliases":["hsa-mir-634","MIRN634"]}},{"id":"fa6eb3a85d504f27bc59f0619f67b017","type":"GENE","name":"MIR635","canonical_id":"hgnc:HGNC:32891","description":"microRNA 635","metadata":{"aliases":["hsa-mir-635","MIRN635"]}},{"id":"c657a887ff3a44869a9ba15ebe2185ba","type":"GENE","name":"MIR636","canonical_id":"hgnc:HGNC:32892","description":"microRNA 636","metadata":{"aliases":["hsa-mir-636","MIRN636"]}},{"id":"ca0f7e9baf9643ce9f6b7464205873c8","type":"GENE","name":"MIR637","canonical_id":"hgnc:HGNC:32893","description":"microRNA 637","metadata":{"aliases":["hsa-mir-637","MIRN637"]}},{"id":"125d33e18b2c4c43872e7c10ccad72e3","type":"GENE","name":"MIR638","canonical_id":"hgnc:HGNC:32894","description":"microRNA 638","metadata":{"aliases":["hsa-mir-638","MIRN638"]}},{"id":"048b7ddbcff94d9d8112b1baf6642fdc","type":"GENE","name":"MIR639","canonical_id":"hgnc:HGNC:32895","description":"microRNA 639","metadata":{"aliases":["hsa-mir-639","MIRN639"]}},{"id":"e74eaf69e0234caaa30258432228ff4c","type":"GENE","name":"MIR640","canonical_id":"hgnc:HGNC:32896","description":"microRNA 640","metadata":{"aliases":["hsa-mir-640","MIRN640"]}},{"id":"7c79b316e5bb4853af9830bc78d2b511","type":"GENE","name":"MIR641","canonical_id":"hgnc:HGNC:32897","description":"microRNA 641","metadata":{"aliases":["hsa-mir-641","MIRN641"]}},{"id":"3febc83e91ed4d89a17324c61825f7c1","type":"GENE","name":"MIR642A","canonical_id":"hgnc:HGNC:32898","description":"microRNA 642a","metadata":{"aliases":["hsa-mir-642","MIRN642","MIR642"]}},{"id":"3dfe2e3415444d2697440910bc8e7a1e","type":"GENE","name":"MIR642B","canonical_id":"hgnc:HGNC:38902","description":"microRNA 642b","metadata":{"aliases":["hsa-mir-642b"]}},{"id":"60e7dfdfbb8c4048b7aa339ba54349fc","type":"GENE","name":"MIR643","canonical_id":"hgnc:HGNC:32899","description":"microRNA 643","metadata":{"aliases":["hsa-mir-643","MIRN643"]}},{"id":"402140a75f2e420e9af7423574582008","type":"GENE","name":"MIR644A","canonical_id":"hgnc:HGNC:32900","description":"microRNA 644a","metadata":{"aliases":["hsa-mir-644","MIRN644","MIR644"]}},{"id":"f4e78c8c4aed4021a503866551e4a452","type":"GENE","name":"MIR645","canonical_id":"hgnc:HGNC:32901","description":"microRNA 645","metadata":{"aliases":["hsa-mir-645","MIRN645"]}},{"id":"335f4c1f68434c479b67342adf372c46","type":"GENE","name":"MIR646","canonical_id":"hgnc:HGNC:32902","description":"microRNA 646","metadata":{"aliases":["hsa-mir-646","MIRN646"]}},{"id":"2d551dd75e884d6f967a2a06a16f10ca","type":"GENE","name":"MIR646HG","canonical_id":"hgnc:HGNC:27659","description":"MIR646 host gene","metadata":{"aliases":["C20orf197","LINC02910"]}},{"id":"d37dbd70264842e4bea9f9eddd1c8218","type":"GENE","name":"MIR647","canonical_id":"hgnc:HGNC:32903","description":"microRNA 647","metadata":{"aliases":["hsa-mir-647","MIRN647"]}},{"id":"b2e4ad3dc7c04f618b98dce6316db5a3","type":"GENE","name":"MIR648","canonical_id":"hgnc:HGNC:32904","description":"microRNA 648","metadata":{"aliases":["hsa-mir-648","MIRN648"]}},{"id":"66c817b8370b46c3b2c9b6ff8f098520","type":"GENE","name":"MIR649","canonical_id":"hgnc:HGNC:32905","description":"microRNA 649","metadata":{"aliases":["hsa-mir-649","MIRN649"]}},{"id":"b2e46c0ec0414a63a713d342df5f4598","type":"GENE","name":"MIR6499","canonical_id":"hgnc:HGNC:49962","description":"microRNA 6499","metadata":{"aliases":["hsa-mir-6499"]}},{"id":"ef851c347767497cacb7c5d742da9a27","type":"GENE","name":"MIR650","canonical_id":"hgnc:HGNC:32906","description":"microRNA 650","metadata":{"aliases":["hsa-mir-650","MIRN650"]}},{"id":"1b276a31fac5474889ff90f3e215551d","type":"GENE","name":"MIR6500","canonical_id":"hgnc:HGNC:49935","description":"microRNA 6500","metadata":{"aliases":["hsa-mir-6500"]}},{"id":"d9e14efeb85148ab9812cdb5437a01a2","type":"GENE","name":"MIR6501","canonical_id":"hgnc:HGNC:50033","description":"microRNA 6501","metadata":{"aliases":["hsa-mir-6501"]}},{"id":"8cda4af17d9b4c18a6a96232cfde1c91","type":"GENE","name":"MIR6502","canonical_id":"hgnc:HGNC:50062","description":"microRNA 6502","metadata":{"aliases":["hsa-mir-6502"]}},{"id":"b0dc9755ac02426faefa37d59486bde0","type":"GENE","name":"MIR6503","canonical_id":"hgnc:HGNC:49968","description":"microRNA 6503","metadata":{"aliases":["hsa-mir-6503"]}},{"id":"1fe3552dd90b4ba6a4f7b4802bc343ba","type":"GENE","name":"MIR6504","canonical_id":"hgnc:HGNC:49976","description":"microRNA 6504","metadata":{"aliases":["hsa-mir-6504"]}},{"id":"4f28762189d8498a86aa25b86e4592c3","type":"GENE","name":"MIR6505","canonical_id":"hgnc:HGNC:50104","description":"microRNA 6505","metadata":{"aliases":["hsa-mir-6505"]}},{"id":"d3ff7d7797fe43369787ac19dd2d1018","type":"GENE","name":"MIR6506","canonical_id":"hgnc:HGNC:50158","description":"microRNA 6506","metadata":{"aliases":["hsa-mir-6506"]}},{"id":"d29bef9101514701b0baa70ad707fe6e","type":"GENE","name":"MIR6507","canonical_id":"hgnc:HGNC:50199","description":"microRNA 6507","metadata":{"aliases":["hsa-mir-6507"]}},{"id":"b1cccd28504b4086b4e5aecd92bf5bc2","type":"GENE","name":"MIR6508","canonical_id":"hgnc:HGNC:50217","description":"microRNA 6508","metadata":{"aliases":["hsa-mir-6508"]}},{"id":"13d49e9ee65c417ba8d1b07747c7c72d","type":"GENE","name":"MIR6509","canonical_id":"hgnc:HGNC:50207","description":"microRNA 6509","metadata":{"aliases":["hsa-mir-6509"]}},{"id":"ed3033541817467085548a94acd750ae","type":"GENE","name":"MIR651","canonical_id":"hgnc:HGNC:32907","description":"microRNA 651","metadata":{"aliases":["hsa-mir-651","MIRN651"]}},{"id":"fbf4eed5d4104c5fa0c132ef6c09368c","type":"GENE","name":"MIR6510","canonical_id":"hgnc:HGNC:50101","description":"microRNA 6510","metadata":{"aliases":["hsa-mir-6510"]}},{"id":"dbff6d81a5bb41ab8987f99f81cc3e8c","type":"GENE","name":"MIR6511A1","canonical_id":"hgnc:HGNC:50119","description":"microRNA 6511a-1","metadata":{"aliases":["hsa-mir-6511a-1"]}},{"id":"c45662fc356e44e9ad20ec12bba01c91","type":"GENE","name":"MIR6511A2","canonical_id":"hgnc:HGNC:50150","description":"microRNA 6511a-2","metadata":{"aliases":["hsa-mir-6511a-2"]}},{"id":"295b375f53164d9bb6913f94f5fd907d","type":"GENE","name":"MIR6511A3","canonical_id":"hgnc:HGNC:50265","description":"microRNA 6511a-3","metadata":{"aliases":["hsa-mir-6511a-3"]}},{"id":"475b901b73fb4997b155f8cf3817ec8e","type":"GENE","name":"MIR6511A4","canonical_id":"hgnc:HGNC:50188","description":"microRNA 6511a-4","metadata":{"aliases":["hsa-mir-6511a-4"]}},{"id":"d89d2ffc50e445ef9a7a4227d77de852","type":"GENE","name":"MIR6511B1","canonical_id":"hgnc:HGNC:50228","description":"microRNA 6511b-1","metadata":{"aliases":["hsa-mir-6511b-1"]}},{"id":"551ed429d2a249ea91b3ff815e4cd7ca","type":"GENE","name":"MIR6511B2","canonical_id":"hgnc:HGNC:50230","description":"microRNA 6511b-2","metadata":{"aliases":["hsa-mir-6511b-2"]}},{"id":"1de8ecaaa8f548ed99681521ce1884b6","type":"GENE","name":"MIR6512","canonical_id":"hgnc:HGNC:50259","description":"microRNA 6512","metadata":{"aliases":["hsa-mir-6512"]}},{"id":"8eb2c4cae2ef4af480516d1f362874f7","type":"GENE","name":"MIR6513","canonical_id":"hgnc:HGNC:50247","description":"microRNA 6513","metadata":{"aliases":["hsa-mir-6513"]}},{"id":"a75748c5051246208ac975c4aa063e43","type":"GENE","name":"MIR6514","canonical_id":"hgnc:HGNC:50147","description":"microRNA 6514","metadata":{"aliases":["hsa-mir-6514"]}},{"id":"77c851339f614a5e9db6993d309e7638","type":"GENE","name":"MIR6515","canonical_id":"hgnc:HGNC:50227","description":"microRNA 6515","metadata":{"aliases":["hsa-mir-6515"]}},{"id":"c49557c110c34b01ba7e89f30fb622f6","type":"GENE","name":"MIR6516","canonical_id":"hgnc:HGNC:50233","description":"microRNA 6516","metadata":{"aliases":["hsa-mir-6516"]}},{"id":"0be16c2c08f549b7893c66419ede4602","type":"GENE","name":"MIR652","canonical_id":"hgnc:HGNC:32908","description":"microRNA 652","metadata":{"aliases":["hsa-mir-652","MIRN652"]}},{"id":"63d1ad323be84338a5feae79cd792abf","type":"GENE","name":"MIR6529","canonical_id":"hgnc:HGNC:54165","description":"microRNA 6529","metadata":{"aliases":["hsa-mir-6529"]}},{"id":"613beca5bb944af6a83394585557899e","type":"GENE","name":"MIR653","canonical_id":"hgnc:HGNC:32909","description":"microRNA 653","metadata":{"aliases":["hsa-mir-653","MIRN653"]}},{"id":"96616536a03e434c8882bf2a3a43f97a","type":"GENE","name":"MIR654","canonical_id":"hgnc:HGNC:32910","description":"microRNA 654","metadata":{"aliases":["hsa-mir-654","MIRN654"]}},{"id":"1ab5ba863dd14952a63b7bf317252ba2","type":"GENE","name":"MIR655","canonical_id":"hgnc:HGNC:32911","description":"microRNA 655","metadata":{"aliases":["hsa-mir-655","MIRN655"]}},{"id":"4f3d91950b6e47acba6e0b3e6dcaaa0b","type":"GENE","name":"MIR656","canonical_id":"hgnc:HGNC:32912","description":"microRNA 656","metadata":{"aliases":["hsa-mir-656","MIRN656"]}},{"id":"fd11adf86e9b4ff2a4f6a968c5e4a496","type":"GENE","name":"MIR657","canonical_id":"hgnc:HGNC:32913","description":"microRNA 657","metadata":{"aliases":["hsa-mir-657","MIRN657"]}},{"id":"c226d3a02cee4337a0a6536ed47533d2","type":"GENE","name":"MIR658","canonical_id":"hgnc:HGNC:32914","description":"microRNA 658","metadata":{"aliases":["hsa-mir-658","MIRN658"]}},{"id":"24bc70016d264e27b041e337eebb83b5","type":"GENE","name":"MIR659","canonical_id":"hgnc:HGNC:32915","description":"microRNA 659","metadata":{"aliases":["hsa-mir-659","MIRN659"]}},{"id":"bfa4012f907f48cd99b9f5a1a878a614","type":"GENE","name":"MIR660","canonical_id":"hgnc:HGNC:32916","description":"microRNA 660","metadata":{"aliases":["hsa-mir-660","MIRN660"]}},{"id":"d1c057eb70ba44f3aa969f709f9ac559","type":"GENE","name":"MIR661","canonical_id":"hgnc:HGNC:32917","description":"microRNA 661","metadata":{"aliases":["hsa-mir-661","MIRN661"]}},{"id":"3c19fd292fb5436d966b93cb9b84d5a8","type":"GENE","name":"MIR662","canonical_id":"hgnc:HGNC:32918","description":"microRNA 662","metadata":{"aliases":["hsa-mir-662","MIRN662"]}},{"id":"6a153244166f4359807d25f0c8346f59","type":"GENE","name":"MIR663A","canonical_id":"hgnc:HGNC:32919","description":"microRNA 663a","metadata":{"aliases":["hsa-mir-663","miR-663a","MIRN663","MIR663"]}},{"id":"64fbba13343246b5b0cd25766d6a6f7a","type":"GENE","name":"MIR663AHG","canonical_id":"hgnc:HGNC:27662","description":"MIR663A host gene","metadata":{"aliases":["RP3-410C9.1"]}},{"id":"8a36317404ff4e1782af2c20ae4dbe5a","type":"GENE","name":"MIR663B","canonical_id":"hgnc:HGNC:35270","description":"microRNA 663b","metadata":{"aliases":["hsa-mir-663b","MIRN663B"]}},{"id":"8de8b3588f164f76b159e952bf97dba2","type":"GENE","name":"MIR664A","canonical_id":"hgnc:HGNC:35370","description":"microRNA 664a","metadata":{"aliases":["hsa-mir-664","MIRN664","MIR664"]}},{"id":"ae0c952ce87e4e9490660d44121da89f","type":"GENE","name":"MIR664B","canonical_id":"hgnc:HGNC:43501","description":"microRNA 664b","metadata":{"aliases":["hsa-mir-664b","MIR644B"]}},{"id":"5d1f936e6e904fb784b2a382417e4a61","type":"GENE","name":"MIR665","canonical_id":"hgnc:HGNC:33662","description":"microRNA 665","metadata":{"aliases":["hsa-mir-665","MIRN665"]}},{"id":"4419df33e4544fa2bf74994ae8666e82","type":"GENE","name":"MIR668","canonical_id":"hgnc:HGNC:33135","description":"microRNA 668","metadata":{"aliases":["hsa-mir-668","MIRN668"]}},{"id":"9000cb06080d4fac847c1a7822184f75","type":"GENE","name":"MIR670","canonical_id":"hgnc:HGNC:37304","description":"microRNA 670","metadata":{"aliases":["hsa-mir-670"]}},{"id":"51279915084341588a1d94ee72a0c821","type":"GENE","name":"MIR670HG","canonical_id":"hgnc:HGNC:49204","description":"MIR670 host gene","metadata":null},{"id":"417cd4ead7de4bb99b8683fbebff034b","type":"GENE","name":"MIR671","canonical_id":"hgnc:HGNC:33134","description":"microRNA 671","metadata":{"aliases":["hsa-mir-671","MIRN671"]}},{"id":"47f727a519a24974872b8c2d808bc1af","type":"GENE","name":"MIR6715A","canonical_id":"hgnc:HGNC:49996","description":"microRNA 6715a","metadata":{"aliases":["hsa-mir-6715a"]}},{"id":"ae90c2bc3970492c856d931bbf2a89d3","type":"GENE","name":"MIR6715B","canonical_id":"hgnc:HGNC:50249","description":"microRNA 6715b","metadata":{"aliases":["hsa-mir-6715b"]}},{"id":"318d338a30b6463080bccc930d71c613","type":"GENE","name":"MIR6716","canonical_id":"hgnc:HGNC:50048","description":"microRNA 6716","metadata":{"aliases":["hsa-mir-6716"]}},{"id":"44c59bbfe5c84d9084ffbb8de60b1ab4","type":"GENE","name":"MIR6717","canonical_id":"hgnc:HGNC:50000","description":"microRNA 6717","metadata":{"aliases":["hsa-mir-6717"]}},{"id":"7fcb6dc801de4b368770ebdeea6110a3","type":"GENE","name":"MIR6718","canonical_id":"hgnc:HGNC:50195","description":"microRNA 6718","metadata":{"aliases":["hsa-mir-6718"]}},{"id":"8b9b6d0088664ca1953a0c2c4c401882","type":"GENE","name":"MIR6719","canonical_id":"hgnc:HGNC:50012","description":"microRNA 6719","metadata":{"aliases":["hsa-mir-6719"]}},{"id":"6a634c58b77c4d259db4c6f66547c54f","type":"GENE","name":"MIR6720","canonical_id":"hgnc:HGNC:50032","description":"microRNA 6720","metadata":{"aliases":["hsa-mir-6720"]}},{"id":"a04ad224dfc0488eb612a9b01104aecb","type":"GENE","name":"MIR6721","canonical_id":"hgnc:HGNC:50049","description":"microRNA 6721","metadata":{"aliases":["hsa-mir-6721"]}},{"id":"fa85f7fb6c6744f0a38af74b409cb347","type":"GENE","name":"MIR6722","canonical_id":"hgnc:HGNC:49927","description":"microRNA 6722","metadata":{"aliases":["hsa-mir-6722"]}},{"id":"314c612cb54a4578a51e61e8b0995452","type":"GENE","name":"MIR6724-1","canonical_id":"hgnc:HGNC:50837","description":"microRNA 6724-1","metadata":null},{"id":"eac8102d63f34658a6d6d59cb8216a98","type":"GENE","name":"MIR6724-2","canonical_id":"hgnc:HGNC:50832","description":"microRNA 6724-2","metadata":null},{"id":"80f0b03761e244f49bc482d88a0e94f5","type":"GENE","name":"MIR6724-3","canonical_id":"hgnc:HGNC:50842","description":"microRNA 6724-3","metadata":null},{"id":"469596ad3e6741b0b4c9a61b1cd66dbc","type":"GENE","name":"MIR6724-4","canonical_id":"hgnc:HGNC:50830","description":"microRNA 6724-4","metadata":null},{"id":"4d7e5402592f4bf692d63c1641c0b29c","type":"GENE","name":"MIR6726","canonical_id":"hgnc:HGNC:50009","description":"microRNA 6726","metadata":{"aliases":["hsa-mir-6726"]}},{"id":"becdb976807241218767d31a080c4548","type":"GENE","name":"MIR6727","canonical_id":"hgnc:HGNC:50171","description":"microRNA 6727","metadata":{"aliases":["hsa-mir-6727"]}},{"id":"7564bd077209402187b5fef870208759","type":"GENE","name":"MIR6728","canonical_id":"hgnc:HGNC:49961","description":"microRNA 6728","metadata":{"aliases":["hsa-mir-6728"]}},{"id":"70a6635a861c481d9fc0a8dbacd319cc","type":"GENE","name":"MIR6729","canonical_id":"hgnc:HGNC:50103","description":"microRNA 6729","metadata":{"aliases":["hsa-mir-6729"]}},{"id":"f07e53d172414dd68d3ea778e6331ef0","type":"GENE","name":"MIR6730","canonical_id":"hgnc:HGNC:50222","description":"microRNA 6730","metadata":{"aliases":["hsa-mir-6730"]}},{"id":"cbb36154b92c4c5388c41c9396d55821","type":"GENE","name":"MIR6731","canonical_id":"hgnc:HGNC:50036","description":"microRNA 6731","metadata":{"aliases":["hsa-mir-6731"]}},{"id":"d51eedb98995449fbbfa57668b65ea72","type":"GENE","name":"MIR6732","canonical_id":"hgnc:HGNC:50066","description":"microRNA 6732","metadata":{"aliases":["hsa-mir-6732"]}},{"id":"48988bb06f8b44ec82e02ce2638f709f","type":"GENE","name":"MIR6733","canonical_id":"hgnc:HGNC:50239","description":"microRNA 6733","metadata":{"aliases":["hsa-mir-6733"]}},{"id":"6f653205a25f413aa2d83177e0c7d43d","type":"GENE","name":"MIR6734","canonical_id":"hgnc:HGNC:50219","description":"microRNA 6734","metadata":{"aliases":["hsa-mir-6734"]}},{"id":"829f66e82fe4482a84ec993987f8e1fe","type":"GENE","name":"MIR6735","canonical_id":"hgnc:HGNC:50126","description":"microRNA 6735","metadata":{"aliases":["hsa-mir-6735"]}},{"id":"c2d98d665475493fb65de7d21b2d8d42","type":"GENE","name":"MIR6736","canonical_id":"hgnc:HGNC:50072","description":"microRNA 6736","metadata":{"aliases":["hsa-mir-6736"]}},{"id":"c93877dcae8d49528a83135f4936c6a0","type":"GENE","name":"MIR6737","canonical_id":"hgnc:HGNC:50273","description":"microRNA 6737","metadata":{"aliases":["hsa-mir-6737"]}},{"id":"e1d594f0e649498aa63c2bc29170d9ed","type":"GENE","name":"MIR6738","canonical_id":"hgnc:HGNC:49939","description":"microRNA 6738","metadata":{"aliases":["hsa-mir-6738"]}},{"id":"c66ac4aba4e44428b8df54c046fd8e8a","type":"GENE","name":"MIR6739","canonical_id":"hgnc:HGNC:50165","description":"microRNA 6739","metadata":{"aliases":["hsa-mir-6739"]}},{"id":"491cf322e1c74a449938d8a5225c0695","type":"GENE","name":"MIR6740","canonical_id":"hgnc:HGNC:50082","description":"microRNA 6740","metadata":{"aliases":["hsa-mir-6740"]}},{"id":"024e9de3b5f140bb850758c46230a6da","type":"GENE","name":"MIR6741","canonical_id":"hgnc:HGNC:50004","description":"microRNA 6741","metadata":{"aliases":["hsa-mir-6741"]}},{"id":"743e9367bbb649f8a4f19775d809d0b4","type":"GENE","name":"MIR6742","canonical_id":"hgnc:HGNC:50090","description":"microRNA 6742","metadata":{"aliases":["hsa-mir-6742"]}},{"id":"6cd2e622f5224136a24788dfb7c58317","type":"GENE","name":"MIR6743","canonical_id":"hgnc:HGNC:50008","description":"microRNA 6743","metadata":{"aliases":["hsa-mir-6743"]}},{"id":"a1393672b8974ab0811d091b87930447","type":"GENE","name":"MIR6744","canonical_id":"hgnc:HGNC:50051","description":"microRNA 6744","metadata":{"aliases":["hsa-mir-6744"]}},{"id":"5d7efa4ee7744def81ff1588887a5fa0","type":"GENE","name":"MIR6745","canonical_id":"hgnc:HGNC:50106","description":"microRNA 6745","metadata":{"aliases":["hsa-mir-6745"]}},{"id":"accb8c9c028243d2b6c634f22a7981cf","type":"GENE","name":"MIR6746","canonical_id":"hgnc:HGNC:49925","description":"microRNA 6746","metadata":{"aliases":["hsa-mir-6746"]}},{"id":"bdbb4db357c74811840940e2496b918b","type":"GENE","name":"MIR6747","canonical_id":"hgnc:HGNC:50027","description":"microRNA 6747","metadata":{"aliases":["hsa-mir-6747"]}},{"id":"77f3e822991c4c45a27977e22f152d1f","type":"GENE","name":"MIR6748","canonical_id":"hgnc:HGNC:50141","description":"microRNA 6748","metadata":{"aliases":["hsa-mir-6748"]}},{"id":"6beafb81bd654b888528b38ef2e15bb9","type":"GENE","name":"MIR6749","canonical_id":"hgnc:HGNC:50087","description":"microRNA 6749","metadata":{"aliases":["hsa-mir-6749"]}},{"id":"10564cd47cf34ed88db862f01311dafd","type":"GENE","name":"MIR675","canonical_id":"hgnc:HGNC:33351","description":"microRNA 675","metadata":{"aliases":["hsa-mir-675","MIRN675"]}},{"id":"c3e9643113a146148412fd4eecf7dd86","type":"GENE","name":"MIR6750","canonical_id":"hgnc:HGNC:49965","description":"microRNA 6750","metadata":{"aliases":["hsa-mir-6750"]}},{"id":"e2159138c4d246e9afc5777fd5676097","type":"GENE","name":"MIR6751","canonical_id":"hgnc:HGNC:49983","description":"microRNA 6751","metadata":{"aliases":["hsa-mir-6751"]}},{"id":"8efa7ef776f44e8186f04fe981fc2b46","type":"GENE","name":"MIR6752","canonical_id":"hgnc:HGNC:50020","description":"microRNA 6752","metadata":{"aliases":["hsa-mir-6752"]}},{"id":"7edac0df971948e1bed7db6a29df5e7f","type":"GENE","name":"MIR6753","canonical_id":"hgnc:HGNC:50255","description":"microRNA 6753","metadata":{"aliases":["hsa-mir-6753"]}},{"id":"b92665e498ce444c94275a2eb0532b0c","type":"GENE","name":"MIR6754","canonical_id":"hgnc:HGNC:50203","description":"microRNA 6754","metadata":{"aliases":["hsa-mir-6754"]}},{"id":"833ce8d01e1140acb10b58d8a58e8073","type":"GENE","name":"MIR6755","canonical_id":"hgnc:HGNC:50224","description":"microRNA 6755","metadata":{"aliases":["hsa-mir-6755"]}},{"id":"f6d8183e29bd432487ac44becf06e1ef","type":"GENE","name":"MIR6756","canonical_id":"hgnc:HGNC:49974","description":"microRNA 6756","metadata":{"aliases":["hsa-mir-6756"]}},{"id":"54dfa8f33f87401981c7afff1f99d152","type":"GENE","name":"MIR6757","canonical_id":"hgnc:HGNC:50160","description":"microRNA 6757","metadata":{"aliases":["hsa-mir-6757"]}},{"id":"736e56a78c24425eaaf9eda3e45861e6","type":"GENE","name":"MIR6758","canonical_id":"hgnc:HGNC:50038","description":"microRNA 6758","metadata":{"aliases":["hsa-mir-6758"]}},{"id":"19fc885f5a4044a4b10201201a3be596","type":"GENE","name":"MIR6759","canonical_id":"hgnc:HGNC:50063","description":"microRNA 6759","metadata":{"aliases":["hsa-mir-6759"]}},{"id":"226dfa0ed25d4b98bd312df7aefefcc8","type":"GENE","name":"MIR676","canonical_id":"hgnc:HGNC:38880","description":"microRNA 676","metadata":{"aliases":["hsa-mir-676"]}},{"id":"09f46198374047adab09c9fde41f299e","type":"GENE","name":"MIR6760","canonical_id":"hgnc:HGNC:49955","description":"microRNA 6760","metadata":{"aliases":["hsa-mir-6760"]}},{"id":"fd520b3b8a6048b8b97b0fd1b0790565","type":"GENE","name":"MIR6761","canonical_id":"hgnc:HGNC:49949","description":"microRNA 6761","metadata":{"aliases":["hsa-mir-6761"]}},{"id":"79173b123e29466283efb58d7adca64b","type":"GENE","name":"MIR6762","canonical_id":"hgnc:HGNC:50168","description":"microRNA 6762","metadata":{"aliases":["hsa-mir-6762"]}},{"id":"b9819445746f47d1805a19e66a749114","type":"GENE","name":"MIR6763","canonical_id":"hgnc:HGNC:50139","description":"microRNA 6763","metadata":{"aliases":["hsa-mir-6763"]}},{"id":"7973f5952c944ee5ba0c00d164cb6263","type":"GENE","name":"MIR6764","canonical_id":"hgnc:HGNC:49994","description":"microRNA 6764","metadata":{"aliases":["hsa-mir-6764"]}},{"id":"e2c750bb30f343d8a29a1ee47d97d125","type":"GENE","name":"MIR6765","canonical_id":"hgnc:HGNC:50030","description":"microRNA 6765","metadata":{"aliases":["hsa-mir-6765"]}},{"id":"20307e56e13045aea97c57ff4ba39f81","type":"GENE","name":"MIR6766","canonical_id":"hgnc:HGNC:49941","description":"microRNA 6766","metadata":{"aliases":["hsa-mir-6766"]}},{"id":"8e5dec12ec76411184e1f432ed16cc53","type":"GENE","name":"MIR6767","canonical_id":"hgnc:HGNC:50133","description":"microRNA 6767","metadata":{"aliases":["hsa-mir-6767"]}},{"id":"ec37d9a36d7842b683492190d4ddee58","type":"GENE","name":"MIR6768","canonical_id":"hgnc:HGNC:50264","description":"microRNA 6768","metadata":{"aliases":["hsa-mir-6768"]}},{"id":"65072349eb364fe9b83fe5a3765cb51d","type":"GENE","name":"MIR6769A","canonical_id":"hgnc:HGNC:50079","description":"microRNA 6769a","metadata":{"aliases":["hsa-mir-6769a"]}},{"id":"897945c7649a4db0b5e52be6504d765e","type":"GENE","name":"MIR6769B","canonical_id":"hgnc:HGNC:50016","description":"microRNA 6769b","metadata":{"aliases":["hsa-mir-6769b"]}},{"id":"abb33a35b1704dc2a9001a53eaddeec7","type":"GENE","name":"MIR6770-1","canonical_id":"hgnc:HGNC:50223","description":"microRNA 6770-1","metadata":{"aliases":["hsa-mir-6770-1"]}},{"id":"376f3f1fe1c94105a07fa27779f46e25","type":"GENE","name":"MIR6770-2","canonical_id":"hgnc:HGNC:50115","description":"microRNA 6770-2","metadata":{"aliases":["hsa-mir-6770-2"]}},{"id":"ecbe7423e8db4c3a8e6977bdd040bd2f","type":"GENE","name":"MIR6770-3","canonical_id":"hgnc:HGNC:50034","description":"microRNA 6770-3","metadata":{"aliases":["hsa-mir-6770-3"]}},{"id":"1a9d6ba56ae04572a08eabf4397b932e","type":"GENE","name":"MIR6771","canonical_id":"hgnc:HGNC:50212","description":"microRNA 6771","metadata":{"aliases":["hsa-mir-6771"]}},{"id":"a81af72b5be84dcaa446d3c93ece3712","type":"GENE","name":"MIR6772","canonical_id":"hgnc:HGNC:50064","description":"microRNA 6772","metadata":{"aliases":["hsa-mir-6772"]}},{"id":"f51ad0c5c7fd4a13850d86d44ed044be","type":"GENE","name":"MIR6773","canonical_id":"hgnc:HGNC:50132","description":"microRNA 6773","metadata":{"aliases":["hsa-mir-6773"]}},{"id":"118514d69b70485dbfe95637693f879a","type":"GENE","name":"MIR6774","canonical_id":"hgnc:HGNC:50202","description":"microRNA 6774","metadata":{"aliases":["hsa-mir-6774"]}},{"id":"22b0c10928934e7c87555199cec25d74","type":"GENE","name":"MIR6775","canonical_id":"hgnc:HGNC:50100","description":"microRNA 6775","metadata":{"aliases":["hsa-mir-6775"]}},{"id":"220a5a3234fc4bf59f6884eaa9dc1fe9","type":"GENE","name":"MIR6776","canonical_id":"hgnc:HGNC:50193","description":"microRNA 6776","metadata":{"aliases":["hsa-mir-6776"]}},{"id":"7da967b0dfe54c74a1533aa352b79c39","type":"GENE","name":"MIR6777","canonical_id":"hgnc:HGNC:50173","description":"microRNA 6777","metadata":{"aliases":["hsa-mir-6777"]}},{"id":"1eee9e9c12d7442f97c4df394684d786","type":"GENE","name":"MIR6778","canonical_id":"hgnc:HGNC:50183","description":"microRNA 6778","metadata":{"aliases":["hsa-mir-6778"]}},{"id":"cb2da40a9bf0475c94e929a186c6e5c0","type":"GENE","name":"MIR6779","canonical_id":"hgnc:HGNC:50148","description":"microRNA 6779","metadata":{"aliases":["hsa-mir-6779"]}},{"id":"93d9f1f891694657b462eae521fa686f","type":"GENE","name":"MIR6780A","canonical_id":"hgnc:HGNC:50069","description":"microRNA 6780a","metadata":{"aliases":["hsa-mir-6780a"]}},{"id":"76b35078d9ed44858f906311454d0daa","type":"GENE","name":"MIR6780B","canonical_id":"hgnc:HGNC:50237","description":"microRNA 6780b","metadata":{"aliases":["hsa-mir-6780b"]}},{"id":"d92c65660666488eacd66b89505a865c","type":"GENE","name":"MIR6781","canonical_id":"hgnc:HGNC:50185","description":"microRNA 6781","metadata":{"aliases":["hsa-mir-6781"]}},{"id":"4caa17e351be45158b832b1b6bbd61d8","type":"GENE","name":"MIR6782","canonical_id":"hgnc:HGNC:50270","description":"microRNA 6782","metadata":{"aliases":["hsa-mir-6782"]}},{"id":"7e03db4204dc40e7891c341309ad0e55","type":"GENE","name":"MIR6783","canonical_id":"hgnc:HGNC:50159","description":"microRNA 6783","metadata":{"aliases":["hsa-mir-6783"]}},{"id":"77b43b76ce254492a194bf6e5112d895","type":"GENE","name":"MIR6784","canonical_id":"hgnc:HGNC:49988","description":"microRNA 6784","metadata":{"aliases":["hsa-mir-6784"]}},{"id":"87919b3e8b1644b197ef488e78d903ef","type":"GENE","name":"MIR6785","canonical_id":"hgnc:HGNC:50206","description":"microRNA 6785","metadata":{"aliases":["hsa-mir-6785"]}},{"id":"fc991ba4ccf94173b2b48b128cb2e539","type":"GENE","name":"MIR6786","canonical_id":"hgnc:HGNC:49970","description":"microRNA 6786","metadata":{"aliases":["hsa-mir-6786"]}},{"id":"fd9a36c4785b42149d425d0cb5b39948","type":"GENE","name":"MIR6787","canonical_id":"hgnc:HGNC:50209","description":"microRNA 6787","metadata":{"aliases":["hsa-mir-6787"]}},{"id":"7643992acbea4a678ee9d2bc4dbaf565","type":"GENE","name":"MIR6788","canonical_id":"hgnc:HGNC:50078","description":"microRNA 6788","metadata":{"aliases":["hsa-mir-6788"]}},{"id":"72ff25fa864142c69ca3e1577092953b","type":"GENE","name":"MIR6789","canonical_id":"hgnc:HGNC:50094","description":"microRNA 6789","metadata":{"aliases":["hsa-mir-6789"]}},{"id":"1c81087090c64259b5bec09296d1860b","type":"GENE","name":"MIR6790","canonical_id":"hgnc:HGNC:50161","description":"microRNA 6790","metadata":{"aliases":["hsa-mir-6790"]}},{"id":"ccc0543bf1934625ba6256d65225fe72","type":"GENE","name":"MIR6791","canonical_id":"hgnc:HGNC:50097","description":"microRNA 6791","metadata":{"aliases":["hsa-mir-6791"]}},{"id":"c4d5c5f67f8d40078276845231f80006","type":"GENE","name":"MIR6792","canonical_id":"hgnc:HGNC:50054","description":"microRNA 6792","metadata":{"aliases":["hsa-mir-6792"]}},{"id":"c447e17fd60849d78dbee8b83e3085fd","type":"GENE","name":"MIR6793","canonical_id":"hgnc:HGNC:50251","description":"microRNA 6793","metadata":{"aliases":["hsa-mir-6793"]}},{"id":"62649fcb528e4a7186f0c1eb2fcf93f9","type":"GENE","name":"MIR6794","canonical_id":"hgnc:HGNC:50117","description":"microRNA 6794","metadata":{"aliases":["hsa-mir-6794"]}},{"id":"eaf48af844c944df85904858856857d8","type":"GENE","name":"MIR6795","canonical_id":"hgnc:HGNC:50031","description":"microRNA 6795","metadata":{"aliases":["hsa-mir-6795"]}},{"id":"9b5a38c5571b43cbbe205dabe4d2bf20","type":"GENE","name":"MIR6796","canonical_id":"hgnc:HGNC:50186","description":"microRNA 6796","metadata":{"aliases":["hsa-mir-6796"]}},{"id":"afc4fdb5795441b48d1034862a0d516b","type":"GENE","name":"MIR6797","canonical_id":"hgnc:HGNC:50169","description":"microRNA 6797","metadata":{"aliases":["hsa-mir-6797"]}},{"id":"6a3fa5d91517487da0a1bd32d6ba291e","type":"GENE","name":"MIR6798","canonical_id":"hgnc:HGNC:50013","description":"microRNA 6798","metadata":{"aliases":["hsa-mir-6798"]}},{"id":"eb310820ff5c4ef29a25c53b36d02bfa","type":"GENE","name":"MIR6799","canonical_id":"hgnc:HGNC:50162","description":"microRNA 6799","metadata":{"aliases":["hsa-mir-6799"]}},{"id":"a502b9566fb2461ba9e94588ac77caf1","type":"GENE","name":"MIR6800","canonical_id":"hgnc:HGNC:50042","description":"microRNA 6800","metadata":{"aliases":["hsa-mir-6800"]}},{"id":"1c70dda4b8da434da221a705ca813c48","type":"GENE","name":"MIR6801","canonical_id":"hgnc:HGNC:50178","description":"microRNA 6801","metadata":{"aliases":["hsa-mir-6801"]}},{"id":"ae5c342ebf1b468392a342c13218d459","type":"GENE","name":"MIR6802","canonical_id":"hgnc:HGNC:50154","description":"microRNA 6802","metadata":{"aliases":["hsa-mir-6802"]}},{"id":"a62852a0469f41a89c8858cf30237066","type":"GENE","name":"MIR6803","canonical_id":"hgnc:HGNC:50035","description":"microRNA 6803","metadata":{"aliases":["hsa-mir-6803"]}},{"id":"5617db6c33704c21a6d823d5cd18924d","type":"GENE","name":"MIR6804","canonical_id":"hgnc:HGNC:50253","description":"microRNA 6804","metadata":{"aliases":["hsa-mir-6804"]}},{"id":"ef329745991e4bd4bf73e2f658c09f7e","type":"GENE","name":"MIR6805","canonical_id":"hgnc:HGNC:50215","description":"microRNA 6805","metadata":{"aliases":["hsa-mir-6805"]}},{"id":"ac17a247939f48bea70fcff2754527ec","type":"GENE","name":"MIR6806","canonical_id":"hgnc:HGNC:49937","description":"microRNA 6806","metadata":{"aliases":["hsa-mir-6806"]}},{"id":"88c91d1087044d7188e9ea77925bc06f","type":"GENE","name":"MIR6807","canonical_id":"hgnc:HGNC:50191","description":"microRNA 6807","metadata":{"aliases":["hsa-mir-6807"]}},{"id":"79bdd12ecd244fe98c3897947bc1b538","type":"GENE","name":"MIR6808","canonical_id":"hgnc:HGNC:50046","description":"microRNA 6808","metadata":{"aliases":["hsa-mir-6808"]}},{"id":"4116cc1a989c484abcd59a3f98c1a184","type":"GENE","name":"MIR6809","canonical_id":"hgnc:HGNC:49926","description":"microRNA 6809","metadata":{"aliases":["hsa-mir-6809"]}},{"id":"9c902915b0ac40c881f870c4ce0f2431","type":"GENE","name":"MIR6810","canonical_id":"hgnc:HGNC:49987","description":"microRNA 6810","metadata":{"aliases":["hsa-mir-6810"]}},{"id":"573c122378d342c7b2fef28f8e48f80e","type":"GENE","name":"MIR6811","canonical_id":"hgnc:HGNC:49944","description":"microRNA 6811","metadata":{"aliases":["hsa-mir-6811"]}},{"id":"bacd772abb4c4c70807823d0449e1b11","type":"GENE","name":"MIR6812","canonical_id":"hgnc:HGNC:50116","description":"microRNA 6812","metadata":{"aliases":["hsa-mir-6812"]}},{"id":"31b7f1662afa4969a62c3fc9ad240cb1","type":"GENE","name":"MIR6813","canonical_id":"hgnc:HGNC:50017","description":"microRNA 6813","metadata":{"aliases":["hsa-mir-6813"]}},{"id":"088195c6973d491bb9012ca7abecb275","type":"GENE","name":"MIR6814","canonical_id":"hgnc:HGNC:50145","description":"microRNA 6814","metadata":{"aliases":["hsa-mir-6814"]}},{"id":"475074ea2aee4797bfd4ebe80bb37f85","type":"GENE","name":"MIR6815","canonical_id":"hgnc:HGNC:50225","description":"microRNA 6815","metadata":{"aliases":["hsa-mir-6815"]}},{"id":"c5c3894c09e94dfcaa9b05165c91cb04","type":"GENE","name":"MIR6816","canonical_id":"hgnc:HGNC:50256","description":"microRNA 6816","metadata":{"aliases":["hsa-mir-6816"]}},{"id":"772eb4598f4d4631a41901c89012517c","type":"GENE","name":"MIR6817","canonical_id":"hgnc:HGNC:50112","description":"microRNA 6817","metadata":{"aliases":["hsa-mir-6817"]}},{"id":"4434238cef2d414ea2abbc1f362b3bb8","type":"GENE","name":"MIR6818","canonical_id":"hgnc:HGNC:49940","description":"microRNA 6818","metadata":{"aliases":["hsa-mir-6818"]}},{"id":"91b47768a69a4978823ffbda385668fa","type":"GENE","name":"MIR6819","canonical_id":"hgnc:HGNC:50155","description":"microRNA 6819","metadata":{"aliases":["hsa-mir-6819"]}},{"id":"fa82ac1423c348f9b87445f95b2e2c98","type":"GENE","name":"MIR6820","canonical_id":"hgnc:HGNC:50095","description":"microRNA 6820","metadata":{"aliases":["hsa-mir-6820"]}},{"id":"37aaeb38f2334ab78ea45a4fed31c470","type":"GENE","name":"MIR6821","canonical_id":"hgnc:HGNC:49980","description":"microRNA 6821","metadata":{"aliases":["hsa-mir-6821"]}},{"id":"c3c9813c675a4b8b9d90b6297c4cafe0","type":"GENE","name":"MIR6822","canonical_id":"hgnc:HGNC:49999","description":"microRNA 6822","metadata":{"aliases":["hsa-mir-6822"]}},{"id":"993e860f9b0a43bd99002be879314705","type":"GENE","name":"MIR6823","canonical_id":"hgnc:HGNC:49952","description":"microRNA 6823","metadata":{"aliases":["hsa-mir-6823"]}},{"id":"8d6061eea90544f0a4239b4a5feef0b0","type":"GENE","name":"MIR6824","canonical_id":"hgnc:HGNC:49946","description":"microRNA 6824","metadata":{"aliases":["hsa-mir-6824"]}},{"id":"73d6d5c0327446cab8be263908628eef","type":"GENE","name":"MIR6825","canonical_id":"hgnc:HGNC:50208","description":"microRNA 6825","metadata":{"aliases":["hsa-mir-6825"]}},{"id":"ae8982c775314c989ca4b6acb9a9d21c","type":"GENE","name":"MIR6826","canonical_id":"hgnc:HGNC:50001","description":"microRNA 6826","metadata":{"aliases":["hsa-mir-6826"]}},{"id":"e52fd21176d24d819f937a1a8b9d18b2","type":"GENE","name":"MIR6827","canonical_id":"hgnc:HGNC:50234","description":"microRNA 6827","metadata":{"aliases":["hsa-mir-6827"]}},{"id":"407463a459284d8d8c6d5ae347944942","type":"GENE","name":"MIR6828","canonical_id":"hgnc:HGNC:50057","description":"microRNA 6828","metadata":{"aliases":["hsa-mir-6828"]}},{"id":"183625a468a643c48935a2b7cd930c1f","type":"GENE","name":"MIR6829","canonical_id":"hgnc:HGNC:50055","description":"microRNA 6829","metadata":{"aliases":["hsa-mir-6829"]}},{"id":"21aab613b6314b2c8233769eecd2bc8f","type":"GENE","name":"MIR6830","canonical_id":"hgnc:HGNC:49966","description":"microRNA 6830","metadata":{"aliases":["hsa-mir-6830"]}},{"id":"e7c3cadc724448cd96c7125da6be39b7","type":"GENE","name":"MIR6831","canonical_id":"hgnc:HGNC:49936","description":"microRNA 6831","metadata":{"aliases":["hsa-mir-6831"]}},{"id":"3b5de3b5c9a54760a3579049b2d42185","type":"GENE","name":"MIR6832","canonical_id":"hgnc:HGNC:50140","description":"microRNA 6832","metadata":{"aliases":["hsa-mir-6832"]}},{"id":"07c6c7a182bf49a0a52e096ff7bd7003","type":"GENE","name":"MIR6833","canonical_id":"hgnc:HGNC:50245","description":"microRNA 6833","metadata":{"aliases":["hsa-mir-6833"]}},{"id":"2ad694e3d82440f9aa7592136f894f61","type":"GENE","name":"MIR6834","canonical_id":"hgnc:HGNC:50108","description":"microRNA 6834","metadata":{"aliases":["hsa-mir-6834"]}},{"id":"0f93e4bf0bba47bab927e4b261622394","type":"GENE","name":"MIR6835","canonical_id":"hgnc:HGNC:49963","description":"microRNA 6835","metadata":{"aliases":["hsa-mir-6835"]}},{"id":"7b5297b181cc49d289a1ee513fe1c485","type":"GENE","name":"MIR6836","canonical_id":"hgnc:HGNC:50067","description":"microRNA 6836","metadata":{"aliases":["hsa-mir-6836"]}},{"id":"07da8a49fc914001be3c0309748f2722","type":"GENE","name":"MIR6837","canonical_id":"hgnc:HGNC:50125","description":"microRNA 6837","metadata":{"aliases":["hsa-mir-6837"]}},{"id":"5939dada6b9e47b4a7d6bc5f273aee60","type":"GENE","name":"MIR6838","canonical_id":"hgnc:HGNC:50050","description":"microRNA 6838","metadata":{"aliases":["hsa-mir-6838"]}},{"id":"8004677ebba24948bfb5de7d7bc32dd3","type":"GENE","name":"MIR6839","canonical_id":"hgnc:HGNC:49953","description":"microRNA 6839","metadata":{"aliases":["hsa-mir-6839"]}},{"id":"f2171969c3584a36b84c6ce6892efa45","type":"GENE","name":"MIR6840","canonical_id":"hgnc:HGNC:50138","description":"microRNA 6840","metadata":{"aliases":["hsa-mir-6840"]}},{"id":"071f7280abef4102b5116655bbee8b5e","type":"GENE","name":"MIR6841","canonical_id":"hgnc:HGNC:50070","description":"microRNA 6841","metadata":{"aliases":["hsa-mir-6841"]}},{"id":"a60a434ed3c84228a8ef42202b457896","type":"GENE","name":"MIR6842","canonical_id":"hgnc:HGNC:50254","description":"microRNA 6842","metadata":{"aliases":["hsa-mir-6842"]}},{"id":"1d7f3a23720a44509b9e2d85227802f5","type":"GENE","name":"MIR6843","canonical_id":"hgnc:HGNC:50240","description":"microRNA 6843","metadata":{"aliases":["hsa-mir-6843"]}},{"id":"5d1ab4bb391142229aa57abd9657040c","type":"GENE","name":"MIR6844","canonical_id":"hgnc:HGNC:50135","description":"microRNA 6844","metadata":{"aliases":["hsa-mir-6844"]}},{"id":"970a7398b2934a24b092b4640a716b0a","type":"GENE","name":"MIR6845","canonical_id":"hgnc:HGNC:49956","description":"microRNA 6845","metadata":{"aliases":["hsa-mir-6845"]}},{"id":"281945b4470f423f9991da63c5eff686","type":"GENE","name":"MIR6846","canonical_id":"hgnc:HGNC:50026","description":"microRNA 6846","metadata":{"aliases":["hsa-mir-6846"]}},{"id":"20ad7eb3a43646e384de1a7ce48e6ba3","type":"GENE","name":"MIR6847","canonical_id":"hgnc:HGNC:50022","description":"microRNA 6847","metadata":{"aliases":["hsa-mir-6847"]}},{"id":"1e449b26fbab4236836c8e7429c746b9","type":"GENE","name":"MIR6848","canonical_id":"hgnc:HGNC:50176","description":"microRNA 6848","metadata":{"aliases":["hsa-mir-6848"]}},{"id":"310379100123490fbff3bbba46820236","type":"GENE","name":"MIR6849","canonical_id":"hgnc:HGNC:49991","description":"microRNA 6849","metadata":{"aliases":["hsa-mir-6849"]}},{"id":"bc80b92c03ad407a825c7903d86a0ed5","type":"GENE","name":"MIR6850","canonical_id":"hgnc:HGNC:50093","description":"microRNA 6850","metadata":{"aliases":["hsa-mir-6850"]}},{"id":"643b5865907e48948dd820aad325334b","type":"GENE","name":"MIR6851","canonical_id":"hgnc:HGNC:50083","description":"microRNA 6851","metadata":{"aliases":["hsa-mir-6851"]}},{"id":"0526c713673344d7b775dad99bf73942","type":"GENE","name":"MIR6852","canonical_id":"hgnc:HGNC:49993","description":"microRNA 6852","metadata":{"aliases":["hsa-mir-6852"]}},{"id":"62f0b649442847f5944a826fbb84643d","type":"GENE","name":"MIR6853","canonical_id":"hgnc:HGNC:49945","description":"microRNA 6853","metadata":{"aliases":["hsa-mir-6853"]}},{"id":"9690ddfdfa094735862b944af33b1c07","type":"GENE","name":"MIR6854","canonical_id":"hgnc:HGNC:50084","description":"microRNA 6854","metadata":{"aliases":["hsa-mir-6854"]}},{"id":"1eb0c193631e412ca65e814fc75bb31f","type":"GENE","name":"MIR6855","canonical_id":"hgnc:HGNC:50061","description":"microRNA 6855","metadata":{"aliases":["hsa-mir-6855"]}},{"id":"0d489ea4b48943519ceece5fd54c3369","type":"GENE","name":"MIR6856","canonical_id":"hgnc:HGNC:50242","description":"microRNA 6856","metadata":{"aliases":["hsa-mir-6856"]}},{"id":"abe48728cc584fe1bd149b2ee9093244","type":"GENE","name":"MIR6857","canonical_id":"hgnc:HGNC:50263","description":"microRNA 6857","metadata":{"aliases":["hsa-mir-6857"]}},{"id":"94de0f15e0484ce4875e88b36a75b9ba","type":"GENE","name":"MIR6858","canonical_id":"hgnc:HGNC:50250","description":"microRNA 6858","metadata":{"aliases":["hsa-mir-6858"]}},{"id":"455566a745154fa68cb640f2aa724d7d","type":"GENE","name":"MIR6859-1","canonical_id":"hgnc:HGNC:50039","description":"microRNA 6859-1","metadata":{"aliases":["hsa-mir-6859-1"]}},{"id":"6fd040643c484016a3e7a08ac87eb0c2","type":"GENE","name":"MIR6859-2","canonical_id":"hgnc:HGNC:49954","description":"microRNA 6859-2","metadata":{"aliases":["hsa-mir-6859-2"]}},{"id":"f89502546a294dea8480c6474d66ccf2","type":"GENE","name":"MIR6859-3","canonical_id":"hgnc:HGNC:50248","description":"microRNA 6859-3","metadata":{"aliases":["hsa-mir-6859-3"]}},{"id":"93150c2aba534e18a3c46aa611ba14d9","type":"GENE","name":"MIR6859-4","canonical_id":"hgnc:HGNC:50840","description":"microRNA 6859-4","metadata":null},{"id":"523605bcb87d427991875a30048edc70","type":"GENE","name":"MIR6860","canonical_id":"hgnc:HGNC:50086","description":"microRNA 6860","metadata":{"aliases":["hsa-mir-6860"]}},{"id":"7583e343fa194461878a2245905361a8","type":"GENE","name":"MIR6861","canonical_id":"hgnc:HGNC:50129","description":"microRNA 6861","metadata":{"aliases":["hsa-mir-6861"]}},{"id":"d84d042b18704620936df96502448d1e","type":"GENE","name":"MIR6862-1","canonical_id":"hgnc:HGNC:50052","description":"microRNA 6862-1","metadata":{"aliases":["hsa-mir-6862-1"]}},{"id":"9ce58b0fbc444584a6ed1e0a9e452bed","type":"GENE","name":"MIR6862-2","canonical_id":"hgnc:HGNC:50192","description":"microRNA 6862-2","metadata":{"aliases":["hsa-mir-6862-2"]}},{"id":"3b18c240f71e45819ffeb681bf2f1ae2","type":"GENE","name":"MIR6863","canonical_id":"hgnc:HGNC:49942","description":"microRNA 6863","metadata":{"aliases":["hsa-mir-6863"]}},{"id":"e34c7b7f085843f1b4dc4c17131ba543","type":"GENE","name":"MIR6864","canonical_id":"hgnc:HGNC:50226","description":"microRNA 6864","metadata":{"aliases":["hsa-mir-6864"]}},{"id":"1b97d2888f7b400dad353586c8a7e57a","type":"GENE","name":"MIR6865","canonical_id":"hgnc:HGNC:50182","description":"microRNA 6865","metadata":{"aliases":["hsa-mir-6865"]}},{"id":"2ca8e16d66a84eecbd1f1d33770c1faf","type":"GENE","name":"MIR6866","canonical_id":"hgnc:HGNC:49932","description":"microRNA 6866","metadata":{"aliases":["hsa-mir-6866"]}},{"id":"64a02381d82e4983b4b79a15f7a024df","type":"GENE","name":"MIR6867","canonical_id":"hgnc:HGNC:50134","description":"microRNA 6867","metadata":{"aliases":["hsa-mir-6867"]}},{"id":"cd48d3580cf44ddb9656bc4bd3742563","type":"GENE","name":"MIR6868","canonical_id":"hgnc:HGNC:50096","description":"microRNA 6868","metadata":{"aliases":["hsa-mir-6868"]}},{"id":"cb2ecc79ab3641db8e0b23929f49c365","type":"GENE","name":"MIR6869","canonical_id":"hgnc:HGNC:50056","description":"microRNA 6869","metadata":{"aliases":["hsa-mir-6869"]}},{"id":"957aa8bdef3c48858de2eea32b1e0ac4","type":"GENE","name":"MIR6870","canonical_id":"hgnc:HGNC:50184","description":"microRNA 6870","metadata":{"aliases":["hsa-mir-6870"]}},{"id":"a3d6e2b37bd84851b255d747e33d3a2c","type":"GENE","name":"MIR6871","canonical_id":"hgnc:HGNC:49964","description":"microRNA 6871","metadata":{"aliases":["hsa-mir-6871"]}},{"id":"8428eefa2bbc4fa7a41424bbb29b9632","type":"GENE","name":"MIR6872","canonical_id":"hgnc:HGNC:50037","description":"microRNA 6872","metadata":{"aliases":["hsa-mir-6872"]}},{"id":"4330a40af6254173bfa4b9c40cdfa814","type":"GENE","name":"MIR6873","canonical_id":"hgnc:HGNC:50231","description":"microRNA 6873","metadata":{"aliases":["hsa-mir-6873"]}},{"id":"d5221a3c81c044249bb1ef3bfada4295","type":"GENE","name":"MIR6874","canonical_id":"hgnc:HGNC:50146","description":"microRNA 6874","metadata":{"aliases":["hsa-mir-6874"]}},{"id":"d32f7a601775413d8daf708272980d57","type":"GENE","name":"MIR6875","canonical_id":"hgnc:HGNC:50015","description":"microRNA 6875","metadata":{"aliases":["hsa-mir-6875"]}},{"id":"6accc13bc67b46cd91a8a3301f1f36a0","type":"GENE","name":"MIR6876","canonical_id":"hgnc:HGNC:50181","description":"microRNA 6876","metadata":{"aliases":["hsa-mir-6876"]}},{"id":"e219db0d39f049628c5b64f5517eb599","type":"GENE","name":"MIR6877","canonical_id":"hgnc:HGNC:50205","description":"microRNA 6877","metadata":{"aliases":["hsa-mir-6877"]}},{"id":"8cdf4073795d416a9d8bed08daf677d2","type":"GENE","name":"MIR6878","canonical_id":"hgnc:HGNC:50269","description":"microRNA 6878","metadata":{"aliases":["hsa-mir-6878"]}},{"id":"7acb218e4562404884f93539a5fce5db","type":"GENE","name":"MIR6879","canonical_id":"hgnc:HGNC:49957","description":"microRNA 6879","metadata":{"aliases":["hsa-mir-6879"]}},{"id":"964ba6857a6444d0afbca8f7edea57c2","type":"GENE","name":"MIR6880","canonical_id":"hgnc:HGNC:50187","description":"microRNA 6880","metadata":{"aliases":["hsa-mir-6880"]}},{"id":"5438deece06c440f83717201cb7f7e36","type":"GENE","name":"MIR6881","canonical_id":"hgnc:HGNC:50098","description":"microRNA 6881","metadata":{"aliases":["hsa-mir-6881"]}},{"id":"24c300fed3684983aa2730f812669a87","type":"GENE","name":"MIR6882","canonical_id":"hgnc:HGNC:49928","description":"microRNA 6882","metadata":{"aliases":["hsa-mir-6882"]}},{"id":"401fb8ed341f4b9f9c795bef581e91b9","type":"GENE","name":"MIR6883","canonical_id":"hgnc:HGNC:50019","description":"microRNA 6883","metadata":{"aliases":["hsa-mir-6883"]}},{"id":"1eb2ae201f6840dcaaf6bbefca61a698","type":"GENE","name":"MIR6884","canonical_id":"hgnc:HGNC:50091","description":"microRNA 6884","metadata":{"aliases":["hsa-mir-6884"]}},{"id":"ea23841444804177823d36e87f8a9867","type":"GENE","name":"MIR6885","canonical_id":"hgnc:HGNC:50221","description":"microRNA 6885","metadata":{"aliases":["hsa-mir-6885"]}},{"id":"9f3e9209cc3c410684d4843eef002af6","type":"GENE","name":"MIR6886","canonical_id":"hgnc:HGNC:50121","description":"microRNA 6886","metadata":{"aliases":["hsa-mir-6886"]}},{"id":"622737c961af4b9c8891651800bfc4e7","type":"GENE","name":"MIR6887","canonical_id":"hgnc:HGNC:50065","description":"microRNA 6887","metadata":{"aliases":["hsa-mir-6887"]}},{"id":"0dd3692a73634b0c9f13d64476048326","type":"GENE","name":"MIR6888","canonical_id":"hgnc:HGNC:50071","description":"microRNA 6888","metadata":{"aliases":["hsa-mir-6888"]}},{"id":"a220db920be7476a8d2f07deff43211a","type":"GENE","name":"MIR6889","canonical_id":"hgnc:HGNC:50014","description":"microRNA 6889","metadata":{"aliases":["hsa-mir-6889"]}},{"id":"0d20a5c8ed1c49d7a5d74c38f9277745","type":"GENE","name":"MIR6890","canonical_id":"hgnc:HGNC:49990","description":"microRNA 6890","metadata":{"aliases":["hsa-mir-6890"]}},{"id":"62058efa7f814010abf6190b1236d15a","type":"GENE","name":"MIR6891","canonical_id":"hgnc:HGNC:50243","description":"microRNA 6891","metadata":{"aliases":["hsa-mir-6891"]}},{"id":"df9a35d705fc404fbe7026ffbbf817de","type":"GENE","name":"MIR6892","canonical_id":"hgnc:HGNC:50053","description":"microRNA 6892","metadata":{"aliases":["hsa-mir-6892"]}},{"id":"58c666e0311a4a7e9bf690a709385716","type":"GENE","name":"MIR6893","canonical_id":"hgnc:HGNC:50130","description":"microRNA 6893","metadata":{"aliases":["hsa-mir-6893"]}},{"id":"ed48bc1386a248bfb804cc28b8981532","type":"GENE","name":"MIR6894","canonical_id":"hgnc:HGNC:49938","description":"microRNA 6894","metadata":{"aliases":["hsa-mir-6894"]}},{"id":"bad892e9dfb145dcbd2e713467b919cb","type":"GENE","name":"MIR6895","canonical_id":"hgnc:HGNC:50210","description":"microRNA 6895","metadata":{"aliases":["hsa-mir-6895"]}},{"id":"fe22737ed9824f40b165680daec8b9a7","type":"GENE","name":"MIR7-1","canonical_id":"hgnc:HGNC:31638","description":"microRNA 7-1","metadata":{"aliases":["hsa-mir-7-1","MIRN7-1"]}},{"id":"0ff3e87e4f3d46e4ab7e5523e28e57f6","type":"GENE","name":"MIR7-2","canonical_id":"hgnc:HGNC:31639","description":"microRNA 7-2","metadata":{"aliases":["hsa-mir-7-2","MIRN7-2"]}},{"id":"3e0925af079344ebba09cc029cfeabf7","type":"GENE","name":"MIR7-3","canonical_id":"hgnc:HGNC:31640","description":"microRNA 7-3","metadata":{"aliases":["hsa-mir-7-3","MIRN7-3"]}},{"id":"e90926e757b94ddab2945f3885531d49","type":"GENE","name":"MIR7-3HG","canonical_id":"hgnc:HGNC:30049","description":"MIR7-3 host gene","metadata":{"aliases":["PGSF1","PGSF1a","PGSF1b","Huh7","uc002mbe.2","C19orf30","NCRNA00306","LINC00306"]}},{"id":"e821002f3d934fadaf3fc4c7156c5831","type":"GENE","name":"MIR708","canonical_id":"hgnc:HGNC:33654","description":null,"metadata":null},{"id":"afe13e896ea64e5f91652ee95423b2ab","type":"GENE","name":"MIR7106","canonical_id":"hgnc:HGNC:50085","description":"microRNA 7106","metadata":{"aliases":["hsa-mir-7106"]}},{"id":"8f77ccc8e3094d3f92f001cf36f0609e","type":"GENE","name":"MIR7107","canonical_id":"hgnc:HGNC:50006","description":"microRNA 7107","metadata":{"aliases":["hsa-mir-7107"]}},{"id":"2534a9ef86864652b6f00c237f495c8d","type":"GENE","name":"MIR7108","canonical_id":"hgnc:HGNC:49998","description":"microRNA 7108","metadata":{"aliases":["hsa-mir-7108"]}},{"id":"6ac599e212c1429aba2e4beb6a420611","type":"GENE","name":"MIR7109","canonical_id":"hgnc:HGNC:50122","description":"microRNA 7109","metadata":{"aliases":["hsa-mir-7109"]}},{"id":"994a5679122840c29765f40f0efe14b7","type":"GENE","name":"MIR711","canonical_id":"hgnc:HGNC:37316","description":"microRNA 711","metadata":{"aliases":["hsa-mir-711"]}},{"id":"9bd8f4e7771041df8a13c5c386f148af","type":"GENE","name":"MIR7110","canonical_id":"hgnc:HGNC:50024","description":"microRNA 7110","metadata":{"aliases":["hsa-mir-7110"]}},{"id":"4ecad6f894cf4699af1dd1d25e4d24fe","type":"GENE","name":"MIR7111","canonical_id":"hgnc:HGNC:50073","description":"microRNA 7111","metadata":{"aliases":["hsa-mir-7111"]}},{"id":"b793430a499f4832a9c37c354115b512","type":"GENE","name":"MIR7112","canonical_id":"hgnc:HGNC:50149","description":"microRNA 7112","metadata":{"aliases":["hsa-mir-7112-2","hsa-mir-7112-1","MIR7112-2","MIR7112-1"]}},{"id":"a328b686f33b42388be17ea51a863942","type":"GENE","name":"MIR7113","canonical_id":"hgnc:HGNC:49947","description":"microRNA 7113","metadata":{"aliases":["hsa-mir-7113"]}},{"id":"d9c5dd7d1da94143bb3c6d8a20fbd579","type":"GENE","name":"MIR7114","canonical_id":"hgnc:HGNC:50157","description":"microRNA 7114","metadata":{"aliases":["hsa-mir-7114"]}},{"id":"df991ed4df27478baf3020d5f6b02eb8","type":"GENE","name":"MIR7150","canonical_id":"hgnc:HGNC:49982","description":"microRNA 7150","metadata":{"aliases":["hsa-mir-7150"]}},{"id":"fe67ae2d48b6483e88b91220cbb47a48","type":"GENE","name":"MIR7151","canonical_id":"hgnc:HGNC:50170","description":"microRNA 7151","metadata":{"aliases":["hsa-mir-7151"]}},{"id":"61881e1d1b6b456281bf55377f82b750","type":"GENE","name":"MIR7152","canonical_id":"hgnc:HGNC:50257","description":"microRNA 7152","metadata":{"aliases":["hsa-mir-7152"]}},{"id":"e4b666e10a1c4acb88fded23c89f4fcc","type":"GENE","name":"MIR7153","canonical_id":"hgnc:HGNC:50190","description":"microRNA 7153","metadata":{"aliases":["hsa-mir-7153"]}},{"id":"e77c1a8a3b8a413eaf5e1c42bc1d2fec","type":"GENE","name":"MIR7154","canonical_id":"hgnc:HGNC:49972","description":"microRNA 7154","metadata":{"aliases":["hsa-mir-7154"]}},{"id":"3b70bb6af6054a1cbbd3e64a7873f8a1","type":"GENE","name":"MIR7155","canonical_id":"hgnc:HGNC:50005","description":"microRNA 7155","metadata":{"aliases":["hsa-mir-7155"]}},{"id":"c6a02df341c04928b3b552a0f9868d39","type":"GENE","name":"MIR7156","canonical_id":"hgnc:HGNC:50023","description":"microRNA 7156","metadata":{"aliases":["hsa-mir-7156"]}},{"id":"3d9acbb055b0428b9da7b42e62f40dbd","type":"GENE","name":"MIR7157","canonical_id":"hgnc:HGNC:50010","description":"microRNA 7157","metadata":{"aliases":["hsa-mir-7157"]}},{"id":"63ac011ae26b44458ba5c9c3472a3f67","type":"GENE","name":"MIR7158","canonical_id":"hgnc:HGNC:49971","description":"microRNA 7158","metadata":{"aliases":["hsa-mir-7158"]}},{"id":"3f7498fc9921481f816276cdaefe56de","type":"GENE","name":"MIR7159","canonical_id":"hgnc:HGNC:49978","description":"microRNA 7159","metadata":{"aliases":["hsa-mir-7159"]}},{"id":"2e5a7e24e33149c898a1dd05d074d613","type":"GENE","name":"MIR7160","canonical_id":"hgnc:HGNC:50028","description":"microRNA 7160","metadata":{"aliases":["hsa-mir-7160"]}},{"id":"d038d8a0d95342d5806cd5358e989044","type":"GENE","name":"MIR7161","canonical_id":"hgnc:HGNC:49985","description":"microRNA 7161","metadata":{"aliases":["hsa-mir-7161"]}},{"id":"88584269c86e44219dedab55b26ea53d","type":"GENE","name":"MIR7162","canonical_id":"hgnc:HGNC:50189","description":"microRNA 7162","metadata":{"aliases":["hsa-mir-7162"]}},{"id":"49a3eda10a4f4751afd20b6767e4a707","type":"GENE","name":"MIR718","canonical_id":"hgnc:HGNC:37317","description":"microRNA 718","metadata":{"aliases":["hsa-mir-718"]}},{"id":"28f9024f99f54b1389f95a1e85e6deee","type":"GENE","name":"MIR744","canonical_id":"hgnc:HGNC:33658","description":"microRNA 744","metadata":{"aliases":["hsa-mir-744","MIRN744"]}},{"id":"57286f90b0954009b62672cdeba91dda","type":"GENE","name":"MIR7515","canonical_id":"hgnc:HGNC:49839","description":"microRNA 7515","metadata":{"aliases":["hsa-mir-7515"]}},{"id":"f8f3a959209c43f58a62a55707c00cc5","type":"GENE","name":"MIR758","canonical_id":"hgnc:HGNC:33133","description":"microRNA 758","metadata":{"aliases":["hsa-mir-758","MIRN758"]}},{"id":"e09419a860034023bd80ef4b80b330cd","type":"GENE","name":"MIR759","canonical_id":"hgnc:HGNC:37307","description":"microRNA 759","metadata":{"aliases":["hsa-mir-759"]}},{"id":"9bbd98a5eae64988a53f2a807a615b09","type":"GENE","name":"MIR760","canonical_id":"hgnc:HGNC:33666","description":"microRNA 760","metadata":{"aliases":["hsa-mir-760","MIRN760"]}},{"id":"ca34a2b50c7548f59a9e81f7aff15f49","type":"GENE","name":"MIR761","canonical_id":"hgnc:HGNC:37305","description":"microRNA 761","metadata":{"aliases":["hsa-mir-761"]}},{"id":"f4a531ec64f1469abc4980fc96ebd5ab","type":"GENE","name":"MIR762","canonical_id":"hgnc:HGNC:37303","description":"microRNA 762","metadata":{"aliases":["hsa-mir-762"]}},{"id":"752b657d29b041ad9bbfb871b887a7fc","type":"GENE","name":"MIR762HG","canonical_id":"hgnc:HGNC:51386","description":"MIR762 host gene","metadata":null},{"id":"077bc5dd30e44f92905cedeb8302f7af","type":"GENE","name":"MIR764","canonical_id":"hgnc:HGNC:37306","description":"microRNA 764","metadata":{"aliases":["hsa-mir-764"]}},{"id":"fbd2563ad3f2447da3d71cc133217011","type":"GENE","name":"MIR765","canonical_id":"hgnc:HGNC:33141","description":"microRNA 765","metadata":{"aliases":["hsa-mir-765","MIRN765"]}},{"id":"738743f8fd884f3d8249d579d6eb33f2","type":"GENE","name":"MIR766","canonical_id":"hgnc:HGNC:33139","description":"microRNA 766","metadata":{"aliases":["hsa-mir-766","MIRN766"]}},{"id":"aba6e03e0a014e7dbdbb4e4e4a6cb8ef","type":"GENE","name":"MIR767","canonical_id":"hgnc:HGNC:33136","description":"microRNA 767","metadata":{"aliases":["hsa-mir-767","MIRN767"]}},{"id":"9860d075ce254ee8a2a44df92f8ec37a","type":"GENE","name":"MIR769","canonical_id":"hgnc:HGNC:33138","description":"microRNA 769","metadata":{"aliases":["hsa-mir-769","MIRN769"]}},{"id":"45baa058a58e4a26b7c1f834d356c290","type":"GENE","name":"MIR770","canonical_id":"hgnc:HGNC:33143","description":"microRNA 770","metadata":{"aliases":["hsa-mir-770","MIRN770"]}},{"id":"cc5ef55b71974ed7b93f9e1d517de4a8","type":"GENE","name":"MIR7702","canonical_id":"hgnc:HGNC:50216","description":"microRNA 7702","metadata":{"aliases":["hsa-mir-7702"]}},{"id":"1dd9f261ce0e405a8e2d20f6ed4fbefc","type":"GENE","name":"MIR7703","canonical_id":"hgnc:HGNC:50271","description":"microRNA 7703","metadata":{"aliases":["hsa-mir-7703"]}},{"id":"70301bb65bf84f5b9176bec70c7549f5","type":"GENE","name":"MIR7704","canonical_id":"hgnc:HGNC:50089","description":"microRNA 7704","metadata":{"aliases":["hsa-mir-7704"]}},{"id":"aea6091c70084ef3b4e24ceed861cc6b","type":"GENE","name":"MIR7705","canonical_id":"hgnc:HGNC:50143","description":"microRNA 7705","metadata":{"aliases":["hsa-mir-7705"]}},{"id":"db7b06dd9e604916b19edaf2135c0940","type":"GENE","name":"MIR7706","canonical_id":"hgnc:HGNC:50110","description":"microRNA 7706","metadata":{"aliases":["hsa-mir-7706"]}},{"id":"7fa2ff80e2e84ddab0e376355ae30b24","type":"GENE","name":"MIR7843","canonical_id":"hgnc:HGNC:50074","description":"microRNA 7843","metadata":{"aliases":["hsa-mir-7843"]}},{"id":"c9605accff2c4b51b53b6e6db0e728fd","type":"GENE","name":"MIR7844","canonical_id":"hgnc:HGNC:50044","description":"microRNA 7844","metadata":{"aliases":["hsa-mir-7844"]}},{"id":"7ddb45f866f74418ac103d0e7546d8fd","type":"GENE","name":"MIR7845","canonical_id":"hgnc:HGNC:50267","description":"microRNA 7845","metadata":{"aliases":["hsa-mir-7845"]}},{"id":"bf2a86842350496eae1f64b37ae37865","type":"GENE","name":"MIR7846","canonical_id":"hgnc:HGNC:50029","description":"microRNA 7846","metadata":{"aliases":["hsa-mir-7846"]}},{"id":"92462a0d64544cfe9bc2e171d7e9f9a9","type":"GENE","name":"MIR7847","canonical_id":"hgnc:HGNC:50153","description":"microRNA 7847","metadata":{"aliases":["hsa-mir-7847"]}},{"id":"df073a9f57fa4d738786219a661be2e6","type":"GENE","name":"MIR7848","canonical_id":"hgnc:HGNC:50058","description":"microRNA 7848","metadata":{"aliases":["hsa-mir-7848"]}},{"id":"f76ada31c674480cba8052445f86683d","type":"GENE","name":"MIR7849","canonical_id":"hgnc:HGNC:50166","description":"microRNA 7849","metadata":{"aliases":["hsa-mir-7849"]}},{"id":"12ef61c6e1d64857978a6a3afb5346ee","type":"GENE","name":"MIR7850","canonical_id":"hgnc:HGNC:50118","description":"microRNA 7850","metadata":{"aliases":["hsa-mir-7850"]}},{"id":"e37f8859457f4fb18081f5eb1658bcef","type":"GENE","name":"MIR7851","canonical_id":"hgnc:HGNC:50127","description":"microRNA 7851","metadata":{"aliases":["hsa-mir-7851"]}},{"id":"d7e4792479ab4a729219fabed315fde1","type":"GENE","name":"MIR7852","canonical_id":"hgnc:HGNC:50201","description":"microRNA 7852","metadata":{"aliases":["hsa-mir-7852"]}},{"id":"cd6ec6e87fdb4b90adba015fab788388","type":"GENE","name":"MIR7853","canonical_id":"hgnc:HGNC:49933","description":"microRNA 7853","metadata":{"aliases":["hsa-mir-7853"]}},{"id":"ca8d75b241ae49359aca0e020cab971c","type":"GENE","name":"MIR7854","canonical_id":"hgnc:HGNC:50047","description":"microRNA 7854","metadata":{"aliases":["hsa-mir-7854"]}},{"id":"1ec1073af4614b1f8af55f4d98b819a9","type":"GENE","name":"MIR7855","canonical_id":"hgnc:HGNC:50244","description":"microRNA 7855","metadata":{"aliases":["hsa-mir-7855"]}},{"id":"3257f65ce149427bbd43238b36197cc3","type":"GENE","name":"MIR7856","canonical_id":"hgnc:HGNC:50268","description":"microRNA 7856","metadata":{"aliases":["hsa-mir-7856"]}},{"id":"edf4ed1319fe4042bbb930a013f4c8a0","type":"GENE","name":"MIR7973-1","canonical_id":"hgnc:HGNC:50040","description":"microRNA 7973-1","metadata":{"aliases":["hsa-mir-7973-1"]}},{"id":"28278c2d84e64775a5ea4b7cb7d320a1","type":"GENE","name":"MIR7973-2","canonical_id":"hgnc:HGNC:50080","description":"microRNA 7973-2","metadata":{"aliases":["hsa-mir-7973-2"]}},{"id":"873eaa6b341546eda0e8e5b72ca7f8f5","type":"GENE","name":"MIR7974","canonical_id":"hgnc:HGNC:49992","description":"microRNA 7974","metadata":{"aliases":["hsa-mir-7974"]}},{"id":"891fc44e4ea34e84bf760ac5366469ac","type":"GENE","name":"MIR7975","canonical_id":"hgnc:HGNC:49967","description":"microRNA 7975","metadata":{"aliases":["hsa-mir-7975"]}},{"id":"743adcffb7d1414596a272e3d3177d02","type":"GENE","name":"MIR7976","canonical_id":"hgnc:HGNC:50092","description":"microRNA 7976","metadata":{"aliases":["hsa-mir-7976"]}},{"id":"dce3ba589447466d908ac98d076660ae","type":"GENE","name":"MIR7977","canonical_id":"hgnc:HGNC:49969","description":"microRNA 7977","metadata":{"aliases":["hsa-mir-7977"]}},{"id":"5fb1f58728bf49e39924fc7e68a5b34f","type":"GENE","name":"MIR7978","canonical_id":"hgnc:HGNC:50113","description":"microRNA 7978","metadata":{"aliases":["hsa-mir-7978"]}},{"id":"608edbabc0534f60babd8a470b7762ac","type":"GENE","name":"MIR802","canonical_id":"hgnc:HGNC:33140","description":"microRNA 802","metadata":{"aliases":["hsa-mir-802","MIRN802"]}},{"id":"0c7ab579aaa24f2abd4f464f483ba3ef","type":"GENE","name":"MIR8052","canonical_id":"hgnc:HGNC:50252","description":"microRNA 8052","metadata":{"aliases":["hsa-mir-8052"]}},{"id":"57b09f63bf0d42e7ae70f33740dc3409","type":"GENE","name":"MIR8053","canonical_id":"hgnc:HGNC:50137","description":"microRNA 8053","metadata":{"aliases":["hsa-mir-8053"]}},{"id":"5beac424ea6e425ab9aed5b3b514d90d","type":"GENE","name":"MIR8054","canonical_id":"hgnc:HGNC:50177","description":"microRNA 8054","metadata":{"aliases":["hsa-mir-8054"]}},{"id":"f0d9128b62da49d7845df4ff835cec2f","type":"GENE","name":"MIR8055","canonical_id":"hgnc:HGNC:50241","description":"microRNA 8055","metadata":{"aliases":["hsa-mir-8055"]}},{"id":"929c619c3c61416cbe6bf7ec19f73e60","type":"GENE","name":"MIR8056","canonical_id":"hgnc:HGNC:49948","description":"microRNA 8056","metadata":{"aliases":["hsa-mir-8056"]}},{"id":"893bcc4072ac46eeb90294186409f38c","type":"GENE","name":"MIR8057","canonical_id":"hgnc:HGNC:49960","description":"microRNA 8057","metadata":{"aliases":["hsa-mir-8057"]}},{"id":"196cf2f753cc4957be2d0078eba06f50","type":"GENE","name":"MIR8058","canonical_id":"hgnc:HGNC:50018","description":"microRNA 8058","metadata":{"aliases":["hsa-mir-8058"]}},{"id":"e6818b361d4a4eccba4a480d9d86ea51","type":"GENE","name":"MIR8059","canonical_id":"hgnc:HGNC:50068","description":"microRNA 8059","metadata":{"aliases":["hsa-mir-8059"]}},{"id":"1ac2764194d041938b6d97834d2600e7","type":"GENE","name":"MIR8060","canonical_id":"hgnc:HGNC:50180","description":"microRNA 8060","metadata":{"aliases":["hsa-mir-8060"]}},{"id":"3fa6105184a14985a1c55d160e654ec3","type":"GENE","name":"MIR8061","canonical_id":"hgnc:HGNC:50077","description":"microRNA 8061","metadata":{"aliases":["hsa-mir-8061"]}},{"id":"bab7333e22a04541b0f7602a91d1b525","type":"GENE","name":"MIR8062","canonical_id":"hgnc:HGNC:49975","description":"microRNA 8062","metadata":{"aliases":["hsa-mir-8062"]}},{"id":"c261f79e2b2c4641b212957877a3e44e","type":"GENE","name":"MIR8063","canonical_id":"hgnc:HGNC:50088","description":"microRNA 8063","metadata":{"aliases":["hsa-mir-8063"]}},{"id":"79f00342db8b467280f9b04e7f1e5148","type":"GENE","name":"MIR8064","canonical_id":"hgnc:HGNC:50236","description":"microRNA 8064","metadata":{"aliases":["hsa-mir-8064"]}},{"id":"a53e476cafa3427285cd2998cc14106d","type":"GENE","name":"MIR8065","canonical_id":"hgnc:HGNC:49959","description":"microRNA 8065","metadata":{"aliases":["hsa-mir-8065"]}},{"id":"97a83b1ec374458c8383d73b8ea40417","type":"GENE","name":"MIR8066","canonical_id":"hgnc:HGNC:50043","description":"microRNA 8066","metadata":{"aliases":["hsa-mir-8066"]}},{"id":"43cc924922154c04a2e831155d05e18a","type":"GENE","name":"MIR8067","canonical_id":"hgnc:HGNC:49934","description":"microRNA 8067","metadata":{"aliases":["hsa-mir-8067"]}},{"id":"d95c2d4eadf44747a8117e38eccb62bc","type":"GENE","name":"MIR8068","canonical_id":"hgnc:HGNC:50238","description":"microRNA 8068","metadata":{"aliases":["hsa-mir-8068"]}},{"id":"0eceecc289c84cb8815665ecb4d74672","type":"GENE","name":"MIR8069","canonical_id":"hgnc:HGNC:50836","description":"microRNA 8069","metadata":{"aliases":["MIR8069-2"]}},{"id":"5ff0e84c15f0459b911d953ce89cd6d7","type":"GENE","name":"MIR8070","canonical_id":"hgnc:HGNC:50274","description":"microRNA 8070","metadata":{"aliases":["hsa-mir-8070"]}},{"id":"4249251577a9415fa324f006a74fa93d","type":"GENE","name":"MIR8071-1","canonical_id":"hgnc:HGNC:50041","description":"microRNA 8071-1","metadata":{"aliases":["hsa-mir-8071-1"]}},{"id":"d8a75932fa454319a93291d7ac3a2833","type":"GENE","name":"MIR8071-2","canonical_id":"hgnc:HGNC:49958","description":"microRNA 8071-2","metadata":{"aliases":["hsa-mir-8071-2"]}},{"id":"2495530076324a689be45550bf7f4051","type":"GENE","name":"MIR8072","canonical_id":"hgnc:HGNC:50174","description":"microRNA 8072","metadata":{"aliases":["hsa-mir-8072"]}},{"id":"e3771470194544e9a05a6d11214baa7f","type":"GENE","name":"MIR8073","canonical_id":"hgnc:HGNC:50131","description":"microRNA 8073","metadata":{"aliases":["hsa-mir-8073"]}},{"id":"3dadf4161895463b8c0cfe412231ea5b","type":"GENE","name":"MIR8074","canonical_id":"hgnc:HGNC:50105","description":"microRNA 8074","metadata":{"aliases":["hsa-mir-8074"]}},{"id":"2560d1fa276d463fbba2f81df12f02ff","type":"GENE","name":"MIR8075","canonical_id":"hgnc:HGNC:50172","description":"microRNA 8075","metadata":{"aliases":["hsa-mir-8075"]}},{"id":"f4d07cac087447cc9cd9154714efd24b","type":"GENE","name":"MIR8076","canonical_id":"hgnc:HGNC:49997","description":"microRNA 8076","metadata":{"aliases":["hsa-mir-8076"]}},{"id":"52cb35114f2347d797fce09b4338a6f8","type":"GENE","name":"MIR8077","canonical_id":"hgnc:HGNC:50266","description":"microRNA 8077","metadata":{"aliases":["hsa-mir-8077"]}},{"id":"0bd4a16e843945a1937eb16e72e78e29","type":"GENE","name":"MIR8078","canonical_id":"hgnc:HGNC:50102","description":"microRNA 8078","metadata":{"aliases":["hsa-mir-8078"]}},{"id":"6f61441692a7474a87fbac3205b67d27","type":"GENE","name":"MIR8079","canonical_id":"hgnc:HGNC:50021","description":"microRNA 8079","metadata":{"aliases":["hsa-mir-8079"]}},{"id":"4d09496b897f482794204ffe3044760c","type":"GENE","name":"MIR8080","canonical_id":"hgnc:HGNC:49989","description":"microRNA 8080","metadata":{"aliases":["hsa-mir-8080"]}},{"id":"3ace1085c7974b5ea617f81bb0f207bc","type":"GENE","name":"MIR8081","canonical_id":"hgnc:HGNC:50123","description":"microRNA 8081","metadata":{"aliases":["hsa-mir-8081"]}},{"id":"ccb5170f79004644ae39f19b66ec429f","type":"GENE","name":"MIR8082","canonical_id":"hgnc:HGNC:50111","description":"microRNA 8082","metadata":{"aliases":["hsa-mir-8082"]}},{"id":"00841fd864804b7b99858d243a6a59ed","type":"GENE","name":"MIR8083","canonical_id":"hgnc:HGNC:50211","description":"microRNA 8083","metadata":{"aliases":["hsa-mir-8083"]}},{"id":"df14256fb702454bbc4eaf97375fca69","type":"GENE","name":"MIR8084","canonical_id":"hgnc:HGNC:50075","description":"microRNA 8084","metadata":{"aliases":["hsa-mir-8084"]}},{"id":"cd689caece734cfcb89d44bc967e0da6","type":"GENE","name":"MIR8085","canonical_id":"hgnc:HGNC:50120","description":"microRNA 8085","metadata":{"aliases":["hsa-mir-8085"]}},{"id":"b5bb398ac0ce49849273636c4e8104f4","type":"GENE","name":"MIR8086","canonical_id":"hgnc:HGNC:50107","description":"microRNA 8086","metadata":{"aliases":["hsa-mir-8086"]}},{"id":"c7edc07153f3457c969136af39b0ee8f","type":"GENE","name":"MIR8087","canonical_id":"hgnc:HGNC:50059","description":"microRNA 8087","metadata":{"aliases":["hsa-mir-8087"]}},{"id":"e5780a25d1be47b59fffacb181158bcd","type":"GENE","name":"MIR8088","canonical_id":"hgnc:HGNC:50167","description":"microRNA 8088","metadata":{"aliases":["hsa-mir-8088"]}},{"id":"80e41d3450494f1ca6b7748ad003377b","type":"GENE","name":"MIR8089","canonical_id":"hgnc:HGNC:50196","description":"microRNA 8089","metadata":{"aliases":["hsa-mir-8089"]}},{"id":"c596949d6e024a0db2411c193cee9d67","type":"GENE","name":"MIR8485","canonical_id":"hgnc:HGNC:50839","description":"microRNA 8485","metadata":null},{"id":"45e21481ddcc4267bfd61fe45a5165df","type":"GENE","name":"MIR873","canonical_id":"hgnc:HGNC:33663","description":"microRNA 873","metadata":{"aliases":["hsa-mir-873","MIRN873"]}},{"id":"3f619523bf8a4ddcae6ba2000932ec6f","type":"GENE","name":"MIR874","canonical_id":"hgnc:HGNC:33643","description":"microRNA 874","metadata":{"aliases":["hsa-mir-874","MIRN874"]}},{"id":"1bffed9858bf45e7983bc469e7cdc726","type":"GENE","name":"MIR875","canonical_id":"hgnc:HGNC:33652","description":"microRNA 875","metadata":{"aliases":["hsa-mir-875","MIRN875"]}},{"id":"5e7e27d62f3c47f6af98868158a02da4","type":"GENE","name":"MIR876","canonical_id":"hgnc:HGNC:33653","description":"microRNA 876","metadata":{"aliases":["hsa-mir-876","MIRN876"]}},{"id":"864e5630a5724af692f4d1ccaeaf2fcc","type":"GENE","name":"MIR877","canonical_id":"hgnc:HGNC:33660","description":"microRNA 877","metadata":{"aliases":["hsa-mir-877","MIRN877"]}},{"id":"2d3ebb770de74c17b66b425f331b75d3","type":"GENE","name":"MIR885","canonical_id":"hgnc:HGNC:33659","description":"microRNA 885","metadata":{"aliases":["hsa-mir-885","MIRN885"]}},{"id":"0d4b20d5daf1423bb2accd81d70de92c","type":"GENE","name":"MIR887","canonical_id":"hgnc:HGNC:33661","description":"microRNA 887","metadata":{"aliases":["hsa-mir-887","MIRN887"]}},{"id":"55bb63e15ba0485d95aebfe9b6a92b24","type":"GENE","name":"MIR888","canonical_id":"hgnc:HGNC:33648","description":"microRNA 888","metadata":{"aliases":["hsa-mir-888","MIRN888"]}},{"id":"3684ede245ef4374bbae3182711f5aaf","type":"GENE","name":"MIR889","canonical_id":"hgnc:HGNC:33651","description":"microRNA 889","metadata":{"aliases":["hsa-mir-889","MIRN889"]}},{"id":"a10170961803456cb372d527be2a2f43","type":"GENE","name":"MIR890","canonical_id":"hgnc:HGNC:33644","description":"microRNA 890","metadata":{"aliases":["hsa-mir-890","MIRN890"]}},{"id":"f95c527c0fe24229a408d15d7f3a75d4","type":"GENE","name":"MIR891A","canonical_id":"hgnc:HGNC:33635","description":"microRNA 891a","metadata":{"aliases":["hsa-mir-891a","MIRN891A"]}},{"id":"d4c64a1b16b04b05919a059258ff3570","type":"GENE","name":"MIR891B","canonical_id":"hgnc:HGNC:33645","description":"microRNA 891b","metadata":{"aliases":["hsa-mir-891b","MIRN891B"]}},{"id":"bf991710a21741aaaf543e160e6f2285","type":"GENE","name":"MIR892A","canonical_id":"hgnc:HGNC:33639","description":"microRNA 892a","metadata":{"aliases":["hsa-mir-892a","MIRN892A"]}},{"id":"382de2d572fb421fbb279627f992b551","type":"GENE","name":"MIR892B","canonical_id":"hgnc:HGNC:33649","description":"microRNA 892b","metadata":{"aliases":["hsa-mir-892b","MIRN892B"]}},{"id":"1b14bbd6d3504152a11a0c1066bd60e0","type":"GENE","name":"MIR892C","canonical_id":"hgnc:HGNC:50194","description":"microRNA 892c","metadata":{"aliases":["hsa-mir-892c"]}},{"id":"75490e076e52417ca08ce4cb7125edee","type":"GENE","name":"MIR9-1","canonical_id":"hgnc:HGNC:31641","description":"microRNA 9-1","metadata":{"aliases":["hsa-mir-9-1","MIRN9-1"]}},{"id":"74dc5fb82ea74f1282e7c1c5fabbcc0c","type":"GENE","name":"MIR9-1HG","canonical_id":"hgnc:HGNC:30780","description":"MIR9-1 host gene","metadata":{"aliases":["CROC4","C1orf61"]}},{"id":"746b0660582d4f8c89a7b74dade4e48c","type":"GENE","name":"MIR9-2","canonical_id":"hgnc:HGNC:31642","description":"microRNA 9-2","metadata":{"aliases":["hsa-mir-9-2","MIRN9-2"]}},{"id":"a697499360f246838463d8dff7414d3a","type":"GENE","name":"MIR9-2HG","canonical_id":"hgnc:HGNC:42810","description":"MIR9-2 host gene","metadata":{"aliases":["uc.166","EyeLinc1","Visc","LOC645323","ECONEXIN","NDIME","LINC00461","LINC02060"]}},{"id":"4d588f47387148b99f425b93ebb2a6f1","type":"GENE","name":"MIR9-3","canonical_id":"hgnc:HGNC:31646","description":"microRNA 9-3","metadata":{"aliases":["hsa-mir-9-3","MIRN9-3"]}},{"id":"63f23d69a80f49329dea26b0503130f9","type":"GENE","name":"MIR9-3HG","canonical_id":"hgnc:HGNC:27388","description":"MIR9-3 host gene","metadata":{"aliases":["BS-DRL1","lnc-FANCI-2","LINC00925"]}},{"id":"e7345590974d408ba0a37b61937e6fa7","type":"GENE","name":"MIR920","canonical_id":"hgnc:HGNC:33670","description":"microRNA 920","metadata":{"aliases":["hsa-mir-920","MIRN920"]}},{"id":"33c40b4ea1e44f0db8eecf5247af5cb8","type":"GENE","name":"MIR921","canonical_id":"hgnc:HGNC:33671","description":"microRNA 921","metadata":{"aliases":["hsa-mir-921","MIRN921"]}},{"id":"5ab99f50dfd744fd8ea28fd7fb13d45b","type":"GENE","name":"MIR922","canonical_id":"hgnc:HGNC:33672","description":"microRNA 922","metadata":{"aliases":["hsa-mir-922","MIRN922"]}},{"id":"9d6327c83f284c40a1b1b493bf6991ce","type":"GENE","name":"MIR924","canonical_id":"hgnc:HGNC:33674","description":"microRNA 924","metadata":{"aliases":["hsa-mir-924","MIRN924"]}},{"id":"f999f61f5d9746718d3e2480a5f4983c","type":"GENE","name":"MIR924HG","canonical_id":"hgnc:HGNC:44332","description":"MIR924 host gene","metadata":{"aliases":["LINC00669"]}},{"id":"c423ea123c1f4bc091eec0ffdd10ba45","type":"GENE","name":"MIR92A1","canonical_id":"hgnc:HGNC:31643","description":"microRNA 92a-1","metadata":{"aliases":["hsa-mir-92-1","hsa-mir-92a-1","MIRN92-1","MIRN92A1"]}},{"id":"0ca57648cb1147dc896a6b843877ce9b","type":"GENE","name":"MIR92A2","canonical_id":"hgnc:HGNC:31644","description":"microRNA 92a-2","metadata":{"aliases":["hsa-mir-92-2","hsa-mir-92a-2","MIRN92-2","MIRN92A2"]}},{"id":"c300f62da5714642a112515435873d0a","type":"GENE","name":"MIR92B","canonical_id":"hgnc:HGNC:32920","description":"microRNA 92b","metadata":{"aliases":["hsa-mir-92b","MIRN92B"]}},{"id":"0cf7b13d25be4e6f945aaa980ae395d0","type":"GENE","name":"MIR93","canonical_id":"hgnc:HGNC:31645","description":"microRNA 93","metadata":{"aliases":["hsa-mir-93","MIRN93"]}},{"id":"9b10914c54a142b48081d97f52225d9d","type":"GENE","name":"MIR933","canonical_id":"hgnc:HGNC:33676","description":"microRNA 933","metadata":{"aliases":["hsa-mir-933","MIRN933"]}},{"id":"299a8cf3ccd54fb68235470ae63217a3","type":"GENE","name":"MIR934","canonical_id":"hgnc:HGNC:33677","description":"microRNA 934","metadata":{"aliases":["hsa-mir-934","MIRN934"]}},{"id":"4317e067e41345049bd1fc5735e72313","type":"GENE","name":"MIR935","canonical_id":"hgnc:HGNC:33678","description":"microRNA 935","metadata":{"aliases":["hsa-mir-935","MIRN935"]}},{"id":"53ccfc1f5215461e87a37038935cd921","type":"GENE","name":"MIR936","canonical_id":"hgnc:HGNC:33679","description":"microRNA 936","metadata":{"aliases":["hsa-mir-936","MIRN936"]}},{"id":"84ad68382d154f5e8ce1433d51e659ae","type":"GENE","name":"MIR937","canonical_id":"hgnc:HGNC:33680","description":"microRNA 937","metadata":{"aliases":["hsa-mir-937","MIRN937"]}},{"id":"145348372d384f8ca29dcf0652609986","type":"GENE","name":"MIR938","canonical_id":"hgnc:HGNC:33681","description":"microRNA 938","metadata":{"aliases":["hsa-mir-938","MIRN938"]}},{"id":"2a946f46e30c4bcdaf47e8f25c986728","type":"GENE","name":"MIR939","canonical_id":"hgnc:HGNC:33682","description":"microRNA 939","metadata":{"aliases":["hsa-mir-939","MIRN939"]}},{"id":"87f3731449344e4fa853a206e2e369bc","type":"GENE","name":"MIR940","canonical_id":"hgnc:HGNC:33683","description":"microRNA 940","metadata":{"aliases":["hsa-mir-940","MIRN940"]}},{"id":"46eb7788e8c847a6beebcf38e5aaf85b","type":"GENE","name":"MIR941-1","canonical_id":"hgnc:HGNC:33684","description":"microRNA 941-1","metadata":{"aliases":["hsa-mir-941-1","MIRN941-1"]}},{"id":"19e79012a9ed4fb1bb0c290374b84263","type":"GENE","name":"MIR941-2","canonical_id":"hgnc:HGNC:33685","description":"microRNA 941-2","metadata":{"aliases":["hsa-mir-941-2","MIRN941-2"]}},{"id":"87b83df5bab645cd8aae2ec15b9731fe","type":"GENE","name":"MIR941-3","canonical_id":"hgnc:HGNC:33686","description":"microRNA 941-3","metadata":{"aliases":["hsa-mir-941-3","MIRN941-3"]}},{"id":"c6974cc256c046c8b0364da77175f4c8","type":"GENE","name":"MIR941-4","canonical_id":"hgnc:HGNC:33687","description":"microRNA 941-4","metadata":{"aliases":["hsa-mir-941-4","MIRN941-4"]}},{"id":"a79d3fe3301b46858f8c34b68e72d459","type":"GENE","name":"MIR941-5","canonical_id":"hgnc:HGNC:50845","description":"microRNA 941-5","metadata":null},{"id":"4d9d15c48d7d466582233f02fd33fdf5","type":"GENE","name":"MIR942","canonical_id":"hgnc:HGNC:33688","description":"microRNA 942","metadata":{"aliases":["hsa-mir-942","MIRN942"]}},{"id":"0aeecc72d1e74e4bb63a481f47f689f6","type":"GENE","name":"MIR943","canonical_id":"hgnc:HGNC:33689","description":"microRNA 943","metadata":{"aliases":["hsa-mir-943","MIRN943"]}},{"id":"b7e040722a1e41089a91a4e96c942ded","type":"GENE","name":"MIR944","canonical_id":"hgnc:HGNC:33690","description":"microRNA 944","metadata":{"aliases":["hsa-mir-944","MIRN944"]}},{"id":"0cce5d9a2bec4d8a8bb20dad312ba602","type":"GENE","name":"MIR95","canonical_id":"hgnc:HGNC:31647","description":"microRNA 95","metadata":{"aliases":["hsa-mir-95","MIRN95"]}},{"id":"5bfc5dcb880840b8a0ca13479f9cb8a5","type":"GENE","name":"MIR9500","canonical_id":"hgnc:HGNC:50841","description":"microRNA 9500","metadata":null},{"id":"61408ea05db64eeaa2c838b7b5692bc9","type":"GENE","name":"MIR96","canonical_id":"hgnc:HGNC:31648","description":"microRNA 96","metadata":{"aliases":["hsa-mir-96","MIRN96","DFNA50"]}},{"id":"66bead9ba82a4aa69c504a96f5c15d5e","type":"GENE","name":"MIR9718","canonical_id":"hgnc:HGNC:53988","description":"microRNA 9718","metadata":{"aliases":["hsa-mir-9718"]}},{"id":"02d108e44b404ad3ad1fe66ff1f4899d","type":"GENE","name":"MIR98","canonical_id":"hgnc:HGNC:31649","description":"microRNA 98","metadata":{"aliases":["hsa-mir-98","MIRLET7L","MIRN98"]}},{"id":"4733f20fe6204d67acbd7b1f0a59298f","type":"GENE","name":"MIR9851","canonical_id":"hgnc:HGNC:53989","description":"microRNA 9851","metadata":{"aliases":["hsa-mir-9851"]}},{"id":"5bc2082ff1604a6b894000432005d2a8","type":"GENE","name":"MIR9898","canonical_id":"hgnc:HGNC:53990","description":"microRNA 9898","metadata":{"aliases":["hsa-mir-9898"]}},{"id":"d9fe02bc41b142a6b4f2b46278f8f330","type":"GENE","name":"MIR9899","canonical_id":"hgnc:HGNC:53991","description":"microRNA 9899","metadata":{"aliases":["hsa-mir-9899"]}},{"id":"cca3f07f2d814868a63de9e25884f018","type":"GENE","name":"MIR9900","canonical_id":"hgnc:HGNC:53992","description":"microRNA 9900","metadata":{"aliases":["hsa-mir-9900"]}},{"id":"70e8c912cc8c4a9aaeec5f87673516ae","type":"GENE","name":"MIR9901","canonical_id":"hgnc:HGNC:53993","description":"microRNA 9901","metadata":{"aliases":["hsa-mir-9901"]}},{"id":"9a6225677b4c445db9a08c701b01079f","type":"GENE","name":"MIR9902-1","canonical_id":"hgnc:HGNC:53994","description":"microRNA 9902-1","metadata":{"aliases":["hsa-mir-9902-1"]}},{"id":"b66cbfb37fff4e9287b08ffe5da70af2","type":"GENE","name":"MIR9902-2","canonical_id":"hgnc:HGNC:53995","description":"microRNA 9902-2","metadata":{"aliases":["hsa-mir-9902-2"]}},{"id":"0c1c81f2042c41608285294b227970de","type":"GENE","name":"MIR9903","canonical_id":"hgnc:HGNC:53996","description":"microRNA 9903","metadata":{"aliases":["hsa-mir-9903"]}},{"id":"c51229ab6b1d43fcbb06a884dcdd772d","type":"GENE","name":"MIR9983","canonical_id":"hgnc:HGNC:53997","description":"microRNA 9983","metadata":{"aliases":["hsa-mir-9983"]}},{"id":"49fc32a97c3c43fba993bc1397c34b68","type":"GENE","name":"MIR9985","canonical_id":"hgnc:HGNC:53998","description":"microRNA 9985","metadata":{"aliases":["hsa-mir-9985"]}},{"id":"a4d3d943e65b482b9c8788f562e78889","type":"GENE","name":"MIR9986","canonical_id":"hgnc:HGNC:53999","description":"microRNA 9986","metadata":{"aliases":["hsa-mir-9986"]}},{"id":"3ca0bc069ea743058719a92d869ca388","type":"GENE","name":"MIR99A","canonical_id":"hgnc:HGNC:31650","description":"microRNA 99a","metadata":{"aliases":["hsa-mir-99a","MIRN99A"]}},{"id":"12ef5cc6e32e488e969e2b0ab8550cbf","type":"GENE","name":"MIR99AHG","canonical_id":"hgnc:HGNC:1274","description":"mir-99a-let-7c cluster host gene","metadata":{"aliases":["MONC","DILA1","C21orf35","FLJ38295","C21orf34","LINC00478"]}},{"id":"1c748922cf94445ba5acaeb3f08d540d","type":"GENE","name":"MIR99B","canonical_id":"hgnc:HGNC:31651","description":"microRNA 99b","metadata":{"aliases":["hsa-mir-99b","MIRN99B"]}},{"id":"75eb9d217b734b61a0078ade2b580a91","type":"TRIAL","name":"MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT07782021","description":"Crohn's Disease; Perianal Fistula","metadata":null},{"id":"c58047402b0d4747a226a0b00c84692d","type":"GENE","name":"MIRLET7A1","canonical_id":"hgnc:HGNC:31476","description":"microRNA let-7a-1","metadata":{"aliases":["hsa-let-7a-1","MIRNLET7A1"]}},{"id":"2548882b422347ac8b642482b1cb23a1","type":"GENE","name":"MIRLET7A1HG","canonical_id":"hgnc:HGNC:53970","description":"miRlet-7a-1/let-7f-1/let-7d cluster host gene","metadata":null},{"id":"72ce1da0fdb14024b94becc61c0945dc","type":"GENE","name":"MIRLET7A2","canonical_id":"hgnc:HGNC:31477","description":"microRNA let-7a-2","metadata":{"aliases":["hsa-let-7a-2","MIRNLET7A2"]}},{"id":"3739b47833b6449eb62689778c6eae8b","type":"GENE","name":"MIRLET7A3","canonical_id":"hgnc:HGNC:31478","description":"microRNA let-7a-3","metadata":{"aliases":["hsa-let-7a-3","MIRNLET7A3"]}},{"id":"23d4518fff7f46d0817d7b78d9f4a63d","type":"GENE","name":"MIRLET7B","canonical_id":"hgnc:HGNC:31479","description":"microRNA let-7b","metadata":{"aliases":["hsa-let-7b","MIRNLET7B"]}},{"id":"b6063bc5fedc4d75baf8dc28c87e7a3b","type":"GENE","name":"MIRLET7BHG","canonical_id":"hgnc:HGNC:37189","description":"MIRLET7B and MIRLET7A3 host gene","metadata":{"aliases":["linc-Ppara","PRR34-AS1"]}},{"id":"0e9ccff00b5f4b48a2bb8df3a5130764","type":"GENE","name":"MIRLET7C","canonical_id":"hgnc:HGNC:31480","description":"microRNA let-7c","metadata":{"aliases":["hsa-let-7c","MIRNLET7C"]}},{"id":"11dc3fbdbb3a45f5a9de394d5b30e84d","type":"GENE","name":"MIRLET7D","canonical_id":"hgnc:HGNC:31481","description":"microRNA let-7d","metadata":{"aliases":["hsa-let-7d","MIRNLET7D"]}},{"id":"e3616ac610c54adfa1804f95ffa52397","type":"GENE","name":"MIRLET7E","canonical_id":"hgnc:HGNC:31482","description":"microRNA let-7e","metadata":{"aliases":["hsa-let-7e","MIRNLET7E"]}},{"id":"981d6d797b1e4c3080b0e1aeb1e68bad","type":"GENE","name":"MIRLET7F1","canonical_id":"hgnc:HGNC:31483","description":"microRNA let-7f-1","metadata":{"aliases":["hsa-let-7f-1","MIRNLET7F1"]}},{"id":"24ca0ef9e3f444a2895c4029b31f5990","type":"GENE","name":"MIRLET7F2","canonical_id":"hgnc:HGNC:31484","description":"microRNA let-7f-2","metadata":{"aliases":["hsa-let-7f-2","MIRNLET7F2"]}},{"id":"388cfc501a8f456e9076cbffa8a932c7","type":"GENE","name":"MIRLET7G","canonical_id":"hgnc:HGNC:31485","description":"microRNA let-7g","metadata":{"aliases":["hsa-let-7g","MIRNLET7G"]}},{"id":"f7f8e722e70d47b7a55427a008d97e85","type":"GENE","name":"MIRLET7I","canonical_id":"hgnc:HGNC:31486","description":"microRNA let-7i","metadata":{"aliases":["hsa-let-7i","MIRNLET7I"]}},{"id":"4a1614db8be5494cb793e5fd2d1aa38c","type":"GENE","name":"MIRLET7IHG","canonical_id":"hgnc:HGNC:55478","description":"MIRLET7I host gene","metadata":null},{"id":"94754191ce8c4d30ab54cbadee40ed61","type":"TRIAL","name":"MIRT and Rotigotine in the Early Stage of PD","canonical_id":"clinicaltrials.gov:NCT02100176","description":"Parkinson's Disease","metadata":null},{"id":"70c95e85c9fe4bf2b9c75fcb76c05b05","type":"GENE","name":"MIS12","canonical_id":"hgnc:HGNC:24967","description":"MIS12 kinetochore complex component","metadata":{"aliases":["MGC2488","hMIS12","KNTC2AP","MTW1"]}},{"id":"0660d6cad3474b0a86cb7cc7753690d2","type":"GO_TERM","name":"MIS12/MIND type complex","canonical_id":"go:GO:0000444","description":"\"A multiprotein kinetochore subcomplex that binds to centromeric chromatin and forms part of the outer kinetochore. It helps to recruit outer kinetochore subunits that will bind to microtubules. In humans, it consists of MIS12, DSN1, NSL1 and PMF1.\" [GOC:krc, PMID:14633972, PMID:16585270]","metadata":null},{"id":"a95ad1146f664069a96fb9864f1c9c76","type":"GENE","name":"MIS18A","canonical_id":"hgnc:HGNC:1286","description":"MIS18 kinetochore protein A","metadata":{"aliases":["B28","FASP1","hMis18alpha","C21orf46","C21orf45"]}},{"id":"616a20af61b8460c88ac5b76b31394fd","type":"GENE","name":"MIS18A-AS1","canonical_id":"hgnc:HGNC:40106","description":"MIS18A antisense RNA 1","metadata":null},{"id":"021538bf51484de3924d527a5708e30d","type":"GENE","name":"MIS18BP1","canonical_id":"hgnc:HGNC:20190","description":"MIS18 binding protein 1","metadata":{"aliases":["M18BP1","FLJ11186","KIAA1903","KNL2","C14orf106"]}},{"id":"425ce50d8acc46b6ab07f0ce9b5b88e9","type":"GENE","name":"MISFA","canonical_id":"hgnc:HGNC:44122","description":"mitochondrial sheath formation associated","metadata":{"aliases":["Kastor","Polluks","TSCL1","SPTY2D1-AS1","SPTY2D1OS"]}},{"id":"0ec4f15ef21c4883aa1720d4580a163b","type":"GENE","name":"MISO1","canonical_id":"hgnc:HGNC:26434","description":"mitochondrial inner membrane subdomain organizer 1","metadata":{"aliases":["MISO","FLJ31139","AC3-33","C3orf33"]}},{"id":"e4aa5e003cf2471a898396a105436603","type":"GENE","name":"MISP","canonical_id":"hgnc:HGNC:27000","description":"mitotic spindle positioning","metadata":{"aliases":["DKFZp686H18209","Caprice","MISP1","C19orf21"]}},{"id":"fe55bdb94c1640d6a54c502a976cabd1","type":"GENE","name":"MISP3","canonical_id":"hgnc:HGNC:26963","description":"MISP family member 3","metadata":null},{"id":"8de8ec2794c3490c80ad689727a60f89","type":"GO_TERM","name":"MIT domain binding","canonical_id":"go:GO:0090541","description":"\"Binding to a MIT protein domain. The MIT domain is found in vacuolar sorting proteins, spastin (probable ATPase involved in the assembly or function of nuclear protein complexes), and a sorting nexin, which may play a role in intracellular trafficking.\" [GOC:pm, InterPro:IPR007330]","metadata":null},{"id":"1892590eeadf4fc0ba8bf357a5d4bb7d","type":"GENE","name":"MITA1","canonical_id":"hgnc:HGNC:56733","description":"metabolism induced tumor activator 1","metadata":{"aliases":["IL7AS","hNAIL"]}},{"id":"052772d4170348d0ac900f28ccb21945","type":"GENE","name":"MITD1","canonical_id":"hgnc:HGNC:25207","description":"microtubule interacting and trafficking domain containing 1","metadata":{"aliases":["LOC129531"]}},{"id":"41c7d8aaefb04809aec21487e1773b28","type":"GENE","name":"MITF","canonical_id":"hgnc:HGNC:7105","description":null,"metadata":null},{"id":"1d1fdfb303a049a58bf8ee2087f7b3fb","type":"GENE","name":"MIX23","canonical_id":"hgnc:HGNC:31136","description":"mitochondrial matrix import factor 23","metadata":{"aliases":["FLJ33273","CCDC58"]}},{"id":"f7923c8582f7457b85e4599e674bcbe3","type":"GENE","name":"MIX23P1","canonical_id":"hgnc:HGNC:32457","description":"MIX23 pseudogene 1","metadata":{"aliases":["CCDC58P1"]}},{"id":"41675bb26a4e45eaa11cd2339d393520","type":"GENE","name":"MIX23P2","canonical_id":"hgnc:HGNC:45025","description":"MIX23 pseudogene 2","metadata":{"aliases":["CCDC58P2"]}},{"id":"330ca186b35d4bdeb15b3056a773e834","type":"GENE","name":"MIX23P3","canonical_id":"hgnc:HGNC:45026","description":"MIX23 pseudogene 3","metadata":{"aliases":["CCDC58P3"]}},{"id":"1fb3c153fe934390a3b19f99f4434e61","type":"GENE","name":"MIX23P4","canonical_id":"hgnc:HGNC:45027","description":"MIX23 pseudogene 4","metadata":{"aliases":["CCDC58P4"]}},{"id":"880dc46f74d0481f8d4c5a7563e43a91","type":"GENE","name":"MIX23P5","canonical_id":"hgnc:HGNC:45028","description":"MIX23 pseudogene 5","metadata":{"aliases":["CCDC58P5"]}},{"id":"31b8da6ba7e34a15a29dc79ba9a37fb6","type":"GENE","name":"MIXL1","canonical_id":"hgnc:HGNC:13363","description":"Mix paired-like homeobox","metadata":{"aliases":["MILD1","MIXL"]}},{"id":"75a8926928b14bd9ba978279e9db015e","type":"TRIAL","name":"MIcrovascular dysfuNction In Moderate-severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT04271540","description":"Psoriasis; Cardiovascular Disease","metadata":null},{"id":"f324e2f350ba489a8ec63fdaccc4c390","type":"TRIAL","name":"MInimal Residual Disease Adapted Strategy","canonical_id":"clinicaltrials.gov:NCT04934475","description":"Multiple Myeloma","metadata":null},{"id":"2cb569cabf444e05a0cf14530f4e16ef","type":"TRIAL","name":"MIrabegron With oveRACtive bLadder Symptoms in mEn","canonical_id":"clinicaltrials.gov:NCT02361502","description":"Overactive Bladder","metadata":null},{"id":"2739a8fda67c4401992b4408fc88c171","type":"TRIAL","name":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","canonical_id":"clinicaltrials.gov:NCT01302691","description":"Hypertension","metadata":null},{"id":"62865b9548d44dc7be3e657787729516","type":"TRIAL","name":"MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)","canonical_id":"clinicaltrials.gov:NCT00897104","description":"Migraine Headache","metadata":null},{"id":"7a19aaed3d23400796630867fc23d1df","type":"TRIAL","name":"MK0462 in Treatment of Migraine With Recurrence (MK0462-022)","canonical_id":"clinicaltrials.gov:NCT00897949","description":"Migraine Headache","metadata":null},{"id":"d3e4a1d9ac364e22af7f7317109b6b07","type":"TRIAL","name":"MK0524 Asthma POC Study (0524-008)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00783601","description":"Asthma","metadata":null},{"id":"80a02fc5637d400f9ec871b166038736","type":"GENE","name":"MKI67","canonical_id":"hgnc:HGNC:7107","description":null,"metadata":null},{"id":"59a2ea410aa9483699c27d36e30bd6ed","type":"GENE","name":"MKI67P1","canonical_id":"hgnc:HGNC:49230","description":"marker of proliferation Ki-67 pseudogene 1","metadata":null},{"id":"bd8c62874cac479b95aee7f0e4a00327","type":"GENE","name":"MKKS","canonical_id":"hgnc:HGNC:7108","description":"MKKS centrosomal shuttling protein","metadata":{"aliases":["BBS6"]}},{"id":"0f72f9c1a50a4a2f836a28b31d690ada","type":"GENE","name":"MKL1","canonical_id":"hgnc:HGNC:14334","description":null,"metadata":null},{"id":"a4796cb31e304cfbad243aa54834a443","type":"GENE","name":"MKLN1","canonical_id":"hgnc:HGNC:7109","description":"muskelin 1","metadata":{"aliases":["TWA2"]}},{"id":"087b2697d0934a9ba8147dd2acf59a8a","type":"GENE","name":"MKLN1-AS","canonical_id":"hgnc:HGNC:40374","description":"MKLN1 antisense RNA","metadata":{"aliases":["MKLN1-AS2"]}},{"id":"57e8ebbfba614091b10d8c52e4488ca8","type":"GENE","name":"MKNK1","canonical_id":"hgnc:HGNC:7110","description":"MAPK interacting serine/threonine kinase 1","metadata":{"aliases":["MNK1"]}},{"id":"be862c9c490543c9832a527947ac1cd4","type":"GENE","name":"MKNK1-AS1","canonical_id":"hgnc:HGNC:44129","description":"MKNK1 antisense RNA 1","metadata":null},{"id":"612f6ef4b657415a8a3d54946502ce07","type":"GENE","name":"MKNK2","canonical_id":"hgnc:HGNC:7111","description":null,"metadata":null},{"id":"68698f2bfd734ace9f3bfaca35ab601c","type":"GENE","name":"MKNK2P1","canonical_id":"hgnc:HGNC:44970","description":"MAP kinase interacting serine/threonine kinase 2 pseudogene 1","metadata":null},{"id":"9945fa6a33274e01b8b8c9e15a6314b6","type":"GENE","name":"MKRN1","canonical_id":"hgnc:HGNC:7112","description":"makorin ring finger protein 1","metadata":{"aliases":["RNF61"]}},{"id":"461c7e4fc7c94843ad11ab7dc6b17e9e","type":"GENE","name":"MKRN10P","canonical_id":"hgnc:HGNC:57038","description":"makorin ring finger protein 10, pseudogene","metadata":null},{"id":"c6891646d0324aeda96340465e1d9cf3","type":"GENE","name":"MKRN2","canonical_id":"hgnc:HGNC:7113","description":"makorin ring finger protein 2","metadata":{"aliases":["RNF62","HSPC070"]}},{"id":"1118fbf8101a44b4afb7d55b00be0fad","type":"GENE","name":"MKRN2OS","canonical_id":"hgnc:HGNC:40375","description":"MKRN2 opposite strand","metadata":{"aliases":["MKRN2-AS1","C3orf83"]}},{"id":"3d6ec4228c274fa8a87d6f0aefaf8a4b","type":"GENE","name":"MKRN3","canonical_id":"hgnc:HGNC:7114","description":"makorin ring finger protein 3","metadata":{"aliases":["RNF63","ZFP127","MGC88288","ZNF127","D15S9"]}},{"id":"8ac8adc0696a42ae878a4111aa00c898","type":"GENE","name":"MKRN4P","canonical_id":"hgnc:HGNC:7115","description":"makorin ring finger protein 4, pseudogene","metadata":{"aliases":["ZNF-Xp","RNF64","ZNF127L1","MKRN4","MKRNP5"]}},{"id":"314c1e63de2b45aba5865fb61f17c6ec","type":"GENE","name":"MKRN5P","canonical_id":"hgnc:HGNC:7117","description":"makorin ring finger protein 5, pseudogene","metadata":{"aliases":["ZNF-Xq","ZNF127L2","MKRNP1"]}},{"id":"ec2440f162614133bf903777172e6da0","type":"GENE","name":"MKRN6P","canonical_id":"hgnc:HGNC:7118","description":"makorin ring finger protein 6, pseudogene","metadata":{"aliases":["MKRNP2"]}},{"id":"027a5de1831042adb68c8b79a8339f52","type":"GENE","name":"MKRN7P","canonical_id":"hgnc:HGNC:7119","description":"makorin ring finger protein 7, pseudogene","metadata":{"aliases":["ZNF127L5","MKRNP3"]}},{"id":"d8c8d0b600b74190b04ef85980b06154","type":"GENE","name":"MKRN8P","canonical_id":"hgnc:HGNC:7120","description":"makorin ring finger protein 8, pseudogene","metadata":{"aliases":["LOC391033","ZNF127L4","MKRNP4"]}},{"id":"0b88ab29188047ae980580374145893b","type":"GENE","name":"MKRN9P","canonical_id":"hgnc:HGNC:7116","description":"makorin ring finger protein 9, pseudogene","metadata":{"aliases":["MKRN9","RNF65","ZNF127L3","MKRN5","MKRNP6"]}},{"id":"ad6be54228ad42e29aa3a2a1a9876aa1","type":"GO_TERM","name":"MKS complex","canonical_id":"go:GO:0036038","description":"\"A protein complex that is located at the ciliary transition zone and consists of several proteins some of which are membrane bound. Acts as an organiser of transition zone inner structure, specifically the Y-shaped links, in conjunction with the NPHP complex. The MKS complex also acts as part of the selective barrier that prevents diffusion of proteins between the ciliary cytoplasm and cellular cytoplasm as well as between the ciliary membrane and plasma membrane.\" [GOC:cilia, GOC:sp, PMID:21422230, PMID:21565611, PMID:21725307, PMID:22179047, PMID:25869670, PMID:26595381, PMID:26982032]","metadata":null},{"id":"35efb02ec8a240b3833e86220502c688","type":"GENE","name":"MKS1","canonical_id":"hgnc:HGNC:7121","description":"MKS transition zone complex subunit 1","metadata":{"aliases":["FLJ20345","POC12","BBS13","MKS"]}},{"id":"15651f642357445bb137381d55bc2a84","type":"GENE","name":"MKX","canonical_id":"hgnc:HGNC:23729","description":"mohawk homeobox","metadata":{"aliases":["MGC39616","C10orf48","IRXL1"]}},{"id":"2d568875d2c942c396233dcca9eef475","type":"GENE","name":"MKX-AS1","canonical_id":"hgnc:HGNC:50686","description":"MKX antisense RNA 1","metadata":null},{"id":"6b7268a3fb714cd29921208dea375839","type":"TRIAL","name":"ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma","canonical_id":"clinicaltrials.gov:NCT03005639","description":"Stage IIIB-C Melanoma","metadata":null},{"id":"a6e5f58660924529acebb628be4592ee","type":"GENE","name":"MLANA","canonical_id":"hgnc:HGNC:7124","description":null,"metadata":null},{"id":"9a39eebcb7234fde84ea2c1f6f522f49","type":"GENE","name":"MLC1","canonical_id":"hgnc:HGNC:17082","description":"modulator of VRAC current 1","metadata":{"aliases":["MLC","KIAA0027","LVM","VL"]}},{"id":"dfd055b5cdd145558b0a463a116efbb3","type":"GENE","name":"MLDHR","canonical_id":"hgnc:HGNC:55481","description":"mitochondrial lactate dehydrogenase regulator","metadata":{"aliases":["MP31","PTENURF"]}},{"id":"3a693594ddf54648a3e0fb90ef11a229","type":"GENE","name":"MLEC","canonical_id":"hgnc:HGNC:28973","description":"malectin","metadata":{"aliases":["KIAA0152"]}},{"id":"c3860adf0eef4ea086a1cf90a0c87921","type":"GENE","name":"MLECP1","canonical_id":"hgnc:HGNC:51122","description":"malectin pseudogene 1","metadata":null},{"id":"8b2c117865044acbbb39bc3250cec079","type":"GENE","name":"MLF1","canonical_id":"hgnc:HGNC:7125","description":"myeloid leukemia factor 1","metadata":null},{"id":"5bff3b41ab8546b89b83f0f88f8ba407","type":"GENE","name":"MLF1-DT","canonical_id":"hgnc:HGNC:55620","description":"MLF1 divergent transcript","metadata":null},{"id":"e0d66ae8dcbb4fd290283b1437104469","type":"GENE","name":"MLF2","canonical_id":"hgnc:HGNC:7126","description":"myeloid leukemia factor 2","metadata":{"aliases":["NTN4"]}},{"id":"52ea755bdae04af4aa6292b5dce6bb7a","type":"GENE","name":"MLH1","canonical_id":"hgnc:HGNC:7127","description":null,"metadata":null},{"id":"b6160d43337f495ab0ed8d8a81a9b50e","type":"GENE","name":"MLH3","canonical_id":"hgnc:HGNC:7128","description":"mutL homolog 3","metadata":null},{"id":"586235f0eba24c1ca5a261b4e742774d","type":"GENE","name":"MLIP","canonical_id":"hgnc:HGNC:21355","description":"muscular LMNA interacting protein","metadata":{"aliases":["MGC18257","CIP","C6orf142"]}},{"id":"71f1934b950e48f8992bb88b686c4a4f","type":"GENE","name":"MLIP-AS1","canonical_id":"hgnc:HGNC:40963","description":"MLIP antisense RNA 1","metadata":null},{"id":"f6ee4a32d410440ca6e82048fe697b91","type":"GENE","name":"MLIP-IT1","canonical_id":"hgnc:HGNC:41461","description":"MLIP intronic transcript 1","metadata":null},{"id":"60091f066c1043339efd52ad7b11508c","type":"GENE","name":"MLKL","canonical_id":"hgnc:HGNC:26617","description":"mixed lineage kinase domain like pseudokinase","metadata":{"aliases":["FLJ34389"]}},{"id":"e04b89361d5041b1beada40e5a5c75a3","type":"GO_TERM","name":"MLL1 complex","canonical_id":"go:GO:0071339","description":"\"A protein complex that can methylate lysine-4 of histone H3. MLL1/MLL is the catalytic methyltransferase subunit, and the complex also contains the core components ASH2L, HCFC1/HCF1 WDR5 and RBBP5.\" [GOC:sp, PMID:15960975]","metadata":null},{"id":"85b2437f5a824d508f766b6e5e8976ca","type":"GO_TERM","name":"MLL1/2 complex","canonical_id":"go:GO:0044665","description":"\"A protein complex that can methylate lysine-4 of histone H3, and which contains either of the protein subunits MLL1 or MLL2 in human, or equivalent in other species.\" [GOC:sart, PMID:21875999]","metadata":null},{"id":"ef59fc4d0ee8416098bf21a23775e7e8","type":"GENE","name":"MLL2","canonical_id":"hgnc:HGNC:15840","description":null,"metadata":null},{"id":"d33c86c1565848b2bac506b6031a1dd2","type":"GENE","name":"MLL3","canonical_id":"hgnc:HGNC:13726","description":null,"metadata":null},{"id":"f21fc713594242cd9505dc702e710470","type":"GO_TERM","name":"MLL3/4 complex","canonical_id":"go:GO:0044666","description":"\"A protein complex that can methylate lysine-4 of histone H3, and which contains either of the protein subunits MLL3 or MLL4 in mammals, or equivalent in other species.\" [GOC:sart, PMID:21875999]","metadata":null},{"id":"967265e8eac047ec8c90dc48d69cdf6d","type":"GENE","name":"MLLT1","canonical_id":"hgnc:HGNC:7134","description":"MLLT1 super elongation complex subunit","metadata":{"aliases":["ENL","LTG19","YEATS1"]}},{"id":"ecddbb4a13274344a66d9a75cf5ca414","type":"GENE","name":"MLLT10","canonical_id":"hgnc:HGNC:16063","description":null,"metadata":null},{"id":"340bed082c774933a3d23a428d809df0","type":"GENE","name":"MLLT10P1","canonical_id":"hgnc:HGNC:15794","description":"MLLT10 pseudogene 1","metadata":{"aliases":["bA348I14.3","MLLT10L"]}},{"id":"30c3342d88464423b594b5b555adc7c2","type":"GENE","name":"MLLT10P2","canonical_id":"hgnc:HGNC:39141","description":"MLLT10 pseudogene 2","metadata":null},{"id":"6c3c8b75a5a04692acf5ff8a685af36c","type":"GENE","name":"MLLT11","canonical_id":"hgnc:HGNC:16997","description":"MLLT11 transcription factor 7 cofactor","metadata":{"aliases":["AF1Q"]}},{"id":"6c8c7476fa434b6eb6649410b5f0a688","type":"GENE","name":"MLLT3","canonical_id":"hgnc:HGNC:7136","description":null,"metadata":null},{"id":"76419e5165604da7882801caa8cbdc66","type":"GENE","name":"MLLT6","canonical_id":"hgnc:HGNC:7138","description":"MLLT6, PHD finger containing","metadata":{"aliases":["AF17","FLJ23480"]}},{"id":"d5e552fb4bea46b0a161537a6a6f82f1","type":"GENE","name":"MLN","canonical_id":"hgnc:HGNC:7141","description":"motilin","metadata":null},{"id":"b5e974c43fd4457fac14cd2897ca2c2f","type":"GENE","name":"MLN-AS1","canonical_id":"hgnc:HGNC:59383","description":"MLN antisense RNA 1","metadata":null},{"id":"de18707269a0448686147fd0d9b70d51","type":"GENE","name":"MLNR","canonical_id":"hgnc:HGNC:4495","description":"motilin receptor","metadata":{"aliases":["GPR38"]}},{"id":"181ab46621834ea6bd8bc11909419017","type":"GENE","name":"MLPH","canonical_id":"hgnc:HGNC:29643","description":"melanophilin","metadata":{"aliases":["l1Rk3","l(1)-3Rk","Slac-2a","ln","exophilin-3","SLAC2-A"]}},{"id":"bce0441635b14bcf829264ade85676b9","type":"GENE","name":"MLST8","canonical_id":"hgnc:HGNC:24825","description":"MTOR associated protein MLST8","metadata":{"aliases":["Lst8","Pop3","GBL","GbetaL"]}},{"id":"5330a3d654dd4a098fe991cb06fa73a7","type":"GENE","name":"MLX","canonical_id":"hgnc:HGNC:11645","description":null,"metadata":null},{"id":"ae3149ff346b4968bbac2ce5724ecb80","type":"GENE","name":"MLXIP","canonical_id":"hgnc:HGNC:17055","description":"MLX interacting protein","metadata":{"aliases":["MONDOA","KIAA0867","MIR","bHLHe36"]}},{"id":"7e96c908448e4637abafc4676fd11712","type":"GENE","name":"MLXIPL","canonical_id":"hgnc:HGNC:12744","description":null,"metadata":null},{"id":"2f43bddd359143ec8fa73b099267271b","type":"GENE","name":"MLXP1","canonical_id":"hgnc:HGNC:54600","description":"MLX pseudogene 1","metadata":null},{"id":"06d9f937d6d64ab384306b4869ae9965","type":"GENE","name":"MLYCD","canonical_id":"hgnc:HGNC:7150","description":null,"metadata":null},{"id":"0315b01fa02546e88efbb6059a0a9ae5","type":"GENE","name":"MMAA","canonical_id":"hgnc:HGNC:18871","description":"metabolism of cobalamin associated A","metadata":{"aliases":["cblA"]}},{"id":"764b37523a4b406db86e8ff8b3645a6a","type":"GENE","name":"MMAB","canonical_id":"hgnc:HGNC:19331","description":"metabolism of cobalamin associated B","metadata":{"aliases":["cblB","CFAP23"]}},{"id":"e43ba4c3f9da4ca9a3a49d41670aa7df","type":"GENE","name":"MMACHC","canonical_id":"hgnc:HGNC:24525","description":null,"metadata":null},{"id":"d11bddd22149425fa9c1f672755a3c9f","type":"GENE","name":"MMACHCP1","canonical_id":"hgnc:HGNC:56579","description":"MMACHC pseudogene 1","metadata":null},{"id":"2adead7606d547699b9c861709744b7f","type":"GENE","name":"MMADHC","canonical_id":"hgnc:HGNC:25221","description":"metabolism of cobalamin associated D","metadata":{"aliases":["CL25022","cblD","C2orf25"]}},{"id":"20dd88e35a9f410db7f3afec2b0d7dfb","type":"GENE","name":"MMADHC-DT","canonical_id":"hgnc:HGNC:41087","description":"MMADHC divergent transcript","metadata":null},{"id":"a771ee606bbe41c683c902cc82efdd7a","type":"GENE","name":"MMADHCP1","canonical_id":"hgnc:HGNC:54996","description":"MMADHC pseudogene 1","metadata":null},{"id":"b520253217d54ce2bee23efbf4c3df70","type":"GENE","name":"MMADHCP2","canonical_id":"hgnc:HGNC:54997","description":"MMADHC pseudogene 2","metadata":null},{"id":"719965f779c2420d8170ab52d93defb4","type":"GENE","name":"MMD","canonical_id":"hgnc:HGNC:7153","description":"monocyte to macrophage differentiation associated","metadata":{"aliases":["MMA","PAQR11"]}},{"id":"9f565fff4f4344eabce254f203bc1596","type":"GENE","name":"MMD2","canonical_id":"hgnc:HGNC:30133","description":"monocyte to macrophage differentiation associated 2","metadata":{"aliases":["PAQR10"]}},{"id":"fb4ef0c9730a450d9cb6de237ef36ef3","type":"GENE","name":"MME","canonical_id":"hgnc:HGNC:7154","description":null,"metadata":null},{"id":"07fa1b8c900f49349770adf774ddd628","type":"GENE","name":"MME-AS1","canonical_id":"hgnc:HGNC:40376","description":"MME antisense RNA 1","metadata":null},{"id":"ffb795302c894a62a28be105e862f7ea","type":"GENE","name":"MMEL1","canonical_id":"hgnc:HGNC:14668","description":"membrane metalloendopeptidase like 1","metadata":{"aliases":["SEP","NL1","NL2","NEPII","MMEL2"]}},{"id":"696010440945488cbfb8870bbe5f7665","type":"GENE","name":"MMEL1-AS1","canonical_id":"hgnc:HGNC:40695","description":"MMEL1 antisense RNA 1","metadata":null},{"id":"b499526bba0a46709c31e44f9d604ff1","type":"TRIAL","name":"MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients","canonical_id":"clinicaltrials.gov:NCT00231764","description":"Kidney Transplantation","metadata":null},{"id":"6bfc3958b87f4a52a61fe756201fede0","type":"GENE","name":"MMGT1","canonical_id":"hgnc:HGNC:28100","description":"membrane magnesium transporter 1","metadata":{"aliases":["EMC5","TMEM32"]}},{"id":"8d8e2719e9ff42758a792e68517d2731","type":"GENE","name":"MMP1","canonical_id":"hgnc:HGNC:7155","description":null,"metadata":null},{"id":"554e0acd74e140cb9686863cac12ac53","type":"PROTEIN","name":"MMP1","canonical_id":"uniprot:P03956","description":null,"metadata":null},{"id":"13b3e5bc7f7c4b39a96e0a50cb77fe67","type":"GENE","name":"MMP10","canonical_id":"hgnc:HGNC:7156","description":null,"metadata":null},{"id":"8cc54329da3a42c68541659f23911622","type":"GENE","name":"MMP11","canonical_id":"hgnc:HGNC:7157","description":null,"metadata":null},{"id":"4ff0f4d7f86346a0882ef6666914bc4e","type":"GENE","name":"MMP12","canonical_id":"hgnc:HGNC:7158","description":null,"metadata":null},{"id":"1a76cfe905db422abfd773235fe2c23f","type":"GENE","name":"MMP12P1","canonical_id":"hgnc:HGNC:59240","description":"MMP12 pseudogene 1","metadata":null},{"id":"0a29c091208f47deb51e210f13ee7036","type":"GENE","name":"MMP13","canonical_id":"hgnc:HGNC:7159","description":null,"metadata":null},{"id":"c858d2905732474baa27d4211b8f6fcd","type":"PROTEIN","name":"MMP13","canonical_id":"uniprot:P45452","description":null,"metadata":null},{"id":"e21b7c3e956b4a03bb57b0094d1f382f","type":"GENE","name":"MMP14","canonical_id":"hgnc:HGNC:7160","description":null,"metadata":null},{"id":"23c552e2ab2f463ca1a8ecd095f975c3","type":"GENE","name":"MMP15","canonical_id":"hgnc:HGNC:7161","description":"matrix metallopeptidase 15","metadata":{"aliases":["MT2-MMP","MTMMP2","SMCP-2"]}},{"id":"b406a415345e4d83ac3f440b7e347a97","type":"GENE","name":"MMP16","canonical_id":"hgnc:HGNC:7162","description":"matrix metallopeptidase 16","metadata":{"aliases":["MT3-MMP","DKFZp761D112","C8orf57"]}},{"id":"636b934c8a5445f3944f3fea71045994","type":"GENE","name":"MMP17","canonical_id":"hgnc:HGNC:7163","description":null,"metadata":null},{"id":"8db5ce0859214d1a8398bee17ea561e2","type":"GENE","name":"MMP19","canonical_id":"hgnc:HGNC:7165","description":"matrix metallopeptidase 19","metadata":{"aliases":["RASI-1","MMP18"]}},{"id":"14c49ae88f3c4c5bab3de3e2e4138984","type":"GENE","name":"MMP2","canonical_id":"hgnc:HGNC:7166","description":null,"metadata":null},{"id":"f3db19276da74c8a8295de30ce0a269a","type":"GENE","name":"MMP2-AS1","canonical_id":"hgnc:HGNC:53142","description":"MMP2 antisense RNA 1","metadata":{"aliases":["ENST00000569037"]}},{"id":"69516e47bba34c2f94b989163da17f40","type":"GENE","name":"MMP20","canonical_id":"hgnc:HGNC:7167","description":null,"metadata":null},{"id":"22d4d2d699ae4d5a98f761de95eec6c0","type":"GENE","name":"MMP20-AS1","canonical_id":"hgnc:HGNC:56362","description":"MMP20 antisense RNA 1","metadata":{"aliases":["AP000851.1"]}},{"id":"bac503d34df04a2bb6bfbeb74a1a4f2d","type":"GENE","name":"MMP21","canonical_id":"hgnc:HGNC:14357","description":"matrix metallopeptidase 21","metadata":null},{"id":"fb887c44fca74cfa8f6c69513902eedb","type":"GENE","name":"MMP23A","canonical_id":"hgnc:HGNC:7170","description":"matrix metallopeptidase 23A (pseudogene)","metadata":{"aliases":["MIFR","MMP21"]}},{"id":"795e411f79524cf58ac35210002e019a","type":"GENE","name":"MMP23B","canonical_id":"hgnc:HGNC:7171","description":"matrix metallopeptidase 23B","metadata":{"aliases":["MIFR","MIFR-1","MMP22"]}},{"id":"e3f2aa92282748d4a9fbbaadfae87134","type":"GENE","name":"MMP24","canonical_id":"hgnc:HGNC:7172","description":"matrix metallopeptidase 24","metadata":{"aliases":["MT5-MMP"]}},{"id":"8c52eb12ed3c45dba5dac6067008dba2","type":"GENE","name":"MMP24OS","canonical_id":"hgnc:HGNC:44421","description":"MMP24 opposite strand","metadata":{"aliases":["MMP24-AS1"]}},{"id":"d3a99699d631486b949d67a7d9ab0480","type":"GENE","name":"MMP25","canonical_id":"hgnc:HGNC:14246","description":"matrix metallopeptidase 25","metadata":{"aliases":["MT6-MMP","MMPL1","MMP20"]}},{"id":"1e99f5578b6a44e1857b1d84097ef606","type":"GENE","name":"MMP25-AS1","canonical_id":"hgnc:HGNC:51372","description":"MMP25 antisense RNA 1","metadata":null},{"id":"806f1b653ce74ddfa56543bd153076e4","type":"GENE","name":"MMP26","canonical_id":"hgnc:HGNC:14249","description":"matrix metallopeptidase 26","metadata":{"aliases":["endometase","MGC126590","MGC126592"]}},{"id":"11b3a76392cf4b188070f9edf04449e8","type":"GENE","name":"MMP27","canonical_id":"hgnc:HGNC:14250","description":"matrix metallopeptidase 27","metadata":null},{"id":"58793abaff2f438c83fe44708b58bb27","type":"GENE","name":"MMP28","canonical_id":"hgnc:HGNC:14366","description":null,"metadata":null},{"id":"4c89b48fb78240a899b24efacd5e5446","type":"GENE","name":"MMP3","canonical_id":"hgnc:HGNC:7173","description":null,"metadata":null},{"id":"7e17b256dae345f59c66c6161f75010c","type":"GENE","name":"MMP7","canonical_id":"hgnc:HGNC:7174","description":null,"metadata":null},{"id":"58930483572d4bdeb0c9b5525840b84f","type":"PROTEIN","name":"MMP7","canonical_id":"uniprot:P09237","description":null,"metadata":null},{"id":"9f9886a54c9742afb92782db1996364e","type":"GENE","name":"MMP8","canonical_id":"hgnc:HGNC:7175","description":"matrix metallopeptidase 8","metadata":{"aliases":["CLG1"]}},{"id":"4d61f6d4a3164b1e88a495cf32250cc0","type":"PROTEIN","name":"MMP8","canonical_id":"uniprot:P22894","description":null,"metadata":null},{"id":"990030c97607435c805f9143897f9341","type":"GENE","name":"MMP9","canonical_id":"hgnc:HGNC:7176","description":null,"metadata":null},{"id":"9312b0e328554458a4e4e7a168c314af","type":"GENE","name":"MMRN1","canonical_id":"hgnc:HGNC:7178","description":null,"metadata":null},{"id":"3eb25582bd5f4c00b47ff53c6a7e58d8","type":"GENE","name":"MMRN1-AS1","canonical_id":"hgnc:HGNC:58852","description":"MMRN1 antisense RNA 1","metadata":null},{"id":"f8531f6199cd41bda99077a5b1526468","type":"GENE","name":"MMRN2","canonical_id":"hgnc:HGNC:19888","description":"multimerin 2","metadata":{"aliases":["EndoGlyx-1","FLJ13465","EMILIN3"]}},{"id":"99627e8df7a4409cb92513c6a1fdca2f","type":"GENE","name":"MMS19","canonical_id":"hgnc:HGNC:13824","description":"MMS19 cytosolic iron-sulfur assembly component","metadata":{"aliases":["MET18","hMMS19","CIAO4","MMS19L"]}},{"id":"f0aa22ce03454a8d90a5f19bdad117c3","type":"GENE","name":"MMS22L","canonical_id":"hgnc:HGNC:21475","description":"MMS22 like, DNA repair protein","metadata":{"aliases":["dJ39B17.2","C6orf167"]}},{"id":"7139a05d38894b6d9b1864ec03bc86ed","type":"GENE","name":"MMUT","canonical_id":"hgnc:HGNC:7526","description":"methylmalonyl-CoA mutase","metadata":{"aliases":["MCM","MUT"]}},{"id":"8d35e0c789d9457582c18f6c1972da8d","type":"GO_TERM","name":"MMXD complex","canonical_id":"go:GO:0071817","description":"\"A protein complex that contains the proteins MMS19, MIP18 and XPD, localizes to mitotic spindle during mitosis, and is required for proper chromosome segregation.\" [GOC:sp, PMID:20797633]","metadata":null},{"id":"d8c8c8ca7020429c99829c14b75528f2","type":"TRIAL","name":"MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT07029776","description":"Multiple Myeloma (MM)","metadata":null},{"id":"180cbccb4ce24599a514e5c9b4ad7645","type":"GENE","name":"MN1","canonical_id":"hgnc:HGNC:7180","description":"MN1 proto-oncogene, transcriptional regulator","metadata":{"aliases":["MGCR1-PEN","MGCR1","MGCR"]}},{"id":"0d57c1b9960d42049cb3af1004562fab","type":"GENE","name":"MNAT1","canonical_id":"hgnc:HGNC:7181","description":null,"metadata":null},{"id":"6df23b9d7d49443b8bf04e712e13db7d","type":"GENE","name":"MND1","canonical_id":"hgnc:HGNC:24839","description":"meiotic nuclear divisions 1","metadata":{"aliases":["GAJ"]}},{"id":"1fb99755866745989548c82c238d5e48","type":"GENE","name":"MND1P1","canonical_id":"hgnc:HGNC:56794","description":"MND1 pseudogene 1","metadata":null},{"id":"67d455a474234beeb0fdc71ad7fe0a82","type":"GENE","name":"MNDA","canonical_id":"hgnc:HGNC:7183","description":null,"metadata":null},{"id":"b2dd418611b24ac0906d0077b81fa1aa","type":"GENE","name":"MNMIP1","canonical_id":"hgnc:HGNC:26236","description":"manchette microtubule inner protein 1","metadata":{"aliases":["FLJ22938","C1orf113","SH3D21"]}},{"id":"f7e351006f3e4aa495832729e48e7ac3","type":"GENE","name":"MNS1","canonical_id":"hgnc:HGNC:29636","description":"meiosis specific nuclear structural 1","metadata":{"aliases":["CFAP127","FLJ11222","SPATA40"]}},{"id":"94d450c56c9248a8a0a95ff3e969da72","type":"GENE","name":"MNT","canonical_id":"hgnc:HGNC:7188","description":"MAX network transcriptional repressor","metadata":{"aliases":["ROX","MXD6","MAD6","bHLHd3","lncRNA-HAL"]}},{"id":"11130db112c24934850cb658c6706044","type":"GENE","name":"MNX1","canonical_id":"hgnc:HGNC:4979","description":"motor neuron and pancreas homeobox 1","metadata":{"aliases":["HB9","HOXHB9","SCRA1","HLXB9"]}},{"id":"06a8626698b349a787fb385bac2c0f3a","type":"GENE","name":"MNX1-AS1","canonical_id":"hgnc:HGNC:48954","description":"MNX1 antisense RNA 1","metadata":{"aliases":["CCAT5","LOC645249","MAYA"]}},{"id":"52e4134bdae64310886e7bb8cfcc5f10","type":"GENE","name":"MNX1-AS2","canonical_id":"hgnc:HGNC:40278","description":"MNX1 antisense RNA 2","metadata":{"aliases":["ENST00000429228"]}},{"id":"4089dcfd33464599b8eb739c66e88580","type":"GENE","name":"MOAP1","canonical_id":"hgnc:HGNC:16658","description":"modulator of apoptosis 1","metadata":{"aliases":["MAP-1","PNMA4"]}},{"id":"022b52258ce84744ab0fa19ee38fc41d","type":"GENE","name":"MOB1A","canonical_id":"hgnc:HGNC:16015","description":"MOB kinase activator 1A","metadata":{"aliases":["FLJ10788","MOB1","FLJ11595","Mob4B","Mats1","C2orf6","MOBK1B","MOBKL1B"]}},{"id":"f2123bb080ca4f27861e0ffb8c4f40a9","type":"GENE","name":"MOB1AP1","canonical_id":"hgnc:HGNC:42638","description":"MOB kinase activator 1A pseudogene 1","metadata":{"aliases":["MOBKL1BP1"]}},{"id":"655aeccab35b4c0d9a9515259aea65bb","type":"GENE","name":"MOB1AP2","canonical_id":"hgnc:HGNC:42639","description":"MOB kinase activator 1A pseudogene 2","metadata":{"aliases":["MOBKL1BP2"]}},{"id":"37086f8a4310474ea8287dd97be23d73","type":"GENE","name":"MOB1B","canonical_id":"hgnc:HGNC:29801","description":"MOB kinase activator 1B","metadata":{"aliases":["MOB4A","MOBKL1A"]}},{"id":"eeeee5db5b13466aa06b8e073bf006b2","type":"GENE","name":"MOB1B-AS1","canonical_id":"hgnc:HGNC:58808","description":"MOB1B antisense RNA 1","metadata":null},{"id":"ff30a858b227407495966c9c07cf1d6a","type":"GENE","name":"MOB2","canonical_id":"hgnc:HGNC:24904","description":"MOB kinase activator 2","metadata":{"aliases":["HCCA2"]}},{"id":"afc12f4df2b14362a95dc077703baa6d","type":"GENE","name":"MOB3A","canonical_id":"hgnc:HGNC:29802","description":"MOB kinase activator 3A","metadata":{"aliases":["MOB1C","MOB-LAK","moblak","MOBKL2A"]}},{"id":"e8c441e9ede84a5daf379542608dbb8e","type":"GENE","name":"MOB3B","canonical_id":"hgnc:HGNC:23825","description":"MOB kinase activator 3B","metadata":{"aliases":["MOB1D","FLJ13204","MOBKL2B","C9orf35"]}},{"id":"9094bc3da34c491d957da2ab8c000fdb","type":"GENE","name":"MOB3C","canonical_id":"hgnc:HGNC:29800","description":"MOB kinase activator 3C","metadata":{"aliases":["MOB1E","MOBKL2C"]}},{"id":"b9f96dd2fefb4b2c8413c13f23f674b1","type":"GENE","name":"MOB4","canonical_id":"hgnc:HGNC:17261","description":"MOB family member 4, phocein","metadata":{"aliases":["MOB3","DKFZP564M112","CGI-95","2C4D","PHOCN","PREI3","MOBKL3"]}},{"id":"c7aac5537a2a4f2d91fee467c0e37449","type":"GENE","name":"MOB4P1","canonical_id":"hgnc:HGNC:54749","description":"MOB4 pseudogene 1","metadata":null},{"id":"a0093114f7b949399867e20e6be3ac5a","type":"GENE","name":"MOB4P2","canonical_id":"hgnc:HGNC:54750","description":"MOB4 pseudogene 2","metadata":null},{"id":"fa6948abbcb54cea8190a121420f0add","type":"GENE","name":"MOBP","canonical_id":"hgnc:HGNC:7189","description":"myelin associated oligodendrocyte basic protein","metadata":null},{"id":"eb5ab6b6435640ec8cf4c67bb1351de8","type":"GENE","name":"MOCOS","canonical_id":"hgnc:HGNC:18234","description":"molybdenum cofactor sulfurase","metadata":{"aliases":["HMCS","FLJ20733","MOS","MCS"]}},{"id":"1b91d953f33b4f5a816f7bf51666daab","type":"GENE","name":"MOCS1","canonical_id":"hgnc:HGNC:7190","description":"molybdenum cofactor synthesis 1","metadata":{"aliases":["MOCOD","MOCS1A","MOCS1B"]}},{"id":"80b68d6bb2ff4fae960c113b5e56b3c6","type":"GENE","name":"MOCS1-DT","canonical_id":"hgnc:HGNC:59398","description":"MOCS1 divergent transcript","metadata":null},{"id":"29abe3bb09d44b0699654aa812b66621","type":"GENE","name":"MOCS1P1","canonical_id":"hgnc:HGNC:7191","description":"molybdenum cofactor synthesis 1 pseudogene 1","metadata":{"aliases":["MOCS1P2"]}},{"id":"aa29f87fc58946aeb096e518ba0d7bcc","type":"GENE","name":"MOCS2","canonical_id":"hgnc:HGNC:7193","description":"molybdenum cofactor synthesis 2","metadata":{"aliases":["MOCO1","MOCS2A","MOCS2B"]}},{"id":"c427674f860b4adc932d1ad87aea133c","type":"GENE","name":"MOCS2-DT","canonical_id":"hgnc:HGNC:27417","description":"MOCS2 divergent transcript","metadata":null},{"id":"f9bf4961ef8147acb42acde7341aefeb","type":"GENE","name":"MOCS3","canonical_id":"hgnc:HGNC:15765","description":"molybdenum cofactor synthesis 3","metadata":{"aliases":["UBA4","dJ914P20.3"]}},{"id":"66c0bab1639649daa6dec3a02548d855","type":"GENE","name":"MOCS3P1","canonical_id":"hgnc:HGNC:20021","description":"molybdenum cofactor synthesis 3 pseudogene 1","metadata":{"aliases":["MOCS3P"]}},{"id":"f7e012c834e74ad3b3e235fe13cc2003","type":"GENE","name":"MOCS3P2","canonical_id":"hgnc:HGNC:39444","description":"molybdenum cofactor synthesis 3 pseudogene 2","metadata":null},{"id":"adc69ff5ca3d428297d23509ebdbce1c","type":"GENE","name":"MOG","canonical_id":"hgnc:HGNC:7197","description":"myelin oligodendrocyte glycoprotein","metadata":{"aliases":["BTN6","BTNL11"]}},{"id":"7fc1d4d8acb941ce987f9f27e878e8d2","type":"GENE","name":"MOGAT1","canonical_id":"hgnc:HGNC:18210","description":"monoacylglycerol O-acyltransferase 1","metadata":{"aliases":["DGAT2L","MGAT1","DGAT2L1"]}},{"id":"7afdffc50b3e4b0fa400dea1a3b6a599","type":"GENE","name":"MOGAT2","canonical_id":"hgnc:HGNC:23248","description":"monoacylglycerol O-acyltransferase 2","metadata":{"aliases":["MGAT2","DGAT2L5","FLJ22644"]}},{"id":"a4d739bb8db14db6b3bab72b7a49c4c0","type":"GENE","name":"MOGAT3","canonical_id":"hgnc:HGNC:23249","description":"monoacylglycerol O-acyltransferase 3","metadata":{"aliases":["DC7","MGAT3","DGAT2L2"]}},{"id":"3f81ff8b70114972aa513e91e96b1646","type":"GENE","name":"MOGS","canonical_id":"hgnc:HGNC:24862","description":"mannosyl-oligosaccharide glucosidase","metadata":{"aliases":["GCS1","CWH41","DER7"]}},{"id":"526b13e8184e47d8bc98bac9fbd981f2","type":"GENE","name":"MOK","canonical_id":"hgnc:HGNC:9833","description":"MOK protein kinase","metadata":{"aliases":["RAGE1","STK30","RAGE"]}},{"id":"a2052366571b4247a7a1b0864892516b","type":"GENE","name":"MON1A","canonical_id":"hgnc:HGNC:28207","description":"MON1 vesicular trafficking associated A","metadata":{"aliases":["MGC13272","SAND1"]}},{"id":"0919633928334519a5ba55dc36d0901c","type":"GENE","name":"MON1B","canonical_id":"hgnc:HGNC:25020","description":"MON1 vesicular trafficking associated B","metadata":{"aliases":["SAND2","HSRG1","KIAA0872"]}},{"id":"47e9c56c3ee14097b246cd1a205cc481","type":"GENE","name":"MON2","canonical_id":"hgnc:HGNC:29177","description":"MON2 regulator of endosome-to-Golgi trafficking","metadata":{"aliases":["KIAA1040"]}},{"id":"6e91937dda0042f99b7adf38cb3cc95d","type":"GENE","name":"MON2-AS1","canonical_id":"hgnc:HGNC:56698","description":"MON2 antisense RNA 1","metadata":{"aliases":["AC079035.1"]}},{"id":"07a76b08eb584540b52a52a395a68964","type":"GENE","name":"MORC1","canonical_id":"hgnc:HGNC:7198","description":"MORC family CW-type zinc finger 1","metadata":{"aliases":["ZCW6","CT33","MORC"]}},{"id":"026b9633f8614d69b890d0595a3ca2c4","type":"GENE","name":"MORC1-AS1","canonical_id":"hgnc:HGNC:40377","description":"MORC1 antisense RNA 1","metadata":null},{"id":"de98645cdae145aea9d8cc32b8fd994a","type":"GENE","name":"MORC2","canonical_id":"hgnc:HGNC:23573","description":"MORC family CW-type zinc finger 2","metadata":{"aliases":["ZCW3","KIAA0852","AC004542.C22.1","ZCWCC1"]}},{"id":"ef78bf1fed874acab3edd703fffa066c","type":"GENE","name":"MORC2-AS1","canonical_id":"hgnc:HGNC:26662","description":"MORC2 antisense RNA 1","metadata":{"aliases":["FLJ35801","C22orf27","NCRNA00325"]}},{"id":"8c065b5e9e904d55b01cca29e6a99d1f","type":"GENE","name":"MORC3","canonical_id":"hgnc:HGNC:23572","description":"MORC family CW-type zinc finger 3","metadata":{"aliases":["ZCW5","NXP2","KIAA0136","ZCWCC3"]}},{"id":"dd002cd877e0492a83823ada8e1a1fea","type":"GENE","name":"MORC4","canonical_id":"hgnc:HGNC:23485","description":"MORC family CW-type zinc finger 4","metadata":{"aliases":["ZCW4","FLJ11565","ZCWCC2"]}},{"id":"2e4932931c954b4f87160dda55eb3bb2","type":"GENE","name":"MORF4","canonical_id":"hgnc:HGNC:15773","description":"mortality factor 4 (pseudogene)","metadata":{"aliases":["SEN","SEN1"]}},{"id":"2bf9b9ad428b47f395e0d5ee83d39615","type":"GENE","name":"MORF4L1","canonical_id":"hgnc:HGNC:16989","description":"mortality factor 4 like 1","metadata":{"aliases":["MRG15","MORFRG15","HsT17725","Eaf3","MEAF3"]}},{"id":"e4ad3e5bb81c44da969eb1eab857c2f9","type":"GENE","name":"MORF4L1P1","canonical_id":"hgnc:HGNC:20400","description":"mortality factor 4 like 1 pseudogene 1","metadata":{"aliases":["MRG1","MORF4LP1"]}},{"id":"56aebe8912b24f9784ed9382dcab6780","type":"GENE","name":"MORF4L1P2","canonical_id":"hgnc:HGNC:20401","description":"mortality factor 4 like 1 pseudogene 2","metadata":{"aliases":["MORF4LP2"]}},{"id":"648f955ed02b4c4b9c8220b5d510fc2a","type":"GENE","name":"MORF4L1P3","canonical_id":"hgnc:HGNC:20402","description":"mortality factor 4 like 1 pseudogene 3","metadata":{"aliases":["MRG11","MORF4LP3"]}},{"id":"53c511b2860e45f9a1f5664f1cbe5600","type":"GENE","name":"MORF4L1P4","canonical_id":"hgnc:HGNC:39257","description":"mortality factor 4 like 1 pseudogene 4","metadata":null},{"id":"a253eb460f7744bf977e82d4356edd10","type":"GENE","name":"MORF4L1P5","canonical_id":"hgnc:HGNC:35425","description":"mortality factor 4 like 1 pseudogene 5","metadata":{"aliases":["MORF4LP5"]}},{"id":"b8944d10907d4385a4e3b9a7fd1f9e97","type":"GENE","name":"MORF4L1P6","canonical_id":"hgnc:HGNC:39258","description":"mortality factor 4 like 1 pseudogene 6","metadata":null},{"id":"62e81d63bd51458f8989d14fa9024f13","type":"GENE","name":"MORF4L1P7","canonical_id":"hgnc:HGNC:39259","description":"mortality factor 4 like 1 pseudogene 7","metadata":null},{"id":"cb521e32e6d14d9baeffd44cb3fe3f68","type":"GENE","name":"MORF4L2","canonical_id":"hgnc:HGNC:16849","description":"mortality factor 4 like 2","metadata":{"aliases":["KIAA0026","MRGX"]}},{"id":"960c4eabe08c4f2cb1d3caf22737ca0b","type":"GENE","name":"MORF4L2-AS1","canonical_id":"hgnc:HGNC:27991","description":"MORF4L2 antisense RNA 1","metadata":null},{"id":"9b3a1893832e43a5a5d6c29612a2c850","type":"GENE","name":"MORF4L2P1","canonical_id":"hgnc:HGNC:20403","description":"mortality factor 4 like 2 pseudogene 1","metadata":{"aliases":["MRG4","MORF4LP4"]}},{"id":"176f839f879c4937bc8b379fffb6ddf3","type":"GENE","name":"MORN1","canonical_id":"hgnc:HGNC:25852","description":"MORN repeat containing 1","metadata":{"aliases":["FLJ13941"]}},{"id":"40f198acd35b4c08a3051b115bae103f","type":"GENE","name":"MORN2","canonical_id":"hgnc:HGNC:30166","description":"MORN repeat containing 2","metadata":{"aliases":["MOPT"]}},{"id":"90cdb79838ad4b3dab97d2cb8eab820c","type":"GENE","name":"MORN3","canonical_id":"hgnc:HGNC:29807","description":"MORN repeat containing 3","metadata":null},{"id":"a1d15a60e9a94184a3ce20cbc5c681b2","type":"GENE","name":"MORN4","canonical_id":"hgnc:HGNC:24001","description":"MORN repeat containing 4","metadata":{"aliases":["bA548K23.4","FLJ25925","rtp","C10orf83"]}},{"id":"26064ab7400a4d8cbaa57f03023378bf","type":"GENE","name":"MORN5","canonical_id":"hgnc:HGNC:17841","description":"MORN repeat containing 5","metadata":{"aliases":["FLJ46909","C9orf113","C9orf18"]}},{"id":"c852b44801f14786b60516f9311bcc3c","type":"GENE","name":"MOS","canonical_id":"hgnc:HGNC:7199","description":"MOS proto-oncogene, serine/threonine kinase","metadata":null},{"id":"9f654071586c4929a4ddf5aa9472333d","type":"GENE","name":"MOSMO","canonical_id":"hgnc:HGNC:27087","description":"modulator of smoothened","metadata":{"aliases":["ATTHOG","BC030336","C16orf52"]}},{"id":"b13015baf30e437b81af28ff9568179d","type":"GENE","name":"MOSPD1","canonical_id":"hgnc:HGNC:25235","description":"motile sperm domain containing 1","metadata":{"aliases":["dJ473B4"]}},{"id":"8c76ecb4b84f42ee807745829f1c1cab","type":"GENE","name":"MOSPD2","canonical_id":"hgnc:HGNC:28381","description":"motile sperm domain containing 2","metadata":{"aliases":["MGC26706"]}},{"id":"bc5350effeb840dca3c16506a299caf9","type":"GENE","name":"MOSPD3","canonical_id":"hgnc:HGNC:25078","description":"motile sperm domain containing 3","metadata":{"aliases":["CDS3","NET30"]}},{"id":"9e0cd038e3f147208540141168213915","type":"TRIAL","name":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","canonical_id":"clinicaltrials.gov:NCT00605683","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"165fcb1d2dce44968c1e2631e38df336","type":"TRIAL","name":"MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)","canonical_id":"clinicaltrials.gov:NCT01028586","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"b23c5babdccd4b0597e59fe23ab2d787","type":"GENE","name":"MOV10","canonical_id":"hgnc:HGNC:7200","description":"Mov10 RNA helicase","metadata":{"aliases":["gb110","MGC2948","fSAP113"]}},{"id":"5a4eda1b89604bfa94cd5e5d9d36b15c","type":"GENE","name":"MOV10L1","canonical_id":"hgnc:HGNC:7201","description":"Mov10 like RNA helicase 1","metadata":{"aliases":["DJ402G11.8","DKFZp434B0717","CHAMP"]}},{"id":"8cd893708f5d48188ab73f15c5206eca","type":"GENE","name":"MOXD1","canonical_id":"hgnc:HGNC:21063","description":"monooxygenase DBH like 1","metadata":{"aliases":["DKFZP564G202","MOX","dJ248E1.1"]}},{"id":"039c304a28cb4c3c8e3097ab693d1f50","type":"GENE","name":"MOXD2P","canonical_id":"hgnc:HGNC:33605","description":"monooxygenase DBH like 2, pseudogene","metadata":{"aliases":["MOXD2"]}},{"id":"28a13d5bbf624e9490723dee29e4886b","type":"GO_TERM","name":"MOZ/MORF histone acetyltransferase complex","canonical_id":"go:GO:0070776","description":"\"A histone acetyltransferase complex that has histone H3 acetyltransferase and coactivator activities. Subunits of the human complex include MYST3/MOZ, MYST4/MORF, ING5, EAF6 and one of BRPF1, BRD1/BRPF2 and BRPF3.\" [PMID:18794358]","metadata":null},{"id":"12f61dd2478a44888493427ef3ae80c1","type":"TRIAL","name":"MP-AzeFlu Allergen Chamber - Onset of Action Study","canonical_id":"clinicaltrials.gov:NCT03004131","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"c8a452c4d320468981ef78e37aa60ee8","type":"TRIAL","name":"MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia","canonical_id":"clinicaltrials.gov:NCT03675139","description":"Endometrial Hyperplasia Without Atypia","metadata":null},{"id":"658f15ffede4416888c38e493d3fbe06","type":"GENE","name":"MPC1","canonical_id":"hgnc:HGNC:21606","description":"mitochondrial pyruvate carrier 1","metadata":{"aliases":["dJ68L15.3","CGI-129","SLC54A1","BRP44L"]}},{"id":"14d99da05dd54b359c7810af056005f4","type":"GENE","name":"MPC1-DT","canonical_id":"hgnc:HGNC:55366","description":"MPC1 divergent transcript","metadata":null},{"id":"85100bb7a02246c59af8e3ca7ad39a01","type":"GENE","name":"MPC1L","canonical_id":"hgnc:HGNC:44205","description":"mitochondrial pyruvate carrier 1 like","metadata":{"aliases":["SLC54A3"]}},{"id":"437f20a59d084cabb7253b65274d013b","type":"GENE","name":"MPC2","canonical_id":"hgnc:HGNC:24515","description":"mitochondrial pyruvate carrier 2","metadata":{"aliases":["DKFZP564B167","SLC54A2","BRP44"]}},{"id":"04402060ff89407994b27bee09cc7a66","type":"GENE","name":"MPDU1","canonical_id":"hgnc:HGNC:7207","description":"mannose-P-dolichol utilization defect 1","metadata":{"aliases":["SL15","Lec35","PQLC5","CDGIf","SLC66A5"]}},{"id":"f57a15d90b9b409f825dba565a0d4e22","type":"GENE","name":"MPDU1-AS1","canonical_id":"hgnc:HGNC:40379","description":"MPDU1 antisense RNA 1","metadata":{"aliases":["AC016876.1"]}},{"id":"9895f7b4b88e4959a7e8c3ca71bf0e51","type":"GENE","name":"MPDZ","canonical_id":"hgnc:HGNC:7208","description":"multiple PDZ domain crumbs cell polarity complex component","metadata":{"aliases":["MUPP1"]}},{"id":"b98761549b264617b8e1c73e284feb50","type":"GENE","name":"MPEG1","canonical_id":"hgnc:HGNC:29619","description":"macrophage expressed 1","metadata":{"aliases":["P2","MPS-1","MPG1"]}},{"id":"6af0cb19aad84d9083951564f4ab5eb2","type":"GO_TERM","name":"MPF complex","canonical_id":"go:GO:0031387","description":"\"A complex consisting of a Cdc2-class (also known as Cdc28) cyclin-dependent kinase and an M-phase cyclin such as S. pombe Cdc13. The MPF complex phosphorylates and activates the anaphase promoting complex (APC).\" [PMID:12045216]","metadata":null},{"id":"a2723a8257894a46aa621eff91a8411c","type":"GENE","name":"MPG","canonical_id":"hgnc:HGNC:7211","description":null,"metadata":null},{"id":"20454afe32a24f63a52448c668a89435","type":"GENE","name":"MPHOSPH10","canonical_id":"hgnc:HGNC:7213","description":"M-phase phosphoprotein 10","metadata":{"aliases":["MPP10","MPP10P","CT90","PPP1R106"]}},{"id":"6507bf4dba324391971319863062ecd2","type":"GENE","name":"MPHOSPH10P1","canonical_id":"hgnc:HGNC:55687","description":"MPHOSPH10 pseudogene 1","metadata":null},{"id":"51424cd3fbb040a5b9edf73f5d5a4e9c","type":"GENE","name":"MPHOSPH10P2","canonical_id":"hgnc:HGNC:55688","description":"MPHOSPH10 pseudogene 2","metadata":null},{"id":"89f58453e1914665ada9d86b94960baf","type":"GENE","name":"MPHOSPH10P3","canonical_id":"hgnc:HGNC:55689","description":"MPHOSPH10 pseudogene 3","metadata":null},{"id":"b3704122f66b40dba33819c9a55350e0","type":"GENE","name":"MPHOSPH10P4","canonical_id":"hgnc:HGNC:55690","description":"MPHOSPH10 pseudogene 4","metadata":null},{"id":"5a08fae314334420935d985cd52008ec","type":"GENE","name":"MPHOSPH10P5","canonical_id":"hgnc:HGNC:55691","description":"MPHOSPH10 pseudogene 5","metadata":null},{"id":"ba7d1261d84743d7bc57116d381d403c","type":"GENE","name":"MPHOSPH10P6","canonical_id":"hgnc:HGNC:55693","description":"MPHOSPH10 pseudogene 6","metadata":null},{"id":"618319de8a8b41e7b223b0a387bad734","type":"GENE","name":"MPHOSPH10P7","canonical_id":"hgnc:HGNC:55694","description":"MPHOSPH10 pseudogene 7","metadata":null},{"id":"c91ea2219d294c659d54d93b239d94f7","type":"GENE","name":"MPHOSPH10P8","canonical_id":"hgnc:HGNC:55695","description":"MPHOSPH10 pseudogene 8","metadata":null},{"id":"c44a3e281b57425183362cf2472906ed","type":"GENE","name":"MPHOSPH10P9","canonical_id":"hgnc:HGNC:55696","description":"MPHOSPH10 pseudogene 9","metadata":null},{"id":"8a860458141b497a9fc70913f6004a28","type":"GENE","name":"MPHOSPH6","canonical_id":"hgnc:HGNC:7214","description":"M-phase phosphoprotein 6","metadata":{"aliases":["MPP6"]}},{"id":"3170e486c69a4fa8b8c6716e00f6eabb","type":"GENE","name":"MPHOSPH6-DT","canonical_id":"hgnc:HGNC:55377","description":"MPHOSPH6 divergent transcript","metadata":null},{"id":"4fcdab51ad2e46fb868097353f3fca7d","type":"GENE","name":"MPHOSPH6P1","canonical_id":"hgnc:HGNC:54549","description":"MPHOSPH6 pseudogene 1","metadata":null},{"id":"124cb08828c945339a6818289723649b","type":"GENE","name":"MPHOSPH8","canonical_id":"hgnc:HGNC:29810","description":"M-phase phosphoprotein 8","metadata":{"aliases":["mpp8","HSMPP8"]}},{"id":"613c4f35febc49b6b536c26f10052f62","type":"GENE","name":"MPHOSPH9","canonical_id":"hgnc:HGNC:7215","description":"M-phase phosphoprotein 9","metadata":{"aliases":["MPP9"]}},{"id":"79d0db320ca94c1ea739bac89b7d25c9","type":"GENE","name":"MPI","canonical_id":"hgnc:HGNC:7216","description":"mannose phosphate isomerase","metadata":null},{"id":"6f6116d527e84ea4908120e93c0be02d","type":"GENE","name":"MPIG6B","canonical_id":"hgnc:HGNC:13937","description":"megakaryocyte and platelet inhibitory receptor G6b","metadata":{"aliases":["G6b","NG31","G6b-B","C6orf25"]}},{"id":"4a788899b54544d2bfd9a4985c7af41f","type":"GENE","name":"MPL","canonical_id":"hgnc:HGNC:7217","description":null,"metadata":null},{"id":"cd116ccd55114a79a37a2b4f1404e457","type":"PROTEIN","name":"MPL","canonical_id":"uniprot:P40238","description":null,"metadata":null},{"id":"888dc8f6624f43dfbf06e7cc773d3ece","type":"GENE","name":"MPLKIP","canonical_id":"hgnc:HGNC:16002","description":"M-phase specific PLK1 interacting protein","metadata":{"aliases":["ORF20","TTDN1","C7orf11"]}},{"id":"f144d3edf2e741819e7ad41924fb8bcd","type":"GENE","name":"MPND","canonical_id":"hgnc:HGNC:25934","description":"MPN domain containing","metadata":{"aliases":["FLJ14981"]}},{"id":"0938ac8ac0fc47a78db65c227052d5a9","type":"GENE","name":"MPO","canonical_id":"hgnc:HGNC:7218","description":null,"metadata":null},{"id":"063655a435c5417da82936beb8abd43a","type":"GENE","name":"MPP1","canonical_id":"hgnc:HGNC:7219","description":"MAGUK p55 scaffold protein 1","metadata":{"aliases":["PEMP","DXS552E"]}},{"id":"9366f71a3a514c94a2bfd4d06cf9017b","type":"GENE","name":"MPP2","canonical_id":"hgnc:HGNC:7220","description":"MAGUK p55 scaffold protein 2","metadata":{"aliases":["DKFZp761D0712","DLG2"]}},{"id":"e26a1f9fb3324bd48e22a727b4ad5abe","type":"GENE","name":"MPP3","canonical_id":"hgnc:HGNC:7221","description":"MAGUK p55 scaffold protein 3","metadata":{"aliases":["DLG3"]}},{"id":"b700a0ce46974a6893333f69b9651690","type":"GENE","name":"MPP4","canonical_id":"hgnc:HGNC:13680","description":"MAGUK p55 scaffold protein 4","metadata":{"aliases":["DLG6"]}},{"id":"14e401c4c2534a4fb2836604aa3a37e0","type":"GENE","name":"MPP7","canonical_id":"hgnc:HGNC:26542","description":"MAGUK p55 scaffold protein 7","metadata":{"aliases":["FLJ32798"]}},{"id":"cc2c5956380945bdab06e6947e03226c","type":"GO_TERM","name":"MPP7-DLG1-LIN7 complex","canonical_id":"go:GO:0097025","description":"\"A heterotrimeric protein complex formed by the association of MMP7, DLG1 and either LIN7A or LIN7C; regulates the stability and localization of DLG1 to cell junctions.\" [GOC:BHF, PMID:17237226]","metadata":null},{"id":"41834a1e318f42ab85a723e5651f7b98","type":"GENE","name":"MPP7-DT","canonical_id":"hgnc:HGNC:54139","description":"MPP7 divergent transcript","metadata":null},{"id":"1f88933948194dc9859924cc5348d028","type":"GENE","name":"MPPE1","canonical_id":"hgnc:HGNC:15988","description":"metallophosphoesterase 1","metadata":{"aliases":["PGAP5","Cdc1"]}},{"id":"fa91f73103bd49ecb02cea8a9f7a0937","type":"GENE","name":"MPPE1P1","canonical_id":"hgnc:HGNC:20143","description":"metallophosphoesterase 1 pseudogene 1","metadata":{"aliases":["MPPE1P"]}},{"id":"e8de854cd09549c4bfbaa9dce705c1e4","type":"GENE","name":"MPPE1P2","canonical_id":"hgnc:HGNC:56972","description":"MPPE1 pseudogene 2","metadata":null},{"id":"0b6adddc209848d5a5f0cb12302a2945","type":"GENE","name":"MPPED1","canonical_id":"hgnc:HGNC:1306","description":"metallophosphoesterase domain containing 1","metadata":{"aliases":["239AB","FAM1A","C22orf1"]}},{"id":"a8f97fa9c5f8426c960c7107c9191377","type":"GENE","name":"MPPED2","canonical_id":"hgnc:HGNC:1180","description":"metallophosphoesterase domain containing 2","metadata":{"aliases":["239FB","D11S302E","Hs.46638","FAM1B","dJ873F21.1","dJ1024C24.1","C11orf8"]}},{"id":"ea67b80168484b959fe69fcfa36fd1e5","type":"GENE","name":"MPPED2-AS1","canonical_id":"hgnc:HGNC:53909","description":"MPPED2 antisense RNA 1","metadata":{"aliases":["RP5-1024C24.1"]}},{"id":"54b307f476b145f3b8a6c14174462ecf","type":"GENE","name":"MPRIP","canonical_id":"hgnc:HGNC:30321","description":"myosin phosphatase Rho interacting protein","metadata":{"aliases":["RHOIP3","M-RIP","p116Rip"]}},{"id":"3f7f5cfaa5b44075ab4366636d4c7890","type":"GENE","name":"MPRIP-AS1","canonical_id":"hgnc:HGNC:41263","description":"MPRIP antisense RNA 1","metadata":null},{"id":"23c7e18a4fa3477eba2a719575cfa801","type":"GENE","name":"MPRIPP1","canonical_id":"hgnc:HGNC:44594","description":"myosin phosphatase Rho interacting protein pseudogene 1","metadata":null},{"id":"bbfd69796799490886564f17db4db6bb","type":"GENE","name":"MPST","canonical_id":"hgnc:HGNC:7223","description":"mercaptopyruvate sulfurtransferase","metadata":{"aliases":["MST","TST2","TUM1"]}},{"id":"55b6667666954a58976e53cce0525d25","type":"GENE","name":"MPTX1","canonical_id":"hgnc:HGNC:48364","description":"mucosal pentraxin 1 (pseudogene)","metadata":{"aliases":["MPTX1P"]}},{"id":"08e8f9fb032f48b79cace0c291c57595","type":"GENE","name":"MPV17","canonical_id":"hgnc:HGNC:7224","description":"mitochondrial inner membrane protein MPV17","metadata":{"aliases":["SYM1"]}},{"id":"4c97aed7c61d4712b309795daf109810","type":"GENE","name":"MPV17L","canonical_id":"hgnc:HGNC:26827","description":"MPV17 mitochondrial inner membrane protein like","metadata":{"aliases":["FLJ39599","M-LPH","M-LPH1","M-LPH2","MPV17L1"]}},{"id":"9194dfb4eb654d3292ca4ad562cfcf08","type":"GENE","name":"MPV17L2","canonical_id":"hgnc:HGNC:28177","description":"MPV17 mitochondrial inner membrane protein like 2","metadata":{"aliases":["FKSG24","MGC12972"]}},{"id":"557c04608b4c45008498929f2cc93c03","type":"GENE","name":"MPV17L2P1","canonical_id":"hgnc:HGNC:54962","description":"MPV17L2 pseudogene 1","metadata":null},{"id":"9600fb6f7876416e9b9d83c1ea7d7e86","type":"GENE","name":"MPZ","canonical_id":"hgnc:HGNC:7225","description":null,"metadata":null},{"id":"7c419a56dbf04abf83021eff6d5e297d","type":"GENE","name":"MPZL1","canonical_id":"hgnc:HGNC:7226","description":"myelin protein zero like 1","metadata":{"aliases":["PZR","FLJ21047"]}},{"id":"d06cdc2ec9f1458f95ac854f490d3455","type":"GENE","name":"MPZL1P1","canonical_id":"hgnc:HGNC:58579","description":"MPZL1 pseudogene 1","metadata":null},{"id":"73f452d52879435daeef9edf71d64b89","type":"GENE","name":"MPZL2","canonical_id":"hgnc:HGNC:3496","description":"myelin protein zero like 2","metadata":{"aliases":["EVA","EVA1"]}},{"id":"fa0fa6b107464cc5bf2a866c0f386439","type":"GENE","name":"MPZL3","canonical_id":"hgnc:HGNC:27279","description":"myelin protein zero like 3","metadata":null},{"id":"8aaae9be59594728bb1ce68058d2cded","type":"TRIAL","name":"MR Antagonist and LSD1","canonical_id":"clinicaltrials.gov:NCT04840342","description":"Hypertension; Mineralocorticoid Excess","metadata":null},{"id":"b3bf7e9703b34b0fb05f415ea3117d3d","type":"GENE","name":"MR1","canonical_id":"hgnc:HGNC:4975","description":"major histocompatibility complex, class I-related","metadata":{"aliases":["HLALS"]}},{"id":"bbf133c71f674072a0aaddc1326c0455","type":"GENE","name":"MRAP","canonical_id":"hgnc:HGNC:1304","description":"melanocortin 2 receptor accessory protein","metadata":{"aliases":["B27","FALP","MRAP1","C21orf61"]}},{"id":"8ff9b4ce11b8448eba6b30baf231ce6c","type":"GENE","name":"MRAP-AS1","canonical_id":"hgnc:HGNC:40108","description":"MRAP antisense RNA 1","metadata":null},{"id":"afa8ba03519640a3b0586495f60b289e","type":"GENE","name":"MRAP2","canonical_id":"hgnc:HGNC:21232","description":"melanocortin 2 receptor accessory protein 2","metadata":{"aliases":["bA51G5.2","C6orf117"]}},{"id":"4c81b3c2264149f2b33423d4811155b4","type":"GENE","name":"MRAS","canonical_id":"hgnc:HGNC:7227","description":"muscle RAS oncogene homolog","metadata":{"aliases":["M-RAs","R-RAS3","RRAS3"]}},{"id":"45c9b68ebf0f4d809fa252ff40f0c02a","type":"GENE","name":"MRC1","canonical_id":"hgnc:HGNC:7228","description":"mannose receptor C-type 1","metadata":{"aliases":["CLEC13D","CD206","bA541I19.1","CLEC13DL","MRC1L1"]}},{"id":"a7845b8493c04c43b1f7edba4c59761d","type":"GENE","name":"MRC2","canonical_id":"hgnc:HGNC:16875","description":"mannose receptor C-type 2","metadata":{"aliases":["KIAA0709","ENDO180","CLEC13E","CD280"]}},{"id":"28dd9d7840a34657af6e4517ed066a81","type":"TRIAL","name":"MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics","canonical_id":"clinicaltrials.gov:NCT02869893","description":"Healthy Volunteers","metadata":null},{"id":"c9177bb50c3645afbb4d64066d11c701","type":"TRIAL","name":"MRD-positive AML Clinical Study","canonical_id":"clinicaltrials.gov:NCT07131059","description":"AML, Adult","metadata":null},{"id":"246e2317c126465aafd608964e84c2fc","type":"GENE","name":"MRE11","canonical_id":"hgnc:HGNC:7230","description":"MRE11 double strand break repair nuclease","metadata":{"aliases":["ATLD","MRE11A"]}},{"id":"d2210bd3e33f4979999b4bbd284d47d0","type":"GENE","name":"MRE11P1","canonical_id":"hgnc:HGNC:7231","description":"MRE11 homolog, double strand break repair nuclease pseudogene 1","metadata":{"aliases":["MRE11B"]}},{"id":"ea8ee93dc3e347a5afe8466898b2abe7","type":"GENE","name":"MREG","canonical_id":"hgnc:HGNC:25478","description":"melanoregulin","metadata":{"aliases":["FLJ10116","DSU","WDT2"]}},{"id":"9179a4a285264d198fa48728c7a8d05d","type":"GENE","name":"MREGP1","canonical_id":"hgnc:HGNC:50749","description":"melanoregulin pseudogene 1","metadata":null},{"id":"e37485f4002e473ca99d667a03129c3f","type":"GO_TERM","name":"MRF binding","canonical_id":"go:GO:0043426","description":"\"Binding to Myogenic Regulatory Factor (MRF), a member of the basic Helix-Loop-Helix (bHLH) superfamily of transcription factors.\" [PMID:10966875]","metadata":null},{"id":"b04c23da2742422fb4df8eebdb8d33ed","type":"GENE","name":"MRFAP1","canonical_id":"hgnc:HGNC:24549","description":"Morf4 family associated protein 1","metadata":{"aliases":["PAM14","PGR1"]}},{"id":"a23d942fdf0745459b6eb3ede3456b83","type":"GENE","name":"MRFAP1-AS1","canonical_id":"hgnc:HGNC:58723","description":"MRFAP1 antisense RNA 1","metadata":null},{"id":"bd8074bea2e44444a162982a6932be26","type":"GENE","name":"MRFAP1L1","canonical_id":"hgnc:HGNC:28796","description":"Morf4 family associated protein 1 like 1","metadata":{"aliases":["MGC9651"]}},{"id":"6c1df5a083c04d0ba576be5081a1915b","type":"GENE","name":"MRFAP1L1-DT","canonical_id":"hgnc:HGNC:58724","description":"MRFAP1L1 divergent transcript","metadata":null},{"id":"1e5ed065fe5f46dba6b25817b0c45480","type":"GENE","name":"MRFAP1L2","canonical_id":"hgnc:HGNC:25109","description":"Morf4 family associated protein 1 like 2","metadata":null},{"id":"d2290de02c914f9198581d6883f9261e","type":"GENE","name":"MRFAP1P1","canonical_id":"hgnc:HGNC:55909","description":"MRFAP1 pseudogene 1","metadata":{"aliases":["HDRACA"]}},{"id":"36598fd74aab409ead5467d7be140e7e","type":"GENE","name":"MRGBP","canonical_id":"hgnc:HGNC:15866","description":"MRG domain binding protein","metadata":{"aliases":["FLJ10914","MRG15BP","Eaf7","C20orf20"]}},{"id":"e9f0bfc6fc32482d86a7bf591bf952d7","type":"GENE","name":"MRGPRD","canonical_id":"hgnc:HGNC:29626","description":"MAS related GPR family member D","metadata":{"aliases":["mrgD"]}},{"id":"c3d73a0cfb304c3788ac0cef0c315cb7","type":"GENE","name":"MRGPRE","canonical_id":"hgnc:HGNC:30694","description":"MAS related GPR family member E","metadata":{"aliases":["mrgE","GPR167"]}},{"id":"7b062b2f6a8d4cc286c7ca5ad36c44bb","type":"GENE","name":"MRGPRF","canonical_id":"hgnc:HGNC:24828","description":"MAS related GPR family member F","metadata":{"aliases":["MGC21621","mrgF","GPR168","GPR140"]}},{"id":"3c0c831df3ad456783629f2e0f9dd1b8","type":"GENE","name":"MRGPRF-AS1","canonical_id":"hgnc:HGNC:51140","description":"MRGPRF antisense RNA 1","metadata":null},{"id":"6a979ea719344dd1a27ef0a59f46f6b8","type":"GENE","name":"MRGPRG","canonical_id":"hgnc:HGNC:24829","description":"MAS related GPR family member G","metadata":{"aliases":["mrgG","GPR169"]}},{"id":"1678a1e7a30c4df9985f7edba32e59c6","type":"GENE","name":"MRGPRG-AS1","canonical_id":"hgnc:HGNC:26691","description":"MRGPRG antisense RNA 1","metadata":{"aliases":["FLJ36102","HSD-40","C11orf36"]}},{"id":"67f94ac967b543199b94ea37fa185e7d","type":"GENE","name":"MRGPRX1","canonical_id":"hgnc:HGNC:17962","description":"MAS related GPR family member X1","metadata":{"aliases":["MRGX1"]}},{"id":"df7346cfec9b418996ddf06e4d2b1d76","type":"GENE","name":"MRGPRX10P","canonical_id":"hgnc:HGNC:54334","description":"MAS related GPR family member X10, pseudogene","metadata":null},{"id":"1bf04fe4dd7c4689bfc96c472246e2b6","type":"GENE","name":"MRGPRX11P","canonical_id":"hgnc:HGNC:54335","description":"MAS related GPR family member X11, pseudogene","metadata":null},{"id":"9d84c111489b4eaf801e08a9ac3ae009","type":"GENE","name":"MRGPRX12P","canonical_id":"hgnc:HGNC:54336","description":"MAS related GPR family member X12, pseudogene","metadata":null},{"id":"3f52c2fee7f6474993964c3571e20d39","type":"GENE","name":"MRGPRX13P","canonical_id":"hgnc:HGNC:54337","description":"MAS related GPR family member X13, pseudogene","metadata":null},{"id":"fe3bd524fac94043960f9d0d8d4c88d4","type":"GENE","name":"MRGPRX2","canonical_id":"hgnc:HGNC:17983","description":"MAS related GPR family member X2","metadata":{"aliases":["MRGX2"]}},{"id":"c59dbcad04bb4e43aa19ee2fe268b387","type":"GENE","name":"MRGPRX3","canonical_id":"hgnc:HGNC:17980","description":"MAS related GPR family member X3","metadata":{"aliases":["MRGX3"]}},{"id":"dd1cf9587d36426a9110d03ea3419789","type":"GENE","name":"MRGPRX4","canonical_id":"hgnc:HGNC:17617","description":"MAS related GPR family member X4","metadata":{"aliases":["MRGX4"]}},{"id":"c0aa1a47fd6147f0a73a92f91246dd56","type":"GENE","name":"MRGPRX5P","canonical_id":"hgnc:HGNC:54329","description":"MAS related GPR family member X5, pseudogene","metadata":null},{"id":"b8b9fc47f22940ab9adc7b4100ca139c","type":"GENE","name":"MRGPRX6P","canonical_id":"hgnc:HGNC:54330","description":"MAS related GPR family member X6, pseudogene","metadata":null},{"id":"f06a0baf76fe417ab13cf53968a0686c","type":"GENE","name":"MRGPRX7P","canonical_id":"hgnc:HGNC:54331","description":"MAS related GPR family member X7, pseudogene","metadata":null},{"id":"6a0f39cb0e604a77b1e919c5ee95878e","type":"GENE","name":"MRGPRX8P","canonical_id":"hgnc:HGNC:54332","description":"MAS related GPR family member X8, pseudogene","metadata":null},{"id":"09615204e22848359db2bb7bb83687af","type":"GENE","name":"MRGPRX9P","canonical_id":"hgnc:HGNC:54333","description":"MAS related GPR family member X9, pseudogene","metadata":null},{"id":"c224e137091e4d528c85a1076b15f1cd","type":"TRIAL","name":"MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)","canonical_id":"clinicaltrials.gov:NCT07780344","description":"Cystic Fibrosis (CF)","metadata":null},{"id":"5945aa802b404cd98e1c6f9aa94f0c90","type":"GENE","name":"MRI1","canonical_id":"hgnc:HGNC:28469","description":"methylthioribose-1-phosphate isomerase 1","metadata":{"aliases":["MGC3207","Ypr118w","mtnA","MRDI"]}},{"id":"bd43a463bc774878b30790b264804fe0","type":"GENE","name":"MRLN","canonical_id":"hgnc:HGNC:48649","description":"myoregulin","metadata":{"aliases":["M1","MUSER1","MLN","Linc-RAM","LINC00948"]}},{"id":"a1d5e9fb32ea40d2b371171de47fa319","type":"GENE","name":"MRM1","canonical_id":"hgnc:HGNC:26202","description":"mitochondrial rRNA methyltransferase 1","metadata":{"aliases":["FLJ22578"]}},{"id":"fcf875e9c9db44b3be4019ddfaecfff4","type":"GENE","name":"MRM2","canonical_id":"hgnc:HGNC:16352","description":"mitochondrial rRNA methyltransferase 2","metadata":{"aliases":["FJH1","RRMJ2","FTSJ2"]}},{"id":"9d67a08cd1d64feab7b0f40dd9495cb7","type":"GENE","name":"MRM3","canonical_id":"hgnc:HGNC:18485","description":"mitochondrial rRNA methyltransferase 3","metadata":{"aliases":["FLJ10581","HC90","RMTL1","RNMTL1"]}},{"id":"9926e01e93dd4187a28aa3e3d86d9353","type":"GENE","name":"MRM3-AS1","canonical_id":"hgnc:HGNC:58307","description":"MRM3 antisense RNA 1","metadata":{"aliases":["AC087392.4"]}},{"id":"b4dbd72869ec40cfa339e6b99f2f347a","type":"GENE","name":"MRM3P1","canonical_id":"hgnc:HGNC:44905","description":"MRM3 pseudogene 1","metadata":{"aliases":["RNMTL1P1"]}},{"id":"8a9485d573774486af18039a104b0653","type":"GENE","name":"MRM3P2","canonical_id":"hgnc:HGNC:44906","description":"MRM3 pseudogene 2","metadata":{"aliases":["RNMTL1P2"]}},{"id":"de11d7ee9ea74e5795e4151397742272","type":"GENE","name":"MRNIP","canonical_id":"hgnc:HGNC:30817","description":"MRN complex interacting protein","metadata":{"aliases":["MGC65027","MGC78537","DKFZp686L2452","LOC51149","C5orf45"]}},{"id":"176447a9fae741c48bfd014fdf070fa9","type":"GENE","name":"MRNIP-DT","canonical_id":"hgnc:HGNC:56030","description":"MRNIP divergent transcript","metadata":null},{"id":"d45152af8c4e4fd8b6503e587911bc79","type":"GENE","name":"MRO","canonical_id":"hgnc:HGNC:24121","description":"maestro","metadata":{"aliases":["B29","FLJ30140","C18orf3"]}},{"id":"675a2a10310f4f99a725e06f92539d87","type":"GENE","name":"MROCKI","canonical_id":"hgnc:HGNC:50323","description":"MARCKS cis regulating lncRNA promoter of cytokines and inflammation","metadata":{"aliases":["LOC285758","ROCKI","LINC01268"]}},{"id":"726c068eda664301834c09f101291718","type":"GENE","name":"MROH1","canonical_id":"hgnc:HGNC:26958","description":"maestro heat like repeat family member 1","metadata":{"aliases":["KIAA1833","HEATR7A"]}},{"id":"1653730f770345619827c9bbf9d999e8","type":"GENE","name":"MROH2A","canonical_id":"hgnc:HGNC:27936","description":"maestro heat like repeat family member 2A","metadata":{"aliases":["HEATR7B1"]}},{"id":"06653934cf2d44cfb9b276db32b005d6","type":"GENE","name":"MROH2B","canonical_id":"hgnc:HGNC:26857","description":"maestro heat like repeat family member 2B","metadata":{"aliases":["DKFZp781F0822","FLJ40243","SPIF","HEATR7B2"]}},{"id":"88f0de00e07746fa8ff0d17bae88067a","type":"GENE","name":"MROH2B-DT","canonical_id":"hgnc:HGNC:59034","description":"MROH2B divergent transcript","metadata":null},{"id":"e240c0ad7726479bb54406a2ebb0af3d","type":"GENE","name":"MROH3P","canonical_id":"hgnc:HGNC:33122","description":"maestro heat like repeat family member 3, pseudogene","metadata":{"aliases":["C1orf81"]}},{"id":"09bc21064d19461ead54bf12523f3d5a","type":"GENE","name":"MROH4P","canonical_id":"hgnc:HGNC:44902","description":"maestro heat like repeat family member 4, pseudogene","metadata":null},{"id":"5f1a56a6750c48efa8f39e2364167fb3","type":"GENE","name":"MROH5","canonical_id":"hgnc:HGNC:42976","description":"maestro heat like repeat family member 5 (gene/pseudogene)","metadata":{"aliases":["FLJ43860"]}},{"id":"4d1e990047964705aa18a67cae52903d","type":"GENE","name":"MROH6","canonical_id":"hgnc:HGNC:27814","description":"maestro heat like repeat family member 6","metadata":{"aliases":["C8orf73"]}},{"id":"a4e71195a3144018a0c69f8fa9b9d85d","type":"GENE","name":"MROH7","canonical_id":"hgnc:HGNC:24802","description":"maestro heat like repeat family member 7","metadata":{"aliases":["FLJ46354","C1orf175","HEATR8"]}},{"id":"2cf2bc032fad4f878d6b1ec61c83c6ac","type":"GENE","name":"MROH7-TTC4","canonical_id":"hgnc:HGNC:49180","description":"MROH7-TTC4 readthrough (NMD candidate)","metadata":null},{"id":"5f54fad649794b17a6972fa208d8ca8b","type":"GENE","name":"MROH8","canonical_id":"hgnc:HGNC:16125","description":"maestro heat like repeat family member 8","metadata":{"aliases":["dJ621N11.4","dJ621N11.3","C20orf131","C20orf132"]}},{"id":"7584da5d1ece47229a93543cec2b457f","type":"GENE","name":"MROH9","canonical_id":"hgnc:HGNC:26287","description":"maestro heat like repeat family member 9","metadata":{"aliases":["FLJ23550","ARMC11","C1orf129"]}},{"id":"f15907d5dcf446a58fdbf1e828467e36","type":"GENE","name":"MRPL1","canonical_id":"hgnc:HGNC:14275","description":"mitochondrial ribosomal protein L1","metadata":{"aliases":["BM022","uL1m"]}},{"id":"d7a95f62e645446495ee4e4bd69f1971","type":"GENE","name":"MRPL1-AS1","canonical_id":"hgnc:HGNC:58832","description":"MRPL1 antisense RNA 1","metadata":null},{"id":"c3177432874440dd839b7d168e2b9b76","type":"GENE","name":"MRPL10","canonical_id":"hgnc:HGNC:14055","description":"mitochondrial ribosomal protein L10","metadata":{"aliases":["RPML8","MRP-L8","L10MT","MRP-L10","MRPL8","MGC17973","uL10m"]}},{"id":"23a3e7ffcbd84134ae674351eddc9171","type":"GENE","name":"MRPL11","canonical_id":"hgnc:HGNC:14042","description":"mitochondrial ribosomal protein L11","metadata":{"aliases":["uL11m"]}},{"id":"3d0534d1f28247169cc688e0841bc33d","type":"GENE","name":"MRPL11P2","canonical_id":"hgnc:HGNC:29694","description":"mitochondrial ribosomal protein L11 pseudogene 2","metadata":null},{"id":"444a20fa9b8249368984e46159143962","type":"GENE","name":"MRPL11P3","canonical_id":"hgnc:HGNC:29695","description":"mitochondrial ribosomal protein L11 pseudogene 3","metadata":null},{"id":"5352bcca8dd044cabf59473e8544c8f3","type":"GENE","name":"MRPL12","canonical_id":"hgnc:HGNC:10378","description":"mitochondrial ribosomal protein L12","metadata":{"aliases":["MRPL7/L12","MRPL7","bL12m","RPML12"]}},{"id":"27be3a7713fb4802894cef25fb0f6868","type":"GENE","name":"MRPL13","canonical_id":"hgnc:HGNC:14278","description":"mitochondrial ribosomal protein L13","metadata":{"aliases":["L13","RPL13","L13mt","RPML13","L13A","uL13m"]}},{"id":"783d23c860cf44918245a102bc2bc545","type":"GENE","name":"MRPL14","canonical_id":"hgnc:HGNC:14279","description":"mitochondrial ribosomal protein L14","metadata":{"aliases":["RPML32","MRP-L32","uL14m"]}},{"id":"6971969abe274e7aa7f6c2ca561f3618","type":"GENE","name":"MRPL14-AS1","canonical_id":"hgnc:HGNC:59413","description":"MRPL14 antisense RNA 1","metadata":null},{"id":"4e85eaa81c1947999ebc30df575da655","type":"GENE","name":"MRPL14P1","canonical_id":"hgnc:HGNC:29696","description":"mitochondrial ribosomal protein L14 pseudogene 1","metadata":null},{"id":"b9319153544342dd9eece324e581d454","type":"GENE","name":"MRPL15","canonical_id":"hgnc:HGNC:14054","description":"mitochondrial ribosomal protein L15","metadata":{"aliases":["RPML7","MRP-L7","HSPC145","L15mt","MRP-L15","uL15m"]}},{"id":"14348e7f101146e7ac3bc9bc64b08116","type":"GENE","name":"MRPL15P1","canonical_id":"hgnc:HGNC:29697","description":"mitochondrial ribosomal protein L15 pseudogene 1","metadata":null},{"id":"4cca378972a640feaba20e093f7448ab","type":"GENE","name":"MRPL16","canonical_id":"hgnc:HGNC:14476","description":"mitochondrial ribosomal protein L16","metadata":{"aliases":["FLJ20484","PNAS-111","uL16m"]}},{"id":"39310a5a7a7d4572aa52e35d1608c405","type":"GENE","name":"MRPL17","canonical_id":"hgnc:HGNC:14053","description":"mitochondrial ribosomal protein L17","metadata":{"aliases":["RPML26","MRP-L26","bL17m"]}},{"id":"604fb071bc9648e9941e8019d642b891","type":"GENE","name":"MRPL18","canonical_id":"hgnc:HGNC:14477","description":"mitochondrial ribosomal protein L18","metadata":{"aliases":["HSPC071","uL18m"]}},{"id":"a4dde426506c45a58da4a6b32af1e1c9","type":"GENE","name":"MRPL19","canonical_id":"hgnc:HGNC:14052","description":"mitochondrial ribosomal protein L19","metadata":{"aliases":["MRP-L15","RPML15","KIAA0104","RLX1","bL19m"]}},{"id":"ec83ff5ddbc4418fa31ecd3b232f3891","type":"GENE","name":"MRPL2","canonical_id":"hgnc:HGNC:14056","description":"mitochondrial ribosomal protein L2","metadata":{"aliases":["MRP-L14","RPML14","CGI-22","uL2m"]}},{"id":"e2bdeec9b90d47ac95eccbe7d3454595","type":"GENE","name":"MRPL20","canonical_id":"hgnc:HGNC:14478","description":"mitochondrial ribosomal protein L20","metadata":{"aliases":["FLJ10024","bL20m"]}},{"id":"a5d6aeec06804b9dbae49d59b806f1b0","type":"GENE","name":"MRPL20-AS1","canonical_id":"hgnc:HGNC:27125","description":"MRPL20 antisense RNA 1","metadata":null},{"id":"d839fa5fe75547258f3d5e1054a78dac","type":"GENE","name":"MRPL20-DT","canonical_id":"hgnc:HGNC:54814","description":"MRPL20 divergent transcript","metadata":null},{"id":"0ce0299144ee4549b47812f8d099207e","type":"GENE","name":"MRPL20P1","canonical_id":"hgnc:HGNC:29699","description":"mitochondrial ribosomal protein L20 pseudogene 1","metadata":null},{"id":"8c2fed4502944f54a9c2e1d0715f8698","type":"GENE","name":"MRPL21","canonical_id":"hgnc:HGNC:14479","description":"mitochondrial ribosomal protein L21","metadata":{"aliases":["bL21m"]}},{"id":"a0ee0f4de68845e787b8633d51f07018","type":"GENE","name":"MRPL22","canonical_id":"hgnc:HGNC:14480","description":"mitochondrial ribosomal protein L22","metadata":{"aliases":["MRP-L25","RPML25","HSPC158","uL22m"]}},{"id":"e4345d26f9674684b760ab4793f5c029","type":"GENE","name":"MRPL22P1","canonical_id":"hgnc:HGNC:29700","description":"mitochondrial ribosomal protein L22 pseudogene 1","metadata":null},{"id":"51e9eab9b8704e28a8a2935ea75f3edd","type":"GENE","name":"MRPL23","canonical_id":"hgnc:HGNC:10322","description":"mitochondrial ribosomal protein L23","metadata":{"aliases":["L23MRP","uL23m","RPL23L"]}},{"id":"8397b985052b4d3fba47d4d68383c300","type":"GENE","name":"MRPL23-AS1","canonical_id":"hgnc:HGNC:42812","description":"MRPL23 antisense RNA 1","metadata":{"aliases":["TP53LC10"]}},{"id":"c444b445b2604230b7de798d5314a5b5","type":"GENE","name":"MRPL24","canonical_id":"hgnc:HGNC:14037","description":"mitochondrial ribosomal protein L24","metadata":{"aliases":["MRP-L18","uL24m"]}},{"id":"d53a2425205e419bb7530ccb26c8c2c1","type":"GENE","name":"MRPL27","canonical_id":"hgnc:HGNC:14483","description":"mitochondrial ribosomal protein L27","metadata":{"aliases":["bL27m"]}},{"id":"2a4668adde82492d9d278eeeee9d1873","type":"GENE","name":"MRPL28","canonical_id":"hgnc:HGNC:14484","description":"mitochondrial ribosomal protein L28","metadata":{"aliases":["p15","bL28m","MAAT1"]}},{"id":"df79dbd1f5dc4f02993d55857660067f","type":"GENE","name":"MRPL2P1","canonical_id":"hgnc:HGNC:29698","description":"mitochondrial ribosomal protein L2 pseudogene 1","metadata":null},{"id":"593b762ca399446a803873ad5298fa81","type":"GENE","name":"MRPL3","canonical_id":"hgnc:HGNC:10379","description":"mitochondrial ribosomal protein L3","metadata":{"aliases":["MRL3","uL3m","RPML3"]}},{"id":"109c89e8efb0421cbb9f19a18afeedff","type":"GENE","name":"MRPL30","canonical_id":"hgnc:HGNC:14036","description":"mitochondrial ribosomal protein L30","metadata":{"aliases":["MRP-L28","RPML28","uL30m"]}},{"id":"7af44024df1c488a9e09c9c8e2f4007a","type":"GENE","name":"MRPL30P1","canonical_id":"hgnc:HGNC:29702","description":"mitochondrial ribosomal protein L30 pseudogene 1","metadata":null},{"id":"1a731ca1049b49c89632395426be6533","type":"GENE","name":"MRPL30P2","canonical_id":"hgnc:HGNC:29703","description":"mitochondrial ribosomal protein L30 pseudogene 2","metadata":null},{"id":"73436d79baf643c0a7cdd8d16dca0bdf","type":"GENE","name":"MRPL32","canonical_id":"hgnc:HGNC:14035","description":"mitochondrial ribosomal protein L32","metadata":{"aliases":["HSPC283","L32mt","MRP-L32","bMRP-59b","bL32m"]}},{"id":"2ec7441b49914a6795c8bd407cbe9c2b","type":"GENE","name":"MRPL32P1","canonical_id":"hgnc:HGNC:29704","description":"MRPL32 pseudogene 1","metadata":null},{"id":"65dfb5059c1049d7a3cbf9a4a8af4ee2","type":"GENE","name":"MRPL32P2","canonical_id":"hgnc:HGNC:54964","description":"MRPL32 pseudogene 2","metadata":null},{"id":"a067bd3e9bd7435c8b5794f6976f046a","type":"GENE","name":"MRPL33","canonical_id":"hgnc:HGNC:14487","description":"mitochondrial ribosomal protein L33","metadata":{"aliases":["RPL33L","bL33m","C2orf1"]}},{"id":"7a38386d4317405e846cceb4a83d8b15","type":"GENE","name":"MRPL34","canonical_id":"hgnc:HGNC:14488","description":"mitochondrial ribosomal protein L34","metadata":{"aliases":["L34mt","MGC2633","MGC24974","bL34m"]}},{"id":"bb4061efa7bf41ec871a31c6b0deabac","type":"GENE","name":"MRPL35","canonical_id":"hgnc:HGNC:14489","description":"mitochondrial ribosomal protein L35","metadata":{"aliases":["bL35m"]}},{"id":"34f8689d8d984d2e91cd2b39b44aec48","type":"GENE","name":"MRPL35P1","canonical_id":"hgnc:HGNC:29705","description":"mitochondrial ribosomal protein L35 pseudogene 1","metadata":null},{"id":"7776218b8a4c4752b88b6c3b29c53b33","type":"GENE","name":"MRPL35P2","canonical_id":"hgnc:HGNC:29706","description":"mitochondrial ribosomal protein L35 pseudogene 2","metadata":null},{"id":"f992b929ad1e4bb4a68adb8b9d109fc0","type":"GENE","name":"MRPL35P3","canonical_id":"hgnc:HGNC:23731","description":"mitochondrial ribosomal protein L35 pseudogene 3","metadata":null},{"id":"9376f74a0ae64b51b241f13f43310cfc","type":"GENE","name":"MRPL35P4","canonical_id":"hgnc:HGNC:29707","description":"mitochondrial ribosomal protein L35 pseudogene 4","metadata":null},{"id":"ba574d5a716e475c9435b16edff45d98","type":"GENE","name":"MRPL36","canonical_id":"hgnc:HGNC:14490","description":"mitochondrial ribosomal protein L36","metadata":{"aliases":["RPMJ","L36mt","PRPL36","MRP-L36","bL36m"]}},{"id":"20e1755fa7134b83821f2941ffd84333","type":"GENE","name":"MRPL36P1","canonical_id":"hgnc:HGNC:29708","description":"mitochondrial ribosomal protein L36 pseudogene 1","metadata":null},{"id":"6c50df3e701f4011b8619010bee43686","type":"GENE","name":"MRPL37","canonical_id":"hgnc:HGNC:14034","description":"mitochondrial ribosomal protein L37","metadata":{"aliases":["RPML2","MRP-L2","mL37"]}},{"id":"68dadf5f330744d592174e1cbd2832d8","type":"GENE","name":"MRPL37P1","canonical_id":"hgnc:HGNC:31003","description":"mitochondrial ribosomal protein L37 pseudogene 1","metadata":{"aliases":["HsT4307"]}},{"id":"b702b6d471da4983bbf8ac4ea8f22508","type":"GENE","name":"MRPL38","canonical_id":"hgnc:HGNC:14033","description":"mitochondrial ribosomal protein L38","metadata":{"aliases":["RPML3","MRP-L3","HSPC262","MGC4810","mL38"]}},{"id":"a0b475795fcf46428f6d0dcd682a14f2","type":"GENE","name":"MRPL39","canonical_id":"hgnc:HGNC:14027","description":"mitochondrial ribosomal protein L39","metadata":{"aliases":["RPML5","MRP-L5","MGC104174","PRED66","PRED22","C21orf92","L39mt","MSTP003","MGC3400","FLJ20451","mL39"]}},{"id":"a213087471384eb8a0843256ccccee63","type":"GENE","name":"MRPL3P1","canonical_id":"hgnc:HGNC:29701","description":"mitochondrial ribosomal protein L3 pseudogene 1","metadata":null},{"id":"f18f1088039c406fa9933e94d2e3b529","type":"GENE","name":"MRPL4","canonical_id":"hgnc:HGNC:14276","description":"mitochondrial ribosomal protein L4","metadata":{"aliases":["CGI-28","uL4m"]}},{"id":"8fe5693bcc56483e8c40c3e2844923e2","type":"GENE","name":"MRPL40","canonical_id":"hgnc:HGNC:14491","description":"mitochondrial ribosomal protein L40","metadata":{"aliases":["MRP-L22","mL40","NLVCF"]}},{"id":"e7e01ae032f246599914ba0b78f9bd0d","type":"GENE","name":"MRPL40P1","canonical_id":"hgnc:HGNC:44532","description":"mitochondrial ribosomal protein L40 pseudogene 1","metadata":null},{"id":"39d3bd9696974781942848dbe36b3adc","type":"GENE","name":"MRPL41","canonical_id":"hgnc:HGNC:14492","description":"mitochondrial ribosomal protein L41","metadata":{"aliases":["MRP-L27","RPML27","BMRP","PIG3","MRPL27","mL41"]}},{"id":"a2a2ea6ce81a42d3a91eb2e4e96dd0a8","type":"GENE","name":"MRPL42","canonical_id":"hgnc:HGNC:14493","description":"mitochondrial ribosomal protein L42","metadata":{"aliases":["MRPS32","MRP-L31","RPML31","PTD007","HSPC204","MRPL31","mL42"]}},{"id":"31d910d7cafc4e329bfd91ef37180596","type":"GENE","name":"MRPL42P1","canonical_id":"hgnc:HGNC:29710","description":"mitochondrial ribosomal protein L42 pseudogene 1","metadata":null},{"id":"3bab68883b3f4572b26d6c63defae9b0","type":"GENE","name":"MRPL42P2","canonical_id":"hgnc:HGNC:29711","description":"mitochondrial ribosomal protein L42 pseudogene 2","metadata":null},{"id":"a9fe9a595ec142e39c68e6457a3f7b64","type":"GENE","name":"MRPL42P3","canonical_id":"hgnc:HGNC:29712","description":"mitochondrial ribosomal protein L42 pseudogene 3","metadata":null},{"id":"97d841281f3148abb931de59283474ba","type":"GENE","name":"MRPL42P4","canonical_id":"hgnc:HGNC:29713","description":"mitochondrial ribosomal protein L42 pseudogene 4","metadata":null},{"id":"96a9abfdd6b042abae24277898bf7cbe","type":"GENE","name":"MRPL42P5","canonical_id":"hgnc:HGNC:29714","description":"mitochondrial ribosomal protein L42 pseudogene 5","metadata":null},{"id":"09bdae7986e24c5f88258e684c576d32","type":"GENE","name":"MRPL42P6","canonical_id":"hgnc:HGNC:44533","description":"mitochondrial ribosomal protein L42 pseudogene 6","metadata":null},{"id":"52dd15bad526425c913a6d4e49a5cca4","type":"GENE","name":"MRPL43","canonical_id":"hgnc:HGNC:14517","description":"mitochondrial ribosomal protein L43","metadata":{"aliases":["bMRP36a","mL43"]}},{"id":"ed1925ad16bb4017954e033c78a697b5","type":"GENE","name":"MRPL44","canonical_id":"hgnc:HGNC:16650","description":"mitochondrial ribosomal protein L44","metadata":{"aliases":["FLJ12701","FLJ13990","mL44"]}},{"id":"352066cfa8fc464f962c06b85e565bf4","type":"GENE","name":"MRPL45","canonical_id":"hgnc:HGNC:16651","description":"mitochondrial ribosomal protein L45","metadata":{"aliases":["MGC11321","Mba1","mL45"]}},{"id":"41a503685c3b4245879c91ab14b64a0f","type":"GENE","name":"MRPL45P1","canonical_id":"hgnc:HGNC:29715","description":"mitochondrial ribosomal protein L45 pseudogene 1","metadata":null},{"id":"0fcd5801a3204f15b8c678ce5eeb78b3","type":"GENE","name":"MRPL45P2","canonical_id":"hgnc:HGNC:29716","description":"mitochondrial ribosomal protein L45 pseudogene 2","metadata":null},{"id":"c74ba4f9e47b4c7abd078d8cccd251cb","type":"GENE","name":"MRPL46","canonical_id":"hgnc:HGNC:1192","description":"mitochondrial ribosomal protein L46","metadata":{"aliases":["LIECG2","P2ECSL","mL46","C15orf4"]}},{"id":"d463df21e0ed4a3f999d8e731c96967a","type":"GENE","name":"MRPL47","canonical_id":"hgnc:HGNC:16652","description":"mitochondrial ribosomal protein L47","metadata":{"aliases":["CGI-204","NCM1","uL29m"]}},{"id":"51793a3fa1d14f109f5912756f15097c","type":"GENE","name":"MRPL48","canonical_id":"hgnc:HGNC:16653","description":"mitochondrial ribosomal protein L48","metadata":{"aliases":["CGI-118","mL48"]}},{"id":"4ae6d3ac675a45e88b6295b185dad337","type":"GENE","name":"MRPL48P1","canonical_id":"hgnc:HGNC:21379","description":"mitochondrial ribosomal protein L48 pseudogene 1","metadata":{"aliases":["MRPL48L1","dJ290I10.4"]}},{"id":"97b7046c90244c44baafa8d1eee1bfd9","type":"GENE","name":"MRPL49","canonical_id":"hgnc:HGNC:1176","description":"mitochondrial ribosomal protein L49","metadata":{"aliases":["NOF","NOF1","L49mt","mL49","C11orf4"]}},{"id":"c7449bd35094485f866f653ab4c956b9","type":"GENE","name":"MRPL49P1","canonical_id":"hgnc:HGNC:29717","description":"mitochondrial ribosomal protein L49 pseudogene 1","metadata":null},{"id":"f783c9bac0424bd689d5beaaab103903","type":"GENE","name":"MRPL49P2","canonical_id":"hgnc:HGNC:29718","description":"mitochondrial ribosomal protein L49 pseudogene 2","metadata":null},{"id":"68e0e78fd6774c719b06fa1e25e3286b","type":"GENE","name":"MRPL50","canonical_id":"hgnc:HGNC:16654","description":"mitochondrial ribosomal protein L50","metadata":{"aliases":["FLJ20493","MRP-L50","mL50"]}},{"id":"70f4b5e1320d4aaabfe84a1daadd1aae","type":"GENE","name":"MRPL50P1","canonical_id":"hgnc:HGNC:29719","description":"mitochondrial ribosomal protein L50 pseudogene 1","metadata":null},{"id":"d515127bfa39492989ab01585d3031ea","type":"GENE","name":"MRPL50P2","canonical_id":"hgnc:HGNC:29720","description":"mitochondrial ribosomal protein L50 pseudogene 2","metadata":null},{"id":"84a58d63a9384c64870d5f975d246a65","type":"GENE","name":"MRPL50P3","canonical_id":"hgnc:HGNC:29721","description":"mitochondrial ribosomal protein L50 pseudogene 3","metadata":null},{"id":"4c43ffe5d849486dad87da14c4b3244f","type":"GENE","name":"MRPL50P4","canonical_id":"hgnc:HGNC:29722","description":"mitochondrial ribosomal protein L50 pseudogene 4","metadata":null},{"id":"5f09bdfded08478a876fea4e8c98f72b","type":"GENE","name":"MRPL51","canonical_id":"hgnc:HGNC:14044","description":"mitochondrial ribosomal protein L51","metadata":{"aliases":["CDA09","HSPC241","bMRP64","mL51","MRP64"]}},{"id":"5661cb9dc589450db5f4cf868bfcc546","type":"GENE","name":"MRPL51P1","canonical_id":"hgnc:HGNC:29723","description":"mitochondrial ribosomal protein L51 pseudogene 1","metadata":null},{"id":"9b77fd4eb4fa4d69abb28582e57da087","type":"GENE","name":"MRPL51P2","canonical_id":"hgnc:HGNC:29724","description":"mitochondrial ribosomal protein L51 pseudogene 2","metadata":null},{"id":"aa7dd8590b274d7eb9e2f48069f7bf65","type":"GENE","name":"MRPL52","canonical_id":"hgnc:HGNC:16655","description":"mitochondrial ribosomal protein L52","metadata":{"aliases":["mL52"]}},{"id":"14361b535e9d490dbc9a5025e11eaefd","type":"GENE","name":"MRPL53","canonical_id":"hgnc:HGNC:16684","description":"mitochondrial ribosomal protein L53","metadata":{"aliases":["mL53"]}},{"id":"53601f07bb1f4dd28ae85c4cd1f41fa1","type":"GENE","name":"MRPL53P1","canonical_id":"hgnc:HGNC:29725","description":"mitochondrial ribosomal protein L53 pseudogene 1","metadata":null},{"id":"4d11a6effe504f2ab12e5ea5a1b69697","type":"GENE","name":"MRPL54","canonical_id":"hgnc:HGNC:16685","description":"mitochondrial ribosomal protein L54","metadata":{"aliases":["mL54"]}},{"id":"6827cfa1a0d14ab59ff594d0b335777b","type":"GENE","name":"MRPL55","canonical_id":"hgnc:HGNC:16686","description":"mitochondrial ribosomal protein L55","metadata":{"aliases":["bL31m"]}},{"id":"8507090a987a4d249d9163aa6dacbcaf","type":"GENE","name":"MRPL57","canonical_id":"hgnc:HGNC:14514","description":"mitochondrial ribosomal protein L57","metadata":{"aliases":["mL63","MRP63"]}},{"id":"02ea79755ba64d8ca316a830b85691cd","type":"GENE","name":"MRPL57P1","canonical_id":"hgnc:HGNC:29686","description":"mitochondrial ribosomal protein L57 pseudogene 1","metadata":{"aliases":["MRP63P1"]}},{"id":"ed67c3bb41994ff3aca807d0b78c8217","type":"GENE","name":"MRPL57P10","canonical_id":"hgnc:HGNC:23965","description":"mitochondrial ribosomal protein L57 pseudogene 10","metadata":{"aliases":["MRP63P10"]}},{"id":"c9d3e425bc304ac4aedb7f21697d5afc","type":"GENE","name":"MRPL57P2","canonical_id":"hgnc:HGNC:29687","description":"mitochondrial ribosomal protein L57 pseudogene 2","metadata":{"aliases":["MRP63P2"]}},{"id":"06d2a0ce2f3c4c71be973b1d0b4427db","type":"GENE","name":"MRPL57P3","canonical_id":"hgnc:HGNC:29688","description":"mitochondrial ribosomal protein L57 pseudogene 3","metadata":{"aliases":["MRP63P3"]}},{"id":"73631965929440a29e4d311a8a1fdaf7","type":"GENE","name":"MRPL57P6","canonical_id":"hgnc:HGNC:29689","description":"mitochondrial ribosomal protein L57 pseudogene 6","metadata":{"aliases":["MRP63P6"]}},{"id":"fd8b4d56d83c43b78dbc63be55c47fe1","type":"GENE","name":"MRPL57P7","canonical_id":"hgnc:HGNC:29690","description":"mitochondrial ribosomal protein L57 pseudogene 7","metadata":{"aliases":["MRP63P7"]}},{"id":"a144219b343c4c4d9640128650dacc37","type":"GENE","name":"MRPL57P8","canonical_id":"hgnc:HGNC:29691","description":"mitochondrial ribosomal protein L57 pseudogene 8","metadata":{"aliases":["MRP63P8"]}},{"id":"b22e0198131e457cb57f3ed24ff819a2","type":"GENE","name":"MRPL57P9","canonical_id":"hgnc:HGNC:29692","description":"mitochondrial ribosomal protein L57 pseudogene 9","metadata":{"aliases":["MRP63P9"]}},{"id":"c5d651a220484262b08a952686c2a66a","type":"GENE","name":"MRPL58","canonical_id":"hgnc:HGNC:5359","description":"mitochondrial ribosomal protein L58","metadata":{"aliases":["DS-1","mL62","ICT1"]}},{"id":"b9863031e6654aaba8352144a95cb84e","type":"GENE","name":"MRPL9","canonical_id":"hgnc:HGNC:14277","description":"mitochondrial ribosomal protein L9","metadata":{"aliases":["bL9m"]}},{"id":"623722f237444e6abaf9b4796027e893","type":"GENE","name":"MRPL9P1","canonical_id":"hgnc:HGNC:29726","description":"mitochondrial ribosomal protein L9 pseudogene 1","metadata":null},{"id":"b482de820d264bf1a55c8f4248c486cc","type":"GENE","name":"MRPS10","canonical_id":"hgnc:HGNC:14502","description":"mitochondrial ribosomal protein S10","metadata":{"aliases":["FLJ10567","uS10m"]}},{"id":"aaa82121b1804a6aba2ad00953966b8a","type":"GENE","name":"MRPS10P1","canonical_id":"hgnc:HGNC:29728","description":"mitochondrial ribosomal protein S10 pseudogene 1","metadata":null},{"id":"9b80dd3b168f46d7b3f4a53b524ac92b","type":"GENE","name":"MRPS10P2","canonical_id":"hgnc:HGNC:29727","description":"mitochondrial ribosomal protein S10 pseudogene 2","metadata":{"aliases":["MRPS10P3","MRPS10P4"]}},{"id":"942ba64993734acead113747473735c2","type":"GENE","name":"MRPS10P5","canonical_id":"hgnc:HGNC:29729","description":"mitochondrial ribosomal protein S10 pseudogene 5","metadata":null},{"id":"ff5f6be566174b49873ec4ddc62d42ab","type":"GENE","name":"MRPS11","canonical_id":"hgnc:HGNC:14050","description":"mitochondrial ribosomal protein S11","metadata":{"aliases":["FLJ23406","HCC-2","FLJ22512","uS11m"]}},{"id":"d878f6309c6e43fd9ac115f91ebea219","type":"GENE","name":"MRPS11P1","canonical_id":"hgnc:HGNC:16584","description":"mitochondrial ribosomal protein S11 pseudogene 1","metadata":{"aliases":["dJ746H2.1"]}},{"id":"ebfbf834e26a4b79b580501383c3ae88","type":"GENE","name":"MRPS12","canonical_id":"hgnc:HGNC:10380","description":"mitochondrial ribosomal protein S12","metadata":{"aliases":["RPS12","RPSM12","uS12m","RPMS12"]}},{"id":"45db09288d93475fa7a52f5165685dec","type":"GENE","name":"MRPS14","canonical_id":"hgnc:HGNC:14049","description":"mitochondrial ribosomal protein S14","metadata":{"aliases":["HSMRPS14","uS14m"]}},{"id":"7efc402b620c4cdaa1c40919eea45bdb","type":"GENE","name":"MRPS15","canonical_id":"hgnc:HGNC:14504","description":"mitochondrial ribosomal protein S15","metadata":{"aliases":["FLJ11564","uS15m"]}},{"id":"9dbc789ab88b4368a16a27ec38dca8c1","type":"GENE","name":"MRPS15P1","canonical_id":"hgnc:HGNC:29730","description":"mitochondrial ribosomal protein S15 pseudogene 1","metadata":null},{"id":"342691104fae44dba601ba601b039b1a","type":"GENE","name":"MRPS15P2","canonical_id":"hgnc:HGNC:29731","description":"mitochondrial ribosomal protein S15 pseudogene 2","metadata":null},{"id":"c5492d3e78fa4d3eadbf4c1ed309245e","type":"GENE","name":"MRPS16","canonical_id":"hgnc:HGNC:14048","description":"mitochondrial ribosomal protein S16","metadata":{"aliases":["CGI-132","bS16m"]}},{"id":"2219910d0eb34ef5a5804a6ca35490d3","type":"GENE","name":"MRPS16P1","canonical_id":"hgnc:HGNC:29732","description":"mitochondrial ribosomal protein S16 pseudogene 1","metadata":null},{"id":"415a9a64f885489589a416d12cee5020","type":"GENE","name":"MRPS16P2","canonical_id":"hgnc:HGNC:16541","description":"mitochondrial ribosomal protein S16 pseudogene 2","metadata":{"aliases":["bA379F14.1","MRPS16P"]}},{"id":"ca27265f2d5d48dd81495a039751f8c0","type":"GENE","name":"MRPS16P3","canonical_id":"hgnc:HGNC:29733","description":"mitochondrial ribosomal protein S16 pseudogene 3","metadata":null},{"id":"10893ff32fe64b60801feba6236f9e2f","type":"GENE","name":"MRPS17","canonical_id":"hgnc:HGNC:14047","description":"mitochondrial ribosomal protein S17","metadata":{"aliases":["HSPC011","RPMS17","MRP-S17","uS17m"]}},{"id":"6c8756e3bf0345939c6f61918cf987ef","type":"GENE","name":"MRPS17P1","canonical_id":"hgnc:HGNC:29734","description":"mitochondrial ribosomal protein S17 pseudogene 1","metadata":null},{"id":"f67c6927badb4982b1ff2253b6895c94","type":"GENE","name":"MRPS17P3","canonical_id":"hgnc:HGNC:29736","description":"mitochondrial ribosomal protein S17 pseudogene 3","metadata":null},{"id":"6d8f519e11fb476ea58d3cc992094dcf","type":"GENE","name":"MRPS17P5","canonical_id":"hgnc:HGNC:29737","description":"mitochondrial ribosomal protein S17 pseudogene 5","metadata":null},{"id":"149c907308954c52b869e172b963a893","type":"GENE","name":"MRPS17P6","canonical_id":"hgnc:HGNC:29738","description":"mitochondrial ribosomal protein S17 pseudogene 6","metadata":null},{"id":"6bba0a11c2924c258ae5078d8fdac716","type":"GENE","name":"MRPS17P7","canonical_id":"hgnc:HGNC:29735","description":"mitochondrial ribosomal protein S17 pseudogene 7","metadata":null},{"id":"00b319f769134d7b8b9ef465a013e229","type":"GENE","name":"MRPS17P9","canonical_id":"hgnc:HGNC:29739","description":"mitochondrial ribosomal protein S17 pseudogene 9","metadata":null},{"id":"f4991940c1bb45fdb8b47617935304c9","type":"GENE","name":"MRPS18A","canonical_id":"hgnc:HGNC:14515","description":"mitochondrial ribosomal protein S18A","metadata":{"aliases":["FLJ10548","MRPS18-3","mL66"]}},{"id":"c4fc7355700d4711b797c1bb90b54891","type":"GENE","name":"MRPS18AP1","canonical_id":"hgnc:HGNC:29740","description":"mitochondrial ribosomal protein S18A pseudogene 1","metadata":null},{"id":"df35cfd4b35d4670818c2889e0005f8f","type":"GENE","name":"MRPS18B","canonical_id":"hgnc:HGNC:14516","description":"mitochondrial ribosomal protein S18B","metadata":{"aliases":["MRPS18-2","PTD017","C6orf14","HSPC183","mS40"]}},{"id":"d136687453f34e11b47b857a97931ded","type":"GENE","name":"MRPS18BP1","canonical_id":"hgnc:HGNC:29741","description":"mitochondrial ribosomal protein S18B pseudogene 1","metadata":null},{"id":"cf2ea077abaa40e8992bddc22a8bfaaa","type":"GENE","name":"MRPS18BP2","canonical_id":"hgnc:HGNC:29742","description":"mitochondrial ribosomal protein S18B pseudogene 2","metadata":null},{"id":"22008671a429430096114d7f056e039b","type":"GENE","name":"MRPS18C","canonical_id":"hgnc:HGNC:16633","description":"mitochondrial ribosomal protein S18C","metadata":{"aliases":["MRPS18-1","CGI-134","FLJ11146","FLJ22967","bS18m"]}},{"id":"6fbb1a442b374ae0972b6e2734baa49b","type":"GENE","name":"MRPS18CP2","canonical_id":"hgnc:HGNC:29743","description":"MRPS18C pseudogene 2","metadata":null},{"id":"6b3a8183e682480fa235a43d39894395","type":"GENE","name":"MRPS18CP3","canonical_id":"hgnc:HGNC:29744","description":"MRPS18C pseudogene 3","metadata":null},{"id":"246c3aa059964996a96bd53375ff1bda","type":"GENE","name":"MRPS18CP4","canonical_id":"hgnc:HGNC:29745","description":"MRPS18C pseudogene 4","metadata":null},{"id":"6e5c0e22696f49d685bd3b1a7fafe100","type":"GENE","name":"MRPS18CP5","canonical_id":"hgnc:HGNC:29746","description":"MRPS18C pseudogene 5","metadata":null},{"id":"c349b0200ef24831b75289e6292d8d7c","type":"GENE","name":"MRPS18CP6","canonical_id":"hgnc:HGNC:29747","description":"MRPS18C pseudogene 6","metadata":null},{"id":"2777da5db0d14905a55797fd34c2c32c","type":"GENE","name":"MRPS18CP7","canonical_id":"hgnc:HGNC:44530","description":"MRPS18C pseudogene 7","metadata":null},{"id":"7606bd3c40154919a115d08cc210b9ac","type":"GENE","name":"MRPS2","canonical_id":"hgnc:HGNC:14495","description":"mitochondrial ribosomal protein S2","metadata":{"aliases":["CGI-91","uS2m"]}},{"id":"c60aae36fe7248fb9ddf2009a4eeaef0","type":"GENE","name":"MRPS21","canonical_id":"hgnc:HGNC:14046","description":"mitochondrial ribosomal protein S21","metadata":{"aliases":["bS21m"]}},{"id":"4a5b2f19e2e64e23810dfbcaa292fe3a","type":"GENE","name":"MRPS21P1","canonical_id":"hgnc:HGNC:29748","description":"mitochondrial ribosomal protein S21 pseudogene 1","metadata":null},{"id":"1c39ee2e34154f49bcbb411332da8da2","type":"GENE","name":"MRPS21P2","canonical_id":"hgnc:HGNC:29749","description":"mitochondrial ribosomal protein S21 pseudogene 2","metadata":null},{"id":"66e4d1ee9e39427bba1ebe0ee778a499","type":"GENE","name":"MRPS21P3","canonical_id":"hgnc:HGNC:29750","description":"mitochondrial ribosomal protein S21 pseudogene 3","metadata":null},{"id":"67fb52bc59844838a1147a4845381032","type":"GENE","name":"MRPS21P4","canonical_id":"hgnc:HGNC:29751","description":"mitochondrial ribosomal protein S21 pseudogene 4","metadata":null},{"id":"8f6cb6f8bfc54211b50b03fc5e81920a","type":"GENE","name":"MRPS21P5","canonical_id":"hgnc:HGNC:29752","description":"mitochondrial ribosomal protein S21 pseudogene 5","metadata":null},{"id":"73d9b56d0e964490b96bed4bdcd96580","type":"GENE","name":"MRPS21P6","canonical_id":"hgnc:HGNC:29753","description":"mitochondrial ribosomal protein S21 pseudogene 6","metadata":null},{"id":"bdd7f269f4c94c9d85d620bbe91c2dea","type":"GENE","name":"MRPS21P7","canonical_id":"hgnc:HGNC:29754","description":"mitochondrial ribosomal protein S21 pseudogene 7","metadata":null},{"id":"f9096a5643304abb834ec319523d0e0c","type":"GENE","name":"MRPS21P8","canonical_id":"hgnc:HGNC:29755","description":"mitochondrial ribosomal protein S21 pseudogene 8","metadata":null},{"id":"22c9424c14c642fabaf51303fb8c75c7","type":"GENE","name":"MRPS21P9","canonical_id":"hgnc:HGNC:29756","description":"mitochondrial ribosomal protein S21 pseudogene 9","metadata":null},{"id":"429b8bf7c90647dea13261573a18fbfc","type":"GENE","name":"MRPS22","canonical_id":"hgnc:HGNC:14508","description":"mitochondrial ribosomal protein S22","metadata":{"aliases":["MRP-S22","GK002","C3orf5","GIBT","mS22"]}},{"id":"f35bde9086334308a3e3c4e08523686c","type":"GENE","name":"MRPS22P1","canonical_id":"hgnc:HGNC:29757","description":"mitochondrial ribosomal protein S22 pseudogene 1","metadata":null},{"id":"b8c0cc599fed4fcd859fd569fe457dcb","type":"GENE","name":"MRPS23","canonical_id":"hgnc:HGNC:14509","description":"mitochondrial ribosomal protein S23","metadata":{"aliases":["MRP-S23","CGI-138","HSPC329","mS23"]}},{"id":"2f7a0ff16924456f9ad9a5e59ae3320f","type":"GENE","name":"MRPS23P1","canonical_id":"hgnc:HGNC:29758","description":"mitochondrial ribosomal protein S23 pseudogene 1","metadata":null},{"id":"da9c2a6a35fc4804b1f43f96b22a1425","type":"GENE","name":"MRPS24","canonical_id":"hgnc:HGNC:14510","description":"mitochondrial ribosomal protein S24","metadata":{"aliases":["MRP-S24","HSPC335"]}},{"id":"b06dcf58bb9946e88d3001c55990a940","type":"GENE","name":"MRPS24P1","canonical_id":"hgnc:HGNC:29759","description":"mitochondrial ribosomal protein S24 pseudogene 1","metadata":null},{"id":"aaf35eb480d2409a8b9de033a35f221a","type":"GENE","name":"MRPS25","canonical_id":"hgnc:HGNC:14511","description":"mitochondrial ribosomal protein S25","metadata":{"aliases":["MRP-S25","FLJ00023","DKFZp313H0817","RPMS25","mS25"]}},{"id":"66a8809363444af1b58b83d06f9effa6","type":"GENE","name":"MRPS25P1","canonical_id":"hgnc:HGNC:29760","description":"mitochondrial ribosomal protein S25 pseudogene 1","metadata":null},{"id":"c6303086784042869818f58889e389d3","type":"GENE","name":"MRPS26","canonical_id":"hgnc:HGNC:14045","description":"mitochondrial ribosomal protein S26","metadata":{"aliases":["MRP-S13","MRP-S26","RPMS13","dJ534B8.3","mS26","C20orf193"]}},{"id":"99b97f779d89423cbf4aa616aaefab8a","type":"GENE","name":"MRPS27","canonical_id":"hgnc:HGNC:14512","description":"mitochondrial ribosomal protein S27","metadata":{"aliases":["KIAA0264","mS27"]}},{"id":"8d01150715c64e6089526eebb1e1278f","type":"GENE","name":"MRPS28","canonical_id":"hgnc:HGNC:14513","description":"mitochondrial ribosomal protein S28","metadata":{"aliases":["MRP-S28","HSPC007","MRPS35"]}},{"id":"0f7a2f51e7da4033ace9729d7d35d713","type":"GENE","name":"MRPS30","canonical_id":"hgnc:HGNC:8769","description":"mitochondrial ribosomal protein S30","metadata":{"aliases":["PAP","mL65","PDCD9"]}},{"id":"a4e96380aee2496fadb68d2d95f8e66f","type":"GENE","name":"MRPS30-DT","canonical_id":"hgnc:HGNC:53420","description":"MRPS30 divergent transcript","metadata":{"aliases":["BRCAT54","BRCAT107","LINC02224"]}},{"id":"d17b9f16e5ef46e3a580fa44f7abae5f","type":"GENE","name":"MRPS31","canonical_id":"hgnc:HGNC:16632","description":"mitochondrial ribosomal protein S31","metadata":{"aliases":["IMOGN38","mS31"]}},{"id":"2c6745d1c8b34c8b814ed1e5912c0d52","type":"GENE","name":"MRPS31P1","canonical_id":"hgnc:HGNC:29763","description":"mitochondrial ribosomal protein S31 pseudogene 1","metadata":null},{"id":"61cbc38fd98346bdb4b5e5d7b056f801","type":"GENE","name":"MRPS31P2","canonical_id":"hgnc:HGNC:39252","description":"mitochondrial ribosomal protein S31 pseudogene 2","metadata":null},{"id":"7651ae0654094dc0b54f3bb95dccd3be","type":"GENE","name":"MRPS31P4","canonical_id":"hgnc:HGNC:42649","description":"mitochondrial ribosomal protein S31 pseudogene 4","metadata":null},{"id":"27ad5cb3d70a4be3931a604dfb45d59f","type":"GENE","name":"MRPS31P5","canonical_id":"hgnc:HGNC:39253","description":"mitochondrial ribosomal protein S31 pseudogene 5","metadata":{"aliases":["MRPS31P3"]}},{"id":"f148da5f745b499d8387e839e8f1407b","type":"GENE","name":"MRPS33","canonical_id":"hgnc:HGNC:16634","description":"mitochondrial ribosomal protein S33","metadata":{"aliases":["CGI-139","mS33"]}},{"id":"1e77fa72984c432f92aae10c192f8d9d","type":"GENE","name":"MRPS33P1","canonical_id":"hgnc:HGNC:29764","description":"mitochondrial ribosomal protein S33 pseudogene 1","metadata":null},{"id":"e35b000c0a5042c5963c36d11005ea77","type":"GENE","name":"MRPS33P2","canonical_id":"hgnc:HGNC:29765","description":"mitochondrial ribosomal protein S33 pseudogene 2","metadata":null},{"id":"8320b21f8b114016a3fc952bde8e3ef1","type":"GENE","name":"MRPS33P3","canonical_id":"hgnc:HGNC:29766","description":"mitochondrial ribosomal protein S33 pseudogene 3","metadata":null},{"id":"a93bba93c436447094d41d4742853509","type":"GENE","name":"MRPS33P4","canonical_id":"hgnc:HGNC:29767","description":"mitochondrial ribosomal protein S33 pseudogene 4","metadata":null},{"id":"cf76d880a38747aab338c6875b8a13bd","type":"GENE","name":"MRPS34","canonical_id":"hgnc:HGNC:16618","description":"mitochondrial ribosomal protein S34","metadata":{"aliases":["MRP-S12","MGC2616","mS34"]}},{"id":"9e79e954410e476b86e76343650cb26f","type":"GENE","name":"MRPS35","canonical_id":"hgnc:HGNC:16635","description":"mitochondrial ribosomal protein S35","metadata":{"aliases":["MRPS28","MDS023","mS35"]}},{"id":"b090ad3894084e7d93da8d88040569c4","type":"GENE","name":"MRPS35-DT","canonical_id":"hgnc:HGNC:55490","description":"MRPS35 divergent transcript","metadata":null},{"id":"f9f2d288f03d4f4f809f8d9f4d70f456","type":"GENE","name":"MRPS35P1","canonical_id":"hgnc:HGNC:29768","description":"mitochondrial ribosomal protein S35 pseudogene 1","metadata":null},{"id":"d817727479de431d8e04fbbbba11e198","type":"GENE","name":"MRPS35P2","canonical_id":"hgnc:HGNC:29769","description":"mitochondrial ribosomal protein S35 pseudogene 2","metadata":null},{"id":"e34952cfff20452e851d76fdaa225df9","type":"GENE","name":"MRPS35P3","canonical_id":"hgnc:HGNC:29770","description":"mitochondrial ribosomal protein S35 pseudogene 3","metadata":null},{"id":"f1a4ace6e0aa4674b7704dd733285ba6","type":"GENE","name":"MRPS36P1","canonical_id":"hgnc:HGNC:29771","description":"mitochondrial ribosomal protein S36 pseudogene 1","metadata":null},{"id":"65bbf844bf3545149dff9277c2d558db","type":"GENE","name":"MRPS36P2","canonical_id":"hgnc:HGNC:29772","description":"mitochondrial ribosomal protein S36 pseudogene 2","metadata":null},{"id":"bb531a987d7a4e558697ae495b346a8c","type":"GENE","name":"MRPS36P3","canonical_id":"hgnc:HGNC:29773","description":"mitochondrial ribosomal protein S36 pseudogene 3","metadata":null},{"id":"3f24763dc91742a095ef13ebbd2aaa2e","type":"GENE","name":"MRPS36P4","canonical_id":"hgnc:HGNC:29774","description":"mitochondrial ribosomal protein S36 pseudogene 4","metadata":null},{"id":"bf9cbef7a0ee47e58b26d0bf45b28bcd","type":"GENE","name":"MRPS36P5","canonical_id":"hgnc:HGNC:29775","description":"mitochondrial ribosomal protein S36 pseudogene 5","metadata":null},{"id":"bd6779b907174ffc8994cc11ab3a6df2","type":"GENE","name":"MRPS36P6","canonical_id":"hgnc:HGNC:29776","description":"mitochondrial ribosomal protein S36 pseudogene 6","metadata":null},{"id":"8dccb55f6ff44e6da35cc670beb27589","type":"GENE","name":"MRPS5","canonical_id":"hgnc:HGNC:14498","description":"mitochondrial ribosomal protein S5","metadata":{"aliases":["MRP-S5","S5mt","uS5m"]}},{"id":"57cbfed503ef46d6b92098470354709f","type":"GENE","name":"MRPS5P3","canonical_id":"hgnc:HGNC:29778","description":"mitochondrial ribosomal protein S5 pseudogene 3","metadata":null},{"id":"531d55d167a14a4ea776fd7d3ec43248","type":"GENE","name":"MRPS5P4","canonical_id":"hgnc:HGNC:29779","description":"mitochondrial ribosomal protein S5 pseudogene 4","metadata":null},{"id":"68bf50e525784ff2975daf82fed55bdf","type":"GENE","name":"MRPS6","canonical_id":"hgnc:HGNC:14051","description":"mitochondrial ribosomal protein S6","metadata":{"aliases":["MRP-S6","RPMS6","bS6m","C21orf101"]}},{"id":"cfe815bd15b547ce97f2903d5a049a02","type":"GENE","name":"MRPS6P1","canonical_id":"hgnc:HGNC:29780","description":"mitochondrial ribosomal protein S6 pseudogene 1","metadata":null},{"id":"4bab1fb5fdaf4aa19ccc6813284c922a","type":"GENE","name":"MRPS6P2","canonical_id":"hgnc:HGNC:29781","description":"mitochondrial ribosomal protein S6 pseudogene 2","metadata":null},{"id":"f5853eae3b1b4d1a92cb4fc6bbd4bb64","type":"GENE","name":"MRPS6P4","canonical_id":"hgnc:HGNC:29782","description":"mitochondrial ribosomal protein S6 pseudogene 4","metadata":null},{"id":"7956842a68e94cf796de3a7bcc399b29","type":"GENE","name":"MRPS7","canonical_id":"hgnc:HGNC:14499","description":"mitochondrial ribosomal protein S7","metadata":{"aliases":["MRP-S","RP-S7","RPMS7","uS7m"]}},{"id":"318bf4ff072848e5b40800f8b99e3c5a","type":"GENE","name":"MRPS7P1","canonical_id":"hgnc:HGNC:29783","description":"mitochondrial ribosomal protein S7 pseudogene 1","metadata":null},{"id":"fc84654dd8d84ee9938df066c567617a","type":"GENE","name":"MRPS7P2","canonical_id":"hgnc:HGNC:29784","description":"mitochondrial ribosomal protein S7 pseudogene 2","metadata":null},{"id":"cb849b0912fd4d299cac6d9614332e14","type":"GENE","name":"MRPS9","canonical_id":"hgnc:HGNC:14501","description":"mitochondrial ribosomal protein S9","metadata":{"aliases":["RPMS9","MRP-S9","S9mt","uS9m"]}},{"id":"956946f838774a1f9d53ba0c2a6988c8","type":"GENE","name":"MRPS9-AS1","canonical_id":"hgnc:HGNC:40688","description":"MRPS9 antisense RNA 1","metadata":{"aliases":["UTAT33"]}},{"id":"876768e0e27e4278af16a18b2b940274","type":"GENE","name":"MRPS9-AS2","canonical_id":"hgnc:HGNC:40687","description":"MRPS9 antisense RNA 2","metadata":null},{"id":"47609e13d6734300a5d2526e58bd2a98","type":"GENE","name":"MRRF","canonical_id":"hgnc:HGNC:7234","description":"mitochondrial ribosome recycling factor","metadata":{"aliases":["mtRRF","RRF"]}},{"id":"d67ae12e35344d3b9e0cd47de8f3b515","type":"GENE","name":"MRRFP1","canonical_id":"hgnc:HGNC:35238","description":"mitochondrial ribosome recycling factor pseudogene 1","metadata":{"aliases":["MRRFP"]}},{"id":"0c21bbe45cb340d485fc3c7ee2c399c0","type":"GENE","name":"MRS2","canonical_id":"hgnc:HGNC:13785","description":"magnesium transporter MRS2","metadata":{"aliases":["MRS2L"]}},{"id":"27e9a239bcfb4c9aaa8d72bdf89e0232","type":"GENE","name":"MRS2P1","canonical_id":"hgnc:HGNC:20590","description":"MRS2 pseudogene 1","metadata":{"aliases":["MRS2LP1"]}},{"id":"7f4c3b1ee43d44ee88321f82c3c07cee","type":"GENE","name":"MRS2P2","canonical_id":"hgnc:HGNC:33942","description":"MRS2 pseudogene 2","metadata":null},{"id":"bcc3bef89b4d42e3a4d6478a5bdfc3d0","type":"TRIAL","name":"MRSA Decolonization in Complicated Carriage","canonical_id":"clinicaltrials.gov:NCT05268120","description":"MRSA","metadata":null},{"id":"461d8ca991ed4fcfadf375b851402931","type":"GENE","name":"MRTFA-AS1","canonical_id":"hgnc:HGNC:40681","description":"MRTFA antisense RNA 1","metadata":null},{"id":"b5b34e9c34414dc181fda1c78215ceb4","type":"GENE","name":"MRTFA-AS2","canonical_id":"hgnc:HGNC:58611","description":"MRTFA antisense RNA 2","metadata":null},{"id":"99a40a7d5e5f4db4b34846caef12d9f2","type":"GENE","name":"MRTFB","canonical_id":"hgnc:HGNC:29819","description":"myocardin related transcription factor B","metadata":{"aliases":["MRTF-B","FLJ31823","MKL2"]}},{"id":"242ab1d2d8aa44ff91fa8194f60baafe","type":"GENE","name":"MRTO4","canonical_id":"hgnc:HGNC:18477","description":"MRT4 homolog, ribosome maturation factor","metadata":{"aliases":["dJ657E11.4","MRT4","C1orf33"]}},{"id":"83856cc3b1c842f18db769a7ffba0caa","type":"GENE","name":"MRVI1","canonical_id":"hgnc:HGNC:7237","description":null,"metadata":null},{"id":"5ed6f7ee54b4480eb3a10e29e9088526","type":"TRIAL","name":"MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains","canonical_id":"clinicaltrials.gov:NCT01198834","description":"Ankle Sprains","metadata":null},{"id":"6f6ce44ebb1b42f990e11d62a8bbdc1d","type":"TRIAL","name":"MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas","canonical_id":"clinicaltrials.gov:NCT00098891","description":"Adult Grade III Lymphomatoid Granulomatosis; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Gr\u2026","metadata":null},{"id":"316bc0899aa74fcdbe7703ca836df340","type":"TRIAL","name":"MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial","canonical_id":"clinicaltrials.gov:NCT01910259","description":"Secondary Progressive Multiple Sclerosis","metadata":null},{"id":"5423499ec444402eadf08a8c561733e7","type":"GENE","name":"MS4A1","canonical_id":"hgnc:HGNC:7315","description":null,"metadata":null},{"id":"ce1b3e96ceef441cbf07e290aebd3c42","type":"PROTEIN","name":"MS4A1","canonical_id":"uniprot:P11836","description":null,"metadata":null},{"id":"85fa5f22f1b54bdba33b4c317a521f0f","type":"GENE","name":"MS4A10","canonical_id":"hgnc:HGNC:13368","description":"membrane spanning 4-domains A10","metadata":{"aliases":["CD20L7","MS4A9"]}},{"id":"69ede3c93a4b47b986c424ca7b36f4a3","type":"GENE","name":"MS4A12","canonical_id":"hgnc:HGNC:13370","description":"membrane spanning 4-domains A12","metadata":{"aliases":["Ms4a10","FLJ20217"]}},{"id":"6b81fe4a408b4c97b0ff3575bf354b13","type":"GENE","name":"MS4A13","canonical_id":"hgnc:HGNC:16674","description":"membrane spanning 4-domains A13","metadata":null},{"id":"6bccb3a084d3470f923d596aa808dabd","type":"GENE","name":"MS4A14","canonical_id":"hgnc:HGNC:30706","description":"membrane spanning 4-domains A14","metadata":{"aliases":["NYD-SP21","FLJ32856","DKFZp434H092","MS4A16"]}},{"id":"011408dc18f84e00a722169526477cfe","type":"GENE","name":"MS4A15","canonical_id":"hgnc:HGNC:28573","description":"membrane spanning 4-domains A15","metadata":null},{"id":"5c1f3e64aa9c4f2ca0e85ca3b42cf5fd","type":"GENE","name":"MS4A18","canonical_id":"hgnc:HGNC:37636","description":"membrane spanning 4-domains A18","metadata":null},{"id":"8b44210160734c17a04d74930a771a26","type":"GENE","name":"MS4A19P","canonical_id":"hgnc:HGNC:53877","description":"membrane spanning 4-domains A19, pseudogene","metadata":null},{"id":"dfe595afbe954f1c880ee6335a660ec9","type":"GENE","name":"MS4A2","canonical_id":"hgnc:HGNC:7316","description":null,"metadata":null},{"id":"bb4f17e4b15e4fd6aa7634c8b588d409","type":"GENE","name":"MS4A3","canonical_id":"hgnc:HGNC:7317","description":"membrane spanning 4-domains A3","metadata":{"aliases":["HTM4","CD20L"]}},{"id":"1cf0b50ceeb14b45b18107071914e8a2","type":"GENE","name":"MS4A4A","canonical_id":"hgnc:HGNC:13371","description":"membrane spanning 4-domains A4A","metadata":{"aliases":["CD20L1","MS4A7","MS4A4"]}},{"id":"37b8c116f7284afaba92c95804b558ac","type":"GENE","name":"MS4A4E","canonical_id":"hgnc:HGNC:14284","description":"membrane spanning 4-domains A4E","metadata":null},{"id":"9206f009454e40f8a35a4a63e4d65d46","type":"GENE","name":"MS4A5","canonical_id":"hgnc:HGNC:13374","description":"membrane spanning 4-domains A5","metadata":{"aliases":["CD20L2"]}},{"id":"34fabb37ec7947ec8a98fd888c1dc43a","type":"GENE","name":"MS4A6A","canonical_id":"hgnc:HGNC:13375","description":"membrane spanning 4-domains A6A","metadata":{"aliases":["CD20L3","MS4A6"]}},{"id":"63dc96c53cc8467ba7c2e742d3ab0a49","type":"GENE","name":"MS4A6E","canonical_id":"hgnc:HGNC:14285","description":"membrane spanning 4-domains A6E","metadata":null},{"id":"301eb81d1a2743c6af0e7f59dc3cdab9","type":"GENE","name":"MS4A7","canonical_id":"hgnc:HGNC:13378","description":"membrane spanning 4-domains A7","metadata":{"aliases":["CD20L4","CFFM4","MS4A8"]}},{"id":"19ffefd9ef1048318ef4bb361df9a63a","type":"GENE","name":"MS4A8","canonical_id":"hgnc:HGNC:13380","description":"membrane spanning 4-domains A8","metadata":{"aliases":["MS4A4","CD20L5","MS4A8B"]}},{"id":"fdb0bd7dbdaa4ddcbaceec7fd3464d63","type":"GENE","name":"MSANTD1","canonical_id":"hgnc:HGNC:33741","description":"Myb/SANT DNA binding domain containing 1","metadata":{"aliases":["LOC345222","C4orf44"]}},{"id":"55813d02d3b14f7ea9ff1009db97704d","type":"GENE","name":"MSANTD2","canonical_id":"hgnc:HGNC:26266","description":"Myb/SANT DNA binding domain containing 2","metadata":{"aliases":["FLJ23342","C11orf61"]}},{"id":"151e6fe2eb9a46c5b9fd4d816615cccb","type":"GENE","name":"MSANTD2-AS1","canonical_id":"hgnc:HGNC:55601","description":"MSANTD2 antisense RNA 1","metadata":{"aliases":["BCLET"]}},{"id":"5782a8c61cdb422f80cd041ec772b374","type":"GENE","name":"MSANTD2P1","canonical_id":"hgnc:HGNC:39637","description":"Myb/SANT DNA binding domain containing 2 pseudogene 1","metadata":null},{"id":"d0ec9d49948e4396b7924222ccdc1bb8","type":"GENE","name":"MSANTD3","canonical_id":"hgnc:HGNC:23370","description":"Myb/SANT DNA binding domain containing 3","metadata":{"aliases":["MGC17337","C9orf30"]}},{"id":"7a8e364dad0645fd934d06df382c8641","type":"GENE","name":"MSANTD3-TMEFF1","canonical_id":"hgnc:HGNC:38838","description":"MSANTD3-TMEFF1 readthrough","metadata":{"aliases":["C9orf30-TMEFF1"]}},{"id":"1fe9489c8b534302817bf5fe02885915","type":"GENE","name":"MSANTD3P1","canonical_id":"hgnc:HGNC:55780","description":"MSANTD3 pseudogene 1","metadata":null},{"id":"6bd9eb4623a641aab4d3f533fb270e15","type":"GENE","name":"MSANTD4","canonical_id":"hgnc:HGNC:29383","description":"Myb/SANT DNA binding domain containing 4 with coiled-coils","metadata":{"aliases":["KIAA1826"]}},{"id":"ddcd4fde80404c749d63b7faf92def80","type":"GENE","name":"MSANTD5","canonical_id":"hgnc:HGNC:55184","description":"Myb/SANT DNA binding domain containing 5","metadata":null},{"id":"87bf2e4a2edd4559aae3730311869b35","type":"GENE","name":"MSANTD7","canonical_id":"hgnc:HGNC:56248","description":"Myb/SANT DNA binding domain containing 7","metadata":null},{"id":"e8523a525a23402698cf88fe5b83fb1d","type":"GENE","name":"MSBP1","canonical_id":"hgnc:HGNC:7318","description":"minisatellite binding protein 1","metadata":null},{"id":"31e972329e6b4d08a60c2270c3ee567f","type":"GENE","name":"MSBP2","canonical_id":"hgnc:HGNC:7319","description":"minisatellite binding protein 2","metadata":null},{"id":"94aad2520ecd4590bce5ca6b07bc07cb","type":"GENE","name":"MSC","canonical_id":"hgnc:HGNC:7321","description":null,"metadata":null},{"id":"0374ab51edbf4be8b2378fe5daa6ccff","type":"GENE","name":"MSC-AS1","canonical_id":"hgnc:HGNC:48724","description":"MSC antisense RNA 1","metadata":{"aliases":["MAT1"]}},{"id":"179932fd625f487fa61b5ba8f478e5fe","type":"GENE","name":"MSGN1","canonical_id":"hgnc:HGNC:14907","description":"mesogenin 1","metadata":{"aliases":["pMesogenin1"]}},{"id":"238f32d6e0b94a30b62044e155af2305","type":"GENE","name":"MSH2","canonical_id":"hgnc:HGNC:7325","description":null,"metadata":null},{"id":"489736bb469a47c7a6ef455a912fc9b4","type":"GENE","name":"MSH2-OT1","canonical_id":"hgnc:HGNC:40319","description":"MSH2 overlapping transcript 1","metadata":null},{"id":"747f09c36b4f42b6bc7733a9c80fa66d","type":"GENE","name":"MSH3","canonical_id":"hgnc:HGNC:7326","description":"mutS homolog 3","metadata":{"aliases":["DUP","MRP1"]}},{"id":"c5a24ea4c87b40c5a48356b5c823950e","type":"GENE","name":"MSH4","canonical_id":"hgnc:HGNC:7327","description":"mutS homolog 4","metadata":null},{"id":"25d3f437b3d7458ea95b373978daba5c","type":"GENE","name":"MSH5","canonical_id":"hgnc:HGNC:7328","description":"mutS homolog 5","metadata":{"aliases":["G7"]}},{"id":"5133550d890449ea80b84e9a89ed6cff","type":"GENE","name":"MSH5-SAPCD1","canonical_id":"hgnc:HGNC:41994","description":"MSH5-SAPCD1 readthrough (NMD candidate)","metadata":{"aliases":["MSH5-C6orf26"]}},{"id":"99de4458d6304e41b57505d78f9bd643","type":"GENE","name":"MSH6","canonical_id":"hgnc:HGNC:7329","description":null,"metadata":null},{"id":"557b95ecb5874c8fae3c28dde32d9f9d","type":"GENE","name":"MSI1","canonical_id":"hgnc:HGNC:7330","description":"musashi RNA binding protein 1","metadata":null},{"id":"36b62606b75e43e5b5a13b53c4a9b489","type":"GENE","name":"MSI2","canonical_id":"hgnc:HGNC:18585","description":"musashi RNA binding protein 2","metadata":null},{"id":"0ba78bb6b09f421199c2dc09302900e4","type":"GENE","name":"MSI2-AS1","canonical_id":"hgnc:HGNC:58556","description":"MSI2 antisense RNA 1","metadata":null},{"id":"e9d54cedae1c4ce2adcdb0c3ba841e86","type":"GO_TERM","name":"MSL complex","canonical_id":"go:GO:0072487","description":"\"A histone acetyltransferase complex that catalyzes the acetylation of a histone H4 lysine residue at position 16. In human, it contains the catalytic subunit MOF, and MSL1, MSL2 and MSL3.\" [PMID:16227571, PMID:20018852]","metadata":null},{"id":"20980c0645b343d3a86009b97f0bcdc9","type":"GENE","name":"MSL1","canonical_id":"hgnc:HGNC:27905","description":null,"metadata":null},{"id":"5ac65065ab1a47d3b35469c5a39596b7","type":"GENE","name":"MSL2","canonical_id":"hgnc:HGNC:25544","description":"MSL complex subunit 2","metadata":{"aliases":["FLJ10546","KIAA1585","msl-2","RNF184","MSL2L1"]}},{"id":"70cfdc6ef141497c865e40fe5b00fa85","type":"GENE","name":"MSL3","canonical_id":"hgnc:HGNC:7370","description":"MSL complex subunit 3","metadata":{"aliases":["MSL3L1"]}},{"id":"65c207c666ec48f593c89ca9df6ab349","type":"GENE","name":"MSL3-DT","canonical_id":"hgnc:HGNC:56856","description":"MSL3 divergent transcript","metadata":null},{"id":"c442f79737434f7a838c6c07bb93f318","type":"GENE","name":"MSL3B","canonical_id":"hgnc:HGNC:17837","description":"MSL complex subunit 3B","metadata":{"aliases":["MSL3L2","MSL3P1"]}},{"id":"dab60abea67e45c6ab8902c7d5792bd6","type":"GENE","name":"MSL3P2","canonical_id":"hgnc:HGNC:56831","description":"MSL3 pseudogene 2","metadata":null},{"id":"045b8d1aad8d49e9a8ad2e0fbb6ebe26","type":"GENE","name":"MSL3P3","canonical_id":"hgnc:HGNC:56832","description":"MSL3 pseudogene 3","metadata":null},{"id":"849f3ad6c87b4f91aa74bc5a7ee31b5a","type":"GENE","name":"MSLN","canonical_id":"hgnc:HGNC:7371","description":null,"metadata":null},{"id":"cecf3a44f58a45fdada5554bda9b7a40","type":"GENE","name":"MSLNL","canonical_id":"hgnc:HGNC:14170","description":"mesothelin like","metadata":{"aliases":["MPFL","C16orf37"]}},{"id":"01b8e333adc44d6299ee8a80d3ebef7a","type":"GENE","name":"MSMB","canonical_id":"hgnc:HGNC:7372","description":null,"metadata":null},{"id":"532f1b3db68147b58aa26bc3db93a14f","type":"GENE","name":"MSMO1","canonical_id":"hgnc:HGNC:10545","description":"methylsterol monooxygenase 1","metadata":{"aliases":["DESP4","ERG25","SC4MOL"]}},{"id":"aa14ac7adfd241be82bd0af9f7433350","type":"GENE","name":"MSMP","canonical_id":"hgnc:HGNC:29663","description":"microseminoprotein, prostate associated","metadata":{"aliases":["PC-3","PSMP"]}},{"id":"7df03d931572490395735177df0849f7","type":"GENE","name":"MSN","canonical_id":"hgnc:HGNC:7373","description":"moesin","metadata":null},{"id":"82e9be535a754e59991829ef849b3e2c","type":"GENE","name":"MSNP1","canonical_id":"hgnc:HGNC:7374","description":"moesin pseudogene 1","metadata":{"aliases":["MSNL1"]}},{"id":"7cede3dd843244d998b508e6eebed2b6","type":"GENE","name":"MSR1","canonical_id":"hgnc:HGNC:7376","description":null,"metadata":null},{"id":"794200ea89ce40f5bbd1832740656bd2","type":"GENE","name":"MSRA","canonical_id":"hgnc:HGNC:7377","description":"methionine sulfoxide reductase A","metadata":null},{"id":"e76834cd4d0e48f0a88ae47ea2096e18","type":"GENE","name":"MSRA-DT","canonical_id":"hgnc:HGNC:55400","description":"MSRA divergent transcript","metadata":null},{"id":"6fe380d18efc48989a5571cef22f8703","type":"GENE","name":"MSRB1","canonical_id":"hgnc:HGNC:14133","description":"methionine sulfoxide reductase B1","metadata":{"aliases":["SelR","SepR","SelX","SELENOX","SELENOR","SEPX1"]}},{"id":"8e139e77c4db4fa3b89ab7d8469f9f5d","type":"GENE","name":"MSRB1P1","canonical_id":"hgnc:HGNC:43985","description":"methionine sulfoxide reductase B1 pseudogene 1","metadata":null},{"id":"1a77b3794b414ba88f884fd7780a0a2d","type":"GENE","name":"MSRB2","canonical_id":"hgnc:HGNC:17061","description":"methionine sulfoxide reductase B2","metadata":{"aliases":["PILB","CGI-131","CBS1","CBS-1","MSRB"]}},{"id":"f33e3a03941b49aab28120a318e70e18","type":"GENE","name":"MSRB3","canonical_id":"hgnc:HGNC:27375","description":"methionine sulfoxide reductase B3","metadata":{"aliases":["FLJ36866","DKFZp686C1178","DFNB74"]}},{"id":"71080c4241454b0a9eb3b8068ff858de","type":"GENE","name":"MSRB3-AS1","canonical_id":"hgnc:HGNC:53386","description":"MSRB3 antisense RNA 1","metadata":{"aliases":["RP11-230G5.2"]}},{"id":"6cf12805f68e4dc6a4d02de9e33a04b5","type":"GENE","name":"MSS51","canonical_id":"hgnc:HGNC:21000","description":"MSS51 mitochondrial translational activator","metadata":{"aliases":["FLJ39565","ZMYND17"]}},{"id":"817d555b19114e1f8884ab85c3bf13b4","type":"GENE","name":"MST1","canonical_id":"hgnc:HGNC:7380","description":null,"metadata":null},{"id":"d882d6b662fd42bf8cb85c26fb5b9cbd","type":"GENE","name":"MST1L","canonical_id":"hgnc:HGNC:7390","description":"macrophage stimulating 1 like (pseudogene)","metadata":{"aliases":["D1F15S1A","MSPL7","MSPL-7","MSTP7","MSTP9","MST1P","MST1P7"]}},{"id":"6d9349fb96ff4e15830a9f88df941ac1","type":"GENE","name":"MST1P2","canonical_id":"hgnc:HGNC:7383","description":"macrophage stimulating 1 pseudogene 2","metadata":{"aliases":["MSPL2","MSPL-2","MSTP2"]}},{"id":"585707a2f96e49ac8ab14a2feb2cae4f","type":"GENE","name":"MST1R","canonical_id":"hgnc:HGNC:7381","description":"macrophage stimulating 1 receptor","metadata":{"aliases":["CDw136","CD136","RON","PTK8","SEA"]}},{"id":"01b63801947a40289af251c65a3c29c3","type":"PROTEIN","name":"MST1R","canonical_id":"uniprot:Q04912","description":null,"metadata":null},{"id":"cb8ba8a4d50d4cf0a13b931f2198afc5","type":"GENE","name":"MSTN","canonical_id":"hgnc:HGNC:4223","description":"myostatin","metadata":{"aliases":["GDF8"]}},{"id":"41fbce8abd2b49d69027d4964d59b6cc","type":"GENE","name":"MSTO1","canonical_id":"hgnc:HGNC:29678","description":"misato mitochondrial distribution and morphology regulator 1","metadata":{"aliases":["FLJ10504","LST005","MST","misato"]}},{"id":"ad67502cef8348048149ddcea759fa22","type":"GENE","name":"MSTO2P","canonical_id":"hgnc:HGNC:26329","description":"misato family member 2, pseudogene","metadata":{"aliases":["MSTO2"]}},{"id":"1b42ae1bca8a4529a674e9d0926dfc3d","type":"GENE","name":"MSX1","canonical_id":"hgnc:HGNC:7391","description":null,"metadata":null},{"id":"bddf783c2f444b93969d6aee7437db6a","type":"GENE","name":"MSX2","canonical_id":"hgnc:HGNC:7392","description":null,"metadata":null},{"id":"6625d1aa185645e7b959873c103cca9c","type":"GENE","name":"MSX2P1","canonical_id":"hgnc:HGNC:24976","description":"msh homeobox 2 pseudogene 1","metadata":{"aliases":["HSHPX5","HPX5","MSX2P"]}},{"id":"4f1a78e4f04a4de386c08c2835f7dc06","type":"GENE","name":"MT-7SDNA","canonical_id":"hgnc:HGNC:7409","description":"mitochondrially encoded 7S DNA","metadata":{"aliases":["MT7SDNA"]}},{"id":"7fd307d75f224ef09ad32f30aefaf35a","type":"GENE","name":"MT-ATP6","canonical_id":"hgnc:HGNC:7414","description":"mitochondrially encoded ATP synthase membrane subunit 6","metadata":{"aliases":["ATP6","ATPase-6","Su6m","MTATP6","RP"]}},{"id":"71b784b5c1964baa9a5fb4d517baef3e","type":"GENE","name":"MT-ATP8","canonical_id":"hgnc:HGNC:7415","description":"mitochondrially encoded ATP synthase membrane subunit 8","metadata":{"aliases":["ATP8","A6L","URFA6L","MTATP8"]}},{"id":"5ebf4a1c3cd644c89469761b6c835633","type":"GENE","name":"MT-ATT","canonical_id":"hgnc:HGNC:7416","description":"mitochondrially encoded membrane attachment site","metadata":{"aliases":["MTATT"]}},{"id":"12a1bf1325784348a3bc7ac05f310b8b","type":"GENE","name":"MT-CO2","canonical_id":"hgnc:HGNC:7421","description":"mitochondrially encoded cytochrome c oxidase II","metadata":{"aliases":["COX2","CO2","MTCO2"]}},{"id":"837722b614ab4b219d5e21c37a67bd41","type":"GENE","name":"MT-CO3","canonical_id":"hgnc:HGNC:7422","description":"mitochondrially encoded cytochrome c oxidase III","metadata":{"aliases":["COX3","COIII","CO3","MTCO3"]}},{"id":"d9b2ec906ae04c8cb08cff6da1a048bb","type":"GENE","name":"MT-CSB1","canonical_id":"hgnc:HGNC:7424","description":"mitochondrially encoded conserved sequence block I","metadata":{"aliases":["CSB-I","MTCSB1"]}},{"id":"6fb0b274a50544aea4d8a75b92879019","type":"GENE","name":"MT-CSB2","canonical_id":"hgnc:HGNC:7425","description":"mitochondrially encoded conserved sequence block II","metadata":{"aliases":["CSB-II","MTCSB2"]}},{"id":"4b1e7a6edcf8486da61bc6eda02f4a6b","type":"GENE","name":"MT-CSB3","canonical_id":"hgnc:HGNC:7426","description":"mitochondrially encoded conserved sequence block III","metadata":{"aliases":["CSB-III","MTCSB3"]}},{"id":"e654712f900145dd8aa739e394188ba9","type":"GENE","name":"MT-CYB","canonical_id":"hgnc:HGNC:7427","description":"mitochondrially encoded cytochrome b","metadata":{"aliases":["COB","CYTB","UQCR3","MTCYB"]}},{"id":"3725535adb184c348db373f78e8c1238","type":"GENE","name":"MT-HPR","canonical_id":"hgnc:HGNC:7438","description":"mitochondrially encoded replication primer","metadata":{"aliases":["HPR","MTHPR"]}},{"id":"aa99e9a6d15b48d9a6e13dca83f8856d","type":"GENE","name":"MT-HSP1","canonical_id":"hgnc:HGNC:7439","description":"mitochondrially encoded major H-strand promoter","metadata":{"aliases":["MTHSP1"]}},{"id":"a3a681da48b349339d82490e2d07288e","type":"GENE","name":"MT-HSP2","canonical_id":"hgnc:HGNC:7440","description":"mitochondrially encoded minor H-strand promoter","metadata":{"aliases":["MTHSP2"]}},{"id":"82cf75b578e947a49583c47efe5f2b88","type":"GENE","name":"MT-LIPCAR","canonical_id":"hgnc:HGNC:50279","description":"mitochondrially encoded long non-coding cardiac associated RNA","metadata":{"aliases":["uc022bqs.1","LIPCAR"]}},{"id":"d2bfe03807bb4c22a9bd00460dc304af","type":"GENE","name":"MT-LSP","canonical_id":"hgnc:HGNC:7447","description":"mitochondrially encoded L-strand promoter","metadata":{"aliases":["MTLSP"]}},{"id":"c4074f3cc87a4a6a9f3143cba2e78de4","type":"GENE","name":"MT-ND1","canonical_id":"hgnc:HGNC:7455","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1","metadata":{"aliases":["ND1","NAD1","MTND1"]}},{"id":"e4278e1ddc324fb6ae6797a20d18d305","type":"GENE","name":"MT-ND2","canonical_id":"hgnc:HGNC:7456","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2","metadata":{"aliases":["ND2","NAD2","MTND2"]}},{"id":"a4727990bffe47c99b6ffe5f6781381a","type":"GENE","name":"MT-ND3","canonical_id":"hgnc:HGNC:7458","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3","metadata":{"aliases":["ND3","NAD3","MTND3"]}},{"id":"634f5fbdd9b946b9ba9a2bf4e3e1a554","type":"GENE","name":"MT-ND4","canonical_id":"hgnc:HGNC:7459","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4","metadata":{"aliases":["ND4","NAD4","MTND4","LHON"]}},{"id":"db152c06e85043a394b862f4c851b6ec","type":"GENE","name":"MT-ND4L","canonical_id":"hgnc:HGNC:7460","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L","metadata":{"aliases":["ND4L","NAD4L","MTND4L"]}},{"id":"3c9fa8b1c0d24bf89a8c9a8a95c0e0fa","type":"GENE","name":"MT-ND5","canonical_id":"hgnc:HGNC:7461","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5","metadata":{"aliases":["ND5","NAD5","MTND5"]}},{"id":"ffdcec7aa5004c918bae2f5c6abf6ce5","type":"GENE","name":"MT-ND6","canonical_id":"hgnc:HGNC:7462","description":"mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6","metadata":{"aliases":["NAD6","ND6","MTND6"]}},{"id":"544feca89c2a4eae9773708324ba788e","type":"GENE","name":"MT-OHR","canonical_id":"hgnc:HGNC:7465","description":"mitochondrially encoded heavy strand origin of replication","metadata":{"aliases":["MTOHR"]}},{"id":"c855f225a46f461db2e5d14f1f9c2d0c","type":"GENE","name":"MT-OLR","canonical_id":"hgnc:HGNC:7466","description":"mitochondrially encoded light strand origin of replication","metadata":{"aliases":["OriL","MTOLR"]}},{"id":"c5bb980d757c4a43843357fc54394af0","type":"GENE","name":"MT-RNR1","canonical_id":"hgnc:HGNC:7470","description":"mitochondrially encoded 12S rRNA","metadata":{"aliases":["12S","MOTS-c","MTRNR1"]}},{"id":"9c698c694f1847968ee9030372e2d51b","type":"GENE","name":"MT-RNR2","canonical_id":"hgnc:HGNC:7471","description":"mitochondrially encoded 16S rRNA","metadata":{"aliases":["HN","16S","MTRNR2"]}},{"id":"a144949ed836432f9b874ca165184910","type":"GENE","name":"MT-RNR3","canonical_id":"hgnc:HGNC:7472","description":"mitochondrially encoded 5S-like sequence","metadata":{"aliases":["MTRNR3"]}},{"id":"7443fb4f1e1e4d1eacca08e697297a26","type":"GENE","name":"MT-TA","canonical_id":"hgnc:HGNC:7475","description":"mitochondrially encoded tRNA-Ala (GCN)","metadata":{"aliases":["trnA","MTTA"]}},{"id":"ffdd6e1f429f47e690a582c25426cc0e","type":"GENE","name":"MT-TAS","canonical_id":"hgnc:HGNC:7476","description":"mitochondrially encoded termination associated sequence","metadata":{"aliases":["MTTAS"]}},{"id":"15179ebdf08d4fc9ae0c28f797a8ae91","type":"GENE","name":"MT-TC","canonical_id":"hgnc:HGNC:7477","description":"mitochondrially encoded tRNA-Cys (UGU/C)","metadata":{"aliases":["trnC","MTTC"]}},{"id":"2b88c813093d4f5699920032ad25ad96","type":"GENE","name":"MT-TD","canonical_id":"hgnc:HGNC:7478","description":"mitochondrially encoded tRNA-Asp (GAU/C)","metadata":{"aliases":["trnD","MTTD"]}},{"id":"7f8d508d333f4ffc934204a10f20ec26","type":"GENE","name":"MT-TE","canonical_id":"hgnc:HGNC:7479","description":"mitochondrially encoded tRNA-Glu (GAA/G)","metadata":{"aliases":["trnE","MTTE"]}},{"id":"7c1cf862bfad46d3bc315a8592447bc8","type":"GENE","name":"MT-TER","canonical_id":"hgnc:HGNC:7480","description":"mitochondrially encoded transcription terminator","metadata":{"aliases":["MTTER"]}},{"id":"4295b26402b04eee8ce9e4b1f4c7f7af","type":"GENE","name":"MT-TF","canonical_id":"hgnc:HGNC:7481","description":"mitochondrially encoded tRNA-Phe (UUU/C)","metadata":{"aliases":["trnF","MTTF"]}},{"id":"b0c634fc6fb349cba7c2aa5ec2b4695a","type":"GENE","name":"MT-TFH","canonical_id":"hgnc:HGNC:7482","description":"mitochondrially encoded transcription factor binding site H","metadata":{"aliases":["MTTFH"]}},{"id":"4c03660fa79f4793ad8ccf3089c375a4","type":"GENE","name":"MT-TFL","canonical_id":"hgnc:HGNC:7483","description":"mitochondrially encoded transcription factor binding site L","metadata":{"aliases":["MTTFL"]}},{"id":"8d5be475360240f79dd7ba9c5d25b239","type":"GENE","name":"MT-TFX","canonical_id":"hgnc:HGNC:7484","description":"mitochondrially encoded transcription factor binding site X","metadata":{"aliases":["MTTFX"]}},{"id":"d49f1272db6a4a08a547c1b866943122","type":"GENE","name":"MT-TFY","canonical_id":"hgnc:HGNC:7485","description":"mitochondrially encoded transcription factor binding site Y","metadata":{"aliases":["MTTFY"]}},{"id":"32ff1bcf18e24a55b4e4bdb29a3120e1","type":"GENE","name":"MT-TG","canonical_id":"hgnc:HGNC:7486","description":"mitochondrially encoded tRNA-Gly (GGN)","metadata":{"aliases":["trnG","MTTG"]}},{"id":"d016d97bf62f40dc97c320b96704b9f7","type":"GENE","name":"MT-TH","canonical_id":"hgnc:HGNC:7487","description":"mitochondrially encoded tRNA-His (CAU/C)","metadata":{"aliases":["trnH","MTTH"]}},{"id":"f0e80e6e2dcb473d970f166b1968a915","type":"GENE","name":"MT-TI","canonical_id":"hgnc:HGNC:7488","description":"mitochondrially encoded tRNA-Ile (AUU/C)","metadata":{"aliases":["trnI","MTTI"]}},{"id":"92f01a45e6954933a1edd715f85e06fd","type":"GENE","name":"MT-TK","canonical_id":"hgnc:HGNC:7489","description":"mitochondrially encoded tRNA-Lys (AAA/G)","metadata":{"aliases":["trnK","MERRF","MTTK"]}},{"id":"17e31834f060445fbe90a302bd858930","type":"GENE","name":"MT-TL1","canonical_id":"hgnc:HGNC:7490","description":"mitochondrially encoded tRNA-Leu (UUA/G) 1","metadata":{"aliases":["TRNL1","MTTL1"]}},{"id":"4280d9f1535c406c952c6a912adb6f8a","type":"GENE","name":"MT-TL2","canonical_id":"hgnc:HGNC:7491","description":"mitochondrially encoded tRNA-Leu (CUN) 2","metadata":{"aliases":["TRNL2","MTTL2"]}},{"id":"486501ede0794465b6557ef6bebb21a3","type":"GENE","name":"MT-TM","canonical_id":"hgnc:HGNC:7492","description":"mitochondrially encoded tRNA-Met (AUA/G)","metadata":{"aliases":["trnM","MTTM"]}},{"id":"ca237094711243449f66715efc68869c","type":"GENE","name":"MT-TN","canonical_id":"hgnc:HGNC:7493","description":"mitochondrially encoded tRNA-Asn (AAU/C)","metadata":{"aliases":["trnN","MTTN"]}},{"id":"05e3a71331cc4e77b8b38583bb6c4a38","type":"GENE","name":"MT-TP","canonical_id":"hgnc:HGNC:7494","description":"mitochondrially encoded tRNA-Pro (CCN)","metadata":{"aliases":["trnP","MTTP"]}},{"id":"e98d5e79db0b41a7bb8a96748f443cdc","type":"GENE","name":"MT-TQ","canonical_id":"hgnc:HGNC:7495","description":"mitochondrially encoded tRNA-Gln (CAA/G)","metadata":{"aliases":["trnQ","MTTQ"]}},{"id":"3cfb5c2d3d2340c7a47fb7419e114f44","type":"GENE","name":"MT-TR","canonical_id":"hgnc:HGNC:7496","description":"mitochondrially encoded tRNA-Arg (CGN)","metadata":{"aliases":["trnR","MTTR"]}},{"id":"830d8316480a4fe6b69ea1935db13406","type":"GENE","name":"MT-TS1","canonical_id":"hgnc:HGNC:7497","description":"mitochondrially encoded tRNA-Ser (UCN) 1","metadata":{"aliases":["TRNS1","MTTS1"]}},{"id":"a81a5bed24bf4c9e818dcba1d7d34054","type":"GENE","name":"MT-TS2","canonical_id":"hgnc:HGNC:7498","description":"mitochondrially encoded tRNA-Ser (AGU/C) 2","metadata":{"aliases":["TRNS2","RP8","MTTS2"]}},{"id":"4ca31b09eaf746e2bdafc1a25b475ac5","type":"GENE","name":"MT-TT","canonical_id":"hgnc:HGNC:7499","description":"mitochondrially encoded tRNA-Thr (ACN)","metadata":{"aliases":["trnT","MTTT","LIMM"]}},{"id":"4da90a35e7ed48a888792b4a3f4cbafd","type":"GENE","name":"MT-TV","canonical_id":"hgnc:HGNC:7500","description":"mitochondrially encoded tRNA-Val (GUN)","metadata":{"aliases":["trnV","MTTV"]}},{"id":"42fd64540a664a22ae1ddcb53e121461","type":"GENE","name":"MT-TW","canonical_id":"hgnc:HGNC:7501","description":"mitochondrially encoded tRNA-Trp (UGA/G)","metadata":{"aliases":["trnW","MTTW"]}},{"id":"d1dc5b4a68ba47af82885933913077a3","type":"GENE","name":"MT-TY","canonical_id":"hgnc:HGNC:7502","description":"mitochondrially encoded tRNA-Tyr (UAU/C)","metadata":{"aliases":["trnY","MTTY"]}},{"id":"a697acda64064c00af2b8387013ef2d1","type":"GENE","name":"MT1A","canonical_id":"hgnc:HGNC:7393","description":"metallothionein 1A","metadata":{"aliases":["MT1","MT1S"]}},{"id":"bb82a040a5e343698195b096674dd829","type":"GENE","name":"MT1B","canonical_id":"hgnc:HGNC:7394","description":"metallothionein 1B","metadata":{"aliases":["MT1","MT1Q"]}},{"id":"2ac43fb3a2a743c6abf848b6e50e2339","type":"GENE","name":"MT1CP","canonical_id":"hgnc:HGNC:7395","description":"metallothionein 1C, pseudogene","metadata":null},{"id":"dbccae2f2b5d4c29ab693bd75738be07","type":"GENE","name":"MT1DP","canonical_id":"hgnc:HGNC:7396","description":"metallothionein 1D, pseudogene","metadata":{"aliases":["MTM"]}},{"id":"5c11b4783dc14da8b356e3267b58adf8","type":"GENE","name":"MT1E","canonical_id":"hgnc:HGNC:7397","description":null,"metadata":null},{"id":"ebb7d716a677466f94268f90c14f5d48","type":"GENE","name":"MT1F","canonical_id":"hgnc:HGNC:7398","description":null,"metadata":null},{"id":"4d85d2330cda46318a8fac1eae0cabe7","type":"GENE","name":"MT1G","canonical_id":"hgnc:HGNC:7399","description":null,"metadata":null},{"id":"af8a7618d3d74c4086e5bd3c5f295c61","type":"GENE","name":"MT1H","canonical_id":"hgnc:HGNC:7400","description":"metallothionein 1H","metadata":{"aliases":["MT1"]}},{"id":"54a4f41bda8d4669a152bb47e83a8465","type":"GENE","name":"MT1HL1","canonical_id":"hgnc:HGNC:31864","description":"metallothionein 1H like 1","metadata":{"aliases":["MT1P2"]}},{"id":"b7fdc83fbcf1439c921c00cbb8019749","type":"GENE","name":"MT1IP","canonical_id":"hgnc:HGNC:7401","description":"metallothionein 1I, pseudogene","metadata":{"aliases":["MTE","MT1","MT1I"]}},{"id":"bfa38b138c654012acd4f2fc9244d9c8","type":"GENE","name":"MT1JP","canonical_id":"hgnc:HGNC:7402","description":"metallothionein 1J, pseudogene","metadata":{"aliases":["MTB","MT1","MT1NP","MT1J"]}},{"id":"3be1b55015d149e4a6a8a1c9f7a6cc95","type":"GENE","name":"MT1L","canonical_id":"hgnc:HGNC:7404","description":"metallothionein 1L (pseudogene)","metadata":{"aliases":["MTF","MT1R","MT1LP","MT1"]}},{"id":"1839ea25ba2b4a2cadd3b0e7ad3e6dbc","type":"GENE","name":"MT1M","canonical_id":"hgnc:HGNC:14296","description":"metallothionein 1M","metadata":{"aliases":["MT1","MT1K"]}},{"id":"12e21292f6c8499088c877459cafad39","type":"GENE","name":"MT1P1","canonical_id":"hgnc:HGNC:23681","description":"metallothionein 1 pseudogene 1","metadata":{"aliases":["bA435O5.3"]}},{"id":"cb9cb4e85e9e46e284fec2688e5270c5","type":"GENE","name":"MT1P3","canonical_id":"hgnc:HGNC:16120","description":"metallothionein 1 pseudogene 3","metadata":{"aliases":["dJ614O4.6","C20orf127","MTL4"]}},{"id":"9095f18b352542089a1144d59cb98fe2","type":"GENE","name":"MT1X","canonical_id":"hgnc:HGNC:7405","description":"metallothionein 1X","metadata":{"aliases":["MT-1l","MT1"]}},{"id":"b0184971d87441c2948c474e8525b629","type":"GENE","name":"MT1XP1","canonical_id":"hgnc:HGNC:7442","description":"metallothionein 1X pseudogene 1","metadata":{"aliases":["MTL1"]}},{"id":"2bb5959045a14fa5a0d7f6fcbda2856a","type":"GENE","name":"MT2A","canonical_id":"hgnc:HGNC:7406","description":null,"metadata":null},{"id":"232177baac034227bc408f02c6d5f1d9","type":"GENE","name":"MT2P1","canonical_id":"hgnc:HGNC:7407","description":"metallothionein 2 pseudogene 1","metadata":null},{"id":"9dcb22ba8b9049ef9f3b2865a93299ae","type":"GENE","name":"MT3","canonical_id":"hgnc:HGNC:7408","description":"metallothionein 3","metadata":{"aliases":["GIF"]}},{"id":"f22b8a9b5f60410f9e5d04afdaed4d13","type":"GENE","name":"MT4","canonical_id":"hgnc:HGNC:18705","description":"metallothionein 4","metadata":{"aliases":["MTIV"]}},{"id":"5e95fba42f2e43fa8a411bfcd3662023","type":"GENE","name":"MTA1","canonical_id":"hgnc:HGNC:7410","description":null,"metadata":null},{"id":"61411020ebf74ae5af9342e07a866343","type":"GENE","name":"MTA1-DT","canonical_id":"hgnc:HGNC:56032","description":"MTA1 divergent transcript","metadata":{"aliases":["AL928654.1"]}},{"id":"7d264fda5ea04535adcabf6b9c97accf","type":"GENE","name":"MTA2","canonical_id":"hgnc:HGNC:7411","description":null,"metadata":null},{"id":"a8a9f677bf3446a59fdf10459fa160d2","type":"GENE","name":"MTA3","canonical_id":"hgnc:HGNC:23784","description":null,"metadata":null},{"id":"dfbac380d0784c36aac0cb0240e0d8f9","type":"GENE","name":"MTA3P1","canonical_id":"hgnc:HGNC:54535","description":"MTA3 pseudogene 1","metadata":null},{"id":"50b55f587d1044459d2595634a821752","type":"GENE","name":"MTAP","canonical_id":"hgnc:HGNC:7413","description":"methylthioadenosine phosphorylase","metadata":{"aliases":["MSAP","c86fus"]}},{"id":"41758a63de9d4ddd85be07b072d803db","type":"GENE","name":"MTAPP1","canonical_id":"hgnc:HGNC:42442","description":"methylthioadenosine phosphorylase pseudogene 1","metadata":null},{"id":"30ea6d2f6b5c4615bb11f68e8242aaef","type":"GENE","name":"MTAPP2","canonical_id":"hgnc:HGNC:42443","description":"methylthioadenosine phosphorylase pseudogene 2","metadata":null},{"id":"5d912faf1e89446bb87325f94b6c45b8","type":"GENE","name":"MTARC1","canonical_id":"hgnc:HGNC:26189","description":"mitochondrial amidoxime reducing component 1","metadata":{"aliases":["FLJ22390","MOSC1","MARC1"]}},{"id":"f9f0ebc8605847b0b88637b3b0c065bb","type":"GENE","name":"MTARC2","canonical_id":"hgnc:HGNC:26064","description":"mitochondrial amidoxime reducing component 2","metadata":{"aliases":["FLJ20605","MOSC2","MARC2"]}},{"id":"5f89c2082a12498383dc6fc744413f61","type":"GENE","name":"MTARC2P1","canonical_id":"hgnc:HGNC:56378","description":"MTARC2 pseudogene 1","metadata":null},{"id":"af9c1824b7d84285a3c3fe0dc226fa05","type":"GENE","name":"MTATP6P1","canonical_id":"hgnc:HGNC:44575","description":"MT-ATP6 pseudogene 1","metadata":null},{"id":"adaf6caa1a364c41a53be09a14cc2f20","type":"GENE","name":"MTATP6P10","canonical_id":"hgnc:HGNC:52056","description":"MT-ATP6 pseudogene 10","metadata":null},{"id":"22c57586c1d548eabf431dd3898b871b","type":"GENE","name":"MTATP6P11","canonical_id":"hgnc:HGNC:52057","description":"MT-ATP6 pseudogene 11","metadata":null},{"id":"23196253a00149f9bcf7ce6c52a19bd3","type":"GENE","name":"MTATP6P12","canonical_id":"hgnc:HGNC:52082","description":"MT-ATP6 pseudogene 12","metadata":null},{"id":"0373c9cd5f1d4d088194cde6cbf2a96f","type":"GENE","name":"MTATP6P13","canonical_id":"hgnc:HGNC:52058","description":"MT-ATP6 pseudogene 13","metadata":null},{"id":"7a7df6e15c764c0780186924d8b7732a","type":"GENE","name":"MTATP6P14","canonical_id":"hgnc:HGNC:52059","description":"MT-ATP6 pseudogene 14","metadata":null},{"id":"8aa034aca65e4f05a8977df42178838e","type":"GENE","name":"MTATP6P15","canonical_id":"hgnc:HGNC:52060","description":"MT-ATP6 pseudogene 15","metadata":null},{"id":"31adc5cf4da7404e9f7042758ca58c16","type":"GENE","name":"MTATP6P16","canonical_id":"hgnc:HGNC:52061","description":"MT-ATP6 pseudogene 16","metadata":null},{"id":"acd7567618aa46d399d50c7bf56d0f26","type":"GENE","name":"MTATP6P17","canonical_id":"hgnc:HGNC:52062","description":"MT-ATP6 pseudogene 17","metadata":null},{"id":"3ab7881300834178aebd84dcd0570254","type":"GENE","name":"MTATP6P18","canonical_id":"hgnc:HGNC:52063","description":"MT-ATP6 pseudogene 18","metadata":null},{"id":"612689a1af9d40c98900f96387efbca3","type":"GENE","name":"MTATP6P19","canonical_id":"hgnc:HGNC:52064","description":"MT-ATP6 pseudogene 19","metadata":null},{"id":"9ad3c0ed6c824f079ca53a0e7f4f8fcb","type":"GENE","name":"MTATP6P2","canonical_id":"hgnc:HGNC:44576","description":"MT-ATP6 pseudogene 2","metadata":null},{"id":"81af93f0d24f45108cdb8ecd875981d9","type":"GENE","name":"MTATP6P20","canonical_id":"hgnc:HGNC:52176","description":"MT-ATP6 pseudogene 20","metadata":null},{"id":"91f2c9fc96cf4940a500feb75affa152","type":"GENE","name":"MTATP6P21","canonical_id":"hgnc:HGNC:52177","description":"MT-ATP6 pseudogene 21","metadata":null},{"id":"00adbcfa0c48412caf9674415b6885e7","type":"GENE","name":"MTATP6P22","canonical_id":"hgnc:HGNC:52178","description":"MT-ATP6 pseudogene 22","metadata":null},{"id":"c8eeea71a1cb4c77a9c78039764f84aa","type":"GENE","name":"MTATP6P23","canonical_id":"hgnc:HGNC:52179","description":"MT-ATP6 pseudogene 23","metadata":null},{"id":"19d3741aa5d64fb299cd7f2d32aebf0b","type":"GENE","name":"MTATP6P24","canonical_id":"hgnc:HGNC:52180","description":"MT-ATP6 pseudogene 24","metadata":null},{"id":"06aad50d59c5419799f2d29a05bcf365","type":"GENE","name":"MTATP6P25","canonical_id":"hgnc:HGNC:52181","description":"MT-ATP6 pseudogene 25","metadata":null},{"id":"00d6204b5e0d4f43bebcf001bb037f44","type":"GENE","name":"MTATP6P26","canonical_id":"hgnc:HGNC:52182","description":"MT-ATP6 pseudogene 26","metadata":null},{"id":"593911b1acc44711903ab03ad1491e68","type":"GENE","name":"MTATP6P27","canonical_id":"hgnc:HGNC:52183","description":"MT-ATP6 pseudogene 27","metadata":null},{"id":"28df855435ee4016942f1942a2b7d907","type":"GENE","name":"MTATP6P28","canonical_id":"hgnc:HGNC:52184","description":"MT-ATP6 pseudogene 28","metadata":null},{"id":"96ae7ddc1eb14ed1aa7687ee1d2d77e5","type":"GENE","name":"MTATP6P29","canonical_id":"hgnc:HGNC:52187","description":"MT-ATP6 pseudogene 29","metadata":null},{"id":"4e09935ce1e24b51b274426626cd811a","type":"GENE","name":"MTATP6P3","canonical_id":"hgnc:HGNC:44577","description":"MT-ATP6 pseudogene 3","metadata":null},{"id":"cd7e06207aec46e6a7577b8af44fd1d9","type":"GENE","name":"MTATP6P30","canonical_id":"hgnc:HGNC:52185","description":"MT-ATP6 pseudogene 30","metadata":null},{"id":"e59716a34fab4b52ae52224ed34b1598","type":"GENE","name":"MTATP6P31","canonical_id":"hgnc:HGNC:52186","description":"MT-ATP6 pseudogene 31","metadata":null},{"id":"648c4387ea7448138a826f1cf822e03d","type":"GENE","name":"MTATP6P4","canonical_id":"hgnc:HGNC:44578","description":"MT-ATP6 pseudogene 4","metadata":null},{"id":"769214b748364ddd86ec08a8ab007351","type":"GENE","name":"MTATP6P5","canonical_id":"hgnc:HGNC:44579","description":"MT-ATP6 pseudogene 5","metadata":null},{"id":"34ba0045140b442d96536c8f4e63281a","type":"GENE","name":"MTATP6P6","canonical_id":"hgnc:HGNC:44580","description":"MT-ATP6 pseudogene 6","metadata":null},{"id":"77227fb300ad4fe38ca034ef3163d001","type":"GENE","name":"MTATP6P7","canonical_id":"hgnc:HGNC:44581","description":"MT-ATP6 pseudogene 7","metadata":null},{"id":"3c71da88574f4bfd98af70a03b276161","type":"GENE","name":"MTATP6P8","canonical_id":"hgnc:HGNC:44582","description":"MT-ATP6 pseudogene 8","metadata":null},{"id":"bfcc20f9b6cc441991b17732ecb169b2","type":"GENE","name":"MTATP6P9","canonical_id":"hgnc:HGNC:44583","description":"MT-ATP6 pseudogene 9","metadata":null},{"id":"92a8434ed8054f91a34ee1b2b703a49d","type":"GENE","name":"MTATP8P1","canonical_id":"hgnc:HGNC:44571","description":"MT-ATP8 pseudogene 1","metadata":null},{"id":"06a7050e4b774ce8901f38add818cd8e","type":"GENE","name":"MTATP8P2","canonical_id":"hgnc:HGNC:44572","description":"MT-ATP8 pseudogene 2","metadata":null},{"id":"1587084d5227497e88762d211bc09637","type":"GENE","name":"MTATP8P3","canonical_id":"hgnc:HGNC:44573","description":"MT-ATP8 pseudogene 3","metadata":null},{"id":"fde98b35434449c6a77fc2d28ee8b96b","type":"GENE","name":"MTATP8P4","canonical_id":"hgnc:HGNC:44574","description":"MT-ATP8 pseudogene 4","metadata":null},{"id":"28cc9fb4a2fa4f58abd7c2625753a689","type":"GENE","name":"MTBP","canonical_id":"hgnc:HGNC:7417","description":"MDM2 binding protein","metadata":null},{"id":"b947e47a604e47c8a840d8e1404419d0","type":"GENE","name":"MTCH1","canonical_id":"hgnc:HGNC:17586","description":"mitochondrial carrier 1","metadata":{"aliases":["CGI-64","PSAP","SLC25A49"]}},{"id":"c4571dd1fdba48d2ae3c2c00a23e6f43","type":"GENE","name":"MTCH1P1","canonical_id":"hgnc:HGNC:55886","description":"MTCH1 pseudogene 1","metadata":null},{"id":"6f66226f0db34f51892d5a599bcf5c01","type":"GENE","name":"MTCH1P2","canonical_id":"hgnc:HGNC:55887","description":"MTCH1 pseudogene 2","metadata":null},{"id":"f3e3290400fb42938193e99f28686738","type":"GENE","name":"MTCH2","canonical_id":"hgnc:HGNC:17587","description":"mitochondrial carrier 2","metadata":{"aliases":["SLC25A50","MIMP"]}},{"id":"b1d55a257a6c4a8095762cbbbd5c5c2c","type":"GENE","name":"MTCH2P1","canonical_id":"hgnc:HGNC:56546","description":"MTCH2 pseudogene 1","metadata":null},{"id":"bd3480bc46e1446ca8960a767997a3a4","type":"GENE","name":"MTCH2P2","canonical_id":"hgnc:HGNC:56547","description":"MTCH2 pseudogene 2","metadata":null},{"id":"bde95d39029a44d2b2f94e05c8c47fbe","type":"GENE","name":"MTCH2P3","canonical_id":"hgnc:HGNC:56548","description":"MTCH2 pseudogene 3","metadata":null},{"id":"e725e6fffa2c46a69683b341559076f1","type":"GENE","name":"MTCH2P4","canonical_id":"hgnc:HGNC:56549","description":"MTCH2 pseudogene 4","metadata":null},{"id":"3f0618ebe18144bf91554cd24edbde1d","type":"GENE","name":"MTCL1","canonical_id":"hgnc:HGNC:29121","description":"microtubule crosslinking factor 1","metadata":{"aliases":["KIAA0802","CCDC165","SOGA2"]}},{"id":"4b386ab835a5403bb0a29ce6801e7cc2","type":"GENE","name":"MTCL1P1","canonical_id":"hgnc:HGNC:42040","description":"MTCL1 pseudogene 1","metadata":{"aliases":["CCDC165P1","SOGA2P1"]}},{"id":"bb4c7d5bcf0f4bf1883ea0a486606d32","type":"GENE","name":"MTCL2","canonical_id":"hgnc:HGNC:16111","description":"microtubule crosslinking factor 2","metadata":{"aliases":["dJ132F21.1","FLJ44670","SOGA","C20orf117","KIAA0889","SOGA1"]}},{"id":"63fe62f4ed56459ea6301514d48d780b","type":"GENE","name":"MTCL3","canonical_id":"hgnc:HGNC:21494","description":"MTCL family member 3","metadata":{"aliases":["dJ403A15.3","C6orf174","SOGA3"]}},{"id":"334c64a07320497b9e0ded14b359908b","type":"GENE","name":"MTCO1P1","canonical_id":"hgnc:HGNC:7420","description":"MT-CO1 pseudogene 1","metadata":null},{"id":"5cf8a2a15e204de4b145c6f0dd7b0a70","type":"GENE","name":"MTCO1P10","canonical_id":"hgnc:HGNC:52012","description":"MT-CO1 pseudogene 10","metadata":null},{"id":"ad0e665dce704d8680082ddbd70af49f","type":"GENE","name":"MTCO1P11","canonical_id":"hgnc:HGNC:52013","description":"MT-CO1 pseudogene 11","metadata":null},{"id":"c0e89558ca274a3fb51eb4a6d84d288d","type":"GENE","name":"MTCO1P12","canonical_id":"hgnc:HGNC:52014","description":"MT-CO1 pseudogene 12","metadata":null},{"id":"192b1430b4e04d0dbf2ce82eced51b5a","type":"GENE","name":"MTCO1P13","canonical_id":"hgnc:HGNC:52015","description":"MT-CO1 pseudogene 13","metadata":null},{"id":"e649dd55f19e48b1ab58531751b3950d","type":"GENE","name":"MTCO1P14","canonical_id":"hgnc:HGNC:52016","description":"MT-CO1 pseudogene 14","metadata":null},{"id":"ffef4d6a838748c293edfd55b7820b79","type":"GENE","name":"MTCO1P15","canonical_id":"hgnc:HGNC:52017","description":"MT-CO1 pseudogene 15","metadata":null},{"id":"b0526741884e494bb6eee2db02cae891","type":"GENE","name":"MTCO1P16","canonical_id":"hgnc:HGNC:52018","description":"MT-CO1 pseudogene 16","metadata":null},{"id":"7319ad05e76f45e4a6aa3bc2f278a544","type":"GENE","name":"MTCO1P17","canonical_id":"hgnc:HGNC:52019","description":"MT-CO1 pseudogene 17","metadata":null},{"id":"a18914a13d4d4dc0bad18a53185f6ed1","type":"GENE","name":"MTCO1P18","canonical_id":"hgnc:HGNC:52020","description":"MT-CO1 pseudogene 18","metadata":null},{"id":"5362af7f47e44daaa856a73a441938a2","type":"GENE","name":"MTCO1P19","canonical_id":"hgnc:HGNC:52021","description":"MT-CO1 pseudogene 19","metadata":null},{"id":"7c7423fc8feb4552abc7af71065d83fe","type":"GENE","name":"MTCO1P2","canonical_id":"hgnc:HGNC:19932","description":"MT-CO1 pseudogene 2","metadata":null},{"id":"1aabd20580da469fafa6ea6e46251179","type":"GENE","name":"MTCO1P20","canonical_id":"hgnc:HGNC:52085","description":"MT-CO1 pseudogene 20","metadata":null},{"id":"d6a9021f9bfd496496d70da5c4f63d57","type":"GENE","name":"MTCO1P21","canonical_id":"hgnc:HGNC:52086","description":"MT-CO1 pseudogene 21","metadata":null},{"id":"05b85e64157746bfabef04171ebfd330","type":"GENE","name":"MTCO1P22","canonical_id":"hgnc:HGNC:52087","description":"MT-CO1 pseudogene 22","metadata":null},{"id":"3c3715ee3fd8430d8166bfe1a2626df4","type":"GENE","name":"MTCO1P23","canonical_id":"hgnc:HGNC:52088","description":"MT-CO1 pseudogene 23","metadata":null},{"id":"dc42e8b5a71d420ba25e9e9f63213c8a","type":"GENE","name":"MTCO1P24","canonical_id":"hgnc:HGNC:52089","description":"MT-CO1 pseudogene 24","metadata":null},{"id":"d76bb5160daf4bd48a414461fdbe6b0b","type":"GENE","name":"MTCO1P25","canonical_id":"hgnc:HGNC:52090","description":"MT-CO1 pseudogene 25","metadata":null},{"id":"d90dfcacb7b349e9b76004a3fedfee44","type":"GENE","name":"MTCO1P26","canonical_id":"hgnc:HGNC:52091","description":"MT-CO1 pseudogene 26","metadata":null},{"id":"5ef1726b97034e7c908a31619d1ac2e6","type":"GENE","name":"MTCO1P27","canonical_id":"hgnc:HGNC:52092","description":"MT-CO1 pseudogene 27","metadata":null},{"id":"6792d2ace1c44d9fb8832e7fda69928a","type":"GENE","name":"MTCO1P28","canonical_id":"hgnc:HGNC:52093","description":"MT-CO1 pseudogene 28","metadata":null},{"id":"635f03a196c843a2a95cdd81916867ad","type":"GENE","name":"MTCO1P29","canonical_id":"hgnc:HGNC:52094","description":"MT-CO1 pseudogene 29","metadata":null},{"id":"9a003c7659a04e6b8b31516170e93386","type":"GENE","name":"MTCO1P3","canonical_id":"hgnc:HGNC:39604","description":"MT-CO1 pseudogene 3","metadata":null},{"id":"44a3cb36b5f34fdf9fd7941a8135190c","type":"GENE","name":"MTCO1P30","canonical_id":"hgnc:HGNC:52095","description":"MT-CO1 pseudogene 30","metadata":null},{"id":"818a969f50fd4fedb40ad8149cb85cc0","type":"GENE","name":"MTCO1P31","canonical_id":"hgnc:HGNC:52096","description":"MT-CO1 pseudogene 31","metadata":null},{"id":"f051e1b5531e4586aad0723782fdf711","type":"GENE","name":"MTCO1P32","canonical_id":"hgnc:HGNC:52097","description":"MT-CO1 pseudogene 32","metadata":null},{"id":"b9f9036000f14c7f87464e86e865935d","type":"GENE","name":"MTCO1P33","canonical_id":"hgnc:HGNC:52098","description":"MT-CO1 pseudogene 33","metadata":null},{"id":"8d05075b306d4f9fa020e25534d0ccbd","type":"GENE","name":"MTCO1P34","canonical_id":"hgnc:HGNC:52099","description":"MT-CO1 pseudogene 34","metadata":null},{"id":"17e712e682b844ed9944f56514c8432e","type":"GENE","name":"MTCO1P35","canonical_id":"hgnc:HGNC:52100","description":"MT-CO1 pseudogene 35","metadata":null},{"id":"e38e7a329e6847b99010d288b3e7b23c","type":"GENE","name":"MTCO1P36","canonical_id":"hgnc:HGNC:52101","description":"MT-CO1 pseudogene 36","metadata":null},{"id":"7fa38e893b4c4122930df29560fd49fc","type":"GENE","name":"MTCO1P37","canonical_id":"hgnc:HGNC:52102","description":"MT-CO1 pseudogene 37","metadata":null},{"id":"0a0ef33905f347729bb0a5d54328f2cf","type":"GENE","name":"MTCO1P38","canonical_id":"hgnc:HGNC:52103","description":"MT-CO1 pseudogene 38","metadata":null},{"id":"1288475e448d434c96f3a7b02f7d74e2","type":"GENE","name":"MTCO1P39","canonical_id":"hgnc:HGNC:52104","description":"MT-CO1 pseudogene 39","metadata":null},{"id":"4ff47f0066054e3797692f358f4514b3","type":"GENE","name":"MTCO1P4","canonical_id":"hgnc:HGNC:50350","description":"MT-CO1 pseudogene 4","metadata":null},{"id":"6778a59f859c441bb9b37fa6e72efef0","type":"GENE","name":"MTCO1P40","canonical_id":"hgnc:HGNC:52105","description":"MT-CO1 pseudogene 40","metadata":null},{"id":"009801cbcb2241d4a5be713e58a6c548","type":"GENE","name":"MTCO1P41","canonical_id":"hgnc:HGNC:52106","description":"MT-CO1 pseudogene 41","metadata":null},{"id":"123a77680450484d94c44f080890f97f","type":"GENE","name":"MTCO1P42","canonical_id":"hgnc:HGNC:52107","description":"MT-CO1 pseudogene 42","metadata":null},{"id":"1bded767a7434def9cf1d8a113670768","type":"GENE","name":"MTCO1P43","canonical_id":"hgnc:HGNC:52108","description":"MT-CO1 pseudogene 43","metadata":null},{"id":"19d4eb0f40da478cae71a029f07ca7db","type":"GENE","name":"MTCO1P44","canonical_id":"hgnc:HGNC:52109","description":"MT-CO1 pseudogene 44","metadata":null},{"id":"3d877fc7fd394293862ee6f91ebd0e20","type":"GENE","name":"MTCO1P45","canonical_id":"hgnc:HGNC:52110","description":"MT-CO1 pseudogene 45","metadata":null},{"id":"93a9f8a48e864ef1acf7af2e21b9df95","type":"GENE","name":"MTCO1P46","canonical_id":"hgnc:HGNC:52111","description":"MT-CO1 pseudogene 46","metadata":null},{"id":"1d7b513791cf435099f78c0570462b07","type":"GENE","name":"MTCO1P47","canonical_id":"hgnc:HGNC:52112","description":"MT-CO1 pseudogene 47","metadata":null},{"id":"d453d88cdb7e489f8ad304b700a3b842","type":"GENE","name":"MTCO1P48","canonical_id":"hgnc:HGNC:52113","description":"MT-CO1 pseudogene 48","metadata":null},{"id":"d19cbf4d3c9a4a7cb45777d6a19f5e9c","type":"GENE","name":"MTCO1P49","canonical_id":"hgnc:HGNC:52114","description":"MT-CO1 pseudogene 49","metadata":null},{"id":"8ae73e32b3b4418985dc03811a478dc5","type":"GENE","name":"MTCO1P5","canonical_id":"hgnc:HGNC:51300","description":"MT-CO1 pseudogene 5","metadata":{"aliases":["AC026166.2-001"]}},{"id":"1da51a53b6944330bc8a3ce7f77e89a3","type":"GENE","name":"MTCO1P50","canonical_id":"hgnc:HGNC:52115","description":"MT-CO1 pseudogene 50","metadata":null},{"id":"a1c6ffeab43a482fbec3a7f25e19634c","type":"GENE","name":"MTCO1P51","canonical_id":"hgnc:HGNC:52116","description":"MT-CO1 pseudogene 51","metadata":null},{"id":"a88b9f61f0654a0a9df44bd63c03249c","type":"GENE","name":"MTCO1P52","canonical_id":"hgnc:HGNC:52117","description":"MT-CO1 pseudogene 52","metadata":null},{"id":"bbeb629af7044ee2a1c6f94e7e9f8ca9","type":"GENE","name":"MTCO1P53","canonical_id":"hgnc:HGNC:52118","description":"MT-CO1 pseudogene 53","metadata":null},{"id":"838d6c6ed15e47419b5ae62d01182296","type":"GENE","name":"MTCO1P54","canonical_id":"hgnc:HGNC:52119","description":"MT-CO1 pseudogene 54","metadata":null},{"id":"6a9191b787744c3a9409f20616281723","type":"GENE","name":"MTCO1P55","canonical_id":"hgnc:HGNC:52120","description":"MT-CO1 pseudogene 55","metadata":null},{"id":"8c0a8aba730346b6b9bce05b3b5d7117","type":"GENE","name":"MTCO1P56","canonical_id":"hgnc:HGNC:52121","description":"MT-CO1 pseudogene 56","metadata":null},{"id":"ec68a90be3d4413d95e7c0a5b833f3b7","type":"GENE","name":"MTCO1P57","canonical_id":"hgnc:HGNC:52315","description":"MT-CO1 pseudogene 57","metadata":null},{"id":"56407cf5aa0740d987458c8e19001768","type":"GENE","name":"MTCO1P58","canonical_id":"hgnc:HGNC:56576","description":"MT-CO1 pseudogene 58","metadata":null},{"id":"b8a25cbf25644d31990c125ae07de18c","type":"GENE","name":"MTCO1P59","canonical_id":"hgnc:HGNC:56944","description":"MT-CO1 pseudogene 59","metadata":null},{"id":"9d1295f8d44445adae7b84399a7b52dd","type":"GENE","name":"MTCO1P6","canonical_id":"hgnc:HGNC:52008","description":"MT-CO1 pseudogene 6","metadata":null},{"id":"124d5c356d554ae08d41676a43cd30f6","type":"GENE","name":"MTCO1P7","canonical_id":"hgnc:HGNC:52009","description":"MT-CO1 pseudogene 7","metadata":null},{"id":"116aa554cf7749a09de2af7d40a1605b","type":"GENE","name":"MTCO1P8","canonical_id":"hgnc:HGNC:52010","description":"MT-CO1 pseudogene 8","metadata":null},{"id":"6f0e69ac79b143a4a978aa9fbf677998","type":"GENE","name":"MTCO1P9","canonical_id":"hgnc:HGNC:52011","description":"MT-CO1 pseudogene 9","metadata":null},{"id":"42051d9a33d34eac8638db0101e62ed1","type":"GENE","name":"MTCO2P1","canonical_id":"hgnc:HGNC:16564","description":"MT-CO2 pseudogene 1","metadata":{"aliases":["dJ342K12.1","MTCO2L"]}},{"id":"074fbad046f24ee6b9cc1f7eb2330d84","type":"GENE","name":"MTCO2P10","canonical_id":"hgnc:HGNC:52026","description":"MT-CO2 pseudogene 10","metadata":null},{"id":"26ec1da906b7408b96a98e8c9134aa67","type":"GENE","name":"MTCO2P11","canonical_id":"hgnc:HGNC:52027","description":"MT-CO2 pseudogene 11","metadata":null},{"id":"95ae7d6a7e1e4203981caeb1593c6b16","type":"GENE","name":"MTCO2P12","canonical_id":"hgnc:HGNC:52028","description":"MT-CO2 pseudogene 12","metadata":null},{"id":"c529657da6374eed944eae8c99d36d71","type":"GENE","name":"MTCO2P13","canonical_id":"hgnc:HGNC:52029","description":"MT-CO2 pseudogene 13","metadata":null},{"id":"968775fc35b84b8f8b889ca6913e4704","type":"GENE","name":"MTCO2P14","canonical_id":"hgnc:HGNC:52030","description":"MT-CO2 pseudogene 14","metadata":null},{"id":"48b0129b521d4d419e341042310625f4","type":"GENE","name":"MTCO2P15","canonical_id":"hgnc:HGNC:52031","description":"MT-CO2 pseudogene 15","metadata":null},{"id":"3cfda6a242634a1da5c254049691235a","type":"GENE","name":"MTCO2P16","canonical_id":"hgnc:HGNC:52032","description":"MT-CO2 pseudogene 16","metadata":null},{"id":"e84c6abef5004d1d8c279d8bf23838ce","type":"GENE","name":"MTCO2P17","canonical_id":"hgnc:HGNC:52033","description":"MT-CO2 pseudogene 17","metadata":null},{"id":"c270f07d074f4c40923e7a30bf27bc9f","type":"GENE","name":"MTCO2P18","canonical_id":"hgnc:HGNC:52034","description":"MT-CO2 pseudogene 18","metadata":null},{"id":"b3fa4cd26ce741dabd5d73e529456dbf","type":"GENE","name":"MTCO2P19","canonical_id":"hgnc:HGNC:52035","description":"MT-CO2 pseudogene 19","metadata":null},{"id":"b4a9738c9f0848f3890564002c05ab48","type":"GENE","name":"MTCO2P2","canonical_id":"hgnc:HGNC:25354","description":"MT-CO2 pseudogene 2","metadata":{"aliases":["HsT4010"]}},{"id":"f85b5c62249a41f3851b0f5a9f91898d","type":"GENE","name":"MTCO2P20","canonical_id":"hgnc:HGNC:52149","description":"MT-CO2 pseudogene 20","metadata":null},{"id":"bcb888eeee8f46d988091ecd5b4e738d","type":"GENE","name":"MTCO2P21","canonical_id":"hgnc:HGNC:52150","description":"MT-CO2 pseudogene 21","metadata":null},{"id":"f3068b62f1ee49e694095d380820125b","type":"GENE","name":"MTCO2P22","canonical_id":"hgnc:HGNC:52151","description":"MT-CO2 pseudogene 22","metadata":null},{"id":"ddd34455179d4fb7a283735a29b609b5","type":"GENE","name":"MTCO2P23","canonical_id":"hgnc:HGNC:52152","description":"MT-CO2 pseudogene 23","metadata":null},{"id":"1d6d342aa27c48e0b9d5cdc44de43958","type":"GENE","name":"MTCO2P24","canonical_id":"hgnc:HGNC:52153","description":"MT-CO2 pseudogene 24","metadata":null},{"id":"55d41e8b93334333bd42ca8b38a6713c","type":"GENE","name":"MTCO2P25","canonical_id":"hgnc:HGNC:52154","description":"MT-CO2 pseudogene 25","metadata":null},{"id":"f0e0974e0c4741bab1cef85389fd02f0","type":"GENE","name":"MTCO2P26","canonical_id":"hgnc:HGNC:52155","description":"MT-CO2 pseudogene 26","metadata":null},{"id":"41098bfad9d9400da93ecc86140faf60","type":"GENE","name":"MTCO2P27","canonical_id":"hgnc:HGNC:52156","description":"MT-CO2 pseudogene 27","metadata":null},{"id":"ac19474fbbbf47d6adf3ad07e4d99bab","type":"GENE","name":"MTCO2P28","canonical_id":"hgnc:HGNC:52157","description":"MT-CO2 pseudogene 28","metadata":null},{"id":"4f8f19b131764708aa306e8c44f64a0c","type":"GENE","name":"MTCO2P29","canonical_id":"hgnc:HGNC:52158","description":"MT-CO2 pseudogene 29","metadata":null},{"id":"a3c776a4f7bb440a84a113ef7fcbc10b","type":"GENE","name":"MTCO2P3","canonical_id":"hgnc:HGNC:39576","description":"MT-CO2 pseudogene 3","metadata":null},{"id":"b11dfe63f58d4d6db97ef8117e984a96","type":"GENE","name":"MTCO2P30","canonical_id":"hgnc:HGNC:52159","description":"MT-CO2 pseudogene 30","metadata":null},{"id":"a86317273d70403f85d0907477339d68","type":"GENE","name":"MTCO2P31","canonical_id":"hgnc:HGNC:52160","description":"MT-CO2 pseudogene 31","metadata":null},{"id":"d7fb3393ee41455e9eeb28ef0ab56eda","type":"GENE","name":"MTCO2P32","canonical_id":"hgnc:HGNC:52161","description":"MT-CO2 pseudogene 32","metadata":null},{"id":"3e9f1516c0d94036a93955bacdfaf923","type":"GENE","name":"MTCO2P33","canonical_id":"hgnc:HGNC:52162","description":"MT-CO2 pseudogene 33","metadata":null},{"id":"806fb88037264154ba8ab756d599c69a","type":"GENE","name":"MTCO2P34","canonical_id":"hgnc:HGNC:52316","description":"MT-CO2 pseudogene 34","metadata":null},{"id":"fe94f2dde30b40d6ab09d469dfae447e","type":"GENE","name":"MTCO2P4","canonical_id":"hgnc:HGNC:50349","description":"MT-CO2 pseudogene 4","metadata":null},{"id":"79b363f1aecf47a48cb2645c331df201","type":"GENE","name":"MTCO2P5","canonical_id":"hgnc:HGNC:52124","description":"MT-CO2 pseudogene 5","metadata":null},{"id":"b1c0f72884774c799700f6c01100098d","type":"GENE","name":"MTCO2P6","canonical_id":"hgnc:HGNC:52022","description":"MT-CO2 pseudogene 6","metadata":null},{"id":"39519ac3b3a3401096552e71f449d8e3","type":"GENE","name":"MTCO2P7","canonical_id":"hgnc:HGNC:52023","description":"MT-CO2 pseudogene 7","metadata":null},{"id":"e5b82e063017484f8fc919d4b8e6c188","type":"GENE","name":"MTCO2P8","canonical_id":"hgnc:HGNC:52024","description":"MT-CO2 pseudogene 8","metadata":null},{"id":"7145469c31004a7b9588627897991530","type":"GENE","name":"MTCO2P9","canonical_id":"hgnc:HGNC:52025","description":"MT-CO2 pseudogene 9","metadata":null},{"id":"7d6ca29defc04a19925668638d935812","type":"GENE","name":"MTCO3P1","canonical_id":"hgnc:HGNC:31342","description":"MT-CO3 pseudogene 1","metadata":{"aliases":["U92032.1"]}},{"id":"7e22d69a68f64da7938baf86766d584b","type":"GENE","name":"MTCO3P10","canonical_id":"hgnc:HGNC:52040","description":"MT-CO3 pseudogene 10","metadata":null},{"id":"1d674c4d3630417fa6f0e4e5cfccedc7","type":"GENE","name":"MTCO3P11","canonical_id":"hgnc:HGNC:52041","description":"MT-CO3 pseudogene 11","metadata":null},{"id":"330f8cac737a4258abbdac34a83056b6","type":"GENE","name":"MTCO3P12","canonical_id":"hgnc:HGNC:52042","description":"MT-CO3 pseudogene 12","metadata":null},{"id":"3a12cfc536e64dd9957321fe283b11fe","type":"GENE","name":"MTCO3P13","canonical_id":"hgnc:HGNC:52043","description":"MT-CO3 pseudogene 13","metadata":null},{"id":"2d42382e5ffd405c8a11d43c4c6d1e56","type":"GENE","name":"MTCO3P14","canonical_id":"hgnc:HGNC:52044","description":"MT-CO3 pseudogene 14","metadata":null},{"id":"dc87715c451341e1a3381471a11e22f9","type":"GENE","name":"MTCO3P15","canonical_id":"hgnc:HGNC:52045","description":"MT-CO3 pseudogene 15","metadata":null},{"id":"34287ed15a4d4ae6a39390839c5594b7","type":"GENE","name":"MTCO3P16","canonical_id":"hgnc:HGNC:52046","description":"MT-CO3 pseudogene 16","metadata":null},{"id":"92f4febcb12b4e54a72a8999e4788d0f","type":"GENE","name":"MTCO3P17","canonical_id":"hgnc:HGNC:52047","description":"MT-CO3 pseudogene 17","metadata":null},{"id":"89c15ee3973f45caaacbb3aef27711e8","type":"GENE","name":"MTCO3P18","canonical_id":"hgnc:HGNC:52048","description":"MT-CO3 pseudogene 18","metadata":null},{"id":"2bdb4756222d4ba3aef3db7ade2333e1","type":"GENE","name":"MTCO3P19","canonical_id":"hgnc:HGNC:52049","description":"MT-CO3 pseudogene 19","metadata":null},{"id":"15397b2a025940498bcc44145e27ff9d","type":"GENE","name":"MTCO3P2","canonical_id":"hgnc:HGNC:39681","description":"MT-CO3 pseudogene 2","metadata":null},{"id":"363fd56122134812b5172fd9c386051d","type":"GENE","name":"MTCO3P20","canonical_id":"hgnc:HGNC:52122","description":"MT-CO3 pseudogene 20","metadata":null},{"id":"0e8e95cd6b1044b592a6bb161d7ccf0c","type":"GENE","name":"MTCO3P21","canonical_id":"hgnc:HGNC:52083","description":"MT-CO3 pseudogene 21","metadata":null},{"id":"a2eeac81e59445778766d6e6f143707f","type":"GENE","name":"MTCO3P22","canonical_id":"hgnc:HGNC:52125","description":"MT-CO3 pseudogene 22","metadata":null},{"id":"0143b4dff66e4760987851c52bccff86","type":"GENE","name":"MTCO3P23","canonical_id":"hgnc:HGNC:52126","description":"MT-CO3 pseudogene 23","metadata":null},{"id":"4b0793be6ffb431da56fb094237400aa","type":"GENE","name":"MTCO3P24","canonical_id":"hgnc:HGNC:52127","description":"MT-CO3 pseudogene 24","metadata":null},{"id":"61f80fc1af554fddb662c968b52ffe4e","type":"GENE","name":"MTCO3P25","canonical_id":"hgnc:HGNC:52128","description":"MT-CO3 pseudogene 25","metadata":null},{"id":"f1bd6605cdaf4da492c8758f139f722e","type":"GENE","name":"MTCO3P26","canonical_id":"hgnc:HGNC:52129","description":"MT-CO3 pseudogene 26","metadata":null},{"id":"0dbb61236c05479d89edbada6d3b8065","type":"GENE","name":"MTCO3P27","canonical_id":"hgnc:HGNC:52130","description":"MT-CO3 pseudogene 27","metadata":null},{"id":"4ed7509a1807494c8460c8e15b9111f7","type":"GENE","name":"MTCO3P28","canonical_id":"hgnc:HGNC:52131","description":"MT-CO3 pseudogene 28","metadata":null},{"id":"8146d28c50ec4126b8a62c491171678a","type":"GENE","name":"MTCO3P29","canonical_id":"hgnc:HGNC:52132","description":"MT-CO3 pseudogene 29","metadata":null},{"id":"db75fdf807954f06b45a6389dd5118ec","type":"GENE","name":"MTCO3P3","canonical_id":"hgnc:HGNC:52080","description":"MT-CO3 pseudogene 3","metadata":null},{"id":"0e97f025a9154600baf47f44a4dc71d0","type":"GENE","name":"MTCO3P30","canonical_id":"hgnc:HGNC:52133","description":"MT-CO3 pseudogene 30","metadata":null},{"id":"84e274d51a8b4e45a58f306aac52cfb3","type":"GENE","name":"MTCO3P31","canonical_id":"hgnc:HGNC:52134","description":"MT-CO3 pseudogene 31","metadata":null},{"id":"b8e4558282e045f39aaf1f0d78877caf","type":"GENE","name":"MTCO3P32","canonical_id":"hgnc:HGNC:52135","description":"MT-CO3 pseudogene 32","metadata":null},{"id":"d0440b03fbc848a49c0c315da329a433","type":"GENE","name":"MTCO3P33","canonical_id":"hgnc:HGNC:52136","description":"MT-CO3 pseudogene 33","metadata":null},{"id":"7c06ed01fad6405e94095005e1468301","type":"GENE","name":"MTCO3P34","canonical_id":"hgnc:HGNC:52137","description":"MT-CO3 pseudogene 34","metadata":null},{"id":"bb67eff773304ebc9a0b9a7b2afd2518","type":"GENE","name":"MTCO3P35","canonical_id":"hgnc:HGNC:52138","description":"MT-CO3 pseudogene 35","metadata":null},{"id":"3bfa07946fc649e5a051be3a96890db9","type":"GENE","name":"MTCO3P36","canonical_id":"hgnc:HGNC:52139","description":"MT-CO3 pseudogene 36","metadata":null},{"id":"9d2f14f915d54ef5a01f439a0ce0bbc7","type":"GENE","name":"MTCO3P37","canonical_id":"hgnc:HGNC:52140","description":"MT-CO3 pseudogene 37","metadata":null},{"id":"13662878023545e9b7a727bcf84eb2b7","type":"GENE","name":"MTCO3P38","canonical_id":"hgnc:HGNC:52141","description":"MT-CO3 pseudogene 38","metadata":null},{"id":"9a6d7fea0dcb47bdba3e61fbe0ee5279","type":"GENE","name":"MTCO3P39","canonical_id":"hgnc:HGNC:52142","description":"MT-CO3 pseudogene 39","metadata":null},{"id":"4b3469ab1ec1449b9cf15917db2ed30a","type":"GENE","name":"MTCO3P4","canonical_id":"hgnc:HGNC:52079","description":"MT-CO3 pseudogene 4","metadata":null},{"id":"f7961f922d2a40eda7651cc5c116537b","type":"GENE","name":"MTCO3P40","canonical_id":"hgnc:HGNC:52143","description":"MT-CO3 pseudogene 40","metadata":null},{"id":"480b9a0689ce4a48b6ef2e8843c1d035","type":"GENE","name":"MTCO3P41","canonical_id":"hgnc:HGNC:52144","description":"MT-CO3 pseudogene 41","metadata":null},{"id":"ca16b3e2e05a44809ea378898b9d88f0","type":"GENE","name":"MTCO3P42","canonical_id":"hgnc:HGNC:52145","description":"MT-CO3 pseudogene 42","metadata":null},{"id":"4221f7a5a0944c6c84149cfffd80637f","type":"GENE","name":"MTCO3P43","canonical_id":"hgnc:HGNC:52146","description":"MT-CO3 pseudogene 43","metadata":null},{"id":"10e484abdc704838aefc3f17f6c9b5b0","type":"GENE","name":"MTCO3P44","canonical_id":"hgnc:HGNC:52147","description":"MT-CO3 pseudogene 44","metadata":null},{"id":"eb261fdde1084795bc52e3d9097fea24","type":"GENE","name":"MTCO3P45","canonical_id":"hgnc:HGNC:52148","description":"MT-CO3 pseudogene 45","metadata":null},{"id":"e4928aad411c4044bdc122b145a9e43d","type":"GENE","name":"MTCO3P46","canonical_id":"hgnc:HGNC:52165","description":"MT-CO3 pseudogene 46","metadata":null},{"id":"e82e2d8317c74c59817fecb14f3cb985","type":"GENE","name":"MTCO3P47","canonical_id":"hgnc:HGNC:56430","description":"MT-CO3 pseudogene 47","metadata":null},{"id":"f35288d1c7364a8db710db9847367034","type":"GENE","name":"MTCO3P5","canonical_id":"hgnc:HGNC:52123","description":"MT-CO3 pseudogene 5","metadata":null},{"id":"c43b2322ce8542c4ac07035629f934f8","type":"GENE","name":"MTCO3P6","canonical_id":"hgnc:HGNC:52036","description":"MT-CO3 pseudogene 6","metadata":null},{"id":"5c46654e1b614e05a24c65dc9f0aed4e","type":"GENE","name":"MTCO3P7","canonical_id":"hgnc:HGNC:52037","description":"MT-CO3 pseudogene 7","metadata":null},{"id":"2b8eba01646f4c84bae16270f80fc48c","type":"GENE","name":"MTCO3P8","canonical_id":"hgnc:HGNC:52038","description":"MT-CO3 pseudogene 8","metadata":null},{"id":"83a40aaf36784b6e8ea3bae0f8d752b8","type":"GENE","name":"MTCO3P9","canonical_id":"hgnc:HGNC:52039","description":"MT-CO3 pseudogene 9","metadata":null},{"id":"0cb757a4fe1b46b8824fe73080d689d3","type":"GENE","name":"MTCP1","canonical_id":"hgnc:HGNC:7423","description":"mature T cell proliferation 1","metadata":{"aliases":["P13MTCP1","p8MTCP1","TCL1C"]}},{"id":"969ee3ce7c864534be399842e75fb1fd","type":"GENE","name":"MTCYBP1","canonical_id":"hgnc:HGNC:38729","description":"MT-CYB pseudogene 1","metadata":null},{"id":"4584c14ac4154a809c2b1d747ca392ee","type":"GENE","name":"MTCYBP10","canonical_id":"hgnc:HGNC:51961","description":"MT-CYB pseudogene 10","metadata":null},{"id":"843687dffe104bafb60caf0e3297a5fd","type":"GENE","name":"MTCYBP11","canonical_id":"hgnc:HGNC:51962","description":"MT-CYB pseudogene 11","metadata":null},{"id":"3f5d6bca8cdc4ee38d96f82d42c95a76","type":"GENE","name":"MTCYBP12","canonical_id":"hgnc:HGNC:51963","description":"MT-CYB pseudogene 12","metadata":null},{"id":"c2baa05c6c64408fbb0827da0e74cbd5","type":"GENE","name":"MTCYBP13","canonical_id":"hgnc:HGNC:51975","description":"MT-CYB pseudogene 13","metadata":null},{"id":"013388ea0ee04e6693c4f2a2419f8c02","type":"GENE","name":"MTCYBP14","canonical_id":"hgnc:HGNC:51960","description":"MT-CYB pseudogene 14","metadata":null},{"id":"7ac58820844a464fb77f057b67a9a59c","type":"GENE","name":"MTCYBP15","canonical_id":"hgnc:HGNC:51968","description":"MT-CYB pseudogene 15","metadata":null},{"id":"4cd6c8cdbea9462784e5ce1b058892aa","type":"GENE","name":"MTCYBP16","canonical_id":"hgnc:HGNC:51969","description":"MT-CYB pseudogene 16","metadata":null},{"id":"9b2377eea6984b3888a00490f4043520","type":"GENE","name":"MTCYBP17","canonical_id":"hgnc:HGNC:51970","description":"MT-CYB pseudogene 17","metadata":null},{"id":"540ff61caf1b40908cda54fd7621c852","type":"GENE","name":"MTCYBP18","canonical_id":"hgnc:HGNC:51976","description":"MT-CYB pseudogene 18","metadata":null},{"id":"2f3d505b64534da898f2db32ece66c0c","type":"GENE","name":"MTCYBP19","canonical_id":"hgnc:HGNC:51971","description":"MT-CYB pseudogene 19","metadata":null},{"id":"16ed228d8ed14343ac6964f6b05af117","type":"GENE","name":"MTCYBP2","canonical_id":"hgnc:HGNC:38807","description":"MT-CYB pseudogene 2","metadata":null},{"id":"053e3211d121412883d4bcd465fbc5a3","type":"GENE","name":"MTCYBP20","canonical_id":"hgnc:HGNC:51973","description":"MT-CYB pseudogene 20","metadata":null},{"id":"652262062f39430f8bac4f104021134f","type":"GENE","name":"MTCYBP21","canonical_id":"hgnc:HGNC:51977","description":"MT-CYB pseudogene 21","metadata":null},{"id":"2f80f02fd12240dbbbb87ab1689a4ea9","type":"GENE","name":"MTCYBP22","canonical_id":"hgnc:HGNC:51979","description":"MT-CYB pseudogene 22","metadata":null},{"id":"b1e0632a60f94acfbfee1b863b858b07","type":"GENE","name":"MTCYBP23","canonical_id":"hgnc:HGNC:51980","description":"MT-CYB pseudogene 23","metadata":null},{"id":"648ca5aee46b400991a61b28063c33fc","type":"GENE","name":"MTCYBP24","canonical_id":"hgnc:HGNC:51983","description":"MT-CYB pseudogene 24","metadata":null},{"id":"5c9c9c5b06a04b87864677b3ce47088e","type":"GENE","name":"MTCYBP25","canonical_id":"hgnc:HGNC:51991","description":"MT-CYB pseudogene 25","metadata":null},{"id":"8310d540be1f48a783ef20505c1513c6","type":"GENE","name":"MTCYBP26","canonical_id":"hgnc:HGNC:51992","description":"MT-CYB pseudogene 26","metadata":null},{"id":"80b30f52d3764a01ace5f6a6db459ed5","type":"GENE","name":"MTCYBP27","canonical_id":"hgnc:HGNC:51993","description":"MT-CYB pseudogene 27","metadata":null},{"id":"ad60d117974f4166b68df3fbfa3e5074","type":"GENE","name":"MTCYBP28","canonical_id":"hgnc:HGNC:51994","description":"MT-CYB pseudogene 28","metadata":null},{"id":"8eb249e4ee844714a0377f112aa4d757","type":"GENE","name":"MTCYBP29","canonical_id":"hgnc:HGNC:51995","description":"MT-CYB pseudogene 29","metadata":null},{"id":"de8716db39014d2a87698ba35bd8ab34","type":"GENE","name":"MTCYBP3","canonical_id":"hgnc:HGNC:39579","description":"MT-CYB pseudogene 3","metadata":null},{"id":"94d6b8ec93344f1db17f5a8ea580a4a8","type":"GENE","name":"MTCYBP30","canonical_id":"hgnc:HGNC:51996","description":"MT-CYB pseudogene 30","metadata":null},{"id":"3d4ebf6ff28d4d9189cea554b0f8a700","type":"GENE","name":"MTCYBP31","canonical_id":"hgnc:HGNC:51997","description":"MT-CYB pseudogene 31","metadata":null},{"id":"417572c43e024925801cdc1d465d7c2d","type":"GENE","name":"MTCYBP32","canonical_id":"hgnc:HGNC:52174","description":"MT-CYB pseudogene 32","metadata":null},{"id":"d0a835c88b88426e96137357d32f8764","type":"GENE","name":"MTCYBP33","canonical_id":"hgnc:HGNC:52301","description":"MT-CYB pseudogene 33","metadata":null},{"id":"29a73363fdd644b5abf34fbe3f82bb4d","type":"GENE","name":"MTCYBP34","canonical_id":"hgnc:HGNC:52302","description":"MT-CYB pseudogene 34","metadata":null},{"id":"d63e78a33a26437c9768d710c6741acf","type":"GENE","name":"MTCYBP35","canonical_id":"hgnc:HGNC:52303","description":"MT-CYB pseudogene 35","metadata":null},{"id":"800b483ae32749c995cd069a18ede1f7","type":"GENE","name":"MTCYBP36","canonical_id":"hgnc:HGNC:52304","description":"MT-CYB pseudogene 36","metadata":null},{"id":"3cea9cc7a8ce4bb683ce7d47e20b2954","type":"GENE","name":"MTCYBP37","canonical_id":"hgnc:HGNC:52305","description":"MT-CYB pseudogene 37","metadata":null},{"id":"7c6a8cff81f847e1a90b94d3397b946c","type":"GENE","name":"MTCYBP38","canonical_id":"hgnc:HGNC:52306","description":"MT-CYB pseudogene 38","metadata":null},{"id":"a01ba7409934487d944ec15d3c4d1e93","type":"GENE","name":"MTCYBP39","canonical_id":"hgnc:HGNC:52307","description":"MT-CYB pseudogene 39","metadata":null},{"id":"58e9106733d1409295604aab3374fed5","type":"GENE","name":"MTCYBP4","canonical_id":"hgnc:HGNC:41923","description":"MT-CYB pseudogene 4","metadata":null},{"id":"2541fe0c327d4db6942cc7537c3111c5","type":"GENE","name":"MTCYBP40","canonical_id":"hgnc:HGNC:52308","description":"MT-CYB pseudogene 40","metadata":null},{"id":"f0d0499f7c5f4c1595cb0c8fc953c7e4","type":"GENE","name":"MTCYBP41","canonical_id":"hgnc:HGNC:52309","description":"MT-CYB pseudogene 41","metadata":null},{"id":"2c10b7ccfef247a7b2232192e906888f","type":"GENE","name":"MTCYBP42","canonical_id":"hgnc:HGNC:52310","description":"MT-CYB pseudogene 42","metadata":null},{"id":"fdf2bf12e99c45ee95143d00b4f16c30","type":"GENE","name":"MTCYBP43","canonical_id":"hgnc:HGNC:52311","description":"MT-CYB pseudogene 43","metadata":null},{"id":"f85b61ca89a1490c9cf107af79c2dcfd","type":"GENE","name":"MTCYBP44","canonical_id":"hgnc:HGNC:52312","description":"MT-CYB pseudogene 44","metadata":null},{"id":"351eb8b819384332bdb711fe9c602270","type":"GENE","name":"MTCYBP45","canonical_id":"hgnc:HGNC:52313","description":"MT-CYB pseudogene 45","metadata":null},{"id":"e0d8641c9d9c4dc1a28ea49f3468623d","type":"GENE","name":"MTCYBP5","canonical_id":"hgnc:HGNC:51967","description":"MT-CYB pseudogene 5","metadata":null},{"id":"ac92f67887c849f9a4f85193a6af3b78","type":"GENE","name":"MTCYBP6","canonical_id":"hgnc:HGNC:51974","description":"MT-CYB pseudogene 6","metadata":null},{"id":"88f55410de4e4258aa43ecbdfc19da46","type":"GENE","name":"MTCYBP7","canonical_id":"hgnc:HGNC:51964","description":"MT-CYB pseudogene 7","metadata":null},{"id":"d1eaac2a78d74a28b61179dc54d01c84","type":"GENE","name":"MTCYBP8","canonical_id":"hgnc:HGNC:51965","description":"MT-CYB pseudogene 8","metadata":null},{"id":"d5748e7eae3f49bebcdd4972b3c744db","type":"GENE","name":"MTCYBP9","canonical_id":"hgnc:HGNC:51966","description":"MT-CYB pseudogene 9","metadata":null},{"id":"fcc257399b5f4d459be60b3c9143c108","type":"GENE","name":"MTDH","canonical_id":"hgnc:HGNC:29608","description":null,"metadata":null},{"id":"f0c085903c2c4237bf6db7b2022d46ef","type":"GENE","name":"MTDHP1","canonical_id":"hgnc:HGNC:52357","description":"metadherin pseudogene 1","metadata":null},{"id":"7436b0924607438c9b1c6dc880d664ce","type":"GENE","name":"MTDHP2","canonical_id":"hgnc:HGNC:52358","description":"metadherin pseudogene 2","metadata":null},{"id":"caae3daddbb8493685b0c04af5f1dd51","type":"GENE","name":"MTDHP3","canonical_id":"hgnc:HGNC:52359","description":"metadherin pseudogene 3","metadata":null},{"id":"2356db3a1326442d94709c962b551fe2","type":"GENE","name":"MTDHP4","canonical_id":"hgnc:HGNC:52360","description":"metadherin pseudogene 4","metadata":null},{"id":"9e1becc772694cab9416f01d666de9a2","type":"GENE","name":"MTDHP5","canonical_id":"hgnc:HGNC:52361","description":"metadherin pseudogene 5","metadata":null},{"id":"f9e0b15c0f8945ccba878002d9fd2b9f","type":"GENE","name":"MTERF1","canonical_id":"hgnc:HGNC:21463","description":"mitochondrial transcription termination factor 1","metadata":{"aliases":["MTERF"]}},{"id":"1cb4c959ddd2436e9ee1c0107f629ca2","type":"GENE","name":"MTERF1P1","canonical_id":"hgnc:HGNC:56424","description":"MTERF1 pseudogene 1","metadata":null},{"id":"922af30dfdb1441e80f364b7637d4a5d","type":"GENE","name":"MTERF2","canonical_id":"hgnc:HGNC:30779","description":"mitochondrial transcription termination factor 2","metadata":{"aliases":["FLJ14062","MTERFD3"]}},{"id":"e1b1c9d444f84d54999963f28cfd3c03","type":"GENE","name":"MTERF3","canonical_id":"hgnc:HGNC:24258","description":"mitochondrial transcription termination factor 3","metadata":{"aliases":["CGI-12","FLJ10939","MTERFD1"]}},{"id":"aab494a329694c1d94aa69d6594c9d2e","type":"GENE","name":"MTERF4","canonical_id":"hgnc:HGNC:28785","description":"mitochondrial transcription termination factor 4","metadata":{"aliases":["MGC61716","MTERFD2"]}},{"id":"0883a33c007646b6ba83ba0c079a2e87","type":"GENE","name":"MTF1","canonical_id":"hgnc:HGNC:7428","description":null,"metadata":null},{"id":"835d571ec0c14ab8be9ab57150ea68f1","type":"GENE","name":"MTF2","canonical_id":"hgnc:HGNC:29535","description":null,"metadata":null},{"id":"8c87cc10f39245a19cc5fc205bfe4efb","type":"GENE","name":"MTFMT","canonical_id":"hgnc:HGNC:29666","description":"mitochondrial methionyl-tRNA formyltransferase","metadata":{"aliases":["FMT1"]}},{"id":"008de19a63ac407e8a0752c5509cc222","type":"GENE","name":"MTFP1","canonical_id":"hgnc:HGNC:26945","description":"mitochondrial fission process 1","metadata":{"aliases":["MTP18","HSPC242"]}},{"id":"0f189ceee6644df18b53a3de15236442","type":"GENE","name":"MTFR1","canonical_id":"hgnc:HGNC:29510","description":"mitochondrial fission regulator 1","metadata":{"aliases":["CHPPR","KIAA0009","FAM54A2"]}},{"id":"855883c1cf214a20bcf36033665fa7f3","type":"GENE","name":"MTFR1L","canonical_id":"hgnc:HGNC:28836","description":"mitochondrial fission regulator 1 like","metadata":{"aliases":["FAM54B"]}},{"id":"9bc7a8920ad441198bffa1ba3183b0a5","type":"GENE","name":"MTFR1P1","canonical_id":"hgnc:HGNC:54981","description":"MTFR1 pseudogene 1","metadata":null},{"id":"a4d3b41d65f9487680590b5f118edbb6","type":"GENE","name":"MTFR2","canonical_id":"hgnc:HGNC:21115","description":"mitochondrial fission regulator 2","metadata":{"aliases":["DUFD1","FAM54A"]}},{"id":"b838218478024b2a9202dd83f69390d9","type":"GENE","name":"MTFR2P1","canonical_id":"hgnc:HGNC:54773","description":"MTFR2 pseudogene 1","metadata":null},{"id":"c1087184f6bd411291e4e0249468785c","type":"GENE","name":"MTFR2P2","canonical_id":"hgnc:HGNC:54774","description":"MTFR2 pseudogene 2","metadata":{"aliases":["MTFR2P1"]}},{"id":"92608bf7577b4a8e8732244f0f436232","type":"GENE","name":"MTG1","canonical_id":"hgnc:HGNC:32159","description":"mitochondrial ribosome associated GTPase 1","metadata":{"aliases":["GTPBP7"]}},{"id":"ce75d06912414426be06a75228791f8e","type":"GENE","name":"MTG2","canonical_id":"hgnc:HGNC:16239","description":"mitochondrial ribosome associated GTPase 2","metadata":{"aliases":["FLJ10741","dJ1005F21.2","ObgH1","GTPBP5"]}},{"id":"d3f81d68fb6a45d0adbe2a55c7352a7b","type":"GENE","name":"MTHFD1","canonical_id":"hgnc:HGNC:7432","description":"methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1","metadata":{"aliases":["MTHFC","MTHFD"]}},{"id":"bdc8a45ec67f49dca7539066c5576489","type":"GENE","name":"MTHFD1L","canonical_id":"hgnc:HGNC:21055","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like","metadata":{"aliases":["DKFZP586G1517","FLJ21145","FTHFSDC1"]}},{"id":"e4bbc496a2b2429c94c21054769aa1c2","type":"GENE","name":"MTHFD1LP1","canonical_id":"hgnc:HGNC:59176","description":"MTHFD1L pseudogene 1","metadata":null},{"id":"c78ec9a3d7f14371adbbd348ba39ae3e","type":"GENE","name":"MTHFD1P1","canonical_id":"hgnc:HGNC:7433","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 pseudogene 1","metadata":{"aliases":["MTHFDL1","MTHFDP1"]}},{"id":"46c913cdad4941e5bfa6cad87be14c5d","type":"GENE","name":"MTHFD2","canonical_id":"hgnc:HGNC:7434","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase","metadata":null},{"id":"d552514d7a864a1da9bff0ef55981d5c","type":"GENE","name":"MTHFD2L","canonical_id":"hgnc:HGNC:31865","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 like","metadata":{"aliases":["MGC72244"]}},{"id":"821868bb82764015914424fda6797771","type":"GENE","name":"MTHFD2L-AS1","canonical_id":"hgnc:HGNC:58816","description":"MTHFD2L antisense RNA 1","metadata":null},{"id":"eba2f064920f41e888143f4a6f526317","type":"GENE","name":"MTHFD2P1","canonical_id":"hgnc:HGNC:48859","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 1","metadata":null},{"id":"f0aebc0c50124603afd0b3504d2aff51","type":"GENE","name":"MTHFD2P2","canonical_id":"hgnc:HGNC:48860","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 2","metadata":null},{"id":"0937cc1db9034d7fa636372b7019d4b4","type":"GENE","name":"MTHFD2P3","canonical_id":"hgnc:HGNC:48866","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 3","metadata":null},{"id":"8f9d257764be4ae9b2f6a7e7ab290ee7","type":"GENE","name":"MTHFD2P4","canonical_id":"hgnc:HGNC:48862","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 4","metadata":null},{"id":"f545d5c28b964234b8d5f3cf9897efd3","type":"GENE","name":"MTHFD2P5","canonical_id":"hgnc:HGNC:48863","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 5","metadata":null},{"id":"759ea1d33e6543d58bc1d35e783f6146","type":"GENE","name":"MTHFD2P6","canonical_id":"hgnc:HGNC:48864","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 6","metadata":null},{"id":"86e4abbd2bb84638bffcf831be6d0b23","type":"GENE","name":"MTHFD2P7","canonical_id":"hgnc:HGNC:48865","description":"methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 7","metadata":null},{"id":"13080e09b1c14816a874851245c42347","type":"GENE","name":"MTHFR","canonical_id":"hgnc:HGNC:7436","description":null,"metadata":null},{"id":"b0fec4bd25844747aab21dff03690518","type":"GENE","name":"MTHFS","canonical_id":"hgnc:HGNC:7437","description":"methenyltetrahydrofolate synthetase","metadata":{"aliases":["HsT19268"]}},{"id":"d79133ca537e4a32ba8191b30467ad79","type":"GENE","name":"MTHFSD","canonical_id":"hgnc:HGNC:25778","description":"methenyltetrahydrofolate synthetase domain containing","metadata":{"aliases":["FLJ12998"]}},{"id":"8eb46ab6c0fa467ea21088c061956357","type":"GENE","name":"MTIF2","canonical_id":"hgnc:HGNC:7441","description":"mitochondrial translational initiation factor 2","metadata":{"aliases":["IF-2mt"]}},{"id":"b9d0154f28d849569836172ba8991dc8","type":"GENE","name":"MTIF2P1","canonical_id":"hgnc:HGNC:14861","description":"mitochondrial translational initiation factor 2 pseudogene 1","metadata":null},{"id":"90f2e4cc1ae24b77b2b92ffcb78cd262","type":"GENE","name":"MTIF3","canonical_id":"hgnc:HGNC:29788","description":"mitochondrial translational initiation factor 3","metadata":{"aliases":["IF-3mt","IF3(mt)"]}},{"id":"992051e51b3746c4975c37139dbed50b","type":"GENE","name":"MTL3P","canonical_id":"hgnc:HGNC:7444","description":"metallothionein-like 3, pseudogene","metadata":{"aliases":["MTL3"]}},{"id":"25dd9217788e491f9176504daa03db09","type":"GENE","name":"MTLN","canonical_id":"hgnc:HGNC:27339","description":"mitoregulin","metadata":{"aliases":["MOXI","LEMP","MPM","TILR","NCRNA00116","LINC00116","SMIM37"]}},{"id":"a174042792b643458c1bc2e3e9e9874f","type":"GENE","name":"MTM1","canonical_id":"hgnc:HGNC:7448","description":"myotubularin 1","metadata":null},{"id":"e4d2998410864b9c960b249250b3ceec","type":"GENE","name":"MTMR1","canonical_id":"hgnc:HGNC:7449","description":"myotubularin related protein 1","metadata":null},{"id":"aeb85d51956f478c9eaea4ed8f8caf6f","type":"GENE","name":"MTMR10","canonical_id":"hgnc:HGNC:25999","description":"myotubularin related protein 10","metadata":{"aliases":["FLJ20313"]}},{"id":"29f82912a00d4f6e8e5a6e4374c9cf08","type":"GENE","name":"MTMR11","canonical_id":"hgnc:HGNC:24307","description":"myotubularin related protein 11","metadata":{"aliases":["CRA"]}},{"id":"1a583796a7dd43219821f8013a18cda9","type":"GENE","name":"MTMR12","canonical_id":"hgnc:HGNC:18191","description":"myotubularin related protein 12","metadata":{"aliases":["3-PAP","FLJ20476","KIAA1682","3PAP","PIP3AP"]}},{"id":"b11005841e914064aec1aa6f02a16aa4","type":"GENE","name":"MTMR12-DT","canonical_id":"hgnc:HGNC:59022","description":"MTMR12 divergent transcript","metadata":null},{"id":"70f9b91d4b494f948a6bb65ffeedec8d","type":"GENE","name":"MTMR12P1","canonical_id":"hgnc:HGNC:55888","description":"MTMR12 pseudogene 1","metadata":null},{"id":"17107e14e53a4f48b5f0b186fc9206cd","type":"GENE","name":"MTMR14","canonical_id":"hgnc:HGNC:26190","description":"myotubularin related protein 14","metadata":{"aliases":["FLJ22405","FLJ90311","hJumpy","hEDTP","C3orf29"]}},{"id":"ff3a75664c6a47aba81a3951cb522b0b","type":"GENE","name":"MTMR2","canonical_id":"hgnc:HGNC:7450","description":"myotubularin related protein 2","metadata":{"aliases":["KIAA1073","CMT4B"]}},{"id":"e70cb27a1b1f42a091601b6479a204d6","type":"GENE","name":"MTMR3","canonical_id":"hgnc:HGNC:7451","description":"myotubularin related protein 3","metadata":{"aliases":["KIAA0371","ZFYVE10","FYVE-DSP1"]}},{"id":"cd041dbcba734047925582c6c0926471","type":"GENE","name":"MTMR4","canonical_id":"hgnc:HGNC:7452","description":"myotubularin related protein 4","metadata":{"aliases":["KIAA0647","ZFYVE11"]}},{"id":"4ee2cc38310741da931373969180c924","type":"GENE","name":"MTMR6","canonical_id":"hgnc:HGNC:7453","description":"myotubularin related protein 6","metadata":null},{"id":"6c0161a29aec4d59baed48403abe7048","type":"GENE","name":"MTMR7","canonical_id":"hgnc:HGNC:7454","description":"myotubularin related protein 7","metadata":null},{"id":"21833643ea71413e829724f91af633ea","type":"GENE","name":"MTMR8","canonical_id":"hgnc:HGNC:16825","description":"myotubularin related protein 8","metadata":{"aliases":["FLJ20126"]}},{"id":"29ed4109fb584446989eff4fc465b873","type":"GENE","name":"MTMR9","canonical_id":"hgnc:HGNC:14596","description":"myotubularin related protein 9","metadata":{"aliases":["DKFZp434K171","LIP-STYX","C8orf9","MTMR8"]}},{"id":"d26aff47bc6a43538387c537a84c39bf","type":"GENE","name":"MTMR9-AS1","canonical_id":"hgnc:HGNC:58409","description":"MTMR9 antisense RNA 1","metadata":null},{"id":"f896618e6bda48578ad4b69c8aa9397b","type":"GENE","name":"MTMR9LP","canonical_id":"hgnc:HGNC:27920","description":"myotubularin related protein 9 like, pseudogene","metadata":{"aliases":["MTMR9L"]}},{"id":"43b2348a1eca4fa8868bebe99fdff658","type":"GENE","name":"MTMR9P1","canonical_id":"hgnc:HGNC:56931","description":"MTMR9 pseudogene 1","metadata":null},{"id":"de67c1b98d7744c095219a100f0312d1","type":"GENE","name":"MTNAP1","canonical_id":"hgnc:HGNC:29601","description":"mitochondrial nucleoid associated protein 1","metadata":{"aliases":["HLC-8","MIG3","FLJ20721","SPEP1","C17orf80"]}},{"id":"d2379d84952042e9af6eb052adcbc613","type":"GENE","name":"MTNAP1P1","canonical_id":"hgnc:HGNC:57041","description":"MTNAP1 pseudogene 1","metadata":null},{"id":"a8724076b2f740a887d751304e2c31b4","type":"GENE","name":"MTND1P1","canonical_id":"hgnc:HGNC:38728","description":"MT-ND1 pseudogene 1","metadata":null},{"id":"e059567d987c4c7f946ac15db5f0999e","type":"GENE","name":"MTND1P10","canonical_id":"hgnc:HGNC:42097","description":"MT-ND1 pseudogene 10","metadata":null},{"id":"ac4c833ec2484cfd81a61428b4f32b1b","type":"GENE","name":"MTND1P11","canonical_id":"hgnc:HGNC:42060","description":"MT-ND1 pseudogene 11","metadata":null},{"id":"f03f8d73f8524c29acd90e4649a42040","type":"GENE","name":"MTND1P12","canonical_id":"hgnc:HGNC:42061","description":"MT-ND1 pseudogene 12","metadata":null},{"id":"d3968de6e3bd49aaa360912f5efb4e4e","type":"GENE","name":"MTND1P13","canonical_id":"hgnc:HGNC:42096","description":"MT-ND1 pseudogene 13","metadata":null},{"id":"ba179434b8ec4d21bbb9f040297ecb4b","type":"GENE","name":"MTND1P14","canonical_id":"hgnc:HGNC:42063","description":"MT-ND1 pseudogene 14","metadata":null},{"id":"49779d7196e845e5a67e0c4711753665","type":"GENE","name":"MTND1P15","canonical_id":"hgnc:HGNC:42064","description":"MT-ND1 pseudogene 15","metadata":null},{"id":"5388eab48ee44296842197bc674ed704","type":"GENE","name":"MTND1P16","canonical_id":"hgnc:HGNC:42065","description":"MT-ND1 pseudogene 16","metadata":null},{"id":"15c258502f9f4210a0e8a637791b8361","type":"GENE","name":"MTND1P17","canonical_id":"hgnc:HGNC:42095","description":"MT-ND1 pseudogene 17","metadata":null},{"id":"90857565e37f46379053d2bb7b18b95d","type":"GENE","name":"MTND1P18","canonical_id":"hgnc:HGNC:42067","description":"MT-ND1 pseudogene 18","metadata":null},{"id":"2ac1975f8cd24717b0614e4d0c1c236f","type":"GENE","name":"MTND1P19","canonical_id":"hgnc:HGNC:42094","description":"MT-ND1 pseudogene 19","metadata":null},{"id":"2d4ab0d669f542b591b7ed4fb8a12f7b","type":"GENE","name":"MTND1P2","canonical_id":"hgnc:HGNC:42051","description":"MT-ND1 pseudogene 2","metadata":null},{"id":"f735fd8e78e94de48b0c07f52991cae9","type":"GENE","name":"MTND1P20","canonical_id":"hgnc:HGNC:42069","description":"MT-ND1 pseudogene 20","metadata":null},{"id":"1852482c55044429a452712cbf3debca","type":"GENE","name":"MTND1P21","canonical_id":"hgnc:HGNC:42070","description":"MT-ND1 pseudogene 21","metadata":null},{"id":"bdb7c32c5d0c4d9eb1c560bf4feefcaf","type":"GENE","name":"MTND1P22","canonical_id":"hgnc:HGNC:42093","description":"MT-ND1 pseudogene 22","metadata":null},{"id":"5aefd4694168409d853817b0b12202a4","type":"GENE","name":"MTND1P23","canonical_id":"hgnc:HGNC:42092","description":"MT-ND1 pseudogene 23","metadata":null},{"id":"defabf8aacb24433b9159257ba9b532d","type":"GENE","name":"MTND1P24","canonical_id":"hgnc:HGNC:42073","description":"MT-ND1 pseudogene 24","metadata":null},{"id":"fed9d4e12d8347859bbd7d2011509ba0","type":"GENE","name":"MTND1P25","canonical_id":"hgnc:HGNC:42091","description":"MT-ND1 pseudogene 25","metadata":null},{"id":"54164b3e351a4c749b05121cfda556d1","type":"GENE","name":"MTND1P26","canonical_id":"hgnc:HGNC:42075","description":"MT-ND1 pseudogene 26","metadata":null},{"id":"5c61887661a14f6288e6ca04d338add9","type":"GENE","name":"MTND1P27","canonical_id":"hgnc:HGNC:42076","description":"MT-ND1 pseudogene 27","metadata":null},{"id":"726674542a42408fa1d7f8df9971d1e1","type":"GENE","name":"MTND1P28","canonical_id":"hgnc:HGNC:42077","description":"MT-ND1 pseudogene 28","metadata":null},{"id":"ecf73c9147574b4fa35c9d43ef48ec3d","type":"GENE","name":"MTND1P29","canonical_id":"hgnc:HGNC:42078","description":"MT-ND1 pseudogene 29","metadata":null},{"id":"4870cba70105456aab0fffd0fc1477f1","type":"GENE","name":"MTND1P3","canonical_id":"hgnc:HGNC:42052","description":"MT-ND1 pseudogene 3","metadata":null},{"id":"5e8b09efa7f2498bb709ce93ddf6ef86","type":"GENE","name":"MTND1P30","canonical_id":"hgnc:HGNC:42079","description":"MT-ND1 pseudogene 30","metadata":null},{"id":"a792fdc8103c473f8916515d13ed646f","type":"GENE","name":"MTND1P31","canonical_id":"hgnc:HGNC:42080","description":"MT-ND1 pseudogene 31","metadata":null},{"id":"98be916d25cb40368ba5260b7227ca33","type":"GENE","name":"MTND1P32","canonical_id":"hgnc:HGNC:42081","description":"MT-ND1 pseudogene 32","metadata":null},{"id":"c9b6ac6701d5421fab18d239682802fe","type":"GENE","name":"MTND1P33","canonical_id":"hgnc:HGNC:42082","description":"MT-ND1 pseudogene 33","metadata":null},{"id":"f0d6351758e74daa85a0dbff4bb79ccf","type":"GENE","name":"MTND1P34","canonical_id":"hgnc:HGNC:42090","description":"MT-ND1 pseudogene 34","metadata":null},{"id":"24f650d0c40d49acb2b6f78d2e86c0eb","type":"GENE","name":"MTND1P35","canonical_id":"hgnc:HGNC:42088","description":"MT-ND1 pseudogene 35","metadata":null},{"id":"25c8e9665b004e8fbfdc01b1eaa5bac6","type":"GENE","name":"MTND1P36","canonical_id":"hgnc:HGNC:42086","description":"MT-ND1 pseudogene 36","metadata":null},{"id":"9caeda2fea764c94a8d32a268ac42533","type":"GENE","name":"MTND1P37","canonical_id":"hgnc:HGNC:52314","description":"MT-ND1 pseudogene 37","metadata":null},{"id":"7e053d0dc79f402ea1d74668f31f88d2","type":"GENE","name":"MTND1P4","canonical_id":"hgnc:HGNC:42053","description":"MT-ND1 pseudogene 4","metadata":null},{"id":"62928431a34443b89d6930c61d5b3774","type":"GENE","name":"MTND1P5","canonical_id":"hgnc:HGNC:42104","description":"MT-ND1 pseudogene 5","metadata":null},{"id":"af8ec0de5b1f4b0eb3974d54883f7aa3","type":"GENE","name":"MTND1P6","canonical_id":"hgnc:HGNC:42103","description":"MT-ND1 pseudogene 6","metadata":null},{"id":"eb2a248ec4e947a09b207dc419183f0b","type":"GENE","name":"MTND1P7","canonical_id":"hgnc:HGNC:42102","description":"MT-ND1 pseudogene 7","metadata":null},{"id":"48372d285bb34a1aba6d0a79ac50d988","type":"GENE","name":"MTND1P8","canonical_id":"hgnc:HGNC:42100","description":"MT-ND1 pseudogene 8","metadata":null},{"id":"6caa36c13d414d94a340322bd5dad000","type":"GENE","name":"MTND1P9","canonical_id":"hgnc:HGNC:42099","description":"MT-ND1 pseudogene 9","metadata":null},{"id":"47e57eb204b9437ba82b1f1c55783d54","type":"GENE","name":"MTND2P1","canonical_id":"hgnc:HGNC:7457","description":"MT-ND2 pseudogene 1","metadata":null},{"id":"2b565748f0ef4b69b379efabf2ddf001","type":"GENE","name":"MTND2P10","canonical_id":"hgnc:HGNC:42140","description":"MT-ND2 pseudogene 10","metadata":null},{"id":"91f4598fb8b54b3890bdccd2ef57e641","type":"GENE","name":"MTND2P11","canonical_id":"hgnc:HGNC:42112","description":"MT-ND2 pseudogene 11","metadata":null},{"id":"8bbe7ae9912e45efa10b5131ab9c6780","type":"GENE","name":"MTND2P12","canonical_id":"hgnc:HGNC:42113","description":"MT-ND2 pseudogene 12","metadata":null},{"id":"0640d4c46639417db36efbf6fd6f1ef9","type":"GENE","name":"MTND2P13","canonical_id":"hgnc:HGNC:42114","description":"MT-ND2 pseudogene 13","metadata":null},{"id":"b7e6f1f2f0744b61878ab4de68eaae7c","type":"GENE","name":"MTND2P14","canonical_id":"hgnc:HGNC:42115","description":"MT-ND2 pseudogene 14","metadata":null},{"id":"480979d541ec486987f1b9bc5e9f08e8","type":"GENE","name":"MTND2P15","canonical_id":"hgnc:HGNC:42116","description":"MT-ND2 pseudogene 15","metadata":null},{"id":"73ad8cbcd2ca42238f7bb463ca215399","type":"GENE","name":"MTND2P16","canonical_id":"hgnc:HGNC:42117","description":"MT-ND2 pseudogene 16","metadata":null},{"id":"62630ec466ea467d9fbc8c43780a29f7","type":"GENE","name":"MTND2P17","canonical_id":"hgnc:HGNC:42118","description":"MT-ND2 pseudogene 17","metadata":null},{"id":"1135446e7e7d4fadbcfc0ba862d8fbd1","type":"GENE","name":"MTND2P18","canonical_id":"hgnc:HGNC:42119","description":"MT-ND2 pseudogene 18","metadata":null},{"id":"4624840ab4ba4df68d32651b8156d043","type":"GENE","name":"MTND2P19","canonical_id":"hgnc:HGNC:42120","description":"MT-ND2 pseudogene 19","metadata":null},{"id":"8890899f4c9c41d1b6d9f58bdebc20c8","type":"GENE","name":"MTND2P2","canonical_id":"hgnc:HGNC:23767","description":"MT-ND2 pseudogene 2","metadata":null},{"id":"428e5395565849be81b69a31c463841b","type":"GENE","name":"MTND2P20","canonical_id":"hgnc:HGNC:42121","description":"MT-ND2 pseudogene 20","metadata":null},{"id":"07c0351a0eae455db62d9ea0ea1cea73","type":"GENE","name":"MTND2P21","canonical_id":"hgnc:HGNC:42122","description":"MT-ND2 pseudogene 21","metadata":null},{"id":"8ca768c5538e454f971671c013d010ae","type":"GENE","name":"MTND2P22","canonical_id":"hgnc:HGNC:42123","description":"MT-ND2 pseudogene 22","metadata":null},{"id":"df3a5832904c416e9507bf90e58812c7","type":"GENE","name":"MTND2P23","canonical_id":"hgnc:HGNC:42124","description":"MT-ND2 pseudogene 23","metadata":null},{"id":"138dd31211534c49b376c16ee02a7328","type":"GENE","name":"MTND2P24","canonical_id":"hgnc:HGNC:42125","description":"MT-ND2 pseudogene 24","metadata":null},{"id":"6ee0e065d5974b5c867c7bd6a7f5dec8","type":"GENE","name":"MTND2P25","canonical_id":"hgnc:HGNC:42126","description":"MT-ND2 pseudogene 25","metadata":null},{"id":"949dd186646748e0abff071d706d616b","type":"GENE","name":"MTND2P26","canonical_id":"hgnc:HGNC:42127","description":"MT-ND2 pseudogene 26","metadata":null},{"id":"6ec4e13735fc4736adaaeb2d6e72dcd6","type":"GENE","name":"MTND2P27","canonical_id":"hgnc:HGNC:42128","description":"MT-ND2 pseudogene 27","metadata":null},{"id":"b2d6e8dd561c4e358a12d2a0c9e0738e","type":"GENE","name":"MTND2P28","canonical_id":"hgnc:HGNC:42129","description":"MT-ND2 pseudogene 28","metadata":null},{"id":"14170a5809f0463ca8814cfb5dddd2d6","type":"GENE","name":"MTND2P29","canonical_id":"hgnc:HGNC:42130","description":"MT-ND2 pseudogene 29","metadata":null},{"id":"68c570f421314971b2293ed0516049e2","type":"GENE","name":"MTND2P3","canonical_id":"hgnc:HGNC:38727","description":"MT-ND2 pseudogene 3","metadata":null},{"id":"31b3722282fc4521ad84c071ec42b135","type":"GENE","name":"MTND2P30","canonical_id":"hgnc:HGNC:42131","description":"MT-ND2 pseudogene 30","metadata":null},{"id":"f88888b44ff04172af2df3452745cf6d","type":"GENE","name":"MTND2P31","canonical_id":"hgnc:HGNC:42132","description":"MT-ND2 pseudogene 31","metadata":null},{"id":"b9c97778b6a7452c81005feb2a7db338","type":"GENE","name":"MTND2P32","canonical_id":"hgnc:HGNC:42139","description":"MT-ND2 pseudogene 32","metadata":null},{"id":"5b7b06ad7d424ed3ad32dc19f8612929","type":"GENE","name":"MTND2P33","canonical_id":"hgnc:HGNC:42134","description":"MT-ND2 pseudogene 33","metadata":null},{"id":"827f028a2dcb40d9b77274c879ccafac","type":"GENE","name":"MTND2P34","canonical_id":"hgnc:HGNC:52065","description":"MT-ND2 pseudogene 34","metadata":null},{"id":"1a933c1fcddb4859b21fe12d6b2cb65e","type":"GENE","name":"MTND2P35","canonical_id":"hgnc:HGNC:52066","description":"MT-ND2 pseudogene 35","metadata":null},{"id":"d16a7d3885c64553ab8aabda28410194","type":"GENE","name":"MTND2P36","canonical_id":"hgnc:HGNC:52067","description":"MT-ND2 pseudogene 36","metadata":null},{"id":"56e0b1ba85b54580aa1dbd4ee0601904","type":"GENE","name":"MTND2P37","canonical_id":"hgnc:HGNC:52068","description":"MT-ND2 pseudogene 37","metadata":null},{"id":"2ee3bf3e78944789a99727680feb4c7f","type":"GENE","name":"MTND2P38","canonical_id":"hgnc:HGNC:52069","description":"MT-ND2 pseudogene 38","metadata":null},{"id":"24657cf694084606a856a6aba588b877","type":"GENE","name":"MTND2P39","canonical_id":"hgnc:HGNC:52070","description":"MT-ND2 pseudogene 39","metadata":null},{"id":"e6ef2338eaa34c4fa73c3c3f7c45d9f6","type":"GENE","name":"MTND2P4","canonical_id":"hgnc:HGNC:42105","description":"MT-ND2 pseudogene 4","metadata":null},{"id":"8e78e8e4763d42038d1d64be0e1f2892","type":"GENE","name":"MTND2P40","canonical_id":"hgnc:HGNC:52084","description":"MT-ND2 pseudogene 40","metadata":null},{"id":"b1a84f40d5e24d1abc98757fa6ccd50a","type":"GENE","name":"MTND2P41","canonical_id":"hgnc:HGNC:52317","description":"MT-ND2 pseudogene 41","metadata":null},{"id":"c4eb86620ca14f30ba570a492799749e","type":"GENE","name":"MTND2P5","canonical_id":"hgnc:HGNC:42106","description":"MT-ND2 pseudogene 5","metadata":null},{"id":"f3274f56269043c1a6641c617ea3e1f3","type":"GENE","name":"MTND2P6","canonical_id":"hgnc:HGNC:42107","description":"MT-ND2 pseudogene 6","metadata":null},{"id":"a5fce0de5caa41cc93a9deaa5af46a0b","type":"GENE","name":"MTND2P7","canonical_id":"hgnc:HGNC:42141","description":"MT-ND2 pseudogene 7","metadata":null},{"id":"9081ecaa6485467ca269c41f9b732fd6","type":"GENE","name":"MTND2P8","canonical_id":"hgnc:HGNC:42109","description":"MT-ND2 pseudogene 8","metadata":null},{"id":"a44fb96dfa5643e3876e58931d4021de","type":"GENE","name":"MTND2P9","canonical_id":"hgnc:HGNC:42110","description":"MT-ND2 pseudogene 9","metadata":null},{"id":"d7750b0b1b4c4c2e89a7ee39dbdf06b9","type":"GENE","name":"MTND3P1","canonical_id":"hgnc:HGNC:39856","description":"MT-ND3 pseudogene 1","metadata":null},{"id":"4660520422484f9a88f03a54ab75ca29","type":"GENE","name":"MTND3P10","canonical_id":"hgnc:HGNC:42150","description":"MT-ND3 pseudogene 10","metadata":null},{"id":"210dc68f03964e28b76d578ee11b66f1","type":"GENE","name":"MTND3P11","canonical_id":"hgnc:HGNC:52071","description":"MT-ND3 pseudogene 11","metadata":null},{"id":"d4ca4bb1a44245b884e1c6c41672c033","type":"GENE","name":"MTND3P12","canonical_id":"hgnc:HGNC:52072","description":"MT-ND3 pseudogene 12","metadata":null},{"id":"57bfddccc45f4ac9a95af918df6fc970","type":"GENE","name":"MTND3P13","canonical_id":"hgnc:HGNC:52073","description":"MT-ND3 pseudogene 13","metadata":null},{"id":"f3e51e7f96104eb1be0afac54684f53d","type":"GENE","name":"MTND3P14","canonical_id":"hgnc:HGNC:52074","description":"MT-ND3 pseudogene 14","metadata":null},{"id":"997c7600b8d24377b50d40048e285c8b","type":"GENE","name":"MTND3P15","canonical_id":"hgnc:HGNC:52075","description":"MT-ND3 pseudogene 15","metadata":null},{"id":"f203c486871e4e31ba6c0032aec6edc2","type":"GENE","name":"MTND3P16","canonical_id":"hgnc:HGNC:52076","description":"MT-ND3 pseudogene 16","metadata":null},{"id":"c1109b0ec13a452e98366dffaed84346","type":"GENE","name":"MTND3P17","canonical_id":"hgnc:HGNC:52077","description":"MT-ND3 pseudogene 17","metadata":null},{"id":"4349878b0c3845faa2844d547434d662","type":"GENE","name":"MTND3P18","canonical_id":"hgnc:HGNC:52078","description":"MT-ND3 pseudogene 18","metadata":null},{"id":"c3919b1f5b9d4816a0c9cffce585983f","type":"GENE","name":"MTND3P19","canonical_id":"hgnc:HGNC:52081","description":"MT-ND3 pseudogene 19","metadata":null},{"id":"ecc58a6a16ae4d22851db1d456286088","type":"GENE","name":"MTND3P2","canonical_id":"hgnc:HGNC:42142","description":"MT-ND3 pseudogene 2","metadata":null},{"id":"3cb26f95b1a24b4dadce3b2f41cd8d5b","type":"GENE","name":"MTND3P20","canonical_id":"hgnc:HGNC:52166","description":"MT-ND3 pseudogene 20","metadata":null},{"id":"4eef29659d2b4abd9413495349f7aa72","type":"GENE","name":"MTND3P21","canonical_id":"hgnc:HGNC:52167","description":"MT-ND3 pseudogene 21","metadata":null},{"id":"5511d10b34644823ab13e506c131353d","type":"GENE","name":"MTND3P22","canonical_id":"hgnc:HGNC:52168","description":"MT-ND3 pseudogene 22","metadata":null},{"id":"2a6e757fb9dd425d94e31c5540e9f5ca","type":"GENE","name":"MTND3P23","canonical_id":"hgnc:HGNC:52169","description":"MT-ND3 pseudogene 23","metadata":null},{"id":"59880f4a2e86416aab400571d4d4bf28","type":"GENE","name":"MTND3P24","canonical_id":"hgnc:HGNC:52170","description":"MT-ND3 pseudogene 24","metadata":null},{"id":"a660c00a6aff4a4eac3ea8333dbe8e77","type":"GENE","name":"MTND3P25","canonical_id":"hgnc:HGNC:52172","description":"MT-ND3 pseudogene 25","metadata":null},{"id":"07dfa9d7d06a40c6862f88c3cf629a64","type":"GENE","name":"MTND3P3","canonical_id":"hgnc:HGNC:42155","description":"MT-ND3 pseudogene 3","metadata":null},{"id":"a0b044c528bd429ab7245c7dbf0cb9aa","type":"GENE","name":"MTND3P4","canonical_id":"hgnc:HGNC:42144","description":"MT-ND3 pseudogene 4","metadata":null},{"id":"8c41ae5ef72a4502bb2cd264315dca4b","type":"GENE","name":"MTND3P5","canonical_id":"hgnc:HGNC:42154","description":"MT-ND3 pseudogene 5","metadata":null},{"id":"3ad75b56e41f45f6b7f7fbabde5d1427","type":"GENE","name":"MTND3P6","canonical_id":"hgnc:HGNC:42146","description":"MT-ND3 pseudogene 6","metadata":null},{"id":"00d76940f0fa45a49eaf77ac5682a25c","type":"GENE","name":"MTND3P7","canonical_id":"hgnc:HGNC:42147","description":"MT-ND3 pseudogene 7","metadata":null},{"id":"96c7bd6139b04abc84da755c0431debf","type":"GENE","name":"MTND3P8","canonical_id":"hgnc:HGNC:42153","description":"MT-ND3 pseudogene 8","metadata":null},{"id":"443ca08daaa648beb81b9bd56c8f8a4f","type":"GENE","name":"MTND3P9","canonical_id":"hgnc:HGNC:42149","description":"MT-ND3 pseudogene 9","metadata":null},{"id":"a60e1e5631ec499c82ad23d9accd791f","type":"GENE","name":"MTND4LP1","canonical_id":"hgnc:HGNC:31347","description":"MT-ND4L pseudogene 1","metadata":{"aliases":["MTND4L2"]}},{"id":"832cea2fb4d7446f9dbe56587ddc2413","type":"GENE","name":"MTND4LP10","canonical_id":"hgnc:HGNC:42244","description":"MT-ND4L pseudogene 10","metadata":null},{"id":"406a950701f749149aa2c2a608e517de","type":"GENE","name":"MTND4LP11","canonical_id":"hgnc:HGNC:42245","description":"MT-ND4L pseudogene 11","metadata":null},{"id":"c437df30730f45429361de1dfbfb6ed1","type":"GENE","name":"MTND4LP12","canonical_id":"hgnc:HGNC:42246","description":"MT-ND4L pseudogene 12","metadata":null},{"id":"ad30bb7881ae462ba231922b001bfbae","type":"GENE","name":"MTND4LP13","canonical_id":"hgnc:HGNC:42247","description":"MT-ND4L pseudogene 13","metadata":null},{"id":"d017484343c74428a404d491e6645a82","type":"GENE","name":"MTND4LP14","canonical_id":"hgnc:HGNC:42248","description":"MT-ND4L pseudogene 14","metadata":null},{"id":"d73dd22bba7e4bb0a988adc05381d5d6","type":"GENE","name":"MTND4LP15","canonical_id":"hgnc:HGNC:42249","description":"MT-ND4L pseudogene 15","metadata":null},{"id":"b7cffd9c7d194c3ca9f12f5725aaa27f","type":"GENE","name":"MTND4LP16","canonical_id":"hgnc:HGNC:42250","description":"MT-ND4L pseudogene 16","metadata":null},{"id":"ec98603086754116a82e82c7589d6cf2","type":"GENE","name":"MTND4LP17","canonical_id":"hgnc:HGNC:42251","description":"MT-ND4L pseudogene 17","metadata":null},{"id":"ff52d9a2e7b143ec98c71882f169150b","type":"GENE","name":"MTND4LP18","canonical_id":"hgnc:HGNC:42252","description":"MT-ND4L pseudogene 18","metadata":null},{"id":"cd3acd0a318246718d93e32245e65327","type":"GENE","name":"MTND4LP19","canonical_id":"hgnc:HGNC:42253","description":"MT-ND4L pseudogene 19","metadata":null},{"id":"ca9001f7046d41fa89807ae19f55d0de","type":"GENE","name":"MTND4LP2","canonical_id":"hgnc:HGNC:42236","description":"MT-ND4L pseudogene 2","metadata":null},{"id":"4a5681ac702d4fb6982daf739720a805","type":"GENE","name":"MTND4LP20","canonical_id":"hgnc:HGNC:42254","description":"MT-ND4L pseudogene 20","metadata":null},{"id":"5d030e6e06124a15b5796f49daacfa27","type":"GENE","name":"MTND4LP21","canonical_id":"hgnc:HGNC:42255","description":"MT-ND4L pseudogene 21","metadata":null},{"id":"f22dd87c8a25435dbb9210bc374da6ad","type":"GENE","name":"MTND4LP22","canonical_id":"hgnc:HGNC:42256","description":"MT-ND4L pseudogene 22","metadata":null},{"id":"e07d3ac4fc6f4a03a6b6dc830e44d15f","type":"GENE","name":"MTND4LP23","canonical_id":"hgnc:HGNC:42257","description":"MT-ND4L pseudogene 23","metadata":null},{"id":"cd5dc56ff0b3438f8a9b98097d38a06e","type":"GENE","name":"MTND4LP24","canonical_id":"hgnc:HGNC:42258","description":"MT-ND4L pseudogene 24","metadata":null},{"id":"51b24c194dc940d8a387dcb4782916b8","type":"GENE","name":"MTND4LP25","canonical_id":"hgnc:HGNC:42259","description":"MT-ND4L pseudogene 25","metadata":null},{"id":"5fc701965338493d85dcd816051bc048","type":"GENE","name":"MTND4LP26","canonical_id":"hgnc:HGNC:42260","description":"MT-ND4L pseudogene 26","metadata":null},{"id":"43730265f01f4ded8a2d9b1ed7a54786","type":"GENE","name":"MTND4LP27","canonical_id":"hgnc:HGNC:42261","description":"MT-ND4L pseudogene 27","metadata":null},{"id":"ca2ae5e5b0bc4d63b00506d67dbc2305","type":"GENE","name":"MTND4LP28","canonical_id":"hgnc:HGNC:42262","description":"MT-ND4L pseudogene 28","metadata":null},{"id":"8e64cb878c73429c95eb5fc6b2df0c3a","type":"GENE","name":"MTND4LP29","canonical_id":"hgnc:HGNC:42263","description":"MT-ND4L pseudogene 29","metadata":null},{"id":"257804d30dca4d6db38b1efffe6865d4","type":"GENE","name":"MTND4LP3","canonical_id":"hgnc:HGNC:42265","description":"MT-ND4L pseudogene 3","metadata":null},{"id":"7fe208a977cb4927a01a6bdfa034cea1","type":"GENE","name":"MTND4LP30","canonical_id":"hgnc:HGNC:42264","description":"MT-ND4L pseudogene 30","metadata":null},{"id":"95573e28e6ce4660964236b0670deb7c","type":"GENE","name":"MTND4LP31","canonical_id":"hgnc:HGNC:52171","description":"MT-ND4L pseudogene 31","metadata":null},{"id":"0e089a12cc134a25be3eec44ad106945","type":"GENE","name":"MTND4LP32","canonical_id":"hgnc:HGNC:52318","description":"MT-ND4L pseudogene 32","metadata":null},{"id":"714e5abcffa04c7eb355a3716d711052","type":"GENE","name":"MTND4LP4","canonical_id":"hgnc:HGNC:42238","description":"MT-ND4L pseudogene 4","metadata":null},{"id":"fc3b2dacb10946c984f7a9f3e7c56330","type":"GENE","name":"MTND4LP5","canonical_id":"hgnc:HGNC:42239","description":"MT-ND4L pseudogene 5","metadata":null},{"id":"156789e5cba045b8861abdcc26758b10","type":"GENE","name":"MTND4LP6","canonical_id":"hgnc:HGNC:42240","description":"MT-ND4L pseudogene 6","metadata":null},{"id":"177a7baffe0a4d759df18bea790eaa8d","type":"GENE","name":"MTND4LP7","canonical_id":"hgnc:HGNC:42241","description":"MT-ND4L pseudogene 7","metadata":null},{"id":"bc447eac9b7f47f2bac7291654eed3d1","type":"GENE","name":"MTND4LP8","canonical_id":"hgnc:HGNC:42242","description":"MT-ND4L pseudogene 8","metadata":null},{"id":"468c3d2205ea4511a99b6559460dc825","type":"GENE","name":"MTND4LP9","canonical_id":"hgnc:HGNC:42243","description":"MT-ND4L pseudogene 9","metadata":null},{"id":"0d3e5f7ad0f94a6aaad40dd1cd282fdf","type":"GENE","name":"MTND4P1","canonical_id":"hgnc:HGNC:42035","description":"MT-ND4 pseudogene 1","metadata":null},{"id":"00dc758c1a4f439fa94b581557a01f13","type":"GENE","name":"MTND4P10","canonical_id":"hgnc:HGNC:42225","description":"MT-ND4 pseudogene 10","metadata":null},{"id":"b4c955f907144db1bbbd0544f0e33bf6","type":"GENE","name":"MTND4P11","canonical_id":"hgnc:HGNC:42223","description":"MT-ND4 pseudogene 11","metadata":null},{"id":"d2b4c8dd72ab4355a17d78ca04811ad9","type":"GENE","name":"MTND4P12","canonical_id":"hgnc:HGNC:42199","description":"MT-ND4 pseudogene 12","metadata":null},{"id":"8a5d9b73a1af4b5b9cc0ce195699e3c4","type":"GENE","name":"MTND4P13","canonical_id":"hgnc:HGNC:42222","description":"MT-ND4 pseudogene 13","metadata":null},{"id":"20d029afd9804b029168c0dec9418927","type":"GENE","name":"MTND4P14","canonical_id":"hgnc:HGNC:42201","description":"MT-ND4 pseudogene 14","metadata":null},{"id":"79d7813a978a4f7788bdbe8f81844dfe","type":"GENE","name":"MTND4P15","canonical_id":"hgnc:HGNC:42202","description":"MT-ND4 pseudogene 15","metadata":null},{"id":"491e2137c4c8494695cb4d39faec5c24","type":"GENE","name":"MTND4P16","canonical_id":"hgnc:HGNC:42203","description":"MT-ND4 pseudogene 16","metadata":null},{"id":"4fb87399ca7143a9bd99a21233555439","type":"GENE","name":"MTND4P17","canonical_id":"hgnc:HGNC:42204","description":"MT-ND4 pseudogene 17","metadata":null},{"id":"4d87708b577b491daaabdb7120669204","type":"GENE","name":"MTND4P18","canonical_id":"hgnc:HGNC:42205","description":"MT-ND4 pseudogene 18","metadata":null},{"id":"984e4dd7bdcc4c7dac8ec815763db71b","type":"GENE","name":"MTND4P19","canonical_id":"hgnc:HGNC:42206","description":"MT-ND4 pseudogene 19","metadata":null},{"id":"a02c9ddd5c9b42d4a2152b2d5db43b29","type":"GENE","name":"MTND4P2","canonical_id":"hgnc:HGNC:42189","description":"MT-ND4 pseudogene 2","metadata":null},{"id":"5a696d7fb1e747b7a7cd58d4b94bb3b9","type":"GENE","name":"MTND4P20","canonical_id":"hgnc:HGNC:42207","description":"MT-ND4 pseudogene 20","metadata":null},{"id":"ac126b89919e448abf3dcc5fea3c1e40","type":"GENE","name":"MTND4P21","canonical_id":"hgnc:HGNC:42208","description":"MT-ND4 pseudogene 21","metadata":null},{"id":"b4fe0dc68242497684a0f8b7258fb794","type":"GENE","name":"MTND4P22","canonical_id":"hgnc:HGNC:42209","description":"MT-ND4 pseudogene 22","metadata":null},{"id":"0ac44c4280fc475d80801f1015aa681c","type":"GENE","name":"MTND4P23","canonical_id":"hgnc:HGNC:42210","description":"MT-ND4 pseudogene 23","metadata":null},{"id":"276f230c92f64e17a945726e1ae11655","type":"GENE","name":"MTND4P24","canonical_id":"hgnc:HGNC:42220","description":"MT-ND4 pseudogene 24","metadata":null},{"id":"da2ba5ba57ff4661be818a36df35e272","type":"GENE","name":"MTND4P25","canonical_id":"hgnc:HGNC:42212","description":"MT-ND4 pseudogene 25","metadata":null},{"id":"b53ca841f2b248e79c4862cbd5a1af80","type":"GENE","name":"MTND4P26","canonical_id":"hgnc:HGNC:42213","description":"MT-ND4 pseudogene 26","metadata":null},{"id":"3d595ac67c0e4a27bc29eac4d1cbb617","type":"GENE","name":"MTND4P27","canonical_id":"hgnc:HGNC:42214","description":"MT-ND4 pseudogene 27","metadata":null},{"id":"feaf928e90244e87ab306a7a21fe62fe","type":"GENE","name":"MTND4P28","canonical_id":"hgnc:HGNC:42215","description":"MT-ND4 pseudogene 28","metadata":null},{"id":"b6a2bd66181c423099d19e273d5ebeec","type":"GENE","name":"MTND4P29","canonical_id":"hgnc:HGNC:42216","description":"MT-ND4 pseudogene 29","metadata":null},{"id":"2dd8822611414a5ab636d79c8723a169","type":"GENE","name":"MTND4P3","canonical_id":"hgnc:HGNC:42190","description":"MT-ND4 pseudogene 3","metadata":null},{"id":"8c1b9529529a414ca89b373abc4acee2","type":"GENE","name":"MTND4P30","canonical_id":"hgnc:HGNC:42217","description":"MT-ND4 pseudogene 30","metadata":null},{"id":"4b41e5b6f7bc43f4ad487ddf9f0fbaa2","type":"GENE","name":"MTND4P31","canonical_id":"hgnc:HGNC:42218","description":"MT-ND4 pseudogene 31","metadata":null},{"id":"8c9cdcbddac94ab28b5f2ab9b92e9b97","type":"GENE","name":"MTND4P32","canonical_id":"hgnc:HGNC:42219","description":"MT-ND4 pseudogene 32","metadata":null},{"id":"e92ce2785d504e6db07f0db8fd9f062b","type":"GENE","name":"MTND4P33","canonical_id":"hgnc:HGNC:51947","description":"MT-ND4 pseudogene 33","metadata":null},{"id":"d542a34ca9cd4af4838164cb89ea3d77","type":"GENE","name":"MTND4P34","canonical_id":"hgnc:HGNC:51948","description":"MT-ND4 pseudogene 34","metadata":null},{"id":"4f4cb8cae4d244e0b9a942ed1e0e83e4","type":"GENE","name":"MTND4P35","canonical_id":"hgnc:HGNC:51949","description":"MT-ND4 pseudogene 35","metadata":null},{"id":"6f12330f33f64a4b9a6e5fe1ad01db39","type":"GENE","name":"MTND4P36","canonical_id":"hgnc:HGNC:51950","description":"MT-ND4 pseudogene 36","metadata":null},{"id":"6b120a47a16f4f11b400c1daa4d131b0","type":"GENE","name":"MTND4P37","canonical_id":"hgnc:HGNC:52319","description":"MT-ND4 pseudogene 37","metadata":null},{"id":"5f48737c2a0e48999f522c45397ded62","type":"GENE","name":"MTND4P38","canonical_id":"hgnc:HGNC:52320","description":"MT-ND4 pseudogene 38","metadata":null},{"id":"69c09a11a2aa40e883916d9f5f174aca","type":"GENE","name":"MTND4P39","canonical_id":"hgnc:HGNC:52324","description":"MT-ND4 pseudogene 39","metadata":null},{"id":"80f72036b46b415abf1f255896e86688","type":"GENE","name":"MTND4P4","canonical_id":"hgnc:HGNC:42191","description":"MT-ND4 pseudogene 4","metadata":null},{"id":"490dd03a7d624e90accbcfcf940fcf94","type":"GENE","name":"MTND4P40","canonical_id":"hgnc:HGNC:52336","description":"MT-ND4 pseudogene 40","metadata":null},{"id":"9cdfef00d68f48d5a995ee3719b0096a","type":"GENE","name":"MTND4P41","canonical_id":"hgnc:HGNC:52334","description":"MT-ND4 pseudogene 41","metadata":null},{"id":"505780adef9a4a0d930c2e7b0fa6e326","type":"GENE","name":"MTND4P5","canonical_id":"hgnc:HGNC:42192","description":"MT-ND4 pseudogene 5","metadata":null},{"id":"f092478866714dc696d424521c5a5096","type":"GENE","name":"MTND4P6","canonical_id":"hgnc:HGNC:42193","description":"MT-ND4 pseudogene 6","metadata":null},{"id":"e2f07f46b3714058b71019e3d0177321","type":"GENE","name":"MTND4P7","canonical_id":"hgnc:HGNC:42234","description":"MT-ND4 pseudogene 7","metadata":null},{"id":"88b7e48c38e446e8a0c4ffee34c31ec7","type":"GENE","name":"MTND4P8","canonical_id":"hgnc:HGNC:42227","description":"MT-ND4 pseudogene 8","metadata":null},{"id":"e77fa61d3fa945488218d0c1ed1795eb","type":"GENE","name":"MTND4P9","canonical_id":"hgnc:HGNC:42226","description":"MT-ND4 pseudogene 9","metadata":null},{"id":"4d61ac40bb624010b79348ecf162ca13","type":"GENE","name":"MTND5P1","canonical_id":"hgnc:HGNC:39644","description":"MT-ND5 pseudogene 1","metadata":null},{"id":"45a3742c5b1a4d18afa2be5269256ab2","type":"GENE","name":"MTND5P10","canonical_id":"hgnc:HGNC:42272","description":"MT-ND5 pseudogene 10","metadata":null},{"id":"1713580f1e8443dd9d34fa7c94abbe3e","type":"GENE","name":"MTND5P11","canonical_id":"hgnc:HGNC:42273","description":"MT-ND5 pseudogene 11","metadata":null},{"id":"ca622efbf178453cb6b721a87b16b6f0","type":"GENE","name":"MTND5P12","canonical_id":"hgnc:HGNC:42274","description":"MT-ND5 pseudogene 12","metadata":null},{"id":"60b4258060544749b80d7d0b42f34b24","type":"GENE","name":"MTND5P13","canonical_id":"hgnc:HGNC:42304","description":"MT-ND5 pseudogene 13","metadata":null},{"id":"3009b5909a304fbcb9cc8d7501657af3","type":"GENE","name":"MTND5P14","canonical_id":"hgnc:HGNC:42276","description":"MT-ND5 pseudogene 14","metadata":null},{"id":"668ee64da780436cbc0ed7b450bf10c3","type":"GENE","name":"MTND5P15","canonical_id":"hgnc:HGNC:42277","description":"MT-ND5 pseudogene 15","metadata":null},{"id":"f5e3ea5cd098492b93c30b26338e6dc2","type":"GENE","name":"MTND5P16","canonical_id":"hgnc:HGNC:42278","description":"MT-ND5 pseudogene 16","metadata":null},{"id":"a7a9a43da80148dba84fdfcb7187de6f","type":"GENE","name":"MTND5P17","canonical_id":"hgnc:HGNC:42279","description":"MT-ND5 pseudogene 17","metadata":null},{"id":"046d185b62274acb93265d9eca5ddbf3","type":"GENE","name":"MTND5P18","canonical_id":"hgnc:HGNC:42302","description":"MT-ND5 pseudogene 18","metadata":null},{"id":"98a8b87f55184f23bf9904f4fa9ef5a3","type":"GENE","name":"MTND5P19","canonical_id":"hgnc:HGNC:42301","description":"MT-ND5 pseudogene 19","metadata":null},{"id":"d942bc6532054c2c8ae2f21270dd1d63","type":"GENE","name":"MTND5P2","canonical_id":"hgnc:HGNC:41919","description":"MT-ND5 pseudogene 2","metadata":null},{"id":"ec893077d9b742b09ba61a52373243be","type":"GENE","name":"MTND5P20","canonical_id":"hgnc:HGNC:42300","description":"MT-ND5 pseudogene 20","metadata":null},{"id":"5efb79a7a0b2481e91368a912b00473f","type":"GENE","name":"MTND5P21","canonical_id":"hgnc:HGNC:42296","description":"MT-ND5 pseudogene 21","metadata":null},{"id":"5b17cee2754945659c2345f5a038a8e7","type":"GENE","name":"MTND5P22","canonical_id":"hgnc:HGNC:42284","description":"MT-ND5 pseudogene 22","metadata":null},{"id":"dff9703ad5864e7c98fa12f56c4084f3","type":"GENE","name":"MTND5P23","canonical_id":"hgnc:HGNC:42285","description":"MT-ND5 pseudogene 23","metadata":null},{"id":"128c646e12524e7ba5907b945f6f40d5","type":"GENE","name":"MTND5P24","canonical_id":"hgnc:HGNC:42286","description":"MT-ND5 pseudogene 24","metadata":null},{"id":"8618c0bb12c6468baa701fd8084737de","type":"GENE","name":"MTND5P25","canonical_id":"hgnc:HGNC:42287","description":"MT-ND5 pseudogene 25","metadata":null},{"id":"b296b448dda941ec9051fcfe8248db54","type":"GENE","name":"MTND5P26","canonical_id":"hgnc:HGNC:42295","description":"MT-ND5 pseudogene 26","metadata":null},{"id":"f04ae57e53ee4de3a6474cf244ef954f","type":"GENE","name":"MTND5P27","canonical_id":"hgnc:HGNC:42289","description":"MT-ND5 pseudogene 27","metadata":null},{"id":"1b7f79f842f54bf6a3c416df8ee8194e","type":"GENE","name":"MTND5P28","canonical_id":"hgnc:HGNC:42290","description":"MT-ND5 pseudogene 28","metadata":null},{"id":"e80919bbfa50404ea4abc463ff0ba4ac","type":"GENE","name":"MTND5P29","canonical_id":"hgnc:HGNC:42291","description":"MT-ND5 pseudogene 29","metadata":null},{"id":"055dd0e8b0fc4cca9fb9a66fdd63e41c","type":"GENE","name":"MTND5P3","canonical_id":"hgnc:HGNC:42034","description":"MT-ND5 pseudogene 3","metadata":null},{"id":"35d5181546f54dfab601d203816fe24d","type":"GENE","name":"MTND5P30","canonical_id":"hgnc:HGNC:42292","description":"MT-ND5 pseudogene 30","metadata":null},{"id":"8a2ed5083a644e96b7b37255c26144f6","type":"GENE","name":"MTND5P31","canonical_id":"hgnc:HGNC:42293","description":"MT-ND5 pseudogene 31","metadata":null},{"id":"47623563202646eaa2a09f621b126cba","type":"GENE","name":"MTND5P32","canonical_id":"hgnc:HGNC:51951","description":"MT-ND5 pseudogene 32","metadata":null},{"id":"21c1dff3f7714b5aa8d1794d3e26e679","type":"GENE","name":"MTND5P33","canonical_id":"hgnc:HGNC:51952","description":"MT-ND5 pseudogene 33","metadata":null},{"id":"25576e3fcaa4406e89a62380afbe8bc1","type":"GENE","name":"MTND5P34","canonical_id":"hgnc:HGNC:51953","description":"MT-ND5 pseudogene 34","metadata":null},{"id":"3ffd9a56e5e146d795315b55f3d9f70d","type":"GENE","name":"MTND5P35","canonical_id":"hgnc:HGNC:51954","description":"MT-ND5 pseudogene 35","metadata":null},{"id":"213f6c45f2c5410688ecd83323c0093f","type":"GENE","name":"MTND5P36","canonical_id":"hgnc:HGNC:51955","description":"MT-ND5 pseudogene 36","metadata":null},{"id":"61276eb6a9ed47c5b323b60caeb45016","type":"GENE","name":"MTND5P37","canonical_id":"hgnc:HGNC:51956","description":"MT-ND5 pseudogene 37","metadata":null},{"id":"11e910cd08cc4718b2c531b6166d2427","type":"GENE","name":"MTND5P38","canonical_id":"hgnc:HGNC:51957","description":"MT-ND5 pseudogene 38","metadata":null},{"id":"5a9f1e7d130b49a0bf1e0a09576732dd","type":"GENE","name":"MTND5P39","canonical_id":"hgnc:HGNC:51958","description":"MT-ND5 pseudogene 39","metadata":null},{"id":"7e9696279fb74e72a6f88aca2ad1ede9","type":"GENE","name":"MTND5P4","canonical_id":"hgnc:HGNC:42306","description":"MT-ND5 pseudogene 4","metadata":null},{"id":"24be04f0d6a64b77887b945ecd87cb76","type":"GENE","name":"MTND5P40","canonical_id":"hgnc:HGNC:51959","description":"MT-ND5 pseudogene 40","metadata":null},{"id":"f9818ad5bf2a404688f921733e334527","type":"GENE","name":"MTND5P41","canonical_id":"hgnc:HGNC:51972","description":"MT-ND5 pseudogene 41","metadata":null},{"id":"e4c18f0118e742e38043916e03b0e7be","type":"GENE","name":"MTND5P42","canonical_id":"hgnc:HGNC:52321","description":"MT-ND5 pseudogene 42","metadata":null},{"id":"68caa02122414649b0afcbd2290711f6","type":"GENE","name":"MTND5P43","canonical_id":"hgnc:HGNC:52322","description":"MT-ND5 pseudogene 43","metadata":null},{"id":"dc50131500ee46fb8b58e3a4bff51784","type":"GENE","name":"MTND5P44","canonical_id":"hgnc:HGNC:52323","description":"MT-ND5 pseudogene 44","metadata":null},{"id":"8f932fdc08eb43a0bec6ae1d6d2cb8f8","type":"GENE","name":"MTND5P45","canonical_id":"hgnc:HGNC:52333","description":"MT-ND5 pseudogene 45","metadata":null},{"id":"2c6d9e8f476f4bf6aad6f3202169adbb","type":"GENE","name":"MTND5P46","canonical_id":"hgnc:HGNC:52335","description":"MT-ND5 pseudogene 46","metadata":null},{"id":"dc0cf19651af46e9a93d0eb602d1955d","type":"GENE","name":"MTND5P5","canonical_id":"hgnc:HGNC:42307","description":"MT-ND5 pseudogene 5","metadata":null},{"id":"5d1c1568cf694f37abe71d69b13d2f7a","type":"GENE","name":"MTND5P6","canonical_id":"hgnc:HGNC:42268","description":"MT-ND5 pseudogene 6","metadata":null},{"id":"f42aebe9e02047d9bd298c7ce17b888d","type":"GENE","name":"MTND5P7","canonical_id":"hgnc:HGNC:42269","description":"MT-ND5 pseudogene 7","metadata":null},{"id":"a5b6ba1c682748f3a4136a78d2b44142","type":"GENE","name":"MTND5P8","canonical_id":"hgnc:HGNC:42270","description":"MT-ND5 pseudogene 8","metadata":null},{"id":"01a98b50b2f644df8e90168a0823960d","type":"GENE","name":"MTND5P9","canonical_id":"hgnc:HGNC:42305","description":"MT-ND5 pseudogene 9","metadata":null},{"id":"9ddcda2d76494bb7b336a752de7353ca","type":"GENE","name":"MTND6P1","canonical_id":"hgnc:HGNC:38730","description":"MT-ND6 pseudogene 1","metadata":null},{"id":"132a7f69a7eb4b8bb3d18cc4e2027259","type":"GENE","name":"MTND6P10","canonical_id":"hgnc:HGNC:39473","description":"MT-ND6 pseudogene 10","metadata":null},{"id":"b25f8de4ed0b4bccacf6ce225ff08489","type":"GENE","name":"MTND6P11","canonical_id":"hgnc:HGNC:39474","description":"MT-ND6 pseudogene 11","metadata":null},{"id":"fb6566959d8d41b6ae3faf4bdfa8365a","type":"GENE","name":"MTND6P12","canonical_id":"hgnc:HGNC:39475","description":"MT-ND6 pseudogene 12","metadata":null},{"id":"8f143cd4372f4ffe9f59dba7170cfbb7","type":"GENE","name":"MTND6P13","canonical_id":"hgnc:HGNC:39476","description":"MT-ND6 pseudogene 13","metadata":null},{"id":"86c44be14b9c4e159c058082029ab987","type":"GENE","name":"MTND6P14","canonical_id":"hgnc:HGNC:39477","description":"MT-ND6 pseudogene 14","metadata":null},{"id":"d3c849dcac264d699e8f16e9748a27d0","type":"GENE","name":"MTND6P15","canonical_id":"hgnc:HGNC:39478","description":"MT-ND6 pseudogene 15","metadata":null},{"id":"ec6b4397d2e348b9bcb3e4ab414757ba","type":"GENE","name":"MTND6P16","canonical_id":"hgnc:HGNC:39479","description":"MT-ND6 pseudogene 16","metadata":null},{"id":"347ccba0ba5847109491c6b0745982c5","type":"GENE","name":"MTND6P17","canonical_id":"hgnc:HGNC:39480","description":"MT-ND6 pseudogene 17","metadata":null},{"id":"dd7455357dbd48069ca1b7c03b3c6c7a","type":"GENE","name":"MTND6P18","canonical_id":"hgnc:HGNC:39481","description":"MT-ND6 pseudogene 18","metadata":null},{"id":"07e46c5b5afd49d7beb0f685616cf0b3","type":"GENE","name":"MTND6P19","canonical_id":"hgnc:HGNC:39482","description":"MT-ND6 pseudogene 19","metadata":null},{"id":"3e5a0531de814f3194dc748cbb0a5414","type":"GENE","name":"MTND6P2","canonical_id":"hgnc:HGNC:39465","description":"MT-ND6 pseudogene 2","metadata":null},{"id":"4b123c167fcb424c90a30a5655faaf6a","type":"GENE","name":"MTND6P20","canonical_id":"hgnc:HGNC:39483","description":"MT-ND6 pseudogene 20","metadata":null},{"id":"f4d69cb428c44ea9999c4f18961e0983","type":"GENE","name":"MTND6P21","canonical_id":"hgnc:HGNC:39639","description":"MT-ND6 pseudogene 21","metadata":null},{"id":"3414fad67b15403f8f2de1d1ea75af07","type":"GENE","name":"MTND6P22","canonical_id":"hgnc:HGNC:51978","description":"MT-ND6 pseudogene 22","metadata":null},{"id":"4731b178f9b6424e8df3dd9b3d9b0c61","type":"GENE","name":"MTND6P23","canonical_id":"hgnc:HGNC:51981","description":"MT-ND6 pseudogene 23","metadata":null},{"id":"fa3987dc5bd54e379e10bd300dafc626","type":"GENE","name":"MTND6P24","canonical_id":"hgnc:HGNC:51982","description":"MT-ND6 pseudogene 24","metadata":null},{"id":"d3de3c04a596456394f64111900fae77","type":"GENE","name":"MTND6P25","canonical_id":"hgnc:HGNC:51984","description":"MT-ND6 pseudogene 25","metadata":null},{"id":"dee54e4b5c884aabb9d345e88a4d749f","type":"GENE","name":"MTND6P26","canonical_id":"hgnc:HGNC:51985","description":"MT-ND6 pseudogene 26","metadata":null},{"id":"22d76a0577f543f3a52584a77aeb0d08","type":"GENE","name":"MTND6P27","canonical_id":"hgnc:HGNC:51986","description":"MT-ND6 pseudogene 27","metadata":null},{"id":"c06786eaeed7405ab80206d5f76b60a9","type":"GENE","name":"MTND6P28","canonical_id":"hgnc:HGNC:51987","description":"MT-ND6 pseudogene 28","metadata":null},{"id":"6911d39a1d394ee08d60bf47f6a5e81d","type":"GENE","name":"MTND6P29","canonical_id":"hgnc:HGNC:51988","description":"MT-ND6 pseudogene 29","metadata":null},{"id":"1930d56870894aefa621c5271c7ae29a","type":"GENE","name":"MTND6P3","canonical_id":"hgnc:HGNC:39466","description":"MT-ND6 pseudogene 3","metadata":null},{"id":"6558910f6ae140819871f2bb666839c4","type":"GENE","name":"MTND6P30","canonical_id":"hgnc:HGNC:51989","description":"MT-ND6 pseudogene 30","metadata":null},{"id":"8dcdd5fcf1774d848bcc9e12e30ffe5c","type":"GENE","name":"MTND6P31","canonical_id":"hgnc:HGNC:51990","description":"MT-ND6 pseudogene 31","metadata":null},{"id":"b2e6aa287bfd46b8a24db07f43486465","type":"GENE","name":"MTND6P32","canonical_id":"hgnc:HGNC:52173","description":"MT-ND6 pseudogene 32","metadata":null},{"id":"5d774adc6ac242409c6a18875dedb3df","type":"GENE","name":"MTND6P33","canonical_id":"hgnc:HGNC:52175","description":"MT-ND6 pseudogene 33","metadata":null},{"id":"ab491538f4704c4dbd8608b3fe5773d4","type":"GENE","name":"MTND6P34","canonical_id":"hgnc:HGNC:52325","description":"MT-ND6 pseudogene 34","metadata":null},{"id":"276a4074479f4a32ac98ee6ae5914b3a","type":"GENE","name":"MTND6P35","canonical_id":"hgnc:HGNC:52326","description":"MT-ND6 pseudogene 35","metadata":null},{"id":"b2e895ee508e4184b7f5fd17cea605b4","type":"GENE","name":"MTND6P36","canonical_id":"hgnc:HGNC:52327","description":"MT-ND6 pseudogene 36","metadata":null},{"id":"9058cbb64c2a401ebb36a0365a04e077","type":"GENE","name":"MTND6P37","canonical_id":"hgnc:HGNC:52328","description":"MT-ND6 pseudogene 37","metadata":null},{"id":"cdff169be30d44a8b3366dcd79e82739","type":"GENE","name":"MTND6P4","canonical_id":"hgnc:HGNC:39467","description":"MT-ND6 pseudogene 4","metadata":null},{"id":"2da25a18db1f4cf6a16dbf95381a5f1b","type":"GENE","name":"MTND6P5","canonical_id":"hgnc:HGNC:39468","description":"MT-ND6 pseudogene 5","metadata":null},{"id":"07bfcdca10d242d388c47e2c527a78f6","type":"GENE","name":"MTND6P6","canonical_id":"hgnc:HGNC:39469","description":"MT-ND6 pseudogene 6","metadata":null},{"id":"0467296d1cdd4f0ea1e55d3500662046","type":"GENE","name":"MTND6P7","canonical_id":"hgnc:HGNC:39470","description":"MT-ND6 pseudogene 7","metadata":null},{"id":"37e8798fad6d4a5e87f9f5d6c6dce77d","type":"GENE","name":"MTND6P8","canonical_id":"hgnc:HGNC:39471","description":"MT-ND6 pseudogene 8","metadata":null},{"id":"078081dd16e84eaa9d3f829f15066f38","type":"GENE","name":"MTND6P9","canonical_id":"hgnc:HGNC:39472","description":"MT-ND6 pseudogene 9","metadata":null},{"id":"f11e73e0d1de4a98b3ed724433ada954","type":"GENE","name":"MTNR1A","canonical_id":"hgnc:HGNC:7463","description":"melatonin receptor 1A","metadata":{"aliases":["MEL-1A-R"]}},{"id":"96a1865afa244c08a304cb3595e65100","type":"PROTEIN","name":"MTNR1A","canonical_id":"uniprot:P48039","description":null,"metadata":null},{"id":"a17260cf3a614d9489e598ff92e7936e","type":"GENE","name":"MTNR1B","canonical_id":"hgnc:HGNC:7464","description":"melatonin receptor 1B","metadata":null},{"id":"95415c884e124d75ae11faa720f472c7","type":"GENE","name":"MTO1","canonical_id":"hgnc:HGNC:19261","description":"mitochondrial tRNA translation optimization 1","metadata":null},{"id":"72361d8bd4de403eaedd9d7f5f09b6c9","type":"GENE","name":"MTOR","canonical_id":"hgnc:HGNC:3942","description":"mechanistic target of rapamycin kinase","metadata":{"aliases":["mTOR","RAFT1","RAPT1","FLJ44809","FRAP","FRAP2","FRAP1"]}},{"id":"8e71c634d08549b7bd674d558ffae58a","type":"PROTEIN","name":"MTOR","canonical_id":"uniprot:P42345","description":null,"metadata":null},{"id":"a33e3c9b763c4f76929719c106b215ee","type":"GENE","name":"MTOR","canonical_id":"ensembl:ENSG00000198793","description":null,"metadata":null},{"id":"4f85af23aa8842ceabe1b073494056f3","type":"DRUG","name":"MTOR Kinase Inhibitor PP242","canonical_id":"ncit:C128632","description":null,"metadata":null},{"id":"42534a1f13944e2cb7ffeee961b07839","type":"BIOMARKER","name":"MTOR Mutation OR PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation OR AKT2 Mutation","canonical_id":"civic:5287","description":null,"metadata":null},{"id":"02ea33a791534ccea6056602b77fde34","type":"GENE","name":"MTOR-AS1","canonical_id":"hgnc:HGNC:40242","description":"MTOR antisense RNA 1","metadata":null},{"id":"afe797da82fb45afa9cbe8adab422206","type":"GENE","name":"MTPAP","canonical_id":"hgnc:HGNC:25532","description":"mitochondrial poly(A) polymerase","metadata":{"aliases":["FLJ10486","SPAX4","TENT6","PAPD1"]}},{"id":"00a9b88991c74e3bb8acdcb757d78d9d","type":"GENE","name":"MTPN","canonical_id":"hgnc:HGNC:15667","description":"myotrophin","metadata":{"aliases":["MYOTROPHIN","GCDP","V-1"]}},{"id":"24b24a39d24f498e997139765ddec69b","type":"GENE","name":"MTR","canonical_id":"hgnc:HGNC:7468","description":"5-methyltetrahydrofolate-homocysteine methyltransferase","metadata":{"aliases":["cblG"]}},{"id":"ef32a3f53c2b488ea544b516e213f872","type":"GO_TERM","name":"MTREC complex","canonical_id":"go:GO:1990477","description":"\"Protein complex formed by an RNA binding protein Red1, an RNA helicase Mtl1, Red5, Rmn1, Iss10/Pir1, and Ars2/Pir2. This complex is required for the recruitment of the nuclear exosome to Mmi1 nuclear focus. It is likely related to the human CBCN complex. This complex is also known as RNA silencing (NURS) complex.\" [PMID:24210919, PMID:24713849, PMID:32012158]","metadata":null},{"id":"7e952be6f1e94308b36e9dea6379720f","type":"GO_TERM","name":"MTREC complex binding","canonical_id":"go:GO:1905763","description":"\"Binding to a MTREC complex.\" [GOC:TermGenie, PMID:26942678]","metadata":null},{"id":"c4c4a20b187c420eb666bd431459deb4","type":"GENE","name":"MTRES1","canonical_id":"hgnc:HGNC:17971","description":"mitochondrial transcription rescue factor 1","metadata":{"aliases":["HSPC230","PRED31","C6orf203"]}},{"id":"d6cdcb1c26f4440cbfceda9b3628733b","type":"GENE","name":"MTRES1P1","canonical_id":"hgnc:HGNC:54502","description":"MTRES1 pseudogene 1","metadata":null},{"id":"262db1d86b704d378bbb1eae1ff07307","type":"GENE","name":"MTRES1P2","canonical_id":"hgnc:HGNC:54503","description":"MTRES1 pseudogene 2","metadata":null},{"id":"5bf4c77a1c944a50bd8aa4916f1f3aa0","type":"GENE","name":"MTREX","canonical_id":"hgnc:HGNC:18734","description":"Mtr4 exosome RNA helicase","metadata":{"aliases":["Mtr4","Dob1","fSAP118","KIAA0052","SKIV2L2"]}},{"id":"f31798bb9b0744f0b61d2dff14924bf3","type":"GENE","name":"MTREX-AS1","canonical_id":"hgnc:HGNC:59045","description":"MTREX antisense RNA 1","metadata":null},{"id":"fa0e3dce73694723a6e2f789b3e8d985","type":"GENE","name":"MTRF1","canonical_id":"hgnc:HGNC:7469","description":"mitochondrial translation release factor 1","metadata":{"aliases":["RF1","MTTRF1","MGC47721"]}},{"id":"73141bd449a647aa915b6c6248aad8fb","type":"GENE","name":"MTRF1L","canonical_id":"hgnc:HGNC:21051","description":"mitochondrial translation release factor 1 like","metadata":{"aliases":["HMRF1L","mtRF1a"]}},{"id":"bb7bb2bd440344a49e50182b76668226","type":"GENE","name":"MTRF1LP1","canonical_id":"hgnc:HGNC:50611","description":"mitochondrial translational release factor 1 like pseudogene 1","metadata":null},{"id":"c16e0405df344e0ca79d6e149a69e63f","type":"GENE","name":"MTRF1LP2","canonical_id":"hgnc:HGNC:50612","description":"mitochondrial translational release factor 1 like pseudogene 2","metadata":null},{"id":"b4a04b4ea23443d190d222bfb3ad66ce","type":"GENE","name":"MTRFR","canonical_id":"hgnc:HGNC:26784","description":"mitochondrial translation release factor in rescue","metadata":{"aliases":["FLJ38663","SPG55","COXPD7","mtRF-R","C12orf65"]}},{"id":"a59f906c5a44410aa8ec8d6b4f40ca80","type":"GENE","name":"MTRNR2L1","canonical_id":"hgnc:HGNC:37155","description":"MT-RNR2 like 1 (pseudogene)","metadata":{"aliases":["RNA143598"]}},{"id":"1ec6ca1e675f4ff2b883f7b0dd2aacd8","type":"GENE","name":"MTRNR2L10","canonical_id":"hgnc:HGNC:37167","description":"MT-RNR2 like 10 (pseudogene)","metadata":null},{"id":"f49fcbadc92c43a5b6e1a9b8bd3666a8","type":"GENE","name":"MTRNR2L11","canonical_id":"hgnc:HGNC:37168","description":"MT-RNR2 like 11 (pseudogene)","metadata":null},{"id":"7e0f6a989f914a2aac3be2b4769a73c4","type":"GENE","name":"MTRNR2L12","canonical_id":"hgnc:HGNC:37169","description":"MT-RNR2 like 12 (pseudogene)","metadata":null},{"id":"f16a08224ca048c19ad503636c72a474","type":"GENE","name":"MTRNR2L13","canonical_id":"hgnc:HGNC:37170","description":"MT-RNR2 like 13 (pseudogene)","metadata":null},{"id":"fac23d5fa5cb494cb154b9c8fdd97371","type":"GENE","name":"MTRNR2L2","canonical_id":"hgnc:HGNC:37156","description":"MT-RNR2 like 2 (pseudogene)","metadata":null},{"id":"9b96888d892341c8970ac9897ddff58b","type":"GENE","name":"MTRNR2L3","canonical_id":"hgnc:HGNC:37157","description":"MT-RNR2 like 3 (pseudogene)","metadata":null},{"id":"5a1a636aae8d4effaea0b861f7ec7974","type":"GENE","name":"MTRNR2L4","canonical_id":"hgnc:HGNC:37161","description":"MT-RNR2 like 4 (pseudogene)","metadata":null},{"id":"09f340c2798748ddbd7423051a7b4321","type":"GENE","name":"MTRNR2L5","canonical_id":"hgnc:HGNC:37162","description":"MT-RNR2 like 5 (pseudogene)","metadata":null},{"id":"416174e3b3c84154a543611d316c99e2","type":"GENE","name":"MTRNR2L6","canonical_id":"hgnc:HGNC:37163","description":"MT-RNR2 like 6 (pseudogene)","metadata":null},{"id":"cf5797f0263f465a9cdd330c700c9720","type":"GENE","name":"MTRNR2L7","canonical_id":"hgnc:HGNC:37164","description":"MT-RNR2 like 7 (pseudogene)","metadata":null},{"id":"d65829ce7f1b4133b21b3ad7ebea4a96","type":"GENE","name":"MTRNR2L8","canonical_id":"hgnc:HGNC:37165","description":"MT-RNR2 like 8 (pseudogene)","metadata":null},{"id":"3c16f0ea323b4466834090ebed460f83","type":"GENE","name":"MTRNR2L9","canonical_id":"hgnc:HGNC:37166","description":"MT-RNR2 like 9 (pseudogene)","metadata":null},{"id":"88bcc67783a04818bae176fd85738c0b","type":"GENE","name":"MTRR","canonical_id":"hgnc:HGNC:7473","description":"5-methyltetrahydrofolate-homocysteine methyltransferase reductase","metadata":{"aliases":["cblE"]}},{"id":"3794f6e559204bc79d55852717de3064","type":"GENE","name":"MTSS1","canonical_id":"hgnc:HGNC:20443","description":"MTSS I-BAR domain containing 1","metadata":{"aliases":["KIAA0429","MIMA","MIMB","MIM"]}},{"id":"cbb88f70e684463b8b99f4a3d4d8b8f3","type":"GENE","name":"MTSS2","canonical_id":"hgnc:HGNC:25094","description":"MTSS I-BAR domain containing 2","metadata":{"aliases":["ABBA-1","LOC92154","ABBA","MTSS1L"]}},{"id":"185130b391d9425c9852db92b1df140d","type":"GENE","name":"MTTP","canonical_id":"hgnc:HGNC:7467","description":null,"metadata":null},{"id":"59c040ca76b84b55b7a358923396d973","type":"GENE","name":"MTTP-AS1","canonical_id":"hgnc:HGNC:54189","description":"MTTP antisense RNA 1","metadata":null},{"id":"60737b52e9d544769fb27fc34d27ddb3","type":"GENE","name":"MTURN","canonical_id":"hgnc:HGNC:25457","description":"maturin, neural progenitor differentiation regulator homolog","metadata":{"aliases":["FLJ25903","Ells1","C7orf41"]}},{"id":"56759104bd19410096cd2a8825b3ff9a","type":"GENE","name":"MTUS1","canonical_id":"hgnc:HGNC:29789","description":"microtubule associated scaffold protein 1","metadata":{"aliases":["MTSG1","KIAA1288","DKFZp586D1519","FLJ14295","ATIP1","MP44","ATBP","ICIS","ATIP3"]}},{"id":"192794547242465db18e904ca6c44347","type":"GENE","name":"MTUS1-DT","canonical_id":"hgnc:HGNC:55525","description":"MTUS1 divergent transcript","metadata":null},{"id":"1f43d6214838493290bef8b0bf5ae1ac","type":"GENE","name":"MTUS2","canonical_id":"hgnc:HGNC:20595","description":"microtubule associated scaffold protein 2","metadata":{"aliases":["TIP150","CAZIP","ICIS","KIAA0774"]}},{"id":"78ca5786914b44e99d2945524bfc751b","type":"GENE","name":"MTUS2-AS1","canonical_id":"hgnc:HGNC:40924","description":"MTUS2 antisense RNA 1","metadata":null},{"id":"81b2a0986843480493632ebe1e83fb04","type":"GENE","name":"MTUS2-AS2","canonical_id":"hgnc:HGNC:40923","description":"MTUS2 antisense RNA 2","metadata":null},{"id":"9cad201a63ad46b1bc5adfcdcf7ef97d","type":"TRIAL","name":"MTX Discontinuation and Vaccine Response","canonical_id":"clinicaltrials.gov:NCT02748785","description":"Arthritis, Rheumatoid","metadata":null},{"id":"184a635f9a9542d49983a689ca7f4aec","type":"GENE","name":"MTX1","canonical_id":"hgnc:HGNC:7504","description":"metaxin 1","metadata":{"aliases":["MTXN","MTX"]}},{"id":"d03dd2dcc0d74c268efd21dca83a0eec","type":"GENE","name":"MTX1LP","canonical_id":"hgnc:HGNC:7505","description":"metaxin 1 like, pseudogene","metadata":{"aliases":["MTXP","MTX1P","MTX1P1"]}},{"id":"1f00666c90e848b3a2124ff8ead3cce2","type":"GENE","name":"MTX2","canonical_id":"hgnc:HGNC:7506","description":"metaxin 2","metadata":null},{"id":"e5810628c5ab4c5ea110fb60df59c2fd","type":"GENE","name":"MTX2P1","canonical_id":"hgnc:HGNC:56269","description":"MTX2 pseudogene 1","metadata":null},{"id":"834f5194acf34a038eaecda815eb2702","type":"GENE","name":"MTX3","canonical_id":"hgnc:HGNC:24812","description":"metaxin 3","metadata":null},{"id":"08a605243fc447cdba2a12196d6b773d","type":"GO_TERM","name":"MUB1-RAD6-UBR2 ubiquitin ligase complex","canonical_id":"go:GO:1990304","description":"\"A ubiquitin ligase complex consisting of MUB1, RAD6 and UBR2 components. It ubiquitinates, and targets for destruction, the RPN4 transcription factor, which upregulates the proteasome genes. The binding of MUB1 may position the RPN4 ubiquitylation site proximal to the Ubiquitin-RAD6 thioester and allow the transfer of Ubiquitin from RAD6 to RPN4. One of its components, MUB1, is a short-lived protein ubiquitinated by the UBR2-RAD6 ubiquitin conjugating enzyme.\" [GOC:bhm, PMID:18070918]","metadata":null},{"id":"4f62de918fad4c88b5e65510c59263c4","type":"GENE","name":"MUC1","canonical_id":"hgnc:HGNC:7508","description":null,"metadata":null},{"id":"ec784e90035d4743a43bdb0abfbcc212","type":"GENE","name":"MUC12","canonical_id":"hgnc:HGNC:7510","description":"mucin 12, cell surface associated","metadata":{"aliases":["MUC11"]}},{"id":"79a6b0e79e934c1b94bccea26e7979db","type":"GENE","name":"MUC12-AS1","canonical_id":"hgnc:HGNC:40382","description":"MUC12 antisense RNA 1","metadata":null},{"id":"433e6ea6179349e8a53bdc8d0618a33a","type":"GENE","name":"MUC13","canonical_id":"hgnc:HGNC:7511","description":"mucin 13, cell surface associated","metadata":{"aliases":["DRCC1"]}},{"id":"97d83adbd3ff40b39bef6100629a1077","type":"GENE","name":"MUC15","canonical_id":"hgnc:HGNC:14956","description":"mucin 15, cell surface associated","metadata":null},{"id":"2eb16d05a3ef4510977469a37fbd3749","type":"GENE","name":"MUC16","canonical_id":"hgnc:HGNC:15582","description":"mucin 16, cell surface associated","metadata":{"aliases":["CA125","FLJ14303","CA-125"]}},{"id":"36597c14c962494bb44bcaa255a03d64","type":"GENE","name":"MUC17","canonical_id":"hgnc:HGNC:16800","description":null,"metadata":null},{"id":"3feca3c0af054d80b8191669d69ed753","type":"GENE","name":"MUC19","canonical_id":"hgnc:HGNC:14362","description":"mucin 19, oligomeric (gene/pseudogene)","metadata":{"aliases":["FLJ35746"]}},{"id":"4775675598924d05b0718707c3a96618","type":"GENE","name":"MUC2","canonical_id":"hgnc:HGNC:7512","description":null,"metadata":null},{"id":"958ebb5565b14072ab86d320b0994e30","type":"GENE","name":"MUC20","canonical_id":"hgnc:HGNC:23282","description":"mucin 20, cell surface associated","metadata":{"aliases":["FLJ14408","KIAA1359"]}},{"id":"08b4034f16774eb4ba00e30e0eba9347","type":"GENE","name":"MUC20-OT1","canonical_id":"hgnc:HGNC:53807","description":"MUC20 overlapping transcript","metadata":{"aliases":["MUCP1"]}},{"id":"2a6ff1ac59214c74b6660f0f09475f61","type":"GENE","name":"MUC20P1","canonical_id":"hgnc:HGNC:51921","description":"mucin 20, cell surface associated pseudogene 1","metadata":null},{"id":"69d0a07184ce417dbea1c21865b4447d","type":"GENE","name":"MUC21","canonical_id":"hgnc:HGNC:21661","description":"mucin 21, cell surface associated","metadata":{"aliases":["bCX31G15.2","C6orf205"]}},{"id":"0a702a21960340c39e64648fb260042d","type":"GENE","name":"MUC22","canonical_id":"hgnc:HGNC:39755","description":"mucin 22","metadata":{"aliases":["PBMUCL1"]}},{"id":"c1fb7ae8e9774aba9e2ce74e37c8d972","type":"GENE","name":"MUC3A","canonical_id":"hgnc:HGNC:7513","description":null,"metadata":null},{"id":"ceab509a583c4f7faeb76378efdaf3dd","type":"GENE","name":"MUC3B","canonical_id":"hgnc:HGNC:13384","description":"mucin 3B, cell surface associated","metadata":null},{"id":"6893e0fa325c46ef8e335b66fe71a500","type":"GENE","name":"MUC4","canonical_id":"hgnc:HGNC:7514","description":null,"metadata":null},{"id":"b66e127d297043d181146af0b9e4dec2","type":"GENE","name":"MUC5AC","canonical_id":"hgnc:HGNC:7515","description":null,"metadata":null},{"id":"562511b9562348ca83cf64850c08ee86","type":"GENE","name":"MUC5B","canonical_id":"hgnc:HGNC:7516","description":null,"metadata":null},{"id":"8e8a019892f54f11819001e76fbeed95","type":"GENE","name":"MUC5B-AS1","canonical_id":"hgnc:HGNC:53936","description":"MUC5B antisense RNA 1","metadata":null},{"id":"cc4592ef68ab479293da60ca46737ca5","type":"GENE","name":"MUC6","canonical_id":"hgnc:HGNC:7517","description":null,"metadata":null},{"id":"62cbaec4009840bcb405aa70c7f52fde","type":"GENE","name":"MUC7","canonical_id":"hgnc:HGNC:7518","description":"mucin 7, secreted","metadata":{"aliases":["FLJ27047","MG2"]}},{"id":"928ec2b9693647ae82100192ce4aeb0d","type":"GENE","name":"MUC8","canonical_id":"hgnc:HGNC:7519","description":"mucin 8","metadata":null},{"id":"1820622dde9548dea3664853e3897bdc","type":"GENE","name":"MUCL1","canonical_id":"hgnc:HGNC:30588","description":"mucin like 1","metadata":{"aliases":["SBEM"]}},{"id":"9d627af0dc5b4a0cb2dfb517e3b9c1c9","type":"GENE","name":"MUCL3","canonical_id":"hgnc:HGNC:21666","description":"mucin like 3","metadata":{"aliases":["PBLT","bCX105N19.6","C6orf37","DPCR1"]}},{"id":"78a969a925484e8abf0e87adf82152de","type":"GENE","name":"MUL1","canonical_id":"hgnc:HGNC:25762","description":"mitochondrial E3 ubiquitin protein ligase 1","metadata":{"aliases":["FLJ12875","MULAN","RNF218","MAPL","GIDE","C1orf166"]}},{"id":"33a51147be8649a4874cbddeed7281bc","type":"GENE","name":"MUPP","canonical_id":"hgnc:HGNC:49202","description":"major urinary protein, pseudogene","metadata":null},{"id":"42b2aa0beb8a4fae982503083ccdf61f","type":"GENE","name":"MUS81","canonical_id":"hgnc:HGNC:29814","description":"MUS81 structure-specific endonuclease subunit","metadata":{"aliases":["FLJ44872","SLX3"]}},{"id":"19db2379992c4915a0c9dd8d807a212b","type":"GENE","name":"MUSK","canonical_id":"hgnc:HGNC:7525","description":"muscle associated receptor tyrosine kinase","metadata":null},{"id":"99dd372148754dbc845b421d514f4ca0","type":"GENE","name":"MUSTN1","canonical_id":"hgnc:HGNC:22144","description":"musculoskeletal, embryonic nuclear protein 1","metadata":{"aliases":["Mustang"]}},{"id":"f7157c3a247d467fbac0bfea3edb16ab","type":"GENE","name":"MUTYH","canonical_id":"hgnc:HGNC:7527","description":"mutY DNA glycosylase","metadata":{"aliases":["MYH"]}},{"id":"8c3b207007a84724ade98f48d3e91712","type":"GENE","name":"MVB12A","canonical_id":"hgnc:HGNC:25153","description":"multivesicular body subunit 12A","metadata":{"aliases":["FLJ32495","FAM125A"]}},{"id":"783bfe660984415da87091def7ad7227","type":"GENE","name":"MVB12B","canonical_id":"hgnc:HGNC:23368","description":"multivesicular body subunit 12B","metadata":{"aliases":["FLJ00001","C9orf28","FAM125B"]}},{"id":"eb44683deed7434fa19f78d70724034f","type":"GENE","name":"MVD","canonical_id":"hgnc:HGNC:7529","description":"mevalonate diphosphate decarboxylase","metadata":{"aliases":["MPD"]}},{"id":"c457d4d7acb9411f9ad285d5113b25ea","type":"GENE","name":"MVK","canonical_id":"hgnc:HGNC:7530","description":"mevalonate kinase","metadata":{"aliases":["LRBP","MK"]}},{"id":"6c050067ad19427695bf0229eb26a0a9","type":"GENE","name":"MVP","canonical_id":"hgnc:HGNC:7531","description":null,"metadata":null},{"id":"b118defe15fb4c8a8de745ed87c41fe9","type":"GENE","name":"MVP-DT","canonical_id":"hgnc:HGNC:56029","description":"MVP divergent transcript","metadata":{"aliases":["AC009133.12"]}},{"id":"385fb5f7be9546e98284f63001764a8c","type":"GO_TERM","name":"MWP complex","canonical_id":"go:GO:1990811","description":"\"A protein ternary complex that anchors microtubule minus ends to mitotic spindle pole bodies. The founding complex contains a microtubule anchoring protein (Msd1 in fission yeast), A WD-repeat Wdr8 family protein and and a minus end-directed kinesin.\" [PMID:25987607, PMID:29021344]","metadata":null},{"id":"3587a5c6a9714ac4b76c254ec0087cb3","type":"GENE","name":"MX1","canonical_id":"hgnc:HGNC:7532","description":null,"metadata":null},{"id":"2a8198acc85f45e8b6c0b94703b9eb03","type":"GENE","name":"MX1-AS1","canonical_id":"hgnc:HGNC:40383","description":"MX1 antisense RNA 1","metadata":{"aliases":["hLinfRNA3","AP001610.5"]}},{"id":"1e7fbfb630dc47edbd9b6e3868c482bf","type":"GENE","name":"MX2","canonical_id":"hgnc:HGNC:7533","description":"MX dynamin like GTPase 2","metadata":{"aliases":["MXB"]}},{"id":"40465e26e9b94c77b1478311c4a8db66","type":"GENE","name":"MXD1","canonical_id":"hgnc:HGNC:6761","description":null,"metadata":null},{"id":"5dde48da39d8454889fd918f564e0e8e","type":"GENE","name":"MXD3","canonical_id":"hgnc:HGNC:14008","description":"MAX dimerization protein 3","metadata":{"aliases":["MAD3","bHLHc13"]}},{"id":"873dacf5b4f440148a1193bfdcd62d25","type":"GENE","name":"MXD4","canonical_id":"hgnc:HGNC:13906","description":null,"metadata":null},{"id":"28acaf0f5509460ebe15d6672bf65857","type":"GENE","name":"MXI1","canonical_id":"hgnc:HGNC:7534","description":null,"metadata":null},{"id":"4aa57dd77c9f44eea033aeef9fc25f0e","type":"GENE","name":"MXRA5","canonical_id":"hgnc:HGNC:7539","description":"matrix remodeling associated 5","metadata":{"aliases":["DKFZp564I1922"]}},{"id":"f6e8456e847f469d8de8d6ddcfffa7c2","type":"GENE","name":"MXRA5Y","canonical_id":"hgnc:HGNC:23932","description":"matrix remodeling associated 5 Y-linked (pseudogene)","metadata":{"aliases":["ADLICANP","MXRA5P","MXRA5P1"]}},{"id":"20262b93149a498ea9afdc091d77bc76","type":"GENE","name":"MXRA7","canonical_id":"hgnc:HGNC:7541","description":"matrix remodeling associated 7","metadata":{"aliases":["FLJ46603","TMAP1","PS1TP1"]}},{"id":"1222c9b1b8bc4f0783320a01579405a7","type":"GENE","name":"MXRA7P1","canonical_id":"hgnc:HGNC:54643","description":"MXRA7 pseudogene 1","metadata":null},{"id":"c5c4ee4f22fc4fa9952e3dd03c45a534","type":"GENE","name":"MXRA8","canonical_id":"hgnc:HGNC:7542","description":"matrix remodeling associated 8","metadata":{"aliases":["DKFZp586E2023"]}},{"id":"b5fd9518a48c40bdbf2fce7578ed2324","type":"GENE","name":"MYADM","canonical_id":"hgnc:HGNC:7544","description":"myeloid associated differentiation marker","metadata":null},{"id":"75151211d1b3452884bb80897f303624","type":"GENE","name":"MYADM-AS1","canonical_id":"hgnc:HGNC:40384","description":"MYADM antisense RNA 1","metadata":null},{"id":"780e351ca78a42458d752175898be0e5","type":"GENE","name":"MYADM-AS2","canonical_id":"hgnc:HGNC:40385","description":"MYADM antisense RNA 2","metadata":{"aliases":["VEAL2"]}},{"id":"81de67f6e78a41be8f16ec859f3d0625","type":"GENE","name":"MYADML","canonical_id":"hgnc:HGNC:31019","description":"myeloid associated differentiation marker like (pseudogene)","metadata":null},{"id":"c49fb0e4b19940cc8312e4babf51887a","type":"GENE","name":"MYADML2","canonical_id":"hgnc:HGNC:34548","description":"myeloid associated differentiation marker like 2","metadata":{"aliases":["LOC255275"]}},{"id":"fb40ec12c9454592a3ba3690b4c20a44","type":"GENE","name":"MYB","canonical_id":"hgnc:HGNC:7545","description":null,"metadata":null},{"id":"08d3d82d112f49bfa12949fb16b7d8fe","type":"GENE","name":"MYB-AS1","canonical_id":"hgnc:HGNC:37457","description":"MYB antisense RNA 1","metadata":{"aliases":["RP1-32B1.3","NCRNA00209","MYBAS","MYB-AS"]}},{"id":"6272b7a6aaf14649a809d835df4f3f75","type":"GENE","name":"MYBBP1A","canonical_id":"hgnc:HGNC:7546","description":null,"metadata":null},{"id":"f8ea0a02c8364851b869aaedd910293e","type":"GENE","name":"MYBL1","canonical_id":"hgnc:HGNC:7547","description":null,"metadata":null},{"id":"54580925ae304af5861ca0700faab466","type":"GENE","name":"MYBL2","canonical_id":"hgnc:HGNC:7548","description":null,"metadata":null},{"id":"1607c3dca2a04153ac79224e54e15cfc","type":"GENE","name":"MYBPC1","canonical_id":"hgnc:HGNC:7549","description":"myosin binding protein C1","metadata":{"aliases":["ssMyBP-C"]}},{"id":"aca792c02da9464a8118283857f7499e","type":"GENE","name":"MYBPC2","canonical_id":"hgnc:HGNC:7550","description":"myosin binding protein C2","metadata":{"aliases":["MYBPCF","MGC163408","fsMyBP-C"]}},{"id":"51f8fa78a7194c619231009a4c5afd34","type":"GENE","name":"MYBPC3","canonical_id":"hgnc:HGNC:7551","description":"myosin binding protein C3","metadata":{"aliases":["FHC","cMyBP-C","CMH4"]}},{"id":"cfcc9ae4ea68463189bcbf604acdbc5f","type":"GENE","name":"MYBPH","canonical_id":"hgnc:HGNC:7552","description":"myosin binding protein H","metadata":null},{"id":"a8454660c6d74d078bb9bfa59f80b501","type":"GENE","name":"MYBPHL","canonical_id":"hgnc:HGNC:30434","description":"myosin binding protein H like","metadata":null},{"id":"b7f316392d20417abaa06a4863c4eafe","type":"GENE","name":"MYC","canonical_id":"hgnc:HGNC:7553","description":null,"metadata":null},{"id":"7f1d44791e6c4f37a88947b8bc6fbd61","type":"GENE","name":"MYC","canonical_id":"ensembl:ENSG00000136997","description":null,"metadata":null},{"id":"b1db32951c8d4f9caa8931bafdd1229c","type":"GENE","name":"MYCBP","canonical_id":"hgnc:HGNC:7554","description":null,"metadata":null},{"id":"8c3f05060a0f4c67beed5ff6a620fd0c","type":"GENE","name":"MYCBP2","canonical_id":"hgnc:HGNC:23386","description":"MYC binding protein 2","metadata":{"aliases":["PAM","KIAA0916","FLJ10106","PHR1"]}},{"id":"8d63bd275bdc4f868c4b2d0693d4c80d","type":"GENE","name":"MYCBP2-AS1","canonical_id":"hgnc:HGNC:41023","description":"MYCBP2 antisense RNA 1","metadata":null},{"id":"440d9b36046e4447aec08924d798296d","type":"GENE","name":"MYCBP2-AS2","canonical_id":"hgnc:HGNC:41024","description":"MYCBP2 antisense RNA 2","metadata":null},{"id":"8de8fa9743f84ffda6a49919a26128c6","type":"GENE","name":"MYCBPAP","canonical_id":"hgnc:HGNC:19677","description":"MYCBP associated protein","metadata":{"aliases":["AMAP-1","DKFZp434N1415"]}},{"id":"a103335765204889a603afdbdcf6f145","type":"GENE","name":"MYCL","canonical_id":"hgnc:HGNC:7555","description":"MYCL proto-oncogene, bHLH transcription factor","metadata":{"aliases":["LMYC","bHLHe38","MYCL1"]}},{"id":"5674ce4d48354522ae2b1125aef5f3d6","type":"GENE","name":"MYCL-AS1","canonical_id":"hgnc:HGNC:40386","description":"MYCL antisense RNA 1","metadata":null},{"id":"30ff3f94ee4c4187a468a5fdc2699c14","type":"GENE","name":"MYCLP1","canonical_id":"hgnc:HGNC:7556","description":"MYCL pseudogene 1","metadata":{"aliases":["MYCL2","MYCL1P1"]}},{"id":"5eb703713746413fa9218334f77b1a74","type":"GENE","name":"MYCLP2","canonical_id":"hgnc:HGNC:48924","description":"MYCL pseudogene 2","metadata":null},{"id":"d1a4b9210c3141d0beacc1dc7b072e0c","type":"GENE","name":"MYCLP3","canonical_id":"hgnc:HGNC:7557","description":"MYCL pseudogene 3","metadata":{"aliases":["MYCL3"]}},{"id":"2228528b2acf46d3bbc4fba338330b54","type":"GENE","name":"MYCN","canonical_id":"hgnc:HGNC:7559","description":null,"metadata":null},{"id":"75d32c0ca5f24ad69b5c408605f772a3","type":"GENE","name":"MYCNOS","canonical_id":"hgnc:HGNC:16911","description":"MYCN opposite strand","metadata":{"aliases":["NCYM","N-CYM","MYCN-AS1"]}},{"id":"80ccd4c9d36144c4a3298f713e8a0eb4","type":"GENE","name":"MYCNUT","canonical_id":"hgnc:HGNC:32684","description":"MYCN upstream transcript","metadata":{"aliases":["lncUSMycN","MYCNUN"]}},{"id":"714905d4d2304f6091494024b677bce1","type":"GENE","name":"MYCT1","canonical_id":"hgnc:HGNC:23172","description":"MYC target 1","metadata":{"aliases":["MTLC","FLJ21269"]}},{"id":"476d0ea4ea7a40488100c8e16fd6e4ce","type":"GENE","name":"MYD88","canonical_id":"hgnc:HGNC:7562","description":null,"metadata":null},{"id":"b32d4f58190e4248b7ac3a77958d48fc","type":"GENE","name":"MYDGF","canonical_id":"hgnc:HGNC:16948","description":"myeloid derived growth factor","metadata":{"aliases":["R33729_1","IL25","SF20","IL-25","IL-27","IL27","IL27w","C19orf10"]}},{"id":"220ec524f0044261b86a285c202927e3","type":"GENE","name":"MYEF2","canonical_id":"hgnc:HGNC:17940","description":null,"metadata":null},{"id":"9626cc9800864dc9be791ebebeef3ef8","type":"TRIAL","name":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","canonical_id":"clinicaltrials.gov:NCT05564390","description":"Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Acute Myeloid Leukemia, Myelodysplasia-Related; Myelodysplastic Syndrome","metadata":null},{"id":"4a4876b8a6434819a8d085e79df48dbf","type":"GENE","name":"MYEOV","canonical_id":"hgnc:HGNC:7563","description":"myeloma overexpressed","metadata":{"aliases":["OCIM"]}},{"id":"8571a4c7193d45d09f9284c64e1b11ba","type":"GENE","name":"MYF5","canonical_id":"hgnc:HGNC:7565","description":"myogenic factor 5","metadata":{"aliases":["bHLHc2"]}},{"id":"addb7467f0824c8c824c40de2943fe3b","type":"GENE","name":"MYF6","canonical_id":"hgnc:HGNC:7566","description":null,"metadata":null},{"id":"2b071e2e2a5d40c588e7646557fde774","type":"GENE","name":"MYG1","canonical_id":"hgnc:HGNC:17590","description":"MYG1 exonuclease","metadata":{"aliases":["MYG","Gamm1","C12orf10"]}},{"id":"24d7dbc1801142c489bf27b3227a2b5e","type":"GENE","name":"MYG1-AS1","canonical_id":"hgnc:HGNC:54810","description":"MYG1 antisense RNA 1","metadata":null},{"id":"42be5730a9da4ca19c93d7e08b6158e6","type":"GENE","name":"MYG1P1","canonical_id":"hgnc:HGNC:54725","description":"MYG1 pseudogene 1","metadata":{"aliases":["C12orf10P1"]}},{"id":"1cbe55c30fe5491eb82a61e842776c1e","type":"GENE","name":"MYH1","canonical_id":"hgnc:HGNC:7567","description":"myosin heavy chain 1","metadata":{"aliases":["MYHSA1","MYHa","MyHC-2X/D","MGC133384"]}},{"id":"e5e9705e70e04446a010742fbcb45df5","type":"GENE","name":"MYH10","canonical_id":"hgnc:HGNC:7568","description":null,"metadata":null},{"id":"8cd46b737c434328955e2a10cd681b97","type":"GENE","name":"MYH11","canonical_id":"hgnc:HGNC:7569","description":null,"metadata":null},{"id":"feb45230891e46e2bfcfa0f6d3fec718","type":"GENE","name":"MYH13","canonical_id":"hgnc:HGNC:7571","description":"myosin heavy chain 13","metadata":{"aliases":["MyHC-eo"]}},{"id":"1539b4b3c511448e8ff4d08602394098","type":"GENE","name":"MYH14","canonical_id":"hgnc:HGNC:23212","description":"myosin heavy chain 14","metadata":{"aliases":["FLJ13881","KIAA2034","MHC16","MYH17","DFNA4"]}},{"id":"1a96f9db44b2421cae4b29ebff30bcc1","type":"GENE","name":"MYH15","canonical_id":"hgnc:HGNC:31073","description":"myosin heavy chain 15","metadata":{"aliases":["KIAA1000"]}},{"id":"c74a59dec8c24c99aa4b7aab22930233","type":"GENE","name":"MYH16","canonical_id":"hgnc:HGNC:31038","description":"myosin heavy chain 16","metadata":{"aliases":["MHC20","MYH16P","MYH5"]}},{"id":"b88c6753897d4424a3c13d191822d337","type":"GENE","name":"MYH2","canonical_id":"hgnc:HGNC:7572","description":"myosin heavy chain 2","metadata":{"aliases":["MYH2A","MYHSA2","MyHC-IIa","MYHas8","MyHC-2A","IBM3"]}},{"id":"1b1346cda4ec4ab299b0358a9e5dfd01","type":"GENE","name":"MYH3","canonical_id":"hgnc:HGNC:7573","description":"myosin heavy chain 3","metadata":{"aliases":["MYHC-EMB","MYHSE1","HEMHC","SMHCE"]}},{"id":"6c49ab72b76c4daf9d8d551af70f96f0","type":"GENE","name":"MYH4","canonical_id":"hgnc:HGNC:7574","description":"myosin heavy chain 4","metadata":{"aliases":["MYH2B","MyHC-2B","MyHC-IIb"]}},{"id":"ff8ba6c278e74aa1a2c9051722bb7e09","type":"GENE","name":"MYH6","canonical_id":"hgnc:HGNC:7576","description":null,"metadata":null},{"id":"73879d0703d5433da7099bd4b0d4c44f","type":"GENE","name":"MYH7","canonical_id":"hgnc:HGNC:7577","description":"myosin heavy chain 7","metadata":{"aliases":["CMD1S","CMH1","MPD1"]}},{"id":"28fd46946fe14e5b811af792cf968531","type":"GENE","name":"MYH7B","canonical_id":"hgnc:HGNC:15906","description":"myosin heavy chain 7B","metadata":{"aliases":["KIAA1512","dJ756N5.1","MYH14","MHC14","lncMYH7b"]}},{"id":"c0a2c78bbb49402cbfca965ea736a358","type":"GENE","name":"MYH8","canonical_id":"hgnc:HGNC:7578","description":"myosin heavy chain 8","metadata":{"aliases":["MyHC-peri","MyHC-pn"]}},{"id":"1475f57e4af148e7b20f99e96ae21fc9","type":"GENE","name":"MYH9","canonical_id":"hgnc:HGNC:7579","description":null,"metadata":null},{"id":"67acfe8f8a39451589a256e26b2da928","type":"GENE","name":"MYH9-DT","canonical_id":"hgnc:HGNC:55867","description":"MYH9 divergent transcript","metadata":null},{"id":"ae771af1a4a44f3eb1303e2be7493d0b","type":"GENE","name":"MYHAS","canonical_id":"hgnc:HGNC:50609","description":"myosin heavy chain gene cluster antisense RNA","metadata":{"aliases":["linc-MYH"]}},{"id":"1ac062fb975347659861c423536fc2b9","type":"GENE","name":"MYL1","canonical_id":"hgnc:HGNC:7582","description":"myosin light chain 1","metadata":{"aliases":["MLC1","MLC1F","MLC3F","MLC-1","MLC1/3"]}},{"id":"35f413d0e1ec44028aa9e12439baecc1","type":"GENE","name":"MYL10","canonical_id":"hgnc:HGNC:29825","description":"myosin light chain 10","metadata":{"aliases":["MGC3479","MYLC2PL","PLRLC"]}},{"id":"ebff4df420e44281ac19fc10d7fe8a72","type":"GENE","name":"MYL11","canonical_id":"hgnc:HGNC:29824","description":"myosin light chain 11","metadata":{"aliases":["MRLC2","HUMMLC2B","MYLPF"]}},{"id":"a88f5de6e58b4a57aa59bb71a2f665b1","type":"GENE","name":"MYL12-AS1","canonical_id":"hgnc:HGNC:55331","description":"MYL12A and MYL12B antisense RNA 1","metadata":null},{"id":"554fef3545f94c16b5f9caf2603e99e0","type":"GENE","name":"MYL12A","canonical_id":"hgnc:HGNC:16701","description":"myosin light chain 12A","metadata":{"aliases":["MLCB","MYL2B","MRLC3","MRCL3"]}},{"id":"8e2ecc5e60334708b1353b3a04822972","type":"GENE","name":"MYL12AP1","canonical_id":"hgnc:HGNC:51648","description":"MYL12A pseudogene 1","metadata":null},{"id":"336622803d604e249c7da25ba5a03789","type":"GENE","name":"MYL12B","canonical_id":"hgnc:HGNC:29827","description":"myosin light chain 12B","metadata":{"aliases":["MRLC2"]}},{"id":"02e3e46a4d35443490685d512382238d","type":"GENE","name":"MYL12BP1","canonical_id":"hgnc:HGNC:51649","description":"MYL12B pseudogene 1","metadata":null},{"id":"4838641e05654e1681d51ee643dacb01","type":"GENE","name":"MYL12BP2","canonical_id":"hgnc:HGNC:51650","description":"MYL12B pseudogene 2","metadata":null},{"id":"cc93aff766fb4a369ec8858d8426def7","type":"GENE","name":"MYL12BP3","canonical_id":"hgnc:HGNC:7589","description":"MYL12B pseudogene 3","metadata":{"aliases":["BING3","MYL8P"]}},{"id":"82362fcf3d8947599fb9b393852ee7a3","type":"GENE","name":"MYL2","canonical_id":"hgnc:HGNC:7583","description":"myosin light chain 2","metadata":{"aliases":["CMH10"]}},{"id":"63cfbcd41fbf4ee1bbb6181d3d8e53f6","type":"GENE","name":"MYL3","canonical_id":"hgnc:HGNC:7584","description":"myosin light chain 3","metadata":{"aliases":["CMH8","VLC1","MLC1V","MLC1SB"]}},{"id":"dc4a83c275324e33b9af62997123f84d","type":"GENE","name":"MYL4","canonical_id":"hgnc:HGNC:7585","description":"myosin light chain 4","metadata":{"aliases":["ALC1","AMLC","GT1","PRO1957"]}},{"id":"d55dfdc07e224bd6abdca2f01a0a0457","type":"GENE","name":"MYL5","canonical_id":"hgnc:HGNC:7586","description":"myosin light chain 5","metadata":null},{"id":"a600bff35629447585d5b7f9e7d05ad1","type":"GENE","name":"MYL6","canonical_id":"hgnc:HGNC:7587","description":"myosin light chain 6","metadata":{"aliases":["ESMLC","MLC3NM","MLC1SM"]}},{"id":"20c0ecb8fd684026b0ac5d11352a08a1","type":"GENE","name":"MYL6B","canonical_id":"hgnc:HGNC:29823","description":"myosin light chain 6B","metadata":{"aliases":["MLC1SA"]}},{"id":"6e3d7c4e82fb49a1aedb58612dede843","type":"GENE","name":"MYL6B-AS1","canonical_id":"hgnc:HGNC:55472","description":"MYL6B antisense RNA 1","metadata":null},{"id":"a4e40b8c9c354e04b6b9ff1de0f1db87","type":"GENE","name":"MYL6BP1","canonical_id":"hgnc:HGNC:51647","description":"MYL6B pseudogene 1","metadata":null},{"id":"7615b155d95741a9a7929b809d7664cd","type":"GENE","name":"MYL6P1","canonical_id":"hgnc:HGNC:7588","description":"MYL6 pseudogene 1","metadata":{"aliases":["MYL6P"]}},{"id":"7c20a8a5a56c42429849108b5dc78f8b","type":"GENE","name":"MYL6P2","canonical_id":"hgnc:HGNC:23772","description":"MYL6 pseudogene 2","metadata":null},{"id":"0c572d2d8e314e959ccea2dbc874596b","type":"GENE","name":"MYL6P3","canonical_id":"hgnc:HGNC:37812","description":"MYL6 pseudogene 3","metadata":null},{"id":"b42bbf0f4327486b8b798939fda2bf85","type":"GENE","name":"MYL6P4","canonical_id":"hgnc:HGNC:37813","description":"MYL6 pseudogene 4","metadata":null},{"id":"6efbb225074040cfa561d7866a999b8b","type":"GENE","name":"MYL6P5","canonical_id":"hgnc:HGNC:51646","description":"MYL6 pseudogene 5","metadata":null},{"id":"b6d22d3c6d35468cb6f9fc647af363e7","type":"GENE","name":"MYL7","canonical_id":"hgnc:HGNC:21719","description":null,"metadata":null},{"id":"7e9330791cd34521ad847ea37be7c107","type":"GENE","name":"MYL9","canonical_id":"hgnc:HGNC:15754","description":null,"metadata":null},{"id":"f24b11ac5f8b44c68a0e85ff20bb5b63","type":"GENE","name":"MYLIP","canonical_id":"hgnc:HGNC:21155","description":"myosin regulatory light chain interacting protein","metadata":{"aliases":["MIR","IDOL"]}},{"id":"930d4d37a6f24c8ca6e338766453d5f4","type":"GENE","name":"MYLK","canonical_id":"hgnc:HGNC:7590","description":"myosin light chain kinase","metadata":{"aliases":["MLCK","smMLCK","MYLK1","MLCK1","KRP","Telokin","MLCK108","MLCK210","MYLK-L"]}},{"id":"805d46f392704bdd9cdafc7df23be0f4","type":"GENE","name":"MYLK-AS1","canonical_id":"hgnc:HGNC:42440","description":"MYLK antisense RNA 1","metadata":{"aliases":["MYLK-AS2"]}},{"id":"e2f02bf551e94e5ca1ef6b6a67070a7b","type":"GENE","name":"MYLK2","canonical_id":"hgnc:HGNC:16243","description":"myosin light chain kinase 2","metadata":{"aliases":["skMLCK","KMLC","MLCK2"]}},{"id":"e62e0117785446828f42c622c99a5dbc","type":"GENE","name":"MYLK3","canonical_id":"hgnc:HGNC:29826","description":"myosin light chain kinase 3","metadata":{"aliases":["caMLCK","MLCK"]}},{"id":"1291e245826641609961bcd309363574","type":"GENE","name":"MYLK4","canonical_id":"hgnc:HGNC:27972","description":"myosin light chain kinase family member 4","metadata":{"aliases":["SgK085"]}},{"id":"bb80e387f27f41fea67e7006ed6decf5","type":"GENE","name":"MYLK4-AS1","canonical_id":"hgnc:HGNC:59329","description":"MYLK4 antisense RNA 1","metadata":null},{"id":"a25deb865b4444ebb24d0fe43f63ab10","type":"GENE","name":"MYLKP1","canonical_id":"hgnc:HGNC:7591","description":"myosin light chain kinase pseudogene 1","metadata":{"aliases":["MYLKP"]}},{"id":"14ef951fa1544f51b83bf8c3d44c19f9","type":"GENE","name":"MYLKP2","canonical_id":"hgnc:HGNC:56499","description":"MYLK pseudogene 2","metadata":null},{"id":"168f368656e84bb9acfbbdd69de7941d","type":"GENE","name":"MYMK","canonical_id":"hgnc:HGNC:33778","description":"myomaker, myoblast fusion factor","metadata":{"aliases":["TMEM226","MYOMAKER","TMEM8C"]}},{"id":"7c17b363797f4586b519255b92ba575f","type":"GENE","name":"MYMX","canonical_id":"hgnc:HGNC:52391","description":"myomixer, myoblast fusion factor","metadata":{"aliases":["MINION"]}},{"id":"f5b2b77c22a94b10bb9d56e596e8a060","type":"GENE","name":"MYNN","canonical_id":"hgnc:HGNC:14955","description":"myoneurin","metadata":{"aliases":["SBBIZ1","ZBTB31","ZNF902"]}},{"id":"e95771facf5d43f19ba22244e64d548e","type":"GENE","name":"MYO10","canonical_id":"hgnc:HGNC:7593","description":"myosin X","metadata":{"aliases":["KIAA0799","MyoX"]}},{"id":"f1f2cba759f841599bda148ea09b57ee","type":"GENE","name":"MYO15A","canonical_id":"hgnc:HGNC:7594","description":"myosin XVA","metadata":{"aliases":["DFNB3","MYO15"]}},{"id":"4bbe85397f4e47c6a591d94c9ffa1fd9","type":"GENE","name":"MYO15B","canonical_id":"hgnc:HGNC:14083","description":"myosin XVB","metadata":{"aliases":["MYO15BP"]}},{"id":"045e47392c7b45e0ad81456fefc72cbf","type":"GENE","name":"MYO16","canonical_id":"hgnc:HGNC:29822","description":"myosin XVI","metadata":{"aliases":["MYR8","KIAA0865","Myo16b","NYAP3","PPP1R107"]}},{"id":"ae717c4627054e3ea0a2faa1894349ab","type":"GENE","name":"MYO16-AS1","canonical_id":"hgnc:HGNC:39913","description":"MYO16 antisense RNA 1","metadata":null},{"id":"03d91e0be0784fb78230316878872982","type":"GENE","name":"MYO16-AS2","canonical_id":"hgnc:HGNC:39914","description":"MYO16 antisense RNA 2","metadata":null},{"id":"25174ff681a442b8ac99f7dd5ff9a057","type":"GENE","name":"MYO18A","canonical_id":"hgnc:HGNC:31104","description":"myosin XVIIIA","metadata":{"aliases":["KIAA0216","MysPDZ","TIAF1"]}},{"id":"0d2f5f5009b744e487acb8fffe90f4cb","type":"GENE","name":"MYO18B","canonical_id":"hgnc:HGNC:18150","description":"myosin XVIIIB","metadata":{"aliases":["BK125H2.1"]}},{"id":"e087b05ab3fd45298b5f7a28340f794a","type":"GENE","name":"MYO18B-AS1","canonical_id":"hgnc:HGNC:40831","description":"MYO18B antisense RNA 1","metadata":null},{"id":"b8acea8fed704b5e8d99354b88c4d176","type":"GENE","name":"MYO19","canonical_id":"hgnc:HGNC:26234","description":"myosin XIX","metadata":{"aliases":["FLJ22865","MYOHD1"]}},{"id":"92ac33345bf34baa975a7711bae53ee4","type":"GENE","name":"MYO1A","canonical_id":"hgnc:HGNC:7595","description":"myosin IA","metadata":{"aliases":["MYHL","DFNA48","BBMI"]}},{"id":"7693bcc2c3b945248c14306e530898e9","type":"GENE","name":"MYO1B","canonical_id":"hgnc:HGNC:7596","description":"myosin IB","metadata":{"aliases":["myr1"]}},{"id":"321d28105a234f4ebc2b11b0a982a3a5","type":"GENE","name":"MYO1B-AS1","canonical_id":"hgnc:HGNC:55807","description":"MYO1B antisense RNA 1","metadata":null},{"id":"edb3077b05e441e8a74b6e3314e61416","type":"GENE","name":"MYO1C","canonical_id":"hgnc:HGNC:7597","description":"myosin IC","metadata":{"aliases":["myr2","NMI","MyoIC"]}},{"id":"e4c636c037b54349b25fb68cf406dd9f","type":"GENE","name":"MYO1D","canonical_id":"hgnc:HGNC:7598","description":"myosin ID","metadata":{"aliases":["KIAA0727","myr4","PPP1R108"]}},{"id":"ed7d4016486649208de0b0d14addb833","type":"GENE","name":"MYO1D-AS1","canonical_id":"hgnc:HGNC:58309","description":"MYO1D antisense RNA 1","metadata":null},{"id":"4cb0a5955ae444c39e3abee83df00991","type":"GENE","name":"MYO1D-DT","canonical_id":"hgnc:HGNC:55837","description":"MYO1D divergent transcript","metadata":{"aliases":["lncCRLA"]}},{"id":"f8c9e3c88fc444658acd00250aabda57","type":"GENE","name":"MYO1E","canonical_id":"hgnc:HGNC:7599","description":"myosin IE","metadata":{"aliases":["MYO1C","HuncM-IC","MGC104638"]}},{"id":"de6350e1ce514db1bd9fd9a1e7876600","type":"GENE","name":"MYO1F","canonical_id":"hgnc:HGNC:7600","description":"myosin IF","metadata":null},{"id":"d87be1bd318047c3b6f3c4733718f067","type":"GENE","name":"MYO1G","canonical_id":"hgnc:HGNC:13880","description":"myosin IG","metadata":{"aliases":["HA-2"]}},{"id":"20ebb24234b046ccbcbf68fe425974b1","type":"GENE","name":"MYO1H","canonical_id":"hgnc:HGNC:13879","description":"myosin IH","metadata":{"aliases":["FLJ37587"]}},{"id":"d8cbce6c59444880833e2b11c0ff23bd","type":"GENE","name":"MYO3A","canonical_id":"hgnc:HGNC:7601","description":"myosin IIIA","metadata":{"aliases":["DFNB30"]}},{"id":"f4983ac0b2cd4aa59581963f6c974648","type":"GENE","name":"MYO3B","canonical_id":"hgnc:HGNC:15576","description":"myosin IIIB","metadata":null},{"id":"a3ffa4841bfb4a84adb80739e321a531","type":"GENE","name":"MYO3B-AS1","canonical_id":"hgnc:HGNC:40713","description":"MYO3B antisense RNA 1","metadata":null},{"id":"76928f2e31c6478fb03b1f7bf85b5ae2","type":"GENE","name":"MYO5A","canonical_id":"hgnc:HGNC:7602","description":"myosin VA","metadata":{"aliases":["MYO5","GS1","MYR12","MYH12"]}},{"id":"32cc161bfa9c4625801494330cfb07ff","type":"GENE","name":"MYO5B","canonical_id":"hgnc:HGNC:7603","description":"myosin VB","metadata":{"aliases":["KIAA1119"]}},{"id":"aaef3f7b300749f9ba30397d1c5fc227","type":"GENE","name":"MYO5BP1","canonical_id":"hgnc:HGNC:38495","description":"myosin VB pseudogene 1","metadata":null},{"id":"d04029094a3f4ddb9dcd3691d1308578","type":"GENE","name":"MYO5BP2","canonical_id":"hgnc:HGNC:38496","description":"myosin VB pseudogene 2","metadata":null},{"id":"954cb0449e2b4f9b9862bfca237c651c","type":"GENE","name":"MYO5BP3","canonical_id":"hgnc:HGNC:38497","description":"myosin VB pseudogene 3","metadata":null},{"id":"b3b2ac7244e64076b5a1dc506bd24ad1","type":"GENE","name":"MYO5C","canonical_id":"hgnc:HGNC:7604","description":"myosin VC","metadata":{"aliases":["MGC74969"]}},{"id":"59cc4b55f56e4355af8ec429257d021f","type":"GENE","name":"MYO6","canonical_id":"hgnc:HGNC:7605","description":"myosin VI","metadata":{"aliases":["KIAA0389","DFNA22","DFNB37"]}},{"id":"c3d45a80bc2c4fcea91f3384e28f8c79","type":"GENE","name":"MYO7A","canonical_id":"hgnc:HGNC:7606","description":"myosin VIIA","metadata":{"aliases":["NSRD2","USH1B","DFNB2","DFNA11"]}},{"id":"7677a3448341432288b700db8bd792ed","type":"GENE","name":"MYO7B","canonical_id":"hgnc:HGNC:7607","description":"myosin VIIB","metadata":null},{"id":"002681e7425549ed899f0e0e12e08a75","type":"GENE","name":"MYO7B-AS1","canonical_id":"hgnc:HGNC:58165","description":"MYO7B antisense RNA 1","metadata":{"aliases":["RP11-286H15.1"]}},{"id":"8496d75e5ea54b36ba182d060ab8209e","type":"GENE","name":"MYO9A","canonical_id":"hgnc:HGNC:7608","description":"myosin IXA","metadata":{"aliases":["FLJ11061","FLJ13244","MGC71859"]}},{"id":"d3b2c91870f34447bf4e116df0f008e9","type":"GENE","name":"MYO9A-AS1","canonical_id":"hgnc:HGNC:58543","description":"MYO9A antisense RNA 1","metadata":null},{"id":"9c295df64e264f85beaf3284dfa4d2aa","type":"GENE","name":"MYO9B","canonical_id":"hgnc:HGNC:7609","description":"myosin IXB","metadata":{"aliases":["CELIAC4"]}},{"id":"ccde8b8e144b48458cb4b3423be1bfd8","type":"GENE","name":"MYOC","canonical_id":"hgnc:HGNC:7610","description":"myocilin","metadata":{"aliases":["TIGR","JOAG1","GLC1A"]}},{"id":"ee5108be31a04660ae33e39e60f20bf8","type":"GENE","name":"MYOCD","canonical_id":"hgnc:HGNC:16067","description":null,"metadata":null},{"id":"7bbaec2ff69a41438ec949af535d25c1","type":"GENE","name":"MYOCD-AS1","canonical_id":"hgnc:HGNC:40750","description":"MYOCD antisense RNA 1","metadata":null},{"id":"b5bbacca02824bdeab055f71db5cecc7","type":"GENE","name":"MYOCOS","canonical_id":"hgnc:HGNC:53429","description":"myocilin opposite strand","metadata":null},{"id":"a7eedad1be744f5ea76c133a8a73cfa0","type":"GENE","name":"MYOD1","canonical_id":"hgnc:HGNC:7611","description":null,"metadata":null},{"id":"cfc4c0b75b7749e7aea67ed29decbc7f","type":"GENE","name":"MYOF","canonical_id":"hgnc:HGNC:3656","description":"myoferlin","metadata":{"aliases":["KIAA1207","FER1L3"]}},{"id":"a6a9330caa46429680e881919697136f","type":"GENE","name":"MYOG","canonical_id":"hgnc:HGNC:7612","description":null,"metadata":null},{"id":"1852724cc6814e74b7ce81b9548ead9d","type":"GENE","name":"MYOM1","canonical_id":"hgnc:HGNC:7613","description":"myomesin 1","metadata":null},{"id":"8aabb914e57e437c84e25c50076bbf78","type":"GENE","name":"MYOM2","canonical_id":"hgnc:HGNC:7614","description":"myomesin 2","metadata":null},{"id":"0260da005ae04c778e8659d4269df7be","type":"GENE","name":"MYOM3","canonical_id":"hgnc:HGNC:26679","description":"myomesin 3","metadata":{"aliases":["FLJ35961"]}},{"id":"b5212b029e124ea792004cca9ff7bc09","type":"GENE","name":"MYOM3-AS1","canonical_id":"hgnc:HGNC:41158","description":"MYOM3 antisense RNA 1","metadata":null},{"id":"44d4b903a7bc47cea7ea6411b3b65949","type":"GENE","name":"MYOPARR","canonical_id":"hgnc:HGNC:54178","description":"myogenin promoter associated myogenic regulatory antisense long non coding RNA","metadata":null},{"id":"c6158e27c1964de785f0df1f0fa56bac","type":"GENE","name":"MYORG","canonical_id":"hgnc:HGNC:19918","description":"myogenesis regulating glycosidase","metadata":{"aliases":["NET37","KIAA1161"]}},{"id":"6091efd13f2d468d8a06510010d96427","type":"GENE","name":"MYOSLID","canonical_id":"hgnc:HGNC:51821","description":"myocardin-induced smooth muscle lncRNA, inducer of differentiation","metadata":null},{"id":"84220d189a91461eacd8f0d8fd47666b","type":"GENE","name":"MYOSLID-AS1","canonical_id":"hgnc:HGNC:54063","description":"MYOSLID antisense RNA 1","metadata":null},{"id":"f0a3675fc6274b8e99d902c4e1b6db1f","type":"GENE","name":"MYOT","canonical_id":"hgnc:HGNC:12399","description":"myotilin","metadata":{"aliases":["TTID","LGMD1A","LGMD1"]}},{"id":"90beabf2aed244db9c97b9865c191fe4","type":"GENE","name":"MYOZ1","canonical_id":"hgnc:HGNC:13752","description":"myozenin 1","metadata":{"aliases":["FATZ","CS-2","MYOZ"]}},{"id":"af8223861f04432e86d89dc050827eef","type":"GENE","name":"MYOZ2","canonical_id":"hgnc:HGNC:1330","description":"myozenin 2","metadata":{"aliases":["CS-1","FATZ-2","C4orf5"]}},{"id":"d7e5fd79ad604027ad3f44c7e3d1a42c","type":"GENE","name":"MYOZ2-AS1","canonical_id":"hgnc:HGNC:58878","description":"MYOZ2 antisense RNA 1","metadata":null},{"id":"bef8030deb48466e9082c4a23b25a6cb","type":"GENE","name":"MYOZ3","canonical_id":"hgnc:HGNC:18565","description":"myozenin 3","metadata":{"aliases":["CS-3","CS3","FRP3","FATZ-3"]}},{"id":"049d0f2ec20d4dc8bdbfd9cb786a35da","type":"GENE","name":"MYOZ3-AS1","canonical_id":"hgnc:HGNC:40846","description":"MYOZ3 antisense RNA 1","metadata":null},{"id":"dadf0f5b57d849e0909ff68068171920","type":"GENE","name":"MYPN","canonical_id":"hgnc:HGNC:23246","description":"myopalladin","metadata":{"aliases":["MYOP"]}},{"id":"47cbc9b2257542ed9c8227aa13a694e5","type":"GENE","name":"MYPOP","canonical_id":"hgnc:HGNC:20178","description":"Myb related transcription factor, partner of profilin","metadata":{"aliases":["P42pop"]}},{"id":"e7b61621ccce4fa4aa41feafa80ead4d","type":"GENE","name":"MYRACL","canonical_id":"hgnc:HGNC:53467","description":"myelination regulating oligodendrocyte associated lncRNA","metadata":{"aliases":["uc.163","CTD-2316B1","LINC02488"]}},{"id":"37745c4570904c61baa28d61a689a354","type":"GENE","name":"MYREM","canonical_id":"hgnc:HGNC:56685","description":"MYBPC2 cis regulating lncRNA enhancer of myogenesis","metadata":{"aliases":["Charme","lncFAM","HSCHARME","lncFAM71E1-2:2"]}},{"id":"6e530895ddfd4bc2a6d9274082786743","type":"GENE","name":"MYRF","canonical_id":"hgnc:HGNC:1181","description":"myelin regulatory factor","metadata":{"aliases":["Ndt80","pqn-47","MRF","C11orf9"]}},{"id":"822ab3edd04a458796b954505713f904","type":"GENE","name":"MYRF-AS1","canonical_id":"hgnc:HGNC:24506","description":"MYRF antisense RNA 1","metadata":{"aliases":["DKFZP434K028"]}},{"id":"a1cfed3a117b400bb6777e0f09fcf25c","type":"GENE","name":"MYRFL","canonical_id":"hgnc:HGNC:26316","description":"myelin regulatory factor like","metadata":{"aliases":["FLJ25056","bcm1377","C12orf15","C12orf28"]}},{"id":"6c2865438e9647ccb5ed57bc73d83fd3","type":"GENE","name":"MYRIP","canonical_id":"hgnc:HGNC:19156","description":"myosin VIIA and Rab interacting protein","metadata":{"aliases":["DKFZp586F1018","exophilin-8","SLAC2-C","SLAC2C"]}},{"id":"c1d70924d5424e7086eafc79bc61875e","type":"GENE","name":"MYSM1","canonical_id":"hgnc:HGNC:29401","description":"Myb like, SWIRM and MPN domains 1","metadata":{"aliases":["KIAA1915"]}},{"id":"03becdb724ee4a2d86c03f14ca4f7125","type":"GENE","name":"MYT1","canonical_id":"hgnc:HGNC:7622","description":"myelin transcription factor 1","metadata":{"aliases":["MTF1","MYTI","ZC2HC4A","NZF2","ZC2H2C1","PLPB1"]}},{"id":"54f82e7fcf1e4ac588f51eb0946fab32","type":"GENE","name":"MYT1L","canonical_id":"hgnc:HGNC:7623","description":"myelin transcription factor 1 like","metadata":{"aliases":["KIAA1106","NZF1","ZC2HC4B","ZC2H2C2"]}},{"id":"82c4321f7b044fdb96688ba36fc84227","type":"GENE","name":"MYT1L-AS1","canonical_id":"hgnc:HGNC:49274","description":"MYT1L antisense RNA 1","metadata":null},{"id":"572de503ef254412b5fe2c3c017dbcf3","type":"GENE","name":"MYT1L-AS2","canonical_id":"hgnc:HGNC:40388","description":"MYT1L antisense RNA 2","metadata":null},{"id":"ca42cfeeed254ff6998d3c7b7a05d768","type":"GENE","name":"MYZAP","canonical_id":"hgnc:HGNC:43444","description":"myocardial zonula adherens protein","metadata":{"aliases":["MYOZAP","Gup","Gup1","GCOM1"]}},{"id":"684573bac44b4c3f87039de6612f5da2","type":"GENE","name":"MZB1","canonical_id":"hgnc:HGNC:30125","description":"marginal zone B and B1 cell specific protein","metadata":{"aliases":["PACAP","MGC29506","HSPC190","pERp1","MEDA-7"]}},{"id":"f9b47c471fbe433690096f484f46284a","type":"GENE","name":"MZF1","canonical_id":"hgnc:HGNC:13108","description":null,"metadata":null},{"id":"dd920b9376c34749b031a02e8926308a","type":"GENE","name":"MZF1-AS1","canonical_id":"hgnc:HGNC:51271","description":"MZF1 antisense RNA 1","metadata":null},{"id":"88100f9e4f064bbc860647f738f7f961","type":"GENE","name":"MZT1","canonical_id":"hgnc:HGNC:33830","description":"mitotic spindle organizing protein 1","metadata":{"aliases":["LOC440145","FLJ21869","MGC150539","RP11-11C5.2","MOZART1","C13orf37"]}},{"id":"747ff9d28a114c75ae1921e92e67d613","type":"GENE","name":"MZT1P1","canonical_id":"hgnc:HGNC:50605","description":"mitotic spindle organizing protein 1 pseudogene 1","metadata":null},{"id":"e26c5e1750b14a098c55beaa6d3c6dd8","type":"GENE","name":"MZT1P2","canonical_id":"hgnc:HGNC:50606","description":"mitotic spindle organizing protein 1 pseudogene 2","metadata":null},{"id":"140ac54a05384d83828882b35a24a9da","type":"GENE","name":"MZT2A","canonical_id":"hgnc:HGNC:33187","description":"mitotic spindle organizing protein 2A","metadata":{"aliases":["MOZART2A","FAM128A"]}},{"id":"1195c1f534f746758a96eafc795c41ce","type":"GENE","name":"MZT2B","canonical_id":"hgnc:HGNC:25886","description":"mitotic spindle organizing protein 2B","metadata":{"aliases":["FLJ14346","MOZART2B","FAM128B"]}},{"id":"20619af254bb4c52a393db1c7179e4d3","type":"GO_TERM","name":"MacAB-TolC complex","canonical_id":"go:GO:1990196","description":"\"The MacAB-TolC complex is a macrolide transporter complex found in E.coli and related gram-negative bacteria. Its transport activity is specific to macrolide compounds containing 14- and 15-membered lactones. It consists of the dimeric inner membrane ATPase MacB, the hexameric, periplasmic membrane fusion protein MacA and the trimeric outer membrane factor TolC.\" [GOC:bhm, PMID:10879525, PMID:18955484, PMID:19254725]","metadata":null},{"id":"b52c9fcb57d84f3fb924fe3f838d78da","type":"TRIAL","name":"Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study","canonical_id":"clinicaltrials.gov:NCT00903331","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"edf8aee6a5fb402dbf76f6916c3f69d4","type":"TRIAL","name":"Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi\u00ae' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg","canonical_id":"clinicaltrials.gov:NCT06553924","description":"PAH","metadata":null},{"id":"431a52e21e3b4ac1a3043d47e14a7169","type":"TRIAL","name":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","canonical_id":"clinicaltrials.gov:NCT01474109","description":"Systemic Sclerosis; Ulcers","metadata":null},{"id":"fe9612c13296439594686cc10cd3af33","type":"TRIAL","name":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","canonical_id":"clinicaltrials.gov:NCT01474122","description":"Digital Ulcers","metadata":null},{"id":"77e6eb104adb4d5189b100f8b84cb71d","type":"TRIAL","name":"Macitentan in Pulmonary Hypertension of Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT02651272","description":"Pulmonary Hypertension; Sickle Cell Disease","metadata":null},{"id":"7a4f41c0aebe4f15a3ff50c6f83004de","type":"TRIAL","name":"Macitentan to Prevent PRVO","canonical_id":"clinicaltrials.gov:NCT05946811","description":"Pulmonary Embolism","metadata":null},{"id":"8c4cb1c3f71847719f4c2aaf03e5cea4","type":"DISEASE","name":"Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome","canonical_id":"efo:0009050","description":null,"metadata":null},{"id":"7ecda0b93f454c7e949ce137cb8e5bf7","type":"TRIAL","name":"Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00134667","description":"Age-Related Macular Degeneration","metadata":null},{"id":"153d67e8553a4ad09f191e1a603c040b","type":"TRIAL","name":"Macugen for Histoplasmosis","canonical_id":"clinicaltrials.gov:NCT00272766","description":"Ocular Histoplasmosis; Choroidal Neovascularization","metadata":null},{"id":"3b43549327b249cd8122e1c6f19c3fd3","type":"TRIAL","name":"Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)","canonical_id":"clinicaltrials.gov:NCT01486771","description":"Proliferative Diabetic Retinopathy","metadata":null},{"id":"5a50280a7e4247ad93ad0af0045943d6","type":"TRIAL","name":"Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics","canonical_id":"clinicaltrials.gov:NCT00346983","description":"Cystoid Macular Edema","metadata":null},{"id":"9401dfb42fad4159b682d23fcc0ab3bc","type":"TRIAL","name":"Macular Edema Nepafenac vs. Difluprednate Uveitis Trial","canonical_id":"clinicaltrials.gov:NCT01939691","description":"Uveitis; Macular Edema","metadata":null},{"id":"ea0c4dd18ef24655bf6abce0d3e62c84","type":"GO_TERM","name":"Mad-Max complex","canonical_id":"go:GO:0070443","description":"\"A transcriptional repressor complex that consists of a heterodimer of the bHLH-ZIP proteins Mad and Max.\" [PMID:8224841]","metadata":null},{"id":"cae191aa958946c293bf6f9d8de56a01","type":"GO_TERM","name":"Mad-Max-mSin3A complex","canonical_id":"go:GO:0070439","description":"\"A transcriptional repressor complex that contains a heterodimer of the bHLH-ZIP proteins Mad and Max, plus mSin3A, a homolog of the yeast Sin3p.\" [PMID:7889570]","metadata":null},{"id":"2dd35085d7704269888911e60450075b","type":"GO_TERM","name":"Mad-Max-mSin3B complex","canonical_id":"go:GO:0070440","description":"\"A transcriptional repressor complex that contains a heterodimer of the bHLH-ZIP proteins Mad and Max, plus mSin3B, a homolog of the yeast Sin3p.\" [PMID:7889570]","metadata":null},{"id":"ce9e060b048945578f10e88ca26fdad6","type":"DISEASE","name":"Maffucci syndrome","canonical_id":"mondo:0013808","description":null,"metadata":null},{"id":"240e6b4f72a2459cb463b95e75f04537","type":"TRIAL","name":"Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT01136421","description":"COPD Exacerbation","metadata":null},{"id":"0bcf63d1211a493594505375fce86f20","type":"TRIAL","name":"Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning","canonical_id":"clinicaltrials.gov:NCT07777835","description":"Organophosphate Poisoning","metadata":null},{"id":"291566e4bc584eefa13fbd2a5cda002c","type":"TRIAL","name":"Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines","canonical_id":"clinicaltrials.gov:NCT05967442","description":"Migraine; Headache","metadata":null},{"id":"9ccc2c59844d43ebb957afce001f8b87","type":"DRUG","name":"Magnesium oxide","canonical_id":"mesh:D008277","description":null,"metadata":null},{"id":"50cecfad7b214fc28125a6cad19520ea","type":"DRUG","name":"Magnesium salicylate","canonical_id":"mesh:C496892","description":null,"metadata":null},{"id":"a6e37c8a739d493a9e0825aa5690c911","type":"TRIAL","name":"Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT01051440","description":"Bipolar Depression","metadata":null},{"id":"23882d49627f404294cec81bd94b3564","type":"TRIAL","name":"Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma","canonical_id":"clinicaltrials.gov:NCT01342757","description":"Adult Glioblastoma; Depression; Recurrent Adult Brain Tumor","metadata":null},{"id":"37e07ef3741640ca93661ca24e0a717c","type":"TRIAL","name":"Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03916419","description":"Stage IIB Non-Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer","metadata":null},{"id":"be85a323900b49b4a505a6c5b86237e0","type":"TRIAL","name":"Magnetic Seizure Therapy for Psychotic Disorders","canonical_id":"clinicaltrials.gov:NCT06581302","description":"Psychotic Disorders","metadata":null},{"id":"583dba9aaab84e39a00edd528721dc5a","type":"TRIAL","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","canonical_id":"clinicaltrials.gov:NCT06152575","description":"Multiple Myeloma","metadata":null},{"id":"8bd77b3519d345e8b1725f84959f0264","type":"TRIAL","name":"Maintaining Nonsmoking: Older Smokers - 1","canonical_id":"clinicaltrials.gov:NCT00086385","description":"Tobacco Use Disorder","metadata":null},{"id":"b9024f3aea454fc2962b783ff6264ddf","type":"TRIAL","name":"Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker","canonical_id":"clinicaltrials.gov:NCT02043821","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"c5c2447406204dc69c8ef785c9d656f8","type":"TRIAL","name":"Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma","canonical_id":"clinicaltrials.gov:NCT01096368","description":"Anaplastic Ependymoma; Brain Ependymoma; Cellular Ependymoma; Clear Cell Ependymoma; Ependymoma; Papillary Ependymoma","metadata":null},{"id":"45e612c7caf34992b02149b5c4c15eda","type":"TRIAL","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)","canonical_id":"clinicaltrials.gov:NCT06419179","description":"Small Cell Lung Carcinoma","metadata":null},{"id":"97c9520d2b754728983c348765f97087","type":"TRIAL","name":"Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT05127174","description":"Myeloproliferative Neoplasm","metadata":null},{"id":"962a1317a628469e82ad5b1c35ca52d7","type":"TRIAL","name":"Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC","canonical_id":"clinicaltrials.gov:NCT06497530","description":"Extensive-Stage Small Cell Lung Cancer","metadata":null},{"id":"ce41657db52946c19a3c0842a56d8373","type":"TRIAL","name":"Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT04895046","description":"HRD; Cholangiocarcinoma; Metastatic Cancer","metadata":null},{"id":"d37277859780466a8d2016966560b44a","type":"TRIAL","name":"Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)","canonical_id":"clinicaltrials.gov:NCT03862651","description":"Platelet Aggregation Inhibitors","metadata":null},{"id":"c2af481bf417443bb0ffd26c584128ad","type":"TRIAL","name":"Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy","canonical_id":"clinicaltrials.gov:NCT03140670","description":"Pancreatic Cancer","metadata":null},{"id":"fa64fb6a93d44762ba2a7baced79fb8e","type":"TRIAL","name":"Maintenance Zanzalintinib With Etoposide After HDCT in GCT","canonical_id":"clinicaltrials.gov:NCT06937866","description":"Germ Cell Tumor","metadata":null},{"id":"81baa9c4b75a4c3582123b850a54232f","type":"TRIAL","name":"Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD","canonical_id":"clinicaltrials.gov:NCT00191035","description":"Attention-Deficit/Hyperactivity Disorder","metadata":null},{"id":"4aebc78d1584479c96a4021de76ca792","type":"TRIAL","name":"Maintenance of Platelet Inhibition With Cangrelor","canonical_id":"clinicaltrials.gov:NCT00767507","description":"Acute Coronary Syndrome (ACS)","metadata":null},{"id":"52bd147c2e01406db01a25662a457a83","type":"TRIAL","name":"Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose","canonical_id":"clinicaltrials.gov:NCT01421134","description":"Major Depressive Disorder With Mixed Features","metadata":null},{"id":"6b6905356b754922aebf25f4227daef6","type":"TRIAL","name":"Major Depressive Disorder With Mixed Features","canonical_id":"clinicaltrials.gov:NCT01423240","description":"Major Depressive Disorder","metadata":null},{"id":"9717a914b2094ab68fed2d8540d6e29d","type":"GO_TERM","name":"MalFGK2 complex","canonical_id":"go:GO:1990176","description":"\"Protein complex involved in maltose transport through the plasma membrane. In E. coli, the complex is a tetramer and consists of a cytoplasmic ATPase MalK homodimer together with a heterodimeric transmembrane subunit MalF-MalG.\" [GOC:bhm, PMID:19250913]","metadata":null},{"id":"b3f107618c894dd28df62542e7b7b72b","type":"DISEASE","name":"Malaria","canonical_id":"mesh:D008288","description":null,"metadata":null},{"id":"c97095a5dfcc4fc2af72a537f7dfb67f","type":"PROTEIN","name":"Malaria protein EXP-1","canonical_id":"uniprot:P04926","description":null,"metadata":null},{"id":"5bf6d66d350e4575b42d3977c9360013","type":"TRIAL","name":"Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study","canonical_id":"clinicaltrials.gov:NCT00427882","description":"Prostatic Hyperplasia","metadata":null},{"id":"61a4c0fbc6614dc5bd0481cc331a2e05","type":"TRIAL","name":"Malignancy Meta Analysis for BRL49653","canonical_id":"clinicaltrials.gov:NCT01195259","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"a30abf4787734ad9b7139bb4f13cec90","type":"DISEASE","name":"Malignant Exocrine Pancreas Neoplasm","canonical_id":"doid:1795","description":null,"metadata":null},{"id":"ae1c1045c4a5458f98de5782dbc369ec","type":"DISEASE","name":"Malignant Mesothelioma","canonical_id":"doid:1790","description":null,"metadata":null},{"id":"f264b4c88264493ab360565d00cad8ab","type":"DISEASE","name":"Malignant Pleural Mesothelioma","canonical_id":"doid:7474","description":null,"metadata":null},{"id":"6dccb15a42f5456493e3fd3c52c0d5ba","type":"DISEASE","name":"Malignant hyperthermia","canonical_id":"mesh:C535694","description":null,"metadata":null},{"id":"44cfdd52b9aa4ac09e0b903c4d473b7c","type":"DISEASE","name":"Malignant lymphoma","canonical_id":"mesh:D008223","description":null,"metadata":null},{"id":"bc0ef23038bf464b916970a2595cb78c","type":"DISEASE","name":"Malignant melanoma","canonical_id":"mesh:D008545","description":null,"metadata":null},{"id":"62a123c9d7ad48c9928c1de42d64de32","type":"DISEASE","name":"Malignant tumor of esophagus","canonical_id":"mesh:D004938","description":null,"metadata":null},{"id":"27d291cb6ddf4b6d923d08fb74b5ecbc","type":"DISEASE","name":"Malignant tumor of head and/or neck","canonical_id":"mesh:D006258","description":null,"metadata":null},{"id":"e6e40078f4c347b9b91d8090b107da5c","type":"DISEASE","name":"Malignant tumor of ovary","canonical_id":"mesh:D010051","description":null,"metadata":null},{"id":"0055cddc00ce4576abcf17fda8a8f4d2","type":"DISEASE","name":"Malignant tumor of penis","canonical_id":"mesh:D010412","description":null,"metadata":null},{"id":"864ecbe7d60b4148bb09850900a20634","type":"DISEASE","name":"Malignant tumor of stomach","canonical_id":"mesh:D013274","description":null,"metadata":null},{"id":"53384d230c3849f8b0e2c851510137bb","type":"DISEASE","name":"Malignant tumor of testis","canonical_id":"mesh:D013736","description":null,"metadata":null},{"id":"72bcf3b9e1944bdd929db5de47a92f1b","type":"GO_TERM","name":"Malpighian tubule bud morphogenesis","canonical_id":"go:GO:0061332","description":"\"The morphogenetic process in which a bud forms from the embryonic hindgut tube to form the Malpighian tubule. A bud is a protrusion that forms from the tube by localized changes in cell shape and position.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"0ac959432ed249028dcc185e84e7d4f9","type":"GO_TERM","name":"Malpighian tubule development","canonical_id":"go:GO:0072002","description":"\"The process whose specific outcome is the progression of the Malpighian tubule over time, from its formation to the mature structure. A Malpighian tubule is a fine, thin-walled excretory tubule in insects which leads into the posterior part of the gut.\" [FBbt:00005786, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"1104613b142e4ed7a889f924cb1469e9","type":"GO_TERM","name":"Malpighian tubule morphogenesis","canonical_id":"go:GO:0007443","description":"\"The process in which the anatomical structures of the Malpighian tubule are generated and organized. This process takes place entirely during the embryonic phase. A Malpighian tubule is a fine, thin-walled excretory tubule in insects which leads into the posterior part of the gut.\" [GOC:bf, ISBN:0582227089]","metadata":null},{"id":"87c87803c6d745e985846cdd7b2779ed","type":"GO_TERM","name":"Malpighian tubule principal cell differentiation","canonical_id":"go:GO:0061329","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a Malpighian tubule principal cell. A Malpighian tubule principal cell is an epithelial secretory cell that transports cations into the lumen of the tubule.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"a960e94557e34c58b75ad327ae78cc2f","type":"GO_TERM","name":"Malpighian tubule stellate cell differentiation","canonical_id":"go:GO:0061330","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a Malpighian tubule stellate cell. A Malpighian tubule stellate cell is a specialized epithelial secretory cell that moves chloride ions and water across the tubule epithelium.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"60c06516b4514bc6bbd454ef7c3a183f","type":"GO_TERM","name":"Malpighian tubule tip cell differentiation","canonical_id":"go:GO:0061382","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a Malpighian tubule tip cell. A Malpighian tubule tip cell is a mitogenic signaling cell that controls the proliferation of its neighboring cells.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:7821213]","metadata":null},{"id":"bcd71dc8e30e46d9be6c444e3e252266","type":"TRIAL","name":"Mammogram Pretreatment With Ulipristal Acetate","canonical_id":"clinicaltrials.gov:NCT07434128","description":"Mammography Screening; Breast Density","metadata":null},{"id":"c3501a264574409695bb3d802ebc150f","type":"TRIAL","name":"Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease","canonical_id":"clinicaltrials.gov:NCT04540861","description":"Multiple Sclerosis","metadata":null},{"id":"cad22e030e9f44a4bda27c09e767a0d9","type":"TRIAL","name":"Managed Access Program for Momelotinib in Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT05582083","description":"Myelofibrosis; Primary Myelofibrosis","metadata":null},{"id":"c3d5f7e88c3546b6b163a02beaeae706","type":"TRIAL","name":"Managed Access Programs for AIN457, Secukinumab","canonical_id":"clinicaltrials.gov:NCT05583604","description":"Hidradenitis Suppurativa (HS)","metadata":null},{"id":"5438e68ad3bd4202ab6c4dee4158d4cd","type":"TRIAL","name":"Managed Access Programs for BYL719, Alpelisib","canonical_id":"clinicaltrials.gov:NCT04085653","description":"PIK3CA-Related Overgrowth Spectrum (PROS); Breast Cancer","metadata":null},{"id":"538b34aa0ed24c9a8ca4600562314e5a","type":"TRIAL","name":"Managed Access Programs for EXV811, Atrasentan","canonical_id":"clinicaltrials.gov:NCT07319585","description":"IgA Nephropathy","metadata":null},{"id":"eb03a9eb54d2418d8d9460862b88de1e","type":"TRIAL","name":"Managed Access Programs for INC280, Capmatinib","canonical_id":"clinicaltrials.gov:NCT04741789","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"04c401de8a72426ea494bce47c8da98c","type":"TRIAL","name":"Managed Access Programs for LDK378, Ceritinib","canonical_id":"clinicaltrials.gov:NCT05100134","description":"Anaplastic Lymphoma Kinase (ALK)- Positive Tumors; Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"75cab9312d3a47c0a7a7afcefa5ec75a","type":"TRIAL","name":"Managed Access Programs for PKC412, Midostaurin","canonical_id":"clinicaltrials.gov:NCT05219266","description":"FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia; Acute Myeloid Leukemia; Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic Mastocytosis With an Associated Hematologic Neoplasm","metadata":null},{"id":"e5b729e78523494ba3cccc6f6a347c86","type":"TRIAL","name":"Management of Abnormal Uterine Bleeding","canonical_id":"clinicaltrials.gov:NCT06369012","description":"Abnormal Uterine Bleeding","metadata":null},{"id":"f5a84c4df851480898c942f74f6c3553","type":"TRIAL","name":"Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate","canonical_id":"clinicaltrials.gov:NCT02337881","description":"Labor Preterm Requiring Hospitalization","metadata":null},{"id":"e428db810afc4bfe8b54e8200608b9c4","type":"TRIAL","name":"Management of Acute Tinnitus With Migraine Medications","canonical_id":"clinicaltrials.gov:NCT06799169","description":"Tinnitus","metadata":null},{"id":"9eee9b4fbe3d42d6a116b3aee7746a75","type":"TRIAL","name":"Management of Catatonic Features in Adolescents With Profound Autism","canonical_id":"clinicaltrials.gov:NCT07498387","description":"Autism Spectrum Disorder; Catatonia","metadata":null},{"id":"58225a8539c049979c242dc37b3381d3","type":"TRIAL","name":"Management of Cerebral Vascular Spasm in Posttraumatic Subarachnoid Hemorrhage Using Combination Therapy","canonical_id":"clinicaltrials.gov:NCT05131867","description":"Oral Nimodipine; Milrinone; Vascular Spasm After Traumatic Subarachnoidhaemorrhage","metadata":null},{"id":"860ee4a7532a4300a5f0a7a878b614c3","type":"TRIAL","name":"Management of Decompensated HCV Cirrhotic Patients","canonical_id":"clinicaltrials.gov:NCT03547895","description":"Decompensated Cirrhosis","metadata":null},{"id":"6f24da5c6a9b4905b01fa882c2339c76","type":"TRIAL","name":"Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)","canonical_id":"clinicaltrials.gov:NCT01295294","description":"Uterine Hemorrhage","metadata":null},{"id":"0e849c16fe004a90902eeed50e8ea7c1","type":"TRIAL","name":"Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19","canonical_id":"clinicaltrials.gov:NCT05052008","description":"Migraine Disorders","metadata":null},{"id":"3e6f26f7ca034081a0bb253aa4ae12f3","type":"TRIAL","name":"Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)","canonical_id":"clinicaltrials.gov:NCT04070209","description":"Metastatic Prostate Cancer; Castration-resistant Prostate Cancer","metadata":null},{"id":"8fcc50023fa74d3a8371d6239e7ae57c","type":"TRIAL","name":"Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response","canonical_id":"clinicaltrials.gov:NCT04351126","description":"Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"67ded169ec6d4dbebd52a4d0fa5df53e","type":"TRIAL","name":"Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT03944070","description":"Wet Macular Degeneration; Cataract Extraction","metadata":null},{"id":"5a34a9e3d48f46598fad098c34b9b129","type":"TRIAL","name":"Management of Signs and Symptoms Associated With Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT04015219","description":"Dry Eye Syndromes","metadata":null},{"id":"80790acc41e746559b743673bbeb88cd","type":"TRIAL","name":"Management of Uterine Leiomyomata and Adenomyosis","canonical_id":"clinicaltrials.gov:NCT05153928","description":"Abnormal Uterine Bleeding","metadata":null},{"id":"1b3e350960174e2cb1397e736384de43","type":"TRIAL","name":"Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy","canonical_id":"clinicaltrials.gov:NCT05431595","description":"Delirium; Epileptics; Neuroleptics","metadata":null},{"id":"72343c3f17b84e099ce0a4a3e9eddfcc","type":"TRIAL","name":"Managing Outpatient Hysteroscopy-associated Pain","canonical_id":"clinicaltrials.gov:NCT05801172","description":"Pain; Hysteroscopic Surgery","metadata":null},{"id":"c889c7d87ac54546855f76e55331ac24","type":"TRIAL","name":"Manipulation of Arterial Pressure in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT00848770","description":"Stroke, Acute","metadata":null},{"id":"fbff2d3aef1d4636bbe9881a807ab941","type":"DRUG","name":"Mannitol","canonical_id":"mesh:D008353","description":null,"metadata":null},{"id":"03bc86965fff496f917da99ec61d0726","type":"DISEASE","name":"Mantle cell lymphoma","canonical_id":"mesh:D020522","description":null,"metadata":null},{"id":"3a74af7ed2b946b8a6fe0bf33e907bcb","type":"DRUG","name":"Maprotiline","canonical_id":"mesh:D008376","description":null,"metadata":null},{"id":"0251bee7789e43c5860b6e3d25725943","type":"TRIAL","name":"Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients","canonical_id":"clinicaltrials.gov:NCT01013987","description":"HIV-1 Adults Patients; AIDS; Triple Class Failure","metadata":null},{"id":"d6bb13464a7544c08091de9d751aadee","type":"TRIAL","name":"Maraviroc Compassionate Use","canonical_id":"clinicaltrials.gov:NCT00719823","description":"Human Immunodeficiency Virus Type 1","metadata":null},{"id":"ef62a516c9c341db83bba04df6ab6284","type":"TRIAL","name":"Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels","canonical_id":"clinicaltrials.gov:NCT00987948","description":"HIV Infections","metadata":null},{"id":"7d162a6d067c41aba575062842faa1f8","type":"TRIAL","name":"Maraviroc and NeuroAIDS Pathogenesis","canonical_id":"clinicaltrials.gov:NCT02159027","description":"AIDS Dementia Complex","metadata":null},{"id":"5120908056664ec5a7e9a052158cee8f","type":"DRUG","name":"Margetuximab","canonical_id":"ncit:C91733","description":null,"metadata":null},{"id":"28efad38356d4d4b9eb7ad7bfa7e8929","type":"TRIAL","name":"Margetuximab Expanded Access Program","canonical_id":"clinicaltrials.gov:NCT03133988","description":"HER2-positive Breast Cancer; HER2-positive Carcinoma","metadata":null},{"id":"267fd32f441f45bf9f32f54c359969ed","type":"TRIAL","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02492711","description":"HER-2 Positive Breast Cancer; Metastatic Neoplasm","metadata":null},{"id":"328ddeec43ef4ac49c65f82668ab82fd","type":"TRIAL","name":"Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05227131","description":"Metastatic Breast Cancer; Advanced Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"0b7c06a9c58e4ce2a10934d51e37b91a","type":"DISEASE","name":"Maroteaux-Lamy syndrome","canonical_id":"mesh:D009087","description":null,"metadata":null},{"id":"44b7d3fdb0ee4914973fd5e8f1323afc","type":"TRIAL","name":"Marsili Syndrome as a Gateway to Novel Analgesic Targets","canonical_id":"clinicaltrials.gov:NCT07755930","description":"Marsili Syndrome","metadata":null},{"id":"3b73aca1417145138ea66832e16d1ac9","type":"TRIAL","name":"Mask Ventilation Before and After Neuromuscular Blockade","canonical_id":"clinicaltrials.gov:NCT02237443","description":"Anesthesia","metadata":null},{"id":"512b6b4f227a46f587796f720cf98941","type":"TRIAL","name":"Massage Therapy for Chronic Low Back Pain","canonical_id":"clinicaltrials.gov:NCT01973010","description":"Low Back Pain","metadata":null},{"id":"e683abda252642458b86864f86eb5d05","type":"TRIAL","name":"Mast Cell Treatment in Post-tick Bite Illness (PTBI)","canonical_id":"clinicaltrials.gov:NCT07526558","description":"Post-tick Bite Illness; Mast Cell Stabilizer","metadata":null},{"id":"c9682b15a62a4470979266b35e10cbbb","type":"TRIAL","name":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","canonical_id":"clinicaltrials.gov:NCT03167216","description":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","metadata":null},{"id":"843421b4f5434bcabf43c36006d75130","type":"DISEASE","name":"Mast cell leukemia","canonical_id":"mesh:D007946","description":null,"metadata":null},{"id":"77a93d225b334c3ba4a4009c1e2b0658","type":"TRIAL","name":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03967223","description":"Neoplasms","metadata":null},{"id":"a9e6c5f6c42d4ea6b7c3bd658e0731fb","type":"TRIAL","name":"Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China","canonical_id":"clinicaltrials.gov:NCT07620951","description":"EGFR Mutant Advanced Non-small Cell Lung Cancer; Central Nervous System (CNS) Metastases","metadata":null},{"id":"0cb12de226524907a54eaf0d010de6bc","type":"GO_TERM","name":"Maurer's cleft","canonical_id":"go:GO:0020036","description":"\"A disk-like structure that appears at the periphery of a red blood cell infected by an apicomplexan parasite, characterized by a translucent lumen and an electron-dense coat of variable thickness; often appears to be tethered to the host cell membrane by fibrous connections with the erythrocyte cytoskeleton.\" [PMID:16705161]","metadata":null},{"id":"b29bbb5033e744f38b7870675790ec61","type":"TRIAL","name":"Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment","canonical_id":"clinicaltrials.gov:NCT05717582","description":"Metastatic Prostate Cancer; Castration-Sensitive Prostate Cancer","metadata":null},{"id":"b8f797d382ed4334b24e27081c85be05","type":"TRIAL","name":"Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00298155","description":"Cancer; Prostate Neoplasms","metadata":null},{"id":"e793a133352d4adba966929989350182","type":"TRIAL","name":"Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04042103","description":"Plaque Psoriasis","metadata":null},{"id":"d9ea2b9771d64816a1583975193e630c","type":"TRIAL","name":"Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05186805","description":"Atopic Dermatitis","metadata":null},{"id":"ff882acfc9c34961ad9447b742f4b2f7","type":"TRIAL","name":"Maximizing Outcomes in Treating Acute Migraine","canonical_id":"clinicaltrials.gov:NCT03896009","description":"Migraine","metadata":null},{"id":"e685fc65e7b7495fbd585556b9bc8778","type":"TRIAL","name":"Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00317434","description":"Ovarian Cancer","metadata":null},{"id":"aef94ac210a34a5f8b050c6d38ce001b","type":"DRUG","name":"Mazindol","canonical_id":"mesh:D008454","description":null,"metadata":null},{"id":"4b01d42109574998943223e09c5e5884","type":"TRIAL","name":"Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT02808104","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"feb49176481d44aa88e6ccaa03bd779c","type":"TRIAL","name":"Mazindol for Cocaine Abuse - 2","canonical_id":"clinicaltrials.gov:NCT00000277","description":"Cocaine-Related Disorders","metadata":null},{"id":"2f36386ec3fc4f3d8ead9c5fb050febb","type":"GO_TERM","name":"Mcs4 RR-MAPKKK complex","canonical_id":"go:GO:1990315","description":"\"A protein complex that consists of a phospho relay component and a MAPK cascade component. The complex is involved in signaling oxidative stress and osmostress.\" [PMID:24255738]","metadata":null},{"id":"df9fcd73056343098e856ad86a4c1954","type":"GO_TERM","name":"MdtBC Complex","canonical_id":"go:GO:1990203","description":"\"A protein complex containing two transmembrane subunits; a MdtB dimer and one unit of MdtC. Capable of exporting substrates across the cell membrane. Involved in conferring antibiotic resistance of Gram-negative bacteria by transporting drugs across the membrane.\" [GOC:bhm, PMID:20038594]","metadata":null},{"id":"9bddf7cd8f8d47eea93a761614f03a4d","type":"TRIAL","name":"Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT01626469","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"5442686cfe34451eb4a9999ef94d4891","type":"TRIAL","name":"Measurement of Sweat Sodium Concentration in Patients With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06354842","description":"Chronic Kidney Diseases","metadata":null},{"id":"2653dd2f450f4b1c9d2133b0e30327df","type":"TRIAL","name":"Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal","canonical_id":"clinicaltrials.gov:NCT03954483","description":"Anxiety","metadata":null},{"id":"6e0dbc5100db48988e1c5a92be733d6b","type":"TRIAL","name":"Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics","canonical_id":"clinicaltrials.gov:NCT03535402","description":"Rheumatoid Arthritis","metadata":null},{"id":"79bef5caa38f42b5b2e10a47b8a735e3","type":"TRIAL","name":"Measuring Acute Drug Demand in Humans","canonical_id":"clinicaltrials.gov:NCT05829655","description":"Opioid Use Disorder; Opioid Dependence","metadata":null},{"id":"b9cf64c9bd0c480db77dbfe1ff028fa0","type":"TRIAL","name":"Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172","canonical_id":"clinicaltrials.gov:NCT01222351","description":"Late Onset Alzheimer Disease","metadata":null},{"id":"c693e1ac6a4548bda04d8fa48d06385d","type":"TRIAL","name":"Measuring Placebo Effect by Elimination and Investigating Mechanism of Action","canonical_id":"clinicaltrials.gov:NCT00426010","description":"Placebo Effect; Placebo Mechanisms of Action","metadata":null},{"id":"8f70131d69b34890af18fa065a8199c2","type":"TRIAL","name":"Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study","canonical_id":"clinicaltrials.gov:NCT03460964","description":"Diabetes Mellitus","metadata":null},{"id":"1dcf183086b14596a0e0424166a7db68","type":"TRIAL","name":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","canonical_id":"clinicaltrials.gov:NCT04550494","description":"Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; HER2-Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Locally Advanced Gastric Carcinoma; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Ovarian Carcinoma; Locally Advanced Pancreatic Carcinoma; Locally Advanced Prostate Carcinoma; Metastatic Breast Carcinoma; Met\u2026","metadata":null},{"id":"b2a539cbcb7c44b493601d95843a5c2c","type":"DRUG","name":"Mebendazole","canonical_id":"mesh:D008463","description":null,"metadata":null},{"id":"2fc2923385fb4b00b1b064c3cc469e34","type":"TRIAL","name":"Mecamylamine for Autonomic Dysreflexia Prophylaxis","canonical_id":"clinicaltrials.gov:NCT03914677","description":"Spinal Cord Injuries","metadata":null},{"id":"c4d004a224af4af398097d50232e565d","type":"TRIAL","name":"Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00563797","description":"Alcohol Dependence; Depression","metadata":null},{"id":"9f66a24a1650483b8892c41c9410f03e","type":"TRIAL","name":"Mechanical Intracranial Artery DilAtation Using Stent-retriever for Cerebral Vasospasm","canonical_id":"clinicaltrials.gov:NCT06615882","description":"Intracranial Vasospasm","metadata":null},{"id":"97bd7a1af8944ac68e9c768adb549850","type":"TRIAL","name":"Mechanism of Action of Ocrelizumab in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03344094","description":"Multiple Sclerosis; Immune System Diseases","metadata":null},{"id":"cce775d0fc9640b4a5196d495bfa43e5","type":"TRIAL","name":"Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2","canonical_id":"clinicaltrials.gov:NCT03005184","description":"Heart Failure NYHA Class I; Heart Failure NYHA Class II; Heart Failure NYHA Class III","metadata":null},{"id":"1831f34dfa374a06a3526594928adadc","type":"TRIAL","name":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","canonical_id":"clinicaltrials.gov:NCT04113109","description":"Heart Failure","metadata":null},{"id":"d9a02e31f8b3487fbc9368b4473ea29a","type":"TRIAL","name":"Mechanisms Underlying Metabolic Syndrome in Obesity","canonical_id":"clinicaltrials.gov:NCT00579813","description":"Metabolic Syndrome; Insulin Resistance; Prediabetes","metadata":null},{"id":"3c32df5b5fd8479aacb7a7f8ba950f83","type":"TRIAL","name":"Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity","canonical_id":"clinicaltrials.gov:NCT01473732","description":"Chronic Allograft Injury; Calcineurin Inhibitor Toxicity","metadata":null},{"id":"2c30b1f371e54b6c9dcc20302c15f9ac","type":"TRIAL","name":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","canonical_id":"clinicaltrials.gov:NCT04503460","description":"Asthma","metadata":null},{"id":"31faa767ea824d899d78a1fcbc8edd97","type":"TRIAL","name":"Mechanisms of Altered Ventilatory Control in Heart Failure","canonical_id":"clinicaltrials.gov:NCT02421341","description":"Heart Failure","metadata":null},{"id":"127a270b529143928200b9d2ae627ec8","type":"TRIAL","name":"Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)","canonical_id":"clinicaltrials.gov:NCT01953120","description":"Renal Transplant Rejection","metadata":null},{"id":"97aee40381ba42a7b893ff4296063833","type":"TRIAL","name":"Mechanisms of Diuretic Resistance in Heart Failure, Aim 1","canonical_id":"clinicaltrials.gov:NCT05323487","description":"Heart Failure","metadata":null},{"id":"1af86c33731549d1b5606f791e7c0218","type":"TRIAL","name":"Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM","canonical_id":"clinicaltrials.gov:NCT00820573","description":"Diabetes","metadata":null},{"id":"bc583a244fa24e67b4fb797a264b5f17","type":"TRIAL","name":"Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT02928510","description":"Absence of Signs or Symptoms; B-Cell Non-Hodgkin Lymphoma; Digestive System Signs and Symptoms; Indolent Adult Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma","metadata":null},{"id":"3001174adc7a4b89a214df9885781d8f","type":"TRIAL","name":"Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension","canonical_id":"clinicaltrials.gov:NCT01862497","description":"Intradialytic Hypertension","metadata":null},{"id":"77b84337e58041f1b32d3bc2149eda24","type":"TRIAL","name":"Mechanisms of Lorcaserin for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT04396834","description":"Tobacco Use Disorder; Smoking Cessation","metadata":null},{"id":"08241820ab974d169f9a197a6ecb466e","type":"TRIAL","name":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","canonical_id":"clinicaltrials.gov:NCT01209455","description":"Poisoning","metadata":null},{"id":"8e63d3e2f0704f00b1a1a6838f8a1d36","type":"TRIAL","name":"Mechanisms of Refractory Hypertension (Reserpine)","canonical_id":"clinicaltrials.gov:NCT03223272","description":"Refractory Hypertension","metadata":null},{"id":"df902946bcd149789d6020a23dab5c47","type":"TRIAL","name":"Mechanisms of Semaglutide Therapy in Heart Failure Patients","canonical_id":"clinicaltrials.gov:NCT06541509","description":"Heart Failure; Obesity","metadata":null},{"id":"7053ea8bddf544929585f8d60fd32cbc","type":"TRIAL","name":"Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance","canonical_id":"clinicaltrials.gov:NCT02156271","description":"Insomnia","metadata":null},{"id":"1a90069db4964da5a4afde8b83f2d0db","type":"TRIAL","name":"Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery","canonical_id":"clinicaltrials.gov:NCT01765270","description":"Type 2 Diabetes Mellitus; Cardiovascular Disease","metadata":null},{"id":"43f20ca945f54f5cab707a9a60dd8ed7","type":"TRIAL","name":"Mechanistic Characterization of Uterine Pain","canonical_id":"clinicaltrials.gov:NCT04145518","description":"Dysmenorrhea (Disorder); Dysmenorrhea Primary; Dysmenorrhea Secondary; Endometrial Diseases; Leiomyoma; Fibroid Uterus","metadata":null},{"id":"8a79361071364d8cbf6ecfbbc1463173","type":"TRIAL","name":"Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)","canonical_id":"clinicaltrials.gov:NCT07820995","description":"IgA Nephropathy (IgAN); Immunoglobulin A Nephropathy (IgAN)","metadata":null},{"id":"27b0cf7c2b93412abea803a26bc43240","type":"TRIAL","name":"Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders","canonical_id":"clinicaltrials.gov:NCT03764098","description":"Alcohol Use","metadata":null},{"id":"cbe19730ad7140f2b637ec259edfa9af","type":"TRIAL","name":"Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept","canonical_id":"clinicaltrials.gov:NCT02353780","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"d84a61112dc64004a8f4e0910477aca5","type":"TRIAL","name":"Mechanistic Studies of Teriflunomide in RRMS","canonical_id":"clinicaltrials.gov:NCT03464448","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"099c9b099ddc40f180156ad3a2314418","type":"TRIAL","name":"Mechanistic Study of Ocrevus","canonical_id":"clinicaltrials.gov:NCT04459988","description":"Multiple Sclerosis","metadata":null},{"id":"f007c60ef9af4ab1aec0f662fb7ece9a","type":"DRUG","name":"Mechlorethamine","canonical_id":"mesh:D008466","description":null,"metadata":null},{"id":"2112d1123a8646b28c88ca75a241cd41","type":"DRUG","name":"Meclofenamic acid","canonical_id":"mesh:D008469","description":null,"metadata":null},{"id":"d3cdcbedfa484fc5b4f85f5321336b30","type":"DISEASE","name":"Meconium ileus","canonical_id":"hp:0004401","description":null,"metadata":null},{"id":"febce774636743b68cedba60a1926c59","type":"TRIAL","name":"Medical Abortion for Emergency Contraception Failure","canonical_id":"clinicaltrials.gov:NCT00677755","description":"Emergency Contraception; Abortion, Induced","metadata":null},{"id":"6f4e11402fed4758b9d54dd302b5b7b6","type":"TRIAL","name":"Medical Management of Late Intrauterine Death.","canonical_id":"clinicaltrials.gov:NCT02488642","description":"Cervical Pregnancy; Maternal Care for Late Fetal Death","metadata":null},{"id":"e96bf72b568447d0aa3704405ab611cb","type":"TRIAL","name":"Medical Management of Sleep Disturbance During Opioid Tapering","canonical_id":"clinicaltrials.gov:NCT03789214","description":"Opioid Dependence; Opioid Withdrawal; Sleep Disturbance","metadata":null},{"id":"079b8e2f2dc2442e894ebfac596ba76f","type":"TRIAL","name":"Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi","canonical_id":"clinicaltrials.gov:NCT05977647","description":"Ureteric Stone of Lower Third of Ureter","metadata":null},{"id":"d6a0cd6ddbd14714a8a3bc7972cacaf7","type":"TRIAL","name":"Medical Therapies for Chronic Post-Traumatic Headaches","canonical_id":"clinicaltrials.gov:NCT00862095","description":"Headache","metadata":null},{"id":"eacb87c76e954e9f98790802cc410758","type":"TRIAL","name":"Medical Therapy of Prostatic Symptoms","canonical_id":"clinicaltrials.gov:NCT00021814","description":"Prostatic Hyperplasia; Prostatic Hypertrophy, Benign","metadata":null},{"id":"0683b3e80e094abb93597b1c5cd6a938","type":"TRIAL","name":"Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease","canonical_id":"clinicaltrials.gov:NCT07025226","description":"Glioma","metadata":null},{"id":"dd3fa5230c8f4a9cadca40139f46101c","type":"TRIAL","name":"Medication Development in Alcoholism: Suvorexant Versus Placebo","canonical_id":"clinicaltrials.gov:NCT04229095","description":"Alcohol Use Disorder (AUD)","metadata":null},{"id":"4a44184f597f404d9ef865d8d4de35e0","type":"TRIAL","name":"Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters","canonical_id":"clinicaltrials.gov:NCT01028014","description":"Urethral Sphincter Activity","metadata":null},{"id":"cdfd72625c56464781a321cbfdec4e20","type":"TRIAL","name":"Medication Enhanced Rapid Therapy","canonical_id":"clinicaltrials.gov:NCT02099825","description":"Anxiety Disorders","metadata":null},{"id":"92e91bc2de434016bedef9b48483ea51","type":"TRIAL","name":"Medication and Counseling for Controlled Drinking","canonical_id":"clinicaltrials.gov:NCT01115894","description":"Alcohol Dependence; Alcohol Abuse","metadata":null},{"id":"735398863eb546fab3aa91d480b749e7","type":"TRIAL","name":"Medication in Early Diabetes (MED) Study","canonical_id":"clinicaltrials.gov:NCT00437970","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"00560b0c9c5e4a81bbdef5908c9194db","type":"TRIAL","name":"Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT06491108","description":"Enlarged Prostate With Lower Urinary Tract Symptoms","metadata":null},{"id":"9dd164fd20204df8acfb7e31092e48d4","type":"TRIAL","name":"Medications for Obstructive Sleep Apnea In Children With Down Syndrome","canonical_id":"clinicaltrials.gov:NCT04115878","description":"Obstructive Sleep Apnea; Down Syndrome","metadata":null},{"id":"2ed687ff88e6473787e6b35212be33ba","type":"TRIAL","name":"Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","canonical_id":"clinicaltrials.gov:NCT05933603","description":"Obstructive Sleep Apnea; Down Syndrome","metadata":null},{"id":"574f8b987be74698abedc5d7669b30a3","type":"TRIAL","name":"Medications for Stopping Cocaine Dependence and Preventing Relapse","canonical_id":"clinicaltrials.gov:NCT00218023","description":"Cocaine Abuse; Cocaine-Related Disorders","metadata":null},{"id":"3b8cf7831e204ad084fb99d560cdd01d","type":"TRIAL","name":"Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study","canonical_id":"clinicaltrials.gov:NCT04547179","description":"Migraine","metadata":null},{"id":"43dac703bc8a4a4d85c27b8e9c400df8","type":"TRIAL","name":"Medicine-induced Cardiac Hemodialysis on COVID-19","canonical_id":"clinicaltrials.gov:NCT05711810","description":"Severe Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic; Infection Viral","metadata":null},{"id":"6189cfa20f464c229294c1ae759e937a","type":"TRIAL","name":"Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema","canonical_id":"clinicaltrials.gov:NCT04910503","description":"Diabetic Macular Edema","metadata":null},{"id":"5bda69a8ad1b400c90ef92f50eebaa19","type":"TRIAL","name":"Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol","canonical_id":"clinicaltrials.gov:NCT03560375","description":"Diabetes Mellitus, Type 2; Sarcopenia; Weight Loss","metadata":null},{"id":"20077ab3761a4a37b07ba6d6b3e178b5","type":"DRUG","name":"Medroxyprogesterone","canonical_id":"mesh:D008525","description":null,"metadata":null},{"id":"f332f5dc650443228cec982942a87530","type":"TRIAL","name":"Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00577122","description":"Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"0c57bb9f6f164bbfa35c2820b1fcb7fd","type":"TRIAL","name":"Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00830414","description":"Healthy","metadata":null},{"id":"353e0855f7b74f5a9afd6b39646ab37e","type":"TRIAL","name":"Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","canonical_id":"clinicaltrials.gov:NCT05675787","description":"Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I","metadata":null},{"id":"2f42fce215714928bd80b81fade5297f","type":"TRIAL","name":"Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT03018249","description":"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma","metadata":null},{"id":"2882956e22b14af188f3a78151bb190b","type":"TRIAL","name":"Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus","canonical_id":"clinicaltrials.gov:NCT00064025","description":"Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Recurrent Uterine Corpus Carcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer","metadata":null},{"id":"39e92e19bf3b40488a790b81aa8686f0","type":"DISEASE","name":"Medullary thyroid carcinoma","canonical_id":"mesh:C536914","description":null,"metadata":null},{"id":"cf421df543ac4ac9a1e24f8d79441f58","type":"DRUG","name":"Mefenamic Acid","canonical_id":"mesh:D008528","description":null,"metadata":null},{"id":"04460ae409bf4be8b98549fb83380c38","type":"DRUG","name":"Mefloquine","canonical_id":"mesh:D015767","description":null,"metadata":null},{"id":"541a5122ffa04b128b6d14e0ab7bdbd7","type":"DISEASE","name":"Megaloblastic anemia (Methotrexate Treatment)","canonical_id":"mesh:D000749","description":null,"metadata":null},{"id":"3e8ba57fd12a4c9f84beb708d956290b","type":"TRIAL","name":"Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma","canonical_id":"clinicaltrials.gov:NCT04491643","description":"Endometrial Carcinoma Stage I","metadata":null},{"id":"4165a1f8ffca43efb9006bf44d704b0e","type":"TRIAL","name":"Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite","canonical_id":"clinicaltrials.gov:NCT01501396","description":"Anorexia","metadata":null},{"id":"85b0e918b6e3406582c6fe0fabca9756","type":"GO_TERM","name":"Mei2 nuclear dot complex","canonical_id":"go:GO:0033620","description":"\"A ribonucleoprotein complex that forms during meiotic prophase in a fixed position in the horsetail nucleus; contains Mei2 and meiRNA. May play a role in the progression of meiosis I.\" [GOC:vw, PMID:12808043]","metadata":null},{"id":"c1057d0b5ad7456292a4759c6ed9a73b","type":"DISEASE","name":"Meibomian gland dysfunction","canonical_id":"mesh:D000080343","description":null,"metadata":null},{"id":"a7db3923feec42f99edcc13690c900a3","type":"PROTEIN","name":"Melanocyte-stimulating hormone receptor","canonical_id":"uniprot:Q01726","description":null,"metadata":null},{"id":"b28589487d3a4a8780412a379a9d5ee3","type":"DISEASE","name":"Melanoma","canonical_id":"doid:1909","description":null,"metadata":null},{"id":"caf27b7c765d49d497c4469d5d909c24","type":"TRIAL","name":"Melanoma Metastasized to the Brain and Steroids","canonical_id":"clinicaltrials.gov:NCT03563729","description":"Malignant Melanoma","metadata":null},{"id":"d47c7d91d3064379ab70f732bbc61c74","type":"TRIAL","name":"Melatonin 3mg and 5mg Compared to Cognitive Behavioral Therapy for Insomnia (CBT-I) in the Treatment of Insomnia","canonical_id":"clinicaltrials.gov:NCT02798367","description":"Insomnia Disorder","metadata":null},{"id":"ccdfe715895a49d09b3f1c41571783b0","type":"TRIAL","name":"Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01428661","description":"Major Depressive Disorder","metadata":null},{"id":"a4184eb9db9045429929d86f9224d111","type":"TRIAL","name":"Melatonin Agonist for Shift-time Workers.","canonical_id":"clinicaltrials.gov:NCT07382843","description":"Circadian Rhythm Disorders","metadata":null},{"id":"7a973704ad0a442385200cf8f8449d19","type":"TRIAL","name":"Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19","canonical_id":"clinicaltrials.gov:NCT04470297","description":"Covid19; Lung Injury","metadata":null},{"id":"fc3b030fb47446078a15de2db45a4b9c","type":"TRIAL","name":"Melatonin Decreases Eye Pressure in Normotensive Patients","canonical_id":"clinicaltrials.gov:NCT03193112","description":"Depressive Disorder","metadata":null},{"id":"bf985165dc294a60acdedd07fd93abbd","type":"TRIAL","name":"Melatonin Gel as an Adjuvant in the Surgical Management of Intrabony Defects","canonical_id":"clinicaltrials.gov:NCT06821425","description":"Periodontal Disease, AVDC Stage 3","metadata":null},{"id":"ea60180e65fe43359b78b10cfee8e58f","type":"TRIAL","name":"Melatonin Supplementation and Performance","canonical_id":"clinicaltrials.gov:NCT02876770","description":"Motor Activity","metadata":null},{"id":"ea01fbbf9a534377ad2bbf2ff1494d77","type":"TRIAL","name":"Melatonin Versus Hydroxizin for Pre Operative Anxiety in Elderly Patients With Hip Fracture","canonical_id":"clinicaltrials.gov:NCT05224167","description":"Preoperative Anxiety","metadata":null},{"id":"059825e072e5436a8ae4467fc64c017e","type":"TRIAL","name":"Melatonin and Its Effect on the Perioperative Opioid Needs in Pediatric Patients Undergoing Laparoscopic Surgery.","canonical_id":"clinicaltrials.gov:NCT05728892","description":"Postoperative Pain","metadata":null},{"id":"36df68e439ce4e2aab8e9a80b8fd2ec4","type":"TRIAL","name":"Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms","canonical_id":"clinicaltrials.gov:NCT07617922","description":"Ureteral Stent-Related Symptoms; Ureteral Calculi; Lower Urinary Tract Symptoms","metadata":null},{"id":"b71109ee425a4b7ba9511afc95658ecd","type":"TRIAL","name":"Melatonin for Cerebral Palsy Children's Sleep and Health","canonical_id":"clinicaltrials.gov:NCT04392063","description":"Cerebral Palsy; Melatonin; Growth; Children, Only","metadata":null},{"id":"41a9e8b91a7e430fa3541646cea8939e","type":"TRIAL","name":"Melatonin for Prevention of Kidney Injury","canonical_id":"clinicaltrials.gov:NCT05084196","description":"Acute Kidney Injury; Adverse Drug Event","metadata":null},{"id":"ec70096357a748eeb0f8205a56a153f4","type":"TRIAL","name":"Melatonin for Prevention of Metabolic Side Effects of Olanzapine","canonical_id":"clinicaltrials.gov:NCT01593774","description":"Schizophrenia","metadata":null},{"id":"6b880738e550420a98db49b7d00c3244","type":"TRIAL","name":"Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol","canonical_id":"clinicaltrials.gov:NCT02903901","description":"Delirium","metadata":null},{"id":"d75e638b2bbf42488ec60f594f0732ce","type":"TRIAL","name":"Melatonin for Treatment of Delirium in Critically Ill Adult Patients","canonical_id":"clinicaltrials.gov:NCT05713877","description":"Delirium","metadata":null},{"id":"f98801a4df684b4fa693a637d13ebc97","type":"TRIAL","name":"Melatonin in ADHD and Sleep Problems","canonical_id":"clinicaltrials.gov:NCT04318067","description":"Attention Deficit Hyperactivity Disorder; Sleep Disorder","metadata":null},{"id":"7d0334ed5ae942608b142cb962a6cc0b","type":"TRIAL","name":"Melatonin in Pediatric FD Population","canonical_id":"clinicaltrials.gov:NCT04684199","description":"Dyspepsia","metadata":null},{"id":"b21fe10562dd41ecb155dacb5aa2f993","type":"TRIAL","name":"Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population","canonical_id":"clinicaltrials.gov:NCT02333149","description":"Attention Deficit/Hyperactivity Disorder; Initial Insomnia","metadata":null},{"id":"f4a37f8c06ce438089e744e692c5f0fc","type":"TRIAL","name":"Melatonin on Anxiety and Sleep Quality in Adults Undergoing Coronary Artery Bypass Graft Surgery","canonical_id":"clinicaltrials.gov:NCT06237556","description":"Melatonin; Anxiety; Sleep Quality; Coronary Artery Bypass Graft","metadata":null},{"id":"5d0dbfc5e45f41cda68c9a4714c3c1b2","type":"TRIAL","name":"Melatonin vs Midazolam in Children Undergoing Tonsillectomy","canonical_id":"clinicaltrials.gov:NCT07336095","description":"Emergence Delirium, Anesthesia; Child; Anxiety; Midazolam Premedication; Melatonin Bioavailability; Tonsillectomy","metadata":null},{"id":"d3e57502bade4bb38e97fc2142370ae5","type":"DRUG","name":"Melevodopa","canonical_id":"mesh:C035420","description":null,"metadata":null},{"id":"a0c2945bc78143f385fbfa6ac40f448b","type":"DRUG","name":"Meloxicam","canonical_id":"mesh:C065757","description":null,"metadata":null},{"id":"a095591a6e9040e7ba2e46c14e488d21","type":"TRIAL","name":"Meloxicam 15 mg Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00840879","description":"Healthy","metadata":null},{"id":"1d0ef261976a4cfab91df475c337711e","type":"TRIAL","name":"Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients","canonical_id":"clinicaltrials.gov:NCT06704113","description":"Dental Pain; Sensation Disorders","metadata":null},{"id":"1e5e90d7979b441bb68b80df18356dda","type":"TRIAL","name":"Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)","canonical_id":"clinicaltrials.gov:NCT05291598","description":"Total Knee Replacement; Total Hip Replacement","metadata":null},{"id":"34eb973816284b5e9b3326c17f84a9f1","type":"TRIAL","name":"Meloxicam vs Placebo for Mobilization","canonical_id":"clinicaltrials.gov:NCT02003625","description":"Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Multiple Myeloma; Hematopoietic Stem Cells","metadata":null},{"id":"c93e2e3545e848c5b4cadb701d644ea6","type":"DRUG","name":"Melphalan","canonical_id":"mesh:D008558","description":null,"metadata":null},{"id":"20d2052ccb1142a5a278258fb9fe9acc","type":"DRUG","name":"Melphalan","canonical_id":"ncit:C633","description":null,"metadata":null},{"id":"425c33c5c5c44ce3a198f261ac7fece5","type":"TRIAL","name":"Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00482846","description":"Mucositis; Multiple Myeloma","metadata":null},{"id":"384819ac6b844df79d68439e27176215","type":"TRIAL","name":"Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05013437","description":"Multiple Myeloma","metadata":null},{"id":"fb83115c55db418dbf1be3efaf5108c0","type":"TRIAL","name":"Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03100877","description":"Plasma Cell Leukemia in Remission; Plasma Cell Myeloma","metadata":null},{"id":"07955d140853403c9677c68c41112dab","type":"TRIAL","name":"Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment","canonical_id":"clinicaltrials.gov:NCT00392691","description":"Lymphoma","metadata":null},{"id":"3dd4f2317ed14b679d221c8a0ad1c123","type":"TRIAL","name":"Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment","canonical_id":"clinicaltrials.gov:NCT01876823","description":"Mild Cognitive Impairment; Major Depressive Disorder; Alzheimer's Disease","metadata":null},{"id":"804cd377e4334ef386cf91dfcceac2e0","type":"TRIAL","name":"Memantine Versus Donepezil in Early Stages of Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00505167","description":"Dementia, Alzheimer Type","metadata":null},{"id":"37f4ae66c4144762942d9930f4d3e11d","type":"TRIAL","name":"Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01533493","description":"Attention Deficit Hyperactivity Disorder (ADHD); Executive Function Deficits (EFD)","metadata":null},{"id":"5b482711dfb940409d61db4b227e9c3a","type":"TRIAL","name":"Memory Consolidation in Pharmacologically Enhanced Naps","canonical_id":"clinicaltrials.gov:NCT00777829","description":"Sleep","metadata":null},{"id":"8f4aabcb82ec45e797c02836eb576435","type":"DRUG","name":"Menatetrenone","canonical_id":"mesh:C030814","description":null,"metadata":null},{"id":"d905d262fd4c455880529265ab2431a9","type":"DISEASE","name":"Meniere disease","canonical_id":"mondo:0007972","description":null,"metadata":null},{"id":"9d120604bfd94e3e81c011a492f89ac8","type":"DISEASE","name":"Meningitis","canonical_id":"mesh:D008581","description":null,"metadata":null},{"id":"a3ec5d048bec46a08b3e0b5c0a9acc4e","type":"DISEASE","name":"Meningitis, Escherichia coli","canonical_id":"mesh:D020814","description":null,"metadata":null},{"id":"dcb2e5c2c0d9411e8851ea026d2c1203","type":"DISEASE","name":"Meningitis, Fungal","canonical_id":"mesh:D016921","description":null,"metadata":null},{"id":"380bf61d0c9c48d5aee82afdd679c7b9","type":"DISEASE","name":"Meningitis, Listeria","canonical_id":"mesh:D008584","description":null,"metadata":null},{"id":"9ff89a1108ea4a6785084479caba7628","type":"DISEASE","name":"Meningococcal meningitis","canonical_id":"mesh:D008585","description":null,"metadata":null},{"id":"9b43dbd5eaf44b3abd0b628ff171ddc0","type":"DISEASE","name":"Menopausal flushing","canonical_id":"mesh:D019584","description":null,"metadata":null},{"id":"a1bf813639e1473fb12c76275999a00d","type":"TRIAL","name":"Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C","canonical_id":"clinicaltrials.gov:NCT01402583","description":"Chronic Hepatitis C","metadata":null},{"id":"856b166271ff4ac790d873ed0310a3c9","type":"DISEASE","name":"Menorrhagia","canonical_id":"hp:0000132","description":null,"metadata":null},{"id":"39c57bd66d9e46cc830461176d668495","type":"DISEASE","name":"Menorrhagia","canonical_id":"mesh:D008595","description":null,"metadata":null},{"id":"8be4813ff9844d4faccb44be0e0e905e","type":"TRIAL","name":"Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity","canonical_id":"clinicaltrials.gov:NCT00664755","description":"Nicotine Dependence","metadata":null},{"id":"fa38a83010f84d20a34ff365e9cccc64","type":"TRIAL","name":"Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)","canonical_id":"clinicaltrials.gov:NCT00329355","description":"Migraine; Migraine Disorders","metadata":null},{"id":"04ed5745f17748fb8d5ab0527659d5f9","type":"DISEASE","name":"Menstrual disorder","canonical_id":"efo:0010270","description":null,"metadata":null},{"id":"976d3272d84b48608783cb5d3b8bdb40","type":"TRIAL","name":"Mental Ability Challenge Study in Adults With and Without HIV","canonical_id":"clinicaltrials.gov:NCT03244488","description":"HIV-1-infection; Aging, Premature; Cognitive Impairment; Memory Impairment; HIV-Associated Cognitive Motor Complex","metadata":null},{"id":"43432de9ad5340e1b3d90be932a7973b","type":"TRIAL","name":"Mentored Patient-Oriented Research Career Development Award","canonical_id":"clinicaltrials.gov:NCT00203684","description":"Asthma; Distal Lung Inflammation","metadata":null},{"id":"937f56d967eb4dddbf28435a6ad4bedd","type":"DRUG","name":"Mepacrine","canonical_id":"mesh:D011796","description":null,"metadata":null},{"id":"2a36dba7dcac4887b67960d3512b11fd","type":"DRUG","name":"Mepenzolate","canonical_id":"mesh:C005101","description":null,"metadata":null},{"id":"a8cc22c12e96480d831d78ad9ffeeee8","type":"DRUG","name":"Mephentermine","canonical_id":"mesh:D008616","description":null,"metadata":null},{"id":"7cd82f5417cf431dbab8ca9bf85736d1","type":"TRIAL","name":"Mepo for Eosinophilic Esophagitis (EoE) Study","canonical_id":"clinicaltrials.gov:NCT03656380","description":"EoE; Eosinophilic Esophagitis","metadata":null},{"id":"7b9864ebf1c54a26a8663b7bd559d2ed","type":"TRIAL","name":"Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis","canonical_id":"clinicaltrials.gov:NCT05189613","description":"Bronchial Asthma; Bronchiectasis","metadata":null},{"id":"fc9550b82a8f4b73b44a4a60aea3c461","type":"TRIAL","name":"Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level","canonical_id":"clinicaltrials.gov:NCT04133909","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"d9492a6cd86243d5a1343029bcebd59e","type":"TRIAL","name":"Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis","canonical_id":"clinicaltrials.gov:NCT01463644","description":"Chronic Obstructive Pulmonary Diseases; Chronic Airways Limitation; Bronchitis","metadata":null},{"id":"1291374c6ed0473384096039fdee9d16","type":"TRIAL","name":"Mepolizumab in Nasal Polyposis","canonical_id":"clinicaltrials.gov:NCT01362244","description":"Nasal Polyps","metadata":null},{"id":"2004da96d781474494a9f280473819b4","type":"DRUG","name":"Meprobamate","canonical_id":"mesh:D008620","description":null,"metadata":null},{"id":"19c02857c79043549bdf76ab6acc0ae8","type":"DRUG","name":"Mercaptopurine","canonical_id":"mesh:D015122","description":null,"metadata":null},{"id":"959a8ab47cb4458086eb505c209f2cce","type":"DISEASE","name":"Merkel Cell Carcinoma","canonical_id":"doid:3965","description":null,"metadata":null},{"id":"9eeed538125a4a22a613aef91964e0b1","type":"DISEASE","name":"Merkel cell carcinoma","canonical_id":"mesh:D015266","description":null,"metadata":null},{"id":"cafb99ff54214012a630c505f8d7aeb3","type":"DISEASE","name":"Merkel cell skin cancer","canonical_id":"efo:1001471","description":null,"metadata":null},{"id":"18b0ac244067421093d02271677ea645","type":"DRUG","name":"Mesalazine","canonical_id":"mesh:D019804","description":null,"metadata":null},{"id":"70d8cbff22064b1d819d78b07a908d9c","type":"TRIAL","name":"Mesalazine Therapy in Patients With Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT00626288","description":"Irritable Bowel Syndrome","metadata":null},{"id":"e7f0990257384ee28cd5453a58b66e51","type":"TRIAL","name":"Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)","canonical_id":"clinicaltrials.gov:NCT01316718","description":"Irritable Bowel Syndrome With Diarrhoea","metadata":null},{"id":"ce40a444a13a4a289b0be9d66b977dee","type":"TRIAL","name":"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04034238","description":"Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, Pancreatic","metadata":null},{"id":"b62b7a0fa6534791a235cbfe200fb756","type":"TRIAL","name":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT03654833","description":"Mesothelioma, Malignant","metadata":null},{"id":"5ba7a2bced1a46a0a9b18bd270b933f7","type":"TRIAL","name":"Mesotherapy In Lateral Epicondylitis","canonical_id":"clinicaltrials.gov:NCT04201249","description":"Lateral Epicondylitis","metadata":null},{"id":"113f543d7ed5408ab026c9e1c7c3693f","type":"DRUG","name":"Mestranol","canonical_id":"mesh:D008656","description":null,"metadata":null},{"id":"c45850be47e94533b3ff535ba5ac25af","type":"GO_TERM","name":"Met1-linked polyubiquitin deubiquitinase activity","canonical_id":"go:GO:0061815","description":"\"Catalysis of the hydrolysis of ubiquitin units from Met1-linked (or linear) polyubiquitin chains.\" [GOC:dph, PMID:26503766, PMID:27702987]","metadata":null},{"id":"dfe119a115a64ee885e57c0dd7364906","type":"TRIAL","name":"Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304","canonical_id":"clinicaltrials.gov:NCT01457989","description":"Epilepsy, Partial","metadata":null},{"id":"5a8bbdd9093142e5aeaa162872942a41","type":"TRIAL","name":"Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)","canonical_id":"clinicaltrials.gov:NCT00887510","description":"Hypertension","metadata":null},{"id":"ec295a0e5cd640799934ce13aad6e2ab","type":"TRIAL","name":"Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin","canonical_id":"clinicaltrials.gov:NCT00576784","description":"Type 2 Diabetes Mellitus; Insulin Resistance","metadata":null},{"id":"fdc95664e58043cd977267f89d7d29a7","type":"TRIAL","name":"Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans","canonical_id":"clinicaltrials.gov:NCT00625170","description":"Insulin Resistance; Dyslipidemia","metadata":null},{"id":"392bdba8227d486084ee809257682452","type":"TRIAL","name":"Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans","canonical_id":"clinicaltrials.gov:NCT00625014","description":"Insulin Resistance; Dyslipidemia","metadata":null},{"id":"331de782feeb4378896847e4c1b09cc3","type":"TRIAL","name":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","canonical_id":"clinicaltrials.gov:NCT07045935","description":"Prolactinoma","metadata":null},{"id":"e92badfe90864041b7090d79edcb9f7a","type":"TRIAL","name":"Metabolic Syndrome in PCOS: Precursors and Interventions","canonical_id":"clinicaltrials.gov:NCT00442689","description":"Polycystic Ovary Syndrome; Metabolic Syndrome","metadata":null},{"id":"22db410b9eae421babcec9ceb0913720","type":"TRIAL","name":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","canonical_id":"clinicaltrials.gov:NCT05702853","description":"B-cell Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia","metadata":null},{"id":"60e089fa5c5647e4a7415691619ae10e","type":"TRIAL","name":"Metabolism Informed Smoking Treatment: The MIST RCT","canonical_id":"clinicaltrials.gov:NCT04590404","description":"Smoking","metadata":null},{"id":"17688aa72b3f445190ba8b03278b071f","type":"TRIAL","name":"Metabolism-informed Care for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT03227679","description":"Tobacco Use; Tobacco Use Cessation","metadata":null},{"id":"6c9d385c43ff4984be3adf227e686933","type":"PROTEIN","name":"Metabotropic glutamate receptor 5","canonical_id":"uniprot:P41594","description":null,"metadata":null},{"id":"d4a71b1dfad34c1096ea088c0adc4035","type":"TRIAL","name":"Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI","canonical_id":"clinicaltrials.gov:NCT03698253","description":"Colorectal Cancer","metadata":null},{"id":"a46b65b147354f5e82e469229d337273","type":"TRIAL","name":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","canonical_id":"clinicaltrials.gov:NCT07194044","description":"Metastatic Ewing Sarcoma","metadata":null},{"id":"919c259ed4ee41ce87b960f6ef256bef","type":"DRUG","name":"Metformin","canonical_id":"mesh:D008687","description":null,"metadata":null},{"id":"95f20aff57f4422fbbf73f3e1ccb8a25","type":"TRIAL","name":"Metformin Safety and Efficacy in Osteoarthritis.","canonical_id":"clinicaltrials.gov:NCT06231758","description":"Osteo Arthritis Knee","metadata":null},{"id":"1998707d14664bb79b0539d249c816aa","type":"TRIAL","name":"Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients","canonical_id":"clinicaltrials.gov:NCT01003483","description":"Obesity","metadata":null},{"id":"bd3ce439f44241faa6fad1557154c3bf","type":"TRIAL","name":"Metformin and Furosemide Drug-Drug Interaction Study","canonical_id":"clinicaltrials.gov:NCT02028689","description":"Healthy","metadata":null},{"id":"c8a34e0adb8647d39305dfd6d54ec02c","type":"TRIAL","name":"Metformin-Dipyridamole Interaction Trial","canonical_id":"clinicaltrials.gov:NCT01613755","description":"Diabetes","metadata":null},{"id":"ab68f43c24ec41939830ae3a32ce087c","type":"TRIAL","name":"MethaLoad Dose-Finding Study","canonical_id":"clinicaltrials.gov:NCT06877858","description":"Opioid Use Disorder (OUD)","metadata":null},{"id":"5b180b011d814b71974db4b537471006","type":"DRUG","name":"Methacarbamol","canonical_id":"mesh:D008721","description":null,"metadata":null},{"id":"fa171ff2453c41e4901dad169301a4d6","type":"TRIAL","name":"Methadone Anesthesia For Kidney Transplant Receptors","canonical_id":"clinicaltrials.gov:NCT04908345","description":"Renal Failure Chronic; Surgery","metadata":null},{"id":"ea5f5b4287f24f4bb53beca1fa1fec87","type":"TRIAL","name":"Methadone Versus Morphine for Cancer-Related Pain","canonical_id":"clinicaltrials.gov:NCT00573937","description":"Neoplasms; Pain","metadata":null},{"id":"b8c6ac6bc69c4702bfe0ba5eb5d66af8","type":"TRIAL","name":"Methadone and Hydromorphone For Spinal Surgery","canonical_id":"clinicaltrials.gov:NCT02107339","description":"Hydromorphone Use; Acute Postoperative Pain; Patient Satisfaction; Chronic Persistent Surgical Pain","metadata":null},{"id":"c42d2ad19abb474dbbc970d86535f2e5","type":"TRIAL","name":"Methadone for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery","canonical_id":"clinicaltrials.gov:NCT03778372","description":"Emergence Delirium; Strabismus","metadata":null},{"id":"ce4dd148d36c46409ad60dfcc973ac58","type":"TRIAL","name":"Methadone for Spinal Fusion Surgery.","canonical_id":"clinicaltrials.gov:NCT04764825","description":"Pain, Postoperative; Back Pain; Opioid Use; Methadone; Degenerative Spondylolisthesis; Stenosis, Spinal","metadata":null},{"id":"a6f90c052ff14b74ab2a8d4b29f904b1","type":"TRIAL","name":"Methadone in TKA for Post-op Pain and Opioid Reduction","canonical_id":"clinicaltrials.gov:NCT07226076","description":"Post Operative Pain","metadata":null},{"id":"6a6b73c9b2184344ad66c0356a85daea","type":"TRIAL","name":"Methadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study","canonical_id":"clinicaltrials.gov:NCT07222072","description":"Post Operative Pain; Spinal Surgery","metadata":null},{"id":"b6f2cff79f4b40759512c2bffb99f8c3","type":"DRUG","name":"Methadyl Acetate","canonical_id":"mesh:D008692","description":null,"metadata":null},{"id":"87546f97564346f2bdd2efeff6c6fbc0","type":"DRUG","name":"Methamphetamine","canonical_id":"mesh:D008694","description":null,"metadata":null},{"id":"779fcc743bae4bcc93d26e2f6cb1a7f9","type":"TRIAL","name":"Methamphetamine Abuse Treatment in Patients With AIDS - 1","canonical_id":"clinicaltrials.gov:NCT00000321","description":"Substance-Related Disorders","metadata":null},{"id":"214fd040595d4211a4eea99c5507d958","type":"DISEASE","name":"Methanol poisoning","canonical_id":"mesh:D000138","description":null,"metadata":null},{"id":"f37a0e8127b24f5d83783f8b714bbda5","type":"GO_TERM","name":"Methanosarcina-phenazine hydrogenase activity","canonical_id":"go:GO:0051911","description":"\"Catalysis of the reaction: H2 + 2-(2,3-dihydropentaprenyloxy)phenazine = 2-dihydropentaprenyloxyphenazine.\" [EC:1.12.98.3]","metadata":null},{"id":"f5af6dbce48d469ca3ecb76b3f1d74a5","type":"DRUG","name":"Methanthelinium","canonical_id":"mesh:C084588","description":null,"metadata":null},{"id":"0165ad44908047e2b0af9f512fc46a42","type":"DRUG","name":"Metharbital","canonical_id":"mesh:C084822","description":null,"metadata":null},{"id":"174d3364eed443758c6e540035160e31","type":"DRUG","name":"Methazolamide","canonical_id":"mesh:D008704","description":null,"metadata":null},{"id":"6203537f88574a218b4a5be3bc049d99","type":"DISEASE","name":"Methemoglobinemia","canonical_id":"mesh:D008708","description":null,"metadata":null},{"id":"d5190fee449b46ea93b845b0927d2e31","type":"TRIAL","name":"Methimazole in Patients With Progressive Glioblastoma","canonical_id":"clinicaltrials.gov:NCT05607407","description":"Glioblastoma; Glioma","metadata":null},{"id":"4abad0d2931d468d8e7a5530b9aa6b3f","type":"TRIAL","name":"Methimazole to Treat Polymyositis and Dermatomyositis","canonical_id":"clinicaltrials.gov:NCT00001421","description":"Dermatomyositis; Polymyositis","metadata":null},{"id":"0afd716307fb493b9135cb3fbe0e1388","type":"TRIAL","name":"Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure","canonical_id":"clinicaltrials.gov:NCT05100017","description":"Kidney Calculi; Kidney Diseases; Nephrolithiasis; Urolithiasis; Ureteral Diseases; Ureteral Calculi","metadata":null},{"id":"84294bd394b3488bb47a0e4135b8d897","type":"TRIAL","name":"Methoclopramide for Gastroesophageal Reflux in Premature Infants","canonical_id":"clinicaltrials.gov:NCT02907632","description":"Gastroesophageal Reflux","metadata":null},{"id":"7d1c36bf783f49818018f04d10461673","type":"TRIAL","name":"Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments","canonical_id":"clinicaltrials.gov:NCT05638932","description":"COVID-19","metadata":null},{"id":"8c58ae76fc014dde81ff6e25efeac74f","type":"TRIAL","name":"Methods Decreasing Bleeding in Open Myomectomy","canonical_id":"clinicaltrials.gov:NCT05806307","description":"Misoprostol Allergy; Oxytocin Allergy; Tranexamic Acid Allergy; Ethamsylate Allergy; Myoma; Blood Loss, Surgical","metadata":null},{"id":"fce4a17685444cd3afa27615ab12e0c1","type":"TRIAL","name":"Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00002487","description":"Ovarian Cancer","metadata":null},{"id":"f5d72071c2c048bbba7becbdfef16bcb","type":"TRIAL","name":"Methotrexate Treatment for Ectopic Pregnancy","canonical_id":"clinicaltrials.gov:NCT01855568","description":"Ectopic Pregnancy","metadata":null},{"id":"da81e90fc11045368f1b1889467afc6c","type":"TRIAL","name":"Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments","canonical_id":"clinicaltrials.gov:NCT07501507","description":"Erosive Hand Osteoarthritis","metadata":null},{"id":"9992cf37d7004022967b86aaaef4dd64","type":"TRIAL","name":"Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT01188798","description":"Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia; Chronic Myelocytic Leukemia; Hodgkin's Disease; Myelodysplastic Syndrome","metadata":null},{"id":"cbbc3b2c0324482199a861b0786361ab","type":"TRIAL","name":"Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03254589","description":"Rheumatoid Arthritis; Stiffness, Aortic; Endothelial Dysfunction; Cardiovascular Risk Factor","metadata":null},{"id":"943a28791c164eb198a03029c41c4961","type":"TRIAL","name":"Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL","canonical_id":"clinicaltrials.gov:NCT05583071","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"a7ffd4b46e3e4522884986f0eb13d836","type":"TRIAL","name":"Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage","canonical_id":"clinicaltrials.gov:NCT00905034","description":"Leukemia, Lymphocytic, Acute","metadata":null},{"id":"ded8ad27ac5e4ee4a29a9549aaca80e0","type":"TRIAL","name":"Methotrexate-Inadequate Response Study","canonical_id":"clinicaltrials.gov:NCT00559585","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"e46f1ba4ced7454a99a2b87bae54f01a","type":"DRUG","name":"Methoxamine","canonical_id":"mesh:D008729","description":null,"metadata":null},{"id":"77daa05f06b14a93ab6919ba177a8c0b","type":"DRUG","name":"Methoxsalen","canonical_id":"mesh:D008730","description":null,"metadata":null},{"id":"f35f72680778435285b36583ce42ce32","type":"TRIAL","name":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","canonical_id":"clinicaltrials.gov:NCT02535312","description":"Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm","metadata":null},{"id":"6b594fa000fb4aa6bff0679e6b9cb274","type":"DRUG","name":"Methscopolamine","canonical_id":"mesh:D019832","description":null,"metadata":null},{"id":"075e6019ab304282a63daccaac196f94","type":"DRUG","name":"Methylclothiazide","canonical_id":"mesh:D008736","description":null,"metadata":null},{"id":"15bcaa1e15fa460a92af2b34327ff370","type":"DRUG","name":"Methylergometrine","canonical_id":"mesh:D008755","description":null,"metadata":null},{"id":"c8c658c7bc2a457ab251898b42297893","type":"TRIAL","name":"Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients","canonical_id":"clinicaltrials.gov:NCT01889290","description":"Opioid Use, Unspecified With Other Opioid-induced Disorder","metadata":null},{"id":"660a1e47f00f4a7a8042c305c00d70c4","type":"TRIAL","name":"Methylnaltrexone Use for Opioid-induced Postoperative Constipation","canonical_id":"clinicaltrials.gov:NCT01773096","description":"Constipation","metadata":null},{"id":"dc3f285c77bf4181a4461629d870e1f4","type":"TRIAL","name":"Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients","canonical_id":"clinicaltrials.gov:NCT02942550","description":"STEMI; Morphine; Ticagrelor; Methylnaltrexone","metadata":null},{"id":"26ad6434452d43c58d15b61bbad5c891","type":"TRIAL","name":"Methylnaltrexone for Opioid Induced Constipation","canonical_id":"clinicaltrials.gov:NCT01955213","description":"Constipation","metadata":null},{"id":"ef02f3ce2dd14d9f9ec2a20ce3439028","type":"TRIAL","name":"Methylnaltrexone for Opioid-induced Constipation in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01004393","description":"Neoplasms; Constipation; Opioid-Related Disorders","metadata":null},{"id":"81f47f8ae5b549939a58c78c9ebd5c0e","type":"TRIAL","name":"Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit","canonical_id":"clinicaltrials.gov:NCT01050595","description":"Opioid-induced Constipation","metadata":null},{"id":"8ce097b37d1e4f9ab34013d0a288ea3b","type":"TRIAL","name":"Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT01117376","description":"Gastroparesis","metadata":null},{"id":"89b09627764141bfbe5ea56cb0662861","type":"TRIAL","name":"Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation","canonical_id":"clinicaltrials.gov:NCT03523520","description":"Constipation Drug Induced","metadata":null},{"id":"f843fa3a46fc425692fa72135af307f7","type":"TRIAL","name":"Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A \"Window of Opportunity\" Pilot Study.","canonical_id":"clinicaltrials.gov:NCT06162377","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"2ac3ae0225c246c09c0cb0d6e7ae5566","type":"TRIAL","name":"Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11","canonical_id":"clinicaltrials.gov:NCT00015301","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"900fcfc48e6149538fc3e2328fe2b324","type":"TRIAL","name":"Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00223561","description":"ADHD","metadata":null},{"id":"c3030c54ef844b9b900d9e90c51e909f","type":"TRIAL","name":"Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue","canonical_id":"clinicaltrials.gov:NCT06905587","description":"Brain Tumor, Pediatric; Cancer-related Fatigue; Methylphenidate","metadata":null},{"id":"261fa67c946340b3816e773576e9f378","type":"TRIAL","name":"Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors","canonical_id":"clinicaltrials.gov:NCT00031798","description":"Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Depression; Fatigue; Quality of Life","metadata":null},{"id":"8d8637d0f8d447dfba6914352f3c4257","type":"TRIAL","name":"Methylphenidate-Duloxetine Combinations for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT02700711","description":"Cocaine Use Disorder","metadata":null},{"id":"98b3407bb83c4df9a5e55b81536d6b50","type":"TRIAL","name":"Methylprednisolone During the Switch Between Natalizumab and Fingolimod","canonical_id":"clinicaltrials.gov:NCT02769689","description":"Multiple Sclerosis","metadata":null},{"id":"6702980678d44c93a7446219afc8cd99","type":"TRIAL","name":"Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT00053976","description":"Graft Versus Host Disease","metadata":null},{"id":"950eb8837c884104b05adc9c32418eee","type":"DRUG","name":"Methylthioninium chloride","canonical_id":"mesh:D008751","description":null,"metadata":null},{"id":"e1ba3788eec14d1ba509cb7ab1214085","type":"DRUG","name":"Metipranolol","canonical_id":"mesh:D014290","description":null,"metadata":null},{"id":"f16eec43f1684ed0aa0d230935aadd63","type":"DRUG","name":"Metixene","canonical_id":"mesh:C005111","description":null,"metadata":null},{"id":"7de06da0cca0479ca4c227f8690cf805","type":"DRUG","name":"Metoclopramide","canonical_id":"mesh:D008787","description":null,"metadata":null},{"id":"eea4adb36c8f4dc084738a34e2993f77","type":"TRIAL","name":"Metoclopramide Pilot Trial","canonical_id":"clinicaltrials.gov:NCT02098915","description":"Gastroschisis","metadata":null},{"id":"6475610a5a7a4a6bba1a7bf4bad24582","type":"TRIAL","name":"Metoclopramide Use in Very Low Birth Weight Newborns","canonical_id":"clinicaltrials.gov:NCT00242450","description":"Infant, Premature","metadata":null},{"id":"38713e92129f4b0e8a3f763dde768e32","type":"TRIAL","name":"Metoclopramide Versus Hyoscine Butylbromide in Shortening Duration of First Stage of Labour","canonical_id":"clinicaltrials.gov:NCT05222646","description":"Duration of Labour","metadata":null},{"id":"206b2707cad04756beac791adc1f7883","type":"TRIAL","name":"Metoclopramide for Acute Upper GI Bleeding","canonical_id":"clinicaltrials.gov:NCT04771481","description":"Acute Upper Gastrointestinal Bleeding; Effect of Drug","metadata":null},{"id":"ca240356074a4db690c322d4d91bd8a7","type":"TRIAL","name":"Metoclopramide for Post Traumatic Headache","canonical_id":"clinicaltrials.gov:NCT03220958","description":"Post-Traumatic Headache","metadata":null},{"id":"7f165780971d4d81b65c2e47fc86f0e6","type":"TRIAL","name":"Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy","canonical_id":"clinicaltrials.gov:NCT03840057","description":"Gastro Intestinal Bleeding; Upper Gastrointestinal Bleeding","metadata":null},{"id":"207547048fbc46f0a6af953e9215e64d","type":"TRIAL","name":"Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT05633758","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"6bbe1472388f431d882f9d306bee7b6c","type":"TRIAL","name":"Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.","canonical_id":"clinicaltrials.gov:NCT02620384","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"7d0cf5ed08b741d78417746d3f5da8c5","type":"DRUG","name":"Metoprolol","canonical_id":"mesh:D008790","description":null,"metadata":null},{"id":"b56e2a5f9b184892ae9a89b079243508","type":"TRIAL","name":"Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis","canonical_id":"clinicaltrials.gov:NCT01676285","description":"Cirrhosis; Cirrhotic Cardiomyopathy; Cardiac Remodeling","metadata":null},{"id":"dac8e254232b4fb0adeef7dd780ce3db","type":"TRIAL","name":"Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)","canonical_id":"clinicaltrials.gov:NCT05847517","description":"Acute Respiratory Distress Syndrome (ARDS)","metadata":null},{"id":"5fcc812ff2ce4d17994496488feb6097","type":"TRIAL","name":"Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","canonical_id":"clinicaltrials.gov:NCT02446431","description":"Solid Tumor","metadata":null},{"id":"e2b77a1f1e42404db8d04dbaa88c16fd","type":"TRIAL","name":"Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS","canonical_id":"clinicaltrials.gov:NCT07138274","description":"Mild Autonomous Cortisol Secretion (MACS); Autonomous Cortisol Secretion (ACS)","metadata":null},{"id":"ff17a26a61ba45bc8b29470282ca7c66","type":"TRIAL","name":"Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)","canonical_id":"clinicaltrials.gov:NCT07268222","description":"Mild Autonomous Cortisol Secretion (MACS)","metadata":null},{"id":"d18f201d8de048a5bb273c04a004f7df","type":"TRIAL","name":"Metyrapone as Additive Treatment in Major Depression","canonical_id":"clinicaltrials.gov:NCT00125554","description":"Major Depressive Disorder","metadata":null},{"id":"1c4eff38dc3a4c3280311a83c0dd22de","type":"TRIAL","name":"Metyrapone for Mild Autonomous Cortisol Secretion (MACS)","canonical_id":"clinicaltrials.gov:NCT06106295","description":"Autonomous Cortisol Secretion; Mild Autonomous Cortisol Secretion (MACS)","metadata":null},{"id":"60ef1829c44c43418c1bd695346b8f68","type":"TRIAL","name":"Mexiletine and Non Dystrophic Myotonias","canonical_id":"clinicaltrials.gov:NCT02336477","description":"Non-dystrophic Myotonias; Paramyotonia Congenita; Myotonia Congenita","metadata":null},{"id":"7272fc68bc094c919639be616813f90d","type":"TRIAL","name":"Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease","canonical_id":"clinicaltrials.gov:NCT02561702","description":"Charcot Marie Tooth Disease","metadata":null},{"id":"89bc228276c1450db1e17a9f600e447c","type":"TRIAL","name":"Mexiletine for the Treatment of Focal Dystonia","canonical_id":"clinicaltrials.gov:NCT00001784","description":"Blepharospasm; Dystonia; Spasm","metadata":null},{"id":"6593b0d7659d4fe59f64ad0a223618cd","type":"TRIAL","name":"Mexiletine for the Treatment of Muscle Cramps in ALS","canonical_id":"clinicaltrials.gov:NCT01811355","description":"Muscle Cramps in Amyotrophic Lateral Sclerosis","metadata":null},{"id":"084a5fca43df46d88ca00aa6e5b988cc","type":"TRIAL","name":"Mexiletine in Sporadic Amyotrophic Lateral Sclerosis","canonical_id":"clinicaltrials.gov:NCT02781454","description":"Sporadic Amyotrophic Lateral Sclerosis","metadata":null},{"id":"b4e6f8854dc64960bc72cdc2ce961943","type":"TRIAL","name":"Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)","canonical_id":"clinicaltrials.gov:NCT01849770","description":"Sporadic Amyotrophic Lateral Sclerosis","metadata":null},{"id":"45c19ab51f9a46ecae127cfc0478d512","type":"GO_TERM","name":"Meynert cell differentiation","canonical_id":"go:GO:1905270","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a Meynert cell.\" [GO_REF:0000086, GOC:TermGenie, PMID:4142639]","metadata":null},{"id":"c1fa45d067e34e048deab819d58a1942","type":"TRIAL","name":"MgSO4 vs Metoclopramide for Headache in Pregnant Women","canonical_id":"clinicaltrials.gov:NCT00632606","description":"Headache","metadata":null},{"id":"37d7ecbf437145bf922b9f9a97b7a7d3","type":"TRIAL","name":"Michelangelo - Oasis 5","canonical_id":"clinicaltrials.gov:NCT00139815","description":"Thromboembolism","metadata":null},{"id":"65ae9a2bc2b842cf9badf84ed012b092","type":"TRIAL","name":"Microbiome Derived Metabolism and Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT05065671","description":"Microbial Colonization","metadata":null},{"id":"5610fb22bf994124bf67015773face52","type":"TRIAL","name":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","canonical_id":"clinicaltrials.gov:NCT02972476","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"2ea072cef23e4f8da74fa686ff9fadb9","type":"TRIAL","name":"Microcirculation & ASICs","canonical_id":"clinicaltrials.gov:NCT01246180","description":"Physiological Conditions","metadata":null},{"id":"b336acb1e4aa4f7cb7e4b66a54445fcb","type":"TRIAL","name":"Microcirculation Guided Therapy Versus \"Standard Treatment\" of Severe Sepsis","canonical_id":"clinicaltrials.gov:NCT00484133","description":"Severe Sepsis; Microcirculation","metadata":null},{"id":"04dca5c2663b4a58ba1a713a76b5e2ab","type":"TRIAL","name":"Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07757867","description":"Microneedling-Assisted Delivery; Cetirizine; Latanoprost; Alopecia Areata","metadata":null},{"id":"301c5398266f4d4fae9813245014d81d","type":"TRIAL","name":"Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT05586724","description":"Menopausal Symptoms","metadata":null},{"id":"f9381574d9984e35ace568d34337fc06","type":"DISEASE","name":"Micropenis","canonical_id":"hp:0000054","description":null,"metadata":null},{"id":"adb17adfee3d46028c155fd53fd817bd","type":"PROTEIN","name":"Microtubule-associated protein 2","canonical_id":"uniprot:P11137","description":null,"metadata":null},{"id":"8f4f33b9cb514a379625d0a0e32cec94","type":"TRIAL","name":"Microvascular Blood Flow in Sickle Cell Anemia","canonical_id":"clinicaltrials.gov:NCT01566890","description":"Sickle Cell Disease; Sickle Cell Anemia","metadata":null},{"id":"076e06e4571848c9bb1794bcca3e18c5","type":"TRIAL","name":"Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve","canonical_id":"clinicaltrials.gov:NCT03249272","description":"Hypertrophic Cardiomyopathy; Non-ischemic Dilated Cardiomyopathy; Microvascular Ischaemia of Myocardium","metadata":null},{"id":"f9ec1f92a2db48ab9768259cc9c4a4bb","type":"TRIAL","name":"Midazolam Alone Versus Midazolam With Ketorolac for Sedation During Flexible Bronchoscopy.","canonical_id":"clinicaltrials.gov:NCT07352059","description":"Sedation and Analgesia Management in Patients Undergoing Flexible Bronchoscopy","metadata":null},{"id":"131faed5317f483c831f9a07b2138b74","type":"TRIAL","name":"Midazolam Drug-Drug Interaction Study With Lurasidone HCl","canonical_id":"clinicaltrials.gov:NCT01082263","description":"Schizophrenia Patients","metadata":null},{"id":"158bab966c83478c9dfbfdf9beb72223","type":"DRUG","name":"Midodrine","canonical_id":"mesh:D008879","description":null,"metadata":null},{"id":"0ccf0298baff42399213a79ebe836fd2","type":"TRIAL","name":"Midodrine and Fludrocortisone for Vasovagal Syncope","canonical_id":"clinicaltrials.gov:NCT04595942","description":"Syncope, Vasovagal","metadata":null},{"id":"039c4c2da6304e00a6c91ebfde7fe38c","type":"TRIAL","name":"Midostaurin (PKC412) for Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT01282502","description":"Adenocarcinoma of the Rectum","metadata":null},{"id":"ba6a4f21e7704a10984a7f2dbdc357a1","type":"TRIAL","name":"Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02624570","description":"Acute Myeloid Leukemia (AML) With; FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)","metadata":null},{"id":"cd4611ded3724e1ea1456682face6c8f","type":"TRIAL","name":"Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia","canonical_id":"clinicaltrials.gov:NCT03686345","description":"Core Binding Factor Acute Myeloid Leukemia (CBF-AML)","metadata":null},{"id":"7d03e84c163a4ac1888071b846d9f41b","type":"TRIAL","name":"Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT01093573","description":"Untreated Adult Acute Myeloid Leukemia","metadata":null},{"id":"dc0a03eaf69249ad85ec471c61fe9b01","type":"TRIAL","name":"Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation","canonical_id":"clinicaltrials.gov:NCT02634827","description":"Acute Myeloid Leukemia With FLT3/ITD Mutation; Acute Myeloid Leukemia With Gene Mutations; FLT3 Tyrosine Kinase Domain Point Mutation; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia","metadata":null},{"id":"23674c50e1b24bc2910854490995e6aa","type":"TRIAL","name":"Midostaurin in Indolent Systemic Mastocytosis","canonical_id":"clinicaltrials.gov:NCT01920204","description":"Indolent Systemic Mastocytosis","metadata":null},{"id":"60066427e40a4e9a8dc878f3d6982754","type":"TRIAL","name":"Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT03951961","description":"Acute Myeloid Leukemia, Adult","metadata":null},{"id":"07ea4e02a7144f11aa39af625dc8f2f7","type":"TRIAL","name":"Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant","canonical_id":"clinicaltrials.gov:NCT02723435","description":"Acute Myeloid Leukemia With Gene Mutations; Adult Acute Myeloid Leukemia in Remission","metadata":null},{"id":"dff6011b599b4cb29a0840d2abda5048","type":"TRIAL","name":"MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention","canonical_id":"clinicaltrials.gov:NCT03961334","description":"Stroke, Ischemic","metadata":null},{"id":"a54e39fcf8ee4172b0f92fcd52aa9897","type":"TRIAL","name":"Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor","canonical_id":"clinicaltrials.gov:NCT03259542","description":"Drug Interaction Potentiation; Healthy","metadata":null},{"id":"6ae7fcefe34c4aaf9defb51364d2b6bd","type":"TRIAL","name":"Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT","canonical_id":"clinicaltrials.gov:NCT00285818","description":"Depression","metadata":null},{"id":"831f1de68e3d441bbff02912018e9695","type":"TRIAL","name":"Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks","canonical_id":"clinicaltrials.gov:NCT00986921","description":"Abortion","metadata":null},{"id":"eb6da41187734840919c780235cb66b3","type":"TRIAL","name":"Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction","canonical_id":"clinicaltrials.gov:NCT00383032","description":"Abortion, Induced","metadata":null},{"id":"f827ffeeae75482faf85cec115817e82","type":"TRIAL","name":"Mifepristone and Mid-Trimester Termination of Pregnancy","canonical_id":"clinicaltrials.gov:NCT00382538","description":"Abortion, Induced; Abortion, Second Trimester","metadata":null},{"id":"eb7d89fcf51e4d75aedb76bd4cacd207","type":"TRIAL","name":"Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location","canonical_id":"clinicaltrials.gov:NCT05839899","description":"Abortion","metadata":null},{"id":"28b252906ae3463eb9c2c7e5133c820b","type":"TRIAL","name":"Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks","canonical_id":"clinicaltrials.gov:NCT05119439","description":"Medical Abortion","metadata":null},{"id":"a3fd110ec812433ebda9bc7e2b7cd32a","type":"TRIAL","name":"Mifepristone at Same Time Multicenter Study","canonical_id":"clinicaltrials.gov:NCT00269568","description":"Abortion Seekers","metadata":null},{"id":"01c3646e3149435bb2c54a099740b91e","type":"TRIAL","name":"Mifepristone vs Misoprostol","canonical_id":"clinicaltrials.gov:NCT06502158","description":"Cervical Preparation","metadata":null},{"id":"5a52c6851a8d4eae83b978585eb1c3e7","type":"TRIAL","name":"Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death","canonical_id":"clinicaltrials.gov:NCT02633761","description":"Fetal Death","metadata":null},{"id":"82ab43dc6f8644a0ab4ec5ee04406bc1","type":"DRUG","name":"Miglitol","canonical_id":"mesh:C045621","description":null,"metadata":null},{"id":"28a2057d24bd4a13980e0b73a2c35f66","type":"TRIAL","name":"Miglustat / OGT 918 in the Treatment of Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00537602","description":"Cystic Fibrosis","metadata":null},{"id":"ecbddb81408e4691a39c1e75859d23e2","type":"TRIAL","name":"Miglustat in Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00742092","description":"Cystic Fibrosis","metadata":null},{"id":"c5fe650ce46e423c86185ae867555413","type":"TRIAL","name":"Miglustat in Niemann-Pick Type C Disease","canonical_id":"clinicaltrials.gov:NCT00517153","description":"Niemann-Pick Type C Disease","metadata":null},{"id":"f73be23f8588409b96483c4a61161a8f","type":"TRIAL","name":"Miglustat on Gaucher Disease Type IIIB","canonical_id":"clinicaltrials.gov:NCT02520934","description":"Gaucher Disease","metadata":null},{"id":"c1de12833fd44f8ea196806969893bc0","type":"DISEASE","name":"Migraine","canonical_id":"mesh:D008881","description":null,"metadata":null},{"id":"7911b62d82ce4d7bb568b51e1ece5eff","type":"TRIAL","name":"Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I","canonical_id":"clinicaltrials.gov:NCT06503848","description":"Migraine Disorders","metadata":null},{"id":"f651add0fc764159a61392d3a6003a94","type":"TRIAL","name":"Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.","canonical_id":"clinicaltrials.gov:NCT05635604","description":"Migraine","metadata":null},{"id":"7164b21256d9495ab2f5608ec6a469bd","type":"TRIAL","name":"Migraine Medication Effects on Urinary Symptoms","canonical_id":"clinicaltrials.gov:NCT06212661","description":"Overactive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome; Overactive Detrusor; Migraine; Interstitial Cystitis","metadata":null},{"id":"0e10d783f246454494c583155cc6d313","type":"TRIAL","name":"Migraine Treatment in ED","canonical_id":"clinicaltrials.gov:NCT02643719","description":"Migraine","metadata":null},{"id":"dc7022631fd14470860f8475dce8a25d","type":"TRIAL","name":"Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT03552029","description":"Acute Myeloid Leukemia","metadata":null},{"id":"e4ecbcc4b62741cdbb18293441e504a4","type":"TRIAL","name":"Mild Cognitive Impairment in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01519271","description":"Parkinson's Disease; Mild Cognitive Impairment","metadata":null},{"id":"cd776ed0866a4dfb9d1fc6420910207a","type":"DRUG","name":"Milnacipran","canonical_id":"mesh:C048107","description":null,"metadata":null},{"id":"6ea6c469c8ce4fdd8329fe6e46f20b10","type":"TRIAL","name":"Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)","canonical_id":"clinicaltrials.gov:NCT01471379","description":"Irritable Bowel Syndrome","metadata":null},{"id":"218123fe595e43af93bdab822cc240cf","type":"TRIAL","name":"Milnacipran for Chronic Pain in Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT01510457","description":"Knee Osteoarthritis; Degenerative Joint Disease; Chronic Pain","metadata":null},{"id":"2ee0dcd3fc4247a9ac0a01ed32b3aedb","type":"TRIAL","name":"Milnacipran for Lumbosacral Radicular Pain","canonical_id":"clinicaltrials.gov:NCT01777581","description":"Radicular Pain Related to Lumbosacral Disc Disease","metadata":null},{"id":"18a36cb7d18e43e2bfb8aaae0ec34a77","type":"TRIAL","name":"Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01225991","description":"Rheumatoid Arthritis","metadata":null},{"id":"ee1847500e484c019414698aaa101246","type":"TRIAL","name":"Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism","canonical_id":"clinicaltrials.gov:NCT01337700","description":"Autism Spectrum Disorder; Asperger Syndrome; Aspergers Syndrome","metadata":null},{"id":"44682579adeb4c068b31673a929f06fb","type":"TRIAL","name":"Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01207453","description":"Arthritis, Rheumatoid","metadata":null},{"id":"b226ba51aecd484e9f81dfeb3bd29cef","type":"TRIAL","name":"Milrinone During Living Donor Hepatectomy","canonical_id":"clinicaltrials.gov:NCT00966745","description":"Hepatectomy","metadata":null},{"id":"011188d600084108805a353b0f7b06a8","type":"TRIAL","name":"Milrinone Versus Placebo in Patients With Septic Shock","canonical_id":"clinicaltrials.gov:NCT05122884","description":"Septic Shock; Cardiac Output","metadata":null},{"id":"f05401fa9006429d8384196d95f609f7","type":"TRIAL","name":"Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial","canonical_id":"clinicaltrials.gov:NCT06679855","description":"Post-ligation Cardiac Syndrome","metadata":null},{"id":"34bd25058f324f808ea807f6d7aec56c","type":"TRIAL","name":"Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT02712788","description":"Cerebral Vasospasm","metadata":null},{"id":"e39bf5d12016400a97204a48e412c51e","type":"TRIAL","name":"Milrinone in Congenital Diaphragmatic Hernia","canonical_id":"clinicaltrials.gov:NCT02951130","description":"Congenital Diaphragmatic Hernia; Persistent Pulmonary Hypertension of the Newborn; Hypoxemic Respiratory Failure; Pulmonary Hypoplasia","metadata":null},{"id":"220beb50e2d14d68b65fb815b78e0c7a","type":"TRIAL","name":"Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT04153383","description":"Ischemic Heart Disease","metadata":null},{"id":"0e061b35737b40b89f5ee2fe490e54c5","type":"TRIAL","name":"Milrinone on Right Ventricular Strain in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT06077721","description":"Ischemic Heart Disease; Valvular Heart Disease","metadata":null},{"id":"52da9ea322c4493fb5ea165101fac568","type":"TRIAL","name":"Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN","canonical_id":"clinicaltrials.gov:NCT03683069","description":"Hypertension; Genetics Hypertension","metadata":null},{"id":"b211bd2175f14793821ee30f8967c646","type":"TRIAL","name":"Mineralocorticoid Receptor Antagonists in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02809963","description":"Diabetes Type 2","metadata":null},{"id":"654a9e2e36494946a60bf84b95cf3206","type":"TRIAL","name":"Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications","canonical_id":"clinicaltrials.gov:NCT01406015","description":"Obesity; Insulin Resistance","metadata":null},{"id":"795476ee5c664c0daa814da038b35678","type":"TRIAL","name":"Mineralocorticoid Receptor in the Treatment of Severe Depression","canonical_id":"clinicaltrials.gov:NCT00295347","description":"Major Depression","metadata":null},{"id":"66ce602596ac436ba3e2f9b8b588df54","type":"TRIAL","name":"Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression","canonical_id":"clinicaltrials.gov:NCT03062150","description":"Major Depression","metadata":null},{"id":"7d1c6eb76f0b4af0b3da98fc69150630","type":"TRIAL","name":"Mineralocorticoid Use in COVID-19 Patients","canonical_id":"clinicaltrials.gov:NCT05453214","description":"COVID-19; ARDS","metadata":null},{"id":"8f51f4d91fad4051a6d62866e8f00ca7","type":"TRIAL","name":"Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00429572","description":"Breast Cancer","metadata":null},{"id":"062502e1bfec4cd5a048dd671361007b","type":"TRIAL","name":"Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study","canonical_id":"clinicaltrials.gov:NCT05873790","description":"Lung Cancer","metadata":null},{"id":"22b3a8a4bf47476c83d0c4218f0b1943","type":"TRIAL","name":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06353022","description":"Multiple Myeloma","metadata":null},{"id":"8554f1a629e24da48c4da2aee3e29ec4","type":"TRIAL","name":"Minimally Invasive Coronary Artery Bypass Supported by Cangrelor","canonical_id":"clinicaltrials.gov:NCT07514962","description":"Coronary Artery Disease; Antiplatelet Therapy; Minimally Invasive Coronary Revascularization Surgery","metadata":null},{"id":"4bf736edcc5246aba7fe3f5559faba9a","type":"TRIAL","name":"Minimally Invasive Surgical Therapy for BPH","canonical_id":"clinicaltrials.gov:NCT00064649","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"f926d4b075f34910a624557d94b56166","type":"TRIAL","name":"Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.","canonical_id":"clinicaltrials.gov:NCT00716755","description":"Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Delusional Disorder; Psychotic Disorder","metadata":null},{"id":"0cccaae3b6704d1589d5731cf8e73353","type":"TRIAL","name":"Minirin Versus Oxybutynin for Nocturnal Enuresis in Children","canonical_id":"clinicaltrials.gov:NCT02538302","description":"Nocturnal Enuresis","metadata":null},{"id":"9d5f39e4ca7c488eb919204ec0d2b84e","type":"TRIAL","name":"Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT01320982","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"29cfb69aa3be4e4a8271c3b191221144","type":"TISSUE","name":"Minor Salivary Gland","canonical_id":"uberon:UBERON:0006330","description":null,"metadata":null},{"id":"fcf8f2bc16a3403cbe450d6e82297e43","type":"DISEASE","name":"Miosis","canonical_id":"hp:0000616","description":null,"metadata":null},{"id":"0b2f8a9806b34806b1dd31725f30473e","type":"TRIAL","name":"Mirabegron And Ureteral Stent-related Pain (MAP) Trial","canonical_id":"clinicaltrials.gov:NCT04286152","description":"Nephrolithiasis","metadata":null},{"id":"e497a2df6141434ba05c3f3d1d824882","type":"TRIAL","name":"Mirabegron Combined With Behavioral Intervention for Overactive Bladder\uff1aa Prospective Multicenter Randomized Controlled Clinical Study","canonical_id":"clinicaltrials.gov:NCT05452434","description":"Overactive Bladder","metadata":null},{"id":"7f5231b7e5b04309b86e72a322c5adf6","type":"TRIAL","name":"Mirabegron and Brown Adipose Tissue","canonical_id":"clinicaltrials.gov:NCT03012113","description":"Obesity","metadata":null},{"id":"eb88d3cf38e942e3a3ddabba9e4f4ee1","type":"TRIAL","name":"Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT03187795","description":"Spinal Cord Injuries; Urinary Bladder, Neurogenic","metadata":null},{"id":"4ff755324e9c40b2beecc9ce6b53a92b","type":"TRIAL","name":"Mirabegron and Physiological Function in Cold Environments","canonical_id":"clinicaltrials.gov:NCT04766021","description":"Resting Energy Expenditure; Thermogenesis; Brown Adipose Tissue","metadata":null},{"id":"ff16f384a9ee4acd9690d7ab557623ae","type":"TRIAL","name":"Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain","canonical_id":"clinicaltrials.gov:NCT02744430","description":"Ureteral Obstruction; Flank Pain","metadata":null},{"id":"b6308e4ebd664691a6f3deeb163dead2","type":"TRIAL","name":"Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study","canonical_id":"clinicaltrials.gov:NCT03600766","description":"BPH; Erectile Dysfunction; Prostate Hyperplasia; Erectile Abnormalities; Prostatic Neoplasms","metadata":null},{"id":"40b582c009824023b2109c42979c0d86","type":"TRIAL","name":"Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women","canonical_id":"clinicaltrials.gov:NCT02981459","description":"Urinary Frequency/Urgency; Bladder Irritable; Bladder Pain Syndrome","metadata":null},{"id":"3d02240d1e784eb3a0f2de1af7e795fc","type":"TRIAL","name":"Mirabegron in Parkinson Disease and Impaired Cognition","canonical_id":"clinicaltrials.gov:NCT02536976","description":"Parkinson Disease; Overactive Bladder; Impaired Cognition","metadata":null},{"id":"c0904ab5594c4e48b5e0ab110881b148","type":"TRIAL","name":"Mirabegron in Patients With Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT07305298","description":"Dry AMD; Overactive Bladder","metadata":null},{"id":"af39e980eb1040f094e4386a625c3ea1","type":"DRUG","name":"Mirdametinib","canonical_id":"ncit:C52195","description":null,"metadata":null},{"id":"528322e1c6f4439bb704a5422a8bb830","type":"TRIAL","name":"Mirdametinib + BGB-3245 in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05580770","description":"Advanced Solid Tumor","metadata":null},{"id":"9fa4de15ef454e74951e8aedfc407c88","type":"TRIAL","name":"Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).","canonical_id":"clinicaltrials.gov:NCT06159166","description":"NF1; Cutaneous Neurofibroma; Monotherapy","metadata":null},{"id":"7fac6008869548058fc6de2dd1f86df6","type":"TRIAL","name":"Mirdametinib in Histiocytic Disorders","canonical_id":"clinicaltrials.gov:NCT06153173","description":"Langerhans Cell Histiocytosis (LCH); Juvenile Xanthogranuloma (JXG); Rosai-Dorfman Disease (RDD); Histiocytic Disorders","metadata":null},{"id":"be5e9a64873a4d0ca6d349081d968e89","type":"TRIAL","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","canonical_id":"clinicaltrials.gov:NCT07237100","description":"Advanced Unresectable Melanoma; Metastatic Melanoma","metadata":null},{"id":"0325f441a75845f3b035d75b8c7b5fb8","type":"TRIAL","name":"Mirena Extension Trial","canonical_id":"clinicaltrials.gov:NCT02985541","description":"Contraception","metadata":null},{"id":"70a4b7da0faa49bbb4504e9b796131c1","type":"TRIAL","name":"Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months","canonical_id":"clinicaltrials.gov:NCT06904274","description":"Endometrial Hyperplasia","metadata":null},{"id":"133414b836a643c1aacca568e67074ce","type":"TRIAL","name":"Mirena in Idiopathic Menorrhagia","canonical_id":"clinicaltrials.gov:NCT00868153","description":"Idiopathic Menorrhagia","metadata":null},{"id":"d0c50b574b65456d900834587fe7c714","type":"TRIAL","name":"Mirena or Conventional Medical Treatment for Menorrhagia","canonical_id":"clinicaltrials.gov:NCT00864136","description":"Menorrhagia","metadata":null},{"id":"7216d079690b4534b45a1272a8fb0417","type":"TRIAL","name":"Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study","canonical_id":"clinicaltrials.gov:NCT06937086","description":"Ulcerative Colitis; Obesity or Overweight","metadata":null},{"id":"2747e8c0ea4a4fbda1731c80dcdbd045","type":"TRIAL","name":"Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","canonical_id":"clinicaltrials.gov:NCT06937099","description":"Crohn's Disease; Obesity or Overweight","metadata":null},{"id":"744d158450b7400884d32fa0c5ad11c3","type":"TRIAL","name":"Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch","canonical_id":"clinicaltrials.gov:NCT06864403","description":"Pouchitis; Pouches, Ileoanal; Pouch, Ileal","metadata":null},{"id":"bb59a47d4f994edbbddef063553c7787","type":"DRUG","name":"Mirtazapine","canonical_id":"mesh:C035133","description":null,"metadata":null},{"id":"c8cf759fd4a745d9ae41f683bfc8cd75","type":"TRIAL","name":"Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01598584","description":"Pancreatic Cancer","metadata":null},{"id":"812e71764b314d5baba5d7657d8144bc","type":"TRIAL","name":"Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety","canonical_id":"clinicaltrials.gov:NCT00960830","description":"Depression; Anxiety","metadata":null},{"id":"abb443a423b340af969cd880624abda7","type":"TRIAL","name":"Mirtazapine and Methamphetamine Drug-drug Interaction Study","canonical_id":"clinicaltrials.gov:NCT04614584","description":"Methamphetamine Use Disorder; Drug Interaction; Cardiovascular Abnormalities","metadata":null},{"id":"64ebca6b29744705829598d39f26a253","type":"TRIAL","name":"Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia","canonical_id":"clinicaltrials.gov:NCT02541526","description":"Heroin Dependence; Amphetamine Dependence","metadata":null},{"id":"100ff0b31bdf4a6daa85b14f24f475ec","type":"TRIAL","name":"Mirtazapine for Acute and Chronic Post Mastectomy Pain","canonical_id":"clinicaltrials.gov:NCT06499090","description":"Breast Cancer","metadata":null},{"id":"3cc9090f81b7416abecd69a93833daa9","type":"TRIAL","name":"Mirtazapine for Sleep Disorders in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01867775","description":"Alzheimer's Disease; Sleep Disorders","metadata":null},{"id":"487816b116e94dda9073005db8594693","type":"TRIAL","name":"Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression","canonical_id":"clinicaltrials.gov:NCT00249444","description":"Cocaine Dependence; Depression","metadata":null},{"id":"51b0090202b3440aa61496d3810d99c6","type":"TRIAL","name":"Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia","canonical_id":"clinicaltrials.gov:NCT03254173","description":"Advanced Cancer; Cancer Associated Anorexia - Cachexia","metadata":null},{"id":"bcb2173d8e494e64b057d4aaf18f052a","type":"TRIAL","name":"Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment","canonical_id":"clinicaltrials.gov:NCT06323837","description":"Stimulant Use Disorder","metadata":null},{"id":"fb21ea8b235346508a3be9f9004b3da0","type":"TRIAL","name":"Mirtazapine in Cancer-related Poly-symptomatology","canonical_id":"clinicaltrials.gov:NCT04763135","description":"Cancer; Neoplasms; Neoplasm Metastasis","metadata":null},{"id":"a27956a47bb449cfa07657c4868edb2f","type":"TRIAL","name":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT03552471","description":"BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer","metadata":null},{"id":"691985cf380b4f518d605b1ecae8cf0f","type":"GO_TERM","name":"Mis6-Sim4 complex","canonical_id":"go:GO:0031511","description":"\"A protein complex that forms part of the inner kinetochore, which is involved in the loading of the centromeric histone h3 variant CENP-A onto centromeres and in centromere specific heterochromatin formation. The complex contains about 12 proteins, of which two are known as Mis6 and Sim4 in S. pombe and CENP-I and CENP-H in human.\" [GOC:vw, PMID:12719471, PMID:15897182]","metadata":null},{"id":"e820089b1c4e4ae4a654a07a11629b94","type":"TRIAL","name":"Misopristol Versus Pitocin for Second Trimester Abortion","canonical_id":"clinicaltrials.gov:NCT00784797","description":"Abortion, Missed","metadata":null},{"id":"d3c12f6d3ef4497bbb58a7df0cc46d1b","type":"DRUG","name":"Misoprostol","canonical_id":"mesh:D016595","description":null,"metadata":null},{"id":"fbf4ea9a29044c7cbd50a55e2b80703e","type":"TRIAL","name":"Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions","canonical_id":"clinicaltrials.gov:NCT04492072","description":"Cesarean Section; Misoprostol; Oxytocin; High Risk Pregnancy","metadata":null},{"id":"678f8ab472f346de93777fa5d80569b3","type":"TRIAL","name":"Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.","canonical_id":"clinicaltrials.gov:NCT07325201","description":"Type 1 Diabetes Mellitus; Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM); Chronic Kidney Disease; Diabetic Ketoacidosis; Ketones","metadata":null},{"id":"d9059b82e8714f91bd4efc9e9c2d95c8","type":"TRIAL","name":"Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT06969287","description":"Delirium; Surgery-Complications","metadata":null},{"id":"eb87f020d78c40c88e6c89cd979c306e","type":"TRIAL","name":"Mitochondria and Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT03177798","description":"Hemodialysis-Induced Symptom; Mitochondrial Diseases","metadata":null},{"id":"6c8b5ef9e87942daa6f5be03c0262f22","type":"TRIAL","name":"Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle","canonical_id":"clinicaltrials.gov:NCT04558190","description":"Insulin Resistance","metadata":null},{"id":"ffe4957c779f4f8aa9d50ccd5ea9de93","type":"TRIAL","name":"Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate","canonical_id":"clinicaltrials.gov:NCT00732485","description":"Burn","metadata":null},{"id":"9a491a4dc6d34290b544c9b2f9e57826","type":"TRIAL","name":"Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)","canonical_id":"clinicaltrials.gov:NCT03109301","description":"Neoplasms, Nerve Tissue; Neurofibromatosis 1; Heredodegenerative Disorders, Nervous System; Peripheral Nervous System Diseases","metadata":null},{"id":"22f945d7711e4f4d83272bc3630dabce","type":"DRUG","name":"Mitogen-Activated Protein Kinase Kinase Inhibitor","canonical_id":"ncit:C69145","description":null,"metadata":null},{"id":"253ee4668c8c418fbc10bd4f5b791aaa","type":"DRUG","name":"Mitomycin","canonical_id":"ncit:C1820","description":null,"metadata":null},{"id":"b8dc921091c344e29ece893fc9b79baf","type":"DRUG","name":"Mitoxantrone","canonical_id":"mesh:D008942","description":null,"metadata":null},{"id":"55da8af30b5146af9b387d453ae19042","type":"TRIAL","name":"Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05857982","description":"Relapsed/Refractory Multiple Myeloma","metadata":null},{"id":"a2b26549e5f848ee8da4571fcf06801d","type":"TRIAL","name":"Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT07288814","description":"Relapsed or Refractory Peripheral T Cell Lymphoma","metadata":null},{"id":"18ad8dda13bd4f55b2bb7e686e55917f","type":"TRIAL","name":"Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia","canonical_id":"clinicaltrials.gov:NCT01842672","description":"Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Lymphoblastic Lymphoma; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma/Leukemia","metadata":null},{"id":"f94265fe18e442829351101571d569b7","type":"TRIAL","name":"Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00004071","description":"Prostate Cancer","metadata":null},{"id":"94d5936845684c97878254ad0dcb2877","type":"GO_TERM","name":"Mo(VI)-molybdopterin cytosine dinucleotide biosynthetic process","canonical_id":"go:GO:1902760","description":"\"The chemical reactions and pathways resulting in the formation of Mo(VI)-molybdopterin cytosine dinucleotide.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:23201473]","metadata":null},{"id":"4d6a41f1c69f4958bc39d4ba6302acde","type":"GO_TERM","name":"Mo-molybdopterin cofactor biosynthetic process","canonical_id":"go:GO:0006777","description":"\"The chemical reactions and pathways resulting in the formation of the Mo-molybdopterin cofactor, essential for the catalytic activity of some enzymes. The cofactor consists of a mononuclear molybdenum (Mo) ion coordinated by one or two molybdopterin ligands.\" [ISSN:09498257, PMID:22370186, PMID:23201473]","metadata":null},{"id":"ca24d45e56c1471783c76e8ae2a2eba6","type":"GO_TERM","name":"Mo-molybdopterin cofactor catabolic process","canonical_id":"go:GO:0032326","description":"\"The chemical reactions and pathways resulting in the breakdown of the Mo-molybdopterin cofactor, essential for the catalytic activity of some enzymes. The cofactor consists of a mononuclear molybdenum (Mo) ion coordinated by one or two molybdopterin ligands.\" [GOC:mah]","metadata":null},{"id":"8594daf08f0b473fa47a607f3180a6e2","type":"GO_TERM","name":"Mo-molybdopterin cofactor metabolic process","canonical_id":"go:GO:0019720","description":"\"The chemical reactions and pathways involving the Mo-molybdopterin cofactor, essential for the catalytic activity of some enzymes. The cofactor consists of a mononuclear molybdenum (Mo) ion coordinated by one or two molybdopterin ligands.\" [PMID:23539623, PMID:35956883]","metadata":null},{"id":"59acc3f2b55c40eda0bf46c0fa7cf3ff","type":"TRIAL","name":"Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy","canonical_id":"clinicaltrials.gov:NCT00152919","description":"Prostatic Neoplasms","metadata":null},{"id":"7eb78639c7c447c982acc889bc723b59","type":"TRIAL","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT00322491","description":"Lymphoma, Non-Hodgkin; Multiple Myeloma","metadata":null},{"id":"73f864b0c26048be89e7dd404d6d2214","type":"TRIAL","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT05087212","description":"Autologous Haematopoietic Stem Cell Transplant","metadata":null},{"id":"5afbbdf6b2294dff85c74983e42769c3","type":"TRIAL","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients","canonical_id":"clinicaltrials.gov:NCT00103610","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"91f69ab6b3254cf29e7e6a05bf70b6af","type":"TRIAL","name":"Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients","canonical_id":"clinicaltrials.gov:NCT00322387","description":"Lymphoma, Non-Hodgkin; Multiple Myeloma","metadata":null},{"id":"33f02e54c4f74991901adc3471d3bb88","type":"DRUG","name":"Mobocertinib","canonical_id":"ncit:C126752","description":null,"metadata":null},{"id":"692f7e6370b34dee9a931adb6f587ccf","type":"TRIAL","name":"Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02429375","description":"Hodgkin Lymphoma","metadata":null},{"id":"d5084974ca404674882182f526607134","type":"DRUG","name":"Moclobemide","canonical_id":"mesh:D020912","description":null,"metadata":null},{"id":"e99aca4e5a204e8690cbc0d8bee4a720","type":"GO_TERM","name":"ModE complex","canonical_id":"go:GO:1990198","description":"\"A dimeric protein complex containing two ModE subunits. Binds directly to DNA to regulate transcription, and is involved in (positively and negatively) regulating various aspects of molybdenum metabolism.\" [GOC:bhm, PMID:12581638]","metadata":null},{"id":"56ff6d7730ae4761a2c95b335964e03b","type":"DRUG","name":"Modafinil","canonical_id":"mesh:C048833","description":null,"metadata":null},{"id":"974d7008f27e40708b20601df7af1375","type":"TRIAL","name":"Modafinil - Escitalopram Study for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01601730","description":"Cocaine Dependence; Cocaine Abuse; Cocaine Addiction; Substance Abuse","metadata":null},{"id":"412976907159459683757e602a59067a","type":"TRIAL","name":"Modeling Stress-precipitated Smoking Behavior for Medication Development","canonical_id":"clinicaltrials.gov:NCT00773357","description":"Smoking","metadata":null},{"id":"94f88f9a2aea4d0c88264865f04f3ba6","type":"TRIAL","name":"Modification of Epilepsy Screen Questionnaire and Treatment Feasibility Evaluation","canonical_id":"clinicaltrials.gov:NCT04939675","description":"Epilepsy","metadata":null},{"id":"4e3f33e233d24a80b7dfe887d3d1168c","type":"TRIAL","name":"Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT01014741","description":"Persistent Atrial Fibrillation","metadata":null},{"id":"e39f039f38b84a7bb78f29c002b294bd","type":"TRIAL","name":"Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04484012","description":"Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma","metadata":null},{"id":"503125c3bc4d4881aca951bb67e5b92d","type":"TRIAL","name":"Modified MRCUKALL\u216b/ECOGE2993 Regimen for ALL","canonical_id":"clinicaltrials.gov:NCT02660762","description":"Leukaemia,Lymphoblastic","metadata":null},{"id":"9715e42ac51f46a2b96a1b9f8b4cee1e","type":"TRIAL","name":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT07420296","description":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","metadata":null},{"id":"3b786c0eebed4d92a2908b12cb06c0a7","type":"TRIAL","name":"Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT01247493","description":"Acute Myeloid Leukemia","metadata":null},{"id":"d5555c82955c4ffbaaaa859cb41d4768","type":"TRIAL","name":"Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients","canonical_id":"clinicaltrials.gov:NCT00129038","description":"Coronary Arteriosclerosis","metadata":null},{"id":"9f92b69dff5b43868456c1066f0a0836","type":"TRIAL","name":"Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron","canonical_id":"clinicaltrials.gov:NCT00889499","description":"Pain; Chronic Disease","metadata":null},{"id":"dc1fd873590d468d89e6dfec6ab360be","type":"TRIAL","name":"Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm","canonical_id":"clinicaltrials.gov:NCT03462641","description":"Parkinson Disease","metadata":null},{"id":"2a702ed0aaf444e38d68e2297e6c315a","type":"TRIAL","name":"Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm","canonical_id":"clinicaltrials.gov:NCT03440112","description":"Parkinson Disease","metadata":null},{"id":"69ae4b75f45a4fba9428f6ad4cf4e174","type":"TRIAL","name":"Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease","canonical_id":"clinicaltrials.gov:NCT02045056","description":"Preclinical Alzheimer's Disease","metadata":null},{"id":"dd45567b9c0b4c03a34deba024dddba3","type":"TRIAL","name":"Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics","canonical_id":"clinicaltrials.gov:NCT00605904","description":"Alcoholism","metadata":null},{"id":"eac1d309ffe246c894a954761f44bafa","type":"TRIAL","name":"Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01477060","description":"Metastatic Breast Cancer","metadata":null},{"id":"4a8b8f46d23041faaf52fefb1d2a0684","type":"TRIAL","name":"Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02641522","description":"Type 1 Diabetes","metadata":null},{"id":"3fb065c2f28642c4acf631a8b34d5b0b","type":"TRIAL","name":"Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00835042","description":"Healthy","metadata":null},{"id":"e7d4166b2a414d70a68fca6c784cd493","type":"TRIAL","name":"Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00834067","description":"Healthy","metadata":null},{"id":"bb0cb8a394684960bca6d3d1f75fbe34","type":"TRIAL","name":"Moexipril for Primary Biliary Cirrhosis","canonical_id":"clinicaltrials.gov:NCT00588302","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"2e639d81b371428bb0c4df3fdcafec06","type":"TRIAL","name":"Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & S\u00e9zary Syndrome","canonical_id":"clinicaltrials.gov:NCT04256018","description":"Sezary Syndrome; Mycosis Fungoides","metadata":null},{"id":"88a09931ec264ce1a8466b7f30cd33f7","type":"TRIAL","name":"Mogamulizumab Q4week Dosing in Participants With R/R CTCL","canonical_id":"clinicaltrials.gov:NCT04745234","description":"Cutaneous T-Cell Lymphoma, Relapsed; Cutaneous T-Cell Lymphoma Refractory","metadata":null},{"id":"0a37d6cf553648f0b6a061754a4ee771","type":"TRIAL","name":"Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT05414500","description":"Cutaneous T Cell Lymphoma; Mycosis Fungoides","metadata":null},{"id":"9577f7ea10e546b38b40950a03d7d571","type":"TRIAL","name":"Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT04676087","description":"Mycosis Fungoides; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome","metadata":null},{"id":"db365ab359dc4de1a2d390f4ea451d73","type":"TRIAL","name":"Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03309878","description":"Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Transformed B-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"ad30e9d9fc8347c5b4c896ab83189fbd","type":"TRIAL","name":"Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT04979520","description":"Hidradenitis Suppurativa; Acne Inversa","metadata":null},{"id":"17072b8ede6f4c96bc0ac2fb396d82d5","type":"TRIAL","name":"Molecular Determinants for Therapy Response on Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02208128","description":"Renal Cell Carcinoma","metadata":null},{"id":"24c921a240aa466cb4aef5af0e267ffe","type":"TRIAL","name":"Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT","canonical_id":"clinicaltrials.gov:NCT04105634","description":"Cardiac Amyloidosis","metadata":null},{"id":"623594cc6a024af0a66fd44d6b6f6a0b","type":"TRIAL","name":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","canonical_id":"clinicaltrials.gov:NCT03184090","description":"Metastatic Breast Cancer","metadata":null},{"id":"92dcf6f43b9a4e199de35ecee3153a0b","type":"TRIAL","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","canonical_id":"clinicaltrials.gov:NCT03784014","description":"Soft Tissue Sarcoma","metadata":null},{"id":"3582e13968144cbab5427e34e86cbb7f","type":"TRIAL","name":"Molecular Signatures in Inflammatory Skin Disease","canonical_id":"clinicaltrials.gov:NCT03358693","description":"Atopic Dermatitis; Psoriasis","metadata":null},{"id":"9fd43b17e7fc4e69bc52ed3193cf7db6","type":"TRIAL","name":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","canonical_id":"clinicaltrials.gov:NCT05535166","description":"Medulloblastoma","metadata":null},{"id":"3634182e77664897b2305eb4871c191a","type":"TRIAL","name":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04355858","description":"Breast Cancer; Metastatic Cancer","metadata":null},{"id":"fec0cc92b23047118d38bb37c2b38280","type":"TRIAL","name":"Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02244489","description":"Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"555860aa3f2e49ba83da00649dc06df2","type":"TRIAL","name":"Momelotinib During and After HCT in Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT07104799","description":"Myelofibrosis; Hematopoietic Cell Transplantation (HCT)","metadata":null},{"id":"d8d2308c042e490bb5c40de9012957d7","type":"TRIAL","name":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT01969838","description":"Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"a2932a2107d64b2aa9ea29fcad96ac79","type":"TRIAL","name":"Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia","canonical_id":"clinicaltrials.gov:NCT07071155","description":"Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Overlap Neoplasms; Chronic Neutrophilic Leukemia","metadata":null},{"id":"36f2d430c92a4ef0b2c8d1d3a818430f","type":"TRIAL","name":"Momelotinib in VEXAS Syndrome","canonical_id":"clinicaltrials.gov:NCT07098936","description":"VEXAS Syndome; Myelo Dysplastic Syndrome","metadata":null},{"id":"498660933a7d4f86a5c71b6096928df7","type":"GO_TERM","name":"Mon1-Ccz1 complex","canonical_id":"go:GO:0035658","description":"\"A protein complex that functions as a guanine nucleotide exchange factor (GEF) and converts Rab-GDP to Rab-GTP. In S. cerevisiae, this complex consists of at least Mon1 and Ccz1, and serves as a GEF for the Rab Ypt7p.\" [GOC:rb, PMID:20797862]","metadata":null},{"id":"9ee672da7d69408f927799631cfa0ef2","type":"TRIAL","name":"Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO\u00ae (Rozanolixizumab)","canonical_id":"clinicaltrials.gov:NCT07570589","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"c41d1ff835214b7b9f1b37734e4bbee0","type":"TRIAL","name":"Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure","canonical_id":"clinicaltrials.gov:NCT06038682","description":"ARDS; COVID-19","metadata":null},{"id":"10c6753932a448638eb8212ac47932fd","type":"TRIAL","name":"Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT","canonical_id":"clinicaltrials.gov:NCT05938478","description":"Atopic Dermatitis; Eczema","metadata":null},{"id":"af80a5d99410462382d50994dd831c17","type":"TRIAL","name":"Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children","canonical_id":"clinicaltrials.gov:NCT02484261","description":"Leukemia","metadata":null},{"id":"934ed7592e8b4d2ea469d1f336d42006","type":"TRIAL","name":"Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin","canonical_id":"clinicaltrials.gov:NCT01178138","description":"Continuous Methamphetamine Abuse","metadata":null},{"id":"07f95c4125e14f5095883e099892a2ab","type":"TRIAL","name":"Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04887467","description":"Parkinson Disease","metadata":null},{"id":"0462638f510c4c88afc907dbdd91493c","type":"TRIAL","name":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","canonical_id":"clinicaltrials.gov:NCT01763827","description":"Hyperlipidemia","metadata":null},{"id":"6f4e09c7eaba4aefadb3933b4b4427b9","type":"TRIAL","name":"Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT01041638","description":"High Risk Neuroblastoma","metadata":null},{"id":"0a8b0c54af064c34b71dccd53c8734ef","type":"TRIAL","name":"Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00003543","description":"Colorectal Cancer","metadata":null},{"id":"7a3ceed53cf840b2be1958aef035a36d","type":"TRIAL","name":"Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00017381","description":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Noncontiguous Stage I\u2026","metadata":null},{"id":"67b4134d251c48f8b3789b28b7073dc0","type":"TRIAL","name":"Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00031642","description":"Lymphoma","metadata":null},{"id":"5df706a2a67c439cb67580646abed021","type":"TRIAL","name":"Monoclonal Antibody Therapy in Treating Patients With Leukemia","canonical_id":"clinicaltrials.gov:NCT00019227","description":"Lymphoma; Radiation Toxicity","metadata":null},{"id":"c52975c1cfd24a309a5bba6f46801592","type":"TRIAL","name":"Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00004874","description":"Lymphoma","metadata":null},{"id":"fcfd64f97a51471fa30de2af3a24a3ee","type":"TRIAL","name":"Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00005061","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"c5279ce0e20449328001fd97c0fd9b4f","type":"TRIAL","name":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00006695","description":"Lymphoma","metadata":null},{"id":"ab3027a52ccd451aa38b09add3ab253d","type":"TRIAL","name":"Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma","canonical_id":"clinicaltrials.gov:NCT00077532","description":"Melanoma (Skin)","metadata":null},{"id":"90247f82a10146ef8991ebb292b6895f","type":"TRIAL","name":"Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study","canonical_id":"clinicaltrials.gov:NCT05281770","description":"Migraine; Migraine With Aura; Migraine Without Aura; Chronic Migraine; Episodic Migraine","metadata":null},{"id":"4381769ba57144b5b4f643a815a09d2c","type":"TRIAL","name":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00998881","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"69e3877b890346eaab1c9ad121efe87f","type":"TRIAL","name":"Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.","canonical_id":"clinicaltrials.gov:NCT00150813","description":"Epilepsy, Tonic-clonic","metadata":null},{"id":"c30a5e0688974d02a7981cb4abdd54fc","type":"TRIAL","name":"Monotherapy With Rapamycin in Long-standing Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02803892","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"d6d615f65d3e45bfa19ff98b7c7c5e94","type":"TRIAL","name":"Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil","canonical_id":"clinicaltrials.gov:NCT02047019","description":"Hypertension","metadata":null},{"id":"0227bba6c9264293966f214905277c7a","type":"DRUG","name":"Montelukast","canonical_id":"mesh:C093875","description":null,"metadata":null},{"id":"18ad3ff1563e4a6ab33eb9c9a4f3780a","type":"TRIAL","name":"Montelukast - a Treatment Choice for COVID-19","canonical_id":"clinicaltrials.gov:NCT04714515","description":"Covid19; SARS-CoV-2 Infection","metadata":null},{"id":"2a5da0fc85cc4c1cbd43a156df78fc72","type":"TRIAL","name":"Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)","canonical_id":"clinicaltrials.gov:NCT00446056","description":"Asthma","metadata":null},{"id":"6969062e243840c699e98f28745a66de","type":"TRIAL","name":"Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02551536","description":"Allergic Rhinitis","metadata":null},{"id":"ea6f2b390dfa4141a60bbc4b3fbc7db2","type":"TRIAL","name":"Montelukast and Loratadine in Children With Asthma","canonical_id":"clinicaltrials.gov:NCT03372473","description":"Asthma in Children","metadata":null},{"id":"8572a0b0f3564140bbe9e1f81ebba7ea","type":"TRIAL","name":"Montelukast in Children With Wheezing","canonical_id":"clinicaltrials.gov:NCT00775697","description":"Wheezing","metadata":null},{"id":"b7e8bf883d554dc8bdb0209ae9efca41","type":"TRIAL","name":"Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)","canonical_id":"clinicaltrials.gov:NCT00974571","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"d981eb3313174dab93604592f85b9a3c","type":"TRIAL","name":"Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)","canonical_id":"clinicaltrials.gov:NCT00963599","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"adb37a20dfd64a5dbcec89b450842e2f","type":"TRIAL","name":"Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)","canonical_id":"clinicaltrials.gov:NCT00972738","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"09f12da95d9444d6ade4473e2226d63b","type":"TRIAL","name":"Montelukast in Very Low Birthweight Infants","canonical_id":"clinicaltrials.gov:NCT00492102","description":"Bronchopulmonary Dysplasia","metadata":null},{"id":"a1d44b979c2d4f81b8ba09e788ffa887","type":"TRIAL","name":"Morphine Versus Ketorolac in Low Back Pain","canonical_id":"clinicaltrials.gov:NCT02782286","description":"Low Back Pain","metadata":null},{"id":"45fef3afe2f048bbab677cfd17efce1c","type":"TRIAL","name":"Morphological Changes of Ciliary Body and Trabecular Meshwork","canonical_id":"clinicaltrials.gov:NCT05352854","description":"Glaucoma; Myopia","metadata":null},{"id":"fe03a27607c143489ef3b501b49a654f","type":"TRIAL","name":"Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT05169658","description":"Non-Hodgkin Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Indolent B-Cell Non-Hodgkin Lymphoma; Marginal Zone Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","metadata":null},{"id":"307084d1e73243748686e5de3a72f372","type":"TRIAL","name":"Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT06453044","description":"Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma","metadata":null},{"id":"ac7c9a5275de45b6843c118e5211b9c4","type":"TRIAL","name":"Mosunetuzumab for CLL MRD Clearance","canonical_id":"clinicaltrials.gov:NCT07052695","description":"Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma","metadata":null},{"id":"125e7b993f97450f855fd2ee4e8e32c3","type":"DISEASE","name":"Motion Sickness","canonical_id":"mesh:D009041","description":null,"metadata":null},{"id":"5d50914b077b48e9816dc1460d493626","type":"TRIAL","name":"Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients","canonical_id":"clinicaltrials.gov:NCT05855577","description":"Parkinson Disease; Gait Analysis; Therapy, Directly Observed; Metabolic Disease","metadata":null},{"id":"903989d8fb2d45ca9f8a43750191ce55","type":"TRIAL","name":"Motor Network Physiology","canonical_id":"clinicaltrials.gov:NCT04957095","description":"Parkinson Disease; Essential Tremor","metadata":null},{"id":"815ca03ca0b74386a28d14a6e8e3c67b","type":"TRIAL","name":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","canonical_id":"clinicaltrials.gov:NCT04302870","description":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","metadata":null},{"id":"a491334ea45a480e8898fdb8c0c0e572","type":"TRIAL","name":"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT02338050","description":"Acute Lymphoblastic Leukemia (ALL)","metadata":null},{"id":"ccf387d966544832a46238ea86f047e4","type":"TRIAL","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT01829711","description":"Leukemia, Hairy Cell","metadata":null},{"id":"f12508cd95904ed79da172c5b76808bd","type":"TRIAL","name":"Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT03805932","description":"Hairy Cell Leukemia","metadata":null},{"id":"594fa6a4bda347e4b77d488055b49c87","type":"DRUG","name":"Moxisylyte","canonical_id":"mesh:D013948","description":null,"metadata":null},{"id":"6bda029511f1454180fba637ceadaa23","type":"DRUG","name":"Moxonidine","canonical_id":"mesh:C043482","description":null,"metadata":null},{"id":"481c76b1b40444f49ff708f461867880","type":"TRIAL","name":"Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT04023565","description":"Arterial Hypertension; Metabolic Syndrome","metadata":null},{"id":"379cd829e1ed493eb780830ba74a5566","type":"TRIAL","name":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT07188090","description":"Multiple Myeloma; Hodgkin Lymphoma; Non-hodgkin Lymphoma","metadata":null},{"id":"0aed12c37637495f98b67f267b84acbf","type":"TRIAL","name":"Mozobil for Autologous Stem Cell Mobilization","canonical_id":"clinicaltrials.gov:NCT01164345","description":"Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Stem Cell Mobilization; Autologous Stem Cell Transplantation","metadata":null},{"id":"2a1f8846bbdd476e8ca83083ba4c9150","type":"GO_TERM","name":"Mpp10 complex","canonical_id":"go:GO:0034457","description":"\"A protein complex that forms a subcomplex of the 90S preribosome. In S. cerevisiae, it is composed of Mpp10p, Imp3p and Imp4p.\" [GOC:mah, PMID:17515605]","metadata":null},{"id":"8f1dabbcdc3f4cb8b2e428da7f8d9c3a","type":"GO_TERM","name":"Mre11 complex","canonical_id":"go:GO:0030870","description":"\"Trimeric protein complex that possesses endonuclease activity; involved in meiotic recombination, DNA repair and checkpoint signaling. In Saccharomyces cerevisiae, the complex comprises Mre11p, Rad50p, and Xrs2p; complexes identified in other species generally contain proteins orthologous to the Saccharomyces cerevisiae proteins.\" [GOC:mah, GOC:vw, PMID:11988766, PMID:17674145]","metadata":null},{"id":"af4c1e857e5e4fb892d7447766471172","type":"GO_TERM","name":"Mre11 complex assembly","canonical_id":"go:GO:0072685","description":"\"The aggregation, arrangement and bonding together of a set of components to form an Mre11 complex, a trimeric protein complex that possesses endonuclease activity and is involved in meiotic recombination, DNA repair and checkpoint signaling.\" [GOC:mah, PMID:19211838]","metadata":null},{"id":"41ba016186bf4feb9b57ed09e8f140b2","type":"GO_TERM","name":"Mrh5C translation activator complex","canonical_id":"go:GO:0180049","description":"\"A protein complex capable of translation activator activity, and is involved in the activation of cox1 mRNA for translation. In fission yeast this complex consists of a scaffold (Sls1), a helicase (Mrh5), and PPR repeat proteins Prr4 and Mtf2.\" [PMID:34634819, PMID:38499152]","metadata":null},{"id":"f441cd07fe204482b220af5918c2fe67","type":"TRIAL","name":"MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms","canonical_id":"clinicaltrials.gov:NCT01418209","description":"Hot Flashes; Menopause; Vasomotor Disturbance","metadata":null},{"id":"4c4992ec9e3b498abf9afd79075b30e2","type":"GO_TERM","name":"MsbA transporter complex","canonical_id":"go:GO:1990199","description":"\"An ATP-binding cassette (ABC) transporter complex made up of a dimer of MsbA. Facilitates the export across the plasma membrane of, amongst others, lipid A and lipopolysaccharide. In contrast to most ABC transporter complexes, each chain of the homodimer contains both the transmembrane domain (TMD) and the cytoplasmic ATP-binding domain (NBD).\" [GOC:bhm, PMID:18024585]","metadata":null},{"id":"063ae88720e94be7b1bdb1d22cccabed","type":"GO_TERM","name":"Mst2 histone acetyltransferase complex","canonical_id":"go:GO:0036410","description":"\"A protein complex that can catalyze the acetylation of lysine at position 14 in histone H3, and contains Mst2 as the catalytic subunit. In fission yeast, contains at least Mst2, Nto1, Ptf2, Ptf1 and Eaf6.\" [GOC:vw, PMID:21289066]","metadata":null},{"id":"da936f41dbd24ddaa1b0d2704ddc3caa","type":"DISEASE","name":"Muckle-Wells syndrome","canonical_id":"mondo:0008633","description":null,"metadata":null},{"id":"0bde8f7472f04995a39d2f74f9fc4cca","type":"DISEASE","name":"Mucopolysaccharidosis IV","canonical_id":"mesh:D009085","description":null,"metadata":null},{"id":"6fa63abcbf494ee58bcc9c47c96c06f0","type":"DISEASE","name":"Mucopolysaccharidosis, MPS-I","canonical_id":"mesh:D008059","description":null,"metadata":null},{"id":"3d9c44213d2d4296a6fa3ae4476fa57f","type":"DISEASE","name":"Mucopolysaccharidosis, MPS-II","canonical_id":"mesh:D016532","description":null,"metadata":null},{"id":"1ee29af691724880a0fb75db06c2e388","type":"DISEASE","name":"Mucormycosis","canonical_id":"mesh:D009091","description":null,"metadata":null},{"id":"ccb069c880494c8d8d8f68197d41c0f4","type":"DISEASE","name":"Mucosal Melanoma","canonical_id":"doid:0050929","description":null,"metadata":null},{"id":"b8adac29b65143daa85f60332cf02331","type":"DISEASE","name":"Muenke syndrome","canonical_id":"mondo:0011274","description":null,"metadata":null},{"id":"9f861fa9458246f2930069ce26da3db0","type":"GO_TERM","name":"Mullerian duct regression","canonical_id":"go:GO:0001880","description":"\"The process in which the Mullerian ducts, primordia of the oviducts, uterus and upper vagina, undergo regression in male embryos.\" [GOC:dph, PMID:12368913]","metadata":null},{"id":"05431249030b4c058de4b418823dc8ff","type":"TRIAL","name":"Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals","canonical_id":"clinicaltrials.gov:NCT06805656","description":"Hiv; HIV I Infection","metadata":null},{"id":"9eee5effd2d348e0aec8ae40cf6e68f5","type":"TRIAL","name":"Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure","canonical_id":"clinicaltrials.gov:NCT02961829","description":"Chronic Infection; HIV","metadata":null},{"id":"2dc1bd37aa934edda38e4664f1d10dc8","type":"TRIAL","name":"Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma","canonical_id":"clinicaltrials.gov:NCT01845038","description":"Glaucoma","metadata":null},{"id":"94e11d1cf23b42b79cdd0387699567e7","type":"TRIAL","name":"Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders","canonical_id":"clinicaltrials.gov:NCT00000597","description":"Anemia, Aplastic; Hematologic Diseases; Pancytopenia; Blood Disease","metadata":null},{"id":"19747a3286864583a797d4094089d3e5","type":"TRIAL","name":"Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics","canonical_id":"clinicaltrials.gov:NCT03219008","description":"Depressive Disorder","metadata":null},{"id":"4d29dbbc6cff42f38940279f5e467191","type":"TRIAL","name":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01910610","description":"Colorectal Cancer Metastatic","metadata":null},{"id":"ad0e8791298b47749c79a21c3f332c26","type":"TRIAL","name":"Multi-System Analysis of Opioid Receptor Binding","canonical_id":"clinicaltrials.gov:NCT05528848","description":"Healthy; Opioid Use Disorder","metadata":null},{"id":"27313eddf07b47c8b65883095a1d2a31","type":"TRIAL","name":"Multi-arm Optimization of Stroke Thrombolysis","canonical_id":"clinicaltrials.gov:NCT03735979","description":"Acute Ischemic Stroke","metadata":null},{"id":"c0c88e42463145018e35b06f26de2bfa","type":"TRIAL","name":"Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03562507","description":"Renal Cell Carcinoma, Metastatic","metadata":null},{"id":"9f6ab1b2a98a421fb0767909a2b86278","type":"TRIAL","name":"Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00779116","description":"Allergies","metadata":null},{"id":"88dcd6ffe84c47e697ced0645ec33cc9","type":"TRIAL","name":"Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients","canonical_id":"clinicaltrials.gov:NCT07064109","description":"ACS - Acute Coronary Syndrome","metadata":null},{"id":"c38d3107dc2d48efa9f4ffe248a6577b","type":"TRIAL","name":"Multi-site Adaptive Trials for COVID-19","canonical_id":"clinicaltrials.gov:NCT04370262","description":"COVID-19","metadata":null},{"id":"f7db4aa26f364bc88b47a034cc38eca8","type":"DISEASE","name":"Multibacillary leprosy","canonical_id":"mesh:D056006","description":null,"metadata":null},{"id":"56e55aa9c3aa4140b66febafc2efc237","type":"TRIAL","name":"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.","canonical_id":"clinicaltrials.gov:NCT05172050","description":"SARS CoV 2 Infection","metadata":null},{"id":"1a621f230fb54fa3a36f449b70ea7c06","type":"TRIAL","name":"Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (\u2265 65; < 80 Years).","canonical_id":"clinicaltrials.gov:NCT04751877","description":"Multiple Myeloma; Myeloma","metadata":null},{"id":"d77b177d7329435ca7e6d5bf3ad58954","type":"TRIAL","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","canonical_id":"clinicaltrials.gov:NCT04910386","description":"Biliary Tract Neoplasms","metadata":null},{"id":"5a94359013fe4f75aebe577674a3d2ee","type":"TRIAL","name":"Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01178047","description":"Parkinson's Disease","metadata":null},{"id":"d0dc9f1e63774e9e825745bfb3c44e23","type":"TRIAL","name":"Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis","canonical_id":"clinicaltrials.gov:NCT02643212","description":"Cirrhosis","metadata":null},{"id":"f9f78046c8f54efcbd3e3b9d31e73868","type":"TRIAL","name":"Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL\u00ae) in Patients With Benign Prostate Hypertrophy","canonical_id":"clinicaltrials.gov:NCT00542165","description":"BPH/LUTS/Sexual Functions","metadata":null},{"id":"73e2528a72da4c9ba9b2c48df7585292","type":"TRIAL","name":"Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.","canonical_id":"clinicaltrials.gov:NCT06271330","description":"Age-related Macular Degeneration","metadata":null},{"id":"cbca30ab77c440948c25b70ed649072a","type":"TRIAL","name":"Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT02133924","description":"Acute Graft Versus Host Disease","metadata":null},{"id":"aa1b2a32583b42cc95c33fb0105687e9","type":"TRIAL","name":"Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)","canonical_id":"clinicaltrials.gov:NCT00000586","description":"Anemia, Sickle Cell; Hematologic Diseases; Hemoglobinopathies","metadata":null},{"id":"5719cf522d064376be82e09e6ecbc855","type":"TRIAL","name":"Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)","canonical_id":"clinicaltrials.gov:NCT01598441","description":"Pulmonary Hypertension","metadata":null},{"id":"c1e44cb37fb645a986856640d5b9d98d","type":"TRIAL","name":"Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","canonical_id":"clinicaltrials.gov:NCT02677948","description":"Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic","metadata":null},{"id":"d347f19d4cf641d1b7a97c706d6fad54","type":"TRIAL","name":"Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide","canonical_id":"clinicaltrials.gov:NCT02502864","description":"Breast Cancer; Breast Cancer Female","metadata":null},{"id":"2bcb8a07d4cb468ab950eb12699d0097","type":"TRIAL","name":"Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations","canonical_id":"clinicaltrials.gov:NCT00203034","description":"Parkinson's Disease","metadata":null},{"id":"72ae2b2fed784f7c89aaae91991a3e00","type":"TRIAL","name":"Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00551707","description":"Rheumatoid Arthritis","metadata":null},{"id":"01826d6503344aa6ab7735cab80447c2","type":"TRIAL","name":"Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery","canonical_id":"clinicaltrials.gov:NCT00375934","description":"Pain, Postoperative","metadata":null},{"id":"c216f2031c9d468eab0956e5d7bf8813","type":"TRIAL","name":"Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02218606","description":"Prostate Cancer","metadata":null},{"id":"8b631d0a5b17434dad49454b2932857d","type":"TRIAL","name":"Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","canonical_id":"clinicaltrials.gov:NCT06080074","description":"Heart Failure; Cardiogenic Shock; Congenital Heart Disease; Cardiomyopathies","metadata":null},{"id":"1f847f004bf14dc18d2100810250b122","type":"TRIAL","name":"Multicenter Uveitis Steroid Treatment (MUST) Trial","canonical_id":"clinicaltrials.gov:NCT00132691","description":"Uveitis","metadata":null},{"id":"0f5a3094e8aa4738a8712ad1190e2e58","type":"TRIAL","name":"Multicenter, Phase\u2163, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib","canonical_id":"clinicaltrials.gov:NCT02389920","description":"Leukemia, Chronic Myeloid","metadata":null},{"id":"7bc0eec34e2a43089333f6c99340ae29","type":"TRIAL","name":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT06265545","description":"AML; Refractory; Relapsed","metadata":null},{"id":"6b01097484da49fa88cf7ba97e92297d","type":"TRIAL","name":"Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI","canonical_id":"clinicaltrials.gov:NCT00229515","description":"Myocardial Infarction","metadata":null},{"id":"ac182fd6c1bb4395842bba5ec86b620d","type":"TRIAL","name":"Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOl\u00e9dronique Acid to STER\u00e9otaxique Radiotherapy in the Treatment of Vertebral Metastases","canonical_id":"clinicaltrials.gov:NCT03951493","description":"Vertebral Metastasis","metadata":null},{"id":"44cf24d6b5a34a05a11de9f0af474efa","type":"TRIAL","name":"Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.","canonical_id":"clinicaltrials.gov:NCT05777902","description":"Multiple Sclerosis","metadata":null},{"id":"5e953d2babb744e5b722831fda7228ff","type":"TRIAL","name":"Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research","canonical_id":"clinicaltrials.gov:NCT01016886","description":"Breast Cancer; Heart Failure","metadata":null},{"id":"acc1200f24484d9cbd64c60418dd2aab","type":"TRIAL","name":"Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH","canonical_id":"clinicaltrials.gov:NCT04098250","description":"Post-Traumatic Headache","metadata":null},{"id":"ea964846725f422493f8f39424b5e9d2","type":"TRIAL","name":"Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy","canonical_id":"clinicaltrials.gov:NCT07573696","description":"Nonsmall Cell Lung Cancer Stage III","metadata":null},{"id":"b453186a7b7343489bea0d7094ff9e29","type":"TRIAL","name":"Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT06082063","description":"Cardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure","metadata":null},{"id":"c253bb400e8449268e05f17b37ac1594","type":"TRIAL","name":"Multimodal Analgesia in Shoulder Arthroplasty","canonical_id":"clinicaltrials.gov:NCT03586934","description":"Shoulder Pain; Opioid Use","metadata":null},{"id":"9296307e512c4c0799242a98bbccba4c","type":"TRIAL","name":"Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02330926","description":"Cachexia; Neoplasms","metadata":null},{"id":"e5896f0292fd48a59c6592594ec665fc","type":"TRIAL","name":"Multimodal Opioid-Free Anesthesia in RIRS","canonical_id":"clinicaltrials.gov:NCT07636070","description":"Kidney Stone; Retrograde Intrarenal Surgery (RIRS); Postoperative Pain","metadata":null},{"id":"dae46c42118c46ae8e665a085c25c1fc","type":"TRIAL","name":"Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery","canonical_id":"clinicaltrials.gov:NCT03573115","description":"Acne Vulgaris; Microparticles","metadata":null},{"id":"0fc40d634387409db1e404288ca73260","type":"TRIAL","name":"Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy","canonical_id":"clinicaltrials.gov:NCT04429022","description":"Pain, Postoperative","metadata":null},{"id":"95d6b4c68895484aa47a84603310adc8","type":"TRIAL","name":"Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment","canonical_id":"clinicaltrials.gov:NCT06032728","description":"Renal Cell Carcinoma","metadata":null},{"id":"867773d6d93b4404804bc11cf5e49b9c","type":"TRIAL","name":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT02990338","description":"Plasma Cell Myeloma","metadata":null},{"id":"9a3d68fda8454ed8b85a97cf9af9ca1e","type":"TRIAL","name":"Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00861757","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"3a7de420c2ca4686a87e7a0694c9a878","type":"TRIAL","name":"Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer","canonical_id":"clinicaltrials.gov:NCT07836712","description":"Advanced Hepatocellular Carcinoma; Advanced Melanoma; Locally Advanced Melanoma; Metastatic Melanoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8","metadata":null},{"id":"702cfbff412e4016b9fcb0d57bdb3933","type":"TRIAL","name":"Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552","canonical_id":"clinicaltrials.gov:NCT01110590","description":"Erectile Dysfunction","metadata":null},{"id":"e6ebfed008aa4e37b6bf529e7e059f31","type":"TRIAL","name":"Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A\u03b2 IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01677572","description":"Alzheimer's Disease","metadata":null},{"id":"d908347a965449ec81e8dca8caa3f678","type":"TRIAL","name":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","canonical_id":"clinicaltrials.gov:NCT02044094","description":"Opioid Use Disorder","metadata":null},{"id":"7e6cbc2b31c84f63853871b8b53067fc","type":"TRIAL","name":"Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02430909","description":"Rheumatoid Arthritis","metadata":null},{"id":"fcc5b7afe14b4082893636c07a044f92","type":"TRIAL","name":"Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations","canonical_id":"clinicaltrials.gov:NCT00387777","description":"Healthy","metadata":null},{"id":"180ab41c16e3445f8fa43a2ca49f6652","type":"TRIAL","name":"Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT06316336","description":"Healthy Vollunteer","metadata":null},{"id":"f7020de7ef68441cb163db796f2e7a99","type":"TRIAL","name":"Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02182401","description":"Healthy","metadata":null},{"id":"e7e7491b6a4648fe9378a8680c68b142","type":"DISEASE","name":"Multiple Endocrine Neoplasia","canonical_id":"mesh:D009377","description":null,"metadata":null},{"id":"ff55314338d543b2b6e4aacc64fee6b2","type":"DISEASE","name":"Multiple Myeloma","canonical_id":"doid:9538","description":null,"metadata":null},{"id":"168417e86df4406585953573467aa2f2","type":"DISEASE","name":"Multiple Organ Failure","canonical_id":"efo:1001373","description":null,"metadata":null},{"id":"a55542a3cacf4f63b353e1657ad153a3","type":"DISEASE","name":"Multiple Sclerosis","canonical_id":"mesh:D009103","description":null,"metadata":null},{"id":"946030edc82842e78a04ef50a3eeb627","type":"TRIAL","name":"Multiple Treatments for Ebola Virus Disease (EVD)","canonical_id":"clinicaltrials.gov:NCT02380625","description":"Ebola Virus Disease","metadata":null},{"id":"6f259545907c4a23969d55bc5cfcda31","type":"DISEASE","name":"Multiple meyloma","canonical_id":"mesh:D009101","description":null,"metadata":null},{"id":"4e44ddd5be3f4484895208e7f39aa2d1","type":"TRIAL","name":"Multiple-dose Pharmacokinetics Study of \"SYN006 HFA MDI\" Administered Orally to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02165033","description":"Asthma","metadata":null},{"id":"d27f6c0122a140fdb294769522018149","type":"TRIAL","name":"Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males","canonical_id":"clinicaltrials.gov:NCT01725009","description":"Healthy Volunteers","metadata":null},{"id":"046ec83b21244d3682dd5eb524055b71","type":"TRIAL","name":"Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion","canonical_id":"clinicaltrials.gov:NCT03851263","description":"Coronary Artery Disease","metadata":null},{"id":"081a23e75dfd44e088bf7b914fdc6322","type":"TRIAL","name":"Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging","canonical_id":"clinicaltrials.gov:NCT00857792","description":"Coronary Disease","metadata":null},{"id":"646bcaecfff845cd8e3d00ee084ee523","type":"DRUG","name":"Mupirocin","canonical_id":"mesh:D016712","description":null,"metadata":null},{"id":"d90ecc0232b14adca18a70f04d08070e","type":"TRIAL","name":"Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT03050827","description":"Diabetic; Neuropathic, Polyneuropathy (Manifestation)","metadata":null},{"id":"a3f0bffd908346cf8f3d575fc9c1eeda","type":"TRIAL","name":"Muscle Fatigue and Carbonic Anhydrase Inhibitors","canonical_id":"clinicaltrials.gov:NCT02758470","description":"Hypoxia","metadata":null},{"id":"aca9904568294c549ba1be020f91747b","type":"TRIAL","name":"Muscle Impact of Treating Osteoporosis","canonical_id":"clinicaltrials.gov:NCT05666310","description":"Sarcopenia; Osteoporosis","metadata":null},{"id":"f55e4386347c4cba931863b7d130e637","type":"TRIAL","name":"Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy","canonical_id":"clinicaltrials.gov:NCT06709066","description":"Anesthesia; Bronchoscopy; Muscle Relaxants","metadata":null},{"id":"0482668a4b0b452db108bcd764382d7f","type":"TRIAL","name":"Muscle Relaxation for Short Procedures","canonical_id":"clinicaltrials.gov:NCT01902641","description":"Intubating Conditions; Fasciculations; Postoperative Myalgia; Patient Satisfaction; Sore Throat","metadata":null},{"id":"a760f94ba78f4a16bde6f2c94e4099e8","type":"TISSUE","name":"Muscle Skeletal","canonical_id":"uberon:UBERON:0011907","description":null,"metadata":null},{"id":"2213104bfb6f47e6948c72493274b3ed","type":"TRIAL","name":"Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache.","canonical_id":"clinicaltrials.gov:NCT02746250","description":"Tension-type Headache","metadata":null},{"id":"c1094760eb9a4ce3a92a04abad7814b1","type":"TRIAL","name":"Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique","canonical_id":"clinicaltrials.gov:NCT03847545","description":"Multiple Sclerosis","metadata":null},{"id":"e73964cbbe194504a698461b39382786","type":"DISEASE","name":"Muscle spasm","canonical_id":"hp:0003394","description":null,"metadata":null},{"id":"89c5f7b09d214d3387fdd6694d6670bc","type":"DISEASE","name":"Muscle weakness","canonical_id":"hp:0001324","description":null,"metadata":null},{"id":"6ffc2f52c6de46129bacdb8b3a8fac64","type":"DISEASE","name":"Muscular Dystrophy, Duchenne","canonical_id":"mesh:D020388","description":null,"metadata":null},{"id":"ea29ec413c534a14ac1e50941c2e4f42","type":"DISEASE","name":"Musculoskeletal Diseases","canonical_id":"mesh:D009140","description":null,"metadata":null},{"id":"695355653dbb428585d141f994a718ff","type":"GO_TERM","name":"MutLalpha complex","canonical_id":"go:GO:0032389","description":"\"A heterodimer involved in the recognition of base-base and small insertion/deletion mismatches. In human the complex consists of two subunits, MLH1 and PMS2.\" [GOC:vk]","metadata":null},{"id":"06e9d82bf1004f93b6f74052c7d18f19","type":"GO_TERM","name":"MutLalpha complex binding","canonical_id":"go:GO:0032405","description":"\"Binding to a MutLalpha mismatch repair complex.\" [GOC:vk]","metadata":null},{"id":"1f5f0bc07a2b43e4ae3d6c54fea863f5","type":"GO_TERM","name":"MutLbeta complex","canonical_id":"go:GO:0032390","description":"\"A heterodimer involved in the recognition of base-base and small insertion/deletion mismatches. In human the complex consists of two subunits, MLH1 and PMS1.\" [GOC:vk]","metadata":null},{"id":"50ca057dda384a87b2334f26923ed73e","type":"GO_TERM","name":"MutLbeta complex binding","canonical_id":"go:GO:0032406","description":"\"Binding to a MutLbeta mismatch repair complex.\" [GOC:vk]","metadata":null},{"id":"81602a0ca856472582f08f8b8ec1720e","type":"GO_TERM","name":"MutLgamma complex","canonical_id":"go:GO:0097587","description":"\"A heterodimer involved in the recognition of base-base and small insertion/deletion mismatches. In S. cerevisiae the complex consists of two subunits, Mlh1 and Mlh3.\" [GOC:jd, PMID:10570173]","metadata":null},{"id":"2afcaf6950c24491bbbe1210c9197320","type":"GO_TERM","name":"MutS complex","canonical_id":"go:GO:1990710","description":"\"A homodimeric mismatch repair complex involved in binding to and correcting insertion/deletion mutations.\" [GOC:bhm, PMID:21666597]","metadata":null},{"id":"13d2a6d71f6047ecbec47bfc17c7f10d","type":"GO_TERM","name":"MutSalpha complex","canonical_id":"go:GO:0032301","description":"\"A heterodimer involved in the recognition and repair of base-base and small insertion/deletion mismatches. In human the complex consists of two subunits, MSH2 and MSH6.\" [PMID:11005803]","metadata":null},{"id":"bd1670512c0a437b9494afe5ae259813","type":"GO_TERM","name":"MutSalpha complex binding","canonical_id":"go:GO:0032407","description":"\"Binding to a MutSalpha mismatch repair complex.\" [GOC:vk]","metadata":null},{"id":"3004374d5c63494ebb638a0b45bc00ac","type":"GO_TERM","name":"MutSbeta complex","canonical_id":"go:GO:0032302","description":"\"A heterodimer involved in binding to and correcting insertion/deletion mutations. In human the complex consists of two subunits, MSH2 and MSH3.\" [PMID:11005803]","metadata":null},{"id":"f07ce7c451ab4a2590f15e6e233a0a63","type":"GO_TERM","name":"MutSbeta complex binding","canonical_id":"go:GO:0032408","description":"\"Binding to a MutSbeta mismatch repair complex.\" [GOC:vk]","metadata":null},{"id":"582b2a83964045e2aef2b6efe410e923","type":"GO_TERM","name":"MutSgamma complex","canonical_id":"go:GO:0062128","description":"\"A heterodimer involved in the stabilization of DNA recombination intermediates, the promotion of crossover recombination, and the proper assembly of the synaptonemal complex in meiotic prophase nuclei. In yeast the complex consists of two subunits, Msh4 and Msh5.\" [PMID:27648641, PMID:7622037, PMID:8001134, PMID:9374523]","metadata":null},{"id":"311b1222a7ce49ea8df5e6edd11bb034","type":"TRIAL","name":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02091141","description":"Neoplasms; Solid Tumors; Biliary Cancer; Salivary Cancer; Bladder Cancer","metadata":null},{"id":"86d6c889e4a34056b2bb72446bd8c93e","type":"GO_TERM","name":"MyD88-dependent toll-like receptor 2 signaling pathway","canonical_id":"go:GO:0035661","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like 2 receptor where the MyD88 adaptor molecule mediates transduction of the signal. Toll-like 2 receptors are pattern recognition receptors that bind microbial pattern motifs to initiate an innate immune response.\" [GOC:BHF, PMID:20385024]","metadata":null},{"id":"578af8a67dc44946a1deaf60b914d3d2","type":"GO_TERM","name":"MyD88-dependent toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0035660","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like 4 receptor, where the MyD88 adaptor molecule mediates transduction of the signal. Toll-like 4 receptors bind bacterial lipopolysaccharide (LPS) to initiate an innate immune response.\" [GOC:BHF, PMID:18304834, PMID:20385024]","metadata":null},{"id":"455267e58f1a4a33b84bd17d194aebf7","type":"GO_TERM","name":"MyD88-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0002755","description":"\"A toll-like receptor signaling pathway in which the MyD88 adaptor molecule mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate an innate immune response.\" [GOC:add, ISBN:0781735149, PMID:12467241, PMID:12524386, PMID:12855817, PMID:15585605, PMID:15728447]","metadata":null},{"id":"e40561085b704151bdbdfa6432156578","type":"GO_TERM","name":"MyD88-independent toll-like receptor signaling pathway","canonical_id":"go:GO:0002756","description":"\"A toll-like receptor signaling pathway not relying on the MyD88 adaptor molecule. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate an immune response.\" [GOC:add, ISBN:0781735149, PMID:12467241, PMID:12524386, PMID:12855817, PMID:15585605, PMID:15728447]","metadata":null},{"id":"eb2a95b136594b48833ef60e2c33fef2","type":"DISEASE","name":"Myalgia","canonical_id":"hp:0003326","description":null,"metadata":null},{"id":"d14c4a7f75ec418582c6e9a4d6bc7fae","type":"DISEASE","name":"Myalgia","canonical_id":"mesh:D063806","description":null,"metadata":null},{"id":"d9ff688a0c6c47418670e87243389b82","type":"TRIAL","name":"Myasthenia Gravis Inebilizumab Trial","canonical_id":"clinicaltrials.gov:NCT04524273","description":"Myasthenia Gravis","metadata":null},{"id":"34ffb95ef8b04eca9b33981035d34017","type":"DISEASE","name":"Myasthenia gravis","canonical_id":"mesh:D009157","description":null,"metadata":null},{"id":"bdc3129889854eecb273e169cdf0a124","type":"GO_TERM","name":"Myb complex","canonical_id":"go:GO:0031523","description":"\"A multisubunit complex consisting of Myb and other proteins that regulates site specific DNA replication, gene amplification and transcriptional repression.\" [PMID:12490953, PMID:15545624]","metadata":null},{"id":"16862911814245b7878cb506bf448848","type":"GO_TERM","name":"Myc-Max complex","canonical_id":"go:GO:0071943","description":"\"A transcription factor complex that consists of a heterodimer of the bHLH-ZIP proteins Myc and Max.\" [GOC:cna, PMID:16620027, PMID:16620031, PMID:20170194]","metadata":null},{"id":"b54794c1119d48fbb2c0ce419c662c76","type":"DISEASE","name":"Mycetoma","canonical_id":"mesh:D008271","description":null,"metadata":null},{"id":"5cf6c36ec5cc4168bec96a189b724c13","type":"TRIAL","name":"Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN","canonical_id":"clinicaltrials.gov:NCT00301613","description":"Henoch-Schoenlein Purpura; Nephritis","metadata":null},{"id":"2dc28a21022347439fa0b1085f4607c9","type":"TRIAL","name":"Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)","canonical_id":"clinicaltrials.gov:NCT00657059","description":"IgA Nephropathy","metadata":null},{"id":"74ac7b8901224f5b8842e440e2b0b6f0","type":"TRIAL","name":"Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation","canonical_id":"clinicaltrials.gov:NCT00206076","description":"Liver Disease","metadata":null},{"id":"38fc6bd7fa8541cca2c1cc3c359d7b16","type":"TRIAL","name":"Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.","canonical_id":"clinicaltrials.gov:NCT00204022","description":"Lupus Nephritis","metadata":null},{"id":"8b3a3a95c75e42ffb786bd80c62ab15b","type":"DISEASE","name":"Mycosis fungoides","canonical_id":"mesh:D009182","description":null,"metadata":null},{"id":"51b86f5e6cd14f0f83ec346506f266da","type":"DISEASE","name":"Mydriasis","canonical_id":"hp:0011499","description":null,"metadata":null},{"id":"fe57991d836d459582102c49ee21232d","type":"DISEASE","name":"Mydriasis","canonical_id":"mesh:D015878","description":null,"metadata":null},{"id":"0ef37317e8914e108f4fe29b7f0f1627","type":"TRIAL","name":"Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases","canonical_id":"clinicaltrials.gov:NCT00309842","description":"Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelofibrosis; MDS; Refractory Anemia; Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Non-Hodgkin's Lymphoma; Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes","metadata":null},{"id":"752473ed309741a0930a64ed602a46b8","type":"TRIAL","name":"Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)","canonical_id":"clinicaltrials.gov:NCT03645824","description":"Myelofibrosis","metadata":null},{"id":"cca55be53387451c906ef2bb86226853","type":"DISEASE","name":"Myeloproliferative disorder","canonical_id":"mesh:D009196","description":null,"metadata":null},{"id":"17c38116f56941dda897f713a5eb36c6","type":"GO_TERM","name":"Myo2p-Vac17p-Vac8p transport complex","canonical_id":"go:GO:0071563","description":"\"A protein complex that is involved in transport of vacuoles to a newly formed daughter cell. In yeast, this complex is composed of Myo2p, Vac17p, and Vac8p.\" [GOC:jp, PMID:12594460]","metadata":null},{"id":"2bf82bdfe28a464291589314ffcac3bd","type":"TRIAL","name":"Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress","canonical_id":"clinicaltrials.gov:NCT01370265","description":"Coronary Artery Disease","metadata":null},{"id":"cd152cf2205c4664906b62c037e1fa39","type":"TRIAL","name":"Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle","canonical_id":"clinicaltrials.gov:NCT00001891","description":"Coronary Disease; Heart Diseases","metadata":null},{"id":"aa8995e20bdf4d10affa65ed6a3486ea","type":"TRIAL","name":"Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial","canonical_id":"clinicaltrials.gov:NCT02432885","description":"Myocardial Fibrosis; Muscular Dystrophies","metadata":null},{"id":"b5ea08988cb0423a984bc4e92a6208b7","type":"DISEASE","name":"Myocardial Infarction","canonical_id":"mesh:D009203","description":null,"metadata":null},{"id":"9e63835c7cc847f28e64c7e86b663676","type":"TRIAL","name":"Myocardial Infarction With ST-Elevation","canonical_id":"clinicaltrials.gov:NCT00638638","description":"Myocardial Infarction","metadata":null},{"id":"60c6b40860694bc98eb590c6e94a7dc0","type":"TRIAL","name":"Myocardial Perfusion Assessment With Multidetector Computed Tomography","canonical_id":"clinicaltrials.gov:NCT00846079","description":"Coronary Artery Disease","metadata":null},{"id":"c30359766ec94988a324e380a892de9d","type":"DISEASE","name":"Myoclonic seizure","canonical_id":"mesh:D004831","description":null,"metadata":null},{"id":"cc1b331b1ae044608bab759ed3548100","type":"TRIAL","name":"Myofascial Pain Patients' Response to the Administration of Low Doses of Amitriptyline and Citalopram Compared With the Use of Bite Splint","canonical_id":"clinicaltrials.gov:NCT04777838","description":"Muscle Type Temporomandibular Disorders; Myofascial Pain of the Masticatory Muscles","metadata":null},{"id":"0496ab14c30d4abd8709ed2be9b9b7fe","type":"DISEASE","name":"Myokymia","canonical_id":"hp:0002411","description":null,"metadata":null},{"id":"d90a696daeab4bc59381da0a6efd8e53","type":"TRIAL","name":"Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L","canonical_id":"clinicaltrials.gov:NCT04856306","description":"Heavy Menstrual Bleeding; Fibroid Uterus","metadata":null},{"id":"e366cd08cf8045fda7a42f833b53cb74","type":"TRIAL","name":"Myrbetriq\u2122 (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement","canonical_id":"clinicaltrials.gov:NCT02462837","description":"Urinary Bladder, Overactive; Pain; Lower Urinary Tract Symptoms","metadata":null},{"id":"aee6ef52503c4a03a397eb9caecd5a98","type":"PROTEIN","name":"Myristoylated alanine-rich C kinase substrate","canonical_id":"uniprot:P29966","description":null,"metadata":null},{"id":"4ea18050bf0f417c9c2ab7c559c6c293","type":"DISEASE","name":"Myxedema","canonical_id":"mesh:D009230","description":null,"metadata":null},{"id":"9dcfefcf35ed409fb65d65a0164c456d","type":"DISEASE","name":"M\u00e9ni\u00e8re's disease","canonical_id":"mesh:D008575","description":null,"metadata":null},{"id":"6613020cb2af46909b5146b4f085b01a","type":"GO_TERM","name":"N',N'',N'''-triacetylfusarinine C biosynthetic process","canonical_id":"go:GO:1900551","description":"\"The chemical reactions and pathways resulting in the formation of N',N'',N'''-triacetylfusarinine C.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1dcbc61480994bb6bd0f5e0f5bcb69b6","type":"GO_TERM","name":"N',N'',N'''-triacetylfusarinine C catabolic process","canonical_id":"go:GO:1900550","description":"\"The chemical reactions and pathways resulting in the breakdown of N',N'',N'''-triacetylfusarinine C.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ce933ae9de644490b96525f246fa6500","type":"GO_TERM","name":"N(1)-acetylpolyamine oxidase activity","canonical_id":"go:GO:0052903","description":"\"Catalysis of the reaction: N(1)-acetylspermine + O2 + H2O = 3-acetamidopropanal + spermidine + H2O2. Also converts N(1)-acetylspermidine to putrescine, and N(1),N(12)-diacetylspermine to N(1)-acetylspermidine.\" [EC:1.5.3.13]","metadata":null},{"id":"8dc0ec9186d3424ca3ffbd1ba9a65ce5","type":"GO_TERM","name":"N(6),N(6),N(6)-trimethyl-L-lysine transmembrane transporter activity","canonical_id":"go:GO:7770026","description":"\"Enables the transfer of N(6),N(6),N(6)-trimethyl-L-lysine from one side of a membrane to the other.\" [PMID:41075780, PMID:41075794]","metadata":null},{"id":"bc1f701704e340998fddccacad295a41","type":"GO_TERM","name":"N(8)-acetylspermidine oxidase (propane-1,3-diamine-forming) activity","canonical_id":"go:GO:0052897","description":"\"Catalysis of the reaction: N(8)-acetylspermidine + O2 + H2O = 4-acetamidobutanal + propane-1,3-diamine + H2O2. Also active with N(1)-acetylspermine, weak activity with N(1),N(12)- diacetylspermine.\" [EC:1.5.3.15, RHEA:25972]","metadata":null},{"id":"96c9e6bc07c847b898f0c84c19ae6ed3","type":"GO_TERM","name":"N(alpha)-benzyloxycarbonylleucine hydrolase activity","canonical_id":"go:GO:0047413","description":"\"Catalysis of the reaction: N-benzyloxycarbonyl-L-leucine + H2O + H+ = L-leucine + benzyl alcohol + CO2.\" [EC:3.5.1.64, RHEA:18901]","metadata":null},{"id":"f6b68cf1a6b54a0391401baaf8f52096","type":"GO_TERM","name":"N,N'-diacetylbacilliosaminyl-1-phosphate transferase activity","canonical_id":"go:GO:0102334","description":"\"Catalysis of the reaction: ditrans,polycis-undecaprenyl phosphate + UDP-N,N'-diacetylbacillosamine = N,N'-diacetyl-alpha-D-bacillosaminyl-diphospho-tri-trans,hepta-cis-undecaprenol + UMP.\" [EC:2.7.8.36, GOC:pz]","metadata":null},{"id":"c0accf387dc746c299a669295eff1e3e","type":"GO_TERM","name":"N,N'-diacetylbacillosaminyl-diphospho-undecaprenol alpha-1,3-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0102335","description":"\"Catalysis of the reaction: N,N'-diacetyl-alpha-D-bacillosaminyl-diphospho-tri-trans,hepta-cis-undecaprenol + UDP-N-acetyl-D-galactosamine = N-acetyl-D-galactosaminyl-alpha-(1->3)-N,N'-diacetyl-alpha-D-bacillosaminyl-diphospho-tri-trans,hepta-cis-undecaprenol + UDP + H+.\" [EC:2.4.1.290, GOC:pz]","metadata":null},{"id":"7fd4ef0ffe0943e7896cc76c9173049d","type":"GO_TERM","name":"N,N'-diacetylchitobiose import","canonical_id":"go:GO:1902815","description":"\"The directed movement of N,N'-diacetylchitobiose into a cell or organelle.\" [GO_REF:0000073, GOC:am, GOC:TermGenie, PMID:9405618]","metadata":null},{"id":"273a6f7045cc40f0aa18465e19d7ba17","type":"GO_TERM","name":"N,N-dimethylaniline monooxygenase activity","canonical_id":"go:GO:0004499","description":"\"Catalysis of the reaction: N,N-dimethylaniline + NADPH + H+ + O2 = N,N-dimethylaniline N-oxide + NADP+ + H2O.\" [RHEA:24468]","metadata":null},{"id":"ba5d4bacbde14764a6b9344bcc808c58","type":"GO_TERM","name":"N,N-dimethylformamidase activity","canonical_id":"go:GO:0050116","description":"\"Catalysis of the reaction: N,N-dimethylformamide + H2O = dimethylamine + formate.\" [EC:3.5.1.56, RHEA:19517]","metadata":null},{"id":"2d2a4457e5b2435796badcb63b54b311","type":"GO_TERM","name":"N-(4-aminobenzoyl)-L-glutamate synthetase activity","canonical_id":"go:GO:0052625","description":"\"Catalysis of the reaction: 4-aminobenzoate + L-glutamate + ATP = N-(4-aminobenzoyl)-L-glutamate + AMP + diphosphate + H+.\" [MetaCyc:RXN-10884, PMID:19189963]","metadata":null},{"id":"cfb4d3485f514b31bf26df62d4697374","type":"GO_TERM","name":"N-(4-hydroxybenzoyl)-L-glutamate synthetase activity","canonical_id":"go:GO:0052628","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + L-glutamate + ATP = N-(4-hydroxybenzoyl)-L-glutamate + AMP + diphosphate + H+.\" [MetaCyc:RXN-10887, PMID:19189963]","metadata":null},{"id":"ff24b349944b493bb53e21c21a739149","type":"GO_TERM","name":"N-(5-amino-5-carboxypentanoyl)-L-cysteinyl-D-valine synthase activity","canonical_id":"go:GO:0050564","description":"\"Catalysis of the reaction: L-2-aminoadipate + L-cysteine + L-valine + 3 ATP + H2O = N-[(5S)-5-amino-5-carboxypentanoyl]-L-cysteinyl-D-valine + 3 AMP + 3 diphosphate + 6 H+.\" [EC:6.3.2.26, RHEA:23196]","metadata":null},{"id":"1593c611985d489fa59571c21da57435","type":"GO_TERM","name":"N-(long-chain-acyl)ethanolamine deacylase activity","canonical_id":"go:GO:0047412","description":"\"Catalysis of the reaction: H2O + N-(long-chain-acyl)ethanolamine = ethanolamine + a fatty acid.\" [EC:3.5.1.60, MetaCyc:3.5.1.60-RXN]","metadata":null},{"id":"3b09aa086fa342f2b5696c936d03d718","type":"GO_TERM","name":"N-1-naphthylphthalamic acid binding","canonical_id":"go:GO:0010013","description":"\"Binding to N-1-naphthylphthalamic acid, an auxin transport inhibitor.\" [GOC:sm]","metadata":null},{"id":"8f7954824288432891e8dd687f3c85f7","type":"TRIAL","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","canonical_id":"clinicaltrials.gov:NCT06061809","description":"Glioblastoma","metadata":null},{"id":"f169f0b30b784390a546b3e6458dcfa2","type":"TRIAL","name":"N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT07217496","description":"Metastatic Urothelial Carcinoma; Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Urothelial Cancer; Bladder Cancer","metadata":null},{"id":"089507dc362f4e64bbc700658ea6214f","type":"TRIAL","name":"N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT02200770","description":"Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders","metadata":null},{"id":"08c9db2896a04c7897f98e4d0b7c70bf","type":"GO_TERM","name":"N-acetyl-L-aspartate-L-glutamate ligase activity","canonical_id":"go:GO:0072590","description":"\"Catalysis of the reaction: ATP + N-acetyl-L-aspartate + L-glutamate = ADP + phosphate + N-acetylaspartyl-glutamate.\" [PMID:20643647, PMID:20657015]","metadata":null},{"id":"b3c30e93ea9a4fb292bdd9ef2291d7b4","type":"GO_TERM","name":"N-acetyl-anhydromuramoyl-L-alanine amidase activity","canonical_id":"go:GO:0009392","description":"\"Catalysis of the reaction: GlcNAc-1,6-anhMurNAc-L-Ala-gamma-D-Glu-DAP-D-Ala + H2O glcNAc-1,6-anhMurNAc + L-Ala-gamma-D-Glu-DAP-D-Ala.\" [MetaCyc:RXN0-5225]","metadata":null},{"id":"e9628321ad554f61805f1db24f3c9f7d","type":"GO_TERM","name":"N-acetyl-beta-D-glucosaminide beta-(1,3)-galactosyltransferase activity","canonical_id":"go:GO:0008499","description":"\"Catalysis of the reaction: an N-acetyl-beta-D-glucosaminyl derivative + UDP-alpha-D-galactose = a beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl derivative + H+ + UDP.\" [PMID:10212226, RHEA:53432]","metadata":null},{"id":"016415559e3c49a3a54f9ff259829134","type":"GO_TERM","name":"N-acetyl-beta-alanine deacetylase activity","canonical_id":"go:GO:0050117","description":"\"Catalysis of the reaction: N-acetyl-beta-alanine + H2O = beta-alanine + acetate.\" [EC:3.5.1.21, RHEA:23212]","metadata":null},{"id":"da42165168604de48040b288a67ad8b7","type":"GO_TERM","name":"N-acetyl-beta-glucosaminyl-derivative 4-beta-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0033842","description":"\"Catalysis of the reaction: an N-acetyl-beta-D-glucosaminyl derivative + UDP-N-acetyl-alpha-D-galactosamine = an N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + UDP + H+.\" [RHEA:20493]","metadata":null},{"id":"e226fb750fd24c64be1386ed3e48bf59","type":"GO_TERM","name":"N-acetyl-gamma-aminoadipyl-phosphate reductase (NADP+) activity","canonical_id":"go:GO:0043870","description":"\"Catalysis of the reaction: N(2)-acetyl-L-aminoadipate-semialdehyde + NADP+ + phosphate = N(2)-acetyl-L-gamma-aminoadipyl phosphate + NADPH.\" [RHEA:41948]","metadata":null},{"id":"70bb1ab07fff440ca71d1738517896f0","type":"GO_TERM","name":"N-acetyl-gamma-glutamyl-phosphate reductase (NADP+) activity","canonical_id":"go:GO:0003942","description":"\"Catalysis of the reaction: N-acetyl-L-glutamate 5-semialdehyde + NADP+ + phosphate = N-acetyl-5-glutamyl phosphate + NADPH + H+.\" [RHEA:21588]","metadata":null},{"id":"0a13787fd59944868f50c851aacbedde","type":"GO_TERM","name":"N-acetylcitrulline deacetylase activity","canonical_id":"go:GO:0043909","description":"\"Catalysis of the reaction: N-acetyl-L-citrulline + H2O = citrulline + acetate.\" [GOC:jl, PMID:16750290, RHEA:61092]","metadata":null},{"id":"1d067b73f56c48869b202cd412d4bb59","type":"GO_TERM","name":"N-acetyldiaminopimelate deacetylase activity","canonical_id":"go:GO:0050118","description":"\"Catalysis of the reaction: H2O + N-acetyl-(2S,6S)-2,6-diaminoheptanedioate = (2S,6S)-2,6-diaminoheptanedioate + acetate.\" [RHEA:20405]","metadata":null},{"id":"55ddde4011dd40f3bc06322a41ec56e8","type":"GO_TERM","name":"N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase activity","canonical_id":"go:GO:0050659","description":"\"Catalysis of the reactions: n 3'-phosphoadenylyl sulfate + chondroitin 4'-sulfate = n adenosine 3',5'-bisphosphate + chondroitin 4',6'-bissulfate + n H+, and n 3'-phosphoadenylyl sulfate + dermatan 4'-sulfate = n adenosine 3',5'-bisphosphate + dermatan 4',6'-bissulfate + n H+.\" [EC:2.8.2.33]","metadata":null},{"id":"8f60cd4d131140908809f9f3312d018c","type":"GO_TERM","name":"N-acetylgalactosamine binding","canonical_id":"go:GO:0046871","description":"\"Binding to N-acetylgalactosamine, 2-acetamido-2-deoxygalactopyranose, the n-acetyl derivative of galactosamine.\" [GOC:ai, PMID:18384150]","metadata":null},{"id":"dc0ab189e9f642e78cc7f2d30e88ad82","type":"GO_TERM","name":"N-acetylgalactosamine kinase activity","canonical_id":"go:GO:0033858","description":"\"Catalysis of the reaction: ATP + N-acetyl-D-galactosamine = ADP + N-acetyl-alpha-D-galactosamine 1-phosphate.\" [EC:2.7.1.157]","metadata":null},{"id":"63becb77e8724fcbada7dc556a6ba222","type":"GO_TERM","name":"N-acetylgalactosamine transmembrane transporter activity","canonical_id":"go:GO:0015571","description":"\"Enables the transfer of N-acetylgalactosamine from one side of a membrane to the other. N-acetylgalactosamine, 2-acetamido-2-deoxygalactopyranose, is the n-acetyl derivative of galactosamine.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"62df00a21a1847fd946a1e04bfddc0a2","type":"GO_TERM","name":"N-acetylgalactosamine transport","canonical_id":"go:GO:0015763","description":"\"The directed movement of N-acetylgalactosamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. N-acetylgalactosamine, 2-acetamido-2-deoxygalactopyranose, is the n-acetyl derivative of galactosamine.\" [GOC:ai]","metadata":null},{"id":"1c537a58a1bc4df8aae7d4eea00050a5","type":"GO_TERM","name":"N-acetylgalactosamine-4-sulfatase activity","canonical_id":"go:GO:0003943","description":"\"Catalysis of the hydrolysis of the 4-sulfate groups of the N-acetyl-D-galactosamine 4-sulfate units of chondroitin sulfate and dermatan sulfate.\" [EC:3.1.6.12]","metadata":null},{"id":"fc5ffc8f0f0246b6950c626f0c2d616b","type":"GO_TERM","name":"N-acetylgalactosamine-6-phosphate deacetylase activity","canonical_id":"go:GO:0047419","description":"\"Catalysis of the reaction: H2O + N-acetyl-D-galactosamine 6-phosphate = acetate + D-galactosamine 6-phosphate.\" [RHEA:18149]","metadata":null},{"id":"0e32e2992c8845899c7e719f0afe21a0","type":"GO_TERM","name":"N-acetylgalactosamine-6-sulfatase activity","canonical_id":"go:GO:0043890","description":"\"Catalysis of the hydrolysis of the 6-sulfate groups of the N-acetyl-D-galactosamine 6-sulfate units of chondroitin sulfate and of the D-galactose 6-sulfate units of keratan sulfate.\" [EC:3.1.6.4]","metadata":null},{"id":"3197941285a44774bab2063ca063e5c8","type":"GO_TERM","name":"N-acetylgalactosaminide beta-1,3-galactosyltransferase activity","canonical_id":"go:GO:0016263","description":"\"Catalysis of the reaction: an N-acetyl-alpha-D-galactosaminyl derivative + UDP-alpha-D-galactose = a beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl derivative + UDP + H+.\" [RHEA:15621]","metadata":null},{"id":"38c03fe8c43346688c2da719906fdb52","type":"GO_TERM","name":"N-acetylgalactosaminoglycan deacetylase activity","canonical_id":"go:GO:0047375","description":"\"Catalysis of the reaction: H2O + N-acetyl-D-galactosaminoglycan = acetate + D-galactosaminoglycan.\" [EC:3.1.1.58, MetaCyc:3.1.1.58-RXN]","metadata":null},{"id":"86bccca4925d46a7a7958547a46b2de2","type":"GO_TERM","name":"N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity","canonical_id":"go:GO:0050510","description":"\"Catalysis of the reaction: N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan + UDP-alpha-D-glucuronate = beta-D-glucuronosyl-(1,3)-N-acetyl-beta-D-galactosaminyl-(1,4)-beta-D-glucuronosyl-proteoglycan + UDP.\" [EC:2.4.1.226]","metadata":null},{"id":"9467ea0ffb5d4003a41dd4595224b694","type":"GO_TERM","name":"N-acetylglucosamine 6-O-sulfotransferase activity","canonical_id":"go:GO:0001517","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + N-acetyl-D-glucosamine = adenosine 3',5'-bisphosphate + N-acetyl-D-glucosamine 6-sulfate.\" [GOC:ai, GOC:hjd]","metadata":null},{"id":"44bd96759a5c447689b9bcccc5298bd6","type":"GO_TERM","name":"N-acetylglucosamine biosynthetic process","canonical_id":"go:GO:0006045","description":"\"The chemical reactions and pathways resulting in the formation of N-acetylglucosamine. The D isomer is a common structural unit of glycoproteins in plants, bacteria and animals; it is often the terminal sugar of an oligosaccharide group of a glycoprotein.\" [ISBN:0198506732]","metadata":null},{"id":"f10932564c004a73804d6bd61ecacaf5","type":"GO_TERM","name":"N-acetylglucosamine catabolic process","canonical_id":"go:GO:0006046","description":"\"The chemical reactions and pathways resulting in the breakdown of N-acetylglucosamine. The D isomer is a common structural unit of glycoproteins in plants, bacteria and animals; it is often the terminal sugar of an oligosaccharide group of a glycoprotein.\" [ISBN:0198506732]","metadata":null},{"id":"10862ec7da6b4b0bb3d6bac8ba90e60c","type":"GO_TERM","name":"N-acetylglucosamine deacetylase activity","canonical_id":"go:GO:0050119","description":"\"Catalysis of the reaction: N-acetyl-D-glucosamine + H2O = D-glucosamine + acetate.\" [EC:3.5.1.33, RHEA:20593]","metadata":null},{"id":"d380967cb4a642f7855172ef31b1756e","type":"GO_TERM","name":"N-acetylglucosamine kinase activity","canonical_id":"go:GO:0045127","description":"\"Catalysis of the reaction: N-acetyl-D-glucosamine + ATP = N-acetyl-D-glucosamine 6-phosphate + ADP + H+.\" [RHEA:17417]","metadata":null},{"id":"1a5ad68ac37e48bf8a38f5cfa13ae3fb","type":"GO_TERM","name":"N-acetylglucosamine metabolic process","canonical_id":"go:GO:0006044","description":"\"The chemical reactions and pathways involving N-acetylglucosamine. The D isomer is a common structural unit of glycoproteins in plants, bacteria and animals; it is often the terminal sugar of an oligosaccharide group of a glycoprotein.\" [ISBN:0198506732]","metadata":null},{"id":"158f1d242900479ba92046709212ebbd","type":"GO_TERM","name":"N-acetylglucosamine transmembrane transporter activity","canonical_id":"go:GO:0015572","description":"\"Enables the transfer of N-acetylglucosamine from one side of a membrane to the other. The D isomer of N-acetylglucosamine is a common structural unit of glycoproteins in plants, bacteria and animals; it is often the terminal sugar of an oligosaccharide group of a glycoprotein.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729, PMID:41075780]","metadata":null},{"id":"0290e63e7fc940f09b3a45e40b07f906","type":"GO_TERM","name":"N-acetylglucosamine transport","canonical_id":"go:GO:0015764","description":"\"The directed movement of N-acetylglucosamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"d94d66aab45b4112aaf0b77256019731","type":"GO_TERM","name":"N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity","canonical_id":"go:GO:0003944","description":"\"Catalysis of the reaction: glycoprotein N-acetyl-D-glucosaminyl-phospho-D-mannose + H2O = N-acetyl-D-glucosamine + glycoprotein phospho-D-mannose.\" [EC:3.1.4.45]","metadata":null},{"id":"e15ef96c49e54887bf8e4524e71594c8","type":"GO_TERM","name":"N-acetylglucosamine-6-phosphate deacetylase activity","canonical_id":"go:GO:0008448","description":"\"Catalysis of the reaction: H2O + N-acetyl-D-glucosamine 6-phosphate = acetate + D-glucosamine 6-phosphate.\" [RHEA:22936]","metadata":null},{"id":"e7542651e62d4d0e9f02d4fab2e9e15f","type":"GO_TERM","name":"N-acetylglucosamine-6-sulfatase activity","canonical_id":"go:GO:0008449","description":"\"Catalysis of the hydrolysis of the 6-sulfate group of the N-acetyl-D-glucosamine 6-sulfate units of heparan sulfate and keratan sulfate.\" [EC:3.1.6.14]","metadata":null},{"id":"4bb7fb5c7abb4c5195b45ac77d48d745","type":"GO_TERM","name":"N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity","canonical_id":"go:GO:0050509","description":"\"Catalysis of the reaction: 3-O-{alpha-D-GlcNAc-[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n)-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-seryl-[protein] + UDP-alpha-D-glucuronate = 3-O-{[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n+1)-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-seryl-[protein] + H+ + UDP.\" [EC:2.4.1.225, MetaCyc:2.4.1.225-RXN, RHEA:20908]","metadata":null},{"id":"4e1acdef223a491ab77d957f800b0ffe","type":"GO_TERM","name":"N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0004577","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + N-acetyl-D-glucosaminyl-diphosphodolichol = UDP + N,N''-diacetylchitobiosyldiphosphodolichol.\" [EC:2.4.1.141]","metadata":null},{"id":"58bad91d07b14695a48a91380c61eafb","type":"GO_TERM","name":"N-acetylglucosaminyldiphosphoundecaprenol N-acetyl-beta-D-mannosaminyltransferase activity","canonical_id":"go:GO:0047244","description":"\"Catalysis of the reaction: N-acetyl-D-glucosaminyldiphosphoundecaprenol + UDP-N-acetyl-D-mannosamine = N-acetyl-beta-D-mannosaminyl-1,4-N-acetyl-D-glucosaminyldiphosphoundecaprenol + UDP.\" [EC:2.4.1.187]","metadata":null},{"id":"91331dbcdec4434f8201cbf2e7ab3adb","type":"GO_TERM","name":"N-acetylglucosaminyldiphosphoundecaprenol glucosyltransferase activity","canonical_id":"go:GO:0047245","description":"\"Catalysis of the reaction: N-acetyl-D-glucosaminyldiphosphoundecaprenol + UDP-D-glucose = beta-D-glucosyl-1,4-N-acetyl-D-glucosaminyldiphosphoundecaprenol + UDP.\" [EC:2.4.1.188, MetaCyc:2.4.1.188-RXN]","metadata":null},{"id":"8f01eee00854495d95e5f6485a751520","type":"GO_TERM","name":"N-acetylglucosaminylinositol deacetylase activity","canonical_id":"go:GO:0035595","description":"\"Catalysis of the reaction: 1D-myo-inositol 2-acetamido-2-deoxy-alpha-D-glucopyranoside + H2O = 1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside + acetate. This reaction is the hydrolysis of an acetyl group from N-acetylglucosaminylinositol.\" [RHEA:26180]","metadata":null},{"id":"63886b76fccb4ea0b4f259d81fe457e9","type":"GO_TERM","name":"N-acetylglucosaminylphosphatidylinositol deacetylase activity","canonical_id":"go:GO:0000225","description":"\"Catalysis of the reaction: N-acetyl-D-glucosaminylphosphatidylinositol + H2O = D-glucosaminylphosphatidylinositol + acetate. This reaction is the second step of the biosynthesis of glycosylphosphatidylinositol (GPI), used to anchor various eukaryotic proteins to the cell-surface membrane.\" [EC:3.5.1.89]","metadata":null},{"id":"5db8df65621149ea8fbe01f8dd3b15ea","type":"GO_TERM","name":"N-acetylhexosamine 1-dehydrogenase activity","canonical_id":"go:GO:0050120","description":"\"Catalysis of the reaction: N-acetyl-D-glucosamine + H2O + NAD+ = N-acetyl-D-glucosaminate + 2 H+ + NADH.\" [EC:1.1.1.240, RHEA:23144]","metadata":null},{"id":"d9e3865bcb254f0180bd3c7d791ef16c","type":"GO_TERM","name":"N-acetyllactosamine beta-1,3-glucuronosyltransferase activity","canonical_id":"go:GO:0046987","description":"\"Catalysis of the transfer, in a beta 1,3 linkage, of D-glucuronic acid (GlcUA) from UDP-D-glucuronic acid to N-acetyllactosamine (galactosyl beta-1,4-N-acetylglucosamine).\" [GOC:bf, PMID:12511570]","metadata":null},{"id":"ada1dcecc5794ff2baded2b600d86d90","type":"GO_TERM","name":"N-acetyllactosamine synthase activity","canonical_id":"go:GO:0003945","description":"\"Catalysis of the reaction: UDP-galactose + N-acetyl-D-glucosamine = UDP + N-acetyllactosamine.\" [EC:2.4.1.90]","metadata":null},{"id":"cd059dfd97fd472fb36f9baf5849d159","type":"GO_TERM","name":"N-acetyllactosaminide 3-alpha-galactosyltransferase activity","canonical_id":"go:GO:0047276","description":"\"Catalysis of the reaction: beta-D-galactosyl-(1,4)-beta-N-acetyl-D-glucosaminyl-R + UDP-galactose = alpha-D-galactosyl-(1,3)-beta-D-galactosyl-(1,4)-beta-N-acetyl-D-glucosaminyl-R + UDP.\" [EC:2.4.1.87, RHEA:13013]","metadata":null},{"id":"e5f575b45398483c9c5edb836e04255e","type":"GO_TERM","name":"N-acetyllactosaminide alpha-2,3-sialyltransferase activity","canonical_id":"go:GO:0008118","description":"\"Catalysis of the reaction: a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + CMP-N-acetyl-beta-neuraminate = an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + CMP + H+.\" [PMID:10206952, RHEA:52316]","metadata":null},{"id":"3dcb5e8dba1b4301a082e0e9c4460a3a","type":"GO_TERM","name":"N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0008532","description":"\"Catalysis of the reaction: a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + UDP-N-acetyl-alpha-D-glucosamine = an N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + H+ + UDP.\" [RHEA:14389]","metadata":null},{"id":"357f4981eccc404c8bddf81ab3fcb3a1","type":"GO_TERM","name":"N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0008109","description":"\"Catalysis of the reaction: a beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative + UDP-N-acetyl-alpha-D-glucosamine = an N-acetyl-beta-D-glucosaminyl-1,6-beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative + UDP + H+.\" [RHEA:17413]","metadata":null},{"id":"560872f6677f4561924d4c0d72444719","type":"GO_TERM","name":"N-acetylmannosamine biosynthetic process","canonical_id":"go:GO:0006052","description":"\"The chemical reactions and pathways resulting in the formation of N-acetylmannosamine, the acetylated derivative of mannosamine, 2-amino-2-deoxymannose.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"d4ed581cedd54cd985875e72b2fa106a","type":"GO_TERM","name":"N-acetylmannosamine catabolic process","canonical_id":"go:GO:0006053","description":"\"The chemical reactions and pathways resulting in the breakdown of N-acetylmannosamine, the acetylated derivative of mannosamine, 2-amino-2-deoxymannose.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"8081e3857b4f478687a8fb3843324294","type":"GO_TERM","name":"N-acetylmannosamine metabolic process","canonical_id":"go:GO:0006051","description":"\"The chemical reactions and pathways involving N-acetylmannosamine, the acetylated derivative of mannosamine, 2-amino-2-deoxymannose.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"282cf5b323714a23a2065920b492a5ac","type":"GO_TERM","name":"N-acetylmuramic acid catabolic process","canonical_id":"go:GO:0097173","description":"\"The chemical reactions and pathways resulting in the breakdown of N-acetylmuramic acid (MurNAc), a monosaccharide derivative of N-acetylglucosamine.\" [GOC:yaf]","metadata":null},{"id":"9654e8600e4d43a886ad21dfe51c0608","type":"GO_TERM","name":"N-acetylmuramic acid metabolic process","canonical_id":"go:GO:0097172","description":"\"The chemical reactions and pathways involving N-acetylmuramic acid (MurNAc), a monosaccharide derivative of N-acetylglucosamine.\" [GOC:yaf]","metadata":null},{"id":"39e5f2bfcd1f416184539de4d9c8bbe1","type":"GO_TERM","name":"N-acetylmuramoyl-L-alanine amidase activity","canonical_id":"go:GO:0008745","description":"\"Catalysis of the hydrolysis of the link between N-acetylmuramoyl residues and L-amino acid residues in certain bacterial cell-wall glycopeptides.\" [EC:3.5.1.28, PMID:22748813]","metadata":null},{"id":"4f304b79974c486aa478781533af65c7","type":"GO_TERM","name":"N-acetylneuraminate 4-O-acetyltransferase activity","canonical_id":"go:GO:0047185","description":"\"Catalysis of the reaction: N-acetylneuraminate + acetyl-CoA = N-acetyl-4-O-acetylneuraminate + CoA.\" [EC:2.3.1.44, RHEA:18305]","metadata":null},{"id":"f759bc8aa0b740b5a26ff0c7b8afae0b","type":"GO_TERM","name":"N-acetylneuraminate 9-O-acetyltransferase activity","canonical_id":"go:GO:0047186","description":"\"Catalysis of the reaction: CMP-N-acetyl-beta-neuraminate + acetyl-CoA = CMP-N-acetyl-9-O-acetyl-beta-neuraminate + CoA.\" [EC:2.3.1.45, RHEA:81827]","metadata":null},{"id":"37a3f2d5971543e68598b61e9b714dbd","type":"GO_TERM","name":"N-acetylneuraminate biosynthetic process","canonical_id":"go:GO:0046380","description":"\"The chemical reactions and pathways resulting in the formation of N-acetylneuraminate, the anion of 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-non-3-ulosonic acid.\" [ISBN:0198506732]","metadata":null},{"id":"6ec1ee73d6ce42ba996201aaeee59c26","type":"GO_TERM","name":"N-acetylneuraminate catabolic process","canonical_id":"go:GO:0019262","description":"\"The chemical reactions and pathways resulting in the breakdown of N-acetylneuraminate, the anion of 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-non-3-ulosonic acid.\" [ISBN:0198506732]","metadata":null},{"id":"8433e523a5544092a32db2968f89b6e0","type":"GO_TERM","name":"N-acetylneuraminate lyase activity","canonical_id":"go:GO:0008747","description":"\"Catalysis of the reaction: N-acetylneuraminate = N-acetyl-D-mannosamine + pyruvate.\" [EC:4.1.3.3, RHEA:23296]","metadata":null},{"id":"8227fef511e64c409d11bdcf2a512ea3","type":"GO_TERM","name":"N-acetylneuraminate metabolic process","canonical_id":"go:GO:0006054","description":"\"The chemical reactions and pathways involving N-acetylneuraminate, the anion of 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-non-3-ulosonic acid.\" [ISBN:0198506732]","metadata":null},{"id":"b8ed4f8a3fe541009d73519629181f55","type":"GO_TERM","name":"N-acetylneuraminate synthase activity","canonical_id":"go:GO:0050462","description":"\"Catalysis of the reaction: phosphoenolpyruvate + N-acetyl-D-mannosamine + H2O = phosphate + N-acetylneuraminate.\" [EC:2.5.1.56]","metadata":null},{"id":"354e047001434f85829d768155eb474a","type":"GO_TERM","name":"N-acetylneuraminylgalactosylglucosylceramide beta-1,4-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0047233","description":"\"Catalysis of the reaction: an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl derivative + UDP-N-acetyl-alpha-D-galactosamine = an N-acetyl-beta-D-galactosaminyl-(1->4)-[N-acetyl-alpha-neuraminyl-(2->3)]-beta-D-galactosyl derivative + UDP + H+.\" [RHEA:81947]","metadata":null},{"id":"779cfc68f5444250be06152aa6c13987","type":"GO_TERM","name":"N-acetylornithine carbamoyltransferase activity","canonical_id":"go:GO:0043857","description":"\"Catalysis of the reaction: N(2)-acetyl-L-ornithine + carbamoyl phosphate = N(2)-acetyl-L-citrulline + H+ + phosphate.\" [EC:2.1.3.9, RHEA:18609]","metadata":null},{"id":"96caaa496dd7461fb151fa68a8a765a4","type":"GO_TERM","name":"N-acetyltaurine hydrolase activity","canonical_id":"go:GO:0141215","description":"\"Catalysis of the reaction: N-acetyltaurine + H2O = acetate + taurine.\" [PMID:39112712, RHEA:81107]","metadata":null},{"id":"e97a0680bf484b7e91c1c1467a8723fb","type":"GO_TERM","name":"N-acetyltransferase activity","canonical_id":"go:GO:0008080","description":"\"Catalysis of the transfer of an acetyl group to a nitrogen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"f8cbe1b7f2c642b3af648b438f67f7d1","type":"GO_TERM","name":"N-acyl homoserine lactone synthase activity","canonical_id":"go:GO:0061579","description":"\"Catalysis of the reaction: a fatty acyl-[ACP] + S-adenosyl-L-methionine = an N-acyl-L-homoserine lactone + S-methyl-5'-thioadenosine + holo-[ACP] + H+.\" [RHEA:10096]","metadata":null},{"id":"6a329b841d514d6fb7bde0d00a2e12ce","type":"GO_TERM","name":"N-acyl-D-amino-acid deacylase activity","canonical_id":"go:GO:0047420","description":"\"Catalysis of the reaction: H2O + N-acyl-D-amino acid = D-amino acid + an acid.\" [EC:3.5.1.81, MetaCyc:3.5.1.81-RXN]","metadata":null},{"id":"0fba11cd8aa44aabbb1702715bca81d4","type":"GO_TERM","name":"N-acyl-D-aspartate deacylase activity","canonical_id":"go:GO:0047422","description":"\"Catalysis of the reaction: N-acyl-D-aspartate + H2O = D-aspartate + a carboxylate.\" [EC:3.5.1.83, RHEA:18285]","metadata":null},{"id":"7decbfceacd14efcbb8a1e7af4abef99","type":"GO_TERM","name":"N-acyl-D-glutamate deacylase activity","canonical_id":"go:GO:0047421","description":"\"Catalysis of the reaction: N-acyl-D-glutamate + H2O = D-glutamate + a carboxylate.\" [EC:3.5.1.82, RHEA:12833]","metadata":null},{"id":"4712f030b39b4a8b8782a4b73145d902","type":"GO_TERM","name":"N-acylethanolamine metabolic process","canonical_id":"go:GO:0070291","description":"\"The chemical reactions and pathways involving N-acylethanolamines. An N-acylethanolamine is an ethanolamine substituted at nitrogen by an acyl group.\" [CHEBI:52640, GOC:elh, PMID:14634025, PMID:15878693]","metadata":null},{"id":"8e08092058fa4038a5ab2f91ea372fbc","type":"GO_TERM","name":"N-acylglucosamine 2-epimerase activity","canonical_id":"go:GO:0050121","description":"\"Catalysis of the reaction: N-acyl-D-glucosamine = N-acyl-D-mannosamine.\" [EC:5.1.3.8, MetaCyc:N-ACYLGLUCOSAMINE-2-EPIMERASE-RXN]","metadata":null},{"id":"347b1b96387241f58485e810b5cda955","type":"GO_TERM","name":"N-acylglucosamine-6-phosphate 2-epimerase activity","canonical_id":"go:GO:0047465","description":"\"Catalysis of the reaction: an N-acyl-D-glucosamine 6-phosphate = an N-acyl-D-mannosamine 6-phosphate.\" [RHEA:23932]","metadata":null},{"id":"66467a9b5dc94a10b7c4451d04880a19","type":"GO_TERM","name":"N-acylhexosamine oxidase activity","canonical_id":"go:GO:0050122","description":"\"Catalysis of the reaction: N-acetyl-D-glucosamine + H2O + O2 = N-acetyl-D-glucosaminate + H2O2 + H+.\" [EC:1.1.3.29, RHEA:13029]","metadata":null},{"id":"8a7d151011b6458a9db07a66bb900bd5","type":"GO_TERM","name":"N-acylmannosamine 1-dehydrogenase activity","canonical_id":"go:GO:0050123","description":"\"Catalysis of the reaction: N-acyl-D-mannosamine + NAD+ = N-acyl-D-mannosaminolactone + H+ + NADH.\" [EC:1.1.1.233, RHEA:11540]","metadata":null},{"id":"a2cf4c654013434bb22caa63134ebc95","type":"GO_TERM","name":"N-acylmannosamine kinase activity","canonical_id":"go:GO:0009384","description":"\"Catalysis of the reaction: ATP + N-acyl-D-mannosamine = ADP + N-acyl-D-mannosamine 6-phosphate.\" [EC:2.7.1.60]","metadata":null},{"id":"649a92f99c384b4d9d33e88761a35177","type":"GO_TERM","name":"N-acylneuraminate cytidylyltransferase activity","canonical_id":"go:GO:0008781","description":"\"Catalysis of the reaction: CTP + N-acylneuraminate = diphosphate + CMP-N-acylneuraminate.\" [EC:2.7.7.43]","metadata":null},{"id":"a52fe5cf0ea3472d851cadeb7f215ed7","type":"GO_TERM","name":"N-acylneuraminate-9-phosphatase activity","canonical_id":"go:GO:0050124","description":"\"Catalysis of the reaction: N-acylneuraminate 9-phosphate + H2O = N-acylneuraminate + phosphate.\" [EC:3.1.3.29, MetaCyc:N-ACYLNEURAMINATE-9-PHOSPHATASE-RXN]","metadata":null},{"id":"78a5f6ffbdb048e0839740d9dd0e3bf8","type":"GO_TERM","name":"N-acylneuraminate-9-phosphate synthase activity","canonical_id":"go:GO:0047444","description":"\"Catalysis of the reaction: H2O + phosphoenolpyruvate + N-acyl-D-mannosamine 6-phosphate = phosphate + N-acylneuraminate 9-phosphate.\" [EC:2.5.1.57]","metadata":null},{"id":"d752781cee2d4c439dcde195183a2013","type":"GO_TERM","name":"N-acylphosphatidylethanolamine metabolic process","canonical_id":"go:GO:0070292","description":"\"The chemical reactions and pathways involving N-acylphosphatidylethanolamines. An N-acylphosphatidylethanolamine is a phosphatidylethanolamine substituted at nitrogen by an acyl group.\" [GOC:elh, GOC:mah, PMID:14634025, PMID:15878693]","metadata":null},{"id":"27742c38c28e4dc9bed97c4c4255b4e2","type":"GO_TERM","name":"N-acylphosphatidylethanolamine-specific phospholipase D activity","canonical_id":"go:GO:0070290","description":"\"Catalysis of the reaction: an N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine (NAPE) + H2O = an N-acylethanolamine (NAE) + a 1,2-diacyl-sn-glycero-3-phosphate + H+.\" [PMID:14634025, PMID:15878693, RHEA:33159]","metadata":null},{"id":"cc8f133239a64e998f570de0ef838ca5","type":"GO_TERM","name":"N-acylsphingosine amidohydrolase activity","canonical_id":"go:GO:0017040","description":"\"Catalysis of the reaction: an N-acylsphing-4-enine + H2O = a fatty acid + sphing-4-enine.\" [RHEA:20856]","metadata":null},{"id":"3bb45ebebb4d498284068bb53f1fb4bf","type":"GO_TERM","name":"N-acylsphingosine galactosyltransferase activity","canonical_id":"go:GO:0003851","description":"\"Catalysis of the reaction: N-acylsphing-4-enine + UDP-alpha-D-galactose = a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine + H+ + UDP.\" [EC:2.4.1.47]","metadata":null},{"id":"b53f10ce49d64c74b590f658ff5fc8fb","type":"GO_TERM","name":"N-benzoyl-4-hydroxyanthranilate 4-O-methyltransferase activity","canonical_id":"go:GO:0030771","description":"\"Catalysis of the reaction: N-benzoyl-4-hydroxyanthranilate + S-adenosyl-L-methionine(1+) = N-benzoyl-4-methoxyanthranilate + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.105, RHEA:17405]","metadata":null},{"id":"a800c6edc3d1478c9aefef5074856500","type":"GO_TERM","name":"N-benzoyl-L-glutamate synthetase activity","canonical_id":"go:GO:0052626","description":"\"Catalysis of the reaction: benzoate + L-glutamate + ATP = N-benzoyl-L-glutamate + AMP + diphosphate + H+.\" [MetaCyc:RXN-10886, PMID:19189963]","metadata":null},{"id":"2a704e3389384a059e16e8693f1cfc57","type":"GO_TERM","name":"N-benzyloxycarbonylglycine hydrolase activity","canonical_id":"go:GO:0050125","description":"\"Catalysis of the reaction: N-benzyloxycarbonylglycine + H2O + H+ = benzyl alcohol + CO2 + glycine.\" [EC:3.5.1.58, RHEA:20900]","metadata":null},{"id":"1073c89646854440b0ec323ef3a266b7","type":"GO_TERM","name":"N-box binding","canonical_id":"go:GO:0071820","description":"\"Binding to an N-box, a DNA motif with the consensus sequence CACNAG that is found in the promoters of genes expressed preferentially at synapses.\" [GOC:yaf, PMID:11498047]","metadata":null},{"id":"ce683831e2f04d9b96364935a12714b5","type":"GO_TERM","name":"N-carbamoyl-D-amino acid hydrolase activity","canonical_id":"go:GO:0047417","description":"\"Catalysis of the reaction: an N-carbamoyl-D-amino acid + H2O + 2 H+ = a D-alpha-amino acid + NH4+ + CO2.\" [RHEA:11000]","metadata":null},{"id":"de4e457d5fe747fea4f3cfafce103b43","type":"GO_TERM","name":"N-carbamoyl-L-amino-acid hydrolase activity","canonical_id":"go:GO:0050538","description":"\"Catalysis of the reaction: N-carbamoyl-L-2-amino acid + H2O = L-2-amino acid + NH3 + CO2. The N-carbamoyl-L-2-amino acid is a 2-ureido carboxylate.\" [EC:3.5.1.87, MetaCyc:3.5.1.87-RXN]","metadata":null},{"id":"eef2ae09390c41a687b83e2ff13ee58e","type":"GO_TERM","name":"N-carbamoylputrescine amidase activity","canonical_id":"go:GO:0050126","description":"\"Catalysis of the reaction: N-carbamoylputrescine + H2O + 2 H+ = CO2 + NH4 + putrescine.\" [EC:3.5.1.53, RHEA:22284]","metadata":null},{"id":"e6b81682b8054b9c98d653c914961040","type":"GO_TERM","name":"N-carbamoylsarcosine amidase activity","canonical_id":"go:GO:0050127","description":"\"Catalysis of the reaction: N-carbamoylsarcosine + H2O + 2 H+ = CO2 + NH4 + sarcosine.\" [EC:3.5.1.59, RHEA:20057]","metadata":null},{"id":"7f11ed77c9164b79a4618a3ba16a98f7","type":"GO_TERM","name":"N-cyclopropylmelamine catabolic process","canonical_id":"go:GO:0042202","description":"\"The chemical reactions and pathways resulting in the breakdown of N-cyclopropylmelamine, a triazine compound commonly used as an insecticide.\" [UM-BBD_pathwayID:cpm]","metadata":null},{"id":"4589821e56ad462eae2d9f4e8b08fee7","type":"GO_TERM","name":"N-ethylmaleimide reductase activity","canonical_id":"go:GO:0008748","description":"\"Catalysis of the reaction: N-ethylmaleimide + NADPH + 2 H+ = N-ethylsuccinimide + NADP+.\" [MetaCyc:RXN0-5101]","metadata":null},{"id":"12eab8d922704d1794ffb37eacd31080","type":"GO_TERM","name":"N-feruloylglycine deacylase activity","canonical_id":"go:GO:0050128","description":"\"Catalysis of the reaction: N-feruloylglycine + H2O = ferulate + glycine.\" [EC:3.5.1.71, RHEA:10484]","metadata":null},{"id":"6397aec85d814a5e970dba181b5eeff1","type":"GO_TERM","name":"N-formyl peptide receptor activity","canonical_id":"go:GO:0004982","description":"\"Combining with an N-formyl peptide to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"99c0f1d29c09413a905faf240eb53e31","type":"GO_TERM","name":"N-formylglutamate deformylase activity","canonical_id":"go:GO:0050129","description":"\"Catalysis of the reaction: N-formyl-L-glutamate + H2O = L-glutamate + formate.\" [EC:3.5.1.68, RHEA:12476]","metadata":null},{"id":"23f9f3705c8b4e5da0adb5d8079b470c","type":"GO_TERM","name":"N-glutamylanilide hydrolase activity","canonical_id":"go:GO:0102572","description":"\"Catalysis of the reaction: N5-phenyl-L-glutamine + H2O = L-glutamate + aniline + H+.\" [GOC:pz]","metadata":null},{"id":"7fffe579fc3a4d3dac5fbd6bc52439ac","type":"GO_TERM","name":"N-glycan processing","canonical_id":"go:GO:0006491","description":"\"The conversion of N-linked glycan (N = nitrogen) structures from the initially transferred oligosaccharide to a mature form, by the actions of glycosidases and glycosyltransferases. The early processing steps are conserved and play roles in glycoprotein folding and trafficking.\" [PMID:12736198, PMID:35536965]","metadata":null},{"id":"ad88641465b84457b5c48d584438940d","type":"GO_TERM","name":"N-glycan processing to lysosome","canonical_id":"go:GO:0016256","description":"\"The modification of high-mannose N-glycans by UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase and the subsequent removal of the N-acetylglucosamine residues yielding mannose-6-P that occurs in the ER-Golgi apparatus to N-glycans destined for the lysosome.\" [PMID:35536965]","metadata":null},{"id":"8596d68a474241c7b75573db5e3b46b4","type":"GO_TERM","name":"N-glycolylneuraminic acid (Neu5Gc) cytidylyltransferase activity","canonical_id":"go:GO:0090632","description":"\"Catalysis of the reaction: CTP + Neu5Gc = diphosphate + CMP-Neu5Gc.\" [ISBN:978-1-60805-067-3, PMID:11479279, PMID:8381411]","metadata":null},{"id":"b24485be22b44c5fba2760743297df82","type":"GO_TERM","name":"N-hydroxy-2-acetamidofluorene reductase [NAD(P)H] activity","canonical_id":"go:GO:0047137","description":"\"Catalysis of the reaction: 2-acetamidofluorene + NAD(P)+ + H2O = N-hydroxy-2-acetamidofluorene + NAD(P)H + H+.\" [EC:1.7.1.12]","metadata":null},{"id":"6af4c8c0a5014fa285156ac224b0d43b","type":"GO_TERM","name":"N-hydroxyarylamine O-acetyltransferase activity","canonical_id":"go:GO:0046990","description":"\"Catalysis of the reaction: acetyl-CoA + an N-hydroxyarylamine = CoA + an N-acetoxyarylamine.\" [EC:2.3.1.118, MetaCyc:2.3.1.118-RXN]","metadata":null},{"id":"263d27ded56e44d898a449031fc1c05b","type":"GO_TERM","name":"N-isopropylammelide isopropylaminohydrolase activity","canonical_id":"go:GO:0018764","description":"\"Catalysis of the reaction: N-isopropylammelide + H2O = cyanuric acid + isopropylamine.\" [EC:3.5.4.42]","metadata":null},{"id":"0fed4f171ba84c5ca065584fb7a5e0fe","type":"GO_TERM","name":"N-malonyltransferase activity","canonical_id":"go:GO:0050735","description":"\"Catalysis of the transfer of a malonyl group to a nitrogen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"4e84a56854c14ad98d469cb933106897","type":"GO_TERM","name":"N-malonylurea hydrolase activity","canonical_id":"go:GO:0033970","description":"\"Catalysis of the reaction: 3-oxo-3-ureidopropanoate + H2O = H+ + malonate + urea.\" [EC:3.5.1.95, RHEA:17361]","metadata":null},{"id":"277e4def326c40029f98b033129188b5","type":"GO_TERM","name":"N-methyl nucleosidase activity","canonical_id":"go:GO:0033960","description":"\"Catalysis of the reaction: 7-methylxanthosine + H2O = 7-methylxanthine + H+ + ribofuranose.\" [EC:3.2.2.25, RHEA:10880]","metadata":null},{"id":"e82adf8cd67945b89a8bf2ba33166ffb","type":"DRUG","name":"N-methyl scopolamine","canonical_id":"gtopdb:316","description":null,"metadata":null},{"id":"24d8d06b6d714a308288594e6c98819a","type":"GO_TERM","name":"N-methyl-2-oxoglutaramate hydrolase activity","canonical_id":"go:GO:0050130","description":"\"Catalysis of the reaction: N-methyl-2-oxoglutaramate + H2O = 2-oxoglutarate + methylammonium.\" [EC:3.5.1.36, RHEA:24108]","metadata":null},{"id":"5b1ea689cef74b5582e8b79a7ab18378","type":"GO_TERM","name":"N-methyl-L-alanine dehydrogenase activity","canonical_id":"go:GO:0050132","description":"\"Catalysis of the reaction: N-methyl-L-alanine + NADP+ + H2O = methylamine + pyruvate + NADPH + H+.\" [RHEA:21768]","metadata":null},{"id":"f101cd6b607849f4a601a74e75d162e8","type":"GO_TERM","name":"N-methyl-L-amino-acid oxidase activity","canonical_id":"go:GO:0050131","description":"\"Catalysis of the reaction: an N-methyl-L-amino acid + H2O + O2 = an L-amino acid + formaldehyde + H2O2.\" [EC:1.5.3.2]","metadata":null},{"id":"5253c859e1d544a996c92a9e1f38071e","type":"GO_TERM","name":"N-methylcoclaurine 3'-monooxygenase activity","canonical_id":"go:GO:0050593","description":"\"Catalysis of the reaction: (S)-N-methylcoclaurine + H+ + NADPH + O2 = (S)-3'-hydroxy-N-methylcoclaurine + H2O + NADP+.\" [EC:1.14.14.102, RHEA:16649]","metadata":null},{"id":"f778277b1b09453197e071cf7ee19e84","type":"GO_TERM","name":"N-methylhydantoinase (ATP-hydrolyzing) activity","canonical_id":"go:GO:0047423","description":"\"Catalysis of the reaction: N-methylhydantoin + ATP + 2 H2O = N-carbamoylsarcosine + ADP + 3 H+ + phosphate.\" [EC:3.5.2.14, RHEA:11720]","metadata":null},{"id":"f11500895ddf4a9b9581be3c9ae58be7","type":"GO_TERM","name":"N-methylnicotinate transmembrane transporter activity","canonical_id":"go:GO:0090417","description":"\"Enables the transfer of N-methylnicotinate from one side of a membrane to the other.\" [GOC:tb]","metadata":null},{"id":"cc70467cff0f430498f6a98fecfb6192","type":"GO_TERM","name":"N-methylnicotinate transport","canonical_id":"go:GO:2001143","description":"\"The directed movement of a N-methylnicotinateacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:obol]","metadata":null},{"id":"f1ece5829ec24658bd2ddc49cc999138","type":"GO_TERM","name":"N-methylphosphoethanolamine cytidylyltransferase activity","canonical_id":"go:GO:0047353","description":"\"Catalysis of the reaction: N-methylethanolamine phosphate + CTP = CDP-N-methylethanolamine + diphosphate.\" [EC:2.7.7.57, RHEA:10576]","metadata":null},{"id":"efc7e162c1ce456f9ae14ca8ad356d6d","type":"GO_TERM","name":"N-methyltransferase activity","canonical_id":"go:GO:0008170","description":"\"Catalysis of the transfer of a methyl group to the nitrogen atom of an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"60d269055c634897a1932a3e1558c3c2","type":"GO_TERM","name":"N-retinylidene-phosphatidylethanolamine flippase activity","canonical_id":"go:GO:0140347","description":"\"Catalysis of the movement of N-retinylidene-N-retinylphosphatidylethanolamine from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:10412977]","metadata":null},{"id":"634af75c117147beb866d79861ec5474","type":"GO_TERM","name":"N-substituted formamide deformylase activity","canonical_id":"go:GO:0033966","description":"\"Catalysis of the reaction: N-benzylformamide + H2O = formate + benzylamine.\" [RHEA:12096]","metadata":null},{"id":"66770e1225c946d88bb340581c879fb7","type":"GO_TERM","name":"N-succinylarginine dihydrolase activity","canonical_id":"go:GO:0009015","description":"\"Catalysis of the reaction: N(2)-succinyl-L-arginine + 2 H2O + 2 H+ = N(2)-succinyl-L-ornithine + CO2 + 2 NH4.\" [EC:3.5.3.23, RHEA:19533]","metadata":null},{"id":"d7da3629634545279cfd24f8d053f760","type":"GO_TERM","name":"N-succinyltransferase activity","canonical_id":"go:GO:0016749","description":"\"Catalysis of the transfer of a succinyl group to a nitrogen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"d8d78074840646459341aca3f4f38dae","type":"GO_TERM","name":"N-sulfoglucosamine sulfohydrolase activity","canonical_id":"go:GO:0016250","description":"\"Catalysis of the reaction: N-sulfo-D-glucosamine + H2O = D-glucosamine + sulfate.\" [EC:3.10.1.1]","metadata":null},{"id":"89568ff0969046c995fd6df2f02b9acf","type":"GO_TERM","name":"N-sulfoglucosamine-3-sulfatase activity","canonical_id":"go:GO:0033889","description":"\"Catalysis of the hydrolysis of the 3-sulfate groups of the N-sulfo-D-glucosamine 3-O-sulfate units of heparin.\" [EC:3.1.6.15]","metadata":null},{"id":"27cab9326453416ba601113a85ff1c5f","type":"GO_TERM","name":"N-terminal peptidyl-L-cysteine N-palmitoylation","canonical_id":"go:GO:0018009","description":"\"The covalent attachment of a palmitoyl group to a nitrogen (N) atom in an N-terminal cysteine residue to form N-palmitoyl-L-cysteine.\" [RESID:AA0060]","metadata":null},{"id":"a369cca49628434b8c2869ae29903e82","type":"GO_TERM","name":"N-terminal peptidyl-alanine trimethylation","canonical_id":"go:GO:0018012","description":"\"The trimethylation of the N-terminal alanine of proteins to form the derivative peptidyl-N,N,N-trimethyl-L-alanine.\" [RESID:AA0062]","metadata":null},{"id":"3e7b5e06abad466e89458cda65f9fe01","type":"GO_TERM","name":"N-terminal peptidyl-aspartic acid acetylation","canonical_id":"go:GO:0017190","description":"\"The acetylation of the N-terminal aspartic acid of proteins; catalyzed by aspartate N-acetyltransferase.\" [RESID:AA0042]","metadata":null},{"id":"d8721f81afad4dad85a16b66b1ab1fb5","type":"GO_TERM","name":"N-terminal peptidyl-glutamic acid acetylation","canonical_id":"go:GO:0018002","description":"\"The acetylation of the N-terminal glutamic acid of proteins to form the derivate acetyl-glutamic acid.\" [RESID:AA0044]","metadata":null},{"id":"2ff266a308864734a07347998e2da12f","type":"GO_TERM","name":"N-terminal peptidyl-glutamine acetylation","canonical_id":"go:GO:0017192","description":"\"The acetylation of a glutamine residue in protein to form the N5-methyl-L-glutamine derivative. The occurrence of this modification has not been confirmed. Its annotation in sequence databases is either due to the misidentification of 2-pyrrolidone-5-carboxylic acid, or to inappropriate homolog comparisons when proteolytic modification is more probable.\" [RESID:AA0045]","metadata":null},{"id":"1310692805264844a960ee02ecbf1156","type":"GO_TERM","name":"N-terminal peptidyl-glycine N-myristoylation","canonical_id":"go:GO:0018008","description":"\"The myristoylation of the N-terminal glycine of proteins to form the derivative N-myristoyl-glycine.\" [RESID:AA0059]","metadata":null},{"id":"ab7c81699d724a2fa2af0eaa835acfbd","type":"GO_TERM","name":"N-terminal peptidyl-glycine methylation","canonical_id":"go:GO:0018013","description":"\"The methylation of the N-terminal glycine of proteins to form the derivative N-methylglycine.\" [RESID:AA0063]","metadata":null},{"id":"cb3a196c1ebe4b00a9f46cde3881eab0","type":"GO_TERM","name":"N-terminal peptidyl-lysine acetylation","canonical_id":"go:GO:0018076","description":"\"The acetylation of the N-terminal lysine of proteins.\" [GOC:ai]","metadata":null},{"id":"5af6ed3afa1248af80aea71b28634bf7","type":"GO_TERM","name":"N-terminal peptidyl-methionine acetylation","canonical_id":"go:GO:0017196","description":"\"The acetylation of the N-terminal methionine of proteins to form the derivative N-acetyl-L-methionine.\" [RESID:AA0049]","metadata":null},{"id":"166bdae26863499cb106b61d3a5a6925","type":"GO_TERM","name":"N-terminal peptidyl-proline dimethylation","canonical_id":"go:GO:0018016","description":"\"The methylation of the N-terminal proline of proteins to form the derivative N,N-dimethyl-L-proline.\" [RESID:AA0066]","metadata":null},{"id":"5b8f3f188d50488b8390dae023f7169f","type":"GO_TERM","name":"N-terminal peptidyl-serine dimethylation","canonical_id":"go:GO:0035572","description":"\"The dimethylation of the N-terminal serine of proteins to form the derivative N,N-dimethylserine.\" [PMID:20668449]","metadata":null},{"id":"5c565979fccb4df69a6dc520cd706617","type":"GO_TERM","name":"N-terminal peptidyl-serine trimethylation","canonical_id":"go:GO:0035573","description":"\"The trimethylation of the N-terminal serine of proteins to form the derivative N,N,N-trimethylserine.\" [PMID:20668449]","metadata":null},{"id":"d7235f69730f4af49e9f65bbd60a34c7","type":"GO_TERM","name":"N-terminal protein N-methyltransferase activity","canonical_id":"go:GO:0071885","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine (AdoMet) to the alpha-amino group of the N-terminal amino or imino acid residue of a protein substrate. For example, yeast Tae1p and mammalian family member METTL11A preferentially modify the N-terminal residue of substrates with the N-terminal sequence X-Pro-Lys, where X can be Pro, Ala, or Ser.\" [PMID:20481588]","metadata":null},{"id":"481d675ef1504a428b0273b8a48ca647","type":"GO_TERM","name":"N-terminal protein acetyltransferase complex","canonical_id":"go:GO:0031414","description":"\"A complex that catalyzes the transfer of an acetyl group to the N-terminal residue of a protein acceptor molecule.\" [GOC:mah]","metadata":null},{"id":"aa42e8822e2e46ab8181782ce2bb91d3","type":"GO_TERM","name":"N-terminal protein amino acid acetylation","canonical_id":"go:GO:0006474","description":"\"The acetylation of the N-terminal amino acid of proteins.\" [GOC:ai]","metadata":null},{"id":"f952a00f01e6404b885c594b02c27305","type":"GO_TERM","name":"N-terminal protein amino acid carbamoylation","canonical_id":"go:GO:0050990","description":"\"The carbamoylation of the N-terminal amino acid of proteins.\" [GOC:ai]","metadata":null},{"id":"18258963ef2d42f8bc673cb5f5dcbe0a","type":"GO_TERM","name":"N-terminal protein amino acid carboxylation","canonical_id":"go:GO:0050989","description":"\"The carboxylation of the N-terminal amino acid of proteins.\" [GOC:ai]","metadata":null},{"id":"4276efc676f64f07b8a700f2c588677d","type":"GO_TERM","name":"N-terminal protein amino acid deamination","canonical_id":"go:GO:0031363","description":"\"The removal of an amino group from the N-terminal amino acid residue of a protein.\" [GOC:mah]","metadata":null},{"id":"5e7212066fdd4c7e980ef484a1b2326b","type":"GO_TERM","name":"N-terminal protein amino acid deamination, from side chain","canonical_id":"go:GO:0031364","description":"\"The removal of an amino group from the side chain of an N-terminal asparagine or glutamine residue of a protein.\" [GOC:mah]","metadata":null},{"id":"1323c86b44f740bbb7dc8e6c597b2afd","type":"GO_TERM","name":"N-terminal protein amino acid methylation","canonical_id":"go:GO:0006480","description":"\"The methylation of the N-terminal amino acid of a protein.\" [GOC:ai]","metadata":null},{"id":"3f688be47cb9453cb56f8e837e4d55aa","type":"GO_TERM","name":"N-terminal protein amino acid modification","canonical_id":"go:GO:0031365","description":"\"The alteration of the N-terminal amino acid residue in a protein.\" [GOC:mah]","metadata":null},{"id":"158712927a944c188d72db8c96f41862","type":"GO_TERM","name":"N-terminal protein amino acid propionylation","canonical_id":"go:GO:0061606","description":"\"The propionylation of the N-terminal amino acid of proteins.\" [GOC:dph, PMID:17267393, PMID:23043182]","metadata":null},{"id":"4bb00477bb28494f8070dd7b814ba404","type":"GO_TERM","name":"N-terminal protein formylation","canonical_id":"go:GO:0018004","description":"\"The formylation of the N-terminal amino acid of proteins.\" [GOC:ai]","metadata":null},{"id":"1b761af1b134472582a6c60e3e525eac","type":"GO_TERM","name":"N-terminal protein lipidation","canonical_id":"go:GO:0006498","description":"\"The covalent attachment of a lipid group to the amino terminus of a protein.\" [GOC:jl]","metadata":null},{"id":"4bed778843284991af8b2cc8e57bd32c","type":"GO_TERM","name":"N-terminal protein myristoylation","canonical_id":"go:GO:0006499","description":"\"The covalent attachment of a myristoyl group to the N-terminal amino acid residue of a protein.\" [GOC:mah]","metadata":null},{"id":"37766940730a4d9d8ae010453923625e","type":"GO_TERM","name":"N-terminal protein palmitoylation","canonical_id":"go:GO:0006500","description":"\"The covalent attachment of a palmitoyl group to the N-terminal amino acid residue of a protein.\" [GOC:mah]","metadata":null},{"id":"121d68ccddd34ed79bb2dd606c2e4ced","type":"GO_TERM","name":"N-vanillate-L-glutamate synthetase activity","canonical_id":"go:GO:0052627","description":"\"Catalysis of the reaction: vanillate + L-glutamate + ATP = N-vanillate-L-glutamate + AMP + diphosphate + H+.\" [MetaCyc:RXN-10885, PMID:19189963]","metadata":null},{"id":"f6230c34544947a795a07915b899de88","type":"GO_TERM","name":"N2-(2-carboxyethyl)arginine synthase activity","canonical_id":"go:GO:0033848","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + L-arginine = N(2)-(2-carboxyethyl)-L-arginine + H+ + phosphate.\" [EC:2.5.1.66, RHEA:10556]","metadata":null},{"id":"55e033ab1b4a48f6936b7ba30af4c4fa","type":"GO_TERM","name":"N2-acetyl-L-aminoadipate kinase activity","canonical_id":"go:GO:0043744","description":"\"Catalysis of the reaction: ATP + N-acetyl-L-2-aminoadipate = ADP + N-acetyl-L-2-aminoadipate 6-phosphate.\" [PMID:25392000, PMID:26966182, RHEA:41944]","metadata":null},{"id":"de5902c0ae484eaeb44ca5d019c46198","type":"GO_TERM","name":"N2-acetyl-L-ornithine:2-oxoglutarate 5-transaminase activity","canonical_id":"go:GO:0003992","description":"\"Catalysis of the reaction: N(2)-acetyl-L-ornithine + 2-oxoglutarate = N-acetyl-L-glutamate 5-semialdehyde + L-glutamate.\" [RHEA:18049]","metadata":null},{"id":"2426cb71567847f08b7e204c1a7e9723","type":"TRIAL","name":"N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT00885326","description":"Neuroblastoma","metadata":null},{"id":"05012667ee354f26a29b9905b4b4b489","type":"GO_TERM","name":"N4-(beta-N-acetylglucosaminyl)-L-asparaginase activity","canonical_id":"go:GO:0003948","description":"\"Catalysis of the reaction: N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine + H2O = N-acetyl-beta-D-glucosaminylamine + L-aspartate + H+.\" [EC:3.5.1.26, RHEA:11544]","metadata":null},{"id":"9312cca8da0f443a829b001ac8fd1859","type":"GO_TERM","name":"N4-acetylcytidine amidohydrolase activity","canonical_id":"go:GO:0106251","description":"\"Catalysis of the reaction N4-acetylcytidine +H2O = cytidine + acetate.\" [GOC:imk, PMID:31964920, RHEA:62932]","metadata":null},{"id":"5528bf25f5b14ef2a12dc20d71067928","type":"GENE","name":"N4BP1","canonical_id":"hgnc:HGNC:29850","description":"NEDD4 binding protein 1","metadata":null},{"id":"f59e015c19da45e6b7b15148c368821d","type":"GENE","name":"N4BP2","canonical_id":"hgnc:HGNC:29851","description":"NEDD4 binding protein 2","metadata":{"aliases":["B3BP"]}},{"id":"c0c0d2b67b6940ec97d29abd0f8ae58f","type":"GENE","name":"N4BP2L1","canonical_id":"hgnc:HGNC:25037","description":"NEDD4 binding protein 2 like 1","metadata":{"aliases":["CG018"]}},{"id":"85687232a2b840baa097a80ab3bd0be2","type":"GENE","name":"N4BP2L2","canonical_id":"hgnc:HGNC:26916","description":"NEDD4 binding protein 2 like 2","metadata":{"aliases":["CG005","PFAAP5"]}},{"id":"0370ca92684c401b890d766977f9dd2d","type":"GENE","name":"N4BP2L2-IT2","canonical_id":"hgnc:HGNC:25038","description":"N4BPL2 intronic transcript 2","metadata":{"aliases":["CG030"]}},{"id":"44554946a798460e946140c0d54d9e2e","type":"GENE","name":"N4BP3","canonical_id":"hgnc:HGNC:29852","description":"NEDD4 binding protein 3","metadata":{"aliases":["LZTS4"]}},{"id":"c61dc5d793454094818d8b4826708012","type":"GENE","name":"N4BP3-AS1","canonical_id":"hgnc:HGNC:59314","description":"N4BP3 antisense RNA 1","metadata":null},{"id":"42f7cbdfa0534f0ab1744ec6e3dc52d4","type":"GO_TERM","name":"N5,N10-methenyltetrahydromethanopterin hydrogenase activity","canonical_id":"go:GO:0047068","description":"\"Catalysis of the reaction: 5,10-methenyl-5,6,7,8-tetrahydromethanopterin + H(2) = 5,10-methylenetetrahydromethanopterin + H+.\" [EC:1.12.98.2, RHEA:20017]","metadata":null},{"id":"0140797f9e604a8ba20ef9e773fc23ae","type":"GO_TERM","name":"N5-(carboxyethyl)ornithine synthase activity","canonical_id":"go:GO:0047126","description":"\"Catalysis of the reaction: N(5)-[1(S)-1-carboxyethyl]-L-ornithine + H2O + NADP+ = L-ornithine + H+ + NADPH + pyruvate.\" [EC:1.5.1.24, RHEA:18661]","metadata":null},{"id":"d6f5f221ef504158b8d78b9eeb1de3db","type":"GO_TERM","name":"N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity","canonical_id":"go:GO:0004018","description":"\"Catalysis of the reaction: N6-(1,2-dicarboxyethyl)AMP = fumarate + AMP.\" [RHEA:16853]","metadata":null},{"id":"98f6bf96331b4349a280ec7db6e8670b","type":"GO_TERM","name":"N6-acetyl-beta-lysine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047317","description":"\"Catalysis of the reaction: 2-oxoglutarate + 3-amino-6-acetamidohexanoate = L-glutamate + 3-oxo-6-acetamidohexanoate.\" [RHEA:16889]","metadata":null},{"id":"dbf5a6646a0c41c3a79f6f56dded275f","type":"GO_TERM","name":"N6-hydroxylysine O-acetyltransferase activity","canonical_id":"go:GO:0050133","description":"\"Catalysis of the reaction: N(6)-hydroxy-L-lysine + acetyl-CoA = N(6)-acetyl-N(6)-hydroxy-L-lysine + CoA.\" [EC:2.3.1.102, RHEA:22388]","metadata":null},{"id":"4d3cc481961a4179af831053a66e4f3f","type":"GO_TERM","name":"N6-methyl-(d)ATP hydrolase activity","canonical_id":"go:GO:0106431","description":"\"Catalysis of the reaction N6-methyl-(d)ATP + H2O = N6-methyl-(d)AMP + diphosphate + H+.\" [PMID:32144205]","metadata":null},{"id":"cad5800c875e476cabd5e02b2642f635","type":"GO_TERM","name":"N6-methyl-AMP deaminase activity","canonical_id":"go:GO:0062154","description":"\"Catalysis of the reaction: H+ + H2O + N6-methyl-AMP = IMP + methylamine. Can also use N6-methyl-dAMP as a substrate.\" [PMID:29884623, RHEA:16001]","metadata":null},{"id":"3adbea648e5144ce8ac5939edf219c04","type":"GO_TERM","name":"N6-methyl-lysine oxidase activity","canonical_id":"go:GO:0050134","description":"\"Catalysis of the reaction: N(6)-methyl-L-lysine + H2O + O2 = L-lysine + formaldehyde + H2O2.\" [EC:1.5.3.4, RHEA:23200]","metadata":null},{"id":"df31ed57152d4b80bb17918b56153d74","type":"GO_TERM","name":"N6-methyladenosine-containing RNA reader activity","canonical_id":"go:GO:1990247","description":"\"A protein adaptor that recognizes and binds an RNA molecule modified by N6-methyladenosine (m6A), a modification present at internal sites of mRNAs and some non-coding RNAs.\" [PMID:22575960, PMID:24284625]","metadata":null},{"id":"bdea5f146ad149b79cd6935eacdbf757","type":"GENE","name":"NAA10","canonical_id":"hgnc:HGNC:18704","description":"N-alpha-acetyltransferase 10, NatA catalytic subunit","metadata":{"aliases":["DXS707","TE2","ARD1","ARD1A"]}},{"id":"ab95e49f10444dd3b18f6080ca079d0f","type":"GENE","name":"NAA11","canonical_id":"hgnc:HGNC:28125","description":"N-alpha-acetyltransferase 11, NatA catalytic subunit","metadata":{"aliases":["ARD2","hARD2","ARD1B"]}},{"id":"b93182dc4de54c16aa76b1eba9f5ef7c","type":"GENE","name":"NAA15","canonical_id":"hgnc:HGNC:30782","description":"N-alpha-acetyltransferase 15, NatA auxiliary subunit","metadata":{"aliases":["TBDN100","NATH","FLJ13340","NARG1"]}},{"id":"e3c9d71ee21b4342acbc60949ce57d90","type":"GENE","name":"NAA16","canonical_id":"hgnc:HGNC:26164","description":"N-alpha-acetyltransferase 16, NatA auxiliary subunit","metadata":{"aliases":["FLJ22054","MGC40612","PRO2435","NARG1L"]}},{"id":"11ab8360540d4802a332d019f8ef79f3","type":"GENE","name":"NAA20","canonical_id":"hgnc:HGNC:15908","description":"N-alpha-acetyltransferase 20, NatB catalytic subunit","metadata":{"aliases":["dJ1002M8.1","NAT3","NAT5"]}},{"id":"648be20c0ece4c4e90c50a41474bf110","type":"GENE","name":"NAA20P1","canonical_id":"hgnc:HGNC:55133","description":"NAA20 pseudogene 1","metadata":null},{"id":"0c9cc5a9d02b46adae19a17d29a7faa8","type":"GENE","name":"NAA25","canonical_id":"hgnc:HGNC:25783","description":"N-alpha-acetyltransferase 25, NatB auxiliary subunit","metadata":{"aliases":["FLJ13089","C12orf30"]}},{"id":"348fdcc81677488f93684d1bf1ff7e1b","type":"GENE","name":"NAA30","canonical_id":"hgnc:HGNC:19844","description":"N-alpha-acetyltransferase 30, NatC catalytic subunit","metadata":{"aliases":["FLJ35355","MAK3","Mak3p","C14orf35","NAT12"]}},{"id":"f0d9a3ad442249a6833acf8719cfa27b","type":"GENE","name":"NAA35","canonical_id":"hgnc:HGNC:24340","description":"N-alpha-acetyltransferase 35, NatC auxiliary subunit","metadata":{"aliases":["FLJ21613","FLJ22643","bA379P1.1","MAK10"]}},{"id":"bbc336c5f2ac4a60ab7362d30a758929","type":"GENE","name":"NAA38","canonical_id":"hgnc:HGNC:28212","description":"N-alpha-acetyltransferase 38, NatC auxiliary subunit","metadata":{"aliases":["MGC14151","PFAAP2","LSMD1"]}},{"id":"171410811d4d494e93259e80f11ea495","type":"GENE","name":"NAA40","canonical_id":"hgnc:HGNC:25845","description":"N-alpha-acetyltransferase 40, NatD catalytic subunit","metadata":{"aliases":["FLJ13848","NAT11"]}},{"id":"26b6c35b29d24fa7be2fbe07b40ec89f","type":"GENE","name":"NAA40P1","canonical_id":"hgnc:HGNC:56897","description":"NAA40 pseudogene 1","metadata":null},{"id":"1c814929b25045a5a98ee4931ac66fb8","type":"GENE","name":"NAA50","canonical_id":"hgnc:HGNC:29533","description":"N-alpha-acetyltransferase 50, NatE catalytic subunit","metadata":{"aliases":["FLJ13194","NAT5","San","MAK3","NAT13"]}},{"id":"2dfa57d8e42f4cdbbe524c2ed7d848d9","type":"GENE","name":"NAA50P1","canonical_id":"hgnc:HGNC:55920","description":"NAA50 pseudogene 1","metadata":null},{"id":"9bb7723585434f44873cc499ec7f36fc","type":"GENE","name":"NAA50P2","canonical_id":"hgnc:HGNC:56631","description":"NAA50 pseudogene 2","metadata":null},{"id":"f014198b60024a4cb0373576ccd12fc8","type":"GENE","name":"NAA60","canonical_id":"hgnc:HGNC:25875","description":"N-alpha-acetyltransferase 60, NatF catalytic subunit","metadata":{"aliases":["FLJ14154","HAT4","NatF","hNaa60","NAT15"]}},{"id":"bd052024fdcd4fa9b542a71065cef31c","type":"GENE","name":"NAA80","canonical_id":"hgnc:HGNC:30252","description":"N-alpha-acetyltransferase 80, NatH catalytic subunit","metadata":{"aliases":["FUS2","NAT6"]}},{"id":"2f41222e94f449c4bd9f9c80e5dae6a8","type":"GENE","name":"NAAA","canonical_id":"hgnc:HGNC:736","description":"N-acylethanolamine acid amidase","metadata":{"aliases":["ASAHL"]}},{"id":"443f92f186d341a09ebf28ebdf41e95a","type":"GO_TERM","name":"NAADP-sensitive calcium-release channel activity","canonical_id":"go:GO:0072345","description":"\"Enables the transmembrane transfer of a calcium ion by a channel that opens when nicotinic acid adenine dinucleotide phosphate (NAADP) has been bound by the channel complex or one of its constituent parts.\" [PMID:19387438, PMID:19557428]","metadata":null},{"id":"ebf34b97c74e400b9862e9bc464b242f","type":"GENE","name":"NAALAD2","canonical_id":"hgnc:HGNC:14526","description":"N-acetylated alpha-linked acidic dipeptidase 2","metadata":{"aliases":["NAALADASE2","GCPIII"]}},{"id":"65b536cb8686442582f56ea979533244","type":"GENE","name":"NAALADL1","canonical_id":"hgnc:HGNC:23536","description":"N-acetylated alpha-linked acidic dipeptidase like 1","metadata":{"aliases":["HILAP"]}},{"id":"6a517e3cab3a439dbbb9a1e3ba72b269","type":"GENE","name":"NAALADL2","canonical_id":"hgnc:HGNC:23219","description":"N-acetylated alpha-linked acidic dipeptidase like 2","metadata":null},{"id":"bd6cc81181b04e528a2b0d373bcebe62","type":"GENE","name":"NAALADL2-AS1","canonical_id":"hgnc:HGNC:41016","description":"NAALADL2 antisense RNA 1","metadata":null},{"id":"fc4539311b8042748f481c7cbdb18cd3","type":"GENE","name":"NAALADL2-AS2","canonical_id":"hgnc:HGNC:41015","description":"NAALADL2 antisense RNA 2","metadata":null},{"id":"b959c611c66b4efb875685f328c1be1b","type":"GENE","name":"NAALADL2-AS3","canonical_id":"hgnc:HGNC:41014","description":"NAALADL2 antisense RNA 3","metadata":null},{"id":"1293bd3d7eeb483b9fa4a96dea324e10","type":"GENE","name":"NAB1","canonical_id":"hgnc:HGNC:7626","description":null,"metadata":null},{"id":"ab2a629d1a504026aa89ec483324a8c9","type":"GENE","name":"NAB1P1","canonical_id":"hgnc:HGNC:55156","description":"NAB1 pseudogene 1","metadata":null},{"id":"5616b3a60cdf48cf92ef820311464e0f","type":"GENE","name":"NAB2","canonical_id":"hgnc:HGNC:7627","description":null,"metadata":null},{"id":"99bfdf29b0a0414899474c468462e647","type":"GENE","name":"NABP1","canonical_id":"hgnc:HGNC:26232","description":"nucleic acid binding protein 1","metadata":{"aliases":["FLJ22833","DKFZp667M1322","FLJ13624","MGC111163","SSB2","hSSB2","SOSS-B2","OBFC2A","NABP1-OT1"]}},{"id":"217839429e7d4d97844b01f14650ea12","type":"GENE","name":"NABP2","canonical_id":"hgnc:HGNC:28412","description":"nucleic acid binding protein 2","metadata":{"aliases":["MGC2731","SSB1","hSSB1","SOSS-B1","OBFC2B"]}},{"id":"6eb479f5636b48cb8508fc41a25b5708","type":"GENE","name":"NACA","canonical_id":"hgnc:HGNC:7629","description":"nascent polypeptide associated complex subunit alpha","metadata":{"aliases":["NACA1","Alpha-NAC"]}},{"id":"11e72350347d4eab91be237fab651703","type":"GENE","name":"NACA2","canonical_id":"hgnc:HGNC:23290","description":"nascent polypeptide associated complex subunit alpha 2","metadata":{"aliases":["MGC71999","NACAL"]}},{"id":"6f7db54465154076b2956d3a91080508","type":"GENE","name":"NACA3P","canonical_id":"hgnc:HGNC:33442","description":"NACA family member 3, pseudogene","metadata":{"aliases":["NACA3"]}},{"id":"9561406230234a0b8fdf173f9ad5b079","type":"GENE","name":"NACA4P","canonical_id":"hgnc:HGNC:24688","description":"NACA family member 4, pseudogene","metadata":{"aliases":["FKSG17","NACAP1"]}},{"id":"61605049d4c14da9995479f4c547373a","type":"GENE","name":"NACAD","canonical_id":"hgnc:HGNC:22196","description":"NAC alpha domain containing","metadata":{"aliases":["KIAA0363"]}},{"id":"4b5b67694a624e0b875759eef7b75560","type":"GENE","name":"NACAP10","canonical_id":"hgnc:HGNC:53906","description":"NACA pseudogene 10","metadata":null},{"id":"b7374bc3ea1a48b18728c5c793489e66","type":"GENE","name":"NACAP2","canonical_id":"hgnc:HGNC:49489","description":"NACA pseudogene 2","metadata":null},{"id":"f8e3bef466e64584a23bfe11a3a8b697","type":"GENE","name":"NACAP5","canonical_id":"hgnc:HGNC:49492","description":"NACA pseudogene 5","metadata":null},{"id":"83450aaed11242b9b637bbd779ceee7e","type":"GENE","name":"NACAP6","canonical_id":"hgnc:HGNC:49493","description":"NACA pseudogene 6","metadata":null},{"id":"ac38c382f4e649ea96978b05b3c6d18d","type":"GENE","name":"NACAP7","canonical_id":"hgnc:HGNC:49494","description":"NACA pseudogene 7","metadata":null},{"id":"1e357dd228bb4cb288e1be15dcbac060","type":"GENE","name":"NACAP8","canonical_id":"hgnc:HGNC:49490","description":"NACA pseudogene 8","metadata":{"aliases":["NACAP3"]}},{"id":"7314121796db479f9699fcaa39d9a404","type":"GENE","name":"NACAP9","canonical_id":"hgnc:HGNC:49491","description":"NACA pseudogene 9","metadata":{"aliases":["NACAP4"]}},{"id":"a25012f0aa47415da3e00caeb41631ca","type":"GENE","name":"NACC1","canonical_id":"hgnc:HGNC:20967","description":"nucleus accumbens associated 1","metadata":{"aliases":["NAC1","NAC-1","BEND8","BTBD30","BTBD14B"]}},{"id":"997c7538ba8e4e23b01a3906eb8abfcf","type":"GENE","name":"NACC1-AS1","canonical_id":"hgnc:HGNC:58320","description":"NACC1 antisense RNA 1","metadata":null},{"id":"32b934d2b9c14fb68d6e1734ed6b3bcd","type":"GENE","name":"NACC2","canonical_id":"hgnc:HGNC:23846","description":"NACC family member 2","metadata":{"aliases":["MGC23427","BEND9","BTBD31","BTBD14A"]}},{"id":"bc210cfac5564a24b34238c1d9a14d3a","type":"GO_TERM","name":"NACHT domain binding","canonical_id":"go:GO:0032089","description":"\"Binding to a NACHT (NAIP, CIITA, HET-E and TP1) domain. The NACHT domain consists of seven distinct conserved motifs, including an ATP/GTPase specific P-loop, a Mg2+-binding site and five more specific motifs.\" [GOC:rl]","metadata":null},{"id":"d6698f80326f4214b6893c1e711546e1","type":"GO_TERM","name":"NAD DNA ADP-ribosyltransferase activity","canonical_id":"go:GO:0140294","description":"\"Catalysis of the transfer of the ADP-ribose group of NAD+ to a residue in double-stranded DNA.\" [PMID:27471034, PMID:29361132, PMID:29520010]","metadata":null},{"id":"445315859a6e49a69aacfcd6a38cb272","type":"GO_TERM","name":"NAD binding","canonical_id":"go:GO:0051287","description":"\"Binding to nicotinamide adenine dinucleotide, a coenzyme involved in many redox and biosynthetic reactions; binding may be to either the oxidized form, NAD+, or the reduced form, NADH.\" [GOC:ai]","metadata":null},{"id":"9e8a107313054ab5a4a75cdc8f30af5c","type":"GO_TERM","name":"NAD transmembrane transport","canonical_id":"go:GO:0035352","description":"\"The process in which a nicotinamide adenine dinucleotide is transported across a membrane; transport may be of either the oxidized form, NAD, or the reduced form, NADH.\" [GOC:bf]","metadata":null},{"id":"93d378b05f274cc788a02355d250fdfa","type":"GO_TERM","name":"NAD transmembrane transporter activity","canonical_id":"go:GO:0051724","description":"\"Enables the transfer of NAD from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"a197b68e15914af289fcf8ec796b71c4","type":"GO_TERM","name":"NAD transport","canonical_id":"go:GO:0043132","description":"\"The directed movement of nicotinamide adenine dinucleotide into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore; transport may be of either the oxidized form, NAD, or the reduced form, NADH.\" [GOC:jl]","metadata":null},{"id":"d2d4ef04403d44c2962b2b0daed94d6c","type":"GO_TERM","name":"NAD(P)+ transhydrogenase (Si-specific) activity","canonical_id":"go:GO:0003957","description":"\"Catalysis of the reaction: NADPH + NAD+ = NADP+ + NADH.\" [RHEA:11692]","metadata":null},{"id":"4ef42dda2af34f2880916cd5ca073cb1","type":"GO_TERM","name":"NAD(P)H dehydrogenase (quinone) activity","canonical_id":"go:GO:0003955","description":"\"Catalysis of the reaction: NAD(P)H + H+ + a quinone = NAD(P)+ + a quinol.\" [EC:1.6.5.2]","metadata":null},{"id":"24baff42f5c74b06b2e3d2c4bce49ec3","type":"GO_TERM","name":"NAD(P)H dehydrogenase complex (plastoquinone)","canonical_id":"go:GO:0010598","description":"\"Complex that possesses NAD(P)H dehydrogenase (plastoquinone) activity. The complex is one of the components of the electron transport chain. It is involved in electron transport from an unidentified electron donor, possibly NADH, NADPH or ferredoxin(Fd) to the plastoquinone pool.\" [PMID:15608332]","metadata":null},{"id":"7916c2caccd44306960623315b01d197","type":"GO_TERM","name":"NAD(P)H dehydrogenase complex assembly","canonical_id":"go:GO:0010275","description":"\"The aggregation, arrangement and bonding together of a set of components to form NAD(P)H dehydrogenase complex, which is involved in electron transport from an unidentified electron donor, possibly NAD(P)H or ferredoxin(Fd) to the plastoquinone pool.\" [GOC:sm]","metadata":null},{"id":"72df53297b8b4aaf9399775383dd2f08","type":"GO_TERM","name":"NAD(P)H oxidase H2O2-forming activity","canonical_id":"go:GO:0016174","description":"\"Catalysis of the reaction: NAD(P)H + H+ + O2 = NAD(P)+ + H2O2.\" [EC:1.6.3.1, PMID:10401672, PMID:10601291, PMID:11822874]","metadata":null},{"id":"57bcfb12d7354e26a99ffa4b01e86170","type":"GO_TERM","name":"NAD(P)H sulfur oxidoreductase (CoA-dependent) activity","canonical_id":"go:GO:0043914","description":"\"Catalysis of the reaction: hydrogen sulfide + NAD(P)+ = sulfur + NAD(P)H.\" [EC:1.8.1.18, PMID:17449625]","metadata":null},{"id":"5a75a01d402f43eebf7a2af4e7efdff6","type":"GO_TERM","name":"NAD(P)HX epimerase activity","canonical_id":"go:GO:0052856","description":"\"Catalysis of the reactions: (6R)-NADHX = (6S)-NADHX and (6R)-NADPHX = (6S)-NADPHX.\" [EC:5.1.99.6, PMID:21994945]","metadata":null},{"id":"c52d166253bd409198a9f740f6c34d6d","type":"GO_TERM","name":"NAD+ binding","canonical_id":"go:GO:0070403","description":"\"Binding to the oxidized form, NAD, of nicotinamide adenine dinucleotide, a coenzyme involved in many redox and biosynthetic reactions.\" [GOC:mah]","metadata":null},{"id":"3d298eb34d714a2084f4a428be379eba","type":"GO_TERM","name":"NAD+ biosynthetic process","canonical_id":"go:GO:0009435","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide (NAD+), a coenzyme that interconverts with its reduced form, NADH, in many redox and catabolic reactions. NAD+ is derived from various sources including vitamin B3.\" [PMID:28648096]","metadata":null},{"id":"b1fe6046b4e44fe4aeb6fd3c8a19a079","type":"GO_TERM","name":"NAD+ biosynthetic process via the salvage pathway","canonical_id":"go:GO:0034355","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide-adenine dinucleotide (NAD+) from vitamin B3 derivatives (including nicotinic acid (NA) and nicotinamide (NAM)), beta-nicotinamide D-ribonucleotide (NMN), nicotinamide riboside (NR) or nicotinate riboside (NAR), without de novo synthesis.\" [GOC:sjm, PMID:12648681, PMID:27374990]","metadata":null},{"id":"d26d8ff123f54b109cea3eacf7b58b85","type":"GO_TERM","name":"NAD+ catabolic process","canonical_id":"go:GO:0019677","description":"\"The chemical reactions and pathways resulting in the breakdown of nicotinamide adenine dinucleotide (NAD+), a coenzyme that interconverts with its reduced form, NADH, in many redox and catabolic reactions.\" [PMID:28648096]","metadata":null},{"id":"bfbb88021b184409b5d770f47fb27ef0","type":"GO_TERM","name":"NAD+ diphosphatase activity","canonical_id":"go:GO:0000210","description":"\"Catalysis of the reaction: NAD+ + H2O = AMP + NMN.\" [RHEA:11800]","metadata":null},{"id":"650d45e636cb4d46b7a72566a9ca2b4a","type":"GO_TERM","name":"NAD+ kinase activity","canonical_id":"go:GO:0003951","description":"\"Catalysis of the reaction: ATP + NAD+ = ADP + H+ + NADP+.\" [RHEA:18629]","metadata":null},{"id":"10fba6e711b24614af62cf182414adba","type":"GO_TERM","name":"NAD+ metabolic process","canonical_id":"go:GO:0019674","description":"\"The chemical reactions and pathways involving nicotinamide adenine dinucleotide (NAD+), a coenzyme that interconverts with its reduced form, NADH, in many redox and catabolic reactions.\" [PMID:28648096]","metadata":null},{"id":"d8a07b1055c940bd919a3ada42b18255","type":"GO_TERM","name":"NAD+ nucleosidase activity","canonical_id":"go:GO:0003953","description":"\"Catalysis of the reaction: NAD+ + H2O = ADP-D-ribose + nicotinamide + H+.\" [PMID:11866528, PMID:7805847, RHEA:16301]","metadata":null},{"id":"29d6b8158f1b457cbe1d6be79692b23d","type":"GO_TERM","name":"NAD+ nucleosidase activity, cyclic ADP-ribose generating","canonical_id":"go:GO:0061809","description":"\"Catalysis of the reaction: NAD+ + H2O = ADP-D-ribose + nicotinamide + H+, in a two step reaction: first an ADP-ribosyl cyclase reaction to synthesise cyclic ADP-ribose, followed by a cyclic ADP-ribose hydrolase reaction to generate (linear) ADP-ribose.\" [EC:3.2.2.6, PMID:11866528]","metadata":null},{"id":"e4f838f86c884ad2b34960087094e85b","type":"GO_TERM","name":"NAD+ poly-ADP-ribosyltransferase activity","canonical_id":"go:GO:0003950","description":"\"Catalysis of the reaction: NAD+ + (ADP-D-ribosyl)(n)-acceptor = nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.\" [EC:2.4.2.30]","metadata":null},{"id":"bf0b4efb8172472cbb5b81efdf0583e7","type":"GO_TERM","name":"NAD+ synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0003952","description":"\"Catalysis of the reaction: deamido-NAD+ + L-glutamine + ATP + H2O = L-glutamate + AMP + diphosphate + NAD+ + H+.\" [RHEA:24384]","metadata":null},{"id":"796b97ccfd594df7ab82c617be9e57ce","type":"GO_TERM","name":"NAD+ synthase activity","canonical_id":"go:GO:0008795","description":"\"Catalysis of the reaction: deamido-NAD+ + NH4+ + ATP = AMP + diphosphate + NAD+ + H+.\" [RHEA:21188]","metadata":null},{"id":"3512170c7d994ec7b8b631347f2b28fc","type":"GO_TERM","name":"NAD+-dinitrogen-reductase ADP-D-ribosyltransferase activity","canonical_id":"go:GO:0030701","description":"\"Catalysis of the reaction: NAD+ + [dinitrogen reductase] = nicotinamide + ADP-D-ribosyl-[dinitrogen reductase].\" [EC:2.4.2.37]","metadata":null},{"id":"5ab59ddd26034041be3cca01c9cd00e9","type":"GO_TERM","name":"NAD+-diphthamide ADP-ribosyltransferase activity","canonical_id":"go:GO:0047286","description":"\"Catalysis of the reaction: peptide diphthamide + NAD+ = peptide N-(ADP-D-ribosyl)diphthamide + niacinamide.\" [EC:2.4.2.36]","metadata":null},{"id":"0820d0d44d9146a1950724234f71ccb2","type":"GO_TERM","name":"NAD+-histone H2BE2 glutamate ADP-ribosyltransferase activity","canonical_id":"go:GO:0140844","description":"\"Catalysis of the transfer of ADP-ribose groups to the glutamate-2 residue of the N-terminal tail of histone H2B (or an equivalent residue).\" [PMID:27530147]","metadata":null},{"id":"4aaba502407a43809f7454510df7959a","type":"GO_TERM","name":"NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activity","canonical_id":"go:GO:0140822","description":"\"Catalysis of the transfer of ADP-ribose groups to the glutamate-35 residue of the N-terminal tail of histone H2B (or an equivalent residue).\" [PMID:32822587]","metadata":null},{"id":"76116ebc85a448e7833ca648d33e9cb5","type":"GO_TERM","name":"NAD+-histone H2BS6 serine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140816","description":"\"Catalysis of the transfer of ADP-ribose groups to the serine-6 or an equivalent residue of the N-terminal tail of histone H2B.\" [PMID:34874266]","metadata":null},{"id":"bc39eabfbcd04dcab6a231cc4918be84","type":"GO_TERM","name":"NAD+-histone H3S10 serine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140817","description":"\"Catalysis of the transfer of ADP-ribose groups to the serine-10 or an equivalent residue of the N-terminal tail of histone H3.\" [PMID:34874266]","metadata":null},{"id":"b20d5f0270cb45b9a469c194c5f0b28f","type":"GO_TERM","name":"NAD+-protein mono-ADP-ribosyltransferase activity","canonical_id":"go:GO:1990404","description":"\"Catalysis of the reaction: amino acyl-[protein] + NAD+ = H+ + (ADP-D-ribosyl)-amino acyl-[protein] + nicotinamide.\" [PMID:1899243]","metadata":null},{"id":"ba596c514dda40cda102be0af06c0bf5","type":"GO_TERM","name":"NAD+-protein-C-terminal glycine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140802","description":"\"Catalysis of the reaction: [protein]-C-terminal glycine + NAD+ = [protein]-C-terminal O-(ADP-D-ribosyl)-glycine + nicotinamide.\" [PMID:28525742, RHEA:58268]","metadata":null},{"id":"628024596a324c488314cdcd6a4e0286","type":"GO_TERM","name":"NAD+-protein-arginine ADP-ribosyltransferase activity","canonical_id":"go:GO:0106274","description":"\"Catalysis of the reaction: L-arginyl-[protein] + NAD+ = H+ + (ADP-D-ribosyl)-L-arginyl-[protein] + nicotinamide.\" [RHEA:19149]","metadata":null},{"id":"fe0445c3b8e44aa58c44404115154809","type":"GO_TERM","name":"NAD+-protein-aspartate ADP-ribosyltransferase activity","canonical_id":"go:GO:0140806","description":"\"Catalysis of the reaction: L-aspartyl-[protein] + NAD+ = 4-O-(ADP-D-ribosyl)-L-aspartyl-[protein] + nicotinamide.\" [PMID:19764761, PMID:25043379, RHEA:54424]","metadata":null},{"id":"73a5d753f4a14c069b4fc4f8aebd3344","type":"GO_TERM","name":"NAD+-protein-cysteine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140803","description":"\"Catalysis of the reaction: L-cysteinyl-[protein] + NAD+ = H+ + nicotinamide + S-(ADP-D-ribosyl)-L-cysteinyl-[protein].\" [PMID:25043379, RHEA:56612]","metadata":null},{"id":"e8e836f5ef0c4ddb8f9259295a3d855f","type":"GO_TERM","name":"NAD+-protein-glutamate ADP-ribosyltransferase activity","canonical_id":"go:GO:0140807","description":"\"Catalysis of the reaction: L-glutamyl-[protein] + NAD+ = 5-O-(ADP-D-ribosyl)-L-glutamyl-[protein] + nicotinamide.\" [PMID:19764761, PMID:25043379, RHEA:58224]","metadata":null},{"id":"2de8296e5fff4092b99dc41904b730c8","type":"GO_TERM","name":"NAD+-protein-histidine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140815","description":"\"Catalysis of the reaction: L-histidyl-[protein] + NAD+ = H+ + Nt-(ADP-D-ribosyl)-L-histidyl-[protein] + nicotinamide.\" [PMID:35393539, RHEA:72071]","metadata":null},{"id":"053b8c970a4845709995bc288ade0394","type":"GO_TERM","name":"NAD+-protein-lysine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140804","description":"\"Catalysis of the reaction: L-lysyl-[protein] + NAD+ = H+ + N(6)-(ADP-D-ribosyl)-L-lysyl-[protein] + nicotinamide.\" [PMID:25043379, RHEA:58220]","metadata":null},{"id":"f2a6dd69028940c29c9e53f269d985ca","type":"GO_TERM","name":"NAD+-protein-serine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140805","description":"\"Catalysis of the reaction: L-seryl-[protein] + NAD+ = H+ + nicotinamide + O-(ADP-D-ribosyl)-L-seryl-[protein].\" [PMID:32028527, PMID:33186521, RHEA:58232]","metadata":null},{"id":"98af47f4d85945eb864e84db4dc77888","type":"GO_TERM","name":"NAD+-protein-tyrosine ADP-ribosyltransferase activity","canonical_id":"go:GO:0140808","description":"\"Catalysis of the reaction: L-tyrosyl-[protein] + NAD+ = H+ + nicotinamide + O-(ADP-D-ribosyl)-L-tyrosyl-[protein].\" [PMID:29954836, PMID:30257210, RHEA:58236]","metadata":null},{"id":"940f6ee519a9452bb6866bdeb4bcf14e","type":"GO_TERM","name":"NAD-cap decapping","canonical_id":"go:GO:0110155","description":"\"Cleavage of the 5'-NAD-cap of an RNA. The NAD-cap is present at the 5'-end of some RNAs in both bacetria and eukaryotes. While it promotes RNA stability in bacteria, it promotes RNA decay in eukaryotes.\" [GOC:sp, PMID:25533955, PMID:28283058, PMID:31101919]","metadata":null},{"id":"38e82e1649bb4120abda21dc3f4452c7","type":"GO_TERM","name":"NAD-dependent protein biotinidase activity","canonical_id":"go:GO:0106420","description":"\"Catalysis of the reaction: H2O + N6-biotinyl-L-lysyl-[protein] + NAD+ = 2''-O-biotinyl-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [PMID:25525879, RHEA:70479]","metadata":null},{"id":"5c7b687772ce403bace52d16301e31d5","type":"GO_TERM","name":"NAD-dependent protein de-2-hydroxyisobutyrylase activity","canonical_id":"go:GO:0160013","description":"\"Catalysis of the reaction: H2O + N6-(2-hydroxyisobutanoyl)-L-lysyl-[protein] + NAD+ = 2''-O-(2-hydroxyisobutanoyl)-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [PMID:31328167]","metadata":null},{"id":"e54df981675d44fdaac717873e01ca5d","type":"GO_TERM","name":"NAD-dependent protein decrotonylase activity","canonical_id":"go:GO:0160011","description":"\"Catalysis of the reaction: H2O + N6-(2E)-butenoyl-L-lysyl-[protein] + NAD+ = 2''-O-(2E)-but-2-enoyl-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [PMID:28497810]","metadata":null},{"id":"831255f000434d7187aba79ef05bcce6","type":"GO_TERM","name":"NAD-dependent protein demyristoylase activity","canonical_id":"go:GO:0140773","description":"\"Catalysis of the reaction: N6-tetradecanoyl-L-lysyl-[protein] + NAD+ + H2O = tetradecanoyl-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [PMID:23552949, RHEA:70567]","metadata":null},{"id":"8e9667a32fbf4a2f930d5e70f3197362","type":"GO_TERM","name":"NAD-dependent protein depalmitoylase activity","canonical_id":"go:GO:0140774","description":"\"Catalysis of the reaction: N6-octadecanoyl-L-lysyl-[protein] + NAD+ + H2O = octadecanoyl-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [PMID:23552949, RHEA:70563]","metadata":null},{"id":"649d10af77fa4695bd57bea2e9b78958","type":"GO_TERM","name":"NAD-dependent protein lipoamidase activity","canonical_id":"go:GO:0106419","description":"\"Catalysis of the reaction: (R)-N6-lipoyl-L-lysyl-[protein] + H2O + NAD+ = 2''-O-lipoyl-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [PMID:25525879, RHEA:63640]","metadata":null},{"id":"25c03b247d504a738ac189e97506d6c1","type":"GO_TERM","name":"NAD-dependent protein lysine deacetylase activity","canonical_id":"go:GO:0034979","description":"\"Catalysis of the reaction: N(6)-acetyl-L-lysyl-[protein] + NAD+ + H2O = L-lysyl-[protein] + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group from a protein to NAD, producing nicotinamide.\" [GOC:BHF, GOC:mah, RHEA:43636]","metadata":null},{"id":"c54ff08e82714067bacc9d901d50d8b1","type":"GO_TERM","name":"NAD-dependent protein lysine deacylase activity","canonical_id":"go:GO:0141218","description":"\"Catalysis of the reaction: N6-acyl-L-lysyl-[protein] + NAD+ + H2O = 2''-O-acyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein].\" [PMID:35044827, RHEA:54172]","metadata":null},{"id":"1c0fecfda33b4f3fbef72cc96fe67e73","type":"GO_TERM","name":"NAD-dependent protein lysine delactylase activity","canonical_id":"go:GO:0141208","description":"\"Catalysis of the reaction: H2O + N6-lactoyl-L-lysyl-[protein] + NAD = L-lysyl-[protein] + nicotinamide +2''-O-lactoyl-ADP-D-ribose, transfering a lactoyl group attached to a lysine residue in a protein to NAD.\" [PMID:38512451, RHEA:80287]","metadata":null},{"id":"45674e893332437ab675aad9c8238555","type":"GO_TERM","name":"NAD-dependent protein-lysine depropionylase activity","canonical_id":"go:GO:0106231","description":"\"Catalysis of the reaction:H2O + N(6)-propanoyl-L-lysyl-[protein] + NAD+ = 3''-O-propanoyl-ADP-D-ribose + L-lysyl-[protein] + nicotinamide.\" [GOC:sp, PMID:30026585, RHEA:23500]","metadata":null},{"id":"bde081f42daf427a97682b6aa4e25e79","type":"GO_TERM","name":"NAD-malic enzyme C4 photosynthesis","canonical_id":"go:GO:0009763","description":"\"The process of C4 photosynthesis, as it occurs in plants in which the enzyme decarboxylating C4 acids in the bundle sheath is NAD-malic enzyme.\" [PMID:11788762]","metadata":null},{"id":"2ca5e3476465473b89f4eb2cd7dfb614","type":"GO_TERM","name":"NADH binding","canonical_id":"go:GO:0070404","description":"\"Binding to the reduced form, NADH, of nicotinamide adenine dinucleotide, a coenzyme involved in many redox and biosynthetic reactions.\" [GOC:mah]","metadata":null},{"id":"f33682b5824c46cbb678d6ff8c79c701","type":"GO_TERM","name":"NADH dehydrogenase (menaquinone) (non-electrogenic) activity","canonical_id":"go:GO:0103036","description":"\"Catalysis of the reaction: a menaquinone + NADH + H+ = a menaquinol + NAD+.\" [RHEA:29235]","metadata":null},{"id":"407c8250c5f24ed885d3407030cb34b4","type":"GO_TERM","name":"NADH dehydrogenase (quinone) (non-electrogenic) activity","canonical_id":"go:GO:0050136","description":"\"Catalysis of the reaction: NADH + H+ + a quinone = NAD+ + a quinol.\" [RHEA:46160]","metadata":null},{"id":"26a04f53e624403e815c95c2c9f0d9b5","type":"GO_TERM","name":"NADH dehydrogenase (ubiquinone) (non-electrogenic) activity","canonical_id":"go:GO:0120555","description":"\"Catalysis of the reaction: a ubiquinone + NADH + H+ = a ubiquinol + NAD+.\" [RHEA:23152]","metadata":null},{"id":"0822543860d840669c321db83606c8cd","type":"GO_TERM","name":"NADH dehydrogenase (ubiquinone) activity","canonical_id":"go:GO:0008137","description":"\"Catalysis of the reaction: NADH + ubiquinone + 5 H+(in) = NAD+ + ubiquinol + 4 H+(out).\" [RHEA:29091]","metadata":null},{"id":"2524a85ee8e148caa1a2b9dffdc993f9","type":"PROTEIN","name":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial","canonical_id":"uniprot:P56181","description":null,"metadata":null},{"id":"e41900cab1e04ebdb2d9ca305d49d5ce","type":"GO_TERM","name":"NADH dehydrogenase activity","canonical_id":"go:GO:0003954","description":"\"Catalysis of the reaction: NADH + H+ + acceptor = NAD+ + reduced acceptor.\" [RHEA:11356]","metadata":null},{"id":"7b3c3f1ab2e349929c2e8cf8f11147e7","type":"GO_TERM","name":"NADH dehydrogenase complex","canonical_id":"go:GO:0030964","description":"\"An integral membrane complex that possesses NADH oxidoreductase activity. The complex is one of the components of the electron transport chain. It catalyzes the transfer of a pair of electrons from NADH to a quinone.\" [GOC:mah]","metadata":null},{"id":"42eca84373ba46f4b7f9fd70c07e058b","type":"GO_TERM","name":"NADH dehydrogenase complex (plastoquinone)","canonical_id":"go:GO:0071685","description":"\"An NADH dehydrogenase complex that catalyzes the transfer of electrons to plastoquinone. The complex is involved in the non-photochemical reduction of plastoquinones and the cyclic electron transport around photosystem I, and is found in plastid thylakoids.\" [DOI:10.1078/0176-1617-00593, GOC:mah]","metadata":null},{"id":"104f9426ac904832a8fd87350f80198a","type":"GO_TERM","name":"NADH dehydrogenase complex (plastoquinone) assembly","canonical_id":"go:GO:0010258","description":"\"The aggregation, arrangement and bonding together of a set of components to form NADH:plastoquinone dehydrogenase complex, which is involved in the non-photochemical reduction of plastoquinones, as well as the cyclic electron transport around photosystem I.\" [PMID:15608332]","metadata":null},{"id":"349e11125005448ba9ba4acdd25a3e17","type":"GO_TERM","name":"NADH dehydrogenase complex assembly","canonical_id":"go:GO:0010257","description":"\"The aggregation, arrangement and bonding together of a set of components to form an NADH dehydrogenase complex.\" [GOC:sm]","metadata":null},{"id":"575af90a236141ff8020f6b3c0220ffc","type":"GO_TERM","name":"NADH kinase activity","canonical_id":"go:GO:0042736","description":"\"Catalysis of the reaction: ATP + NADH = ADP + 2 H+ + NADPH.\" [EC:2.7.1.86, RHEA:12260]","metadata":null},{"id":"f0fb76c6bc7c417ba61f5b68fa78debc","type":"GO_TERM","name":"NADH peroxidase activity","canonical_id":"go:GO:0016692","description":"\"Catalysis of the reaction: H2O2 + NADH + H+ = 2 H2O + NAD+.\" [EC:1.11.1.1, RHEA:18509]","metadata":null},{"id":"f127fe2e0fc145e3bc70296beeaf5f0c","type":"GO_TERM","name":"NADH pyrophosphatase activity","canonical_id":"go:GO:0035529","description":"\"Catalysis of the reaction: NADH + H2O = AMP + NMNH + 2 H+.\" [PMID:12399474, PMID:20181750, RHEA:48868]","metadata":null},{"id":"f31853a991a043c1854f53fc4763c05a","type":"GO_TERM","name":"NADH-dependent peroxiredoxin activity","canonical_id":"go:GO:0102039","description":"\"Catalysis of the reaction: a hydroperoxide + H+ + NADH = an alcohol + H2O + NAD+.\" [GOC:pz, PMID:12517450, RHEA:62628]","metadata":null},{"id":"bebaeaf61bc74258942406bc13d0bef9","type":"GENE","name":"NADK","canonical_id":"hgnc:HGNC:29831","description":"NAD kinase","metadata":{"aliases":["FLJ13052","NADK1"]}},{"id":"a5e520bdfe2e4a9faef5249be7adfb3a","type":"GENE","name":"NADK2","canonical_id":"hgnc:HGNC:26404","description":"NAD kinase 2, mitochondrial","metadata":{"aliases":["FLJ30596","MNADK","C5orf33","NADKD1"]}},{"id":"d703f58505ab41ae9933e5617bbfe70a","type":"GENE","name":"NADK2-AS1","canonical_id":"hgnc:HGNC:41143","description":"NADK2 antisense RNA 1","metadata":{"aliases":["NADKD1-AS1"]}},{"id":"78eddcbefc31425c9afa20107506b7cf","type":"GO_TERM","name":"NADP binding","canonical_id":"go:GO:0050661","description":"\"Binding to nicotinamide-adenine dinucleotide phosphate, a coenzyme involved in many redox and biosynthetic reactions; binding may be to either the oxidized form, NADP+, or the reduced form, NADPH.\" [GOC:ai]","metadata":null},{"id":"b5b7deafe9e84599866ef6688ea67ddd","type":"GO_TERM","name":"NADP phosphatase activity","canonical_id":"go:GO:0019178","description":"\"Catalysis of the reaction: H2O + NADP+ = NAD+ + phosphate.\" [RHEA:28050]","metadata":null},{"id":"bf74a260120b4ed38a6493ff8b066b0d","type":"GO_TERM","name":"NADP+ binding","canonical_id":"go:GO:0070401","description":"\"Binding to the oxidized form, NADP+, of nicotinamide-adenine dinucleotide phosphate, a coenzyme involved in many redox and biosynthetic reactions.\" [GOC:mah]","metadata":null},{"id":"87225bdd2eac48409aa89f11ab4c799f","type":"GO_TERM","name":"NADP+ biosynthetic process","canonical_id":"go:GO:0006741","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide phosphate (NADP+) from NAD+. NADP+ is a coenzyme that interconverts with its reduced form, NADPH, in many redox and biosynthetic reactions.\" [GOC:curators]","metadata":null},{"id":"d93ab44186504ed2aa324b6f057429ee","type":"GO_TERM","name":"NADP+ catabolic process","canonical_id":"go:GO:0006742","description":"\"The chemical reactions and pathways resulting in the breakdown of nicotinamide adenine dinucleotide phosphate (NADP+), a coenzyme that interconverts with its reduced form, NADPH, in many redox and biosynthetic reactions.\" [GOC:mah]","metadata":null},{"id":"6aa7ccdfb9fa4474a8b0ecab6293d8d6","type":"GO_TERM","name":"NADP+ metabolic process","canonical_id":"go:GO:0006739","description":"\"The chemical reactions and pathways involving nicotinamide adenine dinucleotide phosphate (NADP+), a coenzyme that interconverts with its reduced form, NADPH, in many redox and biosynthetic reactions.\" [GOC:mah]","metadata":null},{"id":"23cc432d0ec84678a3b1c3b0c5814555","type":"GO_TERM","name":"NADP+ nucleosidase activity","canonical_id":"go:GO:0050135","description":"\"Catalysis of the reaction: NADP+ + H2O = ADP-D-ribose 2'-phosphate + nicotinamide + H+.\" [RHEA:19849]","metadata":null},{"id":"ad4033adb8dc42e1902ac003857c9741","type":"GO_TERM","name":"NADP-malic enzyme C4 photosynthesis","canonical_id":"go:GO:0009762","description":"\"The process of C4 photosynthesis, as it occurs in plants in which the enzyme decarboxylating C4 acids in the bundle sheath is NADP-malic enzyme.\" [PMID:11788762]","metadata":null},{"id":"700eab38806d4c98be60312e2d4b8c81","type":"GO_TERM","name":"NADPH binding","canonical_id":"go:GO:0070402","description":"\"Binding to the reduced form, NADPH, of nicotinamide-adenine dinucleotide phosphate, a coenzyme involved in many redox and biosynthetic reactions.\" [GOC:mah]","metadata":null},{"id":"1f05551c0e9c4d8397426f4940edff35","type":"GO_TERM","name":"NADPH dehydrogenase (quinone) activity","canonical_id":"go:GO:0008753","description":"\"Catalysis of the reaction: NADPH + H+ + a quinone = NADP+ + a quinol.\" [RHEA:46164]","metadata":null},{"id":"f483008f41974e4cabacbfce6eab08c8","type":"GO_TERM","name":"NADPH dehydrogenase activity","canonical_id":"go:GO:0003959","description":"\"Catalysis of the reaction: NADPH + H+ + acceptor = NADP+ + reduced acceptor.\" [RHEA:13149]","metadata":null},{"id":"98ee069107af4fc48d2421a1cf711168","type":"GO_TERM","name":"NADPH oxidase complex","canonical_id":"go:GO:0043020","description":"\"A enzyme complex of which the core is a heterodimer composed of a light (alpha) and heavy (beta) chain, and requires the cytosolic regulatory subunits at least NCF1/p47-phox, NCF2/p67-phox, NCF4/p40-phox and the small GTPase RAC1 or RAC2 for activity. Functions in superoxide generation by the NADPH-dependent reduction of O2.\" [GOC:jl, PMID:11483596, PMID:12440767]","metadata":null},{"id":"a681672cb0fc4f198d3dab68068a1069","type":"GO_TERM","name":"NADPH peroxidase activity","canonical_id":"go:GO:0050137","description":"\"Catalysis of the reaction: H2O2 + H+ + NADPH = 2 H2O + NADP+.\" [EC:1.11.1.2, RHEA:15173]","metadata":null},{"id":"9a0ab5f2d0e94fd7bd68622af9b10ed3","type":"GO_TERM","name":"NADPH phosphatase activity","canonical_id":"go:GO:0102757","description":"\"Catalysis of the reaction: NADPH + H2O = NADH + hydrogenphosphate.\" [GOC:pz, RHEA:60664]","metadata":null},{"id":"5afbb183726c4afcb0c5b129fda5ae50","type":"GO_TERM","name":"NADPH pyrophosphatase activity","canonical_id":"go:GO:0010943","description":"\"Catalysis of the reaction: NADPH + H2O = NMNH + ADP.\" [GOC:tb, PMID:12790796, RHEA:60820]","metadata":null},{"id":"bb9373985c2447739da8908ebc8be525","type":"GO_TERM","name":"NADPH regeneration","canonical_id":"go:GO:0006740","description":"\"A metabolic process that replenishes the cellular or compartmental pool of NADPH by transfer of reducing equivalents from a donor substrate to NADP+, independent of the route or compartment involved.\" [PMID:33028807, PMID:34074675]","metadata":null},{"id":"6d6111fbf68a4e1eaaa19e6c36e16687","type":"GO_TERM","name":"NADPH-cytochrome-c2 reductase activity","canonical_id":"go:GO:0015047","description":"\"Catalysis of the reaction: NADPH + H+ + 2 ferricytochrome c2 = NADP+ + 2 ferrocytochrome c2.\" [EC:1.6.2.5]","metadata":null},{"id":"a091904024f94d9fa1269777f8ad6c53","type":"GO_TERM","name":"NADPH-hemoprotein reductase activity","canonical_id":"go:GO:0003958","description":"\"Catalysis of the reaction: NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein.\" [EC:1.6.2.4]","metadata":null},{"id":"f137adb872b44e11baeed1a47432bce9","type":"GO_TERM","name":"NADPH-iron-sulfur [2Fe-2S] protein oxidoreductase activity","canonical_id":"go:GO:0160246","description":"\"Catalysis of the reaction: 2 oxidized [2Fe-2S]-[protein] + NADPH = 2 reduced [2Fe-2S]-[protein] + NADP+ + H+.\" [RHEA:67716]","metadata":null},{"id":"ef6fea8115634b6486c25538336f5f8c","type":"GENE","name":"NADSYN1","canonical_id":"hgnc:HGNC:29832","description":"NAD synthetase 1","metadata":{"aliases":["FLJ10631"]}},{"id":"84b6bf217eec4885ae6d9d504d238166","type":"GENE","name":"NAE1","canonical_id":"hgnc:HGNC:621","description":"NEDD8 activating enzyme E1 subunit 1","metadata":{"aliases":["ula-1","APP-BP1","APPBP1"]}},{"id":"82719f21403a41cd91fad30b67dadc6c","type":"GO_TERM","name":"NAE1-UBA3 complex","canonical_id":"go:GO:0120500","description":"\"A heterodimeric E1 complex that activates the ubiquitin-like protein NEDD8. In humans the subunits are NAE1 (also known as APPBP1) and UBA3.\" [PMID:12740388, PMID:21931660]","metadata":null},{"id":"4440d500856a4f04a4e181b9b1e61d71","type":"GENE","name":"NAF1","canonical_id":"hgnc:HGNC:25126","description":"nuclear assembly factor 1 ribonucleoprotein","metadata":null},{"id":"b86233fe6e6a454888b97cadc1aa1c35","type":"GENE","name":"NAF1-AS1","canonical_id":"hgnc:HGNC:58903","description":"NAF1 antisense RNA 1","metadata":null},{"id":"750d9cefb0c849cdb83e9cf9fdbee90d","type":"GENE","name":"NAGA","canonical_id":"hgnc:HGNC:7631","description":"alpha-N-acetylgalactosaminidase","metadata":{"aliases":["D22S674"]}},{"id":"5f84a96da74c441b946507379ab56837","type":"GENE","name":"NAGK","canonical_id":"hgnc:HGNC:17174","description":"N-acetylglucosamine kinase","metadata":{"aliases":["GNK"]}},{"id":"58101953d1874873854e19565c8ee944","type":"GENE","name":"NAGLU","canonical_id":"hgnc:HGNC:7632","description":"N-acetyl-alpha-glucosaminidase","metadata":{"aliases":["NAG"]}},{"id":"7eb1d4f19b2446ffa1cbffb23882c026","type":"GENE","name":"NAGPA","canonical_id":"hgnc:HGNC:17378","description":"N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase","metadata":{"aliases":["APAA","UCE"]}},{"id":"144ace63c3434b2ea492a5009070bb41","type":"GENE","name":"NAGPA-AS1","canonical_id":"hgnc:HGNC:44184","description":"NAGPA antisense RNA 1","metadata":null},{"id":"18ad249a19ef4ef682fcff9a4172594a","type":"GENE","name":"NAGS","canonical_id":"hgnc:HGNC:17996","description":"N-acetylglutamate synthase","metadata":{"aliases":["AGAS","ARGA","NAT7"]}},{"id":"fdd20c59b22b4a27a7aee8a13d09be8d","type":"GO_TERM","name":"NAGS/NAGK complex","canonical_id":"go:GO:0106098","description":"\"A protein complex that acts both as N-acetylglutamate synthase (NAGS) catalysing the production of N-Acetylglutamate from glutamate and acetyl-CoA, and as N-acetylglutamate kinase (NAGK) catalysing the reaction ATP + N-acetyl-L-glutamate = ADP + N-acetyl-L-glutamyl 5-phosphate.\" [GOC:lnp, PMID:11553611]","metadata":null},{"id":"ad3f52ed659e45f88e497445756df88a","type":"GENE","name":"NAIF1","canonical_id":"hgnc:HGNC:25446","description":"nuclear apoptosis inducing factor 1","metadata":{"aliases":["DKFZp762G199","bA379C10.2","C9orf90"]}},{"id":"254d1f035977451b9f7435655d301060","type":"GENE","name":"NAIP","canonical_id":"hgnc:HGNC:7634","description":null,"metadata":null},{"id":"aa5922cd0c7643a3acbc354af3437360","type":"GENE","name":"NAIP-AS1","canonical_id":"hgnc:HGNC:59064","description":"NAIP antisense RNA 1","metadata":null},{"id":"90b5278d0af94a57b3fe81b6289572a9","type":"GENE","name":"NAIPP1","canonical_id":"hgnc:HGNC:54492","description":"NAIP pseudogene 1","metadata":null},{"id":"528225cdd6234a90985315fb2c8e7e02","type":"GENE","name":"NAIPP2","canonical_id":"hgnc:HGNC:16042","description":"NAIP pseudogene 2","metadata":{"aliases":["BIRC","NAIP1B"]}},{"id":"47329a1cbb8e47859891309ce2d4f8b1","type":"GENE","name":"NAIPP3","canonical_id":"hgnc:HGNC:54493","description":"NAIP pseudogene 3","metadata":null},{"id":"717517db450d45d7bf5ff81f71ac4b15","type":"GENE","name":"NAIPP4","canonical_id":"hgnc:HGNC:54494","description":"NAIP pseudogene 4","metadata":null},{"id":"841ca9ac95ea4fd082e812a9299139be","type":"GENE","name":"NALCN","canonical_id":"hgnc:HGNC:19082","description":"sodium leak channel, non-selective","metadata":{"aliases":["bA430M15.1","CanIon","VGCNL1"]}},{"id":"4b0bb7a1512a433a989b9237d863e20c","type":"GENE","name":"NALCN-AS1","canonical_id":"hgnc:HGNC:42743","description":"NALCN antisense RNA 1","metadata":null},{"id":"4bf2c5e8f3d545eaa7530cb769a31fae","type":"GENE","name":"NALF1","canonical_id":"hgnc:HGNC:33877","description":"NALCN channel auxiliary factor 1","metadata":{"aliases":["NLF-1","FAM155A"]}},{"id":"ada0f420ffbc4aecb683e043cdfb0f97","type":"GENE","name":"NALF1-IT1","canonical_id":"hgnc:HGNC:41503","description":"NALF1 intronic transcript 1","metadata":{"aliases":["FAM155A-IT1"]}},{"id":"07bab352d1644a269129c9ae7cf4dbb4","type":"GENE","name":"NALF2","canonical_id":"hgnc:HGNC:30701","description":"NALCN channel auxiliary factor 2","metadata":{"aliases":["TED","TMEM28","CXorf63","FAM155B"]}},{"id":"983c78afe242416c9cd420a9735ef0aa","type":"GENE","name":"NALT1","canonical_id":"hgnc:HGNC:51192","description":"NOTCH1 associated lncRNA in T cell acute lymphoblastic leukemia 1","metadata":{"aliases":["TCONS_l2_00029132","MIR4674HG","LINC01573"]}},{"id":"d7a0bc7258b34363a056ff653f7db5f1","type":"GENE","name":"NAMA","canonical_id":"hgnc:HGNC:42408","description":"non-protein coding RNA, associated with MAP kinase pathway and growth arrest","metadata":{"aliases":["STX17-AS1","STX17-DT"]}},{"id":"2854dbb4e2684c3bbe1c51cd6ab158e4","type":"GENE","name":"NAMPT","canonical_id":"hgnc:HGNC:30092","description":null,"metadata":null},{"id":"c17fce904f2c4716871388f3d8f9f4e9","type":"GENE","name":"NAMPT-AS1","canonical_id":"hgnc:HGNC:56696","description":"NAMPT antisense RNA 1","metadata":{"aliases":["AC007032.1"]}},{"id":"4aa49ce460224cb290e56f609cfa5426","type":"GENE","name":"NAMPTP1","canonical_id":"hgnc:HGNC:17633","description":"nicotinamide phosphoribosyltransferase pseudogene 1","metadata":{"aliases":["bA92J19.4","PBEF2","NAMPTL"]}},{"id":"09f7970e78834efbb46d69dd713f89b2","type":"GENE","name":"NAMPTP2","canonical_id":"hgnc:HGNC:51314","description":"nicotinamide phosphoribosyltransferase pseudogene 2","metadata":null},{"id":"484856eb30b448d6aad3cb9b8e4010d4","type":"GENE","name":"NAMPTP3","canonical_id":"hgnc:HGNC:51313","description":"nicotinamide phosphoribosyltransferase pseudogene 3","metadata":null},{"id":"6606f54164594f2cb20d8aef124b9e95","type":"GENE","name":"NANOG","canonical_id":"hgnc:HGNC:20857","description":null,"metadata":null},{"id":"06c7919508dc41eb905d7a184b6e69ae","type":"GENE","name":"NANOGNB","canonical_id":"hgnc:HGNC:24958","description":"NANOG neighbor homeobox","metadata":null},{"id":"0ed26e4ea18249f1b96593fcf367cc81","type":"GENE","name":"NANOGNBP1","canonical_id":"hgnc:HGNC:42158","description":"NANOGNB pseudogene 1","metadata":null},{"id":"26ef01923d8643fbbafaab9d80bdd46a","type":"GENE","name":"NANOGNBP2","canonical_id":"hgnc:HGNC:42159","description":"NANOGNB pseudogene 2","metadata":null},{"id":"eb76423115d546419f4d22f4589ad587","type":"GENE","name":"NANOGNBP3","canonical_id":"hgnc:HGNC:42160","description":"NANOGNB pseudogene 3","metadata":null},{"id":"6e2f6f563ceb498f9325ac18e7c813b7","type":"GENE","name":"NANOGP1","canonical_id":"hgnc:HGNC:23099","description":"Nanog homeobox pseudogene 1","metadata":{"aliases":["NANOG2"]}},{"id":"c5ecb40472374094a6a322979c6c200f","type":"GENE","name":"NANOGP10","canonical_id":"hgnc:HGNC:23108","description":"Nanog homeobox pseudogene 10","metadata":null},{"id":"053aa1579ce54d2abc51d14a85bfbcd7","type":"GENE","name":"NANOGP11","canonical_id":"hgnc:HGNC:32941","description":"Nanog homeobox pseudogene 11","metadata":null},{"id":"f92efb68bd9746e397188b8dd8165420","type":"GENE","name":"NANOGP2","canonical_id":"hgnc:HGNC:23100","description":"Nanog homeobox pseudogene 2","metadata":{"aliases":["NANOGP4"]}},{"id":"cbcc48324cd149cdb5d3a521d141f087","type":"GENE","name":"NANOGP3","canonical_id":"hgnc:HGNC:23101","description":"Nanog homeobox pseudogene 3","metadata":null},{"id":"c735f29c43c44b7ca0ba84e6498b64b9","type":"GENE","name":"NANOGP4","canonical_id":"hgnc:HGNC:23102","description":"Nanog homeobox pseudogene 4","metadata":{"aliases":["NANOGP2"]}},{"id":"e98771349c354a4f86b57e3cf589aad4","type":"GENE","name":"NANOGP5","canonical_id":"hgnc:HGNC:23103","description":"Nanog homeobox pseudogene 5","metadata":null},{"id":"dd61c081184947f981983890548f924d","type":"GENE","name":"NANOGP6","canonical_id":"hgnc:HGNC:23104","description":"Nanog homeobox pseudogene 6","metadata":null},{"id":"e0c2ec0872c44e6796fa3cde7384a185","type":"GENE","name":"NANOGP7","canonical_id":"hgnc:HGNC:23105","description":"Nanog homeobox pseudogene 7","metadata":{"aliases":["NANOGP3"]}},{"id":"52818bcacf5549ff83b2ce780b44a866","type":"GENE","name":"NANOGP8","canonical_id":"hgnc:HGNC:23106","description":"Nanog homeobox retrogene P8","metadata":null},{"id":"8327e77766c14902a282f9c7aa81b69f","type":"GENE","name":"NANOGP9","canonical_id":"hgnc:HGNC:23107","description":"Nanog homeobox pseudogene 9","metadata":null},{"id":"1b405fa0b2954ca499bbafdb86bc2187","type":"GENE","name":"NANOS1","canonical_id":"hgnc:HGNC:23044","description":"nanos C2HC-type zinc finger 1","metadata":{"aliases":["NOS1"]}},{"id":"0b1a0fc5c4704a049a6551da9c095dd1","type":"GENE","name":"NANOS2","canonical_id":"hgnc:HGNC:23292","description":"nanos C2HC-type zinc finger 2","metadata":{"aliases":["NOS2"]}},{"id":"be868eb8c1324947a81787e6af8f0057","type":"GENE","name":"NANOS3","canonical_id":"hgnc:HGNC:22048","description":"nanos C2HC-type zinc finger 3","metadata":{"aliases":["NANOS1L","NOS3"]}},{"id":"ef409f028f744ea6a9aec41884fd9f7c","type":"GENE","name":"NANP","canonical_id":"hgnc:HGNC:16140","description":"N-acetylneuraminic acid phosphatase","metadata":{"aliases":["dJ694B14.3","MGC26833","C20orf147","HDHD4"]}},{"id":"575e73d6838a4e6fba03dcec685d06d7","type":"GENE","name":"NANPP1","canonical_id":"hgnc:HGNC:58502","description":"NANP pseudogene 1","metadata":null},{"id":"04e39aa735f9445181049af2302956e9","type":"GENE","name":"NANPP2","canonical_id":"hgnc:HGNC:58503","description":"NANP pseudogene 2","metadata":null},{"id":"24540e59510046d88961d5280993f2f5","type":"GENE","name":"NANPP3","canonical_id":"hgnc:HGNC:58504","description":"NANP pseudogene 3","metadata":null},{"id":"f76096d81b9f4230bd5cd8318444c5c1","type":"GENE","name":"NANS","canonical_id":"hgnc:HGNC:19237","description":"N-acetylneuraminate synthase","metadata":{"aliases":["SAS"]}},{"id":"02f021cd6d364072921fe9b011407128","type":"TRIAL","name":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","canonical_id":"clinicaltrials.gov:NCT03107988","description":"Neuroblastoma","metadata":null},{"id":"d3443977f81742319a47cb23179a5f07","type":"TRIAL","name":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","canonical_id":"clinicaltrials.gov:NCT06450041","description":"Neuroblastoma","metadata":null},{"id":"f08c6799019248188c200bb4a52d819e","type":"TRIAL","name":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","canonical_id":"clinicaltrials.gov:NCT07261241","description":"Neuroblastoma","metadata":null},{"id":"64af90d75a9042d6917531f8e52a733d","type":"GENE","name":"NAP1L1","canonical_id":"hgnc:HGNC:7637","description":"nucleosome assembly protein 1 like 1","metadata":{"aliases":["NRP","NAP1","NAP1L","MGC8688","MGC23410"]}},{"id":"18201b542a4b4a5b8e2d62f81ce1b3e6","type":"GENE","name":"NAP1L1P1","canonical_id":"hgnc:HGNC:38004","description":"nucleosome assembly protein 1 like 1 pseudogene 1","metadata":null},{"id":"95c100ed66b0411b8822afa3cc986eb3","type":"GENE","name":"NAP1L1P2","canonical_id":"hgnc:HGNC:38005","description":"nucleosome assembly protein 1 like 1 pseudogene 2","metadata":null},{"id":"548d1225141c4863b526c1023fda9fc5","type":"GENE","name":"NAP1L1P3","canonical_id":"hgnc:HGNC:38007","description":"nucleosome assembly protein 1 like 1 pseudogene 3","metadata":null},{"id":"470cd84c8c544691a74d55a20a8770d2","type":"GENE","name":"NAP1L2","canonical_id":"hgnc:HGNC:7638","description":"nucleosome assembly protein 1 like 2","metadata":{"aliases":["BPX","MGC26243"]}},{"id":"b1a5bec7d398461fa33675f9fc96f4bf","type":"GENE","name":"NAP1L3","canonical_id":"hgnc:HGNC:7639","description":"nucleosome assembly protein 1 like 3","metadata":{"aliases":["MB20","NPL3","MGC26312"]}},{"id":"1c8fd1acc4eb4bcabfd1ec7f24b71b73","type":"GENE","name":"NAP1L4","canonical_id":"hgnc:HGNC:7640","description":"nucleosome assembly protein 1 like 4","metadata":{"aliases":["NAP2"]}},{"id":"17e778268b57412696db044ba72afcac","type":"GENE","name":"NAP1L4P1","canonical_id":"hgnc:HGNC:39740","description":"nucleosome assembly protein 1 like 4 pseudogene 1","metadata":null},{"id":"08bcf2a736ca48b9956b240210aca7f1","type":"GENE","name":"NAP1L4P2","canonical_id":"hgnc:HGNC:39739","description":"nucleosome assembly protein 1 like 4 pseudogene 2","metadata":null},{"id":"dc84fc695710420496289721afa9148a","type":"GENE","name":"NAP1L4P3","canonical_id":"hgnc:HGNC:39738","description":"nucleosome assembly protein 1 like 4 pseudogene 3","metadata":null},{"id":"82768355d80647e3969dfebcebd8ee93","type":"GENE","name":"NAP1L5","canonical_id":"hgnc:HGNC:19968","description":"nucleosome assembly protein 1 like 5","metadata":{"aliases":["DRLM"]}},{"id":"06bd7541c41746dba33d9688ea625a81","type":"GENE","name":"NAP1L5P1","canonical_id":"hgnc:HGNC:56578","description":"NAP1L5 pseudogene 1","metadata":null},{"id":"be208188e38b48aa97b4c00b2c2a53e1","type":"GENE","name":"NAP1L6P","canonical_id":"hgnc:HGNC:31706","description":"nucleosome assembly protein 1 like 6, pseudogene","metadata":{"aliases":["FLJ33596","lncNAP1L6","NAP1L6"]}},{"id":"6073103841104bd8b148907428b38a3b","type":"GENE","name":"NAPA","canonical_id":"hgnc:HGNC:7641","description":"NSF attachment protein alpha","metadata":null},{"id":"ae05138f58c140ee8b800cc304a71ba4","type":"GENE","name":"NAPA-AS1","canonical_id":"hgnc:HGNC:44118","description":"NAPA antisense RNA 1","metadata":null},{"id":"9ee0ae573dfb409da7ecbd87c46e25d4","type":"GENE","name":"NAPB","canonical_id":"hgnc:HGNC:15751","description":"NSF attachment protein beta","metadata":{"aliases":["SNAP-BETA","SNAPB"]}},{"id":"ea0c6f431cd54d3992ac5f2f6a0befd6","type":"GENE","name":"NAPEPLD","canonical_id":"hgnc:HGNC:21683","description":"N-acyl phosphatidylethanolamine phospholipase D","metadata":{"aliases":["FMP30","C7orf18","NAPE-PLD"]}},{"id":"45b6e66bde084e3da0047f24af8aa5ee","type":"GENE","name":"NAPG","canonical_id":"hgnc:HGNC:7642","description":"NSF attachment protein gamma","metadata":null},{"id":"e85601c8110c4a1293b130a654426ca9","type":"GENE","name":"NAPGP1","canonical_id":"hgnc:HGNC:45165","description":"N-ethylmaleimide-sensitive factor attachment protein, gamma pseudogene 1","metadata":null},{"id":"24dac625205742fab7d48015d8a5ce6e","type":"GENE","name":"NAPGP2","canonical_id":"hgnc:HGNC:45166","description":"N-ethylmaleimide-sensitive factor attachment protein, gamma pseudogene 2","metadata":null},{"id":"1b8ffa2a242347b5b3a95aa704b625e1","type":"GENE","name":"NAPRT","canonical_id":"hgnc:HGNC:30450","description":"nicotinate phosphoribosyltransferase","metadata":{"aliases":["PP3856","NAPRT1"]}},{"id":"026156a519d04bb69e1b5341bb65f9c0","type":"GENE","name":"NAPRT-AS1","canonical_id":"hgnc:HGNC:59250","description":"NAPRT antisense RNA 1","metadata":{"aliases":["AC067930.4"]}},{"id":"75d11f1e6d59409a8002d893299e13dc","type":"GENE","name":"NAPSA","canonical_id":"hgnc:HGNC:13395","description":"napsin A aspartic peptidase","metadata":{"aliases":["NAP1","NAPA","Kdap","KAP","NR1H2-AS1"]}},{"id":"44e3b81e783f4136b9e77aefc8ef1a78","type":"GENE","name":"NAPSB","canonical_id":"hgnc:HGNC:13396","description":"napsin B aspartic peptidase (pseudogene)","metadata":{"aliases":["NAP1L","NAP2","NAPB","NAPSBP"]}},{"id":"05609842692b42bfb3ff65d93856a932","type":"GENE","name":"NARF","canonical_id":"hgnc:HGNC:29916","description":"nuclear prelamin A recognition factor","metadata":{"aliases":["FLJ10067","DKFZp434G0420","IOP2"]}},{"id":"3ecebf0cacb14a83accd9d3a2eea9b4d","type":"GENE","name":"NARF-AS1","canonical_id":"hgnc:HGNC:53622","description":"NARF antisense RNA 1","metadata":{"aliases":["ENST00000582249.1"]}},{"id":"cee594167415436fbc9305667691413c","type":"GENE","name":"NARF-AS2","canonical_id":"hgnc:HGNC:55327","description":"NARF antisense RNA 2","metadata":null},{"id":"ca79a0dd2b7a4b7a8045da367e9e26ca","type":"GENE","name":"NARF-IT1","canonical_id":"hgnc:HGNC:43651","description":"NARF intronic transcript 1","metadata":{"aliases":["NARF-OT1"]}},{"id":"6447922641934082a46773c8f4e15354","type":"GENE","name":"NARS1","canonical_id":"hgnc:HGNC:7643","description":"asparaginyl-tRNA synthetase 1","metadata":{"aliases":["AsnRS","NARS"]}},{"id":"de63d10150ea43d7a5a5f4ec94d278ee","type":"GENE","name":"NARS1P1","canonical_id":"hgnc:HGNC:19933","description":"asparaginyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["NARSP","NARSP1"]}},{"id":"813776a4b36d4bcabe9929f4e7e831b0","type":"GENE","name":"NARS1P2","canonical_id":"hgnc:HGNC:50481","description":"asparaginyl-tRNA synthetase 1 pseudogene 2","metadata":{"aliases":["NARSP2"]}},{"id":"dfc76776981b4262893996e583a9c07f","type":"GENE","name":"NARS2","canonical_id":"hgnc:HGNC:26274","description":"asparaginyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["FLJ23441","SLM5","DFNB94"]}},{"id":"b4b37bf5a1fd4b4f9c5a8eca52d1efd5","type":"GENE","name":"NARS2-AS1","canonical_id":"hgnc:HGNC:58264","description":"NARS2 antisense RNA 1","metadata":null},{"id":"8e7c4223dde24aebb865811bca88bcdd","type":"TRIAL","name":"NAS Treatment - Opiate Versus Non-Opiate","canonical_id":"clinicaltrials.gov:NCT01734551","description":"Neonatal Abstinence Syndrome","metadata":null},{"id":"fa87c4b8c1d1424ebbb3450cbe40ebbb","type":"GENE","name":"NASP","canonical_id":"hgnc:HGNC:7644","description":"nuclear autoantigenic sperm protein","metadata":{"aliases":["FLB7527","FLJ31599","FLJ35510","MGC19722","MGC20372","MGC2297","DKFZp547F162","PRO1999"]}},{"id":"ddc2eb031cbd40e595a54ed9726cefc0","type":"GENE","name":"NASPP1","canonical_id":"hgnc:HGNC:29910","description":"nuclear autoantigenic sperm protein pseudogene 1","metadata":null},{"id":"e2b4094df93440b9844b0d0c85bcc79a","type":"GENE","name":"NAT1","canonical_id":"hgnc:HGNC:7645","description":null,"metadata":null},{"id":"4687c21c15a3413c9eee0cd83d354e89","type":"GENE","name":"NAT10","canonical_id":"hgnc:HGNC:29830","description":"N-acetyltransferase 10","metadata":{"aliases":["hALP","FLJ10774","FLJ12179","NET43","KIAA1709","Kre33"]}},{"id":"c75090f605fe4d1d9d76477865ab8e60","type":"GENE","name":"NAT14","canonical_id":"hgnc:HGNC:28918","description":"N-acetyltransferase 14 (putative)","metadata":{"aliases":["KLP1"]}},{"id":"70bbf474f9f24178bf2b1a21c4d51736","type":"GENE","name":"NAT16","canonical_id":"hgnc:HGNC:22030","description":"N-acetyltransferase 16 (putative)","metadata":{"aliases":["FLJ39237","C7orf52"]}},{"id":"d3bfc5ccd5a64e688a6cb3692a6ddaea","type":"GENE","name":"NAT2","canonical_id":"hgnc:HGNC:7646","description":"N-acetyltransferase 2","metadata":{"aliases":["AAC2"]}},{"id":"6889dd7407874c1988d476473dbc8380","type":"GENE","name":"NAT8","canonical_id":"hgnc:HGNC:18069","description":"N-acetyltransferase 8 (putative)","metadata":{"aliases":["Hcml1","TSC501","ATase2"]}},{"id":"72c270d18e174380aaab4686319fe25d","type":"GENE","name":"NAT8B","canonical_id":"hgnc:HGNC:30235","description":"N-acetyltransferase 8B (putative, gene/pseudogene)","metadata":{"aliases":["Hcml2","NAT8BP","CML2"]}},{"id":"c9a9b88972904e80938db9d1c1cf38f5","type":"GENE","name":"NAT9","canonical_id":"hgnc:HGNC:23133","description":"N-acetyltransferase 9","metadata":{"aliases":["DKFZP564C103"]}},{"id":"fb45275a38c24efc84ed391b85533ef1","type":"GENE","name":"NATD1","canonical_id":"hgnc:HGNC:30770","description":"N-acetyltransferase domain containing 1","metadata":{"aliases":["MGC33894","Gtlf3b","C17orf103"]}},{"id":"e082c55f4a154ef78bb5d78ca2490e9a","type":"GENE","name":"NATP","canonical_id":"hgnc:HGNC:15","description":"N-acetyltransferase pseudogene","metadata":{"aliases":["NATP1","AACP"]}},{"id":"8b8702f109094f42af69bb40f385a45d","type":"TRIAL","name":"NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)","canonical_id":"clinicaltrials.gov:NCT05340621","description":"RAS Mutation; NRAS Gene Mutation; Melanoma","metadata":null},{"id":"e605936e588647348ac94a5d9686f6fa","type":"GENE","name":"NAV1","canonical_id":"hgnc:HGNC:15989","description":"neuron navigator 1","metadata":{"aliases":["FLJ12560","FLJ14203","KIAA1151","MGC14961","POMFIL3","steerin-1","DKFZp781D0314"]}},{"id":"37340d0aeb8249d7a8e232f5eb974b09","type":"GENE","name":"NAV2","canonical_id":"hgnc:HGNC:15997","description":"neuron navigator 2","metadata":{"aliases":["FLJ10633","FLJ11030","HELAD1","KIAA1419","POMFIL2","RAINB1","FLJ23707"]}},{"id":"69f797a22f544e2aa0d83e63c7f9d846","type":"GENE","name":"NAV2-AS1","canonical_id":"hgnc:HGNC:40744","description":"NAV2 antisense RNA 1","metadata":null},{"id":"fbbefb31c7664581a7fb03281b0d001f","type":"GENE","name":"NAV2-AS2","canonical_id":"hgnc:HGNC:40743","description":"NAV2 antisense RNA 2","metadata":null},{"id":"c440ce1a6d6146af9619e2d2e3085d31","type":"GENE","name":"NAV2-AS3","canonical_id":"hgnc:HGNC:40742","description":"NAV2 antisense RNA 3","metadata":null},{"id":"239806bcdc964592be9b30a1c0896b54","type":"GENE","name":"NAV2-AS4","canonical_id":"hgnc:HGNC:40741","description":"NAV2 antisense RNA 4","metadata":null},{"id":"62689489190849deb5cad38708913ba3","type":"GENE","name":"NAV2-AS5","canonical_id":"hgnc:HGNC:40740","description":"NAV2 antisense RNA 5","metadata":null},{"id":"72590f29e86f43bd9d0ad023b09b785d","type":"GENE","name":"NAV2-IT1","canonical_id":"hgnc:HGNC:41416","description":"NAV2 intronic transcript 1","metadata":null},{"id":"9b5e64903e1c40feab6d10303b13b302","type":"GENE","name":"NAV3","canonical_id":"hgnc:HGNC:15998","description":"neuron navigator 3","metadata":{"aliases":["KIAA0938","POMFIL1"]}},{"id":"3b75bd415e7043b68848a70491a4f95c","type":"GENE","name":"NAV3-AS1","canonical_id":"hgnc:HGNC:58287","description":"NAV3 antisense RNA 1","metadata":null},{"id":"10f3afdb4bc84e15b54d3535c0ba597a","type":"GENE","name":"NAXD","canonical_id":"hgnc:HGNC:25576","description":"NAD(P)HX dehydratase","metadata":{"aliases":["LP3298","FLJ10769","CARKD"]}},{"id":"13532d387e984d898b5468ed142c2e4b","type":"GENE","name":"NAXD-AS1","canonical_id":"hgnc:HGNC:56341","description":"NAXD antisense RNA 1","metadata":{"aliases":["AL139385.1"]}},{"id":"6a00b5e106a34c5aaa09d63db07034fb","type":"GENE","name":"NAXE","canonical_id":"hgnc:HGNC:18453","description":"NAD(P)HX epimerase","metadata":{"aliases":["AIBP","MGC119143","MGC119144","MGC119145","YJEFN1","APOA1BP"]}},{"id":"55ea01a7ec1c4829b52d10d25c7a598b","type":"GENE","name":"NAXEP1","canonical_id":"hgnc:HGNC:58582","description":"NAXE pseudogene 1","metadata":null},{"id":"5e0d8994e7f84c8a8c1684e648c6be5b","type":"GENE","name":"NAXEP2","canonical_id":"hgnc:HGNC:58583","description":"NAXE pseudogene 2","metadata":null},{"id":"a684983b12b547e3a71d28933b24578f","type":"TRIAL","name":"NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions","canonical_id":"clinicaltrials.gov:NCT05540288","description":"Behavioural Addiction","metadata":null},{"id":"4432f91d8a704f4e870bdd35ad322204","type":"GENE","name":"NBAS","canonical_id":"hgnc:HGNC:15625","description":"NBAS subunit of NRZ tethering complex","metadata":{"aliases":["NAG"]}},{"id":"139829a5b7c14fa297d5f6c80fab414c","type":"GENE","name":"NBAT1","canonical_id":"hgnc:HGNC:49075","description":"neuroblastoma associated transcript 1","metadata":{"aliases":["NBAT-1","CASC14"]}},{"id":"c557985d49ee4baab4ff11782e6fd0a1","type":"GENE","name":"NBDY","canonical_id":"hgnc:HGNC:50713","description":"negative regulator of P-body association","metadata":{"aliases":["NoBody","LINC01420"]}},{"id":"da0589611b584e63867ff5c48fea27e8","type":"GENE","name":"NBEA","canonical_id":"hgnc:HGNC:7648","description":"neurobeachin","metadata":{"aliases":["KIAA1544","BCL8B","FLJ10197","LYST2"]}},{"id":"a8ee73b376984fd9bad08d5f21e4ef3b","type":"GENE","name":"NBEAL1","canonical_id":"hgnc:HGNC:20681","description":"neurobeachin like 1","metadata":{"aliases":["MGC164581","ALS2CR17","ALS2CR16"]}},{"id":"5158263394c1421392aede89d1a55518","type":"GENE","name":"NBEAL2","canonical_id":"hgnc:HGNC:31928","description":"neurobeachin like 2","metadata":{"aliases":["KIAA0540"]}},{"id":"beb32587f7094bdf9f238fc0bd8771a8","type":"GENE","name":"NBEAP1","canonical_id":"hgnc:HGNC:1007","description":"neurobeachin pseudogene 1","metadata":{"aliases":["BCL8A","BCL8"]}},{"id":"9ed732ea0ced41189c26751d9c7f4869","type":"GENE","name":"NBEAP2","canonical_id":"hgnc:HGNC:40003","description":"neurobeachin pseudogene 2","metadata":{"aliases":["BCL8D"]}},{"id":"ee4d4ef2b64f404aa2cad9b7dc304555","type":"GENE","name":"NBEAP3","canonical_id":"hgnc:HGNC:40004","description":"neurobeachin pseudogene 3","metadata":{"aliases":["BCL8C"]}},{"id":"377dd743c9f54256a4301671c2d94caf","type":"GENE","name":"NBEAP4","canonical_id":"hgnc:HGNC:40009","description":"neurobeachin pseudogene 4","metadata":null},{"id":"217297ebddbb4aae8799d4b83b43aaeb","type":"GENE","name":"NBEAP5","canonical_id":"hgnc:HGNC:40010","description":"neurobeachin pseudogene 5","metadata":null},{"id":"65dbab06a2ed49f0aca60cc6ece70e8f","type":"GENE","name":"NBEAP6","canonical_id":"hgnc:HGNC:40011","description":"neurobeachin pseudogene 6","metadata":null},{"id":"002ee966d746476ab92bc778dc87a271","type":"GENE","name":"NBL1","canonical_id":"hgnc:HGNC:7650","description":"NBL1, DAN family BMP antagonist","metadata":{"aliases":["D1S1733E","NB","DAN","NO3","DAND1"]}},{"id":"185468a997b844a3b435464f367e8acc","type":"GENE","name":"NBN","canonical_id":"hgnc:HGNC:7652","description":null,"metadata":null},{"id":"9e5f3c395c424f4f846d074b7e962806","type":"GENE","name":"NBPF1","canonical_id":"hgnc:HGNC:26088","description":"NBPF member 1","metadata":{"aliases":["FLJ20719","KIAA1693"]}},{"id":"b747f110effb43148ded585064e733d9","type":"GENE","name":"NBPF10","canonical_id":"hgnc:HGNC:31992","description":"NBPF member 10","metadata":{"aliases":["AG1"]}},{"id":"1f127a0ff7304773be17ce455fead80f","type":"GENE","name":"NBPF11","canonical_id":"hgnc:HGNC:31993","description":"NBPF member 11","metadata":{"aliases":["NBPF24"]}},{"id":"82cd70a43fe6471ca2e8539a0a1ad806","type":"GENE","name":"NBPF12","canonical_id":"hgnc:HGNC:24297","description":"NBPF member 12","metadata":{"aliases":["COAS1","KIAA1245"]}},{"id":"964f9906cbf3484b8e39811ea7be5af5","type":"GENE","name":"NBPF13P","canonical_id":"hgnc:HGNC:31995","description":"NBPF member 13, pseudogene","metadata":null},{"id":"34a7a0fcfe93484da7ca8b97a40e19e9","type":"GENE","name":"NBPF14","canonical_id":"hgnc:HGNC:25232","description":"NBPF member 14","metadata":{"aliases":["DJ328E19.C1.1"]}},{"id":"052ee230a29646d5a1cefd0fb666277a","type":"GENE","name":"NBPF15","canonical_id":"hgnc:HGNC:28791","description":"NBPF member 15","metadata":{"aliases":["MGC8902","NBPF16"]}},{"id":"9347711bb5434df1abd7840983bb7751","type":"GENE","name":"NBPF17P","canonical_id":"hgnc:HGNC:31997","description":"NBPF member 17, pseudogene","metadata":{"aliases":["NBPF23P","NBPF23"]}},{"id":"8066cab8a01f479a9eb78f381ddc72ff","type":"GENE","name":"NBPF18P","canonical_id":"hgnc:HGNC:31998","description":"NBPF member 18, pseudogene","metadata":null},{"id":"4d8682a1a62b456698ba86eb0df2c3a5","type":"GENE","name":"NBPF19","canonical_id":"hgnc:HGNC:31999","description":"NBPF member 19","metadata":null},{"id":"f7d696b8ab134329b02a0cc513c93d94","type":"GENE","name":"NBPF20","canonical_id":"hgnc:HGNC:32000","description":"NBPF member 20","metadata":null},{"id":"87c6df95607941f6ac77609e441bcf43","type":"GENE","name":"NBPF21P","canonical_id":"hgnc:HGNC:32001","description":"NBPF member 21, pseudogene","metadata":null},{"id":"831c6bb906834c6dabf3ce3367d8d1d1","type":"GENE","name":"NBPF22P","canonical_id":"hgnc:HGNC:28731","description":"NBPF member 22, pseudogene","metadata":{"aliases":["MGC48637"]}},{"id":"ae8ac31b335140659d1bd5df5157fdfd","type":"GENE","name":"NBPF25P","canonical_id":"hgnc:HGNC:45046","description":"NBPF member 25, pseudogene","metadata":null},{"id":"315dd024a360440199fa6d7ca4f2e72d","type":"GENE","name":"NBPF26","canonical_id":"hgnc:HGNC:49571","description":"NBPF member 26","metadata":null},{"id":"69c6e4bdc1f048cd82e3e703fe8c7aa5","type":"GENE","name":"NBPF2P","canonical_id":"hgnc:HGNC:31987","description":"NBPF member 2, pseudogene","metadata":null},{"id":"7f4b2acf7cb64cda8e4dd43eb88ebcf3","type":"GENE","name":"NBPF3","canonical_id":"hgnc:HGNC:25076","description":"NBPF member 3","metadata":{"aliases":["AE2"]}},{"id":"2aba02f7f6b54ab4ac531a8fb098d7bf","type":"GENE","name":"NBPF4","canonical_id":"hgnc:HGNC:26550","description":"NBPF member 4","metadata":{"aliases":["FLJ32833"]}},{"id":"a83ff03fbee04e5cb8549f2ceaafdfe7","type":"GENE","name":"NBPF5P","canonical_id":"hgnc:HGNC:24491","description":"NBPF member 5, pseudogene","metadata":{"aliases":["NBPF5"]}},{"id":"7e0e0415907a46a58d308b94c99fd55c","type":"GENE","name":"NBPF6","canonical_id":"hgnc:HGNC:31988","description":"NBPF member 6","metadata":null},{"id":"fbbbfc40f78d4ea58416f31f995bbf66","type":"GENE","name":"NBPF7P","canonical_id":"hgnc:HGNC:31989","description":"NBPF member 7, pseudogene","metadata":{"aliases":["NBPF7"]}},{"id":"4e85286eabab4b90a5567dc4cc6df04b","type":"GENE","name":"NBPF8","canonical_id":"hgnc:HGNC:31990","description":"NBPF member 8","metadata":{"aliases":["NBPF8P"]}},{"id":"4120b8ecc5df47a88aeda0b91132977d","type":"GENE","name":"NBPF9","canonical_id":"hgnc:HGNC:31991","description":"NBPF member 9","metadata":{"aliases":["AE01"]}},{"id":"f64eaf5bd5d64d14b9e328f4b9a3ccba","type":"GENE","name":"NBR1","canonical_id":"hgnc:HGNC:6746","description":"NBR1 autophagy cargo receptor","metadata":{"aliases":["CA125","KIAA0049","1A1-3B","M17S2"]}},{"id":"5f03c74876b94b15a8f6cdf550d48a52","type":"GENE","name":"NBR2","canonical_id":"hgnc:HGNC:20691","description":"neighbor of BRCA1 lncRNA 2","metadata":{"aliases":["NCRNA00192"]}},{"id":"9eac0a7d7db84dce814d512a862b42fd","type":"GENE","name":"NCAL1","canonical_id":"hgnc:HGNC:56663","description":"NK cell activity associated lncRNA 1","metadata":null},{"id":"13c10e05fa954d998ccb9454b4b6b677","type":"GENE","name":"NCALD","canonical_id":"hgnc:HGNC:7655","description":"neurocalcin delta","metadata":null},{"id":"795bbe93ad5048af8e896cbd6eef6af1","type":"GENE","name":"NCAM1","canonical_id":"hgnc:HGNC:7656","description":null,"metadata":null},{"id":"d386fccad7a14f1b9f6904af582696bc","type":"GENE","name":"NCAM1-AS1","canonical_id":"hgnc:HGNC:48675","description":"NCAM1 antisense RNA 1","metadata":null},{"id":"a186bdd5610142fda261b0961119e78e","type":"GENE","name":"NCAM1-AS2","canonical_id":"hgnc:HGNC:58155","description":"NCAM1 antisense RNA 2","metadata":{"aliases":["RP11-629G13.1"]}},{"id":"243e5fc84b454dbc85bd47cd8fa22b22","type":"GENE","name":"NCAM2","canonical_id":"hgnc:HGNC:7657","description":"neural cell adhesion molecule 2","metadata":{"aliases":["NCAM21","MGC51008"]}},{"id":"c53caba557dd42019ee601c0de31d171","type":"GENE","name":"NCAN","canonical_id":"hgnc:HGNC:2465","description":"neurocan","metadata":{"aliases":["CSPG3"]}},{"id":"33fd446981044b4985bc679689985fbb","type":"GENE","name":"NCAPD2","canonical_id":"hgnc:HGNC:24305","description":"non-SMC condensin I complex subunit D2","metadata":{"aliases":["CNAP1","hCAP-D2","CAP-D2","KIAA0159"]}},{"id":"cf08d691a419495b993a4cc7c72c8930","type":"GENE","name":"NCAPD2P1","canonical_id":"hgnc:HGNC:43831","description":"non-SMC condensin I complex subunit D2 pseudogene 1","metadata":null},{"id":"aa34b5784ed840fcb0c4257d9593b997","type":"GENE","name":"NCAPD3","canonical_id":"hgnc:HGNC:28952","description":"non-SMC condensin II complex subunit D3","metadata":{"aliases":["hCAP-D3","CAP-D3","hHCP-6","KIAA0056","FLJ42888","hcp-6"]}},{"id":"34602873dc4141cf83d519660f1786df","type":"GENE","name":"NCAPG","canonical_id":"hgnc:HGNC:24304","description":"non-SMC condensin I complex subunit G","metadata":{"aliases":["FLJ12450","hCAP-G","CAP-G","YCG1"]}},{"id":"8f358d9b8a0549e8ba285c08d9c9c72f","type":"GENE","name":"NCAPG2","canonical_id":"hgnc:HGNC:21904","description":"non-SMC condensin II complex subunit G2","metadata":{"aliases":["FLJ20311","MTB","CAP-G2","hCAP-G2","LUZP5"]}},{"id":"e33d080e51da418b92d17e23238b56b2","type":"GENE","name":"NCAPGP1","canonical_id":"hgnc:HGNC:51904","description":"non-SMC condensin I complex subunit G pseudogene 1","metadata":null},{"id":"a08934f2e54b4341a8dbf846d77bc186","type":"GENE","name":"NCAPGP2","canonical_id":"hgnc:HGNC:51905","description":"non-SMC condensin I complex subunit G pseudogene 2","metadata":null},{"id":"e7a8335558654151b0fc3418e4799b0d","type":"GENE","name":"NCAPH","canonical_id":"hgnc:HGNC:1112","description":"non-SMC condensin I complex subunit H","metadata":{"aliases":["CAP-H","hCAP-H","NCAPH1","BRRN1"]}},{"id":"7b2038edaabf4d44ba1ec586ce1accdc","type":"GENE","name":"NCAPH2","canonical_id":"hgnc:HGNC:25071","description":"non-SMC condensin II complex subunit H2","metadata":{"aliases":["384D8-2","hCAP-H2","CAP-H2"]}},{"id":"98d7d79bdcfc413aa00c98f41c55c17a","type":"GENE","name":"NCBP1","canonical_id":"hgnc:HGNC:7658","description":null,"metadata":null},{"id":"f6c73152c7f24c6d8fe4805d5d4e5623","type":"GENE","name":"NCBP2","canonical_id":"hgnc:HGNC:7659","description":"nuclear cap binding protein subunit 2","metadata":{"aliases":["NIP1","CBP20","Cbc2"]}},{"id":"cb7fab49d44a4859a92516781edb5570","type":"GENE","name":"NCBP2-AS1","canonical_id":"hgnc:HGNC:40392","description":"NCBP2 antisense RNA 1","metadata":null},{"id":"9770de43837d428bb489d2df8502d0a5","type":"GENE","name":"NCBP2AS2","canonical_id":"hgnc:HGNC:25121","description":"NCBP2 antisense 2 (head to head)","metadata":{"aliases":["HIAR","KRASIM","NCBP2-AS2"]}},{"id":"886fe876fe464d89a0da459dc4f46dcb","type":"GENE","name":"NCBP2L","canonical_id":"hgnc:HGNC:31795","description":"nuclear cap binding protein subunit 2 like","metadata":null},{"id":"74e508ca970c4a6eb1fa1304f5aa40f2","type":"GENE","name":"NCBP3","canonical_id":"hgnc:HGNC:24612","description":"nuclear cap binding subunit 3","metadata":{"aliases":["HSA277841","ELG","C17orf85"]}},{"id":"5a44ea188d2c40e1bf97d86086d2b1f7","type":"GENE","name":"NCCRP1","canonical_id":"hgnc:HGNC:33739","description":"NCCRP1, F-box associated domain containing","metadata":{"aliases":["LOC342897","NCCRP-1","FBXO50"]}},{"id":"0d3838278b9e4048839a18264db914cb","type":"GENE","name":"NCDN","canonical_id":"hgnc:HGNC:17597","description":"neurochondrin","metadata":{"aliases":["NCDN-1","NCDN-2"]}},{"id":"46a5c0de8fa94d678015e9eb51c0ea6c","type":"GENE","name":"NCEH1","canonical_id":"hgnc:HGNC:29260","description":"neutral cholesterol ester hydrolase 1","metadata":{"aliases":["KIAA1363","NCEH","AADACL1"]}},{"id":"df389ab39e5c4e789b9b3d7502d67031","type":"GENE","name":"NCF1","canonical_id":"hgnc:HGNC:7660","description":null,"metadata":null},{"id":"1a149d6a3d1e4bbdada8ce34e70685fd","type":"GENE","name":"NCF1B","canonical_id":"hgnc:HGNC:32522","description":"neutrophil cytosolic factor 1B (pseudogene)","metadata":{"aliases":["SH3PXD1B"]}},{"id":"63ef422e6b7d4facb4e8816a89a25743","type":"GENE","name":"NCF1C","canonical_id":"hgnc:HGNC:32523","description":"neutrophil cytosolic factor 1C (pseudogene)","metadata":{"aliases":["SH3PXD1C"]}},{"id":"1245420bec504a959a50d15ffed32cb2","type":"GENE","name":"NCF2","canonical_id":"hgnc:HGNC:7661","description":null,"metadata":null},{"id":"aa0a13cd4d3b4e70be813dabb1d3fec1","type":"GENE","name":"NCF4","canonical_id":"hgnc:HGNC:7662","description":"neutrophil cytosolic factor 4","metadata":{"aliases":["p40phox","SH3PXD4"]}},{"id":"563051b71a984314af428c39eb068d49","type":"GENE","name":"NCF4-AS1","canonical_id":"hgnc:HGNC:40393","description":"NCF4 antisense RNA 1","metadata":{"aliases":["CTA-833B7.2"]}},{"id":"ecedbaacc60844a6ba3be422390ad026","type":"GENE","name":"NCK1","canonical_id":"hgnc:HGNC:7664","description":"NCK adaptor protein 1","metadata":{"aliases":["NCKalpha","NCK"]}},{"id":"99de87a6835c4ae4a2955ad5ed7e3d00","type":"GENE","name":"NCK1-DT","canonical_id":"hgnc:HGNC:49645","description":"NCK1 divergent transcript","metadata":{"aliases":["SLC35G2-AS1","NCK1-AS1"]}},{"id":"0a75226843324ba5a5202e49b35c26d1","type":"GENE","name":"NCK2","canonical_id":"hgnc:HGNC:7665","description":"NCK adaptor protein 2","metadata":{"aliases":["NCKbeta"]}},{"id":"e4cffbec74344dbf8ca06739afdb4085","type":"GENE","name":"NCK2-AS1","canonical_id":"hgnc:HGNC:40394","description":"NCK2 antisense RNA 1","metadata":null},{"id":"7edb0ab7eeed4b7580cd5c0a34b74d4d","type":"GENE","name":"NCKAP1","canonical_id":"hgnc:HGNC:7666","description":"NCK associated protein 1","metadata":{"aliases":["Nap1","HEM2","NAP125"]}},{"id":"19258dfb594e4dd6bffafb85eb31d968","type":"GENE","name":"NCKAP1L","canonical_id":"hgnc:HGNC:4862","description":"NCK associated protein 1 like","metadata":{"aliases":["HEM1"]}},{"id":"15ebbd169b1a4ef1bce866f8bce3578e","type":"GENE","name":"NCKAP1P1","canonical_id":"hgnc:HGNC:55028","description":"NCKAP1 pseudogene 1","metadata":null},{"id":"4c3abc36011c4d3ea5249969cb27de1f","type":"GENE","name":"NCKAP5","canonical_id":"hgnc:HGNC:29847","description":"NCK associated protein 5","metadata":{"aliases":["NAP5","ERIH1","ERIH2"]}},{"id":"ef94a05e7a714b56abd1b49ee6c2335d","type":"GENE","name":"NCKAP5-AS1","canonical_id":"hgnc:HGNC:41246","description":"NCKAP5 antisense RNA 1","metadata":null},{"id":"134046c4da8544eb912de058f0ed1f3b","type":"GENE","name":"NCKAP5-AS2","canonical_id":"hgnc:HGNC:54065","description":"NCKAP5 antisense RNA 2","metadata":null},{"id":"794a3323390f491e978f1a3f204b706e","type":"GENE","name":"NCKAP5-IT1","canonical_id":"hgnc:HGNC:41497","description":"NCKAP5 intronic transcript 1","metadata":null},{"id":"1468476c766e470e98fea35e0d391d24","type":"GENE","name":"NCKAP5L","canonical_id":"hgnc:HGNC:29321","description":"NCK associated protein 5 like","metadata":{"aliases":["KIAA1602"]}},{"id":"105071a027c04495bc72c8cb4b7bd18c","type":"GENE","name":"NCKIPSD","canonical_id":"hgnc:HGNC:15486","description":"NCK interacting protein with SH3 domain","metadata":{"aliases":["AF3P21","SPIN90","ORF1","WISH","WASLBP","DIP1"]}},{"id":"3cad77912eef4d1581c5d0ff149c770c","type":"GENE","name":"NCL","canonical_id":"hgnc:HGNC:7667","description":null,"metadata":null},{"id":"ecab5edea4104a43aed300bf5ed3b8c3","type":"GENE","name":"NCLN","canonical_id":"hgnc:HGNC:26923","description":"nicalin","metadata":{"aliases":["NICALIN","NET59"]}},{"id":"cd009acfad6b4f51824c46386c44f6d2","type":"GENE","name":"NCMAP","canonical_id":"hgnc:HGNC:29332","description":"non-compact myelin associated protein","metadata":{"aliases":["FLJ42528","MP11","C1orf130"]}},{"id":"7e3b4638be7642db89d8d8b8fa25ca3f","type":"GENE","name":"NCOA1","canonical_id":"hgnc:HGNC:7668","description":null,"metadata":null},{"id":"4c3d3d1e84ed4279a440940e675a9368","type":"GENE","name":"NCOA2","canonical_id":"hgnc:HGNC:7669","description":null,"metadata":null},{"id":"28ff2406046241659d3c505e924200d9","type":"GENE","name":"NCOA3","canonical_id":"hgnc:HGNC:7670","description":null,"metadata":null},{"id":"9e3cebe923924a6c885a36ff104657e2","type":"GENE","name":"NCOA4","canonical_id":"hgnc:HGNC:7671","description":null,"metadata":null},{"id":"ba2d1839e856447c99d47c732d99f482","type":"GENE","name":"NCOA4P1","canonical_id":"hgnc:HGNC:20022","description":"nuclear receptor coactivator 4 pseudogene 1","metadata":{"aliases":["NCOA4P"]}},{"id":"6e0b892cc26f47099aeefa36a1ecf3cc","type":"GENE","name":"NCOA4P2","canonical_id":"hgnc:HGNC:52403","description":"nuclear receptor coactivator 4 pseudogene 2","metadata":null},{"id":"ac626a565e044516bd6cc01cc02037b9","type":"GENE","name":"NCOA4P3","canonical_id":"hgnc:HGNC:52404","description":"nuclear receptor coactivator 4 pseudogene 3","metadata":null},{"id":"c1a4b43b5cb74422817bd8686c23931b","type":"GENE","name":"NCOA4P4","canonical_id":"hgnc:HGNC:52405","description":"nuclear receptor coactivator 4 pseudogene 4","metadata":null},{"id":"0a099bb144254ad69e478b1a967a665b","type":"GENE","name":"NCOA5","canonical_id":"hgnc:HGNC:15909","description":"nuclear receptor coactivator 5","metadata":{"aliases":["bA465L10.6","CIA"]}},{"id":"46edd5a120d446efa22a0e96ceb5519e","type":"GENE","name":"NCOA5LP","canonical_id":"hgnc:HGNC:55095","description":"nuclear receptor coactivator 5 like, pseudogene","metadata":null},{"id":"f08278f325b6486e908e3cc1aa40fce1","type":"GENE","name":"NCOA6","canonical_id":"hgnc:HGNC:15936","description":null,"metadata":null},{"id":"4549cf8f0d384597b76d74d4ce7f6f4e","type":"GENE","name":"NCOA7","canonical_id":"hgnc:HGNC:21081","description":"nuclear receptor coactivator 7","metadata":{"aliases":["ERAP140","dJ187J11.3","TLDC4"]}},{"id":"967dc724bedd45f9a6f9218922f3313b","type":"GENE","name":"NCOA7-AS1","canonical_id":"hgnc:HGNC:40954","description":"NCOA7 antisense RNA 1","metadata":null},{"id":"d5ddbf1ab4754ce694ceedfb0643c856","type":"GENE","name":"NCOR1","canonical_id":"hgnc:HGNC:7672","description":null,"metadata":null},{"id":"3378d158a9b64ba4b53315b259986c26","type":"GENE","name":"NCOR1P1","canonical_id":"hgnc:HGNC:16724","description":"NCOR1 pseudogene 1","metadata":{"aliases":["bB329D4.2","C20orf191"]}},{"id":"68922df17b3c487b98d19f69d52831d6","type":"GENE","name":"NCOR1P2","canonical_id":"hgnc:HGNC:42997","description":"NCOR1 pseudogene 2","metadata":null},{"id":"c98d44b3fc0a42b4ba3afc83be8d59be","type":"GENE","name":"NCOR1P3","canonical_id":"hgnc:HGNC:42996","description":"NCOR1 pseudogene 3","metadata":null},{"id":"a9088e96f31f49c5bcf65828f3d30c9c","type":"GENE","name":"NCOR1P4","canonical_id":"hgnc:HGNC:54557","description":"NCOR1 pseudogene 4","metadata":null},{"id":"41f490514d554ae8893bb1e08fc50d4a","type":"GENE","name":"NCOR2","canonical_id":"hgnc:HGNC:7673","description":null,"metadata":null},{"id":"43e2cb046b994bb1926687a2d39db51c","type":"GENE","name":"NCOR2-AS1","canonical_id":"hgnc:HGNC:58613","description":"NCOR2 antisense RNA 1","metadata":null},{"id":"e03eddd00dd14c62a0416eb3d6ca229f","type":"GENE","name":"NCR1","canonical_id":"hgnc:HGNC:6731","description":"natural cytotoxicity triggering receptor 1","metadata":{"aliases":["NK-p46","NKP46","CD335","LY94"]}},{"id":"e28e4a052a9d47348f3dbde8380ee9d6","type":"GENE","name":"NCR2","canonical_id":"hgnc:HGNC:6732","description":"natural cytotoxicity triggering receptor 2","metadata":{"aliases":["NK-p44","CD336","LY95"]}},{"id":"33d4ff3b648e42468881f4a5db53a83b","type":"GENE","name":"NCR3","canonical_id":"hgnc:HGNC:19077","description":"natural cytotoxicity triggering receptor 3","metadata":{"aliases":["1C7","NKp30","CD337","LY117"]}},{"id":"2669f94e0503465c9e6236502d0a9ee0","type":"GENE","name":"NCR3LG1","canonical_id":"hgnc:HGNC:42400","description":"natural killer cell cytotoxicity receptor 3 ligand 1","metadata":{"aliases":["DKFZp686O24166","B7-H6"]}},{"id":"ef9f97b567234104a0ca960e94269119","type":"GENE","name":"NCRUPAR","canonical_id":"hgnc:HGNC:37153","description":"non-protein coding RNA, upstream of F2R/PAR1","metadata":{"aliases":["ncR-uPAR","NCRNA00193"]}},{"id":"3991d1294ec0452abcbcc6324792231a","type":"GENE","name":"NCS1","canonical_id":"hgnc:HGNC:3953","description":"neuronal calcium sensor 1","metadata":{"aliases":["NCS-1","FREQ"]}},{"id":"efbc337238e64d2f9033c4a8c4491809","type":"GENE","name":"NCSTN","canonical_id":"hgnc:HGNC:17091","description":"nicastrin","metadata":{"aliases":["KIAA0253","APH2"]}},{"id":"c73b91eabed04616abfb4be60c1ba43a","type":"GENE","name":"NCSTNP1","canonical_id":"hgnc:HGNC:39606","description":"nicastrin pseudogene 1","metadata":null},{"id":"9a7bada2e7584c589163d06ba78d604c","type":"TRIAL","name":"NCT Neuro Master Match - N\u00b2M\u00b2 (NOA-20)","canonical_id":"clinicaltrials.gov:NCT03158389","description":"Glioblastoma, Adult","metadata":null},{"id":"d7232a5ea90743d4821333cf0d8f8dd5","type":"GENE","name":"NDC1","canonical_id":"hgnc:HGNC:25525","description":"NDC1 transmembrane nucleoporin","metadata":{"aliases":["FLJ10407","NET3","TMEM48"]}},{"id":"86606431f8e04a9aaa4f8e44000ebb99","type":"GENE","name":"NDC80","canonical_id":"hgnc:HGNC:16909","description":null,"metadata":null},{"id":"6bef3502b3a841179846a187ca077536","type":"GENE","name":"NDE1","canonical_id":"hgnc:HGNC:17619","description":"nudE neurodevelopment protein 1","metadata":{"aliases":["nudE","FLJ20101","NDE"]}},{"id":"05be62653a014172b5ccd9c7c8446dc4","type":"GENE","name":"NDE1P1","canonical_id":"hgnc:HGNC:49115","description":"nudE neurodevelopment protein 1 pseudogene 1","metadata":null},{"id":"a862e376ece448b1a1af970ce9d6f887","type":"GENE","name":"NDE1P2","canonical_id":"hgnc:HGNC:49116","description":"nudE neurodevelopment protein 1 pseudogene 2","metadata":null},{"id":"27831a77ae864f24aa0f086d31e17dc6","type":"GENE","name":"NDEL1","canonical_id":"hgnc:HGNC:17620","description":"nudE neurodevelopment protein 1 like 1","metadata":{"aliases":["NUDEL","MITAP1","NDE1L1","NDE2"]}},{"id":"7167163dcbb84a86b20a7425a3b55c93","type":"GENE","name":"NDFIP1","canonical_id":"hgnc:HGNC:17592","description":"Nedd4 family interacting protein 1","metadata":{"aliases":["N4WBP5","MGC10924"]}},{"id":"e66c3d259606495b8ec16d9416a244df","type":"GENE","name":"NDFIP1P1","canonical_id":"hgnc:HGNC:49866","description":"Nedd4 family interacting protein 1 pseudogene 1","metadata":null},{"id":"93ef6ec3ce93427c89461cbcb0d6fa66","type":"GENE","name":"NDFIP2","canonical_id":"hgnc:HGNC:18537","description":"Nedd4 family interacting protein 2","metadata":{"aliases":["KIAA1165","N4wbp5a"]}},{"id":"cc8cf4c7cade4874b80e17472355c3fb","type":"GENE","name":"NDFIP2-AS1","canonical_id":"hgnc:HGNC:40844","description":"NDFIP2 antisense RNA 1","metadata":null},{"id":"c637ec867081479298dc9039fa8234cc","type":"GENE","name":"NDN","canonical_id":"hgnc:HGNC:7675","description":"necdin, MAGE family member","metadata":{"aliases":["HsT16328","PWCR"]}},{"id":"8a3a3c58538c4a838e93e57c11413850","type":"GENE","name":"NDNF","canonical_id":"hgnc:HGNC:26256","description":"neuron derived neurotrophic factor","metadata":{"aliases":["FLJ23191","C4orf31"]}},{"id":"c32b0d6f15ea474d9c6c50ba8ceff386","type":"GENE","name":"NDNF-AS1","canonical_id":"hgnc:HGNC:55553","description":"NDNF antisense RNA 1","metadata":null},{"id":"a36659808f424ce3918240dbc9af8a2b","type":"GENE","name":"NDOR1","canonical_id":"hgnc:HGNC:29838","description":"NADPH dependent diflavin oxidoreductase 1","metadata":{"aliases":["NR1","bA350O14.9","CIAE1"]}},{"id":"ec9957c6f1364981b653cfe2fba147b1","type":"GENE","name":"NDP","canonical_id":"hgnc:HGNC:7678","description":"norrin cystine knot growth factor NDP","metadata":{"aliases":["norrin","EVR2"]}},{"id":"d6ee0ef805d04af09bddd6886f5b4a11","type":"GENE","name":"NDP-AS1","canonical_id":"hgnc:HGNC:40395","description":"NDP antisense RNA 1","metadata":null},{"id":"78a221e00a204bb68c76faf2facca788","type":"GENE","name":"NDRG1","canonical_id":"hgnc:HGNC:7679","description":null,"metadata":null},{"id":"1df49e3024764db3aa5809b60ea6819f","type":"GENE","name":"NDRG2","canonical_id":"hgnc:HGNC:14460","description":null,"metadata":null},{"id":"1210f7f5213148c783d298d043550fa2","type":"GENE","name":"NDRG3","canonical_id":"hgnc:HGNC:14462","description":"NDRG family member 3","metadata":null},{"id":"9dc3e671751a435bb808ff0e04cf24cd","type":"GENE","name":"NDRG4","canonical_id":"hgnc:HGNC:14466","description":"NDRG family member 4","metadata":{"aliases":["KIAA1180","SMAP-8"]}},{"id":"d621ff1f02ed48f3b30f642a64915d55","type":"GENE","name":"NDST1","canonical_id":"hgnc:HGNC:7680","description":"N-deacetylase and N-sulfotransferase 1","metadata":{"aliases":["NST1","HSST"]}},{"id":"f7ee8da06f404162a084f7ce11fd835b","type":"GENE","name":"NDST1-AS1","canonical_id":"hgnc:HGNC:52899","description":"NDST1 antisense RNA 1","metadata":null},{"id":"9e92c33a22844ae69c4597a7126e00d2","type":"GENE","name":"NDST2","canonical_id":"hgnc:HGNC:7681","description":"N-deacetylase and N-sulfotransferase 2","metadata":{"aliases":["NST2","HSST2"]}},{"id":"b6156996ad3d4ec79c590e7d4bb0be33","type":"GENE","name":"NDST3","canonical_id":"hgnc:HGNC:7682","description":"N-deacetylase and N-sulfotransferase 3","metadata":{"aliases":["HSST3"]}},{"id":"35cd731cee924a61974aabd356e497db","type":"GENE","name":"NDST3-AS1","canonical_id":"hgnc:HGNC:58877","description":"NDST3 antisense RNA 1","metadata":null},{"id":"56aea26395e24e26a2687325b808d815","type":"GENE","name":"NDST4","canonical_id":"hgnc:HGNC:20779","description":"N-deacetylase and N-sulfotransferase 4","metadata":null},{"id":"ee30a12012554faabc44a1ebe9430da6","type":"GENE","name":"NDUFA1","canonical_id":"hgnc:HGNC:7683","description":"NADH:ubiquinone oxidoreductase subunit A1","metadata":{"aliases":["MWFE","CI-MWFE"]}},{"id":"05bf30e1104449de870a080ab2a0bdbb","type":"GENE","name":"NDUFA10","canonical_id":"hgnc:HGNC:7684","description":"NADH:ubiquinone oxidoreductase subunit A10","metadata":{"aliases":["CI-42k"]}},{"id":"4a1d9f9273a04112a8b63eb539819103","type":"GENE","name":"NDUFA11","canonical_id":"hgnc:HGNC:20371","description":"NADH:ubiquinone oxidoreductase subunit A11","metadata":{"aliases":["B14.7"]}},{"id":"e102ce93c06b4a269252cb87c7dce254","type":"GENE","name":"NDUFA12","canonical_id":"hgnc:HGNC:23987","description":"NADH:ubiquinone oxidoreductase subunit A12","metadata":{"aliases":["DAP13","B17.2"]}},{"id":"a47d2ebc592549bd8246576faa1ff6cf","type":"GENE","name":"NDUFA12P1","canonical_id":"hgnc:HGNC:39419","description":"NADH:ubiquinone oxidoreductase subunit A12 pseudogene 1","metadata":null},{"id":"5eebedad56cc465b8b2b6ad8035c0ece","type":"GENE","name":"NDUFA13","canonical_id":"hgnc:HGNC:17194","description":"NADH:ubiquinone oxidoreductase subunit A13","metadata":{"aliases":["CGI-39","CDA016","GRIM-19","GRIM19","B16.6"]}},{"id":"2b5279b2cdc84d5798630487e3330ce3","type":"GENE","name":"NDUFA2","canonical_id":"hgnc:HGNC:7685","description":"NADH:ubiquinone oxidoreductase subunit A2","metadata":{"aliases":["B8"]}},{"id":"e71e2c05993648efad5b13fb0c1a1e3c","type":"GENE","name":"NDUFA3","canonical_id":"hgnc:HGNC:7686","description":"NADH:ubiquinone oxidoreductase subunit A3","metadata":{"aliases":["B9"]}},{"id":"7937ae0cab95400da18bd6bb0121c262","type":"GENE","name":"NDUFA3P1","canonical_id":"hgnc:HGNC:45043","description":"NADH:ubiquinone oxidoreductase subunit A3 pseudogene 1","metadata":null},{"id":"23b05ccb060e43bdbd43056a1ae75b2a","type":"GENE","name":"NDUFA3P2","canonical_id":"hgnc:HGNC:45051","description":"NADH:ubiquinone oxidoreductase subunit A3 pseudogene 2","metadata":null},{"id":"6a96361440ae43728ea283d8d054f437","type":"GENE","name":"NDUFA3P3","canonical_id":"hgnc:HGNC:45052","description":"NADH:ubiquinone oxidoreductase subunit A3 pseudogene 3","metadata":null},{"id":"356094144255434486c2f32abd2045b7","type":"GENE","name":"NDUFA3P4","canonical_id":"hgnc:HGNC:45053","description":"NADH:ubiquinone oxidoreductase subunit A3 pseudogene 4","metadata":null},{"id":"14649af063a54f209298883c4a03d931","type":"GENE","name":"NDUFA3P5","canonical_id":"hgnc:HGNC:45054","description":"NADH:ubiquinone oxidoreductase subunit A3 pseudogene 5","metadata":null},{"id":"d837ab800c6b42fb838b978fa0653382","type":"GENE","name":"NDUFA3P6","canonical_id":"hgnc:HGNC:45055","description":"NADH:ubiquinone oxidoreductase subunit A3 pseudogene 6","metadata":null},{"id":"06d6f1aa158f4ad7b87791c4ad3e539b","type":"GENE","name":"NDUFA5","canonical_id":"hgnc:HGNC:7688","description":"NADH:ubiquinone oxidoreductase subunit A5","metadata":{"aliases":["B13","NUFM","CI-13KD-B","UQOR13","CI-13kB"]}},{"id":"a198e1ef7f3542f9915768076d716edd","type":"GENE","name":"NDUFA5P1","canonical_id":"hgnc:HGNC:7689","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 1","metadata":null},{"id":"ca8d4ae74d984e1e916cfbd2241600da","type":"GENE","name":"NDUFA5P10","canonical_id":"hgnc:HGNC:48852","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 10","metadata":null},{"id":"ad0697b3797b4f679e4107ded2f095b6","type":"GENE","name":"NDUFA5P11","canonical_id":"hgnc:HGNC:48853","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 11","metadata":null},{"id":"7c4402d31d844b9eae66d41ab823306f","type":"GENE","name":"NDUFA5P12","canonical_id":"hgnc:HGNC:48854","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 12","metadata":null},{"id":"2734fff2b2384091a879a72c8b2ca0b1","type":"GENE","name":"NDUFA5P2","canonical_id":"hgnc:HGNC:48855","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 2","metadata":null},{"id":"2ac2763ef2214f84a302a5f6e4e303fa","type":"GENE","name":"NDUFA5P3","canonical_id":"hgnc:HGNC:48845","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 3","metadata":null},{"id":"84f0b592ad604701813c37f3b257afa1","type":"GENE","name":"NDUFA5P4","canonical_id":"hgnc:HGNC:48846","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 4","metadata":null},{"id":"85ff45e058c946b9988cf853844a8945","type":"GENE","name":"NDUFA5P5","canonical_id":"hgnc:HGNC:48847","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 5","metadata":null},{"id":"ccc8b84b16e84b238a3147c6a3c0886e","type":"GENE","name":"NDUFA5P6","canonical_id":"hgnc:HGNC:48848","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 6","metadata":null},{"id":"07623ad8cce74a189b36114601668372","type":"GENE","name":"NDUFA5P7","canonical_id":"hgnc:HGNC:48849","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 7","metadata":null},{"id":"855eaa6d13f44147a2a2747edf6eb77b","type":"GENE","name":"NDUFA5P8","canonical_id":"hgnc:HGNC:48850","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 8","metadata":null},{"id":"e1d4c23a9fc2431c81225b3139dfb430","type":"GENE","name":"NDUFA5P9","canonical_id":"hgnc:HGNC:48851","description":"NADH:ubiquinone oxidoreductase subunit A5 pseudogene 9","metadata":null},{"id":"0ece23c875624d7c92467be89bf24672","type":"GENE","name":"NDUFA6","canonical_id":"hgnc:HGNC:7690","description":"NADH:ubiquinone oxidoreductase subunit A6","metadata":{"aliases":["B14","LYRM6","CI-B14","NADHB14"]}},{"id":"7b063e3fa0c74087a28eca14dcca2296","type":"GENE","name":"NDUFA6-DT","canonical_id":"hgnc:HGNC:45273","description":"NDUFA6 divergent transcript","metadata":{"aliases":["NDUFA6-AS1"]}},{"id":"99b16d81847d4f95ad40ec70b25e18b6","type":"GENE","name":"NDUFA7","canonical_id":"hgnc:HGNC:7691","description":"NADH:ubiquinone oxidoreductase subunit A7","metadata":{"aliases":["B14.5a"]}},{"id":"c0a63409d21a42cd92fecba8be06553a","type":"GENE","name":"NDUFA8","canonical_id":"hgnc:HGNC:7692","description":"NADH:ubiquinone oxidoreductase subunit A8","metadata":{"aliases":["PGIV","MGC793"]}},{"id":"a7de5ba65dd542e8ae4976779b4a4751","type":"GENE","name":"NDUFA8P1","canonical_id":"hgnc:HGNC:52264","description":"NADH:ubiquinone oxidoreductase subunit A8 pseudogene 1","metadata":null},{"id":"947df6ac62c74136a065dce5842ca226","type":"GENE","name":"NDUFA9","canonical_id":"hgnc:HGNC:7693","description":"NADH:ubiquinone oxidoreductase subunit A9","metadata":{"aliases":["SDR22E1","CI-39k","COQ11","NDUFS2L"]}},{"id":"97a5a4c87aa741e9a02ccbd21cd2ad5e","type":"GENE","name":"NDUFA9P1","canonical_id":"hgnc:HGNC:19252","description":"NADH:ubiquinone oxidoreductase subunit A9 pseudogene 1","metadata":{"aliases":["dJ106I20.2"]}},{"id":"6f5c3dba928e435caa23eb983afd5104","type":"GENE","name":"NDUFAB1","canonical_id":"hgnc:HGNC:7694","description":"NADH:ubiquinone oxidoreductase subunit AB1","metadata":{"aliases":["mtACP","mt-ACP","SDAP","FASN2A","ACP","ACP1"]}},{"id":"bb7b82767a534e9697fab5bfd3e3f775","type":"GENE","name":"NDUFAB1P1","canonical_id":"hgnc:HGNC:52265","description":"NADH:ubiquinone oxidoreductase subunit AB1 pseudogene 1","metadata":null},{"id":"867407816bed4cde88a73c42afccc569","type":"GENE","name":"NDUFAF1","canonical_id":"hgnc:HGNC:18828","description":"NADH:ubiquinone oxidoreductase complex assembly factor 1","metadata":{"aliases":["CIA30","CGI-65"]}},{"id":"fd7bf45ffbba41648a73a196f79c6535","type":"GENE","name":"NDUFAF1P1","canonical_id":"hgnc:HGNC:58605","description":"NDUFAF1 pseudogene 1","metadata":null},{"id":"7c62f62e25c44408a1448b0c107aa744","type":"GENE","name":"NDUFAF2","canonical_id":"hgnc:HGNC:28086","description":"NADH:ubiquinone oxidoreductase complex assembly factor 2","metadata":{"aliases":["B17.2L","MMTN","mimitin","NDUFA12L"]}},{"id":"fd5209072fbf479490cb8fd4bbfefce0","type":"GENE","name":"NDUFAF2P1","canonical_id":"hgnc:HGNC:54722","description":"NDUFAF2 pseudogene 1","metadata":null},{"id":"4e685be7abaf419c9c5852b68441553d","type":"GENE","name":"NDUFAF2P2","canonical_id":"hgnc:HGNC:54723","description":"NDUFAF2 pseudogene 2","metadata":null},{"id":"83d033da6efa40759c403fd3a98b7a5f","type":"GENE","name":"NDUFAF3","canonical_id":"hgnc:HGNC:29918","description":"NADH:ubiquinone oxidoreductase complex assembly factor 3","metadata":{"aliases":["MGC10527","DKFZP564J0123","E3-3","2P1","C3orf60"]}},{"id":"202d623181d74c0d9371e2829c58d8e6","type":"GENE","name":"NDUFAF4","canonical_id":"hgnc:HGNC:21034","description":"NADH:ubiquinone oxidoreductase complex assembly factor 4","metadata":{"aliases":["HSPC125","bA22L21.1","My013","HRPAP20","C6orf66"]}},{"id":"ad5fe7ebbd214750a5459516a64f7c71","type":"GENE","name":"NDUFAF4P1","canonical_id":"hgnc:HGNC:44194","description":"NADH:ubiquinone oxidoreductase complex assembly factor 4 pseudogene 1","metadata":null},{"id":"74a4ca6ea4c542d6807c74cb05ae2081","type":"GENE","name":"NDUFAF4P2","canonical_id":"hgnc:HGNC:44541","description":"NADH:ubiquinone oxidoreductase complex assembly factor 4 pseudogene 2","metadata":null},{"id":"cb794c829657438bb29ab9244a05799b","type":"GENE","name":"NDUFAF4P3","canonical_id":"hgnc:HGNC:44542","description":"NADH:ubiquinone oxidoreductase complex assembly factor 4 pseudogene 3","metadata":null},{"id":"cd0f7e4e87cd4e298751c7e33db87857","type":"GENE","name":"NDUFAF4P4","canonical_id":"hgnc:HGNC:44543","description":"NADH:ubiquinone oxidoreductase complex assembly factor 4 pseudogene 4","metadata":null},{"id":"8432c743e082494bae90bba82791b03b","type":"GENE","name":"NDUFAF5","canonical_id":"hgnc:HGNC:15899","description":"NADH:ubiquinone oxidoreductase complex assembly factor 5","metadata":{"aliases":["dJ842G6.1","C20orf7"]}},{"id":"5aa793e07d804a258e3a7ddda5c41dea","type":"GENE","name":"NDUFAF6","canonical_id":"hgnc:HGNC:28625","description":"NADH:ubiquinone oxidoreductase complex assembly factor 6","metadata":{"aliases":["lncREST","MGC40214","C8orf38"]}},{"id":"5eee1df6eef54b658e2bfab4a5ed481c","type":"GENE","name":"NDUFAF7","canonical_id":"hgnc:HGNC:28816","description":"NADH:ubiquinone oxidoreductase complex assembly factor 7","metadata":{"aliases":["PRO1853","MidA","C2orf56"]}},{"id":"f44ba1b2c3364ad08380825e729ca931","type":"GENE","name":"NDUFAF8","canonical_id":"hgnc:HGNC:33551","description":"NADH:ubiquinone oxidoreductase complex assembly factor 8","metadata":{"aliases":["C17orf89"]}},{"id":"287a654ed1ea4a30a44f79f9e132cd2f","type":"GENE","name":"NDUFB1","canonical_id":"hgnc:HGNC:7695","description":"NADH:ubiquinone oxidoreductase subunit B1","metadata":{"aliases":["MNLL","CI-MNLL"]}},{"id":"bce47dd6603245739636b9c5af1d2be3","type":"GENE","name":"NDUFB10","canonical_id":"hgnc:HGNC:7696","description":"NADH:ubiquinone oxidoreductase subunit B10","metadata":{"aliases":["PDSW"]}},{"id":"cfdb068e3088428ca6074e30d761f4db","type":"GENE","name":"NDUFB10P1","canonical_id":"hgnc:HGNC:52272","description":"NADH:ubiquinone oxidoreductase subunit B10 pseudogene 1","metadata":null},{"id":"09af9ed67bda4db6bfcd6bd55d49962f","type":"GENE","name":"NDUFB10P2","canonical_id":"hgnc:HGNC:52273","description":"NADH:ubiquinone oxidoreductase subunit B10 pseudogene 2","metadata":null},{"id":"cd0eb9d9191b4c26b40eac581428088f","type":"GENE","name":"NDUFB11","canonical_id":"hgnc:HGNC:20372","description":"NADH:ubiquinone oxidoreductase subunit B11","metadata":{"aliases":["ESSS","NP17.3","Np15"]}},{"id":"fa9fe790afd54ab1898514788f02f699","type":"GENE","name":"NDUFB11P1","canonical_id":"hgnc:HGNC:33980","description":"NADH:ubiquinone oxidoreductase subunit B11 pseudogene 1","metadata":{"aliases":["NDUFB11P"]}},{"id":"f9880cd8b8de4a60885e18df4bc422d0","type":"GENE","name":"NDUFB1P1","canonical_id":"hgnc:HGNC:30893","description":"NADH:ubiquinone oxidoreductase subunit B1 pseudogene 1","metadata":{"aliases":["bcm3095","NDUFB1P"]}},{"id":"cf3ef29b244a409597629707cb8e0bc0","type":"GENE","name":"NDUFB1P2","canonical_id":"hgnc:HGNC:37815","description":"NADH:ubiquinone oxidoreductase subunit B1 pseudogene 2","metadata":null},{"id":"1776934209e24f35937bb87897e1057e","type":"GENE","name":"NDUFB2","canonical_id":"hgnc:HGNC:7697","description":"NADH:ubiquinone oxidoreductase subunit B2","metadata":{"aliases":["AGGG","CI-AGGG"]}},{"id":"b517c5b70ca44b0380573241ffcde7ef","type":"GENE","name":"NDUFB2-AS1","canonical_id":"hgnc:HGNC:40396","description":"NDUFB2 antisense RNA 1","metadata":null},{"id":"6cb119ff8e5c438c8e4bfabde452cf00","type":"GENE","name":"NDUFB2P1","canonical_id":"hgnc:HGNC:52266","description":"NADH:ubiquinone oxidoreductase subunit B2 pseudogene 2","metadata":null},{"id":"07020739246840cfb01f278fe7b73376","type":"GENE","name":"NDUFB3","canonical_id":"hgnc:HGNC:7698","description":"NADH:ubiquinone oxidoreductase subunit B3","metadata":{"aliases":["B12"]}},{"id":"85f0a52813f6499f879741d55b389573","type":"GENE","name":"NDUFB3P1","canonical_id":"hgnc:HGNC:13673","description":"NADH:ubiquinone oxidoreductase subunit B3 pseudogene 1","metadata":null},{"id":"41d49f36e4e14b99a618c55f406d60d3","type":"GENE","name":"NDUFB3P2","canonical_id":"hgnc:HGNC:13674","description":"NADH:ubiquinone oxidoreductase subunit B3 pseudogene 2","metadata":null},{"id":"e18a03982c6c47948bbad270e3db9b2e","type":"GENE","name":"NDUFB3P3","canonical_id":"hgnc:HGNC:13675","description":"NADH:ubiquinone oxidoreductase subunit B3 pseudogene 3","metadata":null},{"id":"e24800e47ac64235b13adbe315c0b620","type":"GENE","name":"NDUFB3P4","canonical_id":"hgnc:HGNC:13676","description":"NADH:ubiquinone oxidoreductase subunit B3 pseudogene 4","metadata":null},{"id":"855f07ecf36441eba6d1d4379de01ed5","type":"GENE","name":"NDUFB3P5","canonical_id":"hgnc:HGNC:13677","description":"NADH:ubiquinone oxidoreductase subunit B3 pseudogene 5","metadata":null},{"id":"6b3e460edfe7432dbdfe2d2314fa8d6a","type":"GENE","name":"NDUFB4","canonical_id":"hgnc:HGNC:7699","description":"NADH:ubiquinone oxidoreductase subunit B4","metadata":{"aliases":["B15"]}},{"id":"8697bc5c302b4b72a1eee263814146cc","type":"GENE","name":"NDUFB4P1","canonical_id":"hgnc:HGNC:45248","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 1","metadata":null},{"id":"2af8bf2632194aa2979137b2ba2b08b0","type":"GENE","name":"NDUFB4P10","canonical_id":"hgnc:HGNC:45258","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 10","metadata":null},{"id":"07db13fdc63b46c593ec61c554d92eac","type":"GENE","name":"NDUFB4P11","canonical_id":"hgnc:HGNC:45259","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 11","metadata":null},{"id":"0af227a87adf425b91ed9335899cb58a","type":"GENE","name":"NDUFB4P12","canonical_id":"hgnc:HGNC:45260","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 12","metadata":null},{"id":"69bb2d3ed60a47ea9145ea34062215e8","type":"GENE","name":"NDUFB4P2","canonical_id":"hgnc:HGNC:45250","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 2","metadata":null},{"id":"79d9fd119c1142a48d5fd5ede25831af","type":"GENE","name":"NDUFB4P3","canonical_id":"hgnc:HGNC:45251","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 3","metadata":null},{"id":"e29a3661030a40698e23a98bdd68e732","type":"GENE","name":"NDUFB4P4","canonical_id":"hgnc:HGNC:45252","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 4","metadata":null},{"id":"e2202cabdde94f529d9d137e0db316bc","type":"GENE","name":"NDUFB4P5","canonical_id":"hgnc:HGNC:45253","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 5","metadata":null},{"id":"4bd9b304848e4880871b99ff898b26fa","type":"GENE","name":"NDUFB4P6","canonical_id":"hgnc:HGNC:45254","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 6","metadata":null},{"id":"9cfbaf4d9ab842be9282c96fd6ef129a","type":"GENE","name":"NDUFB4P7","canonical_id":"hgnc:HGNC:45255","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 7","metadata":null},{"id":"730f4035805b4a889eb3a46d24c05cbe","type":"GENE","name":"NDUFB4P8","canonical_id":"hgnc:HGNC:45256","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 8","metadata":null},{"id":"cfdb715068ee46a081838ad53a5aee95","type":"GENE","name":"NDUFB4P9","canonical_id":"hgnc:HGNC:45257","description":"NADH:ubiquinone oxidoreductase subunit B4 pseudogene 9","metadata":null},{"id":"865a95bb62764455a0fc49d297a1737a","type":"GENE","name":"NDUFB5","canonical_id":"hgnc:HGNC:7700","description":"NADH:ubiquinone oxidoreductase subunit B5","metadata":{"aliases":["SGDH","CI-SGDH","MGC12314"]}},{"id":"83d8dab7750e4b479bcd45caada25a3a","type":"GENE","name":"NDUFB5P1","canonical_id":"hgnc:HGNC:52267","description":"NADH:ubiquinone oxidoreductase subunit B5 pseudogene 1","metadata":null},{"id":"d4e59481027843d3988d32fb23dd4f06","type":"GENE","name":"NDUFB5P2","canonical_id":"hgnc:HGNC:52268","description":"NADH:ubiquinone oxidoreductase subunit B5 pseudogene 2","metadata":null},{"id":"bd0b465e9c7d427bb99ae776e1747f0d","type":"GENE","name":"NDUFB6","canonical_id":"hgnc:HGNC:7701","description":"NADH:ubiquinone oxidoreductase subunit B6","metadata":{"aliases":["B17","CI"]}},{"id":"2e41f89ab8a5492793869f5a5009be91","type":"GENE","name":"NDUFB7","canonical_id":"hgnc:HGNC:7702","description":"NADH:ubiquinone oxidoreductase subunit B7","metadata":{"aliases":["B18","CI-B18","MGC2480"]}},{"id":"5343e7c7e5f64f84b367e9796961539b","type":"GENE","name":"NDUFB8","canonical_id":"hgnc:HGNC:7703","description":"NADH:ubiquinone oxidoreductase subunit B8","metadata":{"aliases":["ASHI","CI-ASHI"]}},{"id":"9d438ba505e0447882eb5fe37d446d59","type":"GENE","name":"NDUFB8P1","canonical_id":"hgnc:HGNC:20023","description":"NADH:ubiquinone oxidoreductase subunit B8 pseudogene 1","metadata":null},{"id":"30bb52045a964862aac2dc4877915a4f","type":"GENE","name":"NDUFB8P2","canonical_id":"hgnc:HGNC:33978","description":"NADH:ubiquinone oxidoreductase subunit B8 pseudogene 2","metadata":null},{"id":"76827e7dc0724bb2a54b1bb3a64d76a0","type":"GENE","name":"NDUFB8P3","canonical_id":"hgnc:HGNC:33979","description":"NADH:ubiquinone oxidoreductase subunit B8 pseudogene 3","metadata":null},{"id":"20f9e400d2bd49f4911d965c404f2e63","type":"GENE","name":"NDUFB9","canonical_id":"hgnc:HGNC:7704","description":"NADH:ubiquinone oxidoreductase subunit B9","metadata":{"aliases":["B22","UQOR22","LYRM3"]}},{"id":"d35738d82c594f86a1196f0691dddc83","type":"GENE","name":"NDUFB9P1","canonical_id":"hgnc:HGNC:52269","description":"NADH:ubiquinone oxidoreductase subunit B9 pseudogene 1","metadata":null},{"id":"12369aaed9c04e239497f70313ac01a8","type":"GENE","name":"NDUFB9P2","canonical_id":"hgnc:HGNC:52270","description":"NADH:ubiquinone oxidoreductase subunit B9 pseudogene 2","metadata":null},{"id":"957f8e739e5a4e89b6924dec8f35b816","type":"GENE","name":"NDUFB9P3","canonical_id":"hgnc:HGNC:52271","description":"NADH:ubiquinone oxidoreductase subunit B9 pseudogene 3","metadata":null},{"id":"0a1a498ee6634f659d95135285184847","type":"GENE","name":"NDUFC1","canonical_id":"hgnc:HGNC:7705","description":"NADH:ubiquinone oxidoreductase subunit C1","metadata":{"aliases":["KFYI"]}},{"id":"fe4459249c2244d499d058e0fe7e0684","type":"GENE","name":"NDUFC2","canonical_id":"hgnc:HGNC:7706","description":"NADH:ubiquinone oxidoreductase subunit C2","metadata":{"aliases":["B14.5b","HLC-1"]}},{"id":"dac75cd2321340f096e8fa9da58d4db3","type":"GENE","name":"NDUFC2-KCTD14","canonical_id":"hgnc:HGNC:42956","description":"NDUFC2-KCTD14 readthrough","metadata":null},{"id":"83317cbab0584b5ca6bfb91efbf63667","type":"GENE","name":"NDUFS1","canonical_id":"hgnc:HGNC:7707","description":"NADH:ubiquinone oxidoreductase core subunit S1","metadata":{"aliases":["CI-75k"]}},{"id":"5dc3a022025046c7b7de8b2e4e925640","type":"GENE","name":"NDUFS2","canonical_id":"hgnc:HGNC:7708","description":"NADH:ubiquinone oxidoreductase core subunit S2","metadata":{"aliases":["CI-49"]}},{"id":"3ab30ab2a85d436b9d495462bf0ce8dc","type":"GENE","name":"NDUFS3","canonical_id":"hgnc:HGNC:7710","description":"NADH:ubiquinone oxidoreductase core subunit S3","metadata":{"aliases":["CI-30"]}},{"id":"f2d40ee31b944d3c828e224f0a748dd3","type":"GENE","name":"NDUFS4","canonical_id":"hgnc:HGNC:7711","description":"NADH:ubiquinone oxidoreductase subunit S4","metadata":{"aliases":["AQDQ","CI-18"]}},{"id":"237ca8a58dc3430a92b10d11927b0756","type":"GENE","name":"NDUFS5","canonical_id":"hgnc:HGNC:7712","description":"NADH:ubiquinone oxidoreductase subunit S5","metadata":{"aliases":["CI-15k"]}},{"id":"ae99cf3b322a498e9cf782d7537eda20","type":"GENE","name":"NDUFS5P1","canonical_id":"hgnc:HGNC:44039","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 1","metadata":null},{"id":"f6a9ca9b636542f7a2952509e56cedd3","type":"GENE","name":"NDUFS5P2","canonical_id":"hgnc:HGNC:44040","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 2","metadata":null},{"id":"71356e536e5b4f53becfa209a9c39306","type":"GENE","name":"NDUFS5P3","canonical_id":"hgnc:HGNC:44041","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 3","metadata":null},{"id":"6626e04e61274d83a436a7923bbb1536","type":"GENE","name":"NDUFS5P4","canonical_id":"hgnc:HGNC:44042","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 4","metadata":null},{"id":"1dc507b1aa1a42f4ae85cb3f8e643dfc","type":"GENE","name":"NDUFS5P5","canonical_id":"hgnc:HGNC:44043","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 5","metadata":null},{"id":"e49de31562724f4b96fe734cbad5eed8","type":"GENE","name":"NDUFS5P6","canonical_id":"hgnc:HGNC:44044","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 6","metadata":null},{"id":"ea60a0655a214494b1c2cecbb7f0b5f8","type":"GENE","name":"NDUFS5P7","canonical_id":"hgnc:HGNC:44045","description":"NADH:ubiquinone oxidoreductase subunit S5 pseudogene 7","metadata":null},{"id":"21df7357473c4468b6fc8a18f2d5f2bf","type":"GENE","name":"NDUFS6","canonical_id":"hgnc:HGNC:7713","description":"NADH:ubiquinone oxidoreductase subunit S6","metadata":{"aliases":["CI-13kA"]}},{"id":"a641fc9302d34867bdcfd08d3786be4a","type":"GENE","name":"NDUFS6P1","canonical_id":"hgnc:HGNC:52274","description":"NADH:ubiquinone oxidoreductase subunit S6 pseudogene 1","metadata":null},{"id":"5a1734c76b1d4cf0a987a5777da6ce9b","type":"GENE","name":"NDUFS7","canonical_id":"hgnc:HGNC:7714","description":"NADH:ubiquinone oxidoreductase core subunit S7","metadata":{"aliases":["PSST","FLJ46880","FLJ45860","CI-20"]}},{"id":"68af9165d5ec4db2bdbf696a59ef2e0f","type":"GENE","name":"NDUFS7-AS1","canonical_id":"hgnc:HGNC:58410","description":"NDUFS7 antisense RNA 1","metadata":null},{"id":"330561920ec846199089a03e858cf98c","type":"GENE","name":"NDUFS8","canonical_id":"hgnc:HGNC:7715","description":"NADH:ubiquinone oxidoreductase core subunit S8","metadata":{"aliases":["TYKY","CI-23k"]}},{"id":"feed2d2164c247c5ac6dd9840d97c2f1","type":"GENE","name":"NDUFV1","canonical_id":"hgnc:HGNC:7716","description":null,"metadata":null},{"id":"ea8ec4071eb74549bb8692bf3b64e3df","type":"GENE","name":"NDUFV1-DT","canonical_id":"hgnc:HGNC:26915","description":"NDUFV1 divergent transcript","metadata":{"aliases":["FLJ90834","C11orf72"]}},{"id":"171672b16d9a4f4f8b77f28f819d3388","type":"GENE","name":"NDUFV2","canonical_id":"hgnc:HGNC:7717","description":null,"metadata":null},{"id":"34048dee9e0f4a3bb35e95b7def901e6","type":"GENE","name":"NDUFV2-AS1","canonical_id":"hgnc:HGNC:50826","description":"NDUFV2 antisense RNA 1","metadata":null},{"id":"f340d6c270a54d9285e896a4d81d5b06","type":"GENE","name":"NDUFV2P1","canonical_id":"hgnc:HGNC:7718","description":"NADH:ubiquinone oxidoreductase core subunit V2 pseudogene 1","metadata":null},{"id":"c4fc3bc8554c435484e76fe996165632","type":"GENE","name":"NDUFV3","canonical_id":"hgnc:HGNC:7719","description":"NADH:ubiquinone oxidoreductase subunit V3","metadata":{"aliases":["CI-10k"]}},{"id":"4483d5e84b35431a90e725f82cbc1f16","type":"GENE","name":"NEAT1","canonical_id":"hgnc:HGNC:30815","description":null,"metadata":null},{"id":"3397034bf7664bb982d687739897b214","type":"GENE","name":"NEB","canonical_id":"hgnc:HGNC:7720","description":"nebulin","metadata":{"aliases":["NEB177D","NEM2"]}},{"id":"a750e05306b74df58d854ffd55bf51c4","type":"GENE","name":"NEBL","canonical_id":"hgnc:HGNC:16932","description":"nebulette","metadata":{"aliases":["LASP2","LNEBL","bA165O3.1","C10orf113"]}},{"id":"654cb908cd984dac94c26d1676157171","type":"GENE","name":"NEBL-AS1","canonical_id":"hgnc:HGNC:44899","description":"NEBL antisense RNA 1","metadata":null},{"id":"323ad14dba70437b836350cfffcbeeaf","type":"GENE","name":"NECAB1","canonical_id":"hgnc:HGNC:20983","description":"N-terminal EF-hand calcium binding protein 1","metadata":{"aliases":["EFCBP1"]}},{"id":"a33828cb46724300a60ce81e35616319","type":"GENE","name":"NECAB2","canonical_id":"hgnc:HGNC:23746","description":"N-terminal EF-hand calcium binding protein 2","metadata":{"aliases":["EFCBP2"]}},{"id":"b3f219837a0a4ec09ac9badcc8e1368b","type":"GENE","name":"NECAB3","canonical_id":"hgnc:HGNC:15851","description":"N-terminal EF-hand calcium binding protein 3","metadata":{"aliases":["XB51","dJ63M2.4","NIP1","dJ63M2.5","EFCBP3","SYTIP2","APBA2BP"]}},{"id":"bfb93db3010d43da98b00a3aa64bdb2f","type":"GENE","name":"NECAP1","canonical_id":"hgnc:HGNC:24539","description":"NECAP endocytosis associated 1","metadata":{"aliases":["DKFZP566B183"]}},{"id":"56d21c492fd04083a44d8738717ad2e8","type":"GENE","name":"NECAP1P1","canonical_id":"hgnc:HGNC:43912","description":"NECAP endocytosis associated 1 pseudogene 1","metadata":null},{"id":"3dd8bb3d469b47a0a3e482ae7205db8b","type":"GENE","name":"NECAP1P2","canonical_id":"hgnc:HGNC:43913","description":"NECAP endocytosis associated 1 pseudogene 2","metadata":null},{"id":"64c67080d3a24600a9d0437e2c270a30","type":"GENE","name":"NECAP2","canonical_id":"hgnc:HGNC:25528","description":"NECAP endocytosis associated 2","metadata":{"aliases":["FLJ10420"]}},{"id":"68db80813aed4f65830f964c6b8d2cd6","type":"GENE","name":"NECTIN1","canonical_id":"hgnc:HGNC:9706","description":"nectin cell adhesion molecule 1","metadata":{"aliases":["PRR","PRR1","PVRR1","SK-12","HIgR","CLPED1","CD111","OFC7","Nectin-1","HVEC","ED4","PVRL1"]}},{"id":"645d89d9d6f742a9b9305700584842c9","type":"GENE","name":"NECTIN1-AS1","canonical_id":"hgnc:HGNC:54270","description":"NECTIN1 antisense RNA 1","metadata":null},{"id":"9f2a706ced394526a58358140c51142d","type":"GENE","name":"NECTIN1-DT","canonical_id":"hgnc:HGNC:55513","description":"NECTIN1 divergent transcript","metadata":null},{"id":"4af2a2a400d64a1c9a1f53fd7442a9c0","type":"GENE","name":"NECTIN2","canonical_id":"hgnc:HGNC:9707","description":"nectin cell adhesion molecule 2","metadata":{"aliases":["PVRR2","PRR2","CD112","Nectin-2","HVEB","PVRL2"]}},{"id":"41049b0fc1454b799b6d4880bff5fbd6","type":"GENE","name":"NECTIN2P1","canonical_id":"hgnc:HGNC:56474","description":"NECTIN2 pseudogene 1","metadata":null},{"id":"ef49902ba9374660bf23e6181aad7baf","type":"GENE","name":"NECTIN3","canonical_id":"hgnc:HGNC:17664","description":"nectin cell adhesion molecule 3","metadata":{"aliases":["nectin-3","PPR3","PVRR3","DKFZP566B0846","CDw113","CD113","PVRL3"]}},{"id":"cbb25bdf966c4af79f56706600b2ca7f","type":"GENE","name":"NECTIN3-AS1","canonical_id":"hgnc:HGNC:40813","description":"NECTIN3 antisense RNA 1","metadata":{"aliases":["PVRL3-AS1"]}},{"id":"09881e1ea1b348eb86d3d027f95c3d02","type":"GENE","name":"NECTIN4","canonical_id":"hgnc:HGNC:19688","description":"nectin cell adhesion molecule 4","metadata":{"aliases":["nectin-4","PRR4","LNIR","PVRL4"]}},{"id":"b8bba6f10984435cbd2f384f827d4b47","type":"PROTEIN","name":"NECTIN4","canonical_id":"uniprot:Q96NY8","description":null,"metadata":null},{"id":"5fe03231c0534a47a490b67522eb08cb","type":"GENE","name":"NECTIN4-AS1","canonical_id":"hgnc:HGNC:40893","description":"NECTIN4 antisense RNA 1","metadata":{"aliases":["AL591806.1"]}},{"id":"6df7ed7c6a604455ad64fd5a6616accd","type":"GENE","name":"NEDD1","canonical_id":"hgnc:HGNC:7723","description":"NEDD1 gamma-tubulin ring complex targeting factor","metadata":{"aliases":["GCP-WD","TUBGCP7"]}},{"id":"ba22d58d46fe4948b42a68084e83da39","type":"GENE","name":"NEDD4","canonical_id":"hgnc:HGNC:7727","description":null,"metadata":null},{"id":"58d87d6b13434b8796470be47c9b1336","type":"GENE","name":"NEDD4L","canonical_id":"hgnc:HGNC:7728","description":null,"metadata":null},{"id":"33992bda025e4763a9246805edbbafff","type":"GENE","name":"NEDD4L-AS1","canonical_id":"hgnc:HGNC:58681","description":"NEDD4L antisense RNA 1","metadata":null},{"id":"01f2d0c060fe47778d4473cc378aed0e","type":"GENE","name":"NEDD8","canonical_id":"hgnc:HGNC:7732","description":"NEDD8 ubiquitin like modifier","metadata":{"aliases":["Nedd-8"]}},{"id":"27915743867d4ddfb1adfecdc3ec073c","type":"GO_TERM","name":"NEDD8 activating enzyme activity","canonical_id":"go:GO:0019781","description":"\"Catalysis of the initiation of the NEDD8 (RUB1) conjugation cascade.\" [PMID:12646924]","metadata":null},{"id":"c31de19b61134d48a4395d78fc59564e","type":"GO_TERM","name":"NEDD8 conjugating enzyme activity","canonical_id":"go:GO:0061654","description":"\"Isoenergetic transfer of NEDD8 from one protein to another via the reaction X-NEDD8 + Y = Y-NEDD8 + X, where both the X-NEDD8 and Y-NEDD8 linkages are thioester bonds between the C-terminal amino acid of NEDD8 and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"aa32a96d07d4408699c16ec29318a387","type":"GO_TERM","name":"NEDD8 ligase activity","canonical_id":"go:GO:0061663","description":"\"Catalysis of the transfer of NEDD8 to a substrate protein via the reaction X-NEDD8 + S = X + S-NEDD8, where X is either an E2 or E3 enzyme, the X-NEDD8 linkage is a thioester bond, and the S-NEDD8 linkage is an isopeptide bond between the C-terminal amino acid of NEDD8 and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"f971cb727c764f399266cce623f481e2","type":"GO_TERM","name":"NEDD8 transferase activity","canonical_id":"go:GO:0019788","description":"\"Catalysis of the transfer of NEDD8 from one protein to another via the reaction X-NEDD8 + Y = Y-NEDD8 + X, where both X-NEDD8 and Y-NEDD8 are covalent linkages.\" [GOC:mah]","metadata":null},{"id":"4d8cefcbc2034c0abeccafe0f9dd5173","type":"GENE","name":"NEDD8-MDP1","canonical_id":"hgnc:HGNC:39551","description":"NEDD8-MDP1 readthrough","metadata":null},{"id":"741e13c22e6e49519577030207bd7ec7","type":"GENE","name":"NEDD8P1","canonical_id":"hgnc:HGNC:54555","description":"NEDD8 pseudogene 1","metadata":null},{"id":"8b58ed9fe9204393b4d6ff7ec0b65a02","type":"GENE","name":"NEDD9","canonical_id":"hgnc:HGNC:7733","description":"neural precursor cell expressed, developmentally down-regulated 9","metadata":{"aliases":["HEF1","CAS-L","CASS2"]}},{"id":"1264638c38ef4b64b68ad3cb340ee384","type":"GENE","name":"NEDD9-AS1","canonical_id":"hgnc:HGNC:59345","description":"NEDD9 antisense RNA 1","metadata":null},{"id":"827deb6a43e2473cb40d91c5fa193089","type":"GENE","name":"NEFH","canonical_id":"hgnc:HGNC:7737","description":"neurofilament heavy chain","metadata":{"aliases":["NF-H","NFH"]}},{"id":"6cfac7c03bf24f8c8ba35cdd7d96b2c3","type":"GENE","name":"NEFHP1","canonical_id":"hgnc:HGNC:7738","description":"NEFH pseudogene 1","metadata":{"aliases":["NEFHL"]}},{"id":"e6146c5dae7b42dba487ec3395f615bc","type":"GENE","name":"NEFHP2","canonical_id":"hgnc:HGNC:56959","description":"NEFH pseudogene 2","metadata":null},{"id":"2a39bbdd8b024f7faa99912553a9c06b","type":"GENE","name":"NEFL","canonical_id":"hgnc:HGNC:7739","description":null,"metadata":null},{"id":"868c6d8531fc464f9acb4a81bec3ec15","type":"GENE","name":"NEFLP1","canonical_id":"hgnc:HGNC:37662","description":"neurofilament light pseudogene 1","metadata":null},{"id":"2388cbc0a2a643f2b99d5247f515e1c0","type":"GENE","name":"NEFM","canonical_id":"hgnc:HGNC:7734","description":"neurofilament medium chain","metadata":{"aliases":["NFM","NF-M","NEF3"]}},{"id":"f525f4785fc7458db044b2d666e89198","type":"GENE","name":"NEFMP1","canonical_id":"hgnc:HGNC:45030","description":"neurofilament medium pseudogene 1","metadata":null},{"id":"264e40ec016c40fbac7c3b6d7339b7f5","type":"GENE","name":"NEGR1","canonical_id":"hgnc:HGNC:17302","description":"neuronal growth regulator 1","metadata":{"aliases":["KILON","MGC46680","Ntra","IGLON4"]}},{"id":"f211b54c5bda4d50a2bab6bbec280801","type":"GENE","name":"NEGR1-IT1","canonical_id":"hgnc:HGNC:41432","description":"NEGR1 intronic transcript 1","metadata":null},{"id":"7ed072586ae7415ab6f0e73eacbb1d5a","type":"GENE","name":"NEIL1","canonical_id":"hgnc:HGNC:18448","description":null,"metadata":null},{"id":"ce6abf4fb21f4bfcbb0d955484759aed","type":"GENE","name":"NEIL1-AS1","canonical_id":"hgnc:HGNC:58160","description":"NEIL1 antisense RNA 1","metadata":null},{"id":"b76d58aa97d245ffa05669c2c099f52f","type":"GENE","name":"NEIL2","canonical_id":"hgnc:HGNC:18956","description":"nei like DNA glycosylase 2","metadata":{"aliases":["NEH2","FLJ31644","MGC2832","MGC4505"]}},{"id":"ac7f91b747c04abeb7d8723a755d82db","type":"GENE","name":"NEIL3","canonical_id":"hgnc:HGNC:24573","description":"nei like DNA glycosylase 3","metadata":{"aliases":["FLJ10858","hFPG2","FPG2","hNEI3","ZGRF3"]}},{"id":"b5940d3e00d04460bccaaac4638e3a59","type":"GENE","name":"NEIL3-AS1","canonical_id":"hgnc:HGNC:58914","description":"NEIL3 antisense RNA 1","metadata":null},{"id":"ff1a2af0fd8242baac4a639ede797b96","type":"GENE","name":"NEK1","canonical_id":"hgnc:HGNC:7744","description":"NIMA related kinase 1","metadata":{"aliases":["NY-REN-55","KIAA1901"]}},{"id":"75e28ecd4754460bb9f5dbd46572928c","type":"GENE","name":"NEK10","canonical_id":"hgnc:HGNC:18592","description":"NIMA related kinase 10","metadata":{"aliases":["FLJ32685"]}},{"id":"89684f64d0e44a24b0b78d32455f3968","type":"GENE","name":"NEK11","canonical_id":"hgnc:HGNC:18593","description":"NIMA related kinase 11","metadata":{"aliases":["FLJ23495"]}},{"id":"5a96cdd2a92748929ed984fdf36c52c6","type":"GENE","name":"NEK11-AS1","canonical_id":"hgnc:HGNC:58249","description":"NEK11 antisense RNA 1","metadata":null},{"id":"21e2acf57c7c4885b847df87f8860acb","type":"GENE","name":"NEK2","canonical_id":"hgnc:HGNC:7745","description":"NIMA related kinase 2","metadata":{"aliases":["NLK1","NEK2A","RP67","PPP1R111"]}},{"id":"390cb66f6bd043e6bdef9bb3dce5d8d9","type":"GENE","name":"NEK2-DT","canonical_id":"hgnc:HGNC:28085","description":"NEK2 divergent transcript","metadata":null},{"id":"f3298333486d48bca5eb88a7d6091436","type":"GENE","name":"NEK2P1","canonical_id":"hgnc:HGNC:19272","description":"NEK2 pseudogene 1","metadata":{"aliases":["NEK2P"]}},{"id":"9ef9f441e9e14f199356838f71bfc681","type":"GENE","name":"NEK2P2","canonical_id":"hgnc:HGNC:37816","description":"NEK2 pseudogene 2","metadata":null},{"id":"cd8f8bdcb0ba4f489cf35a63fe2d1e4d","type":"GENE","name":"NEK2P3","canonical_id":"hgnc:HGNC:37817","description":"NEK2 pseudogene 3","metadata":null},{"id":"2ae0ca3cfbf34a9fa26fc1b4749b60ca","type":"GENE","name":"NEK2P4","canonical_id":"hgnc:HGNC:37818","description":"NEK2 pseudogene 4","metadata":null},{"id":"c1135ca6f2dc4e079caec198a046eb2d","type":"GENE","name":"NEK3","canonical_id":"hgnc:HGNC:7746","description":"NIMA related kinase 3","metadata":{"aliases":["HSPK36","MGC29949"]}},{"id":"d2e002b4222d4032ae63c70685b05821","type":"GENE","name":"NEK4","canonical_id":"hgnc:HGNC:11399","description":"NIMA related kinase 4","metadata":{"aliases":["NRK2","pp12301","STK2"]}},{"id":"eface07d53c74ac7953b54fc82e199ba","type":"GENE","name":"NEK4P1","canonical_id":"hgnc:HGNC:39649","description":"NIMA-related kinase 4 pseudogene 1","metadata":null},{"id":"8e730cb0e1bd43fe9fa460b84a6d356e","type":"GENE","name":"NEK4P2","canonical_id":"hgnc:HGNC:39650","description":"NIMA-related kinase 4 pseudogene 2","metadata":null},{"id":"6c1e1491d8a447a3b5b0d2cbae9da9b2","type":"GENE","name":"NEK4P3","canonical_id":"hgnc:HGNC:39651","description":"NIMA-related kinase 4 pseudogene 3","metadata":null},{"id":"bf10b1e3bbe442c0bdeee57ed8aefa02","type":"GENE","name":"NEK5","canonical_id":"hgnc:HGNC:7748","description":"NIMA related kinase 5","metadata":null},{"id":"74c5e7dfa5d74c36b7d21c974407bce3","type":"GENE","name":"NEK6","canonical_id":"hgnc:HGNC:7749","description":"NIMA related kinase 6","metadata":{"aliases":["SID6-1512"]}},{"id":"ec2c7a67edeb43858c05d3cfadea17f5","type":"GENE","name":"NEK7","canonical_id":"hgnc:HGNC:13386","description":"NIMA related kinase 7","metadata":null},{"id":"5a137467737a442b9660e610bf8bc6fa","type":"GENE","name":"NEK8","canonical_id":"hgnc:HGNC:13387","description":"NIMA related kinase 8","metadata":{"aliases":["NPHP9"]}},{"id":"ec29a12d65fb4dc3aefd6670c639b6e1","type":"GENE","name":"NEK9","canonical_id":"hgnc:HGNC:18591","description":"NIMA related kinase 9","metadata":{"aliases":["Nek8","NERCC","DKFZp434D0935","MGC16714","NERCC1"]}},{"id":"763a746194934582bd1f2d472eb8852f","type":"GO_TERM","name":"NELF complex","canonical_id":"go:GO:0032021","description":"\"A complex of five proteins, designated NELF-A, -B, -C, -D, and -E in human, that can physically associate with RNP polymerase II to induce transcriptional pausing.\" [PMID:12612062]","metadata":null},{"id":"7f0b5d8545c64a6787c4628c4c7460cd","type":"GENE","name":"NELFA","canonical_id":"hgnc:HGNC:12768","description":"negative elongation factor complex member A","metadata":{"aliases":["NELF-A","WHSC2"]}},{"id":"0f9ee3fffe4742bc86f19e8e77424f5a","type":"GENE","name":"NELFB","canonical_id":"hgnc:HGNC:24324","description":null,"metadata":null},{"id":"31a5f624efb540ebbd87a6a79071af11","type":"GENE","name":"NELFCD","canonical_id":"hgnc:HGNC:15934","description":null,"metadata":null},{"id":"421c65aac7fe46019dcf2e9ff7dcc32c","type":"GENE","name":"NELFE","canonical_id":"hgnc:HGNC:13974","description":"negative elongation factor complex member E","metadata":{"aliases":["RD","D6S45","NELF-E","RDP","RDBP"]}},{"id":"b19d58a262fa49e8a71c38b45f47fcf6","type":"GENE","name":"NELL1","canonical_id":"hgnc:HGNC:7750","description":"neural EGFL like 1","metadata":{"aliases":["IDH3GL","FLJ45906"]}},{"id":"f8198e1b4c1b428d9e0180a2193087eb","type":"GENE","name":"NELL1-AS1","canonical_id":"hgnc:HGNC:58265","description":"NELL1 antisense RNA 1","metadata":null},{"id":"5e04ede760de4c65b3ac7468ae36fbe6","type":"GENE","name":"NELL1-AS2","canonical_id":"hgnc:HGNC:58439","description":"NELL1 antisense RNA 2","metadata":null},{"id":"5646ae07f2f64240a560e2860ffe98cd","type":"GENE","name":"NELL2","canonical_id":"hgnc:HGNC:7751","description":null,"metadata":null},{"id":"0b22dd1d7508494682b2f219be9cfe07","type":"GENE","name":"NEMF","canonical_id":"hgnc:HGNC:10663","description":"nuclear export mediator factor","metadata":{"aliases":["NY-CO-1","FLJ10051","RQC2","SDCCAG1"]}},{"id":"528ea8fb6d5646c2bfd78c53168b144b","type":"TRIAL","name":"NEMO1:NEonatal Seizure Using Medication Off-patent","canonical_id":"clinicaltrials.gov:NCT01434225","description":"Neonatal Seizures","metadata":null},{"id":"f55d38a342224bd987295c4fdd5a85f2","type":"GENE","name":"NEMP1","canonical_id":"hgnc:HGNC:29001","description":"nuclear envelope integral membrane protein 1","metadata":{"aliases":["KIAA0286","TMEM194","TMEM194A"]}},{"id":"e8beec2a41ce4d6bb77f8f19128829dc","type":"GENE","name":"NEMP2","canonical_id":"hgnc:HGNC:33700","description":"nuclear envelope integral membrane protein 2","metadata":{"aliases":["TMEM194B"]}},{"id":"c37d218bee9f44c6aade0ef46861c397","type":"GENE","name":"NEMP2-DT","canonical_id":"hgnc:HGNC:55713","description":"NEMP2 divergent transcript","metadata":null},{"id":"4da29fb03def4fbf8e36511a2158f52b","type":"GENE","name":"NENF","canonical_id":"hgnc:HGNC:30384","description":"neudesin neurotrophic factor","metadata":{"aliases":["CIR2","SCIRP10","SPUF"]}},{"id":"b2463df2d6cc44479c0bd81a5b0351d4","type":"GENE","name":"NENFP1","canonical_id":"hgnc:HGNC:50298","description":"neudesin neurotrophic factor pseudogene 1","metadata":null},{"id":"8e5def97e24f4532a8a2a84f4e009faf","type":"GENE","name":"NENFP2","canonical_id":"hgnc:HGNC:50299","description":"neudesin neurotrophic factor pseudogene 2","metadata":null},{"id":"bdca22a905424554bb6464868e01d603","type":"GENE","name":"NENFP3","canonical_id":"hgnc:HGNC:50300","description":"neudesin neurotrophic factor pseudogene 3","metadata":null},{"id":"295877345f8a4450973c72584ceecf85","type":"GENE","name":"NEO1","canonical_id":"hgnc:HGNC:7754","description":"neogenin 1","metadata":{"aliases":["NGN","HsT17534","IGDCC2","NTN1R2"]}},{"id":"c51b937f68ea450189c09fce956deafa","type":"TRIAL","name":"NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02689921","description":"Breast Neoplasms","metadata":null},{"id":"9da7923051f24707ae02d88352a2a1f4","type":"TRIAL","name":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT06379217","description":"Metastatic Neuroendocrine Prostate Cancer","metadata":null},{"id":"fe42fac0785447ab91b3feaf63aa3527","type":"GENE","name":"NEPNP","canonical_id":"hgnc:HGNC:33184","description":"nephrocan, pseudogene","metadata":{"aliases":["NPN","NEPN"]}},{"id":"024a21bd70034d059c97e725ac0c57f2","type":"GENE","name":"NEPRO-AS1","canonical_id":"hgnc:HGNC:41049","description":"NEPRO antisense RNA 1","metadata":null},{"id":"cab1ac3708004ff78cf925bc8ca208bc","type":"GENE","name":"NES","canonical_id":"hgnc:HGNC:7756","description":null,"metadata":null},{"id":"3bd6fdd91d994e12a89317dbbc936807","type":"GENE","name":"NET1","canonical_id":"hgnc:HGNC:14592","description":"neuroepithelial cell transforming 1","metadata":{"aliases":["ARHGEF8","NET1A"]}},{"id":"44a2bcf44f8b4c418f3a2f2e056fa034","type":"GENE","name":"NETO1","canonical_id":"hgnc:HGNC:13823","description":"neuropilin and tolloid like 1","metadata":{"aliases":["BTCL1","BCTL1"]}},{"id":"0ebd16c7aa6f4defa939eb4b7ec1a7d3","type":"GENE","name":"NETO1-DT","canonical_id":"hgnc:HGNC:55333","description":"NETO1 divergent transcript","metadata":null},{"id":"52e24b104b5b466d80ae5e6a1774268e","type":"GENE","name":"NETO2","canonical_id":"hgnc:HGNC:14644","description":"neuropilin and tolloid like 2","metadata":{"aliases":["FLJ10430","NEOT2"]}},{"id":"8e8b2c9c91d44f8b94288ec01bcedf62","type":"GENE","name":"NEU1","canonical_id":"hgnc:HGNC:7758","description":"neuraminidase 1","metadata":{"aliases":["NEU"]}},{"id":"d8dd8063b8364343a388726cf74febba","type":"GENE","name":"NEU2","canonical_id":"hgnc:HGNC:7759","description":"neuraminidase 2","metadata":{"aliases":["SIAL2"]}},{"id":"37a9a2d95ef249d49ac0f4564bc1a61b","type":"GENE","name":"NEU3","canonical_id":"hgnc:HGNC:7760","description":"neuraminidase 3","metadata":null},{"id":"b38f5b5e49f944da9f060e7062ad85db","type":"GENE","name":"NEU4","canonical_id":"hgnc:HGNC:21328","description":"neuraminidase 4","metadata":null},{"id":"f6a31a461cd447e5af80df6964c37ac7","type":"GENE","name":"NEUID","canonical_id":"hgnc:HGNC:58703","description":"neuronal identity associated lncRNA","metadata":null},{"id":"1b6055ad7e264f3bac96f486ae4498ec","type":"GENE","name":"NEURL1","canonical_id":"hgnc:HGNC:7761","description":"neuralized E3 ubiquitin protein ligase 1","metadata":{"aliases":["h-neu","RNF67","neu-1","NEURL"]}},{"id":"1b8f2ddff3744e228e95ec5b1705db9d","type":"GENE","name":"NEURL1-AS1","canonical_id":"hgnc:HGNC:51220","description":"NEURL1 antisense RNA 1","metadata":null},{"id":"85af4f5b6f0e464ca9c39d11c27db0e8","type":"GENE","name":"NEURL1B","canonical_id":"hgnc:HGNC:35422","description":"neuralized E3 ubiquitin protein ligase 1B","metadata":{"aliases":["DKFZP761M1511","Neur2","RNF67B"]}},{"id":"cdc6becc35984c36bc5bebc0ac3e54d2","type":"GENE","name":"NEURL1B-AS1","canonical_id":"hgnc:HGNC:59304","description":"NEURL1B antisense RNA 1","metadata":null},{"id":"1891721a7a8b4d18b0867806b392a342","type":"GENE","name":"NEURL2","canonical_id":"hgnc:HGNC:16156","description":"neuralized E3 ubiquitin protein ligase 2","metadata":{"aliases":["dJ337O18.6","FLJ30259","Ozz","Ozz-E3","C20orf163"]}},{"id":"9fd6709269ed4b759030b4959de11a20","type":"GENE","name":"NEURL3","canonical_id":"hgnc:HGNC:25162","description":"neuralized E3 ubiquitin protein ligase 3","metadata":{"aliases":["Lincr","LOC93082","RNF132"]}},{"id":"c8dfc4f4a7464501a5621ed52cb0df48","type":"GENE","name":"NEURL4","canonical_id":"hgnc:HGNC:34410","description":"neuralized E3 ubiquitin protein ligase 4","metadata":{"aliases":["KIAA1787"]}},{"id":"b2858995faf5406794a51386add2f260","type":"GENE","name":"NEUROD1","canonical_id":"hgnc:HGNC:7762","description":null,"metadata":null},{"id":"7f276a2374f344c5b50b76923cac9ed8","type":"GENE","name":"NEUROD1-DT","canonical_id":"hgnc:HGNC:58078","description":"NEUROD1 divergent transcript","metadata":{"aliases":["REIR-3"]}},{"id":"1e421ec711c646c795e5f2bb78dd90d4","type":"GENE","name":"NEUROD2","canonical_id":"hgnc:HGNC:7763","description":"neuronal differentiation 2","metadata":{"aliases":["NDRF","bHLHa1"]}},{"id":"5bd45df15c754b6284fab8596ad7820d","type":"GENE","name":"NEUROD4","canonical_id":"hgnc:HGNC:13802","description":"neuronal differentiation 4","metadata":{"aliases":["Atoh3","ATH-3","MATH-3","bHLHa4"]}},{"id":"17dc4d3378b745d0a1978c74955c5d85","type":"GENE","name":"NEUROD4-AS1","canonical_id":"hgnc:HGNC:59216","description":"NEUROD4 antisense RNA 1","metadata":null},{"id":"35a05d6d34f64627b183dd26b2f518ba","type":"GENE","name":"NEUROD6","canonical_id":"hgnc:HGNC:13804","description":"neuronal differentiation 6","metadata":{"aliases":["Atoh2","NEX1M","Math-2","bHLHa2","Nex1"]}},{"id":"e7fdedcb83e747e69c0ba9d8061b7d5d","type":"GENE","name":"NEUROG1","canonical_id":"hgnc:HGNC:7764","description":"neurogenin 1","metadata":{"aliases":["AKA","Math4C","ngn1","bHLHa6","NEUROD3"]}},{"id":"f68049a7dcea44fc8baf3997ce40d7ae","type":"GENE","name":"NEUROG2","canonical_id":"hgnc:HGNC:13805","description":"neurogenin 2","metadata":{"aliases":["Atoh4","Math4A","ngn-2","bHLHa8","NGN2"]}},{"id":"9fb2382164834d4e9eb41ec21d36572a","type":"GENE","name":"NEUROG2-AS1","canonical_id":"hgnc:HGNC:40656","description":"NEUROG2 and ZGRF1 antisense RNA 1","metadata":null},{"id":"1876a16860da4d73933f8430a27fdfbf","type":"GENE","name":"NEUROG3","canonical_id":"hgnc:HGNC:13806","description":null,"metadata":null},{"id":"ad34eaa20a1e4adf8c3becf99332606f","type":"GENE","name":"NEXMIF","canonical_id":"hgnc:HGNC:29433","description":"neurite extension and migration factor","metadata":{"aliases":["XPN","MRX98","KIDLIA","KIAA2022"]}},{"id":"e2a4304d30e64dfc82b3c8aa0b317538","type":"GENE","name":"NEXN","canonical_id":"hgnc:HGNC:29557","description":"nexilin F-actin binding protein","metadata":{"aliases":["nexilin","NELIN"]}},{"id":"5dec178b7ba74412a55ae54dfc900335","type":"GENE","name":"NEXN-AS1","canonical_id":"hgnc:HGNC:31983","description":"NEXN antisense RNA 1","metadata":{"aliases":["FLJ90637","C1orf118"]}},{"id":"2fc6f4e9f8f9485f8ed4df681e081a2e","type":"GO_TERM","name":"NF-kappaB binding","canonical_id":"go:GO:0051059","description":"\"Binding to NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters.\" [GOC:ai]","metadata":null},{"id":"90290fc41a0e49aa8bdd32d66b840779","type":"GO_TERM","name":"NF-kappaB complex","canonical_id":"go:GO:0071159","description":"\"A protein complex that consists of a homo- or heterodimer of members of a family of structurally related proteins that contain a conserved N-terminal region called the Rel homology domain (RHD). In the nucleus, NF-kappaB complexes act as transcription factors. In unstimulated cells, NF-kappaB dimers are sequestered in the cytoplasm by IkappaB monomers; signals that induce NF-kappaB activity cause degradation of IkappaB, allowing NF-kappaB dimers to translocate to the nucleus and induce gene expression.\" [ISBN:0849327946]","metadata":null},{"id":"9c09cb79a907436587c8d2f68756dbda","type":"GO_TERM","name":"NF-kappaB p50/p65 complex","canonical_id":"go:GO:0035525","description":"\"A heterodimer of NF-kappa B p50 and p65 subunits.\" [GO:add, PMID:20393192, PMID:9299584]","metadata":null},{"id":"1b9dbcccfa294d4e9038b5ef40214c31","type":"GENE","name":"NF1","canonical_id":"hgnc:HGNC:7765","description":null,"metadata":null},{"id":"a0679760da574326a1be56343dc8860b","type":"GENE","name":"NF1P1","canonical_id":"hgnc:HGNC:7772","description":"neurofibromin 1 pseudogene 1","metadata":{"aliases":["NF1HHS"]}},{"id":"89c3e2dfeae343bf921f41c8ddb71dde","type":"GENE","name":"NF1P10","canonical_id":"hgnc:HGNC:51737","description":"neurofibromin 1 pseudogene 10","metadata":null},{"id":"ad7954dad7e948238599497023ae57e9","type":"GENE","name":"NF1P11","canonical_id":"hgnc:HGNC:51738","description":"neurofibromin 1 pseudogene 11","metadata":null},{"id":"1b70f333456d443b8ded9df67e9afd75","type":"GENE","name":"NF1P12","canonical_id":"hgnc:HGNC:51739","description":"neurofibromin 1 pseudogene 12","metadata":null},{"id":"0dccc8f1cd034171be2fd3ba8b77d56c","type":"GENE","name":"NF1P2","canonical_id":"hgnc:HGNC:38664","description":"neurofibromin 1 pseudogene 2","metadata":null},{"id":"601e139eda024b6e9532b500e820c723","type":"GENE","name":"NF1P3","canonical_id":"hgnc:HGNC:7766","description":"neurofibromin 1 pseudogene 3","metadata":{"aliases":["NF1L1"]}},{"id":"be455d5938f74f728af637db831e5276","type":"GENE","name":"NF1P4","canonical_id":"hgnc:HGNC:7769","description":"neurofibromin 1 pseudogene 4","metadata":{"aliases":["NF1L4"]}},{"id":"9ae5026daed84830a338da9b73acfb9c","type":"GENE","name":"NF1P5","canonical_id":"hgnc:HGNC:7770","description":"neurofibromin 1 pseudogene 5","metadata":{"aliases":["NF1L5"]}},{"id":"a689c207b8cd4b96b53c5dd8a4141826","type":"GENE","name":"NF1P6","canonical_id":"hgnc:HGNC:7771","description":"neurofibromin 1 pseudogene 6","metadata":{"aliases":["Em:AP000532.C22.1","NF1L6"]}},{"id":"4d62ee6921034c1888332dbc86335f60","type":"GENE","name":"NF1P7","canonical_id":"hgnc:HGNC:34230","description":"neurofibromin 1 pseudogene 7","metadata":{"aliases":["NF1L7"]}},{"id":"2f50c2cf2ac84b0a9c0f8133f2079fb9","type":"GENE","name":"NF1P8","canonical_id":"hgnc:HGNC:7767","description":"neurofibromin 1 pseudogene 8","metadata":{"aliases":["NF1L2"]}},{"id":"e4f077c76f3a4f0189ef191d2f3a98e8","type":"GENE","name":"NF1P9","canonical_id":"hgnc:HGNC:51736","description":"neurofibromin 1 pseudogene 9","metadata":null},{"id":"1bcc8809b60e44118d938724bc60d270","type":"GENE","name":"NF2","canonical_id":"hgnc:HGNC:7773","description":"NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor","metadata":{"aliases":["merlin","ACN","SCH","BANF","merlin-1"]}},{"id":"6d13202f6f21427dba40ec9df131f5bb","type":"GENE","name":"NFAM1","canonical_id":"hgnc:HGNC:29872","description":"NFAT activating protein with ITAM motif 1","metadata":{"aliases":["CNAIP"]}},{"id":"44b7f2d0f1b948f48876275d08f4d6b8","type":"GENE","name":"NFASC","canonical_id":"hgnc:HGNC:29866","description":"neurofascin","metadata":{"aliases":["NRCAML","KIAA0756","FLJ46866","NF"]}},{"id":"4efd06093ebc4e05aae476633c73a3ff","type":"GO_TERM","name":"NFAT protein binding","canonical_id":"go:GO:0051525","description":"\"Binding to NFAT (nuclear factor of activated T cells) proteins, a family of transcription factors. NFAT proteins have crucial roles in the development and function of the immune system.\" [PMID:15928679]","metadata":null},{"id":"77926523be574c15a471623116ba5c1d","type":"GENE","name":"NFAT5","canonical_id":"hgnc:HGNC:7774","description":null,"metadata":null},{"id":"05e36e7226314c44a7c53549fac678f8","type":"GENE","name":"NFATC1","canonical_id":"hgnc:HGNC:7775","description":null,"metadata":null},{"id":"f37bcf74723c4503ba6f3e4f3c60302a","type":"GENE","name":"NFATC2","canonical_id":"hgnc:HGNC:7776","description":null,"metadata":null},{"id":"48d92c79f3294c91b6508e32e5b5f19f","type":"GENE","name":"NFATC2IP","canonical_id":"hgnc:HGNC:25906","description":"nuclear factor of activated T cells 2 interacting protein","metadata":{"aliases":["FLJ14639","NIP45","RAD60","ESC2"]}},{"id":"7d7ed8aa2630428d823c41477695ecf8","type":"GENE","name":"NFATC2IP-AS1","canonical_id":"hgnc:HGNC:56085","description":"NFATC2IP antisense RNA 1","metadata":null},{"id":"e7173cfa43884e8394b0683394ea1f5d","type":"GENE","name":"NFATC3","canonical_id":"hgnc:HGNC:7777","description":null,"metadata":null},{"id":"1ab58172fcf748cfb65a08ae1886268e","type":"GENE","name":"NFATC4","canonical_id":"hgnc:HGNC:7778","description":"nuclear factor of activated T cells 4","metadata":{"aliases":["NFAT3"]}},{"id":"b7b0f229be7c481480c7c2fb6c13070d","type":"GENE","name":"NFE2","canonical_id":"hgnc:HGNC:7780","description":null,"metadata":null},{"id":"982367b85d2742ea8b4b8561370b20ce","type":"GENE","name":"NFE2L1","canonical_id":"hgnc:HGNC:7781","description":null,"metadata":null},{"id":"971e9b00ce01481aac8e0e364427bbb2","type":"GENE","name":"NFE2L1-DT","canonical_id":"hgnc:HGNC:54812","description":"NFE2L1 divergent transcript","metadata":null},{"id":"4c3cb2c093604f10a3fba9761613f91e","type":"GENE","name":"NFE2L2","canonical_id":"hgnc:HGNC:7782","description":null,"metadata":null},{"id":"f27af77e59314519bdbb761d284a1f84","type":"GENE","name":"NFE2L3","canonical_id":"hgnc:HGNC:7783","description":"NFE2 like bZIP transcription factor 3","metadata":{"aliases":["Nrf3"]}},{"id":"21964ff24051450292f2566270fcc0ae","type":"GENE","name":"NFE2L3P1","canonical_id":"hgnc:HGNC:22278","description":"nuclear factor, erythroid 2 like 3 pseudogene 1","metadata":null},{"id":"4cf6bb1196cc4d2ab77c051899ab591e","type":"GENE","name":"NFE2L3P2","canonical_id":"hgnc:HGNC:44191","description":"nuclear factor, erythroid 2 like 3 pseudogene 2","metadata":null},{"id":"78ddc98e15924b2186e3c6650c431a68","type":"GENE","name":"NFE4","canonical_id":"hgnc:HGNC:29902","description":"nuclear factor, erythroid 4","metadata":{"aliases":["NF-E4"]}},{"id":"f88a07eac8ae440ebec108e7e8e43a6d","type":"GENE","name":"NFIA","canonical_id":"hgnc:HGNC:7784","description":null,"metadata":null},{"id":"1ff25d71d5e64fab9943d02ff3f4e2d7","type":"GENE","name":"NFIA-AS1","canonical_id":"hgnc:HGNC:40402","description":"NFIA antisense RNA 1","metadata":{"aliases":["RP5-833A20.1"]}},{"id":"812135e9b1b043f9975d011c925c7e3f","type":"GENE","name":"NFIA-AS2","canonical_id":"hgnc:HGNC:40401","description":"NFIA antisense RNA 2","metadata":null},{"id":"0300cd411625487eaa29def9951793d9","type":"GENE","name":"NFIB","canonical_id":"hgnc:HGNC:7785","description":null,"metadata":null},{"id":"7c0f040c5c724a01b717221d84b1a97d","type":"GENE","name":"NFIB-AS1","canonical_id":"hgnc:HGNC:56058","description":"NFIB antisense RNA 1","metadata":{"aliases":["AL136366.1"]}},{"id":"a4179cf826444738b882e78b0909a19b","type":"GENE","name":"NFIC","canonical_id":"hgnc:HGNC:7786","description":null,"metadata":null},{"id":"cdd0ed38ba5943d5b843d9da13c0fa6f","type":"GENE","name":"NFIL3","canonical_id":"hgnc:HGNC:7787","description":null,"metadata":null},{"id":"1bddaadc1b184a87880c502f3f17d925","type":"GENE","name":"NFILZ","canonical_id":"hgnc:HGNC:52681","description":"NFIL3 like basic leucine zipper","metadata":{"aliases":["LINC01862"]}},{"id":"dcfcac2a66f54864973bb0c7768bf621","type":"GENE","name":"NFIX","canonical_id":"hgnc:HGNC:7788","description":null,"metadata":null},{"id":"14999e037509400595bff5f6c144d62b","type":"GENE","name":"NFIX-AS1","canonical_id":"hgnc:HGNC:58573","description":"NFIX antisense RNA 1","metadata":null},{"id":"049ee4a7a17645f3896c057f46c07816","type":"GENE","name":"NFKB1","canonical_id":"hgnc:HGNC:7794","description":null,"metadata":null},{"id":"df36b69759c84d2c988f7a93f5aeb4c1","type":"GENE","name":"NFKB1-AS1","canonical_id":"hgnc:HGNC:58149","description":"NFKB1 antisense RNA 1","metadata":{"aliases":["RP11-499E18.1"]}},{"id":"039de690cbc7450ca214911e5da7c068","type":"GENE","name":"NFKB1-AS2","canonical_id":"hgnc:HGNC:58861","description":"NFKB1 antisense RNA 2","metadata":null},{"id":"62959b90d0284b108beaaad1c6691e20","type":"GENE","name":"NFKB2","canonical_id":"hgnc:HGNC:7795","description":null,"metadata":null},{"id":"6e708b88cf7a49e79a1acb3ffb15f943","type":"GENE","name":"NFKBIA","canonical_id":"hgnc:HGNC:7797","description":null,"metadata":null},{"id":"97fe0ab85fc64976a03cbb67f3af7fad","type":"GENE","name":"NFKBIB","canonical_id":"hgnc:HGNC:7798","description":null,"metadata":null},{"id":"2c428186706543d4860fb783051d06c8","type":"GENE","name":"NFKBID","canonical_id":"hgnc:HGNC:15671","description":"NFKB inhibitor delta","metadata":{"aliases":["TA-NFKBH","IkappaBNS","IkBNS"]}},{"id":"31d10e618b77484d95c90c3d3740856f","type":"GENE","name":"NFKBIE","canonical_id":"hgnc:HGNC:7799","description":"NFKB inhibitor epsilon","metadata":{"aliases":["IKBE"]}},{"id":"c40624a7a07e4e1eb8278096cf7e9f11","type":"GENE","name":"NFKBIL1","canonical_id":"hgnc:HGNC:7800","description":"NFKB inhibitor like 1","metadata":{"aliases":["IKBL","NFKBIL"]}},{"id":"516618b971514cb8ae3bae188f5456fb","type":"GENE","name":"NFKBIZ","canonical_id":"hgnc:HGNC:29805","description":null,"metadata":null},{"id":"e3fe887a31e547e7a4dc8e5ca086195c","type":"GENE","name":"NFRKB","canonical_id":"hgnc:HGNC:7802","description":null,"metadata":null},{"id":"67d44c9e690b4480997534f1eddc570b","type":"GENE","name":"NFS1","canonical_id":"hgnc:HGNC:15910","description":"NFS1 cysteine desulfurase","metadata":{"aliases":["NifS","IscS"]}},{"id":"2017029db3c04a8391e4149d4022f999","type":"GENE","name":"NFU1","canonical_id":"hgnc:HGNC:16287","description":"NFU1 iron-sulfur cluster scaffold","metadata":{"aliases":["CGI-33","NifU","NIFUC","HIRIP5"]}},{"id":"9bee4eeef02740f2895eb99881fdad07","type":"GENE","name":"NFU1P1","canonical_id":"hgnc:HGNC:44553","description":"NFU1 iron-sulfur cluster scaffold pseudogene 1","metadata":null},{"id":"4c4f20d5475f4ab7a4d5545fae06af5c","type":"GENE","name":"NFU1P2","canonical_id":"hgnc:HGNC:44554","description":"NFU1 iron-sulfur cluster scaffold pseudogene 2","metadata":null},{"id":"f697f6e8c7d643ae9939e0132b641056","type":"GENE","name":"NFX1","canonical_id":"hgnc:HGNC:7803","description":"nuclear transcription factor, X-box binding 1","metadata":{"aliases":["NFX2","MGC20369","Tex42","TEG-42"]}},{"id":"750866345fd7400e9a053cbc2387c76d","type":"GENE","name":"NFXL1","canonical_id":"hgnc:HGNC:18726","description":"nuclear transcription factor, X-box binding like 1","metadata":{"aliases":["HOZFP"]}},{"id":"68a2a5ba9cdb47b697d26173ba4affa2","type":"GENE","name":"NFYA","canonical_id":"hgnc:HGNC:7804","description":null,"metadata":null},{"id":"1022de99c7804ffa8645ad81a227107e","type":"GENE","name":"NFYAP1","canonical_id":"hgnc:HGNC:34078","description":"nuclear transcription factor Y subunit alpha pseudogene 1","metadata":{"aliases":["NFYAP"]}},{"id":"a87f2a29c15b456b8b8df644868b05d9","type":"GENE","name":"NFYB","canonical_id":"hgnc:HGNC:7805","description":null,"metadata":null},{"id":"0678c5c167f4484089442200014bac63","type":"GENE","name":"NFYBP1","canonical_id":"hgnc:HGNC:54604","description":"NFYB pseudogene 1","metadata":null},{"id":"6118c10f99134df89de8989d39aee7cd","type":"GENE","name":"NFYC","canonical_id":"hgnc:HGNC:7806","description":null,"metadata":null},{"id":"3e6f173f3e544127ad941853951158da","type":"GENE","name":"NFYC-AS1","canonical_id":"hgnc:HGNC:49451","description":"NFYC antisense RNA 1","metadata":{"aliases":["0808y08y"]}},{"id":"9c7b716cb16247c493795588737345cd","type":"GENE","name":"NFYCP1","canonical_id":"hgnc:HGNC:54923","description":"NFYC pseudogene 1","metadata":null},{"id":"7239a13532654caa86c87d73cde46030","type":"GENE","name":"NFYCP2","canonical_id":"hgnc:HGNC:54924","description":"NFYC pseudogene 2","metadata":null},{"id":"ec25e7946ad24809a0bcac252fb40d1a","type":"GENE","name":"NGB","canonical_id":"hgnc:HGNC:14077","description":"neuroglobin","metadata":null},{"id":"c345bc4735134490a3b145d58e0e6cd9","type":"GENE","name":"NGDN","canonical_id":"hgnc:HGNC:20271","description":"neuroguidin","metadata":{"aliases":["DKFZP564O092","LCP5","lpd-2","NGD","CANu1","C14orf120"]}},{"id":"617c77ffe8c84ff5a015e353f0414e9a","type":"GENE","name":"NGEF","canonical_id":"hgnc:HGNC:7807","description":"neuronal guanine nucleotide exchange factor","metadata":{"aliases":["ARHGEF27"]}},{"id":"ad7427482a8f409e99dad8778e36e9e4","type":"GENE","name":"NGF","canonical_id":"hgnc:HGNC:7808","description":null,"metadata":null},{"id":"4415e1800eb24ff9bf15029d5b9f0117","type":"GENE","name":"NGF-AS1","canonical_id":"hgnc:HGNC:53922","description":"NGF antisense RNA 1","metadata":{"aliases":["RP4-663N10.1"]}},{"id":"64746c5ac2624a9d86d941caf4f314ac","type":"GENE","name":"NGFR","canonical_id":"hgnc:HGNC:7809","description":null,"metadata":null},{"id":"2aafc31fafb64bf59a8462be8b04c8f7","type":"GENE","name":"NGFR-AS1","canonical_id":"hgnc:HGNC:55555","description":"NGFR antisense RNA 1","metadata":null},{"id":"dd79abaa97c840ddb4141d603696ae9b","type":"GENE","name":"NGLY1","canonical_id":"hgnc:HGNC:17646","description":"N-glycanase 1","metadata":{"aliases":["FLJ11005","PNG1","PNG-1"]}},{"id":"0e9728e6071f4119bfa56086e5bca529","type":"GENE","name":"NGRN","canonical_id":"hgnc:HGNC:18077","description":"neugrin, neurite outgrowth associated","metadata":{"aliases":["DSC92"]}},{"id":"268387c692784c9fa21ccf69f748a758","type":"GENE","name":"NGRNP1","canonical_id":"hgnc:HGNC:56570","description":"NGRN pseudogene 1","metadata":null},{"id":"91ceeb3d154f429490767880168c6577","type":"GENE","name":"NGRNP2","canonical_id":"hgnc:HGNC:56571","description":"NGRN pseudogene 2","metadata":null},{"id":"8bb5330b9ff24a08a5e364fdf2cbc303","type":"GENE","name":"NGRNP3","canonical_id":"hgnc:HGNC:56572","description":"NGRN pseudogene 3","metadata":null},{"id":"83d84190a4ac4e379419b02250a2675c","type":"GENE","name":"NGRNP4","canonical_id":"hgnc:HGNC:56903","description":"NGRN pseudogene 4","metadata":null},{"id":"8633597778a843c28754e26026799fa7","type":"TRIAL","name":"NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)","canonical_id":"clinicaltrials.gov:NCT00322465","description":"Urethritis","metadata":null},{"id":"0e5e77bc81fa4703b1385acf070848ac","type":"GO_TERM","name":"NHE3/E3KARP/ACTN4 complex","canonical_id":"go:GO:0032766","description":"\"A heterotrimeric protein complex formed by the association of NHE3, E3KARP and alpha-actinin upon an increase in calcium ion concentration; found in clusters localized on plasma membrane and in intracellular compartments.\" [PMID:11948184]","metadata":null},{"id":"7ea0ba5b2a5c4f76bedaad33166450a4","type":"GENE","name":"NHEG1","canonical_id":"hgnc:HGNC:56731","description":"neuroblastoma highly expressed DDX5 stabilizing lncRNA 1","metadata":null},{"id":"94f84dd07f1d4ce1a9de84d76161365b","type":"GENE","name":"NHEJ1","canonical_id":"hgnc:HGNC:25737","description":"non-homologous end joining factor 1","metadata":{"aliases":["Cernunnos","XLF","FLJ12610"]}},{"id":"b73a422a125b4be6a09df0c17bd59940","type":"GENE","name":"NHERF1","canonical_id":"hgnc:HGNC:11075","description":"NHERF family PDZ scaffold protein 1","metadata":{"aliases":["NHERF","EBP50","NHERF-1","NHE-RF","SLC9A3R1"]}},{"id":"3dbd2451967c4920933dd4ffb29fa429","type":"GENE","name":"NHERF2","canonical_id":"hgnc:HGNC:11076","description":"NHERF family PDZ scaffold protein 2","metadata":{"aliases":["SIP-1","TKA-1","NHERF-2","E3KARP","OCTS2","SLC9A3R2"]}},{"id":"3736ab6956a64a3e81f4b0e1685ff7e7","type":"GENE","name":"NHERF4","canonical_id":"hgnc:HGNC:19891","description":"NHERF family PDZ scaffold protein 4","metadata":{"aliases":["FLJ22756","IKEPP","NaPi-Cap2","PDZK2","PDZD3"]}},{"id":"24e6f8a465b34532b3946b7d403e5432","type":"GENE","name":"NHIP","canonical_id":"hgnc:HGNC:55561","description":"neuronal hypoxia inducible, placenta associated","metadata":null},{"id":"c695891702a4489db0ecf40c744a2eef","type":"TRIAL","name":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT01451515","description":"Lymphoblastic Lymphoma","metadata":null},{"id":"782167c3e12343d0aeadcbab59927eb7","type":"TRIAL","name":"NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy","canonical_id":"clinicaltrials.gov:NCT00000578","description":"Asthma; Lung Diseases","metadata":null},{"id":"c8dc57cc91cf4785b3151227d025bd7b","type":"GENE","name":"NHLH1","canonical_id":"hgnc:HGNC:7817","description":"nescient helix-loop-helix 1","metadata":{"aliases":["NSCL","NSCL1","bHLHa35","HEN1"]}},{"id":"f08a64344528491ca4ee7340f1ee9a05","type":"GENE","name":"NHLH2","canonical_id":"hgnc:HGNC:7818","description":null,"metadata":null},{"id":"d0287beb09e94a749eb148d846ea8442","type":"GENE","name":"NHLRC1","canonical_id":"hgnc:HGNC:21576","description":"NHL repeat containing E3 ubiquitin protein ligase 1","metadata":{"aliases":["bA204B7.2","EPM2B"]}},{"id":"6f49c69b01e14d02a23bd207441141fa","type":"GENE","name":"NHLRC2","canonical_id":"hgnc:HGNC:24731","description":"NHL repeat containing 2","metadata":{"aliases":["FLJ25621","FLJ20147","FLJ33312","MGC45492","DKFZp779F115"]}},{"id":"62c250f91bb744b69f737e08ab76d309","type":"GENE","name":"NHLRC3","canonical_id":"hgnc:HGNC:33751","description":"NHL repeat containing 3","metadata":null},{"id":"4e0686f61cd84a7483cc0c1d72f3695d","type":"GENE","name":"NHLRC4","canonical_id":"hgnc:HGNC:26700","description":"NHL repeat containing 4","metadata":null},{"id":"2fc32d1477a34a269c4482feaaef3be4","type":"GENE","name":"NHP2","canonical_id":"hgnc:HGNC:14377","description":"NHP2 ribonucleoprotein","metadata":{"aliases":["FLJ20479","NOLA2"]}},{"id":"27434c56f7f84aa9a804244ad8b55952","type":"GENE","name":"NHP2P1","canonical_id":"hgnc:HGNC:23582","description":"NHP2 ribonucleoprotein pseudogene 1","metadata":{"aliases":["bA360G10.4","NOLA2P1"]}},{"id":"135c80c4073a49ebb21c13a44e14c2ba","type":"GENE","name":"NHP2P2","canonical_id":"hgnc:HGNC:22797","description":"NHP2 ribonucleoprotein pseudogene 2","metadata":{"aliases":["TCAG_30283"]}},{"id":"2278295550174a6c9033f40ff0ff2a31","type":"GENE","name":"NHS","canonical_id":"hgnc:HGNC:7820","description":"NHS actin remodeling regulator","metadata":null},{"id":"2009dcb38dd4460c8383b86442b94216","type":"GENE","name":"NHS-AS1","canonical_id":"hgnc:HGNC:40403","description":"NHS antisense RNA 1","metadata":null},{"id":"bec7f304247849679149c65a5b946ad1","type":"GENE","name":"NHSL1","canonical_id":"hgnc:HGNC:21021","description":"NHS like 1","metadata":{"aliases":["bA43P8.1","KIAA1357","C6orf63"]}},{"id":"1aedc8904f3746fdbc0dd8d4ca42f7ea","type":"GENE","name":"NHSL1-AS1","canonical_id":"hgnc:HGNC:40947","description":"NHSL1 antisense RNA 1","metadata":{"aliases":["FLJ46906"]}},{"id":"9b01bdaa221948c790a5b896901239a2","type":"GENE","name":"NHSL2","canonical_id":"hgnc:HGNC:33737","description":"NHS like 2","metadata":null},{"id":"ad8207e7406d462191b16a3b77acc62d","type":"GENE","name":"NHSL3","canonical_id":"hgnc:HGNC:29301","description":"NHS like 3","metadata":{"aliases":["KIAA1522"]}},{"id":"add4e29e3d8b416597d86258d61d72be","type":"GENE","name":"NIBAN1","canonical_id":"hgnc:HGNC:16784","description":"niban apoptosis regulator 1","metadata":{"aliases":["NIBAN","GIG39","C1orf24","FAM129A"]}},{"id":"4d83bf56764e4b21b2e2de73c8e66b31","type":"GENE","name":"NIBAN2","canonical_id":"hgnc:HGNC:25282","description":"niban apoptosis regulator 2","metadata":{"aliases":["DKFZP434H0820","FLJ13518","FLJ22151","FLJ22298","bA356B19.6","MINERVA","C9orf88","FAM129B"]}},{"id":"f8f7ad42bbe945d28974a67089af0043","type":"GENE","name":"NIBAN3","canonical_id":"hgnc:HGNC:24130","description":"niban apoptosis regulator 3","metadata":{"aliases":["FLJ39802","BCNP1","FAM129C"]}},{"id":"9492ec63fdb84a28aa1003161caef3dc","type":"GENE","name":"NICN1","canonical_id":"hgnc:HGNC:18317","description":"nicolin 1, tubulin polyglutamylase complex subunit","metadata":{"aliases":["MGC12936"]}},{"id":"09f21d0d60a0404e96820c04b394324c","type":"GENE","name":"NICN2P","canonical_id":"hgnc:HGNC:18322","description":"nicolin 2, pseudogene","metadata":null},{"id":"73bf80146d294a5a86d0e91ce7621c00","type":"GENE","name":"NICOL1","canonical_id":"hgnc:HGNC:34437","description":"NELL2 interacting cell ontogeny regulator 1","metadata":{"aliases":["NICOL","C4orf48"]}},{"id":"65e7ecc7f0a7428f89e392db1ebad292","type":"GENE","name":"NID1","canonical_id":"hgnc:HGNC:7821","description":"nidogen 1","metadata":{"aliases":["entactin","NID"]}},{"id":"98999276dd2f4a079330f928cbbdbf68","type":"GENE","name":"NID2","canonical_id":"hgnc:HGNC:13389","description":"nidogen 2","metadata":null},{"id":"df202eb284c340639358edbec780e194","type":"GENE","name":"NIF3L1","canonical_id":"hgnc:HGNC:13390","description":"NGG1 interacting factor 3 like 1","metadata":{"aliases":["CALS-7","MDS015","ALS2CR1"]}},{"id":"df2e9bfa692e49689066baae1d74ca13","type":"GENE","name":"NIFK","canonical_id":"hgnc:HGNC:17838","description":"nucleolar protein interacting with the FHA domain of MKI67","metadata":{"aliases":["Nop15","Nopp34","hNIFK","MKI67IP"]}},{"id":"ae6c70f546214f6190a44ef375c32d1e","type":"GENE","name":"NIFK-AS1","canonical_id":"hgnc:HGNC:27385","description":"NIFK antisense RNA 1","metadata":null},{"id":"39d298d27832492fb227c2e8bcc7cac2","type":"GENE","name":"NIFKP1","canonical_id":"hgnc:HGNC:44949","description":"NIFK pseudogene 1","metadata":{"aliases":["MKI67IPP1"]}},{"id":"21502ee5d0ba4ae1bb34c5eb9d280870","type":"GENE","name":"NIFKP2","canonical_id":"hgnc:HGNC:44950","description":"NIFK pseudogene 2","metadata":{"aliases":["MKI67IPP2"]}},{"id":"f5e33636b6354b6097474ae5868ea32e","type":"GENE","name":"NIFKP3","canonical_id":"hgnc:HGNC:44951","description":"NIFK pseudogene 3","metadata":{"aliases":["MKI67IPP3"]}},{"id":"ac977a25eb1946a5a57eb27ced26c9fa","type":"GENE","name":"NIFKP4","canonical_id":"hgnc:HGNC:44952","description":"NIFK pseudogene 4","metadata":{"aliases":["MKI67IPP4"]}},{"id":"da0ea82330fe4043883d3d6bdde034c8","type":"GENE","name":"NIFKP5","canonical_id":"hgnc:HGNC:44953","description":"NIFK pseudogene 5","metadata":{"aliases":["MKI67IPP5"]}},{"id":"d33393560d9b4c329fe02f0c325d5a82","type":"GENE","name":"NIFKP6","canonical_id":"hgnc:HGNC:44954","description":"NIFK pseudogene 6","metadata":{"aliases":["MKI67IPP6"]}},{"id":"ce0f86614c244e688af7ae84b3a6e4a3","type":"GENE","name":"NIFKP7","canonical_id":"hgnc:HGNC:44955","description":"NIFK pseudogene 7","metadata":{"aliases":["MKI67IPP7"]}},{"id":"40e04c5b21c544db99c693adc915a7ce","type":"GENE","name":"NIFKP8","canonical_id":"hgnc:HGNC:44956","description":"NIFK pseudogene 8","metadata":{"aliases":["MKI67IPP8"]}},{"id":"08f99e60faca4125b48527bc2844acb9","type":"GENE","name":"NIFKP9","canonical_id":"hgnc:HGNC:44957","description":"NIFK pseudogene 9","metadata":{"aliases":["MKI67IPP9"]}},{"id":"7df7799487584533bb85715f17ccfe91","type":"GENE","name":"NIHCOLE","canonical_id":"hgnc:HGNC:53024","description":"ncRNA involved in NHEJ oncogenic ligation efficiency","metadata":{"aliases":["RP11-138J23.1","LINC02163"]}},{"id":"08c9e9d654ca4091966a3389d40c8667","type":"GENE","name":"NIM1K","canonical_id":"hgnc:HGNC:28646","description":"NIM1 serine/threonine protein kinase","metadata":{"aliases":["MGC42105","NIM1"]}},{"id":"9e88d89c4c8642c48a85a8358fedfbea","type":"GENE","name":"NIM1K-DT","canonical_id":"hgnc:HGNC:59037","description":"NIM1K divergent transcript","metadata":null},{"id":"6183aaf51dca4c2386069d171a108ad4","type":"GENE","name":"NIN","canonical_id":"hgnc:HGNC:14906","description":"ninein","metadata":null},{"id":"e2cf702b35e04e4e9899f8062fb40308","type":"GENE","name":"NINJ1","canonical_id":"hgnc:HGNC:7824","description":"ninjurin 1","metadata":{"aliases":["NIN1"]}},{"id":"d5eee4eda5534c3685138ccbaa063542","type":"GENE","name":"NINJ2","canonical_id":"hgnc:HGNC:7825","description":"ninjurin 2","metadata":null},{"id":"d572772ac66e4c60a5c710707710ed7b","type":"GENE","name":"NINJ2-AS1","canonical_id":"hgnc:HGNC:40405","description":"NINJ2 antisense RNA 1","metadata":null},{"id":"1079d2e77342440580df03a7632f8b11","type":"GENE","name":"NINL","canonical_id":"hgnc:HGNC:29163","description":"ninein like","metadata":{"aliases":["KIAA0980","NLP"]}},{"id":"b770d5fa71344ff08689e4832bef76cb","type":"GENE","name":"NIP7","canonical_id":"hgnc:HGNC:24328","description":"nucleolar pre-rRNA processing protein NIP7","metadata":{"aliases":["CGI-37","FLJ10296","HSPC031","KD93"]}},{"id":"c03c1410dd974e31a1a503f0fc9af769","type":"GENE","name":"NIP7P1","canonical_id":"hgnc:HGNC:45180","description":"NIP7 pseudogene 1","metadata":null},{"id":"99d24e446b914f969fa612863ed17561","type":"GENE","name":"NIP7P2","canonical_id":"hgnc:HGNC:45181","description":"NIP7 pseudogene 2","metadata":null},{"id":"a53972eeadb044129b6e521ab4ea00fd","type":"GENE","name":"NIP7P3","canonical_id":"hgnc:HGNC:45182","description":"NIP7 pseudogene 3","metadata":null},{"id":"ccf2cbd553894ba7aa84fd5a8eb3b512","type":"GENE","name":"NIPA1","canonical_id":"hgnc:HGNC:17043","description":"NIPA magnesium transporter 1","metadata":{"aliases":["MGC35570","SLC57A1","SPG6"]}},{"id":"93508cd547544b328b9d884236b243fd","type":"GENE","name":"NIPA2","canonical_id":"hgnc:HGNC:17044","description":"NIPA magnesium transporter 2","metadata":{"aliases":["SLC57A2"]}},{"id":"614e81acddf54dcd88e235552af04d32","type":"GENE","name":"NIPA2P1","canonical_id":"hgnc:HGNC:42041","description":"NIPA2 pseudogene 1","metadata":null},{"id":"4528cd0400df4d3cb27aeb293a4c0045","type":"GENE","name":"NIPA2P2","canonical_id":"hgnc:HGNC:42042","description":"NIPA2 pseudogene 2","metadata":null},{"id":"e0e4cbcabae24860ba7c73760de682e2","type":"GENE","name":"NIPA2P3","canonical_id":"hgnc:HGNC:42043","description":"NIPA2 pseudogene 3","metadata":null},{"id":"f54797cb8a014e06b2b8c5cfc2b96064","type":"GENE","name":"NIPA2P4","canonical_id":"hgnc:HGNC:42044","description":"NIPA2 pseudogene 4","metadata":null},{"id":"eb2f56b47ada4f6e89d43d146cc7661f","type":"GENE","name":"NIPA2P5","canonical_id":"hgnc:HGNC:42045","description":"NIPA2 pseudogene 5","metadata":null},{"id":"e23ab90d7b554cb181d7e9b3502ffa82","type":"GENE","name":"NIPAL1","canonical_id":"hgnc:HGNC:27194","description":"NIPA like domain containing 1","metadata":{"aliases":["DKFZp686A06115","SLC57A3","NIPA3","NPAL1"]}},{"id":"3d21a8ca56c5477498c168ca3dbd44ea","type":"GENE","name":"NIPAL1P1","canonical_id":"hgnc:HGNC:56952","description":"NIPAL1 pseudogene 1","metadata":null},{"id":"3c893ed2437844f78855d0c58d543969","type":"GENE","name":"NIPAL2","canonical_id":"hgnc:HGNC:25854","description":"NIPA like domain containing 2","metadata":{"aliases":["FLJ13955","SLC57A4","NPAL2"]}},{"id":"aa2f76199b1c4337891b1ddfed4bef50","type":"GENE","name":"NIPAL2-AS1","canonical_id":"hgnc:HGNC:56271","description":"NIPAL2 antisense RNA 1","metadata":{"aliases":["lnc-POP1-1"]}},{"id":"edaaa4e736cc490d9d25f0e31f0b9493","type":"GENE","name":"NIPAL3","canonical_id":"hgnc:HGNC:25233","description":"NIPA like domain containing 3","metadata":{"aliases":["DJ462O23.2","SLC57A5","NPAL3"]}},{"id":"722f0223e2104bc8b7e0982acedf13de","type":"GENE","name":"NIPAL4","canonical_id":"hgnc:HGNC:28018","description":"NIPA like domain containing 4","metadata":{"aliases":["ICHYN","SLC57A6","NIPA4"]}},{"id":"f683e7a69c9d45f88333aa4cb84b3d1e","type":"GENE","name":"NIPAL4-DT","canonical_id":"hgnc:HGNC:55542","description":"NIPAL4 divergent transcript","metadata":null},{"id":"26cfdbbbaf3b4280b4a48c85736959a6","type":"GENE","name":"NIPBL","canonical_id":"hgnc:HGNC:28862","description":"NIPBL cohesin loading factor","metadata":{"aliases":["IDN3","DKFZp434L1319","FLJ11203","FLJ12597","FLJ13354","FLJ13648","Scc2"]}},{"id":"3eb0f032df3342d28364f438f91e2e61","type":"GENE","name":"NIPBL-DT","canonical_id":"hgnc:HGNC:51293","description":"NIPBL divergent transcript","metadata":{"aliases":["NIPBL-AS","NIPBL-AS1"]}},{"id":"13889cd77d81488b95cc6b2e97322f08","type":"GENE","name":"NIPSNAP1","canonical_id":"hgnc:HGNC:7827","description":"nipsnap homolog 1","metadata":null},{"id":"7204d10efb784db2844cc9338e9ab1e3","type":"GENE","name":"NIPSNAP2","canonical_id":"hgnc:HGNC:4179","description":"nipsnap homolog 2","metadata":{"aliases":["GBAS"]}},{"id":"0c45bba4bf6f4267b9e06f79932252e5","type":"GENE","name":"NIPSNAP3A","canonical_id":"hgnc:HGNC:23619","description":"nipsnap homolog 3A","metadata":{"aliases":["DKFZp564D177","FLJ13953","HSPC299","MGC14553","NIPSNAP4","TassC"]}},{"id":"2ab847fb02d44bc2b480ec469d4e087a","type":"GENE","name":"NIPSNAP3B","canonical_id":"hgnc:HGNC:23641","description":"nipsnap homolog 3B","metadata":{"aliases":["FLJ11275","NIPSNAP3","SNAP1"]}},{"id":"edc961335fc343219a9e3e9169b7ca50","type":"TRIAL","name":"NIRS Ticagrelor Evaluation","canonical_id":"clinicaltrials.gov:NCT02282332","description":"Coronary Artery Disease","metadata":null},{"id":"1532d7b7d9974cb2ad273cd5196024cf","type":"GENE","name":"NISCH","canonical_id":"hgnc:HGNC:18006","description":"nischarin","metadata":{"aliases":["KIAA0975","I-1","IRAS"]}},{"id":"97db468e79134d3aa7b5bb5b7bb6f761","type":"GENE","name":"NIT1","canonical_id":"hgnc:HGNC:7828","description":"nitrilase 1","metadata":null},{"id":"f5b92b110e5348d6a3410b9da501fb42","type":"GENE","name":"NIT2","canonical_id":"hgnc:HGNC:29878","description":"nitrilase family member 2","metadata":null},{"id":"6416cb941af740ecb848e4d512730ece","type":"TRIAL","name":"NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab","canonical_id":"clinicaltrials.gov:NCT04211675","description":"Relapsed Neuroblastoma; Refractory Neuroblastoma","metadata":null},{"id":"7f11ae4dac2046d8b79e955b8b9d3f35","type":"GO_TERM","name":"NK T cell activation","canonical_id":"go:GO:0051132","description":"\"The change in morphology and behavior of a mature or immature natural killer T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"a30c622b1860494586338ef32b6b414f","type":"GO_TERM","name":"NK T cell differentiation","canonical_id":"go:GO:0001865","description":"\"The process in which a precursor cell type acquires the specialized features of a NK T cell.\" [GOC:add, ISBN:0781735149, PMID:10704459]","metadata":null},{"id":"ce12ba13e696445f8c35da204a5cdd88","type":"GO_TERM","name":"NK T cell lineage commitment","canonical_id":"go:GO:0002364","description":"\"The process in which a pro-T cell becomes committed to becoming an NK T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"3c612c010a75463a8a2494713dffdd10","type":"GO_TERM","name":"NK T cell proliferation","canonical_id":"go:GO:0001866","description":"\"The expansion of a NK T cell population by cell division.\" [GOC:add, ISBN:0781735149, PMID:10704459]","metadata":null},{"id":"b3dd1a6dcf0648f09cd389aac09b229a","type":"GENE","name":"NKAIN1","canonical_id":"hgnc:HGNC:25743","description":"sodium/potassium transporting ATPase interacting 1","metadata":{"aliases":["FLJ12650","FAM77C"]}},{"id":"15480c87e55e426dba541ffb3c3515be","type":"GENE","name":"NKAIN1P1","canonical_id":"hgnc:HGNC:38593","description":"NKAIN1 pseudogene 1","metadata":null},{"id":"9f7ecab5d5be4c998b7233bd1e36b97c","type":"GENE","name":"NKAIN1P2","canonical_id":"hgnc:HGNC:54726","description":"NKAIN1 pseudogene 2","metadata":null},{"id":"734e33dac47a422a897db72c7ce795bb","type":"GENE","name":"NKAIN2","canonical_id":"hgnc:HGNC:16443","description":"sodium/potassium transporting ATPase interacting 2","metadata":{"aliases":["FAM77B","TCBA1"]}},{"id":"5e3b77fabf224b7d8a222c5302417156","type":"GENE","name":"NKAIN3","canonical_id":"hgnc:HGNC:26829","description":"sodium/potassium transporting ATPase interacting 3","metadata":{"aliases":["FLJ39630","FAM77D","NKAIN3-IT1"]}},{"id":"88d1309ba2f04114bf6998c0f22eb0a4","type":"GENE","name":"NKAIN4","canonical_id":"hgnc:HGNC:16191","description":"sodium/potassium transporting ATPase interacting 4","metadata":{"aliases":["bA261N11.2","FAM77A","C20orf58"]}},{"id":"a8a55a00741f4ed6afa7c9e6de92e51d","type":"GENE","name":"NKAP","canonical_id":"hgnc:HGNC:29873","description":"NFKB activating protein","metadata":{"aliases":["FLJ22626"]}},{"id":"292eed87660e491a9926584f767b39f1","type":"GENE","name":"NKAPD1","canonical_id":"hgnc:HGNC:25569","description":"NKAP domain containing 1","metadata":{"aliases":["Ahed","FLJ10726","C11orf57"]}},{"id":"a461ef4970da4c53a33ae9d1126df1e3","type":"GENE","name":"NKAPL","canonical_id":"hgnc:HGNC:21584","description":"NFKB activating protein like","metadata":{"aliases":["bA424I5.1","C6orf194"]}},{"id":"cbb1598365d94bc7bba5c9bae10e04a2","type":"GENE","name":"NKAPP1","canonical_id":"hgnc:HGNC:26706","description":"NFKB activating protein pseudogene 1","metadata":{"aliases":["FLJ36576","CXorf42"]}},{"id":"c53f70b96e334513a2301107dccb4c14","type":"GENE","name":"NKD1","canonical_id":"hgnc:HGNC:17045","description":"NKD inhibitor of Wnt signaling pathway 1","metadata":null},{"id":"4ff9b25b60d242178a1c2ddc0ce3bd8d","type":"GENE","name":"NKD1-AS1","canonical_id":"hgnc:HGNC:58215","description":"NKD1 antisense RNA 1","metadata":null},{"id":"e29dcc0ddf894458a3723889491cb33b","type":"GENE","name":"NKD2","canonical_id":"hgnc:HGNC:17046","description":"NKD inhibitor of Wnt signaling pathway 2","metadata":{"aliases":["Naked2"]}},{"id":"917aed0526b94c35a298a94c12863308","type":"GENE","name":"NKG7","canonical_id":"hgnc:HGNC:7830","description":"natural killer cell granule protein 7","metadata":{"aliases":["GIG1","GMP-17"]}},{"id":"1576dd66a22644afb1b8ada93f141b3f","type":"GENE","name":"NKILA","canonical_id":"hgnc:HGNC:51599","description":"NF-kappaB interacting lncRNA","metadata":null},{"id":"ed2b9ff32e5844a5babc23fba44c7ebf","type":"GENE","name":"NKIRAS1","canonical_id":"hgnc:HGNC:17899","description":"NFKB inhibitor interacting Ras like 1","metadata":{"aliases":["KBRAS1","kappaB-Ras1"]}},{"id":"4264cd83e15943eeac8c1cefdc727b4e","type":"GENE","name":"NKIRAS2","canonical_id":"hgnc:HGNC:17898","description":"NFKB inhibitor interacting Ras like 2","metadata":{"aliases":["KBRAS2","DKFZP434N1526","kappaB-Ras2"]}},{"id":"4c044cc4af154b1d97692999e2c94867","type":"GENE","name":"NKPD1","canonical_id":"hgnc:HGNC:24739","description":"NTPase KAP family P-loop domain containing 1","metadata":{"aliases":["FLJ33600"]}},{"id":"b97a5972524a4e1faf67f6ec69d023d6","type":"GENE","name":"NKRF","canonical_id":"hgnc:HGNC:19374","description":"NFKB repressing factor","metadata":{"aliases":["XTBD3","ITBA4","NRF"]}},{"id":"fbdcafefee324d19b922f87826edc4ae","type":"GENE","name":"NKTR","canonical_id":"hgnc:HGNC:7833","description":"natural killer cell triggering receptor","metadata":{"aliases":["p104","CypNK"]}},{"id":"75abbdf662874623a7250d961fc8aac7","type":"TRIAL","name":"NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)","canonical_id":"clinicaltrials.gov:NCT00598975","description":"Tumor; Colorectal Cancer","metadata":null},{"id":"b8803f9e7246445bb155896f94a2def1","type":"GENE","name":"NKX1-1","canonical_id":"hgnc:HGNC:24975","description":"NK1 homeobox 1","metadata":{"aliases":["HSPX153","SAX2"]}},{"id":"da40eb9a77bc406581db83d2dcd5d922","type":"GENE","name":"NKX1-2","canonical_id":"hgnc:HGNC:31652","description":"NK1 homeobox 2","metadata":{"aliases":["bB238F13.2","C10orf121"]}},{"id":"a8046f19025b4b009e6d749f6b08918a","type":"GENE","name":"NKX2-1","canonical_id":"hgnc:HGNC:11825","description":null,"metadata":null},{"id":"e19cce2e79294863b8d918043fa34aac","type":"GENE","name":"NKX2-1-AS1","canonical_id":"hgnc:HGNC:40585","description":"NKX2-1 antisense RNA 1","metadata":null},{"id":"46551fac0b2147a78a763a78410c40f9","type":"GENE","name":"NKX2-2","canonical_id":"hgnc:HGNC:7835","description":null,"metadata":null},{"id":"5162724992c04d20b3f12b208f83710b","type":"GENE","name":"NKX2-2-AS1","canonical_id":"hgnc:HGNC:37154","description":"NKX2-2 antisense RNA 1","metadata":{"aliases":["NKX2-2AS"]}},{"id":"7715694f23504169983b68e65911d29f","type":"GENE","name":"NKX2-3","canonical_id":"hgnc:HGNC:7836","description":null,"metadata":null},{"id":"ff112e7711fd4778a3593e694a8748f9","type":"GENE","name":"NKX2-4","canonical_id":"hgnc:HGNC:7837","description":"NK2 homeobox 4","metadata":{"aliases":["NKX2.4","NKX2D"]}},{"id":"c179034dc1d24d48b10e141ded5133e2","type":"GENE","name":"NKX2-5","canonical_id":"hgnc:HGNC:2488","description":null,"metadata":null},{"id":"55653a68bc0f4a2c80c98da269455868","type":"GENE","name":"NKX2-6","canonical_id":"hgnc:HGNC:32940","description":"NK2 homeobox 6","metadata":{"aliases":["CSX2","NKX4-2"]}},{"id":"3a8b47943879467ca23e4f6bdd56e5bb","type":"GENE","name":"NKX2-8","canonical_id":"hgnc:HGNC:16364","description":"NK2 homeobox 8","metadata":{"aliases":["NKX2.8","Nkx2-9","NKX2H"]}},{"id":"e0452f6e4a0244cf8b8d07e58ff77a55","type":"GENE","name":"NKX3-1","canonical_id":"hgnc:HGNC:7838","description":null,"metadata":null},{"id":"644c0557a1f3446da9e24195d8310caf","type":"GENE","name":"NKX3-2","canonical_id":"hgnc:HGNC:951","description":"NK3 homeobox 2","metadata":{"aliases":["NKX3B","NKX3.2","BAPX1"]}},{"id":"0279ca8197c845e7b1eb73e76b09c549","type":"GENE","name":"NKX6-1","canonical_id":"hgnc:HGNC:7839","description":null,"metadata":null},{"id":"316b44769d95470889dda803690a09d8","type":"GENE","name":"NKX6-1-DT","canonical_id":"hgnc:HGNC:58839","description":"NKX6-1 divergent transcript","metadata":null},{"id":"7eafdaf8f57b4e088ea5866037eb1400","type":"GENE","name":"NKX6-2","canonical_id":"hgnc:HGNC:19321","description":"NK6 homeobox 2","metadata":{"aliases":["NKX6B","GTX","NKX6.1"]}},{"id":"ef70c313411f4a868e8772216864a73d","type":"GENE","name":"NKX6-3","canonical_id":"hgnc:HGNC:26328","description":"NK6 homeobox 3","metadata":{"aliases":["FLJ25169"]}},{"id":"01ea1895c02b4ce58a9b2bcc79aedbf2","type":"GENE","name":"NLE1","canonical_id":"hgnc:HGNC:19889","description":"notchless homolog 1","metadata":{"aliases":["FLJ10458","Rsa4","NLE"]}},{"id":"5f66caefcf37466394cdb8e20cacef63","type":"GENE","name":"NLGN1","canonical_id":"hgnc:HGNC:14291","description":"neuroligin 1","metadata":{"aliases":["KIAA1070","NLG1"]}},{"id":"b25381851f9d41339fcb8a02e2979ba4","type":"GENE","name":"NLGN1-AS1","canonical_id":"hgnc:HGNC:40676","description":"NLGN1 antisense RNA 1","metadata":null},{"id":"177105d62e504ae5b70f4398a044cbbb","type":"GENE","name":"NLGN2","canonical_id":"hgnc:HGNC:14290","description":"neuroligin 2","metadata":{"aliases":["KIAA1366"]}},{"id":"9db7e1ea64674936adf1f1b68f980c71","type":"GENE","name":"NLGN3","canonical_id":"hgnc:HGNC:14289","description":"neuroligin 3","metadata":{"aliases":["HNL3","KIAA1480","ASPGX1","AUTSX1"]}},{"id":"f586070cfb244b8b84a6f6503c56a1d4","type":"GENE","name":"NLGN4X","canonical_id":"hgnc:HGNC:14287","description":"neuroligin 4 X-linked","metadata":{"aliases":["KIAA1260","NLGN","HLNX","NLGN4"]}},{"id":"1c1544f8094f4c0da9fc26cbc048c7d5","type":"GENE","name":"NLGN4Y","canonical_id":"hgnc:HGNC:15529","description":"neuroligin 4 Y-linked","metadata":{"aliases":["KIAA0951"]}},{"id":"edcc2ef8f72742428e3d17e6275b909c","type":"GENE","name":"NLGN4Y-AS1","canonical_id":"hgnc:HGNC:38793","description":"NLGN4Y antisense RNA 1","metadata":{"aliases":["NLGN4YAS","NLGN4Y-AS"]}},{"id":"2ab6c0cc8185452984e9c98cb952c1bf","type":"GENE","name":"NLK","canonical_id":"hgnc:HGNC:29858","description":null,"metadata":null},{"id":"8efdea77472e458c803b829cd0615a71","type":"GENE","name":"NLN","canonical_id":"hgnc:HGNC:16058","description":"neurolysin","metadata":{"aliases":["KIAA1226","AGTBP"]}},{"id":"8afa0f65dc8c4f09ad00308ff18eb06e","type":"GENE","name":"NLRC3","canonical_id":"hgnc:HGNC:29889","description":"NLR family CARD domain containing 3","metadata":{"aliases":["CLR16.2","FLJ00348","NOD3"]}},{"id":"aea1780f1b9143c08521b756f2193a99","type":"GENE","name":"NLRC4","canonical_id":"hgnc:HGNC:16412","description":null,"metadata":null},{"id":"82e826aa062b4ed1bbac71ef1915361d","type":"GENE","name":"NLRC5","canonical_id":"hgnc:HGNC:29933","description":"NLR family CARD domain containing 5","metadata":{"aliases":["NOD27","CLR16.1","FLJ21709"]}},{"id":"888eed1034b643d7b1b0ae4cd483811e","type":"GENE","name":"NLRP1","canonical_id":"hgnc:HGNC:14374","description":"NLR family pyrin domain containing 1","metadata":{"aliases":["KIAA0926","DKFZp586O1822","CARD7","NAC","CLR17.1","DEFCAP","VAMAS1","NALP1","SLEV1"]}},{"id":"8982033878324bbb8a99b2f787c62fb6","type":"GO_TERM","name":"NLRP1 inflammasome complex","canonical_id":"go:GO:0072558","description":"\"An inflammasome complex that consists of two components, NLRP1 (NALP1) and caspase-1 or caspase-5. The exact mechanisms of NLRP1 activation remain obscure, but potassium ion efflux appears to be essential.\" [GOC:add, GOC:BHF, GOC:vp, PMID:20303873]","metadata":null},{"id":"133da84f3f2b468da690debddcfcd401","type":"GO_TERM","name":"NLRP1 inflammasome complex assembly","canonical_id":"go:GO:1904784","description":"\"The aggregation, arrangement and bonding together of a set of components to form a NLRP1 inflammasome complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:19124602]","metadata":null},{"id":"141dcf2ceca243f88f68a4b8f0ccd807","type":"GENE","name":"NLRP10","canonical_id":"hgnc:HGNC:21464","description":"NLR family pyrin domain containing 10","metadata":{"aliases":["NOD8","PAN5","Pynod","CLR11.1","NALP10"]}},{"id":"c29db142bcfb4d61bfa664a9f97b2ab4","type":"GENE","name":"NLRP11","canonical_id":"hgnc:HGNC:22945","description":"NLR family pyrin domain containing 11","metadata":{"aliases":["PYPAF6","NOD17","PAN10","CLR19.6","NALP11"]}},{"id":"eb007b7ff2a3418abed50bb74bc1d8af","type":"GENE","name":"NLRP12","canonical_id":"hgnc:HGNC:22938","description":"NLR family pyrin domain containing 12","metadata":{"aliases":["RNO2","PYPAF7","Monarch1","PAN6","CLR19.3","NALP12"]}},{"id":"c3512e5b3e8d49c7ad0ae68bc8f62183","type":"GENE","name":"NLRP13","canonical_id":"hgnc:HGNC:22937","description":"NLR family pyrin domain containing 13","metadata":{"aliases":["NOD14","PAN13","CLR19.7","NALP13"]}},{"id":"e2ddb9ca68014918bb7f3253a65b0abe","type":"GENE","name":"NLRP14","canonical_id":"hgnc:HGNC:22939","description":"NLR family pyrin domain containing 14","metadata":{"aliases":["NOD5","GC-LRR","Nalp-iota","PAN8","CLR11.2","NALP14"]}},{"id":"12346e269aa849149086f3c9826b8c90","type":"GENE","name":"NLRP2","canonical_id":"hgnc:HGNC:22948","description":null,"metadata":null},{"id":"bb9cc9e886e9481b89de4768b739a18b","type":"GENE","name":"NLRP2B","canonical_id":"hgnc:HGNC:29887","description":"NLR family pyrin domain containing 2B","metadata":{"aliases":["NOD24","NALP2P","CLRX.1","POP4","NLRP2P"]}},{"id":"a8519f5689b44927b1032bd65cd240c4","type":"GENE","name":"NLRP3","canonical_id":"hgnc:HGNC:16400","description":"NLR family pyrin domain containing 3","metadata":{"aliases":["AGTAVPRL","AII","AVP","FCAS","FCU","NALP3","PYPAF1","MWS","CLR1.1","C1orf7","CIAS1","DFNA34"]}},{"id":"54fec420e62a4392bce71207d9676c4a","type":"GO_TERM","name":"NLRP3 inflammasome complex","canonical_id":"go:GO:0072559","description":"\"An inflammasome complex that consists of three components, NLRP3 (NALP3), PYCARD and caspase-1. It is activated upon exposure to whole pathogens, as well as a number of structurally diverse pathogen- and danger-associated molecular patterns (PAMPs and DAMPs) and environmental irritants. Whole pathogens demonstrated to activate the NLRP3 inflammasome complex include the fungi Candida albicans and Saccharomyces cerevisiae, bacteria that produce pore-forming toxins, including Listeria monocytogenes and Staphylococcus aureus, and viruses such as Sendai virus, adenovirus, and influenza virus.\" [GOC:add, GOC:BHF, GOC:vp, PMID:20303873]","metadata":null},{"id":"672bcdaf7b814153b523ae5c6b67a9b6","type":"GO_TERM","name":"NLRP3 inflammasome complex assembly","canonical_id":"go:GO:0044546","description":"\"The aggregation, arrangement and bonding together of a set of components to form the NLRP3 inflammasome complex, occurring at the level of an individual cell.\" [GOC:jl, PMID:21048113]","metadata":null},{"id":"48146085529f4f759b946bf921a5ca25","type":"GENE","name":"NLRP3P1","canonical_id":"hgnc:HGNC:29886","description":"NLR family pyrin domain containing 3 pseudogene 1","metadata":{"aliases":["NOD13","NLRP3P"]}},{"id":"4c5d1af2d6c44ebda5b86519f24a8860","type":"GENE","name":"NLRP4","canonical_id":"hgnc:HGNC:22943","description":"NLR family pyrin domain containing 4","metadata":{"aliases":["PYPAF4","FLJ32126","PAN2","RNH2","CLR19.5","CT58","NALP4"]}},{"id":"8786d7198e6546619a29a2774b750485","type":"GENE","name":"NLRP5","canonical_id":"hgnc:HGNC:21269","description":"NLR family pyrin domain containing 5","metadata":{"aliases":["PYPAF8","MATER","PAN11","CLR19.8","NALP5"]}},{"id":"e30804525e6d4fef9773f7c6360bf050","type":"GENE","name":"NLRP6","canonical_id":"hgnc:HGNC:22944","description":"NLR family pyrin domain containing 6","metadata":{"aliases":["PYPAF5","PAN3","CLR11.4","NALP6"]}},{"id":"15aea16080f6413db1900edd5f918c8c","type":"GO_TERM","name":"NLRP6 inflammasome complex","canonical_id":"go:GO:0140738","description":"\"An inflammasome complex that consists of NLRP6, PYCARD/ASC and caspase-1 or caspase-4/caspase-11.\" [PMID:30674671, PMID:34678144]","metadata":null},{"id":"aada2963a0f540b1b4433633df310fa8","type":"GO_TERM","name":"NLRP6 inflammasome complex assembly","canonical_id":"go:GO:0140739","description":"\"The aggregation, arrangement and bonding together of a set of components to form a NLRP6 inflammasome complex.\" [PMID:30674671, PMID:34678144]","metadata":null},{"id":"5428154a62d64f8883b92547b9a53249","type":"GENE","name":"NLRP7","canonical_id":"hgnc:HGNC:22947","description":"NLR family pyrin domain containing 7","metadata":{"aliases":["PYPAF3","NOD12","PAN7","CLR19.4","NALP7"]}},{"id":"ac3e60155b2f45cfb834be080c2bf3ee","type":"GENE","name":"NLRP7P1","canonical_id":"hgnc:HGNC:55131","description":"NLRP7 pseudogene 1","metadata":null},{"id":"0771c9fee5a14493a690a540d3feac9c","type":"GENE","name":"NLRP8","canonical_id":"hgnc:HGNC:22940","description":"NLR family pyrin domain containing 8","metadata":{"aliases":["NOD16","PAN4","CLR19.2","NALP8"]}},{"id":"635f87c6b50e4a97a21b0e4cf9617f22","type":"GENE","name":"NLRP9","canonical_id":"hgnc:HGNC:22941","description":"NLR family pyrin domain containing 9","metadata":{"aliases":["NOD6","PAN12","CLR19.1","NALP9"]}},{"id":"54fa0a739d5f44b1b509b7877c323ed7","type":"GENE","name":"NLRP9P1","canonical_id":"hgnc:HGNC:29888","description":"NLR family pyrin domain containing 9 pseudogene 1","metadata":{"aliases":["NOD25","NLRP9P"]}},{"id":"9e5674ba7b32499b809929002d1a1896","type":"GENE","name":"NLRX1","canonical_id":"hgnc:HGNC:29890","description":"NLR family member X1","metadata":{"aliases":["NOD9","CLR11.3"]}},{"id":"30b67dc578824e759fc29ff746987605","type":"GO_TERM","name":"NLS-bearing protein import into nucleus","canonical_id":"go:GO:0006607","description":"\"The directed movement of a protein bearing a nuclear localization signal (NLS) from the cytoplasm into the nucleus, across the nuclear envelope.\" [GOC:ai]","metadata":null},{"id":"c3925db8d00c4a51aeaf3127d4b8b7d1","type":"GO_TERM","name":"NLS-dependent protein nuclear import complex","canonical_id":"go:GO:0042564","description":"\"A dimer consisting of an alpha and a beta-subunit that imports proteins with an NLS into the nucleus through a nuclear pore.\" [GOC:jl, PMID:9323123, PMID:9323134, Wikipedia:Importin]","metadata":null},{"id":"c3fc43fd7c5c46cf8eb5958a592d3c94","type":"GENE","name":"NMB","canonical_id":"hgnc:HGNC:7842","description":"neuromedin B","metadata":{"aliases":["MGC2277","MGC3936","MGC17211"]}},{"id":"6b14f5400d694ecbad8bc30eac8e42e1","type":"GENE","name":"NMBR","canonical_id":"hgnc:HGNC:7843","description":"neuromedin B receptor","metadata":{"aliases":["BB1","BB1R","BRS1"]}},{"id":"7e64c102d57c4d7290d55f250639047a","type":"GENE","name":"NMBR-AS1","canonical_id":"hgnc:HGNC:40406","description":"NMBR antisense RNA 1","metadata":{"aliases":["RP11-137J7.2"]}},{"id":"760850c26bb3436c9c181288880d6d2d","type":"GENE","name":"NMD3","canonical_id":"hgnc:HGNC:24250","description":"NMD3 ribosome export adaptor","metadata":{"aliases":["CGI-07"]}},{"id":"01276cb172fb45578086dd1c09eef8f0","type":"GENE","name":"NMD3P1","canonical_id":"hgnc:HGNC:22672","description":"NMD3 ribosome export adaptor pseudogene 1","metadata":{"aliases":["NMD3P"]}},{"id":"e6a6494676b940838f76543524cbbac1","type":"GENE","name":"NMD3P2","canonical_id":"hgnc:HGNC:37820","description":"NMD3 ribosome export adaptor pseudogene 2","metadata":null},{"id":"60c1185b0602419ba503c8546bc86b15","type":"GO_TERM","name":"NMDA glutamate receptor activity","canonical_id":"go:GO:0004972","description":"\"A cation channel that opens in response to binding by extracellular glutmate, but only if glycine or D-serine is also bound and the membrane is depolarized. Voltage gating is indirect, due to ejection of bound magnesium from the pore at permissive voltages.\" [GOC:mah, PMID:10049997, PMID:7790891]","metadata":null},{"id":"79676b3e0d044568b6762c3cf93a0469","type":"GO_TERM","name":"NMDA glutamate receptor clustering","canonical_id":"go:GO:0097114","description":"\"The receptor clustering process in which N-methyl-D-aspartate (NMDA) receptors are localized to distinct domains in the cell membrane.\" [GOC:BHF, GOC:sjp, PMID:15620359]","metadata":null},{"id":"903e267fd529452e9a33be7369e7319e","type":"GO_TERM","name":"NMDA selective glutamate receptor complex","canonical_id":"go:GO:0017146","description":"\"An assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex. NMDA receptors are composed of assemblies of NR1 subunits (Figure 3) and NR2 subunits, which can be one of four separate gene products (NR2A-D). Expression of both subunits are required to form functional channels. The glutamate binding domain is formed at the junction of NR1 and NR2 subunits. NMDA receptors are permeable to calcium ions as well as being permeable to other ions. Thus NMDA receptor activation leads to a calcium influx into the post-synaptic cells, a signal thought to be crucial for the induction of NMDA-receptor dependent LTP and LTD.\" [PMID:8294079]","metadata":null},{"id":"c4e74c6c3afb43a8ad2f31bca08b5ee3","type":"GO_TERM","name":"NMDA selective glutamate receptor signaling pathway","canonical_id":"go:GO:0098989","description":"\"The series of molecular signals initiated by glutamate binding to an NMDA-selective glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dos, ISBN:9780071120005]","metadata":null},{"id":"e44be4d9a36641c4b06154712083ae33","type":"GENE","name":"NME1","canonical_id":"hgnc:HGNC:7849","description":null,"metadata":null},{"id":"ea07145332d24528ab4611f39af79202","type":"GENE","name":"NME1-NME2","canonical_id":"hgnc:HGNC:33531","description":"NME1-NME2 readthrough","metadata":{"aliases":["NM23-LV","NMELV"]}},{"id":"f9704b29b6ef443cb30da90180072a20","type":"GENE","name":"NME1P1","canonical_id":"hgnc:HGNC:39904","description":"NME/NM23 nucleoside diphosphate kinase 1 pseudogene 1","metadata":null},{"id":"0292194cf660441f84a012e28d527875","type":"GENE","name":"NME2","canonical_id":"hgnc:HGNC:7850","description":"NME/NM23 nucleoside diphosphate kinase 2","metadata":{"aliases":["NM23-H2","NDPKB"]}},{"id":"737db64a3e4946ae8f47002d724f591a","type":"GENE","name":"NME2P1","canonical_id":"hgnc:HGNC:31358","description":"NME2 pseudogene 1","metadata":null},{"id":"a715d52454354ad7b1403da6fae15bd4","type":"GENE","name":"NME2P2","canonical_id":"hgnc:HGNC:54766","description":"NME2 pseudogene 2","metadata":null},{"id":"48e54ffd69d54f6a9fccce2c6e743961","type":"GENE","name":"NME2P3","canonical_id":"hgnc:HGNC:54767","description":"NME2 pseudogene 3","metadata":null},{"id":"8eea3d380e8f4fa5803c4fe6bbc6be29","type":"GENE","name":"NME3","canonical_id":"hgnc:HGNC:7851","description":null,"metadata":null},{"id":"b49148be6bbb448c92eb8dbf6260f05d","type":"GENE","name":"NME4","canonical_id":"hgnc:HGNC:7852","description":"NME/NM23 nucleoside diphosphate kinase 4","metadata":{"aliases":["nm23-H4","NM23H4","NDPKD"]}},{"id":"434aba43d0854738a70ce2485dd90ac5","type":"GENE","name":"NME5","canonical_id":"hgnc:HGNC:7853","description":"NME/NM23 family member 5","metadata":{"aliases":["nm23-H5","RSPH23"]}},{"id":"25c6c6b45eb54ccda11a3c4da9b994df","type":"GENE","name":"NME6","canonical_id":"hgnc:HGNC:20567","description":"NME/NM23 nucleoside diphosphate kinase 6","metadata":{"aliases":["NM23-H6","IPIA-ALPHA"]}},{"id":"3f36a10f68a44e96a8d3a490e0c5a823","type":"GENE","name":"NME7","canonical_id":"hgnc:HGNC:20461","description":"NME/NM23 family member 7","metadata":{"aliases":["FLJ37194","NM23-H7","CFAP67"]}},{"id":"d8ba8ce3e3d440e2bae57ed16e88f25f","type":"GENE","name":"NME8","canonical_id":"hgnc:HGNC:16473","description":"NME/NM23 family member 8","metadata":{"aliases":["CILD6","SPTRX2","NM23-H8","DNAI8","TXNDC3"]}},{"id":"2072250b6213402faebd0db7ca49bee0","type":"GENE","name":"NME9","canonical_id":"hgnc:HGNC:21343","description":"NME/NM23 family member 9","metadata":{"aliases":["TXL-2","NM23-H9","TXNDC6"]}},{"id":"5024381ec93f48f49a8e2d9a1a88515d","type":"GENE","name":"NMI","canonical_id":"hgnc:HGNC:7854","description":"N-myc and STAT interactor","metadata":null},{"id":"d1069944e3934e08a20979f37cde51c6","type":"GO_TERM","name":"NMN nucleosidase activity","canonical_id":"go:GO:0019160","description":"\"Catalysis of the reaction: H2O + nicotinamide mononucleotide = D-ribose 5-phosphate + H+ + nicotinamide.\" [EC:3.2.2.14, RHEA:23140]","metadata":null},{"id":"43f6aa217ac74949b9c510c7239ef70a","type":"GENE","name":"NMNAT1","canonical_id":"hgnc:HGNC:17877","description":"nicotinamide nucleotide adenylyltransferase 1","metadata":{"aliases":["NMNAT","PNAT1","LCA9"]}},{"id":"1a11daf68d964261b7ef59ef8d8bc4be","type":"GENE","name":"NMNAT1P1","canonical_id":"hgnc:HGNC:20024","description":"NMNAT1 pseudogene 1","metadata":{"aliases":["NMNATP"]}},{"id":"4f52eb9461464fc8b3654c2ad0c5a666","type":"GENE","name":"NMNAT1P2","canonical_id":"hgnc:HGNC:49164","description":"NMNAT1 pseudogene 2","metadata":null},{"id":"ac5764b0fafa40e4bd4cf704f2a582ee","type":"GENE","name":"NMNAT1P3","canonical_id":"hgnc:HGNC:49165","description":"NMNAT1 pseudogene 3","metadata":null},{"id":"a21a979fc69a4936b39d63b421c7e998","type":"GENE","name":"NMNAT1P4","canonical_id":"hgnc:HGNC:49166","description":"NMNAT1 pseudogene 4","metadata":null},{"id":"112bfe9b504441f88ac43c219aacd737","type":"GENE","name":"NMNAT1P5","canonical_id":"hgnc:HGNC:49167","description":"NMNAT1 pseudogene 5","metadata":null},{"id":"e69cc652aaf1471a948c90c8a7562bb0","type":"GENE","name":"NMNAT2","canonical_id":"hgnc:HGNC:16789","description":null,"metadata":null},{"id":"dc4da88aa82448f4ac6693846129d61c","type":"GENE","name":"NMNAT3","canonical_id":"hgnc:HGNC:20989","description":"nicotinamide nucleotide adenylyltransferase 3","metadata":{"aliases":["PNAT3"]}},{"id":"9d51ffa3694d48ec9dcd0448e0c1cb97","type":"GENE","name":"NMRAL1","canonical_id":"hgnc:HGNC:24987","description":"NmrA like redox sensor 1","metadata":{"aliases":["FLJ25918","HSCARG","SDR48A1"]}},{"id":"ad93ed8186e447cc93df1531ac2d6b27","type":"GENE","name":"NMRAL2P","canonical_id":"hgnc:HGNC:52332","description":"NmrA like redox sensor 2, pseudogene","metadata":{"aliases":["LOC344887","NMRAL1P1"]}},{"id":"94a2323418044004b05a12ceae1f3368","type":"GENE","name":"NMRK1","canonical_id":"hgnc:HGNC:26057","description":"nicotinamide riboside kinase 1","metadata":{"aliases":["FLJ20559","NRK1","bA235O14.2","C9orf95"]}},{"id":"571ccd4d9b95491686fb30f9fd93377b","type":"GENE","name":"NMRK2","canonical_id":"hgnc:HGNC:17871","description":"nicotinamide riboside kinase 2","metadata":{"aliases":["MIBP","NRK2","ITGB1BP3"]}},{"id":"c3124a0040704557bfce3f5c466a833a","type":"GENE","name":"NMS","canonical_id":"hgnc:HGNC:32203","description":"neuromedin S","metadata":null},{"id":"15cf2fc795994722a66fd3c41919df58","type":"GENE","name":"NMT1","canonical_id":"hgnc:HGNC:7857","description":"N-myristoyltransferase 1","metadata":{"aliases":["NMT"]}},{"id":"493b1cc70fd240e2a92a0a9772936914","type":"GENE","name":"NMT2","canonical_id":"hgnc:HGNC:7858","description":"N-myristoyltransferase 2","metadata":null},{"id":"bafa65e9304c459ca33e38a9f69e5cd7","type":"GENE","name":"NMTRL-TAA1-1","canonical_id":"hgnc:HGNC:34892","description":"nuclear-encoded mitochondrial tRNA-Leu (TAA) 1-1","metadata":{"aliases":["nmt-tRNA-Leu-TAA-1-1","TRNAL31"]}},{"id":"e1b5d15107874525836233968813823d","type":"GENE","name":"NMTRL-TAA2-1","canonical_id":"hgnc:HGNC:35097","description":"nuclear-encoded mitochondrial tRNA-Leu (TAA) 2-1","metadata":{"aliases":["nmt-tRNA-Leu-TAA-2-1","TRNAL46P"]}},{"id":"cc0a70db289246099f2a444441a3ea2b","type":"GENE","name":"NMTRL-TAA3-1","canonical_id":"hgnc:HGNC:35095","description":"nuclear-encoded mitochondrial tRNA-Leu (TAA) 3-1","metadata":{"aliases":["nmt-tRNA-Leu-TAA-3-1","TRNAL45P"]}},{"id":"41c86ab3699045beb7b02acb226bb4a9","type":"GENE","name":"NMTRL-TAA4-1","canonical_id":"hgnc:HGNC:34945","description":"nuclear-encoded mitochondrial tRNA-Leu (TAA) 4-1","metadata":{"aliases":["nmt-tRNA-Leu-TAA-4-1","TRNAL37"]}},{"id":"bf4c7b1883104048be2d031f5e261aaf","type":"GENE","name":"NMTRL-TAA5-1","canonical_id":"hgnc:HGNC:35038","description":"nuclear-encoded mitochondrial tRNA-Leu (TAA) 5-1","metadata":{"aliases":["nmt-tRNA-Leu-TAA-5-1","TRNAL42P"]}},{"id":"cb2f463605e74bab97f32db260ea818a","type":"GENE","name":"NMTRL-TAA6-1","canonical_id":"hgnc:HGNC:35027","description":"nuclear-encoded mitochondrial tRNA-Leu (TAA) 6-1","metadata":{"aliases":["nmt-tRNA-Leu-TAA-6-1","TRNAL41P"]}},{"id":"7fe187da7260444da6aceaf96e9d68e8","type":"GENE","name":"NMTRP-TGG1-1","canonical_id":"hgnc:HGNC:35035","description":"nuclear-encoded mitochondrial tRNA-Pro (TGG) 1-1","metadata":{"aliases":["nmt-tRNA-Pro-TGG-1-1","TRNAP23P"]}},{"id":"4678e1389dcf4ec4a3b1c4cb1135bd98","type":"GENE","name":"NMTRQ-CTG1-1","canonical_id":"hgnc:HGNC:35033","description":"nuclear-encoded mitochondrial tRNA-Gln (CTG) 1-1","metadata":{"aliases":["nmt-tRNA-Gln-CTG-1-1","TRNAQ38P"]}},{"id":"a7e81f4bac60427ea0667438708db906","type":"GENE","name":"NMTRQ-TTG1-1","canonical_id":"hgnc:HGNC:35048","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 1-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-1-1","TRNAQ40P"]}},{"id":"f2ff37ecaa134e709fe917c48b7f2b0f","type":"GENE","name":"NMTRQ-TTG10-1","canonical_id":"hgnc:HGNC:35099","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 10-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-10-1","TRNAQ50P"]}},{"id":"732b7bafce964292ab1f35d3db323c7c","type":"GENE","name":"NMTRQ-TTG11-1","canonical_id":"hgnc:HGNC:35076","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 11-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-11-1","TRNAQ43P"]}},{"id":"a23dc03bc6694e0a9e206a75b31dfb6b","type":"GENE","name":"NMTRQ-TTG12-1","canonical_id":"hgnc:HGNC:35051","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 12-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-12-1","TRNAQ41P"]}},{"id":"821d0af61f974313bc18e2d171525001","type":"GENE","name":"NMTRQ-TTG13-1","canonical_id":"hgnc:HGNC:35112","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 13-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-13-1","TRNAQ52P"]}},{"id":"41c5b0d515204a97882b7bcd5d5f0aa3","type":"GENE","name":"NMTRQ-TTG14-1","canonical_id":"hgnc:HGNC:34617","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 14-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-14-1","TRNAQ9"]}},{"id":"721492a975d745a3af1a2922fab60939","type":"GENE","name":"NMTRQ-TTG15-1","canonical_id":"hgnc:HGNC:35117","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 15-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-15-1","TRNAQ54P"]}},{"id":"1f0365ad421045b0aabf0657a3c3dbca","type":"GENE","name":"NMTRQ-TTG2-1","canonical_id":"hgnc:HGNC:35091","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 2-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-2-1","TRNAQ48P"]}},{"id":"69b883e6c79240c3828c492bd8c9efce","type":"GENE","name":"NMTRQ-TTG3-1","canonical_id":"hgnc:HGNC:34778","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 3-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-3-1","TRNAQ18"]}},{"id":"9500ee47e9dd49edb025e2c79dbb6492","type":"GENE","name":"NMTRQ-TTG4-1","canonical_id":"hgnc:HGNC:35062","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 4-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-4-1","TRNAQ42P"]}},{"id":"ef8f005a11794bcf95c7cac375929c5b","type":"GENE","name":"NMTRQ-TTG5-1","canonical_id":"hgnc:HGNC:34965","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 5-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-5-1","TRNAQ31"]}},{"id":"d42848cbb13f432f92843e67eac1b472","type":"GENE","name":"NMTRQ-TTG6-1","canonical_id":"hgnc:HGNC:35085","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 6-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-6-1","TRNAQ47P"]}},{"id":"876394480f7d445aaf113f23dfabd95f","type":"GENE","name":"NMTRQ-TTG7-1","canonical_id":"hgnc:HGNC:35015","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 7-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-7-1","TRNAQ34P"]}},{"id":"174f7104ecc4451a8c25be7fd9364683","type":"GENE","name":"NMTRQ-TTG8-1","canonical_id":"hgnc:HGNC:35018","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 8-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-8-1","TRNAQ35P"]}},{"id":"0b0d214b812f4c8aacb15f92b020dbb0","type":"GENE","name":"NMTRQ-TTG9-1","canonical_id":"hgnc:HGNC:35022","description":"nuclear-encoded mitochondrial tRNA-Gln (TTG) 9-1","metadata":{"aliases":["nmt-tRNA-Gln-TTG-9-1","TRNAQ36P"]}},{"id":"c7d5391909b94985a225523138c5e8a4","type":"GENE","name":"NMTRS-TGA1-1","canonical_id":"hgnc:HGNC:34614","description":"nuclear-encoded mitochondrial tRNA-Ser (TGA) 1-1","metadata":{"aliases":["nmt-tRNA-Ser-TGA-1-1","TRNAS8"]}},{"id":"7f6213fe9ae94194897c8baac8a3006e","type":"GENE","name":"NMTRS-TGA2-1","canonical_id":"hgnc:HGNC:35100","description":"nuclear-encoded mitochondrial tRNA-Ser (TGA) 2-1","metadata":{"aliases":["nmt-tRNA-Ser-TGA-2-1","TRNAS31P"]}},{"id":"b98c79cb792343ce8d7a43687c9344eb","type":"GENE","name":"NMTRS-TGA3-1","canonical_id":"hgnc:HGNC:35087","description":"nuclear-encoded mitochondrial tRNA-Ser (TGA) 3-1","metadata":{"aliases":["nmt-tRNA-Ser-TGA-3-1","TRNAS30P"]}},{"id":"7ddbcfdec4a2454dbae107b913877a90","type":"GENE","name":"NMTRV-TAC1-1","canonical_id":"hgnc:HGNC:35088","description":"nuclear-encoded mitochondrial tRNA-Val (TAC) 1-1","metadata":{"aliases":["nmt-tRNA-Val-TAC-1-1","TRNAV37P"]}},{"id":"ff208bbe6c494570b7f1563bacd4d0b5","type":"GENE","name":"NMU","canonical_id":"hgnc:HGNC:7859","description":null,"metadata":null},{"id":"4cdb9f04ea8745a6a8024e7b03293ccc","type":"GENE","name":"NMU-AS1","canonical_id":"hgnc:HGNC:58791","description":"NMU antisense RNA 1","metadata":null},{"id":"0ca431dc5f844d06add02d1ace5f5410","type":"GENE","name":"NMUR1","canonical_id":"hgnc:HGNC:4518","description":"neuromedin U receptor 1","metadata":{"aliases":["GPC-R","FM-3","NMU1R","GPR66"]}},{"id":"cd93338309174577b52e53c9db466662","type":"GENE","name":"NMUR2","canonical_id":"hgnc:HGNC:16454","description":"neuromedin U receptor 2","metadata":{"aliases":["NMU2R"]}},{"id":"3ff98a21a1be4ea4b08e1c2dcf5d3b52","type":"GENE","name":"NMUR2-AS1","canonical_id":"hgnc:HGNC:59285","description":"NMUR2 antisense RNA 1","metadata":null},{"id":"7516334d59574bceaf50a39e9b90ec8c","type":"GENE","name":"NNAT","canonical_id":"hgnc:HGNC:7860","description":"neuronatin","metadata":{"aliases":["Peg5"]}},{"id":"16ef15d1e644430787a3b3012b625a4a","type":"GENE","name":"NNMT","canonical_id":"hgnc:HGNC:7861","description":"nicotinamide N-methyltransferase","metadata":null},{"id":"51cb51cbc3a44713b3e00d9431917d03","type":"GENE","name":"NNT","canonical_id":"hgnc:HGNC:7863","description":"nicotinamide nucleotide transhydrogenase","metadata":null},{"id":"a02ac129f3f049ebb4ecffc64e0293fd","type":"GENE","name":"NNT-AS1","canonical_id":"hgnc:HGNC:49005","description":"NNT antisense RNA 1","metadata":{"aliases":["RP11-159F24.1"]}},{"id":"86927b09b2dd4c2bacc424228fdadc69","type":"DRUG","name":"NO","canonical_id":"gtopdb:2509","description":null,"metadata":null},{"id":"d176d2fe54f94c9d8f5415a6ab7a0e2b","type":"GENE","name":"NOA1","canonical_id":"hgnc:HGNC:28473","description":"nitric oxide associated 1","metadata":{"aliases":["MGC3232","hAtNOS1","hNOA1","MTG3","C4orf14"]}},{"id":"79e0ec6bc13a46a9aa4820df11183b61","type":"TRIAL","name":"NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03666650","description":"Blood Coagulation Disorder","metadata":null},{"id":"89a461f312674d29b601528056be1036","type":"TRIAL","name":"NOAC Portuguese Real World Study","canonical_id":"clinicaltrials.gov:NCT04808934","description":"Stroke; Systemic Embolism; Major Bleeding","metadata":null},{"id":"f962517ec1f1483b9e7cbf25d73d7546","type":"TRIAL","name":"NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications","canonical_id":"clinicaltrials.gov:NCT04662515","description":"Surgery, Oral; Hemorrhage; Postoperative Complications; Oral Surgical Procedures; Anticoagulants Causing Adverse Effects in Therapeutic Use; Anticoagulant-induced Bleeding","metadata":null},{"id":"371e42e6b3824fe0ae9a502de8251d0c","type":"GENE","name":"NOAZFP","canonical_id":"hgnc:HGNC:15462","description":"nucleolar atypical zinc finger","metadata":{"aliases":["NOA36","HSA6591","ZNF330"]}},{"id":"d166d31fc1864b2491e507421a3836ba","type":"GENE","name":"NOB1","canonical_id":"hgnc:HGNC:29540","description":"NIN1 (RPN12) binding protein 1 homolog","metadata":{"aliases":["NOB1P","ART-4","MST158","PSMD8BP1"]}},{"id":"e7e95900f6cb424d837b9333f9f20609","type":"GENE","name":"NOBOX","canonical_id":"hgnc:HGNC:22448","description":"NOBOX oogenesis homeobox","metadata":{"aliases":["OG2","Og2x"]}},{"id":"572c25e4e27f485e86591c92e0db97be","type":"GENE","name":"NOC2L","canonical_id":"hgnc:HGNC:24517","description":"NOC2 like nucleolar associated transcriptional repressor","metadata":{"aliases":["DKFZP564C186","NET7","NET15","NIR","PPP1R112"]}},{"id":"53a94e1b167a4b728bfeea3e016c5638","type":"GENE","name":"NOC2LP1","canonical_id":"hgnc:HGNC:52285","description":"NOC2 like nucleolar associated transcriptional repressor pseudogene 1","metadata":null},{"id":"43609ab2207448f7a6085d650489bf9a","type":"GENE","name":"NOC2LP2","canonical_id":"hgnc:HGNC:52286","description":"NOC2 like nucleolar associated transcriptional repressor pseudogene 2","metadata":null},{"id":"e87a76edfbef42c8bf4ae1a7ec2d2952","type":"GENE","name":"NOC3L","canonical_id":"hgnc:HGNC:24034","description":"NOC3 like DNA replication regulator","metadata":{"aliases":["AD24","FLJ12820","FAD24","C10orf117"]}},{"id":"876808389f854276bdfea011f4e4bedc","type":"GENE","name":"NOC4L","canonical_id":"hgnc:HGNC:28461","description":"nucleolar complex associated 4 homolog","metadata":{"aliases":["MGC3162","NET49","UTP19","Noc4"]}},{"id":"8dd7df8ee46842628173301ea1d4771a","type":"GENE","name":"NOCT","canonical_id":"hgnc:HGNC:14254","description":"nocturnin","metadata":{"aliases":["CCR4L","Ccr4c","NOC","CCRN4L"]}},{"id":"c9f31d45c46f495a9eaf3c1e0db81690","type":"GENE","name":"NOD1","canonical_id":"hgnc:HGNC:16390","description":null,"metadata":null},{"id":"fb7200358d68437bb6052b9e92189aee","type":"GENE","name":"NOD2","canonical_id":"hgnc:HGNC:5331","description":null,"metadata":null},{"id":"2297fdd615384a04bf03ef87536643fd","type":"GENE","name":"NODAL","canonical_id":"hgnc:HGNC:7865","description":null,"metadata":null},{"id":"b57e11d407614045b3dc3483bbcc8817","type":"GENE","name":"NOG","canonical_id":"hgnc:HGNC:7866","description":"noggin","metadata":{"aliases":["SYNS1","SYM1"]}},{"id":"c03f483583a7482893fa00d0abc1524b","type":"GENE","name":"NOL10","canonical_id":"hgnc:HGNC:25862","description":"nucleolar protein 10","metadata":{"aliases":["FLJ14075","PQBP5"]}},{"id":"81d79c4dca784225ab7e73950d4afc33","type":"GENE","name":"NOL11","canonical_id":"hgnc:HGNC:24557","description":"nucleolar protein 11","metadata":{"aliases":["DKFZP586L0724"]}},{"id":"eefd8d0793444732ba9fdcf90fb57ae5","type":"GENE","name":"NOL11P1","canonical_id":"hgnc:HGNC:58576","description":"NOL11 pseudogene 1","metadata":null},{"id":"67346885ef1e41e999b725085ca6a629","type":"GENE","name":"NOL12","canonical_id":"hgnc:HGNC:28585","description":"nucleolar protein 12","metadata":{"aliases":["MGC3731","Nop25","RRP17"]}},{"id":"e720a079a6b048f19f71610aa49b9702","type":"GENE","name":"NOL3","canonical_id":"hgnc:HGNC:7869","description":"nucleolar protein 3","metadata":{"aliases":["ARC","NOP30","MYP","CARD2"]}},{"id":"9f3d51fa5a344fda85f70f77a2171ce5","type":"GENE","name":"NOL4","canonical_id":"hgnc:HGNC:7870","description":"nucleolar protein 4","metadata":{"aliases":["NOLP","HRIHFB2255","CT125"]}},{"id":"869d7fdf000547a4b9b0037f70d30725","type":"GENE","name":"NOL4L","canonical_id":"hgnc:HGNC:16106","description":"nucleolar protein 4 like","metadata":{"aliases":["dJ1184F4.2","DKFZP566G1424","dJ1184F4.4","C20orf113","C20orf112"]}},{"id":"76aa1be40a63409a91befb998d73add4","type":"GENE","name":"NOL4L-AS1","canonical_id":"hgnc:HGNC:40756","description":"NOL4L antisense RNA 1","metadata":null},{"id":"02716580cb39411880427741996a1b40","type":"GENE","name":"NOL4L-DT","canonical_id":"hgnc:HGNC:44310","description":"NOL4L divergent transcript","metadata":null},{"id":"e565d739331e4436a63e32e633794d12","type":"GENE","name":"NOL6","canonical_id":"hgnc:HGNC:19910","description":"nucleolar protein 6","metadata":{"aliases":["bA311H10.1","Nrap","FLJ21959","MGC14896","MGC14921","MGC20838","UTP22"]}},{"id":"e7b8d85d57e644bc9402df7c450a2b74","type":"GENE","name":"NOL7","canonical_id":"hgnc:HGNC:21040","description":null,"metadata":null},{"id":"4ac88c4965ec489fa0c172622bd98328","type":"GENE","name":"NOL8","canonical_id":"hgnc:HGNC:23387","description":"nucleolar protein 8","metadata":{"aliases":["FLJ20736","Nop132","C9orf34"]}},{"id":"2afab84a53154b758d1df98d8f205e33","type":"GENE","name":"NOL8P1","canonical_id":"hgnc:HGNC:49557","description":"nucleolar protein 8 pseudogene 1","metadata":null},{"id":"cd84cb895f5c4985a01af20c643ef961","type":"GENE","name":"NOL9","canonical_id":"hgnc:HGNC:26265","description":"nucleolar protein 9","metadata":{"aliases":["FLJ23323","NET6","Grc3"]}},{"id":"b2315dae49bd4d598f1d6c6c141832d1","type":"TRIAL","name":"NOLAN: Naproxen or Loratadine and Neulasta","canonical_id":"clinicaltrials.gov:NCT01712009","description":"Bone Pain in Stage I - III Breast Cancer","metadata":null},{"id":"5d9faef682664cdd83e553f26b0da559","type":"GENE","name":"NOLC1","canonical_id":"hgnc:HGNC:15608","description":null,"metadata":null},{"id":"89755250f9a5412088714025665b292f","type":"GENE","name":"NOLC1P1","canonical_id":"hgnc:HGNC:54890","description":"NOLC1 pseudogene 1","metadata":null},{"id":"3c7a5f3c9832479bbac89154e738564d","type":"GENE","name":"NOM1","canonical_id":"hgnc:HGNC:13244","description":"nucleolar protein with MIF4G domain 1","metadata":{"aliases":["SGD1","PPP1R113","C7orf3"]}},{"id":"a7230cb33b0440588e5150f8a57dea7d","type":"GENE","name":"NOMO1","canonical_id":"hgnc:HGNC:30060","description":"NODAL modulator 1","metadata":{"aliases":["PM5"]}},{"id":"81e926ecf6314f669e272f4eb8d1469d","type":"GENE","name":"NOMO2","canonical_id":"hgnc:HGNC:22652","description":"NODAL modulator 2","metadata":{"aliases":["NOMO","PM5"]}},{"id":"164284ed7946423bb86efd76ec7ffb93","type":"GENE","name":"NOMO3","canonical_id":"hgnc:HGNC:25242","description":"NODAL modulator 3","metadata":null},{"id":"29b897a482a04eaea4df73ff4aba96e2","type":"GENE","name":"NONO","canonical_id":"hgnc:HGNC:7871","description":null,"metadata":null},{"id":"b41fb93f89134f2bbb937ab85b4e4b81","type":"GENE","name":"NONOP1","canonical_id":"hgnc:HGNC:42031","description":"non-POU domain containing, octamer-binding pseudogene 1","metadata":null},{"id":"49970502b0fd42bcbcab0137c1f3b1eb","type":"GENE","name":"NONOP2","canonical_id":"hgnc:HGNC:42032","description":"non-POU domain containing, octamer-binding pseudogene 2","metadata":null},{"id":"8cc26d9271e04539ad6846dafd1420fc","type":"GENE","name":"NOP10","canonical_id":"hgnc:HGNC:14378","description":"NOP10 ribonucleoprotein","metadata":{"aliases":["NOP10P","MGC70651","NOLA3"]}},{"id":"e82c9ab8985a41a5943e3cd5381ebd58","type":"GENE","name":"NOP14","canonical_id":"hgnc:HGNC:16821","description":"NOP14 nucleolar protein","metadata":{"aliases":["RES4-25","UTP2","C4orf9","NOL14"]}},{"id":"38362f374b2c4cbcb45aff95a557fa25","type":"GENE","name":"NOP14-AS1","canonical_id":"hgnc:HGNC:20205","description":"NOP14 antisense RNA 1","metadata":{"aliases":["RES4-24","C4orf10"]}},{"id":"ef1e283eb71345ce8eb308df9c157533","type":"GENE","name":"NOP16","canonical_id":"hgnc:HGNC:26934","description":"NOP16 nucleolar protein","metadata":{"aliases":["HSPC111","HSPC185","LOC51491"]}},{"id":"e4fa51bd004b4bb2b4ddfcb9ba12959d","type":"GENE","name":"NOP2","canonical_id":"hgnc:HGNC:7867","description":"NOP2 nucleolar protein","metadata":{"aliases":["NOP120","NSUN1","p120","NOL1"]}},{"id":"c3cf3fff86144d5f87e385e63a24b8d0","type":"GENE","name":"NOP35P1","canonical_id":"hgnc:HGNC:58642","description":"NOP53 pseudogene 1","metadata":null},{"id":"8b24a7a5184b4c6ca19edda67909fe57","type":"GENE","name":"NOP53","canonical_id":"hgnc:HGNC:4333","description":"NOP53 ribosome biogenesis factor","metadata":{"aliases":["PICT-1","PICT1","GLTSCR2"]}},{"id":"881d589d70af461c909a1ae6a9594a32","type":"GENE","name":"NOP53-AS1","canonical_id":"hgnc:HGNC:51587","description":"NOP53 antisense RNA 1","metadata":{"aliases":["GLTSCR2-AS1"]}},{"id":"64aeb07fb0684f50b3d7b7a131ddde62","type":"GENE","name":"NOP56","canonical_id":"hgnc:HGNC:15911","description":"NOP56 ribonucleoprotein","metadata":{"aliases":["SCA36","NOL5A"]}},{"id":"fec49b15a5fd4502918b68402d97ac93","type":"GENE","name":"NOP56P1","canonical_id":"hgnc:HGNC:13962","description":"NOP56 ribonucleoprotein pseudogene 1","metadata":{"aliases":["NOP56-L","dJ207F6.1","NOL5B","NOL5BP"]}},{"id":"fffe7055bbe648eda2cd311a922ff075","type":"GENE","name":"NOP56P2","canonical_id":"hgnc:HGNC:49800","description":"NOP56 ribonucleoprotein pseudogene 2","metadata":null},{"id":"3b9cabcd2d3042388877488234970430","type":"GENE","name":"NOP56P3","canonical_id":"hgnc:HGNC:49801","description":"NOP56 ribonucleoprotein pseudogene 3","metadata":null},{"id":"b328c2f6843b44fab2f158c315efd738","type":"GENE","name":"NOP58","canonical_id":"hgnc:HGNC:29926","description":"NOP58 ribonucleoprotein","metadata":{"aliases":["NOP5","HSPC120"]}},{"id":"cc4f890120a84458934d69de05db723a","type":"GENE","name":"NOP9","canonical_id":"hgnc:HGNC:19826","description":"NOP9 nucleolar protein","metadata":{"aliases":["C14orf21"]}},{"id":"ec8e23b57ac244e59a9852c643a459c2","type":"GENE","name":"NOPCHAP1","canonical_id":"hgnc:HGNC:28628","description":"NOP protein chaperone 1","metadata":{"aliases":["MGC40397","DDSR1","C12orf45"]}},{"id":"b14d2dbeb5184ac78d537bb7911e9bbd","type":"GENE","name":"NORAD","canonical_id":"hgnc:HGNC:44311","description":"non-coding RNA activated by DNA damage","metadata":{"aliases":["LINC00657"]}},{"id":"68c0d32618434dea94cbe7c10e552bdd","type":"GENE","name":"NOS1","canonical_id":"hgnc:HGNC:7872","description":null,"metadata":null},{"id":"c152155e339441a7ace138b4ba2258c5","type":"GENE","name":"NOS1AP","canonical_id":"hgnc:HGNC:16859","description":"nitric oxide synthase 1 adaptor protein","metadata":{"aliases":["KIAA0464","CAPON"]}},{"id":"82771a3ac6bb4f85bb209c453a64a03b","type":"GENE","name":"NOS2","canonical_id":"hgnc:HGNC:7873","description":null,"metadata":null},{"id":"ae46decd183f404f80bec3d0795f8dfc","type":"GO_TERM","name":"NOS2-CD74 complex","canonical_id":"go:GO:0035693","description":"\"A protein complex comprising nitric oxide synthase 2 and CD74. This stable complex formation is thought to prevent CD74 degradation by caspases.\" [GOC:BHF, PMID:18003616]","metadata":null},{"id":"cf6ca85813d949979fa1220265c1b8cc","type":"GENE","name":"NOS2P1","canonical_id":"hgnc:HGNC:7875","description":"nitric oxide synthase 2 pseudogene 1","metadata":{"aliases":["NOS2C"]}},{"id":"8449fdcaa2a04b06b55c1fc6d84eae23","type":"GENE","name":"NOS2P2","canonical_id":"hgnc:HGNC:7874","description":"nitric oxide synthase 2 pseudogene 2","metadata":{"aliases":["NOS2B"]}},{"id":"2354239a50e34f44b55d972428afe86f","type":"GENE","name":"NOS2P3","canonical_id":"hgnc:HGNC:35124","description":"nitric oxide synthase 2 pseudogene 3","metadata":null},{"id":"7cb442cb1b0341fc9b4db60786dffa2a","type":"GENE","name":"NOS2P4","canonical_id":"hgnc:HGNC:50720","description":"nitric oxide synthase 2 pseudogene 4","metadata":null},{"id":"b6278055fd63428fb1ae4e37ba2de3d1","type":"GENE","name":"NOS3","canonical_id":"hgnc:HGNC:7876","description":null,"metadata":null},{"id":"4be67c93c9494d15ba1a721e997971c9","type":"GENE","name":"NOSIP","canonical_id":"hgnc:HGNC:17946","description":"nitric oxide synthase interacting protein","metadata":{"aliases":["CGI-25"]}},{"id":"b4a4e36f5f514b81a1807dd5056671f8","type":"GENE","name":"NOSTRIN","canonical_id":"hgnc:HGNC:20203","description":"nitric oxide synthase trafficking","metadata":{"aliases":["MGC20702"]}},{"id":"67d82e8251b54d37a529a0f5ed669820","type":"GENE","name":"NOTCH1","canonical_id":"hgnc:HGNC:7881","description":null,"metadata":null},{"id":"d08c7f44fc4848fa835c7c1f33e5f8f5","type":"GENE","name":"NOTCH1","canonical_id":"ensembl:ENSG00000148400","description":null,"metadata":null},{"id":"db9de74c6d0045428eb54fcd59b4d409","type":"GENE","name":"NOTCH2","canonical_id":"hgnc:HGNC:7882","description":"notch receptor 2","metadata":null},{"id":"c5bd225608fd434ab94d464ccd3983b9","type":"GENE","name":"NOTCH2NLA","canonical_id":"hgnc:HGNC:31862","description":"notch 2 N-terminal like A","metadata":{"aliases":["N2N","NOTCH2NL"]}},{"id":"071782d1ad9042da951f6d1f4ff6758a","type":"GENE","name":"NOTCH2NLB","canonical_id":"hgnc:HGNC:53923","description":"notch 2 N-terminal like B","metadata":null},{"id":"9b50795a14e64816992cbb561375c627","type":"GENE","name":"NOTCH2NLC","canonical_id":"hgnc:HGNC:53924","description":"notch 2 N-terminal like C","metadata":null},{"id":"94ad7927b64547a1b4ea91eb2ad6d62c","type":"GENE","name":"NOTCH2NLR","canonical_id":"hgnc:HGNC:53925","description":"notch 2 N-terminal like R","metadata":null},{"id":"adedc518e05d47c993492890cc7edec6","type":"GENE","name":"NOTCH2P1","canonical_id":"hgnc:HGNC:44253","description":"notch 2 pseudogene 1","metadata":null},{"id":"c4528a48e61547bf88db35a577964296","type":"GENE","name":"NOTCH3","canonical_id":"hgnc:HGNC:7883","description":null,"metadata":null},{"id":"59736f7e2bb44ed2844be49675ea6c7c","type":"GENE","name":"NOTCH4","canonical_id":"hgnc:HGNC:7884","description":null,"metadata":null},{"id":"64d4240f8ca4441a8eef081ef953e67f","type":"GENE","name":"NOTO","canonical_id":"hgnc:HGNC:31839","description":"notochord homeobox","metadata":null},{"id":"e6677ecfa956479e8c8b05f34b2a40bc","type":"GENE","name":"NOTUM","canonical_id":"hgnc:HGNC:27106","description":null,"metadata":null},{"id":"8640fa6bd19147a1b6bee020b8b66fa5","type":"GENE","name":"NOV","canonical_id":"hgnc:HGNC:9099","description":null,"metadata":null},{"id":"7843f11bf9a348db987ad25c8c714688","type":"GENE","name":"NOVA1","canonical_id":"hgnc:HGNC:7886","description":"NOVA alternative splicing regulator 1","metadata":{"aliases":["NOVA-1"]}},{"id":"3d999d2d222747a380ed5e181ba8885b","type":"GENE","name":"NOVA1-DT","canonical_id":"hgnc:HGNC:19827","description":"NOVA1 divergent transcript","metadata":{"aliases":["C14orf22","NOVA1-AS1","LINC02588"]}},{"id":"4d6a70003e3e498ca89af32251d094c3","type":"GENE","name":"NOVA2","canonical_id":"hgnc:HGNC:7887","description":"NOVA alternative splicing regulator 2","metadata":{"aliases":["ANOVA","NOVA-2","NOVA3"]}},{"id":"d033fcb2b8bc40babc1a0a527f8943f5","type":"GENE","name":"NOX1","canonical_id":"hgnc:HGNC:7889","description":null,"metadata":null},{"id":"b4dcddcfcb0f4ab08e18a451c9c14caa","type":"GENE","name":"NOX3","canonical_id":"hgnc:HGNC:7890","description":"NADPH oxidase 3","metadata":{"aliases":["GP91-3"]}},{"id":"66b8dfeef439442e83a66d3487a71091","type":"GENE","name":"NOX4","canonical_id":"hgnc:HGNC:7891","description":null,"metadata":null},{"id":"96c8020587a3475284fac5ebd4bb95c5","type":"GENE","name":"NOX4P1","canonical_id":"hgnc:HGNC:56735","description":"NOX4 pseudogene 1","metadata":null},{"id":"835dbb5ba81c4643801a263d819ad4c7","type":"GENE","name":"NOX5","canonical_id":"hgnc:HGNC:14874","description":null,"metadata":null},{"id":"2f9403dfb46d4cfe8065a099ad9b247e","type":"GO_TERM","name":"NOXA-BCL-2 complex","canonical_id":"go:GO:0097147","description":"\"A heterodimeric protein complex consisting of NOXA and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"9721f5bebbc94c6c9dc79c5a7b287cc4","type":"GO_TERM","name":"NOXA-BCL-xl complex","canonical_id":"go:GO:0097146","description":"\"A heterodimeric protein complex consisting of NOXA and BCL-xl, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"cb5c846fdec94d0da117af7f4e3457e6","type":"GENE","name":"NOXA1","canonical_id":"hgnc:HGNC:10668","description":"NADPH oxidase activator 1","metadata":{"aliases":["NY-CO-31","FLJ25475","SDCCAG31"]}},{"id":"5249a46437e64d6d97244687167a98c5","type":"GENE","name":"NOXO1","canonical_id":"hgnc:HGNC:19404","description":"NADPH oxidase organizer 1","metadata":{"aliases":["P41NOXA","P41NOXB","P41NOXC","SH3PXD5","SNX28"]}},{"id":"cc6fdea43de14416a37d94e7508808ad","type":"GENE","name":"NOXRED1","canonical_id":"hgnc:HGNC:20487","description":"NADP dependent oxidoreductase domain containing 1","metadata":{"aliases":["FLJ32809","C14orf148"]}},{"id":"974147426fd04a38b599e45b4c0cbb98","type":"TRIAL","name":"NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas","canonical_id":"clinicaltrials.gov:NCT05262556","description":"Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Neoplasm; Neuroendocrine Carcinoma; Mixed Neuroendocrine-Non Neuroendocrine Neoplasm","metadata":null},{"id":"33f7fa2b2f5e40eb801719bfd49ace29","type":"GENE","name":"NPAP1","canonical_id":"hgnc:HGNC:1190","description":"nuclear pore associated protein 1","metadata":{"aliases":["C15orf2"]}},{"id":"3304296c2ff44a11b2d6eb346e755aa6","type":"GENE","name":"NPAP1L","canonical_id":"hgnc:HGNC:53980","description":"nuclear pore associated protein 1 like (pseudogene)","metadata":null},{"id":"9f6ba317098e4a2bb4e232ef7821dd9d","type":"GENE","name":"NPAP1P1","canonical_id":"hgnc:HGNC:45018","description":"nuclear pore associated protein 1 pseudogene 1","metadata":null},{"id":"0ca06414f1934a82bd3b588ee5a146df","type":"GENE","name":"NPAP1P2","canonical_id":"hgnc:HGNC:45019","description":"nuclear pore associated protein 1 pseudogene 2","metadata":null},{"id":"218ce4f066664f5b8a2ac5368a381c7e","type":"GENE","name":"NPAP1P3","canonical_id":"hgnc:HGNC:45020","description":"nuclear pore associated protein 1 pseudogene 3","metadata":null},{"id":"f7875dca4c5b4fd28f90a8edef60a0cc","type":"GENE","name":"NPAP1P4","canonical_id":"hgnc:HGNC:45021","description":"nuclear pore associated protein 1 pseudogene 4","metadata":null},{"id":"d83fd2aa02e54658939e9e44038432e0","type":"GENE","name":"NPAP1P5","canonical_id":"hgnc:HGNC:45022","description":"nuclear pore associated protein 1 pseudogene 5","metadata":null},{"id":"5aaccc4543154de5b9c6f3e8e9ded3b9","type":"GENE","name":"NPAP1P6","canonical_id":"hgnc:HGNC:45023","description":"nuclear pore associated protein 1 pseudogene 6","metadata":null},{"id":"3d97373aa207445aa567a81117d8db98","type":"GENE","name":"NPAP1P7","canonical_id":"hgnc:HGNC:51473","description":"nuclear pore associated protein 1 pseudogene 7","metadata":null},{"id":"fb3a5645fdf7486a84822a512ed76bab","type":"GENE","name":"NPAP1P8","canonical_id":"hgnc:HGNC:51474","description":"nuclear pore associated protein 1 pseudogene 8","metadata":null},{"id":"01f6d55e50844eac9e1c532ce438635a","type":"GENE","name":"NPAP1P9","canonical_id":"hgnc:HGNC:56659","description":"nuclear pore associated protein 1 pseudogene 9","metadata":null},{"id":"143b6c1987d14feb92b3740ca1b630a2","type":"GENE","name":"NPAS1","canonical_id":"hgnc:HGNC:7894","description":"neuronal PAS domain protein 1","metadata":{"aliases":["MOP5","PASD5","bHLHe11"]}},{"id":"0dc52afd4f7447599a161b4dbeeff56b","type":"GENE","name":"NPAS2","canonical_id":"hgnc:HGNC:7895","description":null,"metadata":null},{"id":"141c4d790f4a41309d9bf34b6e2582f5","type":"GENE","name":"NPAS2-AS1","canonical_id":"hgnc:HGNC:40408","description":"NPAS2 antisense RNA 1","metadata":null},{"id":"5ab96193cf3c4919900e8c55f11cf8a9","type":"GENE","name":"NPAS3","canonical_id":"hgnc:HGNC:19311","description":null,"metadata":null},{"id":"8c9c50897041403d99d89fbb5a3bf436","type":"GENE","name":"NPAS4","canonical_id":"hgnc:HGNC:18983","description":"neuronal PAS domain protein 4","metadata":{"aliases":["PASD10","NXF","Le-PAS","bHLHe79"]}},{"id":"9de12348971d46c6bd9bdd6afe873cbc","type":"GENE","name":"NPAT","canonical_id":"hgnc:HGNC:7896","description":null,"metadata":null},{"id":"2daff231d70247c08f6d89d8487d00ca","type":"GENE","name":"NPB","canonical_id":"hgnc:HGNC:30099","description":"neuropeptide B","metadata":{"aliases":["PPL7","PPNPB"]}},{"id":"fa006cca83e045b28035a04fc306d37c","type":"GENE","name":"NPBWR1","canonical_id":"hgnc:HGNC:4522","description":"neuropeptides B and W receptor 1","metadata":{"aliases":["GPR7"]}},{"id":"550ba148df16405fa82833f10aee232e","type":"GENE","name":"NPBWR2","canonical_id":"hgnc:HGNC:4530","description":"neuropeptides B and W receptor 2","metadata":{"aliases":["GPR8"]}},{"id":"12ec8cd1d4484db49145afa7930d35f1","type":"GENE","name":"NPC1","canonical_id":"hgnc:HGNC:7897","description":"NPC intracellular cholesterol transporter 1","metadata":{"aliases":["SLC65A1"]}},{"id":"2fee4faad25c466ba7ae9bff6dcc6c25","type":"GENE","name":"NPC1L1","canonical_id":"hgnc:HGNC:7898","description":null,"metadata":null},{"id":"7d3eb9b54fea4623bcb652c71b0bec47","type":"PROTEIN","name":"NPC1L1","canonical_id":"uniprot:Q9UHC9","description":null,"metadata":null},{"id":"29e3f394e67d42abbe5b61e2042aef74","type":"GENE","name":"NPC2","canonical_id":"hgnc:HGNC:14537","description":"NPC intracellular cholesterol transporter 2","metadata":{"aliases":["HE1","NP-C2","EDDM1"]}},{"id":"c935d7eeb7ef4d7aaabe6ea15ea471b2","type":"GENE","name":"NPDC1","canonical_id":"hgnc:HGNC:7899","description":"neural proliferation, differentiation and control 1","metadata":{"aliases":["DKFZp586J0523","CAB-","CAB1"]}},{"id":"36954ac33dd245dfae8ad7f0150dc9b7","type":"GENE","name":"NPEPL1","canonical_id":"hgnc:HGNC:16244","description":"aminopeptidase like 1","metadata":{"aliases":["FLJ11583","bA261P9.2"]}},{"id":"d9208f142519439aa8a446b5a0f9a436","type":"GENE","name":"NPEPPS","canonical_id":"hgnc:HGNC:7900","description":"aminopeptidase puromycin sensitive","metadata":{"aliases":["PSA","MP100"]}},{"id":"049e69e899544a56b39b2de39d9d92f9","type":"GENE","name":"NPEPPSP1","canonical_id":"hgnc:HGNC:44259","description":"NPEPPS pseudogene 1","metadata":null},{"id":"fbd7b077e29b448ca7fcf91eaac6ab87","type":"GENE","name":"NPEPPSP2","canonical_id":"hgnc:HGNC:56399","description":"NPEPPS pseudogene 2","metadata":null},{"id":"62e03ff0d85248a3b118301e9d4eddc7","type":"GENE","name":"NPFF","canonical_id":"hgnc:HGNC:7901","description":"neuropeptide FF-amide peptide precursor","metadata":{"aliases":["FMRFAL"]}},{"id":"02f4970194ca4f7f83394f9231ecc050","type":"GENE","name":"NPFFR1","canonical_id":"hgnc:HGNC:17425","description":"neuropeptide FF receptor 1","metadata":{"aliases":["OT7T022","NPFF1R1","GPR147"]}},{"id":"f87da1c102da463e860cd90377c3acab","type":"GENE","name":"NPFFR2","canonical_id":"hgnc:HGNC:4525","description":"neuropeptide FF receptor 2","metadata":{"aliases":["NPFF2","NPGPR","GPR74"]}},{"id":"c8bef6bf7b6e4c33b48dfcb15ac070d0","type":"GO_TERM","name":"NPHP complex","canonical_id":"go:GO:1990957","description":"\"A protein complex that is located at the ciliary transition zone and consists of the NPHP4 and NPHP1 proteins. It acts as an organiser of the transition zone inner structure, specifically the Y-shaped links, in conjunction with the MKS complex. It is involved in ciliary protein trafficking and is required for correct functioning of the WNT and Hippo signaling pathways.\" [GOC:cilia, PMID:18337471, PMID:21422230, PMID:21498478, PMID:21555462, PMID:25150219]","metadata":null},{"id":"0106208f2522453fa7f2865a690647e9","type":"GENE","name":"NPHP1","canonical_id":"hgnc:HGNC:7905","description":"nephrocystin 1","metadata":{"aliases":["JBTS4","SLSN1","NPH1"]}},{"id":"38b514f3d7d3464d821183730f7eb33b","type":"GENE","name":"NPHP3","canonical_id":"hgnc:HGNC:7907","description":"nephrocystin 3","metadata":{"aliases":["NPH3","KIAA2000","FLJ30691","FLJ36696","MKS7","SLSN3","CFAP31"]}},{"id":"20c672bd7e5d45d299313fbf0f423e39","type":"GENE","name":"NPHP3-ACAD11","canonical_id":"hgnc:HGNC:48351","description":"NPHP3-ACAD11 readthrough (NMD candidate)","metadata":null},{"id":"ec99c7beeacf4248b466db9783c8a15a","type":"GENE","name":"NPHP3-AS1","canonical_id":"hgnc:HGNC:24129","description":"NPHP3 antisense RNA 1","metadata":{"aliases":["NCRNA00119"]}},{"id":"cf10640bd68b49599be88bd47b7f0018","type":"GENE","name":"NPHP4","canonical_id":"hgnc:HGNC:19104","description":"nephrocystin 4","metadata":{"aliases":["SLSN4","KIAA0673","POC10"]}},{"id":"6f128ce718d74c32bdd9bdefee4d9dde","type":"GENE","name":"NPHS1","canonical_id":"hgnc:HGNC:7908","description":null,"metadata":null},{"id":"8f61c310e0e04d44b7f048567cbe1614","type":"GENE","name":"NPHS2","canonical_id":"hgnc:HGNC:13394","description":null,"metadata":null},{"id":"905a651034f443c581d8bddf3c87297d","type":"TRIAL","name":"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma","canonical_id":"clinicaltrials.gov:NCT00667082","description":"Non-Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Lymphoma; Multiple Myeloma","metadata":null},{"id":"61347acee26842bf856baa21cc8cbc6b","type":"GENE","name":"NPIPA1","canonical_id":"hgnc:HGNC:7909","description":"nuclear pore complex interacting protein family member A1","metadata":{"aliases":["morpheus","NPIP"]}},{"id":"b4a44d09569e4eafba3ed5c8c1268009","type":"GENE","name":"NPIPA2","canonical_id":"hgnc:HGNC:41979","description":"nuclear pore complex interacting protein family member A2","metadata":null},{"id":"66b79a0720a64eb19c9d43c4150e9b2b","type":"GENE","name":"NPIPA3","canonical_id":"hgnc:HGNC:41978","description":"nuclear pore complex interacting protein family member A3","metadata":null},{"id":"df5acbc1e3404251bfef59c4049f6a89","type":"GENE","name":"NPIPA5","canonical_id":"hgnc:HGNC:41980","description":"nuclear pore complex interacting protein family member A5","metadata":null},{"id":"63d027a57e7240b2bd803a8242276331","type":"GENE","name":"NPIPA6","canonical_id":"hgnc:HGNC:27893","description":"nuclear pore complex interacting protein family, member A6","metadata":null},{"id":"12013b1cd85d4cd18c5c339783962878","type":"GENE","name":"NPIPA7","canonical_id":"hgnc:HGNC:41982","description":"nuclear pore complex interacting protein family member A7","metadata":null},{"id":"e53526fd34aa40fdaf37c7686991a2e6","type":"GENE","name":"NPIPA8","canonical_id":"hgnc:HGNC:41983","description":"nuclear pore complex interacting protein family member A8","metadata":{"aliases":["LCR16a9"]}},{"id":"2e84f49b0c924d8a90a9cff618d5551f","type":"GENE","name":"NPIPA9","canonical_id":"hgnc:HGNC:41984","description":"nuclear pore complex interacting protein family member A9","metadata":null},{"id":"32be410db04349aaa7d314ade109aa50","type":"GENE","name":"NPIPB10P","canonical_id":"hgnc:HGNC:37455","description":"nuclear pore complex interacting protein family, member B10, pseudogene","metadata":null},{"id":"d5d08948205f48aa814dc8760b9e17a4","type":"GENE","name":"NPIPB11","canonical_id":"hgnc:HGNC:37453","description":"nuclear pore complex interacting protein family member B11","metadata":null},{"id":"2cf3fa3b414644b88355a7cbd1192d6a","type":"GENE","name":"NPIPB12","canonical_id":"hgnc:HGNC:37491","description":"nuclear pore complex interacting protein family member B12","metadata":null},{"id":"c3cc8b1e703a441aad842e10cd626bdf","type":"GENE","name":"NPIPB13","canonical_id":"hgnc:HGNC:41989","description":"nuclear pore complex interacting protein family, member B13","metadata":null},{"id":"48804ed149c34e8e94d95e1388f163d1","type":"GENE","name":"NPIPB14P","canonical_id":"hgnc:HGNC:41990","description":"nuclear pore complex interacting protein family member B14, pseudogene","metadata":null},{"id":"668f68a17f1042d48273a16998390584","type":"GENE","name":"NPIPB15","canonical_id":"hgnc:HGNC:34409","description":"nuclear pore complex interacting protein family member B15","metadata":{"aliases":["LOC440348","NPIPL2"]}},{"id":"ec59a7492f99420eab5805bbb4181496","type":"GENE","name":"NPIPB1P","canonical_id":"hgnc:HGNC:37452","description":"nuclear pore complex interacting protein family member B1, pseudogene","metadata":null},{"id":"2f796d3c35104086be423fced3506cbe","type":"GENE","name":"NPIPB2","canonical_id":"hgnc:HGNC:37451","description":"nuclear pore complex interacting protein family member B2","metadata":null},{"id":"c2a1d9f734bb421da2d20df2f5827b89","type":"GENE","name":"NPIPB3","canonical_id":"hgnc:HGNC:28989","description":"nuclear pore complex interacting protein family member B3","metadata":{"aliases":["KIAA0220","NPIPL3"]}},{"id":"b597d9fb2e874669bd88fbe048043b05","type":"GENE","name":"NPIPB4","canonical_id":"hgnc:HGNC:41985","description":"nuclear pore complex interacting protein family member B4","metadata":null},{"id":"11e0123ca35c4b33bc13bd7a01cd6ae4","type":"GENE","name":"NPIPB5","canonical_id":"hgnc:HGNC:37233","description":"nuclear pore complex interacting protein family member B5","metadata":null},{"id":"28aca1ad761d4f6886c0fc0930b0c17e","type":"GENE","name":"NPIPB6","canonical_id":"hgnc:HGNC:37454","description":"nuclear pore complex interacting protein family member B6","metadata":null},{"id":"320de1a92d634966a47b33913adb4687","type":"GENE","name":"NPIPB7","canonical_id":"hgnc:HGNC:33832","description":"nuclear pore complex interacting protein family member B7","metadata":{"aliases":["LOC440350","NPIPL1"]}},{"id":"271dfe8c5406460aae5bb0c4faff7065","type":"GENE","name":"NPIPB8","canonical_id":"hgnc:HGNC:37490","description":"nuclear pore complex interacting protein family member B8","metadata":null},{"id":"0abea7457f084b65a2cc293857396d47","type":"GENE","name":"NPIPB9","canonical_id":"hgnc:HGNC:41987","description":"nuclear pore complex interacting protein family member B9","metadata":null},{"id":"d1b97f1e0b53405cae288a868f1e8ce6","type":"GENE","name":"NPIPP1","canonical_id":"hgnc:HGNC:35407","description":"nuclear pore complex interacting protein pseudogene 1","metadata":{"aliases":["NPIPA4P"]}},{"id":"4f88270e69da477aa7f426a0ab7ac520","type":"GENE","name":"NPL","canonical_id":"hgnc:HGNC:16781","description":"N-acetylneuraminate pyruvate lyase","metadata":{"aliases":["NPL1","DHDPS1","C1orf13"]}},{"id":"4f942bb82b3b46a688c11b4131b9bcea","type":"GENE","name":"NPLOC4","canonical_id":"hgnc:HGNC:18261","description":"NPL4 homolog, ubiquitin recognition factor","metadata":{"aliases":["NPL4","FLJ20657","KIAA1499"]}},{"id":"472da768599b463aaff86994a7a25e2c","type":"GENE","name":"NPLP1","canonical_id":"hgnc:HGNC:54747","description":"NPL pseudogene 1","metadata":null},{"id":"5ae4b769cd1d44cf82989b4ff9182247","type":"GENE","name":"NPM1","canonical_id":"hgnc:HGNC:7910","description":null,"metadata":null},{"id":"9ca0a5e01ce643e69e66562a641b0895","type":"GENE","name":"NPM1P1","canonical_id":"hgnc:HGNC:7911","description":"nucleophosmin 1 pseudogene 1","metadata":{"aliases":["NG1-1.6","NPMP1"]}},{"id":"b521fe0254c4490c8da6a2dc9d2f52c3","type":"GENE","name":"NPM1P10","canonical_id":"hgnc:HGNC:7912","description":"nucleophosmin 1 pseudogene 10","metadata":null},{"id":"04a5f332cc4b47c88d3790a51d783990","type":"GENE","name":"NPM1P11","canonical_id":"hgnc:HGNC:7913","description":"nucleophosmin 1 pseudogene 11","metadata":null},{"id":"4ea3128dc88e4ec492ee17afbbc25b5d","type":"GENE","name":"NPM1P12","canonical_id":"hgnc:HGNC:7914","description":"nucleophosmin 1 pseudogene 12","metadata":null},{"id":"28994b29062d4d7db40e06081d9f8abe","type":"GENE","name":"NPM1P13","canonical_id":"hgnc:HGNC:7915","description":"nucleophosmin 1 pseudogene 13","metadata":null},{"id":"0eeee2889e3b40c886dd0ca9b3aead08","type":"GENE","name":"NPM1P14","canonical_id":"hgnc:HGNC:7916","description":"nucleophosmin 1 pseudogene 14","metadata":null},{"id":"7f3bfdb177d34806b5fef3efd97ecebd","type":"GENE","name":"NPM1P17","canonical_id":"hgnc:HGNC:7919","description":"nucleophosmin 1 pseudogene 17","metadata":null},{"id":"7d484371ab2a46fdb7bb2607515a2b1f","type":"GENE","name":"NPM1P18","canonical_id":"hgnc:HGNC:7920","description":"nucleophosmin 1 pseudogene 18","metadata":null},{"id":"78cdad698dd94cd3bf46b701b6314538","type":"GENE","name":"NPM1P19","canonical_id":"hgnc:HGNC:7921","description":"nucleophosmin 1 pseudogene 19","metadata":null},{"id":"23b44c7b2e834f70ab1f339e0935c9dc","type":"GENE","name":"NPM1P2","canonical_id":"hgnc:HGNC:7922","description":"nucleophosmin 1 pseudogene 2","metadata":{"aliases":["NG2-6","NPMP2"]}},{"id":"6d869d7897b64715a955936a98c8930a","type":"GENE","name":"NPM1P20","canonical_id":"hgnc:HGNC:20140","description":"nucleophosmin 1 pseudogene 20","metadata":null},{"id":"c478640bce814e0c8012c0a95a9c95d2","type":"GENE","name":"NPM1P21","canonical_id":"hgnc:HGNC:13855","description":"nucleophosmin 1 pseudogene 21","metadata":null},{"id":"4dae6db6c901484bba68009f2ef7552c","type":"GENE","name":"NPM1P22","canonical_id":"hgnc:HGNC:39679","description":"nucleophosmin 1 pseudogene 22","metadata":null},{"id":"4f49fc42cafb45838aabbb0b724a8618","type":"GENE","name":"NPM1P23","canonical_id":"hgnc:HGNC:44513","description":"nucleophosmin 1 pseudogene 23","metadata":null},{"id":"bbb21a5d538c4465aa4dc1ee4a4787d2","type":"GENE","name":"NPM1P24","canonical_id":"hgnc:HGNC:45097","description":"nucleophosmin 1 pseudogene 24","metadata":null},{"id":"81334a36c13c4289885c28ce150de0bb","type":"GENE","name":"NPM1P25","canonical_id":"hgnc:HGNC:45204","description":"nucleophosmin 1 pseudogene 25","metadata":null},{"id":"227d06ae14754bb7a994da0fbc8d3553","type":"GENE","name":"NPM1P26","canonical_id":"hgnc:HGNC:45205","description":"nucleophosmin 1 pseudogene 26","metadata":null},{"id":"2251f94e13fd4b6ab689b39856da6c25","type":"GENE","name":"NPM1P27","canonical_id":"hgnc:HGNC:45206","description":"nucleophosmin 1 pseudogene 27","metadata":null},{"id":"b7d24b57da75484c9b05163943e69404","type":"GENE","name":"NPM1P28","canonical_id":"hgnc:HGNC:45207","description":"nucleophosmin 1 pseudogene 28","metadata":null},{"id":"0c2c83e67f6c49faaf8fe499610e1141","type":"GENE","name":"NPM1P29","canonical_id":"hgnc:HGNC:45208","description":"nucleophosmin 1 pseudogene 29","metadata":null},{"id":"de8fadb797244e15b4cd80581ddd870f","type":"GENE","name":"NPM1P3","canonical_id":"hgnc:HGNC:7923","description":"nucleophosmin 1 pseudogene 3","metadata":{"aliases":["NG3-3","NPMP3","NPM1P15"]}},{"id":"77635c02bdd94909987dd8f11f256ea8","type":"GENE","name":"NPM1P30","canonical_id":"hgnc:HGNC:45209","description":"nucleophosmin 1 pseudogene 30","metadata":null},{"id":"64603f11cc0d4104a128a0f117d4926f","type":"GENE","name":"NPM1P31","canonical_id":"hgnc:HGNC:45210","description":"nucleophosmin 1 pseudogene 31","metadata":null},{"id":"47e70adafc384e19861406fd3a74a58e","type":"GENE","name":"NPM1P32","canonical_id":"hgnc:HGNC:45211","description":"nucleophosmin 1 pseudogene 32","metadata":null},{"id":"93e91ad72c0740fbbc0bd1b2df92f843","type":"GENE","name":"NPM1P33","canonical_id":"hgnc:HGNC:45212","description":"nucleophosmin 1 pseudogene 33","metadata":null},{"id":"a0d281ba6c5e451bb783cab26ba583a2","type":"GENE","name":"NPM1P34","canonical_id":"hgnc:HGNC:45213","description":"nucleophosmin 1 pseudogene 34","metadata":null},{"id":"2446718cd87f4557b05069d40f09c22b","type":"GENE","name":"NPM1P35","canonical_id":"hgnc:HGNC:45214","description":"nucleophosmin 1 pseudogene 35","metadata":null},{"id":"f009442af8684075937708deaf121b68","type":"GENE","name":"NPM1P36","canonical_id":"hgnc:HGNC:45215","description":"nucleophosmin 1 pseudogene 36","metadata":null},{"id":"011c2c8527fc480aa7699ed4a2410e28","type":"GENE","name":"NPM1P37","canonical_id":"hgnc:HGNC:45216","description":"nucleophosmin 1 pseudogene 37","metadata":null},{"id":"90e6e62c2eaa42a6819be95635557162","type":"GENE","name":"NPM1P38","canonical_id":"hgnc:HGNC:45217","description":"nucleophosmin 1 pseudogene 38","metadata":null},{"id":"f7887a156d0a4570819305ad05cef2fc","type":"GENE","name":"NPM1P39","canonical_id":"hgnc:HGNC:45218","description":"nucleophosmin 1 pseudogene 39","metadata":null},{"id":"f4518a3ef3d04ec4bac2243582cad97c","type":"GENE","name":"NPM1P4","canonical_id":"hgnc:HGNC:7924","description":"nucleophosmin 1 pseudogene 4","metadata":{"aliases":["NG4-5","NPMP4"]}},{"id":"53f5013199d146dfb31e114890e2b956","type":"GENE","name":"NPM1P40","canonical_id":"hgnc:HGNC:45219","description":"nucleophosmin 1 pseudogene 40","metadata":null},{"id":"3cd3bad7ea9b4788b7a0e929d02e03cf","type":"GENE","name":"NPM1P41","canonical_id":"hgnc:HGNC:45220","description":"nucleophosmin 1 pseudogene 41","metadata":null},{"id":"743e1a23b2134d56bf6caadef38e2cb3","type":"GENE","name":"NPM1P42","canonical_id":"hgnc:HGNC:45221","description":"nucleophosmin 1 pseudogene 42","metadata":null},{"id":"28c9bed38a0a4e5a942befee9b9bb4ff","type":"GENE","name":"NPM1P43","canonical_id":"hgnc:HGNC:45222","description":"nucleophosmin 1 pseudogene 43","metadata":null},{"id":"a0a18bb353de42afa55a0be715ef6c56","type":"GENE","name":"NPM1P44","canonical_id":"hgnc:HGNC:45223","description":"nucleophosmin 1 pseudogene 44","metadata":null},{"id":"0818f900a8684deea1130c069e8d9d0b","type":"GENE","name":"NPM1P45","canonical_id":"hgnc:HGNC:45224","description":"nucleophosmin 1 pseudogene 45","metadata":null},{"id":"e0641cb849434d7b94801fb089913f2f","type":"GENE","name":"NPM1P46","canonical_id":"hgnc:HGNC:45225","description":"nucleophosmin 1 pseudogene 46","metadata":null},{"id":"a6c64a8b25eb4ccebd0752e15f83906e","type":"GENE","name":"NPM1P47","canonical_id":"hgnc:HGNC:45226","description":"nucleophosmin 1 pseudogene 47","metadata":null},{"id":"9cee1cf97e864c5f9cec9b610d6d1730","type":"GENE","name":"NPM1P48","canonical_id":"hgnc:HGNC:45227","description":"nucleophosmin 1 pseudogene 48","metadata":null},{"id":"fc426f444d3b4d18890a548d7280b957","type":"GENE","name":"NPM1P49","canonical_id":"hgnc:HGNC:45228","description":"nucleophosmin 1 pseudogene 49","metadata":null},{"id":"d96c9510e5c44a8ea429af8656e94dab","type":"GENE","name":"NPM1P5","canonical_id":"hgnc:HGNC:7925","description":"nucleophosmin 1 pseudogene 5","metadata":{"aliases":["NG5-4","NPMP5"]}},{"id":"e4d8ba5ba6694f2bbdd3fcf2c4bcf180","type":"GENE","name":"NPM1P50","canonical_id":"hgnc:HGNC:45229","description":"nucleophosmin 1 pseudogene 50","metadata":null},{"id":"8e1cc3d214ed435688f195b7b0c4d780","type":"GENE","name":"NPM1P51","canonical_id":"hgnc:HGNC:45230","description":"nucleophosmin 1 pseudogene 51","metadata":null},{"id":"b9d03a23bad046f4826c8da64600622d","type":"GENE","name":"NPM1P52","canonical_id":"hgnc:HGNC:45231","description":"nucleophosmin 1 pseudogene 52","metadata":null},{"id":"c8b7f120a12740a181ffb506b4e57d3f","type":"GENE","name":"NPM1P6","canonical_id":"hgnc:HGNC:7926","description":"nucleophosmin 1 pseudogene 6","metadata":{"aliases":["NG6-4","NPMP6"]}},{"id":"9fb18d8411c44d509c0bf596ebb0969b","type":"GENE","name":"NPM1P7","canonical_id":"hgnc:HGNC:7927","description":"nucleophosmin 1 pseudogene 7","metadata":{"aliases":["NG7-6","NPMP7","NPM1P16"]}},{"id":"cf258114643047a295b5fb5c53972c1f","type":"GENE","name":"NPM1P8","canonical_id":"hgnc:HGNC:7928","description":"nucleophosmin 1 pseudogene 8","metadata":null},{"id":"e0f496605f7f4323ae5a2cd206c3fe2f","type":"GENE","name":"NPM1P9","canonical_id":"hgnc:HGNC:7929","description":"nucleophosmin 1 pseudogene 9","metadata":null},{"id":"45e042a3478f46b8b7057a7299132124","type":"GENE","name":"NPM2","canonical_id":"hgnc:HGNC:7930","description":"nucleophosmin/nucleoplasmin 2","metadata":null},{"id":"e5ddcf90fb624ac3b27ef60db3aed28e","type":"GENE","name":"NPM3","canonical_id":"hgnc:HGNC:7931","description":"nucleophosmin/nucleoplasmin 3","metadata":null},{"id":"dd2ba2ea423a431faa233740c092b2d3","type":"GENE","name":"NPNT","canonical_id":"hgnc:HGNC:27405","description":"nephronectin","metadata":{"aliases":["EGFL6L","POEM"]}},{"id":"e7640704e07c4a84aa751adbe296093b","type":"GENE","name":"NPNT-AS1","canonical_id":"hgnc:HGNC:58424","description":"NPNT antisense RNA 1","metadata":null},{"id":"6bb16ea31e4944ae9a0e83e6579c89d4","type":"GENE","name":"NPPA","canonical_id":"hgnc:HGNC:7939","description":null,"metadata":null},{"id":"2f0bc5eb27744cb4be57be9d2ac1718d","type":"GENE","name":"NPPA-AS1","canonical_id":"hgnc:HGNC:37635","description":"NPPA antisense RNA 1","metadata":{"aliases":["NPPAAS","NPPA-AS"]}},{"id":"0ab42d4513d440a7b3cf326a212f20bb","type":"GENE","name":"NPPB","canonical_id":"hgnc:HGNC:7940","description":null,"metadata":null},{"id":"50b76fe965d04e8fa161fc9aa3e52701","type":"GENE","name":"NPPC","canonical_id":"hgnc:HGNC:7941","description":"natriuretic peptide C","metadata":{"aliases":["CNP"]}},{"id":"4cc4f15933e64575a1fbc3485a5f2d16","type":"GENE","name":"NPR1","canonical_id":"hgnc:HGNC:7943","description":"natriuretic peptide receptor 1","metadata":{"aliases":["GUCY2A","ANPa","ANPRA","NPRA"]}},{"id":"c020f5a3e86a4473b67d79b79e489415","type":"GENE","name":"NPR2","canonical_id":"hgnc:HGNC:7944","description":"natriuretic peptide receptor 2","metadata":{"aliases":["GUCY2B","ANPb","GC-B","ANPRB","NPRB","AMDM"]}},{"id":"ab3b936c71dc408085cb406f9109f9be","type":"GENE","name":"NPR3","canonical_id":"hgnc:HGNC:7945","description":"natriuretic peptide receptor 3","metadata":{"aliases":["GUCY2B","FLJ14054","NPRC","ANPRC","C5orf23"]}},{"id":"413b541fa7c14e60b3fb0aea0d51cf9e","type":"GENE","name":"NPRL2","canonical_id":"hgnc:HGNC:24969","description":"NPR2 like, GATOR1 complex subunit","metadata":{"aliases":["NPR2L","NPR2","TUSC4"]}},{"id":"eeeee6b78120495da52907f1cdb71c86","type":"GENE","name":"NPRL3","canonical_id":"hgnc:HGNC:14124","description":"NPR3 like, GATOR1 complex subunit","metadata":{"aliases":["CGTHBA","RMD11","NPR3","MARE","HS-40","C16orf35"]}},{"id":"7ca6bac51e2843389d75dc71d2285406","type":"GENE","name":"NPS","canonical_id":"hgnc:HGNC:33940","description":"neuropeptide S","metadata":null},{"id":"d6ba17f6e4274685bc13bc04c6111971","type":"GENE","name":"NPSR1","canonical_id":"hgnc:HGNC:23631","description":null,"metadata":null},{"id":"0e875619da9a4c8aad5aa330bd6c64c8","type":"GENE","name":"NPSR1-AS1","canonical_id":"hgnc:HGNC:22128","description":"NPSR1 antisense RNA 1","metadata":{"aliases":["AAA1","IMAGE:4827585"]}},{"id":"f8d217b327cb4e77adeddfb744dfb41a","type":"GENE","name":"NPTN","canonical_id":"hgnc:HGNC:17867","description":"neuroplastin","metadata":{"aliases":["SDR1","GP55","GP65","np65","np55","SDFR1"]}},{"id":"289e718c9186424aac9b25118fc5dce4","type":"GENE","name":"NPTN-IT1","canonical_id":"hgnc:HGNC:45091","description":"NPTN intronic transcript 1","metadata":{"aliases":["lncRNA-LET"]}},{"id":"c5a03134af904ad6b80ccc3f3caa9942","type":"GENE","name":"NPTX1","canonical_id":"hgnc:HGNC:7952","description":"neuronal pentraxin 1","metadata":null},{"id":"2a8314b2828945498b71315271672711","type":"GENE","name":"NPTX2","canonical_id":"hgnc:HGNC:7953","description":"neuronal pentraxin 2","metadata":null},{"id":"8d7af098d3484627889d45c9799a5b33","type":"GENE","name":"NPTXR","canonical_id":"hgnc:HGNC:7954","description":"neuronal pentraxin receptor","metadata":null},{"id":"00e7c1f995c14c2ead7ceb74100c2339","type":"GENE","name":"NPVF","canonical_id":"hgnc:HGNC:13782","description":"neuropeptide VF precursor","metadata":{"aliases":["RFRP","C7orf9"]}},{"id":"a345d62b007f4083bc2942ef6ff6b718","type":"GENE","name":"NPW","canonical_id":"hgnc:HGNC:30509","description":"neuropeptide W","metadata":{"aliases":["PPL8"]}},{"id":"c3303dcd2a1d40ecbf1019e92e9f97c6","type":"GENE","name":"NPY","canonical_id":"hgnc:HGNC:7955","description":null,"metadata":null},{"id":"c185c5129ac1419093d957b15c88c1ec","type":"GENE","name":"NPY1R","canonical_id":"hgnc:HGNC:7956","description":"neuropeptide Y receptor Y1","metadata":{"aliases":["NPYR"]}},{"id":"c47500ab0ad04560bdb72e3601065498","type":"GENE","name":"NPY2R","canonical_id":"hgnc:HGNC:7957","description":"neuropeptide Y receptor Y2","metadata":null},{"id":"af23485914d945a6bb1def038b115157","type":"GENE","name":"NPY2R-AS1","canonical_id":"hgnc:HGNC:55549","description":"NPY2R antisense RNA 1","metadata":null},{"id":"fa8a2bf3325f41e4b2f11b1d76c92795","type":"GENE","name":"NPY4R","canonical_id":"hgnc:HGNC:9329","description":"neuropeptide Y receptor Y4","metadata":{"aliases":["Y4","PP1","PPYR1"]}},{"id":"cbbb5c5bcbc448efaabb72ae45c19731","type":"GENE","name":"NPY4R2","canonical_id":"hgnc:HGNC:52383","description":"neuropeptide Y receptor Y4-2","metadata":{"aliases":["CH17-360D5.1"]}},{"id":"9cc3c8cdf9cb4aed908d24be5aee37bc","type":"GENE","name":"NPY5R","canonical_id":"hgnc:HGNC:7958","description":"neuropeptide Y receptor Y5","metadata":{"aliases":["NPYR5"]}},{"id":"15512eb9959c41969c3305a98e52fca8","type":"GENE","name":"NPY6RP","canonical_id":"hgnc:HGNC:7959","description":"neuropeptide Y receptor Y6, pseudogene","metadata":{"aliases":["PP2","NPY1RL","NPY6RP","NPY6R"]}},{"id":"a4ab91e70ca44d08ba0ea5278a8a81ba","type":"GENE","name":"NQO1","canonical_id":"hgnc:HGNC:2874","description":null,"metadata":null},{"id":"4e63bbee70844e0a9503df6e92322bec","type":"GENE","name":"NQO1-AS1","canonical_id":"hgnc:HGNC:58115","description":"NQO1 antisense RNA 1","metadata":{"aliases":["NQO1-AS"]}},{"id":"12cfc956fa0f4a3a9ba9c921b77cfcb4","type":"GENE","name":"NQO1-DT","canonical_id":"hgnc:HGNC:55344","description":"NQO1 divergent transcript","metadata":{"aliases":["FASRL"]}},{"id":"5492af7a6ae34515a15969d5c531aa9e","type":"GENE","name":"NQO2","canonical_id":"hgnc:HGNC:7856","description":null,"metadata":null},{"id":"bf87437b4ecf443397fe4d42dc407591","type":"GENE","name":"NQO2-AS1","canonical_id":"hgnc:HGNC:40407","description":"NQO2 antisense RNA 1","metadata":null},{"id":"060fdc9b811241399bc7e955778e708c","type":"GENE","name":"NR0B1","canonical_id":"hgnc:HGNC:7960","description":null,"metadata":null},{"id":"7e396f4fac66463783d405f496652ea5","type":"GENE","name":"NR0B2","canonical_id":"hgnc:HGNC:7961","description":null,"metadata":null},{"id":"92249b679826496aa22e710a82a672fe","type":"GENE","name":"NR1D1","canonical_id":"hgnc:HGNC:7962","description":null,"metadata":null},{"id":"470532208c30492780cd19452f214515","type":"GENE","name":"NR1D2","canonical_id":"hgnc:HGNC:7963","description":"nuclear receptor subfamily 1 group D member 2","metadata":{"aliases":["BD73","RVR","EAR-1r","HZF2","Hs.37288","REVERBB","REVERBbeta"]}},{"id":"25ec695eb6554921ad280cc2dd57de49","type":"GENE","name":"NR1H2","canonical_id":"hgnc:HGNC:7965","description":null,"metadata":null},{"id":"0ac1e70d35464dd782a13fff7216cc95","type":"GENE","name":"NR1H3","canonical_id":"hgnc:HGNC:7966","description":null,"metadata":null},{"id":"f7b415a3b6d146f79e5866e0ff482057","type":"GENE","name":"NR1H4","canonical_id":"hgnc:HGNC:7967","description":null,"metadata":null},{"id":"c93b4bb8a2b94756a1d10183b719cd35","type":"PROTEIN","name":"NR1H4","canonical_id":"uniprot:Q96RI1","description":null,"metadata":null},{"id":"d98db1d7823e426382438b50e2849294","type":"GENE","name":"NR1H5P","canonical_id":"hgnc:HGNC:32673","description":"nuclear receptor subfamily 1 group H member 5, pseudogene","metadata":{"aliases":["Fxrb","NR1H5"]}},{"id":"da5712d9c0624faead15e23ef9b96273","type":"GENE","name":"NR1I2","canonical_id":"hgnc:HGNC:7968","description":null,"metadata":null},{"id":"90b7867e473b464180fff32f6fb737fe","type":"GENE","name":"NR1I3","canonical_id":"hgnc:HGNC:7969","description":null,"metadata":null},{"id":"02c3f6ded7d845e391691df14228c4f7","type":"GENE","name":"NR1I4","canonical_id":"hgnc:HGNC:7970","description":"nuclear receptor subfamily 1 group I member 4","metadata":{"aliases":["CAR2"]}},{"id":"6df30967c6054c169423a138885e9e0f","type":"GENE","name":"NR2C1","canonical_id":"hgnc:HGNC:7971","description":"nuclear receptor subfamily 2 group C member 1","metadata":{"aliases":["TR2-11","TR2"]}},{"id":"3c350d58b31645fc8b77f064f0b4bf1e","type":"GENE","name":"NR2C2","canonical_id":"hgnc:HGNC:7972","description":null,"metadata":null},{"id":"84056e4172c241cbbb40abb5adbb2c15","type":"GENE","name":"NR2C2AP","canonical_id":"hgnc:HGNC:30763","description":"nuclear receptor 2C2 associated protein","metadata":{"aliases":["TRA16"]}},{"id":"dbb335b54cd64d60ba8811c1c1e30db5","type":"GENE","name":"NR2E1","canonical_id":"hgnc:HGNC:7973","description":"nuclear receptor subfamily 2 group E member 1","metadata":{"aliases":["TLL","XTLL","TLX"]}},{"id":"fe197700516e4700ad4b15572e842ace","type":"GENE","name":"NR2E3","canonical_id":"hgnc:HGNC:7974","description":null,"metadata":null},{"id":"17bf0f7863e24236a44926904bb2aad8","type":"GENE","name":"NR2F1","canonical_id":"hgnc:HGNC:7975","description":null,"metadata":null},{"id":"d05b36c2d0ab499fa1bc83a6823201b6","type":"GENE","name":"NR2F1-AS1","canonical_id":"hgnc:HGNC:48622","description":"NR2F1 regulatory antisense RNA 1","metadata":{"aliases":["NAS1","FLJ42709"]}},{"id":"a0e6eb17378c4ade83a785d6d6f62ad8","type":"GENE","name":"NR2F2","canonical_id":"hgnc:HGNC:7976","description":null,"metadata":null},{"id":"5a594a078ec24fe68e6762e6b79cea6d","type":"GENE","name":"NR2F2-AS1","canonical_id":"hgnc:HGNC:44222","description":"NR2F2 antisense RNA 1","metadata":null},{"id":"9a5e7c583b334f7bb09d6351547395d7","type":"GENE","name":"NR2F6","canonical_id":"hgnc:HGNC:7977","description":null,"metadata":null},{"id":"81db3ee46c6e4dc09ddaea054fac65de","type":"GENE","name":"NR3C1","canonical_id":"hgnc:HGNC:7978","description":null,"metadata":null},{"id":"a239528edfb640dc99c738a18ef6f50f","type":"PROTEIN","name":"NR3C1","canonical_id":"uniprot:P04150","description":null,"metadata":null},{"id":"0633120603ff4e4ab09cac78ded0951e","type":"GENE","name":"NR3C1-AS1","canonical_id":"hgnc:HGNC:59268","description":"NR3C1 antisense RNA 1","metadata":null},{"id":"2a16804311524b8f899ccadce5ad5089","type":"GENE","name":"NR3C1P1","canonical_id":"hgnc:HGNC:4592","description":"nuclear receptor subfamily 3 group C member 1 pseudogene 1","metadata":{"aliases":["GRLL1","NR3C1P"]}},{"id":"57d408ef25eb4778b6421ef5f9d9a072","type":"GENE","name":"NR3C2","canonical_id":"hgnc:HGNC:7979","description":null,"metadata":null},{"id":"baf397826625437f8c248890b0f3f365","type":"PROTEIN","name":"NR3C2","canonical_id":"uniprot:P08235","description":null,"metadata":null},{"id":"b5e75103f10c483ba96bef8a50971cb3","type":"GENE","name":"NR3C2-AS1","canonical_id":"hgnc:HGNC:58891","description":"NR3C2 antisense RNA 1","metadata":null},{"id":"8d1f7cef82ad404687162e16e4de75e8","type":"GENE","name":"NR3C2-DT","canonical_id":"hgnc:HGNC:58892","description":"NR3C2 divergent transcript","metadata":null},{"id":"0138ff052f3541f6b2505bdb1e77c5f0","type":"GENE","name":"NR4A1","canonical_id":"hgnc:HGNC:7980","description":null,"metadata":null},{"id":"fd8179d272a449ceb74f062753bd73fb","type":"GENE","name":"NR4A1AS","canonical_id":"hgnc:HGNC:54409","description":"NR4A1 antisense RNA","metadata":{"aliases":["NR4A1-AS1","RP11-1100L3.8","lncMMPA"]}},{"id":"5e1b83c76b7543d481af9f070ebd2e1a","type":"GENE","name":"NR4A2","canonical_id":"hgnc:HGNC:7981","description":null,"metadata":null},{"id":"4dfe1bc3d7a04a4a8179084f6dcf4c9c","type":"GENE","name":"NR4A3","canonical_id":"hgnc:HGNC:7982","description":null,"metadata":null},{"id":"e7720d805162464eb340f368ddb89c70","type":"GENE","name":"NR5A1","canonical_id":"hgnc:HGNC:7983","description":null,"metadata":null},{"id":"042bb08c299f4878865e80ae2133925f","type":"GENE","name":"NR5A2","canonical_id":"hgnc:HGNC:7984","description":null,"metadata":null},{"id":"ccb6eadb734047af8cc7eeaed6111738","type":"GENE","name":"NR6A1","canonical_id":"hgnc:HGNC:7985","description":"nuclear receptor subfamily 6 group A member 1","metadata":{"aliases":["GCNF1","RTR","CT150","GCNF"]}},{"id":"2ce446901e8145f1be327385a96f8637","type":"GENE","name":"NRAD1","canonical_id":"hgnc:HGNC:26981","description":"non-coding RNA in the aldehyde dehydrogenase 1A pathway","metadata":{"aliases":["NCRNA00284","LINC00284"]}},{"id":"a25658c15af04c198094e7cc5e1632f3","type":"GENE","name":"NRADDP","canonical_id":"hgnc:HGNC:19337","description":"neurotrophin receptor associated death domain, pseudogene","metadata":null},{"id":"5847561631224f0da9dc06faf6bd0706","type":"GENE","name":"NRAL","canonical_id":"hgnc:HGNC:56652","description":"NRF2 regulation associated lncRNA","metadata":null},{"id":"1446089522324ccd9088f0349e4b29d4","type":"GENE","name":"NRAP","canonical_id":"hgnc:HGNC:7988","description":"nebulin related anchoring protein","metadata":null},{"id":"3d64871ab077437c952f79b45bbc70b7","type":"GENE","name":"NRARP","canonical_id":"hgnc:HGNC:33843","description":"NOTCH regulated ankyrin repeat protein","metadata":{"aliases":["MGC61598"]}},{"id":"1cefa0af76f04178ba79a593668a768f","type":"GENE","name":"NRAS","canonical_id":"hgnc:HGNC:7989","description":null,"metadata":null},{"id":"d38830749196409c8924249698ec3d0b","type":"GENE","name":"NRAV","canonical_id":"hgnc:HGNC:48588","description":"negative regulator of antiviral response","metadata":{"aliases":["DYNLL1-AS1"]}},{"id":"699bb54046244a77a1ce3a58f6f39aa0","type":"GENE","name":"NRBF2","canonical_id":"hgnc:HGNC:19692","description":"nuclear receptor binding factor 2","metadata":{"aliases":["DKFZp564C1664","FLJ30395","COPR1","COPR2"]}},{"id":"7815f74675be468f9fac8ae967eded98","type":"GENE","name":"NRBF2P1","canonical_id":"hgnc:HGNC:44604","description":"nuclear receptor binding factor 2 pseudogene 1","metadata":null},{"id":"a520e3244d8845fc8fd727b64c96912a","type":"GENE","name":"NRBF2P2","canonical_id":"hgnc:HGNC:44605","description":"nuclear receptor binding factor 2 pseudogene 2","metadata":null},{"id":"c2b304b61d1a403299097da2d5b097fe","type":"GENE","name":"NRBF2P3","canonical_id":"hgnc:HGNC:44606","description":"nuclear receptor binding factor 2 pseudogene 3","metadata":null},{"id":"5e901541d60d4c21a72486da1e871bd7","type":"GENE","name":"NRBF2P4","canonical_id":"hgnc:HGNC:44607","description":"nuclear receptor binding factor 2 pseudogene 4","metadata":null},{"id":"4c5b66fc72464d768b6e4b7253acc0d6","type":"GENE","name":"NRBF2P5","canonical_id":"hgnc:HGNC:44683","description":"nuclear receptor binding factor 2 pseudogene 5","metadata":null},{"id":"3e28b81145d84fabbc05f496099427dc","type":"GENE","name":"NRBF2P6","canonical_id":"hgnc:HGNC:54797","description":"NRBF2 pseudogene 6","metadata":null},{"id":"5eb567930d0043ae9e233c6558fea30b","type":"GENE","name":"NRBP1","canonical_id":"hgnc:HGNC:7993","description":"nuclear receptor binding protein 1","metadata":{"aliases":["BCON3","MUDPNP","MADM","NRBP"]}},{"id":"821b3485e06e4db9aba6693de007a9fb","type":"GENE","name":"NRBP2","canonical_id":"hgnc:HGNC:19339","description":"nuclear receptor binding protein 2","metadata":{"aliases":["DKFZp434P086"]}},{"id":"e4a536a660c248babf99f8843f13d556","type":"GENE","name":"NRCAM","canonical_id":"hgnc:HGNC:7994","description":null,"metadata":null},{"id":"4f5a802ae4b84d7c91dec69884d12890","type":"GENE","name":"NRDC","canonical_id":"hgnc:HGNC:7995","description":"nardilysin convertase","metadata":{"aliases":["hNRD1","hNRD2","NRD1"]}},{"id":"2b11c8a32a1d441795e1387d8bcf84cb","type":"GENE","name":"NRDE2","canonical_id":"hgnc:HGNC:20186","description":"NRDE-2, necessary for RNA interference, domain containing","metadata":{"aliases":["FLJ14051","C14orf102"]}},{"id":"9770205bd2cc4b7ca1fac61ebc0bbe5f","type":"GENE","name":"NREP","canonical_id":"hgnc:HGNC:16834","description":"neuronal regeneration related protein","metadata":{"aliases":["P311","D4S114","PRO1873","PTZ17","SEZ17","C5orf13"]}},{"id":"65fb5e934901444587dd48961a8ffdf3","type":"GENE","name":"NREP-AS1","canonical_id":"hgnc:HGNC:40780","description":"NREP antisense RNA 1","metadata":null},{"id":"0bd960dae23c48d2a8902d474d0eee55","type":"GENE","name":"NREPP1","canonical_id":"hgnc:HGNC:58664","description":"NREP pseudogene 1","metadata":null},{"id":"6a51ff163def478a84aeb4ef770b75c5","type":"GENE","name":"NREPP2","canonical_id":"hgnc:HGNC:58665","description":"NREP pseudogene 2","metadata":null},{"id":"afae7dae990d474688d1d6fb0fabe4fd","type":"GENE","name":"NRF1","canonical_id":"hgnc:HGNC:7996","description":null,"metadata":null},{"id":"e7e46be78cbb4061b2eafded5b07777e","type":"GENE","name":"NRG1","canonical_id":"hgnc:HGNC:7997","description":"neuregulin 1","metadata":{"aliases":["HRG","NDF","GGF","HGL","NRG1-IT2"]}},{"id":"6a12fb9d6857490f8f94433ad13f87e3","type":"GENE","name":"NRG1-IT1","canonical_id":"hgnc:HGNC:43633","description":"NRG1 intronic transcript 1","metadata":null},{"id":"66adf2a9519046768e644b1c96142b09","type":"GENE","name":"NRG1-IT3","canonical_id":"hgnc:HGNC:43635","description":"NRG1 intronic transcript 3","metadata":null},{"id":"30b65be21d364845adf89e77dbe79597","type":"GENE","name":"NRG2","canonical_id":"hgnc:HGNC:7998","description":"neuregulin 2","metadata":{"aliases":["Don-1","NTAK","HRG2"]}},{"id":"58c82ef0e5074502ac05bc46275e88ff","type":"GENE","name":"NRG2-AS1","canonical_id":"hgnc:HGNC:40412","description":"NRG2 antisense RNA 1","metadata":null},{"id":"75e5bc5f33054a3c96ede699695a9cfe","type":"GENE","name":"NRG3","canonical_id":"hgnc:HGNC:7999","description":"neuregulin 3","metadata":null},{"id":"6b49988a119a4d418408ec666dda1fee","type":"GENE","name":"NRG3-AS1","canonical_id":"hgnc:HGNC:31429","description":"NRG3 antisense RNA 1","metadata":{"aliases":["Em:AC010157.1","C10orf100"]}},{"id":"910c36b4fc944bb7b8fc0c6e51fbb6de","type":"GENE","name":"NRG4","canonical_id":"hgnc:HGNC:29862","description":"neuregulin 4","metadata":{"aliases":["HRG4"]}},{"id":"c1e1cdf1515645cfa43dbd70cd4ea485","type":"GENE","name":"NRGN","canonical_id":"hgnc:HGNC:8000","description":"neurogranin","metadata":{"aliases":["RC3"]}},{"id":"3dba696b2f924eaf8fd4a7987f5a95d6","type":"GENE","name":"NRGN-AS1","canonical_id":"hgnc:HGNC:58070","description":"NRGN antisense RNA 1","metadata":{"aliases":["RP11-677M14.2","Nrgn-AS"]}},{"id":"38b288f7c78240159ca4b2c2a0fade3b","type":"GENE","name":"NRIP1","canonical_id":"hgnc:HGNC:8001","description":null,"metadata":null},{"id":"e548641fee0c4012b2c5fac810a413c7","type":"GENE","name":"NRIP2","canonical_id":"hgnc:HGNC:23078","description":"nuclear receptor interacting protein 2","metadata":{"aliases":["DKFZP761G1913"]}},{"id":"f2ad51c96c0c4a18b6141bc2858eba7f","type":"GENE","name":"NRIP3","canonical_id":"hgnc:HGNC:1167","description":"nuclear receptor interacting protein 3","metadata":{"aliases":["C11orf14"]}},{"id":"3917be585b56464687f17286ccdf7bb0","type":"GENE","name":"NRIP3-DT","canonical_id":"hgnc:HGNC:55524","description":"NRIP3 divergent transcript","metadata":null},{"id":"714d8ce6ef8f4dc4baab89a815dc987d","type":"GENE","name":"NRIR","canonical_id":"hgnc:HGNC:51269","description":"negative regulator of interferon response","metadata":{"aliases":["lncRNA-CMPK2","lncCMPK2"]}},{"id":"2ef411c80f3c4b70b7613b8f4758e831","type":"GENE","name":"NRK","canonical_id":"hgnc:HGNC:25391","description":"Nik related kinase","metadata":{"aliases":["DKFZp686A17109"]}},{"id":"c6d50a571f0b46f99d43d7ad4cfe0025","type":"GENE","name":"NRL","canonical_id":"hgnc:HGNC:8002","description":null,"metadata":null},{"id":"fd6668ce9fe1433f9e440a22358a6cb0","type":"GENE","name":"NRM","canonical_id":"hgnc:HGNC:8003","description":"nurim","metadata":{"aliases":["NRM29"]}},{"id":"511cb62599ba4dd4891dc95ff9c7db6b","type":"GENE","name":"NRN1","canonical_id":"hgnc:HGNC:17972","description":"neuritin 1","metadata":{"aliases":["NRN"]}},{"id":"4630be9a563947029cbed44b280057c9","type":"GENE","name":"NRN1-AS1","canonical_id":"hgnc:HGNC:59340","description":"NRN1 antisense RNA 1","metadata":null},{"id":"7c9047e72d9145d4b68081bccb0a0d2d","type":"GENE","name":"NRN1L","canonical_id":"hgnc:HGNC:29811","description":"neuritin 1 like","metadata":{"aliases":["UNQ2446","MRCC2446"]}},{"id":"d5183d63dd464f92b74d6dabdc5b9c54","type":"GENE","name":"NRON","canonical_id":"hgnc:HGNC:37079","description":"non-coding repressor of NFAT","metadata":{"aliases":["NCRNA00194"]}},{"id":"b6b76d15dc6945daa842441ea388f349","type":"GENE","name":"NRP1","canonical_id":"hgnc:HGNC:8004","description":null,"metadata":null},{"id":"906cbe340c5f43b98fc2e7f9accc4fc0","type":"GENE","name":"NRP2","canonical_id":"hgnc:HGNC:8005","description":"neuropilin 2","metadata":{"aliases":["VEGF165R2"]}},{"id":"a4d2e7d4f60543a090b4279a0c0d8fe4","type":"GENE","name":"NRP2-AS1","canonical_id":"hgnc:HGNC:40415","description":"NRP2 antisense RNA 1","metadata":{"aliases":["hLinfRNA2"]}},{"id":"e2415116b7e04724a228146c05d86e38","type":"GENE","name":"NRROS","canonical_id":"hgnc:HGNC:24613","description":"negative regulator of reactive oxygen species","metadata":{"aliases":["UNQ3030","ELLP3030","MGC50789","GARPL1","LRRC33"]}},{"id":"8610e36404b8425a8b40be23780b90bf","type":"GENE","name":"NRSN1","canonical_id":"hgnc:HGNC:17881","description":"neurensin 1","metadata":{"aliases":["p24","VMP"]}},{"id":"338e34ad12e9406297d125748286a3f7","type":"GENE","name":"NRSN2","canonical_id":"hgnc:HGNC:16229","description":"neurensin 2","metadata":{"aliases":["dJ1103G7.6","C20orf98"]}},{"id":"5fb56a0407924e0fb7344c1b65aeb679","type":"GENE","name":"NRSN2-AS1","canonical_id":"hgnc:HGNC:51222","description":"NRSN2 antisense RNA 1","metadata":null},{"id":"9d52a40bf5ab4500abb11a10c949e228","type":"GENE","name":"NRTN","canonical_id":"hgnc:HGNC:8007","description":"neurturin","metadata":{"aliases":["NTN"]}},{"id":"394d506593544c908c1688da6e819964","type":"TRIAL","name":"NRX-101 for Bipolar Depression With Subacute Suicidal Ideation","canonical_id":"clinicaltrials.gov:NCT03395392","description":"Bipolar Depression; Suicidal Ideation and Behavior","metadata":null},{"id":"48a9c26370c8463d992fd42bc757386a","type":"TRIAL","name":"NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis","canonical_id":"clinicaltrials.gov:NCT06128213","description":"Urinary Tract Infections; Pyelonephritis","metadata":null},{"id":"976b27420ad749c6848e79554a52c4f2","type":"TRIAL","name":"NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation","canonical_id":"clinicaltrials.gov:NCT03396068","description":"Bipolar Depression; Suicidal Ideation","metadata":null},{"id":"3be09708cb984d9486a4e8374a61e5cf","type":"GENE","name":"NRXN1","canonical_id":"hgnc:HGNC:8008","description":null,"metadata":null},{"id":"22d6670917be47a9816323777a101cd7","type":"GENE","name":"NRXN1-DT","canonical_id":"hgnc:HGNC:52686","description":"NRXN1 divergent transcript","metadata":{"aliases":["AK127244"]}},{"id":"3e6fedbf709b4993b2b06536b14d0000","type":"GENE","name":"NRXN2","canonical_id":"hgnc:HGNC:8009","description":"neurexin 2","metadata":null},{"id":"17f083b262614a178ad7980ee9ae8253","type":"GENE","name":"NRXN2-AS1","canonical_id":"hgnc:HGNC:40416","description":"NRXN2 antisense RNA 1","metadata":null},{"id":"9561e68ba5884c1297e4158f8d2061c9","type":"GENE","name":"NRXN3","canonical_id":"hgnc:HGNC:8010","description":"neurexin 3","metadata":{"aliases":["KIAA0743","C14orf60"]}},{"id":"7ad5f0e7ffba48c7bcf8160ffa5cb496","type":"GENE","name":"NRXN3-AS1","canonical_id":"hgnc:HGNC:58459","description":"NRXN3 antisense RNA 1","metadata":null},{"id":"872a9d47bf4e4758b98e9f0495d4aae3","type":"GENE","name":"NRXN3-AS2","canonical_id":"hgnc:HGNC:58461","description":"NRXN3 antisense RNA 2","metadata":null},{"id":"f90471911e584096bd6c47b7974a6718","type":"GENE","name":"NRXN3-AS3","canonical_id":"hgnc:HGNC:58616","description":"NRXN3 antisense RNA 3","metadata":null},{"id":"37137ad3ce8a442bba63a3754af02cbe","type":"PROTEIN","name":"NS5b","canonical_id":"uniprot:O39930","description":null,"metadata":null},{"id":"36b410fc7ae2448bac0849341c8bc19e","type":"GENE","name":"NSA2","canonical_id":"hgnc:HGNC:30728","description":"NSA2 ribosome biogenesis factor","metadata":{"aliases":["HUSSY-29","HCLG1","FLJ94393","TINP1"]}},{"id":"038bc6bad7e4444e9993d04437887dd8","type":"GENE","name":"NSA2P1","canonical_id":"hgnc:HGNC:54580","description":"NSA2 pseudogene 1","metadata":null},{"id":"b9e3e5b0aec74ae08e033e004d8aab11","type":"GENE","name":"NSA2P2","canonical_id":"hgnc:HGNC:54581","description":"NSA2 pseudogene 2","metadata":null},{"id":"6a2dc2e00e5c484fa3e3a059a7719d58","type":"GENE","name":"NSA2P3","canonical_id":"hgnc:HGNC:54582","description":"NSA2 pseudogene 3","metadata":null},{"id":"cb39a675aae94c7a87743f968680c4fe","type":"GENE","name":"NSA2P4","canonical_id":"hgnc:HGNC:54583","description":"NSA2 pseudogene 4","metadata":null},{"id":"f582161cb95649679567d0143d701dd8","type":"GENE","name":"NSA2P5","canonical_id":"hgnc:HGNC:54584","description":"NSA2 pseudogene 5","metadata":null},{"id":"0a889f043bd0406cbada2c0597caed93","type":"GENE","name":"NSA2P6","canonical_id":"hgnc:HGNC:54587","description":"NSA2 pseudogene 6","metadata":null},{"id":"d4aea61a6ff34a149d5dd8227e68be05","type":"GENE","name":"NSA2P7","canonical_id":"hgnc:HGNC:54588","description":"NSA2 pseudogene 7","metadata":null},{"id":"f69532057b6c43189ae0e9a542a5352a","type":"TRIAL","name":"NSAID Use and Healing After Tibia Fractures and Achilles Tendon Ruptures","canonical_id":"clinicaltrials.gov:NCT03880981","description":"Musculoskeletal Injury","metadata":null},{"id":"82f20d520ea34c5798ca3a6b4999cfa4","type":"TRIAL","name":"NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)","canonical_id":"clinicaltrials.gov:NCT06861920","description":"Dysmenorrhea; Chronic Pelvic Pain; Pelvic Pain","metadata":null},{"id":"544b2c977c404387ba406a3a7bb194d8","type":"TRIAL","name":"NSAID vs Steroid in Trabeculectomy Wound Management","canonical_id":"clinicaltrials.gov:NCT03751059","description":"Glaucoma","metadata":null},{"id":"cb89fc71464447868c053f574407720e","type":"TRIAL","name":"NSAIDS Following Elective Lumbar Spine Fusion","canonical_id":"clinicaltrials.gov:NCT07743606","description":"NSAID (Non-Steroidal Anti-Inflammatory Drug); Lumbar Spine Fusion; Ketorolac; Postoperative Pain","metadata":null},{"id":"d00c53dbf8574be48aa8ec33a2330614","type":"TRIAL","name":"NSAIDS Versus Opioids in Acute SER II Ankle Fractures","canonical_id":"clinicaltrials.gov:NCT02373254","description":"Ankle Fracture","metadata":null},{"id":"7f83d23f65c24ac685942031c2c86ee5","type":"TRIAL","name":"NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT02758782","description":"Ankylosing Spondylitis","metadata":null},{"id":"3b02af6fa4134589b54d5b1bfa8fab05","type":"TRIAL","name":"NSAIDs With Morphine-PCA Compared to Epidural Analgesia in Thoracotomy Pain","canonical_id":"clinicaltrials.gov:NCT01541137","description":"Postoperative Pain","metadata":null},{"id":"c76cb368d1ac48808395b10f1bf64aaf","type":"TRIAL","name":"NSAIDs and PGE2 Levels in Vitrectomy Patients","canonical_id":"clinicaltrials.gov:NCT02361645","description":"Vitreous Inflammation","metadata":null},{"id":"3c5e52576a0c407dac51697bc22bc391","type":"TRIAL","name":"NSAIDs in Sciatica NSAIDS IN SCIATICA","canonical_id":"clinicaltrials.gov:NCT03347929","description":"Sciatica","metadata":null},{"id":"abde5a7c37d749f69acc7ecdc61a3f81","type":"GENE","name":"NSD1","canonical_id":"hgnc:HGNC:14234","description":"nuclear receptor binding SET domain protein 1","metadata":{"aliases":["ARA267","FLJ22263","KMT3B","STO"]}},{"id":"49083f7b418e4ca1b6f8483a74579c0e","type":"GENE","name":"NSD3","canonical_id":"hgnc:HGNC:12767","description":"nuclear receptor binding SET domain protein 3","metadata":{"aliases":["FLJ20353","WHISTLE","KMT3F","WHSC1L1"]}},{"id":"21b44a7df9de418780cb9a8fa9ebf038","type":"GENE","name":"NSDHL","canonical_id":"hgnc:HGNC:13398","description":"NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL","metadata":{"aliases":["XAP104","H105e3","SDR31E1"]}},{"id":"2c01c03b97de4863be178924e000a6b4","type":"GENE","name":"NSF","canonical_id":"hgnc:HGNC:8016","description":"N-ethylmaleimide sensitive factor, vesicle fusing ATPase","metadata":{"aliases":["SKD2","SEC18"]}},{"id":"f221301bfede4b1296e1422b3a2984c5","type":"GENE","name":"NSFL1C","canonical_id":"hgnc:HGNC:15912","description":null,"metadata":null},{"id":"1c691a1af48740ef9be390867cc92512","type":"GENE","name":"NSFP1","canonical_id":"hgnc:HGNC:31405","description":"N-ethylmaleimide-sensitive factor pseudogene 1","metadata":{"aliases":["NSFP"]}},{"id":"4e7ef6343e9345a891ef88824a573d87","type":"GENE","name":"NSG1","canonical_id":"hgnc:HGNC:18790","description":"neuronal vesicle trafficking associated 1","metadata":{"aliases":["P21","D4S234E","NEEP21"]}},{"id":"53037d820e4740ed859859a0dee4bbc0","type":"GENE","name":"NSG2","canonical_id":"hgnc:HGNC:24955","description":"neuronal vesicle trafficking associated 2","metadata":{"aliases":["HMP19","CALY3"]}},{"id":"a0444e2ed43e4e55a0f8c49396c71060","type":"GENE","name":"NSG2-AS1","canonical_id":"hgnc:HGNC:41074","description":"NSG2 antisense RNA 1","metadata":null},{"id":"63e48a3d83054eb884d16cc1453b5a25","type":"GO_TERM","name":"NSL complex","canonical_id":"go:GO:0044545","description":"\"A histone acetyltransferase complex that catalyzes the acetylation of a histone H4 lysine residues at several positions. In human, it contains the catalytic subunit MOF, NSL1/KIAA1267, NSL2/KANSL2, NSL3/KANSL3, MCRS1, PHF20, OGT1, WDR5 and HCF1.\" [GOC:lb, PMID:20018852]","metadata":null},{"id":"5e9734e7b0e04333a74797a93728c6e5","type":"GENE","name":"NSL1","canonical_id":"hgnc:HGNC:24548","description":"NSL1 component of MIS12 kinetochore complex","metadata":{"aliases":["DC8","DKFZP566O1646","MIS14","C1orf48"]}},{"id":"0ad7592af94b444292cd73627d2ea6fe","type":"GENE","name":"NSMAF","canonical_id":"hgnc:HGNC:8017","description":"neutral sphingomyelinase activation associated factor","metadata":{"aliases":["FAN","GRAMD5"]}},{"id":"680619c8ec3d4d418c4360ca0cfbbcdc","type":"GENE","name":"NSMCE1","canonical_id":"hgnc:HGNC:29897","description":"NSE1 component of SMC5/6 complex","metadata":{"aliases":["NSE1"]}},{"id":"0e359889675e4a24bb7b4e9aca3a3a97","type":"GENE","name":"NSMCE1-DT","canonical_id":"hgnc:HGNC:51368","description":"NSMCE1 divergent transcript","metadata":null},{"id":"908fddd6cd76476e9bd2cc7fc8af538c","type":"GENE","name":"NSMCE2","canonical_id":"hgnc:HGNC:26513","description":"NSE2 SUMO ligase component of SMC5/6 complex","metadata":{"aliases":["FLJ32440","MMS21","NSE2","ZMIZ7","C8orf36"]}},{"id":"40837136ca40469cb82d5f6393c85be1","type":"GENE","name":"NSMCE3","canonical_id":"hgnc:HGNC:7677","description":"NSE3 component of SMC5/6 complex","metadata":{"aliases":["HCA4","MAGEG1","MAGEL3","NSE3","NDNL2"]}},{"id":"f7c0807422bb410893b09ca4d47c784f","type":"GENE","name":"NSMCE4A","canonical_id":"hgnc:HGNC:25935","description":"NSE4A component of SMC5/6 complex","metadata":{"aliases":["FLJ20003","bA500G22.3","NSE4A","C10orf86"]}},{"id":"c1df2fa17b66406099dbbcf37e650388","type":"GENE","name":"NSMF","canonical_id":"hgnc:HGNC:29843","description":"NMDA receptor synaptonuclear signaling and neuronal migration factor","metadata":{"aliases":["NELF"]}},{"id":"85095a9da2694504a0cb6195e7793f2b","type":"GENE","name":"NSRP1","canonical_id":"hgnc:HGNC:25305","description":"nuclear speckle splicing regulatory protein 1","metadata":{"aliases":["DKFZP434K1421","NSrp70","CCDC55"]}},{"id":"de737a3ad14a4082954ce437b04acd12","type":"GENE","name":"NSRP1P1","canonical_id":"hgnc:HGNC:38087","description":"nuclear speckle splicing regulatory protein 1 pseudogene 1","metadata":{"aliases":["CCDC55P1"]}},{"id":"5bd753a00f9b4596838a0d77c1828497","type":"GENE","name":"NSUN2","canonical_id":"hgnc:HGNC:25994","description":"NOP2/Sun RNA methyltransferase 2","metadata":{"aliases":["FLJ20303","TRM4","Misu","SAKI","MRT5"]}},{"id":"41970346498b4cc09962404a80ec11e7","type":"GENE","name":"NSUN3","canonical_id":"hgnc:HGNC:26208","description":"NOP2/Sun RNA methyltransferase 3","metadata":{"aliases":["FLJ22609"]}},{"id":"3b80f6740cf34479bad401bdf9adc7c2","type":"GENE","name":"NSUN4","canonical_id":"hgnc:HGNC:31802","description":"NOP2/Sun RNA methyltransferase 4","metadata":{"aliases":["MGC22960","SHTAP"]}},{"id":"658dffae1dd449eea1519b26991f4595","type":"GENE","name":"NSUN5","canonical_id":"hgnc:HGNC:16385","description":"NOP2/Sun RNA methyltransferase 5","metadata":{"aliases":["NOL1R","p120(NOL1)","FLJ10267","NSUN5A","Ynl022cL","WBSCR20","WBSCR20A"]}},{"id":"8d9bb6de44274117ac7a0b7767ba94b6","type":"GENE","name":"NSUN5P1","canonical_id":"hgnc:HGNC:19146","description":"NSUN5 pseudogene 1","metadata":{"aliases":["WBSCR20B","NSUN5B"]}},{"id":"89c5de5570c046be835adf1de94ee7b6","type":"GENE","name":"NSUN5P2","canonical_id":"hgnc:HGNC:16609","description":"NSUN5 pseudogene 2","metadata":{"aliases":["WBSCR20C","MGC15057","FLJ11626","DKFZp434K058","NOL1R2","WBSCR20B","NSUN5C"]}},{"id":"2af9caacf86341c18bffb94e23853f63","type":"GENE","name":"NSUN6","canonical_id":"hgnc:HGNC:23529","description":"NOP2/Sun RNA methyltransferase 6","metadata":{"aliases":["FLJ23743","NOPD1","ARL5B-AS1"]}},{"id":"db4b4111d01f4351a8c59cd5f77aa8b3","type":"GENE","name":"NSUN7","canonical_id":"hgnc:HGNC:25857","description":"NOP2/Sun RNA methyltransferase family member 7","metadata":{"aliases":["FLJ14001"]}},{"id":"46d0cc740d984a29832026e8e653d9fd","type":"GENE","name":"NSUN7-AS1","canonical_id":"hgnc:HGNC:58762","description":"NSUN7 antisense RNA 1","metadata":null},{"id":"a29e5f5fdd544c898890ba74db8da901","type":"GENE","name":"NT5C","canonical_id":"hgnc:HGNC:17144","description":"5', 3'-nucleotidase, cytosolic","metadata":{"aliases":["DNT1","DNT-1","PN-I","cdN","dNT-1","UMPH2"]}},{"id":"fb7c414ce72c4f2ea82d606eae3ac0f8","type":"GENE","name":"NT5C1A","canonical_id":"hgnc:HGNC:17819","description":"5'-nucleotidase, cytosolic IA","metadata":{"aliases":["CN-I","CN-IA","CN1A","CN1","MGC119199","MGC119201"]}},{"id":"c05c56a722174783bc278c7ad6292be3","type":"GENE","name":"NT5C1B","canonical_id":"hgnc:HGNC:17818","description":"5'-nucleotidase, cytosolic IB","metadata":{"aliases":["AIRP","CN-IB"]}},{"id":"4b12f61e1a1b4b59a78de6879ad0130c","type":"GENE","name":"NT5C1B-RDH14","canonical_id":"hgnc:HGNC:38831","description":"NT5C1B-RDH14 readthrough","metadata":null},{"id":"c4f73390807f47e896910bdf6762f6eb","type":"GENE","name":"NT5C2","canonical_id":"hgnc:HGNC:8022","description":"5'-nucleotidase, cytosolic II","metadata":{"aliases":["PNT5","GMP","cN-II","SPG65","NT5B","SPG45"]}},{"id":"71b55fe5810f411c8694f962479fcacb","type":"GENE","name":"NT5C3A","canonical_id":"hgnc:HGNC:17820","description":"5'-nucleotidase, cytosolic IIIA","metadata":{"aliases":["UMPH1","PSN1","PN-I","UMPH","P5'N-1","cN-III","p36","POMP","hUMP1","NT5C3"]}},{"id":"3d3446284e344b30b639fa0d4eeb92b9","type":"GENE","name":"NT5C3AP1","canonical_id":"hgnc:HGNC:18530","description":"NT5C3A pseudogene 1","metadata":{"aliases":["UMPH1P","NT5C3P1"]}},{"id":"3b3d2051cc7d4a1e8d7d0eaa3c80f4f2","type":"GENE","name":"NT5C3AP2","canonical_id":"hgnc:HGNC:54578","description":"NT5C3A pseudogene 2","metadata":null},{"id":"96bbb464dd824bfd9853363d331103a9","type":"GENE","name":"NT5C3B","canonical_id":"hgnc:HGNC:28300","description":"5'-nucleotidase, cytosolic IIIB","metadata":{"aliases":["MGC20781","cN-IIIB","NT5C3L"]}},{"id":"ac6036b76916485b86cd6ce9af5f357a","type":"GENE","name":"NT5CP1","canonical_id":"hgnc:HGNC:20046","description":"5',3'-nucleotidase, cytosolic pseudogene 1","metadata":null},{"id":"4777a062e5b5439f93e9cdff42834b3f","type":"GENE","name":"NT5CP2","canonical_id":"hgnc:HGNC:20047","description":"5',3'-nucleotidase, cytosolic pseudogene 2","metadata":null},{"id":"157ae74f816e479db9ffbb0151682040","type":"GENE","name":"NT5CP3","canonical_id":"hgnc:HGNC:39789","description":"5',3'-nucleotidase, cytosolic pseudogene 3","metadata":null},{"id":"da947ebc7fdd44e6a84294d5aab43b1b","type":"GENE","name":"NT5DC1","canonical_id":"hgnc:HGNC:21556","description":"5'-nucleotidase domain containing 1","metadata":{"aliases":["dJ486I3.1","MGC24302","NT5C2L1"]}},{"id":"34824770b2be47e0bdd3525e68c0ef83","type":"GENE","name":"NT5DC1P1","canonical_id":"hgnc:HGNC:55018","description":"NT5DC1 pseudogene 1","metadata":null},{"id":"818c0b446d1b4c70bee8f69d37763b08","type":"GENE","name":"NT5DC1P2","canonical_id":"hgnc:HGNC:55019","description":"NT5DC1 pseudogene 2","metadata":null},{"id":"87091374c863460187aa86a40ddb6c15","type":"GENE","name":"NT5DC2","canonical_id":"hgnc:HGNC:25717","description":"5'-nucleotidase domain containing 2","metadata":{"aliases":["FLJ12442"]}},{"id":"a9a740baed6847f9bcd06d8f39507f3e","type":"GENE","name":"NT5DC3","canonical_id":"hgnc:HGNC:30826","description":"5'-nucleotidase domain containing 3","metadata":{"aliases":["TU12B1-TY","FLJ11266"]}},{"id":"2ca5e233cb45485380e20128682cea65","type":"GENE","name":"NT5DC4","canonical_id":"hgnc:HGNC:27678","description":"5'-nucleotidase domain containing 4","metadata":null},{"id":"e94f505f241c4c72905fcf579a3cb2fd","type":"GENE","name":"NT5E","canonical_id":"hgnc:HGNC:8021","description":null,"metadata":null},{"id":"586c10ddf25e4e6b81342a969ded5b13","type":"GENE","name":"NT5ELP","canonical_id":"hgnc:HGNC:55194","description":"5' nucleotidase, ecto-like, pseudogene","metadata":null},{"id":"821df26d4e1c4261a6741ed61428ee9d","type":"GENE","name":"NT5M","canonical_id":"hgnc:HGNC:15769","description":"5',3'-nucleotidase, mitochondrial","metadata":{"aliases":["dNT-2","dNT2","mdN"]}},{"id":"ee6b01e9db454a6c9bcc3a5f7c882208","type":"GENE","name":"NTAN1","canonical_id":"hgnc:HGNC:29909","description":"N-terminal asparagine amidase","metadata":null},{"id":"0800ff384dd446afa5acec3c1ecac56a","type":"GENE","name":"NTAN1P1","canonical_id":"hgnc:HGNC:45261","description":"N-terminal asparagine amidase pseudogene 1","metadata":null},{"id":"a880fe49be094c21bb75e34fb45eb0d5","type":"GENE","name":"NTAN1P2","canonical_id":"hgnc:HGNC:45262","description":"N-terminal asparagine amidase pseudogene 2","metadata":null},{"id":"7a9efc1e1ce942398d07213505dcb1a4","type":"GENE","name":"NTAN1P3","canonical_id":"hgnc:HGNC:45263","description":"N-terminal asparagine amidase pseudogene 3","metadata":null},{"id":"bc53b89696bf43f28fb637471691eef5","type":"GENE","name":"NTAQ1","canonical_id":"hgnc:HGNC:25490","description":"N-terminal glutamine amidase 1","metadata":{"aliases":["FLJ10204","C8orf32","WDYHV1"]}},{"id":"8b51c31102654056a74d1492c4d8d7fa","type":"GENE","name":"NTF3","canonical_id":"hgnc:HGNC:8023","description":null,"metadata":null},{"id":"145580667f3b4bc7bdec27ff5652b034","type":"GENE","name":"NTF4","canonical_id":"hgnc:HGNC:8024","description":"neurotrophin 4","metadata":{"aliases":["NT-4/5","GLC1O","NTF5"]}},{"id":"ca479f8472de4895bb8fe9fd96fdf6a8","type":"GENE","name":"NTF6A","canonical_id":"hgnc:HGNC:8025","description":"neurotrophin 6 alpha (pseudogene)","metadata":{"aliases":["PSI-NT4","NTF5P","NTF6"]}},{"id":"c25e650329eb4762b5c87576dd58ee73","type":"GENE","name":"NTF6B","canonical_id":"hgnc:HGNC:8026","description":"neurotrophin 6 beta (pseudogene)","metadata":null},{"id":"253d5c4855f84e5c9954a109b4e780d9","type":"GENE","name":"NTF6G","canonical_id":"hgnc:HGNC:8027","description":"neurotrophin 6 gamma (pseudogene)","metadata":null},{"id":"ed05f022881f4cb29a9db5ec00ad2264","type":"GENE","name":"NTHL1","canonical_id":"hgnc:HGNC:8028","description":"nth like DNA glycosylase 1","metadata":{"aliases":["NTH1","OCTS3"]}},{"id":"91da7385241e4fbb91fcda5f33278a26","type":"GENE","name":"NTM","canonical_id":"hgnc:HGNC:17941","description":"neurotrimin","metadata":{"aliases":["HNT","NTRI","IGLON2","CEPU-1"]}},{"id":"5f04cc2ae5c3419db57431311774f4ed","type":"GENE","name":"NTM-AS1","canonical_id":"hgnc:HGNC:32293","description":"NTM antisense RNA 1","metadata":{"aliases":["FLJ45436","C11orf39"]}},{"id":"440514556c3f4f9491844a5771aeb4f7","type":"GENE","name":"NTM-AS2","canonical_id":"hgnc:HGNC:40821","description":"NTM antisense RNA 2","metadata":null},{"id":"af017272b66d449cb73543f4552e12fe","type":"GENE","name":"NTM-AS3","canonical_id":"hgnc:HGNC:40822","description":"NTM antisense RNA 3","metadata":null},{"id":"0d8368d83a4d49c0b9b59278c39054e8","type":"GENE","name":"NTM-AS4","canonical_id":"hgnc:HGNC:58354","description":"NTM antisense RNA 4","metadata":null},{"id":"e61452f517804bf7bb9073237ce63d25","type":"GENE","name":"NTM-IT","canonical_id":"hgnc:HGNC:41437","description":"NTM intronic transcript","metadata":{"aliases":["NTM-IT3"]}},{"id":"b177074601404022aec7c4d8bb2c78f9","type":"GENE","name":"NTMT1","canonical_id":"hgnc:HGNC:23373","description":"N-terminal Xaa-Pro-Lys N-methyltransferase 1","metadata":{"aliases":["AD-003","HOMT1A","NRMT1","NRMT","C9orf32","METTL11A"]}},{"id":"30de1e5d6590463894ccd10a16e57f21","type":"GENE","name":"NTMT2","canonical_id":"hgnc:HGNC:31932","description":"N-terminal Xaa-Pro-Lys N-methyltransferase 2","metadata":{"aliases":["HOMT1B","C1orf184","METTL11B"]}},{"id":"b5e7c6e3ad8c411aae0008a6061b76c9","type":"GENE","name":"NTN1","canonical_id":"hgnc:HGNC:8029","description":"netrin 1","metadata":{"aliases":["NTN1L","NET1"]}},{"id":"331460ba5fc84111b9a029514116ba0a","type":"GENE","name":"NTN3","canonical_id":"hgnc:HGNC:8030","description":"netrin 3","metadata":{"aliases":["NTN2L"]}},{"id":"77eda9b13e714868ad3205eb6fc9cdf6","type":"GENE","name":"NTN4","canonical_id":"hgnc:HGNC:13658","description":"netrin 4","metadata":null},{"id":"1c50415b987348ff8e6335e0c2e927a2","type":"GENE","name":"NTN5","canonical_id":"hgnc:HGNC:25208","description":"netrin 5","metadata":null},{"id":"50750c000b0448368054ee9e7bf61068","type":"GENE","name":"NTNG1","canonical_id":"hgnc:HGNC:23319","description":"netrin G1","metadata":{"aliases":["KIAA0976","Lmnt1","NetG1","NetrinG1"]}},{"id":"3476adc81a4145e4b6e7c3194f196640","type":"GENE","name":"NTNG2","canonical_id":"hgnc:HGNC:14288","description":"netrin G2","metadata":{"aliases":["KIAA1857","Lmnt2","NetrinG2","NTNG1"]}},{"id":"e7316892e9f34b8b8fa6209f4ab768f1","type":"GENE","name":"NTPCR","canonical_id":"hgnc:HGNC:28204","description":"nucleoside-triphosphatase, cancer-related","metadata":{"aliases":["MGC13186","HCR-NTPase","THEP1","C1orf57"]}},{"id":"9e3164f916c5400cb19edaa8739b9d91","type":"GENE","name":"NTRAS","canonical_id":"hgnc:HGNC:52478","description":"non-coding transcript regulating alternative splicing","metadata":{"aliases":["RP11-354K1.1","LINC01693"]}},{"id":"5685121b6e204273b0c76c5af9c26541","type":"GENE","name":"NTRK1","canonical_id":"hgnc:HGNC:8031","description":null,"metadata":null},{"id":"41ebc67166a5405a8f61891e8029996b","type":"GENE","name":"NTRK1","canonical_id":"ensembl:ENSG00000198400","description":null,"metadata":null},{"id":"30a541b9d89b4732a29927de80448abe","type":"PROTEIN","name":"NTRK1","canonical_id":"uniprot:P04629","description":null,"metadata":null},{"id":"250de38dc79a44caa2cf912033d62bde","type":"GENE","name":"NTRK2","canonical_id":"hgnc:HGNC:8032","description":"neurotrophic receptor tyrosine kinase 2","metadata":{"aliases":["TRKB"]}},{"id":"2607d00739dc484d82c2f023b97da7a6","type":"GENE","name":"NTRK3","canonical_id":"hgnc:HGNC:8033","description":null,"metadata":null},{"id":"eb8c5b4e86db4b87b57fbadbcc49103c","type":"GENE","name":"NTRK3-AS1","canonical_id":"hgnc:HGNC:27532","description":"NTRK3 antisense RNA 1","metadata":null},{"id":"c2e9ad129ea442c59489d38c56d04a95","type":"GENE","name":"NTS","canonical_id":"hgnc:HGNC:8038","description":null,"metadata":null},{"id":"3756a69516e1482a8da410c8580298cc","type":"GENE","name":"NTSR1","canonical_id":"hgnc:HGNC:8039","description":"neurotensin receptor 1","metadata":{"aliases":["NTR"]}},{"id":"f3ac29a98439441abcbecca3f21f35e5","type":"GENE","name":"NTSR1-AS1","canonical_id":"hgnc:HGNC:40418","description":"NTSR1 antisense RNA 1","metadata":null},{"id":"93f5aaecd8754707b0e7ec76a1c0b1a0","type":"GENE","name":"NTSR2","canonical_id":"hgnc:HGNC:8040","description":"neurotensin receptor 2","metadata":{"aliases":["NTR2"]}},{"id":"f50f55c4ff804ad9a3016fa5ffa93bdc","type":"GENE","name":"NUAK1","canonical_id":"hgnc:HGNC:14311","description":"NUAK family kinase 1","metadata":{"aliases":["ARK5","KIAA0537"]}},{"id":"6f4020c6352e46aead819ef6a6d4e5db","type":"GENE","name":"NUAK2","canonical_id":"hgnc:HGNC:29558","description":"NUAK family kinase 2","metadata":{"aliases":["SNARK","FLJ90349"]}},{"id":"cab3715561744745bceda3ebc7bd04ae","type":"GENE","name":"NUB1","canonical_id":"hgnc:HGNC:17623","description":"negative regulator of ubiquitin like proteins 1","metadata":{"aliases":["BS4","NYREN18","NUB1L"]}},{"id":"6c568570d61a42df8d67661b8ef60527","type":"GENE","name":"NUBP1","canonical_id":"hgnc:HGNC:8041","description":"NUBP iron-sulfur cluster assembly factor 1, cytosolic","metadata":{"aliases":["NBP35","CIAO5","NBP1"]}},{"id":"aa24ad3ed4a74660af57a557d70c5e8d","type":"GENE","name":"NUBP2","canonical_id":"hgnc:HGNC:8042","description":"NUBP iron-sulfur cluster assembly factor 2, cytosolic","metadata":{"aliases":["CFD1","CIAO6"]}},{"id":"1c5ca2d501a840a9b3e392b60a91fa1a","type":"GENE","name":"NUBPL","canonical_id":"hgnc:HGNC:20278","description":"NUBP iron-sulfur cluster assembly factor, mitochondrial","metadata":{"aliases":["FLJ12660","IND1","huInd1","C14orf127"]}},{"id":"7fc9d3ecfc164bd6936e466247c27ce0","type":"GENE","name":"NUBPL-DT","canonical_id":"hgnc:HGNC:55483","description":"NUBPL divergent transcript","metadata":null},{"id":"6e0d487e0e014606868b836280f12394","type":"GENE","name":"NUCB1","canonical_id":"hgnc:HGNC:8043","description":null,"metadata":null},{"id":"16693f1c1a1b4efb9d4a504fb61fd915","type":"GENE","name":"NUCB1-AS1","canonical_id":"hgnc:HGNC:40419","description":"NUCB1 antisense RNA 1","metadata":null},{"id":"d5c3eab549f24751b6e670f19b659132","type":"GENE","name":"NUCB2","canonical_id":"hgnc:HGNC:8044","description":"nucleobindin 2","metadata":{"aliases":["NEFA"]}},{"id":"aab496997f9e4db3ac7118718f3c6a88","type":"GENE","name":"NUCKS1","canonical_id":"hgnc:HGNC:29923","description":"nuclear casein kinase and cyclin dependent kinase substrate 1","metadata":{"aliases":["NUCKS"]}},{"id":"a825acd8e4a24199b1730767fdbb0939","type":"GENE","name":"NUCKS1P1","canonical_id":"hgnc:HGNC:51943","description":"nuclear casein kinase and cyclin dependent kinase substrate 1 pseudogene 1","metadata":null},{"id":"2ef7e5ac81724cefbd332544e8083a6d","type":"GENE","name":"NUCLEOLINP1","canonical_id":"hgnc:HGNC:35472","description":"nucleolin pseudogene 1","metadata":{"aliases":["NCLP1"]}},{"id":"ed5fc14f9ff94d3bb59e8b203e150983","type":"GENE","name":"NUCLEOLINP2","canonical_id":"hgnc:HGNC:35473","description":"nucleolin pseudogene 2","metadata":{"aliases":["bA85L21.1","NCLP2"]}},{"id":"8ffd5162fd6440bc8bd5f5947440cb1b","type":"GENE","name":"NUDC","canonical_id":"hgnc:HGNC:8045","description":"nuclear distribution C, dynein complex regulator","metadata":null},{"id":"f7d995955d7d4ef4b45340f3e59a25a7","type":"GENE","name":"NUDCD1","canonical_id":"hgnc:HGNC:24306","description":"NudC domain containing 1","metadata":{"aliases":["CML66","FLJ14991"]}},{"id":"01bee05357e54cea86cb51119cbdc8ef","type":"GENE","name":"NUDCD2","canonical_id":"hgnc:HGNC:30535","description":"NudC domain containing 2","metadata":{"aliases":["DKFZp686E10109","NudCL2"]}},{"id":"537a0dda267740858beb9b404666ec2b","type":"GENE","name":"NUDCD3","canonical_id":"hgnc:HGNC:22208","description":"NudC domain containing 3","metadata":{"aliases":["KIAA1068","NudCL"]}},{"id":"ac5e0d4d7e2e499b8b0a2d944fd7db2a","type":"GENE","name":"NUDCP1","canonical_id":"hgnc:HGNC:8046","description":"nuclear distribution C pseudogene 1","metadata":null},{"id":"e754a9b2ad97447b8892ac56cbfeaf2c","type":"GENE","name":"NUDCP2","canonical_id":"hgnc:HGNC:8047","description":"nuclear distribution C pseudogene 2","metadata":null},{"id":"4ccba9305b804794b2c3954a31dee236","type":"GENE","name":"NUDT1","canonical_id":"hgnc:HGNC:8048","description":"nudix hydrolase 1","metadata":{"aliases":["MTH1"]}},{"id":"7ce3f9fe37e74b0b95995998eb2af908","type":"GENE","name":"NUDT10","canonical_id":"hgnc:HGNC:17621","description":"nudix hydrolase 10","metadata":{"aliases":["DIPP3a","hDIPP3alpha"]}},{"id":"0f0b44f6b0c448a9b92e0678f26c917c","type":"GENE","name":"NUDT11","canonical_id":"hgnc:HGNC:18011","description":"nudix hydrolase 11","metadata":{"aliases":["DIPP3b","FLJ10628","hDIPP3beta"]}},{"id":"41152eb90aae4e8e870d67716b215a3b","type":"GENE","name":"NUDT12","canonical_id":"hgnc:HGNC:18826","description":"nudix hydrolase 12","metadata":{"aliases":["DKFZP761I172"]}},{"id":"b47bb1519d6948bbaa2875f35c437172","type":"GENE","name":"NUDT13","canonical_id":"hgnc:HGNC:18827","description":"nudix hydrolase 13","metadata":{"aliases":["DKFZp586P2219"]}},{"id":"b6f1196a1d7941838766aa6a90135390","type":"GENE","name":"NUDT14","canonical_id":"hgnc:HGNC:20141","description":"nudix hydrolase 14","metadata":{"aliases":["UGPP"]}},{"id":"566c099dd8b34681ba043e8d84fb427d","type":"GENE","name":"NUDT15","canonical_id":"hgnc:HGNC:23063","description":"nudix hydrolase 15","metadata":{"aliases":["MTH2","FLJ10956"]}},{"id":"8ae571d80b644be9b50848c2dc307376","type":"GENE","name":"NUDT15P1","canonical_id":"hgnc:HGNC:17266","description":"nudix hydrolase 15 pseudogene 1","metadata":null},{"id":"56714e11c92a4452bc6fbac6eb18f35b","type":"GENE","name":"NUDT15P2","canonical_id":"hgnc:HGNC:20784","description":"nudix hydrolase 15 pseudogene 2","metadata":null},{"id":"6061c91932614b369c2b0f0f155faa34","type":"GENE","name":"NUDT16","canonical_id":"hgnc:HGNC:26442","description":"nudix hydrolase 16","metadata":{"aliases":["FLJ31265"]}},{"id":"25658eb55083474fbc7e757f30f14e5d","type":"GENE","name":"NUDT16-DT","canonical_id":"hgnc:HGNC:27947","description":"NUDT16 divergent transcript","metadata":null},{"id":"902d7feda3664d06b017f43d7ee6ff45","type":"GENE","name":"NUDT16L1","canonical_id":"hgnc:HGNC:28154","description":"nudix hydrolase 16 like 1","metadata":{"aliases":["SDOS","TIRR"]}},{"id":"93b8ad379baf42e39760a5205c62f22c","type":"GENE","name":"NUDT16L2P","canonical_id":"hgnc:HGNC:27189","description":"nudix hydrolase 16 like 2, pseudogene","metadata":{"aliases":["FLJ20525","NUDT16P","NUDT16P1"]}},{"id":"fea068ff42004dd3b1ff3c18075e6604","type":"GENE","name":"NUDT17","canonical_id":"hgnc:HGNC:26618","description":"nudix hydrolase 17","metadata":{"aliases":["FLJ34433"]}},{"id":"c2611637fff548ed81b26c05d6c66146","type":"GENE","name":"NUDT18","canonical_id":"hgnc:HGNC:26194","description":"nudix hydrolase 18","metadata":{"aliases":["FLJ22494","MTH3"]}},{"id":"fe923a9f3e994c949419aff12f5bec2a","type":"GENE","name":"NUDT19","canonical_id":"hgnc:HGNC:32036","description":"nudix hydrolase 19","metadata":{"aliases":["RP2"]}},{"id":"579e27b25c8e4ecb8f43b0b0d63188fd","type":"GENE","name":"NUDT19-DT","canonical_id":"hgnc:HGNC:55296","description":"NUDT19 divergent transcript","metadata":null},{"id":"cf1baf13fdc947a0a2fe6fff7f40d380","type":"GENE","name":"NUDT19P1","canonical_id":"hgnc:HGNC:43585","description":"NUDT19 pseudogene 1","metadata":null},{"id":"74786bb6ad2d4681a6086be767ce6869","type":"GENE","name":"NUDT19P2","canonical_id":"hgnc:HGNC:43586","description":"NUDT19 pseudogene 2","metadata":null},{"id":"79db05f2b15340c58ae77cddeddba833","type":"GENE","name":"NUDT19P3","canonical_id":"hgnc:HGNC:43587","description":"NUDT19 pseudogene 3","metadata":null},{"id":"c2cbb6070b334e0a93504704d648f066","type":"GENE","name":"NUDT19P4","canonical_id":"hgnc:HGNC:43588","description":"NUDT19 pseudogene 4","metadata":null},{"id":"c94154a2258b4a34b30ea5559e71673c","type":"GENE","name":"NUDT19P5","canonical_id":"hgnc:HGNC:43589","description":"NUDT19 pseudogene 5","metadata":null},{"id":"bb3310d4ec5d4b2f81f5e4f60efc181a","type":"GENE","name":"NUDT19P6","canonical_id":"hgnc:HGNC:55061","description":"NUDT19 pseudogene 6","metadata":null},{"id":"d3d8c39c08ab4bcdb348d9a2ffc004a6","type":"GENE","name":"NUDT2","canonical_id":"hgnc:HGNC:8049","description":"nudix hydrolase 2","metadata":{"aliases":["APAH1"]}},{"id":"30be08780e6b47fe8fb5a24548c09e83","type":"GENE","name":"NUDT21","canonical_id":"hgnc:HGNC:13870","description":"nudix hydrolase 21","metadata":{"aliases":["CFIM25","CPSF5"]}},{"id":"ca5edb18d94049c18479af095716d012","type":"GENE","name":"NUDT21P1","canonical_id":"hgnc:HGNC:39461","description":"nudix hydrolase 21 pseudogene 1","metadata":null},{"id":"0969ea71321c4a79a696cf41e78f616c","type":"GENE","name":"NUDT22","canonical_id":"hgnc:HGNC:28189","description":"nudix hydrolase 22","metadata":{"aliases":["MGC13045"]}},{"id":"128e4a50fb02417e94bc5d909238d39d","type":"GENE","name":"NUDT3","canonical_id":"hgnc:HGNC:8050","description":"nudix hydrolase 3","metadata":{"aliases":["DIPP"]}},{"id":"bfe42c2bddb6461c8364f40c55e9ee07","type":"GENE","name":"NUDT4","canonical_id":"hgnc:HGNC:8051","description":"nudix hydrolase 4","metadata":{"aliases":["DIPP2","HDCMB47P","KIAA0487","DIPP2alpha","DIPP2beta"]}},{"id":"6b5f0397e28144459cc06048b75a72f7","type":"GENE","name":"NUDT4B","canonical_id":"hgnc:HGNC:18012","description":"nudix hydrolase 4B","metadata":{"aliases":["NUDT4P1"]}},{"id":"a29ffdb37fa1415e833ef7d1f94ba919","type":"GENE","name":"NUDT4P2","canonical_id":"hgnc:HGNC:18013","description":"nudix hydrolase 4 pseudogene 2","metadata":null},{"id":"a580d4eaf4a2496789b81b22ec72d223","type":"GENE","name":"NUDT5","canonical_id":"hgnc:HGNC:8052","description":"nudix hydrolase 5","metadata":{"aliases":["hYSAH1","YSA1H"]}},{"id":"d55f5db174cb497087efaf4b9b133326","type":"GENE","name":"NUDT5P1","canonical_id":"hgnc:HGNC:56926","description":"NUDT5 pseudogene 1","metadata":null},{"id":"6e8b2c5d4dd0437083c7d3eddbe745d0","type":"GENE","name":"NUDT6","canonical_id":"hgnc:HGNC:8053","description":"nudix hydrolase 6","metadata":{"aliases":["gfg-1","gfg","FGF2AS","FGF-AS"]}},{"id":"ef93cb66eb0a45a0a3b96ccb700aa754","type":"GENE","name":"NUDT7","canonical_id":"hgnc:HGNC:8054","description":"nudix hydrolase 7","metadata":null},{"id":"addb5d66871649389514074c4947830f","type":"GENE","name":"NUDT8","canonical_id":"hgnc:HGNC:8055","description":"nudix hydrolase 8","metadata":{"aliases":["FLJ41567"]}},{"id":"9cddd858d9e349ba8834ae0647ee8703","type":"GENE","name":"NUDT9","canonical_id":"hgnc:HGNC:8056","description":"nudix hydrolase 9","metadata":{"aliases":["MGC3037"]}},{"id":"1541dee55c754556a8f618c7f5f858d7","type":"GENE","name":"NUDT9P1","canonical_id":"hgnc:HGNC:28523","description":"nudix hydrolase 9 pseudogene 1","metadata":{"aliases":["MGC34007","bA56M3.1","C10orf98"]}},{"id":"74a6fec9ee764338bb1cc85773dc774c","type":"GENE","name":"NUF2","canonical_id":"hgnc:HGNC:14621","description":"NUF2 component of NDC80 kinetochore complex","metadata":{"aliases":["NUF2R","CT106","CDCA1"]}},{"id":"91f16ca55a844056be187e4d5501527a","type":"GENE","name":"NUFIP1","canonical_id":"hgnc:HGNC:8057","description":"nuclear FMR1 interacting protein 1","metadata":{"aliases":["NUFIP","Rsa1"]}},{"id":"64072905bc814c5ea9e8db358324af7f","type":"GENE","name":"NUFIP1P1","canonical_id":"hgnc:HGNC:8058","description":"NUFIP1 pseudogene 1","metadata":{"aliases":["NUFIP1P"]}},{"id":"90499c21e4fa4963a9675f7633b19244","type":"GENE","name":"NUFIP2","canonical_id":"hgnc:HGNC:17634","description":"nuclear FMR1 interacting protein 2","metadata":{"aliases":["KIAA1321","MGC117262","PIG1","182-FIP","FIP-82","82-FIP","NUFP2"]}},{"id":"d6555e77318d42f780f31c85ce7a5de6","type":"GENE","name":"NUGGC","canonical_id":"hgnc:HGNC:33550","description":"nuclear GTPase, germinal center associated","metadata":{"aliases":["HMFN0672","SLIP-GC","C8orf80"]}},{"id":"7498125ad423480a9cd0d4bf2bdceb8f","type":"GENE","name":"NUMA1","canonical_id":"hgnc:HGNC:8059","description":"nuclear mitotic apparatus protein 1","metadata":{"aliases":["NUMA"]}},{"id":"a306bc104ea54dfe88495777137f382e","type":"GENE","name":"NUMA1-AS1","canonical_id":"hgnc:HGNC:58252","description":"NUMA1 antisense RNA 1","metadata":null},{"id":"9548efa5f6af44fd85236c06de1c46dc","type":"GENE","name":"NUMB","canonical_id":"hgnc:HGNC:8060","description":"NUMB endocytic adaptor protein","metadata":{"aliases":["C14orf41"]}},{"id":"076cc9d67c5b4dbeaf67ebb0cf02c5b2","type":"GENE","name":"NUMBL","canonical_id":"hgnc:HGNC:8061","description":"NUMB like endocytic adaptor protein","metadata":{"aliases":["NUMB-R","CTG3a","CAG3A","TNRC23","NUMBR","NUMBLIKE"]}},{"id":"e83822562b5e4d49a182fee4e81fc43f","type":"GENE","name":"NUP107","canonical_id":"hgnc:HGNC:29914","description":"nucleoporin 107","metadata":{"aliases":["NUP84"]}},{"id":"36f5f148efc34ddbbcc7f1d98c20d172","type":"GENE","name":"NUP107-DT","canonical_id":"hgnc:HGNC:55587","description":"NUP107 divergent transcript","metadata":null},{"id":"37bcfb0bfeb0412ebdd31dfc929e55a5","type":"GENE","name":"NUP133","canonical_id":"hgnc:HGNC:18016","description":"nucleoporin 133","metadata":{"aliases":["FLJ10814"]}},{"id":"35b09b7d296e4aa192d5923e43cae6a8","type":"GENE","name":"NUP133-DT","canonical_id":"hgnc:HGNC:55870","description":"NUP133 divergent transcript","metadata":null},{"id":"a379b0e5fb424acda21cf075d463a284","type":"GENE","name":"NUP153","canonical_id":"hgnc:HGNC:8062","description":"nucleoporin 153","metadata":{"aliases":["HNUP153"]}},{"id":"15c1fb877d324b93b687cfbfc7328045","type":"GENE","name":"NUP153-AS1","canonical_id":"hgnc:HGNC:55217","description":"NUP153 antisense RNA 1","metadata":null},{"id":"1e01688b84964495878e56f901dd0034","type":"GENE","name":"NUP155","canonical_id":"hgnc:HGNC:8063","description":"nucleoporin 155","metadata":{"aliases":["KIAA0791","N155"]}},{"id":"800143c4a3314a49bc2442cfeb4d7d4a","type":"GENE","name":"NUP160","canonical_id":"hgnc:HGNC:18017","description":"nucleoporin 160","metadata":{"aliases":["KIAA0197","FLJ22583"]}},{"id":"fad4250c0bdc40f4a1e94811d3daa33a","type":"GENE","name":"NUP188","canonical_id":"hgnc:HGNC:17859","description":"nucleoporin 188","metadata":{"aliases":["KIAA0169"]}},{"id":"94a8a03d9c4346f896f40ca05c5cce09","type":"GENE","name":"NUP205","canonical_id":"hgnc:HGNC:18658","description":"nucleoporin 205","metadata":{"aliases":["KIAA0225","C7orf14"]}},{"id":"39473bd2ef944b398fe14ee12786711a","type":"GENE","name":"NUP210","canonical_id":"hgnc:HGNC:30052","description":"nucleoporin 210","metadata":{"aliases":["GP210","POM210","FLJ22389","KIAA0906"]}},{"id":"12f428d4f8334e16ac28898737edd65a","type":"GENE","name":"NUP210L","canonical_id":"hgnc:HGNC:29915","description":"nucleoporin 210 like","metadata":null},{"id":"66f5a1fa445445639485a0bc090893bb","type":"GENE","name":"NUP210P1","canonical_id":"hgnc:HGNC:27399","description":"nucleoporin 210 pseudogene 1","metadata":{"aliases":["C3orf46"]}},{"id":"aaed2853a6924d9aa5a14b2d53445f70","type":"GENE","name":"NUP210P2","canonical_id":"hgnc:HGNC:42707","description":"nucleoporin 210 pseudogene 2","metadata":null},{"id":"76f2d145a8d44090ac8012890194b5a8","type":"GENE","name":"NUP210P3","canonical_id":"hgnc:HGNC:42712","description":"nucleoporin 210 pseudogene 3","metadata":null},{"id":"67fdcf6cda2f423d89442c9479466226","type":"GENE","name":"NUP214","canonical_id":"hgnc:HGNC:8064","description":"nucleoporin 214","metadata":{"aliases":["CAIN","CAN","D9S46E","N214"]}},{"id":"a9d308a1e0a14559b368a2fb64c3bfb7","type":"GENE","name":"NUP214-AS1","canonical_id":"hgnc:HGNC:58241","description":"NUP214 antisense RNA 1","metadata":null},{"id":"cf6d2f53963445158cd74541a844ec00","type":"GENE","name":"NUP35","canonical_id":"hgnc:HGNC:29797","description":"nucleoporin 35","metadata":{"aliases":["MP44"]}},{"id":"ddc9fde1621345b5b6cce867b22f17e3","type":"GENE","name":"NUP35P1","canonical_id":"hgnc:HGNC:52370","description":"nucleoporin 35 pseudogene 1","metadata":null},{"id":"5be73f407a854b31b7dbc495469fac2e","type":"GENE","name":"NUP35P2","canonical_id":"hgnc:HGNC:52371","description":"nucleoporin 35 pseudogene 2","metadata":null},{"id":"835c83a76acb4c2a99a1713818badf6c","type":"GENE","name":"NUP37","canonical_id":"hgnc:HGNC:29929","description":"nucleoporin 37","metadata":{"aliases":["MGC5585","FLJ22618"]}},{"id":"4f54774bccbf4afca0864dfae842c354","type":"GENE","name":"NUP42","canonical_id":"hgnc:HGNC:17010","description":"nucleoporin 42","metadata":{"aliases":["NLP_1","CG1","hCG1","H_RG271G13.9","NUPL2"]}},{"id":"5858ac2ebedc4de6a95c42bde9060367","type":"GENE","name":"NUP43","canonical_id":"hgnc:HGNC:21182","description":"nucleoporin 43","metadata":{"aliases":["bA350J20.1","FLJ13287"]}},{"id":"e0aa2bcae5604344bfc0b711425540bd","type":"GENE","name":"NUP50","canonical_id":"hgnc:HGNC:8065","description":"nucleoporin 50","metadata":{"aliases":["NPAP60L"]}},{"id":"3032b0d398504d15affeecc8d5b9499c","type":"GENE","name":"NUP50-DT","canonical_id":"hgnc:HGNC:50502","description":"NUP50 divergent transcript","metadata":{"aliases":["NUP50-AS1"]}},{"id":"b4c75f5a9c90464398a2bcb2620ea625","type":"GENE","name":"NUP50P1","canonical_id":"hgnc:HGNC:20025","description":"nucleoporin 50 pseudogene 1","metadata":{"aliases":["NUP50P"]}},{"id":"abc31bfc71344d5e89bb3ef9b4b27288","type":"GENE","name":"NUP50P2","canonical_id":"hgnc:HGNC:29928","description":"nucleoporin 50 pseudogene 2","metadata":null},{"id":"b0a296c7bbe540a198a76170bbabdd18","type":"GENE","name":"NUP50P3","canonical_id":"hgnc:HGNC:29927","description":"nucleoporin 50 pseudogene 3","metadata":null},{"id":"65d942582b224d3b926a1b88078eb65d","type":"GENE","name":"NUP50P4","canonical_id":"hgnc:HGNC:56784","description":"NUP50 pseudogene 4","metadata":null},{"id":"218354f3d88742bf986346713e7d6f54","type":"GENE","name":"NUP54","canonical_id":"hgnc:HGNC:17359","description":"nucleoporin 54","metadata":null},{"id":"2decbdba8564456c9e0b380561013ccc","type":"GENE","name":"NUP54-DT","canonical_id":"hgnc:HGNC:58820","description":"NUP54 divergent transcript","metadata":null},{"id":"4d16c572c58947068b35697b267a2a9e","type":"GENE","name":"NUP58","canonical_id":"hgnc:HGNC:20261","description":"nucleoporin 58","metadata":{"aliases":["KIAA0410","NUP45","NUPL1"]}},{"id":"36260849a47c4162a697891adc75c634","type":"GENE","name":"NUP58P1","canonical_id":"hgnc:HGNC:44052","description":"nucleoporin 58 pseudogene 1","metadata":{"aliases":["NUPL1P1"]}},{"id":"0d74100a3e1546d09816af41845f9112","type":"GENE","name":"NUP62","canonical_id":"hgnc:HGNC:8066","description":"nucleoporin 62","metadata":{"aliases":["p62","DKFZp547L134","IBSN","SNDI","MGC841","FLJ20822","FLJ43869"]}},{"id":"4ec7ff0db94d47a1a70d71dc9dec24ec","type":"GENE","name":"NUP62CL","canonical_id":"hgnc:HGNC:25960","description":"nucleoporin 62 C-terminal like","metadata":{"aliases":["FLJ20130"]}},{"id":"cb9cb17cd0114e55900eb1a38908819f","type":"GENE","name":"NUP85","canonical_id":"hgnc:HGNC:8734","description":"nucleoporin 85","metadata":{"aliases":["NUP75","FLJ12549"]}},{"id":"685f33ebc84e4f08a5a1a45e7948cc23","type":"GENE","name":"NUP88","canonical_id":"hgnc:HGNC:8067","description":"nucleoporin 88","metadata":{"aliases":["MGC8530"]}},{"id":"dee37b52c9e64b9dab989b71267114d5","type":"GENE","name":"NUP93","canonical_id":"hgnc:HGNC:28958","description":"nucleoporin 93","metadata":{"aliases":["KIAA0095"]}},{"id":"628b533d73e441b7964ce99f56d3bae3","type":"GENE","name":"NUP93-DT","canonical_id":"hgnc:HGNC:55370","description":"NUP93 divergent transcript","metadata":null},{"id":"6349435aadb343c9bd3d2afd4176fe47","type":"GENE","name":"NUP98","canonical_id":"hgnc:HGNC:8068","description":"nucleoporin 98 and 96 precursor","metadata":{"aliases":["NUP96","Nup98-Nup96","Nup98-96","NUP196"]}},{"id":"8813f3b6e052461686ab659c78624ecd","type":"GENE","name":"NUPR1","canonical_id":"hgnc:HGNC:29990","description":null,"metadata":null},{"id":"56a093aa0e0a4b2b9abd0590abb82d39","type":"GENE","name":"NUPR2","canonical_id":"hgnc:HGNC:44164","description":"nuclear protein 2, transcriptional regulator","metadata":{"aliases":["P8","NUPR1L"]}},{"id":"74e575ec069a45e8af031b24d21dc09b","type":"GENE","name":"NUPR2P1","canonical_id":"hgnc:HGNC:56769","description":"NUPR2 pseudogene 1","metadata":null},{"id":"3fbac5e1ee254bb4aaf1c0bf4127a756","type":"GO_TERM","name":"NURF complex","canonical_id":"go:GO:0016589","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (SNF2L in mammals), a NURF301 homolog (BPTF in humans), and additional subunits, though the composition of these additional subunits varies slightly with species. NURF is involved in regulation of transcription from TRNA polymerase II promoters.\" [GOC:bf, GOC:krc, PMID:10779516, PMID:11279013, PMID:15284901, PMID:16568949, PMID:21810179]","metadata":null},{"id":"91e5956b798648688a30f955e20ebfdf","type":"GENE","name":"NUS1","canonical_id":"hgnc:HGNC:21042","description":"NUS1 dehydrodolichyl diphosphate synthase subunit","metadata":{"aliases":["MGC7199","NgBR","TANGO14","C6orf68"]}},{"id":"2f88e6f406764400b93a4612c525d47e","type":"GENE","name":"NUS1P1","canonical_id":"hgnc:HGNC:38472","description":"NUS1 pseudogene 1","metadata":null},{"id":"a0374462605b437db4584678b4af27f8","type":"GENE","name":"NUS1P2","canonical_id":"hgnc:HGNC:38473","description":"NUS1 pseudogene 2","metadata":null},{"id":"d4824be4b95845c4b9178dc25f85778c","type":"GENE","name":"NUS1P3","canonical_id":"hgnc:HGNC:30934","description":"NUS1 pseudogene 3","metadata":{"aliases":["YDD19"]}},{"id":"8144b5e7623246159cc1ceb076b761dd","type":"GENE","name":"NUS1P4","canonical_id":"hgnc:HGNC:38474","description":"NUS1 pseudogene 4","metadata":null},{"id":"29fa24ce0e1c4ba88d5a86a21217dfd3","type":"GENE","name":"NUSAP1","canonical_id":"hgnc:HGNC:18538","description":"nucleolar and spindle associated protein 1","metadata":{"aliases":["FLJ13421","LNP","ANKT","SAPL","BM037","PRO0310p1","Q0310"]}},{"id":"59ca4424ccd34558bf71b2af78517af4","type":"GENE","name":"NUTF2","canonical_id":"hgnc:HGNC:13722","description":"nuclear transport factor 2","metadata":{"aliases":["NTF2","PP15"]}},{"id":"87958a56178c49fa822943b272890b8f","type":"GENE","name":"NUTF2P2","canonical_id":"hgnc:HGNC:19934","description":"nuclear transport factor 2 pseudogene 2","metadata":null},{"id":"637a3f098e2743348f2b5e38d4a796d7","type":"GENE","name":"NUTF2P3","canonical_id":"hgnc:HGNC:50452","description":"nuclear transport factor 2 pseudogene 3","metadata":null},{"id":"dc6197aeb2334c9ba73682b1328c0a7d","type":"GENE","name":"NUTF2P4","canonical_id":"hgnc:HGNC:50453","description":"nuclear transport factor 2 pseudogene 4","metadata":null},{"id":"d83f206fc1d044d1aa94b6d653830541","type":"GENE","name":"NUTF2P5","canonical_id":"hgnc:HGNC:50454","description":"nuclear transport factor 2 pseudogene 5","metadata":null},{"id":"74eea6d42c314e9abc881ee7294c2114","type":"GENE","name":"NUTF2P6","canonical_id":"hgnc:HGNC:50455","description":"nuclear transport factor 2 pseudogene 6","metadata":null},{"id":"93e1ef6d0b7647cd886a5e10ec8130b3","type":"GENE","name":"NUTF2P7","canonical_id":"hgnc:HGNC:50458","description":"nuclear transport factor 2 pseudogene 7","metadata":null},{"id":"712d6291dbbb41b0831d01c2095b6186","type":"GENE","name":"NUTF2P8","canonical_id":"hgnc:HGNC:50457","description":"nuclear transport factor 2 pseudogene 8","metadata":null},{"id":"488aba795b1b4e8abee09d936ef7093c","type":"GENE","name":"NUTM1","canonical_id":"hgnc:HGNC:29919","description":"NUT midline carcinoma family member 1","metadata":{"aliases":["NUT","DKFZp434O192","FAM22H","C15orf55"]}},{"id":"26caac4c47164ebfa13d5c266d3a0400","type":"GENE","name":"NUTM2A","canonical_id":"hgnc:HGNC:23438","description":"NUT family member 2A","metadata":{"aliases":["FAM22A"]}},{"id":"6ee26bd4f48f4423aa1eefcd25946e8c","type":"GENE","name":"NUTM2A-AS1","canonical_id":"hgnc:HGNC:45161","description":"NUTM2A antisense RNA 1","metadata":{"aliases":["FAM22A-AS1"]}},{"id":"526c68eebc584d59b15d39aedaa9b96b","type":"GENE","name":"NUTM2B","canonical_id":"hgnc:HGNC:23445","description":"NUT family member 2B","metadata":{"aliases":["bA119F19.1","FAM22B"]}},{"id":"da198c435263485b99db6696088c8c0c","type":"GENE","name":"NUTM2B-AS1","canonical_id":"hgnc:HGNC:51204","description":"NUTM2B antisense RNA 1","metadata":null},{"id":"4fc18c1e3e86479aa6336df337c6ad05","type":"GENE","name":"NUTM2D","canonical_id":"hgnc:HGNC:23447","description":"NUT family member 2D","metadata":{"aliases":["FAM22D"]}},{"id":"33659c9c967a4928957dce5b4ac9514b","type":"GENE","name":"NUTM2E","canonical_id":"hgnc:HGNC:23448","description":"NUT family member 2E","metadata":{"aliases":["FAM22E"]}},{"id":"8404c61f983b47ac80652ac3a2435fc3","type":"GENE","name":"NUTM2F","canonical_id":"hgnc:HGNC:23450","description":"NUT family member 2F","metadata":{"aliases":["DKFZp434I1117","FAM22F"]}},{"id":"bfd216a188cb48769973bec08e6c9f2a","type":"GENE","name":"NUTM2G","canonical_id":"hgnc:HGNC:23449","description":"NUT family member 2G","metadata":{"aliases":["FAM22G"]}},{"id":"308c617ab97b4b35bf3262a8d852c3a9","type":"GENE","name":"NUTM2HP","canonical_id":"hgnc:HGNC:45017","description":"NUT family member 2H, pseudogene","metadata":{"aliases":["FAM22HP"]}},{"id":"5a20ff30c9fb43e0aa344a7d2bac4ab3","type":"GENE","name":"NVL","canonical_id":"hgnc:HGNC:8070","description":"nuclear VCP like","metadata":{"aliases":["NVL2"]}},{"id":"19ef0c4cb5a144bda7c11554b86d7eb7","type":"GO_TERM","name":"NVT complex","canonical_id":"go:GO:0061957","description":"\"A protein complex that is capable of contributing to protein localization by the NVT pathway. In fission yeast, the Nvt complex consists of Ape2, Lap2 and Nbr1.\" [PMID:26365378]","metadata":null},{"id":"cc4c7d46ea1b48e3bf8451dd03909ae0","type":"TRIAL","name":"NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial","canonical_id":"clinicaltrials.gov:NCT06141200","description":"Essential Hypertension","metadata":null},{"id":"645ca68e1f9248ac85971b1396264634","type":"GENE","name":"NWD1","canonical_id":"hgnc:HGNC:27619","description":"NACHT and WD repeat domain containing 1","metadata":null},{"id":"aac11681cf8d491f8059734c06ce2207","type":"GENE","name":"NWD2","canonical_id":"hgnc:HGNC:29229","description":"NACHT and WD repeat domain containing 2","metadata":{"aliases":["KIAA1239"]}},{"id":"571085c8a19245369b85f6ce1c9eb9ec","type":"GENE","name":"NXF1","canonical_id":"hgnc:HGNC:8071","description":"nuclear RNA export factor 1","metadata":{"aliases":["TAP","Mex67","DKFZp667O0311"]}},{"id":"330763c497f54a099ae4c5872df775f2","type":"GENE","name":"NXF2","canonical_id":"hgnc:HGNC:8072","description":"nuclear RNA export factor 2","metadata":{"aliases":["CT39","TAPL-2"]}},{"id":"b04fc9f539ae487b8ed60e5a586388a7","type":"GENE","name":"NXF2B","canonical_id":"hgnc:HGNC:23984","description":"nuclear RNA export factor 2B","metadata":{"aliases":["bA353J17.1"]}},{"id":"97a1925133c8448485e095f77d7f68f7","type":"GENE","name":"NXF3","canonical_id":"hgnc:HGNC:8073","description":"nuclear RNA export factor 3","metadata":null},{"id":"2670ebd91ceb422cb2ce2d1908493a7e","type":"GENE","name":"NXF4","canonical_id":"hgnc:HGNC:8074","description":"nuclear RNA export factor 4 (pseudogene)","metadata":null},{"id":"81c3dcc6a8164732b500b8d1d5341264","type":"GENE","name":"NXF5","canonical_id":"hgnc:HGNC:8075","description":"nuclear RNA export factor 5","metadata":null},{"id":"477aee299f1942faad0c32959fdb642c","type":"GENE","name":"NXN","canonical_id":"hgnc:HGNC:18008","description":"nucleoredoxin","metadata":{"aliases":["FLJ12614","NRX"]}},{"id":"4c837486c36d4d89bf07811ac0b9996b","type":"GENE","name":"NXN-AS1","canonical_id":"hgnc:HGNC:58546","description":"NXN antisense RNA 1","metadata":null},{"id":"11370d913f634e8ca76cd96cfd615c19","type":"GENE","name":"NXNL1","canonical_id":"hgnc:HGNC:25179","description":"nucleoredoxin like 1","metadata":{"aliases":["RDCVF","TXNL6"]}},{"id":"5a14f051244741f696406efaf55357e2","type":"GENE","name":"NXNL2","canonical_id":"hgnc:HGNC:30482","description":"nucleoredoxin like 2","metadata":{"aliases":["RdCVF2","C9orf121"]}},{"id":"56e6dbef280b4302871121d450142fad","type":"GENE","name":"NXNP1","canonical_id":"hgnc:HGNC:50561","description":"nucleoredoxin pseudogene 1","metadata":null},{"id":"a847e23b93cc4f0985bb46b0d82c3f69","type":"GENE","name":"NXPE1","canonical_id":"hgnc:HGNC:28527","description":"neurexophilin and PC-esterase domain family member 1","metadata":{"aliases":["MGC34290","FAM55A"]}},{"id":"231ab880a88d4e2aaf7fd3839325869a","type":"GENE","name":"NXPE2","canonical_id":"hgnc:HGNC:26331","description":"neurexophilin and PC-esterase domain family member 2","metadata":{"aliases":["FLJ25224","FAM55B"]}},{"id":"7ba3310c05c648ab978b1a601e6e58ca","type":"GENE","name":"NXPE2P1","canonical_id":"hgnc:HGNC:44082","description":"neurexophilin and PC-esterase domain family member 2 pseudogene 1","metadata":null},{"id":"1f609a77fa1249308137acf5482200de","type":"GENE","name":"NXPE3","canonical_id":"hgnc:HGNC:28238","description":"neurexophilin and PC-esterase domain family member 3","metadata":{"aliases":["MGC15606","FAM55C"]}},{"id":"574d64719b9b4edf8df70fdab41acaec","type":"GENE","name":"NXPE4","canonical_id":"hgnc:HGNC:23117","description":"neurexophilin and PC-esterase domain family member 4","metadata":{"aliases":["FLJ20127","C11orf33","FAM55D"]}},{"id":"371dd2df51fd4889ac19149781d3397b","type":"GENE","name":"NXPH1","canonical_id":"hgnc:HGNC:20693","description":"neurexophilin 1","metadata":null},{"id":"cd91f0d51b7a469d8f78a7a5fe88fe2d","type":"GENE","name":"NXPH2","canonical_id":"hgnc:HGNC:8076","description":"neurexophilin 2","metadata":{"aliases":["NPH2"]}},{"id":"bb5b7598d17c4220964d14974b918394","type":"GENE","name":"NXPH3","canonical_id":"hgnc:HGNC:8077","description":"neurexophilin 3","metadata":{"aliases":["NPH3"]}},{"id":"621a8aa179f5448789ff232f418c631b","type":"GENE","name":"NXPH4","canonical_id":"hgnc:HGNC:8078","description":"neurexophilin 4","metadata":{"aliases":["NPH4"]}},{"id":"6c590ab6380a45beae7cf4b9005cf55f","type":"GENE","name":"NXT1","canonical_id":"hgnc:HGNC:15913","description":"nuclear transport factor 2 like export factor 1","metadata":{"aliases":["P15","MTR2"]}},{"id":"48476e2ef27548bda2908b2ce884af4b","type":"GENE","name":"NXT1-AS1","canonical_id":"hgnc:HGNC:40734","description":"NXT1 antisense RNA 1","metadata":null},{"id":"cb1a853f547f4de794af17f5ca999f14","type":"GENE","name":"NXT1P1","canonical_id":"hgnc:HGNC:39708","description":"nuclear transport factor 2 like export factor 1 pseudogene 1","metadata":null},{"id":"fcff1874647c4f2298b7af10d61e3484","type":"GENE","name":"NXT2","canonical_id":"hgnc:HGNC:18151","description":"nuclear transport factor 2 like export factor 2","metadata":{"aliases":["P15-2"]}},{"id":"7a10180ff85c457595d080889d211087","type":"GENE","name":"NXTAR","canonical_id":"hgnc:HGNC:56212","description":"negative expression of androgen receptor regulating lncRNA","metadata":null},{"id":"68954dec8cf74c7296a1e4ad23dcae0c","type":"GENE","name":"NYAP1","canonical_id":"hgnc:HGNC:22009","description":"neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1","metadata":{"aliases":["FLJ37538","C7orf51","KIAA1486L"]}},{"id":"9ad55ba6357d41ae8c5b36fa0b0c5ed0","type":"GENE","name":"NYAP2","canonical_id":"hgnc:HGNC:29291","description":"neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2","metadata":{"aliases":["KIAA1486"]}},{"id":"00ced49e4284425b8dbff2f435ec1865","type":"GENE","name":"NYNRIN","canonical_id":"hgnc:HGNC:20165","description":"NYN domain and retroviral integrase containing","metadata":{"aliases":["FLJ11811","CGIN1","KIAA1305"]}},{"id":"21d72269a4fb49c29a922956ef260b65","type":"GENE","name":"NYX","canonical_id":"hgnc:HGNC:8082","description":"nyctalopin","metadata":{"aliases":["CLRP","CSNB1A","CSNB1","CSNB4"]}},{"id":"84e216b4b219473ab4db694d303eefdf","type":"TRIAL","name":"Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer","canonical_id":"clinicaltrials.gov:NCT02769832","description":"Small Cell Lung Cancer (SCLC)","metadata":null},{"id":"2c95f971eb5146b1983b0caff4712927","type":"TRIAL","name":"Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01493310","description":"Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"d3597918694440c3aab33c1394632089","type":"TRIAL","name":"Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05251766","description":"Breast Cancer; Chemotherapy Effect","metadata":null},{"id":"c70440ca5fb54803a37bd5ff125684ad","type":"TRIAL","name":"NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT06781281","description":"Breast Cancer Invasive","metadata":null},{"id":"eb615de954254f1db567c4d174a3603e","type":"DRUG","name":"Nabumetone","canonical_id":"mesh:D000077430","description":null,"metadata":null},{"id":"24e621c84fb74c989d9b47900916ef22","type":"DRUG","name":"Nadolol","canonical_id":"mesh:D009248","description":null,"metadata":null},{"id":"33710f6abb17466a9a0cc88047c7efc5","type":"TRIAL","name":"Nadolol Versus Propranolol in Children With Infantile Hemangiomas","canonical_id":"clinicaltrials.gov:NCT02505971","description":"Infantile Hemangioma","metadata":null},{"id":"32898ff3af1e4a638bd9f6944b2f0171","type":"TRIAL","name":"Nadolol for Proliferating Infantile Hemangiomas","canonical_id":"clinicaltrials.gov:NCT01010308","description":"Infantile Hemangioma","metadata":null},{"id":"cd6ebbd86da14a8bb076adfa49b33b3d","type":"TRIAL","name":"Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)","canonical_id":"clinicaltrials.gov:NCT01486485","description":"Acute Kidney Injury","metadata":null},{"id":"940b7677a4c34d7590972e906c1e1583","type":"TRIAL","name":"Nafamostat Efficacy in Phase 3 Registrational CRRT Study","canonical_id":"clinicaltrials.gov:NCT06150742","description":"Acute Kidney Injury","metadata":null},{"id":"3e06dade5cc142b1b61cf77af1fe421a","type":"TRIAL","name":"Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy","canonical_id":"clinicaltrials.gov:NCT06078839","description":"Sepsis; Sepsis-induced Coagulopathy; Nafamostat Mesilate","metadata":null},{"id":"8794886c167f47358ed0f2dd02089341","type":"TRIAL","name":"Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT07518303","description":"Sepsis; Acute Kidney Injury; Continuous Renal Replacement Therapy (CRRT)","metadata":null},{"id":"7765f9409b5a4c7892f3538e1c56e2ba","type":"DRUG","name":"Naftifine","canonical_id":"mesh:C029178","description":null,"metadata":null},{"id":"50c0e593becb47a998c039bda658f43e","type":"TRIAL","name":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule\u00b1SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06662006","description":"Advanced Metastatic Pancreatic Cancer","metadata":null},{"id":"5489e9dea4884c5ea10929e94ad7a026","type":"DRUG","name":"Nalbuphine","canonical_id":"mesh:D009266","description":null,"metadata":null},{"id":"7e8d943972fc4ca3b21f27d419289c43","type":"TRIAL","name":"Nalbuphine Dosing and Its Impact on Anxiety and Depression in Ectopic Pregnancy Surgery","canonical_id":"clinicaltrials.gov:NCT07009808","description":"Ectopic Pregnancy; Anxiety; Depression; Nalbuphine","metadata":null},{"id":"18928fc157bd443ca6c46833a88fdbbb","type":"TRIAL","name":"Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT07271849","description":"Postoperative Pain, Acute; Hemodynamics; Total Knee Arthroplasty (TKA)","metadata":null},{"id":"2f2d8a7da0ab4b10a889e001ce5aa82a","type":"TRIAL","name":"Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03825887","description":"Acute Myeloid Leukemia; Stem Cell Leukemia","metadata":null},{"id":"e062a945978749a4a4385fc7c06c41b6","type":"TRIAL","name":"Nalbuphine Versus Morphine for Perioperative Tumor Ablation","canonical_id":"clinicaltrials.gov:NCT05073744","description":"Nalbuphine Allergy; Ablation; Safety","metadata":null},{"id":"baf49307c05a464599e4a14b9d6abd74","type":"TRIAL","name":"Nalbuphine and Flurbiprofen for Oculoplastic Surgery","canonical_id":"clinicaltrials.gov:NCT03422887","description":"Surgery; Anesthesia; Pain","metadata":null},{"id":"f5a1752fdace47bb800ece29c1d3b7c7","type":"TRIAL","name":"Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia","canonical_id":"clinicaltrials.gov:NCT02678585","description":"Postoperative Pain","metadata":null},{"id":"30f5164af832452db37b9e7d9d684997","type":"TRIAL","name":"Nalbuphine in ARDS Patients After Surgery","canonical_id":"clinicaltrials.gov:NCT06037330","description":"Acute Respiratory Distress Syndrome","metadata":null},{"id":"e54e892027df4d509df816163245430c","type":"TRIAL","name":"Naldebain for Pain Management After Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT05266027","description":"Arthropathy of Knee Joint","metadata":null},{"id":"ea1aa09a78d44b88af5ffe0077b43dcf","type":"TRIAL","name":"Naldebain\u00ae Extended-release Injection After Cesarean Section in Pain Management","canonical_id":"clinicaltrials.gov:NCT05446311","description":"Post Operative Pain; Caesarean Section; Analgesia","metadata":null},{"id":"f7a938d4ac24447db2bfaec8e0ec927b","type":"TRIAL","name":"Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience","canonical_id":"clinicaltrials.gov:NCT07231796","description":"Cancer; Opioid Induced Constipation (OIC)","metadata":null},{"id":"e8615c5760154da9973392bf7328087e","type":"TRIAL","name":"Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling","canonical_id":"clinicaltrials.gov:NCT00132119","description":"Pathological Gambling","metadata":null},{"id":"81afde74de044fb89395f4c79f8f101c","type":"TRIAL","name":"Nalmefene Implant in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07325279","description":"Opioid Abuse and Addiction","metadata":null},{"id":"cf5866f098ca4be78150a40ad60bae27","type":"TRIAL","name":"Nalmefene Smoking Cessation Study","canonical_id":"clinicaltrials.gov:NCT00202696","description":"Smoking Cessation","metadata":null},{"id":"8c6c2696874f4f828891141b11b5b922","type":"TRIAL","name":"Nalmefene in Alcohol Dependence and Borderline Personality Disorder","canonical_id":"clinicaltrials.gov:NCT02752503","description":"Alcohol Use Disorder; Borderline Personality Disorder","metadata":null},{"id":"c5832d7e2ae14b7ab9cf10df1ecb1313","type":"TRIAL","name":"Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.","canonical_id":"clinicaltrials.gov:NCT02824354","description":"Cirrhosis; Alcohol Dependence; Nalmefene","metadata":null},{"id":"39fbfd24ff674415a4bcd973bdec1f3b","type":"TRIAL","name":"Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose","canonical_id":"clinicaltrials.gov:NCT06408714","description":"Opioid Overdose; Opiate Overdose","metadata":null},{"id":"790f9edd133a4aa4a784eaa93592c8b8","type":"TRIAL","name":"Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects","canonical_id":"clinicaltrials.gov:NCT03034408","description":"Alcohol Use Disorder","metadata":null},{"id":"071146df0bcd4593a1ff9039d31e7cb2","type":"TRIAL","name":"Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids","canonical_id":"clinicaltrials.gov:NCT02977286","description":"Constipation","metadata":null},{"id":"0b0a10424f504eb4a23bf3e61affdba9","type":"DRUG","name":"Naloxone","canonical_id":"mesh:D009270","description":null,"metadata":null},{"id":"131f752934da4e5597a295831fcfe575","type":"TRIAL","name":"Naloxone Treatment in Sk\u00e5ne County - Effect on Drug-related Mortality and Overdose-related Complications","canonical_id":"clinicaltrials.gov:NCT03570099","description":"Opioid Abuse","metadata":null},{"id":"2e8b9604a8d14318a5572297269f4885","type":"TRIAL","name":"Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function","canonical_id":"clinicaltrials.gov:NCT01367561","description":"Healthy Males","metadata":null},{"id":"c3e1572bb2c64ed99fe02266c6298b1b","type":"TRIAL","name":"Naloxone, Hypoglycemia and Exercise","canonical_id":"clinicaltrials.gov:NCT03149770","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"ee0c6068e2be4800a8c52b33408fd4e7","type":"TRIAL","name":"Naltrexone & SSRI in Alcoholics With Depression/PTSD","canonical_id":"clinicaltrials.gov:NCT00338962","description":"Alcoholism; Depression; PTSD","metadata":null},{"id":"b830e0ac7eca4a78a8052b5a967932da","type":"TRIAL","name":"Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts","canonical_id":"clinicaltrials.gov:NCT00142948","description":"Heroin Dependence","metadata":null},{"id":"aa64ed33599d43e4a40aba2a8d06b65c","type":"TRIAL","name":"Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia","canonical_id":"clinicaltrials.gov:NCT01389167","description":"Opiate Dependence","metadata":null},{"id":"4e48a6ed4319474a9a3514681c69367c","type":"TRIAL","name":"Naltrexone and Propranolol Combined With Immunotherapy","canonical_id":"clinicaltrials.gov:NCT05968690","description":"Advanced Melanoma","metadata":null},{"id":"08d5ff83c0ba4f4ea6befe551cc6f87e","type":"TRIAL","name":"Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers","canonical_id":"clinicaltrials.gov:NCT00502216","description":"Smoking; Nicotine Dependence","metadata":null},{"id":"467da0eb608949a285acf758a685c260","type":"TRIAL","name":"Naltrexone for Prolonged Grief Disorder","canonical_id":"clinicaltrials.gov:NCT06140420","description":"Naltrexone HCl 50 MG Oral Tablet; Placebo","metadata":null},{"id":"a02ebbae58884c5982a67603c2a45c23","type":"TRIAL","name":"Naltrexone for Relapse Prevention","canonical_id":"clinicaltrials.gov:NCT00000442","description":"Alcoholism","metadata":null},{"id":"2bcc05bb669e40e5ba1d957966e2a003","type":"TRIAL","name":"Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)","canonical_id":"clinicaltrials.gov:NCT03559686","description":"Rheumatoid Arthritis","metadata":null},{"id":"5e92028ac31d4408b04e6f58259ec838","type":"TRIAL","name":"Named Patient Program With Rotigotine Transdermal System","canonical_id":"clinicaltrials.gov:NCT01095484","description":"Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine","metadata":null},{"id":"7ec05dc6b00d4f9f80841ac7ef0ba0df","type":"TRIAL","name":"Nandrolone Decanoate in the Treatment of Telomeropathies","canonical_id":"clinicaltrials.gov:NCT02055456","description":"Aplastic Anemia; Bone Marrow Failure Syndromes; Idiopathic Pulmonary Fibrosis; Telomere Shortening","metadata":null},{"id":"0492f283fb1443b8af031f2a85e1dde0","type":"TRIAL","name":"Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study","canonical_id":"clinicaltrials.gov:NCT03879408","description":"Pain","metadata":null},{"id":"efdf66f70b294965acbda94141862751","type":"GO_TERM","name":"NarGHI complex","canonical_id":"go:GO:0044799","description":"\"A heterotrimeric protein complex with iron-sulfur and molybdenum cofactors that functions as a terminal reductase in electron transport pathways that operate during anaerobic nitrate respiration. In E. coli electrons are passed from the FdnGHI complex to the NarGHI complex via menoquinone and menaquinol. Within NarGHI, electrons are passed from the two heme molecules in the NarI subunit down a Fe-S cluster chain in the NarH and NarG subunits to the Molybdenum cofactor, Mo-bisMGD, in the NarG subunit.\" [GOC:bhm, PMID:11289299, PMID:12910261, PMID:17964535]","metadata":null},{"id":"fd879d7069c04fe781e883de9f6b0762","type":"DRUG","name":"Naratriptan","canonical_id":"mesh:C106783","description":null,"metadata":null},{"id":"8117eb2243c041c4b6c53bb627dc91af","type":"TRIAL","name":"Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction","canonical_id":"clinicaltrials.gov:NCT00487578","description":"Post Traumatic Headache","metadata":null},{"id":"77a3de8f72cb414f8df978674bf993af","type":"DISEASE","name":"Narcolepsy","canonical_id":"mesh:D009290","description":null,"metadata":null},{"id":"ad7942f899b74ce1928c09592c02d580","type":"TRIAL","name":"Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children","canonical_id":"clinicaltrials.gov:NCT01047241","description":"Pain","metadata":null},{"id":"6524de7ea606494caafbf8022182b214","type":"DISEASE","name":"Nasal Congestion","canonical_id":"mesh:D015508","description":null,"metadata":null},{"id":"817539a21ba54114b6467718eea1efea","type":"TRIAL","name":"Nasal Ocular Reflexes Contribute to Eye Symptoms","canonical_id":"clinicaltrials.gov:NCT00117832","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"1bac6f645b474d75869aa5a78f618f06","type":"DISEASE","name":"Nasal congestion","canonical_id":"hp:0001742","description":null,"metadata":null},{"id":"73b0d19607a549858f60b721c530c8fe","type":"DISEASE","name":"Nasal polyp","canonical_id":"mesh:D009298","description":null,"metadata":null},{"id":"128b2586ca4149b4a1cc6f7c13169f8b","type":"DISEASE","name":"Nasal polyposis","canonical_id":"hp:0100582","description":null,"metadata":null},{"id":"3c55e58aa7ef494781db2385e604e5f6","type":"TRIAL","name":"Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)","canonical_id":"clinicaltrials.gov:NCT00070707","description":"Rhinitis, Allergic, Seasonal; Asthma","metadata":null},{"id":"a035a47d3b5d442293f7b663b3ebd397","type":"TRIAL","name":"Nasonex\u00ae Nasal Suspension 50 \u03bcg Long-term Designated Drug Use Investigation (Study P05876)","canonical_id":"clinicaltrials.gov:NCT00903721","description":"Allergic Rhinitis","metadata":null},{"id":"67ef6ca07ead4d578f409db8b0d61f21","type":"GO_TERM","name":"NatA complex","canonical_id":"go:GO:0031415","description":"\"A conserved complex that catalyzes the transfer of an acetyl group to an N-terminal Ser, Ala, Gly, or Thr residue of a protein acceptor molecule. In Saccharomyces the complex includes Nat1p and Ard1p, and may contain additional proteins.\" [PMID:12890471]","metadata":null},{"id":"ddf66a3d6b91492da1c3f8e83c8ac888","type":"GO_TERM","name":"NatB complex","canonical_id":"go:GO:0031416","description":"\"A conserved complex that catalyzes the transfer of an acetyl group to the N-terminal residue of a protein acceptor molecule that has a Met-Glu, Met-Asp, Met-Asn, or Met-Met N-terminus. In Saccharomyces the complex includes Nat3p and Mdm20p.\" [PMID:12890471]","metadata":null},{"id":"d40c69a1d33f4129aee504247f4e3ea3","type":"GO_TERM","name":"NatC complex","canonical_id":"go:GO:0031417","description":"\"A conserved complex that catalyzes the transfer of an acetyl group to the N-terminal residue of a protein acceptor molecule that has a Met-Ile, Met-Leu, Met-Trp, or Met-Phe N-terminus. In Saccharomyces the complex includes Mak3p, Mak10p, and Mak31p.\" [PMID:12890471]","metadata":null},{"id":"ca659f5b218545c3a10364e107d113e1","type":"DRUG","name":"Natalizumab","canonical_id":"mesh:D000069442","description":null,"metadata":null},{"id":"2b125b785a1a4ad5a5c366a41976e00b","type":"TRIAL","name":"Natalizumab De-escalation With Interferon Beta-1b","canonical_id":"clinicaltrials.gov:NCT01144052","description":"Relapsing-remitting Multiple Sclerosis","metadata":null},{"id":"d44ed49fedb3447eb4c132f597bdd199","type":"TRIAL","name":"Natalizumab High Titer Immunogenicity and Safety","canonical_id":"clinicaltrials.gov:NCT00516893","description":"Multiple Sclerosis","metadata":null},{"id":"91d19e7c13b444f3be4d4254e0896362","type":"TRIAL","name":"Natalizumab Re-Initiation of Dosing","canonical_id":"clinicaltrials.gov:NCT00306592","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"d6e90225051141278d6d09e859426760","type":"TRIAL","name":"Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies","canonical_id":"clinicaltrials.gov:NCT02241785","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"88a7c3ec5e194f12948245bec062a813","type":"DRUG","name":"Nateglinide","canonical_id":"mesh:C060142","description":null,"metadata":null},{"id":"f3c241346f6b43079fd00dbb94c130e7","type":"TRIAL","name":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02664935","description":"Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma","metadata":null},{"id":"5aba01a05dce46868045b44af5741237","type":"TRIAL","name":"Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC","canonical_id":"clinicaltrials.gov:NCT00338455","description":"Congestive Heart Failure; Cardiac Transplantation; Renal Insufficiency; Renal Failure","metadata":null},{"id":"a64dc43852464f629afa4856e203ba3a","type":"TRIAL","name":"Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant","canonical_id":"clinicaltrials.gov:NCT06416735","description":"Hypertension Essential; Salt Excess; Genetic Hypertension","metadata":null},{"id":"029b4f72152540c69a2fd2e55fbc92e9","type":"TRIAL","name":"Natural Killer (NK) Cell Transplantation for AML","canonical_id":"clinicaltrials.gov:NCT00187096","description":"Acute Myeloid Leukemia","metadata":null},{"id":"c1af175706d74490b016b91166d5b48c","type":"TRIAL","name":"Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT05601466","description":"AML, Adult","metadata":null},{"id":"1dc7ea810a26480db5f5c4a5d4e0222c","type":"TRIAL","name":"Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment","canonical_id":"clinicaltrials.gov:NCT00843570","description":"Infertility","metadata":null},{"id":"868cc8a8c10a47158aac7fc0234b901e","type":"TRIAL","name":"Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE","canonical_id":"clinicaltrials.gov:NCT04726553","description":"Systemic Lupus Erythematosus (SLE)","metadata":null},{"id":"128e6c43e5554a5b9718db73eddfb800","type":"TRIAL","name":"Naturopathic Treatment for the Prevention of Cardiovascular Disease","canonical_id":"clinicaltrials.gov:NCT00718796","description":"Cardiovascular Disease","metadata":null},{"id":"846231895ccb48cab51b02590d786e74","type":"DISEASE","name":"Nausea","canonical_id":"hp:0002018","description":null,"metadata":null},{"id":"1fd9be6b6b534040b440eb77f2ba8761","type":"DISEASE","name":"Nausea","canonical_id":"mesh:D009325","description":null,"metadata":null},{"id":"2ca5feced8bf4f9b83dca249c6a39ed6","type":"DISEASE","name":"Nausea and vomiting","canonical_id":"hp:0002017","description":null,"metadata":null},{"id":"b74df0eb22d9481199cd6d5aaf251a79","type":"TRIAL","name":"Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT02295124","description":"Nausea","metadata":null},{"id":"88c2fb101d804562a46541dca50fdc69","type":"TRIAL","name":"Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT05489887","description":"Neuroblastoma","metadata":null},{"id":"c8e146fb3a1f480ebf822dca479dd3ab","type":"TRIAL","name":"Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT04560166","description":"Neuroblastoma Recurrent","metadata":null},{"id":"0734135aef674e4480f232d583b324fb","type":"TRIAL","name":"Naxitamab and GM-CSF in People With Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT04501757","description":"High-Risk Neuroblastoma","metadata":null},{"id":"f3c2896b90be4a3599177653733af0c6","type":"TRIAL","name":"Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.","canonical_id":"clinicaltrials.gov:NCT06047535","description":"Neuroblastoma","metadata":null},{"id":"2e3f17d30fbc47f695f81b2cbd791f37","type":"TRIAL","name":"Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.","canonical_id":"clinicaltrials.gov:NCT04909515","description":"Neuroblastoma","metadata":null},{"id":"f99c83855b9b43d9931a13b105df87bf","type":"TRIAL","name":"Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow","canonical_id":"clinicaltrials.gov:NCT03363373","description":"Neuroblastoma","metadata":null},{"id":"07a1a3c547e545a5a9a6c90186236468","type":"GO_TERM","name":"Ndc80 complex","canonical_id":"go:GO:0031262","description":"\"An essential outer kinetochore complex involved in the attachment of microtubule ends to the chromosomes during mitosis.\" [GOC:vw, PMID:28502666, PMID:34810257]","metadata":null},{"id":"bb748526cdfc4996ae45a626b613cfad","type":"GO_TERM","name":"Nebenkern","canonical_id":"go:GO:0016006","description":"\"A product of the fusion of the mitochondria during spermatogenesis. After the completion of meiosis the mitochondria of the spermatid collect along side the nucleus and fuse into two masses; these wrap around each other to produce the spherical Nebenkern. During flagellum elongation the Nebenkern unfolds and the two derivatives (major and minor mitochondrial derivatives) elongate down the axoneme.\" [GOC:ma, PMID:25265054]","metadata":null},{"id":"a6053e54bd9140088298750495a5b475","type":"GO_TERM","name":"Nebenkern assembly","canonical_id":"go:GO:0007287","description":"\"Fusion of mitochondria during insect spermatid differentiation to form two masses, which wrap around each other to form a densely packed sphere called the Nebenkern.\" [GOC:bf, ISBN:0879694238, PMID:9550716]","metadata":null},{"id":"9786607607624298b27078c0e3bce1aa","type":"DRUG","name":"Nebivolol","canonical_id":"mesh:D000068577","description":null,"metadata":null},{"id":"1e6e49f3c3f543ffb8635f05f20a8050","type":"TRIAL","name":"Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)","canonical_id":"clinicaltrials.gov:NCT01595516","description":"Prehypertension; Hypertension","metadata":null},{"id":"db1ca2fe83954b6b85a0e6b25061c17c","type":"TRIAL","name":"Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury","canonical_id":"clinicaltrials.gov:NCT04511923","description":"Covid19; ARDS, Human; Lung Injury, Acute; Ventilation Perfusion Mismatch","metadata":null},{"id":"4b85267abc45436caa6414a38f5e06e9","type":"TRIAL","name":"Nebulized Dexmedetomidine Versus Oral Sumatriptan in Treatment of Post Dural Puncture Headache in Cesarean Section","canonical_id":"clinicaltrials.gov:NCT06514040","description":"Post-Dural Puncture Headache","metadata":null},{"id":"9217f5c7ad1c4070943c8663abd27a86","type":"TRIAL","name":"Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population","canonical_id":"clinicaltrials.gov:NCT02077010","description":"Heart Failure; Cardiomyopathy","metadata":null},{"id":"6c4a96147cac4cb2912d379e07206ddc","type":"TRIAL","name":"Nebulized Ketamine for Severe Asthma Attacks in Children","canonical_id":"clinicaltrials.gov:NCT07728851","description":"Asthma Acute; Exacerbation of Allergic Asthma","metadata":null},{"id":"5387f5a410f84f5ca23350a012c5919a","type":"TRIAL","name":"Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn","canonical_id":"clinicaltrials.gov:NCT04898114","description":"Persistent Pulmonary Hypertension of Newborn","metadata":null},{"id":"7d5addd415d149f19c0e4b862c636008","type":"TRIAL","name":"Nebulized Procaterol Versus Nebule Salbutamol for the Treatment of Moderate Acute Asthma","canonical_id":"clinicaltrials.gov:NCT00990847","description":"Moderate Acute Asthma","metadata":null},{"id":"336a57f0f081435eb8abda0572f9a2f9","type":"DRUG","name":"Necitumumab","canonical_id":"mesh:C527969","description":null,"metadata":null},{"id":"7e3e7065cba94d79b88a5b473090595c","type":"TRIAL","name":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04285671","description":"Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"c662779c4ab042198a8e4b79746115ee","type":"TRIAL","name":"Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001","canonical_id":"clinicaltrials.gov:NCT03574818","description":"Squamous Cell Lung Cancer","metadata":null},{"id":"64c0dfb7f9314a4580be80012198e811","type":"DISEASE","name":"Necrobiosis Lipoidica","canonical_id":"mesh:D009335","description":null,"metadata":null},{"id":"a171c0f4f7ad441c83cb33cb9da7af7b","type":"DRUG","name":"Nedocromil","canonical_id":"mesh:D017835","description":null,"metadata":null},{"id":"c55e4ebb3ea14af78e627a2d34913df2","type":"TRIAL","name":"Nefazodone in the Treatment of Cocaine Dependence and Depression - 4","canonical_id":"clinicaltrials.gov:NCT00015210","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"c25acb48a80c4159a46043ccb80e7713","type":"TRIAL","name":"Nefazodone in the Treatment of Social Phobia","canonical_id":"clinicaltrials.gov:NCT00231348","description":"Social Anxiety Disorder (SAD)","metadata":null},{"id":"15376a469b0c4cec808527a485db9166","type":"TRIAL","name":"Nefecon and Ambrisentan in IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT07030894","description":"IgA Nephropathy; Chronic Kidney Disease; Proteinuria","metadata":null},{"id":"7d91cd44147348769e9750f723ea92ad","type":"DRUG","name":"Nelfinavir","canonical_id":"mesh:D019888","description":null,"metadata":null},{"id":"b92f96f45dde424b8fbbd5d6527f312e","type":"GO_TERM","name":"Nem1-Spo7 phosphatase complex","canonical_id":"go:GO:0071595","description":"\"A protein serine/threonine phosphatase complex that is involved in nuclear envelope organization, and contains proteins known in budding yeast as Nem1p and Spo7p.\" [GOC:mah, PMID:9822591]","metadata":null},{"id":"44e704cfc41d43d28088b37c9950b26d","type":"TRIAL","name":"Nemolizumab for LS","canonical_id":"clinicaltrials.gov:NCT07704775","description":"Lichen Sclerosus of Vulva","metadata":null},{"id":"fe5a0c8da07f47c6b71c8b8327f3fec8","type":"TRIAL","name":"Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus","canonical_id":"clinicaltrials.gov:NCT07843420","description":"Chronic Hepatic Pruritus; Cholestatic Liver Disease; Primary Biliary Cholangitis; Cholestasis; Primary Sclerosing Cholangitis","metadata":null},{"id":"25a7d233c52a433d9161748b8eb0ff66","type":"TRIAL","name":"Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.","canonical_id":"clinicaltrials.gov:NCT07396168","description":"Lichen Plano-Pilaris","metadata":null},{"id":"928a1b8448674afe9273637282df6cff","type":"TRIAL","name":"Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","canonical_id":"clinicaltrials.gov:NCT00553358","description":"Neoplasms, Breast","metadata":null},{"id":"694710455e9c430a874c505caeebecdf","type":"TRIAL","name":"Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)","canonical_id":"clinicaltrials.gov:NCT06999980","description":"Cutaneous Melanoma; Mucosal Melanoma","metadata":null},{"id":"37906be193f8406594f09f18ab634937","type":"TRIAL","name":"Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study","canonical_id":"clinicaltrials.gov:NCT05761132","description":"Vulva Cancer; Vulva Neoplasm; Squamous Cell Cancer","metadata":null},{"id":"fe85ba5fd5f240a4a50d701742b35cae","type":"TRIAL","name":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04539808","description":"Pancreatic Adenocarcinoma; Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8; Stage I Pancreatic Cancer American Joint Committee on Cancer v8; Stage III Pancreatic Cancer American Joint Committee on Cancer v8; Stage IV Pancreatic Cancer American Joint Committee on Cancer v8","metadata":null},{"id":"859e249fcb5f412b98552c7dbbb2c753","type":"TRIAL","name":"Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT01538381","description":"Carcinoma, Squamous Cell of Head and Neck","metadata":null},{"id":"c97e07ae839d456f96b74e0146aaee52","type":"TRIAL","name":"Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03124433","description":"Cancer of the Prostate","metadata":null},{"id":"5972c88339e74984b2ace24d6d45e8c4","type":"TRIAL","name":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06925243","description":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]); Neoadjuvant Therapy; Adjuvant Chemotherapy; pCR Rate; MPR; ORR,OS,PFS","metadata":null},{"id":"5eb9fff9dcbd427c89431fa429eb9cf8","type":"TRIAL","name":"Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT04022343","description":"Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8","metadata":null},{"id":"03856e52e5634d298ba4ddda6a42f5f1","type":"TRIAL","name":"Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06023875","description":"Head and Neck Squamous Cell Carcinoma; Locally Advanced Operable","metadata":null},{"id":"70453d919796437c88468f9ab6fa5571","type":"TRIAL","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","canonical_id":"clinicaltrials.gov:NCT03916627","description":"Non-small Cell Lung Cancer; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"e835007f659d4ec3935d27cee3056ea2","type":"TRIAL","name":"Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04975152","description":"Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma","metadata":null},{"id":"391ae7f56e1249439b0c4cee99c99681","type":"TRIAL","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","canonical_id":"clinicaltrials.gov:NCT06449313","description":"Non-small Cell Lung Cancer Stage III","metadata":null},{"id":"24ac0425a4b247fe8e45b327fb1febec","type":"TRIAL","name":"Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA","canonical_id":"clinicaltrials.gov:NCT01531205","description":"Prostate Cancer","metadata":null},{"id":"b6eb49046a0c497f9af3969ff56138ba","type":"TRIAL","name":"Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT06289751","description":"Cervical Cancer; Neoadjuvant Chemoimmunotherapy; Radical Hysterectomy; Extrafascial Hysterectomy","metadata":null},{"id":"76cc0727c4f54b9db151e00d45bed98a","type":"TRIAL","name":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07134218","description":"Rectal Cancer","metadata":null},{"id":"711757ac07e549c09dc6c8b60c0af360","type":"TRIAL","name":"Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07866313","description":"MSS-type Low Rectal Cancer\uff0cNeoadjuvant Chemoradiotherapy, QL1706","metadata":null},{"id":"c82be7337a184570bf4baa1049bd6971","type":"TRIAL","name":"Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06303583","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"093dbb561b9d4234848ebda523fb8799","type":"TRIAL","name":"Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00270894","description":"Breast Neoplasm","metadata":null},{"id":"70d2882714d240aab66b98999df8d348","type":"TRIAL","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","canonical_id":"clinicaltrials.gov:NCT07351487","description":"TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"eafd7538709045f5aeb8292932aa2dba","type":"TRIAL","name":"Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02685657","description":"Triple Negative Breast Cancer","metadata":null},{"id":"185bbc1c2e94468699f1363a5de27df4","type":"TRIAL","name":"Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)","canonical_id":"clinicaltrials.gov:NCT04410887","description":"Stomach Cancer; Gastric Cancer","metadata":null},{"id":"89474d141ef849dcad4e6f36a6563884","type":"TRIAL","name":"Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)","canonical_id":"clinicaltrials.gov:NCT06874933","description":"HR+/HER2- Breast Cancer","metadata":null},{"id":"189bf5bf6a124aa1b86f36e94bb9012d","type":"TRIAL","name":"Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT06927128","description":"UTUC; NAC","metadata":null},{"id":"657805a3994d4ba8b5d5a02257f8fec5","type":"TRIAL","name":"Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC","canonical_id":"clinicaltrials.gov:NCT05516589","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"ca05c4d01011408492adb6ff17db6fbf","type":"TRIAL","name":"Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT06430658","description":"Esophagus Cancer","metadata":null},{"id":"fac097f4e3dd4d68b630e73b9f76b1fb","type":"TRIAL","name":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06631521","description":"Prostate CA; Prostate Cancer (Adenocarcinoma); Prostate Cancer Surgery","metadata":null},{"id":"12fae10db478438595ebb7ba47dd329d","type":"TRIAL","name":"Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02215876","description":"Breast Cancer","metadata":null},{"id":"867f6b9d3a084d979f3cee8495cf15d2","type":"TRIAL","name":"Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT00086736","description":"Prostate Cancer","metadata":null},{"id":"86f9385e328d4a6987d2201cb098317b","type":"TRIAL","name":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05306041","description":"HER2-positive Breast Cancer","metadata":null},{"id":"b89b6fdff3fe4bb98183655d388cfb09","type":"TRIAL","name":"Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07801898","description":"Invasive Breast Cancer (Stage I-III)","metadata":null},{"id":"f244f7b25b7e421797cb546c4b525da5","type":"TRIAL","name":"Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06734182","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"e52d318ce9134907968cbd515c9488c8","type":"TRIAL","name":"Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05645094","description":"Locally Advanced Rectal Carcinoma; MSI-High","metadata":null},{"id":"4322ba39fcc54f69b1e58db5c81397ea","type":"TRIAL","name":"Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC","canonical_id":"clinicaltrials.gov:NCT07465276","description":"Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of the Head and Neck","metadata":null},{"id":"63fdefc27dba45f1aba49901e5016b1a","type":"TRIAL","name":"Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04894188","description":"Prostate Cancer","metadata":null},{"id":"2f2149e92deb44b6a107a1b66682ef15","type":"TRIAL","name":"Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05132985","description":"NSCLC; EGF-R Positive Non-Small Cell Lung Cancer","metadata":null},{"id":"69674f704cde41debeb52101118f8249","type":"TRIAL","name":"Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans","canonical_id":"clinicaltrials.gov:NCT00243191","description":"Dermatofibrosarcoma Protuberans","metadata":null},{"id":"561af6de50594e629e63f5dfb7d2f4fc","type":"TRIAL","name":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","canonical_id":"clinicaltrials.gov:NCT03026140","description":"Colon Carcinoma","metadata":null},{"id":"2440d47da16749baa68f9a07d5b99d25","type":"TRIAL","name":"Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC","canonical_id":"clinicaltrials.gov:NCT05807542","description":"Esophagus Cancer","metadata":null},{"id":"2b82cdcef2c54d2c96385220c0bd7499","type":"TRIAL","name":"Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05444998","description":"Breast Cancer","metadata":null},{"id":"cbbe7036b0154528b2c557410b21ec37","type":"TRIAL","name":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06694454","description":"Non-small Cell Lung Cancer (NSCLC); Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Carcinoma; Non Small Cell Lung Cancer; Non Small Cell Lung Carcinoma","metadata":null},{"id":"b8fa910dc8c44cc68731b8e18d754919","type":"TRIAL","name":"Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)","canonical_id":"clinicaltrials.gov:NCT07055399","description":"Locally Advanced Cervical Cancer","metadata":null},{"id":"33ed6ee551834cfd96409bfe0078bdfd","type":"TRIAL","name":"Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT07867392","description":"Gastric Adenocarcinoma","metadata":null},{"id":"8a195b111bb94a8a92800e6f6332f413","type":"TRIAL","name":"Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00821886","description":"Breast Cancer","metadata":null},{"id":"cb4b20dd356645949e8b0421171b6c74","type":"TRIAL","name":"Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02762006","description":"Renal Cell Carcinoma; Kidney Cancer","metadata":null},{"id":"ee1101f910ef4988a9c7c0aace73bb6f","type":"TRIAL","name":"Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06624475","description":"Basal Cell Carcinoma","metadata":null},{"id":"375ee276783e43b0bd7ec304f03d24ee","type":"TRIAL","name":"Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04331067","description":"Triple Negative Breast Cancer","metadata":null},{"id":"6c5946dc7c4144cb952af2a53376c300","type":"TRIAL","name":"Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06288191","description":"Cutaneous Squamous Cell Carcinoma","metadata":null},{"id":"923bc005735f47e2b42773a61c1c74ff","type":"TRIAL","name":"Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma","canonical_id":"clinicaltrials.gov:NCT04139902","description":"Melanoma Stage III; Melanoma Stage IV","metadata":null},{"id":"b722a682672945d59422719754ce58d2","type":"TRIAL","name":"Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus","canonical_id":"clinicaltrials.gov:NCT05969496","description":"Renal Cancer; Kidney Cancer; Renal Cell Carcinoma; Inferior Vena Cava Thrombosis","metadata":null},{"id":"0ff36ee13d0a4a6589dfe8f2b0c528ff","type":"TRIAL","name":"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status","canonical_id":"clinicaltrials.gov:NCT02339532","description":"Breast Cancer","metadata":null},{"id":"e21ee82b34d34a84b0fa9ecf5bab0535","type":"TRIAL","name":"Neoadjuvant QL1706 Therapy for ESCC","canonical_id":"clinicaltrials.gov:NCT06908382","description":"Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"2f48926a7ee0497b9a09adee9347e438","type":"TRIAL","name":"Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC","canonical_id":"clinicaltrials.gov:NCT07693959","description":"MIBC","metadata":null},{"id":"b982a4f84c49408096f98dc451b9991c","type":"TRIAL","name":"Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)","canonical_id":"clinicaltrials.gov:NCT07165847","description":"Immunotherapy; Gastric Cancer (GC); Radiotherapy; Neoadjuvant Therapy; Neoadjuvant Chemoimmunotherapy","metadata":null},{"id":"9ab1fe1757df48f88649f76bd434dbf9","type":"TRIAL","name":"Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02568839","description":"Early-Stage Breast Carcinoma; HER-2 Positive Breast Cancer","metadata":null},{"id":"2f3e93fe3294419bb9e1e71725b75340","type":"TRIAL","name":"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","canonical_id":"clinicaltrials.gov:NCT02603679","description":"Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor","metadata":null},{"id":"0f1fe87d0f7f4e34ae03ba0ab6a0d1d1","type":"TRIAL","name":"Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02619669","description":"Breast Cancer","metadata":null},{"id":"e58f4b8852ad479f8ee42730f1519c5f","type":"TRIAL","name":"Neoadjuvant SNF Precision Therapy Phase III","canonical_id":"clinicaltrials.gov:NCT06913777","description":"Neoadjuvant Therapy","metadata":null},{"id":"7e1d3fca6f274a849a8447ebc0389aeb","type":"TRIAL","name":"Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06055465","description":"Lung Cancer","metadata":null},{"id":"57b5653e50524c518b79f8c2347f0d59","type":"TRIAL","name":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07492914","description":"Resectable Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"0886e3a4c6ef48c899e4426b9eefc56e","type":"TRIAL","name":"Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","canonical_id":"clinicaltrials.gov:NCT07283692","description":"Triple Negative Breast Cancer","metadata":null},{"id":"1101d17b3440420ebb152576e1b6427c","type":"TRIAL","name":"Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance","canonical_id":"clinicaltrials.gov:NCT07509424","description":"Rectal Cancer","metadata":null},{"id":"87f3f8e358ec4a599bf4f1020a0a09ba","type":"TRIAL","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00833248","description":"Prostate Cancer","metadata":null},{"id":"70b3da42faa14ef7a9fd9853ae5cdd87","type":"TRIAL","name":"Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer","canonical_id":"clinicaltrials.gov:NCT05148546","description":"Renal Cell Carcinoma","metadata":null},{"id":"603b7928c9ea45faad39fb60613f5d60","type":"TRIAL","name":"Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin","canonical_id":"clinicaltrials.gov:NCT01847677","description":"Cancer, Ovarian","metadata":null},{"id":"37a63d954b7348fdb9931552053cbb00","type":"TRIAL","name":"Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model","canonical_id":"clinicaltrials.gov:NCT06420440","description":"HCC","metadata":null},{"id":"11c412243a834574b042fe9608e10307","type":"TRIAL","name":"Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06575257","description":"Prostate Cancer","metadata":null},{"id":"7fca32b0936648639ce398cc98bdc7c7","type":"TRIAL","name":"Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT01843647","description":"Non-small-cell Lung Cancer","metadata":null},{"id":"8b571b1545f84a369db5118b533e8871","type":"TRIAL","name":"Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC","canonical_id":"clinicaltrials.gov:NCT06699498","description":"Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy; PD-L1; Anlotinib","metadata":null},{"id":"6d482e35a14d4c1ea0960b6e06a4af5e","type":"TRIAL","name":"Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin","canonical_id":"clinicaltrials.gov:NCT07518706","description":"HCC - Hepatocellular Carcinoma","metadata":null},{"id":"1eccef5dde92422c8118de69ef3e82a5","type":"TRIAL","name":"Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study","canonical_id":"clinicaltrials.gov:NCT06162559","description":"Breast Cancer","metadata":null},{"id":"15c03f191f1b4c27b13576bd58eef9e7","type":"TRIAL","name":"Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01565499","description":"Breast Cancer","metadata":null},{"id":"5887dcd528504406999c0b0b7b232cb3","type":"TRIAL","name":"Neoadjuvant Treatment of Colon Cancer","canonical_id":"clinicaltrials.gov:NCT01108107","description":"Colon Cancer","metadata":null},{"id":"221d8070e9d240c8aa87e97d497ee058","type":"TRIAL","name":"Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole","canonical_id":"clinicaltrials.gov:NCT05163106","description":"Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer; Luminal A Breast Cancer; Luminal B Breast Cancer","metadata":null},{"id":"afcc96442cb24254bd140e2cb62c62ce","type":"TRIAL","name":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib \u00b1 Camrelizumab","canonical_id":"clinicaltrials.gov:NCT06516289","description":"BRCA-Mutated Breast Carcinoma; HER2-negative Breast Cancer","metadata":null},{"id":"8cc87c09e8a0409eacf3b1ea478e95e7","type":"TRIAL","name":"Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04465097","description":"Breast Cancer","metadata":null},{"id":"e00f3e94e2fe471289367826fa399320","type":"TRIAL","name":"Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","canonical_id":"clinicaltrials.gov:NCT06563999","description":"Lung Cancer Stage III; Mutation","metadata":null},{"id":"5f9684bdda2f4a3fb3d1754ff8eedaab","type":"TRIAL","name":"Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03035188","description":"Basal Cell Carcinoma","metadata":null},{"id":"c4b5dc37deb2439d98adb9af7b90dafc","type":"TRIAL","name":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT06295159","description":"Melanoma Stage III; Melanoma Stage IV; Advanced Melanoma; Melanoma","metadata":null},{"id":"c9311e90c1974d8483607d5d943f7950","type":"TRIAL","name":"Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations","canonical_id":"clinicaltrials.gov:NCT06054191","description":"NSCLC; BRAF V600 Mutation; MET Exon 14 Mutation","metadata":null},{"id":"0f2f9901521245ec9afcb1cf66bb8aa9","type":"TRIAL","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05116462","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"d0c943de0bfe4cd688f88d86cb02a9c1","type":"TRIAL","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","canonical_id":"clinicaltrials.gov:NCT07412613","description":"Resectable Colon Cancer; MSI-H/dMMR Colorectal Cancer","metadata":null},{"id":"87d7b0fd2c4148a3bbe765c55298e8b3","type":"TRIAL","name":"Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06614231","description":"NSCLC, Stage IIIA; NSCLC (non-small Cell Lung Cancer)","metadata":null},{"id":"c751dd688c45439599998382c6db513b","type":"TRIAL","name":"Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy","canonical_id":"clinicaltrials.gov:NCT03199040","description":"Triple Negative Breast Cancer; Triple Negative Breast Neoplasms; TNBC - Triple-Negative Breast Cancer; Triple-negative Breast Carcinoma","metadata":null},{"id":"1634d02838b34bf490766ca79d7aef7b","type":"TRIAL","name":"Neonatal White Matter Injury Trial (WRAP)","canonical_id":"clinicaltrials.gov:NCT07688746","description":"White Matter Injury; Brain Injury, Fetus and Neonate; Neonatal Brain Injury; Periventricular Leukomalacia; Periventricular White Matter Abnormalities","metadata":null},{"id":"91a1781176fb4ad38c9fccf062b075ad","type":"DISEASE","name":"Neonatal insulin-dependent diabetes mellitus","canonical_id":"hp:0000857","description":null,"metadata":null},{"id":"dd8b5c47f4a941ff886956fdb2223cde","type":"DRUG","name":"Neostigmine","canonical_id":"mesh:D009388","description":null,"metadata":null},{"id":"09d35a4cd139475ba6d7b78837199562","type":"TRIAL","name":"Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)","canonical_id":"clinicaltrials.gov:NCT00305630","description":"Choroidal Neovascularization; Age-Related Macular Degeneration","metadata":null},{"id":"5e5bf94e15c7445d9c249de9ca7b7a21","type":"DISEASE","name":"Nephroblastoma","canonical_id":"mesh:D009396","description":null,"metadata":null},{"id":"e6a3ee086bd342319ee1eeed1222d82a","type":"TRIAL","name":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","canonical_id":"clinicaltrials.gov:NCT00535925","description":"Diabetic Nephropathy","metadata":null},{"id":"b5b1097e8f254e0db2829dafcafcc736","type":"DISEASE","name":"Nephrotic Syndrome","canonical_id":"mesh:D009404","description":null,"metadata":null},{"id":"f0fcfa29c0e8423fb22959d8ae0858cd","type":"DRUG","name":"Neratinib","canonical_id":"ncit:C49094","description":null,"metadata":null},{"id":"3002f8a2fd92493d99f5a5d2665aae92","type":"TRIAL","name":"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03289039","description":"Breast Cancer","metadata":null},{"id":"71cc4d6b15bd451184d403ab420631e8","type":"TRIAL","name":"Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01670877","description":"Breast Neoplasms","metadata":null},{"id":"2df67d19b34242f5a8e00b7d26b49547","type":"TRIAL","name":"Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07333937","description":"Brest Cancer","metadata":null},{"id":"4bc8b2174fb445a69380ff793d0531a1","type":"TRIAL","name":"Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05154396","description":"HER2-positive Breast Cancer","metadata":null},{"id":"2e055651552944bca931dda3807b8537","type":"TRIAL","name":"Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer","canonical_id":"clinicaltrials.gov:NCT06109467","description":"GastroEsophageal Cancer; Gastric Cancer","metadata":null},{"id":"1d59a17d3eae46a7a412d069c686afb1","type":"TRIAL","name":"Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations","canonical_id":"clinicaltrials.gov:NCT06519110","description":"Advanced Solid Tumor","metadata":null},{"id":"42658eb34baf4fb7a5dba097672fd533","type":"TRIAL","name":"Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01827267","description":"HER2-mutant Non-Small Cell Lung Cancer","metadata":null},{"id":"10b6f798cb034f2ab9eafb4422a1f49e","type":"TRIAL","name":"Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test","canonical_id":"clinicaltrials.gov:NCT05243641","description":"Metastatic Breast Cancer; Breast Cancer","metadata":null},{"id":"5c796ca661a54744a79320e70a356c58","type":"TRIAL","name":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","canonical_id":"clinicaltrials.gov:NCT03065387","description":"Advanced Malignant Solid Neoplasm; EGFR Gene Amplification; EGFR Gene Mutation; ERBB2 Gene Amplification; ERBB2 Gene Mutation; ERBB3 Gene Mutation; ERBB4 Gene Mutation; KRAS Gene Mutation; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm","metadata":null},{"id":"7c5f76e605944ff483b82095ff97dacb","type":"TRIAL","name":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03101748","description":"Breast Inflammatory Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7","metadata":null},{"id":"3f8182b7b0674c3e87182dc8c07e415c","type":"TRIAL","name":"Neratinib in Combination With Ruxolitinib in Patients With mTNBC","canonical_id":"clinicaltrials.gov:NCT06008275","description":"Metastatic Triple-Negative Breast Carcinoma; Breast Cancer","metadata":null},{"id":"35156015dbf94bbaa21ff00e4a297eb9","type":"TRIAL","name":"Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04781374","description":"Metastatic Prostate Adenocarcinoma; Castration-resistant Prostate Cancer; Prostate Cancer; Prostate Cancer Metastatic","metadata":null},{"id":"15d0faeaaf1f4d899435b408edcfa777","type":"TISSUE","name":"Nerve Tibial","canonical_id":"uberon:UBERON:0001323","description":null,"metadata":null},{"id":"3639dc45dfcc4d9fa6a2771db26cb2bc","type":"TRIAL","name":"Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00080808","description":"Prostate Cancer","metadata":null},{"id":"4ffd56b0dba14509a70c8a34aca93765","type":"TRIAL","name":"Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT03040726","description":"Malignant Neoplasm; Nausea; Vomiting","metadata":null},{"id":"ce227d4754db40f984f44d1e78101702","type":"TRIAL","name":"Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD","canonical_id":"clinicaltrials.gov:NCT03661788","description":"ADHD","metadata":null},{"id":"ba4f1c613a4449779f5f17a42b2e1606","type":"TRIAL","name":"Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE","canonical_id":"clinicaltrials.gov:NCT05762146","description":"Ischemic Stroke, Acute","metadata":null},{"id":"f545117eee904ffaa29643d6d4125cc7","type":"TRIAL","name":"Neuraceq\u2122 PET for Detection of Brain Changes in Young Athletes Post-concussion","canonical_id":"clinicaltrials.gov:NCT05270083","description":"Concussion, Brain","metadata":null},{"id":"7f23c01c923f412cb71751ec3c67d7f6","type":"TRIAL","name":"Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)","canonical_id":"clinicaltrials.gov:NCT00665678","description":"Posttraumatic Stress Disorder (PTSD)","metadata":null},{"id":"ef9edf8e0c834c3bbf868bfee4d402ae","type":"TRIAL","name":"Neural Correlates of Lidocaine Analgesia","canonical_id":"clinicaltrials.gov:NCT05501600","description":"Anesthesia; Pain","metadata":null},{"id":"e4feb3f97b884bc1b513320a68890362","type":"TRIAL","name":"Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse","canonical_id":"clinicaltrials.gov:NCT06609369","description":"Tobacco Use; Tobacco Cessation; Insomnia","metadata":null},{"id":"60c31d9f005444cfa6cdac5704890208","type":"TRIAL","name":"Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)","canonical_id":"clinicaltrials.gov:NCT03128021","description":"Major Depressive Disorder","metadata":null},{"id":"cb3b12657a4f43a987d8d35ffbf1988e","type":"TRIAL","name":"Neural Substrates in Nicotine Withdrawal","canonical_id":"clinicaltrials.gov:NCT01001520","description":"Tobacco Use Disorder","metadata":null},{"id":"84317cbd313843b0af26f6c5df1a8075","type":"DISEASE","name":"Neuralgia","canonical_id":"mesh:D009437","description":null,"metadata":null},{"id":"9c06d074ac3f458389c5dbd0b54527a0","type":"PROTEIN","name":"Neuraminidase","canonical_id":"uniprot:P03472","description":null,"metadata":null},{"id":"3096095796ef4a9082cb4cec30ce41bc","type":"PROTEIN","name":"Neuraminidase","canonical_id":"uniprot:P03468","description":null,"metadata":null},{"id":"780115ea9bb1459fbb3cb16649bc8242","type":"TRIAL","name":"Neuraxial Ultrasound for Thoracic Epidural Placement","canonical_id":"clinicaltrials.gov:NCT02785055","description":"Analgesia, Epidural","metadata":null},{"id":"8d5b5dcf32b44c8bb91ef6084c70a6df","type":"TRIAL","name":"Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity","canonical_id":"clinicaltrials.gov:NCT03309943","description":"Cigarette Smoking","metadata":null},{"id":"e6459ea80f9045038354ed6400df1746","type":"TRIAL","name":"Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD","canonical_id":"clinicaltrials.gov:NCT01709695","description":"ADHD; Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"1c1af2407246437a9d7b69fe3fab93b9","type":"TRIAL","name":"Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation","canonical_id":"clinicaltrials.gov:NCT01924429","description":"ADHD","metadata":null},{"id":"9642bba2ec514d93a334ed2ff7699333","type":"TRIAL","name":"Neurobiology of Opioid Dependence: 4 - 4","canonical_id":"clinicaltrials.gov:NCT00000195","description":"Opioid-Related Disorders","metadata":null},{"id":"078d5c9356864c4d801d228508e7c916","type":"DISEASE","name":"Neuroblastoma","canonical_id":"mesh:D009447","description":null,"metadata":null},{"id":"dc51a67b73cd40589f97b99d3d58c1e0","type":"DISEASE","name":"Neuroblastoma","canonical_id":"doid:769","description":null,"metadata":null},{"id":"9ea70b8b78d843758a96380eb82340f9","type":"TRIAL","name":"Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade","canonical_id":"clinicaltrials.gov:NCT00225498","description":"Schizophrenia","metadata":null},{"id":"b508b73241ea4df98fcfa44e0522e997","type":"DISEASE","name":"Neurodevelopmental delay","canonical_id":"hp:0012758","description":null,"metadata":null},{"id":"2b2aadc0adb6400ca281f5fc3964273a","type":"DISEASE","name":"Neurogenic bladder","canonical_id":"mesh:D001750","description":null,"metadata":null},{"id":"4b58c3aa91bf411696d57069d263da23","type":"TRIAL","name":"Neuroimaging GABA Physiology in Fragile X Syndrome","canonical_id":"clinicaltrials.gov:NCT04308954","description":"Fragile X Syndrome (FXS); Idiopathic Intellectual Developmental Disorder (IDD)","metadata":null},{"id":"31810336031f4dc79c266303f461492f","type":"TRIAL","name":"Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer","canonical_id":"clinicaltrials.gov:NCT02153281","description":"Major Depressive Disorder","metadata":null},{"id":"c261be8d53554be5b6973b2c44207848","type":"TRIAL","name":"Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria","canonical_id":"clinicaltrials.gov:NCT01412437","description":"PKU","metadata":null},{"id":"9792ded3a0de4ea083bd9d5f5f1577b4","type":"TRIAL","name":"Neuroimaging of Dystonia","canonical_id":"clinicaltrials.gov:NCT02046447","description":"Primary Cervical Dystonia; DYT 1 Dystonia","metadata":null},{"id":"56f7972d619e420d9b9de2d9b77c506d","type":"TRIAL","name":"Neuroimaging of the Effects of Concerta in the Treatment of ADHD","canonical_id":"clinicaltrials.gov:NCT00778310","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"b484eb1b44ab46da8f00f068a08401be","type":"TRIAL","name":"Neuromodulation and Language Acquisition (Project Stage Ia)","canonical_id":"clinicaltrials.gov:NCT00102284","description":"Healthy","metadata":null},{"id":"ef488e609c8a436d92599c6800bcb285","type":"TRIAL","name":"Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT01055171","description":"Alcohol Dependence; PTSD","metadata":null},{"id":"40c0464a36df4d24a73b350bd40fb149","type":"TRIAL","name":"Neuromodulation to Facilitate the Effect of Ketamine","canonical_id":"clinicaltrials.gov:NCT01816958","description":"Depression; Chronic Pain; Substance Abuse","metadata":null},{"id":"b006bcc258534f6d9a16579f36e5df02","type":"TRIAL","name":"Neuromyelitis Optica (NMO) & Cetirizine","canonical_id":"clinicaltrials.gov:NCT02865018","description":"Neuromyelitis Optica","metadata":null},{"id":"e0339e97ef3347da801f80f31ee4fa9b","type":"PROTEIN","name":"Neuronal acetylcholine receptor subunit alpha-10","canonical_id":"uniprot:Q9GZZ6","description":null,"metadata":null},{"id":"3ece4f7d45ec40f8ae4d0d56d8934e8e","type":"PROTEIN","name":"Neuronal acetylcholine receptor subunit alpha-2","canonical_id":"uniprot:Q15822","description":null,"metadata":null},{"id":"5ccdb87b20814f2e8dadbe6d86a1c41c","type":"TRIAL","name":"Neuropeptide Y and Sympathovagal Balance","canonical_id":"clinicaltrials.gov:NCT03933787","description":"Physical Activity; Sympathetic Nervous System; Secretion; Catecholamine","metadata":null},{"id":"6f2dc16c2c77459aabc708f0813ef77f","type":"TRIAL","name":"Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors","canonical_id":"clinicaltrials.gov:NCT02338037","description":"Metastatic Malignant Neoplasm in the Adult Brain; Primary Brain Tumor","metadata":null},{"id":"79db4c7108a148a1807d9ad919e0c41b","type":"TRIAL","name":"Neurophysiologic Changes in Patients With Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT01213121","description":"Bipolar Depression","metadata":null},{"id":"0ff1a506f7d14d7d8ea20de393165bec","type":"TRIAL","name":"Neurophysiologic Monitoring of Antidepressant Treatment","canonical_id":"clinicaltrials.gov:NCT01360190","description":"Major Depressive Disorder","metadata":null},{"id":"ad78eb22dab24b18aea63743e83e6735","type":"TRIAL","name":"Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT04361721","description":"Chronic Migraine","metadata":null},{"id":"c00f1f1c71b847b69a6abe5a50aa9ca4","type":"TRIAL","name":"Neurophysiology of Prophylactic Treatment in Migraine","canonical_id":"clinicaltrials.gov:NCT04019496","description":"Migraine","metadata":null},{"id":"33f790381bfe4917bddc85af372a7265","type":"TRIAL","name":"Neuroplasticity:Melatonin and Transcranial Current Stimulation in Healthy Subjects.","canonical_id":"clinicaltrials.gov:NCT02195271","description":"Analgesia Disorder; Pain","metadata":null},{"id":"e04a0ccbf9584f408370b7a587ab40ce","type":"TRIAL","name":"Neuroprotection With Phenytoin in Optic Neuritis","canonical_id":"clinicaltrials.gov:NCT01451593","description":"Optic Neuritis; Multiple Sclerosis","metadata":null},{"id":"6b5403adbf0f40b58e036ff9f2f76234","type":"TRIAL","name":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","canonical_id":"clinicaltrials.gov:NCT06778824","description":"Gut-Brain Disorders; GERD Without Erosive Esophagitis","metadata":null},{"id":"b457c50da4f84286babbc7f40b253b3d","type":"DISEASE","name":"Neurosyphilis","canonical_id":"mesh:D009494","description":null,"metadata":null},{"id":"e1618e859b3f4a41a8c9060c118a4308","type":"PROTEIN","name":"Neurotensin receptor type 2","canonical_id":"uniprot:O95665","description":null,"metadata":null},{"id":"a60d774242b046b0824dd7701ad0eee3","type":"TRIAL","name":"Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis","canonical_id":"clinicaltrials.gov:NCT05672472","description":"Acute Respiratory Distress Syndrome","metadata":null},{"id":"0e33248f5cd941c984b29e2c2149c21b","type":"TRIAL","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","canonical_id":"clinicaltrials.gov:NCT04564157","description":"Non-Small Cell Lung Cancer; Adjuvant Chemotherapy","metadata":null},{"id":"3a25596fbd1347b8a633bf2f62188ac5","type":"TRIAL","name":"New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00161018","description":"Schizophrenia","metadata":null},{"id":"de39a65a09c346c8b2aaeee187d86d02","type":"TRIAL","name":"New Approaches to Cocaine Abuse Medications (A) - 6","canonical_id":"clinicaltrials.gov:NCT00000271","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"1cfea1a7c8eb4f19ad0d44246626e6fd","type":"TRIAL","name":"New Clinical End-points in Patients With Primary Sj\u00f6gren's Syndrome","canonical_id":"clinicaltrials.gov:NCT05113004","description":"Primary Sj\u00f6gren's Syndrome (pSS)","metadata":null},{"id":"494945477c9e4a109653e3f3c639dad0","type":"TRIAL","name":"New Formulations of Propafenone to Treat Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02710669","description":"Atrial Fibrillation","metadata":null},{"id":"28fd9ee281204fbaad23a49f97682e66","type":"TRIAL","name":"New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)","canonical_id":"clinicaltrials.gov:NCT04600115","description":"MRI Scans","metadata":null},{"id":"d3342d4292334a0291bef83dbd141b10","type":"TRIAL","name":"New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial","canonical_id":"clinicaltrials.gov:NCT00100178","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"8c0b7f6418b74e2a97729d9bbbe09237","type":"TRIAL","name":"New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT00074828","description":"Total Knee Replacement; Total Hip Replacement","metadata":null},{"id":"cd8e32fc271a4ef7bfbed91df46d53bc","type":"TRIAL","name":"New Perspective on Exploring the Post-apneic BP Surge in Patients With OSA","canonical_id":"clinicaltrials.gov:NCT06172998","description":"Obstructive Sleep Apnea","metadata":null},{"id":"ba7d4caced9c44c0bbd9a0976a20f22f","type":"TRIAL","name":"New Treatment for Nocturnal Enuresis in Children","canonical_id":"clinicaltrials.gov:NCT06497647","description":"Nocturnal Enuresis in Children","metadata":null},{"id":"688ca2bdf8f24113b7ea360d0567e878","type":"TRIAL","name":"New Version Pulmicort Turbuhaler USA Children","canonical_id":"clinicaltrials.gov:NCT00642161","description":"Asthma","metadata":null},{"id":"1e12999e15964ca69ff6543695096f2b","type":"TRIAL","name":"Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial","canonical_id":"clinicaltrials.gov:NCT01030458","description":"Blood Pressure","metadata":null},{"id":"97604ef07ea346ba8c24f45fdf6147ec","type":"TRIAL","name":"Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT00901901","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"226cd6c8b2d8414aa8d4cbaf45c513d2","type":"TRIAL","name":"Next Generation Personalized Neuroblastoma Therapy","canonical_id":"clinicaltrials.gov:NCT02780128","description":"Neuroblastoma; Cancer","metadata":null},{"id":"dbbe4fc8612149e098de9fb95122d742","type":"TRIAL","name":"Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT01888497","description":"Healthy","metadata":null},{"id":"f94ed3b3f1674792bd609242e5f342f1","type":"TRIAL","name":"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.","canonical_id":"clinicaltrials.gov:NCT02703636","description":"Mild to Moderate Alzheimer's Disease","metadata":null},{"id":"7bfb595e936f455487993ce4f87f753f","type":"DRUG","name":"Niacin","canonical_id":"mesh:D009525","description":null,"metadata":null},{"id":"6d73b17a150045fa92d15badfa283eee","type":"GO_TERM","name":"Nicalin-NOMO complex","canonical_id":"go:GO:0106249","description":"\"A protein complex regulating Nodal signaling. Subunits are highly conserved in vertebrates and include Nicalin, NOMO and TMEM147.\" [GOC:al, GOC:bhm, PMID:20538592]","metadata":null},{"id":"ece5b8bc2d9b4e6ebd79b125d6b4211d","type":"DRUG","name":"Nicardipine","canonical_id":"mesh:D009529","description":null,"metadata":null},{"id":"0c646bd1ea154169b5dffa4b7036c785","type":"TRIAL","name":"Nicardipine Versus Labetalol During Intubation","canonical_id":"clinicaltrials.gov:NCT01041066","description":"Patients Who Are Intubated for General Anesthesia; Endotracheal Intubation","metadata":null},{"id":"53e15ae401674b4f9538296b80c0c571","type":"TRIAL","name":"Nicardipine vs Esmolol Craniotomy Emergence","canonical_id":"clinicaltrials.gov:NCT01951950","description":"Brain Tumors","metadata":null},{"id":"ef0c70461cd3406b94adb81e66ab9478","type":"TRIAL","name":"Nicardipine vs. Labetalol","canonical_id":"clinicaltrials.gov:NCT07277283","description":"Acute Ischemic Stroke; Hypertensive Crisis","metadata":null},{"id":"5f9c096b515140159d6441719da25edd","type":"TRIAL","name":"Nickel Desensitization Using Topical Therapy","canonical_id":"clinicaltrials.gov:NCT01413477","description":"Allergic Contact Dermatitis","metadata":null},{"id":"77ef337c2a7340f29fca46063285639c","type":"TRIAL","name":"Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients","canonical_id":"clinicaltrials.gov:NCT01011699","description":"Chronic Renal Failure; Hemodialysis","metadata":null},{"id":"c5d0775d35a040be89bcfd7da7ced7de","type":"DISEASE","name":"Nicotine dependence","canonical_id":"mesh:D014029","description":null,"metadata":null},{"id":"816a82d05cab48a897e1810c8a99e1ae","type":"TRIAL","name":"Nicotinic Modulation of the Default Network","canonical_id":"clinicaltrials.gov:NCT01223404","description":"Magnetic Resonance Imaging; Cognition; Nicotine; Mecamylamine","metadata":null},{"id":"296869d52ec54300adbffcf4441613fd","type":"TRIAL","name":"Nicotinic Receptor Augmentation of SSRI Antidepressants","canonical_id":"clinicaltrials.gov:NCT00319319","description":"Depressive Disorder","metadata":null},{"id":"6ad027b3e2614b35a5184af7c60dc0be","type":"DRUG","name":"Nicotinyl alcohol","canonical_id":"mesh:D009540","description":null,"metadata":null},{"id":"e1af82fddc2c4f00b3d8cb3fc3fd0436","type":"DISEASE","name":"Niemann-Pick disease","canonical_id":"mondo:0001982","description":null,"metadata":null},{"id":"1afc6a763d1740b292bc8d2d65c6261e","type":"DISEASE","name":"Niemann-Pick disease type C","canonical_id":"mondo:0018982","description":null,"metadata":null},{"id":"52785076d9cd48489084b413a1881dcb","type":"DISEASE","name":"Niemann-Pick disease, type C","canonical_id":"mesh:D052556","description":null,"metadata":null},{"id":"6d28c0a313e5426c9f667244c48eb03f","type":"DRUG","name":"Nifedipine","canonical_id":"mesh:D009543","description":null,"metadata":null},{"id":"0a7cc4d9595f476784f7cd2d5359334d","type":"TRIAL","name":"Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study","canonical_id":"clinicaltrials.gov:NCT07363343","description":"Hypertension; Postpartum Preeclampsia","metadata":null},{"id":"c95b950d587d4e4ba050e35251ad9a4c","type":"TRIAL","name":"Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium","canonical_id":"clinicaltrials.gov:NCT02711670","description":"Kidney Stones","metadata":null},{"id":"1af9d906dec04086a717ad6d2b450409","type":"TRIAL","name":"Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients","canonical_id":"clinicaltrials.gov:NCT05718024","description":"Intensive Care Unit; Mechanical Ventilation; Dexmedetomidine; Esketamine; Sleep Quality","metadata":null},{"id":"97a1cd9ec16d43e3b68780f545515d03","type":"TRIAL","name":"Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK","canonical_id":"clinicaltrials.gov:NCT00976612","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"72a59e579f25461e91be20fbf08b8ee8","type":"TRIAL","name":"Nilotinib Pre and Post Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00750659","description":"Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Stem Cell Transplantation","metadata":null},{"id":"38dbc2f2748a456191a15790050e4bd6","type":"TRIAL","name":"Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03228303","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"d583019fa6154e72bb271ba88cd2f07f","type":"TRIAL","name":"Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT01252017","description":"Patients Who Have Received Allo-HSCT","metadata":null},{"id":"1203efe97d8e4ea9862fba2630850e4a","type":"TRIAL","name":"Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase","canonical_id":"clinicaltrials.gov:NCT00905593","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"3f7bbb6dffd3485a8a3a1f835e515ff8","type":"TRIAL","name":"Nilotinib in Cognitively Impaired Parkinson Disease Patients 001","canonical_id":"clinicaltrials.gov:NCT02281474","description":"Parkinson's Disease; Parkinson's Disease Dementia; Diffuse Lewy Body Disease","metadata":null},{"id":"f43271d61be3474a93fd3d5f53076249","type":"TRIAL","name":"Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor","canonical_id":"clinicaltrials.gov:NCT01207492","description":"Pigmented Villonodular Synovitis; Diffuse-type Giant Cell Tumor; Tenosynovial Giant Cell Tumor","metadata":null},{"id":"39243569878746c389542580b3ad2035","type":"TRIAL","name":"Nilotinib in the Treatment of Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT01166139","description":"Systemic Sclerosis","metadata":null},{"id":"3bd01b8d296847be937b6ac51392ce8a","type":"TRIAL","name":"Nimodipine for Treating Acute Massive Cerebral Infarction","canonical_id":"clinicaltrials.gov:NCT02248233","description":"Cerebral Infarction","metadata":null},{"id":"3a39e730334745a0919fcfb4640344e5","type":"TRIAL","name":"Nimodipine in Vestibular Schwanommas","canonical_id":"clinicaltrials.gov:NCT04801953","description":"Vestibular Schwannoma","metadata":null},{"id":"12d1143af5ab4e3099a6fa6e9fc499a6","type":"TRIAL","name":"Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT","canonical_id":"clinicaltrials.gov:NCT01672801","description":"Unexplained Infertility; Polycystic Ovarian Syndrome; Anovulatory","metadata":null},{"id":"42781a08244e49c08387965bae72cdc8","type":"TRIAL","name":"Nintedanib (BIBF 1120) in Mesothelioma","canonical_id":"clinicaltrials.gov:NCT01907100","description":"Mesothelioma","metadata":null},{"id":"2b9daf2cc35a44e2813a16b38c30bc1e","type":"TRIAL","name":"Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02300298","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"bf00f5d3786145de8e31495242961021","type":"TRIAL","name":"Nintedanib Treatment in Unicentric Castleman Disease","canonical_id":"clinicaltrials.gov:NCT06643091","description":"Castleman Disease","metadata":null},{"id":"fb710a885b8f4e1bb415246dc58623d5","type":"TRIAL","name":"Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)","canonical_id":"clinicaltrials.gov:NCT01979952","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"e852d0de2ef045ebb5b4a42d8aad1576","type":"TRIAL","name":"Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)","canonical_id":"clinicaltrials.gov:NCT07583589","description":"Idiopathic Pulmonary Fibrosis (IPF)","metadata":null},{"id":"bbc305023f4b4a5580ec18fae72f9d37","type":"TRIAL","name":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03513484","description":"Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A; Fibroblast Growth Factor Basic Form Measurement; FLT3 Internal Tandem Duplication; Recurrent Adult Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"97f97fb8d7334f83995227f0486919f6","type":"TRIAL","name":"Nintedanib for Improving Reproductive Outcomes in Adenomyosis","canonical_id":"clinicaltrials.gov:NCT07162961","description":"Adenomyosis of Uterus","metadata":null},{"id":"cdf2618cd52240a3ad1d0a93217a5807","type":"TRIAL","name":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02299141","description":"Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer","metadata":null},{"id":"23fb384c166a4386b3c37c11ba9494b8","type":"TRIAL","name":"Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens","canonical_id":"clinicaltrials.gov:NCT01948141","description":"Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage III Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer","metadata":null},{"id":"c8eef601753347a3bf31c1419be60911","type":"TRIAL","name":"Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors","canonical_id":"clinicaltrials.gov:NCT02399215","description":"Carcinoid Tumor; Metastatic Carcinoid Tumor; Neuroendocrine Neoplasm","metadata":null},{"id":"bd8c7f36409d4dc981a0d11cb410b9d4","type":"TRIAL","name":"Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT01225887","description":"Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Squamous Cell Carcinoma; Endometrial Transitional Cell Carcinoma; Endometrial Undifferentiated Carcinoma; Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm; Recurrent Uterine Corpus Carcinoma","metadata":null},{"id":"1f42eb8acca244f997ea11178397007e","type":"TRIAL","name":"Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics","canonical_id":"clinicaltrials.gov:NCT02619162","description":"Breast Cancer","metadata":null},{"id":"b352cc33d0714e7e9e5a35e0fc6c0cc5","type":"TRIAL","name":"Nipocalimab in Moderate to Severe Sjogren's Disease","canonical_id":"clinicaltrials.gov:NCT06741969","description":"Sjogrens Syndrome","metadata":null},{"id":"b77c26aa0b4248daaba4866a2583367f","type":"DRUG","name":"Niraparib","canonical_id":"ncit:C80059","description":null,"metadata":null},{"id":"0328bec3e1c2404e9dbfbbde5aa23256","type":"TRIAL","name":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04584255","description":"Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; Breast Cancer; HER2-negative Breast Cancer; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; Deleterious PALB2 Gene Mutation","metadata":null},{"id":"f7d57d2d3f194710a2e9b18a8d4e8c28","type":"TRIAL","name":"Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma","canonical_id":"clinicaltrials.gov:NCT04716686","description":"Endometrial Carcinoma; Serous Carcinoma","metadata":null},{"id":"ca759c3b5ac94379961e16c7594c62a2","type":"TRIAL","name":"Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies","canonical_id":"clinicaltrials.gov:NCT03209401","description":"Solid Tumor, Adult; Homologous Recombination Deficiency","metadata":null},{"id":"2e50abbbdc28411189f1b63de2b7a1cd","type":"TRIAL","name":"Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression","canonical_id":"clinicaltrials.gov:NCT06180356","description":"Ovarian Cancer; Oligometastatic Disease; Serous Ovarian Tumor","metadata":null},{"id":"b79b0865c3c04f198652a5f827ee8956","type":"TRIAL","name":"Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor","canonical_id":"clinicaltrials.gov:NCT04734665","description":"Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor","metadata":null},{"id":"a3553f1040ec4fd59bea4c5dc6b7391f","type":"TRIAL","name":"Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers","canonical_id":"clinicaltrials.gov:NCT06365970","description":"MMR-D/MSI-H Colorectal Cancers","metadata":null},{"id":"41d6c50ea3d2442a8bb6acafdec8ca19","type":"TRIAL","name":"Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04502602","description":"Advanced Solid Tumor; Ovarian Cancer","metadata":null},{"id":"3cc602addcd44adeaf3af733ac4edf7e","type":"TRIAL","name":"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT04673448","description":"Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; BRCA-Associated Malignant Neoplasm; BRCA Hereditary Ovarian Carcinoma; Metastatic BRCA Hereditary Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Pancreatic Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage \u2026","metadata":null},{"id":"8eca441a2e2e4b7ea8eb82a86d82cbc3","type":"TRIAL","name":"Niraparib and Temozolomide in Patients Glioblastoma","canonical_id":"clinicaltrials.gov:NCT06258018","description":"Glioma, Malignant","metadata":null},{"id":"80d581421cc6423d9aae08d042c509ae","type":"TRIAL","name":"Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05442749","description":"Metastatic Pancreatic Cancer","metadata":null},{"id":"76405a901cc0498bab5ec5c55968d3fd","type":"TRIAL","name":"Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer","canonical_id":"clinicaltrials.gov:NCT04068753","description":"Recurrent Cervix Cancer; Progressive Cervix Cancer","metadata":null},{"id":"42dad881efbf474a969dcce0912ecab3","type":"PROTEIN","name":"Nischarin","canonical_id":"uniprot:Q9Y2I1","description":null,"metadata":null},{"id":"3a39458f302f4b6185a59dc3bec83dbb","type":"DRUG","name":"Nisoldipine","canonical_id":"mesh:D015737","description":null,"metadata":null},{"id":"71eed053f54d425aaebba6bf343bc9d1","type":"DRUG","name":"Nitazoxanide","canonical_id":"mesh:C041747","description":null,"metadata":null},{"id":"714769c6774a464f80c31cfdab2e8af2","type":"DRUG","name":"Nitisinone","canonical_id":"mesh:C077073","description":null,"metadata":null},{"id":"1439fe80547e4f97866e0a2d2087165b","type":"TRIAL","name":"Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria","canonical_id":"clinicaltrials.gov:NCT01390077","description":"Alkaptonuria","metadata":null},{"id":"e7eb9411f5154b5c87f300dab42ac04b","type":"TRIAL","name":"Nitisinone for Type 1B Oculocutaneous Albinism","canonical_id":"clinicaltrials.gov:NCT01838655","description":"Albinism; Vision Loss","metadata":null},{"id":"ac364ec3370344b38b5a5af9a2febd0c","type":"DRUG","name":"Nitric Oxide","canonical_id":"mesh:D009569","description":null,"metadata":null},{"id":"22308a2515ca4f42a306ba19fcc241a2","type":"TRIAL","name":"Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation","canonical_id":"clinicaltrials.gov:NCT00185887","description":"Fetal Distress","metadata":null},{"id":"b6ce5661d04b4c4f8143574858b2f8b4","type":"DRUG","name":"Nivolumab","canonical_id":"ncit:C68814","description":null,"metadata":null},{"id":"3bb5eb829c5445d39cecefe8c43848a5","type":"TRIAL","name":"Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers","canonical_id":"clinicaltrials.gov:NCT03785210","description":"Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis","metadata":null},{"id":"431fe899107c47d1b663b56bb5ad2db3","type":"TRIAL","name":"Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04377048","description":"Stage IV Pancreatic Cancer","metadata":null},{"id":"13628204781a45d7a5f1a4e92f362312","type":"TRIAL","name":"Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03521830","description":"Basal Cell Carcinoma","metadata":null},{"id":"33d09c1417a34f52bc90c1c2ce891448","type":"TRIAL","name":"Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide","canonical_id":"clinicaltrials.gov:NCT03184194","description":"Myeloma","metadata":null},{"id":"8f5160c98970444cb772730e17da1096","type":"TRIAL","name":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","canonical_id":"clinicaltrials.gov:NCT04552223","description":"Metastatic Uveal Melanoma","metadata":null},{"id":"99741f81850b4189a70e8de7a5282006","type":"TRIAL","name":"Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression","canonical_id":"clinicaltrials.gov:NCT03724968","description":"Metastatic Melanoma; Advanced Melanoma; Metastatic Melanoma Stratified by MHC-II Expression","metadata":null},{"id":"3c2f10d4635a41bc952c008a16a9e867","type":"TRIAL","name":"Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03023527","description":"Multiple Myeloma","metadata":null},{"id":"3556077d9cd143828d92a8ea831bbd33","type":"TRIAL","name":"Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery","canonical_id":"clinicaltrials.gov:NCT04177953","description":"Pleural Mesothelioma Malignant","metadata":null},{"id":"9b29ee1fac86425b9573186212cfb334","type":"TRIAL","name":"Nivolumab With Chemotherapy in Refractory MDS","canonical_id":"clinicaltrials.gov:NCT03259516","description":"Myelodysplastic Syndromes","metadata":null},{"id":"8054ea2c338242b785d3e9777b803e94","type":"TRIAL","name":"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)","canonical_id":"clinicaltrials.gov:NCT02973113","description":"NonHodgkin Lymphoma; Lymphoproliferative Disorders; EBV Related Lymphoma; EBV-Related PTLD; Hodgkin Lymphoma; EBV Related Non-Hodgkin's Lymphoma; EBV Related Hodgkin's Lymphoma","metadata":null},{"id":"a1939fb590874cf1a9ba6698cc9ebba9","type":"TRIAL","name":"Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome","canonical_id":"clinicaltrials.gov:NCT03767439","description":"Basal Cell Nevus Syndrome","metadata":null},{"id":"d790b2bfcb214f06a853302e2d981ec7","type":"TRIAL","name":"Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer","canonical_id":"clinicaltrials.gov:NCT04965714","description":"Resectable Hepatocellular Carcinoma","metadata":null},{"id":"26ee12901a54453da18d19f88691b1fe","type":"TRIAL","name":"Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)","canonical_id":"clinicaltrials.gov:NCT03689699","description":"Prostate Cancer; Adenocarcinoma of the Prostate","metadata":null},{"id":"9d9fadf1654d46e6bcef9f9e726c1568","type":"TRIAL","name":"Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02758717","description":"Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma","metadata":null},{"id":"e2fdcac40e6b46de9e16f5a564c6585e","type":"TRIAL","name":"Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation","canonical_id":"clinicaltrials.gov:NCT02420912","description":"Loss of Chromosome 17p; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome","metadata":null},{"id":"c93c985270ee4e0a95bcc1466ff16fac","type":"TRIAL","name":"Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer","canonical_id":"clinicaltrials.gov:NCT03146650","description":"Major Salivary Gland Carcinoma; Minor Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVC Major Salivary Gland Carcinoma","metadata":null},{"id":"7aef6c76df8e49c58918bd17732c2878","type":"TRIAL","name":"Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma","canonical_id":"clinicaltrials.gov:NCT03623854","description":"Chordoma; Locally Advanced Chordoma; Metastatic Chordoma; Unresectable Chordoma","metadata":null},{"id":"467da506e99f4deea7f1b9430617a513","type":"TRIAL","name":"Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin","canonical_id":"clinicaltrials.gov:NCT04204837","description":"Squamous Cell Carcinoma of the Skin","metadata":null},{"id":"c2e673da7a1141bd96d57733607e0e5f","type":"TRIAL","name":"Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes","canonical_id":"clinicaltrials.gov:NCT04187833","description":"Metastatic or Unresectable Melanoma","metadata":null},{"id":"0d7028bd5c134063abd1b04b402df101","type":"TRIAL","name":"Nivolumab+Ipilimumab+RT in MSS mCRC","canonical_id":"clinicaltrials.gov:NCT04575922","description":"Metastatic Microsatellite Stable Colorectal Cancer","metadata":null},{"id":"d0d40d88145f49f6a4e0f309a5dee192","type":"TRIAL","name":"Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na\u00efve to Prior Immunotherapy in the Metastatic Setting","canonical_id":"clinicaltrials.gov:NCT03743766","description":"Melanoma","metadata":null},{"id":"7d2fde57267441bc8fe58005a67cb972","type":"TRIAL","name":"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03468985","description":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7","metadata":null},{"id":"6b40130f27ea42dab9b4c035c69022d7","type":"DISEASE","name":"Nizon-Isidor syndrome","canonical_id":"mondo:0030030","description":null,"metadata":null},{"id":"31e159a6140a4113b9b1e4b8408200d4","type":"GO_TERM","name":"Nkx-2.5 complex","canonical_id":"go:GO:1990664","description":"\"A transcription factor complex formed by two or more subunits of Nkx-2.5. Nkx-2.5 is an evolutionary conserved transcription factor important for the specification and differentiation of cardiomyocytes during heart development. It is also required for spleen development. It binds DNA either as a monomer, or a homodimer, or a heterodimer complex to activate or inhibit expression of genes.\" [GOC:ame, PMID:22849347]","metadata":null},{"id":"1ae41fe8bfb54ef1ba21158664493abf","type":"TRIAL","name":"No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track","canonical_id":"clinicaltrials.gov:NCT06966674","description":"No-Reflow; STEMI; Intracoronary; Tirofiban","metadata":null},{"id":"c276823667b1407e902e75e198d8d118","type":"GO_TERM","name":"NoRC complex","canonical_id":"go:GO:0090536","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (specifically SNF2H in mammals, which contain two ISWI homologs) and a Tip5 homolog. In mammals, NoRC is involved in regulation of transcription from RNAP I and RNA polymerase III promoters.\" [GOC:krc]","metadata":null},{"id":"df5c16ae58de4a66b9ad9ef214c0eabf","type":"GO_TERM","name":"Noc complex","canonical_id":"go:GO:0030689","description":"\"Any of several heterodimers containing one or two Noc proteins, associated with preribosomal complexes; involved in ribosome biogenesis.\" [PMID:12446671]","metadata":null},{"id":"b55d8d3481484b768b6082a01095437d","type":"GO_TERM","name":"Noc1p-Noc2p complex","canonical_id":"go:GO:0030690","description":"\"A heterodimer associated with 90S and 66S preribosomes. Predominantly, but not exclusively, nucleolar; involved in ribosomal large subunit biogenesis.\" [PMID:12446671]","metadata":null},{"id":"361d0d810a20454cacd502bb53beb0b3","type":"GO_TERM","name":"Noc2p-Noc3p complex","canonical_id":"go:GO:0030691","description":"\"A heterodimer associated with 66S preribosomes; predominantly nucleoplasmic, but also locates to the nucleolus; involved in ribosomal large subunit biogenesis.\" [PMID:12446671]","metadata":null},{"id":"a0b8441b8ead4103ab8f9a5248392e15","type":"GO_TERM","name":"Noc4p-Nop14p complex","canonical_id":"go:GO:0030692","description":"\"A heterodimer associated with precursors of the eukaryotic small ribosomal subunit, including the 90S preribosome; involved in small subunit biogenesis.\" [PMID:12446671]","metadata":null},{"id":"ca00935dce504dfdae71eee652b17d5c","type":"DISEASE","name":"Nocardia Infections","canonical_id":"mesh:D009617","description":null,"metadata":null},{"id":"059c8e8c787e4461bf78f8b531109831","type":"DISEASE","name":"Nocturia","canonical_id":"mesh:D053158","description":null,"metadata":null},{"id":"d5f34b391a45425585d42e9cefe53f01","type":"DISEASE","name":"Nocturnal enuresis","canonical_id":"mesh:D053206","description":null,"metadata":null},{"id":"831ca854437a4c2b88d193bce933abf4","type":"TRIAL","name":"Non Motors Aspects in De Novo Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02786667","description":"Parkinson Disease; Apathy","metadata":null},{"id":"b03ec44f80eb4e2293abc8d13c7b7393","type":"DISEASE","name":"Non-Hodgkin's lymphoma","canonical_id":"mesh:D008228","description":null,"metadata":null},{"id":"9e270c9a91454644b089959305592feb","type":"TRIAL","name":"Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT06718062","description":"Hypertension,Essential; Hyperuricemia","metadata":null},{"id":"0dc2ce97b50440499008221f95d33af7","type":"TRIAL","name":"Non-Interventional Study Of Celsentri\u00ae In Treatment Experienced Patients With CCR5-Tropic HIV-Infection","canonical_id":"clinicaltrials.gov:NCT00850395","description":"HIV-1","metadata":null},{"id":"eb9e5bd6fa224f70b49d685e8ac4cdfa","type":"TRIAL","name":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","canonical_id":"clinicaltrials.gov:NCT02989649","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"4576775d24334011bb44504bcd7cd554","type":"TRIAL","name":"Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","canonical_id":"clinicaltrials.gov:NCT06669299","description":"Ventricular Tachycardia (VT)","metadata":null},{"id":"7e1165896124434fbd3cd5324cca75b6","type":"TRIAL","name":"Non-Narcotic Pain Control After ACL Reconstruction","canonical_id":"clinicaltrials.gov:NCT06973785","description":"ACL - Anterior Cruciate Ligament Rupture; ACL Injuries","metadata":null},{"id":"58c832dd8a964515ae07aa5230068a7a","type":"TRIAL","name":"Non-alcoholic Fatty Liver Disease and Its Treatment","canonical_id":"clinicaltrials.gov:NCT05480007","description":"NAFLD","metadata":null},{"id":"752e55d5214848d7bd6ac7227a9ec304","type":"TRIAL","name":"Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04301414","description":"Prostate Cancer","metadata":null},{"id":"802badd1917a4c62941c4dbf1d4a584b","type":"TRIAL","name":"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT05090449","description":"Healthy","metadata":null},{"id":"146f494df554417bbde7828af867d862","type":"TRIAL","name":"Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation","canonical_id":"clinicaltrials.gov:NCT01894035","description":"Pulmonary Hypertension","metadata":null},{"id":"b6d81ed43632438088f0b16682f7aee1","type":"TRIAL","name":"Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction","canonical_id":"clinicaltrials.gov:NCT01590537","description":"Contraception","metadata":null},{"id":"b9a2e7a07239400ab85190c893280d4f","type":"TRIAL","name":"Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07827586","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"8c61ac7991d7422592eee5ab7261623c","type":"TRIAL","name":"Non-interventional Study of Therapy for Threatened Miscarriage","canonical_id":"clinicaltrials.gov:NCT03309735","description":"Threatened Miscarriage","metadata":null},{"id":"65dd4601888242d1bd4b29734af962ca","type":"TRIAL","name":"Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia","canonical_id":"clinicaltrials.gov:NCT06930859","description":"Breast Cancer","metadata":null},{"id":"0ab71b980def42df81c6cb18ab4a5167","type":"TRIAL","name":"Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT02825160","description":"Hypertension, Pulmonary","metadata":null},{"id":"a238f3c970ea40639efd8d149e97c7c9","type":"TRIAL","name":"Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01452217","description":"Chronic Pancreatitis","metadata":null},{"id":"ca0bce0a14ea40829890678afde07c8e","type":"TRIAL","name":"Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.","canonical_id":"clinicaltrials.gov:NCT01882530","description":"Post Operative Analgesia","metadata":null},{"id":"46f827109e6c4c65b07bbefc380d1ba5","type":"TRIAL","name":"Non-opioid Based Pain Control After Thyroidectomy","canonical_id":"clinicaltrials.gov:NCT03988075","description":"Pain; Thyroidectomy","metadata":null},{"id":"edd042a9a72d42daa4f31a5a9733fbb1","type":"DISEASE","name":"Non-small cell lung cancer","canonical_id":"mesh:D002289","description":null,"metadata":null},{"id":"6f415b6975b148ea9c8988dced3dfb2f","type":"TRIAL","name":"Non-steroidal Anti-inflammatory Drugs in Pleurodesis","canonical_id":"clinicaltrials.gov:NCT06731647","description":"Non-steroidal Anti-inflammatory Drugs; Pleurodesis; Pneumothorax; Pain Management","metadata":null},{"id":"93c0a132108d485a8ba338306cae8ffc","type":"TRIAL","name":"Non-surgical Interventions for Infertility in Endometriosis","canonical_id":"clinicaltrials.gov:NCT06560814","description":"Endometriosis; Infertility, Female","metadata":null},{"id":"9a432ce59b154f1caf60832fca01e38a","type":"TRIAL","name":"NonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow","canonical_id":"clinicaltrials.gov:NCT06373978","description":"Elbow Pain; Chronic Pain","metadata":null},{"id":"637d1b7c961946dfb159a9e273bb404f","type":"DISEASE","name":"Noninfectious Uveitis","canonical_id":"mesh:D014605","description":null,"metadata":null},{"id":"32df486204ed4e94abdd887dc4d37f92","type":"TRIAL","name":"Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases","canonical_id":"clinicaltrials.gov:NCT02991157","description":"Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"0e6bb15932dc41e69afd697ca421ad18","type":"TRIAL","name":"Noninvasive Markers of Functional Nausea in Children","canonical_id":"clinicaltrials.gov:NCT03593811","description":"Nausea","metadata":null},{"id":"605d7c7fd37a45c99fcedaecbeb74a5c","type":"DISEASE","name":"Nonmetastatic prostate cancer","canonical_id":"mesh:D011471","description":null,"metadata":null},{"id":"66121434d55f4e159e587b4ce2752f68","type":"TRIAL","name":"Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT03077542","description":"Sickle Cell Disease","metadata":null},{"id":"cc15443d50e64a4e8db9347acd7c0a9f","type":"TRIAL","name":"Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure","canonical_id":"clinicaltrials.gov:NCT02105766","description":"Sickle Cell Disease; Thalassemia; Stem Cell Transplantation; Graft vs Host Disease","metadata":null},{"id":"67234ca2990e4a8f9a1e144ba591f3eb","type":"TRIAL","name":"Nonopioid Analgesia After Arthroscopic Meniscus Surgery","canonical_id":"clinicaltrials.gov:NCT03820193","description":"Meniscus Disorder; Narcotic Use","metadata":null},{"id":"754661f827174603a0d2e5abf5078da5","type":"TRIAL","name":"Nonopioid Analgesia After Labral Surgery","canonical_id":"clinicaltrials.gov:NCT03825809","description":"Narcotic Use","metadata":null},{"id":"9b9b1274b2aa45f5a65b73e0534b83da","type":"TRIAL","name":"Nonopioid Analgesia After Rotator Cuff Repair","canonical_id":"clinicaltrials.gov:NCT03818919","description":"Rotator Cuff Tear","metadata":null},{"id":"18440923303c41a0bd3a5d25327ed565","type":"PROTEIN","name":"Nonstructural protein 5A","canonical_id":"uniprot:Q5L478","description":null,"metadata":null},{"id":"8de8f773f0224c2faa5eb7ced5443078","type":"PROTEIN","name":"Nonstructural protein 5b","canonical_id":"uniprot:P87764","description":null,"metadata":null},{"id":"a723f0e9f6bf49bf866bedc2146a2705","type":"DISEASE","name":"Noonan syndrome","canonical_id":"mondo:0018997","description":null,"metadata":null},{"id":"bd0b48971131439eb97ef68650cd6d01","type":"DISEASE","name":"Noonan syndrome","canonical_id":"mesh:D009634","description":null,"metadata":null},{"id":"e99566d0ff4d44169936e9b626103d43","type":"DISEASE","name":"Noonan syndrome 3","canonical_id":"mondo:0012371","description":null,"metadata":null},{"id":"e77c00fc866a4e5a94f233853679665f","type":"DISEASE","name":"Noonan syndrome 7","canonical_id":"mondo:0013379","description":null,"metadata":null},{"id":"8a8dc387b99e4525a065fc71d0492a84","type":"DISEASE","name":"Noonan syndrome with multiple lentigines","canonical_id":"mondo:0007893","description":null,"metadata":null},{"id":"a72ab77006444432bd809601308ad017","type":"TRIAL","name":"Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans","canonical_id":"clinicaltrials.gov:NCT03957174","description":"Healthy","metadata":null},{"id":"27a59c748b224aae80f568b6ee76acb8","type":"TRIAL","name":"Noradrenergic Activity, Cognition and Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT02470026","description":"Major Depressive Disorder; Early Life Trauma","metadata":null},{"id":"1f85bde114af4a3d9d2ac1be6ee7acfb","type":"TRIAL","name":"Noradrenergic Add-on Therapy With Guanfacine","canonical_id":"clinicaltrials.gov:NCT03116126","description":"Alzheimer Disease","metadata":null},{"id":"d9c1fffd4f3249599e1cd2be974cb7a2","type":"TRIAL","name":"Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery","canonical_id":"clinicaltrials.gov:NCT03702400","description":"Hypotension; Spinal Anesthesia","metadata":null},{"id":"521b6d0544a74f69b4bfbbcd5b304d12","type":"TRIAL","name":"Norepinephrine-targeted Therapy for Action Control in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT03115827","description":"Parkinson Disease","metadata":null},{"id":"b1fccfc23b904ea88fe47712bf8c6ed6","type":"DRUG","name":"Norethindrone acetate","canonical_id":"mesh:C024262","description":null,"metadata":null},{"id":"f8087755c8474d66bf06c8e4c82e6a65","type":"DRUG","name":"Norgestimate","canonical_id":"mesh:C017576","description":null,"metadata":null},{"id":"b86773b63805435aa0432f28c3233253","type":"DRUG","name":"Norgestrel","canonical_id":"mesh:D009644","description":null,"metadata":null},{"id":"780bd2e5d5fc4858bd2adb3a5478be65","type":"GO_TERM","name":"Norrin signaling pathway","canonical_id":"go:GO:0110135","description":"\"The series of molecular signals initiated by binding of the cysteine knot protein Norrin to a Frizzled 4 (Fzd4) family receptor on the surface of the target cell and ending with a change in cell state.\" [GOC:BHF, GOC:rl, PMID:15035989, PMID:17955262]","metadata":null},{"id":"d70472ad9353403587784befbcc0d8cd","type":"TRIAL","name":"North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)","canonical_id":"clinicaltrials.gov:NCT01408030","description":"Telangiectasia, Hereditary Hemorrhagic; Epistaxis","metadata":null},{"id":"c31dec077a714c1daa6db1eae31b5185","type":"TRIAL","name":"Nortriptyline Compared With Amitriptyline for Migraine Prevention at SQUH","canonical_id":"clinicaltrials.gov:NCT07856056","description":"Migraine","metadata":null},{"id":"9eb861a4122d4631bbc929a3f80b01c2","type":"TRIAL","name":"Nortriptyline and the Risk of Serious Adverse Events","canonical_id":"clinicaltrials.gov:NCT07527481","description":"Chronic Kidney Disease","metadata":null},{"id":"2824d29eaacc45a9b54f0bd57e175270","type":"TRIAL","name":"Nortriptyline for Idiopathic Gastroparesis","canonical_id":"clinicaltrials.gov:NCT00765895","description":"Idiopathic Gastroparesis","metadata":null},{"id":"37c6b386abd4423481fc86a166ff0cb9","type":"TRIAL","name":"Nortriptyline for the Treatment of Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT03652571","description":"Functional Dyspepsia","metadata":null},{"id":"f1612037a6664316b38beeac6ae8876d","type":"DISEASE","name":"Nosocomial pneumonia","canonical_id":"mesh:D000077299","description":null,"metadata":null},{"id":"c052f8a4c25f45ffbbef4ed1e1e775c3","type":"GO_TERM","name":"Notch binding","canonical_id":"go:GO:0005112","description":"\"Binding to a Notch (N) protein, a surface receptor.\" [GOC:ceb]","metadata":null},{"id":"97bba98db1f846f8a810c0ebf3a93307","type":"GO_TERM","name":"Notch receptor processing","canonical_id":"go:GO:0007220","description":"\"The series of successive proteolytic cleavages of the Notch protein, which result in an active form of the receptor.\" [PMID:12651094, PMID:14986688]","metadata":null},{"id":"b4389418037746b6962f8c411293e2a3","type":"GO_TERM","name":"Notch receptor processing, ligand-dependent","canonical_id":"go:GO:0035333","description":"\"The proteolytic cleavages to the Notch protein that occur as a result of ligand binding. Ligand binding at the cell surface exposes an otherwise inaccessible cleavage site in the extracellular portion of Notch, which when cleaved releases a membrane-tethered form of the Notch intracellular domain. Subsequent cleavage within the transmembrane domain then leads to the release of the soluble Notch intracellular domain (NICD).\" [GOC:bf, PMID:12651094]","metadata":null},{"id":"6732656511a444acbcfe2300ea6df421","type":"GO_TERM","name":"Notch receptor processing, ligand-independent","canonical_id":"go:GO:0035334","description":"\"The proteolytic cleavages to the Notch protein that occur prior to ligand binding. A primary cleavage event within the extracellular domain whilst the Notch protein in still in the secretory pathway, leads to the transportation of a processed heterodimer to the cell surface.\" [GOC:bf, PMID:12651094]","metadata":null},{"id":"49ad9d808b2e4ad58e922a8fa8ada33c","type":"GO_TERM","name":"Notch signaling involved in heart development","canonical_id":"go:GO:0061314","description":"\"The series of molecular signals initiated by binding of an extracellular ligand to a Notch receptor on the surface of the target cell and contributing to the progression of the heart over time.\" [GOC:mtg_heart]","metadata":null},{"id":"f09fe3aebfd249cba76776995c6b1995","type":"GO_TERM","name":"Notch signaling pathway","canonical_id":"go:GO:0007219","description":"\"The series of molecular signals initiated by an extracellular ligand binding to the receptor Notch on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:curators, GOC:signaling]","metadata":null},{"id":"077fe88f7ab14102a7d1963fcce390e1","type":"GO_TERM","name":"Notch signaling pathway involved in arterial endothelial cell fate commitment","canonical_id":"go:GO:0060853","description":"\"The series of molecular signals initiated by binding of an extracellular ligand to a Notch receptor on the surface of the target cell and contributing to the commitment of a cell to an arterial endothelial cell fate.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"c3eedf973320458bbc62b2c97ad4a8db","type":"GO_TERM","name":"Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation","canonical_id":"go:GO:0003270","description":"\"The series of molecular signals initiated by binding of an extracellular ligand to a Notch receptor on the surface of the target cell contributing to the modulation of the frequency, rate or extent of cardioblast proliferation in the secondary heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"5ab8846d1bca4d79abb28a47e160d753","type":"TRIAL","name":"Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies","canonical_id":"clinicaltrials.gov:NCT02343679","description":"Hematologic Malignancies","metadata":null},{"id":"f3e59e58e60c4dd2b9e74593173081f2","type":"TRIAL","name":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","canonical_id":"clinicaltrials.gov:NCT04374019","description":"COVID; Sars-CoV2","metadata":null},{"id":"50ae25cbcca14fc6a9120e10e8eef900","type":"TRIAL","name":"Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)","canonical_id":"clinicaltrials.gov:NCT05946148","description":"Non-Alcoholic Fatty Liver Disease; Liver Steatosis","metadata":null},{"id":"5bc44b59f5864aed8cd69bbc64d819cf","type":"TRIAL","name":"Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening","canonical_id":"clinicaltrials.gov:NCT04675788","description":"Long QT Syndrome; Abnormalities, Drug-Induced","metadata":null},{"id":"fd918c3c21c443aebe50af02dcccec38","type":"TRIAL","name":"Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients","canonical_id":"clinicaltrials.gov:NCT01465503","description":"Bleeding","metadata":null},{"id":"64657a0ca1644b9aa0cf08ad47ce8598","type":"TRIAL","name":"Novel Combination Therapy for Osteoporosis in Men","canonical_id":"clinicaltrials.gov:NCT03994172","description":"Male Osteoporosis","metadata":null},{"id":"cf18f520f939430bbb5d14a84f5ded59","type":"TRIAL","name":"Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05002816","description":"Multiple Myeloma","metadata":null},{"id":"90533175a2f0467d97fbe3e21efb8ec7","type":"TRIAL","name":"Novel Desensitization Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT05345717","description":"Kidney Transplantation; End Stage Kidney Disease (ESRD)","metadata":null},{"id":"05a6d8440a1043118112279bafa7c52b","type":"TRIAL","name":"Novel Dose Escalation to Predict Treatment With Hydroxyurea","canonical_id":"clinicaltrials.gov:NCT02042222","description":"Sickle Cell Disease","metadata":null},{"id":"004ea60bf86b4faf8bf485bd27c1d6fd","type":"TRIAL","name":"Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT04392960","description":"AL Amyloidosis","metadata":null},{"id":"ffbc8ca819684534b275914d24ad551a","type":"TRIAL","name":"Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids","canonical_id":"clinicaltrials.gov:NCT00746031","description":"Fibroid; Leiomyoma","metadata":null},{"id":"b1a03260fbe04a95a59d29e60f17f2c1","type":"TRIAL","name":"Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06265077","description":"Breast Cancer; Filgrastim Adverse Reaction","metadata":null},{"id":"090bbbd2edb44afeae7b37e332077be3","type":"TRIAL","name":"Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04069273","description":"Gastric Cancer; GastroEsophageal Cancer; Adenocarcinoma","metadata":null},{"id":"ee98040d21794633b346935dc10a5cf7","type":"TRIAL","name":"Novel Topical Therapies for the Treatment of Genital Pain","canonical_id":"clinicaltrials.gov:NCT02099006","description":"Female Genital Diseases","metadata":null},{"id":"43bc47e503224bcd9a7fbc30b26c5d3f","type":"TRIAL","name":"Novel Treatment for Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT01228214","description":"Coronary Artery Disease","metadata":null},{"id":"0e4751251fc14197b0311f6cb1197d74","type":"TRIAL","name":"Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01553318","description":"Fibromyalgia","metadata":null},{"id":"42e7bf33198143cfb7e243c8603e91e2","type":"TRIAL","name":"Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal","canonical_id":"clinicaltrials.gov:NCT04939623","description":"Chronic Pain; Drug Dependence of Morphine Type; Symptom, Withdrawal","metadata":null},{"id":"ffae06bc3a6d4e39bc256ea949dcb690","type":"GO_TERM","name":"Nrd1 complex","canonical_id":"go:GO:0035649","description":"\"A complex that functions in transcription termination of RNA polymerase II transcribed non-coding RNAs. This complex interacts with the carboxy-terminal domain (CTD) of PolII and the terminator sequences in the nascent RNA transcript. In yeast this complex consists of Nrd1p, Nab3p, and Sen1p.\" [GOC:jh, PMID:10655211, PMID:16427013, PMID:21084293]","metadata":null},{"id":"14c4c83956ca4d93b3597564ea1ad0b1","type":"GO_TERM","name":"Nsk1-Dlc1 complex","canonical_id":"go:GO:0044816","description":"\"A dimer of Nsk1 (nucleolus spindle kinetochore 1) and the dynein light chain, Dlc1. The dimers form an oligomeric chain structure. Functions in the regulation of kinetochore-microtubule interactions and chromosome segregation.\" [GOC:vw, PMID:22065639]","metadata":null},{"id":"c0c2989d50c64917a4a06c393e6445f4","type":"GO_TERM","name":"NuA3 histone acetyltransferase complex","canonical_id":"go:GO:0033100","description":"\"A Gcn5-independent multisubunit complex that catalyzes the acetylation of histone H3. The budding yeast complex includes Sas3p, Taf30p, and Yng1p.\" [PMID:10817755, PMID:17157260]","metadata":null},{"id":"9aaf4f73b8d44f9785cfa166a0d5961c","type":"GO_TERM","name":"NuA3a histone acetyltransferase complex","canonical_id":"go:GO:1990467","description":"\"A NuA3 complex that catalyzes the acetylation of Histone H3. In S. cerevisiae, this complex consists of Eaf6p, Nto1p, Sas3p, Taf14p, Yng1p and associates with H3K4me3 using Yng1p.\" [GOC:rb, PMID:25104842]","metadata":null},{"id":"cc845c7cc2b14cd980789b4b441cb7ad","type":"GO_TERM","name":"NuA3b histone acetyltransferase complex","canonical_id":"go:GO:1990468","description":"\"A NuA3 complex that catalyzes the acetylation of Histone H3. In S. cerevisiae, this complex consists of Eaf6p, Nto1p, Sas3p, Taf14p, Pdp3 and associates with H3K4me3 via Pdp3p.\" [GOC:rb, PMID:25104842]","metadata":null},{"id":"6f84e62c5f904709afa9222f9ab4966a","type":"GO_TERM","name":"NuA4 histone acetyltransferase complex","canonical_id":"go:GO:0035267","description":"\"A complex having histone acetylase activity on chromatin, as well as ATPase, DNA helicase and structural DNA binding activities. The complex is thought to be involved in double-strand DNA break repair. Subunits of the human complex include HTATIP/TIP60, TRRAP, RUVBL1, BUVBL2, beta-actin and BAF53/ACTL6A. In yeast, the complex has 13 subunits, including the catalytic subunit Esa1 (homologous to human Tip60).\" [GOC:ecd, PMID:10966108, PMID:14966270]","metadata":null},{"id":"64f25f9a147f4330ac48d17a996a4b40","type":"GO_TERM","name":"NuA4 histone acetyltransferase complex binding","canonical_id":"go:GO:0062060","description":"\"Binding to a NuA4 histone acetyltransferase complex.\" [PMID:15528408]","metadata":null},{"id":"78614f50bfa44d0bbafbfd8196bbfc27","type":"GO_TERM","name":"NuRD complex","canonical_id":"go:GO:0016581","description":"\"An approximately 2 MDa multi-subunit complex that exhibits ATP-dependent chromatin remodeling activity in addition to histone deacetylase (HDAC) activity, and has been shown to establish transcriptional repression of a number of target genes in vertebrates, invertebrates and fungi. Amongst its subunits, the NuRD complex contains histone deacetylases, histone binding proteins and Mi-2-like proteins.\" [PMID:10589671, PMID:11743021, PMID:17289569]","metadata":null},{"id":"e80f15258093450b8068bdcaf6cba931","type":"GO_TERM","name":"NuRD complex binding","canonical_id":"go:GO:0120325","description":"\"Binding to a NuRD complex.\" [GOC:krc, GOC:lb, PMID:25150861]","metadata":null},{"id":"794c504abe304084bb7ab47e711a5ccc","type":"DRUG","name":"Nusinersen","canonical_id":"mesh:C000590926","description":null,"metadata":null},{"id":"6271a37642eb462d88f94154927c349c","type":"TRIAL","name":"Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2","canonical_id":"clinicaltrials.gov:NCT02278562","description":"ESRD","metadata":null},{"id":"e8c389662a244ec985e426fccea527bf","type":"TRIAL","name":"Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation","canonical_id":"clinicaltrials.gov:NCT07554885","description":"Immune Checkpoint Inhibitor-Related Pneumonitis; Drug-Related Side Effects and Adverse Reactions; Neoplasms","metadata":null},{"id":"091242a372884f509cf08859f47e22cb","type":"TRIAL","name":"Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention","canonical_id":"clinicaltrials.gov:NCT00723398","description":"Breast Cancer","metadata":null},{"id":"a3700a7bfc9340bbb28474e3eab14d90","type":"TRIAL","name":"Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects","canonical_id":"clinicaltrials.gov:NCT05223478","description":"Mydriasis; Dilation","metadata":null},{"id":"e3f8342b8c694254880a9d802aed8760","type":"GO_TERM","name":"O antigen biosynthetic process","canonical_id":"go:GO:0009243","description":"\"The chemical reactions and pathways resulting in the formation of the O side chain of a lipopolysaccharide, which determines the antigenic specificity of the organism. It is made up of about 50 repeating units of a branched tetrasaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"a9233995300446caa61272292a12c51b","type":"GO_TERM","name":"O antigen polymerase activity","canonical_id":"go:GO:0008755","description":"\"Catalysis of the polymerization of o-antigen chains. O-antigens are tetra- and pentasaccharide repeat units of the cell walls of Gram-negative bacteria and are a component of lipopolysaccharide.\" [GOC:jl, PMID:12045108]","metadata":null},{"id":"bff64932da354f6fa28d6d8cee03184f","type":"GO_TERM","name":"O-acetyl-ADP-ribose deacetylase activity","canonical_id":"go:GO:0061463","description":"\"Catalysis of the reaction O-acetyl-ADP-ribose + H2O = ADP-ribose + acetate. Removes the acetyl group from either the 2'' or 3'' position of O-acetyl-ADP-ribose.\" [EC:3.1.1.106]","metadata":null},{"id":"f613e500ee584a18abf08e07a081460f","type":"GO_TERM","name":"O-acetylhomoserine aminocarboxypropyltransferase activity","canonical_id":"go:GO:0003961","description":"\"Catalysis of the reaction: O-acetyl-L-homoserine + methanethiol = L-methionine + acetate. Also reacts with other thiols and H2S, producing homocysteine or thioethers.\" [EC:2.5.1.49]","metadata":null},{"id":"2d399cbfc5664a83923c02964260a974","type":"GO_TERM","name":"O-acetylhomoserine sulfhydrylase activity","canonical_id":"go:GO:0051009","description":"\"Catalysis of the reaction: O-acetyl-L-homoserine + hydrogen sulfide = homocysteine + acetate.\" [MetaCyc:ACETYLHOMOSER-CYS-RXN, RHEA:27822]","metadata":null},{"id":"cb20d492c6de47fda874e52b1c595cc9","type":"GO_TERM","name":"O-acetyltransferase activity","canonical_id":"go:GO:0016413","description":"\"Catalysis of the transfer of an acetyl group to an oxygen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"bef27d3ccea44883bc123bcdf1e4f76e","type":"GO_TERM","name":"O-acyl-L-carnitine transmembrane transport","canonical_id":"go:GO:1902616","description":"\"The process in which O-acyl-L-carnitine is transported across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"ab8d77295e38474d9ca5b33a247c4f69","type":"GO_TERM","name":"O-acyl-L-carnitine transmembrane transporter activity","canonical_id":"go:GO:0015227","description":"\"Enables the transfer of O-acyl-L-carnitine from one side of a membrane to the other. O-acyl-L-carnitine is the condensation product of a carboxylic acid and carnitine and is the transport form for a fatty acid crossing the mitochondrial membrane.\" [GOC:ai]","metadata":null},{"id":"6f90cf45d4e84dc1a108e9c079f1b3d7","type":"GO_TERM","name":"O-antigen ligase activity","canonical_id":"go:GO:0008754","description":"\"Catalysis of the reaction: a lipid-linked O antigen + a lipid A-core oligosaccharide = a lipopolysaccharide + a polyisoprenyl diphosphate.\" [EC:2.4.99.26]","metadata":null},{"id":"02fdba062f2645f4a31af62596e25d14","type":"GO_TERM","name":"O-demethylpuromycin O-methyltransferase activity","canonical_id":"go:GO:0030739","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + O-demethylpuromycin = S-adenosyl-L-homocysteine + puromycin.\" [EC:2.1.1.38]","metadata":null},{"id":"9f2def13500148b09c68dafbd3992bfb","type":"GO_TERM","name":"O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0033829","description":"\"Catalysis of the transfer of a beta-D-GlcNAc residue from UDP-D-GlcNAc to the fucose residue of a fucosylated protein acceptor.\" [EC:2.4.1.222]","metadata":null},{"id":"6101bb16aedf4dd5b2fd962a81e9a2f3","type":"GO_TERM","name":"O-fucosylpeptide 3-beta-glucosyltransferase activity","canonical_id":"go:GO:0160265","description":"\"Catalysis of the transfer of a alpha-D-glucose residue from UDP-alpha-D-glucose to the fucose residue of a fucosylated protein acceptor.\" [PMID:16899492]","metadata":null},{"id":"96bbd501451e4088a846638c8fc2ef75","type":"GO_TERM","name":"O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0050737","description":"\"Catalysis of the transfer of a hydroxycinnamoyl group to an oxygen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"08fe4676fdcc4d6b8670db8b8c4f8a8b","type":"GO_TERM","name":"O-linoleoyltransferase activity","canonical_id":"go:GO:0032576","description":"\"Catalysis of the transfer of a linoleoyl ((9Z,12Z)-octadeca-9,12-dienoyl) group to an oxygen atom on the acceptor molecule.\" [GOC:cb]","metadata":null},{"id":"a9509961df14465cbe9827591ff26612","type":"GO_TERM","name":"O-malonyltransferase activity","canonical_id":"go:GO:0050736","description":"\"Catalysis of the transfer of a malonyl group to an oxygen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"70cca40d84064a6786aa552f0bfe5da8","type":"GO_TERM","name":"O-methyltransferase activity","canonical_id":"go:GO:0008171","description":"\"Catalysis of the transfer of a methyl group to the oxygen atom of an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"d37867206a7b4ae98cc50a353c10bf7b","type":"GO_TERM","name":"O-palmitoyltransferase activity","canonical_id":"go:GO:0016416","description":"\"Catalysis of the transfer of a palmitoyl group to an oxygen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"f8db0322f0c84ddd84ae6752e4af73cf","type":"GO_TERM","name":"O-phospho-L-serine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0004648","description":"\"Catalysis of the reaction: O-phospho-L-serine + 2-oxoglutarate = 3-phosphonooxypyruvate + L-glutamate.\" [RHEA:14329]","metadata":null},{"id":"0f6f652a840d46e98edc139b98a8d819","type":"GO_TERM","name":"O-phosphoserine sulfhydrylase activity","canonical_id":"go:GO:0033847","description":"\"Catalysis of the reaction: O-phospho-L-serine + hydrogen sulfide = L-cysteine + phosphate.\" [EC:2.5.1.65]","metadata":null},{"id":"0e55772580e645c38a5471bcf99bc5cf","type":"GO_TERM","name":"O-phosphoseryl-tRNA(Sec) selenium transferase activity","canonical_id":"go:GO:0098621","description":"\"Catalysis of the reaction: O-phospho-L-seryl-tRNA(Sec) + selenophosphate + H2O = L-selenocysteinyl-tRNA(Sec) + 2 phosphate.\" [PMID:17142313, PMID:19608919, RHEA:25041]","metadata":null},{"id":"ebc54fdbf75d4a5eb8f5d5a19ce847af","type":"GO_TERM","name":"O-sialoglycoprotein catabolic process","canonical_id":"go:GO:0045173","description":"\"The chemical reactions and pathways resulting in the breakdown of O-sialoglycoproteins, glycoproteins which contain sialic acid as one of their carbohydrates. They are often found on or in the cell or tissue membranes and participate in a variety of biological activities.\" [GOC:curators, PMID:8824323]","metadata":null},{"id":"55a2b2fd055c453ca202126445f7ff28","type":"GO_TERM","name":"O-sinapoyltransferase activity","canonical_id":"go:GO:0016753","description":"\"Catalysis of the transfer of a sinapoyl group to an oxygen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"e6d0052ea9bf4acd9c1a08c99e837a02","type":"GO_TERM","name":"O-succinylbenzoate synthase activity","canonical_id":"go:GO:0043748","description":"\"Catalysis of the reaction: 2-succinylbenzoate + H2O = 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate.\" [PMID:8335646]","metadata":null},{"id":"829a1696a5154dba9efdee58ab2ca388","type":"GO_TERM","name":"O-succinyltransferase activity","canonical_id":"go:GO:0016750","description":"\"Catalysis of the transfer of a succinyl group to an oxygen atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"a9a185247c564e99aefbb7956b1cf23f","type":"GO_TERM","name":"O6-alkylguanine-DNA binding","canonical_id":"go:GO:0032132","description":"\"Binding to an O6-alkylguanine adduct in DNA.\" [GOC:mah, PMID:16679453]","metadata":null},{"id":"3676a606ecba4a5bae32d7f3b539d4e5","type":"TRIAL","name":"O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT00005961","description":"Melanoma (Skin)","metadata":null},{"id":"6511f97442254ec7a7d6d4e3c4db405d","type":"GO_TERM","name":"O6-methyl-dGTP hydrolase activity","canonical_id":"go:GO:0106433","description":"\"Catalysis of the reaction O6-methyl-dGTP + H2O = O6-methyl-dGMP + diphosphate + H+.\" [PMID:30304478, RHEA:67600]","metadata":null},{"id":"6c03d83bb06e4753ab5d85ae6bae6d96","type":"GENE","name":"OACYLP","canonical_id":"hgnc:HGNC:44362","description":"O-acyltransferase like, pseudogene","metadata":{"aliases":["ACYL3P"]}},{"id":"eb94fadf460a423bad9784bd3d348703","type":"GENE","name":"OAF","canonical_id":"hgnc:HGNC:28752","description":"out at first homolog","metadata":{"aliases":["MGC52117"]}},{"id":"108e9c3f5abb4fd5acc47c9667d4ea11","type":"GENE","name":"OARD1","canonical_id":"hgnc:HGNC:21257","description":"O-acyl-ADP-ribose deacylase 1","metadata":{"aliases":["MGC19570","dJ34B21.3","TARG1","C6orf130"]}},{"id":"dec516d48898420f94c1e5a240d0fecd","type":"GENE","name":"OAS1","canonical_id":"hgnc:HGNC:8086","description":null,"metadata":null},{"id":"ff944302a05e4487880ccc7936f1d4f6","type":"GENE","name":"OAS2","canonical_id":"hgnc:HGNC:8087","description":"2'-5'-oligoadenylate synthetase 2","metadata":null},{"id":"41c4ab3443944e6c9e9d2b32d01f4167","type":"GENE","name":"OAS3","canonical_id":"hgnc:HGNC:8088","description":"2'-5'-oligoadenylate synthetase 3","metadata":null},{"id":"bcee746b6aa248bcaa02326106289096","type":"TRIAL","name":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00064428","description":"Thromboembolism","metadata":null},{"id":"21129a6a2aef4f81b43f61ecf3108245","type":"GENE","name":"OASL","canonical_id":"hgnc:HGNC:8090","description":"2'-5'-oligoadenylate synthetase like","metadata":{"aliases":["TRIP14","p59OASL","OASL1"]}},{"id":"945b07f56aec4ef69a2108f3ab90048e","type":"GENE","name":"OASL2P","canonical_id":"hgnc:HGNC:53738","description":"2'-5' oligoadenylate synthetase like 2, pseudogene","metadata":null},{"id":"837507422c5e41e7af4a9c23fad0ab6f","type":"GENE","name":"OAT","canonical_id":"hgnc:HGNC:8091","description":null,"metadata":null},{"id":"3554e70722fb4b209025ff2b2cf5ffcb","type":"GENE","name":"OATP1","canonical_id":"hgnc:HGNC:8094","description":"ornithine aminotransferase pseudogene 1","metadata":{"aliases":["OATL3"]}},{"id":"9d653e2503214e8fa1dd50636c7ae9e9","type":"GENE","name":"OAZ1","canonical_id":"hgnc:HGNC:8095","description":"ornithine decarboxylase antizyme 1","metadata":{"aliases":["AZI","MGC138338","AZ1","OAZ"]}},{"id":"97fb07fd2ff1499ca255edefb9abb67a","type":"GENE","name":"OAZ1P1","canonical_id":"hgnc:HGNC:54556","description":"OAZ1 pseudogene 1","metadata":null},{"id":"509cb3bc50f640db893c0ccbbba6fba0","type":"GENE","name":"OAZ2","canonical_id":"hgnc:HGNC:8096","description":"ornithine decarboxylase antizyme 2","metadata":null},{"id":"26c2ac9f98324807bf9bbe67a5505703","type":"GENE","name":"OAZ3","canonical_id":"hgnc:HGNC:8097","description":"ornithine decarboxylase antizyme 3","metadata":null},{"id":"f562f90d85b74fe185022f8939c2d321","type":"TRIAL","name":"OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.","canonical_id":"clinicaltrials.gov:NCT00577031","description":"Colorectal Cancer","metadata":null},{"id":"86743199c74a4aaf9ee658a56f8d5f37","type":"TRIAL","name":"OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme","canonical_id":"clinicaltrials.gov:NCT07779343","description":"Obesity Difficult Airway Airway Management; Obesity Adult Onset; Obesity and Cardiovascular Risk; Obesity Type 2 Diabetes Mellitus","metadata":null},{"id":"1212d7ffb59c4b288f8c5649bdafa012","type":"GENE","name":"OBI1","canonical_id":"hgnc:HGNC:20308","description":"ORC ubiquitin ligase 1","metadata":{"aliases":["FLJ13449","C13orf7","RNF219"]}},{"id":"c9e3978eef4546e09f2e4e5589076308","type":"GENE","name":"OBI1-AS1","canonical_id":"hgnc:HGNC:42700","description":"OBI1 antisense RNA 1","metadata":{"aliases":["uc.354","POU4F1-AS1","RNF219-AS1"]}},{"id":"b2ff27cf63324af0a35a09bec503ee95","type":"GENE","name":"OBP2A","canonical_id":"hgnc:HGNC:23380","description":"odorant binding protein 2A","metadata":{"aliases":["hOBPIIa","OBP","LCN13"]}},{"id":"31b54dd6d81247c9b2439aefa8134c38","type":"GENE","name":"OBP2B","canonical_id":"hgnc:HGNC:23381","description":"odorant binding protein 2B","metadata":{"aliases":["hOBPIIb","LCN14"]}},{"id":"9c8b728e340c422499dcb2a4817cbe66","type":"GENE","name":"OBSCN","canonical_id":"hgnc:HGNC:15719","description":"obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF","metadata":{"aliases":["KIAA1556","UNC89","KIAA1639","ARHGEF30"]}},{"id":"c4eb4a3f51e049ec8c4d9c1728e74080","type":"GENE","name":"OBSCN-AS1","canonical_id":"hgnc:HGNC:32047","description":"OBSCN antisense RNA 1","metadata":{"aliases":["FLJ31994","C1orf145"]}},{"id":"8a1cfef15e6e4061b3c1d24b20837629","type":"GENE","name":"OBSCN-AS2","canonical_id":"hgnc:HGNC:58608","description":"OBSCN antisense RNA 2","metadata":null},{"id":"29486680170547e2a1fc20dba7f05083","type":"GENE","name":"OBSL1","canonical_id":"hgnc:HGNC:29092","description":"obscurin like cytoskeletal adaptor 1","metadata":{"aliases":["KIAA0657"]}},{"id":"dc728e0d2ff646faa39c8c52c2602e5c","type":"GENE","name":"OC90","canonical_id":"hgnc:HGNC:8100","description":"otoconin 90","metadata":{"aliases":["PLA2L"]}},{"id":"6de729cfe17941f992e3fc9ea6f5c841","type":"GENE","name":"OCA2","canonical_id":"hgnc:HGNC:8101","description":null,"metadata":null},{"id":"194d6152fbd94954805598b66a0f32e9","type":"GENE","name":"OCEL1","canonical_id":"hgnc:HGNC:26221","description":"occludin/ELL domain containing 1","metadata":{"aliases":["FLJ22709"]}},{"id":"fe7143f87f8e4d92aa5420a1e3b45c35","type":"GENE","name":"OCIAD1","canonical_id":"hgnc:HGNC:16074","description":"OCIA domain containing 1","metadata":{"aliases":["FLJ20455","TPA018","OCIA","Asrij"]}},{"id":"5c40e48d26304bffa56e1420b7b6b00c","type":"GENE","name":"OCIAD1-AS1","canonical_id":"hgnc:HGNC:40751","description":"OCIAD1 antisense RNA 1","metadata":null},{"id":"4e0c1e53448244fbaf8092dccbf53679","type":"GENE","name":"OCIAD2","canonical_id":"hgnc:HGNC:28685","description":"OCIA domain containing 2","metadata":{"aliases":["MGC45416"]}},{"id":"308147fa1bbb460a9db13b3baa3143a1","type":"GENE","name":"OCIAD2P1","canonical_id":"hgnc:HGNC:31827","description":"OCIA domain containing 2 pseudogene 1","metadata":null},{"id":"0568153575d6454dae1b2370aebfaef9","type":"GENE","name":"OCLN","canonical_id":"hgnc:HGNC:8104","description":null,"metadata":null},{"id":"c5f8d8180e78425ea594fae87428ded1","type":"GENE","name":"OCLNP1","canonical_id":"hgnc:HGNC:53916","description":"OCLN pseudogene 1","metadata":null},{"id":"6d955cdc03de40cebc282d347da8a8fc","type":"GENE","name":"OCM","canonical_id":"hgnc:HGNC:8105","description":"oncomodulin","metadata":{"aliases":["OCM1"]}},{"id":"9c25fadeea964bdc90f83b2009272b39","type":"GENE","name":"OCM2","canonical_id":"hgnc:HGNC:34396","description":"oncomodulin 2","metadata":null},{"id":"099ea4a4b21e490188056a676bbca8c2","type":"TRIAL","name":"OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women","canonical_id":"clinicaltrials.gov:NCT02744131","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"e9c713a3e0644703ab4fde92c7a3316d","type":"GENE","name":"OCRL","canonical_id":"hgnc:HGNC:8108","description":"OCRL inositol polyphosphate-5-phosphatase","metadata":{"aliases":["OCRL1","Dent-2"]}},{"id":"db44cf5890124f8ba3db7183a149f860","type":"GENE","name":"OCSTAMP","canonical_id":"hgnc:HGNC:16116","description":"osteoclast stimulatory transmembrane protein","metadata":{"aliases":["dJ257E24.3","C20orf123"]}},{"id":"938d5c1f5a9d457aa6f7714e5c7e4fc7","type":"GENE","name":"ODAD1","canonical_id":"hgnc:HGNC:26560","description":"outer dynein arm docking complex subunit 1","metadata":{"aliases":["FLJ32926","CILD20","CCDC114"]}},{"id":"611f207754ae41eaa5b8fc4569c18148","type":"GENE","name":"ODAD2","canonical_id":"hgnc:HGNC:25583","description":"outer dynein arm docking complex subunit 2","metadata":{"aliases":["FLJ10817","FLJ10376","DKFZP434P1735","CILD23","gudu","ARMC4"]}},{"id":"1b7d5dc544cd42d489fb9a13b40dfac6","type":"GENE","name":"ODAD2P1","canonical_id":"hgnc:HGNC:44937","description":"outer dynein arm docking complex subunit 2 pseudogene 1","metadata":{"aliases":["ARMC4P1"]}},{"id":"fb33ba678c8a4440ae31ba1cf0f1f3ff","type":"GENE","name":"ODAD3","canonical_id":"hgnc:HGNC:28303","description":"outer dynein arm docking complex subunit 3","metadata":{"aliases":["MGC20983","ODA10","CCDC151"]}},{"id":"e7f3be5e21074eb29f6e62aeb15d6531","type":"GENE","name":"ODAD4","canonical_id":"hgnc:HGNC:25280","description":"outer dynein arm docking complex subunit 4","metadata":{"aliases":["DKFZP434H0115","TTC25"]}},{"id":"efd0051443724422adbfcbe5e17ccf49","type":"GENE","name":"ODAM","canonical_id":"hgnc:HGNC:26043","description":"odontogenic, ameloblast associated","metadata":{"aliases":["APin","FLJ20513"]}},{"id":"4e21119d7b15477dbc7bc432b3eee6b6","type":"GENE","name":"ODAPH","canonical_id":"hgnc:HGNC:26300","description":"odontogenesis associated phosphoprotein","metadata":{"aliases":["FLJ23657","AI2A4","C4orf26"]}},{"id":"59521e5b22cc4f50b1c4ebfa401b1049","type":"GENE","name":"ODC1","canonical_id":"hgnc:HGNC:8109","description":null,"metadata":null},{"id":"82e5c45491ee401c8d0825a48ac3c9eb","type":"GENE","name":"ODC1-DT","canonical_id":"hgnc:HGNC:54070","description":"ODC1 divergent transcript","metadata":{"aliases":["lncRNA-MIF"]}},{"id":"0f04b084040940d79dbacd6cb5f9364e","type":"GENE","name":"ODCP","canonical_id":"hgnc:HGNC:8110","description":"ornithine decarboxylase pseudogene","metadata":{"aliases":["ODC2"]}},{"id":"c665e7ce0bc742e9bfc853b94dbe86d0","type":"GENE","name":"ODF1","canonical_id":"hgnc:HGNC:8113","description":"outer dense fiber of sperm tails 1","metadata":{"aliases":["ODFPG","ODF27","RT7","HSPB10","CT133"]}},{"id":"54fd63f163f249fa90529c077d149285","type":"GENE","name":"ODF2","canonical_id":"hgnc:HGNC:8114","description":"outer dense fiber of sperm tails 2","metadata":{"aliases":["ODF84","CT134"]}},{"id":"b0bafcc86d5d40c4b382496ff4f7d1ab","type":"GENE","name":"ODF2-AS1","canonical_id":"hgnc:HGNC:49461","description":"ODF2 antisense RNA 1","metadata":null},{"id":"31ce73a1b586444fac1d05b2adce3bd9","type":"GENE","name":"ODF2L","canonical_id":"hgnc:HGNC:29225","description":"outer dense fiber of sperm tails 2 like","metadata":{"aliases":["KIAA1229"]}},{"id":"1367db64d7db49d6b65702719b84ba12","type":"GENE","name":"ODF4","canonical_id":"hgnc:HGNC:19056","description":"outer dense fiber of sperm tails 4","metadata":{"aliases":["OPPO1","CT136"]}},{"id":"62a1eb90a9204c1eb4c1da100be1b319","type":"GENE","name":"ODR4","canonical_id":"hgnc:HGNC:24299","description":"odr-4 GPCR localization factor homolog","metadata":{"aliases":["FLJ20505","odr-4","TTG1","C1orf27"]}},{"id":"35466c784dc844cf8c18b8ea4501aa23","type":"TRIAL","name":"OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07221799","description":"Multiple Sclerosis; Neuropathic Pain","metadata":null},{"id":"de07f1a137ba470dbfa0abd3a48e8611","type":"GENE","name":"OFCC1","canonical_id":"hgnc:HGNC:21017","description":"orofacial cleft 1 candidate 1 (pseudogene)","metadata":{"aliases":["OFCC1P","MRDS1","Opo"]}},{"id":"d83e5ebcc6c24c808a35b80479aab093","type":"GENE","name":"OFD1","canonical_id":"hgnc:HGNC:2567","description":"OFD1 centriole and centriolar satellite protein","metadata":{"aliases":["71-7A","JBTS10","CXorf5","RP23"]}},{"id":"ec6b8d64397942c081fea88ea349cc29","type":"GENE","name":"OFD1P10Y","canonical_id":"hgnc:HGNC:23882","description":"OFD1 pseudogene 10 Y-linked","metadata":{"aliases":["OFDYP10","OFD1P10","OFD1PY10"]}},{"id":"79577370b8bd40f2b3809273d113b566","type":"GENE","name":"OFD1P11Y","canonical_id":"hgnc:HGNC:23883","description":"OFD1 pseudogene 11 Y-linked","metadata":{"aliases":["OFDYP11","OFD1P11","OFD1PY11"]}},{"id":"ed2dc116635141bcbe794658f28d2c9d","type":"GENE","name":"OFD1P12Y","canonical_id":"hgnc:HGNC:23884","description":"OFD1 pseudogene 12 Y-linked","metadata":{"aliases":["OFDYP12","OFD1P12","OFD1PY12"]}},{"id":"2a51fba26e3643d38680a0c4c26dbf63","type":"GENE","name":"OFD1P13Y","canonical_id":"hgnc:HGNC:23885","description":"OFD1 pseudogene 13 Y-linked","metadata":{"aliases":["OFDYP13","OFD1P13","OFD1PY13"]}},{"id":"fc9e7a6622a24b21a219803a900135a9","type":"GENE","name":"OFD1P14Y","canonical_id":"hgnc:HGNC:23886","description":"OFD1 pseudogene 14 Y-linked","metadata":{"aliases":["OFDYP14","OFD1P14","OFD1PY14"]}},{"id":"0dd3763eee054d68b77ca967d5ef473e","type":"GENE","name":"OFD1P15Y","canonical_id":"hgnc:HGNC:23887","description":"OFD1 pseudogene 15 Y-linked","metadata":{"aliases":["OFDYP15","OFD1P15","OFD1PY15"]}},{"id":"b53320cf6b0748f6bb4ca87d9b55d028","type":"GENE","name":"OFD1P16Y","canonical_id":"hgnc:HGNC:18213","description":"OFD1 pseudogene 16 Y-linked","metadata":{"aliases":["OFDYP16","OFD1P16","OFD1PY16"]}},{"id":"e64f94ed0a53415da9a808f0e34bc396","type":"GENE","name":"OFD1P17","canonical_id":"hgnc:HGNC:1332","description":"OFD1 pseudogene 17","metadata":{"aliases":["71-7A3","71-7A5","C5orf1","OFD1P1"]}},{"id":"58b8aff5be9649ad934b88634cd78ed9","type":"GENE","name":"OFD1P18Y","canonical_id":"hgnc:HGNC:2589","description":"OFD1 pseudogene 18 Y-linked","metadata":{"aliases":["71-7A2","CYorf1","OFD1P18","OFD1PY18"]}},{"id":"c42392c6addd4e93a008c1ce631cd762","type":"GENE","name":"OFD1P1Y","canonical_id":"hgnc:HGNC:23873","description":"OFD1 pseudogene 1 Y-linked","metadata":{"aliases":["OFDYP1","OFD1P1"]}},{"id":"7287b6d238624886ba1fe28de242d191","type":"GENE","name":"OFD1P2Y","canonical_id":"hgnc:HGNC:23874","description":"OFD1 pseudogene 2 Y-linked","metadata":{"aliases":["OFDYP2","OFD1P2","OFD1PY2"]}},{"id":"b253ef4aedfe462ba908c6cfeb0e9ef6","type":"GENE","name":"OFD1P3Y","canonical_id":"hgnc:HGNC:23875","description":"OFD1 pseudogene 3 Y-linked","metadata":{"aliases":["OFDYP3","OFD1P3","OFD1PY3","OFD1P19Y","OFD1P19","OFD1PY19"]}},{"id":"0cd4e563d508448fabc65c053ed74a31","type":"GENE","name":"OFD1P4Y","canonical_id":"hgnc:HGNC:23876","description":"OFD1 pseudogene 4 Y-linked","metadata":{"aliases":["OFDYP4","OFD1P4","OFD1PY4"]}},{"id":"4b1d36f0d9b84e99aa6647b4be5aa244","type":"GENE","name":"OFD1P5Y","canonical_id":"hgnc:HGNC:23877","description":"OFD1 pseudogene 5 Y-linked","metadata":{"aliases":["OFDYP5","OFD1P5","OFD1PY5"]}},{"id":"86d5242e47464187b97f2ed7f7eb0f01","type":"GENE","name":"OFD1P6Y","canonical_id":"hgnc:HGNC:13657","description":"OFD1 pseudogene 6 Y-linked","metadata":{"aliases":["OFD1P2","OFDYP6","OFD1P6","OFD1PY6"]}},{"id":"4e66c19e02484a14b5393da84aa94988","type":"GENE","name":"OFD1P7Y","canonical_id":"hgnc:HGNC:23879","description":"OFD1 pseudogene 7 Y-linked","metadata":{"aliases":["OFDYP7","OFD1P7","OFD1PY7"]}},{"id":"16eb111e2cf94bdf86663a6080368657","type":"GENE","name":"OFD1P8Y","canonical_id":"hgnc:HGNC:23880","description":"OFD1 pseudogene 8 Y-linked","metadata":{"aliases":["OFDYP8","OFD1P8","OFD1PY8"]}},{"id":"22b052249e68431a82a73dcd3178ba76","type":"GENE","name":"OFD1P9Y","canonical_id":"hgnc:HGNC:23881","description":"OFD1 pseudogene 9 Y-linked","metadata":{"aliases":["OFDYP9","OFD1P9","OFD1PY9"]}},{"id":"767a1cd827a440849cc10c23850a30ea","type":"GENE","name":"OGA","canonical_id":"hgnc:HGNC:7056","description":"O-GlcNAcase","metadata":{"aliases":["MEA5","NCOAT","MGEA5"]}},{"id":"ef1d9a8688fd456da11fe9b7914ea043","type":"GENE","name":"OGDH","canonical_id":"hgnc:HGNC:8124","description":"oxoglutarate dehydrogenase","metadata":{"aliases":["E1k","OGDC-E1","OGDH2","KGD1"]}},{"id":"b7d2f28d77474ed1ad2c82ebb43dd3b3","type":"GENE","name":"OGDHL","canonical_id":"hgnc:HGNC:25590","description":"oxoglutarate dehydrogenase L","metadata":{"aliases":["FLJ10851"]}},{"id":"d73acffbfda0458ba6d3fe93a28fb294","type":"GENE","name":"OGFOD1","canonical_id":"hgnc:HGNC:25585","description":"2-oxoglutarate and iron dependent oxygenase domain containing 1","metadata":{"aliases":["KIAA1612","FLJ10826","TPA1"]}},{"id":"9c4dfc91470b46ee8c2df7740c6ec360","type":"GENE","name":"OGFOD1P1","canonical_id":"hgnc:HGNC:39202","description":"2-oxoglutarate and iron dependent oxygenase domain containing 1 pseudogene 1","metadata":null},{"id":"6cdb500865d54fd8891433eb2fe1df49","type":"GENE","name":"OGFOD2","canonical_id":"hgnc:HGNC:25823","description":"2-oxoglutarate and iron dependent oxygenase domain containing 2","metadata":{"aliases":["FLJ13491","FLJ37501"]}},{"id":"62de65b38a6e458089ad03829e361bd5","type":"GENE","name":"OGFOD3","canonical_id":"hgnc:HGNC:26174","description":"2-oxoglutarate and iron dependent oxygenase domain containing 3","metadata":{"aliases":["FLJ22222","C17orf101"]}},{"id":"0488950ec6ab4772a78da324f0497258","type":"GENE","name":"OGFR","canonical_id":"hgnc:HGNC:15768","description":"opioid growth factor receptor","metadata":{"aliases":["7-60"]}},{"id":"b944239cbc164772add1301e85dcd416","type":"GENE","name":"OGFR-AS1","canonical_id":"hgnc:HGNC:40724","description":"OGFR antisense RNA 1","metadata":null},{"id":"dd5b61a4433442acb3046c5bc5d9d248","type":"GENE","name":"OGFRL1","canonical_id":"hgnc:HGNC:21378","description":"opioid growth factor receptor like 1","metadata":{"aliases":["dJ331H24.1"]}},{"id":"19e56444e14c4b68a78ba2f0c661e41c","type":"GENE","name":"OGFRP1","canonical_id":"hgnc:HGNC:50511","description":"opioid growth factor receptor pseudogene 1","metadata":null},{"id":"217bdee1c40c4ce29e597c5a3db006c9","type":"GENE","name":"OGG1","canonical_id":"hgnc:HGNC:8125","description":null,"metadata":null},{"id":"31ac7dce731e476baa12053a23caa69a","type":"GENE","name":"OGN","canonical_id":"hgnc:HGNC:8126","description":null,"metadata":null},{"id":"65ac03a05f0b4bf4a2bfa74bb5921d4f","type":"GENE","name":"OGT","canonical_id":"hgnc:HGNC:8127","description":"O-linked N-acetylglucosamine (GlcNAc) transferase","metadata":{"aliases":["O-GLCNAC","HRNT1","MGC22921","FLJ23071","OGT1"]}},{"id":"d016621401174eef9f20ddba9a2d3202","type":"GENE","name":"OIP5","canonical_id":"hgnc:HGNC:20300","description":"Opa interacting protein 5","metadata":{"aliases":["MIS18B","hMIS18beta","CT86"]}},{"id":"80d33195cdc44c12a143b0b0677fb055","type":"GENE","name":"OIP5-AS1","canonical_id":"hgnc:HGNC:43563","description":"OIP5 antisense RNA 1","metadata":{"aliases":["cyrano","linc-OIP5"]}},{"id":"d375392147e6427494722c0d92ddc669","type":"GENE","name":"OIT3","canonical_id":"hgnc:HGNC:29953","description":"oncoprotein induced transcript 3","metadata":{"aliases":["LZP","FLJ39116"]}},{"id":"8ace39648ace4c898c668eead5441621","type":"GENE","name":"OLA1","canonical_id":"hgnc:HGNC:28833","description":"Obg like ATPase 1","metadata":{"aliases":["PTD004","GTPBP9"]}},{"id":"400e7033894641c6a20802b66f3777d0","type":"GENE","name":"OLA1P1","canonical_id":"hgnc:HGNC:45274","description":"OLA1 pseudogene 1","metadata":null},{"id":"7751a3da635c4a41a40a78b3ac5bc8bf","type":"GENE","name":"OLA1P2","canonical_id":"hgnc:HGNC:45277","description":"OLA1 pseudogene 2","metadata":null},{"id":"a721120604634fc18e57593d43bee65a","type":"GENE","name":"OLA1P3","canonical_id":"hgnc:HGNC:45278","description":"OLA1 pseudogene 3","metadata":null},{"id":"a88de8752cc4407cbf99c4b419490271","type":"GENE","name":"OLAH","canonical_id":"hgnc:HGNC:25625","description":"oleoyl-ACP hydrolase","metadata":{"aliases":["TE2","SAST","FLJ11106","THEDC1"]}},{"id":"23642dbda2104bb4bb2de7f2594e32bb","type":"TRIAL","name":"OLE Study With Filgotinib in JIA","canonical_id":"clinicaltrials.gov:NCT07553182","description":"Juvenile Idiopathic Arthritis (JIA)","metadata":null},{"id":"ef96fa4866fc44458dd3e481806fb8df","type":"GENE","name":"OLFM1","canonical_id":"hgnc:HGNC:17187","description":"olfactomedin 1","metadata":{"aliases":["NOE1","OlfA","AMY","NOELIN"]}},{"id":"0c3b5d2374fa45db83ce3696983b6407","type":"GENE","name":"OLFM2","canonical_id":"hgnc:HGNC:17189","description":"olfactomedin 2","metadata":{"aliases":["OlfC","NOE2"]}},{"id":"4becf11a8c7747959b0b506ab65b533a","type":"GENE","name":"OLFM3","canonical_id":"hgnc:HGNC:17990","description":"olfactomedin 3","metadata":{"aliases":["NOE3"]}},{"id":"1bf7f7ab049b4845b6c60cbb35f811e1","type":"GENE","name":"OLFM4","canonical_id":"hgnc:HGNC:17190","description":null,"metadata":null},{"id":"4a669e386aa84e83b69d07bf363b03c8","type":"GENE","name":"OLFM5P","canonical_id":"hgnc:HGNC:51927","description":"olfactomedin family member 5, pseudogene","metadata":null},{"id":"34c7cd567c1b44518ad1686d00dee2a5","type":"GENE","name":"OLFML1","canonical_id":"hgnc:HGNC:24473","description":"olfactomedin like 1","metadata":{"aliases":["UNQ564","ONT2"]}},{"id":"96d377aed6e241028b57a7289f4d111f","type":"GENE","name":"OLFML2A","canonical_id":"hgnc:HGNC:27270","description":"olfactomedin like 2A","metadata":{"aliases":["FLJ00237"]}},{"id":"8dddb2ec2abe439683196e590dea67fb","type":"GENE","name":"OLFML2B","canonical_id":"hgnc:HGNC:24558","description":"olfactomedin like 2B","metadata":{"aliases":["DKFZP586L151"]}},{"id":"387aba25ede443c38ac0c558765e7b2f","type":"GENE","name":"OLFML3","canonical_id":"hgnc:HGNC:24956","description":"olfactomedin like 3","metadata":{"aliases":["HNOEL-iso","OLF44"]}},{"id":"dfccb828e58c47cfb8adfc04c917106a","type":"GENE","name":"OLIG1","canonical_id":"hgnc:HGNC:16983","description":"oligodendrocyte transcription factor 1","metadata":{"aliases":["BHLHB6","bHLHe21"]}},{"id":"517037e8e6e14e6cb070287cf414c7a6","type":"GENE","name":"OLIG2","canonical_id":"hgnc:HGNC:9398","description":null,"metadata":null},{"id":"6a8f1a3747b74663919f2614f3db8bca","type":"GENE","name":"OLIG3","canonical_id":"hgnc:HGNC:18003","description":"oligodendrocyte transcription factor 3","metadata":{"aliases":["Bhlhb7","bHLHe20"]}},{"id":"9fdfd4e5fb154b42aaeb33d67619a2f0","type":"GENE","name":"OLMALINC","canonical_id":"hgnc:HGNC:28060","description":"oligodendrocyte maturation-associated long intergenic non-coding RNA","metadata":{"aliases":["bA34D15.5","FLJ12974","HI-LNC80","C10orf75","NCRNA00263","LINC00263"]}},{"id":"c4c99fc16fe44e03ab6f9f89abc37e0d","type":"GENE","name":"OLR1","canonical_id":"hgnc:HGNC:8133","description":null,"metadata":null},{"id":"509d8147cd0642299db74df4af429e4f","type":"GENE","name":"OMA1","canonical_id":"hgnc:HGNC:29661","description":"OMA1 zinc metallopeptidase","metadata":{"aliases":["MPRP-1","YKR087C","ZMPOMA1","FLJ33782"]}},{"id":"78bbf5b6417c4aa7a6177852446be345","type":"GENE","name":"OMD","canonical_id":"hgnc:HGNC:8134","description":"osteomodulin","metadata":{"aliases":["osteoadherin","SLRR2C"]}},{"id":"e3cd87f9db1b4d9cbbfbdaa6bd7878b5","type":"GENE","name":"OMG","canonical_id":"hgnc:HGNC:8135","description":"oligodendrocyte myelin glycoprotein","metadata":{"aliases":["OMGP"]}},{"id":"c55e52bed5374940a652cca7fbe2cedf","type":"GENE","name":"OMP","canonical_id":"hgnc:HGNC:8136","description":"olfactory marker protein","metadata":null},{"id":"85233de7aa0047a5bb9c3b25823127e7","type":"GENE","name":"ONECUT1","canonical_id":"hgnc:HGNC:8138","description":null,"metadata":null},{"id":"7f6fe44adaf44544a715e03f66c23f33","type":"GENE","name":"ONECUT2","canonical_id":"hgnc:HGNC:8139","description":null,"metadata":null},{"id":"9f1e8fd08e344cf2837ac39a79648014","type":"GENE","name":"ONECUT3","canonical_id":"hgnc:HGNC:13399","description":"one cut homeobox 3","metadata":null},{"id":"eb9054019784458988650bf5892ddbeb","type":"GENE","name":"OOEP","canonical_id":"hgnc:HGNC:21382","description":"oocyte expressed protein","metadata":{"aliases":["Em:AC019205.2","KHDC2","C6orf156"]}},{"id":"d1c29360916e4f53be9d55e7866efb23","type":"GENE","name":"OOEP-AS1","canonical_id":"hgnc:HGNC:39192","description":"OOEP antisense RNA 1","metadata":{"aliases":["OOEP-AS"]}},{"id":"107d57e5f4bd4095b2dc337ea7ced2c5","type":"GENE","name":"OOEPP1","canonical_id":"hgnc:HGNC:54933","description":"OOEP pseudogene 1","metadata":null},{"id":"7789dda94d074dc3ab25cc498afaeb7b","type":"GENE","name":"OOEPP2","canonical_id":"hgnc:HGNC:54934","description":"OOEP pseudogene 2","metadata":null},{"id":"4b8b9e650a0c4527bb62c89f8328307e","type":"GENE","name":"OOSP1","canonical_id":"hgnc:HGNC:49233","description":"oocyte secreted protein 1","metadata":null},{"id":"2076b4ce7f6e4ee78393f662b887336f","type":"GENE","name":"OOSP1P1","canonical_id":"hgnc:HGNC:49240","description":"oocyte secreted protein 1 pseudogene 1","metadata":null},{"id":"40230d4d1d45463cb37ea9ba770b07e2","type":"GENE","name":"OOSP1P2","canonical_id":"hgnc:HGNC:49241","description":"oocyte secreted protein 1 pseudogene 2","metadata":null},{"id":"bdd6b853382d4bd4949c0dbcf251885b","type":"GENE","name":"OOSP2","canonical_id":"hgnc:HGNC:26699","description":"oocyte secreted protein 2","metadata":{"aliases":["FLJ36198","OOSP2A","TMEM122","PLAC1L"]}},{"id":"d3fb1a5a3b294457994ddcc4c8f6d443","type":"GENE","name":"OOSP3","canonical_id":"hgnc:HGNC:53903","description":"oocyte secreted protein family member 3","metadata":null},{"id":"c2f781b0162a43ac939944a2a8fc112d","type":"GENE","name":"OOSP4A","canonical_id":"hgnc:HGNC:53904","description":"oocyte secreted protein family member 4A","metadata":null},{"id":"f231c87bfac44b40a92950c133488aac","type":"GENE","name":"OOSP4B","canonical_id":"hgnc:HGNC:53905","description":"oocyte secreted protein family member 4B","metadata":null},{"id":"0253ba587e444fdb898038bc40ef6e2e","type":"TRIAL","name":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06016738","description":"Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma","metadata":null},{"id":"3eb3b11f97da45b0b3e47fdb5063674a","type":"GENE","name":"OPA1","canonical_id":"hgnc:HGNC:8140","description":"OPA1 mitochondrial dynamin like GTPase","metadata":{"aliases":["NTG","KIAA0567","FLJ12460","NPG","MGM1"]}},{"id":"adef65f2d79344248d981e60caf22c2d","type":"GENE","name":"OPA1-AS1","canonical_id":"hgnc:HGNC:40421","description":"OPA1 antisense RNA 1","metadata":null},{"id":"f0869eec921f41e1afdbfa9e47e00c87","type":"GENE","name":"OPA3","canonical_id":"hgnc:HGNC:8142","description":"outer mitochondrial membrane lipid metabolism regulator OPA3","metadata":{"aliases":["FLJ22187","MGA3"]}},{"id":"d1d57d95ba7042999df1d45c86010454","type":"GENE","name":"OPALIN","canonical_id":"hgnc:HGNC:20707","description":"oligodendrocytic myelin paranodal and inner loop protein","metadata":{"aliases":["TMP10","HTMP10","TMEM10"]}},{"id":"3a3bbeffa3b844218637d5f2d65ce4f0","type":"GENE","name":"OPCML","canonical_id":"hgnc:HGNC:8143","description":"opioid binding protein/cell adhesion molecule like","metadata":{"aliases":["OPCM","OBCAM","IGLON1"]}},{"id":"da7642edb93648e7a43d08774831d7b0","type":"GENE","name":"OPCML-IT1","canonical_id":"hgnc:HGNC:41366","description":"OPCML intronic transcript 1","metadata":null},{"id":"09a22fa3c9bd4d09b4b97bdc1a90786c","type":"GENE","name":"OPCML-IT2","canonical_id":"hgnc:HGNC:41365","description":"OPCML intronic transcript 2","metadata":null},{"id":"9d3e7f1794774313b1a19cadd9464d9e","type":"GENE","name":"OPHN1","canonical_id":"hgnc:HGNC:8148","description":"oligophrenin 1","metadata":{"aliases":["OPN1","ARHGAP41","MRX60"]}},{"id":"1af115ce561f44939143d751cefa21c0","type":"TRIAL","name":"OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity","canonical_id":"clinicaltrials.gov:NCT07140783","description":"Vision Loss Night; Vision Disorders","metadata":null},{"id":"928c20bd48eb4927b3dbf80d49aeec42","type":"GENE","name":"OPLAH","canonical_id":"hgnc:HGNC:8149","description":"5-oxoprolinase, ATP-hydrolysing","metadata":{"aliases":["OPLA","5-Opase"]}},{"id":"8228f1664ad84825a91fc1f1130e47f0","type":"GENE","name":"OPN1LW","canonical_id":"hgnc:HGNC:9936","description":"opsin 1, long wave sensitive","metadata":{"aliases":["COD5","CBBM","RCP","CBP"]}},{"id":"a64bdafe65914af0a7dd4b498b9f7bb5","type":"GENE","name":"OPN1MW","canonical_id":"hgnc:HGNC:4206","description":"opsin 1, medium wave sensitive","metadata":{"aliases":["OPN1MW1","COD5","GCP","CBBM","CBD"]}},{"id":"5c48578d660d4f77b80fc55889f8afda","type":"GENE","name":"OPN1MW2","canonical_id":"hgnc:HGNC:26952","description":"opsin 1, medium wave sensitive 2","metadata":null},{"id":"cf73772a14ce425ab6276c5d9639cacc","type":"GENE","name":"OPN1MW3","canonical_id":"hgnc:HGNC:51831","description":"opsin 1, medium wave sensitive 3","metadata":null},{"id":"abb4fc63cb534a5c9761cecabd9fdd4f","type":"GENE","name":"OPN1SW","canonical_id":"hgnc:HGNC:1012","description":"opsin 1, short wave sensitive","metadata":{"aliases":["BOP","CBT","BCP"]}},{"id":"913d9322841747e8ba5ea92b1195b8b6","type":"GENE","name":"OPN3","canonical_id":"hgnc:HGNC:14007","description":"opsin 3","metadata":{"aliases":["ERO","NMO-1","encephalopsin","PPP1R116","ECPN"]}},{"id":"43210f6e42d44e058c3a5f34c8f41a01","type":"GENE","name":"OPN4","canonical_id":"hgnc:HGNC:14449","description":"opsin 4","metadata":{"aliases":["MOP","melanopsin"]}},{"id":"fc19aaea971d4802ba2305f7b5762db9","type":"GENE","name":"OPN5","canonical_id":"hgnc:HGNC:19992","description":"opsin 5","metadata":{"aliases":["neuropsin","dJ402H5.1","TMEM13"]}},{"id":"761f9744c92243fc969320128c6bd340","type":"GENE","name":"OPRD1","canonical_id":"hgnc:HGNC:8153","description":"opioid receptor delta 1","metadata":null},{"id":"157a7b7e3c0946f2b542b12c7567369d","type":"GENE","name":"OPRK1","canonical_id":"hgnc:HGNC:8154","description":"opioid receptor kappa 1","metadata":{"aliases":["KOR","OPRK"]}},{"id":"05385237b94c4b5089e4d4352a2f981b","type":"PROTEIN","name":"OPRK1","canonical_id":"uniprot:P41145","description":null,"metadata":null},{"id":"e8e1855c12cb450a8cd0a50076d491c9","type":"GENE","name":"OPRL1","canonical_id":"hgnc:HGNC:8155","description":"opioid related nociceptin receptor 1","metadata":{"aliases":["NOCIR","ORL1","OOR","KOR-3","NOPr","PNOCR"]}},{"id":"eb94624504814733bb4ac89326f9e4de","type":"GENE","name":"OPRM1","canonical_id":"hgnc:HGNC:8156","description":null,"metadata":null},{"id":"42dbbdc1e61145d7b07fd545e1f55a8e","type":"PROTEIN","name":"OPRM1","canonical_id":"uniprot:P35372","description":null,"metadata":null},{"id":"8b2a45af0c3b4084ba2ea249cca6b5b2","type":"GENE","name":"OPRPN","canonical_id":"hgnc:HGNC:17279","description":"opiorphin prepropeptide","metadata":{"aliases":["BPLP","PRL1","PROL1"]}},{"id":"6fc9346301244d36aba65130e66daa0f","type":"TRIAL","name":"OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00130403","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"f16adc7cf9994e928c4033920eee5dab","type":"GENE","name":"OPTC","canonical_id":"hgnc:HGNC:8158","description":"opticin","metadata":null},{"id":"c16da198d26340549e71b39a0a80180e","type":"TRIAL","name":"OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults","canonical_id":"clinicaltrials.gov:NCT05949424","description":"Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma","metadata":null},{"id":"202c1a6e3efb489db6a80231094efefd","type":"TRIAL","name":"OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial","canonical_id":"clinicaltrials.gov:NCT01955200","description":"Coronary Artery Disease","metadata":null},{"id":"4762196a495246309857afbf00dac48b","type":"GENE","name":"OPTN","canonical_id":"hgnc:HGNC:17142","description":null,"metadata":null},{"id":"13ba767535924840b70cf0cb8cc42d7e","type":"TRIAL","name":"OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)","canonical_id":"clinicaltrials.gov:NCT00076089","description":"Chronic Obstructive Pulmonary Disease; COPD","metadata":null},{"id":"33c55e46e4974b74a1539301b71a8c70","type":"TRIAL","name":"OPsumit USers Registry","canonical_id":"clinicaltrials.gov:NCT02126943","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"96eed881dbd8445ba237863ded6d4bfb","type":"TRIAL","name":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)","canonical_id":"clinicaltrials.gov:NCT01589393","description":"Traumatic Intracranial Haemorrhage","metadata":null},{"id":"1d406c40598e45df8230ea154aae0a0a","type":"GENE","name":"OR10A2","canonical_id":"hgnc:HGNC:8161","description":"olfactory receptor family 10 subfamily A member 2","metadata":{"aliases":["OST363","OR10A2P"]}},{"id":"c4abeb0170f743efa6b400b099575477","type":"GENE","name":"OR10A3","canonical_id":"hgnc:HGNC:8162","description":"olfactory receptor family 10 subfamily A member 3","metadata":{"aliases":["HTPCRX12","HSHTPCRX12"]}},{"id":"b663a45193af42b9960e88cdf43a7ba0","type":"GENE","name":"OR10A4","canonical_id":"hgnc:HGNC:15130","description":"olfactory receptor family 10 subfamily A member 4","metadata":{"aliases":["OR10A4P"]}},{"id":"a7210a30f21b45babb42bea81fccf93d","type":"GENE","name":"OR10A5","canonical_id":"hgnc:HGNC:15131","description":"olfactory receptor family 10 subfamily A member 5","metadata":{"aliases":["OR11-403","JCG6","OR10A1"]}},{"id":"9cad70f50ccd40829805665ce461f24e","type":"GENE","name":"OR10A6","canonical_id":"hgnc:HGNC:15132","description":"olfactory receptor family 10 subfamily A member 6 (gene/pseudogene)","metadata":null},{"id":"76137e936a054309acfe1981faff686e","type":"GENE","name":"OR10A7","canonical_id":"hgnc:HGNC:15329","description":"olfactory receptor family 10 subfamily A member 7","metadata":null},{"id":"34b8b8f87e3c4115a88f1953bbaf7969","type":"GENE","name":"OR10AA1P","canonical_id":"hgnc:HGNC:14989","description":"olfactory receptor family 10 subfamily AA member 1 pseudogene","metadata":null},{"id":"6fbf194b791445adb4743df07a974d9f","type":"GENE","name":"OR10AB1P","canonical_id":"hgnc:HGNC:14804","description":"olfactory receptor family 10 subfamily AB member 1 pseudogene","metadata":null},{"id":"f8a81db9ec074191babe636fd3777b11","type":"GENE","name":"OR10AC1","canonical_id":"hgnc:HGNC:14758","description":"olfactory receptor family 10 subfamily AC member 1 (gene/pseudogene)","metadata":{"aliases":["OR10AC1P"]}},{"id":"02dc35ae3ee4457eae5a3abe79bb2026","type":"GENE","name":"OR10AD1","canonical_id":"hgnc:HGNC:14819","description":"olfactory receptor family 10 subfamily AD member 1","metadata":{"aliases":["OR10AD1P"]}},{"id":"58a5eb05afba45dabb6f8a70cdcf0d16","type":"GENE","name":"OR10AE1P","canonical_id":"hgnc:HGNC:14990","description":"olfactory receptor family 10 subfamily AE member 1 pseudogene","metadata":{"aliases":["OR10AE2P"]}},{"id":"9bb60868631d4f0e81ba99c1d7f485ea","type":"GENE","name":"OR10AE3P","canonical_id":"hgnc:HGNC:31235","description":"olfactory receptor family 10 subfamily AE member 3 pseudogene","metadata":null},{"id":"d0be9b29e970405d84866b6583e7a2ff","type":"GENE","name":"OR10AF1P","canonical_id":"hgnc:HGNC:19606","description":"olfactory receptor family 10 subfamily AF member 1 pseudogene","metadata":null},{"id":"96f4a91dd84b4b83a76ff3159b5bbf88","type":"GENE","name":"OR10AG1","canonical_id":"hgnc:HGNC:19607","description":"olfactory receptor family 10 subfamily AG member 1","metadata":null},{"id":"8829ab47e8124750a94bc2a287f3ba92","type":"GENE","name":"OR10AH1P","canonical_id":"hgnc:HGNC:19647","description":"olfactory receptor family 10 subfamily AH member 1 pseudogene","metadata":null},{"id":"6c2813e3243c44f3a770a6df5bdb2aad","type":"GENE","name":"OR10AK1P","canonical_id":"hgnc:HGNC:31236","description":"olfactory receptor family 10 subfamily AK member 1 pseudogene","metadata":null},{"id":"eecac2540912498db9b8c6afd4781930","type":"GENE","name":"OR10B1P","canonical_id":"hgnc:HGNC:8163","description":"olfactory receptor family 10 subfamily B member 1 pseudogene","metadata":{"aliases":["OR10B2"]}},{"id":"dc10f54fc3c343729a901f5f1de1bc02","type":"GENE","name":"OR10C1","canonical_id":"hgnc:HGNC:8165","description":"olfactory receptor family 10 subfamily C member 1","metadata":{"aliases":["hs6M1-17","OR10C1P","OR10C2"]}},{"id":"94d564eec7a348f88b063c17df6f5c16","type":"GENE","name":"OR10D1P","canonical_id":"hgnc:HGNC:8166","description":"olfactory receptor family 10 subfamily D member 1 pseudogene","metadata":{"aliases":["OST074","HTPCRX03","OR10D2P"]}},{"id":"d82f6148c0da43b089bf07584765e94a","type":"GENE","name":"OR10D3","canonical_id":"hgnc:HGNC:8168","description":"olfactory receptor family 10 subfamily D member 3","metadata":{"aliases":["HTPCRX09","OR10D3P"]}},{"id":"21fd2a597b1644aa8b9d7e8bcf911437","type":"GENE","name":"OR10D4P","canonical_id":"hgnc:HGNC:14770","description":"olfactory receptor family 10 subfamily D member 4 pseudogene","metadata":{"aliases":["OR10D4","OR10D6P"]}},{"id":"e26d5507f3a3471e8df0e4c92757c910","type":"GENE","name":"OR10D5P","canonical_id":"hgnc:HGNC:14838","description":"olfactory receptor family 10 subfamily D member 5 pseudogene","metadata":null},{"id":"fa9e6b44e63140aa89385702f679ef14","type":"GENE","name":"OR10G1P","canonical_id":"hgnc:HGNC:8169","description":"olfactory receptor family 10 subfamily G member 1 pseudogene","metadata":null},{"id":"c34d946de6b345bbbe4fe68d41cbb7e6","type":"GENE","name":"OR10G2","canonical_id":"hgnc:HGNC:8170","description":"olfactory receptor family 10 subfamily G member 2","metadata":null},{"id":"4435bf4884ad47c080eee68da8478fbd","type":"GENE","name":"OR10G3","canonical_id":"hgnc:HGNC:8171","description":"olfactory receptor family 10 subfamily G member 3","metadata":null},{"id":"005fbac4949345e58fc2f91bb0aa9b27","type":"GENE","name":"OR10G4","canonical_id":"hgnc:HGNC:14809","description":"olfactory receptor family 10 subfamily G member 4","metadata":null},{"id":"cfd2c51492ad42c683900f92cdfefffa","type":"GENE","name":"OR10G5P","canonical_id":"hgnc:HGNC:14811","description":"olfactory receptor family 10 subfamily G member 5 pseudogene","metadata":null},{"id":"bf3483f2852b45348d0d52828f9678e9","type":"GENE","name":"OR10G6","canonical_id":"hgnc:HGNC:14836","description":"olfactory receptor family 10 subfamily G member 6","metadata":{"aliases":["OR10G6Q","OR10G6P"]}},{"id":"41a6aab80e074511a1f35741e5b9972f","type":"GENE","name":"OR10G7","canonical_id":"hgnc:HGNC:14842","description":"olfactory receptor family 10 subfamily G member 7","metadata":null},{"id":"15489a32f9a74a539b3878298defce86","type":"GENE","name":"OR10G8","canonical_id":"hgnc:HGNC:14845","description":"olfactory receptor family 10 subfamily G member 8","metadata":null},{"id":"cc39c5ad1895452097470cf9a392c0f0","type":"GENE","name":"OR10G9","canonical_id":"hgnc:HGNC:15129","description":"olfactory receptor family 10 subfamily G member 9","metadata":{"aliases":["OR10G10P"]}},{"id":"3ac9a91a3d9241f9a5eb2c1567f10ea9","type":"GENE","name":"OR10H1","canonical_id":"hgnc:HGNC:8172","description":"olfactory receptor family 10 subfamily H member 1","metadata":null},{"id":"8e2078dcf62e48cda8815bbee1e86d28","type":"GENE","name":"OR10H2","canonical_id":"hgnc:HGNC:8173","description":"olfactory receptor family 10 subfamily H member 2","metadata":null},{"id":"581b38cac8eb4d978dc5b3fad4bf8d3f","type":"GENE","name":"OR10H3","canonical_id":"hgnc:HGNC:8174","description":"olfactory receptor family 10 subfamily H member 3","metadata":null},{"id":"5a3b99388c174d1b941a459a3ce811d5","type":"GENE","name":"OR10H4","canonical_id":"hgnc:HGNC:15388","description":"olfactory receptor family 10 subfamily H member 4","metadata":null},{"id":"4f09e74fc3554b5ebf32dfc8c998eb2a","type":"GENE","name":"OR10H5","canonical_id":"hgnc:HGNC:15389","description":"olfactory receptor family 10 subfamily H member 5","metadata":null},{"id":"2b6c284e97e04742aba4ab6736194b55","type":"GENE","name":"OR10J1","canonical_id":"hgnc:HGNC:8175","description":"olfactory receptor family 10 subfamily J member 1","metadata":{"aliases":["HGMP07J","HSHGMP07J"]}},{"id":"0f5d4fff17774065a950e206df4dcd43","type":"GENE","name":"OR10J2P","canonical_id":"hgnc:HGNC:14991","description":"olfactory receptor family 10 subfamily J member 2 pseudogene","metadata":null},{"id":"8d10b50168aa4f01be4ac1e6798092f1","type":"GENE","name":"OR10J3","canonical_id":"hgnc:HGNC:14992","description":"olfactory receptor family 10 subfamily J member 3 (gene/pseudogene)","metadata":{"aliases":["OR10J3P"]}},{"id":"1d27a0a6d99a442baf0f6587c734a480","type":"GENE","name":"OR10J4","canonical_id":"hgnc:HGNC:15408","description":"olfactory receptor family 10 subfamily J member 4 (gene/pseudogene)","metadata":{"aliases":["OST717","OR10J4P"]}},{"id":"aa70a3f4667e4a9faf2f077d06f35913","type":"GENE","name":"OR10J5","canonical_id":"hgnc:HGNC:14993","description":"olfactory receptor family 10 subfamily J member 5","metadata":null},{"id":"80907404f24b4302b39142b1d47a0152","type":"GENE","name":"OR10J6P","canonical_id":"hgnc:HGNC:14994","description":"olfactory receptor family 10 subfamily J member 6 pseudogene","metadata":{"aliases":["OR10J6"]}},{"id":"4e4d1b10fbe24cb0af1b98d6ba4a5b31","type":"GENE","name":"OR10J7P","canonical_id":"hgnc:HGNC:19637","description":"olfactory receptor family 10 subfamily J member 7 pseudogene","metadata":null},{"id":"e147cbb6e50e48ed93550d70d58434a3","type":"GENE","name":"OR10J8P","canonical_id":"hgnc:HGNC:19638","description":"olfactory receptor family 10 subfamily J member 8 pseudogene","metadata":null},{"id":"ce475d227f8847c88e44f859ca1e491b","type":"GENE","name":"OR10J9P","canonical_id":"hgnc:HGNC:19639","description":"olfactory receptor family 10 subfamily J member 9 pseudogene","metadata":null},{"id":"99b9d510e3e645088b5b810449031837","type":"GENE","name":"OR10K1","canonical_id":"hgnc:HGNC:14693","description":"olfactory receptor family 10 subfamily K member 1","metadata":null},{"id":"b3a70e6c13de427aaa02d6bd5a31c5e6","type":"GENE","name":"OR10K2","canonical_id":"hgnc:HGNC:14826","description":"olfactory receptor family 10 subfamily K member 2","metadata":null},{"id":"832fcc08631d4e72bb46bc42f28eee61","type":"GENE","name":"OR10N1P","canonical_id":"hgnc:HGNC:14689","description":"olfactory receptor family 10 subfamily N member 1 pseudogene","metadata":null},{"id":"571e08621ba94b539f0d77e15ec14e1e","type":"GENE","name":"OR10P1","canonical_id":"hgnc:HGNC:15378","description":"olfactory receptor family 10 subfamily P member 1","metadata":{"aliases":["OST701","OR10P1P","OR10P2P","OR10P3P"]}},{"id":"150ddd5d353148bbb64fd97f197b4909","type":"GENE","name":"OR10Q1","canonical_id":"hgnc:HGNC:15134","description":"olfactory receptor family 10 subfamily Q member 1","metadata":null},{"id":"cd04076b67cf43e08360bdb2352d6979","type":"GENE","name":"OR10Q2P","canonical_id":"hgnc:HGNC:15135","description":"olfactory receptor family 10 subfamily Q member 2 pseudogene","metadata":null},{"id":"6b4268f38431412d8c12a26d77fc34c8","type":"GENE","name":"OR10R1P","canonical_id":"hgnc:HGNC:14813","description":"olfactory receptor family 10 subfamily R member 1 pseudogene","metadata":null},{"id":"ae5534cf257c4291999ae2b947460e3b","type":"GENE","name":"OR10R2","canonical_id":"hgnc:HGNC:14820","description":"olfactory receptor family 10 subfamily R member 2","metadata":{"aliases":["OR10R2Q"]}},{"id":"52786b162fbc412ab144d5fa723b6d0d","type":"GENE","name":"OR10R3P","canonical_id":"hgnc:HGNC:14829","description":"olfactory receptor family 10 subfamily R member 3 pseudogene","metadata":null},{"id":"c1850cb9cb834c2ebf77171e365da60f","type":"GENE","name":"OR10S1","canonical_id":"hgnc:HGNC:14807","description":"olfactory receptor family 10 subfamily S member 1","metadata":null},{"id":"f4bd04b9dc5c4ba5be88e3c3e8438031","type":"GENE","name":"OR10T1P","canonical_id":"hgnc:HGNC:14812","description":"olfactory receptor family 10 subfamily T member 1 pseudogene","metadata":null},{"id":"7cd3ae0058614b7c928eb193ed777795","type":"GENE","name":"OR10T2","canonical_id":"hgnc:HGNC:14816","description":"olfactory receptor family 10 subfamily T member 2","metadata":null},{"id":"720e1ed2fe9049e1be3370483ba59cea","type":"GENE","name":"OR10U1P","canonical_id":"hgnc:HGNC:15332","description":"olfactory receptor family 10 subfamily U member 1 pseudogene","metadata":null},{"id":"fe11ce6e143d4dda9a1ccb8eb2a1c403","type":"GENE","name":"OR10V1","canonical_id":"hgnc:HGNC:15136","description":"olfactory receptor family 10 subfamily V member 1","metadata":null},{"id":"91346b5431584d40bf4a06693022706f","type":"GENE","name":"OR10V2P","canonical_id":"hgnc:HGNC:15137","description":"olfactory receptor family 10 subfamily V member 2 pseudogene","metadata":null},{"id":"55f3542d4be94ef19d025d75f9db0e4a","type":"GENE","name":"OR10V3P","canonical_id":"hgnc:HGNC:15138","description":"olfactory receptor family 10 subfamily V member 3 pseudogene","metadata":null},{"id":"dd806c3839704e2dbd47a454915fe04d","type":"GENE","name":"OR10V7P","canonical_id":"hgnc:HGNC:31237","description":"olfactory receptor family 10 subfamily V member 7 pseudogene","metadata":null},{"id":"d5e4c4c8b29f42c69e2dc3437859cef0","type":"GENE","name":"OR10W1","canonical_id":"hgnc:HGNC:15139","description":"olfactory receptor family 10 subfamily W member 1","metadata":{"aliases":["OR10W1P"]}},{"id":"1f31703eb1984606b0dc8d4a7260678b","type":"GENE","name":"OR10X1","canonical_id":"hgnc:HGNC:14995","description":"olfactory receptor family 10 subfamily X member 1","metadata":{"aliases":["OR10X1P"]}},{"id":"ddb6b0739a9b4c0ba9b5c4d5ec9f1db3","type":"GENE","name":"OR10Y1P","canonical_id":"hgnc:HGNC:15140","description":"olfactory receptor family 10 subfamily Y member 1 pseudogene","metadata":null},{"id":"976f6ed0874240ba91f7a9c60a86d309","type":"GENE","name":"OR10Z1","canonical_id":"hgnc:HGNC:14996","description":"olfactory receptor family 10 subfamily Z member 1","metadata":null},{"id":"bb1e9e47a9264901a4aaabfe7f0bac92","type":"GENE","name":"OR11A1","canonical_id":"hgnc:HGNC:8176","description":"olfactory receptor family 11 subfamily A member 1","metadata":{"aliases":["hs6M1-18","OR11A2"]}},{"id":"3b94d46ed84c4dcfb175829e7c01ce05","type":"GENE","name":"OR11G1P","canonical_id":"hgnc:HGNC:15345","description":"olfactory receptor family 11 subfamily G member 1 pseudogene","metadata":null},{"id":"1f35cae82d334101b8fb0ab3de397e94","type":"GENE","name":"OR11G2","canonical_id":"hgnc:HGNC:15346","description":"olfactory receptor family 11 subfamily G member 2","metadata":null},{"id":"4f7969ae9d484edb911427116fa41aeb","type":"GENE","name":"OR11H1","canonical_id":"hgnc:HGNC:15404","description":"olfactory receptor family 11 subfamily H member 1","metadata":{"aliases":["OR22-1"]}},{"id":"f426a8b9382a49a3bf74359c5303d7f2","type":"GENE","name":"OR11H12","canonical_id":"hgnc:HGNC:30738","description":"olfactory receptor family 11 subfamily H member 12","metadata":null},{"id":"613628c6ea3e4c499545bf81ab14bc0a","type":"GENE","name":"OR11H13P","canonical_id":"hgnc:HGNC:29997","description":"olfactory receptor family 11 subfamily H member 13 pseudogene","metadata":null},{"id":"98aee93fad484b0c802feab38bf833e0","type":"GENE","name":"OR11H2","canonical_id":"hgnc:HGNC:14716","description":"olfactory receptor family 11 subfamily H member 2","metadata":{"aliases":["OR11H2P","OR11H8P","C14orf15"]}},{"id":"c296274a0b9842628b19d47f911dccb4","type":"GENE","name":"OR11H3P","canonical_id":"hgnc:HGNC:15367","description":"olfactory receptor family 11 subfamily H member 3 pseudogene","metadata":null},{"id":"84a28b0faed44dccb562d95ed5d15dfa","type":"GENE","name":"OR11H4","canonical_id":"hgnc:HGNC:15347","description":"olfactory receptor family 11 subfamily H member 4","metadata":null},{"id":"bbb3085b76c0480ebb9e2edb446b8128","type":"GENE","name":"OR11H5P","canonical_id":"hgnc:HGNC:15348","description":"olfactory receptor family 11 subfamily H member 5 pseudogene","metadata":null},{"id":"ae37369a004b4dc29aeba6177a07b3b2","type":"GENE","name":"OR11H6","canonical_id":"hgnc:HGNC:15349","description":"olfactory receptor family 11 subfamily H member 6","metadata":null},{"id":"e3d10684e5ed43ffb2930d65a781a76f","type":"GENE","name":"OR11H7","canonical_id":"hgnc:HGNC:15350","description":"olfactory receptor family 11 subfamily H member 7 (gene/pseudogene)","metadata":{"aliases":["OR11H7P"]}},{"id":"c0ce5793a71546f392c510f94938e961","type":"GENE","name":"OR11I1P","canonical_id":"hgnc:HGNC:14997","description":"olfactory receptor family 11 subfamily I member 1 pseudogene","metadata":{"aliases":["OR11I2P"]}},{"id":"abec9643f77946cf90d5708092cb7bb9","type":"GENE","name":"OR11J1P","canonical_id":"hgnc:HGNC:15369","description":"olfactory receptor family 11 subfamily J member 1 pseudogene","metadata":null},{"id":"4882e32ffb2b4c9abedcfa4ac404fd04","type":"GENE","name":"OR11J2P","canonical_id":"hgnc:HGNC:15370","description":"olfactory receptor family 11 subfamily J member 2 pseudogene","metadata":null},{"id":"ce90a767984c40c8840ed5c107a98a71","type":"GENE","name":"OR11J5P","canonical_id":"hgnc:HGNC:31238","description":"olfactory receptor family 11 subfamily J member 5 pseudogene","metadata":null},{"id":"279a9b0f37f0488e94c1586e816a806e","type":"GENE","name":"OR11J6P","canonical_id":"hgnc:HGNC:38588","description":"olfactory receptor family 11 subfamily J member 6 pseudogene","metadata":null},{"id":"98b4601fd790433483ae26c0aecdd008","type":"GENE","name":"OR11J7P","canonical_id":"hgnc:HGNC:38589","description":"olfactory receptor family 11 subfamily J member 7 pseudogene","metadata":null},{"id":"9d91f06989ee47e599481be4d2a7a48e","type":"GENE","name":"OR11K1BP","canonical_id":"hgnc:HGNC:55117","description":"olfactory receptor family 11 subfamily K member 1B pseudogene","metadata":null},{"id":"bdc2fb14667d40dc99fe2e1d16979994","type":"GENE","name":"OR11K1P","canonical_id":"hgnc:HGNC:15371","description":"olfactory receptor family 11 subfamily K member 1 pseudogene","metadata":null},{"id":"93808bd9338e42349926ac2255985bda","type":"GENE","name":"OR11K2P","canonical_id":"hgnc:HGNC:19635","description":"olfactory receptor family 11 subfamily K member 2 pseudogene","metadata":null},{"id":"1b1a638e649d4c3984758ecc68fcb989","type":"GENE","name":"OR11L1","canonical_id":"hgnc:HGNC:14998","description":"olfactory receptor family 11 subfamily L member 1","metadata":null},{"id":"44df5b2326db4e57b259a63bc59e25cb","type":"GENE","name":"OR11M1P","canonical_id":"hgnc:HGNC:15333","description":"olfactory receptor family 11 subfamily M member 1 pseudogene","metadata":null},{"id":"55676dd7b42f4fd2b9c9a212033ba523","type":"GENE","name":"OR11N1P","canonical_id":"hgnc:HGNC:19582","description":"olfactory receptor family 11 subfamily N member 1 pseudogene","metadata":null},{"id":"f4aea4029d3e4d82b48aae3c1d398ea8","type":"GENE","name":"OR11P1P","canonical_id":"hgnc:HGNC:19636","description":"olfactory receptor family 11 subfamily P member 1 pseudogene","metadata":null},{"id":"84949a0ac21941d4a12685a7b4937998","type":"GENE","name":"OR11Q1P","canonical_id":"hgnc:HGNC:31239","description":"olfactory receptor family 11 subfamily Q member 1 pseudogene","metadata":null},{"id":"7116e4f385034ae1aa16651b01021e53","type":"GENE","name":"OR12D1","canonical_id":"hgnc:HGNC:8177","description":"olfactory receptor family 12 subfamily D member 1 (gene/pseudogene)","metadata":{"aliases":["hs6M1-19","OR12D1P"]}},{"id":"463b68a93c2b420e8acdc70feb5d3340","type":"GENE","name":"OR12D2","canonical_id":"hgnc:HGNC:8178","description":"olfactory receptor family 12 subfamily D member 2","metadata":{"aliases":["hs6M1-20"]}},{"id":"d7eab9a0f43d47a5a4df424bc8693a26","type":"GENE","name":"OR12D3","canonical_id":"hgnc:HGNC:13963","description":"olfactory receptor family 12 subfamily D member 3","metadata":{"aliases":["hs6M1-27"]}},{"id":"905045b9659b49bea0fda522d70c56b8","type":"GENE","name":"OR13A1","canonical_id":"hgnc:HGNC:14772","description":"olfactory receptor family 13 subfamily A member 1","metadata":null},{"id":"e0f16353982a429abdd6643a3a73a58a","type":"GENE","name":"OR13C1P","canonical_id":"hgnc:HGNC:14699","description":"olfactory receptor family 13 subfamily C member 1 pseudogene","metadata":null},{"id":"84ffbcba299f49d3b9460333b2bbbae0","type":"GENE","name":"OR13C2","canonical_id":"hgnc:HGNC:14701","description":"olfactory receptor family 13 subfamily C member 2","metadata":null},{"id":"945f411851ba4f0e9d15cdc70704e02a","type":"GENE","name":"OR13C3","canonical_id":"hgnc:HGNC:14704","description":"olfactory receptor family 13 subfamily C member 3","metadata":null},{"id":"051d310993bf49259997b95b3e82bd47","type":"GENE","name":"OR13C4","canonical_id":"hgnc:HGNC:14722","description":"olfactory receptor family 13 subfamily C member 4","metadata":null},{"id":"319d62efdb4942aaab00123b8e3edc57","type":"GENE","name":"OR13C5","canonical_id":"hgnc:HGNC:15100","description":"olfactory receptor family 13 subfamily C member 5","metadata":null},{"id":"974b764477ed41549eec58a4f2d4a99f","type":"GENE","name":"OR13C6P","canonical_id":"hgnc:HGNC:15101","description":"olfactory receptor family 13 subfamily C member 6 pseudogene","metadata":null},{"id":"3e83719cb49246adb19dfe7dfde3dadb","type":"GENE","name":"OR13C7","canonical_id":"hgnc:HGNC:15102","description":"olfactory receptor family 13 subfamily C member 7 (gene/pseudogene)","metadata":{"aliases":["OST706","OR13C7P"]}},{"id":"1da566dcb09c4321a5fff2ea31f939f2","type":"GENE","name":"OR13C8","canonical_id":"hgnc:HGNC:15103","description":"olfactory receptor family 13 subfamily C member 8","metadata":null},{"id":"e65dbd305d114913827b7cfe025df3cc","type":"GENE","name":"OR13C9","canonical_id":"hgnc:HGNC:15104","description":"olfactory receptor family 13 subfamily C member 9","metadata":null},{"id":"0288ca2e58b04ad7942664f02ec553e9","type":"GENE","name":"OR13D1","canonical_id":"hgnc:HGNC:14695","description":"olfactory receptor family 13 subfamily D member 1","metadata":null},{"id":"de9a4da99f614d26a34d48f7072b426c","type":"GENE","name":"OR13D2P","canonical_id":"hgnc:HGNC:15105","description":"olfactory receptor family 13 subfamily D member 2 pseudogene","metadata":null},{"id":"6745018bbd884410a06774b07a2249e6","type":"GENE","name":"OR13D3P","canonical_id":"hgnc:HGNC:15106","description":"olfactory receptor family 13 subfamily D member 3 pseudogene","metadata":null},{"id":"91b459ca9edc46a5bb8c6c443db54d93","type":"GENE","name":"OR13E1P","canonical_id":"hgnc:HGNC:15107","description":"olfactory receptor family 13 subfamily E member 1 pseudogene","metadata":{"aliases":["OST741","OR13E2"]}},{"id":"905cc1459fc44d84ab570f478bea5fae","type":"GENE","name":"OR13F1","canonical_id":"hgnc:HGNC:14723","description":"olfactory receptor family 13 subfamily F member 1","metadata":null},{"id":"5a678e6ba6254010a52f43551059f649","type":"GENE","name":"OR13G1","canonical_id":"hgnc:HGNC:14999","description":"olfactory receptor family 13 subfamily G member 1","metadata":null},{"id":"f8eb663fc445463bb7c6d73460bdfd44","type":"GENE","name":"OR13H1","canonical_id":"hgnc:HGNC:14755","description":"olfactory receptor family 13 subfamily H member 1","metadata":null},{"id":"1d4077d330624ddba483412b4e14db15","type":"GENE","name":"OR13I1P","canonical_id":"hgnc:HGNC:14732","description":"olfactory receptor family 13 subfamily I member 1 pseudogene","metadata":{"aliases":["OR13I2P"]}},{"id":"a7512a3ed7cb4c258f118461db3cbd66","type":"GENE","name":"OR13J1","canonical_id":"hgnc:HGNC:15108","description":"olfactory receptor family 13 subfamily J member 1","metadata":null},{"id":"5aaed7d9400f4561ae69b95f89af7d0f","type":"GENE","name":"OR13K1P","canonical_id":"hgnc:HGNC:14721","description":"olfactory receptor family 13 subfamily K member 1 pseudogene","metadata":null},{"id":"cffddc917b694a33a11f730e250a0103","type":"GENE","name":"OR13Z1P","canonical_id":"hgnc:HGNC:31240","description":"olfactory receptor family 13 subfamily Z member 1 pseudogene","metadata":null},{"id":"33542a6386fb433b8155b8e9cbe87429","type":"GENE","name":"OR13Z2P","canonical_id":"hgnc:HGNC:31241","description":"olfactory receptor family 13 subfamily Z member 2 pseudogene","metadata":null},{"id":"584d64c394a34f9381de227d9170dd73","type":"GENE","name":"OR13Z3P","canonical_id":"hgnc:HGNC:31242","description":"olfactory receptor family 13 subfamily Z member 3 pseudogene","metadata":null},{"id":"933de878801541f797562027934f678b","type":"GENE","name":"OR14A16","canonical_id":"hgnc:HGNC:15022","description":"olfactory receptor family 14 subfamily A member 16","metadata":{"aliases":["OR5AT1"]}},{"id":"861c01d7d0014b8480f211f8dcc5f644","type":"GENE","name":"OR14A2","canonical_id":"hgnc:HGNC:15024","description":"olfactory receptor family 14 subfamily A member 2","metadata":{"aliases":["OR5AX1P","OR5AX1"]}},{"id":"ce1d6fb5784d4666b43b0af29d1add0e","type":"GENE","name":"OR14C36","canonical_id":"hgnc:HGNC:15026","description":"olfactory receptor family 14 subfamily C member 36","metadata":{"aliases":["OR5BF1"]}},{"id":"cc3c17f5b0e544fa87126daf1eecc9c4","type":"GENE","name":"OR14I1","canonical_id":"hgnc:HGNC:19575","description":"olfactory receptor family 14 subfamily I member 1","metadata":{"aliases":["OR5BU1P","OR5BU1"]}},{"id":"0324f5ff27444433b7b2d08ee347c2c4","type":"GENE","name":"OR14J1","canonical_id":"hgnc:HGNC:13971","description":"olfactory receptor family 14 subfamily J member 1","metadata":{"aliases":["hs6M1-28","OR5U1"]}},{"id":"e0f1c8e906174444a974ddf1d59b42e4","type":"GENE","name":"OR14J1-AS1","canonical_id":"hgnc:HGNC:59378","description":"OR14J1 antisense RNA 1","metadata":null},{"id":"4e832d0428d14ac0b6cdbc3d37eaabd1","type":"GENE","name":"OR14K1","canonical_id":"hgnc:HGNC:15025","description":"olfactory receptor family 14 subfamily K member 1","metadata":{"aliases":["OR5AY1"]}},{"id":"f8fb435b2b34490996d9d82ee3ff7686","type":"GENE","name":"OR14L1","canonical_id":"hgnc:HGNC:15023","description":"olfactory receptor family 14 subfamily L member 1","metadata":{"aliases":["OR5AV1","OR5AV1P","OR14L1P"]}},{"id":"f012537357ea409da85a4be95683e7af","type":"GENE","name":"OR1A1","canonical_id":"hgnc:HGNC:8179","description":"olfactory receptor family 1 subfamily A member 1","metadata":{"aliases":["OR17-7"]}},{"id":"aecaff895bbc42d1a6ad6bd531a8d4f3","type":"GENE","name":"OR1A2","canonical_id":"hgnc:HGNC:8180","description":"olfactory receptor family 1 subfamily A member 2","metadata":{"aliases":["OR17-6"]}},{"id":"46521f0081c64305be87dd2ec0904587","type":"GENE","name":"OR1AA1P","canonical_id":"hgnc:HGNC:14750","description":"olfactory receptor family 1 subfamily AA member 1 pseudogene","metadata":null},{"id":"23ff6b879fb0470c97bc7bb748fb86bd","type":"GENE","name":"OR1AB1P","canonical_id":"hgnc:HGNC:15390","description":"olfactory receptor family 1 subfamily AB member 1 pseudogene","metadata":null},{"id":"82e8ef1da51447b1887822b424db187a","type":"GENE","name":"OR1AC1P","canonical_id":"hgnc:HGNC:31243","description":"olfactory receptor family 1 subfamily AC member 1 pseudogene","metadata":null},{"id":"f6422e93d4704ea1a0184b005b5cdb6d","type":"GENE","name":"OR1B1","canonical_id":"hgnc:HGNC:8181","description":"olfactory receptor family 1 subfamily B member 1","metadata":{"aliases":["OR9-B"]}},{"id":"21608954cf774807860bae3657d72065","type":"GENE","name":"OR1C1","canonical_id":"hgnc:HGNC:8182","description":"olfactory receptor family 1 subfamily C member 1","metadata":{"aliases":["TPCR27","HSTPCR27"]}},{"id":"d0d4aac7b479422383affcae739d91ee","type":"GENE","name":"OR1D2","canonical_id":"hgnc:HGNC:8183","description":"olfactory receptor family 1 subfamily D member 2","metadata":{"aliases":["OR17-4","OLFR1"]}},{"id":"8dd108fa1cde476dbb1c84f20c211632","type":"GENE","name":"OR1D3P","canonical_id":"hgnc:HGNC:8184","description":"olfactory receptor family 1 subfamily D member 3 pseudogene","metadata":{"aliases":["OR17-23","OR11-13","OR11-22","OR1D6P","OR1D7P"]}},{"id":"87ce82cd2c8142a1b89c539d227b19d9","type":"GENE","name":"OR1D4","canonical_id":"hgnc:HGNC:8185","description":"olfactory receptor family 1 subfamily D member 4","metadata":{"aliases":["OR17-30"]}},{"id":"d3487e8e9418457387f843d547fad442","type":"GENE","name":"OR1D5","canonical_id":"hgnc:HGNC:8186","description":"olfactory receptor family 1 subfamily D member 5","metadata":{"aliases":["OR17-31"]}},{"id":"b1f6399a9c3940f9a5e9eeedfb13909f","type":"GENE","name":"OR1E1","canonical_id":"hgnc:HGNC:8189","description":"olfactory receptor family 1 subfamily E member 1","metadata":{"aliases":["OR17-2","HGM071","OR17-32","OR13-66","OR1E9P","OR1E5","OR1E6"]}},{"id":"1c04e299a7f64143baa710e433252df6","type":"GENE","name":"OR1E2","canonical_id":"hgnc:HGNC:8190","description":"olfactory receptor family 1 subfamily E member 2","metadata":{"aliases":["OR17-93","OR17-135","OR1E4"]}},{"id":"5e974e658b0241059d6eba70304a1652","type":"GENE","name":"OR1E3","canonical_id":"hgnc:HGNC:8191","description":"olfactory receptor family 1 subfamily E member 3 (gene/pseudogene)","metadata":{"aliases":["OR17-210","OR1E3P"]}},{"id":"fcc5994d4896464bbcee3f129bf365b8","type":"GENE","name":"OR1F1","canonical_id":"hgnc:HGNC:8194","description":"olfactory receptor family 1 subfamily F member 1","metadata":{"aliases":["Olfmf","OR16-36","OR16-37","OR16-88","OR16-89","OR16-90","OLFMF","OR3-145","OR1F4","OR1F6","OR1F7","OR1F8","OR1F9","OR1F5","OR1F10","OR1F13P"]}},{"id":"7e60dae715db473aaf2d589c5a56b6c8","type":"GENE","name":"OR1F12P","canonical_id":"hgnc:HGNC:13964","description":"olfactory receptor family 1 subfamily F member 12, pseudogene","metadata":{"aliases":["hs6M1-35P","OR1F12Q","OR1F12"]}},{"id":"a9612d39f5e644d3a7eb6657b400e0f5","type":"GENE","name":"OR1F2P","canonical_id":"hgnc:HGNC:8196","description":"olfactory receptor family 1 subfamily F member 2 pseudogene","metadata":{"aliases":["OLFMF2","OR1F3P","OR1F2"]}},{"id":"06d78da2b02a490dbcf5de4197f2b372","type":"GENE","name":"OR1G1","canonical_id":"hgnc:HGNC:8204","description":"olfactory receptor family 1 subfamily G member 1","metadata":{"aliases":["OR17-209","OR1G2"]}},{"id":"8c616a183afa4e6886664bc5cc770546","type":"GENE","name":"OR1H1P","canonical_id":"hgnc:HGNC:8206","description":"olfactory receptor family 1 subfamily H member 1 pseudogene","metadata":{"aliases":["OST26","OR1H1"]}},{"id":"442a9ef3582c4fb9911396d303762207","type":"GENE","name":"OR1I1","canonical_id":"hgnc:HGNC:8207","description":"olfactory receptor family 1 subfamily I member 1","metadata":{"aliases":["OR1I1P","OR19-20","OR1I1Q"]}},{"id":"1ec229985c434444b5c69d4f7996ca73","type":"GENE","name":"OR1J1","canonical_id":"hgnc:HGNC:8208","description":"olfactory receptor family 1 subfamily J member 1","metadata":{"aliases":["hg32"]}},{"id":"3acea3af051641759dfcdb60b9cdb4f8","type":"GENE","name":"OR1J2","canonical_id":"hgnc:HGNC:8209","description":"olfactory receptor family 1 subfamily J member 2","metadata":{"aliases":["OST044","OR1J3","OR1J5"]}},{"id":"68a88c10fd7d4f35b7dbc4d2e3a5192f","type":"GENE","name":"OR1J4","canonical_id":"hgnc:HGNC:8211","description":"olfactory receptor family 1 subfamily J member 4","metadata":{"aliases":["HTPCRX01","HSHTPCRX01"]}},{"id":"a35dab9d53ac4db2895df8e003aea788","type":"GENE","name":"OR1K1","canonical_id":"hgnc:HGNC:8212","description":"olfactory receptor family 1 subfamily K member 1","metadata":{"aliases":["hg99","MNAB"]}},{"id":"1d40284a47534b039b4ad6af3fdeb6df","type":"GENE","name":"OR1L1","canonical_id":"hgnc:HGNC:8213","description":"olfactory receptor family 1 subfamily L member 1","metadata":{"aliases":["OR9-C","OR1L2"]}},{"id":"5ceea768328f4ed2acc1fb9344fb6237","type":"GENE","name":"OR1L3","canonical_id":"hgnc:HGNC:8215","description":"olfactory receptor family 1 subfamily L member 3","metadata":{"aliases":["OR9-D"]}},{"id":"33219ab56b9f4c01b781cdee4f9ef5e9","type":"GENE","name":"OR1L4","canonical_id":"hgnc:HGNC:8216","description":"olfactory receptor family 1 subfamily L member 4","metadata":{"aliases":["OR9-E","OR1L5"]}},{"id":"f90c408479074e6e9bb3144c35454e33","type":"GENE","name":"OR1L6","canonical_id":"hgnc:HGNC:8218","description":"olfactory receptor family 1 subfamily L member 6","metadata":{"aliases":["OR1L7"]}},{"id":"bd085a87d46d469bbc4f520a12d57e81","type":"GENE","name":"OR1L8","canonical_id":"hgnc:HGNC:15110","description":"olfactory receptor family 1 subfamily L member 8","metadata":null},{"id":"2013798916cd4545ae42e956007f0fab","type":"GENE","name":"OR1M1","canonical_id":"hgnc:HGNC:8220","description":"olfactory receptor family 1 subfamily M member 1","metadata":{"aliases":["OR19-6"]}},{"id":"9d3608fe2e6c48c3b4764d927a8997f0","type":"GENE","name":"OR1M4P","canonical_id":"hgnc:HGNC:31244","description":"olfactory receptor family 1 subfamily M member 4 pseudogene","metadata":null},{"id":"58d387425ba045dea7c6cdcb55a8d00e","type":"GENE","name":"OR1N1","canonical_id":"hgnc:HGNC:8221","description":"olfactory receptor family 1 subfamily N member 1","metadata":{"aliases":["OR1-26","OR1N3"]}},{"id":"c05c71a5c9294e67976c64d056e6287a","type":"GENE","name":"OR1N2","canonical_id":"hgnc:HGNC:15111","description":"olfactory receptor family 1 subfamily N member 2","metadata":null},{"id":"4817ebb4ee15428399ce1b075ad368a5","type":"GENE","name":"OR1P1","canonical_id":"hgnc:HGNC:8222","description":"olfactory receptor family 1 subfamily P member 1 (gene/pseudogene)","metadata":{"aliases":["OR17-208","OR1P1P"]}},{"id":"43bae46d18e44562a96e52911d578ccd","type":"GENE","name":"OR1Q1","canonical_id":"hgnc:HGNC:8223","description":"olfactory receptor family 1 subfamily Q member 1","metadata":{"aliases":["OST226","OR9-A","HSTPCR106","OST226OR9-A","TPCR106","OR1Q2","OR1Q3"]}},{"id":"ec845301bdbb45d6af16ea1636b4b10b","type":"GENE","name":"OR1Q1BP","canonical_id":"hgnc:HGNC:55113","description":"olfactory receptor family 1 subfamily Q member 1B pseudogene","metadata":null},{"id":"d1636979acca4d25b3715da889f88b05","type":"GENE","name":"OR1R1","canonical_id":"hgnc:HGNC:8226","description":"olfactory receptor family 1 subfamily R member 1","metadata":{"aliases":["OR17-1","OR20A1P","OR1R2P","OR1R3P","OR1R1P"]}},{"id":"f70e338678ec4410aff714ec6215f712","type":"GENE","name":"OR1S1","canonical_id":"hgnc:HGNC:8227","description":"olfactory receptor family 1 subfamily S member 1","metadata":{"aliases":["OST034"]}},{"id":"d91fd1aeab7743409bfc7094e47a908d","type":"GENE","name":"OR1S2","canonical_id":"hgnc:HGNC:15141","description":"olfactory receptor family 1 subfamily S member 2","metadata":null},{"id":"b96eb5ce653344b79ce1afd11b5437ce","type":"GENE","name":"OR1X1P","canonical_id":"hgnc:HGNC:15062","description":"olfactory receptor family 1 subfamily X member 1 pseudogene","metadata":null},{"id":"d45a20aaa9054166ba5f42187d88fbbf","type":"GENE","name":"OR1X5P","canonical_id":"hgnc:HGNC:31245","description":"olfactory receptor family 1 subfamily X member 5 pseudogene","metadata":null},{"id":"54ffec6fdec848b8972595a1b330085f","type":"GENE","name":"OR2A1","canonical_id":"hgnc:HGNC:8229","description":"olfactory receptor family 2 subfamily A member 1","metadata":null},{"id":"2910beaefb264a62b61d7c4f3c3df22d","type":"GENE","name":"OR2A1-AS1","canonical_id":"hgnc:HGNC:49168","description":"OR2A1 antisense RNA 1","metadata":null},{"id":"82975de10ab54589a6da36c9b708bdda","type":"GENE","name":"OR2A12","canonical_id":"hgnc:HGNC:15082","description":"olfactory receptor family 2 subfamily A member 12","metadata":{"aliases":["OR2A12P"]}},{"id":"795cc97dcae249eda1c7f9f8dd2f67e4","type":"GENE","name":"OR2A13P","canonical_id":"hgnc:HGNC:15083","description":"olfactory receptor family 2 subfamily A member 13 pseudogene","metadata":null},{"id":"0aef748b4f6f44f183f0f5779453bed3","type":"GENE","name":"OR2A14","canonical_id":"hgnc:HGNC:15084","description":"olfactory receptor family 2 subfamily A member 14","metadata":{"aliases":["OST182","OR2A14P","OR2A6"]}},{"id":"c0afd49c6ca34364ab1eaf8c3c56b925","type":"GENE","name":"OR2A15P","canonical_id":"hgnc:HGNC:15085","description":"olfactory receptor family 2 subfamily A member 15 pseudogene","metadata":{"aliases":["OR2A28P"]}},{"id":"4d2305c2ab984c8f8039d7600a9e60c9","type":"GENE","name":"OR2A2","canonical_id":"hgnc:HGNC:8230","description":"olfactory receptor family 2 subfamily A member 2","metadata":{"aliases":["OST008","OR2A2P","OR2A17P"]}},{"id":"3c345d6f5a184f8cb3a8fb20891c25c1","type":"GENE","name":"OR2A20P","canonical_id":"hgnc:HGNC:15413","description":"olfactory receptor family 2 subfamily A member 20 pseudogene","metadata":{"aliases":["OR2A20"]}},{"id":"db53dbbb76b04392a17e39611332ffeb","type":"GENE","name":"OR2A25","canonical_id":"hgnc:HGNC:19562","description":"olfactory receptor family 2 subfamily A member 25","metadata":{"aliases":["OR2A25P","OR2A27"]}},{"id":"461b0d8949e547beb6413dd855955304","type":"GENE","name":"OR2A3P","canonical_id":"hgnc:HGNC:8231","description":"olfactory receptor family 2 subfamily A member 3 pseudogene","metadata":null},{"id":"fb2800cd57f34a01840867f56c6eb88e","type":"GENE","name":"OR2A4","canonical_id":"hgnc:HGNC:14729","description":"olfactory receptor family 2 subfamily A member 4","metadata":{"aliases":["OR2A10"]}},{"id":"4b5a05c95b35437d977a96f8fef244cb","type":"GENE","name":"OR2A41P","canonical_id":"hgnc:HGNC:31246","description":"olfactory receptor family 2 subfamily A member 41 pseudogene","metadata":null},{"id":"faeb01816a6e49c88be0683609bb8a89","type":"GENE","name":"OR2A42","canonical_id":"hgnc:HGNC:31230","description":"olfactory receptor family 2 subfamily A member 42","metadata":null},{"id":"262624460f7d4122af1ce835628a1d8d","type":"GENE","name":"OR2A5","canonical_id":"hgnc:HGNC:8232","description":"olfactory receptor family 2 subfamily A member 5","metadata":{"aliases":["OR7-138","OR7-141","OR2A8","OR2A26"]}},{"id":"4ab9074d56604a4eadfb74b173fb19a1","type":"GENE","name":"OR2A7","canonical_id":"hgnc:HGNC:8234","description":"olfactory receptor family 2 subfamily A member 7","metadata":{"aliases":["HSDJ0798C17"]}},{"id":"a17e269749924e60a419e5396ccbf264","type":"GENE","name":"OR2A9P","canonical_id":"hgnc:HGNC:8236","description":"olfactory receptor family 2 subfamily A member 9 pseudogene","metadata":{"aliases":["HSDJ0798C17","OR2A9"]}},{"id":"bf99bdb2bc58475a960c81ca63a22a09","type":"GENE","name":"OR2AD1P","canonical_id":"hgnc:HGNC:14749","description":"olfactory receptor family 2 subfamily AD member 1 pseudogene","metadata":{"aliases":["OR2AD1","hs6M1-8P"]}},{"id":"3057c5b075a846ccb9cbf59680aef810","type":"GENE","name":"OR2AE1","canonical_id":"hgnc:HGNC:15087","description":"olfactory receptor family 2 subfamily AE member 1","metadata":{"aliases":["OR2AE2"]}},{"id":"289cb24006f94dbe8ba23cb12fef587f","type":"GENE","name":"OR2AF1P","canonical_id":"hgnc:HGNC:14719","description":"olfactory receptor family 2 subfamily AF member 1 pseudogene","metadata":{"aliases":["OR2AF2P"]}},{"id":"fddd3e1afa9a4604a247f5ebeb8e50ab","type":"GENE","name":"OR2AG1","canonical_id":"hgnc:HGNC:15142","description":"olfactory receptor family 2 subfamily AG member 1","metadata":{"aliases":["OR2AG3"]}},{"id":"634628ac67bd4e28a2640984ec25a5a6","type":"GENE","name":"OR2AG2","canonical_id":"hgnc:HGNC:15143","description":"olfactory receptor family 2 subfamily AG member 2","metadata":{"aliases":["OR2AG2P"]}},{"id":"9f79e77a4d914a4f8727b054ed2f8ede","type":"GENE","name":"OR2AH1P","canonical_id":"hgnc:HGNC:15144","description":"olfactory receptor family 2 subfamily AH member 1 pseudogene","metadata":null},{"id":"defe7677371a48c3b6be81d53277213f","type":"GENE","name":"OR2AI1P","canonical_id":"hgnc:HGNC:15063","description":"olfactory receptor family 2 subfamily AI member 1 pseudogene","metadata":null},{"id":"5ef4e45d891542c4b96fbc9d39b2598a","type":"GENE","name":"OR2AJ1","canonical_id":"hgnc:HGNC:15001","description":"olfactory receptor family 2 subfamily AJ member 1","metadata":{"aliases":["OR2AJ1Q","OR2AJ1P"]}},{"id":"124088148fdf48f1a9bfba6a5558874d","type":"GENE","name":"OR2AK2","canonical_id":"hgnc:HGNC:19569","description":"olfactory receptor family 2 subfamily AK member 2","metadata":{"aliases":["OR2AK1P"]}},{"id":"49090f869d494ee5b4333b6fbcbccfe6","type":"GENE","name":"OR2AL1P","canonical_id":"hgnc:HGNC:14712","description":"olfactory receptor family 2 subfamily AL member 1 pseudogene","metadata":null},{"id":"bb566e2108c54e36aa45f607db455c26","type":"GENE","name":"OR2AM1P","canonical_id":"hgnc:HGNC:15113","description":"olfactory receptor family 2 subfamily AM member 1 pseudogene","metadata":null},{"id":"6dc2d3bc8c4e4bfd86b02add450bdfe6","type":"GENE","name":"OR2AO1P","canonical_id":"hgnc:HGNC:31247","description":"olfactory receptor family 2 subfamily AO member 1 pseudogene","metadata":null},{"id":"7f37bbf4b0f04376a6e30792c06b904c","type":"GENE","name":"OR2AP1","canonical_id":"hgnc:HGNC:15335","description":"olfactory receptor family 2 subfamily AP member 1","metadata":{"aliases":["OR2AP1P"]}},{"id":"2000106f07b7439fb824ac7a62912c31","type":"GENE","name":"OR2AQ1P","canonical_id":"hgnc:HGNC:15003","description":"olfactory receptor family 2 subfamily AQ member 1 pseudogene","metadata":null},{"id":"c3a708aa25d24d88b7801a50656bd60b","type":"GENE","name":"OR2AS1P","canonical_id":"hgnc:HGNC:15004","description":"olfactory receptor family 2 subfamily AS member 1 pseudogene","metadata":null},{"id":"af5a63c22bef4038a91577bce7979317","type":"GENE","name":"OR2AS2P","canonical_id":"hgnc:HGNC:31248","description":"olfactory receptor family 2 subfamily AS member 2 pseudogene","metadata":null},{"id":"4923fca1666043a08a24b7c0fca6bca4","type":"GENE","name":"OR2AT1P","canonical_id":"hgnc:HGNC:15145","description":"olfactory receptor family 2 subfamily AT member 1 pseudogene","metadata":null},{"id":"1205d1f629954f71bab183f2150d306b","type":"GENE","name":"OR2AT2P","canonical_id":"hgnc:HGNC:19619","description":"olfactory receptor family 2 subfamily AT member 2 pseudogene","metadata":null},{"id":"d037f4a8ad1d436a85a8d402fce2fbf9","type":"GENE","name":"OR2AT4","canonical_id":"hgnc:HGNC:19620","description":"olfactory receptor family 2 subfamily AT member 4","metadata":null},{"id":"c63a08889e014965b3e821df0e8388d5","type":"GENE","name":"OR2B11","canonical_id":"hgnc:HGNC:31249","description":"olfactory receptor family 2 subfamily B member 11","metadata":null},{"id":"89a07bb7c8774b3db3f966be9c44d057","type":"GENE","name":"OR2B2","canonical_id":"hgnc:HGNC:13966","description":"olfactory receptor family 2 subfamily B member 2","metadata":{"aliases":["hs6M1-10","OR6-1","OR2B2Q","OR2B9"]}},{"id":"1f5d8d63aa86472a9170f2d663b89886","type":"GENE","name":"OR2B3","canonical_id":"hgnc:HGNC:8238","description":"olfactory receptor family 2 subfamily B member 3","metadata":{"aliases":["OR6-4","OR2B3P"]}},{"id":"cdaac30418674135b1b17142826217cb","type":"GENE","name":"OR2B4P","canonical_id":"hgnc:HGNC:8239","description":"olfactory receptor family 2 subfamily B member 4 pseudogene","metadata":{"aliases":["hs6M1-22"]}},{"id":"025925db9ba24746b363f3490db3d674","type":"GENE","name":"OR2B6","canonical_id":"hgnc:HGNC:8241","description":"olfactory receptor family 2 subfamily B member 6","metadata":{"aliases":["OR6-31","dJ408B20.2","OR5-40","OR5-41","OR2B6P","OR2B1","OR2B1P","OR2B5"]}},{"id":"241c378cbeb44988928d2dd44bfea8af","type":"GENE","name":"OR2B7P","canonical_id":"hgnc:HGNC:13967","description":"olfactory receptor family 2 subfamily B member 7 pseudogene","metadata":{"aliases":["hs6M1-31P"]}},{"id":"3623888b1d854e43983dcb21d8cdaa2a","type":"GENE","name":"OR2B8","canonical_id":"hgnc:HGNC:13968","description":"olfactory receptor family 2 subfamily B member 8 (gene/pseudogene)","metadata":{"aliases":["hs6M1-29P","OR2B8P"]}},{"id":"9a6d0576c3a1402b94d8e82487b74315","type":"GENE","name":"OR2BH1P","canonical_id":"hgnc:HGNC:31250","description":"olfactory receptor family 2 subfamily BH member 1 pseudogene","metadata":null},{"id":"e931b0f4235145b3b1e362a32bda8d2d","type":"GENE","name":"OR2C1","canonical_id":"hgnc:HGNC:8242","description":"olfactory receptor family 2 subfamily C member 1","metadata":{"aliases":["OLFmf3","OR2C2P"]}},{"id":"e333a5f445d74f17ab329e2ce851c09a","type":"GENE","name":"OR2C3","canonical_id":"hgnc:HGNC:15005","description":"olfactory receptor family 2 subfamily C member 3","metadata":{"aliases":["OST742","OR2C4","OR2C5P"]}},{"id":"658a1065046c4f8290e85fd46e96f82d","type":"GENE","name":"OR2D2","canonical_id":"hgnc:HGNC:8244","description":"olfactory receptor family 2 subfamily D member 2","metadata":{"aliases":["OR11-610","hg27","OR2D1"]}},{"id":"d5a5a7c546624841bc9b1947e1cbc5aa","type":"GENE","name":"OR2D3","canonical_id":"hgnc:HGNC:15146","description":"olfactory receptor family 2 subfamily D member 3","metadata":null},{"id":"6be281c849614e6bbe0dc072c764ca60","type":"GENE","name":"OR2E1P","canonical_id":"hgnc:HGNC:15507","description":"olfactory receptor family 2 subfamily E member 1 pseudogene","metadata":{"aliases":["hs6M1-9","hs6M1-9p","HS29K1","HSNH0569I24","OR2E1","OR2E2"]}},{"id":"4c78a269a8cc4fc4985843d5a9d8d083","type":"GENE","name":"OR2F1","canonical_id":"hgnc:HGNC:8246","description":"olfactory receptor family 2 subfamily F member 1","metadata":{"aliases":["OLF3","OR7-140","OR7-139","OR14-60","OR2F4","OR2F5","OR2F3","OR2F3P"]}},{"id":"b17df125bc6f4b78944950fbc47d7ec5","type":"GENE","name":"OR2F2","canonical_id":"hgnc:HGNC:8247","description":"olfactory receptor family 2 subfamily F member 2","metadata":{"aliases":["OR7-1"]}},{"id":"49e91b16e68348569ee70339d179cc7d","type":"GENE","name":"OR2G1P","canonical_id":"hgnc:HGNC:8251","description":"olfactory receptor family 2 subfamily G member 1 pseudogene","metadata":{"aliases":["OST619","hs6M1-25"]}},{"id":"9045f80b055748af9980742f7ab7bd27","type":"GENE","name":"OR2G2","canonical_id":"hgnc:HGNC:15007","description":"olfactory receptor family 2 subfamily G member 2","metadata":null},{"id":"d4e601f8d0d64f3fbf39b80c0be437a3","type":"GENE","name":"OR2G3","canonical_id":"hgnc:HGNC:15008","description":"olfactory receptor family 2 subfamily G member 3","metadata":null},{"id":"a175e34b915f485fa478c08873bb0847","type":"GENE","name":"OR2G6","canonical_id":"hgnc:HGNC:27019","description":"olfactory receptor family 2 subfamily G member 6","metadata":null},{"id":"2386ce7e475f473e9ec6871679e9d09e","type":"GENE","name":"OR2H1","canonical_id":"hgnc:HGNC:8252","description":"olfactory receptor family 2 subfamily H member 1","metadata":{"aliases":["OR6-2","OR2H6","OR2H8"]}},{"id":"6a683e37fc1844dc8b3c65bfcedfe4da","type":"GENE","name":"OR2H2","canonical_id":"hgnc:HGNC:8253","description":"olfactory receptor family 2 subfamily H member 2","metadata":{"aliases":["hs6M1-12"]}},{"id":"c023184497694bdc8242d8ed56946417","type":"GENE","name":"OR2H4P","canonical_id":"hgnc:HGNC:8255","description":"olfactory receptor family 2 subfamily H member 4 pseudogene","metadata":{"aliases":["OR6-3","OR2H4","hs6M1-7","dJ80I19.6"]}},{"id":"caf22f0109774ff99ded0986afbb8a6a","type":"GENE","name":"OR2H5P","canonical_id":"hgnc:HGNC:8256","description":"olfactory receptor family 2 subfamily H member 5 pseudogene","metadata":{"aliases":["OR2H5","hs6M1-13","HS271M21"]}},{"id":"929646a7503242d8b27e9b2e7902e2db","type":"GENE","name":"OR2I1","canonical_id":"hgnc:HGNC:8258","description":"olfactory receptor family 2 subfamily I member 1 (gene/pseudogene)","metadata":{"aliases":["HS6M1-14","OR2I2","OR2I1P","OR2I3P","OR2I4P"]}},{"id":"77fe9211569a4e67913caa768e6799ab","type":"GENE","name":"OR2J1","canonical_id":"hgnc:HGNC:8259","description":"olfactory receptor family 2 subfamily J member 1","metadata":{"aliases":["OR6-5","hs6M1-4","dJ80I19.2","OR2J1P"]}},{"id":"70d8a640b67f49628ac1698bb24d02f4","type":"GENE","name":"OR2J2","canonical_id":"hgnc:HGNC:8260","description":"olfactory receptor family 2 subfamily J member 2","metadata":{"aliases":["OR6-8","hs6M1-6","dJ80I19.4"]}},{"id":"ad44cb447ea8422797db60c94e7def71","type":"GENE","name":"OR2J3","canonical_id":"hgnc:HGNC:8261","description":"olfactory receptor family 2 subfamily J member 3","metadata":{"aliases":["OR6-6"]}},{"id":"fd71ec03a07b4fa5a107e7064b30aa6d","type":"GENE","name":"OR2J4P","canonical_id":"hgnc:HGNC:8262","description":"olfactory receptor family 2 subfamily J member 4 pseudogene","metadata":{"aliases":["OR6-9","hs6M1-5","dJ80I19.5"]}},{"id":"27841261d19b40d1b8cda920b3fc32f4","type":"GENE","name":"OR2K2","canonical_id":"hgnc:HGNC:8264","description":"olfactory receptor family 2 subfamily K member 2","metadata":{"aliases":["HTPCRH06","HSHTPCRH06","OR2AR1P"]}},{"id":"1911103c709243dbafba2b2583e7d324","type":"GENE","name":"OR2L13","canonical_id":"hgnc:HGNC:19578","description":"olfactory receptor family 2 subfamily L member 13","metadata":{"aliases":["OR2L14"]}},{"id":"5b618c4066224fcb99f6f8c1fc9bbc72","type":"GENE","name":"OR2L1P","canonical_id":"hgnc:HGNC:8265","description":"olfactory receptor family 2 subfamily L member 1 pseudogene","metadata":{"aliases":["HTPCRX02","HSHTPCRX02","OR2L1","OR2L7P"]}},{"id":"67258b7b4e284a25ac7a9a1ab8c14701","type":"GENE","name":"OR2L2","canonical_id":"hgnc:HGNC:8266","description":"olfactory receptor family 2 subfamily L member 2","metadata":{"aliases":["HTPCRH07","HSHTPCRH07","OR2L4P","OR2L12"]}},{"id":"56813a286d2a454aac0de9fb8d7a1977","type":"GENE","name":"OR2L3","canonical_id":"hgnc:HGNC:15009","description":"olfactory receptor family 2 subfamily L member 3","metadata":null},{"id":"16fc386ff59b49578ab401b79e87eb43","type":"GENE","name":"OR2L5","canonical_id":"hgnc:HGNC:15011","description":"olfactory receptor family 2 subfamily L member 5","metadata":{"aliases":["OR2L11","OR2L5P"]}},{"id":"928d5facf3fd4088957a99992d9e1318","type":"GENE","name":"OR2L6P","canonical_id":"hgnc:HGNC:15012","description":"olfactory receptor family 2 subfamily L member 6 pseudogene","metadata":null},{"id":"016f5dcf2c00464dad7e9f1cb7fd2926","type":"GENE","name":"OR2L8","canonical_id":"hgnc:HGNC:15014","description":"olfactory receptor family 2 subfamily L member 8","metadata":null},{"id":"57c60e5edc86415b87b74bbe90e77082","type":"GENE","name":"OR2L9P","canonical_id":"hgnc:HGNC:15015","description":"olfactory receptor family 2 subfamily L member 9 pseudogene","metadata":null},{"id":"cc39756932c04c628c48735d3fc1f4ae","type":"GENE","name":"OR2M1P","canonical_id":"hgnc:HGNC:8267","description":"olfactory receptor family 2 subfamily M member 1 pseudogene","metadata":{"aliases":["OST037","OR2M1"]}},{"id":"449f66af4f504c60ad37fa78493ca445","type":"GENE","name":"OR2M2","canonical_id":"hgnc:HGNC:8268","description":"olfactory receptor family 2 subfamily M member 2","metadata":{"aliases":["OST423","OR2M2Q"]}},{"id":"a3801c41087a4e7886a7652debec46a0","type":"GENE","name":"OR2M3","canonical_id":"hgnc:HGNC:8269","description":"olfactory receptor family 2 subfamily M member 3","metadata":{"aliases":["OST003","OR2M6","OR2M3P"]}},{"id":"9cbf906915ff4781b3ceead02945d896","type":"GENE","name":"OR2M4","canonical_id":"hgnc:HGNC:8270","description":"olfactory receptor family 2 subfamily M member 4","metadata":{"aliases":["HTPCRX18","TPCR100","HSHTPCRX18","OST710"]}},{"id":"d4c193482578491897afc902753a52bb","type":"GENE","name":"OR2M5","canonical_id":"hgnc:HGNC:19576","description":"olfactory receptor family 2 subfamily M member 5","metadata":{"aliases":["OR2M5P"]}},{"id":"531fcfaf149346c4853b03fdf93fc70b","type":"GENE","name":"OR2M7","canonical_id":"hgnc:HGNC:19594","description":"olfactory receptor family 2 subfamily M member 7","metadata":null},{"id":"efc4edd7741c448e912053edb52f635a","type":"GENE","name":"OR2N1P","canonical_id":"hgnc:HGNC:8271","description":"olfactory receptor family 2 subfamily N member 1 pseudogene","metadata":{"aliases":["OR6-7"]}},{"id":"ff887d2916e747e897e68faa705ad4e3","type":"GENE","name":"OR2P1P","canonical_id":"hgnc:HGNC:8272","description":"olfactory receptor family 2 subfamily P member 1 pseudogene","metadata":{"aliases":["hs6M1-26"]}},{"id":"b70d87f380834586944bda921061f338","type":"GENE","name":"OR2Q1P","canonical_id":"hgnc:HGNC:8273","description":"olfactory receptor family 2 subfamily Q member 1 pseudogene","metadata":{"aliases":["OR7-2"]}},{"id":"6a8899a190794eb491a588c6bc619b69","type":"GENE","name":"OR2R1P","canonical_id":"hgnc:HGNC:8274","description":"olfactory receptor family 2 subfamily R member 1, pseudogene","metadata":{"aliases":["OST058","OR2R1"]}},{"id":"8b28d28d76a142a282d1df5920c3e0f1","type":"GENE","name":"OR2S1P","canonical_id":"hgnc:HGNC:8275","description":"olfactory receptor family 2 subfamily S member 1 pseudogene","metadata":{"aliases":["OST611"]}},{"id":"813344547a834dde9551439be0200563","type":"GENE","name":"OR2S2","canonical_id":"hgnc:HGNC:8276","description":"olfactory receptor family 2 subfamily S member 2","metadata":null},{"id":"b4ebf7e9b8b54e2da70e15e1256785a9","type":"GENE","name":"OR2T1","canonical_id":"hgnc:HGNC:8277","description":"olfactory receptor family 2 subfamily T member 1","metadata":{"aliases":["OR1-25"]}},{"id":"e121e2846745418ba5db2761a55b8ae5","type":"GENE","name":"OR2T10","canonical_id":"hgnc:HGNC:19573","description":"olfactory receptor family 2 subfamily T member 10","metadata":null},{"id":"e8790c1f49294dfb86ece88a907b20da","type":"GENE","name":"OR2T11","canonical_id":"hgnc:HGNC:19574","description":"olfactory receptor family 2 subfamily T member 11","metadata":{"aliases":["OR2T11Q"]}},{"id":"cc0e6331950548f5ac0c2b8da9a9d35b","type":"GENE","name":"OR2T12","canonical_id":"hgnc:HGNC:19592","description":"olfactory receptor family 2 subfamily T member 12","metadata":null},{"id":"68c737eea96d48349e253882f4acb4c1","type":"GENE","name":"OR2T2","canonical_id":"hgnc:HGNC:14725","description":"olfactory receptor family 2 subfamily T member 2","metadata":{"aliases":["OR2T2P"]}},{"id":"67952e84ac5b47108bbc28b93baf4f16","type":"GENE","name":"OR2T27","canonical_id":"hgnc:HGNC:31252","description":"olfactory receptor family 2 subfamily T member 27","metadata":null},{"id":"72b3358c99044f7498af00ded4fd0381","type":"GENE","name":"OR2T29","canonical_id":"hgnc:HGNC:31253","description":"olfactory receptor family 2 subfamily T member 29","metadata":null},{"id":"133742228ff54ca3847a1294a1a346ed","type":"GENE","name":"OR2T3","canonical_id":"hgnc:HGNC:14727","description":"olfactory receptor family 2 subfamily T member 3","metadata":null},{"id":"454f07ea75d44125ba66491c941e4c22","type":"GENE","name":"OR2T32P","canonical_id":"hgnc:HGNC:31254","description":"olfactory receptor family 2 subfamily T member 32 pseudogene","metadata":null},{"id":"36e608cf87a2456eb4a4a18ff48d16cd","type":"GENE","name":"OR2T33","canonical_id":"hgnc:HGNC:31255","description":"olfactory receptor family 2 subfamily T member 33","metadata":null},{"id":"f03a2e9a9e5d4e16916a3192700a675a","type":"GENE","name":"OR2T34","canonical_id":"hgnc:HGNC:31256","description":"olfactory receptor family 2 subfamily T member 34","metadata":null},{"id":"dee0969b271048b3b8e58ea310606632","type":"GENE","name":"OR2T35","canonical_id":"hgnc:HGNC:31257","description":"olfactory receptor family 2 subfamily T member 35 (gene/pseudogene)","metadata":null},{"id":"c8760688df2d47d080112f6528553470","type":"GENE","name":"OR2T4","canonical_id":"hgnc:HGNC:15016","description":"olfactory receptor family 2 subfamily T member 4","metadata":{"aliases":["OR2T4Q"]}},{"id":"eae65328b5694d7a9d7a164a22a4382a","type":"GENE","name":"OR2T5","canonical_id":"hgnc:HGNC:15017","description":"olfactory receptor family 2 subfamily T member 5","metadata":null},{"id":"ede7d4f0cb4840f6b9695c9e281f8b57","type":"GENE","name":"OR2T6","canonical_id":"hgnc:HGNC:15018","description":"olfactory receptor family 2 subfamily T member 6","metadata":{"aliases":["OST703","OR2T6P","OR2T9"]}},{"id":"effd29acb61a4f1abd2013011a339b0c","type":"GENE","name":"OR2T7","canonical_id":"hgnc:HGNC:15019","description":"olfactory receptor family 2 subfamily T member 7 (gene/pseudogene)","metadata":{"aliases":["OST723","OR2T7P"]}},{"id":"1ae781efffe34446bd6281ac18533c8a","type":"GENE","name":"OR2T8","canonical_id":"hgnc:HGNC:15020","description":"olfactory receptor family 2 subfamily T member 8","metadata":{"aliases":["OR2T8P"]}},{"id":"82e235d0423d4cb28fea99de8f200b7c","type":"GENE","name":"OR2U1P","canonical_id":"hgnc:HGNC:8278","description":"olfactory receptor family 2 subfamily U member 1 pseudogene","metadata":{"aliases":["hs6M1-24","OR2AU1P"]}},{"id":"2280caddddc644a5929e52c543870938","type":"GENE","name":"OR2U2P","canonical_id":"hgnc:HGNC:8279","description":"olfactory receptor family 2 subfamily U member 2 pseudogene","metadata":{"aliases":["hs6M1-23"]}},{"id":"6536d2fd1e41463381f790865d81b1ae","type":"GENE","name":"OR2V1","canonical_id":"hgnc:HGNC:8280","description":"olfactory receptor family 2 subfamily V member 1","metadata":{"aliases":["OST265","OR2V1P"]}},{"id":"07b766f22fd34aef8634966fc1ab12d8","type":"GENE","name":"OR2V2","canonical_id":"hgnc:HGNC:15341","description":"olfactory receptor family 2 subfamily V member 2","metadata":{"aliases":["OST713","OR2V3"]}},{"id":"cb10e59b57104b12a94a69a917ca723e","type":"GENE","name":"OR2W1","canonical_id":"hgnc:HGNC:8281","description":"olfactory receptor family 2 subfamily W member 1","metadata":{"aliases":["hs6M1-15"]}},{"id":"bc9c58f613d24ab8b972fcc8525a7841","type":"GENE","name":"OR2W1-AS1","canonical_id":"hgnc:HGNC:50896","description":"OR2W1 antisense RNA 1","metadata":null},{"id":"2bb7d84d090040fd86819829d8b4f8d1","type":"GENE","name":"OR2W2P","canonical_id":"hgnc:HGNC:13970","description":"olfactory receptor family 2 subfamily W member 2 pseudogene","metadata":{"aliases":["hs6M1-30P"]}},{"id":"3474691075c0451b9abc3463f2fcbbb3","type":"GENE","name":"OR2W3","canonical_id":"hgnc:HGNC:15021","description":"olfactory receptor family 2 subfamily W member 3","metadata":{"aliases":["OST718","OR2W8P","OR2W3P"]}},{"id":"73e93f5125084a5c998d74927b1e5687","type":"GENE","name":"OR2W4P","canonical_id":"hgnc:HGNC:15071","description":"olfactory receptor family 2 subfamily W member 4 pseudogene","metadata":null},{"id":"41862eac48554f11add744d0cfe6f06d","type":"GENE","name":"OR2W5","canonical_id":"hgnc:HGNC:15424","description":"olfactory receptor family 2 subfamily W member 5 (gene/pseudogene)","metadata":{"aliases":["OST722","OR2W5P"]}},{"id":"b165398a6e8f408384971c40db1e1d80","type":"GENE","name":"OR2W6P","canonical_id":"hgnc:HGNC:15072","description":"olfactory receptor family 2 subfamily W member 6 pseudogene","metadata":{"aliases":["OR2W7P"]}},{"id":"9c60c3e5f22140f580ff3b21d259cc7a","type":"GENE","name":"OR2X1P","canonical_id":"hgnc:HGNC:31258","description":"olfactory receptor family 2 subfamily X member 1 pseudogene","metadata":null},{"id":"c25500e4edff4eaaa159dd046a14048c","type":"GENE","name":"OR2Y1","canonical_id":"hgnc:HGNC:14837","description":"olfactory receptor family 2 subfamily Y member 1","metadata":null},{"id":"926f9f5516c94ce58e15ace46200d365","type":"GENE","name":"OR2Z1","canonical_id":"hgnc:HGNC:15391","description":"olfactory receptor family 2 subfamily Z member 1","metadata":{"aliases":["OR2Z2"]}},{"id":"4a727d2dc7274f3884b2e6643b204a76","type":"GENE","name":"OR3A1","canonical_id":"hgnc:HGNC:8282","description":"olfactory receptor family 3 subfamily A member 1","metadata":{"aliases":["OLFRA03","OR40","OR17-40"]}},{"id":"c483d238f4bd489c9d0dd113897812af","type":"GENE","name":"OR3A2","canonical_id":"hgnc:HGNC:8283","description":"olfactory receptor family 3 subfamily A member 2","metadata":{"aliases":["OLFRA04","OR228","OR17-228"]}},{"id":"dcb320a3ccfa49f4ae4ddcfb6383390a","type":"GENE","name":"OR3A3","canonical_id":"hgnc:HGNC:8284","description":"olfactory receptor family 3 subfamily A member 3","metadata":{"aliases":["OR17-201","OR17-137","OR17-16","OR3A6","OR3A7","OR3A8P"]}},{"id":"56386e68eed64254beb56c4a3e563796","type":"GENE","name":"OR3A4P","canonical_id":"hgnc:HGNC:15510","description":"olfactory receptor family 3 subfamily A member 4 pseudogene","metadata":{"aliases":["OR3A4"]}},{"id":"543f37fcf24a451e89bcf39798c77625","type":"GENE","name":"OR3A5P","canonical_id":"hgnc:HGNC:8286","description":"olfactory receptor family 3 subfamily A member 5 pseudogene","metadata":{"aliases":["OLFRA06","OR25","OR17-25","RP11-64J4.6-001"]}},{"id":"e15a0ed5f407455097ba58eb8b2de1bd","type":"GENE","name":"OR3B1P","canonical_id":"hgnc:HGNC:14839","description":"olfactory receptor family 3 subfamily B member 1 pseudogene","metadata":null},{"id":"62646400a40e4efbb4618ed418e71f98","type":"GENE","name":"OR3D1P","canonical_id":"hgnc:HGNC:25339","description":"olfactory receptor family 3 subfamily D member 1 pseudogene","metadata":null},{"id":"78cc90f305a741a69a1a0c25b5a5f7b9","type":"GENE","name":"OR4A10P","canonical_id":"hgnc:HGNC:15147","description":"olfactory receptor family 4 subfamily A member 10 pseudogene","metadata":{"aliases":["OR4A25P"]}},{"id":"dc8ae450e84f4ffc821721d97841e222","type":"GENE","name":"OR4A11P","canonical_id":"hgnc:HGNC:15148","description":"olfactory receptor family 4 subfamily A member 11 pseudogene","metadata":null},{"id":"a13db4f95efd45eaa5578548ab1641ed","type":"GENE","name":"OR4A12P","canonical_id":"hgnc:HGNC:15149","description":"olfactory receptor family 4 subfamily A member 12 pseudogene","metadata":null},{"id":"d015446dcd57431cb4e51806fbaf0c66","type":"GENE","name":"OR4A13P","canonical_id":"hgnc:HGNC:15150","description":"olfactory receptor family 4 subfamily A member 13 pseudogene","metadata":null},{"id":"5c0b37f5373644eabe88b61aa9182a89","type":"GENE","name":"OR4A14P","canonical_id":"hgnc:HGNC:15151","description":"olfactory receptor family 4 subfamily A member 14 pseudogene","metadata":null},{"id":"83d9380c53644e03bf5c5570ce8d5310","type":"GENE","name":"OR4A15","canonical_id":"hgnc:HGNC:15152","description":"olfactory receptor family 4 subfamily A member 15","metadata":null},{"id":"7dc370a01b5444b7943000d18127f7a1","type":"GENE","name":"OR4A16","canonical_id":"hgnc:HGNC:15153","description":"olfactory receptor family 4 subfamily A member 16","metadata":{"aliases":["OR4A16Q"]}},{"id":"1edb41cb6aa7467094dd21bd72738fbe","type":"GENE","name":"OR4A17P","canonical_id":"hgnc:HGNC:15154","description":"olfactory receptor family 4 subfamily A member 17 pseudogene","metadata":{"aliases":["OR4A22P"]}},{"id":"163fa84c90c34b6c842b23b2442c2338","type":"GENE","name":"OR4A18P","canonical_id":"hgnc:HGNC:15155","description":"olfactory receptor family 4 subfamily A member 18 pseudogene","metadata":null},{"id":"389f320face643288cc5db22a869db13","type":"GENE","name":"OR4A19P","canonical_id":"hgnc:HGNC:15156","description":"olfactory receptor family 4 subfamily A member 19 pseudogene","metadata":null},{"id":"06f9328f77864c2db7ea1a74dd0dcdfc","type":"GENE","name":"OR4A1P","canonical_id":"hgnc:HGNC:8289","description":"olfactory receptor family 4 subfamily A member 1 pseudogene","metadata":{"aliases":["OR11-30","OR4A20P"]}},{"id":"0a5ea631a27f42bda672dd418c16fc44","type":"GENE","name":"OR4A21P","canonical_id":"hgnc:HGNC:15158","description":"olfactory receptor family 4 subfamily A member 21 pseudogene","metadata":null},{"id":"b4838823d65942849430f37e917712b5","type":"GENE","name":"OR4A2P","canonical_id":"hgnc:HGNC:15159","description":"olfactory receptor family 4 subfamily A member 2 pseudogene","metadata":null},{"id":"8338c7ae73c94ba8b3ffe2fa57791ea2","type":"GENE","name":"OR4A3P","canonical_id":"hgnc:HGNC:15160","description":"olfactory receptor family 4 subfamily A member 3 pseudogene","metadata":null},{"id":"dd3658fa1a5345948171c98b90757fa2","type":"GENE","name":"OR4A40P","canonical_id":"hgnc:HGNC:31259","description":"olfactory receptor family 4 subfamily A member 40 pseudogene","metadata":null},{"id":"703aed22a16f44349aa2b4bd4688c458","type":"GENE","name":"OR4A41P","canonical_id":"hgnc:HGNC:31260","description":"olfactory receptor family 4 subfamily A member 41 pseudogene","metadata":null},{"id":"3e4bcaa5ca924cf49b4734154e256a00","type":"GENE","name":"OR4A42P","canonical_id":"hgnc:HGNC:31261","description":"olfactory receptor family 4 subfamily A member 42 pseudogene","metadata":null},{"id":"5d77c04fca9e4fb698af45b77e40f40f","type":"GENE","name":"OR4A43P","canonical_id":"hgnc:HGNC:31262","description":"olfactory receptor family 4 subfamily A member 43 pseudogene","metadata":null},{"id":"bd41abda0e1a4a119c90d4760389d2df","type":"GENE","name":"OR4A44P","canonical_id":"hgnc:HGNC:31263","description":"olfactory receptor family 4 subfamily A member 44 pseudogene","metadata":null},{"id":"f6a57f3aea4c4b26b1a78ff67f3947e8","type":"GENE","name":"OR4A45P","canonical_id":"hgnc:HGNC:31264","description":"olfactory receptor family 4 subfamily A member 45 pseudogene","metadata":null},{"id":"17e7e88782404e2a96ef21af5cf2dbef","type":"GENE","name":"OR4A46P","canonical_id":"hgnc:HGNC:31265","description":"olfactory receptor family 4 subfamily A member 46 pseudogene","metadata":null},{"id":"47d0130594eb4c768b7d2a43ab630b06","type":"GENE","name":"OR4A47","canonical_id":"hgnc:HGNC:31266","description":"olfactory receptor family 4 subfamily A member 47","metadata":null},{"id":"0f57f5bbf582440785dd40e998e08c02","type":"GENE","name":"OR4A48P","canonical_id":"hgnc:HGNC:31267","description":"olfactory receptor family 4 subfamily A member 48 pseudogene","metadata":null},{"id":"e8dda2f217c045c4b452f30db6c832c5","type":"GENE","name":"OR4A49P","canonical_id":"hgnc:HGNC:31268","description":"olfactory receptor family 4 subfamily A member 49 pseudogene","metadata":null},{"id":"71bc63de39ec4a77bbb2f7a1b800b4aa","type":"GENE","name":"OR4A4P","canonical_id":"hgnc:HGNC:15161","description":"olfactory receptor family 4 subfamily A member 4 pseudogene","metadata":{"aliases":["OR4A4"]}},{"id":"f75c5914eb72458ea84fd79b38eafb5f","type":"GENE","name":"OR4A5","canonical_id":"hgnc:HGNC:15162","description":"olfactory receptor family 4 subfamily A member 5","metadata":null},{"id":"0a7b5c28979a47b488211eb0d190071e","type":"GENE","name":"OR4A50P","canonical_id":"hgnc:HGNC:31269","description":"olfactory receptor family 4 subfamily A member 50 pseudogene","metadata":null},{"id":"7c8d6f3455ec408193410f624f545dea","type":"GENE","name":"OR4A6P","canonical_id":"hgnc:HGNC:15163","description":"olfactory receptor family 4 subfamily A member 6 pseudogene","metadata":null},{"id":"404db162c76b448f9fe51ab1d3a68872","type":"GENE","name":"OR4A7P","canonical_id":"hgnc:HGNC:15164","description":"olfactory receptor family 4 subfamily A member 7 pseudogene","metadata":null},{"id":"6294810ea2d14852af11358be9b3211c","type":"GENE","name":"OR4A8","canonical_id":"hgnc:HGNC:15165","description":"olfactory receptor family 4 subfamily A member 8 (gene/pseudogene)","metadata":{"aliases":["OR4A8P"]}},{"id":"3cbb6a7235b24b20b3a0e6e85c72e842","type":"GENE","name":"OR4A9P","canonical_id":"hgnc:HGNC:15166","description":"olfactory receptor family 4 subfamily A member 9 pseudogene","metadata":null},{"id":"ce3488962bbf4472ae751353a531b812","type":"GENE","name":"OR4B1","canonical_id":"hgnc:HGNC:8290","description":"olfactory receptor family 4 subfamily B member 1","metadata":{"aliases":["OST208"]}},{"id":"b81cbae1cf084239a591ab082b160072","type":"GENE","name":"OR4B2P","canonical_id":"hgnc:HGNC:8291","description":"olfactory receptor family 4 subfamily B member 2 pseudogene","metadata":{"aliases":["hg449"]}},{"id":"be9c1da45cfe4779bae1576866a2fbc6","type":"GENE","name":"OR4C10P","canonical_id":"hgnc:HGNC:14800","description":"olfactory receptor family 4 subfamily C member 10 pseudogene","metadata":null},{"id":"cd384f33c56649d6a403a7208f0abefd","type":"GENE","name":"OR4C11","canonical_id":"hgnc:HGNC:15167","description":"olfactory receptor family 4 subfamily C member 11","metadata":{"aliases":["OR4C11P"]}},{"id":"3354075464e442708cd84c418a1df9cc","type":"GENE","name":"OR4C12","canonical_id":"hgnc:HGNC:15168","description":"olfactory receptor family 4 subfamily C member 12","metadata":null},{"id":"289b15f2ddc94b079707eb6ac40b6214","type":"GENE","name":"OR4C13","canonical_id":"hgnc:HGNC:15169","description":"olfactory receptor family 4 subfamily C member 13","metadata":null},{"id":"ee7bafe4165e4b2b96d2606e2aa4c091","type":"GENE","name":"OR4C14P","canonical_id":"hgnc:HGNC:15170","description":"olfactory receptor family 4 subfamily C member 14 pseudogene","metadata":null},{"id":"a41ee0c51b0d4a2caf890e786edc2f31","type":"GENE","name":"OR4C15","canonical_id":"hgnc:HGNC:15171","description":"olfactory receptor family 4 subfamily C member 15","metadata":null},{"id":"9eb82841b9ad49048592e395a8ea0215","type":"GENE","name":"OR4C16","canonical_id":"hgnc:HGNC:15172","description":"olfactory receptor family 4 subfamily C member 16","metadata":null},{"id":"c8be80c3b02a41de9e061eebe0fefc6d","type":"GENE","name":"OR4C1P","canonical_id":"hgnc:HGNC:8292","description":"olfactory receptor family 4 subfamily C member 1 pseudogene","metadata":{"aliases":["HTPCRX11","HSHTPCRX11","OR4C1"]}},{"id":"772347c6043c434489347ec38850a9e2","type":"GENE","name":"OR4C2P","canonical_id":"hgnc:HGNC:14696","description":"olfactory receptor family 4 subfamily C member 2 pseudogene","metadata":{"aliases":["OR4C8P"]}},{"id":"6ddd833135754633ad36bee4910dae78","type":"GENE","name":"OR4C3","canonical_id":"hgnc:HGNC:14697","description":"olfactory receptor family 4 subfamily C member 3","metadata":null},{"id":"7c5e9ecdd8504e65b36c5db95378758d","type":"GENE","name":"OR4C45","canonical_id":"hgnc:HGNC:31270","description":"olfactory receptor family 4 subfamily C member 45 (gene/pseudogene)","metadata":null},{"id":"a371a0e3ac2d41058e0dd26c91be135d","type":"GENE","name":"OR4C46","canonical_id":"hgnc:HGNC:31271","description":"olfactory receptor family 4 subfamily C member 46","metadata":null},{"id":"79c2cb37554b43dca7dbf9a0cfafd7eb","type":"GENE","name":"OR4C48P","canonical_id":"hgnc:HGNC:31272","description":"olfactory receptor family 4 subfamily C member 48 pseudogene","metadata":null},{"id":"a7fa8829cf01432399d24c4386d1db80","type":"GENE","name":"OR4C49P","canonical_id":"hgnc:HGNC:31273","description":"olfactory receptor family 4 subfamily C member 49 pseudogene","metadata":null},{"id":"d4977adaa3d64f2086f6843dbc9b092c","type":"GENE","name":"OR4C4P","canonical_id":"hgnc:HGNC:14700","description":"olfactory receptor family 4 subfamily C member 4 pseudogene","metadata":{"aliases":["OR4C47P","OR4C17P","OR4C17"]}},{"id":"56adf6804cf34764989a3b52093212e9","type":"GENE","name":"OR4C5","canonical_id":"hgnc:HGNC:14702","description":"olfactory receptor family 4 subfamily C member 5","metadata":{"aliases":["OR4C5Q","OR4C5P"]}},{"id":"4508f4eb893549938ea388b66d5dd50f","type":"GENE","name":"OR4C50P","canonical_id":"hgnc:HGNC:31274","description":"olfactory receptor family 4 subfamily C member 50 pseudogene","metadata":null},{"id":"c9dee429f6ff4c12b48cf3b12c381387","type":"GENE","name":"OR4C6","canonical_id":"hgnc:HGNC:14743","description":"olfactory receptor family 4 subfamily C member 6","metadata":null},{"id":"d465f91d2e70447292936b73a3d1af59","type":"GENE","name":"OR4C7P","canonical_id":"hgnc:HGNC:14768","description":"olfactory receptor family 4 subfamily C member 7 pseudogene","metadata":null},{"id":"907b296faa7d4eee8152a5653734f6ed","type":"GENE","name":"OR4C9P","canonical_id":"hgnc:HGNC:14796","description":"olfactory receptor family 4 subfamily C member 9 pseudogene","metadata":null},{"id":"830a3ba1f36b47279bc149efc34f3a25","type":"GENE","name":"OR4D1","canonical_id":"hgnc:HGNC:8293","description":"olfactory receptor family 4 subfamily D member 1","metadata":{"aliases":["TPCR16","OR4D3"]}},{"id":"4aff0bbceb584b1190fe45881d128739","type":"GENE","name":"OR4D10","canonical_id":"hgnc:HGNC:15173","description":"olfactory receptor family 4 subfamily D member 10","metadata":{"aliases":["OST711","OR4D10P"]}},{"id":"b15ce800daf94a4f8a4d7388a69599a2","type":"GENE","name":"OR4D11","canonical_id":"hgnc:HGNC:15174","description":"olfactory receptor family 4 subfamily D member 11","metadata":{"aliases":["OR4D11P"]}},{"id":"7955771a4c05491cb7e2ebf749cca2b8","type":"GENE","name":"OR4D2","canonical_id":"hgnc:HGNC:8294","description":"olfactory receptor family 4 subfamily D member 2","metadata":null},{"id":"3d2f32aa7a9c439e9557286875184d35","type":"GENE","name":"OR4D5","canonical_id":"hgnc:HGNC:14852","description":"olfactory receptor family 4 subfamily D member 5","metadata":null},{"id":"15329a460e3046dca6917cb02c292937","type":"GENE","name":"OR4D6","canonical_id":"hgnc:HGNC:15175","description":"olfactory receptor family 4 subfamily D member 6","metadata":null},{"id":"b7747c2ad9704182a8df27178ded221d","type":"GENE","name":"OR4D7P","canonical_id":"hgnc:HGNC:15176","description":"olfactory receptor family 4 subfamily D member 7 pseudogene","metadata":{"aliases":["OST724"]}},{"id":"86c983eecace4989a3fa6e97c9dfb9e3","type":"GENE","name":"OR4D8P","canonical_id":"hgnc:HGNC:15177","description":"olfactory receptor family 4 subfamily D member 8 pseudogene","metadata":null},{"id":"0a18f14611d74e6282c0c38f6d1cd259","type":"GENE","name":"OR4D9","canonical_id":"hgnc:HGNC:15178","description":"olfactory receptor family 4 subfamily D member 9","metadata":null},{"id":"5de58c0bf1bf41f78c7ddd214e969219","type":"GENE","name":"OR4E1","canonical_id":"hgnc:HGNC:8296","description":"olfactory receptor family 4 subfamily E member 1","metadata":{"aliases":["OR4E1P"]}},{"id":"c5b4ed0b0a954288a7fb5c179e286862","type":"GENE","name":"OR4E2","canonical_id":"hgnc:HGNC:8297","description":"olfactory receptor family 4 subfamily E member 2","metadata":null},{"id":"5bb5f89a50ee4a6e9222dcab9eb5ac1e","type":"GENE","name":"OR4F13P","canonical_id":"hgnc:HGNC:15076","description":"olfactory receptor family 4 subfamily F member 13 pseudogene","metadata":null},{"id":"b783527b78f846a7b73388a85ad03145","type":"GENE","name":"OR4F14P","canonical_id":"hgnc:HGNC:15077","description":"olfactory receptor family 4 subfamily F member 14 pseudogene","metadata":{"aliases":["OR4F14"]}},{"id":"85cd972e121a443890b92fb186e1f4df","type":"GENE","name":"OR4F15","canonical_id":"hgnc:HGNC:15078","description":"olfactory receptor family 4 subfamily F member 15","metadata":null},{"id":"611ff4720171409b829945cb5be0c128","type":"GENE","name":"OR4F16","canonical_id":"hgnc:HGNC:15079","description":"olfactory receptor family 4 subfamily F member 16","metadata":null},{"id":"cb7c7aeb81cf42fa9a22b79c27adc8bf","type":"GENE","name":"OR4F17","canonical_id":"hgnc:HGNC:15381","description":"olfactory receptor family 4 subfamily F member 17","metadata":{"aliases":["OR4F19","OR4F11P","OR4F18"]}},{"id":"22ee3a33343543b7ba7e9bc8d87b4911","type":"GENE","name":"OR4F1P","canonical_id":"hgnc:HGNC:8298","description":"olfactory receptor family 4 subfamily F member 1 pseudogene","metadata":{"aliases":["HSDJ0609N19","OR4F1"]}},{"id":"c66f7aae7a374934a7ea1e85d879dfd7","type":"GENE","name":"OR4F21","canonical_id":"hgnc:HGNC:19583","description":"olfactory receptor family 4 subfamily F member 21","metadata":{"aliases":["OR4F21P"]}},{"id":"badc98775bfb4ad3bfdf49d4a7ca0264","type":"GENE","name":"OR4F28P","canonical_id":"hgnc:HGNC:31229","description":"olfactory receptor family 4 subfamily F member 28 pseudogene","metadata":null},{"id":"1e1aac1a124e48eead9764b3854c0ef4","type":"GENE","name":"OR4F29","canonical_id":"hgnc:HGNC:31275","description":"olfactory receptor family 4 subfamily F member 29","metadata":null},{"id":"6646bcfb6e0f4736b44a182aea13313f","type":"GENE","name":"OR4F2P","canonical_id":"hgnc:HGNC:8299","description":"olfactory receptor family 4 subfamily F member 2 pseudogene","metadata":{"aliases":["OR4F2","hs6M1-11","S191N21"]}},{"id":"e2a307898ef54d79bd0a39f7f6ed95d9","type":"GENE","name":"OR4F3","canonical_id":"hgnc:HGNC:8300","description":"olfactory receptor family 4 subfamily F member 3","metadata":null},{"id":"c7578d712e3e4a358b3435177d79dd77","type":"GENE","name":"OR4F4","canonical_id":"hgnc:HGNC:8301","description":"olfactory receptor family 4 subfamily F member 4","metadata":{"aliases":["OR4F18"]}},{"id":"19659ac23021407e8819bcbc725c6177","type":"GENE","name":"OR4F5","canonical_id":"hgnc:HGNC:14825","description":"olfactory receptor family 4 subfamily F member 5","metadata":null},{"id":"2c24aff2d61b41568ac8ce4a2c08410b","type":"GENE","name":"OR4F6","canonical_id":"hgnc:HGNC:15372","description":"olfactory receptor family 4 subfamily F member 6","metadata":{"aliases":["OR4F12"]}},{"id":"0ad7417c6685471f96728be02f02d40d","type":"GENE","name":"OR4F7P","canonical_id":"hgnc:HGNC:15089","description":"olfactory receptor family 4 subfamily F member 7 pseudogene","metadata":{"aliases":["OR4F10"]}},{"id":"b7ccb8480e374af5896b7ada143a5dbf","type":"GENE","name":"OR4F8BP","canonical_id":"hgnc:HGNC:55111","description":"olfactory receptor family 4 subfamily F member 8B pseudogene","metadata":null},{"id":"8b7ed45e57594596b52d5324a1ded424","type":"GENE","name":"OR4F8P","canonical_id":"hgnc:HGNC:15395","description":"olfactory receptor family 4 subfamily F member 8 pseudogene","metadata":{"aliases":["OR4F20P","OR4F9P"]}},{"id":"c08667a67f33449e96f634ca8f71d421","type":"GENE","name":"OR4G11P","canonical_id":"hgnc:HGNC:31276","description":"olfactory receptor family 4 subfamily G member 11 pseudogene","metadata":null},{"id":"36d9623f1c3345ebac33372293dbac3a","type":"GENE","name":"OR4G1P","canonical_id":"hgnc:HGNC:8302","description":"olfactory receptor family 4 subfamily G member 1 pseudogene","metadata":{"aliases":["OLB","OR4G8P"]}},{"id":"8f25f65eb81e43db9df4c85b13924c72","type":"GENE","name":"OR4G2P","canonical_id":"hgnc:HGNC:8303","description":"olfactory receptor family 4 subfamily G member 2 pseudogene","metadata":{"aliases":["OR4G7P"]}},{"id":"6118cabe01b840d28048a857b0838e11","type":"GENE","name":"OR4G3P","canonical_id":"hgnc:HGNC:8304","description":"olfactory receptor family 4 subfamily G member 3 pseudogene","metadata":{"aliases":["OLC","OLC-7501","OR4G3","OR4G5P"]}},{"id":"13f9d1a703fe460e8d33d5a244d8648d","type":"GENE","name":"OR4G4P","canonical_id":"hgnc:HGNC:14822","description":"olfactory receptor family 4 subfamily G member 4 pseudogene","metadata":null},{"id":"b979cb8e2dda49c587fa764065cd385f","type":"GENE","name":"OR4G6P","canonical_id":"hgnc:HGNC:15039","description":"olfactory receptor family 4 subfamily G member 6 pseudogene","metadata":null},{"id":"92b0953caef642a2b5f082574d28a527","type":"GENE","name":"OR4H12P","canonical_id":"hgnc:HGNC:19433","description":"olfactory receptor family 4 subfamily H member 12 pseudogene","metadata":{"aliases":["C14orf14","OR4H12"]}},{"id":"59b9bb383d3542ca938993ab06d7b48f","type":"GENE","name":"OR4H6BP","canonical_id":"hgnc:HGNC:55112","description":"olfactory receptor family 4 subfamily H member 6B pseudogene","metadata":null},{"id":"b9685277eb5349afba98d5783584181e","type":"GENE","name":"OR4H6P","canonical_id":"hgnc:HGNC:8312","description":"olfactory receptor family 4 subfamily H member 6 pseudogene","metadata":{"aliases":["OR15-71","OR4H6","OR15-82","OR4H9","OR5-39","OR5-84","OR4-114","OR4-115","OR4-119","OR15-69","OR15-80","OR15-81","OR14-58","OR4H9P","OR4H10P","OR4H5P","OR4H11P","OR4H5","OR4H7","OR4H7P","OR4H2P","OR4H3P","OR4H11","OR4H2","OR4H3","OR4H1P","OR4H4P","OR4H10","OR4H4","OR4H8P","OR4H8"]}},{"id":"4fa5404e46d84967b9d214873c67e9c6","type":"GENE","name":"OR4K1","canonical_id":"hgnc:HGNC:14726","description":"olfactory receptor family 4 subfamily K member 1","metadata":null},{"id":"24b460607e5b46fea567d25cd422a4c9","type":"GENE","name":"OR4K11P","canonical_id":"hgnc:HGNC:15402","description":"olfactory receptor family 4 subfamily K member 11 pseudogene","metadata":{"aliases":["OR21-1"]}},{"id":"882f71a212c044a1a2b1a28da6a309d0","type":"GENE","name":"OR4K12P","canonical_id":"hgnc:HGNC:15403","description":"olfactory receptor family 4 subfamily K member 12 pseudogene","metadata":{"aliases":["OR21-2"]}},{"id":"4aa804630ef0453c87fc6e25738ae3c8","type":"GENE","name":"OR4K13","canonical_id":"hgnc:HGNC:15351","description":"olfactory receptor family 4 subfamily K member 13","metadata":null},{"id":"7cc801e7c89f4f6a9fe366aca1123b42","type":"GENE","name":"OR4K14","canonical_id":"hgnc:HGNC:15352","description":"olfactory receptor family 4 subfamily K member 14","metadata":null},{"id":"b74929dc910d4d908a45a59355730b65","type":"GENE","name":"OR4K15","canonical_id":"hgnc:HGNC:15353","description":"olfactory receptor family 4 subfamily K member 15","metadata":{"aliases":["OR4K15Q"]}},{"id":"803263020f9340c4bfcadd544d5ed08e","type":"GENE","name":"OR4K16P","canonical_id":"hgnc:HGNC:15354","description":"olfactory receptor family 4 subfamily K member 16 pseudogene","metadata":null},{"id":"8fe8b3054b81449098fdfaff2ef18aa0","type":"GENE","name":"OR4K17","canonical_id":"hgnc:HGNC:15355","description":"olfactory receptor family 4 subfamily K member 17","metadata":null},{"id":"50d3e47927774d1783948d07de6d33cc","type":"GENE","name":"OR4K2","canonical_id":"hgnc:HGNC:14728","description":"olfactory receptor family 4 subfamily K member 2","metadata":null},{"id":"d2310f64d7e940229d748ced9eda5407","type":"GENE","name":"OR4K3","canonical_id":"hgnc:HGNC:14731","description":"olfactory receptor family 4 subfamily K member 3 (gene/pseudogene)","metadata":{"aliases":["OR4K3P"]}},{"id":"f9d00647203f4f518f28069ffa7dcb9c","type":"GENE","name":"OR4K4P","canonical_id":"hgnc:HGNC:14744","description":"olfactory receptor family 4 subfamily K member 4 pseudogene","metadata":null},{"id":"c888a337d9a4450abd9a5b2697a36131","type":"GENE","name":"OR4K5","canonical_id":"hgnc:HGNC:14745","description":"olfactory receptor family 4 subfamily K member 5","metadata":null},{"id":"0f4e49efb98d457ea941821829f89c71","type":"GENE","name":"OR4K6P","canonical_id":"hgnc:HGNC:14748","description":"olfactory receptor family 4 subfamily K member 6 pseudogene","metadata":null},{"id":"15170c7dff1740e3b7cebde71f391636","type":"GENE","name":"OR4K7P","canonical_id":"hgnc:HGNC:14756","description":"olfactory receptor family 4 subfamily K member 7 pseudogene","metadata":{"aliases":["OR4K10P"]}},{"id":"71b4bc5151bc43469322ddca211d3a3c","type":"GENE","name":"OR4K8P","canonical_id":"hgnc:HGNC:14787","description":"olfactory receptor family 4 subfamily K member 8 pseudogene","metadata":{"aliases":["OR4K9P"]}},{"id":"ae63526bd28e4e858f29522622db13e1","type":"GENE","name":"OR4L1","canonical_id":"hgnc:HGNC:15356","description":"olfactory receptor family 4 subfamily L member 1","metadata":{"aliases":["OR4L2P"]}},{"id":"11f9db6223a44d96bc9fe4d802b520d3","type":"GENE","name":"OR4M1","canonical_id":"hgnc:HGNC:14735","description":"olfactory receptor family 4 subfamily M member 1","metadata":null},{"id":"0819eed28afb4192a44f9aa2084f0b70","type":"GENE","name":"OR4M2","canonical_id":"hgnc:HGNC:15373","description":"olfactory receptor family 4 subfamily M member 2","metadata":null},{"id":"f664e6413dc64f7da2d5bbe69c73d495","type":"GENE","name":"OR4M2-OT1","canonical_id":"hgnc:HGNC:56199","description":"OR4M2 overlapping transcript 1","metadata":null},{"id":"db074dd3639e41779dccb6b0cc42f051","type":"GENE","name":"OR4M2B","canonical_id":"hgnc:HGNC:55109","description":"olfactory receptor family 4 subfamily M member 2B","metadata":null},{"id":"26f55736cbdb40cbb564f7abc0cde632","type":"GENE","name":"OR4N1P","canonical_id":"hgnc:HGNC:14740","description":"olfactory receptor family 4 subfamily N member 1 pseudogene","metadata":null},{"id":"1d1ba4b5afc147d0906c162ac7023614","type":"GENE","name":"OR4N2","canonical_id":"hgnc:HGNC:14742","description":"olfactory receptor family 4 subfamily N member 2","metadata":null},{"id":"f56a53a68bf84f2db2b0f7f4def00eac","type":"GENE","name":"OR4N3BP","canonical_id":"hgnc:HGNC:55116","description":"olfactory receptor family 4 subfamily N member 3B pseudogene","metadata":null},{"id":"8e46edf8a546448686052c709d1a20de","type":"GENE","name":"OR4N3P","canonical_id":"hgnc:HGNC:15374","description":"olfactory receptor family 4 subfamily N member 3 pseudogene","metadata":null},{"id":"6664eec6a994419e8e077e0be011342b","type":"GENE","name":"OR4N4","canonical_id":"hgnc:HGNC:15375","description":"olfactory receptor family 4 subfamily N member 4","metadata":null},{"id":"a7550fad08bc4b51b221af8f92c8f803","type":"GENE","name":"OR4N4C","canonical_id":"hgnc:HGNC:55110","description":"olfactory receptor family 4 subfamily N member 4C","metadata":null},{"id":"2269ec782a1346f59b64270b23612233","type":"GENE","name":"OR4N5","canonical_id":"hgnc:HGNC:15358","description":"olfactory receptor family 4 subfamily N member 5","metadata":null},{"id":"fd28417c04c442fda297dcb2e5a32cc4","type":"GENE","name":"OR4P1P","canonical_id":"hgnc:HGNC:14754","description":"olfactory receptor family 4 subfamily P member 1 pseudogene","metadata":null},{"id":"77319b773f1d4a1895e3c44265c6c053","type":"GENE","name":"OR4P4","canonical_id":"hgnc:HGNC:15180","description":"olfactory receptor family 4 subfamily P member 4","metadata":{"aliases":["OR4P3P"]}},{"id":"7afc62a487b3455e86082e0b60759f75","type":"GENE","name":"OR4Q1P","canonical_id":"hgnc:HGNC:15376","description":"olfactory receptor family 4 subfamily Q member 1 pseudogene","metadata":null},{"id":"a1a5b2c91e4d49ec9d2f4ce9cad23a4f","type":"GENE","name":"OR4Q2","canonical_id":"hgnc:HGNC:15359","description":"olfactory receptor family 4 subfamily Q member 2 (gene/pseudogene)","metadata":{"aliases":["OR4Q2P"]}},{"id":"fa0d073d852f4c1fa821445b6d59058e","type":"GENE","name":"OR4Q3","canonical_id":"hgnc:HGNC:15426","description":"olfactory receptor family 4 subfamily Q member 3","metadata":{"aliases":["C14orf13","OR4Q4"]}},{"id":"d675bba915cf44019cebe31961803c0e","type":"GENE","name":"OR4R1P","canonical_id":"hgnc:HGNC:14798","description":"olfactory receptor family 4 subfamily R member 1 pseudogene","metadata":null},{"id":"d08aa9e6d14f4790b6178bc1f532db93","type":"GENE","name":"OR4R2P","canonical_id":"hgnc:HGNC:15181","description":"olfactory receptor family 4 subfamily R member 2 pseudogene","metadata":null},{"id":"341c968c2bb54597bc5d279020c46500","type":"GENE","name":"OR4R3P","canonical_id":"hgnc:HGNC:15182","description":"olfactory receptor family 4 subfamily R member 3 pseudogene","metadata":null},{"id":"7da6fddb64014f67b0c449c5da40238e","type":"GENE","name":"OR4S1","canonical_id":"hgnc:HGNC:14705","description":"olfactory receptor family 4 subfamily S member 1","metadata":null},{"id":"21b22550f993484692a782bf06ee0520","type":"GENE","name":"OR4S2","canonical_id":"hgnc:HGNC:15183","description":"olfactory receptor family 4 subfamily S member 2","metadata":{"aliases":["OST725","OR4S2P"]}},{"id":"ea5b3194048d418fb8851adc44af7945","type":"GENE","name":"OR4T1P","canonical_id":"hgnc:HGNC:15360","description":"olfactory receptor family 4 subfamily T member 1 pseudogene","metadata":null},{"id":"00e1475a74d64982ba8cdb0e7145d2d4","type":"GENE","name":"OR4U1P","canonical_id":"hgnc:HGNC:15361","description":"olfactory receptor family 4 subfamily U member 1 pseudogene","metadata":null},{"id":"5e534a1567e845d2ab9ce6115a55117e","type":"GENE","name":"OR4V1P","canonical_id":"hgnc:HGNC:14736","description":"olfactory receptor family 4 subfamily V member 1 pseudogene","metadata":null},{"id":"c30475bd01dd4cddadd3ca9c33580f4b","type":"GENE","name":"OR4W1P","canonical_id":"hgnc:HGNC:15405","description":"olfactory receptor family 4 subfamily W member 1 pseudogene","metadata":null},{"id":"2729fd8779a340b3b81d964d8648cdb8","type":"GENE","name":"OR4X1","canonical_id":"hgnc:HGNC:14854","description":"olfactory receptor family 4 subfamily X member 1","metadata":null},{"id":"321ff6c06b224c5ebaa526a8190a5972","type":"GENE","name":"OR4X2","canonical_id":"hgnc:HGNC:15184","description":"olfactory receptor family 4 subfamily X member 2","metadata":null},{"id":"f51db31dedd84c4a8f06f6618bdd7a4c","type":"GENE","name":"OR4X7P","canonical_id":"hgnc:HGNC:31277","description":"olfactory receptor family 4 subfamily X member 7 pseudogene","metadata":null},{"id":"efbaf4819d1f4158879c0d0a1bf65029","type":"GENE","name":"OR51A10P","canonical_id":"hgnc:HGNC:15185","description":"olfactory receptor family 51 subfamily A member 10 pseudogene","metadata":{"aliases":["OR51A11P","OR51A13"]}},{"id":"d21636ff77154e38bd29c34d3ec07e10","type":"GENE","name":"OR51A1P","canonical_id":"hgnc:HGNC:8316","description":"olfactory receptor family 51 subfamily A member 1 pseudogene","metadata":null},{"id":"dbad606bb10a4a4a88886224c872fe21","type":"GENE","name":"OR51A2","canonical_id":"hgnc:HGNC:14764","description":"olfactory receptor family 51 subfamily A member 2","metadata":null},{"id":"c4189258ef5d409db9a5b5f621bce457","type":"GENE","name":"OR51A3P","canonical_id":"hgnc:HGNC:14794","description":"olfactory receptor family 51 subfamily A member 3 pseudogene","metadata":null},{"id":"c2567300d7ad4f7dac3c6f3ff421ef9b","type":"GENE","name":"OR51A4","canonical_id":"hgnc:HGNC:14795","description":"olfactory receptor family 51 subfamily A member 4","metadata":null},{"id":"db901d0c84ab47f79fb799d2f4eb2624","type":"GENE","name":"OR51A5P","canonical_id":"hgnc:HGNC:14801","description":"olfactory receptor family 51 subfamily A member 5 pseudogene","metadata":null},{"id":"80179af143974a5bb6d27f14361d7247","type":"GENE","name":"OR51A6P","canonical_id":"hgnc:HGNC:15187","description":"olfactory receptor family 51 subfamily A member 6 pseudogene","metadata":null},{"id":"15b7766cdd47429e9c4714b24ed53c32","type":"GENE","name":"OR51A7","canonical_id":"hgnc:HGNC:15188","description":"olfactory receptor family 51 subfamily A member 7","metadata":null},{"id":"f275365917584dd989c7a1be5a7ada54","type":"GENE","name":"OR51A8P","canonical_id":"hgnc:HGNC:15189","description":"olfactory receptor family 51 subfamily A member 8 pseudogene","metadata":null},{"id":"b00e4b59a6034147aa52d57df5478bbf","type":"GENE","name":"OR51A9P","canonical_id":"hgnc:HGNC:15190","description":"olfactory receptor family 51 subfamily A member 9 pseudogene","metadata":null},{"id":"cf004c93c7e54c43a13fa1d0cebab5e6","type":"GENE","name":"OR51AB1P","canonical_id":"hgnc:HGNC:31278","description":"olfactory receptor family 51 subfamily AB member 1 pseudogene","metadata":null},{"id":"22aff17cd8da42dd9af33b40493c09fa","type":"GENE","name":"OR51B2","canonical_id":"hgnc:HGNC:14703","description":"olfactory receptor family 51 subfamily B member 2","metadata":{"aliases":["OR51B1P"]}},{"id":"0189954fb3e34bf5be2d108ef74d40c5","type":"GENE","name":"OR51B3P","canonical_id":"hgnc:HGNC:14706","description":"olfactory receptor family 51 subfamily B member 3 pseudogene","metadata":null},{"id":"c8675527a2cb45a59f3dab37c76956b3","type":"GENE","name":"OR51B4","canonical_id":"hgnc:HGNC:14708","description":"olfactory receptor family 51 subfamily B member 4","metadata":null},{"id":"6b6f6a0439ed472f9c343f8a40f6ac1a","type":"GENE","name":"OR51B5","canonical_id":"hgnc:HGNC:19599","description":"olfactory receptor family 51 subfamily B member 5","metadata":null},{"id":"5d6164e3c5eb490889c4c6efc9fe100c","type":"GENE","name":"OR51B6","canonical_id":"hgnc:HGNC:19600","description":"olfactory receptor family 51 subfamily B member 6","metadata":null},{"id":"7df511ac57414071b333f61a131b9ad0","type":"GENE","name":"OR51B8P","canonical_id":"hgnc:HGNC:31279","description":"olfactory receptor family 51 subfamily B member 8 pseudogene","metadata":null},{"id":"8ecb5e90137a43429a4101d2609b6376","type":"GENE","name":"OR51C1","canonical_id":"hgnc:HGNC:15191","description":"olfactory receptor family 51 subfamily C member 1","metadata":{"aliases":["OST734","OR51C1P","OR51C2P","OR51C3P"]}},{"id":"ae108c7ee3bb49698d92ce418dc5f1e8","type":"GENE","name":"OR51C4P","canonical_id":"hgnc:HGNC:31280","description":"olfactory receptor family 51 subfamily C member 4 pseudogene","metadata":null},{"id":"5ff22169a4554aa2a704faa93afadc97","type":"GENE","name":"OR51D1","canonical_id":"hgnc:HGNC:15193","description":"olfactory receptor family 51 subfamily D member 1","metadata":{"aliases":["OR51D1Q"]}},{"id":"43a7ed1e24614457ac07742c3f9ab619","type":"GENE","name":"OR51E1","canonical_id":"hgnc:HGNC:15194","description":"olfactory receptor family 51 subfamily E member 1","metadata":{"aliases":["GPR136","OR51E1P","OR52A3P","GPR164"]}},{"id":"27c7c185617b4e398b2f48f0e1c6943b","type":"GENE","name":"OR51E2","canonical_id":"hgnc:HGNC:15195","description":"olfactory receptor family 51 subfamily E member 2","metadata":{"aliases":["PSGR"]}},{"id":"5d95d05da9cf45cea51ad06252d12827","type":"GENE","name":"OR51F1","canonical_id":"hgnc:HGNC:15196","description":"olfactory receptor family 51 subfamily F member 1","metadata":{"aliases":["OR51F1P"]}},{"id":"e3649927b02444a2a2416d0526693786","type":"GENE","name":"OR51F2","canonical_id":"hgnc:HGNC:15197","description":"olfactory receptor family 51 subfamily F member 2","metadata":null},{"id":"c5ba204b0ef1472890976188866bb0c4","type":"GENE","name":"OR51F3P","canonical_id":"hgnc:HGNC:31281","description":"olfactory receptor family 51 subfamily F member 3 pseudogene","metadata":null},{"id":"f8282d30ed4645189e14618ce09bf244","type":"GENE","name":"OR51F4P","canonical_id":"hgnc:HGNC:31282","description":"olfactory receptor family 51 subfamily F member 4 pseudogene","metadata":null},{"id":"3b319e43fc654169a6eb5c118b22b4c6","type":"GENE","name":"OR51F5P","canonical_id":"hgnc:HGNC:31283","description":"olfactory receptor family 51 subfamily F member 5 pseudogene","metadata":null},{"id":"35de63b62f1d4aa0bfa0567b6aa15128","type":"GENE","name":"OR51G1","canonical_id":"hgnc:HGNC:14738","description":"olfactory receptor family 51 subfamily G member 1","metadata":{"aliases":["OR51G3P"]}},{"id":"e5269f815ab1458584f0fa16290b2f45","type":"GENE","name":"OR51G2","canonical_id":"hgnc:HGNC:15198","description":"olfactory receptor family 51 subfamily G member 2","metadata":null},{"id":"f08a5f25346544a4a0ca8dbc34e63234","type":"GENE","name":"OR51H1","canonical_id":"hgnc:HGNC:14833","description":"olfactory receptor family 51 subfamily H member 1","metadata":{"aliases":["OR51H1P"]}},{"id":"dd654dd6477e478e8f5c384b0d0a5015","type":"GENE","name":"OR51H2P","canonical_id":"hgnc:HGNC:15199","description":"olfactory receptor family 51 subfamily H member 2 pseudogene","metadata":null},{"id":"e81cf5be2bd94dd0bd8695ed8d50b1cd","type":"GENE","name":"OR51I1","canonical_id":"hgnc:HGNC:15200","description":"olfactory receptor family 51 subfamily I member 1","metadata":null},{"id":"2bdb56e31cb84c14b3862116bda3268b","type":"GENE","name":"OR51I2","canonical_id":"hgnc:HGNC:15201","description":"olfactory receptor family 51 subfamily I member 2","metadata":null},{"id":"67abd9fc01e146b9b4dd15a5063d0173","type":"GENE","name":"OR51J1","canonical_id":"hgnc:HGNC:14856","description":"olfactory receptor family 51 subfamily J member 1","metadata":{"aliases":["OR51J2","OR51J1P"]}},{"id":"7229cb4123c1400db9c8c5587bb5369a","type":"GENE","name":"OR51K1P","canonical_id":"hgnc:HGNC:15202","description":"olfactory receptor family 51 subfamily K member 1 pseudogene","metadata":null},{"id":"bf10a81344f64570b838d14934f6ed8a","type":"GENE","name":"OR51L1","canonical_id":"hgnc:HGNC:14759","description":"olfactory receptor family 51 subfamily L member 1","metadata":null},{"id":"f966de5ee1de40a3b5b4654fa468942b","type":"GENE","name":"OR51M1","canonical_id":"hgnc:HGNC:14847","description":"olfactory receptor family 51 subfamily M member 1","metadata":null},{"id":"53eccaa412ec4f85ac0266d6df2640d0","type":"GENE","name":"OR51N1P","canonical_id":"hgnc:HGNC:14757","description":"olfactory receptor family 51 subfamily N member 1 pseudogene","metadata":null},{"id":"66931d6a26f24a659388c7cf0c2fd376","type":"GENE","name":"OR51P1P","canonical_id":"hgnc:HGNC:14762","description":"olfactory receptor family 51 subfamily P member 1 pseudogene","metadata":{"aliases":["OR51P2P"]}},{"id":"6f198a7e469e41209f9c69f0adf817c4","type":"GENE","name":"OR51Q1","canonical_id":"hgnc:HGNC:14851","description":"olfactory receptor family 51 subfamily Q member 1","metadata":null},{"id":"2e3187e6e98c4727a01adca93c3bffb1","type":"GENE","name":"OR51R1P","canonical_id":"hgnc:HGNC:15203","description":"olfactory receptor family 51 subfamily R member 1 pseudogene","metadata":null},{"id":"5e63a633e100440dacd4017918c20cb9","type":"GENE","name":"OR51S1","canonical_id":"hgnc:HGNC:15204","description":"olfactory receptor family 51 subfamily S member 1","metadata":null},{"id":"90f67f7aaa5f4bb0bbacbdea111537a3","type":"GENE","name":"OR51T1","canonical_id":"hgnc:HGNC:15205","description":"olfactory receptor family 51 subfamily T member 1","metadata":null},{"id":"f6f2f904d70444899bcb77bad2ff3d95","type":"GENE","name":"OR51V1","canonical_id":"hgnc:HGNC:19597","description":"olfactory receptor family 51 subfamily V member 1","metadata":{"aliases":["OR51A12"]}},{"id":"17223d7fcaf341ff89a108fea450256f","type":"GENE","name":"OR52A1","canonical_id":"hgnc:HGNC:8318","description":"olfactory receptor family 52 subfamily A member 1","metadata":{"aliases":["HPFH1OR"]}},{"id":"698f0c59e7e14ee5847673225ed6e852","type":"GENE","name":"OR52A4P","canonical_id":"hgnc:HGNC:19579","description":"olfactory receptor family 52 subfamily A member 4 pseudogene","metadata":{"aliases":["OR52A4"]}},{"id":"05f8586396994d7ba38dbfbf5348b6e0","type":"GENE","name":"OR52A5","canonical_id":"hgnc:HGNC:19580","description":"olfactory receptor family 52 subfamily A member 5","metadata":null},{"id":"f7f23f7567104128b7c79db53016c434","type":"GENE","name":"OR52B1P","canonical_id":"hgnc:HGNC:15206","description":"olfactory receptor family 52 subfamily B member 1 pseudogene","metadata":null},{"id":"4e58011cb97a4470a4868650e259c337","type":"GENE","name":"OR52B2","canonical_id":"hgnc:HGNC:15207","description":"olfactory receptor family 52 subfamily B member 2","metadata":null},{"id":"6bbfeb40659a4c9bb33267a204031dfc","type":"GENE","name":"OR52B3P","canonical_id":"hgnc:HGNC:15208","description":"olfactory receptor family 52 subfamily B member 3 pseudogene","metadata":null},{"id":"01b0d2124708444e82d287b47e69d8b2","type":"GENE","name":"OR52B4","canonical_id":"hgnc:HGNC:15209","description":"olfactory receptor family 52 subfamily B member 4","metadata":null},{"id":"e3d0ad49b5bf4c2c942ae8627f3f073a","type":"GENE","name":"OR52B5P","canonical_id":"hgnc:HGNC:15210","description":"olfactory receptor family 52 subfamily B member 5 pseudogene","metadata":null},{"id":"5e3005e2c58a4e34ba7d2e78cca80ffd","type":"GENE","name":"OR52B6","canonical_id":"hgnc:HGNC:15211","description":"olfactory receptor family 52 subfamily B member 6","metadata":null},{"id":"e4a7c327c25a4cb4bfeb5c4f59c694a9","type":"GENE","name":"OR52D1","canonical_id":"hgnc:HGNC:15212","description":"olfactory receptor family 52 subfamily D member 1","metadata":null},{"id":"e91a3046682e499f984ad365528244d9","type":"GENE","name":"OR52E1","canonical_id":"hgnc:HGNC:14766","description":"olfactory receptor family 52 subfamily E member 1 (gene/pseudogene)","metadata":{"aliases":["OR52E1P"]}},{"id":"8823edfb79324d598fb6a24fac532958","type":"GENE","name":"OR52E2","canonical_id":"hgnc:HGNC:14769","description":"olfactory receptor family 52 subfamily E member 2","metadata":null},{"id":"e2a28349fc9f45af8d915b66d42c76ab","type":"GENE","name":"OR52E3P","canonical_id":"hgnc:HGNC:14793","description":"olfactory receptor family 52 subfamily E member 3 pseudogene","metadata":null},{"id":"b064c1f8bb5d40c4a06d9d3a3037ab41","type":"GENE","name":"OR52E4","canonical_id":"hgnc:HGNC:15213","description":"olfactory receptor family 52 subfamily E member 4","metadata":null},{"id":"79d56108bcbb46678a134cea2f47c0b1","type":"GENE","name":"OR52E5","canonical_id":"hgnc:HGNC:15214","description":"olfactory receptor family 52 subfamily E member 5","metadata":null},{"id":"6895e6f8f7d247c3ac9c864e64cf06a0","type":"GENE","name":"OR52E6","canonical_id":"hgnc:HGNC:15215","description":"olfactory receptor family 52 subfamily E member 6","metadata":null},{"id":"f352380e31924560b99ca40dc04c98d6","type":"GENE","name":"OR52E7P","canonical_id":"hgnc:HGNC:15216","description":"olfactory receptor family 52 subfamily E member 7 pseudogene","metadata":null},{"id":"0d94fe5644d14ee38b47b36cbc7653d9","type":"GENE","name":"OR52E8","canonical_id":"hgnc:HGNC:15217","description":"olfactory receptor family 52 subfamily E member 8","metadata":null},{"id":"3001040cf6a94452a80d6a3fd65b1dab","type":"GENE","name":"OR52H1","canonical_id":"hgnc:HGNC:15218","description":"olfactory receptor family 52 subfamily H member 1","metadata":null},{"id":"91eabf9d548146d3ad4b1596348b15c6","type":"GENE","name":"OR52H2P","canonical_id":"hgnc:HGNC:15219","description":"olfactory receptor family 52 subfamily H member 2 pseudogene","metadata":null},{"id":"9a9ac4a3c0704bdab920cb912da2d14f","type":"GENE","name":"OR52I1","canonical_id":"hgnc:HGNC:15220","description":"olfactory receptor family 52 subfamily I member 1","metadata":null},{"id":"b2c61960be2246d4a4608b396687b91c","type":"GENE","name":"OR52I2","canonical_id":"hgnc:HGNC:15221","description":"olfactory receptor family 52 subfamily I member 2","metadata":null},{"id":"0056f0019a744ea582d8aa14d4142ee8","type":"GENE","name":"OR52J1P","canonical_id":"hgnc:HGNC:14760","description":"olfactory receptor family 52 subfamily J member 1 pseudogene","metadata":null},{"id":"75c140d325564d17ab1000d072f13f80","type":"GENE","name":"OR52J2P","canonical_id":"hgnc:HGNC:14797","description":"olfactory receptor family 52 subfamily J member 2 pseudogene","metadata":{"aliases":["OR52J4P"]}},{"id":"24ec391db98b4732be573b346451b4fc","type":"GENE","name":"OR52J3","canonical_id":"hgnc:HGNC:14799","description":"olfactory receptor family 52 subfamily J member 3","metadata":null},{"id":"15134b2223ef453bb4fc1d353dcba191","type":"GENE","name":"OR52K1","canonical_id":"hgnc:HGNC:15222","description":"olfactory receptor family 52 subfamily K member 1","metadata":null},{"id":"1d22d28563774e76924ba2fec97c69d2","type":"GENE","name":"OR52K2","canonical_id":"hgnc:HGNC:15223","description":"olfactory receptor family 52 subfamily K member 2","metadata":null},{"id":"fa3c483c060f4bf48432dbace969bc38","type":"GENE","name":"OR52K3P","canonical_id":"hgnc:HGNC:15224","description":"olfactory receptor family 52 subfamily K member 3 pseudogene","metadata":null},{"id":"3e1849694e7548d0ab821b9557a5548e","type":"GENE","name":"OR52L1","canonical_id":"hgnc:HGNC:14785","description":"olfactory receptor family 52 subfamily L member 1","metadata":null},{"id":"26ee5b336b1645e88b9f0941ca47ed7b","type":"GENE","name":"OR52L2P","canonical_id":"hgnc:HGNC:14788","description":"olfactory receptor family 52 subfamily L member 2 pseudogene","metadata":{"aliases":["OR52L2"]}},{"id":"8b7c54a818a74db592cedac5b28c44c3","type":"GENE","name":"OR52M1","canonical_id":"hgnc:HGNC:15225","description":"olfactory receptor family 52 subfamily M member 1","metadata":{"aliases":["OR52M1P"]}},{"id":"f6f3c378c9124c76829768be717472ad","type":"GENE","name":"OR52M2P","canonical_id":"hgnc:HGNC:15226","description":"olfactory receptor family 52 subfamily M member 2 pseudogene","metadata":{"aliases":["OR52M4"]}},{"id":"1b6d64ea93704c678c4a18853ea7100c","type":"GENE","name":"OR52N1","canonical_id":"hgnc:HGNC:14853","description":"olfactory receptor family 52 subfamily N member 1","metadata":null},{"id":"a43d7f986f904394b720350cad325690","type":"GENE","name":"OR52N2","canonical_id":"hgnc:HGNC:15228","description":"olfactory receptor family 52 subfamily N member 2","metadata":null},{"id":"89e4241ac49444978b8926c222089283","type":"GENE","name":"OR52N3P","canonical_id":"hgnc:HGNC:15229","description":"olfactory receptor family 52 subfamily N member 3 pseudogene","metadata":null},{"id":"1cd885aea4f34219b17dd3a6fcbb5dbb","type":"GENE","name":"OR52N4","canonical_id":"hgnc:HGNC:15230","description":"olfactory receptor family 52 subfamily N member 4","metadata":null},{"id":"6bd7b532e01948b09f46bbe98b9d0a25","type":"GENE","name":"OR52N5","canonical_id":"hgnc:HGNC:15231","description":"olfactory receptor family 52 subfamily N member 5","metadata":{"aliases":["OR52N5Q"]}},{"id":"f4f5abdb93a446e8b41b12bf094c14a1","type":"GENE","name":"OR52P1","canonical_id":"hgnc:HGNC:15232","description":"olfactory receptor family 52 subfamily P member 1 (gene/pseudogene)","metadata":{"aliases":["OR52P1P"]}},{"id":"af5828aaffb84239958b3e330b44b3a9","type":"GENE","name":"OR52P2P","canonical_id":"hgnc:HGNC:15233","description":"olfactory receptor family 52 subfamily P member 2 pseudogene","metadata":null},{"id":"85a03e9bdd0146d28a7d8d28454a97e4","type":"GENE","name":"OR52Q1P","canonical_id":"hgnc:HGNC:15234","description":"olfactory receptor family 52 subfamily Q member 1 pseudogene","metadata":null},{"id":"504822b33de949b29e7f0f78d356f81a","type":"GENE","name":"OR52R1","canonical_id":"hgnc:HGNC:15235","description":"olfactory receptor family 52 subfamily R member 1","metadata":null},{"id":"d840c203842a48e4982dfa23f2b4470e","type":"GENE","name":"OR52S1P","canonical_id":"hgnc:HGNC:14805","description":"olfactory receptor family 52 subfamily S member 1 pseudogene","metadata":null},{"id":"b7b164d94e4f435e885fd985754c7115","type":"GENE","name":"OR52T1P","canonical_id":"hgnc:HGNC:15236","description":"olfactory receptor family 52 subfamily T member 1 pseudogene","metadata":null},{"id":"9c04451a7c5843c7814f29949df65a84","type":"GENE","name":"OR52U1P","canonical_id":"hgnc:HGNC:15237","description":"olfactory receptor family 52 subfamily U member 1 pseudogene","metadata":null},{"id":"469f3238e9984cc29742236636637fdc","type":"GENE","name":"OR52V1P","canonical_id":"hgnc:HGNC:15238","description":"olfactory receptor family 52 subfamily V member 1 pseudogene","metadata":null},{"id":"bd5e031900984cbcbb0cda2c8375f6ad","type":"GENE","name":"OR52W1","canonical_id":"hgnc:HGNC:15239","description":"olfactory receptor family 52 subfamily W member 1","metadata":{"aliases":["OR52W1P"]}},{"id":"4c9001cd5ed9435380dd7ffcf3620985","type":"GENE","name":"OR52X1P","canonical_id":"hgnc:HGNC:14790","description":"olfactory receptor family 52 subfamily X member 1 pseudogene","metadata":null},{"id":"5631d9333af940b6a076931fa280df4c","type":"GENE","name":"OR52Y1P","canonical_id":"hgnc:HGNC:15240","description":"olfactory receptor family 52 subfamily Y member 1 pseudogene","metadata":{"aliases":["OR52Y2P"]}},{"id":"1cbf95a8595e409880de12da1a46a5f8","type":"GENE","name":"OR52Z1","canonical_id":"hgnc:HGNC:19596","description":"olfactory receptor family 52 subfamily Z member 1 (gene/pseudogene)","metadata":{"aliases":["OR52Z1P"]}},{"id":"61aae7c7b46f47cd89b32381e8bab5ff","type":"GENE","name":"OR55B1P","canonical_id":"hgnc:HGNC:15241","description":"olfactory receptor family 55 subfamily B member 1 pseudogene","metadata":{"aliases":["OR55B2P","OR55C1P"]}},{"id":"9301cc0e775d4db8af574da8d7a567fe","type":"GENE","name":"OR56A1","canonical_id":"hgnc:HGNC:14781","description":"olfactory receptor family 56 subfamily A member 1","metadata":null},{"id":"fa1218906754413ebfd59b4240cb06c4","type":"GENE","name":"OR56A3","canonical_id":"hgnc:HGNC:14786","description":"olfactory receptor family 56 subfamily A member 3","metadata":{"aliases":["OR56A6","OR56A3P"]}},{"id":"0eb0c5fc285b45d4b8bcbda3d572bdc3","type":"GENE","name":"OR56A4","canonical_id":"hgnc:HGNC:14791","description":"olfactory receptor family 56 subfamily A member 4","metadata":null},{"id":"c7b6d41325484fe3820dc149e83fa4c4","type":"GENE","name":"OR56A5","canonical_id":"hgnc:HGNC:14792","description":"olfactory receptor family 56 subfamily A member 5","metadata":{"aliases":["OR56A5P"]}},{"id":"ce4e15ff285b48e4bbc8b1a8a07abb32","type":"GENE","name":"OR56A7P","canonical_id":"hgnc:HGNC:15244","description":"olfactory receptor family 56 subfamily A member 7 pseudogene","metadata":null},{"id":"e9a9783951de42e193f9670f6b91671b","type":"GENE","name":"OR56B1","canonical_id":"hgnc:HGNC:15245","description":"olfactory receptor family 56 subfamily B member 1","metadata":{"aliases":["OR56B1P"]}},{"id":"6942093371ee4cb0a2373a0744e5f2d6","type":"GENE","name":"OR56B2","canonical_id":"hgnc:HGNC:15246","description":"olfactory receptor family 56 subfamily B member 2","metadata":{"aliases":["OR56B2P"]}},{"id":"0a9b43135eeb46da965d6ca7601e821b","type":"GENE","name":"OR56B3P","canonical_id":"hgnc:HGNC:15247","description":"olfactory receptor family 56 subfamily B member 3 pseudogene","metadata":null},{"id":"f4e7cb6ffb064f8c95cfd552d9bb22d8","type":"GENE","name":"OR56B4","canonical_id":"hgnc:HGNC:15248","description":"olfactory receptor family 56 subfamily B member 4","metadata":null},{"id":"91c29afca6d9414d839592f2f95f1ab2","type":"GENE","name":"OR5A1","canonical_id":"hgnc:HGNC:8319","description":"olfactory receptor family 5 subfamily A member 1","metadata":{"aliases":["OST181","OR5A1P"]}},{"id":"353e2a67676c4ce9bf8a51f0b8dbe3dd","type":"GENE","name":"OR5A2","canonical_id":"hgnc:HGNC:15249","description":"olfactory receptor family 5 subfamily A member 2","metadata":null},{"id":"95888b9431714b699fff2556c3a44935","type":"GENE","name":"OR5AC1","canonical_id":"hgnc:HGNC:15047","description":"olfactory receptor family 5 subfamily AC member 1 (gene/pseudogene)","metadata":{"aliases":["OR5AC1P"]}},{"id":"397cbdc62b4f4592a2007babbd9a793a","type":"GENE","name":"OR5AC2","canonical_id":"hgnc:HGNC:15431","description":"olfactory receptor family 5 subfamily AC member 2","metadata":{"aliases":["HSA1"]}},{"id":"1bb062c212fb4fcd9179f1bb54dc7359","type":"GENE","name":"OR5AC4P","canonical_id":"hgnc:HGNC:31284","description":"olfactory receptor family 5 subfamily AC member 4 pseudogene","metadata":null},{"id":"c7b2d557ea9e48ceb9b299b0ebcff6a6","type":"GENE","name":"OR5AH1P","canonical_id":"hgnc:HGNC:14714","description":"olfactory receptor family 5 subfamily AH member 1 pseudogene","metadata":null},{"id":"756f92b117704c0b85eb3624cf723460","type":"GENE","name":"OR5AK1P","canonical_id":"hgnc:HGNC:15250","description":"olfactory receptor family 5 subfamily AK member 1 pseudogene","metadata":{"aliases":["OR5AK5P"]}},{"id":"c67f827ebfa740ee8f70e15bae6a1cea","type":"GENE","name":"OR5AK2","canonical_id":"hgnc:HGNC:15251","description":"olfactory receptor family 5 subfamily AK member 2","metadata":null},{"id":"4036080af140444cbd6cf352a9de7753","type":"GENE","name":"OR5AK3P","canonical_id":"hgnc:HGNC:15252","description":"olfactory receptor family 5 subfamily AK member 3 pseudogene","metadata":{"aliases":["OR5AK3"]}},{"id":"232ab835247440c58f1681d72eeb60ae","type":"GENE","name":"OR5AK4P","canonical_id":"hgnc:HGNC:15253","description":"olfactory receptor family 5 subfamily AK member 4 pseudogene","metadata":null},{"id":"31352d5c78754bed94f37ad5a5d88167","type":"GENE","name":"OR5AL1","canonical_id":"hgnc:HGNC:14844","description":"olfactory receptor family 5 subfamily AL member 1 (gene/pseudogene)","metadata":{"aliases":["OR5AL1P"]}},{"id":"c7c6e8f1a2ca44cc9b7452e54a65bf2c","type":"GENE","name":"OR5AL2P","canonical_id":"hgnc:HGNC:14850","description":"olfactory receptor family 5 subfamily AL member 2 pseudogene","metadata":null},{"id":"e8c3748249fa4720bf4725df5b8a39e7","type":"GENE","name":"OR5AM1P","canonical_id":"hgnc:HGNC:15254","description":"olfactory receptor family 5 subfamily AM member 1 pseudogene","metadata":null},{"id":"114b8a8802dd4d8a91bf08f91cd05e78","type":"GENE","name":"OR5AN1","canonical_id":"hgnc:HGNC:15255","description":"olfactory receptor family 5 subfamily AN member 1","metadata":null},{"id":"ade43898d62649dab2c6eafa3952dd55","type":"GENE","name":"OR5AN2P","canonical_id":"hgnc:HGNC:15256","description":"olfactory receptor family 5 subfamily AN member 2 pseudogene","metadata":null},{"id":"980abfaa64ee42ceb35dfb602c5d5767","type":"GENE","name":"OR5AO1P","canonical_id":"hgnc:HGNC:31285","description":"olfactory receptor family 5 subfamily AO member 1 pseudogene","metadata":null},{"id":"62db76dd4cf248afbdc69879bfc45a90","type":"GENE","name":"OR5AP1P","canonical_id":"hgnc:HGNC:15257","description":"olfactory receptor family 5 subfamily AP member 1 pseudogene","metadata":null},{"id":"efa28d22ea994685b9e7bfd263163980","type":"GENE","name":"OR5AP2","canonical_id":"hgnc:HGNC:15258","description":"olfactory receptor family 5 subfamily AP member 2","metadata":null},{"id":"eb77be1e0d3943048f25f9ae2cea9d40","type":"GENE","name":"OR5AQ1P","canonical_id":"hgnc:HGNC:15259","description":"olfactory receptor family 5 subfamily AQ member 1 pseudogene","metadata":null},{"id":"fe09350b3d604a44b3266c789628289d","type":"GENE","name":"OR5AR1","canonical_id":"hgnc:HGNC:15260","description":"olfactory receptor family 5 subfamily AR member 1","metadata":null},{"id":"2350e03a901e4ad7a9e997ace104e25a","type":"GENE","name":"OR5AS1","canonical_id":"hgnc:HGNC:15261","description":"olfactory receptor family 5 subfamily AS member 1","metadata":null},{"id":"83d0ad133dbb4cfc96c9b000fd58f181","type":"GENE","name":"OR5AU1","canonical_id":"hgnc:HGNC:15362","description":"olfactory receptor family 5 subfamily AU member 1","metadata":null},{"id":"42312021997347f2b040279e32c2c7b0","type":"GENE","name":"OR5AW1P","canonical_id":"hgnc:HGNC:15406","description":"olfactory receptor family 5 subfamily AW member 1 pseudogene","metadata":null},{"id":"ed9b4d8555c14bca8f652a574d75e18d","type":"GENE","name":"OR5AZ1P","canonical_id":"hgnc:HGNC:15262","description":"olfactory receptor family 5 subfamily AZ member 1 pseudogene","metadata":null},{"id":"02cc63f6eaa94d1c91f36cfccfc8e326","type":"GENE","name":"OR5B10P","canonical_id":"hgnc:HGNC:8320","description":"olfactory receptor family 5 subfamily B member 10 pseudogene","metadata":{"aliases":["OR13-67","OR13-34","OR13-64","OR5B11P","OR5B4P","OR5B10","OR5B11","OR5B18P"]}},{"id":"8d4df0f78fee483a8c2c8569e18911c4","type":"GENE","name":"OR5B12","canonical_id":"hgnc:HGNC:15432","description":"olfactory receptor family 5 subfamily B member 12","metadata":{"aliases":["OST743","OR5B12P","OR5B16"]}},{"id":"57ac04087d894a6ebf7acc8222897b8f","type":"GENE","name":"OR5B15P","canonical_id":"hgnc:HGNC:15265","description":"olfactory receptor family 5 subfamily B member 15 pseudogene","metadata":null},{"id":"cfb65cd7455d49d8811ab8eac95be4ff","type":"GENE","name":"OR5B17","canonical_id":"hgnc:HGNC:15267","description":"olfactory receptor family 5 subfamily B member 17","metadata":{"aliases":["OR5B20P"]}},{"id":"4c802a933c9142139cec6542407d34e6","type":"GENE","name":"OR5B19P","canonical_id":"hgnc:HGNC:15269","description":"olfactory receptor family 5 subfamily B member 19 pseudogene","metadata":null},{"id":"51a76205d09449c68827b5ed9a265fa9","type":"GENE","name":"OR5B1P","canonical_id":"hgnc:HGNC:8322","description":"olfactory receptor family 5 subfamily B member 1 pseudogene","metadata":{"aliases":["OR8-122","OR8-123","OR6-57","OR6-55","OR3-144","OR912-92","OR5B9P","OR5B9","OR5B5P","OR5B14P","OR5B7P","OR5B7","OR5B8","OR5B8P","OR5B5","OR5B6","OR5B6P"]}},{"id":"c41333b2f95842d894dff1d81034044f","type":"GENE","name":"OR5B2","canonical_id":"hgnc:HGNC:8323","description":"olfactory receptor family 5 subfamily B member 2","metadata":{"aliases":["OST073"]}},{"id":"7f8fa4eadd0c4a30a708ae09f14b3bf5","type":"GENE","name":"OR5B21","canonical_id":"hgnc:HGNC:19616","description":"olfactory receptor family 5 subfamily B member 21","metadata":null},{"id":"8b7dd83cb89b42ee8ec0193430875120","type":"GENE","name":"OR5B3","canonical_id":"hgnc:HGNC:8324","description":"olfactory receptor family 5 subfamily B member 3","metadata":{"aliases":["OST129","OR5B13"]}},{"id":"d00a3ac1546a48e5addfb22fa7a8e5a2","type":"GENE","name":"OR5BA1P","canonical_id":"hgnc:HGNC:15270","description":"olfactory receptor family 5 subfamily BA member 1 pseudogene","metadata":null},{"id":"6d136d5f8f27448bba6f07283b7e168d","type":"GENE","name":"OR5BB1P","canonical_id":"hgnc:HGNC:15271","description":"olfactory receptor family 5 subfamily BB member 1 pseudogene","metadata":null},{"id":"14a2195573424fcf884e5bd16ab1b443","type":"GENE","name":"OR5BC1P","canonical_id":"hgnc:HGNC:15272","description":"olfactory receptor family 5 subfamily BC member 1 pseudogene","metadata":null},{"id":"4320cb3bbf434adfad7757bd57562d44","type":"GENE","name":"OR5BD1P","canonical_id":"hgnc:HGNC:14843","description":"olfactory receptor family 5 subfamily BD member 1 pseudogene","metadata":null},{"id":"296c3eb2fa2649f09a083ec886b1c6d5","type":"GENE","name":"OR5BE1P","canonical_id":"hgnc:HGNC:15273","description":"olfactory receptor family 5 subfamily BE member 1 pseudogene","metadata":null},{"id":"e945318e47a046da96377fe0c07c7fbd","type":"GENE","name":"OR5BH1P","canonical_id":"hgnc:HGNC:15407","description":"olfactory receptor family 5 subfamily BH member 1 pseudogene","metadata":{"aliases":["OR5BH2P"]}},{"id":"31b9f896b49541c38783446d55d6879c","type":"GENE","name":"OR5BJ1P","canonical_id":"hgnc:HGNC:15434","description":"olfactory receptor family 5 subfamily BJ member 1 pseudogene","metadata":{"aliases":["OST740"]}},{"id":"2ab467e60eed4c0e88faff8ced05dc20","type":"GENE","name":"OR5BK1P","canonical_id":"hgnc:HGNC:14817","description":"olfactory receptor family 5 subfamily BK member 1 pseudogene","metadata":null},{"id":"eafeebe7ede8437e8b92a5c2ae33723b","type":"GENE","name":"OR5BL1P","canonical_id":"hgnc:HGNC:15275","description":"olfactory receptor family 5 subfamily BL member 1 pseudogene","metadata":null},{"id":"d3a8cf64bbc9486cbd6d7aeb7be4e457","type":"GENE","name":"OR5BM1P","canonical_id":"hgnc:HGNC:14835","description":"olfactory receptor family 5 subfamily BM member 1 pseudogene","metadata":null},{"id":"ab940731fac446aebc3dbb6a3f6b28e4","type":"GENE","name":"OR5BN1P","canonical_id":"hgnc:HGNC:15276","description":"olfactory receptor family 5 subfamily BN member 1 pseudogene","metadata":null},{"id":"9fe4b90d5e154f3a982a993696cc61f3","type":"GENE","name":"OR5BN2P","canonical_id":"hgnc:HGNC:29194","description":"olfactory receptor family 5 subfamily BN member 2 pseudogene","metadata":null},{"id":"48708e59ae5747eb806561bc228f1ff0","type":"GENE","name":"OR5BP1P","canonical_id":"hgnc:HGNC:15277","description":"olfactory receptor family 5 subfamily BP member 1 pseudogene","metadata":null},{"id":"582bf7c949b64c55b23f7ab4378299b8","type":"GENE","name":"OR5BQ1P","canonical_id":"hgnc:HGNC:15278","description":"olfactory receptor family 5 subfamily BQ member 1 pseudogene","metadata":{"aliases":["OR5BQ2P"]}},{"id":"83f6397e91b9476f8c76e792f044f3c3","type":"GENE","name":"OR5BR1P","canonical_id":"hgnc:HGNC:15279","description":"olfactory receptor family 5 subfamily BR member 1 pseudogene","metadata":null},{"id":"e6abb34e2fe0420484e4e6c7e70677e6","type":"GENE","name":"OR5BS1","canonical_id":"hgnc:HGNC:19627","description":"olfactory receptor family 5 subfamily BS member 1","metadata":{"aliases":["OR5BS1P"]}},{"id":"b80ddbdd47114d73895bdad3d479a2cf","type":"GENE","name":"OR5BT1P","canonical_id":"hgnc:HGNC:19629","description":"olfactory receptor family 5 subfamily BT member 1 pseudogene","metadata":null},{"id":"73e889a1a1f841a9b34592c5f7ec02fb","type":"GENE","name":"OR5C1","canonical_id":"hgnc:HGNC:8331","description":"olfactory receptor family 5 subfamily C member 1","metadata":{"aliases":["OR9-F","hRPK-465_F_21","OR5C2P"]}},{"id":"cc982d5945b840bd9f41b63ebc486f96","type":"GENE","name":"OR5D13","canonical_id":"hgnc:HGNC:15280","description":"olfactory receptor family 5 subfamily D member 13","metadata":null},{"id":"326751126eb647eb96771891c45e7883","type":"GENE","name":"OR5D14","canonical_id":"hgnc:HGNC:15281","description":"olfactory receptor family 5 subfamily D member 14","metadata":null},{"id":"bb03af4fe9dc4c039c27cfc76e434791","type":"GENE","name":"OR5D15P","canonical_id":"hgnc:HGNC:15282","description":"olfactory receptor family 5 subfamily D member 15 pseudogene","metadata":null},{"id":"ebc0300ae54a4ee8b4cecb3f8f7e2f7e","type":"GENE","name":"OR5D16","canonical_id":"hgnc:HGNC:15283","description":"olfactory receptor family 5 subfamily D member 16","metadata":null},{"id":"620d50a4908045c28a112c545741cc9a","type":"GENE","name":"OR5D17P","canonical_id":"hgnc:HGNC:15284","description":"olfactory receptor family 5 subfamily D member 17 pseudogene","metadata":null},{"id":"f62962b53e4e4e3395ca0ab3f22ab3be","type":"GENE","name":"OR5D18","canonical_id":"hgnc:HGNC:15285","description":"olfactory receptor family 5 subfamily D member 18","metadata":null},{"id":"dec13c5b556e4358b1764d5d1f5aa3eb","type":"GENE","name":"OR5D2P","canonical_id":"hgnc:HGNC:8335","description":"olfactory receptor family 5 subfamily D member 2 pseudogene","metadata":{"aliases":["OR11-7a","OR912-91","OR8-127","OR912-47","OR18-44","R5D9P","OR18-17","OR18-42","OR18-43","OR912-94","OR8-125","OR5D6P","OR5D10P","OR5D1P","OR5D5P","OR5D12P","OR5D8P","OR5D7P","OR5D9P","OR5D12","OR5D11P","OR5D11"]}},{"id":"1b3547da292d44a7af14851c32f33455","type":"GENE","name":"OR5D3","canonical_id":"hgnc:HGNC:8336","description":"olfactory receptor family 5 subfamily D member 3","metadata":{"aliases":["OR11-8b","OR11-8c","OR5D3P","OR5D4"]}},{"id":"796656c4263048aa9c9b64b661079c6b","type":"GENE","name":"OR5E1P","canonical_id":"hgnc:HGNC:8342","description":"olfactory receptor family 5 subfamily E member 1 pseudogene","metadata":{"aliases":["TPCR24","HSTPCR24","OR5E1"]}},{"id":"f2a7656d830c49cfbabf453b14178727","type":"GENE","name":"OR5F1","canonical_id":"hgnc:HGNC:8343","description":"olfactory receptor family 5 subfamily F member 1","metadata":{"aliases":["OR11-10"]}},{"id":"070ddaed3fc34aaa8c98ccb9014ba8ca","type":"GENE","name":"OR5F2P","canonical_id":"hgnc:HGNC:15286","description":"olfactory receptor family 5 subfamily F member 2 pseudogene","metadata":null},{"id":"f6e0f8e57d7a48b186769362204c941d","type":"GENE","name":"OR5G1P","canonical_id":"hgnc:HGNC:8344","description":"olfactory receptor family 5 subfamily G member 1 pseudogene","metadata":{"aliases":["OR11-104","OR93","OR5G2P"]}},{"id":"935df89bbd2944c98f46cb743f76adcd","type":"GENE","name":"OR5G3","canonical_id":"hgnc:HGNC:15287","description":"olfactory receptor family 5 subfamily G member 3 (gene/pseudogene)","metadata":{"aliases":["OR5G6P","OR5G3P"]}},{"id":"bebfeee9436c445b82fdafeaab394718","type":"GENE","name":"OR5G4P","canonical_id":"hgnc:HGNC:15288","description":"olfactory receptor family 5 subfamily G member 4 pseudogene","metadata":null},{"id":"00f793f42b5f4dcda515a20d529a775d","type":"GENE","name":"OR5G5P","canonical_id":"hgnc:HGNC:15289","description":"olfactory receptor family 5 subfamily G member 5 pseudogene","metadata":null},{"id":"b864321a24464aba8f49805c3c818727","type":"GENE","name":"OR5H1","canonical_id":"hgnc:HGNC:8346","description":"olfactory receptor family 5 subfamily H member 1","metadata":{"aliases":["HTPCRX14","HSHTPCRX14"]}},{"id":"d889369cecf3429fa321a4b4dc1d76f0","type":"GENE","name":"OR5H14","canonical_id":"hgnc:HGNC:31286","description":"olfactory receptor family 5 subfamily H member 14","metadata":null},{"id":"02cbfdb6f8014c8a95a2ceeceb3ffdff","type":"GENE","name":"OR5H15","canonical_id":"hgnc:HGNC:31287","description":"olfactory receptor family 5 subfamily H member 15","metadata":null},{"id":"6d8c70f7001d48bc8a00340acc58333f","type":"GENE","name":"OR5H2","canonical_id":"hgnc:HGNC:14752","description":"olfactory receptor family 5 subfamily H member 2","metadata":null},{"id":"c7a07d3566f34d6d88b8d7370fdf48fc","type":"GENE","name":"OR5H3P","canonical_id":"hgnc:HGNC:14753","description":"olfactory receptor family 5 subfamily H member 3 pseudogene","metadata":null},{"id":"d610fd7dc751459bb8b50eac615772fa","type":"GENE","name":"OR5H4P","canonical_id":"hgnc:HGNC:14763","description":"olfactory receptor family 5 subfamily H member 4 pseudogene","metadata":null},{"id":"6cc6ef4668534f27b7f1f089ede5982f","type":"GENE","name":"OR5H5P","canonical_id":"hgnc:HGNC:14765","description":"olfactory receptor family 5 subfamily H member 5 pseudogene","metadata":null},{"id":"0dd3fd9c8e8a46f591cd796e7a7230d1","type":"GENE","name":"OR5H6","canonical_id":"hgnc:HGNC:14767","description":"olfactory receptor family 5 subfamily H member 6","metadata":null},{"id":"627f4639a71041e99092076358679ca4","type":"GENE","name":"OR5H7P","canonical_id":"hgnc:HGNC:14771","description":"olfactory receptor family 5 subfamily H member 7 pseudogene","metadata":null},{"id":"5edaec2d112f4357b8e60077994db400","type":"GENE","name":"OR5H8","canonical_id":"hgnc:HGNC:14773","description":"olfactory receptor family 5 subfamily H member 8 (gene/pseudogene)","metadata":{"aliases":["OR5H8P"]}},{"id":"012e8be843684c9e9ed1a2500eba5ac5","type":"GENE","name":"OR5I1","canonical_id":"hgnc:HGNC:8347","description":"olfactory receptor family 5 subfamily I member 1","metadata":{"aliases":["HSOlf1","OLF1"]}},{"id":"1664451b952b47e28a15d60ce0bb43ae","type":"GENE","name":"OR5J1P","canonical_id":"hgnc:HGNC:8348","description":"olfactory receptor family 5 subfamily J member 1 pseudogene","metadata":{"aliases":["HTPCRH02","OR5J1"]}},{"id":"fbfc945b3f7145f3bb51845da0f582ee","type":"GENE","name":"OR5J2","canonical_id":"hgnc:HGNC:19612","description":"olfactory receptor family 5 subfamily J member 2","metadata":null},{"id":"50c0b93cec7948a8bb8d77127db3ebe2","type":"GENE","name":"OR5J7P","canonical_id":"hgnc:HGNC:31289","description":"olfactory receptor family 5 subfamily J member 7 pseudogene","metadata":null},{"id":"670acb9dfceb498cac2340586a532cfd","type":"GENE","name":"OR5K1","canonical_id":"hgnc:HGNC:8349","description":"olfactory receptor family 5 subfamily K member 1","metadata":{"aliases":["HTPCRX10","HSHTPCRX10"]}},{"id":"2a45978c6e44449a971ef8c81ba90a7c","type":"GENE","name":"OR5K2","canonical_id":"hgnc:HGNC:14774","description":"olfactory receptor family 5 subfamily K member 2","metadata":null},{"id":"ea1a002b566e411c96a21108b3c1384c","type":"GENE","name":"OR5K3","canonical_id":"hgnc:HGNC:31290","description":"olfactory receptor family 5 subfamily K member 3","metadata":null},{"id":"0dd9b5109ead41ab9bfee8d91533daad","type":"GENE","name":"OR5K4","canonical_id":"hgnc:HGNC:31291","description":"olfactory receptor family 5 subfamily K member 4","metadata":null},{"id":"1f0712162a434e0888dc2d77d4e523fb","type":"GENE","name":"OR5L1","canonical_id":"hgnc:HGNC:8350","description":"olfactory receptor family 5 subfamily L member 1","metadata":{"aliases":["OST262"]}},{"id":"4b07a87b6b0e4f09b63899868d45a8f0","type":"GENE","name":"OR5L2","canonical_id":"hgnc:HGNC:8351","description":"olfactory receptor family 5 subfamily L member 2","metadata":{"aliases":["HTPCRX16","HSHTPCRX16"]}},{"id":"17be113fb0374ead821e84af0f4c8469","type":"GENE","name":"OR5M1","canonical_id":"hgnc:HGNC:8352","description":"olfactory receptor family 5 subfamily M member 1","metadata":{"aliases":["OST050"]}},{"id":"84dc2f45879642f1bf04791bff6203fb","type":"GENE","name":"OR5M10","canonical_id":"hgnc:HGNC:15290","description":"olfactory receptor family 5 subfamily M member 10","metadata":null},{"id":"7938dcca5d5042498003420d1011334a","type":"GENE","name":"OR5M11","canonical_id":"hgnc:HGNC:15291","description":"olfactory receptor family 5 subfamily M member 11","metadata":{"aliases":["OR11-199"]}},{"id":"f52e09ca1e6445bfb5678b5e0a21c217","type":"GENE","name":"OR5M12P","canonical_id":"hgnc:HGNC:15292","description":"olfactory receptor family 5 subfamily M member 12 pseudogene","metadata":null},{"id":"4ec84a80b0fa4f6a801f9bfb32bbe6d8","type":"GENE","name":"OR5M13P","canonical_id":"hgnc:HGNC:15293","description":"olfactory receptor family 5 subfamily M member 13 pseudogene","metadata":null},{"id":"38adf59874f24ac9b43d673504116119","type":"GENE","name":"OR5M14P","canonical_id":"hgnc:HGNC:15057","description":"olfactory receptor family 5 subfamily M member 14 pseudogene","metadata":{"aliases":["OR5M15P"]}},{"id":"3c968b5d45f84586a1d2baec8998f5f1","type":"GENE","name":"OR5M2P","canonical_id":"hgnc:HGNC:14803","description":"olfactory receptor family 5 subfamily M member 2 pseudogene","metadata":null},{"id":"1abc62e9999b4bcc8996989b569fa591","type":"GENE","name":"OR5M3","canonical_id":"hgnc:HGNC:14806","description":"olfactory receptor family 5 subfamily M member 3","metadata":null},{"id":"7efbcbcf0bbc48cfb0a82a4ad1728f6b","type":"GENE","name":"OR5M4P","canonical_id":"hgnc:HGNC:14808","description":"olfactory receptor family 5 subfamily M member 4 pseudogene","metadata":null},{"id":"f3eaf8749fe94facb8cce86645da2795","type":"GENE","name":"OR5M5P","canonical_id":"hgnc:HGNC:14810","description":"olfactory receptor family 5 subfamily M member 5 pseudogene","metadata":null},{"id":"22d86f773d0d4d50bbfd8ae9cf93c5b5","type":"GENE","name":"OR5M6P","canonical_id":"hgnc:HGNC:14814","description":"olfactory receptor family 5 subfamily M member 6 pseudogene","metadata":null},{"id":"807dace2738d43059faf323f9018fdf5","type":"GENE","name":"OR5M7P","canonical_id":"hgnc:HGNC:14818","description":"olfactory receptor family 5 subfamily M member 7 pseudogene","metadata":null},{"id":"135c6b52490446e8a4dc4bdcc64ed1fd","type":"GENE","name":"OR5M8","canonical_id":"hgnc:HGNC:14846","description":"olfactory receptor family 5 subfamily M member 8","metadata":null},{"id":"082fd8266b244bfdb09c40d6f8835edf","type":"GENE","name":"OR5M9","canonical_id":"hgnc:HGNC:15294","description":"olfactory receptor family 5 subfamily M member 9","metadata":null},{"id":"2948253b3af14ca98ef349910d4b266d","type":"GENE","name":"OR5P1P","canonical_id":"hgnc:HGNC:14779","description":"olfactory receptor family 5 subfamily P member 1 pseudogene","metadata":null},{"id":"086eab8f63fb47f2a7d525bbb4af5195","type":"GENE","name":"OR5P2","canonical_id":"hgnc:HGNC:14783","description":"olfactory receptor family 5 subfamily P member 2","metadata":{"aliases":["JCG3"]}},{"id":"31038db9541b400d838421ed0b1f59d2","type":"GENE","name":"OR5P3","canonical_id":"hgnc:HGNC:14784","description":"olfactory receptor family 5 subfamily P member 3","metadata":{"aliases":["JCG1"]}},{"id":"68160fa9765345979c1006b7bc027bab","type":"GENE","name":"OR5P4P","canonical_id":"hgnc:HGNC:15295","description":"olfactory receptor family 5 subfamily P member 4 pseudogene","metadata":{"aliases":["OST730"]}},{"id":"be49a13b668d4ebea56febe428517fbf","type":"GENE","name":"OR5S1P","canonical_id":"hgnc:HGNC:15040","description":"olfactory receptor family 5 subfamily S member 1 pseudogene","metadata":null},{"id":"ce65101a2f6e4b878e67647c2829587b","type":"GENE","name":"OR5T1","canonical_id":"hgnc:HGNC:14821","description":"olfactory receptor family 5 subfamily T member 1","metadata":{"aliases":["OR5T1P"]}},{"id":"c7004f7f957c4490b99610cbe743690e","type":"GENE","name":"OR5T2","canonical_id":"hgnc:HGNC:15296","description":"olfactory receptor family 5 subfamily T member 2","metadata":null},{"id":"b1930b88f7ed45cdbb353d7f9d4d0d4e","type":"GENE","name":"OR5T3","canonical_id":"hgnc:HGNC:15297","description":"olfactory receptor family 5 subfamily T member 3","metadata":{"aliases":["OR5T3Q"]}},{"id":"93e029f8d19042dba90be496767eccf9","type":"GENE","name":"OR5V1","canonical_id":"hgnc:HGNC:13972","description":"olfactory receptor family 5 subfamily V member 1","metadata":{"aliases":["hs6M1-21"]}},{"id":"dbfe48d9fc014854870b9f7f84a836d5","type":"GENE","name":"OR5W1P","canonical_id":"hgnc:HGNC:15298","description":"olfactory receptor family 5 subfamily W member 1 pseudogene","metadata":null},{"id":"333cde89345c418f86d44e34df856c8d","type":"GENE","name":"OR5W2","canonical_id":"hgnc:HGNC:15299","description":"olfactory receptor family 5 subfamily W member 2","metadata":{"aliases":["OR5W2P","OR5W3P"]}},{"id":"3fb086aec5ed4d139c2b5af6cde5239c","type":"GENE","name":"OR6A2","canonical_id":"hgnc:HGNC:15301","description":"olfactory receptor family 6 subfamily A member 2","metadata":{"aliases":["OR11-55","OR6A2P","OR6A1"]}},{"id":"a91d0c405f2146078573cdcc5449559a","type":"GENE","name":"OR6B1","canonical_id":"hgnc:HGNC:8354","description":"olfactory receptor family 6 subfamily B member 1","metadata":{"aliases":["OR7-3"]}},{"id":"2cbc2b620b8c4abf8712188161dcd36d","type":"GENE","name":"OR6B2","canonical_id":"hgnc:HGNC:15041","description":"olfactory receptor family 6 subfamily B member 2","metadata":{"aliases":["OR6B2P"]}},{"id":"a9f3b21ede344deb84841a6c66f7ce3e","type":"GENE","name":"OR6B3","canonical_id":"hgnc:HGNC:15042","description":"olfactory receptor family 6 subfamily B member 3","metadata":{"aliases":["OR6B3Q","OR6B3P"]}},{"id":"93ac7ff0ba9445678c9f93e6ca18c4a2","type":"GENE","name":"OR6C1","canonical_id":"hgnc:HGNC:8355","description":"olfactory receptor family 6 subfamily C member 1","metadata":{"aliases":["OST267"]}},{"id":"af69f7a5ad014c6ab2edfbbc0d66c237","type":"GENE","name":"OR6C2","canonical_id":"hgnc:HGNC:15436","description":"olfactory receptor family 6 subfamily C member 2","metadata":{"aliases":["OR6C67"]}},{"id":"bc04f1c5ec11420ba487887fc0c053f4","type":"GENE","name":"OR6C3","canonical_id":"hgnc:HGNC:15437","description":"olfactory receptor family 6 subfamily C member 3","metadata":{"aliases":["OST709"]}},{"id":"829043e92c7441d19df6c71b3df23940","type":"GENE","name":"OR6C4","canonical_id":"hgnc:HGNC:19632","description":"olfactory receptor family 6 subfamily C member 4","metadata":null},{"id":"32f96638c8da445fbe2b55089bebcb1b","type":"GENE","name":"OR6C5P","canonical_id":"hgnc:HGNC:31292","description":"olfactory receptor family 6 subfamily C member 5 pseudogene","metadata":null},{"id":"a70bc3b3c2014a7b9ce48137b42684be","type":"GENE","name":"OR6C6","canonical_id":"hgnc:HGNC:31293","description":"olfactory receptor family 6 subfamily C member 6","metadata":null},{"id":"e5dacf6d66e54f72aa23e51325bd4c5f","type":"GENE","name":"OR6C64P","canonical_id":"hgnc:HGNC:31294","description":"olfactory receptor family 6 subfamily C member 64 pseudogene","metadata":null},{"id":"2f9b0cd1285d4282a335ccefde8d663a","type":"GENE","name":"OR6C65","canonical_id":"hgnc:HGNC:31295","description":"olfactory receptor family 6 subfamily C member 65","metadata":null},{"id":"2acc0d787d3e4b6b8d04561bb65d7f0c","type":"GENE","name":"OR6C66P","canonical_id":"hgnc:HGNC:31296","description":"olfactory receptor family 6 subfamily C member 66 pseudogene","metadata":null},{"id":"3fbdcd4077344d2394e99cca012f394d","type":"GENE","name":"OR6C68","canonical_id":"hgnc:HGNC:31297","description":"olfactory receptor family 6 subfamily C member 68","metadata":null},{"id":"d754b8d72a534831837e09caf06ce3c0","type":"GENE","name":"OR6C69P","canonical_id":"hgnc:HGNC:31298","description":"olfactory receptor family 6 subfamily C member 69 pseudogene","metadata":null},{"id":"973d950d9d334c0f8a7cda9bcd848301","type":"GENE","name":"OR6C70","canonical_id":"hgnc:HGNC:31299","description":"olfactory receptor family 6 subfamily C member 70","metadata":null},{"id":"28ecbc28661c4ed99194ba2f65f83d82","type":"GENE","name":"OR6C71P","canonical_id":"hgnc:HGNC:31300","description":"olfactory receptor family 6 subfamily C member 71 pseudogene","metadata":null},{"id":"d7b2b9095a15459b8a6cbba794049b34","type":"GENE","name":"OR6C72P","canonical_id":"hgnc:HGNC:31301","description":"olfactory receptor family 6 subfamily C member 72 pseudogene","metadata":null},{"id":"4d1a925431654e699e7f3740a9cb4571","type":"GENE","name":"OR6C73P","canonical_id":"hgnc:HGNC:31302","description":"olfactory receptor family 6 subfamily C member 73 pseudogene","metadata":null},{"id":"f682622f510c4d3b9f048cfa4741a32f","type":"GENE","name":"OR6C74","canonical_id":"hgnc:HGNC:31303","description":"olfactory receptor family 6 subfamily C member 74","metadata":null},{"id":"e9f10d5a4fc044a18d70c33475b0a64a","type":"GENE","name":"OR6C75","canonical_id":"hgnc:HGNC:31304","description":"olfactory receptor family 6 subfamily C member 75","metadata":null},{"id":"48d7d767a5f34c0d98c9b9d2f5ba5142","type":"GENE","name":"OR6C76","canonical_id":"hgnc:HGNC:31305","description":"olfactory receptor family 6 subfamily C member 76","metadata":null},{"id":"26d5baf9c964411694667684f8579b2d","type":"GENE","name":"OR6C7P","canonical_id":"hgnc:HGNC:31306","description":"olfactory receptor family 6 subfamily C member 7 pseudogene","metadata":null},{"id":"baf3f48328854b5db511a1bdc3796c28","type":"GENE","name":"OR6D1P","canonical_id":"hgnc:HGNC:14849","description":"olfactory receptor family 6 subfamily D member 1 pseudogene","metadata":null},{"id":"28a806a0fe684d2b99951804a209a48a","type":"GENE","name":"OR6E1P","canonical_id":"hgnc:HGNC:14739","description":"olfactory receptor family 6 subfamily E member 1 pseudogene","metadata":null},{"id":"fc5c2789ffb6433696d2b241ba1fef01","type":"GENE","name":"OR6F1","canonical_id":"hgnc:HGNC:15027","description":"olfactory receptor family 6 subfamily F member 1","metadata":{"aliases":["OST731"]}},{"id":"09b2971d05394b55876ab6d05b28272d","type":"GENE","name":"OR6J1","canonical_id":"hgnc:HGNC:14707","description":"olfactory receptor family 6 subfamily J member 1","metadata":{"aliases":["OR6J2","OR6J1P"]}},{"id":"9ad1b54a05d04431a715ecffd6a57694","type":"GENE","name":"OR6K1P","canonical_id":"hgnc:HGNC:15028","description":"olfactory receptor family 6 subfamily K member 1 pseudogene","metadata":null},{"id":"6a6d05bef46b4e8c90b34e226dee0d97","type":"GENE","name":"OR6K2","canonical_id":"hgnc:HGNC:15029","description":"olfactory receptor family 6 subfamily K member 2","metadata":null},{"id":"7edfd952baea4b0aad9ae1b1a761d960","type":"GENE","name":"OR6K3","canonical_id":"hgnc:HGNC:15030","description":"olfactory receptor family 6 subfamily K member 3","metadata":null},{"id":"e0bbe601c86c4443867f21bb7600fc93","type":"GENE","name":"OR6K4P","canonical_id":"hgnc:HGNC:15031","description":"olfactory receptor family 6 subfamily K member 4 pseudogene","metadata":null},{"id":"6fdb500cec9548d5b3569419f20b818e","type":"GENE","name":"OR6K5P","canonical_id":"hgnc:HGNC:15032","description":"olfactory receptor family 6 subfamily K member 5 pseudogene","metadata":null},{"id":"271c44d13223479199394f314b94b98d","type":"GENE","name":"OR6K6","canonical_id":"hgnc:HGNC:15033","description":"olfactory receptor family 6 subfamily K member 6","metadata":null},{"id":"7f8d125e3af546bcb3ae5a9ce4cfbc49","type":"GENE","name":"OR6L1P","canonical_id":"hgnc:HGNC:15124","description":"olfactory receptor family 6 subfamily L member 1 pseudogene","metadata":null},{"id":"59d299dbf32540bc8afb7358e331d94e","type":"GENE","name":"OR6L2P","canonical_id":"hgnc:HGNC:15125","description":"olfactory receptor family 6 subfamily L member 2 pseudogene","metadata":null},{"id":"a97d22bb25364ebe90e240c3477f13fd","type":"GENE","name":"OR6M1","canonical_id":"hgnc:HGNC:14711","description":"olfactory receptor family 6 subfamily M member 1","metadata":null},{"id":"ff19b4d9e41843fb98567b041beadb95","type":"GENE","name":"OR6M2P","canonical_id":"hgnc:HGNC:14713","description":"olfactory receptor family 6 subfamily M member 2 pseudogene","metadata":null},{"id":"8f57064c947b41b18e2b84a837349bb6","type":"GENE","name":"OR6M3P","canonical_id":"hgnc:HGNC:14741","description":"olfactory receptor family 6 subfamily M member 3 pseudogene","metadata":null},{"id":"e0d7e9f66b5d4d38878f226f3353d265","type":"GENE","name":"OR6N1","canonical_id":"hgnc:HGNC:15034","description":"olfactory receptor family 6 subfamily N member 1","metadata":null},{"id":"de1c8c701b5e446cbafce42746d62ef6","type":"GENE","name":"OR6N2","canonical_id":"hgnc:HGNC:15035","description":"olfactory receptor family 6 subfamily N member 2","metadata":null},{"id":"51e7f2ec06534bb8870750b8402a3acf","type":"GENE","name":"OR6P1","canonical_id":"hgnc:HGNC:15036","description":"olfactory receptor family 6 subfamily P member 1","metadata":null},{"id":"fe15ebda6c3c4c4eb5e99e8e2bb5757c","type":"GENE","name":"OR6Q1","canonical_id":"hgnc:HGNC:15302","description":"olfactory receptor family 6 subfamily Q member 1","metadata":null},{"id":"17f56994da9b489c9d7ab214e4d473ab","type":"GENE","name":"OR6R1P","canonical_id":"hgnc:HGNC:15037","description":"olfactory receptor family 6 subfamily R member 1 pseudogene","metadata":null},{"id":"cc2e960bab0d4a96be93da846ea82c00","type":"GENE","name":"OR6R2P","canonical_id":"hgnc:HGNC:31307","description":"olfactory receptor family 6 subfamily R member 2 pseudogene","metadata":null},{"id":"8c1b65b85b174321a67fa24ef64e8800","type":"GENE","name":"OR6S1","canonical_id":"hgnc:HGNC:15363","description":"olfactory receptor family 6 subfamily S member 1","metadata":{"aliases":["OR6S1Q"]}},{"id":"4add0e941e1046379e3da56c8049889b","type":"GENE","name":"OR6T1","canonical_id":"hgnc:HGNC:14848","description":"olfactory receptor family 6 subfamily T member 1","metadata":null},{"id":"76bdc9a6e7dd44aa9453583c2a8c1d08","type":"GENE","name":"OR6U2P","canonical_id":"hgnc:HGNC:19631","description":"olfactory receptor family 6 subfamily U member 2 pseudogene","metadata":{"aliases":["OR6U1P"]}},{"id":"208b49dfa79243ed870434f29f331abf","type":"GENE","name":"OR6V1","canonical_id":"hgnc:HGNC:15090","description":"olfactory receptor family 6 subfamily V member 1","metadata":{"aliases":["GPR138"]}},{"id":"8d1b94cca8534fbc8f06a8e932b243b6","type":"GENE","name":"OR6W1P","canonical_id":"hgnc:HGNC:15091","description":"olfactory receptor family 6 subfamily W member 1 pseudogene","metadata":{"aliases":["sdolf","OR6W1"]}},{"id":"bf05e049a92b4556ae3b9fe5fc791f28","type":"GENE","name":"OR6X1","canonical_id":"hgnc:HGNC:14737","description":"olfactory receptor family 6 subfamily X member 1","metadata":null},{"id":"9fc74b6d11484382b754827f0672bd32","type":"GENE","name":"OR6Y1","canonical_id":"hgnc:HGNC:14823","description":"olfactory receptor family 6 subfamily Y member 1","metadata":{"aliases":["OR6Y2"]}},{"id":"1e3c1cfbcec44191959e3536fa77c3fa","type":"GENE","name":"OR7A10","canonical_id":"hgnc:HGNC:8356","description":"olfactory receptor family 7 subfamily A member 10","metadata":null},{"id":"4c356f1c0aaa40c798fcee109418fce9","type":"GENE","name":"OR7A11P","canonical_id":"hgnc:HGNC:8357","description":"olfactory receptor family 7 subfamily A member 11 pseudogene","metadata":{"aliases":["OST527","OR7A11"]}},{"id":"64745ab0045247dfa4550b88433753ef","type":"GENE","name":"OR7A15P","canonical_id":"hgnc:HGNC:8361","description":"olfactory receptor family 7 subfamily A member 15 pseudogene","metadata":{"aliases":["OR19-134","OR19-1","OR19-146","OR7A4P","OR7A16P","OR7A20P"]}},{"id":"dc22a8a418a24559a6699a04359d0bd1","type":"GENE","name":"OR7A17","canonical_id":"hgnc:HGNC:8363","description":"olfactory receptor family 7 subfamily A member 17","metadata":{"aliases":["HTPCRX19"]}},{"id":"8153697592584de9b22c35704ac1d3ca","type":"GENE","name":"OR7A18P","canonical_id":"hgnc:HGNC:15399","description":"olfactory receptor family 7 subfamily A member 18 pseudogene","metadata":null},{"id":"411f99722dda46b1ad06439b0e5e2f04","type":"GENE","name":"OR7A19P","canonical_id":"hgnc:HGNC:15337","description":"olfactory receptor family 7 subfamily A member 19 pseudogene","metadata":null},{"id":"94c4ad8e9fa04d56a48ba65646ba592c","type":"GENE","name":"OR7A1P","canonical_id":"hgnc:HGNC:8364","description":"olfactory receptor family 7 subfamily A member 1 pseudogene","metadata":{"aliases":["OR19-3","OLF4p","hg513","OR7A6P"]}},{"id":"bea48d9d26844fe584e61f06354d512c","type":"GENE","name":"OR7A2P","canonical_id":"hgnc:HGNC:8370","description":"olfactory receptor family 7 subfamily A member 2 pseudogene","metadata":{"aliases":["hg1003","OR19-18","OLF4p","OR7A7","OR7A2"]}},{"id":"a99ea13952764d7f92ff3aec6dffdec6","type":"GENE","name":"OR7A3P","canonical_id":"hgnc:HGNC:8366","description":"olfactory receptor family 7 subfamily A member 3 pseudogene","metadata":{"aliases":["OR11-7b","OR19-12","OR14-59","OR14-11","OR7A12P","OR7A14P","OR7A14","OR7A13P"]}},{"id":"e8585c91b99141fa8755e74b36ea14c2","type":"GENE","name":"OR7A5","canonical_id":"hgnc:HGNC:8368","description":"olfactory receptor family 7 subfamily A member 5","metadata":{"aliases":["HTPCR2"]}},{"id":"cc0cb83213a746239bf1d4d5281666d1","type":"GENE","name":"OR7A8P","canonical_id":"hgnc:HGNC:8371","description":"olfactory receptor family 7 subfamily A member 8 pseudogene","metadata":{"aliases":["OST042","HG83","OR19-11","OR7A9P"]}},{"id":"5ba63a59f1e84666acf23aeeaf27e74a","type":"GENE","name":"OR7C1","canonical_id":"hgnc:HGNC:8373","description":"olfactory receptor family 7 subfamily C member 1","metadata":{"aliases":["OR19-5","OR7C4"]}},{"id":"a4da4eec315d430f964dcf036f053c6c","type":"GENE","name":"OR7C2","canonical_id":"hgnc:HGNC:8374","description":"olfactory receptor family 7 subfamily C member 2","metadata":{"aliases":["OR19-18","OR7C3"]}},{"id":"22d2c7261f714b63a5b1f47fd45012b0","type":"GENE","name":"OR7D11P","canonical_id":"hgnc:HGNC:31308","description":"olfactory receptor family 7 subfamily D member 11 pseudogene","metadata":null},{"id":"18ad657eb95740bea02d46d4eec4424c","type":"GENE","name":"OR7D1P","canonical_id":"hgnc:HGNC:8377","description":"olfactory receptor family 7 subfamily D member 1 pseudogene","metadata":{"aliases":["OR19-A","OR7D3P","OR7D3"]}},{"id":"e1b8756981a04181bda7fecae5ffdb05","type":"GENE","name":"OR7D2","canonical_id":"hgnc:HGNC:8378","description":"olfactory receptor family 7 subfamily D member 2","metadata":{"aliases":["OR19-4","HTPCRH03","FLJ38149"]}},{"id":"2594e409c4aa4c7f96e36c95092dc230","type":"GENE","name":"OR7D4","canonical_id":"hgnc:HGNC:8380","description":"olfactory receptor family 7 subfamily D member 4","metadata":{"aliases":["hg105","OR19-B","OR7D4P"]}},{"id":"6162b5f9b96b480eb62fbd456b6eabc9","type":"GENE","name":"OR7E100P","canonical_id":"hgnc:HGNC:15048","description":"olfactory receptor family 7 subfamily E member 100 pseudogene","metadata":null},{"id":"288b72ae94c2403fbf0313c4d08a42f0","type":"GENE","name":"OR7E101P","canonical_id":"hgnc:HGNC:15342","description":"olfactory receptor family 7 subfamily E member 101 pseudogene","metadata":null},{"id":"31086aa400584b338d514cf1a78ce239","type":"GENE","name":"OR7E102P","canonical_id":"hgnc:HGNC:15043","description":"olfactory receptor family 7 subfamily E member 102 pseudogene","metadata":{"aliases":["OR7E102"]}},{"id":"ab12ee991e00498a9c2ed209680b8200","type":"GENE","name":"OR7E103P","canonical_id":"hgnc:HGNC:19587","description":"olfactory receptor family 7 subfamily E member 103 pseudogene","metadata":{"aliases":["OR4D12P"]}},{"id":"8b1bf4c2adbf4254b714f52207ac5dbf","type":"GENE","name":"OR7E104P","canonical_id":"hgnc:HGNC:15343","description":"olfactory receptor family 7 subfamily E member 104 pseudogene","metadata":null},{"id":"7bc08ec4b029414ebcb74c9be7cb370b","type":"GENE","name":"OR7E105P","canonical_id":"hgnc:HGNC:15364","description":"olfactory receptor family 7 subfamily E member 105 pseudogene","metadata":null},{"id":"5e4d6a81225e4104b1da1396b4984ca4","type":"GENE","name":"OR7E106P","canonical_id":"hgnc:HGNC:15365","description":"olfactory receptor family 7 subfamily E member 106 pseudogene","metadata":{"aliases":["OST215","OR7E40P"]}},{"id":"49627fee4bb14447ad51a0fe28d34e2c","type":"GENE","name":"OR7E108P","canonical_id":"hgnc:HGNC:15117","description":"olfactory receptor family 7 subfamily E member 108 pseudogene","metadata":{"aliases":["OST726"]}},{"id":"0aa4b0cbfc314c478b7b6156feca0086","type":"GENE","name":"OR7E109P","canonical_id":"hgnc:HGNC:15118","description":"olfactory receptor family 7 subfamily E member 109 pseudogene","metadata":{"aliases":["OST721"]}},{"id":"45bd9e91e8904f678265513963285d08","type":"GENE","name":"OR7E10P","canonical_id":"hgnc:HGNC:8381","description":"olfactory receptor family 7 subfamily E member 10 pseudogene","metadata":{"aliases":["OR11-1"]}},{"id":"6f4fcfc012e64e30bf3dd51a67b9ae38","type":"GENE","name":"OR7E110P","canonical_id":"hgnc:HGNC:15126","description":"olfactory receptor family 7 subfamily E member 110 pseudogene","metadata":{"aliases":["hg674","OR912-109","OR912-46","OR912-108","OR912-110","hg523","OR7E68P","OR7E71P","OR7E72P","OR7E73P","OR7E74P","OR7E75P"]}},{"id":"5c4ca7c1e796425b9df52f9b7efe32c1","type":"GENE","name":"OR7E111FP","canonical_id":"hgnc:HGNC:55115","description":"olfactory receptor family 7 subfamily E member 111F pseudogene","metadata":null},{"id":"e7a2c590c2f843ef890a101e9d60175d","type":"GENE","name":"OR7E111P","canonical_id":"hgnc:HGNC:15344","description":"olfactory receptor family 7 subfamily E member 111 pseudogene","metadata":null},{"id":"ac442a56fc114a08b5b2ddda0f2f468a","type":"GENE","name":"OR7E115P","canonical_id":"hgnc:HGNC:15127","description":"olfactory receptor family 7 subfamily E member 115 pseudogene","metadata":{"aliases":["OST704"]}},{"id":"687568c23fdd49e7a1ec7f03bb22398a","type":"GENE","name":"OR7E116P","canonical_id":"hgnc:HGNC:15122","description":"olfactory receptor family 7 subfamily E member 116 pseudogene","metadata":{"aliases":["OST733"]}},{"id":"bc65afe7dec04eb6a0c74a7f1457bd67","type":"GENE","name":"OR7E117P","canonical_id":"hgnc:HGNC:15303","description":"olfactory receptor family 7 subfamily E member 117 pseudogene","metadata":{"aliases":["OST716"]}},{"id":"46ea861d05ef4db0b98e755f79329636","type":"GENE","name":"OR7E11P","canonical_id":"hgnc:HGNC:8382","description":"olfactory receptor family 7 subfamily E member 11 pseudogene","metadata":{"aliases":["OR11-2","OR7E144P"]}},{"id":"0a413d9c648342dc9714c2a8e59c6121","type":"GENE","name":"OR7E121P","canonical_id":"hgnc:HGNC:15049","description":"olfactory receptor family 7 subfamily E member 121 pseudogene","metadata":null},{"id":"5f1d1f051a9d4ec8ad112508fb6dfc61","type":"GENE","name":"OR7E122P","canonical_id":"hgnc:HGNC:15050","description":"olfactory receptor family 7 subfamily E member 122 pseudogene","metadata":{"aliases":["OST719"]}},{"id":"568548a2ea264a1f94d58f40c77ea67c","type":"GENE","name":"OR7E125P","canonical_id":"hgnc:HGNC:15098","description":"olfactory receptor family 7 subfamily E member 125 pseudogene","metadata":{"aliases":["PJCG6"]}},{"id":"2cff75aa4c0b44818dd9af257b1b2eb4","type":"GENE","name":"OR7E126P","canonical_id":"hgnc:HGNC:15304","description":"olfactory receptor family 7 subfamily E member 126 pseudogene","metadata":{"aliases":["hg500","OR11-1"]}},{"id":"d4f79b20a87143c48dfa47bd8073f0c8","type":"GENE","name":"OR7E128P","canonical_id":"hgnc:HGNC:15305","description":"olfactory receptor family 7 subfamily E member 128 pseudogene","metadata":null},{"id":"dfb2f2726fef42398261b692ba3c4167","type":"GENE","name":"OR7E129P","canonical_id":"hgnc:HGNC:15052","description":"olfactory receptor family 7 subfamily E member 129 pseudogene","metadata":null},{"id":"a16b6ebfbe434ce5ba183d9d5a9a6a3c","type":"GENE","name":"OR7E12P","canonical_id":"hgnc:HGNC:8383","description":"olfactory receptor family 7 subfamily E member 12 pseudogene","metadata":{"aliases":["OR11-3","OR7E58P","OR7E79P"]}},{"id":"9ca670fc0ff94e15a97fd30ab5a1d5e7","type":"GENE","name":"OR7E130P","canonical_id":"hgnc:HGNC:15053","description":"olfactory receptor family 7 subfamily E member 130 pseudogene","metadata":{"aliases":["OST702"]}},{"id":"f8eb27af39704398a5c943d2ed9cad34","type":"GENE","name":"OR7E136P","canonical_id":"hgnc:HGNC:19557","description":"olfactory receptor family 7 subfamily E member 136 pseudogene","metadata":{"aliases":["OR7E147P","OR7E139P"]}},{"id":"6f1f7156d49942eeb46e20f2a57ec8ec","type":"GENE","name":"OR7E13P","canonical_id":"hgnc:HGNC:8384","description":"olfactory receptor family 7 subfamily E member 13 pseudogene","metadata":{"aliases":["OR11-4"]}},{"id":"dc678cadbf414fafbccb9b7b3b119666","type":"GENE","name":"OR7E140P","canonical_id":"hgnc:HGNC:19561","description":"olfactory receptor family 7 subfamily E member 140 pseudogene","metadata":null},{"id":"6676e05eff49403081ebd4f8fd1a1e79","type":"GENE","name":"OR7E145P","canonical_id":"hgnc:HGNC:19618","description":"olfactory receptor family 7 subfamily E member 145 pseudogene","metadata":null},{"id":"b1b775681f334f82a794433f230455ca","type":"GENE","name":"OR7E148P","canonical_id":"hgnc:HGNC:19642","description":"olfactory receptor family 7 subfamily E member 148 pseudogene","metadata":{"aliases":["OR7E150P"]}},{"id":"36858eec8e3446ba83a57a13de66f66a","type":"GENE","name":"OR7E149P","canonical_id":"hgnc:HGNC:19589","description":"olfactory receptor family 7 subfamily E member 149 pseudogene","metadata":null},{"id":"061d051a518b445b90e61a08ac459f31","type":"GENE","name":"OR7E14P","canonical_id":"hgnc:HGNC:8385","description":"olfactory receptor family 7 subfamily E member 14 pseudogene","metadata":{"aliases":["OR11-5","OR7E151P"]}},{"id":"411ee9ab3fa6464e836ea2acb2771148","type":"GENE","name":"OR7E154P","canonical_id":"hgnc:HGNC:31309","description":"olfactory receptor family 7 subfamily E member 154 pseudogene","metadata":null},{"id":"8afc73e2db36427d853657959e242b4d","type":"GENE","name":"OR7E155P","canonical_id":"hgnc:HGNC:31310","description":"olfactory receptor family 7 subfamily E member 155 pseudogene","metadata":null},{"id":"02093f325ff648b2a0453bc7ecc6d1b2","type":"GENE","name":"OR7E156P","canonical_id":"hgnc:HGNC:31311","description":"olfactory receptor family 7 subfamily E member 156 pseudogene","metadata":null},{"id":"b52212eb97894915a286f2740709e4aa","type":"GENE","name":"OR7E157P","canonical_id":"hgnc:HGNC:31231","description":"olfactory receptor family 7 subfamily E member 157 pseudogene","metadata":null},{"id":"1923466cc4654c3e8727ec4410ac22d5","type":"GENE","name":"OR7E158P","canonical_id":"hgnc:HGNC:31232","description":"olfactory receptor family 7 subfamily E member 158 pseudogene","metadata":null},{"id":"9d40cb874ae34d7397418ad74f5dd038","type":"GENE","name":"OR7E159P","canonical_id":"hgnc:HGNC:31312","description":"olfactory receptor family 7 subfamily E member 159 pseudogene","metadata":null},{"id":"18f12c9f803d4823bf1d3f28e0d93b73","type":"GENE","name":"OR7E15P","canonical_id":"hgnc:HGNC:8386","description":"olfactory receptor family 7 subfamily E member 15 pseudogene","metadata":{"aliases":["OR11-392","OST001","OR7E80P","OR7E42P"]}},{"id":"b8ff4dcdd9a34520b228d69f8e018fd0","type":"GENE","name":"OR7E160P","canonical_id":"hgnc:HGNC:31233","description":"olfactory receptor family 7 subfamily E member 160 pseudogene","metadata":null},{"id":"abbff05aa59b45019d6bc280fb1ae9ea","type":"GENE","name":"OR7E161P","canonical_id":"hgnc:HGNC:31234","description":"olfactory receptor family 7 subfamily E member 161 pseudogene","metadata":null},{"id":"9e5e4d60c98f4993a1bc8194b833b76a","type":"GENE","name":"OR7E162P","canonical_id":"hgnc:HGNC:28374","description":"olfactory receptor family 7 subfamily E member 162 pseudogene","metadata":null},{"id":"e38a2578720943bdaf0e5a9f66207296","type":"GENE","name":"OR7E163P","canonical_id":"hgnc:HGNC:45040","description":"olfactory receptor family 7 subfamily E member 163 pseudogene","metadata":null},{"id":"b729972486354042930a795a8f71ba6b","type":"GENE","name":"OR7E16P","canonical_id":"hgnc:HGNC:8387","description":"olfactory receptor family 7 subfamily E member 16 pseudogene","metadata":{"aliases":["OR19-133","OR19-9","OR7E60P","OR7E17P"]}},{"id":"4b39367070f24e7584b264768b938807","type":"GENE","name":"OR7E18P","canonical_id":"hgnc:HGNC:8389","description":"olfactory receptor family 7 subfamily E member 18 pseudogene","metadata":{"aliases":["OR19-14","TPCR26","OR7E61","OR7E98P"]}},{"id":"179f6f45eb7c4de494cabe67ef16826f","type":"GENE","name":"OR7E19P","canonical_id":"hgnc:HGNC:8390","description":"olfactory receptor family 7 subfamily E member 19 pseudogene","metadata":{"aliases":["OR19-7","OR7E65"]}},{"id":"6b1c5859d7c943058b600e9198ce7373","type":"GENE","name":"OR7E1P","canonical_id":"hgnc:HGNC:8391","description":"olfactory receptor family 7 subfamily E member 1 pseudogene","metadata":null},{"id":"b471d246c87a4cd9895c17a677246888","type":"GENE","name":"OR7E21P","canonical_id":"hgnc:HGNC:8393","description":"olfactory receptor family 7 subfamily E member 21 pseudogene","metadata":{"aliases":["OR4DG","OST035","OR7E49P","OR7E127P"]}},{"id":"4afa41f51fec408d9fbd08bf40566e37","type":"GENE","name":"OR7E22P","canonical_id":"hgnc:HGNC:8394","description":"olfactory receptor family 7 subfamily E member 22 pseudogene","metadata":{"aliases":["OR6DG","OR3.6"]}},{"id":"5b928a8c1d054bd59c622cb13822cf43","type":"GENE","name":"OR7E23P","canonical_id":"hgnc:HGNC:8395","description":"olfactory receptor family 7 subfamily E member 23 pseudogene","metadata":{"aliases":["OR21-3","OR7E92P"]}},{"id":"4bcc721913864c71a483f21f95e9757a","type":"GENE","name":"OR7E24","canonical_id":"hgnc:HGNC:8396","description":"olfactory receptor family 7 subfamily E member 24","metadata":{"aliases":["OR19-8","HSHT2","OR7E24Q","OR7E24P"]}},{"id":"8695db6c1f384d8da90afba1aa7f0965","type":"GENE","name":"OR7E25P","canonical_id":"hgnc:HGNC:8397","description":"olfactory receptor family 7 subfamily E member 25 pseudogene","metadata":{"aliases":["OR19-C","CIT-B-440L2"]}},{"id":"7839810366664936802caa6a94dc22fe","type":"GENE","name":"OR7E26P","canonical_id":"hgnc:HGNC:8398","description":"olfactory receptor family 7 subfamily E member 26 pseudogene","metadata":{"aliases":["OR1-51","OR1-72","OR1-73","OR912-95","OR7E67P","OR7E69P","OR7E70P","OR7E68P"]}},{"id":"003977c1b0d245d39c9e07cdeba45fd4","type":"GENE","name":"OR7E28P","canonical_id":"hgnc:HGNC:8400","description":"olfactory receptor family 7 subfamily E member 28 pseudogene","metadata":{"aliases":["OST128","hg616","OR7E133P","OR7E107P","OR7E27P"]}},{"id":"3c03bddbe9e44824b864282993d313af","type":"GENE","name":"OR7E29P","canonical_id":"hgnc:HGNC:8401","description":"olfactory receptor family 7 subfamily E member 29 pseudogene","metadata":{"aliases":["OST032"]}},{"id":"340d16092fe449ceaab8229dd4f3d202","type":"GENE","name":"OR7E2P","canonical_id":"hgnc:HGNC:8402","description":"olfactory receptor family 7 subfamily E member 2 pseudogene","metadata":{"aliases":["OR11-6","hg94","OR7F2P","OR7E51P"]}},{"id":"32fc47f024df42d79bf4ee4beda54a37","type":"GENE","name":"OR7E31P","canonical_id":"hgnc:HGNC:8404","description":"olfactory receptor family 7 subfamily E member 31 pseudogene","metadata":{"aliases":["OST205","OR7E32P"]}},{"id":"c2c5c4d61c354ba49825a02565b83ed0","type":"GENE","name":"OR7E33P","canonical_id":"hgnc:HGNC:8406","description":"olfactory receptor family 7 subfamily E member 33 pseudogene","metadata":{"aliases":["hg688"]}},{"id":"d8d5a7a669ad461bb35893a0c8692f24","type":"GENE","name":"OR7E35P","canonical_id":"hgnc:HGNC:8408","description":"olfactory receptor family 7 subfamily E member 35 pseudogene","metadata":{"aliases":["OST018","OR7E120"]}},{"id":"f30a859643244a728cc6fa298d0e50c0","type":"GENE","name":"OR7E36P","canonical_id":"hgnc:HGNC:8409","description":"olfactory receptor family 7 subfamily E member 36 pseudogene","metadata":{"aliases":["OST024","OR7E119P"]}},{"id":"1f36e140d0944e0a921a05e3d217f9ba","type":"GENE","name":"OR7E37P","canonical_id":"hgnc:HGNC:8410","description":"olfactory receptor family 7 subfamily E member 37 pseudogene","metadata":{"aliases":["hg533"]}},{"id":"ab1b3fadbdcb449b8e656a694fa04ec1","type":"GENE","name":"OR7E38P","canonical_id":"hgnc:HGNC:8411","description":"olfactory receptor family 7 subfamily E member 38 pseudogene","metadata":{"aliases":["OST127","OR7E76"]}},{"id":"b776054130c14f8697d0ec6e1ee9a22b","type":"GENE","name":"OR7E39P","canonical_id":"hgnc:HGNC:8412","description":"olfactory receptor family 7 subfamily E member 39 pseudogene","metadata":{"aliases":["hg611","OR7E138P"]}},{"id":"19fda483be1f456e89b023b47bf52f66","type":"GENE","name":"OR7E41P","canonical_id":"hgnc:HGNC:8415","description":"olfactory receptor family 7 subfamily E member 41 pseudogene","metadata":{"aliases":["OR11-20","hg84","OR8-126","OR7F6P","OR7E50P","OR7E95P"]}},{"id":"176e9e3500814fbbb9638f03a95a4557","type":"GENE","name":"OR7E43P","canonical_id":"hgnc:HGNC:8417","description":"olfactory receptor family 7 subfamily E member 43 pseudogene","metadata":{"aliases":["OR4-116"]}},{"id":"bc6730f413434ab4866aa3c444f3bc79","type":"GENE","name":"OR7E46P","canonical_id":"hgnc:HGNC:8420","description":"olfactory receptor family 7 subfamily E member 46 pseudogene","metadata":{"aliases":["OST379","MCEEP"]}},{"id":"ac44fce7a8544fb2a23fb90e037f0e4c","type":"GENE","name":"OR7E47P","canonical_id":"hgnc:HGNC:8421","description":"olfactory receptor family 7 subfamily E member 47 pseudogene","metadata":{"aliases":["OR7E141"]}},{"id":"da71ace24cbf4f689b4bb731787f3ebd","type":"GENE","name":"OR7E4P","canonical_id":"hgnc:HGNC:8424","description":"olfactory receptor family 7 subfamily E member 4 pseudogene","metadata":{"aliases":["OR11-11a","OR7F4P"]}},{"id":"c0776187b9ee440cb84a298353a7af21","type":"GENE","name":"OR7E53P","canonical_id":"hgnc:HGNC:8428","description":"olfactory receptor family 7 subfamily E member 53 pseudogene","metadata":{"aliases":["OR3-143","OR3-142","OR7E78P","OR7E78","OR7E132P"]}},{"id":"2bc314a049b24cf4a4ea319392ee9ba6","type":"GENE","name":"OR7E55P","canonical_id":"hgnc:HGNC:8430","description":"olfactory receptor family 7 subfamily E member 55 pseudogene","metadata":{"aliases":["OR2DG","OR3.2","OST013","OR7E56P"]}},{"id":"a014e1eb32334f84ab8140a07777516f","type":"GENE","name":"OR7E59P","canonical_id":"hgnc:HGNC:8434","description":"olfactory receptor family 7 subfamily E member 59 pseudogene","metadata":{"aliases":["OST119","OR7E59","OR7E137P"]}},{"id":"44fe685c9f764417b63a9c4ca6dbdd7c","type":"GENE","name":"OR7E5P","canonical_id":"hgnc:HGNC:8435","description":"olfactory receptor family 7 subfamily E member 5 pseudogene","metadata":{"aliases":["OR11-12","FLJ31393","OR7F5P"]}},{"id":"0f9cc0a875004503999bb162ebda75de","type":"GENE","name":"OR7E62P","canonical_id":"hgnc:HGNC:8438","description":"olfactory receptor family 7 subfamily E member 62 pseudogene","metadata":{"aliases":["OR7E62","OR2-53","OR7E63","OR7E64","OR7E63P","OR7E64P","OR7E82P"]}},{"id":"124bd59705e84c0990d02a0c2b04d2af","type":"GENE","name":"OR7E66P","canonical_id":"hgnc:HGNC:8442","description":"olfactory receptor family 7 subfamily E member 66 pseudogene","metadata":{"aliases":["hg630","HG630","OR3DG","OR3.3","OR7E6P","OR7E20P"]}},{"id":"ec610db7cad94e85b3f6a2a537fbd102","type":"GENE","name":"OR7E7P","canonical_id":"hgnc:HGNC:8457","description":"olfactory receptor family 7 subfamily E member 7 pseudogene","metadata":null},{"id":"303b2b79d9434ae09322f7629bad053c","type":"GENE","name":"OR7E83P","canonical_id":"hgnc:HGNC:14688","description":"olfactory receptor family 7 subfamily E member 83 pseudogene","metadata":{"aliases":["OR7E134P"]}},{"id":"441b5e79c2054005ad1df66a537e14f9","type":"GENE","name":"OR7E84P","canonical_id":"hgnc:HGNC:14690","description":"olfactory receptor family 7 subfamily E member 84 pseudogene","metadata":{"aliases":["OST185","OR7E54P"]}},{"id":"d7568df9db54460abe1a830c2e7a10f2","type":"GENE","name":"OR7E85BP","canonical_id":"hgnc:HGNC:55114","description":"olfactory receptor family 7 subfamily E member 85B pseudogene","metadata":null},{"id":"c8dfe315ee7440b0a9652fed37d3453d","type":"GENE","name":"OR7E85P","canonical_id":"hgnc:HGNC:14692","description":"olfactory receptor family 7 subfamily E member 85 pseudogene","metadata":{"aliases":["OR7E88P"]}},{"id":"5f243d138beb4462be044841c679a67c","type":"GENE","name":"OR7E86P","canonical_id":"hgnc:HGNC:14694","description":"olfactory receptor family 7 subfamily E member 86 pseudogene","metadata":null},{"id":"dedb53e1ae8040108371cc2e6139aaff","type":"GENE","name":"OR7E87P","canonical_id":"hgnc:HGNC:14709","description":"olfactory receptor family 7 subfamily E member 87 pseudogene","metadata":{"aliases":["OR11-9","OR7E3P","OR7F3P"]}},{"id":"75899443d96343078bf98bc1063d7aa6","type":"GENE","name":"OR7E89P","canonical_id":"hgnc:HGNC:14730","description":"olfactory receptor family 7 subfamily E member 89 pseudogene","metadata":null},{"id":"14bb5f55a7e14c219a1458c568baf3ba","type":"GENE","name":"OR7E8P","canonical_id":"hgnc:HGNC:8458","description":"olfactory receptor family 7 subfamily E member 8 pseudogene","metadata":{"aliases":["OR11-11a"]}},{"id":"c5af4fa751a04d919cbd579796a494c0","type":"GENE","name":"OR7E90P","canonical_id":"hgnc:HGNC:14733","description":"olfactory receptor family 7 subfamily E member 90 pseudogene","metadata":{"aliases":["OST705","OR7E123P"]}},{"id":"d2ebc9fd016843f3be18f6d3abfe9441","type":"GENE","name":"OR7E91P","canonical_id":"hgnc:HGNC:14747","description":"olfactory receptor family 7 subfamily E member 91 pseudogene","metadata":null},{"id":"e0e6ddc6b6b14917ab044935ed2ca63d","type":"GENE","name":"OR7E93P","canonical_id":"hgnc:HGNC:14780","description":"olfactory receptor family 7 subfamily E member 93 pseudogene","metadata":{"aliases":["OR7E131P"]}},{"id":"d7c06954b4bd44219f5d2cd772dc29f4","type":"GENE","name":"OR7E94P","canonical_id":"hgnc:HGNC:14789","description":"olfactory receptor family 7 subfamily E member 94 pseudogene","metadata":null},{"id":"53388fc0bf524d4c9e1421170a572845","type":"GENE","name":"OR7E96P","canonical_id":"hgnc:HGNC:14815","description":"olfactory receptor family 7 subfamily E member 96 pseudogene","metadata":null},{"id":"87cd9a9a8695443c9397ff1fa80d515b","type":"GENE","name":"OR7E97P","canonical_id":"hgnc:HGNC:14834","description":"olfactory receptor family 7 subfamily E member 97 pseudogene","metadata":null},{"id":"c38ac53466af4005a9c50d2b8471846f","type":"GENE","name":"OR7E99P","canonical_id":"hgnc:HGNC:15059","description":"olfactory receptor family 7 subfamily E member 99 pseudogene","metadata":null},{"id":"9021d930a6e64f18bd2e709c3356fbfa","type":"GENE","name":"OR7G1","canonical_id":"hgnc:HGNC:8465","description":"olfactory receptor family 7 subfamily G member 1","metadata":{"aliases":["OR19-15","OR7G1P"]}},{"id":"c52656e17bcc41ff8a764e0c29b1579a","type":"GENE","name":"OR7G15P","canonical_id":"hgnc:HGNC:31313","description":"olfactory receptor family 7 subfamily G member 15 pseudogene","metadata":null},{"id":"f2c9cae97a6b4185bb7f80832edb54cf","type":"GENE","name":"OR7G2","canonical_id":"hgnc:HGNC:8466","description":"olfactory receptor family 7 subfamily G member 2","metadata":{"aliases":["OST260"]}},{"id":"54d7b6a9b7fd48af8383b9d7f40bbca8","type":"GENE","name":"OR7G3","canonical_id":"hgnc:HGNC:8467","description":"olfactory receptor family 7 subfamily G member 3","metadata":{"aliases":["OST085"]}},{"id":"3d0c246c8de44742bd60cc43980168e4","type":"GENE","name":"OR7H1P","canonical_id":"hgnc:HGNC:8468","description":"olfactory receptor family 7 subfamily H member 1 pseudogene","metadata":{"aliases":["OR7H1"]}},{"id":"5030885ca499473d94c36d54972f80f9","type":"GENE","name":"OR7H2P","canonical_id":"hgnc:HGNC:31314","description":"olfactory receptor family 7 subfamily H member 2 pseudogene","metadata":null},{"id":"37f0ac15922e4fc8a534f5cd3d1acf42","type":"GENE","name":"OR7K1P","canonical_id":"hgnc:HGNC:15366","description":"olfactory receptor family 7 subfamily K member 1 pseudogene","metadata":null},{"id":"c02eed56dfe44c2c96b56cb5f5f587ca","type":"GENE","name":"OR7L1P","canonical_id":"hgnc:HGNC:14827","description":"olfactory receptor family 7 subfamily L member 1 pseudogene","metadata":null},{"id":"9b29a9ce4fe748f2ab8c10445e7fb99d","type":"GENE","name":"OR7M1P","canonical_id":"hgnc:HGNC:15128","description":"olfactory receptor family 7 subfamily M member 1 pseudogene","metadata":null},{"id":"a46c3a15ce814ccab035c2f638035acf","type":"GENE","name":"OR8A1","canonical_id":"hgnc:HGNC:8469","description":"olfactory receptor family 8 subfamily A member 1","metadata":{"aliases":["OST025"]}},{"id":"865e2953dde44a369ceb9322b0dd35ec","type":"GENE","name":"OR8A2P","canonical_id":"hgnc:HGNC:15306","description":"olfactory receptor family 8 subfamily A member 2 pseudogene","metadata":null},{"id":"b7e3cbe2635d48c386117b7daeba19d1","type":"GENE","name":"OR8A3P","canonical_id":"hgnc:HGNC:31315","description":"olfactory receptor family 8 subfamily A member 3 pseudogene","metadata":null},{"id":"963f419f485745f8afa90c5b52d26399","type":"GENE","name":"OR8B10P","canonical_id":"hgnc:HGNC:14751","description":"olfactory receptor family 8 subfamily B member 10 pseudogene","metadata":null},{"id":"ef983cf891964368abd2fb1bf0f8d3d1","type":"GENE","name":"OR8B12","canonical_id":"hgnc:HGNC:15307","description":"olfactory receptor family 8 subfamily B member 12","metadata":null},{"id":"dab2f71d96da4a04af5f4b4564a62a5e","type":"GENE","name":"OR8B1P","canonical_id":"hgnc:HGNC:8470","description":"olfactory receptor family 8 subfamily B member 1 pseudogene","metadata":{"aliases":["OR11-561","OR8B11P"]}},{"id":"772f6736dc174cd792cbb84c4e042cd1","type":"GENE","name":"OR8B2","canonical_id":"hgnc:HGNC:8471","description":"olfactory receptor family 8 subfamily B member 2","metadata":null},{"id":"5d98b44a09294187b7513a93885eefd0","type":"GENE","name":"OR8B3","canonical_id":"hgnc:HGNC:8472","description":"olfactory receptor family 8 subfamily B member 3","metadata":null},{"id":"07c7b4422adc4dee863b1cfadf67ea73","type":"GENE","name":"OR8B4","canonical_id":"hgnc:HGNC:8473","description":"olfactory receptor family 8 subfamily B member 4","metadata":{"aliases":["OR8B4P"]}},{"id":"c37c722331a14c9da8e14091a0822753","type":"GENE","name":"OR8B5P","canonical_id":"hgnc:HGNC:8474","description":"olfactory receptor family 8 subfamily B member 5 pseudogene","metadata":null},{"id":"4694f1a802d04e2181adf7459f04d07b","type":"GENE","name":"OR8B6P","canonical_id":"hgnc:HGNC:8475","description":"olfactory receptor family 8 subfamily B member 6 pseudogene","metadata":null},{"id":"c6ac214cae9f408aa76687ef01f9d64e","type":"GENE","name":"OR8B7P","canonical_id":"hgnc:HGNC:8476","description":"olfactory receptor family 8 subfamily B member 7 pseudogene","metadata":{"aliases":["OR8B13P"]}},{"id":"a7244ecd331e450da07e6b1c07766e26","type":"GENE","name":"OR8B8","canonical_id":"hgnc:HGNC:8477","description":"olfactory receptor family 8 subfamily B member 8","metadata":{"aliases":["TPCR85"]}},{"id":"cd027655689648acad679bea9886deeb","type":"GENE","name":"OR8B9P","canonical_id":"hgnc:HGNC:14746","description":"olfactory receptor family 8 subfamily B member 9 pseudogene","metadata":null},{"id":"743a45705cb54468af9d96dfc6c27736","type":"GENE","name":"OR8C1P","canonical_id":"hgnc:HGNC:8478","description":"olfactory receptor family 8 subfamily C member 1 pseudogene","metadata":{"aliases":["OR11-175","OR912-45","OR912-106","OR8C3P","OR8C4P"]}},{"id":"0d432be8407447ae88a30f752e8c4046","type":"GENE","name":"OR8D1","canonical_id":"hgnc:HGNC:8481","description":"olfactory receptor family 8 subfamily D member 1","metadata":{"aliases":["OST004","OR8D3"]}},{"id":"2cb47329359a44f0b5541ef84718177b","type":"GENE","name":"OR8D2","canonical_id":"hgnc:HGNC:8482","description":"olfactory receptor family 8 subfamily D member 2","metadata":null},{"id":"0152dc1846494bd98ed94d6272461875","type":"GENE","name":"OR8D4","canonical_id":"hgnc:HGNC:14840","description":"olfactory receptor family 8 subfamily D member 4","metadata":null},{"id":"05c9ee3f648646108eb67eb478d32a38","type":"GENE","name":"OR8F1P","canonical_id":"hgnc:HGNC:14691","description":"olfactory receptor family 8 subfamily F member 1 pseudogene","metadata":null},{"id":"935e456238e14260947b581171bd4478","type":"GENE","name":"OR8G1","canonical_id":"hgnc:HGNC:8484","description":"olfactory receptor family 8 subfamily G member 1","metadata":{"aliases":["TPCR25","HSTPCR25","OR8G1P"]}},{"id":"9b33cc3836e84daa94115718647cba77","type":"GENE","name":"OR8G2P","canonical_id":"hgnc:HGNC:8485","description":"olfactory receptor family 8 subfamily G member 2 pseudogene","metadata":{"aliases":["TPCR120","HSTPCR120","ORL206","ORL486","OR8G4","OR8G2"]}},{"id":"69e7016300744fa2a23328dd285b5fa5","type":"GENE","name":"OR8G3","canonical_id":"hgnc:HGNC:14698","description":"olfactory receptor family 8 subfamily G member 3 (gene/pseudogene)","metadata":{"aliases":["OR8G3P"]}},{"id":"4c1958b7164144cbb71e79056472f527","type":"GENE","name":"OR8G5","canonical_id":"hgnc:HGNC:19622","description":"olfactory receptor family 8 subfamily G member 5","metadata":{"aliases":["OR8G5P","OR8G6"]}},{"id":"d20763c47c2f4c1bbd32e7fd7b1d7ef7","type":"GENE","name":"OR8G7P","canonical_id":"hgnc:HGNC:19625","description":"olfactory receptor family 8 subfamily G member 7 pseudogene","metadata":null},{"id":"6fbe82f903d14bb7b71402efc09f7b6f","type":"GENE","name":"OR8H1","canonical_id":"hgnc:HGNC:14824","description":"olfactory receptor family 8 subfamily H member 1","metadata":null},{"id":"30995522c09542dfa3823e2f84c287f1","type":"GENE","name":"OR8H2","canonical_id":"hgnc:HGNC:15308","description":"olfactory receptor family 8 subfamily H member 2","metadata":null},{"id":"33abbbe0871245bc93cd6d4dec58ae6b","type":"GENE","name":"OR8H3","canonical_id":"hgnc:HGNC:15309","description":"olfactory receptor family 8 subfamily H member 3","metadata":null},{"id":"05f371d4b9a64d298ec14326a370cd49","type":"GENE","name":"OR8I1P","canonical_id":"hgnc:HGNC:14828","description":"olfactory receptor family 8 subfamily I member 1 pseudogene","metadata":null},{"id":"37045b7cc94a4c3bb07865e62d4624a8","type":"GENE","name":"OR8I2","canonical_id":"hgnc:HGNC:15310","description":"olfactory receptor family 8 subfamily I member 2","metadata":null},{"id":"d85ae3104f394663b6138bde2cddb010","type":"GENE","name":"OR8I4P","canonical_id":"hgnc:HGNC:31316","description":"olfactory receptor family 8 subfamily I member 4 pseudogene","metadata":null},{"id":"97cffae1e65045b89b7c9ac0c7d8e398","type":"GENE","name":"OR8J1","canonical_id":"hgnc:HGNC:14855","description":"olfactory receptor family 8 subfamily J member 1","metadata":null},{"id":"b60242e257e54313b1c2e21b6a1d2256","type":"GENE","name":"OR8J2","canonical_id":"hgnc:HGNC:15311","description":"olfactory receptor family 8 subfamily J member 2 (gene/pseudogene)","metadata":{"aliases":["OR8J2P"]}},{"id":"c6211d8adaeb4cd484d6f0fcd574c77c","type":"GENE","name":"OR8J3","canonical_id":"hgnc:HGNC:15312","description":"olfactory receptor family 8 subfamily J member 3","metadata":null},{"id":"6dba30cf69314756a187665121a89064","type":"GENE","name":"OR8K1","canonical_id":"hgnc:HGNC:14831","description":"olfactory receptor family 8 subfamily K member 1","metadata":null},{"id":"cd2d037e9a6c422d94651190fc17bc3c","type":"GENE","name":"OR8K2P","canonical_id":"hgnc:HGNC:14832","description":"olfactory receptor family 8 subfamily K member 2 pseudogene","metadata":null},{"id":"13e94ee6771342e2bf4b8981d0a4455d","type":"GENE","name":"OR8K3","canonical_id":"hgnc:HGNC:15313","description":"olfactory receptor family 8 subfamily K member 3 (gene/pseudogene)","metadata":null},{"id":"82e451770b2549d8853cdb653a64aff9","type":"GENE","name":"OR8K4P","canonical_id":"hgnc:HGNC:15314","description":"olfactory receptor family 8 subfamily K member 4 pseudogene","metadata":null},{"id":"30c2002462da47819461cf8da03d3ef9","type":"GENE","name":"OR8K5","canonical_id":"hgnc:HGNC:15315","description":"olfactory receptor family 8 subfamily K member 5","metadata":null},{"id":"6dbbd63d1f3747d6af8103833247abb7","type":"GENE","name":"OR8L1P","canonical_id":"hgnc:HGNC:15316","description":"olfactory receptor family 8 subfamily L member 1 pseudogene","metadata":null},{"id":"45da1ec9e04045d8937cd069190bb775","type":"GENE","name":"OR8Q1P","canonical_id":"hgnc:HGNC:15317","description":"olfactory receptor family 8 subfamily Q member 1 pseudogene","metadata":null},{"id":"22890464054b4f95a800c170bd608041","type":"GENE","name":"OR8R1P","canonical_id":"hgnc:HGNC:15318","description":"olfactory receptor family 8 subfamily R member 1 pseudogene","metadata":null},{"id":"e2319a579b074a7aae4f09f60e2448ca","type":"GENE","name":"OR8S1","canonical_id":"hgnc:HGNC:19628","description":"olfactory receptor family 8 subfamily S member 1","metadata":null},{"id":"d116eaeedd9f49d4a2eeaef375e7632f","type":"GENE","name":"OR8S21P","canonical_id":"hgnc:HGNC:31317","description":"olfactory receptor family 8 subfamily S member 21 pseudogene","metadata":null},{"id":"2b930fd6efae4bd09826275c7401e203","type":"GENE","name":"OR8T1P","canonical_id":"hgnc:HGNC:19630","description":"olfactory receptor family 8 subfamily T member 1 pseudogene","metadata":null},{"id":"c45ee5c7151d4ca5a6aa4f673c401d5c","type":"GENE","name":"OR8U1","canonical_id":"hgnc:HGNC:19611","description":"olfactory receptor family 8 subfamily U member 1","metadata":null},{"id":"82d877a24ee74fdb817ed5b3ff70f756","type":"GENE","name":"OR8U3","canonical_id":"hgnc:HGNC:14841","description":"olfactory receptor family 8 subfamily U member 3","metadata":{"aliases":["OR5R1P","OR5R1"]}},{"id":"b2902285cb5d493d97887ecf0752d8e0","type":"GENE","name":"OR8U8","canonical_id":"hgnc:HGNC:27538","description":"olfactory receptor family 8 subfamily U member 8","metadata":null},{"id":"eebe1045a0db4dd8b4a4b834b972a52b","type":"GENE","name":"OR8U9","canonical_id":"hgnc:HGNC:29166","description":"olfactory receptor family 8 subfamily U member 9","metadata":null},{"id":"066d10d661e2431ea7abfeb4e818fe29","type":"GENE","name":"OR8V1P","canonical_id":"hgnc:HGNC:19613","description":"olfactory receptor family 8 subfamily V member 1 pseudogene","metadata":null},{"id":"ed8c39a034484d9197350fd7341713d1","type":"GENE","name":"OR8X1P","canonical_id":"hgnc:HGNC:31318","description":"olfactory receptor family 8 subfamily X member 1 pseudogene","metadata":null},{"id":"fdcac478ed1547b2ab7520dd0a6f8bd6","type":"GENE","name":"OR9A1P","canonical_id":"hgnc:HGNC:8486","description":"olfactory receptor family 9 subfamily A member 1 pseudogene","metadata":{"aliases":["HTPCRX06","HSHTPCRX06","OR9A1"]}},{"id":"d91e97edd71b419d85caf0c01e22af12","type":"GENE","name":"OR9A2","canonical_id":"hgnc:HGNC:15093","description":"olfactory receptor family 9 subfamily A member 2","metadata":null},{"id":"c85470fe9fc949dfb6eaed408fd599b0","type":"GENE","name":"OR9A3P","canonical_id":"hgnc:HGNC:15094","description":"olfactory receptor family 9 subfamily A member 3 pseudogene","metadata":{"aliases":["OR9A6P"]}},{"id":"3c38076d4c7f416cb6b0589071bb43d6","type":"GENE","name":"OR9A4","canonical_id":"hgnc:HGNC:15095","description":"olfactory receptor family 9 subfamily A member 4","metadata":null},{"id":"0a2be7e6f1d74447a04cc64de34a3eff","type":"GENE","name":"OR9G1","canonical_id":"hgnc:HGNC:15319","description":"olfactory receptor family 9 subfamily G member 1","metadata":{"aliases":["OR9G5"]}},{"id":"e8858443c5a840e9a282edac0ddb054f","type":"GENE","name":"OR9G2P","canonical_id":"hgnc:HGNC:15320","description":"olfactory receptor family 9 subfamily G member 2 pseudogene","metadata":{"aliases":["OR9G6"]}},{"id":"3d9d5394e20148bc8f07d5e438de56c0","type":"GENE","name":"OR9G3P","canonical_id":"hgnc:HGNC:15321","description":"olfactory receptor family 9 subfamily G member 3 pseudogene","metadata":null},{"id":"da3ebe0c7d074886a1401a714ee060f8","type":"GENE","name":"OR9G4","canonical_id":"hgnc:HGNC:15322","description":"olfactory receptor family 9 subfamily G member 4","metadata":null},{"id":"3a36c8d73e7b48bfab536005099b54ae","type":"GENE","name":"OR9G9","canonical_id":"hgnc:HGNC:31940","description":"olfactory receptor family 9 subfamily G member 9","metadata":null},{"id":"c6b43f81473746b083d78d7ddd91c0d2","type":"GENE","name":"OR9H1","canonical_id":"hgnc:HGNC:15038","description":"olfactory receptor family 9 subfamily H member 1 (gene/pseudogene)","metadata":{"aliases":["OR9H1P"]}},{"id":"9905c0954a4545b08684a406fa6312b0","type":"GENE","name":"OR9I1","canonical_id":"hgnc:HGNC:14718","description":"olfactory receptor family 9 subfamily I member 1","metadata":null},{"id":"eadfdaf0dbae42ecb4af95328aea21eb","type":"GENE","name":"OR9I2P","canonical_id":"hgnc:HGNC:15324","description":"olfactory receptor family 9 subfamily I member 2 pseudogene","metadata":null},{"id":"fe7482d1aabb4a3689db296391ecae32","type":"GENE","name":"OR9I3P","canonical_id":"hgnc:HGNC:15325","description":"olfactory receptor family 9 subfamily I member 3 pseudogene","metadata":{"aliases":["OST714"]}},{"id":"4f1e4aa765be4506a0ec4046773aeaeb","type":"GENE","name":"OR9K1P","canonical_id":"hgnc:HGNC:15338","description":"olfactory receptor family 9 subfamily K member 1 pseudogene","metadata":null},{"id":"a283b72c3c8f4cbfb79ba5b14c5713f1","type":"GENE","name":"OR9K2","canonical_id":"hgnc:HGNC:15339","description":"olfactory receptor family 9 subfamily K member 2","metadata":null},{"id":"93e5eb9c778d42238a4e61188dd03884","type":"GENE","name":"OR9L1P","canonical_id":"hgnc:HGNC:14761","description":"olfactory receptor family 9 subfamily L member 1 pseudogene","metadata":{"aliases":["OR9L2P"]}},{"id":"b1148340777b43759afcc1da67e75d41","type":"GENE","name":"OR9M1P","canonical_id":"hgnc:HGNC:15327","description":"olfactory receptor family 9 subfamily M member 1, pseudogene","metadata":{"aliases":["OR5BG1P"]}},{"id":"0758cf6b7db944cd91e52ca5f5fda018","type":"GENE","name":"OR9N1P","canonical_id":"hgnc:HGNC:15096","description":"olfactory receptor family 9 subfamily N member 1 pseudogene","metadata":null},{"id":"6d03e9b56743410fa4588186171a0476","type":"GENE","name":"OR9P1P","canonical_id":"hgnc:HGNC:15097","description":"olfactory receptor family 9 subfamily P member 1 pseudogene","metadata":{"aliases":["OR9P2P"]}},{"id":"e807d7d793384e169597de5817511258","type":"GENE","name":"OR9Q1","canonical_id":"hgnc:HGNC:14724","description":"olfactory receptor family 9 subfamily Q member 1","metadata":null},{"id":"1c178977342946bea66c3a43c248ef02","type":"GENE","name":"OR9Q2","canonical_id":"hgnc:HGNC:15328","description":"olfactory receptor family 9 subfamily Q member 2","metadata":{"aliases":["OR9Q2P"]}},{"id":"bca6b2f0a5e04bf3b5d2cb63169ad402","type":"GENE","name":"OR9R1P","canonical_id":"hgnc:HGNC:15340","description":"olfactory receptor family 9 subfamily R member 1 pseudogene","metadata":null},{"id":"abb7324f927044d5b3028611d33a1829","type":"GENE","name":"OR9S24P","canonical_id":"hgnc:HGNC:31288","description":"olfactory receptor family 9 subfamily S member 24 pseudogene","metadata":{"aliases":["OR5J6P"]}},{"id":"261c6885947f442bbeca5d62b7d30ae1","type":"GENE","name":"ORAI1","canonical_id":"hgnc:HGNC:25896","description":"ORAI calcium release-activated calcium modulator 1","metadata":{"aliases":["FLJ14466","CRACM1","TMEM142A"]}},{"id":"3fbe9176b09a42afbcb5a36ed4febd77","type":"GENE","name":"ORAI2","canonical_id":"hgnc:HGNC:21667","description":"ORAI calcium release-activated calcium modulator 2","metadata":{"aliases":["CBCIP2","FLJ12474","FLJ14733","H_NH0514P08.8","C7orf19","TMEM142B"]}},{"id":"9228715636544b4b8904b6d437d6533c","type":"GENE","name":"ORAI3","canonical_id":"hgnc:HGNC:28185","description":"ORAI calcium release-activated calcium modulator 3","metadata":{"aliases":["MGC13024","TMEM142C"]}},{"id":"017876a9cfb84555898bb58662e34ac5","type":"GENE","name":"ORC1","canonical_id":"hgnc:HGNC:8487","description":"origin recognition complex subunit 1","metadata":{"aliases":["HSORC1","PARC1","ORC1L"]}},{"id":"1f3d01d8ea5944c380688bcb19a01be4","type":"GENE","name":"ORC1P1","canonical_id":"hgnc:HGNC:54921","description":"ORC1 pseudogene 1","metadata":null},{"id":"7e125961c76248df9ee193a9bae1d182","type":"GENE","name":"ORC2","canonical_id":"hgnc:HGNC:8488","description":"origin recognition complex subunit 2","metadata":{"aliases":["ORC2L"]}},{"id":"a339e4bc84bb4b0bada33afcc903346f","type":"GENE","name":"ORC3","canonical_id":"hgnc:HGNC:8489","description":"origin recognition complex subunit 3","metadata":{"aliases":["IMAGE50150","LATHEO","ORC3L"]}},{"id":"09981578e3754855a48093235afb2028","type":"GENE","name":"ORC4","canonical_id":"hgnc:HGNC:8490","description":"origin recognition complex subunit 4","metadata":{"aliases":["HsORC4","Orc4p","ORC4L"]}},{"id":"16d8cefb4d244013a82485af847c268e","type":"GENE","name":"ORC5","canonical_id":"hgnc:HGNC:8491","description":"origin recognition complex subunit 5","metadata":{"aliases":["Orc5p","ORC5T","PPP1R117","ORC5L"]}},{"id":"6e6ce46c79d0402c9243a4d2597ebf91","type":"GENE","name":"ORC6","canonical_id":"hgnc:HGNC:17151","description":"origin recognition complex subunit 6","metadata":{"aliases":["ORC6L"]}},{"id":"450bbf35f7794a148de0d40bd67621c1","type":"TRIAL","name":"ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC","canonical_id":"clinicaltrials.gov:NCT06816992","description":"Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC; EGFR-mutated NSCLC","metadata":null},{"id":"0af8b36107bd4494ac134fdcf0ca2d3e","type":"TRIAL","name":"ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03525795","description":"Advanced Solid Tumors","metadata":null},{"id":"734cc87e5a47489e8861cbfa05598b98","type":"GENE","name":"ORM1","canonical_id":"hgnc:HGNC:8498","description":"orosomucoid 1","metadata":{"aliases":["A1AG1"]}},{"id":"b55bd96404624837a3376cc7a8cd3992","type":"GENE","name":"ORM2","canonical_id":"hgnc:HGNC:8499","description":"orosomucoid 2","metadata":{"aliases":["AGP-B","AGP-B'","AGP2"]}},{"id":"146224e12bb0494fba89da76a3a219ed","type":"GENE","name":"ORMDL1","canonical_id":"hgnc:HGNC:16036","description":"ORMDL sphingolipid biosynthesis regulator 1","metadata":null},{"id":"ac40145ffe4c41f19fd0c174d4d9b960","type":"GENE","name":"ORMDL1P1","canonical_id":"hgnc:HGNC:56506","description":"ORMDL1 pseudogene 1","metadata":null},{"id":"c0e16e6333e74e1196f76407590255c2","type":"GENE","name":"ORMDL2","canonical_id":"hgnc:HGNC:16037","description":"ORMDL sphingolipid biosynthesis regulator 2","metadata":{"aliases":["HSPC160","adoplin-2","MST095","MSTP095"]}},{"id":"ea17e9903adf48b29c3c487ab61b6614","type":"GENE","name":"ORMDL3","canonical_id":"hgnc:HGNC:16038","description":null,"metadata":null},{"id":"8b1f03220f854c47b5ba5ee624e1afc1","type":"GENE","name":"OS9","canonical_id":"hgnc:HGNC:16994","description":"OS9 endoplasmic reticulum lectin","metadata":{"aliases":["OS-9","ERLEC2"]}},{"id":"b0905997a6c74ab9a898a95c35031a02","type":"GENE","name":"OS9-AS1","canonical_id":"hgnc:HGNC:58278","description":"OS9 antisense RNA 1","metadata":null},{"id":"918110003d4f4b6b949e3f2ee9c35ef2","type":"GENE","name":"OSBP","canonical_id":"hgnc:HGNC:8503","description":"oxysterol binding protein","metadata":{"aliases":["OSBP1"]}},{"id":"31a91a434a3549f29e1526f2da7bb28d","type":"GENE","name":"OSBP2","canonical_id":"hgnc:HGNC:8504","description":"oxysterol binding protein 2","metadata":{"aliases":["KIAA1664","ORP-4","ORP4","OSBPL1"]}},{"id":"a3034cec10b047cabc74fe41eb04feab","type":"GENE","name":"OSBPL10","canonical_id":"hgnc:HGNC:16395","description":"oxysterol binding protein like 10","metadata":null},{"id":"904f622a6f6c4259a52ab0812d3f5891","type":"GENE","name":"OSBPL10-AS1","canonical_id":"hgnc:HGNC:40767","description":"OSBPL10 antisense RNA 1","metadata":null},{"id":"6201a3a798b449f1b0537db0be6d3243","type":"GENE","name":"OSBPL11","canonical_id":"hgnc:HGNC:16397","description":"oxysterol binding protein like 11","metadata":{"aliases":["ORP-11","ORP11","FLJ13012","FLJ13164"]}},{"id":"64096134751a4936b73960c0de2a6ed2","type":"GENE","name":"OSBPL1A","canonical_id":"hgnc:HGNC:16398","description":"oxysterol binding protein like 1A","metadata":{"aliases":["ORP-1","ORP1","OSBPL1B"]}},{"id":"5806b7e693154a6ea2c72f0f3b5d7999","type":"GENE","name":"OSBPL2","canonical_id":"hgnc:HGNC:15761","description":"oxysterol binding protein like 2","metadata":{"aliases":["KIAA0772","ORP-2","DFNA67"]}},{"id":"32623e748ee04072af7e31045238aac0","type":"GENE","name":"OSBPL3","canonical_id":"hgnc:HGNC:16370","description":"oxysterol binding protein like 3","metadata":{"aliases":["ORP-3","ORP3","KIAA0704","OSBP3"]}},{"id":"16928bb851c744129ce5eaaedd573cb8","type":"GENE","name":"OSBPL5","canonical_id":"hgnc:HGNC:16392","description":"oxysterol binding protein like 5","metadata":{"aliases":["KIAA1534","ORP5","OBPH1"]}},{"id":"2ae4945959a647e8bbd704b1ec8f4cab","type":"GENE","name":"OSBPL6","canonical_id":"hgnc:HGNC:16388","description":"oxysterol binding protein like 6","metadata":{"aliases":["ORP6"]}},{"id":"669ce214cc5d4f43b6162692cda06882","type":"GENE","name":"OSBPL7","canonical_id":"hgnc:HGNC:16387","description":"oxysterol binding protein like 7","metadata":{"aliases":["ORP7","MGC71150"]}},{"id":"347a299349fb43bca31dcbd17ff89834","type":"GENE","name":"OSBPL8","canonical_id":"hgnc:HGNC:16396","description":"oxysterol binding protein like 8","metadata":{"aliases":["OSBP10","ORP8","MST120","MSTP120"]}},{"id":"39d57f3159c24e78b10ab92c1238f8d9","type":"GENE","name":"OSBPL9","canonical_id":"hgnc:HGNC:16386","description":"oxysterol binding protein like 9","metadata":null},{"id":"e622c844f8464534817a52c53c5c3092","type":"GENE","name":"OSBPL9P1","canonical_id":"hgnc:HGNC:48731","description":"oxysterol binding protein like 9 pseudogene 1","metadata":null},{"id":"cfa897d46e1a4880a9c63138b911e99a","type":"GENE","name":"OSBPL9P2","canonical_id":"hgnc:HGNC:48732","description":"oxysterol binding protein like 9 pseudogene 2","metadata":null},{"id":"54297e44887a4feba2a3bb805ed24050","type":"GENE","name":"OSBPL9P3","canonical_id":"hgnc:HGNC:48733","description":"oxysterol binding protein like 9 pseudogene 3","metadata":null},{"id":"80453c2a08414ba1890acbb5314c693a","type":"GENE","name":"OSBPL9P4","canonical_id":"hgnc:HGNC:48734","description":"oxysterol binding protein like 9 pseudogene 4","metadata":null},{"id":"5f61527ae79d4b219abcfd79306b3b48","type":"GENE","name":"OSBPL9P5","canonical_id":"hgnc:HGNC:48735","description":"oxysterol binding protein like 9 pseudogene 5","metadata":null},{"id":"8477690719954700bf60c72f40f7ec59","type":"GENE","name":"OSBPL9P6","canonical_id":"hgnc:HGNC:48736","description":"oxysterol binding protein like 9 pseudogene 6","metadata":null},{"id":"9f1ac54e3ed84380b53d84af8e31c084","type":"GENE","name":"OSCAR","canonical_id":"hgnc:HGNC:29960","description":"osteoclast associated Ig-like receptor","metadata":null},{"id":"c997456bd26445ef8d89bc8d1565f5d4","type":"GENE","name":"OSCP1","canonical_id":"hgnc:HGNC:29971","description":"organic solute carrier partner 1","metadata":{"aliases":["NOR1","C1orf102"]}},{"id":"d88017263ca642f09412a27a9ec7ad4e","type":"GENE","name":"OSER1","canonical_id":"hgnc:HGNC:16105","description":"oxidative stress responsive serine rich 1","metadata":{"aliases":["dJ1183I21.1","HSPC207","Perit1","Osr1","C20orf111"]}},{"id":"da9ed6446dc44c8187221a04c9f1ec0e","type":"GENE","name":"OSER1-DT","canonical_id":"hgnc:HGNC:48585","description":"OSER1 divergent transcript","metadata":{"aliases":["OSER1-AS1"]}},{"id":"af592fe17c044125a4d8c0f7a80c777c","type":"GENE","name":"OSGEP","canonical_id":"hgnc:HGNC:18028","description":"O-sialoglycoprotein endopeptidase","metadata":{"aliases":["PRSMG1","GCPL1","OSGEP1","KAE1","TCS3"]}},{"id":"c9e441610eaa4e71b367ae4d47ec3f84","type":"GENE","name":"OSGEPL1","canonical_id":"hgnc:HGNC:23075","description":"O-sialoglycoprotein endopeptidase like 1","metadata":{"aliases":["Qri7","OSGEPL"]}},{"id":"2cf6b9aba54045f39f76fe8616302a2f","type":"GENE","name":"OSGEPL1-AS1","canonical_id":"hgnc:HGNC:41009","description":"OSGEPL1 antisense RNA 1","metadata":null},{"id":"93abf594ffd6446b817dec0c54c23a61","type":"GENE","name":"OSGIN1","canonical_id":"hgnc:HGNC:30093","description":"oxidative stress induced growth inhibitor 1","metadata":{"aliases":["BDGI","OKL38"]}},{"id":"0bf052a85f7c4025aa9309ef21ff3caa","type":"GENE","name":"OSGIN2","canonical_id":"hgnc:HGNC:1355","description":"oxidative stress induced growth inhibitor family member 2","metadata":{"aliases":["hT41","C8orf1"]}},{"id":"91f7f5e32373453cad8abad33f546a16","type":"GENE","name":"OSM","canonical_id":"hgnc:HGNC:8506","description":null,"metadata":null},{"id":"1dd9383ba5d94586ba94c2ad29f6dbf3","type":"GENE","name":"OSMR","canonical_id":"hgnc:HGNC:8507","description":"oncostatin M receptor","metadata":{"aliases":["OSMRB","OSMRbeta"]}},{"id":"35a2ee6a64d341b9b8bee419201329d0","type":"GENE","name":"OSMR-DT","canonical_id":"hgnc:HGNC:50296","description":"OSMR divergent transcript","metadata":{"aliases":["OSMR-AS1"]}},{"id":"6d203b3875ef4a0a934bf5a4a1ed941f","type":"GENE","name":"OSR1","canonical_id":"hgnc:HGNC:8111","description":"odd-skipped related transcription factor 1","metadata":{"aliases":["ODD"]}},{"id":"0409aed39a2b4abf9965f19298f996d0","type":"GENE","name":"OSR2","canonical_id":"hgnc:HGNC:15830","description":"odd-skipped related transciption factor 2","metadata":{"aliases":["FLJ90037"]}},{"id":"fde0ad66a5ca4db69978e48bfae3aeed","type":"GENE","name":"OST4","canonical_id":"hgnc:HGNC:32483","description":"oligosaccharyltransferase complex subunit 4, non-catalytic","metadata":null},{"id":"5d32839c56a44ae3a51fc414083c3683","type":"GENE","name":"OSTC","canonical_id":"hgnc:HGNC:24448","description":"oligosaccharyltransferase complex non-catalytic subunit","metadata":{"aliases":["DC2"]}},{"id":"b46b7d12a1d84b6db34b1db3a566e8db","type":"GENE","name":"OSTCP1","canonical_id":"hgnc:HGNC:30530","description":"oligosaccharyltransferase complex subunit pseudogene 1","metadata":{"aliases":["DC2L","OSTCL"]}},{"id":"ac12a802399b4aa0b722b9f51fcbe000","type":"GENE","name":"OSTCP2","canonical_id":"hgnc:HGNC:42864","description":"oligosaccharyltransferase complex subunit pseudogene 2","metadata":null},{"id":"d1ffef89e09e4ac4ab560514376f4b90","type":"GENE","name":"OSTCP3","canonical_id":"hgnc:HGNC:42865","description":"oligosaccharyltransferase complex subunit pseudogene 3","metadata":null},{"id":"ea75bbc02173442aaf0c9879c38dca3f","type":"GENE","name":"OSTCP4","canonical_id":"hgnc:HGNC:42866","description":"oligosaccharyltransferase complex subunit pseudogene 4","metadata":null},{"id":"0b92ea03aa474a369ec48dbbc1ddc904","type":"GENE","name":"OSTCP5","canonical_id":"hgnc:HGNC:42867","description":"oligosaccharyltransferase complex subunit pseudogene 5","metadata":null},{"id":"b656a67a3a42465795abcaa2972e8709","type":"GENE","name":"OSTCP6","canonical_id":"hgnc:HGNC:42868","description":"oligosaccharyltransferase complex subunit pseudogene 6","metadata":null},{"id":"63012a89eb384a1d8df4431123e350e5","type":"GENE","name":"OSTCP7","canonical_id":"hgnc:HGNC:42870","description":"oligosaccharyltransferase complex subunit pseudogene 7","metadata":null},{"id":"b6d89bec940e405d9e90bbb90c7a352c","type":"GENE","name":"OSTCP8","canonical_id":"hgnc:HGNC:42869","description":"oligosaccharyltransferase complex subunit pseudogene 8","metadata":null},{"id":"6b0426e3d4c548378c35fafd6eb0ffcd","type":"GENE","name":"OSTF1","canonical_id":"hgnc:HGNC:8510","description":"osteoclast stimulating factor 1","metadata":{"aliases":["SH3P2","OSF","bA235O14.1"]}},{"id":"e2b895cb9a5b4afc96b7bf4b60392056","type":"GENE","name":"OSTF1P1","canonical_id":"hgnc:HGNC:31439","description":"osteoclast stimulating factor 1 pseudogene 1","metadata":{"aliases":["OSTF1P"]}},{"id":"a53b854b421d420bb661c9cc59402b5a","type":"GENE","name":"OSTM1","canonical_id":"hgnc:HGNC:21652","description":"osteoclastogenesis associated transmembrane protein 1","metadata":{"aliases":["HSPC019","GL"]}},{"id":"f3355f8e94d24c39a6ecc80bbda5631d","type":"GENE","name":"OSTM1-AS1","canonical_id":"hgnc:HGNC:43666","description":"OSTM1 antisense RNA 1","metadata":null},{"id":"3dbdcb512d9b43758ee7026966d4615a","type":"GENE","name":"OSTN","canonical_id":"hgnc:HGNC:29961","description":"osteocrin","metadata":null},{"id":"7a196cabed744f53bf6a55f3793cf759","type":"GENE","name":"OSTN-AS1","canonical_id":"hgnc:HGNC:41250","description":"OSTN antisense RNA 1","metadata":null},{"id":"9206154b088f4238a5a923a81600fb66","type":"GENE","name":"OTC","canonical_id":"hgnc:HGNC:8512","description":null,"metadata":null},{"id":"ce20c3c2ce4c482d85e2705258db1f09","type":"TRIAL","name":"OTIS Vedolizumab Pregnancy Exposure Registry","canonical_id":"clinicaltrials.gov:NCT02678052","description":"Colitis, Ulcerative; Crohn's Disease","metadata":null},{"id":"ed039ece5ad64567bec5ab06260ec1ac","type":"GENE","name":"OTOA","canonical_id":"hgnc:HGNC:16378","description":"otoancorin","metadata":{"aliases":["CT108","DFNB22"]}},{"id":"603d323482a34066bf8d7c41a7183106","type":"GENE","name":"OTOAP1","canonical_id":"hgnc:HGNC:53869","description":"OTOA pseudogene 1","metadata":{"aliases":["LOC653786"]}},{"id":"5c447f4e3eb04962b675592312b37173","type":"GENE","name":"OTOF","canonical_id":"hgnc:HGNC:8515","description":"otoferlin","metadata":{"aliases":["FER1L2","DFNB6","DFNB9"]}},{"id":"d4c51f5c7f7741fbb339c57bc33d56b0","type":"GENE","name":"OTOG","canonical_id":"hgnc:HGNC:8516","description":"otogelin","metadata":{"aliases":["mlemp","OTGN","FLJ46346"]}},{"id":"1fa87fdab1a84356b9b2489fec907c37","type":"GENE","name":"OTOGL","canonical_id":"hgnc:HGNC:26901","description":"otogelin like","metadata":{"aliases":["FLJ90579","C12orf64"]}},{"id":"b777a4357dbd41fd92460e5094640b67","type":"GENE","name":"OTOL1","canonical_id":"hgnc:HGNC:34071","description":"otolin 1","metadata":{"aliases":["C1QTNF15","C1QTNF16"]}},{"id":"86321f1658f24ca980982a74f339db9b","type":"GENE","name":"OTOP1","canonical_id":"hgnc:HGNC:19656","description":"otopetrin 1","metadata":null},{"id":"8f8b9234e8394effbc1e0660956854e0","type":"GENE","name":"OTOP1P1","canonical_id":"hgnc:HGNC:59139","description":"OTOP1 pseudogene 1","metadata":null},{"id":"1dbc258e4c694881a5fd246528e2fadc","type":"GENE","name":"OTOP1P2","canonical_id":"hgnc:HGNC:59140","description":"OTOP1 pseudogene 2","metadata":null},{"id":"a3de9f1526504b78a2dfd70569700e32","type":"GENE","name":"OTOP1P3","canonical_id":"hgnc:HGNC:59141","description":"OTOP1 pseudogene 3","metadata":null},{"id":"3e51743b9dd141008bb2d57f0aa706d8","type":"GENE","name":"OTOP1P4","canonical_id":"hgnc:HGNC:59142","description":"OTOP1 pseudogene 4","metadata":null},{"id":"15c953e6831b47be94ccf41c652114af","type":"GENE","name":"OTOP1P5","canonical_id":"hgnc:HGNC:59143","description":"OTOP1 pseudogene 5","metadata":null},{"id":"65c5b4aeadd247e29a135eef117bde16","type":"GENE","name":"OTOP2","canonical_id":"hgnc:HGNC:19657","description":"otopetrin 2","metadata":null},{"id":"c4246ee6341746fdb9915956620b971d","type":"GENE","name":"OTOP3","canonical_id":"hgnc:HGNC:19658","description":"otopetrin 3","metadata":null},{"id":"f36a63eeac0646daa63ee5d4a5eb56cf","type":"GENE","name":"OTOR","canonical_id":"hgnc:HGNC:8517","description":"otoraplin","metadata":{"aliases":["MIAL","MIAL1","FDP"]}},{"id":"6ea7a7f32c9649759de4153edf7a6996","type":"GENE","name":"OTOS","canonical_id":"hgnc:HGNC:22644","description":"otospiralin","metadata":{"aliases":["OTOSP"]}},{"id":"dc47ebb2c7b14f4ab0e284fbfaf7056c","type":"GENE","name":"OTP","canonical_id":"hgnc:HGNC:8518","description":"orthopedia homeobox","metadata":null},{"id":"bc59a26b8cf34012a19a81f068fe3048","type":"GENE","name":"OTP-AS1","canonical_id":"hgnc:HGNC:58154","description":"OTP antisense RNA 1","metadata":null},{"id":"ef31daae4ff2442abf034072d1100390","type":"GENE","name":"OTUB1","canonical_id":"hgnc:HGNC:23077","description":"OTU deubiquitinase, ubiquitin aldehyde binding 1","metadata":{"aliases":["FLJ20113","FLJ40710"]}},{"id":"97fab66edff442f09a7f94d953040035","type":"GENE","name":"OTUB2","canonical_id":"hgnc:HGNC:20351","description":"OTU deubiquitinase, ubiquitin aldehyde binding 2","metadata":{"aliases":["FLJ21916","MGC3102","C14orf137"]}},{"id":"1e4f573bceaa4054b2908bc34afe1be5","type":"GENE","name":"OTUD1","canonical_id":"hgnc:HGNC:27346","description":"OTU deubiquitinase 1","metadata":{"aliases":["DUBA7","OTDC1"]}},{"id":"a1daba3cef5944cdb7a85cdb755a1dac","type":"GENE","name":"OTUD3","canonical_id":"hgnc:HGNC:29038","description":"OTU deubiquitinase 3","metadata":{"aliases":["KIAA0459","DUBA4"]}},{"id":"731a2bbd90a149d08959667473687fdb","type":"GENE","name":"OTUD4","canonical_id":"hgnc:HGNC:24949","description":"OTU deubiquitinase 4","metadata":{"aliases":["HSHIN1","KIAA1046","DUBA6"]}},{"id":"500256cf2a9a4c02a4b342b56395f012","type":"GENE","name":"OTUD4P1","canonical_id":"hgnc:HGNC:33912","description":"OTUD4 pseudogene 1","metadata":{"aliases":["HIN1L"]}},{"id":"a6dbbe608c564c458d061f2cfc25860f","type":"GENE","name":"OTUD5","canonical_id":"hgnc:HGNC:25402","description":"OTU deubiquitinase 5","metadata":{"aliases":["DKFZp761A052","DUBA"]}},{"id":"58b71583451543cdbdff9a0950393480","type":"GENE","name":"OTUD6A","canonical_id":"hgnc:HGNC:32312","description":"OTU deubiquitinase 6A","metadata":{"aliases":["FLJ25831","HSHIN6","DUBA2"]}},{"id":"1dadf8f5da26469488e987ce97bf72d6","type":"GENE","name":"OTUD6B","canonical_id":"hgnc:HGNC:24281","description":"OTU deubiquitinase 6B","metadata":{"aliases":["CGI-77","DUBA5"]}},{"id":"9ab685a6b1984b819c586bf768a8354d","type":"GENE","name":"OTUD6B-AS1","canonical_id":"hgnc:HGNC:50466","description":"OTUD6B antisense RNA 1","metadata":{"aliases":["GS1-251I9.4"]}},{"id":"6f40e76ac1c7406f8d5a523a0738acdf","type":"GENE","name":"OTUD7A","canonical_id":"hgnc:HGNC:20718","description":"OTU deubiquitinase 7A","metadata":{"aliases":["CEZANNE2","C15orf16","OTUD7"]}},{"id":"ee5bde59981b4f5282c5de0e6b6f28c7","type":"GENE","name":"OTUD7B","canonical_id":"hgnc:HGNC:16683","description":"OTU deubiquitinase 7B","metadata":{"aliases":["CEZANNE","ZA20D1"]}},{"id":"e7de6a81ccd04ad0bc5ce1d9a128063d","type":"GENE","name":"OTULIN","canonical_id":"hgnc:HGNC:25118","description":"OTU deubiquitinase with linear linkage specificity","metadata":{"aliases":["FLJ34884","FAM105B"]}},{"id":"80ecab0013ba4233832e6236e5d74491","type":"GENE","name":"OTULIN-DT","canonical_id":"hgnc:HGNC:55368","description":"OTULIN divergent transcript","metadata":null},{"id":"43a21b7eddbe4f018bf438770636a41f","type":"GENE","name":"OTULINL","canonical_id":"hgnc:HGNC:25629","description":"OTU deubiquitinase with linear linkage specificity like","metadata":{"aliases":["FLJ11127","NET20","FAM105A"]}},{"id":"4857593da7d6417389b9613752d9c2a2","type":"GENE","name":"OTX1","canonical_id":"hgnc:HGNC:8521","description":null,"metadata":null},{"id":"9c33bfa52d66456c80512bfe1b92a8c0","type":"GENE","name":"OTX2","canonical_id":"hgnc:HGNC:8522","description":null,"metadata":null},{"id":"819e765dbd514e3cb5e8365286e8e809","type":"GENE","name":"OTX2-AS1","canonical_id":"hgnc:HGNC:43906","description":"OTX2 antisense RNA 1","metadata":{"aliases":["OTX2OS1"]}},{"id":"78215e62d2b541809bc65e459362824e","type":"GENE","name":"OTX2-NT1","canonical_id":"hgnc:HGNC:58076","description":"OTX2 neighbouring transcript 1","metadata":{"aliases":["REIR-1"]}},{"id":"1079c4f845364e9ca3ed12094227ffe3","type":"GENE","name":"OTX2P1","canonical_id":"hgnc:HGNC:33281","description":"OTX2 pseudogene 1","metadata":{"aliases":["OTX2P"]}},{"id":"582b4974d9074ef79f72493ce8e3645e","type":"GENE","name":"OTX2P2","canonical_id":"hgnc:HGNC:54560","description":"OTX2 pseudogene 2","metadata":null},{"id":"326da2cdbe7e4285a110a439001d604e","type":"GENE","name":"OVAAL","canonical_id":"hgnc:HGNC:49422","description":"ovarian adenocarcinoma amplified long non-coding RNA","metadata":{"aliases":["LINC01131","OVAL","RMEL2"]}},{"id":"5d51d4a82a33476e801202ea11699ed1","type":"GENE","name":"OVCA2","canonical_id":"hgnc:HGNC:24203","description":"OVCA2 serine hydrolase domain containing","metadata":null},{"id":"d7df9b92be244f8f862da3e9e8aa87f9","type":"GENE","name":"OVCH1","canonical_id":"hgnc:HGNC:23080","description":"ovochymase 1","metadata":{"aliases":["OVCH"]}},{"id":"c24e9eb5f0d24cf4a4952ebe709afd8a","type":"GENE","name":"OVCH1-AS1","canonical_id":"hgnc:HGNC:44484","description":"OVCH1 antisense RNA 1","metadata":null},{"id":"fb7ed469eb014b98997874c9f9647969","type":"GENE","name":"OVCH2","canonical_id":"hgnc:HGNC:29970","description":"ovochymase 2","metadata":{"aliases":["OVTN"]}},{"id":"1f0d12c7cf494ee09139b411f0dcbdc7","type":"GENE","name":"OVGP1","canonical_id":"hgnc:HGNC:8524","description":"oviductal glycoprotein 1","metadata":{"aliases":["CHIT5","OGP","MUC9"]}},{"id":"418c1b9226d647b28136ecdb51f383dc","type":"GENE","name":"OVOL1","canonical_id":"hgnc:HGNC:8525","description":"ovo like transcriptional repressor 1","metadata":{"aliases":["HOVO1"]}},{"id":"10d99aebaf7b4791aa49514c93f4d06e","type":"GENE","name":"OVOL1-AS1","canonical_id":"hgnc:HGNC:49319","description":"OVOL1 antisense RNA 1","metadata":null},{"id":"d13239d6dc614094b626f5ae3fca6c2a","type":"GENE","name":"OVOL2","canonical_id":"hgnc:HGNC:15804","description":"ovo like zinc finger 2","metadata":{"aliases":["bA504H3.3","HOVO2","CHED","ZNF339","CHED1"]}},{"id":"1fd761a83cd24fcda5516fcf36e25f07","type":"GENE","name":"OVOL3","canonical_id":"hgnc:HGNC:14186","description":"ovo like zinc finger 3","metadata":{"aliases":["HOVO3"]}},{"id":"909cf556de1a4f3ba3f5ab6315164f20","type":"GENE","name":"OVOS1BP","canonical_id":"hgnc:HGNC:58687","description":"ovostatin 1B, pseudogene","metadata":{"aliases":["OVOS1B"]}},{"id":"ec955456628d4956bbffe95f3711c4af","type":"GENE","name":"OVOS1P","canonical_id":"hgnc:HGNC:34045","description":"ovostatin 1, pseudogene","metadata":{"aliases":["OVM"]}},{"id":"6226793303bb497db545cf2b2c269b71","type":"GENE","name":"OVOS2P","canonical_id":"hgnc:HGNC:34046","description":"ovostatin 2, pseudogene","metadata":{"aliases":["DKFZp686C0338","DKFZp434C0631"]}},{"id":"8a5110bf3a1a40ddbfc94dff5f36b094","type":"TRIAL","name":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03390296","description":"Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"a56f1e50caed440f8380da941d772372","type":"GENE","name":"OXA1L","canonical_id":"hgnc:HGNC:8526","description":"OXA1L mitochondrial inner membrane insertase","metadata":{"aliases":["MGC133129","OXA1","OXA1L1"]}},{"id":"1a8377ca65274e56b885739840abe400","type":"GENE","name":"OXA1L-DT","canonical_id":"hgnc:HGNC:55448","description":"OXA1L divergent transcript","metadata":null},{"id":"02ecf1d35888414cbbdafaa5f02f7499","type":"GENE","name":"OXCT1","canonical_id":"hgnc:HGNC:8527","description":"3-oxoacid CoA-transferase 1","metadata":{"aliases":["SCOT","OXCT"]}},{"id":"badb9564fc93439f8afd227298f3a0f3","type":"GENE","name":"OXCT1-AS1","canonical_id":"hgnc:HGNC:40423","description":"OXCT1 antisense RNA 1","metadata":{"aliases":["SARRAH"]}},{"id":"0e5507123fd64420b656f67d2a51edd0","type":"GENE","name":"OXCT1-AS2","canonical_id":"hgnc:HGNC:59036","description":"OXCT1 antisense RNA 2","metadata":null},{"id":"0862609655bf4333b482d9cbfe650d89","type":"GENE","name":"OXCT2","canonical_id":"hgnc:HGNC:18606","description":"3-oxoacid CoA-transferase 2","metadata":{"aliases":["FKSG25","FLJ00030","SCOT-T"]}},{"id":"c28876deb8394caca843739f74b25b07","type":"GENE","name":"OXCT2P1","canonical_id":"hgnc:HGNC:21627","description":"3-oxoacid CoA-transferase 2 pseudogene 1","metadata":{"aliases":["OXCT2P"]}},{"id":"b39b29b1950c437198c4394abd117287","type":"GENE","name":"OXER1","canonical_id":"hgnc:HGNC:24884","description":"oxoeicosanoid receptor 1","metadata":{"aliases":["GPCR","TG1019","GPR170"]}},{"id":"4d7fde8e887b4e8da3dde45ffa8b9daf","type":"GENE","name":"OXGR1","canonical_id":"hgnc:HGNC:4531","description":"oxoglutarate receptor 1","metadata":{"aliases":["P2RY15","P2Y15","aKGR","GPR99","GPR80"]}},{"id":"7ff59f45c5ce4cf0afbd5d3cb51a2047","type":"GENE","name":"OXLD1","canonical_id":"hgnc:HGNC:27901","description":"oxidoreductase like domain containing 1","metadata":{"aliases":["MGC104712","C17orf90"]}},{"id":"0a86f1fdeb20438d8a50df381692da2a","type":"TRIAL","name":"OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT01083485","description":"Post Operative Pain","metadata":null},{"id":"b694e870a07645029dd27edf2e29cf18","type":"GENE","name":"OXNAD1","canonical_id":"hgnc:HGNC:25128","description":"oxidoreductase NAD binding domain containing 1","metadata":{"aliases":["MGC15763","RFTN1-AS1"]}},{"id":"fab7a62514e24c728369e21e113b1e41","type":"GENE","name":"OXR1","canonical_id":"hgnc:HGNC:15822","description":"oxidation resistance 1","metadata":{"aliases":["TLDC3"]}},{"id":"f0ff77f74f5c4bf0b76ab743fcb2811c","type":"GENE","name":"OXR1-AS1","canonical_id":"hgnc:HGNC:55533","description":"OXR1 antisense RNA 1","metadata":null},{"id":"b97d53b9c79c48baa318d9c4c5527907","type":"GENE","name":"OXSM","canonical_id":"hgnc:HGNC:26063","description":"3-oxoacyl-ACP synthase, mitochondrial","metadata":{"aliases":["KS","FLJ20604","FASN2D","CEM1"]}},{"id":"c5966c0bb29c404cb53087db43fb8bab","type":"GENE","name":"OXSR1","canonical_id":"hgnc:HGNC:8508","description":"oxidative stress responsive kinase 1","metadata":{"aliases":["KIAA1101","OSR1"]}},{"id":"925b3f3defcb4f9f9925f70a558cc3e0","type":"GENE","name":"OXT","canonical_id":"hgnc:HGNC:8528","description":null,"metadata":null},{"id":"f778c69abd86466b8a40df3dc4e10810","type":"GENE","name":"OXTR","canonical_id":"hgnc:HGNC:8529","description":null,"metadata":null},{"id":"f8c0d008cd06400785981f67d7f37198","type":"TRIAL","name":"OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab","canonical_id":"clinicaltrials.gov:NCT01243086","description":"Wet Macular Degeneration","metadata":null},{"id":"1b729940099b4a618fc4f341df2f1ecc","type":"TRIAL","name":"Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia","canonical_id":"clinicaltrials.gov:NCT00933985","description":"Acute Leukemias of Ambiguous Lineage; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell \u2026","metadata":null},{"id":"10998917e6a84e50ac9577ae760c18d0","type":"DISEASE","name":"Obesity","canonical_id":"mesh:D009765","description":null,"metadata":null},{"id":"c809fe804aca4c689469f5d0027a08dc","type":"TRIAL","name":"Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)","canonical_id":"clinicaltrials.gov:NCT02177136","description":"Primary Sclerosing Cholangitis (PSC)","metadata":null},{"id":"cf5014cac98744aaa3901241872fe46b","type":"TRIAL","name":"Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes","canonical_id":"clinicaltrials.gov:NCT06691412","description":"Hepatitis B Virus; Steatosis","metadata":null},{"id":"9ca4ae03d5e744b6ac02f53da8da77e4","type":"TRIAL","name":"Obeticholic Acid for Prevention in Barrett's Esophagus","canonical_id":"clinicaltrials.gov:NCT04939051","description":"Barrett Esophagus; Esophageal Adenocarcinoma","metadata":null},{"id":"e709e7b7c88940a791360011cfddd533","type":"TRIAL","name":"Obeticholic Acid in Bariatric and Gallstone Disease","canonical_id":"clinicaltrials.gov:NCT01625026","description":"Obesity; Gallstones","metadata":null},{"id":"447e5ed70d284175ba057246cb75895d","type":"TRIAL","name":"Obeticholic Acid in Bile Acid Diarrhoea","canonical_id":"clinicaltrials.gov:NCT01585025","description":"Primary Bile Acid Malabsorption; Secondary Bile Acid Malabsorption; Chronic Diarrhoea","metadata":null},{"id":"0cab86f755764a929ea40a0bfb9d9d6e","type":"TRIAL","name":"Obeticholic Acid in Morbidly Obese Patients and Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02532335","description":"Obesity","metadata":null},{"id":"a6fae76f46334f59845a7cb26c6f45e2","type":"DRUG","name":"Obinutuzumab","canonical_id":"mesh:C543332","description":null,"metadata":null},{"id":"240510ef458e48648f003962ecd9cb5c","type":"TRIAL","name":"Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 \"OVERALL\"","canonical_id":"clinicaltrials.gov:NCT04920968","description":"CD20-positive Acute Lymphoblastic Leukemia","metadata":null},{"id":"c1ea97fff2b845a08231e3a8b2ed4c7b","type":"TRIAL","name":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT03269669","description":"Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma","metadata":null},{"id":"843a2392469a423982b9584ded923259","type":"TRIAL","name":"Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT02871219","description":"Ann Arbor Stage II Grade 1 Follicular Lymphoma; Ann Arbor Stage II Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Bulky Disease; Fatigue; Fever; Grade 3a Follicular Lymphoma; Night Sweats; Splenomegaly; Weight Loss","metadata":null},{"id":"7b1c93d97b0d4a03b5bb36cf1357305d","type":"TRIAL","name":"Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT02867384","description":"Graft vs. Host Disease","metadata":null},{"id":"fd86089edc1743048e5f92719f221080","type":"TRIAL","name":"Obinutuzumab in the Management of Idiopathic Membranous Nephropathy","canonical_id":"clinicaltrials.gov:NCT05845762","description":"Idiopathic Membranous Nephropathy","metadata":null},{"id":"490de7539ff648dd98cc061b17cf0a39","type":"TRIAL","name":"Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT04309838","description":"Pulmonary Arterial Hypertension; PAH","metadata":null},{"id":"f3d3d77577cf4c2ca4226731e6f213a6","type":"TRIAL","name":"Observation in the Treatment of Graves' Disease","canonical_id":"clinicaltrials.gov:NCT05043233","description":"Patient Acceptance of Health Care","metadata":null},{"id":"9306002ca2b84932945fe2427724f15d","type":"TRIAL","name":"Observation of Clozapine Treatment Safety in Bipolar Disorder.","canonical_id":"clinicaltrials.gov:NCT06011460","description":"Bipolar Disorder","metadata":null},{"id":"8837c349eb4443c1abca2002f7d8e28a","type":"TRIAL","name":"Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years","canonical_id":"clinicaltrials.gov:NCT00250640","description":"Hypertension, Pulmonary","metadata":null},{"id":"a82dc96012174834946c9d7a45b2193f","type":"TRIAL","name":"Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)","canonical_id":"clinicaltrials.gov:NCT00761527","description":"Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial; Urticaria","metadata":null},{"id":"e801c10ad7d04064af083cb71a3a7cc0","type":"TRIAL","name":"Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation","canonical_id":"clinicaltrials.gov:NCT05491343","description":"Arteriovenous Malformations","metadata":null},{"id":"e143b570372047a681575744d9686973","type":"TRIAL","name":"Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix","canonical_id":"clinicaltrials.gov:NCT03193645","description":"Prostate Cancer","metadata":null},{"id":"521a45c4364a4c809a96cde236217dc7","type":"TRIAL","name":"Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study","canonical_id":"clinicaltrials.gov:NCT04823247","description":"Plaque Psoriasis","metadata":null},{"id":"2bcd1cbd82794feba8a8bd4e247dd698","type":"TRIAL","name":"Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication","canonical_id":"clinicaltrials.gov:NCT01858870","description":"Epilepsy","metadata":null},{"id":"164a19c06a264d9faa66a26e300407af","type":"TRIAL","name":"Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis","canonical_id":"clinicaltrials.gov:NCT00322439","description":"Psoriasis","metadata":null},{"id":"373b509d58bf4a51a8ece2a06a067cfa","type":"TRIAL","name":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","canonical_id":"clinicaltrials.gov:NCT04979780","description":"Treatment of Venous Thromboembolism in Cancer Patients; Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","metadata":null},{"id":"7b23f6289a6c4cefba02369977cf2fac","type":"TRIAL","name":"Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene","canonical_id":"clinicaltrials.gov:NCT00847821","description":"Postmenopause","metadata":null},{"id":"2e87a19fbe2d44109bfad23718e22014","type":"TRIAL","name":"Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)","canonical_id":"clinicaltrials.gov:NCT02106156","description":"Chronic Hepatitis C","metadata":null},{"id":"dba6932ceca64b6085ee0902b5858c58","type":"TRIAL","name":"Observational Study Evaluating the Safety of ADASUVE\u00ae in Agitation Associated With Schizophrenia or Bipolar I Disorder","canonical_id":"clinicaltrials.gov:NCT03513549","description":"Agitation,Psychomotor","metadata":null},{"id":"4fde924ecb964b2fb1099756604bc125","type":"TRIAL","name":"Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT01245387","description":"Macular Degeneration; Age-related Macular Degeneration; Neovascular Macular Degeneration","metadata":null},{"id":"7a5c17c48bd247d0be783a7d806f055f","type":"TRIAL","name":"Observational Study for Melanoma Adjuvant Treatment With Tafinlar\u00ae + Mekinist\u00ae (Dabrafenib + Trametinib)","canonical_id":"clinicaltrials.gov:NCT04547946","description":"Malignant Melanoma","metadata":null},{"id":"46b9b7f5a0084d6296c2d1f664cec1a1","type":"TRIAL","name":"Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies","canonical_id":"clinicaltrials.gov:NCT01451879","description":"Pompe Disease","metadata":null},{"id":"a7d40592f2864656af4368c4d84b83ca","type":"TRIAL","name":"Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib","canonical_id":"clinicaltrials.gov:NCT01475110","description":"Chronic Myeloid Leukaemia","metadata":null},{"id":"05e088f1da5f4bbf81b72ed42b85c259","type":"TRIAL","name":"Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole","canonical_id":"clinicaltrials.gov:NCT02236728","description":"Parkinson Disease","metadata":null},{"id":"db9a1f5ccc14444a95b119c7e20b7a4e","type":"TRIAL","name":"Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)","canonical_id":"clinicaltrials.gov:NCT00246194","description":"Schizophrenia","metadata":null},{"id":"c595c043c49543d6aba9446903e47cc2","type":"TRIAL","name":"Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom","canonical_id":"clinicaltrials.gov:NCT05557695","description":"Chronic Lymphocytic Leukemia, CLL","metadata":null},{"id":"a8485309eb5e4da1ab7554d496d1efd2","type":"TRIAL","name":"Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)","canonical_id":"clinicaltrials.gov:NCT00857506","description":"Alzheimer's Disease; Mild Cognitive Impairment","metadata":null},{"id":"0d5e3c7a74204fc7a44ca88cd6ba893d","type":"TRIAL","name":"Observational Study of Golimumab Intravenous Infusion","canonical_id":"clinicaltrials.gov:NCT02390700","description":"Rheumatoid Arthritis","metadata":null},{"id":"e6e133a5946c44e9bd87050ff699c91c","type":"TRIAL","name":"Observational Study of Lumigan\u00ae 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","canonical_id":"clinicaltrials.gov:NCT01568008","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"0e25f555f0794e1f8e26b74ee3f9bcb6","type":"TRIAL","name":"Observational Study of Meloxicam in Any Labeled Indication","canonical_id":"clinicaltrials.gov:NCT02182739","description":"Arthritis, Rheumatoid","metadata":null},{"id":"4f331ca8828940b6b423872570705a24","type":"TRIAL","name":"Observational Study of NovoNorm\u00ae in Subjects With Diabetes","canonical_id":"clinicaltrials.gov:NCT01498913","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"cd4eebe181d24d70b71c1ac3210ba9f3","type":"TRIAL","name":"Observational Study of Patients Receiving Dupixent\u00ae for Atopic Dermatitis (AD)","canonical_id":"clinicaltrials.gov:NCT03992417","description":"Dermatitis Atopic","metadata":null},{"id":"9b949daa5eb248c0bb46ca99e94655e5","type":"TRIAL","name":"Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT04361305","description":"Premature Ejaculation; Erectile Dysfunction","metadata":null},{"id":"b99b0a566f5c4033a4d91b69027e59c7","type":"TRIAL","name":"Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice","canonical_id":"clinicaltrials.gov:NCT04203693","description":"Plaque Psoriasis","metadata":null},{"id":"df8ee552c7a5414db72128293fa549fa","type":"TRIAL","name":"Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.","canonical_id":"clinicaltrials.gov:NCT04633967","description":"Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis","metadata":null},{"id":"4c4289a034fc413f91025c37c737dacc","type":"TRIAL","name":"Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT02271204","description":"Osteoporosis","metadata":null},{"id":"17f5020313ee4965a89d98a61c9c11b0","type":"TRIAL","name":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","canonical_id":"clinicaltrials.gov:NCT06724159","description":"Genitourinary Cancers","metadata":null},{"id":"fcdc257b98514cf382324586846a0da0","type":"TRIAL","name":"Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00709917","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"219364454385413593654afe8a8f672c","type":"TRIAL","name":"Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01288326","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"46e87bb0bcc244b09a6983c389b962c3","type":"TRIAL","name":"Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy","canonical_id":"clinicaltrials.gov:NCT06948396","description":"Asthma","metadata":null},{"id":"38ee6b8d12804f06bb89f2aafba37fb0","type":"TRIAL","name":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","canonical_id":"clinicaltrials.gov:NCT04312503","description":"Schizophrenia","metadata":null},{"id":"5d181ead27df46a09371df965178331e","type":"TRIAL","name":"Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly","canonical_id":"clinicaltrials.gov:NCT04803513","description":"Migraine","metadata":null},{"id":"f6860503a97b40e89edd4878e238eb1e","type":"TRIAL","name":"Observational Study on the Use of Akynzeo\u00ae in Patients Receiving HEC","canonical_id":"clinicaltrials.gov:NCT03649230","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"a208c5db1d8e424898ff31bc600cd4db","type":"TRIAL","name":"Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant","canonical_id":"clinicaltrials.gov:NCT05046613","description":"Migraine","metadata":null},{"id":"4d3b2730a7b14b888612649c61d4271f","type":"TRIAL","name":"Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge\u00ae) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)","canonical_id":"clinicaltrials.gov:NCT02674009","description":"Carcinoma, Basal Cell","metadata":null},{"id":"ffb84551c712425ca06baf58535873e6","type":"TRIAL","name":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT04543331","description":"Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME)","metadata":null},{"id":"9260c81c69d24d379f72002ac8bc4f5b","type":"TRIAL","name":"Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal","canonical_id":"clinicaltrials.gov:NCT04764656","description":"Neovascular Age-related Macular Degeneration (nAMD)","metadata":null},{"id":"a17820dcd4d943dc8081e7e801f9103a","type":"TRIAL","name":"Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT02798107","description":"Hemorrhage","metadata":null},{"id":"ba7be77636a24f969f7ae82084592e3f","type":"TRIAL","name":"Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01945762","description":"Symptomatic, Aggressive, Sporadic, Unresectable, Locally; Advanced/Metastatic Medullary Thyroid Cancer (MTC)","metadata":null},{"id":"2e7658e9f83a4da9a4bdabe5e0723752","type":"TRIAL","name":"Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02474563","description":"Multiple Myeloma","metadata":null},{"id":"50c4ea5d9744470ab5229a6cfbab010f","type":"TRIAL","name":"Observational Study to Evaluate the Efficacy and Safety of Teneligliptin","canonical_id":"clinicaltrials.gov:NCT03793023","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"54969580f7294b0a9860c6e8d81e218c","type":"TRIAL","name":"Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months","canonical_id":"clinicaltrials.gov:NCT01076621","description":"Menopause; Postmenopausal Bleeding","metadata":null},{"id":"0dd2bff5f7684148b223656f7530f610","type":"TRIAL","name":"Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04348448","description":"COVID-19","metadata":null},{"id":"7c482fb635da4c3ebc49125712b0e811","type":"TRIAL","name":"Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT","canonical_id":"clinicaltrials.gov:NCT07003256","description":"Thalassemia in Children","metadata":null},{"id":"62767fdcb41841d681c64b06a37f0580","type":"TRIAL","name":"Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL","canonical_id":"clinicaltrials.gov:NCT04342117","description":"Lymphoma, Small Lymphocytic; Lymphoma; Lymphoma, Non-Hodgkin; Chronic Lymphocytic Leukemia; Follicular Lymphoma","metadata":null},{"id":"59dc17b076564740ac4e1aae4f5c9d1e","type":"TRIAL","name":"Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients","canonical_id":"clinicaltrials.gov:NCT02333383","description":"Ankylosing Spondylitis","metadata":null},{"id":"121717fad71540f4948498adbc676c3f","type":"TRIAL","name":"Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients","canonical_id":"clinicaltrials.gov:NCT01431924","description":"Asthma","metadata":null},{"id":"616a3bf3532246acaf675de541a4b256","type":"DISEASE","name":"Obsessive-compulsive disorder","canonical_id":"mesh:D009771","description":null,"metadata":null},{"id":"e17a5ceb13474cd8831815d2e317f03f","type":"TRIAL","name":"Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT02699138","description":"Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders","metadata":null},{"id":"7d4e584aa4c5428db552b67eead4415f","type":"DISEASE","name":"Obstructive azoospermia","canonical_id":"hp:0011962","description":null,"metadata":null},{"id":"9b1b6f2c38ca4dcf9e5a2d428ea9003f","type":"TRIAL","name":"Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection","canonical_id":"clinicaltrials.gov:NCT05127980","description":"Epstein-Barr Virus (EBV) Infection","metadata":null},{"id":"3a09d43a7ce14aa5815da8dd902e064c","type":"DRUG","name":"Ocrelizumab","canonical_id":"mesh:C533411","description":null,"metadata":null},{"id":"7f2114788dea49b884e3645f5bbddafe","type":"TRIAL","name":"Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03025269","description":"Multiple Sclerosis","metadata":null},{"id":"42d41e4be4d84d00aad3e08a7b37015f","type":"TRIAL","name":"Ocrelizumab Effects on the Metabolome in MS","canonical_id":"clinicaltrials.gov:NCT03873389","description":"Multiple Sclerosis","metadata":null},{"id":"f4ba6ebd264149cc8644807154fe61bf","type":"TRIAL","name":"Ocrelizumab for Psychosis by Autoimmunity","canonical_id":"clinicaltrials.gov:NCT03971487","description":"Schizo-Affective Type of Psychosis; Schizophrenia","metadata":null},{"id":"0d73ce0cbc824f228f40b719dea57581","type":"TRIAL","name":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","canonical_id":"clinicaltrials.gov:NCT04971005","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"8cbeb8ebb105405999dd62349f8d4049","type":"DRUG","name":"Octreotide","canonical_id":"mesh:D015282","description":null,"metadata":null},{"id":"b067585c2b5b4b12af61027590d25016","type":"DISEASE","name":"Ocular Hypertension","canonical_id":"mesh:D009798","description":null,"metadata":null},{"id":"2709f0d93bd049e4acc293f3811d545d","type":"TRIAL","name":"Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra","canonical_id":"clinicaltrials.gov:NCT04120987","description":"Dry Eye","metadata":null},{"id":"5182a72711ed466297bdea4208d0e9c3","type":"TRIAL","name":"Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy","canonical_id":"clinicaltrials.gov:NCT03747614","description":"Dry Eye Syndromes; Inflammation; Microvessels","metadata":null},{"id":"56eea2b3d58241c88a90dce601018a8e","type":"TRIAL","name":"Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops","canonical_id":"clinicaltrials.gov:NCT00596791","description":"Ocular Hypertension; Open-Angle Glaucoma","metadata":null},{"id":"231db31891b54c06ae305ff13b87bbd2","type":"TRIAL","name":"Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops","canonical_id":"clinicaltrials.gov:NCT01087671","description":"Ocular Hypertension; Open-Angle Glaucoma","metadata":null},{"id":"2109de7765f94782958eeacd6c0c84c0","type":"TRIAL","name":"Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis\u00ae in Subjects With Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT03597139","description":"Dry Eye","metadata":null},{"id":"26e51e5575c54546a2556dbaac9761e8","type":"DISEASE","name":"Ocular pain","canonical_id":"hp:0200026","description":null,"metadata":null},{"id":"55abd15100f24d3abdf634c185364a6d","type":"TRIAL","name":"Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery","canonical_id":"clinicaltrials.gov:NCT02816905","description":"Intraocular Pressure","metadata":null},{"id":"30bce334ba4b49b8b2cf9921924f4798","type":"DRUG","name":"Ofatumumab","canonical_id":"mesh:C527517","description":null,"metadata":null},{"id":"f53c6541bcf4456dab8096ab0c05413d","type":"TRIAL","name":"Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation","canonical_id":"clinicaltrials.gov:NCT01809847","description":"Chronic Lymphatic Leukemia","metadata":null},{"id":"c691e79339544f4c8ce284a999df434b","type":"TRIAL","name":"Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)","canonical_id":"clinicaltrials.gov:NCT01520922","description":"Chronic Lymphocytic Leukemia (CLL); Leukaemia, Lymphocytic, Chronic","metadata":null},{"id":"17a1ce1127344b5080bbc6a735f60ff2","type":"TRIAL","name":"Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01457924","description":"Multiple Sclerosis","metadata":null},{"id":"01ad047baeaa449da5bc2e06a47d2f5b","type":"TRIAL","name":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01286272","description":"Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma","metadata":null},{"id":"df66d8aa83b342819f3f42dc82641072","type":"TRIAL","name":"Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT01010568","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"b88a7f33782045ef993247ef81a03470","type":"TRIAL","name":"Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01397591","description":"Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma","metadata":null},{"id":"8c333f1c3fcf44a8832e037db2404f6a","type":"TRIAL","name":"Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT01680965","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"f2993b4cfe0f4056b4f6e550c04fb434","type":"TRIAL","name":"Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT01113632","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"28d4da32c0764aa590402c76c941b273","type":"TRIAL","name":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01527149","description":"Stage I Mantle Cell Lymphoma; Stage II Contiguous Mantle Cell Lymphoma; Stage II Non-Contiguous Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma","metadata":null},{"id":"2ac0984a99ce4f0fa4fabdbe600105c5","type":"TRIAL","name":"Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00742144","description":"Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular","metadata":null},{"id":"138f44ef43a747a680f07d3a6ed98644","type":"TRIAL","name":"Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study","canonical_id":"clinicaltrials.gov:NCT05809986","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"206dc839bfbc4f519507f2a50b8c4a89","type":"TRIAL","name":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","canonical_id":"clinicaltrials.gov:NCT01496976","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"508f74b9d1534bd2a181ccf547cdde42","type":"TRIAL","name":"Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT01024010","description":"Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma","metadata":null},{"id":"82c2a9a61b6b4467ace9fb458e4ac485","type":"TRIAL","name":"Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy","canonical_id":"clinicaltrials.gov:NCT00344617","description":"Choroidal Neovascularisation; Polypoidal Choroidal Vasculopathy","metadata":null},{"id":"b9f289a43c834da09b9597da3d122957","type":"TRIAL","name":"Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.","canonical_id":"clinicaltrials.gov:NCT06323824","description":"Opioid Use Disorder","metadata":null},{"id":"f6e48542cd3748fd86c9725566bf506f","type":"GO_TERM","name":"Okazaki fragment processing involved in mitotic DNA replication","canonical_id":"go:GO:1903461","description":"\"Any DNA replication, Okazaki fragment processing that is involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"509a856c67864f67bdee8562c778fd1f","type":"DISEASE","name":"Okt4 epitope deficiency","canonical_id":"mondo:0013497","description":null,"metadata":null},{"id":"e4b376228ee943ceb6a8cc63dba3abed","type":"TRIAL","name":"OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients","canonical_id":"clinicaltrials.gov:NCT03698227","description":"Advanced Soft Tissue Sarcoma","metadata":null},{"id":"56098f4d29de44309bb7ceb3d9a93bad","type":"DRUG","name":"Olanzapine","canonical_id":"mesh:D000077152","description":null,"metadata":null},{"id":"f6fb34ee95414bf3a5c937b30b4390eb","type":"TRIAL","name":"Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00034801","description":"Depression; Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"abc972f51a594cf4b8a4e5aeee2ff6d7","type":"TRIAL","name":"Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00179231","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"594b7e244bc041adabdb7ecfa4be6381","type":"TRIAL","name":"Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients","canonical_id":"clinicaltrials.gov:NCT04939090","description":"Advanced Malignant Solid Neoplasm; Anorexia; Hematopoietic and Lymphoid Cell Neoplasm","metadata":null},{"id":"3a76f0eeb40b4543afdd1ef8aeb5e597","type":"TRIAL","name":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03578081","description":"Malignant Neoplasm","metadata":null},{"id":"e1effb0fe7d04e3bb5d664e9a9b72b05","type":"TRIAL","name":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03079219","description":"Breast Cancer","metadata":null},{"id":"b0d48a36dc464602af781ddb060b531a","type":"TRIAL","name":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT05403580","description":"Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm","metadata":null},{"id":"fa9c3356bce34dc2998d5ca92c23e4ec","type":"DRUG","name":"Olaparib","canonical_id":"mesh:C531550","description":null,"metadata":null},{"id":"52384a6e820349cf8454d691cdd7569e","type":"DRUG","name":"Olaparib","canonical_id":"ncit:C71721","description":null,"metadata":null},{"id":"a55572309b89457f87ab1d579fdedfcf","type":"TRIAL","name":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","canonical_id":"clinicaltrials.gov:NCT01844986","description":"Newly Diagnosed; Advanced Ovarian Cancer; FIGO Stage III-IV; BRCA Mutation; Complete Response; Partial Response; First Line Platinum Chemotherapy","metadata":null},{"id":"154f685b8f22462980bbb04f8dcb39df","type":"TRIAL","name":"Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03534453","description":"Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive","metadata":null},{"id":"c3da46ecc8c24ac5bcc83a4cbeb8eead","type":"TRIAL","name":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04090567","description":"Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage I\u2026","metadata":null},{"id":"3d2b8f74e7cf433a9a029d0866a781aa","type":"TRIAL","name":"Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial","canonical_id":"clinicaltrials.gov:NCT05967286","description":"Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma","metadata":null},{"id":"401e7d2802dd4b73a2fc6741ef195ca0","type":"TRIAL","name":"Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma","canonical_id":"clinicaltrials.gov:NCT01390571","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"61d0fbf0f7774467918c3d3ecbacce61","type":"TRIAL","name":"Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04951492","description":"Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma","metadata":null},{"id":"f5f3ee38391142ce819f322df93c6d07","type":"TRIAL","name":"Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery","canonical_id":"clinicaltrials.gov:NCT03943173","description":"BRCA-Mutated Ovarian Carcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC\u2026","metadata":null},{"id":"a9cee61c1cc24d47ac7f7cddeba3cc6e","type":"TRIAL","name":"Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT03994627","description":"Soft Tissue Sarcoma","metadata":null},{"id":"7704f3b56cb348abab4ef8803624a24a","type":"TRIAL","name":"Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients","canonical_id":"clinicaltrials.gov:NCT03985722","description":"Sarcoma, Soft Tissue","metadata":null},{"id":"ba697ad78ece4a73bdcf4dcbe598c516","type":"DISEASE","name":"Ollier disease","canonical_id":"mondo:0008145","description":null,"metadata":null},{"id":"6c7d8ae8e7fd446fa97446a268a31e2f","type":"TRIAL","name":"Olmesartan Comparison to Losartan in Hypertensive Subjects","canonical_id":"clinicaltrials.gov:NCT00949884","description":"Hypertension","metadata":null},{"id":"2b97c274c1f94c98bb12f79c43c46956","type":"DRUG","name":"Olmesartan Medoxomil","canonical_id":"mesh:D000068557","description":null,"metadata":null},{"id":"63714e9fdd92403c83f044b9b61e4d77","type":"TRIAL","name":"Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00856271","description":"Essential Hypertension","metadata":null},{"id":"72f2f04959b9495cab4f1b5a3ff4055f","type":"TRIAL","name":"Olmesartan Medoxomil in Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00185185","description":"Essential Hypertension; Atherosclerotic Cardiovascular Disease","metadata":null},{"id":"78f3bb64acc04ce8941762975acefd28","type":"TRIAL","name":"Olmesartan Medoxomil in Hypertension and Renal Impairment","canonical_id":"clinicaltrials.gov:NCT00151827","description":"Essential Hypertension; Renal Impairment","metadata":null},{"id":"7029c9fb1106498b8b299dd835409eb0","type":"TRIAL","name":"Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00311155","description":"Essential Hypertension","metadata":null},{"id":"2b9ce96ba97b40dfb176128415d623fd","type":"TRIAL","name":"Olmesartan as an add-on to Amlodipine in Hypertension","canonical_id":"clinicaltrials.gov:NCT00220233","description":"Essential Hypertension","metadata":null},{"id":"b991f608863b4060b7d0ff526b9d6983","type":"TRIAL","name":"Olmesartan on Ambulatory Blood Pressure Change","canonical_id":"clinicaltrials.gov:NCT00854763","description":"Hypertension","metadata":null},{"id":"835aab27488c4d9abd2fbdca939b6860","type":"TRIAL","name":"Olodaterol Bridging Study in Asthma","canonical_id":"clinicaltrials.gov:NCT01428622","description":"Asthma","metadata":null},{"id":"dbccf05f63e541749818607180c44eaa","type":"DRUG","name":"Olopatadine","canonical_id":"mesh:D000069605","description":null,"metadata":null},{"id":"7295680c90424bee9e39ccf6d3e79fca","type":"TRIAL","name":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01745133","description":"Psoriasis","metadata":null},{"id":"c1544bb6463145ecbaf88643de4aac08","type":"TRIAL","name":"Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions","canonical_id":"clinicaltrials.gov:NCT02968394","description":"Allergy; Bee Venom; Immunotherapy; Omalizumab","metadata":null},{"id":"b9f89d5050f348cf82bfbd19da719f32","type":"TRIAL","name":"Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma","canonical_id":"clinicaltrials.gov:NCT00567476","description":"Asthma","metadata":null},{"id":"3cdff27d199046aa85ce502ef5153f61","type":"TRIAL","name":"Omalizumab Weight-Based Dosing Efficacy Trial","canonical_id":"clinicaltrials.gov:NCT06943534","description":"Allergies; Food Allergy","metadata":null},{"id":"23980991d2de43f7a05e5fb006f9e66d","type":"TRIAL","name":"Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants","canonical_id":"clinicaltrials.gov:NCT03881696","description":"Peanut Allergy; Multi-food Allergy","metadata":null},{"id":"b73d5217fc10480da92bfc71a00b4764","type":"TRIAL","name":"Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome","canonical_id":"clinicaltrials.gov:NCT01294878","description":"Interstitial Cystitis; Painful Bladder Syndrome","metadata":null},{"id":"be2f2a739a6c4d6ab9024c5801df9aac","type":"TRIAL","name":"Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","canonical_id":"clinicaltrials.gov:NCT01202903","description":"Persistent Allergic Asthma","metadata":null},{"id":"e1cd22c65ca14b2387bfc06edfe9af2a","type":"TRIAL","name":"Omalizumab in the Treatment of Peanut Allergy","canonical_id":"clinicaltrials.gov:NCT00949078","description":"Food Allergy; Peanut Allergy","metadata":null},{"id":"521c67e4f6794470be9f63ae24f7f871","type":"TRIAL","name":"Omega 3 FA Supplements as Augmentation in the Treatment of Depression","canonical_id":"clinicaltrials.gov:NCT01803711","description":"Major Depression; Cancer; Diabetes; Cardiovascular Diseases","metadata":null},{"id":"0d7c5fe9464a405f82c79f16dd25db1b","type":"TRIAL","name":"Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C","canonical_id":"clinicaltrials.gov:NCT00097045","description":"Hepatitis C","metadata":null},{"id":"bed89c5317a44f979775b50a8b36c278","type":"DISEASE","name":"Omenn syndrome","canonical_id":"mondo:0011338","description":null,"metadata":null},{"id":"7e2b9ea961904ee58bbb9f1a2d3fc1ec","type":"DRUG","name":"Omeprazole","canonical_id":"mesh:D009853","description":null,"metadata":null},{"id":"283976b8712b428599651dcf59f53e47","type":"TRIAL","name":"Omnaris Versus Levocetirizine Phase 4 Study","canonical_id":"clinicaltrials.gov:NCT01430260","description":"Allergic Rhinitis","metadata":null},{"id":"63e23eda7e8a45d5bfa479fe99ea1300","type":"TRIAL","name":"On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility","canonical_id":"clinicaltrials.gov:NCT03354117","description":"Contraception","metadata":null},{"id":"ba2c04ffb0a649e9bc94d03ca66b9dd8","type":"TRIAL","name":"On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT07081659","description":"Premature (Early) Ejaculation","metadata":null},{"id":"51ef4d017c5a4fb780065f16220b7ba1","type":"TRIAL","name":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","canonical_id":"clinicaltrials.gov:NCT01050114","description":"Overactive Bladder","metadata":null},{"id":"48f2f26e876a4c878b7de4fee4bbd4cf","type":"TRIAL","name":"Once Daily Given Alfuzosin in the Treatment of BPH","canonical_id":"clinicaltrials.gov:NCT00637715","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"292c2431371b4ec486278e2ae14dc457","type":"TRIAL","name":"Once-Daily Asenapine for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01549041","description":"Schizophrenia","metadata":null},{"id":"11b44f7da5f0471c8ab266b6c8a0daec","type":"TRIAL","name":"Once-daily Fixed Combination of Three Antihypertensive Drugs","canonical_id":"clinicaltrials.gov:NCT02710539","description":"Arterial Hypertension","metadata":null},{"id":"6fdaeb90057740e2b3ccc7a4ffcae848","type":"TRIAL","name":"Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT06876116","description":"Dry Eye Disease (DED)","metadata":null},{"id":"2211b229248c4b9cb48e656f3f2df521","type":"DISEASE","name":"Onchocerciasis","canonical_id":"mesh:D009855","description":null,"metadata":null},{"id":"fb85cb8b50f74694a8608f9ef47b28a4","type":"PROTEIN","name":"Oncogene Proteins, Fusion","canonical_id":"uniprot:D015514","description":null,"metadata":null},{"id":"a6659438dc2849388f739c3291545472","type":"TRIAL","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","canonical_id":"clinicaltrials.gov:NCT05271318","description":"Platinum-refractory Ovarian Carcinoma; Platinum-resistant Ovarian Cancer; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Car\u2026","metadata":null},{"id":"fd88e974e50e4568b67d2bec7570b356","type":"TRIAL","name":"Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites","canonical_id":"clinicaltrials.gov:NCT05303844","description":"Refractory Malignant Ascites","metadata":null},{"id":"48a77bce8c14448698ba05973c440605","type":"TRIAL","name":"Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02376413","description":"Local Recurrence of Malignant Tumor of Breast","metadata":null},{"id":"c5b51400d65d449aa2b39da511e0baa2","type":"TRIAL","name":"Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00934921","description":"Healthy","metadata":null},{"id":"e6515762bcf0484480efbca71a972694","type":"TRIAL","name":"Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen","canonical_id":"clinicaltrials.gov:NCT00016380","description":"Cancer","metadata":null},{"id":"e60d925ebf234e04a07e7302a76b080f","type":"TRIAL","name":"Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT00590317","description":"Nausea and Vomiting","metadata":null},{"id":"d4fef409e9504c3a941d43063f1ffc45","type":"TRIAL","name":"One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China","canonical_id":"clinicaltrials.gov:NCT04851457","description":"Ischemic Stroke","metadata":null},{"id":"ce58d30f94f14b1b96369a9cb6cb0754","type":"TRIAL","name":"One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease","canonical_id":"clinicaltrials.gov:NCT04148820","description":"Ischemic Heart Disease","metadata":null},{"id":"369b3a7914144108bd9dd2a36dfda58c","type":"TRIAL","name":"One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00748566","description":"Schizophrenia and Disorders With Psychotic Features","metadata":null},{"id":"9c9c5bcb39f643048d065508f39b89af","type":"TRIAL","name":"One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT01113541","description":"Bipolar Disorder","metadata":null},{"id":"6be91ede39c543419d25f0ef2fb897f4","type":"TRIAL","name":"Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's","canonical_id":"clinicaltrials.gov:NCT00363727","description":"Parkinson's Disease; Parkinson Disease; Dyskinesias","metadata":null},{"id":"6dd1c400efa3488bb7b6fa4cf39c4228","type":"TRIAL","name":"Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)","canonical_id":"clinicaltrials.gov:NCT03861559","description":"Rhinitis, Allergic, Seasonal","metadata":null},{"id":"56287080414b418290bf4e98616df403","type":"DISEASE","name":"Onychomycosis due to dermatophyte","canonical_id":"mesh:D014009","description":null,"metadata":null},{"id":"697d89b7e6c04777bb48694e2fcd1067","type":"TRIAL","name":"Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01279629","description":"Plaque Psoriasis","metadata":null},{"id":"2f86e8c71bf1418c8babc9972e84d60c","type":"TRIAL","name":"Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study","canonical_id":"clinicaltrials.gov:NCT00878943","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"71eea8367b5c499f98eb411376982000","type":"TRIAL","name":"Open Label Arimidex in Gynecomastia","canonical_id":"clinicaltrials.gov:NCT00241436","description":"Gynecomastia","metadata":null},{"id":"a4a2320507e248c98e99da89c967c55a","type":"TRIAL","name":"Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS","canonical_id":"clinicaltrials.gov:NCT00844844","description":"Atypical Hemolytic Uremic Syndrome","metadata":null},{"id":"d2911b663e254e62823059b3bc5373cd","type":"TRIAL","name":"Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS","canonical_id":"clinicaltrials.gov:NCT00844428","description":"Atypical Hemolytic Uremic Syndrome","metadata":null},{"id":"a98849833b314be590c2a3218acb38c7","type":"TRIAL","name":"Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)","canonical_id":"clinicaltrials.gov:NCT00838513","description":"Atypical Hemolytic Uremic Syndrome","metadata":null},{"id":"d5524205b26a4b36be528fb263eb068a","type":"TRIAL","name":"Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT01721993","description":"Healthy Postmenopausal Women","metadata":null},{"id":"d9e6f455c2e64fc38d29103386ecb2e2","type":"TRIAL","name":"Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01188668","description":"Pharmacokinetics; Cytochrome P-450 CYP2D6; CYP3A4 Protein, Human","metadata":null},{"id":"7f8c40fc2c8446c1aed4055ba08e2b00","type":"TRIAL","name":"Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443","canonical_id":"clinicaltrials.gov:NCT00631475","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"37b7540b7bb34b1fad1a44b0b74cb4d1","type":"TRIAL","name":"Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus","canonical_id":"clinicaltrials.gov:NCT02143973","description":"Uremic Pruritus; Pruritus","metadata":null},{"id":"32958ea84214453f8e1b9f0902ad3bc4","type":"TRIAL","name":"Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","canonical_id":"clinicaltrials.gov:NCT00116688","description":"Thrombocytopenia; Idiopathic Thrombocytopenic Purpura","metadata":null},{"id":"77fa622eaa5647f1a452307214192ff3","type":"TRIAL","name":"Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00754221","description":"Fibromyalgia","metadata":null},{"id":"61d9707ed91147f3b2a09ec116963990","type":"TRIAL","name":"Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.","canonical_id":"clinicaltrials.gov:NCT01235221","description":"Multiple Sclerosis","metadata":null},{"id":"f3e2fa80305645508bf0d69872fb11dd","type":"TRIAL","name":"Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00260793","description":"Parkinson's Disease","metadata":null},{"id":"d0bff48499e848cdb96f18885cee97a8","type":"TRIAL","name":"Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00160693","description":"Rheumatoid Arthritis","metadata":null},{"id":"7ad02a8057ae41699aca111e9c8b9063","type":"TRIAL","name":"Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.","canonical_id":"clinicaltrials.gov:NCT01663714","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"37229acbb0b5466da48a3c5840c6c852","type":"TRIAL","name":"Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00280956","description":"Crohn's Disease","metadata":null},{"id":"b4ad282c33a44b3aa4af5d72ad64d2b0","type":"TRIAL","name":"Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT06056570","description":"Gout; Hyperuricemia","metadata":null},{"id":"5e4567ff84624e7186f75a2a957baa8f","type":"TRIAL","name":"Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1","canonical_id":"clinicaltrials.gov:NCT02054299","description":"Drug Metabolism; Membrane Transport","metadata":null},{"id":"bd032c697a8c4637923ace33989e3927","type":"TRIAL","name":"Open Label Pilot Study of Apremilast in Treatment of Rosacea","canonical_id":"clinicaltrials.gov:NCT01045551","description":"Erythematotelangiectatic Rosacea; Papulopustular Rosacea","metadata":null},{"id":"16bfeadfc48e4b5088f01e1872a5e72c","type":"TRIAL","name":"Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB","canonical_id":"clinicaltrials.gov:NCT05212597","description":"Aortic Valve Insufficiency","metadata":null},{"id":"80c323de78914ab0b6162be0e1342927","type":"TRIAL","name":"Open Label Safety Study in Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT03266588","description":"Migraine, With or Without Aura","metadata":null},{"id":"aa29772e772a499d9b24013ecfa2c763","type":"TRIAL","name":"Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy","canonical_id":"clinicaltrials.gov:NCT00160628","description":"Epilepsy, Partial","metadata":null},{"id":"3139891d8e93490f978621c79830847e","type":"TRIAL","name":"Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia","canonical_id":"clinicaltrials.gov:NCT00330785","description":"Hypertension; Dyslipidemia","metadata":null},{"id":"bc30d185cfda47bd8da3dbb901b98f82","type":"TRIAL","name":"Open Label Study in Adolescents and Children With Myotonic Disorders","canonical_id":"clinicaltrials.gov:NCT04624750","description":"Myotonic Dystrophy","metadata":null},{"id":"4ecf323dc80a4b5cbe771a4225b2ae69","type":"TRIAL","name":"Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT00678470","description":"Moderate to Severe Psoriasis","metadata":null},{"id":"e764ca097bf448ed8055c0c5387ba731","type":"TRIAL","name":"Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)","canonical_id":"clinicaltrials.gov:NCT02537431","description":"X-linked Hypophosphatemia","metadata":null},{"id":"a5a3e07fb1ec4e4da4dd58d7adf0be64","type":"TRIAL","name":"Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting","canonical_id":"clinicaltrials.gov:NCT00509990","description":"Atopic Dermatitis","metadata":null},{"id":"f0393828625e44bcb1820e8b2a772683","type":"TRIAL","name":"Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.","canonical_id":"clinicaltrials.gov:NCT00500539","description":"Asthma","metadata":null},{"id":"996d5de16d0840579d0b6d828a62992b","type":"TRIAL","name":"Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ\u2122)","canonical_id":"clinicaltrials.gov:NCT02130999","description":"Non-24-Hour-Sleep-Wake Disorder","metadata":null},{"id":"1cd7679b6bd64cd79d799b015e62bc15","type":"TRIAL","name":"Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea","canonical_id":"clinicaltrials.gov:NCT03079531","description":"Papulopustular Rosacea","metadata":null},{"id":"0a689fd9d4e944edab65319dd14275ea","type":"TRIAL","name":"Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01443364","description":"Rheumatoid Arthritis","metadata":null},{"id":"cb5473bff00c43b29fdb9687bb5da74f","type":"TRIAL","name":"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus","canonical_id":"clinicaltrials.gov:NCT04355052","description":"COVID - 19","metadata":null},{"id":"44060952f90845569bcd186b036c9620","type":"TRIAL","name":"Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT07362017","description":"Moderate-to-severe Chronic Plaque Psoriasis","metadata":null},{"id":"da5908914e1a45f2b337f1703f281c20","type":"TRIAL","name":"Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01124760","description":"Pharmacokinetics","metadata":null},{"id":"5633e4fe2740435682698873923db1be","type":"TRIAL","name":"Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen","canonical_id":"clinicaltrials.gov:NCT01352611","description":"Autism Spectrum Disorder","metadata":null},{"id":"40fa31b054234646863b41d3b0d62efd","type":"TRIAL","name":"Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets","canonical_id":"clinicaltrials.gov:NCT03581591","description":"Hypophosphatemia; Hypophosphatemic Rickets; Pain, Chronic","metadata":null},{"id":"3c6d942add3843db88b1162a3d7ee847","type":"TRIAL","name":"Open Label Trial Studying the Safety and Effectiveness of ILUVIEN\u00ae (190\u03bcg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.","canonical_id":"clinicaltrials.gov:NCT06539481","description":"Non-infectious Uveitis Affecting the Posterior Segment of the Eye","metadata":null},{"id":"13e20ce08d5942eaaa1a9f83661775ad","type":"TRIAL","name":"Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients","canonical_id":"clinicaltrials.gov:NCT01858961","description":"Hepatitis C, Chronic","metadata":null},{"id":"a9aeee64c98442389b65ca099f08ae1a","type":"TRIAL","name":"Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment","canonical_id":"clinicaltrials.gov:NCT00213109","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"f6a75fdc1f1e451695a3484009ce5f27","type":"TRIAL","name":"Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide","canonical_id":"clinicaltrials.gov:NCT00334503","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a53ed64dfae24746be061b6cd3495836","type":"TRIAL","name":"Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT01419717","description":"Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer","metadata":null},{"id":"d18a254084f54b6e888f20a561f68ea7","type":"TRIAL","name":"Open-Label CA-008 (Vocacapsaicin) in Bunionectomy","canonical_id":"clinicaltrials.gov:NCT03885596","description":"Pain","metadata":null},{"id":"9521f743e20e47c9afe274de22e4820f","type":"TRIAL","name":"Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome","canonical_id":"clinicaltrials.gov:NCT00097370","description":"Hypereosinophilic Syndrome","metadata":null},{"id":"feb146e0dc7b4564ac20715ece655764","type":"TRIAL","name":"Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT00635089","description":"Eosinophilic Esophagitis","metadata":null},{"id":"eb341a858e0f4eadaeea9abec7ff47ca","type":"TRIAL","name":"Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097","canonical_id":"clinicaltrials.gov:NCT00310388","description":"Epilepsy","metadata":null},{"id":"8ad9ba28b76443818c4c22971476ca70","type":"TRIAL","name":"Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT01290887","description":"Eosinophilic Asthma","metadata":null},{"id":"36dfd163adfc43e9a8f3142405f2a112","type":"TRIAL","name":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","canonical_id":"clinicaltrials.gov:NCT00649792","description":"Multiple Sclerosis","metadata":null},{"id":"ac8e763bb0f84288813ebbcb1eb5a325","type":"TRIAL","name":"Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04286607","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"c03f84894ddc459db19eb646c65ba155","type":"TRIAL","name":"Open-Label Extension and Safety Study of Talazoparib","canonical_id":"clinicaltrials.gov:NCT02921919","description":"Cancer","metadata":null},{"id":"12d37d43342347799bcaee29a0dfdccf","type":"TRIAL","name":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","canonical_id":"clinicaltrials.gov:NCT01856257","description":"Primary Renal Allograft Candidate; Kidney Transplantation","metadata":null},{"id":"f6d57601424e4a2fb69e702b70dee468","type":"TRIAL","name":"Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT06326645","description":"Short Bowel Syndrome","metadata":null},{"id":"03ed4a1b29104558afc190f7bfe01e62","type":"TRIAL","name":"Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence","canonical_id":"clinicaltrials.gov:NCT01467999","description":"Cannabis Dependence","metadata":null},{"id":"a32d4493a17b402099afe13142d11852","type":"TRIAL","name":"Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease","canonical_id":"clinicaltrials.gov:NCT04400331","description":"Chorea, Huntington","metadata":null},{"id":"226398ef3c8442318004c2966065529f","type":"TRIAL","name":"Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT00116649","description":"Keratosis","metadata":null},{"id":"399194e703654ebfb07bb28b0ca0ee78","type":"TRIAL","name":"Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome","canonical_id":"clinicaltrials.gov:NCT03444038","description":"Tourette Syndrome","metadata":null},{"id":"11a96183c7994ae0a117009186b498f9","type":"TRIAL","name":"Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen","canonical_id":"clinicaltrials.gov:NCT00038103","description":"Breast Neoplasms","metadata":null},{"id":"8e4e9fbea110402c8b63335564fa6ddf","type":"TRIAL","name":"Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis","canonical_id":"clinicaltrials.gov:NCT04292223","description":"Parkinson Disease Psychosis","metadata":null},{"id":"d5838a43e1514d2e92c0b84d616bc92e","type":"TRIAL","name":"Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)","canonical_id":"clinicaltrials.gov:NCT05550207","description":"Migraine","metadata":null},{"id":"172c442f2bb446faa72e13ee23b2108d","type":"TRIAL","name":"Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression","canonical_id":"clinicaltrials.gov:NCT00237666","description":"Bipolar II Disorder; Major Depressive Episode","metadata":null},{"id":"5a650dba892845ddb44a96137ab631d6","type":"TRIAL","name":"Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT03452527","description":"Choroidal Neovascularization; Wet Macular Degeneration","metadata":null},{"id":"ef08c55cf97e47abbec08408c4198abb","type":"TRIAL","name":"Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)","canonical_id":"clinicaltrials.gov:NCT00930644","description":"Short Bowel Syndrome","metadata":null},{"id":"ed693392bb944291998f665e99d4dd81","type":"TRIAL","name":"Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT01118949","description":"Epilepsy","metadata":null},{"id":"3a8147a85e3d4f87a3507d1344b2057f","type":"TRIAL","name":"Open-Label Treatment Extension of Protocol MNTX 301","canonical_id":"clinicaltrials.gov:NCT01367600","description":"Terminal Illness","metadata":null},{"id":"d4944664bef94534959fd36650ade5ca","type":"TRIAL","name":"Open-Label Treatment Extension of Protocol MNTX 302","canonical_id":"clinicaltrials.gov:NCT01367613","description":"Terminal Illness","metadata":null},{"id":"b2ff6ba8a3d84d09862989b9ae6690e3","type":"TRIAL","name":"Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00191880","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"1abc081c331347c4a654f114fdef5c11","type":"TRIAL","name":"Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT00865579","description":"Parkinson's Disease","metadata":null},{"id":"2cea3e7582f14fa993bdabcd31fb0db0","type":"TRIAL","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05563220","description":"Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"06a52e5a9efc4909b3fe4cce052b1e21","type":"TRIAL","name":"Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07172412","description":"Extensive Stage Lung Small Cell Cancer","metadata":null},{"id":"90806d1a9bbb454286ca019037cc45a4","type":"TRIAL","name":"Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00723190","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"a1f41a9c1b914e7285a864cb699f9f69","type":"TRIAL","name":"Open-Label, Extension Study to 810P202","canonical_id":"clinicaltrials.gov:NCT01416064","description":"Impulsive Aggression Comorbid With ADHD in Children","metadata":null},{"id":"f1f18cabcfcd402898a2d6c60e5fdc7c","type":"TRIAL","name":"Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia","canonical_id":"clinicaltrials.gov:NCT07393373","description":"Hypochondroplasia","metadata":null},{"id":"b2cea69060e44254bccc13a94f0bafde","type":"TRIAL","name":"Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03010982","description":"Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma; Mantle-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Advanced Solid Tumors","metadata":null},{"id":"8bb77958a0ce4060906c3e75e2c731f3","type":"TRIAL","name":"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients","canonical_id":"clinicaltrials.gov:NCT03028103","description":"Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma; Mantle Cell Lymphoma; Advanced Solid Tumor; Marginal Zone Lymphoma","metadata":null},{"id":"bb1ccddd9cf447f6a006f9f3799f23cd","type":"TRIAL","name":"Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT05873205","description":"Blood Cancer; Refractory Immune Cytopenias","metadata":null},{"id":"015221167c11440982fc17dbe062f382","type":"TRIAL","name":"Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban","canonical_id":"clinicaltrials.gov:NCT03809481","description":"Heparin-induced Thrombocytopenia","metadata":null},{"id":"29369063f8c8427791501d9717927591","type":"TRIAL","name":"Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00376129","description":"Atopic Dermatitis","metadata":null},{"id":"777e2997a78d41cdba7540908d0308c9","type":"TRIAL","name":"Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.","canonical_id":"clinicaltrials.gov:NCT02283827","description":"Epilepsy","metadata":null},{"id":"4d4d17420fd44a3aac88cfb207dd7b17","type":"TRIAL","name":"Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.","canonical_id":"clinicaltrials.gov:NCT04622553","description":"Myotonic Disorders","metadata":null},{"id":"6f43d40408c24a3aaace57f35e260139","type":"TRIAL","name":"Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial","canonical_id":"clinicaltrials.gov:NCT00310375","description":"Epilepsy","metadata":null},{"id":"3e2a8bdf04af4ed5ad3c327eac9e059a","type":"TRIAL","name":"Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta","canonical_id":"clinicaltrials.gov:NCT03638128","description":"Osteogenesis Imperfecta (OI)","metadata":null},{"id":"23d32f627fd64a4cb07553a4e5e9f9c3","type":"TRIAL","name":"Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT01364597","description":"Epilepsy","metadata":null},{"id":"a9b561e67e4e47a5b2cef4da565fe311","type":"TRIAL","name":"Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials","canonical_id":"clinicaltrials.gov:NCT04949841","description":"Chronic Hand Eczema","metadata":null},{"id":"1d0d94807d284c71b33a54acf91be73c","type":"TRIAL","name":"Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02334501","description":"Healthy","metadata":null},{"id":"46181e7edb2c4291aa19367b3aa77c05","type":"TRIAL","name":"Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","canonical_id":"clinicaltrials.gov:NCT00694304","description":"Major Depressive Disorder","metadata":null},{"id":"53951a6bc27a4b158e8ab8e5095ad16f","type":"TRIAL","name":"Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD","canonical_id":"clinicaltrials.gov:NCT06997965","description":"Crohn Disease","metadata":null},{"id":"8ce5d076b09a46d19966a84764fb16f4","type":"TRIAL","name":"Open-label Study With Bosentan in Interstitial Lung Disease","canonical_id":"clinicaltrials.gov:NCT00319033","description":"Interstitial Lung Disease; Scleroderma","metadata":null},{"id":"5793a5fd598a42f08b9d4b6fc45ac171","type":"TRIAL","name":"Open-label Study of Anakinra in MPS III","canonical_id":"clinicaltrials.gov:NCT04018755","description":"Mucopolysaccharidosis III","metadata":null},{"id":"9c687aa3146541f190961a658fb1274e","type":"TRIAL","name":"Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy","canonical_id":"clinicaltrials.gov:NCT00535392","description":"Epilepsy","metadata":null},{"id":"95ac39d3235f4bf7a8181fa507f31d50","type":"TRIAL","name":"Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus","canonical_id":"clinicaltrials.gov:NCT03288324","description":"Cutaneous Lupus; Systemic Lupus Erythematosus","metadata":null},{"id":"b7974d7238ec47c2a3fb78d024d82199","type":"TRIAL","name":"Open-label Study of the Effects of Montelukast in Patients With Chronic Cough","canonical_id":"clinicaltrials.gov:NCT01754220","description":"Coughing","metadata":null},{"id":"8e9a5f60e2a9404c82508737a3c4d11f","type":"TRIAL","name":"Open-label Study of the Efficacy and Safety of VESIcare\u00ae in Patients With Overactive Bladder Symptoms","canonical_id":"clinicaltrials.gov:NCT00463541","description":"Urinary Bladder, Overactive","metadata":null},{"id":"7aa0ea4e3578416eb79a6715a95ea1cb","type":"TRIAL","name":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","canonical_id":"clinicaltrials.gov:NCT06473779","description":"Severe Asthma","metadata":null},{"id":"fcf287f1bb9745a0946280da652dc930","type":"TRIAL","name":"Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","canonical_id":"clinicaltrials.gov:NCT01509053","description":"Schizophrenia","metadata":null},{"id":"71822031bacd4f0b976e0eed8b9a29da","type":"TRIAL","name":"Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00692172","description":"Psoriasis","metadata":null},{"id":"66bcd9502bdd4ddaa88fce6d0ba18e91","type":"TRIAL","name":"Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures","canonical_id":"clinicaltrials.gov:NCT02192814","description":"Epilepsy; Partial-onset Seizures","metadata":null},{"id":"f9a285cef7274a48aaa06332cc477f54","type":"TRIAL","name":"Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion","canonical_id":"clinicaltrials.gov:NCT00925730","description":"Atopic Dermatitis","metadata":null},{"id":"5821623fda8f45c0a687c1345b21999e","type":"TRIAL","name":"Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT06319170","description":"Schizophrenia, Schizoaffective Disorder","metadata":null},{"id":"bfaa7e808d13407ba12707e5573ec259","type":"TRIAL","name":"Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare","canonical_id":"clinicaltrials.gov:NCT03910543","description":"Cutaneous Sarcoidosis; Granuloma Annulare","metadata":null},{"id":"b7ee8fa4d97045a1abc6c3e236d93e1f","type":"TRIAL","name":"Open-label Ziprasidone Study for Psychosis Treatment in Adolescents","canonical_id":"clinicaltrials.gov:NCT00421954","description":"Schizophreniform Disorder; Schizoaffective Disorder; Psychosis; Depressive Disorder, Major; Bipolar Disorder","metadata":null},{"id":"bd7854bd0a62459cbe1edbae6baab193","type":"TRIAL","name":"Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso","canonical_id":"clinicaltrials.gov:NCT03950739","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"07cf235740bc4dee9c3bf8462808aa41","type":"TRIAL","name":"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01683058","description":"Schizophrenia","metadata":null},{"id":"b84ed6b7d49b4249893e4b3b594b7b2d","type":"TRIAL","name":"Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India","canonical_id":"clinicaltrials.gov:NCT04288895","description":"Major Depressive Disorder","metadata":null},{"id":"053a12cd675d4f22ab4602cd66f6c9e7","type":"TRIAL","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","canonical_id":"clinicaltrials.gov:NCT05491525","description":"Neurogenic Detrusor Overactivity","metadata":null},{"id":"daee96eaeb7645769690da7e30d5af58","type":"TRIAL","name":"Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","canonical_id":"clinicaltrials.gov:NCT02605993","description":"Paroxysmal Nocturnal Hemoglobinuria; PNH","metadata":null},{"id":"54d562e7f78644648cec5c3ada2a864d","type":"TRIAL","name":"Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.","canonical_id":"clinicaltrials.gov:NCT00422422","description":"Epilepsy","metadata":null},{"id":"1168a728bbee46b0b89dc9f8dfdf5207","type":"TRIAL","name":"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02069093","description":"Advanced Breast Cancer","metadata":null},{"id":"f76b4de1a3994e1588f59e978ae6a803","type":"TRIAL","name":"Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers","canonical_id":"clinicaltrials.gov:NCT02045264","description":"Hereditary Angioedema (HAE)","metadata":null},{"id":"6fb0891548bf40c2b32010f85bcde5d5","type":"TRIAL","name":"Opening the \"Black Box\" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma","canonical_id":"clinicaltrials.gov:NCT06740045","description":"Asthma; Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"b1001c151f88448cacdb343f66d0204b","type":"DISEASE","name":"Ophthalmia, Sympathetic","canonical_id":"mesh:D009879","description":null,"metadata":null},{"id":"8e54527e37544fec9c0250acc5d5e908","type":"TRIAL","name":"Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02233023","description":"Parkinson Disease","metadata":null},{"id":"021d896e09d24191846c3b4149360565","type":"TRIAL","name":"OpiCapone Effect on Motor Fluctuations and pAiN","canonical_id":"clinicaltrials.gov:NCT04986982","description":"Parkinson Disease","metadata":null},{"id":"28052c7190284cf6ac765de011f0c98e","type":"TRIAL","name":"OpicApone Sleep dISorder","canonical_id":"clinicaltrials.gov:NCT04986995","description":"Parkinson Disease","metadata":null},{"id":"4e745db1a62745508812a34a72b9ab4a","type":"TRIAL","name":"Opicapone Treatment Initiation Open-Label Study","canonical_id":"clinicaltrials.gov:NCT04787965","description":"Parkinson Disease","metadata":null},{"id":"7839c2a8f88645fd8b37ce4cd7249c8b","type":"TRIAL","name":"Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT06432309","description":"Parkinson Disease; Effect of Drug","metadata":null},{"id":"1e42763959c0400185357aa544127a8f","type":"TRIAL","name":"Opioid Induced Gait Variability","canonical_id":"clinicaltrials.gov:NCT03121547","description":"Opioid Induced Motor Disturbances","metadata":null},{"id":"8dd03504556243fb8466ede86c14bf2f","type":"TRIAL","name":"Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain","canonical_id":"clinicaltrials.gov:NCT00478101","description":"Advanced Solid Cancers","metadata":null},{"id":"49023aa3ebbf4d7bb14fb94881fcd55a","type":"TRIAL","name":"Opioid vs. Benzodiazepine-based Sedation for Mechanically Ventilated Patients in the Internal Medicine Ward","canonical_id":"clinicaltrials.gov:NCT04983615","description":"Mechanically Ventilated Patients","metadata":null},{"id":"38e702d5fd0045db807b05e16ff2e476","type":"DISEASE","name":"Opioid-Related Disorders","canonical_id":"mesh:D009293","description":null,"metadata":null},{"id":"aebedb0a06a3446f8ccbfd4c145c46f3","type":"TRIAL","name":"Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)","canonical_id":"clinicaltrials.gov:NCT01298219","description":"Opioid-induced Bowel Dysfunction","metadata":null},{"id":"6dc19126fff545f68737dc515277e052","type":"TRIAL","name":"Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone","canonical_id":"clinicaltrials.gov:NCT00597428","description":"Opioid-Induced Bowel Dysfunction","metadata":null},{"id":"2020fb2aff1d47f990f972a560852015","type":"TRIAL","name":"Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone","canonical_id":"clinicaltrials.gov:NCT00620061","description":"Opioid-Induced Bowel Dysfunction","metadata":null},{"id":"f162d5259541470ba0342bb44497475c","type":"TRIAL","name":"Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone","canonical_id":"clinicaltrials.gov:NCT00595946","description":"Opioid-Induced Bowel Dysfunction","metadata":null},{"id":"4db428dc7cc2422db53e18142395040d","type":"TRIAL","name":"Opioidergic and Noradrenergic Systems in Central Parkisonian Pain","canonical_id":"clinicaltrials.gov:NCT07127146","description":"Parkinson Disease","metadata":null},{"id":"529417e8a8e9416e823cc4d5dc9f8c05","type":"TRIAL","name":"Opioids and Esophageal Function","canonical_id":"clinicaltrials.gov:NCT01012960","description":"Pharyngeal Dysfunction; Esophageal Dysfunction","metadata":null},{"id":"8d3a3a88f9d343f0a970faad3817d8ab","type":"DRUG","name":"Opipramol","canonical_id":"mesh:D009888","description":null,"metadata":null},{"id":"a35fdaeb82f24bf7a4f0d9093dca01d1","type":"DISEASE","name":"Opisthorchiasis","canonical_id":"mesh:D009889","description":null,"metadata":null},{"id":"78b389ead98a49708823ad973df59a59","type":"GO_TERM","name":"Oplophorus-luciferin 2-monooxygenase activity","canonical_id":"go:GO:0033756","description":"\"Catalysis of the reaction: Oplophorus luciferin + O2 = oxidized Oplophorus luciferin + CO2 + hnu.\" [EC:1.13.12.13]","metadata":null},{"id":"7446b04603c34c5e9e7d2a2582a5543b","type":"TRIAL","name":"Optical and Biochemical Biomarkers in Early Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT03404661","description":"Pancreatic Cancer","metadata":null},{"id":"8a8d0d6dc80d4e5ca3c24adbad09a996","type":"TRIAL","name":"Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload","canonical_id":"clinicaltrials.gov:NCT06166654","description":"Acute Heart Failure","metadata":null},{"id":"fb28c467a726486fb3835e2d2b6f4c42","type":"TRIAL","name":"Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT00320879","description":"Type 2 Diabetes; Microalbuminuria","metadata":null},{"id":"e0b4c5abe73045b6be0d66a96ce690b6","type":"TRIAL","name":"Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)","canonical_id":"clinicaltrials.gov:NCT01441960","description":"Neuromuscular Blockade; ECT","metadata":null},{"id":"cfae20a75581410baa892c2b76d17b2d","type":"TRIAL","name":"Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty","canonical_id":"clinicaltrials.gov:NCT04295486","description":"Venous Thromboembolism","metadata":null},{"id":"d4846d2cdfeb445f9d5ee4054c1ea7a2","type":"TRIAL","name":"Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients","canonical_id":"clinicaltrials.gov:NCT01639599","description":"Gynecological Disease","metadata":null},{"id":"f3a2d1c7a42d4fa59d9a2056ffefec46","type":"TRIAL","name":"Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria","canonical_id":"clinicaltrials.gov:NCT03201939","description":"HIV/AIDS; Albuminuria; Kidney Diseases; Genetic Predisposition","metadata":null},{"id":"f2f7b993c17a46858295edfa2823d91b","type":"TRIAL","name":"Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)","canonical_id":"clinicaltrials.gov:NCT00257959","description":"Ventricular Tachycardia","metadata":null},{"id":"6eee9b554bd148d68cd396c8252fbd32","type":"TRIAL","name":"Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel","canonical_id":"clinicaltrials.gov:NCT03295565","description":"Prostate Cancer Metastatic; Metastasis","metadata":null},{"id":"11e4271201dd4ce88d8d9f711eab081d","type":"TRIAL","name":"Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.","canonical_id":"clinicaltrials.gov:NCT05270434","description":"Pancreatitis, Chronic","metadata":null},{"id":"bfa84a1347c4488b95ffbf0986a6e092","type":"TRIAL","name":"Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain","canonical_id":"clinicaltrials.gov:NCT00992576","description":"Constipation","metadata":null},{"id":"483deca980e04b629afdec6bca8b6e59","type":"TRIAL","name":"Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption","canonical_id":"clinicaltrials.gov:NCT00120042","description":"Placenta, Retained; Postpartum Hemorrhage","metadata":null},{"id":"72a6e5137c3945358186e308c8cb061e","type":"TRIAL","name":"Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02770040","description":"Ulcerative Colitis","metadata":null},{"id":"74ceda5efe484e66b3ca3e69a28d4d4f","type":"TRIAL","name":"Optimization of Golimumab Treatment in Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03669029","description":"Colitis, Ulcerative","metadata":null},{"id":"33a27bf3c8bb4597873797db792a528d","type":"TRIAL","name":"Optimization of Treatment and Management of Schizophrenia in Europe","canonical_id":"clinicaltrials.gov:NCT01248195","description":"Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder","metadata":null},{"id":"2283ee39c5df48a3a02173a600b794e7","type":"TRIAL","name":"Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen","canonical_id":"clinicaltrials.gov:NCT01555814","description":"Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder","metadata":null},{"id":"d01e852500284991a2886aa70de54ffe","type":"TRIAL","name":"Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)","canonical_id":"clinicaltrials.gov:NCT01718288","description":"Peripheral Arterial Disease","metadata":null},{"id":"3d78fefb085b42e6861231252f27a0be","type":"TRIAL","name":"Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis","canonical_id":"clinicaltrials.gov:NCT03920605","description":"Hepatitis B; Liver Fibrosis","metadata":null},{"id":"3ead92d12408419e9d0707e868ea49e4","type":"TRIAL","name":"Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol","canonical_id":"clinicaltrials.gov:NCT03022747","description":"Lymphoblastic Leukemia, Acute, Childhood","metadata":null},{"id":"de2654b600144e349e93441e2328af9c","type":"TRIAL","name":"Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)","canonical_id":"clinicaltrials.gov:NCT07661459","description":"Solid Tumors","metadata":null},{"id":"ebc1b8abb8ee45abbff12641216daf87","type":"TRIAL","name":"Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene","canonical_id":"clinicaltrials.gov:NCT02237937","description":"Major Depression","metadata":null},{"id":"a346933de4db43588af453dc01e6152e","type":"TRIAL","name":"Optimizing Cimzia in Crohn's Patients","canonical_id":"clinicaltrials.gov:NCT01024647","description":"Crohn's Disease","metadata":null},{"id":"d5d1c6dcb9524dfb900e5fa7d7839a58","type":"TRIAL","name":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","canonical_id":"clinicaltrials.gov:NCT02960763","description":"Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression","metadata":null},{"id":"719a7eca451d4368b019a12d569e4ffe","type":"TRIAL","name":"Optimizing Response in Psychosis Study","canonical_id":"clinicaltrials.gov:NCT00314327","description":"Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychotic Disorder Not Otherwise Specified","metadata":null},{"id":"f391244030ed4ab7b6f54295d5922900","type":"TRIAL","name":"Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke","canonical_id":"clinicaltrials.gov:NCT02460900","description":"Smoking; HIV","metadata":null},{"id":"71fd3d4955294a139bb2fb36ccf677e0","type":"TRIAL","name":"Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.","canonical_id":"clinicaltrials.gov:NCT06498037","description":"Cancer Pain","metadata":null},{"id":"6688ec56dc3f4d79acd1d786408851ed","type":"TRIAL","name":"Optimum Treatment for Drug-Resistant Hypertension","canonical_id":"clinicaltrials.gov:NCT02369081","description":"Hypertension, Resistant to Conventional Therapy","metadata":null},{"id":"9363dac9651f46e48e76eaed5eba6a14","type":"TRIAL","name":"Oral Abuse Potential Study of Nalbuphine","canonical_id":"clinicaltrials.gov:NCT04018664","description":"Nalbuphine; Opioid Abuse","metadata":null},{"id":"df3b395ef700448bbc057a9081b12952","type":"TRIAL","name":"Oral Akynzeo\u00ae vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","canonical_id":"clinicaltrials.gov:NCT04817189","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"b17354b6cb6d46c6a077d7e8ff95105f","type":"TRIAL","name":"Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy","canonical_id":"clinicaltrials.gov:NCT01912677","description":"Hypertension in Pregnancy; Preeclampsia","metadata":null},{"id":"1b9d505a84e04010a93c09295756e56a","type":"TRIAL","name":"Oral Bio-equivalence Study","canonical_id":"clinicaltrials.gov:NCT05145621","description":"Bioequivalence; Safety","metadata":null},{"id":"d1fae9df1e1e474d86469c3e14f7548b","type":"TRIAL","name":"Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.","canonical_id":"clinicaltrials.gov:NCT06276127","description":"Atrial Fibrillation With Rapid Ventricular Response; Atrial Flutter With Rapid Ventricular Response","metadata":null},{"id":"939098940f69479cb1a0c08bc249b364","type":"TRIAL","name":"Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)","canonical_id":"clinicaltrials.gov:NCT00300118","description":"Crohn's Disease","metadata":null},{"id":"240ade2768204e37b54ec5885d9f69f3","type":"TRIAL","name":"Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients","canonical_id":"clinicaltrials.gov:NCT04524663","description":"Covid19","metadata":null},{"id":"49ee85d623bd4842b40ca28e92c2b1c9","type":"TRIAL","name":"Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02832089","description":"Atrial Fibrillation","metadata":null},{"id":"8cb2ce3da5d1469190fe12c295503198","type":"TRIAL","name":"Oral Clofarabine Study in Patients With Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00299156","description":"Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"8995706d663b40d29633221ad6963260","type":"TRIAL","name":"Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT00800566","description":"Leukemia; Chronic Lymphocytic Leukemia","metadata":null},{"id":"d909fa2c3f9444e28abcb4af939ad785","type":"TRIAL","name":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","canonical_id":"clinicaltrials.gov:NCT04841096","description":"Type 2 Diabetes","metadata":null},{"id":"7ba4fd96434e4b24b07b6dcb08db17d2","type":"TRIAL","name":"Oral Contraceptive DDI Study","canonical_id":"clinicaltrials.gov:NCT02494609","description":"Healthy","metadata":null},{"id":"75dc721b36e543b2950cca9274e7e36f","type":"TRIAL","name":"Oral Contraceptive Pill and GnRH Antagonist Versus Long Protocol in IVF Patients","canonical_id":"clinicaltrials.gov:NCT01157754","description":"Infertility","metadata":null},{"id":"437f213837094e2eb00c8159a1bebfc8","type":"TRIAL","name":"Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases","canonical_id":"clinicaltrials.gov:NCT01469585","description":"Breakthrough Bleeding","metadata":null},{"id":"02a5a52fee98410dbe5bd5fa301635ab","type":"TRIAL","name":"Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03019003","description":"Head and Neck Cancer","metadata":null},{"id":"843f506d148b44a4bb7b19c16a46f2ef","type":"TRIAL","name":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study","canonical_id":"clinicaltrials.gov:NCT00439777","description":"Pulmonary Embolism","metadata":null},{"id":"b83b96caac0e4e8e9b4eb1394dfc4e84","type":"TRIAL","name":"Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI","canonical_id":"clinicaltrials.gov:NCT03677336","description":"Infertility, Female; Infertility; Genital Diseases, Male; Genital Diseases, Female; Progesterone; Dydrogesterone; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Progestins","metadata":null},{"id":"e301fc52cddf4e24b4ad6eee7564d4a8","type":"TRIAL","name":"Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET","canonical_id":"clinicaltrials.gov:NCT03859921","description":"Subfertility","metadata":null},{"id":"55134600ed2a458b9829bd6341fcfc0c","type":"TRIAL","name":"Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)","canonical_id":"clinicaltrials.gov:NCT04706793","description":"Ulcerative Colitis","metadata":null},{"id":"ceda1950f492499494de090c7406f511","type":"TRIAL","name":"Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy","canonical_id":"clinicaltrials.gov:NCT07845552","description":"Food Allergy","metadata":null},{"id":"06d877e6424c4e13a93564ac8e8d4c70","type":"TRIAL","name":"Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)","canonical_id":"clinicaltrials.gov:NCT05687500","description":"Transient; Hypoglycemia, Neonatal; Preterm; Glibenclamide Adverse Reaction","metadata":null},{"id":"0367da726de24d54bded30373ab7b88c","type":"TRIAL","name":"Oral Guanabenz for Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02423083","description":"Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis","metadata":null},{"id":"8da24b095c8e4494bb82b0217834885d","type":"TRIAL","name":"Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study","canonical_id":"clinicaltrials.gov:NCT05463757","description":"Basal Cell Carcinoma; Locally Advanced Basal Cell Carcinoma; Metastatic Basal Cell Carcinoma; Gorlin Syndrome; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma; Basal Cell Tumor; Skin Cancer; Neoplasm of Skin; Neoplasms, Basal Cell","metadata":null},{"id":"5b46b350a48840aa86591f7115ad4fd1","type":"TRIAL","name":"Oral Huzhang Granules for Acute Gouty Arthritis","canonical_id":"clinicaltrials.gov:NCT04462666","description":"Gouty Arthritis","metadata":null},{"id":"93606126de874ae48d667a85c72298dc","type":"TRIAL","name":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","canonical_id":"clinicaltrials.gov:NCT04409795","description":"Type 1 Diabetes; Monogenic Diabetes","metadata":null},{"id":"5e7eba49fb9343bd86e7065d52b8343c","type":"TRIAL","name":"Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations","canonical_id":"clinicaltrials.gov:NCT04197986","description":"Upper Tract Urothelial Carcinomas; Urothelial Bladder Cancer","metadata":null},{"id":"2ed111d14ddf4b0999ebf194deb18611","type":"TRIAL","name":"Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT01680172","description":"Cancer; Depression; Anxiety","metadata":null},{"id":"3c0b2fe90f5b4c4aa175f33cf6e634b7","type":"TRIAL","name":"Oral Ketorolac for Pain Relief During IUD Insertion","canonical_id":"clinicaltrials.gov:NCT03031795","description":"Contraception","metadata":null},{"id":"daeaccf97ed8450cbba1170dc44a6bb5","type":"TRIAL","name":"Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy","canonical_id":"clinicaltrials.gov:NCT07345715","description":"Oral Melatonin; Nebulized Dexmedetomidine; Emergence Agitation; Children; Adenotonsillectomy","metadata":null},{"id":"ea91b623dddf44449bf8ff05b1e95c7b","type":"TRIAL","name":"Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure","canonical_id":"clinicaltrials.gov:NCT00904488","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"56b97ffa7cde499fae0e4c9bb944108b","type":"TRIAL","name":"Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow","canonical_id":"clinicaltrials.gov:NCT02779582","description":"Perimenopause; Menstrual Cramps","metadata":null},{"id":"64fdecdb189f413fbd021c4dff4b1c90","type":"TRIAL","name":"Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics","canonical_id":"clinicaltrials.gov:NCT05722782","description":"Renal Colic","metadata":null},{"id":"209996f40a5f4680a1d105a5e182dfe1","type":"TRIAL","name":"Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics","canonical_id":"clinicaltrials.gov:NCT02304783","description":"Renal Colic","metadata":null},{"id":"e34efee20ab24c09b4a7cb011c674a6b","type":"TRIAL","name":"Oral Nadolol for the Treatment of Adults With Mild Asthma","canonical_id":"clinicaltrials.gov:NCT00670267","description":"Asthma","metadata":null},{"id":"0adced83d71e4f88b0cf13731c83c71f","type":"TRIAL","name":"Oral Nafamostat in Healthy Volunteers (NAF-101)","canonical_id":"clinicaltrials.gov:NCT04406415","description":"Pharmacokinetics","metadata":null},{"id":"647cff12b8974522a9b4333811f29207","type":"TRIAL","name":"Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia","canonical_id":"clinicaltrials.gov:NCT03325348","description":"Severe Pre-Eclampsia, Antepartum","metadata":null},{"id":"5b05c3f470534845b7e1cb53d37aba2c","type":"TRIAL","name":"Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant","canonical_id":"clinicaltrials.gov:NCT00413270","description":"Chronic Myelogenous Leukemia","metadata":null},{"id":"64b1b1361f03497a8f4d989f54bd89ed","type":"TRIAL","name":"Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation","canonical_id":"clinicaltrials.gov:NCT01536392","description":"Cancer of the Cervix","metadata":null},{"id":"fec70779068941d8bfcd49c9d6c989a7","type":"TRIAL","name":"Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT07552402","description":"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"d10c38f43a514e809cc2816f554b548e","type":"TRIAL","name":"Oral Paricalcitol in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00587158","description":"Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary","metadata":null},{"id":"4984b53828724494b3cd1390c87886e1","type":"TRIAL","name":"Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00796679","description":"Chronic Kidney Disease","metadata":null},{"id":"f06ae835954b4eb29ab209419ad799bd","type":"TRIAL","name":"Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab","canonical_id":"clinicaltrials.gov:NCT01931098","description":"Glioblastoma; Glioblastoma Multiforme; Gliosarcoma; Brain Neoplasms; Central Nervous System Neoplasms","metadata":null},{"id":"550f207bc96e487b85bad07c1f08a981","type":"TRIAL","name":"Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums","canonical_id":"clinicaltrials.gov:NCT03012763","description":"Pharmacokinetics; Magnetic Resonance Imaging; Administration, Oral","metadata":null},{"id":"e10247ed8747458bbc5157d9bf932741","type":"TRIAL","name":"Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome","canonical_id":"clinicaltrials.gov:NCT04470479","description":"Dry Eye","metadata":null},{"id":"8d88de59f1434f8d9d0f29f3ce170e2f","type":"TRIAL","name":"Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02425644","description":"Multiple Sclerosis","metadata":null},{"id":"d6e6d6d3427740108c7dbfd0458eaad4","type":"TRIAL","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07001618","description":"NSCLC (Advanced Non-small Cell Lung Cancer)","metadata":null},{"id":"c9bd7f53d9024748ba7cb421bffa8357","type":"TRIAL","name":"Oral Prednisolone Dosing in Children Hospitalized With Asthma","canonical_id":"clinicaltrials.gov:NCT00257933","description":"Asthma","metadata":null},{"id":"78ed3822b26840f5959681c1b29b3159","type":"TRIAL","name":"Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence","canonical_id":"clinicaltrials.gov:NCT06078969","description":"Langerhans Cell Histiocytosis of Bone","metadata":null},{"id":"484510cde7014418ad302ea1d6314ef6","type":"TRIAL","name":"Oral Progesterone for Prevention of Miscarriage in Threatened Abortion","canonical_id":"clinicaltrials.gov:NCT04788108","description":"Threatened Abortion","metadata":null},{"id":"5f470d1ead0e42fabb032fe911cec772","type":"TRIAL","name":"Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study","canonical_id":"clinicaltrials.gov:NCT01238471","description":"Retinopathy of Prematurity","metadata":null},{"id":"2d4ca98c3d4047a7b3c0141ac0fbec6a","type":"TRIAL","name":"Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT02595541","description":"Pulmonary Hypertension","metadata":null},{"id":"b3189b141fb54e17a712a9f3b297cc2b","type":"DISEASE","name":"Oral Squamous Cell Carcinoma","canonical_id":"doid:0050866","description":null,"metadata":null},{"id":"a2799200a09444d69b40f546405f3d06","type":"TRIAL","name":"Oral Steroid Taper After Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT07070882","description":"Osteoarthritis, Knee","metadata":null},{"id":"d479d0f6a14c418fa1c4c442e3088071","type":"TRIAL","name":"Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women","canonical_id":"clinicaltrials.gov:NCT05584657","description":"Urinary Tract Infections; Cystitis","metadata":null},{"id":"b866a1d4412d461ba5de8fd179264ee7","type":"TRIAL","name":"Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women","canonical_id":"clinicaltrials.gov:NCT03354598","description":"Uncomplicated Urinary Tract Infections","metadata":null},{"id":"164876507d16436f8ba5de1b7a8e7b92","type":"TRIAL","name":"Oral Tramadol Versus Diclofenac For Pain Relief Before Outpatient Hysteroscopy:","canonical_id":"clinicaltrials.gov:NCT02760888","description":"Pain, Procedure","metadata":null},{"id":"1bd3c2052b0d4ce3a298795a08aea0b8","type":"TRIAL","name":"Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study","canonical_id":"clinicaltrials.gov:NCT00767221","description":"IGA Nephropathy","metadata":null},{"id":"a4e65d4e0f3d4916ad50ceada1f7aa18","type":"TRIAL","name":"Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT03037580","description":"Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"22476eb1356e47a9a28fc5b5b5bb38b2","type":"TRIAL","name":"Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT02603068","description":"Pulmonary Hypertension; Pulmonary Fibrosis","metadata":null},{"id":"9e077805bf3a4b98a27c8e32f60d002a","type":"TRIAL","name":"Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia","canonical_id":"clinicaltrials.gov:NCT02521168","description":"Postoperative; Dysfunction Following Cardiac Surgery","metadata":null},{"id":"edc406af84c945d2ac077f36629fc840","type":"TRIAL","name":"Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT07804849","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"7737bca946144ce88c1124eacb704e87","type":"TRIAL","name":"Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control","canonical_id":"clinicaltrials.gov:NCT01655316","description":"Paroxysmal Supraventricular Tachycardia","metadata":null},{"id":"42101dc641fd4088861bfec7a2d4b27a","type":"TRIAL","name":"Oral Versus Intravenous Sedation for Ocular Procedures","canonical_id":"clinicaltrials.gov:NCT03246724","description":"Surgery; Sedation","metadata":null},{"id":"9e75addecfd84095bd0b34562a406e2b","type":"TRIAL","name":"Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles","canonical_id":"clinicaltrials.gov:NCT04758871","description":"Frozen Embryo Transfer; Hormone Replacement Therapy; Dydrogesterone; Infertility, Female","metadata":null},{"id":"cdadcd09213f490fb171804c478b3027","type":"TRIAL","name":"Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05747326","description":"Breast Cancer","metadata":null},{"id":"740a5f516208479e905a602535a4de83","type":"TRIAL","name":"Oral and IV Baclofen in Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT01749319","description":"Baclofen Withdrawal Syndrome","metadata":null},{"id":"3859f38a144d49ad805d56b6931afeb6","type":"TRIAL","name":"Oral and Intravenous Methadone for Analgesia in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT06720415","description":"Anesthesia; Cardiac Surgery","metadata":null},{"id":"2dc04bd226b842ca84ba86e3a9eeffb1","type":"TRIAL","name":"Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT03709160","description":"Heart Failure; Congestive Heart Failure","metadata":null},{"id":"e360ca0661dd48ae8c85d9ae1bb5679b","type":"DISEASE","name":"Oral ulcer","canonical_id":"hp:0000155","description":null,"metadata":null},{"id":"0ab6c1c47b6e4929b30bbe25290928b0","type":"TRIAL","name":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT06195891","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"3136b2177206498c9495a97eaaf1829e","type":"DRUG","name":"Orciprenaline","canonical_id":"mesh:D009921","description":null,"metadata":null},{"id":"3698710990444f85966cce030f1bd8e6","type":"TRIAL","name":"Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking","canonical_id":"clinicaltrials.gov:NCT07214207","description":"Alcohol Use Disorder","metadata":null},{"id":"7d5ed7c327194ddc94e16e03b64a7ba8","type":"TRIAL","name":"Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder","canonical_id":"clinicaltrials.gov:NCT05656534","description":"Alcohol Use Disorder","metadata":null},{"id":"31be292f64834594abaeaae92d201a85","type":"TRIAL","name":"Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05969847","description":"Rectal Cancer","metadata":null},{"id":"3ea04162a3a142c0bae9b68a2fa62032","type":"TRIAL","name":"Organ Protective Effect of Cetirizine In Patients With Severe Burns","canonical_id":"clinicaltrials.gov:NCT06126991","description":"Burns","metadata":null},{"id":"e8faa1f3c47c42679dbb19138a12723e","type":"TRIAL","name":"Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project","canonical_id":"clinicaltrials.gov:NCT00116272","description":"Pregnancy","metadata":null},{"id":"7e6af05673f847f295e87aa50bb3b0ab","type":"DISEASE","name":"Organophosphate poisoning","canonical_id":"mesh:D062025","description":null,"metadata":null},{"id":"d227a1b7ab0a466e873ba99c60b0a9c0","type":"TRIAL","name":"Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)","canonical_id":"clinicaltrials.gov:NCT00160407","description":"Fatty Liver; Hepatitis","metadata":null},{"id":"e9cd6a7a196d467e9033f4458b0f7cec","type":"TRIAL","name":"Orlistat Overcoming Third-generation EGFR-TKI Resistance","canonical_id":"clinicaltrials.gov:NCT06818955","description":"Lung Adenocarcinoma; Osimertinib","metadata":null},{"id":"74bf99720f834c09a6a163245259c720","type":"TRIAL","name":"Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT05496075","description":"Uric Acid","metadata":null},{"id":"d9dd6bfdef074cd88c2b4e8c6ef3ad2e","type":"PROTEIN","name":"Ornithine decarboxylase","canonical_id":"uniprot:P11926","description":null,"metadata":null},{"id":"16712a04739542b9899af88ff82eeb98","type":"DRUG","name":"Orphenadrine","canonical_id":"mesh:D009966","description":null,"metadata":null},{"id":"2210e15524f94ed28cf1d5fceaa90491","type":"DISEASE","name":"Orthomyxoviridae infectious disease","canonical_id":"efo:0007411","description":null,"metadata":null},{"id":"4194fc594dbd4ab28a1da600e6157037","type":"DISEASE","name":"Orthostatic hypotension","canonical_id":"mesh:D007024","description":null,"metadata":null},{"id":"fb440460f697435fbe31ec516bab4643","type":"TRIAL","name":"Osellidine is Used for Analgesia During Daytime Hysteroscopic Surgery","canonical_id":"clinicaltrials.gov:NCT07409311","description":"Gynecological Day Surgery","metadata":null},{"id":"e2295883c1244a488cffb30eafb37876","type":"DRUG","name":"Osimertinib","canonical_id":"ncit:C116377","description":null,"metadata":null},{"id":"b65ca732022047d1b11afb64a08e4c64","type":"TRIAL","name":"Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib","canonical_id":"clinicaltrials.gov:NCT07486648","description":"Lung Cancer (NSCLC); Lung Cancer (Non-Small Cell); Advanced Non-small-cell Lung Cancer","metadata":null},{"id":"87e36c024a9841e0a26c81fa47c73708","type":"TRIAL","name":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","canonical_id":"clinicaltrials.gov:NCT02496663","description":"Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"9e46bfee5508445b9aa16415ca468705","type":"TRIAL","name":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","canonical_id":"clinicaltrials.gov:NCT06067776","description":"Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"678d3ea021ca440dbb91d6008a40615d","type":"TRIAL","name":"Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction","canonical_id":"clinicaltrials.gov:NCT03018106","description":"Sexual Dysfunction, Physiological","metadata":null},{"id":"cacbe7e319b14d65b4e715b300151b73","type":"TRIAL","name":"Osseointegrated Transdermal Femoral Amputation Prostheses","canonical_id":"clinicaltrials.gov:NCT05736640","description":"Osseointegrated Implants; Bone Mineral Density","metadata":null},{"id":"8b823c61fdc745f4b0e0fa74a1e22a16","type":"GO_TERM","name":"Ost-alpha/Ost-beta complex","canonical_id":"go:GO:0044731","description":"\"A heterodimeric protein complex composed of Ost-alpha/SLC51A and Ost-beta/SLC51B subunits and involved in bile acid transport activity.\" [PMID:17650074, PMID:22535958]","metadata":null},{"id":"8b0510ea3ad84d78a1b4fa5b6f3fcd50","type":"DISEASE","name":"Osteitis deformans","canonical_id":"mesh:D010001","description":null,"metadata":null},{"id":"273d2166a5654a9db804b78de817644a","type":"DISEASE","name":"Osteoarthritis","canonical_id":"mesh:D010003","description":null,"metadata":null},{"id":"900b48753ae24acb8b942dae0a7846d2","type":"PROTEIN","name":"Osteocalcin","canonical_id":"uniprot:P02818","description":null,"metadata":null},{"id":"aa06e630aee044c78e0d892bfac8d570","type":"DISEASE","name":"Osteomyelitis","canonical_id":"mesh:D010019","description":null,"metadata":null},{"id":"9389ae7679844bc7995ea7203409221f","type":"TRIAL","name":"Osteoporosis Prevention After Heart Transplant","canonical_id":"clinicaltrials.gov:NCT00000412","description":"Osteoporosis; Cardiac Transplantation","metadata":null},{"id":"0f6319c1c0f34d5f815b7c05591b5573","type":"TRIAL","name":"Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy","canonical_id":"clinicaltrials.gov:NCT04861142","description":"Osteoporosis","metadata":null},{"id":"c841bce6a26a4563908789f7c6f22802","type":"TRIAL","name":"Osteoporosis Treatment in Post-menopausal Women","canonical_id":"clinicaltrials.gov:NCT03006003","description":"Depressive Syndrome","metadata":null},{"id":"8d8cbdb358434d13afdae3bc507e6be1","type":"DRUG","name":"Oteracil","canonical_id":"mesh:D010094","description":null,"metadata":null},{"id":"5545cfaa7aa44e7e81639164797cb03a","type":"TRIAL","name":"Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00138528","description":"Metabolic Syndrome","metadata":null},{"id":"59e09371bc114c00b8a5de94dc9ab18a","type":"DISEASE","name":"Other metabolic disease","canonical_id":"orphanet:91088","description":null,"metadata":null},{"id":"cb8c20e90a1749608682e95a11c9f68a","type":"DISEASE","name":"Otitis externa","canonical_id":"mesh:D010032","description":null,"metadata":null},{"id":"19203801690f4553ab480efbd28b96e5","type":"TRIAL","name":"Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT02352285","description":"Heart Failure With Hyponatremia","metadata":null},{"id":"5441541ccecd4101845786cd5db94b51","type":"TRIAL","name":"Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03092986","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"56dcbaee54e84eed9ffb48dbe78bb990","type":"TRIAL","name":"Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime","canonical_id":"clinicaltrials.gov:NCT06111352","description":"Organophosphorus Poisoning","metadata":null},{"id":"7cc8840a9ad048ea98f037f0feaff2a0","type":"TRIAL","name":"Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience","canonical_id":"clinicaltrials.gov:NCT02485262","description":"Hepatitis C","metadata":null},{"id":"c5d4c185f43f49d9ac39a4579fc9c900","type":"TRIAL","name":"Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor","canonical_id":"clinicaltrials.gov:NCT05276713","description":"Breast Cancer","metadata":null},{"id":"ea7fc3d3a295487bb9cf83ab632d15de","type":"TRIAL","name":"Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim","canonical_id":"clinicaltrials.gov:NCT01439321","description":"Immune Thrombocytopenic Purpura","metadata":null},{"id":"312548a558d54f9294fd08c72095f3e2","type":"TRIAL","name":"Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT02954484","description":"Pain, Postoperative","metadata":null},{"id":"a520a557f15c4abebb8457690ec6ab7c","type":"TRIAL","name":"Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT04537689","description":"Plaque Psoriasis","metadata":null},{"id":"a014d84fa2f14a00b2f2bf267316b3a3","type":"TRIAL","name":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01331694","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"ccf38dcd4f494a84994a716baff7ce0d","type":"TRIAL","name":"Outcomes in Bone Marrow Aplasia.","canonical_id":"clinicaltrials.gov:NCT06493981","description":"Aplastic Anemia Idiopathic","metadata":null},{"id":"35d3de5a126e4462ad2dfaee1224f67f","type":"TRIAL","name":"Outcomes of Injections in Patients Waiting for Total Knee Replacement","canonical_id":"clinicaltrials.gov:NCT03090698","description":"Osteoarthritis of the Knee","metadata":null},{"id":"23ef6c822ba2440bb9fc97c10176e913","type":"TRIAL","name":"Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database","canonical_id":"clinicaltrials.gov:NCT07079644","description":"Advanced Melanoma","metadata":null},{"id":"e5cc54cd48db4ebb8d0f3b7fde192e67","type":"DISEASE","name":"Ovarian Cancer","canonical_id":"doid:2394","description":null,"metadata":null},{"id":"b77f17abfcdb480ebfc033dcacb0836d","type":"DISEASE","name":"Ovarian Carcinoma","canonical_id":"doid:4001","description":null,"metadata":null},{"id":"6727c019fbe14f10acb1c793884729bf","type":"TRIAL","name":"Ovarian Hyperstimulation Syndrome and Cabergoline","canonical_id":"clinicaltrials.gov:NCT01569256","description":"Polycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"8d6dc3c861b44117abb89506960c6ecf","type":"DISEASE","name":"Ovarian Serous Carcinoma","canonical_id":"doid:0050933","description":null,"metadata":null},{"id":"cb660973d23047a794f594fb196c6c24","type":"TISSUE","name":"Ovary","canonical_id":"uberon:UBERON:0000992","description":null,"metadata":null},{"id":"e0a2b3a01b684acf9313799ef4e62fb0","type":"DISEASE","name":"Ovary Serous Adenocarcinoma","canonical_id":"doid:5744","description":null,"metadata":null},{"id":"0119c4ff8ad3472dbaa6379f52ebb7bf","type":"TRIAL","name":"Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT01322009","description":"Pediatric Traumatic Brain Injury","metadata":null},{"id":"10c0259638104f9d9bda70715540b68b","type":"TRIAL","name":"Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT05304546","description":"Malignant Melanoma; Metastatic Melanoma; Immunotherapy; BRAF V600E; Malignant Melanoma Stage IV","metadata":null},{"id":"804b17015f9a40fb946cbcc119787ce2","type":"TRIAL","name":"Overnight Switch From Rasagiline To Safinamide","canonical_id":"clinicaltrials.gov:NCT03843944","description":"Parkinson Disease","metadata":null},{"id":"fce7942081af4c10a220c1aae3c873ee","type":"TRIAL","name":"Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT00558025","description":"Parkinson Disease","metadata":null},{"id":"e1c67bcbe32446958f26bdf2fadb88fe","type":"DISEASE","name":"Overweight","canonical_id":"hp:0025502","description":null,"metadata":null},{"id":"ea24a826ca6147e29c98bef771fca356","type":"DISEASE","name":"Ovulation induction","canonical_id":"mesh:D010062","description":null,"metadata":null},{"id":"ad593a4ca0614cb19671764c2a22c0cc","type":"DRUG","name":"Oxacillin","canonical_id":"mesh:D010068","description":null,"metadata":null},{"id":"047bfb06e2bb4801b955f23486f9a507","type":"DRUG","name":"Oxaliplatin","canonical_id":"ncit:C1181","description":null,"metadata":null},{"id":"e208b70bf52f4889bcc67c4895ec6597","type":"TRIAL","name":"Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases","canonical_id":"clinicaltrials.gov:NCT02557490","description":"Colon Cancer Liver Metastasis","metadata":null},{"id":"04720a6c59dc4498a807bdbedf0bc0e8","type":"TRIAL","name":"Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT00093652","description":"Esophageal Cancer","metadata":null},{"id":"102369e951f5493f8e539934de1722b5","type":"DRUG","name":"Oxazepam","canonical_id":"mesh:D010076","description":null,"metadata":null},{"id":"a7a4f4d8c6f34695981b1ebd0d09a821","type":"DRUG","name":"Oxitropium","canonical_id":"mesh:C017590","description":null,"metadata":null},{"id":"f30f8a99eaba497daf96aa929f95c334","type":"DRUG","name":"Oxprenolol","canonical_id":"mesh:D010096","description":null,"metadata":null},{"id":"f6864fcd4191411199f26043302181a8","type":"DRUG","name":"Oxybutynin","canonical_id":"mesh:C005419","description":null,"metadata":null},{"id":"b2b3663f96e14655a60c8ab54438287c","type":"TRIAL","name":"Oxybutynin Chloride in Managing Hot Flashes","canonical_id":"clinicaltrials.gov:NCT02961790","description":"Breast Carcinoma; Ductal Breast Carcinoma In Situ; Hot Flashes; Lobular Breast Carcinoma In Situ; No Evidence of Disease","metadata":null},{"id":"e3d43838ca414efbb223537b37f5444f","type":"TRIAL","name":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT06966778","description":"Localized Prostate Cancer; Postoperative Urinary Incontinence","metadata":null},{"id":"7a758bb250ec45a4b9aca163236c6dde","type":"TRIAL","name":"Oxycodone in Combination With Parathoracic Nerve Block is Used for Postoperative Analgesia in Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05742256","description":"Oxycodone","metadata":null},{"id":"a7b36c246b1a4dda91f2788431fb03a4","type":"TRIAL","name":"Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma","canonical_id":"clinicaltrials.gov:NCT06566807","description":"Marginal Zone Lymphoma","metadata":null},{"id":"0244190594cc46c6a5d4116c38da66f4","type":"TRIAL","name":"Oxymetazoline Versus Sodium Hypochlorite as Hemostatic Agents in MTA Pulpotomy of Primary Molars","canonical_id":"clinicaltrials.gov:NCT07675330","description":"Pulp Disease, Dental; Pulp Therapy in Primary Molars; Pulpitis - Reversible; Pulp Inflammation; Vital Pulp Therapies; Carious Exposure of Pulp; Primary Molar Tooth; Primary Molar Pulpotomy","metadata":null},{"id":"5c90b416e6a544ee8a622f1c60b5c281","type":"TRIAL","name":"Oxytocin Administration in BDD and OCD","canonical_id":"clinicaltrials.gov:NCT02671266","description":"Body Dysmorphic Disorder; Obsessive-compulsive Disorder","metadata":null},{"id":"ccd5926f5b104cafaa1d6bea70f485dd","type":"TRIAL","name":"Oxytocin Bolus Versus Infusion in High-Risk Patients Undergoing Elective Cesarean Section (INBOX-HR)","canonical_id":"clinicaltrials.gov:NCT07688512","description":"Postpartum Hemorrhage; Uterine Atony; Uterine Atony With Hemorrhage; Elective Cesarean Section","metadata":null},{"id":"8eed9dd254174e79b171432539ada4e9","type":"TRIAL","name":"Oxytocin Effects on Self Versus Other Touch","canonical_id":"clinicaltrials.gov:NCT05899517","description":"Healthy","metadata":null},{"id":"6fa416be0fb048cf8f45bef8e351e505","type":"TRIAL","name":"Oxytocin Effects on the Tolerance of Infidelity","canonical_id":"clinicaltrials.gov:NCT02733237","description":"Healthy","metadata":null},{"id":"444d47268a824245801e4e9be7909712","type":"TRIAL","name":"Oxytocin MEG Study","canonical_id":"clinicaltrials.gov:NCT02568709","description":"Schizophrenia; Oxytocin; Magnetoencephalography (MEG); Social Cognition","metadata":null},{"id":"3aa6d83f7a094a3ca44be4d12dd6e1e0","type":"TRIAL","name":"Oxytocin Treatment of Opioid Dependence","canonical_id":"clinicaltrials.gov:NCT02548728","description":"Opioid Dependence; Opioid Withdrawal","metadata":null},{"id":"521cef4698144886a280fe95abc024d2","type":"TRIAL","name":"Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI \u2265 40kg/m2","canonical_id":"clinicaltrials.gov:NCT03957083","description":"Postpartum Hemorrhage; Obesity","metadata":null},{"id":"255b733a9ca44813a09fa967c60a72a8","type":"TRIAL","name":"Oxytocin to Decrease Blood Loss During Cesarean Section","canonical_id":"clinicaltrials.gov:NCT00891150","description":"Complications; Cesarean Section","metadata":null},{"id":"a481a944c3244772a9cb1a190d207a2a","type":"TRIAL","name":"Oxytocin, Couple Interaction and Wound Healing","canonical_id":"clinicaltrials.gov:NCT01594775","description":"Healthy Volunteers","metadata":null},{"id":"c82c50032fc943c7998e013673393749","type":"TRIAL","name":"Ozanimod in Patients With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT06862960","description":"Alzheimer Disease","metadata":null},{"id":"07a65571f5de4e6691ce9333dd42fdda","type":"DRUG","name":"Ozenoxacin","canonical_id":"mesh:C000592413","description":null,"metadata":null},{"id":"0e7401663c6241db84f81d261e050bd8","type":"GO_TERM","name":"P granule","canonical_id":"go:GO:0043186","description":"\"A small cytoplasmic, non-membranous RNA/protein complex aggregate in the primordial germ cells of many higher eukaryotes.\" [GOC:dph, GOC:kmv, PMID:11262230]","metadata":null},{"id":"c4a8f3c0b26a457b996b8caff50fc40c","type":"GO_TERM","name":"P granule assembly","canonical_id":"go:GO:1903863","description":"\"The aggregation, arrangement and bonding together of a set of components to form a P granule.\" [GO_REF:0000079, GOC:kmv, GOC:TermGenie, PMID:25535836]","metadata":null},{"id":"05529ac161f34fa295e111289e7553ac","type":"GO_TERM","name":"P granule disassembly","canonical_id":"go:GO:1903864","description":"\"The disaggregation of a P granule into its constituent components.\" [GO_REF:0000079, GOC:kmv, GOC:TermGenie, PMID:25535836]","metadata":null},{"id":"d807b136bbcd4a85a3b73688cc7e2610","type":"GO_TERM","name":"P granule organization","canonical_id":"go:GO:0030719","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of polar granules, cytoplasmic, non-membranous RNA/protein complex aggregates in the primordial germ cells of many higher eukaryotes.\" [PMID:10851135, PMID:770367]","metadata":null},{"id":"274bbd5810d64970b19417397e390ccb","type":"GO_TERM","name":"P-TEFb complex","canonical_id":"go:GO:0070691","description":"\"A dimeric positive transcription elongation factor complex b that comprises a cyclin-dependent kinase containing the catalytic subunit, Cdk9, and a regulatory subunit, cyclin T.\" [GOC:mah, GOC:vw, PMID:16721054, PMID:19328067, Wikipedia:P-TEFb]","metadata":null},{"id":"d3875046e43545c9ad52271f27fb6550","type":"GO_TERM","name":"P-TEFb complex binding","canonical_id":"go:GO:0106140","description":"\"Binding to a P-TEFb complex.\" [GOC:pga, PMID:18391197]","metadata":null},{"id":"269198fbb7a54460a357ec0e827e15e6","type":"GO_TERM","name":"P-TEFb-cap methyltransferase complex","canonical_id":"go:GO:0070693","description":"\"A protein complex that is formed by the association of positive transcription elongation factor complex b (P-TEFb) with the mRNA capping methyltransferase.\" [PMID:17332744, PMID:19328067]","metadata":null},{"id":"6c652dcbc78845cab5f7c6b6c2acaf8d","type":"GO_TERM","name":"P-TEFb-cap methyltransferase complex localization","canonical_id":"go:GO:0070817","description":"\"Any process in which the P-TEFb-cap methyltransferase complex is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"2b0f639f3a8e4ff48e07c3d9fb96d2b0","type":"GO_TERM","name":"P-body","canonical_id":"go:GO:0000932","description":"\"A focus in the cytoplasm where mRNAs may become inactivated by decapping or some other mechanism. Protein and RNA localized to these foci are involved in mRNA degradation, nonsense-mediated mRNA decay (NMD), translational repression, and RNA-mediated gene silencing.\" [GOC:clt, PMID:12730603]","metadata":null},{"id":"dd3b183bfea6484888bbe89a9d4c77da","type":"GO_TERM","name":"P-body assembly","canonical_id":"go:GO:0033962","description":"\"The aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic mRNA processing body.\" [GOC:mah, PMID:17429074]","metadata":null},{"id":"d227b3f8c0014f8388b013b5c599eba6","type":"GO_TERM","name":"P-element binding","canonical_id":"go:GO:0003693","description":"\"Binding to a P-element, a class of Drosophila transposon responsible for hybrid dysgenesis.\" [GOC:jl, PMID:9440262]","metadata":null},{"id":"6bcdb05240414763a3909309d987fa3e","type":"GO_TERM","name":"P-type cadmium transporter activity","canonical_id":"go:GO:0008551","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Cd2+(in) = ADP + phosphate + Cd2+(out).\" [PMID:17326661]","metadata":null},{"id":"bebd42817a60482fae824efbbc17b006","type":"GO_TERM","name":"P-type calcium transporter activity","canonical_id":"go:GO:0005388","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Ca2+(in) = ADP + phosphate + Ca2+(out).\" [RHEA:18105]","metadata":null},{"id":"2278b0705baf4f33874c7ee59f7016d4","type":"GO_TERM","name":"P-type calcium transporter activity involved in regulation of cardiac muscle cell membrane potential","canonical_id":"go:GO:0086039","description":"\"A calcium-transporting P-type ATPase activity involved in regulation of the plasma membrane potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"854aaff4c8454ce28bc6c3e140803b17","type":"GO_TERM","name":"P-type calcium transporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:1905059","description":"\"A calcium-transporting P-type ATPase activity involved in regulation of postsynaptic cytosolic calcium ion concentration.\" [GO_REF:0000061, GOC:TermGenie, PMID:20678993]","metadata":null},{"id":"b76b114ce21e477bb567cc9eeb31ea83","type":"GO_TERM","name":"P-type calcium transporter activity involved in regulation of presynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:1905056","description":"\"A calcium-transporting P-type ATPase activity involved in regulation of presynaptic cytosolic calcium ion concentration.\" [GO_REF:0000061, GOC:TermGenie, PMID:22972962]","metadata":null},{"id":"e4d634b5309443d689fff54c71317505","type":"GO_TERM","name":"P-type cobalt transporter activity","canonical_id":"go:GO:0032778","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Co2+(out) = ADP + phosphate + Co2+(in).\" [GOC:mlg, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"3c56afb904db49c0b95f5b8977f08ff0","type":"GO_TERM","name":"P-type divalent copper transporter activity","canonical_id":"go:GO:0043682","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Cu2+(in) = ADP + phosphate + Cu2+(out).\" [RHEA:10376]","metadata":null},{"id":"0d70006f1bde4876bdc169846320b1d9","type":"GO_TERM","name":"P-type ion transporter activity","canonical_id":"go:GO:0015662","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O = ADP + phosphate, to directly drive the transport of ions across a membrane. The reaction is characterized by the transient formation of a high-energy aspartyl-phosphoryl-enzyme intermediate.\" [PMID:10322420, PMID:10600683]","metadata":null},{"id":"ca37defc6c4545878a29dfa407351df7","type":"GO_TERM","name":"P-type magnesium transporter activity","canonical_id":"go:GO:0015444","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Mg2+(out) = ADP + phosphate + Mg2+(in).\" [RHEA:10260]","metadata":null},{"id":"d7eb1fc5aed544feaee83af0eef3b8bf","type":"GO_TERM","name":"P-type manganese transporter activity","canonical_id":"go:GO:0140613","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Mn2+(in) = ADP + H+ + Mn2+(out) + phosphate.\" [PMID:11134055, PMID:15590060, PMID:15831496, PMID:21187401, RHEA:66820]","metadata":null},{"id":"18a09a3bc7064443be0aa4f5e6888204","type":"GO_TERM","name":"P-type monovalent copper transporter activity","canonical_id":"go:GO:0140581","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Cu+(in) = ADP + phosphate + Cu+(out).\" [RHEA:25792]","metadata":null},{"id":"8cbc20057b9f45259479d68a89dd8162","type":"GO_TERM","name":"P-type potassium transmembrane transporter activity","canonical_id":"go:GO:0008556","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + K+(out) = ADP + phosphate + K+(in).\" [RHEA:16777]","metadata":null},{"id":"dfa8cd0ecdbd4ccda32d6aad395bdf17","type":"GO_TERM","name":"P-type potassium:proton transporter activity","canonical_id":"go:GO:0008900","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + H+(in) + K+(out) = ADP + phosphate + H+(out) + K+(in).\" [RHEA:22044]","metadata":null},{"id":"07cb5a5e06f34e0b99cbe398ba23dc24","type":"GO_TERM","name":"P-type proton-exporting transporter activity","canonical_id":"go:GO:0008553","description":"\"Enables the transfer of protons from one side of a membrane to the other according to the reaction: ATP + H2O + H+(in) = ADP + phosphate + H+(out). These transporters use a phosphorylative mechanism, which have a phosphorylated intermediate state during the ion transport cycle.\" [RHEA:20852]","metadata":null},{"id":"2df7e48481914eaeb64130e2a9c273e4","type":"GO_TERM","name":"P-type silver transporter activity","canonical_id":"go:GO:0015445","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Ag+(in) = ADP + phosphate + Ag+(out).\" [RHEA:14733]","metadata":null},{"id":"28516438635946179d3d650d81c482aa","type":"GO_TERM","name":"P-type sodium transporter activity","canonical_id":"go:GO:0008554","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Na+(in) = ADP + phosphate + Na+(out); by a phosphorylative mechanism.\" [PMID:9224683]","metadata":null},{"id":"3df86a0c34e8452c9ce2036984530f70","type":"GO_TERM","name":"P-type sodium:potassium-exchanging transporter activity","canonical_id":"go:GO:0005391","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Na+(in) + K+(out) = ADP + phosphate + Na+(out) + K+(in).\" [EC:7.2.2.13]","metadata":null},{"id":"ab884d2dacef4c9aa41dbea6b8f2e1cc","type":"GO_TERM","name":"P-type transmembrane transporter activity","canonical_id":"go:GO:0140358","description":"\"Primary active transporter that auto-phosphorylates (hence P) at a key conserved aspartate residue, generating a conformational change that allows transport of the substrate. Hydrolysis of the phosphorylated Asp residue, catalyzed by the actuator (A) domain, results in another state with occluded substrates. Upon dissociation of Mg2+ and Pi, the enzyme reverts to the initial state, in which the counter-transported substrate is released into the cytosol.\" [PMID:18075584, PMID:25918123]","metadata":null},{"id":"ca7f1c197d2b4418b2d53454b51f64e4","type":"GO_TERM","name":"P-type zinc transporter activity","canonical_id":"go:GO:0016463","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + Zn2+(in) = ADP + phosphate + Zn2+(out).\" [RHEA:20621]","metadata":null},{"id":"46bd9b09cf8649ef805356d8b3afccde","type":"GO_TERM","name":"P1 peroxisome","canonical_id":"go:GO:0019819","description":"\"A subform of peroxisome that corresponds to an intermediate in a peroxisome assembly pathway, which operates by conversion of peroxisomal subforms in the direction P1, P2 -> P3 -> P4 -> P5 -> P6. P1 peroxisomes are distinguished from the other subforms on the bases of buoyant density and protein content; they contain fewer peroxisomal proteins than the other subforms.\" [PMID:10629216]","metadata":null},{"id":"8829597cea5440b182d8cfc9e2151d0a","type":"GO_TERM","name":"P2 peroxisome","canonical_id":"go:GO:0019820","description":"\"A subform of peroxisome that corresponds to an intermediate in a peroxisome assembly pathway, which operates by conversion of peroxisomal subforms in the direction P1, P2 -> P3 -> P4 -> P5 -> P6. P2 peroxisomes are distinguished from the other subforms on the bases of buoyant density and protein content; they are the least dense of the subforms observed.\" [PMID:10629216]","metadata":null},{"id":"2e2df5888f0546358f40434168c70216","type":"GENE","name":"P2RX1","canonical_id":"hgnc:HGNC:8533","description":"purinergic receptor P2X 1","metadata":{"aliases":["P2X1"]}},{"id":"925728116285439f9ccb4cb5deffb7d7","type":"GENE","name":"P2RX2","canonical_id":"hgnc:HGNC:15459","description":"purinergic receptor P2X 2","metadata":{"aliases":["P2X2","DFNA41"]}},{"id":"a934519c0354488bb9c97fdd9c885786","type":"GENE","name":"P2RX3","canonical_id":"hgnc:HGNC:8534","description":"purinergic receptor P2X 3","metadata":{"aliases":["P2X3"]}},{"id":"a02d85ced2314cf09b2d24b26edfdb47","type":"GENE","name":"P2RX4","canonical_id":"hgnc:HGNC:8535","description":null,"metadata":null},{"id":"974f048c857049b987acdba3f7080370","type":"GENE","name":"P2RX5","canonical_id":"hgnc:HGNC:8536","description":"purinergic receptor P2X 5","metadata":{"aliases":["P2X5","LRH-1"]}},{"id":"43173bd3acd14214a91e8e4a9dac33fe","type":"GENE","name":"P2RX5-TAX1BP3","canonical_id":"hgnc:HGNC:49191","description":"P2RX5-TAX1BP3 readthrough (NMD candidate)","metadata":null},{"id":"6744fc1172a24f10afe9b890b85e613b","type":"GENE","name":"P2RX6","canonical_id":"hgnc:HGNC:8538","description":"purinergic receptor P2X 6","metadata":{"aliases":["P2XM","MGC129625","P2X6","P2RXL1"]}},{"id":"887d73dfa43c4c4e8b7266d9cc39eb78","type":"GENE","name":"P2RX6P","canonical_id":"hgnc:HGNC:34076","description":"purinergic receptor P2X 6 pseudogene","metadata":null},{"id":"741e1b4caa5d4ac88b08b6dfd0c1dd0c","type":"GENE","name":"P2RX7","canonical_id":"hgnc:HGNC:8537","description":"purinergic receptor P2X 7","metadata":{"aliases":["P2X7","MGC20089"]}},{"id":"88acdbb9ec504c08bc9eceed478f8988","type":"GENE","name":"P2RY1","canonical_id":"hgnc:HGNC:8539","description":"purinergic receptor P2Y1","metadata":{"aliases":["P2Y1","SARCC"]}},{"id":"169674de6d3e4c979e5b82fe11262ae4","type":"GENE","name":"P2RY10","canonical_id":"hgnc:HGNC:19906","description":null,"metadata":null},{"id":"1be30a80e370492fbe03c0249f8117d4","type":"GENE","name":"P2RY10BP","canonical_id":"hgnc:HGNC:32924","description":"P2Y receptor family member 10B, pseudogene","metadata":{"aliases":["P2RY10P2"]}},{"id":"b9c301bc3e6b4746af313778ee244cf4","type":"GENE","name":"P2RY11","canonical_id":"hgnc:HGNC:8540","description":"purinergic receptor P2Y11","metadata":{"aliases":["P2Y11"]}},{"id":"f6f322628f774b2594fa9c7c42873b2b","type":"GENE","name":"P2RY12","canonical_id":"hgnc:HGNC:18124","description":"purinergic receptor P2Y12","metadata":{"aliases":["P2Y12","SP1999","HORK3"]}},{"id":"ec27d14c4e4e46fca88d4da7fdea65a6","type":"PROTEIN","name":"P2RY12","canonical_id":"uniprot:Q9H244","description":null,"metadata":null},{"id":"adc8426fcbe04a0181b6c593993c5813","type":"GENE","name":"P2RY13","canonical_id":"hgnc:HGNC:4537","description":"purinergic receptor P2Y13","metadata":{"aliases":["FKSG77","P2Y13","GPR94","GPR86"]}},{"id":"79466a067db7435587598ea21ed13fa6","type":"GENE","name":"P2RY14","canonical_id":"hgnc:HGNC:16442","description":"purinergic receptor P2Y14","metadata":{"aliases":["KIAA0001","GPR105"]}},{"id":"d743b75b23d84c8b9a565e68e4ccd5e4","type":"GENE","name":"P2RY2","canonical_id":"hgnc:HGNC:8541","description":"purinergic receptor P2Y2","metadata":{"aliases":["P2U"]}},{"id":"68f8982a870841ae8cdc4514c28886b6","type":"GENE","name":"P2RY4","canonical_id":"hgnc:HGNC:8542","description":"pyrimidinergic receptor P2Y4","metadata":{"aliases":["NRU","P2Y4","UNR","P2P"]}},{"id":"5176dc2dbf584e46bfb6fa17668967f7","type":"GENE","name":"P2RY6","canonical_id":"hgnc:HGNC:8543","description":"pyrimidinergic receptor P2Y6","metadata":{"aliases":["P2Y6"]}},{"id":"4e7dc2c9c8c94fcba512ff06160e1a3f","type":"GENE","name":"P2RY8","canonical_id":"hgnc:HGNC:15524","description":"P2Y receptor family member 8","metadata":{"aliases":["P2Y8"]}},{"id":"7c12a5e96dcc4a48bc85f58a2b21e5d2","type":"GO_TERM","name":"P2Y1 nucleotide receptor binding","canonical_id":"go:GO:0031812","description":"\"Binding to a P2Y1 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"b667bb49798240309ffd5e57d7c2b40e","type":"GO_TERM","name":"P2Y10 nucleotide receptor binding","canonical_id":"go:GO:0031819","description":"\"Binding to a P2Y10 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"fd4a1b444b734632a2ce5f04c33ab7b6","type":"GO_TERM","name":"P2Y11 nucleotide receptor binding","canonical_id":"go:GO:0031820","description":"\"Binding to a P2Y11 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d6736166cbc94e5b8c3d42914b9376c9","type":"GO_TERM","name":"P2Y2 nucleotide receptor binding","canonical_id":"go:GO:0031813","description":"\"Binding to a P2Y2 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6b40f23de80243448823a62b632009c2","type":"GO_TERM","name":"P2Y4 nucleotide receptor binding","canonical_id":"go:GO:0031814","description":"\"Binding to a P2Y4 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"4ac6ee3a450f48a09b1628f028431945","type":"GO_TERM","name":"P2Y5 nucleotide receptor binding","canonical_id":"go:GO:0031815","description":"\"Binding to a P2Y5 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ca6dfd3fda2b48f397fc00865820af94","type":"GO_TERM","name":"P2Y6 nucleotide receptor binding","canonical_id":"go:GO:0031816","description":"\"Binding to a P2Y6 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6c3841a95d3a410ca89ef5cbdf219eca","type":"GO_TERM","name":"P2Y8 nucleotide receptor binding","canonical_id":"go:GO:0031817","description":"\"Binding to a P2Y8 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ce621c9365434d17b770ba58a4b58912","type":"GO_TERM","name":"P2Y9 nucleotide receptor binding","canonical_id":"go:GO:0031818","description":"\"Binding to a P2Y9 nucleotide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9fa084c0696d414ba141513a0482905d","type":"TRIAL","name":"P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01708603","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"76d2573c64214f0d94435c8bb6c9d7ad","type":"GO_TERM","name":"P3 peroxisome","canonical_id":"go:GO:0019821","description":"\"A subform of peroxisome that corresponds to an intermediate in a peroxisome assembly pathway, which operates by conversion of peroxisomal subforms in the direction P1, P2 -> P3 -> P4 -> P5 -> P6. P3 peroxisomes are formed by fusion of P1 and P2 peroxisomes, and are distinguished from the other subforms on the bases of buoyant density and protein content.\" [PMID:10629216]","metadata":null},{"id":"b095c15b7fd24c48a4620b19a4518946","type":"TRIAL","name":"P3AMI Antiplatelet Trial","canonical_id":"clinicaltrials.gov:NCT02376283","description":"Heart Attack","metadata":null},{"id":"9fc41503906f43ef8df4c034d3380e33","type":"GENE","name":"P3H1","canonical_id":"hgnc:HGNC:19316","description":"prolyl 3-hydroxylase 1","metadata":{"aliases":["GROS1","LEPRECAN","MGC117314","LEPRE1"]}},{"id":"dc5076c698d9455092fc944b0682f082","type":"GENE","name":"P3H2","canonical_id":"hgnc:HGNC:19317","description":"prolyl 3-hydroxylase 2","metadata":{"aliases":["FLJ10718","MLAT4","LEPREL1"]}},{"id":"523c8d5ade4d4668b62c57098f0e7756","type":"GENE","name":"P3H2-AS1","canonical_id":"hgnc:HGNC:40886","description":"P3H2 antisense RNA 1","metadata":{"aliases":["LEPREL1-AS1"]}},{"id":"9c55b090ab204c38bd50435199da979d","type":"GENE","name":"P3H3","canonical_id":"hgnc:HGNC:19318","description":"prolyl 3-hydroxylase 3","metadata":{"aliases":["GRCB","HSU47926","LEPREL2"]}},{"id":"b16ad1dcf4a94a9ebe12b8d9df7c7c71","type":"GENE","name":"P3H4","canonical_id":"hgnc:HGNC:16946","description":"prolyl 3-hydroxylase family member 4 (inactive)","metadata":{"aliases":["SC65","NO55","LEPREL4"]}},{"id":"16ba9123cda6496a9b2256f76b008d4c","type":"GENE","name":"P3R3URF","canonical_id":"hgnc:HGNC:53451","description":"PIK3R3 upstream open reading frame","metadata":null},{"id":"c02f4cea66794cd8923a08d6cc5dd44d","type":"GENE","name":"P3R3URF-PIK3R3","canonical_id":"hgnc:HGNC:54999","description":"P3R3URF-PIK3R3 readthrough","metadata":null},{"id":"166f4349018d4c6385a41c65ad96320e","type":"GO_TERM","name":"P4 peroxisome","canonical_id":"go:GO:0019822","description":"\"A subform of peroxisome that corresponds to an intermediate in a peroxisome assembly pathway, which operates by conversion of peroxisomal subforms in the direction P1, P2 -> P3 -> P4 -> P5 -> P6. P4 peroxisomes are distinguished from the other subforms on the bases of buoyant density and protein content.\" [PMID:10629216]","metadata":null},{"id":"6a8ec58391114dfcb09e8694a7564ce5","type":"GO_TERM","name":"P450-containing electron transport chain","canonical_id":"go:GO:0140647","description":"\"A electron transport chain in which one or more electron carriers operate to transfer electrons from donors to a cytochrome P450 protein or domain. Electron carriers operating in this chain include FAD-containing flavoproteins or domains, FMN domains, ferredoxins and cytochrome b5. The reduced cytochrome P450 functions as the terminal oxidase and participates in a wide range of biochemical pathways.\" [PMID:16042601]","metadata":null},{"id":"e4ee0f6bf9a648bbbb382cb14b16cb9f","type":"GENE","name":"P4HA1","canonical_id":"hgnc:HGNC:8546","description":null,"metadata":null},{"id":"07c67effbd8340e18433af6544b2483f","type":"GENE","name":"P4HA2","canonical_id":"hgnc:HGNC:8547","description":"prolyl 4-hydroxylase subunit alpha 2","metadata":{"aliases":["C-P4Halpha(II)","lncRNA-PE"]}},{"id":"cfddbb1480154b1fbef422fd64af5d5c","type":"GENE","name":"P4HA2-AS1","canonical_id":"hgnc:HGNC:43560","description":"P4HA2 antisense RNA 1","metadata":null},{"id":"531adc355b8047e3bed1f0afe462e2d0","type":"GENE","name":"P4HA3","canonical_id":"hgnc:HGNC:30135","description":"prolyl 4-hydroxylase subunit alpha 3","metadata":{"aliases":["C-P4Halpha(III)"]}},{"id":"f81dc1cbb1aa41539ddf357db422e519","type":"GENE","name":"P4HA3-AS1","canonical_id":"hgnc:HGNC:53160","description":"P4HA3 antisense RNA 1","metadata":null},{"id":"70432075294c47fca97fab3d240e95eb","type":"GENE","name":"P4HB","canonical_id":"hgnc:HGNC:8548","description":"prolyl 4-hydroxylase subunit beta","metadata":{"aliases":["PDIA1","PROHB","DSI","GIT","PDI","PO4HB","P4Hbeta","PO4DB","ERBA2L"]}},{"id":"d59b46bc449744aa8e20dde3a2f12b58","type":"GENE","name":"P4HB-AS1","canonical_id":"hgnc:HGNC:58201","description":"P4HB antisense RNA 1","metadata":null},{"id":"f658aea8142940d8b4e728735330d92a","type":"GENE","name":"P4HTM","canonical_id":"hgnc:HGNC:28858","description":"prolyl 4-hydroxylase, transmembrane","metadata":{"aliases":["P4H-TM","PHD4","PH4","HIFPH4","FLJ20262","EGLN4","PH-4"]}},{"id":"9df6723b8801459f8b16e0fedf53b2ab","type":"GO_TERM","name":"P5 peroxisome","canonical_id":"go:GO:0019823","description":"\"A subform of peroxisome that corresponds to an intermediate in a peroxisome assembly pathway, which operates by conversion of peroxisomal subforms in the direction P1, P2 -> P3 -> P4 -> P5 -> P6. P5 peroxisomes are distinguished from the other subforms on the bases of buoyant density and protein content.\" [PMID:10629216]","metadata":null},{"id":"3148dcc329c24b5ba19e4d337a1e632d","type":"GO_TERM","name":"P6 peroxisome","canonical_id":"go:GO:0019824","description":"\"A subform of peroxisome that corresponds to an intermediate in a peroxisome assembly pathway, which operates by conversion of peroxisomal subforms in the direction P1, P2 -> P3 -> P4 -> P5 -> P6. P6 peroxisomes are distinguished from the other subforms on the bases of buoyant density and protein content, and are equivalent to mature peroxisomes.\" [PMID:10629216]","metadata":null},{"id":"2c06c5d09af2441ab7afea19b02e5045","type":"GENE","name":"PA2G4","canonical_id":"hgnc:HGNC:8550","description":null,"metadata":null},{"id":"397631427d71454290dbfddb427d7866","type":"GENE","name":"PA2G4P1","canonical_id":"hgnc:HGNC:8551","description":"proliferation-associated 2G4 pseudogene 1","metadata":{"aliases":["PA2G4P"]}},{"id":"8a101dd4ff414c5ba27eb3ecebf10390","type":"GENE","name":"PA2G4P2","canonical_id":"hgnc:HGNC:16531","description":"proliferation-associated 2G4 pseudogene 2","metadata":{"aliases":["bA102J14.2","PA2G4L5"]}},{"id":"6c62124d963c43e596aa42b27cfb8c59","type":"GENE","name":"PA2G4P3","canonical_id":"hgnc:HGNC:31731","description":"proliferation-associated 2G4 pseudogene 3","metadata":{"aliases":["HsT2542","PA2G4L4"]}},{"id":"4960441da14642f695818bdeb16af5d0","type":"GENE","name":"PA2G4P4","canonical_id":"hgnc:HGNC:32217","description":"proliferation-associated 2G4 pseudogene 4","metadata":{"aliases":["PA2G4L1"]}},{"id":"bdfa60ac33ff43e49b38b71068e22d03","type":"GENE","name":"PA2G4P5","canonical_id":"hgnc:HGNC:32218","description":"proliferation-associated 2G4 pseudogene 5","metadata":{"aliases":["PA2G4L2"]}},{"id":"15628ead45f14fc78d40d1212156f9c9","type":"GENE","name":"PA2G4P6","canonical_id":"hgnc:HGNC:32219","description":"proliferation-associated 2G4 pseudogene 6","metadata":{"aliases":["PA2G4L3"]}},{"id":"3ac128e473904803b1b126c418214608","type":"GENE","name":"PAAF1","canonical_id":"hgnc:HGNC:25687","description":"proteasomal ATPase associated factor 1","metadata":{"aliases":["FLJ11848","Rpn14","WDR71"]}},{"id":"52595d5c2c4c480b89ae14ad76db1b68","type":"GENE","name":"PABIR1","canonical_id":"hgnc:HGNC:23490","description":"PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1","metadata":{"aliases":["MGC17347","C9orf42","FAM122A"]}},{"id":"9221877c73bc42a3870ee9d4669a6eee","type":"GENE","name":"PABIR2","canonical_id":"hgnc:HGNC:30490","description":"PABIR family member 2","metadata":{"aliases":["DKFZp686L20116","RP11-308B5.5","SPACIA2","FAM122B"]}},{"id":"6bed2879f97d4e59ae5e0af8a41b6ccc","type":"GENE","name":"PABIR3","canonical_id":"hgnc:HGNC:25202","description":"PABIR family member 3","metadata":{"aliases":["RP3-473B4.1","FAM122C"]}},{"id":"4ae56fbfe1fb49c986d6eed923915cc0","type":"GENE","name":"PABPC1","canonical_id":"hgnc:HGNC:8554","description":"poly(A) binding protein cytoplasmic 1","metadata":{"aliases":["PABP1","PABPL1","PAB1","PABPC2"]}},{"id":"306fa00890d3429aa7f86a3e2e15f450","type":"GENE","name":"PABPC1L","canonical_id":"hgnc:HGNC:15797","description":"poly(A) binding protein cytoplasmic 1 like","metadata":{"aliases":["dJ1069P2.3","PABPC1L1","ePAB","C20orf119"]}},{"id":"b9115b67cba94516b0c8a34e6f32b0e8","type":"GENE","name":"PABPC1L2A","canonical_id":"hgnc:HGNC:27989","description":"poly(A) binding protein cytoplasmic 1 like 2A","metadata":{"aliases":["RBM32A"]}},{"id":"44db6ba20181493e89802d8d593ac86d","type":"GENE","name":"PABPC1L2B","canonical_id":"hgnc:HGNC:31852","description":"poly(A) binding protein cytoplasmic 1 like 2B","metadata":{"aliases":["RBM32B"]}},{"id":"1e48e6d4d4fc452db7ed9fa2f501f373","type":"GENE","name":"PABPC1L2B-AS1","canonical_id":"hgnc:HGNC:50345","description":"PABPC1L2B antisense RNA 1","metadata":null},{"id":"d54f1f6cedb64c78837f4208cfc9f708","type":"GENE","name":"PABPC1P1","canonical_id":"hgnc:HGNC:8558","description":"poly(A) binding protein cytoplasmic 1 pseudogene 1","metadata":{"aliases":["PABP1","PABPCP1"]}},{"id":"8ff0d72532644b69a92298aca945479c","type":"GENE","name":"PABPC1P10","canonical_id":"hgnc:HGNC:37992","description":"poly(A) binding protein cytoplasmic 1 pseudogene 10","metadata":{"aliases":["D3S3192","PABPL1"]}},{"id":"c4cd43aec6fe4754bc60c42946611d1d","type":"GENE","name":"PABPC1P11","canonical_id":"hgnc:HGNC:37993","description":"poly(A) binding protein cytoplasmic 1 pseudogene 11","metadata":null},{"id":"f336181bbed2455e8c32dd1153ce41e1","type":"GENE","name":"PABPC1P12","canonical_id":"hgnc:HGNC:37994","description":"poly(A) binding protein cytoplasmic 1 pseudogene 12","metadata":null},{"id":"bb14659fc91b4681ac70f7bd63665f65","type":"GENE","name":"PABPC1P13","canonical_id":"hgnc:HGNC:37995","description":"poly(A) binding protein cytoplasmic 1 pseudogene 13","metadata":null},{"id":"b31db331b2f94e1ca4636ba5a7d992c1","type":"GENE","name":"PABPC1P2","canonical_id":"hgnc:HGNC:8559","description":"poly(A) binding protein cytoplasmic 1 pseudogene 2","metadata":{"aliases":["PABP2","PABP4","PABPCP4","PABPCP2"]}},{"id":"67902fba577544f3a7bf1ad140758834","type":"GENE","name":"PABPC1P3","canonical_id":"hgnc:HGNC:8560","description":"poly(A) binding protein cytoplasmic 1 pseudogene 3","metadata":{"aliases":["PABP3","PABPCP3"]}},{"id":"d2e9adbd4ae44eddbc429a687e6efe06","type":"GENE","name":"PABPC1P4","canonical_id":"hgnc:HGNC:8563","description":"poly(A) binding protein cytoplasmic 1 pseudogene 4","metadata":{"aliases":["PABPL2","PABPCP5"]}},{"id":"6852bb49f06b49009294113349b20ccd","type":"GENE","name":"PABPC1P5","canonical_id":"hgnc:HGNC:37985","description":"poly(A) binding protein cytoplasmic 1 pseudogene 5","metadata":null},{"id":"20649d00183746a3adb5516f89b26b94","type":"GENE","name":"PABPC1P6","canonical_id":"hgnc:HGNC:37986","description":"poly(A) binding protein cytoplasmic 1 pseudogene 6","metadata":null},{"id":"18841f748f48450daea5f0d9839a2272","type":"GENE","name":"PABPC1P7","canonical_id":"hgnc:HGNC:37987","description":"poly(A) binding protein cytoplasmic 1 pseudogene 7","metadata":null},{"id":"2c9d2f8d846a4d21a3df255676e2cf04","type":"GENE","name":"PABPC1P8","canonical_id":"hgnc:HGNC:37988","description":"poly(A) binding protein cytoplasmic 1 pseudogene 8","metadata":null},{"id":"7628b27b20be417a82a9acf38aadd282","type":"GENE","name":"PABPC1P9","canonical_id":"hgnc:HGNC:37991","description":"poly(A) binding protein cytoplasmic 1 pseudogene 9","metadata":null},{"id":"8cc5c58d6a11489ca9022c9ac9989c40","type":"GENE","name":"PABPC3","canonical_id":"hgnc:HGNC:8556","description":"poly(A) binding protein cytoplasmic 3","metadata":{"aliases":["PABP3","tPABP","PABPL3"]}},{"id":"03f1d7d2eb9b46198f61f9a55c548ffe","type":"GENE","name":"PABPC4","canonical_id":"hgnc:HGNC:8557","description":"poly(A) binding protein cytoplasmic 4","metadata":{"aliases":["iPABP","APP-1"]}},{"id":"b699cbc08ddf4044a1f5e30e81b6c4b8","type":"GENE","name":"PABPC4-AS1","canonical_id":"hgnc:HGNC:40424","description":"PABPC4 antisense RNA 1","metadata":null},{"id":"e60f3f9827104467b12bc6fccc5c47a9","type":"GENE","name":"PABPC4L","canonical_id":"hgnc:HGNC:31955","description":"poly(A) binding protein cytoplasmic 4 like","metadata":null},{"id":"1d4058cfd7b14b06a792b13f56b7d869","type":"GENE","name":"PABPC5","canonical_id":"hgnc:HGNC:13629","description":"poly(A) binding protein cytoplasmic 5","metadata":{"aliases":["PABP5"]}},{"id":"8c9757fb940346f0a66195215ac11964","type":"GENE","name":"PABPC5-AS1","canonical_id":"hgnc:HGNC:31845","description":"PABPC5 antisense RNA 1","metadata":{"aliases":["OTTHUMG00000021960","CXorf46"]}},{"id":"e1d3883799e34ffea9da0b7078533561","type":"GENE","name":"PABPN1","canonical_id":"hgnc:HGNC:8565","description":"poly(A) binding protein nuclear 1","metadata":{"aliases":["PAB2","OPMD","PABP2"]}},{"id":"e2ca63c3d9e54800801bb1fe12a229a0","type":"GENE","name":"PABPN1L","canonical_id":"hgnc:HGNC:37237","description":"PABPN1 like, cytoplasmic","metadata":{"aliases":["ePABP2"]}},{"id":"7bc2e18eabe44391816b4a767b9b81b9","type":"GENE","name":"PABPN1P1","canonical_id":"hgnc:HGNC:54988","description":"PABPN1 pseudogene 1","metadata":null},{"id":"038bc43c8e3b4430a3574b3cf4fb7119","type":"GENE","name":"PABPN1P2","canonical_id":"hgnc:HGNC:54989","description":"PABPN1 pseudogene 2","metadata":null},{"id":"983f8f9707a74f009062afeb325dcfc1","type":"GENE","name":"PABX","canonical_id":"hgnc:HGNC:8566","description":"pseudoautosomal boundary region, X-linked","metadata":null},{"id":"b20b7c9aa4f14458b3bda9bff8a4633d","type":"GENE","name":"PABY","canonical_id":"hgnc:HGNC:8567","description":"pseudoautosomal boundary region, Y-linked","metadata":null},{"id":"11194b8540494d38b34ae19f9677cd51","type":"GENE","name":"PACC1","canonical_id":"hgnc:HGNC:25593","description":"proton activated chloride channel 1","metadata":{"aliases":["FLJ10874","PAC","ASOR","PAORAC","C1orf75","TMEM206"]}},{"id":"357fa939dfe743098e770d7a1d694139","type":"GENE","name":"PACERR","canonical_id":"hgnc:HGNC:50552","description":"PTGS2 antisense NFKB1 complex-mediated expression regulator RNA","metadata":{"aliases":["PACER","PTGS2-AS1"]}},{"id":"0807509604244d6caa4ff8f325f922ea","type":"GENE","name":"PACRG","canonical_id":"hgnc:HGNC:19152","description":"parkin coregulated","metadata":{"aliases":["PARK2CRG","FLJ32724","Glup","HAK005771","BUG21","pf12"]}},{"id":"9c23a4c26fcc4f8c9d60060b1ee9bbea","type":"GENE","name":"PACRG-AS1","canonical_id":"hgnc:HGNC:27772","description":"PACRG antisense RNA 1","metadata":null},{"id":"96e160443726435c9b768a6489aee97d","type":"GENE","name":"PACRG-AS2","canonical_id":"hgnc:HGNC:40871","description":"PACRG antisense RNA 2","metadata":null},{"id":"07c4bb66cf02480ab6449be6ca44e13f","type":"GENE","name":"PACRG-AS3","canonical_id":"hgnc:HGNC:52053","description":"PACRG antisense RNA 3","metadata":null},{"id":"df8f97593ba24676ad94287017461a78","type":"GENE","name":"PACRGL","canonical_id":"hgnc:HGNC:28442","description":"parkin coregulated like","metadata":{"aliases":["MGC29898","C4orf28"]}},{"id":"850f4a0809694d43841e9e70669d5533","type":"GENE","name":"PACS1","canonical_id":"hgnc:HGNC:30032","description":"phosphofurin acidic cluster sorting protein 1","metadata":{"aliases":["FLJ10209","KIAA1175"]}},{"id":"76153f3527eb42eb98db6581ff008b60","type":"GENE","name":"PACS2","canonical_id":"hgnc:HGNC:23794","description":"phosphofurin acidic cluster sorting protein 2","metadata":{"aliases":["KIAA0602","PACS1L"]}},{"id":"359c0855c08d4f4cbbfc4f4b0011bcea","type":"GENE","name":"PACSIN1","canonical_id":"hgnc:HGNC:8570","description":"protein kinase C and casein kinase substrate in neurons 1","metadata":{"aliases":["SDPI"]}},{"id":"d257d959545945a28ea166be9590d85f","type":"GENE","name":"PACSIN2","canonical_id":"hgnc:HGNC:8571","description":"protein kinase C and casein kinase substrate in neurons 2","metadata":{"aliases":["SDPII"]}},{"id":"dae0efdb38bf4e558ce1c25eb6e5d20a","type":"GENE","name":"PACSIN3","canonical_id":"hgnc:HGNC:8572","description":"protein kinase C and casein kinase substrate in neurons 3","metadata":{"aliases":["SDPIII"]}},{"id":"27480bff8d424e589b21c3297271181b","type":"GENE","name":"PADI1","canonical_id":"hgnc:HGNC:18367","description":null,"metadata":null},{"id":"825ee44ad6cf40f9a5bc7cfbac8a913c","type":"GENE","name":"PADI2","canonical_id":"hgnc:HGNC:18341","description":"peptidyl arginine deiminase 2","metadata":{"aliases":["KIAA0994","PDI2"]}},{"id":"471ab78adaf4497f870695799b7b85c4","type":"GENE","name":"PADI3","canonical_id":"hgnc:HGNC:18337","description":null,"metadata":null},{"id":"6cb2180c246143768211c8686fe51062","type":"GENE","name":"PADI4","canonical_id":"hgnc:HGNC:18368","description":"peptidyl arginine deiminase 4","metadata":{"aliases":["PAD","PDI5","PDI4","PADI5"]}},{"id":"ff3c04f8bdb04360b7ff1c1edd40fd39","type":"GENE","name":"PADI6","canonical_id":"hgnc:HGNC:20449","description":"peptidyl arginine deiminase 6","metadata":null},{"id":"3cdf1a6090214ab09b5cde4fee81702f","type":"GENE","name":"PAEP","canonical_id":"hgnc:HGNC:8573","description":null,"metadata":null},{"id":"cb670fa5611248158201910491a5a87d","type":"GENE","name":"PAEPP1","canonical_id":"hgnc:HGNC:49600","description":"progestagen associated endometrial protein pseudogene 1","metadata":null},{"id":"1696115966064ca89e8bab89c8f9d1bf","type":"GENE","name":"PAF1","canonical_id":"hgnc:HGNC:25459","description":"PAF1 component of Paf1/RNA polymerase II complex","metadata":{"aliases":["PD2","F23149_1","FLJ11123"]}},{"id":"e79e6ff1874247688b8bc09d568bc272","type":"GENE","name":"PAFAH1B1","canonical_id":"hgnc:HGNC:8574","description":"platelet activating factor acetylhydrolase 1b regulatory subunit 1","metadata":{"aliases":["LIS1","PAFAH","NudF","MDCR","MDS"]}},{"id":"49acdeaf693e48c99d18d3d6fc21bccc","type":"GENE","name":"PAFAH1B1P1","canonical_id":"hgnc:HGNC:8577","description":"platelet activating factor acetylhydrolase 1b regulatory subunit 1 pseudogene 1","metadata":{"aliases":["LIS2","PAFAH1P1"]}},{"id":"e3ef98de3ca04465b35245a628e534b6","type":"GENE","name":"PAFAH1B1P2","canonical_id":"hgnc:HGNC:8578","description":"platelet activating factor acetylhydrolase 1b regulatory subunit 1 pseudogene 2","metadata":{"aliases":["LIS2P","PAFAH1P2"]}},{"id":"fee101ade663488a8d83dff4944c7e04","type":"GENE","name":"PAFAH1B2","canonical_id":"hgnc:HGNC:8575","description":"platelet activating factor acetylhydrolase 1b catalytic subunit 2","metadata":null},{"id":"b286730d08de4c1792aeca81c59165c8","type":"GENE","name":"PAFAH1B2P1","canonical_id":"hgnc:HGNC:54905","description":"PAFAH1B2 pseudogene 1","metadata":null},{"id":"c2637d591b304f6aaf3949c4631bf1fd","type":"GENE","name":"PAFAH1B2P2","canonical_id":"hgnc:HGNC:54906","description":"PAFAH1B2 pseudogene 2","metadata":null},{"id":"4e8259cc0d7d4b88873e56b0b294f79a","type":"GENE","name":"PAFAH1B3","canonical_id":"hgnc:HGNC:8576","description":"platelet activating factor acetylhydrolase 1b catalytic subunit 3","metadata":null},{"id":"befe5733a0f24ddb9f2e48130c6710fd","type":"GENE","name":"PAFAH2","canonical_id":"hgnc:HGNC:8579","description":"platelet activating factor acetylhydrolase 2","metadata":{"aliases":["HSD-PLA2"]}},{"id":"92c413401a5241a3baccf1823998d2b8","type":"GENE","name":"PAG1","canonical_id":"hgnc:HGNC:30043","description":"phosphoprotein membrane anchor with glycosphingolipid microdomains 1","metadata":{"aliases":["PAG","CBP"]}},{"id":"bfbbcb1ea49940058bfa2bc559f06ef9","type":"GENE","name":"PAGE1","canonical_id":"hgnc:HGNC:4107","description":"PAGE family member 1","metadata":{"aliases":["PAGE-1","GAGE-9","CT16.3","GAGEB1"]}},{"id":"9c2496e559af4f37a845dc188a0b4fad","type":"GENE","name":"PAGE2","canonical_id":"hgnc:HGNC:31804","description":"PAGE family member 2","metadata":{"aliases":["MGC62094","PAGE-2","CT16.4","GAGEC2"]}},{"id":"5c412d4f29ed4ea39cef2b4d18bdd254","type":"GENE","name":"PAGE2B","canonical_id":"hgnc:HGNC:31805","description":"PAGE family member 2B","metadata":{"aliases":["CT16.5"]}},{"id":"90d4896836194907ba0fa1854f12ce15","type":"GENE","name":"PAGE3","canonical_id":"hgnc:HGNC:4110","description":"PAGE family member 3","metadata":{"aliases":["PAGE-3","CT16.6","GAGED1"]}},{"id":"a5fcde1146be432296714ddb4f79f62c","type":"GENE","name":"PAGE4","canonical_id":"hgnc:HGNC:4108","description":"PAGE family member 4","metadata":{"aliases":["PAGE-4","CT16.7","GAGEC1"]}},{"id":"a62bb35f7c9b41f699d2972a72f17244","type":"GENE","name":"PAGE4P1","canonical_id":"hgnc:HGNC:56912","description":"PAGE4 pseudogene 1","metadata":null},{"id":"282b8a6165564046bb65a971b4509cec","type":"GENE","name":"PAGE5","canonical_id":"hgnc:HGNC:29992","description":"PAGE family member 5","metadata":{"aliases":["PAGE-5","CT16.1","CT16.2"]}},{"id":"8d87f2a268544f69a75e77058088e643","type":"GENE","name":"PAGR1","canonical_id":"hgnc:HGNC:28707","description":"PAXIP1 associated glutamate rich protein 1","metadata":{"aliases":["MGC4606","GAS","PA1","C16orf53"]}},{"id":"0705c7e70f8843bf8fc720b591917872","type":"GENE","name":"PAH","canonical_id":"hgnc:HGNC:8582","description":"phenylalanine hydroxylase","metadata":{"aliases":["PH"]}},{"id":"1ecf6743afb444aab611a7a5d2fdb792","type":"GENE","name":"PAICS","canonical_id":"hgnc:HGNC:8587","description":"phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase","metadata":{"aliases":["ADE2H1","AIRC","PAIS"]}},{"id":"d2376fbb61de4ac6a51f3b2475e689c0","type":"GENE","name":"PAICSP1","canonical_id":"hgnc:HGNC:8588","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 1","metadata":null},{"id":"2285a0f2877645a899f3ee0dad978b4d","type":"GENE","name":"PAICSP2","canonical_id":"hgnc:HGNC:8589","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 2","metadata":null},{"id":"4cf0a70feb224c3c877fa3094ebbbe3e","type":"GENE","name":"PAICSP3","canonical_id":"hgnc:HGNC:38096","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 3","metadata":null},{"id":"9d8ee933e5224d86a43bdbc5e81aec62","type":"GENE","name":"PAICSP4","canonical_id":"hgnc:HGNC:38097","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 4","metadata":null},{"id":"2b8ae8b587d84462b67303d5b6149f85","type":"GENE","name":"PAICSP5","canonical_id":"hgnc:HGNC:38098","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 5","metadata":null},{"id":"067ca0cc341d470a841b50977f9c7602","type":"GENE","name":"PAICSP6","canonical_id":"hgnc:HGNC:38099","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 6","metadata":null},{"id":"cbf5022ab6bd423aba1d445f8e634827","type":"GENE","name":"PAICSP7","canonical_id":"hgnc:HGNC:38100","description":"phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase pseudogene 7","metadata":null},{"id":"9ba245a725154e4482a6947ec3eb41bc","type":"GENE","name":"PAIP1","canonical_id":"hgnc:HGNC:16945","description":"poly(A) binding protein interacting protein 1","metadata":null},{"id":"d15e7397f8ac4fcfa7aff95ffcab2eed","type":"GENE","name":"PAIP1P1","canonical_id":"hgnc:HGNC:18240","description":"PAIP1 pseudogene 1","metadata":{"aliases":["bQB44E15.5","bPG254M11.3","bCX300M20.3"]}},{"id":"9a5339304643489f810ac36c851fd0eb","type":"GENE","name":"PAIP1P2","canonical_id":"hgnc:HGNC:56189","description":"PAIP1 pseudogene 2","metadata":null},{"id":"078246c3862646f0a75d5462a0c7d1d9","type":"GENE","name":"PAIP2","canonical_id":"hgnc:HGNC:17970","description":"poly(A) binding protein interacting protein 2","metadata":{"aliases":["PAIP2A"]}},{"id":"ba3a8f514de446b9bf678800a6e66e9d","type":"GENE","name":"PAIP2B","canonical_id":"hgnc:HGNC:29200","description":"poly(A) binding protein interacting protein 2B","metadata":{"aliases":["KIAA1155"]}},{"id":"5a1ef655fd5c463cbffcd4f9cbf2b586","type":"GO_TERM","name":"PAK family kinase-Sog2 complex","canonical_id":"go:GO:0099125","description":"\"A protein kinase complex comprising a conserved PAK/GC/Ste20 family kinase, leucine rich repeat protein Sog2 family, which function as part of the cell shape network.\" [PMID:23462181]","metadata":null},{"id":"40afd7a5c3a54618b520e502767cc14d","type":"GENE","name":"PAK1","canonical_id":"hgnc:HGNC:8590","description":null,"metadata":null},{"id":"a32460fdaddb49bbb052928f79535110","type":"GENE","name":"PAK1IP1","canonical_id":"hgnc:HGNC:20882","description":"PAK1 interacting protein 1","metadata":{"aliases":["FLJ20624","hPIP1","PIP1","bA421M1.5","MAK11","WDR84"]}},{"id":"496fdfb8e2d84a60ab88f1132e0b9a1c","type":"GENE","name":"PAK2","canonical_id":"hgnc:HGNC:8591","description":"p21 (RAC1) activated kinase 2","metadata":{"aliases":["PAK65","PAKgamma"]}},{"id":"8ee859a0265f4cf0963e8c1c9618ce61","type":"GENE","name":"PAK3","canonical_id":"hgnc:HGNC:8592","description":"p21 (RAC1) activated kinase 3","metadata":{"aliases":["hPAK3","bPAK","MRX30","MRX47"]}},{"id":"b511531e3d3c4bb68b59af35ee75da9a","type":"GENE","name":"PAK4","canonical_id":"hgnc:HGNC:16059","description":"p21 (RAC1) activated kinase 4","metadata":null},{"id":"4821d0d72f5a4468884871eb68be1a58","type":"GENE","name":"PAK4-AS1","canonical_id":"hgnc:HGNC:58161","description":"PAK4 antisense RNA 1","metadata":{"aliases":["AC011443.1"]}},{"id":"e92b88f4a5334f7da10d6071c9922a63","type":"GENE","name":"PAK5","canonical_id":"hgnc:HGNC:15916","description":"p21 (RAC1) activated kinase 5","metadata":{"aliases":["KIAA1264","PAK7"]}},{"id":"967723d9432c486ab61fb162afd0d3a0","type":"GENE","name":"PAK6","canonical_id":"hgnc:HGNC:16061","description":"p21 (RAC1) activated kinase 6","metadata":{"aliases":["PAK5"]}},{"id":"7a5acd8de76b4f1086a4e70e014f0103","type":"GENE","name":"PAK6-AS1","canonical_id":"hgnc:HGNC:33868","description":"PAK6 antisense RNA 1","metadata":{"aliases":["FLJ38596","C15orf56"]}},{"id":"c483e9e14b694ed89fdaaf852a92590f","type":"GENE","name":"PALB2","canonical_id":"hgnc:HGNC:26144","description":"partner and localizer of BRCA2","metadata":{"aliases":["FLJ21816","FANCN"]}},{"id":"5a065b962b3a4630a4fffc5c28caf9f1","type":"GENE","name":"PALB2-AS1","canonical_id":"hgnc:HGNC:58305","description":"PALB2 antisense RNA 1","metadata":null},{"id":"6fe3c150ee8b4b0cb3f97fd096249508","type":"GENE","name":"PALD1","canonical_id":"hgnc:HGNC:23530","description":"phosphatase domain containing paladin 1","metadata":{"aliases":["PALD","KIAA1274"]}},{"id":"90001c76a04d4a518a36d0522e758aaa","type":"GENE","name":"PALLD","canonical_id":"hgnc:HGNC:17068","description":"palladin, cytoskeletal associated protein","metadata":{"aliases":["KIAA0992","SIH002","CGI-151"]}},{"id":"52c179dcb25648ba97c9b46e9900476a","type":"GENE","name":"PALLD-AS1","canonical_id":"hgnc:HGNC:40789","description":"PALLD antisense RNA 1","metadata":null},{"id":"4734cfe778744a559239874cb2b96ca9","type":"GENE","name":"PALM","canonical_id":"hgnc:HGNC:8594","description":"paralemmin","metadata":{"aliases":["KIAA0270","PALM1"]}},{"id":"ed6470051e9e4855aa578a5c074ea24c","type":"GENE","name":"PALM2","canonical_id":"hgnc:HGNC:15845","description":"paralemmin 2","metadata":null},{"id":"81835bdfd83e42f887295ffd30bbba15","type":"GENE","name":"PALM2AKAP2","canonical_id":"hgnc:HGNC:33529","description":"PALM2 and AKAP2 fusion","metadata":{"aliases":["PALM2-AKAP2"]}},{"id":"bd6412b014b34eedbef0a8fa260ab05f","type":"GENE","name":"PALM2AKAP2-AS1","canonical_id":"hgnc:HGNC:58228","description":"PALM2AKAP2 antisense RNA 1","metadata":null},{"id":"94e9d2856c0f4d5c875e4b67f45f2ad7","type":"GENE","name":"PALM3","canonical_id":"hgnc:HGNC:33274","description":"paralemmin 3","metadata":null},{"id":"97e9ac333a8f49d59c1bc0fc2f47aaf8","type":"GENE","name":"PALMD","canonical_id":"hgnc:HGNC:15846","description":"palmdelphin","metadata":{"aliases":["FLJ20271","PALML","C1orf11"]}},{"id":"df745751491346b29fe207d79f90d0a7","type":"GENE","name":"PALS1","canonical_id":"hgnc:HGNC:18669","description":"protein associated with LIN7 1, MAGUK p55 family member","metadata":{"aliases":["FLJ12615","MPP5"]}},{"id":"74bf550ce3924c9784f0cf5e3d459d53","type":"GENE","name":"PALS2","canonical_id":"hgnc:HGNC:18167","description":"protein associated with LIN7 2, MAGUK p55 family member","metadata":{"aliases":["VAM-1","p55T","MPP6"]}},{"id":"f78d5a08e39f4f3bb1522c76e7b03fd9","type":"GENE","name":"PAM","canonical_id":"hgnc:HGNC:8596","description":"peptidylglycine alpha-amidating monooxygenase","metadata":{"aliases":["PAL","PHM","PAM-1"]}},{"id":"9d966fd38e934aa588578c1e3d877173","type":"GO_TERM","name":"PAM complex, Tim23 associated import motor","canonical_id":"go:GO:0001405","description":"\"Protein complex located on the matrix side of the mitochondrial inner membrane and associated with the TIM23 mitochondrial import inner membrane translocase complex (GO:0005744); ATPase motor activity to drive import of proteins into the mitochondrial matrix.\" [GOC:mcc, GOC:vw, PMID:14517234, PMID:14638855]","metadata":null},{"id":"5c995899cc9141ef830a22864e049d1d","type":"GENE","name":"PAM-AS1","canonical_id":"hgnc:HGNC:59104","description":"PAM antisense RNA 1","metadata":null},{"id":"db3d4ab10ceb40d58c714ab9096aa3d3","type":"GENE","name":"PAM16","canonical_id":"hgnc:HGNC:29679","description":"presequence translocase associated motor 16","metadata":{"aliases":["Magmas","Tim16","TIMM16"]}},{"id":"0551818505e44100a01a7d1b1e4828cc","type":"GO_TERM","name":"PAMP receptor decoy activity","canonical_id":"go:GO:0140320","description":"\"Binding and sequestering PAMP ligands in order to prevent them from binding and activating to the host PAMP receptor. Usually this activity is encoded by a symbiont or a pathogen to prevent activation of the host innate immune response.\" [PMID:20724636]","metadata":null},{"id":"d600bea550014eb39e7367324b60751c","type":"GENE","name":"PAMR1","canonical_id":"hgnc:HGNC:24554","description":"peptidase domain containing associated with muscle regeneration 1","metadata":{"aliases":["RAMP","DKFZP586H2123"]}},{"id":"ae242ccbc2ff407195f558dd4082cf24","type":"GO_TERM","name":"PAN complex","canonical_id":"go:GO:0031251","description":"\"A complex that possesses poly(A)-specific ribonuclease activity; catalyzes the message-specific shortening of mRNA poly(A) tails. Contains at least two subunits, known as Pan2p and Pan3p in Saccharomyces.\" [PMID:9774670]","metadata":null},{"id":"eb0d1a22aa3e4a7a8e9fc66cbc5ebfa3","type":"GENE","name":"PAN2","canonical_id":"hgnc:HGNC:20074","description":"poly(A) specific ribonuclease subunit PAN2","metadata":{"aliases":["KIAA0710","hPAN2","USP52"]}},{"id":"e0aa75ecf9d84089a5179c29f10788c0","type":"GENE","name":"PAN3","canonical_id":"hgnc:HGNC:29991","description":"poly(A) specific ribonuclease subunit PAN3","metadata":null},{"id":"43fb1e975ea14e1ab39818f49fa5ab7c","type":"GENE","name":"PAN3-AS1","canonical_id":"hgnc:HGNC:39932","description":"PAN3 antisense RNA 1","metadata":null},{"id":"d4ab63886cd04fd586b56a42b658d2bb","type":"GENE","name":"PANCR","canonical_id":"hgnc:HGNC:52282","description":"PITX2 adjacent non-coding RNA","metadata":{"aliases":["RP11-380D23.2"]}},{"id":"8aef9186d76943d3a1d79a21530d199e","type":"GENE","name":"PANDAR","canonical_id":"hgnc:HGNC:44048","description":"promoter of CDKN1A antisense DNA damage activated RNA","metadata":{"aliases":["PANDA"]}},{"id":"4583fb934dba4cc98b49dbde72203034","type":"GENE","name":"PANK1","canonical_id":"hgnc:HGNC:8598","description":"pantothenate kinase 1","metadata":{"aliases":["MGC24596","PANK1a","PANK1b","PANK"]}},{"id":"b803cdf573cf48c080cea410ca3acee9","type":"GENE","name":"PANK1-AS1","canonical_id":"hgnc:HGNC:55718","description":"PANK1 antisense RNA 1","metadata":null},{"id":"37fd380be0364b4d8882cbf837869047","type":"GENE","name":"PANK2","canonical_id":"hgnc:HGNC:15894","description":null,"metadata":null},{"id":"b9be7a1e5705423ea9415b9e8ac527b6","type":"GENE","name":"PANK2-AS1","canonical_id":"hgnc:HGNC:40732","description":"PANK2 antisense RNA 1","metadata":null},{"id":"361567df6c654728a37a93f4ad15f563","type":"GENE","name":"PANK3","canonical_id":"hgnc:HGNC:19365","description":"pantothenate kinase 3","metadata":{"aliases":["FLJ12899"]}},{"id":"625d2cde113b4160921264bf785a0d09","type":"GENE","name":"PANK3-DT","canonical_id":"hgnc:HGNC:59298","description":"PANK3 divergent transcript","metadata":null},{"id":"c05586c1efbf420892f46b50a5967273","type":"GENE","name":"PANK3P1","canonical_id":"hgnc:HGNC:58604","description":"PANK3 pseudogene 1","metadata":null},{"id":"f7c081a14a3a4d96a8bcc5a727c5a0e7","type":"GENE","name":"PANK4","canonical_id":"hgnc:HGNC:19366","description":"pantothenate kinase 4 (inactive)","metadata":{"aliases":["FLJ10782"]}},{"id":"b79d676e01594cbaaba18b8880a2c3de","type":"GENE","name":"PANO1","canonical_id":"hgnc:HGNC:51237","description":"proapoptotic nucleolar protein 1","metadata":{"aliases":["PANO"]}},{"id":"25a146f8ec7641d8a9e0276d824b2f51","type":"GENE","name":"PANTR1","canonical_id":"hgnc:HGNC:49513","description":"POU3F3 adjacent non-coding transcript 1","metadata":{"aliases":["linc-Brn1a","linc-POU3F3","LINC01114","LINC01158"]}},{"id":"c3308748343f487fb78e1ae040381bcf","type":"GENE","name":"PANX1","canonical_id":"hgnc:HGNC:8599","description":"pannexin 1","metadata":{"aliases":["MRS1","UNQ2529","PX1"]}},{"id":"231b234e87c4470181ba3118962ac10e","type":"GENE","name":"PANX2","canonical_id":"hgnc:HGNC:8600","description":"pannexin 2","metadata":{"aliases":["hPANX2","PX2"]}},{"id":"62b3b14f381e4b819ab1ed4aee46f9f1","type":"GENE","name":"PANX3","canonical_id":"hgnc:HGNC:20573","description":"pannexin 3","metadata":{"aliases":["Px3"]}},{"id":"5a59b3c41f614c83b215faf5576cd389","type":"GENE","name":"PAOX","canonical_id":"hgnc:HGNC:20837","description":"polyamine oxidase","metadata":{"aliases":["PAO"]}},{"id":"7d21ecddbdbe45bf9453bd9675cfb833","type":"GENE","name":"PAPLN","canonical_id":"hgnc:HGNC:19262","description":"papilin, proteoglycan like sulfated glycoprotein","metadata":{"aliases":["MGC50452"]}},{"id":"ad588d040ae44b8795470d541d756caf","type":"GENE","name":"PAPLN-AS1","canonical_id":"hgnc:HGNC:55451","description":"PAPLN antisense RNA 1","metadata":null},{"id":"401720b534204a8ea40471f179f47e18","type":"GENE","name":"PAPLN-AS2","canonical_id":"hgnc:HGNC:58463","description":"PAPLN antisense RNA 2","metadata":null},{"id":"53e95780f3b64f6fbecda62e0357c5d5","type":"GENE","name":"PAPOLA","canonical_id":"hgnc:HGNC:14981","description":"poly(A) polymerase alpha","metadata":{"aliases":["PAP"]}},{"id":"fe203d86ae2649308051ccf084cc5762","type":"GENE","name":"PAPOLA-DT","canonical_id":"hgnc:HGNC:55380","description":"PAPOLA divergent transcript","metadata":null},{"id":"bef3714f622a4e9cbbadcd3d064aee14","type":"GENE","name":"PAPOLB","canonical_id":"hgnc:HGNC:15970","description":"poly(A) polymerase beta","metadata":{"aliases":["PAPT"]}},{"id":"0a7a02bdd0844d48bac68ef888cdbf83","type":"GENE","name":"PAPOLG","canonical_id":"hgnc:HGNC:14982","description":"poly(A) polymerase gamma","metadata":{"aliases":["FLJ12972"]}},{"id":"39bda5b4b7034fdc87dbc572d9064c5d","type":"GENE","name":"PAPPA","canonical_id":"hgnc:HGNC:8602","description":"pappalysin 1","metadata":{"aliases":["PAPP-A","PAPPA1","IGFBP-4ase","PAPA","ASBABP2","DIPLA1"]}},{"id":"271195c5a0594621a0edd09fd5a0f990","type":"GENE","name":"PAPPA-AS1","canonical_id":"hgnc:HGNC:35152","description":"PAPPA antisense RNA 1","metadata":{"aliases":["PAPPA-AS","DIPAS","TAF4B","TAF2C2","TAFII105","NCRNA00156","PAPPAS"]}},{"id":"8e496353db7f40dfb85b1c20103b1203","type":"GENE","name":"PAPPA-AS2","canonical_id":"hgnc:HGNC:35160","description":"PAPPA antisense RNA 2","metadata":{"aliases":["AGU1"]}},{"id":"7344897fb1364f79a1b58f395e403ab4","type":"GENE","name":"PAPPA2","canonical_id":"hgnc:HGNC:14615","description":"pappalysin 2","metadata":{"aliases":["PAPPE","PAPP-A2","PLAC3"]}},{"id":"fdd77026aa3342a6b62087097578f60d","type":"GENE","name":"PAPSS1","canonical_id":"hgnc:HGNC:8603","description":"3'-phosphoadenosine 5'-phosphosulfate synthase 1","metadata":{"aliases":["ATPSK1","PAPSS"]}},{"id":"cc9f646865764362ac19177546992fc3","type":"GENE","name":"PAPSS1-AS1","canonical_id":"hgnc:HGNC:58866","description":"PAPSS1 antisense RNA 1","metadata":null},{"id":"9bdbc87d70f54ecf9e25e3a7980b1a3f","type":"GENE","name":"PAPSS2","canonical_id":"hgnc:HGNC:8604","description":null,"metadata":null},{"id":"b9b5ffd3f6b74c78ae6688fb816b33a5","type":"GENE","name":"PAQR3","canonical_id":"hgnc:HGNC:30130","description":"progestin and adipoQ receptor family member 3","metadata":null},{"id":"d0865731ffe74dfc9dbe9cd502bb82bb","type":"GENE","name":"PAQR4","canonical_id":"hgnc:HGNC:26386","description":"progestin and adipoQ receptor family member 4","metadata":{"aliases":["FLJ30002"]}},{"id":"20feec7d92f140dd98494d907650b408","type":"GENE","name":"PAQR5","canonical_id":"hgnc:HGNC:29645","description":"progestin and adipoQ receptor family member 5","metadata":{"aliases":["FLJ20190","MPRG"]}},{"id":"9a5036800fc1432193003fd99283c71b","type":"GENE","name":"PAQR5-DT","canonical_id":"hgnc:HGNC:55353","description":"PAQR5 divergent transcript","metadata":null},{"id":"8d6ca755ed264e9ab42c04542524707b","type":"GENE","name":"PAQR6","canonical_id":"hgnc:HGNC:30132","description":"progestin and adipoQ receptor family member 6","metadata":{"aliases":["FLJ22672","PRdelta"]}},{"id":"26e83272b56a4fc38d799d35ce2f9b3a","type":"GENE","name":"PAQR7","canonical_id":"hgnc:HGNC:23146","description":"progestin and adipoQ receptor family member 7","metadata":{"aliases":["mSR","MPRA","PGLP"]}},{"id":"8d7c1766d6374c37876013371f642e21","type":"GENE","name":"PAQR8","canonical_id":"hgnc:HGNC:15708","description":"progestin and adipoQ receptor family member 8","metadata":{"aliases":["LMPB1","MPRB","C6orf33"]}},{"id":"a59cd939b6284b33818542fef7a728ce","type":"GENE","name":"PAQR9","canonical_id":"hgnc:HGNC:30131","description":"progestin and adipoQ receptor family member 9","metadata":{"aliases":["FLJ41938","BLNC1"]}},{"id":"eaa137f62a9a4d889dda7dfe7e7bacd8","type":"GENE","name":"PAQR9-AS1","canonical_id":"hgnc:HGNC:50861","description":"PAQR9 antisense RNA 1","metadata":null},{"id":"4f46a805e4084a3ab76e81aa380ec83e","type":"GO_TERM","name":"PAR polarity complex","canonical_id":"go:GO:0120157","description":"\"A protein kinase complex that is required for the establishment of a cell polarity axis during the cell division cycle. Binds directly to activated CDC42 GTPase and is required for orchestrating a cellular gradient of CDC42. In S. cerevisiae components are: BEM1, CDC24 and CLA4; from worms to vertebrates it contains a PAR6 protein, PAR3 protein and an atypical PKC.\" [GOC:lnp, PMID:11113154, PMID:18005931, PMID:22500799, PMID:28682236]","metadata":null},{"id":"92d7b2c018e9410cafd0dd322f13d0b4","type":"GENE","name":"PARAIL","canonical_id":"hgnc:HGNC:55545","description":"palmitic acid regulated anti-inflammatory lncRNA","metadata":{"aliases":["AF117829.1","RIPK2-DT"]}},{"id":"bae679391c684f67bd4fc20bd793aa98","type":"GENE","name":"PARAL1","canonical_id":"hgnc:HGNC:53772","description":"PPARG activating RBM14 associated lncRNA 1","metadata":{"aliases":["NR_109"]}},{"id":"4dbb49b7765b445bb3abbdc347adb0ba","type":"GENE","name":"PARD3","canonical_id":"hgnc:HGNC:16051","description":"par-3 family cell polarity regulator","metadata":{"aliases":["PARD-3","PAR-3","PAR3","PARD3A","Bazooka","Baz","ASIP","PPP1R118"]}},{"id":"ee9fa1b780664597a83ad38c2d0bf75f","type":"GENE","name":"PARD3-DT","canonical_id":"hgnc:HGNC:44964","description":"PARD3 divergent transcript","metadata":{"aliases":["PARD3-AS1"]}},{"id":"8ee7b49e7af540959aa634a71789bdd2","type":"GENE","name":"PARD3B","canonical_id":"hgnc:HGNC:14446","description":"par-3 family cell polarity regulator beta","metadata":{"aliases":["Par3L","PAR3beta","ALS2CR19"]}},{"id":"c94bb11aad6149a9a0244a289e1e6287","type":"GENE","name":"PARD6A","canonical_id":"hgnc:HGNC:15943","description":"par-6 family cell polarity regulator alpha","metadata":{"aliases":["PAR-6","PAR-6A","TAX40","PAR6alpha","TIP-40"]}},{"id":"8b9a771638d2495299b9484c4df77cfa","type":"GENE","name":"PARD6B","canonical_id":"hgnc:HGNC:16245","description":"par-6 family cell polarity regulator beta","metadata":{"aliases":["PAR-6B"]}},{"id":"15e18850ca334ffd9544ae55253e45be","type":"GENE","name":"PARD6BP1","canonical_id":"hgnc:HGNC:55087","description":"PARD6B pseudogene 1","metadata":null},{"id":"0d9494fedf4a431fa1ccbe3b3764ee12","type":"GENE","name":"PARD6G","canonical_id":"hgnc:HGNC:16076","description":"par-6 family cell polarity regulator gamma","metadata":{"aliases":["PAR-6G","PAR6gamma"]}},{"id":"b6d17d2a28f34952a82a84594ee4c3b1","type":"GENE","name":"PARD6G-AS1","canonical_id":"hgnc:HGNC:44109","description":"PARD6G antisense RNA 1","metadata":null},{"id":"ffe3416b1c584e2494be82cfc5c3a07f","type":"GENE","name":"PARG","canonical_id":"hgnc:HGNC:8605","description":null,"metadata":null},{"id":"39be7b8a9e444b7f8e995e3dfd95bc5c","type":"GENE","name":"PARGP1","canonical_id":"hgnc:HGNC:45008","description":"PARG pseudogene 1","metadata":null},{"id":"d00abff899c149e9aceae07ff355e764","type":"GENE","name":"PARK7","canonical_id":"hgnc:HGNC:16369","description":"Parkinsonism associated deglycase","metadata":{"aliases":["DJ-1","DJ1","GATD2"]}},{"id":"91e9640ec6784efab49e9f5f42815b19","type":"GENE","name":"PARK7P1","canonical_id":"hgnc:HGNC:55066","description":"PARK7 pseudogene 1","metadata":null},{"id":"bcee6f22f85c475b99b843b5a21ecfb2","type":"GENE","name":"PARK7P2","canonical_id":"hgnc:HGNC:55067","description":"PARK7 pseudogene 2","metadata":null},{"id":"7bbd40ad41fe462ca4a5cb2526f5e0a3","type":"GENE","name":"PARL","canonical_id":"hgnc:HGNC:18253","description":"presenilin associated rhomboid like","metadata":{"aliases":["PRO2207","PSARL1","RHBDS1","PSARL"]}},{"id":"9fc3cb02acd242849ba5501f6b83f77c","type":"GENE","name":"PARLP1","canonical_id":"hgnc:HGNC:56485","description":"PARL pseudogene 1","metadata":null},{"id":"6b5e2af0160747418b153cec1bc5c02d","type":"GENE","name":"PARLP2","canonical_id":"hgnc:HGNC:56486","description":"PARL pseudogene 2","metadata":null},{"id":"d5f109748fed45a2be6ceb8c076fd25f","type":"GENE","name":"PARM1","canonical_id":"hgnc:HGNC:24536","description":"prostate androgen-regulated mucin-like protein 1","metadata":{"aliases":["DKFZP564O0823","Cipar1","WSC4"]}},{"id":"8b21f40399cb44fa9af506adbccbb4b6","type":"GENE","name":"PARM1-AS1","canonical_id":"hgnc:HGNC:41051","description":"PARM1 antisense RNA 1","metadata":null},{"id":"9d3b467ac39a4a858dce1f9392a17202","type":"GENE","name":"PARN","canonical_id":"hgnc:HGNC:8609","description":"poly(A)-specific ribonuclease","metadata":{"aliases":["DAN"]}},{"id":"41cef17e5c20430a9b11dfe49ac09b88","type":"TRIAL","name":"PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT05187208","description":"Epithelial Ovarian Cancer; Ovarian Cancer; Ovarian Cancer Stage III; Ovarian Cancer Stage IV","metadata":null},{"id":"4ea512598371435592cd890da9d3dd69","type":"GENE","name":"PARP1","canonical_id":"hgnc:HGNC:270","description":null,"metadata":null},{"id":"f41cb497281046618fd023d460bd7e00","type":"PROTEIN","name":"PARP1","canonical_id":"uniprot:P09874","description":null,"metadata":null},{"id":"454ec08882244431b4bfbaebe529ac95","type":"GENE","name":"PARP1","canonical_id":"ensembl:ENSG00000143799","description":null,"metadata":null},{"id":"f4725037aa5c4679b595734e0d7029c3","type":"GENE","name":"PARP10","canonical_id":"hgnc:HGNC:25895","description":"poly(ADP-ribose) polymerase family member 10","metadata":{"aliases":["FLJ14464","ARTD10"]}},{"id":"8c332df583404c4db3b958e2031421d3","type":"GENE","name":"PARP11","canonical_id":"hgnc:HGNC:1186","description":"poly(ADP-ribose) polymerase family member 11","metadata":{"aliases":["ARTD11","C12orf6"]}},{"id":"d6c7b267c76549adb8ec5a1ea9f3d62c","type":"GENE","name":"PARP11-AS1","canonical_id":"hgnc:HGNC:40103","description":"PARP11 antisense RNA 1","metadata":{"aliases":["lncAPAT"]}},{"id":"580d4ae4e5a84de4be7e9e46a0ca3284","type":"GENE","name":"PARP12","canonical_id":"hgnc:HGNC:21919","description":"poly(ADP-ribose) polymerase family member 12","metadata":{"aliases":["FLJ22693","PARP-12","ZC3H1","ARTD12","ZC3HDC1"]}},{"id":"9b67d4a37d864a3799d46d30d3223df9","type":"GENE","name":"PARP14","canonical_id":"hgnc:HGNC:29232","description":"poly(ADP-ribose) polymerase family member 14","metadata":{"aliases":["KIAA1268","pART8","ARTD8","BAL2"]}},{"id":"2a6f7f1d47454b2f9e117c62c1a72d15","type":"GENE","name":"PARP15","canonical_id":"hgnc:HGNC:26876","description":"poly(ADP-ribose) polymerase family member 15","metadata":{"aliases":["FLJ40597","pART7","ARTD7","BAL3"]}},{"id":"48c0233f2e1f40cb819fb5f966d9cf95","type":"GENE","name":"PARP16","canonical_id":"hgnc:HGNC:26040","description":"poly(ADP-ribose) polymerase family member 16","metadata":{"aliases":["FLJ20509","FLJ25281","pART15","ARTD15","C15orf30"]}},{"id":"df0426bae68343898adef03294e64432","type":"GENE","name":"PARP1P1","canonical_id":"hgnc:HGNC:275","description":"poly(ADP-ribose) polymerase 1 pseudogene 1","metadata":{"aliases":["PPOLP1","ADPRTP1"]}},{"id":"995c28a35eed4da6bffd0c83126eeaf9","type":"GENE","name":"PARP1P2","canonical_id":"hgnc:HGNC:276","description":"poly(ADP-ribose) polymerase 1 pseudogene 2","metadata":{"aliases":["PPOLP2","ADPRTP2"]}},{"id":"6d87a260ba754241b8a67a958db242d2","type":"GENE","name":"PARP2","canonical_id":"hgnc:HGNC:272","description":"poly(ADP-ribose) polymerase 2","metadata":{"aliases":["ARTD2","ADPRTL2"]}},{"id":"a2f1af8ff0b841d081f0f86377275dc8","type":"PROTEIN","name":"PARP2","canonical_id":"uniprot:Q9UGN5","description":null,"metadata":null},{"id":"59f35779484440088164f1f21fa2c9fe","type":"GENE","name":"PARP3","canonical_id":"hgnc:HGNC:273","description":"poly(ADP-ribose) polymerase family member 3","metadata":{"aliases":["ADPRT3","IRT1","hPARP-3","pADPRT-3","ARTD3","ADPRTL3"]}},{"id":"8efa406149bf4d9ab253b0e037f223d3","type":"GENE","name":"PARP4","canonical_id":"hgnc:HGNC:271","description":"poly(ADP-ribose) polymerase family member 4","metadata":{"aliases":["VAULT3","p193","VPARP","VWA5C","ARTD4","ADPRTL1"]}},{"id":"5306d2ee8d37475e925f4e6cdb41ccd3","type":"GENE","name":"PARP4P1","canonical_id":"hgnc:HGNC:18500","description":"poly(ADP-ribose) polymerase family member 4 pseudogene 1","metadata":{"aliases":["PARP4PY1","ADPRTL1P","PARP4P"]}},{"id":"ae7837b6b5024c7590850ce2deaacdb0","type":"GENE","name":"PARP4P2","canonical_id":"hgnc:HGNC:37760","description":"poly(ADP-ribose) polymerase family member 4 pseudogene 2","metadata":null},{"id":"bc105fff788748d3a919de557d6782b5","type":"GENE","name":"PARP4P3","canonical_id":"hgnc:HGNC:274","description":"poly(ADP-ribose) polymerase family member 4 pseudogene 3","metadata":{"aliases":["ADPRTL4"]}},{"id":"24d4ca5107a84b2ca78d8a13cab5cd7a","type":"GENE","name":"PARP6","canonical_id":"hgnc:HGNC:26921","description":"poly(ADP-ribose) polymerase family member 6","metadata":{"aliases":["pART17","ARTD17"]}},{"id":"9ce0ab51ee5944919d86149d14e67dbb","type":"GENE","name":"PARP8","canonical_id":"hgnc:HGNC:26124","description":"poly(ADP-ribose) polymerase family member 8","metadata":{"aliases":["FLJ21308","pART16","ARTD16"]}},{"id":"d6cc68c34c03491ab1813b30b4780497","type":"GENE","name":"PARP8-AS1","canonical_id":"hgnc:HGNC:59040","description":"PARP8 antisense RNA 1","metadata":null},{"id":"a54d7c2a48a94447b4b70295050e8fa1","type":"GENE","name":"PARP9","canonical_id":"hgnc:HGNC:24118","description":"poly(ADP-ribose) polymerase family member 9","metadata":{"aliases":["BAL","BAL1","ARTD9"]}},{"id":"dbb1bf25776d4cc991cd3d78c0346e3c","type":"GENE","name":"PARPBP","canonical_id":"hgnc:HGNC:26074","description":"PARP1 binding protein","metadata":{"aliases":["FLJ20641","PARI","C12orf48"]}},{"id":"0b548f5cdd3349b6901556a993af1e95","type":"GENE","name":"PARS2","canonical_id":"hgnc:HGNC:30563","description":"prolyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["DKFZp727A071"]}},{"id":"da287b9e9e364330af88558ebf5b011a","type":"GENE","name":"PART1","canonical_id":"hgnc:HGNC:17263","description":"prostate androgen-regulated transcript 1","metadata":{"aliases":["DKFZP586D0823","NCRNA00206"]}},{"id":"bf80436300c14a65b509fa38ef091556","type":"GENE","name":"PARTICL","canonical_id":"hgnc:HGNC:50886","description":"promoter of MAT2A antisense radiation-induced circulating long non-coding RNA","metadata":{"aliases":["PARTICLE"]}},{"id":"e58b762da2b54f909730446d06fa0733","type":"GENE","name":"PARVA","canonical_id":"hgnc:HGNC:14652","description":"parvin alpha","metadata":{"aliases":["FLJ12254","FLJ10793","MXRA2"]}},{"id":"1b23f88d7e9e4d498e6611ba963bb952","type":"GENE","name":"PARVB","canonical_id":"hgnc:HGNC:14653","description":"parvin beta","metadata":{"aliases":["CGI-56"]}},{"id":"e33af0296bdf4029be9800a05a25f735","type":"GENE","name":"PARVG","canonical_id":"hgnc:HGNC:14654","description":"parvin gamma","metadata":null},{"id":"fadfec6d1fc9421a9040886655edde4b","type":"GO_TERM","name":"PAS complex","canonical_id":"go:GO:0070772","description":"\"A phosphatidylinositol kinase complex that contains a phosphatidylinositol-3-phosphate 5-kinase subunit (Fab1p in yeast; PIKFYVE in mammals), a kinase activator, and a phosphatase, and may also contain additional proteins; it is involved in regulating the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate. In mammals the complex is composed of PIKFYVE, FIG4 and VAC14. In yeast it is composed of Atg18p, Fig4p, Fab1p, Vac14p and Vac7p.\" [PMID:18950639, PMID:19037259, PMID:19158662]","metadata":null},{"id":"77e6a68e14814cefa80bd7e9f416fb34","type":"GENE","name":"PASD1","canonical_id":"hgnc:HGNC:20686","description":"PAS domain containing repressor 1","metadata":{"aliases":["CT63"]}},{"id":"f62550c0848a4dd0ae5b7f875dd0d972","type":"GENE","name":"PASK","canonical_id":"hgnc:HGNC:17270","description":"PAS domain containing serine/threonine kinase","metadata":{"aliases":["PASKIN","KIAA0135","STK37"]}},{"id":"0ea35dfad086422f812f0647c31705d8","type":"GO_TERM","name":"PAT complex","canonical_id":"go:GO:0160005","description":"\"A transmembrane protein complex located in the endoplasmic reticulum (ER) involved in the correct folding of multipass membrane proteins in the ER membrane. In human, the substrate-binding Asterix (PAT10, WDR83OS) forms an obligate heterodimer with CCDC47.\" [PMID:32814900, PMID:33082068, PMID:33960686]","metadata":null},{"id":"40aca59a2fda4530bf635f0399ae707b","type":"GENE","name":"PATE1","canonical_id":"hgnc:HGNC:24664","description":"prostate and testis expressed 1","metadata":{"aliases":["PATE"]}},{"id":"00de7682ec494e2ba9666b067af825f6","type":"GENE","name":"PATE2","canonical_id":"hgnc:HGNC:32249","description":"prostate and testis expressed 2","metadata":{"aliases":["UNQ3112","LVLF3112","PATE-M","C11orf38"]}},{"id":"db41cf45812b4e51a9bcb83839fa2803","type":"GENE","name":"PATE3","canonical_id":"hgnc:HGNC:35426","description":"prostate and testis expressed 3","metadata":{"aliases":["PATE-DJ","HEL-127"]}},{"id":"83afeae9c3b2471bb6913f32c393ef6c","type":"GENE","name":"PATE4","canonical_id":"hgnc:HGNC:35427","description":"prostate and testis expressed 4","metadata":{"aliases":["FLJ41047","PATE-B"]}},{"id":"3a089d88bd7b4bdca735508255ec476b","type":"GENE","name":"PATJ","canonical_id":"hgnc:HGNC:28881","description":"PATJ crumbs cell polarity complex component","metadata":{"aliases":["Cipp","INADL"]}},{"id":"8cd22bd3f5ce4e20a63f35d54527416c","type":"GENE","name":"PATJ-DT","canonical_id":"hgnc:HGNC:55256","description":"PATJ divergent transcript","metadata":null},{"id":"f57303bd1c134409b958e6a768a2afea","type":"GENE","name":"PATL1","canonical_id":"hgnc:HGNC:26721","description":"PAT1 homolog 1, processing body mRNA decay factor","metadata":{"aliases":["FLJ36874","Pat1b"]}},{"id":"b982903a0ed342058f0f14bd5524e31d","type":"GENE","name":"PATL1-DT","canonical_id":"hgnc:HGNC:55501","description":"PATL1 divergent transcript","metadata":null},{"id":"6d7d4b4866ba4e6f8b0360d5a1bf07f4","type":"GENE","name":"PATL2","canonical_id":"hgnc:HGNC:33630","description":"PAT1 homolog 2","metadata":{"aliases":["Pat1a"]}},{"id":"85201d6b53e84adba4f31c68189c07e7","type":"GENE","name":"PATZ1","canonical_id":"hgnc:HGNC:13071","description":"POZ/BTB and AT hook containing zinc finger 1","metadata":{"aliases":["MAZR","dJ400N23","ZBTB19","ZSG","RIAZ","PATZ","ZNF278"]}},{"id":"cfd18f0146374c45b6e8448b3bfe2bd2","type":"GENE","name":"PAUPAR","canonical_id":"hgnc:HGNC:49670","description":"PAX6 upstream antisense RNA","metadata":null},{"id":"320f864cbe7b42d28347bc781a4f28e9","type":"GENE","name":"PAWR","canonical_id":"hgnc:HGNC:8614","description":null,"metadata":null},{"id":"cd2ca90966be47ed94e129f0904590cd","type":"GENE","name":"PAWRP1","canonical_id":"hgnc:HGNC:45201","description":"pro-apoptotic WT1 regulator pseudogene 1","metadata":null},{"id":"aee40ff52e174ba2a37f6fff7b060f29","type":"GENE","name":"PAWRP2","canonical_id":"hgnc:HGNC:45202","description":"pro-apoptotic WT1 regulator pseudogene 2","metadata":null},{"id":"fdcadf4be662411595db24aed16c6074","type":"GENE","name":"PAX1","canonical_id":"hgnc:HGNC:8615","description":null,"metadata":null},{"id":"f090b546feaa4490ba5f1dfc9dad8f61","type":"GENE","name":"PAX2","canonical_id":"hgnc:HGNC:8616","description":null,"metadata":null},{"id":"10d89f15979941309c730cdb59792707","type":"GENE","name":"PAX3","canonical_id":"hgnc:HGNC:8617","description":null,"metadata":null},{"id":"ae11c1edd7be4585b9c755536bd2c555","type":"GENE","name":"PAX4","canonical_id":"hgnc:HGNC:8618","description":null,"metadata":null},{"id":"cb365fc319034f43b3a726707480035d","type":"GENE","name":"PAX5","canonical_id":"hgnc:HGNC:8619","description":null,"metadata":null},{"id":"5d2e239c1e444c079cc4a1273831cff8","type":"GENE","name":"PAX6","canonical_id":"hgnc:HGNC:8620","description":null,"metadata":null},{"id":"7a7a45f47ed94726829868d55818ca92","type":"GENE","name":"PAX6-AS1","canonical_id":"hgnc:HGNC:53448","description":"PAX6 antisense RNA 1","metadata":null},{"id":"4a1d1d530aac4a1d8dd28bb368e657f4","type":"GENE","name":"PAX7","canonical_id":"hgnc:HGNC:8621","description":"paired box 7","metadata":{"aliases":["Hup1"]}},{"id":"9ce56a9151bd41ff9f87a5796ec1341b","type":"GENE","name":"PAX8","canonical_id":"hgnc:HGNC:8622","description":null,"metadata":null},{"id":"225169374dda42bc8663ebb1e1c2995a","type":"GENE","name":"PAX8-AS1","canonical_id":"hgnc:HGNC:49271","description":"PAX8 antisense RNA 1","metadata":null},{"id":"2d1eeacd81d24d108606c40bd60f1d5c","type":"GENE","name":"PAX9","canonical_id":"hgnc:HGNC:8623","description":"paired box 9","metadata":null},{"id":"81c2d92c0b834e2ea3a3d0fb7ba6dc8a","type":"GENE","name":"PAXBP1","canonical_id":"hgnc:HGNC:13579","description":"PAX3 and PAX7 binding protein 1","metadata":{"aliases":["GCFC","fSAP105","C21orf66","GCFC1"]}},{"id":"9e474ca9284642abbaf8269c104b133c","type":"GENE","name":"PAXBP1-AS1","canonical_id":"hgnc:HGNC:39603","description":"PAXBP1 antisense RNA 1","metadata":{"aliases":["GCFC1-AS1"]}},{"id":"b20627f2420d43289320fcaeb849834d","type":"GENE","name":"PAXBP1P1","canonical_id":"hgnc:HGNC:50352","description":"PAX3 and PAX7 binding protein 1 pseudogene 1","metadata":null},{"id":"e5c18e34b6184193b3037096e520263b","type":"GENE","name":"PAXIP1","canonical_id":"hgnc:HGNC:8624","description":"PAX interacting protein 1","metadata":{"aliases":["CAGF29","CAGF28","TNRC2","PTIP","PAXIP1L"]}},{"id":"1ecb4be718bf47b6bacab63708e036be","type":"GENE","name":"PAXIP1-AS2","canonical_id":"hgnc:HGNC:48958","description":"PAXIP1 antisense RNA 2","metadata":{"aliases":["PAXIP1OS"]}},{"id":"452e9c7fc3ad46f4b9907d7055b970f3","type":"GENE","name":"PAXIP1-DT","canonical_id":"hgnc:HGNC:27328","description":"PAXIP1 divergent transcript","metadata":{"aliases":["PAXIP1-AS1"]}},{"id":"b41abf5db90e4533b68badf8987c74f9","type":"GENE","name":"PAXX","canonical_id":"hgnc:HGNC:27849","description":"PAXX non-homologous end joining factor","metadata":{"aliases":["XLS","C9orf142"]}},{"id":"ab5dc2c40bef45b8839c424e556d3401","type":"TRIAL","name":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04360941","description":"Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"766847f2833f475295d8454ec31d05d2","type":"GENE","name":"PBDC1","canonical_id":"hgnc:HGNC:28790","description":"polysaccharide biosynthesis domain containing 1","metadata":{"aliases":["MGC874","CXorf26"]}},{"id":"eff0910e22a744deb373fd4acb88a7f9","type":"GENE","name":"PBK","canonical_id":"hgnc:HGNC:18282","description":null,"metadata":null},{"id":"1335a673640a434787a46f516a0ba06e","type":"GENE","name":"PBLD","canonical_id":"hgnc:HGNC:23301","description":"phenazine biosynthesis like protein domain containing","metadata":{"aliases":["MAWBP","MAWDBP","FLJ14767"]}},{"id":"fe99b42c30334a35ad3a4bc1704ecbc5","type":"GENE","name":"PBOV1","canonical_id":"hgnc:HGNC:21079","description":"prostate and breast cancer overexpressed 1","metadata":{"aliases":["UC28","UROC28"]}},{"id":"c73088a1055b49b2a6c6c0fb4f6412f0","type":"GENE","name":"PBRM1","canonical_id":"hgnc:HGNC:30064","description":"polybromo 1","metadata":{"aliases":["BAF180","PB1","SMARCH1"]}},{"id":"ac511895e5204c24b0c4bb3515e5a238","type":"GENE","name":"PBX1","canonical_id":"hgnc:HGNC:8632","description":null,"metadata":null},{"id":"c163e5b13c5c467d92a5c670816042b3","type":"GENE","name":"PBX1-AS1","canonical_id":"hgnc:HGNC:40425","description":"PBX1 antisense RNA 1","metadata":null},{"id":"0ede6547367a4d8d9953eeec64a54010","type":"GENE","name":"PBX2","canonical_id":"hgnc:HGNC:8633","description":null,"metadata":null},{"id":"3151796ef279449a850741b8fe496eef","type":"GENE","name":"PBX2P1","canonical_id":"hgnc:HGNC:8635","description":"PBX homeobox 2 pseudogene 1","metadata":{"aliases":["PBX2","PBXP1"]}},{"id":"712718f2eb1641c5951ad8bc9cb52e47","type":"GENE","name":"PBX3","canonical_id":"hgnc:HGNC:8634","description":"PBX homeobox 3","metadata":null},{"id":"d53195ed8ce04f96826101ed966a617e","type":"GENE","name":"PBX3-DT","canonical_id":"hgnc:HGNC:24638","description":"PBX3 divergent transcript","metadata":null},{"id":"4ad28602691b45fd988b1ba8c12d28d2","type":"GENE","name":"PBX4","canonical_id":"hgnc:HGNC:13403","description":"PBX homeobox 4","metadata":null},{"id":"7b328a3d2e75497d9855c64b1257026e","type":"GENE","name":"PBX4-AS1","canonical_id":"hgnc:HGNC:58468","description":"PBX4 antisense RNA 1","metadata":null},{"id":"b5c68065c6ac4dcaac224c9fe68fd0c1","type":"GENE","name":"PBXIP1","canonical_id":"hgnc:HGNC:21199","description":null,"metadata":null},{"id":"a6132548efea4801b060d91f3739e727","type":"GENE","name":"PC","canonical_id":"hgnc:HGNC:8636","description":null,"metadata":null},{"id":"afd352f223eb475dadc7143c92cb56dd","type":"TRIAL","name":"PC-300 Tea Effect on Triglyceride Levels","canonical_id":"clinicaltrials.gov:NCT03649269","description":"Hypertriglyceridemia","metadata":null},{"id":"d916c18f7e894f9b815b653fae88921f","type":"GENE","name":"PCA3","canonical_id":"hgnc:HGNC:8637","description":"prostate cancer associated 3","metadata":{"aliases":["DD3","NCRNA00019","PCAT3","PRUNE2-AS1"]}},{"id":"83ff017be30c494f9be3ad3821dffde8","type":"GENE","name":"PCARE","canonical_id":"hgnc:HGNC:34383","description":"photoreceptor cilium actin regulator","metadata":{"aliases":["FLJ34931","RP54","C2orf71"]}},{"id":"7618cee662ef40efaec0c448e5c05260","type":"GENE","name":"PCAT1","canonical_id":"hgnc:HGNC:43022","description":"prostate cancer associated transcript 1","metadata":{"aliases":["PCAT-1","PCA1","PiHL"]}},{"id":"607b0741f9724e848cc5cbf201d24e5c","type":"GENE","name":"PCAT14","canonical_id":"hgnc:HGNC:48977","description":"prostate cancer associated transcript 14","metadata":null},{"id":"47c3ae5c7bcb45b89d673d463fbff3ee","type":"GENE","name":"PCAT18","canonical_id":"hgnc:HGNC:49211","description":"prostate cancer associated transcript 18","metadata":{"aliases":["LINC01092"]}},{"id":"120190c2981f471fa8d0daa8f6838073","type":"GENE","name":"PCAT19","canonical_id":"hgnc:HGNC:49593","description":"prostate cancer associated transcript 19","metadata":{"aliases":["LINC01190","LOC100505495"]}},{"id":"3ed302c93ff346cd8b86581ba4cb938a","type":"GENE","name":"PCAT2","canonical_id":"hgnc:HGNC:45089","description":"prostate cancer associated transcript 2","metadata":{"aliases":["PCA2","TCONS_00015167"]}},{"id":"285dba601d7944bc823b0057008e2765","type":"GENE","name":"PCAT29","canonical_id":"hgnc:HGNC:50895","description":"prostate cancer associated transcript 29","metadata":null},{"id":"dda1155ce0284e53913da5022d556e46","type":"GENE","name":"PCAT4","canonical_id":"hgnc:HGNC:24853","description":"prostate cancer associated transcript 4","metadata":{"aliases":["GDEP","PCAN1","PCA4"]}},{"id":"eb47eb6a2356420799a2ebd2b1bf7b6a","type":"GENE","name":"PCAT5","canonical_id":"hgnc:HGNC:48665","description":"prostate cancer associated transcript 5","metadata":{"aliases":["TPCAT-10-36067","LINC01452"]}},{"id":"ffbdf95eac9d407eade7356ce56194b5","type":"GENE","name":"PCAT6","canonical_id":"hgnc:HGNC:43714","description":"prostate cancer associated transcript 6","metadata":{"aliases":["ncRNA-a2","PCAN-R1","KDM5BAS1","onco-lncRNA-96","KDM5B-AS1"]}},{"id":"2128a212dfe04f709abe447a033077ba","type":"GENE","name":"PCAT7","canonical_id":"hgnc:HGNC:48824","description":"prostate cancer associated transcript 7","metadata":{"aliases":["PCAN-R2"]}},{"id":"ad9e2a3d396b423cb2505b2266f76862","type":"GENE","name":"PCBD1","canonical_id":"hgnc:HGNC:8646","description":null,"metadata":null},{"id":"965fc310203b45cf92830998a3e70e7c","type":"GENE","name":"PCBD2","canonical_id":"hgnc:HGNC:24474","description":"pterin-4 alpha-carbinolamine dehydratase 2","metadata":{"aliases":["DCOHM","DCOH2"]}},{"id":"5d9390b0dfa04686993d54d8882482c7","type":"GENE","name":"PCBP1","canonical_id":"hgnc:HGNC:8647","description":"poly(rC) binding protein 1","metadata":{"aliases":["HNRPE1","hnRNP-E1","HNRPX","hnRNP-X"]}},{"id":"ec18235fc1704bfa9f79b7de3b71b95e","type":"GENE","name":"PCBP1-AS1","canonical_id":"hgnc:HGNC:42948","description":"PCBP1 antisense RNA 1","metadata":{"aliases":["Linc-GALH"]}},{"id":"6450203982654737b60908dee9eef5fc","type":"GENE","name":"PCBP2","canonical_id":"hgnc:HGNC:8648","description":"poly(rC) binding protein 2","metadata":{"aliases":["HNRPE2","hnRNP-E2","HNRNPE2"]}},{"id":"00471864d0474fb38da85466ece792e1","type":"GENE","name":"PCBP2-OT1","canonical_id":"hgnc:HGNC:49150","description":"PCBP2 overlapping transcript 1","metadata":{"aliases":["TUC338","uc.338","TUC.338"]}},{"id":"61596ed1e6044bb88d1db434c073f6e2","type":"GENE","name":"PCBP2P1","canonical_id":"hgnc:HGNC:8649","description":"PCBP2 pseudogene 1","metadata":null},{"id":"f4771c82e19c4dd69184acdf73954f41","type":"GENE","name":"PCBP2P2","canonical_id":"hgnc:HGNC:8650","description":"PCBP2 pseudogene 2","metadata":null},{"id":"198b3ae6cdaa45bd8bcdca66fb7dee62","type":"GENE","name":"PCBP2P3","canonical_id":"hgnc:HGNC:39032","description":"PCBP2 pseudogene 3","metadata":null},{"id":"eb7d82876de641ce9ba1a9a64a892d13","type":"GENE","name":"PCBP2P4","canonical_id":"hgnc:HGNC:56564","description":"PCBP2 pseudogene 4","metadata":null},{"id":"d45bdc9ddb4e4d118af3f5f6613c7832","type":"GENE","name":"PCBP3","canonical_id":"hgnc:HGNC:8651","description":"poly(rC) binding protein 3","metadata":{"aliases":["FLJ44028","PCBP3-OT1","PCBP3OT"]}},{"id":"6d9068b3f82e46b9bfe58ea286482276","type":"GENE","name":"PCBP3-AS1","canonical_id":"hgnc:HGNC:40426","description":"PCBP3 antisense RNA 1","metadata":null},{"id":"6b293510a9dc44eea1d7604fa03e9071","type":"GENE","name":"PCBP4","canonical_id":"hgnc:HGNC:8652","description":"poly(rC) binding protein 4","metadata":{"aliases":["MCG10","LIP4"]}},{"id":"85bca310c6c94ac3a6811f19097ae83c","type":"GENE","name":"PCCA","canonical_id":"hgnc:HGNC:8653","description":"propionyl-CoA carboxylase subunit alpha","metadata":null},{"id":"319d63d027af4c5886845a4b06b096bf","type":"GENE","name":"PCCA-AS1","canonical_id":"hgnc:HGNC:39901","description":"PCCA antisense RNA 1","metadata":null},{"id":"03076c0cc1214bdd922d180559f651fb","type":"GENE","name":"PCCA-DT","canonical_id":"hgnc:HGNC:53266","description":"PCCA divergent transcript","metadata":null},{"id":"5d9612a1246d4e41b25582252083380b","type":"GENE","name":"PCCB","canonical_id":"hgnc:HGNC:8654","description":"propionyl-CoA carboxylase subunit beta","metadata":null},{"id":"bd24e16f275a44788e39d522d13441ec","type":"GENE","name":"PCDH1","canonical_id":"hgnc:HGNC:8655","description":"protocadherin 1","metadata":{"aliases":["pc42"]}},{"id":"64c455948bb54e85b2315acab251c095","type":"GENE","name":"PCDH1-AS1","canonical_id":"hgnc:HGNC:59266","description":"PCDH1 antisense RNA 1","metadata":null},{"id":"6a2370c19ecb42438b74a732f400f919","type":"GENE","name":"PCDH10","canonical_id":"hgnc:HGNC:13404","description":"protocadherin 10","metadata":{"aliases":["OL-PCDH","KIAA1400"]}},{"id":"4e107f5053a74abaa51495a16d472fbc","type":"GENE","name":"PCDH10-DT","canonical_id":"hgnc:HGNC:53036","description":"PCDH10 divergent transcript","metadata":null},{"id":"c85607d148d64f4bae65cb6098898162","type":"GENE","name":"PCDH11X","canonical_id":"hgnc:HGNC:8656","description":"protocadherin 11 X-linked","metadata":{"aliases":["PCDH-X","PCDHX","PPP1R119","PCDH11"]}},{"id":"5416079d0e904f0e939da5acaff6a61d","type":"GENE","name":"PCDH11Y","canonical_id":"hgnc:HGNC:15813","description":"protocadherin 11 Y-linked","metadata":{"aliases":["PCDHY","PCDH22"]}},{"id":"0deabdfd3a6f4d728817d74789840a45","type":"GENE","name":"PCDH12","canonical_id":"hgnc:HGNC:8657","description":"protocadherin 12","metadata":null},{"id":"32ea024d211f41d783861cf00a69e701","type":"GENE","name":"PCDH15","canonical_id":"hgnc:HGNC:14674","description":"protocadherin related 15","metadata":{"aliases":["CDHR15","USH1F","DFNB23"]}},{"id":"7b0f9a58a40e4b0b8954963219d3d181","type":"GENE","name":"PCDH17","canonical_id":"hgnc:HGNC:14267","description":"protocadherin 17","metadata":{"aliases":["PCDH68","PCH68"]}},{"id":"35d373a526474668bd224597686a92ce","type":"GENE","name":"PCDH18","canonical_id":"hgnc:HGNC:14268","description":"protocadherin 18","metadata":{"aliases":["KIAA1562","PCDH68L"]}},{"id":"0fcb1b52d8154f3fb5d8f30b154d7ff3","type":"GENE","name":"PCDH19","canonical_id":"hgnc:HGNC:14270","description":"protocadherin 19","metadata":{"aliases":["KIAA1313","EIEE9","EFMR"]}},{"id":"6e5a367d23414fb5beb2156c39b095c1","type":"GENE","name":"PCDH20","canonical_id":"hgnc:HGNC:14257","description":"protocadherin 20","metadata":{"aliases":["PCDH13","FLJ22218"]}},{"id":"f97a4c12c13d419eb831036471b513d7","type":"GENE","name":"PCDH7","canonical_id":"hgnc:HGNC:8659","description":"protocadherin 7","metadata":{"aliases":["BH-Pcdh","PPP1R120"]}},{"id":"7f899a33e582472abd53c0c62b1691a3","type":"GENE","name":"PCDH7-AS1","canonical_id":"hgnc:HGNC:58750","description":"PCDH7 antisense RNA 1","metadata":null},{"id":"0c36a2fcfca84d208d6cf91e5e9a8798","type":"GENE","name":"PCDH8","canonical_id":"hgnc:HGNC:8660","description":"protocadherin 8","metadata":{"aliases":["PAPC","ARCADLIN"]}},{"id":"858a751865354e8785c6900244428647","type":"GENE","name":"PCDH8P1","canonical_id":"hgnc:HGNC:39937","description":"protocadherin 8 pseudogene 1","metadata":null},{"id":"4c3aaf5c0d8348a1a77ce963209fb01e","type":"GENE","name":"PCDH9","canonical_id":"hgnc:HGNC:8661","description":"protocadherin 9","metadata":null},{"id":"d44cd3f39049407b86551ffe525b0812","type":"GENE","name":"PCDH9-AS1","canonical_id":"hgnc:HGNC:39897","description":"PCDH9 antisense RNA 1","metadata":null},{"id":"0d2d87da3f52467cb83c8bc19767dd03","type":"GENE","name":"PCDH9-AS2","canonical_id":"hgnc:HGNC:39896","description":"PCDH9 antisense RNA 2","metadata":null},{"id":"4b2894596b384d02afff8d41ee24b843","type":"GENE","name":"PCDH9-AS3","canonical_id":"hgnc:HGNC:40427","description":"PCDH9 antisense RNA 3","metadata":null},{"id":"e4112e6aaa28462686f295e809b99cb5","type":"GENE","name":"PCDH9-AS4","canonical_id":"hgnc:HGNC:40428","description":"PCDH9 antisense RNA 4","metadata":null},{"id":"a428f5a1878041b7aa1d9a6c45b4f276","type":"GENE","name":"PCDHA-AS1","canonical_id":"hgnc:HGNC:59170","description":"protocadherin alpha cluster antisense RNA 1","metadata":null},{"id":"95678a3ecaff4cfcbbf381d99840f1a9","type":"GENE","name":"PCDHA-AS2","canonical_id":"hgnc:HGNC:59171","description":"protocadherin alpha cluster antisense RNA 2","metadata":null},{"id":"da8a814e5b164a8f80c2b07442a98a2c","type":"GENE","name":"PCDHA1","canonical_id":"hgnc:HGNC:8663","description":"protocadherin alpha 1","metadata":null},{"id":"f000239a09da44b99a942e577de05a7f","type":"GENE","name":"PCDHA10","canonical_id":"hgnc:HGNC:8664","description":"protocadherin alpha 10","metadata":{"aliases":["CNR8","CRNR8","CNRN8","PCDH-ALPHA10","CNRS8"]}},{"id":"eecc09340acc43d49922dc1b7e29b3a3","type":"GENE","name":"PCDHA11","canonical_id":"hgnc:HGNC:8665","description":"protocadherin alpha 11","metadata":{"aliases":["CNR7","CRNR7","CNRN7","PCDH-ALPHA11","CNRS7"]}},{"id":"eea509727979419fa43132e95a64d2ea","type":"GENE","name":"PCDHA12","canonical_id":"hgnc:HGNC:8666","description":"protocadherin alpha 12","metadata":{"aliases":["PCDH-ALPHA12"]}},{"id":"3b42e5611fae44e7bdcf8280cbd1151d","type":"GENE","name":"PCDHA13","canonical_id":"hgnc:HGNC:8667","description":"protocadherin alpha 13","metadata":{"aliases":["CNR5","CRNR5","CNRN5","PCDH-ALPHA13","CNRS5"]}},{"id":"67331c7d0afa41768a4ea1e65cf072c3","type":"GENE","name":"PCDHA14","canonical_id":"hgnc:HGNC:2163","description":"protocadherin alpha 14 (pseudogene)","metadata":{"aliases":["CNR3","CRNR3","PCDH-PSI4","CNRS3"]}},{"id":"ca2d9e8db8d3475692196cda10a03789","type":"GENE","name":"PCDHA2","canonical_id":"hgnc:HGNC:8668","description":"protocadherin alpha 2","metadata":null},{"id":"1876fc71ad124fc89ff6ba337a7c6ad4","type":"GENE","name":"PCDHA3","canonical_id":"hgnc:HGNC:8669","description":"protocadherin alpha 3","metadata":{"aliases":["PCDH-ALPHA3"]}},{"id":"6812ca44cc3043248ea1f192a689c1dd","type":"GENE","name":"PCDHA4","canonical_id":"hgnc:HGNC:8670","description":"protocadherin alpha 4","metadata":{"aliases":["CNR1","CRNR1","PCDH-ALPHA4","CNRN1"]}},{"id":"530fa07240c34ca59b69358e0d7be7df","type":"GENE","name":"PCDHA5","canonical_id":"hgnc:HGNC:8671","description":"protocadherin alpha 5","metadata":{"aliases":["CNR6","CRNR6","CNRN6","PCDH-ALPHA5","CNRS6"]}},{"id":"be59d813b3a840f19de88f954c64f531","type":"GENE","name":"PCDHA6","canonical_id":"hgnc:HGNC:8672","description":"protocadherin alpha 6","metadata":{"aliases":["CNR2","CRNR2","PCDH-ALPHA6","CNRS2"]}},{"id":"7a0124ffab0242d5a48777c6c08a6abe","type":"GENE","name":"PCDHA7","canonical_id":"hgnc:HGNC:8673","description":"protocadherin alpha 7","metadata":{"aliases":["CNR4","CRNR4","CNRS4"]}},{"id":"0a0a8ebcdc1d48918a98caf739605b5a","type":"GENE","name":"PCDHA8","canonical_id":"hgnc:HGNC:8674","description":"protocadherin alpha 8","metadata":null},{"id":"972745819fbc4422ab1556a42452ed7a","type":"GENE","name":"PCDHA9","canonical_id":"hgnc:HGNC:8675","description":"protocadherin alpha 9","metadata":{"aliases":["KIAA0345","PCDH-ALPHA9"]}},{"id":"c0966258e29a42008bbaa311292b5e3e","type":"GENE","name":"PCDHA@","canonical_id":"hgnc:HGNC:8662","description":"protocadherin alpha cluster, complex locus","metadata":{"aliases":["CNR1","CNRS1"]}},{"id":"5d47febeb6654c59b6b69643ccd69b43","type":"GENE","name":"PCDHAC1","canonical_id":"hgnc:HGNC:8676","description":"protocadherin alpha subfamily C, 1","metadata":null},{"id":"599c549ecaa54069870a83cd6ccd2a41","type":"GENE","name":"PCDHAC2","canonical_id":"hgnc:HGNC:8677","description":"protocadherin alpha subfamily C, 2","metadata":{"aliases":["PCDH-ALPHA-C2"]}},{"id":"69d025f118b9479d98a6e203e570dd1b","type":"GENE","name":"PCDHACT","canonical_id":"hgnc:HGNC:8678","description":"protocadherin alpha constant","metadata":{"aliases":["PCDHAC"]}},{"id":"6382db7f1d394d8f8de1cc591d86c35f","type":"GENE","name":"PCDHB-AS1","canonical_id":"hgnc:HGNC:59172","description":"protocadherin beta cluster antisense RNA 1","metadata":null},{"id":"b947358d9e664b34bcc91f40a143e3ed","type":"GENE","name":"PCDHB1","canonical_id":"hgnc:HGNC:8680","description":"protocadherin beta 1","metadata":{"aliases":["PCDH-BETA1"]}},{"id":"6de900d9c3f34bcaab01d1e34f8ffb08","type":"GENE","name":"PCDHB1-AS1","canonical_id":"hgnc:HGNC:56111","description":"PCDHB1 antisense RNA 1","metadata":null},{"id":"10f41e6675194ad8902b100918c2ba68","type":"GENE","name":"PCDHB10","canonical_id":"hgnc:HGNC:8681","description":"protocadherin beta 10","metadata":null},{"id":"eef0587ac16048d0b332a3318cc99d9b","type":"GENE","name":"PCDHB11","canonical_id":"hgnc:HGNC:8682","description":"protocadherin beta 11","metadata":{"aliases":["PCDH-BETA11","ME2"]}},{"id":"b073e23ca3464304a51587304b73b9d3","type":"GENE","name":"PCDHB12","canonical_id":"hgnc:HGNC:8683","description":"protocadherin beta 12","metadata":{"aliases":["PCDH-BETA12"]}},{"id":"dbb953f7cdfd4def8aad2cca9cf6c3d2","type":"GENE","name":"PCDHB13","canonical_id":"hgnc:HGNC:8684","description":"protocadherin beta 13","metadata":{"aliases":["PCDH-BETA13"]}},{"id":"2bd8322ca2cf41f582dcda466686091b","type":"GENE","name":"PCDHB14","canonical_id":"hgnc:HGNC:8685","description":"protocadherin beta 14","metadata":{"aliases":["PCDH-BETA14"]}},{"id":"74306bea3258413497baedccae02347a","type":"GENE","name":"PCDHB15","canonical_id":"hgnc:HGNC:8686","description":"protocadherin beta 15","metadata":{"aliases":["PCDH-BETA15"]}},{"id":"8b92e459c8194402b8b5349639df92e8","type":"GENE","name":"PCDHB16","canonical_id":"hgnc:HGNC:14546","description":"protocadherin beta 16","metadata":{"aliases":["PCDHB8a","PCDH3X","KIAA1621","PCDH-BETA16","ME1"]}},{"id":"adb686aa14f246878149a9b25a0761a5","type":"GENE","name":"PCDHB17P","canonical_id":"hgnc:HGNC:14547","description":"protocadherin beta 17 pseudogene","metadata":{"aliases":["PCDH-psi1","PCDHB17"]}},{"id":"558d1809e33048249ba777a92c0d99d0","type":"GENE","name":"PCDHB18P","canonical_id":"hgnc:HGNC:14548","description":"protocadherin beta 18 pseudogene","metadata":{"aliases":["PCDH-psi2","PCDHB18"]}},{"id":"ec8003e4be0b420597eaa7e7c0a06c11","type":"GENE","name":"PCDHB19P","canonical_id":"hgnc:HGNC:14549","description":"protocadherin beta 19 pseudogene","metadata":{"aliases":["PCDH-PSI5"]}},{"id":"06884037904344f8ac34539a34a0d0f1","type":"GENE","name":"PCDHB2","canonical_id":"hgnc:HGNC:8687","description":"protocadherin beta 2","metadata":{"aliases":["PCDH-BETA2"]}},{"id":"91734bb640a249dfae115a2f4b200b2a","type":"GENE","name":"PCDHB3","canonical_id":"hgnc:HGNC:8688","description":"protocadherin beta 3","metadata":{"aliases":["PCDH-BETA3"]}},{"id":"05827e463fa84252a98eac188fd76fb9","type":"GENE","name":"PCDHB4","canonical_id":"hgnc:HGNC:8689","description":"protocadherin beta 4","metadata":{"aliases":["PCDH-BETA4"]}},{"id":"0c02c37c73af4e1a83a7a86f7e31319f","type":"GENE","name":"PCDHB5","canonical_id":"hgnc:HGNC:8690","description":"protocadherin beta 5","metadata":{"aliases":["DKFZp586B0217","PCDH-BETA5"]}},{"id":"640dbc4f31064328bf285370be2a8eea","type":"GENE","name":"PCDHB6","canonical_id":"hgnc:HGNC:8691","description":"protocadherin beta 6","metadata":{"aliases":["PCDH-BETA6"]}},{"id":"54e2f14b1e184dde92d869682c7ef90f","type":"GENE","name":"PCDHB7","canonical_id":"hgnc:HGNC:8692","description":"protocadherin beta 7","metadata":{"aliases":["PCDH-BETA7"]}},{"id":"ff222150ac0b444793d7d33ecc1aa6f1","type":"GENE","name":"PCDHB8","canonical_id":"hgnc:HGNC:8693","description":"protocadherin beta 8","metadata":{"aliases":["PCDH-BETA8","PCDH3I"]}},{"id":"4e63443bbeaf448086da783987dace76","type":"GENE","name":"PCDHB9","canonical_id":"hgnc:HGNC:8694","description":"protocadherin beta 9","metadata":{"aliases":["PCDH-BETA9","PCDH3H"]}},{"id":"c348c8edee31479cbb62ec90c25654d4","type":"GENE","name":"PCDHB@","canonical_id":"hgnc:HGNC:8679","description":"protocadherin beta cluster","metadata":{"aliases":["PCDH3"]}},{"id":"730db22e1fc8401d8f997c370ca580a6","type":"GENE","name":"PCDHG@","canonical_id":"hgnc:HGNC:8695","description":"protocadherin gamma cluster","metadata":{"aliases":["PCDH2","PCDH4"]}},{"id":"1279fe33e4a442eabdb51a9351907dca","type":"GENE","name":"PCDHGA1","canonical_id":"hgnc:HGNC:8696","description":"protocadherin gamma subfamily A, 1","metadata":{"aliases":["PCDH-GAMMA-A1"]}},{"id":"06eff55a17e74c32bd0c3eeb04bc9d43","type":"GENE","name":"PCDHGA10","canonical_id":"hgnc:HGNC:8697","description":"protocadherin gamma subfamily A, 10","metadata":{"aliases":["PCDH-GAMMA-A10"]}},{"id":"bb5278c343f64ed19aec01d76ff5ef9d","type":"GENE","name":"PCDHGA11","canonical_id":"hgnc:HGNC:8698","description":"protocadherin gamma subfamily A, 11","metadata":{"aliases":["PCDH-GAMMA-A11"]}},{"id":"a6fc396548b54cef9bc36ed1d4711bad","type":"GENE","name":"PCDHGA12","canonical_id":"hgnc:HGNC:8699","description":"protocadherin gamma subfamily A, 12","metadata":{"aliases":["KIAA0588","FIB3","PCDH-GAMMA-A12","CDH21"]}},{"id":"736327fe870a413894ebc3caecef3ed3","type":"GENE","name":"PCDHGA2","canonical_id":"hgnc:HGNC:8700","description":"protocadherin gamma subfamily A, 2","metadata":{"aliases":["PCDH-GAMMA-A2"]}},{"id":"bb15b6185e004df5b3c14f0914140735","type":"GENE","name":"PCDHGA3","canonical_id":"hgnc:HGNC:8701","description":"protocadherin gamma subfamily A, 3","metadata":{"aliases":["PCDH-GAMMA-A3"]}},{"id":"56825fc255654ecdbb81f4b06a79b5fd","type":"GENE","name":"PCDHGA4","canonical_id":"hgnc:HGNC:8702","description":"protocadherin gamma subfamily A, 4","metadata":{"aliases":["PCDH-GAMMA-A4"]}},{"id":"58a026059e374ec58ee3627f1fd1beb2","type":"GENE","name":"PCDHGA5","canonical_id":"hgnc:HGNC:8703","description":"protocadherin gamma subfamily A, 5","metadata":{"aliases":["CDH-GAMMA-A5","ME3","PCDH-GAMMA-A5"]}},{"id":"5fe2e9d776e94db4a1bd609db8cd53d8","type":"GENE","name":"PCDHGA6","canonical_id":"hgnc:HGNC:8704","description":"protocadherin gamma subfamily A, 6","metadata":{"aliases":["PCDH-GAMMA-A6"]}},{"id":"c0a3ec4433ec462bbc3f8c79c7f3c895","type":"GENE","name":"PCDHGA7","canonical_id":"hgnc:HGNC:8705","description":"protocadherin gamma subfamily A, 7","metadata":{"aliases":["PCDH-GAMMA-A7"]}},{"id":"1fdae81ef8304eaabef64abf21111a37","type":"GENE","name":"PCDHGA8","canonical_id":"hgnc:HGNC:8706","description":"protocadherin gamma subfamily A, 8","metadata":{"aliases":["KIAA0327","PCDH-GAMMA-A8"]}},{"id":"2de9754414b44b9b8506e07fb8e914ec","type":"GENE","name":"PCDHGA9","canonical_id":"hgnc:HGNC:8707","description":"protocadherin gamma subfamily A, 9","metadata":{"aliases":["PCDH-GAMMA-A9"]}},{"id":"07e011091cc34f9585aa5ce0108bf9fa","type":"GENE","name":"PCDHGB1","canonical_id":"hgnc:HGNC:8708","description":"protocadherin gamma subfamily B, 1","metadata":{"aliases":["PCDH-GAMMA-B1"]}},{"id":"153c138aa15649a691c26367de6765de","type":"GENE","name":"PCDHGB2","canonical_id":"hgnc:HGNC:8709","description":"protocadherin gamma subfamily B, 2","metadata":{"aliases":["PCDH-GAMMA-B2"]}},{"id":"da7ce719724f4c2cad0185b690bd29a3","type":"GENE","name":"PCDHGB3","canonical_id":"hgnc:HGNC:8710","description":"protocadherin gamma subfamily B, 3","metadata":{"aliases":["PCDH-GAMMA-B3"]}},{"id":"ed3db0de843241719dc02a658afbe556","type":"GENE","name":"PCDHGB4","canonical_id":"hgnc:HGNC:8711","description":"protocadherin gamma subfamily B, 4","metadata":{"aliases":["FIB2","CDH20","PCDH-GAMMA-B4"]}},{"id":"fdd1489c74e34f7692a16bc02a85bf08","type":"GENE","name":"PCDHGB5","canonical_id":"hgnc:HGNC:8712","description":"protocadherin gamma subfamily B, 5","metadata":{"aliases":["PCDH-GAMMA-B5"]}},{"id":"28d34f1c0d0843e9a75edefaa590eda4","type":"GENE","name":"PCDHGB6","canonical_id":"hgnc:HGNC:8713","description":"protocadherin gamma subfamily B, 6","metadata":{"aliases":["PCDH-GAMMA-B6"]}},{"id":"3ed9be7665d74d67ae8198e44c95956a","type":"GENE","name":"PCDHGB7","canonical_id":"hgnc:HGNC:8714","description":"protocadherin gamma subfamily B, 7","metadata":{"aliases":["ME6","PCDH-GAMMA-B7"]}},{"id":"35a85cbea82d4d48a64557268e1baf43","type":"GENE","name":"PCDHGB8P","canonical_id":"hgnc:HGNC:8715","description":"protocadherin gamma subfamily B, 8 pseudogene","metadata":{"aliases":["PCDH-PSI3"]}},{"id":"5185488bef0243b18326bb81c185a3e9","type":"GENE","name":"PCDHGB9P","canonical_id":"hgnc:HGNC:15688","description":"protocadherin gamma subfamily B, 9 pseudogene","metadata":{"aliases":["PSI6"]}},{"id":"40e92d95c72c45d984afecac09cd88cc","type":"GENE","name":"PCDHGC3","canonical_id":"hgnc:HGNC:8716","description":"protocadherin gamma subfamily C, 3","metadata":{"aliases":["PC-43","PC43","PCDH-GAMMA-C3","PCDH2"]}},{"id":"6ed1a50172a54272b4dc2b7e27f01081","type":"GENE","name":"PCDHGC4","canonical_id":"hgnc:HGNC:8717","description":"protocadherin gamma subfamily C, 4","metadata":{"aliases":["PCDH-GAMMA-C4"]}},{"id":"3372272a29304fec8116d0471b03d08c","type":"GENE","name":"PCDHGC5","canonical_id":"hgnc:HGNC:8718","description":"protocadherin gamma subfamily C, 5","metadata":{"aliases":["PCDH-GAMMA-C5"]}},{"id":"e32bbefca7ca49e88d0e7dd479d3b43e","type":"GENE","name":"PCDHGCT","canonical_id":"hgnc:HGNC:8719","description":"protocadherin gamma constant","metadata":{"aliases":["PCDHGC"]}},{"id":"d3066dc175134ad5a3ee050a062ad209","type":"GENE","name":"PCED1A","canonical_id":"hgnc:HGNC:16212","description":"PC-esterase domain containing 1A","metadata":{"aliases":["bA12M19.1","FLJ22376","C20orf81","FAM113A"]}},{"id":"2fc2d9d9a1b747a699cfbd8581cedf65","type":"GENE","name":"PCED1B","canonical_id":"hgnc:HGNC:28255","description":"PC-esterase domain containing 1B","metadata":{"aliases":["MGC16044","FAM113B"]}},{"id":"b72d17a8ed1c488b87587963f33a9b52","type":"GENE","name":"PCED1B-AS1","canonical_id":"hgnc:HGNC:44166","description":"PCED1B antisense RNA 1","metadata":null},{"id":"ee8733c285f1486c81ff172986d32cb2","type":"GENE","name":"PCED1CP","canonical_id":"hgnc:HGNC:44083","description":"PC-esterase domain containing 1C, pseudogene","metadata":null},{"id":"8dd7e35d432946ca9630ee5a02f21496","type":"GENE","name":"PCF11","canonical_id":"hgnc:HGNC:30097","description":"PCF11 cleavage and polyadenylation factor subunit","metadata":{"aliases":["KIAA0824"]}},{"id":"0263a9cab3794b6bb553e0a74d971a98","type":"GENE","name":"PCF11-AS1","canonical_id":"hgnc:HGNC:52263","description":"PCF11 antisense RNA 1","metadata":{"aliases":["ENST00000602322.1"]}},{"id":"e6db800ef4564e2ea630dcc2cec744d6","type":"GENE","name":"PCGEM1","canonical_id":"hgnc:HGNC:30145","description":"PCGEM1 prostate-specific transcript","metadata":{"aliases":["NCRNA00071","LINC00071","PCAT9"]}},{"id":"b69c3d3f5e51409f910edea99535fdb6","type":"GENE","name":"PCGF1","canonical_id":"hgnc:HGNC:17615","description":"polycomb group ring finger 1","metadata":{"aliases":["NSPC1","RNF68","MGC10882"]}},{"id":"0e7242be41524a2e848391091d32e5aa","type":"GENE","name":"PCGF2","canonical_id":"hgnc:HGNC:12929","description":null,"metadata":null},{"id":"97a42d587f2d4a1fb8b15fa22a7bfefd","type":"GENE","name":"PCGF3","canonical_id":"hgnc:HGNC:10066","description":"polycomb group ring finger 3","metadata":{"aliases":["FLJ36550","DONG1","RNF3A","MGC40413","RNF3"]}},{"id":"6085d29c589848d68f2a96a2c3cb55fa","type":"GENE","name":"PCGF3-AS1","canonical_id":"hgnc:HGNC:56108","description":"PCGF3 antisense RNA 1","metadata":null},{"id":"9d566bea78aa4557988bae677eb4736e","type":"GENE","name":"PCGF3-AS2","canonical_id":"hgnc:HGNC:40506","description":"PCGF3 antisense RNA 2","metadata":{"aliases":["AC107464.2"]}},{"id":"c64cde4355a64c66945f4582789dbccb","type":"GENE","name":"PCGF5","canonical_id":"hgnc:HGNC:28264","description":"polycomb group ring finger 5","metadata":{"aliases":["MGC16202","RNF159"]}},{"id":"8f75afed43774661b46c5827ca634dcf","type":"GENE","name":"PCGF6","canonical_id":"hgnc:HGNC:21156","description":"polycomb group ring finger 6","metadata":{"aliases":["MBLR","RNF134"]}},{"id":"4d3444068dba4653a7ac20ac5de440b0","type":"GENE","name":"PCGF7P","canonical_id":"hgnc:HGNC:30341","description":"polycomb group ring finger 7 pseudogene","metadata":{"aliases":["RNF134P1"]}},{"id":"e8d3c85271e6450690bcb0e9c2518b9d","type":"GENE","name":"PCHILR","canonical_id":"hgnc:HGNC:55418","description":"prostate cancer associated HIP1 interacting lncRNA","metadata":{"aliases":["PCLN16"]}},{"id":"4d15e49c41f041548b7d6fe6e953e7a0","type":"GENE","name":"PCID2","canonical_id":"hgnc:HGNC:25653","description":"PCI domain containing 2","metadata":{"aliases":["FLJ11305"]}},{"id":"44f287c5fff24000b927f7e926f950e4","type":"GENE","name":"PCIF1","canonical_id":"hgnc:HGNC:16200","description":"phosphorylated CTD interacting factor 1","metadata":{"aliases":["bA465L10.1","PPP1R121","CAPAM","MT-A70","C20orf67"]}},{"id":"cee055df77af421bbcff67ba50008d8f","type":"GENE","name":"PCK1","canonical_id":"hgnc:HGNC:8724","description":null,"metadata":null},{"id":"fe8a1979a489406da1206a06cedc53d9","type":"GENE","name":"PCK2","canonical_id":"hgnc:HGNC:8725","description":null,"metadata":null},{"id":"d0057e7afec04ef6b8db2f3f73187e0b","type":"GENE","name":"PCLAF","canonical_id":"hgnc:HGNC:28961","description":null,"metadata":null},{"id":"e0133bd43dde4c4ea87794ded1538a0b","type":"GENE","name":"PCLO","canonical_id":"hgnc:HGNC:13406","description":"piccolo presynaptic cytomatrix protein","metadata":{"aliases":["KIAA0559","DKFZp779G1236","ACZ"]}},{"id":"7e67ad84e2334349b796c6d573a5c569","type":"GENE","name":"PCM1","canonical_id":"hgnc:HGNC:8727","description":"pericentriolar material 1","metadata":{"aliases":["PTC4"]}},{"id":"bf375e5f7b074c5aa0353e6a12852eb8","type":"GENE","name":"PCMT1","canonical_id":"hgnc:HGNC:8728","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase","metadata":null},{"id":"cb92b21049324addb80de49641f5a3fb","type":"GENE","name":"PCMTD1","canonical_id":"hgnc:HGNC:30483","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1","metadata":{"aliases":["FLJ10883"]}},{"id":"5ae7b3f8ff844e158c0646fcd4993beb","type":"GENE","name":"PCMTD1-DT","canonical_id":"hgnc:HGNC:55791","description":"PCMTD1 divergent transcript","metadata":null},{"id":"4a3d699e23dc491283622c839e2e7061","type":"GENE","name":"PCMTD1P1","canonical_id":"hgnc:HGNC:38804","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 1","metadata":null},{"id":"10b368a6fa114f8ab7b0d56a10bae471","type":"GENE","name":"PCMTD1P2","canonical_id":"hgnc:HGNC:38805","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 2","metadata":null},{"id":"d25b41720e6445fb90e22208400b70b3","type":"GENE","name":"PCMTD1P3","canonical_id":"hgnc:HGNC:38806","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 3","metadata":null},{"id":"b9bb83fe7f484eb2b53a49bfdac26751","type":"GENE","name":"PCMTD1P4","canonical_id":"hgnc:HGNC:51748","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 4","metadata":null},{"id":"21dc59cd6cf94328b65f042fc27c18b4","type":"GENE","name":"PCMTD1P5","canonical_id":"hgnc:HGNC:51749","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 5","metadata":null},{"id":"74939b7d82694df8b9972dc546cc0694","type":"GENE","name":"PCMTD1P6","canonical_id":"hgnc:HGNC:51750","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 6","metadata":null},{"id":"9c5c227e18564aec96f41d633f512eb4","type":"GENE","name":"PCMTD1P7","canonical_id":"hgnc:HGNC:51751","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 7","metadata":null},{"id":"b16ad9c406a34f3f869f86bd8cbbee7b","type":"GENE","name":"PCMTD1P8","canonical_id":"hgnc:HGNC:51752","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 pseudogene 8","metadata":null},{"id":"0581a340fbf54aaa904d81bc356abd85","type":"GENE","name":"PCMTD2","canonical_id":"hgnc:HGNC:15882","description":"protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2","metadata":{"aliases":["FLJ10883","C20orf36"]}},{"id":"2d7695227fff4e43ac226cce18fba42c","type":"GENE","name":"PCNA","canonical_id":"hgnc:HGNC:8729","description":null,"metadata":null},{"id":"9bf8826a8ec8424fbb1f4e9bc17f5fa0","type":"GO_TERM","name":"PCNA complex","canonical_id":"go:GO:0043626","description":"\"A protein complex composed of three identical PCNA monomers, each comprising two similar domains, which are joined in a head-to-tail arrangement to form a homotrimer. Forms a ring-like structure in solution, with a central hole sufficiently large to accommodate the double helix of DNA. Originally characterized as a DNA sliding clamp for replicative DNA polymerases and as an essential component of the replisome, and has also been shown to be involved in other processes including Okazaki fragment processing, DNA repair, translesion DNA synthesis, DNA methylation, chromatin remodeling and cell cycle regulation.\" [GOC:jl, PMID:12829735]","metadata":null},{"id":"32b435507bf0498a84a7073fa8b4f8ba","type":"GENE","name":"PCNA-AS1","canonical_id":"hgnc:HGNC:37184","description":"PCNA antisense RNA 1","metadata":{"aliases":["PCNAAS","PCNA-AS"]}},{"id":"d8c708eb32df4c6ea34ae1457bafa77b","type":"GO_TERM","name":"PCNA-p21 complex","canonical_id":"go:GO:0070557","description":"\"A protein complex that contains the cyclin-dependent protein kinase inhibitor p21WAF1/CIP1 bound to PCNA; formation of the complex inhibits DNA replication.\" [GOC:mah, PMID:7911228, PMID:7915843]","metadata":null},{"id":"826223790ca94086a58e40f77fc61346","type":"GENE","name":"PCNAP1","canonical_id":"hgnc:HGNC:8732","description":"proliferating cell nuclear antigen pseudogene 1","metadata":{"aliases":["p1PCNA"]}},{"id":"0bd557eefe1e4758a43c93355c9b1334","type":"GENE","name":"PCNAP2","canonical_id":"hgnc:HGNC:8733","description":"proliferating cell nuclear antigen pseudogene 2","metadata":{"aliases":["pF2PCNA"]}},{"id":"adae4edf2dc34fc1842adba72583c5bd","type":"GENE","name":"PCNAP3","canonical_id":"hgnc:HGNC:43736","description":"proliferating cell nuclear antigen pseudogene 3","metadata":null},{"id":"a1bc7062b06246e1b585328c034becea","type":"GENE","name":"PCNAP4","canonical_id":"hgnc:HGNC:43737","description":"proliferating cell nuclear antigen pseudogene 4","metadata":null},{"id":"bd816a60b08d45dfb77acdee171ab762","type":"GENE","name":"PCNP","canonical_id":"hgnc:HGNC:30023","description":"PEST proteolytic signal containing nuclear protein","metadata":null},{"id":"c8cbafc459f0451e9e9153958804fa90","type":"GENE","name":"PCNPP1","canonical_id":"hgnc:HGNC:32440","description":"PEST containing nuclear protein pseudogene 1","metadata":{"aliases":["PCNPP"]}},{"id":"439d341430e94c55a1ac6a5057bffb1e","type":"GENE","name":"PCNPP2","canonical_id":"hgnc:HGNC:41974","description":"PEST containing nuclear protein pseudogene 2","metadata":null},{"id":"9cefe14a066f43788420b5dcc5942ff0","type":"GENE","name":"PCNPP3","canonical_id":"hgnc:HGNC:41975","description":"PEST containing nuclear protein pseudogene 3","metadata":null},{"id":"c47bdff9cc624f668348c81199cf9fbb","type":"GENE","name":"PCNPP4","canonical_id":"hgnc:HGNC:41976","description":"PEST containing nuclear protein pseudogene 4","metadata":null},{"id":"f6e4ea1beba6425aa0339fd128641064","type":"GENE","name":"PCNPP5","canonical_id":"hgnc:HGNC:41977","description":"PEST containing nuclear protein pseudogene 5","metadata":null},{"id":"85b3b07523424f90a07c1f896395e2f1","type":"GENE","name":"PCNT","canonical_id":"hgnc:HGNC:16068","description":"pericentrin","metadata":{"aliases":["KEN","KIAA0402","PCN","PCNTB","SCKL4","PCNT2"]}},{"id":"8e49723223e34faaae4999cafdc80490","type":"GENE","name":"PCNX1","canonical_id":"hgnc:HGNC:19740","description":"pecanex 1","metadata":{"aliases":["KIAA0995","KIAA0805","pecanex","PCNXL1","PCNX"]}},{"id":"406bd4adaa4340aa8f712964b3f5bd2f","type":"GENE","name":"PCNX2","canonical_id":"hgnc:HGNC:8736","description":"pecanex 2","metadata":{"aliases":["KIAA0435","FLJ11383","PCNXL2"]}},{"id":"e5e498694116449094a6b62e6739efe3","type":"GENE","name":"PCNX3","canonical_id":"hgnc:HGNC:18760","description":"pecanex 3","metadata":{"aliases":["FLJ22427","PCNXL3"]}},{"id":"61790409cc78433eb47666cce8d299b2","type":"GENE","name":"PCNX4","canonical_id":"hgnc:HGNC:20349","description":"pecanex 4","metadata":{"aliases":["C14orf135","PCNXL4"]}},{"id":"7aa233230d394fefa93ac2f624365ddd","type":"GENE","name":"PCNX4-DT","canonical_id":"hgnc:HGNC:55447","description":"PCNX4 divergent transcript","metadata":null},{"id":"4b7557a1af2346ffb99f5f05cb43a3f7","type":"GENE","name":"PCOLCE","canonical_id":"hgnc:HGNC:8738","description":"procollagen C-endopeptidase enhancer","metadata":{"aliases":["PCPE","PCPE1"]}},{"id":"1ee214ea5d514310a9a078febdb6084b","type":"GENE","name":"PCOLCE-AS1","canonical_id":"hgnc:HGNC:40430","description":"PCOLCE antisense RNA 1","metadata":null},{"id":"7f7b196a5d9a4b369121e59251365b83","type":"GENE","name":"PCOLCE2","canonical_id":"hgnc:HGNC:8739","description":"procollagen C-endopeptidase enhancer 2","metadata":{"aliases":["PCPE2"]}},{"id":"a2d81630004b4885bc999208c81c987c","type":"GENE","name":"PCOTH","canonical_id":"hgnc:HGNC:39839","description":"prostate and testis expressed opposite C1QTNF9B and MIPEP","metadata":{"aliases":["C1QTNF9B-AS1"]}},{"id":"99b068923c5140928c6d8bdb5ba90883","type":"GENE","name":"PCOTHP1","canonical_id":"hgnc:HGNC:39840","description":"PCOTH pseudogene 1","metadata":null},{"id":"0b1f1e56e4ab4ea490e6b62eb36b1f1a","type":"GENE","name":"PCP2","canonical_id":"hgnc:HGNC:30209","description":"Purkinje cell protein 2","metadata":{"aliases":["MGC41903","GPSM4"]}},{"id":"7ca17caff8b44fc08afba52a4b29c5f8","type":"GENE","name":"PCP4","canonical_id":"hgnc:HGNC:8742","description":"Purkinje cell protein 4","metadata":{"aliases":["PEP-19"]}},{"id":"09b5f44baa734f3f8fdcbfa6ef909711","type":"GENE","name":"PCP4L1","canonical_id":"hgnc:HGNC:20448","description":"Purkinje cell protein 4 like 1","metadata":{"aliases":["IQM1"]}},{"id":"a71b40c31b674096b43dd10b087c6d36","type":"GENE","name":"PCSEAT","canonical_id":"hgnc:HGNC:54485","description":"prostate cancer expressed EZH2 associated transcript","metadata":{"aliases":["PRCAT38"]}},{"id":"903be000335b4733b8ec7b6bb7a59d4a","type":"GENE","name":"PCSK1","canonical_id":"hgnc:HGNC:8743","description":null,"metadata":null},{"id":"617b2c638c4846dfa9329910fc4d831d","type":"GENE","name":"PCSK1N","canonical_id":"hgnc:HGNC:17301","description":"proprotein convertase subtilisin/kexin type 1 inhibitor","metadata":{"aliases":["SAAS","SgVIII","SCG8","proSAAS","PEN","BigLEN"]}},{"id":"4bc89baef1974dcf933d108e7b8a4e6f","type":"GENE","name":"PCSK2","canonical_id":"hgnc:HGNC:8744","description":null,"metadata":null},{"id":"1a6f21e00d00439eb8618c52143965ca","type":"GENE","name":"PCSK4","canonical_id":"hgnc:HGNC:8746","description":"proprotein convertase subtilisin/kexin type 4","metadata":{"aliases":["PC4","SPC5","DKFZp434B217","MGC34749"]}},{"id":"ce4fda3c448044919ae72db49696952a","type":"GENE","name":"PCSK5","canonical_id":"hgnc:HGNC:8747","description":"proprotein convertase subtilisin/kexin type 5","metadata":{"aliases":["PC5","PC6","SPC6"]}},{"id":"26b390616fd24481b9911ce4d08f0284","type":"GENE","name":"PCSK6","canonical_id":"hgnc:HGNC:8569","description":null,"metadata":null},{"id":"bb23198e3c2b457a913ace8e5c7342f7","type":"GENE","name":"PCSK6-AS1","canonical_id":"hgnc:HGNC:51448","description":"PCSK6 antisense RNA 1","metadata":null},{"id":"64ad7867a32543d89dafb514a1e39b13","type":"GENE","name":"PCSK7","canonical_id":"hgnc:HGNC:8748","description":"proprotein convertase subtilisin/kexin type 7","metadata":{"aliases":["PC7","PC8","LPC","SPC7"]}},{"id":"4b46b5837888431390d9cb9b860b89e4","type":"GENE","name":"PCSK9","canonical_id":"hgnc:HGNC:20001","description":null,"metadata":null},{"id":"c308f6ba4c87430a87089a444f98a672","type":"PROTEIN","name":"PCSK9","canonical_id":"uniprot:Q8NBP7","description":null,"metadata":null},{"id":"77388407543845c2a5c544be3562f6a0","type":"TRIAL","name":"PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT03507374","description":"Stroke; Intracranial Atherosclerosis; Intraplaque Hemorrhage","metadata":null},{"id":"4b7780ec5c734633a6acaad18ec4ade3","type":"TRIAL","name":"PCSK9 Inhibitor Treatment for Patients With SPG5","canonical_id":"clinicaltrials.gov:NCT04101643","description":"Hereditary Spastic Paraplegia Type 5","metadata":null},{"id":"64373d625e7649c4a90b4d2f6e31e569","type":"TRIAL","name":"PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT06902740","description":"Intracranial Atherosclerosis; Intracranial Artery Stenosis; Atherosclerotic Plaque","metadata":null},{"id":"21f260b7515b46c98db3e8851b467490","type":"TRIAL","name":"PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT07466251","description":"Acute Ischemic Stroke AIS; Intracranial Atherosclerosis ICAS; Atherosclerotic Plaque","metadata":null},{"id":"64f67f35f54a42b7aad5983af164d321","type":"TRIAL","name":"PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis","canonical_id":"clinicaltrials.gov:NCT07119918","description":"Symptomatic Intracranial Atherosclerotic Stenosis","metadata":null},{"id":"65a7064770284802b99f5b9d4f705254","type":"GO_TERM","name":"PCSK9-AnxA2 complex","canonical_id":"go:GO:1990667","description":"\"A protein complex consisting of the serine protease PCSK9 (proprotein convertase subtilisin/kexin-9) and annexin A2 (AnxA2).\" [GOC:BHF, GOC:nc, PMID:22848640]","metadata":null},{"id":"c6addeb69b444da18327d615b5d68f05","type":"GO_TERM","name":"PCSK9-LDLR complex","canonical_id":"go:GO:1990666","description":"\"A protein complex consisting of the serine protease PCSK9 (proprotein convertase subtilisin/kexin-9) and a low-density lipoprotein receptor (LDLR). Interaction typically occurs through the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR, and complex formation promotes degradation of the LDLR through the endosome/lysosome pathway.\" [GOC:BHF, GOC:nc, PMID:18250299, PMID:24440079]","metadata":null},{"id":"fd6ec04078e94430ab02bc5db87a7a77","type":"GENE","name":"PCTP","canonical_id":"hgnc:HGNC:8752","description":"phosphatidylcholine transfer protein","metadata":{"aliases":["STARD2"]}},{"id":"a77d185d8840448ea584c0c08709a4c1","type":"GENE","name":"PCYOX1","canonical_id":"hgnc:HGNC:20588","description":"prenylcysteine oxidase 1","metadata":{"aliases":["KIAA0908","PCL1"]}},{"id":"022d83bbdf0c414c9f954b93ca3774a6","type":"GENE","name":"PCYOX1L","canonical_id":"hgnc:HGNC:28477","description":"prenylcysteine oxidase 1 like","metadata":{"aliases":["MGC3265"]}},{"id":"04da656ee65745ac976c7df776d2028b","type":"GENE","name":"PCYT1A","canonical_id":"hgnc:HGNC:8754","description":null,"metadata":null},{"id":"898962460d42405ebe541490291036f1","type":"GENE","name":"PCYT1B","canonical_id":"hgnc:HGNC:8755","description":"phosphate cytidylyltransferase 1B, choline","metadata":{"aliases":["CCT-beta","CTB","CCTbeta"]}},{"id":"3f6b4ced04644c9db610f19cddf03e1c","type":"GENE","name":"PCYT1B-AS1","canonical_id":"hgnc:HGNC:40431","description":"PCYT1B antisense RNA 1","metadata":null},{"id":"b4bd253168be4b43906f682e2dcf7c54","type":"GENE","name":"PCYT2","canonical_id":"hgnc:HGNC:8756","description":null,"metadata":null},{"id":"88450046b4bf488791f03a40550231ea","type":"TRIAL","name":"PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment","canonical_id":"clinicaltrials.gov:NCT04634162","description":"Coronary Artery Disease","metadata":null},{"id":"13eab1d9a277419593314295f6788f45","type":"TRIAL","name":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07277842","description":"Locally Advanced Low Rectal Adenocarcinoma; pMMR (Microsatellite Stable Rectal Cancer)","metadata":null},{"id":"eb41359a4e0b444abaa9bdf2237e6149","type":"TRIAL","name":"PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05967884","description":"Breast Cancer","metadata":null},{"id":"11514f4a92d44da48b58c1084461935b","type":"TRIAL","name":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT05034536","description":"Metastatic Melanoma","metadata":null},{"id":"463cb1c5da904769b53b18e03e28172c","type":"TRIAL","name":"PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC","canonical_id":"clinicaltrials.gov:NCT06396637","description":"Pancreatic Adenocarcinoma Metastatic","metadata":null},{"id":"9a7e739d86114a82b04927e8ec227e8b","type":"TRIAL","name":"PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy","canonical_id":"clinicaltrials.gov:NCT07014215","description":"NSCLC (Advanced Non-small Cell Lung Cancer); Resistance to Immunotherapy","metadata":null},{"id":"5965ffb0218f495d9d24bff04ceea398","type":"TRIAL","name":"PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)","canonical_id":"clinicaltrials.gov:NCT05357846","description":"Squamous Cell Esophageal Carcinoma; Esophageal Cancer; Oesophageal Cancer","metadata":null},{"id":"89d6120d0a7e4ca29ff6ab9c7997a70d","type":"TRIAL","name":"PD-L1 PET-imaging During CAR T-cell Therapy","canonical_id":"clinicaltrials.gov:NCT05404048","description":"Large B-cell Lymphoma","metadata":null},{"id":"46a35be693764fe1900b074c02741f47","type":"TRIAL","name":"PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer","canonical_id":"clinicaltrials.gov:NCT06335147","description":"Metastatic Colon Cancer","metadata":null},{"id":"97d289daeb274fa98f80d19ec4cd099e","type":"GENE","name":"PDAP1","canonical_id":"hgnc:HGNC:14634","description":"PDGFA associated protein 1","metadata":{"aliases":["PAP1","PAP","HASPP28"]}},{"id":"6be94c88036e4c638ca1aa4f1ee5ba19","type":"GENE","name":"PDAP1P1","canonical_id":"hgnc:HGNC:58505","description":"PDAP1 pseudogene 1","metadata":null},{"id":"fc298aac9c1c4e5b82a7aa584ed6832e","type":"GENE","name":"PDAP1P2","canonical_id":"hgnc:HGNC:58506","description":"PDAP1 pseudogene 2","metadata":null},{"id":"14ca29b07b7048eca457fb87499eacf9","type":"GENE","name":"PDAP1P3","canonical_id":"hgnc:HGNC:58507","description":"PDAP1 pseudogene 3","metadata":null},{"id":"44e695843ace4c048fb726e47c0e09b6","type":"GENE","name":"PDC","canonical_id":"hgnc:HGNC:8759","description":"phosducin","metadata":{"aliases":["MEKA"]}},{"id":"27fa8e02636148698abe73ef740410d2","type":"GENE","name":"PDC-AS1","canonical_id":"hgnc:HGNC:40432","description":"PDC antisense RNA 1","metadata":null},{"id":"b40d4ed790d94ea49d974e95396949c6","type":"GENE","name":"PDCD1","canonical_id":"hgnc:HGNC:8760","description":"programmed cell death 1","metadata":{"aliases":["CD279","PD1","hSLE1","PD-1","SLEB2"]}},{"id":"68eac178ced844fb965e004ed5ca0f99","type":"PROTEIN","name":"PDCD1","canonical_id":"uniprot:Q15116","description":null,"metadata":null},{"id":"c40fc3eb2d77438bbe47d8b7489f01a5","type":"GENE","name":"PDCD10","canonical_id":"hgnc:HGNC:8761","description":"programmed cell death 10","metadata":{"aliases":["TFAR15","CCM3"]}},{"id":"a2a72c2428264548969ca2e2afbc3d49","type":"GENE","name":"PDCD11","canonical_id":"hgnc:HGNC:13408","description":null,"metadata":null},{"id":"7c32cf9a8eeb403283f191678d76b3e0","type":"GENE","name":"PDCD1LG2","canonical_id":"hgnc:HGNC:18731","description":"programmed cell death 1 ligand 2","metadata":{"aliases":["PD-L2","Btdc","PDL2","bA574F11.2","CD273","B7-DC","B7DC"]}},{"id":"0d283d7a274548f7a51a88047f8eaaff","type":"GENE","name":"PDCD2","canonical_id":"hgnc:HGNC:8762","description":null,"metadata":null},{"id":"1a8a7ba24e6d48a88ace8e210cff5cc1","type":"GENE","name":"PDCD2L","canonical_id":"hgnc:HGNC:28194","description":"programmed cell death 2 like","metadata":{"aliases":["MGC13096"]}},{"id":"11ec4a8f4946403e9d58e4e8fd81d438","type":"GENE","name":"PDCD2P1","canonical_id":"hgnc:HGNC:58508","description":"PDCD2 pseudogene 1","metadata":null},{"id":"efe601c5f673456295f4120c0a6ce9ed","type":"GENE","name":"PDCD2P2","canonical_id":"hgnc:HGNC:58509","description":"PDCD2 pseudogene 2","metadata":null},{"id":"8186235ea1c34fc8a02c7697d6c00d0c","type":"GENE","name":"PDCD4","canonical_id":"hgnc:HGNC:8763","description":null,"metadata":null},{"id":"f335515aa116422ea01c64e014179935","type":"GENE","name":"PDCD4-AS1","canonical_id":"hgnc:HGNC:27425","description":"PDCD4 antisense RNA 1","metadata":null},{"id":"45ac900fbe9b47fbbb9f666f31ee9347","type":"GENE","name":"PDCD5","canonical_id":"hgnc:HGNC:8764","description":null,"metadata":null},{"id":"7414724b03094c28a56c06c1a701670d","type":"GENE","name":"PDCD5P1","canonical_id":"hgnc:HGNC:49885","description":"programmed cell death 5 pseudogene 1","metadata":null},{"id":"1f4c9e17adec4cf99d34e9d9626fe90c","type":"GENE","name":"PDCD5P2","canonical_id":"hgnc:HGNC:49886","description":"programmed cell death 5 pseudogene 2","metadata":null},{"id":"271fb6e6e9544b53b85a99193cffe256","type":"GENE","name":"PDCD6","canonical_id":"hgnc:HGNC:8765","description":"programmed cell death 6","metadata":{"aliases":["ALG-2","PEF1B"]}},{"id":"b3c10f0ba78d4ef298de47a295ae12f7","type":"GENE","name":"PDCD6-AHRR","canonical_id":"hgnc:HGNC:54724","description":"PDCD6-AHRR readthrough (NMD candidate)","metadata":null},{"id":"5bf9687da82e4ca9bff4b5ddf48458e4","type":"GENE","name":"PDCD6-DT","canonical_id":"hgnc:HGNC:55580","description":"PDCD6 divergent transcript","metadata":{"aliases":["HRAT5"]}},{"id":"c939be99c2b741f8a2502272ca8208a1","type":"GENE","name":"PDCD6IP","canonical_id":"hgnc:HGNC:8766","description":"programmed cell death 6 interacting protein","metadata":{"aliases":["Alix","AIP1","Hp95"]}},{"id":"75479eb6b91344d89dfd6baef9668696","type":"GENE","name":"PDCD6IP-DT","canonical_id":"hgnc:HGNC:55244","description":"PDCD6IP divergent transcript","metadata":{"aliases":["RP11-10C24.1"]}},{"id":"657a896205ad4bcca54fc3f3829d38f7","type":"GENE","name":"PDCD6IPP1","canonical_id":"hgnc:HGNC:49872","description":"PDCD6IP pseudogene 1","metadata":null},{"id":"7a76d6ce2b024598bcbc88ef6506d1b6","type":"GENE","name":"PDCD6IPP2","canonical_id":"hgnc:HGNC:49873","description":"PDCD6IP pseudogene 2","metadata":null},{"id":"e25332b2726e43a6a59e37fc6b54672d","type":"GENE","name":"PDCD6P1","canonical_id":"hgnc:HGNC:55763","description":"PDCD6 pseudogene 1","metadata":null},{"id":"ffd703e7868f4045b7366808046ccc3f","type":"GENE","name":"PDCD7","canonical_id":"hgnc:HGNC:8767","description":"programmed cell death 7","metadata":{"aliases":["HES18","ES18","59K"]}},{"id":"e39d15c0d0564fdca402d0ab9bd1f286","type":"GENE","name":"PDCL","canonical_id":"hgnc:HGNC:8770","description":"phosducin like","metadata":{"aliases":["PhLP","DKFZp564M1863"]}},{"id":"e9bc39ff8fdd407f97bd9708da331e73","type":"GENE","name":"PDCL2","canonical_id":"hgnc:HGNC:29524","description":"phosducin like 2","metadata":{"aliases":["GCPHLP"]}},{"id":"440608fc173242cdbb2e6a7ed1b55874","type":"GENE","name":"PDCL2P1","canonical_id":"hgnc:HGNC:50340","description":"PDCL2 pseudogene 1","metadata":null},{"id":"6de9be17d91f4bd486ffba0182f9aee2","type":"GENE","name":"PDCL2P2","canonical_id":"hgnc:HGNC:50341","description":"PDCL2 pseudogene 2","metadata":null},{"id":"8a322a48f7fc4facb18ba8b4a28149b7","type":"GENE","name":"PDCL3","canonical_id":"hgnc:HGNC:28860","description":"phosducin like 3","metadata":{"aliases":["VIAF1"]}},{"id":"dfd57cbbd817412f9e11cfb0c9ae10ee","type":"GENE","name":"PDCL3P1","canonical_id":"hgnc:HGNC:31826","description":"PDCL3 pseudogene 1","metadata":null},{"id":"e18a09a63a554a488868b4bca4401ccf","type":"GENE","name":"PDCL3P2","canonical_id":"hgnc:HGNC:31705","description":"PDCL3 pseudogene 2","metadata":null},{"id":"fac03f21b1504a43ad76a58613516270","type":"GENE","name":"PDCL3P3","canonical_id":"hgnc:HGNC:44504","description":"PDCL3 pseudogene 3","metadata":null},{"id":"a235f7cb72da450f96c55bada517f4bf","type":"GENE","name":"PDCL3P4","canonical_id":"hgnc:HGNC:44505","description":"PDCL3 pseudogene 4","metadata":null},{"id":"9affdf13b9cb48878f363d408322c73e","type":"GENE","name":"PDCL3P5","canonical_id":"hgnc:HGNC:44506","description":"PDCL3 pseudogene 5","metadata":null},{"id":"5ab8dd4a55044e9088324d057d4945e1","type":"GENE","name":"PDCL3P6","canonical_id":"hgnc:HGNC:44507","description":"PDCL3 pseudogene 6","metadata":null},{"id":"49b036bdc85f4f909a631f4efdd38a70","type":"GENE","name":"PDCL3P7","canonical_id":"hgnc:HGNC:44508","description":"PDCL3 pseudogene 7","metadata":null},{"id":"76265ddfe732487981991bf33e34ece6","type":"GENE","name":"PDE10A","canonical_id":"hgnc:HGNC:8772","description":"phosphodiesterase 10A","metadata":null},{"id":"3ef77211914d4aea8b07cbaf8ac58428","type":"PROTEIN","name":"PDE10A","canonical_id":"uniprot:Q9Y233","description":null,"metadata":null},{"id":"a5dfd04bec6a4e5faa3fc7a0b583b55d","type":"GENE","name":"PDE11A","canonical_id":"hgnc:HGNC:8773","description":"phosphodiesterase 11A","metadata":null},{"id":"8c9d8af928124f028c613f150dccd058","type":"GENE","name":"PDE11A-AS1","canonical_id":"hgnc:HGNC:40433","description":"PDE11A antisense RNA 1","metadata":null},{"id":"c0ab5218bfd14aef96f7f58957df2d2a","type":"GENE","name":"PDE12","canonical_id":"hgnc:HGNC:25386","description":"phosphodiesterase 12","metadata":{"aliases":["DKFZp667B1218","2'-PDE","3635"]}},{"id":"f741fd056d644ba5a128f83ababb707a","type":"GENE","name":"PDE1A","canonical_id":"hgnc:HGNC:8774","description":"phosphodiesterase 1A","metadata":null},{"id":"dad2980ad5454246a757fd53fe30d73c","type":"GENE","name":"PDE1B","canonical_id":"hgnc:HGNC:8775","description":"phosphodiesterase 1B","metadata":{"aliases":["PDES1B"]}},{"id":"1cdd50bc9817402d817890fbe2bacec4","type":"GENE","name":"PDE1C","canonical_id":"hgnc:HGNC:8776","description":"phosphodiesterase 1C","metadata":{"aliases":["Hcam3"]}},{"id":"8c048771ea334b69af23684df15bfce7","type":"GENE","name":"PDE2A","canonical_id":"hgnc:HGNC:8777","description":"phosphodiesterase 2A","metadata":null},{"id":"715abfe098084bf99263abc0118b6e5d","type":"GENE","name":"PDE2A-AS1","canonical_id":"hgnc:HGNC:40435","description":"PDE2A antisense RNA 1","metadata":null},{"id":"7edbc6df2db44747b442ec5e80cd0d91","type":"GENE","name":"PDE2A-AS2","canonical_id":"hgnc:HGNC:40434","description":"PDE2A antisense RNA 2","metadata":null},{"id":"14eb5cd33d6140d6aaf15d836ce99f00","type":"GENE","name":"PDE3A","canonical_id":"hgnc:HGNC:8778","description":"phosphodiesterase 3A","metadata":{"aliases":["CGI-PDE"]}},{"id":"9715a199aa834bf18ca7414156e337a8","type":"PROTEIN","name":"PDE3A","canonical_id":"uniprot:Q14432","description":null,"metadata":null},{"id":"b87d6170ae4745d8b88a3b1530f5c1f5","type":"GENE","name":"PDE3A-AS1","canonical_id":"hgnc:HGNC:40436","description":"PDE3A antisense RNA 1","metadata":null},{"id":"b981899510f347a686d7c770303b5eee","type":"GENE","name":"PDE3B","canonical_id":"hgnc:HGNC:8779","description":"phosphodiesterase 3B","metadata":{"aliases":["HcGIP1"]}},{"id":"2539cbf9e0d6425ab3d50cd9209a86fa","type":"GENE","name":"PDE4A","canonical_id":"hgnc:HGNC:8780","description":"phosphodiesterase 4A","metadata":{"aliases":["DPDE2"]}},{"id":"5e51cc7aea01494499d47d06c0eb778f","type":"PROTEIN","name":"PDE4A","canonical_id":"uniprot:P27815","description":null,"metadata":null},{"id":"a03929e807c340a4a922b86556166fdf","type":"GENE","name":"PDE4B","canonical_id":"hgnc:HGNC:8781","description":"phosphodiesterase 4B","metadata":{"aliases":["DPDE4"]}},{"id":"4651664962c241368b449e312b9040b6","type":"GENE","name":"PDE4B-AS1","canonical_id":"hgnc:HGNC:40437","description":"PDE4B antisense RNA 1","metadata":null},{"id":"8dc24c86c9e746acaf36e0bc07fc6332","type":"GENE","name":"PDE4C","canonical_id":"hgnc:HGNC:8782","description":"phosphodiesterase 4C","metadata":{"aliases":["DPDE1"]}},{"id":"31de8386a6ee4468b7f15a633070d26d","type":"GENE","name":"PDE4D","canonical_id":"hgnc:HGNC:8783","description":"phosphodiesterase 4D","metadata":{"aliases":["DPDE3"]}},{"id":"93525d2e8f224880934ecd782533c68b","type":"GENE","name":"PDE4D-AS1","canonical_id":"hgnc:HGNC:58182","description":"PDE4D antisense RNA 1","metadata":null},{"id":"0e824585b460445f81c0f69765af1d15","type":"GENE","name":"PDE4D-AS2","canonical_id":"hgnc:HGNC:59057","description":"PDE4D antisense RNA 2","metadata":null},{"id":"8ecea3134cdd49d79481cc476c655329","type":"GENE","name":"PDE4DIP","canonical_id":"hgnc:HGNC:15580","description":"phosphodiesterase 4D interacting protein","metadata":{"aliases":["KIAA0477","KIAA0454","MMGL","CMYA2"]}},{"id":"40d803b916a34d8dbfb55e7d033e964a","type":"GENE","name":"PDE4DIPP1","canonical_id":"hgnc:HGNC:50867","description":"PDE4DIP pseudogene 1","metadata":null},{"id":"b527734dd8f04813b5fbe87604aa1921","type":"GENE","name":"PDE4DIPP10","canonical_id":"hgnc:HGNC:55101","description":"PDE4DIP pseudogene 10","metadata":null},{"id":"7e90fffa353b4dcd81a80d5357bbc5aa","type":"GENE","name":"PDE4DIPP2","canonical_id":"hgnc:HGNC:55081","description":"PDE4DIP pseudogene 2","metadata":null},{"id":"2b188fb078234a3bbdd2530eb387571d","type":"GENE","name":"PDE4DIPP3","canonical_id":"hgnc:HGNC:55082","description":"PDE4DIP pseudogene 3","metadata":null},{"id":"bc94e376cae54ae8848a2e01320b248e","type":"GENE","name":"PDE4DIPP4","canonical_id":"hgnc:HGNC:55083","description":"PDE4DIP pseudogene 4","metadata":null},{"id":"75e5f8853f9c4faa8611e66a77436822","type":"GENE","name":"PDE4DIPP5","canonical_id":"hgnc:HGNC:55084","description":"PDE4DIP pseudogene 5","metadata":null},{"id":"32cbbb0f7744486aaf4c4f989318edb7","type":"GENE","name":"PDE4DIPP6","canonical_id":"hgnc:HGNC:55097","description":"PDE4DIP pseudogene 6","metadata":null},{"id":"465300dbda4f4017876f515238bb511b","type":"GENE","name":"PDE4DIPP7","canonical_id":"hgnc:HGNC:55098","description":"PDE4DIP pseudogene 7","metadata":null},{"id":"d3123ed004974b0b9a8fe4c6b2228cb9","type":"GENE","name":"PDE4DIPP8","canonical_id":"hgnc:HGNC:55099","description":"PDE4DIP pseudogene 8","metadata":null},{"id":"a97968c0b17042ddaaa22e2258e2a625","type":"GENE","name":"PDE4DIPP9","canonical_id":"hgnc:HGNC:55100","description":"PDE4DIP pseudogene 9","metadata":null},{"id":"126115a933f04786bdcde9f34797ea47","type":"GENE","name":"PDE5A","canonical_id":"hgnc:HGNC:8784","description":null,"metadata":null},{"id":"e8c07e084d9e4b5aac7591e603f1fe78","type":"PROTEIN","name":"PDE5A","canonical_id":"uniprot:O76074","description":null,"metadata":null},{"id":"af75c33d28014c05b25292bd58dd6c77","type":"GENE","name":"PDE6A","canonical_id":"hgnc:HGNC:8785","description":null,"metadata":null},{"id":"ed6f186cac6048b3ab52c2dda6d73eb5","type":"GENE","name":"PDE6B","canonical_id":"hgnc:HGNC:8786","description":null,"metadata":null},{"id":"d65da1cc27a2443e87b96ecd37f905dd","type":"GENE","name":"PDE6B-AS1","canonical_id":"hgnc:HGNC:40438","description":"PDE6B antisense RNA 1","metadata":null},{"id":"c4f9da154771418191bf1b8c8b25dc71","type":"GENE","name":"PDE6B-AS2","canonical_id":"hgnc:HGNC:58704","description":"PDE6B antisense RNA 2","metadata":null},{"id":"f6b02bf21f2d4652804cf30b776cbbe4","type":"GENE","name":"PDE6C","canonical_id":"hgnc:HGNC:8787","description":"phosphodiesterase 6C","metadata":{"aliases":["PDEA2","ACHM5","COD4"]}},{"id":"72ce3cd69d41478a99a8c15da8b08a94","type":"GENE","name":"PDE6D","canonical_id":"hgnc:HGNC:8788","description":"phosphodiesterase 6D","metadata":{"aliases":["JBTS22"]}},{"id":"f987b79fcd804fbcaf4275fe1c302d9b","type":"GENE","name":"PDE6G","canonical_id":"hgnc:HGNC:8789","description":"phosphodiesterase 6G","metadata":{"aliases":["RP57","PDEG"]}},{"id":"32a0851480e64ee6851774aa1bd17fdf","type":"GENE","name":"PDE6H","canonical_id":"hgnc:HGNC:8790","description":"phosphodiesterase 6H","metadata":null},{"id":"137b7f08e11545bc9fc424383fb2c2f8","type":"GENE","name":"PDE7A","canonical_id":"hgnc:HGNC:8791","description":null,"metadata":null},{"id":"ceca556e4b82470f8c5507afb2572217","type":"GENE","name":"PDE7A-DT","canonical_id":"hgnc:HGNC:55223","description":"PDE7A divergent transcript","metadata":null},{"id":"85b51667f4004e1f9ed9b2f496d39ee0","type":"GENE","name":"PDE7B","canonical_id":"hgnc:HGNC:8792","description":"phosphodiesterase 7B","metadata":null},{"id":"09663445375c420eac701e43d2d4d1fb","type":"GENE","name":"PDE7B-AS1","canonical_id":"hgnc:HGNC:56334","description":"PDE7B antisense RNA 1","metadata":null},{"id":"1ba428b077f241eba1ce8b15d263f4db","type":"GENE","name":"PDE8A","canonical_id":"hgnc:HGNC:8793","description":"phosphodiesterase 8A","metadata":{"aliases":["HsT19550"]}},{"id":"12371e495c604409bbd1f7c88a981774","type":"GENE","name":"PDE8B","canonical_id":"hgnc:HGNC:8794","description":"phosphodiesterase 8B","metadata":null},{"id":"67caf3e4544b488698829b0dce03fce7","type":"GENE","name":"PDE9A","canonical_id":"hgnc:HGNC:8795","description":"phosphodiesterase 9A","metadata":null},{"id":"444eed60aa744c0b98c1de7f5de0c1de","type":"GENE","name":"PDE9A-AS1","canonical_id":"hgnc:HGNC:40440","description":"PDE9A antisense RNA 1","metadata":null},{"id":"2266ba85e7764cb4ab707682f9ca3403","type":"GENE","name":"PDF","canonical_id":"hgnc:HGNC:30012","description":"peptide deformylase, mitochondrial","metadata":null},{"id":"52ee0400ad904bb8bce4e62b45453b51","type":"GENE","name":"PDGFA","canonical_id":"hgnc:HGNC:8799","description":null,"metadata":null},{"id":"acc3b52429bf4d3a8c862d0787edd8fb","type":"GENE","name":"PDGFA-DT","canonical_id":"hgnc:HGNC:55865","description":"PDGFA divergent transcript","metadata":{"aliases":["HRAT92"]}},{"id":"e8a4d73e492249b48d006926b014e59c","type":"GENE","name":"PDGFB","canonical_id":"hgnc:HGNC:8800","description":null,"metadata":null},{"id":"3f1d9285922e4903a495742141c52cc6","type":"GENE","name":"PDGFC","canonical_id":"hgnc:HGNC:8801","description":null,"metadata":null},{"id":"a4757baf4615428b92c0b80872c057de","type":"GENE","name":"PDGFD","canonical_id":"hgnc:HGNC:30620","description":"platelet derived growth factor D","metadata":{"aliases":["SCDGF-B","MSTP036","IEGF"]}},{"id":"c6787249539d45658ff3f9f0436b0ef8","type":"GENE","name":"PDGFDDN","canonical_id":"hgnc:HGNC:56909","description":"PDGFD downstream neighbor","metadata":{"aliases":["AP002989.1"]}},{"id":"376e2198beab454b8a28f26bd5fff6d0","type":"GENE","name":"PDGFRA","canonical_id":"hgnc:HGNC:8803","description":null,"metadata":null},{"id":"d9bd1482ba714b12a457a407c9dc639f","type":"PROTEIN","name":"PDGFRA","canonical_id":"uniprot:P16234","description":null,"metadata":null},{"id":"8958bdebc4234675869319fafc80fb54","type":"GENE","name":"PDGFRA","canonical_id":"ensembl:ENSG00000134853","description":null,"metadata":null},{"id":"f59936e77ee74209aa580d497ef77457","type":"GENE","name":"PDGFRB","canonical_id":"hgnc:HGNC:8804","description":null,"metadata":null},{"id":"cd79e56a841442589cbd68b35fde47b2","type":"PROTEIN","name":"PDGFRB","canonical_id":"uniprot:P09619","description":null,"metadata":null},{"id":"18e63dedeb4f445ea4ef3e38ca323fea","type":"GENE","name":"PDGFRB","canonical_id":"ensembl:ENSG00000113721","description":null,"metadata":null},{"id":"748a26d9008342fba6f19540bbb73432","type":"GENE","name":"PDGFRL","canonical_id":"hgnc:HGNC:8805","description":"platelet derived growth factor receptor like","metadata":{"aliases":["PRLTS"]}},{"id":"4398dd993a3340bd84360cfdb3c2015c","type":"GENE","name":"PDGFRL2P","canonical_id":"hgnc:HGNC:54778","description":"platelet derived growth factor receptor like 2, pseudogene","metadata":null},{"id":"a11ef22a4b464e5a96130e849cbb2ae7","type":"GENE","name":"PDHA1","canonical_id":"hgnc:HGNC:8806","description":null,"metadata":null},{"id":"d8b982dd401c4a6abbae320a7c0eb0bc","type":"GENE","name":"PDHA1P1","canonical_id":"hgnc:HGNC:44636","description":"PDHA1 pseudogene 1","metadata":null},{"id":"fb7ea4b911bf4eea8e73021b3d4a7021","type":"GENE","name":"PDHA2","canonical_id":"hgnc:HGNC:8807","description":"pyruvate dehydrogenase E1 subunit alpha 2","metadata":{"aliases":["PDHAL"]}},{"id":"dc9968b3a9da46dfb08a13cb9de8a5df","type":"GENE","name":"PDHB","canonical_id":"hgnc:HGNC:8808","description":"pyruvate dehydrogenase E1 subunit beta","metadata":{"aliases":["PDHE1B","E1beta"]}},{"id":"c171b2abe12c4b24b5c1e76a2c73978f","type":"GENE","name":"PDHX","canonical_id":"hgnc:HGNC:21350","description":null,"metadata":null},{"id":"5a1874da6de24854bdcd5c3e611b79f5","type":"GENE","name":"PDIA2","canonical_id":"hgnc:HGNC:14180","description":null,"metadata":null},{"id":"787a21c280214cd3a3707ba020f03dfe","type":"GENE","name":"PDIA3","canonical_id":"hgnc:HGNC:4606","description":"protein disulfide isomerase family A member 3","metadata":{"aliases":["P58","ERp61","ERp57","ERp60","GRP57","PI-PLC","HsT17083","GRP58"]}},{"id":"b2804c91708646958ff950e1ea4f0b81","type":"GENE","name":"PDIA3P1","canonical_id":"hgnc:HGNC:4607","description":"protein disulfide isomerase family A member 3 pseudogene 1","metadata":{"aliases":["GRP58P","PDIA3P"]}},{"id":"da236f89bf454be7b1bbfd44a99fd0f9","type":"GENE","name":"PDIA3P2","canonical_id":"hgnc:HGNC:49403","description":"protein disulfide isomerase family A member 3 pseudogene 2","metadata":null},{"id":"3ce28bd1a1ee401ab7b8469a8c3e47ff","type":"GENE","name":"PDIA4","canonical_id":"hgnc:HGNC:30167","description":"protein disulfide isomerase family A member 4","metadata":{"aliases":["ERP70","ERP72"]}},{"id":"2e4cbb033e194f4981dd7072bdf4a122","type":"GENE","name":"PDIA5","canonical_id":"hgnc:HGNC:24811","description":"protein disulfide isomerase family A member 5","metadata":{"aliases":["PDIR","FLJ30401"]}},{"id":"a0cbfb8c9a4c4c1d83b302eda72e79fd","type":"GENE","name":"PDIA6","canonical_id":"hgnc:HGNC:30168","description":null,"metadata":null},{"id":"cc015fdd937f4de1bb92dd78a4f68797","type":"GENE","name":"PDIK1L","canonical_id":"hgnc:HGNC:18981","description":"PDLIM1 interacting kinase 1 like","metadata":{"aliases":["CLIK1L","STK35L2"]}},{"id":"bb180e809c2e47078fcd33e4d208782d","type":"GENE","name":"PDILT","canonical_id":"hgnc:HGNC:27338","description":"protein disulfide isomerase like, testis expressed","metadata":{"aliases":["PDIA7"]}},{"id":"5edae0f686b04282bb158388c922b955","type":"GENE","name":"PDILT-AS1","canonical_id":"hgnc:HGNC:58553","description":"PDILT antisense RNA 1","metadata":null},{"id":"4d4eefef530046948d3d6af8c3239164","type":"GENE","name":"PDK1","canonical_id":"hgnc:HGNC:8809","description":null,"metadata":null},{"id":"a9982abb8b6f429ca9c71590964e96ec","type":"GENE","name":"PDK1P1","canonical_id":"hgnc:HGNC:49808","description":"pyruvate dehydrogenase kinase 1 pseudogene 1","metadata":null},{"id":"6d39ef18eb5948e1a30a44a289b39164","type":"GENE","name":"PDK1P2","canonical_id":"hgnc:HGNC:55004","description":"PDK1 pseudogene 2","metadata":null},{"id":"b6539909a5584a50a5ccb1885a49f124","type":"GENE","name":"PDK2","canonical_id":"hgnc:HGNC:8810","description":null,"metadata":null},{"id":"060b047c348445669b639f3f0c554bf6","type":"GENE","name":"PDK2-AS1","canonical_id":"hgnc:HGNC:58250","description":"PDK2 antisense RNA 1","metadata":null},{"id":"c757ad4fc9f645ecbe3d4f46cd15d9bb","type":"GENE","name":"PDK3","canonical_id":"hgnc:HGNC:8811","description":"pyruvate dehydrogenase kinase 3","metadata":null},{"id":"fb93bdf334c54addb33f7b7d9a9ff389","type":"GENE","name":"PDK4","canonical_id":"hgnc:HGNC:8812","description":null,"metadata":null},{"id":"94f2ca828b6b4ec3a61b8611e346a719","type":"GENE","name":"PDK4-AS1","canonical_id":"hgnc:HGNC:55767","description":"PDK4 antisense RNA 1","metadata":null},{"id":"d8b2c942ef804b8db29d3143cbc7c80e","type":"GENE","name":"PDLIM1","canonical_id":"hgnc:HGNC:2067","description":"PDZ and LIM domain 1","metadata":{"aliases":["CLP-36","hCLIM1","CLP36","CLIM1"]}},{"id":"dd4090b89a544a0fad84909ed6895598","type":"GENE","name":"PDLIM1P1","canonical_id":"hgnc:HGNC:20026","description":"PDZ and LIM domain 1 pseudogene 1","metadata":{"aliases":["PDLIM1P"]}},{"id":"2978bb1768994069b9758b8ce6455c92","type":"GENE","name":"PDLIM1P2","canonical_id":"hgnc:HGNC:48945","description":"PDZ and LIM domain 1 pseudogene 2","metadata":null},{"id":"c1c4fd705622440ea0e324a6c1ad57cd","type":"GENE","name":"PDLIM1P3","canonical_id":"hgnc:HGNC:48946","description":"PDZ and LIM domain 1 pseudogene 3","metadata":null},{"id":"44050f4e5ec04c6aab705a864e99e550","type":"GENE","name":"PDLIM1P4","canonical_id":"hgnc:HGNC:48947","description":"PDZ and LIM domain 1 pseudogene 4","metadata":null},{"id":"4fdeb30c4d3548f6bc901d85cfc113c1","type":"GENE","name":"PDLIM2","canonical_id":"hgnc:HGNC:13992","description":"PDZ and LIM domain 2","metadata":null},{"id":"c7282ab437f54a728e2255772caf369d","type":"GENE","name":"PDLIM3","canonical_id":"hgnc:HGNC:20767","description":"PDZ and LIM domain 3","metadata":{"aliases":["ALP"]}},{"id":"b1199620bbbb419db67f96d7cf959104","type":"GENE","name":"PDLIM4","canonical_id":"hgnc:HGNC:16501","description":"PDZ and LIM domain 4","metadata":{"aliases":["RIL"]}},{"id":"6d5a63c30d4f41f3baf83abc665fa640","type":"GENE","name":"PDLIM5","canonical_id":"hgnc:HGNC:17468","description":"PDZ and LIM domain 5","metadata":{"aliases":["LIM","Enh"]}},{"id":"70f09c84487d4a8f96d2ab340b07fd19","type":"GENE","name":"PDLIM7","canonical_id":"hgnc:HGNC:22958","description":null,"metadata":null},{"id":"c5778ee4cd3045a6b91553109df0edbf","type":"GENE","name":"PDLIM7-AS1","canonical_id":"hgnc:HGNC:41004","description":"PDLIM7 antisense RNA 1","metadata":null},{"id":"3e96d00ff37d4610b86f88cec4729085","type":"GENE","name":"PDP1","canonical_id":"hgnc:HGNC:9279","description":"pyruvate dehydrogenase phosphatase catalytic subunit 1","metadata":{"aliases":["PDP","PDH","PPM2A","PPM2C"]}},{"id":"2868ad67aa3b4d1283a32e1d04cde059","type":"GENE","name":"PDP2","canonical_id":"hgnc:HGNC:30263","description":"pyruvate dehydrogenase phosphatase catalytic subunit 2","metadata":{"aliases":["KIAA1348","PPM2C2","PPM2B"]}},{"id":"e922b6cf353d49fe93315b6a0e242ab9","type":"GENE","name":"PDPK1","canonical_id":"hgnc:HGNC:8816","description":"3-phosphoinositide dependent protein kinase 1","metadata":{"aliases":["PDK1"]}},{"id":"5907c619c9ae44169822feff45f3fdd4","type":"GENE","name":"PDPK2P","canonical_id":"hgnc:HGNC:49897","description":"3-phosphoinositide dependent protein kinase 2, pseudogene","metadata":null},{"id":"7c756fa9f6ea49d695298a6630e1f833","type":"GENE","name":"PDPN","canonical_id":"hgnc:HGNC:29602","description":"podoplanin","metadata":{"aliases":["T1A-2","Gp38","aggrus","GP40","PA2.26","D2-40"]}},{"id":"8609b046b0434924856a2ef053b95230","type":"GENE","name":"PDPR","canonical_id":"hgnc:HGNC:30264","description":"pyruvate dehydrogenase phosphatase regulatory subunit","metadata":{"aliases":["PDP3"]}},{"id":"29e8eca228894191858132ed8b9a12c6","type":"GENE","name":"PDPR2P","canonical_id":"hgnc:HGNC:27556","description":"pyruvate dehydrogenase phosphatase regulatory subunit 2, pseudogene","metadata":null},{"id":"8eb39e8423d349dcbc2c9067fe4f02fa","type":"TRIAL","name":"PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT03064854","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"03732b66370d44128732b354713c69c8","type":"GENE","name":"PDRG1","canonical_id":"hgnc:HGNC:16119","description":"p53 and DNA damage regulated 1","metadata":{"aliases":["dJ310O13.3","C20orf126"]}},{"id":"5d151602ef3c4ec4906c2901d4bd0378","type":"GENE","name":"PDS5A","canonical_id":"hgnc:HGNC:29088","description":"PDS5 cohesin associated factor A","metadata":{"aliases":["KIAA0648","PIG54","SCC-112"]}},{"id":"d598b6c8751646ef9b77ec995953f9de","type":"GENE","name":"PDS5B","canonical_id":"hgnc:HGNC:20418","description":"PDS5 cohesin associated factor B","metadata":{"aliases":["AS3","KIAA0979","FLJ23236","CG008","APRIN"]}},{"id":"449dfa8b77544d0291ab7312ad643126","type":"GENE","name":"PDS5B-DT","canonical_id":"hgnc:HGNC:55744","description":"PDS5B divergent transcript","metadata":{"aliases":["Linc1749808"]}},{"id":"d433dc0e074d4995a5f0e4d51564c7af","type":"GENE","name":"PDSS1","canonical_id":"hgnc:HGNC:17759","description":"decaprenyl diphosphate synthase subunit 1","metadata":{"aliases":["TPT","COQ1","COQ1A","TPRT"]}},{"id":"58fa7c01d3be4df09204be41a72ce1c9","type":"GENE","name":"PDSS1P1","canonical_id":"hgnc:HGNC:49740","description":"decaprenyl diphosphate synthase subunit 1 pseudogene 1","metadata":null},{"id":"fb4d27562af44ca683bddad15a9044fe","type":"GENE","name":"PDSS1P2","canonical_id":"hgnc:HGNC:49741","description":"decaprenyl diphosphate synthase subunit 1 pseudogene 2","metadata":null},{"id":"500a895a1b0b45e4b145d93bd21951e2","type":"GENE","name":"PDSS2","canonical_id":"hgnc:HGNC:23041","description":"decaprenyl diphosphate synthase subunit 2","metadata":{"aliases":["bA59I9.3","COQ1B","C6orf210"]}},{"id":"172bfbdfa2c34e7f9ffb35930d86bfd1","type":"GENE","name":"PDX1","canonical_id":"hgnc:HGNC:6107","description":null,"metadata":null},{"id":"c35a8ac94c8e43f99acd44491494640b","type":"GO_TERM","name":"PDX1-PBX1b-MRG1 complex","canonical_id":"go:GO:0034978","description":"\"A protein complex that contains the homeodomain proteins PDX1, PBX1b and MRG1 (MEIS2) and is involved in the transcriptional regulation of pancreatic acinar cell-specific genes.\" [PMID:11279116, PMID:9710595]","metadata":null},{"id":"6be1b60114494282a073bc598dacba66","type":"GENE","name":"PDXDC1","canonical_id":"hgnc:HGNC:28995","description":"pyridoxal dependent decarboxylase domain containing 1","metadata":{"aliases":["KIAA0251"]}},{"id":"74dfffb6686f42f6ac012aa2eb2d5457","type":"GENE","name":"PDXDC2P","canonical_id":"hgnc:HGNC:27559","description":"pyridoxal dependent decarboxylase domain containing 2, pseudogene","metadata":{"aliases":["DKFZp761H1120","PDXDC2"]}},{"id":"d6f2576108f6452aa67b79110d012fd0","type":"GENE","name":"PDXDC2P-NPIPB14P","canonical_id":"hgnc:HGNC:53158","description":"PDXDC2P-NPIPB14P readthrough, transcribed pseudogene","metadata":null},{"id":"57ef05d4d7274a55b9c194ad5d9574bb","type":"GENE","name":"PDXK","canonical_id":"hgnc:HGNC:8819","description":"pyridoxal kinase","metadata":{"aliases":["PNK","PKH","FLJ21324","PRED79","FLJ31940","MGC15873","C21orf97","C21orf124"]}},{"id":"9371a12dde3245f49eb8802fa6e38e1a","type":"GENE","name":"PDXP","canonical_id":"hgnc:HGNC:30259","description":"pyridoxal phosphatase","metadata":{"aliases":["dJ37E16.5","FLJ32703","CIN"]}},{"id":"247004fc088841d3828067f87991ae28","type":"GENE","name":"PDXP-DT","canonical_id":"hgnc:HGNC:40525","description":"PDXP divergent transcript","metadata":null},{"id":"b01f5b8767dc4e53bc4d901ddced597d","type":"GENE","name":"PDYN","canonical_id":"hgnc:HGNC:8820","description":"prodynorphin","metadata":{"aliases":["PENKB","ADCA","SCA23"]}},{"id":"2dc23b23532b4b04b7eb29727a13220a","type":"GENE","name":"PDYN-AS1","canonical_id":"hgnc:HGNC:53462","description":"PDYN antisense RNA 1","metadata":null},{"id":"08bc09457e8342989f7f0db1d3689d86","type":"GO_TERM","name":"PDZ domain binding","canonical_id":"go:GO:0030165","description":"\"Binding to a PDZ domain of a protein, a domain found in diverse signaling proteins.\" [GOC:curators, Pfam:PF00595]","metadata":null},{"id":"3112a9dc71de456989d839e0572f6f94","type":"GENE","name":"PDZD11","canonical_id":"hgnc:HGNC:28034","description":"PDZ domain containing 11","metadata":{"aliases":["PDZK11"]}},{"id":"96635af6921740fd886ccde9947add91","type":"GENE","name":"PDZD2","canonical_id":"hgnc:HGNC:18486","description":"PDZ domain containing 2","metadata":{"aliases":["KIAA0300","PDZK3"]}},{"id":"2c5c2d774b47424da3868b107e520a5a","type":"GENE","name":"PDZD2-AS1","canonical_id":"hgnc:HGNC:59019","description":"PDZD2 antisense RNA 1","metadata":null},{"id":"077da4c8939f4983ae4e90dba62f1ece","type":"GENE","name":"PDZD2-AS2","canonical_id":"hgnc:HGNC:59020","description":"PDZD2 antisense RNA 2","metadata":null},{"id":"0ccf159f93ea4b17b288ccde3b5ab751","type":"GENE","name":"PDZD4","canonical_id":"hgnc:HGNC:21167","description":"PDZ domain containing 4","metadata":{"aliases":["KIAA1444","LU1","FLJ34125","PDZRN4L","LNX5","PDZK4"]}},{"id":"f887e5214a774a86a2169bee604f44c3","type":"GENE","name":"PDZD7","canonical_id":"hgnc:HGNC:26257","description":"PDZ domain containing 7","metadata":{"aliases":["FLJ23209","bA108L7.8","PDZK7","DFNB57"]}},{"id":"f8d981df50974cdd80601f8765cfb2fc","type":"GENE","name":"PDZD8","canonical_id":"hgnc:HGNC:26974","description":"PDZ domain containing 8","metadata":{"aliases":["LYVAC","bA129M16.2","FLJ34427","PDZK8"]}},{"id":"f7d4a0f666ef4846b7312c72b3b42761","type":"GENE","name":"PDZD9","canonical_id":"hgnc:HGNC:28740","description":"PDZ domain containing 9","metadata":{"aliases":["MGC50721","C16orf65"]}},{"id":"9beb468692544c7ebfc5b050da0a9769","type":"GENE","name":"PDZK1","canonical_id":"hgnc:HGNC:8821","description":"PDZ domain containing 1","metadata":{"aliases":["PDZD1","NHERF3","CAP70","CLAMP","NaPi-Cap1"]}},{"id":"fe43ae9921334a94b903084ff971626f","type":"GENE","name":"PDZK1IP1","canonical_id":"hgnc:HGNC:16887","description":"PDZK1 interacting protein 1","metadata":{"aliases":["DD96","MAP17","SPAP"]}},{"id":"76c5ab0d741341bb92345fce64b8002a","type":"GENE","name":"PDZK1P1","canonical_id":"hgnc:HGNC:31974","description":"PDZ domain containing 1 pseudogene 1","metadata":{"aliases":["OTTHUMT00000038524","OTTHUMG00000074107","PDZK1P2"]}},{"id":"8e5c2a19acdb4a3a9546f066d09a13d9","type":"GENE","name":"PDZPH1P","canonical_id":"hgnc:HGNC:51488","description":"PDZ and pleckstrin homology domains 1, pseudogene","metadata":null},{"id":"a2769160161c45519e884e242dd336e2","type":"GENE","name":"PDZRN3","canonical_id":"hgnc:HGNC:17704","description":"PDZ domain containing ring finger 3","metadata":{"aliases":["KIAA1095","SEMACAP3","LNX3","SEMCAP3"]}},{"id":"35dd77253bde4206b50f0fa9509335f6","type":"GENE","name":"PDZRN3-AS1","canonical_id":"hgnc:HGNC:40814","description":"PDZRN3 antisense RNA 1","metadata":null},{"id":"1a34a7f7a64a417da4ee8bd57ab94929","type":"GENE","name":"PDZRN4","canonical_id":"hgnc:HGNC:30552","description":"PDZ domain containing ring finger 4","metadata":{"aliases":["DKFZp434B0417","LNX4","FLJ33777","IMAGE5767589"]}},{"id":"8f74b621bd114eebb02e79bce4f106e0","type":"GENE","name":"PDZRN4-AS1","canonical_id":"hgnc:HGNC:58277","description":"PDZRN4 antisense RNA 1","metadata":null},{"id":"5e54fd8fc7624f71b664c116599c7c11","type":"GENE","name":"PEA15","canonical_id":"hgnc:HGNC:8822","description":null,"metadata":null},{"id":"7024baf9b38a47a293d1057e9a310d36","type":"GENE","name":"PEA15-AS1","canonical_id":"hgnc:HGNC:58221","description":"PEA15 antisense RNA 1","metadata":null},{"id":"bfb15acba9dd40389473fc7346a47157","type":"TRIAL","name":"PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy","canonical_id":"clinicaltrials.gov:NCT06915792","description":"Postpartum Hypertension (PPHT)","metadata":null},{"id":"e8f6598096b64ff0a23f0ea432d8058f","type":"GENE","name":"PEAK1","canonical_id":"hgnc:HGNC:29431","description":"pseudopodium enriched atypical kinase 1","metadata":{"aliases":["KIAA2002","sgk269"]}},{"id":"d174ebeb1d8f4152b7df0a0515bb1a00","type":"GENE","name":"PEAK3","canonical_id":"hgnc:HGNC:24793","description":"PEAK family member 3","metadata":{"aliases":["FLJ45778","C19orf35"]}},{"id":"eb19528e27504ce98b947f8e6fa4e66a","type":"GENE","name":"PEAR1","canonical_id":"hgnc:HGNC:33631","description":"platelet endothelial aggregation receptor 1","metadata":{"aliases":["JEDI","FLJ00193","MEGF12"]}},{"id":"4ead57a0c6e3449fae7bd4d820d83edd","type":"TRIAL","name":"PEARL Schizophrenia Maintenance","canonical_id":"clinicaltrials.gov:NCT01435928","description":"Schizophrenia","metadata":null},{"id":"98b0d3aa811d44bab65c39aa63896039","type":"GENE","name":"PEARL1","canonical_id":"hgnc:HGNC:58114","description":"PCDH eRNA associated with R-loop formation 1","metadata":{"aliases":["PEARL"]}},{"id":"c18ef4d5f77b4eb1884af2c10268c633","type":"GENE","name":"PEBP1","canonical_id":"hgnc:HGNC:8630","description":null,"metadata":null},{"id":"923eb18af19a420eaa15ee73d45080e5","type":"GENE","name":"PEBP1P1","canonical_id":"hgnc:HGNC:20054","description":"phosphatidylethanolamine binding protein 1 pseudogene 1","metadata":{"aliases":["PBPP1"]}},{"id":"b483cf1dd0fb4bd19ee780f97cafee32","type":"GENE","name":"PEBP1P2","canonical_id":"hgnc:HGNC:44344","description":"phosphatidylethanolamine binding protein 1 pseudogene 2","metadata":null},{"id":"e1068461f87d415a8c5e62f2cea865a3","type":"GENE","name":"PEBP1P3","canonical_id":"hgnc:HGNC:44345","description":"phosphatidylethanolamine binding protein 1 pseudogene 3","metadata":null},{"id":"dcfa973056714bbb87f5cec8cc385728","type":"GENE","name":"PEBP4","canonical_id":"hgnc:HGNC:28319","description":"phosphatidylethanolamine binding protein 4","metadata":{"aliases":["MGC22776","CORK1","hPEBP4"]}},{"id":"cfd9536efc56493f863769a6ec6502e0","type":"GENE","name":"PEBP4-AS1","canonical_id":"hgnc:HGNC:58414","description":"PEBP4 antisense RNA 1","metadata":null},{"id":"3dcd2d33511c407294b387dc45540a34","type":"GENE","name":"PECAM1","canonical_id":"hgnc:HGNC:8823","description":null,"metadata":null},{"id":"e10ab1230a2a419d9b56ca10d5d33826","type":"GENE","name":"PECR","canonical_id":"hgnc:HGNC:18281","description":"peroxisomal trans-2-enoyl-CoA reductase","metadata":{"aliases":["HSA250303","TERP","SDR29C1"]}},{"id":"a251278419c74335af33cf41025b3232","type":"GENE","name":"PEDS1","canonical_id":"hgnc:HGNC:16735","description":"plasmanylethanolamine desaturase 1","metadata":{"aliases":["Kua","TMEM189"]}},{"id":"8566754154894cd5bfc49822bf8677e1","type":"GENE","name":"PEDS1-UBE2V1","canonical_id":"hgnc:HGNC:33521","description":"PEDS1-UBE2V1 readthrough","metadata":{"aliases":["Kua-UEV","CROC-1B","TMEM189-UBE2V1"]}},{"id":"918da78192d04fb8aa064cc773acd9d9","type":"GENE","name":"PEF1","canonical_id":"hgnc:HGNC:30009","description":"penta-EF-hand domain containing 1","metadata":{"aliases":["PEF1A"]}},{"id":"dfab6f587f754044b6b1de3d7e167091","type":"GENE","name":"PEF1-AS1","canonical_id":"hgnc:HGNC:40154","description":"PEF1 and COL16A1 antisense RNA 1","metadata":null},{"id":"b135b59169ed484ba8d928c295f8b8cc","type":"TRIAL","name":"PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy","canonical_id":"clinicaltrials.gov:NCT00215865","description":"Chronic Hepatitis C Virus Infection","metadata":null},{"id":"1697a690e9fe496da112c61fd5ae5026","type":"GENE","name":"PEG10","canonical_id":"hgnc:HGNC:14005","description":null,"metadata":null},{"id":"81115bb445394dcb9633f430571b2202","type":"GENE","name":"PEG13","canonical_id":"hgnc:HGNC:19969","description":"paternally expressed 13","metadata":null},{"id":"3fe5fcb5fa80448d9cb35b7e52376450","type":"GENE","name":"PEG3","canonical_id":"hgnc:HGNC:8826","description":null,"metadata":null},{"id":"46a4e709ef1e43faa9cceb0145e3a028","type":"GENE","name":"PEG3-AS1","canonical_id":"hgnc:HGNC:35127","description":"PEG3 antisense RNA 1","metadata":{"aliases":["APEG3","NCRNA00155","PEG3AS","PEG3-AS"]}},{"id":"579407bb3a7b48688ffc992ca5a94638","type":"TRIAL","name":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01839487","description":"Metastatic Pancreatic Cancer","metadata":null},{"id":"9289d52de530420992d0568cfa3f1cdb","type":"GENE","name":"PELATON","canonical_id":"hgnc:HGNC:50328","description":"plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage regulation","metadata":{"aliases":["GCRL1","LINC01272","SMIM25"]}},{"id":"7dc1068a10514826b7a9abb043b2e827","type":"GENE","name":"PELI1","canonical_id":"hgnc:HGNC:8827","description":"pellino E3 ubiquitin protein ligase 1","metadata":null},{"id":"8a6b112369dd4661b403e76d7bf2aaf3","type":"GENE","name":"PELI2","canonical_id":"hgnc:HGNC:8828","description":"pellino E3 ubiquitin protein ligase family member 2","metadata":null},{"id":"bea1884859d6476a87cedb34b6edd9c0","type":"GENE","name":"PELI3","canonical_id":"hgnc:HGNC:30010","description":"pellino E3 ubiquitin protein ligase family member 3","metadata":{"aliases":["MGC35521"]}},{"id":"70fae3de8a6147a49c5572d8d171a5a3","type":"GENE","name":"PELO","canonical_id":"hgnc:HGNC:8829","description":null,"metadata":null},{"id":"9de5ea7cb1104c3baba97992a7e92e1f","type":"GENE","name":"PELO-AS1","canonical_id":"hgnc:HGNC:56263","description":"PELO antisense RNA 1","metadata":{"aliases":["CTD-2288O8.1"]}},{"id":"08dc5537f3b3470e9785188ad2d49e77","type":"GENE","name":"PELP1","canonical_id":"hgnc:HGNC:30134","description":null,"metadata":null},{"id":"f5914ff9a2134b51b24e95d3d9e82512","type":"GENE","name":"PELP1-DT","canonical_id":"hgnc:HGNC:55614","description":"PELP1 divergent transcript","metadata":{"aliases":["lnc-EST885"]}},{"id":"9e3360c7e35b4743ae7466335f4f04f6","type":"GENE","name":"PEMT","canonical_id":"hgnc:HGNC:8830","description":"phosphatidylethanolamine N-methyltransferase","metadata":{"aliases":["PEMPT","PEMT2"]}},{"id":"d5c9cf86b8c6419fb5783c694c174420","type":"GENE","name":"PENK","canonical_id":"hgnc:HGNC:8831","description":null,"metadata":null},{"id":"4885580055f947cf9fad4d963a7a9291","type":"GENE","name":"PENK-AS1","canonical_id":"hgnc:HGNC:55519","description":"PENK antisense RNA 1","metadata":null},{"id":"1ea1a7759283468d9559bccc9109de86","type":"GO_TERM","name":"PEP carboxykinase C4 photosynthesis","canonical_id":"go:GO:0009764","description":"\"The process of C4 photosynthesis, as it occurs in plants in which the enzyme decarboxylating C4 acids in the bundle sheath is phosphoenolpyruvate carboxykinase (PEPCK).\" [PMID:11788762]","metadata":null},{"id":"33ec80667a4241db8efb0e523f80c4f3","type":"TRIAL","name":"PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy","canonical_id":"clinicaltrials.gov:NCT01449513","description":"Actinic Keratosis","metadata":null},{"id":"93a44fc16233486cb773728c51bbb956","type":"TRIAL","name":"PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities","canonical_id":"clinicaltrials.gov:NCT01325688","description":"Superficial Basal Cell Carcinoma","metadata":null},{"id":"e9ae77bdea2b493a958add9191d86939","type":"GENE","name":"PEPB","canonical_id":"hgnc:HGNC:8838","description":"peptidase B","metadata":null},{"id":"33c734251dbe436a85e3debb4ea86ada","type":"GENE","name":"PEPC","canonical_id":"hgnc:HGNC:8839","description":"peptidase C","metadata":null},{"id":"22273fe7005b411c8c37397dddeb305f","type":"GENE","name":"PEPD","canonical_id":"hgnc:HGNC:8840","description":"peptidase D","metadata":null},{"id":"5ed5f388e4f74016bed7a3f9a4b9f1f1","type":"GENE","name":"PEPE","canonical_id":"hgnc:HGNC:8841","description":"peptidase E","metadata":null},{"id":"b4a34ee268ac41029ef2d030bb4dda95","type":"GENE","name":"PER1","canonical_id":"hgnc:HGNC:8845","description":null,"metadata":null},{"id":"773419bac35542bdac5d0f98fe62fb0f","type":"GENE","name":"PER2","canonical_id":"hgnc:HGNC:8846","description":null,"metadata":null},{"id":"a4f64b4edcba4d2b980e380419c0dd4e","type":"GENE","name":"PER3","canonical_id":"hgnc:HGNC:8847","description":null,"metadata":null},{"id":"f0debffed6774f78a877f0dd0430c7aa","type":"GENE","name":"PER3P1","canonical_id":"hgnc:HGNC:54525","description":"PER3 pseudogene 1","metadata":{"aliases":["PER4"]}},{"id":"341f67d84d074446a959ddb7128d0145","type":"GENE","name":"PERCC1","canonical_id":"hgnc:HGNC:52293","description":"proline and glutamate rich with coiled coil 1","metadata":null},{"id":"85488772b1da46738826657862601974","type":"GO_TERM","name":"PERK-mediated unfolded protein response","canonical_id":"go:GO:0036499","description":"\"The series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor PERK (PKR-like ER kinase). Begins with activation of PERK in response to endoplasmic reticulum (ER) stress and ends with regulation of a downstream cellular process, e.g. transcription. The main substrate of PERK is the translation initiation factor eIF2alpha. Serine-phosphorylation of eIF2alpha by PERK inactivates eIF2alpha and inhibits general protein translation. In addition, eIF2alpha phosphorylation preferentially increases the translation of selective mRNAs such as ATF4 (activating transcription factor 4), which up regulates a subset of UPR genes required to restore folding capacity.\" [GOC:bf, GOC:PARL, PMID:22013210, PMID:27629041]","metadata":null},{"id":"0428cbccbfd4414aa3c961dde495802b","type":"GENE","name":"PERM1","canonical_id":"hgnc:HGNC:28208","description":"PPARGC1 and ESRR induced regulator, muscle 1","metadata":{"aliases":["MGC13275","RP11-54O7.8","C1orf170"]}},{"id":"06fa30cf03d3423f8d3d46304ca050e6","type":"GENE","name":"PERP","canonical_id":"hgnc:HGNC:17637","description":null,"metadata":null},{"id":"fc981bade0754edf925a450cc8f37e3c","type":"GENE","name":"PERPP1","canonical_id":"hgnc:HGNC:56619","description":"PERP pseudogene 1","metadata":null},{"id":"d97917b16b8c41a4928f7c16d895cea8","type":"GENE","name":"PERPP2","canonical_id":"hgnc:HGNC:56620","description":"PERP pseudogene 2","metadata":null},{"id":"9469e5a2a7484f0e910838bcc48be075","type":"GENE","name":"PERPP3","canonical_id":"hgnc:HGNC:56913","description":"PERP pseudogene 3","metadata":null},{"id":"d736469fa7794addb2c1cda746bce7ad","type":"GENE","name":"PES1","canonical_id":"hgnc:HGNC:8848","description":"pescadillo ribosomal biogenesis factor 1","metadata":{"aliases":["PES","NOP7"]}},{"id":"f8d42917c99349829428a02520a2b90e","type":"GENE","name":"PES1-AS1","canonical_id":"hgnc:HGNC:58216","description":"PES1 antisense RNA 1","metadata":null},{"id":"ce2f1d71bdb740d591ac8437673c3d90","type":"GENE","name":"PES1P1","canonical_id":"hgnc:HGNC:44058","description":"pescadillo ribosomal biogenesis factor 1 pseudogene 1","metadata":null},{"id":"115a6d54815f446f8bc5cad94e8d74d7","type":"GENE","name":"PES1P2","canonical_id":"hgnc:HGNC:44059","description":"pescadillo ribosomal biogenesis factor 1 pseudogene 2","metadata":{"aliases":["RP11-284P20.2"]}},{"id":"64d2490b8b344a5ebbb6dcaf991b2be0","type":"TRIAL","name":"PET Biomarkers in Treatment Resistant Depression","canonical_id":"clinicaltrials.gov:NCT01031810","description":"Major Depressive Disorder","metadata":null},{"id":"8ec17dd01da2468b83df72f659e651d0","type":"TRIAL","name":"PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus","canonical_id":"clinicaltrials.gov:NCT01053312","description":"Normal Pressure Hydrocephalus","metadata":null},{"id":"8788c1c372904575ad1369bd73415c39","type":"TRIAL","name":"PET Imaging of Cyclooxygenase in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT05062083","description":"Multiple Sclerosis","metadata":null},{"id":"fa55a5e26f154caf904d3a3d2e587556","type":"TRIAL","name":"PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","canonical_id":"clinicaltrials.gov:NCT04396873","description":"Parkinson's Disease; Dementia; Alzheimer's Disease; ALS; Mild Cognitive Impairment","metadata":null},{"id":"4460e43aca01468389d262864867835e","type":"TRIAL","name":"PET Imaging of Inflammation and Lipid Lowering Study","canonical_id":"clinicaltrials.gov:NCT04073797","description":"Hypercholesterolemia; Hypercholesterolemia, Familial; Atherosclerosis; Carotid Artery Plaque","metadata":null},{"id":"67f405215925439ea01c5d5d70bc1917","type":"TRIAL","name":"PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome","canonical_id":"clinicaltrials.gov:NCT02743377","description":"Nervous System Disease","metadata":null},{"id":"92143cffa45a4ab9811d2398c764c592","type":"TRIAL","name":"PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","canonical_id":"clinicaltrials.gov:NCT07169630","description":"Alzheimer s Disease; Mild Cognitive Impairment; Healthy","metadata":null},{"id":"ce78ae0662134a68ae648521b818ac70","type":"TRIAL","name":"PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol","canonical_id":"clinicaltrials.gov:NCT04032691","description":"Healthy Volunteers","metadata":null},{"id":"f2d025e2062b4427ab52cd5dbc01bcc4","type":"GO_TERM","name":"PET complex","canonical_id":"go:GO:1990923","description":"\"A protein complex that is composed of at least EXD1, TDRD12 and some PIWI protein. The complex is required for MILI slicing-triggered biogenesis and loading of MIWI2 piRNAs.\" [PMID:26669262]","metadata":null},{"id":"f7ac312e0f4943749e4b4a5ab0c88d1b","type":"TRIAL","name":"PET with [18F]Flumazenil As an Index of Neurodegeneration in MS","canonical_id":"clinicaltrials.gov:NCT03825601","description":"Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"adbb78b5bdd04e9cbb1a05dd3260c0f7","type":"TRIAL","name":"PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding","canonical_id":"clinicaltrials.gov:NCT00562198","description":"Parkinson\u00b4s Disease","metadata":null},{"id":"72761714972b48c19b7bf7aa2839f83d","type":"TRIAL","name":"PET/MRI Evaluation of Cardiac Amyloid","canonical_id":"clinicaltrials.gov:NCT03119558","description":"Cardiac Amyloidosis","metadata":null},{"id":"464f7a428f4f41458b03079654d87b14","type":"GENE","name":"PET100","canonical_id":"hgnc:HGNC:40038","description":"PET100 cytochrome c oxidase chaperone","metadata":{"aliases":["C19orf79"]}},{"id":"62dbfe248b4a4d75b1fa1ca7383814ed","type":"GENE","name":"PET100P1","canonical_id":"hgnc:HGNC:56612","description":"PET100 pseudogene 1","metadata":null},{"id":"3befb60af7fb40e1b9258b341f706761","type":"GENE","name":"PET117","canonical_id":"hgnc:HGNC:40045","description":"PET117 cytochrome c oxidase chaperone","metadata":{"aliases":["CSRP2BP"]}},{"id":"4a5106dbb2164926a03ae79d18a93272","type":"GENE","name":"PET117P1","canonical_id":"hgnc:HGNC:56829","description":"PET117 pseudogene 1","metadata":null},{"id":"ab0190ca27644d7ba6899b4c811b715b","type":"GENE","name":"PEX1","canonical_id":"hgnc:HGNC:8850","description":"peroxisomal biogenesis factor 1","metadata":{"aliases":["ZWS1","ZWS"]}},{"id":"9c0f1a9e5621417b9792e00e863cb59f","type":"GENE","name":"PEX10","canonical_id":"hgnc:HGNC:8851","description":"peroxisomal biogenesis factor 10","metadata":{"aliases":["RNF69"]}},{"id":"0040d877f8a24b0384f88fb755e901c1","type":"GENE","name":"PEX11A","canonical_id":"hgnc:HGNC:8852","description":"peroxisomal biogenesis factor 11 alpha","metadata":{"aliases":["PEX11alpha","PEX11\u03b1","PMP28","MGC119947","MGC138534"]}},{"id":"fd0377663e0a4de792d1b6fa1b78ebc8","type":"GENE","name":"PEX11B","canonical_id":"hgnc:HGNC:8853","description":"peroxisomal biogenesis factor 11 beta","metadata":{"aliases":["PEX11beta","PEX11\u03b2"]}},{"id":"bb9fcbbd4692432ca8bb54eac10405e8","type":"GENE","name":"PEX11G","canonical_id":"hgnc:HGNC:20208","description":"peroxisomal biogenesis factor 11 gamma","metadata":{"aliases":["PEX11gamma","PEX11\u03b3"]}},{"id":"863063083cb546e58299b497ddcc6089","type":"GENE","name":"PEX12","canonical_id":"hgnc:HGNC:8854","description":"peroxisomal biogenesis factor 12","metadata":null},{"id":"0e3c8b8c549d4caeae44224b7694b1db","type":"GENE","name":"PEX12P1","canonical_id":"hgnc:HGNC:39678","description":"peroxisomal biogenesis factor 12 pseudogene 1","metadata":null},{"id":"db87022161ca4ec9bc8a4d773a607672","type":"GENE","name":"PEX13","canonical_id":"hgnc:HGNC:8855","description":"peroxisomal biogenesis factor 13","metadata":null},{"id":"4edae79d2398489aacb0e48311fd9dc8","type":"GENE","name":"PEX14","canonical_id":"hgnc:HGNC:8856","description":"peroxisomal biogenesis factor 14","metadata":null},{"id":"113faa5fb8ef4ed7988ff2e1723e8383","type":"GENE","name":"PEX16","canonical_id":"hgnc:HGNC:8857","description":"peroxisomal biogenesis factor 16","metadata":null},{"id":"4da2bd3f93e641db90d62d65cb7415bf","type":"GENE","name":"PEX19","canonical_id":"hgnc:HGNC:9713","description":"peroxisomal biogenesis factor 19","metadata":{"aliases":["HK33","D1S2223E","PMP1","PMPI","PXMP1","PXF"]}},{"id":"646d96b0aa094accb82a4bf17d201c48","type":"GENE","name":"PEX2","canonical_id":"hgnc:HGNC:9717","description":"peroxisomal biogenesis factor 2","metadata":{"aliases":["PMP35","PAF-1","RNF72","ZWS3","PXMP3"]}},{"id":"6eb17bc16f0f404baa53086af43d7215","type":"GENE","name":"PEX26","canonical_id":"hgnc:HGNC:22965","description":"peroxisomal biogenesis factor 26","metadata":{"aliases":["FLJ20695"]}},{"id":"24e9e71d28934793bf91c4962eec529d","type":"GENE","name":"PEX3","canonical_id":"hgnc:HGNC:8858","description":"peroxisomal biogenesis factor 3","metadata":null},{"id":"9e14830075134352a1a7db7ceec62c69","type":"GENE","name":"PEX39","canonical_id":"hgnc:HGNC:34431","description":"peroxisomal biogenesis factor 39","metadata":{"aliases":["LOC441150","C6orf226"]}},{"id":"e0ce5c81e0c24aabac387150c96993ec","type":"GENE","name":"PEX5","canonical_id":"hgnc:HGNC:9719","description":"peroxisomal biogenesis factor 5","metadata":{"aliases":["PTS1R","PXR1"]}},{"id":"f0a78fe3384746d88737278515c041fc","type":"GENE","name":"PEX5L","canonical_id":"hgnc:HGNC:30024","description":"peroxisomal biogenesis factor 5 like","metadata":{"aliases":["PEX5R","PXR2","TRIP8b"]}},{"id":"e75183a553b54319a36b4bc7b0f039e2","type":"GENE","name":"PEX5L-AS1","canonical_id":"hgnc:HGNC:41251","description":"PEX5L antisense RNA 1","metadata":null},{"id":"ae18dd54162348dca9dcf7f149feeb08","type":"GENE","name":"PEX5L-AS2","canonical_id":"hgnc:HGNC:41252","description":"PEX5L antisense RNA 2","metadata":null},{"id":"281fa50cc5b24c0a8ae46ea0373c5111","type":"GENE","name":"PEX6","canonical_id":"hgnc:HGNC:8859","description":"peroxisomal biogenesis factor 6","metadata":{"aliases":["PXAAA1","PAF-2"]}},{"id":"a3024fc3ed644aa79f4b569b6f2f2fbe","type":"GENE","name":"PEX7","canonical_id":"hgnc:HGNC:8860","description":"peroxisomal biogenesis factor 7","metadata":{"aliases":["PTS2R","RD"]}},{"id":"b113404ca0b44d058f3971e89e479b52","type":"TRIAL","name":"PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)","canonical_id":"clinicaltrials.gov:NCT06875258","description":"Erectile Dysfunction Following Radical Prostatectomy","metadata":null},{"id":"83f52f8252bd4e429e5548be2e9b5207","type":"TRIAL","name":"PF-04191834 Single Dose Bronchodilatory Study In Asthma.","canonical_id":"clinicaltrials.gov:NCT00723021","description":"Asthma","metadata":null},{"id":"4654144a7ebd44c6b64ec2e875c23689","type":"TRIAL","name":"PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01441414","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"42b4da346617408ebdd9a51916572501","type":"TRIAL","name":"PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03685591","description":"Breast Neoplasms; Prostate Neoplasms; Neoplasms, Squamous Cell; Melanoma; Mesothelioma; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell; Liver Neoplasms","metadata":null},{"id":"f23f7660df944b499f5558a6c02e1c86","type":"TRIAL","name":"PF-07284892 in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04800822","description":"Solid Tumor","metadata":null},{"id":"05b02e43da7e48f4a50626545134ace3","type":"GENE","name":"PF4","canonical_id":"hgnc:HGNC:8861","description":null,"metadata":null},{"id":"624af3cbd05545879c7839a7fa418035","type":"GENE","name":"PF4V1","canonical_id":"hgnc:HGNC:8862","description":"platelet factor 4 variant 1","metadata":{"aliases":["SCYB4V1","CXCL4V1","CXCL4L1"]}},{"id":"3aff4131500f4cec9562bafbd266ed8a","type":"GENE","name":"PFAS","canonical_id":"hgnc:HGNC:8863","description":"phosphoribosylformylglycinamidine synthase","metadata":{"aliases":["PURL","FGARAT","KIAA0361","GATD8"]}},{"id":"71460a76013b45ff8d852895fb53ba3b","type":"GENE","name":"PFDN1","canonical_id":"hgnc:HGNC:8866","description":"prefoldin subunit 1","metadata":{"aliases":["PFD1"]}},{"id":"27e71023c7d042239af2d1d698b22c32","type":"GENE","name":"PFDN1P1","canonical_id":"hgnc:HGNC:56382","description":"PFDN1 pseudogene 1","metadata":null},{"id":"e5b8221599814ffb842f5ce2cb7b2878","type":"GENE","name":"PFDN1P2","canonical_id":"hgnc:HGNC:56384","description":"PFDN1 pseudogene 2","metadata":null},{"id":"70cccacf7ce64a4c9eba36474a0a42f1","type":"GENE","name":"PFDN2","canonical_id":"hgnc:HGNC:8867","description":"prefoldin subunit 2","metadata":null},{"id":"2b385b0818594c01bb79b233243a181d","type":"GENE","name":"PFDN4","canonical_id":"hgnc:HGNC:8868","description":null,"metadata":null},{"id":"994b487087764893ac507bc13dfb012c","type":"GENE","name":"PFDN4P1","canonical_id":"hgnc:HGNC:58510","description":"PFDN4 pseudogene 1","metadata":null},{"id":"0d0c1218c346430facfe9827a1a85686","type":"GENE","name":"PFDN4P3","canonical_id":"hgnc:HGNC:58512","description":"PFDN4 pseudogene 3","metadata":null},{"id":"d30754dc20ac4b899cb7f82ce4f4addd","type":"GENE","name":"PFDN5","canonical_id":"hgnc:HGNC:8869","description":"prefoldin subunit 5","metadata":{"aliases":["PFD5","MM-1"]}},{"id":"e2161fb29c634795a79da3b125ef83e3","type":"GENE","name":"PFDN6","canonical_id":"hgnc:HGNC:4926","description":"prefoldin subunit 6","metadata":{"aliases":["KE-2","H2-KE2","PFD6","HKE2"]}},{"id":"ff410d8e242c48db8713a6bc2b447cc5","type":"GENE","name":"PFKFB1","canonical_id":"hgnc:HGNC:8872","description":"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1","metadata":{"aliases":["PFRX"]}},{"id":"9043957701d94ee7a24763c7b7fab2d3","type":"GENE","name":"PFKFB2","canonical_id":"hgnc:HGNC:8873","description":"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2","metadata":null},{"id":"ed00752fc1e84e00ab1aea3ebcc4f9a4","type":"GENE","name":"PFKFB3","canonical_id":"hgnc:HGNC:8874","description":null,"metadata":null},{"id":"0a73f5f1928c495cab18cee64100421c","type":"GENE","name":"PFKFB3-AS1","canonical_id":"hgnc:HGNC:58068","description":"PFKFB3 antisense RNA 1","metadata":null},{"id":"9c9ff55416204d76b59ece04187bd92f","type":"GENE","name":"PFKFB4","canonical_id":"hgnc:HGNC:8875","description":null,"metadata":null},{"id":"80645c4cce2c4dec914c8362f8c195c6","type":"GENE","name":"PFKL","canonical_id":"hgnc:HGNC:8876","description":"phosphofructokinase, liver type","metadata":null},{"id":"445876d469b74dd78266f8525de65e28","type":"GENE","name":"PFKM","canonical_id":"hgnc:HGNC:8877","description":"phosphofructokinase, muscle","metadata":{"aliases":["PFK-1","PPP1R122","PFKX"]}},{"id":"7346aea58aa441b299aaf45529c95b5d","type":"GENE","name":"PFKP","canonical_id":"hgnc:HGNC:8878","description":null,"metadata":null},{"id":"9cb82a7afa09425885b82a976bb3a5bf","type":"GENE","name":"PFKP-DT","canonical_id":"hgnc:HGNC:55177","description":"PFKP divergent transcript","metadata":null},{"id":"c183d901bf234807be16e9269711659e","type":"GENE","name":"PFN1","canonical_id":"hgnc:HGNC:8881","description":"profilin 1","metadata":null},{"id":"86baf337ccba427db102741556cf6536","type":"GENE","name":"PFN1P1","canonical_id":"hgnc:HGNC:42989","description":"profilin 1 pseudogene 1","metadata":null},{"id":"efe74fbd83914b1bb4fe98b397bec373","type":"GENE","name":"PFN1P10","canonical_id":"hgnc:HGNC:42985","description":"profilin 1 pseudogene 10","metadata":null},{"id":"0c4e3899880648e2a3bf6d04c76ae1d4","type":"GENE","name":"PFN1P11","canonical_id":"hgnc:HGNC:42994","description":"profilin 1 pseudogene 11","metadata":null},{"id":"ad39b3f19cb34f2b99e23e024dc5de85","type":"GENE","name":"PFN1P12","canonical_id":"hgnc:HGNC:42995","description":"profilin 1 pseudogene 12","metadata":null},{"id":"56bf7af723e94406b508a6c922834f04","type":"GENE","name":"PFN1P2","canonical_id":"hgnc:HGNC:24298","description":"profilin 1 pseudogene 2","metadata":{"aliases":["COAS3","C1orf152"]}},{"id":"4fd61979630047e7b5ea7d3293ab64c8","type":"GENE","name":"PFN1P3","canonical_id":"hgnc:HGNC:42987","description":"profilin 1 pseudogene 3","metadata":null},{"id":"9658bda9e8664fa9bceb46cc888dc890","type":"GENE","name":"PFN1P4","canonical_id":"hgnc:HGNC:42992","description":"profilin 1 pseudogene 4","metadata":{"aliases":["PFN1P5"]}},{"id":"8c46ae9651f342cc999843866b6febb7","type":"GENE","name":"PFN1P6","canonical_id":"hgnc:HGNC:42988","description":"profilin 1 pseudogene 6","metadata":{"aliases":["PFN1P7"]}},{"id":"3082e359c037421396cd2a97f985334f","type":"GENE","name":"PFN1P8","canonical_id":"hgnc:HGNC:42986","description":"profilin 1 pseudogene 8","metadata":null},{"id":"efa6a2e9727c401e992971134cfe2e86","type":"GENE","name":"PFN1P9","canonical_id":"hgnc:HGNC:42991","description":"profilin 1 pseudogene 9","metadata":null},{"id":"4d29147eb40249de929bf4506214b597","type":"GENE","name":"PFN2","canonical_id":"hgnc:HGNC:8882","description":"profilin 2","metadata":null},{"id":"b8e7101287f74d2fa073d4103e3eddbf","type":"GENE","name":"PFN2-AS1","canonical_id":"hgnc:HGNC:55631","description":"PFN2 antisense RNA 1","metadata":null},{"id":"516793d983514630a3787654b2b2d4e3","type":"GENE","name":"PFN3","canonical_id":"hgnc:HGNC:18627","description":"profilin 3","metadata":null},{"id":"94297c733160483d8774036a95e7ac5f","type":"GENE","name":"PFN4","canonical_id":"hgnc:HGNC:31103","description":"profilin family member 4","metadata":null},{"id":"28fac1e9dfd547ee94aa3b9cf83135fe","type":"GENE","name":"PFN5P","canonical_id":"hgnc:HGNC:53808","description":"profilin 5, pseudogene","metadata":null},{"id":"85ad4f6c8b4c4f7da3dc10fcb72b1d9d","type":"GENE","name":"PFPLP","canonical_id":"hgnc:HGNC:58923","description":"pore forming protein like, pseudogene","metadata":{"aliases":["MPEG2P"]}},{"id":"4f8d180cd3bf4f749de95f143d62b9af","type":"GENE","name":"PGA3","canonical_id":"hgnc:HGNC:8885","description":"pepsinogen A3","metadata":null},{"id":"291d51f8641d409895d5a8f68845152e","type":"GENE","name":"PGA4","canonical_id":"hgnc:HGNC:8886","description":"pepsinogen A4","metadata":null},{"id":"dba2f4cdfd894a909bf2b7bc2deb8de9","type":"GENE","name":"PGA5","canonical_id":"hgnc:HGNC:8887","description":null,"metadata":null},{"id":"b9c731ce22324be79dd1a51e1e12bd19","type":"GENE","name":"PGAM1","canonical_id":"hgnc:HGNC:8888","description":"phosphoglycerate mutase 1","metadata":{"aliases":["PGAM-B","PGAMA"]}},{"id":"c04304939c1c4aa1baebbbcfa9e9b6e4","type":"GENE","name":"PGAM1P1","canonical_id":"hgnc:HGNC:42448","description":"phosphoglycerate mutase 1 pseudogene 1","metadata":null},{"id":"c690d8ca8eb445afab0c7685f2e4db00","type":"GENE","name":"PGAM1P10","canonical_id":"hgnc:HGNC:42457","description":"phosphoglycerate mutase 1 pseudogene 10","metadata":null},{"id":"0e0f978c056f46a791b5da1c29276aa7","type":"GENE","name":"PGAM1P11","canonical_id":"hgnc:HGNC:42464","description":"phosphoglycerate mutase 1 pseudogene 11","metadata":null},{"id":"7ecf0733350540048b6c5f4776c04870","type":"GENE","name":"PGAM1P12","canonical_id":"hgnc:HGNC:42459","description":"phosphoglycerate mutase 1 pseudogene 12","metadata":null},{"id":"15a3bf4916f842598219f0f658230e1d","type":"GENE","name":"PGAM1P13","canonical_id":"hgnc:HGNC:42461","description":"phosphoglycerate mutase 1 pseudogene 13","metadata":null},{"id":"05a7f9ecac584d419d63b77fc32dde92","type":"GENE","name":"PGAM1P2","canonical_id":"hgnc:HGNC:42449","description":"phosphoglycerate mutase 1 pseudogene 2","metadata":null},{"id":"1cd21c65e77549dd9afcdee7ca540add","type":"GENE","name":"PGAM1P3","canonical_id":"hgnc:HGNC:42450","description":"phosphoglycerate mutase 1 pseudogene 3","metadata":null},{"id":"e395db57a89a41c4b4f26e90e79d8ab8","type":"GENE","name":"PGAM1P4","canonical_id":"hgnc:HGNC:42451","description":"phosphoglycerate mutase 1 pseudogene 4","metadata":null},{"id":"272576e523cc4185b3102f57f03cadca","type":"GENE","name":"PGAM1P5","canonical_id":"hgnc:HGNC:42452","description":"phosphoglycerate mutase 1 pseudogene 5","metadata":null},{"id":"c8d4907457b5452dbd2dee45b42d0682","type":"GENE","name":"PGAM1P6","canonical_id":"hgnc:HGNC:42453","description":"phosphoglycerate mutase 1 pseudogene 6","metadata":null},{"id":"bb320ff69f28420f801578585fa509f8","type":"GENE","name":"PGAM1P7","canonical_id":"hgnc:HGNC:42454","description":"phosphoglycerate mutase 1 pseudogene 7","metadata":null},{"id":"45e55c55a0c0402882fcd6427ebcd893","type":"GENE","name":"PGAM1P8","canonical_id":"hgnc:HGNC:42455","description":"phosphoglycerate mutase 1 pseudogene 8","metadata":null},{"id":"299a3aed741f4e39b3ddcc760dd28845","type":"GENE","name":"PGAM1P9","canonical_id":"hgnc:HGNC:42456","description":"phosphoglycerate mutase 1 pseudogene 9","metadata":null},{"id":"278f97d8f95d4886870965b827880252","type":"GENE","name":"PGAM2","canonical_id":"hgnc:HGNC:8889","description":"phosphoglycerate mutase 2","metadata":{"aliases":["PGAM-M"]}},{"id":"0b76c5ea3b0c4d9789575467da2a901b","type":"GENE","name":"PGAM3P","canonical_id":"hgnc:HGNC:16557","description":"phosphoglycerate mutase 3, pseudogene","metadata":{"aliases":["dJ1128N12.1"]}},{"id":"471269ac0cd44834897af748b182cef9","type":"GENE","name":"PGAM4","canonical_id":"hgnc:HGNC:21731","description":"phosphoglycerate mutase family member 4","metadata":{"aliases":["dJ1000K24.1","PGAM3","PGAM-B","PGAM1"]}},{"id":"91fb746762f5401883e4e2a5aae8581e","type":"GENE","name":"PGAM4P1","canonical_id":"hgnc:HGNC:42465","description":"phosphoglycerate mutase family member 4 pseudogene 1","metadata":null},{"id":"a592a038de5044ca9da7089b9ef2d3cb","type":"GENE","name":"PGAM4P2","canonical_id":"hgnc:HGNC:42466","description":"phosphoglycerate mutase family member 4 pseudogene 2","metadata":null},{"id":"cbd07ae2f7a8483fb5fe37f80f3e262c","type":"GENE","name":"PGAM5","canonical_id":"hgnc:HGNC:28763","description":"PGAM family member 5, mitochondrial serine/threonine protein phosphatase","metadata":{"aliases":["MGC5352","BXLBv68"]}},{"id":"d978574ec55e485ea72e5798419c96b5","type":"GENE","name":"PGAM5P1","canonical_id":"hgnc:HGNC:42467","description":"PGAM family member 5, mitochondrial serine/threonine protein phosphatase pseudogene 1","metadata":null},{"id":"827ae9867d83447d8ef43c61335bc488","type":"GENE","name":"PGAP1","canonical_id":"hgnc:HGNC:25712","description":"post-GPI attachment to proteins inositol deacylase 1","metadata":{"aliases":["FLJ12377","Bst1","SPG67"]}},{"id":"168cf0950a214adfb1db90146ad26457","type":"GENE","name":"PGAP2","canonical_id":"hgnc:HGNC:17893","description":"post-GPI attachment to proteins 2","metadata":{"aliases":["FRAG1","CWH43-N","MRT21","MRT17"]}},{"id":"f1bb38f090b04df890b5cd21071ae33d","type":"GENE","name":"PGAP3","canonical_id":"hgnc:HGNC:23719","description":"post-GPI attachment to proteins phospholipase 3","metadata":{"aliases":["MGC9753","CAB2","PP1498","PER1","PERLD1"]}},{"id":"1df78c959f274dfe8486ad9100ddf3b6","type":"GENE","name":"PGAP4","canonical_id":"hgnc:HGNC:28180","description":"post-GPI attachment to proteins GalNAc transferase 4","metadata":{"aliases":["MGC12992","C9orf125","TMEM246"]}},{"id":"ff1f2171b2154a65a3c35bc532f5aaf5","type":"GENE","name":"PGAP6","canonical_id":"hgnc:HGNC:17205","description":"post-GPI attachment to proteins 6","metadata":{"aliases":["M83","TMEM6","TMEM8","TMEM8A"]}},{"id":"57914cc5af234376ab1cace6b7840ace","type":"GENE","name":"PGBD1","canonical_id":"hgnc:HGNC:19398","description":"piggyBac transposable element derived 1","metadata":{"aliases":["HUCEP-4","dJ874C20.4","SCAND4"]}},{"id":"2a28088985a748a496f110f13b80b058","type":"GENE","name":"PGBD2","canonical_id":"hgnc:HGNC:19399","description":"piggyBac transposable element derived 2","metadata":null},{"id":"9c282c4b508f41f69fa0e4fdf8441f6c","type":"GENE","name":"PGBD3","canonical_id":"hgnc:HGNC:19400","description":"piggyBac transposable element derived 3","metadata":{"aliases":["FLJ90201"]}},{"id":"dc1689b969764a51aaa36e192b3e286d","type":"GENE","name":"PGBD3P1","canonical_id":"hgnc:HGNC:19402","description":"piggyBac transposable element derived 3 pseudogene 1","metadata":null},{"id":"a6725b83ebc44095a103c3710a613985","type":"GENE","name":"PGBD3P2","canonical_id":"hgnc:HGNC:19397","description":"piggyBac transposable element derived 3 pseudogene 2","metadata":null},{"id":"0f6a05bb91034f128a481a0eee95182d","type":"GENE","name":"PGBD3P3","canonical_id":"hgnc:HGNC:19396","description":"piggyBac transposable element derived 3 pseudogene 3","metadata":null},{"id":"9eb9d144e50a44eeb3c43fac9b80abba","type":"GENE","name":"PGBD3P4","canonical_id":"hgnc:HGNC:19379","description":"piggyBac transposable element derived 3 pseudogene 4","metadata":null},{"id":"2683affc46dd49a4ab64822be7ec979e","type":"GENE","name":"PGBD4","canonical_id":"hgnc:HGNC:19401","description":"piggyBac transposable element derived 4","metadata":{"aliases":["FLJ32638","FLJ37497"]}},{"id":"9c7a67a9f4644b72a5422e45f64a1cc6","type":"GENE","name":"PGBD4P1","canonical_id":"hgnc:HGNC:44066","description":"piggyBac transposable element derived 4 pseudogene 1","metadata":null},{"id":"0ebf40a079bb42e58b74f05d0aaa19f8","type":"GENE","name":"PGBD4P2","canonical_id":"hgnc:HGNC:44077","description":"piggyBac transposable element derived 4 pseudogene 2","metadata":null},{"id":"d7588133488e40f88a3472f19cb39299","type":"GENE","name":"PGBD4P3","canonical_id":"hgnc:HGNC:44068","description":"piggyBac transposable element derived 4 pseudogene 3","metadata":null},{"id":"03cc9e3a0ad1411c90f295020097b1de","type":"GENE","name":"PGBD4P4","canonical_id":"hgnc:HGNC:44076","description":"piggyBac transposable element derived 4 pseudogene 4","metadata":null},{"id":"2623ad03f9e24225a8d68933efe8712d","type":"GENE","name":"PGBD4P5","canonical_id":"hgnc:HGNC:44070","description":"piggyBac transposable element derived 4 pseudogene 5","metadata":null},{"id":"fbc8b4147bdd4e0787b7d6ee1294beb5","type":"GENE","name":"PGBD4P6","canonical_id":"hgnc:HGNC:44071","description":"piggyBac transposable element derived 4 pseudogene 6","metadata":null},{"id":"19ca916596ba432eb3777ca8c0a63e34","type":"GENE","name":"PGBD4P7","canonical_id":"hgnc:HGNC:44074","description":"piggyBac transposable element derived 4 pseudogene 7","metadata":null},{"id":"59b7f13b11e2415788a409a5a91b8e4d","type":"GENE","name":"PGBD4P8","canonical_id":"hgnc:HGNC:44075","description":"piggyBac transposable element derived 4 pseudogene 8","metadata":null},{"id":"9b3f7dd6396042a7a50ac0db62c2e530","type":"GENE","name":"PGBD5","canonical_id":"hgnc:HGNC:19405","description":"piggyBac transposable element derived 5","metadata":{"aliases":["DKFZp761A0620","FLJ11413"]}},{"id":"5a7da642ee5b4548b995691dadd50e22","type":"GENE","name":"PGBDF","canonical_id":"hgnc:HGNC:29581","description":"plakoglobin binding and degradation factor","metadata":{"aliases":["C17orf50"]}},{"id":"dcc25bd95b084d08953d45c759a8714a","type":"GENE","name":"PGBP","canonical_id":"hgnc:HGNC:39503","description":"pepsinogen B, pseudogene","metadata":{"aliases":["PGCP1"]}},{"id":"09508875b51144f590eadc5a2be7e169","type":"GENE","name":"PGC","canonical_id":"hgnc:HGNC:8890","description":"progastricsin","metadata":null},{"id":"3baea60f5f0846dabd698c18e92afc07","type":"GENE","name":"PGCKA1","canonical_id":"hgnc:HGNC:25618","description":"PDCD10 and GCKIII kinases associated 1","metadata":{"aliases":["FLJ11017","C4orf19"]}},{"id":"c2e5765681404b2985f8b3ab9ac9e241","type":"GENE","name":"PGCKA1-AS1","canonical_id":"hgnc:HGNC:58757","description":"PGCKA1 antisense RNA 1","metadata":null},{"id":"38cff03334db49ca96448d8a4223af26","type":"GENE","name":"PGD","canonical_id":"hgnc:HGNC:8891","description":"phosphogluconate dehydrogenase","metadata":null},{"id":"dbffeffa81a444938ba606b73ad00b40","type":"GENE","name":"PGDP1","canonical_id":"hgnc:HGNC:8892","description":"phosphogluconate dehydrogenase pseudogene 1","metadata":{"aliases":["PGDL1"]}},{"id":"50c866a24838417da909181ff9d6183a","type":"GENE","name":"PGDP2","canonical_id":"hgnc:HGNC:39144","description":"phosphogluconate dehydrogenase pseudogene 2","metadata":null},{"id":"3e8568f54340410bb48b130df199d70f","type":"DRUG","name":"PGE1","canonical_id":"gtopdb:1882","description":null,"metadata":null},{"id":"08a128e92c54468990993b9755840c8b","type":"DRUG","name":"PGE2","canonical_id":"gtopdb:1883","description":null,"metadata":null},{"id":"69397d465485408bb309ea3542897748","type":"GENE","name":"PGF","canonical_id":"hgnc:HGNC:8893","description":null,"metadata":null},{"id":"ecc8c10a8ff5419e8ece912930a7558d","type":"PROTEIN","name":"PGF","canonical_id":"uniprot:P49763","description":null,"metadata":null},{"id":"89c92dfeb9df4792be0c66d44ab1113c","type":"GENE","name":"PGGHG","canonical_id":"hgnc:HGNC:26210","description":"protein-glucosylgalactosylhydroxylysine glucosidase","metadata":{"aliases":["FLJ22635","ATHL1"]}},{"id":"2eb5365dfc2642c8ae6450c2241ea308","type":"GENE","name":"PGGT1B","canonical_id":"hgnc:HGNC:8895","description":"protein geranylgeranyltransferase type I subunit beta","metadata":{"aliases":["GGTI","BGGI"]}},{"id":"2a04b8f38fb24bf7b99d7cd06bd8cb59","type":"GENE","name":"PGGT1BP1","canonical_id":"hgnc:HGNC:45024","description":"protein geranylgeranyltransferase type I subunit beta pseudogene 1","metadata":null},{"id":"f15a728a8e4a4811a6d537167f9d48d3","type":"GENE","name":"PGGT1BP2","canonical_id":"hgnc:HGNC:45112","description":"protein geranylgeranyltransferase type I subunit beta pseudogene 2","metadata":null},{"id":"6f52895f6f0344dabc23fdd279222d63","type":"DRUG","name":"PGI2","canonical_id":"gtopdb:1915","description":null,"metadata":null},{"id":"c8ff0e2927f84ce7bb648306decbbd1d","type":"GENE","name":"PGK1","canonical_id":"hgnc:HGNC:8896","description":null,"metadata":null},{"id":"bd6a2ed621d341a49af064bfe4168232","type":"GENE","name":"PGK1P1","canonical_id":"hgnc:HGNC:8897","description":"phosphoglycerate kinase 1 pseudogene 1","metadata":null},{"id":"98bcaa05e0104bbc83e5d19d47651755","type":"GENE","name":"PGK1P2","canonical_id":"hgnc:HGNC:8899","description":"phosphoglycerate kinase 1, pseudogene 2","metadata":null},{"id":"576e3a84199340bb9c6bc343cf60d0f8","type":"GENE","name":"PGK2","canonical_id":"hgnc:HGNC:8898","description":"phosphoglycerate kinase 2","metadata":{"aliases":["PGKPS","PGK-2"]}},{"id":"272fbb0d77c745c9a2245c281e92b87b","type":"TRIAL","name":"PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","canonical_id":"clinicaltrials.gov:NCT01642472","description":"Uterine Fibroids","metadata":null},{"id":"644cf2cea7a440e6ab83792f62f5aa39","type":"GENE","name":"PGLS","canonical_id":"hgnc:HGNC:8903","description":"6-phosphogluconolactonase","metadata":{"aliases":["6PGL"]}},{"id":"957a1bb354bb45318de73ad65447864a","type":"GENE","name":"PGLS-DT","canonical_id":"hgnc:HGNC:55274","description":"PGLS divergent transcript","metadata":null},{"id":"a88464d40fb34539a22c7077985c3ab1","type":"GENE","name":"PGLYRP1","canonical_id":"hgnc:HGNC:8904","description":"peptidoglycan recognition protein 1","metadata":{"aliases":["TAG7","PGRP","PGRP-S","PGRPS","TNFSF3L","PGLYRP"]}},{"id":"bc71f48a3f1d4f999dcb1261dcd85ad9","type":"GENE","name":"PGLYRP2","canonical_id":"hgnc:HGNC:30013","description":null,"metadata":null},{"id":"1e9e4a59340b4ba08bbcee16cfc79717","type":"GENE","name":"PGLYRP3","canonical_id":"hgnc:HGNC:30014","description":"peptidoglycan recognition protein 3","metadata":{"aliases":["PGRPIA","PGLYRPIalpha","PGRP-Ialpha"]}},{"id":"00c30a182a02495da1f1dbfef730669c","type":"GENE","name":"PGLYRP4","canonical_id":"hgnc:HGNC:30015","description":"peptidoglycan recognition protein 4","metadata":{"aliases":["SBBI67","PGRPIB","PGLYRPIbeta","PGRP-Ibeta"]}},{"id":"d6c652fffd3c4a27bb24270f6b035118","type":"GENE","name":"PGM1","canonical_id":"hgnc:HGNC:8905","description":"phosphoglucomutase 1","metadata":null},{"id":"c5f10c6cb5c04122bd00513024c426ac","type":"GENE","name":"PGM2","canonical_id":"hgnc:HGNC:8906","description":"phosphoglucomutase 2","metadata":{"aliases":["FLJ10983"]}},{"id":"00cdae1b8f2342f58c6a18daaeeb9f7a","type":"GENE","name":"PGM2-DT","canonical_id":"hgnc:HGNC:58758","description":"PGM2 divergent transcript","metadata":null},{"id":"5491480d6822475da1581ae5f5768ee0","type":"GENE","name":"PGM2L1","canonical_id":"hgnc:HGNC:20898","description":"phosphoglucomutase 2 like 1","metadata":{"aliases":["FLJ32029","BM32A"]}},{"id":"393da000b37b410d822f88171bd57bf3","type":"GENE","name":"PGM3","canonical_id":"hgnc:HGNC:8907","description":"phosphoglucomutase 3","metadata":{"aliases":["AGM1","DKFZP434B187","PAGM"]}},{"id":"bfcb3dc7aafe446c9ed23607d257c172","type":"GENE","name":"PGM5","canonical_id":"hgnc:HGNC:8908","description":"phosphoglucomutase 5","metadata":{"aliases":["PGMRP"]}},{"id":"dfc2a95c33734f64a746a1b21367b692","type":"GENE","name":"PGM5-AS1","canonical_id":"hgnc:HGNC:44181","description":"PGM5 antisense RNA 1","metadata":{"aliases":["FAM233A","LOC572558"]}},{"id":"d9aa59d3b4d342a8bd0d951ae1f99246","type":"GENE","name":"PGM5P1","canonical_id":"hgnc:HGNC:28452","description":"phosphoglucomutase 5 pseudogene 1","metadata":null},{"id":"33a0202e64b343ea93dd6923127733b7","type":"GENE","name":"PGM5P2","canonical_id":"hgnc:HGNC:18965","description":"phosphoglucomutase 5 pseudogene 2","metadata":{"aliases":["AK096159"]}},{"id":"824e7926f3274fb79dd4406911b49001","type":"GENE","name":"PGM5P3","canonical_id":"hgnc:HGNC:49604","description":"phosphoglucomutase 5 pseudogene 3","metadata":null},{"id":"9460eec2141c4e1f98e52bcdad9e76d0","type":"GENE","name":"PGM5P3-AS1","canonical_id":"hgnc:HGNC:51194","description":"PGM5P3 antisense RNA 1","metadata":{"aliases":["FAM233B"]}},{"id":"f5cabec480ab49d29414c44f12b3f4b1","type":"GENE","name":"PGM5P4","canonical_id":"hgnc:HGNC:49605","description":"phosphoglucomutase 5 pseudogene 4","metadata":null},{"id":"ab5dc105d84346888c6ad19cc2433ca9","type":"GENE","name":"PGM5P4-AS1","canonical_id":"hgnc:HGNC:51195","description":"PGM5P4 antisense RNA 1","metadata":{"aliases":["FAM233C"]}},{"id":"67366bd7dd5640e4aa29c2affdf35c71","type":"GENE","name":"PGP","canonical_id":"hgnc:HGNC:8909","description":"phosphoglycolate phosphatase","metadata":{"aliases":["AUM","G3PP"]}},{"id":"b800a6cb4a864a72947b32115300c13a","type":"GENE","name":"PGPEP1","canonical_id":"hgnc:HGNC:13568","description":"pyroglutamyl-peptidase I","metadata":{"aliases":["PGP-I","Pcp","PGP","PGPI"]}},{"id":"4c321ae9072e4202b6a34a88a62fe67b","type":"GENE","name":"PGPEP1L","canonical_id":"hgnc:HGNC:27080","description":"pyroglutamyl-peptidase I like","metadata":null},{"id":"bcc69f70341b4f0ca890264b9fdc07d9","type":"GENE","name":"PGR","canonical_id":"hgnc:HGNC:8910","description":null,"metadata":null},{"id":"d7258f5d73a84e7582aee7d1b25cf03c","type":"PROTEIN","name":"PGR","canonical_id":"uniprot:P06401","description":null,"metadata":null},{"id":"3a94b9504b9345288460828575f9464b","type":"GENE","name":"PGR-AS1","canonical_id":"hgnc:HGNC:52650","description":"PGR antisense RNA 1","metadata":{"aliases":["AT1","AT2","AT3"]}},{"id":"aa74b297d147494db3c201db5877bda4","type":"GENE","name":"PGRMC1","canonical_id":"hgnc:HGNC:16090","description":"progesterone receptor membrane component 1","metadata":{"aliases":["HPR6.6"]}},{"id":"c6022af496584e1183021877193b0dbb","type":"GENE","name":"PGRMC2","canonical_id":"hgnc:HGNC:16089","description":"progesterone receptor membrane component 2","metadata":{"aliases":["PMBP","DG6"]}},{"id":"a42b838cd8854a28b1c3052448c0d69d","type":"GENE","name":"PGS1","canonical_id":"hgnc:HGNC:30029","description":"phosphatidylglycerophosphate synthase 1","metadata":{"aliases":["DKFZP762M186"]}},{"id":"70989818b2584f009ef5cdaf2c484eb7","type":"GO_TERM","name":"PH domain binding","canonical_id":"go:GO:0042731","description":"\"Binding to a PH domain (pleckstrin homology) of a protein, a domain of about 100 residues that occurs in a wide range of proteins involved in intracellular signaling or as constituents of the cytoskeleton.\" [GOC:jl, Pfam:PF00169]","metadata":null},{"id":"45326973e663442698c7a34d651596f6","type":"TRIAL","name":"PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab","canonical_id":"clinicaltrials.gov:NCT01131247","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"20cf11cf57e542e0b8c23ad18b278eb5","type":"GENE","name":"PHACTR1","canonical_id":"hgnc:HGNC:20990","description":"phosphatase and actin regulator 1","metadata":{"aliases":["KIAA1733","dJ257A7.2","RPEL1"]}},{"id":"b5fae15b903b46bbaad076a20eea2051","type":"GENE","name":"PHACTR1-AS1","canonical_id":"hgnc:HGNC:59348","description":"PHACTR1 antisense RNA 1","metadata":null},{"id":"7974b3ba80e546bcb43589214b89045e","type":"GENE","name":"PHACTR1-AS2","canonical_id":"hgnc:HGNC:59349","description":"PHACTR1 antisense RNA 2","metadata":null},{"id":"b93837d244cc46beb57e70fa943c9f40","type":"GENE","name":"PHACTR1-AS3","canonical_id":"hgnc:HGNC:59350","description":"PHACTR1 antisense RNA 3","metadata":null},{"id":"28330ee30b724710a2e019c535e01b62","type":"GENE","name":"PHACTR1-AS4","canonical_id":"hgnc:HGNC:59351","description":"PHACTR1 antisense RNA 4","metadata":null},{"id":"c2619c06ba544dba9b0def5588bc711c","type":"GENE","name":"PHACTR1-AS5","canonical_id":"hgnc:HGNC:59352","description":"PHACTR1 antisense RNA 5","metadata":null},{"id":"96a1e5d08ac64e96849ca12d3c08ed57","type":"GENE","name":"PHACTR2","canonical_id":"hgnc:HGNC:20956","description":"phosphatase and actin regulator 2","metadata":{"aliases":["KIAA0680","C6orf56"]}},{"id":"da2c61314b1c451f99e48f8ecdf39101","type":"GENE","name":"PHACTR2-AS1","canonical_id":"hgnc:HGNC:40943","description":"PHACTR2 antisense RNA 1","metadata":{"aliases":["NR027113","lncIHS"]}},{"id":"2cbb568ca6b24e2eb5de1e71e9d150f3","type":"GENE","name":"PHACTR2P1","canonical_id":"hgnc:HGNC:49488","description":"phosphatase and actin regulator 2 pseudogene 1","metadata":null},{"id":"c8c1c737bece47e984b4494d522004a4","type":"GENE","name":"PHACTR3","canonical_id":"hgnc:HGNC:15833","description":"phosphatase and actin regulator 3","metadata":{"aliases":["PPP1R123","C20orf101"]}},{"id":"ba1712f04dc54e37a0a0a9a1f4faf82d","type":"GENE","name":"PHACTR3-AS1","canonical_id":"hgnc:HGNC:40727","description":"PHACTR3 antisense RNA 1","metadata":null},{"id":"7276c03719384d42b7ba6c833a9dc7b5","type":"GENE","name":"PHACTR4","canonical_id":"hgnc:HGNC:25793","description":"phosphatase and actin regulator 4","metadata":{"aliases":["FLJ13171","PPP1R124"]}},{"id":"0edd92996d4e478b90a96fea95b62dcb","type":"GENE","name":"PHAF1","canonical_id":"hgnc:HGNC:29564","description":"phagophore assembly factor 1","metadata":{"aliases":["lin-10","FLJ12076","MYTHO","C16orf6","LIN10","C16orf70"]}},{"id":"2f98add8c427472abaaf05204f8c3f3e","type":"TRIAL","name":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","canonical_id":"clinicaltrials.gov:NCT04983901","description":"Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm","metadata":null},{"id":"9009d4d9a0b14d7dbbad2f15dce02d19","type":"GENE","name":"PHAX","canonical_id":"hgnc:HGNC:10241","description":"phosphorylated adaptor for RNA export","metadata":{"aliases":["FLJ13193","RNUXA"]}},{"id":"d57555be524e4fc48b445923abfb86e3","type":"GENE","name":"PHB","canonical_id":"hgnc:HGNC:8912","description":null,"metadata":null},{"id":"8aa4458da02a4aa1a176ce02c0a0210e","type":"GENE","name":"PHB1P1","canonical_id":"hgnc:HGNC:8913","description":"PHB1 pseudogene 1","metadata":{"aliases":["PHBP1"]}},{"id":"e7bca2d91a8e4b1495341b7da6087d19","type":"GENE","name":"PHB1P10","canonical_id":"hgnc:HGNC:39289","description":"PHB1 pseudogene 10","metadata":{"aliases":["PHBP10"]}},{"id":"e346a05ed9804df785b5eadd4af0ffdb","type":"GENE","name":"PHB1P11","canonical_id":"hgnc:HGNC:39290","description":"PHB1 pseudogene 11","metadata":{"aliases":["PHBP11"]}},{"id":"ecd9315142b74ccea5c45bdd863d1ee3","type":"GENE","name":"PHB1P12","canonical_id":"hgnc:HGNC:39291","description":"PHB1 pseudogene 12","metadata":{"aliases":["PHBP12"]}},{"id":"1c5343a6712d49bbb701e0868a39c603","type":"GENE","name":"PHB1P13","canonical_id":"hgnc:HGNC:39292","description":"PHB1 pseudogene 13","metadata":{"aliases":["PHBP13"]}},{"id":"0bd4ceef257d4a56b5aee7e9550d1654","type":"GENE","name":"PHB1P14","canonical_id":"hgnc:HGNC:39293","description":"PHB1 pseudogene 14","metadata":{"aliases":["PHBP14"]}},{"id":"5755008d994c420c88f26525b9f25bf4","type":"GENE","name":"PHB1P15","canonical_id":"hgnc:HGNC:39294","description":"PHB1 pseudogene 15","metadata":{"aliases":["PHBP15"]}},{"id":"6a74680799a149f184e86e10963dba68","type":"GENE","name":"PHB1P16","canonical_id":"hgnc:HGNC:51549","description":"PHB1 pseudogene 16","metadata":{"aliases":["PHBP16"]}},{"id":"d5aa545c6dc343d1a94cb8cc178e8ff2","type":"GENE","name":"PHB1P17","canonical_id":"hgnc:HGNC:51550","description":"PHB1 pseudogene 17","metadata":{"aliases":["PHBP17"]}},{"id":"dcaae8b521de4180a2967d4eb309d36e","type":"GENE","name":"PHB1P18","canonical_id":"hgnc:HGNC:51551","description":"PHB1 pseudogene 18","metadata":{"aliases":["PHBP18"]}},{"id":"3059f11425014a71a4ad5606a9fd7d1c","type":"GENE","name":"PHB1P19","canonical_id":"hgnc:HGNC:51552","description":"PHB1 pseudogene 19","metadata":{"aliases":["PHBP19"]}},{"id":"6d5545198a6b440f90e71c16316d9944","type":"GENE","name":"PHB1P2","canonical_id":"hgnc:HGNC:8914","description":"PHB1 pseudogene 2","metadata":{"aliases":["PHBP2"]}},{"id":"802607ac06bf4d1fb220eb15ff3343ba","type":"GENE","name":"PHB1P20","canonical_id":"hgnc:HGNC:51553","description":"PHB1 pseudogene 20","metadata":{"aliases":["PHBP20"]}},{"id":"98355b856c2d4c6582d0750e4ba0721c","type":"GENE","name":"PHB1P21","canonical_id":"hgnc:HGNC:51554","description":"PHB1 pseudogene 21","metadata":{"aliases":["PHBP21"]}},{"id":"af32ca8cae1f45bb8a552bed6e0cf599","type":"GENE","name":"PHB1P3","canonical_id":"hgnc:HGNC:8915","description":"PHB1 pseudogene 3","metadata":{"aliases":["PHBP3"]}},{"id":"7ec2f314e0e14950ac23071170b68470","type":"GENE","name":"PHB1P4","canonical_id":"hgnc:HGNC:8916","description":"PHB1 pseudogene 4","metadata":{"aliases":["PHBP4"]}},{"id":"accf7f562e454eaf9d69323f29502702","type":"GENE","name":"PHB1P5","canonical_id":"hgnc:HGNC:39284","description":"PHB1 pseudogene 5","metadata":{"aliases":["PHBP5"]}},{"id":"5c6ef84aa6174161a2ebfb47c6f5d4e7","type":"GENE","name":"PHB1P6","canonical_id":"hgnc:HGNC:39285","description":"PHB1 pseudogene 6","metadata":{"aliases":["PHBP6"]}},{"id":"a5c453e3e5c545049f23e4ff7c5fb9c8","type":"GENE","name":"PHB1P7","canonical_id":"hgnc:HGNC:39286","description":"PHB1 pseudogene 7","metadata":{"aliases":["PHBP7"]}},{"id":"9dbf633d6eae4d9699be55171981cc5e","type":"GENE","name":"PHB1P8","canonical_id":"hgnc:HGNC:39287","description":"PHB1 pseudogene 8","metadata":{"aliases":["PHBP8"]}},{"id":"80609d418c464a178f9e57147b264a17","type":"GENE","name":"PHB1P9","canonical_id":"hgnc:HGNC:39288","description":"PHB1 pseudogene 9","metadata":{"aliases":["PHBP9"]}},{"id":"92a0f9a4c74d418881748f460094326e","type":"GENE","name":"PHB2","canonical_id":"hgnc:HGNC:30306","description":null,"metadata":null},{"id":"49f04597f475431ea0ffce7ccd927bc2","type":"GENE","name":"PHB2P1","canonical_id":"hgnc:HGNC:45249","description":"PHB2 pseudogene 1","metadata":null},{"id":"c7e641a652144a8a9e0ce2a8683ed35b","type":"GENE","name":"PHC1","canonical_id":"hgnc:HGNC:3182","description":"polyhomeotic homolog 1","metadata":{"aliases":["HPH1","RAE28","EDR1"]}},{"id":"0cfb51b3e0024365b3c4c37960e09b1f","type":"GENE","name":"PHC1P1","canonical_id":"hgnc:HGNC:34502","description":"polyhomeotic homolog 1 pseudogene 1","metadata":{"aliases":["PHC1B"]}},{"id":"fa244c0e9fe34a6cb4b65526b6a5e823","type":"GENE","name":"PHC2","canonical_id":"hgnc:HGNC:3183","description":"polyhomeotic homolog 2","metadata":{"aliases":["HPH2","EDR2"]}},{"id":"ff3c2abe4b654f72b298f7e8864abed5","type":"GENE","name":"PHC2-AS1","canonical_id":"hgnc:HGNC:40205","description":"PHC2 antisense RNA 1","metadata":null},{"id":"7981aed4f9a145d2b233e319d7083e60","type":"GENE","name":"PHC3","canonical_id":"hgnc:HGNC:15682","description":"polyhomeotic homolog 3","metadata":{"aliases":["EDR3","FLJ12967","FLJ12729","HPH3"]}},{"id":"b8e5153fceea42ac914904366e8cfdde","type":"GENE","name":"PHETA1","canonical_id":"hgnc:HGNC:26509","description":"PH domain containing endocytic trafficking adaptor 1","metadata":{"aliases":["FLJ32356","SES1","IPIP27A","FAM109A"]}},{"id":"dedbe9e46e5e41a994566193795ca539","type":"GENE","name":"PHETA2","canonical_id":"hgnc:HGNC:27161","description":"PH domain containing endocytic trafficking adaptor 2","metadata":{"aliases":["DKFZp686J07229","SES2","IPIP27B","FAM109B"]}},{"id":"6cd072cbf14a4592a9f9a88b58dcf071","type":"GENE","name":"PHEX","canonical_id":"hgnc:HGNC:8918","description":"phosphate regulating endopeptidase X-linked","metadata":{"aliases":["PEX","HPDR1","HYP1","XLH","HYP","HPDR"]}},{"id":"259d3b620df44be3b139dd4dc94e12c1","type":"GENE","name":"PHF1","canonical_id":"hgnc:HGNC:8919","description":"PHD finger protein 1","metadata":{"aliases":["MTF2L2","TDRD19C","PCL1"]}},{"id":"ef9dec2d418c49c09152d22f615e75fb","type":"GENE","name":"PHF10","canonical_id":"hgnc:HGNC:18250","description":null,"metadata":null},{"id":"9d47e11d794b42bbab46043eb7f96594","type":"GENE","name":"PHF10P1","canonical_id":"hgnc:HGNC:23210","description":"PHD finger protein 10 pseudogene 1","metadata":{"aliases":["XAP135P"]}},{"id":"3c981191ed89448487f69bf2360cf05e","type":"GENE","name":"PHF10P2","canonical_id":"hgnc:HGNC:56986","description":"PHF10 pseudogene 2","metadata":null},{"id":"fa49c01327fe43f18c5320cb9c3fcac2","type":"GENE","name":"PHF11","canonical_id":"hgnc:HGNC:17024","description":"PHD finger protein 11","metadata":{"aliases":["NY-REN-34","BCAP","IGER"]}},{"id":"2b0353ba247a4e079561ed4207b13e03","type":"GENE","name":"PHF12","canonical_id":"hgnc:HGNC:20816","description":"PHD finger protein 12","metadata":{"aliases":["PF1","KIAA1523"]}},{"id":"5871209db4a14654941f00d80ee82666","type":"GENE","name":"PHF13","canonical_id":"hgnc:HGNC:22983","description":"PHD finger protein 13","metadata":{"aliases":["MGC43399"]}},{"id":"7aabb852c7484e75acc5235375ca4a1e","type":"GENE","name":"PHF14","canonical_id":"hgnc:HGNC:22203","description":"PHD finger protein 14","metadata":{"aliases":["KIAA0783"]}},{"id":"aeff923b9f764954ad32b6882986d5f8","type":"GENE","name":"PHF19","canonical_id":"hgnc:HGNC:24566","description":"PHD finger protein 19","metadata":{"aliases":["DKFZP727G051","PCL3","MTF2L1","TDRD19B"]}},{"id":"6be8cdd6179c4a7ea6ecc0e2e0afcd86","type":"GENE","name":"PHF2","canonical_id":"hgnc:HGNC:8920","description":"PHD finger protein 2","metadata":{"aliases":["KIAA0662","JHDM1E","CENP-35","KDM7C"]}},{"id":"d94838a40a76440c8cb7f8798539a021","type":"GENE","name":"PHF20","canonical_id":"hgnc:HGNC:16098","description":"PHD finger protein 20","metadata":{"aliases":["dJ1121G12.1","TDRD20A","C20orf104"]}},{"id":"a071bbf967704d5f8e19ad663b924e13","type":"GENE","name":"PHF20L1","canonical_id":"hgnc:HGNC:24280","description":"PHD finger protein 20 like 1","metadata":{"aliases":["CGI-72","FLJ13649","MGC64923","FLJ21615","TDRD20B"]}},{"id":"73669853a6c04c6ab121132d1ff10810","type":"GENE","name":"PHF21A","canonical_id":"hgnc:HGNC:24156","description":"PHD finger protein 21A","metadata":{"aliases":["BHC80","KIAA1696","BM-006"]}},{"id":"3ff94153aac04b80a80b4436237b8d21","type":"GENE","name":"PHF21B","canonical_id":"hgnc:HGNC:25161","description":"PHD finger protein 21B","metadata":{"aliases":["BHC80L","FLJ34161","PHF4"]}},{"id":"2a6add24bc9d4df0a1c4a3d87afb67c4","type":"GENE","name":"PHF23","canonical_id":"hgnc:HGNC:28428","description":"PHD finger protein 23","metadata":{"aliases":["MGC2941","FLJ16355"]}},{"id":"78d58b65b2aa4e5ba20e77a34765596d","type":"GENE","name":"PHF24","canonical_id":"hgnc:HGNC:29180","description":"PHD finger protein 24","metadata":{"aliases":["GINIP","KIAA1045"]}},{"id":"6711c635a9c84fe9ad03fe8cf9c77ccd","type":"GENE","name":"PHF2P1","canonical_id":"hgnc:HGNC:30241","description":"PHD finger protein 2 pseudogene 1","metadata":{"aliases":["DKFZp686A1627"]}},{"id":"ba8c910067d44d03b0d8e2144f1030f0","type":"GENE","name":"PHF2P2","canonical_id":"hgnc:HGNC:38808","description":"PHD finger protein 2 pseudogene 2","metadata":null},{"id":"8977660bc9f441eb993b26e3ecfa6330","type":"GENE","name":"PHF3","canonical_id":"hgnc:HGNC:8921","description":"PHD finger protein 3","metadata":null},{"id":"424c8c7517d24f8a888bb3e87634d658","type":"GENE","name":"PHF5A","canonical_id":"hgnc:HGNC:18000","description":"PHD finger protein 5A","metadata":{"aliases":["MGC1346","SF3b14b","INI","bK223H9.2","Rds3","SAP14b","SF3B7"]}},{"id":"9b2f22f2dbe842eab652d48a5bab2cef","type":"GENE","name":"PHF5AP1","canonical_id":"hgnc:HGNC:32385","description":"PHF5A pseudogene 1","metadata":{"aliases":["PHF5CP"]}},{"id":"96f0947ab97b45efbbd6dfe4af70ac6b","type":"GENE","name":"PHF5AP2","canonical_id":"hgnc:HGNC:23268","description":"PHF5A pseudogene 2","metadata":{"aliases":["PHF5DP"]}},{"id":"db2dc167226c418486677f007e997cac","type":"GENE","name":"PHF5AP3","canonical_id":"hgnc:HGNC:23267","description":"PHF5A pseudogene 3","metadata":{"aliases":["PHF5EP"]}},{"id":"3bf1c3e9b6ac435a8965a16c5915e5b0","type":"GENE","name":"PHF5AP4","canonical_id":"hgnc:HGNC:23266","description":"PHF5A pseudogene 4","metadata":{"aliases":["PHF5FP"]}},{"id":"05358687c960467782974554d62dff3b","type":"GENE","name":"PHF5AP5","canonical_id":"hgnc:HGNC:23269","description":"PHF5A pseudogene 5","metadata":{"aliases":["PHF5GP"]}},{"id":"72d0e8526a684bd88bbad2bc1e510998","type":"GENE","name":"PHF5AP6","canonical_id":"hgnc:HGNC:23264","description":"PHF5A pseudogene 6","metadata":{"aliases":["PHF5HP"]}},{"id":"7c5e2fbf1e8449c5ba329608d2627b10","type":"GENE","name":"PHF5AP7","canonical_id":"hgnc:HGNC:56552","description":"PHF5A pseudogene 7","metadata":null},{"id":"753145b6bd484e0db870c206b7b86b44","type":"GENE","name":"PHF6","canonical_id":"hgnc:HGNC:18145","description":"PHD finger protein 6","metadata":{"aliases":["KIAA1823","MGC14797","CENP-31","BFLS","BORJ"]}},{"id":"1c4442ecf28f4fea898731c95b927d95","type":"GENE","name":"PHF7","canonical_id":"hgnc:HGNC:18458","description":"PHD finger protein 7","metadata":{"aliases":["NYD-SP6","HSPC226"]}},{"id":"dfb5c41711df460792f7eee4150c2c87","type":"GENE","name":"PHF8","canonical_id":"hgnc:HGNC:20672","description":null,"metadata":null},{"id":"d92cf53153254f839adbbd78577e2f72","type":"GENE","name":"PHGDH","canonical_id":"hgnc:HGNC:8923","description":null,"metadata":null},{"id":"4f225d5cb7a447c2b8c45a5cc7671db9","type":"GENE","name":"PHGR1","canonical_id":"hgnc:HGNC:37226","description":"proline, histidine and glycine rich 1","metadata":null},{"id":"1bbeb2e54b5645d39fea7a601d70ae4b","type":"GENE","name":"PHIP","canonical_id":"hgnc:HGNC:15673","description":"PHIP subunit of CUL4-Ring ligase complex","metadata":{"aliases":["ndrp","BRWD2","RepID","DCAF14","FLJ20705","WDR11"]}},{"id":"077abc2678c84ef28b2b5d7d34eb1cb9","type":"TRIAL","name":"PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00125918","description":"Pulmonary Hypertension","metadata":null},{"id":"2e6ab417229a4c2a9d829d2da9fc2e35","type":"GENE","name":"PHKA1","canonical_id":"hgnc:HGNC:8925","description":"phosphorylase kinase regulatory subunit alpha 1","metadata":{"aliases":["PHKA"]}},{"id":"22a732bbecee4be599aa38175d681a77","type":"GENE","name":"PHKA1-AS1","canonical_id":"hgnc:HGNC:40446","description":"PHKA1 antisense RNA 1","metadata":null},{"id":"8de82b3fb8b4436ca529f532d8e4441f","type":"GENE","name":"PHKA1P1","canonical_id":"hgnc:HGNC:33919","description":"phosphorylase kinase regulatory subunit alpha 1 pseudogene","metadata":null},{"id":"23a6140ea98c41f6aa45f09c60561555","type":"GENE","name":"PHKA2","canonical_id":"hgnc:HGNC:8926","description":"phosphorylase kinase regulatory subunit alpha 2","metadata":{"aliases":["PHK","PYK"]}},{"id":"051160c313f54810813404aae16b7df4","type":"GENE","name":"PHKA2-AS1","canonical_id":"hgnc:HGNC:44110","description":"PHKA2 antisense RNA 1","metadata":null},{"id":"9eddbfefbcca4de2b65c574b0ae3172b","type":"GENE","name":"PHKB","canonical_id":"hgnc:HGNC:8927","description":"phosphorylase kinase regulatory subunit beta","metadata":null},{"id":"bc8656f885694d7b89c38e4300557341","type":"GENE","name":"PHKBP1","canonical_id":"hgnc:HGNC:8928","description":"phosphorylase kinase regulatory subunit beta pseudogene 1","metadata":null},{"id":"12afafb4bbc64f33a38020450fbdd916","type":"GENE","name":"PHKBP2","canonical_id":"hgnc:HGNC:8929","description":"phosphorylase kinase regulatory subunit beta pseudogene 2","metadata":null},{"id":"fa91fa1376d146348ecf8d5958d43f31","type":"GENE","name":"PHKG1","canonical_id":"hgnc:HGNC:8930","description":"phosphorylase kinase catalytic subunit gamma 1","metadata":{"aliases":["PHKG"]}},{"id":"5181e5c74dd244f582d56011e2c77485","type":"GENE","name":"PHKG1P1","canonical_id":"hgnc:HGNC:33916","description":"phosphorylase kinase catalytic subunit gamma 1 pseudogene 1","metadata":null},{"id":"2457069a8e3e4eb88e7da7ba0006b75a","type":"GENE","name":"PHKG1P2","canonical_id":"hgnc:HGNC:33917","description":"phosphorylase kinase catalytic subunit gamma 1 pseudogene 2","metadata":null},{"id":"839d084b4eab4330a1b9555d18bc044c","type":"GENE","name":"PHKG1P3","canonical_id":"hgnc:HGNC:8932","description":"phosphorylase kinase catalytic subunit gamma 1 pseudogene 3","metadata":{"aliases":["PHKg1ps2","PHKGL"]}},{"id":"c7b5d610239e4151aaa6bcf7e93489b6","type":"GENE","name":"PHKG1P4","canonical_id":"hgnc:HGNC:33918","description":"phosphorylase kinase catalytic subunit gamma 1 pseudogene 4","metadata":null},{"id":"553ea165f619450f9c66c6b699c0ca50","type":"GENE","name":"PHKG2","canonical_id":"hgnc:HGNC:8931","description":"phosphorylase kinase catalytic subunit gamma 2","metadata":null},{"id":"b6109ce0b1304be2b10b8714fab6221f","type":"GENE","name":"PHLDA1","canonical_id":"hgnc:HGNC:8933","description":null,"metadata":null},{"id":"ef30ba13466d402e8f0466373a9693c1","type":"GENE","name":"PHLDA1-AS1","canonical_id":"hgnc:HGNC:55461","description":"PHLDA1 antisense RNA 1","metadata":{"aliases":["RP11-290L1.3"]}},{"id":"d4858be6720840a882e3d97d912a797f","type":"GENE","name":"PHLDA1-DT","canonical_id":"hgnc:HGNC:55470","description":"PHLDA1 divergent transcript","metadata":null},{"id":"5844d366d8944d14868b33d37433cff7","type":"GENE","name":"PHLDA2","canonical_id":"hgnc:HGNC:12385","description":"pleckstrin homology like domain family A member 2","metadata":{"aliases":["IPL","BWR1C","HLDA2","TSSC3"]}},{"id":"513ff0637cfa438a9f3c6515f792ad33","type":"GENE","name":"PHLDA3","canonical_id":"hgnc:HGNC:8934","description":"pleckstrin homology like domain family A member 3","metadata":{"aliases":["TIH1"]}},{"id":"97881ca3663e4bd398fb916854b6afc4","type":"GENE","name":"PHLDB1","canonical_id":"hgnc:HGNC:23697","description":"pleckstrin homology like domain family B member 1","metadata":{"aliases":["FLJ00141","LL5a","KIAA0638"]}},{"id":"e6f96bebbdbd4f26bfb7211005ac9fe9","type":"GENE","name":"PHLDB2","canonical_id":"hgnc:HGNC:29573","description":"pleckstrin homology like domain family B member 2","metadata":{"aliases":["LL5beta","FLJ21791","LL5b"]}},{"id":"a9e9ac0cc6b547769f50fff543bef421","type":"GENE","name":"PHLDB3","canonical_id":"hgnc:HGNC:30499","description":"pleckstrin homology like domain family B member 3","metadata":{"aliases":["FLJ40193"]}},{"id":"972d602a91684d8d9af967333b3bc396","type":"GENE","name":"PHLPP1","canonical_id":"hgnc:HGNC:20610","description":"PH domain and leucine rich repeat protein phosphatase 1","metadata":{"aliases":["KIAA0606","SCOP","PPM3A","PLEKHE1","PHLPP"]}},{"id":"98c21fca3d9d493eb8e12290fcdd357e","type":"GENE","name":"PHLPP2","canonical_id":"hgnc:HGNC:29149","description":"PH domain and leucine rich repeat protein phosphatase 2","metadata":{"aliases":["KIAA0931","PPM3B","PHLPPL"]}},{"id":"bd7db27eae324e29ba0b36666227bb64","type":"TRIAL","name":"PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation","canonical_id":"clinicaltrials.gov:NCT03933774","description":"Vitiligo","metadata":null},{"id":"489a4b68895e4e58920750a3ca20c4e1","type":"GENE","name":"PHOSPHO1","canonical_id":"hgnc:HGNC:16815","description":"phosphoethanolamine/phosphocholine phosphatase 1","metadata":null},{"id":"01bf7fa302004081a00522d77ccca3e9","type":"GENE","name":"PHOSPHO2","canonical_id":"hgnc:HGNC:28316","description":"phosphatase, orphan 2","metadata":{"aliases":["MGC22679"]}},{"id":"7eca29e81f2143be80213f67ebcd663e","type":"GENE","name":"PHOX2A","canonical_id":"hgnc:HGNC:691","description":null,"metadata":null},{"id":"f0ac5d08c0e8464083b2997c540f3f4c","type":"GENE","name":"PHOX2B","canonical_id":"hgnc:HGNC:9143","description":null,"metadata":null},{"id":"25ce472d0cf4464c93826f4524c10272","type":"GENE","name":"PHOX2B-AS1","canonical_id":"hgnc:HGNC:40457","description":"PHOX2B antisense RNA 1","metadata":null},{"id":"84349d5fc7a046faa27e8ec8b9385909","type":"TRIAL","name":"PHOspholamban RElated CArdiomyopathy STudy - Intervention","canonical_id":"clinicaltrials.gov:NCT01857856","description":"Phospholamban R14del Mutation-related Cardiomyopathy","metadata":null},{"id":"d453ca58e06b4f3eb732cec93eb34a97","type":"GENE","name":"PHPT1","canonical_id":"hgnc:HGNC:30033","description":"phosphohistidine phosphatase 1","metadata":{"aliases":["PHP14","HSPC141","CGI-202","DKFZp564M173","bA216L13.10"]}},{"id":"bc8a1f0281f6459492fd5736988a264a","type":"GENE","name":"PHRF1","canonical_id":"hgnc:HGNC:24351","description":"PHD and ring finger domains 1","metadata":{"aliases":["KIAA1542","PPP1R125","RNF221"]}},{"id":"fdf7455fb75e464ca23029a3dbf5598a","type":"GENE","name":"PHTF1","canonical_id":"hgnc:HGNC:8939","description":"putative homeodomain transcription factor 1","metadata":{"aliases":["PHTF"]}},{"id":"77bef517781e4bc993a84dd0e90e130b","type":"GENE","name":"PHTF2","canonical_id":"hgnc:HGNC:13411","description":"putative homeodomain transcription factor 2","metadata":{"aliases":["DKFZp434D166"]}},{"id":"435b6b69c22e45eba1794ef686fa88a8","type":"GENE","name":"PHYH","canonical_id":"hgnc:HGNC:8940","description":"phytanoyl-CoA 2-hydroxylase","metadata":{"aliases":["PAHX","RD","PHYH1"]}},{"id":"151e74ad3bac4209ab3e6455d9107b48","type":"GENE","name":"PHYHD1","canonical_id":"hgnc:HGNC:23396","description":"phytanoyl-CoA dioxygenase domain containing 1","metadata":{"aliases":["MGC16638"]}},{"id":"bf041ee7c50e48bd910f85229cb3bbb6","type":"GENE","name":"PHYHIP","canonical_id":"hgnc:HGNC:16865","description":"phytanoyl-CoA 2-hydroxylase interacting protein","metadata":{"aliases":["KIAA0273","PAHX-AP","DYRK1AP3"]}},{"id":"ed483cac27634384bc14cdf06f8e5bf4","type":"GENE","name":"PHYHIPL","canonical_id":"hgnc:HGNC:29378","description":"phytanoyl-CoA 2-hydroxylase interacting protein like","metadata":{"aliases":["KIAA1796","Em:AC025038.1"]}},{"id":"20024f7b81d342eeb261795688ff3c8a","type":"GENE","name":"PHYKPL","canonical_id":"hgnc:HGNC:28249","description":"5-phosphohydroxy-L-lysine phospho-lyase","metadata":{"aliases":["MGC15875","AGXT2L2"]}},{"id":"425091bdfa0340b8a23d6c632d82d7fe","type":"GENE","name":"PI15","canonical_id":"hgnc:HGNC:8946","description":"peptidase inhibitor 15","metadata":{"aliases":["P25TI"]}},{"id":"32d27d0c4ab44661be57aa66de0c0a48","type":"GENE","name":"PI16","canonical_id":"hgnc:HGNC:21245","description":"peptidase inhibitor 16","metadata":{"aliases":["MGC45378","dJ90K10.5","MSMBBP","CD364"]}},{"id":"ee5de9a962cc4308b3e42081e52143a2","type":"GENE","name":"PI16-AS1","canonical_id":"hgnc:HGNC:59393","description":"PI16 antisense RNA 1","metadata":null},{"id":"a1c12f4ed4a848a2a47169ac2f4c4d03","type":"GENE","name":"PI3","canonical_id":"hgnc:HGNC:8947","description":"peptidase inhibitor 3","metadata":{"aliases":["ESI","SKALP","ELAFIN","WAP3","WFDC14","cementoin"]}},{"id":"cf6be3b3112048fd930112481aacc4d4","type":"DRUG","name":"PI3Kbeta Inhibitor AZD8186","canonical_id":"ncit:C107684","description":null,"metadata":null},{"id":"562ba5ac07c34295abd5809f268fc45f","type":"GENE","name":"PI4K2A","canonical_id":"hgnc:HGNC:30031","description":"phosphatidylinositol 4-kinase type 2 alpha","metadata":{"aliases":["PI4KII","DKFZP761G1923","PIK42A"]}},{"id":"6e74f557477745ccb05b65d8cca11f75","type":"GENE","name":"PI4K2B","canonical_id":"hgnc:HGNC:18215","description":"phosphatidylinositol 4-kinase type 2 beta","metadata":{"aliases":["PI4KIIB","FLJ11105","PIK42B"]}},{"id":"bd62fb5d0d0044baa2ea47fb4a55c928","type":"GENE","name":"PI4K2B-DT","canonical_id":"hgnc:HGNC:58747","description":"PI4K2B divergent transcript","metadata":null},{"id":"778d691152dd4c1db9186dd077a759bb","type":"GENE","name":"PI4KA","canonical_id":"hgnc:HGNC:8983","description":"phosphatidylinositol 4-kinase alpha","metadata":{"aliases":["PI4K-ALPHA","pi4K230","PIK4CA"]}},{"id":"cc8c17a428d74f6aa7f8c57be2329202","type":"GENE","name":"PI4KAP1","canonical_id":"hgnc:HGNC:33576","description":"phosphatidylinositol 4-kinase alpha pseudogene 1","metadata":null},{"id":"6ef5b8569b524f278812b7c5f206d89a","type":"GENE","name":"PI4KAP2","canonical_id":"hgnc:HGNC:33577","description":"phosphatidylinositol 4-kinase alpha pseudogene 2","metadata":null},{"id":"fa647540e1df4963b7241ce3175914ad","type":"GENE","name":"PI4KB","canonical_id":"hgnc:HGNC:8984","description":"phosphatidylinositol 4-kinase beta","metadata":{"aliases":["PI4K-BETA","pi4K92","PIK4CB"]}},{"id":"2423e654fcfb4093a179b7068f187d30","type":"GENE","name":"PIANP","canonical_id":"hgnc:HGNC:25338","description":"PILR alpha associated neural protein","metadata":{"aliases":["DKFZp547D2210","PANP","C12orf53"]}},{"id":"8a9824b4c60d440bae17bcbd73799c3c","type":"GENE","name":"PIAS1","canonical_id":"hgnc:HGNC:2752","description":null,"metadata":null},{"id":"db2fcc547be3435cadebb7839cad8e74","type":"GENE","name":"PIAS2","canonical_id":"hgnc:HGNC:17311","description":null,"metadata":null},{"id":"c3c2d7c7aa24419e89249ec778a85cb2","type":"GENE","name":"PIAS3","canonical_id":"hgnc:HGNC:16861","description":null,"metadata":null},{"id":"15d59a8befff463e805417f00674ee89","type":"GENE","name":"PIAS4","canonical_id":"hgnc:HGNC:17002","description":null,"metadata":null},{"id":"fd6de31b9a1e435a861d1c600657cc65","type":"GENE","name":"PIBF1","canonical_id":"hgnc:HGNC:23352","description":"progesterone immunomodulatory binding factor 1","metadata":{"aliases":["CEP90","PIBF","C13orf24"]}},{"id":"0fba111ec1264dd5a793c8a3e48f2425","type":"GENE","name":"PICALM","canonical_id":"hgnc:HGNC:15514","description":"phosphatidylinositol binding clathrin assembly protein","metadata":{"aliases":["CALM","CLTH"]}},{"id":"218b35608fba481eb0950893297a54ab","type":"GENE","name":"PICART1","canonical_id":"hgnc:HGNC:27576","description":"p53 inducible cancer associated RNA transcript 1","metadata":null},{"id":"cde369e5357b487a988814e5d8d57114","type":"GENE","name":"PICK1","canonical_id":"hgnc:HGNC:9394","description":"protein interacting with PRKCA 1","metadata":{"aliases":["dJ1039K5","MGC15204","PRKCABP"]}},{"id":"4cca33a78b094f3aaadbfdada597872d","type":"GENE","name":"PICSAR","canonical_id":"hgnc:HGNC:19725","description":"P38 inhibited cutaneous squamous cell carcinoma associated lincRNA","metadata":{"aliases":["NLC1-C","PRED74","lnc-NLC1-C","C21orf113","NCRNA00162","LINC00162"]}},{"id":"aee9c9d882924265a3582cd30dc476c3","type":"GENE","name":"PID1","canonical_id":"hgnc:HGNC:26084","description":"phosphotyrosine interaction domain containing 1","metadata":{"aliases":["NYGGF4","FLJ20701"]}},{"id":"ffb3a8e571bb4f208ca7acf7bcca053d","type":"GENE","name":"PIDD1","canonical_id":"hgnc:HGNC:16491","description":"p53-induced death domain protein 1","metadata":{"aliases":["MGC16925","DKFZp434D229","LRDD","PIDD"]}},{"id":"79833cfee73442f18272c1ee62258f8b","type":"TRIAL","name":"PIE II: Pharmacological Intervention in the Elderly II","canonical_id":"clinicaltrials.gov:NCT00123955","description":"Diastolic Heart Failure; Heart Failure, Congestive","metadata":null},{"id":"1dad665dc248495c863bc7ae87083a8b","type":"TRIAL","name":"PIEB vs CEI for Labor Analgesia: An MLAC Study","canonical_id":"clinicaltrials.gov:NCT02573597","description":"Pregnancy","metadata":null},{"id":"84aa4dbc8562457080e9112ce74a42f6","type":"GENE","name":"PIERCE1","canonical_id":"hgnc:HGNC:28435","description":"piercer of microtubule wall 1","metadata":{"aliases":["MGC29761","RbEST47","C9orf116"]}},{"id":"0b3c55a8d81c417bbafbdd2236d5f49a","type":"GENE","name":"PIERCE2","canonical_id":"hgnc:HGNC:44654","description":"piercer of microtubule wall 2","metadata":{"aliases":["FLJ27352","C15orf65"]}},{"id":"7f2b762e9bdb4c949372d42958a20f88","type":"GENE","name":"PIEZO1","canonical_id":"hgnc:HGNC:28993","description":"piezo type mechanosensitive ion channel component 1 (Er blood group)","metadata":{"aliases":["KIAA0233","FAM38A"]}},{"id":"257c5b0e81ff4ee39c67bf8b1ea8e672","type":"GENE","name":"PIEZO1-AS1","canonical_id":"hgnc:HGNC:58065","description":"PIEZO1 antisense RNA 1","metadata":null},{"id":"25c8878a1f3e4e82a1eb46ca9310df99","type":"GENE","name":"PIEZO1P1","canonical_id":"hgnc:HGNC:16214","description":"piezo type mechanosensitive ion channel component 1 pseudogene 1","metadata":{"aliases":["bA164D18.1","C20orf83","FAM38CP"]}},{"id":"1c7822edc1db4dc9bad5e99a3524ca55","type":"GENE","name":"PIEZO1P2","canonical_id":"hgnc:HGNC:42861","description":"piezo type mechanosensitive ion channel component 1 pseudogene 2","metadata":null},{"id":"4d7f35fa25cd4e0c84f5f40626848b89","type":"GENE","name":"PIEZO2","canonical_id":"hgnc:HGNC:26270","description":"piezo type mechanosensitive ion channel component 2","metadata":{"aliases":["FLJ23403","FLJ23144","HsT748","HsT771","FLJ34907","FAM38B2","C18orf30","C18orf58","FAM38B"]}},{"id":"f2a0772c0207429696943e1d3f430f6d","type":"GENE","name":"PIF1","canonical_id":"hgnc:HGNC:26220","description":"PIF1 5'-to-3' DNA helicase","metadata":{"aliases":["FLJ22692","C15orf20"]}},{"id":"adad1b6525bb4dbcb6163c3492d63ced","type":"GENE","name":"PIGA","canonical_id":"hgnc:HGNC:8957","description":"phosphatidylinositol glycan anchor biosynthesis class A","metadata":{"aliases":["GPI3","PIG-A"]}},{"id":"ae089fd2568f408ebddc9ecbd0a957c9","type":"GENE","name":"PIGAP1","canonical_id":"hgnc:HGNC:8958","description":"phosphatidylinositol glycan anchor biosynthesis class A pseudogene 1","metadata":null},{"id":"9681bb7e4dee49bbbff327e7ee715dfa","type":"GENE","name":"PIGB","canonical_id":"hgnc:HGNC:8959","description":"phosphatidylinositol glycan anchor biosynthesis class B","metadata":{"aliases":["PIG-B","GPI-MT-III"]}},{"id":"b2bf88f0b7fc43bdb853ad0cd27d845c","type":"GENE","name":"PIGBOS1","canonical_id":"hgnc:HGNC:50696","description":"PIGB opposite strand 1","metadata":null},{"id":"591e9e051d7c4fe1b1c67a6c5b78f9d0","type":"GENE","name":"PIGC","canonical_id":"hgnc:HGNC:8960","description":"phosphatidylinositol glycan anchor biosynthesis class C","metadata":{"aliases":["PIG-C","GPI2"]}},{"id":"654bb359b3764876babd71a9606da923","type":"GENE","name":"PIGCP1","canonical_id":"hgnc:HGNC:8961","description":"phosphatidylinositol glycan anchor biosynthesis class C pseudogene 1","metadata":null},{"id":"fbd28fad7e9c48bda010b38eca9fee88","type":"GENE","name":"PIGCP2","canonical_id":"hgnc:HGNC:45149","description":"phosphatidylinositol glycan anchor biosynthesis class C pseudogene 2","metadata":null},{"id":"28424f6a4070401ea1f73aa8860fa90b","type":"GENE","name":"PIGF","canonical_id":"hgnc:HGNC:8962","description":"phosphatidylinositol glycan anchor biosynthesis class F","metadata":{"aliases":["PIG-F"]}},{"id":"55f8c40af63d4efcb802d4994b282ec4","type":"GENE","name":"PIGFP1","canonical_id":"hgnc:HGNC:8963","description":"phosphatidylinositol glycan anchor biosynthesis class F pseudogene 1","metadata":null},{"id":"bbe47cfdf40d4b54a535b9389172294a","type":"GENE","name":"PIGFP2","canonical_id":"hgnc:HGNC:45150","description":"phosphatidylinositol glycan anchor biosynthesis class F pseudogene 2","metadata":null},{"id":"d307ccd2f57d4300b09d8bd9324ce512","type":"GENE","name":"PIGFP3","canonical_id":"hgnc:HGNC:45151","description":"phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3","metadata":null},{"id":"4f99691d9fb4493c886c4e842369c18b","type":"GENE","name":"PIGG","canonical_id":"hgnc:HGNC:25985","description":"phosphatidylinositol glycan anchor biosynthesis class G (EMM blood group)","metadata":{"aliases":["FLJ20265","GPI7","LAS21"]}},{"id":"1af8e2c70669469a91da68579f637b9d","type":"GENE","name":"PIGH","canonical_id":"hgnc:HGNC:8964","description":"phosphatidylinositol glycan anchor biosynthesis class H","metadata":{"aliases":["GPI-H"]}},{"id":"2c9d4988aba34a40bae45e9d6551879e","type":"GENE","name":"PIGHP1","canonical_id":"hgnc:HGNC:45152","description":"phosphatidylinositol glycan anchor biosynthesis class H pseudogene 1","metadata":null},{"id":"92535b01a72c4c8bbbe21b5d532c3ee4","type":"GENE","name":"PIGK","canonical_id":"hgnc:HGNC:8965","description":"phosphatidylinositol glycan anchor biosynthesis class K","metadata":{"aliases":["hGPI8","GPI8","PIG-K"]}},{"id":"cc044c2343584b688df6fff28644b16f","type":"GENE","name":"PIGL","canonical_id":"hgnc:HGNC:8966","description":"phosphatidylinositol glycan anchor biosynthesis class L","metadata":{"aliases":["PIG-L"]}},{"id":"4b40d42d29164a1cab39a4e45ed35d6b","type":"GENE","name":"PIGM","canonical_id":"hgnc:HGNC:18858","description":"phosphatidylinositol glycan anchor biosynthesis class M","metadata":{"aliases":["GPI-MT-I","PIG-M"]}},{"id":"3838452338c94c0497e4788279c239f0","type":"GENE","name":"PIGN","canonical_id":"hgnc:HGNC:8967","description":"phosphatidylinositol glycan anchor biosynthesis class N","metadata":{"aliases":["MCD4","PIG-N"]}},{"id":"cb5dc321ef0440f6a7149054390df042","type":"GENE","name":"PIGO","canonical_id":"hgnc:HGNC:23215","description":"phosphatidylinositol glycan anchor biosynthesis class O","metadata":{"aliases":["DKFZp434M222","FLJ00135","PIG-O"]}},{"id":"7822ca01e65648afb937945024eed33e","type":"GENE","name":"PIGO-AS1","canonical_id":"hgnc:HGNC:55692","description":"PIGO antisense RNA 1","metadata":null},{"id":"c2d0dac61bc94ffca3e9b61e644a7b3f","type":"GENE","name":"PIGP","canonical_id":"hgnc:HGNC:3046","description":"phosphatidylinositol glycan anchor biosynthesis class P","metadata":{"aliases":["DCRC","DSRC","DSCR5"]}},{"id":"1512f8a5bdca4ae3a1869beb0f213d36","type":"GENE","name":"PIGPP1","canonical_id":"hgnc:HGNC:45153","description":"phosphatidylinositol glycan anchor biosynthesis class P pseudogene 1","metadata":null},{"id":"11d2fc43f81d484e8815f339bed13d93","type":"GENE","name":"PIGPP2","canonical_id":"hgnc:HGNC:45154","description":"phosphatidylinositol glycan anchor biosynthesis class P pseudogene 2","metadata":null},{"id":"d86a7a19196a4391bb6b7dab511f7094","type":"GENE","name":"PIGPP3","canonical_id":"hgnc:HGNC:45155","description":"phosphatidylinositol glycan anchor biosynthesis class P pseudogene 3","metadata":null},{"id":"fde1609499644383a61d13bdcf73c35e","type":"GENE","name":"PIGPP4","canonical_id":"hgnc:HGNC:45156","description":"phosphatidylinositol glycan anchor biosynthesis class P pseudogene 4","metadata":null},{"id":"40840078dd88403695bfeffa1808b388","type":"GENE","name":"PIGQ","canonical_id":"hgnc:HGNC:14135","description":"phosphatidylinositol glycan anchor biosynthesis class Q","metadata":{"aliases":["hGPI1","GPI1"]}},{"id":"0deef74660fa449eab00762389b3510e","type":"GENE","name":"PIGQP1","canonical_id":"hgnc:HGNC:45157","description":"phosphatidylinositol glycan anchor biosynthesis class Q pseudogene 1","metadata":null},{"id":"97bb71e14a7d41e1af2a162ade638900","type":"GENE","name":"PIGR","canonical_id":"hgnc:HGNC:8968","description":null,"metadata":null},{"id":"2290f86860744dc49dd930f586df1da7","type":"GENE","name":"PIGS","canonical_id":"hgnc:HGNC:14937","description":"phosphatidylinositol glycan anchor biosynthesis class S","metadata":{"aliases":["PIG-S"]}},{"id":"8a859b4cbb2d466eb846a4da367c8f21","type":"GENE","name":"PIGT","canonical_id":"hgnc:HGNC:14938","description":"phosphatidylinositol glycan anchor biosynthesis class T","metadata":{"aliases":["PIG-T"]}},{"id":"b5186e31e043424ab404bb2a92db4d51","type":"GENE","name":"PIGU","canonical_id":"hgnc:HGNC:15791","description":"phosphatidylinositol glycan anchor biosynthesis class U","metadata":{"aliases":["bA346K17.2","GAB1","PIG-U","CDC91L1"]}},{"id":"c6b97a7577f64bf2a41b20244e24fb94","type":"GENE","name":"PIGUP1","canonical_id":"hgnc:HGNC:45158","description":"phosphatidylinositol glycan anchor biosynthesis class U pseudogene 1","metadata":null},{"id":"18f86e1f38b342e9b7461b948f71bc0a","type":"GENE","name":"PIGV","canonical_id":"hgnc:HGNC:26031","description":"phosphatidylinositol glycan anchor biosynthesis class V","metadata":{"aliases":["FLJ20477","PIG-V","GPI-MT-II"]}},{"id":"84833440d7bb46d782f8d20dfc9f6acd","type":"GENE","name":"PIGW","canonical_id":"hgnc:HGNC:23213","description":"phosphatidylinositol glycan anchor biosynthesis class W","metadata":{"aliases":["Gwt1","FLJ37433","PIG-W"]}},{"id":"d0c7054338554392a1ea484a81d56c40","type":"GENE","name":"PIGX","canonical_id":"hgnc:HGNC:26046","description":"phosphatidylinositol glycan anchor biosynthesis class X","metadata":{"aliases":["FLJ20522","PIG-X"]}},{"id":"d571cb1adc7b422bb34598fee72f920c","type":"GENE","name":"PIGY","canonical_id":"hgnc:HGNC:28213","description":"phosphatidylinositol glycan anchor biosynthesis class Y","metadata":{"aliases":["MGC14156","PIG-Y"]}},{"id":"87cb39b5eb9342ef9604aaa16b958ec9","type":"GENE","name":"PIGY-DT","canonical_id":"hgnc:HGNC:54080","description":"PIGY divergent transcript","metadata":null},{"id":"12d9e0187c1b4e049de33802733a989e","type":"GENE","name":"PIGYP1","canonical_id":"hgnc:HGNC:58655","description":"PIGY pseudogene 1","metadata":null},{"id":"6ed7d5b07a094078895173a56487eb66","type":"GENE","name":"PIGZ","canonical_id":"hgnc:HGNC:30596","description":"phosphatidylinositol glycan anchor biosynthesis class Z (Gwada blood group)","metadata":{"aliases":["FLJ12768","MGC52163","SMP3","hSMP3","PIG-Z","GPI-MT-IV"]}},{"id":"4144082d7b9f48fabf44d653ad05b023","type":"GENE","name":"PIH1D1","canonical_id":"hgnc:HGNC:26075","description":"PIH1 domain containing 1","metadata":{"aliases":["FLJ20643","Pih1","MOT48","DNAAF14","NOP17"]}},{"id":"b5e10a3b59ed4ddeab192df79df3d7f9","type":"GENE","name":"PIH1D2","canonical_id":"hgnc:HGNC:25210","description":"PIH1 domain containing 2","metadata":{"aliases":["DNAAF15"]}},{"id":"50e113cd577b491b9897e3125dbefe2a","type":"GENE","name":"PIK3AP1","canonical_id":"hgnc:HGNC:30034","description":"phosphoinositide-3-kinase adaptor protein 1","metadata":{"aliases":["BCAP","FLJ35564"]}},{"id":"12d5935b2da84a279fd02a80667d0a73","type":"GENE","name":"PIK3C2A","canonical_id":"hgnc:HGNC:8971","description":"phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha","metadata":{"aliases":["PI3K-C2alpha"]}},{"id":"8a641510da0b4382bfb72a712d17998e","type":"GENE","name":"PIK3C2B","canonical_id":"hgnc:HGNC:8972","description":"phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta","metadata":{"aliases":["C2-PI3K","PI3K-C2beta"]}},{"id":"d61384b45b0949fda0fe8f10f0023739","type":"GENE","name":"PIK3C2G","canonical_id":"hgnc:HGNC:8973","description":"phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma","metadata":null},{"id":"f183e77a6f0c4634b915ca76a1f90187","type":"GENE","name":"PIK3C3","canonical_id":"hgnc:HGNC:8974","description":"phosphatidylinositol 3-kinase catalytic subunit type 3","metadata":{"aliases":["Vps34","hVps34"]}},{"id":"414ecee55a02481da78ef70e3486dd36","type":"GENE","name":"PIK3CA","canonical_id":"hgnc:HGNC:8975","description":null,"metadata":null},{"id":"3e3706a50d33439f812c691b37026538","type":"GENE","name":"PIK3CA","canonical_id":"ensembl:ENSG00000121879","description":null,"metadata":null},{"id":"1771fbb6460c49bdb16546cfe1173b7c","type":"PROTEIN","name":"PIK3CA","canonical_id":"uniprot:P42336","description":null,"metadata":null},{"id":"bf73e6009b4549f99d1a61231497a4d8","type":"BIOMARKER","name":"PIK3CA Amplification","canonical_id":"civic:212","description":null,"metadata":null},{"id":"a3765360e4ba48bbb40cf434751b42b1","type":"BIOMARKER","name":"PIK3CA C420R","canonical_id":"civic:905","description":null,"metadata":null},{"id":"f657a01c47bc4aee801281dcc1f791ab","type":"BIOMARKER","name":"PIK3CA C604R","canonical_id":"civic:3205","description":null,"metadata":null},{"id":"7a311aa749fd46cdbdba55ab147b6b8a","type":"BIOMARKER","name":"PIK3CA D350G","canonical_id":"civic:1561","description":null,"metadata":null},{"id":"f1206d27f1f94a598a6bac05060386ce","type":"BIOMARKER","name":"PIK3CA D350N","canonical_id":"civic:3206","description":null,"metadata":null},{"id":"93cf697802bc4608a48934e6763b67c5","type":"BIOMARKER","name":"PIK3CA E453K OR PIK3CA E453Q OR PIK3CA E453A OR PIK3CA E453D OR PIK3CA E453G OR PIK3CA E453V","canonical_id":"civic:5588","description":null,"metadata":null},{"id":"0ee4eb4dc4254e1faeb783ba40f7318f","type":"BIOMARKER","name":"PIK3CA E542K","canonical_id":"civic:103","description":null,"metadata":null},{"id":"98de959e604f48a8b3de9c7a5ce09b70","type":"BIOMARKER","name":"PIK3CA E542K OR PIK3CA E542Q OR PIK3CA E542A OR PIK3CA E542D OR PIK3CA E542G OR PIK3CA E542R OR PIK3CA E542V","canonical_id":"civic:5563","description":null,"metadata":null},{"id":"317a6516c43c4de9904634334977a86d","type":"BIOMARKER","name":"PIK3CA E542K OR PIK3CA E545K OR PIK3CA H1047R","canonical_id":"civic:5416","description":null,"metadata":null},{"id":"1b57625504b64713a2123f33c00a67ce","type":"BIOMARKER","name":"PIK3CA E545G","canonical_id":"civic:857","description":null,"metadata":null},{"id":"9e082f7311aa4ec4aabd6138832be725","type":"BIOMARKER","name":"PIK3CA E545K","canonical_id":"civic:104","description":null,"metadata":null},{"id":"0fb7b7447b9c40d88c919b9c5c86411e","type":"BIOMARKER","name":"PIK3CA E545K AND FGFR3 S249C AND FGFR3 N540K","canonical_id":"civic:5776","description":null,"metadata":null},{"id":"88b274525f8c4c51880d4fc0e1c106ae","type":"BIOMARKER","name":"PIK3CA E545K OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545D","canonical_id":"civic:5296","description":null,"metadata":null},{"id":"9e8eeac679a340049c6ba0c5d6c870b2","type":"BIOMARKER","name":"PIK3CA E545K OR PIK3CA E545Q OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545V OR PIK3CA E545D OR PIK3CA E545L OR PIK3CA E545R","canonical_id":"civic:5618","description":null,"metadata":null},{"id":"9cf7e1dd7e08478897c921120b82fe37","type":"BIOMARKER","name":"PIK3CA E545Q","canonical_id":"civic:855","description":null,"metadata":null},{"id":"17807db0b91f414a83a6253eb4ce2849","type":"BIOMARKER","name":"PIK3CA E81K","canonical_id":"civic:1408","description":null,"metadata":null},{"id":"d9b85e7f836e4b6e9fbaa6209065009f","type":"BIOMARKER","name":"PIK3CA Exon 10 Mutation","canonical_id":"civic:106","description":null,"metadata":null},{"id":"c0fe45bcf7b6433299d86d6a8a9e69e0","type":"BIOMARKER","name":"PIK3CA Exon 21 Mutation","canonical_id":"civic:105","description":null,"metadata":null},{"id":"398c0283d5e54b168f1231dd32a94d13","type":"BIOMARKER","name":"PIK3CA Exon 21 Mutation AND PIK3CA Exon 10 Mutation","canonical_id":"civic:5317","description":null,"metadata":null},{"id":"d54310c86b96402b8dd49935ff5a03a9","type":"BIOMARKER","name":"PIK3CA Exon 21 Mutation OR PIK3CA Exon 10 Mutation","canonical_id":"civic:5318","description":null,"metadata":null},{"id":"fb2cfb45bd784000905902f907b6d4f3","type":"BIOMARKER","name":"PIK3CA F930S","canonical_id":"civic:3535","description":null,"metadata":null},{"id":"03133dfc1dd44e87aa43644fe4533867","type":"BIOMARKER","name":"PIK3CA G1007R","canonical_id":"civic:3305","description":null,"metadata":null},{"id":"0598d948547f412e9944ad56f5c921ef","type":"BIOMARKER","name":"PIK3CA G1049R","canonical_id":"civic:914","description":null,"metadata":null},{"id":"765dfd76e47f444986efb65656843759","type":"BIOMARKER","name":"PIK3CA G1049S OR PIK3CA G1049R OR PIK3CA G106V OR PIK3CA G106R OR PIK3CA G1049A OR PIK3CA G106S OR PIK3CA G106A OR PIK3CA G106D OR PIK3CA G118D OR PIK3CA G1049C OR PIK3CA G1049D","canonical_id":"civic:5574","description":null,"metadata":null},{"id":"c29f7636de15430e82c4a9c5eac49117","type":"BIOMARKER","name":"PIK3CA H1047L","canonical_id":"civic:1125","description":null,"metadata":null},{"id":"dbea0fccc1124e719b59c15e2bfc98d1","type":"BIOMARKER","name":"PIK3CA H1047R","canonical_id":"civic:107","description":null,"metadata":null},{"id":"29aee4cea5c14d90b4b0265f5332e47a","type":"BIOMARKER","name":"PIK3CA H1047R OR PIK3CA H1047L","canonical_id":"civic:5319","description":null,"metadata":null},{"id":"37bb6019582441d281abb0dc3af3582b","type":"BIOMARKER","name":"PIK3CA H1047R OR PIK3CA H1047Y OR PIK3CA H1047L","canonical_id":"civic:5288","description":null,"metadata":null},{"id":"ed47a1ba1e0c48798cb77b08a3bcedfb","type":"BIOMARKER","name":"PIK3CA H1047R OR PIK3CA H1047Y OR PIK3CA H1047L OR PIK3CA H1047D OR PIK3CA H1047I OR PIK3CA H1047N OR PIK3CA H1047P OR PIK3CA H1047Q OR PIK3CA H1047T","canonical_id":"civic:5556","description":null,"metadata":null},{"id":"e5663bd7640c446abf51ec011a796227","type":"BIOMARKER","name":"PIK3CA I391M","canonical_id":"civic:1209","description":null,"metadata":null},{"id":"c98aa72f042f4af6ac476736976e7031","type":"BIOMARKER","name":"PIK3CA K111N","canonical_id":"civic:1208","description":null,"metadata":null},{"id":"50fb66d9244e4247b9ecfcc2825cdb97","type":"BIOMARKER","name":"PIK3CA K111N AND PTEN Underexpression","canonical_id":"civic:5813","description":null,"metadata":null},{"id":"f0ff64bf0d0f4cc6977bf1a09682b2ca","type":"BIOMARKER","name":"PIK3CA K944N","canonical_id":"civic:3534","description":null,"metadata":null},{"id":"a94cc950f8ad458ea3da2a3e95ab1f55","type":"BIOMARKER","name":"PIK3CA K966E","canonical_id":"civic:3537","description":null,"metadata":null},{"id":"2a4ceeac069c4386b61bb738b9238b26","type":"BIOMARKER","name":"PIK3CA L938*","canonical_id":"civic:3538","description":null,"metadata":null},{"id":"b36fae37bf694dce8f044b82516e1026","type":"BIOMARKER","name":"PIK3CA Mutation","canonical_id":"civic:307","description":null,"metadata":null},{"id":"61ff7f9e98434c01afb0e36f3f971c48","type":"BIOMARKER","name":"PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation","canonical_id":"civic:5065","description":null,"metadata":null},{"id":"4d28bca8f2e44005930ef37534e8e377","type":"BIOMARKER","name":"PIK3CA Mutation OR PTEN Mutation OR PIK3R1 Mutation","canonical_id":"civic:5627","description":null,"metadata":null},{"id":"91ae0e5fa1484d51b3bc314903692e9a","type":"BIOMARKER","name":"PIK3CA Mutation OR RB1 Mutation OR ESR1 Mutation","canonical_id":"civic:5149","description":null,"metadata":null},{"id":"a7bfec7b66b54fd59669530561a46983","type":"BIOMARKER","name":"PIK3CA N1044K","canonical_id":"civic:3306","description":null,"metadata":null},{"id":"70f352fd64e148dca51eba902b35113a","type":"BIOMARKER","name":"PIK3CA N345K","canonical_id":"civic:904","description":null,"metadata":null},{"id":"ac14737a71f04f04a1ae9c2bcae19a07","type":"BIOMARKER","name":"PIK3CA N345K OR PIK3CA N345D OR PIK3CA N345H OR PIK3CA N345I OR PIK3CA N345S OR PIK3CA N345T OR PIK3CA N345Y","canonical_id":"civic:5581","description":null,"metadata":null},{"id":"6cd7c731f7a0401e84e97431ff3f66a4","type":"BIOMARKER","name":"PIK3CA Overexpression","canonical_id":"civic:2235","description":null,"metadata":null},{"id":"b2a21c60661e4d9fb29069cace7a6771","type":"BIOMARKER","name":"PIK3CA P471L","canonical_id":"civic:290","description":null,"metadata":null},{"id":"1aef5623817046c889419dc256972082","type":"BIOMARKER","name":"PIK3CA Q546E OR PIK3CA Q546R","canonical_id":"civic:5299","description":null,"metadata":null},{"id":"dc60214806c8401a83751cb405bd1ec1","type":"BIOMARKER","name":"PIK3CA Q546K","canonical_id":"civic:859","description":null,"metadata":null},{"id":"b7eafa78c12c480bb18578b6538d4785","type":"BIOMARKER","name":"PIK3CA Q546K OR PIK3CA Q546E OR PIK3CA Q546P OR PIK3CA Q546R OR PIK3CA Q546L OR PIK3CA K111E OR PIK3CA K111N OR PIK3CA K111R OR PIK3CA Q546H","canonical_id":"civic:5567","description":null,"metadata":null},{"id":"6d22a2c7f7c9438aaf20cc5512d3b4a1","type":"BIOMARKER","name":"PIK3CA R88Q","canonical_id":"civic:903","description":null,"metadata":null},{"id":"64b54647daad4a2994de26497ac3c137","type":"BIOMARKER","name":"PIK3CA R88Q OR PIK3CA C420R OR PIK3CA M1043V OR PIK3CA M1043I OR PIK3CA M1043T","canonical_id":"civic:5583","description":null,"metadata":null},{"id":"88c9d2559e7844c1a93415c0ff605a64","type":"GENE","name":"PIK3CA-DT","canonical_id":"hgnc:HGNC:52932","description":"PIK3CA divergent transcript","metadata":null},{"id":"b44a2f4d75d544a69e9c91b95a62120c","type":"GENE","name":"PIK3CB","canonical_id":"hgnc:HGNC:8976","description":"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta","metadata":{"aliases":["PIK3C1"]}},{"id":"7a517933685f4bb18372cde9a53829cf","type":"GENE","name":"PIK3CD","canonical_id":"hgnc:HGNC:8977","description":null,"metadata":null},{"id":"bdea4f5a81e2451c984b934c19e3abf7","type":"PROTEIN","name":"PIK3CD","canonical_id":"uniprot:O00329","description":null,"metadata":null},{"id":"9cca3ce5e0c5435e8eb76d93f7db3088","type":"GENE","name":"PIK3CD-AS1","canonical_id":"hgnc:HGNC:32346","description":"PIK3CD antisense RNA 1","metadata":{"aliases":["C1orf200"]}},{"id":"c1ab593bb6aa4b7088b0250d97a2f12b","type":"GENE","name":"PIK3CD-AS2","canonical_id":"hgnc:HGNC:51334","description":"PIK3CD antisense RNA 2","metadata":null},{"id":"2d7f17edbad7499c9f36971fdab148ad","type":"GENE","name":"PIK3CDP1","canonical_id":"hgnc:HGNC:52629","description":"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta pseudogene 1","metadata":null},{"id":"0010e17d74484bb9ad360e7b55862d43","type":"GENE","name":"PIK3CG","canonical_id":"hgnc:HGNC:8978","description":"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma","metadata":null},{"id":"5ed17432f2fc4a80b838e6ab6b853516","type":"GENE","name":"PIK3IP1","canonical_id":"hgnc:HGNC:24942","description":"phosphoinositide-3-kinase interacting protein 1","metadata":{"aliases":["HGFL","MGC17330","TrIP"]}},{"id":"f6033eab459d4b049f74ee6e022d820b","type":"GENE","name":"PIK3IP1-DT","canonical_id":"hgnc:HGNC:41072","description":"PIK3IP1 divergent transcript","metadata":{"aliases":["PIK3IP1-AS1"]}},{"id":"e605a7ddd20f42979f8f0bc3c50d4622","type":"GENE","name":"PIK3R1","canonical_id":"hgnc:HGNC:8979","description":"phosphoinositide-3-kinase regulatory subunit 1","metadata":{"aliases":["GRB1","p85-ALPHA","p85","p85alpha"]}},{"id":"c619f66d3f7e4031a10cd85b3c89b93c","type":"PROTEIN","name":"PIK3R1","canonical_id":"uniprot:P27986","description":null,"metadata":null},{"id":"f9158f6c18da4d42b166362f33799286","type":"GENE","name":"PIK3R2","canonical_id":"hgnc:HGNC:8980","description":"phosphoinositide-3-kinase regulatory subunit 2","metadata":{"aliases":["P85B","p85","p85beta","p85-BETA"]}},{"id":"ec36544bbe7f4c8db112af1ec9f1cc3e","type":"GENE","name":"PIK3R3","canonical_id":"hgnc:HGNC:8981","description":null,"metadata":null},{"id":"c1057504116f497a8e31a6b4c4b3ed49","type":"GENE","name":"PIK3R4","canonical_id":"hgnc:HGNC:8982","description":"phosphoinositide-3-kinase regulatory subunit 4","metadata":{"aliases":["VPS15","p150"]}},{"id":"896ae13c2bd346ce87ea690f716a921e","type":"GENE","name":"PIK3R5","canonical_id":"hgnc:HGNC:30035","description":"phosphoinositide-3-kinase regulatory subunit 5","metadata":{"aliases":["P101-PI3K","p101"]}},{"id":"027187f774c945568d3dc629adfecfe4","type":"GENE","name":"PIK3R5-DT","canonical_id":"hgnc:HGNC:55321","description":"PIK3R5 divergent transcript","metadata":null},{"id":"1f398410425c4bff8e360b0bd9078405","type":"GENE","name":"PIK3R6","canonical_id":"hgnc:HGNC:27101","description":"phosphoinositide-3-kinase regulatory subunit 6","metadata":{"aliases":["FLJ34500","HsT41028","p87PIKAP","C17orf38"]}},{"id":"9f72df760c2f4ae69cdffef9a880d257","type":"GENE","name":"PIKFYVE","canonical_id":"hgnc:HGNC:23785","description":"phosphoinositide kinase, FYVE-type zinc finger containing","metadata":{"aliases":["MGC40423","KIAA0981","PIP5K","p235","ZFYVE29","FAB1","PIP5K3"]}},{"id":"761abe1824f14b1cbf05501eb56cfa1c","type":"GENE","name":"PILRA","canonical_id":"hgnc:HGNC:20396","description":"paired immunoglobin like type 2 receptor alpha","metadata":{"aliases":["FDF03"]}},{"id":"4dbe923b94d04b8e8ac5dffd19f03077","type":"GENE","name":"PILRB","canonical_id":"hgnc:HGNC:18297","description":"paired immunoglobin like type 2 receptor beta","metadata":{"aliases":["FDFACT1","FDFACT2"]}},{"id":"23de3045c46d4407a40a819369f116db","type":"GENE","name":"PIM1","canonical_id":"hgnc:HGNC:8986","description":null,"metadata":null},{"id":"7bd70f5d3ecb4bc1b1e07f95ceed12fe","type":"GENE","name":"PIM2","canonical_id":"hgnc:HGNC:8987","description":"Pim-2 proto-oncogene, serine/threonine kinase","metadata":null},{"id":"572c56b7c86d438e85f5c7317696055a","type":"GENE","name":"PIM3","canonical_id":"hgnc:HGNC:19310","description":"Pim-3 proto-oncogene, serine/threonine kinase","metadata":null},{"id":"d6b4a78f95d8445bb5c2340cc210f5d1","type":"GENE","name":"PIMREG","canonical_id":"hgnc:HGNC:25483","description":"PICALM interacting mitotic regulator","metadata":{"aliases":["FLJ10156","FLJ10491","CATS","RCS1","FAM64A"]}},{"id":"f8a6cf831d674ba69fa35b7881ea6789","type":"GENE","name":"PIMREGP1","canonical_id":"hgnc:HGNC:54612","description":"PIMREG pseudogene 1","metadata":null},{"id":"f097836f613b4001a169ac13d0762858","type":"GENE","name":"PIMREGP2","canonical_id":"hgnc:HGNC:54613","description":"PIMREG pseudogene 2","metadata":null},{"id":"24f1535f831c4c13b276f0595a3ae679","type":"GENE","name":"PIMREGP3","canonical_id":"hgnc:HGNC:54614","description":"PIMREG pseudogene 3","metadata":null},{"id":"d171f1db930945f993b9bb91096bd757","type":"GENE","name":"PIMREGP4","canonical_id":"hgnc:HGNC:54615","description":"PIMREG pseudogene 4","metadata":null},{"id":"1551ed4b5f0d44109522df2b36590078","type":"GENE","name":"PIN1","canonical_id":"hgnc:HGNC:8988","description":null,"metadata":null},{"id":"467eee1a4f984251914c8824bf176ba8","type":"GENE","name":"PIN1-DT","canonical_id":"hgnc:HGNC:55303","description":"PIN1 divergent transcript","metadata":null},{"id":"aa8b25375bbd4b6f9607ab89d991e674","type":"GENE","name":"PIN1P1","canonical_id":"hgnc:HGNC:8989","description":"peptidylprolyl cis/trans isomerase, NIMA-interacting 1 pseudogene 1","metadata":{"aliases":["PIN1L"]}},{"id":"6d12bd2d17d9401f94f7e752b2c29ef0","type":"GENE","name":"PIN4","canonical_id":"hgnc:HGNC:8992","description":"peptidylprolyl cis/trans isomerase, NIMA-interacting 4","metadata":{"aliases":["PAR14","PAR17","EPVH"]}},{"id":"adb88d1327ae4f84b5316d8899d5af8c","type":"GENE","name":"PIN4P1","canonical_id":"hgnc:HGNC:44193","description":"peptidylprolyl cis/trans isomerase, NIMA-interacting 4 pseudogene 1","metadata":null},{"id":"38bcad89d6864b7f9474cb4d93f8bc06","type":"GENE","name":"PINCR","canonical_id":"hgnc:HGNC:53590","description":"p53-induced noncoding RNA","metadata":{"aliases":["RP3-326I13.1"]}},{"id":"3bff80ef71974702876821edcfdb5d90","type":"TRIAL","name":"PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)","canonical_id":"clinicaltrials.gov:NCT01018602","description":"Insulin-dependent Gestational Diabetes","metadata":null},{"id":"a48782bfca7043a5b2f8c807c5939c2b","type":"GENE","name":"PINK1","canonical_id":"hgnc:HGNC:14581","description":"PTEN induced kinase 1","metadata":{"aliases":["BRPK","PARK6"]}},{"id":"3a4033287f3e4db69b7949e16696788e","type":"GENE","name":"PINK1-AS","canonical_id":"hgnc:HGNC:38872","description":"PINK1 antisense RNA","metadata":{"aliases":["FLJ00387","PINK1AS","naPINK1","PINK1-AS1"]}},{"id":"40aaef671cdf4e9f96082fff32b5490e","type":"GENE","name":"PINLYP","canonical_id":"hgnc:HGNC:44206","description":"phospholipase A2 inhibitor and LY6/PLAUR domain containing","metadata":null},{"id":"11e946ffe6344d18ac2f3a1fc3809aa3","type":"GENE","name":"PINX1","canonical_id":"hgnc:HGNC:30046","description":"PIN2 (TERF1) interacting telomerase inhibitor 1","metadata":{"aliases":["LPTL","LPTS","FLJ20565","MGC8850","Gno1","Pxr1"]}},{"id":"aea6d7b21ea549c5bee3c668274bab0a","type":"GENE","name":"PINX1-DT","canonical_id":"hgnc:HGNC:55532","description":"PINX1 divergent transcript","metadata":null},{"id":"9ddd52d87880479f9b4a2c47776cf66e","type":"GENE","name":"PIP","canonical_id":"hgnc:HGNC:8993","description":null,"metadata":null},{"id":"a85ff38435da478985617fb30e6ad082","type":"GENE","name":"PIP4K2A","canonical_id":"hgnc:HGNC:8997","description":"phosphatidylinositol-5-phosphate 4-kinase type 2 alpha","metadata":{"aliases":["PIP5KIIA","PIP5KIIalpha","PIP5K2A"]}},{"id":"1a9f1305d4d74d37b3856201b4b7a471","type":"GENE","name":"PIP4K2B","canonical_id":"hgnc:HGNC:8998","description":"phosphatidylinositol-5-phosphate 4-kinase type 2 beta","metadata":{"aliases":["PIP5KIIB","PIP5KIIbeta","PIP5K2B"]}},{"id":"f1a0d497510947b1a4faffb660075860","type":"GENE","name":"PIP4K2C","canonical_id":"hgnc:HGNC:23786","description":"phosphatidylinositol-5-phosphate 4-kinase type 2 gamma","metadata":{"aliases":["FLJ22055","PIP5K2C"]}},{"id":"2760e6aa9ab44aeb85cbe615d973432e","type":"GENE","name":"PIP4P1","canonical_id":"hgnc:HGNC:19299","description":"phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1","metadata":{"aliases":["MGC26684","C14orf9","TMEM55B"]}},{"id":"6d27fb33dd484ef4aeb7062d4418de54","type":"GENE","name":"PIP4P2","canonical_id":"hgnc:HGNC:25452","description":"phosphatidylinositol-4,5-bisphosphate 4-phosphatase 2","metadata":{"aliases":["DKFZp762O076","TMEM55A"]}},{"id":"f0cbc63f50dd4b6da5a81bcdb134f989","type":"GENE","name":"PIP5K1A","canonical_id":"hgnc:HGNC:8994","description":"phosphatidylinositol-4-phosphate 5-kinase type 1 alpha","metadata":null},{"id":"c523e25d6b63456ea9f03512dbc05e0f","type":"GENE","name":"PIP5K1B","canonical_id":"hgnc:HGNC:8995","description":"phosphatidylinositol-4-phosphate 5-kinase type 1 beta","metadata":{"aliases":["STM7","MSS4"]}},{"id":"cc7efde51f12479db4ec503b60e24e4b","type":"GENE","name":"PIP5K1C","canonical_id":"hgnc:HGNC:8996","description":null,"metadata":null},{"id":"97d15ea54c50429ca14f92c7278f221f","type":"GENE","name":"PIP5K1P1","canonical_id":"hgnc:HGNC:28372","description":"phosphatidylinositol-4-phosphate 5-kinase type 1 pseudogene 1","metadata":{"aliases":["MGC26597"]}},{"id":"a8f5f512fe674f19841af9ca4713851d","type":"GENE","name":"PIP5K1P2","canonical_id":"hgnc:HGNC:38068","description":"phosphatidylinositol-4-phosphate 5-kinase type 1 pseudogene 2","metadata":null},{"id":"d2a250f6efb1458f8c867276d653584f","type":"GENE","name":"PIP5KL1","canonical_id":"hgnc:HGNC:28711","description":"phosphatidylinositol-4-phosphate 5-kinase like 1","metadata":{"aliases":["bA203J24.5","MGC46424","PIPKH"]}},{"id":"15eaaeac457f4516bae8dd906e8a5aff","type":"TRIAL","name":"PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib","canonical_id":"clinicaltrials.gov:NCT02389842","description":"Advanced Solid Tumours; Breast Cancer","metadata":null},{"id":"26a605f5f5154399abfdaf21c5561add","type":"GENE","name":"PIPOX","canonical_id":"hgnc:HGNC:17804","description":"pipecolic acid and sarcosine oxidase","metadata":{"aliases":["LPIPOX"]}},{"id":"4d33e493928749c683a10cbdf0d48442","type":"GENE","name":"PIPSL","canonical_id":"hgnc:HGNC:23733","description":"PIP5K1A and PSMD4 like (pseudogene)","metadata":{"aliases":["PIP5K1A-PSMD4","PIP5K1P3","PSMD4P2","PIP5K1L1"]}},{"id":"157de74d669c4ce095484fcbf13f81d1","type":"GENE","name":"PIR","canonical_id":"hgnc:HGNC:30048","description":null,"metadata":null},{"id":"f7069260a8364dd0a15a7befee1218b3","type":"GENE","name":"PIRAT1","canonical_id":"hgnc:HGNC:37459","description":"PU.1 (SPI1) induced regulator of S100A8 and S100A9 alarmin transcription 1","metadata":{"aliases":["PIRAT","NCRNA00211","LINC00211"]}},{"id":"3b894d99048148efa5ec9eb389cf3383","type":"GENE","name":"PIRC1","canonical_id":"hgnc:HGNC:37505","description":"piwi-interacting RNA cluster 1","metadata":null},{"id":"f7ae2883abee4c9ab3461acc0d34ee87","type":"GENE","name":"PIRC10","canonical_id":"hgnc:HGNC:37514","description":"piwi-interacting RNA cluster 10","metadata":null},{"id":"cf051449858d4bc68c13b6774e09a791","type":"GENE","name":"PIRC100","canonical_id":"hgnc:HGNC:37604","description":"piwi-interacting RNA cluster 100","metadata":null},{"id":"b7149f6bec61403fbad73cbacc32aad5","type":"GENE","name":"PIRC101","canonical_id":"hgnc:HGNC:37605","description":"piwi-interacting RNA cluster 101","metadata":null},{"id":"ff429f4d5a914a05a2a89b582851da69","type":"GENE","name":"PIRC102","canonical_id":"hgnc:HGNC:37606","description":"piwi-interacting RNA cluster 102","metadata":null},{"id":"965e2dfa5f29436e9c61a6f1e0e2c9be","type":"GENE","name":"PIRC103","canonical_id":"hgnc:HGNC:37607","description":"piwi-interacting RNA cluster 103","metadata":null},{"id":"cc512c7ca4714ee6bc7715b33795caad","type":"GENE","name":"PIRC104","canonical_id":"hgnc:HGNC:37608","description":"piwi-interacting RNA cluster 104","metadata":null},{"id":"0c7b64e5a26e476896bd3938a2612a52","type":"GENE","name":"PIRC105","canonical_id":"hgnc:HGNC:37609","description":"piwi-interacting RNA cluster 105","metadata":null},{"id":"12ab1acd0ace46cb89261922558deab3","type":"GENE","name":"PIRC106","canonical_id":"hgnc:HGNC:37610","description":"piwi-interacting RNA cluster 106","metadata":null},{"id":"9edfb97a03504bfabfa33c12b731bf47","type":"GENE","name":"PIRC107","canonical_id":"hgnc:HGNC:37611","description":"piwi-interacting RNA cluster 107","metadata":null},{"id":"63af024046bf45baa95e5829fdbf879c","type":"GENE","name":"PIRC108","canonical_id":"hgnc:HGNC:37612","description":"piwi-interacting RNA cluster 108","metadata":null},{"id":"f2df35ba894446719c4b2f646b3f5a8f","type":"GENE","name":"PIRC109","canonical_id":"hgnc:HGNC:37613","description":"piwi-interacting RNA cluster 109","metadata":null},{"id":"dfa1446d6f6d4f79a3127756bf18e8c2","type":"GENE","name":"PIRC11","canonical_id":"hgnc:HGNC:37515","description":"piwi-interacting RNA cluster 11","metadata":null},{"id":"99b201e59de848e3ad6d01a2ad09b150","type":"GENE","name":"PIRC110","canonical_id":"hgnc:HGNC:37614","description":"piwi-interacting RNA cluster 110","metadata":null},{"id":"f1be95e76e3f428696b273863af0e8fa","type":"GENE","name":"PIRC111","canonical_id":"hgnc:HGNC:37615","description":"piwi-interacting RNA cluster 111","metadata":null},{"id":"9019b0def92c4f5ea86fec6635b07640","type":"GENE","name":"PIRC112","canonical_id":"hgnc:HGNC:37616","description":"piwi-interacting RNA cluster 112","metadata":null},{"id":"bbb0bfbd16b8401f9d9c92da4ce38cb5","type":"GENE","name":"PIRC113","canonical_id":"hgnc:HGNC:37617","description":"piwi-interacting RNA cluster 113","metadata":null},{"id":"983b7d4b9ccf46bc959b75f771497b25","type":"GENE","name":"PIRC114","canonical_id":"hgnc:HGNC:37618","description":"piwi-interacting RNA cluster 114","metadata":null},{"id":"c97d57def05c4f9e9f4c0e65400bfec2","type":"GENE","name":"PIRC12","canonical_id":"hgnc:HGNC:37516","description":"piwi-interacting RNA cluster 12","metadata":null},{"id":"2cf6825acb2746368ea7bbee63d64fc7","type":"GENE","name":"PIRC13","canonical_id":"hgnc:HGNC:37517","description":"piwi-interacting RNA cluster 13","metadata":null},{"id":"c8fda2aee4c4448a966433e579894e46","type":"GENE","name":"PIRC14","canonical_id":"hgnc:HGNC:37518","description":"piwi-interacting RNA cluster 14","metadata":null},{"id":"5d9f37918ed1441aa781606b99b5eb74","type":"GENE","name":"PIRC15","canonical_id":"hgnc:HGNC:37519","description":"piwi-interacting RNA cluster 15","metadata":null},{"id":"176d9caad9404bd79b26b5fc71b41951","type":"GENE","name":"PIRC16","canonical_id":"hgnc:HGNC:37520","description":"piwi-interacting RNA cluster 16","metadata":null},{"id":"25590ccfb12547b48c603b726b5c893e","type":"GENE","name":"PIRC17","canonical_id":"hgnc:HGNC:37521","description":"piwi-interacting RNA cluster 17","metadata":null},{"id":"b895ccb81eb74a1a9cbc8eb0ef8243a5","type":"GENE","name":"PIRC18","canonical_id":"hgnc:HGNC:37522","description":"piwi-interacting RNA cluster 18","metadata":null},{"id":"b3db6489708245d7a51fdac1579e02ca","type":"GENE","name":"PIRC19","canonical_id":"hgnc:HGNC:37523","description":"piwi-interacting RNA cluster 19","metadata":null},{"id":"43f105b90de945b2aced0e244b80ef3e","type":"GENE","name":"PIRC2","canonical_id":"hgnc:HGNC:37506","description":"piwi-interacting RNA cluster 2","metadata":null},{"id":"4a671c3f1e8d493d9721cd76a4ccbf2d","type":"GENE","name":"PIRC20","canonical_id":"hgnc:HGNC:37524","description":"piwi-interacting RNA cluster 20","metadata":null},{"id":"504ee5d5bfcd436aba40e17ddb199c7f","type":"GENE","name":"PIRC21","canonical_id":"hgnc:HGNC:37525","description":"piwi-interacting RNA cluster 21","metadata":null},{"id":"acafe6a953a948bdab6eefed5c0b793c","type":"GENE","name":"PIRC22","canonical_id":"hgnc:HGNC:37526","description":"piwi-interacting RNA cluster 22","metadata":null},{"id":"11d5efab5aa34fd48c4ecd16424d5567","type":"GENE","name":"PIRC23","canonical_id":"hgnc:HGNC:37527","description":"piwi-interacting RNA cluster 23","metadata":null},{"id":"e7f822436e76406293f3099c196ac370","type":"GENE","name":"PIRC24","canonical_id":"hgnc:HGNC:37528","description":"piwi-interacting RNA cluster 24","metadata":null},{"id":"72b453af621042849f336bdc93307aa5","type":"GENE","name":"PIRC25","canonical_id":"hgnc:HGNC:37529","description":"piwi-interacting RNA cluster 25","metadata":null},{"id":"b3a3de1b6b78475e8738d5096ad3987b","type":"GENE","name":"PIRC26","canonical_id":"hgnc:HGNC:37530","description":"piwi-interacting RNA cluster 26","metadata":null},{"id":"519354ae46074c608929a3fa71938d1a","type":"GENE","name":"PIRC27","canonical_id":"hgnc:HGNC:37531","description":"piwi-interacting RNA cluster 27","metadata":null},{"id":"b29d4709c53d4f138ef869d5dde6c628","type":"GENE","name":"PIRC28","canonical_id":"hgnc:HGNC:37532","description":"piwi-interacting RNA cluster 28","metadata":null},{"id":"110adff316764dfca0fe8ac0eb5a94e7","type":"GENE","name":"PIRC29","canonical_id":"hgnc:HGNC:37533","description":"piwi-interacting RNA cluster 29","metadata":null},{"id":"1cd8df8956ac4d5f9eb9aaf4f9b1fce1","type":"GENE","name":"PIRC3","canonical_id":"hgnc:HGNC:37507","description":"piwi-interacting RNA cluster 3","metadata":null},{"id":"f21ad3e0970e4d4c99fa67f4b47bd484","type":"GENE","name":"PIRC30","canonical_id":"hgnc:HGNC:37534","description":"piwi-interacting RNA cluster 30","metadata":null},{"id":"ae5a6291175445dab9eab36ff58a5cde","type":"GENE","name":"PIRC31","canonical_id":"hgnc:HGNC:37535","description":"piwi-interacting RNA cluster 31","metadata":null},{"id":"06825ef1144b46e995c531cca0de68b8","type":"GENE","name":"PIRC32","canonical_id":"hgnc:HGNC:37536","description":"piwi-interacting RNA cluster 32","metadata":null},{"id":"bc6c25f676fd43e0bd69e84ee6687802","type":"GENE","name":"PIRC33","canonical_id":"hgnc:HGNC:37537","description":"piwi-interacting RNA cluster 33","metadata":null},{"id":"4edd9684d2764187acc3d1d9eb9d8043","type":"GENE","name":"PIRC34","canonical_id":"hgnc:HGNC:37538","description":"piwi-interacting RNA cluster 34","metadata":null},{"id":"0485860876694351abf6eeda13e5f370","type":"GENE","name":"PIRC35","canonical_id":"hgnc:HGNC:37539","description":"piwi-interacting RNA cluster 35","metadata":null},{"id":"f093c22a348448ca9b9da6e7be358fdb","type":"GENE","name":"PIRC36","canonical_id":"hgnc:HGNC:37540","description":"piwi-interacting RNA cluster 36","metadata":null},{"id":"a49ca5dbd95c47b097678ccf5af16164","type":"GENE","name":"PIRC37","canonical_id":"hgnc:HGNC:37541","description":"piwi-interacting RNA cluster 37","metadata":null},{"id":"9a49b7dc366c4c66bb89ae6cd22660c4","type":"GENE","name":"PIRC38","canonical_id":"hgnc:HGNC:37542","description":"piwi-interacting RNA cluster 38","metadata":null},{"id":"82c3b95741fc455c802575027f7c4a61","type":"GENE","name":"PIRC39","canonical_id":"hgnc:HGNC:37543","description":"piwi-interacting RNA cluster 39","metadata":null},{"id":"a6cceda8f9464911860b04dda18cf8d9","type":"GENE","name":"PIRC4","canonical_id":"hgnc:HGNC:37508","description":"piwi-interacting RNA cluster 4","metadata":null},{"id":"d167c32672c04fac950cb96e92a097dc","type":"GENE","name":"PIRC40","canonical_id":"hgnc:HGNC:37544","description":"piwi-interacting RNA cluster 40","metadata":null},{"id":"875aedab16374187bda95bf4c21962e0","type":"GENE","name":"PIRC41","canonical_id":"hgnc:HGNC:37545","description":"piwi-interacting RNA cluster 41","metadata":null},{"id":"16d9da2430c64337bd41afc18dcd2c58","type":"GENE","name":"PIRC42","canonical_id":"hgnc:HGNC:37546","description":"piwi-interacting RNA cluster 42","metadata":null},{"id":"c88aaf5cd8234651945d32e8f5cb3452","type":"GENE","name":"PIRC43","canonical_id":"hgnc:HGNC:37547","description":"piwi-interacting RNA cluster 43","metadata":null},{"id":"db7554d69ab7415bb4c4ab4eabec50bb","type":"GENE","name":"PIRC44","canonical_id":"hgnc:HGNC:37548","description":"piwi-interacting RNA cluster 44","metadata":null},{"id":"edbb60af8cb548b6b91f927a2e71f53c","type":"GENE","name":"PIRC45","canonical_id":"hgnc:HGNC:37549","description":"piwi-interacting RNA cluster 45","metadata":null},{"id":"ebd198b276394b20a8440df61de6201e","type":"GENE","name":"PIRC46","canonical_id":"hgnc:HGNC:37550","description":"piwi-interacting RNA cluster 46","metadata":null},{"id":"0482d18f2ba74d2fb6483698a1f32b18","type":"GENE","name":"PIRC47","canonical_id":"hgnc:HGNC:37551","description":"piwi-interacting RNA cluster 47","metadata":null},{"id":"48a15aaa945e4c0ca5e357d731a4e7c8","type":"GENE","name":"PIRC48","canonical_id":"hgnc:HGNC:37552","description":"piwi-interacting RNA cluster 48","metadata":null},{"id":"e0d0268775e3410ba56be613e0d782a4","type":"GENE","name":"PIRC49","canonical_id":"hgnc:HGNC:37553","description":"piwi-interacting RNA cluster 49","metadata":null},{"id":"6004548b0db44bd9bab89868b8abd61d","type":"GENE","name":"PIRC5","canonical_id":"hgnc:HGNC:37509","description":"piwi-interacting RNA cluster 5","metadata":null},{"id":"f0016de08bf94c9386ceb628a399e203","type":"GENE","name":"PIRC50","canonical_id":"hgnc:HGNC:37554","description":"piwi-interacting RNA cluster 50","metadata":null},{"id":"a12ee5ce6f904ef08d6340b8e3d81892","type":"GENE","name":"PIRC51","canonical_id":"hgnc:HGNC:37555","description":"piwi-interacting RNA cluster 51","metadata":null},{"id":"2fdaa7020acc4c4da27ddfb28ad13c2d","type":"GENE","name":"PIRC52","canonical_id":"hgnc:HGNC:37556","description":"piwi-interacting RNA cluster 52","metadata":null},{"id":"130b9690d98542fe857aba3620068dbb","type":"GENE","name":"PIRC53","canonical_id":"hgnc:HGNC:37557","description":"piwi-interacting RNA cluster 53","metadata":null},{"id":"2d4519d779af4095b2ea97e1d434ca70","type":"GENE","name":"PIRC54","canonical_id":"hgnc:HGNC:37558","description":"piwi-interacting RNA cluster 54","metadata":null},{"id":"621acf59d8d84f3492c4b9087c4a25eb","type":"GENE","name":"PIRC55","canonical_id":"hgnc:HGNC:37559","description":"piwi-interacting RNA cluster 55","metadata":null},{"id":"7cca00e5f82542b4afa0f16426e7121d","type":"GENE","name":"PIRC56","canonical_id":"hgnc:HGNC:37560","description":"piwi-interacting RNA cluster 56","metadata":null},{"id":"812d2cdb6a6c4478a4293a85732fc411","type":"GENE","name":"PIRC57","canonical_id":"hgnc:HGNC:37561","description":"piwi-interacting RNA cluster 57","metadata":null},{"id":"7b93205c0d3148f588aae771fa6b30a4","type":"GENE","name":"PIRC58","canonical_id":"hgnc:HGNC:37562","description":"piwi-interacting RNA cluster 58","metadata":null},{"id":"d361f33ead16429394aca8b906dc37df","type":"GENE","name":"PIRC59","canonical_id":"hgnc:HGNC:37563","description":"piwi-interacting RNA cluster 59","metadata":null},{"id":"14db52edd8f24ade87666a72d3131a5a","type":"GENE","name":"PIRC6","canonical_id":"hgnc:HGNC:37510","description":"piwi-interacting RNA cluster 6","metadata":null},{"id":"eb51de39abc6415291404c1e32ca8024","type":"GENE","name":"PIRC60","canonical_id":"hgnc:HGNC:37564","description":"piwi-interacting RNA cluster 60","metadata":null},{"id":"d7821605590f498ab110cc35b869b552","type":"GENE","name":"PIRC61","canonical_id":"hgnc:HGNC:37565","description":"piwi-interacting RNA cluster 61","metadata":null},{"id":"afdf092b3edf4ff5aa6ea0147874e1d4","type":"GENE","name":"PIRC62","canonical_id":"hgnc:HGNC:37566","description":"piwi-interacting RNA cluster 62","metadata":null},{"id":"890c9fed7e934f9ba72c2f17ab9f58d9","type":"GENE","name":"PIRC63","canonical_id":"hgnc:HGNC:37567","description":"piwi-interacting RNA cluster 63","metadata":null},{"id":"9aad2b5d0a9e41cf889e773abc3bec0b","type":"GENE","name":"PIRC64","canonical_id":"hgnc:HGNC:37568","description":"piwi-interacting RNA cluster 64","metadata":null},{"id":"59181fc724994a31adcf8ccae90c613c","type":"GENE","name":"PIRC65","canonical_id":"hgnc:HGNC:37569","description":"piwi-interacting RNA cluster 65","metadata":null},{"id":"171daccfe22047038e3d8b599d7da52d","type":"GENE","name":"PIRC66","canonical_id":"hgnc:HGNC:37570","description":"piwi-interacting RNA cluster 66","metadata":null},{"id":"0acf32a13aaf4166936f298b943ba6fb","type":"GENE","name":"PIRC67","canonical_id":"hgnc:HGNC:37571","description":"piwi-interacting RNA cluster 67","metadata":null},{"id":"047c548919e646b3811799d18f957b5f","type":"GENE","name":"PIRC68","canonical_id":"hgnc:HGNC:37572","description":"piwi-interacting RNA cluster 68","metadata":null},{"id":"e26896ac754446138210e35ad6376852","type":"GENE","name":"PIRC69","canonical_id":"hgnc:HGNC:37573","description":"piwi-interacting RNA cluster 69","metadata":null},{"id":"e8520fbd00d342fe8f8f15b87e1ca8a3","type":"GENE","name":"PIRC7","canonical_id":"hgnc:HGNC:37511","description":"piwi-interacting RNA cluster 7","metadata":null},{"id":"062dd5c2e1ed4129a63d9e0caa4d80c4","type":"GENE","name":"PIRC70","canonical_id":"hgnc:HGNC:37574","description":"piwi-interacting RNA cluster 70","metadata":null},{"id":"286614c3df3f4ad4bcc15247995d90ea","type":"GENE","name":"PIRC71","canonical_id":"hgnc:HGNC:37575","description":"piwi-interacting RNA cluster 71","metadata":null},{"id":"0e5ac98e67514d3e845152062f9bf4fa","type":"GENE","name":"PIRC72","canonical_id":"hgnc:HGNC:37576","description":"piwi-interacting RNA cluster 72","metadata":null},{"id":"a88f08bb22974ef0bf49d809eb229085","type":"GENE","name":"PIRC73","canonical_id":"hgnc:HGNC:37577","description":"piwi-interacting RNA cluster 73","metadata":null},{"id":"4e4a95762f834ebaa1cd4f74b9f1b398","type":"GENE","name":"PIRC74","canonical_id":"hgnc:HGNC:37578","description":"piwi-interacting RNA cluster 74","metadata":null},{"id":"38f4b15e9c5a47d5b50c13b58da81f19","type":"GENE","name":"PIRC75","canonical_id":"hgnc:HGNC:37579","description":"piwi-interacting RNA cluster 75","metadata":null},{"id":"84c824e49f474f7ea72fc046a374ebd5","type":"GENE","name":"PIRC76","canonical_id":"hgnc:HGNC:37580","description":"piwi-interacting RNA cluster 76","metadata":null},{"id":"f0f249d1c6f04f459250c9436f09e0db","type":"GENE","name":"PIRC77","canonical_id":"hgnc:HGNC:37581","description":"piwi-interacting RNA cluster 77","metadata":null},{"id":"e4c6461193aa44b5b3cc5b23f3de37c8","type":"GENE","name":"PIRC78","canonical_id":"hgnc:HGNC:37582","description":"piwi-interacting RNA cluster 78","metadata":null},{"id":"c66057b274e54059b8c546d82d3d6258","type":"GENE","name":"PIRC79","canonical_id":"hgnc:HGNC:37583","description":"piwi-interacting RNA cluster 79","metadata":null},{"id":"de433880a05548b5833947c13d47a612","type":"GENE","name":"PIRC8","canonical_id":"hgnc:HGNC:37512","description":"piwi-interacting RNA cluster 8","metadata":null},{"id":"f55924751dd148a8bcf59b95dcc808ad","type":"GENE","name":"PIRC80","canonical_id":"hgnc:HGNC:37584","description":"piwi-interacting RNA cluster 80","metadata":null},{"id":"45113ccd430b42fcaba7c6426af8a27e","type":"GENE","name":"PIRC81","canonical_id":"hgnc:HGNC:37585","description":"piwi-interacting RNA cluster 81","metadata":null},{"id":"2e430b27d781428e95b72efb57c87f3b","type":"GENE","name":"PIRC82","canonical_id":"hgnc:HGNC:37586","description":"piwi-interacting RNA cluster 82","metadata":null},{"id":"713ae3fafed14eb8bf4917f95346af4a","type":"GENE","name":"PIRC83","canonical_id":"hgnc:HGNC:37587","description":"piwi-interacting RNA cluster 83","metadata":null},{"id":"a18e060f3ebc48b8940a714260919283","type":"GENE","name":"PIRC84","canonical_id":"hgnc:HGNC:37588","description":"piwi-interacting RNA cluster 84","metadata":null},{"id":"f8220f30de714bf0a6afd94772ebab49","type":"GENE","name":"PIRC85","canonical_id":"hgnc:HGNC:37589","description":"piwi-interacting RNA cluster 85","metadata":null},{"id":"48ae6c4b483a440ea218a3f47e659ab5","type":"GENE","name":"PIRC86","canonical_id":"hgnc:HGNC:37590","description":"piwi-interacting RNA cluster 86","metadata":null},{"id":"6e65960603d44aca829616c1ff6d6ddd","type":"GENE","name":"PIRC87","canonical_id":"hgnc:HGNC:37591","description":"piwi-interacting RNA cluster 87","metadata":null},{"id":"e5aa9a8049404c1f998e5175b3c7cf9d","type":"GENE","name":"PIRC88","canonical_id":"hgnc:HGNC:37592","description":"piwi-interacting RNA cluster 88","metadata":null},{"id":"504232ec9daf460795463892c8db50e6","type":"GENE","name":"PIRC89","canonical_id":"hgnc:HGNC:37593","description":"piwi-interacting RNA cluster 89","metadata":null},{"id":"8d95645d688e4185af6ab59a367d152e","type":"GENE","name":"PIRC9","canonical_id":"hgnc:HGNC:37513","description":"piwi-interacting RNA cluster 9","metadata":null},{"id":"844f26966f924f168464c2da7854c044","type":"GENE","name":"PIRC90","canonical_id":"hgnc:HGNC:37594","description":"piwi-interacting RNA cluster 90","metadata":null},{"id":"95130adefd4746c5bf9d7d5e28099dd1","type":"GENE","name":"PIRC91","canonical_id":"hgnc:HGNC:37595","description":"piwi-interacting RNA cluster 91","metadata":null},{"id":"e0665a4e8f364b2d8b05bd085180431d","type":"GENE","name":"PIRC92","canonical_id":"hgnc:HGNC:37596","description":"piwi-interacting RNA cluster 92","metadata":null},{"id":"61dcf07cd44f4decadc0314075565ed3","type":"GENE","name":"PIRC93","canonical_id":"hgnc:HGNC:37597","description":"piwi-interacting RNA cluster 93","metadata":null},{"id":"ee42210ba796474489fb8b857c92477b","type":"GENE","name":"PIRC94","canonical_id":"hgnc:HGNC:37598","description":"piwi-interacting RNA cluster 94","metadata":null},{"id":"00c9c23fe28c4ac8b60973877e2b3836","type":"GENE","name":"PIRC95","canonical_id":"hgnc:HGNC:37599","description":"piwi-interacting RNA cluster 95","metadata":null},{"id":"5495a5eaa9304f6d8b4b77383664b979","type":"GENE","name":"PIRC96","canonical_id":"hgnc:HGNC:37600","description":"piwi-interacting RNA cluster 96","metadata":null},{"id":"a4620d5d00cf4712aaae7331ba527629","type":"GENE","name":"PIRC97","canonical_id":"hgnc:HGNC:37601","description":"piwi-interacting RNA cluster 97","metadata":null},{"id":"f824abf0cef34e5b9449b360fecff3f4","type":"GENE","name":"PIRC98","canonical_id":"hgnc:HGNC:37602","description":"piwi-interacting RNA cluster 98","metadata":null},{"id":"f8ee9d2d666b4c15aa3090036fcfbe08","type":"GENE","name":"PIRC99","canonical_id":"hgnc:HGNC:37603","description":"piwi-interacting RNA cluster 99","metadata":null},{"id":"2016852835b4447abbc14399530274c2","type":"GENE","name":"PIRT","canonical_id":"hgnc:HGNC:37239","description":"phosphoinositide interacting regulator of transient receptor potential channels","metadata":null},{"id":"39184c289d944a84b77734858c26f4d6","type":"GENE","name":"PISD","canonical_id":"hgnc:HGNC:8999","description":"phosphatidylserine decarboxylase","metadata":{"aliases":["dJ858B16.2","PSDC"]}},{"id":"d3e0255f6eb74912b920935a0e1ffcd0","type":"GENE","name":"PISRT1","canonical_id":"hgnc:HGNC:16671","description":"PISRT1 lncRNA","metadata":{"aliases":["NCRNA00195"]}},{"id":"c2460a220797476dbfbb1866de4567b0","type":"GENE","name":"PITHD1","canonical_id":"hgnc:HGNC:25022","description":"PITH domain containing 1","metadata":{"aliases":["HT014","TXNL1CL","C1orf128"]}},{"id":"b3f8dfb24b7f4d66a002763b02b7e66c","type":"GENE","name":"PITPNA","canonical_id":"hgnc:HGNC:9001","description":"phosphatidylinositol transfer protein alpha","metadata":{"aliases":["VIB1A","PITPN"]}},{"id":"99983564fc174b0c81d8e0e5ee60547e","type":"GENE","name":"PITPNA-AS1","canonical_id":"hgnc:HGNC:44116","description":"PITPNA antisense RNA 1","metadata":null},{"id":"65163a870066446e8c5346360cd9610f","type":"GENE","name":"PITPNB","canonical_id":"hgnc:HGNC:9002","description":"phosphatidylinositol transfer protein beta","metadata":{"aliases":["VIB1B"]}},{"id":"87c0d7c9e7264c1886ea2703b2986e03","type":"GENE","name":"PITPNC1","canonical_id":"hgnc:HGNC:21045","description":"phosphatidylinositol transfer protein cytoplasmic 1","metadata":{"aliases":["RDGBB1","RDGBB","RDGB-BETA"]}},{"id":"75a8fd54c708479a8fbdd6042e4f2e61","type":"GENE","name":"PITPNM1","canonical_id":"hgnc:HGNC:9003","description":"phosphatidylinositol transfer protein membrane associated 1","metadata":{"aliases":["DRES9","NIR2","RDGB1","RDGBA1","Rd9","RDGB","PITPNM"]}},{"id":"76eda1d33c774cc7a0685dc21325721d","type":"GENE","name":"PITPNM2","canonical_id":"hgnc:HGNC:21044","description":"phosphatidylinositol transfer protein membrane associated 2","metadata":{"aliases":["RDGBA2","RDGB2","NIR3"]}},{"id":"33fde13f894840b7bc48b62c73096c6d","type":"GENE","name":"PITPNM2-AS1","canonical_id":"hgnc:HGNC:53391","description":"PITPNM2 antisense RNA 1","metadata":null},{"id":"1c4e5be0d5584b869e3010858faef96c","type":"GENE","name":"PITPNM3","canonical_id":"hgnc:HGNC:21043","description":"PITPNM family member 3","metadata":{"aliases":["NIR1","RDGBA3","ACKR6","CORD5"]}},{"id":"48af2e5184944310a50aa0f85d52e36f","type":"GENE","name":"PITRM1","canonical_id":"hgnc:HGNC:17663","description":"pitrilysin metallopeptidase 1","metadata":{"aliases":["MP1","KIAA1104","hMP1","PreP"]}},{"id":"4a334f2a18af4223bd076c7a455a2dce","type":"GENE","name":"PITRM1-AS1","canonical_id":"hgnc:HGNC:44675","description":"PITRM1 antisense RNA 1","metadata":null},{"id":"530b7089aadd42f8bd37639d547c439e","type":"GENE","name":"PITX1","canonical_id":"hgnc:HGNC:9004","description":null,"metadata":null},{"id":"d9ed0e2a631a434086070ba13f24f429","type":"GENE","name":"PITX1-AS1","canonical_id":"hgnc:HGNC:48332","description":"PITX1 antisense RNA 1","metadata":{"aliases":["C5orf66"]}},{"id":"9a2aa0cd8c3c4ecab765a8fbcf46561f","type":"GENE","name":"PITX2","canonical_id":"hgnc:HGNC:9005","description":null,"metadata":null},{"id":"a4ad84cf173949808cea06641fe8a692","type":"GENE","name":"PITX2-DT","canonical_id":"hgnc:HGNC:58870","description":"PITX2 divergent transcript","metadata":null},{"id":"f41e00d36a4649ea999b40213f9af062","type":"GENE","name":"PITX3","canonical_id":"hgnc:HGNC:9006","description":null,"metadata":null},{"id":"398f128c826748e793052cf53579cc2d","type":"GENE","name":"PIWIL1","canonical_id":"hgnc:HGNC:9007","description":"piwi like RNA-mediated gene silencing 1","metadata":{"aliases":["PIWI","HIWI","CT80.1"]}},{"id":"8f870a848f364dd5954cd9e9b9510cb1","type":"GENE","name":"PIWIL2","canonical_id":"hgnc:HGNC:17644","description":"piwi like RNA-mediated gene silencing 2","metadata":{"aliases":["HILI","FLJ10351","Mili","CT80"]}},{"id":"9275a6f3959c46169bd404c34aafd14c","type":"GENE","name":"PIWIL2-DT","canonical_id":"hgnc:HGNC:55522","description":"PIWIL2 divergent transcript","metadata":null},{"id":"4002ba8b94954b31a25c26d70e36eaa7","type":"GENE","name":"PIWIL3","canonical_id":"hgnc:HGNC:18443","description":"piwi like RNA-mediated gene silencing 3","metadata":{"aliases":["HIWI3"]}},{"id":"b903aa34063c42d08bcd7fb9acda5f66","type":"GENE","name":"PIWIL4","canonical_id":"hgnc:HGNC:18444","description":"piwi like RNA-mediated gene silencing 4","metadata":{"aliases":["FLJ36156","HIWI2","Miwi2"]}},{"id":"6eaaa66915b8466fb341ba867ccff15d","type":"GENE","name":"PIWIL4-AS1","canonical_id":"hgnc:HGNC:55493","description":"PIWIL4 antisense RNA 1","metadata":null},{"id":"572551cf1bec4231a67ff46eb22588dc","type":"GENE","name":"PJA1","canonical_id":"hgnc:HGNC:16648","description":"praja ring finger ubiquitin ligase 1","metadata":{"aliases":["FLJ11830","RNF70","PRAJA1"]}},{"id":"c065af5cdb134007a5e1838ed7ec0d37","type":"GENE","name":"PJA2","canonical_id":"hgnc:HGNC:17481","description":"praja ring finger ubiquitin ligase 2","metadata":{"aliases":["KIAA0438","Neurodap1","PRAJA2","RNF131"]}},{"id":"bec86db45c734d87a86a8d887a7d1342","type":"GENE","name":"PJVK","canonical_id":"hgnc:HGNC:29502","description":"pejvakin","metadata":{"aliases":["DFNB59"]}},{"id":"9b95a72fd74c49f8a6f8491557c26bdc","type":"TRIAL","name":"PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly","canonical_id":"clinicaltrials.gov:NCT00532116","description":"Healthy","metadata":null},{"id":"58d98b983730492bb9cd859d454be3f1","type":"TRIAL","name":"PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination","canonical_id":"clinicaltrials.gov:NCT01829893","description":"Benign Prostatic Hyperplasia (BPH)","metadata":null},{"id":"d22330005fdd4c1b87e9a6c26d8b886c","type":"TRIAL","name":"PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval","canonical_id":"clinicaltrials.gov:NCT06196580","description":"Gout and Hyperuricemia","metadata":null},{"id":"3d6580a5d0924d4dafea5c0a7085b082","type":"TRIAL","name":"PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05104931","description":"Pain","metadata":null},{"id":"9de1b463186a4abd8b85271ecf68b05b","type":"TRIAL","name":"PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations","canonical_id":"clinicaltrials.gov:NCT03112148","description":"Healthy","metadata":null},{"id":"3753210b6833422882bf749444bcbfac","type":"TRIAL","name":"PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese","canonical_id":"clinicaltrials.gov:NCT02785601","description":"Depression","metadata":null},{"id":"c2560f1bddf847648568d48a97a8438a","type":"TRIAL","name":"PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment","canonical_id":"clinicaltrials.gov:NCT04849650","description":"Renal Disease, End Stage","metadata":null},{"id":"a004811cf3ee40efa4a4eb2b6ebf13ba","type":"TRIAL","name":"PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB","canonical_id":"clinicaltrials.gov:NCT02412436","description":"HIV-1 Infection; Tuberculosis","metadata":null},{"id":"7e2928a9551641ab8eae03e8f6f5ca1f","type":"TRIAL","name":"PK Study of Sotagliflozin in Subjects With Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT02471274","description":"Hepatic Impairment; Healthy","metadata":null},{"id":"daa25217fc0b4cc79e2a1c53c8a1ffe4","type":"TRIAL","name":"PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen","canonical_id":"clinicaltrials.gov:NCT01190293","description":"HIV Infection","metadata":null},{"id":"c114eb35554a478390db8fb648ec1fa6","type":"TRIAL","name":"PK and Onset of Hezkue Oral Sildenafil Suspension After Alcohol Consumption","canonical_id":"clinicaltrials.gov:NCT07302698","description":"Healthy Volunteers","metadata":null},{"id":"b377f141edec418ca50d326d505ad284","type":"TRIAL","name":"PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function","canonical_id":"clinicaltrials.gov:NCT01429337","description":"Hepatic Impairment","metadata":null},{"id":"78f8178682b6446d826e558812c4e1be","type":"TRIAL","name":"PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02807077","description":"Myelofibrosis","metadata":null},{"id":"605d94d7a03e4ed0a8326801f0b7e7b8","type":"TRIAL","name":"PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06332638","description":"Healthy","metadata":null},{"id":"9ada9d92ad24423cadcec8f3ddeda81c","type":"TRIAL","name":"PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants","canonical_id":"clinicaltrials.gov:NCT02306915","description":"Pharmacokinetics; Pharmacodynamics","metadata":null},{"id":"80fea6f99da248548c039c26f58bf59a","type":"TRIAL","name":"PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT06435442","description":"Healthy","metadata":null},{"id":"7dd23c37d0f04322b480abfe5b274b65","type":"TRIAL","name":"PK/PD Comparison of Guanfacine ER and IR","canonical_id":"clinicaltrials.gov:NCT01904526","description":"Smoking","metadata":null},{"id":"185dc16643e2499f9aff8517e7cf9423","type":"TRIAL","name":"PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT03204279","description":"Chemotherapy-induced Nausea and Vomiting (CINV)","metadata":null},{"id":"bf09940da48f4489b90bce8446479667","type":"TRIAL","name":"PK/PD Study of YZJ-1139","canonical_id":"clinicaltrials.gov:NCT06685341","description":"Insomnia","metadata":null},{"id":"c4d0e2b4686145c39b757dca5c051144","type":"TRIAL","name":"PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00093600","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"95486e41ced142cdba0d910d13b54362","type":"GENE","name":"PKD1","canonical_id":"hgnc:HGNC:9008","description":"polycystin 1, transient receptor potential channel interacting","metadata":{"aliases":["PBP","Pc-1","TRPP1"]}},{"id":"bab1fc609b5d4e8db61ee4c45547bd95","type":"GENE","name":"PKD1-AS1","canonical_id":"hgnc:HGNC:56035","description":"PKD1 antisense RNA 1","metadata":{"aliases":["LUCRC"]}},{"id":"9c836643c80641de8a3d048c49185c8b","type":"GENE","name":"PKD1L1","canonical_id":"hgnc:HGNC:18053","description":"polycystin 1 like 1, transient receptor potential channel interacting","metadata":{"aliases":["PRO19563"]}},{"id":"fc4720ea88fc4ab49bc53ca76b7f874e","type":"GENE","name":"PKD1L1-AS1","canonical_id":"hgnc:HGNC:21911","description":"PKD1L1 antisense RNA 1","metadata":{"aliases":["FLJ21075","C7orf69"]}},{"id":"a78df7e9fe2d4e8a90f3c2879a2aec8f","type":"GENE","name":"PKD1L2","canonical_id":"hgnc:HGNC:21715","description":"polycystin 1 like 2 (gene/pseudogene)","metadata":{"aliases":["KIAA1879"]}},{"id":"55f4e95b5adf4b9a8fd73c8980584550","type":"GENE","name":"PKD1L3","canonical_id":"hgnc:HGNC:21716","description":"polycystin 1 like 3, transient receptor potential channel interacting","metadata":null},{"id":"8381c564f29e4b84af767feaa2d3ed0f","type":"GENE","name":"PKD1P1","canonical_id":"hgnc:HGNC:30065","description":"polycystin 1, transient receptor potential channel interacting pseudogene 1","metadata":null},{"id":"23bd6fcea65947c6994aa913dfea3de8","type":"GENE","name":"PKD1P2","canonical_id":"hgnc:HGNC:30066","description":"polycystin 1, transient receptor potential channel interacting pseudogene 2","metadata":null},{"id":"97d31372df164a859e3be086cb825c67","type":"GENE","name":"PKD1P3","canonical_id":"hgnc:HGNC:30067","description":"polycystin 1, transient receptor potential channel interacting pseudogene 3","metadata":null},{"id":"d8eee4766ff9422fa8f6fd50924bf6e0","type":"GENE","name":"PKD1P4","canonical_id":"hgnc:HGNC:30068","description":"polycystin 1, transient receptor potential channel interacting pseudogene 4","metadata":null},{"id":"a7c850917f5142b7b5c05648a19edf99","type":"GENE","name":"PKD1P5","canonical_id":"hgnc:HGNC:30069","description":"polycystin 1, transient receptor potential channel interacting pseudogene 5","metadata":null},{"id":"fc0ec832469446278cae856431b3de99","type":"GENE","name":"PKD1P6","canonical_id":"hgnc:HGNC:30070","description":"polycystin 1, transient receptor potential channel interacting pseudogene 6","metadata":null},{"id":"13cc743d07cf49969ba74670f90db47d","type":"GENE","name":"PKD2","canonical_id":"hgnc:HGNC:9009","description":"polycystin 2, transient receptor potential cation channel","metadata":{"aliases":["PKD4","PC2","Pc-2","TRPP2"]}},{"id":"874757d6101d4659b3090c57eb7948ad","type":"GENE","name":"PKD2-DT","canonical_id":"hgnc:HGNC:58844","description":"PKD2 divergent transcript","metadata":null},{"id":"d1e35060640b496aa56ba122c0829062","type":"GENE","name":"PKD2L1","canonical_id":"hgnc:HGNC:9011","description":"polycystin 2 like 1, transient receptor potential cation channel","metadata":{"aliases":["PCL","TRPP3","PKD2L","PKDL"]}},{"id":"cc814fd28f394e4da604fb4dd3ba2d4f","type":"GENE","name":"PKD2L2","canonical_id":"hgnc:HGNC:9012","description":"polycystin 2 like 2, transient receptor potential cation channel","metadata":{"aliases":["TRPP5"]}},{"id":"57ebab65f97743899c6ff7e90db4e67f","type":"GENE","name":"PKD2L2-DT","canonical_id":"hgnc:HGNC:55557","description":"PKD2L2 divergent transcript","metadata":null},{"id":"08eead210c9146c3b80a7f07e3875c68","type":"GENE","name":"PKDCC","canonical_id":"hgnc:HGNC:25123","description":"protein kinase domain containing, cytoplasmic","metadata":{"aliases":["SgK493","Vlk"]}},{"id":"544244782c204171a61ee780db5900b9","type":"GENE","name":"PKDREJ","canonical_id":"hgnc:HGNC:9015","description":"polycystin family receptor for egg jelly","metadata":null},{"id":"47a2b2dd70594acc8ede235e3117db11","type":"GENE","name":"PKHD1","canonical_id":"hgnc:HGNC:9016","description":"PKHD1 ciliary IPT domain containing fibrocystin/polyductin","metadata":{"aliases":["ARPKD","FCYT","FPC","TIGM1"]}},{"id":"2243849664d84816bf9c3b49d5fbb2a7","type":"GENE","name":"PKHD1L1","canonical_id":"hgnc:HGNC:20313","description":"PKHD1 like 1","metadata":null},{"id":"2c85af0e398646b6aa561099fb7ec7cf","type":"GENE","name":"PKIA","canonical_id":"hgnc:HGNC:9017","description":"cAMP-dependent protein kinase inhibitor alpha","metadata":{"aliases":["PRKACN1"]}},{"id":"d8d1601d763647d5889029fec8415a8b","type":"GENE","name":"PKIA-AS1","canonical_id":"hgnc:HGNC:51659","description":"PKIA antisense RNA 1","metadata":null},{"id":"50c434eb24af4c278061604499d1283a","type":"GENE","name":"PKIB","canonical_id":"hgnc:HGNC:9018","description":"cAMP-dependent protein kinase inhibitor beta","metadata":{"aliases":["PRKACN2"]}},{"id":"f2950ae9fee649a4b8c58f917fe7ac0f","type":"GENE","name":"PKIG","canonical_id":"hgnc:HGNC:9019","description":"cAMP-dependent protein kinase inhibitor gamma","metadata":null},{"id":"06453e0ed25948a6a50926ca6a28ee09","type":"GENE","name":"PKLR","canonical_id":"hgnc:HGNC:9020","description":null,"metadata":null},{"id":"9d4a568640f5435c939d025fcbe44169","type":"GENE","name":"PKM","canonical_id":"hgnc:HGNC:9021","description":null,"metadata":null},{"id":"c834d861542244309358223488d473b6","type":"GO_TERM","name":"PKM2 protein kinase complex","canonical_id":"go:GO:1990360","description":"\"A protein complex capable of phosphorylating a large number of protein targets. Contributes to cell proliferation under glycose starvation conditions. In human, the complex is present as a dimer.\" [GOC:bhm, PMID:24606918]","metadata":null},{"id":"653c4f5a063d43888a0ea150a412fa34","type":"GO_TERM","name":"PKM2 pyruvate kinase complex","canonical_id":"go:GO:1990361","description":"\"A protein complex capable of pyruvate kinase activity. PKM2 only exists as homotetramer when bound to beta-d-fructofuranose 1,6-bisphosphate (CHEBI:28013).\" [GOC:bhm, PMID:24606918]","metadata":null},{"id":"d8f5e1fd08f847a3a01f4fcd9f4e0b7c","type":"GENE","name":"PKMP1","canonical_id":"hgnc:HGNC:44243","description":"pyruvate kinase M1/2 pseudogene 1","metadata":null},{"id":"cdd7f31fa5114f28ba9138b1d1d848a4","type":"GENE","name":"PKMP2","canonical_id":"hgnc:HGNC:44244","description":"pyruvate kinase M1/2 pseudogene 2","metadata":null},{"id":"2078fb21497148188480d39934afd633","type":"GENE","name":"PKMP3","canonical_id":"hgnc:HGNC:44245","description":"pyruvate kinase M1/2 pseudogene 3","metadata":null},{"id":"4c5d745280244b72a43e47eafd0bcd95","type":"GENE","name":"PKMP4","canonical_id":"hgnc:HGNC:44246","description":"pyruvate kinase M1/2 pseudogene 4","metadata":null},{"id":"cfa4669161734df9b4d28b2af8d7e9d0","type":"GENE","name":"PKMP5","canonical_id":"hgnc:HGNC:44247","description":"pyruvate kinase M1/2 pseudogene 5","metadata":null},{"id":"f263f341255a49f484e39bc98d9fb4af","type":"GENE","name":"PKMYT1","canonical_id":"hgnc:HGNC:29650","description":"protein kinase, membrane associated tyrosine/threonine 1","metadata":{"aliases":["MYT1","PPP1R126"]}},{"id":"13dc8b8fbba64988a3d8cf7020f8858e","type":"GENE","name":"PKMYT1AR","canonical_id":"hgnc:HGNC:56847","description":"PKMYT1 associated lncRNA","metadata":null},{"id":"b0c4347eb9ea4a0cad5c58270face9e9","type":"GENE","name":"PKN1","canonical_id":"hgnc:HGNC:9405","description":"protein kinase N1","metadata":{"aliases":["DBK","PRK1","PKN","MGC46204","PAK1","PRKCL1"]}},{"id":"6abbf061551e450d9c55906a8f32a379","type":"GENE","name":"PKN2","canonical_id":"hgnc:HGNC:9406","description":"protein kinase N2","metadata":{"aliases":["PRK2","Pak-2","STK7","PRKCL2"]}},{"id":"b15174689991473b9e82d8f443b10847","type":"GENE","name":"PKN2-AS1","canonical_id":"hgnc:HGNC:50597","description":"PKN2 antisense RNA 1","metadata":{"aliases":["uc.31"]}},{"id":"18277deb04194b7eba123cea63c5aa8c","type":"GENE","name":"PKN3","canonical_id":"hgnc:HGNC:17999","description":"protein kinase N3","metadata":{"aliases":["PKNbeta","UTDP4-1"]}},{"id":"c1419ba837964159944071e4a9addd0f","type":"GENE","name":"PKNOX1","canonical_id":"hgnc:HGNC:9022","description":null,"metadata":null},{"id":"77acbbee698d4121bcc612d953243297","type":"GENE","name":"PKNOX2","canonical_id":"hgnc:HGNC:16714","description":"PBX/knotted 1 homeobox 2","metadata":null},{"id":"c55f153d5de34163b9300557ceef7916","type":"GENE","name":"PKNOX2-AS1","canonical_id":"hgnc:HGNC:56709","description":"PKNOX2 antisense RNA 1","metadata":{"aliases":["AP001007.1"]}},{"id":"318a2379b38541a4aaab407e7ec9c98b","type":"GENE","name":"PKNOX2-DT","canonical_id":"hgnc:HGNC:50690","description":"PKNOX2 divergent transcript","metadata":{"aliases":["PKNOX2-AS1"]}},{"id":"e5c596347f564319a40c05f252273481","type":"GENE","name":"PKP1","canonical_id":"hgnc:HGNC:9023","description":"plakophilin 1","metadata":{"aliases":["B6P"]}},{"id":"3cbd2df9b1514a02bd0765fa5805f44d","type":"GENE","name":"PKP2","canonical_id":"hgnc:HGNC:9024","description":"plakophilin 2","metadata":null},{"id":"3be87d5f8ef842db995e3d6ec309705e","type":"GENE","name":"PKP2P1","canonical_id":"hgnc:HGNC:13413","description":"plakophilin 2 pseudogene 1","metadata":null},{"id":"8b30a10f2cf14e8fa400df796497292f","type":"GENE","name":"PKP3","canonical_id":"hgnc:HGNC:9025","description":null,"metadata":null},{"id":"c4a59f4c470940cab64c995a56752a2a","type":"GENE","name":"PKP4","canonical_id":"hgnc:HGNC:9026","description":"plakophilin 4","metadata":{"aliases":["p0071"]}},{"id":"6a1818cda0344a9e965800b888c4ce91","type":"GENE","name":"PKP4-AS1","canonical_id":"hgnc:HGNC:52580","description":"PKP4 antisense RNA 1","metadata":null},{"id":"261e31bfb4dc4318b2670c6eeed9655d","type":"GENE","name":"PKP4P1","canonical_id":"hgnc:HGNC:42661","description":"plakophilin 4 pseudogene 1","metadata":null},{"id":"d03dd5a4eef041daaf6665747a748d88","type":"GO_TERM","name":"PKR/eIFalpha signaling","canonical_id":"go:GO:0039585","description":"\"An intracellular signaling cassette that starts with activation and autophosphorylation of PKR (also known as EIF2AK2), which phosphorylates proteins including the translation initiation factor eIF2 to inhibit translation. PKR is activated by stress signals and during the antiviral response, activated by binding to viral double-stranded RNA (dsRNA) leading to inhibition of protein synthesis during viral infection.\" [PMID:21204021, PMID:22102852, PMID:27629041, PMID:9843495, VZ:1576]","metadata":null},{"id":"8b44ec0088e24a4393460a949aacd072","type":"GENE","name":"PLA1A","canonical_id":"hgnc:HGNC:17661","description":"phospholipase A1 member A","metadata":{"aliases":["ps-PLA1"]}},{"id":"e6e8b179941b4e4bb8fba0d33c2919cc","type":"GENE","name":"PLA2G10","canonical_id":"hgnc:HGNC:9029","description":"phospholipase A2 group X","metadata":{"aliases":["GXPLA2"]}},{"id":"d25d27de59c04648bd1427efa80c9728","type":"GENE","name":"PLA2G10BP","canonical_id":"hgnc:HGNC:56598","description":"phospholipase A2 group XB, pseudogene","metadata":null},{"id":"84608dda43b3439c8ae1e3500a97ba05","type":"GENE","name":"PLA2G10CP","canonical_id":"hgnc:HGNC:56599","description":"phospholipase A2 group XC, pseudogene","metadata":null},{"id":"6dc0bbb6840349c1a5312864e94995fa","type":"GENE","name":"PLA2G10DP","canonical_id":"hgnc:HGNC:56600","description":"phospholipase A2 group XD, pseudogene","metadata":null},{"id":"0600f5739be9425cbf82a9fc2c6ae7b0","type":"GENE","name":"PLA2G10EP","canonical_id":"hgnc:HGNC:56601","description":"phospholipase A2 group XE, pseudogene","metadata":null},{"id":"f7928a47bde54f2c9a0f7569b951e8e4","type":"GENE","name":"PLA2G10FP","canonical_id":"hgnc:HGNC:56602","description":"phospholipase A2 group XF, pseudogene","metadata":null},{"id":"c8affeb985b647d7bf77360db6efcb5f","type":"GENE","name":"PLA2G10GP","canonical_id":"hgnc:HGNC:56603","description":"phospholipase A2 group XG, pseudogene","metadata":null},{"id":"7577cc3c67f74ad8a63aabdaec4e7c9f","type":"GENE","name":"PLA2G10HP","canonical_id":"hgnc:HGNC:56604","description":"phospholipase A2 group XH, pseudogene","metadata":null},{"id":"50ea743441574adebe104e9117d40862","type":"GENE","name":"PLA2G10IP","canonical_id":"hgnc:HGNC:56597","description":"phospholipase A2 group XI, pseudogene","metadata":null},{"id":"181f3a9bcc9d402c81d1bad64b39a0c6","type":"GENE","name":"PLA2G10JP","canonical_id":"hgnc:HGNC:56606","description":"phospholipase A2 group XJ, pseudogene","metadata":null},{"id":"db9525ed36964a34b38486fd7f22dcf1","type":"GENE","name":"PLA2G10KP","canonical_id":"hgnc:HGNC:56607","description":"phospholipase A2 group XK, pseudogene","metadata":null},{"id":"b6b56dc583c445829447da17f3a7cdc8","type":"GENE","name":"PLA2G10P1","canonical_id":"hgnc:HGNC:56596","description":"PLA2G10 pseudogene 1","metadata":null},{"id":"a0d5a702ebb64a3a88db7240a5d3546c","type":"GENE","name":"PLA2G12A","canonical_id":"hgnc:HGNC:18554","description":"phospholipase A2 group XIIA","metadata":{"aliases":["PLA2G12"]}},{"id":"aa2ec92f02744a29a5a19c7ea72addfc","type":"GENE","name":"PLA2G12AP1","canonical_id":"hgnc:HGNC:39248","description":"phospholipase A2 group XIIA pseudogene 1","metadata":null},{"id":"1bd2d7e57f8b4b2baccc61305de1cd4c","type":"GENE","name":"PLA2G12AP2","canonical_id":"hgnc:HGNC:39249","description":"phospholipase A2 group XIIA pseudogene 2","metadata":null},{"id":"3d97b0ad9c794e588c9208723f78a883","type":"GENE","name":"PLA2G12B","canonical_id":"hgnc:HGNC:18555","description":"phospholipase A2 group XIIB","metadata":{"aliases":["PLA2G13"]}},{"id":"6a9cc121f81a49d1bdb160c18139607b","type":"GENE","name":"PLA2G15","canonical_id":"hgnc:HGNC:17163","description":"phospholipase A2 group XV","metadata":{"aliases":["LLPL","GXVPLA2","LYPLA3"]}},{"id":"f200785c8e5a4eb78fbd3d5ae106e61b","type":"GENE","name":"PLA2G1B","canonical_id":"hgnc:HGNC:9030","description":"phospholipase A2 group IB","metadata":{"aliases":["PLA2","PPLA2","PLA2A"]}},{"id":"29f43bfb68ee425891bb1bcb8b2c9a45","type":"GENE","name":"PLA2G2A","canonical_id":"hgnc:HGNC:9031","description":null,"metadata":null},{"id":"0465f73ea73845ed889142610fee7bdc","type":"GENE","name":"PLA2G2C","canonical_id":"hgnc:HGNC:9032","description":"phospholipase A2 group IIC","metadata":{"aliases":["UBXN10-AS1"]}},{"id":"ad44914a4cb34c918d7cfe44ea1dad21","type":"GENE","name":"PLA2G2D","canonical_id":"hgnc:HGNC:9033","description":"phospholipase A2 group IID","metadata":{"aliases":["sPLA2S"]}},{"id":"20b5466b914a4468bd0842aa9cc2a7c5","type":"GENE","name":"PLA2G2E","canonical_id":"hgnc:HGNC:13414","description":"phospholipase A2 group IIE","metadata":null},{"id":"b0a4b0d9b7a74de690c8adb5b8ce3fec","type":"GENE","name":"PLA2G2F","canonical_id":"hgnc:HGNC:30040","description":"phospholipase A2 group IIF","metadata":null},{"id":"6fcadee00f6541a78db40c9cf6e20582","type":"GENE","name":"PLA2G3","canonical_id":"hgnc:HGNC:17934","description":"phospholipase A2 group III","metadata":{"aliases":["GIII-SPLA2"]}},{"id":"736f4f3f179c44e2936b09d925c28c0c","type":"GENE","name":"PLA2G4A","canonical_id":"hgnc:HGNC:9035","description":"phospholipase A2 group IVA","metadata":{"aliases":["cPLA2-alpha","PLA2G4"]}},{"id":"899f10ed0aaf4e079fff21a6babbe77e","type":"GENE","name":"PLA2G4B","canonical_id":"hgnc:HGNC:9036","description":"phospholipase A2 group IVB","metadata":{"aliases":["cPLA2-beta","HsT16992"]}},{"id":"56fc65c1741644cbbcda1cfbe6cf4e7d","type":"GENE","name":"PLA2G4C","canonical_id":"hgnc:HGNC:9037","description":"phospholipase A2 group IVC","metadata":{"aliases":["cPLA2-gamma"]}},{"id":"b4a60a0e8b984bfe83f41348e71eb83f","type":"GENE","name":"PLA2G4C-AS1","canonical_id":"hgnc:HGNC:51585","description":"PLA2G4C antisense RNA 1","metadata":{"aliases":["REIR11"]}},{"id":"72c53e926eef448f9b6a148dc986344b","type":"GENE","name":"PLA2G4D","canonical_id":"hgnc:HGNC:30038","description":"phospholipase A2 group IVD","metadata":{"aliases":["cPLA2delta"]}},{"id":"41519345f988428fbf58abc9ae972c1a","type":"GENE","name":"PLA2G4E","canonical_id":"hgnc:HGNC:24791","description":"phospholipase A2 group IVE","metadata":{"aliases":["FLJ45651"]}},{"id":"c2aa2159faa14399bacc5c7e86deaae0","type":"GENE","name":"PLA2G4E-AS1","canonical_id":"hgnc:HGNC:51419","description":"PLA2G4E antisense RNA 1","metadata":null},{"id":"65f4dc5980cc4c7881469e54a4fab7ed","type":"GENE","name":"PLA2G4F","canonical_id":"hgnc:HGNC:27396","description":"phospholipase A2 group IVF","metadata":{"aliases":["PLA2G4F/Z"]}},{"id":"54b5b2715e234f1fa54669f1732cf341","type":"GENE","name":"PLA2G5","canonical_id":"hgnc:HGNC:9038","description":"phospholipase A2 group V","metadata":null},{"id":"08b3c982325e43adb42a924b5d37a123","type":"GENE","name":"PLA2G6","canonical_id":"hgnc:HGNC:9039","description":"phospholipase A2 group VI","metadata":{"aliases":["iPLA2","PNPLA9","PARK14","iPLA2beta","NBIA2"]}},{"id":"cc8fad3424444d1aac5b73e7b10282a4","type":"GENE","name":"PLA2G7","canonical_id":"hgnc:HGNC:9040","description":"phospholipase A2 group VII","metadata":{"aliases":["PAFAH","LDL-PLA2","Lp-PLA2"]}},{"id":"1a23ca4268c24ebfb43e1e7603449fd5","type":"GENE","name":"PLA2R1","canonical_id":"hgnc:HGNC:9042","description":"phospholipase A2 receptor 1","metadata":{"aliases":["PLA2G1R","PLA2IR","PLA2-R","CLEC13C"]}},{"id":"42933f4ba7c44dd2814aa4d255bae08e","type":"GENE","name":"PLAA","canonical_id":"hgnc:HGNC:9043","description":null,"metadata":null},{"id":"9d37b859e79248b3a885218e63e51ed8","type":"GENE","name":"PLAAT1","canonical_id":"hgnc:HGNC:14922","description":"phospholipase A and acyltransferase 1","metadata":{"aliases":["H-REV107","HRASLS1","A-C1","PLA/AT1","PLAAT-1","HRASLS"]}},{"id":"9b6e3ae8ecb0431abd7a8f020964b4ae","type":"GENE","name":"PLAAT2","canonical_id":"hgnc:HGNC:17824","description":"phospholipase A and acyltransferase 2","metadata":{"aliases":["FLJ20556","PLAAT-2","HRASLS2"]}},{"id":"1c81cd2a11024d6285b364c604494de5","type":"GENE","name":"PLAAT3","canonical_id":"hgnc:HGNC:17825","description":"phospholipase A and acyltransferase 3","metadata":{"aliases":["HREV107","H-REV107-1","HREV107-3","MGC118754.","AdPLA","PLAAT-3","HRASLS3","PLA2G16"]}},{"id":"9b56c2cfef394047a3bdc5995a6269ab","type":"GENE","name":"PLAAT4","canonical_id":"hgnc:HGNC:9869","description":"phospholipase A and acyltransferase 4","metadata":{"aliases":["TIG3","HRASLS4","PLAAT-4","RIG1","RARRES3"]}},{"id":"613c1f2298f74f36bb14d066292f9e14","type":"GENE","name":"PLAAT5","canonical_id":"hgnc:HGNC:24978","description":"phospholipase A and acyltransferase 5","metadata":{"aliases":["HRLP5","iNAT","PLAAT-5","HRASLS5"]}},{"id":"7d9ad112277d49c99867b4ab78b4bcfd","type":"GENE","name":"PLAC1","canonical_id":"hgnc:HGNC:9044","description":null,"metadata":null},{"id":"0c17c00130704e9392f841e3e6d1f7ee","type":"GENE","name":"PLAC1-AS1","canonical_id":"hgnc:HGNC:58387","description":"PLAC1 antisense RNA 1","metadata":null},{"id":"af75cd0f1d3b41e397a3140613a2090c","type":"GENE","name":"PLAC4","canonical_id":"hgnc:HGNC:14616","description":"placenta associated 4","metadata":{"aliases":["MGC126664","MGC126666","PRED78","C21orf115"]}},{"id":"5147ff7a0ee04c70927fedc500994571","type":"GENE","name":"PLAC8","canonical_id":"hgnc:HGNC:19254","description":"placenta associated 8","metadata":{"aliases":["onzin","C15"]}},{"id":"8414708780b542e198b2b4b9a9346696","type":"GENE","name":"PLAC8L1","canonical_id":"hgnc:HGNC:31746","description":"PLAC8 like 1","metadata":null},{"id":"d403155136f64595a5c4812d6b2d428d","type":"GENE","name":"PLAC9","canonical_id":"hgnc:HGNC:19255","description":"placenta associated 9","metadata":{"aliases":["placin"]}},{"id":"daa453886df145e6add7ce1ffed2e12b","type":"GENE","name":"PLAC9P1","canonical_id":"hgnc:HGNC:52678","description":"placenta associated 9 pseudogene 1","metadata":null},{"id":"e139bb6d868c41509e1a4f8bd5285fa2","type":"GENE","name":"PLAG1","canonical_id":"hgnc:HGNC:9045","description":null,"metadata":null},{"id":"6aa501fde7824a9da5f56386db1b1aa7","type":"GENE","name":"PLAGL1","canonical_id":"hgnc:HGNC:9046","description":null,"metadata":null},{"id":"39fbc8123ea14570a011906688e31e6c","type":"GENE","name":"PLAGL2","canonical_id":"hgnc:HGNC:9047","description":null,"metadata":null},{"id":"21172d1e79984cb7b49400517bd76a47","type":"GENE","name":"PLAT","canonical_id":"hgnc:HGNC:9051","description":null,"metadata":null},{"id":"ef6e9aca669e498cb1cf68205a6b5eda","type":"PROTEIN","name":"PLAT","canonical_id":"uniprot:P00750","description":null,"metadata":null},{"id":"07407aa4c0a949159583b93582a093cc","type":"TRIAL","name":"PLATFORM Study of Precision Medicine for Rare Tumors","canonical_id":"clinicaltrials.gov:NCT04423185","description":"Rare Tumor","metadata":null},{"id":"e088e5ae9d6b43c1b8d1f60e6e3a5cb0","type":"GENE","name":"PLAU","canonical_id":"hgnc:HGNC:9052","description":null,"metadata":null},{"id":"db316dd6edd545328893f864294d03b4","type":"GENE","name":"PLAUR","canonical_id":"hgnc:HGNC:9053","description":null,"metadata":null},{"id":"be5ec99165ad4b31923547e6723f3d0e","type":"GENE","name":"PLB1","canonical_id":"hgnc:HGNC:30041","description":null,"metadata":null},{"id":"b3e5784c1ae34a2384dc224f29fada45","type":"GENE","name":"PLBD1","canonical_id":"hgnc:HGNC:26215","description":"phospholipase B domain containing 1","metadata":{"aliases":["PLBL1","FLJ22662"]}},{"id":"2d2bf40b06ef4c26a7f0b43b97d7712c","type":"GENE","name":"PLBD1-AS1","canonical_id":"hgnc:HGNC:51143","description":"PLBD1 antisense RNA 1","metadata":null},{"id":"288a409d2b0e4b2ba450f3c65772e464","type":"GENE","name":"PLBD1-AS2","canonical_id":"hgnc:HGNC:58266","description":"PLBD1 antisense RNA 2","metadata":null},{"id":"2e734b009818410d882e99e881e0ecbf","type":"GENE","name":"PLBD2","canonical_id":"hgnc:HGNC:27283","description":"phospholipase B domain containing 2","metadata":{"aliases":["PLBL2","p76"]}},{"id":"82498bd8d027458c9d8f81dd13a28c5d","type":"GO_TERM","name":"PLC activating G protein-coupled glutamate receptor activity","canonical_id":"go:GO:0001639","description":"\"A G protein-coupled receptor that binds glutamate and is linked to the inositol 1,4,5-trisphosphate/calcium signaling system.\" [PMID:9016303]","metadata":null},{"id":"cb59b30846ef48ac949700ff7e3143a5","type":"GENE","name":"PLCB1","canonical_id":"hgnc:HGNC:15917","description":"phospholipase C beta 1","metadata":{"aliases":["KIAA0581","PLC-I","PLC154"]}},{"id":"ef0478a8192f4d008e74c2fd4386121e","type":"GENE","name":"PLCB1-IT1","canonical_id":"hgnc:HGNC:41414","description":"PLCB1 intronic transcript 1","metadata":null},{"id":"3d40a15d6ef4449aa083acbd078568ed","type":"GENE","name":"PLCB2","canonical_id":"hgnc:HGNC:9055","description":"phospholipase C beta 2","metadata":{"aliases":["FLJ38135"]}},{"id":"89f4c87449304db7bd5ee00c49202005","type":"GENE","name":"PLCB2-AS1","canonical_id":"hgnc:HGNC:43662","description":"PLCB2 antisense RNA 1","metadata":null},{"id":"874bd49fe5464111b1f1d3e46f54a3df","type":"GENE","name":"PLCB3","canonical_id":"hgnc:HGNC:9056","description":"phospholipase C beta 3","metadata":null},{"id":"5cedb5f948904177b026609efb79c5e5","type":"GENE","name":"PLCB4","canonical_id":"hgnc:HGNC:9059","description":"phospholipase C beta 4","metadata":null},{"id":"de1e2690e2d34bb48bdeabd8cf98250d","type":"GENE","name":"PLCD1","canonical_id":"hgnc:HGNC:9060","description":"phospholipase C delta 1","metadata":null},{"id":"c20fcfa07358488391231f183e6b813e","type":"GENE","name":"PLCD3","canonical_id":"hgnc:HGNC:9061","description":"phospholipase C delta 3","metadata":null},{"id":"70a53c7dcad24f199e20a4aa2c13e989","type":"GENE","name":"PLCD4","canonical_id":"hgnc:HGNC:9062","description":"phospholipase C delta 4","metadata":null},{"id":"3d4fd2d1753648879eed81846609b09a","type":"GENE","name":"PLCE1","canonical_id":"hgnc:HGNC:17175","description":"phospholipase C epsilon 1","metadata":{"aliases":["KIAA1516","PLCE","NPHS3"]}},{"id":"ca0776b91ecc47c7a772122a27f18914","type":"GENE","name":"PLCE1-AS1","canonical_id":"hgnc:HGNC:45193","description":"PLCE1 antisense RNA 1","metadata":null},{"id":"2a82b88f79a64b1c9223d00e1939f1a1","type":"GENE","name":"PLCE1-AS2","canonical_id":"hgnc:HGNC:51206","description":"PLCE1 antisense RNA 2","metadata":null},{"id":"421c6596f2a1473b8be5dc3217f70b6b","type":"GENE","name":"PLCE1P1","canonical_id":"hgnc:HGNC:51906","description":"phospholipase C epsilon 1 pseudogene 1","metadata":null},{"id":"ff066fbd664d4dbe8d2247b9002c6f1f","type":"GENE","name":"PLCG1","canonical_id":"hgnc:HGNC:9065","description":"phospholipase C gamma 1","metadata":{"aliases":["PLC148","PLC-II","PLCgamma1","NCKAP3","PLC1"]}},{"id":"2c754de374b146018aa12fa240f776fc","type":"GENE","name":"PLCG1-AS1","canonical_id":"hgnc:HGNC:40450","description":"PLCG1 antisense RNA 1","metadata":{"aliases":["TOP1-AS1"]}},{"id":"34b8697eda104ac1a291b594556e7325","type":"GENE","name":"PLCG2","canonical_id":"hgnc:HGNC:9066","description":"phospholipase C gamma 2","metadata":null},{"id":"1ead06c9ff964783afc345c6c2e8b486","type":"GENE","name":"PLCH1","canonical_id":"hgnc:HGNC:29185","description":"phospholipase C eta 1","metadata":{"aliases":["KIAA1069","MGC117152","DKFZp434C1372","PLCeta1","PLCL3"]}},{"id":"9c9b6674fb674eaeba7db22e3cc691a2","type":"GENE","name":"PLCH1-AS1","canonical_id":"hgnc:HGNC:41231","description":"PLCH1 antisense RNA 1","metadata":null},{"id":"5788de170cc945769919e0c08a32c2e7","type":"GENE","name":"PLCH1-AS2","canonical_id":"hgnc:HGNC:41232","description":"PLCH1 antisense RNA 2","metadata":null},{"id":"d828f358eb614a0d9a215cefc06b61f3","type":"GENE","name":"PLCH2","canonical_id":"hgnc:HGNC:29037","description":"phospholipase C eta 2","metadata":{"aliases":["KIAA0450","PLCeta2","RP3-395M20.1","PLC-eta2","PLCL4"]}},{"id":"36cca2d6e75342329913fb4a87f50453","type":"GENE","name":"PLCL1","canonical_id":"hgnc:HGNC:9063","description":"phospholipase C like 1 (inactive)","metadata":{"aliases":["PLC-L","PLCL","PRIP","PPP1R127","PLCE"]}},{"id":"570f1d3c3ed747b4956ded0c149de241","type":"GENE","name":"PLCL2","canonical_id":"hgnc:HGNC:9064","description":"phospholipase C like 2","metadata":{"aliases":["KIAA1092","PLCE2"]}},{"id":"16ee328a9b6e4ff6954c4e090695aadc","type":"GENE","name":"PLCL2-AS1","canonical_id":"hgnc:HGNC:40449","description":"PLCL2 antisense RNA 1","metadata":null},{"id":"da351511ed8344638178c88e5123f41c","type":"GENE","name":"PLCL2UT","canonical_id":"hgnc:HGNC:58366","description":"PLCL2 upstream transcript","metadata":null},{"id":"f9a938b32fb0497ea52260af40a7ef41","type":"GENE","name":"PLCXD1","canonical_id":"hgnc:HGNC:23148","description":"phosphatidylinositol specific phospholipase C X domain containing 1","metadata":{"aliases":["FLJ11323"]}},{"id":"5e7ea65a68cf435b829f2eddd8439206","type":"GENE","name":"PLCXD2","canonical_id":"hgnc:HGNC:26462","description":"phosphatidylinositol specific phospholipase C X domain containing 2","metadata":{"aliases":["FLJ31579"]}},{"id":"865c335c7394471588cf1f4202cb82fb","type":"GENE","name":"PLCXD2-AS1","canonical_id":"hgnc:HGNC:41145","description":"PLCXD2 antisense RNA 1","metadata":null},{"id":"1ddf03f8c18345e699b97f0a330c255b","type":"GENE","name":"PLCXD3","canonical_id":"hgnc:HGNC:31822","description":"phosphatidylinositol specific phospholipase C X domain containing 3","metadata":null},{"id":"7c56f4030f07456086627dea95b5b3d2","type":"GENE","name":"PLCXD3-AS1","canonical_id":"hgnc:HGNC:59035","description":"PLCXD3 antisense RNA 1","metadata":null},{"id":"88720f9690194d9c917ffbb5c54036e0","type":"GENE","name":"PLCZ1","canonical_id":"hgnc:HGNC:19218","description":"phospholipase C zeta 1","metadata":{"aliases":["NYD-SP27","PLCzeta","Czeta"]}},{"id":"9dcdfb36d9ac43dbaa7eaca2a24ff70c","type":"GENE","name":"PLD1","canonical_id":"hgnc:HGNC:9067","description":null,"metadata":null},{"id":"b8b1970fba344943be280192ebba5a25","type":"GENE","name":"PLD2","canonical_id":"hgnc:HGNC:9068","description":"phospholipase D2","metadata":null},{"id":"0c94cd3739424daf8599af0b8310b19b","type":"GENE","name":"PLD3","canonical_id":"hgnc:HGNC:17158","description":"phospholipase D family member 3","metadata":{"aliases":["HU-K4"]}},{"id":"c028d159c97543dea77b5aa2cece5877","type":"GENE","name":"PLD4","canonical_id":"hgnc:HGNC:23792","description":"phospholipase D family member 4","metadata":{"aliases":["C14orf175"]}},{"id":"42f148c0f8334a4d8bcf98023cd8d7c9","type":"GENE","name":"PLD5","canonical_id":"hgnc:HGNC:26879","description":"phospholipase D family member 5","metadata":{"aliases":["FLJ40773"]}},{"id":"17851d27818c48e9ae2a177df6cb38ed","type":"GENE","name":"PLD5-AS1","canonical_id":"hgnc:HGNC:41171","description":"PLD5 antisense RNA 1","metadata":null},{"id":"e9bf1afa509441eaad162c8632f60c51","type":"GENE","name":"PLD5P1","canonical_id":"hgnc:HGNC:55072","description":"PLD5 pseudogene 1","metadata":null},{"id":"e2be787dd7344595bc11bb6818b617f9","type":"GENE","name":"PLD6","canonical_id":"hgnc:HGNC:30447","description":"phospholipase D family member 6","metadata":{"aliases":["Zuc"]}},{"id":"6a7d3788b6524717a4d5f3ef6779a03f","type":"GENE","name":"PLEC","canonical_id":"hgnc:HGNC:9069","description":"plectin","metadata":{"aliases":["PCN","PLTN","EBS1","PLEC1"]}},{"id":"6cba6be4f224452c98e7cb6bf71f7dd7","type":"GENE","name":"PLEK","canonical_id":"hgnc:HGNC:9070","description":"pleckstrin","metadata":{"aliases":["P47","PLEK1"]}},{"id":"17da07bc69af4a86a62965a2bf99ab57","type":"GENE","name":"PLEK2","canonical_id":"hgnc:HGNC:19238","description":"pleckstrin 2","metadata":null},{"id":"c57d01c118c24e32b9a890fac6d5768b","type":"GENE","name":"PLEKHA1","canonical_id":"hgnc:HGNC:14335","description":"pleckstrin homology domain containing A1","metadata":{"aliases":["TAPP1"]}},{"id":"c176301e527a481da803dd12524d3569","type":"GENE","name":"PLEKHA2","canonical_id":"hgnc:HGNC:14336","description":"pleckstrin homology domain containing A2","metadata":{"aliases":["TAPP2"]}},{"id":"f3558597783746a29b661d2109878538","type":"GENE","name":"PLEKHA3","canonical_id":"hgnc:HGNC:14338","description":"pleckstrin homology domain containing A3","metadata":{"aliases":["FAPP1"]}},{"id":"6c657d89c9a24435af360696bbd8a87d","type":"GENE","name":"PLEKHA3P1","canonical_id":"hgnc:HGNC:19648","description":"pleckstrin homology domain containing A3 pseudogene 1","metadata":{"aliases":["PLEKHA3P"]}},{"id":"107c35b124f443cba03df2aac7e41580","type":"GENE","name":"PLEKHA4","canonical_id":"hgnc:HGNC:14339","description":"pleckstrin homology domain containing A4","metadata":{"aliases":["PEPP1"]}},{"id":"97e88f0590b5410f8977afa4694ecfcd","type":"GENE","name":"PLEKHA5","canonical_id":"hgnc:HGNC:30036","description":"pleckstrin homology domain containing A5","metadata":{"aliases":["PEPP2","KIAA1686","FLJ10667"]}},{"id":"483beb41e2954125a664c4166f96ccb4","type":"GENE","name":"PLEKHA6","canonical_id":"hgnc:HGNC:17053","description":"pleckstrin homology domain containing A6","metadata":{"aliases":["PEPP3","KIAA0969"]}},{"id":"626fc6805c964b96a25b5fe4f761ba19","type":"GENE","name":"PLEKHA7","canonical_id":"hgnc:HGNC:27049","description":"pleckstrin homology domain containing A7","metadata":{"aliases":["DKFZp686M22243"]}},{"id":"2f263b09f65b41ddbd88a2b9664cf482","type":"GENE","name":"PLEKHA8","canonical_id":"hgnc:HGNC:30037","description":"pleckstrin homology domain containing A8","metadata":{"aliases":["FAPP2","MGC3358"]}},{"id":"8c46268f6c524dcbbbca1c01eb6215e9","type":"GENE","name":"PLEKHA8P1","canonical_id":"hgnc:HGNC:30222","description":"pleckstrin homology domain containing A8 pseudogene 1","metadata":{"aliases":["FLJ14156","PLEKHA9"]}},{"id":"e50ebce012d74304b732d10d33d1d26c","type":"GENE","name":"PLEKHB1","canonical_id":"hgnc:HGNC:19079","description":"pleckstrin homology domain containing B1","metadata":{"aliases":["PHR1","KPL1","PHRET1"]}},{"id":"b1af41981da74edcbefce54fe7857cf4","type":"GENE","name":"PLEKHB2","canonical_id":"hgnc:HGNC:19236","description":"pleckstrin homology domain containing B2","metadata":{"aliases":["EVT2","FLJ20783"]}},{"id":"4f6698b38e8845bd87033eb53e47c3c1","type":"GENE","name":"PLEKHB2P1","canonical_id":"hgnc:HGNC:56814","description":"PLEKHB2 pseudogene 1","metadata":null},{"id":"d22184f93a6c47c88b184c7c0c2bede0","type":"GENE","name":"PLEKHD1","canonical_id":"hgnc:HGNC:20148","description":"pleckstrin homology and coiled-coil domain containing D1","metadata":{"aliases":["UPF0639"]}},{"id":"4dd517568b854405adce8afc661fc05e","type":"GENE","name":"PLEKHF1","canonical_id":"hgnc:HGNC:20764","description":"pleckstrin homology and FYVE domain containing 1","metadata":{"aliases":["APPD","MGC4090","PHAFIN1","ZFYVE15"]}},{"id":"89c69016860a412cbef056d66984d147","type":"GENE","name":"PLEKHF2","canonical_id":"hgnc:HGNC:20757","description":"pleckstrin homology and FYVE domain containing 2","metadata":{"aliases":["ZFYVE18","PHAFIN2","FLJ13187"]}},{"id":"f9c3f4f2a67c43429965d40a5ec4b625","type":"GENE","name":"PLEKHG1","canonical_id":"hgnc:HGNC:20884","description":"pleckstrin homology and RhoGEF domain containing G1","metadata":{"aliases":["KIAA1209","ARHGEF41"]}},{"id":"9ae117915ba04cbf95e4c4826f5b579f","type":"GENE","name":"PLEKHG2","canonical_id":"hgnc:HGNC:29515","description":"pleckstrin homology and RhoGEF domain containing G2","metadata":{"aliases":["CLG","FLJ00018","ARHGEF42"]}},{"id":"19279e979bd044008e1fe2622ca31088","type":"GENE","name":"PLEKHG3","canonical_id":"hgnc:HGNC:20364","description":"pleckstrin homology and RhoGEF domain containing G3","metadata":{"aliases":["ARHGEF43","KIAA0599"]}},{"id":"6c4e3447443a485983018400e0a7bb1a","type":"GENE","name":"PLEKHG4","canonical_id":"hgnc:HGNC:24501","description":"pleckstrin homology and RhoGEF domain containing G4","metadata":{"aliases":["DKFZP434I216","ARHGEF44","SCA4"]}},{"id":"44e18b5da735492ea70fd090b0cb0a60","type":"GENE","name":"PLEKHG4B","canonical_id":"hgnc:HGNC:29399","description":"pleckstrin homology and RhoGEF domain containing G4B","metadata":{"aliases":["KIAA1909","ARHGEF48"]}},{"id":"dcd31f9044c1453ca755277556b80759","type":"GENE","name":"PLEKHG5","canonical_id":"hgnc:HGNC:29105","description":"pleckstrin homology and RhoGEF domain containing G5","metadata":{"aliases":["KIAA0720","Syx","GEF720","Tech","ARHGEF45"]}},{"id":"45c8ae65a8cc46518d859ec4c82112c8","type":"GENE","name":"PLEKHG6","canonical_id":"hgnc:HGNC:25562","description":"pleckstrin homology and RhoGEF domain containing G6","metadata":{"aliases":["FLJ10665","MYOGEF","ARHGEF46"]}},{"id":"b9b2afe42fcc410f8f5c27fd9df8fe67","type":"GENE","name":"PLEKHG7","canonical_id":"hgnc:HGNC:33829","description":"pleckstrin homology and RhoGEF domain containing G7","metadata":{"aliases":["FLJ46688","C12orf74"]}},{"id":"a5181953d3aa43bb82d1710c22f8d7d4","type":"GENE","name":"PLEKHH1","canonical_id":"hgnc:HGNC:17733","description":"pleckstrin homology, MyTH4 and FERM domain containing H1","metadata":{"aliases":["KIAA1200"]}},{"id":"43ce4958240f4f19b8f3dea14c35611f","type":"GENE","name":"PLEKHH2","canonical_id":"hgnc:HGNC:30506","description":"pleckstrin homology, MyTH4 and FERM domain containing H2","metadata":{"aliases":["KIAA2028","PLEKHH1L"]}},{"id":"c619cf8e48c04b0abc3765cba699844b","type":"GENE","name":"PLEKHH3","canonical_id":"hgnc:HGNC:26105","description":"pleckstrin homology, MyTH4 and FERM domain containing H3","metadata":{"aliases":["FLJ21019"]}},{"id":"fb770197ee3c41b99e815f79c1235bd0","type":"GENE","name":"PLEKHJ1","canonical_id":"hgnc:HGNC:18211","description":"pleckstrin homology domain containing J1","metadata":{"aliases":["FLJ10297"]}},{"id":"7c0e788f107d408b9938776603d5ab96","type":"GENE","name":"PLEKHM1","canonical_id":"hgnc:HGNC:29017","description":"pleckstrin homology and RUN domain containing M1","metadata":{"aliases":["KIAA0356"]}},{"id":"310c19f2ea4f416b937a01a85d285707","type":"GENE","name":"PLEKHM1P1","canonical_id":"hgnc:HGNC:35411","description":"pleckstrin homology and RUN domain containing M1 pseudogene 1","metadata":{"aliases":["LOC440456","PLEKHM1P"]}},{"id":"db5c857075b54c06a5bcdf5119a786e4","type":"GENE","name":"PLEKHM2","canonical_id":"hgnc:HGNC:29131","description":"pleckstrin homology and RUN domain containing M2","metadata":{"aliases":["KIAA0842"]}},{"id":"f1dcc134cef34231a381b5a234df3448","type":"GENE","name":"PLEKHM2-AS1","canonical_id":"hgnc:HGNC:58402","description":"PLEKHM2 antisense RNA 1","metadata":null},{"id":"a4a74d5928014acea8bdea5f8a302714","type":"GENE","name":"PLEKHM3","canonical_id":"hgnc:HGNC:34006","description":"pleckstrin homology domain containing M3","metadata":{"aliases":["DAPR","PLEKHM1L"]}},{"id":"3098aa57b4684a8f8d85285a1619fc6b","type":"GENE","name":"PLEKHN1","canonical_id":"hgnc:HGNC:25284","description":"pleckstrin homology domain containing N1","metadata":{"aliases":["DKFZP434H2010"]}},{"id":"88b3b7ea148b48d3aa56b5ae1be89c69","type":"GENE","name":"PLEKHO1","canonical_id":"hgnc:HGNC:24310","description":"pleckstrin homology domain containing O1","metadata":{"aliases":["CKIP-1","OC120"]}},{"id":"0670efedc64e49ab82686ff57069fced","type":"GENE","name":"PLEKHO2","canonical_id":"hgnc:HGNC:30026","description":"pleckstrin homology domain containing O2","metadata":{"aliases":["DKFZp761K2312","PP1628","pp9099","PLEKHQ1"]}},{"id":"c5d44c94a3bb44a5b30d95045b1a7cd6","type":"GENE","name":"PLEKHS1","canonical_id":"hgnc:HGNC:26285","description":"pleckstrin homology domain containing S1","metadata":{"aliases":["FLJ23537","bA211N11.2","C10orf81"]}},{"id":"1ee0f6cce70c45aa9f4e6dbbea8bff73","type":"GENE","name":"PLET1","canonical_id":"hgnc:HGNC:30053","description":"placenta expressed transcript 1","metadata":{"aliases":["C11orf34"]}},{"id":"f15c2ec6ca374e6192a384206fc57237","type":"GENE","name":"PLG","canonical_id":"hgnc:HGNC:9071","description":null,"metadata":null},{"id":"f7a8646498f64e208b771fa0df739632","type":"PROTEIN","name":"PLG","canonical_id":"uniprot:P00747","description":null,"metadata":null},{"id":"f0930e72054b4089b810251c5bb07a62","type":"GENE","name":"PLGLA","canonical_id":"hgnc:HGNC:9074","description":"plasminogen like A (pseudogene)","metadata":{"aliases":["PLGP2","PLGLA1"]}},{"id":"fed9a21b26824e2094d1d9d0836318a1","type":"GENE","name":"PLGLB1","canonical_id":"hgnc:HGNC:9072","description":"plasminogen like B1","metadata":{"aliases":["PRP-B","PLGL"]}},{"id":"e3894fdb55424e4d81bf77242abdd982","type":"GENE","name":"PLGLB2","canonical_id":"hgnc:HGNC:9073","description":"plasminogen like B2","metadata":{"aliases":["PLGP1"]}},{"id":"73d731d512644f668fd8166834b50956","type":"GENE","name":"PLGRKT","canonical_id":"hgnc:HGNC:23633","description":"plasminogen receptor with a C-terminal lysine","metadata":{"aliases":["MDS030","FLJ14688","AD025","Plg-RKT","C9orf46"]}},{"id":"5c5dfdebf07241748b7833799babcb03","type":"GENE","name":"PLIN1","canonical_id":"hgnc:HGNC:9076","description":null,"metadata":null},{"id":"d79871ffca8141339f182c5566e62ed5","type":"GENE","name":"PLIN2","canonical_id":"hgnc:HGNC:248","description":null,"metadata":null},{"id":"5b11bc242014429f91ae1e621603db1a","type":"GENE","name":"PLIN3","canonical_id":"hgnc:HGNC:16893","description":"perilipin 3","metadata":{"aliases":["TIP47","PP17","M6PRBP1"]}},{"id":"4edc684fa6274ee6a4e4a8d4ccb33bd4","type":"GENE","name":"PLIN3-AS1","canonical_id":"hgnc:HGNC:58206","description":"PLIN3 antisense RNA 1","metadata":null},{"id":"96af5f57ad734b209fc0d7f1c5deab21","type":"GENE","name":"PLIN4","canonical_id":"hgnc:HGNC:29393","description":"perilipin 4","metadata":{"aliases":["S3-12","KIAA1881"]}},{"id":"928b3a48201643d8be77bf8e88a25985","type":"GENE","name":"PLIN5","canonical_id":"hgnc:HGNC:33196","description":"perilipin 5","metadata":{"aliases":["LSDP5","LSDA5","OXPAT","MLDP"]}},{"id":"cc378126247641d2aa2bfc2f798a750a","type":"GENE","name":"PLK1","canonical_id":"hgnc:HGNC:9077","description":null,"metadata":null},{"id":"fca90974904547259b4e16c826863ef7","type":"GENE","name":"PLK2","canonical_id":"hgnc:HGNC:19699","description":"polo like kinase 2","metadata":{"aliases":["SNK"]}},{"id":"ac46cb15fbca4bc794eb6a1640c22dd7","type":"GENE","name":"PLK3","canonical_id":"hgnc:HGNC:2154","description":null,"metadata":null},{"id":"bcd94287a75b425684cccf07a12c75d3","type":"GENE","name":"PLK4","canonical_id":"hgnc:HGNC:11397","description":null,"metadata":null},{"id":"44b24004e41e426ebd8c8b35dcd0f1ec","type":"GENE","name":"PLK4-DT","canonical_id":"hgnc:HGNC:58883","description":"PLK4 divergent transcript","metadata":null},{"id":"735b3463d1c14696b52285681a8c9d39","type":"GENE","name":"PLK5","canonical_id":"hgnc:HGNC:27001","description":"polo like kinase 5 (inactive)","metadata":{"aliases":["SgK384ps","PLK5P"]}},{"id":"7852cb760c684a229ca87371428331f7","type":"GENE","name":"PLLP","canonical_id":"hgnc:HGNC:18553","description":"plasmolipin","metadata":{"aliases":["PMLP","TM4SF11"]}},{"id":"03a5b3242b224a4b899b17058e210a92","type":"GENE","name":"PLLPP1","canonical_id":"hgnc:HGNC:54943","description":"PLLP pseudogene 1","metadata":null},{"id":"da7a31dd87b144e787623f79305ee7e0","type":"GENE","name":"PLN","canonical_id":"hgnc:HGNC:9080","description":"phospholamban","metadata":{"aliases":["CMD1P","PLB"]}},{"id":"e65de0750fa14fae95ad70b557badd33","type":"GENE","name":"PLOD1","canonical_id":"hgnc:HGNC:9081","description":null,"metadata":null},{"id":"94cf7f8562e240e8a1c3e755732213e6","type":"GENE","name":"PLOD2","canonical_id":"hgnc:HGNC:9082","description":"procollagen-lysine,2-oxoglutarate 5-dioxygenase 2","metadata":{"aliases":["LH2","TLH"]}},{"id":"1200f940cbba4a6dac4b9ee2603f5141","type":"GENE","name":"PLOD3","canonical_id":"hgnc:HGNC:9083","description":"procollagen-lysine,2-oxoglutarate 5-dioxygenase 3","metadata":{"aliases":["LH3"]}},{"id":"e606b484335842519bb2e72b3b97e8e5","type":"GENE","name":"PLP1","canonical_id":"hgnc:HGNC:9086","description":"proteolipid protein 1","metadata":{"aliases":["GPM6C","SPG2","PLP"]}},{"id":"eb4d90894b154f05b8f18c0ce776400e","type":"GENE","name":"PLP2","canonical_id":"hgnc:HGNC:9087","description":"proteolipid protein 2","metadata":{"aliases":["A4","A4-LSB","MGC126187"]}},{"id":"c211b32154ac42c59fb1f5a2fc16816d","type":"GENE","name":"PLPBP","canonical_id":"hgnc:HGNC:9457","description":"pyridoxal phosphate binding protein","metadata":{"aliases":["PROSC"]}},{"id":"a8365fad4c2d42c7995386e639834eed","type":"GENE","name":"PLPP1","canonical_id":"hgnc:HGNC:9228","description":"phospholipid phosphatase 1","metadata":{"aliases":["PAP-2a","LPP1","PPAP2A"]}},{"id":"2a1c96148519461aa0837136de9abc85","type":"GENE","name":"PLPP1-DT","canonical_id":"hgnc:HGNC:59046","description":"PLPP1 divergent transcript","metadata":null},{"id":"6bc15375b88d4e2d801150f0ca1a33b5","type":"GENE","name":"PLPP2","canonical_id":"hgnc:HGNC:9230","description":"phospholipid phosphatase 2","metadata":{"aliases":["PAP-2c","LPP2","PPAP2C"]}},{"id":"5b2cbd130adb481190daf2d44d2f9005","type":"GENE","name":"PLPP3","canonical_id":"hgnc:HGNC:9229","description":"phospholipid phosphatase 3","metadata":{"aliases":["PAP-2b","LPP3","PPAP2B"]}},{"id":"d4b60eb4a7b04fc5a015b4d5a93eb5dc","type":"GENE","name":"PLPP4","canonical_id":"hgnc:HGNC:23531","description":"phospholipid phosphatase 4","metadata":{"aliases":["DPPL2","PPAPDC1","PPAPDC1A"]}},{"id":"7174e52e718443768ec7afdc95b7b92f","type":"GENE","name":"PLPP5","canonical_id":"hgnc:HGNC:25026","description":"phospholipid phosphatase 5","metadata":{"aliases":["HTPAP","DPPL1","PPAPDC1B"]}},{"id":"6196d74ee11b49e793fe0cf23b516c3a","type":"GENE","name":"PLPP6","canonical_id":"hgnc:HGNC:23682","description":"phospholipid phosphatase 6","metadata":{"aliases":["FLJ90191","FLJ46512","PDP1","PPAPDC2"]}},{"id":"865f92cd3b0544f38d45815e38e8a0c3","type":"GENE","name":"PLPP7","canonical_id":"hgnc:HGNC:28174","description":"phospholipid phosphatase 7 (inactive)","metadata":{"aliases":["MGC12921","FLJ14662","NET39","C9orf67","PPAPDC3"]}},{"id":"77b819570e014aa2b08fa229af140930","type":"GENE","name":"PLPPR1","canonical_id":"hgnc:HGNC:25993","description":"phospholipid phosphatase related 1","metadata":{"aliases":["PRG-3","MGC26189","FLJ20300","LPPR1"]}},{"id":"c63ab58a9fc1490797dc0cf710b87c17","type":"GENE","name":"PLPPR2","canonical_id":"hgnc:HGNC:29566","description":"phospholipid phosphatase related 2","metadata":{"aliases":["LPPR2","PRG-4"]}},{"id":"a06f1c23dfa047439d6b6f6ec435587a","type":"GENE","name":"PLPPR3","canonical_id":"hgnc:HGNC:23497","description":"phospholipid phosphatase related 3","metadata":{"aliases":["PRG-2","FLJ11535","LPPR3","PRG2"]}},{"id":"64b23f412acb470cb692cc7e9e0f6ab6","type":"GENE","name":"PLPPR4","canonical_id":"hgnc:HGNC:23496","description":"phospholipid phosphatase related 4","metadata":{"aliases":["PRG-1","LPPR4","KIAA0455","PHP1"]}},{"id":"9a83ab8c32db4a2db751d711ef69d2cc","type":"GENE","name":"PLPPR5","canonical_id":"hgnc:HGNC:31703","description":"phospholipid phosphatase related 5","metadata":{"aliases":["PAP2D","PAP2","LPPR5","PRG5"]}},{"id":"b47927b9080349538e4fd25a15125c85","type":"GENE","name":"PLPPR5-AS1","canonical_id":"hgnc:HGNC:55720","description":"PLPPR5 antisense RNA 1","metadata":null},{"id":"87fbb6887eab46e7bd10ad3f23412a59","type":"GENE","name":"PLRG1","canonical_id":"hgnc:HGNC:9089","description":null,"metadata":null},{"id":"4a9033b38bb145c6ac829b6e74529dc1","type":"GENE","name":"PLS1","canonical_id":"hgnc:HGNC:9090","description":"plastin 1","metadata":null},{"id":"ff846aa78cd54bf9b4bb9c970f91cf97","type":"GENE","name":"PLS1-AS1","canonical_id":"hgnc:HGNC:40451","description":"PLS1 antisense RNA 1","metadata":null},{"id":"a650136229014bd2ac1f528c7e79c564","type":"GENE","name":"PLS1P1","canonical_id":"hgnc:HGNC:55926","description":"PLS1 pseudogene 1","metadata":null},{"id":"22c062c9d03c4049aec8f8b7797d6923","type":"GENE","name":"PLS3","canonical_id":"hgnc:HGNC:9091","description":"plastin 3","metadata":{"aliases":["T-plastin"]}},{"id":"c6957f3edc914ad59130f4916b466c0e","type":"GENE","name":"PLS3-AS1","canonical_id":"hgnc:HGNC:50343","description":"PLS3 antisense RNA 1","metadata":null},{"id":"4321488ec67f426dba5290befbdbf676","type":"GENE","name":"PLSCR1","canonical_id":"hgnc:HGNC:9092","description":null,"metadata":null},{"id":"3a927405ed3c46cca37cd4570f0b875d","type":"GENE","name":"PLSCR2","canonical_id":"hgnc:HGNC:16494","description":"phospholipid scramblase 2","metadata":null},{"id":"556f2e56c1c64b9495a801e642f6b497","type":"GENE","name":"PLSCR3","canonical_id":"hgnc:HGNC:16495","description":"phospholipid scramblase 3","metadata":null},{"id":"e43c38ce2c3640e6bfde383ab640e174","type":"GENE","name":"PLSCR4","canonical_id":"hgnc:HGNC:16497","description":"phospholipid scramblase 4","metadata":null},{"id":"78ce17aff16345fd9457df51d684bfd6","type":"GENE","name":"PLSCR4P1","canonical_id":"hgnc:HGNC:56556","description":"PLSCR4 pseudogene 1","metadata":null},{"id":"9def8a08a52b4955925d0e63cca6e82e","type":"GENE","name":"PLSCR5","canonical_id":"hgnc:HGNC:19952","description":"phospholipid scramblase family member 5","metadata":null},{"id":"d6f826697023441a8867aaaa1cb10dc7","type":"GENE","name":"PLSCR5-AS1","canonical_id":"hgnc:HGNC:40907","description":"PLSCR5 antisense RNA 1","metadata":null},{"id":"537c0d4ccdae462ca35f3ae1cb6d5a92","type":"GENE","name":"PLTP","canonical_id":"hgnc:HGNC:9093","description":null,"metadata":null},{"id":"95abf1c9803c44b0bc3411de079293f5","type":"GENE","name":"PLUT","canonical_id":"hgnc:HGNC:43698","description":"PDX1 associated lncRNA, upregulator of transcription","metadata":{"aliases":["PLUTO","HI-LNC71","PDX1-AS1"]}},{"id":"4182bce3814f4e47888ce46a88f4079f","type":"GENE","name":"PLVAP","canonical_id":"hgnc:HGNC:13635","description":"plasmalemma vesicle associated protein","metadata":{"aliases":["gp68","PV-1","PV1","FELS"]}},{"id":"a6003347b2474e63a69c7511255b8d4e","type":"TRIAL","name":"PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers","canonical_id":"clinicaltrials.gov:NCT04209595","description":"Small Cell Lung Cancer; Extra-Pulmonary Small Cell Carcinomas","metadata":null},{"id":"784637310f1042148dc5d303a6a8911a","type":"GENE","name":"PLXDC1","canonical_id":"hgnc:HGNC:20945","description":"plexin domain containing 1","metadata":{"aliases":["TEM3","TEM7"]}},{"id":"674866d13c734a069cd4af1a6b9af75c","type":"GENE","name":"PLXDC2","canonical_id":"hgnc:HGNC:21013","description":"plexin domain containing 2","metadata":{"aliases":["TEM7R","FLJ14623","PLXDC2-OT"]}},{"id":"f48d5d4d0a0e487ba4c2b5925e0f5be7","type":"GENE","name":"PLXDC2-AS1","canonical_id":"hgnc:HGNC:58236","description":"PLXDC2 antisense RNA 1","metadata":null},{"id":"5fb71ba2e3c846f594ec161b36a237fd","type":"GENE","name":"PLXNA2","canonical_id":"hgnc:HGNC:9100","description":"plexin A2","metadata":{"aliases":["OCT","FLJ11751","FLJ30634","KIAA0463","PLXN2"]}},{"id":"d451381b31204ec7b0cde384a2be06f1","type":"GENE","name":"PLXNA3","canonical_id":"hgnc:HGNC:9101","description":"plexin A3","metadata":{"aliases":["SEX","XAP-6","6.3","Plxn3","PLXN4"]}},{"id":"8638d6703f7c462098e0677340e58238","type":"GENE","name":"PLXNA4","canonical_id":"hgnc:HGNC:9102","description":"plexin A4","metadata":{"aliases":["KIAA1550","DKFZp434G0625PRO34003","FAYV2820","PLXNA4A","PLXNA4B"]}},{"id":"b0cc24ddeb1c45e1a6648962e932ce3a","type":"GENE","name":"PLXNA4-AS1","canonical_id":"hgnc:HGNC:40453","description":"PLXNA4 antisense RNA 1","metadata":null},{"id":"ac69a4b957664db8b22acfd3b6bf1679","type":"GENE","name":"PLXNA4-AS2","canonical_id":"hgnc:HGNC:40452","description":"PLXNA4 antisense RNA 2","metadata":null},{"id":"a61dc5a357e84a6f9921609b6939fd67","type":"GENE","name":"PLXNB1","canonical_id":"hgnc:HGNC:9103","description":"plexin B1","metadata":{"aliases":["SEP","KIAA0407","PLXN5"]}},{"id":"8b8dd8730f7844c58251ef67affd4b9f","type":"GENE","name":"PLXNB2","canonical_id":"hgnc:HGNC:9104","description":"plexin B2","metadata":{"aliases":["MM1","KIAA0315","PLEXB2","lncFAL"]}},{"id":"bfc0141a7d604eb2bcd1933766ec7f60","type":"GENE","name":"PLXNB3","canonical_id":"hgnc:HGNC:9105","description":"plexin B3","metadata":{"aliases":["PLEXR","PLEXB3","PLXN6"]}},{"id":"58e2863b433d4f20aba044c8f181c77b","type":"GENE","name":"PLXNB3-AS1","canonical_id":"hgnc:HGNC:40454","description":"PLXNB3 antisense RNA 1","metadata":null},{"id":"2aac7b9185c244e48c0c1d0a134fc8e2","type":"GENE","name":"PLXNC1","canonical_id":"hgnc:HGNC:9106","description":"plexin C1","metadata":{"aliases":["VESPR","CD232"]}},{"id":"9ed76fbc71c74432bc7d7582ad9a40cd","type":"GENE","name":"PLXNC1-AS1","canonical_id":"hgnc:HGNC:58451","description":"PLXNC1 antisense RNA 1","metadata":null},{"id":"90b7efd452cb4a7c99fa6baf523f57a9","type":"GENE","name":"PLXND1","canonical_id":"hgnc:HGNC:9107","description":"plexin D1","metadata":{"aliases":["KIAA0620"]}},{"id":"a50891a4d99a40ff87c8526c091abc41","type":"GENE","name":"PM20D1","canonical_id":"hgnc:HGNC:26518","description":"peptidase M20 domain containing 1","metadata":{"aliases":["FLJ32569","Cps1"]}},{"id":"d54013f59a4944d59520ce7abe3b9138","type":"GENE","name":"PM20D1-AS1","canonical_id":"hgnc:HGNC:27633","description":"PM20D1 antisense RNA 1","metadata":null},{"id":"4fda0c7da72b41a2971544ef0b8ca9d1","type":"GENE","name":"PM20D2","canonical_id":"hgnc:HGNC:21408","description":"peptidase M20 domain containing 2","metadata":{"aliases":["bA63L7.3","ACY1L2"]}},{"id":"0eab8973254f484db87165d18524ef3f","type":"TRIAL","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","canonical_id":"clinicaltrials.gov:NCT06419621","description":"Triple Negative Breast Cancer(TNBC)","metadata":null},{"id":"32908356066249e2825cdcf8377d1315","type":"GENE","name":"PMAIP1","canonical_id":"hgnc:HGNC:9108","description":null,"metadata":null},{"id":"1ec04ec118f646ac881dd7abab826863","type":"GENE","name":"PMAR72","canonical_id":"hgnc:HGNC:58769","description":"plasma membrane associated RNA 72","metadata":null},{"id":"a15d0ea5545e4ed6b80cd174fb3ddd4f","type":"GENE","name":"PMCH","canonical_id":"hgnc:HGNC:9109","description":"pro-melanin concentrating hormone","metadata":{"aliases":["MCH"]}},{"id":"fdd441aa66a14a458df9e80fb9454dd5","type":"GENE","name":"PMCHL1","canonical_id":"hgnc:HGNC:9110","description":"pro-melanin concentrating hormone like 1 (pseudogene)","metadata":null},{"id":"47ea991ce6f340d89ad0317a8ba8850e","type":"GENE","name":"PMCHL2","canonical_id":"hgnc:HGNC:9111","description":"pro-melanin concentrating hormone like 2 (pseudogene)","metadata":null},{"id":"71be4e0fd98641ba9197f6340949aa1a","type":"GENE","name":"PMEL","canonical_id":"hgnc:HGNC:10880","description":null,"metadata":null},{"id":"376b35c3775e43298ef2c487fce0293c","type":"GENE","name":"PMEPA1","canonical_id":"hgnc:HGNC:14107","description":null,"metadata":null},{"id":"85b2f539fbfe49a68959f93456c1641c","type":"GENE","name":"PMF1","canonical_id":"hgnc:HGNC:9112","description":"polyamine modulated factor 1","metadata":null},{"id":"718c1086d20a41f0b4e8342d74fb05d4","type":"GENE","name":"PMF1-BGLAP","canonical_id":"hgnc:HGNC:42953","description":"PMF1-BGLAP readthrough","metadata":null},{"id":"8ed1650a17904b2ea1ae5b01d0d0f8bd","type":"GENE","name":"PMFBP1","canonical_id":"hgnc:HGNC:17728","description":"polyamine modulated factor 1 binding protein 1","metadata":null},{"id":"5950064851ff4af4b722adab7b2365c8","type":"GENE","name":"PMIS2","canonical_id":"hgnc:HGNC:53649","description":"PMIS2 transmembrane protein","metadata":{"aliases":["IFITMD9"]}},{"id":"e82442daa2f04f8c906076c61a9fea37","type":"GENE","name":"PML","canonical_id":"hgnc:HGNC:9113","description":null,"metadata":null},{"id":"79a3531c4f7047ae845a197bf38d7db1","type":"GO_TERM","name":"PML body","canonical_id":"go:GO:0016605","description":"\"A class of nuclear body; they react against SP100 auto-antibodies (PML, promyelocytic leukemia); cells typically contain 10-30 PML bodies per nucleus; alterations in the localization of PML bodies occurs after viral infection.\" [GOC:ma, PMID:10944585]","metadata":null},{"id":"1c92b39c25004186a1735855978a71a1","type":"GO_TERM","name":"PML body organization","canonical_id":"go:GO:0030578","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of PML bodies, a class of nuclear body; they react against SP100 auto-antibodies (PML = promyelocytic leukemia).\" [GOC:mah, PMID:10806078]","metadata":null},{"id":"89a2dcd52c8f45adb6daf019fd80d677","type":"GENE","name":"PMM1","canonical_id":"hgnc:HGNC:9114","description":"phosphomannomutase 1","metadata":{"aliases":["Sec53"]}},{"id":"3dbc1d4e96bc44cba418798796d7c209","type":"GENE","name":"PMM2","canonical_id":"hgnc:HGNC:9115","description":"phosphomannomutase 2","metadata":{"aliases":["CDGS","CDG1a","PMI","PMI1","CDG1"]}},{"id":"db7738506920405e83dc0b7c68e73f78","type":"GENE","name":"PMM2-AS1","canonical_id":"hgnc:HGNC:58482","description":"PMM2 antisense RNA 1","metadata":null},{"id":"8e39c16a96924efa96678eff5877def6","type":"GENE","name":"PMM2P1","canonical_id":"hgnc:HGNC:9116","description":"phosphomannomutase 2 pseudogene 1","metadata":null},{"id":"4d32986bb4144b9893cc40d924c34e18","type":"GENE","name":"PMM2P2","canonical_id":"hgnc:HGNC:21753","description":"phosphomannomutase 2 pseudogene 2","metadata":null},{"id":"7bddbc6a0a3a4bc898198184c8fca676","type":"GENE","name":"PMP2","canonical_id":"hgnc:HGNC:9117","description":"peripheral myelin protein 2","metadata":{"aliases":["MP2","FABP8","M-FABP"]}},{"id":"bfa8766bfdca42ca89d8f69a6be47876","type":"GENE","name":"PMP22","canonical_id":"hgnc:HGNC:9118","description":null,"metadata":null},{"id":"8de04fcc77794d69a93a6506379ef522","type":"GENE","name":"PMPCA","canonical_id":"hgnc:HGNC:18667","description":"peptidase, mitochondrial processing subunit alpha","metadata":{"aliases":["KIAA0123","Alpha-MPP","MAS2","INPP5E","SCAR2","CLA1"]}},{"id":"ab379fc4b3704411a75cd00f6d1d18ca","type":"GENE","name":"PMPCAP1","canonical_id":"hgnc:HGNC:51348","description":"PMPCA pseudogene 1","metadata":null},{"id":"fb30aa212719452cb6801a5367acf4ca","type":"GENE","name":"PMPCB","canonical_id":"hgnc:HGNC:9119","description":"peptidase, mitochondrial processing subunit beta","metadata":{"aliases":["MPPB","MPPP52","MAS1","beta-MPP"]}},{"id":"89c45556990548338c9c0a3140d50d81","type":"TRIAL","name":"PMS to Evaluate the Safety and Efficacy of Picato\u00ae Gel","canonical_id":"clinicaltrials.gov:NCT02421471","description":"Actinic Keratosis","metadata":null},{"id":"7763b7d2bdca442ea6cca2cd213654df","type":"GENE","name":"PMS1","canonical_id":"hgnc:HGNC:9121","description":"PMS1 homolog 1, mismatch repair system component","metadata":{"aliases":["MLH2","PMSL1"]}},{"id":"dbb21a553e2a4b74a648f198defb91cc","type":"GENE","name":"PMS2","canonical_id":"hgnc:HGNC:9122","description":"PMS1 homolog 2, mismatch repair system component","metadata":{"aliases":["H_DJ0042M02.9","HNPCC4","MLH4","PMS-2","PMSL2"]}},{"id":"3f7a3d6c9c6f4a2aaec48784a4af0944","type":"GENE","name":"PMS2CL","canonical_id":"hgnc:HGNC:30061","description":"PMS2 C-terminal like (pseudogene)","metadata":{"aliases":["PMS2P13"]}},{"id":"5ade65d3e0c14ab88197f074219044fd","type":"GENE","name":"PMS2P1","canonical_id":"hgnc:HGNC:9123","description":"PMS1 homolog 2, mismatch repair system component pseudogene 1","metadata":{"aliases":["PMS3","PMS8","PMS2L13","PMSR2","PMSR1","PMS2L6","PMS2L8","PMS2L7","PMS2L1"]}},{"id":"c93c9ab48c354d5db27e4333fd3473a7","type":"GENE","name":"PMS2P10","canonical_id":"hgnc:HGNC:9124","description":"PMS1 homolog 2, mismatch repair system component pseudogene 10","metadata":{"aliases":["PMSR4","PMS2L10"]}},{"id":"0d2ccda44b9a4e109985d38ac4fe63a9","type":"GENE","name":"PMS2P11","canonical_id":"hgnc:HGNC:9125","description":"PMS1 homolog 2, mismatch repair system component pseudogene 11","metadata":{"aliases":["PMSR6","PMS2L11"]}},{"id":"4965d5953add4aa8bd4294ad73876a16","type":"GENE","name":"PMS2P12","canonical_id":"hgnc:HGNC:13641","description":"PMS1 homolog 2, mismatch repair system component pseudogene 12","metadata":{"aliases":["PMSL12","PMS2L12"]}},{"id":"d01df5d1d3fb473cb0b7bf630fa6688b","type":"GENE","name":"PMS2P13","canonical_id":"hgnc:HGNC:55748","description":"PMS1 homolog 2, mismatch repair system component pseudogene 13","metadata":null},{"id":"0cc0863ff8604f43981f271334eb6738","type":"GENE","name":"PMS2P14","canonical_id":"hgnc:HGNC:55747","description":"PMS1 homolog 2, mismatch repair system component pseudogene 14","metadata":null},{"id":"305f52f4eca3444db509649205325712","type":"GENE","name":"PMS2P2","canonical_id":"hgnc:HGNC:9127","description":"PMS1 homolog 2, mismatch repair system component pseudogene 2","metadata":{"aliases":["PMS4","PMS2L2"]}},{"id":"198e1a49dba54ee480448b0cdb6fb24f","type":"GENE","name":"PMS2P3","canonical_id":"hgnc:HGNC:9128","description":"PMS1 homolog 2, mismatch repair system component pseudogene 3","metadata":{"aliases":["PMS5","PMSR3","PMS2L9","PMS2L3"]}},{"id":"7d8593fd5b5e47f982940db760e0478f","type":"GENE","name":"PMS2P4","canonical_id":"hgnc:HGNC:9129","description":"PMS1 homolog 2, mismatch repair system component pseudogene 4","metadata":{"aliases":["PMS6","PMS2L4"]}},{"id":"36f54ed9123e44919c4788cc93963a87","type":"GENE","name":"PMS2P5","canonical_id":"hgnc:HGNC:9130","description":"PMS1 homolog 2, mismatch repair system component pseudogene 5","metadata":{"aliases":["PMS7","MGC34222","PMS2L5"]}},{"id":"639234c3d2104d7392b48966ba8f9713","type":"GENE","name":"PMS2P6","canonical_id":"hgnc:HGNC:33514","description":"PMS1 homolog 2, mismatch repair system component pseudogene 6","metadata":{"aliases":["PMS2L14"]}},{"id":"0b00d12d69b646e28acf9085d0826fc9","type":"GENE","name":"PMS2P7","canonical_id":"hgnc:HGNC:33515","description":"PMS1 homolog 2, mismatch repair system component pseudogene 7","metadata":{"aliases":["PMSR7","PMS2LP2","PMS2L15"]}},{"id":"88f2905be8e240acac14ea3c4fb4961a","type":"GENE","name":"PMS2P8","canonical_id":"hgnc:HGNC:33516","description":"PMS1 homolog 2, mismatch repair system component pseudogene 8","metadata":{"aliases":["PMS2L16"]}},{"id":"0d0d633d8b59499fa461a17984dc8020","type":"GENE","name":"PMS2P9","canonical_id":"hgnc:HGNC:9135","description":"PMS1 homolog 2, mismatch repair system component pseudogene 9","metadata":{"aliases":["PMSR5","PMS2LP1","PMS2L17"]}},{"id":"eb4dc676dbb24df9accb91af09607136","type":"GENE","name":"PMVK","canonical_id":"hgnc:HGNC:9141","description":"phosphomevalonate kinase","metadata":{"aliases":["PMK","PMKA","HUMPMKI"]}},{"id":"70d8c23afdd14cef8b14d372745c3abf","type":"GENE","name":"PNCK","canonical_id":"hgnc:HGNC:13415","description":"pregnancy up-regulated nonubiquitous CaM kinase","metadata":{"aliases":["MGC45419","CaMK1b"]}},{"id":"9df40543df42419caac6a8df11777f99","type":"GENE","name":"PNCRNA-D","canonical_id":"hgnc:HGNC:58269","description":"promoter associated ncRNA regulator of CCND1","metadata":null},{"id":"1a21345a32ef4f3d873ab255f3cda399","type":"GO_TERM","name":"PNGase complex","canonical_id":"go:GO:0120125","description":"\"A protein complex responsible for the catalysis of the reaction: 4-N-(N-acetyl-D-glucosaminyl)-protein + H2O = N-acetyl-beta-D-glucosaminylamine + peptide L-aspartate. This reaction is the hydrolysis of an N4-(acetyl-beta-D-glucosaminyl)asparagine residue in which the N-acetyl-D-glucosamine residue may be further glycosylated, to yield a (substituted) N-acetyl-beta-D-glucosaminylamine and the peptide containing an aspartic residue.\" [GOC:lnp, PMID:15964983, PMID:16249333]","metadata":null},{"id":"692692e7454d4ee3be147301df583b0a","type":"GENE","name":"PNISR","canonical_id":"hgnc:HGNC:21222","description":"PNN interacting serine and arginine rich protein","metadata":{"aliases":["FLJ14752","bA98I9.2","DKFZp564B0769","SRrp130","C6orf111","SFRS18"]}},{"id":"2ac2e8358d894ab1a5d3453afc29a639","type":"GENE","name":"PNISR-AS1","canonical_id":"hgnc:HGNC:40958","description":"PNISR antisense RNA 1","metadata":null},{"id":"d8e34651226447d0af95c99868780423","type":"GENE","name":"PNKD","canonical_id":"hgnc:HGNC:9153","description":"PNKD metallo-beta-lactamase domain containing","metadata":{"aliases":["DYT8","PDC","DKFZp564N1362","FPD1","MR-1","BRP17","FKSG19","TAHCCP2","KIAA1184","KIPP1184","MGC31943","PKND1","MR-1S"]}},{"id":"a698aef262124d90ae5b9ffe2d67fe6d","type":"GENE","name":"PNKDP1","canonical_id":"hgnc:HGNC:49628","description":"PNKD pseudogene 1","metadata":null},{"id":"a7f32fd8910f47d4af09e961b701305f","type":"GENE","name":"PNKP","canonical_id":"hgnc:HGNC:9154","description":"polynucleotide kinase 3'-phosphatase","metadata":{"aliases":["PNK"]}},{"id":"a6ab29976afb4df69c940072d442c91b","type":"GENE","name":"PNLDC1","canonical_id":"hgnc:HGNC:21185","description":"PARN like ribonuclease domain containing exonuclease 1","metadata":{"aliases":["FLJ40240","dJ195P10.2","Trimmer"]}},{"id":"b17300a1e17c4e7fa32025eb19b60260","type":"GENE","name":"PNLIP","canonical_id":"hgnc:HGNC:9155","description":"pancreatic lipase","metadata":{"aliases":["PL"]}},{"id":"a338c52114d34f75aa30995cf9516fe5","type":"PROTEIN","name":"PNLIP","canonical_id":"uniprot:P16233","description":null,"metadata":null},{"id":"14182ad0a9cf49af93065b6380cda7fc","type":"GENE","name":"PNLIPP1","canonical_id":"hgnc:HGNC:45264","description":"pancreatic lipase pseudogene 1","metadata":null},{"id":"e77fc7fc968940d694edbbc41c285eaa","type":"GENE","name":"PNLIPRP1","canonical_id":"hgnc:HGNC:9156","description":"pancreatic lipase related protein 1","metadata":{"aliases":["PLRP1"]}},{"id":"ee6a37d0af2c45e6b08486454dcf5cf3","type":"GENE","name":"PNLIPRP2","canonical_id":"hgnc:HGNC:9157","description":"pancreatic lipase related protein 2 (gene/pseudogene)","metadata":{"aliases":["PLRP2"]}},{"id":"a4a29679cb8649339b52144f8372ea21","type":"GENE","name":"PNLIPRP3","canonical_id":"hgnc:HGNC:23492","description":"pancreatic lipase related protein 3","metadata":null},{"id":"b7bd68f47f9f481884ab0878005776d3","type":"GENE","name":"PNMA1","canonical_id":"hgnc:HGNC:9158","description":"PNMA family member 1","metadata":{"aliases":["MA1"]}},{"id":"ca66abf0e7c449888dd09c40f599fd22","type":"GENE","name":"PNMA2","canonical_id":"hgnc:HGNC:9159","description":"PNMA family member 2","metadata":{"aliases":["MA2","RGAG2"]}},{"id":"d5a29ceb04f948a18a6aa799dd9785c8","type":"GENE","name":"PNMA3","canonical_id":"hgnc:HGNC:18742","description":"PNMA family member 3","metadata":{"aliases":["MA5","MA3","MGC132756","MGC132758"]}},{"id":"4b9d5e8e1df54e43806b017315db1c37","type":"GENE","name":"PNMA5","canonical_id":"hgnc:HGNC:18743","description":"PNMA family member 5","metadata":{"aliases":["KIAA1934"]}},{"id":"255ecd9c00454cb1934d991fa96b3cd8","type":"GENE","name":"PNMA6A","canonical_id":"hgnc:HGNC:28248","description":"PNMA family member 6A","metadata":{"aliases":["MGC15827","PNMA6C"]}},{"id":"05d765948d84480593b5eee97618b2ee","type":"GENE","name":"PNMA6B","canonical_id":"hgnc:HGNC:26681","description":"PNMA family member 6B (pseudogene)","metadata":{"aliases":["PNMA6D"]}},{"id":"bdc7fa5c39d94e61b42e9b92b96a1c1e","type":"GENE","name":"PNMA6E","canonical_id":"hgnc:HGNC:50767","description":"PNMA family member 6E","metadata":null},{"id":"0cb2052ca8824bebb4f88fc63dfa4bda","type":"GENE","name":"PNMA6F","canonical_id":"hgnc:HGNC:53119","description":"PNMA family member 6F","metadata":{"aliases":["PNMA6BL"]}},{"id":"a59586679c54409b80b77d01559dd778","type":"GENE","name":"PNMA8A","canonical_id":"hgnc:HGNC:25578","description":"PNMA family member 8A","metadata":{"aliases":["KIAA1183L","FLJ10781","PNMAL1"]}},{"id":"fc67a5ca94854f46ac5a73c0bbaa4918","type":"GENE","name":"PNMA8B","canonical_id":"hgnc:HGNC:29206","description":"PNMA family member 8B","metadata":{"aliases":["KIAA1183","PNMAL2"]}},{"id":"31cea845891f4362a9fb51054227b9da","type":"GENE","name":"PNMA8C","canonical_id":"hgnc:HGNC:53427","description":"PNMA family member 8C","metadata":null},{"id":"3c89849a7d8748c7985223b6828c1483","type":"GENE","name":"PNMT","canonical_id":"hgnc:HGNC:9160","description":"phenylethanolamine N-methyltransferase","metadata":{"aliases":["PENT"]}},{"id":"65c1b8ab91064c548f210779180b5d7c","type":"GENE","name":"PNN","canonical_id":"hgnc:HGNC:9162","description":"pinin, desmosome associated protein","metadata":{"aliases":["memA"]}},{"id":"91c16f7cbc504731b62fa0906090189b","type":"GENE","name":"PNN-AS1","canonical_id":"hgnc:HGNC:55974","description":"PNN antisense RNA 1","metadata":null},{"id":"c6cac040c60748af9f0bee6f050a8724","type":"GENE","name":"PNO1","canonical_id":"hgnc:HGNC:32790","description":"partner of NOB1 homolog","metadata":{"aliases":["RRP20","KHRBP1"]}},{"id":"7245582b39f04d8a88b2fd7a3fa5f844","type":"GENE","name":"PNOC","canonical_id":"hgnc:HGNC:9163","description":null,"metadata":null},{"id":"e5b2f34763464dc2a48077ecc183b902","type":"GENE","name":"PNP","canonical_id":"hgnc:HGNC:7892","description":"purine nucleoside phosphorylase","metadata":{"aliases":["PUNP","NP"]}},{"id":"72afd94f20584b16a5151bbb23a8b32b","type":"GENE","name":"PNPLA1","canonical_id":"hgnc:HGNC:21246","description":"patatin like domain 1, omega-hydroxyceramide transacylase ","metadata":{"aliases":["FLJ38755","dJ50J22.1"]}},{"id":"ccdc99198c8b4428866fafea3949e233","type":"GENE","name":"PNPLA1-AS1","canonical_id":"hgnc:HGNC:59389","description":"PNPLA1 antisense RNA 1","metadata":null},{"id":"66beb21746e0459da55c7d3a4663773a","type":"GENE","name":"PNPLA10P","canonical_id":"hgnc:HGNC:32928","description":"patatin like phospholipase domain containing 10 pseudogene","metadata":null},{"id":"e2a04ed39a18410cb13eb8a656c5e988","type":"GENE","name":"PNPLA2","canonical_id":"hgnc:HGNC:30802","description":"patatin like domain 2, triacylglycerol lipase","metadata":{"aliases":["desnutrin","TTS-2.2","ATGL","FP17548","iPLA2zeta"]}},{"id":"fbdcb067441a41ddbef13b96c7fdcdee","type":"GENE","name":"PNPLA3","canonical_id":"hgnc:HGNC:18590","description":"patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase ","metadata":{"aliases":["dJ796I17.1","FLJ22012","adiponutrin","iPLA2epsilon","C22orf20","ADPN"]}},{"id":"67361ad2c7b34f07b056114d7edb60d3","type":"GENE","name":"PNPLA4","canonical_id":"hgnc:HGNC:24887","description":"patatin like domain 4, phospholipase and triacylglycerol lipase ","metadata":{"aliases":["DXS1283E","GS2","iPLA2eta"]}},{"id":"54a2da8fd3694dd1845f10c14b6d8ec2","type":"GENE","name":"PNPLA4P1","canonical_id":"hgnc:HGNC:38085","description":"patatin like phospholipase domain containing 4 pseudogene 1","metadata":null},{"id":"597f2108146a47d3adfc79d55ceab96f","type":"GENE","name":"PNPLA5","canonical_id":"hgnc:HGNC:24888","description":"patatin like domain 5, triacylglycerol lipase ","metadata":{"aliases":["dJ388M5.4","GS2L"]}},{"id":"6750672863c745eb8efafc0d1b500092","type":"GENE","name":"PNPLA6","canonical_id":"hgnc:HGNC:16268","description":"patatin like domain 6, lysophospholipase ","metadata":{"aliases":["NTE","sws","iPLA2delta","SPG39"]}},{"id":"e992b715d6c7436f91d86105e51fc7f6","type":"GENE","name":"PNPLA7","canonical_id":"hgnc:HGNC:24768","description":"patatin like domain 7, lysophospholipase","metadata":{"aliases":["FLJ43070","FLJ31318","FLJ44279","RP11-48C7.2","NTEL1","NTE-R1","C9orf111"]}},{"id":"8dd77ad1d4d44f31bebf4f63575bb5d0","type":"GENE","name":"PNPLA8","canonical_id":"hgnc:HGNC:28900","description":"patatin like domain 8, phospholipase A2 ","metadata":{"aliases":["IPLA2G","IPLA2-2","iPLA2gamma"]}},{"id":"f80994d8fa624de5971313f07d6b109a","type":"GENE","name":"PNPO","canonical_id":"hgnc:HGNC:30260","description":"pyridoxamine 5'-phosphate oxidase","metadata":{"aliases":["PDXPO"]}},{"id":"7ad9eab762844a378717e8dc54a4190e","type":"GENE","name":"PNPP1","canonical_id":"hgnc:HGNC:54649","description":"PNP pseudogene 1","metadata":null},{"id":"c825f20fd4d6427fab98ce5b5f0e575c","type":"GENE","name":"PNPT1","canonical_id":"hgnc:HGNC:23166","description":"polyribonucleotide nucleotidyltransferase 1","metadata":{"aliases":["PNPase","OLD35","old-35","DFNB70"]}},{"id":"5e683af937e540cba545702120ddeaf3","type":"GENE","name":"PNPT1P1","canonical_id":"hgnc:HGNC:44468","description":"polyribonucleotide nucleotidyltransferase 1 pseudogene 1","metadata":null},{"id":"6df25a73e56f4e23bd86ed53fe2624e7","type":"GENE","name":"PNPT1P2","canonical_id":"hgnc:HGNC:44469","description":"polyribonucleotide nucleotidyltransferase 1 pseudogene 2","metadata":null},{"id":"df229ecd51cd45b1971da88f0760b52c","type":"GENE","name":"PNRC1","canonical_id":"hgnc:HGNC:17278","description":null,"metadata":null},{"id":"f3b35ea61dcf4360a0507855ff2b3b6b","type":"GENE","name":"PNRC1-DT","canonical_id":"hgnc:HGNC:55238","description":"PNRC1 divergent transcript","metadata":null},{"id":"26e8d89662024287a2c350849acc5d31","type":"GENE","name":"PNRC2","canonical_id":"hgnc:HGNC:23158","description":null,"metadata":null},{"id":"2a32a9377a05423087293e9a0a52bbcc","type":"GENE","name":"PNRC2P1","canonical_id":"hgnc:HGNC:51933","description":"proline rich nuclear receptor coactivator 2 pseudogene 1","metadata":null},{"id":"d06639176e404c0c9a150f9e59b6702e","type":"GENE","name":"PNRC2P2","canonical_id":"hgnc:HGNC:58513","description":"PNRC2 pseudogene 2","metadata":null},{"id":"0fcda3ec43c94200a716fae2ba2d29e9","type":"GENE","name":"PNRC2P3","canonical_id":"hgnc:HGNC:58514","description":"PNRC2 pseudogene 3","metadata":null},{"id":"32f753c072d54b359a01b40cc8f65b2b","type":"GENE","name":"PNRC2P4","canonical_id":"hgnc:HGNC:58515","description":"PNRC2 pseudogene 4","metadata":null},{"id":"a6b03441a3234e73966273e472321982","type":"GENE","name":"POC1A","canonical_id":"hgnc:HGNC:24488","description":"POC1 centriolar protein A","metadata":{"aliases":["DKFZP434C245","WDR51A"]}},{"id":"2d41c54fcee54a8f8c1562f30e00068b","type":"GENE","name":"POC1B","canonical_id":"hgnc:HGNC:30836","description":"POC1 centriolar protein B","metadata":{"aliases":["TUWD12","FLJ14923","WDR51B"]}},{"id":"362ef7aae58c49a0b878f1d2876dd416","type":"GENE","name":"POC1B-AS1","canonical_id":"hgnc:HGNC:52949","description":"POC1B antisense RNA 1","metadata":{"aliases":["RP11-734K2.4"]}},{"id":"1ca2ff39189845c5b509ff52b1c721ac","type":"GENE","name":"POC1B-GALNT4","canonical_id":"hgnc:HGNC:42957","description":"POC1B-GALNT4 readthrough","metadata":null},{"id":"4f6848d3b07048c0b72c9182af8f9471","type":"GENE","name":"POC5","canonical_id":"hgnc:HGNC:26658","description":"POC5 centriolar protein","metadata":{"aliases":["FLJ35779","MGC120442","MGC120443","MGC120444","hPOC5","C5orf37"]}},{"id":"809b6bfe6bc0407fa8e6c9962cf011ef","type":"GENE","name":"POC5-DT","canonical_id":"hgnc:HGNC:59071","description":"POC5 divergent transcript","metadata":null},{"id":"5d29baeeca444a3299aeda7d86404d43","type":"GENE","name":"PODN","canonical_id":"hgnc:HGNC:23174","description":"podocan","metadata":{"aliases":["PCAN","PODOCAN","MGC24995","SLRR5A"]}},{"id":"8e883680c7564af181d99794629cea6c","type":"GENE","name":"PODNL1","canonical_id":"hgnc:HGNC:26275","description":"podocan like 1","metadata":{"aliases":["FLJ23447","SLRR5B"]}},{"id":"fe892588cbab40129e4a2443386dffab","type":"GENE","name":"PODXL","canonical_id":"hgnc:HGNC:9171","description":null,"metadata":null},{"id":"3aab0e86929e40e59b0d3b05a4285c46","type":"GENE","name":"PODXL2","canonical_id":"hgnc:HGNC:17936","description":"podocalyxin like 2","metadata":{"aliases":["PODLX2","endoglycan","EG"]}},{"id":"f650cb06ccbe41d789d409619c153446","type":"TRIAL","name":"POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT01319864","description":"Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL","metadata":null},{"id":"a037b4df5f3f483e80801ce6f6ec9e4d","type":"TRIAL","name":"POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST","canonical_id":"clinicaltrials.gov:NCT03171389","description":"GIST, Malignant; KIT Exon 13 Mutation; KIT Gene Mutation","metadata":null},{"id":"3841aee57bfe4247877e2d106d70b36c","type":"GENE","name":"POF1B","canonical_id":"hgnc:HGNC:13711","description":"POF1B actin binding protein","metadata":{"aliases":["POF","FLJ22792"]}},{"id":"3ebe5bc90dd944bf928f818f42f54cf4","type":"GENE","name":"POFUT1","canonical_id":"hgnc:HGNC:14988","description":"protein O-fucosyltransferase 1","metadata":{"aliases":["O-FUT","O-Fuc-T","KIAA0180","FUT12"]}},{"id":"c05bbe214b8040e89d5defc509d47c59","type":"GENE","name":"POFUT2","canonical_id":"hgnc:HGNC:14683","description":"protein O-fucosyltransferase 2","metadata":{"aliases":["KIAA0958","FUT13","C21orf80"]}},{"id":"318db0befb1646dda373bd54e25327ff","type":"GENE","name":"POFUT3","canonical_id":"hgnc:HGNC:19234","description":"protein O-fucosyltransferase 3","metadata":{"aliases":["FUT10"]}},{"id":"769e8214531a4c889ad0fad26a5a2cae","type":"GENE","name":"POFUT4","canonical_id":"hgnc:HGNC:19233","description":"protein O-fucosyltransferase 4","metadata":{"aliases":["MGC33202","FUT11"]}},{"id":"95019c8f67884a339c161083833ecbd8","type":"GENE","name":"POGK","canonical_id":"hgnc:HGNC:18800","description":"pogo transposable element derived with KRAB domain","metadata":{"aliases":["KIAA15131","LST003","BASS2","KRBOX2"]}},{"id":"414ec3f75e824dc18f91f22cb7d50c3a","type":"GENE","name":"POGLUT1","canonical_id":"hgnc:HGNC:22954","description":"protein O-glucosyltransferase 1","metadata":{"aliases":["MDS010","MGC32995","9630046K23Rik","MDSRP","hCLP46","KDELCL1","Rumi","C3orf9","KTELC1"]}},{"id":"1fad7578c9b944bc8a2d608d8816a499","type":"GENE","name":"POGLUT2","canonical_id":"hgnc:HGNC:19350","description":"protein O-glucosyltransferase 2","metadata":{"aliases":["MGC5302","EP58","KDELC1"]}},{"id":"8720f224a6374bdd937b8de55dcea7c2","type":"GENE","name":"POGLUT2P1","canonical_id":"hgnc:HGNC:39193","description":"POGLUT2 pseudogene 1","metadata":{"aliases":["KDELC1P1"]}},{"id":"1693c12d4ef545c380484691bb763246","type":"GENE","name":"POGLUT3","canonical_id":"hgnc:HGNC:28496","description":"protein O-glucosyltransferase 3","metadata":{"aliases":["MGC33424","KDELC2"]}},{"id":"a40326d664064ad89fd356af6b581719","type":"GENE","name":"POGZ","canonical_id":"hgnc:HGNC:18801","description":"pogo transposable element derived with ZNF domain","metadata":{"aliases":["KIAA0461","ZNF635","ZNF280E"]}},{"id":"08e489baf3bf45a4a62bcc52463e2008","type":"TRIAL","name":"POISE Trial: Perioperative Ischemic Evaluation Study","canonical_id":"clinicaltrials.gov:NCT00182039","description":"Cardiovascular Diseases","metadata":null},{"id":"71786bb3f244469fbc92840e9fbd8a33","type":"TRIAL","name":"POLA+BR for Relapsed or Refractory DLBCL","canonical_id":"clinicaltrials.gov:NCT04535102","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"58d3146bb3194c8ba01a79a8ffcaf8ed","type":"GENE","name":"POLA1","canonical_id":"hgnc:HGNC:9173","description":"DNA polymerase alpha 1, catalytic subunit","metadata":{"aliases":["p180","POLA","NSX"]}},{"id":"33254c54a0284cc2afdd31fb6ef45603","type":"PROTEIN","name":"POLA1","canonical_id":"uniprot:P09884","description":null,"metadata":null},{"id":"ca9e30124ae94442987ff25b7932a678","type":"GENE","name":"POLA1-AS1","canonical_id":"hgnc:HGNC:58980","description":"POLA1 antisense RNA 1","metadata":{"aliases":["uc.469","uc.468"]}},{"id":"0ab0c0c960544bf185ad97079db00dcc","type":"GENE","name":"POLA2","canonical_id":"hgnc:HGNC:30073","description":"DNA polymerase alpha 2, accessory subunit","metadata":{"aliases":["FLJ21662"]}},{"id":"720e11f945de47fe86d85933c3ede806","type":"GENE","name":"POLB","canonical_id":"hgnc:HGNC:9174","description":null,"metadata":null},{"id":"4a5164a795f54e6fbe5a657f7bc86e4d","type":"GENE","name":"POLD1","canonical_id":"hgnc:HGNC:9175","description":null,"metadata":null},{"id":"ed734df874aa4a3f81ea52e2a484e335","type":"GENE","name":"POLD2","canonical_id":"hgnc:HGNC:9176","description":null,"metadata":null},{"id":"ca03cbcd14784e77ac5b3bbe9201c277","type":"GENE","name":"POLD2P1","canonical_id":"hgnc:HGNC:41522","description":"DNA polymerase delta 2, accessory subunit pseudogene 1","metadata":null},{"id":"81a1d59bfb0a4e20985533cfc4c4c286","type":"GENE","name":"POLD3","canonical_id":"hgnc:HGNC:20932","description":"DNA polymerase delta 3, accessory subunit","metadata":{"aliases":["P66","KIAA0039","P68","PPP1R128"]}},{"id":"6178bf0f2e454655a924b11b3267e8d0","type":"GENE","name":"POLD4","canonical_id":"hgnc:HGNC:14106","description":"DNA polymerase delta 4, accessory subunit","metadata":{"aliases":["p12","POLDS"]}},{"id":"68115c19194849b1b86c2d2b9be5612e","type":"GENE","name":"POLDIP2","canonical_id":"hgnc:HGNC:23781","description":"DNA polymerase delta interacting protein 2","metadata":{"aliases":["PDIP38","DKFZP586F1524"]}},{"id":"945919da686c4f83a92bc591fa713e1d","type":"GENE","name":"POLDIP3","canonical_id":"hgnc:HGNC:23782","description":"DNA polymerase delta interacting protein 3","metadata":{"aliases":["PDIP46","KIAA1649","SKAR","PDIP3"]}},{"id":"ab66ac8eb6ac4e2e91b5186f3859b261","type":"GENE","name":"POLE","canonical_id":"hgnc:HGNC:9177","description":"DNA polymerase epsilon, catalytic subunit","metadata":{"aliases":["POLE1"]}},{"id":"6e4cb724572349ff956fdc05d5045300","type":"GENE","name":"POLE2","canonical_id":"hgnc:HGNC:9178","description":null,"metadata":null},{"id":"5bdb943c35bd4c848d9cca530bdf3d93","type":"GENE","name":"POLE3","canonical_id":"hgnc:HGNC:13546","description":"DNA polymerase epsilon 3, accessory subunit","metadata":{"aliases":["CHRAC17","Ybl1","p17","CHARAC17","CHRAC2"]}},{"id":"8cd50812b31044ceba0537e1af3a7acb","type":"GENE","name":"POLE4","canonical_id":"hgnc:HGNC:18755","description":"DNA polymerase epsilon 4, accessory subunit","metadata":{"aliases":["p12"]}},{"id":"c9683abfd9274b6280accceb059cbd6a","type":"GENE","name":"POLE4P1","canonical_id":"hgnc:HGNC:56408","description":"POLE4 pseudogene 1","metadata":null},{"id":"99fd6747c3904876801d68b2fae96edd","type":"GENE","name":"POLG","canonical_id":"hgnc:HGNC:9179","description":"DNA polymerase gamma, catalytic subunit","metadata":{"aliases":["POLG1","POLGA"]}},{"id":"2fa6c048b1644c858ce162802dfda7b8","type":"GENE","name":"POLG-DT","canonical_id":"hgnc:HGNC:55363","description":"POLG divergent transcript","metadata":null},{"id":"1488a1159bcc43e9ae02b33128751c82","type":"GENE","name":"POLG2","canonical_id":"hgnc:HGNC:9180","description":"DNA polymerase gamma 2, accessory subunit","metadata":{"aliases":["MTPOLB","HP55"]}},{"id":"749f4aa77b2d422e870e8bcf9aa6b93c","type":"GENE","name":"POLGARF","canonical_id":"hgnc:HGNC:56246","description":"POLG alternative reading frame","metadata":{"aliases":["ORF-Y"]}},{"id":"82bdd4af46d34616bdaca07ee94ba064","type":"GENE","name":"POLH","canonical_id":"hgnc:HGNC:9181","description":null,"metadata":null},{"id":"e9f8a1dcfa3f4503b8268c38cf49254c","type":"GENE","name":"POLH-AS1","canonical_id":"hgnc:HGNC:40459","description":"POLH antisense RNA 1","metadata":{"aliases":["RP3-337H4.8"]}},{"id":"ad0118f0066043f09862736443e5a487","type":"GENE","name":"POLHP1","canonical_id":"hgnc:HGNC:43967","description":"DNA polymerase eta pseudogene 1","metadata":null},{"id":"2bbb4f3a4c374102baa1be4621938a2e","type":"GENE","name":"POLI","canonical_id":"hgnc:HGNC:9182","description":"DNA polymerase iota","metadata":{"aliases":["RAD3OB","RAD30B"]}},{"id":"f59a4fab73174a7985faaf3bdc91e9f0","type":"GENE","name":"POLK","canonical_id":"hgnc:HGNC:9183","description":null,"metadata":null},{"id":"3de10a5349be42019f79734b5412b44a","type":"GENE","name":"POLK-AS1","canonical_id":"hgnc:HGNC:40460","description":"POLK antisense RNA 1","metadata":null},{"id":"28db42ef3e9341c8bc69c4196b6d9b37","type":"GENE","name":"POLL","canonical_id":"hgnc:HGNC:9184","description":"DNA polymerase lambda","metadata":null},{"id":"783240b420bd4238a05839e5dbee78a0","type":"GENE","name":"POLM","canonical_id":"hgnc:HGNC:9185","description":"DNA polymerase mu","metadata":{"aliases":["Tdt-N"]}},{"id":"77dbf11a405b4b198854aa0e4108ff41","type":"GENE","name":"POLN","canonical_id":"hgnc:HGNC:18870","description":"DNA polymerase nu","metadata":null},{"id":"90a39c20836f4e5380e657c482f9cb9b","type":"GENE","name":"POLQ","canonical_id":"hgnc:HGNC:9186","description":"DNA polymerase theta","metadata":{"aliases":["POLH"]}},{"id":"d377355d1af14f2f86ff1964aa07c4ed","type":"GENE","name":"POLR1A","canonical_id":"hgnc:HGNC:17264","description":null,"metadata":null},{"id":"4bfb8b251195411aa03cac6407510042","type":"GENE","name":"POLR1B","canonical_id":"hgnc:HGNC:20454","description":"RNA polymerase I subunit B","metadata":{"aliases":["Rpo1-2","FLJ21921","FLJ10816","RPA2","RPA135"]}},{"id":"e0e350ae21924cf49026eadf3cc27f98","type":"GENE","name":"POLR1C","canonical_id":"hgnc:HGNC:20194","description":"RNA polymerase I and III subunit C","metadata":{"aliases":["RPA40","RPA39","RPA5","RPAC1","AC40","RPC40"]}},{"id":"c024ee6dac864723bb57fa021602404d","type":"GENE","name":"POLR1D","canonical_id":"hgnc:HGNC:20422","description":"RNA polymerase I and III subunit D","metadata":{"aliases":["RPAC2","RPA16","RPO1-3","RPA9","MGC9850","AC19"]}},{"id":"4736b36929c944f58185c473d6bb5850","type":"GENE","name":"POLR1E","canonical_id":"hgnc:HGNC:17631","description":"RNA polymerase I subunit E","metadata":{"aliases":["FLJ13390","PAF53","FLJ13970","RPA49","PRAF1"]}},{"id":"98d68813720249b4b157f3cdf4bfd15e","type":"GENE","name":"POLR1F","canonical_id":"hgnc:HGNC:18027","description":"RNA polymerase I subunit F","metadata":{"aliases":["RPA43","A43","TWISTNB"]}},{"id":"ebf52dba57b8414a89d091aac9f1b02e","type":"GENE","name":"POLR1G","canonical_id":"hgnc:HGNC:24219","description":"RNA polymerase I subunit G","metadata":{"aliases":["ASE-1","CAST","PAF49","RPA34","A34.5","CD3EAP"]}},{"id":"6686e8179a5741c084fbe1732b9ca2f8","type":"GENE","name":"POLR1HASP","canonical_id":"hgnc:HGNC:13924","description":"POLR1H antisense, pseudogene","metadata":{"aliases":["HTEX4","Em:AB023056.3","HCGVIII","HCGVIII-1","C6orf12","NCRNA00171","ZNRD1AS","ZNRD1-AS","ZNRD1-AS1","HCG8","ZNRD1ASP"]}},{"id":"4d58234a9d77489ab87e30f1378af8db","type":"GENE","name":"POLR2A","canonical_id":"hgnc:HGNC:9187","description":"RNA polymerase II subunit A","metadata":{"aliases":["POLRA","RPB1","POLR2"]}},{"id":"2122960bd6a8460c96898609be482ff3","type":"GENE","name":"POLR2B","canonical_id":"hgnc:HGNC:9188","description":"RNA polymerase II subunit B","metadata":{"aliases":["RPB2"]}},{"id":"cbd4c33002ea44e58e2847e761e15875","type":"GENE","name":"POLR2C","canonical_id":"hgnc:HGNC:9189","description":"RNA polymerase II subunit C","metadata":{"aliases":["RPB3"]}},{"id":"edd6890c0be34a54a99516170ef3994a","type":"GENE","name":"POLR2CP1","canonical_id":"hgnc:HGNC:9190","description":"RNA polymerase II subunit C pseudogene 1","metadata":{"aliases":["POLR2CP"]}},{"id":"fbac007c639d46679d383665d8b5aa50","type":"GENE","name":"POLR2D","canonical_id":"hgnc:HGNC:9191","description":"RNA polymerase II subunit D","metadata":{"aliases":["RPB4"]}},{"id":"a8f0d0d594fb4722b6255ce181554f59","type":"GENE","name":"POLR2DP1","canonical_id":"hgnc:HGNC:54764","description":"POLR2D pseudogene 1","metadata":null},{"id":"6ee750497e4f4cba925fe315a9c77890","type":"GENE","name":"POLR2DP2","canonical_id":"hgnc:HGNC:54765","description":"POLR2D pseudogene 2","metadata":null},{"id":"c049be14a97e472784f80c5845f2cb7e","type":"GENE","name":"POLR2E","canonical_id":"hgnc:HGNC:9192","description":"RNA polymerase II, I and III subunit E","metadata":{"aliases":["RPB5","RPABC1","XAP4","hRPB25","hsRPB5"]}},{"id":"7c026223c4144414a7ce438cea950e29","type":"GENE","name":"POLR2F","canonical_id":"hgnc:HGNC:9193","description":"RNA polymerase II, I and III subunit F","metadata":{"aliases":["RPB6","HRBP14.4"]}},{"id":"aadb7114e74040be9be81290105a0717","type":"GENE","name":"POLR2F-AS1","canonical_id":"hgnc:HGNC:40461","description":"POLR2F antisense RNA 1","metadata":null},{"id":"5cda9efaf9c74fc49066bd6f7e338318","type":"GENE","name":"POLR2G","canonical_id":"hgnc:HGNC:9194","description":"RNA polymerase II subunit G","metadata":{"aliases":["hRPB19","hsRPB7","RPB7"]}},{"id":"c9524dc6aab34dc48b169413baf3d76d","type":"GENE","name":"POLR2H","canonical_id":"hgnc:HGNC:9195","description":"RNA polymerase II, I and III subunit H","metadata":{"aliases":["RPB8"]}},{"id":"f7d829e73cb64c0c9e634e0de3f0d5ac","type":"GENE","name":"POLR2I","canonical_id":"hgnc:HGNC:9196","description":"RNA polymerase II subunit I","metadata":{"aliases":["RPB9","hRPB14.5"]}},{"id":"249ceef4de5f46ceb4617a98b84d815f","type":"GENE","name":"POLR2J","canonical_id":"hgnc:HGNC:9197","description":"RNA polymerase II subunit J","metadata":{"aliases":["RPB11","hRPB14","RPB11A","RPB11m","POLR2J1"]}},{"id":"39b42248203b45c3b1166da734e92d7a","type":"GENE","name":"POLR2J2","canonical_id":"hgnc:HGNC:23208","description":"RNA polymerase II subunit J2","metadata":{"aliases":["RPB11b1"]}},{"id":"98b38fd8634b4897b4df9d0b992db4c8","type":"GENE","name":"POLR2J3","canonical_id":"hgnc:HGNC:33853","description":"RNA polymerase II subunit J3","metadata":null},{"id":"4314148c16664156a8817f03906ed33e","type":"GENE","name":"POLR2J3-UPK3BL2","canonical_id":"hgnc:HGNC:58364","description":"POLR2J3-UPK3BL2 readthrough","metadata":null},{"id":"128b52c54fd747cbb6d7e6531ba849b8","type":"GENE","name":"POLR2J4","canonical_id":"hgnc:HGNC:28195","description":"RNA polymerase II subunit J4 (pseudogene)","metadata":{"aliases":["MGC13098"]}},{"id":"f8fcaad228944078bfcc872d6c5f944c","type":"GENE","name":"POLR2K","canonical_id":"hgnc:HGNC:9198","description":"RNA polymerase II, I and III subunit K","metadata":{"aliases":["RPB10alpha","RPB12"]}},{"id":"c667143ccf1b44e38cf4101e89213f16","type":"GENE","name":"POLR2KP1","canonical_id":"hgnc:HGNC:42650","description":"RNA polymerase II subunit K pseudogene 1","metadata":null},{"id":"223f6a6c4ef2432397cd5c0620553f35","type":"GENE","name":"POLR2KP2","canonical_id":"hgnc:HGNC:42652","description":"RNA polymerase II subunit K pseudogene 2","metadata":null},{"id":"14f9e09dbdf8474f8bebad7a1767e0fc","type":"GENE","name":"POLR2L","canonical_id":"hgnc:HGNC:9199","description":"RNA polymerase II, I and III subunit L","metadata":{"aliases":["RPB10beta","RBP10","RPABC5","RPB7.6","hRPB7.6","hsRPB10b"]}},{"id":"2b9b13d24d724f3195c67b6fbffdb002","type":"GENE","name":"POLR2LP1","canonical_id":"hgnc:HGNC:31340","description":"RNA polymerase II subunit L pseudogene 1","metadata":{"aliases":["AB023060.6","POLR2LP"]}},{"id":"23385c2fe8fb4cb2becb0f190cfe3b8f","type":"GENE","name":"POLR2M","canonical_id":"hgnc:HGNC:14862","description":"RNA polymerase II subunit M","metadata":{"aliases":["Gdown","Gdown1","GRINL1A"]}},{"id":"3f46e1047b494f178b66912a6a60d6d5","type":"GENE","name":"POLR2MP1","canonical_id":"hgnc:HGNC:15712","description":"POLR2M pseudogene 1","metadata":{"aliases":["GLURR2","GRINL1B","GCOM2"]}},{"id":"900f91f9c798430bba85e35fe25a08dc","type":"GENE","name":"POLR3A","canonical_id":"hgnc:HGNC:30074","description":"RNA polymerase III subunit A","metadata":{"aliases":["RPC1","RPC155","hRPC155","C160"]}},{"id":"c86664cc0b0c4b6683c1015fa9b44ceb","type":"GENE","name":"POLR3B","canonical_id":"hgnc:HGNC:30348","description":"RNA polymerase III subunit B","metadata":{"aliases":["RPC2","FLJ10388","C128"]}},{"id":"f055e950a3774759867dc350e0b03f73","type":"GENE","name":"POLR3C","canonical_id":"hgnc:HGNC:30076","description":"RNA polymerase III subunit C","metadata":{"aliases":["RPC62","RPC3","C82"]}},{"id":"c90074f649c6445dbc7d618743b921fb","type":"GENE","name":"POLR3D","canonical_id":"hgnc:HGNC:1080","description":null,"metadata":null},{"id":"13c24f2ba6684cc1b9757661a256888d","type":"GENE","name":"POLR3DP1","canonical_id":"hgnc:HGNC:45107","description":"RNA polymerase III subunit D pseudogene 1","metadata":null},{"id":"f6336080fe51444dbc10eb9b13b8ec11","type":"GENE","name":"POLR3E","canonical_id":"hgnc:HGNC:30347","description":"RNA polymerase III subunit E","metadata":{"aliases":["RPC5","SIN","FLJ10509","C37"]}},{"id":"816aaa50444f46aab445cd23b2e12641","type":"GENE","name":"POLR3F","canonical_id":"hgnc:HGNC:15763","description":"RNA polymerase III subunit F","metadata":{"aliases":["RPC39","RPC6","C34"]}},{"id":"3711c8496d394b368038fa192847e1c1","type":"GENE","name":"POLR3G","canonical_id":"hgnc:HGNC:30075","description":"RNA polymerase III subunit G","metadata":{"aliases":["RPC32","RPC7","C31"]}},{"id":"24b7de3ae5174bd4bfe8343ad8a768ca","type":"GENE","name":"POLR3GL","canonical_id":"hgnc:HGNC:28466","description":"RNA polymerase III subunit GL","metadata":{"aliases":["flj32422","MGC3200"]}},{"id":"85a5402869ac4863907efa4b3ef7b6cf","type":"GENE","name":"POLR3GP1","canonical_id":"hgnc:HGNC:23345","description":"RNA polymerase III subunit G pseudogene 1","metadata":null},{"id":"ca148942eb064dfa85db1c2d3d6b2278","type":"GENE","name":"POLR3GP2","canonical_id":"hgnc:HGNC:50691","description":"RNA polymerase III subunit G pseudogene 2","metadata":null},{"id":"08b21a228e564249a42ead88b8d60189","type":"GENE","name":"POLR3H","canonical_id":"hgnc:HGNC:30349","description":"RNA polymerase III subunit H","metadata":{"aliases":["RPC8","KIAA1665","C25"]}},{"id":"b8a948ff74d44ab19b5242ff2e423311","type":"GENE","name":"POLR3K","canonical_id":"hgnc:HGNC:14121","description":"RNA polymerase III subunit K","metadata":{"aliases":["RPC11","C11"]}},{"id":"96b16f6b1e5a48de9bf0c182d74b493c","type":"GENE","name":"POLR3KP1","canonical_id":"hgnc:HGNC:39577","description":"RNA polymerase III subunit K pseudogene 1","metadata":null},{"id":"b8f68a1547734d1fbbbe21fdeabf0738","type":"GENE","name":"POLR3KP2","canonical_id":"hgnc:HGNC:39578","description":"RNA polymerase III subunit K pseudogene 2","metadata":null},{"id":"30032555103f4c63991f281d9240cdba","type":"GENE","name":"POLRMT","canonical_id":"hgnc:HGNC:9200","description":"RNA polymerase mitochondrial","metadata":{"aliases":["h-mtRPOL","APOLMT","MTRNAP","MTRPOL"]}},{"id":"0be84a9fe3814310b61c094a2e046dec","type":"GENE","name":"POLRMTP1","canonical_id":"hgnc:HGNC:28865","description":"RNA polymerase mitochondrial pseudogene 1","metadata":{"aliases":["POLRMTL"]}},{"id":"924ecd122d1c446b840648d7545734e1","type":"GENE","name":"POM121","canonical_id":"hgnc:HGNC:19702","description":"POM121 transmembrane nucleoporin","metadata":{"aliases":["KIAA0618","DKFZP586G1822","DKFZP586P2220","POM121A"]}},{"id":"ab673a7ae33747b2b3aedd1067475836","type":"GENE","name":"POM121B","canonical_id":"hgnc:HGNC:34004","description":"POM121 transmembrane nucleoporin B (pseudogene)","metadata":null},{"id":"d738fa6cbbe34a13a4c626286163ed82","type":"GENE","name":"POM121C","canonical_id":"hgnc:HGNC:34005","description":"POM121 transmembrane nucleoporin C","metadata":null},{"id":"213b0aefe5ed48c499a761015031b0fe","type":"GENE","name":"POM121L10P","canonical_id":"hgnc:HGNC:35448","description":"POM121 transmembrane nucleoporin like 10, pseudogene","metadata":null},{"id":"7cc10f6bf1414fe4b23c0adcd1e13ea1","type":"GENE","name":"POM121L11P","canonical_id":"hgnc:HGNC:35447","description":"POM121 transmembrane nucleoporin like 11, pseudogene","metadata":{"aliases":["LOC100129643"]}},{"id":"1807ceec35e6445e874605a63be6e2fa","type":"GENE","name":"POM121L12","canonical_id":"hgnc:HGNC:25369","description":"POM121 transmembrane nucleoporin like 12","metadata":{"aliases":["DKFZp564N2472"]}},{"id":"f05cdecee8d0427e843e166dda52b231","type":"GENE","name":"POM121L13P","canonical_id":"hgnc:HGNC:42635","description":"POM121 transmembrane nucleoporin like 13, pseudogene","metadata":null},{"id":"ec7cc4c0c71d41b0a628311c07db1f89","type":"GENE","name":"POM121L14P","canonical_id":"hgnc:HGNC:44414","description":"POM121 transmembrane nucleoporin like 14, pseudogene","metadata":null},{"id":"71c5e1ba744543519fc343c18963516f","type":"GENE","name":"POM121L15P","canonical_id":"hgnc:HGNC:55894","description":"POM121 transmembrane nucleoporin like 15, pseudogene","metadata":null},{"id":"914cc3bdf7c64795ad8ed1a87a244705","type":"GENE","name":"POM121L1P","canonical_id":"hgnc:HGNC:16439","description":"POM121 transmembrane nucleoporin like 1, pseudogene","metadata":{"aliases":["POM121L1"]}},{"id":"e63162f66a1c4baa8531ab5e7129b72a","type":"GENE","name":"POM121L2","canonical_id":"hgnc:HGNC:13973","description":"POM121 transmembrane nucleoporin like 2","metadata":{"aliases":["POM121-L"]}},{"id":"787a4620ae464a019b370166902d5481","type":"GENE","name":"POM121L3P","canonical_id":"hgnc:HGNC:16440","description":"POM121 transmembrane nucleoporin like 3, pseudogene","metadata":{"aliases":["dJ831C21.3","POM121L3"]}},{"id":"9daec612faa1433a9b69cfb9cf83eea8","type":"GENE","name":"POM121L4P","canonical_id":"hgnc:HGNC:19326","description":"POM121 transmembrane nucleoporin like 4, pseudogene","metadata":null},{"id":"e8ba065b7e894d998f026d4a23907547","type":"GENE","name":"POM121L6P","canonical_id":"hgnc:HGNC:31343","description":"POM121 transmembrane nucleoporin like 6, pseudogene","metadata":{"aliases":["bA239L20.2"]}},{"id":"2588482186994d47b406443a8e4c2271","type":"GENE","name":"POM121L7P","canonical_id":"hgnc:HGNC:35444","description":"POM121 transmembrane nucleoporin like 7 pseudogene","metadata":{"aliases":["POM121L7"]}},{"id":"98897781f2be43adbeb4857b098c7329","type":"GENE","name":"POM121L8P","canonical_id":"hgnc:HGNC:35446","description":"POM121 transmembrane nucleoporin like 8, pseudogene","metadata":null},{"id":"c30a4e3227c14c40afaa0b8a7549e0c5","type":"GENE","name":"POM121L9P","canonical_id":"hgnc:HGNC:30080","description":"POM121 transmembrane nucleoporin like 9, pseudogene","metadata":null},{"id":"acf22dfb81aa488bb4586d339761d752","type":"GENE","name":"POMC","canonical_id":"hgnc:HGNC:9201","description":"proopiomelanocortin","metadata":{"aliases":["MSH","POC","CLIP","ACTH","NPP","LPH"]}},{"id":"86705a3c30104863b87e172fe490f94f","type":"GENE","name":"POMGNT1","canonical_id":"hgnc:HGNC:19139","description":null,"metadata":null},{"id":"2add4a708bf4452dbaa806af8ccd67b7","type":"GENE","name":"POMGNT2","canonical_id":"hgnc:HGNC:25902","description":"protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)","metadata":{"aliases":["FLJ14566","AGO61","C3orf39","GTDC2"]}},{"id":"41f3867286fb466993b41a62b8867ad6","type":"GENE","name":"POMGNT2-AS1","canonical_id":"hgnc:HGNC:52825","description":"POMGNT2 antisense RNA 1","metadata":null},{"id":"79368b2683864347b2dff606c55f9498","type":"GENE","name":"POMK","canonical_id":"hgnc:HGNC:26267","description":"protein O-mannose kinase","metadata":{"aliases":["FLJ23356","SgK196"]}},{"id":"203582dfadaf4f94bf777532eed46a1e","type":"GENE","name":"POMP","canonical_id":"hgnc:HGNC:20330","description":"proteasome maturation protein","metadata":{"aliases":["HSPC014","UMP1","C13orf12"]}},{"id":"d414bce0b56345a1bd6e9f0c970de9fc","type":"GENE","name":"POMPP1","canonical_id":"hgnc:HGNC:55007","description":"POMP pseudogene 1","metadata":null},{"id":"fe9c2ce9b8914c96894c358dc1f4ccbc","type":"GENE","name":"POMT1","canonical_id":"hgnc:HGNC:9202","description":"protein O-mannosyltransferase 1","metadata":{"aliases":["LGMD2K"]}},{"id":"3b3c07e622fe440aae7048b693f7e349","type":"GENE","name":"POMT2","canonical_id":"hgnc:HGNC:19743","description":"protein O-mannosyltransferase 2","metadata":{"aliases":["LGMD2N"]}},{"id":"a38bda8f792d4f0ea5abff6756801356","type":"GENE","name":"POMZP3","canonical_id":"hgnc:HGNC:9203","description":"POM121 and ZP3 fusion","metadata":{"aliases":["POM-ZP3","POM121"]}},{"id":"f2e08ea2c07f42398df01253e3135610","type":"GENE","name":"PON1","canonical_id":"hgnc:HGNC:9204","description":null,"metadata":null},{"id":"c222ad2e35f441488b522db970269734","type":"GENE","name":"PON2","canonical_id":"hgnc:HGNC:9205","description":null,"metadata":null},{"id":"cf155525aeb443ca9639c85842ab67ec","type":"GENE","name":"PON3","canonical_id":"hgnc:HGNC:9206","description":"paraoxonase 3","metadata":null},{"id":"5018f89061254c838d91ccfea760d42a","type":"GENE","name":"POP1","canonical_id":"hgnc:HGNC:30129","description":"POP1 ribonuclease P/MRP subunit","metadata":null},{"id":"5f8cb7ccded74ba3bccf46f4ff015010","type":"GENE","name":"POP4","canonical_id":"hgnc:HGNC:30081","description":"POP4 ribonuclease P/MRP subunit","metadata":{"aliases":["RPP29"]}},{"id":"aee092628ddd453ca11a3f8bca9e071e","type":"GENE","name":"POP5","canonical_id":"hgnc:HGNC:17689","description":"POP5 ribonuclease P/MRP subunit","metadata":null},{"id":"c1e4cc4abdc643f5b516d13d264ee606","type":"GENE","name":"POP7","canonical_id":"hgnc:HGNC:19949","description":"POP7 ribonuclease P/MRP subunit","metadata":{"aliases":["RPP20","RPP2"]}},{"id":"7e9da5536e6d4676a237e2cd97cc1382","type":"GENE","name":"POPDC1","canonical_id":"hgnc:HGNC:1152","description":"popeye domain cAMP effector 1","metadata":{"aliases":["POP1","HBVES","BVES"]}},{"id":"a12a30637e9a4c9f9243dbb0b56d0398","type":"GENE","name":"POPDC1-AS1","canonical_id":"hgnc:HGNC:21223","description":"POPDC1 antisense RNA 1","metadata":{"aliases":["bA99L11.2","BVES-AS1","C6orf112"]}},{"id":"bb721d56d3724211823c90fd0e9186d5","type":"GENE","name":"POPDC2","canonical_id":"hgnc:HGNC:17648","description":"popeye domain cAMP effector 2","metadata":{"aliases":["POP2"]}},{"id":"a48433719208467abd196a7e5e41a969","type":"GENE","name":"POPDC3","canonical_id":"hgnc:HGNC:17649","description":"popeye domain cAMP effector 3","metadata":{"aliases":["POP3","MGC22671","bA355M14.1"]}},{"id":"266549fd90454b47a9a2089692d226ff","type":"GENE","name":"POR","canonical_id":"hgnc:HGNC:9208","description":null,"metadata":null},{"id":"58369dfa7d204fc3b7caee618b80cf4d","type":"GENE","name":"PORCN","canonical_id":"hgnc:HGNC:17652","description":"porcupine O-acyltransferase","metadata":{"aliases":["MG61","PORC","PPN","por","DHOF"]}},{"id":"a66ab2d9cd884c1ab714446140d6e845","type":"GENE","name":"PORCN-DT","canonical_id":"hgnc:HGNC:55859","description":"PORCN divergent transcript","metadata":null},{"id":"1486a8606bf545b0b5f7ef6acad00b8b","type":"TRIAL","name":"PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial","canonical_id":"clinicaltrials.gov:NCT02382016","description":"Portopulmonary Hypertension","metadata":null},{"id":"90464e8247684154a55c0ac24697ce6f","type":"GENE","name":"POSTN","canonical_id":"hgnc:HGNC:16953","description":null,"metadata":null},{"id":"2bfcaa90753146b4a595583293ccdda4","type":"GENE","name":"POT1","canonical_id":"hgnc:HGNC:17284","description":"protection of telomeres 1","metadata":{"aliases":["hPot1","DKFZp586D211"]}},{"id":"54e98d6ebf284927aa4c1782ce65d3f0","type":"GENE","name":"POT1-AS1","canonical_id":"hgnc:HGNC:49459","description":"POT1 antisense RNA 1","metadata":null},{"id":"186d77ae7b8248aabb1c3b3866b99c99","type":"GENE","name":"POTEA","canonical_id":"hgnc:HGNC:33893","description":"POTE ankyrin domain family member A (gene/pseudogene)","metadata":{"aliases":["POTE8","POTE-8","CT104.3","A26A1"]}},{"id":"678102c71b774711b31cfacf55624ef6","type":"GENE","name":"POTEB","canonical_id":"hgnc:HGNC:33734","description":"POTE ankyrin domain family member B","metadata":{"aliases":["POTE15","POTE-15","CT104.5","A26B1"]}},{"id":"97b1264e573f40daaffa103e5f510623","type":"GENE","name":"POTEB2","canonical_id":"hgnc:HGNC:48327","description":"POTE ankyrin domain family member B2","metadata":null},{"id":"ada51011ce2c42ea8b4da4c8ea17925a","type":"GENE","name":"POTEB3","canonical_id":"hgnc:HGNC:51240","description":"POTE ankyrin domain family member B3","metadata":null},{"id":"a1d837ede16e4fcaa7603ae83a98d89c","type":"GENE","name":"POTEC","canonical_id":"hgnc:HGNC:33894","description":"POTE ankyrin domain family member C","metadata":{"aliases":["POTE18","POTE-18","DKFZp686J0529","CT104.6","A26B2"]}},{"id":"6217a698ac534d48a323c0f35f74b368","type":"GENE","name":"POTED","canonical_id":"hgnc:HGNC:23822","description":"POTE ankyrin domain family member D","metadata":{"aliases":["POTE","POTE-21","POTE21","CT104.1","ANKRD21","A26B3"]}},{"id":"88571b4bd0c840b78362bed80dcd1f14","type":"GENE","name":"POTEE","canonical_id":"hgnc:HGNC:33895","description":"POTE ankyrin domain family member E","metadata":{"aliases":["POTE2","POTE-2","A26C1","POTE2gamma","CT104.2","A26C1A"]}},{"id":"18b3aafa90fc4709a7665f304969204f","type":"GENE","name":"POTEF","canonical_id":"hgnc:HGNC:33905","description":"POTE ankyrin domain family member F","metadata":{"aliases":["POTEACTIN","POTE2alpha","A26C1B"]}},{"id":"3bfe94e448d24c4f91cecd9a9f471b6d","type":"GENE","name":"POTEF-AS1","canonical_id":"hgnc:HGNC:41294","description":"POTEF antisense RNA 1","metadata":null},{"id":"be6f9eba25174b67881f9e270d2e3f99","type":"GENE","name":"POTEG","canonical_id":"hgnc:HGNC:33896","description":"POTE ankyrin domain family member G","metadata":{"aliases":["POTE14","POTE-14","POTE14alpha","CT104.4","A26C2"]}},{"id":"58b0ae8169d5482ca054f326a6da37ff","type":"GENE","name":"POTEH","canonical_id":"hgnc:HGNC:133","description":"POTE ankyrin domain family member H","metadata":{"aliases":["POTE22","CT104.7","ACTBL1","A26C3"]}},{"id":"044ef4e19747433ab585e3b15a0e510c","type":"GENE","name":"POTEH-AS1","canonical_id":"hgnc:HGNC:40058","description":"POTEH antisense RNA 1","metadata":null},{"id":"026a015c882c407ba113f04a0f1d2995","type":"GENE","name":"POTEI","canonical_id":"hgnc:HGNC:37093","description":"POTE ankyrin domain family member I","metadata":{"aliases":["POTE2beta"]}},{"id":"1b4828e3891c4ebdabda328ade1ddb2d","type":"GENE","name":"POTEJ","canonical_id":"hgnc:HGNC:37094","description":"POTE ankyrin domain family member J","metadata":{"aliases":["POTE2beta"]}},{"id":"88b964a6ef2d44be950570bb08dcb08d","type":"GENE","name":"POTEKP","canonical_id":"hgnc:HGNC:30182","description":"POTE ankyrin domain family member K, pseudogene","metadata":{"aliases":["FKSG30","POTE2delta","ACTBL3","POTEK"]}},{"id":"04285b02e19a496f9f63c0d83ace8507","type":"GENE","name":"POTEM","canonical_id":"hgnc:HGNC:37096","description":"POTE ankyrin domain family member M","metadata":{"aliases":["POTE14beta","P704P","ACT"]}},{"id":"c0b54cbeacbc4ff2b50230d5d2a6e70f","type":"TRIAL","name":"POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC","canonical_id":"clinicaltrials.gov:NCT05782361","description":"Advanced Cancer; Non Small Cell Lung Cancer","metadata":null},{"id":"9b4d86daea54443c89ac0226745549c2","type":"GO_TERM","name":"POU domain binding","canonical_id":"go:GO:0070974","description":"\"Binding to a POU domain of a protein. The POU domain is a bipartite DNA binding domain composed of two subunits separated by a non-conserved region of 15-55 amino acids; it is found in several eukaryotic transcription factors.\" [GOC:mah, GOC:yaf, InterPro:IPR000327]","metadata":null},{"id":"edf7615852c74d08bd61482a3931730a","type":"GENE","name":"POU1F1","canonical_id":"hgnc:HGNC:9210","description":null,"metadata":null},{"id":"289d267041394b3d87ffb54f46ce0041","type":"GENE","name":"POU2AF1","canonical_id":"hgnc:HGNC:9211","description":null,"metadata":null},{"id":"c835170878ea4798a3a0ce77d55ca3f1","type":"GENE","name":"POU2AF2","canonical_id":"hgnc:HGNC:30527","description":"POU class 2 homeobox associating factor 2","metadata":{"aliases":["MGC50104","OCA-T1","C11orf53"]}},{"id":"9d45ff19c2fb4146a28d47dd291b7618","type":"GENE","name":"POU2AF3","canonical_id":"hgnc:HGNC:26978","description":"POU class 2 homeobox associating factor 3","metadata":{"aliases":["CASC13","OCA-T2","C11orf93","COLCA2"]}},{"id":"5c345b78d1a04effb3bbb559020923d8","type":"GENE","name":"POU2F1","canonical_id":"hgnc:HGNC:9212","description":null,"metadata":null},{"id":"2efe675490d8418ca5e6e8a48eae6326","type":"GENE","name":"POU2F1-DT","canonical_id":"hgnc:HGNC:55222","description":"POU2F1 divergent transcript","metadata":null},{"id":"b3da34b5809d4051bd80b4f17eb4cf4a","type":"GENE","name":"POU2F2","canonical_id":"hgnc:HGNC:9213","description":null,"metadata":null},{"id":"72cb709674c74a768122821ea16a5098","type":"GENE","name":"POU2F3","canonical_id":"hgnc:HGNC:19864","description":null,"metadata":null},{"id":"ae6f70320eee4cb9af3445bf793d9153","type":"GENE","name":"POU2F3-AS1","canonical_id":"hgnc:HGNC:58296","description":"POU2F3 antisense RNA 1","metadata":null},{"id":"dd4801bce67643e0836395ba7bc3a3d0","type":"GENE","name":"POU3F1","canonical_id":"hgnc:HGNC:9214","description":null,"metadata":null},{"id":"41d185c6b61b40d296e0460da75cd154","type":"GENE","name":"POU3F2","canonical_id":"hgnc:HGNC:9215","description":null,"metadata":null},{"id":"9c74b1f2777f4f4ba8d13c2be8975314","type":"GENE","name":"POU3F3","canonical_id":"hgnc:HGNC:9216","description":"POU class 3 homeobox 3","metadata":{"aliases":["BRN1","OTF8"]}},{"id":"e40dcffac2784475bc30976bd48a377c","type":"GENE","name":"POU3F4","canonical_id":"hgnc:HGNC:9217","description":null,"metadata":null},{"id":"7384cc3139c54efbb4a8ddd31e1dbf53","type":"GENE","name":"POU4F1","canonical_id":"hgnc:HGNC:9218","description":null,"metadata":null},{"id":"c8062030a3494786a0d0575efaae7953","type":"GENE","name":"POU4F2","canonical_id":"hgnc:HGNC:9219","description":null,"metadata":null},{"id":"b499b8372b284736abda97b7ccfbe21c","type":"GENE","name":"POU4F3","canonical_id":"hgnc:HGNC:9220","description":"POU class 4 homeobox 3","metadata":{"aliases":["BRN3C","DFNA15","DFNA52","DFNA42"]}},{"id":"f85cbfca4ad34ec883f366b8def5e74f","type":"GENE","name":"POU4F3-AS1","canonical_id":"hgnc:HGNC:59273","description":"POU4F3 antisense RNA 1","metadata":null},{"id":"a74066e9ae1d4166b0dcffdb8f06909c","type":"GENE","name":"POU5F1","canonical_id":"hgnc:HGNC:9221","description":null,"metadata":null},{"id":"add433f697014a7baa5a698949ea9c63","type":"GENE","name":"POU5F1B","canonical_id":"hgnc:HGNC:9223","description":"POU class 5 homeobox 1B","metadata":{"aliases":["OTF3C","OTF3P1","POU5F1P1"]}},{"id":"c1e954744e824890831ec899fb3a3be3","type":"GENE","name":"POU5F1P2","canonical_id":"hgnc:HGNC:33309","description":"POU class 5 homeobox 1 pseudogene 2","metadata":null},{"id":"70f2280388454fb5ac8a7605b0d63acb","type":"GENE","name":"POU5F1P3","canonical_id":"hgnc:HGNC:9222","description":"POU class 5 homeobox 1 pseudogene 3","metadata":{"aliases":["POU5FLC12","OTF3L","POU5F1L"]}},{"id":"1fad94f350034fb483768be4bb111b88","type":"GENE","name":"POU5F1P4","canonical_id":"hgnc:HGNC:33310","description":"POU class 5 homeobox 1 pseudogene 4","metadata":{"aliases":["POU5FLC1","Oct4-pg4"]}},{"id":"12463896dbcd43a7be6e54b651aad49d","type":"GENE","name":"POU5F1P5","canonical_id":"hgnc:HGNC:33311","description":"POU class 5 homeobox 1 pseudogene 5","metadata":{"aliases":["Oct4-pg5"]}},{"id":"ebef4e9103cd4581b864e7e37ed4c71c","type":"GENE","name":"POU5F1P6","canonical_id":"hgnc:HGNC:33312","description":"POU class 5 homeobox 1 pseudogene 6","metadata":null},{"id":"0f5e1a18dd8a4e2886f29e916dbe5847","type":"GENE","name":"POU5F1P7","canonical_id":"hgnc:HGNC:33313","description":"POU class 5 homeobox 1 pseudogene 7","metadata":null},{"id":"eabb014209d14ce48c0a236bd7ce73d7","type":"GENE","name":"POU5F2","canonical_id":"hgnc:HGNC:26367","description":"POU domain class 5, transcription factor 2","metadata":{"aliases":["SPRM-1","FLJ25680"]}},{"id":"cadc7966fdc349ae9d3731e660841acf","type":"GENE","name":"POU6F1","canonical_id":"hgnc:HGNC:9224","description":"POU class 6 homeobox 1","metadata":{"aliases":["BRN5","MPOU","TCFB1"]}},{"id":"f60f6cfcba7c4f6b82d6f440110061b1","type":"GENE","name":"POU6F2","canonical_id":"hgnc:HGNC:21694","description":"POU class 6 homeobox 2","metadata":{"aliases":["RPF-1"]}},{"id":"fbf1fb8b154c49bf89417297123b8583","type":"GENE","name":"POU6F2-AS1","canonical_id":"hgnc:HGNC:40979","description":"POU6F2 antisense RNA 1","metadata":null},{"id":"fe3a684a05cc497eb0a6f45c8796e6e2","type":"GENE","name":"POU6F2-AS2","canonical_id":"hgnc:HGNC:21887","description":"POU6F2 antisense RNA 2","metadata":{"aliases":["FLJ12971"]}},{"id":"46ca3f3a3a394d399fde3487f453064c","type":"GO_TERM","name":"POZ domain binding","canonical_id":"go:GO:0031208","description":"\"Binding to a POZ (poxvirus and zinc finger) domain of a protein, a protein-protein interaction domain found in many transcription factors.\" [PMID:7958847]","metadata":null},{"id":"d7d9df9188184f809625c52f6613d2f7","type":"GENE","name":"PP1P","canonical_id":"hgnc:HGNC:28884","description":"pyrophosphatase (inorganic) 1 pseudogene","metadata":null},{"id":"8a475a32193f4fdabbbe5904b545eed6","type":"GENE","name":"PP2D1","canonical_id":"hgnc:HGNC:28406","description":"protein phosphatase 2C like domain containing 1","metadata":{"aliases":["FLJ25449","C3orf48"]}},{"id":"ac0f4fb1bb144280991262bd7d5a81e0","type":"GENE","name":"PPA1","canonical_id":"hgnc:HGNC:9226","description":"inorganic pyrophosphatase 1","metadata":{"aliases":["SID6-8061","Ppase","IOPPP","PP1","PP"]}},{"id":"2713d1911bce434a836e65e9972d1658","type":"GENE","name":"PPA2","canonical_id":"hgnc:HGNC:28883","description":"inorganic pyrophosphatase 2","metadata":{"aliases":["FLJ20459"]}},{"id":"2b2b2aa5de1a44bbae07e56c585e09cd","type":"GENE","name":"PPAN","canonical_id":"hgnc:HGNC:9227","description":"peter pan homolog","metadata":{"aliases":["SSF1","SSF2","SSF","BXDC3"]}},{"id":"c272fcde55c54b84b19c304811f901d3","type":"GENE","name":"PPAN-P2RY11","canonical_id":"hgnc:HGNC:33526","description":"PPAN-P2RY11 readthrough","metadata":null},{"id":"45dd31f1c53242ab8165de24fa34c8b5","type":"GENE","name":"PPARA","canonical_id":"hgnc:HGNC:9232","description":null,"metadata":null},{"id":"fb0b836fef37420ea4dc7d03a4761559","type":"PROTEIN","name":"PPARA","canonical_id":"uniprot:Q07869","description":null,"metadata":null},{"id":"b5e291957cfd4f34aebc0b62c0824086","type":"GENE","name":"PPARD","canonical_id":"hgnc:HGNC:9235","description":null,"metadata":null},{"id":"73513972925b45398e7a604cd2740799","type":"PROTEIN","name":"PPARD","canonical_id":"uniprot:Q03181","description":null,"metadata":null},{"id":"7335dd86921648f5bbd327d2f1ca2d72","type":"GENE","name":"PPARG","canonical_id":"hgnc:HGNC:9236","description":null,"metadata":null},{"id":"4076775533c747aa8848972cce4a7a9d","type":"PROTEIN","name":"PPARG","canonical_id":"uniprot:P37231","description":null,"metadata":null},{"id":"3f9034b5cb1a46ed802f8e5529ee86ca","type":"DISEASE","name":"PPARG-related familial partial lipodystrophy","canonical_id":"mondo:0011448","description":null,"metadata":null},{"id":"5b92c87dbd034332a16f5c33ffad5040","type":"GENE","name":"PPARGC1A","canonical_id":"hgnc:HGNC:9237","description":null,"metadata":null},{"id":"eca2feee98e84fdfada66282fbb07856","type":"GENE","name":"PPARGC1A-AS1","canonical_id":"hgnc:HGNC:40462","description":"PPARGC1A antisense RNA 1","metadata":{"aliases":["AC092834.1"]}},{"id":"a3ae1e29f7f345b7abb9818d93a6732f","type":"GENE","name":"PPARGC1A-AS2","canonical_id":"hgnc:HGNC:58744","description":"PPARGC1A antisense RNA 2","metadata":null},{"id":"68084c82a6aa48f4b8d620aa59b0c3c4","type":"GENE","name":"PPARGC1B","canonical_id":"hgnc:HGNC:30022","description":"PPARG coactivator 1 beta","metadata":{"aliases":["PERC","PGC1B","PPARAGCI\u03b2"]}},{"id":"9506f8971a2c4033adedfc2e635f8f28","type":"GENE","name":"PPAT","canonical_id":"hgnc:HGNC:9238","description":"phosphoribosyl pyrophosphate amidotransferase","metadata":{"aliases":["GPAT","PRAT"]}},{"id":"59185f46b51d41f2b9ac01ec582c9c65","type":"GENE","name":"PPATP1","canonical_id":"hgnc:HGNC:9239","description":"phosphoribosyl pyrophosphate amidotransferase pseudogene 1","metadata":null},{"id":"d4b293b01e8e4848a874690f33e91b2a","type":"GENE","name":"PPATP2","canonical_id":"hgnc:HGNC:48738","description":"phosphoribosyl pyrophosphate amidotransferase pseudogene 2","metadata":null},{"id":"d4fb159b2fd34113bd1cb0523bdbf79e","type":"GENE","name":"PPBP","canonical_id":"hgnc:HGNC:9240","description":null,"metadata":null},{"id":"ee8a2933267a4e498e8b0a0433b6179d","type":"GENE","name":"PPBPP1","canonical_id":"hgnc:HGNC:9241","description":"pro-platelet basic protein pseudogene 1","metadata":{"aliases":["TGB2","PPBPL1"]}},{"id":"37dada10920247dc920ffc2e9ace4d64","type":"GENE","name":"PPBPP2","canonical_id":"hgnc:HGNC:16981","description":"pro-platelet basic protein pseudogene 2","metadata":{"aliases":["SPBPBP","PPBPL2"]}},{"id":"c448e1cf6cfa47dc99ad06c4f2e21af2","type":"GENE","name":"PPCDC","canonical_id":"hgnc:HGNC:28107","description":"phosphopantothenoylcysteine decarboxylase","metadata":{"aliases":["MDS018","FLJ14585"]}},{"id":"b004c60d92cb4368bbfbdface655cdde","type":"GENE","name":"PPCS","canonical_id":"hgnc:HGNC:25686","description":"phosphopantothenoylcysteine synthetase","metadata":{"aliases":["FLJ11838"]}},{"id":"116f713d94594224a11b18955b883566","type":"GENE","name":"PPDPF","canonical_id":"hgnc:HGNC:16142","description":"pancreatic progenitor cell differentiation and proliferation factor","metadata":{"aliases":["dJ697K14.9","exdpf","C20orf149"]}},{"id":"01ae61a8bfc948b4bf7ffa0885fc3f6b","type":"GENE","name":"PPDPFL","canonical_id":"hgnc:HGNC:31745","description":"pancreatic progenitor cell differentiation and proliferation factor like","metadata":{"aliases":["C8orf22"]}},{"id":"7d431dfffa3140b6b108adea6101fc90","type":"GENE","name":"PPDPFP1","canonical_id":"hgnc:HGNC:56491","description":"PPDPF pseudogene 1","metadata":null},{"id":"050dba7786784d5f8f00c2c6c45b9e9d","type":"GENE","name":"PPDPFP2","canonical_id":"hgnc:HGNC:56492","description":"PPDPF pseudogene 2","metadata":null},{"id":"8de5619d29d04bdfab0e8984cd3d8742","type":"GENE","name":"PPEF1","canonical_id":"hgnc:HGNC:9243","description":"protein phosphatase with EF-hand domain 1","metadata":{"aliases":["PPP7CA","PPEF"]}},{"id":"2bfe246b2a6c48f29ba61dfd63be923d","type":"GENE","name":"PPEF1-AS1","canonical_id":"hgnc:HGNC:40463","description":"PPEF1 antisense RNA 1","metadata":null},{"id":"9d1e541ce22942369f31c4d466df0d56","type":"GENE","name":"PPEF2","canonical_id":"hgnc:HGNC:9244","description":"protein phosphatase with EF-hand domain 2","metadata":{"aliases":["PPP7CB"]}},{"id":"a1ce1c1b7d8d49518ab779ac8e3dfc85","type":"GENE","name":"PPEF2-AS1","canonical_id":"hgnc:HGNC:58819","description":"PPEF2 antisense RNA1","metadata":null},{"id":"49db5c822cad471d8a347cfd60e368aa","type":"GENE","name":"PPFIA1","canonical_id":"hgnc:HGNC:9245","description":"PPFI scaffold protein A1","metadata":{"aliases":["LIP.1","LIPRIN"]}},{"id":"fadc906088734c7387be0cf31a169b43","type":"GENE","name":"PPFIA1P1","canonical_id":"hgnc:HGNC:54792","description":"PPFIA1 pseudogene 1","metadata":null},{"id":"87ee2ab5eef4460294b9b0f9a52a781c","type":"GENE","name":"PPFIA2","canonical_id":"hgnc:HGNC:9246","description":"PPFI scaffold protein A2","metadata":null},{"id":"fd6ea9af71ab4999b7cbab73a09a7103","type":"GENE","name":"PPFIA2-AS1","canonical_id":"hgnc:HGNC:53397","description":"PPFIA2 antisense RNA 1","metadata":null},{"id":"efca1335431e4348964a2745b43f2ae5","type":"GENE","name":"PPFIA2-AS2","canonical_id":"hgnc:HGNC:58195","description":"PPFIA2 antisense RNA 2","metadata":null},{"id":"65e32643387c4a30b077c7b9c08f9e59","type":"GENE","name":"PPFIA3","canonical_id":"hgnc:HGNC:9247","description":"PPFI scaffold protein A3","metadata":{"aliases":["KIAA0654","LPNA3","MGC126567","MGC126569"]}},{"id":"b34b34773af744c8b4164222e5253d03","type":"GENE","name":"PPFIA4","canonical_id":"hgnc:HGNC:9248","description":"PPFI scaffold protein A4","metadata":null},{"id":"27c40df5907c4e40aba837269e273ca3","type":"GENE","name":"PPFIBP1","canonical_id":"hgnc:HGNC:9249","description":"PPFIB scaffold protein 1","metadata":{"aliases":["L2","hSGT2","hSgt2p","SGT2","liprin-beta1"]}},{"id":"bab76cc0e0d142968165fb72a48c439d","type":"GENE","name":"PPFIBP2","canonical_id":"hgnc:HGNC:9250","description":"PPFIB scaffold protein 2","metadata":{"aliases":["Cclp1"]}},{"id":"2cadba609aee41b3bbc674c5cea85b86","type":"GENE","name":"PPHLN1","canonical_id":"hgnc:HGNC:19369","description":"periphilin 1","metadata":null},{"id":"92b99d758d6e4b8380acff054ac43f1a","type":"TRIAL","name":"PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena","canonical_id":"clinicaltrials.gov:NCT00526006","description":"Healthy","metadata":null},{"id":"1d1492f0031f484db2ee3fee172e50d6","type":"GENE","name":"PPIA","canonical_id":"hgnc:HGNC:9253","description":"peptidylprolyl isomerase A","metadata":{"aliases":["CYPA"]}},{"id":"936c632dfa4b44c5a3de3d9cf2ff5a37","type":"GENE","name":"PPIAL4A","canonical_id":"hgnc:HGNC:24369","description":"peptidylprolyl isomerase A like 4A","metadata":{"aliases":["COAS2","PPIAL4","PPIAL4B"]}},{"id":"797a326e677d4101bd66d9f554baedd7","type":"GENE","name":"PPIAL4C","canonical_id":"hgnc:HGNC:33995","description":"peptidylprolyl isomerase A like 4C","metadata":null},{"id":"dc230f2d03fb42f49b58f6236db7b758","type":"GENE","name":"PPIAL4D","canonical_id":"hgnc:HGNC:33998","description":"peptidylprolyl isomerase A like 4D","metadata":null},{"id":"bac36d40ddf44d008d81cc187dc63208","type":"GENE","name":"PPIAL4E","canonical_id":"hgnc:HGNC:33997","description":"peptidylprolyl isomerase A like 4E","metadata":null},{"id":"f6f6a19cc8b042058120206bf20e5ec1","type":"GENE","name":"PPIAL4F","canonical_id":"hgnc:HGNC:33999","description":"peptidylprolyl isomerase A like 4F","metadata":null},{"id":"eabf3691d7a042a59faf9b8ed97ca9ca","type":"GENE","name":"PPIAL4G","canonical_id":"hgnc:HGNC:33996","description":"peptidylprolyl isomerase A like 4G","metadata":null},{"id":"82c431ae770e49b6bec6be0603f62570","type":"GENE","name":"PPIAL4H","canonical_id":"hgnc:HGNC:53889","description":"peptidylprolyl isomerase A like 4H","metadata":null},{"id":"5a8ffcb6a4a64ef6b9c928b8d583dcbd","type":"GENE","name":"PPIAP1","canonical_id":"hgnc:HGNC:9254","description":"peptidylprolyl isomerase A pseudogene 1","metadata":{"aliases":["PPIAP"]}},{"id":"25a48067355b45498f51ae9c6429f452","type":"GENE","name":"PPIAP10","canonical_id":"hgnc:HGNC:9264","description":"peptidylprolyl isomerase A pseudogene 10","metadata":{"aliases":["CRP","PPIAL2","PPIP10"]}},{"id":"0aedb479b91c40c8b304599334f6c781","type":"GENE","name":"PPIAP11","canonical_id":"hgnc:HGNC:9263","description":"peptidylprolyl isomerase A pseudogene 11","metadata":{"aliases":["PPIP1"]}},{"id":"a3556216a52043718352e357753bff04","type":"GENE","name":"PPIAP13","canonical_id":"hgnc:HGNC:9266","description":"peptidylprolyl isomerase A pseudogene 13","metadata":{"aliases":["PPIP3"]}},{"id":"caa22600d3da4c7a9b6fa6e552ca9f21","type":"GENE","name":"PPIAP14","canonical_id":"hgnc:HGNC:9267","description":"peptidylprolyl isomerase A pseudogene 14","metadata":{"aliases":["PPIP4"]}},{"id":"82b9637c1f9e45a68fb1eb537d304aad","type":"GENE","name":"PPIAP15","canonical_id":"hgnc:HGNC:9268","description":"peptidylprolyl isomerase A pseudogene 15","metadata":{"aliases":["PPIP5"]}},{"id":"bd163b140c1b488791d880733b4d0f65","type":"GENE","name":"PPIAP16","canonical_id":"hgnc:HGNC:9269","description":"peptidylprolyl isomerase A pseudogene 16","metadata":{"aliases":["PPIP6"]}},{"id":"800d01912ecd40448941f2298ff0c290","type":"GENE","name":"PPIAP17","canonical_id":"hgnc:HGNC:16334","description":"peptidylprolyl isomerase A pseudogene 17","metadata":{"aliases":["bA494B22.1","PPIP11"]}},{"id":"4cb452a63b2842c8917c695f0bb4a6d5","type":"GENE","name":"PPIAP18","canonical_id":"hgnc:HGNC:32454","description":"peptidylprolyl isomerase A pseudogene 18","metadata":null},{"id":"f48b88f0967945df81b5abeea8c1841a","type":"GENE","name":"PPIAP19","canonical_id":"hgnc:HGNC:31663","description":"peptidylprolyl isomerase A pseudogene 19","metadata":{"aliases":["bA108K1.2"]}},{"id":"71e17b9794774fe084ff6fe6966bcd4b","type":"GENE","name":"PPIAP2","canonical_id":"hgnc:HGNC:16542","description":"peptidylprolyl isomerase A pseudogene 2","metadata":{"aliases":["bA384D7.2"]}},{"id":"ac125154c83e4adb8747ac203a33b3d0","type":"GENE","name":"PPIAP20","canonical_id":"hgnc:HGNC:38037","description":"peptidylprolyl isomerase A pseudogene 20","metadata":null},{"id":"c144c036a4a34e4da90a8db272d2d3e8","type":"GENE","name":"PPIAP21","canonical_id":"hgnc:HGNC:16246","description":"peptidylprolyl isomerase A pseudogene 21","metadata":{"aliases":["dJ269M15.1","PPIAL"]}},{"id":"ca9c6df08ba84a03b2b5196cc17e2bc7","type":"GENE","name":"PPIAP22","canonical_id":"hgnc:HGNC:17236","description":"peptidylprolyl isomerase A pseudogene 22","metadata":{"aliases":["PPIA3L","PPIAL3"]}},{"id":"c5d1b8cdfab84e57ba3c893c07fd056a","type":"GENE","name":"PPIAP23","canonical_id":"hgnc:HGNC:39268","description":"peptidylprolyl isomerase A pseudogene 23","metadata":null},{"id":"8d8fcd4ac8fa4a33b3fe7cbe98d295b3","type":"GENE","name":"PPIAP24","canonical_id":"hgnc:HGNC:39269","description":"peptidylprolyl isomerase A pseudogene 24","metadata":null},{"id":"687483d2b5bf4a83929772edefaf8e8c","type":"GENE","name":"PPIAP25","canonical_id":"hgnc:HGNC:39270","description":"peptidylprolyl isomerase A pseudogene 25","metadata":null},{"id":"126dd8af31f94aecb5bb6cb44c3fd999","type":"GENE","name":"PPIAP26","canonical_id":"hgnc:HGNC:39271","description":"peptidylprolyl isomerase A pseudogene 26","metadata":null},{"id":"e293dd4e80ee42298503d3d2cfabd798","type":"GENE","name":"PPIAP27","canonical_id":"hgnc:HGNC:42646","description":"peptidylprolyl isomerase A pseudogene 27","metadata":null},{"id":"94a47029d1f4498eb2ccc8c940838cc9","type":"GENE","name":"PPIAP28","canonical_id":"hgnc:HGNC:39902","description":"peptidylprolyl isomerase A pseudogene 28","metadata":null},{"id":"f5108a2098eb49b09cfb9eac18acf92c","type":"GENE","name":"PPIAP29","canonical_id":"hgnc:HGNC:43021","description":"peptidylprolyl isomerase A pseudogene 29","metadata":null},{"id":"6ebf8115671f46769f246d9bf4ff745a","type":"GENE","name":"PPIAP3","canonical_id":"hgnc:HGNC:16545","description":"peptidylprolyl isomerase A pseudogene 3","metadata":{"aliases":["bA425M5.2"]}},{"id":"a06eaeb5105e45e6a71da82c3c54de3c","type":"GENE","name":"PPIAP30","canonical_id":"hgnc:HGNC:44878","description":"peptidylprolyl isomerase A pseudogene 30","metadata":null},{"id":"0224a23a75ac45fd9451c9f3b7283e27","type":"GENE","name":"PPIAP31","canonical_id":"hgnc:HGNC:44962","description":"peptidylprolyl isomerase A pseudogene 31","metadata":null},{"id":"20224f4cc3364287a71a11e7e5350d54","type":"GENE","name":"PPIAP32","canonical_id":"hgnc:HGNC:49531","description":"peptidylprolyl isomerase A pseudogene 32","metadata":null},{"id":"8ce6ce13c7dd4f4d936e286ca5e5a636","type":"GENE","name":"PPIAP33","canonical_id":"hgnc:HGNC:49752","description":"peptidylprolyl isomerase A pseudogene 33","metadata":null},{"id":"2371debf58c549caa92ecc872652d58c","type":"GENE","name":"PPIAP34","canonical_id":"hgnc:HGNC:53658","description":"peptidylprolyl isomerase A pseudogene 34","metadata":null},{"id":"cb7de79e7c1a4e309ac2eeeb3067d27e","type":"GENE","name":"PPIAP35","canonical_id":"hgnc:HGNC:53659","description":"peptidylprolyl isomerase A pseudogene 35","metadata":null},{"id":"734dfa7654e04d0eb4eb1a449f652d5e","type":"GENE","name":"PPIAP36","canonical_id":"hgnc:HGNC:53660","description":"peptidylprolyl isomerase A pseudogene 36","metadata":null},{"id":"ca32590c64a045d7abd9bf77124c5b39","type":"GENE","name":"PPIAP37","canonical_id":"hgnc:HGNC:53661","description":"peptidylprolyl isomerase A pseudogene 37","metadata":null},{"id":"1edaeb4f67f947bca6f59ed528d6f4b6","type":"GENE","name":"PPIAP38","canonical_id":"hgnc:HGNC:53662","description":"peptidylprolyl isomerase A pseudogene 38","metadata":null},{"id":"11787d2e823a4c3d9fc9d114fb2de53c","type":"GENE","name":"PPIAP39","canonical_id":"hgnc:HGNC:53663","description":"peptidylprolyl isomerase A pseudogene 39","metadata":null},{"id":"b34dc790e0b140439db0c32effa53b70","type":"GENE","name":"PPIAP4","canonical_id":"hgnc:HGNC:19935","description":"peptidylprolyl isomerase A pseudogene 4","metadata":null},{"id":"c210284fd0f947c49ecc39cfeeaa417a","type":"GENE","name":"PPIAP40","canonical_id":"hgnc:HGNC:53664","description":"peptidylprolyl isomerase A pseudogene 40","metadata":null},{"id":"5a53f2d763624e919953713cf2327931","type":"GENE","name":"PPIAP41","canonical_id":"hgnc:HGNC:53665","description":"peptidylprolyl isomerase A pseudogene 41","metadata":null},{"id":"d4d37b7173fe4e36bfabca8d393b82ac","type":"GENE","name":"PPIAP42","canonical_id":"hgnc:HGNC:53666","description":"peptidylprolyl isomerase A pseudogene 42","metadata":null},{"id":"7005a2fc392b417e9632ffd8017ae00d","type":"GENE","name":"PPIAP43","canonical_id":"hgnc:HGNC:53667","description":"peptidylprolyl isomerase A pseudogene 43","metadata":null},{"id":"b8aff05ea1034b43a7f14f567ff18f43","type":"GENE","name":"PPIAP44","canonical_id":"hgnc:HGNC:53668","description":"peptidylprolyl isomerase A pseudogene 44","metadata":null},{"id":"35ea8008604242839bedb6d8fc7ea357","type":"GENE","name":"PPIAP45","canonical_id":"hgnc:HGNC:53669","description":"peptidylprolyl isomerase A pseudogene 45","metadata":null},{"id":"ed39b9f7fe1d4e91b6e18117cc35f00a","type":"GENE","name":"PPIAP46","canonical_id":"hgnc:HGNC:53670","description":"peptidylprolyl isomerase A pseudogene 46","metadata":null},{"id":"657d1a655e01457fa96538114b85f4f1","type":"GENE","name":"PPIAP47","canonical_id":"hgnc:HGNC:53671","description":"peptidylprolyl isomerase A pseudogene 47","metadata":null},{"id":"8f4c9aacac404ae6b5741951aa722a95","type":"GENE","name":"PPIAP48","canonical_id":"hgnc:HGNC:53672","description":"peptidylprolyl isomerase A pseudogene 48","metadata":null},{"id":"da1048928c5b455e9a6122c06db4e998","type":"GENE","name":"PPIAP49","canonical_id":"hgnc:HGNC:53673","description":"peptidylprolyl isomerase A pseudogene 49","metadata":null},{"id":"ec0b5ccc54cc48f1a3b568d64a9ca1c7","type":"GENE","name":"PPIAP5","canonical_id":"hgnc:HGNC:20027","description":"peptidylprolyl isomerase A pseudogene 5","metadata":null},{"id":"5e3017911cb5429ebf9dba78d86c74b5","type":"GENE","name":"PPIAP50","canonical_id":"hgnc:HGNC:53674","description":"peptidylprolyl isomerase A pseudogene 50","metadata":null},{"id":"a5832be963c545bfac91a065246e482e","type":"GENE","name":"PPIAP51","canonical_id":"hgnc:HGNC:53675","description":"peptidylprolyl isomerase A pseudogene 51","metadata":null},{"id":"880dfe7632504dd685ff8ade9892c4d1","type":"GENE","name":"PPIAP52","canonical_id":"hgnc:HGNC:53676","description":"peptidylprolyl isomerase A pseudogene 52","metadata":null},{"id":"cee295cb7e3f4a8d973f7cf0b1e8e77d","type":"GENE","name":"PPIAP53","canonical_id":"hgnc:HGNC:53677","description":"peptidylprolyl isomerase A pseudogene 53","metadata":null},{"id":"c305ff67f1e14c7e86180b498d7fec8c","type":"GENE","name":"PPIAP54","canonical_id":"hgnc:HGNC:53678","description":"peptidylprolyl isomerase A pseudogene 54","metadata":null},{"id":"60117b3b9f4646f6a95773e41caeaf49","type":"GENE","name":"PPIAP55","canonical_id":"hgnc:HGNC:53679","description":"peptidylprolyl isomerase A pseudogene 55","metadata":null},{"id":"eb2de258f2f84af8a03cad71666e2a0c","type":"GENE","name":"PPIAP56","canonical_id":"hgnc:HGNC:53680","description":"peptidylprolyl isomerase A pseudogene 56","metadata":null},{"id":"29fee056b51b47e6b2e1e44fc9aaa50b","type":"GENE","name":"PPIAP57","canonical_id":"hgnc:HGNC:53681","description":"peptidylprolyl isomerase A pseudogene 57","metadata":null},{"id":"ee62119c22594088a98a3bc135fc089a","type":"GENE","name":"PPIAP58","canonical_id":"hgnc:HGNC:53682","description":"peptidylprolyl isomerase A pseudogene 58","metadata":null},{"id":"149e5aa215124350914b5cac08de0f78","type":"GENE","name":"PPIAP59","canonical_id":"hgnc:HGNC:53683","description":"peptidylprolyl isomerase A pseudogene 59","metadata":null},{"id":"2fb0a41c353e4398bad409077408b4df","type":"GENE","name":"PPIAP6","canonical_id":"hgnc:HGNC:20028","description":"peptidylprolyl isomerase A pseudogene 6","metadata":null},{"id":"300c79a95f0a46f997f41f6bbfa75bd1","type":"GENE","name":"PPIAP60","canonical_id":"hgnc:HGNC:53684","description":"peptidylprolyl isomerase A pseudogene 60","metadata":null},{"id":"89441779f49f4211988e65a70161debe","type":"GENE","name":"PPIAP61","canonical_id":"hgnc:HGNC:53685","description":"peptidylprolyl isomerase A pseudogene 61","metadata":null},{"id":"2af97f3e7cda4102aa3d9eee8cdf72ac","type":"GENE","name":"PPIAP62","canonical_id":"hgnc:HGNC:53686","description":"peptidylprolyl isomerase A pseudogene 62","metadata":null},{"id":"3c95aece67fa4b4187fb8d8fac0e1285","type":"GENE","name":"PPIAP63","canonical_id":"hgnc:HGNC:53687","description":"peptidylprolyl isomerase A pseudogene 63","metadata":null},{"id":"d224b311fb3f492eaa57a17d52a6ef63","type":"GENE","name":"PPIAP64","canonical_id":"hgnc:HGNC:53688","description":"peptidylprolyl isomerase A pseudogene 64","metadata":null},{"id":"fa7445a38a2e4c2cb9ee16011eb2dd40","type":"GENE","name":"PPIAP65","canonical_id":"hgnc:HGNC:53689","description":"peptidylprolyl isomerase A pseudogene 65","metadata":null},{"id":"aa9bac4913bb4079859fff37ef6b6282","type":"GENE","name":"PPIAP66","canonical_id":"hgnc:HGNC:53690","description":"peptidylprolyl isomerase A pseudogene 66","metadata":null},{"id":"714242119ee649ad9556eb71cdfceab8","type":"GENE","name":"PPIAP67","canonical_id":"hgnc:HGNC:53691","description":"peptidylprolyl isomerase A pseudogene 67","metadata":null},{"id":"469ff8a134f442efb33c326634635d98","type":"GENE","name":"PPIAP68","canonical_id":"hgnc:HGNC:53692","description":"peptidylprolyl isomerase A pseudogene 68","metadata":null},{"id":"25fd96946f4a49069ffcb214c30a5f08","type":"GENE","name":"PPIAP69","canonical_id":"hgnc:HGNC:53693","description":"peptidylprolyl isomerase A pseudogene 69","metadata":null},{"id":"7cee280397804b9a93b5ae71923531cd","type":"GENE","name":"PPIAP7","canonical_id":"hgnc:HGNC:9270","description":"peptidylprolyl isomerase A pseudogene 7","metadata":{"aliases":["PPIP7"]}},{"id":"b951b19d0d2a4557b1227905efe08e60","type":"GENE","name":"PPIAP70","canonical_id":"hgnc:HGNC:53694","description":"peptidylprolyl isomerase A pseudogene 70","metadata":null},{"id":"1a88d8aa6f9b46e9a10d64ff65320ebd","type":"GENE","name":"PPIAP71","canonical_id":"hgnc:HGNC:53695","description":"peptidylprolyl isomerase A pseudogene 71","metadata":null},{"id":"ad11bf6d23624f7f90ce49da01d32abc","type":"GENE","name":"PPIAP72","canonical_id":"hgnc:HGNC:53696","description":"peptidylprolyl isomerase A pseudogene 72","metadata":null},{"id":"1f45541f46184e1383db808e066d2278","type":"GENE","name":"PPIAP73","canonical_id":"hgnc:HGNC:53697","description":"peptidylprolyl isomerase A pseudogene 73","metadata":null},{"id":"ae60f79585a1415fa276297b70a4cc24","type":"GENE","name":"PPIAP74","canonical_id":"hgnc:HGNC:53698","description":"peptidylprolyl isomerase A pseudogene 74","metadata":null},{"id":"57083f3f763645fd9b146a6c8e6d24d4","type":"GENE","name":"PPIAP75","canonical_id":"hgnc:HGNC:53699","description":"peptidylprolyl isomerase A pseudogene 75","metadata":null},{"id":"3e554e7be5664fdebd218052269c5a87","type":"GENE","name":"PPIAP76","canonical_id":"hgnc:HGNC:53700","description":"peptidylprolyl isomerase A pseudogene 76","metadata":null},{"id":"2bbdcac09b5b48e88f1053a2bb2e0707","type":"GENE","name":"PPIAP77","canonical_id":"hgnc:HGNC:53701","description":"peptidylprolyl isomerase A pseudogene 77","metadata":null},{"id":"a2e3f61338ce4bfd9549c7c2fbb98535","type":"GENE","name":"PPIAP78","canonical_id":"hgnc:HGNC:53702","description":"peptidylprolyl isomerase A pseudogene 78","metadata":null},{"id":"2a3c4e97e08a46be9ac4090251bd399c","type":"GENE","name":"PPIAP79","canonical_id":"hgnc:HGNC:53703","description":"peptidylprolyl isomerase A pseudogene 79","metadata":null},{"id":"1cdb745f7c4c4bd2aca44a20b1c5396d","type":"GENE","name":"PPIAP8","canonical_id":"hgnc:HGNC:9271","description":"peptidylprolyl isomerase A pseudogene 8","metadata":{"aliases":["PPIP8"]}},{"id":"1eb9a3a4465e42e29315db16371a926c","type":"GENE","name":"PPIAP80","canonical_id":"hgnc:HGNC:53704","description":"peptidylprolyl isomerase A pseudogene 80","metadata":null},{"id":"1b75247afd554df299a8fe32492b1114","type":"GENE","name":"PPIAP81","canonical_id":"hgnc:HGNC:53705","description":"peptidylprolyl isomerase A pseudogene 81","metadata":null},{"id":"4a5d763c227a487586fb06094a914d14","type":"GENE","name":"PPIAP82","canonical_id":"hgnc:HGNC:53706","description":"peptidylprolyl isomerase A pseudogene 82","metadata":null},{"id":"150575d8c28b413e9d53e8eea522936e","type":"GENE","name":"PPIAP83","canonical_id":"hgnc:HGNC:53707","description":"peptidylprolyl isomerase A pseudogene 83","metadata":null},{"id":"8461fcaaf2f748d19f48d5c7983507e6","type":"GENE","name":"PPIAP84","canonical_id":"hgnc:HGNC:53708","description":"peptidylprolyl isomerase A pseudogene 84","metadata":null},{"id":"8900ea0eab4d4921a5ff6873ba6eb9de","type":"GENE","name":"PPIAP85","canonical_id":"hgnc:HGNC:53709","description":"peptidylprolyl isomerase A pseudogene 85","metadata":null},{"id":"9459fb6fbdf145edbf7c98e002329dd0","type":"GENE","name":"PPIAP86","canonical_id":"hgnc:HGNC:53710","description":"peptidylprolyl isomerase A pseudogene 86","metadata":null},{"id":"ddfb5a837a3f4da6a944f8b1f23895ef","type":"GENE","name":"PPIAP87","canonical_id":"hgnc:HGNC:53711","description":"peptidylprolyl isomerase A pseudogene 87","metadata":null},{"id":"b7eb1048c6394f50bc8e6606b3213032","type":"GENE","name":"PPIAP88","canonical_id":"hgnc:HGNC:53712","description":"peptidylprolyl isomerase A pseudogene 88","metadata":null},{"id":"ebd8266008dc4c2fbe15a018405a0213","type":"GENE","name":"PPIAP89","canonical_id":"hgnc:HGNC:53713","description":"peptidylprolyl isomerase A pseudogene 89","metadata":null},{"id":"ef9418eeef614f23afed292aef861969","type":"GENE","name":"PPIAP9","canonical_id":"hgnc:HGNC:9272","description":"peptidylprolyl isomerase A pseudogene 9","metadata":{"aliases":["Em:AC006046.3","PPIP9"]}},{"id":"ba1cdac680994b4494bc41b969c61fd3","type":"GENE","name":"PPIAP90","canonical_id":"hgnc:HGNC:53714","description":"peptidylprolyl isomerase A pseudogene 90","metadata":null},{"id":"2f291701cc5f40ca80be922d80deff07","type":"GENE","name":"PPIAP91","canonical_id":"hgnc:HGNC:53715","description":"peptidylprolyl isomerase A pseudogene 91","metadata":null},{"id":"85a0620eab0c4d4d8c94046153dd8105","type":"GENE","name":"PPIAP93","canonical_id":"hgnc:HGNC:54634","description":"PPIA pseudogene 93","metadata":null},{"id":"f1e9bf2efab2467f9e3fd7080995f19c","type":"GENE","name":"PPIB","canonical_id":"hgnc:HGNC:9255","description":"peptidylprolyl isomerase B","metadata":{"aliases":["CYPB","OI9","PPIase","B","CYP-S1","SCYLP"]}},{"id":"959e2f91af554aae964ae2a47df1ba9a","type":"GENE","name":"PPIC","canonical_id":"hgnc:HGNC:9256","description":"peptidylprolyl isomerase C","metadata":{"aliases":["CYPC"]}},{"id":"10938ab3fa6e4c48b77b2c2b491d9d80","type":"GENE","name":"PPIC-AS1","canonical_id":"hgnc:HGNC:40464","description":"PPIC antisense RNA 1","metadata":null},{"id":"848060852d1c4056bc223e3aaaf09ab1","type":"GENE","name":"PPID","canonical_id":"hgnc:HGNC:9257","description":"peptidylprolyl isomerase D","metadata":{"aliases":["CYP-40","CypD"]}},{"id":"8293e1cd28ad4ad982dc2079e7e63225","type":"GENE","name":"PPIE","canonical_id":"hgnc:HGNC:9258","description":"peptidylprolyl isomerase E","metadata":{"aliases":["CyP-33","MGC3736","MGC111222","CypE"]}},{"id":"84dd48a015ce4af2b020936965337656","type":"GENE","name":"PPIEL","canonical_id":"hgnc:HGNC:33195","description":"peptidylprolyl isomerase E like (pseudogene)","metadata":{"aliases":["PPIEP1"]}},{"id":"95508dc7f54d4db2ac3551037682d88f","type":"GENE","name":"PPIF","canonical_id":"hgnc:HGNC:9259","description":"peptidylprolyl isomerase F","metadata":{"aliases":["hCyP3","Cyp-D","CypD"]}},{"id":"849eb884e259448f9316267ebf8ab580","type":"GENE","name":"PPIG","canonical_id":"hgnc:HGNC:14650","description":null,"metadata":null},{"id":"18a588e504e54774bc177ed9d095092f","type":"GENE","name":"PPIGP1","canonical_id":"hgnc:HGNC:34231","description":"peptidylprolyl isomerase G pseudogene 1","metadata":null},{"id":"b7d56b70ea2f4c3399711a7a1d6c3332","type":"GENE","name":"PPIH","canonical_id":"hgnc:HGNC:14651","description":"peptidylprolyl isomerase H","metadata":{"aliases":["USA-CYP","CYP-20","SnuCyp-20","CYPH","MGC5016"]}},{"id":"6d9d093dfae14f17be601963e28d0bb7","type":"GENE","name":"PPIHP1","canonical_id":"hgnc:HGNC:31355","description":"peptidylprolyl isomerase H pseudogene 1","metadata":null},{"id":"e0ad8cb30d6e4c0fb68146d470d62f2c","type":"GENE","name":"PPIHP2","canonical_id":"hgnc:HGNC:31356","description":"peptidylprolyl isomerase H pseudogene 2","metadata":null},{"id":"84b40911a64c4dc1af54ce2ea349cbb4","type":"GENE","name":"PPIL1","canonical_id":"hgnc:HGNC:9260","description":"peptidylprolyl isomerase like 1","metadata":{"aliases":["CYPL1"]}},{"id":"a763ef0db44e40b09e0f9187b29104d7","type":"GENE","name":"PPIL1P1","canonical_id":"hgnc:HGNC:20865","description":"peptidylprolyl isomerase like 1 pseudogene 1","metadata":null},{"id":"ac754238b5934264a6318c892d34ca72","type":"GENE","name":"PPIL2","canonical_id":"hgnc:HGNC:9261","description":"peptidylprolyl isomerase like 2","metadata":{"aliases":["UBOX7","CYC4","Cyp-60"]}},{"id":"d27aa4c62b06456ca8e36005489ac13b","type":"GENE","name":"PPIL3","canonical_id":"hgnc:HGNC:9262","description":"peptidylprolyl isomerase like 3","metadata":{"aliases":["CyPJ"]}},{"id":"0de719a2089e48149dbb48120ba511a3","type":"GENE","name":"PPIL4","canonical_id":"hgnc:HGNC:15702","description":"peptidylprolyl isomerase like 4","metadata":null},{"id":"490f689196134604b22605d17eb411a1","type":"GENE","name":"PPIL6","canonical_id":"hgnc:HGNC:21557","description":"peptidylprolyl isomerase like 6","metadata":{"aliases":["bA425D10.6","MGC41939","dJ919F19.1","RSPH12"]}},{"id":"6b3753a060174bb8b7baa8b052814faf","type":"GENE","name":"PPIP5K1","canonical_id":"hgnc:HGNC:29023","description":"diphosphoinositol pentakisphosphate kinase 1","metadata":{"aliases":["KIAA0377","IPS1","VIP1","HISPPD2A"]}},{"id":"8b053f4380254d38ae050c776e1ca107","type":"GENE","name":"PPIP5K1P1","canonical_id":"hgnc:HGNC:32373","description":"diphosphoinositol pentakisphosphate kinase 1 pseudogene 1","metadata":{"aliases":["HISPPD2BP","KIAA0377P","HISPPD2B"]}},{"id":"a73a9aa87beb4308bc3ab1cb96e38ad4","type":"GENE","name":"PPIP5K2","canonical_id":"hgnc:HGNC:29035","description":"diphosphoinositol pentakisphosphate kinase 2","metadata":{"aliases":["KIAA0433","VIP2","CFAP160","HISPPD1","DFNB100"]}},{"id":"f01fb83eb1224f52b1fa25789108d02e","type":"GENE","name":"PPL","canonical_id":"hgnc:HGNC:9273","description":null,"metadata":null},{"id":"81c8d120c7c949088a1cb2a497626efa","type":"GENE","name":"PPM1A","canonical_id":"hgnc:HGNC:9275","description":"protein phosphatase, Mg2+/Mn2+ dependent 1A","metadata":{"aliases":["MGC9201","PP2Calpha","PP2CA"]}},{"id":"4ee5eb3f3a0a4df986b4143206e6b590","type":"GENE","name":"PPM1AP1","canonical_id":"hgnc:HGNC:30175","description":"protein phosphatase, Mg2+/Mn2+ dependent 1A pseudogene 1","metadata":null},{"id":"20b511b224b742b2b688520910469d4c","type":"GENE","name":"PPM1B","canonical_id":"hgnc:HGNC:9276","description":"protein phosphatase, Mg2+/Mn2+ dependent 1B","metadata":{"aliases":["PPC2BETAX","PP2CB","PP2CBETA"]}},{"id":"61a6120ca37e41ed80de1a4908812799","type":"GENE","name":"PPM1B-DT","canonical_id":"hgnc:HGNC:55161","description":"PPM1B divergent transcript","metadata":null},{"id":"5ee6e546d6ce4890abf075268a32b690","type":"GENE","name":"PPM1D","canonical_id":"hgnc:HGNC:9277","description":null,"metadata":null},{"id":"358bfd0263354269b914d750c93f68d4","type":"GENE","name":"PPM1E","canonical_id":"hgnc:HGNC:19322","description":"protein phosphatase, Mg2+/Mn2+ dependent 1E","metadata":{"aliases":["POPX1","KIAA1072","PP2CH","CaMKP-N"]}},{"id":"2dadddab1bc2452ba380ffd0eed61120","type":"GENE","name":"PPM1F","canonical_id":"hgnc:HGNC:19388","description":"protein phosphatase, Mg2+/Mn2+ dependent 1F","metadata":{"aliases":["FEM-2","KIAA0015","POPX2","CaMKPase","CAMKP"]}},{"id":"19431a2bbe9a421a8f461dc08f1371f7","type":"GENE","name":"PPM1F-AS1","canonical_id":"hgnc:HGNC:40888","description":"PPM1F antisense RNA 1","metadata":null},{"id":"1acd5224d2974426a952aef3f30cc430","type":"GENE","name":"PPM1G","canonical_id":"hgnc:HGNC:9278","description":"protein phosphatase, Mg2+/Mn2+ dependent 1G","metadata":{"aliases":["PP2CG","PP2Cgamma"]}},{"id":"47951fce7ee24f9bad6d1eef9164167e","type":"GENE","name":"PPM1H","canonical_id":"hgnc:HGNC:18583","description":"protein phosphatase, Mg2+/Mn2+ dependent 1H","metadata":{"aliases":["KIAA1157","FLJ13253","NERPP-2C","ARHCL1"]}},{"id":"48a3d07f96284e4e9f22ec34517455cb","type":"GENE","name":"PPM1J","canonical_id":"hgnc:HGNC:20785","description":"protein phosphatase, Mg2+/Mn2+ dependent 1J","metadata":{"aliases":["FLJ35951","MGC19531","DKFZp434P1514","PP2Czeta","PPP2CZ"]}},{"id":"35907f5a236b477ebd8577f185e459f7","type":"GENE","name":"PPM1J-DT","canonical_id":"hgnc:HGNC:55355","description":"PPM1J divergent transcript","metadata":null},{"id":"8a9bf98f973a45598e6e248334b68ce6","type":"GENE","name":"PPM1K","canonical_id":"hgnc:HGNC:25415","description":"protein phosphatase, Mg2+/Mn2+ dependent 1K","metadata":{"aliases":["DKFZp761G058","PP2Ckappa","hPTMP","PP2Cm","BDP"]}},{"id":"97e7054f1a7f4400be3fb0c9ff81f7e4","type":"GENE","name":"PPM1K-DT","canonical_id":"hgnc:HGNC:54093","description":"PPM1K divergent transcript","metadata":null},{"id":"7750a524d1884ecea4a6c7cd32c05ac6","type":"GENE","name":"PPM1L","canonical_id":"hgnc:HGNC:16381","description":"protein phosphatase, Mg2+/Mn2+ dependent 1L","metadata":{"aliases":["PP2CE"]}},{"id":"917578af5296476a8aa43690c872b490","type":"GENE","name":"PPM1L-DT","canonical_id":"hgnc:HGNC:55390","description":"PPM1L divergent transcript","metadata":null},{"id":"483b73adde774a81909515bd1659115b","type":"GENE","name":"PPM1M","canonical_id":"hgnc:HGNC:26506","description":"protein phosphatase, Mg2+/Mn2+ dependent 1M","metadata":{"aliases":["PP2Ceta","FLJ32332"]}},{"id":"21331f45b47045b7ada775a2c1db2234","type":"GENE","name":"PPM1N","canonical_id":"hgnc:HGNC:26845","description":"protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)","metadata":{"aliases":["FLJ40125"]}},{"id":"b75945698fe74446a1135bfe1001e486","type":"GENE","name":"PPME1","canonical_id":"hgnc:HGNC:30178","description":"protein phosphatase methylesterase 1","metadata":{"aliases":["PME-1","ABDH19"]}},{"id":"a2e2b8f479294622be4efc70c70250e0","type":"GENE","name":"PPOX","canonical_id":"hgnc:HGNC:9280","description":null,"metadata":null},{"id":"4373a827649e48d586ddf0e13bb3aaef","type":"GENE","name":"PPP1CA","canonical_id":"hgnc:HGNC:9281","description":"protein phosphatase 1 catalytic subunit alpha","metadata":{"aliases":["PP1A","PP-1A","PP1alpha","PPP1A"]}},{"id":"7a18a9cb0eb245fc91e6df95180ae4d3","type":"GENE","name":"PPP1CB","canonical_id":"hgnc:HGNC:9282","description":"protein phosphatase 1 catalytic subunit beta","metadata":{"aliases":["PP1Cbeta","PPP1CD","PP1Cdelta","PP1B","PP-1B","PP1beta","PP1c","MP","PPP1beta"]}},{"id":"16ef208edbac45ad8bea48bccf8812c2","type":"GENE","name":"PPP1CB-DT","canonical_id":"hgnc:HGNC:55829","description":"PPP1CB divergent transcript","metadata":null},{"id":"2bc3a1d338b74cc896b991ae2ef8015f","type":"GENE","name":"PPP1CC","canonical_id":"hgnc:HGNC:9283","description":"protein phosphatase 1 catalytic subunit gamma","metadata":{"aliases":["PP1C","PP1gamma"]}},{"id":"84008df3d2fd40be97a630107dca854c","type":"GENE","name":"PPP1R10","canonical_id":"hgnc:HGNC:9284","description":"protein phosphatase 1 regulatory subunit 10","metadata":{"aliases":["PNUTS","FB19","CAT53","p99"]}},{"id":"4ecbdafd069e4cd19d86cd81b4aded4d","type":"GENE","name":"PPP1R10P1","canonical_id":"hgnc:HGNC:16325","description":"protein phosphatase 1 regulatory subunit 10 pseudogene 1","metadata":{"aliases":["PPP1R10P"]}},{"id":"894724f5628646d08abbb73bd5a6369b","type":"GENE","name":"PPP1R11","canonical_id":"hgnc:HGNC:9285","description":"protein phosphatase 1 regulatory inhibitor subunit 11","metadata":{"aliases":["HCGV","Tctex5","HCG-V","CFAP255","TCTE5"]}},{"id":"70aab1d8bf84441fba18fbd2db55f3de","type":"GENE","name":"PPP1R11P1","canonical_id":"hgnc:HGNC:16326","description":"protein phosphatase 1 regulatory inhibitor subunit 11 pseudogene 1","metadata":null},{"id":"3094ed2f73cc43b58ccd86701bd62d28","type":"GENE","name":"PPP1R11P2","canonical_id":"hgnc:HGNC:16327","description":"protein phosphatase 1 regulatory inhibitor subunit 11 pseudogene 2","metadata":null},{"id":"34e501876b8e493ba882e5560e418a90","type":"GENE","name":"PPP1R12A","canonical_id":"hgnc:HGNC:7618","description":"protein phosphatase 1 regulatory subunit 12A","metadata":{"aliases":["MBS","M130","MYPT1"]}},{"id":"6310c22c3fe64a2ea857f2e7c6ed2c38","type":"GENE","name":"PPP1R12A-AS1","canonical_id":"hgnc:HGNC:51903","description":"PPP1R12A antisense RNA 1","metadata":{"aliases":["R12A-AS1"]}},{"id":"ba0fe07b328d4eaa8be814e5f929d6ec","type":"GENE","name":"PPP1R12A-AS2","canonical_id":"hgnc:HGNC:55456","description":"PPP1R12A antisense RNA 2","metadata":null},{"id":"a15c3f98e8d54d548e73414c1a07e3c5","type":"GENE","name":"PPP1R12B","canonical_id":"hgnc:HGNC:7619","description":"protein phosphatase 1 regulatory subunit 12B","metadata":{"aliases":["M20","MGC87886","MGC131980","PP1bp55","MYPT2"]}},{"id":"b11cad4e6d6348d0a2dd94c2779c8cab","type":"GENE","name":"PPP1R12BP1","canonical_id":"hgnc:HGNC:18498","description":"protein phosphatase 1 regulatory subunit 12B pseudogene 1","metadata":{"aliases":["PPP1R12BPY1","PPP1R12BP"]}},{"id":"ad46f8e7c6b64343b916a94858694dbd","type":"GENE","name":"PPP1R12BP2","canonical_id":"hgnc:HGNC:23970","description":"protein phosphatase 1 regulatory subunit 12B pseudogene 2","metadata":null},{"id":"95b70bdf4ed84a76bdf36c4954917e87","type":"GENE","name":"PPP1R12C","canonical_id":"hgnc:HGNC:14947","description":"protein phosphatase 1 regulatory subunit 12C","metadata":{"aliases":["DKFZP434D0412","p84","MBS85","p85","AAVS1","LENG3"]}},{"id":"0d3756f454c94155977d0e3e8fbaeeaf","type":"GENE","name":"PPP1R13B","canonical_id":"hgnc:HGNC:14950","description":null,"metadata":null},{"id":"35067e5a64974bc499e46d53de86aec0","type":"GENE","name":"PPP1R13B-DT","canonical_id":"hgnc:HGNC:27069","description":"PPP1R13B divergent transcript","metadata":{"aliases":["HITT","LINC00637"]}},{"id":"f6716c9fb45347008fddd33d190a6f58","type":"GENE","name":"PPP1R13L","canonical_id":"hgnc:HGNC:18838","description":"protein phosphatase 1 regulatory subunit 13 like","metadata":{"aliases":["RAI","IASPP"]}},{"id":"265237dca8984fb48bfe8d22ce08b0c6","type":"GENE","name":"PPP1R14A","canonical_id":"hgnc:HGNC:14871","description":"protein phosphatase 1 regulatory inhibitor subunit 14A","metadata":{"aliases":["CPI-17","PPP1INL"]}},{"id":"113fe43ca76c4b5f8d4595562753c7a0","type":"GENE","name":"PPP1R14B","canonical_id":"hgnc:HGNC:9057","description":"protein phosphatase 1 regulatory inhibitor subunit 14B","metadata":{"aliases":["SOM172","PNG","PHI-1","PLCB3N"]}},{"id":"534ce80915d34a10b9259d5258dde7ca","type":"GENE","name":"PPP1R14B-AS1","canonical_id":"hgnc:HGNC:54233","description":"PPP1R14B antisense RNA 1","metadata":null},{"id":"327a2ed4397e4ed1a9112b659215473e","type":"GENE","name":"PPP1R14BP1","canonical_id":"hgnc:HGNC:9058","description":"protein phosphatase 1 regulatory inhibitor subunit 14B pseudogene 1","metadata":{"aliases":["PLCB3NP"]}},{"id":"b65184d838a643e4986227c328abd807","type":"GENE","name":"PPP1R14BP2","canonical_id":"hgnc:HGNC:16329","description":"protein phosphatase 1 regulatory inhibitor subunit 14B pseudogene 2","metadata":null},{"id":"a6c0a217da26464b9c48a6dafdfbe2ed","type":"GENE","name":"PPP1R14BP3","canonical_id":"hgnc:HGNC:16330","description":"protein phosphatase 1 regulatory inhibitor subunit 14B pseudogene 3","metadata":null},{"id":"5f80e74121454ca981d7743ebd4a618f","type":"GENE","name":"PPP1R14BP4","canonical_id":"hgnc:HGNC:16331","description":"protein phosphatase 1 regulatory inhibitor subunit 14B pseudogene 4","metadata":null},{"id":"01e139e6bb7642c386037dd9e249cbf5","type":"GENE","name":"PPP1R14BP5","canonical_id":"hgnc:HGNC:16332","description":"protein phosphatase 1 regulatory inhibitor subunit 14B pseudogene 5","metadata":null},{"id":"57d178946f6f40409a20ee34366db165","type":"GENE","name":"PPP1R14C","canonical_id":"hgnc:HGNC:14952","description":"protein phosphatase 1 regulatory inhibitor subunit 14C","metadata":{"aliases":["CPI17-like","NY-BR-81","KEPI"]}},{"id":"c921b2c7daf147c8952b16da311d6d20","type":"GENE","name":"PPP1R14D","canonical_id":"hgnc:HGNC:14953","description":"protein phosphatase 1 regulatory inhibitor subunit 14D","metadata":{"aliases":["CPI17-like","FLJ20251","GBPI-1","MGC119014","MGC119016"]}},{"id":"5252a6e4beeb4bad910fbc8088708a3c","type":"GENE","name":"PPP1R15A","canonical_id":"hgnc:HGNC:14375","description":"protein phosphatase 1 regulatory subunit 15A","metadata":{"aliases":["GADD34"]}},{"id":"ac360bac97764a5490eaede90c54a2f1","type":"GENE","name":"PPP1R15B","canonical_id":"hgnc:HGNC:14951","description":"protein phosphatase 1 regulatory subunit 15B","metadata":{"aliases":["FLJ14744"]}},{"id":"14425e0df2274dd198da5f9cb93f667e","type":"GENE","name":"PPP1R15B-AS1","canonical_id":"hgnc:HGNC:55838","description":"PPP1R15B and PIK3C2B antisense RNA 1","metadata":{"aliases":["AL606489.1"]}},{"id":"62897d820f7b4c15b9567ff3d10b243d","type":"GENE","name":"PPP1R16A","canonical_id":"hgnc:HGNC:14941","description":"protein phosphatase 1 regulatory subunit 16A","metadata":{"aliases":["MGC14333","MYPT3"]}},{"id":"fceb5174032849ecbd1d7f12905621f8","type":"GENE","name":"PPP1R16B","canonical_id":"hgnc:HGNC:15850","description":"protein phosphatase 1 regulatory subunit 16B","metadata":{"aliases":["KIAA0823","TIMAP","ANKRD4"]}},{"id":"6809a5aec9e3403ca0212d560dda1d64","type":"GENE","name":"PPP1R17","canonical_id":"hgnc:HGNC:16973","description":"protein phosphatase 1 regulatory subunit 17","metadata":{"aliases":["GSBS","C7orf16"]}},{"id":"d85a7a80f6e949ad800bf0b474c40df0","type":"GENE","name":"PPP1R18","canonical_id":"hgnc:HGNC:29413","description":"protein phosphatase 1 regulatory subunit 18","metadata":{"aliases":["phostensin","KIAA1949"]}},{"id":"409c383f779244fea50689ac4bc9229b","type":"GENE","name":"PPP1R1A","canonical_id":"hgnc:HGNC:9286","description":"protein phosphatase 1 regulatory inhibitor subunit 1A","metadata":null},{"id":"de566bae708f4eceb7797e913dc66507","type":"GENE","name":"PPP1R1AP1","canonical_id":"hgnc:HGNC:16316","description":"protein phosphatase 1 regulatory inhibitor subunit 1A pseudogene 1","metadata":null},{"id":"d105b5ede3bc49fc87018f7c609117ce","type":"GENE","name":"PPP1R1AP2","canonical_id":"hgnc:HGNC:16317","description":"protein phosphatase 1 regulatory inhibitor subunit 1A pseudogene 2","metadata":null},{"id":"ade42be3300245279eb65b6e83472a00","type":"GENE","name":"PPP1R1B","canonical_id":"hgnc:HGNC:9287","description":"protein phosphatase 1 regulatory inhibitor subunit 1B","metadata":{"aliases":["DARPP-32","FLJ20940"]}},{"id":"6b433b31e3ee44c2925a476df9484253","type":"GENE","name":"PPP1R1C","canonical_id":"hgnc:HGNC:14940","description":"protein phosphatase 1 regulatory inhibitor subunit 1C","metadata":{"aliases":["Inhibitor-1-like"]}},{"id":"0c9db65fa8d5454ba1891c9a115f5ee2","type":"GENE","name":"PPP1R2","canonical_id":"hgnc:HGNC:9288","description":"protein phosphatase 1 regulatory inhibitor subunit 2","metadata":{"aliases":["IPP2","PPP1R2A"]}},{"id":"4c325aa870cf44f185d9b132197d91af","type":"GENE","name":"PPP1R21","canonical_id":"hgnc:HGNC:30595","description":"protein phosphatase 1 regulatory subunit 21","metadata":{"aliases":["FLJ16566","Fy-2","FERRY2","CCDC128","KLRAQ1"]}},{"id":"82eadb1c7859421fbe333e40fd69c68e","type":"GENE","name":"PPP1R21-DT","canonical_id":"hgnc:HGNC:55206","description":"PPP1R21 divergent transcript","metadata":null},{"id":"2fcdc4af041a44c2b3e30bb0e5dee5da","type":"GENE","name":"PPP1R26","canonical_id":"hgnc:HGNC:29089","description":"protein phosphatase 1 regulatory subunit 26","metadata":{"aliases":["KIAA0649"]}},{"id":"47ce862b23f04f0c9e1642f2ae05e0b2","type":"GENE","name":"PPP1R26-AS1","canonical_id":"hgnc:HGNC:48717","description":"PPP1R26 antisense RNA 1","metadata":null},{"id":"a5a9ce903c54468fbb0392c3febadc4c","type":"GENE","name":"PPP1R26P1","canonical_id":"hgnc:HGNC:42015","description":"protein phosphatase 1 regulatory subunit 26 pseudogene 1","metadata":{"aliases":["KIAA0649P1"]}},{"id":"19f27124dcb448cb888c3ea851c2c12b","type":"GENE","name":"PPP1R26P2","canonical_id":"hgnc:HGNC:42016","description":"protein phosphatase 1 regulatory subunit 26 pseudogene 2","metadata":{"aliases":["KIAA0649P2"]}},{"id":"aea02fef241e4d44af97cf4303eff2f3","type":"GENE","name":"PPP1R26P3","canonical_id":"hgnc:HGNC:42017","description":"protein phosphatase 1 regulatory subunit 26 pseudogene 3","metadata":{"aliases":["KIAA0649P3"]}},{"id":"19fadabde5a644c4a106c3b16d13036c","type":"GENE","name":"PPP1R26P4","canonical_id":"hgnc:HGNC:42018","description":"protein phosphatase 1 regulatory subunit 26 pseudogene 4","metadata":{"aliases":["KIAA0649P4"]}},{"id":"7af316d7418f44bc8a572006c404d60d","type":"GENE","name":"PPP1R26P5","canonical_id":"hgnc:HGNC:42019","description":"protein phosphatase 1 regulatory subunit 26 pseudogene 5","metadata":{"aliases":["KIAA0649P5"]}},{"id":"e745e0cb85b945fabb7620c7b7e65ae0","type":"GENE","name":"PPP1R27","canonical_id":"hgnc:HGNC:16813","description":"protein phosphatase 1 regulatory subunit 27","metadata":{"aliases":["toonin","DYSFIP1"]}},{"id":"49f85899dce4477bbbfe21ed8a43fdef","type":"GENE","name":"PPP1R2B","canonical_id":"hgnc:HGNC:16318","description":"PPP1R2 family member B","metadata":{"aliases":["MGC87149","PPP1R2P3"]}},{"id":"66ce88a3ea394b6ebfd817169d426239","type":"GENE","name":"PPP1R2C","canonical_id":"hgnc:HGNC:16324","description":"PPP1R2 family member C","metadata":{"aliases":["I-4","PPP1R2P9"]}},{"id":"8d7bc84509bf4793bf25919a85ad80f8","type":"GENE","name":"PPP1R2L1P","canonical_id":"hgnc:HGNC:49194","description":"protein phosphatase 1 regulatory subunit 2 like 1, pseudogene","metadata":{"aliases":["PPP1R2LP"]}},{"id":"8e9b2eb565c849808071cbb8441fefc5","type":"GENE","name":"PPP1R2P1","canonical_id":"hgnc:HGNC:9289","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 1","metadata":{"aliases":["IPP-2P","PPP1R2P"]}},{"id":"ba58984adf784de4ae2b42136e774abc","type":"GENE","name":"PPP1R2P10","canonical_id":"hgnc:HGNC:42008","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 10","metadata":null},{"id":"1350b3f4881f4f9aa4859fd2e01fcc8f","type":"GENE","name":"PPP1R2P2","canonical_id":"hgnc:HGNC:9290","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 2","metadata":null},{"id":"33a8411b5c9d46e38b70cd18b1f594de","type":"GENE","name":"PPP1R2P4","canonical_id":"hgnc:HGNC:16319","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 4","metadata":null},{"id":"769192cb45ce4730b197d172614d86f3","type":"GENE","name":"PPP1R2P5","canonical_id":"hgnc:HGNC:16320","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 5","metadata":null},{"id":"e5f7c694bcf14513b09e37b4600cc67b","type":"GENE","name":"PPP1R2P6","canonical_id":"hgnc:HGNC:16321","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 6","metadata":null},{"id":"783194e1e2654ffc9cdd03830b9e8aa1","type":"GENE","name":"PPP1R2P8","canonical_id":"hgnc:HGNC:16323","description":"protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 8","metadata":null},{"id":"074a222efea143908ff7b214fdba5ee9","type":"GENE","name":"PPP1R35","canonical_id":"hgnc:HGNC:28320","description":"protein phosphatase 1 regulatory subunit 35","metadata":{"aliases":["MGC22793","C7orf47"]}},{"id":"771404f399c949cfbdad61ec91f89d1a","type":"GENE","name":"PPP1R35-AS1","canonical_id":"hgnc:HGNC:41194","description":"PPP1R35 antisense RNA 1","metadata":null},{"id":"bff887e28cbb4504a54898a8522925b2","type":"GENE","name":"PPP1R36","canonical_id":"hgnc:HGNC:20097","description":"protein phosphatase 1 regulatory subunit 36","metadata":{"aliases":["C14orf50"]}},{"id":"e9e5b171ccc24f019b29b7cfa89edbea","type":"GENE","name":"PPP1R37","canonical_id":"hgnc:HGNC:27607","description":"protein phosphatase 1 regulatory subunit 37","metadata":{"aliases":["LRRC68"]}},{"id":"58f176a3d8c74845844d5506a1fbac34","type":"GENE","name":"PPP1R3A","canonical_id":"hgnc:HGNC:9291","description":"protein phosphatase 1 regulatory subunit 3A","metadata":{"aliases":["GM","PPP1R3"]}},{"id":"daf4ad5ecc2e4467b385f5173df7a573","type":"GENE","name":"PPP1R3B","canonical_id":"hgnc:HGNC:14942","description":"protein phosphatase 1 regulatory subunit 3B","metadata":{"aliases":["GL","FLJ14005","PPP1R4"]}},{"id":"31581d20c8374a5ba428ddbf2a19af42","type":"GENE","name":"PPP1R3B-AS1","canonical_id":"hgnc:HGNC:58434","description":"PPP1R3B antisense RNA 1","metadata":null},{"id":"af493423ce224772a85c681a7339e25b","type":"GENE","name":"PPP1R3B-DT","canonical_id":"hgnc:HGNC:56150","description":"PPP1R3B divergent transcript","metadata":{"aliases":["AC02278.4","RP11-10A14.5","AP000695.2"]}},{"id":"172e4083b6b14795a86820fdfe58e299","type":"GENE","name":"PPP1R3C","canonical_id":"hgnc:HGNC:9293","description":null,"metadata":null},{"id":"945cb1eafb234377bdd67f07cd6affe0","type":"GENE","name":"PPP1R3D","canonical_id":"hgnc:HGNC:9294","description":"protein phosphatase 1 regulatory subunit 3D","metadata":{"aliases":["PPP1R6"]}},{"id":"2e8daa6e5fc040bba740b7205f16f4f6","type":"GENE","name":"PPP1R3E","canonical_id":"hgnc:HGNC:14943","description":"protein phosphatase 1 regulatory subunit 3E","metadata":{"aliases":["FLJ00089"]}},{"id":"19029037ad1c42378cb353a6ba3f875b","type":"GENE","name":"PPP1R3F","canonical_id":"hgnc:HGNC:14944","description":"protein phosphatase 1 regulatory subunit 3F","metadata":{"aliases":["Hb2E"]}},{"id":"9922c9241c26437dbbf527d53e30a906","type":"GENE","name":"PPP1R3G","canonical_id":"hgnc:HGNC:14945","description":"protein phosphatase 1 regulatory subunit 3G","metadata":null},{"id":"50d833e113d3488cb3b971cca858f7c5","type":"GENE","name":"PPP1R42","canonical_id":"hgnc:HGNC:33732","description":"protein phosphatase 1 regulatory subunit 42","metadata":{"aliases":["dtr","TLLR","LRRC67"]}},{"id":"c74da7c899cb40118f41c6b9fcfdb9f4","type":"GENE","name":"PPP1R7","canonical_id":"hgnc:HGNC:9295","description":"protein phosphatase 1 regulatory subunit 7","metadata":{"aliases":["sds22"]}},{"id":"bc2d2e86ecfb4b67bd839eab87bbe816","type":"GENE","name":"PPP1R8","canonical_id":"hgnc:HGNC:9296","description":"protein phosphatase 1 regulatory subunit 8","metadata":{"aliases":["ard-1","NIPP-1","PRO2047","ARD1","NIPP1"]}},{"id":"69a4c6aba2ef4511bee171c0a02694a7","type":"GENE","name":"PPP1R8P1","canonical_id":"hgnc:HGNC:9297","description":"protein phosphatase 1 regulatory subunit 8 pseudogene 1","metadata":{"aliases":["PPP1R8P"]}},{"id":"fd7913d641ee4152a84dee51d3ae0d78","type":"GENE","name":"PPP1R9A","canonical_id":"hgnc:HGNC:14946","description":"protein phosphatase 1 regulatory subunit 9A","metadata":{"aliases":["Neurabin-I","KIAA1222","FLJ20068"]}},{"id":"ccdd45f9214a441d8b92dd782dc6a655","type":"GENE","name":"PPP1R9A-AS1","canonical_id":"hgnc:HGNC:40696","description":"PPP1R9A antisense RNA 1","metadata":null},{"id":"6970c6a1ac454eac844f294bd993fbc6","type":"GENE","name":"PPP1R9B","canonical_id":"hgnc:HGNC:9298","description":"protein phosphatase 1 regulatory subunit 9B","metadata":{"aliases":["Spn","SPINO","PPP1R6","PPP1R9"]}},{"id":"f36a89b398f84756b7cdf3fde1e9c189","type":"GENE","name":"PPP2CA","canonical_id":"hgnc:HGNC:9299","description":null,"metadata":null},{"id":"f4ee350957da47148ffbea29b4419e86","type":"GENE","name":"PPP2CA-DT","canonical_id":"hgnc:HGNC:55266","description":"PPP2CA divergent transcript","metadata":null},{"id":"6398ea3d7fe04af58f5abb8d857d1785","type":"GENE","name":"PPP2CB","canonical_id":"hgnc:HGNC:9300","description":"protein phosphatase 2 catalytic subunit beta","metadata":{"aliases":["PP2Abeta"]}},{"id":"807dbfca1511436da640fc7ae9c7f424","type":"GENE","name":"PPP2CBP1","canonical_id":"hgnc:HGNC:9301","description":"protein phosphatase 2 catalytic subunit beta pseudogene 1","metadata":{"aliases":["PPP2CBP"]}},{"id":"62982c4268d44cff9d259c7f0b15aca8","type":"GENE","name":"PPP2R1A","canonical_id":"hgnc:HGNC:9302","description":"protein phosphatase 2 scaffold subunit Aalpha","metadata":{"aliases":["PR65A","PP2A-Aalpha","PP2AA"]}},{"id":"049842d035f04cc89efb45055bee5034","type":"GENE","name":"PPP2R1A-AS1","canonical_id":"hgnc:HGNC:58324","description":"PPP2R1A antisense RNA 1","metadata":null},{"id":"88ca14c1abab44acb2f23c103ed5c923","type":"GENE","name":"PPP2R1B","canonical_id":"hgnc:HGNC:9303","description":"protein phosphatase 2 scaffold subunit Abeta","metadata":{"aliases":["PR65B","PP2A-Abeta"]}},{"id":"0227f986ae7c4f798e1e3f0ff26f4d3d","type":"GENE","name":"PPP2R2A","canonical_id":"hgnc:HGNC:9304","description":"protein phosphatase 2 regulatory subunit Balpha","metadata":{"aliases":["PR52A","PR55A","B55A","PR55alpha","B55alpha"]}},{"id":"cfcefa9710f145d19857d9056d718387","type":"GENE","name":"PPP2R2B","canonical_id":"hgnc:HGNC:9305","description":null,"metadata":null},{"id":"8c5d76e5427944aa9fc4795171b5e702","type":"GENE","name":"PPP2R2B-AS2","canonical_id":"hgnc:HGNC:58421","description":"PPP2R2B antisense RNA 2","metadata":{"aliases":["CTB-99A3.1"]}},{"id":"149e8637a4b3465383bc208a1eb349dc","type":"GENE","name":"PPP2R2B-AS3","canonical_id":"hgnc:HGNC:59274","description":"PPP2R2B antisense RNA 3","metadata":null},{"id":"5f5d03e93fcb4c2e89dd62a3e13c41a7","type":"GENE","name":"PPP2R2B-IT1","canonical_id":"hgnc:HGNC:42984","description":"PPP2R2B intronic transcript 1","metadata":null},{"id":"899b44b4729b413688309627bd7ac42f","type":"GENE","name":"PPP2R2C","canonical_id":"hgnc:HGNC:9306","description":"protein phosphatase 2 regulatory subunit Bgamma","metadata":{"aliases":["PR52","IMYPNO","MGC33570","PR55G","B55gamma"]}},{"id":"6c832f53b4d64e138360c78ae29a45fa","type":"GENE","name":"PPP2R2D","canonical_id":"hgnc:HGNC:23732","description":null,"metadata":null},{"id":"f5c9eb76e6e0402b9122fae5b61d7539","type":"GENE","name":"PPP2R2DP1","canonical_id":"hgnc:HGNC:44544","description":"protein phosphatase 2 regulatory subunit Bdelta pseudogene 1","metadata":null},{"id":"48f090dc4abb4ddda34a2918e25e2ff1","type":"GENE","name":"PPP2R3A","canonical_id":"hgnc:HGNC:9307","description":"protein phosphatase 2 regulatory subunit B''alpha","metadata":{"aliases":["PR130","PR72","PPP2R3"]}},{"id":"72873159ca164ce3af10a4d3484fd201","type":"GENE","name":"PPP2R3B","canonical_id":"hgnc:HGNC:13417","description":"protein phosphatase 2 regulatory subunit B''beta","metadata":{"aliases":["PPP2R3LY","PR48","PR70","PPP2R3L"]}},{"id":"e9dc47901dbc4daaaecc0a4ed23af009","type":"GENE","name":"PPP2R3C","canonical_id":"hgnc:HGNC:17485","description":"protein phosphatase 2 regulatory subunit B''gamma","metadata":{"aliases":["FLJ20644","G4-1","G5PR","C14orf10"]}},{"id":"c6a9ff20e37241f284ab729af083e879","type":"GENE","name":"PPP2R5A","canonical_id":"hgnc:HGNC:9309","description":"protein phosphatase 2 regulatory subunit B'alpha","metadata":{"aliases":["PR61A","B56A","B56alpha"]}},{"id":"47fb004db15c43cc9e4a2826d30e48cc","type":"GENE","name":"PPP2R5B","canonical_id":"hgnc:HGNC:9310","description":"protein phosphatase 2 regulatory subunit B'beta","metadata":{"aliases":["FLJ35411","B56B","PR61B","B56beta"]}},{"id":"d064f3df8c8d4a118a5a3d96c065228e","type":"GENE","name":"PPP2R5C","canonical_id":"hgnc:HGNC:9311","description":"protein phosphatase 2 regulatory subunit B'gamma","metadata":{"aliases":["B56G","PR61G","B56gamma"]}},{"id":"060d61b7cf68418aa20fda6bff4a97d3","type":"GENE","name":"PPP2R5CP","canonical_id":"hgnc:HGNC:17835","description":"protein phosphatase 2 regulatory subunit B'gamma pseudogene","metadata":null},{"id":"30cdd20a341346d5bdbd86bd30a48daa","type":"GENE","name":"PPP2R5D","canonical_id":"hgnc:HGNC:9312","description":"protein phosphatase 2 regulatory subunit B'delta","metadata":{"aliases":["B56D","B56delta"]}},{"id":"c87318ea80f34691bec7029d00a703cb","type":"GENE","name":"PPP2R5D-DT","canonical_id":"hgnc:HGNC:59409","description":"PPP2R5D divergent transcript","metadata":null},{"id":"e45e56440bf042749e40119648f6189b","type":"GENE","name":"PPP2R5E","canonical_id":"hgnc:HGNC:9313","description":"protein phosphatase 2 regulatory subunit B'epsilon","metadata":{"aliases":["B56E","B56epsilon"]}},{"id":"0ab7eb0e2f5e46e38fc0fda157a360a1","type":"GENE","name":"PPP3CA","canonical_id":"hgnc:HGNC:9314","description":"protein phosphatase 3 catalytic subunit alpha","metadata":{"aliases":["CNA1","PPP2B","CALN","CALNA"]}},{"id":"ea12f2c0f3f14806839cba5a9c2f9eea","type":"PROTEIN","name":"PPP3CA","canonical_id":"uniprot:Q08209","description":null,"metadata":null},{"id":"4a353a38b1614d57be67eedd7ed8a827","type":"GENE","name":"PPP3CA-DT","canonical_id":"hgnc:HGNC:58118","description":"PPP3CA divergent transcript","metadata":{"aliases":["FLJ20021","SRSP","FLJ"]}},{"id":"9f5365dc717c4f4085409c52d946eaef","type":"GENE","name":"PPP3CB","canonical_id":"hgnc:HGNC:9315","description":"protein phosphatase 3 catalytic subunit beta","metadata":{"aliases":["CALNA2","CNA2","PP2Bbeta","CALNB"]}},{"id":"49e98952487e428c907057f206163281","type":"GENE","name":"PPP3CB-AS1","canonical_id":"hgnc:HGNC:50750","description":"PPP3CB antisense RNA 1","metadata":{"aliases":["USP54-AS1"]}},{"id":"deb75669c6b04d338deb5706cce8a846","type":"GENE","name":"PPP3CC","canonical_id":"hgnc:HGNC:9316","description":"protein phosphatase 3 catalytic subunit gamma","metadata":{"aliases":["CALNA3","PP2Bgamma"]}},{"id":"37a176f08f3645d18677ba288bd754aa","type":"GENE","name":"PPP3R1","canonical_id":"hgnc:HGNC:9317","description":"protein phosphatase 3 regulatory subunit B, alpha","metadata":{"aliases":["CALNB1","CNB","CNB1"]}},{"id":"7b3ac889e3b045d48a2646ffc2f2f488","type":"GENE","name":"PPP3R1-AS1","canonical_id":"hgnc:HGNC:58298","description":"PPP3R1 and CNRIP1 antisense RNA 1","metadata":null},{"id":"54f12face4484a77919a5737ba2ceb98","type":"GENE","name":"PPP3R2","canonical_id":"hgnc:HGNC:9318","description":"protein phosphatase 3 regulatory subunit B, beta","metadata":{"aliases":["PPP3RL"]}},{"id":"9842c9da49784950a401b5c6b8545413","type":"GENE","name":"PPP4C","canonical_id":"hgnc:HGNC:9319","description":"protein phosphatase 4 catalytic subunit","metadata":{"aliases":["PP4","PPX"]}},{"id":"d3278171cb1448c3b7f66f34340086c5","type":"GENE","name":"PPP4R1","canonical_id":"hgnc:HGNC:9320","description":"protein phosphatase 4 regulatory subunit 1","metadata":{"aliases":["PP4R1"]}},{"id":"46b0545e25914a1ea3cf964cf629562b","type":"GENE","name":"PPP4R1-AS1","canonical_id":"hgnc:HGNC:51112","description":"PPP4R1 antisense RNA 1","metadata":null},{"id":"ee90026829fb437681e1c473dbc49523","type":"GENE","name":"PPP4R1L","canonical_id":"hgnc:HGNC:15755","description":"protein phosphatase 4 regulatory subunit 1 like (pseudogene)","metadata":{"aliases":["bA196N14.4","bA196N14.5","PPP4R1P1","C20orf192"]}},{"id":"a664f2ab91d945749a942a174d3e6d13","type":"GENE","name":"PPP4R2","canonical_id":"hgnc:HGNC:18296","description":"protein phosphatase 4 regulatory subunit 2","metadata":null},{"id":"1936408231c149acb394258fea69a8bf","type":"GENE","name":"PPP4R2P1","canonical_id":"hgnc:HGNC:56513","description":"PPP4R2 pseudogene 1","metadata":null},{"id":"0f741cde5b9840019d6c4d5198bd639e","type":"GENE","name":"PPP4R2P2","canonical_id":"hgnc:HGNC:56514","description":"PPP4R2 pseudogene 2","metadata":null},{"id":"7e08beeddbc74ec48be08e31f064fa0c","type":"GENE","name":"PPP4R2P3","canonical_id":"hgnc:HGNC:56515","description":"PPP4R2 pseudogene 3","metadata":null},{"id":"30e61f595c884e36a25e5273f79365da","type":"GENE","name":"PPP4R2P4","canonical_id":"hgnc:HGNC:56516","description":"PPP4R2 pseudogene 4","metadata":null},{"id":"3ed90fca42fe407594ff335eeb24e3b2","type":"GENE","name":"PPP4R2P5","canonical_id":"hgnc:HGNC:56517","description":"PPP4R2 pseudogene 5","metadata":null},{"id":"c0dcf5f60d0147abb45623bfbf59986a","type":"GENE","name":"PPP4R2P6","canonical_id":"hgnc:HGNC:56518","description":"PPP4R2 pseudogene 6","metadata":null},{"id":"a033d6768cea453aa28c53ef588172a5","type":"GENE","name":"PPP4R3A","canonical_id":"hgnc:HGNC:20219","description":"protein phosphatase 4 regulatory subunit 3A","metadata":{"aliases":["FLJ20707","MSTP033","FLFL1","smk-1","smk1","PP4R3","KIAA2010","SMEK1"]}},{"id":"f91d1af6904a43a19e31ce0451999226","type":"GENE","name":"PPP4R3B","canonical_id":"hgnc:HGNC:29267","description":"protein phosphatase 4 regulatory subunit 3B","metadata":{"aliases":["PSY2","FLFL2","KIAA1387","FLJ31474","SMEK2"]}},{"id":"f47721426f994af3b34e4925c0eedfed","type":"GENE","name":"PPP4R3B-DT","canonical_id":"hgnc:HGNC:55209","description":"PPP4R3B divergent transcript","metadata":null},{"id":"a062a02597f64f6db7f2cfab2aa864ab","type":"GENE","name":"PPP4R3C","canonical_id":"hgnc:HGNC:33146","description":"protein phosphatase 4 regulatory subunit 3C","metadata":{"aliases":["FLJ32867","FLFL3P","smk1","SMEK3P","PPP4R3CP"]}},{"id":"844d23afaa554569a3903f0f25c3104e","type":"GENE","name":"PPP4R4","canonical_id":"hgnc:HGNC:23788","description":"protein phosphatase 4 regulatory subunit 4","metadata":{"aliases":["PP4R4","CFAP14","KIAA1622"]}},{"id":"e46d71f832ab4d2199bd21b0eb1d361c","type":"GENE","name":"PPP5C","canonical_id":"hgnc:HGNC:9322","description":"protein phosphatase 5 catalytic subunit","metadata":{"aliases":["PP5","PPP5"]}},{"id":"c8e4837420ac4860b50cd52e892fecf3","type":"GENE","name":"PPP5C-AS1","canonical_id":"hgnc:HGNC:58175","description":"PPP5C antisense RNA 1","metadata":null},{"id":"135a66941a5247ceb821f6988283d601","type":"GENE","name":"PPP5D1P","canonical_id":"hgnc:HGNC:44209","description":"PPP5 tetratricopeptide repeat domain containing 1, pseudogene","metadata":{"aliases":["PPP5D1"]}},{"id":"31f2bffb3b344607836987c3b5fd8286","type":"GENE","name":"PPP6C","canonical_id":"hgnc:HGNC:9323","description":"protein phosphatase 6 catalytic subunit","metadata":{"aliases":["PP6"]}},{"id":"65859b63c5714ef58eb68ff0b103a53d","type":"GENE","name":"PPP6CP","canonical_id":"hgnc:HGNC:34077","description":"protein phosphatase 6 catalytic subunit pseudogene","metadata":null},{"id":"97a58f9d6d8e45ceaf2eecc7094943a5","type":"GENE","name":"PPP6R1","canonical_id":"hgnc:HGNC:29195","description":"protein phosphatase 6 regulatory subunit 1","metadata":{"aliases":["SAP190","KIAA1115","SAPS1"]}},{"id":"e1c884480e33496d8f6584b64d2c785d","type":"GENE","name":"PPP6R2","canonical_id":"hgnc:HGNC:19253","description":"protein phosphatase 6 regulatory subunit 2","metadata":{"aliases":["dJ579N16.1","SAP190","KIAA0685","SAPS2"]}},{"id":"7e163fe74c9c4a9d9ec3abfc7965d2ea","type":"GENE","name":"PPP6R2P1","canonical_id":"hgnc:HGNC:39605","description":"protein phosphatase 6 regulatory subunit 2 pseudogene 1","metadata":null},{"id":"f588434c10a7488c8e8e883bd3b3000a","type":"GENE","name":"PPP6R3","canonical_id":"hgnc:HGNC:1173","description":"protein phosphatase 6 regulatory subunit 3","metadata":{"aliases":["SAPLa","DKFZp781E2374","DKFZp781O2362","DKFZp781E17107","SAP190","SAPL","PP6R3","FLJ11058","FLJ43065","KIAA1558","MGC125711","MGC125712","C11orf23","SAPS3"]}},{"id":"7497ae821742485e9f63bec9e65c6592","type":"GENE","name":"PPRC1","canonical_id":"hgnc:HGNC:30025","description":"PPARG related coactivator 1","metadata":{"aliases":["PRC","KIAA0595","MGC74642"]}},{"id":"03c0d2a5a19549149a5af6bf085620da","type":"GENE","name":"PPT1","canonical_id":"hgnc:HGNC:9325","description":"palmitoyl-protein thioesterase 1","metadata":{"aliases":["CLN1","INCL","PPT"]}},{"id":"4d65a028895d442ebb95b3c5caa4e00e","type":"GENE","name":"PPT2","canonical_id":"hgnc:HGNC:9326","description":"palmitoyl-protein thioesterase 2","metadata":null},{"id":"c73fc556efff4231b559ab5783cc7d35","type":"GENE","name":"PPT2-EGFL8","canonical_id":"hgnc:HGNC:48343","description":"PPT2-EGFL8 readthrough (NMD candidate)","metadata":null},{"id":"6d85363f2a9d48f0a4151e682bcfec8c","type":"GENE","name":"PPTC7","canonical_id":"hgnc:HGNC:30695","description":"protein phosphatase targeting COQ7","metadata":{"aliases":["TA-PP2C"]}},{"id":"728ca0eba55540099f6fa4a96440c16f","type":"GENE","name":"PPWD1","canonical_id":"hgnc:HGNC:28954","description":"peptidylprolyl isomerase domain and WD repeat containing 1","metadata":{"aliases":["KIAA0073"]}},{"id":"49a59f5523cb44f5a4d6ff575016d086","type":"GENE","name":"PPY","canonical_id":"hgnc:HGNC:9327","description":"pancreatic polypeptide","metadata":{"aliases":["PNP"]}},{"id":"f209674f414d4ad4b10451eb45a0c554","type":"GENE","name":"PPY2P","canonical_id":"hgnc:HGNC:9328","description":"pancreatic polypeptide 2, pseudogene","metadata":{"aliases":["PPY2"]}},{"id":"b43e3b80f9b04ce3b06dd40c265d2ccc","type":"GENE","name":"PQBP1","canonical_id":"hgnc:HGNC:9330","description":"polyglutamine binding protein 1","metadata":{"aliases":["RENS1","MRXS8","SHS","MRX55","MRX2","MRXS3"]}},{"id":"7eb1b0d3fd424045ac03442bf2b80270","type":"GO_TERM","name":"PR-DUB complex","canonical_id":"go:GO:0035517","description":"\"A multimeric protein complex that removes monoubiquitin from histone H2A. In Drosophila and mammals, the core of the complex is composed of Calypso/BAP1 and Asx/ASXL1, respectively.\" [PMID:20436459]","metadata":null},{"id":"a02381a17d244d8d86e7f002e6c87ac5","type":"GO_TERM","name":"PR-toxin biosynthetic process","canonical_id":"go:GO:0140875","description":"\"The chemical reactions and pathways resulting in the formation of PR-toxin, a bicyclic sesquiterpene belonging to the eremophilane class and acting as a mycotoxin.\" [PMID:24239699, PMID:27921136]","metadata":null},{"id":"bf0b352bcda642a797020152bf374d40","type":"GENE","name":"PRAC1","canonical_id":"hgnc:HGNC:30591","description":"PRAC1 small nuclear protein","metadata":{"aliases":["C17orf92","PRAC"]}},{"id":"efd824eaa4e340f79214e0046ae8f286","type":"GENE","name":"PRAC2","canonical_id":"hgnc:HGNC:30143","description":"PRAC2 small nuclear protein","metadata":{"aliases":["C17orf93","NCRNA00253","HOXB13-AS1","HOXB-AS5"]}},{"id":"9a99b00f7a444b9badb78cabe17d772d","type":"GENE","name":"PRADC1","canonical_id":"hgnc:HGNC:16047","description":"protease associated domain containing 1","metadata":{"aliases":["MGC13004","PAP21","hPAP21","C2orf7"]}},{"id":"70b9f7109ac64eb9b30eb0c668f0ca82","type":"GENE","name":"PRADC1P1","canonical_id":"hgnc:HGNC:44534","description":"protease associated domain containing 1 pseudogene 1","metadata":null},{"id":"545f19444604427093bc71e516032178","type":"GENE","name":"PRADX","canonical_id":"hgnc:HGNC:40168","description":"PRC2 and DDX5 associated lncRNA","metadata":null},{"id":"6becf80760544df5ab5d267f646d9e52","type":"GENE","name":"PRAF2","canonical_id":"hgnc:HGNC:28911","description":"PRA1 domain family member 2","metadata":{"aliases":["JM4","Yip6a"]}},{"id":"c67083f859744404a71210cd25f3e1bc","type":"GENE","name":"PRAG1","canonical_id":"hgnc:HGNC:25438","description":"PEAK1 related, kinase-activating pseudokinase 1","metadata":{"aliases":["DKFZp761P0423","SgK223","PRAGMIN","PEAK2","NACK"]}},{"id":"153d7a31db054322b571e4a214472c77","type":"GENE","name":"PRAL","canonical_id":"hgnc:HGNC:52646","description":"p53 regulation associated lncRNA","metadata":{"aliases":["lncRNA-PRAL"]}},{"id":"7c58bb82b47743979fc19d85afaf96b8","type":"GENE","name":"PRAM1","canonical_id":"hgnc:HGNC:30091","description":null,"metadata":null},{"id":"e4a41c91459444bb96ab15e4777390cf","type":"GENE","name":"PRAME","canonical_id":"hgnc:HGNC:9336","description":null,"metadata":null},{"id":"2ad31fa5970d402f840d55a2d3799ffe","type":"GENE","name":"PRAME-AS","canonical_id":"hgnc:HGNC:58774","description":"PRAME antisense RNA","metadata":{"aliases":["LL22NC03-63E9.3"]}},{"id":"04062f2b4f894f23b0f08c92e3231dde","type":"GENE","name":"PRAMEF1","canonical_id":"hgnc:HGNC:28840","description":"PRAME family member 1","metadata":null},{"id":"8332950da17f4303aedd1a9f917271e3","type":"GENE","name":"PRAMEF10","canonical_id":"hgnc:HGNC:27997","description":"PRAME family member 10","metadata":null},{"id":"6bd953d4582e4f8e8ca4a13682eb8d09","type":"GENE","name":"PRAMEF11","canonical_id":"hgnc:HGNC:14086","description":"PRAME family member 11","metadata":null},{"id":"1fdd1646254c42e6abc7b53e0bc3ef0b","type":"GENE","name":"PRAMEF12","canonical_id":"hgnc:HGNC:22125","description":"PRAME family member 12","metadata":{"aliases":["OTTHUMG00000001927"]}},{"id":"d98249346d6d4d74a089b5ba5c236f4e","type":"GENE","name":"PRAMEF13","canonical_id":"hgnc:HGNC:13262","description":"PRAME family member 13","metadata":null},{"id":"eb8849244f4942f790508a46281dd482","type":"GENE","name":"PRAMEF14","canonical_id":"hgnc:HGNC:13576","description":"PRAME family member 14","metadata":{"aliases":["OTTHUMG00000007916"]}},{"id":"a921a55bef70491d9c9dcf209b426fca","type":"GENE","name":"PRAMEF15","canonical_id":"hgnc:HGNC:26764","description":"PRAME family member 15","metadata":{"aliases":["OTTHUMG00000007921"]}},{"id":"8df55d9ebf4b4e6daeb93f8eed55679f","type":"GENE","name":"PRAMEF17","canonical_id":"hgnc:HGNC:29485","description":"PRAME family member 17","metadata":{"aliases":["OTTHUMG00000007909"]}},{"id":"36c4a550ba9c472ca23f7501050c79b3","type":"GENE","name":"PRAMEF18","canonical_id":"hgnc:HGNC:30693","description":"PRAME family member 18","metadata":null},{"id":"9057189d19294980a691488634f1f91f","type":"GENE","name":"PRAMEF19","canonical_id":"hgnc:HGNC:24908","description":"PRAME family member 19","metadata":{"aliases":["OTTHUMG00000007919"]}},{"id":"60dc0c6fad4b4e55905a114ae919f589","type":"GENE","name":"PRAMEF2","canonical_id":"hgnc:HGNC:28841","description":"PRAME family member 2","metadata":{"aliases":["FLJ43580"]}},{"id":"dfc4ffe483e147a484f22ef20cf0f3f8","type":"GENE","name":"PRAMEF20","canonical_id":"hgnc:HGNC:25224","description":"PRAME family member 20","metadata":{"aliases":["OTTHUMG00000007911","OTTHUMT00000008157","PRAMEF21"]}},{"id":"54657144c9b746c584b7381729d78317","type":"GENE","name":"PRAMEF22","canonical_id":"hgnc:HGNC:34393","description":"PRAME family member 22","metadata":{"aliases":["PRAMEF3L"]}},{"id":"eab4b581241b46b090167a0661b7737d","type":"GENE","name":"PRAMEF25","canonical_id":"hgnc:HGNC:49179","description":"PRAME family member 25","metadata":null},{"id":"1986b7ae9ed24a25972c95cc5b5f0aff","type":"GENE","name":"PRAMEF26","canonical_id":"hgnc:HGNC:49178","description":"PRAME family member 26","metadata":null},{"id":"5297ad47b5ab43ad99e88f1b331fd1ad","type":"GENE","name":"PRAMEF27","canonical_id":"hgnc:HGNC:51234","description":"PRAME family member 27","metadata":null},{"id":"77c4fa1933d44527ae5fdfece53ef09a","type":"GENE","name":"PRAMEF28P","canonical_id":"hgnc:HGNC:51890","description":"PRAME family member 28, pseudogene","metadata":{"aliases":["PRAMEF28"]}},{"id":"8ecffe67ad254170a9598bf3f705b852","type":"GENE","name":"PRAMEF29P","canonical_id":"hgnc:HGNC:51891","description":"PRAME family member 29, pseudogene","metadata":null},{"id":"5ef8756e658943c19751cd9cbc83eea7","type":"GENE","name":"PRAMEF30P","canonical_id":"hgnc:HGNC:51892","description":"PRAME family member 30, pseudogene","metadata":null},{"id":"2bc39caf37244547894d66f642e019f2","type":"GENE","name":"PRAMEF31P","canonical_id":"hgnc:HGNC:51893","description":"PRAME family member 31, pseudogene","metadata":null},{"id":"348a094012e64d7ca0b64050be06413b","type":"GENE","name":"PRAMEF32P","canonical_id":"hgnc:HGNC:51894","description":"PRAME family member 32, pseudogene","metadata":null},{"id":"f528d5dccb98453990118bd6c8135532","type":"GENE","name":"PRAMEF33","canonical_id":"hgnc:HGNC:49193","description":"PRAME family member 33","metadata":{"aliases":["PRAMEF33P"]}},{"id":"f3c9134ee9ba4c9f942ecef90b122220","type":"GENE","name":"PRAMEF34P","canonical_id":"hgnc:HGNC:51895","description":"PRAME family member 34, pseudogene","metadata":null},{"id":"43fbe7ef14ed4a57bc8b5bcc2402a274","type":"GENE","name":"PRAMEF35P","canonical_id":"hgnc:HGNC:51896","description":"PRAME family member 35, pseudogene","metadata":null},{"id":"d09a85b562044bd4a3a233961fd713f4","type":"GENE","name":"PRAMEF36P","canonical_id":"hgnc:HGNC:51897","description":"PRAME family member 36, pseudogene","metadata":null},{"id":"c66194b7dca94316988ec1cd1f05c91e","type":"GENE","name":"PRAMEF4","canonical_id":"hgnc:HGNC:31971","description":"PRAME family member 4","metadata":{"aliases":["RP5-845O24.6"]}},{"id":"c4a96a29a5ae48538b8d7f5bd6990e8c","type":"GENE","name":"PRAMEF5","canonical_id":"hgnc:HGNC:27995","description":"PRAME family member 5","metadata":{"aliases":["PRAMEF5L","PRAMEF23"]}},{"id":"0814f5db546942fe87568667506ecc8a","type":"GENE","name":"PRAMEF6","canonical_id":"hgnc:HGNC:30583","description":"PRAME family member 6","metadata":null},{"id":"fcdb1b2a0d1344c98df4e249ca5ef1ee","type":"GENE","name":"PRAMEF7","canonical_id":"hgnc:HGNC:28415","description":"PRAME family member 7","metadata":null},{"id":"a60c9563e4ff48479bcc60139f447844","type":"GENE","name":"PRAMEF8","canonical_id":"hgnc:HGNC:24074","description":"PRAME family member 8","metadata":null},{"id":"c355eb89c3ed4de9ab32b3114ae60b12","type":"GENE","name":"PRAMEF9","canonical_id":"hgnc:HGNC:27996","description":"PRAME family member 9","metadata":null},{"id":"08fa96e46cd64bdf812199050eaf871c","type":"GENE","name":"PRAMENP","canonical_id":"hgnc:HGNC:34302","description":"PRAME N-terminal like, pseudogene","metadata":{"aliases":["FLJ16327","PRAMEL","PRAMEF24P"]}},{"id":"0aa529b6017b426798ed1cb291c7a8f0","type":"GENE","name":"PRANCR","canonical_id":"hgnc:HGNC:51126","description":"progenitor renewal associated non-coding RNA","metadata":{"aliases":["LINC01481","CNOT2-DT"]}},{"id":"9b287cf8d8bb4d779aeb16c1350e25ce","type":"GENE","name":"PRAP1","canonical_id":"hgnc:HGNC:23304","description":"proline rich acidic protein 1","metadata":{"aliases":["UPA"]}},{"id":"426128d76dfa4ba38af2e276c1aa9412","type":"GENE","name":"PRB1","canonical_id":"hgnc:HGNC:9337","description":"proline rich protein BstNI subfamily 1","metadata":{"aliases":["PM","PMF","PMS","PRB1M","PRB1L"]}},{"id":"97d0e34af18d451d8f0eb30d1733433d","type":"GENE","name":"PRB2","canonical_id":"hgnc:HGNC:9338","description":"proline rich protein BstNI subfamily 2","metadata":{"aliases":["PRPPRB1","Ps","cP7"]}},{"id":"9b8d80dd788d4c2281f15b54063ee428","type":"GENE","name":"PRB3","canonical_id":"hgnc:HGNC:9339","description":"proline rich protein BstNI subfamily 3","metadata":{"aliases":["PRG"]}},{"id":"0ed0dc6d9edd4dbb8d9a45b23cb5c9a1","type":"GENE","name":"PRB4","canonical_id":"hgnc:HGNC:9340","description":"proline rich protein BstNI subfamily 4","metadata":null},{"id":"ae4e26c7aac048b18cb0ae94460699a4","type":"GENE","name":"PRC1","canonical_id":"hgnc:HGNC:9341","description":null,"metadata":null},{"id":"f0e85672ae8d4d4198be84a7094e5c4a","type":"GO_TERM","name":"PRC1 complex","canonical_id":"go:GO:0035102","description":"\"A multiprotein complex that mediates monoubiquitination of lysine residues of histone H2A (lysine-118 in Drosophila or lysine-119 in mammals). The complex is required for stable long-term maintenance of transcriptionally repressed states and is involved in chromatin remodeling.\" [GOC:bf, PMID:10412979]","metadata":null},{"id":"833e32e3f9e44ebebf155ad146cabfd1","type":"GO_TERM","name":"PRC1 complex binding","canonical_id":"go:GO:0140259","description":"\"Binding to a PRC1 complex.\" [PMID:15280237]","metadata":null},{"id":"d8e7ea73fc53470eb90f132144e017c2","type":"GENE","name":"PRC1-AS1","canonical_id":"hgnc:HGNC:48587","description":"PRC1 antisense RNA 1","metadata":null},{"id":"0bf687fdc16a49989a59dd582fbd0ca5","type":"GENE","name":"PRCC","canonical_id":"hgnc:HGNC:9343","description":"proline rich mitotic checkpoint control factor","metadata":{"aliases":["RCCP1"]}},{"id":"913e29c4ed94423eb3ce79d8a414db10","type":"GENE","name":"PRCD","canonical_id":"hgnc:HGNC:32528","description":"photoreceptor disc component","metadata":{"aliases":["RP36"]}},{"id":"1230e4fc5bfa46499740216bc01604a6","type":"GENE","name":"PRCP","canonical_id":"hgnc:HGNC:9344","description":"prolylcarboxypeptidase","metadata":{"aliases":["PCP","HUMPCP"]}},{"id":"8c89fd82fdff4acaa742bd86f31d4ce7","type":"GENE","name":"PRCPP1","canonical_id":"hgnc:HGNC:54653","description":"PRCP pseudogene 1","metadata":null},{"id":"9250a3b2e8be4b5b83990878ca5e1f99","type":"GENE","name":"PRDM1","canonical_id":"hgnc:HGNC:9346","description":null,"metadata":null},{"id":"0332f4e71b7a4a7b9f7cae4e752c6c89","type":"GENE","name":"PRDM10","canonical_id":"hgnc:HGNC:13995","description":"PR/SET domain 10","metadata":{"aliases":["KIAA1231","PFM7","MGC131802"]}},{"id":"eafa2fdae6ca424ab614a42e7a843662","type":"GENE","name":"PRDM10-DT","canonical_id":"hgnc:HGNC:30468","description":"PRDM10 divergent transcript","metadata":{"aliases":["FLJ31394","C11orf37","NCRNA00167","LINC00167"]}},{"id":"edf561eab789400ba989756a207b30b8","type":"GENE","name":"PRDM11","canonical_id":"hgnc:HGNC:13996","description":"PR/SET domain 11","metadata":{"aliases":["PFM8"]}},{"id":"344ca3e093e247aba20f72e20897b7c6","type":"GENE","name":"PRDM12","canonical_id":"hgnc:HGNC:13997","description":"PR/SET domain 12","metadata":{"aliases":["PFM9"]}},{"id":"8f7000eab24b4238b6eb785df728fc9d","type":"GENE","name":"PRDM13","canonical_id":"hgnc:HGNC:13998","description":"PR/SET domain 13","metadata":{"aliases":["PFM10"]}},{"id":"b058bffeffdc48529659f1ca6f39f805","type":"GENE","name":"PRDM14","canonical_id":"hgnc:HGNC:14001","description":null,"metadata":null},{"id":"8b17ef6041b844ecba4315f2e26ba35d","type":"GENE","name":"PRDM15","canonical_id":"hgnc:HGNC:13999","description":"PR/SET domain 15","metadata":{"aliases":["ZNF298","C21orf83"]}},{"id":"0eff82d508f94beeb1ca64c094251dba","type":"GENE","name":"PRDM16","canonical_id":"hgnc:HGNC:14000","description":"PR/SET domain 16","metadata":{"aliases":["MEL1","PFM13","KIAA1675","MGC166915","KMT8F"]}},{"id":"fbbd885c25254f799f74fa40e66437d3","type":"GENE","name":"PRDM16-DT","canonical_id":"hgnc:HGNC:48664","description":"PRDM16 divergent transcript","metadata":{"aliases":["FLJ42875","lnc-dPrdm16","LINC00982"]}},{"id":"ac9eb74aade44917ade79a93dc34e1c4","type":"GENE","name":"PRDM2","canonical_id":"hgnc:HGNC:9347","description":null,"metadata":null},{"id":"7d467f11371547c8af67c54a5a297dbf","type":"GENE","name":"PRDM4","canonical_id":"hgnc:HGNC:9348","description":"PR/SET domain 4","metadata":{"aliases":["PFM1"]}},{"id":"6d00de3b4ff647baa30fc1de4f685cdb","type":"GENE","name":"PRDM4-AS1","canonical_id":"hgnc:HGNC:56186","description":"PRDM4 antisense RNA 1","metadata":null},{"id":"84c1fbdfd80846bfb467288c0a334b2a","type":"GENE","name":"PRDM5","canonical_id":"hgnc:HGNC:9349","description":"PR/SET domain 5","metadata":{"aliases":["PFM2"]}},{"id":"00be8430493c47e3b0a849e7ff45235e","type":"GENE","name":"PRDM5-DT","canonical_id":"hgnc:HGNC:58880","description":"PRDM5 divergent transcript","metadata":null},{"id":"a3fe76028ccd468392291b2222fa1cf8","type":"GENE","name":"PRDM6","canonical_id":"hgnc:HGNC:9350","description":"PR/SET domain 6","metadata":{"aliases":["PRISM","KMT8C"]}},{"id":"b552648d45f04f4190fae1b28f73a55a","type":"GENE","name":"PRDM6-AS1","canonical_id":"hgnc:HGNC:55869","description":"PRDM6 antisense RNA 1","metadata":null},{"id":"fc192bd42e6b40568d4375654e30444a","type":"GENE","name":"PRDM7","canonical_id":"hgnc:HGNC:9351","description":"PR/SET domain 7","metadata":{"aliases":["ZNF910"]}},{"id":"828b606dc9f9442fa2185ecb7fa29bc4","type":"GENE","name":"PRDM8","canonical_id":"hgnc:HGNC:13993","description":"PR/SET domain 8","metadata":{"aliases":["KMT8D"]}},{"id":"88cfa0da06a14d599b91fc78bbc248ce","type":"GENE","name":"PRDM8-AS1","canonical_id":"hgnc:HGNC:55581","description":"PRDM8 antisense RNA 1","metadata":null},{"id":"9bcd3c8574884c19a458c396b33813f9","type":"GENE","name":"PRDM9","canonical_id":"hgnc:HGNC:13994","description":"PR/SET domain 9","metadata":{"aliases":["PFM6","ZNF899","KMT8B","Meisetz","MSBP3"]}},{"id":"2fad0a984f504f58a7dcab3adc944327","type":"GENE","name":"PRDM9-AS1","canonical_id":"hgnc:HGNC:59016","description":"PRDM9 antisense RNA 1","metadata":null},{"id":"a75cce9e23514e5798b1a46350255e53","type":"GENE","name":"PRDM9-AS2","canonical_id":"hgnc:HGNC:59017","description":"PRDM9 antisense RNA 2","metadata":null},{"id":"18a48c882f5844a2919b7ee0101711a4","type":"GENE","name":"PRDX1","canonical_id":"hgnc:HGNC:9352","description":"peroxiredoxin 1","metadata":{"aliases":["NKEFA","PAGA"]}},{"id":"597909b90dca493db2af136658e1a2ed","type":"GENE","name":"PRDX1P1","canonical_id":"hgnc:HGNC:11711","description":"peroxiredoxin 1 pseudogene 1","metadata":{"aliases":["PAGB","TDPX2"]}},{"id":"b99c43b2376844c78cb139b51635f1e3","type":"GENE","name":"PRDX2","canonical_id":"hgnc:HGNC:9353","description":"peroxiredoxin 2","metadata":{"aliases":["PRP","NKEFB","TSA","PRXII","PRX2","MGC4104","TDPX1"]}},{"id":"ad1ef89cf4454306b56b430276b5d77f","type":"GENE","name":"PRDX2P1","canonical_id":"hgnc:HGNC:30020","description":"peroxiredoxin 2 pseudogene 1","metadata":null},{"id":"ec75b81cbfeb469c870ce84a4e6019ec","type":"GENE","name":"PRDX2P2","canonical_id":"hgnc:HGNC:44967","description":"peroxiredoxin 2 pseudogene 2","metadata":null},{"id":"d6c2006c98304ef4945995bc3c1ecb3f","type":"GENE","name":"PRDX2P3","canonical_id":"hgnc:HGNC:44968","description":"peroxiredoxin 2 pseudogene 3","metadata":null},{"id":"9c7fc3d3a1c94d3b84007b11dc22dad5","type":"GENE","name":"PRDX2P4","canonical_id":"hgnc:HGNC:44969","description":"peroxiredoxin 2 pseudogene 4","metadata":null},{"id":"23a5343ce3674f9f927737df98856136","type":"GENE","name":"PRDX3","canonical_id":"hgnc:HGNC:9354","description":null,"metadata":null},{"id":"0219a354ac354b3cadae5243fb52e841","type":"GENE","name":"PRDX3P1","canonical_id":"hgnc:HGNC:39264","description":"peroxiredoxin 3 pseudogene 1","metadata":null},{"id":"51b9f7f4f2a74a3ab9eed6506d01fbb8","type":"GENE","name":"PRDX3P2","canonical_id":"hgnc:HGNC:39265","description":"peroxiredoxin 3 pseudogene 2","metadata":null},{"id":"16a372940bf240e9b755d4df67a766ac","type":"GENE","name":"PRDX3P3","canonical_id":"hgnc:HGNC:39266","description":"peroxiredoxin 3 pseudogene 3","metadata":null},{"id":"1587e113129247bfadf000a0c52b6006","type":"GENE","name":"PRDX3P4","canonical_id":"hgnc:HGNC:44643","description":"peroxiredoxin 3 pseudogene 4","metadata":null},{"id":"369da41200ce4f9e83bb23567463543b","type":"GENE","name":"PRDX4","canonical_id":"hgnc:HGNC:17169","description":"peroxiredoxin 4","metadata":{"aliases":["AOE37-2"]}},{"id":"e7b7b317d3fa48c19b7ca5d2f3818367","type":"GENE","name":"PRDX4P1","canonical_id":"hgnc:HGNC:43598","description":"peroxiredoxin 4 pseudogene 1","metadata":null},{"id":"b7c683d4009e43bba7cb016392029fc8","type":"GENE","name":"PRDX4P2","canonical_id":"hgnc:HGNC:43599","description":"peroxiredoxin 4 pseudogene 2","metadata":null},{"id":"9f5f3077fe7543b9a8b1862e15bbdc90","type":"GENE","name":"PRDX5","canonical_id":"hgnc:HGNC:9355","description":null,"metadata":null},{"id":"f824560b455d4896bb5a3f644d3f3b23","type":"GENE","name":"PRDX5P1","canonical_id":"hgnc:HGNC:56432","description":"PRDX5 pseudogene 1","metadata":null},{"id":"487b441e9d3d4609a4b27343b2822379","type":"GENE","name":"PRDX6","canonical_id":"hgnc:HGNC:16753","description":"peroxiredoxin 6","metadata":{"aliases":["AOP2","KIAA0106","1-Cys","NSGPx","PRX","aiPLA2","MGC46173","p29"]}},{"id":"d7b4d144223d4da8900eb6a53fb8f511","type":"GENE","name":"PRDX6-AS1","canonical_id":"hgnc:HGNC:54870","description":"PRDX6 antisense RNA 1","metadata":null},{"id":"3a7bd4ce4cc24aaa856a787536dd2075","type":"TRIAL","name":"PRE-ISPY Phase I/II Oncology Platform Program","canonical_id":"clinicaltrials.gov:NCT05868226","description":"HER2-positive Breast Cancer; Metastatic Cancer; Metastatic Breast Cancer; Metastatic; HER2-positive Metastatic Breast Cancer; HER2 Mutation-Related Tumors; HER-2 Protein Overexpression; HER2-negative Breast Cancer; Triple Negative Breast Cancer; HR Positive; Hormone Receptor-positive Breast Cancer; Estrogen Receptor Positive Tumor; Progesterone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma; Solid Tumor; Solid Tumor, Adult; Solid Carcinoma; HER2 Low Breast Cancer; H\u2026","metadata":null},{"id":"c0f48352624e4e43ac37769edf67fa47","type":"TRIAL","name":"PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer","canonical_id":"clinicaltrials.gov:NCT04404361","description":"COVID19; COVID-19; COVID","metadata":null},{"id":"6904db9fc5ca48d787e9248b8ebb41a8","type":"GENE","name":"PREB","canonical_id":"hgnc:HGNC:9356","description":null,"metadata":null},{"id":"1addf929f599453091a24d6008ae6ba5","type":"GENE","name":"PRECSIT","canonical_id":"hgnc:HGNC:27492","description":"p53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript","metadata":{"aliases":["C13orf29","NCRNA00346","LINC00346"]}},{"id":"2a272b421b3b4879b991b44757ac2adf","type":"TRIAL","name":"PREGNANT Short Cervix Trial","canonical_id":"clinicaltrials.gov:NCT00615550","description":"Preterm Delivery; Short Cervix; Short Uterine Cervical Length","metadata":null},{"id":"1a61a3e553b24ae7bf485ae44d1d760e","type":"GENE","name":"PRELID1","canonical_id":"hgnc:HGNC:30255","description":"PRELI domain containing 1","metadata":{"aliases":["CGI-106","PX19","PRELI"]}},{"id":"9bb88de8d8954d82af18e151184bbd7b","type":"GENE","name":"PRELID1P1","canonical_id":"hgnc:HGNC:43886","description":"PRELID1 pseudogene 1","metadata":null},{"id":"b99b5f26e95649eba80b91466f545d63","type":"GENE","name":"PRELID1P2","canonical_id":"hgnc:HGNC:43887","description":"PRELID1 pseudogene 2","metadata":null},{"id":"2c799d9ba3104315859908577dad281c","type":"GENE","name":"PRELID1P3","canonical_id":"hgnc:HGNC:43888","description":"PRELID1 pseudogene 3","metadata":null},{"id":"eac5d73e7dfa4d71b83a418f8c2bc33e","type":"GENE","name":"PRELID1P4","canonical_id":"hgnc:HGNC:43889","description":"PRELID1 pseudogene 4","metadata":null},{"id":"bd754c0bc1264a2a90793a9770f5f3b4","type":"GENE","name":"PRELID1P5","canonical_id":"hgnc:HGNC:54770","description":"PRELID1 pseudogene 5","metadata":null},{"id":"795172a52d9849b98707cbdcbaff6f5d","type":"GENE","name":"PRELID1P6","canonical_id":"hgnc:HGNC:54771","description":"PRELID1 pseudogene 6","metadata":null},{"id":"d911e248c6c847a4bfd1482f735673e9","type":"GENE","name":"PRELID1P7","canonical_id":"hgnc:HGNC:54772","description":"PRELID1 pseudogene 7","metadata":null},{"id":"6917b471008c409bb3439de28fdccef9","type":"GENE","name":"PRELID2","canonical_id":"hgnc:HGNC:28306","description":"PRELI domain containing 2","metadata":{"aliases":["MGC21644","FLJ38376"]}},{"id":"091247e36f514147b49f8c350735efa4","type":"GENE","name":"PRELID2P1","canonical_id":"hgnc:HGNC:43892","description":"PRELI domain containing 2 pseudogene 1","metadata":null},{"id":"75864a93efae47b9b4a1fd89805bc480","type":"GENE","name":"PRELID3A","canonical_id":"hgnc:HGNC:24639","description":"PRELI domain containing 3A","metadata":{"aliases":["HFL-EDDG1","FLJ31484","C18orf43","SLMO1"]}},{"id":"d63f2b06c7394a7ba27e0f3d56b85843","type":"GENE","name":"PRELID3B","canonical_id":"hgnc:HGNC:15892","description":"PRELI domain containing 3B","metadata":{"aliases":["dJ543J19.5","C20orf45","SLMO2"]}},{"id":"49c2c32bdffd45839e70ea5310ddfe65","type":"GENE","name":"PRELID3BP1","canonical_id":"hgnc:HGNC:49063","description":"PRELI domain containing 3B pseudogene 1","metadata":{"aliases":["SLMO2P1"]}},{"id":"0f3bfe5bfe374a93a0230dedbec93494","type":"GENE","name":"PRELID3BP10","canonical_id":"hgnc:HGNC:49072","description":"PRELI domain containing 3B pseudogene 10","metadata":null},{"id":"91d159d29c5848978c912b9e153d565a","type":"GENE","name":"PRELID3BP11","canonical_id":"hgnc:HGNC:49073","description":"PRELI domain containing 3B pseudogene 11","metadata":{"aliases":["SLMO2P11"]}},{"id":"2eff3df7df004253bd4375ec307ec0d0","type":"GENE","name":"PRELID3BP2","canonical_id":"hgnc:HGNC:49064","description":"PRELI domain containing 3B pseudogene 2","metadata":{"aliases":["SLMO2P2"]}},{"id":"983399ba5b0f498eb22a448cd40db199","type":"GENE","name":"PRELID3BP3","canonical_id":"hgnc:HGNC:49065","description":"PRELI domain containing 3B pseudogene 3","metadata":{"aliases":["SLMO2P3"]}},{"id":"0f32f490897e4335b52334fca4db0f52","type":"GENE","name":"PRELID3BP4","canonical_id":"hgnc:HGNC:49066","description":"PRELI domain containing 3B pseudogene 4","metadata":null},{"id":"f1f2c2bf58c64fb284cc4a317d4819e8","type":"GENE","name":"PRELID3BP5","canonical_id":"hgnc:HGNC:49067","description":"PRELI domain containing 3B pseudogene 5","metadata":null},{"id":"ba9953592aea484799f3bfba03100f5b","type":"GENE","name":"PRELID3BP6","canonical_id":"hgnc:HGNC:49068","description":"PRELI domain containing 3B pseudogene 6","metadata":null},{"id":"0d913ac193f14639b6b5920281df0471","type":"GENE","name":"PRELID3BP7","canonical_id":"hgnc:HGNC:49069","description":"PRELI domain containing 3B pseudogene 7","metadata":null},{"id":"ce360450507741caae1b81c9b27045d9","type":"GENE","name":"PRELID3BP8","canonical_id":"hgnc:HGNC:49070","description":"PRELI domain containing 3B pseudogene 8","metadata":null},{"id":"2b1b7954446942f4a74a9f9abc8b5155","type":"GENE","name":"PRELID3BP9","canonical_id":"hgnc:HGNC:49071","description":"PRELI domain containing 3B pseudogene 9","metadata":null},{"id":"21bd6ecd8a6344af851f758c91c634dc","type":"GENE","name":"PRELP","canonical_id":"hgnc:HGNC:9357","description":"proline and arginine rich end leucine rich repeat protein","metadata":{"aliases":["SLRR2A","prolargin"]}},{"id":"bf9f49dfd3e34c07906ca2a9bc8c9954","type":"GENE","name":"PREP","canonical_id":"hgnc:HGNC:9358","description":"prolyl endopeptidase","metadata":null},{"id":"217b65dc9a084273bb63c940a2cc26d2","type":"GENE","name":"PREP-AS1","canonical_id":"hgnc:HGNC:40466","description":"PREP antisense RNA 1","metadata":null},{"id":"c9fde47569274bc1b4a6c8e81bf99ef0","type":"GENE","name":"PREPL","canonical_id":"hgnc:HGNC:30228","description":"prolyl endopeptidase like","metadata":{"aliases":["KIAA0436"]}},{"id":"b1360a3c3ca94459b6681263256d0e32","type":"TRIAL","name":"PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT07611214","description":"Lupus Nephritis","metadata":null},{"id":"c5b7765bacbe462baae0e41659aaa14b","type":"TRIAL","name":"PRETELL: PREvention of TELomere-related Complications After Lung Transplant","canonical_id":"clinicaltrials.gov:NCT04807309","description":"Short Telomere Length; Lung Transplant","metadata":null},{"id":"0a49c893ba8e42aa9c3de94e2f6b52f7","type":"TRIAL","name":"PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)","canonical_id":"clinicaltrials.gov:NCT00729365","description":"Type 1 Diabetes","metadata":null},{"id":"cf643cd2a31f4ce594377721584fb972","type":"TRIAL","name":"PREVENTion of Clot in Orthopaedic Trauma","canonical_id":"clinicaltrials.gov:NCT02984384","description":"Blood Clot; Trauma","metadata":null},{"id":"02710b5834ab41c99c8bdb64c97a02f9","type":"GENE","name":"PREX1","canonical_id":"hgnc:HGNC:32594","description":"phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1","metadata":{"aliases":["KIAA1415","P-REX1"]}},{"id":"a1f162e8a3f049e5b85397eace168420","type":"GENE","name":"PREX2","canonical_id":"hgnc:HGNC:22950","description":"phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2","metadata":{"aliases":["DEP.2","FLJ12987","P-REX2","PPP1R129","DEPDC2"]}},{"id":"e6ad1dbbb76d4be2908ce791e83b0c44","type":"TRIAL","name":"PREterm Infants With Bronchial Obstruction - Prospective Study of Efficacy and Safety of Inhaled Tiotropium","canonical_id":"clinicaltrials.gov:NCT07827859","description":"Bronchial Obstruction; Premature Birth","metadata":null},{"id":"14efd3fcbaa24db681a2b6cb14ddc85f","type":"TRIAL","name":"PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)","canonical_id":"clinicaltrials.gov:NCT00958438","description":"Gout","metadata":null},{"id":"900f21171ca747e49c6e1d7c3d72dccb","type":"TRIAL","name":"PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1","canonical_id":"clinicaltrials.gov:NCT00829829","description":"Intercritical Gout","metadata":null},{"id":"bd322fdeefb149f5bd07f165d04a2749","type":"TRIAL","name":"PREventing Second Cancers With DOSTARlimab","canonical_id":"clinicaltrials.gov:NCT05855811","description":"Recurrent Cancer; Primary Cancer; Second Cancer","metadata":null},{"id":"8f98f73bd46243f990926f1e5f009885","type":"TRIAL","name":"PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01281787","description":"Lung Cancer; Atrial Fibrillation","metadata":null},{"id":"e8d7795182d94785a6383b70febb24c9","type":"GENE","name":"PRF1","canonical_id":"hgnc:HGNC:9360","description":null,"metadata":null},{"id":"a0be7b2f566540589a340a7da6e4b1e6","type":"GENE","name":"PRG2","canonical_id":"hgnc:HGNC:9362","description":null,"metadata":null},{"id":"df23d29703014cd49beb82d0e672660e","type":"GENE","name":"PRG3","canonical_id":"hgnc:HGNC:9363","description":null,"metadata":null},{"id":"6f3773921bb042fa9645ba18a34acd0e","type":"GENE","name":"PRG4","canonical_id":"hgnc:HGNC:9364","description":"proteoglycan 4","metadata":{"aliases":["JCAP","SZP","MSF","HAPO","bG174L6.2","FLJ32635","CACP"]}},{"id":"c0ee94f56eb142bf85f98aa8884daaf4","type":"GENE","name":"PRH1","canonical_id":"hgnc:HGNC:9366","description":"proline rich protein HaeIII subfamily 1","metadata":{"aliases":["Pa"]}},{"id":"c58dbcbc9c60470fa768fc57e5c310ea","type":"GENE","name":"PRH2","canonical_id":"hgnc:HGNC:9367","description":"proline rich protein HaeIII subfamily 2","metadata":{"aliases":["Pr"]}},{"id":"72d7bc1e4d7b421f8b475bb5679de8e6","type":"GENE","name":"PRICKLE1","canonical_id":"hgnc:HGNC:17019","description":"prickle planar cell polarity protein 1","metadata":{"aliases":["FLJ31937","EPM1B","RILP"]}},{"id":"e0846dcff7b24c778c763f84128a388b","type":"GENE","name":"PRICKLE1-AS1","canonical_id":"hgnc:HGNC:58444","description":"PRICKLE1 antisense RNA 1","metadata":null},{"id":"83f550c5a624411e857cc91a384e6c66","type":"GENE","name":"PRICKLE1P1","canonical_id":"hgnc:HGNC:56609","description":"PRICKLE1 pseudogene 1","metadata":null},{"id":"7c8d343232104804a9a19b27ff87f6a2","type":"GENE","name":"PRICKLE2","canonical_id":"hgnc:HGNC:20340","description":"prickle planar cell polarity protein 2","metadata":{"aliases":["DKFZp686D143"]}},{"id":"82be674b414448d79adf70139a0d65d3","type":"GENE","name":"PRICKLE2-AS1","canonical_id":"hgnc:HGNC:40916","description":"PRICKLE2 antisense RNA 1","metadata":null},{"id":"16cab7655c7c4a84acf34b9f78f20b58","type":"GENE","name":"PRICKLE2-AS2","canonical_id":"hgnc:HGNC:40917","description":"PRICKLE2 antisense RNA 2","metadata":null},{"id":"23d3d5c781a1406281fda111010d9e65","type":"GENE","name":"PRICKLE2-AS3","canonical_id":"hgnc:HGNC:40918","description":"PRICKLE2 antisense RNA 3","metadata":null},{"id":"e152e28c90eb425197eec7089fe34fd4","type":"GENE","name":"PRICKLE2-DT","canonical_id":"hgnc:HGNC:52829","description":"PRICKLE2 divergent transcript","metadata":null},{"id":"d901d9502a6948e381b3e07a260cf80d","type":"GENE","name":"PRICKLE3","canonical_id":"hgnc:HGNC:6645","description":"prickle planar cell polarity protein 3","metadata":{"aliases":["LMO6"]}},{"id":"a7963a2b7be246bc91cfd5002cedf1a7","type":"GENE","name":"PRICKLE4","canonical_id":"hgnc:HGNC:16805","description":"prickle planar cell polarity protein 4","metadata":{"aliases":["OEBT","DKFZp761H221","C6orf49"]}},{"id":"b2d93fee3ac148dc9b808f4536c97a7a","type":"TRIAL","name":"PRILIGY Usage Patterns in Selected Populations","canonical_id":"clinicaltrials.gov:NCT01273545","description":"Sexual Dysfunction, Physiological","metadata":null},{"id":"681ec69ca4bb4ee0bd4b6d55ab4e8b9f","type":"GENE","name":"PRIM1","canonical_id":"hgnc:HGNC:9369","description":"DNA primase subunit 1","metadata":null},{"id":"a545649c5f6a4684861122443da989d9","type":"GENE","name":"PRIM2","canonical_id":"hgnc:HGNC:9370","description":"DNA primase subunit 2","metadata":{"aliases":["PRIM2A"]}},{"id":"3c12ca74d2444343910872ab0961171d","type":"GENE","name":"PRIM2BP","canonical_id":"hgnc:HGNC:55759","description":"primase 2B, pseudogene","metadata":null},{"id":"4d4e777503414a21bcad68e6891537f7","type":"GENE","name":"PRIMA1","canonical_id":"hgnc:HGNC:18319","description":"proline rich membrane anchor 1","metadata":{"aliases":["PRIMA"]}},{"id":"61780521b3ff4e6dbd18185aae35a5db","type":"TRIAL","name":"PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice","canonical_id":"clinicaltrials.gov:NCT00928408","description":"Hyperparathyroidism, Primary","metadata":null},{"id":"ad06b8ad1edb4176b4f33e3984f77e73","type":"GENE","name":"PRIMPOL","canonical_id":"hgnc:HGNC:26575","description":"primase and DNA directed polymerase","metadata":{"aliases":["FLJ33167","CCDC111"]}},{"id":"5bafb55110f749cab80f24e05c81c1d8","type":"GENE","name":"PRINS","canonical_id":"hgnc:HGNC:34235","description":"psoriasis associated non-protein coding RNA induced by stress","metadata":{"aliases":["NCRNA00074"]}},{"id":"ec55c2ea957e479899e943d517e6d712","type":"GENE","name":"PRKAA1","canonical_id":"hgnc:HGNC:9376","description":"protein kinase AMP-activated catalytic subunit alpha 1","metadata":{"aliases":["AMPKa1"]}},{"id":"d5571fa389664511963178d0386d5d37","type":"GENE","name":"PRKAA1-AS1","canonical_id":"hgnc:HGNC:59032","description":"PRKAA1 antisense RNA 1","metadata":null},{"id":"f79c13f5bd684cbd8acaa3400280a4a6","type":"GENE","name":"PRKAA1-DT","canonical_id":"hgnc:HGNC:59033","description":"PRKAA1 divergent transcript","metadata":null},{"id":"39499d5eca0a4dfaa9121f696d436bd6","type":"GENE","name":"PRKAA2","canonical_id":"hgnc:HGNC:9377","description":"protein kinase AMP-activated catalytic subunit alpha 2","metadata":{"aliases":["AMPK","AMPKa2","PRKAA"]}},{"id":"cc55b7bcdb4941f581bd46c8d7126a9e","type":"GENE","name":"PRKAB1","canonical_id":"hgnc:HGNC:9378","description":null,"metadata":null},{"id":"ab7e701d348140ed8fac571cdd57b095","type":"GENE","name":"PRKAB1-AS1","canonical_id":"hgnc:HGNC:58183","description":"PRKAB1, TMEM233 and CCDC60 antisense RNA 1","metadata":null},{"id":"5e79bdc679ac4e88907387604c9c4d98","type":"GENE","name":"PRKAB2","canonical_id":"hgnc:HGNC:9379","description":"protein kinase AMP-activated non-catalytic subunit beta 2","metadata":null},{"id":"e972f1d149754c81b9a3a238534f3ce1","type":"GENE","name":"PRKACA","canonical_id":"hgnc:HGNC:9380","description":"protein kinase cAMP-activated catalytic subunit alpha","metadata":{"aliases":["PKACa"]}},{"id":"8e07e437673a4bb291d5f053b61be82c","type":"GENE","name":"PRKACB","canonical_id":"hgnc:HGNC:9381","description":"protein kinase cAMP-activated catalytic subunit beta","metadata":{"aliases":["PKACb"]}},{"id":"e3fbe3f1ff514d469bc137ec5dc522ec","type":"GENE","name":"PRKACB-DT","canonical_id":"hgnc:HGNC:55245","description":"PRKACB divergent transcript","metadata":null},{"id":"651bd69363534931b9de36755e3b61e2","type":"GENE","name":"PRKACG","canonical_id":"hgnc:HGNC:9382","description":"protein kinase cAMP-activated catalytic subunit gamma","metadata":{"aliases":["PKACg"]}},{"id":"6f3ab755fdfd454c8ff0a7d290168571","type":"GENE","name":"PRKAG1","canonical_id":"hgnc:HGNC:9385","description":"protein kinase AMP-activated non-catalytic subunit gamma 1","metadata":null},{"id":"2587c312b9fa462e9c6a3cc6cde35598","type":"GENE","name":"PRKAG2","canonical_id":"hgnc:HGNC:9386","description":"protein kinase AMP-activated non-catalytic subunit gamma 2","metadata":{"aliases":["AAKG","AAKG2","H91620p","WPWS","CMH6"]}},{"id":"c7b8f69d77784bb2898074ebd2e394d0","type":"GENE","name":"PRKAG2-AS1","canonical_id":"hgnc:HGNC:40468","description":"PRKAG2 antisense RNA 1","metadata":null},{"id":"d83964d30d764058b2230c0f1b699a21","type":"GENE","name":"PRKAG2-AS2","canonical_id":"hgnc:HGNC:40467","description":"PRKAG2 antisense RNA 2","metadata":null},{"id":"c076453a970644b7be39b33e2bf632ff","type":"GENE","name":"PRKAG3","canonical_id":"hgnc:HGNC:9387","description":"protein kinase AMP-activated non-catalytic subunit gamma 3","metadata":null},{"id":"90e3f3e5376047c185a57ed32212777f","type":"GENE","name":"PRKAR1A","canonical_id":"hgnc:HGNC:9388","description":"protein kinase cAMP-dependent type I regulatory subunit alpha","metadata":{"aliases":["CNC1","PRKAR1","TSE1","PKR1","Prkar1alpha"]}},{"id":"0ffd00d321794d3ab58f50b1bbf742af","type":"GENE","name":"PRKAR1AP1","canonical_id":"hgnc:HGNC:9389","description":"protein kinase cAMP-dependent type I regulatory subunit alpha pseudogene 1","metadata":{"aliases":["PRKAR1AP"]}},{"id":"946ea79471404415a85aafb9787650f9","type":"GENE","name":"PRKAR1B","canonical_id":"hgnc:HGNC:9390","description":"protein kinase cAMP-dependent type I regulatory subunit beta","metadata":null},{"id":"110de9ce49dc4299947d694a24eb2428","type":"GENE","name":"PRKAR1B-AS1","canonical_id":"hgnc:HGNC:40470","description":"PRKAR1B antisense RNA 1","metadata":null},{"id":"ca0c7cbff6124da5bd66b37c3a66bcbf","type":"GENE","name":"PRKAR1B-AS2","canonical_id":"hgnc:HGNC:40469","description":"PRKAR1B antisense RNA 2","metadata":null},{"id":"bc22cff58d5542279a00f5eea0010c23","type":"GENE","name":"PRKAR2A","canonical_id":"hgnc:HGNC:9391","description":"protein kinase cAMP-dependent type II regulatory subunit alpha","metadata":{"aliases":["PRKAR2"]}},{"id":"55ef93abf0784302999b5c03d0021fac","type":"GENE","name":"PRKAR2A-AS1","canonical_id":"hgnc:HGNC:40471","description":"PRKAR2A antisense RNA 1","metadata":null},{"id":"503bebbcdcd645749aa5c0ceeb9adff9","type":"GENE","name":"PRKAR2B","canonical_id":"hgnc:HGNC:9392","description":"protein kinase cAMP-dependent type II regulatory subunit beta","metadata":{"aliases":["PRKAR2"]}},{"id":"38ed6ae08d9c49a1bf4b771ef2814297","type":"GENE","name":"PRKAR2B-AS1","canonical_id":"hgnc:HGNC:40472","description":"PRKAR2B antisense RNA 1","metadata":null},{"id":"fd1936fba4c3452990c37c16252f3d8d","type":"GENE","name":"PRKCA","canonical_id":"hgnc:HGNC:9393","description":null,"metadata":null},{"id":"4a275de724c746399283601133adacb6","type":"GENE","name":"PRKCA-AS1","canonical_id":"hgnc:HGNC:51347","description":"PRKCA antisense RNA 1","metadata":null},{"id":"925a262b301b44db925e5a796af78f33","type":"GENE","name":"PRKCB","canonical_id":"hgnc:HGNC:9395","description":null,"metadata":null},{"id":"07b1d96725a34c4faa6c43c2d77a745d","type":"GENE","name":"PRKCD","canonical_id":"hgnc:HGNC:9399","description":"protein kinase C delta","metadata":{"aliases":["PKC\u03b4"]}},{"id":"e774dcd9bfdf47bd9f5d8bfd490e51a3","type":"GENE","name":"PRKCE","canonical_id":"hgnc:HGNC:9401","description":null,"metadata":null},{"id":"96ede78495e247e696fa9d4761bf491f","type":"GENE","name":"PRKCE-AS1","canonical_id":"hgnc:HGNC:40474","description":"PRKCE antisense RNA 1","metadata":null},{"id":"1d809824599f40288304321920331531","type":"GENE","name":"PRKCE-AS2","canonical_id":"hgnc:HGNC:40475","description":"PRKCE antisense RNA 2","metadata":null},{"id":"4be195f97ee8454aa597e4e3d2bacff3","type":"GENE","name":"PRKCG","canonical_id":"hgnc:HGNC:9402","description":"protein kinase C gamma","metadata":{"aliases":["PKCC","MGC57564","PKC\u03b3","PKCG","SCA14"]}},{"id":"734f9ba2b3e74acc83c4122caaa3f528","type":"GENE","name":"PRKCH","canonical_id":"hgnc:HGNC:9403","description":"protein kinase C eta","metadata":{"aliases":["PKC\u03b7","PKC-L","PKCL","PRKCL"]}},{"id":"f5a61f4bdfe94632b3405ab4f35c0875","type":"GENE","name":"PRKCH-AS1","canonical_id":"hgnc:HGNC:55588","description":"PRKCH antisense RNA 1","metadata":null},{"id":"0f18428b48c4404db0bb194c24fdc6a6","type":"GENE","name":"PRKCH-AS2","canonical_id":"hgnc:HGNC:58291","description":"PRKCH antisense RNA 2","metadata":null},{"id":"075ff15a6d474573a7dd2e408f91764b","type":"GENE","name":"PRKCI","canonical_id":"hgnc:HGNC:9404","description":"protein kinase C iota","metadata":{"aliases":["PKC\u03bb/\u03b9","PKC\u03bb","PKC\u03b9","PKCI","DXS1179E"]}},{"id":"ae436d1750f04386bff35ac80efd7802","type":"GENE","name":"PRKCIP1","canonical_id":"hgnc:HGNC:55035","description":"PRKCI pseudogene 1","metadata":null},{"id":"b37373df9e9f41a0afe1112a0475c9d2","type":"GENE","name":"PRKCQ","canonical_id":"hgnc:HGNC:9410","description":null,"metadata":null},{"id":"f40264eca2d043aab8102aa29c1628df","type":"GENE","name":"PRKCQ-AS1","canonical_id":"hgnc:HGNC:44689","description":"PRKCQ antisense RNA 1","metadata":{"aliases":["ENST00000414894.1"]}},{"id":"2a381cc2375645709dfe257b22634e8a","type":"GENE","name":"PRKCSH","canonical_id":"hgnc:HGNC:9411","description":"PRKCSH beta subunit of glucosidase II","metadata":{"aliases":["VASAP-60","GIIB","PKCSH","80K-H","AGE-R2","GIIbeta","GluIIbeta","G19P1","PCLD","PLD1"]}},{"id":"0b933a810356487c825e23b8afb7e356","type":"GENE","name":"PRKCZ","canonical_id":"hgnc:HGNC:9412","description":"protein kinase C zeta","metadata":{"aliases":["PKC\u03b6","PKC2"]}},{"id":"59aa5834c4844583a7d103509dba736e","type":"GENE","name":"PRKCZ-AS1","canonical_id":"hgnc:HGNC:40477","description":"PRKCZ antisense RNA 1","metadata":{"aliases":["RP11-181G12.2"]}},{"id":"69da6c0a6f4c4a06add1527b80ce23f1","type":"GENE","name":"PRKCZ-DT","canonical_id":"hgnc:HGNC:55824","description":"PRKCZ divergent transcript","metadata":null},{"id":"03f13f72a95c41baa299970b149eca80","type":"GENE","name":"PRKD1","canonical_id":"hgnc:HGNC:9407","description":"protein kinase D1","metadata":{"aliases":["PKD1","PKCM","PKD","PKC-mu","PRKCM"]}},{"id":"03d1ac959bed4aa89966e0f7cd780b40","type":"GENE","name":"PRKD2","canonical_id":"hgnc:HGNC:17293","description":"protein kinase D2","metadata":{"aliases":["PKD2","HSPC187","DKFZP586E0820"]}},{"id":"6f45d1ece4a44c36a300eba2f00ed805","type":"GENE","name":"PRKD3","canonical_id":"hgnc:HGNC:9408","description":"protein kinase D3","metadata":{"aliases":["PKD3","EPK2","PRKCN"]}},{"id":"5009d94eb7804fb89c12282b43bba015","type":"PROTEIN","name":"PRKD3","canonical_id":"uniprot:O94806","description":null,"metadata":null},{"id":"c753d0618dff429298ce69a6a857213b","type":"GENE","name":"PRKD3-DT","canonical_id":"hgnc:HGNC:55762","description":"PRKD3 divergent transcript","metadata":null},{"id":"4bcf0b426574440185918df77daebb3b","type":"GENE","name":"PRKDC","canonical_id":"hgnc:HGNC:9413","description":"protein kinase, DNA-activated, catalytic subunit","metadata":{"aliases":["DNPK1","p350","DNAPK","XRCC7","DNA-PKcs","DNAPKc","DNA-PKC","p460","HYRC","HYRC1"]}},{"id":"e9912bebf9064adabf16cd5a5399725f","type":"GENE","name":"PRKG1","canonical_id":"hgnc:HGNC:9414","description":"protein kinase cGMP-dependent 1","metadata":{"aliases":["PGK","PKG","PKG1","PRKGR1B","PRKG1B"]}},{"id":"2e80c48684b747aebbd45ef20d1b4666","type":"GENE","name":"PRKG1-AS1","canonical_id":"hgnc:HGNC:45029","description":"PRKG1 antisense RNA 1","metadata":{"aliases":["RP11-573I11.2"]}},{"id":"a97bc81d4f334847b5fa1621a7bc08c9","type":"GENE","name":"PRKG2","canonical_id":"hgnc:HGNC:9416","description":"protein kinase cGMP-dependent 2","metadata":{"aliases":["cGKII","PRKGR2","PKG2"]}},{"id":"c3ccb14f26194d29978fcf02c8098649","type":"GENE","name":"PRKG2-AS1","canonical_id":"hgnc:HGNC:40478","description":"PRKG2 antisense RNA 1","metadata":null},{"id":"1f9eafd480ec4c8992448e31724065ad","type":"GENE","name":"PRKG2-AS2","canonical_id":"hgnc:HGNC:58836","description":"PRKG2 antisense RNA 2","metadata":null},{"id":"cf02677664854c5aaba7c41a48a5c123","type":"GENE","name":"PRKN","canonical_id":"hgnc:HGNC:8607","description":null,"metadata":null},{"id":"7a82f7856a53466aa32318696847cccd","type":"GENE","name":"PRKRA","canonical_id":"hgnc:HGNC:9438","description":"protein activator of interferon induced protein kinase EIF2AK2","metadata":{"aliases":["PACT","RAX","HSD14","DYT16"]}},{"id":"4d14bbfe2b914304b2e4583426674582","type":"GENE","name":"PRKRAP1","canonical_id":"hgnc:HGNC:33447","description":"PRKRA pseudogene 1","metadata":null},{"id":"b00f019b4eb947a89c754e72e0702c57","type":"GENE","name":"PRKRIP1","canonical_id":"hgnc:HGNC:21894","description":"PRKR interacting protein 1","metadata":{"aliases":["C114","FLJ13902","KRBOX3"]}},{"id":"e96214a4ce8b494c88ecb1d7a52af412","type":"GENE","name":"PRKX","canonical_id":"hgnc:HGNC:9441","description":"protein kinase cAMP-dependent X-linked catalytic subunit","metadata":{"aliases":["PKX1"]}},{"id":"a14d5e3d53d540808432fc90cbe2fb0c","type":"GENE","name":"PRKX-AS1","canonical_id":"hgnc:HGNC:40479","description":"PRKX antisense RNA 1","metadata":null},{"id":"908ca0cff02e4a43b918ac2d26ef4b92","type":"GENE","name":"PRKXP1","canonical_id":"hgnc:HGNC:9442","description":"PRKX pseudogene 1","metadata":null},{"id":"dd7d10626eb6496e9063d65a9e85e12d","type":"GENE","name":"PRKXP2","canonical_id":"hgnc:HGNC:9443","description":"PRKX pseudogene 2","metadata":null},{"id":"ddd435d8400f488aa8639df334a1c8f3","type":"GENE","name":"PRKY","canonical_id":"hgnc:HGNC:9444","description":"protein kinase Y-linked (pseudogene)","metadata":{"aliases":["PRKYP","PRKXP3"]}},{"id":"aa9f3ebde5794735971a21d3610754fa","type":"GENE","name":"PRL","canonical_id":"hgnc:HGNC:9445","description":null,"metadata":null},{"id":"a2fbf04bdbf0468ca9385f0d741e03de","type":"GENE","name":"PRLH","canonical_id":"hgnc:HGNC:17945","description":"prolactin releasing hormone","metadata":{"aliases":["PRH"]}},{"id":"ef8434e83a7548c586713555e0e2021e","type":"GENE","name":"PRLHR","canonical_id":"hgnc:HGNC:4464","description":"prolactin releasing hormone receptor","metadata":{"aliases":["PrRPR","GPR10"]}},{"id":"0dbde0c25d764c8994c55812bfa4ccef","type":"GENE","name":"PRLR","canonical_id":"hgnc:HGNC:9446","description":"prolactin receptor","metadata":null},{"id":"d7c4596796f0425a8eec85f1bd0c0afd","type":"GENE","name":"PRM1","canonical_id":"hgnc:HGNC:9447","description":null,"metadata":null},{"id":"d3d10992fb1e46e6853b1df86d62700a","type":"GENE","name":"PRM2","canonical_id":"hgnc:HGNC:9448","description":"protamine 2","metadata":{"aliases":["CT94.2"]}},{"id":"0a4dc9e73b094b0cb2e679da09a1a28f","type":"GENE","name":"PRM3","canonical_id":"hgnc:HGNC:13732","description":"protamine 3","metadata":null},{"id":"8d52a8534a894d5d8f4b0beb3c77c18e","type":"GENE","name":"PRMT1","canonical_id":"hgnc:HGNC:5187","description":null,"metadata":null},{"id":"1bb39ca88364489588ce9cf381d0b42f","type":"GENE","name":"PRMT1P1","canonical_id":"hgnc:HGNC:49611","description":"protein arginine methyltransferase 1 pseudogene 1","metadata":null},{"id":"56bd8a3931f14c1683ef1cc0d8a31ad2","type":"GENE","name":"PRMT2","canonical_id":"hgnc:HGNC:5186","description":"protein arginine methyltransferase 2","metadata":{"aliases":["MGC111373","HRMT1L1"]}},{"id":"8689913dbb504b81945c033d43903bfc","type":"GENE","name":"PRMT2IP","canonical_id":"hgnc:HGNC:24497","description":"PRMT2 interacting protein","metadata":{"aliases":["DKFZP434H132","FLJ46337","C15orf39"]}},{"id":"b23b506f80ae43f3bd27233abe976057","type":"GENE","name":"PRMT3","canonical_id":"hgnc:HGNC:30163","description":"protein arginine methyltransferase 3","metadata":{"aliases":["HRMT1L3"]}},{"id":"ac698f6c8ca44a2dbaad94623da61ca2","type":"GENE","name":"PRMT5","canonical_id":"hgnc:HGNC:10894","description":"protein arginine methyltransferase 5","metadata":{"aliases":["SKB1Hs","HRMT1L5","SKB1"]}},{"id":"bf31a4cf14f04022b099db7eff22b546","type":"GENE","name":"PRMT5-AS1","canonical_id":"hgnc:HGNC:40533","description":"PRMT5 antisense RNA 1","metadata":null},{"id":"f0576fcb0e3148138aa5511e5d25c694","type":"GENE","name":"PRMT5-DT","canonical_id":"hgnc:HGNC:55482","description":"PRMT5 divergent transcript","metadata":null},{"id":"2fcc34d9fa4d4c209f3126ce6d829355","type":"GENE","name":"PRMT5P1","canonical_id":"hgnc:HGNC:32524","description":"protein arginine methyltransferase 5 pseudogene 1","metadata":null},{"id":"162b26e883024036ae0db57311199f06","type":"GENE","name":"PRMT6","canonical_id":"hgnc:HGNC:18241","description":"protein arginine methyltransferase 6","metadata":{"aliases":["FLJ10559","HRMT1L6"]}},{"id":"113b524677444a3682ab3f72901e1b27","type":"GENE","name":"PRMT7","canonical_id":"hgnc:HGNC:25557","description":"protein arginine methyltransferase 7","metadata":{"aliases":["FLJ10640","KIAA1933"]}},{"id":"f27f1a2c2dbd43479b0ffef03adeb5e8","type":"GENE","name":"PRMT8","canonical_id":"hgnc:HGNC:5188","description":"protein arginine methyltransferase 8","metadata":{"aliases":["HRMT1L3","HRMT1L4"]}},{"id":"115b4659924b419b96b6947e9d866781","type":"GENE","name":"PRMT9","canonical_id":"hgnc:HGNC:25099","description":"protein arginine methyltransferase 9","metadata":{"aliases":["FLJ46629","PRMT10"]}},{"id":"aa08ee2a701e414991a80edec9ac4574","type":"GENE","name":"PRNCR1","canonical_id":"hgnc:HGNC:48942","description":"prostate cancer associated non-coding RNA 1","metadata":{"aliases":["PCAT8"]}},{"id":"a63af1ab84a6453ab6079bb050b8f1c5","type":"GENE","name":"PRND","canonical_id":"hgnc:HGNC:15748","description":"prion like protein doppel","metadata":{"aliases":["DPL","dJ1068H6.4","DOPPEL","PrPLP"]}},{"id":"afeeb0c73a064de7a1480728600ad42c","type":"GENE","name":"PRNP","canonical_id":"hgnc:HGNC:9449","description":null,"metadata":null},{"id":"aede1666601f49ccacfbe5dfa3b0d346","type":"GENE","name":"PRNT","canonical_id":"hgnc:HGNC:18046","description":"prion locus lncRNA, testis expressed","metadata":{"aliases":["M8"]}},{"id":"686f63cffbde417eaa64664e55d18ddd","type":"TRIAL","name":"PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)","canonical_id":"clinicaltrials.gov:NCT04382898","description":"Prostate Cancer","metadata":null},{"id":"2624503a07cc44c696dc34328e4334c1","type":"TRIAL","name":"PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban","canonical_id":"clinicaltrials.gov:NCT04142658","description":"Aortic Valve Disease; Aortic Valve Stenosis; Aortic Valve Failure","metadata":null},{"id":"b82bab6c1e6548719c986ee1dd40eb7c","type":"GENE","name":"PROB1","canonical_id":"hgnc:HGNC:41906","description":"proline rich basic protein 1","metadata":{"aliases":["C5orf65"]}},{"id":"b3c5f68316754d00b6268b676db8fc93","type":"TRIAL","name":"PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis\u00ae) vs Ramipril (Altace\u00ae) Using ABPM in HTN","canonical_id":"clinicaltrials.gov:NCT00274599","description":"Hypertension","metadata":null},{"id":"227bba8f7da243d8a3ed2e73e1c41fca","type":"GENE","name":"PROC","canonical_id":"hgnc:HGNC:9451","description":null,"metadata":null},{"id":"be531db38d204d56a85dc71a3cd9a3f6","type":"GENE","name":"PROCA1","canonical_id":"hgnc:HGNC:28600","description":"protein interacting with cyclin A1","metadata":{"aliases":["MGC39650"]}},{"id":"9b34eb2e751b4638bd4dbc971e123e08","type":"GENE","name":"PROCR","canonical_id":"hgnc:HGNC:9452","description":"protein C receptor","metadata":{"aliases":["EPCR","CCD41","CD201"]}},{"id":"05dde2aeb2e64f8a9ac31fcd4ea8c4e6","type":"GENE","name":"PRODH","canonical_id":"hgnc:HGNC:9453","description":null,"metadata":null},{"id":"47efbbf66f044ed8a2dbeef5a28708fd","type":"GENE","name":"PRODH2","canonical_id":"hgnc:HGNC:17325","description":"proline dehydrogenase 2","metadata":{"aliases":["HSPOX1"]}},{"id":"6626e10c55c24fa9a26194cd3f7f724a","type":"GENE","name":"PRODHLP","canonical_id":"hgnc:HGNC:56289","description":"proline dehydrogenase like, pseudogene","metadata":null},{"id":"0a1b70d8d76a44b293cd2993188f96ad","type":"GENE","name":"PROK1","canonical_id":"hgnc:HGNC:18454","description":"prokineticin 1","metadata":{"aliases":["PK1","PRK1","EGVEGF","EG-VEGF"]}},{"id":"dcf169dfe3b447bdb2d40fb6bb95009d","type":"GENE","name":"PROK2","canonical_id":"hgnc:HGNC:18455","description":"prokineticin 2","metadata":{"aliases":["PK2","BV8","MIT1","KAL4"]}},{"id":"9af7e98504e1490e956265200064186e","type":"GENE","name":"PROK2-DT","canonical_id":"hgnc:HGNC:58092","description":"PROK2 divergent transcript","metadata":{"aliases":["TCONS_00006091"]}},{"id":"7b8bbe47442e4f6d849aefd5fdf339f0","type":"GENE","name":"PROKR1","canonical_id":"hgnc:HGNC:4524","description":"prokineticin receptor 1","metadata":{"aliases":["PKR1","ZAQ","GPR73a","GPR73"]}},{"id":"f07e9dac835a4bb5b52c89211157bfac","type":"GENE","name":"PROKR2","canonical_id":"hgnc:HGNC:15836","description":"prokineticin receptor 2","metadata":{"aliases":["GPR73b","PKR2","GPRg2","dJ680N4.3","GPR73L1","KAL3"]}},{"id":"59f69774d5e8473e979bde571ce7b4a6","type":"GENE","name":"PROLIT1","canonical_id":"hgnc:HGNC:58472","description":"proliferation lncRNA in triple negative breast cancer 1","metadata":null},{"id":"6a372c9b485d41d8ac839e004d806f47","type":"GENE","name":"PROM1","canonical_id":"hgnc:HGNC:9454","description":null,"metadata":null},{"id":"2f3e571359eb4885bf3490f2f03c5c9d","type":"GENE","name":"PROM2","canonical_id":"hgnc:HGNC:20685","description":"prominin 2","metadata":null},{"id":"ed1cdbcaf27544139658c698f686fa18","type":"TRIAL","name":"PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.","canonical_id":"clinicaltrials.gov:NCT03901131","description":"Contraceptive","metadata":null},{"id":"7be0701ac1474c06a12519da4471de1e","type":"GENE","name":"PROP1","canonical_id":"hgnc:HGNC:9455","description":"PROP paired-like homeobox 1","metadata":null},{"id":"055d638ccb014f7a973fdfb4caf8ee35","type":"TRIAL","name":"PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-na\u00efve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","canonical_id":"clinicaltrials.gov:NCT01066793","description":"Hepatitis C, Chronic","metadata":null},{"id":"254c109849bf441f91bb3c301a1cd25e","type":"GENE","name":"PRORP","canonical_id":"hgnc:HGNC:19958","description":"protein only RNase P catalytic subunit","metadata":{"aliases":["MRPP3","KIAA0391"]}},{"id":"7a58ff2497de4504ad95faf8f52e9878","type":"GENE","name":"PRORSD1P","canonical_id":"hgnc:HGNC:34379","description":"prolyl-tRNA synthetase associated domain containing 1, pseudogene","metadata":{"aliases":["Prdxdd1","Ybakd1","ProX","ProXp-ala","NCRNA00117","PRDXDD1P"]}},{"id":"9badb3f52e4b446fb0286b46cee4209a","type":"GENE","name":"PRORY","canonical_id":"hgnc:HGNC:38732","description":"PRORY Y-linked lncRNA","metadata":{"aliases":["CYorf17"]}},{"id":"f0fa7c8e113f438882fef3b9de11c2a2","type":"TRIAL","name":"PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue","canonical_id":"clinicaltrials.gov:NCT00490555","description":"Healthy","metadata":null},{"id":"20b2a65ce0a24c75b899c862d5647ada","type":"GENE","name":"PROS1","canonical_id":"hgnc:HGNC:9456","description":null,"metadata":null},{"id":"6db194ba88324fcb9580d4102ff5ffd2","type":"GENE","name":"PROS2P","canonical_id":"hgnc:HGNC:9458","description":"protein S (beta) pseudogene","metadata":{"aliases":["PROS2","PROSP"]}},{"id":"d0dba76a662c4e668a5cee0e3dd221b2","type":"GENE","name":"PROSER1","canonical_id":"hgnc:HGNC:20291","description":"proline and serine rich 1","metadata":{"aliases":["bA50D16.2","FLJ12661","C13orf23"]}},{"id":"f12570269f384f97bc546810a77ef8cd","type":"GENE","name":"PROSER2","canonical_id":"hgnc:HGNC:23728","description":"proline and serine rich 2","metadata":{"aliases":["MGC35403","C10orf47"]}},{"id":"6326977df7b146b7a230852228bcba62","type":"GENE","name":"PROSER2-AS1","canonical_id":"hgnc:HGNC:27343","description":"PROSER2 antisense RNA 1","metadata":null},{"id":"6b1bef0dea714d75ad9f72a5b6a396de","type":"GENE","name":"PROSER3","canonical_id":"hgnc:HGNC:25204","description":"proline and serine rich 3","metadata":{"aliases":["FLJ30657","C19orf55"]}},{"id":"fea2972a1dee42d583f66c9d3fbd7661","type":"TRIAL","name":"PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT06274047","description":"Androgen Axis Suppression; Prostatectomy; Prostate Cancer","metadata":null},{"id":"0471f8fe4334472096306ce20e2a37d4","type":"GENE","name":"PROX1","canonical_id":"hgnc:HGNC:9459","description":null,"metadata":null},{"id":"b0d56499680c4c109b0da256b371e05f","type":"GENE","name":"PROX1-AS1","canonical_id":"hgnc:HGNC:43656","description":"PROX1 antisense RNA 1","metadata":null},{"id":"4f5aecf6e64249e6bd20bf713ffbac8d","type":"GENE","name":"PROX2","canonical_id":"hgnc:HGNC:26715","description":"prospero homeobox 2","metadata":{"aliases":["FLJ36749"]}},{"id":"16fbded4a4f346b2ad6fbb3dbb66add7","type":"GENE","name":"PROZ","canonical_id":"hgnc:HGNC:9460","description":"protein Z, vitamin K dependent plasma glycoprotein","metadata":{"aliases":["PZ"]}},{"id":"653825abe3034f609215d79f5d3a41f0","type":"TRIAL","name":"PROlonGed ExpoSure Sertraline","canonical_id":"clinicaltrials.gov:NCT01524133","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"a6cc58db385d4bcaae5a6209354c601a","type":"TRIAL","name":"PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V","canonical_id":"clinicaltrials.gov:NCT04870333","description":"Covid19","metadata":null},{"id":"45d0bea6d2a444aca5314a1454aff6f4","type":"TRIAL","name":"PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)","canonical_id":"clinicaltrials.gov:NCT05419193","description":"Stroke; Vascular Accident; Intracranial Hemorrhages; Intracerebral Hemorrhage; Hemorrhagic Stroke; Stroke, Acute","metadata":null},{"id":"eaef04d33aa24f1da72a4d0e9ad961c4","type":"GENE","name":"PRP4K","canonical_id":"hgnc:HGNC:17346","description":"pre-mRNA processing factor kinase PRP4K","metadata":{"aliases":["Prp4","PR4H","KIAA0536","Prp4B","PRPF4B"]}},{"id":"07b28078fc7745fb9dd3865388ca9002","type":"GENE","name":"PRPF18","canonical_id":"hgnc:HGNC:17351","description":"pre-mRNA processing factor 18","metadata":{"aliases":["hPrp18"]}},{"id":"b3d7d949098447cda2e5cbf7183ed8f5","type":"GENE","name":"PRPF19","canonical_id":"hgnc:HGNC:17896","description":"pre-mRNA processing factor 19","metadata":{"aliases":["UBOX4","NMP200","PSO4","hPSO4","SNEV","PRP19"]}},{"id":"80d7d718a0f945b3a98403a315d89947","type":"GENE","name":"PRPF19-DT","canonical_id":"hgnc:HGNC:55484","description":"PRPF19 divergent transcript","metadata":null},{"id":"1f490c6c1cc548bfaa51b371f9182ce7","type":"GENE","name":"PRPF19P1","canonical_id":"hgnc:HGNC:23182","description":"PRPF19 pseudogene 1","metadata":{"aliases":["HsT1682","PRP19P","PRPF19P"]}},{"id":"3466d823a20d4dca8f579d54c58a5c70","type":"GENE","name":"PRPF3","canonical_id":"hgnc:HGNC:17348","description":"pre-mRNA processing factor 3","metadata":{"aliases":["Prp3","hPrp3","SNRNP90","RP18"]}},{"id":"4a74e7e19882441ea58e6c46e1734a73","type":"GENE","name":"PRPF31","canonical_id":"hgnc:HGNC:15446","description":"pre-mRNA processing factor 31","metadata":{"aliases":["NY-BR-99","PRP31","hPrp31","SNRNP61","RP11"]}},{"id":"579cfb1375ef48c4bedc356404297b6e","type":"GENE","name":"PRPF31-AS1","canonical_id":"hgnc:HGNC:40700","description":"PRPF31 antisense RNA 1","metadata":null},{"id":"9a0f656f938c4f34903a97fd96951e63","type":"GENE","name":"PRPF38A","canonical_id":"hgnc:HGNC:25930","description":"pre-mRNA processing factor 38A","metadata":{"aliases":["FLJ14936","Prp38"]}},{"id":"5e7b60593f7a414ea7ead511e52a985d","type":"GENE","name":"PRPF38AP1","canonical_id":"hgnc:HGNC:44692","description":"PRP38 domain containing A pseudogene 1","metadata":null},{"id":"b6031a0f6d774153898a8fc74ae151ba","type":"GENE","name":"PRPF38AP2","canonical_id":"hgnc:HGNC:44693","description":"PRP38 domain containing A pseudogene 2","metadata":null},{"id":"d848a53b3da34d7b8d7fd9ec320bcf9a","type":"GENE","name":"PRPF38B","canonical_id":"hgnc:HGNC:25512","description":"pre-mRNA processing factor 38B","metadata":{"aliases":["FLJ10330","NET1"]}},{"id":"d3d085075bc447b7a636572454c06f7d","type":"GENE","name":"PRPF39","canonical_id":"hgnc:HGNC:20314","description":"pre-mRNA processing factor 39","metadata":{"aliases":["FLJ20666","FLJ11128"]}},{"id":"3450b2799c0d4414b2b48e92e0e5b166","type":"GENE","name":"PRPF39-DT","canonical_id":"hgnc:HGNC:55576","description":"PRPF39 divergent transcript","metadata":null},{"id":"e668089dd7b04addb1f17363f188f9c7","type":"GENE","name":"PRPF4","canonical_id":"hgnc:HGNC:17349","description":"pre-mRNA splicing tri-snRNP complex factor PRPF4","metadata":{"aliases":["Prp4p","HPRP4","HPRP4P","PRP4","SNRNP60"]}},{"id":"8b61945162494ff2a6ce64df2b451bd4","type":"GENE","name":"PRPF40A","canonical_id":"hgnc:HGNC:16463","description":"pre-mRNA processing factor 40A","metadata":{"aliases":["FLJ20585","FBP11","HYPA","NY-REN-6","HIP10","FBP-11","FLAF1","Prp40","FNBP3"]}},{"id":"32c7af16ee464e3294f5960efc140307","type":"GENE","name":"PRPF40B","canonical_id":"hgnc:HGNC:25031","description":"pre-mRNA processing factor 40B","metadata":{"aliases":["HYPC"]}},{"id":"e9cbe18985c54e648f8e4aa9eb06829f","type":"GENE","name":"PRPF4BP1","canonical_id":"hgnc:HGNC:55055","description":"PRPF4B pseudogene 1","metadata":null},{"id":"48538101daae4605ae73140f60ea7928","type":"GENE","name":"PRPF6","canonical_id":"hgnc:HGNC:15860","description":"pre-mRNA processing factor 6","metadata":{"aliases":["TOM","bB152O15.1","ANT-1","U5-102K","Prp6","hPrp6","SNRNP102","RP60","C20orf14"]}},{"id":"89e6fc8013b84bee914d607edbf6dd01","type":"GENE","name":"PRPF8","canonical_id":"hgnc:HGNC:17340","description":"pre-mRNA processing factor 8","metadata":{"aliases":["PRPC8","Prp8","hPrp8","SNRNP220","RP13"]}},{"id":"c9c4372d31ab41b7a8ea22fd58e620b5","type":"GENE","name":"PRPH","canonical_id":"hgnc:HGNC:9461","description":"peripherin","metadata":{"aliases":["PRPH1","NEF4"]}},{"id":"a63e53716d0e4c469b611b63d87bc479","type":"GENE","name":"PRPH2","canonical_id":"hgnc:HGNC:9942","description":"peripherin 2","metadata":{"aliases":["TSPAN22","rd2","CACD2","RP7","RDS"]}},{"id":"882400a33ac54950a6fc8e263efebc4b","type":"GENE","name":"PRPH2-AS1","canonical_id":"hgnc:HGNC:59407","description":"PRPH2 antisense RNA 1","metadata":null},{"id":"0df7a758779d43e8a14f9624bdfaea1b","type":"GENE","name":"PRPS1","canonical_id":"hgnc:HGNC:9462","description":"phosphoribosyl pyrophosphate synthetase 1","metadata":{"aliases":["CMTX5","DFNX1","PRS-I","PPRibP","DFN2"]}},{"id":"54f30b35d68a4665b8f0e48c5308c47a","type":"GENE","name":"PRPS1L1","canonical_id":"hgnc:HGNC:9463","description":"phosphoribosyl pyrophosphate synthetase 1 like 1","metadata":{"aliases":["PRPS3","PRPSL"]}},{"id":"ad78ac4594e04817987f4b601fbb8cf0","type":"GENE","name":"PRPS1P1","canonical_id":"hgnc:HGNC:39427","description":"phosphoribosyl pyrophosphate synthetase 1 pseudogene 1","metadata":null},{"id":"e29d6e4589a84682bf67d098413d53d9","type":"GENE","name":"PRPS1P2","canonical_id":"hgnc:HGNC:9464","description":"phosphoribosyl pyrophosphate synthetase 1 pseudogene 2","metadata":{"aliases":["PRPS1L2"]}},{"id":"68025c435f9d490c98581912bf6438e9","type":"GENE","name":"PRPS2","canonical_id":"hgnc:HGNC:9465","description":"phosphoribosyl pyrophosphate synthetase 2","metadata":null},{"id":"725ac9c4ce9c47ed95da51fb6a17cec4","type":"GENE","name":"PRPSAP1","canonical_id":"hgnc:HGNC:9466","description":"phosphoribosyl pyrophosphate synthetase associated protein 1","metadata":{"aliases":["PAP39"]}},{"id":"ef32c626c5b24845a20cd168241a0986","type":"GENE","name":"PRPSAP2","canonical_id":"hgnc:HGNC:9467","description":"phosphoribosyl pyrophosphate synthetase associated protein 2","metadata":{"aliases":["PAP41"]}},{"id":"330b052b06e5454da5982a59771ec3c9","type":"GENE","name":"PRR11","canonical_id":"hgnc:HGNC:25619","description":"proline rich 11","metadata":{"aliases":["FLJ11029"]}},{"id":"847ca24d1dbe4818b4abc0f948b09719","type":"GENE","name":"PRR11-AS1","canonical_id":"hgnc:HGNC:56242","description":"PRR11 antisense RNA 1","metadata":{"aliases":["AC099850.3","AC099850.4","lnc-SKA2-1","CTD-2510F5.4"]}},{"id":"e2e355cf50ed43dbbd0c2dc093e92384","type":"GENE","name":"PRR11P1","canonical_id":"hgnc:HGNC:56930","description":"PRR11 pseudogene 1","metadata":null},{"id":"27730b8bc9244e29a3a4cca1025983d8","type":"GENE","name":"PRR12","canonical_id":"hgnc:HGNC:29217","description":"proline rich 12","metadata":{"aliases":["KIAA1205"]}},{"id":"191a519abb3342098cc14020218c6f50","type":"GENE","name":"PRR13","canonical_id":"hgnc:HGNC:24528","description":"proline rich 13","metadata":{"aliases":["FLJ23818","DKFZP564J157"]}},{"id":"5ffe833d0af94126953ba22761dc4c58","type":"GENE","name":"PRR13P1","canonical_id":"hgnc:HGNC:50614","description":"proline rich 13 pseudogene 1","metadata":null},{"id":"179e25ecd6d84440b49c5b84f9acb128","type":"GENE","name":"PRR13P2","canonical_id":"hgnc:HGNC:50615","description":"proline rich 13 pseudogene 2","metadata":null},{"id":"c5c8ac9d225a47b4b0f678b7d556b5ea","type":"GENE","name":"PRR13P3","canonical_id":"hgnc:HGNC:50616","description":"proline rich 13 pseudogene 3","metadata":null},{"id":"095c93f66d9a481f9facde4b94dddaf9","type":"GENE","name":"PRR13P4","canonical_id":"hgnc:HGNC:50617","description":"proline rich 13 pseudogene 4","metadata":null},{"id":"2b6caed462fd4f2daa658bb58acb7a58","type":"GENE","name":"PRR13P5","canonical_id":"hgnc:HGNC:50618","description":"proline rich 13 pseudogene 5","metadata":null},{"id":"141b3a7b266b46d981ebc47ead03fba7","type":"GENE","name":"PRR13P6","canonical_id":"hgnc:HGNC:50619","description":"proline rich 13 pseudogene 6","metadata":null},{"id":"4b0142a1ab644b5db2d5b0b4de16f577","type":"GENE","name":"PRR13P7","canonical_id":"hgnc:HGNC:50620","description":"proline rich 13 pseudogene 7","metadata":null},{"id":"665f8a4d99e440eb8d303d16717eaf59","type":"GENE","name":"PRR14","canonical_id":"hgnc:HGNC:28458","description":"proline rich 14","metadata":{"aliases":["MGC3121"]}},{"id":"6e1922c8af0e4c51b84988a574698462","type":"GENE","name":"PRR14L","canonical_id":"hgnc:HGNC:28738","description":"proline rich 14 like","metadata":{"aliases":["MGC50372","C22orf30"]}},{"id":"8cc89c5ed541468ebf1a9e9802d1bc25","type":"GENE","name":"PRR15","canonical_id":"hgnc:HGNC:22310","description":"proline rich 15","metadata":null},{"id":"2b0c5d6d289b46a6a960594116911f37","type":"GENE","name":"PRR15-DT","canonical_id":"hgnc:HGNC:55866","description":"PRR15 divergent transcript","metadata":{"aliases":["AC007255.8"]}},{"id":"6a396300891646f69f70bed58fce62b4","type":"GENE","name":"PRR15L","canonical_id":"hgnc:HGNC:28149","description":"proline rich 15 like","metadata":{"aliases":["MGC11242","ATAD4"]}},{"id":"f633b7f946f04760948b78d70821ac03","type":"GENE","name":"PRR16","canonical_id":"hgnc:HGNC:29654","description":"proline rich 16","metadata":{"aliases":["DSC54"]}},{"id":"aac2f03d45ba49b797682cf8745ea6bd","type":"GENE","name":"PRR18","canonical_id":"hgnc:HGNC:28574","description":"proline rich 18","metadata":{"aliases":["MGC35308"]}},{"id":"ce24cf07f24c4e1a8d7879978dd9143c","type":"GENE","name":"PRR19","canonical_id":"hgnc:HGNC:33728","description":"proline rich 19","metadata":{"aliases":["MGC70924"]}},{"id":"01862d931ccd4e938b98643c5823b6a2","type":"GENE","name":"PRR20A","canonical_id":"hgnc:HGNC:24754","description":"proline rich 20A","metadata":{"aliases":["FLJ40296","PRR20"]}},{"id":"8558ff2dc03d484c9835ba9a4bd3a95b","type":"GENE","name":"PRR20B","canonical_id":"hgnc:HGNC:37220","description":"proline rich 20B","metadata":null},{"id":"e3de381d54a4467e84b63088d75d80e0","type":"GENE","name":"PRR20C","canonical_id":"hgnc:HGNC:37221","description":"proline rich 20C","metadata":null},{"id":"f2213cc5f0554ce69b0b226e634f481f","type":"GENE","name":"PRR20D","canonical_id":"hgnc:HGNC:37222","description":"proline rich 20D","metadata":null},{"id":"0f3df136e4094b808abea736d8a35349","type":"GENE","name":"PRR20E","canonical_id":"hgnc:HGNC:37223","description":"proline rich 20E","metadata":null},{"id":"ab5a572390774b83a9faabd7aa6e88b9","type":"GENE","name":"PRR20FP","canonical_id":"hgnc:HGNC:49097","description":"proline rich 20F, pseudogene","metadata":{"aliases":["PRR20F"]}},{"id":"ea8a01b41df342798359cc8523f8e42b","type":"GENE","name":"PRR20G","canonical_id":"hgnc:HGNC:53837","description":"proline rich 20G","metadata":null},{"id":"a7a271368d73492d9597ca91dda14ffe","type":"GENE","name":"PRR21","canonical_id":"hgnc:HGNC:33866","description":"proline rich 21","metadata":null},{"id":"61f573203a804356a7d56d2e287ae15f","type":"GENE","name":"PRR22","canonical_id":"hgnc:HGNC:28354","description":"proline rich 22","metadata":{"aliases":["MGC24975"]}},{"id":"e8718683122e4831a6a933ea55268f6c","type":"GENE","name":"PRR23A","canonical_id":"hgnc:HGNC:37172","description":"proline rich 23A","metadata":null},{"id":"b8fa949414704ff2afb350f7c5b340d2","type":"GENE","name":"PRR23B","canonical_id":"hgnc:HGNC:33764","description":"proline rich 23B","metadata":{"aliases":["FLJ46116"]}},{"id":"2f825e933c1343398ab46ae58b0f08ed","type":"GENE","name":"PRR23C","canonical_id":"hgnc:HGNC:37173","description":"proline rich 23C","metadata":{"aliases":["FLJ46210"]}},{"id":"44306a6fc8bb4599a721d03fc3af837e","type":"GENE","name":"PRR23D1","canonical_id":"hgnc:HGNC:49420","description":"proline rich 23 domain containing 1","metadata":null},{"id":"b7615e79bee74ca3b582910006d0c531","type":"GENE","name":"PRR23D2","canonical_id":"hgnc:HGNC:49396","description":"proline rich 23 domain containing 2","metadata":null},{"id":"5559b3ad153942dd8192b6aa5a07fe34","type":"GENE","name":"PRR23D3P","canonical_id":"hgnc:HGNC:54637","description":"proline rich 23 domain containing 3, pseudogene","metadata":null},{"id":"e4cd66bc57b24de09b3cb388305f1b74","type":"GENE","name":"PRR23E","canonical_id":"hgnc:HGNC:32481","description":"PRR23 family member E","metadata":{"aliases":["FLJ40141","C3orf56"]}},{"id":"560087be4df14507a014e43cc95bb721","type":"GENE","name":"PRR23E2P","canonical_id":"hgnc:HGNC:56316","description":"PRR23 family member E2, pseudogene","metadata":null},{"id":"21b4c6f17fa24a49ac44bee4a04bc0fc","type":"GENE","name":"PRR25","canonical_id":"hgnc:HGNC:37230","description":"proline rich 25","metadata":{"aliases":["gs64"]}},{"id":"f98d90070cc24a678bc70df7208470ca","type":"GENE","name":"PRR27","canonical_id":"hgnc:HGNC:33193","description":"proline rich 27","metadata":{"aliases":["C4orf40"]}},{"id":"72eda02112964421974c6e11d3b1375f","type":"GENE","name":"PRR29","canonical_id":"hgnc:HGNC:25673","description":"proline rich 29","metadata":{"aliases":["FLJ11724","DKFZp761M2312","C17orf72"]}},{"id":"6c0836b118ba42daa9c6ee7fe106b434","type":"GENE","name":"PRR29-AS1","canonical_id":"hgnc:HGNC:51822","description":"PRR29 antisense RNA 1","metadata":null},{"id":"67acb0b86d314b4bb33d789e6dbd1763","type":"GENE","name":"PRR3","canonical_id":"hgnc:HGNC:21149","description":"proline rich 3","metadata":{"aliases":["CAT56","Em:AB014077.1","Em:AB023052.2"]}},{"id":"6356c30033f94a34b2e89992692b5411","type":"GENE","name":"PRR30","canonical_id":"hgnc:HGNC:28677","description":"proline rich 30","metadata":{"aliases":["MGC44505","C2orf53"]}},{"id":"e685a4a722d546e494e68e150661eb62","type":"GENE","name":"PRR32","canonical_id":"hgnc:HGNC:34498","description":"proline rich 32","metadata":{"aliases":["CXorf64"]}},{"id":"868f565db42a406893746412df5dfd3c","type":"GENE","name":"PRR33","canonical_id":"hgnc:HGNC:35118","description":"proline rich 33","metadata":{"aliases":["LOC728008","C11orf89"]}},{"id":"c32229e7ab414aeeaf51eecb5a08eaa2","type":"GENE","name":"PRR34","canonical_id":"hgnc:HGNC:25606","description":"PRR34 long non-coding RNA","metadata":{"aliases":["FLJ10945","C22orf26"]}},{"id":"81b24a5221f54caaa3012faf48ec7ea0","type":"GENE","name":"PRR35","canonical_id":"hgnc:HGNC:14139","description":"proline rich 35","metadata":{"aliases":["C16orf11"]}},{"id":"cb3e8e4e0a1e4aeb8f9b07b148c68383","type":"GENE","name":"PRR36","canonical_id":"hgnc:HGNC:26172","description":"proline rich 36","metadata":null},{"id":"33d3c4acb49e4f10a964f7d84903ec99","type":"GENE","name":"PRR3P1","canonical_id":"hgnc:HGNC:56391","description":"PRR3 pseudogene 1","metadata":null},{"id":"e9b9268179394c3fbf1e5fcc4d79d81f","type":"GENE","name":"PRR4","canonical_id":"hgnc:HGNC:18020","description":"proline rich 4","metadata":{"aliases":["LPRP","PROL4"]}},{"id":"fb576fa17d6d4c969f9fa131a737379f","type":"GENE","name":"PRR5","canonical_id":"hgnc:HGNC:31682","description":"proline rich 5","metadata":{"aliases":["PP610","FLJ20185k","Protor-1.","PROTOR1"]}},{"id":"994b46d5d3a1453ca6a3bfb058f67fe4","type":"GENE","name":"PRR5-ARHGAP8","canonical_id":"hgnc:HGNC:34512","description":"PRR5-ARHGAP8 readthrough","metadata":null},{"id":"c898bafc43a24fec97b6fbd4c6c357ca","type":"GENE","name":"PRR5L","canonical_id":"hgnc:HGNC:25878","description":"proline rich 5 like","metadata":{"aliases":["FLJ14213","PROTOR-2"]}},{"id":"ffdbe600315c499283805ed18087b621","type":"GENE","name":"PRR7","canonical_id":"hgnc:HGNC:28130","description":"proline rich 7, synaptic","metadata":{"aliases":["MGC10772"]}},{"id":"695651e3f348429eac4281dfc2750db6","type":"GENE","name":"PRR7-AS1","canonical_id":"hgnc:HGNC:27961","description":"PRR7 antisense RNA 1","metadata":null},{"id":"b895dc57d7e147b6b7402b3638445cff","type":"GENE","name":"PRR9","canonical_id":"hgnc:HGNC:32057","description":"proline rich 9","metadata":null},{"id":"f29f70329ad64124af1021f5043a6c8e","type":"GENE","name":"PRRC1","canonical_id":"hgnc:HGNC:28164","description":"proline rich coiled-coil 1","metadata":{"aliases":["FLJ32875"]}},{"id":"928a429d026a4b3da4a0a66de3ceef2b","type":"GENE","name":"PRRC2A","canonical_id":"hgnc:HGNC:13918","description":"proline rich coiled-coil 2A","metadata":{"aliases":["G2","D6S51E","BAT2"]}},{"id":"4130f0638f134c9ea7dcec1e21f84433","type":"GENE","name":"PRRC2B","canonical_id":"hgnc:HGNC:28121","description":"proline rich coiled-coil 2B","metadata":{"aliases":["MGC10526","LQFBS-1","KIAA0515","BAT2L","BAT2L1"]}},{"id":"2f5b449d5ff54b2c90cd2937f2730cbb","type":"GENE","name":"PRRC2C","canonical_id":"hgnc:HGNC:24903","description":"proline rich coiled-coil 2C","metadata":{"aliases":["KIAA1096","XTP2","BAT2D1","BAT2L2"]}},{"id":"9fcca748ad954d02a41a9ccb7ddab4e6","type":"GENE","name":"PRRC2CP1","canonical_id":"hgnc:HGNC:23949","description":"proline rich coiled-coil 2C pseudogene 1","metadata":{"aliases":["BAT2D1P1","BAT2L2P1"]}},{"id":"66ac28aefec34ce3ad0a675c1fee87d0","type":"GENE","name":"PRRG1","canonical_id":"hgnc:HGNC:9469","description":"proline rich and Gla domain 1","metadata":{"aliases":["PRGP1"]}},{"id":"0f36e132722945808a558028047854ff","type":"GENE","name":"PRRG2","canonical_id":"hgnc:HGNC:9470","description":"proline rich and Gla domain 2","metadata":{"aliases":["PRGP2"]}},{"id":"f55fdc117b054b24a27d523e31e2cf36","type":"GENE","name":"PRRG3","canonical_id":"hgnc:HGNC:30798","description":"proline rich and Gla domain 3","metadata":{"aliases":["TMG3"]}},{"id":"b0ea6e37574543e4bb5247a156e68e96","type":"GENE","name":"PRRG4","canonical_id":"hgnc:HGNC:30799","description":"proline rich and Gla domain 4","metadata":{"aliases":["TMG4"]}},{"id":"5342f4c2cad44688a376a7611ea8950a","type":"GENE","name":"PRRT1","canonical_id":"hgnc:HGNC:13943","description":"proline rich transmembrane protein 1","metadata":{"aliases":["NG5","IFITMD7","DSPD1","SynDIG4","C6orf31"]}},{"id":"2d8ae1c292f74eddbca000d012b1eeb8","type":"GENE","name":"PRRT1B","canonical_id":"hgnc:HGNC:53642","description":"proline rich transmembrane protein 1B","metadata":{"aliases":["IFITMD8","DSPD2"]}},{"id":"182804013dbc4541a0f0b5b31b7d1421","type":"GENE","name":"PRRT2","canonical_id":"hgnc:HGNC:30500","description":"proline rich transmembrane protein 2","metadata":{"aliases":["FLJ25513","DKFZp547J199","IFITMD1","FICCA","DSPB3","PKC","EKD1","ICCA","DYT10"]}},{"id":"a1b0df58a45042819ec25a8e6079fa02","type":"GENE","name":"PRRT3","canonical_id":"hgnc:HGNC:26591","description":"proline rich transmembrane protein 3","metadata":{"aliases":["FLJ33674"]}},{"id":"1972de61ebfa49599ab252a0f2775e05","type":"GENE","name":"PRRT3-AS1","canonical_id":"hgnc:HGNC:41151","description":"PRRT3 antisense RNA 1","metadata":null},{"id":"6d621cf5a37642cdaa4f7b4c988e1922","type":"GENE","name":"PRRT4","canonical_id":"hgnc:HGNC:37280","description":"proline rich transmembrane protein 4","metadata":null},{"id":"7e40270ef6f9422aa04ee9aa53f1571c","type":"GENE","name":"PRRX1","canonical_id":"hgnc:HGNC:9142","description":null,"metadata":null},{"id":"468035ca3f8548ef991354f8069ee96b","type":"GENE","name":"PRRX2","canonical_id":"hgnc:HGNC:21338","description":"paired related homeobox 2","metadata":{"aliases":["PRX2","PMX2"]}},{"id":"41649bcb5dcf4fb18d90f206498fec5b","type":"GENE","name":"PRRX2-AS1","canonical_id":"hgnc:HGNC:50684","description":"PRRX2 antisense RNA 1","metadata":null},{"id":"af6dc4f1dec1449886e55a2743629088","type":"GENE","name":"PRSS1","canonical_id":"hgnc:HGNC:9475","description":"serine protease 1","metadata":{"aliases":["TRY1"]}},{"id":"1feca25dd05a403cb15ca90086983074","type":"GENE","name":"PRSS12","canonical_id":"hgnc:HGNC:9477","description":"serine protease 12","metadata":{"aliases":["BSSP-3","MRT1"]}},{"id":"c2e51e6f45c04fdaa53950cff1744ab1","type":"GENE","name":"PRSS16","canonical_id":"hgnc:HGNC:9480","description":"serine protease 16","metadata":{"aliases":["TSSP"]}},{"id":"0f3ae5bd258e42258cf2c3f2afd9c487","type":"GENE","name":"PRSS2","canonical_id":"hgnc:HGNC:9483","description":"serine protease 2","metadata":{"aliases":["TRY2"]}},{"id":"2fca105e96a048159e7c2822413f3a66","type":"GENE","name":"PRSS21","canonical_id":"hgnc:HGNC:9485","description":"serine protease 21","metadata":{"aliases":["ESP-1","TEST1"]}},{"id":"4c6b4ae30f6f4f8b867779c11088ba43","type":"GENE","name":"PRSS22","canonical_id":"hgnc:HGNC:14368","description":"serine protease 22","metadata":{"aliases":["TPSE1","hBSSP-4","BSSP-4","SP001LA"]}},{"id":"1b37a7741a7b4ae0a9ecb3cca8017853","type":"GENE","name":"PRSS23","canonical_id":"hgnc:HGNC:14370","description":"serine protease 23","metadata":{"aliases":["SPUVE","SIG13"]}},{"id":"c862109b50914683aa72d284c170232a","type":"GENE","name":"PRSS23-AS1","canonical_id":"hgnc:HGNC:56071","description":"PRSS23 antisense RNA 1","metadata":null},{"id":"3159c61389a64ef8a10ae51901565977","type":"GENE","name":"PRSS27","canonical_id":"hgnc:HGNC:15475","description":"serine protease 27","metadata":{"aliases":["MPN","CAPH2"]}},{"id":"260c3e4c291e480794b297b954fef1d9","type":"GENE","name":"PRSS29P","canonical_id":"hgnc:HGNC:17542","description":"serine protease 29, pseudogene","metadata":{"aliases":["Isp2"]}},{"id":"179c733629214f3f8d32de1cb7604635","type":"GENE","name":"PRSS3","canonical_id":"hgnc:HGNC:9486","description":"serine protease 3","metadata":{"aliases":["TRY3","TRY4","PRSS4"]}},{"id":"a3b652891eec4812b3ff1b250043da56","type":"GENE","name":"PRSS30P","canonical_id":"hgnc:HGNC:28753","description":"serine protease 30, pseudogene","metadata":{"aliases":["Disp","MGC5228","TMPRSS8","TMPRSS8P"]}},{"id":"8f07222406254c96b27411ab0c2a5d96","type":"GENE","name":"PRSS33","canonical_id":"hgnc:HGNC:30405","description":"serine protease 33","metadata":{"aliases":["EOS"]}},{"id":"d6176f3977674e63ab74b82f90155951","type":"GENE","name":"PRSS35","canonical_id":"hgnc:HGNC:21387","description":"serine protease 35","metadata":{"aliases":["MGC46520","dJ223E3.1","C6orf158"]}},{"id":"e16b1d9c513e4d6a808e2f32bb7709ab","type":"GENE","name":"PRSS36","canonical_id":"hgnc:HGNC:26906","description":"serine protease 36","metadata":{"aliases":["FLJ90661"]}},{"id":"e6097686c63c4d00a71b533e06df403e","type":"GENE","name":"PRSS37","canonical_id":"hgnc:HGNC:29211","description":"serine protease 37","metadata":null},{"id":"6218b68b1fbe49489a1dff5e87df509e","type":"GENE","name":"PRSS38","canonical_id":"hgnc:HGNC:29625","description":"serine protease 38","metadata":{"aliases":["MPN2"]}},{"id":"ee29e314935b4d94b55cc949d614c16d","type":"GENE","name":"PRSS3P1","canonical_id":"hgnc:HGNC:43787","description":"PRSS3 pseudogene 1","metadata":{"aliases":["TRY5"]}},{"id":"91482d4306174f118c4aa6cd1c4699e5","type":"GENE","name":"PRSS3P2","canonical_id":"hgnc:HGNC:43788","description":"PRSS3 pseudogene 2","metadata":{"aliases":["TRY6"]}},{"id":"21bb25ea85c54c129e4a95da7fc57f31","type":"GENE","name":"PRSS3P3","canonical_id":"hgnc:HGNC:43790","description":"PRSS3 pseudogene 3","metadata":{"aliases":["TRY3"]}},{"id":"03f2c0c62c2046ce81100c7c07166fec","type":"GENE","name":"PRSS3P4","canonical_id":"hgnc:HGNC:43789","description":"PRSS3 pseudogene 4","metadata":null},{"id":"4ea106dacfaa4fa48a631d686010b90e","type":"GENE","name":"PRSS3P5","canonical_id":"hgnc:HGNC:51828","description":"PRSS3 pseudogene 5","metadata":{"aliases":["TRY7"]}},{"id":"1dbcf4baee1b45fa8fc87034ed9a144c","type":"GENE","name":"PRSS40A","canonical_id":"hgnc:HGNC:37319","description":"serine protease 40A (pseudogene)","metadata":{"aliases":["PRSS40AP","TISP43"]}},{"id":"37d1829c23bc4dfd845c4904e5e52432","type":"GENE","name":"PRSS40B","canonical_id":"hgnc:HGNC:27164","description":"serine protease 40B (pseudogene)","metadata":{"aliases":["PRSS40BP"]}},{"id":"b382fde3a7a54f9ca8193207b8ac7462","type":"GENE","name":"PRSS41","canonical_id":"hgnc:HGNC:30715","description":"serine protease 41","metadata":{"aliases":["TESSP1"]}},{"id":"d06ee47072244d58b69e2686f0a17371","type":"GENE","name":"PRSS42P","canonical_id":"hgnc:HGNC:30716","description":"serine protease 42, pseudogene","metadata":{"aliases":["TESSP2","PRSS42"]}},{"id":"2126030cf102444c89f6ee415d64c7d1","type":"GENE","name":"PRSS43P","canonical_id":"hgnc:HGNC:37323","description":"serine protease 43, pseudogene","metadata":{"aliases":["TESSP3","PRSS43"]}},{"id":"c37ecdbf88394cf0acbbbaf46418f219","type":"GENE","name":"PRSS44P","canonical_id":"hgnc:HGNC:37324","description":"serine protease 44, pseudogene","metadata":{"aliases":["TESSP4","PRSS44"]}},{"id":"6eacbbcab8d54377bf687844f08ddd7f","type":"GENE","name":"PRSS45P","canonical_id":"hgnc:HGNC:30717","description":"serine protease 45, pseudogene","metadata":{"aliases":["TESSP5","TESPL","PRSS45"]}},{"id":"23083c46ecfc404cad86e8650df63fb4","type":"GENE","name":"PRSS46P","canonical_id":"hgnc:HGNC:37325","description":"serine protease 46, pseudogene","metadata":{"aliases":["TESSP6","PRSS46"]}},{"id":"6aa9b578107e45acae96a337e879d04b","type":"GENE","name":"PRSS47P","canonical_id":"hgnc:HGNC:37326","description":"serine protease 47, pseudogene","metadata":{"aliases":["PRSS47"]}},{"id":"40f2cc134f85480ba0963715739a6d53","type":"GENE","name":"PRSS48","canonical_id":"hgnc:HGNC:24635","description":"serine protease 48","metadata":{"aliases":["ESSPL"]}},{"id":"7e8157a48a084956bc6f42ebcd851cb4","type":"GENE","name":"PRSS50","canonical_id":"hgnc:HGNC:17910","description":null,"metadata":null},{"id":"45b4e09eb88349319fc3c6ed3e2811cf","type":"GENE","name":"PRSS51","canonical_id":"hgnc:HGNC:37321","description":"serine protease 51","metadata":null},{"id":"2c3de43b20c7466fa57ca1bf78429fbe","type":"GENE","name":"PRSS52P","canonical_id":"hgnc:HGNC:37322","description":"serine protease 52, pseudogene","metadata":null},{"id":"c5a0c458e1824e37a5d20d7b74105bdd","type":"GENE","name":"PRSS53","canonical_id":"hgnc:HGNC:34407","description":"serine protease 53","metadata":{"aliases":["POL3S"]}},{"id":"bcb35638bc5a4e16878715efe6d468d2","type":"GENE","name":"PRSS54","canonical_id":"hgnc:HGNC:26336","description":"serine protease 54","metadata":{"aliases":["FLJ25339","KLKBL4","CT67"]}},{"id":"d5be9f1788d04439b69f149e80260782","type":"GENE","name":"PRSS55","canonical_id":"hgnc:HGNC:30824","description":"serine protease 55","metadata":{"aliases":["T-SP1","UNQ9391","CT153"]}},{"id":"179ea42769c848479d4a62409f1e1b00","type":"GENE","name":"PRSS56","canonical_id":"hgnc:HGNC:39433","description":"serine protease 56","metadata":null},{"id":"0059256a8a0e4abb9cf116ab38ee8775","type":"GENE","name":"PRSS57","canonical_id":"hgnc:HGNC:31397","description":"serine protease 57","metadata":{"aliases":["UNQ782","PRSSL1"]}},{"id":"dcfc2b1744a5404f8644b9be4d9bb05f","type":"GENE","name":"PRSS58","canonical_id":"hgnc:HGNC:39125","description":"serine protease 58","metadata":{"aliases":["TRYX3"]}},{"id":"6914d73b2d2b407b89fc5105a5a8efdd","type":"GENE","name":"PRSS59P","canonical_id":"hgnc:HGNC:43791","description":"serine protease 59, pseudogene","metadata":{"aliases":["TRY2P","Tryx5"]}},{"id":"38f772f161d34ff2b919441cc0b7d64c","type":"GENE","name":"PRSS8","canonical_id":"hgnc:HGNC:9491","description":null,"metadata":null},{"id":"a1462dd50e5544ea8d037d1bdfe3d0d0","type":"GENE","name":"PRTFDC1","canonical_id":"hgnc:HGNC:23333","description":"phosphoribosyl transferase domain containing 1","metadata":{"aliases":["HHGP"]}},{"id":"6416646f7ab3478ba64f55abf0ac2f5f","type":"GENE","name":"PRTG","canonical_id":"hgnc:HGNC:26373","description":"protogenin","metadata":{"aliases":["FLJ25756","IGDCC5"]}},{"id":"12be5e32a18e4785ac41cafe8e9878d3","type":"GENE","name":"PRTN3","canonical_id":"hgnc:HGNC:9495","description":null,"metadata":null},{"id":"064b0052d06c4af197af34dc9f5487d5","type":"GENE","name":"PRUNE1","canonical_id":"hgnc:HGNC:13420","description":"prune exopolyphosphatase 1","metadata":{"aliases":["DRES-17","HTCD37","H-PRUNE","PRUNE"]}},{"id":"c4430efa1e4f464bab26a50cf185fa1a","type":"GENE","name":"PRUNE1P1","canonical_id":"hgnc:HGNC:39723","description":"PRUNE1 pseudogene 1","metadata":{"aliases":["PRUNEP1"]}},{"id":"9b263a0d39664866b88083c92b201e6b","type":"GENE","name":"PRUNE2","canonical_id":"hgnc:HGNC:25209","description":"prune homolog 2 with BCH domain","metadata":{"aliases":["BMCC1","BNIPXL","A214N16.3","bA214N16.3","C9orf65","KIAA0367"]}},{"id":"10e4a6f909bd48bc97d2aa13155f51ec","type":"GENE","name":"PRX","canonical_id":"hgnc:HGNC:13797","description":"periaxin","metadata":{"aliases":["KIAA1620"]}},{"id":"b14065d970794fc6924ab3a8dfb4edcb","type":"GENE","name":"PRXL2A","canonical_id":"hgnc:HGNC:28651","description":"peroxiredoxin like 2A","metadata":{"aliases":["MGC4248","PAMM","Adrx","C10orf58","FAM213A"]}},{"id":"29ea4a3e51ee43e698c9f76ea4133769","type":"GENE","name":"PRXL2AP1","canonical_id":"hgnc:HGNC:52407","description":"peroxiredoxin like 2A pseudogene 1","metadata":{"aliases":["FAM213AP1"]}},{"id":"2b7b9883877c4754b9e152a3dc86130f","type":"GENE","name":"PRXL2AP2","canonical_id":"hgnc:HGNC:52408","description":"peroxiredoxin like 2A pseudogene 2","metadata":{"aliases":["FAM213AP2"]}},{"id":"f7fe8a0ec87d442c883c56cab0311a66","type":"GENE","name":"PRXL2B","canonical_id":"hgnc:HGNC:28390","description":"peroxiredoxin like 2B","metadata":{"aliases":["MGC26818","C1orf93","FAM213B"]}},{"id":"df55ad46468b4dacb86f7451a7d1b642","type":"GENE","name":"PRXL2C","canonical_id":"hgnc:HGNC:16881","description":"peroxiredoxin like 2C","metadata":{"aliases":["C9orf21","AAED1"]}},{"id":"f3bb0bc557644af599728e9ad29e8ab5","type":"GENE","name":"PRXL2CP1","canonical_id":"hgnc:HGNC:54977","description":"PRXL2C pseudogene 1","metadata":null},{"id":"5e8264ebd7714d8ba2feafc9d1ee6cbb","type":"GENE","name":"PRY","canonical_id":"hgnc:HGNC:14024","description":"PTPN13 like Y-linked","metadata":{"aliases":["PTPN13LY","PRY1"]}},{"id":"d9f041b6efcc4a7ba663b67c1840ab9d","type":"GENE","name":"PRY2","canonical_id":"hgnc:HGNC:21504","description":"PTPN13 like Y-linked 2","metadata":{"aliases":["PTPN13LY2"]}},{"id":"5a30fd1f1c9f45e1b523a35c35db09fb","type":"GENE","name":"PRYP1","canonical_id":"hgnc:HGNC:34018","description":"PTPN13 like Y-linked pseudogene 1","metadata":{"aliases":["PRYP7","PRY4P"]}},{"id":"a9091191fe7644719c99a9f4d233f9a8","type":"GENE","name":"PRYP2","canonical_id":"hgnc:HGNC:34019","description":"PTPN13 like Y-linked pseudogene 2","metadata":null},{"id":"2df8a19a142a435493e35191b413cf26","type":"GENE","name":"PRYP3","canonical_id":"hgnc:HGNC:34020","description":"PTPN13 like Y-linked pseudogene 3","metadata":null},{"id":"9b5ad668e8294b8185033eb30fff70c9","type":"GENE","name":"PRYP4","canonical_id":"hgnc:HGNC:34021","description":"PTPN13 like Y-linked pseudogene 4","metadata":null},{"id":"439ac6bf1644474c9e8134ed5f449c27","type":"GENE","name":"PRYP5","canonical_id":"hgnc:HGNC:38785","description":"PTPN13 like Y-linked pseudogene 5","metadata":null},{"id":"2e6d73b607b84304840ab353a85368b4","type":"GENE","name":"PRYP6","canonical_id":"hgnc:HGNC:38786","description":"PTPN13 like Y-linked pseudogene 6","metadata":null},{"id":"12520d4026e14a8b8b2609ab51481297","type":"TRIAL","name":"PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI","canonical_id":"clinicaltrials.gov:NCT02479490","description":"Metastatic Renal Cancer","metadata":null},{"id":"ec1c620d3ee348b38fe65fcafe069a7f","type":"TRIAL","name":"PRevention of Macular EDema After Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT01774474","description":"Cystoid Macular Edema; Cataract; Diabetes Mellitus","metadata":null},{"id":"591c2c7dcbc44d1cbfc31397f8ec7367","type":"TRIAL","name":"PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care","canonical_id":"clinicaltrials.gov:NCT00377143","description":"Blood Coagulation Disorders","metadata":null},{"id":"cb8b7f1ffe3c41a7b3bb89b46d05403e","type":"TRIAL","name":"PS-341 Followed by Removal of Prostate for Those With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00425503","description":"Prostate Neoplasms","metadata":null},{"id":"c27229fc46854834806ea78e2efa9a89","type":"TRIAL","name":"PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00028587","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"9ae33fd13c8947da8e632daeaa97f641","type":"TRIAL","name":"PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma","canonical_id":"clinicaltrials.gov:NCT00004002","description":"Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"6b65df91d48f425789cab6cfea0c1f70","type":"GENE","name":"PSAP","canonical_id":"hgnc:HGNC:9498","description":"prosaposin","metadata":{"aliases":["SAP1","GLBA","SAP2"]}},{"id":"c2f24dd49fcb4d5faa291a8130f56c31","type":"GENE","name":"PSAPL1","canonical_id":"hgnc:HGNC:33131","description":"prosaposin like 1","metadata":null},{"id":"9cdf13c2fee04d95b265866a8543ea96","type":"GENE","name":"PSAT1","canonical_id":"hgnc:HGNC:19129","description":"phosphoserine aminotransferase 1","metadata":{"aliases":["PSA","PSAT"]}},{"id":"cbd17e18167547d0b5b1a41af83fdaf2","type":"GENE","name":"PSAT1P1","canonical_id":"hgnc:HGNC:15785","description":"phosphoserine aminotransferase 1 pseudogene 1","metadata":{"aliases":["C8orf62"]}},{"id":"6a35e44d8a4844d19fd1e13cedfbba3e","type":"GENE","name":"PSAT1P2","canonical_id":"hgnc:HGNC:43988","description":"phosphoserine aminotransferase 1 pseudogene 2","metadata":null},{"id":"d143a9c6d4734b18a206bab31b3d322f","type":"GENE","name":"PSAT1P3","canonical_id":"hgnc:HGNC:43989","description":"phosphoserine aminotransferase 1 pseudogene 3","metadata":null},{"id":"f266964adc4742fcbc1c06626b0b3c1f","type":"GENE","name":"PSAT1P4","canonical_id":"hgnc:HGNC:43990","description":"phosphoserine aminotransferase 1 pseudogene 4","metadata":null},{"id":"feb1f17e1cb846619306dc26129d6186","type":"GENE","name":"PSCA","canonical_id":"hgnc:HGNC:9500","description":null,"metadata":null},{"id":"246083f3d55b4b18b04e7f64d866e348","type":"GENE","name":"PSD","canonical_id":"hgnc:HGNC:9507","description":"pleckstrin and Sec7 domain containing","metadata":{"aliases":["KIAA2011","TYL","PSD1","EFA6A","EFA6"]}},{"id":"445e3c08799942959d0e54e7f1cff9a3","type":"GENE","name":"PSD2","canonical_id":"hgnc:HGNC:19092","description":"pleckstrin and Sec7 domain containing 2","metadata":{"aliases":["DKFZp761B0514","EFA6C"]}},{"id":"984fb60f973d4d90a6e4fac5eee7c34e","type":"GENE","name":"PSD2-AS1","canonical_id":"hgnc:HGNC:52765","description":"PSD2 antisense RNA 1","metadata":null},{"id":"43825ab6f57a48c7b52436b738effba8","type":"GENE","name":"PSD3","canonical_id":"hgnc:HGNC:19093","description":"pleckstrin and Sec7 domain containing 3","metadata":{"aliases":["KIAA0942","HCA67","EFA6R","DKFZp761K1423","EFA6D"]}},{"id":"da1922f9f29e432ca35b958361651066","type":"GENE","name":"PSD3-AS1","canonical_id":"hgnc:HGNC:58211","description":"PSD3 antisense RNA 1","metadata":null},{"id":"de2313d18b624b5d82a8ea79985c3c09","type":"GENE","name":"PSD4","canonical_id":"hgnc:HGNC:19096","description":"pleckstrin and Sec7 domain containing 4","metadata":{"aliases":["TIC","EFA6B"]}},{"id":"31cd5cb7c0b94d1f8503fae728d1be25","type":"GENE","name":"PSEN1","canonical_id":"hgnc:HGNC:9508","description":null,"metadata":null},{"id":"95bfa3c6d8ba493c9596557e9ce46ea3","type":"GENE","name":"PSEN2","canonical_id":"hgnc:HGNC:9509","description":null,"metadata":null},{"id":"23bb9fe9efb04f398caa39c1a77f3bc8","type":"GENE","name":"PSENEN","canonical_id":"hgnc:HGNC:30100","description":"presenilin enhancer, gamma-secretase subunit","metadata":{"aliases":["PEN2"]}},{"id":"e22144e6a6c840c2a04f66bad7d7a838","type":"GENE","name":"PSG1","canonical_id":"hgnc:HGNC:9514","description":null,"metadata":null},{"id":"ceeb3519fcd649d7afe55ecd0bbfdd78","type":"GENE","name":"PSG10P","canonical_id":"hgnc:HGNC:9515","description":"pregnancy specific beta-1-glycoprotein 10, pseudogene","metadata":{"aliases":["PSG12","PSG10"]}},{"id":"da29494c510d4ba894ac04ea61cb8c8a","type":"GENE","name":"PSG11","canonical_id":"hgnc:HGNC:9516","description":"pregnancy specific beta-1-glycoprotein 11","metadata":{"aliases":["MGC22484","PSG13","PSG14"]}},{"id":"99254b8505974e45aa1ba0647b8171cb","type":"GENE","name":"PSG11-AS1","canonical_id":"hgnc:HGNC:56358","description":"PSG11, PSG2 and PSG5 antisense RNA 1","metadata":{"aliases":["AC004784.1","CTC-490G23.6"]}},{"id":"ad53c44b3d934fb991529b923bbc4fb3","type":"GENE","name":"PSG2","canonical_id":"hgnc:HGNC:9519","description":"pregnancy specific beta-1-glycoprotein 2","metadata":{"aliases":["PSGGB","PSG1","CEA","PSBG2"]}},{"id":"6d8759ec2ce84383847f9c1142c3fbf0","type":"GENE","name":"PSG3","canonical_id":"hgnc:HGNC:9520","description":null,"metadata":null},{"id":"6638e9d02bf04029907400a8382e6fc3","type":"GENE","name":"PSG4","canonical_id":"hgnc:HGNC:9521","description":"pregnancy specific beta-1-glycoprotein 4","metadata":null},{"id":"5139c3c518f64e17ad3e782a7e65082e","type":"GENE","name":"PSG5","canonical_id":"hgnc:HGNC:9522","description":null,"metadata":null},{"id":"b1c4573d88c24021ad01fdde6aaa04e6","type":"GENE","name":"PSG6","canonical_id":"hgnc:HGNC:9523","description":"pregnancy specific beta-1-glycoprotein 6","metadata":null},{"id":"8e436e3472cc42d9be30b529c2f063d8","type":"GENE","name":"PSG7","canonical_id":"hgnc:HGNC:9524","description":null,"metadata":null},{"id":"1eeaf05631c746c2a2e879eff6376e94","type":"GENE","name":"PSG8","canonical_id":"hgnc:HGNC:9525","description":"pregnancy specific beta-1-glycoprotein 8","metadata":null},{"id":"c37d8b0f667c48259aa739e89a5bf6f5","type":"GENE","name":"PSG8-AS1","canonical_id":"hgnc:HGNC:52550","description":"PSG8 antisense RNA 1","metadata":null},{"id":"6131fa6421804497a40f660b9f4876a5","type":"GENE","name":"PSG9","canonical_id":"hgnc:HGNC:9526","description":"pregnancy specific beta-1-glycoprotein 9","metadata":{"aliases":["PSGII","PSG11"]}},{"id":"2953789792b44c3d967220721d524968","type":"GO_TERM","name":"PSI associated light-harvesting complex I","canonical_id":"go:GO:0009518","description":"\"Protein-pigment complex associated with photosystem I.\" [GOC:lr]","metadata":null},{"id":"738648df9e74410dbe6d88118b2accc2","type":"GO_TERM","name":"PSI associated light-harvesting complex I, LHCIa subcomplex","canonical_id":"go:GO:0030083","description":"\"A pigment protein complex that forms part of the photosystem I associated light-harvesting complex I; contains two proteins (usually about 24 and 21.5 kDa); has a fluorescence maximum between 680 and 690 nm.\" [PMID:8825475]","metadata":null},{"id":"22851596017b4ba39159e6e5a1cc7f5c","type":"GO_TERM","name":"PSI associated light-harvesting complex I, LHCIb subcomplex","canonical_id":"go:GO:0030084","description":"\"A pigment protein complex that forms part of the photosystem I associated light-harvesting complex I; contains two proteins (usually about 20 kDa); has a fluorescence maximum of 730 nm.\" [PMID:8825475]","metadata":null},{"id":"787c16c5e43a400abb5f04b10d4c9ae2","type":"GO_TERM","name":"PSII associated light-harvesting complex II","canonical_id":"go:GO:0009517","description":"\"Protein-pigment complex associated with photosystem II.\" [GOC:lr, ISBN:0582227089]","metadata":null},{"id":"91cd7b7da77b45a9bae4280d6fb94c51","type":"GO_TERM","name":"PSII associated light-harvesting complex II binding","canonical_id":"go:GO:0062066","description":"\"Binding to a PSII associated light-harvesting complex II.\" [PMID:17400553]","metadata":null},{"id":"21983100995f441a839dbafbb9ce6a46","type":"GO_TERM","name":"PSII associated light-harvesting complex II catabolic process","canonical_id":"go:GO:0010304","description":"\"The chemical reactions and pathways resulting in the breakdown of one or more components of the light-harvesting complex of photosystem II.\" [GOC:mah, PMID:16157880]","metadata":null},{"id":"5fb6f435466441cfa999a10f18c7677d","type":"GO_TERM","name":"PSII associated light-harvesting complex II, core complex","canonical_id":"go:GO:0009655","description":"\"The pigment-protein complex primarily associated to PSII in higher plants, green algae and cyanobacteria that directly transfers electrons to the reaction center.\" [GOC:lr]","metadata":null},{"id":"a73db037f5e8422cbe3861dfa7e5a462","type":"GO_TERM","name":"PSII associated light-harvesting complex II, peripheral complex","canonical_id":"go:GO:0009656","description":"\"Pigment-protein complex primarily associated to PSII in plants, green algae and cyanobacteria. Involved in state transitions that cause migration to PSI under certain environmental conditions such as high light.\" [GOC:lr]","metadata":null},{"id":"e3a1764365934fadb22f9428a4ce60f3","type":"GO_TERM","name":"PSII associated light-harvesting complex II, peripheral complex, LHCIIb subcomplex","canonical_id":"go:GO:0030085","description":"\"A pigment protein complex that forms part of the photosystem II associated light-harvesting complex II; contains two proteins (usually about 28 and 27 kDa), and may contain a third; peripherally located relative to other LHC polypeptides.\" [PMID:8825475]","metadata":null},{"id":"19a59f4c3267422b90f9a5c86196acfc","type":"GENE","name":"PSIP1","canonical_id":"hgnc:HGNC:9527","description":null,"metadata":null},{"id":"9e34af660d764e3284d3aa059a729ece","type":"GENE","name":"PSIP1P1","canonical_id":"hgnc:HGNC:31132","description":"PSIP1 pseudogene 1","metadata":{"aliases":["PSIP1P"]}},{"id":"f902d0590f804cba8f74a6baf4a0c166","type":"GENE","name":"PSIP1P2","canonical_id":"hgnc:HGNC:23968","description":"PSIP1 pseudogene 2","metadata":null},{"id":"aa1f8f23cc0b4aa9abfca5750d27acf8","type":"GENE","name":"PSKH1","canonical_id":"hgnc:HGNC:9529","description":"protein serine kinase H1","metadata":null},{"id":"614a05a867214967aab1fdcc52ee3d2d","type":"GENE","name":"PSKH2","canonical_id":"hgnc:HGNC:18997","description":"protein serine kinase H2","metadata":null},{"id":"a3b0027daae641058114217aac00d87a","type":"GENE","name":"PSLNR","canonical_id":"hgnc:HGNC:54405","description":"prostate enriched lncRNA","metadata":{"aliases":["LA16c-83F12.6"]}},{"id":"7ff5711a295545f4bd1efe5fdcc068a2","type":"GENE","name":"PSMA1","canonical_id":"hgnc:HGNC:9530","description":"proteasome 20S subunit alpha 1","metadata":{"aliases":["HC2","NU","PROS30","MGC14542","MGC14575","MGC14751","MGC1667","MGC21459","MGC22853","MGC23915"]}},{"id":"70ad85bdb8b444a68be5aba8caceec9a","type":"GENE","name":"PSMA1P1","canonical_id":"hgnc:HGNC:55003","description":"PSMA1 pseudogene 1","metadata":null},{"id":"d5119e51594a44bca4446debf24eae99","type":"GENE","name":"PSMA2","canonical_id":"hgnc:HGNC:9531","description":"proteasome 20S subunit alpha 2","metadata":{"aliases":["MU","HC3","PMSA2"]}},{"id":"dd8002a00107467cbf451dfe5e088c4c","type":"GENE","name":"PSMA2P1","canonical_id":"hgnc:HGNC:43832","description":"proteasome subunit alpha 2 pseudogene 1","metadata":null},{"id":"c779f650d1b14703b24075c751abb713","type":"GENE","name":"PSMA2P2","canonical_id":"hgnc:HGNC:43833","description":"proteasome subunit alpha 2 pseudogene 2","metadata":null},{"id":"ae7bb95e408c44628c85172297e1433d","type":"GENE","name":"PSMA2P3","canonical_id":"hgnc:HGNC:43834","description":"proteasome subunit alpha 2 pseudogene 3","metadata":{"aliases":["PSMA2L"]}},{"id":"034fbbfcb3af4c889dede69d656c405e","type":"GENE","name":"PSMA3","canonical_id":"hgnc:HGNC:9532","description":"proteasome 20S subunit alpha 3","metadata":{"aliases":["HC8"]}},{"id":"aa30e70c937346e5b9ba68aba4aaafe9","type":"GENE","name":"PSMA3-AS1","canonical_id":"hgnc:HGNC:26445","description":"PSMA3 antisense RNA 1","metadata":{"aliases":["FLJ31306"]}},{"id":"a39f28b1368449c8a930654de3a3e908","type":"GENE","name":"PSMA3P1","canonical_id":"hgnc:HGNC:20029","description":"proteasome subunit alpha 3 pseudogene 1","metadata":{"aliases":["PSMA3P"]}},{"id":"ec194b89c28e4651b164f07f526743b3","type":"GENE","name":"PSMA4","canonical_id":"hgnc:HGNC:9533","description":"proteasome 20S subunit alpha 4","metadata":{"aliases":["HC9","HsT17706"]}},{"id":"22ba56e5b8434bc28f100fe2a7cac3df","type":"GENE","name":"PSMA5","canonical_id":"hgnc:HGNC:9534","description":"proteasome 20S subunit alpha 5","metadata":{"aliases":["ZETA"]}},{"id":"f3a792e1379c494a95727e021b08dbf4","type":"GENE","name":"PSMA5P1","canonical_id":"hgnc:HGNC:54966","description":"PSMA5 pseudogene 1","metadata":null},{"id":"7a64917a89eb4c64a9df47eb8c3305c9","type":"GENE","name":"PSMA6","canonical_id":"hgnc:HGNC:9535","description":"proteasome 20S subunit alpha 6","metadata":{"aliases":["IOTA","PROS27","p27K","MGC22756","MGC2333","MGC23846"]}},{"id":"55ba23bb77424dfab32e15c6fb31ba28","type":"GENE","name":"PSMA6P1","canonical_id":"hgnc:HGNC:17460","description":"proteasome subunit alpha 6 pseudogene 1","metadata":{"aliases":["PSMA6-LIKE","PSMA6Y","PSMA6P"]}},{"id":"1b5aa9f49a6a417a85c8bcfcfbd25a59","type":"GENE","name":"PSMA6P2","canonical_id":"hgnc:HGNC:39607","description":"proteasome subunit alpha 6 pseudogene 2","metadata":null},{"id":"db078058e5f74614ac082b2ffbdb164f","type":"GENE","name":"PSMA6P3","canonical_id":"hgnc:HGNC:39608","description":"proteasome subunit alpha 6 pseudogene 3","metadata":null},{"id":"02dc347abb604d11b9c2d76df12ae2f6","type":"GENE","name":"PSMA6P4","canonical_id":"hgnc:HGNC:39609","description":"proteasome subunit alpha 6 pseudogene 4","metadata":null},{"id":"3e83f2f4db2f473493d3269dac8352ee","type":"GENE","name":"PSMA7","canonical_id":"hgnc:HGNC:9536","description":"proteasome 20S subunit alpha 7","metadata":{"aliases":["XAPC7","C6","HSPC","RC6-1"]}},{"id":"3093e16baaf34229b2f329ab9ef069df","type":"GENE","name":"PSMA7P1","canonical_id":"hgnc:HGNC:20631","description":"proteasome subunit alpha 7 pseudogene 1","metadata":{"aliases":["PSMA7P"]}},{"id":"b9229f93d77248fea0df69e07ca3aa50","type":"GENE","name":"PSMA8","canonical_id":"hgnc:HGNC:22985","description":"proteasome 20S subunit alpha 8","metadata":{"aliases":["MGC26605","PSMA7L"]}},{"id":"9b1e9357e55a46a3b1945ee244bea749","type":"GENE","name":"PSMB1","canonical_id":"hgnc:HGNC:9537","description":"proteasome 20S subunit beta 1","metadata":{"aliases":["PMSB1","HC5"]}},{"id":"502030e0622b4593b6df9d7c58a9fa7c","type":"GENE","name":"PSMB10","canonical_id":"hgnc:HGNC:9538","description":null,"metadata":null},{"id":"1669fa231a9b4ec5992fd5a3bde6aca7","type":"GENE","name":"PSMB11","canonical_id":"hgnc:HGNC:31963","description":"proteasome subunit beta 11","metadata":{"aliases":["beta5t"]}},{"id":"42eac4bf52a045ceaeed467bd8ace72d","type":"GENE","name":"PSMB2","canonical_id":"hgnc:HGNC:9539","description":"proteasome 20S subunit beta 2","metadata":{"aliases":["HC7-I"]}},{"id":"2ac032c9d43544ec8e1858d44ac888e9","type":"GENE","name":"PSMB3","canonical_id":"hgnc:HGNC:9540","description":"proteasome 20S subunit beta 3","metadata":{"aliases":["HC10-II","MGC4147"]}},{"id":"1647ce4f900c4cc0a0ecabc0aef74849","type":"GENE","name":"PSMB3P1","canonical_id":"hgnc:HGNC:20633","description":"proteasome subunit beta 3 pseudogene 1","metadata":{"aliases":["PSMB3P"]}},{"id":"ea46bda32256472f9430affb5131af2c","type":"GENE","name":"PSMB3P2","canonical_id":"hgnc:HGNC:30150","description":"proteasome subunit beta 3 pseudogene 2","metadata":null},{"id":"dddcf16f38dd43cb8cf6b38e968dad35","type":"GENE","name":"PSMB4","canonical_id":"hgnc:HGNC:9541","description":"proteasome 20S subunit beta 4","metadata":{"aliases":["HN3","PROS26"]}},{"id":"ad74123b74204d9aab4a62a2f0e4d3ce","type":"GENE","name":"PSMB5","canonical_id":"hgnc:HGNC:9542","description":null,"metadata":null},{"id":"7935a798d85e49279d0835777d6593f9","type":"GENE","name":"PSMB6","canonical_id":"hgnc:HGNC:9543","description":"proteasome 20S subunit beta 6","metadata":{"aliases":["Y","DELTA"]}},{"id":"25bf63ce785a4a78a3e19afd860ebe88","type":"GENE","name":"PSMB7","canonical_id":"hgnc:HGNC:9544","description":"proteasome 20S subunit beta 7","metadata":{"aliases":["Z"]}},{"id":"c4526634a3654a4ca9e975e83126f64b","type":"GENE","name":"PSMB7P1","canonical_id":"hgnc:HGNC:49192","description":"PSMB7 pseudogene 1","metadata":null},{"id":"f47acbe3f57c4b0992dc3d9939b36664","type":"GENE","name":"PSMB8","canonical_id":"hgnc:HGNC:9545","description":"proteasome 20S subunit beta 8","metadata":{"aliases":["RING10","D6S216E","PSMB5i","beta5i","LMP7"]}},{"id":"0dd7cfa60c2c40528f1557313986466a","type":"GENE","name":"PSMB8-AS1","canonical_id":"hgnc:HGNC:39758","description":"PSMB8 antisense RNA 1","metadata":{"aliases":["XXbac-BPG246D15.8","TAP1-AS1","TAPSAR1"]}},{"id":"18afa672cd3a4d43a86d513ee2fd6044","type":"GENE","name":"PSMB9","canonical_id":"hgnc:HGNC:9546","description":null,"metadata":null},{"id":"495abee2f3b64c35a8d4a10619c46c42","type":"GENE","name":"PSMC1","canonical_id":"hgnc:HGNC:9547","description":"proteasome 26S subunit, ATPase 1","metadata":{"aliases":["S4","p56","RPT2"]}},{"id":"e0e1bbaec5dd40798658804108a0ce30","type":"GENE","name":"PSMC1P1","canonical_id":"hgnc:HGNC:30147","description":"proteasome 26S subunit, ATPase 1 pseudogene 1","metadata":{"aliases":["bcm3415","PSMC1P"]}},{"id":"3e4f1686e6324a4c8335797966d5b8f4","type":"GENE","name":"PSMC1P10","canonical_id":"hgnc:HGNC:39785","description":"proteasome 26S subunit, ATPase 1 pseudogene 10","metadata":null},{"id":"eb9ad8df9c7e42549845a925240fb906","type":"GENE","name":"PSMC1P11","canonical_id":"hgnc:HGNC:39786","description":"proteasome 26S subunit, ATPase 1 pseudogene 11","metadata":null},{"id":"c1f1b7883ef645488325d1abf298b900","type":"GENE","name":"PSMC1P12","canonical_id":"hgnc:HGNC:39787","description":"proteasome 26S subunit, ATPase 1 pseudogene 12","metadata":null},{"id":"a90b0e1328ca41389783a3b0237fd4bc","type":"GENE","name":"PSMC1P13","canonical_id":"hgnc:HGNC:39788","description":"proteasome 26S subunit, ATPase 1 pseudogene 13","metadata":null},{"id":"ef2eae75556d4666961347498a9c099c","type":"GENE","name":"PSMC1P2","canonical_id":"hgnc:HGNC:39777","description":"proteasome 26S subunit, ATPase 1 pseudogene 2","metadata":null},{"id":"22dba950487948e6bfca95405e1895fd","type":"GENE","name":"PSMC1P3","canonical_id":"hgnc:HGNC:39778","description":"proteasome 26S subunit, ATPase 1 pseudogene 3","metadata":null},{"id":"13b69669c90347ff899e7e7606e18d64","type":"GENE","name":"PSMC1P4","canonical_id":"hgnc:HGNC:39779","description":"proteasome 26S subunit, ATPase 1 pseudogene 4","metadata":null},{"id":"05ffcc5963fb4cf189f71408ab57ba93","type":"GENE","name":"PSMC1P5","canonical_id":"hgnc:HGNC:39780","description":"proteasome 26S subunit, ATPase 1 pseudogene 5","metadata":null},{"id":"e91ae19c390a40118de1e879b3f7e01a","type":"GENE","name":"PSMC1P6","canonical_id":"hgnc:HGNC:39781","description":"proteasome 26S subunit, ATPase 1 pseudogene 6","metadata":null},{"id":"4152f98492fa463e8775dd94409c9f12","type":"GENE","name":"PSMC1P7","canonical_id":"hgnc:HGNC:39782","description":"proteasome 26S subunit, ATPase 1 pseudogene 7","metadata":null},{"id":"89dd0cff861240acb8819f4ab5c6ef14","type":"GENE","name":"PSMC1P8","canonical_id":"hgnc:HGNC:39783","description":"proteasome 26S subunit, ATPase 1 pseudogene 8","metadata":null},{"id":"b72dd0b6e65c4b4899350ffc3eec6e41","type":"GENE","name":"PSMC1P9","canonical_id":"hgnc:HGNC:39784","description":"proteasome 26S subunit, ATPase 1 pseudogene 9","metadata":null},{"id":"b9265a1472854a67b3de910b10a182d5","type":"GENE","name":"PSMC2","canonical_id":"hgnc:HGNC:9548","description":"proteasome 26S subunit, ATPase 2","metadata":{"aliases":["MSS1","S7","Nbla10058","RPT1"]}},{"id":"2ef45031d20643789f20c2475cf2a8c1","type":"GENE","name":"PSMC2P1","canonical_id":"hgnc:HGNC:54571","description":"PSMC2 pseudogene 1","metadata":null},{"id":"6c63e6d64ea84e6f8e441887055bf210","type":"GENE","name":"PSMC2P2","canonical_id":"hgnc:HGNC:54573","description":"PSMC2 pseudogene 2","metadata":null},{"id":"471b85f394164fd394e767769b9429bc","type":"GENE","name":"PSMC3","canonical_id":"hgnc:HGNC:9549","description":"proteasome 26S subunit, ATPase 3","metadata":{"aliases":["TBP1","TBP-1","RPT5"]}},{"id":"49462a1c79bd4515ba1ab698755a2be9","type":"GENE","name":"PSMC3IP","canonical_id":"hgnc:HGNC:17928","description":"PSMC3 interacting protein","metadata":{"aliases":["TBPIP","GT198","HUMGT198A","Hop2"]}},{"id":"4b30de41adb146858b5b4f84cfb684e1","type":"GENE","name":"PSMC3P1","canonical_id":"hgnc:HGNC:9550","description":"proteasome 26S subunit, ATPase 3 pseudogene 1","metadata":{"aliases":["PSMC3P"]}},{"id":"705c47362e9945db907ef5235f0bc106","type":"GENE","name":"PSMC4","canonical_id":"hgnc:HGNC:9551","description":"proteasome 26S subunit, ATPase 4","metadata":{"aliases":["TBP7","S6","MGC8570","MGC13687","MGC23214","TBP-7","RPT3","MIP224"]}},{"id":"0e7ce4c9ad554b33a2ae9011eb408425","type":"GENE","name":"PSMC5","canonical_id":"hgnc:HGNC:9552","description":null,"metadata":null},{"id":"35a7b001f6fb4d3ab08e6475c510dc31","type":"GENE","name":"PSMC6","canonical_id":"hgnc:HGNC:9553","description":"proteasome 26S subunit, ATPase 6","metadata":{"aliases":["p42","RPT5"]}},{"id":"1e7914a5cb6c44e7a443381fe07a1041","type":"GENE","name":"PSMC6P1","canonical_id":"hgnc:HGNC:20634","description":"proteasome 26S subunit, ATPase, 6 pseudogene 1","metadata":{"aliases":["PSMC6P"]}},{"id":"b353563ef17e4fcb83b41572c1707e4f","type":"GENE","name":"PSMC6P2","canonical_id":"hgnc:HGNC:30149","description":"proteasome 26S subunit, ATPase, 6 pseudogene 2","metadata":null},{"id":"231a149c99cf448daad3968684efdfaa","type":"GENE","name":"PSMC6P3","canonical_id":"hgnc:HGNC:34012","description":"proteasome 26S subunit, ATPase, 6 pseudogene 3","metadata":null},{"id":"32b0bcdef1c2473cacae4180d5aff2c9","type":"GENE","name":"PSMD1","canonical_id":"hgnc:HGNC:9554","description":"proteasome 26S subunit, non-ATPase 1","metadata":{"aliases":["S1","P112","Rpn2"]}},{"id":"33df731a28bd47af910c699286f119d5","type":"PROTEIN","name":"PSMD1","canonical_id":"uniprot:Q99460","description":null,"metadata":null},{"id":"b6a9b191beef4348b98a73cae0075c41","type":"GENE","name":"PSMD10","canonical_id":"hgnc:HGNC:9555","description":"proteasome 26S subunit, non-ATPase 10","metadata":{"aliases":["p28"]}},{"id":"291f4f7aee784c26ac9e5b06d941b185","type":"GENE","name":"PSMD10P1","canonical_id":"hgnc:HGNC:16602","description":"proteasome 26S subunit, non-ATPase, 10 pseudogene 1","metadata":{"aliases":["dJ914P20.4","PSMD10P"]}},{"id":"4c4b8621ac424801beed7738dc3043d1","type":"GENE","name":"PSMD10P2","canonical_id":"hgnc:HGNC:30151","description":"proteasome 26S subunit, non-ATPase, 10 pseudogene 2","metadata":null},{"id":"9bb8dee4b6964e4fa3aebf0f691520ca","type":"GENE","name":"PSMD10P3","canonical_id":"hgnc:HGNC:30152","description":"proteasome 26S subunit, non-ATPase, 10 pseudogene 3","metadata":null},{"id":"1e6ec6e26dbd4866b40e21a8578386ba","type":"GENE","name":"PSMD11","canonical_id":"hgnc:HGNC:9556","description":null,"metadata":null},{"id":"7bcc48a17e534ab0a844d77456c817c8","type":"GENE","name":"PSMD12","canonical_id":"hgnc:HGNC:9557","description":"proteasome 26S subunit, non-ATPase 12","metadata":{"aliases":["p55","Rpn5"]}},{"id":"3d1b9101161e4999a84984e3078d7fe8","type":"GENE","name":"PSMD12P1","canonical_id":"hgnc:HGNC:30153","description":"PSMD12 pseudogene 1","metadata":{"aliases":["PSMD12P"]}},{"id":"8484a97e4d844394a5e33fb8ab9c9636","type":"GENE","name":"PSMD13","canonical_id":"hgnc:HGNC:9558","description":"proteasome 26S subunit, non-ATPase 13","metadata":{"aliases":["p40.5","Rpn9"]}},{"id":"07c597ff76a548fdbd879d5595028fa2","type":"GENE","name":"PSMD14","canonical_id":"hgnc:HGNC:16889","description":"proteasome 26S subunit, non-ATPase 14","metadata":{"aliases":["POH1","pad1","Rpn11"]}},{"id":"cb2d5596cc7c44c49acbcfe7fb3cbacd","type":"GENE","name":"PSMD14-DT","canonical_id":"hgnc:HGNC:56104","description":"PSMD14 divergent transcript","metadata":{"aliases":["uc.88"]}},{"id":"49e19c3609e644be8e3df9bece18ce15","type":"GENE","name":"PSMD14P1","canonical_id":"hgnc:HGNC:54533","description":"PSMD14 pseudogene 1","metadata":null},{"id":"05cd6740bc3d45eea8307728224bfe7b","type":"GENE","name":"PSMD2","canonical_id":"hgnc:HGNC:9559","description":"proteasome 26S subunit ubiquitin receptor, non-ATPase 2","metadata":{"aliases":["S2","P97","TRAP2","MGC14274","Rpn1"]}},{"id":"064d5a6d72344165b6db3dc324256333","type":"GENE","name":"PSMD2P1","canonical_id":"hgnc:HGNC:30154","description":"proteasome 26S subunit, non-ATPase, 2 pseudogene 1","metadata":null},{"id":"6b9bd470f8904341b60e74b88131baa0","type":"GENE","name":"PSMD3","canonical_id":"hgnc:HGNC:9560","description":null,"metadata":null},{"id":"1f8ced53d09140fda7f424eb9aec9caf","type":"GENE","name":"PSMD3-AS1","canonical_id":"hgnc:HGNC:58140","description":"PSMD3 antisense RNA 1","metadata":{"aliases":["PR11-387H17.6","RP11-387H17.6"]}},{"id":"ddbbd410f56e403fba6013e4d1df7975","type":"GENE","name":"PSMD4","canonical_id":"hgnc:HGNC:9561","description":"proteasome 26S subunit ubiquitin receptor, non-ATPase 4","metadata":{"aliases":["S5A","AF-1","AF","Rpn10"]}},{"id":"9be8535d283940bbbbe0608608e198fb","type":"GENE","name":"PSMD4P1","canonical_id":"hgnc:HGNC:9562","description":"proteasome 26S subunit, non-ATPase 4 pseudogene 1","metadata":{"aliases":["PSMD4P","PSMD15"]}},{"id":"63a852a487a447d2bd644a9a09954142","type":"GENE","name":"PSMD5","canonical_id":"hgnc:HGNC:9563","description":"proteasome 26S subunit, non-ATPase 5","metadata":{"aliases":["S5B","KIAA0072"]}},{"id":"1bde962a0a914a4da5232d1832f59687","type":"GENE","name":"PSMD6","canonical_id":"hgnc:HGNC:9564","description":null,"metadata":null},{"id":"91451d206fb6431c9806946fce51a9b6","type":"GENE","name":"PSMD6-AS1","canonical_id":"hgnc:HGNC:40480","description":"PSMD6 antisense RNA 1","metadata":{"aliases":["ENST00000462717","lnc00462717"]}},{"id":"c38180577f7c48aea6108dbe7457d4b9","type":"GENE","name":"PSMD6-AS2","canonical_id":"hgnc:HGNC:44125","description":"PSMD6 antisense RNA 2","metadata":null},{"id":"979a2f5a5a57440d9c3842ebd9cfcd96","type":"GENE","name":"PSMD7","canonical_id":"hgnc:HGNC:9565","description":"proteasome 26S subunit, non-ATPase 7","metadata":{"aliases":["S12","P40","MOV34","Rpn8"]}},{"id":"fb4876db21b04e9ca1ba0b7374b20129","type":"GENE","name":"PSMD7-DT","canonical_id":"hgnc:HGNC:53056","description":"PSMD7 divergent transcript","metadata":null},{"id":"57c521322e6c4a7d853c9b443fbc9e03","type":"GENE","name":"PSMD7P1","canonical_id":"hgnc:HGNC:7202","description":"proteasome 26S subunit, non-ATPase 7 pseudogene 1","metadata":{"aliases":["MOV34L","PSMD7L"]}},{"id":"36f01c3cac414c2e9d0089c8c50a260b","type":"GENE","name":"PSMD7P2","canonical_id":"hgnc:HGNC:58516","description":"PSMD7 pseudogene 2","metadata":null},{"id":"3e5a45e0794c40e1bbf388ce13d580b1","type":"GENE","name":"PSMD7P3","canonical_id":"hgnc:HGNC:58517","description":"PSMD7 pseudogene 3","metadata":null},{"id":"e034a9221c674ab1bed0dec9cd2ee502","type":"GENE","name":"PSMD7P4","canonical_id":"hgnc:HGNC:58518","description":"PSMD7 pseudogene 4","metadata":null},{"id":"9986bbb60c5d4ba8a3dfb9171d985df1","type":"GENE","name":"PSMD8","canonical_id":"hgnc:HGNC:9566","description":"proteasome 26S subunit, non-ATPase 8","metadata":{"aliases":["S14","Nin1p","p31","HIP6","HYPF","Rpn12"]}},{"id":"a559e808d0f64488a8901be7728aaea9","type":"GENE","name":"PSMD8P1","canonical_id":"hgnc:HGNC:34013","description":"proteasome 26S subunit, non-ATPase, 8 pseudogene 1","metadata":null},{"id":"eee9967d4f1b4df1a2c02c69777d3046","type":"GENE","name":"PSMD9","canonical_id":"hgnc:HGNC:9567","description":"proteasome 26S subunit, non-ATPase 9","metadata":{"aliases":["p27","Rpn4"]}},{"id":"e03ed296740b4fa7bcad1967155922ec","type":"GENE","name":"PSME1","canonical_id":"hgnc:HGNC:9568","description":"proteasome activator subunit 1","metadata":{"aliases":["IFI5111","PA28alpha"]}},{"id":"9240ae6f6442474492d3bbcc97122842","type":"GENE","name":"PSME2","canonical_id":"hgnc:HGNC:9569","description":"proteasome activator subunit 2","metadata":{"aliases":["PA28beta"]}},{"id":"bbc3946a4651468e9bc82987bd1beb10","type":"GENE","name":"PSME2P1","canonical_id":"hgnc:HGNC:20632","description":"proteasome activator subunit 2 pseudogene 1","metadata":{"aliases":["PSME2P"]}},{"id":"4967acfbc8fe410daf412b7e27508642","type":"GENE","name":"PSME2P2","canonical_id":"hgnc:HGNC:30160","description":"proteasome activator subunit 2 pseudogene 2","metadata":null},{"id":"0fbdd90d80fe453d8d741c88403a961e","type":"GENE","name":"PSME2P3","canonical_id":"hgnc:HGNC:30156","description":"proteasome activator subunit 2 pseudogene 3","metadata":null},{"id":"05b68439249f468a85a7e79e36b8e60c","type":"GENE","name":"PSME2P4","canonical_id":"hgnc:HGNC:30157","description":"proteasome activator subunit 2 pseudogene 4","metadata":null},{"id":"6832703ffec14e9abdeebbdc973f9b52","type":"GENE","name":"PSME2P5","canonical_id":"hgnc:HGNC:30158","description":"proteasome activator subunit 2 pseudogene 5","metadata":null},{"id":"cde8b76b04e140c99ec8b41430a669cb","type":"GENE","name":"PSME2P6","canonical_id":"hgnc:HGNC:30159","description":"proteasome activator subunit 2 pseudogene 6","metadata":null},{"id":"8576632ff70a429f83a3b884fb854eb9","type":"GENE","name":"PSME3","canonical_id":"hgnc:HGNC:9570","description":"proteasome activator subunit 3","metadata":{"aliases":["Ki","PA28-gamma","REG-GAMMA","PA28G"]}},{"id":"3eb84c372bde4eda9cbc477a500db29b","type":"GENE","name":"PSME3IP1","canonical_id":"hgnc:HGNC:29856","description":"proteasome activator subunit 3 interacting protein 1","metadata":{"aliases":["NIP30","PIP30","C16orf94","FAM192A"]}},{"id":"423287247c144e39816e4abad0e6742d","type":"GENE","name":"PSME3IP1P1","canonical_id":"hgnc:HGNC:37194","description":"PSME3IP1 pseudogene 1","metadata":{"aliases":["rcNIP30","FAM192B","FAM192BP"]}},{"id":"3756ca6b60f34a4d86b7f78a020ee8ef","type":"GENE","name":"PSME4","canonical_id":"hgnc:HGNC:20635","description":"proteasome activator subunit 4","metadata":{"aliases":["PA200","KIAA0077"]}},{"id":"7c8987d3b19a4a958a4f044fcb901121","type":"GENE","name":"PSMF1","canonical_id":"hgnc:HGNC:9571","description":"proteasome inhibitor subunit 1","metadata":{"aliases":["PI31"]}},{"id":"983a3c03bfec44619da68e6329478c73","type":"GENE","name":"PSMG1","canonical_id":"hgnc:HGNC:3043","description":"proteasome assembly chaperone 1","metadata":{"aliases":["c21-LRP","LRPC21","PAC1","DSCR2"]}},{"id":"540a85320b364ccead2370c5f9236966","type":"GENE","name":"PSMG2","canonical_id":"hgnc:HGNC:24929","description":"proteasome assembly chaperone 2","metadata":{"aliases":["HCCA3","MDS003","MGC15092","CLAST3","HsT1707","PAC2","TNFSF5IP1"]}},{"id":"08aceb21a38448b9a00f3c33a36cc415","type":"GENE","name":"PSMG3","canonical_id":"hgnc:HGNC:22420","description":"proteasome assembly chaperone 3","metadata":{"aliases":["MGC10911","PAC3","C7orf48"]}},{"id":"9ac10eb0d0d64ebcb292bb91f335236a","type":"GENE","name":"PSMG3-AS1","canonical_id":"hgnc:HGNC:22230","description":"PSMG3 antisense RNA 1","metadata":{"aliases":["KIAA1908"]}},{"id":"c04f7795237644c393ee4fb6fa3eab1b","type":"GENE","name":"PSMG3P1","canonical_id":"hgnc:HGNC:56588","description":"PSMG3 pseudogene 1","metadata":null},{"id":"1d9920e356834be5b53f37e564686a34","type":"GENE","name":"PSMG3P2","canonical_id":"hgnc:HGNC:56593","description":"PSMG3 pseudogene 2","metadata":null},{"id":"720d7837ebb243689f8fb8fb988ddd02","type":"GENE","name":"PSMG4","canonical_id":"hgnc:HGNC:21108","description":"proteasome assembly chaperone 4","metadata":{"aliases":["PAC4","C6orf86"]}},{"id":"10016479ec464407b40d93542a00e60c","type":"GENE","name":"PSMG4-AS1","canonical_id":"hgnc:HGNC:59334","description":"PSMG4 antisense RNA 1","metadata":null},{"id":"10033d9194b64fdfb006e2512d49137d","type":"GENE","name":"PSORS1C1","canonical_id":"hgnc:HGNC:17202","description":"psoriasis susceptibility 1 candidate 1","metadata":{"aliases":["SEEK1","C6orf16"]}},{"id":"2b65e84b204e42ad86e39fcaa9b7141a","type":"GENE","name":"PSORS1C2","canonical_id":"hgnc:HGNC:17199","description":"psoriasis susceptibility 1 candidate 2","metadata":{"aliases":["SPR1","C6orf17"]}},{"id":"cbc9f18aba834c7a9c594ccbd16dee8b","type":"GENE","name":"PSORS1C3","canonical_id":"hgnc:HGNC:17203","description":"psoriasis susceptibility 1 candidate 3","metadata":{"aliases":["NCRNA00196"]}},{"id":"f524f45a7b6143ac856e2962d1b7cdf4","type":"GENE","name":"PSPC1","canonical_id":"hgnc:HGNC:20320","description":"paraspeckle component 1","metadata":{"aliases":["PSP1","FLJ10955"]}},{"id":"beeb12deae71445f96f6ff31db1d9cea","type":"GENE","name":"PSPC1-AS2","canonical_id":"hgnc:HGNC:52951","description":"PSPC1 antisense RNA 2","metadata":{"aliases":["RP11-523H24.3"]}},{"id":"18736c3063454229b91a412d6533c9c4","type":"GENE","name":"PSPC1P1","canonical_id":"hgnc:HGNC:42033","description":"paraspeckle component 1 pseudogene 1","metadata":null},{"id":"d29eb130bf9b44f586340d1833dab8b2","type":"GENE","name":"PSPC1P2","canonical_id":"hgnc:HGNC:42643","description":"paraspeckle component 1 pseudogene 2","metadata":null},{"id":"4ae79820ba2f430ea46a10d313819949","type":"GENE","name":"PSPH","canonical_id":"hgnc:HGNC:9577","description":"phosphoserine phosphatase","metadata":{"aliases":["PSP"]}},{"id":"94bdc55a13fa40d5bbbd6503e8e82235","type":"GENE","name":"PSPHP1","canonical_id":"hgnc:HGNC:9578","description":"phosphoserine phosphatase pseudogene 1","metadata":{"aliases":["CO9","PSPHL"]}},{"id":"fe4c74425d914d6b98e1e8c014875365","type":"GENE","name":"PSPN","canonical_id":"hgnc:HGNC:9579","description":"persephin","metadata":{"aliases":["PSP"]}},{"id":"25e4de2dcc5f469182475e4320387c67","type":"GENE","name":"PSRC1","canonical_id":"hgnc:HGNC:24472","description":"proline and serine rich coiled-coil 1","metadata":{"aliases":["DDA3"]}},{"id":"8aca8a8898014ab0a36fa606cbeab090","type":"GENE","name":"PSTK","canonical_id":"hgnc:HGNC:28578","description":"phosphoseryl-tRNA kinase","metadata":{"aliases":["MGC35392","C10orf89"]}},{"id":"49f729bbab364ab3abcb843e6c6c8e49","type":"GENE","name":"PSTPIP1","canonical_id":"hgnc:HGNC:9580","description":"proline-serine-threonine phosphatase interacting protein 1","metadata":{"aliases":["PSTPIP","CD2BP1L","CD2BP1","CD2BP1S","H-PIP","PAPAS"]}},{"id":"47674edfcb3d4f579aeee6db741c79cb","type":"GENE","name":"PSTPIP2","canonical_id":"hgnc:HGNC:9581","description":"proline-serine-threonine phosphatase interacting protein 2","metadata":null},{"id":"bae08fb2dae44c428b789df57d54460b","type":"TRIAL","name":"PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01350128","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"0931c67cb71c4280bd48491b6c0357a3","type":"GENE","name":"PTAFR","canonical_id":"hgnc:HGNC:9582","description":null,"metadata":null},{"id":"b5caabf528424d33ad9059753b747981","type":"PROTEIN","name":"PTAFR","canonical_id":"uniprot:P25105","description":null,"metadata":null},{"id":"eb65ecf8f0be482187ffcb3d547a4359","type":"GENE","name":"PTAR1","canonical_id":"hgnc:HGNC:30449","description":"protein prenyltransferase alpha subunit repeat containing 1","metadata":null},{"id":"ed7eef2b501247e996574fd81e04241b","type":"GO_TERM","name":"PTB domain binding","canonical_id":"go:GO:0051425","description":"\"Binding to a phosphotyrosine-binding (PTB) Binding to a phosphotyrosine-bindin domain.\" [Pfam:PF02174, PMID:15924411]","metadata":null},{"id":"3e3a0ff4be014736bb95e5b26e01f492","type":"GENE","name":"PTBP1","canonical_id":"hgnc:HGNC:9583","description":null,"metadata":null},{"id":"00900fd1d4ac4588a589a81a9b6c1069","type":"GENE","name":"PTBP1P","canonical_id":"hgnc:HGNC:20030","description":"polypyrimidine tract binding protein 1 pseudogene","metadata":null},{"id":"3892aa1345f246cb9e1e24a94fa33896","type":"GENE","name":"PTBP2","canonical_id":"hgnc:HGNC:17662","description":"polypyrimidine tract binding protein 2","metadata":{"aliases":["brPTB","nPTB","PTB","PTBLP"]}},{"id":"a93192dedb25477982208f92ab05c59b","type":"GENE","name":"PTBP3","canonical_id":"hgnc:HGNC:10253","description":"polypyrimidine tract binding protein 3","metadata":{"aliases":["DKFZp781I1117","ROD1"]}},{"id":"0bd2fb2e8d7a4ad5a816108cca8e1335","type":"GENE","name":"PTCD1","canonical_id":"hgnc:HGNC:22198","description":"pentatricopeptide repeat domain 1","metadata":{"aliases":["KIAA0632"]}},{"id":"8bf0ac7aee484bdaad498c3fd1b45982","type":"GENE","name":"PTCD2","canonical_id":"hgnc:HGNC:25734","description":"pentatricopeptide repeat domain 2","metadata":{"aliases":["FLJ12598"]}},{"id":"edce8e08823c4e6b977a86a9456bee27","type":"GENE","name":"PTCD2P1","canonical_id":"hgnc:HGNC:31718","description":"pentatricopeptide repeat domain 2 pseudogene 1","metadata":null},{"id":"9c87f365587f43d48911d3102262d350","type":"GENE","name":"PTCD2P2","canonical_id":"hgnc:HGNC:45168","description":"pentatricopeptide repeat domain 2 pseudogene 2","metadata":null},{"id":"5736087e0eac49fe9c07331ad351fefa","type":"GENE","name":"PTCD3","canonical_id":"hgnc:HGNC:24717","description":"pentatricopeptide repeat domain 3","metadata":{"aliases":["FLJ20758","DKFZp666K071","mS39"]}},{"id":"271b0c0f046e47a795da902cf228079f","type":"GENE","name":"PTCH1","canonical_id":"hgnc:HGNC:9585","description":"patched 1","metadata":{"aliases":["BCNS","SLC65B1","NBCCS","PTCH"]}},{"id":"88d10da62828492cba384756f86dab23","type":"GENE","name":"PTCH1","canonical_id":"ensembl:ENSG00000185920","description":null,"metadata":null},{"id":"ec2a90a61d39428a8036c2425c10423e","type":"GENE","name":"PTCH2","canonical_id":"hgnc:HGNC:9586","description":"patched 2","metadata":{"aliases":["SLC65B2"]}},{"id":"0056d50328ad4d3b8418200162729f7d","type":"GENE","name":"PTCHD1","canonical_id":"hgnc:HGNC:26392","description":"patched domain containing 1","metadata":{"aliases":["SLC65C1","FLJ30296"]}},{"id":"65c8a1c436084c8aa48f532c576764eb","type":"GENE","name":"PTCHD1-AS","canonical_id":"hgnc:HGNC:37703","description":"PTCHD1 and PHEX antisense RNA","metadata":{"aliases":["PTCHD1AS1","PTCHD1AS2","DDX53-AS1","PHEX-AS1"]}},{"id":"69c39040a0054eddabe79fffbda159bf","type":"GENE","name":"PTCHD3","canonical_id":"hgnc:HGNC:24776","description":"patched domain containing 3 (gene/pseudogene)","metadata":{"aliases":["PTR","SLC65C3","FLJ44037"]}},{"id":"6a5492cff0a8411d83dc0fab8c9d1f78","type":"GENE","name":"PTCHD3P1","canonical_id":"hgnc:HGNC:44945","description":"patched domain containing 3 pseudogene 1","metadata":null},{"id":"6bc2945eae404991a9826c0ab935cd66","type":"GENE","name":"PTCHD3P2","canonical_id":"hgnc:HGNC:44946","description":"patched domain containing 3 pseudogene 2","metadata":null},{"id":"af4b158d4298494d93ddc77bf4792823","type":"GENE","name":"PTCHD3P3","canonical_id":"hgnc:HGNC:44947","description":"patched domain containing 3 pseudogene 3","metadata":null},{"id":"c4518dd3a53f45408ee6f5cfcfb132c2","type":"GENE","name":"PTCHD4","canonical_id":"hgnc:HGNC:21345","description":"patched domain containing 4","metadata":{"aliases":["PTCH53","SLC65C2","FLJ41841","dJ402H5.2","C6orf138"]}},{"id":"3fb0b03475424933ba204f593e9bcc99","type":"GENE","name":"PTCRA","canonical_id":"hgnc:HGNC:21290","description":"pre T cell antigen receptor alpha","metadata":{"aliases":["PTA","PT-ALPHA"]}},{"id":"b50703b89022497da04d671c01c6a540","type":"GENE","name":"PTCSC1","canonical_id":"hgnc:HGNC:37127","description":"papillary thyroid carcinoma susceptibility candidate 1","metadata":{"aliases":["AK023948","NCRNA00197","PTCSC"]}},{"id":"ff22d5485c394891a470221c60f737aa","type":"GENE","name":"PTCSC2","canonical_id":"hgnc:HGNC:44086","description":"papillary thyroid carcinoma susceptibility candidate 2","metadata":null},{"id":"bb7b8f8dcaa9441f91ce0021cd421192","type":"GENE","name":"PTCSC3","canonical_id":"hgnc:HGNC:43959","description":"papillary thyroid carcinoma susceptibility candidate 3","metadata":null},{"id":"df58182ebbce46d3af4a10bbffce6bfb","type":"GENE","name":"PTDSS1","canonical_id":"hgnc:HGNC:9587","description":"phosphatidylserine synthase 1","metadata":{"aliases":["KIAA0024","PSSA","PSS1"]}},{"id":"3a1762356d1f4eb19a191767c8aff563","type":"GENE","name":"PTDSS2","canonical_id":"hgnc:HGNC:15463","description":"phosphatidylserine synthase 2","metadata":{"aliases":["PSS2"]}},{"id":"19d080944a9642c695de122c93ef3a54","type":"GENE","name":"PTEN","canonical_id":"hgnc:HGNC:9588","description":null,"metadata":null},{"id":"f35f21e0a81240359ab2502020c0420d","type":"GENE","name":"PTEN","canonical_id":"ensembl:ENSG00000171862","description":null,"metadata":null},{"id":"8c9ed929aaeb4c0290feeadcf2254a3d","type":"GO_TERM","name":"PTEN phosphatase complex","canonical_id":"go:GO:1990455","description":"\"A phospholipid phosphatase complex that catalyses the hydrolysis of the second messenger PtdIns (3,4,5)P3. Will also dephosphorylate PtdIns(3,4)P2, PtdIns3P, and Ins(1,3,4,5)P4. Dimerization is critical for its lipid phosphatase function.\" [GOC:bhm, PMID:24766807]","metadata":null},{"id":"8ca81bc87c1247b49a4e59ba03c7db91","type":"GENE","name":"PTENP1","canonical_id":"hgnc:HGNC:9589","description":"phosphatase and tensin homolog pseudogene 1","metadata":{"aliases":["PTEN2","psiPTEN","PTH2","PTEN-rs","PTENpg1"]}},{"id":"6c92106106984d5e9f63b417106d2685","type":"GENE","name":"PTENP1-AS","canonical_id":"hgnc:HGNC:48773","description":"PTENP1 antisense RNA","metadata":{"aliases":["PTENpg1-asRNA"]}},{"id":"06fdae68fe4143fc8188de94b5d07527","type":"GENE","name":"PTER","canonical_id":"hgnc:HGNC:9590","description":"phosphotriesterase related","metadata":null},{"id":"dec917a93f63471c9add66f2e75a15e8","type":"GO_TERM","name":"PTEX complex","canonical_id":"go:GO:0097619","description":"\"A protein complex that acts as a protein trafficking machinery and is responsible for the export of proteins across the parasitophorous (symbiont-containing) vacuolar membrane and into the human host cell. The PTEX complex is located in the vacuole membrane. It is ATP-powered, and comprises heat shock protein 101 (HSP101; a ClpA/B-like ATPase from the AAA+ superfamily, of a type commonly associated with protein translocons), a parasite protein termed PTEX150, and exported protein 2 (EXP2). EXP2 is the potential channel, as it is the membrane-associated component of the core PTEX complex. Two other proteins, PTEX88 and thioredoxin 2 (TRX2), were also identified as PTEX components.\" [GOC:pr, PMID:19536257, PMID:25043010, PMID:25043043]","metadata":null},{"id":"62b4cc97f5b84adfa28cc74e966d1da9","type":"GENE","name":"PTF1A","canonical_id":"hgnc:HGNC:23734","description":null,"metadata":null},{"id":"cee1304106044195ba3fbda1cd004236","type":"GENE","name":"PTGDR","canonical_id":"hgnc:HGNC:9591","description":"prostaglandin D2 receptor","metadata":{"aliases":["DP","DP1","PTGDR1"]}},{"id":"57cf7aaa1a024583a3de8c746783092e","type":"GENE","name":"PTGDR2","canonical_id":"hgnc:HGNC:4502","description":null,"metadata":null},{"id":"1969108883124391bc1e67cf7f779b90","type":"GENE","name":"PTGDS","canonical_id":"hgnc:HGNC:9592","description":null,"metadata":null},{"id":"a2f6bbad19fd4296938723a2b814ef60","type":"GENE","name":"PTGER1","canonical_id":"hgnc:HGNC:9593","description":"prostaglandin E receptor 1","metadata":{"aliases":["EP1"]}},{"id":"449ac91c1dbf4a67a36bebc5849dc5d2","type":"GENE","name":"PTGER2","canonical_id":"hgnc:HGNC:9594","description":null,"metadata":null},{"id":"f69d0550383046b1813905bef8e5af6b","type":"GENE","name":"PTGER3","canonical_id":"hgnc:HGNC:9595","description":"prostaglandin E receptor 3","metadata":{"aliases":["EP3","lnc003875"]}},{"id":"0c6a7e02833947c4ad85d86e8a31ea4a","type":"PROTEIN","name":"PTGER3","canonical_id":"uniprot:P43115","description":null,"metadata":null},{"id":"1e0da175330a45b489e00c2899ff9543","type":"GENE","name":"PTGER3-AS1","canonical_id":"hgnc:HGNC:40481","description":"PTGER3 antisense RNA 1","metadata":null},{"id":"edbec44c9d404ce6a945b0e4c6b018c3","type":"GENE","name":"PTGER4","canonical_id":"hgnc:HGNC:9596","description":null,"metadata":null},{"id":"7c888504a9f444bbacae8224c1d686e5","type":"GENE","name":"PTGER4P1","canonical_id":"hgnc:HGNC:9597","description":"prostaglandin E receptor 4 pseudogene 1","metadata":null},{"id":"718b1a10007f4fd58739033122649c8b","type":"GENE","name":"PTGER4P2","canonical_id":"hgnc:HGNC:9598","description":"prostaglandin E receptor 4 pseudogene 2","metadata":null},{"id":"d04a8d74ce9d4958abd332fa9f723819","type":"GENE","name":"PTGER4P2-CDK2AP2P2","canonical_id":"hgnc:HGNC:44749","description":"PTGER4P2-CDK2AP2P2 readthrough, transcribed pseudogene","metadata":null},{"id":"ca5b6792ccb9411b8c52b20180d95e9a","type":"GENE","name":"PTGER4P3","canonical_id":"hgnc:HGNC:38498","description":"prostaglandin E receptor 4 pseudogene 3","metadata":null},{"id":"deea50d451a04395abecd5a5ec89dad4","type":"GENE","name":"PTGES","canonical_id":"hgnc:HGNC:9599","description":null,"metadata":null},{"id":"b53e381c6a9f458e848bda1e1cd15112","type":"GENE","name":"PTGES2","canonical_id":"hgnc:HGNC:17822","description":"prostaglandin E synthase 2","metadata":{"aliases":["mPGES-2","FLJ14038","C9orf15"]}},{"id":"2c9340e8da6443c38145cd2e6978cac8","type":"GENE","name":"PTGES2-DT","canonical_id":"hgnc:HGNC:48711","description":"PTGES2 divergent transcript","metadata":{"aliases":["PTGES2-AS1"]}},{"id":"b12816a0b5bc429e834f28c3c6395f29","type":"GENE","name":"PTGES3","canonical_id":"hgnc:HGNC:16049","description":"prostaglandin E synthase 3","metadata":{"aliases":["p23","TEBP","cPGES"]}},{"id":"8024c8e4d4614e79899c13794272f03e","type":"GENE","name":"PTGES3L","canonical_id":"hgnc:HGNC:43943","description":"prostaglandin E synthase 3 like","metadata":null},{"id":"7a4e02cfbf9c431da94617a73a043009","type":"GENE","name":"PTGES3L-AARSD1","canonical_id":"hgnc:HGNC:43946","description":"PTGES3L-AARSD1 readthrough","metadata":null},{"id":"1b5fcec9b0aa49a9a0ed99e8bc5b0d30","type":"GENE","name":"PTGES3P1","canonical_id":"hgnc:HGNC:43824","description":"prostaglandin E synthase 3 pseudogene 1","metadata":null},{"id":"94fed95018714c008cfea5ac5cf5e4d2","type":"GENE","name":"PTGES3P2","canonical_id":"hgnc:HGNC:43822","description":"prostaglandin E synthase 3 pseudogene 2","metadata":null},{"id":"909b40b32d3c4048a12a9e9a9253d900","type":"GENE","name":"PTGES3P3","canonical_id":"hgnc:HGNC:43823","description":"prostaglandin E synthase 3 pseudogene 3","metadata":null},{"id":"36ef666622df4d5395c61cb8568504b6","type":"GENE","name":"PTGES3P4","canonical_id":"hgnc:HGNC:43825","description":"prostaglandin E synthase 3 pseudogene 4","metadata":null},{"id":"586a77a99f4745d2944ea7da6e986d02","type":"GENE","name":"PTGES3P5","canonical_id":"hgnc:HGNC:43826","description":"prostaglandin E synthase 3 pseudogene 5","metadata":null},{"id":"a9fd526b8e3f4d3dbd190aedf8ca6ab8","type":"GENE","name":"PTGFR","canonical_id":"hgnc:HGNC:9600","description":null,"metadata":null},{"id":"d1f9af216260402b8f13c503e751e84f","type":"PROTEIN","name":"PTGFR","canonical_id":"uniprot:P43088","description":null,"metadata":null},{"id":"a4fb8508ec304c5f8c2895e16dfb6745","type":"GENE","name":"PTGFRN","canonical_id":"hgnc:HGNC:9601","description":"prostaglandin F2 receptor inhibitor","metadata":{"aliases":["FPRP","EWI-F","CD9P-1","FLJ11001","KIAA1436","SMAP-6","CD315"]}},{"id":"6e738728bb3146a38fd2093372d204be","type":"GENE","name":"PTGIR","canonical_id":"hgnc:HGNC:9602","description":null,"metadata":null},{"id":"4b66967e787542e0944119b730b01b5f","type":"PROTEIN","name":"PTGIR","canonical_id":"uniprot:P43119","description":null,"metadata":null},{"id":"839b61689bff45e1a84af7afc61b0299","type":"GENE","name":"PTGIS","canonical_id":"hgnc:HGNC:9603","description":"prostaglandin I2 synthase","metadata":{"aliases":["PGIS","CYP8A1"]}},{"id":"faac7207ccaf4ff1a906687ded788719","type":"GENE","name":"PTGR1","canonical_id":"hgnc:HGNC:18429","description":"prostaglandin reductase 1","metadata":{"aliases":["ZADH3","LTB4DH"]}},{"id":"7135dfeb49484281b8e3197fc67e16bb","type":"GENE","name":"PTGR2","canonical_id":"hgnc:HGNC:20149","description":"prostaglandin reductase 2","metadata":{"aliases":["FLJ39091","ZADH1"]}},{"id":"c60d9ed4b7e34011ad5775fd15895ebb","type":"GENE","name":"PTGR3","canonical_id":"hgnc:HGNC:28697","description":"prostaglandin reductase 3","metadata":{"aliases":["MGC45594","PTGR-3","ZADH2"]}},{"id":"71588b2ab7f546068667ccc1f6847949","type":"GENE","name":"PTGS1","canonical_id":"hgnc:HGNC:9604","description":null,"metadata":null},{"id":"0cb67eb046de4d48acc7d9800b2b98e5","type":"GENE","name":"PTGS2","canonical_id":"hgnc:HGNC:9605","description":null,"metadata":null},{"id":"3477bcf664fb4c6eb8ccbebec9374029","type":"PROTEIN","name":"PTGS2","canonical_id":"uniprot:P35354","description":null,"metadata":null},{"id":"1aebb4a39f8c4993a77a059933194121","type":"GENE","name":"PTH","canonical_id":"hgnc:HGNC:9606","description":null,"metadata":null},{"id":"64e13ff6b5814d4c8f59d32a0f25fa89","type":"TRIAL","name":"PTH Analog Type II Odontoid Fracture","canonical_id":"clinicaltrials.gov:NCT04760782","description":"Odontoid Fracture","metadata":null},{"id":"b01aee3e9cde42d0a53045252d5e82f9","type":"TRIAL","name":"PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT02972424","description":"Osteoporotic Fractures","metadata":null},{"id":"8a2f58864ce546de8ee47839246855f8","type":"GENE","name":"PTH1R","canonical_id":"hgnc:HGNC:9608","description":"parathyroid hormone 1 receptor","metadata":{"aliases":["PTHR","PTHR1"]}},{"id":"9cc2f19dfa4d482da2e0de56987fa50f","type":"PROTEIN","name":"PTH1R","canonical_id":"uniprot:Q03431","description":null,"metadata":null},{"id":"631d4c52e24e447184ce8d816bd60557","type":"GENE","name":"PTH2","canonical_id":"hgnc:HGNC:30828","description":"parathyroid hormone 2","metadata":{"aliases":["TIP39"]}},{"id":"dc7fb175581d4e8f8baf55c44c3a56ba","type":"GENE","name":"PTH2R","canonical_id":"hgnc:HGNC:9609","description":"parathyroid hormone 2 receptor","metadata":{"aliases":["PTHR2"]}},{"id":"c0082fa0db104a88bc0e1c53129ec955","type":"GENE","name":"PTHLH","canonical_id":"hgnc:HGNC:9607","description":null,"metadata":null},{"id":"701df58c88e54b3e986d8e04c7d58cb6","type":"GENE","name":"PTK2","canonical_id":"hgnc:HGNC:9611","description":"protein tyrosine kinase 2","metadata":{"aliases":["FAK","FADK","FAK1","PPP1R71"]}},{"id":"aa9926c7db5b44adbaa8d6f7a5e9df86","type":"GENE","name":"PTK2B","canonical_id":"hgnc:HGNC:9612","description":"protein tyrosine kinase 2 beta","metadata":{"aliases":["CAKB","PYK2","RAFTK","PTK","CADTK","FAK2"]}},{"id":"9a1555c6a57244f1bc39b7eb22d68429","type":"GENE","name":"PTK6","canonical_id":"hgnc:HGNC:9617","description":null,"metadata":null},{"id":"42d5ca68536f41ca96a732c69f009459","type":"PROTEIN","name":"PTK6","canonical_id":"uniprot:Q13882","description":null,"metadata":null},{"id":"bd569537609c4a96911efe321fb00969","type":"GENE","name":"PTK7","canonical_id":"hgnc:HGNC:9618","description":"protein tyrosine kinase 7 (inactive)","metadata":{"aliases":["CCK4"]}},{"id":"ab07143151e949218f61782520423850","type":"GENE","name":"PTMA","canonical_id":"hgnc:HGNC:9623","description":null,"metadata":null},{"id":"b8f282f7d714443d9f91e9d62467c16b","type":"GENE","name":"PTMAP1","canonical_id":"hgnc:HGNC:9624","description":"prothymosin alpha pseudogene 1","metadata":{"aliases":["Em:AB023049.6"]}},{"id":"17f364e0e63749b9b07b38c3fe2c3739","type":"GENE","name":"PTMAP10","canonical_id":"hgnc:HGNC:53978","description":"prothymosin alpha pseudogene 10","metadata":null},{"id":"d3d19c32414442b6a5438c025477a746","type":"GENE","name":"PTMAP11","canonical_id":"hgnc:HGNC:53979","description":"prothymosin alpha pseudogene 11","metadata":null},{"id":"e7196b863da04028bba723c499aa93a3","type":"GENE","name":"PTMAP12","canonical_id":"hgnc:HGNC:53982","description":"prothymosin alpha pseudogene 12","metadata":null},{"id":"80875870df114e639a0acd3da9d009ca","type":"GENE","name":"PTMAP13","canonical_id":"hgnc:HGNC:53983","description":"prothymosin alpha pseudogene 13","metadata":null},{"id":"5eecd7c279d7437296a14fe9f3fb83d5","type":"GENE","name":"PTMAP14","canonical_id":"hgnc:HGNC:53984","description":"prothymosin alpha pseudogene 14","metadata":null},{"id":"5fba054af7964eebada5f75b80761785","type":"GENE","name":"PTMAP15","canonical_id":"hgnc:HGNC:53985","description":"prothymosin alpha pseudogene 15","metadata":null},{"id":"60dc4754ba784a19af9229e329995686","type":"GENE","name":"PTMAP2","canonical_id":"hgnc:HGNC:9625","description":"prothymosin alpha pseudogene 2","metadata":null},{"id":"9c5f1ab5a4c84f5985b3269252adcfc5","type":"GENE","name":"PTMAP3","canonical_id":"hgnc:HGNC:9626","description":"prothymosin alpha pseudogene 3","metadata":null},{"id":"df0c5a5c0fc14d62834ac65482929e33","type":"GENE","name":"PTMAP4","canonical_id":"hgnc:HGNC:9627","description":"prothymosin alpha pseudogene 4","metadata":null},{"id":"00e120cbdd5e4fa9b0e2adaa9f94996e","type":"GENE","name":"PTMAP5","canonical_id":"hgnc:HGNC:9628","description":"prothymosin alpha pseudogene 5","metadata":null},{"id":"6ad9c33af9bf4b458fd415226dac3c03","type":"GENE","name":"PTMAP6","canonical_id":"hgnc:HGNC:16573","description":"prothymosin alpha pseudogene 6","metadata":{"aliases":["dJ539E24.2"]}},{"id":"705d15557fce4938b72216deadf1d813","type":"GENE","name":"PTMAP7","canonical_id":"hgnc:HGNC:20031","description":"prothymosin alpha pseudogene 7","metadata":null},{"id":"d027042647b74652a320f493e8cc2028","type":"GENE","name":"PTMAP8","canonical_id":"hgnc:HGNC:42437","description":"prothymosin alpha pseudogene 8","metadata":null},{"id":"d4afedb173754a05b87c72c9168f5760","type":"GENE","name":"PTMAP9","canonical_id":"hgnc:HGNC:34054","description":"prothymosin alpha pseudogene 9","metadata":null},{"id":"79e0177b33e04de0b568240e4f915151","type":"GENE","name":"PTMS","canonical_id":"hgnc:HGNC:9629","description":"parathymosin","metadata":{"aliases":["ParaT"]}},{"id":"f1734b14299249a19a8db0acc3df71eb","type":"GENE","name":"PTN","canonical_id":"hgnc:HGNC:9630","description":null,"metadata":null},{"id":"b8a83faaf8bf45dea51cb4d9e88ecbdb","type":"GENE","name":"PTOV1","canonical_id":"hgnc:HGNC:9632","description":"PTOV1 extended AT-hook containing adaptor protein","metadata":null},{"id":"e6a3e874b55e4667a42441d45a839b09","type":"GENE","name":"PTOV1-AS1","canonical_id":"hgnc:HGNC:44174","description":"PTOV1 antisense RNA 1","metadata":null},{"id":"c70e569114784be0a8144c523c423b3e","type":"GENE","name":"PTOV1-AS2","canonical_id":"hgnc:HGNC:51284","description":"PTOV1 antisense RNA 2","metadata":null},{"id":"9b58b72c44274355beba5a806e39af8a","type":"GENE","name":"PTOV1P1","canonical_id":"hgnc:HGNC:56490","description":"PTOV1 pseudogene 1","metadata":null},{"id":"22554d1dd51d4b4b8b7c7cba1b2c3554","type":"GENE","name":"PTP4A1","canonical_id":"hgnc:HGNC:9634","description":null,"metadata":null},{"id":"ad0fe45ae4ed453d90b4919e5f869a45","type":"GENE","name":"PTP4A1P1","canonical_id":"hgnc:HGNC:41928","description":"PTP4A1 pseudogene 1","metadata":null},{"id":"0715fa57a4514aa19c2e1e75f81ce0b6","type":"GENE","name":"PTP4A1P2","canonical_id":"hgnc:HGNC:41929","description":"PTP4A1 pseudogene 2","metadata":null},{"id":"b4a7ecf7436a44c298b23d66cabe76ce","type":"GENE","name":"PTP4A1P3","canonical_id":"hgnc:HGNC:41930","description":"PTP4A1 pseudogene 3","metadata":null},{"id":"b39b4622d7c542d7a8e11808b80531be","type":"GENE","name":"PTP4A1P4","canonical_id":"hgnc:HGNC:41931","description":"PTP4A1 pseudogene 4","metadata":null},{"id":"07acb1a68c6f40bea88d88ce0679f5f7","type":"GENE","name":"PTP4A1P5","canonical_id":"hgnc:HGNC:41932","description":"PTP4A1 pseudogene 5","metadata":null},{"id":"1533c9771e684d499e31ef73185a1713","type":"GENE","name":"PTP4A1P6","canonical_id":"hgnc:HGNC:41933","description":"PTP4A1 pseudogene 6","metadata":null},{"id":"868ca4589e5f47abbdcd67c1b84db67a","type":"GENE","name":"PTP4A1P7","canonical_id":"hgnc:HGNC:41934","description":"PTP4A1 pseudogene 7","metadata":null},{"id":"72e0ad2c9fe44dcf89e0d39c09d06ec9","type":"GENE","name":"PTP4A2","canonical_id":"hgnc:HGNC:9635","description":"protein tyrosine phosphatase 4A2","metadata":{"aliases":["HU-PP-1","PTPCAAX2","OV-1","ptp-IV1a","PRL-2","PRL2","PTP4A"]}},{"id":"0f72d1f12b704f04b5d970c06389c2ef","type":"GENE","name":"PTP4A2P1","canonical_id":"hgnc:HGNC:9637","description":"PTP4A2 pseudogene 1","metadata":{"aliases":["h-PRL-1","PTP4AP1"]}},{"id":"cfe6c14954f6436b877c7e3469c49561","type":"GENE","name":"PTP4A2P2","canonical_id":"hgnc:HGNC:9638","description":"PTP4A2 pseudogene 2","metadata":{"aliases":["PTP4AP2"]}},{"id":"8623b7f9f54647428936fd78a3b3c777","type":"GENE","name":"PTP4A3","canonical_id":"hgnc:HGNC:9636","description":"protein tyrosine phosphatase 4A3","metadata":{"aliases":["PRL-3","PRL-R","PRL3"]}},{"id":"2cffee8ad4bd41be92a7ff7700a7760f","type":"GENE","name":"PTPA","canonical_id":"hgnc:HGNC:9308","description":null,"metadata":null},{"id":"ff180f6ef63e43378a907f5de31e9c48","type":"GENE","name":"PTPDC1","canonical_id":"hgnc:HGNC:30184","description":"protein tyrosine phosphatase domain containing 1","metadata":{"aliases":["PTP9Q22","FLJ37312"]}},{"id":"d8df07727d904a48b37355ec722c8682","type":"GENE","name":"PTPMT1","canonical_id":"hgnc:HGNC:26965","description":"protein tyrosine phosphatase mitochondrial 1","metadata":{"aliases":["PLIP","DUSP23","MOSP"]}},{"id":"5d75aa00bed0423d97d0fd0eed4ffc46","type":"GENE","name":"PTPN1","canonical_id":"hgnc:HGNC:9642","description":null,"metadata":null},{"id":"3b704b805c4f47dcb321d9509f307943","type":"GENE","name":"PTPN11","canonical_id":"hgnc:HGNC:9644","description":"protein tyrosine phosphatase non-receptor type 11","metadata":{"aliases":["BPTP3","SH-PTP2","SHP-2","PTP2C","SHP2","NS1"]}},{"id":"a941f2a9b6c943f8aa476679fcaded81","type":"GENE","name":"PTPN11BP","canonical_id":"hgnc:HGNC:58112","description":"protein tyrosine phosphatase non-receptor type 11B, pseudogene","metadata":null},{"id":"41995696073340a18754842a8ec1e359","type":"GENE","name":"PTPN11P1","canonical_id":"hgnc:HGNC:56465","description":"PTPN11 pseudogene 1","metadata":null},{"id":"a1edb003bd9c487f9cfdfb26e4d7871e","type":"GENE","name":"PTPN11P2","canonical_id":"hgnc:HGNC:56466","description":"PTPN11 pseudogene 2","metadata":null},{"id":"d96ba745a8e744a78fdb54d833ca246c","type":"GENE","name":"PTPN11P3","canonical_id":"hgnc:HGNC:56467","description":"PTPN11 pseudogene 3","metadata":null},{"id":"e3e40fa9723646d78e89d907eff33ade","type":"GENE","name":"PTPN11P4","canonical_id":"hgnc:HGNC:56468","description":"PTPN11 pseudogene 4","metadata":null},{"id":"23f3f1c7c8e24e4ab3ae92802914d3d0","type":"GENE","name":"PTPN11P5","canonical_id":"hgnc:HGNC:56469","description":"PTPN11 pseudogene 5","metadata":null},{"id":"3e25f8ffc49c42ac9b06ba5e264781fe","type":"GENE","name":"PTPN12","canonical_id":"hgnc:HGNC:9645","description":"protein tyrosine phosphatase non-receptor type 12","metadata":{"aliases":["PTPG1","PTP-PEST"]}},{"id":"2e01213bb0234c9fbe74bdeba25a84c3","type":"GENE","name":"PTPN13","canonical_id":"hgnc:HGNC:9646","description":null,"metadata":null},{"id":"e38f45c4cf3d49dab0b41e8b706e5b2d","type":"GENE","name":"PTPN14","canonical_id":"hgnc:HGNC:9647","description":"protein tyrosine phosphatase non-receptor type 14","metadata":{"aliases":["PEZ","PTPD2"]}},{"id":"966b434be7234a21b7c3d3ae94f9a63e","type":"GENE","name":"PTPN18","canonical_id":"hgnc:HGNC:9649","description":"protein tyrosine phosphatase non-receptor type 18","metadata":{"aliases":["BDP1"]}},{"id":"b292d33953a24050b67aa443d66f9387","type":"GENE","name":"PTPN2","canonical_id":"hgnc:HGNC:9650","description":"protein tyrosine phosphatase non-receptor type 2","metadata":{"aliases":["TCELLPTP","TC-PTP","TCPTP","TC45","TC48","PTPT"]}},{"id":"ad64d61959cc466a937364b1e7613090","type":"GENE","name":"PTPN20","canonical_id":"hgnc:HGNC:23423","description":"protein tyrosine phosphatase non-receptor type 20","metadata":{"aliases":["bA42B19.1","DKFZP566K0524","bA142I17.1","CT126","PTPN20A","PTPN20B"]}},{"id":"d3f983aaf46443f7888dcdd05844bfe1","type":"GENE","name":"PTPN20CP","canonical_id":"hgnc:HGNC:23424","description":"protein tyrosine phosphatase non-receptor type 20C, pseudogene","metadata":{"aliases":["bA164N7.3","PTPN20C"]}},{"id":"b96645e15884407c83a94941b95b3256","type":"GENE","name":"PTPN21","canonical_id":"hgnc:HGNC:9651","description":"protein tyrosine phosphatase non-receptor type 21","metadata":{"aliases":["PTPD1","PTPRL10"]}},{"id":"79da154ed65c4ac69a289a8c672182f2","type":"GENE","name":"PTPN22","canonical_id":"hgnc:HGNC:9652","description":"protein tyrosine phosphatase non-receptor type 22","metadata":{"aliases":["Lyp","Lyp1","Lyp2","PTPN8"]}},{"id":"902324af3e4f40e1b03dd2e5482bb5c5","type":"GENE","name":"PTPN23","canonical_id":"hgnc:HGNC:14406","description":"protein tyrosine phosphatase non-receptor type 23","metadata":{"aliases":["DKFZP564F0923","KIAA1471","HD-PTP"]}},{"id":"0c23fa6673634741963ab1a48fca1a33","type":"GENE","name":"PTPN23-DT","canonical_id":"hgnc:HGNC:55397","description":"PTPN23 divergent transcript","metadata":null},{"id":"e9b11181b7a14742877715cbc408ca4f","type":"GENE","name":"PTPN2P1","canonical_id":"hgnc:HGNC:9653","description":"PTPN2 pseudogene 1","metadata":{"aliases":["PTPN2P","PTPTP1"]}},{"id":"d5498d5b4a3d4c2eba4e13971a0d4ae7","type":"GENE","name":"PTPN2P2","canonical_id":"hgnc:HGNC:9654","description":"PTPN2 pseudogene 2","metadata":null},{"id":"eb12a15b07c845f1b56fe0b106ffb2bc","type":"GENE","name":"PTPN3","canonical_id":"hgnc:HGNC:9655","description":"protein tyrosine phosphatase non-receptor type 3","metadata":{"aliases":["PTPH1"]}},{"id":"6cce5bdd65e7433aa63fdec30db81d20","type":"GENE","name":"PTPN4","canonical_id":"hgnc:HGNC:9656","description":"protein tyrosine phosphatase non-receptor type 4","metadata":{"aliases":["PTPMEG"]}},{"id":"cd110a6fa45c43cc8c1f67c320d7a687","type":"GENE","name":"PTPN5","canonical_id":"hgnc:HGNC:9657","description":"protein tyrosine phosphatase non-receptor type 5","metadata":{"aliases":["STEP","PTPSTEP","STEP61"]}},{"id":"50842c9a15ab42039bb19faeaaac1a56","type":"GENE","name":"PTPN6","canonical_id":"hgnc:HGNC:9658","description":null,"metadata":null},{"id":"4be912aadc094e1fac6644ed14521434","type":"GENE","name":"PTPN7","canonical_id":"hgnc:HGNC:9659","description":"protein tyrosine phosphatase non-receptor type 7","metadata":{"aliases":["HEPTP","LC-PTP"]}},{"id":"45868db2b66c4fb484fc484c27c5756a","type":"GENE","name":"PTPN9","canonical_id":"hgnc:HGNC:9661","description":"protein tyrosine phosphatase non-receptor type 9","metadata":{"aliases":["MEG2"]}},{"id":"5d58d3ee6d2a4930b9d4d6d1605b19fe","type":"GENE","name":"PTPRA","canonical_id":"hgnc:HGNC:9664","description":"protein tyrosine phosphatase receptor type A","metadata":{"aliases":["LRP","HLPR","HPTPA","RPTPA","PTPRL2","PTPA"]}},{"id":"c5b0c72e125348488f8adc08dcd4337d","type":"GENE","name":"PTPRB","canonical_id":"hgnc:HGNC:9665","description":"protein tyrosine phosphatase receptor type B","metadata":{"aliases":["PTPB"]}},{"id":"2c1b9436507f4d27ba43e2432f9dd762","type":"GENE","name":"PTPRB-AS1","canonical_id":"hgnc:HGNC:58150","description":"PTPRB antisense RNA 1","metadata":{"aliases":["SNX20AR"]}},{"id":"5f03e4e2616a4cc9888f1013e488607f","type":"GENE","name":"PTPRC","canonical_id":"hgnc:HGNC:9666","description":null,"metadata":null},{"id":"28eff3d9fb1f43218a96cd8279dcb3a9","type":"GENE","name":"PTPRC-AS1","canonical_id":"hgnc:HGNC:40483","description":"PTPRC antisense RNA 1","metadata":null},{"id":"61692dbd166848cd828e8dc61a0d6c2d","type":"GENE","name":"PTPRCAP","canonical_id":"hgnc:HGNC:9667","description":"protein tyrosine phosphatase receptor type C associated protein","metadata":{"aliases":["LPAP","CD45-AP"]}},{"id":"db4cbcd8807444728f0c8f24563ead69","type":"GENE","name":"PTPRD","canonical_id":"hgnc:HGNC:9668","description":"protein tyrosine phosphatase receptor type D","metadata":{"aliases":["PTPD","HPTP"]}},{"id":"cb1bc572221c4f098899690973e83d1a","type":"GENE","name":"PTPRD-AS1","canonical_id":"hgnc:HGNC:49753","description":"PTPRD antisense RNA 1","metadata":null},{"id":"09a9adde13fc4d5f973ef81fb09bb772","type":"GENE","name":"PTPRD-DT","canonical_id":"hgnc:HGNC:49754","description":"PTPRD divergent transcript","metadata":{"aliases":["PTPRD-AS2"]}},{"id":"f902c71945264d9795e030f923af089f","type":"GENE","name":"PTPRE","canonical_id":"hgnc:HGNC:9669","description":"protein tyrosine phosphatase receptor type E","metadata":{"aliases":["PTPE"]}},{"id":"c3d27092b6b44de984de935473549242","type":"GENE","name":"PTPRE-AS1","canonical_id":"hgnc:HGNC:58380","description":"PTPRE antisense RNA 1","metadata":null},{"id":"9c151d8c63ac492fbf90c1caf219f444","type":"GENE","name":"PTPRF","canonical_id":"hgnc:HGNC:9670","description":"protein tyrosine phosphatase receptor type F","metadata":{"aliases":["LAR"]}},{"id":"0c0d9ae535564756ad74a6668a92f0d3","type":"GENE","name":"PTPRG","canonical_id":"hgnc:HGNC:9671","description":null,"metadata":null},{"id":"d8a0d97fda9d42aa9007462091ac30a6","type":"GENE","name":"PTPRG-AS1","canonical_id":"hgnc:HGNC:44638","description":"PTPRG antisense RNA 1","metadata":null},{"id":"3056e090896d40938f6328e5acf56ea2","type":"GENE","name":"PTPRH","canonical_id":"hgnc:HGNC:9672","description":"protein tyrosine phosphatase receptor type H","metadata":{"aliases":["SAP-1"]}},{"id":"eedd3d07ac8d4ada859c1510561eab0c","type":"GENE","name":"PTPRJ","canonical_id":"hgnc:HGNC:9673","description":"protein tyrosine phosphatase receptor type J","metadata":{"aliases":["DEP1","HPTPeta","CD148"]}},{"id":"28c20eecd5ab418e9491ae0d168e5689","type":"GENE","name":"PTPRJ-AS1","canonical_id":"hgnc:HGNC:50634","description":"PTPRJ antisense RNA 1","metadata":null},{"id":"b07cb043bab149feb0cb8d9446423d9c","type":"GENE","name":"PTPRK","canonical_id":"hgnc:HGNC:9674","description":"protein tyrosine phosphatase receptor type K","metadata":{"aliases":["R-PTP-kappa"]}},{"id":"98e650df218c45c9be41b72006daf0a0","type":"GENE","name":"PTPRK-AS1","canonical_id":"hgnc:HGNC:40484","description":"PTPRK antisense RNA 1","metadata":null},{"id":"6dabbc7befa14bfaa451086cd11c0d8a","type":"GENE","name":"PTPRM","canonical_id":"hgnc:HGNC:9675","description":"protein tyrosine phosphatase receptor type M","metadata":{"aliases":["RPTPU","hR-PTPu","PTPRL1"]}},{"id":"a211bf7caa3c401693bc0b8f8db6abb2","type":"GENE","name":"PTPRN","canonical_id":"hgnc:HGNC:9676","description":"protein tyrosine phosphatase receptor type N","metadata":{"aliases":["IA-2","ICA512"]}},{"id":"d372338c3d824816b535ab7dda3e3317","type":"GENE","name":"PTPRN2","canonical_id":"hgnc:HGNC:9677","description":"protein tyrosine phosphatase receptor type N2","metadata":{"aliases":["KIAA0387","phogrin","ICAAR","IA-2beta"]}},{"id":"812f3fd8ca11430ea1abf4c9cd9dbfbf","type":"GENE","name":"PTPRN2-AS1","canonical_id":"hgnc:HGNC:40488","description":"PTPRN2 antisense RNA 1","metadata":null},{"id":"62095b571a1f464988ca4da919683aaf","type":"GENE","name":"PTPRN2-AS2","canonical_id":"hgnc:HGNC:40489","description":"PTPRN2 antisense RNA 2","metadata":null},{"id":"2b1b21530ca84b41a1b7bf7146a0c895","type":"GENE","name":"PTPRN2-AS3","canonical_id":"hgnc:HGNC:40490","description":"PTPRN2 antisense RNA 3","metadata":null},{"id":"afc92debb55d4406a86a9a4318f9d43f","type":"GENE","name":"PTPRO","canonical_id":"hgnc:HGNC:9678","description":null,"metadata":null},{"id":"3cc52ee6899d4ec5a69c189e33f16326","type":"GENE","name":"PTPRQ","canonical_id":"hgnc:HGNC:9679","description":"protein tyrosine phosphatase receptor type Q","metadata":{"aliases":["DFNB84"]}},{"id":"1c6750c745884ed09136da1483f626b6","type":"GENE","name":"PTPRR","canonical_id":"hgnc:HGNC:9680","description":"protein tyrosine phosphatase receptor type R","metadata":{"aliases":["PTPBR7","PTP-SL","EC-PTP","PCPTP1","PTPRQ"]}},{"id":"868cafe4fcdc4aea902a8e693f5ff9f1","type":"GENE","name":"PTPRR-AS1","canonical_id":"hgnc:HGNC:59227","description":"PTPRR antisense RNA 1","metadata":null},{"id":"6091e3c9f6bb4db8bb720555c24d1118","type":"GENE","name":"PTPRS","canonical_id":"hgnc:HGNC:9681","description":"protein tyrosine phosphatase receptor type S","metadata":{"aliases":["PTPsigma","PTP-sigma"]}},{"id":"99453eddeaac4de7a81a6bc2656fa9fa","type":"GENE","name":"PTPRS-AS1","canonical_id":"hgnc:HGNC:56210","description":"PTPRS antisense RNA 1","metadata":{"aliases":["CTC-482H14.5"]}},{"id":"3608b14390ce4e2d89642c35734691a4","type":"GENE","name":"PTPRT","canonical_id":"hgnc:HGNC:9682","description":"protein tyrosine phosphatase receptor type T","metadata":{"aliases":["RPTPrho","KIAA0283"]}},{"id":"bf491d84ecc74a8d850ed7026520c68c","type":"GENE","name":"PTPRT-AS1","canonical_id":"hgnc:HGNC:40491","description":"PTPRT antisense RNA 1","metadata":null},{"id":"5c3e3cc0ae734f4885ac6d0fe10317fd","type":"GENE","name":"PTPRT-DT","canonical_id":"hgnc:HGNC:55715","description":"PTPRT divergent transcript","metadata":{"aliases":["lnc-SRSF6-1"]}},{"id":"ef6e8acc310b4502b3e079a3ba7e7763","type":"GENE","name":"PTPRU","canonical_id":"hgnc:HGNC:9683","description":"protein tyrosine phosphatase receptor type U","metadata":{"aliases":["PTPRO","hPTP-J","PCP-2","FMI","PTP"]}},{"id":"44bef4d66bcc4dffbb840595a70dafe9","type":"GENE","name":"PTPRVP","canonical_id":"hgnc:HGNC:13421","description":"protein tyrosine phosphatase receptor type V, pseudogene","metadata":{"aliases":["OST-PTP","ESP","PTPRV"]}},{"id":"3261eded3b514538b34ab2bb82a19034","type":"GENE","name":"PTPRZ1","canonical_id":"hgnc:HGNC:9685","description":null,"metadata":null},{"id":"0047e385f78a44398c1e931f0371db66","type":"GENE","name":"PTPRZ2","canonical_id":"hgnc:HGNC:9686","description":"protein tyrosine phosphatase receptor type Z2","metadata":{"aliases":["HTPZP2","PTPRZ"]}},{"id":"552fc50316e140138c6d123bb2a4b9ba","type":"GENE","name":"PTRH1","canonical_id":"hgnc:HGNC:27039","description":"peptidyl-tRNA hydrolase 1 homolog","metadata":{"aliases":["PTH1","C9orf115"]}},{"id":"f99cb18f31d64330be6a65d46847611e","type":"GENE","name":"PTRH2","canonical_id":"hgnc:HGNC:24265","description":"peptidyl-tRNA hydrolase 2","metadata":{"aliases":["BIT1","CGI-147","PTH2","CFAP37"]}},{"id":"03db1cd6fce94c2da23790cf645a52d4","type":"GENE","name":"PTRHD1","canonical_id":"hgnc:HGNC:33782","description":"peptidyl-tRNA hydrolase domain containing 1","metadata":{"aliases":["LOC391356","C2orf79"]}},{"id":"f895d337effc437faa43fa00bff1c970","type":"GENE","name":"PTS","canonical_id":"hgnc:HGNC:9689","description":"6-pyruvoyltetrahydropterin synthase","metadata":{"aliases":["PTPS"]}},{"id":"be02b780f29c48bfa4928da76cb091fc","type":"GENE","name":"PTTG1","canonical_id":"hgnc:HGNC:9690","description":null,"metadata":null},{"id":"81ef71031b7b463b9efde7e8ad76d280","type":"GENE","name":"PTTG1IP","canonical_id":"hgnc:HGNC:13524","description":null,"metadata":null},{"id":"ccaf25b1cf824dc3bba418f97f0992fd","type":"GENE","name":"PTTG1IP2","canonical_id":"hgnc:HGNC:55318","description":"PTTG1IP family member 2","metadata":null},{"id":"d9b739b23fa14ba38becf10817ec8845","type":"GENE","name":"PTTG1P1","canonical_id":"hgnc:HGNC:20055","description":"PTTG1 pseudogene 1","metadata":{"aliases":["PTTG4P"]}},{"id":"d3c6a4a984a045f281c14e1aefe35198","type":"GENE","name":"PTTG1P2","canonical_id":"hgnc:HGNC:56817","description":"PTTG1 pseudogene 2","metadata":null},{"id":"efd62b72e5014b3dbcc75f71cd0703be","type":"GENE","name":"PTTG2","canonical_id":"hgnc:HGNC:9691","description":"pituitary tumor-transforming 2","metadata":null},{"id":"ddb4def8d2b9487d91b2126b7da139c9","type":"GENE","name":"PTTG3P","canonical_id":"hgnc:HGNC:13422","description":"pituitary tumor-transforming 3, pseudogene","metadata":{"aliases":["PTTG1P3","PTTG3"]}},{"id":"37b9d65dbcff4fd59984b4287ac9fa75","type":"GO_TERM","name":"PTW/PP1 phosphatase complex","canonical_id":"go:GO:0072357","description":"\"A protein serine/threonine phosphatase complex that contains a catalytic subunit (PPP1CA, PPP1CB or PPP1CC) and the regulatory subunits PPP1R10 (PNUTS), TOX4 and WDR82, and plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase.\" [GOC:mah, PMID:20516061]","metadata":null},{"id":"240a7bf4ef3446ffbf604afdc23c707b","type":"GENE","name":"PTX3","canonical_id":"hgnc:HGNC:9692","description":"pentraxin 3","metadata":{"aliases":["TSG-14","TNFAIP5"]}},{"id":"685cefca14d147d4a838094a5b926c20","type":"GENE","name":"PTX4","canonical_id":"hgnc:HGNC:14171","description":"pentraxin 4","metadata":{"aliases":["C16orf38"]}},{"id":"cc8202464ad842b39d3b6cd3d8cb46a4","type":"GENE","name":"PUDP","canonical_id":"hgnc:HGNC:16818","description":"pseudouridine 5'-phosphatase","metadata":{"aliases":["DXF68S1E","GS1","FAM16AX","HDHD1A","HDHD1"]}},{"id":"06a2c930ff0c495b95c08113ebf87c93","type":"GENE","name":"PUDPP1","canonical_id":"hgnc:HGNC:20200","description":"pseudouridine 5'-phosphatase pseudogene 1","metadata":{"aliases":["FAM16AY","HDHD1BP","HDHD1P1"]}},{"id":"8af4f0dd5c224b049048b2b7607c7900","type":"GENE","name":"PUDPP2","canonical_id":"hgnc:HGNC:20195","description":"pseudouridine 5'-phosphatase pseudogene 2","metadata":{"aliases":["FAM16B","HDHD1CP","HDHD1P2"]}},{"id":"816b9c5f79644bef8b934eac52f98397","type":"GENE","name":"PUDPP3","canonical_id":"hgnc:HGNC:38118","description":"pseudouridine 5'-phosphatase pseudogene 3","metadata":{"aliases":["HDHD1DP","HDHD1P3"]}},{"id":"c17b92bbb83b4a0e9b08f74773827d1c","type":"GENE","name":"PUF60","canonical_id":"hgnc:HGNC:17042","description":"poly(U) binding splicing factor 60","metadata":{"aliases":["FIR","SIAHBP1","RoBPI"]}},{"id":"b2fe5e18d18a43a6a414281ca1cde4ef","type":"GENE","name":"PUM1","canonical_id":"hgnc:HGNC:14957","description":"pumilio RNA binding family member 1","metadata":{"aliases":["PUMH1","KIAA0099"]}},{"id":"9d1ac8a1ebe846b5a929ca7129bef334","type":"GENE","name":"PUM2","canonical_id":"hgnc:HGNC:14958","description":"pumilio RNA binding family member 2","metadata":{"aliases":["PUMH2","KIAA0235"]}},{"id":"71d7e0a69afb469eb6278b213094444a","type":"GENE","name":"PUM3","canonical_id":"hgnc:HGNC:29676","description":"pumilio RNA binding family member 3","metadata":{"aliases":["XTP5","PEN","PUF6","hPUF-A","HA-8","Puf-A","KIAA0020"]}},{"id":"d6b42d6ea66f49c493dc664f1890add5","type":"GO_TERM","name":"PUMA-BCL-2 complex","canonical_id":"go:GO:0097142","description":"\"A heterodimeric protein complex consisting of PUMA and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"ea48706d69be4c929db36f758e669e9e","type":"GO_TERM","name":"PUMA-BCL-xl complex","canonical_id":"go:GO:0097143","description":"\"A heterodimeric protein complex consisting of PUMA and BCL-xl, members of the Bcl-2 family of anti- and proapoptotic regulators.\" [GOC:so, PMID:14634621]","metadata":null},{"id":"472d79da1b0e49b095f810f3948431a3","type":"GENE","name":"PURA","canonical_id":"hgnc:HGNC:9701","description":null,"metadata":null},{"id":"98b22407eafd4988a12f073cf6578d1a","type":"GENE","name":"PURB","canonical_id":"hgnc:HGNC:9702","description":"purine rich element binding protein B","metadata":{"aliases":["PURBETA"]}},{"id":"13e981185dd34d8b9cb0751b091a642f","type":"GENE","name":"PURG","canonical_id":"hgnc:HGNC:17930","description":"purine rich element binding protein G","metadata":{"aliases":["PURG-A","PURG-B"]}},{"id":"f358b5af428d4abf8037b7bc46610905","type":"GENE","name":"PURPL","canonical_id":"hgnc:HGNC:48995","description":"p53 upregulated regulator of p53 levels","metadata":{"aliases":["LOC643401","RP11-46C20.1","LINC01021"]}},{"id":"fed7d7fa8870438bbc900a22b30a56b8","type":"GENE","name":"PUS1","canonical_id":"hgnc:HGNC:15508","description":"pseudouridine synthase 1","metadata":{"aliases":["MLASA1"]}},{"id":"5c82d41eddf84ade8618d86c7b21c9d4","type":"GENE","name":"PUS1-AS1","canonical_id":"hgnc:HGNC:40706","description":"PUS1 antisense RNA 1","metadata":{"aliases":["AC131009.1"]}},{"id":"2f51e2b9bb9441b5af0ca4d45167d728","type":"GENE","name":"PUS10","canonical_id":"hgnc:HGNC:26505","description":"pseudouridine synthase 10","metadata":{"aliases":["FLJ32312","CCDC139"]}},{"id":"786752af53f14fd283ccf013b8e29b56","type":"GENE","name":"PUS3","canonical_id":"hgnc:HGNC:25461","description":"pseudouridine synthase 3","metadata":{"aliases":["FKSG32","DEG1"]}},{"id":"72edb177733d40c0af3b3c85b64b657c","type":"GENE","name":"PUS7","canonical_id":"hgnc:HGNC:26033","description":"pseudouridine synthase 7","metadata":{"aliases":["FLJ20485"]}},{"id":"0840c0c105f34da0be1bf620608f6b17","type":"GENE","name":"PUS7L","canonical_id":"hgnc:HGNC:25276","description":"pseudouridine synthase 7 like","metadata":{"aliases":["DKFZP434G1415"]}},{"id":"c238c78173da424b85b2767da4a3963d","type":"GENE","name":"PUS7P1","canonical_id":"hgnc:HGNC:49779","description":"pseudouridylate synthase 7 pseudogene 1","metadata":null},{"id":"9f8603e7bfbb4b2984dd9ab6ae35a817","type":"GENE","name":"PUSL1","canonical_id":"hgnc:HGNC:26914","description":"pseudouridine synthase like 1","metadata":{"aliases":["FLJ90811"]}},{"id":"5a3a884ae6a24271bfb5878baba9898b","type":"GENE","name":"PVALB","canonical_id":"hgnc:HGNC:9704","description":"parvalbumin","metadata":{"aliases":["D22S749"]}},{"id":"858cb1208c1b4532bc5c5418a561d1a7","type":"GENE","name":"PVALEF","canonical_id":"hgnc:HGNC:40053","description":"parvalbumin like EF-hand containing","metadata":{"aliases":["AATK-AS1"]}},{"id":"ea4cea6d7e4e4eabbb43730f74cc8a7f","type":"GENE","name":"PVR","canonical_id":"hgnc:HGNC:9705","description":null,"metadata":null},{"id":"5c9d938d81034a96b9da181dfd7f3c06","type":"GENE","name":"PVRIG","canonical_id":"hgnc:HGNC:32190","description":"PVR related immunoglobulin domain containing","metadata":{"aliases":["MGC2463","C7orf15","CD112R"]}},{"id":"80af2f7b02844d1aadba9b56f3ceae59","type":"GENE","name":"PVRIG2P","canonical_id":"hgnc:HGNC:48897","description":"PVR related immunoglobulin domain containing 2, pseudogene","metadata":null},{"id":"8f28511d5f1f41bc9c375dcbb1f02a3a","type":"GENE","name":"PVT1","canonical_id":"hgnc:HGNC:9709","description":"Pvt1 oncogene","metadata":{"aliases":["FFX","HNB","NCRNA00079","LINC00079","onco-lncRNA-100","MIR1204HG","TP53LC09"]}},{"id":"a224b1be342149dfa72ce3fa6013ceb7","type":"GENE","name":"PWAR1","canonical_id":"hgnc:HGNC:30089","description":"Prader Willi/Angelman region RNA 1","metadata":{"aliases":["PAR1","PAR-1"]}},{"id":"2c8c4b6407074bcabfffb5b193c645b0","type":"GENE","name":"PWAR4","canonical_id":"hgnc:HGNC:29998","description":"Prader Willi/Angelman region RNA 4","metadata":{"aliases":["PAR4","PAR-4"]}},{"id":"c4a28cb1c82b401485988f62b26ade7e","type":"GENE","name":"PWAR5","canonical_id":"hgnc:HGNC:30090","description":"Prader Willi/Angelman region RNA 5","metadata":{"aliases":["PAR5","PAR-5"]}},{"id":"3be6e11e7e3041b3823eefbe0aa2cc1a","type":"GENE","name":"PWAR6","canonical_id":"hgnc:HGNC:49129","description":"Prader Willi/Angelman region RNA 6","metadata":{"aliases":["HBT8","PAR-6"]}},{"id":"92086dee2b8e4ce389162c391e3d4b93","type":"GENE","name":"PWARSN","canonical_id":"hgnc:HGNC:30001","description":"Prader Willi/Angelman region RNA, SNRPN neighbor","metadata":{"aliases":["PAR-SN","PARSN"]}},{"id":"f45c056d90274fd8ae752c16cfecf4fa","type":"GENE","name":"PWP1","canonical_id":"hgnc:HGNC:17015","description":"PWP1 homolog, endonuclein","metadata":{"aliases":["IEF-SSP-9502"]}},{"id":"a511976062824adcbe7cfad817f86476","type":"GENE","name":"PWP2","canonical_id":"hgnc:HGNC:9711","description":"PWP2 small subunit processome component","metadata":{"aliases":["EHOC-17","UTP1","PWP2H"]}},{"id":"76b6628974ef486397139b3f19558b3c","type":"GENE","name":"PWRN1","canonical_id":"hgnc:HGNC:33235","description":"Prader-Willi region non-protein coding RNA 1","metadata":{"aliases":["NCRNA00198","LOHAN1"]}},{"id":"8386e392c9764611a637e99e5344d28e","type":"GENE","name":"PWRN2","canonical_id":"hgnc:HGNC:33236","description":"Prader-Willi region non-protein coding RNA 2","metadata":{"aliases":["NCRNA00199"]}},{"id":"726429fee5d2465db886763f96ad981d","type":"GENE","name":"PWRN3","canonical_id":"hgnc:HGNC:49131","description":"Prader-Willi region non-protein coding RNA 3","metadata":null},{"id":"fc8348195f6e423ba4820a92ed598668","type":"GENE","name":"PWRN4","canonical_id":"hgnc:HGNC:49130","description":"Prader-Willi region non-protein coding RNA 4","metadata":{"aliases":["LINC01084"]}},{"id":"30097c7e88484fd889e7279882774328","type":"GENE","name":"PWWP2A","canonical_id":"hgnc:HGNC:29406","description":"PWWP domain containing 2A","metadata":{"aliases":["KIAA1935"]}},{"id":"ec9047514e064b069e72ced860f787b6","type":"GENE","name":"PWWP2AP1","canonical_id":"hgnc:HGNC:39709","description":"PWWP domain containing 2A pseudogene 1","metadata":null},{"id":"c6be7109bde549b6bb817e2c2b2ae273","type":"GENE","name":"PWWP2B","canonical_id":"hgnc:HGNC:25150","description":"PWWP domain containing 2B","metadata":{"aliases":["bA432J24.1","FLJ46823","PWWP2"]}},{"id":"f098722861b04be79687c0ff4fcaf234","type":"GENE","name":"PWWP3A","canonical_id":"hgnc:HGNC:29641","description":"PWWP domain containing 3A, DNA repair factor","metadata":{"aliases":["MUM-1","EXPAND1","MUM1"]}},{"id":"19620e7ca7554d2a87b085acfc94946a","type":"GENE","name":"PWWP3B","canonical_id":"hgnc:HGNC:26583","description":"PWWP domain containing 3B","metadata":{"aliases":["FLJ33516","MUM1L1"]}},{"id":"24f375b02272436cac11cdc68a1170a9","type":"GENE","name":"PWWP4","canonical_id":"hgnc:HGNC:55197","description":"PWWP domain containing 4","metadata":null},{"id":"35cb0c24aea54d3abbe7615a6e12982b","type":"GENE","name":"PXDC1","canonical_id":"hgnc:HGNC:21361","description":"PX domain containing 1","metadata":{"aliases":["C6orf145"]}},{"id":"d2eed3b18ecd4432bd47123051449c3f","type":"GENE","name":"PXDC1-AS1","canonical_id":"hgnc:HGNC:59337","description":"PXDC1 antisense RNA 1","metadata":null},{"id":"ae4e9c4f624f48918ee75a856b976d3e","type":"GENE","name":"PXDN","canonical_id":"hgnc:HGNC:14966","description":"peroxidasin","metadata":{"aliases":["KIAA0230","PRG2","MG50","D2S448","D2S448E","PXN"]}},{"id":"ca9c94b4f3824e2b82833ff61f038e4c","type":"GENE","name":"PXDNL","canonical_id":"hgnc:HGNC:26359","description":"peroxidasin like","metadata":{"aliases":["FLJ25471","PMR1"]}},{"id":"b643516c2b074558995eef554ae44b09","type":"GENE","name":"PXK","canonical_id":"hgnc:HGNC:23326","description":"PX domain containing serine/threonine kinase like","metadata":{"aliases":["FLJ20335","Slob"]}},{"id":"ffb18a3678dd4770b527d6239fec17ee","type":"GENE","name":"PXMP2","canonical_id":"hgnc:HGNC:9716","description":"peroxisomal membrane protein 2","metadata":{"aliases":["PMP22","MPV17L3"]}},{"id":"c3d5c00223324936acb62b6db3cf82f9","type":"GENE","name":"PXMP4","canonical_id":"hgnc:HGNC:15920","description":"peroxisomal membrane protein 4","metadata":{"aliases":["PMP24"]}},{"id":"1ed1befaaa914a5aa12e2f9dd0a6568e","type":"GENE","name":"PXN","canonical_id":"hgnc:HGNC:9718","description":"paxillin","metadata":null},{"id":"4dff3b5f056b4aefb5b023308adb1337","type":"GENE","name":"PXN-AS1","canonical_id":"hgnc:HGNC:44123","description":"PXN antisense RNA 1","metadata":{"aliases":["EyeLinc4"]}},{"id":"ac78969a70ae4cedbd8472a3a3dfbae2","type":"GENE","name":"PXT1","canonical_id":"hgnc:HGNC:18312","description":"peroxisomal testis enriched protein 1","metadata":{"aliases":["STEPP"]}},{"id":"225a93eaa990424eb4065619507de509","type":"GENE","name":"PXYLP1","canonical_id":"hgnc:HGNC:26303","description":"2-phosphoxylose phosphatase 1","metadata":{"aliases":["FLJ23751","ACPL2"]}},{"id":"b537906f880e40bdbc79e04865b158a2","type":"GENE","name":"PYCARD","canonical_id":"hgnc:HGNC:16608","description":"PYD and CARD domain containing","metadata":{"aliases":["TMS-1","CARD5","ASC"]}},{"id":"70beabfdc3e34982ba570476dc4c7ccd","type":"GENE","name":"PYCARD-AS1","canonical_id":"hgnc:HGNC:45036","description":"PYCARD antisense RNA 1","metadata":{"aliases":["C16orf98","PYCARDOS"]}},{"id":"4b9c11792c124eb092e497b55d35b401","type":"GENE","name":"PYCR1","canonical_id":"hgnc:HGNC:9721","description":"pyrroline-5-carboxylate reductase 1","metadata":{"aliases":["P5C"]}},{"id":"75a74dfd54a44f42936f5821aea2c848","type":"GENE","name":"PYCR1-AS1","canonical_id":"hgnc:HGNC:56889","description":"PYCR1 antisense RNA 1","metadata":{"aliases":["RP11-498C9.13"]}},{"id":"282688953a754610883892920dc95108","type":"GENE","name":"PYCR2","canonical_id":"hgnc:HGNC:30262","description":"pyrroline-5-carboxylate reductase 2","metadata":{"aliases":["P5CR2"]}},{"id":"14ac4587352546e2987dcbc3a4e625fb","type":"GENE","name":"PYCR3","canonical_id":"hgnc:HGNC:25846","description":"pyrroline-5-carboxylate reductase 3","metadata":{"aliases":["FLJ13852","PYCRL"]}},{"id":"e6f2e094a060483897790f3e1ae0575b","type":"GENE","name":"PYDC1","canonical_id":"hgnc:HGNC:30261","description":"pyrin domain containing 1","metadata":{"aliases":["ASC2","POP1"]}},{"id":"81eebed67d244bcfb5c64b1cc93bd6f4","type":"GENE","name":"PYDC2","canonical_id":"hgnc:HGNC:33512","description":"pyrin domain containing 2","metadata":{"aliases":["POP2"]}},{"id":"bf791e4e12bb43808d3e5bbb10d7263a","type":"GENE","name":"PYDC2-AS1","canonical_id":"hgnc:HGNC:52874","description":"PYDC2 antisense RNA 1","metadata":{"aliases":["LINCR-0002","RP11-197K6.1"]}},{"id":"e3210833d2e14ed58092eaf6e9a06b54","type":"GENE","name":"PYDC5","canonical_id":"hgnc:HGNC:53781","description":"pyrin domain containing 5","metadata":{"aliases":["POP3"]}},{"id":"04c02219fbc347e38d59f7c02e321e29","type":"GENE","name":"PYGB","canonical_id":"hgnc:HGNC:9723","description":"glycogen phosphorylase B","metadata":null},{"id":"40327922b40e4c5391bcf00424b54ac3","type":"GENE","name":"PYGL","canonical_id":"hgnc:HGNC:9725","description":"glycogen phosphorylase L","metadata":{"aliases":["GSD6"]}},{"id":"024ec58cc569470289fc5ec3ea2984af","type":"GENE","name":"PYGM","canonical_id":"hgnc:HGNC:9726","description":"glycogen phosphorylase, muscle associated","metadata":{"aliases":["GSD5"]}},{"id":"8a384a32482049c8948bf3e5246f58f1","type":"GENE","name":"PYGO1","canonical_id":"hgnc:HGNC:30256","description":"pygopus family PHD finger 1","metadata":null},{"id":"35722de163b74effb4b2854335512f65","type":"GENE","name":"PYGO2","canonical_id":"hgnc:HGNC:30257","description":"pygopus family PHD finger 2","metadata":null},{"id":"cbb7c9bb4f3e4c68965974dc5fbe7602","type":"GENE","name":"PYGO2-AS1","canonical_id":"hgnc:HGNC:55250","description":"PYGO2 and SHC1 antisense RNA 1","metadata":{"aliases":["AL451085.2"]}},{"id":"f74e0efbc3da4aa69993c90a9271cb64","type":"GENE","name":"PYHIN1","canonical_id":"hgnc:HGNC:28894","description":"pyrin and HIN domain family member 1","metadata":{"aliases":["IFIX","MGC23885"]}},{"id":"ad64ba45a28641b9aa7c967acd31553c","type":"GENE","name":"PYHIN5P","canonical_id":"hgnc:HGNC:51820","description":"pyrin and HIN domain family member 5, pseudogene","metadata":null},{"id":"48e714d640cc49cabcf9a7740b7a09f6","type":"GO_TERM","name":"PYM-mago-Y14 complex","canonical_id":"go:GO:1990509","description":"\"Protein complex involved in the disassembly of Mago-Y14 from the spliced mRNA during first round of translation, independently of the translational machinery. Conserved from fission yeast to humans.\" [GOC:bhm, PMID:14968132]","metadata":null},{"id":"eaae919cc6914e109dfb9969ebde87ba","type":"GENE","name":"PYM1","canonical_id":"hgnc:HGNC:30258","description":"PYM1 exon junction complex associated factor","metadata":{"aliases":["PYM","WIBG"]}},{"id":"2ea9cc01a5b14e248747c5f1749ebeff","type":"GENE","name":"PYROXD1","canonical_id":"hgnc:HGNC:26162","description":"pyridine nucleotide-disulphide oxidoreductase domain 1","metadata":{"aliases":["DKFZp762G094","FLJ22028"]}},{"id":"506b0b9f27ab41f0b17e3860b870a5f4","type":"GENE","name":"PYROXD2","canonical_id":"hgnc:HGNC:23517","description":"pyridine nucleotide-disulphide oxidoreductase domain 2","metadata":{"aliases":["FLJ23849","C10orf33"]}},{"id":"4dc8c1eadc0444a0a8352609a9fd82b9","type":"GENE","name":"PYURF","canonical_id":"hgnc:HGNC:44317","description":"PIGY upstream open reading frame","metadata":{"aliases":["PreY"]}},{"id":"4f36c7dc9d3e4d2180683d475a2a923e","type":"GENE","name":"PYY","canonical_id":"hgnc:HGNC:9748","description":"peptide YY","metadata":{"aliases":["PYY1"]}},{"id":"afd79ddfe24c4989b518487c6ac3d00a","type":"GENE","name":"PYY2","canonical_id":"hgnc:HGNC:9749","description":"peptide YY 2 (pseudogene)","metadata":null},{"id":"35b7c4635dc64fadb0e2e30a7b1c2461","type":"GENE","name":"PYY3","canonical_id":"hgnc:HGNC:31855","description":"peptide YY 3 (pseudogene)","metadata":{"aliases":["OTTHUMG00000021515"]}},{"id":"7ff381bd0a434d78a11198af72380f28","type":"GENE","name":"PZP","canonical_id":"hgnc:HGNC:9750","description":"PZP alpha-2-macroglobulin like","metadata":{"aliases":["CPAMD6"]}},{"id":"bb6f81c597414047a66bc1ddd1b429ec","type":"GENE","name":"PZP2P","canonical_id":"hgnc:HGNC:56245","description":"PZP alpha-2-macroglobulin like 2, pseudogene","metadata":{"aliases":["A2MP1"]}},{"id":"989d44625a6d4bdaa282e3ef29c06c7d","type":"DRUG","name":"Paclitaxel","canonical_id":"ncit:C1411","description":null,"metadata":null},{"id":"e2fff24c22d6410baf577ce0b6b04df2","type":"TRIAL","name":"Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT02072317","description":"Advanced Gastric Cancer","metadata":null},{"id":"73da3fa16c554647b9c70f755b68ae28","type":"TRIAL","name":"Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic","canonical_id":"clinicaltrials.gov:NCT00003440","description":"HER2-negative Breast Cancer; HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"1e5b279a5a5e4dce84cba0ecdaea6a0f","type":"TRIAL","name":"Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery","canonical_id":"clinicaltrials.gov:NCT00004887","description":"Lung Cancer","metadata":null},{"id":"dbf178acbb1c49ce874ca85e16620081","type":"TRIAL","name":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00770809","description":"Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7","metadata":null},{"id":"968b3cc6199a4daf8168f40daf2f2534","type":"TRIAL","name":"Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT00023907","description":"Ovarian Cancer; Primary Peritoneal Cavity Cancer","metadata":null},{"id":"b4a3110897aa4977be8e43a2d210ab44","type":"TRIAL","name":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00785291","description":"Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7","metadata":null},{"id":"e4a0feee3dfc430695101e28ec25b62b","type":"TRIAL","name":"Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07763171","description":"Gastroesophageal Adenocarcinoma","metadata":null},{"id":"4aada0c2546e423785f395e981caeb85","type":"TRIAL","name":"Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)","canonical_id":"clinicaltrials.gov:NCT02410551","description":"Myeloproliferative Diseases","metadata":null},{"id":"11f0b49ce9294bb69424122b6266c4df","type":"TRIAL","name":"Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML","canonical_id":"clinicaltrials.gov:NCT02532010","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"32369136687a4fe684b47ad7470b0a84","type":"TRIAL","name":"Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT07394153","description":"Myelofibrosis\uff0cMF","metadata":null},{"id":"32183c08531e4de2bc2c653cd50710f4","type":"TRIAL","name":"Pacritinib Versus Best Available Therapy to Treat Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT01773187","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"83a34261584e4dd288e202dfbaae1cc7","type":"TRIAL","name":"Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT02055781","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"70c28978404a4817b016d98716a3dc17","type":"TRIAL","name":"Pacritinib With Aza for Upfront Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT07387354","description":"Myelodysplastic Syndromes; MDS; Myelodysplastic Syndrome, Unclassifiable; Hematologic Diseases; Bone Marrow Disease; Myeloproliferative Neoplasm","metadata":null},{"id":"1dfd9368218e4b92a085aeb3a700807f","type":"TRIAL","name":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT07148947","description":"Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm","metadata":null},{"id":"28c561832b3d44fc9e9d9b68cf863075","type":"TRIAL","name":"Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations","canonical_id":"clinicaltrials.gov:NCT02323607","description":"Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia","metadata":null},{"id":"02c7a1014b2c42f4ab28639c146a5175","type":"TRIAL","name":"Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04635059","description":"Prostate Cancer","metadata":null},{"id":"5074651d5a4f4eba94b212568e5a5aa8","type":"TRIAL","name":"Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)","canonical_id":"clinicaltrials.gov:NCT02469415","description":"Leukemia","metadata":null},{"id":"b97a962d9c7f4149b593e2169f3b0a79","type":"TRIAL","name":"Pacritinib in CMML","canonical_id":"clinicaltrials.gov:NCT06159491","description":"Chronic Myelomonocytic Leukemia","metadata":null},{"id":"2f339ae902bb4ade8786e56736ac0874","type":"TRIAL","name":"Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT02564536","description":"Chronic Myelomonocytic Leukemia; Juvenile Myelomonocytic Leukemia; Atypical Chronic Myeloid Leukemia; Myeloproliferative Neoplasm; Myelodysplastic Syndromes; Myelofibrosis","metadata":null},{"id":"8ff69ea6a6ec4ab5ab60179fd4352958","type":"TRIAL","name":"Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06675123","description":"Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma","metadata":null},{"id":"3c942cb6c0414d96b1750b554bacc671","type":"TRIAL","name":"Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors","canonical_id":"clinicaltrials.gov:NCT07226713","description":"Prostate Cancer","metadata":null},{"id":"3f90d090a0014494a2194d68014a7dc2","type":"TRIAL","name":"Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)","canonical_id":"clinicaltrials.gov:NCT02342353","description":"Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"56288a94943a4d5187d658afbfddb798","type":"TRIAL","name":"Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders","canonical_id":"clinicaltrials.gov:NCT03601819","description":"Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Chronic Lymphocytic Leukemia; Lymphoproliferative Disorders; Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma","metadata":null},{"id":"493a53bbf55240209b1786349ca33ffe","type":"TRIAL","name":"Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT04858256","description":"T-Cell Neoplasm; Lymphoproliferative Disorders","metadata":null},{"id":"67ef89dfe539413587c74f64a21cc560","type":"TRIAL","name":"Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome","canonical_id":"clinicaltrials.gov:NCT06538181","description":"E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome; VEXAS; Vexas Syndrome","metadata":null},{"id":"5fbb1f82317f44b6bc27ddc6c828c1eb","type":"TRIAL","name":"Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02277093","description":"Colorectal Cancer","metadata":null},{"id":"c266a123780f43bcaea62a8cbb72c2f0","type":"TRIAL","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT07033598","description":"Leukemia, Myelomonocytic, Chronic","metadata":null},{"id":"de415c052bd94daaa15e267edab22c33","type":"TRIAL","name":"Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition","canonical_id":"clinicaltrials.gov:NCT06218628","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Chronic Myelomonocytic Leukemia; Polycythemia Vera; Essential Thrombocytosis","metadata":null},{"id":"ced8c05e472b4dc5a95cbd8e179ca1b4","type":"TRIAL","name":"Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT06303193","description":"Myelodysplastic Syndromes","metadata":null},{"id":"96cee2622c06485bb6aee3c54973d19d","type":"TRIAL","name":"Paediatric Arteriopathy Steroid Aspirin Project","canonical_id":"clinicaltrials.gov:NCT03249844","description":"Arterial Ischemic Stroke","metadata":null},{"id":"37316efaddfd4d7caf92a48304e55579","type":"TRIAL","name":"Paediatric Hepatic International Tumour Trial","canonical_id":"clinicaltrials.gov:NCT03017326","description":"Hepatoblastoma; Carcinoma, Hepatocellular","metadata":null},{"id":"1c0bcc5a8cdc455b885434447ff98fe9","type":"DISEASE","name":"Paget disease","canonical_id":"mondo:0021165","description":null,"metadata":null},{"id":"547b49af3c744dcb909ef7b880772468","type":"DISEASE","name":"Pain","canonical_id":"hp:0012531","description":null,"metadata":null},{"id":"9b6d6c54c41a4e9a8479ecc2c35c61ea","type":"DISEASE","name":"Pain","canonical_id":"mesh:D010146","description":null,"metadata":null},{"id":"de17c0783d4644f9b924ef623099c7f4","type":"TRIAL","name":"Pain Associated With Endometriosis","canonical_id":"clinicaltrials.gov:NCT00758953","description":"Endometriosis","metadata":null},{"id":"f5d1127925614a82a181f90c0cc4fbd7","type":"TRIAL","name":"Pain Control After Lumbar Spine Fusion","canonical_id":"clinicaltrials.gov:NCT06484192","description":"Spine Fusion; NSAID (Non-Steroidal Anti-Inflammatory Drug); Postoperative Pain","metadata":null},{"id":"3cfbeb5a48ef4ef4a07001a965aaeef4","type":"TRIAL","name":"Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries","canonical_id":"clinicaltrials.gov:NCT04523623","description":"Forearm Injuries; Pain, Acute; Pediatric ALL","metadata":null},{"id":"d068c6d7799e4211b1a26cb19c0c57d7","type":"TRIAL","name":"Pain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery","canonical_id":"clinicaltrials.gov:NCT06810336","description":"Brain Injury; Brain Tumors; Craniotomy Surgery; Pain; Postoperative; Postoperative Care","metadata":null},{"id":"0d06a0bfc6c046d4b4b269681cbec1a6","type":"TRIAL","name":"Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin","canonical_id":"clinicaltrials.gov:NCT02612233","description":"Hand Osteoarthritis","metadata":null},{"id":"43eb173865cb439cbe72fbe50470d73c","type":"TRIAL","name":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","canonical_id":"clinicaltrials.gov:NCT06130384","description":"Pain; Intravitreal Injection; Pain, Acute","metadata":null},{"id":"a8a1e9f4190a4e519725bdd081515e03","type":"TRIAL","name":"Pain Relieving Potentials of Combination of Oral Duloxetine and Intravenous Magnesium Sulphate in Post Mastectomy Pain","canonical_id":"clinicaltrials.gov:NCT06087211","description":"Duloxetine; Magnesium Sulphate; Post-mastectomy Pain Syndrome","metadata":null},{"id":"95b0d4040bca4a7e8b945976888aea0f","type":"TRIAL","name":"Pain Therapy After Elective Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01490268","description":"Pain","metadata":null},{"id":"2f145c46b8b54078936d049bf03c84e5","type":"TRIAL","name":"Pain Thresholds Under High-dose Topical Capsaicin","canonical_id":"clinicaltrials.gov:NCT02570841","description":"Pain","metadata":null},{"id":"4e2b4533980144768c2d095949868104","type":"TRIAL","name":"Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine","canonical_id":"clinicaltrials.gov:NCT00270322","description":"Pain, Postoperative; Osteoarthritis","metadata":null},{"id":"9cc909b516214508a02a8838f3494b93","type":"TRIAL","name":"Pain Treatment for Sciatica","canonical_id":"clinicaltrials.gov:NCT00009672","description":"Radiculopathy; Sciatica","metadata":null},{"id":"40d0815af30c413cbff46de7fbff2031","type":"TRIAL","name":"Pain in Parkinson's Disease With Motor Fluctuations.","canonical_id":"clinicaltrials.gov:NCT03648671","description":"Parkinson Disease","metadata":null},{"id":"8a161dd061794e3ca775c815f3fccf9d","type":"DISEASE","name":"Pain, Postoperative","canonical_id":"mesh:D010149","description":null,"metadata":null},{"id":"ee393e9c83a74cccb5ab59b7cf3969bf","type":"TRIAL","name":"Palatability (Taste) of Oral Formulations of Bosutinib","canonical_id":"clinicaltrials.gov:NCT03747679","description":"CML","metadata":null},{"id":"d9a038e651054f9bbef91cef8e2ce30b","type":"DRUG","name":"Palbociclib","canonical_id":"ncit:C49176","description":null,"metadata":null},{"id":"ce66b5557fc14ed3a398a1765a4fe471","type":"TRIAL","name":"Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction","canonical_id":"clinicaltrials.gov:NCT05865132","description":"Esophagus Squamous Cell Carcinoma","metadata":null},{"id":"33c34325aef842f58e0c9c84b1673751","type":"TRIAL","name":"Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate","canonical_id":"clinicaltrials.gov:NCT02600923","description":"Advanced Breast Cancer Female","metadata":null},{"id":"e7128d1b54ab4e75a9d60a9022982ee7","type":"TRIAL","name":"Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04494958","description":"Triple Negative Breast Cancer","metadata":null},{"id":"d5a6b3131f9c4d0b94324b56d95fcaa0","type":"TRIAL","name":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","canonical_id":"clinicaltrials.gov:NCT05554367","description":"Exocrine Pancreas Carcinoma; Malignant Solid Neoplasm; Ovarian Low Grade Serous Adenocarcinoma; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8","metadata":null},{"id":"15ab956882ad4276ae510381c20f94ef","type":"TRIAL","name":"Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)","canonical_id":"clinicaltrials.gov:NCT02605486","description":"Metastatic Breast Cancer (MBC)","metadata":null},{"id":"69767a559a264d21964699ab50e4acbd","type":"TRIAL","name":"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03900884","description":"Breast Neoplasm Female","metadata":null},{"id":"ae0774860cf04a7abcd0f7a18a71b52d","type":"TRIAL","name":"Palifermin After Haploidentical PBSCT","canonical_id":"clinicaltrials.gov:NCT00570999","description":"Non-Hodgkin's Lymphoma or Hodgkin's Disease; Acute Leukaemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia; Osteomyelofibrosis","metadata":null},{"id":"9d2b52eac7ee4deebd59ced94cb62e12","type":"TRIAL","name":"Palifermin DDI (Drug Drug Interaction)","canonical_id":"clinicaltrials.gov:NCT00361348","description":"Healthy Volunteers","metadata":null},{"id":"06490835b4f84b51bf0bd35f2d94056b","type":"TRIAL","name":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT01746849","description":"Leukemia; Multiple Myeloma; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma","metadata":null},{"id":"4438a349c3894f21b54019a77cd6a39d","type":"TRIAL","name":"Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT02313792","description":"Mucositis","metadata":null},{"id":"e2a8f3fac76842dea8e5718a89fc439a","type":"TRIAL","name":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00101582","description":"Mucositis; Solid Tumors; Stomatitis; Head and Neck Cancer; Squamous Cell Carcinoma","metadata":null},{"id":"c551c9579e154d96961ad30f22872477","type":"TRIAL","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","canonical_id":"clinicaltrials.gov:NCT00109031","description":"Cancer; Lymphoma; Leukemia","metadata":null},{"id":"6953d38505a44782b0eb8ab3d6d63fba","type":"TRIAL","name":"Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00360971","description":"Head and Neck Cancer; Mucositis; Pain; Radiation Toxicity","metadata":null},{"id":"6783231a85cd4789bb3a4161bc650ba9","type":"TRIAL","name":"Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer","canonical_id":"clinicaltrials.gov:NCT01233921","description":"Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 N\u2026","metadata":null},{"id":"4ebbd374fc6b4420ad9a971386820060","type":"TRIAL","name":"Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT00728585","description":"Gastrointestinal Mucositis; Malignant Neoplasm","metadata":null},{"id":"42f8abe1ac0b444db3ca5c5ac6dc7ca2","type":"DRUG","name":"Paliperidone Palmitate","canonical_id":"mesh:D000068882","description":null,"metadata":null},{"id":"7ad87175600d405ab0d920317ef9516f","type":"TRIAL","name":"Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00002893","description":"Colorectal Cancer","metadata":null},{"id":"0dcf63ace5154969a6dcf52491278989","type":"DISEASE","name":"Palmoplantar hyperkeratosis","canonical_id":"hp:0000972","description":null,"metadata":null},{"id":"d368ba587e3b4b27a3294a1374b62df8","type":"DISEASE","name":"Palmoplantar keratoderma","canonical_id":"hp:0000982","description":null,"metadata":null},{"id":"8d9bf9978bb147e2bbaceb701ea3b6b7","type":"TRIAL","name":"Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer","canonical_id":"clinicaltrials.gov:NCT00903396","description":"Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Primary Peritoneal Cavity Cancer; Small Intestine Cancer","metadata":null},{"id":"c971fd838b1e40ab962b8507b5f00222","type":"TRIAL","name":"Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP","canonical_id":"clinicaltrials.gov:NCT04576390","description":"Antiemetic; Postoperative Nausea and Vomiting","metadata":null},{"id":"7d2ffd4ff0214aecb61d8415fbbcffb4","type":"TRIAL","name":"Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT01476280","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"b494744f66134c2ca40e10feaadb48f1","type":"TRIAL","name":"Palonosetron and Blood Coagulation","canonical_id":"clinicaltrials.gov:NCT04507711","description":"Blood Coagulation Disorder","metadata":null},{"id":"9618052203d64283b815c5bf4b091080","type":"TRIAL","name":"Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00684463","description":"Neoplasms; Nausea; Vomiting","metadata":null},{"id":"1df4a450506f4ae18effb9518a660a3b","type":"TRIAL","name":"Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)","canonical_id":"clinicaltrials.gov:NCT00410488","description":"Sarcoma; Nausea; Vomiting","metadata":null},{"id":"34aaae9b1c4b4d2188819cb708729a36","type":"DRUG","name":"Pamidronic acid","canonical_id":"mesh:C019248","description":null,"metadata":null},{"id":"922c5dfd48f44ef396a4816420a65a69","type":"TRIAL","name":"Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)","canonical_id":"clinicaltrials.gov:NCT01154829","description":"Schizophrenia","metadata":null},{"id":"048892fa827c4c62b5489b3afec23e9c","type":"TRIAL","name":"Pan Tumor Rollover Study","canonical_id":"clinicaltrials.gov:NCT03899155","description":"Cancer","metadata":null},{"id":"bd767851a33349b1a45b0b92f184edb8","type":"DRUG","name":"Pan-RAF Inhibitor LY3009120","canonical_id":"ncit:C116861","description":null,"metadata":null},{"id":"35fc86a02f9342abbe9c5102db5b7b89","type":"TISSUE","name":"Pancreas","canonical_id":"uberon:UBERON:0001150","description":null,"metadata":null},{"id":"b132f9df8dbf44baa35f62bd1d20de31","type":"DISEASE","name":"Pancreatic Adenocarcinoma","canonical_id":"doid:4074","description":null,"metadata":null},{"id":"4271d5217d4241a2bfe8adf6e13d645b","type":"DISEASE","name":"Pancreatic Cancer","canonical_id":"doid:1793","description":null,"metadata":null},{"id":"15f50fa28cae46fd98b7fd2b1a6125c5","type":"DISEASE","name":"Pancreatic Carcinoma","canonical_id":"doid:4905","description":null,"metadata":null},{"id":"aca010a0e5a34742bcaa8ed8beff69d9","type":"DISEASE","name":"Pancreatic Ductal Adenocarcinoma","canonical_id":"doid:3498","description":null,"metadata":null},{"id":"3e8048a1fdb64498bd776bc3b35f5ab7","type":"DISEASE","name":"Pancreatic Ductal Carcinoma","canonical_id":"doid:3587","description":null,"metadata":null},{"id":"b51dfbeabbed43d6a4758e783d507cc0","type":"TRIAL","name":"Pancreatic Perfusion Using Secretin and MRI","canonical_id":"clinicaltrials.gov:NCT02458118","description":"Chronic Pancreatitis","metadata":null},{"id":"6a0721b8010f40379c99375f95ee8dfb","type":"PROTEIN","name":"Pancreatic alpha-amylase","canonical_id":"uniprot:P04746","description":null,"metadata":null},{"id":"b1372e8c339f4273b1332f6f088d0df7","type":"DISEASE","name":"Panic disorder","canonical_id":"mesh:D016584","description":null,"metadata":null},{"id":"7e3474f360b44dedad745a4836b49d1b","type":"DRUG","name":"Panitumumab","canonical_id":"ncit:C1857","description":null,"metadata":null},{"id":"3bf1fdbcc5a2418bab80e5c8fca6309e","type":"TRIAL","name":"Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)","canonical_id":"clinicaltrials.gov:NCT00788957","description":"Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Colorectal Cancer; Rectal Cancer","metadata":null},{"id":"5dace9aa688b4d7386e8c72cb6e8a715","type":"TRIAL","name":"Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT01389414","description":"Biliary Carcinoma","metadata":null},{"id":"96d85c72e2c64e81babbe67689ad32d9","type":"TRIAL","name":"Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01088620","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"cd32937eb649476ebdd0746d0bf7dcd1","type":"TRIAL","name":"Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01504477","description":"Colorectal Cancer","metadata":null},{"id":"22ea73d5ffd848539d60703cee96a9fb","type":"TRIAL","name":"Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00601627","description":"Pancreatic Cancer","metadata":null},{"id":"80f351cb230b4ef087a09c97a771d6fb","type":"DRUG","name":"Panobinostat","canonical_id":"mesh:C496932","description":null,"metadata":null},{"id":"ad2a92c99c2c4728bbae3612cce8dd00","type":"TRIAL","name":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma","canonical_id":"clinicaltrials.gov:NCT02961816","description":"Lymphoma","metadata":null},{"id":"b5590036aba24b39a15d63fa06deb958","type":"TRIAL","name":"Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00918333","description":"Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adul\u2026","metadata":null},{"id":"86f30b9be6e04998abb2e0e6b32f6505","type":"TRIAL","name":"Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis","canonical_id":"clinicaltrials.gov:NCT01433445","description":"Idiopathic Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia-Vera Myelofibrosis","metadata":null},{"id":"4ea34370a1804be5ad5413149110ff99","type":"DRUG","name":"Pantoprazole","canonical_id":"mesh:C064276","description":null,"metadata":null},{"id":"fadeb9ead306498d9611201598fb77e5","type":"DRUG","name":"Papaverine","canonical_id":"mesh:D010208","description":null,"metadata":null},{"id":"3bbfa0e5612a4f979d68fa802f39fe31","type":"DISEASE","name":"Papillary Thyroid Carcinoma","canonical_id":"doid:3969","description":null,"metadata":null},{"id":"044ed31e9e3e4131b058f1595851af59","type":"DISEASE","name":"Papillon-Lefevre disease","canonical_id":"mondo:0009490","description":null,"metadata":null},{"id":"50fcb94022854e89bdd37890e4653870","type":"GO_TERM","name":"Par3-APC-KIF3A complex","canonical_id":"go:GO:0034748","description":"\"A protein complex that contains Par3, the tumor suppressor protein adenomatous polyposis coli (APC), and the kinesin-related protein KIF3A; involved in establishing neuronal cell polarity.\" [PMID:15556865]","metadata":null},{"id":"3bf861eb04f34946aa27996be3fb6278","type":"TRIAL","name":"Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement","canonical_id":"clinicaltrials.gov:NCT07487246","description":"Pain Management; Abortion; Second Trimester Abortion; Dilation and Evacuation","metadata":null},{"id":"7988c5bf9cdd4fada62e1d606008cecf","type":"TRIAL","name":"Paracervical Injection for Headache in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT04109885","description":"Headache Disorders, Primary; Pain Management; Emergency Department","metadata":null},{"id":"e928cb289a3c4ea98462aba2c91953c6","type":"TRIAL","name":"Paracetamol Effect on Prostaglandins and Blood Pressure","canonical_id":"clinicaltrials.gov:NCT06235320","description":"Pain","metadata":null},{"id":"1752b836c6624906a19617df9a546eba","type":"TRIAL","name":"Paracetamol and Ibuprofen With or Without Famotidine for Calcific Tendinitis of the Shoulder","canonical_id":"clinicaltrials.gov:NCT07539961","description":"Calcific Tendinitis","metadata":null},{"id":"de6b6856a27848209c451d01d9ee2806","type":"DISEASE","name":"Paracoccidioidomycosis","canonical_id":"mesh:D010229","description":null,"metadata":null},{"id":"dd7502d2c892453a93b1ef727937ab17","type":"DRUG","name":"Paramethadione","canonical_id":"mesh:C005731","description":null,"metadata":null},{"id":"a39aadf56c284d029250a2dec2d76d82","type":"TRIAL","name":"Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT05374564","description":"Cardiomyopathies, Primary","metadata":null},{"id":"70a1307085204e6e8cc75d305591f68f","type":"TRIAL","name":"Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis","canonical_id":"clinicaltrials.gov:NCT05926570","description":"Drug Effect","metadata":null},{"id":"92bbdbc33d3f477d8fd885df8b318461","type":"TRIAL","name":"Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT01178450","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"f8f9c11cdff745ca93a76974e8a0f11c","type":"DISEASE","name":"Paratyphoid fever","canonical_id":"mesh:D010284","description":null,"metadata":null},{"id":"22a8e50ba91342388c59efbdd53045a3","type":"TRIAL","name":"Paravertebral Calcitonin in Thoracotomy","canonical_id":"clinicaltrials.gov:NCT06330168","description":"Calcitonin; Paravertebral; Thoracotomy","metadata":null},{"id":"7dea8cfff74347d195367828879969bb","type":"TRIAL","name":"Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery","canonical_id":"clinicaltrials.gov:NCT00770705","description":"Congenital Heart Disease","metadata":null},{"id":"01a7657adc734d2581fe03c1f485b58b","type":"TRIAL","name":"Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04054362","description":"Pancreatic Cancer","metadata":null},{"id":"c79fc7ff625943a99f80caca96ecf33c","type":"TRIAL","name":"Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT00990704","description":"Secondary Hyperparathyroidism; Hemodialysis","metadata":null},{"id":"e1b266d6313f41fa976508a3926ef096","type":"TRIAL","name":"Paricalcitol Improves Anemia of Inflammation","canonical_id":"clinicaltrials.gov:NCT02876211","description":"Anemia","metadata":null},{"id":"f5ac9db6f934440484a1249e759c97bc","type":"TRIAL","name":"Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients","canonical_id":"clinicaltrials.gov:NCT01820767","description":"Chronic Kidney Disease","metadata":null},{"id":"422b186428e64f3e886ceccb978fb76d","type":"TRIAL","name":"Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)","canonical_id":"clinicaltrials.gov:NCT00823303","description":"Secondary Hyperparathyroidism; Chronic Kidney Disease","metadata":null},{"id":"167e12728ad44efc962a9e32fdcdfd50","type":"TRIAL","name":"Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00637897","description":"Breast Cancer","metadata":null},{"id":"80699cc662294e4bb090c3056084b674","type":"TRIAL","name":"Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders","canonical_id":"clinicaltrials.gov:NCT00258258","description":"Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"5d272bf2ecde44a3814cddfbdc6d377a","type":"TRIAL","name":"Paricalcitol in Fabry Disease","canonical_id":"clinicaltrials.gov:NCT02090608","description":"Fabry Disease; Proteinuria","metadata":null},{"id":"8cfcf2f9922447eca2d4575a7d586647","type":"TRIAL","name":"Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases","canonical_id":"clinicaltrials.gov:NCT00634582","description":"Metastatic Cancer; Prostate Cancer","metadata":null},{"id":"2b47805c49b24088a43bb576d291a906","type":"TRIAL","name":"Paricalcitol in Treating Patients With Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT00064376","description":"Leukemia; Myelodysplastic Syndromes","metadata":null},{"id":"a0d059758c584f959bcfd281b7e1afd1","type":"TRIAL","name":"Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery","canonical_id":"clinicaltrials.gov:NCT01197664","description":"Mucinous Adenocarcinoma of the Rectum; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer","metadata":null},{"id":"716f9c5779a94dbf967a6eb92d0328b3","type":"DRUG","name":"Paritaprevir","canonical_id":"mesh:C585405","description":null,"metadata":null},{"id":"9d7ed90e8aad498d81c90b47d39f02e6","type":"GO_TERM","name":"Parkin-FBXW7-Cul1 ubiquitin ligase complex","canonical_id":"go:GO:1990452","description":"\"A ubiquitin ligase complex containing Parkin (PARK2), the F-box protein FBXW7 (also called SEL-10) and a cullin from the Cul1 subfamily; substrate specificity is conferred by the F-box protein.\" [GOC:bf, GOC:PARL, PMID:12628165]","metadata":null},{"id":"558c71d696cf4693b07428480b64c07d","type":"DISEASE","name":"Parkinson disease","canonical_id":"mondo:0005180","description":null,"metadata":null},{"id":"2496f476034e47cd80cc36d2522ab8eb","type":"TRIAL","name":"Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole","canonical_id":"clinicaltrials.gov:NCT00460148","description":"Parkinson Disease","metadata":null},{"id":"babf4617db2b477d83cc2e0bd7768459","type":"DISEASE","name":"Parkinson's disease","canonical_id":"mesh:D010300","description":null,"metadata":null},{"id":"2517dfb06c6248179f3fe3895633d058","type":"DISEASE","name":"Parkinsonian Disorders","canonical_id":"mesh:D020734","description":null,"metadata":null},{"id":"2b7975ad62224e4ca45d71f09e61379d","type":"TRIAL","name":"Parkinsonian Patients Treated With Apomorphine Pump: Observatory of Skin Lesions","canonical_id":"clinicaltrials.gov:NCT05331573","description":"Patients With Parkinson's Disease Treated With Apomorphine Pumps","metadata":null},{"id":"5c4e9c5ca4fc48259774cd27f193068f","type":"DRUG","name":"Paromomycin","canonical_id":"mesh:D010303","description":null,"metadata":null},{"id":"4c1a17b95bb84a208a37ac3999022316","type":"DISEASE","name":"Paronychia","canonical_id":"mesh:D010304","description":null,"metadata":null},{"id":"761461c2f9f046d28604e3816265121c","type":"DRUG","name":"Paroxetine","canonical_id":"mesh:D017374","description":null,"metadata":null},{"id":"c2d89a22e9c4449c908da6462926fddd","type":"TRIAL","name":"Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00841659","description":"Healthy","metadata":null},{"id":"b62b0845e5944af48ac0832426693d15","type":"TRIAL","name":"Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression","canonical_id":"clinicaltrials.gov:NCT00429169","description":"Depression","metadata":null},{"id":"6d62ea76360242fd8cd28567417b4f4e","type":"TRIAL","name":"Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study","canonical_id":"clinicaltrials.gov:NCT00785603","description":"Depression; Pain","metadata":null},{"id":"7fa7ca752fbb4443b06235961c0d44ae","type":"DISEASE","name":"Paroxysmal nocturnal hemoglobinuria","canonical_id":"mesh:D006457","description":null,"metadata":null},{"id":"aec0555cbb22475c9156a62ffe3034eb","type":"DISEASE","name":"Paroxysmal supraventricular tachycardia","canonical_id":"hp:0004763","description":null,"metadata":null},{"id":"71659882d239421daa59c93a12bb4dc8","type":"TRIAL","name":"Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)","canonical_id":"clinicaltrials.gov:NCT01788332","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"57c9c2b8239e411ca1a7101296cf8408","type":"TRIAL","name":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04323956","description":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage II Marginal Zone Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage III Marginal Zone Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Ann Arbor Stage IV Marginal Zone Lymphoma; Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrange\u2026","metadata":null},{"id":"428216e505aa416d89648c771a1d773f","type":"TRIAL","name":"Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT03774810","description":"Insomnia; Insomnia Chronic","metadata":null},{"id":"e0bad36827de4dada082cf1b36986c26","type":"TRIAL","name":"Participant Reported Outcomes With Use of Trifarotene 50 \u03bcg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT03915860","description":"Acne Vulgaris","metadata":null},{"id":"62159fbb53294f7b96c93954515ec2f6","type":"TRIAL","name":"Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01270321","description":"Thyroid Cancer","metadata":null},{"id":"e80b9ea090894622a91826613e3e77bf","type":"TRIAL","name":"Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01313559","description":"Castrate Resistant Prostate Cancer; Chemotherapy Naive Prostate Cancer; Prostate Cancer","metadata":null},{"id":"7221b0bc085345849f6138538123096e","type":"TRIAL","name":"Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01356862","description":"Breast Cancer","metadata":null},{"id":"de7caa76723542168147ef2b0189a271","type":"TRIAL","name":"Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors","canonical_id":"clinicaltrials.gov:NCT02749227","description":"Pituitary Tumor; ACTH-producing Pituitary Tumour","metadata":null},{"id":"48b811e872c845c0a66a6bee41791d66","type":"TRIAL","name":"Pasireotide LAR and Pegvisomant Study in Acromegaly","canonical_id":"clinicaltrials.gov:NCT02668172","description":"Acromegaly","metadata":null},{"id":"c58f013542e44d928cb37b1532ca26c0","type":"TRIAL","name":"Pasireotide LAR in Severe Polycystic Liver Disease","canonical_id":"clinicaltrials.gov:NCT01670110","description":"Somatostatin Analogs; Polycystic Liver Disease; Autosomal Dominant Polycystic Kidney Disease; Autosomal Dominant Polycystic Liver Disease","metadata":null},{"id":"c1b0fad0ff6a4ec99b439718ed8b7efe","type":"TRIAL","name":"Pasireotide Treatment for Neuroendocrine Tumor","canonical_id":"clinicaltrials.gov:NCT02779257","description":"Gastro-enteropancreatic Neuroendocrine Tumor","metadata":null},{"id":"0de576a94510476f8caacf940b7ffa64","type":"TRIAL","name":"Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues","canonical_id":"clinicaltrials.gov:NCT02354508","description":"Acromegaly","metadata":null},{"id":"c268ce02a13e4c2ab632f07879c2a8e3","type":"TRIAL","name":"Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT03514576","description":"Hypoglycemia, Reactive","metadata":null},{"id":"1055b6cde6594c11b0aaab5d18f0a4ca","type":"TRIAL","name":"Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia","canonical_id":"clinicaltrials.gov:NCT05928390","description":"Post-Bariatric Hypoglycemia","metadata":null},{"id":"80f3ec7a65a14bc987206f354d41d3ed","type":"TRIAL","name":"Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis","canonical_id":"clinicaltrials.gov:NCT04826432","description":"Peritoneal Carcinomatosis","metadata":null},{"id":"ee73e21fc1524d9cb3c901d6d523eaf3","type":"TRIAL","name":"Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases","canonical_id":"clinicaltrials.gov:NCT01469572","description":"Neuroendocrine Tumors","metadata":null},{"id":"3828f23d1dea48b88b881b0cc6b091ea","type":"DISEASE","name":"Pasteurella Infections","canonical_id":"mesh:D010326","description":null,"metadata":null},{"id":"8e06a33c065b49989c186f77af0e95da","type":"DISEASE","name":"Patent ductus arteriosus","canonical_id":"hp:0001643","description":null,"metadata":null},{"id":"2e7b505297e64c0cb55bd34e8068d290","type":"DISEASE","name":"Patent ductus arteriosus","canonical_id":"mesh:D004374","description":null,"metadata":null},{"id":"7f42e3f24db54c3fa18e91a16fdaefca","type":"TRIAL","name":"Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)","canonical_id":"clinicaltrials.gov:NCT01342939","description":"Maturity-onset Diabetes of the Young","metadata":null},{"id":"ac28da24aa2a4dabb2b637966df73c11","type":"TRIAL","name":"Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations","canonical_id":"clinicaltrials.gov:NCT02260388","description":"Cryptogenic Sensory Polyneuropathy","metadata":null},{"id":"5b0a4428d20d4585867e15639b1284a6","type":"TRIAL","name":"Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres","canonical_id":"clinicaltrials.gov:NCT06455462","description":"Severe Asthma","metadata":null},{"id":"d53c193978614b289918fa836e84ad49","type":"TRIAL","name":"Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression","canonical_id":"clinicaltrials.gov:NCT00744406","description":"Depression; Major Depressive Disorder","metadata":null},{"id":"c3897705095c4757860e09a9294fe835","type":"TRIAL","name":"Patient Driven Recovery With Nalmefene and Coaching","canonical_id":"clinicaltrials.gov:NCT03279562","description":"Opioid-use Disorder; Harmful; Use, Alcohol","metadata":null},{"id":"8aa213b73481453a95d8db982e2372c1","type":"TRIAL","name":"Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH","canonical_id":"clinicaltrials.gov:NCT03888365","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"ac3d68fb129c4c26b28c8920a409b5b8","type":"TRIAL","name":"Patient Preference Comparison of AZARGA Versus COSOPT","canonical_id":"clinicaltrials.gov:NCT01340014","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"e1f950c7aeef4fd29fa65f3d5828c660","type":"TRIAL","name":"Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen","canonical_id":"clinicaltrials.gov:NCT07061379","description":"PROMs","metadata":null},{"id":"8ea0cf94ddb44694817c8dac2feed529","type":"TRIAL","name":"Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00804648","description":"Glaucoma, Open Angle; Ocular Hypertension","metadata":null},{"id":"4741f08edf2041398361d2c2d3ec3c26","type":"TRIAL","name":"Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00366002","description":"Overactive Bladder (OAB)","metadata":null},{"id":"1628f4ce52e742d49a8eee2c7b17913f","type":"TRIAL","name":"Patient's Pretreatment Expectations About Post-Lyme Symptoms","canonical_id":"clinicaltrials.gov:NCT03462329","description":"Erythema Migrans","metadata":null},{"id":"280b2b1a608343af8d2a73beb5ab7281","type":"TRIAL","name":"Patient-Reported Outcomes for Lemborexant in Chinese Participants With Insomnia","canonical_id":"clinicaltrials.gov:NCT06225947","description":"Insomnia","metadata":null},{"id":"f1c48afdfb2043be80edaa4955773186","type":"TRIAL","name":"Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT05804084","description":"Obstructive Sleep Apnea","metadata":null},{"id":"9cc9f1a32e054c76be5254e0103f7d37","type":"TRIAL","name":"Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin","canonical_id":"clinicaltrials.gov:NCT03440788","description":"Relapsed or Refractory Hodgkin's Lymphoma","metadata":null},{"id":"94869838cb0f46edbc6409b358e6b7f4","type":"TRIAL","name":"Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5","canonical_id":"clinicaltrials.gov:NCT07537400","description":"High-Risk Neuroblastoma","metadata":null},{"id":"7d0f12e58c154693a8d823fa7fd803c1","type":"TRIAL","name":"Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines","canonical_id":"clinicaltrials.gov:NCT03622931","description":"Ovarian Cancer","metadata":null},{"id":"249f701e59a846628209698379410ff9","type":"TRIAL","name":"Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas","canonical_id":"clinicaltrials.gov:NCT01078922","description":"Non-Hodgkin Lymphomas","metadata":null},{"id":"736fadba6b8d4db7b9b0e2872281e464","type":"DRUG","name":"Patiromer calcium","canonical_id":"mesh:C568789","description":null,"metadata":null},{"id":"ea7f4cc3b47f4d6fac33b2b237f74d5b","type":"DRUG","name":"Pazopanib","canonical_id":"ncit:C74547","description":null,"metadata":null},{"id":"91c64bc00c0f4d618226362fd23576e6","type":"TRIAL","name":"Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00454571","description":"Recurrent Prostate Cancer","metadata":null},{"id":"6e60c86d5e6a4314b6819906c96dfa8e","type":"TRIAL","name":"Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT01158521","description":"Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer","metadata":null},{"id":"b4d735670ce94c38ab5dcd53773b649c","type":"TRIAL","name":"Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT01446809","description":"Stage IIA Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma","metadata":null},{"id":"eef257251b0243e98344d5f2d45c0f22","type":"TRIAL","name":"Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas","canonical_id":"clinicaltrials.gov:NCT02357810","description":"Adult Liposarcoma; Metastatic Liposarcoma; Metastatic Osteosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Liposarcoma; Recurrent Osteosarcoma; Stage IV Adult Soft Tissue Sarcoma","metadata":null},{"id":"e55bbaffc2ff419e9fa51c5b25c872e2","type":"TRIAL","name":"Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma","canonical_id":"clinicaltrials.gov:NCT01462630","description":"Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma","metadata":null},{"id":"7d1bf3935542423b9dc10f4852d42bd4","type":"TRIAL","name":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","canonical_id":"clinicaltrials.gov:NCT01841736","description":"Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Neuroendocrine Tumor; Midgut Neuroendocrine Tumor G1; Neuroendocrine Tumor G2; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1","metadata":null},{"id":"e7657ea3e7d145d195da931106342447","type":"TRIAL","name":"Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT01157091","description":"Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer","metadata":null},{"id":"62fa1d2d426d40e49c603637658d77e7","type":"TRIAL","name":"Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome","canonical_id":"clinicaltrials.gov:NCT01436227","description":"Von Hippel-Lindau Syndrome","metadata":null},{"id":"2d752a95a84446a7af2c39b0bd3adcde","type":"TRIAL","name":"Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT05679921","description":"Soft Tissue Sarcoma","metadata":null},{"id":"1e0ecf473a89455fa22db0da2fa62592","type":"TRIAL","name":"Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)","canonical_id":"clinicaltrials.gov:NCT01600573","description":"Ovarian Cancer","metadata":null},{"id":"479d1a25f5c447caa278ffef11cc9cc7","type":"TRIAL","name":"Pazopanib as Single Agent in Advanced NETs","canonical_id":"clinicaltrials.gov:NCT01280201","description":"Advanced/Metastatic Neuroendocrine Tumors","metadata":null},{"id":"f11befcfd1c14bb1aa341a9849d988f0","type":"TRIAL","name":"Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","canonical_id":"clinicaltrials.gov:NCT01524848","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"dd906ed6187347c58cacef7a6da0d0a3","type":"TRIAL","name":"Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01498458","description":"Metastatic Breast Cancer","metadata":null},{"id":"d26e9959454d4ea4a74beab0ed66c73f","type":"TRIAL","name":"Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)","canonical_id":"clinicaltrials.gov:NCT01391611","description":"Gastrointestinal Stromal Tumor (GIST)","metadata":null},{"id":"236297a878504035b0a1375ba9b57c4a","type":"TRIAL","name":"Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01377298","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"86d0206301fc466e941b6a3dccf6c104","type":"TRIAL","name":"Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT00731211","description":"Renal Cell Carcinoma","metadata":null},{"id":"3eff5e0d162a4a0d9650b1723e916075","type":"TRIAL","name":"Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00450879","description":"Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer","metadata":null},{"id":"892945bd9baa40379adfd2f2005c3a4e","type":"GO_TERM","name":"PcG protein complex","canonical_id":"go:GO:0031519","description":"\"A chromatin-associated multiprotein complex containing Polycomb Group proteins. In Drosophila, Polycomb group proteins are involved in the long-term maintenance of gene repression, and PcG protein complexes associate with Polycomb group response elements (PREs) in target genes to regulate higher-order chromatin structure.\" [PMID:9372908]","metadata":null},{"id":"2684ec0f69914174aa83b51597ffc13b","type":"DISEASE","name":"Pdgfra-Associated Chronic Eosinophilic Leukemia","canonical_id":"mesh:C580364","description":null,"metadata":null},{"id":"8fac8f748456403ca2030ed3c30d5b6d","type":"GO_TERM","name":"PeBoW complex","canonical_id":"go:GO:0070545","description":"\"A protein complex that is involved in coordinating ribosome biogenesis with cell cycle progression. In human, it is composed of Pes1, Bop1, and WDR12; in Saccharomyces the proteins are known as Nop7p, Erb1 and Ytm1 respectively.\" [GOC:ab, GOC:mah, PMID:16043514, PMID:17353269]","metadata":null},{"id":"43c3e51d7fc04ae4900852573ff7d1df","type":"TRIAL","name":"PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer","canonical_id":"clinicaltrials.gov:NCT06133517","description":"Urothelial Bladder Carcinoma","metadata":null},{"id":"5548845e61b245c7b58898971a5b3d8e","type":"DISEASE","name":"Pectus excavatum","canonical_id":"hp:0000767","description":null,"metadata":null},{"id":"991c3f9376474f8a9356c312c54de3f7","type":"TRIAL","name":"Pediatric Chronic Kidney Disease Safety and Efficacy","canonical_id":"clinicaltrials.gov:NCT01277510","description":"Chronic Kidney Disease; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Disease; Secondary Hyperparathyroidism","metadata":null},{"id":"81e99ffb6cf7404e9fc10a700473cc60","type":"TRIAL","name":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","canonical_id":"clinicaltrials.gov:NCT03755804","description":"Hodgkin Lymphoma","metadata":null},{"id":"29483adf35b1422bac97fec9577d7599","type":"TRIAL","name":"Pediatric Concussion Outcomes","canonical_id":"clinicaltrials.gov:NCT04226365","description":"Concussion Post Syndrome; Headaches Posttraumatic; Mild Traumatic Brain Injury","metadata":null},{"id":"cfbc2eacc31f49ff8f76d40b47a27630","type":"TRIAL","name":"Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy","canonical_id":"clinicaltrials.gov:NCT05180825","description":"Grade 1 Glioma; Mixed Glio-neuronal Tumors; Pleomorphic Xanthoastrocytoma","metadata":null},{"id":"8f98d7da1b19401388e97c069934d77f","type":"TRIAL","name":"Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy","canonical_id":"clinicaltrials.gov:NCT01649765","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"cb5390ad21bb40a5a0e60135e53d01a7","type":"TRIAL","name":"Pediatric Oncology Nutrition Intervention Trial","canonical_id":"clinicaltrials.gov:NCT06175273","description":"Pediatric Cancer; Nutrition Related Cancer; Nutrition Aspect of Cancer; Muscle Loss; Malnutrition, Child","metadata":null},{"id":"88efa2ce158f44258b330e872c1391aa","type":"TRIAL","name":"Pediatric Patients Aged 1 to 6 Years With APDS","canonical_id":"clinicaltrials.gov:NCT05693129","description":"APDS","metadata":null},{"id":"6ea35f3e15df47099497f8866cffc971","type":"TRIAL","name":"Pediatric Patients Aged 4 to 11 Years With APDS","canonical_id":"clinicaltrials.gov:NCT05438407","description":"APDS","metadata":null},{"id":"9344962375694739ba2884a324d37354","type":"TRIAL","name":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","canonical_id":"clinicaltrials.gov:NCT02559778","description":"Neuroblastoma","metadata":null},{"id":"73555f5c86f74d57a3915839840aafd5","type":"TRIAL","name":"Pediatric Schizophrenia Efficacy and Safety Study","canonical_id":"clinicaltrials.gov:NCT01911429","description":"Schizophrenia","metadata":null},{"id":"5be0da814cfa44e78c3126cfbbeec9e8","type":"TRIAL","name":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02471144","description":"Chronic Severe Plaque-type Psoriasis","metadata":null},{"id":"5e8d20714b9c4448bdc905b9671a7585","type":"TRIAL","name":"Pediatric Teduglutide Registry","canonical_id":"clinicaltrials.gov:NCT04832087","description":"Short Bowel Syndrome","metadata":null},{"id":"fb8666cd5fd541a58b8ba29e1d28e7a0","type":"TRIAL","name":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT04845035","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"2aa899f9121b4c95a8c36d7047ba6430","type":"TRIAL","name":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","canonical_id":"clinicaltrials.gov:NCT00255008","description":"Hepatitis C, Chronic","metadata":null},{"id":"37fd96577e88414c9af3d7cb947d7ed2","type":"TRIAL","name":"Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","canonical_id":"clinicaltrials.gov:NCT00048724","description":"Chronic Hepatitis C; Cirrhosis","metadata":null},{"id":"fca4d9bd0abf4ca19604179d4ee7ca77","type":"TRIAL","name":"PegIntron Injection Surveillance Plan (Study P04123)","canonical_id":"clinicaltrials.gov:NCT00723931","description":"Hepatitis C, Chronic","metadata":null},{"id":"8117f3572ac04fef88a61c3bf5a06419","type":"DRUG","name":"Pegademase","canonical_id":"mesh:C051409","description":null,"metadata":null},{"id":"01c1982feb674bae9ba023b988f4716a","type":"TRIAL","name":"Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula","canonical_id":"clinicaltrials.gov:NCT00040313","description":"Diabetic Macular Edema","metadata":null},{"id":"310daae9d696477e8293ffaa3ebd361e","type":"TRIAL","name":"Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)","canonical_id":"clinicaltrials.gov:NCT00088283","description":"Retinal Vein Occlusion","metadata":null},{"id":"bd9e02e46f534a39a5303a0ccf809af1","type":"TRIAL","name":"Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00087763","description":"Macular Degeneration","metadata":null},{"id":"ed9761ec71fc4602ab3e32b430513c1e","type":"TRIAL","name":"Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema","canonical_id":"clinicaltrials.gov:NCT00790803","description":"Uveitis; Cystoid Macular Edema","metadata":null},{"id":"ba95a19856284912893ceb8606ff2ad4","type":"TRIAL","name":"Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study","canonical_id":"clinicaltrials.gov:NCT01486238","description":"Diabetic Macular Edema","metadata":null},{"id":"f8ac7879f73347b99f95f7c4b315c23f","type":"TRIAL","name":"Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00726700","description":"Lymphoma","metadata":null},{"id":"723d99e72e39486ea719eb3bf4dfb840","type":"TRIAL","name":"Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00035620","description":"Sarcoma; Neutropenia","metadata":null},{"id":"9e21f8edc5904fce8543d6ada3ee11d6","type":"TRIAL","name":"Peginesatide for Anemia in Chronic Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT00228449","description":"Anemia; Chronic Kidney Disease; Chronic Renal Failure","metadata":null},{"id":"61f8301771ae4b1f962d556cf4053ed4","type":"TRIAL","name":"Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00434330","description":"Anemia; Chronic Kidney Disease; Chronic Renal Failure","metadata":null},{"id":"d825075ce16f487a9bd7b5fdc8f35fec","type":"TRIAL","name":"Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT01964300","description":"Childhood Craniopharyngioma","metadata":null},{"id":"bf88406b80cd49ae8596f436668f2851","type":"TRIAL","name":"Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients","canonical_id":"clinicaltrials.gov:NCT00018031","description":"Hepatitis C; HIV Infections","metadata":null},{"id":"46a9e7b553004adb874e379deb87113c","type":"TRIAL","name":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","canonical_id":"clinicaltrials.gov:NCT05182463","description":"Hepatitis B, Chronic","metadata":null},{"id":"3825f70f171c4758b4aa4031b46170c1","type":"TRIAL","name":"Peginterferon and TIL Therapy for Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT02379195","description":"Metastatic Melanoma","metadata":null},{"id":"0845f7a650c045c28f990e579ceb9e23","type":"DRUG","name":"Peginterferon beta-1a","canonical_id":"mesh:C428112","description":null,"metadata":null},{"id":"df9c71ee51bd4e678d3b5f8917c567a7","type":"DRUG","name":"Pegvisomant","canonical_id":"mesh:C406545","description":null,"metadata":null},{"id":"0fd31b4824a34ab09591334b45c947d8","type":"TRIAL","name":"Pegvisomant And Sandostatin LAR Combination Study","canonical_id":"clinicaltrials.gov:NCT00068029","description":"Acromegaly","metadata":null},{"id":"74524ece3eaf4e309986bca12e69d038","type":"TRIAL","name":"Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency","canonical_id":"clinicaltrials.gov:NCT01804413","description":"Adults Growth Hormone Deficiency.","metadata":null},{"id":"15d44724c9184c5d92a03260b9d12eb3","type":"TRIAL","name":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","canonical_id":"clinicaltrials.gov:NCT02001818","description":"Chronic Myeloid Leukaemia","metadata":null},{"id":"eab150926bf340e8b33634240ab37726","type":"TRIAL","name":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","canonical_id":"clinicaltrials.gov:NCT01120795","description":"Chronic Hepatitis C","metadata":null},{"id":"7abd854356a1491fbc1db8a142ce92ef","type":"TRIAL","name":"Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT06791460","description":"Ovarian Cancer Recurrent","metadata":null},{"id":"2ff6877d3ba54e7689beeaffaef837e4","type":"TRIAL","name":"Peking and Rotterdam on Mission to Reduce Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT01653119","description":"Acute Coronary Syndrome; Diabetes Mellitus","metadata":null},{"id":"852b32421bd54cef9adca183e0b67ab4","type":"DISEASE","name":"Pellagra","canonical_id":"mesh:D010383","description":null,"metadata":null},{"id":"e29bd03b9ef84fb7a6d4a6b95a7e87dd","type":"TRIAL","name":"Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00334321","description":"Endometrial Cancer","metadata":null},{"id":"9ac9a55565ae4fe98f9de41b76ecf7a9","type":"TRIAL","name":"Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer","canonical_id":"clinicaltrials.gov:NCT03468218","description":"Metastatic Head and Neck Carcinoma; Paranasal Sinus Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IV Oro\u2026","metadata":null},{"id":"cbc19cb289b6436bbc338c1fc2d31d57","type":"TRIAL","name":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","canonical_id":"clinicaltrials.gov:NCT04003636","description":"Biliary Tract Carcinoma","metadata":null},{"id":"b30e069985954a89848365efe602af61","type":"TRIAL","name":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","canonical_id":"clinicaltrials.gov:NCT06475235","description":"Lymphoma; Primary Central Nervous System Lymphoma","metadata":null},{"id":"d6321c4181024a398445131e4e9f3537","type":"TRIAL","name":"Pembrolizumab + Idelalisib for Lung Cancer Study","canonical_id":"clinicaltrials.gov:NCT03257722","description":"Non Small Cell Lung Cancer; Metastasis; Recurrence","metadata":null},{"id":"789e602f47a5485ab60014ef6ccdf9fe","type":"TRIAL","name":"Pembrolizumab +/- SD-101 in Hormone-Na\u00efve Oligometastatic Prostate Cancer With RT and iADT","canonical_id":"clinicaltrials.gov:NCT03007732","description":"Prostatic Neoplasms","metadata":null},{"id":"43449975fbcb4d23a18f5f13a80b271f","type":"TRIAL","name":"Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT06164275","description":"Classic Hodgkin Lymphoma","metadata":null},{"id":"b06408e5155747339f95232a5c59adf3","type":"TRIAL","name":"Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma","canonical_id":"clinicaltrials.gov:NCT06302569","description":"Bellini Carcinoma; Collecting Duct Carcinoma; Renal Medullary Carcinoma","metadata":null},{"id":"d57c55988966407d950c3e7cb2f591e4","type":"TRIAL","name":"Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT04632459","description":"Gastric Cancer","metadata":null},{"id":"3ce551652151423d92df2c5ebe70741d","type":"TRIAL","name":"Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT07645625","description":"Cervical Cancer","metadata":null},{"id":"dd9a6a69e279434e872bcfb214808678","type":"TRIAL","name":"Pembrolizumab With Axitinib in Recurrent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT04197219","description":"Recurrent Endometrial Cancer","metadata":null},{"id":"2b09c99499eb40b0a53e44f701fa6ecd","type":"TRIAL","name":"Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery","canonical_id":"clinicaltrials.gov:NCT04370509","description":"Metastatic Clear Cell Renal Cell Carcinoma; Recurrent Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Clear Cell Renal Cell Carcinoma","metadata":null},{"id":"466b61ecbbdc4a61941052349a1d1c77","type":"TRIAL","name":"Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03106415","description":"Breast Adenocarcinoma; Metastatic Triple-Negative Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7","metadata":null},{"id":"2d97ac54a4be46c58a36e155a2083f47","type":"TRIAL","name":"Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT05180097","description":"Hodgkin Lymphoma","metadata":null},{"id":"a9394f73649943c4956cf0149f7c9ee3","type":"TRIAL","name":"Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT03044730","description":"Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma","metadata":null},{"id":"57bf90d7afc84582b7588649cd1907a0","type":"TRIAL","name":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","canonical_id":"clinicaltrials.gov:NCT03516279","description":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Minimal Residual Disease","metadata":null},{"id":"23216f97316b4bdcb044e0c53c316e5b","type":"TRIAL","name":"Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05333809","description":"Colorectal Neoplasms","metadata":null},{"id":"32d356f332ac4c0f86929d8762e465c6","type":"TRIAL","name":"Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT05775471","description":"Renal Pelvis and Ureter Urothelial Carcinoma","metadata":null},{"id":"036105a381fe4766b8775e8ebe64ab07","type":"TRIAL","name":"Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma","canonical_id":"clinicaltrials.gov:NCT04318717","description":"Mucosal Melanoma of the Head and Neck","metadata":null},{"id":"3d912b385fe44be2808d51eee664bb8b","type":"TRIAL","name":"Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05041153","description":"Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Ju\u2026","metadata":null},{"id":"2ccedf075bd24ef3a0873cb8dc63514b","type":"TRIAL","name":"Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT05956041","description":"Cutaneous T Cell Lymphoma; Fungoides Mycosis Sezary Syndrome","metadata":null},{"id":"31a59deeeb8e4fe6b96d20631c0a630c","type":"TRIAL","name":"Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT02930902","description":"Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer AJCC v6 and v7; Stage IA Pancreatic Cancer AJCC v6 and v7; Stage IB Pancreatic Cancer AJCC v6 and v7; Stage II Pancreatic Cancer AJCC v6 and v7; Stage IIA Pancreatic Cancer AJCC v6 and v7; Stage IIB Pancreatic Cancer AJCC v6 and v7","metadata":null},{"id":"3a5be1777dfb48d9a7981c3d8e747e8a","type":"TRIAL","name":"Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT03598998","description":"Anaplastic Large Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Peripheral T-Cell Lymphoma, Not Otherwis\u2026","metadata":null},{"id":"77d7e7f6cc5a496ab500268f2c669964","type":"TRIAL","name":"Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer","canonical_id":"clinicaltrials.gov:NCT03463460","description":"Thymic Carcinoma","metadata":null},{"id":"b836d733d6ef42d2b3ba56d8a8712721","type":"TRIAL","name":"Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT06242834","description":"B-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"8f778cc92ca24961ac2902ae8c29cf49","type":"TRIAL","name":"Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma","canonical_id":"clinicaltrials.gov:NCT03426891","description":"Glioblastoma; Brain Tumor; GBM","metadata":null},{"id":"b54ac8dad1da4524be0ec530de97cfd8","type":"TRIAL","name":"Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD","canonical_id":"clinicaltrials.gov:NCT05578222","description":"NSCLC With COPD","metadata":null},{"id":"f24b0c3de1a042ea8166b8a8e10c49c1","type":"TRIAL","name":"Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment","canonical_id":"clinicaltrials.gov:NCT07275216","description":"Classic Hodgkin Lymphoma","metadata":null},{"id":"982ae612286e44c3908b071063b91dd1","type":"TRIAL","name":"Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT03596281","description":"Ovarian Cancer","metadata":null},{"id":"68095995f93349d08407cc53300a991c","type":"TRIAL","name":"Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03396926","description":"Microsatellite Stable; Mismatch Repair Protein Proficient; Stage III Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7","metadata":null},{"id":"e065de9be26743fc8d35f8c5792b8806","type":"TRIAL","name":"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT04675710","description":"Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Squamous Cell Carcinoma","metadata":null},{"id":"de9753f053684c3c996a0a7cb6f0fbe1","type":"TRIAL","name":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT06253494","description":"Endometrial Cancer; Cancer of Endometrium; Carcinoma of Endometrium; Endometrial Carcinoma","metadata":null},{"id":"315e5889828a40db8ec908cfdc192392","type":"TRIAL","name":"Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT05535218","description":"Muscle-invasive Urothelial Carcinoma of the Bladder","metadata":null},{"id":"43c67683685c467c8254c7769fe7dbf1","type":"DRUG","name":"Pemetrexed","canonical_id":"mesh:D000068437","description":null,"metadata":null},{"id":"1ebf887782ee40719beabadc994fec6d","type":"DRUG","name":"Pemetrexed","canonical_id":"ncit:C61614","description":null,"metadata":null},{"id":"13798efa7f0e46acb782426b7893fa1e","type":"TRIAL","name":"Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00738881","description":"Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer","metadata":null},{"id":"da602d41bf7546ac95a65918be3c84c9","type":"TRIAL","name":"Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00383331","description":"Non-Small-Cell Lung Cancer","metadata":null},{"id":"33a434bdb2294faf8716e8d44d9d6bb4","type":"TRIAL","name":"Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00907179","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"b39611d2a1ab4ca6942486b0148c12e6","type":"DRUG","name":"Pemirolast","canonical_id":"mesh:C055139","description":null,"metadata":null},{"id":"6d1d082b8d9d478395ccada4c26b538c","type":"DRUG","name":"Pemoline","canonical_id":"mesh:D010389","description":null,"metadata":null},{"id":"4f3e245c095a4ecca5de1c8532681ee0","type":"DISEASE","name":"Pemphigus","canonical_id":"mesh:D010392","description":null,"metadata":null},{"id":"adf79a4f4f004d6baee9199b2818d677","type":"PROTEIN","name":"Penicillin-binding protein (Streptococcus pyogenes)","canonical_id":"uniprot:Q54906","description":null,"metadata":null},{"id":"1e8c824b13b2417298adbaa744c132b6","type":"PROTEIN","name":"Penicillin-binding protein 1A","canonical_id":"uniprot:O05131","description":null,"metadata":null},{"id":"859e03b16c4542b39a6c5931ac4ad35e","type":"PROTEIN","name":"Penicillin-binding protein 1A","canonical_id":"uniprot:Q04707","description":null,"metadata":null},{"id":"d7989f27a85f446284db27b20954836b","type":"PROTEIN","name":"Penicillin-binding protein 1A (Neisseria meningitidis)","canonical_id":"uniprot:P0A0Z5","description":null,"metadata":null},{"id":"b2ccbcb9fc5c4a2da2fb4ca30e090ebc","type":"PROTEIN","name":"Penicillin-binding protein 1A (Streptococcus pneumoniae)","canonical_id":"uniprot:Q8DR59","description":null,"metadata":null},{"id":"671216bb55954db6876048aed4c76656","type":"PROTEIN","name":"Penicillin-binding protein 2B","canonical_id":"uniprot:P0A3M6","description":null,"metadata":null},{"id":"33d740c552d14ccf96ad84adb82cacbe","type":"PROTEIN","name":"Penicillin-binding protein 2X (Streptococcus pneumoniae)","canonical_id":"uniprot:P59676","description":null,"metadata":null},{"id":"155090fdd79144b38b084e112d0e84ca","type":"PROTEIN","name":"Penicillin-binding protein 2a","canonical_id":"uniprot:Q8DNB6","description":null,"metadata":null},{"id":"39f1c23df177400bb80b46fef93baca6","type":"PROTEIN","name":"Penicillin-binding proteins","canonical_id":"uniprot:P0AD65","description":null,"metadata":null},{"id":"6d50a4a75abb4c52b04d70bfd48e19c7","type":"PROTEIN","name":"Penicillin-binding proteins","canonical_id":"uniprot:P44469","description":null,"metadata":null},{"id":"13d0028d79b84c60bcab98a10eef9601","type":"DISEASE","name":"Penile Induration","canonical_id":"mesh:D010411","description":null,"metadata":null},{"id":"1899689c54a147da8cb1c9c80a211bfc","type":"TRIAL","name":"Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT07752394","description":"Head & Neck Cancer","metadata":null},{"id":"d9dacee99ba1428084d349ececd1ea22","type":"DRUG","name":"Pentamidine","canonical_id":"mesh:D010419","description":null,"metadata":null},{"id":"c42f294dc7634f5e8d6557d7035b7701","type":"DRUG","name":"Pentazocine","canonical_id":"mesh:D010423","description":null,"metadata":null},{"id":"7b45d183f48947fb99edaba2833860b5","type":"TRIAL","name":"Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders","canonical_id":"clinicaltrials.gov:NCT02930005","description":"Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder","metadata":null},{"id":"b71e8a7748964c999cc4f491c40fd72d","type":"DRUG","name":"Pentosan polysulfate","canonical_id":"mesh:D010426","description":null,"metadata":null},{"id":"29651970f02044ee96b5e8c8210faa7a","type":"TRIAL","name":"Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00006968","description":"Kidney Cancer","metadata":null},{"id":"6550c6f0c95f4d58851de566e610f601","type":"TRIAL","name":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00698685","description":"Leukemia; Lymphoma; Hodgkin's Disease; Hematologic Neoplasms; Multiple Myeloma; Carcinoma, Renal Cell","metadata":null},{"id":"1526a7f4e4cd47d6988e153420937763","type":"TRIAL","name":"Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT00096161","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Graft Versus Host Disease; Hodgkin Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Plasma Cell Myeloma; Waldenstrom Macroglobulinemia","metadata":null},{"id":"b506e840c11246a790a94e3fea8be61d","type":"TRIAL","name":"Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00026351","description":"Leukemia; Lymphoma","metadata":null},{"id":"ebe7d4dc7f3442e3b31a574de6a79b63","type":"TRIAL","name":"Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children","canonical_id":"clinicaltrials.gov:NCT00144430","description":"Graft vs Host Disease","metadata":null},{"id":"e20d6edd3dad40cd86a61fcc74d7ab40","type":"TRIAL","name":"Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT00074035","description":"Graft Versus Host Disease","metadata":null},{"id":"815a5a1e7185456ab5b4d446f673344b","type":"TRIAL","name":"Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00669318","description":"Leukemia; Lymphoma","metadata":null},{"id":"07930846786a4eaa920ab0ef17f043d8","type":"TRIAL","name":"Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT01001780","description":"Active Chronic Graft Versus Host Disease","metadata":null},{"id":"5091930144c347dd986bbf9a94a8222e","type":"TRIAL","name":"Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer","canonical_id":"clinicaltrials.gov:NCT00546377","description":"Leukemia; Lymphoma","metadata":null},{"id":"32f6d1487c4145aebb82584c73fee134","type":"TRIAL","name":"Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL","canonical_id":"clinicaltrials.gov:NCT00074282","description":"Leukemia","metadata":null},{"id":"0005da7986cd445a94fb1346ad4b924e","type":"TRIAL","name":"Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00816595","description":"Leukemia; Lymphoma","metadata":null},{"id":"ee0efbda97144a6eb8f31f64b00cf06c","type":"TRIAL","name":"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers","canonical_id":"clinicaltrials.gov:NCT00003658","description":"Leukemia; Lymphoma","metadata":null},{"id":"57b94b9c41bc4046a23e93579598178a","type":"TRIAL","name":"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00541034","description":"Leukemia; Lymphoma","metadata":null},{"id":"9ead86e9cdce4803950ace44e486d387","type":"TRIAL","name":"Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00201721","description":"B-Chronic Lymphocytic Leukemia","metadata":null},{"id":"4a7b366c7f8c4a2a8aca04b9e4998f97","type":"DRUG","name":"Pentoxifylline","canonical_id":"mesh:D010431","description":null,"metadata":null},{"id":"0ff4d9b8b2104536a3355d9d6d0acd01","type":"TRIAL","name":"Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)","canonical_id":"clinicaltrials.gov:NCT00681733","description":"Metabolic Parameters and Liver Histology","metadata":null},{"id":"810693847b9b4f7aa27bbf004de1b6bf","type":"PROTEIN","name":"Pepsin A-5","canonical_id":"uniprot:P0DJD9","description":null,"metadata":null},{"id":"001d2a3d389246cdbf3ab73127043e38","type":"DISEASE","name":"Peptic ulcer","canonical_id":"mesh:D010437","description":null,"metadata":null},{"id":"c99f07f22a964432bf7c948af6e3de35","type":"TRIAL","name":"Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01191034","description":"Metastatic Melanoma","metadata":null},{"id":"527123cfb3114f39854b315af58fdc13","type":"TRIAL","name":"Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma","canonical_id":"clinicaltrials.gov:NCT01403285","description":"Glioblastoma","metadata":null},{"id":"53c56a191e29478a9ebb7d9f9f98250e","type":"PROTEIN","name":"Peptidoglycan D,D-transpeptidase FtsI","canonical_id":"uniprot:R4YB92","description":null,"metadata":null},{"id":"1feda34f03a740d394ea3384661b373b","type":"PROTEIN","name":"Peptidyl-prolyl cis-trans isomerase A","canonical_id":"uniprot:P62937","description":null,"metadata":null},{"id":"58fa388da8954dd1a8dae0dea4629dfc","type":"DRUG","name":"Perazine","canonical_id":"mesh:D010464","description":null,"metadata":null},{"id":"bb002dc921d843d5ac40374e99d61113","type":"DISEASE","name":"Perennial allergic rhinitis","canonical_id":"mesh:D012221","description":null,"metadata":null},{"id":"08e81a2887454e109821c56684c41ab6","type":"TRIAL","name":"Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients","canonical_id":"clinicaltrials.gov:NCT00475059","description":"Kidney Transplantation","metadata":null},{"id":"bfa015197298472a904baa58b46abb43","type":"TRIAL","name":"Performance of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris","canonical_id":"clinicaltrials.gov:NCT04040790","description":"Low Vision","metadata":null},{"id":"3ae93344e24a42e59d27e64f1f53ad91","type":"TRIAL","name":"Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT02327793","description":"Stroke, Acute","metadata":null},{"id":"690300d6340e40e0a69fcd0ca2ce5dcc","type":"TRIAL","name":"Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial","canonical_id":"clinicaltrials.gov:NCT02450253","description":"Dementia, Vascular","metadata":null},{"id":"acf8d08fa6a94cc68061b92429dd2262","type":"TRIAL","name":"Peri-Operative Testosterone Administration in Primary Hip Arthroscopy","canonical_id":"clinicaltrials.gov:NCT06462482","description":"Femoro Acetabular Impingement","metadata":null},{"id":"bbc4ab33e28542b199e92a314396222c","type":"TRIAL","name":"Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT06608914","description":"Osteoarthritis, Hip","metadata":null},{"id":"a29fc5b22aa04751aa7cdb8659731f38","type":"TRIAL","name":"Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin","canonical_id":"clinicaltrials.gov:NCT00370045","description":"Coronary Artery Disease","metadata":null},{"id":"95b169b81c5d49d2868157f87c43f0be","type":"TRIAL","name":"PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT02546648","description":"Atherosclerotic Disease; Perioperative Bleeding","metadata":null},{"id":"2eb937084c8e42e097870bb001730d0d","type":"TRIAL","name":"PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT05031520","description":"Non-Obstructive Coronary Atherosclerosis","metadata":null},{"id":"e5fdd94ae7f24205a33eb4cf1c7bf691","type":"DRUG","name":"Perifosine","canonical_id":"ncit:C1727","description":null,"metadata":null},{"id":"e803b965a2af4a5b9653c5d9074c8887","type":"DRUG","name":"Perindopril","canonical_id":"mesh:D020913","description":null,"metadata":null},{"id":"ad54004ad5364ad0bf6030778f36833f","type":"TRIAL","name":"Perindopril Amlodipine for the Treatment of Hypertension","canonical_id":"clinicaltrials.gov:NCT01556997","description":"Essential Hypertension","metadata":null},{"id":"75e9970a23884e62a3a47610d07a2e8e","type":"TRIAL","name":"Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease","canonical_id":"clinicaltrials.gov:NCT02213224","description":"Nonalcoholic Fatty Liver Disease (NAFLD)","metadata":null},{"id":"0a4db3e5b9d8465f812241f10d2c7744","type":"TRIAL","name":"Perineural Dexamethasone in Supraclavicular Brachial Plexus Block for Anesthesia After Pediatric Hand/Wrist Surgery","canonical_id":"clinicaltrials.gov:NCT06086392","description":"Wrist Disease; Hand Injuries; Wrist Injuries; Hand Disease; Hand Injuries and Disorders","metadata":null},{"id":"da41ae7174af458e9889c5236746416c","type":"TRIAL","name":"Period Pills for Menstrual Regulation: A New Reproductive Health Option","canonical_id":"clinicaltrials.gov:NCT07671989","description":"Menstrual Regulation; Menstrual Health Intervention","metadata":null},{"id":"cf3f3250137f4cd0a3206d855e2420b6","type":"TRIAL","name":"Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery","canonical_id":"clinicaltrials.gov:NCT00502684","description":"Primary Operable Breast Cancer","metadata":null},{"id":"0f73d9112f3647829ae01b25ef5f0fe8","type":"TRIAL","name":"Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant","canonical_id":"clinicaltrials.gov:NCT01759862","description":"Function of Renal Transplant","metadata":null},{"id":"2df2705b23a7454a9a5e2f724fa5853a","type":"TRIAL","name":"Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)","canonical_id":"clinicaltrials.gov:NCT07263919","description":"Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"a11cab4bb1424eec9d5874baf1c7f8a9","type":"TRIAL","name":"Perioperative Efgartigimod for Thymoma and Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT06221501","description":"Myasthenia Gravis","metadata":null},{"id":"ef001336bec8461191fce08710000f66","type":"TRIAL","name":"Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT03638817","description":"Thrombocytopenia","metadata":null},{"id":"f50b6777b8f74dcba2c8ab6d357b5978","type":"TRIAL","name":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","canonical_id":"clinicaltrials.gov:NCT04700124","description":"Bladder Cancer","metadata":null},{"id":"44a058adb0d442f1b16d294f2c6f01ea","type":"TRIAL","name":"Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC","canonical_id":"clinicaltrials.gov:NCT07751276","description":"Head and Neck Squamous Cell Carcinoma HNSCC","metadata":null},{"id":"9f2d4b440e4c4d6d8b08000d7c256734","type":"TRIAL","name":"Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the Eyes","canonical_id":"clinicaltrials.gov:NCT07734740","description":"Dermatochalasis of Upper Eyelid; Blepharoplasty","metadata":null},{"id":"363a31547de242e791f0bff47d7d3f52","type":"TRIAL","name":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","canonical_id":"clinicaltrials.gov:NCT04062656","description":"Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction","metadata":null},{"id":"32d7b63e0a684a0d8e811e084c232294","type":"TRIAL","name":"Perioperative Inflammation and Cyclooxygenase 2 (COX-2)","canonical_id":"clinicaltrials.gov:NCT00122096","description":"Neurosurgery; Pain","metadata":null},{"id":"624ee8ee5bcd4e799fc767dbf2869cea","type":"TRIAL","name":"Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery","canonical_id":"clinicaltrials.gov:NCT03838029","description":"Pancreatic Neoplasms","metadata":null},{"id":"960a705ad00140d3a9231f23e4c478c8","type":"TRIAL","name":"Perioperative Intravenous Nimodipine Trial","canonical_id":"clinicaltrials.gov:NCT07048522","description":"Colectomy; Open Surgery; Pain; Pain, Postoperative; Pain, Acute","metadata":null},{"id":"9cfb5363004c4abcaf133c7af5076f72","type":"TRIAL","name":"Perioperative Measurements of Diastolic Function in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT02285309","description":"Diastolic Dysfunction","metadata":null},{"id":"4e01023d16c443c6b231156dd12464d7","type":"TRIAL","name":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","canonical_id":"clinicaltrials.gov:NCT03924895","description":"Urinary Bladder Cancer, Muscle-invasive","metadata":null},{"id":"7da0b03e58194441aae6df68cf407604","type":"TRIAL","name":"Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-\u03b2 Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial","canonical_id":"clinicaltrials.gov:NCT07847710","description":"Intrahepatic Cholangiocarcinoma (Icc); Neoadjuvant Therapy","metadata":null},{"id":"81889dce62b749d28d3aa595347ce9e3","type":"TRIAL","name":"Perioperative Steroid Dosing on the APR in AIS","canonical_id":"clinicaltrials.gov:NCT05561725","description":"Adolescent Idiopathic Scoliosis (AIS)","metadata":null},{"id":"79f8e7112c754b26aa6596099b315d07","type":"TRIAL","name":"Perioperative Treatment With Tranexamic Acid in Melanoma","canonical_id":"clinicaltrials.gov:NCT05899465","description":"Melanoma","metadata":null},{"id":"27d7542d70a54a67ae66003d17278eb1","type":"TRIAL","name":"Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer","canonical_id":"clinicaltrials.gov:NCT00892242","description":"Adenocarcinoma","metadata":null},{"id":"fc11814a323941e98baa3517997d7b68","type":"TRIAL","name":"Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.","canonical_id":"clinicaltrials.gov:NCT05024253","description":"Ewing Sarcoma of Bone; Osteosarcoma","metadata":null},{"id":"4b0e79b76ed94e648f8ea982bdb55d06","type":"TRIAL","name":"Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study","canonical_id":"clinicaltrials.gov:NCT03323164","description":"Glaucoma; Drugs; Normal Tension Glaucoma; Primary Open-angle Glaucoma","metadata":null},{"id":"22ebc99618dd4288a62accbcf0b184d7","type":"TRIAL","name":"Peripheral Nerve Injections for CRPS","canonical_id":"clinicaltrials.gov:NCT04744675","description":"Complex Regional Pain Syndromes","metadata":null},{"id":"537767cf2d254293baaef063e3631fb6","type":"TRIAL","name":"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00003399","description":"Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"cbe00628ccac4b19b8a1acf4a53e659b","type":"DISEASE","name":"Peripheral T-cell lymphoma","canonical_id":"mesh:D016411","description":null,"metadata":null},{"id":"683dd9c30bc14da2bfc2aa9770f6efa7","type":"TRIAL","name":"Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome","canonical_id":"clinicaltrials.gov:NCT03468465","description":"Urinary Incontinence","metadata":null},{"id":"860f1fa184414fc8bced8d6796a4c44b","type":"DISEASE","name":"Peripheral Vascular Diseases","canonical_id":"mesh:D016491","description":null,"metadata":null},{"id":"3b7edcd34b8c4097b68211b6aea255e0","type":"TRIAL","name":"Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans","canonical_id":"clinicaltrials.gov:NCT03179163","description":"Hypertension,Essential","metadata":null},{"id":"777f1f14f00e448d81afe8d55420d388","type":"DISEASE","name":"Peritoneal Carcinoma","canonical_id":"doid:1791","description":null,"metadata":null},{"id":"ee7a856e44774e23bd0ce28c2d8a35a3","type":"DISEASE","name":"Peritonitis","canonical_id":"mesh:D010538","description":null,"metadata":null},{"id":"cff1fb3cfde3461181b69bc9903f745b","type":"TRIAL","name":"Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT00434850","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"d753032b106e476e90df0f5a0f7d0327","type":"DISEASE","name":"Pernicious anemia","canonical_id":"mesh:D000752","description":null,"metadata":null},{"id":"559cc02ef0a44470a929b31a58519dcd","type":"TRIAL","name":"Persantin Preceding Elective PCI","canonical_id":"clinicaltrials.gov:NCT00767663","description":"Coronary Heart Disease; Percutaneous Transluminal Coronary Angioplasty; Atherosclerosis","metadata":null},{"id":"b2c233f6cf5041be9920ffad32c50901","type":"TRIAL","name":"Persantine: Variation in Response Trial","canonical_id":"clinicaltrials.gov:NCT00763009","description":"Coronary Artery Disease","metadata":null},{"id":"67ac65f97a5b4a1c821072509c7d80af","type":"TRIAL","name":"Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia","canonical_id":"clinicaltrials.gov:NCT03891862","description":"Tardive Dyskinesia (TD)","metadata":null},{"id":"948d50c563824c029a8e86f7ac07c1af","type":"TRIAL","name":"Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment","canonical_id":"clinicaltrials.gov:NCT03573596","description":"CML, Relapsed","metadata":null},{"id":"fffc2db155e046e2b078cddb4a4b6aa3","type":"DISEASE","name":"Persistent Fetal Circulation Syndrome","canonical_id":"mesh:D010547","description":null,"metadata":null},{"id":"e98d1168e1dd40319989fd09c985f354","type":"TRIAL","name":"Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT06080399","description":"Parkinson Disease","metadata":null},{"id":"bf4abce1f76b4fc1b193255e983f7308","type":"TRIAL","name":"Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT02779283","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia","metadata":null},{"id":"d559a05c3fe949209cf02a15afa890be","type":"TRIAL","name":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","canonical_id":"clinicaltrials.gov:NCT07020247","description":"Locally Advanced Rectal Cancer (LARC); Immunotherapy; Radiotherapy; Total Neoadjuvant Therapy; Anal Function Preservation","metadata":null},{"id":"2f4acd7cf9fb4943b21b7344c29f8728","type":"TRIAL","name":"Personalized Medicine for Advanced Biliary Cancer Patients","canonical_id":"clinicaltrials.gov:NCT05615818","description":"Biliary Tract Neoplasms","metadata":null},{"id":"a88e6d9813454249b276c1fa57e0078b","type":"TRIAL","name":"Personalized Post-Operative Pain Management","canonical_id":"clinicaltrials.gov:NCT06669650","description":"Persistent Post Operative Opioid Use; Post-surgical Pain","metadata":null},{"id":"598c2bd0df2f4f37ad54f8fa5b595502","type":"TRIAL","name":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma","canonical_id":"clinicaltrials.gov:NCT04402073","description":"Medulloblastoma","metadata":null},{"id":"d4479a29d03f49be93801f8cccd1bf64","type":"TRIAL","name":"Personalized Sertraline Dosing in Patients With Depression","canonical_id":"clinicaltrials.gov:NCT05210153","description":"Depressive Disorder, Major","metadata":null},{"id":"7d6dc28db4fb4fb49596fae637ba379e","type":"TRIAL","name":"Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)","canonical_id":"clinicaltrials.gov:NCT04859608","description":"Hemolytic-Uremic Syndrome, Atypical","metadata":null},{"id":"8910eeecce34483684883abd791210a1","type":"TRIAL","name":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1\uff0cChemotherapy and Target Therapy for Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06841159","description":"Microsatellite Stable Metastatic Colorectal Cancer","metadata":null},{"id":"8231d6f37cae45c3b545a2ae37964a5f","type":"DRUG","name":"Pertuzumab","canonical_id":"ncit:C38692","description":null,"metadata":null},{"id":"3af6b5082935442a9fb03ab4b594ea65","type":"TRIAL","name":"Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01937117","description":"Breast Cancer","metadata":null},{"id":"06cef9d2e8644d2ba8c2827cb82076d6","type":"TRIAL","name":"Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women","canonical_id":"clinicaltrials.gov:NCT02028364","description":"Breast Cancer","metadata":null},{"id":"e3ac8a2291a8493f9a2d691ad42af824","type":"GO_TERM","name":"Peyer's patch development","canonical_id":"go:GO:0048541","description":"\"The process whose specific outcome is the progression of Peyer's patches over time, from their formation to the mature structure. Peyer's patches are typically found as nodules associated with gut epithelium with distinct internal structures including B- and T-zones for the activation of lymphocytes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"befae8e6f8af4cbbaf7dfe0fb6e6d7bc","type":"GO_TERM","name":"Peyer's patch morphogenesis","canonical_id":"go:GO:0061146","description":"\"The process in which a Peyer's patch is generated and organized. Peyer's patches are typically found as nodules associated with gut epithelium with distinct internal structures including B- and T-zones for the activation of lymphocytes.\" [GOC:dph]","metadata":null},{"id":"8802b0ef00d9405497c8bb3d49bd3133","type":"DISEASE","name":"Pfeiffer syndrome","canonical_id":"mondo:0007043","description":null,"metadata":null},{"id":"60eaeea8678147dd868384a7d9d405f9","type":"TRIAL","name":"Pfizer/IVGTT/Ziprasidone/Olanzapine","canonical_id":"clinicaltrials.gov:NCT00205725","description":"Schizophrenia; Type 2 Diabetes Mellitus","metadata":null},{"id":"8683463c0aed466589e62cb9b838cf83","type":"TRIAL","name":"Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas","canonical_id":"clinicaltrials.gov:NCT00613223","description":"Gliosarcoma; Glioblastoma","metadata":null},{"id":"e97e6f96233141699f984d33670ae76d","type":"TRIAL","name":"Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG","canonical_id":"clinicaltrials.gov:NCT00613132","description":"Glioblastoma; Gliosarcoma","metadata":null},{"id":"2d75c5ad34294a91a8ebe9c1caa8e16e","type":"TRIAL","name":"Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT00613054","description":"Glioblastoma; Gliosarcoma","metadata":null},{"id":"8bf7cc8563c94dd4975a83d6d6110d5d","type":"TRIAL","name":"Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT00653328","description":"Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer","metadata":null},{"id":"6c1cc7fcedb44825b1faedd76d412935","type":"TRIAL","name":"Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC","canonical_id":"clinicaltrials.gov:NCT06553885","description":"Metastatic Colorectal Cancer; Hepatocellular Carcinoma","metadata":null},{"id":"73a11278e5e648b489e78e8e96d24a0d","type":"TRIAL","name":"Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.","canonical_id":"clinicaltrials.gov:NCT01972217","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"08fd92ccef424f22ab658c67a9e48ef3","type":"TRIAL","name":"Ph IIA Study (SOC +/- NS5B)","canonical_id":"clinicaltrials.gov:NCT01193361","description":"Hepatitis C Virus","metadata":null},{"id":"f40024c8ac2140a2b7e5097b31cda6da","type":"TRIAL","name":"Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01335204","description":"Prostate Cancer; Prostatic Neoplasms","metadata":null},{"id":"d0a387022a624e8490d8425e7d7e26f8","type":"TRIAL","name":"Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study","canonical_id":"clinicaltrials.gov:NCT01025505","description":"Treatment; Stem Cell Transplantation","metadata":null},{"id":"90ad6ed8dc7d428ca398f3d5339242e2","type":"TRIAL","name":"Ph1 Administration of VSV-IFN\u03b2-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02923466","description":"Malignant Solid Tumour","metadata":null},{"id":"3f8d4bbcdecf46ec8a677096e413e7bc","type":"TRIAL","name":"Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03538171","description":"Advanced Breast Cancer","metadata":null},{"id":"c13a6a6e039d45e3907abaf746a31a77","type":"TRIAL","name":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06083857","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"e39c69da7f72470d909a87e07ad3cf00","type":"TRIAL","name":"Phamacological Reversal of Airway Instability During Sedation","canonical_id":"clinicaltrials.gov:NCT01171118","description":"Upper Airway Obstruction","metadata":null},{"id":"f1b9b6bf0492441ba691815c1a1a55a3","type":"TRIAL","name":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists","canonical_id":"clinicaltrials.gov:NCT04183192","description":"Healthy Subjects; Pharmacokinetics; Pharmacodynamics","metadata":null},{"id":"1ad29f201394428bbf06a1590183e36d","type":"TRIAL","name":"Pharmacodynamic Drug Interaction Between Cilostazol and Statins","canonical_id":"clinicaltrials.gov:NCT01870466","description":"Healthy","metadata":null},{"id":"c6ae80b40a9e4daa8c135efa06129887","type":"TRIAL","name":"Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT02593929","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"18d91724aaec4d358b914af454608e8b","type":"TRIAL","name":"Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)","canonical_id":"clinicaltrials.gov:NCT04790032","description":"Percutaneous Coronary Intervention","metadata":null},{"id":"6855925d35f9455d8ef1af10f2e396d3","type":"TRIAL","name":"Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin","canonical_id":"clinicaltrials.gov:NCT01596504","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1a240d27427046a484c87c70fc47cad4","type":"TRIAL","name":"Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity","canonical_id":"clinicaltrials.gov:NCT00330525","description":"Obesity; Overweight","metadata":null},{"id":"7a8e0645dd1c4736bb688f792e78988b","type":"TRIAL","name":"Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg","canonical_id":"clinicaltrials.gov:NCT05076474","description":"Bioequivalence","metadata":null},{"id":"766462acdaa2478c957916e25f3c0e85","type":"TRIAL","name":"Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy","canonical_id":"clinicaltrials.gov:NCT02791958","description":"Hypertension","metadata":null},{"id":"26468f38c9a94ed2b28014b05f04b010","type":"TRIAL","name":"Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT04567290","description":"Acute Coronary Syndrome","metadata":null},{"id":"4d22aa7d4f9a42ec8ce5eb6b938ec817","type":"TRIAL","name":"Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg","canonical_id":"clinicaltrials.gov:NCT06719986","description":"Opioid Overdose","metadata":null},{"id":"98e2aade55f3448087b6933c1caf57a0","type":"TRIAL","name":"Pharmacodynamic Evaluation of Intranasal Nalmefene","canonical_id":"clinicaltrials.gov:NCT04828005","description":"Pharmacodynamic","metadata":null},{"id":"abe1cce488d745caad78d22d5f027018","type":"TRIAL","name":"Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.","canonical_id":"clinicaltrials.gov:NCT00232882","description":"Hypertension","metadata":null},{"id":"bc3c94a6cb3e4f45bb7e3c41a3e9c2c7","type":"TRIAL","name":"Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03936933","description":"Breast Cancer","metadata":null},{"id":"023d3ce583d643ebbd8b8c44a1ec0657","type":"TRIAL","name":"Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure","canonical_id":"clinicaltrials.gov:NCT00802230","description":"Heart Failure","metadata":null},{"id":"df7b3d6aa4cc401287ae9c4743b4fe08","type":"TRIAL","name":"Pharmacodynamic Study of Cilostazol in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02554721","description":"Healthy","metadata":null},{"id":"5ca344631ab9494392dc53149d5c24e9","type":"TRIAL","name":"Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure","canonical_id":"clinicaltrials.gov:NCT01089062","description":"Healthy","metadata":null},{"id":"431b594964d14a38aa91aa7403500d1d","type":"TRIAL","name":"Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI","canonical_id":"clinicaltrials.gov:NCT04668144","description":"Coronary Artery Disease; Acute Coronary Syndrome","metadata":null},{"id":"f2fa036f1e1c4c6381b28f78abd64234","type":"TRIAL","name":"Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT01993875","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"3c2901e523704e0e8b72ffb90f83088f","type":"TRIAL","name":"Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol","canonical_id":"clinicaltrials.gov:NCT00940329","description":"Healthy","metadata":null},{"id":"d649f90a9c124ac0a349c76908d0b61e","type":"TRIAL","name":"Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose","canonical_id":"clinicaltrials.gov:NCT01692158","description":"Healthy","metadata":null},{"id":"cc2ea318ce49434fb50b7d01af953cca","type":"TRIAL","name":"Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Crist\u00e1lia) Compared With the Product Liquemine (Roche) in Chronic Renal Failure","canonical_id":"clinicaltrials.gov:NCT00828776","description":"Chronic Renal Failure","metadata":null},{"id":"1ebcb28fb26c4fd08638acf28d0c8ccf","type":"TRIAL","name":"Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation","canonical_id":"clinicaltrials.gov:NCT00918346","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"18725850d60844dcb6f0ba7581fcfbac","type":"TRIAL","name":"Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02347111","description":"Atrial Fibrillation","metadata":null},{"id":"78272c0a4c5c4ff397dbd57ac8592fcc","type":"TRIAL","name":"Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women","canonical_id":"clinicaltrials.gov:NCT01432028","description":"Postmenopause","metadata":null},{"id":"ce0440b66aef4fd69b1db15f84f93409","type":"TRIAL","name":"Pharmacogenetic Study of Mirtazapine Response in Depressed Patients","canonical_id":"clinicaltrials.gov:NCT01039740","description":"Depression","metadata":null},{"id":"b8d3fc517de9469ebd79b9fa909a0f56","type":"TRIAL","name":"Pharmacogenetic Treatments for Alcoholism","canonical_id":"clinicaltrials.gov:NCT01591291","description":"Alcoholism","metadata":null},{"id":"afdd02014acc47ef8e74030b99076fb2","type":"TRIAL","name":"Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse","canonical_id":"clinicaltrials.gov:NCT01953432","description":"Cocaine Dependence","metadata":null},{"id":"33181857c92b4fb09bd1db9ae871a621","type":"TRIAL","name":"Pharmacogenetics of Ace Inhibitor-Associated Angioedema","canonical_id":"clinicaltrials.gov:NCT01413542","description":"Hypertension; Diabetes Type 2","metadata":null},{"id":"951b04bfa2524f08a7e7a41009851bba","type":"TRIAL","name":"Pharmacogenetics of Doxazosin for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01145183","description":"Cocaine Dependence","metadata":null},{"id":"9c7b63d0077f4bbe9470187de4858c79","type":"TRIAL","name":"Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT07388407","description":"Rhematoid Arthritis","metadata":null},{"id":"dbb0ac8a3a1b4e6483c0b5d35f377d2f","type":"TRIAL","name":"Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT00226577","description":"Lung Cancer","metadata":null},{"id":"6514e37a99c44f198f520dd7546c1aab","type":"TRIAL","name":"Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","canonical_id":"clinicaltrials.gov:NCT06554288","description":"Pediatric Disorder; Genetic Predisposition; Dystonia, Secondary; Dystonia; Cerebral Palsy, Dystonic-Rigid; Cerebral Palsy, Dyskinetic; Trihexyphenidyl Adverse Reaction; Pharmacogenomic Drug Interaction","metadata":null},{"id":"799744eb4f1342e68faf619e0454f42d","type":"TRIAL","name":"Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01669252","description":"Breast Cancer","metadata":null},{"id":"f09313c6ab24446c93ee4b4cbc0e4f78","type":"TRIAL","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","canonical_id":"clinicaltrials.gov:NCT01064466","description":"Small Cell Lung Cancer","metadata":null},{"id":"d5d86d149cb04feb86f090161dac4f18","type":"TRIAL","name":"Pharmacogenomics and Post-Operative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT03503292","description":"Postoperative Nausea","metadata":null},{"id":"fbc01dc133b24a4d8120e2d72ed0d78f","type":"TRIAL","name":"Pharmacogenomics in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00593905","description":"Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH WHO Group I","metadata":null},{"id":"4bdc2ab1956b4b76b7902b3ecefebf4e","type":"TRIAL","name":"Pharmacokinetic (PK) Evaluation of Nalmefene Formulations","canonical_id":"clinicaltrials.gov:NCT07543276","description":"Opioid Overdose","metadata":null},{"id":"e10fc58552e24eadb1a60ad09b8d59ba","type":"TRIAL","name":"Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients","canonical_id":"clinicaltrials.gov:NCT01491113","description":"Healthy Subjects; Renal Impairments","metadata":null},{"id":"d253ca1d96d444398f431d5d8dce8e4b","type":"TRIAL","name":"Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03956134","description":"Pharmacokinetics","metadata":null},{"id":"73a96f87f0184db1904dd38524d9f1dc","type":"TRIAL","name":"Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin","canonical_id":"clinicaltrials.gov:NCT02079506","description":"Healthy","metadata":null},{"id":"7937be36c7a84d14919fc8807255d6a7","type":"TRIAL","name":"Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin","canonical_id":"clinicaltrials.gov:NCT04431141","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"869434036aaf4f14af89eb404227d484","type":"TRIAL","name":"Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT00548067","description":"Hypertension","metadata":null},{"id":"2739f468820b46fbb109300245589ac6","type":"TRIAL","name":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","canonical_id":"clinicaltrials.gov:NCT00359281","description":"Healthy","metadata":null},{"id":"9321d3919f2f4dcd8fa30469fa741b2e","type":"TRIAL","name":"Pharmacokinetic Drug-Drug Interaction Study of Rucaparib","canonical_id":"clinicaltrials.gov:NCT02740712","description":"Neoplasms","metadata":null},{"id":"dc1cabe2fb5047588e29f4773c141957","type":"TRIAL","name":"Pharmacokinetic Effect of Y-3 on Repaglinide\uff0cWarfarin and Omeprazole in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07068841","description":"Pharmacokinetic Profiles; Y-3 for Injection; Drug-drug Interaction; Repaglinide Tablets; Warfarin Sodium Tablets; Omeprazole Enteric-coated Capsules; Safty","metadata":null},{"id":"6b8edff0c9cf417cadb02f50f8d43d17","type":"TRIAL","name":"Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants","canonical_id":"clinicaltrials.gov:NCT01392469","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"f94fc4c0fd63454eac7ea17e63829bf0","type":"TRIAL","name":"Pharmacokinetic Evaluation of Anrikefon Injection in the Geriatric Population With the Management of Acute Pain Following Abdominal Laparoscopy","canonical_id":"clinicaltrials.gov:NCT07353983","description":"Postoperative Pain","metadata":null},{"id":"4d2e9c6339f3442fa4a4608cdfd78b09","type":"TRIAL","name":"Pharmacokinetic Evaluation of Brisdelle\u2122 (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT01829919","description":"Postmenopausal Symptoms","metadata":null},{"id":"78180979466148ddbccb542d0062b23e","type":"TRIAL","name":"Pharmacokinetic Evaluation of Intranasal Nalmefene","canonical_id":"clinicaltrials.gov:NCT04759768","description":"Pharmacokinetics","metadata":null},{"id":"ab484a608402405e81616633d9917507","type":"TRIAL","name":"Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens","canonical_id":"clinicaltrials.gov:NCT05219669","description":"Opioid Overdose","metadata":null},{"id":"2671fe5e05004fb69ead3472a5124580","type":"TRIAL","name":"Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02572089","description":"Drug Overdose; Opioid-Related Disorders","metadata":null},{"id":"63902b4a15484e6e87c8bbfbc92ef97d","type":"TRIAL","name":"Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03129347","description":"Opioid-Related Disorders","metadata":null},{"id":"6317cd3a8b0042a692e82ae981e40692","type":"TRIAL","name":"Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function","canonical_id":"clinicaltrials.gov:NCT01766154","description":"Renal Insufficiency","metadata":null},{"id":"f4a7792587b74c8395c1b23501d567d2","type":"TRIAL","name":"Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02526888","description":"Healthy Subjects","metadata":null},{"id":"35492ec78c4f48e4a99eea4a69f62ba2","type":"TRIAL","name":"Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01290211","description":"Healthy","metadata":null},{"id":"6d4ccfb5f2d3400aac17d05c824ee152","type":"TRIAL","name":"Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1","canonical_id":"clinicaltrials.gov:NCT03011463","description":"Pharmacokinetics; Inhibition Enzyme; Drug Interaction Potentiation","metadata":null},{"id":"3ae08fee116a4ff7b2aeaca42374d3ec","type":"TRIAL","name":"Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg","canonical_id":"clinicaltrials.gov:NCT02485041","description":"Drug Interaction Potentiation","metadata":null},{"id":"2300d6580020422f82ff8bb53757812e","type":"TRIAL","name":"Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg","canonical_id":"clinicaltrials.gov:NCT02485028","description":"Drug Interaction Potentiation","metadata":null},{"id":"f3b0a4c1abc04b519198f400dd833c7c","type":"TRIAL","name":"Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05938517","description":"M\u00e9ni\u00e8re's Disease","metadata":null},{"id":"fcef5469c6fe4a5c9f1e7e0754c220d6","type":"TRIAL","name":"Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects","canonical_id":"clinicaltrials.gov:NCT00828581","description":"Obesity","metadata":null},{"id":"9bbcdaebf7dd4041a8e9aa342e638f9f","type":"TRIAL","name":"Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT00828932","description":"Hepatic Impairment","metadata":null},{"id":"561155fc8fff47f086d8aae1d78cf31c","type":"TRIAL","name":"Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment","canonical_id":"clinicaltrials.gov:NCT00828438","description":"Renal Impairment","metadata":null},{"id":"874957e9dc4049ff87c7df2d635a33be","type":"TRIAL","name":"Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State","canonical_id":"clinicaltrials.gov:NCT00828724","description":"Obesity","metadata":null},{"id":"3ee8d4758d564ac4960f776e72cea755","type":"TRIAL","name":"Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01934166","description":"Renal Impairment","metadata":null},{"id":"a142f7055a524321871a86dcde66319f","type":"TRIAL","name":"Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women","canonical_id":"clinicaltrials.gov:NCT02386488","description":"Pharmacokinetics","metadata":null},{"id":"0b2102aa19e940dba892cb876a2cb789","type":"TRIAL","name":"Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus","canonical_id":"clinicaltrials.gov:NCT03060044","description":"Asthma","metadata":null},{"id":"f9cc6564526d400291b1a5796fa9e4b6","type":"TRIAL","name":"Pharmacokinetic Study With Repeated Doses of Stalevo","canonical_id":"clinicaltrials.gov:NCT00693862","description":"Pharmacokinetics","metadata":null},{"id":"934f3c22496346d8b0353ee741c02d42","type":"TRIAL","name":"Pharmacokinetic Study in Healthy Males","canonical_id":"clinicaltrials.gov:NCT02312232","description":"Parkinson's Disease","metadata":null},{"id":"a013d21060ac48d7a66b8986192b7156","type":"TRIAL","name":"Pharmacokinetic Study in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02554734","description":"Parkinson's Disease","metadata":null},{"id":"eed79f2a73294584af74b45764ec3286","type":"TRIAL","name":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01087749","description":"Kidney Disease","metadata":null},{"id":"1b228fd47c04457da237c61bbf0d32ca","type":"TRIAL","name":"Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.","canonical_id":"clinicaltrials.gov:NCT02624557","description":"Hepatic Impairment","metadata":null},{"id":"2f1613bd5005466eab9f7193977ae44f","type":"TRIAL","name":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","canonical_id":"clinicaltrials.gov:NCT00042289","description":"HIV Infections","metadata":null},{"id":"c686c35e6298415c8ab869a0beb4936a","type":"TRIAL","name":"Pharmacokinetic Study of CYCLOSET \u00ae 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects","canonical_id":"clinicaltrials.gov:NCT02078440","description":"Type 2 Diabetes","metadata":null},{"id":"fd9a6e0b05684f06b66dd92100148b0d","type":"TRIAL","name":"Pharmacokinetic Study of Fentanyl 400 \u00b5g Sublingual Spray, Actiq\u00ae 400 \u00b5g Transmucosally, and Fentanyl Citrate Injection 100 \u00b5g Intravenously (iv)","canonical_id":"clinicaltrials.gov:NCT01780233","description":"Pain","metadata":null},{"id":"df75e600b3a14041a8c4b8e27b882b5b","type":"TRIAL","name":"Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction","canonical_id":"clinicaltrials.gov:NCT00483600","description":"Kidney Diseases","metadata":null},{"id":"f2447f2ea6204b169844baa9a09ddde4","type":"TRIAL","name":"Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients","canonical_id":"clinicaltrials.gov:NCT01517295","description":"Chronic Pain","metadata":null},{"id":"8070ce17f6e948b8a46da04bb3f433d7","type":"TRIAL","name":"Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02568176","description":"Healthy","metadata":null},{"id":"eb43b326d6d5497da975fc4faa33058e","type":"TRIAL","name":"Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients","canonical_id":"clinicaltrials.gov:NCT00572650","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"36ece56200f24db681b4866f530d29c7","type":"TRIAL","name":"Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects","canonical_id":"clinicaltrials.gov:NCT02174523","description":"Schizophrenia","metadata":null},{"id":"d34565358b6845448bb2bc3a39258834","type":"TRIAL","name":"Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn","canonical_id":"clinicaltrials.gov:NCT01088997","description":"Persistent Fetal Circulation Syndrome","metadata":null},{"id":"ffea7cedff644932a434f60f320192b0","type":"TRIAL","name":"Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support","canonical_id":"clinicaltrials.gov:NCT00070616","description":"Leukemia; Lymphoma; Myeloma","metadata":null},{"id":"96cce96e1bc24ec3870fe95fdb9d65eb","type":"TRIAL","name":"Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers","canonical_id":"clinicaltrials.gov:NCT05396742","description":"Healthy","metadata":null},{"id":"dd4c52d1cf6c4b899e5c4e429de22a19","type":"TRIAL","name":"Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects","canonical_id":"clinicaltrials.gov:NCT01691872","description":"Epilepsy, Partial","metadata":null},{"id":"0b9a5226376848dea1d5cb0787b9d965","type":"TRIAL","name":"Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 \u00b5g , in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT01354782","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"11cff07ddded4ee2b2e94315f7e06253","type":"TRIAL","name":"Pharmacokinetic Study to Characterize Phenotyping Metrics of the \"Basel\" Cocktail After CYP Induction or Inhibition","canonical_id":"clinicaltrials.gov:NCT01386593","description":"Metabolic Detoxication, Phase I","metadata":null},{"id":"807b4e7cec6443609c13b0de9f114ba6","type":"TRIAL","name":"Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb","canonical_id":"clinicaltrials.gov:NCT01439204","description":"Rheumatoid Arthritis","metadata":null},{"id":"27351f5df1964965b37175294d52a991","type":"TRIAL","name":"Pharmacokinetic Study to Compare the Systemic Exposure of Differin\u00ae Gel, 0.3% or Differin\u00ae Gel, 0.1%","canonical_id":"clinicaltrials.gov:NCT00660985","description":"Acne Vulgaris","metadata":null},{"id":"f48cd6883ceb4ee48378f377b968fb31","type":"TRIAL","name":"Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently","canonical_id":"clinicaltrials.gov:NCT05257447","description":"Pharmacokinetics","metadata":null},{"id":"03dc3f3326804df5a3a9c4d0cce0df5f","type":"TRIAL","name":"Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT00490815","description":"Diabetic Macular Edema","metadata":null},{"id":"245bfc0408ad40a79c07d20c3cb0501a","type":"TRIAL","name":"Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes","canonical_id":"clinicaltrials.gov:NCT04921124","description":"Stress Fracture","metadata":null},{"id":"f83e49cda2b0479ab38922997e0f8fea","type":"TRIAL","name":"Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00424541","description":"Hypertension","metadata":null},{"id":"3d321fd0bdb74cd282ceb340fe1ed828","type":"TRIAL","name":"Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients","canonical_id":"clinicaltrials.gov:NCT02012556","description":"HIV","metadata":null},{"id":"3b9434c01f644b1197ad1633574b9c18","type":"TRIAL","name":"Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00650156","description":"Rheumatoid Arthritis","metadata":null},{"id":"0068f0d976f54c938b14fa3397dae87b","type":"TRIAL","name":"Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination","canonical_id":"clinicaltrials.gov:NCT02684799","description":"Healthy","metadata":null},{"id":"09cbacecc38b4798808160e416ece674","type":"TRIAL","name":"Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02299505","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"a057661193ca48ad9955939203f29bf1","type":"TRIAL","name":"Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT06662123","description":"Healthy Volunteers","metadata":null},{"id":"2da0bf4502de4a2d87434ed826635b1e","type":"TRIAL","name":"Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults","canonical_id":"clinicaltrials.gov:NCT00914862","description":"Insomnia","metadata":null},{"id":"e4f3c447806842ac8c0ef921fe1d497b","type":"TRIAL","name":"Pharmacokinetic and Tolerance Study of Meloxicam Eye Drops in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04322175","description":"Healthy Volunteers","metadata":null},{"id":"18d67da7d889456ebc46b6c7ba36a47c","type":"TRIAL","name":"Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain","canonical_id":"clinicaltrials.gov:NCT01729728","description":"Postoperative Pain; Acute Pain","metadata":null},{"id":"5a2e25fa83184f6392c432471d49f537","type":"TRIAL","name":"Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01551888","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"98c0786b3ebd406d8a2e902d4f97168a","type":"TRIAL","name":"Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT03273088","description":"Phase 1; Bioequivalence","metadata":null},{"id":"911639f8735c4276b43421c50c31e3f4","type":"TRIAL","name":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants","canonical_id":"clinicaltrials.gov:NCT02345148","description":"Healthy","metadata":null},{"id":"5f9b073f9ae14a4fa88186c2ac2fff28","type":"TRIAL","name":"Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM\u00ae at Different Dose Strengths","canonical_id":"clinicaltrials.gov:NCT01788774","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"a9845ac10d7a4853affaed38e479d4e0","type":"TRIAL","name":"Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants","canonical_id":"clinicaltrials.gov:NCT00819468","description":"Hepatic Impairment","metadata":null},{"id":"f1487e77942844d4b8615987953f6344","type":"TRIAL","name":"Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment","canonical_id":"clinicaltrials.gov:NCT01316055","description":"Renal Insufficiency","metadata":null},{"id":"ee246ee15703471c8377a81beb42aa3a","type":"TRIAL","name":"Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat","canonical_id":"clinicaltrials.gov:NCT03992014","description":"Cholestasis","metadata":null},{"id":"8bd0776f66614e8ab996f00ce5e5869e","type":"TRIAL","name":"Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT01447485","description":"Hypertension; Chronic Kidney Disease; Nephrotic Syndrome","metadata":null},{"id":"bc8751e24684426c8bb2f6e4c6da7e13","type":"TRIAL","name":"Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra\u00ae Oral Tablet.","canonical_id":"clinicaltrials.gov:NCT01254383","description":"Erectile Dysfunction","metadata":null},{"id":"2f6b279ee60a4076b9d8ac89cc3342e8","type":"TRIAL","name":"Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium","canonical_id":"clinicaltrials.gov:NCT02201238","description":"Pain","metadata":null},{"id":"939854bc0afc496ba122a0cd76f583b7","type":"TRIAL","name":"Pharmacokinetics Study for Probucol","canonical_id":"clinicaltrials.gov:NCT01000467","description":"Healthy","metadata":null},{"id":"ab45104cdab44c26b6cf551cdb708501","type":"TRIAL","name":"Pharmacokinetics Study of ALO-02 and OxyContin","canonical_id":"clinicaltrials.gov:NCT01557257","description":"Management of Moderate to Severe Pain","metadata":null},{"id":"8a32a927073a43ee828761458eda9917","type":"TRIAL","name":"Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation","canonical_id":"clinicaltrials.gov:NCT02817750","description":"Healthy","metadata":null},{"id":"dc2d968ab7fb40c3bbf90f0348670ec4","type":"TRIAL","name":"Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose","canonical_id":"clinicaltrials.gov:NCT01367496","description":"Healthy Subjects","metadata":null},{"id":"7ebc906e1c8044ff9c96baef7e2d8fdb","type":"TRIAL","name":"Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients","canonical_id":"clinicaltrials.gov:NCT02466373","description":"Delirium; Critical Illness","metadata":null},{"id":"43540b981ed34208be9b4093ba657002","type":"TRIAL","name":"Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients","canonical_id":"clinicaltrials.gov:NCT02215148","description":"Brain Injury; Hyponatremia","metadata":null},{"id":"79461a8e73b844d6a32748a4833109d1","type":"TRIAL","name":"Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants","canonical_id":"clinicaltrials.gov:NCT01391663","description":"Pharmacokinetics and Pharmacodynamics","metadata":null},{"id":"9ce6aa2b3aa54325b297e7b75901f916","type":"TRIAL","name":"Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00935467","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"049708d4114145d5bd79ceb0ec1ac867","type":"TRIAL","name":"Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT00935220","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"9e688111ec5a4540840ada1d4fcdf63c","type":"TRIAL","name":"Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days","canonical_id":"clinicaltrials.gov:NCT03363997","description":"Menopause","metadata":null},{"id":"c11dbf14640641d1bb5b731ea942950b","type":"TRIAL","name":"Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery","canonical_id":"clinicaltrials.gov:NCT06326138","description":"Bariatric Surgery Candidate","metadata":null},{"id":"0aefbad32ed340ea8b28e531e6193656","type":"TRIAL","name":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler\u00ae 2 and Spiriva\u00ae HandiHaler\u00ae in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT02242266","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"dcd5672cfb484507a40bb9bbacef0d95","type":"TRIAL","name":"Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology","canonical_id":"clinicaltrials.gov:NCT00629720","description":"Urinary Bladder Neurogenic","metadata":null},{"id":"68a9320df06b4819b8fb40fdaee00f95","type":"TRIAL","name":"Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT03222349","description":"Epilepsy","metadata":null},{"id":"5353e0fd8e49400b9e4bafea5c1c11c6","type":"TRIAL","name":"Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT01590901","description":"Healthy","metadata":null},{"id":"d8013a91fa4a438993bad7064a2c2441","type":"TRIAL","name":"Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT01134536","description":"Pain, Postoperative; Postoperative Pain","metadata":null},{"id":"8666f1afce3a4af8ad60b8ddff2c92aa","type":"TRIAL","name":"Pharmacokinetics and Safety in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03917628","description":"Healthy","metadata":null},{"id":"35c02ad65636463ba915bdbd2cc689bb","type":"TRIAL","name":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","canonical_id":"clinicaltrials.gov:NCT03511118","description":"Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI","metadata":null},{"id":"dfbab4f5067649e29152a2924bdf26fe","type":"TRIAL","name":"Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT07102719","description":"Healthy Volunteers","metadata":null},{"id":"fb0676167e184cde911203b5d6928f1b","type":"TRIAL","name":"Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT06889350","description":"Healthy Volunteers","metadata":null},{"id":"4f30ff1dad9f4ab6b45cf494a755d858","type":"TRIAL","name":"Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.","canonical_id":"clinicaltrials.gov:NCT06736340","description":"Hepatic Impairment","metadata":null},{"id":"409e3adf1c5b4c19981b42f98780f71f","type":"TRIAL","name":"Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants","canonical_id":"clinicaltrials.gov:NCT06708520","description":"Renal Impairment","metadata":null},{"id":"28b2c4a6c3624df5a367837a7cb7e33d","type":"TRIAL","name":"Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function","canonical_id":"clinicaltrials.gov:NCT00698464","description":"Hepatic Cirrhosis; Alcoholism","metadata":null},{"id":"956b34b6b4c34149a8ea41041e5195a4","type":"TRIAL","name":"Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07646548","description":"Healthy Volunteers","metadata":null},{"id":"0492ad04ce384b99a4562f020ab8dc47","type":"TRIAL","name":"Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01491035","description":"Depressive Disorder; Anxiety Disorder","metadata":null},{"id":"fa16047bbbf64c648c927f554d169d67","type":"TRIAL","name":"Pharmacokinetics and Tolerability of Zavesca\u00ae (Miglustat) In Patients With Juvenile GM2 Gangliosidosis","canonical_id":"clinicaltrials.gov:NCT00418847","description":"Gangliosidoses GM2","metadata":null},{"id":"34b75a0f751a4799b9e367ebe2c41420","type":"TRIAL","name":"Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.","canonical_id":"clinicaltrials.gov:NCT06074016","description":"Healthy","metadata":null},{"id":"a07ce01fb2214555a9f11e94e2688a62","type":"TRIAL","name":"Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function","canonical_id":"clinicaltrials.gov:NCT01028768","description":"Renal Impairment","metadata":null},{"id":"72f8cca9b4ab41009544a56455f615cb","type":"TRIAL","name":"Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino\u00ae) in Patients With Hepatic Disease","canonical_id":"clinicaltrials.gov:NCT01261923","description":"Hepatic Insufficiency","metadata":null},{"id":"496b278e91844d4e8f6c53b043f2bac6","type":"TRIAL","name":"Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04181008","description":"Pharmacokinetics","metadata":null},{"id":"4e54c5873de04a47bc160f50a8714602","type":"TRIAL","name":"Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation","canonical_id":"clinicaltrials.gov:NCT03532399","description":"Drug Effect","metadata":null},{"id":"d93012206c00496f998fabb35574169d","type":"TRIAL","name":"Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients","canonical_id":"clinicaltrials.gov:NCT02119234","description":"COPD","metadata":null},{"id":"aa05bedce6e745b1b59453aa1a0ae579","type":"TRIAL","name":"Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT05486117","description":"Chronic Hand Eczema","metadata":null},{"id":"00c3c577e9514cc2bd3d560d08d7fe7b","type":"TRIAL","name":"Pharmacokinetics of Dipyridamole Administered as Aggrenox\u00ae (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH","canonical_id":"clinicaltrials.gov:NCT02251184","description":"Healthy","metadata":null},{"id":"980bf73194f9470789d94902abf32596","type":"TRIAL","name":"Pharmacokinetics of Eplerenone Tablet","canonical_id":"clinicaltrials.gov:NCT02607657","description":"Healthy Volunteers","metadata":null},{"id":"06b5745ac0e942e6a37bff16a79dd25e","type":"TRIAL","name":"Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)","canonical_id":"clinicaltrials.gov:NCT01188603","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"870b0594715f406593c4069c0b6b1d7f","type":"TRIAL","name":"Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT06339788","description":"Healthy Volunteers","metadata":null},{"id":"5172be9eb3ac4608a3b3c01c774876e8","type":"TRIAL","name":"Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions","canonical_id":"clinicaltrials.gov:NCT02124239","description":"Actinic Keratosis","metadata":null},{"id":"c904af34b50246d0855706dc097535a9","type":"TRIAL","name":"Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis","canonical_id":"clinicaltrials.gov:NCT05885763","description":"End Stage Renal Disease on Hemodialysis","metadata":null},{"id":"28f0a1847ae9441687cbf3022d81b6cf","type":"TRIAL","name":"Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05688085","description":"Healthy Volunteers","metadata":null},{"id":"26b90c42954c4ae1a350e935663cd0a2","type":"TRIAL","name":"Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05663073","description":"Healthy Volunteers","metadata":null},{"id":"b5b6e6183b4b498e951bba862a3714dc","type":"TRIAL","name":"Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors","canonical_id":"clinicaltrials.gov:NCT00906828","description":"Parkinson Disease","metadata":null},{"id":"e1d53e3cb1f648b99ccc8753656df328","type":"TRIAL","name":"Pharmacokinetics of Lisdexamfetamine (Vyvanse\u00ae) in Post-bariatric Surgery Patients","canonical_id":"clinicaltrials.gov:NCT03070509","description":"Lisdexamfetamine","metadata":null},{"id":"83ee204a64324e8b819e6ebd78bf80a3","type":"TRIAL","name":"Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02273466","description":"Healthy","metadata":null},{"id":"a086d22e01e844efabf99f5d4d490ff9","type":"TRIAL","name":"Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)","canonical_id":"clinicaltrials.gov:NCT05090280","description":"Pharmacokinetics","metadata":null},{"id":"d1af289217f144f2b26914cb093fc550","type":"TRIAL","name":"Pharmacokinetics of Paracetamol and Antiepileptic Drugs After Sleeve Gastrectomy","canonical_id":"clinicaltrials.gov:NCT03161509","description":"Bariatric Surgery Candidate","metadata":null},{"id":"fa8b29a83bf04d9cb7b4bfc2b63a8f36","type":"TRIAL","name":"Pharmacokinetics of SP-104","canonical_id":"clinicaltrials.gov:NCT05002946","description":"Healthy","metadata":null},{"id":"9164f6ab8ce34179bf5573a70866a98f","type":"TRIAL","name":"Pharmacokinetics of Sildenafil in Premature Infants","canonical_id":"clinicaltrials.gov:NCT01670136","description":"Persistent Pulmonary Hypertension of the Newborn","metadata":null},{"id":"7586aca41d9f41ceae511d23f25c171b","type":"TRIAL","name":"Pharmacokinetics of Sufentanil After Epidural Administration","canonical_id":"clinicaltrials.gov:NCT06069219","description":"Epidural; Anesthesia; Epidural Analgesia; Abdominal Surgery","metadata":null},{"id":"9a0a4aa41e5f4172b95e501d5b6a6b27","type":"TRIAL","name":"Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02082236","description":"Healthy","metadata":null},{"id":"bf2c69a7bed14f8e99a8e8e6f5137771","type":"TRIAL","name":"Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents","canonical_id":"clinicaltrials.gov:NCT07092813","description":"Pharmacokinetics After Oral Intake","metadata":null},{"id":"c5c14db95d5a41b6be0d8f8f611058ee","type":"TRIAL","name":"Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)","canonical_id":"clinicaltrials.gov:NCT01043926","description":"Insomnia; Hepatic Insufficiency","metadata":null},{"id":"0150a1f57e4743f2bc8b133e2a89222a","type":"TRIAL","name":"Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT01059851","description":"Insomnia","metadata":null},{"id":"227bf2944efc4e8788601359fdb77153","type":"TRIAL","name":"Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine","canonical_id":"clinicaltrials.gov:NCT01540500","description":"Healthy Volunteers","metadata":null},{"id":"688c5e70ca6745a7a8842347516f4a63","type":"TRIAL","name":"Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.","canonical_id":"clinicaltrials.gov:NCT01637636","description":"Healthy","metadata":null},{"id":"580718e7cd354f5c9aba1657c8949170","type":"TRIAL","name":"Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT01271387","description":"Hepatic Impairment","metadata":null},{"id":"daedf8c620544871923f764e1a91bf9c","type":"TRIAL","name":"Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function","canonical_id":"clinicaltrials.gov:NCT01526746","description":"Renal Impairment","metadata":null},{"id":"cebbc9aff36147358afc86f97f036bfa","type":"TRIAL","name":"Pharmacokinetics of Tranexamic Acid After Oral, Intramuscular or Intravenous Administration: a Prospective, Randomised, Cross-over Trial in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT03777488","description":"Healthy Volunteer Study","metadata":null},{"id":"e1a182ebcc854db5b169e3edf198a289","type":"TRIAL","name":"Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT04616274","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"54a0f1b8399649d48cdfce0b4a0334f6","type":"TRIAL","name":"Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients","canonical_id":"clinicaltrials.gov:NCT00818571","description":"Renal Impairment; Diabetes","metadata":null},{"id":"e2af3a2e76c3498c9168e7a6a5d078a3","type":"TRIAL","name":"Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function","canonical_id":"clinicaltrials.gov:NCT04787562","description":"Bacterial Infections","metadata":null},{"id":"1aea2f6e6f3d44149190958c46facb7f","type":"TRIAL","name":"Pharmacokinetics of Zolpidem Orodispersible Tablet","canonical_id":"clinicaltrials.gov:NCT02607696","description":"Healthy Volunteers","metadata":null},{"id":"f1c96b5cc855465584818ef245775c8c","type":"TRIAL","name":"Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose","canonical_id":"clinicaltrials.gov:NCT00577850","description":"Osteopenia; Osteoporosis","metadata":null},{"id":"f6d296615ea44587bcf9bcc38c50d9d3","type":"TRIAL","name":"Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus","canonical_id":"clinicaltrials.gov:NCT00643643","description":"HIV Infections","metadata":null},{"id":"866ab98b8bde413cba8b46b767680ba2","type":"TRIAL","name":"Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00957268","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"bc32c2a209544d61a0a6ff54f459b17d","type":"TRIAL","name":"Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT07660835","description":"Moderate-to-Severe Atopic Dermatitis","metadata":null},{"id":"89963c5b8e5c4425a9e535c5b8a247af","type":"TRIAL","name":"Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04921345","description":"Moderate-to-Severe Atopic Dermatitis","metadata":null},{"id":"9abfa7c595cb43788259fccae1c35f7e","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01568775","description":"End Stage Renal Disease","metadata":null},{"id":"4f7a59260e284f45b540593ea7eda542","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects","canonical_id":"clinicaltrials.gov:NCT06454708","description":"Acne Vulgaris","metadata":null},{"id":"837130db05e2416d8117c645c549348c","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT06276361","description":"Schizophrenia","metadata":null},{"id":"e3c120bcf66e43f5a46c98cafc9fb183","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT01791491","description":"Kidney Transplant","metadata":null},{"id":"a3bfc919ece44c11a68b883bbd85a840","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT03464864","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"bc7024915de447f8b4725deaaac49fdf","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT03276078","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"b6df5f420930498c809c74601a4dd5e6","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses","canonical_id":"clinicaltrials.gov:NCT00672022","description":"GM2 Gangliosidoses; Tay-Sachs; Sandhoff Disease","metadata":null},{"id":"3ef9a33c9ae340c3abfc42d34910f994","type":"TRIAL","name":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","canonical_id":"clinicaltrials.gov:NCT01434888","description":"Healthy Volunteers","metadata":null},{"id":"ec8271978cba4916a2e6af1b4da36870","type":"TRIAL","name":"Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04260009","description":"Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors; Solid Tumors","metadata":null},{"id":"fe68e55da3b44a0a96f730bb999cc565","type":"TRIAL","name":"Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)","canonical_id":"clinicaltrials.gov:NCT02115347","description":"Type 2 Diabetes Mellitus; Hepatic Impairment","metadata":null},{"id":"e47ec446ced04b5fbc9c5dee5e74dde3","type":"TRIAL","name":"Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function","canonical_id":"clinicaltrials.gov:NCT01367509","description":"Renal Impairment","metadata":null},{"id":"94072a9e870a41c9a5ff68cf304fd0cc","type":"TRIAL","name":"Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function","canonical_id":"clinicaltrials.gov:NCT01367522","description":"Liver Dysfunction","metadata":null},{"id":"0034d05372e8482e9c364ba52e00dd16","type":"TRIAL","name":"Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations","canonical_id":"clinicaltrials.gov:NCT06614153","description":"Parkinson's Disease","metadata":null},{"id":"41ffcb7efc7f48a38e993a421ab4457c","type":"TRIAL","name":"Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor","canonical_id":"clinicaltrials.gov:NCT00102674","description":"Healthy","metadata":null},{"id":"3dfad6023fd84aef910f2bdee9ff1280","type":"TRIAL","name":"Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00035178","description":"Kidney Failure, Chronic; Renal Disease, End-Stage","metadata":null},{"id":"07e15a8536e14ec6aa85931453b34e8c","type":"TRIAL","name":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00413790","description":"Healthy","metadata":null},{"id":"29fbc388780f4b1faf743376cf237d36","type":"TRIAL","name":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00703703","description":"Healthy","metadata":null},{"id":"a6a826a808954bf69466356975b771d9","type":"TRIAL","name":"Pharmacologic Study of Oseltamivir in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00439530","description":"Avian Influenza A Virus","metadata":null},{"id":"f251affeb6cc4a4787f0e1e00da1ca0f","type":"TRIAL","name":"Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus","canonical_id":"clinicaltrials.gov:NCT00478335","description":"Nephrogenic Diabetes Insipidus","metadata":null},{"id":"5f6fa8875a034982b7b5753615ec9a96","type":"TRIAL","name":"Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG","canonical_id":"clinicaltrials.gov:NCT03383393","description":"Coronary Ischemia","metadata":null},{"id":"f67da85bbb944009b6fb5c754653d625","type":"TRIAL","name":"Pharmacological Activation of Brown Adipose Tissue Metabolism","canonical_id":"clinicaltrials.gov:NCT02811289","description":"Type 2 Diabetes","metadata":null},{"id":"b16e500602f04c62812f36a1bcf87856","type":"TRIAL","name":"Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","canonical_id":"clinicaltrials.gov:NCT06123026","description":"Lactation Suppressed; Second Trimester Abortion","metadata":null},{"id":"2b1c7ebd26fb4ba191e268df1969798d","type":"TRIAL","name":"Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)","canonical_id":"clinicaltrials.gov:NCT01386177","description":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","metadata":null},{"id":"f7d6cec7cefc48e6b5e8c5f79ddcc144","type":"TRIAL","name":"Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)","canonical_id":"clinicaltrials.gov:NCT00895804","description":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","metadata":null},{"id":"5aabbebe277d4adb913428f89cd6e566","type":"TRIAL","name":"Pharmacological Intervention in Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT00619034","description":"Diabetic Retinopathy","metadata":null},{"id":"9c3b3819963441b5b6a6dd4c1b05e6e7","type":"TRIAL","name":"Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity","canonical_id":"clinicaltrials.gov:NCT00689208","description":"Insulin Resistance","metadata":null},{"id":"6e65abbe281c49549dcb056c21ec23af","type":"TRIAL","name":"Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","canonical_id":"clinicaltrials.gov:NCT04923659","description":"Low Intensity Focussed Ultrasound","metadata":null},{"id":"3a1886f2a84e49219b150a04bc01104f","type":"TRIAL","name":"Pharmacological Modulation of Belief Salience","canonical_id":"clinicaltrials.gov:NCT03754062","description":"Haloperidol; Placebo; L-DOPA","metadata":null},{"id":"9df7bb96308d479f865eecdb75e847c6","type":"TRIAL","name":"Pharmacological Modulation of Brain Oscillations in Memory Processing","canonical_id":"clinicaltrials.gov:NCT05594017","description":"Epilepsy; Seizures; Cognitive Impairment, Mild; Memory Disorders; Memory Loss","metadata":null},{"id":"b7e3c37801c241e2be48ff6bbfe9f452","type":"TRIAL","name":"Pharmacological Modulation of Cocaine Effects - 1","canonical_id":"clinicaltrials.gov:NCT00000201","description":"Cocaine-Related Disorders","metadata":null},{"id":"574ea3f94913461abbd7418e6809705b","type":"TRIAL","name":"Pharmacological Modulation of Hippocampal Activity in Psychosis 2","canonical_id":"clinicaltrials.gov:NCT04559529","description":"Schizophrenia; Psychosis","metadata":null},{"id":"c4bf8b4daf2d470e806ab30c6b4ec50d","type":"TRIAL","name":"Pharmacological Modulation of Peripheral Nerve Excitability","canonical_id":"clinicaltrials.gov:NCT06312254","description":"Peripheral Neuropathy","metadata":null},{"id":"277d7a12c70a45b18a1271b5d07632f1","type":"TRIAL","name":"Pharmacological Properties of Salmeterol","canonical_id":"clinicaltrials.gov:NCT02558088","description":"Pharmacokinetics in Healthy Young Men","metadata":null},{"id":"e0a917cb0427479eb0d11145e976335e","type":"TRIAL","name":"Pharmacological Regulation of Fat Transport in Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00632840","description":"Obesity; Lipid Disorders; Hypertriglyceridemia; Cardiovascular Disease","metadata":null},{"id":"1a1871ead5a645cdb76c9f7f3cbc1980","type":"TRIAL","name":"Pharmacological Treatment In Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT01148043","description":"Osteoarthritis","metadata":null},{"id":"cdccfd37bf4f487da4fa4f281a98df45","type":"TRIAL","name":"Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT06295562","description":"Obstructive Sleep Apnea of Adult","metadata":null},{"id":"0571d3ffe11d480592d262ed675b880c","type":"TRIAL","name":"Pharmacological Treatment of Presbyopia","canonical_id":"clinicaltrials.gov:NCT05564832","description":"Near Vision","metadata":null},{"id":"b243d9c115104fdba4149d8014bfe3c2","type":"TRIAL","name":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)","canonical_id":"clinicaltrials.gov:NCT04599504","description":"Loss-of-control Eating; Obesity/Overweight","metadata":null},{"id":"2351e640a11a40df82fb75e754f1244b","type":"TRIAL","name":"Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)","canonical_id":"clinicaltrials.gov:NCT04605081","description":"Loss-of-Control Eating; Obesity/Overweight","metadata":null},{"id":"573875102bbe443e9ccfab0a2669daf3","type":"TRIAL","name":"Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate","canonical_id":"clinicaltrials.gov:NCT06282848","description":"Myopia","metadata":null},{"id":"48984ba1ed8f453685c806a84c00e986","type":"TRIAL","name":"Pharmacotherapy and Psychotherapy in the Treatment of Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT04126252","description":"Erectile Dysfunction","metadata":null},{"id":"db7f63e9141445b68fe09d6a5bd15d7a","type":"TRIAL","name":"Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers","canonical_id":"clinicaltrials.gov:NCT01638377","description":"Alcohol Dependence","metadata":null},{"id":"269733da2eec41e98cc74a28ee7f027a","type":"TRIAL","name":"Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy","canonical_id":"clinicaltrials.gov:NCT00643500","description":"Epilepsy, Partial","metadata":null},{"id":"3f9e740a0f9044d0ba8cec8a8c23437b","type":"TRIAL","name":"Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00662805","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"63dc7a1bddb74e658e1d8efe729fe684","type":"TRIAL","name":"Pharmacovigilance in Gerontopsychiatric Patients","canonical_id":"clinicaltrials.gov:NCT02374567","description":"Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders","metadata":null},{"id":"7eb9eb6d98a74d7da0a68db560e2797a","type":"TRIAL","name":"Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib","canonical_id":"clinicaltrials.gov:NCT00820417","description":"Colorectal Cancer; Head and Neck Cancer; Non Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"d79eba5f77454f108f055c80d0d85838","type":"TRIAL","name":"Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT05944965","description":"OSA","metadata":null},{"id":"d798a9539c5f4e91ba9ceffdcc182789","type":"DISEASE","name":"Pharyngitis","canonical_id":"mesh:D010612","description":null,"metadata":null},{"id":"a25f8d481b8840e6b0ada5fe837d0bcb","type":"TRIAL","name":"Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain","canonical_id":"clinicaltrials.gov:NCT03058965","description":"Alzheimer Disease; Healthy Volunteers; Progressive Supranuclear Palsy","metadata":null},{"id":"9c7d4fe03e514e529794288e57d2234f","type":"TRIAL","name":"Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)","canonical_id":"clinicaltrials.gov:NCT01888952","description":"Advanced B-cell Lymphoid Malignancies","metadata":null},{"id":"9d7a24cf03184fd9a061653cac7917d5","type":"TRIAL","name":"Phase 1 Bioavailability Study of SYR-322MET","canonical_id":"clinicaltrials.gov:NCT02508168","description":"Healthy Volunteers","metadata":null},{"id":"bc7651c6653e445ebea37c1f93b24309","type":"TRIAL","name":"Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01645930","description":"Multiple Myeloma","metadata":null},{"id":"48d811952cfb42d4a959eec219771b0e","type":"TRIAL","name":"Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT01877226","description":"Healthy","metadata":null},{"id":"ab3fac16e384457ab7e4fcaf1742b27b","type":"TRIAL","name":"Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)","canonical_id":"clinicaltrials.gov:NCT01190514","description":"Depression - Major Depressive Disorder","metadata":null},{"id":"c4d83c283cc14872839baf81d271ace6","type":"TRIAL","name":"Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT06916767","description":"Relapsed CLL; Refractory CLL; Refractory Lymphoma","metadata":null},{"id":"522619226062494fa087500c7ae9a520","type":"TRIAL","name":"Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT00657007","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"6dcd421325784dc6aabfc67b80117408","type":"TRIAL","name":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","canonical_id":"clinicaltrials.gov:NCT03212404","description":"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Malignant Mesothelioma, Advanced; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Classical Hodgkin Lymphoma; Cutaneous Squamous Cell Carcinoma; Non Hodgkin Lymphoma; Endometrial Cancer","metadata":null},{"id":"7d14d6c3ce9e4c6b802f975e7cf66af2","type":"TRIAL","name":"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma","canonical_id":"clinicaltrials.gov:NCT02203526","description":"Primary Central Nervous System Lymphoma","metadata":null},{"id":"15602216740843968a3d175ebdf47a07","type":"TRIAL","name":"Phase 1 Study of Levocetirizine","canonical_id":"clinicaltrials.gov:NCT02447393","description":"Dermatitis","metadata":null},{"id":"84a1e8e7fa794f8580f8c416f3e522c5","type":"TRIAL","name":"Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus","canonical_id":"clinicaltrials.gov:NCT02373215","description":"Uremic Pruritus","metadata":null},{"id":"00e908b5ad5342188ffe0f0a07217e7a","type":"TRIAL","name":"Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy","canonical_id":"clinicaltrials.gov:NCT00777114","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"178eec13a81a40f3a1304786475c3002","type":"TRIAL","name":"Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT02716805","description":"Multiple Myeloma","metadata":null},{"id":"5d55678ea2c747eda018b5061fe3f1f4","type":"TRIAL","name":"Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT02117219","description":"Myelodysplastic Syndrome","metadata":null},{"id":"ab2df82e038449aa8aaf758ca5ceac79","type":"TRIAL","name":"Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01355705","description":"Multiple Myeloma","metadata":null},{"id":"0c3c79b241cf4244aad1ed79c626fe58","type":"TRIAL","name":"Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma","canonical_id":"clinicaltrials.gov:NCT00753168","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"cb40d0580afa4d07ae65f489c2439de9","type":"TRIAL","name":"Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK","canonical_id":"clinicaltrials.gov:NCT06666348","description":"Pediatric Low-grade Glioma","metadata":null},{"id":"a6a31065c79540a792f7273878ecdce0","type":"TRIAL","name":"Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC","canonical_id":"clinicaltrials.gov:NCT03136627","description":"Carcinoma, Renal Cell","metadata":null},{"id":"119186b9630f43be8fb5780890683d47","type":"TRIAL","name":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03037385","description":"RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gl\u2026","metadata":null},{"id":"f5cd5127490845719a7571457810a329","type":"TRIAL","name":"Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02580708","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"56f95865a3b047d68b68bb21f8ed4f43","type":"TRIAL","name":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","canonical_id":"clinicaltrials.gov:NCT06709495","description":"Sarcoma; Sarcoma, Ewing; Desmoplastic Small Round Cell Tumor; Refractory Sarcoma; Osteosarcoma; Rhabdomyosarcoma","metadata":null},{"id":"7af989caaafb450482379186da66cc17","type":"TRIAL","name":"Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04344795","description":"Solid Tumor; Colorectal Cancer; Non Small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma; Endometrial Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; Solid Tumors With PIK3Ca Mutation","metadata":null},{"id":"dd64d37260464486838406140441068a","type":"TRIAL","name":"Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat","canonical_id":"clinicaltrials.gov:NCT00791011","description":"Hodgkin's Lymphoma; Low Grade Lymphoma; Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin's Lymphoma; Diffuse Large Cell Lymphoma","metadata":null},{"id":"6eee7dabd81e4dcbbb5d7a62d02a475a","type":"TRIAL","name":"Phase 1b Safety and Efficacy Study of TRU-016","canonical_id":"clinicaltrials.gov:NCT01644253","description":"Chronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma","metadata":null},{"id":"86d126abe4584c659261813d485df9dd","type":"TRIAL","name":"Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03006887","description":"Solid Tumors","metadata":null},{"id":"62d4497c724247b6bf19c97fb6bcb544","type":"TRIAL","name":"Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05384119","description":"Breast Cancer","metadata":null},{"id":"fff15fbd7268451791397696e5e40b54","type":"TRIAL","name":"Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)","canonical_id":"clinicaltrials.gov:NCT01512199","description":"Metastatic Breast Cancer","metadata":null},{"id":"4b227a8aaf714beca14e81e7eb822160","type":"TRIAL","name":"Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT06677229","description":"Acute Spinal Cord Injury (SCI)","metadata":null},{"id":"09501b75a94742f783ddde81c5b8c734","type":"TRIAL","name":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","canonical_id":"clinicaltrials.gov:NCT06986382","description":"Crohn Disease","metadata":null},{"id":"7885881a366642d49f3cd05870a95690","type":"TRIAL","name":"Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy","canonical_id":"clinicaltrials.gov:NCT00610103","description":"Parkinson's Disease","metadata":null},{"id":"f4787a1c586c44f483a9c978281ad798","type":"TRIAL","name":"Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT07679893","description":"Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)","metadata":null},{"id":"e2872747718049ef95e8b5f78749ef52","type":"TRIAL","name":"Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)","canonical_id":"clinicaltrials.gov:NCT01357655","description":"Leukemia","metadata":null},{"id":"02e527feb78047da95998403f589195e","type":"TRIAL","name":"Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00542425","description":"Osteoporosis","metadata":null},{"id":"fc7a60b8028c42118b1a7141f27bca7b","type":"TRIAL","name":"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","canonical_id":"clinicaltrials.gov:NCT03283371","description":"Epilepsy, Focal Seizures, Partial Seizures","metadata":null},{"id":"56064043a9b84415b15ce1714c670bd6","type":"TRIAL","name":"Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00424021","description":"Pulmonary Hypertension","metadata":null},{"id":"5c1ba827ed2448af9413d170859e93f6","type":"TRIAL","name":"Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies","canonical_id":"clinicaltrials.gov:NCT00593554","description":"Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia","metadata":null},{"id":"c81a5c1e30614d548992e94c9f4b1f08","type":"TRIAL","name":"Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT00233454","description":"Systemic Mastocytosis, Aggressive (ASM); Leukemia, Mast Cell; Hematological Non-mast Cell Lineage Disease (AHNMD)","metadata":null},{"id":"dcd1bce8b20b4abb818efb884b9065ac","type":"TRIAL","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","canonical_id":"clinicaltrials.gov:NCT03944772","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"a556930d013044599cfb76c9c65c9497","type":"TRIAL","name":"Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","canonical_id":"clinicaltrials.gov:NCT00482053","description":"Lymphoma, B-cell; Lymphoma, Non-Hodgkin; Diffuse Large B-cell Lymphoma (DLBCL); Malignant Lymphoma, Non-Hodgkin","metadata":null},{"id":"0ee8bf95ec4e4aebb5ad208ea924c813","type":"TRIAL","name":"Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC","canonical_id":"clinicaltrials.gov:NCT03352414","description":"Ileus","metadata":null},{"id":"66943221ad1c43b5b06163da413e929f","type":"TRIAL","name":"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain","canonical_id":"clinicaltrials.gov:NCT02270983","description":"Opioid-Induced Constipation","metadata":null},{"id":"0f2003e52e9a46e98e3a4e891f6fdaee","type":"TRIAL","name":"Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00423592","description":"Pulmonary Hypertension","metadata":null},{"id":"87ba7e0553fd4e00ad8b6c8a9268fb30","type":"TRIAL","name":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04059484","description":"Breast Cancer Metastatic","metadata":null},{"id":"b55d855617024863bc0f0c446a670e90","type":"TRIAL","name":"Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01674621","description":"Post Menopausal Osteoporosis","metadata":null},{"id":"b645ee0ed4604ffbb753ff8b63bca858","type":"TRIAL","name":"Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT00732940","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"e4b5812893b341348ac53f4d6302d7d4","type":"TRIAL","name":"Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT03410108","description":"ALK-positive Advanced NSCLC","metadata":null},{"id":"58192a2fc40d4456a66bd482ed067d86","type":"TRIAL","name":"Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06053658","description":"Renal Cell Carcinoma","metadata":null},{"id":"ecb3d1c66f2d447e97a60b503d177f9f","type":"TRIAL","name":"Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT03370185","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"243ac9d004a64ea3870c2c7788145533","type":"TRIAL","name":"Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT00787566","description":"Chemotherapy-Induced Nausea and Vomiting","metadata":null},{"id":"c772b5e3666740d4919cc5268d12f232","type":"TRIAL","name":"Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01505413","description":"Pancreatic Cancer","metadata":null},{"id":"8e509fe27e4c46bfa4dc4c1b07ef92fb","type":"TRIAL","name":"Phase 2 Study of Fingolimod in Lung Cancers","canonical_id":"clinicaltrials.gov:NCT06424067","description":"Non Small Cell Lung Cancer; Small-cell Lung Cancer","metadata":null},{"id":"79c4cb29c0054937907973ea56ae4693","type":"TRIAL","name":"Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02115594","description":"Breast Cancer","metadata":null},{"id":"435c4fc16f114b659798fdd6f46d5913","type":"TRIAL","name":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","canonical_id":"clinicaltrials.gov:NCT06043674","description":"Chronic Lymphocytic Leukemia; Richter's Transformation","metadata":null},{"id":"d8bd02fe0228429a9d4488e28275dd31","type":"TRIAL","name":"Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)","canonical_id":"clinicaltrials.gov:NCT00759135","description":"Benign Prostatic Hyperplasia (BPH); Enlarged Prostate","metadata":null},{"id":"16488ff912894155b3c292a0b61554ae","type":"TRIAL","name":"Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients","canonical_id":"clinicaltrials.gov:NCT02430077","description":"Familial Partial Lipodystrophy","metadata":null},{"id":"3ee6969ad68a49ebbeb9a2c8b04bed68","type":"TRIAL","name":"Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT01939899","description":"Follicular Lymphoma","metadata":null},{"id":"402cd6d7a39e4bfdb05c48988ac8d41f","type":"TRIAL","name":"Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia","canonical_id":"clinicaltrials.gov:NCT01675154","description":"Type 1 Hyperlipoproteinemia","metadata":null},{"id":"6a75d8b36d9c468faf494a9e77d2a593","type":"TRIAL","name":"Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT05328102","description":"Diffuse Large-cell B-cell Lymphoma","metadata":null},{"id":"b86315b11ca24e5b8d5afc96c967c818","type":"TRIAL","name":"Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation","canonical_id":"clinicaltrials.gov:NCT02984995","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"8242775380d4425aac958c651e049ecb","type":"TRIAL","name":"Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)","canonical_id":"clinicaltrials.gov:NCT03123588","description":"MPN (Myeloproliferative Neoplasms)","metadata":null},{"id":"86ea0558a5af44fbb6409f2195498d47","type":"TRIAL","name":"Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC","canonical_id":"clinicaltrials.gov:NCT05917431","description":"Unresectable Hepatocellular Carcinoma; Oligometastatic Disease","metadata":null},{"id":"8c12600f0bdf4c3f8372397f8c180bac","type":"TRIAL","name":"Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants","canonical_id":"clinicaltrials.gov:NCT00805142","description":"Pain; Cancer","metadata":null},{"id":"8954fb0e04fd4280a41780c0c10b5089","type":"TRIAL","name":"Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma","canonical_id":"clinicaltrials.gov:NCT00213278","description":"Glioma","metadata":null},{"id":"e1df6a297403406a83536549baf5cdb2","type":"TRIAL","name":"Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis\u00ae in Patients With Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00766337","description":"Age-Related Macular Degeneration; Choroidal Neovascularization","metadata":null},{"id":"0479fd0ed46b4f00abb3aa2384517a2b","type":"TRIAL","name":"Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01828021","description":"Breast Cancer","metadata":null},{"id":"f3ed8e85473348d6a07357bfe88839ec","type":"TRIAL","name":"Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin","canonical_id":"clinicaltrials.gov:NCT00742859","description":"Atrial Fibrillation","metadata":null},{"id":"9de1f8c8e62649ca9d4f297b28c1d677","type":"TRIAL","name":"Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis","canonical_id":"clinicaltrials.gov:NCT01865812","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"c5591825f50d413780c848c8d711a87e","type":"TRIAL","name":"Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz","canonical_id":"clinicaltrials.gov:NCT06240455","description":"Graves Disease","metadata":null},{"id":"133f6bf5a9e94394911d20e861bfccf5","type":"TRIAL","name":"Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02347176","description":"Atopic Dermatitis","metadata":null},{"id":"a4f1e76aea0d4dfe8683a55cb20a7931","type":"TRIAL","name":"Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib","canonical_id":"clinicaltrials.gov:NCT04884191","description":"Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post- Essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"79eb51b1d49a4dda8dae0a9eed394942","type":"TRIAL","name":"Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)","canonical_id":"clinicaltrials.gov:NCT04831450","description":"Head and Neck Squamous Cell Carcinoma; HNSCC; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Oral Cavity; Squamous Cell Carcinoma of Hypopharynx","metadata":null},{"id":"94a7f08497c14e26b4c5e93bd37dc965","type":"TRIAL","name":"Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT01203202","description":"Premature Ejaculation","metadata":null},{"id":"b9449277838e487fae036e83fa85c97e","type":"TRIAL","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","canonical_id":"clinicaltrials.gov:NCT00186628","description":"Leukemia, Mast-Cell; Mantle-cell Lymphoma","metadata":null},{"id":"b19dd1d8991d4c01973069a14f7c5dbd","type":"TRIAL","name":"Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma","canonical_id":"clinicaltrials.gov:NCT07283731","description":"Phase 2; Zanzalintinib; Pembrolizumab; Advanced/Metastatic; Soft-Tissue Sarcoma","metadata":null},{"id":"7d33be1a704a4cefb08cb13a9d6ae81d","type":"TRIAL","name":"Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence","canonical_id":"clinicaltrials.gov:NCT00687713","description":"Methamphetamine Dependence","metadata":null},{"id":"f2b9c58317854007a48006c41c4471aa","type":"TRIAL","name":"Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors","canonical_id":"clinicaltrials.gov:NCT01719861","description":"Small Cell Lung Cancer (SCLC); Neuroendocrine Tumors","metadata":null},{"id":"035530a90be642519b14fa83d919a318","type":"TRIAL","name":"Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients","canonical_id":"clinicaltrials.gov:NCT04155918","description":"Gout Patients","metadata":null},{"id":"dce62ea323d24144a76338ce91cc1c9a","type":"TRIAL","name":"Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema","canonical_id":"clinicaltrials.gov:NCT03683719","description":"Chronic Hand Eczema","metadata":null},{"id":"7b6698fa1d79400e905cbe2a1daffe92","type":"TRIAL","name":"Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout","canonical_id":"clinicaltrials.gov:NCT05818085","description":"Gout","metadata":null},{"id":"96aa3f05e465414e8e5155877b0462f0","type":"TRIAL","name":"Phase 3 /Seroquel SR Acute Mania Monotherapy - US","canonical_id":"clinicaltrials.gov:NCT00422123","description":"Affective Psychosis, Bipolar; Manic Disorder; Manic-Depressive Psychosis; Mania; Manic State; Psychoses, Manic-Depressive","metadata":null},{"id":"cc27d3ea97fe48c0898e5aac9c27b633","type":"TRIAL","name":"Phase 3 Alogliptin Pediatric Study","canonical_id":"clinicaltrials.gov:NCT02856113","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"b450778c40a6415bbe7783d1d0399725","type":"TRIAL","name":"Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment","canonical_id":"clinicaltrials.gov:NCT05118672","description":"Cold; Flu Symptom","metadata":null},{"id":"210376e27e214f648e28bc9520559972","type":"TRIAL","name":"Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301","canonical_id":"clinicaltrials.gov:NCT05286762","description":"ADHD; Attention Deficit Hyperactivity Disorder; ADHD - Combined Type; Attention Deficit Hyperactivity Disorder Combined; Attention-deficit Hyperactivity; Attention Deficit Hyper Activity","metadata":null},{"id":"1252d9cdd8a342abb270380c9fa894d6","type":"TRIAL","name":"Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301","canonical_id":"clinicaltrials.gov:NCT05924594","description":"ADHD; ADHD - Combined Type; Attention Deficit Hyper Activity; Attention Deficit Hyperactivity Disorder; Attention Deficit Disorder With Hyperactivity; Attention Deficit Hyperactivity Disorder Combined; Attention-deficit Hyperactivity","metadata":null},{"id":"6fef9b89922b47c0a751f8b6501115fc","type":"TRIAL","name":"Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.","canonical_id":"clinicaltrials.gov:NCT05631626","description":"ADHD; ADHD - Combined Type; Attention Deficit Hyperactivity Disorder Combined; Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"51095558750e4b83a9a6e6e228f09032","type":"TRIAL","name":"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","canonical_id":"clinicaltrials.gov:NCT04902885","description":"Extensive-stage Small-cell Lung Cancer","metadata":null},{"id":"96bb4130dfe74179a823093b5a5a43fb","type":"TRIAL","name":"Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT05138133","description":"Lupus Nephritis","metadata":null},{"id":"4e1845eff7e943ca86923004436c17ab","type":"TRIAL","name":"Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis","canonical_id":"clinicaltrials.gov:NCT01654731","description":"PBC","metadata":null},{"id":"3e98a51d48b3460d9d3dd4d12ccff55b","type":"TRIAL","name":"Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07700979","description":"Gastric / Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"f3b6f84892654204b20e5ba595a81b10","type":"TRIAL","name":"Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus","canonical_id":"clinicaltrials.gov:NCT05885737","description":"Uremic Pruritus","metadata":null},{"id":"32f740e4474547c891db32eb9da11da2","type":"TRIAL","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","canonical_id":"clinicaltrials.gov:NCT06757634","description":"Breast Cancer","metadata":null},{"id":"4d2225ee602049e384d61e74d77e7919","type":"TRIAL","name":"Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","canonical_id":"clinicaltrials.gov:NCT00735462","description":"Genital Warts","metadata":null},{"id":"004741022f8d4571a1b1567daef1eaea","type":"TRIAL","name":"Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis","canonical_id":"clinicaltrials.gov:NCT01473524","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"8b9a4ad29ccb4f77a58b79e073c5bc7c","type":"TRIAL","name":"Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)","canonical_id":"clinicaltrials.gov:NCT02371369","description":"Pigmented Villonodular Synovitis; Giant Cell Tumors of the Tendon Sheath; Tenosynovial Giant Cell Tumor","metadata":null},{"id":"d728373f71c64979914137c5c0fd7fec","type":"TRIAL","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06982521","description":"PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer","metadata":null},{"id":"b1365937c4924fc5af2fa6c99914db64","type":"TRIAL","name":"Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)","canonical_id":"clinicaltrials.gov:NCT01968213","description":"Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"fc460b03eb7444429f98ce85b43b9a24","type":"TRIAL","name":"Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)","canonical_id":"clinicaltrials.gov:NCT06691984","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"65819e5af1964a42a6a8fe69c6ee8a3d","type":"TRIAL","name":"Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)","canonical_id":"clinicaltrials.gov:NCT02970162","description":"Lambert-Eaton Myasthenic Syndrome","metadata":null},{"id":"90f06c6cb3814a37b4fe907c483f8923","type":"TRIAL","name":"Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma","canonical_id":"clinicaltrials.gov:NCT02281357","description":"Asthma","metadata":null},{"id":"b2ccb79acda44996a887929a5ca16561","type":"TRIAL","name":"Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH","canonical_id":"clinicaltrials.gov:NCT04034485","description":"Homozygous Familial Hypercholesterolemia","metadata":null},{"id":"543d4e44d9aa4060a3866ee63d25376c","type":"TRIAL","name":"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","canonical_id":"clinicaltrials.gov:NCT06643819","description":"Essential Hypertension","metadata":null},{"id":"9c2f9a51d9254ea491a3f3c5333d5e53","type":"TRIAL","name":"Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab","canonical_id":"clinicaltrials.gov:NCT07363642","description":"Severe Asthma","metadata":null},{"id":"246061510b1b4823a5b49e7e46bf0c83","type":"TRIAL","name":"Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT07246564","description":"Myasthenia Gravis","metadata":null},{"id":"e03b98f003b54cbe9ada7d5907d0071b","type":"TRIAL","name":"Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis","canonical_id":"clinicaltrials.gov:NCT02308111","description":"Liver Cirrhosis, Biliary","metadata":null},{"id":"927669c7e21448c489d6f46c83823e76","type":"TRIAL","name":"Phase Analysis and Obstructive CAD on Rubidium PET","canonical_id":"clinicaltrials.gov:NCT01840696","description":"Coronary Artery Disease","metadata":null},{"id":"ffc6029d266f4e009a64eff9e1bf9a38","type":"TRIAL","name":"Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)","canonical_id":"clinicaltrials.gov:NCT01110876","description":"Brain Cancer; Glioblastoma Multiforme","metadata":null},{"id":"4d7468249b114eb0ade6b742df152a81","type":"TRIAL","name":"Phase I BLASST-3 Trial","canonical_id":"clinicaltrials.gov:NCT04972253","description":"Bladder Transitional Cell Carcinoma; Bladder Cancer; Fibroblast Growth Factor Receptor","metadata":null},{"id":"6b389d887b614d8ab2aebfb49360ec43","type":"TRIAL","name":"Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM","canonical_id":"clinicaltrials.gov:NCT01114282","description":"Multiple Myeloma","metadata":null},{"id":"84e0e5f8b82e4ab18fd12ee3a383abdb","type":"TRIAL","name":"Phase I Chinese PK","canonical_id":"clinicaltrials.gov:NCT00503711","description":"Advanced Solid, Malignant Tumors","metadata":null},{"id":"fdd35254d7f04077ac8a6f24c9e944c8","type":"TRIAL","name":"Phase I Combination Ixabepilone + Cisplatin","canonical_id":"clinicaltrials.gov:NCT00832117","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"ac87cc872f834086b9b0f86065ef6917","type":"TRIAL","name":"Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01174888","description":"Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following; Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia","metadata":null},{"id":"5821cf96f6e04ecdba3d9552ac9affe0","type":"TRIAL","name":"Phase I Combination w/ Epirubicin","canonical_id":"clinicaltrials.gov:NCT00322374","description":"Metastatic Breast Cancer","metadata":null},{"id":"f7d97855bc8e44a4960836b41a7cf91b","type":"TRIAL","name":"Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative","canonical_id":"clinicaltrials.gov:NCT02754011","description":"Breast Cancer","metadata":null},{"id":"4b2a583e9719472aaa83463bbdebe5d0","type":"TRIAL","name":"Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder","canonical_id":"clinicaltrials.gov:NCT03143543","description":"Cocaine-Related Disorders; Opioid-Related Disorders","metadata":null},{"id":"094e0444ff2b497ea392aebea950c955","type":"TRIAL","name":"Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination","canonical_id":"clinicaltrials.gov:NCT00507091","description":"Metastatic; Colorectal; Adenocarcinoma","metadata":null},{"id":"e3b34ebf59a9469da5e505eb70f9d12a","type":"TRIAL","name":"Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04161248","description":"Lymphoma, B-Cell","metadata":null},{"id":"1d415c94b6c944d3bdcc6ed7e1ec9734","type":"TRIAL","name":"Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00720018","description":"Migraine Disorders","metadata":null},{"id":"9992be59535748a089399a75e9d4bb89","type":"TRIAL","name":"Phase I Pharmacokinetic Study (BF-BLOCK)","canonical_id":"clinicaltrials.gov:NCT01423305","description":"Asthma","metadata":null},{"id":"de491ed3c93d4096a6cf92d9f4e946cf","type":"TRIAL","name":"Phase I Pharmacokinetic Study (SALBLOCK)","canonical_id":"clinicaltrials.gov:NCT01564199","description":"Healthy Volunteer Study","metadata":null},{"id":"1673050abefd4f1981f4cd7d1c3145f5","type":"TRIAL","name":"Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male","canonical_id":"clinicaltrials.gov:NCT07166887","description":"Healthy Subjects","metadata":null},{"id":"35343856f63f47ecb329691b72cb5244","type":"TRIAL","name":"Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg","canonical_id":"clinicaltrials.gov:NCT00705367","description":"Lupus Nephritis","metadata":null},{"id":"db9ad0a54e4d4fbaaf78a147f6dc11b0","type":"TRIAL","name":"Phase I Study of Aprotinin in Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00354900","description":"Metastatic Breast Cancer","metadata":null},{"id":"c5184f72a3d248acb4648a1dbd64f0e5","type":"TRIAL","name":"Phase I Study of CS-7017 and Bexarotene","canonical_id":"clinicaltrials.gov:NCT01504490","description":"Solid Tumors; Lymphoma; Multiple Myeloma","metadata":null},{"id":"c0d0814562ba42a880cdba8a2300a329","type":"TRIAL","name":"Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01198535","description":"Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Rectal Mucinous Adenocarcinoma; Rectal Signet Ring Cell Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer","metadata":null},{"id":"cd789d6a25974e6c90c44e834a419f9d","type":"TRIAL","name":"Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis","canonical_id":"clinicaltrials.gov:NCT00004368","description":"Cirrhosis; Liver Cirrhosis","metadata":null},{"id":"08a3cdb3bfb04077ae4874c5360a230c","type":"TRIAL","name":"Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02626507","description":"Breast Cancer","metadata":null},{"id":"e45f06fdb34247d7a3b5abf3f0a266bc","type":"TRIAL","name":"Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06981806","description":"Metastatic Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"e7ae9b7c103c4c838f049596ea42da6e","type":"TRIAL","name":"Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation","canonical_id":"clinicaltrials.gov:NCT00903929","description":"Thrombocytopenia; Acute Radiation Syndrome","metadata":null},{"id":"a4038534fa064b6d89b1aad7ad3e196e","type":"TRIAL","name":"Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole","canonical_id":"clinicaltrials.gov:NCT04120636","description":"Macula Edema; Radiation Retinopathy; Branch Retinal Vein Occlusion; Epiretinal Membrane; Central Serous Retinopathy With Pit of Optic Disc; Commotio Retinae; Vitritis","metadata":null},{"id":"595e1219200b4545b21a7b12ce129348","type":"TRIAL","name":"Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01645215","description":"Tumor","metadata":null},{"id":"a0266ffdd04f4b7f9acbe7e315c73885","type":"TRIAL","name":"Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT01838200","description":"Metastatic Melanoma","metadata":null},{"id":"3bbc751ca9b54c4d8aa313df96d781b8","type":"TRIAL","name":"Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00497250","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"258936e68d65419b8be6e788994fa09b","type":"TRIAL","name":"Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00634088","description":"Locally Advanced or Metastatic Breast Cancer","metadata":null},{"id":"52b265c57e744d5e84e6297fe3088ac6","type":"TRIAL","name":"Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)","canonical_id":"clinicaltrials.gov:NCT01742286","description":"ALK-activated Tumors","metadata":null},{"id":"712a93e6e05e4d6780d98947211551d5","type":"TRIAL","name":"Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls","canonical_id":"clinicaltrials.gov:NCT05393076","description":"Pruritus","metadata":null},{"id":"d077dd72cafd4e9da1c2041b1b4c0414","type":"TRIAL","name":"Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT01491139","description":"Carcinoma, Squamous Cell","metadata":null},{"id":"703aecde68e24bd1819c5324fe78f84b","type":"TRIAL","name":"Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00516672","description":"Carcinoma, Renal Cell","metadata":null},{"id":"fd27e5940d174a9e87f1e510f969ce3f","type":"TRIAL","name":"Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome","canonical_id":"clinicaltrials.gov:NCT04185220","description":"Adult T-Cell Lymphoma/Leukemia; Sezary Syndrome; Mycosis Fungoides","metadata":null},{"id":"855a69586228472ca8e152f268c6d285","type":"TRIAL","name":"Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas","canonical_id":"clinicaltrials.gov:NCT02181218","description":"Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse","metadata":null},{"id":"f830669808c14357a0ff497796a6aa98","type":"TRIAL","name":"Phase I Study of Topical CRx-191 in Normal Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00544687","description":"Healthy","metadata":null},{"id":"5067b3154e7140bc8c9afb1954faeba3","type":"TRIAL","name":"Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone","canonical_id":"clinicaltrials.gov:NCT00059631","description":"Prostate Cancer","metadata":null},{"id":"16bef48876f3416a8dfb785aa6b0e4fe","type":"TRIAL","name":"Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT02145637","description":"NSCLC","metadata":null},{"id":"3bcd26b43008427980e766822a09d2f0","type":"TRIAL","name":"Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children","canonical_id":"clinicaltrials.gov:NCT02497716","description":"Thrombosis","metadata":null},{"id":"085e248c46ec40b49b23c7107c58868b","type":"TRIAL","name":"Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib","canonical_id":"clinicaltrials.gov:NCT00729495","description":"Healthy Volunteer","metadata":null},{"id":"ae29ab54c2744e838b168b1b2880209b","type":"TRIAL","name":"Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients","canonical_id":"clinicaltrials.gov:NCT01769768","description":"Advanced Solid Tumor","metadata":null},{"id":"76ea7d996251456caae564694886aa1f","type":"TRIAL","name":"Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT05819892","description":"Endometrial Cancer","metadata":null},{"id":"3c6db02862f049fd8fc11fd8aa635184","type":"TRIAL","name":"Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05722327","description":"Colon Cancer; Colorectal Cancer","metadata":null},{"id":"e6c6c399c7f74b78af6ad0899d3dfb86","type":"TRIAL","name":"Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC","canonical_id":"clinicaltrials.gov:NCT02913196","description":"Prostate Cancer Metastatic","metadata":null},{"id":"449642439e8d469b95fcd1cd47a74c9a","type":"TRIAL","name":"Phase I Trial of Envafolimab for Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT05849311","description":"Healthy Male","metadata":null},{"id":"0025881371f24b31b4ac420af02fe169","type":"TRIAL","name":"Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms","canonical_id":"clinicaltrials.gov:NCT07679334","description":"Myeloproliferative Neoplasm","metadata":null},{"id":"eed51d6893044ac98993566aea8deb3e","type":"TRIAL","name":"Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma","canonical_id":"clinicaltrials.gov:NCT01941849","description":"Phaeochromocytoma; Paraganglioma","metadata":null},{"id":"21b1a7a610a742c6afb20ff015853996","type":"TRIAL","name":"Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00532909","description":"Anal, Colon, and Rectal Cancers; Colorectal Neoplasms; Colon/Rectal Cancer","metadata":null},{"id":"993d5bd3c1b34ba0bd9eaf88f9e71df4","type":"TRIAL","name":"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT01614301","description":"Advanced Melanoma","metadata":null},{"id":"24ddad5494884394a49c3d3da7cef5fe","type":"TRIAL","name":"Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma","canonical_id":"clinicaltrials.gov:NCT02032810","description":"Melanoma; Skin Cancer","metadata":null},{"id":"a01e7daefe174007b3e92b7685d3fedb","type":"TRIAL","name":"Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02151721","description":"Non-Small-Cell Lung Carcinoma","metadata":null},{"id":"4e118f772de4423181d5dafef4bd6ff3","type":"TRIAL","name":"Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex\u00ae (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period","canonical_id":"clinicaltrials.gov:NCT00723983","description":"Migraine Disorders","metadata":null},{"id":"aa2975ad1650419ea497b1477869fa56","type":"TRIAL","name":"Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT05470283","description":"Tumor; Metastatic Melanoma; Melanoma","metadata":null},{"id":"75d07d9c6f91485b9fa7b388faed137e","type":"TRIAL","name":"Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00368875","description":"Male Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"106245fd596e4abcbe52cc2723a075b1","type":"TRIAL","name":"Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT02096042","description":"Leukemia","metadata":null},{"id":"714b0548ceb84f32a91271f2d9e6b6c4","type":"TRIAL","name":"Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02013362","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"a5218038e6de46b9b9d4f1cedf7ddc21","type":"TRIAL","name":"Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00279760","description":"Rheumatoid Arthritis","metadata":null},{"id":"1554649aabd842e5974199947c752d45","type":"TRIAL","name":"Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06105554","description":"Multiple Myeloma","metadata":null},{"id":"04cea621d06d45fd9f89c8ed0d059ffb","type":"TRIAL","name":"Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders","canonical_id":"clinicaltrials.gov:NCT06434363","description":"Autoimmune Disorders; Systemic Sclerosis; Systemic Lupus Erythematosus; Lupus; Lupus Nephritis","metadata":null},{"id":"9254a1eaefe74d00875d81b3a1107baf","type":"TRIAL","name":"Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT07714512","description":"Aplastic Anemia","metadata":null},{"id":"d611e89688d446b89e9926d3367ef7c9","type":"TRIAL","name":"Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML","canonical_id":"clinicaltrials.gov:NCT02311998","description":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts More Than 5 Percent of Bone Marrow Nucleated Cells; CD22 Positive; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","metadata":null},{"id":"8961fbe36049443a88a7e0f334a1b41b","type":"TRIAL","name":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","canonical_id":"clinicaltrials.gov:NCT02185820","description":"Multiple Myeloma","metadata":null},{"id":"1046223fc5bd4b178414de26d51a42a1","type":"TRIAL","name":"Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00450892","description":"Breast Cancer","metadata":null},{"id":"1ef1a5328eff45fbb078d7a728b8977a","type":"TRIAL","name":"Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia","canonical_id":"clinicaltrials.gov:NCT01914484","description":"Chronic Phase Chronic Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blastic Phase Chronic Myeloid Leukemia; Philadelphia Positive Acute Lymphoblastic Leukemia; Resistant to Tyrosine Kinase Inhibitor Therapy","metadata":null},{"id":"2682992aef924211817fa4a61888d7e2","type":"TRIAL","name":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","canonical_id":"clinicaltrials.gov:NCT06085729","description":"Prostate Cancer","metadata":null},{"id":"f62328b3bdc14332b74c67cade5a32da","type":"TRIAL","name":"Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","canonical_id":"clinicaltrials.gov:NCT05531786","description":"Graft vs Host Disease","metadata":null},{"id":"505302f9d5bd4c0a90e3f81185d62f20","type":"TRIAL","name":"Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT00578071","description":"Cancer of the Esophagus","metadata":null},{"id":"3cd24a5c6f264d9a9f1b044366fd867f","type":"TRIAL","name":"Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT","canonical_id":"clinicaltrials.gov:NCT00506922","description":"Leukemia; Lymphoma","metadata":null},{"id":"7859f21033c746de8b07c1bcd0083bf4","type":"TRIAL","name":"Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT06085638","description":"Chronic Myelomonocytic Leukemia","metadata":null},{"id":"b477f9d4fed745e69bbd869270ed0387","type":"TRIAL","name":"Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia","canonical_id":"clinicaltrials.gov:NCT00005898","description":"Fanconi's Anemia","metadata":null},{"id":"91840ea692b5407094e736aa87d2b146","type":"TRIAL","name":"Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL","canonical_id":"clinicaltrials.gov:NCT03379051","description":"Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma","metadata":null},{"id":"f387dd60cdf24a84a9c60f803ff3a672","type":"TRIAL","name":"Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca","canonical_id":"clinicaltrials.gov:NCT00934895","description":"Breast Cancer","metadata":null},{"id":"aa518da2a372442d93c2d3da5ca9cfbe","type":"TRIAL","name":"Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible","canonical_id":"clinicaltrials.gov:NCT02261779","description":"AML","metadata":null},{"id":"0824f16abe524534ba05c7a642d19b53","type":"TRIAL","name":"Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02521051","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"d4f1844f2edf4864ac4fe3c771ad1df9","type":"TRIAL","name":"Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.","canonical_id":"clinicaltrials.gov:NCT07853105","description":"Osteosarcomas; Bone Cancer; Ewing Sarcomas","metadata":null},{"id":"b4e13d33140f411888ebbc68d64a69e2","type":"TRIAL","name":"Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00825734","description":"Metastatic Breast Cancer","metadata":null},{"id":"df0d9430700b43258c629c09ee3e45a3","type":"TRIAL","name":"Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT00372905","description":"Lymphoma","metadata":null},{"id":"89d34013ac174745ac759db66fea632f","type":"TRIAL","name":"Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD","canonical_id":"clinicaltrials.gov:NCT01810718","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"8cec4d98b0dd436a8c5c4c31c71f5b8f","type":"TRIAL","name":"Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05505877","description":"Advanced Solid Tumor","metadata":null},{"id":"454d7d4fb95d46ca9cc9edbb6c4ed57e","type":"TRIAL","name":"Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)","canonical_id":"clinicaltrials.gov:NCT03076203","description":"Prostate Carcinoma Metastatic to the Bone; Stage IV Prostate Adenocarcinoma; Hormone-refractory Prostate Cancer","metadata":null},{"id":"112b0cb6e98042e38e4033c143b04728","type":"TRIAL","name":"Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty","canonical_id":"clinicaltrials.gov:NCT06963320","description":"Circulatory Disease","metadata":null},{"id":"37e04e7ce9d14f57a26ba0f68c7cc23d","type":"TRIAL","name":"Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy","canonical_id":"clinicaltrials.gov:NCT05560308","description":"HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy","metadata":null},{"id":"b60ae026850146068d3db4b8fd685d66","type":"TRIAL","name":"Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC","canonical_id":"clinicaltrials.gov:NCT03573947","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"69393d3cb4a246c7a45e264c8e0ed039","type":"TRIAL","name":"Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT02078219","description":"Gout and Hyperuricemia","metadata":null},{"id":"06b75a31b33e40feb3c4147abfc49f3f","type":"TRIAL","name":"Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476","canonical_id":"clinicaltrials.gov:NCT00545389","description":"Colitis, Ulcerative","metadata":null},{"id":"5e307c678b36438a985c6f80b92466c5","type":"TRIAL","name":"Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT","canonical_id":"clinicaltrials.gov:NCT00246974","description":"Bladder Cancer","metadata":null},{"id":"c4f63da752c74c64a41f4bc8f4977180","type":"TRIAL","name":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","canonical_id":"clinicaltrials.gov:NCT03541928","description":"High-risk Prostate Cancer; Prostate Cancer","metadata":null},{"id":"58593c19359a479c8cfb4dabe7621f8c","type":"TRIAL","name":"Phase II Iressa + Irradiation Followed by Chemo in NSCLC","canonical_id":"clinicaltrials.gov:NCT00333294","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"14ffa66da4a248cdbb688783d704e502","type":"TRIAL","name":"Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole","canonical_id":"clinicaltrials.gov:NCT05286437","description":"Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer","metadata":null},{"id":"96ee78cb33114811aeabf454ef559970","type":"TRIAL","name":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","canonical_id":"clinicaltrials.gov:NCT07472478","description":"Lung Cancer (NSCLC); KRAS G12C Lung Cancer","metadata":null},{"id":"ac9a44bdcdec4f8c91e3495f1c6bd55b","type":"TRIAL","name":"Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma","canonical_id":"clinicaltrials.gov:NCT03502746","description":"Mesothelioma, Malignant","metadata":null},{"id":"91283a101d8a49bdbd7716fa498069f8","type":"TRIAL","name":"Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT01108055","description":"Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable","metadata":null},{"id":"caae218000b64d989818cb690c342b56","type":"TRIAL","name":"Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome","canonical_id":"clinicaltrials.gov:NCT00004652","description":"Tourette Syndrome","metadata":null},{"id":"4515b53218ae486ab095b9eb056e7a84","type":"TRIAL","name":"Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT06962137","description":"Gastric Cancer Adenocarcinoma Metastatic; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"d008f7afa53a4e88a4533808368782b9","type":"TRIAL","name":"Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT00004310","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"bf7c40d73a8144c694c907913cc78c65","type":"TRIAL","name":"Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis","canonical_id":"clinicaltrials.gov:NCT00004482","description":"Myocarditis; Giant Cell Myocarditis","metadata":null},{"id":"ba15b10ae3d848de89e0349eb085c18b","type":"TRIAL","name":"Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02581215","description":"Pancreatic Cancer","metadata":null},{"id":"74359cfdbf874b71a06e35a89ca1575c","type":"TRIAL","name":"Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT01673854","description":"Melanoma","metadata":null},{"id":"1d2885a1ab41476f93d3e0f0f0547302","type":"TRIAL","name":"Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT01945021","description":"Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib","metadata":null},{"id":"88efede18258466e8fe827d38e938589","type":"TRIAL","name":"Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00615524","description":"Hormone-receptor Positive Breast Cancer","metadata":null},{"id":"6d98d08573ad4edaab5b999d7b2b323c","type":"TRIAL","name":"Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01748344","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"db2ed6437a3846c69fbe8ebf588190e3","type":"TRIAL","name":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07205731","description":"Esophageal Squamous Cell Carcinoma (ESCC)","metadata":null},{"id":"4741efa021654911949e290ebc7ad323","type":"TRIAL","name":"Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).","canonical_id":"clinicaltrials.gov:NCT02573038","description":"Choroidal Neovascularization in Angioid Streaks","metadata":null},{"id":"d7bb97a5b97045fc9a9b3b64dbf14498","type":"TRIAL","name":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","canonical_id":"clinicaltrials.gov:NCT00539591","description":"Malignant Melanoma","metadata":null},{"id":"43fe56353068467ba07c6a9e995fe476","type":"TRIAL","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05195632","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"ff596a825a9f44139ac3bb9ff5bf22b7","type":"TRIAL","name":"Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL","canonical_id":"clinicaltrials.gov:NCT07551583","description":"Hodgkin Lymphoma","metadata":null},{"id":"835107ca71c747a1b06427a51f88a846","type":"TRIAL","name":"Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies","canonical_id":"clinicaltrials.gov:NCT00038376","description":"Lymphoma, T-Cell; Mycosis Fungoides; Hematologic Neoplasms","metadata":null},{"id":"3a86dc9867664eee87af62f0ce00fd1b","type":"TRIAL","name":"Phase II Study With Cabozantinib in Patients With RET Positive NSCLC","canonical_id":"clinicaltrials.gov:NCT04131543","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"727de4e320f748a38a9a33b11ad205a2","type":"TRIAL","name":"Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection","canonical_id":"clinicaltrials.gov:NCT00464893","description":"Gastric Cancer; Gastric Adenocarcinoma","metadata":null},{"id":"1399318e725d49b69ebf890b78b9c59d","type":"TRIAL","name":"Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler","canonical_id":"clinicaltrials.gov:NCT01593644","description":"Ischemic Heart Disease","metadata":null},{"id":"acc85c245af24cd4bb31ee9f71b572a6","type":"TRIAL","name":"Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02376452","description":"Colorectal Carcinoma","metadata":null},{"id":"aa47296f3a3f4ff4b707922185095c1d","type":"TRIAL","name":"Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT01652976","description":"Pancreatic Cancer Metastatic","metadata":null},{"id":"8f7b5f04ff674a5cb90f1f5a8f2066ac","type":"TRIAL","name":"Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic \uff08GEP\uff09 Neuroendocrine Carcinoma \uff08NEC, WHO Grade 3\uff09 as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes","canonical_id":"clinicaltrials.gov:NCT03147404","description":"Neuroendocrine Carcinoma, Grade 3","metadata":null},{"id":"3ed707cc270b4f65a63fd0b050580eb9","type":"TRIAL","name":"Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment","canonical_id":"clinicaltrials.gov:NCT03389126","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"ed2de58f16844949ae65a8a924a5d070","type":"TRIAL","name":"Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer","canonical_id":"clinicaltrials.gov:NCT01255137","description":"Adrenal Cortex Neoplasms","metadata":null},{"id":"6b6214654a2945d0af0d8edeee8c4c6e","type":"TRIAL","name":"Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma","canonical_id":"clinicaltrials.gov:NCT01967576","description":"Pheochromocytoma; Paraganglioma","metadata":null},{"id":"20ef66ecab19423c96ad57253d1e6dba","type":"TRIAL","name":"Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT00508001","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"ba2995f4b52c408ea224ad058c0d1c7f","type":"TRIAL","name":"Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00615784","description":"Acute Myeloid Leukemia","metadata":null},{"id":"566e60b25c6f4e399d9eff71005c2398","type":"TRIAL","name":"Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01438307","description":"Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC","metadata":null},{"id":"19ba69906a08401f89252513c6c8c554","type":"TRIAL","name":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04836728","description":"Non-small Cell Lung Cancer Metastatic; First-line Treatment","metadata":null},{"id":"902bbb3e15354d8c9126f4358a80d55a","type":"TRIAL","name":"Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children","canonical_id":"clinicaltrials.gov:NCT07318831","description":"Neuroblastoma (NB); Neuroblastoma in Children","metadata":null},{"id":"3f988bbacc15475eaaf61ac088898341","type":"TRIAL","name":"Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis","canonical_id":"clinicaltrials.gov:NCT00004346","description":"Cerebrotendinous Xanthomatosis","metadata":null},{"id":"226d837ba9b446ff88f8a6c0ae014aca","type":"TRIAL","name":"Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00044889","description":"Acute Myelogenous Leukemia","metadata":null},{"id":"c44206497a444805a2c9c1d38cbb5b74","type":"TRIAL","name":"Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases","canonical_id":"clinicaltrials.gov:NCT02230306","description":"Active Melanoma Brain Metastases","metadata":null},{"id":"18a64598a87147489aa973376c5def56","type":"TRIAL","name":"Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT00487669","description":"Advanced Non-small Cell Lung Cancer","metadata":null},{"id":"94e15a70c79b491998d15849826b3170","type":"TRIAL","name":"Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal","canonical_id":"clinicaltrials.gov:NCT01843452","description":"Carcinoma of Anal Canal","metadata":null},{"id":"99d3698e17374bd0bc969ff103c90caf","type":"TRIAL","name":"Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC","canonical_id":"clinicaltrials.gov:NCT06202014","description":"Pancreatic Cancer; Radiotherapy; Envafolimab; Capecitabine","metadata":null},{"id":"1f8981df8abd4d48a3f4ddd2a0a36a7d","type":"TRIAL","name":"Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT03535259","description":"Hepatocellular Carcinoma, Radiotherapy, Sorafenib","metadata":null},{"id":"5d63e9a5da994285a6b33c5d8f8f4617","type":"TRIAL","name":"Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT04230031","description":"Multiple Myeloma","metadata":null},{"id":"0004e3cca7d4481c93ed927d15dae296","type":"TRIAL","name":"Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06468644","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"25fceb125df64da49eb698019f8fe39b","type":"TRIAL","name":"Phase II Study of Digitoxin to Treat Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00782288","description":"Cystic Fibrosis","metadata":null},{"id":"946213a404e64407909226ad0e07bc0e","type":"TRIAL","name":"Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01658462","description":"Breast Cancer","metadata":null},{"id":"a1d1b84657274028bf87be85fbdb4cf8","type":"TRIAL","name":"Phase II Study of Everolimus Beyond Progression","canonical_id":"clinicaltrials.gov:NCT02269670","description":"Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"9ee88ec1abf7492c8784f1b9b7b49a58","type":"TRIAL","name":"Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral \u03b2-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00750282","description":"Alzheimer Disease; Amyloid Beta-Protein","metadata":null},{"id":"d8f2ddb9975c43009802436291a9eefd","type":"TRIAL","name":"Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral \u03b2-amyloid.","canonical_id":"clinicaltrials.gov:NCT00928304","description":"Down Syndrome; Amyloid Beta-protein","metadata":null},{"id":"42523959eb3a4bfda5aa05a16aa3c3bf","type":"TRIAL","name":"Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT01493479","description":"Follicular Lymphoma","metadata":null},{"id":"14bd6d3b3a934166bd5ab55b12b73c1e","type":"TRIAL","name":"Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)","canonical_id":"clinicaltrials.gov:NCT06733051","description":"Natural Killer T-cell Lymphoma","metadata":null},{"id":"3dc99fa38a8b41c894b66ff15dfca2be","type":"TRIAL","name":"Phase II Study of Herzuma\u00ae Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03698383","description":"HER2-positive Breast Cancer; Metastatic Breast Cancer","metadata":null},{"id":"76c00a8cb6ec407bbc665720a77f780d","type":"TRIAL","name":"Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant","canonical_id":"clinicaltrials.gov:NCT04584307","description":"Multiple Myeloma","metadata":null},{"id":"3c5bca208e4d4406b9e03a443879f1e7","type":"TRIAL","name":"Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC","canonical_id":"clinicaltrials.gov:NCT06769971","description":"Small Cell Lung Cancer","metadata":null},{"id":"5804b4a7b9a64d2284cb52d6eecafc01","type":"TRIAL","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","canonical_id":"clinicaltrials.gov:NCT01772420","description":"Adult Myelodysplastic Syndrome; Anemia; Chronic Myelomonocytic Leukemia","metadata":null},{"id":"10b03ba16b3f4ff5911bbc4fe5be5348","type":"TRIAL","name":"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT02319044","description":"Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck","metadata":null},{"id":"9c5acff08002459dbe2a0a9a37744438","type":"TRIAL","name":"Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT02743429","description":"Neuroblastoma","metadata":null},{"id":"5dfa5504fbe841df8cea57ac26457341","type":"TRIAL","name":"Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)","canonical_id":"clinicaltrials.gov:NCT04568616","description":"Breast Cancer; ER Positive Breast Cancer","metadata":null},{"id":"6e740243bae241deaf3ccab49f3bc9f2","type":"TRIAL","name":"Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer","canonical_id":"clinicaltrials.gov:NCT06830239","description":"Colon Cancer Stage III","metadata":null},{"id":"05f584236915483986058f6a498df186","type":"TRIAL","name":"Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency","canonical_id":"clinicaltrials.gov:NCT05461690","description":"Homologous Recombination Deficiency; Triple Negative Breast Cancer","metadata":null},{"id":"d2471fef1d2a497fa7776e2aa135608d","type":"TRIAL","name":"Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT00823719","description":"Lymphoma, Large-Cell, Diffuse","metadata":null},{"id":"83935815d2e84999b613a3d77a1fb7d5","type":"TRIAL","name":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","canonical_id":"clinicaltrials.gov:NCT06052618","description":"KSHV Inflammatory Cytokine Syndrome (KICS); Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease","metadata":null},{"id":"e29cc6d4585a49efa942ea6b5fe9f61f","type":"TRIAL","name":"Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT06427330","description":"Acute Lymphoid Leukemia","metadata":null},{"id":"a9f40e7054534966ae0479f4b07f237c","type":"TRIAL","name":"Phase II Study of RR110 in Patients With Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00417391","description":"Crohn's Disease","metadata":null},{"id":"fa1583d907bd4df2b31d6b1d05c4fc2b","type":"TRIAL","name":"Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis","canonical_id":"clinicaltrials.gov:NCT00004300","description":"Stereotyped Behavior; Mental Retardation","metadata":null},{"id":"61bd4ace7bc34147878d68b3d64640d0","type":"TRIAL","name":"Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation","canonical_id":"clinicaltrials.gov:NCT05023655","description":"Solid Tumor; ARID1A Gene Mutation","metadata":null},{"id":"1f1ae7b8baa6469985353b7b094307f5","type":"TRIAL","name":"Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00475865","description":"Multiple Sclerosis","metadata":null},{"id":"4fa484259d524aa0a434c63df48a0ace","type":"TRIAL","name":"Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00489489","description":"Multiple Sclerosis","metadata":null},{"id":"30ab4e91c41e4549887f10ef058ed212","type":"TRIAL","name":"Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT07261683","description":"Ovarian Cancer; Immunotherapy; Pembrolizumab","metadata":null},{"id":"f765a94d6f544406a81f8960cfbd027a","type":"TRIAL","name":"Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I","canonical_id":"clinicaltrials.gov:NCT00004328","description":"Pseudohypoaldosteronism","metadata":null},{"id":"c0c5511cfb9c43d8b7ba90a3c0c2c50c","type":"TRIAL","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00563836","description":"Ovarian Cancer; Epithelial Ovarian Cancer","metadata":null},{"id":"66950d6896f147c39974703235a86209","type":"TRIAL","name":"Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis","canonical_id":"clinicaltrials.gov:NCT01900431","description":"Uveitis","metadata":null},{"id":"1ef683f4562c4bcfa7c5b9503f478fa7","type":"TRIAL","name":"Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.","canonical_id":"clinicaltrials.gov:NCT00531115","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"2975feb9dbbf487aa96acdf240ec9e19","type":"TRIAL","name":"Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer","canonical_id":"clinicaltrials.gov:NCT01469546","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"b80b11033b004cb994c4eee80f34c3aa","type":"TRIAL","name":"Phase II Trial GA101 Inbrutinib B CLL","canonical_id":"clinicaltrials.gov:NCT02666898","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"9b55353671f9472b83a2176aa067edf0","type":"TRIAL","name":"Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.","canonical_id":"clinicaltrials.gov:NCT07392658","description":"Metastatic NSCLC - Non-Small Cell Lung Cancer","metadata":null},{"id":"28ff0dfe2fdf4ecb84805f809fa7c2f4","type":"TRIAL","name":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","canonical_id":"clinicaltrials.gov:NCT00381862","description":"Colorectal Cancer; Nausea and Vomiting","metadata":null},{"id":"9bcd4729bc43441b84561ac48757951e","type":"TRIAL","name":"Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01688713","description":"Brain Metastases; Non-small Cell Lung Cancer","metadata":null},{"id":"6bff3006f0164191b53c32b74438d319","type":"TRIAL","name":"Phase II Trial of Erlotinib in Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00497224","description":"Cancer; Pancreas","metadata":null},{"id":"463950021e734ad3b824be026814b469","type":"TRIAL","name":"Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD","canonical_id":"clinicaltrials.gov:NCT02176031","description":"Graft Versus Host Disease","metadata":null},{"id":"84d653a0f597463db877189e88242fb7","type":"TRIAL","name":"Phase II Trial of Pentostatin and Targeted Busulfan","canonical_id":"clinicaltrials.gov:NCT00496340","description":"Hematologic Malignancies","metadata":null},{"id":"b00da77205df4078863ea8ae31655f0b","type":"TRIAL","name":"Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease","canonical_id":"clinicaltrials.gov:NCT00201786","description":"Graft-Versus-Host Disease","metadata":null},{"id":"146e5e69cd6f48188fea5965e1fd8dfc","type":"TRIAL","name":"Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC","canonical_id":"clinicaltrials.gov:NCT00449657","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"830ba13f93cb4db7913ff538d0a93a0e","type":"TRIAL","name":"Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT04289207","description":"Immune Thrombocytopenia","metadata":null},{"id":"9a491ba002284b47afcb3855849a6de4","type":"TRIAL","name":"Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons","canonical_id":"clinicaltrials.gov:NCT02572323","description":"Mild Cognitive Impairment","metadata":null},{"id":"9c2753dce6b04013a0070e646e7067d1","type":"TRIAL","name":"Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer","canonical_id":"clinicaltrials.gov:NCT01807156","description":"Hepatocellular Cancer","metadata":null},{"id":"4ab11ed2f2a4445981607b9b9252c89c","type":"TRIAL","name":"Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors","canonical_id":"clinicaltrials.gov:NCT02015065","description":"GIST","metadata":null},{"id":"ff42fa8825b64bbdb24e9ab19353190a","type":"TRIAL","name":"Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis","canonical_id":"clinicaltrials.gov:NCT00322296","description":"Parapsoriasis","metadata":null},{"id":"e5a9e3ee5f724ea8850bf9545ebf7889","type":"TRIAL","name":"Phase II of Lenvatinib Plus Toripalimab for Advanced HCC","canonical_id":"clinicaltrials.gov:NCT03919383","description":"Hepatocellular Carcinoma","metadata":null},{"id":"51e727d573964ff59e6cecf472a3c921","type":"TRIAL","name":"Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC","canonical_id":"clinicaltrials.gov:NCT04926831","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"8b1acadaeb8a45c98aea772cde39326d","type":"TRIAL","name":"Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00777179","description":"NSCLC","metadata":null},{"id":"0e7b60acc34848af9bcc8f2ab80a9b84","type":"TRIAL","name":"Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment","canonical_id":"clinicaltrials.gov:NCT02204332","description":"Colorectal Cancer","metadata":null},{"id":"8d61819262134c19a14b7272e6a45181","type":"TRIAL","name":"Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT06603142","description":"Primary Gout; Hyperuricemia","metadata":null},{"id":"7e05ae13fe3e460eb7efe1ae53542804","type":"TRIAL","name":"Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)","canonical_id":"clinicaltrials.gov:NCT00792298","description":"Primary Insomnia","metadata":null},{"id":"0ae2cba82891466688f7698f141bf4c9","type":"TRIAL","name":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","canonical_id":"clinicaltrials.gov:NCT04821141","description":"Risk Reduction; Breast Cancer","metadata":null},{"id":"2cbca7bb3bf94682bcaf615f58bf8c9c","type":"TRIAL","name":"Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy\u00ae) in Adult Obese or Overweight Subjects","canonical_id":"clinicaltrials.gov:NCT07150975","description":"Obesity/Overweight in Adult","metadata":null},{"id":"c81907bc8227406faa32121babfb3664","type":"TRIAL","name":"Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT01928628","description":"Hypertension","metadata":null},{"id":"6edac0c420f0401eb4bc5446cdc34ab1","type":"TRIAL","name":"Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy","canonical_id":"clinicaltrials.gov:NCT02770261","description":"Hypertension; Cholesterolemia","metadata":null},{"id":"0c730fb410f54908bbb2b1fd048f488f","type":"TRIAL","name":"Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy","canonical_id":"clinicaltrials.gov:NCT01560624","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"42fce27dffff4d5282d6818e55d6150a","type":"TRIAL","name":"Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures","canonical_id":"clinicaltrials.gov:NCT00004817","description":"Post-Traumatic Seizure Disorder; Head Injuries","metadata":null},{"id":"90bc64ccdba846508804defee829eb1f","type":"TRIAL","name":"Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction","canonical_id":"clinicaltrials.gov:NCT03127592","description":"Pain, Acute","metadata":null},{"id":"97641fb053f043d998dd54af85a4ac8a","type":"TRIAL","name":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","canonical_id":"clinicaltrials.gov:NCT01573351","description":"Hepatitis C Virus","metadata":null},{"id":"bd1f0faa91244f5d89910ebd91cf9226","type":"TRIAL","name":"Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia","canonical_id":"clinicaltrials.gov:NCT00004390","description":"Pain; Herpes Zoster","metadata":null},{"id":"d7d84fb9928249b3ac2f84b944d9a5e4","type":"TRIAL","name":"Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.","canonical_id":"clinicaltrials.gov:NCT07333066","description":"Metastatic Hormone-sensitive Prostate Cancer","metadata":null},{"id":"261d019a7eb64d51a07adb8213ce9633","type":"TRIAL","name":"Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss","canonical_id":"clinicaltrials.gov:NCT00004650","description":"Osteoporosis","metadata":null},{"id":"055593d13dff418d9032c2dc6167fb15","type":"TRIAL","name":"Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)","canonical_id":"clinicaltrials.gov:NCT00215943","description":"Multiple Myeloma","metadata":null},{"id":"703e5aba106b46489e27a1547a53ec2e","type":"TRIAL","name":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00004376","description":"Tourette Syndrome","metadata":null},{"id":"98404311094d49c78a1c429bc51bd0a0","type":"TRIAL","name":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT00004647","description":"Pain; Diabetic Neuropathies; Paresthesia","metadata":null},{"id":"df7d0edba4484a5f8010d198a611ce7a","type":"TRIAL","name":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT00004786","description":"Systemic Sclerosis; Raynaud Disease","metadata":null},{"id":"ba62a50de0734d6ab09069a3c8c5504d","type":"TRIAL","name":"Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy","canonical_id":"clinicaltrials.gov:NCT03626545","description":"Non-Small-Cell Lung","metadata":null},{"id":"d1b3be1867f64f738dc96e0e87cf09ae","type":"TRIAL","name":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","canonical_id":"clinicaltrials.gov:NCT06677060","description":"Heart Failure","metadata":null},{"id":"a2f3f76221094239999fbb3130833a3e","type":"TRIAL","name":"Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00622700","description":"Multiple Sclerosis","metadata":null},{"id":"bc1576a6645344d38141dca5e69fb1fb","type":"TRIAL","name":"Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor","canonical_id":"clinicaltrials.gov:NCT01610284","description":"Breast Cancer","metadata":null},{"id":"7b7b94f8df4944c394ea44ccab7c2e9b","type":"TRIAL","name":"Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.","canonical_id":"clinicaltrials.gov:NCT00048581","description":"Rheumatoid Arthritis","metadata":null},{"id":"1c4fc5810e724dd5bf783ba28d49c49d","type":"TRIAL","name":"Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral \u03b2-amyloid Compared to Histopathology","canonical_id":"clinicaltrials.gov:NCT01020838","description":"Alzheimer Disease","metadata":null},{"id":"176d918f8886488eb251f4a86360cd72","type":"TRIAL","name":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01335399","description":"Multiple Myeloma","metadata":null},{"id":"00f93b99850345c9b7bfba79af191d50","type":"TRIAL","name":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01239797","description":"Lymphoma; Multiple Myeloma","metadata":null},{"id":"6bb7b142260b40ffaa1202eb40b8dbf8","type":"TRIAL","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT06921785","description":"Hepatocellular Carcinoma","metadata":null},{"id":"5d4f2b03b8d947ee894dd0ff40b9c7f1","type":"TRIAL","name":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","canonical_id":"clinicaltrials.gov:NCT04231448","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"be7c899381544628abc08a9a74922711","type":"TRIAL","name":"Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT02316899","description":"Irritable Bowel Syndrome With Constipation (IBS-C)","metadata":null},{"id":"e1845f8d522d4cff99840b0a0ed7399f","type":"TRIAL","name":"Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment","canonical_id":"clinicaltrials.gov:NCT07281833","description":"Breast Cancer; HR-positive Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; HER2-negative Breast Cancer","metadata":null},{"id":"9278b61cd1be4ad29b9a59d9c2f3434c","type":"TRIAL","name":"Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura","canonical_id":"clinicaltrials.gov:NCT02553317","description":"Acquired Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"cd4f9457b0234fc182592e6c7430eabd","type":"TRIAL","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06889688","description":"Breast Cancer Stage IV; Triple -Negative Breast Cancer","metadata":null},{"id":"e7cf08e848a64548a016087f10071e83","type":"TRIAL","name":"Phase III Trial of Febuxostat in Korea Gout Patients","canonical_id":"clinicaltrials.gov:NCT00821392","description":"Gout","metadata":null},{"id":"c9a875ad13194d169632a9ec9e85460b","type":"TRIAL","name":"Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations","canonical_id":"clinicaltrials.gov:NCT01024413","description":"Thoracic Neoplasms","metadata":null},{"id":"7db2dbae1110413d8255c353ba2faac3","type":"TRIAL","name":"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT00765882","description":"Chronic Constipation","metadata":null},{"id":"b73231cab2c0432e93a9924146a3bd11","type":"TRIAL","name":"Phase IIIB Subcutaneous Missed Dose Study","canonical_id":"clinicaltrials.gov:NCT00533897","description":"Rheumatoid Arthritis","metadata":null},{"id":"c94b89ea62454bfca86c72da16ccf9d3","type":"TRIAL","name":"Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02738775","description":"Multiple Sclerosis","metadata":null},{"id":"1acc087a9de84965bd5c65a8ccfe4710","type":"TRIAL","name":"Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)","canonical_id":"clinicaltrials.gov:NCT00486720","description":"Myelodysplastic Syndromes; Blood Disease; Bone Marrow Disease","metadata":null},{"id":"6705a937330f44b29d7bccaa140a6430","type":"TRIAL","name":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","canonical_id":"clinicaltrials.gov:NCT07214103","description":"Septic Shock; Coagulopathy","metadata":null},{"id":"fa5ce3ec836146cd9dfc67efa8857183","type":"TRIAL","name":"Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone","canonical_id":"clinicaltrials.gov:NCT01955694","description":"Heart Failure","metadata":null},{"id":"e6c2f62df1294da192c548a13cd00745","type":"TRIAL","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT07310173","description":"HCC - Hepatocellular Carcinoma","metadata":null},{"id":"860fad46f0c649d7ab4ad31469756123","type":"TRIAL","name":"Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)","canonical_id":"clinicaltrials.gov:NCT02974504","description":"Type2 Diabetes","metadata":null},{"id":"6a05cdc7a930442f87d95b2c482395ff","type":"TRIAL","name":"Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype","canonical_id":"clinicaltrials.gov:NCT05691400","description":"CYP3A4*22","metadata":null},{"id":"26b4b2ccd69e49f0ac3a358d25763e87","type":"TRIAL","name":"Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02301962","description":"Cancer","metadata":null},{"id":"06ace97778494ae6b501393d9b772a75","type":"TRIAL","name":"Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients","canonical_id":"clinicaltrials.gov:NCT00526448","description":"Chronic Hepatitis C","metadata":null},{"id":"7d044cd2eca84ed0bfa556a32cb0bb3d","type":"TRIAL","name":"Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06779097","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"009b55908c904782a7b3eb987afd8e3e","type":"TRIAL","name":"Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06696417","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"a31f514132c14f37846a3bbf978bfa77","type":"TRIAL","name":"Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances","canonical_id":"clinicaltrials.gov:NCT00356096","description":"Restless Legs Syndrome; Depression","metadata":null},{"id":"8d7b772b09e145bdad36761db24c2125","type":"TRIAL","name":"Phase IV to Evaluate the Safety of Self-administered ADASUVE\u00ae in Agitated Patients Outside the Hospital Setting","canonical_id":"clinicaltrials.gov:NCT02525991","description":"Agitation","metadata":null},{"id":"4927ad64e3144bf1b18bb30e03fd249a","type":"TRIAL","name":"Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression","canonical_id":"clinicaltrials.gov:NCT00531947","description":"Major Depressive Disorder","metadata":null},{"id":"ffffd355465d46f0b794a8437f53b604","type":"TRIAL","name":"Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.","canonical_id":"clinicaltrials.gov:NCT01929486","description":"Solid Tumor","metadata":null},{"id":"cbb7617e666346218993b42e127b2d8e","type":"TRIAL","name":"Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC","canonical_id":"clinicaltrials.gov:NCT04846478","description":"Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"241b05367f1446c895ed15733771755c","type":"TRIAL","name":"Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies","canonical_id":"clinicaltrials.gov:NCT02620839","description":"Solid Tumors","metadata":null},{"id":"fc87bde7484a4ca9840fe0e039d8bfcf","type":"TRIAL","name":"Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin","canonical_id":"clinicaltrials.gov:NCT06576037","description":"Solid Tumor","metadata":null},{"id":"1e11bc93ac604170b638c0a03227c171","type":"TRIAL","name":"Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03081494","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"3223e5fbce144e8981e5ebb52fc833ec","type":"TRIAL","name":"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02332850","description":"Multiple Myeloma","metadata":null},{"id":"88a27ae25fa44ed49388f66572395e75","type":"TRIAL","name":"Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL","canonical_id":"clinicaltrials.gov:NCT04134936","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"0192169e6ce1456daf2681536ed178f8","type":"TRIAL","name":"Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification","canonical_id":"clinicaltrials.gov:NCT05510427","description":"Cholangiocarcinoma; Liver Cancer","metadata":null},{"id":"2b37da12243447deb96711938d518b46","type":"TRIAL","name":"Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab","canonical_id":"clinicaltrials.gov:NCT06287229","description":"Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia","metadata":null},{"id":"d8fe73f8f2084567b19464f34ce05a9f","type":"TRIAL","name":"Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors","canonical_id":"clinicaltrials.gov:NCT01927341","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"7797270b626e484f88c980266a5f3e1e","type":"TRIAL","name":"Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC","canonical_id":"clinicaltrials.gov:NCT02795429","description":"Advanced Hepatocellular Carcinoma","metadata":null},{"id":"050557bc04be4651a1863127eb7393ae","type":"TRIAL","name":"Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL","canonical_id":"clinicaltrials.gov:NCT07415980","description":"Double Expressor DLBCL","metadata":null},{"id":"9507f88fe5af4010a108649e87453739","type":"TRIAL","name":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07494448","description":"HER 2 Positive Advanced Breast Cancer; Breast Cancer","metadata":null},{"id":"9366380fe7c74602a349529c6feffdad","type":"TRIAL","name":"Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07680569","description":"GC/GEJC","metadata":null},{"id":"97107a434a104a0a820ebe8cbad81951","type":"TRIAL","name":"Phase \u2160 Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet","canonical_id":"clinicaltrials.gov:NCT01735890","description":"Healthy","metadata":null},{"id":"2b24c0fcfcce45a193e35dccec506538","type":"TRIAL","name":"Phase \u2161 Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage \u2163AB Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT00816816","description":"Nasopharyngeal Carcinoma","metadata":null},{"id":"9a92ecc641c34cf085534def5a118ee3","type":"TRIAL","name":"Phase \u2162 Clinical Trial of Buagafuran Capsules in the Treatment of GAD","canonical_id":"clinicaltrials.gov:NCT06243614","description":"Generalized Anxiety Disorder","metadata":null},{"id":"b68be0b788bd437386ab109ce64b19ed","type":"TRIAL","name":"PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity","canonical_id":"clinicaltrials.gov:NCT04621136","description":"Retinopathy of Prematurity","metadata":null},{"id":"784ddaa2ca4c48d883b62c0b7287fd03","type":"DRUG","name":"Phenacemide","canonical_id":"mesh:C005396","description":null,"metadata":null},{"id":"069ff767c5f94e8390794179bebb3ea3","type":"DRUG","name":"Phenazopyridine","canonical_id":"mesh:D010621","description":null,"metadata":null},{"id":"82c7a23f20e541a9933a02dde17ccf7c","type":"DRUG","name":"Phenelzine","canonical_id":"mesh:D010624","description":null,"metadata":null},{"id":"942c6a16dc894c89af0ff38ab4720c7b","type":"TRIAL","name":"Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel","canonical_id":"clinicaltrials.gov:NCT01253642","description":"Hormone-Resistant Prostate Cancer; Metastatic Prostatic Adenocarcinoma; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma","metadata":null},{"id":"9cd92c0a6b1546fe90c89f11f4bb0592","type":"TRIAL","name":"Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02217709","description":"Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer","metadata":null},{"id":"281baa7ec4474871ab98391108a3cd41","type":"DRUG","name":"Phenindamine","canonical_id":"mesh:C005430","description":null,"metadata":null},{"id":"5501c77822b04c4f81fb66de5f8317b1","type":"TRIAL","name":"Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment","canonical_id":"clinicaltrials.gov:NCT06279195","description":"Pelvic Pain","metadata":null},{"id":"82485835e66d44f8bb7c0af1d6e7c879","type":"TRIAL","name":"Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT00091377","description":"Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer","metadata":null},{"id":"e872ccd78e7f438a9d9515988bc0afac","type":"TRIAL","name":"Phenoxybenzamine Versus Doxazosin in PCC Patients","canonical_id":"clinicaltrials.gov:NCT01379898","description":"Pheochromocytoma","metadata":null},{"id":"0ddfaa0c6bb746bd9594de693f0f8758","type":"DRUG","name":"Phensuximide","canonical_id":"mesh:C100129","description":null,"metadata":null},{"id":"3002fdc45dc540af9d41767e98073feb","type":"DRUG","name":"Phentermine","canonical_id":"mesh:D010645","description":null,"metadata":null},{"id":"f44037467256400ca742df0f57911153","type":"DRUG","name":"Phentolamine","canonical_id":"mesh:D010646","description":null,"metadata":null},{"id":"89f41cc713114fd68eb44c9f3d4d48e4","type":"TRIAL","name":"Phentolamine Mesylate as a Reversal of Local Anesthesics","canonical_id":"clinicaltrials.gov:NCT03740386","description":"Anesthesia, Local","metadata":null},{"id":"b18d47a4cc064b7ca3c515865d774dc8","type":"PROTEIN","name":"Phenylalanine-4-hydroxylase","canonical_id":"uniprot:P00439","description":null,"metadata":null},{"id":"034e9472cdc74da290daaf824d0994d4","type":"TRIAL","name":"Phenylephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia","canonical_id":"clinicaltrials.gov:NCT04576663","description":"Adverse Effect","metadata":null},{"id":"fd947ef24fe04777b6ee8f2f7895f5d9","type":"TRIAL","name":"Phenylephrine Versus Norepinephrine in Septic Shock","canonical_id":"clinicaltrials.gov:NCT00481442","description":"Septic Shock","metadata":null},{"id":"02f502e712a544b680b744760175cf25","type":"TRIAL","name":"Phenylephrine and Pulse Pressure Variability","canonical_id":"clinicaltrials.gov:NCT05011357","description":"Intraoperative Hypotension","metadata":null},{"id":"e43456467c6a4e78b7e4b1913885b3a4","type":"DRUG","name":"Phenylpropanolamine","canonical_id":"mesh:D010665","description":null,"metadata":null},{"id":"0732b410cba6421db3adb5da4e8bb57c","type":"DRUG","name":"Phenytoin","canonical_id":"mesh:D010672","description":null,"metadata":null},{"id":"c692291dc8af4d65bbf8afd4078e4aab","type":"TRIAL","name":"Phenytoin Cream for the Treatment of Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT04647877","description":"Chronic Idiopathic Axonal Polyneuropathy","metadata":null},{"id":"5eca89e042f448afbf4bb9f603a7fc38","type":"TRIAL","name":"Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes","canonical_id":"clinicaltrials.gov:NCT00591006","description":"Healthy","metadata":null},{"id":"2433c630cd764ee7b315bc9e22c5f24f","type":"TRIAL","name":"Phenytoin as an Augmentation for SSRI Failures","canonical_id":"clinicaltrials.gov:NCT00146237","description":"Depression","metadata":null},{"id":"81800fc33a47467b8772eae06880b664","type":"TRIAL","name":"Phenytoin in Treatment of Atrophic Post Acne Scars.","canonical_id":"clinicaltrials.gov:NCT06942468","description":"Atrophic Acne Scar","metadata":null},{"id":"1a91ea99324042a593cd59f7b6426210","type":"DISEASE","name":"Pheochromocytoma","canonical_id":"mesh:D010673","description":null,"metadata":null},{"id":"9253ad6d46cf4082936199f06cd09644","type":"TRIAL","name":"Phlebotomy and Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT02460445","description":"Hyperandrogenism; Metabolic Cardiovascular Syndrome","metadata":null},{"id":"3b61d0b1e1bd4835a59d6c1212828630","type":"GO_TERM","name":"Pho85-Pho80 CDK-cyclin complex","canonical_id":"go:GO:1990860","description":"\"A cyclin dependent kinase (CDK) complex that contains a kinase subunit and a regulatory cyclin subunit. An example of this complex in budding yeast S. cerevisiae consists of the Pho85 kinase and the Pho80 cyclin.\" [GOC:rb, PMID:8108735]","metadata":null},{"id":"69e44f16ab284836b92600493d11e416","type":"DRUG","name":"Phosphatidylinositide 3-Kinase Inhibitor","canonical_id":"ncit:C2152","description":null,"metadata":null},{"id":"0cc027c54b8f4709bad7a9532d09d4f5","type":"TRIAL","name":"Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma","canonical_id":"clinicaltrials.gov:NCT04108377","description":"Asthma","metadata":null},{"id":"d6f4a9f2de7e4d3c8099370b6f4287df","type":"TRIAL","name":"Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT01812434","description":"Cardiac Allograft Vasculopathy","metadata":null},{"id":"cb794dc5bbad4ac8b30db8ce03a74026","type":"TRIAL","name":"Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure","canonical_id":"clinicaltrials.gov:NCT01156636","description":"Pulmonary Hypertension; Diastolic Heart Failure","metadata":null},{"id":"fe9984fa02334842abd967bfab6ed36e","type":"GO_TERM","name":"Photinus-luciferin 4-monooxygenase (ATP-hydrolyzing) activity","canonical_id":"go:GO:0047077","description":"\"Catalysis of the reaction: O2 + ATP + Photinus luciferin = light + diphosphate + AMP + CO2 + oxidized Photinus luciferin.\" [EC:1.13.12.7]","metadata":null},{"id":"d5959ca2d7f54c00a9f4820c899979be","type":"TRIAL","name":"Photodynamic Therapy and Microvesicles","canonical_id":"clinicaltrials.gov:NCT03960125","description":"Photodynamic Therapy; Microvesicle Particle","metadata":null},{"id":"a32819e546804bff872c34efe9fd5a1b","type":"TRIAL","name":"Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas","canonical_id":"clinicaltrials.gov:NCT02639117","description":"Basal Cell Carcinoma","metadata":null},{"id":"bd81d5ef559342c78aa06f2cfc71d4cf","type":"TRIAL","name":"Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC","canonical_id":"clinicaltrials.gov:NCT06999707","description":"HCC - Hepatocellular Carcinoma; Tremelimumab; Durvalumab; Radiotherapy","metadata":null},{"id":"5a563722f29f4e0b86cc4952f3329a3b","type":"TRIAL","name":"Phototherapy Combination With Topicals in Vitiligo","canonical_id":"clinicaltrials.gov:NCT04440371","description":"Vitiligo, Generalized","metadata":null},{"id":"2942e628736b4312a6a44817c613ac09","type":"TRIAL","name":"Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)","canonical_id":"clinicaltrials.gov:NCT06235281","description":"Mycosis Fungoides","metadata":null},{"id":"e9297d7cf65b4e4f844f4fdc198a072b","type":"TRIAL","name":"Physical Activity Promotion and Clinical Remission in Severe Asthma","canonical_id":"clinicaltrials.gov:NCT07735494","description":"Severe Asthma","metadata":null},{"id":"391a776f2983413c8f00f8da2815a9e6","type":"TRIAL","name":"Physiologic Interactions Between the Adrenal- and the Parathyroid Glands","canonical_id":"clinicaltrials.gov:NCT02572960","description":"Osteoporosis; Vitamin D Deficiency; Cardiovascular Disease","metadata":null},{"id":"9a38ddc8eae24b2da78a5e43167ced43","type":"TRIAL","name":"Physiologic Monitoring of Antidepressant Response","canonical_id":"clinicaltrials.gov:NCT00792168","description":"Major Depression","metadata":null},{"id":"3936c72eae8e400c8d0b7711a2eae178","type":"TRIAL","name":"Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab","canonical_id":"clinicaltrials.gov:NCT02186886","description":"Ulcerative Colitis","metadata":null},{"id":"db9867ad029a45faae5d23577bb4890f","type":"TRIAL","name":"Physiological, Behavioral and Subjective Effects of Drugs (GHB)","canonical_id":"clinicaltrials.gov:NCT00058955","description":"Sedative Abuse","metadata":null},{"id":"b99de0f711284946bc7babaff1b215db","type":"TRIAL","name":"Physiology of GERD and Treatment Response","canonical_id":"clinicaltrials.gov:NCT04292470","description":"GERD","metadata":null},{"id":"25cd04a5099946caa62f0854f2c17a94","type":"TRIAL","name":"Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.","canonical_id":"clinicaltrials.gov:NCT03545347","description":"Hip Fractures","metadata":null},{"id":"b971f6ce81204419bfa8e560c639248b","type":"DRUG","name":"Physostigmine","canonical_id":"mesh:D010830","description":null,"metadata":null},{"id":"e2df303f0e154e0b845581f10fa26063","type":"TRIAL","name":"Physostigmine After General Anesthesia","canonical_id":"clinicaltrials.gov:NCT00850850","description":"Postoperative Nausea and Vomiting; Anesthesia Recovery Period","metadata":null},{"id":"c23cc789d57a41afaa0f694694e7afea","type":"TRIAL","name":"Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients","canonical_id":"clinicaltrials.gov:NCT04501965","description":"Covid19","metadata":null},{"id":"47b8ea5f6aeb44ff9b1272d60c5fda7f","type":"DRUG","name":"Phytomenadione","canonical_id":"mesh:D014812","description":null,"metadata":null},{"id":"524c9dfad40249d782131cca0bb87f6c","type":"GO_TERM","name":"Pi Mi complex","canonical_id":"go:GO:0062071","description":"\"A transcription factor complex composed of a homeodomain protein and the M-specific peptide Mi that acts at the regulatory region of genes required for the activation of meiosis.\" [PMID:30089908]","metadata":null},{"id":"6dec60fc9894414ab5daab858ef09cfd","type":"TRIAL","name":"PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)","canonical_id":"clinicaltrials.gov:NCT01320254","description":"Cholangiocarcinomas","metadata":null},{"id":"6406763eb8894cff890393ef7fbfa8cd","type":"GO_TERM","name":"Pick body","canonical_id":"go:GO:0097419","description":"\"Cellular inclusion composed of numerous tau fibrils arranged in a disorderly array. Tau protein is a major component, though Pick bodies also contain ubiquitin, alpha-synuclein, and apolipoprotein E.\" [NIF_Subcellular:nlx_subcell_20090102]","metadata":null},{"id":"9b87de220a524aec9968c827fad537fe","type":"DRUG","name":"Pictilisib","canonical_id":"ncit:C165479","description":null,"metadata":null},{"id":"95bbba70aac4416a896377c059e33aaf","type":"DRUG","name":"Pictilisib Bismesylate","canonical_id":"ncit:C82380","description":null,"metadata":null},{"id":"0bff46c8d5fe4ebf9af2198e70428588","type":"DRUG","name":"Pidnarulex","canonical_id":"ncit:C126798","description":null,"metadata":null},{"id":"867380b0a9354ba99defe6844cf3633b","type":"DRUG","name":"Pilaralisib","canonical_id":"ncit:C71705","description":null,"metadata":null},{"id":"856c6a46b7aa47bb91a769ce9e2aaffa","type":"TRIAL","name":"Pilocarpine After Combined Cataract/Trabectome Surgery","canonical_id":"clinicaltrials.gov:NCT04005079","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"6ef476ae90cf4984860749190df29739","type":"TRIAL","name":"Pilocarpine Microneedles for Sweat Induction (PMN-SI)","canonical_id":"clinicaltrials.gov:NCT04732195","description":"Cystic Fibrosis","metadata":null},{"id":"0b6be4c8060444b390862287b5b07f5a","type":"TRIAL","name":"Pilocarpine Use After Kahook Goniotomy","canonical_id":"clinicaltrials.gov:NCT03933631","description":"Glaucoma","metadata":null},{"id":"8732d8fe791744268978510e4497b7bf","type":"TRIAL","name":"Pilocarpine and Brimonidine in Patients With Monofocal Lenses","canonical_id":"clinicaltrials.gov:NCT03825081","description":"Presbyopia; Pseudophakia","metadata":null},{"id":"a6d284ce63cd4ae181944717dd1f2e3a","type":"TRIAL","name":"Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids","canonical_id":"clinicaltrials.gov:NCT00003686","description":"Oral Complications; Quality of Life","metadata":null},{"id":"38abd8ebaed8489a867e996984777648","type":"TRIAL","name":"Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00343382","description":"Breast Cancer; Vaginal Dryness","metadata":null},{"id":"1768588c712e4c8eb5b949918bca9dcf","type":"TRIAL","name":"Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms","canonical_id":"clinicaltrials.gov:NCT05006911","description":"Presbyopia","metadata":null},{"id":"896be4725717476d8f204c77fb8607bd","type":"TRIAL","name":"Pilot Assessment of Lopinavir/Ritonavir and Maraviroc","canonical_id":"clinicaltrials.gov:NCT00981318","description":"HIV Infections; Acquired Immunodeficiency Syndrome","metadata":null},{"id":"ed2269c61c1148d4816ceb9a54705bb2","type":"TRIAL","name":"Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia","canonical_id":"clinicaltrials.gov:NCT01614990","description":"Cancer Cachexia","metadata":null},{"id":"dc91c6dee6454c69aab5dcd3f290eec5","type":"TRIAL","name":"Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients","canonical_id":"clinicaltrials.gov:NCT04360551","description":"COVID-19","metadata":null},{"id":"ac87d50a607944cab71b9afc78db3575","type":"TRIAL","name":"Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis","canonical_id":"clinicaltrials.gov:NCT00412464","description":"Thrombosis; Heparin-induced Thrombocytopenia","metadata":null},{"id":"e71d89f2030944a087b145ae0f12cfc5","type":"TRIAL","name":"Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE","canonical_id":"clinicaltrials.gov:NCT00687609","description":"Attention Deficit Hyperactivity Disorder; Cannabis Abuse","metadata":null},{"id":"9b3da622c2ae4282bc0119b86218c52d","type":"TRIAL","name":"Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT01542502","description":"Heart Failure","metadata":null},{"id":"c27e03a8ad03452eaf77ac571a77f8bd","type":"TRIAL","name":"Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)","canonical_id":"clinicaltrials.gov:NCT03897348","description":"Alcohol Use Disorder","metadata":null},{"id":"7c668b1c59fe4bd799761bcbdece06fb","type":"TRIAL","name":"Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT00558506","description":"Ankylosing Spondylitis","metadata":null},{"id":"5cf6511a96274ab988e34f38a18e124f","type":"TRIAL","name":"Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's","canonical_id":"clinicaltrials.gov:NCT05491902","description":"Alzheimer Disease","metadata":null},{"id":"9240390d97714b30aedee02e1a6d1434","type":"TRIAL","name":"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo","canonical_id":"clinicaltrials.gov:NCT04971200","description":"Skin and Connective Tissue Diseases; Skin Diseases; Pigmentation Disorder; Hypopigmentation; Biologic; Vitiligo","metadata":null},{"id":"a74309ebf79b4d34acfe9e41bda7ca7b","type":"TRIAL","name":"Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01385280","description":"Estrogen Receptor-positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"68fd92183bc44012b939e360068d7aec","type":"TRIAL","name":"Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men","canonical_id":"clinicaltrials.gov:NCT00540124","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"a91393b0d3b84c8f9cf85dd80788f943","type":"TRIAL","name":"Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel","canonical_id":"clinicaltrials.gov:NCT01666418","description":"Melanoma","metadata":null},{"id":"bdbea672b26d4ef6a407b4b892ce4e4e","type":"TRIAL","name":"Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy","canonical_id":"clinicaltrials.gov:NCT00837252","description":"Retinal Disease","metadata":null},{"id":"5413201719b34c0bbdb774c641f5fccc","type":"TRIAL","name":"Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT00959725","description":"Diabetic Macular Edema","metadata":null},{"id":"89caae694dfc43a9a8234b8ceb360639","type":"TRIAL","name":"Pilot Study for the NorCAPITAL Trial","canonical_id":"clinicaltrials.gov:NCT01507701","description":"Chronic Fatigue Syndrome","metadata":null},{"id":"9dba6184a8a54dabb22df9abbe171002","type":"TRIAL","name":"Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin","canonical_id":"clinicaltrials.gov:NCT02811055","description":"Type 2 Diabetes; Hypertension","metadata":null},{"id":"0bbad14780a34930b3254f9b860dd1cb","type":"TRIAL","name":"Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease","canonical_id":"clinicaltrials.gov:NCT04747847","description":"Kawasaki Disease","metadata":null},{"id":"9f423a3cd0624437afee410c549c74d4","type":"TRIAL","name":"Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers","canonical_id":"clinicaltrials.gov:NCT04821375","description":"Increased Risk for Development of Breast Cancer","metadata":null},{"id":"645248f0c1244aab923d9779839d3120","type":"TRIAL","name":"Pilot Study of Bumetanide for Newborn Seizures","canonical_id":"clinicaltrials.gov:NCT00830531","description":"Seizures","metadata":null},{"id":"9718a83f56514c09b12320f60c2caf04","type":"TRIAL","name":"Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03048942","description":"HER2 Negative Metastatic Breast Cancer","metadata":null},{"id":"6592e77a41bf4d52b7221e17406db044","type":"TRIAL","name":"Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)","canonical_id":"clinicaltrials.gov:NCT01418430","description":"HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)","metadata":null},{"id":"c37e0c04263d468b955d8451c7592c2b","type":"TRIAL","name":"Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas","canonical_id":"clinicaltrials.gov:NCT02419287","description":"Anaplastic Large Cell Lymphoma, ALK-Positive","metadata":null},{"id":"f545e4a9a0b349c287bdc7c84e2db082","type":"TRIAL","name":"Pilot Study of DRibble Vaccine for Prostate Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02234921","description":"Adenocarcinoma of the Prostate","metadata":null},{"id":"0b09171e0c56403e97de5acb77025f00","type":"TRIAL","name":"Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT00006137","description":"IGA Glomerulonephritis","metadata":null},{"id":"a2c3100a8d6e42ec82cb6a94eef9281a","type":"TRIAL","name":"Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain","canonical_id":"clinicaltrials.gov:NCT00034710","description":"Neuralgia; Pain; Peripheral Nervous System Diseases; Herpes Zoster","metadata":null},{"id":"7112e085f8104d07b753442dd1b8f31a","type":"TRIAL","name":"Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00677092","description":"Nephrogenic Systemic Fibrosis","metadata":null},{"id":"533a8b39414f4f0d91f448940df5ae3b","type":"TRIAL","name":"Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01490216","description":"Cocaine Dependence","metadata":null},{"id":"a6ff9aacd98c4cffaa55644861d137a3","type":"TRIAL","name":"Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients","canonical_id":"clinicaltrials.gov:NCT01291459","description":"HIV","metadata":null},{"id":"b46615f81b3d49dc883da83ba06de5c3","type":"TRIAL","name":"Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06636591","description":"Breast Cancer Female; HER2-negative Breast Cancer","metadata":null},{"id":"91ea4a0f087d4b49a0a111c996ac4ad9","type":"TRIAL","name":"Pilot Study of Perindopril in Childhood Cancer Survivors","canonical_id":"clinicaltrials.gov:NCT01948232","description":"Childhood Cancer Survivors","metadata":null},{"id":"2c460b6e824d402596af925f1f6bb80c","type":"TRIAL","name":"Pilot Study of Physostigmine-Enhanced Opioid Analgesia","canonical_id":"clinicaltrials.gov:NCT01394445","description":"Postoperative Pain","metadata":null},{"id":"7d68f0d9359b44d480ab8d439b284203","type":"TRIAL","name":"Pilot Study of Slow Release Oral Milrinone in Patients With Advanced Heart Failure","canonical_id":"clinicaltrials.gov:NCT01956006","description":"Heart Failure","metadata":null},{"id":"30f6337aa61f47a298e5983488952c9f","type":"TRIAL","name":"Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02303041","description":"Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome","metadata":null},{"id":"ba4379b5d48d40029b1cd6a56f64c298","type":"TRIAL","name":"Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating","canonical_id":"clinicaltrials.gov:NCT00237510","description":"Antidepressant Induced Excessive Sweating","metadata":null},{"id":"258c650f526746e0b5c426819802bf08","type":"TRIAL","name":"Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease","canonical_id":"clinicaltrials.gov:NCT01727206","description":"Erdheim-Chester Disease","metadata":null},{"id":"0e84114b4eec4195be74afb29127c9fc","type":"TRIAL","name":"Pilot Study of Tolcapone in Smokers","canonical_id":"clinicaltrials.gov:NCT01202955","description":"Nicotine Dependence","metadata":null},{"id":"f9cd4d61996d43f79971496b90e06ca1","type":"TRIAL","name":"Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma","canonical_id":"clinicaltrials.gov:NCT00980551","description":"Retinoblastoma","metadata":null},{"id":"55962ad2c47b4017a0f78fa20ab73173","type":"TRIAL","name":"Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT01404702","description":"Neuroblastoma","metadata":null},{"id":"0d8232659e3c417c835824f2379821dd","type":"TRIAL","name":"Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis","canonical_id":"clinicaltrials.gov:NCT01781936","description":"Uveitis Affecting the Posterior Segment","metadata":null},{"id":"92c0d1ebdfbf476c9d0f0a4cb206a0ea","type":"TRIAL","name":"Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome","canonical_id":"clinicaltrials.gov:NCT00467831","description":"Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease","metadata":null},{"id":"b71928d4436a4d99bc900849191498c9","type":"TRIAL","name":"Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users","canonical_id":"clinicaltrials.gov:NCT03341078","description":"Methamphetamine-dependence","metadata":null},{"id":"284b164c1bf94e8bbe2782b28410c9f3","type":"TRIAL","name":"Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity","canonical_id":"clinicaltrials.gov:NCT03523273","description":"Obesity","metadata":null},{"id":"8fce4cf423434aafadb6d68372124dd5","type":"TRIAL","name":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","canonical_id":"clinicaltrials.gov:NCT00438243","description":"Cystoid Macular Edema","metadata":null},{"id":"64df24128dae47009d3562ec7487c5b8","type":"TRIAL","name":"Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome","canonical_id":"clinicaltrials.gov:NCT00990691","description":"Rett Syndrome","metadata":null},{"id":"8d9202c8f41b4f39b5b8fb3b55f8fc40","type":"TRIAL","name":"Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms","canonical_id":"clinicaltrials.gov:NCT03991520","description":"Endometriosis; Anakinra; Markers of Inflammation","metadata":null},{"id":"305ec37d844c4f3c9b4d3105b82a2b95","type":"TRIAL","name":"Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure","canonical_id":"clinicaltrials.gov:NCT01300650","description":"Heart Failure","metadata":null},{"id":"c96173e9764d48678f75ae27e76dc244","type":"TRIAL","name":"Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT02684123","description":"Alopecia Areata","metadata":null},{"id":"8086c8107f7540f7913b61c9eee50e1a","type":"TRIAL","name":"Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00964678","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"7005a58893bf4fd58ce2201add6c15b9","type":"TRIAL","name":"Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT04367051","description":"Heart Failure","metadata":null},{"id":"f900c16e37bb4268b4e714acf79bf880","type":"TRIAL","name":"Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine","canonical_id":"clinicaltrials.gov:NCT00846495","description":"Migraine","metadata":null},{"id":"eff22c577c244286b0639e7c1ac171ad","type":"TRIAL","name":"Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer","canonical_id":"clinicaltrials.gov:NCT01725048","description":"Major Depressive Disorder; Neoplasms","metadata":null},{"id":"ead5e46377a74ce19199c791729207d6","type":"TRIAL","name":"Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01814397","description":"Breast Cancer; Pain; Arthralgia","metadata":null},{"id":"74765888baae4876bdda86705a749338","type":"TRIAL","name":"Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization","canonical_id":"clinicaltrials.gov:NCT01625715","description":"Peanut Allergies in Children","metadata":null},{"id":"11614d1992184890a977023042266fe3","type":"TRIAL","name":"Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04060043","description":"Prostate Cancer","metadata":null},{"id":"d5b99b3764534d338b6d943d28fdf7aa","type":"TRIAL","name":"Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications","canonical_id":"clinicaltrials.gov:NCT03953170","description":"Ileostomy - Stoma","metadata":null},{"id":"27d34507421e4b8aaf8cbe71a71a9e59","type":"TRIAL","name":"Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients","canonical_id":"clinicaltrials.gov:NCT02842983","description":"Shock, Septic","metadata":null},{"id":"1de9aa6f18f545dfaf9c0d525e9d9992","type":"TRIAL","name":"Pilot Study: Effects of Nimodipine on Alcohol Drinking","canonical_id":"clinicaltrials.gov:NCT06900998","description":"Alcohol Use Disorder","metadata":null},{"id":"64d87a64450742c381f680c8abcbb15f","type":"TRIAL","name":"Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)","canonical_id":"clinicaltrials.gov:NCT04180085","description":"Heart Transplant Failure","metadata":null},{"id":"404124d9937949cf870c3943c7b9c5be","type":"TRIAL","name":"Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)","canonical_id":"clinicaltrials.gov:NCT02085018","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"e4198605325f439f8aaebb4957a25266","type":"TRIAL","name":"Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents","canonical_id":"clinicaltrials.gov:NCT00994448","description":"Adolescent Methamphetamine Abuse","metadata":null},{"id":"2631168acca24afaa174f0cf660dd348","type":"TRIAL","name":"Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)","canonical_id":"clinicaltrials.gov:NCT02493049","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"8145abe833034b7291edb74284aaae4c","type":"TRIAL","name":"Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation","canonical_id":"clinicaltrials.gov:NCT03468140","description":"End Stage Liver Disease","metadata":null},{"id":"03f4fc293fad4a7781cb0ca93dbb88db","type":"TRIAL","name":"Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells","canonical_id":"clinicaltrials.gov:NCT00777400","description":"Autoimmune Diseases","metadata":null},{"id":"22b5e49ce18d483ba121a4d801532079","type":"DRUG","name":"Pilsicainide","canonical_id":"mesh:C042288","description":null,"metadata":null},{"id":"4b3cb37f34c340b2b68fc91c81dd0de9","type":"DRUG","name":"Pimavanserin","canonical_id":"mesh:C510793","description":null,"metadata":null},{"id":"8e77ba1aab474e7da28132826cfa03d7","type":"TRIAL","name":"Pimavanserin Treatment in TS","canonical_id":"clinicaltrials.gov:NCT04794413","description":"Tourette Syndrome; Tardive Dyskinesia","metadata":null},{"id":"88fe301beea84d68b1951272caa6a589","type":"TRIAL","name":"Pimavanserin and Aggression and Social Cognition.","canonical_id":"clinicaltrials.gov:NCT05895513","description":"Intermittent Explosive Disorder","metadata":null},{"id":"fc8d0578cec64ea3b56cf0df70cf768e","type":"TRIAL","name":"Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT04188392","description":"Post-traumatic Stress Disorder; Insomnia","metadata":null},{"id":"f2ca231d89984896a6ba68710d606b6b","type":"TRIAL","name":"Pimavanserin for Insomnia in Veterans With PTSD","canonical_id":"clinicaltrials.gov:NCT05441280","description":"Post-traumatic Stress Disorder; Insomnia","metadata":null},{"id":"f43bb8ad0503486292353eb69d969dd6","type":"TRIAL","name":"Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept","canonical_id":"clinicaltrials.gov:NCT04809116","description":"Insomnia Chronic; Posttraumatic Stress Disorder","metadata":null},{"id":"8210aca3f88f49a0826ca0535c54d100","type":"TRIAL","name":"Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT05999240","description":"Autism Spectrum Disorder","metadata":null},{"id":"3b2b1ad5b5d5454082d7908274920b2b","type":"TRIAL","name":"Pimavanserin for Sleep in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT05796167","description":"Parkinson Disease","metadata":null},{"id":"d8767f134bf94087b1a39b98b4018a11","type":"TRIAL","name":"Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT05523895","description":"Irritability Associated With Autism Spectrum Disorder","metadata":null},{"id":"e20699c62eed431aa52bceb131614034","type":"TRIAL","name":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","canonical_id":"clinicaltrials.gov:NCT04373317","description":"Parkinson's Disease Psychosis","metadata":null},{"id":"4956d9e9ff844d56846479d2ae80dc33","type":"DRUG","name":"Pimecrolimus","canonical_id":"mesh:C117268","description":null,"metadata":null},{"id":"2bed1df201be4fd099160571a598206e","type":"TRIAL","name":"Pimecrolimus Cream 1% (Elidel\u00ae) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.","canonical_id":"clinicaltrials.gov:NCT01177566","description":"Atopic Dermatitis","metadata":null},{"id":"7b700dafe7684e018201389f24da4969","type":"TRIAL","name":"Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00121381","description":"Dermatitis, Atopic","metadata":null},{"id":"3779cf2dd30045fdaa1be12fddf7c04b","type":"TRIAL","name":"Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis","canonical_id":"clinicaltrials.gov:NCT00232115","description":"Perioral Dermatitis","metadata":null},{"id":"97114fada2bb4a0680967da3d3247d03","type":"TRIAL","name":"Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis","canonical_id":"clinicaltrials.gov:NCT00226707","description":"Chronic Hand Dermatitis","metadata":null},{"id":"3615d3aa3ecf4622b99b0a1b44c04900","type":"TRIAL","name":"Pimecrolimus Cream for Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT00297037","description":"Oral Lichen Planus","metadata":null},{"id":"30ffc1a70238492b97ee361849a0fd23","type":"DRUG","name":"Pindolol","canonical_id":"mesh:D010869","description":null,"metadata":null},{"id":"47f07ce4a3ea49f8aa73c41e2c126009","type":"DISEASE","name":"Pinta","canonical_id":"mesh:D010874","description":null,"metadata":null},{"id":"500f3721e7d04fbaa14126d27ab273f4","type":"DRUG","name":"Pioglitazone","canonical_id":"mesh:D000077205","description":null,"metadata":null},{"id":"346f03a838d74357a40a36055516d0f9","type":"TRIAL","name":"Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia","canonical_id":"clinicaltrials.gov:NCT00099021","description":"Head and Neck Cancer; Oral Leukoplakia","metadata":null},{"id":"90ff6a647da64af8a7e807105410fb63","type":"TRIAL","name":"Pioglitazone Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\"","canonical_id":"clinicaltrials.gov:NCT02002975","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7bb762794dc344528f3fa054e5db9bb1","type":"TRIAL","name":"Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT03566225","description":"Pioglitazone","metadata":null},{"id":"8b9a407444e44cd4b31ae9533c81bc42","type":"TRIAL","name":"Pioglitazone and Losartan Provides Additional Renoprotection","canonical_id":"clinicaltrials.gov:NCT00364988","description":"Type 2 Diabetes; Diabetic Nephropathy","metadata":null},{"id":"8af0684ab52242ff85ec45f22a34a131","type":"TRIAL","name":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","canonical_id":"clinicaltrials.gov:NCT04419337","description":"Diabetes Mellitus; Stroke","metadata":null},{"id":"5aef0b9d5cf645f0a2d5cd805c108d06","type":"TRIAL","name":"Pioglitazone to Treat Fatty Liver in People With HIV Infection","canonical_id":"clinicaltrials.gov:NCT00441272","description":"HIV Infections; Hepatic Steatosis; Insulin Resistance","metadata":null},{"id":"6105765a3912461b938a79e54d4489ab","type":"TRIAL","name":"Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia","canonical_id":"clinicaltrials.gov:NCT05727761","description":"Oral Leukoplakia","metadata":null},{"id":"52764c4aea0047ceb4e4f80b84027f96","type":"GO_TERM","name":"Pip2-Oaf1 complex","canonical_id":"go:GO:0089716","description":"\"A heterodimeric complex consisting of Zn(2)Cys(6) containing transcription factors Pip2 and Oaf1. It binds to the oleate response element (ORE), found in the promoters of fatty acid-inducible genes in Saccharomyces where, in the presence of oleate this bound complex activates the transcription of genes encoding peroxisomal proteins.\" [PMID:8972187, PMID:9288897]","metadata":null},{"id":"dd49be3fb7844838b6fffed1e4fd3ccd","type":"DRUG","name":"Pirbuterol","canonical_id":"mesh:C009118","description":null,"metadata":null},{"id":"069fff0466b148cf918a237c4d8ca4c8","type":"DRUG","name":"Piretanide","canonical_id":"mesh:C015451","description":null,"metadata":null},{"id":"b87386f897384f7c99e1d50d7effa472","type":"DRUG","name":"Pirfenidone","canonical_id":"mesh:C093844","description":null,"metadata":null},{"id":"b9cc0516efa844149b095cfc19c90c76","type":"DRUG","name":"Piribedil","canonical_id":"mesh:D010891","description":null,"metadata":null},{"id":"572020e5fff742c4be912fdd965566d8","type":"DRUG","name":"Pirlindole","canonical_id":"mesh:C009830","description":null,"metadata":null},{"id":"c872c33161e04f98aa017c70bf2de47b","type":"TRIAL","name":"Piroxicam Premedication for Postendodontic Pain in Non-vital Mandibular Molars","canonical_id":"clinicaltrials.gov:NCT03998826","description":"Non-Vital Tooth","metadata":null},{"id":"044baf8149364adea122bb170834439d","type":"TRIAL","name":"Piroxicam Versus Diclofenac for Post Caesarean Section Analgesia","canonical_id":"clinicaltrials.gov:NCT06943092","description":"Analgesia; Post Caserean","metadata":null},{"id":"7a39dcbd6ea3461987a735033b08359a","type":"TRIAL","name":"Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception","canonical_id":"clinicaltrials.gov:NCT03614494","description":"Emergency Contraception","metadata":null},{"id":"a59762f3ee3e4784bb8e2d044271f077","type":"TRIAL","name":"Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching","canonical_id":"clinicaltrials.gov:NCT03153657","description":"Tooth Sensitivity; Toothache","metadata":null},{"id":"b5453fe2ec01437b8cb0c380cc17aad3","type":"TRIAL","name":"Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax","canonical_id":"clinicaltrials.gov:NCT05317936","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"e94f5ba25ce54fc596a62e9e5b42dad1","type":"DRUG","name":"Pitavastatin","canonical_id":"mesh:C108475","description":null,"metadata":null},{"id":"420ac97e76d3456397b60a43820cfab5","type":"TRIAL","name":"Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA","canonical_id":"clinicaltrials.gov:NCT02739568","description":"Excessive Daytime Sleepiness; Obstructive Sleep Apnea","metadata":null},{"id":"2adc07b18a654bff881dfc23071f471d","type":"TRIAL","name":"Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness","canonical_id":"clinicaltrials.gov:NCT02978651","description":"Excessive Daytime Sleepiness; Obstructive Sleep Apnea","metadata":null},{"id":"d53a45585c1c4c368190b5d6e72df364","type":"TRIAL","name":"Pitolisant Effects on Affect and Cognition Exploratory Study (PEACE Study)","canonical_id":"clinicaltrials.gov:NCT05849675","description":"Anhedonia; Cognitive Function","metadata":null},{"id":"1fcf028c3fa2496ca87a81644479d888","type":"TRIAL","name":"Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers","canonical_id":"clinicaltrials.gov:NCT04596267","description":"Alcohol Use Disorder; Alcohol Drinking","metadata":null},{"id":"7431c90670a14908880cc4db5930694e","type":"TRIAL","name":"Pitolisant in Refractory Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT05581576","description":"Restless Legs Syndrome","metadata":null},{"id":"02463c5e20e74d8cafe11222fb040559","type":"TRIAL","name":"Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)","canonical_id":"clinicaltrials.gov:NCT01800045","description":"Narcolepsy With Cataplexy; Excessive Daytime Sleepiness","metadata":null},{"id":"9b4f9b2f2ce3462fb13ae2c0fe772d7f","type":"TISSUE","name":"Pituitary","canonical_id":"uberon:UBERON:0000007","description":null,"metadata":null},{"id":"ea5223edefb240fd8865d8e6de117a30","type":"DISEASE","name":"Pituitary dwarfism","canonical_id":"mesh:D004393","description":null,"metadata":null},{"id":"9579bf33b4f04b8d9526e401d139b249","type":"DISEASE","name":"Pityriasis versicolor","canonical_id":"mesh:D014010","description":null,"metadata":null},{"id":"e6798bce6b4a4a3c8a10aa83f9a86a03","type":"TRIAL","name":"Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed","canonical_id":"clinicaltrials.gov:NCT01350609","description":"Hypertension, Essential","metadata":null},{"id":"edca39e6d0f74d32b3b414247912ea45","type":"TRIAL","name":"Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01760980","description":"Healthy","metadata":null},{"id":"d751056d89344b4c9b7a1774100e2d11","type":"TRIAL","name":"Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT00864500","description":"Healthy","metadata":null},{"id":"f661dfb0537f499f9104dc74832b47b8","type":"TRIAL","name":"Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2","canonical_id":"clinicaltrials.gov:NCT01685827","description":"Human African Trypanosomiasis (HAT); Sleeping Sickness","metadata":null},{"id":"30478a63f3f949d99e8eb4d2254a3fd4","type":"TRIAL","name":"Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00989664","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"f8560d164c7444ab8d69133677820d52","type":"DRUG","name":"Pixantrone","canonical_id":"mesh:C086548","description":null,"metadata":null},{"id":"4780bcbf4e334ba2917ca296692897b9","type":"TRIAL","name":"Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes","canonical_id":"clinicaltrials.gov:NCT01928888","description":"Heartburn","metadata":null},{"id":"62162f911a094f7bb0bdec3b7b85bbe8","type":"TRIAL","name":"Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy","canonical_id":"clinicaltrials.gov:NCT01386255","description":"Cerebral Palsy; GERD","metadata":null},{"id":"31547f6ac04f4a28869c11de0b0dab18","type":"TRIAL","name":"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess","canonical_id":"clinicaltrials.gov:NCT00994110","description":"Pancreatic Cancer","metadata":null},{"id":"0b29695332a841a89fdc8c0364991dc1","type":"TRIAL","name":"Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms","canonical_id":"clinicaltrials.gov:NCT01919216","description":"Major Depressive Disorder","metadata":null},{"id":"75297c87be2c48c48005ea4c79ae85b4","type":"TRIAL","name":"Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT00773812","description":"Autistic Disorder; Pervasive Developmental Disorder","metadata":null},{"id":"c568622a1ef04fa0937da5b85c14b1e5","type":"TRIAL","name":"Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","canonical_id":"clinicaltrials.gov:NCT04719832","description":"Asthma","metadata":null},{"id":"bec2d17518d34b949b536da0cb94a491","type":"TRIAL","name":"Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00656188","description":"Erectile Dysfunction","metadata":null},{"id":"c9f892525436468ba35499731c517f04","type":"DISEASE","name":"Plague","canonical_id":"mesh:D010930","description":null,"metadata":null},{"id":"099577d63eec443b913e9ff5161ee9df","type":"TRIAL","name":"Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial","canonical_id":"clinicaltrials.gov:NCT02678182","description":"Adenocarcinoma of the Oesophagus; Adenocarcinoma of the Gastro-oesophageal Junction; Adenocarcinoma of the Stomach","metadata":null},{"id":"85463be1905146e1b4318d50499ee9a0","type":"TRIAL","name":"Plasma Lipoprotein Response to Glucagon-like Peptide-2","canonical_id":"clinicaltrials.gov:NCT03422666","description":"Hyperlipidemias","metadata":null},{"id":"ccea7ae869bf4573a24e0ec33889e9f9","type":"TRIAL","name":"Plasma Modifications Associated With Rivaroxaban\u00ae Treatment for Stroke Prevention","canonical_id":"clinicaltrials.gov:NCT02273700","description":"Atrial Fibrillation","metadata":null},{"id":"80ce68ec90014154a714c464971ce40c","type":"PROTEIN","name":"Plasma protease C1 inhibitor","canonical_id":"uniprot:P05155","description":null,"metadata":null},{"id":"9e9d123dab694f6cad164477b2e8d9b0","type":"TRIAL","name":"Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag","canonical_id":"clinicaltrials.gov:NCT00888901","description":"Idiopathic Thrombocytopenic Purpura","metadata":null},{"id":"19c99c71b4ea479782e0f2138b7cdd0c","type":"TRIAL","name":"Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI","canonical_id":"clinicaltrials.gov:NCT03247738","description":"ST Segment Elevation Myocardial Infarction; Percutaneous Coronary Intervention","metadata":null},{"id":"b01a521ce8624643b5b3cc49f90c1cba","type":"TRIAL","name":"Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT02748330","description":"Coronary Artery Disease; Diabetes Mellitus, Type 2","metadata":null},{"id":"da9053c356434850aaff2875276df574","type":"TRIAL","name":"Platelet Inhibition to Target Reperfusion Injury","canonical_id":"clinicaltrials.gov:NCT03102723","description":"STEMI","metadata":null},{"id":"2b13f99153b74831b1d944543839d866","type":"TRIAL","name":"Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis","canonical_id":"clinicaltrials.gov:NCT02518152","description":"Chronic Periodontitis","metadata":null},{"id":"1100fad1b8464475b6b7033026b2b6d8","type":"TRIAL","name":"Platelet Sub-study of the TWILIGHT Trial","canonical_id":"clinicaltrials.gov:NCT04001374","description":"Coronary Artery Disease; Myocardial Infarction","metadata":null},{"id":"8a6efb63c29c4a609a6e099097056354","type":"TRIAL","name":"Platelet-Inhibitor Drug Trial in Coronary Angioplasty","canonical_id":"clinicaltrials.gov:NCT00000510","description":"Angina Pectoris; Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Ischemia","metadata":null},{"id":"0fe8efc67a8b4e23ab2a08690b752965","type":"TRIAL","name":"Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment","canonical_id":"clinicaltrials.gov:NCT02645227","description":"Chronic Periodontitis","metadata":null},{"id":"cc8aa535db8f4422abc48a24eb8beaa8","type":"TRIAL","name":"Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)","canonical_id":"clinicaltrials.gov:NCT07713745","description":"Neurofibromatosis Type 2; Vestibular Schwannoma; Non-vestibular Schwannoma; Meningioma; Ependymoma; NF2-related Schwannomatosis; NF2","metadata":null},{"id":"71be5191ad27440ab4ec19edf1199211","type":"TRIAL","name":"Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)","canonical_id":"clinicaltrials.gov:NCT03527147","description":"NHL; DLBCL; Non-hodgkin's Lymphoma; Diffuse Large B Cell Lymphoma","metadata":null},{"id":"3df28194771f44ce9cca79b815fd3578","type":"TRIAL","name":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06649331","description":"Advanced Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Breast Cancer","metadata":null},{"id":"2d838f311cf84b758db231cef80f4736","type":"TRIAL","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","canonical_id":"clinicaltrials.gov:NCT04126200","description":"Multiple Myeloma","metadata":null},{"id":"a932108b2ef946cf9ace9580b4b310e0","type":"TRIAL","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","canonical_id":"clinicaltrials.gov:NCT05358249","description":"KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Neoplasms, Colorectal","metadata":null},{"id":"1648b0c2079147c5818f0b5ff4f60a4a","type":"TRIAL","name":"Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients","canonical_id":"clinicaltrials.gov:NCT04097821","description":"Myelofibrosis","metadata":null},{"id":"638e56eb610c41d9ae98037124df74a0","type":"TRIAL","name":"Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3","canonical_id":"clinicaltrials.gov:NCT06926673","description":"Neoplasms","metadata":null},{"id":"38cb584b79d54626a0695720874a5ffb","type":"TRIAL","name":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","canonical_id":"clinicaltrials.gov:NCT05440851","description":"Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High","metadata":null},{"id":"1162210d75ba48aaa8e8f5a01d57ff84","type":"DRUG","name":"Platinum Compound","canonical_id":"ncit:C1450","description":null,"metadata":null},{"id":"2cc6bbc0a5f7459684e3421e17a34bb1","type":"TRIAL","name":"Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy","canonical_id":"clinicaltrials.gov:NCT03904108","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"64629677f28e45d8a57500fd28d4f29b","type":"DRUG","name":"Plerixafor","canonical_id":"mesh:C088327","description":null,"metadata":null},{"id":"7e6880b7225741739ca7ad2f55febefd","type":"TRIAL","name":"Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)","canonical_id":"clinicaltrials.gov:NCT01186224","description":"Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoma; Lymphoproliferative Disorders","metadata":null},{"id":"090492d19e9042948eb43e0b1ca08c9b","type":"TRIAL","name":"Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02221492","description":"Lymphoma","metadata":null},{"id":"6a387df10fe54722a701c3c54be33cbf","type":"TRIAL","name":"Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome","canonical_id":"clinicaltrials.gov:NCT02231879","description":"Myelokathexis; Infections; Neutropenia; Warts; Hypogammaglobulinemia","metadata":null},{"id":"c1375cbb0a7e4dadbb842caa2a1856ec","type":"TRIAL","name":"Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04177810","description":"Metastatic Pancreatic Cancer","metadata":null},{"id":"8dbae47e089846be969e598474778689","type":"TRIAL","name":"Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT01160354","description":"Acute Myelogenous Leukemia","metadata":null},{"id":"fb8bf5973248491a908eae75958852a4","type":"TRIAL","name":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin","canonical_id":"clinicaltrials.gov:NCT00822770","description":"Stem Cell Transplantation; Leukemia","metadata":null},{"id":"66b1f85bfb3041dfa09e2a914c7a3961","type":"TRIAL","name":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT01065129","description":"Myelodysplastic Syndromes","metadata":null},{"id":"c51cb397dc6a467187504d1c55239993","type":"TRIAL","name":"Plerixafor for Stem Cell Mobilization in Normal Donors","canonical_id":"clinicaltrials.gov:NCT01818284","description":"Blood And Marrow Transplantation","metadata":null},{"id":"3d8c3c1a65e34362a97eefb15fadba81","type":"TRIAL","name":"Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients","canonical_id":"clinicaltrials.gov:NCT03547830","description":"Chronic Granulomatous Disease","metadata":null},{"id":"10dfbf75918c43c492ba572bd15727f1","type":"TRIAL","name":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","canonical_id":"clinicaltrials.gov:NCT04902040","description":"Advanced Bladder Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Merkel Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA\u2026","metadata":null},{"id":"a4c3b41c323f44668ec3a13186e97064","type":"DISEASE","name":"Pneumococcal infectious disease","canonical_id":"mesh:D011008","description":null,"metadata":null},{"id":"2d712de23fb444b88d4926dde47fde12","type":"DISEASE","name":"Pneumococcal meningitis","canonical_id":"mesh:D008586","description":null,"metadata":null},{"id":"500699d3df644c40b194cb5fd963b573","type":"DISEASE","name":"Pneumococcal pneumonia","canonical_id":"mesh:D011018","description":null,"metadata":null},{"id":"42e21d58388c4dadabea857c3d6f45d3","type":"DISEASE","name":"Pneumonia","canonical_id":"mesh:D011014","description":null,"metadata":null},{"id":"b524c0f6481d4ee9a7d84fb169ea6f1b","type":"DISEASE","name":"Pneumonia due to Mycoplasma pneumoniae","canonical_id":"mesh:D011019","description":null,"metadata":null},{"id":"d3e27157b6444001859992633945809c","type":"DISEASE","name":"Pneumonia, Necrotizing","canonical_id":"mesh:D000071067","description":null,"metadata":null},{"id":"783af7ce631d4ee4b2266115063b3a28","type":"TRIAL","name":"Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL","canonical_id":"clinicaltrials.gov:NCT07638787","description":"Large B-cell Lymphoma","metadata":null},{"id":"b18cdbd062144669ae4af6f62e035a78","type":"TRIAL","name":"Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients","canonical_id":"clinicaltrials.gov:NCT06176729","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"af5e718fa2e4434d9c68345974129221","type":"TRIAL","name":"Pola-ZR2P in Previously Untreated DLBCL","canonical_id":"clinicaltrials.gov:NCT06664411","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"0c49d27f99684749b9eae4a98cd0afbc","type":"TRIAL","name":"Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)","canonical_id":"clinicaltrials.gov:NCT06040320","description":"Post-transplant Lymphoproliferative Disorder","metadata":null},{"id":"2b0ec0c798f8485e96ef18eac29c746f","type":"TRIAL","name":"Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL","canonical_id":"clinicaltrials.gov:NCT06468943","description":"Effects of Chemotherapy; Safety Issues","metadata":null},{"id":"c2bef51bd0c14a4186fc8ca1ce290645","type":"TRIAL","name":"Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation","canonical_id":"clinicaltrials.gov:NCT04679012","description":"Richter Syndrome; Chronic Lymphocytic Leukemia","metadata":null},{"id":"813fa5c7951341639b2d09497924d53d","type":"TRIAL","name":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04665765","description":"Diffuse Large B-Cell Lymphoma Unclassifiable; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed B-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"43cba4b1734c41459f661f88db6e1c45","type":"TRIAL","name":"Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars","canonical_id":"clinicaltrials.gov:NCT07606391","description":"Keloid and Hypertrophic Scars","metadata":null},{"id":"87547f569fcb45078f62776985309750","type":"TRIAL","name":"Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1","canonical_id":"clinicaltrials.gov:NCT03721679","description":"Solid Cancer","metadata":null},{"id":"09ccc7b446f044ff8f248db1681602d0","type":"DISEASE","name":"Polycystic Kidney, Autosomal Dominant","canonical_id":"mesh:D016891","description":null,"metadata":null},{"id":"bcdf1a0acab0494687731c22a3412138","type":"DISEASE","name":"Polycythemia vera","canonical_id":"mesh:D011087","description":null,"metadata":null},{"id":"000ab2dcc2014044a452dd2a4bad4b8a","type":"TRIAL","name":"Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT04697485","description":"HF - Heart Failure; Diabetes Mellitus","metadata":null},{"id":"4ec48fb1ece74e5d89480916d0e4e627","type":"TRIAL","name":"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine","canonical_id":"clinicaltrials.gov:NCT05850091","description":"Coronary Artery Disease","metadata":null},{"id":"1d0be8fa5e4741d0a5cc773042cd6230","type":"TRIAL","name":"Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites","canonical_id":"clinicaltrials.gov:NCT01980329","description":"Cytochrome P450 CYP3A5 Enzyme Polymorphism; Healthy Subjects; Pharmacokinetics of Maraviroc","metadata":null},{"id":"f35e0d30e9164416906617c5d3b55077","type":"TRIAL","name":"Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma","canonical_id":"clinicaltrials.gov:NCT01786616","description":"Asthma","metadata":null},{"id":"4c6e2607bbb54db1b9b21e898bdf47a6","type":"DISEASE","name":"Polymyalgia Rheumatica","canonical_id":"mesh:D011111","description":null,"metadata":null},{"id":"41c982c2ca754090bcaed66d74406844","type":"DRUG","name":"Polymyxin B","canonical_id":"mesh:D011112","description":null,"metadata":null},{"id":"8bd5daff99f74f3c9c09201215fed912","type":"TRIAL","name":"Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","canonical_id":"clinicaltrials.gov:NCT06930885","description":"Atherothrombotic Diseases; Atherosclerotic Cardiovascular Disease (ASCVD)","metadata":null},{"id":"4279ffb5e9894191845a26731ea9a966","type":"TRIAL","name":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","canonical_id":"clinicaltrials.gov:NCT05155137","description":"Stroke; Cognitive Decline","metadata":null},{"id":"b139b2726ca54afdac9a93acfefe9a62","type":"TRIAL","name":"Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance","canonical_id":"clinicaltrials.gov:NCT00991276","description":"Restless Legs Syndrome","metadata":null},{"id":"1500b866e7d245a28e145ce5cda854f2","type":"DISEASE","name":"Polyuria","canonical_id":"hp:0000103","description":null,"metadata":null},{"id":"3737a417fcd34fe7b2a86f6051b805dd","type":"DISEASE","name":"Polyuria","canonical_id":"mesh:D011141","description":null,"metadata":null},{"id":"8b5240b01794409c9807ca0c870e6035","type":"DRUG","name":"Pomalidomide","canonical_id":"mesh:C467566","description":null,"metadata":null},{"id":"dfde6b18903e4cfa8f5bf891d53a06b2","type":"TRIAL","name":"Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib","canonical_id":"clinicaltrials.gov:NCT01746836","description":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","metadata":null},{"id":"75849253cf1943fb8b400430c835db3f","type":"TRIAL","name":"Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions","canonical_id":"clinicaltrials.gov:NCT02265341","description":"Malignant Hepatobiliary Neoplasm","metadata":null},{"id":"5d3b41e31c13412a9f5be78f29b7c822","type":"TRIAL","name":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","canonical_id":"clinicaltrials.gov:NCT05306301","description":"Chemotherapy; Leukemia, Acute Lymphoblastic","metadata":null},{"id":"909df118c9624c09ab071e90ef1b5b62","type":"TRIAL","name":"Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL","canonical_id":"clinicaltrials.gov:NCT04554459","description":"Acute Lymphoblastic Leukemia, Adult; Ph+ ALL; Newly Diagnosed","metadata":null},{"id":"ac3d31d0cef94c66978c89b9135ab9ff","type":"TRIAL","name":"Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)","canonical_id":"clinicaltrials.gov:NCT01207440","description":"Chronic Myeloid Leukemia; Ph+ Acute Lymphoblastic Leukemia","metadata":null},{"id":"cfc79bb464344c29a223d919607a74da","type":"TRIAL","name":"Ponatinib for FLT3-ITD Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT02428543","description":"Acute Myeloid Lukemia","metadata":null},{"id":"f80b8de9eac041679ee48011046f737a","type":"TRIAL","name":"Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.","canonical_id":"clinicaltrials.gov:NCT02272998","description":"Malignant Neoplasm","metadata":null},{"id":"75b49d7e7bc14db6b1e04789b1d4db2f","type":"TRIAL","name":"Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT03838692","description":"Medullary Thyroid Cancer","metadata":null},{"id":"93c560c3f5a04c4e8dd77addbc2128d9","type":"TRIAL","name":"Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)","canonical_id":"clinicaltrials.gov:NCT01650805","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"a889c52e93c6474cb02254b54a37fef3","type":"TRIAL","name":"Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses","canonical_id":"clinicaltrials.gov:NCT02467270","description":"Myeloid Leukemia, Chronic, Chronic Phase","metadata":null},{"id":"4074c214dc014536bc2a96f53f4e144c","type":"TRIAL","name":"Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma","canonical_id":"clinicaltrials.gov:NCT01888562","description":"Endometrial Neoplasms","metadata":null},{"id":"2d9c0cbf5a2447d096b71922bead8a86","type":"TRIAL","name":"Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program","canonical_id":"clinicaltrials.gov:NCT02640976","description":"Infertility","metadata":null},{"id":"8c06247ad90c4d869d080dbdfe889484","type":"TRIAL","name":"Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN","canonical_id":"clinicaltrials.gov:NCT04379180","description":"Persistent Pulmonary Hypertension of the Newborn","metadata":null},{"id":"f3b153a38c124cedae24466665911ee5","type":"TRIAL","name":"Population Pharmacokinetics of Antiepileptic in Pediatrics","canonical_id":"clinicaltrials.gov:NCT03196466","description":"Epilepsy","metadata":null},{"id":"c4bea0b96e8c4954877f3caac36e1471","type":"TRIAL","name":"Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT07747948","description":"Non Valvular Atrial Fibrillation (nv AF)","metadata":null},{"id":"d91d7c108679441298f70ac3d3f71445","type":"TRIAL","name":"Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT05320627","description":"Non-Valvular Atrial Fibrillation","metadata":null},{"id":"fb719cc1561d40c0b4aed4e538fa0640","type":"TRIAL","name":"Population Pharmacokinetics of Propafenone and Propranolol in Children Patients","canonical_id":"clinicaltrials.gov:NCT05463614","description":"Arrhythmia","metadata":null},{"id":"0d7afad1134f4184b8b3d558e1ef815d","type":"DRUG","name":"Poractant alfa","canonical_id":"mesh:C068291","description":null,"metadata":null},{"id":"40bba48aa1204b39aab7411ab334e7ac","type":"DRUG","name":"Porfimer sodium","canonical_id":"mesh:D017323","description":null,"metadata":null},{"id":"c8f1a08bf1e346ab87f7f71740387f9f","type":"TRIAL","name":"Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects","canonical_id":"clinicaltrials.gov:NCT01265394","description":"Healthy","metadata":null},{"id":"2a1d77ff8f4e453da797c7e41a18c0bb","type":"TRIAL","name":"Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels","canonical_id":"clinicaltrials.gov:NCT01165554","description":"Brain Fibrillarab Levels","metadata":null},{"id":"c0c9c631397b4281906607a064a04361","type":"TRIAL","name":"Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)","canonical_id":"clinicaltrials.gov:NCT04546126","description":"Radiotracer; Hypertension; Cholesterol","metadata":null},{"id":"60f0b99dae5b4f8dbf5582d52548a7cc","type":"TRIAL","name":"Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280","canonical_id":"clinicaltrials.gov:NCT00681746","description":"Anxiety","metadata":null},{"id":"d5b6e2c097e34b8cb11344fe67e5a48e","type":"TRIAL","name":"Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325","canonical_id":"clinicaltrials.gov:NCT00681720","description":"Anxiety","metadata":null},{"id":"b2d766bd78e94827a1ef902950b799af","type":"TRIAL","name":"Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL","canonical_id":"clinicaltrials.gov:NCT00832221","description":"Depression","metadata":null},{"id":"c1340cd278d5467ab14350fac1260d03","type":"TRIAL","name":"Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus","canonical_id":"clinicaltrials.gov:NCT01092546","description":"Normal Pressure Hydrocephalus","metadata":null},{"id":"04969080303140fc8ca1105708aa34fd","type":"TRIAL","name":"Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04776499","description":"Drug Drug Interaction; Safety Issues","metadata":null},{"id":"f63cf7e67c70495eb65695861defc4be","type":"TRIAL","name":"Possible Role of Roflumilast in Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT04755946","description":"Diabetic Nephropathies","metadata":null},{"id":"a12589ff995f42768e519d6e2e45a8d7","type":"TRIAL","name":"Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease","canonical_id":"clinicaltrials.gov:NCT02103465","description":"Parkinson's Disease","metadata":null},{"id":"60592c617ae64a22a8ba5c05364281fe","type":"TRIAL","name":"Post Burn Pruritus Study in Patients Undergoing Wound Healing","canonical_id":"clinicaltrials.gov:NCT00137202","description":"Itching","metadata":null},{"id":"c4b7f66e363b49c7a9a85195b87ba4ab","type":"TRIAL","name":"Post IVIG Medication in Children With Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT04741139","description":"Immune Thrombocytopenia","metadata":null},{"id":"99b28050c6494fc695464a7adad0e42c","type":"TRIAL","name":"Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.","canonical_id":"clinicaltrials.gov:NCT05959304","description":"Diabetic Macular Edema","metadata":null},{"id":"739cfe85705f45a4bfdbcb88ee4f34b7","type":"TRIAL","name":"Post Marketing Surveillance Study on Emselex After Launch in Germany","canonical_id":"clinicaltrials.gov:NCT00786448","description":"Overactive Bladder","metadata":null},{"id":"8c334f1666c641dc86bbbc6233bf0fe2","type":"TRIAL","name":"Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea","canonical_id":"clinicaltrials.gov:NCT02156895","description":"Advanced Renal Cell Carcinoma","metadata":null},{"id":"07cccc00d5c94dbdab0feed1474f2510","type":"TRIAL","name":"Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00538330","description":"Breast Cancer","metadata":null},{"id":"2810cd50058840bfb4bd5290b4a74e35","type":"TRIAL","name":"Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment","canonical_id":"clinicaltrials.gov:NCT04954365","description":"Nausea and Vomiting, Postoperative","metadata":null},{"id":"2d6bdf3bd6934ca19e21b504216bdcc7","type":"TRIAL","name":"Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan","canonical_id":"clinicaltrials.gov:NCT03309618","description":"Myocardial Infarction","metadata":null},{"id":"e26469896d954d9d9fa828b283ea643e","type":"TRIAL","name":"Post- Thoracotomy Paravertebral Block","canonical_id":"clinicaltrials.gov:NCT02886429","description":"Pain, Postoperative","metadata":null},{"id":"33acc6ef7aa9418989a3aaeb9fff9062","type":"TRIAL","name":"Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent","canonical_id":"clinicaltrials.gov:NCT04933552","description":"Multiple Sclerosis","metadata":null},{"id":"d49e905f28dc4e1f960b5139595d1174","type":"TRIAL","name":"Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures","canonical_id":"clinicaltrials.gov:NCT00771927","description":"Epilepsies, Partial","metadata":null},{"id":"2d1b34fb1a7a40afb4dc97961a454f84","type":"TRIAL","name":"Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03318770","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"4b971ef8b6ca446b9e04a59569601bb2","type":"TRIAL","name":"Post-Marketing Assessment of Immunogenicity and Safety of Unituxin\u00ae in High-Risk Neuroblastoma Patients","canonical_id":"clinicaltrials.gov:NCT02693171","description":"Neuroblastoma","metadata":null},{"id":"5d4e0c5d768c44fea4e75b130cff6bdf","type":"TRIAL","name":"Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS","canonical_id":"clinicaltrials.gov:NCT07308574","description":"aHUS; Atypical Hemolytic Uremic Syndrome","metadata":null},{"id":"4e0a108f2ac04ef6b6e51b34e679031e","type":"TRIAL","name":"Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)","canonical_id":"clinicaltrials.gov:NCT02291874","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e76ca050fc164ddf95093a3b1a650c1b","type":"TRIAL","name":"Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT04107051","description":"Alcohol Dependence","metadata":null},{"id":"ddfc30b62dc34fb59fee7370d3602824","type":"TRIAL","name":"Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD","canonical_id":"clinicaltrials.gov:NCT02847624","description":"Polycystic Kidney, Autosomal Dominant","metadata":null},{"id":"e2c8c11e0aee4ca9890b187ee0a4520b","type":"TRIAL","name":"Post-Marketing Surveillance of Ventavis\u00ae in Chinese Patients With Primary Pulmonary Hypertension (PPH)","canonical_id":"clinicaltrials.gov:NCT00882947","description":"Primary Hypertension","metadata":null},{"id":"f409e53475de4c67b2b763c6d164f2c3","type":"TRIAL","name":"Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery","canonical_id":"clinicaltrials.gov:NCT04060771","description":"Anesthesia; Strabismus; PONV","metadata":null},{"id":"11aa494f448d4fd6a9f7cce7149da404","type":"TRIAL","name":"Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy","canonical_id":"clinicaltrials.gov:NCT04173442","description":"Atopic Dermatitis (AD); Asthma","metadata":null},{"id":"cec4ac9f73504af2964cce65359990c1","type":"TRIAL","name":"Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)","canonical_id":"clinicaltrials.gov:NCT01077843","description":"Ankylosing Spondylitis","metadata":null},{"id":"e2d90102ea65455f907eec7148dafb0c","type":"TRIAL","name":"Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04066504","description":"Basal Cell Carcinoma","metadata":null},{"id":"8b105593f8b04479bfda3bf88ca2d444","type":"TRIAL","name":"Post-marketing Observational Study in Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00234884","description":"Rheumatoid Arthritis","metadata":null},{"id":"f07d63e30600450e8878a0ef994fae93","type":"TRIAL","name":"Post-marketing Study Assessing the Long-Term Safety of Abatacept","canonical_id":"clinicaltrials.gov:NCT02169544","description":"Rheumatoid Arthritis","metadata":null},{"id":"d6dca49fc2fd4f6eb61792f74e88accd","type":"TRIAL","name":"Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)","canonical_id":"clinicaltrials.gov:NCT01463891","description":"Inoperable or Recurrent Breast Cancer","metadata":null},{"id":"1cae77b2cace4ad99d7f62ec40a25101","type":"TRIAL","name":"Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02162251","description":"Alzheimer's Desease","metadata":null},{"id":"d31d05a474a540e18f2908d314343c44","type":"TRIAL","name":"Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)","canonical_id":"clinicaltrials.gov:NCT03471728","description":"Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases); Irritable Bowel Syndrome With Constipation (IBS-C)","metadata":null},{"id":"c50691a4fe7843e1a3590602d0b977f4","type":"TRIAL","name":"Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)","canonical_id":"clinicaltrials.gov:NCT01005056","description":"Contraception","metadata":null},{"id":"c322bf65921f44de9187cf4d00efff0f","type":"TRIAL","name":"Post-operative Pain Control After Photorefractive Keratectomy Comparing Acetaminophen/Codeine vs Acetaminophen/Oxycodone","canonical_id":"clinicaltrials.gov:NCT04399122","description":"Post-operative Pain Control","metadata":null},{"id":"927df9dbd0fb477ea8bc1db6fe419d18","type":"TRIAL","name":"Post-operative Pain Management in Children With Supracondylar Humerus Fractures","canonical_id":"clinicaltrials.gov:NCT05640674","description":"Supracondylar Humerus Fracture","metadata":null},{"id":"bf612ef5ba1242f4b82a001416365705","type":"TRIAL","name":"Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia","canonical_id":"clinicaltrials.gov:NCT01095939","description":"Renal Alteration","metadata":null},{"id":"5c04c95f92bc4d05bad6ec1b96e6f450","type":"TRIAL","name":"Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)","canonical_id":"clinicaltrials.gov:NCT05221619","description":"Warm Autoimmune Hemolytic Anemia","metadata":null},{"id":"29e9959c9b13499ab4ffb0307194220c","type":"DISEASE","name":"Postencephalitic parkinsonism","canonical_id":"mesh:D010301","description":null,"metadata":null},{"id":"64f30e8d16424d5aa4bf0e0242963aeb","type":"TRIAL","name":"Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations","canonical_id":"clinicaltrials.gov:NCT00831350","description":"Retinal Vein Occlusion; Posterior Vitreous Detachment","metadata":null},{"id":"74f4115308ec420c851048db6886d608","type":"TRIAL","name":"Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06078982","description":"Gastric Cancer; HER2-low-expressing Gastric Cancer","metadata":null},{"id":"64d8ec4171244e9a9a6e0f2b098cd3f4","type":"DISEASE","name":"Postherpetic neuralgia","canonical_id":"mesh:D051474","description":null,"metadata":null},{"id":"34d1e6937bcd43f98a78b44e413060c3","type":"TRIAL","name":"Postmenopausal Hormone Therapy in Unstable Angina","canonical_id":"clinicaltrials.gov:NCT00000601","description":"Angina, Unstable; Cardiovascular Diseases; Coronary Disease; Heart Diseases; Postmenopause","metadata":null},{"id":"635ff055d7524693b8e5ab19da4a5003","type":"DISEASE","name":"Postmenopausal osteoporosis","canonical_id":"mesh:D015663","description":null,"metadata":null},{"id":"21c462bfd04f403882ca61f073cab97d","type":"TRIAL","name":"Postoperative Analgesia Impact of Narcotic Free Anesthesia","canonical_id":"clinicaltrials.gov:NCT01544959","description":"Pain, Postoperative; Breast Cancer; Postoperative Nausea and Vomiting","metadata":null},{"id":"2c0c200204fa4479b53a9edf2586e3f3","type":"TRIAL","name":"Postoperative Analgesia in Laminectomy","canonical_id":"clinicaltrials.gov:NCT02255955","description":"Postoperative Pain; Postoperative Laminectomy Pain","metadata":null},{"id":"f007a5d0eebc49b0816795ad349d4df9","type":"TRIAL","name":"Postoperative Analgesia in Laparoscopic Gynecological Surgeries","canonical_id":"clinicaltrials.gov:NCT06491485","description":"Postoperative Pain","metadata":null},{"id":"4d3e10f2162945e8b85409da4dde4b97","type":"TRIAL","name":"Postoperative Analgesic Effect of Hydromorphone on Partial Pulmonary Resection Under Video-assisted Thoracoscopy","canonical_id":"clinicaltrials.gov:NCT03648008","description":"Pain, Postoperative; Thoracic Surgery, Video-Assisted","metadata":null},{"id":"796413edb3484974abea2d51ef074cf0","type":"TRIAL","name":"Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery","canonical_id":"clinicaltrials.gov:NCT05695664","description":"Intravenous Drug Usage; Ibuprofen; Ketorolac; Knee Arthroscopy; Postoperative Pain","metadata":null},{"id":"97b2e9b3b7fe40e2aaed492bbef59eac","type":"TRIAL","name":"Postoperative Experience of 2 WALANT-type Modes of Anesthesia Used in Ambulatory Surgery of the Upper Limb.","canonical_id":"clinicaltrials.gov:NCT05343299","description":"Anesthesia, Local; Hand Surgery; Wrist Surgery; Elbow Surgery","metadata":null},{"id":"6e0cbd9d4f2b46eba9db64eaf8588800","type":"TRIAL","name":"Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence","canonical_id":"clinicaltrials.gov:NCT03443856","description":"Gastric and Esophagogastric Junction Adenocarcinoma","metadata":null},{"id":"fbed0fac3e9845a3bb09b7de379374f5","type":"DISEASE","name":"Postoperative Nausea and Vomiting","canonical_id":"mesh:D020250","description":null,"metadata":null},{"id":"e84274d953024beea8ddf223311e586e","type":"TRIAL","name":"Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant","canonical_id":"clinicaltrials.gov:NCT02597907","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"861b1b7c1416406d9e6816e7fb91ba17","type":"TRIAL","name":"Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen","canonical_id":"clinicaltrials.gov:NCT00188071","description":"Abortion, Induced","metadata":null},{"id":"9fc4edba67914e3180d7022bfbcded7f","type":"TRIAL","name":"Postoperative Pain Control in Septum and Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT04149964","description":"Post-operative Pain; Sinus Surgery","metadata":null},{"id":"7b97098e81f24ea688cad10193ae13ba","type":"TRIAL","name":"Postoperative Pain Management Following Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT06561438","description":"Postoperative Pain","metadata":null},{"id":"e3261c1254c14762b179e0cc93b2765c","type":"TRIAL","name":"Postoperative Pain Management in Rhinoplasty","canonical_id":"clinicaltrials.gov:NCT03584152","description":"Pain, Postoperative","metadata":null},{"id":"fe4fecd153e6426c8c471af217e1abf2","type":"TRIAL","name":"Postoperative Pain Management of Caesarean Section","canonical_id":"clinicaltrials.gov:NCT05009771","description":"Postoperative Pain; Caesarean Section; Analgesia","metadata":null},{"id":"917c1cd8907543d1a57e3c04794351e1","type":"TRIAL","name":"Postoperative Pain and Discomfort After Orbital Decompression","canonical_id":"clinicaltrials.gov:NCT03562611","description":"Surgery; Anesthesia; Pain","metadata":null},{"id":"7c55f4f610b1444cb8908ab0c945984e","type":"TRIAL","name":"Postoperative Radiotherapy With Nimotuzumab \u00b1 Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07535567","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"e0cea62eec3e455b93dec2e896d22c36","type":"TRIAL","name":"Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement","canonical_id":"clinicaltrials.gov:NCT01551485","description":"Sleep Duration on the First Night After Surgery","metadata":null},{"id":"00674c17b52945b8b9fa40afa80b6bd0","type":"TRIAL","name":"Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing TURP","canonical_id":"clinicaltrials.gov:NCT02142595","description":"Sleep Quality of Patients Undergoing TURP","metadata":null},{"id":"f8ca4358fd304316a4022d490fec988b","type":"TRIAL","name":"Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients","canonical_id":"clinicaltrials.gov:NCT05408104","description":"Heart Failure; Heart Assist Device; Hyponatremic","metadata":null},{"id":"6d222c3a364a405e98701e3afccb0099","type":"TRIAL","name":"Postoperative Vomiting in Children - Is Dextrose an Effective Prophylactic Anti-emetic?","canonical_id":"clinicaltrials.gov:NCT01912807","description":"Postoperative Vomiting","metadata":null},{"id":"c246aef0a2cc4792a69cb72dbf96e673","type":"TRIAL","name":"Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes","canonical_id":"clinicaltrials.gov:NCT01022645","description":"Gestational Diabetes; Glucose Intolerance; Type 2 Diabetes; Intrauterine Contraception","metadata":null},{"id":"846baafff8dd451b9c078dbfc6fc1f4f","type":"TRIAL","name":"Postpartum Hypertension Study","canonical_id":"clinicaltrials.gov:NCT05139238","description":"Postpartum Pregnancy-Induced Hypertension; Postpartum Preeclampsia; Pregnancy-Induced Hypertension in Postpartum; Hypertensive Emergency","metadata":null},{"id":"dfda1583f96d4929a8fda50e13dead32","type":"TRIAL","name":"Postpartum Management of Gestational Hypertensive Disorders Using Furosemide","canonical_id":"clinicaltrials.gov:NCT04343235","description":"Hypertension, Pregnancy-Induced","metadata":null},{"id":"456a9af7a0b144a6b45cf23464211c8e","type":"TRIAL","name":"Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02713477","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e77d53b667a24f7184549cf1863b807d","type":"TRIAL","name":"Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study","canonical_id":"clinicaltrials.gov:NCT03200782","description":"Postprandial Hypoglycemia; Bariatric Surgery; Late Dumping Syndrome","metadata":null},{"id":"27be2ba624484c52aa41d00bb851222f","type":"DISEASE","name":"Posttraumatic stress disorder","canonical_id":"mesh:D013313","description":null,"metadata":null},{"id":"4c72ca474d64496ab313267321fd6e6f","type":"DRUG","name":"Potassium chloride","canonical_id":"mesh:D011189","description":null,"metadata":null},{"id":"458385b3f9554b12a5d630e926a5d21f","type":"DRUG","name":"Potassium hydrogencarbonate","canonical_id":"mesh:C026329","description":null,"metadata":null},{"id":"a26ca48ad4484685b75cc05924b5d292","type":"PROTEIN","name":"Potassium voltage-gated channel subfamily A member 3","canonical_id":"uniprot:P22001","description":null,"metadata":null},{"id":"e939380a03a045e8b5fb4ddc2f140a46","type":"PROTEIN","name":"Potassium voltage-gated channel subfamily A member 5","canonical_id":"uniprot:P22460","description":null,"metadata":null},{"id":"3ba4eabdf88d4b50bb8dbbfe389bf7db","type":"TRIAL","name":"Potassium-competitive Acid Blocker Versus Double Dose Proton Pump Inhibitors in High High-risk Peptic Ulcer Bleeding","canonical_id":"clinicaltrials.gov:NCT07772700","description":"Bleeding","metadata":null},{"id":"bb17c746cae74085925595810be7dc74","type":"PROTEIN","name":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2","canonical_id":"uniprot:Q9UL51","description":null,"metadata":null},{"id":"09271ae8e32640bdba1f1931bd1eaf42","type":"PROTEIN","name":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","canonical_id":"uniprot:Q9Y3Q4","description":null,"metadata":null},{"id":"ff9cb5884aa342f08dc9cded23ed701c","type":"TRIAL","name":"Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline","canonical_id":"clinicaltrials.gov:NCT01400425","description":"Progressive Cognitive Decline","metadata":null},{"id":"b672a73209ce4c1788dadb13d442435e","type":"TRIAL","name":"Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients","canonical_id":"clinicaltrials.gov:NCT01710163","description":"Bipolar I Disorder","metadata":null},{"id":"a670aff4dfed4f24a25c5eba151bad9d","type":"TRIAL","name":"PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2","canonical_id":"clinicaltrials.gov:NCT03582176","description":"Elbow Fracture; Elbow Injury; Elbow Dislocation","metadata":null},{"id":"39c220f680ef45cdac83451a124bad2f","type":"TRIAL","name":"Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03848754","description":"Relapsed Adult AML","metadata":null},{"id":"d2e0aca094794d44be903e0e3bce65cb","type":"TRIAL","name":"Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET","canonical_id":"clinicaltrials.gov:NCT01202994","description":"Alzheimer's Disease","metadata":null},{"id":"8d1b59aa4a274de8bccfececb064b9c1","type":"DISEASE","name":"Prader-Willi syndrome","canonical_id":"mondo:0008300","description":null,"metadata":null},{"id":"e2ea781822e34c8bab7741cebc651c77","type":"DISEASE","name":"Prader-Willi syndrome","canonical_id":"mesh:D011218","description":null,"metadata":null},{"id":"30a4bf558b7e4d5e8a043980b0b41bc1","type":"TRIAL","name":"Pragmatic Research on Diuretic Management in Early BPD Pilot","canonical_id":"clinicaltrials.gov:NCT05898022","description":"Bronchopulmonary Dysplasia","metadata":null},{"id":"4f6eee012a3943eca1400ddfa020f98a","type":"TRIAL","name":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT01947140","description":"Lymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma","metadata":null},{"id":"763763deb8ba4ce79955cf3271de9ab4","type":"TRIAL","name":"Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06671717","description":"Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma","metadata":null},{"id":"272a5cd040164e92b6abe211059511bf","type":"TRIAL","name":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT07225985","description":"Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"c1cee28c6ef846f18739437beb0ee6a8","type":"TRIAL","name":"Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01134341","description":"Cutaneous T-cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Primary Cutaneous Anaplastic Large Cell Lymphoma","metadata":null},{"id":"8049010261a04316957608e4587d122b","type":"TRIAL","name":"Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy","canonical_id":"clinicaltrials.gov:NCT01129206","description":"Adenocarcinoma of the Esophagus; Adenocarcinomas of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus; Stage IV Esophageal Cancer","metadata":null},{"id":"dc1060f3e1d243179c533c400a07fdb4","type":"TRIAL","name":"Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01206465","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"5679fd8d811a4b818043f5140aea9843","type":"TRIAL","name":"Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT01178944","description":"Adenocarcinoma of the Gastroesophageal Junction; Esophageal Undifferentiated Carcinoma; Gastric Adenocarcinoma; Gastric Squamous Cell Carcinoma; Recurrent Esophageal Adenocarcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Gastric Carcinoma; Stage IIIB Esophageal Adenocarcinoma; Stage IIIB Esophageal Squamous Cell Carcinoma; Stage IIIB Gastric Cancer; Stage IIIC Esophageal Adenocarcinoma; Stage IIIC Esophageal Squamous Cell Carcinoma; Stage IIIC Gastric Cancer; Stage IV Esophagea\u2026","metadata":null},{"id":"0c5cf6199a4047f7a1e631fa813279b0","type":"TRIAL","name":"Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03356678","description":"Relapsed or Refractory Peripheral T-cell Lymphoma","metadata":null},{"id":"afd11de59266405ea3aa0530790d94b9","type":"TRIAL","name":"Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients","canonical_id":"clinicaltrials.gov:NCT01420679","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"2d11c3bb7b4549169c8d85cba8baf995","type":"DRUG","name":"Pralidoxime","canonical_id":"mesh:C028797","description":null,"metadata":null},{"id":"ea65d46a5d3f41008c5490c199b14234","type":"TRIAL","name":"Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07704658","description":"NSCLC (Non-small Cell Lung Cancer); Thyroid Cancer; Solid Tumor Malignancies; Advanced Malignancies","metadata":null},{"id":"a0b8a158d8a444a09e66d77dd6ffccf9","type":"TRIAL","name":"Praluent\u00ae (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study","canonical_id":"clinicaltrials.gov:NCT03379558","description":"Hypercholesterolemia","metadata":null},{"id":"ce9515b6b7cf4f9187f0b9a76744b8c6","type":"TRIAL","name":"Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients","canonical_id":"clinicaltrials.gov:NCT01191944","description":"Parkinson Disease","metadata":null},{"id":"663cd061f1ec43d1a26a4d0675582345","type":"TRIAL","name":"Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms","canonical_id":"clinicaltrials.gov:NCT00297778","description":"Parkinson Disease; Depression","metadata":null},{"id":"e2f86f85559b407092d55d5b3b5b51bb","type":"TRIAL","name":"Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01673724","description":"Parkinson's Disease","metadata":null},{"id":"14c64441f11c4bcfbf43b102d0cc8076","type":"TRIAL","name":"Pramipexole and Emotional Processing","canonical_id":"clinicaltrials.gov:NCT03681509","description":"Emotions; Motivation; Reward; Dopamine","metadata":null},{"id":"6d59fb00640742fe8f745ca52870ec48","type":"TRIAL","name":"Pramipexole and Morphine for Renal Colic","canonical_id":"clinicaltrials.gov:NCT04160520","description":"Renal Colic","metadata":null},{"id":"ed5a50cae4d64db2953b2fba77dbd980","type":"TRIAL","name":"Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients","canonical_id":"clinicaltrials.gov:NCT03817554","description":"Restless Legs Syndrome","metadata":null},{"id":"ab2d0646352847e0b182fd72b0d22595","type":"TRIAL","name":"Pramipexole to Enhance Social Connections","canonical_id":"clinicaltrials.gov:NCT06269146","description":"Anxiety Disorders; Anxiety; Depression; Social Disconnection","metadata":null},{"id":"d7e9258321e64c1bb2763d0f6769b051","type":"DRUG","name":"Prasterone","canonical_id":"mesh:D003687","description":null,"metadata":null},{"id":"daa686b3d95e445e8f135702c0177b14","type":"DRUG","name":"Prasugrel Hydrochloride","canonical_id":"mesh:D000068799","description":null,"metadata":null},{"id":"028411f8a3234a29b305930478624cc8","type":"DRUG","name":"Pravastatin","canonical_id":"mesh:D017035","description":null,"metadata":null},{"id":"a4641cc7740347b5b5de2756582da349","type":"TRIAL","name":"Pravastatin Sodium 40 mg Tablets Food Challenge Study","canonical_id":"clinicaltrials.gov:NCT00834847","description":"Healthy","metadata":null},{"id":"4ecfdef1ed9845d1b40b1620f546f79c","type":"TRIAL","name":"Pravastatin Sodium 80 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00830258","description":"Healthy","metadata":null},{"id":"a1cfdae4aae14faf98aa3ddacb84c512","type":"TRIAL","name":"Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT00599625","description":"Crohn's Disease","metadata":null},{"id":"b33b9516bff24090bb368f7902f7a69c","type":"TRIAL","name":"Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT04284657","description":"Autosomal Dominant Polycystic Kidney Disease","metadata":null},{"id":"04ced9e7f6604408a97a368eb849725d","type":"TRIAL","name":"Pravastatin and Ventilatory Associated Pneumonia","canonical_id":"clinicaltrials.gov:NCT00702130","description":"Ventilator Associated Pneumonia","metadata":null},{"id":"0f7a6c6d1fff456ebc03f7f4dc828615","type":"TRIAL","name":"Pravastatin to Prevent Preeclampsia","canonical_id":"clinicaltrials.gov:NCT03944512","description":"Preeclampsia; Obstetric Labor Complications; Hypertension in Pregnancy","metadata":null},{"id":"3aa315d4ba1045148930fbb5cb0b5879","type":"DRUG","name":"Praziquantel","canonical_id":"mesh:D011223","description":null,"metadata":null},{"id":"762f43348e4d49c7a93d04cc0d677c11","type":"TRIAL","name":"Prazosin Alcohol Dependence IVR Study","canonical_id":"clinicaltrials.gov:NCT00167687","description":"Alcoholism","metadata":null},{"id":"03009bacfa2540d5857121703266251f","type":"TRIAL","name":"Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD","canonical_id":"clinicaltrials.gov:NCT02226367","description":"Alcohol Use Disorders; Stress Disorders, Posttraumatic; Combat Disorders","metadata":null},{"id":"7824cf545e904cba9ac2433e6b0fa7a6","type":"TRIAL","name":"Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance","canonical_id":"clinicaltrials.gov:NCT00108420","description":"Stress Disorder, Post-Traumatic","metadata":null},{"id":"03fdb50992db423f9db9b90255cc735b","type":"TRIAL","name":"Prazosin Use in Adults With Anxiety Disorders","canonical_id":"clinicaltrials.gov:NCT03894345","description":"Anxiety; Anxiety Disorders","metadata":null},{"id":"bed64ac592af44e0b0c800c37b1f793c","type":"TRIAL","name":"Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)","canonical_id":"clinicaltrials.gov:NCT03221751","description":"Dementia","metadata":null},{"id":"77b64210dbc54782b16e44689a7faad7","type":"TRIAL","name":"Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders","canonical_id":"clinicaltrials.gov:NCT02322047","description":"Alcohol Use Disorder; Posttraumatic Stress Disorder (PTSD)","metadata":null},{"id":"01767a1fc2af4129aca37fdd43d37c78","type":"TRIAL","name":"Prazosin as an Antimanic Agent in Severe Mania or Mixed States","canonical_id":"clinicaltrials.gov:NCT01621165","description":"Bipolar, Mania; Bipolar, Mixed State","metadata":null},{"id":"762945e284384f2ca60f73a277411b92","type":"TRIAL","name":"Prazosin for Agitation in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT03710642","description":"Alzheimer's Disease; Disruptive Behavior","metadata":null},{"id":"d0afda890c1943bf8a3f63c7a7b4a3f7","type":"TRIAL","name":"Prazosin for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT01642433","description":"Nicotine Dependence","metadata":null},{"id":"701d25627a1c4d4ba8bb6bab663b38d3","type":"TRIAL","name":"Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse","canonical_id":"clinicaltrials.gov:NCT00585780","description":"Alcohol Dependence","metadata":null},{"id":"5a67d26a8c78487a81b8660aae46bd81","type":"TRIAL","name":"Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees","canonical_id":"clinicaltrials.gov:NCT00261729","description":"Sleep Disorders; Stress Disorders, Post-Traumatic","metadata":null},{"id":"126e41c3b83d4fbab5a09b3102c2bffa","type":"TRIAL","name":"Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC","canonical_id":"clinicaltrials.gov:NCT04204928","description":"Non-Small Cell Lung Cancer; Medullary Thyroid Cancer","metadata":null},{"id":"13450894ebd9439daf085c319c30ecaf","type":"TRIAL","name":"Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04599712","description":"Metastatic Non-Small Cell Lung Cancer","metadata":null},{"id":"81c3cd179cd14780adc156da11d27cbc","type":"TRIAL","name":"Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain","canonical_id":"clinicaltrials.gov:NCT00149253","description":"a Single-Dose of Etoricoxib; Post-Operative Morphine Consumption; Total Pain Relief Over 8 Hr(TOPAR8); Post Transabdominal Hysterectomy","metadata":null},{"id":"4ff513512bfb4eec9b4c26933be4beef","type":"TRIAL","name":"Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis","canonical_id":"clinicaltrials.gov:NCT04173169","description":"Infertility; Endometriosis","metadata":null},{"id":"20f30664bad64a8f84d7d75634d1f2c8","type":"TRIAL","name":"Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp","canonical_id":"clinicaltrials.gov:NCT06375811","description":"Infertility; Endometriosis","metadata":null},{"id":"33889b273cf540c690061af9e53614c8","type":"TRIAL","name":"Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04272801","description":"Breast Cancer Female","metadata":null},{"id":"3bd7dd7c63db4648a4d75b0d7f009a9d","type":"TRIAL","name":"Pre-Release VIVITROL for Opioid Dependent Inmates","canonical_id":"clinicaltrials.gov:NCT01563718","description":"Substance-Related Disorders","metadata":null},{"id":"423b079a5e2f4c42a215a766a5ad948e","type":"TRIAL","name":"Pre-Surgical Intervention for Targeted Therapies for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01004744","description":"Invasive Breast Cancer","metadata":null},{"id":"40645b1ca0664ab28e4efea7cbe4477b","type":"TRIAL","name":"Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment","canonical_id":"clinicaltrials.gov:NCT00456014","description":"Depression","metadata":null},{"id":"334080bb6c7e4b8fb8512c6c448a0361","type":"TRIAL","name":"Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)","canonical_id":"clinicaltrials.gov:NCT05522556","description":"Alopecia Areata","metadata":null},{"id":"49358a7bacbb4934b5868920a0af4a46","type":"TRIAL","name":"Pre-emptive Anakinra for Cytokine Event Reduction","canonical_id":"clinicaltrials.gov:NCT06703216","description":"B-Acute Lymphoblastic Leukemia; CAR-T Cell Therapy; Cytokine Release Syndrome; Immune Effector Cell Associated Neurotoxicity Syndrome; Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome","metadata":null},{"id":"9cb5b2be74f14c6388bdaf0b0f1446cd","type":"TRIAL","name":"Pre-emptive Analgesic Administration in Primary Tooth Extraction","canonical_id":"clinicaltrials.gov:NCT03786029","description":"Local Anesthesia; Tooth Extraction","metadata":null},{"id":"65243d39fcf4451cbb766351172726d4","type":"TRIAL","name":"Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain","canonical_id":"clinicaltrials.gov:NCT04169854","description":"Postoperative Pain; Lidocaine","metadata":null},{"id":"81e72ec002a44ec0b1c1dee9d151f721","type":"TRIAL","name":"Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity","canonical_id":"clinicaltrials.gov:NCT02993991","description":"Squamous Cell Carcinoma, Head And Neck; Squamous Cell Carcinoma Mouth; Resectable Squamous Cell Carcinoma of Oral Cavity","metadata":null},{"id":"669827a3e34146d494c38328e26b8b60","type":"TRIAL","name":"Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT06620991","description":"Preoperative; Phentolamine; Intraoperative; Esmolol; Hypotensive Anesthesia; Functional Endoscopic Sinus Surgery","metadata":null},{"id":"e658b4245d3c4add943f1514a8c387da","type":"TRIAL","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","canonical_id":"clinicaltrials.gov:NCT05845450","description":"Colorectal Cancer; Resectable Colorectal Carcinoma","metadata":null},{"id":"d6fa9afd87cd4d02a79cbf91b9695b5e","type":"TRIAL","name":"Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT06191094","description":"Diabetic Retinopathy; Vitreous Hemorrhage Due to Diabetes Mellitus","metadata":null},{"id":"10987fb24fa6405e93ca967e8100cad8","type":"TRIAL","name":"Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT06311929","description":"HCC","metadata":null},{"id":"83dd783f219440e28eb002a2bfc601b3","type":"TRIAL","name":"Precision Cancer Therapy in Rare Cancers","canonical_id":"clinicaltrials.gov:NCT06119789","description":"Rare Malignant Neoplasm","metadata":null},{"id":"540a45d6123441f58c272d4b67518d5a","type":"TRIAL","name":"Precision Care for Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT06580041","description":"Major Depressive Disorder; Depression; Depressive Disorder, Major","metadata":null},{"id":"8df90828e38c4890b30e6db6f14d65f6","type":"TRIAL","name":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","canonical_id":"clinicaltrials.gov:NCT03885830","description":"CML, Chronic Phase; CML (Chronic Myelogenous Leukemia; CML - Philadelphia Chromosome; Chronic Myeloid Leukemia; Chronic Myeloid Leukemia, Chronic Phase","metadata":null},{"id":"5ee6358f326b4c09a3d17cad631dadd0","type":"TRIAL","name":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","canonical_id":"clinicaltrials.gov:NCT03833440","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"15acfacec41044709bb155a1640c6d49","type":"TRIAL","name":"Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure","canonical_id":"clinicaltrials.gov:NCT07779642","description":"ARDS (Acute Respiratory Distress Syndrome); Acute Hypoxic Respiratory Failure","metadata":null},{"id":"3c651b85ede84d0f942ab696ea840c27","type":"TRIAL","name":"Precision Medicine Offers Belatacept Monotherapy","canonical_id":"clinicaltrials.gov:NCT02939365","description":"Transplantation","metadata":null},{"id":"f1bed63950a841c08380af72f3b2ac00","type":"TRIAL","name":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","canonical_id":"clinicaltrials.gov:NCT06739395","description":"Solid Tumor; Precision Medicine","metadata":null},{"id":"89b512b26b1946c68e1d5071ba414a14","type":"TRIAL","name":"Precision T1D Platform - New Therapies for Cardio-Renal Complications","canonical_id":"clinicaltrials.gov:NCT07594145","description":"Type 1 Diabetes; T1D Heart Failure; Cardio-renal Vascular Function and Failure; Diabetic Chronic Kidney Disease","metadata":null},{"id":"81a1802c5c9041e8a833e4be0c0cb9fd","type":"TRIAL","name":"Precision Treatment With Angiotensin Converting Enzyme Inhibitor","canonical_id":"clinicaltrials.gov:NCT05535595","description":"Hypertension","metadata":null},{"id":"3b2e241dc0c04ca3bfc33fb45c205efe","type":"TRIAL","name":"Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping","canonical_id":"clinicaltrials.gov:NCT06561022","description":"Breast Cancer","metadata":null},{"id":"403a0899ffae4ea9877886940d63e8ce","type":"TRIAL","name":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","canonical_id":"clinicaltrials.gov:NCT06145308","description":"Salivary Gland Carcinoma; Precision Therapy","metadata":null},{"id":"8f149dc6ac0743038ed80078cdbecfd2","type":"TRIAL","name":"Precision Use of TXA in Intracerebral Hemorrhage","canonical_id":"clinicaltrials.gov:NCT07365150","description":"Intracerebral Hemorrhage","metadata":null},{"id":"06f2a7b5a26c487c9f2d38afbbfb6f72","type":"TRIAL","name":"Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis","canonical_id":"clinicaltrials.gov:NCT04583501","description":"Chronic Rhinosinusitis With Nasal Polyps; Nasal Polyps","metadata":null},{"id":"fd69cb8936e74a62afb654879de65686","type":"DISEASE","name":"Precocious puberty","canonical_id":"mesh:D011629","description":null,"metadata":null},{"id":"607cecf0aaaa4c4ab43f127fff648949","type":"DISEASE","name":"Precocious puberty in males","canonical_id":"hp:0008185","description":null,"metadata":null},{"id":"89588309696a47279d67228ae29b6487","type":"TRIAL","name":"Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg","canonical_id":"clinicaltrials.gov:NCT05888766","description":"Migraine Disorders","metadata":null},{"id":"29edebd6ebb740d08c479055a88e3981","type":"TRIAL","name":"Predicting Inflammatory Skin Disease Response to IL-23 Blockade","canonical_id":"clinicaltrials.gov:NCT04541329","description":"Psoriasis Vulgaris","metadata":null},{"id":"1d5670e601604fff9e448a9cc65df6cc","type":"TRIAL","name":"Predicting Medication Response in Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT01404871","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"ed6dbfa0ef834ded8ce87439c10e1ca2","type":"TRIAL","name":"Predicting Response to Capecitabine in Women With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00953537","description":"Breast Cancer","metadata":null},{"id":"bffe56475029425f89bfbb257692b8bf","type":"TRIAL","name":"Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT04865250","description":"NSCLC Stage II; NSCLC, Stage IIIA; NSCLC Stage IIIB","metadata":null},{"id":"851d5ebb7a17416ab6482e34ba0da964","type":"TRIAL","name":"Predicting SSRI Efficacy in Veterans With PTSD","canonical_id":"clinicaltrials.gov:NCT04183205","description":"Posttraumatic Stress Disorder; Major Depressive Disorder","metadata":null},{"id":"845e320377904ea792ff8cdedc16c3fa","type":"TRIAL","name":"Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients","canonical_id":"clinicaltrials.gov:NCT01377987","description":"Heart Failures","metadata":null},{"id":"61e9348e87d24e2290a16fcfa9370c3e","type":"TRIAL","name":"Predicting Worsening Acute Kidney Injury With a Water-Pill (Furosemide) Test and Blood Markers in Patients With Low Albumin","canonical_id":"clinicaltrials.gov:NCT07688733","description":"Acute Kidney Injury; Hypoalbuminemia","metadata":null},{"id":"1b9cd5b136b641e9a2e28a440abf7bb6","type":"TRIAL","name":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","canonical_id":"clinicaltrials.gov:NCT06805812","description":"Breast Adenocarcinoma; Breast Cancer Stage IV; Breast Cancer, Metastatic; Breast Carcinoma; Breast Diseases; Breast Neoplasms; Breast Neoplasms, Male; Breast Cancer; Breast Cancer With Metastatic Bone Disease; Breast Cancers; Breast Neoplasm; Breast Tumors; HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer; HR+ Advanced or Metastatic Breast Cancer; HR+/HER2- Breast Cancer; HRpos Breast Neoplasms; HR-positive, HER2-negative Advanced Breast Cancer; HR-positive, HER2-negative and PIK3CA Mut\u2026","metadata":null},{"id":"61569e9af1fa4b2f80d0b8d5e220a962","type":"TRIAL","name":"Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils","canonical_id":"clinicaltrials.gov:NCT02023151","description":"Allergic Asthma","metadata":null},{"id":"2a93bb957f44439bad89f994f3a02ce1","type":"TRIAL","name":"Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels","canonical_id":"clinicaltrials.gov:NCT03223233","description":"Wound Infection; Cesarean Wound Disruption","metadata":null},{"id":"b12f28c713e9411585d061d7a3032c19","type":"TRIAL","name":"Prediction Model for Response to Biologics and Small Molecular Agent for UC","canonical_id":"clinicaltrials.gov:NCT05186623","description":"Ulcerative Colitis","metadata":null},{"id":"efd92982c4dc47c7b2fc3cb8dbc6b05e","type":"TRIAL","name":"Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs","canonical_id":"clinicaltrials.gov:NCT03660293","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"6d141585a6c9425ab31cfba97757bc5c","type":"TRIAL","name":"Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development","canonical_id":"clinicaltrials.gov:NCT01487395","description":"Alzheimer Disease; Battery","metadata":null},{"id":"4426f4390aad4d0faf64bcdf25d282b3","type":"TRIAL","name":"Prediction of Drug Interactions With CYP2C9 Substrates","canonical_id":"clinicaltrials.gov:NCT00226538","description":"Healthy Volunteers","metadata":null},{"id":"7cabe9750ca945a0b6b2e3cc9b9453dd","type":"TRIAL","name":"Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica","canonical_id":"clinicaltrials.gov:NCT01914042","description":"Neuropathic Pain","metadata":null},{"id":"ed119ff961c94201bd8f591f877805e2","type":"TRIAL","name":"Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain","canonical_id":"clinicaltrials.gov:NCT01864265","description":"Rheumatoid Arthritis","metadata":null},{"id":"d05b04cb64e748e689cca14cd41740f5","type":"TRIAL","name":"Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers","canonical_id":"clinicaltrials.gov:NCT03033095","description":"Spondylitis, Ankylosing","metadata":null},{"id":"1f3af53aa2494117a081933616c4dca3","type":"TRIAL","name":"Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data","canonical_id":"clinicaltrials.gov:NCT04897958","description":"Prostate Cancer","metadata":null},{"id":"58b7d0039d774cab9eb6d7a628742088","type":"TRIAL","name":"Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation","canonical_id":"clinicaltrials.gov:NCT05866575","description":"Major Depressive Disorder","metadata":null},{"id":"a72b4503f8064f3096ab846811062fb8","type":"TRIAL","name":"Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment","canonical_id":"clinicaltrials.gov:NCT05442008","description":"Migraine","metadata":null},{"id":"04799eeaece547ddb20a7ffbbc9739aa","type":"TRIAL","name":"Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate","canonical_id":"clinicaltrials.gov:NCT03051620","description":"Osteoporosis","metadata":null},{"id":"beaaba2ff91248fb99005bceb91523d3","type":"TRIAL","name":"Predictive Value of Mid-luteal Serum Progesterone Levels in Egg Donation Cycles","canonical_id":"clinicaltrials.gov:NCT02696694","description":"Pregnancy","metadata":null},{"id":"b031ad57027e4943881da50b26be52ab","type":"TRIAL","name":"Predictors of Cognitive Outcomes in Geriatric Depression","canonical_id":"clinicaltrials.gov:NCT05273996","description":"Major Depressive Disorder; Neuroticism; Cognitive Change; Stress","metadata":null},{"id":"7592b8c68c454b55a7aee53f22acaf8e","type":"TRIAL","name":"Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure","canonical_id":"clinicaltrials.gov:NCT00633685","description":"Posttraumatic Stress Disorder, Combat-related","metadata":null},{"id":"4199cd7d50544c1889f7b23575a934dd","type":"DRUG","name":"Prednicarbate","canonical_id":"mesh:C035287","description":null,"metadata":null},{"id":"1d1775b9879141578936576d701abf68","type":"TRIAL","name":"Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms","canonical_id":"clinicaltrials.gov:NCT02299115","description":"Infantile Spasms","metadata":null},{"id":"c39dae3a3ae54ad98f4187e0a074d9c1","type":"TRIAL","name":"Prednisone for Heart Failure Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT00919243","description":"Heart Failure; Hyperuricemia","metadata":null},{"id":"74a257e941a142cb8cb63433ec9b7c2c","type":"TRIAL","name":"Prednisone for Heart Failure Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT02129764","description":"Heart Failure, Hyperuricemia","metadata":null},{"id":"2f2e9cbf1c204360a8d3a812ef46b30d","type":"TRIAL","name":"Preeclampsia Postpartum Antihypertensive Treatment","canonical_id":"clinicaltrials.gov:NCT04298034","description":"Preeclampsia; Hypertension in Pregnancy","metadata":null},{"id":"a2b5e35048ea44d9b0cb5bd3ac72cb0f","type":"TRIAL","name":"Preeclampsia: A Marker for Future Cardiovascular Risk in Women","canonical_id":"clinicaltrials.gov:NCT01519297","description":"Preeclampsia; Pregnancy Induced Hypertension","metadata":null},{"id":"85f9577325d54a2ca41a5d5388ba7424","type":"TRIAL","name":"Preemptive Analgesia With Amitryptyline for Prevention of Pain in Women After Hysterectomy","canonical_id":"clinicaltrials.gov:NCT03587025","description":"Pain, Postoperative","metadata":null},{"id":"f39eea8cdabf4abd94cca8c151021068","type":"TRIAL","name":"Preemptive Analgesia for Primary Dysmenorrhoea","canonical_id":"clinicaltrials.gov:NCT03323671","description":"Primary Dysmenorrhea","metadata":null},{"id":"0b4e0a087ff6498caf35e79e0d181eb4","type":"TRIAL","name":"Preemptive Analgesia in Cruciate Reconstruction","canonical_id":"clinicaltrials.gov:NCT01017380","description":"Anterior Cruciate Ligament Injury","metadata":null},{"id":"5b556abf5c2345d482d242abc0fea02a","type":"TRIAL","name":"Preemptive Analgesia in Laparoscopic Hysterectomy","canonical_id":"clinicaltrials.gov:NCT07401927","description":"Postoperative Analgesia; Laparoscopic Hysterectomy","metadata":null},{"id":"83e1d76940f64e979dda1e4627bb4e18","type":"TRIAL","name":"Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT03943927","description":"Post-operative Atrial Fibrillation","metadata":null},{"id":"042debeb86474ba58b57d9c91ddd9d1c","type":"TRIAL","name":"Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)","canonical_id":"clinicaltrials.gov:NCT00794768","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"a64af66e213445b3849b3a64c1711c9c","type":"TRIAL","name":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)","canonical_id":"clinicaltrials.gov:NCT00794846","description":"Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis","metadata":null},{"id":"a485fee84184427e8117d5bf80d3c43a","type":"TRIAL","name":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)","canonical_id":"clinicaltrials.gov:NCT00794495","description":"Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis","metadata":null},{"id":"8c58631962ea4b7daaac579a58de38ec","type":"TRIAL","name":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)","canonical_id":"clinicaltrials.gov:NCT00794599","description":"Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis","metadata":null},{"id":"2c9dbbf9f9f04c2396bb1666a1ed3476","type":"DRUG","name":"Pregabalin","canonical_id":"mesh:D000069583","description":null,"metadata":null},{"id":"a0279fc957f54e929d51374b6a80db98","type":"TRIAL","name":"Pregabalin for Opiate Withdrawal Syndrome","canonical_id":"clinicaltrials.gov:NCT03017430","description":"Opioid Withdrawal","metadata":null},{"id":"313e6c57e33843e3a94b12536d2d36c8","type":"TRIAL","name":"Pregabalin for the Treatment of Uremic Pruritus","canonical_id":"clinicaltrials.gov:NCT01852318","description":"Uremic Pruritus","metadata":null},{"id":"0e43452f578a4a01b9d5ea0a840c0dcd","type":"TRIAL","name":"Pregnancy Rate by HCG Administration Versus Urinary LH Surge Method in Patients Undergoing IUI","canonical_id":"clinicaltrials.gov:NCT02638285","description":"Pregnancy","metadata":null},{"id":"fc3c276c36be460393dc82aff6b10737","type":"TRIAL","name":"Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist","canonical_id":"clinicaltrials.gov:NCT01888744","description":"Reproductive Endocrinology; Fertility; Optimal Stimulation Protocol","metadata":null},{"id":"c6c48a2782364c27808194fa79477478","type":"TRIAL","name":"Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT03617016","description":"Dyspepsia","metadata":null},{"id":"fdb408850c7d4979ba4b73a702f4ff1d","type":"DISEASE","name":"Premature ejaculation","canonical_id":"mesh:D061686","description":null,"metadata":null},{"id":"b6b6a3dbb7cc44f79d1ce5b92006b834","type":"DISEASE","name":"Premature labor","canonical_id":"mesh:D007752","description":null,"metadata":null},{"id":"79653dd53e2c4996ad50c963d509b28d","type":"TRIAL","name":"Premedication by Clonidine Intranasal in Pediatric Surgery","canonical_id":"clinicaltrials.gov:NCT03725930","description":"Child Preschool","metadata":null},{"id":"b7dc19a39ff345d9ad9737bfd970bd1c","type":"TRIAL","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","canonical_id":"clinicaltrials.gov:NCT05663866","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"271a04a3548f4b6a84582ba278b9d11d","type":"TRIAL","name":"Premenstrual Dysphoric Disorder and Antiepileptic Drugs","canonical_id":"clinicaltrials.gov:NCT00612235","description":"Epilepsy","metadata":null},{"id":"6c74ce886bc94b74b598bd50ae92afa9","type":"DISEASE","name":"Premenstrual dysphoric disorder","canonical_id":"mesh:D065446","description":null,"metadata":null},{"id":"f7541f55d73f4e5ea827487e388fca16","type":"TRIAL","name":"Preoperative Alpha Blockade for Pheochromocytoma","canonical_id":"clinicaltrials.gov:NCT03176693","description":"Pheochromocytoma; Paraganglioma","metadata":null},{"id":"f615ea4a0b4546aabb8a0fb2074a2667","type":"TRIAL","name":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","canonical_id":"clinicaltrials.gov:NCT06784791","description":"Lung Cancer (NSCLC)","metadata":null},{"id":"5070b12ee0dc4dc1bbe1d2f0e626aacc","type":"TRIAL","name":"Preoperative BAMCOG and Cortisol and Postoperative DeltaScan in AVR Patients (Aortic Valve Replacement)","canonical_id":"clinicaltrials.gov:NCT05209555","description":"Delirium; Cognitive Impairment; Cognitive Dysfunction; Cognitive Dysfunction, Postoperative; Delirium in Old Age; Postoperative Delirium","metadata":null},{"id":"adb135192e4f41a083d403044afb7702","type":"TRIAL","name":"Preoperative Bexarotene Treatment for Cushing's Disease","canonical_id":"clinicaltrials.gov:NCT00845351","description":"Cushing's Disease","metadata":null},{"id":"9cb87795c6374bcbbbbb6cad1111b975","type":"TRIAL","name":"Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis","canonical_id":"clinicaltrials.gov:NCT02605746","description":"Glioblastoma; Brain Metastases","metadata":null},{"id":"7e946b3f4a8149f5bbf98e709486fe8c","type":"TRIAL","name":"Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly","canonical_id":"clinicaltrials.gov:NCT02992886","description":"Rectal Neoplasms Malignant","metadata":null},{"id":"372e11796fd640cf841d83cfb21e4e7c","type":"TRIAL","name":"Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT01308190","description":"Rectal Cancer","metadata":null},{"id":"316e0665363d4070ab7d1ff46760467d","type":"TRIAL","name":"Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy","canonical_id":"clinicaltrials.gov:NCT00766636","description":"Pancreatic Cancer","metadata":null},{"id":"765292a2b542475cb58ca10a05affcac","type":"TRIAL","name":"Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC","canonical_id":"clinicaltrials.gov:NCT00960297","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"59ce00554b3b4adfb6d0bf83972d657e","type":"TRIAL","name":"Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)","canonical_id":"clinicaltrials.gov:NCT01833572","description":"Non-small-cell Lung Cancer","metadata":null},{"id":"49f7bdb0a1e74de28e62bb56fb251a6e","type":"TRIAL","name":"Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","canonical_id":"clinicaltrials.gov:NCT07171203","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"2464b557b1fc439abf692b9db9b74f29","type":"TRIAL","name":"Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)","canonical_id":"clinicaltrials.gov:NCT04427293","description":"Triple Negative Breast Cancer","metadata":null},{"id":"d218433c4bb6481883b7cb8b0d8a61b6","type":"TRIAL","name":"Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial","canonical_id":"clinicaltrials.gov:NCT05514912","description":"Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8","metadata":null},{"id":"7e43df0e65a643d19c37a4f90c0484cd","type":"TRIAL","name":"Preoperative Nebulized Dexmedetomidine Versus Nebulized Magnesium Sulphate in Reducing Emergence Agitation in FESS","canonical_id":"clinicaltrials.gov:NCT07677917","description":"Screening","metadata":null},{"id":"623909c80b234be3bd7eb196bb65e00c","type":"TRIAL","name":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05752136","description":"Rectal Cancer","metadata":null},{"id":"69b09e2927a44ea29fe0ff400e719906","type":"TRIAL","name":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)","canonical_id":"clinicaltrials.gov:NCT05216653","description":"MSS Locally Advanced Rectal Adenocarcinoma","metadata":null},{"id":"1e38f790f0c8424e8110d8367057b828","type":"TRIAL","name":"Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT07616609","description":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","metadata":null},{"id":"9107230f5d3248a0ac0bd2a7a267078d","type":"TRIAL","name":"Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research","canonical_id":"clinicaltrials.gov:NCT05885776","description":"Breast Cancer","metadata":null},{"id":"55766e0a0a114ef682f48ccb81764303","type":"TRIAL","name":"Preoperative Ultrasound-Guided Peri- Capsular Nerve Group Block on Postoperative Analgesia After Shoulder Arthroscopic Surgery","canonical_id":"clinicaltrials.gov:NCT06790732","description":"Preoperative; Ultrasound-Guided; PeriCapsular Nerve Group Block; Postoperative Analgesia; Shoulder Arthroscopic Surgery","metadata":null},{"id":"5e19a101370441ee94cdaa300d42f54e","type":"TRIAL","name":"Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain","canonical_id":"clinicaltrials.gov:NCT01189071","description":"Overactive Bladder; Renal Colic; Pain, Postoperative","metadata":null},{"id":"dcc0f7145e364771a14f8c02ab9bbab5","type":"TRIAL","name":"Preoperative Use of Montelukast Sodium","canonical_id":"clinicaltrials.gov:NCT02494466","description":"Airway Reactivity","metadata":null},{"id":"08944e9f9fd94aafaad06b5c52081c7e","type":"TRIAL","name":"Prepulse Inhibition of Startle in Cocaine Dependence - 7","canonical_id":"clinicaltrials.gov:NCT00015249","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"366f4175ccdd472aa4b1ed4c8fd2c0d4","type":"TRIAL","name":"Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)","canonical_id":"clinicaltrials.gov:NCT00414921","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"93032750e78a43c8aca386114c4409b0","type":"TRIAL","name":"Prescription of Letrozole for Uterine Myoma","canonical_id":"clinicaltrials.gov:NCT06143631","description":"Leiomyoma, Uterine; Leiomyoma; Fibroid; Fibroid Uterus","metadata":null},{"id":"f6be53d12a65474b8660834b522eee15","type":"TRIAL","name":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT01026831","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"e78a269cf6184abeb8df835cc23b6eb1","type":"TRIAL","name":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","canonical_id":"clinicaltrials.gov:NCT01254604","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"9c7ba7a5c0ef479cb8d990c23e282538","type":"TRIAL","name":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","canonical_id":"clinicaltrials.gov:NCT04828057","description":"Ocular Surface Disease; Primary Open Angle Glaucoma","metadata":null},{"id":"8fbdca1093a243d0bcf2850472e09f5b","type":"TRIAL","name":"Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma","canonical_id":"clinicaltrials.gov:NCT04455126","description":"Glaucoma","metadata":null},{"id":"6980d161e787409cbf88422691eca66d","type":"TRIAL","name":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","canonical_id":"clinicaltrials.gov:NCT03612817","description":"Glaucoma, Open-Angle","metadata":null},{"id":"0c86f7638b684d589a610d8763fb877c","type":"TRIAL","name":"Pressure Assessment to Improve Outcomes After TAVR: a Registry","canonical_id":"clinicaltrials.gov:NCT03923530","description":"Hypertension; Aortic Stenosis, Calcific; Quality of Life; Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"f03509aaedb545399daebc209491bb5d","type":"TRIAL","name":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis","canonical_id":"clinicaltrials.gov:NCT05395910","description":"Peritoneal Carcinomatosis","metadata":null},{"id":"7067e4b42dd44376bdf58391011f059f","type":"TRIAL","name":"Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)","canonical_id":"clinicaltrials.gov:NCT03324828","description":"Anxiety","metadata":null},{"id":"4b752af33a3146dcb2470ee2202c2b04","type":"TRIAL","name":"Pretreatment With CPA-EE, Metformin and Myoinositol in PCOS With High AMH","canonical_id":"clinicaltrials.gov:NCT07513480","description":"PCOS","metadata":null},{"id":"6a875c3df5c74064a5a06eacdba9ab6e","type":"TRIAL","name":"Prevail Drug Balloon Study","canonical_id":"clinicaltrials.gov:NCT05562089","description":"Myocardial Infarction; Drug-Coated Balloon","metadata":null},{"id":"cfdd00d7bc9344d1962b1440dc048ac6","type":"TRIAL","name":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","canonical_id":"clinicaltrials.gov:NCT07487142","description":"H Pylori Infection","metadata":null},{"id":"8f7c1f879ee24823a6c71977fca0bd32","type":"TRIAL","name":"PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage","canonical_id":"clinicaltrials.gov:NCT01013532","description":"Brain Ischemia; Intracranial Hemorrhages","metadata":null},{"id":"22959b54eca44f5d9b3ef971f4e8a4f5","type":"TRIAL","name":"PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study","canonical_id":"clinicaltrials.gov:NCT02483169","description":"Brain Ischemia; Intracranial Hemorrhages","metadata":null},{"id":"6d3c3d493eb7494c9edd2e7a00d24334","type":"TRIAL","name":"Preventative Effect of Combining Dexamethasone with Ondansetron on Postoperative Nausea, Vomiting and Shivering in Children Undergoing Caudal Anesthesia on Hypospadias Surgery","canonical_id":"clinicaltrials.gov:NCT06747975","description":"Caudal Anesthesia","metadata":null},{"id":"d5017f8bd25143da9b7750aa16ece275","type":"TRIAL","name":"Preventing ESRD in Overt Nephropathy of Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00494715","description":"Diabetes","metadata":null},{"id":"fd97016e7ef4469fbdc1203c708e56f9","type":"TRIAL","name":"Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex","canonical_id":"clinicaltrials.gov:NCT02849457","description":"Tuberous Sclerosis Complex","metadata":null},{"id":"f3621bba38564eda97282c802a5d9fd2","type":"TRIAL","name":"Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)","canonical_id":"clinicaltrials.gov:NCT03841357","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"5aec2646186147e6bc1a788fd9c7f3dc","type":"TRIAL","name":"Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial","canonical_id":"clinicaltrials.gov:NCT05377619","description":"Dyspepsia","metadata":null},{"id":"b5c125a65f5045ad93f5ed71fcccc6ac","type":"TRIAL","name":"Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol","canonical_id":"clinicaltrials.gov:NCT01174290","description":"Subsyndromal Delirium","metadata":null},{"id":"b7029a3d38324f52a5a11844142c7dea","type":"TRIAL","name":"Preventing Microalbuminuria in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00503152","description":"Diabetes","metadata":null},{"id":"73fb1982a8be4c1499cb5edd63990584","type":"TRIAL","name":"Preventing Osteoporosis Using Denosumab","canonical_id":"clinicaltrials.gov:NCT02753283","description":"Osteoporosis, Postmenopausal; Osteoporosis; Osteoporotic Fractures","metadata":null},{"id":"39b87b2cd371444fb5953f2715631532","type":"TRIAL","name":"Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy","canonical_id":"clinicaltrials.gov:NCT02213900","description":"Delirium; Cognitive Impairment; Post-traumatic Stress Disorder; Depression; Anxiety","metadata":null},{"id":"0f1944cab4404af2bfa17c53fdf556d7","type":"TRIAL","name":"Preventing Tolerance to Oxymetazoline in Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00846326","description":"Allergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa","metadata":null},{"id":"3f8b1b48eaa543848182154b5cb88c57","type":"TRIAL","name":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis","canonical_id":"clinicaltrials.gov:NCT06475820","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Malignant Lymphoma; Myelodysplastic Syndromes","metadata":null},{"id":"b3ad1ed7a66d4a10aa91621fe7e85702","type":"TRIAL","name":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","canonical_id":"clinicaltrials.gov:NCT05515029","description":"Acute Lymphoblastic Leukemia; Myeloblastic Leukemia; Biphenotypic Acute Leukemia; Malignant Lymphoma; Myelodysplastic Syndromes; Juvenile Myelomonocytic Leukemia","metadata":null},{"id":"395927268de649f6ad67478e3de20162","type":"TRIAL","name":"Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","canonical_id":"clinicaltrials.gov:NCT06756152","description":"Biphenotypic Acute Leukemia; Acute Lymphoblastic Leukemia; Myeloblastic Leukemia; Bilinear Leukemia; Malignant Lymphoma, Non-Hodgkin; Myelodysplastic Syndrome","metadata":null},{"id":"14dba8ce7a7e4e3fa340b5dde701795c","type":"TRIAL","name":"Preventing the Return of Depression in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT00000377","description":"Depression","metadata":null},{"id":"fb69485365d949e095e4244d084b5e25","type":"TRIAL","name":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","canonical_id":"clinicaltrials.gov:NCT04409834","description":"COVID-19; Venous Thromboembolism; Arterial Thrombosis","metadata":null},{"id":"aac2956beb17468197d718a34563beb5","type":"TRIAL","name":"Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter","canonical_id":"clinicaltrials.gov:NCT00736294","description":"Atrial Fibrillation; Atrial Flutter","metadata":null},{"id":"238dfadaf62440c08d743b4f6b193f81","type":"TRIAL","name":"Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00501709","description":"Type 1 Diabetes","metadata":null},{"id":"d2fa618b1b204b9b94e2e146014a0506","type":"TRIAL","name":"Prevention of Bone Loss After Acute SCI by Zoledronic Acid","canonical_id":"clinicaltrials.gov:NCT02325414","description":"Spinal Cord Injury; Acute Spinal Cord Injury; Bone Loss; Osteoporosis","metadata":null},{"id":"9cca5153db6449669e47b21e0a018daa","type":"TRIAL","name":"Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.","canonical_id":"clinicaltrials.gov:NCT01913990","description":"Emesis","metadata":null},{"id":"fc7574601dad4eebb87c22076adaad06","type":"TRIAL","name":"Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia","canonical_id":"clinicaltrials.gov:NCT06147232","description":"Nephropathy; Diabetic Nephropathies; Diabetes Mellitus, Type 1; Albuminuria; Diabetic Complications Renal; Diabetic Complications Cardiovascular; Hypoxia","metadata":null},{"id":"c28330d55079491ca783dd320a3ec303","type":"TRIAL","name":"Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI","canonical_id":"clinicaltrials.gov:NCT03406819","description":"ST Segment Elevation Myocardial Infarction; Primary Percutaneous Coronary Intervention","metadata":null},{"id":"b40d881743c742f4bd37790d2295474b","type":"TRIAL","name":"Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen","canonical_id":"clinicaltrials.gov:NCT07413809","description":"Multiple Myeloma","metadata":null},{"id":"332ee028d74f4e63a75571a4c1c0e821","type":"TRIAL","name":"Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)","canonical_id":"clinicaltrials.gov:NCT02145182","description":"Delayed Graft Function","metadata":null},{"id":"d39aade6c7dc4705901bd79bbddaceb1","type":"TRIAL","name":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","canonical_id":"clinicaltrials.gov:NCT00475085","description":"Nausea","metadata":null},{"id":"2896ec57c38c4a6c90cc279bb08ef9aa","type":"TRIAL","name":"Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life","canonical_id":"clinicaltrials.gov:NCT04900948","description":"Atopic Dermatitis","metadata":null},{"id":"917923638eea4f0383d556b9ba057adb","type":"TRIAL","name":"Prevention of Dichloroacetate Toxicity","canonical_id":"clinicaltrials.gov:NCT00031161","description":"Acidosis, Lactic; Chronic Disease","metadata":null},{"id":"f547339b43964f23a78d238a7b2725d4","type":"TRIAL","name":"Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream","canonical_id":"clinicaltrials.gov:NCT01349556","description":"Medication Reaction","metadata":null},{"id":"10236b3b19334180baa5c88278ba9afd","type":"TRIAL","name":"Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.","canonical_id":"clinicaltrials.gov:NCT00138983","description":"Rheumatoid Arthritis; Polymyalgia Rheumatica; Giant Cell Arteritis; Polymyositis; Wegener's Granulomatosis","metadata":null},{"id":"305b30951f3143e3ab7335b60970281e","type":"TRIAL","name":"Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients","canonical_id":"clinicaltrials.gov:NCT07244419","description":"Hematopoietic Stem Cell Transplantation; Graft Failure","metadata":null},{"id":"957cce7ee82f4204aa76be121f6d1785","type":"TRIAL","name":"Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor","canonical_id":"clinicaltrials.gov:NCT05834777","description":"Intradialytic Hypotension","metadata":null},{"id":"04d1ceac099940599ca1804581da589f","type":"TRIAL","name":"Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00630695","description":"Lymphocele","metadata":null},{"id":"e0f02b6a879b49e5877a063d33696eb3","type":"TRIAL","name":"Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals","canonical_id":"clinicaltrials.gov:NCT00700128","description":"Migraines; Bleeding; Spotting","metadata":null},{"id":"4f423a6f2b9b4bb2aa2a5da5e5ca6c6d","type":"TRIAL","name":"Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin","canonical_id":"clinicaltrials.gov:NCT06886464","description":"Acute Kidney Injury","metadata":null},{"id":"1ad3bbe8bb2e40849c7e455a5b31502e","type":"TRIAL","name":"Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)","canonical_id":"clinicaltrials.gov:NCT00177619","description":"Prostatic Neoplasms","metadata":null},{"id":"a264a36104db47b5b5cd5ec019dadfdf","type":"TRIAL","name":"Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06135493","description":"Peripheral Neuropathy Due to Chemotherapy","metadata":null},{"id":"add63aa5ca6c43fe8f108df12d8ed954","type":"TRIAL","name":"Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac","canonical_id":"clinicaltrials.gov:NCT05947461","description":"Post-ERCP Acute Pancreatitis; NSAIDs; Indomethacin; Diclofenac; Endoscopic Retrograde Cholangiopancreatography","metadata":null},{"id":"28a166b2e2fc4c108bfcea8c9da26c3a","type":"TRIAL","name":"Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Vitrectomy Under Local Anesthesia","canonical_id":"clinicaltrials.gov:NCT02386059","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"23fe1ddf37e641c8864920c00cc81723","type":"TRIAL","name":"Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty","canonical_id":"clinicaltrials.gov:NCT03808155","description":"Urinary Retention Postoperative; Arthropathy of Knee; Arthropathy of Hip","metadata":null},{"id":"beea3e5c4f7f45c7bcd3309ce3187adf","type":"TRIAL","name":"Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone","canonical_id":"clinicaltrials.gov:NCT05299398","description":"Postpartum Depression","metadata":null},{"id":"0b86797316374e4db5b410d9647103a0","type":"TRIAL","name":"Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas","canonical_id":"clinicaltrials.gov:NCT04285749","description":"Malignant Melanoma","metadata":null},{"id":"e1d148819a6348389edb7afaf68aae92","type":"TRIAL","name":"Prevention of Renal and Vascular Endstage Disease Intervention Trial","canonical_id":"clinicaltrials.gov:NCT03073018","description":"Microalbuminuria; Cardiovascular Diseases; Renal Disease","metadata":null},{"id":"434ac790e0ad48dc83caebb380eb3ca4","type":"TRIAL","name":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06616987","description":"Breast Cancer Metastatic","metadata":null},{"id":"d2b82826caf74609a917bd1d33d8915b","type":"TRIAL","name":"Prevention of Severe Postpartum Hypertension","canonical_id":"clinicaltrials.gov:NCT02450773","description":"Hypertension","metadata":null},{"id":"f95149658ab44628815ba841dbcd529c","type":"TRIAL","name":"Prevention of Spinal Induced Shivering During CS","canonical_id":"clinicaltrials.gov:NCT02588547","description":"Spinal Induced Shivering","metadata":null},{"id":"4828bc488aa042c78b75de6c451643e9","type":"TRIAL","name":"Prevention of Thrombocytopenia in Glioblastoma Patients","canonical_id":"clinicaltrials.gov:NCT02227576","description":"Thrombocytopenia; Glioblastoma","metadata":null},{"id":"960396afe7e44c9fa82bb0882cbd7cf9","type":"TRIAL","name":"Preventive Analgesia With Anrikefon in Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT07566663","description":"Postoperative Pain","metadata":null},{"id":"f4ed770d073341d495cad1e6b10c31dc","type":"TRIAL","name":"Preventive Approach Using Venlafaxine","canonical_id":"clinicaltrials.gov:NCT05875610","description":"Peripheral Neuropathy Due to Chemotherapy","metadata":null},{"id":"e43240d68d9f430da9a687e171aefd97","type":"TRIAL","name":"Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination","canonical_id":"clinicaltrials.gov:NCT03393377","description":"Atherosclerosis","metadata":null},{"id":"17e897de50a04c0983c3871013340979","type":"TRIAL","name":"Preventive EXACYL\u00ae on Perioperative Bleeding During Orthognathism of Maxillary Surgery","canonical_id":"clinicaltrials.gov:NCT02702128","description":"Peri-operative Hemorrhage or Hematoma; Surgery; Retrognathism","metadata":null},{"id":"69ee52dc225c4d2e9c6bf5cc9fb4a1b5","type":"TRIAL","name":"Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail","canonical_id":"clinicaltrials.gov:NCT02961998","description":"Hepatocellular Carcinoma","metadata":null},{"id":"438ca5bd14074600bd0b0acfd6931432","type":"TRIAL","name":"Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity","canonical_id":"clinicaltrials.gov:NCT01149304","description":"Colorectal Cancer; Liver Metastases; Irradiation Damage; Radiation Induced Liver Disease","metadata":null},{"id":"23506b3999084923b635a86ac49850d0","type":"TRIAL","name":"Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED","canonical_id":"clinicaltrials.gov:NCT05520723","description":"Triple Negative Breast Cancer; Breast Cancer; Advanced HR+/HER2- Breast Cancer","metadata":null},{"id":"f7d6d698e13b45729a5cbd9eb12c501a","type":"DRUG","name":"Prilocaine","canonical_id":"mesh:D011318","description":null,"metadata":null},{"id":"139a075452ad4b1583aedbf111fd8793","type":"TRIAL","name":"Primary Aldosteronism LC-MS/MS-specific Cutoffs","canonical_id":"clinicaltrials.gov:NCT05959863","description":"Primary Aldosteronism","metadata":null},{"id":"288628b6046e4359b8a42a12a07a9b57","type":"TRIAL","name":"Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours","canonical_id":"clinicaltrials.gov:NCT00260416","description":"Acute Myocardial Infarction","metadata":null},{"id":"a67fe82c6cab414f8d01d8eacee0bd33","type":"TRIAL","name":"Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01172223","description":"Breast Cancer","metadata":null},{"id":"26d0166a55b64b7d9edfe90dd8673c4d","type":"TRIAL","name":"Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?","canonical_id":"clinicaltrials.gov:NCT02227264","description":"Primary Hyperparathyroidism","metadata":null},{"id":"3f9cf1c1c0564cf7ba6a49e111c5924a","type":"TRIAL","name":"Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia","canonical_id":"clinicaltrials.gov:NCT01861535","description":"Vulvar Intraepithelial Neoplasia","metadata":null},{"id":"970d368c216846c8b1d81dc558e7e9cf","type":"TRIAL","name":"Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects","canonical_id":"clinicaltrials.gov:NCT01364675","description":"Pre-diabetes; Pre-hypertension","metadata":null},{"id":"47f2c4c5ddc545bab17655288ac87845","type":"TRIAL","name":"Primary Prevention of Hypertension in Obese Adolescents","canonical_id":"clinicaltrials.gov:NCT00288158","description":"Obesity; Pre-Hypertension; Hyperuricemia","metadata":null},{"id":"bda234e6a4f84fc6ab61e524726a6099","type":"DISEASE","name":"Primary cutaneous T-cell lymphoma","canonical_id":"mesh:D016410","description":null,"metadata":null},{"id":"7d099f87eea04df8b63169a2b4486ba3","type":"DISEASE","name":"Primary hemophagocytic lymphohistiocytosis","canonical_id":"orphanet:158038","description":null,"metadata":null},{"id":"28d02f2240224e7ba36d73e3dacd6cef","type":"DISEASE","name":"Primary malignant neoplasm of brain","canonical_id":"mesh:D001932","description":null,"metadata":null},{"id":"04fcfb38b7724a56b7922b07027f84a0","type":"DISEASE","name":"Primary progressive multiple sclerosis","canonical_id":"mesh:D020528","description":null,"metadata":null},{"id":"33cbc5c5769b4640b808aa0199d2a73e","type":"DISEASE","name":"Prinzmetal angina","canonical_id":"mondo:0006021","description":null,"metadata":null},{"id":"d3bff39ec2454059ae775c7b30cda74b","type":"DISEASE","name":"Prinzmetal angina","canonical_id":"mesh:D000788","description":null,"metadata":null},{"id":"580c38bb518c4adfa47f08052d4acce7","type":"TRIAL","name":"Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma","canonical_id":"clinicaltrials.gov:NCT00849095","description":"Asthma","metadata":null},{"id":"ae959d6510d54d3b917724d200db9844","type":"TRIAL","name":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03903835","description":"Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","metadata":null},{"id":"72ac72f4c52b4d1aabfd64e80d1c3c46","type":"TRIAL","name":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","canonical_id":"clinicaltrials.gov:NCT04341181","description":"Cancer; Tumors; Neoplasms; Neoplasia","metadata":null},{"id":"fd0031517c984a9987b3620d02dd01f4","type":"GO_TERM","name":"ProVWX complex","canonical_id":"go:GO:1990222","description":"\"The ProVWX complex belongs to the family of ATP-binding cassette (ABC) transporter proteins complexes. It consists of a cytoplasmic ATPase subunit ProV, a transmembrane subunit ProW and a periplasmic binding protein ProX. It is capable of translocating a wide variety of solute (e.g. glycine betaine) across the plasma membrane and is activated under osmotic stress conditions.\" [GOC:bhm, PMID:23249124]","metadata":null},{"id":"4a9c64102e1e4add82fd738494f62246","type":"TRIAL","name":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","canonical_id":"clinicaltrials.gov:NCT06398106","description":"Psoriasis Vulgaris","metadata":null},{"id":"fbbe26caa4ff43d2b8d878b7d1d99ff7","type":"PROTEIN","name":"Probable arabinosyltransferase C","canonical_id":"uniprot:P9WNL5","description":null,"metadata":null},{"id":"e5baee21291243ada0af78c815370e1b","type":"DRUG","name":"Probenecid","canonical_id":"mesh:D011339","description":null,"metadata":null},{"id":"138f8dabda64455f839e630219075fc7","type":"TRIAL","name":"Probenecid Administration for Alcohol Craving and Consumption","canonical_id":"clinicaltrials.gov:NCT07118618","description":"Alcohol Use Disorder (AUD); Alcohol Consumption; Craving","metadata":null},{"id":"e6f6cef693e64f91ad9e2aaa5649456b","type":"TRIAL","name":"Probenecid as Medication for Alcohol Use Disorder (PROB)","canonical_id":"clinicaltrials.gov:NCT04218357","description":"Alcohol Use Disorder","metadata":null},{"id":"eda1bf3816884302a61cd2b9f1828d33","type":"TRIAL","name":"Probiotic Intervention on Body Weight","canonical_id":"clinicaltrials.gov:NCT06989177","description":"Obesity; Homeostasis; Weight Loss; Probiotic Intervention","metadata":null},{"id":"593599106bbf474aaca693b1508e42d4","type":"TRIAL","name":"Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT05776940","description":"Immunoglobulin Light-chain Amyloidosis","metadata":null},{"id":"be4879f5c2c840e8bf7ce9e513aa8b10","type":"TRIAL","name":"Probiotic and Colchicine in COVID-19","canonical_id":"clinicaltrials.gov:NCT05911022","description":"COVID-19","metadata":null},{"id":"975b30f28f4f4fdfb797cccb985ec2b1","type":"TRIAL","name":"Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06892093","description":"HER2-positive Breast Cancer; Diarrhea Caused by Drug; Neratinib","metadata":null},{"id":"45d14ba492624d4cb534990ea209edcc","type":"TRIAL","name":"Probiotics in Advanced Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT06904573","description":"Advanced Urothelial Carcinoma; Probiotics; Immunotherapy","metadata":null},{"id":"03b32eaa13c048bdbf779db94cd41bc5","type":"TRIAL","name":"Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy","canonical_id":"clinicaltrials.gov:NCT00655330","description":"Type 2 Diabetes Mellitus; Nephropathy","metadata":null},{"id":"6b5b5f25672e4c05a399bf054ef9d4cd","type":"TRIAL","name":"Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis","canonical_id":"clinicaltrials.gov:NCT06225752","description":"Ischemic Stroke; TIA","metadata":null},{"id":"8882fc266c98410a97d7ac92f147f846","type":"DRUG","name":"Procaine benzylpenicillin","canonical_id":"mesh:D010402","description":null,"metadata":null},{"id":"fd9ecc2f8107494c87952d152d23dbe4","type":"TRIAL","name":"Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department","canonical_id":"clinicaltrials.gov:NCT02898948","description":"Systemic Inflammatory Response Syndrome; Fever","metadata":null},{"id":"205e4ddf9a23451389649455020c96e1","type":"TRIAL","name":"Procalcitonin Antibiotic Consensus Trial (ProACT)","canonical_id":"clinicaltrials.gov:NCT02130986","description":"Lower Respiratory Tract Infection (LRTI)","metadata":null},{"id":"295806e3e2304f06b36470ee1045fd7f","type":"TRIAL","name":"Procalcitonin and Threatened Premature Delivery","canonical_id":"clinicaltrials.gov:NCT01977079","description":"Pregnancy; Premature Delivery","metadata":null},{"id":"35d61e4ebc134dc59cd02f6de60290fa","type":"TRIAL","name":"Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU","canonical_id":"clinicaltrials.gov:NCT01494675","description":"Sepsis","metadata":null},{"id":"444778d87cd94a3e9be5c5978d10282a","type":"TRIAL","name":"Procalcitonin to Guide Obtaining Bloodcultures in the ICU Intensive Care Infection Score","canonical_id":"clinicaltrials.gov:NCT01847079","description":"Infection","metadata":null},{"id":"d175a271eb124fc8a140a46f383cc451","type":"TRIAL","name":"Procedural Learning in Participants With ADHD","canonical_id":"clinicaltrials.gov:NCT00446537","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"a46520d29e724373a72dc5dada3f3b24","type":"TRIAL","name":"Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness","canonical_id":"clinicaltrials.gov:NCT06450899","description":"Acute Mountain Sickness","metadata":null},{"id":"379cfc90d19e42aea9b9c57ea8fe265d","type":"TRIAL","name":"Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine","canonical_id":"clinicaltrials.gov:NCT01629329","description":"Migraine Headaches","metadata":null},{"id":"03ff85759ba04e3583cd762daa2d3cb5","type":"TRIAL","name":"Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department","canonical_id":"clinicaltrials.gov:NCT00573599","description":"Acute Migraine Headache","metadata":null},{"id":"2c9da45a78094bf5bf3fbfb2e5d43e24","type":"TRIAL","name":"Prochlorperazine vs Metoclopramide","canonical_id":"clinicaltrials.gov:NCT00364806","description":"Migraine","metadata":null},{"id":"88c6d612f7dc42a6b3d4b37327659498","type":"DISEASE","name":"Proctitis","canonical_id":"mesh:D011349","description":null,"metadata":null},{"id":"5e27b3e395674715b828ecd146607266","type":"DRUG","name":"Procyclidine","canonical_id":"mesh:D011352","description":null,"metadata":null},{"id":"d3ad87bd4893447e9175ebf38c45ee87","type":"DRUG","name":"Progesterone","canonical_id":"mesh:D011374","description":null,"metadata":null},{"id":"98cd7ccfffbc4067ad567a01e4214ede","type":"TRIAL","name":"Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT06812559","description":"Controlled Ovarian Hyperstimulation; Polycystic Ovarian Syndrome","metadata":null},{"id":"5845119750ba47719df6598321c5ad25","type":"TRIAL","name":"Progesterone Versus Progesterone Plus Dydrogesterone in FET","canonical_id":"clinicaltrials.gov:NCT03998761","description":"Infertility","metadata":null},{"id":"ecaddfc69fc5476ab2a72e6a7be81b84","type":"TRIAL","name":"Progesterone and Doppler in Recurrent Abortion","canonical_id":"clinicaltrials.gov:NCT03267771","description":"Abortion in First Trimester","metadata":null},{"id":"1e678e951176427389a639ffa9a048ad","type":"TRIAL","name":"Progesterone in Gender Affirming Hormone Therapy Study","canonical_id":"clinicaltrials.gov:NCT06807580","description":"Transgender Women","metadata":null},{"id":"5137f7cc7eb344c68872ae6b60e6b9b4","type":"TRIAL","name":"Progesterone in Luteal Phase Deficiency","canonical_id":"clinicaltrials.gov:NCT02950948","description":"Luteal Phase Defect","metadata":null},{"id":"0373cec66110492aa4931535f346485f","type":"TRIAL","name":"Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus","canonical_id":"clinicaltrials.gov:NCT01126255","description":"Vulvar Lichen Sclerosus","metadata":null},{"id":"ee3373dd1da3407b92f40689f73254f2","type":"TRIAL","name":"Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles","canonical_id":"clinicaltrials.gov:NCT05112692","description":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","metadata":null},{"id":"9d9e592b8ab7463d9fe81303c96e5e83","type":"TRIAL","name":"Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01651520","description":"Multiple Sclerosis","metadata":null},{"id":"28cdf2df3cc04830ad253559d0593557","type":"TRIAL","name":"Prognosis in UC After First Biological","canonical_id":"clinicaltrials.gov:NCT05530122","description":"Ulcerative Colitis","metadata":null},{"id":"c5ecb88348a048c79eb5f0f5633f7205","type":"TRIAL","name":"Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00724958","description":"Crohn's Disease","metadata":null},{"id":"23601b34dc43404a88da669f7f04854c","type":"TRIAL","name":"Programmed Intermittent Epidural Bolus For Laboring Obstetrical Women","canonical_id":"clinicaltrials.gov:NCT03712735","description":"Labor Pain","metadata":null},{"id":"fb055a3a128f41579ecef025fbef2486","type":"TRIAL","name":"Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04156087","description":"Pancreatic Cancer Non-resectable","metadata":null},{"id":"d9081ca711bc4da7a254a3d3b1ddb699","type":"DRUG","name":"Proguanil","canonical_id":"mesh:D002727","description":null,"metadata":null},{"id":"f56b8ef55e9b4f4bbf40c599d15d60a1","type":"TRIAL","name":"Project HOPES: Healthy Options for Pain and Ending Smoking. A Program for Cancer Survivors.","canonical_id":"clinicaltrials.gov:NCT06029907","description":"Smoking Cessation; Pain","metadata":null},{"id":"9336d287da1b42ce888c518fd610462f","type":"TRIAL","name":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT01847638","description":"Cataract; Retinal Edema; Inflammation","metadata":null},{"id":"f5cabe3364f041188f23ffcf3940b7b8","type":"TRIAL","name":"Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients","canonical_id":"clinicaltrials.gov:NCT00356759","description":"Atrial Fibrillation; Heart Valve Diseases; Venous Thrombosis","metadata":null},{"id":"5e54f24eeb3d43b2aa317ebb0045f9e0","type":"TRIAL","name":"Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine","canonical_id":"clinicaltrials.gov:NCT01031979","description":"Post-Traumatic Stress Disorder","metadata":null},{"id":"75ae0086aecd47418508fbbe1603ea14","type":"TRIAL","name":"Prolonged Protection From Bone Disease in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02286830","description":"Multiple Myeloma","metadata":null},{"id":"04249a4a92e34219b574f330ce8419b4","type":"DISEASE","name":"Prolonged QT interval","canonical_id":"hp:0001657","description":null,"metadata":null},{"id":"2c0b6c10b7e7450db117eda9e49fb365","type":"TRIAL","name":"Prolonging Remission in Depressed Elderly (PRIDE)","canonical_id":"clinicaltrials.gov:NCT01028508","description":"Depression","metadata":null},{"id":"c95bd0aa911f4deea3f6189414b65bc7","type":"TRIAL","name":"Prometa Protocol for Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00262639","description":"Alcohol Dependence","metadata":null},{"id":"db35a3a356514b51a0931357702c9970","type":"TRIAL","name":"Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT05953389","description":"Autism Spectrum Disorder","metadata":null},{"id":"8a948aa0fc3742d68c4ec4385478513e","type":"TRIAL","name":"Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","canonical_id":"clinicaltrials.gov:NCT07074977","description":"Chronic Pruritus of Unknown Origin","metadata":null},{"id":"95a9d858504d4d7098c1b45fd381e282","type":"TRIAL","name":"Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT04348890","description":"Pediatric Ulcerative Colitis","metadata":null},{"id":"bde3ccc7432740f99212dcd73de5895a","type":"TRIAL","name":"Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT07569419","description":"Cystic Fibrosis (CF)","metadata":null},{"id":"a3c23dd65d894c34bed1509c9db45cf1","type":"TRIAL","name":"Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder","canonical_id":"clinicaltrials.gov:NCT01585207","description":"Tourette's Disorder","metadata":null},{"id":"a539c4a9eff449a8a77a20679e8e87f9","type":"TRIAL","name":"Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","canonical_id":"clinicaltrials.gov:NCT06957691","description":"Prostate Cancer; Prostate Cancer (Adenocarcinoma); Prostate Cancer Metastatic Disease; Prostate Cancer Recurrent; Prostate Carcinoma; Prostate Neoplasm; Prostate Adenocarcinoma; Prostate Cancer With Bone Metastasis; Vasomotor Disturbance; Vasomotor Symptoms; Vasomotor Symptoms (VMS); Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men; Vasomotor Symptoms; Hot Flashes; Androgen Deprivation Therapy; Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma; An\u2026","metadata":null},{"id":"603d4401e69f4e7caad4dd48e19b6f97","type":"TRIAL","name":"ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu","canonical_id":"clinicaltrials.gov:NCT06824363","description":"Solid Tumor, Adult; Malignant Solid Tumor; Stomach Adenocarcinoma; Esophageal Adenocarcinoma","metadata":null},{"id":"bb3e15bc344b425bb8772c1302d4721f","type":"TRIAL","name":"Propafenone Versus Amiodarone in Septic Shock","canonical_id":"clinicaltrials.gov:NCT03029169","description":"Supraventricular Arrhythmia; Septic Shock","metadata":null},{"id":"5086514d22124089bd6b49461b4befc4","type":"TRIAL","name":"Propafenone in the Treatment of Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT03674658","description":"Atrial Fibrillation","metadata":null},{"id":"70884c9917184bbdbad66f27a172f1b7","type":"DRUG","name":"Propantheline","canonical_id":"mesh:D011413","description":null,"metadata":null},{"id":"43e2f60060fc4e4394204b0df13b4aca","type":"TRIAL","name":"Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases","canonical_id":"clinicaltrials.gov:NCT07130786","description":"Seizures; Primary Motor Cortex; Brain Metastases From Non-small Cell Lung Cancer (NSCLC); Brain Metastases, Adult; Brain Metastases From Extra-cranial Solid Tumors","metadata":null},{"id":"feb428ca0f3c4d76bedce2908b0f3d2e","type":"TRIAL","name":"Prophylactic Effects of Agomelatine for Poststroke Depression","canonical_id":"clinicaltrials.gov:NCT05426304","description":"Depression; Acute Ischemic Stroke","metadata":null},{"id":"d370ec0119f2424baa365055f673b586","type":"TRIAL","name":"Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section","canonical_id":"clinicaltrials.gov:NCT06681805","description":"Prophylactic; Mirtazapine; Intrathecal; Morphine; Nausea; Vomiting","metadata":null},{"id":"225e059c5d6d467ead17fdc0fa2a2658","type":"TRIAL","name":"Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering","canonical_id":"clinicaltrials.gov:NCT03679052","description":"Shivering","metadata":null},{"id":"96287ae7d93a488da33b4dc26a98f06a","type":"TRIAL","name":"Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering","canonical_id":"clinicaltrials.gov:NCT03675555","description":"Shivering","metadata":null},{"id":"bd337a4c1f3d4e9bbe2996269616dbbd","type":"TRIAL","name":"Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.","canonical_id":"clinicaltrials.gov:NCT01781377","description":"PREGNANCY","metadata":null},{"id":"931f49ee20c64b0fbe2ff041f332c255","type":"TRIAL","name":"Prophylactic Treatment: Lessdrops\u2122 vs Standard Drops Regimen","canonical_id":"clinicaltrials.gov:NCT03578276","description":"Cataract","metadata":null},{"id":"7338e46ae12e400391aa41eaa3e1252f","type":"TRIAL","name":"Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00038558","description":"Hodgkin Disease","metadata":null},{"id":"6a7667cde948470686f153036f0a1aba","type":"TRIAL","name":"Prophylactic Use of Milrinone After Congenital Heart Surgery in Infants","canonical_id":"clinicaltrials.gov:NCT03823781","description":"Low Cardiac Output Syndrome; Cardiac Surgical Procedures; Infant","metadata":null},{"id":"7f56c47240d94be7af5dbe8a319dc989","type":"TRIAL","name":"Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study","canonical_id":"clinicaltrials.gov:NCT07038551","description":"Opioid-Induced Nausea and Vomitting(OINV)","metadata":null},{"id":"1f8ce494d4794b32a99cf009f4a876d1","type":"TRIAL","name":"Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT00767559","description":"Pulmonary Embolism","metadata":null},{"id":"82269a7f27994c4ab3cca9ad064be007","type":"TRIAL","name":"Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section","canonical_id":"clinicaltrials.gov:NCT02194192","description":"Anesthesia; Adverse Effect, Spinal and Epidural","metadata":null},{"id":"314691d412154565b1108c2686373d4d","type":"TRIAL","name":"Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy","canonical_id":"clinicaltrials.gov:NCT04538625","description":"Cancer Therapy-Related Diarrhea; Chemotherapy-related Diarrhea; Adult Solid Tumor; Prophylaxis of Diarrhea; Symptomatic Relief of Diarrhea; Targeted Therapy-related Diarrhea","metadata":null},{"id":"ced8dfe69be04615b1811b727f2618f0","type":"TRIAL","name":"Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)","canonical_id":"clinicaltrials.gov:NCT03090880","description":"Venous Thromboembolism; Lung Neoplasm","metadata":null},{"id":"1722f0724fe3413dbeb00baf99915df5","type":"TRIAL","name":"Propofol Versus Dexmedetomidine Effect on Prevention Emergence Agitation","canonical_id":"clinicaltrials.gov:NCT06312618","description":"Emergence Agitation","metadata":null},{"id":"aaec85eea2854c13b99e4f4960eddb40","type":"TRIAL","name":"Propofol Versus Ketamine for Rapid Sequence Intubation in Critically Ill Patients","canonical_id":"clinicaltrials.gov:NCT05092152","description":"Acute Respiratory Failure","metadata":null},{"id":"77932bd67d58427b872eab04336c7130","type":"TRIAL","name":"Propofol Versus Sevoflurane Anesthesia on the Intraocular Pressure and Hemodynamics in Patient Undergoing Cyclophotocoagulation","canonical_id":"clinicaltrials.gov:NCT07445672","description":"Patient Cataract","metadata":null},{"id":"acd671cdeb8c4c029dd2322daaacf9a4","type":"TRIAL","name":"Propofol-butorphanol Anesthesia During Uterine Curettage","canonical_id":"clinicaltrials.gov:NCT00795314","description":"Abortion; Curettage","metadata":null},{"id":"495d2c6bd65d4c9a8666673d0b07f20b","type":"TRIAL","name":"Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia","canonical_id":"clinicaltrials.gov:NCT03781115","description":"Schizophrenia","metadata":null},{"id":"a2b869d57b634f498887ce6abe53d668","type":"DRUG","name":"Propranolol","canonical_id":"mesh:D011433","description":null,"metadata":null},{"id":"ac1cd61a51df47fc9f7355c85bc41ab9","type":"TRIAL","name":"Propranolol Adjuvant Treatment of Focal Refractory Epilepsy (PATFRE)","canonical_id":"clinicaltrials.gov:NCT06719804","description":"Epilepsy, Drug Resistant","metadata":null},{"id":"cdd435bc5e8e46f3b7b6b2b4345c0478","type":"TRIAL","name":"Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT03384836","description":"Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7","metadata":null},{"id":"a8d4e506b0b04653880d71e713948ef1","type":"TRIAL","name":"Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05979818","description":"Non Small Cell Lung Cancer; Propranolol","metadata":null},{"id":"3638209aceb54eb99c31a685c1754ed1","type":"TRIAL","name":"Propranolol Rescue of Prolonged Labor","canonical_id":"clinicaltrials.gov:NCT04299438","description":"Pregnancy, Prolonged","metadata":null},{"id":"cf05fc97dbd94448995e61535f4068af","type":"TRIAL","name":"Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients","canonical_id":"clinicaltrials.gov:NCT03348683","description":"Induction of Labor Affected Fetus / Newborn","metadata":null},{"id":"74e608ca34bb4922aee3e0c389af057e","type":"TRIAL","name":"Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence","canonical_id":"clinicaltrials.gov:NCT07452978","description":"PTSD - Post Traumatic Stress Disorder","metadata":null},{"id":"0cf69064dd074a3186ecabb5639b0c12","type":"TRIAL","name":"Propranolol for Treatment of Cocaine Addiction - 2","canonical_id":"clinicaltrials.gov:NCT00000197","description":"Cocaine-Related Disorders","metadata":null},{"id":"4abc7a50c9c7438eab8f364cfa3a09c8","type":"DRUG","name":"Propylene glycol","canonical_id":"mesh:D019946","description":null,"metadata":null},{"id":"3226a86fa23045b282d4c1c184685bc2","type":"TRIAL","name":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","canonical_id":"clinicaltrials.gov:NCT02924727","description":"Acute Myocardial Infarction","metadata":null},{"id":"46359a2daf07489eb69063a718f4c4b6","type":"TRIAL","name":"Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo","canonical_id":"clinicaltrials.gov:NCT00575549","description":"Evaluation of Troponin I Levels","metadata":null},{"id":"1a8b679e7944453c9ea9850bcec7c2c7","type":"TRIAL","name":"Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05940051","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"802272543a92435394faed43d43e66b2","type":"TRIAL","name":"Prospective Cohort Study on PEG-IFN-\u03b1-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","canonical_id":"clinicaltrials.gov:NCT07231276","description":"HBV; Chronic Hepatitis B Virus","metadata":null},{"id":"0d8f0955575c4b119e2764e3f8662857","type":"TRIAL","name":"Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance","canonical_id":"clinicaltrials.gov:NCT03574857","description":"Heart Failure; Heart Failure With Reduced Ejection Fraction; Heart Failure Acute; Cardiovascular Diseases","metadata":null},{"id":"6081bf91d67445aeb6e5988dc4622a4f","type":"TRIAL","name":"Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients","canonical_id":"clinicaltrials.gov:NCT01803763","description":"Chronic Urticaria; Chronic Idiopathic Urticaria; Chronic Spontaneous Urticaria","metadata":null},{"id":"5ce1c7125ef84620a9bfa9ff76efca4e","type":"TRIAL","name":"Prospective Evaluation Analysis and Kinetics Registry","canonical_id":"clinicaltrials.gov:NCT05247320","description":"Atrial Arrhythmia","metadata":null},{"id":"cdb87c3ad6db4fca9bdcd7f4c0667fd6","type":"TRIAL","name":"Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation","canonical_id":"clinicaltrials.gov:NCT06717958","description":"AML; MDS","metadata":null},{"id":"93862f0a72ed463f94849bc457cdddfc","type":"TRIAL","name":"Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod","canonical_id":"clinicaltrials.gov:NCT06529406","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"b0ae882b6bd34500b1265c9e8ad715ba","type":"TRIAL","name":"Prospective Evaluation of Topical Anesthesia in Children","canonical_id":"clinicaltrials.gov:NCT04378283","description":"Skin Lacerations","metadata":null},{"id":"528e16993716497ba9615bb582d92ab4","type":"TRIAL","name":"Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain","canonical_id":"clinicaltrials.gov:NCT01946555","description":"Tumor; Cancer Pain; Breakthrough Cancer Pain; Neuropathic Pain","metadata":null},{"id":"089070441f3d43999a5016bdc6767bcf","type":"TRIAL","name":"Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04330040","description":"Ovarian Cancer; Breast Cancer","metadata":null},{"id":"fe2889f0da4740079db50def69256db2","type":"TRIAL","name":"Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07124858","description":"Metastatic Colorectal Cancer (CRC); Antineoplastic Agents, Immunological; VEGFR-TKI","metadata":null},{"id":"b5628a55d29540fd93a6230c8d33978a","type":"TRIAL","name":"Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting","canonical_id":"clinicaltrials.gov:NCT01337323","description":"Rhinitis, Allergic, Seasonal; Seasonal Allergic Rhinitis","metadata":null},{"id":"80d1f4358e8342758918a29963d2c964","type":"TRIAL","name":"Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)","canonical_id":"clinicaltrials.gov:NCT05817942","description":"Ulcerative Colitis","metadata":null},{"id":"ef2da717b5074e3fbea62d22f899bd04","type":"TRIAL","name":"Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France","canonical_id":"clinicaltrials.gov:NCT05323591","description":"Rheumatoid Arthritis","metadata":null},{"id":"8e3e39d8fd4b4b1ca5efaf44e020ad3d","type":"TRIAL","name":"Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT04871919","description":"Rheumatoid Arthritis","metadata":null},{"id":"0d2728a097fa4aee82e8ae2df5be5912","type":"TRIAL","name":"Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.","canonical_id":"clinicaltrials.gov:NCT04133428","description":"Heart Failure","metadata":null},{"id":"1c5ebc39a0b347f8a829c29e38310152","type":"TRIAL","name":"Prospective Observational Study on Plerixafor After Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01700608","description":"Lymphoma; Myeloma","metadata":null},{"id":"14d79915b4b44cdd88a42b5dc4d430d9","type":"TRIAL","name":"Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT01866449","description":"Glioblastoma Multiforme (GBM) WHO Grade IV","metadata":null},{"id":"342ac9729efa4b76a23663eb65acf210","type":"TRIAL","name":"Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02581501","description":"Pancreatic Cancer","metadata":null},{"id":"059d5278a59c4b859ef6cdf857e4e77c","type":"TRIAL","name":"Prospective Randomised Investigation of the Safety and Efficacy of Micardis\u00ae vs Ramipril Using ABPM","canonical_id":"clinicaltrials.gov:NCT00274612","description":"Hypertension","metadata":null},{"id":"1f8e73b2486c4ed7b95a814041c03626","type":"TRIAL","name":"Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)","canonical_id":"clinicaltrials.gov:NCT02624765","description":"Fetal Atrial Flutter Without Hydrops; Fetal Supraventricular Tachycardia Without Hydrops; Fetal Supraventricular Tachycardia With Hydrops","metadata":null},{"id":"8e2ce8820f274728ac74fd0318857bd2","type":"TRIAL","name":"Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen","canonical_id":"clinicaltrials.gov:NCT00346216","description":"Arthritis, Rheumatoid","metadata":null},{"id":"bcf0bb1ea97c43abb0d8a5fa2d84efc0","type":"TRIAL","name":"Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy","canonical_id":"clinicaltrials.gov:NCT01703351","description":"Lung Neoplasms; Postoperative Pain","metadata":null},{"id":"4c6f0c8039a648fb994471e0022d8e60","type":"TRIAL","name":"Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users","canonical_id":"clinicaltrials.gov:NCT06659029","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"e10d1ec0de534e918f3097eb05051de8","type":"TRIAL","name":"Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users","canonical_id":"clinicaltrials.gov:NCT06594068","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"75773386c70742f48a08d5e1b58f30aa","type":"TRIAL","name":"Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)","canonical_id":"clinicaltrials.gov:NCT02388750","description":"Nausea; Vomiting","metadata":null},{"id":"db377be12d404d0b8ce18a6b0e8bacc0","type":"TRIAL","name":"Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation","canonical_id":"clinicaltrials.gov:NCT02249741","description":"Cirrhosis","metadata":null},{"id":"6492e4a6085045d68da0bc4e943d81eb","type":"TRIAL","name":"Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy","canonical_id":"clinicaltrials.gov:NCT01747044","description":"Fibromylagia","metadata":null},{"id":"1ce90e14b31440648cde0c5a463b93f7","type":"TRIAL","name":"Prospective Study on HIV-related Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01468740","description":"HIV-associated Hodgkin Lymphoma","metadata":null},{"id":"1d5df725a51f48b0b96dc572070a6df6","type":"TRIAL","name":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01727427","description":"Unsuspected Pulmonary Embolism","metadata":null},{"id":"f07cc3762fec4c55a0044a35895cc2bf","type":"TRIAL","name":"Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab","canonical_id":"clinicaltrials.gov:NCT04377555","description":"Multiple Sclerosis, Relapsing","metadata":null},{"id":"baf9b5fdcb4c4420a0e0d96831deb71a","type":"TRIAL","name":"Prospective Survey of Menstrual Migraine & Prevention With Eletriptan","canonical_id":"clinicaltrials.gov:NCT00259649","description":"Migraine","metadata":null},{"id":"f411ce7dc29b4d57a6a81dda30872b11","type":"TRIAL","name":"Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population","canonical_id":"clinicaltrials.gov:NCT02483793","description":"Disorder of Urinary Stent","metadata":null},{"id":"cba645f60bab4c3a996b898f7e644877","type":"TRIAL","name":"Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy","canonical_id":"clinicaltrials.gov:NCT05672979","description":"Age-Related Macular Degeneration; Pachychoroid Neovasculopathy","metadata":null},{"id":"568822682606472bab77fdda1b4d467b","type":"TRIAL","name":"Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders","canonical_id":"clinicaltrials.gov:NCT07154654","description":"Myotonic Disorders","metadata":null},{"id":"8ae9f3ed39844f2f85124ef787663f80","type":"TRIAL","name":"Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.","canonical_id":"clinicaltrials.gov:NCT00555438","description":"Major Orthopaedic Surgery and Renal Impairment","metadata":null},{"id":"1ed7676bf1f8429788f587c99bd7396c","type":"TRIAL","name":"Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT05311475","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"0a5dd704b68b49e99d2e6bc8edd20afd","type":"TRIAL","name":"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen\u00ae (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.","canonical_id":"clinicaltrials.gov:NCT01281098","description":"High Risk Proliferative Diabetic Retinopathy; Diabetes Mellitus Type I; Diabetes Mellitus Type II","metadata":null},{"id":"aa471a1df73a49ff87cbbbcd2827e036","type":"TRIAL","name":"Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT05976997","description":"Newly Diagnosed Peripheral T-cell Lymphoma","metadata":null},{"id":"95706d87b11f43d9a7e16c3d5954264a","type":"TRIAL","name":"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","canonical_id":"clinicaltrials.gov:NCT04737928","description":"Glaucoma, Primary Open Angle","metadata":null},{"id":"5c869f3e9dac4b7aab12a94fa6e94c1d","type":"PROTEIN","name":"Prostaglandin D2 receptor 2","canonical_id":"uniprot:Q9Y5Y4","description":null,"metadata":null},{"id":"277b3c48c754432f8723edcd11b4348e","type":"PROTEIN","name":"Prostaglandin E2 receptor EP1 subtype","canonical_id":"uniprot:P34995","description":null,"metadata":null},{"id":"c9b32b02eedd4938a25a6c2ba0da8e4c","type":"PROTEIN","name":"Prostaglandin E2 receptor EP2 subtype","canonical_id":"uniprot:P43116","description":null,"metadata":null},{"id":"02d57ba893ff4832a144943b60bc3e89","type":"PROTEIN","name":"Prostaglandin E2 receptor EP4 subtype","canonical_id":"uniprot:P35408","description":null,"metadata":null},{"id":"b80363698e6046108b3cf7e680884441","type":"TRIAL","name":"Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)","canonical_id":"clinicaltrials.gov:NCT02059655","description":"Graves' Ophthalmopathy","metadata":null},{"id":"785f745449af4921bbe0a14ad6bc51ee","type":"PROTEIN","name":"Prostaglandin G/H synthase 1","canonical_id":"uniprot:P23219","description":null,"metadata":null},{"id":"30fe893571d440deba2b230a71301ad2","type":"PROTEIN","name":"Prostaglandin G/H synthase 2","canonical_id":"uniprot:P3535","description":null,"metadata":null},{"id":"5e7015e0cd694399981d03edd16ff1cd","type":"TISSUE","name":"Prostate","canonical_id":"uberon:UBERON:0002367","description":null,"metadata":null},{"id":"94d67cc947e14fccb09e63fb470d0795","type":"TRIAL","name":"Prostate Adenocarcinoma TransCutaneous Hormones","canonical_id":"clinicaltrials.gov:NCT00303784","description":"Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer","metadata":null},{"id":"7c91d02ad6c44d43b70d6026bffe2cd7","type":"DISEASE","name":"Prostate Cancer","canonical_id":"doid:10283","description":null,"metadata":null},{"id":"ade8ff1c8a86493e8cab7be1a05ee8b0","type":"DISEASE","name":"Prostatitis","canonical_id":"mesh:D011472","description":null,"metadata":null},{"id":"93dd43aa1eaa460f98fc27c335dbc48a","type":"PROTEIN","name":"Protease","canonical_id":"uniprot:Q72874","description":null,"metadata":null},{"id":"ea2d6c92e32c47f1897346c4cb55eedb","type":"PROTEIN","name":"Proteasome subunit beta type-5","canonical_id":"uniprot:P28074","description":null,"metadata":null},{"id":"e60b86b2574c40599f1c345285768192","type":"TRIAL","name":"Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)","canonical_id":"clinicaltrials.gov:NCT06195267","description":"Aortic Dissection; Systemic Inflammatory Response Syndrome; Cardiovascular Diseases (CVD)","metadata":null},{"id":"47aa53cd4eae467eac155851c446eb68","type":"TRIAL","name":"Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis","canonical_id":"clinicaltrials.gov:NCT04973670","description":"ARDS","metadata":null},{"id":"84bd1c3b040f4655b456cdc6300402ce","type":"TRIAL","name":"Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)","canonical_id":"clinicaltrials.gov:NCT04699279","description":"Acute Aortic Syndrome; Aortopathy","metadata":null},{"id":"12f79aa1533e4234828479bf4ae70d94","type":"PROTEIN","name":"Protective antigen","canonical_id":"uniprot:P13423","description":null,"metadata":null},{"id":"0b1d5b9a822842d1ab19bd759fd15642","type":"PROTEIN","name":"Protein P","canonical_id":"uniprot:Q05486","description":null,"metadata":null},{"id":"6cb4948d54e74c29984fb9fc1972f464","type":"PROTEIN","name":"Protein S100-P","canonical_id":"uniprot:P25815","description":null,"metadata":null},{"id":"f2face493ab2449c94909c812ce59459","type":"PROTEIN","name":"Protein cereblon","canonical_id":"uniprot:Q96SW2","description":null,"metadata":null},{"id":"38fe26fb888340f79aed692e30786745","type":"PROTEIN","name":"Protein kinase C delta type","canonical_id":"uniprot:Q05655","description":null,"metadata":null},{"id":"147a3174c70b4a338b65a0dca87edae5","type":"TRIAL","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07825753","description":"Advanced or Metastatic Pancreatic Adenocarcinoma; Advanced or Metastatic Breast Cancer (BC)","metadata":null},{"id":"8ef7c326397e4da0aa2e033c58e301e0","type":"PROTEIN","name":"Proteinase-activated receptor 1","canonical_id":"uniprot:P25116","description":null,"metadata":null},{"id":"b405259b9ae64275a8a0f0375950e4f7","type":"DISEASE","name":"Proteinuria","canonical_id":"hp:0000093","description":null,"metadata":null},{"id":"86aa04b286cb413895e4878877b9f412","type":"TRIAL","name":"Proteolytic Enzyme Induction Within the Human Myocardial Interstitium","canonical_id":"clinicaltrials.gov:NCT00744211","description":"Heart Disease","metadata":null},{"id":"de2b73ee299543979d686eb65a66f090","type":"TRIAL","name":"Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00550537","description":"Lung Cancer","metadata":null},{"id":"0fd8877a36324c9095ef419069683c57","type":"TRIAL","name":"Protocol for Women at Increased Risk of Developing Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00291694","description":"Breast Cancer","metadata":null},{"id":"e0a0677410ae4106aea0f75d982ced2e","type":"TRIAL","name":"Protocol in Acute Myeloid Leukemia With FLT3-ITD","canonical_id":"clinicaltrials.gov:NCT01477606","description":"Acute Myeloid Leukemia","metadata":null},{"id":"a9e552b2235d4ba49dd1d3d7e3b37ae7","type":"TRIAL","name":"Protocol to Assess the Severity of Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT00673244","description":"Acute Kidney Failure","metadata":null},{"id":"f951831c87034a2183f259f80429876a","type":"TRIAL","name":"Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain","canonical_id":"clinicaltrials.gov:NCT00627367","description":"Acute Pain","metadata":null},{"id":"6f7e012fe24346c59ed4ef4ccfb05faf","type":"TRIAL","name":"Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)","canonical_id":"clinicaltrials.gov:NCT04149470","description":"Eosinophilic Esophagitis","metadata":null},{"id":"ef3c2f61e99c4aa3b9aa70ba3e721d4b","type":"TRIAL","name":"Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.","canonical_id":"clinicaltrials.gov:NCT06025227","description":"Colitis, Ulcerative","metadata":null},{"id":"b8ee34e497454715bb47162c364796ed","type":"GO_TERM","name":"Prp19 complex","canonical_id":"go:GO:0000974","description":"\"A protein complex consisting of Prp19 and associated proteins that is involved in the transition from the precatalytic spliceosome to the activated form that catalyzes step 1 of splicing, and which remains associated with the spliceosome through the second catalytic step. It is widely conserved, found in both yeast and mammals, though the exact composition varies. In S. cerevisiae, it contains Prp19p, Ntc20p, Snt309p, Isy1p, Syf2p, Cwc2p, Prp46p, Clf1p, Cef1p, and Syf1p.\" [GOC:krc, PMID:16540691, PMID:19239890]","metadata":null},{"id":"2942d595881e4940b221194052e8e8ca","type":"DISEASE","name":"Pruritus","canonical_id":"hp:0000989","description":null,"metadata":null},{"id":"fb144764032f47ec88e2a76fa6f30d9f","type":"DISEASE","name":"Pruritus ani","canonical_id":"mesh:D011538","description":null,"metadata":null},{"id":"86ffa733c23b40d4bd6d21c84facd453","type":"DRUG","name":"Pseudoephedrine","canonical_id":"mesh:D054199","description":null,"metadata":null},{"id":"8ab6a8c95ea9410491c9b2fa7db85ca5","type":"DISEASE","name":"Pseudomembranous enterocolitis","canonical_id":"mesh:D004761","description":null,"metadata":null},{"id":"3366871c7d38428889450bd64ce462b3","type":"DISEASE","name":"Pseudomyxoma Peritonei","canonical_id":"doid:3559","description":null,"metadata":null},{"id":"83dc63d05de64e27b86f55285154da93","type":"TRIAL","name":"Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification","canonical_id":"clinicaltrials.gov:NCT03106402","description":"Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification","metadata":null},{"id":"7a47c5b5b53a443890f71a671e94c71c","type":"TRIAL","name":"Psilocybin Administration With 5-HT1a Blockade","canonical_id":"clinicaltrials.gov:NCT07565493","description":"Psychedelic Effects in Healthy Volunteers","metadata":null},{"id":"b690f6145fc54f51a08832f51bdc0e34","type":"TRIAL","name":"Psilocybin Efficacy With or Without Pimavanserin Pretreatment","canonical_id":"clinicaltrials.gov:NCT07610135","description":"Mood (Psychological Function); Well Being; Mood; Healthy","metadata":null},{"id":"93141e4bdef24c9c9af5f60927d12eeb","type":"TRIAL","name":"Psilocybin Therapy for Depression in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT06455293","description":"Parkinson Disease; Depression","metadata":null},{"id":"5300d07e6beb490e9ff840425c17eace","type":"TRIAL","name":"Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT06592833","description":"Major Depressive Disorder","metadata":null},{"id":"1c31cdce8ed248159a8ade0a4672fe34","type":"TRIAL","name":"Psilocybin in Chronic Low Back Pain and Depression","canonical_id":"clinicaltrials.gov:NCT06355414","description":"Chronic Low-back Pain; Depression","metadata":null},{"id":"70aa583369fd4d189e7eff107444417a","type":"DISEASE","name":"Psittacosis","canonical_id":"mesh:D009956","description":null,"metadata":null},{"id":"e0e21f27b0a64091924fc8270332cdd2","type":"DISEASE","name":"Psoriasis","canonical_id":"mesh:D011565","description":null,"metadata":null},{"id":"2d6fb949429548d8a0457a9aff3cb317","type":"DISEASE","name":"Psoriasis with arthropathy","canonical_id":"mesh:D015535","description":null,"metadata":null},{"id":"7838f35df35d4dcc9aab9b5bb181d82d","type":"TRIAL","name":"Psoriatic Immune Response to Tildrakizumab","canonical_id":"clinicaltrials.gov:NCT05390515","description":"Psoriasis Vulgaris","metadata":null},{"id":"677d187988214b6c90807a7e5ef91ddc","type":"TRIAL","name":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","canonical_id":"clinicaltrials.gov:NCT03797872","description":"Psoriatic Arthritis","metadata":null},{"id":"ca5d767407db41a0820aba6847abb967","type":"TRIAL","name":"Psychobiological Mechanisms Underlying Chronic Pain","canonical_id":"clinicaltrials.gov:NCT04674670","description":"Fibromyalgia; Pain, Chronic; Chronic Pain, Widespread","metadata":null},{"id":"4e6c14583c154b8dbab87f3745e94235","type":"TRIAL","name":"Psychopharmacological Treatment of Emotional Distress","canonical_id":"clinicaltrials.gov:NCT06133114","description":"Suicide Crisis Syndrome; Psychological Distress","metadata":null},{"id":"2b4f201cc8f54c9aa6d863d6ab966af1","type":"TRIAL","name":"Psychopharmacology for Cocaine Dependence - Buspirone","canonical_id":"clinicaltrials.gov:NCT01267292","description":"Cocaine Dependence","metadata":null},{"id":"5eb5fb179f6b4f6aa3e89b98f6f311de","type":"TRIAL","name":"Psychotherapy and Pharmacotherapy in Dissociative Disorders","canonical_id":"clinicaltrials.gov:NCT00630981","description":"Dissociative Disorders","metadata":null},{"id":"ab75ded9e6824909aec331a02c5f933b","type":"DISEASE","name":"Psychotic Disorders","canonical_id":"mesh:D011618","description":null,"metadata":null},{"id":"fc82b14eda074dfdafb29591dd449e12","type":"DISEASE","name":"Puberty, Delayed","canonical_id":"mesh:D011628","description":null,"metadata":null},{"id":"5b93f5ff57fd4b33afb2442f839ccbbc","type":"TRIAL","name":"Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan","canonical_id":"clinicaltrials.gov:NCT00625469","description":"Pulmonary Arterial Hypertension; Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"71e93a75e20e470ebed0e5a2244d816e","type":"DISEASE","name":"Pulmonary Fibrosis","canonical_id":"mesh:D011658","description":null,"metadata":null},{"id":"aeed19dce60641188ddfc927d980f7af","type":"TRIAL","name":"Pulmonary Gas Exchange Response to Indacaterol in COPD","canonical_id":"clinicaltrials.gov:NCT02547558","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"6144f509139e4e64b2caddb677c9b0f1","type":"TRIAL","name":"Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT05487261","description":"Heart Failure","metadata":null},{"id":"b9cd1b37dfa249a8b4ebbff3d7131be8","type":"DISEASE","name":"Pulmonary arterial hypertension","canonical_id":"mesh:D000081029","description":null,"metadata":null},{"id":"e198622f5bb64952af320b9791a4e1f1","type":"DISEASE","name":"Pulmonary artery stenosis","canonical_id":"mesh:D000071079","description":null,"metadata":null},{"id":"35e6dfbd881d45dcb97b4b3a289305c9","type":"DISEASE","name":"Pulmonary edema","canonical_id":"mesh:D011654","description":null,"metadata":null},{"id":"e07aee8fa90b4e31af9d31cdbc6c05e0","type":"DISEASE","name":"Pulmonary embolism","canonical_id":"mesh:D011655","description":null,"metadata":null},{"id":"268169dcb2eb4a3597a4c1edd76e217b","type":"DISEASE","name":"Pulmonary emphysema","canonical_id":"mesh:D011656","description":null,"metadata":null},{"id":"62e871421aba4679b45ddf72e453ce4a","type":"DISEASE","name":"Pulmonary hypertension","canonical_id":"mesh:D006976","description":null,"metadata":null},{"id":"7f8cc772d1bb4a2fa4249aa46699d299","type":"PROTEIN","name":"Pulmonary surfactant-associated protein B","canonical_id":"uniprot:P07988","description":null,"metadata":null},{"id":"cc1985b5fa9c4e47a6c1685adb4f4e3d","type":"DISEASE","name":"Pulmonary tuberculosis","canonical_id":"mesh:D014397","description":null,"metadata":null},{"id":"4187f4b0b5ea4564a2171977d2ab07bf","type":"TRIAL","name":"Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00235287","description":"Kidney Failure, Chronic; Cardiovascular Diseases","metadata":null},{"id":"98f0dc6caa9240cd91081072b4ccf54c","type":"TRIAL","name":"Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT06096337","description":"Persistent Atrial Fibrillation","metadata":null},{"id":"b2143f502ed94c6eb07fb7f98c37381a","type":"GO_TERM","name":"Pup conjugating enzyme activity","canonical_id":"go:GO:0061655","description":"\"Isoenergetic transfer of Pup from one protein to another via the reaction X-Pup + Y = Y-Pup + X, where both the X-Pup and Y-Pup linkages are thioester bonds between the C-terminal amino acid of Pup and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"eb9a1c2d4d274e2b89b21d16f279ab3a","type":"GO_TERM","name":"Pup ligase activity","canonical_id":"go:GO:0061664","description":"\"Catalysis of the transfer of Pup to a substrate protein via the reaction X-Pup + S = X + S-Pup, where X is either an E2 or E3 enzyme, the X-Pup linkage is a thioester bond, and the S-Pup linkage is an isopeptide bond between the C-terminal amino acid of Pup and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"fec261b3065c46e2a10a7d9003eb675d","type":"GO_TERM","name":"Pup transferase activity","canonical_id":"go:GO:0072496","description":"\"Catalysis of the transfer of Pup from one protein to another via the reaction X-Pup + Y = Y-Pup + X, where both X-Pup and Y-Pup are covalent linkages.\" [GOC:sp]","metadata":null},{"id":"b274eafa47d0440fac1c067c202941bd","type":"TRIAL","name":"Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients","canonical_id":"clinicaltrials.gov:NCT07743060","description":"Benign Prostatic Hyperplasia; Silodosin; Tamsulosin; Choroid; Iris Disease; Tomography, Optical Coherence","metadata":null},{"id":"5c15f476ce9c485a9410578d32f62496","type":"TRIAL","name":"Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine","canonical_id":"clinicaltrials.gov:NCT01560442","description":"Opiate Dependent; Previous Illicit Drug Use","metadata":null},{"id":"3619fb0381aa4a3f91a100f3f138ca1a","type":"GO_TERM","name":"Purkinje myocyte action potential","canonical_id":"go:GO:0086017","description":"\"An action potential that occurs in a Purkinje myocyte.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"762da644ebbb4bccb1fa5c8b2bdc6f4a","type":"GO_TERM","name":"Purkinje myocyte development","canonical_id":"go:GO:0003165","description":"\"The process whose specific outcome is the progression of a Purkinje myocyte over time, from its formation to the mature structure. The Purkinje myocyte (also known as cardiac Purkinje fiber) is part of the cardiac conduction system that receives signals from the bundle of His and innervates the ventricular cardiac muscle.\" [GOC:mtg_cardiac_conduct_nov11, GOC:mtg_heart]","metadata":null},{"id":"47abd8f8d96740ca9052136edb55f875","type":"GO_TERM","name":"Purkinje myocyte differentiation","canonical_id":"go:GO:0003168","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a Purkinje myocyte (also known as cardiac Purkinje fiber cell). These cells are specialized cardiomyocytes that receive signals from the bundle of His and innervate the ventricular cardiac muscle.\" [GOC:mtg_cardiac_conduct_nov11, GOC:mtg_heart]","metadata":null},{"id":"d9becaa37588437da1f071683aba5249","type":"GO_TERM","name":"Purkinje myocyte to ventricular cardiac muscle cell communication","canonical_id":"go:GO:0086068","description":"\"The process that mediates interactions between a Purkinje myocyte and its surroundings that contributes to the process of the Purkinje myocyte communicating with a ventricular cardiac muscle cell in cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"364511588495476b8cf13d36022ac5a7","type":"GO_TERM","name":"Purkinje myocyte to ventricular cardiac muscle cell communication by electrical coupling","canonical_id":"go:GO:0086055","description":"\"The process that mediates signaling interactions between a Purkinje myocyte and a ventricular cardiac muscle cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"8a4da41570f246739d1d1e20518333c8","type":"GO_TERM","name":"Purkinje myocyte to ventricular cardiac muscle cell signaling","canonical_id":"go:GO:0086029","description":"\"Any process that mediates the transfer of information from a Purkinje myocyte to a ventricular cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"607611bb62f04534aefc5a3535f07c02","type":"GO_TERM","name":"Pwp2p-containing subcomplex of 90S preribosome","canonical_id":"go:GO:0034388","description":"\"A protein complex that forms a subcomplex of the 90S preribosome and can interact directly with the 5' External Transcribed Spacer (ETS) of the full length pre-rRNA transcript. In S. cerevisiae, it sediments at 25-30 S and is composed of Pwp2p, Dip2p, Utp21p, Utp13p, Utp18p, and Utp6p.\" [GOC:krc, PMID:15231838]","metadata":null},{"id":"10c7cd220c9e4a1bac21096309acc3ef","type":"DISEASE","name":"Pyelonephritis","canonical_id":"mesh:D011704","description":null,"metadata":null},{"id":"0918e7cfe9f44da795aef39e2eb37f65","type":"DISEASE","name":"Pyoderma gangrenosum","canonical_id":"mesh:D017511","description":null,"metadata":null},{"id":"6b86456c5a6946909d4c29b034fa48c6","type":"DRUG","name":"Pyrazinamide","canonical_id":"mesh:D011718","description":null,"metadata":null},{"id":"e1555e5cf9a547b8a17104a86da64e61","type":"TRIAL","name":"Pyridostigmine and Amifampridine for Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT05919407","description":"Myasthenia Gravis","metadata":null},{"id":"6c7fc79f73174cd9852bcb20312b8bc1","type":"PROTEIN","name":"Pyridoxal kinase","canonical_id":"uniprot:O00764","description":null,"metadata":null},{"id":"c04a7a347818445683d3581f252f6e27","type":"GO_TERM","name":"Pyrin domain binding","canonical_id":"go:GO:0032090","description":"\"Binding to a Pyrin (PAAD/DAPIN) domain, a protein-protein interaction domain that has the same fold as the Death domain.\" [GOC:rl]","metadata":null},{"id":"db5baa9789fd49bd80049bbdbd0ba38f","type":"DRUG","name":"Pyronaridine","canonical_id":"mesh:C027871","description":null,"metadata":null},{"id":"b732a7b2cbf044a7aa85ca751b231e36","type":"TRIAL","name":"Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05800756","description":"Breast Cancer","metadata":null},{"id":"2e5811462167468f9fae1477e9578709","type":"TRIAL","name":"Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab","canonical_id":"clinicaltrials.gov:NCT05572645","description":"Breast Cancer","metadata":null},{"id":"659c3c476a4748baa47731cc2498f226","type":"PROTEIN","name":"Pyruvate dehydrogenase [NADP(+)] (Cryptosporidium parvum)","canonical_id":"uniprot:Q968X7","description":null,"metadata":null},{"id":"4ea83c86c21d4fb7b8da3345ab9d3bd2","type":"PROTEIN","name":"Pyruvate-flavodoxin oxidoreductase (Giardia intestinalis)","canonical_id":"uniprot:A8B852","description":null,"metadata":null},{"id":"fa4f097326d5493b960a7c3bf29d3d0f","type":"DISEASE","name":"Q fever","canonical_id":"mesh:D011778","description":null,"metadata":null},{"id":"7419132696994a0ab28351c786f71750","type":"GENE","name":"QARS1","canonical_id":"hgnc:HGNC:9751","description":"glutaminyl-tRNA synthetase 1","metadata":{"aliases":["QARS"]}},{"id":"f9371a2aa6374bbe8b55a95257c7a2c9","type":"GENE","name":"QDPR","canonical_id":"hgnc:HGNC:9752","description":"quinoid dihydropteridine reductase","metadata":{"aliases":["DHPR","PKU2","SDR33C1"]}},{"id":"d08b2934095a456a8b1b5a637cf430f0","type":"GENE","name":"QKI","canonical_id":"hgnc:HGNC:21100","description":"QKI, KH domain containing RNA binding","metadata":{"aliases":["QK3"]}},{"id":"feaa28ae431646df82fd826e53533437","type":"GENE","name":"QKILA","canonical_id":"hgnc:HGNC:55255","description":"QKI interacting lncRNA","metadata":{"aliases":["Loc490"]}},{"id":"cba80a8f3b024f828e3b50c22a107808","type":"TRIAL","name":"QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","canonical_id":"clinicaltrials.gov:NCT07649473","description":"Colon Cancer; Synchronous Liver Metastases","metadata":null},{"id":"589303bd60534f46a45379d46c2556f0","type":"TRIAL","name":"QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC","canonical_id":"clinicaltrials.gov:NCT05799820","description":"Colorectal Carcinoma","metadata":null},{"id":"bcd67894043a45378a66c869eddfada4","type":"TRIAL","name":"QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy","canonical_id":"clinicaltrials.gov:NCT07782840","description":"Breast Cancer","metadata":null},{"id":"abee572841f748b7a0d23f0e5c840119","type":"TRIAL","name":"QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT","canonical_id":"clinicaltrials.gov:NCT07327788","description":"Hepatecellular Carcinoma; RALOX-HAIC\uff08Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin; Bevacizumab; Type VP3/4 Portal Vein Tumor Thrombosis; Iparomlimab and Tuvonralimab Injection; QL1706","metadata":null},{"id":"96ab91fe8bfb4ca5b02affb72cf8c53a","type":"TRIAL","name":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT07315035","description":"Gastric Cancer Stage III","metadata":null},{"id":"572b9ae40e6d4332b779f969d187502d","type":"TRIAL","name":"QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ","canonical_id":"clinicaltrials.gov:NCT07716449","description":"Gastric or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"6beec12961be489390c5b5fe866b9922","type":"GENE","name":"QNG1","canonical_id":"hgnc:HGNC:28144","description":"Q-nucleotide N-glycosylase 1","metadata":{"aliases":["MGC10999","C9orf64"]}},{"id":"28049782ea6c484b8a4d4038987db825","type":"GENE","name":"QPCT","canonical_id":"hgnc:HGNC:9753","description":"glutaminyl-peptide cyclotransferase","metadata":{"aliases":["QC","GCT"]}},{"id":"28dddff9b8384ce98310bb4c2b5e1f2d","type":"GENE","name":"QPCTL","canonical_id":"hgnc:HGNC:25952","description":"glutaminyl-peptide cyclotransferase like","metadata":{"aliases":["FLJ20084"]}},{"id":"7f7b0d3e5f6848708f44e52537e5f35d","type":"GENE","name":"QPRT","canonical_id":"hgnc:HGNC:9755","description":"quinolinate phosphoribosyltransferase","metadata":{"aliases":["QPRTase"]}},{"id":"b5fa7324fb7b47ab99e83f83b558c0b9","type":"TRIAL","name":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01474018","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1ab973cd03bd43aa9675300cc2cf3345","type":"GENE","name":"QRFP","canonical_id":"hgnc:HGNC:29982","description":"pyroglutamylated RFamide peptide","metadata":{"aliases":["26RFa","P518","prepro-26RFa"]}},{"id":"967e5a8151f54ae4ac9d4ba4eeb6c492","type":"GENE","name":"QRFPR","canonical_id":"hgnc:HGNC:15565","description":"pyroglutamylated RFamide peptide receptor","metadata":{"aliases":["GPR103"]}},{"id":"91d4c20f550b4818bbc06ad6b9415bb5","type":"GENE","name":"QRICH1","canonical_id":"hgnc:HGNC:24713","description":"glutamine rich 1","metadata":{"aliases":["FLJ20259","VERBRAS","AB-DIP"]}},{"id":"2ba3079985e24086ac3de929b805d5b5","type":"GENE","name":"QRICH2","canonical_id":"hgnc:HGNC:25326","description":"glutamine rich 2","metadata":{"aliases":["DKFZP434P0316"]}},{"id":"7f19faf56ab64255a91faeacd52491c3","type":"GENE","name":"QRSL1","canonical_id":"hgnc:HGNC:21020","description":"glutaminyl-tRNA amidotransferase subunit QRSL1","metadata":{"aliases":["GatA","FLJ10989","FLJ12189","DKFZP564C1278","FLJ13447","GATA"]}},{"id":"30c63bb165db403c82587b79736f426e","type":"GENE","name":"QRSL1P1","canonical_id":"hgnc:HGNC:43667","description":"QRSL1 pseudogene 1","metadata":null},{"id":"effe14aa6ee8478b89f6c598554b2d14","type":"GENE","name":"QRSL1P2","canonical_id":"hgnc:HGNC:43668","description":"QRSL1 pseudogene 2","metadata":null},{"id":"0bd444f763b343359f489bb9a4bb2691","type":"GENE","name":"QRSL1P3","canonical_id":"hgnc:HGNC:43669","description":"QRSL1 pseudogene 3","metadata":null},{"id":"3049827a077d4d118d0583e1739af81b","type":"GENE","name":"QSER1","canonical_id":"hgnc:HGNC:26154","description":"glutamine and serine rich 1","metadata":{"aliases":["FLJ21924"]}},{"id":"b27e03bba60f41c7854e4366f3e5c278","type":"GENE","name":"QSOX1","canonical_id":"hgnc:HGNC:9756","description":"quiescin sulfhydryl oxidase 1","metadata":{"aliases":["QSCN6"]}},{"id":"10d215bb5543405b8af45666ad99136f","type":"GENE","name":"QSOX2","canonical_id":"hgnc:HGNC:30249","description":"quiescin sulfhydryl oxidase 2","metadata":{"aliases":["SOXN","DKFZp762A2013","QSCN6L1"]}},{"id":"21275e55f48444b89c204ba2f6a117a7","type":"GENE","name":"QTGAL","canonical_id":"hgnc:HGNC:21727","description":"queuosine-tRNA galactosyltransferase","metadata":{"aliases":["B3GNT8","B3GNTL1"]}},{"id":"63130e9572444fc89dc88132779e5b43","type":"GENE","name":"QTMAN","canonical_id":"hgnc:HGNC:20887","description":"queuosine-tRNA mannosyltransferase","metadata":{"aliases":["FLJ11753","Hmat-Xa","GTDC1"]}},{"id":"150567e697fc42d3b5e6403cd1c74d4c","type":"GENE","name":"QTMAN-AS1","canonical_id":"hgnc:HGNC:58227","description":"QTMAN antisense RNA 1","metadata":{"aliases":["GTDC1-AS1"]}},{"id":"502ddc3ce7f949ed874834607e5a8790","type":"GENE","name":"QTRT1","canonical_id":"hgnc:HGNC:23797","description":"queuine tRNA-ribosyltransferase catalytic subunit 1","metadata":{"aliases":["TGT"]}},{"id":"a66f3f7c046e4b9592a22bdc327f4438","type":"GENE","name":"QTRT1P1","canonical_id":"hgnc:HGNC:39179","description":"queuine tRNA-ribosyltransferase catalytic subunit 1 pseudogene 1","metadata":null},{"id":"3d52b5e36667415a9ea4c2af0355d94d","type":"GENE","name":"QTRT2","canonical_id":"hgnc:HGNC:25771","description":"queuine tRNA-ribosyltransferase accessory subunit 2","metadata":{"aliases":["FLJ12960","QTRTD1"]}},{"id":"17b4060a3d064fe5963d863917d8fab6","type":"TRIAL","name":"QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","canonical_id":"clinicaltrials.gov:NCT03136406","description":"Pancreatic Cancer","metadata":null},{"id":"51be9aa7e5f540a6b22f4219cd73008d","type":"TRIAL","name":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","canonical_id":"clinicaltrials.gov:NCT03169790","description":"Non Hodgkin Lymphoma","metadata":null},{"id":"a0db27d4075c418ba3b0710016c7d8f2","type":"TRIAL","name":"QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy","canonical_id":"clinicaltrials.gov:NCT03853317","description":"Merkel Cell Carcinoma","metadata":null},{"id":"438fb039448e44a8980c1d40cbb67b25","type":"TRIAL","name":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","canonical_id":"clinicaltrials.gov:NCT03387111","description":"Squamous Cell Carcinoma","metadata":null},{"id":"b0dbef0f108549cdb15d28c0f146b44e","type":"TRIAL","name":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01315249","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"9c6f56a371564feeabff3cf0f09cb4d6","type":"TRIAL","name":"Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT05558280","description":"Osteosarcoma in Children","metadata":null},{"id":"c8cb7857cc5b4b21b261fdf328e42ff6","type":"TRIAL","name":"Quadro-Iliac Plane Block for Pain Control After Posterior Spinal Instrumentation Surgery","canonical_id":"clinicaltrials.gov:NCT07711522","description":"Posterior Spinal Instrumentation Patients","metadata":null},{"id":"fa18a3550e1944a6a1b155c34075b1e2","type":"TRIAL","name":"Quadruple Immunotherapy for Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT05754684","description":"Neuroblastoma Recurrent","metadata":null},{"id":"bc6faee6a9834f75a27a933b0c0fce99","type":"TRIAL","name":"Quality of Life Study in Adults With Facial Eczema","canonical_id":"clinicaltrials.gov:NCT00120302","description":"Atopic Dermatitis","metadata":null},{"id":"c09bc878547d4cf69de2c46957fb7a3d","type":"TRIAL","name":"Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine","canonical_id":"clinicaltrials.gov:NCT02513290","description":"Allergic Rhinitis","metadata":null},{"id":"e8afbce78b6c4bd29e07081975c1e2b9","type":"TRIAL","name":"Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis","canonical_id":"clinicaltrials.gov:NCT04733066","description":"Short Bowel Syndrome; Intestinal Failure","metadata":null},{"id":"9f6f58ac55f5430f8c3dd181ccacffa0","type":"TRIAL","name":"Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","canonical_id":"clinicaltrials.gov:NCT07113210","description":"Presbyopia; Glasses; Dry Eye","metadata":null},{"id":"6bc96131737d47c7940105a43075669e","type":"TRIAL","name":"Quantifying Hepatic Mitochondrial Fluxes in Humans","canonical_id":"clinicaltrials.gov:NCT05305287","description":"Non-Alcoholic Fatty Liver Disease; Type 2 Diabetes; Mitochondrial Metabolism Disorders","metadata":null},{"id":"2a077a89c9e948978e7730781b8c7957","type":"TRIAL","name":"Quantitating the Impact of Plerixafor","canonical_id":"clinicaltrials.gov:NCT02522572","description":"Transplants and Implants","metadata":null},{"id":"a6a97be7489e488598e8943e907baf54","type":"TRIAL","name":"Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT","canonical_id":"clinicaltrials.gov:NCT03170817","description":"Coronary Artery Disease","metadata":null},{"id":"80d1ce329b8e41cd9dfb28046a495b2d","type":"TRIAL","name":"Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation","canonical_id":"clinicaltrials.gov:NCT02831218","description":"Percutaneous Transluminal Coronary Angioplasty","metadata":null},{"id":"a3869bc8c5a944c3b6c66de69161d255","type":"TRIAL","name":"Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension","canonical_id":"clinicaltrials.gov:NCT03963336","description":"Idiopathic Intracranial Hypertension","metadata":null},{"id":"9385e47077d243ef87f4ad781fb3959e","type":"DRUG","name":"Quarfloxin","canonical_id":"ncit:C71726","description":null,"metadata":null},{"id":"69f0201b3af5494e9b5b8746158f19a0","type":"TRIAL","name":"Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients","canonical_id":"clinicaltrials.gov:NCT00564564","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"37774fff07bb496ba37153fdbd23414f","type":"TRIAL","name":"Quetiapine Augmentation in Severe Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT00254735","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"f73d747295fd46058f8fc9abaf03104a","type":"TRIAL","name":"Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT04280965","description":"Post Traumatic Stress Disorder","metadata":null},{"id":"8f8cac4374284c1ba954fc12a4a5a1eb","type":"TRIAL","name":"Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00672490","description":"Acute Mania in Bipolar Disorder","metadata":null},{"id":"91e761338b2849359387110bd399f91f","type":"TRIAL","name":"Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00278941","description":"Major Depressive Disorder","metadata":null},{"id":"bfddb232c998456aa86f747f1a2bdf74","type":"TRIAL","name":"Quetiapine and the Dopaminergic Epigenetic Control","canonical_id":"clinicaltrials.gov:NCT00370500","description":"Schizophrenia","metadata":null},{"id":"48749b1883134cd2b49e3c6a8af9c3cd","type":"TRIAL","name":"Quetiapine for the Treatment of Insomnia in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00232570","description":"Alzheimer's Disease; Insomnia","metadata":null},{"id":"7c8d6c8da7774823ab065d6688d29ad1","type":"TRIAL","name":"Quetiapine in Co-Morbid Depressive and Anxiety Disorders","canonical_id":"clinicaltrials.gov:NCT00688818","description":"Major Depressive Disorder; Dysthymic Disorder; Anxiety Disorders; Generalized Anxiety Disorder; Social Anxiety Disorder; Panic Disorder; Post-traumatic Stress Disorder","metadata":null},{"id":"d9c38b4a8ca54c87b12a1b4b19688a41","type":"TRIAL","name":"Quickstart of Nexplanon\u00ae at Medical Abortion","canonical_id":"clinicaltrials.gov:NCT01920022","description":"Early Pregnancy Termination; Medical Abortion; Postabortion Contraception","metadata":null},{"id":"ee0e781f2c7b4de9ad18b6fda90b8cdd","type":"TRIAL","name":"Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation","canonical_id":"clinicaltrials.gov:NCT05593757","description":"Short-coupled Idiopathic Ventricular Fibrillation","metadata":null},{"id":"5618b9411ca143d69f89ada2b03b15f8","type":"DRUG","name":"Quinine","canonical_id":"mesh:D011803","description":null,"metadata":null},{"id":"d3b412c2ce5c49e4bb70981d3a50cc1b","type":"TRIAL","name":"Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT01892371","description":"FLT3 Gene Mutation Negative; FLT3 Internal Tandem Duplication Positive; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome","metadata":null},{"id":"a062e91d392647238b1ad3d48813991d","type":"TRIAL","name":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT02668653","description":"Acute Myeloid Leukemia; Leukemia","metadata":null},{"id":"6bb19156599c439795bca1dbae2566f3","type":"TRIAL","name":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","canonical_id":"clinicaltrials.gov:NCT06578247","description":"Leukemia","metadata":null},{"id":"1acecc594a5a4036a854d9546f18c91a","type":"TRIAL","name":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT03661307","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"378d539d03e249cca2f66369530b212a","type":"TRIAL","name":"Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy","canonical_id":"clinicaltrials.gov:NCT06540456","description":"Lower Back Pain; Lumbosacral Radiculopathy","metadata":null},{"id":"c9794c20e8604c51b9a88e53338a824c","type":"TRIAL","name":"Qvar vs FP in Pediatrics","canonical_id":"clinicaltrials.gov:NCT01877954","description":"Asthma","metadata":null},{"id":"2fd02036a2704ef8857386362742667f","type":"TRIAL","name":"R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis","canonical_id":"clinicaltrials.gov:NCT00140218","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"a025ad35f98142259fda56e1fc235581","type":"TRIAL","name":"R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT01446900","description":"Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"b49dcd266987476c9c78d5cb0a366bc2","type":"TRIAL","name":"R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00992030","description":"Hodgkin Lymphoma","metadata":null},{"id":"91313b989a4240ab9381c2c72d86c5f1","type":"TRIAL","name":"R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02428751","description":"Lymphoma, Large B-Cell, Diffuse","metadata":null},{"id":"0def7f29c7a847608dca76b563d37868","type":"TRIAL","name":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00450801","description":"Lymphoma","metadata":null},{"id":"b128a16912424168bf5480b301c94729","type":"GO_TERM","name":"R-SMAD binding","canonical_id":"go:GO:0070412","description":"\"Binding to a receptor-regulated SMAD signaling protein.\" [GOC:BHF, GOC:vk, PMID:19114992]","metadata":null},{"id":"b6e0733d83414f10b478dbd98c7c43bc","type":"TRIAL","name":"R-Verapamil for the Prophylaxis of Episodic Cluster Headache","canonical_id":"clinicaltrials.gov:NCT02209155","description":"Episodic Cluster Headache","metadata":null},{"id":"62c24189a24e414b8b1732987e85abe0","type":"GO_TERM","name":"R-lactaldehyde reductase activity","canonical_id":"go:GO:0052660","description":"\"Catalysis of the reaction: (R)-propane-1,2-diol + NAD+ = (R)-lactaldehyde + NADH + H+.\" [RHEA:23872]","metadata":null},{"id":"20b3af478ac243d6ad8361ea080cd7fd","type":"GO_TERM","name":"R-linalool synthase activity","canonical_id":"go:GO:0034008","description":"\"Catalysis of the reaction: geranyl diphosphate + H2O = (R)-linalool + diphosphate.\" [EC:4.2.3.26, RHEA:15809]","metadata":null},{"id":"db0c505e867943b38b6e90ce57b30a72","type":"GO_TERM","name":"R-loop processing","canonical_id":"go:GO:0062176","description":"\"A DNA metabolic process that results in the disassembly of R-loops. R-loops are three-stranded nucleic acid structures consisitng of an RNA:DNA heteroduplex and a looped-out non-template strand. Aberrant formation and persistence of R-loops block transcription elongation and cause DNA damage. Mechanisms that resolve R-loops are essential for genome stability.\" [PMID:27252122, PMID:28790157, PMID:33986538]","metadata":null},{"id":"1d69a59d25cf4bfd9860dc2598bc546c","type":"GO_TERM","name":"R1/R6 cell differentiation","canonical_id":"go:GO:0048052","description":"\"The process in which relatively unspecialized cells acquire the specialized features of R1 and R6 photoreceptors. An example of this process is found in Drosophila melanogaster.\" [GOC:jid]","metadata":null},{"id":"0197709aa12e44c78b5e417084d8b619","type":"GO_TERM","name":"R1/R6 cell fate commitment","canonical_id":"go:GO:0007462","description":"\"The process in which the R1/R6 photoreceptors commit to their cell fate. R1 and R6 are paired photoreceptors which contribute the outer rhabdomeres.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"7501352951d24b1fa78e67ca2f06239a","type":"GO_TERM","name":"R1/R6 development","canonical_id":"go:GO:0048053","description":"\"The process whose specific outcome is the progression of the R1 and R6 pair of photoreceptors in the eye over time, from their formation to the mature structures. R1 and R6 are paired photoreceptors that contribute to the outer rhabdomeres. An example of this process is found in Drosophila melanogaster.\" [GOC:jid]","metadata":null},{"id":"b9d25806c2434482899abd30b286dd91","type":"GO_TERM","name":"R2/R5 cell differentiation","canonical_id":"go:GO:0048054","description":"\"The process in which relatively unspecialized cells acquire the specialized features of R2 and R5 photoreceptors. An example of this process is found in Drosophila melanogaster.\" [GOC:jid]","metadata":null},{"id":"5bf3bfc0c98043aca0fda025db7bf9b6","type":"GO_TERM","name":"R2/R5 cell fate commitment","canonical_id":"go:GO:0007463","description":"\"The process in which the R2/R5 photoreceptors commit to their cell fate. R2 and R5 are paired photoreceptors which contribute the outer rhabdomeres.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"841b1e931b5e44219b930d44ab176449","type":"GO_TERM","name":"R2/R5 development","canonical_id":"go:GO:0048055","description":"\"The process whose specific outcome is the progression of the R2 and R5 pair of photoreceptors in the eye over time, from their formation to the mature structures. R2 and R5 are paired photoreceptors that contribute to the outer rhabdomeres. An example of this process is found in Drosophila melanogaster.\" [GOC:jid]","metadata":null},{"id":"68166127136c4673841aa1e6842ee59a","type":"GO_TERM","name":"R2TP complex","canonical_id":"go:GO:0097255","description":"\"A highly conserved protein complex comprised of two ATP-dependent DNA helicases (Rvb1p and Rvb2p in yeast, Pontin52 and Reptin52 in humans), Pih1p in yeast or PIH1D1 in humans, and Tah1 in yeast or RPAP3 in humans. The complex associates with Hsp90 and is thought to have a role in assembly of large protein or protein/nucleic acid complexes. In this role it is involved in multiple processes such as box C/D snoRNP biogenesis, phosphatidylinositol-3 kinase-related protein kinase (PIKK) signaling, RNA polymerase II assembly, and others.\" [GOC:mcc, PMID:15766533, PMID:21925213]","metadata":null},{"id":"e9b98d0ba1f145db97ef2fa3ffd09ddf","type":"GO_TERM","name":"R3/R4 cell differentiation","canonical_id":"go:GO:0048056","description":"\"The process in which relatively unspecialized cells acquire the specialized features of R3 and R4 photoreceptors. An example of this process is found in Drosophila melanogaster.\" [GOC:jid]","metadata":null},{"id":"3a6ccec2295847e593d6876972a1acc3","type":"GO_TERM","name":"R3/R4 cell fate commitment","canonical_id":"go:GO:0007464","description":"\"The process in which the R3/R4 photoreceptors commit to their cell fate. R3 and R4 are paired photoreceptors which contribute the outer rhabdomeres.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"826a59f7081849e4a5c901a599a70c1e","type":"GO_TERM","name":"R3/R4 development","canonical_id":"go:GO:0048057","description":"\"The process whose specific outcome is the progression of the R3 and R4 pair of photoreceptors in the eye over time, from their formation to the mature structures. R3 and R4 are paired photoreceptors that contribute to the outer rhabdomeres. An example of this process is found in Drosophila melanogaster.\" [GOC:jid]","metadata":null},{"id":"0577df0734cb4067aa14f5d26273e448","type":"GENE","name":"R3HCC1","canonical_id":"hgnc:HGNC:27329","description":"R3H domain and coiled-coil containing 1","metadata":{"aliases":["DKFZp564N123"]}},{"id":"4c990ff02c9f4e03beaa485645d0c021","type":"GENE","name":"R3HCC1L","canonical_id":"hgnc:HGNC:23512","description":"R3H domain and coiled-coil containing 1 like","metadata":{"aliases":["GIDRP88","PSORT","C10orf28"]}},{"id":"26328e3dd4e0410ca371d96d2dfd051c","type":"GENE","name":"R3HDM1","canonical_id":"hgnc:HGNC:9757","description":"R3H domain containing 1","metadata":{"aliases":["KIAA0029","R3HDM"]}},{"id":"9e68647059564cf0876141034871dea8","type":"GENE","name":"R3HDM2","canonical_id":"hgnc:HGNC:29167","description":"R3H domain containing 2","metadata":{"aliases":["KIAA1002"]}},{"id":"6c0f736e3af0497e9d4a6cd9232182e1","type":"GENE","name":"R3HDM2-DT","canonical_id":"hgnc:HGNC:55457","description":"R3HDM2 divergent transcript","metadata":null},{"id":"b8910e334279492787efb8642f7e858d","type":"GENE","name":"R3HDM2P1","canonical_id":"hgnc:HGNC:44056","description":"R3H domain containing 2 pseudogene 1","metadata":null},{"id":"a1928ef02da64489bf8266c2af38932d","type":"GENE","name":"R3HDM2P2","canonical_id":"hgnc:HGNC:44057","description":"R3H domain containing 2 pseudogene 2","metadata":null},{"id":"b51ae14bc2ca47b7bb0c09ebc53a0528","type":"GENE","name":"R3HDM4","canonical_id":"hgnc:HGNC:28270","description":"R3H domain containing 4","metadata":{"aliases":["MGC16353","C19orf22"]}},{"id":"e5f15fb703c746478308a785b0067308","type":"GENE","name":"R3HDML","canonical_id":"hgnc:HGNC:16249","description":"R3H domain containing like","metadata":{"aliases":["dJ881L22.3"]}},{"id":"545c41cab58d4c60be7a3ab00500ce2c","type":"GENE","name":"R3HDML-AS1","canonical_id":"hgnc:HGNC:55830","description":"R3HDML antisense RNA 1","metadata":{"aliases":["RP5-881L22.5"]}},{"id":"75e4bdeaec1544e69bbb0dfba6600298","type":"GO_TERM","name":"R7 cell development","canonical_id":"go:GO:0045467","description":"\"The process whose specific outcome is the progression of the R7 photoreceptor over time, from its formation to the mature structure. The R7 photoreceptor is the last photoreceptor to develop in the ommatidium.\" [PMID:11880339]","metadata":null},{"id":"56e27332b0634fffbc361fc1a4baeebb","type":"GO_TERM","name":"R7 cell differentiation","canonical_id":"go:GO:0045466","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of the R7 photoreceptor.\" [PMID:11880339]","metadata":null},{"id":"f0f55597e4d24d03bb0b6d0f8225a67a","type":"GO_TERM","name":"R7 cell fate commitment","canonical_id":"go:GO:0007465","description":"\"The process in which the R7 photoreceptor commits to its cell fate. The R7 receptor contributes the central part of the rhabdomere in the apical parts of the ommatidium.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"6965268f527547e7a4ef831b88ae94a5","type":"GO_TERM","name":"R8 cell development","canonical_id":"go:GO:0045463","description":"\"The process whose specific outcome is the progression of the R8 photoreceptor over time, from its formation to the mature structure. The R8 photoreceptor is the founding receptor of each ommatidium.\" [PMID:11880339]","metadata":null},{"id":"fbc2a5b0af1a490e8a3ab8ce2c38c472","type":"GO_TERM","name":"R8 cell differentiation","canonical_id":"go:GO:0045465","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of the R8 photoreceptor.\" [PMID:11880339]","metadata":null},{"id":"2f0e8b3ebf9e4d79bade4e4fd2d53881","type":"GO_TERM","name":"R8 cell fate commitment","canonical_id":"go:GO:0007460","description":"\"The process in which the R8 photoreceptor commits to its cell fate. The R8 receptor contributes the central part of the rhabdomere in the basal parts of the ommatidium.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"7936a4f76f2441cba4e1f1eb82421a74","type":"GO_TERM","name":"R8 cell fate specification","canonical_id":"go:GO:0045464","description":"\"The process in which a cell becomes capable of differentiating autonomously into an R8 cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [PMID:11880339]","metadata":null},{"id":"6b0522b08b24418f9185c37f4841b752","type":"GO_TERM","name":"R8 cell-mediated photoreceptor organization","canonical_id":"go:GO:0045470","description":"\"The regionalization process that coordinates the recruitment and organization of other non-R8 photoreceptors by the R8 photoreceptor.\" [PMID:11880339]","metadata":null},{"id":"2b624efaab934aabaeeded751100351f","type":"GENE","name":"RAB10","canonical_id":"hgnc:HGNC:9759","description":"RAB10, member RAS oncogene family","metadata":null},{"id":"41b074eab113445fb2e0b6aba3212842","type":"GENE","name":"RAB11A","canonical_id":"hgnc:HGNC:9760","description":"RAB11A, member RAS oncogene family","metadata":{"aliases":["YL8"]}},{"id":"e63220011b7e4771a0120dda65550c95","type":"GENE","name":"RAB11AP1","canonical_id":"hgnc:HGNC:45188","description":"RAB11A, member RAS oncogene family pseudogene 1","metadata":null},{"id":"cc8f6aef21274f569ee4a56f13281833","type":"GENE","name":"RAB11AP2","canonical_id":"hgnc:HGNC:45189","description":"RAB11A, member RAS oncogene family pseudogene 2","metadata":null},{"id":"61d52a8372b3459ba97f269968656b73","type":"GENE","name":"RAB11B","canonical_id":"hgnc:HGNC:9761","description":"RAB11B, member RAS oncogene family","metadata":{"aliases":["H-YPT3"]}},{"id":"fa8af1d1d60647baab9ba2b128a59dcc","type":"GENE","name":"RAB11B-AS1","canonical_id":"hgnc:HGNC:44178","description":"RAB11B antisense RNA 1","metadata":{"aliases":["MIR4999HG"]}},{"id":"fccfea493f404e5590799959d350cb13","type":"GENE","name":"RAB11FIP1","canonical_id":"hgnc:HGNC:30265","description":"RAB11 family interacting protein 1","metadata":{"aliases":["RCP","FLJ22622","FLJ22524","Rab11-FIP1"]}},{"id":"44f573782b3d411e973fde368e7a79a3","type":"GENE","name":"RAB11FIP1P1","canonical_id":"hgnc:HGNC:42366","description":"RAB11 family interacting protein 1 pseudogene 1","metadata":null},{"id":"1e58620fdc7740b6abf6e535bb8e7f90","type":"GENE","name":"RAB11FIP2","canonical_id":"hgnc:HGNC:29152","description":"RAB11 family interacting protein 2","metadata":{"aliases":["KIAA0941","nRip11","Rab11-FIP2"]}},{"id":"ce0ba2fd22ca4a15a0d10c5405fedc68","type":"GENE","name":"RAB11FIP3","canonical_id":"hgnc:HGNC:17224","description":"RAB11 family interacting protein 3","metadata":{"aliases":["KIAA0665","Rab11-FIP3","eferin"]}},{"id":"552b6fc384dd4f9797c7922004b8ebf0","type":"GENE","name":"RAB11FIP4","canonical_id":"hgnc:HGNC:30267","description":"RAB11 family interacting protein 4","metadata":{"aliases":["RAB11-FIP4","KIAA1821","MGC11316","FLJ00131"]}},{"id":"6c5f2cdb544f483dbea9fb4ebb168a52","type":"GENE","name":"RAB11FIP5","canonical_id":"hgnc:HGNC:24845","description":"RAB11 family interacting protein 5","metadata":{"aliases":["GAF1","KIAA0857","RIP11","pp75"]}},{"id":"c5715333284f44ebaf72d08fe81da413","type":"GENE","name":"RAB12","canonical_id":"hgnc:HGNC:31332","description":"RAB12, member RAS oncogene family","metadata":null},{"id":"c76ea4d5c7a24a5cad5745c9f5ae1621","type":"GENE","name":"RAB12-AS1","canonical_id":"hgnc:HGNC:58203","description":"RAB12 antisense RNA 1","metadata":null},{"id":"a7bed0e9273b4b0d805a921c57a3916e","type":"GENE","name":"RAB13","canonical_id":"hgnc:HGNC:9762","description":"RAB13, member RAS oncogene family","metadata":null},{"id":"18c8afe958c34f5aace430c919a5c5ee","type":"GENE","name":"RAB14","canonical_id":"hgnc:HGNC:16524","description":"RAB14, member RAS oncogene family","metadata":{"aliases":["FBP","RAB-14"]}},{"id":"d42accc61d624dadaf3c29161b0297ce","type":"GENE","name":"RAB15","canonical_id":"hgnc:HGNC:20150","description":"RAB15, member RAS oncogene family","metadata":null},{"id":"1a8126f193c041dabcedd69e391d49c2","type":"GENE","name":"RAB17","canonical_id":"hgnc:HGNC:16523","description":"RAB17, member RAS oncogene family","metadata":null},{"id":"136b10c075034ec7a5274fb6b212e6cf","type":"GENE","name":"RAB17-DT","canonical_id":"hgnc:HGNC:56028","description":"RAB17 divergent transcript","metadata":null},{"id":"729dc4a8571a44a5b064052af9d1ba46","type":"GENE","name":"RAB18","canonical_id":"hgnc:HGNC:14244","description":"RAB18, member RAS oncogene family","metadata":null},{"id":"4ecbd0e0d0ae416ca0a3e5e46d39fba9","type":"GENE","name":"RAB19","canonical_id":"hgnc:HGNC:19982","description":"RAB19, member RAS oncogene family","metadata":{"aliases":["RAB19B"]}},{"id":"2e2ea8cba1494044a5706faae5bba652","type":"GENE","name":"RAB1A","canonical_id":"hgnc:HGNC:9758","description":"RAB1A, member RAS oncogene family","metadata":{"aliases":["YPT1","RAB1"]}},{"id":"5c950fb217ed475b85f6b811c92de0d6","type":"GENE","name":"RAB1AP1","canonical_id":"hgnc:HGNC:54644","description":"RAB1A pseudogene 1","metadata":null},{"id":"238ae3efb2954a52ada7f0594008538d","type":"GENE","name":"RAB1AP2","canonical_id":"hgnc:HGNC:54645","description":"RAB1A pseudogene 2","metadata":null},{"id":"3bba378a0143446fa7d40a6057f60778","type":"GENE","name":"RAB1B","canonical_id":"hgnc:HGNC:18370","description":"RAB1B, member RAS oncogene family","metadata":null},{"id":"aaac366f44f14c2198df582d115b9906","type":"GENE","name":"RAB1C","canonical_id":"hgnc:HGNC:23683","description":"RAB1C, member RAS oncogene family (pseudogene)","metadata":null},{"id":"926b8353ef564b9f86bd8e03144cd7dc","type":"GENE","name":"RAB20","canonical_id":"hgnc:HGNC:18260","description":"RAB20, member RAS oncogene family","metadata":{"aliases":["FLJ20429"]}},{"id":"9453d7b7d8fe4c70853b46641154c74a","type":"GENE","name":"RAB21","canonical_id":"hgnc:HGNC:18263","description":"RAB21, member RAS oncogene family","metadata":{"aliases":["KIAA0118"]}},{"id":"e0b3f36550c8417298a15f46d7dbf272","type":"GENE","name":"RAB22A","canonical_id":"hgnc:HGNC:9764","description":"RAB22A, member RAS oncogene family","metadata":null},{"id":"5398493a3cb241ab9f66d863d5a36447","type":"GENE","name":"RAB23","canonical_id":"hgnc:HGNC:14263","description":"RAB23, member RAS oncogene family","metadata":null},{"id":"5091d79da23140a5b77d3d26549f420c","type":"GENE","name":"RAB24","canonical_id":"hgnc:HGNC:9765","description":"RAB24, member RAS oncogene family","metadata":null},{"id":"321e5e89950e42b7b9534d128cb93a79","type":"GENE","name":"RAB25","canonical_id":"hgnc:HGNC:18238","description":"RAB25, member RAS oncogene family","metadata":{"aliases":["CATX-8"]}},{"id":"5c7c2da6fdb1425ea2a6c77b50530c65","type":"GENE","name":"RAB26","canonical_id":"hgnc:HGNC:14259","description":"RAB26, member RAS oncogene family","metadata":null},{"id":"08a372d9c8e9438a84b31ced7caedc3b","type":"GENE","name":"RAB27A","canonical_id":"hgnc:HGNC:9766","description":"RAB27A, member RAS oncogene family","metadata":{"aliases":["RAB27","RAM","GS2","HsT18676"]}},{"id":"12a722570c2e4b4397f915234968bfad","type":"GENE","name":"RAB27B","canonical_id":"hgnc:HGNC:9767","description":"RAB27B, member RAS oncogene family","metadata":null},{"id":"f43bb0ed6b674cda85b8f3203c7dfd63","type":"GENE","name":"RAB27B-AS1","canonical_id":"hgnc:HGNC:58316","description":"RAB27B antisense RNA 1","metadata":null},{"id":"f2b6062f25d549afb9bf3ae60898490a","type":"GENE","name":"RAB28","canonical_id":"hgnc:HGNC:9768","description":"RAB28, member RAS oncogene family","metadata":null},{"id":"322680afd79442e294e802d0514deda9","type":"GENE","name":"RAB28-DT","canonical_id":"hgnc:HGNC:58737","description":"RAB28 divergent transcript","metadata":null},{"id":"4913ad9407d6484ea7b9e5aa3a9dd98f","type":"GENE","name":"RAB28P1","canonical_id":"hgnc:HGNC:50380","description":"RAB28, member RAS oncogene family pseudogene 1","metadata":null},{"id":"848498bc88bd4257bc07d0040885f2c1","type":"GENE","name":"RAB28P2","canonical_id":"hgnc:HGNC:50381","description":"RAB28, member RAS oncogene family pseudogene 2","metadata":null},{"id":"3d288c7ff4324114a8ad3b28c8ba8b1a","type":"GENE","name":"RAB28P3","canonical_id":"hgnc:HGNC:50382","description":"RAB28, member RAS oncogene family pseudogene 3","metadata":null},{"id":"e0a329d5e02c44beb168385259e692eb","type":"GENE","name":"RAB28P4","canonical_id":"hgnc:HGNC:51548","description":"RAB28, member RAS oncogene family pseudogene 4","metadata":null},{"id":"7fac7197583648cf8061c0cfdf996b17","type":"GENE","name":"RAB28P5","canonical_id":"hgnc:HGNC:51547","description":"RAB28, member RAS oncogene family pseudogene 5","metadata":null},{"id":"7bffcafd6839491091c4ebe8e1fe541d","type":"GENE","name":"RAB29","canonical_id":"hgnc:HGNC:9789","description":"RAB29, member RAS oncogene family","metadata":{"aliases":["RAB7L","RAB7L1"]}},{"id":"51de39ad5df14b39929e787eb953aae8","type":"GENE","name":"RAB2A","canonical_id":"hgnc:HGNC:9763","description":"RAB2A, member RAS oncogene family","metadata":{"aliases":["RAB2"]}},{"id":"0d26e40bee7b4291a9969dbb86880bf9","type":"GENE","name":"RAB2B","canonical_id":"hgnc:HGNC:20246","description":"RAB2B, member RAS oncogene family","metadata":{"aliases":["FLJ14824"]}},{"id":"146ea68a61664ac2a670d9a34342d06f","type":"GENE","name":"RAB30","canonical_id":"hgnc:HGNC:9770","description":"RAB30, member RAS oncogene family","metadata":null},{"id":"040d03ab5e374b999af312d12f4ec273","type":"GENE","name":"RAB30-DT","canonical_id":"hgnc:HGNC:48672","description":"RAB30 divergent transcript","metadata":{"aliases":["LFPM","RAB30-AS1"]}},{"id":"d9dbdf01898d4600a1ecbc257c08dc9a","type":"GENE","name":"RAB31","canonical_id":"hgnc:HGNC:9771","description":"RAB31, member RAS oncogene family","metadata":{"aliases":["Rab22B"]}},{"id":"7b143152e9b54d20b9664174ad2e3c32","type":"GENE","name":"RAB31P1","canonical_id":"hgnc:HGNC:58651","description":"RAB31 pseudogene 1","metadata":null},{"id":"37696e4024ce406cafc250d2c2a69a6e","type":"GENE","name":"RAB32","canonical_id":"hgnc:HGNC:9772","description":"RAB32, member RAS oncogene family","metadata":null},{"id":"e133d076b00948dea9b720be7fe4aea9","type":"GENE","name":"RAB33A","canonical_id":"hgnc:HGNC:9773","description":"RAB33A, member RAS oncogene family","metadata":{"aliases":["RabS10"]}},{"id":"512ccc8475404d5a87f3b75498f86feb","type":"GENE","name":"RAB33B","canonical_id":"hgnc:HGNC:16075","description":"RAB33B, member RAS oncogene family","metadata":{"aliases":["DKFZP434G099"]}},{"id":"30b5a540a7464b80be45a506387fd6bf","type":"GENE","name":"RAB33B-AS1","canonical_id":"hgnc:HGNC:55153","description":"RAB33B antisense RNA 1","metadata":null},{"id":"ceb42596e624458786345f7d1adc208f","type":"GENE","name":"RAB34","canonical_id":"hgnc:HGNC:16519","description":"RAB34, member RAS oncogene family","metadata":{"aliases":["RAB39","RAH","NARR"]}},{"id":"30c66cf1e35c4582816e4189552b3b9d","type":"GENE","name":"RAB35","canonical_id":"hgnc:HGNC:9774","description":"RAB35, member RAS oncogene family","metadata":{"aliases":["H-ray"]}},{"id":"539139e89fbe4ef389e8f8283822021b","type":"GENE","name":"RAB35-AS1","canonical_id":"hgnc:HGNC:56348","description":"RAB35 antisense RNA 1","metadata":{"aliases":["AC004812.2"]}},{"id":"dded71962a024179aff3a92533385507","type":"GENE","name":"RAB36","canonical_id":"hgnc:HGNC:9775","description":"RAB36, member RAS oncogene family","metadata":null},{"id":"b9149601e4624bf6aff24aa5c074ff7f","type":"GENE","name":"RAB37","canonical_id":"hgnc:HGNC:30268","description":"RAB37, member RAS oncogene family","metadata":null},{"id":"78e0271775184d06bfef3e957f21b703","type":"GENE","name":"RAB37-AS1","canonical_id":"hgnc:HGNC:58558","description":"RAB37 antisense RNA 1","metadata":null},{"id":"01c03f5c92e24a688652289e37b549a1","type":"GENE","name":"RAB38","canonical_id":"hgnc:HGNC:9776","description":"RAB38, member RAS oncogene family","metadata":{"aliases":["NY-MEL-1"]}},{"id":"e77709f9cddc41b5ac1d901652e68060","type":"GENE","name":"RAB39A","canonical_id":"hgnc:HGNC:16521","description":"RAB39A, member RAS oncogene family","metadata":{"aliases":["RAB39"]}},{"id":"2ef168c1f0d94923ae7860920883fc6a","type":"GENE","name":"RAB39B","canonical_id":"hgnc:HGNC:16499","description":"RAB39B, member RAS oncogene family","metadata":{"aliases":["MRX72","WSN"]}},{"id":"279ed4fb041e4b7b8ea43853ab9ee466","type":"GENE","name":"RAB3A","canonical_id":"hgnc:HGNC:9777","description":null,"metadata":null},{"id":"4c6f450d7c134ca7ad77f6bd6dc14fa1","type":"GENE","name":"RAB3B","canonical_id":"hgnc:HGNC:9778","description":"RAB3B, member RAS oncogene family","metadata":null},{"id":"cd94b1b200624a4181849a22a1c37a38","type":"GENE","name":"RAB3C","canonical_id":"hgnc:HGNC:30269","description":"RAB3C, member RAS oncogene family","metadata":null},{"id":"66a3aac9990b481f80b4fa43eed1db83","type":"GENE","name":"RAB3C-AS1","canonical_id":"hgnc:HGNC:41259","description":"RAB3C antisense RNA 1","metadata":null},{"id":"61846a9a912a4513bc5da5e63b39c2df","type":"GENE","name":"RAB3D","canonical_id":"hgnc:HGNC:9779","description":"RAB3D, member RAS oncogene family","metadata":{"aliases":["RAB16","D2-2","RAD3D","GOV"]}},{"id":"045a5ca66a4647c3907d0a3160c3be4c","type":"GENE","name":"RAB3GAP1","canonical_id":"hgnc:HGNC:17063","description":"RAB3 GTPase activating protein catalytic subunit 1","metadata":{"aliases":["RAB3GAP","KIAA0066","RAB3GAP130","WARBM1"]}},{"id":"51602432ba564d9d9851ed9e461c174c","type":"GENE","name":"RAB3GAP2","canonical_id":"hgnc:HGNC:17168","description":"RAB3 GTPase activating non-catalytic protein subunit 2","metadata":{"aliases":["RAB3-GAP150","KIAA0839","DKFZP434D245","SPG69"]}},{"id":"234256038a7b45319619c329bad2b024","type":"GENE","name":"RAB3IL1","canonical_id":"hgnc:HGNC:9780","description":"RAB3A interacting protein like 1","metadata":{"aliases":["GRAB"]}},{"id":"5926481c9661492c88c05acdca2c6aa2","type":"GENE","name":"RAB3IP","canonical_id":"hgnc:HGNC:16508","description":"RAB3A interacting protein","metadata":{"aliases":["RABIN3","FLJ22548","RABIN8"]}},{"id":"62674b36e3da4883a833974ce7acae1d","type":"GENE","name":"RAB3IP-DT","canonical_id":"hgnc:HGNC:59225","description":"RAB3IP divergent transcript","metadata":null},{"id":"88dbac401f3a41c88771813e1b2e3f76","type":"GENE","name":"RAB40A","canonical_id":"hgnc:HGNC:18283","description":"RAB40A, member RAS oncogene family","metadata":{"aliases":["RAR2A","Rar-2"]}},{"id":"82e4e8d0698c4cd0bf33f42ec326d414","type":"GENE","name":"RAB40AL","canonical_id":"hgnc:HGNC:25410","description":"RAB40A like","metadata":{"aliases":["RAR2","RLGP"]}},{"id":"f12b7d3808874b238f68ae0b1bae8eb0","type":"GENE","name":"RAB40B","canonical_id":"hgnc:HGNC:18284","description":"RAB40B, member RAS oncogene family","metadata":{"aliases":["SEC4L","RAR"]}},{"id":"5d3bca7f3b894d8282234b0d564d2320","type":"GENE","name":"RAB40C","canonical_id":"hgnc:HGNC:18285","description":"RAB40C, member RAS oncogene family","metadata":{"aliases":["RARL","RASL8C"]}},{"id":"a1d416a3739f4df394229f492e1820b7","type":"GENE","name":"RAB41","canonical_id":"hgnc:HGNC:18293","description":"RAB41, member RAS oncogene family","metadata":null},{"id":"d51cc7d027ee41a78df215de73c74d5b","type":"GENE","name":"RAB42","canonical_id":"hgnc:HGNC:28702","description":"RAB42, member RAS oncogene family","metadata":{"aliases":["MGC45806"]}},{"id":"92b02e2dfdfe45f4b5d2c68224eabb37","type":"GENE","name":"RAB42P1","canonical_id":"hgnc:HGNC:19799","description":"RAB42, member RAS oncogene family, pseudogene 1","metadata":{"aliases":["RAB42","RAB42P"]}},{"id":"3b78e8ea2fa7418d8f763138ba7323d0","type":"GENE","name":"RAB43","canonical_id":"hgnc:HGNC:19983","description":"RAB43, member RAS oncogene family","metadata":{"aliases":["RAB41","RAB11B","ISY1"]}},{"id":"ba57799bbdaf43bcb839ea297f6b1bf8","type":"GENE","name":"RAB43P1","canonical_id":"hgnc:HGNC:33153","description":"RAB43 pseudogene 1","metadata":{"aliases":["RAB41P","RAB43P"]}},{"id":"9130479c5f3e444ca1fae96b8ceeeffc","type":"GENE","name":"RAB44","canonical_id":"hgnc:HGNC:21068","description":"RAB44, member RAS oncogene family","metadata":{"aliases":["dJ431A14.3","RASD3","RASL13"]}},{"id":"e09df1c96fad48abae4282ac96d44ab1","type":"GENE","name":"RAB4A","canonical_id":"hgnc:HGNC:9781","description":"RAB4A, member RAS oncogene family","metadata":{"aliases":["HRES-1/RAB4","RAB4"]}},{"id":"318699c4a9cc414dbcddcd7c23dd41b1","type":"GENE","name":"RAB4A-AS1","canonical_id":"hgnc:HGNC:55934","description":"RAB4A antisense RNA 1","metadata":null},{"id":"8419a96ac9dd4cdeb3a1b6004cfa997b","type":"GENE","name":"RAB4B","canonical_id":"hgnc:HGNC:9782","description":null,"metadata":null},{"id":"b3ee178afc9e48f8971d50df9234c48e","type":"GENE","name":"RAB4B-EGLN2","canonical_id":"hgnc:HGNC:44465","description":"RAB4B-EGLN2 readthrough (NMD candidate)","metadata":{"aliases":["RERT-lncRNA"]}},{"id":"256387e4f45d49359cf35153766a6ba8","type":"GENE","name":"RAB5A","canonical_id":"hgnc:HGNC:9783","description":"RAB5A, member RAS oncogene family","metadata":{"aliases":["RAB5"]}},{"id":"15f292eb8b3847c985bc4f2c3eacc090","type":"GENE","name":"RAB5B","canonical_id":"hgnc:HGNC:9784","description":"RAB5B, member RAS oncogene family","metadata":null},{"id":"b5bbcacb33404f6cba2d59cc331304aa","type":"GENE","name":"RAB5C","canonical_id":"hgnc:HGNC:9785","description":"RAB5C, member RAS oncogene family","metadata":{"aliases":["RAB5CL","RABL"]}},{"id":"627575cbac7d4bbf9ee6636816d6d0dd","type":"GENE","name":"RAB5C-AS1","canonical_id":"hgnc:HGNC:55289","description":"RAB5C antisense RNA 1","metadata":null},{"id":"7366b3ed78b1464389a67de34817db6a","type":"GENE","name":"RAB5CP1","canonical_id":"hgnc:HGNC:45104","description":"RAB5C, member RAS oncogene family pseudogene 1","metadata":null},{"id":"2fd907c2a53d4774bc4a4fa3c9c821b8","type":"GENE","name":"RAB5CP2","canonical_id":"hgnc:HGNC:45106","description":"RAB5C, member RAS oncogene family pseudogene 2","metadata":null},{"id":"5ab69809b05245559db9ab1362f5fc47","type":"GENE","name":"RAB5IF","canonical_id":"hgnc:HGNC:15870","description":"RAB5 interacting factor","metadata":{"aliases":["PNAS-11","RIP5","RCAF1","OPTI","C20orf24"]}},{"id":"19f18806af3a4eb8bd0be677751a03ee","type":"GENE","name":"RAB6A","canonical_id":"hgnc:HGNC:9786","description":"RAB6A, member RAS oncogene family","metadata":{"aliases":["RAB6"]}},{"id":"6b09010b6c4647ceada602cfd9fb4979","type":"GENE","name":"RAB6B","canonical_id":"hgnc:HGNC:14902","description":"RAB6B, member RAS oncogene family","metadata":null},{"id":"295d92c3426e417496d22b2b58862a7d","type":"GENE","name":"RAB6C","canonical_id":"hgnc:HGNC:16525","description":"RAB6C, member RAS oncogene family","metadata":{"aliases":["WTH3"]}},{"id":"adbc98de4d0d4d32ab2d424782da634a","type":"GENE","name":"RAB6C-AS1","canonical_id":"hgnc:HGNC:49278","description":"RAB6C antisense RNA 1","metadata":null},{"id":"2cdc8558f2364dd1a961300593d22d33","type":"GENE","name":"RAB6D","canonical_id":"hgnc:HGNC:30272","description":"RAB6D, member RAS oncogene family","metadata":{"aliases":["RAB6CL","WTH3DI"]}},{"id":"108ebb3a16dc465f92232b1dcc0f3d25","type":"GENE","name":"RAB7A","canonical_id":"hgnc:HGNC:9788","description":"RAB7A, member RAS oncogene family","metadata":{"aliases":["RAB7","CMT2B"]}},{"id":"9b031c15d8114e4f8386dabf4e694503","type":"GENE","name":"RAB7B","canonical_id":"hgnc:HGNC:30513","description":"RAB7B, member RAS oncogene family","metadata":{"aliases":["MGC9726","MGC16212"]}},{"id":"771b223aaa6c41b09cb1cc0a7aca3b40","type":"GENE","name":"RAB8A","canonical_id":"hgnc:HGNC:7007","description":"RAB8A, member RAS oncogene family","metadata":{"aliases":["RAB8","MEL"]}},{"id":"fa7ff53bb356463b872b1daafac12682","type":"GENE","name":"RAB8B","canonical_id":"hgnc:HGNC:30273","description":"RAB8B, member RAS oncogene family","metadata":null},{"id":"67ff1953ac8345fdb83cc02bb2ef96a8","type":"GENE","name":"RAB9A","canonical_id":"hgnc:HGNC:9792","description":"RAB9A, member RAS oncogene family","metadata":{"aliases":["RAB9"]}},{"id":"2a133332663644919e373f3cf93fe3c8","type":"GENE","name":"RAB9AP1","canonical_id":"hgnc:HGNC:38104","description":"RAB9A, member RAS oncogene family pseudogene 1","metadata":null},{"id":"34b72be32f9148c091255646af2f35ca","type":"GENE","name":"RAB9AP2","canonical_id":"hgnc:HGNC:38106","description":"RAB9A, member RAS oncogene family pseudogene 2","metadata":null},{"id":"30d755dfe15b46bb8e5ea511f262b2cd","type":"GENE","name":"RAB9AP3","canonical_id":"hgnc:HGNC:38107","description":"RAB9A, member RAS oncogene family pseudogene 3","metadata":null},{"id":"f31620ae412747cabda04433fd0d04ab","type":"GENE","name":"RAB9AP4","canonical_id":"hgnc:HGNC:38108","description":"RAB9A, member RAS oncogene family pseudogene 4","metadata":null},{"id":"406fd2e60dbe424893e217f6ba9de944","type":"GENE","name":"RAB9AP5","canonical_id":"hgnc:HGNC:38109","description":"RAB9A, member RAS oncogene family pseudogene 5","metadata":null},{"id":"cd241f604289426c8dc409d3af5bac88","type":"GENE","name":"RAB9B","canonical_id":"hgnc:HGNC:14090","description":"RAB9B, member RAS oncogene family","metadata":{"aliases":["RAB9L"]}},{"id":"91c82457529347a58556d8726db538f7","type":"GENE","name":"RAB9BP1","canonical_id":"hgnc:HGNC:9793","description":"RAB9B, member RAS oncogene family pseudogene 1","metadata":{"aliases":["RAB9P1"]}},{"id":"fadebd0af9b2495999d679a5aff52c92","type":"GENE","name":"RABAC1","canonical_id":"hgnc:HGNC:9794","description":"Rab acceptor 1","metadata":{"aliases":["PRA1","PRAF1","YIP3"]}},{"id":"feced8a8bdda48dfb8a2dd690144af5f","type":"GENE","name":"RABEP1","canonical_id":"hgnc:HGNC:17677","description":"rabaptin, RAB GTPase binding effector protein 1","metadata":{"aliases":["neurocrescin","RAB5EP","RABPT5","rabaptin-5"]}},{"id":"4acc2efc068d420aa4eb3ab4e58d56f0","type":"GENE","name":"RABEP2","canonical_id":"hgnc:HGNC:24817","description":"rabaptin, RAB GTPase binding effector protein 2","metadata":{"aliases":["FRA","FLJ23282"]}},{"id":"b302da1c4e934c94a412eb9af385a812","type":"GENE","name":"RABEPK","canonical_id":"hgnc:HGNC:16896","description":"Rab9 effector protein with kelch motifs","metadata":{"aliases":["RAB9P40","bA65N13.1"]}},{"id":"f685adec58cf4f3bb36788e7a49ea2b2","type":"GENE","name":"RABEPKP1","canonical_id":"hgnc:HGNC:39791","description":"Rab9 effector protein with kelch motifs pseudogene 1","metadata":null},{"id":"61a5e358b10d40d78da852091495bd76","type":"GENE","name":"RABGAP1","canonical_id":"hgnc:HGNC:17155","description":"RAB GTPase activating protein 1","metadata":{"aliases":["GAPCenA","TBC1D11"]}},{"id":"b9275d1be9c04991a3664fd47ab89248","type":"GENE","name":"RABGAP1L","canonical_id":"hgnc:HGNC:24663","description":"RAB GTPase activating protein 1 like","metadata":{"aliases":["HHL","TBC1D18","KIAA0471","FLJ38519"]}},{"id":"0b5943bc8ae04b63b471612035fa0782","type":"GENE","name":"RABGAP1L-AS1","canonical_id":"hgnc:HGNC:41057","description":"RABGAP1L antisense RNA 1","metadata":null},{"id":"0fd1d3d6d715413ea37bf5f815c7f930","type":"GENE","name":"RABGAP1L-DT","canonical_id":"hgnc:HGNC:54296","description":"RABGAP1L divergent transcript","metadata":null},{"id":"bcb75667b3c64ef9885795d8a8804472","type":"GENE","name":"RABGAP1L-IT1","canonical_id":"hgnc:HGNC:41471","description":"RABGAP1L intronic transcript 1","metadata":null},{"id":"d186cb79034b445994122ce901b6a2f8","type":"GENE","name":"RABGEF1","canonical_id":"hgnc:HGNC:17676","description":"RAB guanine nucleotide exchange factor 1","metadata":{"aliases":["rabex-5","RABEX5"]}},{"id":"a4fb508bd7864f5a9957d38082c0ac1e","type":"GENE","name":"RABGEF1P1","canonical_id":"hgnc:HGNC:55751","description":"RABGEF1 pseudogene 1","metadata":null},{"id":"3aa647c4927144a5bea947b1c7f542c2","type":"GENE","name":"RABGEF1P2","canonical_id":"hgnc:HGNC:55752","description":"RABGEF1 pseudogene 2","metadata":null},{"id":"b68abccf8bda40cf8534432c3f98595a","type":"GENE","name":"RABGEF1P3","canonical_id":"hgnc:HGNC:55753","description":"RABGEF1 pseudogene 3","metadata":null},{"id":"9bfd924cab154895a15ea20746d64b3d","type":"GENE","name":"RABGGTA","canonical_id":"hgnc:HGNC:9795","description":"Rab geranylgeranyltransferase subunit alpha","metadata":{"aliases":["PTAR3"]}},{"id":"2656fe0eb1c24e1280b46a14ca0239ad","type":"GENE","name":"RABGGTB","canonical_id":"hgnc:HGNC:9796","description":"Rab geranylgeranyltransferase subunit beta","metadata":null},{"id":"f0a8b637331d4d34b94736a462abfa50","type":"GENE","name":"RABGGTBP1","canonical_id":"hgnc:HGNC:56479","description":"RABGGTB pseudogene 1","metadata":null},{"id":"bb895dc2f79c40768af93133762270c2","type":"GENE","name":"RABIF","canonical_id":"hgnc:HGNC:9797","description":"RAB interacting factor","metadata":{"aliases":["mss4","RASGRF3"]}},{"id":"5fdf99db9e1c424a95f819d617b5b2bd","type":"GENE","name":"RABL2A","canonical_id":"hgnc:HGNC:9799","description":"RAB, member of RAS oncogene family like 2A","metadata":null},{"id":"94c567c3fc0e45cd8591c9a0b9a80fb0","type":"GENE","name":"RABL2B","canonical_id":"hgnc:HGNC:9800","description":"RAB, member of RAS oncogene family like 2B","metadata":null},{"id":"d7db670d443040eb935728d81d512770","type":"GENE","name":"RABL3","canonical_id":"hgnc:HGNC:18072","description":"RAB, member of RAS oncogene family like 3","metadata":{"aliases":["MGC23920"]}},{"id":"6318ffacb1624203a51363b6006741ea","type":"GENE","name":"RABL6","canonical_id":"hgnc:HGNC:24703","description":"RAB, member RAS oncogene family like 6","metadata":{"aliases":["FLJ10101","FLJ13045","pp8875","bA216L13.9","Parf","RBEL1","C9orf86"]}},{"id":"c1341924619f49a1894fe39dc8b13dc8","type":"GENE","name":"RAC1","canonical_id":"hgnc:HGNC:9801","description":null,"metadata":null},{"id":"f8bcd8c32e3044e9be1250f3b33c5671","type":"GENE","name":"RAC1P1","canonical_id":"hgnc:HGNC:31001","description":"Rac family small GTPase 1 pseudogene 1","metadata":{"aliases":["HsT2789"]}},{"id":"a3ec3ba0be074b2ab62b050719d36243","type":"GENE","name":"RAC1P2","canonical_id":"hgnc:HGNC:31414","description":"Rac family small GTPase 1 pseudogene 2","metadata":{"aliases":["Psi2Rac1"]}},{"id":"cf09aa07071b4347b1b71de15a6407e5","type":"GENE","name":"RAC1P3","canonical_id":"hgnc:HGNC:31833","description":"Rac family small GTPase 1 pseudogene 3","metadata":{"aliases":["Psi3Rac1"]}},{"id":"db84480f2fce4b478533ee815169dc0b","type":"GENE","name":"RAC1P4","canonical_id":"hgnc:HGNC:31113","description":"Rac family small GTPase 1 pseudogene 4","metadata":{"aliases":["Psi4Rac1","RAC4"]}},{"id":"a2de8a3f647342868f51cf78b08e2293","type":"GENE","name":"RAC1P5","canonical_id":"hgnc:HGNC:30593","description":"Rac family small GTPase 1 pseudogene 5","metadata":{"aliases":["Psi1Rac1"]}},{"id":"957eb6c74ce34266a1fe5fcf9bb4b8cf","type":"GENE","name":"RAC1P6","canonical_id":"hgnc:HGNC:42006","description":"Rac family small GTPase 1 pseudogene 6","metadata":null},{"id":"933dbe4202e6436f84bb791ab8c1bd77","type":"GENE","name":"RAC1P7","canonical_id":"hgnc:HGNC:42007","description":"Rac family small GTPase 1 pseudogene 7","metadata":null},{"id":"3d30df473351450bbe63fd387a5aa02c","type":"GENE","name":"RAC1P8","canonical_id":"hgnc:HGNC:42005","description":"Rac family small GTPase 1 pseudogene 8","metadata":null},{"id":"09e4bc77ecbb4d9eb6685ec7bcb691ce","type":"GENE","name":"RAC1P9","canonical_id":"hgnc:HGNC:50774","description":"Rac family small GTPase 1 pseudogene 9","metadata":null},{"id":"072233bcfe3e40039fc2c458e4144ec0","type":"GENE","name":"RAC2","canonical_id":"hgnc:HGNC:9802","description":"Rac family small GTPase 2","metadata":{"aliases":["EN-7"]}},{"id":"6c8302f5d5cf41a8a7e809f65583e5a9","type":"GENE","name":"RAC3","canonical_id":"hgnc:HGNC:9803","description":"Rac family small GTPase 3","metadata":null},{"id":"5b3de2421fb24cbaa0d367ff8f85d642","type":"TRIAL","name":"RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial","canonical_id":"clinicaltrials.gov:NCT05049668","description":"Severe Aplastic Anemia","metadata":null},{"id":"804d754d49e9439b8661b56a1081eb05","type":"GENE","name":"RACGAP1","canonical_id":"hgnc:HGNC:9804","description":null,"metadata":null},{"id":"bcfeb57e9d5b48038b8e68c25ca4312b","type":"GENE","name":"RACGAP1P1","canonical_id":"hgnc:HGNC:24689","description":"Rac GTPase activating protein 1 pseudogene 1","metadata":{"aliases":["FKSG42","RACGAP1P"]}},{"id":"9735bf0c8af94206a3b7a287e47a37ce","type":"GENE","name":"RACK1","canonical_id":"hgnc:HGNC:4399","description":"receptor for activated C kinase 1","metadata":{"aliases":["Gnb2-rs1","H12.3","GNB2L1"]}},{"id":"3d6c4ed75dc14ec4882127cd7cad9024","type":"GENE","name":"RACK1P1","canonical_id":"hgnc:HGNC:55463","description":"RACK1 pseudogene 1","metadata":null},{"id":"46eef236c26049a2928165bfffad56b2","type":"GENE","name":"RACK1P2","canonical_id":"hgnc:HGNC:55464","description":"RACK1 pseudogene 2","metadata":null},{"id":"ec3532674e544542843f371b723ae54d","type":"GENE","name":"RACK1P3","canonical_id":"hgnc:HGNC:55465","description":"RACK1 pseudogene 3","metadata":null},{"id":"d61ccfee38fd45298630ac496e968ecb","type":"TRIAL","name":"RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma","canonical_id":"clinicaltrials.gov:NCT01252251","description":"Uveal Melanoma","metadata":null},{"id":"370f4129610e44ec952b21a786e2ed7a","type":"TRIAL","name":"RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00968253","description":"Leukemia; Acute Lymphocytic Leukemia","metadata":null},{"id":"6fcaae7e4e824db69e8fdc584578a85c","type":"TRIAL","name":"RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01058655","description":"Gastrointestinal Cancer","metadata":null},{"id":"68150d9916654492b6275aab0bd6a9d4","type":"TRIAL","name":"RAD001 and Bicalutamide for Androgen Independent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00630344","description":"Prostate Cancer","metadata":null},{"id":"5f788c227598479792bdbd6ae0124fbf","type":"TRIAL","name":"RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.","canonical_id":"clinicaltrials.gov:NCT01188889","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"af77f75588c049b8a2d28b8a6bed7f1f","type":"GENE","name":"RAD1","canonical_id":"hgnc:HGNC:9806","description":"RAD1 checkpoint DNA exonuclease","metadata":{"aliases":["HRAD1","REC1"]}},{"id":"778a0e8a0f014aa9a0b7a4780cc1555e","type":"GENE","name":"RAD17","canonical_id":"hgnc:HGNC:9807","description":"RAD17 checkpoint clamp loader component","metadata":{"aliases":["Rad24","RAD17Sp","CCYC"]}},{"id":"d02ca359f1fd42079d43ddefc1b85f75","type":"GENE","name":"RAD17P1","canonical_id":"hgnc:HGNC:9808","description":"RAD17 pseudogene 1","metadata":{"aliases":["HRAD17P1"]}},{"id":"904a6c5938ec48da932ed6381f4b01c5","type":"GENE","name":"RAD17P2","canonical_id":"hgnc:HGNC:9809","description":"RAD17 pseudogene 2","metadata":{"aliases":["HRAD17P2"]}},{"id":"a68680b8ffdb41769e32326133187487","type":"GENE","name":"RAD18","canonical_id":"hgnc:HGNC:18278","description":"RAD18 E3 ubiquitin protein ligase","metadata":{"aliases":["RNF73"]}},{"id":"04fb81c603084465816ad72f7e37afbb","type":"GENE","name":"RAD1P1","canonical_id":"hgnc:HGNC:49479","description":"RAD1 pseudogene 1","metadata":null},{"id":"0034ed4501784cb790b830c53970730f","type":"GENE","name":"RAD1P2","canonical_id":"hgnc:HGNC:49480","description":"RAD1 pseudogene 2","metadata":null},{"id":"958f1eae45204f19b423bde9bde8de2f","type":"GENE","name":"RAD21","canonical_id":"hgnc:HGNC:9811","description":null,"metadata":null},{"id":"7493e03d3b7c47759358b4318e604f6c","type":"GENE","name":"RAD21-AS1","canonical_id":"hgnc:HGNC:32158","description":"RAD21 antisense RNA 1","metadata":{"aliases":["C8orf81","NCRNA00255"]}},{"id":"42f50c44b918493da1f58fd326f8dfe3","type":"GENE","name":"RAD21L1","canonical_id":"hgnc:HGNC:16271","description":"RAD21 cohesin complex component like 1","metadata":{"aliases":["dJ545L17.2","RAD21L"]}},{"id":"3d1ea5167b6249d6b9a21a0ebf64cefc","type":"GENE","name":"RAD21P1","canonical_id":"hgnc:HGNC:55032","description":"RAD21 pseudogene 1","metadata":null},{"id":"65e9356aa319424c96028a052aeb7b1c","type":"GENE","name":"RAD23A","canonical_id":"hgnc:HGNC:9812","description":"RAD23 nucleotide excision repair protein A","metadata":{"aliases":["HHR23A","MGC111083"]}},{"id":"750a49148995487486515bc7c2df41bf","type":"GENE","name":"RAD23B","canonical_id":"hgnc:HGNC:9813","description":"RAD23 nucleotide excision repair protein B","metadata":{"aliases":["HHR23B","P58","HR23B"]}},{"id":"2b0af173abc44221bd922d4aca9ac624","type":"GENE","name":"RAD23BP1","canonical_id":"hgnc:HGNC:44509","description":"RAD23B pseudogene 1","metadata":null},{"id":"fc7bfedc82e841ca93d2bd0aff26b233","type":"GENE","name":"RAD23BP2","canonical_id":"hgnc:HGNC:44510","description":"RAD23B pseudogene 2","metadata":null},{"id":"d7534e1132654128a8b5b3c34b38550c","type":"GENE","name":"RAD23BP3","canonical_id":"hgnc:HGNC:9814","description":"RAD23B pseudogene 3","metadata":{"aliases":["RAD23BLP"]}},{"id":"db328451929e421780598ae9b5f58e42","type":"GENE","name":"RAD50","canonical_id":"hgnc:HGNC:9816","description":"RAD50 double strand break repair protein","metadata":{"aliases":["hRad50","RAD50-2"]}},{"id":"d66c7465046e439299d4c8992496157b","type":"GENE","name":"RAD51","canonical_id":"hgnc:HGNC:9817","description":null,"metadata":null},{"id":"991e90cfff2d4462a0a0fd54d14cd8f9","type":"GENE","name":"RAD51-AS1","canonical_id":"hgnc:HGNC:48621","description":"RAD51 antisense RNA 1","metadata":{"aliases":["TODRA"]}},{"id":"cf70dabc70524f2593d5595f631211c5","type":"GENE","name":"RAD51AP1","canonical_id":"hgnc:HGNC:16956","description":null,"metadata":null},{"id":"e0dd6f0c28b0486a8ca9ee0c0126e832","type":"GENE","name":"RAD51AP1P1","canonical_id":"hgnc:HGNC:49646","description":"RAD51AP1 pseudogene 1","metadata":null},{"id":"5d6017867d2e4fd9972b4f88fffb7719","type":"GENE","name":"RAD51AP2","canonical_id":"hgnc:HGNC:34417","description":"RAD51 associated protein 2","metadata":{"aliases":["FLJ17540"]}},{"id":"e5537b1cd24d4992b3ace1fe9e914114","type":"GENE","name":"RAD51B","canonical_id":"hgnc:HGNC:9822","description":null,"metadata":null},{"id":"8743e0c57e0b442599d5fa35e8361765","type":"GENE","name":"RAD51B-AS1","canonical_id":"hgnc:HGNC:58171","description":"RAD51B antisense RNA 1","metadata":{"aliases":["CTD-2566J3.1"]}},{"id":"dc49e00c031c4de3b3679dda99628ffc","type":"GENE","name":"RAD51C","canonical_id":"hgnc:HGNC:9820","description":"RAD51 paralog C","metadata":{"aliases":["RAD51L2","FANCO"]}},{"id":"8d0c8b25973945999b1c7850b465c4e6","type":"GENE","name":"RAD51D","canonical_id":"hgnc:HGNC:9823","description":"RAD51 paralog D","metadata":{"aliases":["R51H3","Trad","HsTRAD","RAD51L3"]}},{"id":"ca18eb9d2a344e53a99ad9a22684e1e0","type":"GENE","name":"RAD52","canonical_id":"hgnc:HGNC:9824","description":"RAD52 DNA repair protein","metadata":null},{"id":"b0d97e9f7dec4b27a2ce9682b4d6d261","type":"GO_TERM","name":"RAD52-ERCC4-ERCC1 complex","canonical_id":"go:GO:0070312","description":"\"A nucleotide-excision repair complex formed by the association of the heterodimeric endonuclease XPF/ERCC4-ERCC1 (Rad1p and Rad10p in S. cerevisiae) with the RAD52 protein.\" [PMID:14734547]","metadata":null},{"id":"c85e19a687eb43eb92c0fe846997e581","type":"GENE","name":"RAD52P1","canonical_id":"hgnc:HGNC:54559","description":"RAD52 pseudogene 1","metadata":null},{"id":"52fd32f8a1004b009a0be4438df048d2","type":"GENE","name":"RAD54B","canonical_id":"hgnc:HGNC:17228","description":"RAD54 homolog B","metadata":{"aliases":["RDH54"]}},{"id":"1fdecdc83ed245d3a6a6d722e802dcf1","type":"GENE","name":"RAD54L","canonical_id":"hgnc:HGNC:9826","description":"RAD54 like","metadata":{"aliases":["hHR54","hRAD54","RAD54A"]}},{"id":"f9d1a87d6b724bf3960feda999bfaf9e","type":"GENE","name":"RAD54L2","canonical_id":"hgnc:HGNC:29123","description":"RAD54 like 2","metadata":{"aliases":["KIAA0809","SRISNF2L","ARIP4"]}},{"id":"e87cc2f23a114d858a7220c288c9b7c5","type":"GENE","name":"RAD54L2P1","canonical_id":"hgnc:HGNC:54570","description":"RAD54L2 pseudogene 1","metadata":null},{"id":"df57307e3f6c42a8822d4fa832de119b","type":"GO_TERM","name":"RAD6-UBR2 ubiquitin ligase complex","canonical_id":"go:GO:1990305","description":"\"A ubiquitin ligase complex consisting of RAD6 and UBR2 components. It may act in a quality control pathway for proteins synthesized on cytosolic ribosomes. The UBR2 component lacks sequence motifs required for N-end rule degradation.\" [GOC:bhm, PMID:15504724]","metadata":null},{"id":"346b2b4c53fe42e2977ad0129180cbc7","type":"GENE","name":"RAD9A","canonical_id":"hgnc:HGNC:9827","description":null,"metadata":null},{"id":"408fe34e0c834ae08ffeb3cb24eb931f","type":"GENE","name":"RAD9B","canonical_id":"hgnc:HGNC:21700","description":"RAD9 checkpoint clamp component B","metadata":{"aliases":["FLJ40346"]}},{"id":"c8643cb2fd284acebef37610be08af39","type":"GO_TERM","name":"RADAR pathway","canonical_id":"go:GO:0170074","description":"\"A quality control pathway that degrades peroxisomal matrix protein receptors when the recycling machinery is blocked. When recycling to the cytosol fails, cargo-free receptors accumulate at the peroxisomal membrane, where they are polyubiquitinated and subsequently degraded by the ubiquitin-proteasome system (UPS).\" [PMID:16390998, PMID:17011644, PMID:41076631]","metadata":null},{"id":"d07ed4637edc43e09457b505a4c834b0","type":"TRIAL","name":"RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07808138","description":"Non Small Cell Lung Cancer; Immunotherapy","metadata":null},{"id":"9967fff0b9c641418a58d2e531050cb1","type":"GENE","name":"RADIL","canonical_id":"hgnc:HGNC:22226","description":"Rap associating with DIL domain","metadata":{"aliases":["FLJ10324","KIAA1849","RASIP2"]}},{"id":"10cc7bb9bbc04a4db2340e20da69da97","type":"TRIAL","name":"RADVAX\u2122: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA","canonical_id":"clinicaltrials.gov:NCT01497808","description":"Metastatic Melanoma","metadata":null},{"id":"14acb8ce21e9494db79a9a9082feef6a","type":"GENE","name":"RADX","canonical_id":"hgnc:HGNC:25486","description":"RPA1 related single stranded DNA binding protein, X-linked","metadata":{"aliases":["FLJ14191","FLJ10178","CXorf57"]}},{"id":"00010ed37eae48958dac3b60531294c2","type":"GENE","name":"RAE1","canonical_id":"hgnc:HGNC:9828","description":"ribonucleic acid export 1","metadata":{"aliases":["Mnrp41","Gle2"]}},{"id":"7c00185bb8da4c618ac8d382bccdfa87","type":"GENE","name":"RAET1E","canonical_id":"hgnc:HGNC:16793","description":"retinoic acid early transcript 1E","metadata":{"aliases":["LETAL","bA350J20.7","ULBP4"]}},{"id":"49f94eb53cc24c2dbe3bd7b110a6daba","type":"GENE","name":"RAET1E-AS1","canonical_id":"hgnc:HGNC:48994","description":"RAET1E antisense RNA 1","metadata":{"aliases":["RAET1G-AS1"]}},{"id":"9b6e2dc896e0430694aa00b9283e6421","type":"GENE","name":"RAET1F","canonical_id":"hgnc:HGNC:16794","description":"retinoic acid early transcript 1F (pseudogene)","metadata":null},{"id":"643da2bc667a4d8bb0bda9866cda4381","type":"GENE","name":"RAET1G","canonical_id":"hgnc:HGNC:16795","description":"retinoic acid early transcript 1G","metadata":{"aliases":["ULBP5"]}},{"id":"5d08aee4cfe14253be6269e256207671","type":"GENE","name":"RAET1K","canonical_id":"hgnc:HGNC:16797","description":"retinoic acid early transcript 1K (pseudogene)","metadata":null},{"id":"991bd518b4944b789b44ba6a30a3acbf","type":"GENE","name":"RAET1L","canonical_id":"hgnc:HGNC:16798","description":"retinoic acid early transcript 1L","metadata":null},{"id":"093a4a15d5b0447f9131af20a34fe548","type":"GENE","name":"RAET1M","canonical_id":"hgnc:HGNC:16799","description":"retinoic acid early transcript 1M (pseudogene)","metadata":null},{"id":"9ef92b640941435891e08be7f183fc4e","type":"GENE","name":"RAF1","canonical_id":"hgnc:HGNC:9829","description":"Raf-1 proto-oncogene, serine/threonine kinase","metadata":{"aliases":["Raf-1","c-Raf","CRAF"]}},{"id":"b30c69b80dd74b0baf4caf3f22ae32fe","type":"PROTEIN","name":"RAF1","canonical_id":"uniprot:P04049","description":null,"metadata":null},{"id":"147a699b7404450e9fada7e254643a12","type":"GENE","name":"RAF1P1","canonical_id":"hgnc:HGNC:9830","description":"RAF1 pseudogene 1","metadata":null},{"id":"d8b2173c97014e32a1731bdd1300fbdc","type":"GENE","name":"RAG1","canonical_id":"hgnc:HGNC:9831","description":null,"metadata":null},{"id":"add5d40011524f20a3ac8d6d79dc0311","type":"GENE","name":"RAG2","canonical_id":"hgnc:HGNC:9832","description":null,"metadata":null},{"id":"63a3cc88d8eb4d4fb739c2b9d8a67ceb","type":"GO_TERM","name":"RAGE receptor binding","canonical_id":"go:GO:0050786","description":"\"Binding to a RAGE receptor, the receptor for advanced glycation end-products.\" [GOC:ai]","metadata":null},{"id":"9f4227ea2f7f4a8d856e1c5d3cfe9de2","type":"GENE","name":"RAI1","canonical_id":"hgnc:HGNC:9834","description":"retinoic acid induced 1","metadata":{"aliases":["DKFZP434A139","SMS","KIAA1820","MGC12824","SMCR"]}},{"id":"fca96c498a5743a098b3d55622380887","type":"GENE","name":"RAI1-AS1","canonical_id":"hgnc:HGNC:40496","description":"RAI1 antisense RNA 1","metadata":null},{"id":"a2ed3ed6c88047bdb6c20ac4f46f0815","type":"GENE","name":"RAI14","canonical_id":"hgnc:HGNC:14873","description":"retinoic acid induced 14","metadata":{"aliases":["NORPEG","KIAA1334","RAI13","DKFZp564G013"]}},{"id":"1007b4512c7d4c3dad66bf267fec58df","type":"GENE","name":"RAI14-DT","canonical_id":"hgnc:HGNC:55983","description":"RAI14 divergent transcript","metadata":null},{"id":"107832ae401c4ff6aabd8402cd3fab8b","type":"GENE","name":"RAI2","canonical_id":"hgnc:HGNC:9835","description":"retinoic acid induced 2","metadata":null},{"id":"93b453a554c3444cac2636496a3f5378","type":"GENE","name":"RALA","canonical_id":"hgnc:HGNC:9839","description":"RAS like proto-oncogene A","metadata":{"aliases":["RAL"]}},{"id":"716909be2b5c4329adc9ee8e1150c5d2","type":"GENE","name":"RALB","canonical_id":"hgnc:HGNC:9840","description":"RAS like proto-oncogene B","metadata":null},{"id":"2f93d3950b0f4c4088e6bc9374d6056e","type":"GENE","name":"RALBP1","canonical_id":"hgnc:HGNC:9841","description":"ralA binding protein 1","metadata":{"aliases":["RLIP76","RIP1","RIP"]}},{"id":"2d83a39f6578458c92c8756b3af50ac7","type":"GENE","name":"RALBP1P1","canonical_id":"hgnc:HGNC:54696","description":"RALBP1 pseudogene 1","metadata":null},{"id":"7e74b867f2e74bebb77b0759a1f9a946","type":"GENE","name":"RALBP1P2","canonical_id":"hgnc:HGNC:54697","description":"RALBP1 pseudogene 2","metadata":null},{"id":"d0e4963952464b36a62a28734891b2ea","type":"GENE","name":"RALGAPA1","canonical_id":"hgnc:HGNC:17770","description":"Ral GTPase activating protein catalytic subunit alpha 1","metadata":{"aliases":["GRIPE","DKFZp667F074","KIAA0884","Tulip1","RalGAPalpha1","GARNL1"]}},{"id":"8277b3545b51492284367b8ee73d67d4","type":"GENE","name":"RALGAPA1P1","canonical_id":"hgnc:HGNC:23203","description":"RALGAPA1 pseudogene 1","metadata":{"aliases":["DKFZp566D133","GARNL2","GARNL2P","RALGAPA1P"]}},{"id":"27404bc83902434cbedb530b667204d8","type":"GENE","name":"RALGAPA2","canonical_id":"hgnc:HGNC:16207","description":"Ral GTPase activating protein catalytic subunit alpha 2","metadata":{"aliases":["dJ1049G11.4","AS250","KIAA1272","RapGAPalpha2","C20orf74"]}},{"id":"7d089886b9ac4505ad9e6ff79c80407f","type":"GENE","name":"RALGAPB","canonical_id":"hgnc:HGNC:29221","description":"Ral GTPase activating protein non-catalytic subunit beta","metadata":{"aliases":["DKFZp781M2411","RalGAPbeta","KIAA1219"]}},{"id":"b48065d3a7b4447db045bb590632baa6","type":"GENE","name":"RALGDS","canonical_id":"hgnc:HGNC:9842","description":"ral guanine nucleotide dissociation stimulator","metadata":{"aliases":["RGF","RalGEF","RGDS"]}},{"id":"fa6cbc8ebaef4b91a06fe4ce1f52d12c","type":"GENE","name":"RALGPS1","canonical_id":"hgnc:HGNC:16851","description":"Ral GEF with PH domain and SH3 binding motif 1","metadata":{"aliases":["RALGPS1A","RALGEF2","KIAA0351"]}},{"id":"313dd05b404746949b0f68b556c36f53","type":"GENE","name":"RALGPS2","canonical_id":"hgnc:HGNC:30279","description":"Ral GEF with PH domain and SH3 binding motif 2","metadata":{"aliases":["KIAA0351","FLJ10244","FLJ25604"]}},{"id":"c577231e15c94891a574ebdf89382dde","type":"GENE","name":"RALGPS2-AS1","canonical_id":"hgnc:HGNC:55163","description":"RALGPS2 antisense RNA 1","metadata":{"aliases":["lnc-ANGPTL1-3"]}},{"id":"9a3e5eab2afd4cb7a63f0f41ef4448f2","type":"TRIAL","name":"RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)","canonical_id":"clinicaltrials.gov:NCT03813641","description":"Colorectal Cancer","metadata":null},{"id":"f51e69604e84424e8e8ab32ea8eccbd3","type":"GENE","name":"RALY","canonical_id":"hgnc:HGNC:15921","description":"RALY heterogeneous nuclear ribonucleoprotein","metadata":{"aliases":["P542","HNRPCL2"]}},{"id":"f6d10cf8f4ba4709a680988bb5368acf","type":"GENE","name":"RALY-AS1","canonical_id":"hgnc:HGNC:50743","description":"RALY antisense RNA 1","metadata":null},{"id":"931b4033e87c4d669354d73c6f115ff0","type":"GENE","name":"RALYL","canonical_id":"hgnc:HGNC:27036","description":"RALY RNA binding protein like","metadata":{"aliases":["HNRPCL3"]}},{"id":"5a6dca833c9649529e68a51c2375a775","type":"GO_TERM","name":"RAM/MOR signaling","canonical_id":"go:GO:0062200","description":"\"An intracellular signaling cascade that starts with the activation of S. cerevisiae Kic1p, which activate Mob2p and Cbk1p. Cbk1p phosphorylates Ace2p, which results in its nuclear translocation, where it regulates transcription of genes involved in polarity and morphogenesis.\" [PMID:15731009, PMID:16096637, PMID:20805322, PMID:20826805, PMID:21246752, PMID:22629372, PMID:23212898]","metadata":null},{"id":"a5e05e7ec9dc4be8bc6d826156d2f2a3","type":"GENE","name":"RAMAC","canonical_id":"hgnc:HGNC:31022","description":"RNA guanine-7 methyltransferase activating subunit","metadata":{"aliases":["HsT19360","C15orf18","MGC2560","RAM","FAM103A1","RAMMET"]}},{"id":"839ab312c0e9401e97ab69efab00d901","type":"GENE","name":"RAMACL","canonical_id":"hgnc:HGNC:21234","description":"RNA guanine-7 methyltransferase activating subunit like","metadata":{"aliases":["dJ427A4.2","C6orf119","FAM103A2P","RAMMETL"]}},{"id":"2e34917c4487436c8a5a306560dfdf1a","type":"GENE","name":"RAMP1","canonical_id":"hgnc:HGNC:9843","description":"receptor activity modifying protein 1","metadata":null},{"id":"6a188c7be0e640ae9fe76efb2d39710c","type":"GENE","name":"RAMP2","canonical_id":"hgnc:HGNC:9844","description":"receptor activity modifying protein 2","metadata":null},{"id":"240ba25af12c4df5a134279fa99c2f72","type":"GENE","name":"RAMP2-AS1","canonical_id":"hgnc:HGNC:44358","description":"RAMP2 antisense RNA 1","metadata":null},{"id":"4d371a18bb364682953a7ad42cccdff8","type":"GENE","name":"RAMP3","canonical_id":"hgnc:HGNC:9845","description":"receptor activity modifying protein 3","metadata":null},{"id":"379fb596428e4f90bada31b55ed6246e","type":"GENE","name":"RAN","canonical_id":"hgnc:HGNC:9846","description":"RAN, member RAS oncogene family","metadata":{"aliases":["ARA24","TC4","Gsp1"]}},{"id":"f87a60335fee4251a4b327b696d44328","type":"GENE","name":"RANBP1","canonical_id":"hgnc:HGNC:9847","description":"RAN binding protein 1","metadata":{"aliases":["HTF9A"]}},{"id":"493a051ee11d4e38bca68eee06b1f123","type":"GENE","name":"RANBP10","canonical_id":"hgnc:HGNC:29285","description":"RAN binding protein 10","metadata":{"aliases":["KIAA1464"]}},{"id":"d6f56489383546508211fdc1aef74191","type":"GENE","name":"RANBP17","canonical_id":"hgnc:HGNC:14428","description":"RAN binding protein 17","metadata":null},{"id":"24c318fa04ec40208932cb7801bfb5bf","type":"GENE","name":"RANBP1P1","canonical_id":"hgnc:HGNC:54908","description":"RANBP1 pseudogene 1","metadata":null},{"id":"ceb822919d40414b846191757fdac694","type":"GENE","name":"RANBP2","canonical_id":"hgnc:HGNC:9848","description":"RAN binding protein 2","metadata":{"aliases":["NUP358","ADANE","ANE1"]}},{"id":"c0896f0ebc994e82a593880da2c488c2","type":"GENE","name":"RANBP3","canonical_id":"hgnc:HGNC:9850","description":"RAN binding protein 3","metadata":null},{"id":"b6986fd4cde442cfbf334e579e2450a7","type":"GENE","name":"RANBP3-DT","canonical_id":"hgnc:HGNC:55312","description":"RANBP3 divergent transcript","metadata":null},{"id":"4f4c0521b1d242de839889c9d87ee88d","type":"GENE","name":"RANBP3L","canonical_id":"hgnc:HGNC:26353","description":"RAN binding protein 3 like","metadata":{"aliases":["FLJ25422"]}},{"id":"fe1ac72604634e6fafedea0f75dfe26a","type":"GENE","name":"RANBP6","canonical_id":"hgnc:HGNC:9851","description":"RAN binding protein 6","metadata":null},{"id":"a008feacafc2461f99954b9ac09e2bb7","type":"GENE","name":"RANBP9","canonical_id":"hgnc:HGNC:13727","description":"RAN binding protein 9","metadata":{"aliases":["RanBPM"]}},{"id":"ecfa356d1d534a2dae5115c3b534d2cf","type":"GENE","name":"RANBP9-AS1","canonical_id":"hgnc:HGNC:59357","description":"RANBP9 antisense RNA 1","metadata":null},{"id":"70777a06d56b488395646cb2eac4949b","type":"GENE","name":"RANGAP1","canonical_id":"hgnc:HGNC:9854","description":"Ran GTPase activating protein 1","metadata":{"aliases":["Fug1","KIAA1835","SD"]}},{"id":"fd575dbd36f942bba2b39730915cc343","type":"GENE","name":"RANGRF","canonical_id":"hgnc:HGNC:17679","description":"RAN guanine nucleotide release factor","metadata":{"aliases":["MOG1","HSPC165","HSPC236","RANGNRF"]}},{"id":"24554aa514d24a83b26a8ad722f2a21d","type":"GENE","name":"RANP1","canonical_id":"hgnc:HGNC:21631","description":"RAN pseudogene 1","metadata":{"aliases":["Em:AB014080.2"]}},{"id":"7b364b4ef55b405e94b54ffdd30c72e8","type":"GENE","name":"RANP2","canonical_id":"hgnc:HGNC:39857","description":"RAN pseudogene 2","metadata":null},{"id":"cad5befd61454ca99521d8b169050a7e","type":"GENE","name":"RANP3","canonical_id":"hgnc:HGNC:39858","description":"RAN pseudogene 3","metadata":null},{"id":"3a501aa7172146b89240c4206168aff1","type":"GENE","name":"RANP4","canonical_id":"hgnc:HGNC:39859","description":"RAN pseudogene 4","metadata":null},{"id":"9953b2b5faa041bc9d45c3f8b8c69ec0","type":"GENE","name":"RANP5","canonical_id":"hgnc:HGNC:39860","description":"RAN pseudogene 5","metadata":null},{"id":"6b9f8a4afec84a79b028c8f13094ff6f","type":"GENE","name":"RANP6","canonical_id":"hgnc:HGNC:39861","description":"RAN pseudogene 6","metadata":null},{"id":"fee7710de4c64a159d6a9d3a8a58f95a","type":"GENE","name":"RANP7","canonical_id":"hgnc:HGNC:39862","description":"RAN pseudogene 7","metadata":null},{"id":"e1bb33e26e154106b6777bcebb9f9e70","type":"GENE","name":"RANP8","canonical_id":"hgnc:HGNC:39863","description":"RAN pseudogene 8","metadata":null},{"id":"bdb2e787e797478f983113c728645e2b","type":"GENE","name":"RANP9","canonical_id":"hgnc:HGNC:39864","description":"RAN pseudogene 9","metadata":null},{"id":"b5f752ab549644cf943bb433fce21ff8","type":"GENE","name":"RAP1A","canonical_id":"hgnc:HGNC:9855","description":null,"metadata":null},{"id":"15e46da74d2740c9bb3f1acb6b91995d","type":"GENE","name":"RAP1AP","canonical_id":"hgnc:HGNC:9856","description":"RAP1A, member of RAS oncogene family pseudogene","metadata":{"aliases":["KREV1P","SMGP21A"]}},{"id":"eae89b6424a04d2ba51f2e48c519adff","type":"GENE","name":"RAP1B","canonical_id":"hgnc:HGNC:9857","description":"RAP1B, member of RAS oncogene family","metadata":{"aliases":["K-REV","RAL1B","DKFZp586H0723"]}},{"id":"1f7c48cdf6094d128c9c7e00c143fd24","type":"GENE","name":"RAP1BL","canonical_id":"hgnc:HGNC:55079","description":"RAP1B like (pseudogene)","metadata":{"aliases":["hRap1B-retro"]}},{"id":"4ee8743ef29a417183430446cc9459d4","type":"GENE","name":"RAP1BP1","canonical_id":"hgnc:HGNC:49780","description":"RAP1B pseudogene 1","metadata":null},{"id":"ecbbc0a9ddc1464a8bdf849834cf2b3e","type":"GENE","name":"RAP1BP2","canonical_id":"hgnc:HGNC:49781","description":"RAP1B pseudogene 2","metadata":null},{"id":"6519702ef81e40d78fe955a8f635d018","type":"GENE","name":"RAP1BP3","canonical_id":"hgnc:HGNC:49782","description":"RAP1B pseudogene 3","metadata":null},{"id":"d2e325aafe69475f9b1c802e5ed8a588","type":"GENE","name":"RAP1GAP","canonical_id":"hgnc:HGNC:9858","description":"RAP1 GTPase activating protein","metadata":{"aliases":["KIAA0474","RAP1GAP1","RAP1GAPII","RAP1GA1"]}},{"id":"da1638da75fd4167bd32ced4fc8099e7","type":"GENE","name":"RAP1GAP2","canonical_id":"hgnc:HGNC:29176","description":"RAP1 GTPase activating protein 2","metadata":{"aliases":["KIAA1039","GARNL4"]}},{"id":"e472b93503bd4c7c83bf109901ae5a5b","type":"GENE","name":"RAP1GAP2-AS1","canonical_id":"hgnc:HGNC:58549","description":"RAP1GAP2 antisense RNA 1","metadata":null},{"id":"e37f546eee84497aa60da145d2805723","type":"GENE","name":"RAP1GDS1","canonical_id":"hgnc:HGNC:9859","description":"Rap1 GTPase-GDP dissociation stimulator 1","metadata":{"aliases":["SmgGDS"]}},{"id":"425c324020674eb3ae39ef1921f953e9","type":"GENE","name":"RAP1GDS1-AS1","canonical_id":"hgnc:HGNC:58856","description":"RAP1GDS1 antisense RNA 1","metadata":null},{"id":"6b32b719172140e7bc23cf8fb85d36cc","type":"GENE","name":"RAP2A","canonical_id":"hgnc:HGNC:9861","description":"RAP2A, member of RAS oncogene family","metadata":{"aliases":["K-REV","RAP2"]}},{"id":"842563b6a4124c1aa8b729fd37ad1083","type":"GENE","name":"RAP2B","canonical_id":"hgnc:HGNC:9862","description":"RAP2B, member of RAS oncogene family","metadata":null},{"id":"6c2256f99d5e42aab5e4a30736befe01","type":"GENE","name":"RAP2C","canonical_id":"hgnc:HGNC:21165","description":"RAP2C, member of RAS oncogene family","metadata":{"aliases":["DKFZp313B211"]}},{"id":"05eca086b00b48308de3474aaea92787","type":"GENE","name":"RAP2C-AS1","canonical_id":"hgnc:HGNC:40957","description":"RAP2C antisense RNA 1","metadata":null},{"id":"f92ac7854b5c42038bb69da73cd7bd4b","type":"GENE","name":"RAP2CP1","canonical_id":"hgnc:HGNC:49146","description":"RAP2C pseudogene 1","metadata":null},{"id":"e7dd625c94bb448f9b91823cfccad664","type":"GENE","name":"RAPGEF1","canonical_id":"hgnc:HGNC:4568","description":"Rap guanine nucleotide exchange factor 1","metadata":{"aliases":["C3G","GRF2"]}},{"id":"b48c43445ae64ba78fdd7980015dd985","type":"GENE","name":"RAPGEF2","canonical_id":"hgnc:HGNC:16854","description":"Rap guanine nucleotide exchange factor 2","metadata":{"aliases":["PDZ-GEF1","RA-GEF","DKFZP586O1422","KIAA0313","PDZGEF1"]}},{"id":"302be7bee2334b489c17b2ff3e9f1df4","type":"GENE","name":"RAPGEF3","canonical_id":"hgnc:HGNC:16629","description":"Rap guanine nucleotide exchange factor 3","metadata":{"aliases":["cAMP-GEFI","EPAC","bcm910"]}},{"id":"0398ef7cf17142358b38b926f23982d0","type":"GENE","name":"RAPGEF4","canonical_id":"hgnc:HGNC:16626","description":"Rap guanine nucleotide exchange factor 4","metadata":{"aliases":["cAMP-GEFII","CGEF2"]}},{"id":"4e0567578fa940a5830799153efc6904","type":"GENE","name":"RAPGEF4-AS1","canonical_id":"hgnc:HGNC:28081","description":"RAPGEF4 antisense RNA 1","metadata":null},{"id":"2772d632f8d943c0b278e50ea29927c9","type":"GENE","name":"RAPGEF5","canonical_id":"hgnc:HGNC:16862","description":"Rap guanine nucleotide exchange factor 5","metadata":{"aliases":["KIAA0277","GFR","MR-GEF"]}},{"id":"c4ca8eda85c3448891156ce56f984477","type":"GENE","name":"RAPGEF6","canonical_id":"hgnc:HGNC:20655","description":"Rap guanine nucleotide exchange factor 6","metadata":{"aliases":["RA-GEF-2","PDZ-GEF2","PDZGEF2"]}},{"id":"58c668a5058d4329987fc4e705dff940","type":"GENE","name":"RAPGEFL1","canonical_id":"hgnc:HGNC:17428","description":"Rap guanine nucleotide exchange factor like 1","metadata":{"aliases":["Link-GEFII"]}},{"id":"c3fad93549e3409ebc656a8744e2abca","type":"GENE","name":"RAPH1","canonical_id":"hgnc:HGNC:14436","description":"Ras association (RalGDS/AF-6) and pleckstrin homology domains 1","metadata":{"aliases":["Lpd","KIAA1681","ALS2CR9","ALS2CR18"]}},{"id":"6b94a6d7e17d41be93fe6791227d3267","type":"GENE","name":"RAPSN","canonical_id":"hgnc:HGNC:9863","description":"receptor associated protein of the synapse","metadata":{"aliases":["RNF205","CMS1D","CMS1E"]}},{"id":"2eabaaa84959434da3df2a09e764da3b","type":"GENE","name":"RARA","canonical_id":"hgnc:HGNC:9864","description":null,"metadata":null},{"id":"62d2bf10655c40fe8d059f19aaf31fb8","type":"PROTEIN","name":"RARA","canonical_id":"uniprot:P10276","description":null,"metadata":null},{"id":"5ebad39516614c96be7648305b4479e7","type":"GENE","name":"RARA-AS1","canonical_id":"hgnc:HGNC:49577","description":"RARA antisense RNA 1","metadata":null},{"id":"71a9c33cf6724f9b9e95cd2596afc040","type":"GENE","name":"RARB","canonical_id":"hgnc:HGNC:9865","description":null,"metadata":null},{"id":"38ee8a0dbe774ca792ab2d0c575eb968","type":"PROTEIN","name":"RARB","canonical_id":"uniprot:P10826","description":null,"metadata":null},{"id":"65cc946236cb487c8da9046a84cd62f2","type":"GENE","name":"RARB-AS1","canonical_id":"hgnc:HGNC:54077","description":"RARB antisense RNA 1","metadata":null},{"id":"1a11fb30a8984746b4740a34471004d0","type":"GENE","name":"RARG","canonical_id":"hgnc:HGNC:9866","description":null,"metadata":null},{"id":"7aaed9c8850f402d80750a0591619826","type":"PROTEIN","name":"RARG","canonical_id":"uniprot:P13631","description":null,"metadata":null},{"id":"f6083b6973b442e3bfc1ea7486d09983","type":"GENE","name":"RARRES1","canonical_id":"hgnc:HGNC:9867","description":null,"metadata":null},{"id":"40efd4318c0440c4beea53803c2ef213","type":"GENE","name":"RARRES2","canonical_id":"hgnc:HGNC:9868","description":"retinoic acid receptor responder 2","metadata":{"aliases":["TIG2","HP10433"]}},{"id":"53ab52776f2542da8d455f4bd564f7ed","type":"GENE","name":"RARRES2P1","canonical_id":"hgnc:HGNC:48700","description":"retinoic acid receptor responder 2 pseudogene 1","metadata":null},{"id":"e37b20386573460fa60d8d2af1f3c6cd","type":"GENE","name":"RARRES2P10","canonical_id":"hgnc:HGNC:51742","description":"retinoic acid receptor responder 2 pseudogene 10","metadata":null},{"id":"acc24dd08077475486f3068ed6156231","type":"GENE","name":"RARRES2P11","canonical_id":"hgnc:HGNC:51743","description":"retinoic acid receptor responder 2 pseudogene 11","metadata":null},{"id":"f9627baf1d2c43fd96d1ae177eaf501c","type":"GENE","name":"RARRES2P2","canonical_id":"hgnc:HGNC:48701","description":"retinoic acid receptor responder 2 pseudogene 2","metadata":null},{"id":"486fa5d237af48ab8c5db916dc5336b0","type":"GENE","name":"RARRES2P3","canonical_id":"hgnc:HGNC:48702","description":"retinoic acid receptor responder 2 pseudogene 3","metadata":null},{"id":"a076b39de5aa42db874820db8e4d3a20","type":"GENE","name":"RARRES2P4","canonical_id":"hgnc:HGNC:48703","description":"retinoic acid receptor responder 2 pseudogene 4","metadata":null},{"id":"0b358a87567044ef9d0d7cf456a6eb63","type":"GENE","name":"RARRES2P5","canonical_id":"hgnc:HGNC:48704","description":"retinoic acid receptor responder 2 pseudogene 5","metadata":null},{"id":"7b67acd4a4804d02b5d5ce9985642b1c","type":"GENE","name":"RARRES2P6","canonical_id":"hgnc:HGNC:48705","description":"retinoic acid receptor responder 2 pseudogene 6","metadata":null},{"id":"69e008c4497a43019216ed436c02a57b","type":"GENE","name":"RARRES2P7","canonical_id":"hgnc:HGNC:48709","description":"retinoic acid receptor responder 2 pseudogene 7","metadata":null},{"id":"de04d012870d4da0bf318f40885200cf","type":"GENE","name":"RARRES2P8","canonical_id":"hgnc:HGNC:48707","description":"retinoic acid receptor responder 2 pseudogene 8","metadata":null},{"id":"3cf9e510ee1a423d8da86a0691256647","type":"GENE","name":"RARRES2P9","canonical_id":"hgnc:HGNC:48708","description":"retinoic acid receptor responder 2 pseudogene 9","metadata":null},{"id":"68a711b6abf34c398b6079064c43c79c","type":"GENE","name":"RARS1","canonical_id":"hgnc:HGNC:9870","description":"arginyl-tRNA synthetase 1","metadata":{"aliases":["DALRD1","RARS"]}},{"id":"d23a9731a7cd43b1a18b4b25a246a111","type":"GENE","name":"RARS1P1","canonical_id":"hgnc:HGNC:49893","description":"arginyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["RARSP1"]}},{"id":"3e209f1607ff445cad15304e255c5523","type":"GENE","name":"RARS2","canonical_id":"hgnc:HGNC:21406","description":"arginyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["MGC14993","MGC23778","PRO1992","dJ382I10.6","DALRD2","RARSL"]}},{"id":"1794982dc9514014a6616aa14f6cb3e6","type":"TRIAL","name":"RAS Quantification in Patients With Aliskiren or Candesartan","canonical_id":"clinicaltrials.gov:NCT01827202","description":"Hypertension; Chronic Kidney Disease; Proteinuria","metadata":null},{"id":"f2610265f87145fda773f76fefb88b5c","type":"GENE","name":"RASA1","canonical_id":"hgnc:HGNC:9871","description":"RAS p21 protein activator 1","metadata":{"aliases":["GAP","CM-AVM","p120GAP","p120RASGAP","p120","RASA"]}},{"id":"a55f7aaa195d42d395754ec1b316f280","type":"GENE","name":"RASA2","canonical_id":"hgnc:HGNC:9872","description":"RAS p21 protein activator 2","metadata":{"aliases":["GAP1M"]}},{"id":"84a6c66692e64524a19ad00e4eac2bf8","type":"GENE","name":"RASA2-IT1","canonical_id":"hgnc:HGNC:41376","description":"RASA2 intronic transcript 1","metadata":null},{"id":"06c7134c635b42b28a816cbad860c638","type":"GENE","name":"RASA3","canonical_id":"hgnc:HGNC:20331","description":"RAS p21 protein activator 3","metadata":{"aliases":["GAP1IP4BP","GAPIII"]}},{"id":"fa4f109f55634eb5bbccaea850d646d3","type":"GENE","name":"RASA3-IT1","canonical_id":"hgnc:HGNC:39938","description":"RASA3 intronic transcript 1","metadata":null},{"id":"486226d1cbc347b6a077be0deb4d65e3","type":"GENE","name":"RASA4","canonical_id":"hgnc:HGNC:23181","description":"RAS p21 protein activator 4","metadata":{"aliases":["KIAA0538","CAPRI","GAPL"]}},{"id":"1a8dca4188b8420ebac663af63849d77","type":"GENE","name":"RASA4B","canonical_id":"hgnc:HGNC:35202","description":"RAS p21 protein activator 4B","metadata":null},{"id":"fab8deb8c9ec4fe1b7d1267becea907f","type":"GENE","name":"RASA4CP","canonical_id":"hgnc:HGNC:44185","description":"RAS p21 protein activator 4C, pseudogene","metadata":null},{"id":"2952d1549e7849f09678ee32b43c5bac","type":"GENE","name":"RASA4DP","canonical_id":"hgnc:HGNC:44226","description":"RAS p21 protein activator 4D, pseudogene","metadata":null},{"id":"8189721ca61b4219a89d75b007bd79a7","type":"GENE","name":"RASA4EP","canonical_id":"hgnc:HGNC:55754","description":"RAS p21 protein activator 4E, pseudogene","metadata":null},{"id":"1c5b0b4bf6c84c57ba15b29a3c3131b9","type":"GENE","name":"RASAL1","canonical_id":"hgnc:HGNC:9873","description":"RAS protein activator like 1","metadata":{"aliases":["RASAL"]}},{"id":"8a8053878df24748be5944d4926a3d36","type":"GENE","name":"RASAL2","canonical_id":"hgnc:HGNC:9874","description":"RAS protein activator like 2","metadata":{"aliases":["nGAP"]}},{"id":"dbc41b449cc0486d9bf6bef3f50d4d19","type":"GENE","name":"RASAL2-AS1","canonical_id":"hgnc:HGNC:44170","description":"RASAL2 antisense RNA 1","metadata":null},{"id":"2f02865fd5d24dfbb387b52c5143e2bf","type":"GENE","name":"RASAL3","canonical_id":"hgnc:HGNC:26129","description":"RAS protein activator like 3","metadata":{"aliases":["FLJ21438"]}},{"id":"9d8c73e66da54658af2e8f6c9c3562ef","type":"GENE","name":"RASD1","canonical_id":"hgnc:HGNC:15828","description":"ras related dexamethasone induced 1","metadata":{"aliases":["DEXRAS1","AGS1"]}},{"id":"5a6c0b751e364019a5454fdded01be8c","type":"GENE","name":"RASD2","canonical_id":"hgnc:HGNC:18229","description":"RASD family member 2","metadata":{"aliases":["TEM2","Rhes","MGC:4834"]}},{"id":"567a8303f6bb4ece9e93d6f792a76a5b","type":"GENE","name":"RASEF","canonical_id":"hgnc:HGNC:26464","description":"RAS and EF-hand domain containing","metadata":{"aliases":["FLJ31614","TSG","RAB45"]}},{"id":"71557403df794a9580a47aa8ca9ed230","type":"GENE","name":"RASGEF1A","canonical_id":"hgnc:HGNC:24246","description":"RasGEF domain family member 1A","metadata":{"aliases":["CG4853","FLJ37817"]}},{"id":"88cbacbc332c4ba1b6ff2c758d3d4755","type":"GENE","name":"RASGEF1B","canonical_id":"hgnc:HGNC:24881","description":null,"metadata":null},{"id":"be3668c2a0f14886ad8eaff845608b7a","type":"GENE","name":"RASGEF1C","canonical_id":"hgnc:HGNC:27400","description":"RasGEF domain family member 1C","metadata":{"aliases":["FLJ35841"]}},{"id":"269d7d1e8cd74646ab465646b5048cfa","type":"GENE","name":"RASGRF1","canonical_id":"hgnc:HGNC:9875","description":"Ras protein specific guanine nucleotide releasing factor 1","metadata":{"aliases":["CDC25L","CDC25","GRF55","H-GRF55","GNRP","PP13187","GRF1"]}},{"id":"dc11b0b1dab5453bbcc9e0945a989c99","type":"GENE","name":"RASGRF2","canonical_id":"hgnc:HGNC:9876","description":"Ras protein specific guanine nucleotide releasing factor 2","metadata":{"aliases":["GRF2","Ras-GRF2"]}},{"id":"d96a549f296448c881810cfbf4211ed9","type":"GENE","name":"RASGRF2-AS1","canonical_id":"hgnc:HGNC:40499","description":"RASGRF2 antisense RNA 1","metadata":{"aliases":["CTC-459I6.1"]}},{"id":"d9a7d38d3d3c44179ee49e069afb25b4","type":"GENE","name":"RASGRF2-AS2","canonical_id":"hgnc:HGNC:59088","description":"RASGRF2 antisense RNA 2","metadata":null},{"id":"6304d46b8aea43dcbfffb1f348771df0","type":"GENE","name":"RASGRP1","canonical_id":"hgnc:HGNC:9878","description":null,"metadata":null},{"id":"961ac789e5484e969637be29b5877a6a","type":"GENE","name":"RASGRP2","canonical_id":"hgnc:HGNC:9879","description":"RAS guanyl releasing protein 2","metadata":{"aliases":["CALDAG-GEFI"]}},{"id":"ad3882b28607483185190d95411994b3","type":"GENE","name":"RASGRP3","canonical_id":"hgnc:HGNC:14545","description":null,"metadata":null},{"id":"0df49b45a07e46d1934bad672ea3e8b9","type":"GENE","name":"RASGRP3-AS1","canonical_id":"hgnc:HGNC:40689","description":"RASGRP3 antisense RNA 1","metadata":null},{"id":"9549d50f11c54ba39e14063541c0b933","type":"GENE","name":"RASGRP4","canonical_id":"hgnc:HGNC:18958","description":"RAS guanyl releasing protein 4","metadata":null},{"id":"d84600dd4cad4521bd708da2815e844c","type":"GENE","name":"RASIP1","canonical_id":"hgnc:HGNC:24716","description":"Ras interacting protein 1","metadata":{"aliases":["FLJ20401","RAIN"]}},{"id":"ff09a1bba5f34fcd91d2be5bfc4e6a71","type":"GENE","name":"RASL10A","canonical_id":"hgnc:HGNC:16954","description":"RAS like family 10 member A","metadata":{"aliases":["RRP22"]}},{"id":"34f5c02aa32f4461ae739457d816c8fa","type":"GENE","name":"RASL10B","canonical_id":"hgnc:HGNC:30295","description":"RAS like family 10 member B","metadata":{"aliases":["VTS58635","RRP17"]}},{"id":"6f1c466025e84911a19d5cf9e481d9cc","type":"GENE","name":"RASL11A","canonical_id":"hgnc:HGNC:23802","description":"RAS like family 11 member A","metadata":null},{"id":"af1253da15a24bfbabbbe49ec9dedc93","type":"GENE","name":"RASL11B","canonical_id":"hgnc:HGNC:23804","description":"RAS like family 11 member B","metadata":null},{"id":"d73f1540b9df468c9ab77817caa1bbba","type":"GENE","name":"RASL12","canonical_id":"hgnc:HGNC:30289","description":"RAS like family 12","metadata":{"aliases":["RIS"]}},{"id":"236bf1f37fd24aed88f00f32582df63d","type":"GENE","name":"RASSF1","canonical_id":"hgnc:HGNC:9882","description":null,"metadata":null},{"id":"c876c943d3014f469849779a8d7396d6","type":"GENE","name":"RASSF1-AS1","canonical_id":"hgnc:HGNC:49091","description":"RASSF1 antisense RNA 1","metadata":{"aliases":["ANRASSF1"]}},{"id":"8092efd3c0ca461d9055cc49ab0a134a","type":"GENE","name":"RASSF10","canonical_id":"hgnc:HGNC:33984","description":"Ras association domain family member 10","metadata":null},{"id":"16eb9f8b728c49e0a2f86eb779212bf5","type":"GENE","name":"RASSF10-DT","canonical_id":"hgnc:HGNC:54255","description":"RASSF10 divergent transcript","metadata":{"aliases":["LINC02738"]}},{"id":"1ae20f3d681640cdbecc24f0becdf72b","type":"GENE","name":"RASSF2","canonical_id":"hgnc:HGNC:9883","description":"Ras association domain family member 2","metadata":{"aliases":["KIAA0168","CENP-34"]}},{"id":"86292b508e524e779593d8fee3f6d832","type":"GENE","name":"RASSF3","canonical_id":"hgnc:HGNC:14271","description":"Ras association domain family member 3","metadata":null},{"id":"523c34c8045749a7af9a21ab8f48f75f","type":"GENE","name":"RASSF3-AS1","canonical_id":"hgnc:HGNC:55489","description":"RASSF3 antisense RNA 1","metadata":{"aliases":["RASSF3-DT"]}},{"id":"9e0372d64bff416cbdd865d6226431c0","type":"GENE","name":"RASSF3-AS2","canonical_id":"hgnc:HGNC:59222","description":"RASSF3 antisense RNA 2","metadata":null},{"id":"751578d21da74cfbbf64b62cd8535305","type":"GENE","name":"RASSF4","canonical_id":"hgnc:HGNC:20793","description":"Ras association domain family member 4","metadata":{"aliases":["AD037","MGC44914"]}},{"id":"5b975d68bf4b4b368d93d2aab5be65b5","type":"GENE","name":"RASSF5","canonical_id":"hgnc:HGNC:17609","description":"Ras association domain family member 5","metadata":{"aliases":["Maxp1","NORE1","RAPL"]}},{"id":"6ce9adfa460744bbb5ae75f0c87e8ec5","type":"GENE","name":"RASSF6","canonical_id":"hgnc:HGNC:20796","description":"Ras association domain family member 6","metadata":null},{"id":"9d094f3b926647d0977ee407428a93f3","type":"GENE","name":"RASSF7","canonical_id":"hgnc:HGNC:1166","description":"Ras association domain family member 7","metadata":{"aliases":["HRC1","HRAS1","FAP88","CFAP88","C11orf13"]}},{"id":"e0399ee2706b42a8bda2fc355e83690e","type":"GENE","name":"RASSF8","canonical_id":"hgnc:HGNC:13232","description":"Ras association domain family member 8","metadata":{"aliases":["HoJ-1","C12orf2"]}},{"id":"ddd745b6e6c744c8b66f82974b31af20","type":"GENE","name":"RASSF8-AS1","canonical_id":"hgnc:HGNC:48637","description":"RASSF8 antisense RNA 1","metadata":null},{"id":"2a80dfb7f9e94efe8f6e7783338a75c2","type":"GENE","name":"RASSF9","canonical_id":"hgnc:HGNC:15739","description":"Ras association domain family member 9","metadata":{"aliases":["P-CIP1","PAMCI"]}},{"id":"1ff029ebfb82475992ea41e683630ae0","type":"DISEASE","name":"RASopathy","canonical_id":"mondo:0021060","description":null,"metadata":null},{"id":"66d2fa62533440bfbdebffc5179ae0d9","type":"GO_TERM","name":"RAVE complex","canonical_id":"go:GO:0043291","description":"\"A multisubunit complex that in Saccharomyces is composed of three subunits, Rav1p, Rav2p and Skp1p. Acts transiently to catalyze assembly of cytoplasmic V1, with membrane embedded V0 to form the V-ATPase holoenzyme.\" [PMID:11283612, PMID:11844802]","metadata":null},{"id":"81ec7d1246ec4ddb8e38e546aa6b0d76","type":"GENE","name":"RAVER1","canonical_id":"hgnc:HGNC:30296","description":"ribonucleoprotein, PTB binding 1","metadata":{"aliases":["KIAA1978"]}},{"id":"22418e7747e34118a354f2952d35c908","type":"GENE","name":"RAVER2","canonical_id":"hgnc:HGNC:25577","description":"ribonucleoprotein, PTB binding 2","metadata":{"aliases":["KIAA1579","FLJ10770"]}},{"id":"367bf82e0ce84dcdb891c0180a24a70d","type":"GENE","name":"RAX","canonical_id":"hgnc:HGNC:18662","description":"retina and anterior neural fold homeobox","metadata":{"aliases":["RX","RAX1"]}},{"id":"318d98e82ff44e7b938e093b2483ce8e","type":"GENE","name":"RAX2","canonical_id":"hgnc:HGNC:18286","description":"retina and anterior neural fold homeobox 2","metadata":{"aliases":["MGC15631","ARMD6","CORD11","RAXL1"]}},{"id":"8547f20d151e40d1a2ed8bde457aaa00","type":"GENE","name":"RB1","canonical_id":"hgnc:HGNC:9884","description":null,"metadata":null},{"id":"05125a5383ad4f7ca8ed95d4e714f7fe","type":"GENE","name":"RB1","canonical_id":"ensembl:ENSG00000139687","description":null,"metadata":null},{"id":"73ad8a8d1206442fb8de9f6016b278df","type":"GENE","name":"RB1-DT","canonical_id":"hgnc:HGNC:42778","description":"RB1 divergent transcript","metadata":{"aliases":["ncRNA-RB1","LINC00441"]}},{"id":"e7c4633365b7479da9d2313a0af43a8e","type":"GENE","name":"RB1CC1","canonical_id":"hgnc:HGNC:15574","description":null,"metadata":null},{"id":"a526a1266c6d4a9ab87ecfd0aea6a836","type":"GENE","name":"RBAK","canonical_id":"hgnc:HGNC:17680","description":"RB associated KRAB zinc finger","metadata":{"aliases":["ZNF769"]}},{"id":"0a2fec50864649a390012125babc4469","type":"GENE","name":"RBAK-RBAKDN","canonical_id":"hgnc:HGNC:42971","description":"RBAK-RBAKDN readthrough","metadata":null},{"id":"2cbfa515e0aa42729e3f5f2f64fbbd14","type":"GENE","name":"RBAKDN","canonical_id":"hgnc:HGNC:33770","description":"RBAK downstream neighbor","metadata":null},{"id":"b4857cb3c50044ea9b48543219451464","type":"GENE","name":"RBBP4","canonical_id":"hgnc:HGNC:9887","description":"RB binding protein 4, chromatin remodeling factor","metadata":{"aliases":["RbAp48","NURF55","lin-53"]}},{"id":"7c8b087c6cd9474992c013f52543dc8d","type":"GENE","name":"RBBP4P1","canonical_id":"hgnc:HGNC:42368","description":"RBBP4 pseudogene 1","metadata":null},{"id":"3fdd59332b7d4f4fb52f5c09a7d34723","type":"GENE","name":"RBBP4P2","canonical_id":"hgnc:HGNC:42369","description":"RBBP4 pseudogene 2","metadata":null},{"id":"2bd5cf69d1ba40cca12f4f1050d2756d","type":"GENE","name":"RBBP4P3","canonical_id":"hgnc:HGNC:42370","description":"RBBP4 pseudogene 3","metadata":null},{"id":"3e922d30f3e84232937ffe626fa6feaf","type":"GENE","name":"RBBP4P4","canonical_id":"hgnc:HGNC:42371","description":"RBBP4 pseudogene 4","metadata":null},{"id":"f6fe15c8a31144d1badf43a17af039df","type":"GENE","name":"RBBP4P5","canonical_id":"hgnc:HGNC:42372","description":"RBBP4 pseudogene 5","metadata":null},{"id":"39892f9377354f3fbffd84750223e66d","type":"GENE","name":"RBBP4P6","canonical_id":"hgnc:HGNC:42373","description":"RBBP4 pseudogene 6","metadata":null},{"id":"5246938f44ba434da3ec115dc5af19ae","type":"GENE","name":"RBBP4P7","canonical_id":"hgnc:HGNC:56458","description":"RBBP4 pseudogene 7","metadata":null},{"id":"4a8fa1ffce4f49eda37e5163372c931d","type":"GENE","name":"RBBP5","canonical_id":"hgnc:HGNC:9888","description":"RB binding protein 5, histone lysine methyltransferase complex subunit","metadata":{"aliases":["RBQ3","SWD1"]}},{"id":"a8a3b33a9e0544a39470a131a877eb90","type":"GENE","name":"RBBP6","canonical_id":"hgnc:HGNC:9889","description":"RB binding protein 6, ubiquitin ligase","metadata":{"aliases":["P2P-R","PACT","SNAMA"]}},{"id":"54c9234577234db5850c93010279ef40","type":"GENE","name":"RBBP6P1","canonical_id":"hgnc:HGNC:45108","description":"RBBP6 pseudogene 1","metadata":null},{"id":"234291d7225e45ddb0e3893988fcb5c7","type":"GENE","name":"RBBP7","canonical_id":"hgnc:HGNC:9890","description":null,"metadata":null},{"id":"f03c1c9c9f044bcfb82b76828529d67a","type":"GENE","name":"RBBP8","canonical_id":"hgnc:HGNC:9891","description":null,"metadata":null},{"id":"614cf9c4732442d18111f54be28b71e0","type":"GENE","name":"RBBP8-AS1","canonical_id":"hgnc:HGNC:58091","description":"RBBP8 antisense RNA 1","metadata":{"aliases":["AC090912.1"]}},{"id":"006e0c1e275944c8bb2979889e5c2e26","type":"GENE","name":"RBBP8NL","canonical_id":"hgnc:HGNC:16144","description":"RBBP8 N-terminal like","metadata":{"aliases":["dJ908M14.3","C20orf151"]}},{"id":"9939c290d61a483094edf8556bc44fb2","type":"GENE","name":"RBBP8P1","canonical_id":"hgnc:HGNC:39583","description":"RBBP8 pseudogene 1","metadata":null},{"id":"fbdbd1df55f14056bf79efb6837d2fc2","type":"GENE","name":"RBBP8P2","canonical_id":"hgnc:HGNC:39584","description":"RBBP8 pseudogene 2","metadata":null},{"id":"c5ee446745b84fbd8eaff6de5f71e353","type":"GENE","name":"RBBP9","canonical_id":"hgnc:HGNC:9892","description":"RB binding protein 9, serine hydrolase","metadata":{"aliases":["Bog"]}},{"id":"7023ac97854a4785bbc28a3ce2d82ab2","type":"GENE","name":"RBCK1","canonical_id":"hgnc:HGNC:15864","description":"RANBP2-type and C3HC4-type zinc finger containing 1","metadata":{"aliases":["RBCK2","XAP4","RNF54","ZRANB4","UBCE7IP3","HOIL1","C20orf18"]}},{"id":"74403db0f71545ddbf41849356903cef","type":"GENE","name":"RBFA","canonical_id":"hgnc:HGNC:26120","description":"ribosome binding factor A","metadata":{"aliases":["FLJ21172","HsT169","C18orf22"]}},{"id":"6bb07e1394f04c148877e662d843f7e1","type":"GENE","name":"RBFADN","canonical_id":"hgnc:HGNC:48591","description":"RBFA downstream neighbor","metadata":null},{"id":"a95ff9c785b440daa8e2181cb7bdff6c","type":"GENE","name":"RBFOX1","canonical_id":"hgnc:HGNC:18222","description":"RNA binding fox-1 homolog 1","metadata":{"aliases":["A2BP1","FOX-1","HRNBP1"]}},{"id":"74bf7111f623404e9eb8710c70debb3b","type":"GENE","name":"RBFOX2","canonical_id":"hgnc:HGNC:9906","description":"RNA binding fox-1 homolog 2","metadata":{"aliases":["HNRBP2","FOX-2","HRNBP2","RBM9"]}},{"id":"12f1a925cbb74170b4b4c6bedc290904","type":"GENE","name":"RBFOX3","canonical_id":"hgnc:HGNC:27097","description":"RNA binding fox-1 homolog 3","metadata":{"aliases":["FOX-3","NeuN","HRNBP3"]}},{"id":"8985f47acb2c45e9baed094e5861b529","type":"GENE","name":"RBIS","canonical_id":"hgnc:HGNC:32235","description":"ribosomal biogenesis factor","metadata":{"aliases":["C8orf59"]}},{"id":"ce53526f0f33473a93919c5405223476","type":"GENE","name":"RBISP1","canonical_id":"hgnc:HGNC:51355","description":"RBIS pseudogene 1","metadata":{"aliases":["C8orf59P1"]}},{"id":"985236c45bda43a08bf03a233e0223fb","type":"GENE","name":"RBISP2","canonical_id":"hgnc:HGNC:51357","description":"RBIS pseudogene 2","metadata":{"aliases":["C8orf59P2"]}},{"id":"9c208a8d8cac4d6fb671daf9fedde88c","type":"GENE","name":"RBISP3","canonical_id":"hgnc:HGNC:56396","description":"RBIS pseudogene 3","metadata":null},{"id":"6336f713505d43d3ac1f2d59afcdca46","type":"GENE","name":"RBISP4","canonical_id":"hgnc:HGNC:56397","description":"RBIS pseudogene 4","metadata":null},{"id":"5fdbbd8b86a7436db76d05e67037fa60","type":"GENE","name":"RBISP5","canonical_id":"hgnc:HGNC:56395","description":"RBIS pseudogene 5","metadata":null},{"id":"4398fdc2b4314d59befc8a816b87d990","type":"GENE","name":"RBISP6","canonical_id":"hgnc:HGNC:56398","description":"RBIS pseudogene 6","metadata":null},{"id":"cb2dfa6a62244dd5a18c88bc5c526e13","type":"GENE","name":"RBKS","canonical_id":"hgnc:HGNC:30325","description":"ribokinase","metadata":{"aliases":["DKFZp686G13268","RBSK"]}},{"id":"2950fa33e1804cc7a91452545c2892ce","type":"GO_TERM","name":"RBL family protein binding","canonical_id":"go:GO:0061675","description":"\"Binding to a member of the rhamnose-binding lectin (RBL) family, a family of animal lectins that show specific binding activities to L-rhamnose or D-galactose.\" [PMID:22312473]","metadata":null},{"id":"529a9579673b4c37bc4bf11d4d9863e7","type":"GENE","name":"RBL1","canonical_id":"hgnc:HGNC:9893","description":null,"metadata":null},{"id":"cba7c7d41f36485c9c43fb1d2e96bf50","type":"GENE","name":"RBL2","canonical_id":"hgnc:HGNC:9894","description":null,"metadata":null},{"id":"ace3691cc3de4917b172e50d70b7859f","type":"GENE","name":"RBM10","canonical_id":"hgnc:HGNC:9896","description":"RNA binding motif protein 10","metadata":{"aliases":["DXS8237E","KIAA0122","GPATC9","ZRANB5","GPATCH9","S1-1"]}},{"id":"636322d08a774788b040836ca08c9a6a","type":"GENE","name":"RBM11","canonical_id":"hgnc:HGNC:9897","description":"RNA binding motif protein 11","metadata":null},{"id":"d431a53861eb48e4aaf210aba4d5fe9c","type":"GENE","name":"RBM11P1","canonical_id":"hgnc:HGNC:43743","description":"RNA binding motif protein 11 pseudogene 1","metadata":null},{"id":"22544a6636ac4fa492970f9b705206c4","type":"GENE","name":"RBM12","canonical_id":"hgnc:HGNC:9898","description":"RNA binding motif protein 12","metadata":{"aliases":["HRIHFB2091","KIAA0765","SWAN"]}},{"id":"2184fbde1e2a4387946f94b4cd94eb5f","type":"GENE","name":"RBM12B","canonical_id":"hgnc:HGNC:32310","description":"RNA binding motif protein 12B","metadata":null},{"id":"d24a90a93f80428d8898218871175e4c","type":"GENE","name":"RBM12B-AS1","canonical_id":"hgnc:HGNC:28818","description":"RBM12B antisense RNA 1","metadata":{"aliases":["PRO1905","C8orf39"]}},{"id":"08403fe6dfff45e58bfcd45fc3db1a86","type":"GENE","name":"RBM12B-DT","canonical_id":"hgnc:HGNC:55529","description":"RBM12B divergent transcript","metadata":null},{"id":"311328bc9fc447598a242cb93e37a268","type":"GENE","name":"RBM14","canonical_id":"hgnc:HGNC:14219","description":"RNA binding motif protein 14","metadata":{"aliases":["SIP","SYTIP1","COAA","DKFZp779J0927"]}},{"id":"3ed6d0756368456dbc150d3584bd7860","type":"GENE","name":"RBM14-RBM4","canonical_id":"hgnc:HGNC:38840","description":"RBM14-RBM4 readthrough","metadata":null},{"id":"cb6cbd9422f1497e91fa73bfc521e768","type":"GENE","name":"RBM15","canonical_id":"hgnc:HGNC:14959","description":"RNA binding motif protein 15","metadata":{"aliases":["OTT","OTT1"]}},{"id":"5209e309a3e840388c4b89f063987b82","type":"GENE","name":"RBM15-AS1","canonical_id":"hgnc:HGNC:53636","description":"RBM15 antisense RNA 1","metadata":{"aliases":["AS-RBM15"]}},{"id":"0db3256e5fa54fc788a7ccb47c95a2ed","type":"GENE","name":"RBM15B","canonical_id":"hgnc:HGNC:24303","description":"RNA binding motif protein 15B","metadata":{"aliases":["HUMAGCGB","OTT3"]}},{"id":"319d592183ed414bbb173c55293d0a88","type":"GENE","name":"RBM17","canonical_id":"hgnc:HGNC:16944","description":"RNA binding motif protein 17","metadata":{"aliases":["SPF45","MGC14439"]}},{"id":"48cbb3cf77694c06a6ededf07a6ea308","type":"GENE","name":"RBM17P1","canonical_id":"hgnc:HGNC:50366","description":"RNA binding motif protein 17 pseudogene 1","metadata":null},{"id":"e5f11eac1fbe4379ac1dcf2d97015d94","type":"GENE","name":"RBM17P2","canonical_id":"hgnc:HGNC:50367","description":"RNA binding motif protein 17 pseudogene 2","metadata":null},{"id":"42a10099613941ec9ac6e4de418f738c","type":"GENE","name":"RBM17P3","canonical_id":"hgnc:HGNC:50368","description":"RNA binding motif protein 17 pseudogene 3","metadata":null},{"id":"540d59c168c5470d9652ce8b365d88b5","type":"GENE","name":"RBM17P4","canonical_id":"hgnc:HGNC:50369","description":"RNA binding motif protein 17 pseudogene 4","metadata":null},{"id":"4120969029214cbe86a53b69142d0823","type":"GENE","name":"RBM18","canonical_id":"hgnc:HGNC:28413","description":"RNA binding motif protein 18","metadata":{"aliases":["MGC2734"]}},{"id":"8a38cbe439d0489cbd21442a4f6c51f0","type":"GENE","name":"RBM19","canonical_id":"hgnc:HGNC:29098","description":"RNA binding motif protein 19","metadata":{"aliases":["DKFZp586F1023","KIAA0682","Mrd1"]}},{"id":"e615482387464420900855a84aa35f4d","type":"GENE","name":"RBM19-AS1","canonical_id":"hgnc:HGNC:58446","description":"RBM19 antisense RNA 1","metadata":null},{"id":"b8714ba862d244c480421b22a2d3ca48","type":"GENE","name":"RBM20","canonical_id":"hgnc:HGNC:27424","description":"RNA binding motif protein 20","metadata":null},{"id":"fe383f31115c4a768abcdec700e4dd52","type":"GENE","name":"RBM22","canonical_id":"hgnc:HGNC:25503","description":"RNA binding motif protein 22","metadata":{"aliases":["FLJ10290","ZC3H16","fSAP47","Cwc2"]}},{"id":"ee6ed6e77db84e6886d21288531caff4","type":"GENE","name":"RBM22P1","canonical_id":"hgnc:HGNC:31466","description":"RNA binding motif protein 22 pseudogene 1","metadata":null},{"id":"a3fc099b6bdf418fb33d50ec28d658fc","type":"GENE","name":"RBM22P11","canonical_id":"hgnc:HGNC:39704","description":"RNA binding motif protein 22 pseudogene 11","metadata":{"aliases":["RBM22P8"]}},{"id":"082c010f644e4012b9e46e02c11ef8c5","type":"GENE","name":"RBM22P12","canonical_id":"hgnc:HGNC:49207","description":"RNA binding motif protein 22 pseudogene 12","metadata":null},{"id":"4845eeb104d1465ebc2a602ee4f37446","type":"GENE","name":"RBM22P13","canonical_id":"hgnc:HGNC:49208","description":"RNA binding motif protein 22 pseudogene 13","metadata":null},{"id":"afd19b8dd1a549a390a2ef48c7b44cc6","type":"GENE","name":"RBM22P2","canonical_id":"hgnc:HGNC:39695","description":"RNA binding motif protein 22 pseudogene 2","metadata":null},{"id":"23a1ad8dfc144c5988bcf106f98dd38b","type":"GENE","name":"RBM22P3","canonical_id":"hgnc:HGNC:39696","description":"RNA binding motif protein 22 pseudogene 3","metadata":null},{"id":"93f4c012a7144ee8a7a612a2a2d2be16","type":"GENE","name":"RBM22P4","canonical_id":"hgnc:HGNC:39697","description":"RNA binding motif protein 22 pseudogene 4","metadata":null},{"id":"9c58772139d64a4295ac36d2f42b039d","type":"GENE","name":"RBM22P5","canonical_id":"hgnc:HGNC:39698","description":"RNA binding motif protein 22 pseudogene 5","metadata":null},{"id":"58d705752d0e49deaa17e2d6714ca315","type":"GENE","name":"RBM22P6","canonical_id":"hgnc:HGNC:39699","description":"RNA binding motif protein 22 pseudogene 6","metadata":{"aliases":["RBM22P10"]}},{"id":"2cb1a6b41e954381ae32701927e517b4","type":"GENE","name":"RBM22P7","canonical_id":"hgnc:HGNC:39700","description":"RNA binding motif protein 22 pseudogene 7","metadata":{"aliases":["RBM22P9"]}},{"id":"63157ebfd9344020b6ff2fe21d4543a9","type":"GENE","name":"RBM23","canonical_id":"hgnc:HGNC:20155","description":"RNA binding motif protein 23","metadata":{"aliases":["FLJ10482","CAPERbeta","RNPC4"]}},{"id":"88108cfdf1754e459719cb90cbf324de","type":"GENE","name":"RBM24","canonical_id":"hgnc:HGNC:21539","description":"RNA binding motif protein 24","metadata":{"aliases":["FLJ30829","dJ259A10.1","RNPC6"]}},{"id":"f4b0cfe90224442eb2d5ded7a7c6decf","type":"GENE","name":"RBM24-AS1","canonical_id":"hgnc:HGNC:59362","description":"RBM24 antisense RNA 1","metadata":null},{"id":"84eacf96cf4647cea2ff74b34218e135","type":"GENE","name":"RBM25","canonical_id":"hgnc:HGNC:23244","description":"RNA binding motif protein 25","metadata":{"aliases":["S164","fSAP94","NET52","Snu71","RNPC7"]}},{"id":"b18168ee149841749d423a9d890f6ff8","type":"GENE","name":"RBM25-AS1","canonical_id":"hgnc:HGNC:55437","description":"RBM25 antisense RNA 1","metadata":null},{"id":"2c3feaee67ed48b6a0f75298a4293027","type":"GENE","name":"RBM26","canonical_id":"hgnc:HGNC:20327","description":"RNA binding motif protein 26","metadata":{"aliases":["PRO1777","SE70-2","FLJ20957","ZC3H17","ARRS2","PPP1R132","C13orf10"]}},{"id":"13f3102aea054eeb87823e9f5a57208d","type":"GENE","name":"RBM26-AS1","canonical_id":"hgnc:HGNC:39805","description":"RBM26 antisense RNA 1","metadata":null},{"id":"c6c4741c0fd44db386d214331290cd55","type":"GENE","name":"RBM27","canonical_id":"hgnc:HGNC:29243","description":"RNA binding motif protein 27","metadata":{"aliases":["KIAA1311","ARRS1","Psc1","ZC3H20"]}},{"id":"f4bf84e837b6466281fe70841fb18aab","type":"GENE","name":"RBM27-POU4F3","canonical_id":"hgnc:HGNC:58349","description":"RBM27-POU4F3 readthrough","metadata":null},{"id":"5a1f5400f16e45ffb5828618f661b2e4","type":"GENE","name":"RBM28","canonical_id":"hgnc:HGNC:21863","description":"RNA binding motif protein 28","metadata":{"aliases":["FLJ10377","NOP4"]}},{"id":"30fcfc07bd2b453ba42f22d37335c9c7","type":"GENE","name":"RBM3","canonical_id":"hgnc:HGNC:9900","description":"RNA binding motif protein 3","metadata":{"aliases":["IS1-RNPL"]}},{"id":"4c104a9d3f934519b14d118eefa99977","type":"GENE","name":"RBM33","canonical_id":"hgnc:HGNC:27223","description":"RNA binding motif protein 33","metadata":{"aliases":["DKFZp686F102","MGC20460","DKFZp434D1319","PRR8"]}},{"id":"bf905bd2cad3488a8ea273b7912e5839","type":"GENE","name":"RBM33-DT","canonical_id":"hgnc:HGNC:56024","description":"RBM33 divergent transcript","metadata":null},{"id":"9bab4ad15d634054a88d13e3543510a9","type":"GENE","name":"RBM34","canonical_id":"hgnc:HGNC:28965","description":"RNA binding motif protein 34","metadata":{"aliases":["KIAA0117"]}},{"id":"892db2f810744c4a8b62b385cd44dc16","type":"GENE","name":"RBM38","canonical_id":"hgnc:HGNC:15818","description":null,"metadata":null},{"id":"98a5feacf0954e88aa1e436362040c8b","type":"GENE","name":"RBM38-AS1","canonical_id":"hgnc:HGNC:40725","description":"RBM38 antisense RNA 1","metadata":null},{"id":"ea90fb6abc664499a638a6d29d6d71c8","type":"GENE","name":"RBM39","canonical_id":"hgnc:HGNC:15923","description":"RNA binding motif protein 39","metadata":{"aliases":["CC1.3","HCC1","CAPER","fSAP59","CAPERalpha","RNPC2"]}},{"id":"e7fb6efed668430c9a934e97b6220cd4","type":"GENE","name":"RBM39P1","canonical_id":"hgnc:HGNC:54942","description":"RBM39 pseudogene 1","metadata":null},{"id":"9a1cdb7e5fda49b99bf6576c4c6c0267","type":"GENE","name":"RBM4","canonical_id":"hgnc:HGNC:9901","description":"RNA binding motif protein 4","metadata":{"aliases":["LARK","RBM4A","ZCRB3A","ZCCHC21"]}},{"id":"995d2ad14c9e48cc8ead3a281619c4fc","type":"GENE","name":"RBM41","canonical_id":"hgnc:HGNC:25617","description":"RNA binding motif protein 41","metadata":{"aliases":["FLJ11016"]}},{"id":"1a017d340892493d8041e87b87cb2d2c","type":"GENE","name":"RBM42","canonical_id":"hgnc:HGNC:28117","description":"RNA binding motif protein 42","metadata":{"aliases":["MGC10433"]}},{"id":"a7880722dc95465c84c20cb667211e21","type":"GENE","name":"RBM43","canonical_id":"hgnc:HGNC:24790","description":"RNA binding motif protein 43","metadata":{"aliases":["FLJ45645","C2orf38"]}},{"id":"36539aecf10448aaa6a7a851b5f91930","type":"GENE","name":"RBM43P1","canonical_id":"hgnc:HGNC:46024","description":"RNA binding motif protein 43 pseudogene 1","metadata":null},{"id":"db87740da6414f478188e3668453ad3f","type":"GENE","name":"RBM44","canonical_id":"hgnc:HGNC:24756","description":"RNA binding motif protein 44","metadata":{"aliases":["FLJ40411"]}},{"id":"1d4583eb0891416fbf20663e6b7ec4a1","type":"GENE","name":"RBM45","canonical_id":"hgnc:HGNC:24468","description":"RNA binding motif protein 45","metadata":{"aliases":["DRB1","FLJ44612"]}},{"id":"cff46feee5d449d08ef28a085a6b627a","type":"GENE","name":"RBM46","canonical_id":"hgnc:HGNC:28401","description":"RNA binding motif protein 46","metadata":{"aliases":["MGC27016","CT68"]}},{"id":"649898830131480fbf8cac1a28e6b989","type":"GENE","name":"RBM46-AS1","canonical_id":"hgnc:HGNC:58901","description":"RBM46 antisense RNA 1","metadata":null},{"id":"05d36a70df3b443fa852c6c35f1599c3","type":"GENE","name":"RBM47","canonical_id":"hgnc:HGNC:30358","description":"RNA binding motif protein 47","metadata":{"aliases":["FLJ20273","NET18"]}},{"id":"847aadb6429e41e9b911236b9d7a6b89","type":"GENE","name":"RBM47-AS1","canonical_id":"hgnc:HGNC:41264","description":"RBM47 antisense RNA 1","metadata":null},{"id":"e5388ca44f944e439a0eff0423ae7cc7","type":"GENE","name":"RBM47-AS2","canonical_id":"hgnc:HGNC:58777","description":"RBM47 antisense RNA 2","metadata":null},{"id":"7c46fcb856f4496b8888bdf8967ce764","type":"GENE","name":"RBM48","canonical_id":"hgnc:HGNC:21785","description":"RNA binding motif protein 48","metadata":{"aliases":["DKFZp564O0523","HSPC304","C7orf64"]}},{"id":"90cfd59febc14c0fb5f0d17a87d9abfa","type":"GENE","name":"RBM48P1","canonical_id":"hgnc:HGNC:44054","description":"RNA binding motif protein 48 pseudogene 1","metadata":null},{"id":"d0c51bc820644a229512e8abc3d028b3","type":"GENE","name":"RBM4B","canonical_id":"hgnc:HGNC:28842","description":"RNA binding motif protein 4B","metadata":{"aliases":["MGC10871","ZCCHC15","RBM4L","ZCRB3B","ZCCHC21B","RBM30"]}},{"id":"68d8e022b3fe4e0aa06f48b84e1bf5fe","type":"GENE","name":"RBM5","canonical_id":"hgnc:HGNC:9902","description":"RNA binding motif protein 5","metadata":{"aliases":["LUCA15","LUCA-15","H37"]}},{"id":"6ccde4163eb049a7b9317ad3cca1729b","type":"GENE","name":"RBM5-AS1","canonical_id":"hgnc:HGNC:48871","description":"RBM5 antisense RNA 1","metadata":{"aliases":["LUST"]}},{"id":"c24e8ae7e5b74932becbe56008e6f648","type":"GENE","name":"RBM6","canonical_id":"hgnc:HGNC:9903","description":"RNA binding motif protein 6","metadata":{"aliases":["DEF-3","3G2","NY-LU-12","g16","DEF3"]}},{"id":"677e2d1027404e349385049ed8dac752","type":"GENE","name":"RBM7","canonical_id":"hgnc:HGNC:9904","description":"RNA binding motif protein 7","metadata":null},{"id":"3c16d33418eb49c1855f3677e49fb952","type":"GENE","name":"RBM7P1","canonical_id":"hgnc:HGNC:54704","description":"RBM7 pseudogene 1","metadata":null},{"id":"e207a9b94b0142219f41ba2d83a67ae0","type":"GENE","name":"RBM8A","canonical_id":"hgnc:HGNC:9905","description":"RNA binding motif protein 8A","metadata":{"aliases":["ZNRP","BOV-1A","BOV-1B","BOV-1C","Y14","RBM8"]}},{"id":"2c3da27371e34aefadf52e9b6af16116","type":"GENE","name":"RBM8B","canonical_id":"hgnc:HGNC:13426","description":"RNA binding motif protein 8B (pseudogene)","metadata":{"aliases":["RMB8AP1"]}},{"id":"50b894189e5f4335b4c9858a71903445","type":"GENE","name":"RBMS1","canonical_id":"hgnc:HGNC:9907","description":"RNA binding motif single stranded interacting protein 1","metadata":{"aliases":["SCR2","MSSP-1","MSSP-2","MSSP-3","YC1","HCC-4","DKFZp564H0764","C2orf12"]}},{"id":"463343673dd14d88a9e6f3cade9583b1","type":"GENE","name":"RBMS1P1","canonical_id":"hgnc:HGNC:9908","description":"RNA binding motif single stranded interacting protein 1 pseudogene 1","metadata":{"aliases":["MSSP1","RBMS1P"]}},{"id":"d44b2a529ba842c9aa261e4b4a71b6a5","type":"GENE","name":"RBMS2","canonical_id":"hgnc:HGNC:9909","description":"RNA binding motif single stranded interacting protein 2","metadata":{"aliases":["SCR3"]}},{"id":"a62e296887c641b8a2f4eb94b9383f81","type":"GENE","name":"RBMS2P1","canonical_id":"hgnc:HGNC:30994","description":"RNA binding motif single stranded interacting protein 2 pseudogene 1","metadata":{"aliases":["RBMS2P"]}},{"id":"74bf1379cdc84ba19901881e1820653b","type":"GENE","name":"RBMS3","canonical_id":"hgnc:HGNC:13427","description":"RNA binding motif single stranded interacting protein 3","metadata":null},{"id":"6d6994f7fb4440c181054a61049e9cfd","type":"GENE","name":"RBMS3-AS1","canonical_id":"hgnc:HGNC:39987","description":"RBMS3 antisense RNA 1","metadata":null},{"id":"97d9476af50f4223aafa2a9fdee98ef3","type":"GENE","name":"RBMS3-AS2","canonical_id":"hgnc:HGNC:39988","description":"RBMS3 antisense RNA 2","metadata":null},{"id":"585df2ebbd9948b28ac44c20c792d27e","type":"GENE","name":"RBMS3-AS3","canonical_id":"hgnc:HGNC:39989","description":"RBMS3 antisense RNA 3","metadata":null},{"id":"53d1bcead4014726a993362d78d8534a","type":"GENE","name":"RBMX","canonical_id":"hgnc:HGNC:9910","description":null,"metadata":null},{"id":"dcbb67709978429b9cf1598a0ff51da7","type":"GENE","name":"RBMX2","canonical_id":"hgnc:HGNC:24282","description":"RNA binding motif protein X-linked 2","metadata":{"aliases":["CGI-79","Snu17"]}},{"id":"4638591ef27c47caa35ab23252df3945","type":"GENE","name":"RBMX2P1","canonical_id":"hgnc:HGNC:39923","description":"RBMX2 pseudogene 1","metadata":null},{"id":"bab156c33b594c16be2932ed891d379e","type":"GENE","name":"RBMX2P2","canonical_id":"hgnc:HGNC:39924","description":"RBMX2 pseudogene 2","metadata":null},{"id":"c13891ebc64443ac978c05ec2de42c55","type":"GENE","name":"RBMX2P3","canonical_id":"hgnc:HGNC:39925","description":"RBMX2 pseudogene 3","metadata":null},{"id":"126aa5a9bdf2464a9911609a1bf15e51","type":"GENE","name":"RBMX2P4","canonical_id":"hgnc:HGNC:39926","description":"RBMX2 pseudogene 4","metadata":null},{"id":"fffdd8ad3de148d4806bc3e534ce949d","type":"GENE","name":"RBMX2P5","canonical_id":"hgnc:HGNC:39927","description":"RBMX2 pseudogene 5","metadata":null},{"id":"d49230eb1eb6422da49097fa6dbb2d2c","type":"GENE","name":"RBMXL1","canonical_id":"hgnc:HGNC:25073","description":"RBMX like 1","metadata":{"aliases":["KAT3"]}},{"id":"b8ad33ab779f43e98caf7a742f8eb9e1","type":"GENE","name":"RBMXL2","canonical_id":"hgnc:HGNC:17886","description":"RBMX like 2","metadata":{"aliases":["HNRNPG-T","HNRPGT"]}},{"id":"4a4af4d42aa74b5195194c9f66d03941","type":"GENE","name":"RBMXL3","canonical_id":"hgnc:HGNC:26859","description":"RBMX like 3","metadata":{"aliases":["FLJ40249","CXorf55"]}},{"id":"cbcf7bbf6f7f4e669a1bcec924cbcc25","type":"GENE","name":"RBMXP1","canonical_id":"hgnc:HGNC:9911","description":"RBMX pseudogene 1","metadata":{"aliases":["HNRNP-G","HNRPG"]}},{"id":"12b56557c58c4e9783ba1a00a4fffd06","type":"GENE","name":"RBMXP2","canonical_id":"hgnc:HGNC:23284","description":"RBMX pseudogene 2","metadata":null},{"id":"fbd412c4084c4bd68feda8021b09058a","type":"GENE","name":"RBMXP3","canonical_id":"hgnc:HGNC:33949","description":"RBMX pseudogene 3","metadata":null},{"id":"35791826e2a342b4a927705fc0216773","type":"GENE","name":"RBMXP4","canonical_id":"hgnc:HGNC:34028","description":"RBMX pseudogene 4","metadata":null},{"id":"c231cab494cf4c63926f7812598d51c7","type":"GENE","name":"RBMXP5","canonical_id":"hgnc:HGNC:54979","description":"RBMX pseudogene 5","metadata":null},{"id":"948fe064df5e427ba91853368bd75f49","type":"GENE","name":"RBMY1A1","canonical_id":"hgnc:HGNC:9912","description":"RNA binding motif protein Y-linked family 1 member A1","metadata":{"aliases":["YRRM1","YRRM2","RBM1","RBM2"]}},{"id":"a0f9d0c300f344f89ab61b5f4545715d","type":"GENE","name":"RBMY1A3P","canonical_id":"hgnc:HGNC:18849","description":"RNA binding motif protein Y-linked family 1 member A3, pseudogene","metadata":null},{"id":"03d51bc03f224008b91a2935ed54176b","type":"GENE","name":"RBMY1B","canonical_id":"hgnc:HGNC:23914","description":"RNA binding motif protein Y-linked family 1 member B","metadata":null},{"id":"9b13eb8a22cc4e9daa9de323f68b2812","type":"GENE","name":"RBMY1C","canonical_id":"hgnc:HGNC:9914","description":"RNA binding motif protein Y-linked family 1 member C","metadata":null},{"id":"ceff2202aae2466992585992fdb20074","type":"GENE","name":"RBMY1D","canonical_id":"hgnc:HGNC:23915","description":"RNA binding motif protein Y-linked family 1 member D","metadata":null},{"id":"ef6dbb2d0ca64c35ae1b4391998df18e","type":"GENE","name":"RBMY1E","canonical_id":"hgnc:HGNC:23916","description":"RNA binding motif protein Y-linked family 1 member E","metadata":null},{"id":"676f8f92a5984a778ab9555e11f14cb3","type":"GENE","name":"RBMY1F","canonical_id":"hgnc:HGNC:23974","description":"RNA binding motif protein Y-linked family 1 member F","metadata":{"aliases":["MGC33094"]}},{"id":"94d40aadc55f4bd3922c0f3a81aa34b0","type":"GENE","name":"RBMY1GP","canonical_id":"hgnc:HGNC:9915","description":"RNA binding motif protein Y-linked family 1 member G, pseudogene","metadata":{"aliases":["RBMY1G"]}},{"id":"63e4ffa02ce84f66915a1c7ee6446c38","type":"GENE","name":"RBMY1HP","canonical_id":"hgnc:HGNC:9916","description":"RNA binding motif protein Y-linked family 1 member H, pseudogene","metadata":{"aliases":["RBMY1H"]}},{"id":"8a0c826a9f524fbb858f7c44ab4965a8","type":"GENE","name":"RBMY1J","canonical_id":"hgnc:HGNC:23917","description":"RNA binding motif protein Y-linked family 1 member J","metadata":null},{"id":"b6fc8e36481240768a92e55e76232efb","type":"GENE","name":"RBMY1KP","canonical_id":"hgnc:HGNC:38750","description":"RNA binding motif protein Y-linked family 1 member K, pseudogene","metadata":{"aliases":["RBMY1K"]}},{"id":"afcf7611fe29460dbf97516348632635","type":"GENE","name":"RBMY2AP","canonical_id":"hgnc:HGNC:9917","description":"RNA binding motif protein Y-linked family 2 member A, pseudogene","metadata":{"aliases":["RBMY2A"]}},{"id":"8c615010effd497cb0a48ac42ec3f055","type":"GENE","name":"RBMY2BP","canonical_id":"hgnc:HGNC:9918","description":"RNA binding motif protein Y-linked family 2 member B, pseudogene","metadata":{"aliases":["RBMY2B"]}},{"id":"aeb5094c99f649a6a13a259deec9e4e2","type":"GENE","name":"RBMY2CP","canonical_id":"hgnc:HGNC:23260","description":"RNA binding motif protein Y-linked family 2 member C, pseudogene","metadata":null},{"id":"8662e4f6536040b69b6553f4878d65cf","type":"GENE","name":"RBMY2DP","canonical_id":"hgnc:HGNC:23259","description":"RNA binding motif protein Y-linked family 2 member D, pseudogene","metadata":null},{"id":"e2ab0adefe8f4ff092e42513098542d6","type":"GENE","name":"RBMY2EP","canonical_id":"hgnc:HGNC:23890","description":"RNA binding motif protein Y-linked family 2 member E, pseudogene","metadata":null},{"id":"2b5e2bf44e5941a28cfda0547079868a","type":"GENE","name":"RBMY2FP","canonical_id":"hgnc:HGNC:23891","description":"RNA binding motif protein Y-linked family 2 member F, pseudogene","metadata":{"aliases":["MGC26641"]}},{"id":"9a875f4733924fc487717c5b18f22129","type":"GENE","name":"RBMY2GP","canonical_id":"hgnc:HGNC:23892","description":"RNA binding motif protein Y-linked family 2 member G, pseudogene","metadata":null},{"id":"fa6154cdb92842eb9d46c85efe9521cd","type":"GENE","name":"RBMY2HP","canonical_id":"hgnc:HGNC:23893","description":"RNA binding motif protein Y-linked family 2 member H, pseudogene","metadata":null},{"id":"f29e238ca9814109836aa4b21c0645f0","type":"GENE","name":"RBMY2JP","canonical_id":"hgnc:HGNC:23918","description":"RNA binding motif protein Y-linked family 2 member J, pseudogene","metadata":null},{"id":"4441555ef6ac4838b42ae3873e06064b","type":"GENE","name":"RBMY2KP","canonical_id":"hgnc:HGNC:23888","description":"RNA binding motif protein Y-linked family 2 member K, pseudogene","metadata":null},{"id":"47af405752534cdcaf1883c77aa25883","type":"GENE","name":"RBMY2MP","canonical_id":"hgnc:HGNC:23889","description":"RNA binding motif protein Y-linked family 2 member M, pseudogene","metadata":null},{"id":"21231342bd3e4d8496134facf72ccdf2","type":"GENE","name":"RBMY2NP","canonical_id":"hgnc:HGNC:23919","description":"RNA binding motif protein Y-linked family 2 member N, pseudogene","metadata":null},{"id":"ace178851be94a1a9813792dd2b84196","type":"GENE","name":"RBMY2OP","canonical_id":"hgnc:HGNC:23894","description":"RNA binding motif protein Y-linked family 2 member O, pseudogene","metadata":null},{"id":"94abfeb32f794f7d93b3ca7c70ea4a08","type":"GENE","name":"RBMY2QP","canonical_id":"hgnc:HGNC:23895","description":"RNA binding motif protein Y-linked family 2 member Q, pseudogene","metadata":null},{"id":"83f5130a78db49ff968c7d560f92d6ff","type":"GENE","name":"RBMY2SP","canonical_id":"hgnc:HGNC:23896","description":"RNA binding motif protein Y-linked family 2 member S, pseudogene","metadata":null},{"id":"ab99e71b3c264d97af3e35349b55dde9","type":"GENE","name":"RBMY2TP","canonical_id":"hgnc:HGNC:23897","description":"RNA binding motif protein Y-linked family 2 member T, pseudogene","metadata":null},{"id":"2eb0e4c518014d7ca09be468e9b75324","type":"GENE","name":"RBMY2UP","canonical_id":"hgnc:HGNC:23898","description":"RNA binding motif protein Y-linked family 2 member U, pseudogene","metadata":null},{"id":"a68ae28392ba4c3cb11e5d88e06b67cd","type":"GENE","name":"RBMY2VP","canonical_id":"hgnc:HGNC:23899","description":"RNA binding motif protein Y-linked family 2 member V, pseudogene","metadata":null},{"id":"484e73eca2f4401f8118cb9b394d8eff","type":"GENE","name":"RBMY2WP","canonical_id":"hgnc:HGNC:23900","description":"RNA binding motif protein Y-linked family 2 member W, pseudogene","metadata":null},{"id":"65ac88f1d85d49c0b11bb9d9472ae5fb","type":"GENE","name":"RBMY2XP","canonical_id":"hgnc:HGNC:23901","description":"RNA binding motif protein Y-linked family 2 member X, pseudogene","metadata":null},{"id":"ae1ff6b01bb84d14a8d14ee441a25c82","type":"GENE","name":"RBMY2YP","canonical_id":"hgnc:HGNC:23902","description":"RNA binding motif protein Y-linked family 2 member Y, pseudogene","metadata":null},{"id":"e1d4653746834e648ebc4c77fb86256c","type":"GENE","name":"RBMY3AP","canonical_id":"hgnc:HGNC:23286","description":"RNA binding motif protein Y-linked family 3 member A, pseudogene","metadata":{"aliases":["SPATA14","RBMY4P","RBMY3P"]}},{"id":"60308955d3f14f3da1717e8f088ff5df","type":"GENE","name":"RBP1","canonical_id":"hgnc:HGNC:9919","description":"retinol binding protein 1","metadata":{"aliases":["CRABP-I","CRBP1","CRBP","RBPC","CRBPI","CRBP-I","hCRBP1"]}},{"id":"91425fd9dd24400e88e7aeb428b2c04d","type":"GENE","name":"RBP2","canonical_id":"hgnc:HGNC:9920","description":"retinol binding protein 2","metadata":{"aliases":["CRBP2","RBPC2","CRBPII","CRABP-II"]}},{"id":"f471eb3c207b4009afb8e59b9e3e8824","type":"GENE","name":"RBP3","canonical_id":"hgnc:HGNC:9921","description":null,"metadata":null},{"id":"a000db3d991c4bd69e98b215263983f8","type":"GENE","name":"RBP4","canonical_id":"hgnc:HGNC:9922","description":"retinol binding protein 4","metadata":null},{"id":"41957c986a374d6c9e643d7a665659ad","type":"GENE","name":"RBP5","canonical_id":"hgnc:HGNC:15847","description":"retinol binding protein 5","metadata":{"aliases":["CRBPIII","CRBP3","CRBP-III"]}},{"id":"0d8419a6ba744b6497c72f2ba2296ad5","type":"GENE","name":"RBP7","canonical_id":"hgnc:HGNC:30316","description":"retinol binding protein 7","metadata":{"aliases":["CRBPIV"]}},{"id":"74d0fb2028544dc4b86a6e58cb00d5f8","type":"GENE","name":"RBPJ","canonical_id":"hgnc:HGNC:5724","description":null,"metadata":null},{"id":"0d903d72aa3348c4a44342cd01655272","type":"GENE","name":"RBPJ-AS1","canonical_id":"hgnc:HGNC:58749","description":"RBPJ antisense RNA 1","metadata":null},{"id":"3edc87f93d7c4db0ae10c7aa0009eb33","type":"GENE","name":"RBPJL","canonical_id":"hgnc:HGNC:13761","description":"recombination signal binding protein for immunoglobulin kappa J region like","metadata":{"aliases":["RBP-L","SUH","SUHL","RBPSUHL"]}},{"id":"ec03c5b3e3924af6ab96a2e5b26665af","type":"GENE","name":"RBPJP1","canonical_id":"hgnc:HGNC:5725","description":"RBPJ pseudogene 1","metadata":{"aliases":["IGKJRBP1","RBPSUHP1"]}},{"id":"f670ba3192f143699d35d6408daa2df7","type":"GENE","name":"RBPJP2","canonical_id":"hgnc:HGNC:5726","description":"RBPJ pseudogene 2","metadata":{"aliases":["IGKJRBP2","RBPSUHP2"]}},{"id":"fde6edeacf964869a56fb9fdcef63786","type":"GENE","name":"RBPJP3","canonical_id":"hgnc:HGNC:13686","description":"RBPJ pseudogene 3","metadata":{"aliases":["K2","RBPSUHP3"]}},{"id":"ddbbbaeef2ab41e4a91e9062a558d9d8","type":"GENE","name":"RBPJP4","canonical_id":"hgnc:HGNC:13687","description":"RBPJ pseudogene 4","metadata":{"aliases":["K7","RBPSUHP4"]}},{"id":"47a7294a2a294dbbb853103f78ea6be2","type":"GENE","name":"RBPJP5","canonical_id":"hgnc:HGNC:37485","description":"RBPJ pseudogene 5","metadata":null},{"id":"74784369acc4471c8e3131c36809f3b4","type":"GENE","name":"RBPJP6","canonical_id":"hgnc:HGNC:37486","description":"RBPJ pseudogene 6","metadata":null},{"id":"f5f1600a4fd544ff91e95de3b8ca5f12","type":"GENE","name":"RBPJP7","canonical_id":"hgnc:HGNC:37487","description":"RBPJ pseudogene 7","metadata":null},{"id":"521c9806277e4db8abb891325e1b7551","type":"GENE","name":"RBPMS","canonical_id":"hgnc:HGNC:19097","description":"RNA binding protein, mRNA processing factor","metadata":{"aliases":["HERMES"]}},{"id":"84b6dbd98176468c8b0ed85c53c4ce63","type":"GENE","name":"RBPMS-AS1","canonical_id":"hgnc:HGNC:48721","description":"RBPMS antisense RNA 1","metadata":{"aliases":["TP53LC06"]}},{"id":"83e12a6b77d24657909491160d7c1660","type":"GENE","name":"RBPMS2","canonical_id":"hgnc:HGNC:19098","description":"RNA binding protein, mRNA processing factor 2","metadata":null},{"id":"1746e4e305d64061a01350e11c05354a","type":"GENE","name":"RBPMS2P1","canonical_id":"hgnc:HGNC:50509","description":"RBPMS2 pseudogene 1","metadata":null},{"id":"ecbde42bf0b848949775fd93217ab924","type":"GENE","name":"RBPMSLP","canonical_id":"hgnc:HGNC:9923","description":"RNA binding protein with multiple splicing-like pseudogene","metadata":null},{"id":"54b39bd448df422a89b8efc6a87c1777","type":"GENE","name":"RBSN","canonical_id":"hgnc:HGNC:20759","description":"rabenosyn, RAB effector","metadata":{"aliases":["ZFYVE20"]}},{"id":"0d9d0f99ccae42ee908f6cad65eaf1c7","type":"GENE","name":"RBX1","canonical_id":"hgnc:HGNC:9928","description":"ring-box 1","metadata":{"aliases":["ROC1","RNF75","BA554C12.1"]}},{"id":"45e179b84c55494e8bc1384bd1d04e65","type":"GENE","name":"RBX1P1","canonical_id":"hgnc:HGNC:54740","description":"RBX1 pseudogene 1","metadata":null},{"id":"ebb1191f09f748d9ad2a7830164277fd","type":"GENE","name":"RBX1P2","canonical_id":"hgnc:HGNC:54741","description":"RBX1 pseudogene 2","metadata":null},{"id":"be7c81378b4940d5812f4a47a5a44a78","type":"GO_TERM","name":"RC-1 DNA recombination complex","canonical_id":"go:GO:0070467","description":"\"A protein complex that contains DNA ligase III, DNA polymerase epsilon, a 5'-3' exonuclease, and the SMC1 and SMC2 proteins, and is involved in recombinational repair of deletions and gaps in DNA.\" [PMID:8392064, PMID:8670910]","metadata":null},{"id":"ef6605793df34c238251a79062932343","type":"TRIAL","name":"RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT05540483","description":"Biliary Carcinoma","metadata":null},{"id":"e406cf88b22847469fe002e06fd72b9d","type":"GENE","name":"RC3H1","canonical_id":"hgnc:HGNC:29434","description":"ring finger and CCCH-type domains 1","metadata":{"aliases":["KIAA2025","roquin","RP5-1198E17.5","RNF198"]}},{"id":"e1374025a3de4b57871fa9b3190e284a","type":"GENE","name":"RC3H1-DT","canonical_id":"hgnc:HGNC:54295","description":"RC3H1 divergent transcript","metadata":{"aliases":["LINC02776"]}},{"id":"6c39b7de3409414da46129f3fd501e32","type":"GENE","name":"RC3H1-IT1","canonical_id":"hgnc:HGNC:41496","description":"RC3H1 intronic transcript 1","metadata":null},{"id":"f5cdae0a4071447fb99615f6b5a66db2","type":"GENE","name":"RC3H2","canonical_id":"hgnc:HGNC:21461","description":"ring finger and CCCH-type domains 2","metadata":{"aliases":["FLJ20301","FLJ20713","RNF164","MNAB"]}},{"id":"503658c6b88f443e948709a83837415b","type":"TRIAL","name":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","canonical_id":"clinicaltrials.gov:NCT06185400","description":"Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors; ERBB2 Gene Duplication; Disitamab Vedotin","metadata":null},{"id":"65a118861c6d4a9cb126cd66295df112","type":"TRIAL","name":"RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression","canonical_id":"clinicaltrials.gov:NCT05940896","description":"Solid Tumor","metadata":null},{"id":"b261108904c04f069cfde8157eb4af66","type":"GO_TERM","name":"RCAF complex","canonical_id":"go:GO:0035059","description":"\"A protein complex that facilitates the assembly of nucleosomes on to newly synthesized DNA. In Drosophila, the complex comprises ASF1 and histones H3 and H4.\" [GOC:bf, PMID:10591219]","metadata":null},{"id":"8e9b1482341a4b39a6024c480c6e2f50","type":"GENE","name":"RCAN1","canonical_id":"hgnc:HGNC:3040","description":null,"metadata":null},{"id":"16d4a978ce56430387cbe63c79ce5b38","type":"GENE","name":"RCAN2","canonical_id":"hgnc:HGNC:3041","description":"regulator of calcineurin 2","metadata":{"aliases":["ZAKI-4","DSCR1L1"]}},{"id":"c3c3f24e2d4243ffbf90024660e55a16","type":"GENE","name":"RCAN2-AS1","canonical_id":"hgnc:HGNC:59265","description":"RCAN2 antisense RNA 1","metadata":{"aliases":["CARUF"]}},{"id":"5113e3c193884f11b29368737b3c81e2","type":"GENE","name":"RCAN2-DT","canonical_id":"hgnc:HGNC:55661","description":"RCAN2 divergent transcript","metadata":null},{"id":"4274b4a1c76c422cb18563e5373f1eca","type":"GENE","name":"RCAN3","canonical_id":"hgnc:HGNC:3042","description":"regulator of calcineurin 3","metadata":{"aliases":["DSCR1L2"]}},{"id":"4c766615f0684b97a569914f90d384bd","type":"GENE","name":"RCAN3AS","canonical_id":"hgnc:HGNC:39009","description":"RCAN3 antisense RNA","metadata":{"aliases":["TCONS_00001428","NCMAP-DT"]}},{"id":"bc83559f9efb407397edfcde3b3a9a6a","type":"GENE","name":"RCBTB1","canonical_id":"hgnc:HGNC:18243","description":"RCC1 and BTB domain containing protein 1","metadata":{"aliases":["FLJ10716","CLLD7","CLLL7"]}},{"id":"2985084ac5de42f084c853c2ca927635","type":"GENE","name":"RCBTB2","canonical_id":"hgnc:HGNC:1914","description":"RCC1 and BTB domain containing protein 2","metadata":{"aliases":["CHC1L"]}},{"id":"eef9738ab2434e93875db8f8c4035d4c","type":"GENE","name":"RCBTB2P1","canonical_id":"hgnc:HGNC:45167","description":"RCC1 and BTB domain containing protein 2 pseudogene 1","metadata":null},{"id":"b1e49f9b2f36490ba5dd819af49ee416","type":"GENE","name":"RCC1","canonical_id":"hgnc:HGNC:1913","description":null,"metadata":null},{"id":"60fa4d5828dd40a4864b333c5441f39c","type":"GENE","name":"RCC1L","canonical_id":"hgnc:HGNC:14948","description":"RCC1 like","metadata":{"aliases":["WBSCR16"]}},{"id":"dd2c671160224f2f94b56132a749ea3f","type":"GENE","name":"RCC2","canonical_id":"hgnc:HGNC:30297","description":"regulator of chromosome condensation 2","metadata":{"aliases":["TD-60"]}},{"id":"9bca9c921c064c29a65ec511a9faa435","type":"GENE","name":"RCC2-AS1","canonical_id":"hgnc:HGNC:41262","description":"RCC2 antisense RNA 1","metadata":{"aliases":["LCPAT1","ENST00000439577"]}},{"id":"ccddc37fca55424797f1ed150896fab0","type":"GENE","name":"RCC2P1","canonical_id":"hgnc:HGNC:37710","description":"regulator of chromosome condensation 2 pseudogene 1","metadata":null},{"id":"794c460692d84dc880f0bacbb515a98e","type":"GENE","name":"RCC2P2","canonical_id":"hgnc:HGNC:38419","description":"regulator of chromosome condensation 2 pseudogene 2","metadata":null},{"id":"f065c92c067f44d48dc4bd9c5755c247","type":"GENE","name":"RCC2P3","canonical_id":"hgnc:HGNC:42379","description":"regulator of chromosome condensation 2 pseudogene 3","metadata":null},{"id":"c2699f63dac24a35bebc670537cdd943","type":"GENE","name":"RCC2P4","canonical_id":"hgnc:HGNC:42380","description":"regulator of chromosome condensation 2 pseudogene 4","metadata":null},{"id":"5128173847bf4d6ca963a58ba66baaef","type":"GENE","name":"RCC2P5","canonical_id":"hgnc:HGNC:42381","description":"regulator of chromosome condensation 2 pseudogene 5","metadata":null},{"id":"1c16c50c49df4d0e8ecdffba22ce7d9f","type":"GENE","name":"RCC2P6","canonical_id":"hgnc:HGNC:42382","description":"regulator of chromosome condensation 2 pseudogene 6","metadata":null},{"id":"c78518bafcc5435990ee8e342e0cd747","type":"GENE","name":"RCC2P7","canonical_id":"hgnc:HGNC:42383","description":"regulator of chromosome condensation 2 pseudogene 7","metadata":null},{"id":"95295d743ce14f16882ac485a0de1dd0","type":"GENE","name":"RCC2P8","canonical_id":"hgnc:HGNC:42384","description":"regulator of chromosome condensation 2 pseudogene 8","metadata":null},{"id":"1fe7b071bfdc4844b9b472171b5f032f","type":"GENE","name":"RCCD1","canonical_id":"hgnc:HGNC:30457","description":"RCC1 domain containing 1","metadata":{"aliases":["MGC14386"]}},{"id":"3d6f45f692ea4f3986397d041a19e1b2","type":"GENE","name":"RCCD1-AS1","canonical_id":"hgnc:HGNC:54811","description":"RCCD1 and UNC45A antisense RNA 1","metadata":null},{"id":"197f2e80d09146e0a8d0a7c3d8bde57f","type":"GENE","name":"RCE1","canonical_id":"hgnc:HGNC:13721","description":"Ras converting CAAX endopeptidase 1","metadata":{"aliases":["hRCE1","FACE-2","FACE2","RCE1A","RCE1B"]}},{"id":"6ba50dcfa34e4fd1ba218ee4571bc479","type":"GENE","name":"RCHY1","canonical_id":"hgnc:HGNC:17479","description":"ring finger and CHY zinc finger domain containing 1","metadata":{"aliases":["CHIMP","DKFZp586C1620","PRO1996","RNF199","ARNIP","PIRH2","ZCHY","ZNF363"]}},{"id":"359f49b522e94160ac46750058994a45","type":"GENE","name":"RCL1","canonical_id":"hgnc:HGNC:17687","description":"RNA terminal phosphate cyclase like 1","metadata":{"aliases":["RPCL1","RNAC"]}},{"id":"e39557d726234aff8633e74fc47324cc","type":"GENE","name":"RCN1","canonical_id":"hgnc:HGNC:9934","description":"reticulocalbin 1","metadata":{"aliases":["Rcal","PIG20","FLJ37041","RCN"]}},{"id":"709062ab18c548c8be3a61fa799febd3","type":"GENE","name":"RCN1P1","canonical_id":"hgnc:HGNC:39205","description":"reticulocalbin 1 pseudogene 1","metadata":null},{"id":"22992a52b9884924a5da51454c244945","type":"GENE","name":"RCN1P2","canonical_id":"hgnc:HGNC:39204","description":"reticulocalbin 1 pseudogene 2","metadata":null},{"id":"dabc8e3267d24778a82cac2e635f5e15","type":"GENE","name":"RCN2","canonical_id":"hgnc:HGNC:9935","description":"reticulocalbin 2","metadata":{"aliases":["ERC-55","E6BP","ERC55","TCBP49"]}},{"id":"aee592f5902b4cf3840246e1ab87ea1e","type":"GENE","name":"RCN3","canonical_id":"hgnc:HGNC:21145","description":"reticulocalbin 3","metadata":{"aliases":["RLP49"]}},{"id":"efbd9cfaf09147dc977cdffee326c35d","type":"GENE","name":"RCOR1","canonical_id":"hgnc:HGNC:17441","description":"REST corepressor 1","metadata":{"aliases":["COREST","KIAA0071","RCOR"]}},{"id":"25b8c938d1034ff182c566b3e6654994","type":"GENE","name":"RCOR2","canonical_id":"hgnc:HGNC:27455","description":"REST corepressor 2","metadata":null},{"id":"befd4f9afbdc4c4a8da16704ccfdac7e","type":"GENE","name":"RCOR2P1","canonical_id":"hgnc:HGNC:58652","description":"RCOR2 pseudogene 1","metadata":null},{"id":"5fb220a6527649719e20963cff0c07ee","type":"GENE","name":"RCOR3","canonical_id":"hgnc:HGNC:25594","description":"REST corepressor 3","metadata":{"aliases":["FLJ10876"]}},{"id":"64ce51904a7c4a8289ff37196035dea0","type":"GENE","name":"RCSD1","canonical_id":"hgnc:HGNC:28310","description":"RCSD domain containing 1","metadata":{"aliases":["MK2S4","MGC21854","CapZIP"]}},{"id":"c57307426b0d4bcca2570fd6ec8a1a58","type":"TRIAL","name":"RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response","canonical_id":"clinicaltrials.gov:NCT04738773","description":"Eye Tracking; Gambling Disorder; Naltrexone","metadata":null},{"id":"cddadfcb3de040479ab07982ee7ff5da","type":"TRIAL","name":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","canonical_id":"clinicaltrials.gov:NCT05531591","description":"Depression; Dementia; Mild Cognitive Impairment; Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression","metadata":null},{"id":"e05e730296ea427a9c45ee00bd73c48e","type":"TRIAL","name":"RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity","canonical_id":"clinicaltrials.gov:NCT02529631","description":"Overweight; Obesity","metadata":null},{"id":"ffed62e99a96493397d0cbbd921a0654","type":"GENE","name":"RCVRN","canonical_id":"hgnc:HGNC:9937","description":"recoverin","metadata":{"aliases":["RCV1"]}},{"id":"ee50130c171144bf8b4396fead8948c0","type":"TRIAL","name":"RCVS: The Rational Approach to Diagnosis and Treatment","canonical_id":"clinicaltrials.gov:NCT03150524","description":"Reversible Cerebral Vasoconstriction Syndrome","metadata":null},{"id":"31f75b03da374b6e9dab07f0f2b80add","type":"GENE","name":"RD3","canonical_id":"hgnc:HGNC:19689","description":"RD3 regulator of GUCY2D","metadata":{"aliases":["LCA12","C1orf36"]}},{"id":"1171a6975d21435dac9069b365beaaaa","type":"GENE","name":"RD3L","canonical_id":"hgnc:HGNC:40912","description":"RD3 like","metadata":{"aliases":["TDRD9AS1","TDRD9-AS1"]}},{"id":"177fe4d48c2748649e8cb66fd86d797b","type":"TRIAL","name":"RDEA3170 and Febuxostat Combination Study in Gout Subjects","canonical_id":"clinicaltrials.gov:NCT02246673","description":"Gout","metadata":null},{"id":"43ac68fb7e8e4984992a3e93d11ec736","type":"TRIAL","name":"RDEA3170 and Febuxostat Drug Interaction Study","canonical_id":"clinicaltrials.gov:NCT01883167","description":"Healthy","metadata":null},{"id":"4e1bb31515ac4a06be4b960244ca0faf","type":"GENE","name":"RDH10","canonical_id":"hgnc:HGNC:19975","description":"retinol dehydrogenase 10","metadata":{"aliases":["SDR16C4"]}},{"id":"bb608e4f66cc4fb2b05b5c03858bb251","type":"GENE","name":"RDH10-AS1","canonical_id":"hgnc:HGNC:51658","description":"RDH10 antisense RNA 1","metadata":null},{"id":"1f2b9b676db84900b336b09064612115","type":"GENE","name":"RDH11","canonical_id":"hgnc:HGNC:17964","description":"retinol dehydrogenase 11","metadata":{"aliases":["MDT1","SDR7C1","ARSDR1"]}},{"id":"d3491a369af54a72a72a1bb58344eee2","type":"GENE","name":"RDH12","canonical_id":"hgnc:HGNC:19977","description":"retinol dehydrogenase 12","metadata":{"aliases":["FLJ30273","SDR7C2","LCA13","RP53"]}},{"id":"a071ef092d004f3b86131dfbc3c92d7a","type":"GENE","name":"RDH13","canonical_id":"hgnc:HGNC:19978","description":"retinol dehydrogenase 13","metadata":{"aliases":["SDR7C3"]}},{"id":"2eab55aa37204884be829bcfd1870d60","type":"GENE","name":"RDH14","canonical_id":"hgnc:HGNC:19979","description":"retinol dehydrogenase 14","metadata":{"aliases":["PAN2","SDR7C4"]}},{"id":"476d33dd841245c7a132e76c69eefc6f","type":"GENE","name":"RDH16","canonical_id":"hgnc:HGNC:29674","description":"retinol dehydrogenase 16","metadata":{"aliases":["RODH-4","SDR9C8"]}},{"id":"1eb89b2877674a8697c3a4985b577bb2","type":"GENE","name":"RDH5","canonical_id":"hgnc:HGNC:9940","description":"retinol dehydrogenase 5","metadata":{"aliases":["HSD17B9","SDR9C5","RDH1"]}},{"id":"7053b8b47ece41429475d06ed9078495","type":"GENE","name":"RDH8","canonical_id":"hgnc:HGNC:14423","description":"retinol dehydrogenase 8","metadata":{"aliases":["PRRDH","SDR28C2"]}},{"id":"12afe7cb018c4eb8963cb3e3df153c69","type":"GENE","name":"RDM1","canonical_id":"hgnc:HGNC:19950","description":"RAD52 motif containing 1","metadata":{"aliases":["MGC33977","RAD52B"]}},{"id":"48ace085e93a4ea597765e607bc541ae","type":"GENE","name":"RDM1P1","canonical_id":"hgnc:HGNC:53917","description":"RDM1 pseudogene 1","metadata":null},{"id":"76cdc0735d824aff8e1b78d7a0aa6e1b","type":"GENE","name":"RDM1P2","canonical_id":"hgnc:HGNC:53918","description":"RDM1 pseudogene 2","metadata":null},{"id":"354d57a7882f4e7ea1c934e7adba153c","type":"GENE","name":"RDM1P3","canonical_id":"hgnc:HGNC:53919","description":"RDM1 pseudogene 3","metadata":null},{"id":"83b8ce921a4940a297dd3bc12bdbc761","type":"GENE","name":"RDM1P4","canonical_id":"hgnc:HGNC:53920","description":"RDM1 pseudogene 4","metadata":null},{"id":"e06876486d24476187376691bca865e7","type":"GENE","name":"RDM1P5","canonical_id":"hgnc:HGNC:53921","description":"RDM1 pseudogene 5","metadata":null},{"id":"7531cf52279c436a852caae540d6df9b","type":"GENE","name":"RDUR","canonical_id":"hgnc:HGNC:27190","description":"RIG-I dependent antiviral response regulator RNA","metadata":{"aliases":["LINC02085"]}},{"id":"e94d558e1aa642768534d343dfc045ea","type":"GENE","name":"RDX","canonical_id":"hgnc:HGNC:9944","description":null,"metadata":null},{"id":"7b61049ee5b44658b89791bcbab6de97","type":"GENE","name":"RDXP1","canonical_id":"hgnc:HGNC:9945","description":"RDX pseudogene 1","metadata":null},{"id":"bf50891edb624fda9a16077413a307e6","type":"GENE","name":"RDXP2","canonical_id":"hgnc:HGNC:9946","description":"radixin pseudogene 2","metadata":null},{"id":"f766adcb66e945acacb1096b2da8ac31","type":"GENE","name":"RDXP3","canonical_id":"hgnc:HGNC:54912","description":"RDX pseudogene 3","metadata":null},{"id":"f8976fcfc25c41d8a79bd5f6bc9a2cc2","type":"TRIAL","name":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","canonical_id":"clinicaltrials.gov:NCT03610711","description":"Gastroesophageal Cancer; Immune Checkpoint Inhibition","metadata":null},{"id":"4d0e55f0c8284d28997786296581340f","type":"TRIAL","name":"REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT03742323","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"41435d608e9b4e5399c23d9d38973f5b","type":"TRIAL","name":"REALITY MONITORING AND DOPAMINE","canonical_id":"clinicaltrials.gov:NCT05711082","description":"Neurosciences","metadata":null},{"id":"86b554ec8a2c4d098e3a79d3f6a410d7","type":"GENE","name":"REC114","canonical_id":"hgnc:HGNC:25065","description":"REC114 meiotic recombination protein","metadata":{"aliases":["LOC283677","FLJ27520","FLJ36860","FLJ44083","CT147","C15orf60"]}},{"id":"bba5b5146f8a4efd9d9f202c75777051","type":"GENE","name":"REC8","canonical_id":"hgnc:HGNC:16879","description":"REC8 meiotic recombination protein","metadata":{"aliases":["Rec8p","kleisin-alpha","REC8L1"]}},{"id":"933d2dd77dec451bbe124d8e6f43f658","type":"GENE","name":"RECK","canonical_id":"hgnc:HGNC:11345","description":null,"metadata":null},{"id":"4ef464fc34374c1bb84b1abb2ca3d421","type":"TRIAL","name":"RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine","canonical_id":"clinicaltrials.gov:NCT05513560","description":"Long COVID; Post COVID Condition; Post Acute Sequelae of COVID-19","metadata":null},{"id":"96bd2fe6b57c46e9914e0e8298c19bf9","type":"TRIAL","name":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","canonical_id":"clinicaltrials.gov:NCT00379769","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"abe62b7fecf54759a038840ccb06b297","type":"GENE","name":"RECQL","canonical_id":"hgnc:HGNC:9948","description":"RecQ like helicase","metadata":{"aliases":["RecQ1","RecQL1"]}},{"id":"46a44fba1781431a9c7e42a6872737c1","type":"GENE","name":"RECQL4","canonical_id":"hgnc:HGNC:9949","description":null,"metadata":null},{"id":"4931f283394a4772b1dc0ffc191d1d4b","type":"GENE","name":"RECQL5","canonical_id":"hgnc:HGNC:9950","description":"RecQ like helicase 5","metadata":{"aliases":["RecQ5","FLJ90603"]}},{"id":"1c999c9f07134cc4989127607257c1a1","type":"TRIAL","name":"REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels","canonical_id":"clinicaltrials.gov:NCT05669755","description":"Cardiovascular Disease","metadata":null},{"id":"e82c4f1649e44802bde2b3c0fbce4dd8","type":"GENE","name":"REDIC1","canonical_id":"hgnc:HGNC:26846","description":"regulator of DNA class I crossover intermediates 1","metadata":{"aliases":["FLJ40126","C12orf40"]}},{"id":"82908bf613cf47d9a723916eaefa90a5","type":"TRIAL","name":"REDucing Hot FLASHes in Women Using Endocrine Therapy.","canonical_id":"clinicaltrials.gov:NCT06106529","description":"Breast Cancer; Hot Flash Due to Medication","metadata":null},{"id":"c05fed08b9754b2cb4c7fb79d339ad94","type":"GENE","name":"REELD1","canonical_id":"hgnc:HGNC:53638","description":"reeler domain containing 1","metadata":null},{"id":"c373c769e6204d6190d988f9733ee36a","type":"GENE","name":"REEP1","canonical_id":"hgnc:HGNC:25786","description":"receptor accessory protein 1","metadata":{"aliases":["FLJ13110","SPG31","Yip2a","C2orf23"]}},{"id":"ed6ad44ea1ee429fbae08b1d00fafdfa","type":"GENE","name":"REEP2","canonical_id":"hgnc:HGNC:17975","description":"receptor accessory protein 2","metadata":{"aliases":["SGC32445","SPG72","Yip2d","C5orf19"]}},{"id":"2274ae426a8b424893b92eecfd031af5","type":"GENE","name":"REEP3","canonical_id":"hgnc:HGNC:23711","description":"receptor accessory protein 3","metadata":{"aliases":["Yip2b","C10orf74"]}},{"id":"7830bfd39ca04fb49b3798b97ef60aa2","type":"GENE","name":"REEP4","canonical_id":"hgnc:HGNC:26176","description":"receptor accessory protein 4","metadata":{"aliases":["FLJ22246","FLJ22277","PP432","Yip2c","C8orf20"]}},{"id":"0367b226993e485bbb16bc5102504661","type":"GENE","name":"REEP5","canonical_id":"hgnc:HGNC:30077","description":null,"metadata":null},{"id":"6b18b08a36a04d35956a6b7b5b465f0e","type":"GENE","name":"REEP5-AS1","canonical_id":"hgnc:HGNC:59112","description":"REEP5 antisense RNA 1","metadata":null},{"id":"d7179aa327f44308872c3bb489bb7828","type":"GENE","name":"REEP6","canonical_id":"hgnc:HGNC:30078","description":"receptor accessory protein 6","metadata":{"aliases":["DP1L1","FLJ25383","Yip2f","TB1","C19orf32"]}},{"id":"5b97c0bc07a94f989b15c9cfe1895d8d","type":"GENE","name":"REG1A","canonical_id":"hgnc:HGNC:9951","description":"regenerating family member 1 alpha","metadata":{"aliases":["PSP","PTP","PSPS","PSPS1","REG"]}},{"id":"321900ab84ec4080b746d9491c978b35","type":"GENE","name":"REG1B","canonical_id":"hgnc:HGNC:9952","description":"regenerating family member 1 beta","metadata":{"aliases":["REGL","PSPS2","REGH","REGI-BETA"]}},{"id":"4d8e969ddf98419d9e0e34e4b7c5df71","type":"GENE","name":"REG1CP","canonical_id":"hgnc:HGNC:9953","description":"regenerating family member 1 gamma, pseudogene","metadata":{"aliases":["RS","REGL","REG1P"]}},{"id":"cc750d91cd6d40f8b31ce30f680d229e","type":"GENE","name":"REG3A","canonical_id":"hgnc:HGNC:8601","description":"regenerating family member 3 alpha","metadata":{"aliases":["HIP","REG-III","REG3","PBCGF","PAP1","PAP"]}},{"id":"9079b6a9c3fb4361bbb0138b76598364","type":"GENE","name":"REG3G","canonical_id":"hgnc:HGNC:29595","description":"regenerating family member 3 gamma","metadata":{"aliases":["UNQ429","LPPM429","PAP1B"]}},{"id":"47e520f285e343a499fbc5ce50cc754b","type":"GENE","name":"REG4","canonical_id":"hgnc:HGNC:22977","description":null,"metadata":null},{"id":"4479920cb8f343a29fef260306968d22","type":"TRIAL","name":"REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants","canonical_id":"clinicaltrials.gov:NCT07850921","description":"Metastatic Castration-Resistant Prostate Cancer; mCRPC","metadata":null},{"id":"46dcb09c3af84f4b8ee8266c275b1fef","type":"TRIAL","name":"REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03951831","description":"Prostate Cancer Metastatic","metadata":null},{"id":"a45d6fdf07a846b183a505ed2e3ea147","type":"TRIAL","name":"REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression","canonical_id":"clinicaltrials.gov:NCT02584465","description":"Ovarian Carcinoma","metadata":null},{"id":"5ebf827bc90040deb3253c6896a571e9","type":"GENE","name":"REL","canonical_id":"hgnc:HGNC:9954","description":null,"metadata":null},{"id":"8b923addcd2f4786b48e6581e9237d3a","type":"GENE","name":"REL-DT","canonical_id":"hgnc:HGNC:49572","description":"REL divergent transcript","metadata":{"aliases":["FLJ16341","LINC01185"]}},{"id":"22bb325c64b349e18b3ccd07f1773154","type":"GENE","name":"RELA","canonical_id":"hgnc:HGNC:9955","description":null,"metadata":null},{"id":"749c61a872a142589030c7815349303b","type":"GENE","name":"RELA-DT","canonical_id":"hgnc:HGNC:54185","description":"RELA divergent transcript","metadata":null},{"id":"fbe132d1dcca4ff4b2b1c6250a432bd1","type":"GENE","name":"RELB","canonical_id":"hgnc:HGNC:9956","description":null,"metadata":null},{"id":"63d3d5d2b4fa48dabc4237f0992d5460","type":"GENE","name":"RELCH","canonical_id":"hgnc:HGNC:29289","description":"RAB11 binding and LisH domain, coiled-coil and HEAT repeat containing","metadata":{"aliases":["HsT885","HsT3308","FLJ33841","KIAA1468"]}},{"id":"1fecc2859af24074911a7ee7933e83fd","type":"GENE","name":"RELL1","canonical_id":"hgnc:HGNC:27379","description":"RELT like 1","metadata":null},{"id":"a8e69b4c13304e2ebe376cf835b163b7","type":"GENE","name":"RELL2","canonical_id":"hgnc:HGNC:26902","description":"RELT like 2","metadata":{"aliases":["FLJ90583","C5orf16"]}},{"id":"4a8abc9a779c4402aa4df0067e40397e","type":"GENE","name":"RELN","canonical_id":"hgnc:HGNC:9957","description":null,"metadata":null},{"id":"786131c95e76456a95e367a0b4afcede","type":"GENE","name":"RELT","canonical_id":"hgnc:HGNC:13764","description":"RELT TNF receptor","metadata":{"aliases":["FLJ14993","TNFRSF19L"]}},{"id":"cbf4947eee1643be86a1f8e01df7eacc","type":"GENE","name":"REM1","canonical_id":"hgnc:HGNC:15922","description":"RRAD and GEM like GTPase 1","metadata":{"aliases":["GES","REM"]}},{"id":"ac5125fed4094532aa0db0fb3a622a75","type":"GENE","name":"REM2","canonical_id":"hgnc:HGNC:20248","description":"RRAD and GEM like GTPase 2","metadata":{"aliases":["FLJ38964"]}},{"id":"25d2f79de58043b5ae6e6fb17926d8c7","type":"TRIAL","name":"REMAP ECMO - Beta Receptor Modulation Trial","canonical_id":"clinicaltrials.gov:NCT06522594","description":"Heart Failure; Cardiogenic Shock","metadata":null},{"id":"1536b2be3ce541418f3788c3705987c2","type":"TRIAL","name":"REMIfentanil (2 vs. 4 mcg/kg) Facilitated Intubation Without Neuromuscular Blockade Versus Succinylcholine and Rocuronium With Sugammadex for Endotracheal Intubation in Spine Surgery Requiring Motor Evoked Potential Monitoring","canonical_id":"clinicaltrials.gov:NCT07835295","description":"Airway Management; Endotracheal Intubation","metadata":null},{"id":"921626e498794dca934e404d85a20ca1","type":"GENE","name":"REN","canonical_id":"hgnc:HGNC:9958","description":null,"metadata":null},{"id":"d7ee1dc71baa4e7a9f22e8469554038a","type":"GENE","name":"RENBP","canonical_id":"hgnc:HGNC:9959","description":"renin binding protein","metadata":{"aliases":["RNBP","RBP"]}},{"id":"db3e52327d1143ff8d080e7935ba0a8c","type":"GENE","name":"RENO1","canonical_id":"hgnc:HGNC:54096","description":"regulator of early neurogenesis 1","metadata":null},{"id":"923f292046a54ff5bbd2446eb41e987f","type":"GO_TERM","name":"RENT complex","canonical_id":"go:GO:0030869","description":"\"A protein complex that mediates transcriptional silencing at the rDNA locus (the name derives from regulator of nucleolar silencing and telophase). In Saccharomyces the complex contains Net1p, Sir2p, Cdc14p, and at least one more subunit.\" [PMID:12196389]","metadata":null},{"id":"0baa7346105f47d79b2f2cd6afa57fd0","type":"GENE","name":"REP15","canonical_id":"hgnc:HGNC:33748","description":"RAB15 effector protein","metadata":{"aliases":["RAB15EP"]}},{"id":"456d5eda321b40be9d092c0533f554d6","type":"TRIAL","name":"REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension","canonical_id":"clinicaltrials.gov:NCT02310672","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"61aa896ea05e4ede8269b32db6a7a75a","type":"TRIAL","name":"REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy","canonical_id":"clinicaltrials.gov:NCT00874679","description":"Erectile Dysfunction","metadata":null},{"id":"60c8cb430be34fcdbdb18cf29d9ca3f9","type":"GENE","name":"REPIN1","canonical_id":"hgnc:HGNC:17922","description":"replication initiator 1","metadata":{"aliases":["RIP60","AP4","H_DJ0584D14.12","Zfp464","ZNF464"]}},{"id":"924517228c4e45d79d0047e2fa4c5b5d","type":"GENE","name":"REPIN1-AS1","canonical_id":"hgnc:HGNC:41201","description":"REPIN1 antisense RNA 1","metadata":null},{"id":"8a2c76ad0e5c460495187ce2c129b207","type":"TRIAL","name":"REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant","canonical_id":"clinicaltrials.gov:NCT05733286","description":"Delirium in Old Age","metadata":null},{"id":"321f739723b249bd93da7cd6e9cde87c","type":"GENE","name":"REPS1","canonical_id":"hgnc:HGNC:15578","description":"RALBP1 associated Eps domain containing 1","metadata":null},{"id":"5f64603b79874a1d859850ab5fd3c0bc","type":"GENE","name":"REPS2","canonical_id":"hgnc:HGNC:9963","description":null,"metadata":null},{"id":"96ec691d442e488ca93aabb4f4a713d3","type":"TRIAL","name":"REQUIP RLS Post Marketing Surveillance","canonical_id":"clinicaltrials.gov:NCT01327339","description":"Restless Legs Syndrome","metadata":null},{"id":"8714564542154c39a4d2c9e4a82896b6","type":"GENE","name":"RER1","canonical_id":"hgnc:HGNC:30309","description":"retention in endoplasmic reticulum sorting receptor 1","metadata":null},{"id":"66116bfa51ce46b783f07b50c70ad1f2","type":"GENE","name":"RERE","canonical_id":"hgnc:HGNC:9965","description":"arginine-glutamic acid dipeptide repeats","metadata":{"aliases":["KIAA0458","ARP","ARG","DNB1","ATN2","ATN1L"]}},{"id":"f9b06af6b7af46208a9512ca6e5eaaf6","type":"GENE","name":"RERE-AS1","canonical_id":"hgnc:HGNC:40501","description":"RERE antisense RNA 1","metadata":null},{"id":"1a92d094e26c46d299653f222c543ca9","type":"GENE","name":"REREP1Y","canonical_id":"hgnc:HGNC:38795","description":"arginine-glutamic acid dipeptide repeats pseudogene 1 Y-linked","metadata":null},{"id":"92c848f12cd442deafa8a9b55de1fb8a","type":"GENE","name":"REREP2Y","canonical_id":"hgnc:HGNC:38796","description":"arginine-glutamic acid dipeptide repeats pseudogene 2 Y-linked","metadata":null},{"id":"e996036e11e04f12992eeae982c33b67","type":"GENE","name":"REREP3","canonical_id":"hgnc:HGNC:38797","description":"arginine-glutamic acid dipeptide repeats pseudogene 3","metadata":null},{"id":"9a7d3b9b0aa142ea950ae2dea351cb6c","type":"GENE","name":"RERG","canonical_id":"hgnc:HGNC:15980","description":"RAS like estrogen regulated growth inhibitor","metadata":{"aliases":["MGC15754"]}},{"id":"073eb148d7f044f283feafcb85e8509d","type":"GENE","name":"RERG-AS1","canonical_id":"hgnc:HGNC:39990","description":"RERG antisense RNA 1","metadata":null},{"id":"6e0a4cd7e45a48aa809ea2d2e0f20342","type":"GENE","name":"RERG-IT1","canonical_id":"hgnc:HGNC:39991","description":"RERG intronic transcript 1","metadata":null},{"id":"5667cf9cc77146d3aed72fd2cb9facba","type":"GENE","name":"RERGL","canonical_id":"hgnc:HGNC:26213","description":"RERG like","metadata":{"aliases":["FLJ22655"]}},{"id":"8fba0605e0f4430cb7f24fe844f78ac5","type":"GO_TERM","name":"RES complex","canonical_id":"go:GO:0070274","description":"\"A protein complex that is required for efficient splicing, and prevents leakage of unspliced pre-mRNAs from the nucleus (named for pre-mRNA REtention and Splicing). In Saccharomyces, the complex consists of Ist3p, Bud13p, and Pml1p.\" [PMID:15565172, PMID:18809678, PMID:19010333, PMID:19033360]","metadata":null},{"id":"0c29450b9be34f468297a939a4827a2e","type":"GENE","name":"RESF1","canonical_id":"hgnc:HGNC:25559","description":"retroelement silencing factor 1","metadata":{"aliases":["FLJ20696","FLJ10652","UTA2-1","GET","C12orf35","KIAA1551"]}},{"id":"e783c7b474f14168bb67721dcf921fbb","type":"TRIAL","name":"RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT03675893","description":"Endometrial Cancer","metadata":null},{"id":"86b4d92f3d274fa79c5982ea93012d18","type":"GENE","name":"RESP18","canonical_id":"hgnc:HGNC:33762","description":"regulated endocrine specific protein 18","metadata":null},{"id":"42116ffb128a466eb1b528effc2c5c20","type":"TRIAL","name":"RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)","canonical_id":"clinicaltrials.gov:NCT04620733","description":"Primary Biliary Cholangitis","metadata":null},{"id":"d75ac25b067d447f8713bd755736d797","type":"GENE","name":"REST","canonical_id":"hgnc:HGNC:9966","description":null,"metadata":null},{"id":"dfc85580661246e48852ae381538f955","type":"TRIAL","name":"REST - Replacing Steroids in the Transplant Ineligble","canonical_id":"clinicaltrials.gov:NCT04939844","description":"Multiple Myeloma","metadata":null},{"id":"dbb7d186cbda4d6aa2ded1071ae2af4b","type":"GENE","name":"RET","canonical_id":"hgnc:HGNC:9967","description":null,"metadata":null},{"id":"bda3d50a04fb4e029f88c49361389ce9","type":"PROTEIN","name":"RET","canonical_id":"uniprot:P07949","description":null,"metadata":null},{"id":"874860e187a44aaf8e10c16fed6d68ed","type":"GENE","name":"RET","canonical_id":"ensembl:ENSG00000165731","description":null,"metadata":null},{"id":"4d2c024562234ed089d53a717febeabf","type":"TRIAL","name":"RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative","canonical_id":"clinicaltrials.gov:NCT02867761","description":"COPD (Chronic Obstructive Pulmonary Disease)","metadata":null},{"id":"08cfb6080a2848f58965b8ba96d54671","type":"GENE","name":"RETN","canonical_id":"hgnc:HGNC:20389","description":null,"metadata":null},{"id":"3c8f70faecf6445ca05514b79ede48dc","type":"GENE","name":"RETNLB","canonical_id":"hgnc:HGNC:20388","description":null,"metadata":null},{"id":"d66f469f68f94688a0eb74d304d7eb93","type":"GENE","name":"RETREG1","canonical_id":"hgnc:HGNC:25964","description":"reticulophagy regulator 1","metadata":{"aliases":["FLJ20152","JK1","FAM134B"]}},{"id":"c01d3d4383824260ba1ec5e47cb97199","type":"GENE","name":"RETREG1-AS1","canonical_id":"hgnc:HGNC:55551","description":"RETREG1 antisense RNA 1","metadata":null},{"id":"3794d4f6584e48499e665e31c7d750c8","type":"GENE","name":"RETREG2","canonical_id":"hgnc:HGNC:28450","description":"reticulophagy regulator family member 2","metadata":{"aliases":["MGC3035","MAG-2","C2orf17","FAM134A"]}},{"id":"66ca86255f2e4fb981a3017d4839c29d","type":"GENE","name":"RETREG3","canonical_id":"hgnc:HGNC:27258","description":"reticulophagy regulator family member 3","metadata":{"aliases":["DKFZp686B1036","FLJ33806","FAM134C"]}},{"id":"9dd25b07ed8141319eed133cbddc8f39","type":"GENE","name":"RETSAT","canonical_id":"hgnc:HGNC:25991","description":"retinol saturase","metadata":{"aliases":["FLJ20296"]}},{"id":"54a7b37123e34eb1a6d41c95ad89a706","type":"GENE","name":"REV1","canonical_id":"hgnc:HGNC:14060","description":"REV1 DNA directed polymerase","metadata":{"aliases":["REV1L"]}},{"id":"6290995b2caa4c00bf0ff50c1ef69794","type":"GENE","name":"REV3L","canonical_id":"hgnc:HGNC:9968","description":"REV3 like, DNA directed polymerase zeta catalytic subunit","metadata":{"aliases":["POLZ","REV3"]}},{"id":"d42e3397e274418980a58b7784eb9b7b","type":"GENE","name":"REV3L-AS1","canonical_id":"hgnc:HGNC:58340","description":"REV3L antisense RNA 1","metadata":null},{"id":"34a303d289534758986f526fceb39f31","type":"GENE","name":"REV3L-IT1","canonical_id":"hgnc:HGNC:41377","description":"REV3L intronic transcript 1","metadata":null},{"id":"1eee498b4a9a41af969dc089ff012ccc","type":"TRIAL","name":"REVErsing Airway Remodelling With Tezepelumab","canonical_id":"clinicaltrials.gov:NCT05651841","description":"Airway Remodelling, Asthmatic","metadata":null},{"id":"6f26046838a64a2ab7b497da240e521a","type":"GENE","name":"REX1BD","canonical_id":"hgnc:HGNC:26098","description":"required for excision 1-B domain containing","metadata":{"aliases":["FLJ20850","FLJ30108","FLJ34606","FLJ37391","C19orf60"]}},{"id":"cf10f26d41a24af6b344661445def93b","type":"GENE","name":"REXO1","canonical_id":"hgnc:HGNC:24616","description":"RNA exonuclease 1 homolog","metadata":{"aliases":["EloA-BP1","KIAA1138","TCEB3BP1"]}},{"id":"1a016c25bd8c4791925455a1bdd44fc6","type":"GENE","name":"REXO1L10P","canonical_id":"hgnc:HGNC:44433","description":"REXO1 like 10, pseudogene","metadata":null},{"id":"50eb0a49d29d4fe0b50446d78a324a44","type":"GENE","name":"REXO1L11P","canonical_id":"hgnc:HGNC:44434","description":"REXO1 like 11, pseudogene","metadata":null},{"id":"15206e53748440089f20635e09ade008","type":"GENE","name":"REXO1L12P","canonical_id":"hgnc:HGNC:44435","description":"REXO1 like 12, pseudogene","metadata":null},{"id":"761ad4c5c7604ed19674a6a5a78d5aab","type":"GENE","name":"REXO1L1P","canonical_id":"hgnc:HGNC:24660","description":"REXO1 like 1, pseudogene","metadata":{"aliases":["GOR","REXO1L1"]}},{"id":"22ce4f14badd45c4ae6bef2fa01902ac","type":"GENE","name":"REXO1L2P","canonical_id":"hgnc:HGNC:32239","description":"REXO1 like 2, pseudogene","metadata":null},{"id":"5838d767b779471da9eb56d9b6bc21c0","type":"GENE","name":"REXO1L3P","canonical_id":"hgnc:HGNC:32240","description":"REXO1 like 3, pseudogene","metadata":null},{"id":"d6049b4f842e44ab971cd16f12c4686b","type":"GENE","name":"REXO1L4P","canonical_id":"hgnc:HGNC:32241","description":"REXO1 like 4, pseudogene","metadata":null},{"id":"4cb937fad09243a093ef0567c19ec00f","type":"GENE","name":"REXO1L5P","canonical_id":"hgnc:HGNC:32242","description":"REXO1 like 5, pseudogene","metadata":null},{"id":"c344864f48434ef699cda248cc3c2bb5","type":"GENE","name":"REXO1L6P","canonical_id":"hgnc:HGNC:32243","description":"REXO1 like 6, pseudogene","metadata":{"aliases":["REXO1L7P"]}},{"id":"1f0e4d6fb3f048c796b8aceaedf690f8","type":"GENE","name":"REXO1L8P","canonical_id":"hgnc:HGNC:35429","description":"REXO1 like 8, pseudogene","metadata":{"aliases":["REXO1L8"]}},{"id":"d802d59a709c4009bbbc35b426c16aff","type":"GENE","name":"REXO1L9P","canonical_id":"hgnc:HGNC:44432","description":"REXO1 like 9, pseudogene","metadata":null},{"id":"3be0cd51c5ac47a897a7fa46fe61537a","type":"GENE","name":"REXO2","canonical_id":"hgnc:HGNC:17851","description":"RNA exonuclease 2","metadata":{"aliases":["DKFZP566E144","SFN","CGI-114"]}},{"id":"9ba14e563f174191a946f019b44b82a1","type":"GENE","name":"REXO4","canonical_id":"hgnc:HGNC:12820","description":"RNA exonuclease 4","metadata":{"aliases":["hPMC2","XPMC2H"]}},{"id":"993ec1434b284a71a3cf106a52a85301","type":"GENE","name":"REXO5","canonical_id":"hgnc:HGNC:24661","description":"RNA exonuclease 5","metadata":{"aliases":["NEF-sp"]}},{"id":"ce1e1d1d29b84666a060d330f20afb41","type":"GENE","name":"REXO6P","canonical_id":"hgnc:HGNC:16506","description":"RNA exonuclease 6, pseudogene","metadata":{"aliases":["C9orf14","NCRNA00032","LINC00032"]}},{"id":"091d1d05a1914a2ebaea6a4f09b9d969","type":"TRIAL","name":"REal-life ON PARKinson's - ITaly (REONPARK-IT)","canonical_id":"clinicaltrials.gov:NCT07403799","description":"Parkinson Disease","metadata":null},{"id":"353f0f347fed43af90408065f27d71c6","type":"TRIAL","name":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","canonical_id":"clinicaltrials.gov:NCT05164198","description":"Ankylosing Spondylitis; Axial Spondyloarthritis","metadata":null},{"id":"7741b7d4823547168ddb79b496ae60b1","type":"TRIAL","name":"REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","canonical_id":"clinicaltrials.gov:NCT04667078","description":"Acute Ischemia","metadata":null},{"id":"a566078b854a474f851e971806a9354d","type":"GENE","name":"RFC1","canonical_id":"hgnc:HGNC:9969","description":"replication factor C subunit 1","metadata":{"aliases":["A1","PO-GA","RFC140","MHCBFB"]}},{"id":"32198d2f948d404f81384d710b5c5c3f","type":"GENE","name":"RFC1-AS1","canonical_id":"hgnc:HGNC:58776","description":"RFC1 antisense RNA 1","metadata":null},{"id":"150b64b197e541d3a7fb4ad6a19dc182","type":"GENE","name":"RFC2","canonical_id":"hgnc:HGNC:9970","description":"replication factor C subunit 2","metadata":{"aliases":["A1","RFC40"]}},{"id":"e6a8c34457e7442ebdd609fe4141f4f3","type":"GENE","name":"RFC3","canonical_id":"hgnc:HGNC:9971","description":null,"metadata":null},{"id":"2a228e199fdc4f2e8bdf6754dc9b46e1","type":"GENE","name":"RFC3P1","canonical_id":"hgnc:HGNC:44531","description":"replication factor C 3 pseudogene 1","metadata":null},{"id":"c7cb3be0e68f457b8ab221bd5f78aa59","type":"GENE","name":"RFC4","canonical_id":"hgnc:HGNC:9972","description":"replication factor C subunit 4","metadata":{"aliases":["A1","RFC37"]}},{"id":"eeb68f56321144db938047a2a3a4e8d8","type":"GENE","name":"RFC5","canonical_id":"hgnc:HGNC:9973","description":"replication factor C subunit 5","metadata":{"aliases":["RFC36"]}},{"id":"12d516b5fcd0485eb220c57ac0602d1d","type":"GENE","name":"RFC5P1","canonical_id":"hgnc:HGNC:50450","description":"replication factor C 5 pseudogene 1","metadata":null},{"id":"2486a9ef5f51438abd47aa9e820d9f2a","type":"GENE","name":"RFESD","canonical_id":"hgnc:HGNC:29587","description":"Rieske Fe-S domain containing","metadata":null},{"id":"b5ca29d9edc948a5af358bb78ea15430","type":"GENE","name":"RFESDP1","canonical_id":"hgnc:HGNC:39420","description":"Rieske (Fe-S) domain containing pseudogene 1","metadata":null},{"id":"017fe9aa137a41ac86b5e2a1c0a0a47e","type":"GENE","name":"RFFL","canonical_id":"hgnc:HGNC:24821","description":"ring finger and FYVE like domain containing E3 ubiquitin protein ligase","metadata":{"aliases":["rififylin","fring","RNF189","RNF34L","CARP2","CARP-2"]}},{"id":"caeae6c0d6ec48e1a8410216801225c6","type":"GENE","name":"RFK","canonical_id":"hgnc:HGNC:30324","description":"riboflavin kinase","metadata":{"aliases":["FLJ11149","RIFK"]}},{"id":"ef74f2053d16475b80e9512a32c8fbb3","type":"GENE","name":"RFKP1","canonical_id":"hgnc:HGNC:39181","description":"riboflavin kinase pseudogene 1","metadata":null},{"id":"752aba828ebe484d932baba07810ce24","type":"GENE","name":"RFKP2","canonical_id":"hgnc:HGNC:39182","description":"riboflavin kinase pseudogene 2","metadata":null},{"id":"d642db264f5b42b69c88906ad12a63cf","type":"GENE","name":"RFKP3","canonical_id":"hgnc:HGNC:56487","description":"RFK pseudogene 3","metadata":null},{"id":"7206c540537e4466b5cb58449739b9a1","type":"GENE","name":"RFKP4","canonical_id":"hgnc:HGNC:56488","description":"RFK pseudogene 4","metadata":null},{"id":"e15f477bc8b446dd94c4c5b69c39be7f","type":"GENE","name":"RFKP5","canonical_id":"hgnc:HGNC:56489","description":"RFK pseudogene 5","metadata":null},{"id":"090e21f3b5ae4a08b34b524357a78920","type":"GENE","name":"RFKP6","canonical_id":"hgnc:HGNC:56566","description":"RFK pseudogene 6","metadata":null},{"id":"7bc09763e5ca478caa84afdd2c58b390","type":"GENE","name":"RFLNA","canonical_id":"hgnc:HGNC:27051","description":"refilin A","metadata":{"aliases":["FLJ44614","Cfm2","RefilinA","FAM101A"]}},{"id":"ea67761bfa3f4332be4fafb8f8bdb4b2","type":"GENE","name":"RFLNB","canonical_id":"hgnc:HGNC:28705","description":"refilin B","metadata":{"aliases":["MGC45871","RefilinB","Cfm1","FAM101B"]}},{"id":"80c56eaa6eba4998b2762e73bde2c538","type":"GENE","name":"RFNG","canonical_id":"hgnc:HGNC:9974","description":"RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase","metadata":null},{"id":"e64aa8c241da4a3b965e74d243cd389a","type":"GENE","name":"RFPL1","canonical_id":"hgnc:HGNC:9977","description":"ret finger protein like 1","metadata":{"aliases":["RNF78"]}},{"id":"9283d7341ae8496eab2aa3d7f171e7ea","type":"GENE","name":"RFPL1S","canonical_id":"hgnc:HGNC:9978","description":"RFPL1 antisense RNA 1","metadata":{"aliases":["RFPL1-AS","NCRNA00006","RFPL1-AS1"]}},{"id":"c40e7b07455f443e95c963c7d04082a1","type":"GENE","name":"RFPL2","canonical_id":"hgnc:HGNC:9979","description":"ret finger protein like 2","metadata":{"aliases":["RNF79"]}},{"id":"6f7a244622bd4eafab22228afa7c923b","type":"GENE","name":"RFPL3","canonical_id":"hgnc:HGNC:9980","description":"ret finger protein like 3","metadata":{"aliases":["RNF120"]}},{"id":"4d1b2ca0059a43aa9280b925298601e4","type":"GENE","name":"RFPL3S","canonical_id":"hgnc:HGNC:9981","description":"RFPL3 antisense","metadata":{"aliases":["RFPL3-AS","NCRNA00005","RFPL3-AS1"]}},{"id":"d01d07562674455d8fd3d2930cc748cd","type":"GENE","name":"RFPL4A","canonical_id":"hgnc:HGNC:16449","description":"ret finger protein like 4A","metadata":{"aliases":["RNF210","RFPL4"]}},{"id":"388e9b04b8ab46be9ce4f38b801cc8cf","type":"GENE","name":"RFPL4AL1","canonical_id":"hgnc:HGNC:45147","description":"ret finger protein like 4A like 1","metadata":{"aliases":["RNF210B"]}},{"id":"c461e5942cfb49ceaf11529464c95cc3","type":"GENE","name":"RFPL4AP1","canonical_id":"hgnc:HGNC:45138","description":"ret finger protein like 4A pseudogene 1","metadata":null},{"id":"f7c68da49d5a41f298f01e4a703002b0","type":"GENE","name":"RFPL4AP2","canonical_id":"hgnc:HGNC:45145","description":"ret finger protein like 4A pseudogene 2","metadata":null},{"id":"0796106467964b2eac29da68c632f7b9","type":"GENE","name":"RFPL4AP3","canonical_id":"hgnc:HGNC:45139","description":"ret finger protein like 4A pseudogene 3","metadata":null},{"id":"54f8b512813a47278fd3ee9cfe13cef5","type":"GENE","name":"RFPL4AP4","canonical_id":"hgnc:HGNC:45140","description":"ret finger protein like 4A pseudogene 4","metadata":null},{"id":"2b98fa03caf64336b1eab97a671b067f","type":"GENE","name":"RFPL4AP5","canonical_id":"hgnc:HGNC:45144","description":"ret finger protein like 4A pseudogene 5","metadata":null},{"id":"85f3cd324fc8408584a9273085066ee7","type":"GENE","name":"RFPL4AP6","canonical_id":"hgnc:HGNC:45142","description":"ret finger protein like 4A pseudogene 6","metadata":null},{"id":"b54cbf34dc0145258c6b9ad0b9c3dbff","type":"GENE","name":"RFPL4AP7","canonical_id":"hgnc:HGNC:45143","description":"ret finger protein like 4A pseudogene 7","metadata":null},{"id":"6043b3cf4abc489e95d46034b405ea88","type":"GENE","name":"RFPL4B","canonical_id":"hgnc:HGNC:33264","description":"ret finger protein like 4B","metadata":{"aliases":["RNF211"]}},{"id":"443804fe170446a98beeb914a593970e","type":"GENE","name":"RFT1","canonical_id":"hgnc:HGNC:30220","description":"RFT1 glycolipid translocator homolog","metadata":{"aliases":["CDG1N","SLC76A1"]}},{"id":"662160306e00418682cc64b319e27098","type":"GENE","name":"RFTN1","canonical_id":"hgnc:HGNC:30278","description":"raftlin, lipid raft linker 1","metadata":{"aliases":["MIG2","KIAA0084","FLJ23866","Raftlin"]}},{"id":"f92a0f772a7145928f8606b916988d4a","type":"GENE","name":"RFTN1P1","canonical_id":"hgnc:HGNC:23971","description":"raftlin, lipid raft linker 1 pseudogene 1","metadata":null},{"id":"88e76ac0c6a343cb950d2e85ad7fb63a","type":"GENE","name":"RFTN2","canonical_id":"hgnc:HGNC:26402","description":"raftlin family member 2","metadata":{"aliases":["FLJ30574","Raftlin-2","C2orf11"]}},{"id":"39a9542ec31548db89c39f43f613707e","type":"GENE","name":"RFWD2","canonical_id":"hgnc:HGNC:17440","description":null,"metadata":null},{"id":"20846533693c48dbbc820057726ddb0d","type":"GENE","name":"RFWD3","canonical_id":"hgnc:HGNC:25539","description":"ring finger and WD repeat domain 3","metadata":{"aliases":["FLJ10520","RNF201","FANCW"]}},{"id":"447fc306ab57481ab3df09ec12b4b940","type":"GENE","name":"RFX1","canonical_id":"hgnc:HGNC:9982","description":null,"metadata":null},{"id":"5beee226faeb417891ec3afe48fa0584","type":"GENE","name":"RFX2","canonical_id":"hgnc:HGNC:9983","description":null,"metadata":null},{"id":"557c309c0d62421cb5fadc9d8e105513","type":"GENE","name":"RFX2-AS1","canonical_id":"hgnc:HGNC:58204","description":"RFX2 antisense RNA 1","metadata":null},{"id":"e4ea24cf2c3a47ca87f1f4273bdc9b07","type":"GENE","name":"RFX2-AS2","canonical_id":"hgnc:HGNC:58205","description":"RFX2 antisense RNA 2","metadata":null},{"id":"f0ba3e90a37c486dae6b82aba1d94637","type":"GENE","name":"RFX3","canonical_id":"hgnc:HGNC:9984","description":null,"metadata":null},{"id":"087ef2a53a0e4d41b58eb81464f85610","type":"GENE","name":"RFX3-DT","canonical_id":"hgnc:HGNC:51197","description":"RFX3 divergent transcript","metadata":{"aliases":["RFX3-AS1"]}},{"id":"188e63013c38466e8575bdb41bca5edd","type":"GENE","name":"RFX4","canonical_id":"hgnc:HGNC:9985","description":"regulatory factor X4","metadata":null},{"id":"9822a86c8548469c8a3667a47a062148","type":"GENE","name":"RFX4-AS1","canonical_id":"hgnc:HGNC:58967","description":"RFX4 antisense RNA 1","metadata":{"aliases":["uc.346"]}},{"id":"d1c207bc601f4d09b9cd84ef8c3b05fb","type":"GENE","name":"RFX5","canonical_id":"hgnc:HGNC:9986","description":null,"metadata":null},{"id":"c0c5b1e479fb4813ac4d2080b4e52c58","type":"GENE","name":"RFX5-AS1","canonical_id":"hgnc:HGNC:40503","description":"RFX5 antisense RNA 1","metadata":{"aliases":["GBAT2"]}},{"id":"8a2547a699844eed9af6a15c0f206373","type":"GENE","name":"RFX6","canonical_id":"hgnc:HGNC:21478","description":"regulatory factor X6","metadata":{"aliases":["MGC33442","dJ955L16.1","RFXDC1"]}},{"id":"dcf1251c162145af9fc9390adbeb605b","type":"GENE","name":"RFX7","canonical_id":"hgnc:HGNC:25777","description":"regulatory factor X7","metadata":{"aliases":["FLJ12994","RFXDC2"]}},{"id":"bf42aa68e6f947aca11c344c0f1ce34f","type":"GENE","name":"RFX8","canonical_id":"hgnc:HGNC:37253","description":"regulatory factor X8","metadata":{"aliases":["FLJ42986"]}},{"id":"04320e39e67a49d1a58c4fea86495d83","type":"GENE","name":"RFXANK","canonical_id":"hgnc:HGNC:9987","description":null,"metadata":null},{"id":"089e15d1d0af44d0aa843c17a7d922ff","type":"GENE","name":"RFXAP","canonical_id":"hgnc:HGNC:9988","description":null,"metadata":null},{"id":"446dd5c7e8c144b0bc126d6e1b2d6b19","type":"GENE","name":"RGCC","canonical_id":"hgnc:HGNC:20369","description":"regulator of cell cycle","metadata":{"aliases":["bA157L14.2","RGC-32","RGC32","C13orf15"]}},{"id":"3d2851f41e36479ea347e203ba0266db","type":"GENE","name":"RGL1","canonical_id":"hgnc:HGNC:30281","description":"ral guanine nucleotide dissociation stimulator like 1","metadata":{"aliases":["RGL"]}},{"id":"039b444d80e7494d8cbc017f31e8b1df","type":"GENE","name":"RGL2","canonical_id":"hgnc:HGNC:9769","description":"ral guanine nucleotide dissociation stimulator like 2","metadata":{"aliases":["KE1.5","HKE1.5","RAB2L"]}},{"id":"39d3cf8589a84928a6e7543a7faa3d7c","type":"GENE","name":"RGL3","canonical_id":"hgnc:HGNC:30282","description":"ral guanine nucleotide dissociation stimulator like 3","metadata":{"aliases":["FLJ32585"]}},{"id":"280d9df8c2074f3cb7d5499e520e3d4c","type":"GENE","name":"RGL4","canonical_id":"hgnc:HGNC:31911","description":"ral guanine nucleotide dissociation stimulator like 4","metadata":{"aliases":["Rgr"]}},{"id":"a17677ed49154c168b1b2727dbddad55","type":"GENE","name":"RGL4P1","canonical_id":"hgnc:HGNC:56833","description":"RGL4 pseudogene 1","metadata":null},{"id":"1566d2dfb6e246668701a6bc3fddb906","type":"GENE","name":"RGMA","canonical_id":"hgnc:HGNC:30308","description":"repulsive guidance molecule BMP co-receptor a","metadata":{"aliases":["RGM"]}},{"id":"17680e2e0d7848d984d65606a2770ac4","type":"GENE","name":"RGMB","canonical_id":"hgnc:HGNC:26896","description":"repulsive guidance molecule BMP co-receptor b","metadata":{"aliases":["FLJ90406","DRAGON"]}},{"id":"2aa6f842d4834ebeb44ff1f38126f87d","type":"GENE","name":"RGMB-AS1","canonical_id":"hgnc:HGNC:48666","description":"RGMB antisense RNA 1","metadata":null},{"id":"f8ba685ab3f8460c94acd52e0c20fc91","type":"GENE","name":"RGN","canonical_id":"hgnc:HGNC:9989","description":null,"metadata":null},{"id":"a202a3ee10d84d8aaf58e31a3a9c66e7","type":"GENE","name":"RGP1","canonical_id":"hgnc:HGNC:21965","description":"RGP1 partner of RAB6A GEF complex","metadata":{"aliases":["KIAA0258"]}},{"id":"3564a8f73847448daab8ab925b9f5e42","type":"GENE","name":"RGPD1","canonical_id":"hgnc:HGNC:32414","description":"RANBP2 like and GRIP domain containing 1","metadata":{"aliases":["RGP1"]}},{"id":"3d216e37df2c44e0a8a03bbf9b5443b9","type":"GENE","name":"RGPD2","canonical_id":"hgnc:HGNC:32415","description":"RANBP2 like and GRIP domain containing 2","metadata":{"aliases":["RGP2","RANBP2L2"]}},{"id":"45b02c70109345739a8d3479c2050db2","type":"GENE","name":"RGPD3","canonical_id":"hgnc:HGNC:32416","description":"RANBP2 like and GRIP domain containing 3","metadata":{"aliases":["RGP3"]}},{"id":"8035064b5b5646ed84d319d5f8e04465","type":"GENE","name":"RGPD4","canonical_id":"hgnc:HGNC:32417","description":"RANBP2 like and GRIP domain containing 4","metadata":{"aliases":["RGP4","DKFZp686P0288"]}},{"id":"197bb2e56cc147c2b367f6a2c81e989b","type":"GENE","name":"RGPD4-DT","canonical_id":"hgnc:HGNC:49273","description":"RGPD4 divergent transcript","metadata":{"aliases":["RGPD4-AS1"]}},{"id":"1d8058f0d09547dcbe8ff579de01965e","type":"GENE","name":"RGPD5","canonical_id":"hgnc:HGNC:32418","description":"RANBP2 like and GRIP domain containing 5","metadata":{"aliases":["RGP5","BS-63","DKFZp686I1842"]}},{"id":"89c1d19deede493dbf4c192d2c1fd1cf","type":"GENE","name":"RGPD6","canonical_id":"hgnc:HGNC:32419","description":"RANBP2 like and GRIP domain containing 6","metadata":{"aliases":["RGP6"]}},{"id":"684efb0057954c4786c5513481b47282","type":"GENE","name":"RGPD8","canonical_id":"hgnc:HGNC:9849","description":"RANBP2 like and GRIP domain containing 8","metadata":{"aliases":["RanBP2alpha","RANBP2L1"]}},{"id":"bacba8d81a54431a9c4f0aaf477f7d78","type":"GENE","name":"RGR","canonical_id":"hgnc:HGNC:9990","description":"retinal G protein coupled receptor","metadata":{"aliases":["RP44"]}},{"id":"d8f6bd6e4c174046821748ae384dbee1","type":"GENE","name":"RGS1","canonical_id":"hgnc:HGNC:9991","description":"regulator of G protein signaling 1","metadata":{"aliases":["1R20","IR20","BL34","IER1"]}},{"id":"4d3f651a48ca414f8a86466c57fadd26","type":"GENE","name":"RGS10","canonical_id":"hgnc:HGNC:9992","description":null,"metadata":null},{"id":"dd2784bff9b74597aaab347b228bd379","type":"GENE","name":"RGS11","canonical_id":"hgnc:HGNC:9993","description":"regulator of G protein signaling 11","metadata":null},{"id":"7690ed63d72442f8b6660ca3478976a9","type":"GENE","name":"RGS12","canonical_id":"hgnc:HGNC:9994","description":"regulator of G protein signaling 12","metadata":null},{"id":"80db8b4b15cb462d80115a0340d44793","type":"GENE","name":"RGS12-DT","canonical_id":"hgnc:HGNC:58717","description":"RGS12 divergent transcript","metadata":null},{"id":"0bfdf58c42684481aeecaff2e751de71","type":"GENE","name":"RGS13","canonical_id":"hgnc:HGNC:9995","description":"regulator of G protein signaling 13","metadata":null},{"id":"afd041b9878b49c59a17c4cfd2f92f7f","type":"GENE","name":"RGS14","canonical_id":"hgnc:HGNC:9996","description":"regulator of G protein signaling 14","metadata":null},{"id":"0aa5d9154318441ca53ebb868f76a434","type":"GENE","name":"RGS16","canonical_id":"hgnc:HGNC:9997","description":"regulator of G protein signaling 16","metadata":{"aliases":["A28-RGS14","RGS-r"]}},{"id":"147dc58a7986416ea93d5891a250bbbd","type":"GENE","name":"RGS17","canonical_id":"hgnc:HGNC:14088","description":"regulator of G protein signaling 17","metadata":{"aliases":["RGSZ2","RGS-17"]}},{"id":"1e1404e4d4144e25b971aa05e9134f16","type":"GENE","name":"RGS17P1","canonical_id":"hgnc:HGNC:39729","description":"regulator of G protein signaling 17 pseudogene 1","metadata":null},{"id":"0b20e1d381284f47828005b3e918a43c","type":"GENE","name":"RGS18","canonical_id":"hgnc:HGNC:14261","description":"regulator of G protein signaling 18","metadata":{"aliases":["RGS13"]}},{"id":"53a002da3e3c41239b671b379d21792e","type":"GENE","name":"RGS19","canonical_id":"hgnc:HGNC:13735","description":"regulator of G protein signaling 19","metadata":{"aliases":["GAIP","RGSGAIP"]}},{"id":"a77aa5259ff9467e8770de08e55006b8","type":"GENE","name":"RGS2","canonical_id":"hgnc:HGNC:9998","description":"regulator of G protein signaling 2","metadata":{"aliases":["G0S8"]}},{"id":"04c61f505c3346288650c65dd1b4a7f3","type":"GENE","name":"RGS2-AS1","canonical_id":"hgnc:HGNC:49018","description":"RSG2 antisense RNA 1","metadata":{"aliases":["LINC01032"]}},{"id":"e2ce644a54954ffcb26941d58db0471e","type":"GENE","name":"RGS20","canonical_id":"hgnc:HGNC:14600","description":"regulator of G protein signaling 20","metadata":{"aliases":["RGSZ1","ZGAP1"]}},{"id":"05a668c3ed8846f1aad8a8bc3660f026","type":"GENE","name":"RGS21","canonical_id":"hgnc:HGNC:26839","description":"regulator of G protein signaling 21","metadata":null},{"id":"9469f0b8952a425d9046ccc8d9e78174","type":"GENE","name":"RGS22","canonical_id":"hgnc:HGNC:24499","description":"regulator of G protein signaling 22","metadata":{"aliases":["DKFZP434I092","PRTD-NY2","CT145"]}},{"id":"47a7b5597ac341f18814c0243131bb91","type":"GENE","name":"RGS3","canonical_id":"hgnc:HGNC:9999","description":"regulator of G protein signaling 3","metadata":{"aliases":["C2PA","FLJ20370","PDZ-RGS3"]}},{"id":"1c7206f6c7c84faa8ac4b1c918e7c478","type":"GENE","name":"RGS3-AS1","canonical_id":"hgnc:HGNC:58614","description":"RGS3 antisense RNA 1","metadata":null},{"id":"e5c6bf85803f4140a35b36f2720f4b7b","type":"GENE","name":"RGS4","canonical_id":"hgnc:HGNC:10000","description":null,"metadata":null},{"id":"1c57ff77f5da4464ab32491cc0c0fbc4","type":"GENE","name":"RGS5","canonical_id":"hgnc:HGNC:10001","description":"regulator of G protein signaling 5","metadata":null},{"id":"bc782133bd3049d98ae463267f5df64e","type":"GENE","name":"RGS5-AS1","canonical_id":"hgnc:HGNC:40504","description":"RGS5 antisense RNA 1","metadata":null},{"id":"fe9356e1e02048bba85fa25d0948c3f9","type":"GENE","name":"RGS6","canonical_id":"hgnc:HGNC:10002","description":"regulator of G protein signaling 6","metadata":null},{"id":"f29baa99755347d9871364e584d0a34c","type":"GO_TERM","name":"RGS6-DNMT1-DMAP1 complex","canonical_id":"go:GO:0070313","description":"\"A protein complex formed by the association of RGS6, a negative regulator of heterotrimeric G protein signaling, with the DMAP1-Dnmt1 transcriptional repressor complex; in the complex, RGS6 inhibits the transcriptional repressor activity of DMAP1.\" [GOC:mah, PMID:14734556]","metadata":null},{"id":"48da8214907448fba672f897e804577e","type":"GENE","name":"RGS7","canonical_id":"hgnc:HGNC:10003","description":"regulator of G protein signaling 7","metadata":null},{"id":"51b199d14bb549e0944ab015ee99e9bf","type":"GENE","name":"RGS7BP","canonical_id":"hgnc:HGNC:23271","description":"regulator of G protein signaling 7 binding protein","metadata":{"aliases":["R7BP"]}},{"id":"b90ec2dd073248d286ff93a5a407c761","type":"GENE","name":"RGS8","canonical_id":"hgnc:HGNC:16810","description":"regulator of G protein signaling 8","metadata":{"aliases":["MGC119067","MGC119068","MGC119069"]}},{"id":"697099580f5b4748bbaa0c5592bb7f9c","type":"GENE","name":"RGS9","canonical_id":"hgnc:HGNC:10004","description":"regulator of G protein signaling 9","metadata":{"aliases":["PERRS","RGS9L","MGC26458","MGC111763"]}},{"id":"1bad5d15561d403b8e2c02e0143d39a0","type":"GENE","name":"RGS9BP","canonical_id":"hgnc:HGNC:30304","description":"regulator of G protein signaling 9 binding protein","metadata":{"aliases":["FLJ45744","PERRS","R9AP"]}},{"id":"8075904848e14b188c92f996cee53b3b","type":"GENE","name":"RGSL1","canonical_id":"hgnc:HGNC:18636","description":"regulator of G protein signaling like 1","metadata":{"aliases":["RGSL2"]}},{"id":"5ea38d37ca684e288e7973f7abe01eaf","type":"GENE","name":"RHAG","canonical_id":"hgnc:HGNC:10006","description":"Rh associated glycoprotein","metadata":{"aliases":["RH50A","CD241","SLC42A1"]}},{"id":"b297b0e28d314784b52e4b0ead7891c7","type":"GENE","name":"RHBDD1","canonical_id":"hgnc:HGNC:23081","description":"rhomboid domain containing 1","metadata":{"aliases":["DKFZp547E052","RHBDL4"]}},{"id":"387dff29cfe140dfb3cba6579409eaaa","type":"GENE","name":"RHBDD2","canonical_id":"hgnc:HGNC:23082","description":"rhomboid domain containing 2","metadata":{"aliases":["NPD007","RHBDL7"]}},{"id":"abc63982d4a148ae9a52968d35272608","type":"GENE","name":"RHBDD3","canonical_id":"hgnc:HGNC:1308","description":"rhomboid domain containing 3","metadata":{"aliases":["PTAG","C22orf3"]}},{"id":"04f795527f394944ae905c328d31eeda","type":"GENE","name":"RHBDF1","canonical_id":"hgnc:HGNC:20561","description":"rhomboid 5 homolog 1","metadata":{"aliases":["EGFR-RS","FLJ2235","Dist1","iRhom1","C16orf8"]}},{"id":"e470d005ac1343a68c96375bde7b89f7","type":"GENE","name":"RHBDF1P1","canonical_id":"hgnc:HGNC:44499","description":"RHBDF1 pseudogene 1","metadata":null},{"id":"068a7be8f54a40bf935b86169b5dcbc0","type":"GENE","name":"RHBDF2","canonical_id":"hgnc:HGNC:20788","description":"rhomboid 5 homolog 2","metadata":{"aliases":["FLJ22341","RHBDL5","TOCG","iRhom2","RHBDL6","TOC"]}},{"id":"4264b9ad0114436ba23dd7a7e8763177","type":"GENE","name":"RHBDL1","canonical_id":"hgnc:HGNC:10007","description":"rhomboid like 1","metadata":{"aliases":["RRP","RHBDL"]}},{"id":"1cdd31356ec845dcafa205ceba6f5c82","type":"GENE","name":"RHBDL2","canonical_id":"hgnc:HGNC:16083","description":"rhomboid like 2","metadata":{"aliases":["FLJ20435"]}},{"id":"7d3d1bbf317242c88d60c9ae002fe0e5","type":"GENE","name":"RHBDL3","canonical_id":"hgnc:HGNC:16502","description":"rhomboid like 3","metadata":{"aliases":["VRHO","RHBDL4"]}},{"id":"851f4575915643bda4251dc3cb535661","type":"GENE","name":"RHBG","canonical_id":"hgnc:HGNC:14572","description":"Rh family B glycoprotein","metadata":{"aliases":["SLC42A2"]}},{"id":"f1abe788d06143d28435921abe4d5ecd","type":"GENE","name":"RHCE","canonical_id":"hgnc:HGNC:10008","description":"Rh blood group CcEe antigens","metadata":{"aliases":["CD240CE","SLC42A4","RH"]}},{"id":"87d97ebed99247688dfc5b2ccac36fcc","type":"GENE","name":"RHCG","canonical_id":"hgnc:HGNC:18140","description":"Rh family C glycoprotein","metadata":{"aliases":["RHGK","PDRC2","SLC42A3","C15orf6"]}},{"id":"f455357131304a3cb95138705b049f81","type":"GENE","name":"RHD","canonical_id":"hgnc:HGNC:10009","description":"Rh blood group D antigen","metadata":{"aliases":["Rh30a","Rh4","RhPI","RhII","DIIIc","CD240D","SLC42A5","RH"]}},{"id":"69e7b04c46ff4c42baf6a3c898719dc6","type":"GENE","name":"RHEB","canonical_id":"hgnc:HGNC:10011","description":"Ras homolog, mTORC1 binding","metadata":{"aliases":["RHEB2"]}},{"id":"2a11e75333904d87821e16c9f7037526","type":"GENE","name":"RHEBL1","canonical_id":"hgnc:HGNC:21166","description":"RHEB like 1","metadata":{"aliases":["MGC34869","FLJ25797","RHEB2"]}},{"id":"df55312bf7f047988dca0cdfcc8735a9","type":"GENE","name":"RHEBP1","canonical_id":"hgnc:HGNC:10010","description":"RHEB pseudogene 1","metadata":{"aliases":["RHEB","RHEB1"]}},{"id":"d565705a7376407aa233a34a8b73872b","type":"GENE","name":"RHEBP2","canonical_id":"hgnc:HGNC:44991","description":"RHEB pseudogene 2","metadata":null},{"id":"4476f14ad3b14e7ebe22c64fed9a1656","type":"GENE","name":"RHEBP3","canonical_id":"hgnc:HGNC:44992","description":"RHEB pseudogene 3","metadata":null},{"id":"6cb5c6ebb02d43bcb29b8623bba2c57b","type":"GENE","name":"RHEX","canonical_id":"hgnc:HGNC:25341","description":"regulator of hemoglobinization and erythroid cell expansion","metadata":{"aliases":["FLJ16052","C1orf186"]}},{"id":"cea5ae0b27714940aa4c526cbe4bf9eb","type":"GO_TERM","name":"RHG protein domain binding","canonical_id":"go:GO:0089719","description":"\"Binding to an RHG (reaper/hid/grimm) domain/motif (AKA iap binding motif).\" [GOC:dos, GOC:ha]","metadata":null},{"id":"fe4144227e894dc9b6dc566052b7b52c","type":"GENE","name":"RHNO1","canonical_id":"hgnc:HGNC:28206","description":"RAD9-HUS1-RAD1 interacting nuclear orphan 1","metadata":{"aliases":["HKMT1188","MGC13204","RHINO","C12orf32"]}},{"id":"79fbdb1013b24470a16da47961e83d8b","type":"GENE","name":"RHO","canonical_id":"hgnc:HGNC:10012","description":null,"metadata":null},{"id":"a8330439b27944cdbd47df191fe16eaf","type":"GENE","name":"RHOA","canonical_id":"hgnc:HGNC:667","description":null,"metadata":null},{"id":"7bb54a6148c54c08b8a1f8ed3510e10f","type":"GENE","name":"RHOA-IT1","canonical_id":"hgnc:HGNC:41308","description":"RHOA intronic transcript 1","metadata":null},{"id":"4815d788a2bb4e03bd83e2f1603dc1f3","type":"GENE","name":"RHOB","canonical_id":"hgnc:HGNC:668","description":null,"metadata":null},{"id":"b39335b98b544ca3a27c4a49b9539a13","type":"GENE","name":"RHOBTB1","canonical_id":"hgnc:HGNC:18738","description":"Rho related BTB domain containing 1","metadata":{"aliases":["KIAA0740"]}},{"id":"e531a8aeabda41bba57d5d4ec6cbc6f4","type":"GENE","name":"RHOBTB2","canonical_id":"hgnc:HGNC:18756","description":"Rho related BTB domain containing 2","metadata":{"aliases":["KIAA0717","DBC2"]}},{"id":"fcacffa0ba3a4f8c9d0ea183473d4fcc","type":"GENE","name":"RHOBTB2-AS1","canonical_id":"hgnc:HGNC:58239","description":"RHOBTB2 antisense RNA 1","metadata":null},{"id":"b59e14895e1c48b5be76342f0dee3f02","type":"GENE","name":"RHOBTB3","canonical_id":"hgnc:HGNC:18757","description":"Rho related BTB domain containing 3","metadata":{"aliases":["KIAA0878"]}},{"id":"5ca38fc4df314b6db946d5b555eabe11","type":"GENE","name":"RHOC","canonical_id":"hgnc:HGNC:669","description":null,"metadata":null},{"id":"efd641f2bbe84b72ba47aaa1bc32197a","type":"GENE","name":"RHOD","canonical_id":"hgnc:HGNC:670","description":"ras homolog family member D","metadata":{"aliases":["RhoHP1","Rho","ARHD"]}},{"id":"f0a24ba1814a45c294d4d9b7fe939347","type":"GENE","name":"RHOF","canonical_id":"hgnc:HGNC:15703","description":"ras homolog family member F, filopodia associated","metadata":{"aliases":["FLJ20247","RIF","ARHF"]}},{"id":"e8804c3956794663b23750fce2324d0e","type":"GENE","name":"RHOG","canonical_id":"hgnc:HGNC:672","description":"ras homolog family member G","metadata":{"aliases":["MGC125835","MGC125836","ARHG"]}},{"id":"d571307e15c04f769b0cea42ed6b6094","type":"GENE","name":"RHOG2P","canonical_id":"hgnc:HGNC:54953","description":"RHOG family member 2, pseudogene","metadata":null},{"id":"86423a36e556439aae94d2769cc86c8d","type":"GENE","name":"RHOH","canonical_id":"hgnc:HGNC:686","description":"ras homolog family member H","metadata":{"aliases":["TTF","ARHH"]}},{"id":"1820710451054b63bc55f899f488385b","type":"GENE","name":"RHOJ","canonical_id":"hgnc:HGNC:688","description":"ras homolog family member J","metadata":{"aliases":["FLJ14445","TCL","RASL7B","ARHJ"]}},{"id":"f1421ef474a5422e9e5cbbcfaf856b8e","type":"GENE","name":"RHOQ","canonical_id":"hgnc:HGNC:17736","description":"ras homolog family member Q","metadata":{"aliases":["TC10","RASL7A","ARHQ"]}},{"id":"7f18e38c9fc04496b59900885fdec52f","type":"GENE","name":"RHOQ-AS1","canonical_id":"hgnc:HGNC:40816","description":"RHOQ antisense RNA 1","metadata":null},{"id":"9dde937b85d7482bb86e3934cd5d987c","type":"GENE","name":"RHOQP1","canonical_id":"hgnc:HGNC:20003","description":"ras homolog family member Q pseudogene 1","metadata":{"aliases":["ARHQP","RHOQP"]}},{"id":"5c4989d5004a4e009a187e47e8336c15","type":"GENE","name":"RHOQP2","canonical_id":"hgnc:HGNC:37836","description":"ras homolog family member Q pseudogene 2","metadata":null},{"id":"25830ec12c6c447d9d9acabd1fa74dd2","type":"GENE","name":"RHOQP3","canonical_id":"hgnc:HGNC:37837","description":"ras homolog family member Q pseudogene 3","metadata":null},{"id":"19c10ee6b4174273942823fb408eaafd","type":"GENE","name":"RHOT1","canonical_id":"hgnc:HGNC:21168","description":"ras homolog family member T1","metadata":{"aliases":["MIRO-1","FLJ11040","MIRO1","ARHT1"]}},{"id":"12a91929c58c4130a361104490f170fa","type":"GENE","name":"RHOT1P1","canonical_id":"hgnc:HGNC:23777","description":"ras homolog family member T1 pseudogene 1","metadata":{"aliases":["RHOT3","RHOT1P"]}},{"id":"2a7befce9f8d4dc2a80d36f8bafdbc7e","type":"GENE","name":"RHOT1P2","canonical_id":"hgnc:HGNC:37838","description":"ras homolog family member T1 pseudogene 2","metadata":null},{"id":"284f62a4353e4480bf094af76f18856b","type":"GENE","name":"RHOT1P3","canonical_id":"hgnc:HGNC:37839","description":"ras homolog family member T1 pseudogene 3","metadata":null},{"id":"fd64751d81dd42308054b9ef1b6fc5a2","type":"GENE","name":"RHOT2","canonical_id":"hgnc:HGNC:21169","description":"ras homolog family member T2","metadata":{"aliases":["MIRO-2","MIRO2","C16orf39","ARHT2"]}},{"id":"763320318d034499977e260bb82e1ab6","type":"GENE","name":"RHOU","canonical_id":"hgnc:HGNC:17794","description":"ras homolog family member U","metadata":{"aliases":["WRCH-1","DJ646B12.2","FLJ10616","WRCH1","CDC42L1","hG28K","fJ646B12.2","ARHU"]}},{"id":"88c5b1219b764851b5f7f6eb586438aa","type":"GENE","name":"RHOV","canonical_id":"hgnc:HGNC:18313","description":"ras homolog family member V","metadata":{"aliases":["Chp","WRCH2","ARHV"]}},{"id":"5c6c5baa8a714bb1a9b6d0f9c8297b1f","type":"GENE","name":"RHOXF1","canonical_id":"hgnc:HGNC:29993","description":"Rhox homeobox family member 1","metadata":{"aliases":["OTEX","PEPP1"]}},{"id":"f6db56e6d8af476fab013c2a7b564b75","type":"GENE","name":"RHOXF1-AS1","canonical_id":"hgnc:HGNC:51582","description":"RHOXF1 antisense RNA 1","metadata":null},{"id":"969f09d1f40646159c5364c8fb7248c3","type":"GENE","name":"RHOXF1P1","canonical_id":"hgnc:HGNC:51580","description":"Rhox homeobox family member 1 pseudogene 1","metadata":{"aliases":["TCONS_00017086"]}},{"id":"5a41b44dc73844729ab6e400ef82ec38","type":"GENE","name":"RHOXF1P2","canonical_id":"hgnc:HGNC:51611","description":"Rhox homeobox family member 1 pseudogene 2","metadata":null},{"id":"0e4423cb0f2b4c25923cde63b42e85a5","type":"GENE","name":"RHOXF1P3","canonical_id":"hgnc:HGNC:51612","description":"Rhox homeobox family member 1 pseudogene 3","metadata":{"aliases":["XCP","lncRNA1456"]}},{"id":"cd46498b9b9e4f258808c593bb0d28be","type":"GENE","name":"RHOXF2","canonical_id":"hgnc:HGNC:30011","description":"Rhox homeobox family member 2","metadata":{"aliases":["THG1","PEPP-2","PEPP2","CT107"]}},{"id":"59f775e410f64806a5af458c64fe9fe8","type":"GENE","name":"RHOXF2B","canonical_id":"hgnc:HGNC:33519","description":"Rhox homeobox family member 2B","metadata":null},{"id":"df2fe398948b4b678881a0e165e7f824","type":"GENE","name":"RHPN1","canonical_id":"hgnc:HGNC:19973","description":"rhophilin Rho GTPase binding protein 1","metadata":{"aliases":["KIAA1929","RHPN","ODF5"]}},{"id":"83cefeb93492419396008cb27da1d4b7","type":"GENE","name":"RHPN1-AS1","canonical_id":"hgnc:HGNC:28457","description":"RHPN1 antisense RNA 1","metadata":{"aliases":["MGC3113","C8orf51"]}},{"id":"1077858643f24ca693075118e757c961","type":"GENE","name":"RHPN2","canonical_id":"hgnc:HGNC:19974","description":"rhophilin Rho GTPase binding protein 2","metadata":null},{"id":"51f2e422532145e6922c1456d8622668","type":"GENE","name":"RHPN2P1","canonical_id":"hgnc:HGNC:37708","description":"rhophilin Rho GTPase binding protein 2 pseudogene 1","metadata":null},{"id":"96c6de524e814d69acbab45fadf9c107","type":"TRIAL","name":"RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE","canonical_id":"clinicaltrials.gov:NCT01082146","description":"Pharmacokinetics; Metabolism","metadata":null},{"id":"1f8c0582731e47ac9d09ffcfa1e25848","type":"GENE","name":"RIBC1","canonical_id":"hgnc:HGNC:26537","description":"RIB43A domain with coiled-coils 1","metadata":{"aliases":["FLJ32783"]}},{"id":"7f1085f5e0d04fa19d9f39d2dcf72753","type":"GENE","name":"RIBC2","canonical_id":"hgnc:HGNC:13241","description":"RIB43A domain with coiled-coils 2","metadata":{"aliases":["DKFZp566F0546","FLJ25720","C22orf11"]}},{"id":"734bcbc1f07e4c5f9440fedcb6ca467e","type":"GENE","name":"RIC1","canonical_id":"hgnc:HGNC:17686","description":"RIC1 partner of RAB6A GEF complex","metadata":{"aliases":["bA207C16.1","KIAA1432"]}},{"id":"65af0d11b27140c4b847d3d9cb774438","type":"GENE","name":"RIC3","canonical_id":"hgnc:HGNC:30338","description":"RIC3 acetylcholine receptor chaperone","metadata":{"aliases":["FLJ11608","PRO1385","AYST720"]}},{"id":"7de80a0204b84e2cb41b3c46d83722a3","type":"GENE","name":"RIC3-DT","canonical_id":"hgnc:HGNC:54191","description":"RIC3 divergent transcript","metadata":null},{"id":"eed42f4418ba43bcb015d67eb5c98e64","type":"GENE","name":"RIC8A","canonical_id":"hgnc:HGNC:29550","description":"RIC8 guanine nucleotide exchange factor A","metadata":{"aliases":["synembryn","synembryn-A"]}},{"id":"4134b8e3eaf3484e86c9dbbe10cd6925","type":"GENE","name":"RIC8B","canonical_id":"hgnc:HGNC:25555","description":"RIC8 guanine nucleotide exchange factor B","metadata":{"aliases":["FLJ10620","hSyn","RIC8"]}},{"id":"010ea66f0bff46199b4c6941a0418a47","type":"TRIAL","name":"RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus","canonical_id":"clinicaltrials.gov:NCT04159974","description":"Esophageal Adenocarcinoma","metadata":null},{"id":"574a523002994c2cb5536789451e7c8e","type":"TRIAL","name":"RICE: Remission by Intra-articular Injection Plus CErtolizumab","canonical_id":"clinicaltrials.gov:NCT02293590","description":"Rheumatoid Arthritis","metadata":null},{"id":"541fbfb94de246869f9c5e07296eb632","type":"GENE","name":"RICTOR","canonical_id":"hgnc:HGNC:28611","description":"RPTOR independent companion of MTOR complex 2","metadata":{"aliases":["MGC39830","AVO3","PIA","KIAA1999"]}},{"id":"e5c6556e4aec4e8a826f8203b68476c9","type":"GENE","name":"RICTOR-DT","canonical_id":"hgnc:HGNC:59031","description":"RICTOR divergent transcript","metadata":null},{"id":"a3e7f925efbe4692aeb0e4c4a4637ac4","type":"GENE","name":"RIDA","canonical_id":"hgnc:HGNC:16897","description":"reactive intermediate imine deaminase A","metadata":{"aliases":["UK114","P14.5","PSP","HRSP12"]}},{"id":"34a5934470bf476a9875d1f8b3a7111b","type":"GENE","name":"RIDAP1","canonical_id":"hgnc:HGNC:58519","description":"RIDA pseudogene 1","metadata":null},{"id":"dba9adb075da44928951de489cbf7b8a","type":"GENE","name":"RIDAP2","canonical_id":"hgnc:HGNC:58520","description":"RIDA pseudogene 2","metadata":null},{"id":"1e91d288535e4291be4bf16b8c34b669","type":"GENE","name":"RIDAP3","canonical_id":"hgnc:HGNC:58521","description":"RIDA pseudogene 3","metadata":null},{"id":"725ce34c37ee4bd6b8c89289f6c1b2aa","type":"GENE","name":"RIF1","canonical_id":"hgnc:HGNC:23207","description":"replication timing regulatory factor 1","metadata":{"aliases":["FLJ12870","FLJ10599"]}},{"id":"7eacce0293f54911a4cd670871abad82","type":"GO_TERM","name":"RIG-I binding","canonical_id":"go:GO:0039552","description":"\"Binding to RIG-I, a cytosolic pattern recognition receptor that initiates an antiviral signaling pathway upon binding to viral RNA.\" [GOC:bf, PMID:21233210]","metadata":null},{"id":"e484e7ff06c148f4b0c5789f8b97ce7f","type":"GO_TERM","name":"RIG-I signaling pathway","canonical_id":"go:GO:0039529","description":"\"The series of molecular signals initiated by the binding ssRNA or dsRNA from another organism to the cytoplasmic pattern recognition receptor (PRR) RIG-1 (also known as DDX58). RIG-I detects RNA synthesized during viral replication or shed by non-viral pathogens, and triggers a signaling pathway to protect the host against infection, for example by inducing the expression of cytokines.\" [GOC:bf, PMID:17328678, PMID:19620789, PMID:21435580, PMID:25579795]","metadata":null},{"id":"fd810924590c4e17aea1ce8f92978c6d","type":"GENE","name":"RIIAD1","canonical_id":"hgnc:HGNC:26686","description":"regulatory subunit of type II PKA R-subunit domain containing 1","metadata":{"aliases":["FLJ36032","NCRNA00166","C1orf230"]}},{"id":"6741d551ca2b4c4e9bce3c07cb855d11","type":"GENE","name":"RILP","canonical_id":"hgnc:HGNC:30266","description":"Rab interacting lysosomal protein","metadata":{"aliases":["FLJ31193"]}},{"id":"ed9b601eb9054739bcd7069b6a3ff566","type":"GENE","name":"RILPL1","canonical_id":"hgnc:HGNC:26814","description":"Rab interacting lysosomal protein like 1","metadata":{"aliases":["FLJ39378"]}},{"id":"a8250e65dc914f38aea662a0d3790b0b","type":"GENE","name":"RILPL2","canonical_id":"hgnc:HGNC:28787","description":"Rab interacting lysosomal protein like 2","metadata":{"aliases":["MGC7036","FLJ30380","FLJ32372"]}},{"id":"9865bfcc3ca443539196acf1055aa713","type":"GENE","name":"RIMBP2","canonical_id":"hgnc:HGNC:30339","description":"RIMS binding protein 2","metadata":{"aliases":["KIAA0318","RBP2","MGC15831","RIM-BP2","PPP1R133"]}},{"id":"5553f67429074e0d9b406f27156c3c8f","type":"GENE","name":"RIMBP2-AS1","canonical_id":"hgnc:HGNC:58273","description":"RIMBP2 antisense RNA 1","metadata":null},{"id":"b75d13cf59fa4e28973025c1e00c7b2a","type":"GENE","name":"RIMBP3","canonical_id":"hgnc:HGNC:29344","description":"RIMS binding protein 3","metadata":{"aliases":["KIAA1666","RIMBP3.1","RIMBP3A"]}},{"id":"1060f160ee6543b58909df920de6571c","type":"GENE","name":"RIMBP3B","canonical_id":"hgnc:HGNC:33891","description":"RIMS binding protein 3B","metadata":null},{"id":"1cd93acd7a86480886a393c5c744ea0a","type":"GENE","name":"RIMBP3C","canonical_id":"hgnc:HGNC:33892","description":"RIMS binding protein 3C","metadata":null},{"id":"79e0feebfcff45e8befef491c0cab720","type":"GENE","name":"RIMKLA","canonical_id":"hgnc:HGNC:28725","description":"ribosomal modification protein rimK like family member A","metadata":{"aliases":["MGC47816","RP11-157D18.1","NAAGS-II","FAM80A"]}},{"id":"e030cc68bb394f7a8c6bcd5f7d090874","type":"GENE","name":"RIMKLB","canonical_id":"hgnc:HGNC:29228","description":"ribosomal modification protein rimK like family member B","metadata":{"aliases":["KIAA1238","NAAGS","NAAGS-I","FAM80B"]}},{"id":"d1aa710d87b34a4e8f10f04e2535923e","type":"GENE","name":"RIMKLBP1","canonical_id":"hgnc:HGNC:34034","description":"ribosomal modification protein rimK like family member B pseudogene 1","metadata":{"aliases":["FAM80C","RIMKLP","FAM80B2","RIMKLB2"]}},{"id":"a86031174d2e4031b8c020b2e1f415cb","type":"GENE","name":"RIMKLBP2","canonical_id":"hgnc:HGNC:39163","description":"ribosomal modification protein rimK like family member B pseudogene 2","metadata":null},{"id":"77ae2630024a423db602eac7a4259073","type":"GENE","name":"RIMOC1","canonical_id":"hgnc:HGNC:27750","description":"RAB7A interacting MON1-CCZ1 complex subunit 1","metadata":{"aliases":["LOC285636","C5orf51"]}},{"id":"568d72cf1b5448919c70f5eab2aeddc9","type":"GENE","name":"RIMS1","canonical_id":"hgnc:HGNC:17282","description":"regulating synaptic membrane exocytosis 1","metadata":{"aliases":["RIM","KIAA0340","RIM1","RAB3IP2","CORD7"]}},{"id":"411698bf778549aeb155bf64c17c4b0c","type":"GENE","name":"RIMS2","canonical_id":"hgnc:HGNC:17283","description":"regulating synaptic membrane exocytosis 2","metadata":{"aliases":["KIAA0751","RIM2","OBOE","RAB3IP3"]}},{"id":"b3366a8cf7824bbbb0b64fba4e9f8a48","type":"GENE","name":"RIMS2-AS1","canonical_id":"hgnc:HGNC:59251","description":"RIMS2 antisense RNA 1","metadata":{"aliases":["AC012213.1"]}},{"id":"33ac78492454484381af2949de10f309","type":"GENE","name":"RIMS3","canonical_id":"hgnc:HGNC:21292","description":"regulating synaptic membrane exocytosis 3","metadata":{"aliases":["RIM3","NIM3"]}},{"id":"3575fe7ca1404b979d85359791ba0a71","type":"GENE","name":"RIMS4","canonical_id":"hgnc:HGNC:16183","description":"regulating synaptic membrane exocytosis 4","metadata":{"aliases":["dJ781B1.3","C20orf190"]}},{"id":"170c959088274f9bad70a31e7d3d9866","type":"GENE","name":"RIN1","canonical_id":"hgnc:HGNC:18749","description":"Ras and Rab interactor 1","metadata":null},{"id":"bc4f884a5edc4d098394bc753f7cc702","type":"GENE","name":"RIN2","canonical_id":"hgnc:HGNC:18750","description":"Ras and Rab interactor 2","metadata":{"aliases":["RASSF4"]}},{"id":"f839ec118dad40989c57bc58260ffcf2","type":"GENE","name":"RIN3","canonical_id":"hgnc:HGNC:18751","description":"Ras and Rab interactor 3","metadata":{"aliases":["FLJ22439"]}},{"id":"ec47798c15554cf0bb36ed478109446b","type":"GO_TERM","name":"RING-like zinc finger domain binding","canonical_id":"go:GO:0071535","description":"\"Binding to a RING-like zinc finger domain domain of a protein. The RING-like domain is a zinc finger domain that is related to the C3HC4 RING finger domain.\" [GOC:mah, InterPro:IPR014857]","metadata":null},{"id":"26e8cca86ca04b4086ee0d74a08f7915","type":"GENE","name":"RING1","canonical_id":"hgnc:HGNC:10018","description":"ring finger protein 1","metadata":{"aliases":["RNF1"]}},{"id":"8b94edd752a746c2b33bc0b75edaa813","type":"GENE","name":"RINL","canonical_id":"hgnc:HGNC:24795","description":"Ras and Rab interactor like","metadata":{"aliases":["FLJ45909"]}},{"id":"25453a7582514834bc397e3574573b8f","type":"GENE","name":"RINT1","canonical_id":"hgnc:HGNC:21876","description":"RAD50 interactor 1","metadata":{"aliases":["FLJ11785","RINT-1"]}},{"id":"edcac98799c84e858ea45a27578ea36e","type":"GENE","name":"RIOK1","canonical_id":"hgnc:HGNC:18656","description":"RIO kinase 1","metadata":{"aliases":["AD034","FLJ30006","bA288G3.1","RRP10"]}},{"id":"752aa5aaf0e54857a43476b5cd228d0c","type":"GENE","name":"RIOK2","canonical_id":"hgnc:HGNC:18999","description":"RIO kinase 2","metadata":{"aliases":["FLJ11159"]}},{"id":"2afcfadef28b434ca8f7cac947b0cde6","type":"GENE","name":"RIOK3","canonical_id":"hgnc:HGNC:11451","description":"RIO kinase 3","metadata":{"aliases":["SUDD"]}},{"id":"44f8a3083fa74ab3916e90d10b4f920d","type":"GENE","name":"RIOK3P1","canonical_id":"hgnc:HGNC:39714","description":"RIO kinase 3 pseudogene 1","metadata":null},{"id":"52a607fda9e14501a4438a95692b1401","type":"GENE","name":"RIOX1","canonical_id":"hgnc:HGNC:20968","description":"ribosomal oxygenase 1","metadata":{"aliases":["FLJ21802","NO66","MAPJD","JMJD9","C14orf169"]}},{"id":"971f050328a5419c8b1564cfe8999862","type":"GENE","name":"RIOX2","canonical_id":"hgnc:HGNC:19441","description":"ribosomal oxygenase 2","metadata":{"aliases":["MINA53","FLJ14393","mdig","NO52","JMJD10","MINA"]}},{"id":"c3a21a22b8b44a27bc4b7a653522f447","type":"GO_TERM","name":"RIP homotypic interaction motif binding","canonical_id":"go:GO:0071551","description":"\"Binding to a RIP homotypic interaction motif (RHIM) of a protein. The RHIM is a 16-amino-acid motif found in some members, including RIP3, of a family of related kinases.\" [GOC:mah, PMID:11734559]","metadata":null},{"id":"9bf2289c7a424030ac64bd31591a2bb0","type":"GENE","name":"RIPK1","canonical_id":"hgnc:HGNC:10019","description":"receptor interacting serine/threonine kinase 1","metadata":{"aliases":["RIP","RIP1","RIP-1"]}},{"id":"70c0b67ab9bf4f07b1646fd054215a09","type":"GENE","name":"RIPK1-AS1","canonical_id":"hgnc:HGNC:59332","description":"RIPK1 antisense RNA 1","metadata":null},{"id":"d4d288d9962a45c78bc1c9f07e100110","type":"GENE","name":"RIPK2","canonical_id":"hgnc:HGNC:10020","description":null,"metadata":null},{"id":"2a23a19d8c8f47bf84f0d535254a680c","type":"GENE","name":"RIPK3","canonical_id":"hgnc:HGNC:10021","description":"receptor interacting serine/threonine kinase 3","metadata":{"aliases":["RIP3"]}},{"id":"1d61f768bfc444689d072e34e2fd28e3","type":"GENE","name":"RIPK4","canonical_id":"hgnc:HGNC:496","description":"receptor interacting serine/threonine kinase 4","metadata":{"aliases":["DIK","ANKK2","RIP4","PKK","ANKRD3"]}},{"id":"26e4de4c6859461087c169d6783ed124","type":"GENE","name":"RIPOR1","canonical_id":"hgnc:HGNC:25836","description":"RHO family interacting cell polarization regulator 1","metadata":{"aliases":["FLJ13725","FAM65A"]}},{"id":"565c2946fac34aa595f0e6a533c518ed","type":"GENE","name":"RIPOR2","canonical_id":"hgnc:HGNC:13872","description":"RHO family interacting cell polarization regulator 2","metadata":{"aliases":["KIAA0386","DIFF48","MYONAP","C6orf32","FAM65B"]}},{"id":"b43a3c77e66448108555be30669ab384","type":"GENE","name":"RIPOR2-AS1","canonical_id":"hgnc:HGNC:59374","description":"RIPOR2 antisense RNA 1","metadata":null},{"id":"55519136604b403abf475b616c73f705","type":"GENE","name":"RIPOR3","canonical_id":"hgnc:HGNC:16168","description":"RIPOR family member 3","metadata":{"aliases":["dJ530I15.2","dJ530I15.3","C20orf175","C20orf176","FAM65C"]}},{"id":"33af8c68193e4b24bb36e0871e63c392","type":"GENE","name":"RIPOR3-AS1","canonical_id":"hgnc:HGNC:40760","description":"RIPOR3 antisense RNA 1","metadata":{"aliases":["sin-lncRNA"]}},{"id":"7a194375c98d45538a083eaf7d472018","type":"GENE","name":"RIPPLY1","canonical_id":"hgnc:HGNC:25117","description":"ripply transcriptional repressor 1","metadata":null},{"id":"3d788079f4b84742beeb5788bc1148ce","type":"GENE","name":"RIPPLY2","canonical_id":"hgnc:HGNC:21390","description":"ripply transcriptional repressor 2","metadata":{"aliases":["dJ237I15.1","C6orf159"]}},{"id":"7bdf94a44cca4c2f82e45861176614a0","type":"GENE","name":"RIPPLY3","canonical_id":"hgnc:HGNC:3047","description":"ripply transcriptional repressor 3","metadata":{"aliases":["DSCR6"]}},{"id":"6b792f79c9b94222b2e27ef2d82223c7","type":"GENE","name":"RIPPLY3P1","canonical_id":"hgnc:HGNC:23340","description":"RIPPLY3 pseudogene 1","metadata":{"aliases":["DSCR6P1"]}},{"id":"6043dfe55b4546abaa5105cabd910c21","type":"GO_TERM","name":"RISC complex","canonical_id":"go:GO:0016442","description":"\"A ribonucleoprotein complex that contains members of the Argonaute family of proteins, small interfering RNAs (siRNAs) or microRNAs (miRNAs), and miRNA or siRNA-complementary mRNAs, in addition to a number of accessory factors. The RISC complex is involved in posttranscriptional repression of gene expression through downregulation of translation or induction of mRNA degradation.\" [PMID:10749213, PMID:15145345]","metadata":null},{"id":"a5adf3ac2274415a981d74e594d96b94","type":"GO_TERM","name":"RISC complex assembly","canonical_id":"go:GO:0070922","description":"\"The process in which a single-stranded small RNA is incorporated within the RNA-initiated silencing complex (RISC). The assembly includes the maturation of the small RNA, the stabilization of the complex by accessory proteins of the RISC complex, duplex separation and the release of the second strand, forming a base-pairing complement complex that mediates gene silencing by small RNA.\" [PMID:14512631, PMID:14744438, PMID:19239886, PMID:22233755, PMID:27184117]","metadata":null},{"id":"f5bd4e649f914a68985647f466bceeb9","type":"GO_TERM","name":"RISC complex binding","canonical_id":"go:GO:1905172","description":"\"Binding to a RISC complex.\" [GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24882364]","metadata":null},{"id":"716832321a174135a606a18d690dc528","type":"GO_TERM","name":"RISC-loading complex","canonical_id":"go:GO:0070578","description":"\"A trimeric protein complex required for the formation of a mature RNA-induced silencing complex (RISC). In humans the complex is composed of the endonuclease Dicer (DICER1), TRBP (TARBP2) and the Argonaute protein Ago2 (EIF2C2/AGO2). Within the complex, Dicer and TRBP are required to process precursor miRNAs (pre-miRNAs) to mature miRNAs and then load them onto Ago2. Ago2 bound to the mature miRNA constitutes the minimal RISC and may subsequently dissociate from Dicer and TRBP. This complex has endoribonuclease activity.\" [GOC:ab, GOC:BHF, GOC:nc, GOC:rph, PMID:18178619, PMID:19820710]","metadata":null},{"id":"23eed56f7ed5465282071933527a75ef","type":"GENE","name":"RIT1","canonical_id":"hgnc:HGNC:10023","description":"Ras like without CAAX 1","metadata":{"aliases":["RIBB","ROC1","MGC125864","MGC125865","RIT"]}},{"id":"d2dedd1dc46945e8b99dcdad5951a354","type":"GENE","name":"RIT2","canonical_id":"hgnc:HGNC:10017","description":"Ras like without CAAX 2","metadata":{"aliases":["RIBA","RIN"]}},{"id":"24678f04dc29422687daafb555919bbb","type":"GENE","name":"RITA1","canonical_id":"hgnc:HGNC:25925","description":"RBPJ interacting and tubulin associated 1","metadata":{"aliases":["FLJ14827","RITA","C12orf52"]}},{"id":"9a77c8b6f73e4af7907457e3612746a3","type":"GO_TERM","name":"RITS complex","canonical_id":"go:GO:0030958","description":"\"A protein complex required for heterochromatin assembly; contains an Argonaute homolog, a chromodomain protein, and at least one additional protein; named for RNA-induced initiation of transcriptional gene silencing.\" [PMID:14704433]","metadata":null},{"id":"13e6d9d69a6b426fa2e8962698710a4a","type":"GO_TERM","name":"RITS complex assembly","canonical_id":"go:GO:1904802","description":"\"The aggregation, arrangement and bonding together of a set of components to form a RITS complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:26443059]","metadata":null},{"id":"6d6e66d9aa8841218b649d920963be71","type":"GO_TERM","name":"RITS complex localization","canonical_id":"go:GO:0034630","description":"\"Any process in which a RITS complex is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"d8b9bd24160e42b3aa2cf4c44fa65179","type":"TRIAL","name":"RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.","canonical_id":"clinicaltrials.gov:NCT02746744","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"b80e0b2f39a24d8694fe08b55910966d","type":"TRIAL","name":"RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","canonical_id":"clinicaltrials.gov:NCT05758831","description":"Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis","metadata":null},{"id":"de95856dfdc44a08b1f63daa0bf71422","type":"GENE","name":"RLBP1","canonical_id":"hgnc:HGNC:10024","description":"retinaldehyde binding protein 1","metadata":{"aliases":["CRALBP"]}},{"id":"be8906afc3fe49f2ae11757b60073c33","type":"GENE","name":"RLF","canonical_id":"hgnc:HGNC:10025","description":"RLF zinc finger","metadata":{"aliases":["ZNF292L","Zn-15L"]}},{"id":"c34eadeba60f434cb1cae3a9b6e717e1","type":"GENE","name":"RLFP1","canonical_id":"hgnc:HGNC:16738","description":"RLF pseudogene 1","metadata":{"aliases":["RLFP"]}},{"id":"8942758491894421b8abd2cbf3e4b94a","type":"GENE","name":"RLIG1","canonical_id":"hgnc:HGNC:25322","description":"RNA 5'-phosphate and 3'-OH ligase 1","metadata":{"aliases":["DKFZp434N2030","C12orf29"]}},{"id":"44a6f52c0d864cb28326859aba4a2f68","type":"GENE","name":"RLIG1P1","canonical_id":"hgnc:HGNC:56325","description":"RLIG1 pseudogene 1","metadata":{"aliases":["C12orf29P1"]}},{"id":"ec56f691c1ab4425a40cff53b9cf9d0d","type":"GENE","name":"RLIG1P2","canonical_id":"hgnc:HGNC:56326","description":"RLIG1 pseudogene 2","metadata":{"aliases":["C12orf29P2"]}},{"id":"bf1d207f343a4529bd0360da6adc216e","type":"GENE","name":"RLIG1P3","canonical_id":"hgnc:HGNC:56327","description":"RLIG1 pseudogene 3","metadata":{"aliases":["C12orf29P3"]}},{"id":"bc072691793d4b15a9f50a7323da8eb3","type":"GENE","name":"RLIM","canonical_id":"hgnc:HGNC:13429","description":"ring finger protein, LIM domain interacting","metadata":{"aliases":["NY-REN-43","MGC15161","RNF12"]}},{"id":"06a21f54cee54f23ac1df96a245af98b","type":"GENE","name":"RLIMP1","canonical_id":"hgnc:HGNC:39682","description":"ring finger protein, LIM domain interacting pseudogene 1","metadata":null},{"id":"ea5c6e5be7194617a65142a2fc9b1134","type":"GENE","name":"RLIMP2","canonical_id":"hgnc:HGNC:39683","description":"ring finger protein, LIM domain interacting pseudogene 2","metadata":null},{"id":"f5e95760918845b7997b38173923c266","type":"GENE","name":"RLIMP3","canonical_id":"hgnc:HGNC:39684","description":"ring finger protein, LIM domain interacting pseudogene 3","metadata":null},{"id":"68bbbd6e77ca447db60602d0da527c90","type":"GENE","name":"RLN1","canonical_id":"hgnc:HGNC:10026","description":null,"metadata":null},{"id":"a7b7e91169eb4f27a5a6066dcec1f47f","type":"GENE","name":"RLN2","canonical_id":"hgnc:HGNC:10027","description":null,"metadata":null},{"id":"ab9b4234bf0f40c0a524765e9383c16d","type":"GENE","name":"RLN3","canonical_id":"hgnc:HGNC:17135","description":"relaxin 3","metadata":{"aliases":["ZINS4","RXN3","H3"]}},{"id":"9003353949e540b19829c10fa29a7948","type":"TRIAL","name":"RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole","canonical_id":"clinicaltrials.gov:NCT00314860","description":"Restless Legs Syndrome; Restless Legs Syndrome (RLS)","metadata":null},{"id":"b12ac9c98b4f4c64abdc2c62cbb0be4b","type":"GENE","name":"RMC1","canonical_id":"hgnc:HGNC:24326","description":"regulator of MON1-CCZ1","metadata":{"aliases":["MIC1","HsT2591","C18orf8","WDR98"]}},{"id":"5e89137c63ab4766b721b0b930a6b6c2","type":"GENE","name":"RMDN1","canonical_id":"hgnc:HGNC:24285","description":"regulator of microtubule dynamics 1","metadata":{"aliases":["CGI-90","FLJ20665","RMD1","FAM82B"]}},{"id":"cc3c8cd6624c4d21befe6c7b0cd9ad54","type":"GENE","name":"RMDN2","canonical_id":"hgnc:HGNC:26567","description":"regulator of microtubule dynamics 2","metadata":{"aliases":["FLJ32954","RMD2","FAM82A","FAM82A1"]}},{"id":"3ab5fff9340e4fceafa880baa3fbbc9a","type":"GENE","name":"RMDN2-AS1","canonical_id":"hgnc:HGNC:41150","description":"RMDN2 antisense RNA 1","metadata":null},{"id":"5cfe0d7c4e544264946cf9c809a6bfff","type":"GENE","name":"RMDN3","canonical_id":"hgnc:HGNC:25550","description":"regulator of microtubule dynamics 3","metadata":{"aliases":["FLJ10579","PTPIP51","RMD3","FAM82C","FAM82A2"]}},{"id":"d6c65bd71d3c426bbc21120af04df0b2","type":"GENE","name":"RMEL3","canonical_id":"hgnc:HGNC:53975","description":"enriched in melanoma 3","metadata":null},{"id":"01b0636a765248ee9bbff4725e5e8ebf","type":"GENE","name":"RMI1","canonical_id":"hgnc:HGNC:25764","description":"RecQ mediated genome instability 1","metadata":{"aliases":["FLJ12888","BLAP75","C9orf76"]}},{"id":"ce2577f887394853a1e30f9e36721a42","type":"GENE","name":"RMI2","canonical_id":"hgnc:HGNC:28349","description":"RecQ mediated genome instability 2","metadata":{"aliases":["MGC24665","BLAP18","C16orf75"]}},{"id":"a45c2d4ba74d4b829c06667749493dda","type":"GENE","name":"RMI2-AS1","canonical_id":"hgnc:HGNC:58548","description":"RMI2 antisense RNA 1","metadata":null},{"id":"e63ef52cc3fd4335bf79cb0c5492bb8c","type":"GENE","name":"RMND1","canonical_id":"hgnc:HGNC:21176","description":"required for meiotic nuclear division 1 homolog","metadata":{"aliases":["bA351K16.3","FLJ20627","RMD1","C6orf96"]}},{"id":"da097c8d3864461d987970420dd93291","type":"GENE","name":"RMND5A","canonical_id":"hgnc:HGNC:25850","description":"required for meiotic nuclear division 5 homolog A","metadata":{"aliases":["FLJ13910","RMD5","GID2","GID2A","p44CTLH"]}},{"id":"1cd97551f30340e8b346ca2e8686d81f","type":"GENE","name":"RMND5B","canonical_id":"hgnc:HGNC:26181","description":"required for meiotic nuclear division 5 homolog B","metadata":{"aliases":["FLJ22318","GID2","GID2B"]}},{"id":"0601ac1fa5de431db64a8ffceeb1f86c","type":"GENE","name":"RMP24","canonical_id":"hgnc:HGNC:28802","description":"ribonuclease MRP subunit p24","metadata":{"aliases":["PNAS-131","PNAS-124","HsT3108","C18orf21"]}},{"id":"01a1b1984ce949b8bfc00e065e9310b9","type":"GENE","name":"RMP24P1","canonical_id":"hgnc:HGNC:57042","description":"RMP24 pseudogene 1","metadata":{"aliases":["C18orf21"]}},{"id":"72f9dbdeccc64f589d07b90dd04bc2ff","type":"GENE","name":"RMP64","canonical_id":"hgnc:HGNC:24496","description":"ribonuclease MRP subunit p64","metadata":{"aliases":["DKFZP434F2021","NET17","C3orf17","NEPRO"]}},{"id":"90306da3ef1b46fe827516fe65b17562","type":"GENE","name":"RMRP","canonical_id":"hgnc:HGNC:10031","description":"RNA component of mitochondrial RNA processing endoribonuclease","metadata":{"aliases":["RMRPR","RRP2","NME1","CHH"]}},{"id":"6500e20002564a669b42c9ce6b4ed84d","type":"GENE","name":"RMRPP5","canonical_id":"hgnc:HGNC:47035","description":"RNA component of mitochondrial RNA processing endoribonuclease pseudogene 5","metadata":null},{"id":"00db5264dff949548c1ac9f8ed563de8","type":"GENE","name":"RMST","canonical_id":"hgnc:HGNC:29893","description":"rhabdomyosarcoma 2 associated transcript","metadata":{"aliases":["NCRMS","NCRNA00054","LINC00054"]}},{"id":"49a26196ffad442d8b6f97cc0fde285f","type":"GENE","name":"RN7SK","canonical_id":"hgnc:HGNC:10037","description":"RNA component of 7SK nuclear ribonucleoprotein","metadata":{"aliases":["7SK"]}},{"id":"ddcac3e2ea024b53adf5e4581f9f0d1c","type":"GENE","name":"RN7SKP1","canonical_id":"hgnc:HGNC:42619","description":"RN7SK pseudogene 1","metadata":null},{"id":"14f47841a88549c3864f00e3dc950e6d","type":"GENE","name":"RN7SKP10","canonical_id":"hgnc:HGNC:42628","description":"RN7SK pseudogene 10","metadata":null},{"id":"de75e207f7744ad9bf07da7da6a2c391","type":"GENE","name":"RN7SKP100","canonical_id":"hgnc:HGNC:45824","description":"RN7SK pseudogene 100","metadata":null},{"id":"425690d71f824359b46548b38165d4cf","type":"GENE","name":"RN7SKP101","canonical_id":"hgnc:HGNC:45825","description":"RN7SK pseudogene 101","metadata":null},{"id":"548b649c261246efb7eaa6307c442056","type":"GENE","name":"RN7SKP102","canonical_id":"hgnc:HGNC:45826","description":"RN7SK pseudogene 102","metadata":null},{"id":"fc27ca74739e4851ab836851ae9c6971","type":"GENE","name":"RN7SKP103","canonical_id":"hgnc:HGNC:45827","description":"RN7SK pseudogene 103","metadata":null},{"id":"1e57602f7ea5405d84525649c0479eb6","type":"GENE","name":"RN7SKP104","canonical_id":"hgnc:HGNC:45828","description":"RN7SK pseudogene 104","metadata":null},{"id":"fc3088e404744b938a2368c457334cbd","type":"GENE","name":"RN7SKP105","canonical_id":"hgnc:HGNC:45829","description":"RN7SK pseudogene 105","metadata":null},{"id":"bd47678729de4bb686a44b3ebdc2753b","type":"GENE","name":"RN7SKP106","canonical_id":"hgnc:HGNC:45830","description":"RN7SK pseudogene 106","metadata":null},{"id":"5b79bf13f9604df682e03485e3af9b3d","type":"GENE","name":"RN7SKP107","canonical_id":"hgnc:HGNC:45831","description":"RN7SK pseudogene 107","metadata":null},{"id":"9211da63c75a467598fb7a0406f3c3c2","type":"GENE","name":"RN7SKP108","canonical_id":"hgnc:HGNC:45832","description":"RN7SK pseudogene 108","metadata":null},{"id":"cc47224da94f4ebb8669a08a654705bf","type":"GENE","name":"RN7SKP109","canonical_id":"hgnc:HGNC:45833","description":"RN7SK pseudogene 109","metadata":null},{"id":"26a8fa33a6f84818b57b5b4d17a8a441","type":"GENE","name":"RN7SKP11","canonical_id":"hgnc:HGNC:45735","description":"RN7SK pseudogene 11","metadata":null},{"id":"b90d56b274d54ce6a194ccaa4609491b","type":"GENE","name":"RN7SKP110","canonical_id":"hgnc:HGNC:45834","description":"RN7SK pseudogene 110","metadata":null},{"id":"41c10c2877384ec1a3b5f9e783c7b0f0","type":"GENE","name":"RN7SKP111","canonical_id":"hgnc:HGNC:45835","description":"RN7SK pseudogene 111","metadata":null},{"id":"41a612e9b89749e4bfb06368e0c09d48","type":"GENE","name":"RN7SKP112","canonical_id":"hgnc:HGNC:45836","description":"RN7SK pseudogene 112","metadata":null},{"id":"fb3914e32c1447a8861894cf673adcbb","type":"GENE","name":"RN7SKP113","canonical_id":"hgnc:HGNC:45837","description":"RN7SK pseudogene 113","metadata":null},{"id":"c9d9d60a2f334f8db97b75db91b8175b","type":"GENE","name":"RN7SKP114","canonical_id":"hgnc:HGNC:45838","description":"RN7SK pseudogene 114","metadata":null},{"id":"5c3db91e8f7141708654da7611479576","type":"GENE","name":"RN7SKP115","canonical_id":"hgnc:HGNC:45839","description":"RN7SK pseudogene 115","metadata":null},{"id":"8f1af6e519484dd7ace6f106621327d6","type":"GENE","name":"RN7SKP116","canonical_id":"hgnc:HGNC:45840","description":"RN7SK pseudogene 116","metadata":null},{"id":"870d594bdee04523bd0136915aaf417b","type":"GENE","name":"RN7SKP117","canonical_id":"hgnc:HGNC:45841","description":"RN7SK pseudogene 117","metadata":null},{"id":"197605c92a6d407c83aa658c87d02757","type":"GENE","name":"RN7SKP118","canonical_id":"hgnc:HGNC:45842","description":"RN7SK pseudogene 118","metadata":null},{"id":"7c3ab981de9048f6acc9e50294ec2f9e","type":"GENE","name":"RN7SKP119","canonical_id":"hgnc:HGNC:45843","description":"RN7SK pseudogene 119","metadata":null},{"id":"a8922aa0a644463c868a2d44c7ffbc3f","type":"GENE","name":"RN7SKP12","canonical_id":"hgnc:HGNC:45736","description":"RN7SK pseudogene 12","metadata":null},{"id":"290aa4c1034149f19922009209ea599f","type":"GENE","name":"RN7SKP120","canonical_id":"hgnc:HGNC:45844","description":"RN7SK pseudogene 120","metadata":null},{"id":"6d5efb7f4b18467b9180acc1717d803b","type":"GENE","name":"RN7SKP121","canonical_id":"hgnc:HGNC:45845","description":"RN7SK pseudogene 121","metadata":null},{"id":"d005dc0a06b74b0eaeda39b82d044ab1","type":"GENE","name":"RN7SKP122","canonical_id":"hgnc:HGNC:45846","description":"RN7SK pseudogene 122","metadata":null},{"id":"097ed61875e449b7b27a250ce34ac4c4","type":"GENE","name":"RN7SKP123","canonical_id":"hgnc:HGNC:45847","description":"RN7SK pseudogene 123","metadata":null},{"id":"cec871e4f0ab4971b6b17525465057e6","type":"GENE","name":"RN7SKP124","canonical_id":"hgnc:HGNC:45848","description":"RN7SK pseudogene 124","metadata":null},{"id":"99c951e6c10445a69c22bd7e4c57721a","type":"GENE","name":"RN7SKP125","canonical_id":"hgnc:HGNC:45849","description":"RN7SK pseudogene 125","metadata":null},{"id":"fae328e5a7ad41e78446fb5d8103b72f","type":"GENE","name":"RN7SKP126","canonical_id":"hgnc:HGNC:45850","description":"RN7SK pseudogene 126","metadata":null},{"id":"fe8572144b864e91b8071b74e40266a3","type":"GENE","name":"RN7SKP127","canonical_id":"hgnc:HGNC:45851","description":"RN7SK pseudogene 127","metadata":null},{"id":"167985bd7ff144c09e8ecc2d2f21bd16","type":"GENE","name":"RN7SKP128","canonical_id":"hgnc:HGNC:45852","description":"RN7SK pseudogene 128","metadata":null},{"id":"294b761db0b046d985fba8a5f69a4215","type":"GENE","name":"RN7SKP129","canonical_id":"hgnc:HGNC:45853","description":"RN7SK pseudogene 129","metadata":null},{"id":"5fd951f85cdf4442a894cc8f876a54f0","type":"GENE","name":"RN7SKP13","canonical_id":"hgnc:HGNC:45737","description":"RN7SK pseudogene 13","metadata":null},{"id":"b9ada0e1691b4c86938eb1a4693261db","type":"GENE","name":"RN7SKP130","canonical_id":"hgnc:HGNC:45854","description":"RN7SK pseudogene 130","metadata":null},{"id":"219a48f2cdb741a69c005bc134a5c607","type":"GENE","name":"RN7SKP131","canonical_id":"hgnc:HGNC:45855","description":"RN7SK pseudogene 131","metadata":null},{"id":"4c944e7c96b5443191c030c6e72c0978","type":"GENE","name":"RN7SKP132","canonical_id":"hgnc:HGNC:45856","description":"RN7SK pseudogene 132","metadata":null},{"id":"43613dfce0424a36b5ba2fc694fe599f","type":"GENE","name":"RN7SKP133","canonical_id":"hgnc:HGNC:45857","description":"RN7SK pseudogene 133","metadata":null},{"id":"59543a3305e8488fb852e60be45bdde0","type":"GENE","name":"RN7SKP134","canonical_id":"hgnc:HGNC:45858","description":"RN7SK pseudogene 134","metadata":null},{"id":"225c0e7240994ade81cd76e9d4102365","type":"GENE","name":"RN7SKP135","canonical_id":"hgnc:HGNC:45859","description":"RN7SK pseudogene 135","metadata":null},{"id":"0ad6566925ee4fb9b15102cf7a4f9e16","type":"GENE","name":"RN7SKP136","canonical_id":"hgnc:HGNC:45860","description":"RN7SK pseudogene 136","metadata":null},{"id":"c23176a49aab417aad2bfe4b2a2ddef8","type":"GENE","name":"RN7SKP137","canonical_id":"hgnc:HGNC:45861","description":"RN7SK pseudogene 137","metadata":null},{"id":"7d2508b3604f42bfab38e3f4a8bbb29f","type":"GENE","name":"RN7SKP139","canonical_id":"hgnc:HGNC:45863","description":"RN7SK pseudogene 139","metadata":null},{"id":"320dae81a89341a0bbf3a2f8eb772183","type":"GENE","name":"RN7SKP14","canonical_id":"hgnc:HGNC:45738","description":"RN7SK pseudogene 14","metadata":null},{"id":"5f311e8eb7314b4dbb1f173554e78ecd","type":"GENE","name":"RN7SKP140","canonical_id":"hgnc:HGNC:45864","description":"RN7SK pseudogene 140","metadata":null},{"id":"7109c7b46d7a43878f6f1fa8152affd7","type":"GENE","name":"RN7SKP141","canonical_id":"hgnc:HGNC:45865","description":"RN7SK pseudogene 141","metadata":null},{"id":"12e6c39499a942b49e99b68a17a2f979","type":"GENE","name":"RN7SKP142","canonical_id":"hgnc:HGNC:45866","description":"RN7SK pseudogene 142","metadata":null},{"id":"8299021e2f034497b12d1510adf64a3d","type":"GENE","name":"RN7SKP143","canonical_id":"hgnc:HGNC:45867","description":"RN7SK pseudogene 143","metadata":null},{"id":"d581adee97c248348854ca1e5b727c0d","type":"GENE","name":"RN7SKP144","canonical_id":"hgnc:HGNC:45868","description":"RN7SK pseudogene 144","metadata":null},{"id":"66dfee4be8434d0baf3ee5de479c5757","type":"GENE","name":"RN7SKP145","canonical_id":"hgnc:HGNC:45869","description":"RN7SK pseudogene 145","metadata":null},{"id":"4daf17d5679f499aba8184e6fdb3bf13","type":"GENE","name":"RN7SKP146","canonical_id":"hgnc:HGNC:45870","description":"RN7SK pseudogene 146","metadata":null},{"id":"7024e56017b54c31be7c058af6a25ef6","type":"GENE","name":"RN7SKP147","canonical_id":"hgnc:HGNC:45871","description":"RN7SK pseudogene 147","metadata":null},{"id":"2f3a6fa7a7074e5fb740d2de36433140","type":"GENE","name":"RN7SKP148","canonical_id":"hgnc:HGNC:45872","description":"RN7SK pseudogene 148","metadata":null},{"id":"9692080c786249218ffc00a70d660776","type":"GENE","name":"RN7SKP149","canonical_id":"hgnc:HGNC:45873","description":"RN7SK pseudogene 149","metadata":null},{"id":"33f4eb12d7c14e16b1851332d738870c","type":"GENE","name":"RN7SKP15","canonical_id":"hgnc:HGNC:45739","description":"RN7SK pseudogene 15","metadata":null},{"id":"2edb9f9c1d46441dae5e430784d8122f","type":"GENE","name":"RN7SKP150","canonical_id":"hgnc:HGNC:45874","description":"RN7SK pseudogene 150","metadata":null},{"id":"98e522e53a9a4d74ab895f02c046614f","type":"GENE","name":"RN7SKP151","canonical_id":"hgnc:HGNC:45875","description":"RN7SK pseudogene 151","metadata":null},{"id":"d3830722f73b44b99960beb0f7658bd2","type":"GENE","name":"RN7SKP152","canonical_id":"hgnc:HGNC:45876","description":"RN7SK pseudogene 152","metadata":null},{"id":"7040cafa651a4f119b7548515e27fbc3","type":"GENE","name":"RN7SKP153","canonical_id":"hgnc:HGNC:45877","description":"RN7SK pseudogene 153","metadata":null},{"id":"b77eb6b9802143d882e76914008192ac","type":"GENE","name":"RN7SKP154","canonical_id":"hgnc:HGNC:45878","description":"RN7SK pseudogene 154","metadata":null},{"id":"6ee61204aa9c42a88ca09bda0cba86d0","type":"GENE","name":"RN7SKP155","canonical_id":"hgnc:HGNC:45879","description":"RN7SK pseudogene 155","metadata":null},{"id":"42b11de6e50941c6acc3f8404d3a6bac","type":"GENE","name":"RN7SKP156","canonical_id":"hgnc:HGNC:45880","description":"RN7SK pseudogene 156","metadata":null},{"id":"df901409f63f49ba80ec7cc5948d5a4e","type":"GENE","name":"RN7SKP157","canonical_id":"hgnc:HGNC:45881","description":"RN7SK pseudogene 157","metadata":null},{"id":"a8f76f6e174e477c855cf7c092b9eaf1","type":"GENE","name":"RN7SKP158","canonical_id":"hgnc:HGNC:45882","description":"RN7SK pseudogene 158","metadata":null},{"id":"6ef396faf4404ac5bd345acdd61b3295","type":"GENE","name":"RN7SKP159","canonical_id":"hgnc:HGNC:45883","description":"RN7SK pseudogene 159","metadata":null},{"id":"fb6626e99a4b4514b9b2ccb53dccf52c","type":"GENE","name":"RN7SKP16","canonical_id":"hgnc:HGNC:45740","description":"RN7SK pseudogene 16","metadata":null},{"id":"1c0c1b14a56b49aaa2289fad58035cc3","type":"GENE","name":"RN7SKP160","canonical_id":"hgnc:HGNC:45884","description":"RN7SK pseudogene 160","metadata":null},{"id":"a665257b65a04d65b0b701c95d86a833","type":"GENE","name":"RN7SKP161","canonical_id":"hgnc:HGNC:45885","description":"RN7SK pseudogene 161","metadata":null},{"id":"cddc4690669d48179cb13643bde18131","type":"GENE","name":"RN7SKP162","canonical_id":"hgnc:HGNC:45886","description":"RN7SK pseudogene 162","metadata":null},{"id":"314c7ed1b6f04fd09d19ad538e726c5c","type":"GENE","name":"RN7SKP163","canonical_id":"hgnc:HGNC:45887","description":"RN7SK pseudogene 163","metadata":null},{"id":"f06e4e8e87b141a29a098aaa3cfd49a1","type":"GENE","name":"RN7SKP164","canonical_id":"hgnc:HGNC:45888","description":"RN7SK pseudogene 164","metadata":null},{"id":"6277935b69ca42a1bf37705a237b4e97","type":"GENE","name":"RN7SKP165","canonical_id":"hgnc:HGNC:45889","description":"RN7SK pseudogene 165","metadata":null},{"id":"becca17a4285467b91cc53828347c471","type":"GENE","name":"RN7SKP166","canonical_id":"hgnc:HGNC:45890","description":"RN7SK pseudogene 166","metadata":null},{"id":"f1cad8bd50eb47b998bfd924b281c8ff","type":"GENE","name":"RN7SKP167","canonical_id":"hgnc:HGNC:45891","description":"RN7SK pseudogene 167","metadata":null},{"id":"04eb69402e1e491390a82abffdb9ef1c","type":"GENE","name":"RN7SKP168","canonical_id":"hgnc:HGNC:45892","description":"RN7SK pseudogene 168","metadata":null},{"id":"8e31d14751b947f89ee86af50d4ebc31","type":"GENE","name":"RN7SKP169","canonical_id":"hgnc:HGNC:45893","description":"RN7SK pseudogene 169","metadata":null},{"id":"b3eb9ae76f2140e39409ecc3818cedba","type":"GENE","name":"RN7SKP17","canonical_id":"hgnc:HGNC:45741","description":"RN7SK pseudogene 17","metadata":null},{"id":"759937a0c21349e096c0e549c590ce23","type":"GENE","name":"RN7SKP170","canonical_id":"hgnc:HGNC:45894","description":"RN7SK pseudogene 170","metadata":null},{"id":"8dd7cf8202bc4f1286f466fc85949eb1","type":"GENE","name":"RN7SKP171","canonical_id":"hgnc:HGNC:45895","description":"RN7SK pseudogene 171","metadata":null},{"id":"eff45ed42f5a4eaeb10381d53d0d1069","type":"GENE","name":"RN7SKP172","canonical_id":"hgnc:HGNC:45896","description":"RN7SK pseudogene 172","metadata":null},{"id":"8fd0a0f5b89a4a968c9c6e0911020b07","type":"GENE","name":"RN7SKP173","canonical_id":"hgnc:HGNC:45897","description":"RN7SK pseudogene 173","metadata":null},{"id":"3449fc2b637b4024990e49ab544eb2cf","type":"GENE","name":"RN7SKP174","canonical_id":"hgnc:HGNC:45898","description":"RN7SK pseudogene 174","metadata":null},{"id":"4057fc26c06a407e9388824c2c21873c","type":"GENE","name":"RN7SKP175","canonical_id":"hgnc:HGNC:45899","description":"RN7SK pseudogene 175","metadata":null},{"id":"7209025275f74f2eb44466422b8d98e3","type":"GENE","name":"RN7SKP176","canonical_id":"hgnc:HGNC:45900","description":"RN7SK pseudogene 176","metadata":null},{"id":"012977364d1a4a6ab91f1ed8c293a55b","type":"GENE","name":"RN7SKP177","canonical_id":"hgnc:HGNC:45901","description":"RN7SK pseudogene 177","metadata":null},{"id":"7415f574399d40ee96ef519805886409","type":"GENE","name":"RN7SKP178","canonical_id":"hgnc:HGNC:45902","description":"RN7SK pseudogene 178","metadata":null},{"id":"8e244539e303461d8a39477b74510a0c","type":"GENE","name":"RN7SKP179","canonical_id":"hgnc:HGNC:45903","description":"RN7SK pseudogene 179","metadata":null},{"id":"583f947657444d818e9ef5a4a6d1b8b6","type":"GENE","name":"RN7SKP18","canonical_id":"hgnc:HGNC:45742","description":"RN7SK pseudogene 18","metadata":null},{"id":"af44927daf534551b83e0876dbf2972e","type":"GENE","name":"RN7SKP180","canonical_id":"hgnc:HGNC:45904","description":"RN7SK pseudogene 180","metadata":null},{"id":"9c88c6e35a9649fc9d540e04a6387c0b","type":"GENE","name":"RN7SKP181","canonical_id":"hgnc:HGNC:45905","description":"RN7SK pseudogene 181","metadata":null},{"id":"917203eae5bb4474ac6e0d53732b9379","type":"GENE","name":"RN7SKP182","canonical_id":"hgnc:HGNC:45906","description":"RN7SK pseudogene 182","metadata":null},{"id":"262c8bd75be44daeb2409274dfe4d26a","type":"GENE","name":"RN7SKP183","canonical_id":"hgnc:HGNC:45907","description":"RN7SK pseudogene 183","metadata":null},{"id":"04d0837b8dcd4c898ebceb5f2c2aae88","type":"GENE","name":"RN7SKP184","canonical_id":"hgnc:HGNC:45908","description":"RN7SK pseudogene 184","metadata":null},{"id":"1dcac7232065456a911747f3d26cfebf","type":"GENE","name":"RN7SKP185","canonical_id":"hgnc:HGNC:45909","description":"RN7SK pseudogene 185","metadata":null},{"id":"a843a75133864b2391da9d96ca978b32","type":"GENE","name":"RN7SKP186","canonical_id":"hgnc:HGNC:45910","description":"RN7SK pseudogene 186","metadata":{"aliases":["RN7SKP138"]}},{"id":"e829e4ee9bc54e878dbdd0ab02ce7190","type":"GENE","name":"RN7SKP187","canonical_id":"hgnc:HGNC:45911","description":"RN7SK pseudogene 187","metadata":null},{"id":"6ca1f50eb93f48729ed81e95cb3d096a","type":"GENE","name":"RN7SKP188","canonical_id":"hgnc:HGNC:45912","description":"RN7SK pseudogene 188","metadata":null},{"id":"bd3493dc5c184320aead78fc8e0de117","type":"GENE","name":"RN7SKP189","canonical_id":"hgnc:HGNC:45913","description":"RN7SK pseudogene 189","metadata":null},{"id":"358d4b5b1992417a8c407dbb4186ada6","type":"GENE","name":"RN7SKP19","canonical_id":"hgnc:HGNC:45743","description":"RN7SK pseudogene 19","metadata":null},{"id":"09c8dea822e047bc8853517290b416f7","type":"GENE","name":"RN7SKP190","canonical_id":"hgnc:HGNC:45914","description":"RN7SK pseudogene 190","metadata":null},{"id":"b9d780834fc44326b3fab0bac5b94236","type":"GENE","name":"RN7SKP191","canonical_id":"hgnc:HGNC:45915","description":"RN7SK pseudogene 191","metadata":null},{"id":"923a17a949c946bb9e130880c497d41d","type":"GENE","name":"RN7SKP192","canonical_id":"hgnc:HGNC:45916","description":"RN7SK pseudogene 192","metadata":null},{"id":"bd280edccc244a14835d5c6f559e1cf8","type":"GENE","name":"RN7SKP193","canonical_id":"hgnc:HGNC:45917","description":"RN7SK pseudogene 193","metadata":null},{"id":"a6da06c46f0344af86d6d770f7246136","type":"GENE","name":"RN7SKP194","canonical_id":"hgnc:HGNC:45918","description":"RN7SK pseudogene 194","metadata":null},{"id":"3006ef703af9473982a94817a6769d80","type":"GENE","name":"RN7SKP195","canonical_id":"hgnc:HGNC:45919","description":"RN7SK pseudogene 195","metadata":null},{"id":"579a17b508aa40e0b754d84e31741cf5","type":"GENE","name":"RN7SKP196","canonical_id":"hgnc:HGNC:45920","description":"RN7SK pseudogene 196","metadata":null},{"id":"546255b914c94c1daaba027996578170","type":"GENE","name":"RN7SKP197","canonical_id":"hgnc:HGNC:45921","description":"RN7SK pseudogene 197","metadata":null},{"id":"79285c3c6375496bb746750c4688a83b","type":"GENE","name":"RN7SKP198","canonical_id":"hgnc:HGNC:45922","description":"RN7SK pseudogene 198","metadata":null},{"id":"86ecb75b5f2044039f76c46d0852e1fe","type":"GENE","name":"RN7SKP199","canonical_id":"hgnc:HGNC:45923","description":"RN7SK pseudogene 199","metadata":null},{"id":"af4f62d50c7145658328cadaa7215d13","type":"GENE","name":"RN7SKP2","canonical_id":"hgnc:HGNC:42620","description":"RN7SK pseudogene 2","metadata":null},{"id":"2bf6dfd187404231a8b107bec7badd56","type":"GENE","name":"RN7SKP20","canonical_id":"hgnc:HGNC:45744","description":"RN7SK pseudogene 20","metadata":null},{"id":"f748353976bf47e4a963e67985f56cba","type":"GENE","name":"RN7SKP200","canonical_id":"hgnc:HGNC:45924","description":"RN7SK pseudogene 200","metadata":null},{"id":"068a7327f9e74dd1b209452beba4e55e","type":"GENE","name":"RN7SKP202","canonical_id":"hgnc:HGNC:45926","description":"RN7SK pseudogene 202","metadata":null},{"id":"dff6e8e0fda746d18d6a7701333c3adb","type":"GENE","name":"RN7SKP203","canonical_id":"hgnc:HGNC:45927","description":"RN7SK pseudogene 203","metadata":null},{"id":"a59192a60a7e4090a57ff78667f9148f","type":"GENE","name":"RN7SKP204","canonical_id":"hgnc:HGNC:45928","description":"RN7SK pseudogene 204","metadata":null},{"id":"5c6f6ffffcf047be9322bfc3f6891474","type":"GENE","name":"RN7SKP205","canonical_id":"hgnc:HGNC:45929","description":"RN7SK pseudogene 205","metadata":null},{"id":"37a796b0f6404f46a2bebe233641fd40","type":"GENE","name":"RN7SKP206","canonical_id":"hgnc:HGNC:45930","description":"RN7SK pseudogene 206","metadata":null},{"id":"75702fa20faf4431a2086d219bf485b8","type":"GENE","name":"RN7SKP207","canonical_id":"hgnc:HGNC:45931","description":"RN7SK pseudogene 207","metadata":null},{"id":"54cc14d76e02498088e9685b36565be4","type":"GENE","name":"RN7SKP208","canonical_id":"hgnc:HGNC:45932","description":"RN7SK pseudogene 208","metadata":null},{"id":"92a0470c9ab1442a9a777b78dd7bf95e","type":"GENE","name":"RN7SKP209","canonical_id":"hgnc:HGNC:45933","description":"RN7SK pseudogene 209","metadata":null},{"id":"db955d413bdd42fcb39b1c1beaf19cd6","type":"GENE","name":"RN7SKP21","canonical_id":"hgnc:HGNC:45745","description":"RN7SK pseudogene 21","metadata":null},{"id":"c7daeb8d353141c4afe3e3b075ed754a","type":"GENE","name":"RN7SKP210","canonical_id":"hgnc:HGNC:45934","description":"RN7SK pseudogene 210","metadata":null},{"id":"6d91301c052c41f88a7056c66f598997","type":"GENE","name":"RN7SKP211","canonical_id":"hgnc:HGNC:45935","description":"RN7SK pseudogene 211","metadata":null},{"id":"1deebef6a84c4205bacd93af163f3e3e","type":"GENE","name":"RN7SKP212","canonical_id":"hgnc:HGNC:45936","description":"RN7SK pseudogene 212","metadata":null},{"id":"2058553b8f0149c9a9d6d6615c4a5045","type":"GENE","name":"RN7SKP213","canonical_id":"hgnc:HGNC:45937","description":"RN7SK pseudogene 213","metadata":null},{"id":"2b76ecb1480a4da7911cd3dcdf6d4d0b","type":"GENE","name":"RN7SKP214","canonical_id":"hgnc:HGNC:45938","description":"RN7SK pseudogene 214","metadata":null},{"id":"6e99afbf409b4d5da7781f3fc1806cf7","type":"GENE","name":"RN7SKP216","canonical_id":"hgnc:HGNC:45940","description":"RN7SK pseudogene 216","metadata":null},{"id":"76ae4fed9c9b42289c246988b3c08664","type":"GENE","name":"RN7SKP217","canonical_id":"hgnc:HGNC:45941","description":"RN7SK pseudogene 217","metadata":null},{"id":"36fd4edf6dc04459ae8a487b64be6a94","type":"GENE","name":"RN7SKP218","canonical_id":"hgnc:HGNC:45942","description":"RN7SK pseudogene 218","metadata":null},{"id":"8faf14985e344d418944f0aed86fac96","type":"GENE","name":"RN7SKP219","canonical_id":"hgnc:HGNC:45943","description":"RN7SK pseudogene 219","metadata":null},{"id":"faf15e52a5dc423386fdfd21498297e2","type":"GENE","name":"RN7SKP22","canonical_id":"hgnc:HGNC:45746","description":"RN7SK pseudogene 22","metadata":null},{"id":"bf4bc6f870dd4bc28614e2f06a0505b4","type":"GENE","name":"RN7SKP220","canonical_id":"hgnc:HGNC:45944","description":"RN7SK pseudogene 220","metadata":null},{"id":"c8cb46b067444ca7b2b336d88d480fb0","type":"GENE","name":"RN7SKP221","canonical_id":"hgnc:HGNC:45945","description":"RN7SK pseudogene 221","metadata":null},{"id":"8c184e83728545a3b7151a960e8d55df","type":"GENE","name":"RN7SKP222","canonical_id":"hgnc:HGNC:45946","description":"RN7SK pseudogene 222","metadata":null},{"id":"93ca3e25c9d5479b83ad3308583b7f60","type":"GENE","name":"RN7SKP223","canonical_id":"hgnc:HGNC:45947","description":"RN7SK pseudogene 223","metadata":null},{"id":"a78c37a8aeed4ed6a220bb6334dd236d","type":"GENE","name":"RN7SKP224","canonical_id":"hgnc:HGNC:45948","description":"RN7SK pseudogene 224","metadata":null},{"id":"4f07df7c228c480d9a6ca87659c03645","type":"GENE","name":"RN7SKP225","canonical_id":"hgnc:HGNC:45949","description":"RN7SK pseudogene 225","metadata":null},{"id":"688e4598badc41c799b13b05f1538f72","type":"GENE","name":"RN7SKP226","canonical_id":"hgnc:HGNC:45950","description":"RN7SK pseudogene 226","metadata":null},{"id":"7fd442ef47df42fabc7e6c0b31727b4b","type":"GENE","name":"RN7SKP227","canonical_id":"hgnc:HGNC:45951","description":"RN7SK pseudogene 227","metadata":null},{"id":"5b8b3fa2ee754a7fa66fa99aa5e7888e","type":"GENE","name":"RN7SKP228","canonical_id":"hgnc:HGNC:45952","description":"RN7SK pseudogene 228","metadata":null},{"id":"0463344fa8804af4a1853db1f127c2ea","type":"GENE","name":"RN7SKP229","canonical_id":"hgnc:HGNC:45953","description":"RN7SK pseudogene 229","metadata":null},{"id":"e89b9761c07d4e67aaa38f452491e883","type":"GENE","name":"RN7SKP23","canonical_id":"hgnc:HGNC:45747","description":"RN7SK pseudogene 23","metadata":null},{"id":"b52bf85ecff2445cb3c8739ce14e0f32","type":"GENE","name":"RN7SKP230","canonical_id":"hgnc:HGNC:45954","description":"RN7SK pseudogene 230","metadata":null},{"id":"f7314506897e497f9890b3151c800ab0","type":"GENE","name":"RN7SKP231","canonical_id":"hgnc:HGNC:45955","description":"RN7SK pseudogene 231","metadata":null},{"id":"f86922fb265f40b8adcafa45d97f2a31","type":"GENE","name":"RN7SKP232","canonical_id":"hgnc:HGNC:45956","description":"RN7SK pseudogene 232","metadata":null},{"id":"c665ec2aa09144d18460a59e9918bdd9","type":"GENE","name":"RN7SKP233","canonical_id":"hgnc:HGNC:45957","description":"RN7SK pseudogene 233","metadata":null},{"id":"0cff3f569d01444ba410391af17486fc","type":"GENE","name":"RN7SKP234","canonical_id":"hgnc:HGNC:45958","description":"RN7SK pseudogene 234","metadata":null},{"id":"7ca937c1814d4860a039102bebadecd9","type":"GENE","name":"RN7SKP235","canonical_id":"hgnc:HGNC:45959","description":"RN7SK pseudogene 235","metadata":null},{"id":"a225ab56a05341cc81ae421ca0239f15","type":"GENE","name":"RN7SKP236","canonical_id":"hgnc:HGNC:45960","description":"RN7SK pseudogene 236","metadata":null},{"id":"a8e04d788c2241839e4edafd679d5435","type":"GENE","name":"RN7SKP237","canonical_id":"hgnc:HGNC:45961","description":"RN7SK pseudogene 237","metadata":null},{"id":"f8987926ce984bc3ac6a11f23029dac7","type":"GENE","name":"RN7SKP238","canonical_id":"hgnc:HGNC:45962","description":"RN7SK pseudogene 238","metadata":null},{"id":"4e9b92bad71f4b0abad224f3e78ccc24","type":"GENE","name":"RN7SKP239","canonical_id":"hgnc:HGNC:45963","description":"RN7SK pseudogene 239","metadata":null},{"id":"8f56c1f5c36a4ce0bb35f928a72964c8","type":"GENE","name":"RN7SKP24","canonical_id":"hgnc:HGNC:45748","description":"RN7SK pseudogene 24","metadata":null},{"id":"10396827bbea4c088697fe5cee986b19","type":"GENE","name":"RN7SKP240","canonical_id":"hgnc:HGNC:45964","description":"RN7SK pseudogene 240","metadata":null},{"id":"429eca91ee7d4052b8e30c00f2deea69","type":"GENE","name":"RN7SKP241","canonical_id":"hgnc:HGNC:45965","description":"RN7SK pseudogene 241","metadata":null},{"id":"3c82529d5a324aa0919902ece84b9277","type":"GENE","name":"RN7SKP242","canonical_id":"hgnc:HGNC:45966","description":"RN7SK pseudogene 242","metadata":null},{"id":"f735c50041ea44d7a5834dd2628e4920","type":"GENE","name":"RN7SKP243","canonical_id":"hgnc:HGNC:45967","description":"RN7SK pseudogene 243","metadata":null},{"id":"57cec7baba84495799721140146d31bb","type":"GENE","name":"RN7SKP244","canonical_id":"hgnc:HGNC:45968","description":"RN7SK pseudogene 244","metadata":null},{"id":"e3f025985e63477b880864801b331594","type":"GENE","name":"RN7SKP245","canonical_id":"hgnc:HGNC:45969","description":"RN7SK pseudogene 245","metadata":null},{"id":"111220e1018f43d6b983031e2af85786","type":"GENE","name":"RN7SKP246","canonical_id":"hgnc:HGNC:45970","description":"RN7SK pseudogene 246","metadata":null},{"id":"047c839f077b42c7b348b5eb04009c0c","type":"GENE","name":"RN7SKP247","canonical_id":"hgnc:HGNC:45971","description":"RN7SK pseudogene 247","metadata":null},{"id":"3f60abaeee0941adb0062bc04078baac","type":"GENE","name":"RN7SKP248","canonical_id":"hgnc:HGNC:45972","description":"RN7SK pseudogene 248","metadata":null},{"id":"077d6f2e613b4879b0fa227a10a001ac","type":"GENE","name":"RN7SKP249","canonical_id":"hgnc:HGNC:45973","description":"RN7SK pseudogene 249","metadata":null},{"id":"47a98cff1a8f477181f8712f6b0f2c5f","type":"GENE","name":"RN7SKP25","canonical_id":"hgnc:HGNC:45749","description":"RN7SK pseudogene 25","metadata":null},{"id":"5c3d98417eaf4087afe5c36d9025e1c7","type":"GENE","name":"RN7SKP250","canonical_id":"hgnc:HGNC:45974","description":"RN7SK pseudogene 250","metadata":null},{"id":"69d399ab2160458583a73a722aa4974a","type":"GENE","name":"RN7SKP251","canonical_id":"hgnc:HGNC:45975","description":"RN7SK pseudogene 251","metadata":null},{"id":"94d440df43ef4102980ad5ee6826c9f4","type":"GENE","name":"RN7SKP252","canonical_id":"hgnc:HGNC:45976","description":"RN7SK pseudogene 252","metadata":null},{"id":"30c82ae351b14c11a45ef19c0d78c283","type":"GENE","name":"RN7SKP253","canonical_id":"hgnc:HGNC:45977","description":"RN7SK pseudogene 253","metadata":null},{"id":"db499bee6c5140a8a51eeef74d64e31f","type":"GENE","name":"RN7SKP254","canonical_id":"hgnc:HGNC:45978","description":"RN7SK pseudogene 254","metadata":null},{"id":"bcde3b6e0e904dc2a5e137dd22115b6e","type":"GENE","name":"RN7SKP255","canonical_id":"hgnc:HGNC:45979","description":"RN7SK pseudogene 255","metadata":null},{"id":"6f5587828d344ba5b56a62a05e3f53d0","type":"GENE","name":"RN7SKP256","canonical_id":"hgnc:HGNC:45980","description":"RN7SK pseudogene 256","metadata":null},{"id":"7934bb67c5cd4b75bd824a3d8df45909","type":"GENE","name":"RN7SKP257","canonical_id":"hgnc:HGNC:45981","description":"RN7SK pseudogene 257","metadata":null},{"id":"3aa11f9cd2f44c789261ebd068cdc3cf","type":"GENE","name":"RN7SKP258","canonical_id":"hgnc:HGNC:45982","description":"RN7SK pseudogene 258","metadata":null},{"id":"4b4fd27cca1a45b7bc397043386091be","type":"GENE","name":"RN7SKP259","canonical_id":"hgnc:HGNC:45983","description":"RN7SK pseudogene 259","metadata":null},{"id":"1f1f73f0e7a5431e8b35e4d53abedd77","type":"GENE","name":"RN7SKP26","canonical_id":"hgnc:HGNC:45750","description":"RN7SK pseudogene 26","metadata":null},{"id":"11e165b5cf514f3e85b99bebc4b28af8","type":"GENE","name":"RN7SKP260","canonical_id":"hgnc:HGNC:45984","description":"RN7SK pseudogene 260","metadata":null},{"id":"592b7dad0d034bafba7a284e6fe4736e","type":"GENE","name":"RN7SKP261","canonical_id":"hgnc:HGNC:45985","description":"RN7SK pseudogene 261","metadata":null},{"id":"b960c696cdff47a098597003bd66513e","type":"GENE","name":"RN7SKP262","canonical_id":"hgnc:HGNC:45986","description":"RN7SK pseudogene 262","metadata":null},{"id":"6984d1d6bae0465b927542535089f8f8","type":"GENE","name":"RN7SKP263","canonical_id":"hgnc:HGNC:45987","description":"RN7SK pseudogene 263","metadata":null},{"id":"0d29f2cd490d4d6aa469614f0cb80566","type":"GENE","name":"RN7SKP264","canonical_id":"hgnc:HGNC:45988","description":"RN7SK pseudogene 264","metadata":null},{"id":"4ad3e3836f304e4e9a8e962f9b5c1872","type":"GENE","name":"RN7SKP265","canonical_id":"hgnc:HGNC:45989","description":"RN7SK pseudogene 265","metadata":null},{"id":"0e5b736365454cdbb8b07f3282d1f9da","type":"GENE","name":"RN7SKP266","canonical_id":"hgnc:HGNC:45990","description":"RN7SK pseudogene 266","metadata":null},{"id":"c7921c0d89df43bb90d920ac697e35c2","type":"GENE","name":"RN7SKP267","canonical_id":"hgnc:HGNC:45991","description":"RN7SK pseudogene 267","metadata":null},{"id":"d667d04ce5a34f54be41d3349c9adf1d","type":"GENE","name":"RN7SKP268","canonical_id":"hgnc:HGNC:45992","description":"RN7SK pseudogene 268","metadata":null},{"id":"81bf5b6d63ca4f39af31399a03e2cbba","type":"GENE","name":"RN7SKP269","canonical_id":"hgnc:HGNC:45993","description":"RN7SK pseudogene 269","metadata":null},{"id":"685cd915cd0846609ee5ec062dd6f937","type":"GENE","name":"RN7SKP27","canonical_id":"hgnc:HGNC:45751","description":"RN7SK pseudogene 27","metadata":null},{"id":"b43661076f4e494b981a6f3d8bda62f3","type":"GENE","name":"RN7SKP270","canonical_id":"hgnc:HGNC:45994","description":"RN7SK pseudogene 270","metadata":null},{"id":"6145c1100a7b4fc887f69d1999b47c98","type":"GENE","name":"RN7SKP271","canonical_id":"hgnc:HGNC:45995","description":"RN7SK pseudogene 271","metadata":null},{"id":"c92faa765b14419b9f631e95ef51bae1","type":"GENE","name":"RN7SKP272","canonical_id":"hgnc:HGNC:45996","description":"RN7SK pseudogene 272","metadata":null},{"id":"14af1737eecb4be4b3e6c0f276ec2009","type":"GENE","name":"RN7SKP273","canonical_id":"hgnc:HGNC:45997","description":"RN7SK pseudogene 273","metadata":null},{"id":"516b156d45bc46958c90b72961f4c3e9","type":"GENE","name":"RN7SKP275","canonical_id":"hgnc:HGNC:45999","description":"RN7SK pseudogene 275","metadata":null},{"id":"fe48dda16925477e919b4c2ee0fdd5cb","type":"GENE","name":"RN7SKP276","canonical_id":"hgnc:HGNC:46000","description":"RN7SK pseudogene 276","metadata":null},{"id":"e3d70ca159e8452eb1587aea4a6f73a7","type":"GENE","name":"RN7SKP277","canonical_id":"hgnc:HGNC:46001","description":"RN7SK pseudogene 277","metadata":null},{"id":"931f0c12d98d4808a2110dd64aef99ba","type":"GENE","name":"RN7SKP278","canonical_id":"hgnc:HGNC:46002","description":"RN7SK pseudogene 278","metadata":null},{"id":"2571e40ac8614c2baba4b4572f519b31","type":"GENE","name":"RN7SKP279","canonical_id":"hgnc:HGNC:46003","description":"RN7SK pseudogene 279","metadata":null},{"id":"dc4f64cc7c594c91ba4e16794b865d2a","type":"GENE","name":"RN7SKP28","canonical_id":"hgnc:HGNC:45752","description":"RN7SK pseudogene 28","metadata":null},{"id":"88498fe346b6498997d3309c3458916f","type":"GENE","name":"RN7SKP280","canonical_id":"hgnc:HGNC:46004","description":"RN7SK pseudogene 280","metadata":null},{"id":"0751fb18c8194919bf23f80c6561fe36","type":"GENE","name":"RN7SKP281","canonical_id":"hgnc:HGNC:46005","description":"RN7SK pseudogene 281","metadata":null},{"id":"9468cdf842164ad4bf4d47e19363f474","type":"GENE","name":"RN7SKP282","canonical_id":"hgnc:HGNC:46006","description":"RN7SK pseudogene 282","metadata":null},{"id":"5571e99fffe04c6eb3e7489a6a09f198","type":"GENE","name":"RN7SKP283","canonical_id":"hgnc:HGNC:46007","description":"RN7SK pseudogene 283","metadata":null},{"id":"6ea62cbfb84c4764940a1481729785df","type":"GENE","name":"RN7SKP284","canonical_id":"hgnc:HGNC:46008","description":"RN7SK pseudogene 284","metadata":null},{"id":"d322c76103c849c494ed879f9a0d43df","type":"GENE","name":"RN7SKP285","canonical_id":"hgnc:HGNC:46009","description":"RN7SK pseudogene 285","metadata":null},{"id":"d5f7468dd3d54f7c9fc436eb3f8645a4","type":"GENE","name":"RN7SKP286","canonical_id":"hgnc:HGNC:46010","description":"RN7SK pseudogene 286","metadata":null},{"id":"383ef336415c4b0fb40adb476b9aba1d","type":"GENE","name":"RN7SKP287","canonical_id":"hgnc:HGNC:46011","description":"RN7SK pseudogene 287","metadata":null},{"id":"2b109836d27148bc838190590c2845a8","type":"GENE","name":"RN7SKP288","canonical_id":"hgnc:HGNC:46012","description":"RN7SK pseudogene 288","metadata":null},{"id":"0d15a3d30e9b4611a20733589bcde1ac","type":"GENE","name":"RN7SKP289","canonical_id":"hgnc:HGNC:46013","description":"RN7SK pseudogene 289","metadata":null},{"id":"c7fbdf2c70624a0082de074585c712a4","type":"GENE","name":"RN7SKP29","canonical_id":"hgnc:HGNC:45753","description":"RN7SK pseudogene 29","metadata":null},{"id":"39b1317bc1bf4f978c3609071a1026aa","type":"GENE","name":"RN7SKP290","canonical_id":"hgnc:HGNC:46014","description":"RN7SK pseudogene 290","metadata":null},{"id":"4ea12f9500c641919318735b60d53d42","type":"GENE","name":"RN7SKP291","canonical_id":"hgnc:HGNC:46015","description":"RN7SK pseudogene 291","metadata":null},{"id":"5515629b1bbc462184f1d9b05c7da0bc","type":"GENE","name":"RN7SKP292","canonical_id":"hgnc:HGNC:46016","description":"RN7SK pseudogene 292","metadata":null},{"id":"bfcb26c9a1924a0aa480c264d230458b","type":"GENE","name":"RN7SKP293","canonical_id":"hgnc:HGNC:46017","description":"RN7SK pseudogene 293","metadata":null},{"id":"c2969e46ac5442a2ab4a05a2cf014d6d","type":"GENE","name":"RN7SKP294","canonical_id":"hgnc:HGNC:46018","description":"RN7SK pseudogene 294","metadata":null},{"id":"14de23c7d752405d9a75f6009dc0fd24","type":"GENE","name":"RN7SKP295","canonical_id":"hgnc:HGNC:46019","description":"RN7SK pseudogene 295","metadata":null},{"id":"b8523f117e504c9ab0d4d0d16d5702d3","type":"GENE","name":"RN7SKP296","canonical_id":"hgnc:HGNC:46020","description":"RN7SK pseudogene 296","metadata":null},{"id":"fb914db8c9884c24a168c73ca8ea1640","type":"GENE","name":"RN7SKP297","canonical_id":"hgnc:HGNC:46021","description":"RN7SK pseudogene 297","metadata":null},{"id":"7a4761d1385347e0b07d8109e9c68c31","type":"GENE","name":"RN7SKP298","canonical_id":"hgnc:HGNC:46022","description":"RN7SK pseudogene 298","metadata":null},{"id":"5b980605282d4ba09d7273fcf269ab0b","type":"GENE","name":"RN7SKP299","canonical_id":"hgnc:HGNC:46023","description":"RN7SK pseudogene 299","metadata":null},{"id":"5122558100cd436fbca1350567269b7e","type":"GENE","name":"RN7SKP3","canonical_id":"hgnc:HGNC:42621","description":"RN7SK pseudogene 3","metadata":null},{"id":"82ee205802f948debcdecd7faf4fdaae","type":"GENE","name":"RN7SKP30","canonical_id":"hgnc:HGNC:45754","description":"RN7SK pseudogene 30","metadata":null},{"id":"868eb3a7fbc048098774fe40030253b9","type":"GENE","name":"RN7SKP31","canonical_id":"hgnc:HGNC:45755","description":"RN7SK pseudogene 31","metadata":null},{"id":"b283078cc82d43649298abc44c743de8","type":"GENE","name":"RN7SKP32","canonical_id":"hgnc:HGNC:45756","description":"RN7SK pseudogene 32","metadata":null},{"id":"398809474cf64dc9b7c76ef92cd39189","type":"GENE","name":"RN7SKP33","canonical_id":"hgnc:HGNC:45757","description":"RN7SK pseudogene 33","metadata":null},{"id":"5636e59a37b44164a930b220ac97f11d","type":"GENE","name":"RN7SKP34","canonical_id":"hgnc:HGNC:45758","description":"RN7SK pseudogene 34","metadata":null},{"id":"6336cf2be6514d329afdad5d682b35ec","type":"GENE","name":"RN7SKP35","canonical_id":"hgnc:HGNC:45759","description":"RN7SK pseudogene 35","metadata":null},{"id":"e1bd0a601cb34d0096e903e9c4fdcc7a","type":"GENE","name":"RN7SKP36","canonical_id":"hgnc:HGNC:45760","description":"RN7SK pseudogene 36","metadata":null},{"id":"f3df057e3760418989abcd5507af0ced","type":"GENE","name":"RN7SKP37","canonical_id":"hgnc:HGNC:45761","description":"RN7SK pseudogene 37","metadata":null},{"id":"27b70a93b5a94bffb23409cc35b1a6fd","type":"GENE","name":"RN7SKP38","canonical_id":"hgnc:HGNC:45762","description":"RN7SK pseudogene 38","metadata":null},{"id":"e56e87df46774175821b39fa6e40f73c","type":"GENE","name":"RN7SKP39","canonical_id":"hgnc:HGNC:45763","description":"RN7SK pseudogene 39","metadata":null},{"id":"88ce4896ab8340b08b5a3fae50742dfc","type":"GENE","name":"RN7SKP4","canonical_id":"hgnc:HGNC:42622","description":"RN7SK pseudogene 4","metadata":null},{"id":"2e613313104b4f7d8efcbd567f053384","type":"GENE","name":"RN7SKP40","canonical_id":"hgnc:HGNC:45764","description":"RN7SK pseudogene 40","metadata":null},{"id":"1a111a36bb5e4e51aad2352f901d00cb","type":"GENE","name":"RN7SKP42","canonical_id":"hgnc:HGNC:45766","description":"RN7SK pseudogene 42","metadata":null},{"id":"953d3c4beb524ea4be8c442aed06ea0a","type":"GENE","name":"RN7SKP43","canonical_id":"hgnc:HGNC:45767","description":"RN7SK pseudogene 43","metadata":null},{"id":"e0f6d4e2db5d407fab393c256ae50a60","type":"GENE","name":"RN7SKP44","canonical_id":"hgnc:HGNC:45768","description":"RN7SK pseudogene 44","metadata":null},{"id":"34a536b737bd4e269c31db3c88794d00","type":"GENE","name":"RN7SKP45","canonical_id":"hgnc:HGNC:45769","description":"RN7SK pseudogene 45","metadata":null},{"id":"961cf183cfa64b429e19623114c4b3ac","type":"GENE","name":"RN7SKP46","canonical_id":"hgnc:HGNC:45770","description":"RN7SK pseudogene 46","metadata":null},{"id":"69be84eae52b4bb38cd4c9f8ebde14d7","type":"GENE","name":"RN7SKP47","canonical_id":"hgnc:HGNC:45771","description":"RN7SK pseudogene 47","metadata":null},{"id":"60a0f85fa33e425dab91134d6245461b","type":"GENE","name":"RN7SKP48","canonical_id":"hgnc:HGNC:45772","description":"RN7SK pseudogene 48","metadata":null},{"id":"efb1f2cddb6e4e1c8a42a84fa87c58c4","type":"GENE","name":"RN7SKP49","canonical_id":"hgnc:HGNC:45773","description":"RN7SK pseudogene 49","metadata":null},{"id":"8236adaa47d64b568fdbb73fd1a949ba","type":"GENE","name":"RN7SKP5","canonical_id":"hgnc:HGNC:42623","description":"RN7SK pseudogene 5","metadata":null},{"id":"9fa50126ed0a4c6d9944b6455eca621a","type":"GENE","name":"RN7SKP50","canonical_id":"hgnc:HGNC:45774","description":"RN7SK pseudogene 50","metadata":null},{"id":"1ba9b06dfd0340b9888916891095d5f0","type":"GENE","name":"RN7SKP51","canonical_id":"hgnc:HGNC:45775","description":"RN7SK pseudogene 51","metadata":null},{"id":"33b4393a3bd34890984bc794ce7e395e","type":"GENE","name":"RN7SKP52","canonical_id":"hgnc:HGNC:45776","description":"RN7SK pseudogene 52","metadata":null},{"id":"869270a7764c4b7ebb2734e347806580","type":"GENE","name":"RN7SKP53","canonical_id":"hgnc:HGNC:45777","description":"RN7SK pseudogene 53","metadata":null},{"id":"abef4b6d778c43d5a9c967962647e280","type":"GENE","name":"RN7SKP54","canonical_id":"hgnc:HGNC:45778","description":"RN7SK pseudogene 54","metadata":null},{"id":"893bf5bbb1394165a362a3527626f0dc","type":"GENE","name":"RN7SKP55","canonical_id":"hgnc:HGNC:45779","description":"RN7SK pseudogene 55","metadata":null},{"id":"bf1f97bb136d4d5f8f8dd99f5af88765","type":"GENE","name":"RN7SKP56","canonical_id":"hgnc:HGNC:45780","description":"RN7SK pseudogene 56","metadata":null},{"id":"7317a3f767214ce48d91489104e50a08","type":"GENE","name":"RN7SKP57","canonical_id":"hgnc:HGNC:45781","description":"RN7SK pseudogene 57","metadata":null},{"id":"eb63f74f055d4533981e75f99cb5bbde","type":"GENE","name":"RN7SKP58","canonical_id":"hgnc:HGNC:45782","description":"RN7SK pseudogene 58","metadata":null},{"id":"d8b645797a004a5f96e452b84c12f09e","type":"GENE","name":"RN7SKP59","canonical_id":"hgnc:HGNC:45783","description":"RN7SK pseudogene 59","metadata":null},{"id":"5acdc68175114abebf7477cf9d5f5926","type":"GENE","name":"RN7SKP6","canonical_id":"hgnc:HGNC:42624","description":"RN7SK pseudogene 6","metadata":null},{"id":"0013e73d6e8b41f8afd68b4a5d087cae","type":"GENE","name":"RN7SKP60","canonical_id":"hgnc:HGNC:45784","description":"RN7SK pseudogene 60","metadata":null},{"id":"db6b96f6f3564ccfbc905cf1a49fb8a3","type":"GENE","name":"RN7SKP61","canonical_id":"hgnc:HGNC:45785","description":"RN7SK pseudogene 61","metadata":null},{"id":"ae445ec8ac994ebe96a1e707f72aae10","type":"GENE","name":"RN7SKP62","canonical_id":"hgnc:HGNC:45786","description":"RN7SK pseudogene 62","metadata":null},{"id":"b158ee64d8b540629c210d6ebabf00fb","type":"GENE","name":"RN7SKP63","canonical_id":"hgnc:HGNC:45787","description":"RN7SK pseudogene 63","metadata":null},{"id":"ccf4a43f1ff84fa2aeb95f39a72c07ba","type":"GENE","name":"RN7SKP64","canonical_id":"hgnc:HGNC:45788","description":"RN7SK pseudogene 64","metadata":null},{"id":"478b9970305c498e85ed8f67a3fb25c1","type":"GENE","name":"RN7SKP65","canonical_id":"hgnc:HGNC:45789","description":"RN7SK pseudogene 65","metadata":null},{"id":"291d50b05f164f2b944f10ae8fd93c29","type":"GENE","name":"RN7SKP66","canonical_id":"hgnc:HGNC:45790","description":"RN7SK pseudogene 66","metadata":null},{"id":"e82517526c534ab1bd026a621f964b83","type":"GENE","name":"RN7SKP67","canonical_id":"hgnc:HGNC:45791","description":"RN7SK pseudogene 67","metadata":null},{"id":"718b1a92f00e40809e43610b0a2b33d7","type":"GENE","name":"RN7SKP68","canonical_id":"hgnc:HGNC:45792","description":"RN7SK pseudogene 68","metadata":null},{"id":"65017aef36b744dfa431d37b7bc99a93","type":"GENE","name":"RN7SKP69","canonical_id":"hgnc:HGNC:45793","description":"RN7SK pseudogene 69","metadata":null},{"id":"c1bbec00faa84bfd9210981a6b485853","type":"GENE","name":"RN7SKP7","canonical_id":"hgnc:HGNC:42625","description":"RN7SK pseudogene 7","metadata":null},{"id":"039f560d7b70450b8c126f15604f0f00","type":"GENE","name":"RN7SKP70","canonical_id":"hgnc:HGNC:45794","description":"RN7SK pseudogene 70","metadata":null},{"id":"42fb24e22ac141c48068bf68efd7a6fc","type":"GENE","name":"RN7SKP71","canonical_id":"hgnc:HGNC:45795","description":"RN7SK pseudogene 71","metadata":null},{"id":"ad5d0a60a850468994616e5ddb50df36","type":"GENE","name":"RN7SKP72","canonical_id":"hgnc:HGNC:45796","description":"RN7SK pseudogene 72","metadata":null},{"id":"19358d11a1054604aa8dca52350f49d1","type":"GENE","name":"RN7SKP73","canonical_id":"hgnc:HGNC:45797","description":"RN7SK pseudogene 73","metadata":null},{"id":"eff1ef9fa0e9494991846a05648c189f","type":"GENE","name":"RN7SKP74","canonical_id":"hgnc:HGNC:45798","description":"RN7SK pseudogene 74","metadata":null},{"id":"6d9d898157374276be413a0452489fe1","type":"GENE","name":"RN7SKP75","canonical_id":"hgnc:HGNC:45799","description":"RN7SK pseudogene 75","metadata":null},{"id":"9d4bea0db70a477288c818776baf90a7","type":"GENE","name":"RN7SKP76","canonical_id":"hgnc:HGNC:45800","description":"RN7SK pseudogene 76","metadata":null},{"id":"08e1305a60fd47bdb3e0fe7dd5ac5915","type":"GENE","name":"RN7SKP77","canonical_id":"hgnc:HGNC:45801","description":"RN7SK pseudogene 77","metadata":null},{"id":"ffe9d4e07bc2486785c5f4f9251668d1","type":"GENE","name":"RN7SKP78","canonical_id":"hgnc:HGNC:45802","description":"RN7SK pseudogene 78","metadata":null},{"id":"f23c8cd6f4484617af2830242dd35a98","type":"GENE","name":"RN7SKP79","canonical_id":"hgnc:HGNC:45803","description":"RN7SK pseudogene 79","metadata":null},{"id":"dc26b78655b0404cb58ac182bbd6ad1c","type":"GENE","name":"RN7SKP8","canonical_id":"hgnc:HGNC:42626","description":"RN7SK pseudogene 8","metadata":null},{"id":"f18b626d49a94107b210304b3c1f58be","type":"GENE","name":"RN7SKP80","canonical_id":"hgnc:HGNC:45804","description":"RN7SK pseudogene 80","metadata":null},{"id":"53896230436641c4a8ced3e450441025","type":"GENE","name":"RN7SKP81","canonical_id":"hgnc:HGNC:45805","description":"RN7SK pseudogene 81","metadata":null},{"id":"89d8b92eeee64f05b5c9beac5c2958b5","type":"GENE","name":"RN7SKP82","canonical_id":"hgnc:HGNC:45806","description":"RN7SK pseudogene 82","metadata":null},{"id":"c3fa26ba9167463bb4fafb3603018191","type":"GENE","name":"RN7SKP83","canonical_id":"hgnc:HGNC:45807","description":"RN7SK pseudogene 83","metadata":null},{"id":"6441902360e049a88714cb56bc6abcd8","type":"GENE","name":"RN7SKP85","canonical_id":"hgnc:HGNC:45809","description":"RN7SK pseudogene 85","metadata":null},{"id":"9c428db98faf469bbfc171a8aad4b22b","type":"GENE","name":"RN7SKP86","canonical_id":"hgnc:HGNC:45810","description":"RN7SK pseudogene 86","metadata":null},{"id":"81dca3461a9d4594bb0a274cfa96d609","type":"GENE","name":"RN7SKP87","canonical_id":"hgnc:HGNC:45811","description":"RN7SK pseudogene 87","metadata":null},{"id":"2f0d0d8029b341d1bcb46ec5ae36b95a","type":"GENE","name":"RN7SKP88","canonical_id":"hgnc:HGNC:45812","description":"RN7SK pseudogene 88","metadata":null},{"id":"8384c6765e48438e84f1b36ca450845b","type":"GENE","name":"RN7SKP89","canonical_id":"hgnc:HGNC:45813","description":"RN7SK pseudogene 89","metadata":null},{"id":"e06e4b0db8704b7694359a361c61db69","type":"GENE","name":"RN7SKP9","canonical_id":"hgnc:HGNC:42627","description":"RN7SK pseudogene 9","metadata":null},{"id":"eb6c46f7ad1c46a4ba8924e5bd9b7fba","type":"GENE","name":"RN7SKP90","canonical_id":"hgnc:HGNC:45814","description":"RN7SK pseudogene 90","metadata":null},{"id":"63e0ca3b96e94169996ea68f89bfc2f3","type":"GENE","name":"RN7SKP91","canonical_id":"hgnc:HGNC:45815","description":"RN7SK pseudogene 91","metadata":null},{"id":"95b7fd509b124297babedc33ed8f08ee","type":"GENE","name":"RN7SKP92","canonical_id":"hgnc:HGNC:45816","description":"RN7SK pseudogene 92","metadata":null},{"id":"1926f0e7a77b46c694ecfc01d82b00fc","type":"GENE","name":"RN7SKP93","canonical_id":"hgnc:HGNC:45817","description":"RN7SK pseudogene 93","metadata":null},{"id":"b6835f8e616d49a2b65c08b5283073ae","type":"GENE","name":"RN7SKP94","canonical_id":"hgnc:HGNC:45818","description":"RN7SK pseudogene 94","metadata":null},{"id":"494599587cc5435085864e4ba5d2fa61","type":"GENE","name":"RN7SKP95","canonical_id":"hgnc:HGNC:45819","description":"RN7SK pseudogene 95","metadata":null},{"id":"dbc71e65b965473092a7a7cd270ba635","type":"GENE","name":"RN7SKP96","canonical_id":"hgnc:HGNC:45820","description":"RN7SK pseudogene 96","metadata":null},{"id":"12aed8daa3a54681873755177c14452e","type":"GENE","name":"RN7SKP97","canonical_id":"hgnc:HGNC:45821","description":"RN7SK pseudogene 97","metadata":null},{"id":"df778a8d95774e13afbcdaa859d052e4","type":"GENE","name":"RN7SKP98","canonical_id":"hgnc:HGNC:45822","description":"RN7SK pseudogene 98","metadata":null},{"id":"85f148ed04ca4d819dfc79eba16e2dec","type":"GENE","name":"RN7SKP99","canonical_id":"hgnc:HGNC:45823","description":"RN7SK pseudogene 99","metadata":null},{"id":"0310f906eab344a28f8b811637cf1e5f","type":"GENE","name":"RN7SL1","canonical_id":"hgnc:HGNC:10038","description":"RNA component of signal recognition particle 7SL1","metadata":{"aliases":["7SL","7L1a","RNSRP1","RN7SL"]}},{"id":"814161e99f2f43d0a337cd8ef9697805","type":"GENE","name":"RN7SL100P","canonical_id":"hgnc:HGNC:46116","description":"RNA, 7SL, cytoplasmic 100, pseudogene","metadata":null},{"id":"55d8df660f5a46428c06d069c50f25f0","type":"GENE","name":"RN7SL101P","canonical_id":"hgnc:HGNC:46117","description":"RNA, 7SL, cytoplasmic 101, pseudogene","metadata":null},{"id":"b2c2ee37eb9e4375a945d50142e910a7","type":"GENE","name":"RN7SL104P","canonical_id":"hgnc:HGNC:46120","description":"RNA, 7SL, cytoplasmic 104, pseudogene","metadata":null},{"id":"a9c1fecb24ae4de981202c3039b44b4b","type":"GENE","name":"RN7SL105P","canonical_id":"hgnc:HGNC:46121","description":"RNA, 7SL, cytoplasmic 105, pseudogene","metadata":null},{"id":"0b4a111166ba4633b9b304d836e02614","type":"GENE","name":"RN7SL106P","canonical_id":"hgnc:HGNC:46122","description":"RNA, 7SL, cytoplasmic 106, pseudogene","metadata":null},{"id":"69952a69ae2e408d8a8e4ea0dbc2429a","type":"GENE","name":"RN7SL107P","canonical_id":"hgnc:HGNC:46123","description":"RNA, 7SL, cytoplasmic 107, pseudogene","metadata":null},{"id":"fa4e2c6f98c043afac0037282bff1e8b","type":"GENE","name":"RN7SL108P","canonical_id":"hgnc:HGNC:46124","description":"RNA, 7SL, cytoplasmic 108, pseudogene","metadata":null},{"id":"b9bc39c2a6094a779ba0a2bc4bc44635","type":"GENE","name":"RN7SL110P","canonical_id":"hgnc:HGNC:46126","description":"RNA, 7SL, cytoplasmic 110, pseudogene","metadata":null},{"id":"c73a9ead48884073a4a8f01c2c3e2448","type":"GENE","name":"RN7SL111P","canonical_id":"hgnc:HGNC:46127","description":"RNA, 7SL, cytoplasmic 111, pseudogene","metadata":null},{"id":"f267f0e2cdac449b8c0c9b107fbd9c5a","type":"GENE","name":"RN7SL113P","canonical_id":"hgnc:HGNC:46129","description":"RNA, 7SL, cytoplasmic 113, pseudogene","metadata":null},{"id":"adffd91c1bd24f76b77729bcb400744c","type":"GENE","name":"RN7SL116P","canonical_id":"hgnc:HGNC:46132","description":"RNA, 7SL, cytoplasmic 116, pseudogene","metadata":null},{"id":"ab7aa3ea54f54175b9e145ddf22c70aa","type":"GENE","name":"RN7SL117P","canonical_id":"hgnc:HGNC:46133","description":"RNA, 7SL, cytoplasmic 117, pseudogene","metadata":null},{"id":"96cca795772c45fe874c63da27081e67","type":"GENE","name":"RN7SL118P","canonical_id":"hgnc:HGNC:46134","description":"RNA, 7SL, cytoplasmic 118, pseudogene","metadata":null},{"id":"ffd596a1ff89469ebfdaf5c06f2d8e96","type":"GENE","name":"RN7SL11P","canonical_id":"hgnc:HGNC:46027","description":"RNA, 7SL, cytoplasmic 11, pseudogene","metadata":null},{"id":"2a879def0d98491fbd38768932f42280","type":"GENE","name":"RN7SL120P","canonical_id":"hgnc:HGNC:46136","description":"RNA, 7SL, cytoplasmic 120, pseudogene","metadata":null},{"id":"ec95547b10924f188d16aaf3d58eb6c8","type":"GENE","name":"RN7SL121P","canonical_id":"hgnc:HGNC:46137","description":"RNA, 7SL, cytoplasmic 121, pseudogene","metadata":null},{"id":"91927c7f0cd341b79035766bf96ea3f2","type":"GENE","name":"RN7SL122P","canonical_id":"hgnc:HGNC:46138","description":"RNA, 7SL, cytoplasmic 122, pseudogene","metadata":null},{"id":"84308ee052cf47a39df230f591442915","type":"GENE","name":"RN7SL123P","canonical_id":"hgnc:HGNC:46139","description":"RNA, 7SL, cytoplasmic 123, pseudogene","metadata":null},{"id":"9234c6e9322448a49c0ea4ce5348863a","type":"GENE","name":"RN7SL124P","canonical_id":"hgnc:HGNC:46140","description":"RNA, 7SL, cytoplasmic 124, pseudogene","metadata":null},{"id":"85997c8158fb4d55bad94c9a0958c1e6","type":"GENE","name":"RN7SL125P","canonical_id":"hgnc:HGNC:46141","description":"RNA, 7SL, cytoplasmic 125, pseudogene","metadata":null},{"id":"3f46f72ff7764aa2b19b3a7bd244207a","type":"GENE","name":"RN7SL126P","canonical_id":"hgnc:HGNC:46142","description":"RNA, 7SL, cytoplasmic 126, pseudogene","metadata":null},{"id":"c97466508d704876b2ac681efb73c331","type":"GENE","name":"RN7SL127P","canonical_id":"hgnc:HGNC:46143","description":"RNA, 7SL, cytoplasmic 127, pseudogene","metadata":null},{"id":"b11911aec2de4e30b87b0ba021442219","type":"GENE","name":"RN7SL128P","canonical_id":"hgnc:HGNC:46144","description":"RNA, 7SL, cytoplasmic 128, pseudogene","metadata":null},{"id":"d6046d92996d44e587842d22159afc08","type":"GENE","name":"RN7SL12P","canonical_id":"hgnc:HGNC:46028","description":"RNA, 7SL, cytoplasmic 12, pseudogene","metadata":null},{"id":"6d47e7ed3c7741cc92b3ca725a800ab6","type":"GENE","name":"RN7SL130P","canonical_id":"hgnc:HGNC:46146","description":"RNA, 7SL, cytoplasmic 130, pseudogene","metadata":null},{"id":"e86c820674e142f3b62f9b022c327e38","type":"GENE","name":"RN7SL131P","canonical_id":"hgnc:HGNC:46147","description":"RNA, 7SL, cytoplasmic 131, pseudogene","metadata":null},{"id":"6f6cdfe65632416f8a3461cff85ee9d9","type":"GENE","name":"RN7SL132P","canonical_id":"hgnc:HGNC:46148","description":"RNA, 7SL, cytoplasmic 132, pseudogene","metadata":null},{"id":"61ce0ad35569495aa13f8830b442cd65","type":"GENE","name":"RN7SL134P","canonical_id":"hgnc:HGNC:46150","description":"RNA, 7SL, cytoplasmic 134, pseudogene","metadata":null},{"id":"8772ffac4be742e69a6139d8bc5253a5","type":"GENE","name":"RN7SL135P","canonical_id":"hgnc:HGNC:46151","description":"RNA, 7SL, cytoplasmic 135, pseudogene","metadata":null},{"id":"3051e4cc809e43c28b0214fe6de19023","type":"GENE","name":"RN7SL138P","canonical_id":"hgnc:HGNC:46154","description":"RNA, 7SL, cytoplasmic 138, pseudogene","metadata":null},{"id":"8938cbb990b24515853dbaa396212e53","type":"GENE","name":"RN7SL140P","canonical_id":"hgnc:HGNC:46156","description":"RNA, 7SL, cytoplasmic 140, pseudogene","metadata":null},{"id":"c7da678224c34d25ae5de8e23171e07c","type":"GENE","name":"RN7SL141P","canonical_id":"hgnc:HGNC:46157","description":"RNA, 7SL, cytoplasmic 141, pseudogene","metadata":null},{"id":"e2ae6d8b61fa42f59476ecc7f8fd2ed9","type":"GENE","name":"RN7SL143P","canonical_id":"hgnc:HGNC:46159","description":"RNA, 7SL, cytoplasmic 143, pseudogene","metadata":null},{"id":"44327c7408f742b6ac785169838129f5","type":"GENE","name":"RN7SL144P","canonical_id":"hgnc:HGNC:46160","description":"RNA, 7SL, cytoplasmic 144, pseudogene","metadata":null},{"id":"06b4261b2e574dd78dd3fd45889e3925","type":"GENE","name":"RN7SL145P","canonical_id":"hgnc:HGNC:46161","description":"RNA, 7SL, cytoplasmic 145, pseudogene","metadata":null},{"id":"6778efccab0148a096ff0ab001530e56","type":"GENE","name":"RN7SL146P","canonical_id":"hgnc:HGNC:46162","description":"RNA, 7SL, cytoplasmic 146, pseudogene","metadata":null},{"id":"0fa2e0235ff64baab9671664e210f6e3","type":"GENE","name":"RN7SL147P","canonical_id":"hgnc:HGNC:46163","description":"RNA, 7SL, cytoplasmic 147, pseudogene","metadata":null},{"id":"eb4c204f0e1f4c229723617eb84b449a","type":"GENE","name":"RN7SL148P","canonical_id":"hgnc:HGNC:46164","description":"RNA, 7SL, cytoplasmic 148, pseudogene","metadata":null},{"id":"739e4f71044a45098dae3a4c7a75244d","type":"GENE","name":"RN7SL149P","canonical_id":"hgnc:HGNC:46165","description":"RNA, 7SL, cytoplasmic 149, pseudogene","metadata":null},{"id":"6ed64816156e409a83e8f533a10c38f8","type":"GENE","name":"RN7SL14P","canonical_id":"hgnc:HGNC:46030","description":"RNA, 7SL, cytoplasmic 14, pseudogene","metadata":null},{"id":"8a01ae1e9f894bcf90e9859460e771c3","type":"GENE","name":"RN7SL150P","canonical_id":"hgnc:HGNC:46166","description":"RNA, 7SL, cytoplasmic 150, pseudogene","metadata":null},{"id":"c4ed20dd7c8245f18bf53f2899e984d4","type":"GENE","name":"RN7SL151P","canonical_id":"hgnc:HGNC:46167","description":"RNA, 7SL, cytoplasmic 151, pseudogene","metadata":null},{"id":"58df9682f80f4aa4af065fb6e6f1946a","type":"GENE","name":"RN7SL152P","canonical_id":"hgnc:HGNC:46168","description":"RNA, 7SL, cytoplasmic 152, pseudogene","metadata":null},{"id":"2edbde9c86e540ffb6c09a7a397c4b3d","type":"GENE","name":"RN7SL153P","canonical_id":"hgnc:HGNC:46169","description":"RNA, 7SL, cytoplasmic 153, pseudogene","metadata":null},{"id":"35bd7423a3ec412ca769806a4435f07c","type":"GENE","name":"RN7SL154P","canonical_id":"hgnc:HGNC:46170","description":"RNA, 7SL, cytoplasmic 154, pseudogene","metadata":null},{"id":"b4afd61e149142a08062911120bd99f5","type":"GENE","name":"RN7SL155P","canonical_id":"hgnc:HGNC:46171","description":"RNA, 7SL, cytoplasmic 155, pseudogene","metadata":null},{"id":"e3125a6cb20543b19fc5b3189841ecfd","type":"GENE","name":"RN7SL156P","canonical_id":"hgnc:HGNC:46172","description":"RNA, 7SL, cytoplasmic 156, pseudogene","metadata":null},{"id":"1889ad5767bd4c2081d8fa97859dee9c","type":"GENE","name":"RN7SL159P","canonical_id":"hgnc:HGNC:46175","description":"RNA, 7SL, cytoplasmic 159, pseudogene","metadata":null},{"id":"1a11551df5534e66bacd94cb372cc36d","type":"GENE","name":"RN7SL15P","canonical_id":"hgnc:HGNC:46031","description":"RNA, 7SL, cytoplasmic 15, pseudogene","metadata":null},{"id":"d154ee6969b54a76a9d4ae4af5aba1b4","type":"GENE","name":"RN7SL160P","canonical_id":"hgnc:HGNC:46176","description":"RNA, 7SL, cytoplasmic 160, pseudogene","metadata":null},{"id":"d03f7ebf983f43d391d94ad3f4c9559a","type":"GENE","name":"RN7SL162P","canonical_id":"hgnc:HGNC:46178","description":"RNA, 7SL, cytoplasmic 162, pseudogene","metadata":null},{"id":"79d45772ab784bf0ab3a8f73a3336b15","type":"GENE","name":"RN7SL163P","canonical_id":"hgnc:HGNC:46179","description":"RNA, 7SL, cytoplasmic 163, pseudogene","metadata":null},{"id":"13be04fb908644998d75e9c26f3806eb","type":"GENE","name":"RN7SL164P","canonical_id":"hgnc:HGNC:46180","description":"RNA, 7SL, cytoplasmic 164, pseudogene","metadata":null},{"id":"6cddb0e76ad84e589644e327e1751b34","type":"GENE","name":"RN7SL165P","canonical_id":"hgnc:HGNC:46181","description":"RNA, 7SL, cytoplasmic 165, pseudogene","metadata":null},{"id":"07576dd92a224beaa1848999c6b7491b","type":"GENE","name":"RN7SL166P","canonical_id":"hgnc:HGNC:46182","description":"RNA, 7SL, cytoplasmic 166, pseudogene","metadata":null},{"id":"7d736b60974040bd847cc1557fca63fe","type":"GENE","name":"RN7SL167P","canonical_id":"hgnc:HGNC:46183","description":"RNA, 7SL, cytoplasmic 167, pseudogene","metadata":null},{"id":"3e2a076da19b4144a1daa6e62b80209a","type":"GENE","name":"RN7SL168P","canonical_id":"hgnc:HGNC:46184","description":"RNA, 7SL, cytoplasmic 168, pseudogene","metadata":null},{"id":"8ae53a68d90a4fea87abdcbd3d010aae","type":"GENE","name":"RN7SL169P","canonical_id":"hgnc:HGNC:46185","description":"RNA, 7SL, cytoplasmic 169, pseudogene","metadata":null},{"id":"250e74052eb4414abd10310ac440d3c7","type":"GENE","name":"RN7SL16P","canonical_id":"hgnc:HGNC:46032","description":"RNA, 7SL, cytoplasmic 16, pseudogene","metadata":null},{"id":"e037f05cb92347bc8bfaa77e42a5426f","type":"GENE","name":"RN7SL170P","canonical_id":"hgnc:HGNC:46186","description":"RNA, 7SL, cytoplasmic 170, pseudogene","metadata":null},{"id":"e9fa67ea323e4d7c82fabe875756f8cc","type":"GENE","name":"RN7SL172P","canonical_id":"hgnc:HGNC:46188","description":"RNA, 7SL, cytoplasmic 172, pseudogene","metadata":null},{"id":"3460346a8be248f48c46d93b41b5ba6a","type":"GENE","name":"RN7SL173P","canonical_id":"hgnc:HGNC:46189","description":"RNA, 7SL, cytoplasmic 173, pseudogene","metadata":null},{"id":"8c7788f3e78245759cc73140dfa42e5d","type":"GENE","name":"RN7SL174P","canonical_id":"hgnc:HGNC:46190","description":"RNA, 7SL, cytoplasmic 174, pseudogene","metadata":null},{"id":"c53c14f8ee7045e188bd1c12d1413957","type":"GENE","name":"RN7SL176P","canonical_id":"hgnc:HGNC:46192","description":"RNA, 7SL, cytoplasmic 176, pseudogene","metadata":null},{"id":"8ee178c2726d4378aa89a3f4c583e6d7","type":"GENE","name":"RN7SL177P","canonical_id":"hgnc:HGNC:46193","description":"RNA, 7SL, cytoplasmic 177, pseudogene","metadata":null},{"id":"1debac2038034fcdb57fbe0b424bb04e","type":"GENE","name":"RN7SL178P","canonical_id":"hgnc:HGNC:46194","description":"RNA, 7SL, cytoplasmic 178, pseudogene","metadata":null},{"id":"1faf024bda9145b9971e9a6ca59f66e8","type":"GENE","name":"RN7SL180P","canonical_id":"hgnc:HGNC:46196","description":"RNA, 7SL, cytoplasmic 180, pseudogene","metadata":null},{"id":"f366d02691be4707854e54df6a518034","type":"GENE","name":"RN7SL181P","canonical_id":"hgnc:HGNC:46197","description":"RNA, 7SL, cytoplasmic 181, pseudogene","metadata":null},{"id":"127fef86cdde4dc4af3bfe5588988e89","type":"GENE","name":"RN7SL182P","canonical_id":"hgnc:HGNC:46198","description":"RNA, 7SL, cytoplasmic 182, pseudogene","metadata":null},{"id":"90f6939ae18f413094305df9fb3eae53","type":"GENE","name":"RN7SL183P","canonical_id":"hgnc:HGNC:46199","description":"RNA, 7SL, cytoplasmic 183, pseudogene","metadata":null},{"id":"8e435da0666c44908484689d99efdaa8","type":"GENE","name":"RN7SL184P","canonical_id":"hgnc:HGNC:46200","description":"RNA, 7SL, cytoplasmic 184, pseudogene","metadata":null},{"id":"8d196411dbec42568b1a1dfddb2d388d","type":"GENE","name":"RN7SL185P","canonical_id":"hgnc:HGNC:46201","description":"RNA, 7SL, cytoplasmic 185, pseudogene","metadata":null},{"id":"b31b8da5015c41cf969a16b37f8d98ed","type":"GENE","name":"RN7SL186P","canonical_id":"hgnc:HGNC:46202","description":"RNA, 7SL, cytoplasmic 186, pseudogene","metadata":null},{"id":"2a5b8765691b4ebc818d09e1838c80d5","type":"GENE","name":"RN7SL187P","canonical_id":"hgnc:HGNC:46203","description":"RNA, 7SL, cytoplasmic 187, pseudogene","metadata":null},{"id":"e993459262154529beac1a29188f0982","type":"GENE","name":"RN7SL188P","canonical_id":"hgnc:HGNC:46204","description":"RNA, 7SL, cytoplasmic 188, pseudogene","metadata":null},{"id":"f26ef024da1f4fb79799aca5892105e7","type":"GENE","name":"RN7SL189P","canonical_id":"hgnc:HGNC:46205","description":"RNA, 7SL, cytoplasmic 189, pseudogene","metadata":null},{"id":"0c2bf253cb8f4294912b9b254d7579d3","type":"GENE","name":"RN7SL18P","canonical_id":"hgnc:HGNC:46034","description":"RNA, 7SL, cytoplasmic 18, pseudogene","metadata":null},{"id":"7faf93d047634e57a1e87ebf9fa3d2c7","type":"GENE","name":"RN7SL190P","canonical_id":"hgnc:HGNC:46206","description":"RNA, 7SL, cytoplasmic 190, pseudogene","metadata":null},{"id":"e19e50b7f991450fb266b4061ffbeaa1","type":"GENE","name":"RN7SL191P","canonical_id":"hgnc:HGNC:46207","description":"RNA, 7SL, cytoplasmic 191, pseudogene","metadata":null},{"id":"6a88cd6030bf460baedb2e7f4bdeb023","type":"GENE","name":"RN7SL192P","canonical_id":"hgnc:HGNC:46208","description":"RNA, 7SL, cytoplasmic 192, pseudogene","metadata":null},{"id":"c5ce31be50cb4e93b6aa0042b42e7998","type":"GENE","name":"RN7SL193P","canonical_id":"hgnc:HGNC:46209","description":"RNA, 7SL, cytoplasmic 193, pseudogene","metadata":null},{"id":"8f55ab45d05f4e99b10f90bdc7a12f89","type":"GENE","name":"RN7SL196P","canonical_id":"hgnc:HGNC:46212","description":"RNA, 7SL, cytoplasmic 196, pseudogene","metadata":null},{"id":"a4db7cc471d34b2b9b160f1bf211a146","type":"GENE","name":"RN7SL197P","canonical_id":"hgnc:HGNC:46213","description":"RNA, 7SL, cytoplasmic 197, pseudogene","metadata":null},{"id":"bb4b462df293494db403aa2466cc8091","type":"GENE","name":"RN7SL198P","canonical_id":"hgnc:HGNC:46214","description":"RNA, 7SL, cytoplasmic 198, pseudogene","metadata":null},{"id":"d0d2d0d8073045e289a4b1e01d63a249","type":"GENE","name":"RN7SL199P","canonical_id":"hgnc:HGNC:46215","description":"RNA, 7SL, cytoplasmic 199, pseudogene","metadata":null},{"id":"409d6197378b416285b04796ab0281dc","type":"GENE","name":"RN7SL19P","canonical_id":"hgnc:HGNC:46035","description":"RNA, 7SL, cytoplasmic 19, pseudogene","metadata":null},{"id":"ec633db3431643c68c697876637f2cdd","type":"GENE","name":"RN7SL2","canonical_id":"hgnc:HGNC:23134","description":"RNA component of signal recognition particle 7SL2","metadata":{"aliases":["7SL1c","7L30.1","RNSRP2"]}},{"id":"b5622385f7c34bfb9d54dc6d7b80b244","type":"GENE","name":"RN7SL200P","canonical_id":"hgnc:HGNC:46216","description":"RNA, 7SL, cytoplasmic 200, pseudogene","metadata":null},{"id":"50ddab1c6ec842c4b1a40fdfa73ac7f2","type":"GENE","name":"RN7SL201P","canonical_id":"hgnc:HGNC:46217","description":"RNA, 7SL, cytoplasmic 201, pseudogene","metadata":null},{"id":"7c14a038bb9a42e288516bdf30faf818","type":"GENE","name":"RN7SL202P","canonical_id":"hgnc:HGNC:46218","description":"RNA, 7SL, cytoplasmic 202, pseudogene","metadata":null},{"id":"ebd8dc43d9704074bc1871f8bff0a05b","type":"GENE","name":"RN7SL203P","canonical_id":"hgnc:HGNC:46219","description":"RNA, 7SL, cytoplasmic 203, pseudogene","metadata":null},{"id":"15d3bc615d1849f7af9d3896ec67bf47","type":"GENE","name":"RN7SL204P","canonical_id":"hgnc:HGNC:46220","description":"RNA, 7SL, cytoplasmic 204, pseudogene","metadata":null},{"id":"85cc839aa3174504933484b0553fb488","type":"GENE","name":"RN7SL205P","canonical_id":"hgnc:HGNC:46221","description":"RNA, 7SL, cytoplasmic 205, pseudogene","metadata":null},{"id":"794708d90f26464f97c382a3dd172be5","type":"GENE","name":"RN7SL208P","canonical_id":"hgnc:HGNC:46224","description":"RNA, 7SL, cytoplasmic 208, pseudogene","metadata":null},{"id":"4ddef3a3a4f544e99e3a8d8ba0e5a2af","type":"GENE","name":"RN7SL209P","canonical_id":"hgnc:HGNC:46225","description":"RNA, 7SL, cytoplasmic 209, pseudogene","metadata":null},{"id":"b4b8c3c597494ad3abdf7f5e45e9c971","type":"GENE","name":"RN7SL20P","canonical_id":"hgnc:HGNC:46036","description":"RNA, 7SL, cytoplasmic 20, pseudogene","metadata":null},{"id":"1d4c83ee9ce242fe953771980068877b","type":"GENE","name":"RN7SL210P","canonical_id":"hgnc:HGNC:46226","description":"RNA, 7SL, cytoplasmic 210, pseudogene","metadata":null},{"id":"8a536477c2cc40ff984a44c73299a7a5","type":"GENE","name":"RN7SL211P","canonical_id":"hgnc:HGNC:46227","description":"RNA, 7SL, cytoplasmic 211, pseudogene","metadata":null},{"id":"dd13a2eff28b4be3804c466f3b245952","type":"GENE","name":"RN7SL213P","canonical_id":"hgnc:HGNC:46229","description":"RNA, 7SL, cytoplasmic 213, pseudogene","metadata":null},{"id":"849493dd1f5c47a4bb74a8ddb47ab53c","type":"GENE","name":"RN7SL214P","canonical_id":"hgnc:HGNC:46230","description":"RNA, 7SL, cytoplasmic 214, pseudogene","metadata":null},{"id":"ef14a06577264b999f45cbbfb2ef4221","type":"GENE","name":"RN7SL215P","canonical_id":"hgnc:HGNC:46231","description":"RNA, 7SL, cytoplasmic 215, pseudogene","metadata":null},{"id":"401bbbcd86414da6ac4f48775174690e","type":"GENE","name":"RN7SL216P","canonical_id":"hgnc:HGNC:46232","description":"RNA, 7SL, cytoplasmic 216, pseudogene","metadata":null},{"id":"f7de5f494812406bb6c9827fb6708e4a","type":"GENE","name":"RN7SL217P","canonical_id":"hgnc:HGNC:46233","description":"RNA, 7SL, cytoplasmic 217, pseudogene","metadata":null},{"id":"c023cfb9fe8c49058a85a4c0b05cabc1","type":"GENE","name":"RN7SL218P","canonical_id":"hgnc:HGNC:46234","description":"RNA, 7SL, cytoplasmic 218, pseudogene","metadata":null},{"id":"55364d728daf425197835968fa1ed098","type":"GENE","name":"RN7SL219P","canonical_id":"hgnc:HGNC:46235","description":"RNA, 7SL, cytoplasmic 219, pseudogene","metadata":null},{"id":"1d94c67ff5d947c4bbfb2c17afed4112","type":"GENE","name":"RN7SL220P","canonical_id":"hgnc:HGNC:46236","description":"RNA, 7SL, cytoplasmic 220, pseudogene","metadata":null},{"id":"084b1e86838241ddb2e1a74145db86db","type":"GENE","name":"RN7SL221P","canonical_id":"hgnc:HGNC:46237","description":"RNA, 7SL, cytoplasmic 221, pseudogene","metadata":null},{"id":"140d3d01b13145f481a2ec9f566d8258","type":"GENE","name":"RN7SL222P","canonical_id":"hgnc:HGNC:46238","description":"RNA, 7SL, cytoplasmic 222, pseudogene","metadata":null},{"id":"fa8243a8ed134a1189553dcc259453d7","type":"GENE","name":"RN7SL223P","canonical_id":"hgnc:HGNC:46239","description":"RNA, 7SL, cytoplasmic 223, pseudogene","metadata":null},{"id":"470fa8b15d1b41729d2094a35d0917cb","type":"GENE","name":"RN7SL225P","canonical_id":"hgnc:HGNC:46241","description":"RNA, 7SL, cytoplasmic 225, pseudogene","metadata":null},{"id":"11ffe70b9faf4511934566e5207f0da8","type":"GENE","name":"RN7SL228P","canonical_id":"hgnc:HGNC:46244","description":"RNA, 7SL, cytoplasmic 228, pseudogene","metadata":null},{"id":"4e6d76785e4a4f05ac6ce8e63b25aead","type":"GENE","name":"RN7SL229P","canonical_id":"hgnc:HGNC:46245","description":"RNA, 7SL, cytoplasmic 229, pseudogene","metadata":null},{"id":"d86aa25bd3fe4293962bc7a604bf6446","type":"GENE","name":"RN7SL22P","canonical_id":"hgnc:HGNC:46038","description":"RNA, 7SL, cytoplasmic 22, pseudogene","metadata":null},{"id":"d86cb3d110d54580bca99a3cb86d9a23","type":"GENE","name":"RN7SL230P","canonical_id":"hgnc:HGNC:46246","description":"RNA, 7SL, cytoplasmic 230, pseudogene","metadata":null},{"id":"751f3fd22b6d4467802923a366b93491","type":"GENE","name":"RN7SL231P","canonical_id":"hgnc:HGNC:46247","description":"RNA, 7SL, cytoplasmic 231, pseudogene","metadata":null},{"id":"b98c11c70a4f4c1293164fb4b1618c57","type":"GENE","name":"RN7SL233P","canonical_id":"hgnc:HGNC:46249","description":"RNA, 7SL, cytoplasmic 233, pseudogene","metadata":null},{"id":"a6f00a5dd14947b198fc7c703f98c5b4","type":"GENE","name":"RN7SL234P","canonical_id":"hgnc:HGNC:46250","description":"RNA, 7SL, cytoplasmic 234, pseudogene","metadata":null},{"id":"ab842dfc2b21426cb0e1263e9e9db22b","type":"GENE","name":"RN7SL236P","canonical_id":"hgnc:HGNC:46252","description":"RNA, 7SL, cytoplasmic 236, pseudogene","metadata":null},{"id":"5bccaaa102d84c02afed28bd48f1f4a1","type":"GENE","name":"RN7SL237P","canonical_id":"hgnc:HGNC:46253","description":"RNA, 7SL, cytoplasmic 237, pseudogene","metadata":null},{"id":"33bc1974673e44cb84b48aa1d75e803b","type":"GENE","name":"RN7SL238P","canonical_id":"hgnc:HGNC:46254","description":"RNA, 7SL, cytoplasmic 238, pseudogene","metadata":null},{"id":"1c11b51e1a4048519cdfa897d608c8ce","type":"GENE","name":"RN7SL239P","canonical_id":"hgnc:HGNC:46255","description":"RNA, 7SL, cytoplasmic 239, pseudogene","metadata":null},{"id":"4632d93d01f9469a902711f46554279c","type":"GENE","name":"RN7SL23P","canonical_id":"hgnc:HGNC:46039","description":"RNA, 7SL, cytoplasmic 23, pseudogene","metadata":null},{"id":"211489b767d0433d9ec4bccf20812890","type":"GENE","name":"RN7SL240P","canonical_id":"hgnc:HGNC:46256","description":"RNA, 7SL, cytoplasmic 240, pseudogene","metadata":null},{"id":"6c6b7e25d9b9406aad8030e6ae27bcbd","type":"GENE","name":"RN7SL241P","canonical_id":"hgnc:HGNC:46257","description":"RNA, 7SL, cytoplasmic 241, pseudogene","metadata":null},{"id":"94795cb6a7d44494b355b1185c98b41f","type":"GENE","name":"RN7SL242P","canonical_id":"hgnc:HGNC:46258","description":"RNA, 7SL, cytoplasmic 242, pseudogene","metadata":null},{"id":"a42f558edeb741f08cdbb55f49816c41","type":"GENE","name":"RN7SL244P","canonical_id":"hgnc:HGNC:46260","description":"RNA, 7SL, cytoplasmic 244, pseudogene","metadata":null},{"id":"1d3f18e2decd4e4fbe50444c36ee69fb","type":"GENE","name":"RN7SL246P","canonical_id":"hgnc:HGNC:46262","description":"RNA, 7SL, cytoplasmic 246, pseudogene","metadata":null},{"id":"b9437dd0cb0e4fb58970da2516244206","type":"GENE","name":"RN7SL248P","canonical_id":"hgnc:HGNC:46264","description":"RNA, 7SL, cytoplasmic 248, pseudogene","metadata":{"aliases":["RN7SL527P"]}},{"id":"df0ed912d3de4529bf7e0d0957bde962","type":"GENE","name":"RN7SL250P","canonical_id":"hgnc:HGNC:46266","description":"RNA, 7SL, cytoplasmic 250, pseudogene","metadata":null},{"id":"c0c8f9d61ca9479190f46b6d41c39c49","type":"GENE","name":"RN7SL251P","canonical_id":"hgnc:HGNC:46267","description":"RNA, 7SL, cytoplasmic 251, pseudogene","metadata":null},{"id":"55ca9fe1ba3c4ad284f0af4c231d9671","type":"GENE","name":"RN7SL252P","canonical_id":"hgnc:HGNC:46268","description":"RNA, 7SL, cytoplasmic 252, pseudogene","metadata":null},{"id":"c929eb4e5a914007b1619e1ef2ddca10","type":"GENE","name":"RN7SL253P","canonical_id":"hgnc:HGNC:46269","description":"RNA, 7SL, cytoplasmic 253, pseudogene","metadata":null},{"id":"1c15451edc684721bfe2108660ac2cd2","type":"GENE","name":"RN7SL254P","canonical_id":"hgnc:HGNC:46270","description":"RNA, 7SL, cytoplasmic 254, pseudogene","metadata":null},{"id":"4fd5b71a3f6e4db0998bef5c4a04ec81","type":"GENE","name":"RN7SL255P","canonical_id":"hgnc:HGNC:46271","description":"RNA, 7SL, cytoplasmic 255, pseudogene","metadata":null},{"id":"7f323f324a614e2d8f397c9e85145bbd","type":"GENE","name":"RN7SL258P","canonical_id":"hgnc:HGNC:46274","description":"RNA, 7SL, cytoplasmic 258, pseudogene","metadata":null},{"id":"6922cdbca6e74adcb277d137cf932555","type":"GENE","name":"RN7SL259P","canonical_id":"hgnc:HGNC:46275","description":"RNA, 7SL, cytoplasmic 259, pseudogene","metadata":null},{"id":"d8e45ded615d4a26958000d20a5098c2","type":"GENE","name":"RN7SL25P","canonical_id":"hgnc:HGNC:46041","description":"RNA, 7SL, cytoplasmic 25, pseudogene","metadata":null},{"id":"2891f7218e67477e95f6046857224739","type":"GENE","name":"RN7SL260P","canonical_id":"hgnc:HGNC:46276","description":"RNA, 7SL, cytoplasmic 260, pseudogene","metadata":null},{"id":"443fed90c5df4bc1909d33997eb9ee8a","type":"GENE","name":"RN7SL261P","canonical_id":"hgnc:HGNC:46277","description":"RNA, 7SL, cytoplasmic 261, pseudogene","metadata":null},{"id":"2b94a97837d64f27af2a0f402222ed78","type":"GENE","name":"RN7SL262P","canonical_id":"hgnc:HGNC:46278","description":"RNA, 7SL, cytoplasmic 262, pseudogene","metadata":null},{"id":"3aecd7c4b3f2426cb2c07f4ccbd0130e","type":"GENE","name":"RN7SL263P","canonical_id":"hgnc:HGNC:46279","description":"RNA, 7SL, cytoplasmic 263, pseudogene","metadata":null},{"id":"456ed4e790cc4e59bb953331772b9832","type":"GENE","name":"RN7SL265P","canonical_id":"hgnc:HGNC:46281","description":"RNA, 7SL, cytoplasmic 265, pseudogene","metadata":null},{"id":"5eacbdda88d649f79d13ba777dc13ebe","type":"GENE","name":"RN7SL266P","canonical_id":"hgnc:HGNC:46282","description":"RNA, 7SL, cytoplasmic 266, pseudogene","metadata":null},{"id":"7d7ef6ac98d24ba5b8a89e32e5081216","type":"GENE","name":"RN7SL267P","canonical_id":"hgnc:HGNC:46283","description":"RNA, 7SL, cytoplasmic 267, pseudogene","metadata":null},{"id":"5db1853caed34fe6b00525f73153a9de","type":"GENE","name":"RN7SL268P","canonical_id":"hgnc:HGNC:46284","description":"RNA, 7SL, cytoplasmic 268, pseudogene","metadata":null},{"id":"ba15e16f6d8649c0b807ba857a410320","type":"GENE","name":"RN7SL269P","canonical_id":"hgnc:HGNC:46285","description":"RNA, 7SL, cytoplasmic 269, pseudogene","metadata":null},{"id":"a4866ecabde14e079fc5e9889edf14e5","type":"GENE","name":"RN7SL26P","canonical_id":"hgnc:HGNC:46042","description":"RNA, 7SL, cytoplasmic 26, pseudogene","metadata":null},{"id":"da9512e42812448a97b50e9968e8dc17","type":"GENE","name":"RN7SL270P","canonical_id":"hgnc:HGNC:46286","description":"RNA, 7SL, cytoplasmic 270, pseudogene","metadata":null},{"id":"0061d4dbeba74696bb5534240a26dfc4","type":"GENE","name":"RN7SL271P","canonical_id":"hgnc:HGNC:46287","description":"RNA, 7SL, cytoplasmic 271, pseudogene","metadata":null},{"id":"7ac8c11913744e92911e1920099cf869","type":"GENE","name":"RN7SL272P","canonical_id":"hgnc:HGNC:46288","description":"RNA, 7SL, cytoplasmic 272, pseudogene","metadata":null},{"id":"811a65a1d54f4a6bafe48aebbf4b339f","type":"GENE","name":"RN7SL273P","canonical_id":"hgnc:HGNC:46289","description":"RNA, 7SL, cytoplasmic 273, pseudogene","metadata":null},{"id":"7293874e6af247b2aceed450c3f357a6","type":"GENE","name":"RN7SL274P","canonical_id":"hgnc:HGNC:46290","description":"RNA, 7SL, cytoplasmic 274, pseudogene","metadata":{"aliases":["RN7SL694P"]}},{"id":"bd7f95f650484255b3dfc8a7b479dcff","type":"GENE","name":"RN7SL275P","canonical_id":"hgnc:HGNC:46291","description":"RNA, 7SL, cytoplasmic 275, pseudogene","metadata":null},{"id":"fb3ce615f9db496093be0713a6425a24","type":"GENE","name":"RN7SL277P","canonical_id":"hgnc:HGNC:46293","description":"RNA, 7SL, cytoplasmic 277, pseudogene","metadata":null},{"id":"f61abfc7cf2547c78ca292e683b5277b","type":"GENE","name":"RN7SL278P","canonical_id":"hgnc:HGNC:46294","description":"RNA, 7SL, cytoplasmic 278, pseudogene","metadata":null},{"id":"80b77436330d40eb82d2e886eedb6932","type":"GENE","name":"RN7SL279P","canonical_id":"hgnc:HGNC:46295","description":"RNA, 7SL, cytoplasmic 279, pseudogene","metadata":null},{"id":"3910c85c33e940ebb39379aa0984b142","type":"GENE","name":"RN7SL280P","canonical_id":"hgnc:HGNC:46296","description":"RNA, 7SL, cytoplasmic 280, pseudogene","metadata":null},{"id":"756918d8945f4b438ea70d64f17b8d6a","type":"GENE","name":"RN7SL282P","canonical_id":"hgnc:HGNC:46298","description":"RNA, 7SL, cytoplasmic 282, pseudogene","metadata":null},{"id":"dce3318227574dcf8a0cdc2be12865a0","type":"GENE","name":"RN7SL283P","canonical_id":"hgnc:HGNC:46299","description":"RNA, 7SL, cytoplasmic 283, pseudogene","metadata":null},{"id":"23062807d0e349909f57d6a1023a00f7","type":"GENE","name":"RN7SL284P","canonical_id":"hgnc:HGNC:46300","description":"RNA, 7SL, cytoplasmic 284, pseudogene","metadata":null},{"id":"4bdc231e44a44364acddb858e2f9933e","type":"GENE","name":"RN7SL285P","canonical_id":"hgnc:HGNC:46301","description":"RNA, 7SL, cytoplasmic 285, pseudogene","metadata":null},{"id":"f6615646d7f349b4bcbc9a6f04316b74","type":"GENE","name":"RN7SL286P","canonical_id":"hgnc:HGNC:46302","description":"RNA, 7SL, cytoplasmic 286, pseudogene","metadata":null},{"id":"4bb9fab6073f419883193db749dfe543","type":"GENE","name":"RN7SL288P","canonical_id":"hgnc:HGNC:46304","description":"RNA, 7SL, cytoplasmic 288, pseudogene","metadata":null},{"id":"623b441111e5441696568d00699736bf","type":"GENE","name":"RN7SL28P","canonical_id":"hgnc:HGNC:46044","description":"RNA, 7SL, cytoplasmic 28, pseudogene","metadata":null},{"id":"385c833c08774156838a9cd7b45ab8df","type":"GENE","name":"RN7SL290P","canonical_id":"hgnc:HGNC:46306","description":"RNA, 7SL, cytoplasmic 290, pseudogene","metadata":null},{"id":"2e3e8f24a75143a4bfb7e6a304a85544","type":"GENE","name":"RN7SL291P","canonical_id":"hgnc:HGNC:46307","description":"RNA, 7SL, cytoplasmic 291, pseudogene","metadata":null},{"id":"0a9be669523b44ac8c43e740ff495d7d","type":"GENE","name":"RN7SL292P","canonical_id":"hgnc:HGNC:46308","description":"RNA, 7SL, cytoplasmic 292, pseudogene","metadata":null},{"id":"c9f69dcd3b564bcca2b440818584ac87","type":"GENE","name":"RN7SL293P","canonical_id":"hgnc:HGNC:46309","description":"RNA, 7SL, cytoplasmic 293, pseudogene","metadata":null},{"id":"3195b0a06ed14d32a01daefe4d69d2fe","type":"GENE","name":"RN7SL294P","canonical_id":"hgnc:HGNC:46310","description":"RNA, 7SL, cytoplasmic 294, pseudogene","metadata":null},{"id":"5d5ae72efba547ce8bd2811977f7ce02","type":"GENE","name":"RN7SL296P","canonical_id":"hgnc:HGNC:46312","description":"RNA, 7SL, cytoplasmic 296, pseudogene","metadata":null},{"id":"ac2c132b31334faf9292c78eb47d0f6d","type":"GENE","name":"RN7SL297P","canonical_id":"hgnc:HGNC:46313","description":"RNA, 7SL, cytoplasmic 297, pseudogene","metadata":null},{"id":"ec91b9ab6d9245d4b23734b042af5248","type":"GENE","name":"RN7SL299P","canonical_id":"hgnc:HGNC:46315","description":"RNA, 7SL, cytoplasmic 299, pseudogene","metadata":null},{"id":"6362d6e0d7da48c392380ee692c10db3","type":"GENE","name":"RN7SL3","canonical_id":"hgnc:HGNC:23135","description":"RNA component of signal recognition particle 7SL3","metadata":{"aliases":["7L30.2","RNSRP3","RN7SL631P"]}},{"id":"e765da2fbdf342e8b118f0a65e5ffbdf","type":"GENE","name":"RN7SL300P","canonical_id":"hgnc:HGNC:46316","description":"RNA, 7SL, cytoplasmic 300, pseudogene","metadata":null},{"id":"e2d37db3e08e47d49cace68490dec420","type":"GENE","name":"RN7SL301P","canonical_id":"hgnc:HGNC:46317","description":"RNA, 7SL, cytoplasmic 301, pseudogene","metadata":null},{"id":"0278a3cecf714cd5a993d51e7cc69cc4","type":"GENE","name":"RN7SL302P","canonical_id":"hgnc:HGNC:46318","description":"RNA, 7SL, cytoplasmic 302, pseudogene","metadata":null},{"id":"689f2e9e8ea44b6fb88d47616df87a8a","type":"GENE","name":"RN7SL303P","canonical_id":"hgnc:HGNC:46319","description":"RNA, 7SL, cytoplasmic 303, pseudogene","metadata":null},{"id":"e6c51b19c76e4489b0e48f125415a7e5","type":"GENE","name":"RN7SL304P","canonical_id":"hgnc:HGNC:46320","description":"RNA, 7SL, cytoplasmic 304, pseudogene","metadata":null},{"id":"d4a0c2b24e674c4683230f8bceae91c4","type":"GENE","name":"RN7SL305P","canonical_id":"hgnc:HGNC:46321","description":"RNA, 7SL, cytoplasmic 305, pseudogene","metadata":null},{"id":"5287254462294c399b97932c993c6c9f","type":"GENE","name":"RN7SL306P","canonical_id":"hgnc:HGNC:46322","description":"RNA, 7SL, cytoplasmic 306, pseudogene","metadata":null},{"id":"9de1c6b3b85643e5aa84ada559f8eb91","type":"GENE","name":"RN7SL307P","canonical_id":"hgnc:HGNC:46323","description":"RNA, 7SL, cytoplasmic 307, pseudogene","metadata":null},{"id":"f76f17a4e52f42e69e0de63e5a0626e9","type":"GENE","name":"RN7SL308P","canonical_id":"hgnc:HGNC:46324","description":"RNA, 7SL, cytoplasmic 308, pseudogene","metadata":null},{"id":"c557d8035a234860ae9585c58c4c53df","type":"GENE","name":"RN7SL309P","canonical_id":"hgnc:HGNC:46325","description":"RNA, 7SL, cytoplasmic 309, pseudogene","metadata":null},{"id":"459e9dd5bc4241ed82bee83517f0981b","type":"GENE","name":"RN7SL30P","canonical_id":"hgnc:HGNC:46046","description":"RNA, 7SL, cytoplasmic 30, pseudogene","metadata":null},{"id":"60e8c0130e6a4e34930bbb71eabebd1f","type":"GENE","name":"RN7SL310P","canonical_id":"hgnc:HGNC:46326","description":"RNA, 7SL, cytoplasmic 310, pseudogene","metadata":null},{"id":"784a4a985aa64f87846c3745cce0d22f","type":"GENE","name":"RN7SL311P","canonical_id":"hgnc:HGNC:46327","description":"RNA, 7SL, cytoplasmic 311, pseudogene","metadata":null},{"id":"cace83d279a1410bab8a696b37c4a7e9","type":"GENE","name":"RN7SL313P","canonical_id":"hgnc:HGNC:46329","description":"RNA, 7SL, cytoplasmic 313, pseudogene","metadata":null},{"id":"0387a5e6f0cc4488ac7ac14491450695","type":"GENE","name":"RN7SL314P","canonical_id":"hgnc:HGNC:46330","description":"RNA, 7SL, cytoplasmic 314, pseudogene","metadata":null},{"id":"60da96148aa64a59b88e82271b5ca9c8","type":"GENE","name":"RN7SL316P","canonical_id":"hgnc:HGNC:46332","description":"RNA, 7SL, cytoplasmic 316, pseudogene","metadata":null},{"id":"d9cc418d41094a6e9e9d74585ea707b6","type":"GENE","name":"RN7SL317P","canonical_id":"hgnc:HGNC:46333","description":"RNA, 7SL, cytoplasmic 317, pseudogene","metadata":null},{"id":"9f0e00fcef024a39b2708fe27197c94b","type":"GENE","name":"RN7SL318P","canonical_id":"hgnc:HGNC:46334","description":"RNA, 7SL, cytoplasmic 318, pseudogene","metadata":null},{"id":"60d7f4244338413f8109d61e51b0a6a2","type":"GENE","name":"RN7SL319P","canonical_id":"hgnc:HGNC:46335","description":"RNA, 7SL, cytoplasmic 319, pseudogene","metadata":null},{"id":"37a05ea252f4460abb32b2b421a77c60","type":"GENE","name":"RN7SL320P","canonical_id":"hgnc:HGNC:46336","description":"RNA, 7SL, cytoplasmic 320, pseudogene","metadata":null},{"id":"25ca7aad682748aa9f45207b8f5e0d71","type":"GENE","name":"RN7SL321P","canonical_id":"hgnc:HGNC:46337","description":"RNA, 7SL, cytoplasmic 321, pseudogene","metadata":null},{"id":"53ab721599f64a79a66966c2a968ccda","type":"GENE","name":"RN7SL322P","canonical_id":"hgnc:HGNC:46338","description":"RNA, 7SL, cytoplasmic 322, pseudogene","metadata":null},{"id":"41d50a4501da405cb6ec40a37abfbfd2","type":"GENE","name":"RN7SL323P","canonical_id":"hgnc:HGNC:46339","description":"RNA, 7SL, cytoplasmic 323, pseudogene","metadata":null},{"id":"24f89380654c48d598d7fc79889b6c1d","type":"GENE","name":"RN7SL325P","canonical_id":"hgnc:HGNC:46341","description":"RNA, 7SL, cytoplasmic 325, pseudogene","metadata":null},{"id":"1154902ddf374256bf8dae222d97ebe5","type":"GENE","name":"RN7SL326P","canonical_id":"hgnc:HGNC:46342","description":"RNA, 7SL, cytoplasmic 326, pseudogene","metadata":null},{"id":"90b68750450a4d818683fad230f3fffb","type":"GENE","name":"RN7SL327P","canonical_id":"hgnc:HGNC:46343","description":"RNA, 7SL, cytoplasmic 327, pseudogene","metadata":null},{"id":"3141c61afc014180b0524a221e5809db","type":"GENE","name":"RN7SL328P","canonical_id":"hgnc:HGNC:46344","description":"RNA, 7SL, cytoplasmic 328, pseudogene","metadata":null},{"id":"9117cbafbb784e3e9f0d76a8e1496f32","type":"GENE","name":"RN7SL329P","canonical_id":"hgnc:HGNC:46345","description":"RNA, 7SL, cytoplasmic 329, pseudogene","metadata":null},{"id":"fa90aef9f8554d73a20710a604355046","type":"GENE","name":"RN7SL32P","canonical_id":"hgnc:HGNC:46048","description":"RNA, 7SL, cytoplasmic 32, pseudogene","metadata":null},{"id":"b0941ed8572f49e8930fec968b4e8f43","type":"GENE","name":"RN7SL330P","canonical_id":"hgnc:HGNC:46346","description":"RNA, 7SL, cytoplasmic 330, pseudogene","metadata":null},{"id":"fd67de16073d4ed3a3148bd144e5338c","type":"GENE","name":"RN7SL331P","canonical_id":"hgnc:HGNC:46347","description":"RNA, 7SL, cytoplasmic 331, pseudogene","metadata":null},{"id":"a4e252c292e24faa8fc51290b246ae8d","type":"GENE","name":"RN7SL332P","canonical_id":"hgnc:HGNC:46348","description":"RNA, 7SL, cytoplasmic 332, pseudogene","metadata":null},{"id":"7abd077821784773a91240918c21b2d0","type":"GENE","name":"RN7SL333P","canonical_id":"hgnc:HGNC:46349","description":"RNA, 7SL, cytoplasmic 333, pseudogene","metadata":null},{"id":"965f27a86fdd4879ac1081aff040d775","type":"GENE","name":"RN7SL334P","canonical_id":"hgnc:HGNC:46350","description":"RNA, 7SL, cytoplasmic 334, pseudogene","metadata":null},{"id":"8ba1b860df634a32824a33ebc7f585e1","type":"GENE","name":"RN7SL335P","canonical_id":"hgnc:HGNC:46351","description":"RNA, 7SL, cytoplasmic 335, pseudogene","metadata":null},{"id":"7f89e29c57ec4d6d96653737c04664fc","type":"GENE","name":"RN7SL336P","canonical_id":"hgnc:HGNC:46352","description":"RNA, 7SL, cytoplasmic 336, pseudogene","metadata":null},{"id":"6860e6e08d1741a692dac279d433ee26","type":"GENE","name":"RN7SL337P","canonical_id":"hgnc:HGNC:46353","description":"RNA, 7SL, cytoplasmic 337, pseudogene","metadata":null},{"id":"4739c1aa7b5944038a9da93d9493bab4","type":"GENE","name":"RN7SL338P","canonical_id":"hgnc:HGNC:46354","description":"RNA, 7SL, cytoplasmic 338, pseudogene","metadata":null},{"id":"fede472d324d4472a4796ca509d19d3c","type":"GENE","name":"RN7SL339P","canonical_id":"hgnc:HGNC:46355","description":"RNA, 7SL, cytoplasmic 339, pseudogene","metadata":null},{"id":"642bbfc4e4ca40e8b25cf6a96dc1884c","type":"GENE","name":"RN7SL33P","canonical_id":"hgnc:HGNC:46049","description":"RNA, 7SL, cytoplasmic 33, pseudogene","metadata":null},{"id":"d8d35231e3634091bd2ff79697097a05","type":"GENE","name":"RN7SL340P","canonical_id":"hgnc:HGNC:46356","description":"RNA, 7SL, cytoplasmic 340, pseudogene","metadata":null},{"id":"461792293c1f4027bddaf497fa8f3179","type":"GENE","name":"RN7SL341P","canonical_id":"hgnc:HGNC:46357","description":"RNA, 7SL, cytoplasmic 341, pseudogene","metadata":null},{"id":"f0073c1c69ed45e6bf17e3d85b02a15d","type":"GENE","name":"RN7SL342P","canonical_id":"hgnc:HGNC:46358","description":"RNA, 7SL, cytoplasmic 342, pseudogene","metadata":null},{"id":"6d3136f230e5489187454a5f1359c18c","type":"GENE","name":"RN7SL343P","canonical_id":"hgnc:HGNC:46359","description":"RNA, 7SL, cytoplasmic 343, pseudogene","metadata":null},{"id":"521516e6da1c43b5aac221f7c84a0bcf","type":"GENE","name":"RN7SL344P","canonical_id":"hgnc:HGNC:46360","description":"RNA, 7SL, cytoplasmic 344, pseudogene","metadata":null},{"id":"448083ac7a3d427885e20635255504cd","type":"GENE","name":"RN7SL346P","canonical_id":"hgnc:HGNC:46362","description":"RNA, 7SL, cytoplasmic 346, pseudogene","metadata":null},{"id":"58d36ab0e64d4162bf981089827532c5","type":"GENE","name":"RN7SL34P","canonical_id":"hgnc:HGNC:46050","description":"RNA, 7SL, cytoplasmic 34, pseudogene","metadata":null},{"id":"46f5a9612e7a4e20b641a014c976762a","type":"GENE","name":"RN7SL350P","canonical_id":"hgnc:HGNC:46366","description":"RNA, 7SL, cytoplasmic 350, pseudogene","metadata":null},{"id":"3d521f5ddfcc474d9c6cf3dd0f5fcdfd","type":"GENE","name":"RN7SL351P","canonical_id":"hgnc:HGNC:46367","description":"RNA, 7SL, cytoplasmic 351, pseudogene","metadata":null},{"id":"343b4ef282104b45a7c94053ef27376f","type":"GENE","name":"RN7SL352P","canonical_id":"hgnc:HGNC:46368","description":"RNA, 7SL, cytoplasmic 352, pseudogene","metadata":null},{"id":"c8f3ee81cb654a97b420ff3e2cf6ef2b","type":"GENE","name":"RN7SL353P","canonical_id":"hgnc:HGNC:46369","description":"RNA, 7SL, cytoplasmic 353, pseudogene","metadata":{"aliases":["RN7SL579P"]}},{"id":"c633f3a7ed0845f7bf3755cca54232b7","type":"GENE","name":"RN7SL354P","canonical_id":"hgnc:HGNC:46370","description":"RNA, 7SL, cytoplasmic 354, pseudogene","metadata":null},{"id":"11e115481b65446facd3fe2895c1acf9","type":"GENE","name":"RN7SL356P","canonical_id":"hgnc:HGNC:46372","description":"RNA, 7SL, cytoplasmic 356, pseudogene","metadata":null},{"id":"692827ec392e426b9a464bcb41c068ce","type":"GENE","name":"RN7SL357P","canonical_id":"hgnc:HGNC:46373","description":"RNA, 7SL, cytoplasmic 357, pseudogene","metadata":null},{"id":"63cb488219694c41ba634d4bcf5d4340","type":"GENE","name":"RN7SL359P","canonical_id":"hgnc:HGNC:46375","description":"RNA, 7SL, cytoplasmic 359, pseudogene","metadata":null},{"id":"a1ff3932d8ea4e0b822b2bac3e64a9b0","type":"GENE","name":"RN7SL35P","canonical_id":"hgnc:HGNC:46051","description":"RNA, 7SL, cytoplasmic 35, pseudogene","metadata":null},{"id":"59548f59868b4f7ebb97526e3018632f","type":"GENE","name":"RN7SL361P","canonical_id":"hgnc:HGNC:46377","description":"RNA, 7SL, cytoplasmic 361, pseudogene","metadata":null},{"id":"0438e457890a410c8a463591247a626d","type":"GENE","name":"RN7SL362P","canonical_id":"hgnc:HGNC:46378","description":"RNA, 7SL, cytoplasmic 362, pseudogene","metadata":null},{"id":"8708f038684a4f7bb738a32b38f3fcd4","type":"GENE","name":"RN7SL363P","canonical_id":"hgnc:HGNC:46379","description":"RNA, 7SL, cytoplasmic 363, pseudogene","metadata":null},{"id":"90f06cdee9454a4499e7728e8d0990f1","type":"GENE","name":"RN7SL364P","canonical_id":"hgnc:HGNC:46380","description":"RNA, 7SL, cytoplasmic 364, pseudogene","metadata":null},{"id":"e800c1a6a5d24e5e8e866a9ffaafdcb7","type":"GENE","name":"RN7SL366P","canonical_id":"hgnc:HGNC:46382","description":"RNA, 7SL, cytoplasmic 366, pseudogene","metadata":null},{"id":"fcd254ac34ca4ba1aa22271d6b3a3a4f","type":"GENE","name":"RN7SL368P","canonical_id":"hgnc:HGNC:46384","description":"RNA, 7SL, cytoplasmic 368, pseudogene","metadata":null},{"id":"1f9f4a5b89e040a9a5807d3f7ac5f61a","type":"GENE","name":"RN7SL369P","canonical_id":"hgnc:HGNC:46385","description":"RNA, 7SL, cytoplasmic 369, pseudogene","metadata":null},{"id":"499a8c174ccd43a2b0c10cebd0c65910","type":"GENE","name":"RN7SL36P","canonical_id":"hgnc:HGNC:46052","description":"RNA, 7SL, cytoplasmic 36, pseudogene","metadata":null},{"id":"5fbadf44d64f469695dda1833a72c7c2","type":"GENE","name":"RN7SL370P","canonical_id":"hgnc:HGNC:46386","description":"RNA, 7SL, cytoplasmic 370, pseudogene","metadata":null},{"id":"4c54050231014c01a824c5e8cba8f1e9","type":"GENE","name":"RN7SL371P","canonical_id":"hgnc:HGNC:46387","description":"RNA, 7SL, cytoplasmic 371, pseudogene","metadata":null},{"id":"6b1a7806888f48fa8a5cdc41e3ef56cc","type":"GENE","name":"RN7SL372P","canonical_id":"hgnc:HGNC:46388","description":"RNA, 7SL, cytoplasmic 372, pseudogene","metadata":null},{"id":"17a59609520c4922bd1f59f2177ae8eb","type":"GENE","name":"RN7SL375P","canonical_id":"hgnc:HGNC:46391","description":"RNA, 7SL, cytoplasmic 375, pseudogene","metadata":null},{"id":"bf4007354ca5437b802f6d8ca1c16503","type":"GENE","name":"RN7SL376P","canonical_id":"hgnc:HGNC:46392","description":"RNA, 7SL, cytoplasmic 376, pseudogene","metadata":null},{"id":"7d15dd882183476da3cb2d1419eecff1","type":"GENE","name":"RN7SL377P","canonical_id":"hgnc:HGNC:46393","description":"RNA, 7SL, cytoplasmic 377, pseudogene","metadata":null},{"id":"02a5c0491f414c189cbefe856e835b5c","type":"GENE","name":"RN7SL378P","canonical_id":"hgnc:HGNC:46394","description":"RNA, 7SL, cytoplasmic 378, pseudogene","metadata":null},{"id":"71badb42028247349c6c4dcde566d9ec","type":"GENE","name":"RN7SL379P","canonical_id":"hgnc:HGNC:46395","description":"RNA, 7SL, cytoplasmic 379, pseudogene","metadata":null},{"id":"6595a3ae7e6d40779f796df36167feee","type":"GENE","name":"RN7SL37P","canonical_id":"hgnc:HGNC:46053","description":"RNA, 7SL, cytoplasmic 37, pseudogene","metadata":null},{"id":"8ab2f27d12b0443098a02da102c325da","type":"GENE","name":"RN7SL380P","canonical_id":"hgnc:HGNC:46396","description":"RNA, 7SL, cytoplasmic 380, pseudogene","metadata":null},{"id":"9397c7dd3e5c4dea88c96490cb531aa1","type":"GENE","name":"RN7SL381P","canonical_id":"hgnc:HGNC:46397","description":"RNA, 7SL, cytoplasmic 381, pseudogene","metadata":null},{"id":"31814e044f41468b90ef30a1767aa967","type":"GENE","name":"RN7SL382P","canonical_id":"hgnc:HGNC:46398","description":"RNA, 7SL, cytoplasmic 382, pseudogene","metadata":null},{"id":"15d2febb71654f568e766ed29f480545","type":"GENE","name":"RN7SL383P","canonical_id":"hgnc:HGNC:46399","description":"RNA, 7SL, cytoplasmic 383, pseudogene","metadata":null},{"id":"d2c93784f2634136adb923441346db69","type":"GENE","name":"RN7SL384P","canonical_id":"hgnc:HGNC:46400","description":"RNA, 7SL, cytoplasmic 384, pseudogene","metadata":null},{"id":"c9abea52013145ebad637a58211db692","type":"GENE","name":"RN7SL385P","canonical_id":"hgnc:HGNC:46401","description":"RNA, 7SL, cytoplasmic 385, pseudogene","metadata":null},{"id":"2a5e62e7d13d4c99a9327e043e9ec427","type":"GENE","name":"RN7SL386P","canonical_id":"hgnc:HGNC:46402","description":"RNA, 7SL, cytoplasmic 386, pseudogene","metadata":null},{"id":"d7ad1cc08c7a44c8ada50023859fd11b","type":"GENE","name":"RN7SL387P","canonical_id":"hgnc:HGNC:46403","description":"RNA, 7SL, cytoplasmic 387, pseudogene","metadata":null},{"id":"b822cdfb03f4422aadd32f3ce5df699e","type":"GENE","name":"RN7SL388P","canonical_id":"hgnc:HGNC:46404","description":"RNA, 7SL, cytoplasmic 388, pseudogene","metadata":null},{"id":"37b2cb5ac51443eaa957cca40a5ad1ff","type":"GENE","name":"RN7SL38P","canonical_id":"hgnc:HGNC:46054","description":"RNA, 7SL, cytoplasmic 38, pseudogene","metadata":null},{"id":"e96e49923d1e461ea9c7f7b328073918","type":"GENE","name":"RN7SL390P","canonical_id":"hgnc:HGNC:46406","description":"RNA, 7SL, cytoplasmic 390, pseudogene","metadata":null},{"id":"57794af7eb9a4a29943699c6e51e2a1f","type":"GENE","name":"RN7SL391P","canonical_id":"hgnc:HGNC:46407","description":"RNA, 7SL, cytoplasmic 391, pseudogene","metadata":null},{"id":"e81a93877a804c979482e1f0ab08579d","type":"GENE","name":"RN7SL392P","canonical_id":"hgnc:HGNC:46408","description":"RNA, 7SL, cytoplasmic 392, pseudogene","metadata":null},{"id":"a5d63ede38b4446695f717f6a2c98475","type":"GENE","name":"RN7SL393P","canonical_id":"hgnc:HGNC:46409","description":"RNA, 7SL, cytoplasmic 393, pseudogene","metadata":null},{"id":"769899df8edb41529fcf2c22fc0d9b56","type":"GENE","name":"RN7SL394P","canonical_id":"hgnc:HGNC:46410","description":"RNA, 7SL, cytoplasmic 394, pseudogene","metadata":null},{"id":"44e4fa09faa14dd4bd26822163ca6526","type":"GENE","name":"RN7SL395P","canonical_id":"hgnc:HGNC:46411","description":"RNA, 7SL, cytoplasmic 395, pseudogene","metadata":null},{"id":"232ca5da957f40f1bcf159cb168ec0e8","type":"GENE","name":"RN7SL396P","canonical_id":"hgnc:HGNC:46412","description":"RNA, 7SL, cytoplasmic 396, pseudogene","metadata":null},{"id":"4516b53bb16342fdade3df4eac752d2f","type":"GENE","name":"RN7SL397P","canonical_id":"hgnc:HGNC:46413","description":"RNA, 7SL, cytoplasmic 397, pseudogene","metadata":null},{"id":"1a09561f0a424c91b08ca57585cdf8ef","type":"GENE","name":"RN7SL398P","canonical_id":"hgnc:HGNC:46414","description":"RNA, 7SL, cytoplasmic 398, pseudogene","metadata":null},{"id":"923924139dbd4249abb22ee9c5ffddb5","type":"GENE","name":"RN7SL399P","canonical_id":"hgnc:HGNC:46415","description":"RNA, 7SL, cytoplasmic 399, pseudogene","metadata":null},{"id":"8bc5fc7f257d4c78a27187f987cc421d","type":"GENE","name":"RN7SL39P","canonical_id":"hgnc:HGNC:46055","description":"RNA, 7SL, cytoplasmic 39, pseudogene","metadata":null},{"id":"f27f290e44b046278a2ae935faeb4acd","type":"GENE","name":"RN7SL400P","canonical_id":"hgnc:HGNC:46416","description":"RNA, 7SL, cytoplasmic 400, pseudogene","metadata":null},{"id":"74eaac7d0796471389a61f2c294fdb72","type":"GENE","name":"RN7SL401P","canonical_id":"hgnc:HGNC:46417","description":"RNA, 7SL, cytoplasmic 401, pseudogene","metadata":null},{"id":"4583c10747194413b9f84b248b4871b1","type":"GENE","name":"RN7SL402P","canonical_id":"hgnc:HGNC:46418","description":"RNA, 7SL, cytoplasmic 402, pseudogene","metadata":null},{"id":"c7e4a2b63b95424b9bbed3eba8469afc","type":"GENE","name":"RN7SL403P","canonical_id":"hgnc:HGNC:46419","description":"RNA, 7SL, cytoplasmic 403, pseudogene","metadata":null},{"id":"ff7a181198854fd798d0f950442672ae","type":"GENE","name":"RN7SL404P","canonical_id":"hgnc:HGNC:46420","description":"RNA, 7SL, cytoplasmic 404, pseudogene","metadata":null},{"id":"ee8fea5072fa476fa4ea452cda93aaaa","type":"GENE","name":"RN7SL405P","canonical_id":"hgnc:HGNC:46421","description":"RNA, 7SL, cytoplasmic 405, pseudogene","metadata":null},{"id":"77e35fb8e5cb48fa80b631671280cb4c","type":"GENE","name":"RN7SL408P","canonical_id":"hgnc:HGNC:46424","description":"RNA, 7SL, cytoplasmic 408, pseudogene","metadata":null},{"id":"2012072c2c304275b35b944aa24b217b","type":"GENE","name":"RN7SL40P","canonical_id":"hgnc:HGNC:46056","description":"RNA, 7SL, cytoplasmic 40, pseudogene","metadata":null},{"id":"3326010557fc483aa7301447956afb56","type":"GENE","name":"RN7SL411P","canonical_id":"hgnc:HGNC:46427","description":"RNA, 7SL, cytoplasmic 411, pseudogene","metadata":null},{"id":"8d574a289665465e98f80538d31c415f","type":"GENE","name":"RN7SL413P","canonical_id":"hgnc:HGNC:46429","description":"RNA, 7SL, cytoplasmic 413, pseudogene","metadata":null},{"id":"8903842f53e7486282a4d02f39b6f56f","type":"GENE","name":"RN7SL414P","canonical_id":"hgnc:HGNC:46430","description":"RNA, 7SL, cytoplasmic 414, pseudogene","metadata":null},{"id":"4099079cf1d6429fbf390b258760d5cf","type":"GENE","name":"RN7SL415P","canonical_id":"hgnc:HGNC:46431","description":"RNA, 7SL, cytoplasmic 415, pseudogene","metadata":null},{"id":"e75f613ab56b4c65b53ae69bb1c31c43","type":"GENE","name":"RN7SL416P","canonical_id":"hgnc:HGNC:46432","description":"RNA, 7SL, cytoplasmic 416, pseudogene","metadata":null},{"id":"ae22c13634ae46798ee833ec79c43291","type":"GENE","name":"RN7SL417P","canonical_id":"hgnc:HGNC:46433","description":"RNA, 7SL, cytoplasmic 417, pseudogene","metadata":null},{"id":"fddebd5055fe4d5890879c87d69b1833","type":"GENE","name":"RN7SL418P","canonical_id":"hgnc:HGNC:46434","description":"RNA, 7SL, cytoplasmic 418, pseudogene","metadata":null},{"id":"de3af351029b4ba98ebea8474da9f04d","type":"GENE","name":"RN7SL419P","canonical_id":"hgnc:HGNC:46435","description":"RNA, 7SL, cytoplasmic 419, pseudogene","metadata":null},{"id":"795b920acf364106becd4512a414878c","type":"GENE","name":"RN7SL41P","canonical_id":"hgnc:HGNC:46057","description":"RNA, 7SL, cytoplasmic 41, pseudogene","metadata":null},{"id":"fc17c95d5acd44429b2815b1bb98de81","type":"GENE","name":"RN7SL420P","canonical_id":"hgnc:HGNC:46436","description":"RNA, 7SL, cytoplasmic 420, pseudogene","metadata":null},{"id":"fbf36e92460343518d1334f058974329","type":"GENE","name":"RN7SL422P","canonical_id":"hgnc:HGNC:46438","description":"RNA, 7SL, cytoplasmic 422, pseudogene","metadata":null},{"id":"1adb6de7a95244b3a3b626cfd6305c47","type":"GENE","name":"RN7SL423P","canonical_id":"hgnc:HGNC:46439","description":"RNA, 7SL, cytoplasmic 423, pseudogene","metadata":null},{"id":"e7647e9b7c984f7aacf1b9184b6710d3","type":"GENE","name":"RN7SL424P","canonical_id":"hgnc:HGNC:46440","description":"RNA, 7SL, cytoplasmic 424, pseudogene","metadata":null},{"id":"4f2bfa6937d840e681a3f9be22900d74","type":"GENE","name":"RN7SL425P","canonical_id":"hgnc:HGNC:46441","description":"RNA, 7SL, cytoplasmic 425, pseudogene","metadata":null},{"id":"61bf6c9faf334e949d40bbd26dc03955","type":"GENE","name":"RN7SL426P","canonical_id":"hgnc:HGNC:46442","description":"RNA, 7SL, cytoplasmic 426, pseudogene","metadata":null},{"id":"5b3db166e3d644869f583c05e21747da","type":"GENE","name":"RN7SL428P","canonical_id":"hgnc:HGNC:46444","description":"RNA, 7SL, cytoplasmic 428, pseudogene","metadata":null},{"id":"a8226608f9e8472fbe553ce6594d4d3b","type":"GENE","name":"RN7SL429P","canonical_id":"hgnc:HGNC:46445","description":"RNA, 7SL, cytoplasmic 429, pseudogene","metadata":null},{"id":"61e5525fc1984b0583f998c84d2ab754","type":"GENE","name":"RN7SL42P","canonical_id":"hgnc:HGNC:46058","description":"RNA, 7SL, cytoplasmic 42, pseudogene","metadata":null},{"id":"d86f927a13e3485c98c61ec6aa360c1f","type":"GENE","name":"RN7SL430P","canonical_id":"hgnc:HGNC:46446","description":"RNA, 7SL, cytoplasmic 430, pseudogene","metadata":null},{"id":"f9835b74ce444cce97901fd29ff8965e","type":"GENE","name":"RN7SL431P","canonical_id":"hgnc:HGNC:46447","description":"RNA, 7SL, cytoplasmic 431, pseudogene","metadata":null},{"id":"4011c38304c94e92861d170a33565eca","type":"GENE","name":"RN7SL432P","canonical_id":"hgnc:HGNC:46448","description":"RNA, 7SL, cytoplasmic 432, pseudogene","metadata":null},{"id":"479f0c1b69cd47b195bc9bde9857d8f9","type":"GENE","name":"RN7SL434P","canonical_id":"hgnc:HGNC:46450","description":"RNA, 7SL, cytoplasmic 434, pseudogene","metadata":null},{"id":"886da7d758754c5f8be45ca4f7b19b3a","type":"GENE","name":"RN7SL435P","canonical_id":"hgnc:HGNC:46451","description":"RNA, 7SL, cytoplasmic 435, pseudogene","metadata":null},{"id":"d20aa0e7d92d47d28d584d07e79a8978","type":"GENE","name":"RN7SL438P","canonical_id":"hgnc:HGNC:46454","description":"RNA, 7SL, cytoplasmic 438, pseudogene","metadata":null},{"id":"c66b397dee7b4f6faf3460d8f4d13927","type":"GENE","name":"RN7SL43P","canonical_id":"hgnc:HGNC:46059","description":"RNA, 7SL, cytoplasmic 43, pseudogene","metadata":null},{"id":"bb250399ee3d4b329ea551cc3377e723","type":"GENE","name":"RN7SL440P","canonical_id":"hgnc:HGNC:46456","description":"RNA, 7SL, cytoplasmic 440, pseudogene","metadata":null},{"id":"d35a69c8a004441dac72c5adba3db1f5","type":"GENE","name":"RN7SL441P","canonical_id":"hgnc:HGNC:46457","description":"RNA, 7SL, cytoplasmic 441, pseudogene","metadata":null},{"id":"9fc3047e4c9542df848f67665bb4a813","type":"GENE","name":"RN7SL442P","canonical_id":"hgnc:HGNC:46458","description":"RNA, 7SL, cytoplasmic 442, pseudogene","metadata":null},{"id":"8ee25f54c8254177b292977bdacb5b8b","type":"GENE","name":"RN7SL443P","canonical_id":"hgnc:HGNC:46459","description":"RNA, 7SL, cytoplasmic 443, pseudogene","metadata":null},{"id":"76ba2878c800468799686fecd8659b7d","type":"GENE","name":"RN7SL444P","canonical_id":"hgnc:HGNC:46460","description":"RNA, 7SL, cytoplasmic 444, pseudogene","metadata":null},{"id":"91720422c219485eabec9df17e1b2630","type":"GENE","name":"RN7SL445P","canonical_id":"hgnc:HGNC:46461","description":"RNA, 7SL, cytoplasmic 445, pseudogene","metadata":null},{"id":"4b824f5e8592491ca6e486fc7d54b9c2","type":"GENE","name":"RN7SL446P","canonical_id":"hgnc:HGNC:46462","description":"RNA, 7SL, cytoplasmic 446, pseudogene","metadata":null},{"id":"d10e62e2e66b46559ac81a0e5e64782d","type":"GENE","name":"RN7SL447P","canonical_id":"hgnc:HGNC:46463","description":"RNA, 7SL, cytoplasmic 447, pseudogene","metadata":null},{"id":"d4d58255f892454ea9480a8c7dd88155","type":"GENE","name":"RN7SL448P","canonical_id":"hgnc:HGNC:46464","description":"RNA, 7SL, cytoplasmic 448, pseudogene","metadata":null},{"id":"025b398297aa49099a4ab096378c2b77","type":"GENE","name":"RN7SL449P","canonical_id":"hgnc:HGNC:46465","description":"RNA, 7SL, cytoplasmic 449, pseudogene","metadata":null},{"id":"56522779bb7c4842bba942aed3b3e7b1","type":"GENE","name":"RN7SL44P","canonical_id":"hgnc:HGNC:46060","description":"RNA, 7SL, cytoplasmic 44, pseudogene","metadata":null},{"id":"241eda6dbbe9420d98eabf8097b6c0c3","type":"GENE","name":"RN7SL451P","canonical_id":"hgnc:HGNC:46467","description":"RNA, 7SL, cytoplasmic 451, pseudogene","metadata":null},{"id":"9477394d97ba4459b5186f1f09b81278","type":"GENE","name":"RN7SL452P","canonical_id":"hgnc:HGNC:46468","description":"RNA, 7SL, cytoplasmic 452, pseudogene","metadata":null},{"id":"29dc103151bd46bab4098e85e713f328","type":"GENE","name":"RN7SL453P","canonical_id":"hgnc:HGNC:46469","description":"RNA, 7SL, cytoplasmic 453, pseudogene","metadata":null},{"id":"ee703842a8bb4039863f4f0acf380130","type":"GENE","name":"RN7SL454P","canonical_id":"hgnc:HGNC:46470","description":"RNA, 7SL, cytoplasmic 454, pseudogene","metadata":null},{"id":"e9f16b620aab4eca92731c42d1faecb6","type":"GENE","name":"RN7SL455P","canonical_id":"hgnc:HGNC:46471","description":"RNA, 7SL, cytoplasmic 455, pseudogene","metadata":null},{"id":"0c74b90044cf48dc8f113b85852fac74","type":"GENE","name":"RN7SL456P","canonical_id":"hgnc:HGNC:46472","description":"RNA, 7SL, cytoplasmic 456, pseudogene","metadata":null},{"id":"e08c55372362464e92d388ef400e1f96","type":"GENE","name":"RN7SL457P","canonical_id":"hgnc:HGNC:46473","description":"RNA, 7SL, cytoplasmic 457, pseudogene","metadata":null},{"id":"55d13088af1b41a68907b26854d0c450","type":"GENE","name":"RN7SL459P","canonical_id":"hgnc:HGNC:46475","description":"RNA, 7SL, cytoplasmic 459, pseudogene","metadata":null},{"id":"cc0d1af419404fdf98a96196e0fe79ff","type":"GENE","name":"RN7SL45P","canonical_id":"hgnc:HGNC:46061","description":"RNA, 7SL, cytoplasmic 45, pseudogene","metadata":null},{"id":"9a5110daa1314508af1ec246ea116d85","type":"GENE","name":"RN7SL460P","canonical_id":"hgnc:HGNC:46476","description":"RNA, 7SL, cytoplasmic 460, pseudogene","metadata":null},{"id":"613c5373ed5e4053ab0b419b0085e902","type":"GENE","name":"RN7SL461P","canonical_id":"hgnc:HGNC:46477","description":"RNA, 7SL, cytoplasmic 461, pseudogene","metadata":null},{"id":"b5bc5a84039a4d109d4268266aaec239","type":"GENE","name":"RN7SL462P","canonical_id":"hgnc:HGNC:46478","description":"RNA, 7SL, cytoplasmic 462, pseudogene","metadata":null},{"id":"9110ccc12fb84cd98cefda8d39cd4a4a","type":"GENE","name":"RN7SL464P","canonical_id":"hgnc:HGNC:46480","description":"RNA, 7SL, cytoplasmic 464, pseudogene","metadata":null},{"id":"9d2e13e1f20640919023f1c9b8621690","type":"GENE","name":"RN7SL465P","canonical_id":"hgnc:HGNC:46481","description":"RNA, 7SL, cytoplasmic 465, pseudogene","metadata":null},{"id":"10f369d4d65c45e5965fbb487bdd1647","type":"GENE","name":"RN7SL466P","canonical_id":"hgnc:HGNC:46482","description":"RNA, 7SL, cytoplasmic 466, pseudogene","metadata":null},{"id":"92360c0fcc5040cb83831e5ee9106fe6","type":"GENE","name":"RN7SL468P","canonical_id":"hgnc:HGNC:46484","description":"RNA, 7SL, cytoplasmic 468, pseudogene","metadata":null},{"id":"8a91e8d86c1e43ad97845df695cd3cd8","type":"GENE","name":"RN7SL469P","canonical_id":"hgnc:HGNC:46485","description":"RNA, 7SL, cytoplasmic 469, pseudogene","metadata":null},{"id":"69f2088a952d4d2e872e77d7b436f11e","type":"GENE","name":"RN7SL470P","canonical_id":"hgnc:HGNC:46486","description":"RNA, 7SL, cytoplasmic 470, pseudogene","metadata":null},{"id":"570ac4e6371c4365b113498ab0e30e5b","type":"GENE","name":"RN7SL471P","canonical_id":"hgnc:HGNC:46487","description":"RNA, 7SL, cytoplasmic 471, pseudogene","metadata":{"aliases":["RN7SL257P"]}},{"id":"9d6ed840e41d4bf9859d4d44691f89fe","type":"GENE","name":"RN7SL472P","canonical_id":"hgnc:HGNC:46488","description":"RNA, 7SL, cytoplasmic 472, pseudogene","metadata":null},{"id":"af2ed54e3fcb4307afee150d698631b3","type":"GENE","name":"RN7SL473P","canonical_id":"hgnc:HGNC:46489","description":"RNA, 7SL, cytoplasmic 473, pseudogene","metadata":null},{"id":"e8e9b59a30b54d98b2dbef604e7f27d6","type":"GENE","name":"RN7SL474P","canonical_id":"hgnc:HGNC:46490","description":"RNA, 7SL, cytoplasmic 474, pseudogene","metadata":null},{"id":"881fcf01edd94c8ebbdf5cd38bbf7600","type":"GENE","name":"RN7SL475P","canonical_id":"hgnc:HGNC:46491","description":"RNA, 7SL, cytoplasmic 475, pseudogene","metadata":null},{"id":"13f7254e26ce4576b6ffa33e5029a581","type":"GENE","name":"RN7SL477P","canonical_id":"hgnc:HGNC:46493","description":"RNA, 7SL, cytoplasmic 477, pseudogene","metadata":null},{"id":"fba2a4cf043d4ce9859422fef5dd8a09","type":"GENE","name":"RN7SL478P","canonical_id":"hgnc:HGNC:46494","description":"RNA, 7SL, cytoplasmic 478, pseudogene","metadata":null},{"id":"8c9a85caa5444441a9209223fb2c4bdb","type":"GENE","name":"RN7SL479P","canonical_id":"hgnc:HGNC:46495","description":"RNA, 7SL, cytoplasmic 479, pseudogene","metadata":null},{"id":"aba22679d4f2418b979765048dd34545","type":"GENE","name":"RN7SL47P","canonical_id":"hgnc:HGNC:46063","description":"RNA, 7SL, cytoplasmic 47, pseudogene","metadata":null},{"id":"babf8d7f539a484184bf87fc9323c32e","type":"GENE","name":"RN7SL480P","canonical_id":"hgnc:HGNC:46496","description":"RNA, 7SL, cytoplasmic 480, pseudogene","metadata":null},{"id":"1b93a56418df4163b3ebb2bfe3a05f33","type":"GENE","name":"RN7SL481P","canonical_id":"hgnc:HGNC:46497","description":"RNA, 7SL, cytoplasmic 481, pseudogene","metadata":null},{"id":"30dd8123619747ac86737bed92719095","type":"GENE","name":"RN7SL482P","canonical_id":"hgnc:HGNC:46498","description":"RNA, 7SL, cytoplasmic 482, pseudogene","metadata":null},{"id":"b485de51752d452fac80eb3cadce8b5e","type":"GENE","name":"RN7SL483P","canonical_id":"hgnc:HGNC:46499","description":"RNA, 7SL, cytoplasmic 483, pseudogene","metadata":null},{"id":"2237cb67e98a4becb2b4f3325fde1ac6","type":"GENE","name":"RN7SL484P","canonical_id":"hgnc:HGNC:46500","description":"RNA, 7SL, cytoplasmic 484, pseudogene","metadata":null},{"id":"3f3765e8c88147cd82e2bb24de9c8d94","type":"GENE","name":"RN7SL487P","canonical_id":"hgnc:HGNC:46503","description":"RNA, 7SL, cytoplasmic 487, pseudogene","metadata":null},{"id":"724b65693dea4866b4b8fdc4039e7b35","type":"GENE","name":"RN7SL488P","canonical_id":"hgnc:HGNC:46504","description":"RNA, 7SL, cytoplasmic 488, pseudogene","metadata":null},{"id":"47767aaafa8e4c3fb339ead759a439b9","type":"GENE","name":"RN7SL489P","canonical_id":"hgnc:HGNC:46505","description":"RNA, 7SL, cytoplasmic 489, pseudogene","metadata":null},{"id":"32dad1683f0e426bae57da4ec4a8d908","type":"GENE","name":"RN7SL48P","canonical_id":"hgnc:HGNC:46064","description":"RNA, 7SL, cytoplasmic 48, pseudogene","metadata":null},{"id":"2e702f6fe736480eaff2dd6efe199318","type":"GENE","name":"RN7SL491P","canonical_id":"hgnc:HGNC:46507","description":"RNA, 7SL, cytoplasmic 491, pseudogene","metadata":null},{"id":"22e6941cd4d049bc96be3cb27552c946","type":"GENE","name":"RN7SL492P","canonical_id":"hgnc:HGNC:46508","description":"RNA, 7SL, cytoplasmic 492, pseudogene","metadata":null},{"id":"bd32e960953740e78af2a1eb43dcd960","type":"GENE","name":"RN7SL493P","canonical_id":"hgnc:HGNC:46509","description":"RNA, 7SL, cytoplasmic 493, pseudogene","metadata":null},{"id":"30605eccfb434d93b44967b0bb168961","type":"GENE","name":"RN7SL494P","canonical_id":"hgnc:HGNC:46510","description":"RNA, 7SL, cytoplasmic 494, pseudogene","metadata":null},{"id":"0b3216e678ae466987dd77c1af2568b7","type":"GENE","name":"RN7SL495P","canonical_id":"hgnc:HGNC:46511","description":"RNA, 7SL, cytoplasmic 495, pseudogene","metadata":null},{"id":"85023f6b6dc9439da97bbb04572841e7","type":"GENE","name":"RN7SL496P","canonical_id":"hgnc:HGNC:46512","description":"RNA, 7SL, cytoplasmic 496, pseudogene","metadata":null},{"id":"65a1beff9f514bee84dbb5c7dd802114","type":"GENE","name":"RN7SL497P","canonical_id":"hgnc:HGNC:46513","description":"RNA, 7SL, cytoplasmic 497, pseudogene","metadata":null},{"id":"8ba0f284dd77459eb95b0eb36c6b6461","type":"GENE","name":"RN7SL498P","canonical_id":"hgnc:HGNC:46514","description":"RNA, 7SL, cytoplasmic 498, pseudogene","metadata":null},{"id":"b837ec251e00426c9d151c516c655fe8","type":"GENE","name":"RN7SL499P","canonical_id":"hgnc:HGNC:46515","description":"RNA, 7SL, cytoplasmic 499, pseudogene","metadata":null},{"id":"d27affeaf8b94f178b6b83a686518d33","type":"GENE","name":"RN7SL49P","canonical_id":"hgnc:HGNC:46065","description":"RNA, 7SL, cytoplasmic 49, pseudogene","metadata":null},{"id":"8b854adb8eab4568b7fb65dd01a79196","type":"GENE","name":"RN7SL4P","canonical_id":"hgnc:HGNC:10039","description":"RNA, 7SL, cytoplasmic 4, pseudogene","metadata":{"aliases":["7L28","RN7SLP1","RN7SL427P"]}},{"id":"841b1cf1a9854b54a9fb5433139047bd","type":"GENE","name":"RN7SL500P","canonical_id":"hgnc:HGNC:46516","description":"RNA, 7SL, cytoplasmic 500, pseudogene","metadata":null},{"id":"bbd64e3581cd42e0a6fe65cfa0f8745c","type":"GENE","name":"RN7SL502P","canonical_id":"hgnc:HGNC:46518","description":"RNA, 7SL, cytoplasmic 502, pseudogene","metadata":null},{"id":"ea697c08bf664cc4afb29d0d35aa3219","type":"GENE","name":"RN7SL503P","canonical_id":"hgnc:HGNC:46519","description":"RNA, 7SL, cytoplasmic 503, pseudogene","metadata":null},{"id":"f99dc61a21784c49a0e7efb7ddca220c","type":"GENE","name":"RN7SL504P","canonical_id":"hgnc:HGNC:46520","description":"RNA, 7SL, cytoplasmic 504, pseudogene","metadata":null},{"id":"fb2e39829c6148a384ef1cd67fa52036","type":"GENE","name":"RN7SL505P","canonical_id":"hgnc:HGNC:46521","description":"RNA, 7SL, cytoplasmic 505, pseudogene","metadata":null},{"id":"ee4012dee92f4dd2b5ef215b8754d4a2","type":"GENE","name":"RN7SL507P","canonical_id":"hgnc:HGNC:46523","description":"RNA, 7SL, cytoplasmic 507, pseudogene","metadata":null},{"id":"43a1298593fc429180ecc5cec42535a6","type":"GENE","name":"RN7SL508P","canonical_id":"hgnc:HGNC:46524","description":"RNA, 7SL, cytoplasmic 508, pseudogene","metadata":null},{"id":"a54e6ccc2af54d719fd6684cedc98eca","type":"GENE","name":"RN7SL509P","canonical_id":"hgnc:HGNC:46525","description":"RNA, 7SL, cytoplasmic 509, pseudogene","metadata":null},{"id":"2ee9554f145f4fa38de24b686fd5da6f","type":"GENE","name":"RN7SL50P","canonical_id":"hgnc:HGNC:46066","description":"RNA, 7SL, cytoplasmic 50, pseudogene","metadata":null},{"id":"57ddc17af7c344ebbbe336ed4cb7cdbb","type":"GENE","name":"RN7SL510P","canonical_id":"hgnc:HGNC:46526","description":"RNA, 7SL, cytoplasmic 510, pseudogene","metadata":null},{"id":"7ff9bb796426432696f8252b71ab552c","type":"GENE","name":"RN7SL513P","canonical_id":"hgnc:HGNC:46529","description":"RNA, 7SL, cytoplasmic 513, pseudogene","metadata":null},{"id":"321370d9d19e4b69ab79d69990bd190b","type":"GENE","name":"RN7SL515P","canonical_id":"hgnc:HGNC:46531","description":"RNA, 7SL, cytoplasmic 515, pseudogene","metadata":null},{"id":"874a29ef592b4b71b97253634cc5a282","type":"GENE","name":"RN7SL516P","canonical_id":"hgnc:HGNC:46532","description":"RNA, 7SL, cytoplasmic 516, pseudogene","metadata":null},{"id":"f81052b9e5884f3e82519035c3d95396","type":"GENE","name":"RN7SL517P","canonical_id":"hgnc:HGNC:46533","description":"RNA, 7SL, cytoplasmic 517, pseudogene","metadata":null},{"id":"b7ac74ca16d74a7d8345e7739fba8150","type":"GENE","name":"RN7SL518P","canonical_id":"hgnc:HGNC:46534","description":"RNA, 7SL, cytoplasmic 518, pseudogene","metadata":null},{"id":"a47739c0b5d44c5bb182d8f5df50fb1b","type":"GENE","name":"RN7SL519P","canonical_id":"hgnc:HGNC:46535","description":"RNA, 7SL, cytoplasmic 519, pseudogene","metadata":null},{"id":"0e71e3bd68134327b85157cfa1c34d71","type":"GENE","name":"RN7SL51P","canonical_id":"hgnc:HGNC:46067","description":"RNA, 7SL, cytoplasmic 51, pseudogene","metadata":null},{"id":"1cd4b595ab164c8fa769bf6cef1d8bb9","type":"GENE","name":"RN7SL520P","canonical_id":"hgnc:HGNC:46536","description":"RNA, 7SL, cytoplasmic 520, pseudogene","metadata":null},{"id":"62859df20a854b9ba39c64a856b38264","type":"GENE","name":"RN7SL521P","canonical_id":"hgnc:HGNC:46537","description":"RNA, 7SL, cytoplasmic 521, pseudogene","metadata":null},{"id":"9f2257ff1f254e03a5253fde94fe4fbc","type":"GENE","name":"RN7SL523P","canonical_id":"hgnc:HGNC:46539","description":"RNA, 7SL, cytoplasmic 523, pseudogene","metadata":null},{"id":"bc5ef2a4d11c422bb2d305c0b8e590a9","type":"GENE","name":"RN7SL524P","canonical_id":"hgnc:HGNC:46540","description":"RNA, 7SL, cytoplasmic 524, pseudogene","metadata":null},{"id":"5bba960d0828402e990c89796feacde7","type":"GENE","name":"RN7SL525P","canonical_id":"hgnc:HGNC:46541","description":"RNA, 7SL, cytoplasmic 525, pseudogene","metadata":null},{"id":"7a74c1c86eaa4ac1a77cab61ae23e305","type":"GENE","name":"RN7SL526P","canonical_id":"hgnc:HGNC:46542","description":"RNA, 7SL, cytoplasmic 526, pseudogene","metadata":null},{"id":"40c12f921bd649dc84316493b2fcd97e","type":"GENE","name":"RN7SL52P","canonical_id":"hgnc:HGNC:46068","description":"RNA, 7SL, cytoplasmic 52, pseudogene","metadata":null},{"id":"aa21969834c64c3db196ee3e50d790b2","type":"GENE","name":"RN7SL530P","canonical_id":"hgnc:HGNC:46546","description":"RNA, 7SL, cytoplasmic 530, pseudogene","metadata":null},{"id":"30bb184484494de7b94ddfea63b21fa1","type":"GENE","name":"RN7SL531P","canonical_id":"hgnc:HGNC:46547","description":"RNA, 7SL, cytoplasmic 531, pseudogene","metadata":null},{"id":"4a97a618c58f4f9a8608874241ebc017","type":"GENE","name":"RN7SL535P","canonical_id":"hgnc:HGNC:46551","description":"RNA, 7SL, cytoplasmic 535, pseudogene","metadata":null},{"id":"c0996d73cc914d1cbf074aedc8758871","type":"GENE","name":"RN7SL536P","canonical_id":"hgnc:HGNC:46552","description":"RNA, 7SL, cytoplasmic 536, pseudogene","metadata":null},{"id":"e9046cd24bd44808b9c1d5ccc77cdec1","type":"GENE","name":"RN7SL538P","canonical_id":"hgnc:HGNC:46554","description":"RNA, 7SL, cytoplasmic 538, pseudogene","metadata":null},{"id":"caa4a83857004d519bb0590ab304dcd7","type":"GENE","name":"RN7SL539P","canonical_id":"hgnc:HGNC:46555","description":"RNA, 7SL, cytoplasmic 539, pseudogene","metadata":null},{"id":"c0eb40b2c4834861ade2340c3977db72","type":"GENE","name":"RN7SL541P","canonical_id":"hgnc:HGNC:46557","description":"RNA, 7SL, cytoplasmic 541, pseudogene","metadata":null},{"id":"f5fff49001b8452189eb2cb9e94e0a66","type":"GENE","name":"RN7SL542P","canonical_id":"hgnc:HGNC:46558","description":"RNA, 7SL, cytoplasmic 542, pseudogene","metadata":null},{"id":"3f3715e671cc484c91586bd17f332de1","type":"GENE","name":"RN7SL543P","canonical_id":"hgnc:HGNC:46559","description":"RNA, 7SL, cytoplasmic 543, pseudogene","metadata":null},{"id":"89f0eb5778704767bb28dd086503259e","type":"GENE","name":"RN7SL544P","canonical_id":"hgnc:HGNC:46560","description":"RNA, 7SL, cytoplasmic 544, pseudogene","metadata":null},{"id":"9009b683469941d79a3c93b06aacf91d","type":"GENE","name":"RN7SL545P","canonical_id":"hgnc:HGNC:46561","description":"RNA, 7SL, cytoplasmic 545, pseudogene","metadata":null},{"id":"4c5b5f26a9ac4dc88f0f932f998241ad","type":"GENE","name":"RN7SL546P","canonical_id":"hgnc:HGNC:46562","description":"RNA, 7SL, cytoplasmic 546, pseudogene","metadata":null},{"id":"902ebb3427374d9ba9763b6d880a8bf9","type":"GENE","name":"RN7SL547P","canonical_id":"hgnc:HGNC:46563","description":"RNA, 7SL, cytoplasmic 547, pseudogene","metadata":null},{"id":"a373b51f65934f04a0e054439511e345","type":"GENE","name":"RN7SL549P","canonical_id":"hgnc:HGNC:46565","description":"RNA, 7SL, cytoplasmic 549, pseudogene","metadata":null},{"id":"e53bdf1cafa44caa91486959016ca8c3","type":"GENE","name":"RN7SL551P","canonical_id":"hgnc:HGNC:46567","description":"RNA, 7SL, cytoplasmic 551, pseudogene","metadata":null},{"id":"ff0806a18de84ddca6014e0f376c0f02","type":"GENE","name":"RN7SL552P","canonical_id":"hgnc:HGNC:46568","description":"RNA, 7SL, cytoplasmic 552, pseudogene","metadata":null},{"id":"ea396d3d75284f95b9edd35362414231","type":"GENE","name":"RN7SL553P","canonical_id":"hgnc:HGNC:46569","description":"RNA, 7SL, cytoplasmic 553, pseudogene","metadata":null},{"id":"7b469e11857945239047714199727b2d","type":"GENE","name":"RN7SL554P","canonical_id":"hgnc:HGNC:46570","description":"RNA, 7SL, cytoplasmic 554, pseudogene","metadata":null},{"id":"150787bb430f4f80ab3bc62b6c4d9dba","type":"GENE","name":"RN7SL555P","canonical_id":"hgnc:HGNC:46571","description":"RNA, 7SL, cytoplasmic 555, pseudogene","metadata":null},{"id":"e2fc04bd20514bd09c8f4a8f65925597","type":"GENE","name":"RN7SL556P","canonical_id":"hgnc:HGNC:46572","description":"RNA, 7SL, cytoplasmic 556, pseudogene","metadata":null},{"id":"6df031cca13c48aa87f115d76412c65a","type":"GENE","name":"RN7SL557P","canonical_id":"hgnc:HGNC:46573","description":"RNA, 7SL, cytoplasmic 557, pseudogene","metadata":null},{"id":"2ff1db11f70f40a0b0b1d71f80d435ed","type":"GENE","name":"RN7SL558P","canonical_id":"hgnc:HGNC:46574","description":"RNA, 7SL, cytoplasmic 558, pseudogene","metadata":null},{"id":"bbb26ecdea214a91a5a753a2ee88f671","type":"GENE","name":"RN7SL559P","canonical_id":"hgnc:HGNC:46575","description":"RNA, 7SL, cytoplasmic 559, pseudogene","metadata":null},{"id":"ed2857b5bd5f4e749f97397e46d964cf","type":"GENE","name":"RN7SL55P","canonical_id":"hgnc:HGNC:46071","description":"RNA, 7SL, cytoplasmic 55, pseudogene","metadata":null},{"id":"74142ca1a6ac4cd9ad9945eb18f5c2ba","type":"GENE","name":"RN7SL560P","canonical_id":"hgnc:HGNC:46576","description":"RNA, 7SL, cytoplasmic 560, pseudogene","metadata":null},{"id":"9a4f10edb46148cca85667acc245af83","type":"GENE","name":"RN7SL561P","canonical_id":"hgnc:HGNC:46577","description":"RNA, 7SL, cytoplasmic 561, pseudogene","metadata":null},{"id":"3230dc75ff5a49718929f9260ecb0e7e","type":"GENE","name":"RN7SL563P","canonical_id":"hgnc:HGNC:46579","description":"RNA, 7SL, cytoplasmic 563, pseudogene","metadata":null},{"id":"e496277d55524fff980accfe7907925c","type":"GENE","name":"RN7SL564P","canonical_id":"hgnc:HGNC:46580","description":"RNA, 7SL, cytoplasmic 564, pseudogene","metadata":null},{"id":"5f23a3ba3c614c87afcd9bcac643b533","type":"GENE","name":"RN7SL565P","canonical_id":"hgnc:HGNC:46581","description":"RNA, 7SL, cytoplasmic 565, pseudogene","metadata":null},{"id":"61d80bd4fb4f438eb6f46e952f90b648","type":"GENE","name":"RN7SL566P","canonical_id":"hgnc:HGNC:46582","description":"RNA, 7SL, cytoplasmic 566, pseudogene","metadata":null},{"id":"8406d8f8c8f84dad9be331e17a4952e3","type":"GENE","name":"RN7SL567P","canonical_id":"hgnc:HGNC:46583","description":"RNA, 7SL, cytoplasmic 567, pseudogene","metadata":null},{"id":"991f9670f3594484ae756758f8919ceb","type":"GENE","name":"RN7SL568P","canonical_id":"hgnc:HGNC:46584","description":"RNA, 7SL, cytoplasmic 568, pseudogene","metadata":null},{"id":"af510a90c5c641f6a722ca6b60f2bf74","type":"GENE","name":"RN7SL569P","canonical_id":"hgnc:HGNC:46585","description":"RNA, 7SL, cytoplasmic 569, pseudogene","metadata":null},{"id":"c0839d326410424e89c103cafd2fcb1f","type":"GENE","name":"RN7SL570P","canonical_id":"hgnc:HGNC:46586","description":"RNA, 7SL, cytoplasmic 570, pseudogene","metadata":null},{"id":"e2437ae09a304ee7a72d53daa0f08a65","type":"GENE","name":"RN7SL571P","canonical_id":"hgnc:HGNC:46587","description":"RNA, 7SL, cytoplasmic 571, pseudogene","metadata":null},{"id":"ca874efc8a284b298d717e1b321aa065","type":"GENE","name":"RN7SL573P","canonical_id":"hgnc:HGNC:46589","description":"RNA, 7SL, cytoplasmic 573, pseudogene","metadata":null},{"id":"a4364e4bc81e4fc3952b6d3d80dadca4","type":"GENE","name":"RN7SL574P","canonical_id":"hgnc:HGNC:46590","description":"RNA, 7SL, cytoplasmic 574, pseudogene","metadata":null},{"id":"6c70ed5d0394479083a5f37361a4df64","type":"GENE","name":"RN7SL575P","canonical_id":"hgnc:HGNC:46591","description":"RNA, 7SL, cytoplasmic 575, pseudogene","metadata":null},{"id":"7bf72d147f8b4659b12c9119e54c9038","type":"GENE","name":"RN7SL577P","canonical_id":"hgnc:HGNC:46593","description":"RNA, 7SL, cytoplasmic 577, pseudogene","metadata":null},{"id":"3906bf14d9984d93a904668189ab65cc","type":"GENE","name":"RN7SL578P","canonical_id":"hgnc:HGNC:46594","description":"RNA, 7SL, cytoplasmic 578, pseudogene","metadata":null},{"id":"58bab8bfe08e4f58a87f5c4f77ae2590","type":"GENE","name":"RN7SL57P","canonical_id":"hgnc:HGNC:46073","description":"RNA, 7SL, cytoplasmic 57, pseudogene","metadata":null},{"id":"0d13f4ef866d479687408b82a319507d","type":"GENE","name":"RN7SL580P","canonical_id":"hgnc:HGNC:46596","description":"RNA, 7SL, cytoplasmic 580, pseudogene","metadata":null},{"id":"ed2e634763b043428c9f7c974f4b8d65","type":"GENE","name":"RN7SL581P","canonical_id":"hgnc:HGNC:46597","description":"RNA, 7SL, cytoplasmic 581, pseudogene","metadata":null},{"id":"82b4ddcdf85d401596c5fe2a40edaf33","type":"GENE","name":"RN7SL582P","canonical_id":"hgnc:HGNC:46598","description":"RNA, 7SL, cytoplasmic 582, pseudogene","metadata":null},{"id":"ba64606da7ce47beb531735cca9d4132","type":"GENE","name":"RN7SL583P","canonical_id":"hgnc:HGNC:46599","description":"RNA, 7SL, cytoplasmic 583, pseudogene","metadata":null},{"id":"7dd9559f1cf24c93ae969d8150d0e4b4","type":"GENE","name":"RN7SL584P","canonical_id":"hgnc:HGNC:46600","description":"RNA, 7SL, cytoplasmic 584, pseudogene","metadata":null},{"id":"068a207b7bf64401817a0317a381ecf5","type":"GENE","name":"RN7SL585P","canonical_id":"hgnc:HGNC:46601","description":"RNA, 7SL, cytoplasmic 585, pseudogene","metadata":null},{"id":"92ed06289a274795adb8781908d918a3","type":"GENE","name":"RN7SL586P","canonical_id":"hgnc:HGNC:46602","description":"RNA, 7SL, cytoplasmic 586, pseudogene","metadata":null},{"id":"d18402e167154962b7425c0034113fe3","type":"GENE","name":"RN7SL587P","canonical_id":"hgnc:HGNC:46603","description":"RNA, 7SL, cytoplasmic 587, pseudogene","metadata":null},{"id":"0e1128348ec9432a8ec1cfb958ced0b2","type":"GENE","name":"RN7SL589P","canonical_id":"hgnc:HGNC:46605","description":"RNA, 7SL, cytoplasmic 589, pseudogene","metadata":null},{"id":"a803592babeb48538ca4d319dc3a1ecb","type":"GENE","name":"RN7SL58P","canonical_id":"hgnc:HGNC:46074","description":"RNA, 7SL, cytoplasmic 58, pseudogene","metadata":null},{"id":"b4e6a49d531b45e9a4d082b317d724f5","type":"GENE","name":"RN7SL591P","canonical_id":"hgnc:HGNC:46607","description":"RNA, 7SL, cytoplasmic 591, pseudogene","metadata":null},{"id":"9c9252add0d144deb8f03cfe9c35038e","type":"GENE","name":"RN7SL592P","canonical_id":"hgnc:HGNC:46608","description":"RNA, 7SL, cytoplasmic 592, pseudogene","metadata":null},{"id":"3b2a245809834d73929d9ae45273eaf7","type":"GENE","name":"RN7SL594P","canonical_id":"hgnc:HGNC:46610","description":"RNA, 7SL, cytoplasmic 594, pseudogene","metadata":null},{"id":"384e53ecae0e43279d7754930f7a736b","type":"GENE","name":"RN7SL596P","canonical_id":"hgnc:HGNC:46612","description":"RNA, 7SL, cytoplasmic 596, pseudogene","metadata":null},{"id":"aea54f58be6b485bacc0b166b36050de","type":"GENE","name":"RN7SL597P","canonical_id":"hgnc:HGNC:46613","description":"RNA, 7SL, cytoplasmic 597, pseudogene","metadata":null},{"id":"c6cf9706699440c8ac21743840a714d9","type":"GENE","name":"RN7SL598P","canonical_id":"hgnc:HGNC:46614","description":"RNA, 7SL, cytoplasmic 598, pseudogene","metadata":null},{"id":"5f704722e8ff464b96203904a9bf2eba","type":"GENE","name":"RN7SL5P","canonical_id":"hgnc:HGNC:10040","description":"RNA, 7SL, cytoplasmic 5, pseudogene","metadata":{"aliases":["7LEM1","RN7SLP2","RN7SL249P"]}},{"id":"bab69b8df72f4c42a9a04e6c2ed6ca32","type":"GENE","name":"RN7SL600P","canonical_id":"hgnc:HGNC:46616","description":"RNA, 7SL, cytoplasmic 600, pseudogene","metadata":null},{"id":"9aa5a791952d40ef938fd80e17fc9f9d","type":"GENE","name":"RN7SL601P","canonical_id":"hgnc:HGNC:46617","description":"RNA, 7SL, cytoplasmic 601, pseudogene","metadata":null},{"id":"8240679c9f864f5ab1ec508b82bb196e","type":"GENE","name":"RN7SL602P","canonical_id":"hgnc:HGNC:46618","description":"RNA, 7SL, cytoplasmic 602, pseudogene","metadata":null},{"id":"9a62397cab0b46aca975071f935afcad","type":"GENE","name":"RN7SL604P","canonical_id":"hgnc:HGNC:46620","description":"RNA, 7SL, cytoplasmic 604, pseudogene","metadata":null},{"id":"de17517b737942938406c2526af577d8","type":"GENE","name":"RN7SL605P","canonical_id":"hgnc:HGNC:46621","description":"RNA, 7SL, cytoplasmic 605, pseudogene","metadata":null},{"id":"e74d3ca2f7fa47f18bf6448d312ce486","type":"GENE","name":"RN7SL606P","canonical_id":"hgnc:HGNC:46622","description":"RNA, 7SL, cytoplasmic 606, pseudogene","metadata":null},{"id":"3ef11079804b43d18005a3de2d2c24e1","type":"GENE","name":"RN7SL607P","canonical_id":"hgnc:HGNC:46623","description":"RNA, 7SL, cytoplasmic 607, pseudogene","metadata":null},{"id":"03e39ffca4b94f98aae9015e90638179","type":"GENE","name":"RN7SL608P","canonical_id":"hgnc:HGNC:46624","description":"RNA, 7SL, cytoplasmic 608, pseudogene","metadata":null},{"id":"a6256fb672a74e3680305c1653a84fbf","type":"GENE","name":"RN7SL60P","canonical_id":"hgnc:HGNC:46076","description":"RNA, 7SL, cytoplasmic 60, pseudogene","metadata":null},{"id":"63df776bdfe24880a332c0cb2a6d4f04","type":"GENE","name":"RN7SL610P","canonical_id":"hgnc:HGNC:46626","description":"RNA, 7SL, cytoplasmic 610, pseudogene","metadata":null},{"id":"963e005c8c044b6d9e30c019319aa989","type":"GENE","name":"RN7SL612P","canonical_id":"hgnc:HGNC:46628","description":"RNA, 7SL, cytoplasmic 612, pseudogene","metadata":null},{"id":"8d8c381be77a45079bbde81581d51412","type":"GENE","name":"RN7SL614P","canonical_id":"hgnc:HGNC:46630","description":"RNA, 7SL, cytoplasmic 614, pseudogene","metadata":null},{"id":"05b06fb143084132aefe2c426721d639","type":"GENE","name":"RN7SL615P","canonical_id":"hgnc:HGNC:46631","description":"RNA, 7SL, cytoplasmic 615, pseudogene","metadata":null},{"id":"884ff5562ba04160b72e39ae4ee4ed2d","type":"GENE","name":"RN7SL616P","canonical_id":"hgnc:HGNC:46632","description":"RNA, 7SL, cytoplasmic 616, pseudogene","metadata":null},{"id":"ad09c5247e9e479f9fd77939e4485a3d","type":"GENE","name":"RN7SL617P","canonical_id":"hgnc:HGNC:46633","description":"RNA, 7SL, cytoplasmic 617, pseudogene","metadata":null},{"id":"5862a595be9d41149ff52f152ba1dc62","type":"GENE","name":"RN7SL618P","canonical_id":"hgnc:HGNC:46634","description":"RNA, 7SL, cytoplasmic 618, pseudogene","metadata":null},{"id":"6fad2c20a4de4a10934f5f9d0848a364","type":"GENE","name":"RN7SL619P","canonical_id":"hgnc:HGNC:46635","description":"RNA, 7SL, cytoplasmic 619, pseudogene","metadata":null},{"id":"96968bc64a364e1a83096b2dbd82bea2","type":"GENE","name":"RN7SL620P","canonical_id":"hgnc:HGNC:46636","description":"RNA, 7SL, cytoplasmic 620, pseudogene","metadata":null},{"id":"57015f48548344b7899c4f89cdeca38e","type":"GENE","name":"RN7SL621P","canonical_id":"hgnc:HGNC:46637","description":"RNA, 7SL, cytoplasmic 621, pseudogene","metadata":null},{"id":"115780fc6fab418db0f215cf84084823","type":"GENE","name":"RN7SL622P","canonical_id":"hgnc:HGNC:46638","description":"RNA, 7SL, cytoplasmic 622, pseudogene","metadata":null},{"id":"a6b5cc0d58ce4792a85c3ebbf4f4800a","type":"GENE","name":"RN7SL623P","canonical_id":"hgnc:HGNC:46639","description":"RNA, 7SL, cytoplasmic 623, pseudogene","metadata":null},{"id":"a065d331d7ea4e9e81aa7d83ba4f220f","type":"GENE","name":"RN7SL624P","canonical_id":"hgnc:HGNC:46640","description":"RNA, 7SL, cytoplasmic 624, pseudogene","metadata":null},{"id":"229e1776de314edc87e3147e37db4926","type":"GENE","name":"RN7SL625P","canonical_id":"hgnc:HGNC:46641","description":"RNA, 7SL, cytoplasmic 625, pseudogene","metadata":null},{"id":"164914b1b39840ca9d2e753997be4a0c","type":"GENE","name":"RN7SL627P","canonical_id":"hgnc:HGNC:46643","description":"RNA, 7SL, cytoplasmic 627, pseudogene","metadata":null},{"id":"8afe4f20124b4b5faa7e884be5a391b8","type":"GENE","name":"RN7SL628P","canonical_id":"hgnc:HGNC:46644","description":"RNA, 7SL, cytoplasmic 628, pseudogene","metadata":null},{"id":"638add67ecf94235a940306ae7ee9ceb","type":"GENE","name":"RN7SL629P","canonical_id":"hgnc:HGNC:46645","description":"RNA, 7SL, cytoplasmic 629, pseudogene","metadata":null},{"id":"b04b29d625d34081bcdde426942edb8b","type":"GENE","name":"RN7SL62P","canonical_id":"hgnc:HGNC:46078","description":"RNA, 7SL, cytoplasmic 62, pseudogene","metadata":null},{"id":"cdb1c097699e4092a37e094d199e883c","type":"GENE","name":"RN7SL630P","canonical_id":"hgnc:HGNC:46646","description":"RNA, 7SL, cytoplasmic 630, pseudogene","metadata":null},{"id":"4c5a5234bc2141c3bb393b776c421b97","type":"GENE","name":"RN7SL632P","canonical_id":"hgnc:HGNC:46648","description":"RNA, 7SL, cytoplasmic 632, pseudogene","metadata":null},{"id":"afd459dbe973438bb1086c95151e4476","type":"GENE","name":"RN7SL633P","canonical_id":"hgnc:HGNC:46649","description":"RNA, 7SL, cytoplasmic 633, pseudogene","metadata":null},{"id":"7c0000283cdf473994fb3c0e78d9a7d1","type":"GENE","name":"RN7SL634P","canonical_id":"hgnc:HGNC:46650","description":"RNA, 7SL, cytoplasmic 634, pseudogene","metadata":null},{"id":"48de2da51b9c414eaf522faf88dfde04","type":"GENE","name":"RN7SL635P","canonical_id":"hgnc:HGNC:46651","description":"RNA, 7SL, cytoplasmic 635, pseudogene","metadata":null},{"id":"34d47e7c2ee94dfda60bd36688de6285","type":"GENE","name":"RN7SL636P","canonical_id":"hgnc:HGNC:46652","description":"RNA, 7SL, cytoplasmic 636, pseudogene","metadata":null},{"id":"65e0a614a79241cbb277cfdbbba8b1fe","type":"GENE","name":"RN7SL638P","canonical_id":"hgnc:HGNC:46654","description":"RNA, 7SL, cytoplasmic 638, pseudogene","metadata":null},{"id":"1d1cbb4ef5254e12977ca88df63bef48","type":"GENE","name":"RN7SL63P","canonical_id":"hgnc:HGNC:46079","description":"RNA, 7SL, cytoplasmic 63, pseudogene","metadata":null},{"id":"ad935c2da4a34b53bd65059f674924fc","type":"GENE","name":"RN7SL640P","canonical_id":"hgnc:HGNC:46656","description":"RNA, 7SL, cytoplasmic 640, pseudogene","metadata":null},{"id":"a9e93fae2e7945fb9315cf1d554d3443","type":"GENE","name":"RN7SL643P","canonical_id":"hgnc:HGNC:46659","description":"RNA, 7SL, cytoplasmic 643, pseudogene","metadata":null},{"id":"71ba3579b427478f88caacd79b32de88","type":"GENE","name":"RN7SL644P","canonical_id":"hgnc:HGNC:46660","description":"RNA, 7SL, cytoplasmic 644, pseudogene","metadata":null},{"id":"eacd9aec9ee74b578d15fca4effff31a","type":"GENE","name":"RN7SL645P","canonical_id":"hgnc:HGNC:46661","description":"RNA, 7SL, cytoplasmic 645, pseudogene","metadata":null},{"id":"85650b7b6f00474cb8051c9af0d28587","type":"GENE","name":"RN7SL646P","canonical_id":"hgnc:HGNC:46662","description":"RNA, 7SL, cytoplasmic 646, pseudogene","metadata":null},{"id":"2d09ce6a4f114cfe8c3997a684842d95","type":"GENE","name":"RN7SL647P","canonical_id":"hgnc:HGNC:46663","description":"RNA, 7SL, cytoplasmic 647, pseudogene","metadata":null},{"id":"5aa3d5ffef0e42769bb200814501415d","type":"GENE","name":"RN7SL648P","canonical_id":"hgnc:HGNC:46664","description":"RNA, 7SL, cytoplasmic 648, pseudogene","metadata":null},{"id":"601297ab20b74ba5aa482f2e23a69706","type":"GENE","name":"RN7SL649P","canonical_id":"hgnc:HGNC:46665","description":"RNA, 7SL, cytoplasmic 649, pseudogene","metadata":null},{"id":"fec850caf7714071b498583f6f30409f","type":"GENE","name":"RN7SL650P","canonical_id":"hgnc:HGNC:46666","description":"RNA, 7SL, cytoplasmic 650, pseudogene","metadata":null},{"id":"2d3a9313700a47349d846a7687a28c7e","type":"GENE","name":"RN7SL652P","canonical_id":"hgnc:HGNC:46668","description":"RNA, 7SL, cytoplasmic 652, pseudogene","metadata":null},{"id":"142d3efc4fc146e899d61146feab9af7","type":"GENE","name":"RN7SL653P","canonical_id":"hgnc:HGNC:46669","description":"RNA, 7SL, cytoplasmic 653, pseudogene","metadata":null},{"id":"b5b2ad5a44e44d6bacfd487151663b9e","type":"GENE","name":"RN7SL654P","canonical_id":"hgnc:HGNC:46670","description":"RNA, 7SL, cytoplasmic 654, pseudogene","metadata":null},{"id":"188d24c6d02c4c43a6af281ed4f8bf53","type":"GENE","name":"RN7SL655P","canonical_id":"hgnc:HGNC:46671","description":"RNA, 7SL, cytoplasmic 655, pseudogene","metadata":null},{"id":"1935a32a433e48cf97eae56b9eb87d7c","type":"GENE","name":"RN7SL656P","canonical_id":"hgnc:HGNC:46672","description":"RNA, 7SL, cytoplasmic 656, pseudogene","metadata":null},{"id":"8857076e447145498f37166988a8664c","type":"GENE","name":"RN7SL657P","canonical_id":"hgnc:HGNC:46673","description":"RNA, 7SL, cytoplasmic 657, pseudogene","metadata":null},{"id":"a54bed87758e4e8fa2e1b98df3ac1c3a","type":"GENE","name":"RN7SL658P","canonical_id":"hgnc:HGNC:46674","description":"RNA, 7SL, cytoplasmic 658, pseudogene","metadata":null},{"id":"1eb3fa4c5ab94fe2b4bb12861b9283d3","type":"GENE","name":"RN7SL659P","canonical_id":"hgnc:HGNC:46675","description":"RNA, 7SL, cytoplasmic 659, pseudogene","metadata":null},{"id":"b6bdc98a5d0a4585918fd0cd46bb5678","type":"GENE","name":"RN7SL65P","canonical_id":"hgnc:HGNC:46081","description":"RNA, 7SL, cytoplasmic 65, pseudogene","metadata":null},{"id":"369edaac6f07456eb913150a66d3de9a","type":"GENE","name":"RN7SL660P","canonical_id":"hgnc:HGNC:46676","description":"RNA, 7SL, cytoplasmic 660, pseudogene","metadata":null},{"id":"8fbcdea92a3c40abbce57d14783420b6","type":"GENE","name":"RN7SL663P","canonical_id":"hgnc:HGNC:46679","description":"RNA, 7SL, cytoplasmic 663, pseudogene","metadata":null},{"id":"d1be1143db0b4f138c09fe15c37c1209","type":"GENE","name":"RN7SL664P","canonical_id":"hgnc:HGNC:46680","description":"RNA, 7SL, cytoplasmic 664, pseudogene","metadata":null},{"id":"2d1b85ee5576422db8121a20f0db6396","type":"GENE","name":"RN7SL665P","canonical_id":"hgnc:HGNC:46681","description":"RNA, 7SL, cytoplasmic 665, pseudogene","metadata":null},{"id":"f0ddb7d140414fb79df1b115391a5d06","type":"GENE","name":"RN7SL666P","canonical_id":"hgnc:HGNC:46682","description":"RNA, 7SL, cytoplasmic 666, pseudogene","metadata":null},{"id":"4b50b82c09d24ac486c392a891fa05c7","type":"GENE","name":"RN7SL667P","canonical_id":"hgnc:HGNC:46683","description":"RNA, 7SL, cytoplasmic 667, pseudogene","metadata":null},{"id":"47071af81bd54f1bba09f57327eba00b","type":"GENE","name":"RN7SL668P","canonical_id":"hgnc:HGNC:46684","description":"RNA, 7SL, cytoplasmic 668, pseudogene","metadata":null},{"id":"24a803b0bb29425e996149f4dec65caa","type":"GENE","name":"RN7SL66P","canonical_id":"hgnc:HGNC:46082","description":"RNA, 7SL, cytoplasmic 66, pseudogene","metadata":null},{"id":"b653316b38714d8ea98ab027e84b7c51","type":"GENE","name":"RN7SL670P","canonical_id":"hgnc:HGNC:46686","description":"RNA, 7SL, cytoplasmic 670, pseudogene","metadata":null},{"id":"3da30177498f468686a309be3daa34b6","type":"GENE","name":"RN7SL671P","canonical_id":"hgnc:HGNC:46687","description":"RNA, 7SL, cytoplasmic 671, pseudogene","metadata":null},{"id":"86b406943e674265b2ba454f98886cd7","type":"GENE","name":"RN7SL672P","canonical_id":"hgnc:HGNC:46688","description":"RNA, 7SL, cytoplasmic 672, pseudogene","metadata":null},{"id":"7f1e2f25d5d54495b441fc31077f5449","type":"GENE","name":"RN7SL673P","canonical_id":"hgnc:HGNC:46689","description":"RNA, 7SL, cytoplasmic 673, pseudogene","metadata":null},{"id":"ca71b0d5d1ea4a4592c9646b47c370c9","type":"GENE","name":"RN7SL674P","canonical_id":"hgnc:HGNC:46690","description":"RNA, 7SL, cytoplasmic 674, pseudogene","metadata":null},{"id":"0b8bc50ab4a841b2afde442ccf7696b2","type":"GENE","name":"RN7SL675P","canonical_id":"hgnc:HGNC:46691","description":"RNA, 7SL, cytoplasmic 675, pseudogene","metadata":null},{"id":"bf7fa9b445464efb87610ae15569ecf5","type":"GENE","name":"RN7SL676P","canonical_id":"hgnc:HGNC:46692","description":"RNA, 7SL, cytoplasmic 676, pseudogene","metadata":null},{"id":"ae5db4200821481781bedf571e27f50c","type":"GENE","name":"RN7SL677P","canonical_id":"hgnc:HGNC:46693","description":"RNA, 7SL, cytoplasmic 677, pseudogene","metadata":null},{"id":"98cb5f361e4d4b24b58229d191069b39","type":"GENE","name":"RN7SL678P","canonical_id":"hgnc:HGNC:46694","description":"RNA, 7SL, cytoplasmic 678, pseudogene","metadata":null},{"id":"d33bb7733b664a4390041e2d1792d6a1","type":"GENE","name":"RN7SL679P","canonical_id":"hgnc:HGNC:46695","description":"RNA, 7SL, cytoplasmic 679, pseudogene","metadata":null},{"id":"fcacb27fc47f40a2adf50ffd297b2b03","type":"GENE","name":"RN7SL67P","canonical_id":"hgnc:HGNC:46083","description":"RNA, 7SL, cytoplasmic 67, pseudogene","metadata":null},{"id":"0e9e2fe5299d4e079aff430299483bf7","type":"GENE","name":"RN7SL680P","canonical_id":"hgnc:HGNC:46696","description":"RNA, 7SL, cytoplasmic 680, pseudogene","metadata":null},{"id":"aefb94b4220f4c398990b3992d948dab","type":"GENE","name":"RN7SL681P","canonical_id":"hgnc:HGNC:46697","description":"RNA, 7SL, cytoplasmic 681, pseudogene","metadata":null},{"id":"c3d975e6ebc0434fba5d27bafb9fe5ae","type":"GENE","name":"RN7SL683P","canonical_id":"hgnc:HGNC:46699","description":"RNA, 7SL, cytoplasmic 683, pseudogene","metadata":null},{"id":"15cab61ba7a246fda8cf9f40c492b8c3","type":"GENE","name":"RN7SL684P","canonical_id":"hgnc:HGNC:46700","description":"RNA, 7SL, cytoplasmic 684, pseudogene","metadata":null},{"id":"d6031a18d2104ef48cbc5ac1e1c38b5c","type":"GENE","name":"RN7SL685P","canonical_id":"hgnc:HGNC:46701","description":"RNA, 7SL, cytoplasmic 685, pseudogene","metadata":null},{"id":"77756ce75c5a417ca3b5240eba0a2733","type":"GENE","name":"RN7SL687P","canonical_id":"hgnc:HGNC:46703","description":"RNA, 7SL, cytoplasmic 687, pseudogene","metadata":null},{"id":"5c9fa620dd1543399a534dbecda20764","type":"GENE","name":"RN7SL688P","canonical_id":"hgnc:HGNC:46704","description":"RNA, 7SL, cytoplasmic 688, pseudogene","metadata":null},{"id":"6a4128dab38d4a459ee5884febe40731","type":"GENE","name":"RN7SL689P","canonical_id":"hgnc:HGNC:46705","description":"RNA, 7SL, cytoplasmic 689, pseudogene","metadata":null},{"id":"83f3a3f6aadb4df1b3a44f531c360026","type":"GENE","name":"RN7SL68P","canonical_id":"hgnc:HGNC:46084","description":"RNA, 7SL, cytoplasmic 68, pseudogene","metadata":null},{"id":"89da521e39f54302b19497313571f196","type":"GENE","name":"RN7SL690P","canonical_id":"hgnc:HGNC:46706","description":"RNA, 7SL, cytoplasmic 690, pseudogene","metadata":null},{"id":"58a362fbb7fe4a94867c56db2e04e2bb","type":"GENE","name":"RN7SL691P","canonical_id":"hgnc:HGNC:46707","description":"RNA, 7SL, cytoplasmic 691, pseudogene","metadata":null},{"id":"0694b9a647e5406ab50b761f72b49e78","type":"GENE","name":"RN7SL692P","canonical_id":"hgnc:HGNC:46708","description":"RNA, 7SL, cytoplasmic 692, pseudogene","metadata":null},{"id":"99326ab031a14fb3897b2febcbfca0a7","type":"GENE","name":"RN7SL693P","canonical_id":"hgnc:HGNC:46709","description":"RNA, 7SL, cytoplasmic 693, pseudogene","metadata":null},{"id":"180880a5866c4dc299268b30aea15c8c","type":"GENE","name":"RN7SL697P","canonical_id":"hgnc:HGNC:46713","description":"RNA, 7SL, cytoplasmic 697, pseudogene","metadata":null},{"id":"a98eff39ea7047149474486e635b0f44","type":"GENE","name":"RN7SL698P","canonical_id":"hgnc:HGNC:46714","description":"RNA, 7SL, cytoplasmic 698, pseudogene","metadata":null},{"id":"a86a4a6f2f9e403d9a0c484bb05f45aa","type":"GENE","name":"RN7SL69P","canonical_id":"hgnc:HGNC:46085","description":"RNA, 7SL, cytoplasmic 69, pseudogene","metadata":null},{"id":"f675f8ea7c73421586ae2e41072d252c","type":"GENE","name":"RN7SL6P","canonical_id":"hgnc:HGNC:10041","description":"RNA, 7SL, cytoplasmic 6, pseudogene","metadata":{"aliases":["7L7","RN7SLP3","RN7SL848P"]}},{"id":"ae92d62ec8314447aafadf7a28800d61","type":"GENE","name":"RN7SL700P","canonical_id":"hgnc:HGNC:46716","description":"RNA, 7SL, cytoplasmic 700, pseudogene","metadata":null},{"id":"14f2d5cf79b643b88a447185adfab4e1","type":"GENE","name":"RN7SL702P","canonical_id":"hgnc:HGNC:46718","description":"RNA, 7SL, cytoplasmic 702, pseudogene","metadata":null},{"id":"3177435122834bbfae6542572d4a3ca6","type":"GENE","name":"RN7SL703P","canonical_id":"hgnc:HGNC:46719","description":"RNA, 7SL, cytoplasmic 703, pseudogene","metadata":null},{"id":"0bd4eb097feb4e1581d8bfd1998a42d8","type":"GENE","name":"RN7SL704P","canonical_id":"hgnc:HGNC:46720","description":"RNA, 7SL, cytoplasmic 704, pseudogene","metadata":null},{"id":"c5b31aeeea75492eba75bbcee5f9bada","type":"GENE","name":"RN7SL705P","canonical_id":"hgnc:HGNC:46721","description":"RNA, 7SL, cytoplasmic 705, pseudogene","metadata":null},{"id":"921d03e4e5c34fe1ac55ea6c97443004","type":"GENE","name":"RN7SL706P","canonical_id":"hgnc:HGNC:46722","description":"RNA, 7SL, cytoplasmic 706, pseudogene","metadata":null},{"id":"f15c225171b9489f8329c482869e7c21","type":"GENE","name":"RN7SL708P","canonical_id":"hgnc:HGNC:46724","description":"RNA, 7SL, cytoplasmic 708, pseudogene","metadata":null},{"id":"e9a354b053fd44b596a5a51619d609cf","type":"GENE","name":"RN7SL709P","canonical_id":"hgnc:HGNC:46725","description":"RNA, 7SL, cytoplasmic 709, pseudogene","metadata":null},{"id":"f6468a5a77104ae991d95eafe6541d5d","type":"GENE","name":"RN7SL70P","canonical_id":"hgnc:HGNC:46086","description":"RNA, 7SL, cytoplasmic 70, pseudogene","metadata":null},{"id":"98d7b6fbdd1849a6b06197650974eef0","type":"GENE","name":"RN7SL711P","canonical_id":"hgnc:HGNC:46727","description":"RNA, 7SL, cytoplasmic 711, pseudogene","metadata":null},{"id":"e5542fd07a8d4ed58dd0df27a7716ef1","type":"GENE","name":"RN7SL712P","canonical_id":"hgnc:HGNC:46728","description":"RNA, 7SL, cytoplasmic 712, pseudogene","metadata":null},{"id":"3a02d6789a2e4eefa246de142bcc3814","type":"GENE","name":"RN7SL713P","canonical_id":"hgnc:HGNC:46729","description":"RNA, 7SL, cytoplasmic 713, pseudogene","metadata":null},{"id":"3264cc17a8a14587a237047a230747dc","type":"GENE","name":"RN7SL714P","canonical_id":"hgnc:HGNC:46730","description":"RNA, 7SL, cytoplasmic 714, pseudogene","metadata":null},{"id":"b0c6945b04754032b16fc9e485ee5343","type":"GENE","name":"RN7SL715P","canonical_id":"hgnc:HGNC:46731","description":"RNA, 7SL, cytoplasmic 715, pseudogene","metadata":null},{"id":"1775a825c5d5490aa2e80f9e53ec2d9a","type":"GENE","name":"RN7SL716P","canonical_id":"hgnc:HGNC:46732","description":"RNA, 7SL, cytoplasmic 716, pseudogene","metadata":null},{"id":"3625ee1e1d0b4ee6bb856fa056bc60c6","type":"GENE","name":"RN7SL717P","canonical_id":"hgnc:HGNC:46733","description":"RNA, 7SL, cytoplasmic 717, pseudogene","metadata":null},{"id":"622a6aabed734eaa9a09c831885dc7af","type":"GENE","name":"RN7SL718P","canonical_id":"hgnc:HGNC:46734","description":"RNA, 7SL, cytoplasmic 718, pseudogene","metadata":null},{"id":"b664c5a05af94d0abe4fe45095f44dfc","type":"GENE","name":"RN7SL719P","canonical_id":"hgnc:HGNC:46735","description":"RNA, 7SL, cytoplasmic 719, pseudogene","metadata":null},{"id":"fbdff22becea4be7b35f47c7970d17f3","type":"GENE","name":"RN7SL720P","canonical_id":"hgnc:HGNC:46736","description":"RNA, 7SL, cytoplasmic 720, pseudogene","metadata":null},{"id":"826b5321955a46aca79a9ed3fcba1d5a","type":"GENE","name":"RN7SL722P","canonical_id":"hgnc:HGNC:46738","description":"RNA, 7SL, cytoplasmic 722, pseudogene","metadata":null},{"id":"2d3d8eed430743fcbf899875a211297d","type":"GENE","name":"RN7SL724P","canonical_id":"hgnc:HGNC:46740","description":"RNA, 7SL, cytoplasmic 724, pseudogene","metadata":null},{"id":"24db6c2060a14bb7815620146b3b0cd8","type":"GENE","name":"RN7SL725P","canonical_id":"hgnc:HGNC:46741","description":"RNA, 7SL, cytoplasmic 725, pseudogene","metadata":null},{"id":"c1caecb4d4034daaafcb0aa968c99933","type":"GENE","name":"RN7SL726P","canonical_id":"hgnc:HGNC:46742","description":"RNA, 7SL, cytoplasmic 726, pseudogene","metadata":null},{"id":"cb378f1d90f54a86834529219f9cb326","type":"GENE","name":"RN7SL727P","canonical_id":"hgnc:HGNC:46743","description":"RNA, 7SL, cytoplasmic 727, pseudogene","metadata":null},{"id":"d4ce4abacf7d492fb6d34c2efae4ede9","type":"GENE","name":"RN7SL728P","canonical_id":"hgnc:HGNC:46744","description":"RNA, 7SL, cytoplasmic 728, pseudogene","metadata":null},{"id":"30f0dacacfdf4ea988349f8f3cc33f12","type":"GENE","name":"RN7SL72P","canonical_id":"hgnc:HGNC:46088","description":"RNA, 7SL, cytoplasmic 72, pseudogene","metadata":null},{"id":"5cab7c0de0c548378a99f9f013796c18","type":"GENE","name":"RN7SL731P","canonical_id":"hgnc:HGNC:46747","description":"RNA, 7SL, cytoplasmic 731, pseudogene","metadata":null},{"id":"958989a3c97c423f836c5a3ced268a99","type":"GENE","name":"RN7SL732P","canonical_id":"hgnc:HGNC:46748","description":"RNA, 7SL, cytoplasmic 732, pseudogene","metadata":null},{"id":"fba5f20ab5c24e8492c0dc49d92d0b50","type":"GENE","name":"RN7SL733P","canonical_id":"hgnc:HGNC:46749","description":"RNA, 7SL, cytoplasmic 733, pseudogene","metadata":null},{"id":"257ba2cd09db4dda8cdcffa19634ba70","type":"GENE","name":"RN7SL734P","canonical_id":"hgnc:HGNC:46750","description":"RNA, 7SL, cytoplasmic 734, pseudogene","metadata":null},{"id":"a71e2d75020b4d85b511b302a3230168","type":"GENE","name":"RN7SL735P","canonical_id":"hgnc:HGNC:46751","description":"RNA, 7SL, cytoplasmic 735, pseudogene","metadata":null},{"id":"13c05bdb77304800bdf593c02c7ece52","type":"GENE","name":"RN7SL736P","canonical_id":"hgnc:HGNC:46752","description":"RNA, 7SL, cytoplasmic 736, pseudogene","metadata":null},{"id":"28a17f2047c146ea87b2f210f6e11137","type":"GENE","name":"RN7SL737P","canonical_id":"hgnc:HGNC:46753","description":"RNA, 7SL, cytoplasmic 737, pseudogene","metadata":null},{"id":"4ba0ec4ac9f7457a988378e2cf4b197c","type":"GENE","name":"RN7SL738P","canonical_id":"hgnc:HGNC:46754","description":"RNA, 7SL, cytoplasmic 738, pseudogene","metadata":null},{"id":"4863799f2b8c4075998e4a1663715e5f","type":"GENE","name":"RN7SL73P","canonical_id":"hgnc:HGNC:46089","description":"RNA, 7SL, cytoplasmic 73, pseudogene","metadata":null},{"id":"2c295e3b4599416ca0c5588fe8d0b8aa","type":"GENE","name":"RN7SL740P","canonical_id":"hgnc:HGNC:46756","description":"RNA, 7SL, cytoplasmic 740, pseudogene","metadata":null},{"id":"2ae08d3ae83c45c6989bb2d3d76d71f1","type":"GENE","name":"RN7SL741P","canonical_id":"hgnc:HGNC:46757","description":"RNA, 7SL, cytoplasmic 741, pseudogene","metadata":null},{"id":"d3b1f822724a4c19bb16ac9c00f47b0d","type":"GENE","name":"RN7SL743P","canonical_id":"hgnc:HGNC:46759","description":"RNA, 7SL, cytoplasmic 743, pseudogene","metadata":null},{"id":"8f29af6d17144a19a6bd4a5a9f2768e6","type":"GENE","name":"RN7SL744P","canonical_id":"hgnc:HGNC:46760","description":"RNA, 7SL, cytoplasmic 744, pseudogene","metadata":null},{"id":"3895f6f3906243349ea747e2cff4dee0","type":"GENE","name":"RN7SL745P","canonical_id":"hgnc:HGNC:46761","description":"RNA, 7SL, cytoplasmic 745, pseudogene","metadata":null},{"id":"36c589832caa45fbae3bab09b01a44c0","type":"GENE","name":"RN7SL748P","canonical_id":"hgnc:HGNC:46764","description":"RNA, 7SL, cytoplasmic 748, pseudogene","metadata":null},{"id":"d1ac461589c3470f965ed79c623ded85","type":"GENE","name":"RN7SL749P","canonical_id":"hgnc:HGNC:46765","description":"RNA, 7SL, cytoplasmic 749, pseudogene","metadata":null},{"id":"5be12f6ed9ec478e8cd13ea99a9167bc","type":"GENE","name":"RN7SL74P","canonical_id":"hgnc:HGNC:46090","description":"RNA, 7SL, cytoplasmic 74, pseudogene","metadata":null},{"id":"638e38f141054c93bc7dd48b8cc398fc","type":"GENE","name":"RN7SL750P","canonical_id":"hgnc:HGNC:46766","description":"RNA, 7SL, cytoplasmic 750, pseudogene","metadata":null},{"id":"fa00b03340a64268acc83836b0d5b724","type":"GENE","name":"RN7SL751P","canonical_id":"hgnc:HGNC:46767","description":"RNA, 7SL, cytoplasmic 751, pseudogene","metadata":null},{"id":"01c2549ffe174189a46f15b51557bd43","type":"GENE","name":"RN7SL752P","canonical_id":"hgnc:HGNC:46768","description":"RNA, 7SL, cytoplasmic 752, pseudogene","metadata":null},{"id":"ca3219ddd4444baa9ecce051cdec91e5","type":"GENE","name":"RN7SL753P","canonical_id":"hgnc:HGNC:46769","description":"RNA, 7SL, cytoplasmic 753, pseudogene","metadata":null},{"id":"7a372b86938b43aeb936d8cb1ce5bbdd","type":"GENE","name":"RN7SL754P","canonical_id":"hgnc:HGNC:46770","description":"RNA, 7SL, cytoplasmic 754, pseudogene","metadata":null},{"id":"28aa620f59384a089f5e038d0fc83cd5","type":"GENE","name":"RN7SL756P","canonical_id":"hgnc:HGNC:46772","description":"RNA, 7SL, cytoplasmic 756, pseudogene","metadata":null},{"id":"eaf34af097324924be03d7ab3ddf5206","type":"GENE","name":"RN7SL757P","canonical_id":"hgnc:HGNC:46773","description":"RNA, 7SL, cytoplasmic 757, pseudogene","metadata":null},{"id":"b1cc5b665ddb4201a94f2ab5b25bc517","type":"GENE","name":"RN7SL759P","canonical_id":"hgnc:HGNC:46775","description":"RNA, 7SL, cytoplasmic 759, pseudogene","metadata":null},{"id":"bb4c01d692d647abb7d856eb32f062af","type":"GENE","name":"RN7SL75P","canonical_id":"hgnc:HGNC:46091","description":"RNA, 7SL, cytoplasmic 75, pseudogene","metadata":null},{"id":"52159c3509cc4a83b72b6378b0334b7c","type":"GENE","name":"RN7SL760P","canonical_id":"hgnc:HGNC:46776","description":"RNA, 7SL, cytoplasmic 760, pseudogene","metadata":null},{"id":"722dfe1fa39047d59bd1f25978bdb2c8","type":"GENE","name":"RN7SL761P","canonical_id":"hgnc:HGNC:46777","description":"RNA, 7SL, cytoplasmic 761, pseudogene","metadata":null},{"id":"957abc4e6a5b4e39a69237f114a003d8","type":"GENE","name":"RN7SL762P","canonical_id":"hgnc:HGNC:46778","description":"RNA, 7SL, cytoplasmic 762, pseudogene","metadata":null},{"id":"04df890991eb4fbb94d343d2183eee07","type":"GENE","name":"RN7SL763P","canonical_id":"hgnc:HGNC:46779","description":"RNA, 7SL, cytoplasmic 763, pseudogene","metadata":null},{"id":"eef175e53cdd42ddbc661c354b6097d0","type":"GENE","name":"RN7SL764P","canonical_id":"hgnc:HGNC:46780","description":"RNA, 7SL, cytoplasmic 764, pseudogene","metadata":null},{"id":"50a0c6f7fb8943fcab01501c6b6fc64b","type":"GENE","name":"RN7SL766P","canonical_id":"hgnc:HGNC:46782","description":"RNA, 7SL, cytoplasmic 766, pseudogene","metadata":null},{"id":"fb04ee3f5774465fa4c92dfad168cf2e","type":"GENE","name":"RN7SL767P","canonical_id":"hgnc:HGNC:46783","description":"RNA, 7SL, cytoplasmic 767, pseudogene","metadata":null},{"id":"6d81d8b9fc3448768444238611ab32af","type":"GENE","name":"RN7SL769P","canonical_id":"hgnc:HGNC:46785","description":"RNA, 7SL, cytoplasmic 769, pseudogene","metadata":null},{"id":"ed8cda93afe94b26a8d0bdf2cfb72830","type":"GENE","name":"RN7SL76P","canonical_id":"hgnc:HGNC:46092","description":"RNA, 7SL, cytoplasmic 76, pseudogene","metadata":null},{"id":"fc9496c4f7864c259a0e0a9f92ac0ab3","type":"GENE","name":"RN7SL771P","canonical_id":"hgnc:HGNC:46787","description":"RNA, 7SL, cytoplasmic 771, pseudogene","metadata":null},{"id":"a196deaebed7468b9f951d157ef131aa","type":"GENE","name":"RN7SL774P","canonical_id":"hgnc:HGNC:46790","description":"RNA, 7SL, cytoplasmic 774, pseudogene","metadata":null},{"id":"a8dd27e745bb4b05ade64017d9c76448","type":"GENE","name":"RN7SL775P","canonical_id":"hgnc:HGNC:46791","description":"RNA, 7SL, cytoplasmic 775, pseudogene","metadata":null},{"id":"d839974e12d74f5791afc4a082ca38cb","type":"GENE","name":"RN7SL776P","canonical_id":"hgnc:HGNC:46792","description":"RNA, 7SL, cytoplasmic 776, pseudogene","metadata":null},{"id":"52ccd3747bad4016a3a18a5e68df6000","type":"GENE","name":"RN7SL778P","canonical_id":"hgnc:HGNC:46794","description":"RNA, 7SL, cytoplasmic 778, pseudogene","metadata":null},{"id":"2c09b3b388a447aa8bd6f57c3fba6631","type":"GENE","name":"RN7SL77P","canonical_id":"hgnc:HGNC:46093","description":"RNA, 7SL, cytoplasmic 77, pseudogene","metadata":null},{"id":"ad70a94fe220441abf00364591c07a7a","type":"GENE","name":"RN7SL782P","canonical_id":"hgnc:HGNC:46798","description":"RNA, 7SL, cytoplasmic 782, pseudogene","metadata":null},{"id":"8b74b5fbab2e4c72af28ec160eebb141","type":"GENE","name":"RN7SL783P","canonical_id":"hgnc:HGNC:46799","description":"RNA, 7SL, cytoplasmic 783, pseudogene","metadata":null},{"id":"1d4377203ba14ce1bcf37fab4e77c0a7","type":"GENE","name":"RN7SL784P","canonical_id":"hgnc:HGNC:46800","description":"RNA, 7SL, cytoplasmic 784, pseudogene","metadata":null},{"id":"6d5a48e5c6de4dc1af77e60f98aee394","type":"GENE","name":"RN7SL785P","canonical_id":"hgnc:HGNC:46801","description":"RNA, 7SL, cytoplasmic 785, pseudogene","metadata":null},{"id":"4e9473a5a70a460587dc309b713172e6","type":"GENE","name":"RN7SL786P","canonical_id":"hgnc:HGNC:46802","description":"RNA, 7SL, cytoplasmic 786, pseudogene","metadata":null},{"id":"c175c62e456f460e991ece0ceb3566d1","type":"GENE","name":"RN7SL787P","canonical_id":"hgnc:HGNC:46803","description":"RNA, 7SL, cytoplasmic 787, pseudogene","metadata":null},{"id":"e398f92ed0584105aea5790da5435294","type":"GENE","name":"RN7SL788P","canonical_id":"hgnc:HGNC:46804","description":"RNA, 7SL, cytoplasmic 788, pseudogene","metadata":null},{"id":"95100c30b5e34664a85e7cd6af8aac5c","type":"GENE","name":"RN7SL789P","canonical_id":"hgnc:HGNC:46805","description":"RNA, 7SL, cytoplasmic 789, pseudogene","metadata":null},{"id":"662a123ead4f47619f2048628058daa3","type":"GENE","name":"RN7SL78P","canonical_id":"hgnc:HGNC:46094","description":"RNA, 7SL, cytoplasmic 78, pseudogene","metadata":null},{"id":"ecd5af3eaae74407bb0f3a8833a9ce20","type":"GENE","name":"RN7SL790P","canonical_id":"hgnc:HGNC:46806","description":"RNA, 7SL, cytoplasmic 790, pseudogene","metadata":null},{"id":"e25cc66a0f184a359c85592be69bc0ab","type":"GENE","name":"RN7SL791P","canonical_id":"hgnc:HGNC:46807","description":"RNA, 7SL, cytoplasmic 791, pseudogene","metadata":null},{"id":"32cb191887384c66948cbbe58a1fbdea","type":"GENE","name":"RN7SL792P","canonical_id":"hgnc:HGNC:46808","description":"RNA, 7SL, cytoplasmic 792, pseudogene","metadata":null},{"id":"b8a8912499d84260b74d919e351b6838","type":"GENE","name":"RN7SL793P","canonical_id":"hgnc:HGNC:46809","description":"RNA, 7SL, cytoplasmic 793, pseudogene","metadata":null},{"id":"8ece9286817441ea857a7f18d61e5f10","type":"GENE","name":"RN7SL794P","canonical_id":"hgnc:HGNC:46810","description":"RNA, 7SL, cytoplasmic 794, pseudogene","metadata":null},{"id":"246f9593629c4f86a44e692ee3a4a740","type":"GENE","name":"RN7SL795P","canonical_id":"hgnc:HGNC:46811","description":"RNA, 7SL, cytoplasmic 795, pseudogene","metadata":null},{"id":"c8be18962e5c45098d482484a8a7073d","type":"GENE","name":"RN7SL796P","canonical_id":"hgnc:HGNC:46812","description":"RNA, 7SL, cytoplasmic 796, pseudogene","metadata":null},{"id":"921c1800ba5f4ee3b5d8bf05e6b3e560","type":"GENE","name":"RN7SL797P","canonical_id":"hgnc:HGNC:46813","description":"RNA, 7SL, cytoplasmic 797, pseudogene","metadata":null},{"id":"61317ab0c3ab4a3b99774da7688f78f1","type":"GENE","name":"RN7SL798P","canonical_id":"hgnc:HGNC:46814","description":"RNA, 7SL, cytoplasmic 798, pseudogene","metadata":null},{"id":"30027a10854b484a8f3382d047598f55","type":"GENE","name":"RN7SL799P","canonical_id":"hgnc:HGNC:46815","description":"RNA, 7SL, cytoplasmic 799, pseudogene","metadata":null},{"id":"b216f1b8b59d4477adf60a2c32423299","type":"GENE","name":"RN7SL79P","canonical_id":"hgnc:HGNC:46095","description":"RNA, 7SL, cytoplasmic 79, pseudogene","metadata":null},{"id":"81cb1fa6d3984b808ba3bee6fa9212d9","type":"GENE","name":"RN7SL7P","canonical_id":"hgnc:HGNC:10042","description":"RNA, 7SL, cytoplasmic 7, pseudogene","metadata":{"aliases":["7L23","RN7SLP4","RN7SL27P"]}},{"id":"6833cb708be841e88b83b0e1bbe88376","type":"GENE","name":"RN7SL800P","canonical_id":"hgnc:HGNC:46816","description":"RNA, 7SL, cytoplasmic 800, pseudogene","metadata":null},{"id":"289313dd7ae940aeba560bc0db373a7f","type":"GENE","name":"RN7SL801P","canonical_id":"hgnc:HGNC:46817","description":"RNA, 7SL, cytoplasmic 801, pseudogene","metadata":null},{"id":"85c770700adf478184fc626aaad92274","type":"GENE","name":"RN7SL802P","canonical_id":"hgnc:HGNC:46818","description":"RNA, 7SL, cytoplasmic 802, pseudogene","metadata":null},{"id":"f2fb3ba78ecd4174b323a114e1d7d3ec","type":"GENE","name":"RN7SL803P","canonical_id":"hgnc:HGNC:46819","description":"RNA, 7SL, cytoplasmic 803, pseudogene","metadata":null},{"id":"ddf03b9dfb7541829933a98b2971c64d","type":"GENE","name":"RN7SL804P","canonical_id":"hgnc:HGNC:46820","description":"RNA, 7SL, cytoplasmic 804, pseudogene","metadata":null},{"id":"efb11bfb2a5541c3b8656c07b48b09de","type":"GENE","name":"RN7SL806P","canonical_id":"hgnc:HGNC:46822","description":"RNA, 7SL, cytoplasmic 806, pseudogene","metadata":null},{"id":"82397b62d4f241fda75a2400d59d3798","type":"GENE","name":"RN7SL807P","canonical_id":"hgnc:HGNC:46823","description":"RNA, 7SL, cytoplasmic 807, pseudogene","metadata":null},{"id":"2208acc293bf42cd8156014747b67282","type":"GENE","name":"RN7SL808P","canonical_id":"hgnc:HGNC:46824","description":"RNA, 7SL, cytoplasmic 808, pseudogene","metadata":null},{"id":"bf10866b8151469eb561236dc5dfe545","type":"GENE","name":"RN7SL809P","canonical_id":"hgnc:HGNC:46825","description":"RNA, 7SL, cytoplasmic 809, pseudogene","metadata":null},{"id":"f8936fef9fa1415e8c08ac8fa64a446f","type":"GENE","name":"RN7SL810P","canonical_id":"hgnc:HGNC:46826","description":"RNA, 7SL, cytoplasmic 810, pseudogene","metadata":null},{"id":"d2f177b9eaaf4db08480e0c739e7df6a","type":"GENE","name":"RN7SL811P","canonical_id":"hgnc:HGNC:46827","description":"RNA, 7SL, cytoplasmic 811, pseudogene","metadata":null},{"id":"ed6dcacbdce44fd28e4ac508d61e2c66","type":"GENE","name":"RN7SL812P","canonical_id":"hgnc:HGNC:46828","description":"RNA, 7SL, cytoplasmic 812, pseudogene","metadata":null},{"id":"ad707ae341df409381863cd77740f93c","type":"GENE","name":"RN7SL813P","canonical_id":"hgnc:HGNC:46829","description":"RNA, 7SL, cytoplasmic 813, pseudogene","metadata":null},{"id":"1a216950169d47d88ff8406dce8a5944","type":"GENE","name":"RN7SL814P","canonical_id":"hgnc:HGNC:46830","description":"RNA, 7SL, cytoplasmic 814, pseudogene","metadata":null},{"id":"ddefee99e5d644859ea8da49ea21f950","type":"GENE","name":"RN7SL815P","canonical_id":"hgnc:HGNC:46831","description":"RNA, 7SL, cytoplasmic 815, pseudogene","metadata":null},{"id":"c61d44fbe74a475b8219354989c08f16","type":"GENE","name":"RN7SL817P","canonical_id":"hgnc:HGNC:46833","description":"RNA, 7SL, cytoplasmic 817, pseudogene","metadata":null},{"id":"7a6aaf0d20674705b57be52a44c57fe7","type":"GENE","name":"RN7SL818P","canonical_id":"hgnc:HGNC:46834","description":"RNA, 7SL, cytoplasmic 818, pseudogene","metadata":null},{"id":"b589079d3d1946f2bc391a78587b86ab","type":"GENE","name":"RN7SL819P","canonical_id":"hgnc:HGNC:46835","description":"RNA, 7SL, cytoplasmic 819, pseudogene","metadata":null},{"id":"7c616e6e08a34f83913b01f378799c53","type":"GENE","name":"RN7SL81P","canonical_id":"hgnc:HGNC:46097","description":"RNA, 7SL, cytoplasmic 81, pseudogene","metadata":null},{"id":"33a6069020e64a46adb4fb10eec15844","type":"GENE","name":"RN7SL820P","canonical_id":"hgnc:HGNC:46836","description":"RNA, 7SL, cytoplasmic 820, pseudogene","metadata":null},{"id":"71683bd9d91a4c54a33915b676ca0648","type":"GENE","name":"RN7SL822P","canonical_id":"hgnc:HGNC:46838","description":"RNA, 7SL, cytoplasmic 822, pseudogene","metadata":null},{"id":"3299daaffc054c9081a0e731dcfedfdc","type":"GENE","name":"RN7SL823P","canonical_id":"hgnc:HGNC:46839","description":"RNA, 7SL, cytoplasmic 823, pseudogene","metadata":null},{"id":"5fce7c8e95eb4bc6ae98756577bb07cf","type":"GENE","name":"RN7SL824P","canonical_id":"hgnc:HGNC:46840","description":"RNA, 7SL, cytoplasmic 824, pseudogene","metadata":null},{"id":"ed6f9dbf96624641a8f0b93f85b7a9a9","type":"GENE","name":"RN7SL825P","canonical_id":"hgnc:HGNC:46841","description":"RNA, 7SL, cytoplasmic 825, pseudogene","metadata":null},{"id":"c892f666d74f43d88597bbe8b36db385","type":"GENE","name":"RN7SL826P","canonical_id":"hgnc:HGNC:46842","description":"RNA, 7SL, cytoplasmic 826, pseudogene","metadata":null},{"id":"675709e2ed0141e6b4b83b3c2068ccf5","type":"GENE","name":"RN7SL827P","canonical_id":"hgnc:HGNC:46843","description":"RNA, 7SL, cytoplasmic 827, pseudogene","metadata":null},{"id":"e4cc4f585ccc459b8a0ac216b15b9399","type":"GENE","name":"RN7SL828P","canonical_id":"hgnc:HGNC:46844","description":"RNA, 7SL, cytoplasmic 828, pseudogene","metadata":null},{"id":"772a3e9f1eb94aeeb14390bb9100f589","type":"GENE","name":"RN7SL82P","canonical_id":"hgnc:HGNC:46098","description":"RNA, 7SL, cytoplasmic 82, pseudogene","metadata":null},{"id":"0e7fec97c43a46459c48178c0411d8a0","type":"GENE","name":"RN7SL831P","canonical_id":"hgnc:HGNC:46847","description":"RNA, 7SL, cytoplasmic 831, pseudogene","metadata":null},{"id":"d114bf8512d04437a7f569704d2de6b1","type":"GENE","name":"RN7SL832P","canonical_id":"hgnc:HGNC:46848","description":"RNA, 7SL, cytoplasmic 832, pseudogene","metadata":null},{"id":"77a962b158d34b03a967d8fe639de194","type":"GENE","name":"RN7SL833P","canonical_id":"hgnc:HGNC:46849","description":"RNA, 7SL, cytoplasmic 833, pseudogene","metadata":null},{"id":"a4caa6a019c64102a19ab30cfdc11ddd","type":"GENE","name":"RN7SL834P","canonical_id":"hgnc:HGNC:46850","description":"RNA, 7SL, cytoplasmic 834, pseudogene","metadata":null},{"id":"2908f2c4f3284e2cb5247b3d590748ae","type":"GENE","name":"RN7SL835P","canonical_id":"hgnc:HGNC:46851","description":"RNA, 7SL, cytoplasmic 835, pseudogene","metadata":null},{"id":"6e695afcc2684225afe6cc792d9d69e9","type":"GENE","name":"RN7SL836P","canonical_id":"hgnc:HGNC:46852","description":"RNA, 7SL, cytoplasmic 836, pseudogene","metadata":null},{"id":"555c438eb316461786d6e28b690d854e","type":"GENE","name":"RN7SL837P","canonical_id":"hgnc:HGNC:46853","description":"RNA, 7SL, cytoplasmic 837, pseudogene","metadata":null},{"id":"0761e98fde964d8b8e7a514f3688c36a","type":"GENE","name":"RN7SL838P","canonical_id":"hgnc:HGNC:46854","description":"RNA, 7SL, cytoplasmic 838, pseudogene","metadata":null},{"id":"3501c3d16a4e45769c01aa71d0fe07c0","type":"GENE","name":"RN7SL83P","canonical_id":"hgnc:HGNC:46099","description":"RNA, 7SL, cytoplasmic 83, pseudogene","metadata":null},{"id":"6bf802fdc20e40d4989c1401aefb66cc","type":"GENE","name":"RN7SL840P","canonical_id":"hgnc:HGNC:46856","description":"RNA, 7SL, cytoplasmic 840, pseudogene","metadata":null},{"id":"dca2c88f26974b5e879d937757053081","type":"GENE","name":"RN7SL841P","canonical_id":"hgnc:HGNC:46857","description":"RNA, 7SL, cytoplasmic 841, pseudogene","metadata":null},{"id":"e70c0f3e224a463ea561303cc303b469","type":"GENE","name":"RN7SL842P","canonical_id":"hgnc:HGNC:46858","description":"RNA, 7SL, cytoplasmic 842, pseudogene","metadata":null},{"id":"c638ebe4e0ed41138248872bb282468c","type":"GENE","name":"RN7SL843P","canonical_id":"hgnc:HGNC:46859","description":"RNA, 7SL, cytoplasmic 843, pseudogene","metadata":null},{"id":"f4f447cc3bc44954ab311fcaf22a749c","type":"GENE","name":"RN7SL845P","canonical_id":"hgnc:HGNC:46861","description":"RNA, 7SL, cytoplasmic 845, pseudogene","metadata":null},{"id":"1253bb6a9d0e42b5bdab4466d9b5ac35","type":"GENE","name":"RN7SL846P","canonical_id":"hgnc:HGNC:46862","description":"RNA, 7SL, cytoplasmic 846, pseudogene","metadata":null},{"id":"d52753eafefa45fcbf98b3e714e6637a","type":"GENE","name":"RN7SL847P","canonical_id":"hgnc:HGNC:46863","description":"RNA, 7SL, cytoplasmic 847, pseudogene","metadata":null},{"id":"f07fe3dacad84aa49c87fae5a6ddf8ef","type":"GENE","name":"RN7SL849P","canonical_id":"hgnc:HGNC:46865","description":"RNA, 7SL, cytoplasmic 849, pseudogene","metadata":null},{"id":"8dc3f70903f4417498fe857075b75fde","type":"GENE","name":"RN7SL850P","canonical_id":"hgnc:HGNC:46866","description":"RNA, 7SL, cytoplasmic 850, pseudogene","metadata":null},{"id":"efb0304549b943dea557b7787cd1515b","type":"GENE","name":"RN7SL851P","canonical_id":"hgnc:HGNC:46867","description":"RNA, 7SL, cytoplasmic 851, pseudogene","metadata":null},{"id":"0c04b7d9de2043bca6d392fa5b70e500","type":"GENE","name":"RN7SL853P","canonical_id":"hgnc:HGNC:46869","description":"RNA, 7SL, cytoplasmic 853, pseudogene","metadata":null},{"id":"ab6b2a1247954e5f977f2ae6a2fb6256","type":"GENE","name":"RN7SL854P","canonical_id":"hgnc:HGNC:46870","description":"RNA, 7SL, cytoplasmic 854, pseudogene","metadata":null},{"id":"dec32141f325418185a06df672890115","type":"GENE","name":"RN7SL856P","canonical_id":"hgnc:HGNC:46872","description":"RNA, 7SL, cytoplasmic 856, pseudogene","metadata":null},{"id":"a25ad102696b42d4b8bd4a256ef9a0aa","type":"GENE","name":"RN7SL860P","canonical_id":"hgnc:HGNC:46876","description":"RNA, 7SL, cytoplasmic 860, pseudogene","metadata":null},{"id":"970196874f4f452d8a16ea8fca6489c8","type":"GENE","name":"RN7SL861P","canonical_id":"hgnc:HGNC:46877","description":"RNA, 7SL, cytoplasmic 861, pseudogene","metadata":null},{"id":"645218a6752a425b9a654cbb5759bded","type":"GENE","name":"RN7SL862P","canonical_id":"hgnc:HGNC:46878","description":"RNA, 7SL, cytoplasmic 862, pseudogene","metadata":null},{"id":"929f5f62c5674b35b11590095994bfa8","type":"GENE","name":"RN7SL863P","canonical_id":"hgnc:HGNC:46879","description":"RNA, 7SL, cytoplasmic 863, pseudogene","metadata":null},{"id":"3cea5a4ce344498686ef350cf51e025b","type":"GENE","name":"RN7SL864P","canonical_id":"hgnc:HGNC:46880","description":"RNA, 7SL, cytoplasmic 864, pseudogene","metadata":null},{"id":"0dadf504244d469387979e5c0c988163","type":"GENE","name":"RN7SL865P","canonical_id":"hgnc:HGNC:46881","description":"RNA, 7SL, cytoplasmic 865, pseudogene","metadata":null},{"id":"7516cc378f534075a9bcece8041a51ce","type":"GENE","name":"RN7SL868P","canonical_id":"hgnc:HGNC:46884","description":"RNA, 7SL, cytoplasmic 868, pseudogene","metadata":null},{"id":"5d50ceb66a054c398ad6f8a9a41a631c","type":"GENE","name":"RN7SL869P","canonical_id":"hgnc:HGNC:46885","description":"RNA, 7SL, cytoplasmic 869, pseudogene","metadata":null},{"id":"3f2ff7eb99ea4c53950c74e170c19a24","type":"GENE","name":"RN7SL870P","canonical_id":"hgnc:HGNC:46886","description":"RNA, 7SL, cytoplasmic 870, pseudogene","metadata":null},{"id":"573ec5963b91455898e6d060b4459c8c","type":"GENE","name":"RN7SL87P","canonical_id":"hgnc:HGNC:46103","description":"RNA, 7SL, cytoplasmic 87, pseudogene","metadata":null},{"id":"c04c3b438d6e4459aef2d617a998e1ff","type":"GENE","name":"RN7SL88P","canonical_id":"hgnc:HGNC:46104","description":"RNA, 7SL, cytoplasmic 88, pseudogene","metadata":null},{"id":"50709aa44fcc4bd98dd6973c36b25116","type":"GENE","name":"RN7SL89P","canonical_id":"hgnc:HGNC:46105","description":"RNA, 7SL, cytoplasmic 89, pseudogene","metadata":null},{"id":"fda12ba74acb4836a42a407fc52a092b","type":"GENE","name":"RN7SL8P","canonical_id":"hgnc:HGNC:10043","description":"RNA, 7SL, cytoplasmic 8, pseudogene","metadata":{"aliases":["7L63","RN7SLP5","RN7SL433P"]}},{"id":"7f489146869d40af99054369e7eb2101","type":"GENE","name":"RN7SL91P","canonical_id":"hgnc:HGNC:46107","description":"RNA, 7SL, cytoplasmic 91, pseudogene","metadata":null},{"id":"b99d5919ddca47859c1ad56c9a66fa05","type":"GENE","name":"RN7SL92P","canonical_id":"hgnc:HGNC:46108","description":"RNA, 7SL, cytoplasmic 92, pseudogene","metadata":null},{"id":"9f7d38199e574deda3b6321a3f14cf9d","type":"GENE","name":"RN7SL93P","canonical_id":"hgnc:HGNC:46109","description":"RNA, 7SL, cytoplasmic 93, pseudogene","metadata":null},{"id":"0bd97c363d494cc28b1ba8d28c10b2b8","type":"GENE","name":"RN7SL96P","canonical_id":"hgnc:HGNC:46112","description":"RNA, 7SL, cytoplasmic 96, pseudogene","metadata":null},{"id":"0a67843dfa2349299d4f8c4318b267c3","type":"GENE","name":"RN7SL97P","canonical_id":"hgnc:HGNC:46113","description":"RNA, 7SL, cytoplasmic 97, pseudogene","metadata":null},{"id":"ebd65852e56c4809a10de1ce56991d69","type":"GENE","name":"RN7SL98P","canonical_id":"hgnc:HGNC:46114","description":"RNA, 7SL, cytoplasmic 98, pseudogene","metadata":null},{"id":"4789680ffbb04381b591792d3e0005cc","type":"GO_TERM","name":"RNA (guanine-N7)-methylation","canonical_id":"go:GO:0036265","description":"\"The addition of a methyl group to the N7 atom in the base portion of a guanine nucleotide residue in an RNA molecule.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"28037923dcf3463e8a665430b071abcf","type":"GO_TERM","name":"RNA 2',3'-cyclic 3'-phosphodiesterase activity","canonical_id":"go:GO:0008664","description":"\"Catalysis the reaction: a 3'-end 2',3'-cyclophospho-ribonucleotide-RNA + H2O = a 3'-end 2'-phospho-ribonucleotide-RNA + H+.\" [PMID:25239919, RHEA:11828]","metadata":null},{"id":"36d07280284042afa5cc2c8a8ea07ce6","type":"GO_TERM","name":"RNA 2',3'-cyclic phosphatase activity","canonical_id":"go:GO:0160272","description":"\"Catalysis of the reaction: a 3'-end 2',3'-cyclophospho-ribonucleotide-RNA + 2 H2O = a 3'-end ribonucleotide-RNA + phosphate + H+.\" [PMID:32732418, RHEA:85011]","metadata":null},{"id":"c73b1fe3b96e4b5aa444dcd4ef050926","type":"GO_TERM","name":"RNA 2'-O-methyltransferase activity","canonical_id":"go:GO:0062105","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + RNA = S-adenosyl-L-homocysteine + RNA containing 2'-O-methylribonucleotide.\" [PMID:30626973, RHEA:58956]","metadata":null},{"id":"9b169afc65e04b30a8928acd65f68de6","type":"GO_TERM","name":"RNA 2'-O-ribose methylation guide activity","canonical_id":"go:GO:0030561","description":"\"Specifies the site of 2'-O-ribose methylation in an RNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"d1832ccc355c40aa84ff00b8ed56ba7f","type":"GO_TERM","name":"RNA 2'-phosphatase activity","canonical_id":"go:GO:0160273","description":"\"Catalysis of the reaction: H2O + a 3'-end 2'-phospho-ribonucleotide-RNA = a 3'-end ribonucleotide-RNA + phosphate.\" [PMID:36180430, RHEA:85191]","metadata":null},{"id":"1c79a2f84ea248998f3ec427720224d3","type":"GO_TERM","name":"RNA 3'-end processing","canonical_id":"go:GO:0031123","description":"\"Any process involved in forming the mature 3' end of an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"9e1eb7413d894ce2974fec1f805e5197","type":"GO_TERM","name":"RNA 5'-cap (guanine-N7)-methylation","canonical_id":"go:GO:0106005","description":"\"The process whereby a guanine in 5-cap is methylated at the N7 position of guanine.\" [GOC:hjd]","metadata":null},{"id":"09a300dac9bb4c2ebad7e93a677517ef","type":"GO_TERM","name":"RNA 5'-end processing","canonical_id":"go:GO:0000966","description":"\"Any process involved in forming the mature 5' end of an RNA molecule.\" [GOC:krc]","metadata":null},{"id":"cd2a7940141f408ca8c1eb840721ae69","type":"GO_TERM","name":"RNA 5'-gamma-phosphate methyltransferase activity","canonical_id":"go:GO:1990276","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the 5'-gamma-phosphate in an RNA molecule.\" [GOC:al, GOC:vw, PMID:22740346]","metadata":null},{"id":"9afcdd3f1a6b449383a34ac007a40f06","type":"GO_TERM","name":"RNA 7-methylguanosine cap binding","canonical_id":"go:GO:0000340","description":"\"Binding to a 7-methylguanosine group added cotranscriptionally to the 5' end of RNA molecules transcribed by polymerase II.\" [GOC:krc]","metadata":null},{"id":"39147f8f1dd14646a784e3aa453e8167","type":"TRIAL","name":"RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)","canonical_id":"clinicaltrials.gov:NCT07266545","description":"Unipolar Depression; Bipolar Depression","metadata":null},{"id":"4e7a77b852124882a41a9843587eb373","type":"GO_TERM","name":"RNA N6-methyladenosine methyltransferase complex","canonical_id":"go:GO:0036396","description":"\"A RNA methyltransferase complex that catalyzes the post-transcriptional methylation of adenosine to form N6-methyladenosine (m6A). In budding yeast, the MIS complex consists of Mum2p, Ime4p and Slz1p. In vertebrates, the complex consists of METTL3, METTL14 and associated components WTAP, ZC3H13, VIRMA, CBLL1/HAKAI and in some cases of RBM15 (RBM15 or RBM15B).\" [GOC:dgf, GOC:sp, PMID:22685417, PMID:24316715, PMID:24407421, PMID:29507755, PMID:29535189, PMID:29547716]","metadata":null},{"id":"fd4834f50d7a489089ef19a8d22182df","type":"GO_TERM","name":"RNA NAD+-cap (NAD+-forming) hydrolase activity","canonical_id":"go:GO:0110152","description":"\"Catalysis of the reaction: a 5'-end NAD+-phospho-ribonucleoside in mRNA + H2O = a 5'-end phospho-ribonucleoside in mRNA + H+ + NAD+.\" [GOC:sp, PMID:28283058, RHEA:60880]","metadata":null},{"id":"680ba752ab95421a953edf2707399c41","type":"GO_TERM","name":"RNA NAD-cap (NMN-forming) hydrolase activity","canonical_id":"go:GO:0110153","description":"\"Catalysis of the reaction: a 5'-end NAD+-phospho-ribonucleoside in mRNA + H2O = a 5'-end phospho-adenosine-phospho-ribonucleoside in mRNA + beta-nicotinamide D-ribonucleotide + 2 H+.\" [GOC:sp, PMID:25533955, PMID:31101919, RHEA:60876]","metadata":null},{"id":"2cdc19b579cf45b08c545afd04b49a01","type":"GO_TERM","name":"RNA acetylation","canonical_id":"go:GO:1990884","description":"\"The posttranscriptional addition of one or more acetyl groups to specific residues in an RNA molecule.\" [PMID:25402480]","metadata":null},{"id":"45c0e35772e14cbe8f578af251e3a8fa","type":"GO_TERM","name":"RNA adenosine-uridine insertion","canonical_id":"go:GO:0070711","description":"\"The modification of an RNA molecule by insertion of an adenosine-uridine dinucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"87a7649ff2784c989576295844514f20","type":"GO_TERM","name":"RNA binding","canonical_id":"go:GO:0003723","description":"\"Binding to an RNA molecule or a portion thereof.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"d10f5da144314792993cf5c81caa0ede","type":"GO_TERM","name":"RNA biosynthetic process","canonical_id":"go:GO:0032774","description":"\"The chemical reactions and pathways resulting in the formation of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage. Includes polymerization of ribonucleotide monomers. Refers not only to transcription but also to e.g. viral RNA replication.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"4197e4d922a14279a8386ae837b4393a","type":"GO_TERM","name":"RNA cap 4 binding","canonical_id":"go:GO:0000342","description":"\"Binding to a hypermethylated cap structure consisting of 7-methylguanosine (m(7)G) followed by four methylated nucleotides (cap 4): 7-methylguanosine-ppp-N6, N6, 2'-O-trimethyladenosine-p-2'-O-methyladenosine-p-2'-O-methylcytosine-p-N3, 2'-O-dimethyluridine Such caps are known to be found at the 5' ends of SL RNAs of trypanosomatid protozoa.\" [GOC:krc, PMID:10880518, PMID:12121975]","metadata":null},{"id":"8eb05a828ac347cfa87817bc6f9003ea","type":"GO_TERM","name":"RNA cap binding","canonical_id":"go:GO:0000339","description":"\"Binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an RNA molecule.\" [GOC:krc]","metadata":null},{"id":"453bc003aa4e459c88c9fb3756422dc4","type":"GO_TERM","name":"RNA cap binding complex","canonical_id":"go:GO:0034518","description":"\"A protein complex that binds to an RNA cap structure to mediate RNA processing and/or translation initiation.\" [GOC:mah]","metadata":null},{"id":"a605dbae5d864f2091285b167afe37f9","type":"GO_TERM","name":"RNA cap trimethylguanosine synthase activity","canonical_id":"go:GO:0071164","description":"\"Catalysis of two successive methyl transfer reactions from AdoMet to the N-2 atom of guanosine, thereby converting 7-methylguanosine in an RNA cap to 2,2,7 trimethylguanosine.\" [PMID:11983179, PMID:18775984]","metadata":null},{"id":"97d8a172433844d6baa33c7a1123f3d1","type":"GO_TERM","name":"RNA capping","canonical_id":"go:GO:0036260","description":"\"The sequence of enzymatic reactions by which a cap structure is added to the 5' end of nascent RNA polymerase transcripts. Examples of RNA capping include 7-methyl-G caps found on all RNA polymerase II transcripts and nucleotide-containing cofactor caps, such as NAD(H) or FAD, found on bacterial trancripts.\" [GOC:bf, GOC:krc, GOC:mah, PMID:18775984, PMID:27383794, PMID:29681497, PMID:30353673]","metadata":null},{"id":"1c07b07fe1ca466ba71fabcd84ee5838","type":"GO_TERM","name":"RNA catabolic process","canonical_id":"go:GO:0006401","description":"\"The chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage.\" [ISBN:0198506732]","metadata":null},{"id":"16768bf04fdf47258c5441ff95ab3d01","type":"GO_TERM","name":"RNA cytidine insertion","canonical_id":"go:GO:0070708","description":"\"The modification of an RNA molecule by insertion of a cytidine nucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"2ea72d4df4c04240a9a0e9270cd9c1c1","type":"GO_TERM","name":"RNA cytidine-uridine insertion","canonical_id":"go:GO:0070712","description":"\"The modification of an RNA molecule by insertion of an cytidine-uridine dinucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"1ae13461192040358226741a2d81e03e","type":"GO_TERM","name":"RNA decapping","canonical_id":"go:GO:0110154","description":"\"Cleavage of the 5'-cap of an RNA.\" [GOC:sp, PMID:25533955, PMID:31101919]","metadata":null},{"id":"099c157255ac4a049bdf89f386c40858","type":"GO_TERM","name":"RNA decapping complex","canonical_id":"go:GO:0098745","description":"\"A protein complex consisting of a Dcp1 regulatory subunit and a Dcp2 catalytic subunit that has mRNA cap binding activity and is involved in decapping of nuclear-transcribed mRNA.\" [GOC:dos, GOC:vw, PMID:22323607]","metadata":null},{"id":"31e507d1ff464307b205dc243cea8a7a","type":"GO_TERM","name":"RNA destabilization","canonical_id":"go:GO:0050779","description":"\"Any process that decreases the stability of an RNA molecule, making it more vulnerable to degradative processes.\" [GOC:ai]","metadata":null},{"id":"1955c691f501480986e50e25eb267224","type":"GO_TERM","name":"RNA dihydrouridine synthase activity","canonical_id":"go:GO:0106413","description":"\"Catalysis of the reaction: RNA-uracil + NAD(P)+ = RNA-dihydrouridine + NAD(P)H + H+.\" [PMID:12581659, PMID:25073379]","metadata":null},{"id":"7cd861e5ad694f75a2a4d7a7058bbf45","type":"GO_TERM","name":"RNA dinucleotide insertion","canonical_id":"go:GO:0070707","description":"\"The modification of an RNA molecule by insertion of a dinucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"e3e9bc85798a4d93a33c805ea96c4d1f","type":"GO_TERM","name":"RNA endonuclease activity","canonical_id":"go:GO:0004521","description":"\"Catalysis of the cleavage of ester linkages within ribonucleic acid by creating internal breaks.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"1aab3c36077a455eaa2aa45938557315","type":"GO_TERM","name":"RNA endonuclease activity producing 3'-phosphomonoesters, hydrolytic mechanism","canonical_id":"go:GO:0016892","description":"\"Catalysis of the hydrolysis of ester linkages within ribonucleic acids by creating internal breaks to yield 3'-phosphomonoesters.\" [GOC:ai]","metadata":null},{"id":"03d3ce3a097745d08ba4dbd2d9de01dd","type":"GO_TERM","name":"RNA endonuclease activity producing 5'-phosphomonoesters, hydrolytic mechanism","canonical_id":"go:GO:0016891","description":"\"Catalysis of the hydrolysis of ester linkages within ribonucleic acids by creating internal breaks to yield 5'-phosphomonoesters.\" [GOC:ai]","metadata":null},{"id":"e1d091c8109e405c85b1a86b06c08a7a","type":"GO_TERM","name":"RNA exon ligation","canonical_id":"go:GO:0000378","description":"\"The RNA metabolic process that joins two exons, each of which has free ends that were generated by endonucleolytic cleavages, by a ligation reaction.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"a9749e69a39c43a18fc327f1852ade97","type":"GO_TERM","name":"RNA exonuclease activity","canonical_id":"go:GO:0004532","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' or 3' terminus of an RNA molecule.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"8dc325c3b25e418b9dd096272949bc4b","type":"GO_TERM","name":"RNA exonuclease activity, producing 5'-phosphomonoesters","canonical_id":"go:GO:0016896","description":"\"Catalysis of the hydrolysis of ester linkages within ribonucleic acids by removing nucleotide residues from the 3' or 5' end to yield 5' phosphomonoesters.\" [GOC:ai]","metadata":null},{"id":"e8d8616ffb0b489e8315c2e129b4ffbb","type":"GO_TERM","name":"RNA export from nucleus","canonical_id":"go:GO:0006405","description":"\"The directed movement of RNA from the nucleus to the cytoplasm.\" [GOC:ma]","metadata":null},{"id":"6ae21328837f4aa6987d16f4f3b3909e","type":"GO_TERM","name":"RNA folding","canonical_id":"go:GO:0034337","description":"\"The process of assisting in the covalent and noncovalent assembly of single or multimeric RNAs into the correct tertiary structure.\" [GOC:mah, PMID:10393192]","metadata":null},{"id":"4e03ae949507473e93f86e454cb680b3","type":"GO_TERM","name":"RNA folding chaperone","canonical_id":"go:GO:0140691","description":"\"Binding to an RNA or an RNA-containing complex to assist the folding process.\" [PMID:31165735]","metadata":null},{"id":"38343641e7994ef0b63aa9a67a5eca9c","type":"GO_TERM","name":"RNA fragment catabolic process","canonical_id":"go:GO:0000292","description":"\"The chemical reactions and pathways resulting in the breakdown of a fragment of RNA, such as excised introns or sequences removed from ribosomal RNA during processing.\" [GOC:mah]","metadata":null},{"id":"e6379cf3d8904ed5877c38f17a4474c1","type":"GO_TERM","name":"RNA glycosylase activity","canonical_id":"go:GO:0030597","description":"\"Catalysis of the hydrolysis of N-glycosidic bonds in an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"3c3616c69f2b440298631e7180f4beed","type":"GO_TERM","name":"RNA guanosine insertion","canonical_id":"go:GO:0070709","description":"\"The modification of an RNA molecule by insertion of a guanosine nucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"281758866c5b4aea9a3dfe1b782bbc8e","type":"GO_TERM","name":"RNA guanosine-cytidine insertion","canonical_id":"go:GO:0070713","description":"\"The modification of an RNA molecule by insertion of an guanosine-cytidine dinucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"df6a24de71fa4155a820e40b68cf1a75","type":"GO_TERM","name":"RNA guanosine-uridine insertion","canonical_id":"go:GO:0070714","description":"\"The modification of an RNA molecule by insertion of an guanosine-uridine insertion dinucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"2145c92e6d894c6bbfb14d6a88fe0b37","type":"GO_TERM","name":"RNA guanylyltransferase activity","canonical_id":"go:GO:0008192","description":"\"Catalysis of the posttranscriptional addition of a guanyl residue to the 5' end of an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"36de514f25e246f7b3d4680ba50fd4b4","type":"GO_TERM","name":"RNA helicase activity","canonical_id":"go:GO:0003724","description":"\"Unwinding of an RNA helix, driven by ATP hydrolysis.\" [GOC:jl, PMID:19158098]","metadata":null},{"id":"cf7b54201936497eb47e8d162087aae9","type":"GO_TERM","name":"RNA helicase inhibitor activity","canonical_id":"go:GO:1990119","description":"\"Binds to and stops, prevents or reduces the activity of an RNA helicase.\" [GOC:rb, PMID:23721653]","metadata":null},{"id":"da38d277590a4055b608b48e98c47202","type":"GO_TERM","name":"RNA import into mitochondrion","canonical_id":"go:GO:0035927","description":"\"The process in which a rRNA, ribosomal ribonucleic acid, is transported from the cytosol into the mitochondrial matrix.\" [GOC:ans, PMID:20691904]","metadata":null},{"id":"3afc4a7f27784c659ce6c9d730d154c8","type":"GO_TERM","name":"RNA import into nucleus","canonical_id":"go:GO:0006404","description":"\"The import of RNA from the cytoplasm to the nucleus.\" [GOC:ma]","metadata":null},{"id":"1018c5de24164074b4a16b5ebc81d310","type":"GO_TERM","name":"RNA lariat debranching enzyme activator activity","canonical_id":"go:GO:0061632","description":"\"Binds to and increases the activity of an RNA lariat debranching enzyme.\" [GOC:dph, PMID:24919400]","metadata":null},{"id":"04c94314feca41cc9d5f512441f3d176","type":"GO_TERM","name":"RNA lariat debranching enzyme activity","canonical_id":"go:GO:0008419","description":"\"Catalysis of the hydrolysis of branched RNA structures that contain vicinal 2'-5'- and 3'-5'-phosphodiester bonds at a branch point nucleotide.\" [PMID:7519612]","metadata":null},{"id":"46e1cace94d049489cf95c4444a30a7e","type":"GO_TERM","name":"RNA ligase (ATP) activity","canonical_id":"go:GO:0003972","description":"\"Catalysis of the reaction: ATP + (ribonucleotide)n-3'-hydroxyl + 5'-phospho-(ribonucleotide)m = (ribonucleotide)n+m + AMP + diphosphate.\" [EC:6.5.1.3]","metadata":null},{"id":"07f1c11b246f42218469ea5b63583e73","type":"GO_TERM","name":"RNA ligase (GTP) activity","canonical_id":"go:GO:0170057","description":"\"Catalysis of the joining of an RNA with 3'-phosphate or 2',3'-cyclic-phosphate ends to an RNA with 5'-hydroxy ends according to either (i) a 3'-end 3'-phospho-ribonucleotide-RNA + a 5'-end dephospho-ribonucleoside-RNA + GTP = a ribonucleotidyl-ribonucleotide-RNA + diphosphate + GMP; or (ii) a 3'-end 2',3'-cyclophospho-ribonucleotide-RNA + a 5'-end dephospho-ribonucleoside-RNA + GTP + H2O = a ribonucleotidyl-ribonucleotide-RNA + diphosphate + GMP + H+.\" [EC:6.5.1.8, PMID:21311021]","metadata":null},{"id":"08ff8d77c78f48daa7c1479cbf973d63","type":"GO_TERM","name":"RNA ligase activity","canonical_id":"go:GO:0008452","description":"\"Catalysis of the formation of a phosphodiester bond between a hydroxyl group at the end of one RNA chain and the phosphate group at the end of another.\" [GOC:mah]","metadata":null},{"id":"0159f7c136d94b109cc58a659433dc7b","type":"GO_TERM","name":"RNA localization","canonical_id":"go:GO:0006403","description":"\"A process in which RNA is transported to, or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"b27ace27715c4fa7b10f63d218c64e7f","type":"GO_TERM","name":"RNA localization to Cajal body","canonical_id":"go:GO:0090670","description":"\"A process in which an RNA is transported to, or maintained in, a Cajal body.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:25467444]","metadata":null},{"id":"b9ded235a36341bdb4992ee64c8b14ea","type":"GO_TERM","name":"RNA localization to chromatin","canonical_id":"go:GO:1990280","description":"\"A process in which RNA is transported to and maintained in a part of a chromosome that is organized into chromatin.\" [GOC:dos, GOC:mah, PMID:22582262]","metadata":null},{"id":"f8ba515fcf9449bca47d076bae1ad7bc","type":"GO_TERM","name":"RNA localization to nucleus","canonical_id":"go:GO:0090685","description":"\"A macromolecular localization process in which RNA is transported to and maintained in a location within the nucleus.\" [GOC:mah, PMID:26305931]","metadata":null},{"id":"87e93f663038448984f8ea04f54fe6c7","type":"GO_TERM","name":"RNA metabolic process","canonical_id":"go:GO:0016070","description":"\"The cellular chemical reactions and pathways involving RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage.\" [ISBN:0198506732]","metadata":null},{"id":"794c3471b12f498193aa25d2701e5ff7","type":"GO_TERM","name":"RNA methylation","canonical_id":"go:GO:0001510","description":"\"Posttranscriptional addition of a methyl group to either a nucleotide or 2'-O ribose in a polyribonucleotide. Usually uses S-adenosylmethionine as a cofactor.\" [GOC:hjd, PMID:21823225]","metadata":null},{"id":"875ce275df2c4bb797d4c92d1d0e5a27","type":"GO_TERM","name":"RNA methyltransferase activity","canonical_id":"go:GO:0008173","description":"\"Catalysis of the transfer of a methyl group from a donor to a nucleoside residue in an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"a1aaadf654564fd9bd7a37839c255cf7","type":"GO_TERM","name":"RNA modification","canonical_id":"go:GO:0009451","description":"\"The covalent alteration of one or more nucleotides within an RNA molecule to produce an RNA molecule with a sequence that differs from that coded genetically.\" [GOC:curators, ISBN:1555811337]","metadata":null},{"id":"cc7270582467402e8267115a3139f724","type":"GO_TERM","name":"RNA modification guide activity","canonical_id":"go:GO:0030555","description":"\"Specifies the site of a posttranscriptional modification in an RNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"8f5bfc65776e4914b4cd443b21060a9e","type":"GO_TERM","name":"RNA nuclear export complex","canonical_id":"go:GO:0042565","description":"\"A complex which usually consists of three components, e.g. in Xenopus and yeast, the export receptor CRM1 (also known as exportin 1), the Ran protein and any RNA with a nuclear export sequence (NES). The complex acts to export RNA molecules with a NES from the nucleus through a nuclear pore.\" [GOC:jl, PMID:9323123]","metadata":null},{"id":"41b3e2c214944b9fb7d88749d9e23a53","type":"GO_TERM","name":"RNA nuclease activity","canonical_id":"go:GO:0004540","description":"\"Catalysis of the cleavage of phosphodiester bonds in chains of RNA.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"42f78b002bce43d4a73f547758a6f173","type":"GO_TERM","name":"RNA nucleotide deletion","canonical_id":"go:GO:0070706","description":"\"The modification of an RNA molecule by removal of a single nucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"0a9b4be91db74a3d854bb87c122f5e42","type":"GO_TERM","name":"RNA nucleotide insertion","canonical_id":"go:GO:0070705","description":"\"The modification of an RNA molecule by insertion of one or more nucleotides.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"e78668a30d5047258c2398b8403a3666","type":"GO_TERM","name":"RNA polyadenylation at postsynapse","canonical_id":"go:GO:0140235","description":"\"A polyadenylation event (the enzymatic addition of a sequence of adenylyl residues at the 3' end of an RNA molecule) that takes place at a postsynapse.\" [PMID:22727665]","metadata":null},{"id":"d870fcfd33e1451ab478aa9f0a3e3412","type":"GO_TERM","name":"RNA polymerase I assembly","canonical_id":"go:GO:1990113","description":"\"The aggregation, arrangement and bonding together of a set of components to form the eukaryotic RNA polymerase I complex.\" [GOC:rb, PMID:23459708]","metadata":null},{"id":"5da513abe953421e8297dede8aa13020","type":"GO_TERM","name":"RNA polymerase I cis-regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0001165","description":"\"Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase I. RNA polymerase I elements are referred to either enhancers or upstream control element (UCE, or alternately referred to as the upstream element).\" [GOC:txnOH, PMID:12865296, PMID:14969726, PMID:8057832]","metadata":null},{"id":"03d70f96e9c44e6cae86dc40048efc67","type":"GO_TERM","name":"RNA polymerase I complex","canonical_id":"go:GO:0005736","description":"\"RNA polymerase I, one of three nuclear DNA-directed RNA polymerases found in all eukaryotes, is a multisubunit complex; typically it produces rRNAs. Two large subunits comprise the most conserved portion including the catalytic site and share similarity with other eukaryotic and bacterial multisubunit RNA polymerases. The remainder of the complex is composed of smaller subunits (generally ten or more), some of which are also found in RNA polymerase III and others of which are also found in RNA polymerases II and III. Although the core is competent to mediate ribonucleic acid synthesis, it requires additional factors to select the appropriate template.\" [GOC:krc, GOC:mtg_sensu]","metadata":null},{"id":"a4d9fd7e3bdc46a4869a2b4dc8903562","type":"GO_TERM","name":"RNA polymerase I core binding","canonical_id":"go:GO:0001042","description":"\"Binding to a RNA polymerase I core enzyme, a multisubunit eukaryotic nuclear RNA polymerase typically composed of seventeen subunits.\" [GOC:txnOH]","metadata":null},{"id":"e81cc635a9324b03a56083d60f13ba66","type":"GO_TERM","name":"RNA polymerase I core factor complex","canonical_id":"go:GO:0070860","description":"\"A RNA polymerase I-specific transcription factor complex that is required for the transcription of rDNA by RNA polymerase I. In yeast the complex consists of Rrn6p, Rrn7p, and Rrn11p.\" [PMID:8702872]","metadata":null},{"id":"4a4e3ede5f634488a052df8a9cafa116","type":"GO_TERM","name":"RNA polymerase I core promoter sequence-specific DNA binding","canonical_id":"go:GO:0001164","description":"\"Binding to a regulatory region composed of the transcription start site and binding sites for transcription factors of the RNA polymerase I transcription machinery. This site is often referred to as the CORE element. In mammalian cells, the CORE element functions in conjunction with the Upstream Control Element (UCE), while in fungi, protozoa, and plants, the CORE element functions without a UCE.\" [GOC:txnOH, PMID:12865296, PMID:14969726, PMID:8057832]","metadata":null},{"id":"2c583e32e68e4b908d8cfa67795531a4","type":"GO_TERM","name":"RNA polymerase I general transcription initiation factor activity","canonical_id":"go:GO:0001181","description":"\"A general transcription initiation factor activity that contributes to transcription start site selection and transcription initiation of genes transcribed by RNA polymerase I. Factors required for RNA polymerase I transcription initiation include upstream activation factor (UAF), core factor (CF), TATA binding protein (TBP) and RRN3. In all species characterized, RNA polymerase I transcribes a large polycistronic transcript that is processed into several mature rRNAs (3 or 4 depending on the species), including the large subunit rRNA (28S in humans), the small subunit rRNA (18S in humans), as well as one or two additional smaller rRNAs (the 5.8S rRNA in humans). In most species, this large rRNA transcript is the sole product of RNA polymerase I. However there are rare exceptions, such as Trypanosoma brucei, where RNA polymerase I also transcribes certain mRNAs.\" [GOC:txnOH-2018, PMID:11500378, PMID:17972917, PMID:25346433, PMID:28340337, PMID:28842442, PMID:31358304]","metadata":null},{"id":"319bade46c744b92b9b32a88886b4f08","type":"GO_TERM","name":"RNA polymerase I general transcription initiation factor binding","canonical_id":"go:GO:0001179","description":"\"Binding to an RNA polymerase I transcription factor, a protein required to initiate or regulate transcription by RNA polymerase I.\" [GOC:txnOH]","metadata":null},{"id":"b73d0d0ca2a2464dbe99839b257e4cc7","type":"GO_TERM","name":"RNA polymerase I preinitiation complex assembly","canonical_id":"go:GO:0001188","description":"\"The formation of a large multiprotein-DNA complex that self-assembles on gene promoter through the sequential recruitment of the general initiation factors that compose the preinitiation complex (PIC) (which includes including UBF, SL1, RRN3 and TBP in human). The PIC engages RNA polymerase I on its DNA template strand and sparks polymerization of the first few RNA nucleotides.\" [GOC:txnOH, PMID:14969726]","metadata":null},{"id":"2b199631969949009cb589b3234a9889","type":"GO_TERM","name":"RNA polymerase I promoter clearance","canonical_id":"go:GO:0001182","description":"\"A process that mediates the transition from the initiation to the elongation phases of transcription by RNA polymerase I, generally including a conformational change from the initiation conformation to the elongation conformation. Promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors.\" [GOC:txnOH, PMID:18559419]","metadata":null},{"id":"7efd54f223c346218e0e29d4cb07ae2d","type":"GO_TERM","name":"RNA polymerase I transcription regulator complex","canonical_id":"go:GO:0000120","description":"\"A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase I.\" [GOC:mah]","metadata":null},{"id":"152715fe0ddb4bafbb57f219e15131f4","type":"GO_TERM","name":"RNA polymerase I transcription regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0001163","description":"\"Binding to a specific sequence of DNA that is part of a regulatory region that controls the transcription of a gene or cistron by RNA polymerase I.\" [GOC:txnOH]","metadata":null},{"id":"ac0b13db1a714307bfe4cfd7d7b808ff","type":"GO_TERM","name":"RNA polymerase I transcription repressor complex","canonical_id":"go:GO:0090570","description":"\"A protein complex, located in the nucleus, that possesses activity that prevents or downregulates transcription from a RNA polymerase I promoter.\" [GOC:tb]","metadata":null},{"id":"0857ed78af1b4dba8edb6d9d338cfbb3","type":"GO_TERM","name":"RNA polymerase I upstream activating factor complex","canonical_id":"go:GO:0000500","description":"\"A complex required for the transcription of rDNA by RNA polymerase I. In yeast the complex consists of Rrrn5p, Rrn9p, Rrn10p, histones H3 and H4, and Uaf30p.\" [PMID:11500378]","metadata":null},{"id":"8769fea07eee494f9c74995f9ae62b58","type":"GO_TERM","name":"RNA polymerase II C-terminal domain O-GlcNAc transferase activity","canonical_id":"go:GO:0140841","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + RNA polymerase II large subunit CTD heptapeptide repeat (YSPTSPS) = UDP + RNA polymerase II large subunit CTD heptapeptide repeat 3-O-(N-acetyl-D-glucosaminyl)-L-serine.\" [PMID:22605332]","metadata":null},{"id":"1c2c26a7713e4895a7de3c3c7384de30","type":"GO_TERM","name":"RNA polymerase II C-terminal domain S5 O-GlcNAc transferase activity","canonical_id":"go:GO:0140842","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + RNA polymerase II large subunit CTD heptapeptide repeat (YSPTSPS) = UDP + RNA polymerase II large subunit CTD heptapeptide repeat 3-O-(N-acetyl-D-glucosaminyl)-L-serine (position 5).\" [PMID:22605332]","metadata":null},{"id":"01b7bdf92854456f849e3a389d606c18","type":"GO_TERM","name":"RNA polymerase II C-terminal domain S7 O-GlcNAc transferase activity","canonical_id":"go:GO:0140843","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + RNA polymerase II large subunit CTD heptapeptide repeat (YSPTSPS) = UDP + RNA polymerase II large subunit CTD heptapeptide repeat 3-O-(N-acetyl-D-glucosaminyl)-L-serine (position 7).\" [PMID:22605332]","metadata":null},{"id":"7f0b9fb64b4b4dba924db2fa5f0c060c","type":"GO_TERM","name":"RNA polymerase II C-terminal domain binding","canonical_id":"go:GO:0099122","description":"\"Binding to the C-terminal domain (CTD) of the largest subunit of RNA polymerase II. The CTD is comprised of repeats of a heptapeptide with the consensus sequence YSPTSPS. The number of repeats varies with the species and a minimum number of repeats is required for RNAP II function.\" [PMID:20889714]","metadata":null},{"id":"9a3f95dd48af4f229aa7c14538aae9fe","type":"GO_TERM","name":"RNA polymerase II C-terminal domain phosphoserine binding","canonical_id":"go:GO:1990269","description":"\"Binding to phosphorylated serine residues in the C-terminal domain of RNA polymerase II.\" [GOC:di, PMID:22796944]","metadata":null},{"id":"64587fc7dd0742b3bef73b534e86bc46","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat P3 isomerase activity","canonical_id":"go:GO:0140839","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) cis-proline (omega=180) (position 3) = RNA polymerase II large subunit trans-proline (omega=0) (position 3).\" [PMID:28248323]","metadata":null},{"id":"edee205a4aaa4932a49801ca6af9faa8","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat P6 isomerase activity","canonical_id":"go:GO:0140840","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) cis-proline (omega=180) (position 6) = RNA polymerase II large subunit trans-proline (omega=0) (position 6).\" [PMID:28248323]","metadata":null},{"id":"8a52d1d95ed146d3b444f95180fbda27","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat S2 kinase activity","canonical_id":"go:GO:0140834","description":"\"Catalysis of the reaction: ATP + RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) = ADP + H+ + RNA polymerase II large subunit phosphoserine (position 2).\" [PMID:28248323]","metadata":null},{"id":"b3c202b4cc1b4b999700f3aac0047233","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat S2 phosphatase activity","canonical_id":"go:GO:0180006","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat--phospho-L-serine (consensus YSPTSPS)(position 2) + H2O = RNA polymerase II large subunit + phosphate.\" [PMID:22622228]","metadata":null},{"id":"d37a37f4feb144d2869f795391d1555f","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat S5 kinase activity","canonical_id":"go:GO:0140836","description":"\"Catalysis of the reaction: ATP + RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) = ADP + H+ + RNA polymerase II large subunit phosphoserine (position 5).\" [PMID:28248323]","metadata":null},{"id":"c4e59fd032d542ea958d15101f4474d1","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat S5 phosphatase activity","canonical_id":"go:GO:0180007","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat--phospho-L-serine (consensus YSPTSPS)(position 5) + H2O = RNA polymerase II large subunit + phosphate.\" [PMID:22622228]","metadata":null},{"id":"af8f630b3b9b4f759d00d8d2c72d2a20","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat S7 kinase activity","canonical_id":"go:GO:0140837","description":"\"Catalysis of the reaction: ATP + RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) = ADP + H+ + RNA polymerase II large subunit phosphoserine (position 7).\" [PMID:28248323]","metadata":null},{"id":"c67957961b6142bc87bb7c95baccc4b7","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat S7 phosphatase activity","canonical_id":"go:GO:0180008","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat--phospho-L-serine (consensus YSPTSPS)(position 7) + H2O = RNA polymerase II large subunit + phosphate.\" [PMID:22622228]","metadata":null},{"id":"cb44b5b9d7394db3adbf81fc2a4c424a","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat T4 kinase activity","canonical_id":"go:GO:0140835","description":"\"Catalysis of the reaction: ATP + RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) = ADP + H+ + RNA polymerase II large subunit phosphothreonine (position 4).\" [PMID:28248323]","metadata":null},{"id":"29aac25e23cb495b871037b90a683416","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat T4 phosphatase activity","canonical_id":"go:GO:0180005","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat--phospho-L-threonine (consensus YSPTSPS)(position 4) + H2O = RNA polymerase II large subunit + phosphate.\" [PMID:22622228]","metadata":null},{"id":"2bdd129d07b84781bfedcf6c1d878078","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat Y1 kinase activity","canonical_id":"go:GO:0140833","description":"\"Catalysis of the reaction: ATP + RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) = ADP + H+ + RNA polymerase II large subunit phosphotyrosine (position 1).\" [PMID:28248323]","metadata":null},{"id":"2fa736ff4a604c55bc9fd8c722a44660","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat Y1 phosphatase activity","canonical_id":"go:GO:0180004","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat--phospho-L-tyrosine (consensus YSPTSPS)(position 1) + H2O = RNA polymerase II large subunit + phosphate.\" [PMID:22622228]","metadata":null},{"id":"d778cb1189e04d87bf20275a7edc9e91","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat kinase activity","canonical_id":"go:GO:0008353","description":"\"Catalysis of the reaction: ATP + RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) = ADP + H+ + phosphorylated RNA polymerase II.\" [EC:2.7.11.23, GOC:mah, PMID:28248323]","metadata":null},{"id":"eb0eac8554f54d6b8f542e6d585a967c","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat modifying activity","canonical_id":"go:GO:0140994","description":"\"A catalytic activity that acts on the RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS). Reversible modifications cof the RNA polymerase II CTD repeats contribute to regulation of RNA polymerase activity.\" [GOC:pg]","metadata":null},{"id":"c563f7f1a6f94d3591cb3abe7a6eb7f7","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat peptidyl-prolyl isomerase activity","canonical_id":"go:GO:0140838","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat (consensus YSPTSPS) cis-proline (omega=180) = RNA polymerase II large subunit trans-proline (omega=0).\" [PMID:28248323]","metadata":null},{"id":"63b2a2ef453a489681c5d43de55fc470","type":"GO_TERM","name":"RNA polymerase II CTD heptapeptide repeat phosphatase activity","canonical_id":"go:GO:0008420","description":"\"Catalysis of the reaction: RNA polymerase II large subunit CTD heptapeptide repeat--phospho-L-serine/threonine (consensus YSPTSPS) + H2O = RNA polymerase II large subunit + phosphate.\" [PMID:22622228]","metadata":null},{"id":"fc82a8eddd724756ac8a12b557fe51c1","type":"GO_TERM","name":"RNA polymerase II cis-regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0000978","description":"\"Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II.\" [GOC:txnOH-2018]","metadata":null},{"id":"821994b59bf446c68c065dc4496736a9","type":"GO_TERM","name":"RNA polymerase II cis-regulatory region sequence-specific DNA binding, bending","canonical_id":"go:GO:0044377","description":"\"Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II, and distorting the original structure of DNA, typically a straight helix, into a bend, or increasing the bend if the original structure was intrinsically bent due to its sequence.\" [GOC:jl, GOC:pg]","metadata":null},{"id":"49e34aae56bd4e6cb5c5f8adc106be0d","type":"GO_TERM","name":"RNA polymerase II complex binding","canonical_id":"go:GO:0000993","description":"\"Binding to an RNA polymerase II core enzyme, a multisubunit eukaryotic nuclear RNA polymerase typically composed of twelve subunits.\" [GOC:txnOH]","metadata":null},{"id":"e4075b362448472d81aef404055429d3","type":"GO_TERM","name":"RNA polymerase II core complex assembly","canonical_id":"go:GO:1990114","description":"\"The aggregation, arrangement and bonding together of a set of components to form the eukaryotic RNA polymerase II core complex.\" [GOC:rb, PMID:23459708]","metadata":null},{"id":"5186471c55bc41ebb2a0c73eff8e4cfe","type":"GO_TERM","name":"RNA polymerase II core promoter sequence-specific DNA binding","canonical_id":"go:GO:0000979","description":"\"Binding to a DNA sequence that is part of the core promoter of a RNA polymerase II-transcribed gene.\" [GOC:pg, GOC:txnOH, PMID:12381658]","metadata":null},{"id":"ef5014dd688c4c34b80e98f77fdb5717","type":"GO_TERM","name":"RNA polymerase II general transcription initiation factor activity","canonical_id":"go:GO:0016251","description":"\"A general transcription initiation factor activity that contributes to transcription start site selection and transcription initiation of genes transcribed by RNA polymerase II. The general transcription factors for RNA polymerase II include TFIIB, TFIID, TFIIE, TFIIF, TFIIH and TATA-binding protein (TBP). In most species, RNA polymerase II transcribes all messenger RNAs (mRNAs), most untranslated regulatory RNAs, the majority of the snoRNAs, four of the five snRNAs (U1, U2, U4, and U5), and other small noncoding RNAs. For some small RNAs there is variability between species as to whether it is transcribed by RNA polymerase II or RNA polymerase III. However there are also rare exceptions, such as Trypanosoma brucei, where RNA polymerase I transcribes certain mRNAs in addition to its normal role in rRNA transcription.\" [GOC:txnOH-2018, PMID:10384286, PMID:10747032, PMID:23442138, PMID:25693126]","metadata":null},{"id":"aa515d2b4a6245e0b21dd35686bd6aec","type":"GO_TERM","name":"RNA polymerase II general transcription initiation factor binding","canonical_id":"go:GO:0001091","description":"\"Binding to a basal RNA polymerase II transcription factor, any of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II and defined as a basal or general transcription factor.\" [GOC:txnOH, PMID:16858867]","metadata":null},{"id":"a6699272fe5b42319a87ff5b3acf199d","type":"GO_TERM","name":"RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0001162","description":"\"Binding to an RNA polymerase II intronic DNA sequence that regulates the transcription of the transcript it is contained within.\" [GOC:txnOH]","metadata":null},{"id":"09a458421a2740fc92f53b096f1f4086","type":"GO_TERM","name":"RNA polymerase II preinitiation complex assembly","canonical_id":"go:GO:0051123","description":"\"The formation of a large multiprotein-DNA complex that self-assembles on gene promoter through the sequential recruitment of the general initiation factors that compose the preinitiation complex (PIC) (which may include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH complexes). The PIC engages RNA polymerase II on its DNA template strand and sparks polymerization of the first few RNA nucleotides of the nascent transcript, of which 8 are base-paired with the DNA template within a DNA bubble. PIC assembly may result in a pause step, which marks the end of the PIC assembly and may be followed by promoter clearance (exact synonym: promoter escape). For RNA polymerase II PIC assembly is preceded by the formation of a nucleosome-free region that allows the transcription machinery to access the promoter DNA.\" [GOC:txnOH, PMID:15020047, PMID:31300188]","metadata":null},{"id":"bc79fefa1e0f4fedb08e8e84755a718b","type":"GO_TERM","name":"RNA polymerase II promoter clearance","canonical_id":"go:GO:0001111","description":"\"A process that mediates the transition from the initiation to the elongation phases of transcription by RNA polymerase II, generally including a conformational change from the initiation conformation to the elongation conformation. Promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors.\" [GOC:txnOH, PMID:15020047, PMID:22982364, PMID:31628251]","metadata":null},{"id":"fd4799e7e2654c3db951dd3bbfd08ed8","type":"GO_TERM","name":"RNA polymerase II termination complex","canonical_id":"go:GO:0110103","description":"\"A conserved protein complex capable of 5'-3' exoribonuclease activity. It is able to promote RNA polymerase II (RNAPII) transcription termination by degrading pre-mRNA from the newly formed 5' phosphorylated end.\" [GOC:lnp, PMID:23200120, PMID:25722373]","metadata":null},{"id":"414dc627e80c4db7a49d03f7adaea317","type":"GO_TERM","name":"RNA polymerase II transcription initiation surveillance","canonical_id":"go:GO:0160240","description":"\"A process that promotes premature RNA polymerase II transcription termination of transcripts that are unfavorably configured for transcriptional elongation by releasing RNA polymerase II from bound DNA or promoting RNA polymerase II degradation.\" [PMID:33385327, PMID:34762484]","metadata":null},{"id":"67ad2b73a41240b8af35ba6c88c7af3c","type":"GO_TERM","name":"RNA polymerase II transcription regulator complex","canonical_id":"go:GO:0090575","description":"\"A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase II.\" [GOC:tb]","metadata":null},{"id":"e90645cf8a39494798352158b247a6a4","type":"GO_TERM","name":"RNA polymerase II transcription regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0000977","description":"\"Binding to a specific sequence of DNA that is part of a regulatory region that controls the transcription of a gene or cistron by RNA polymerase II.\" [GOC:txnOH]","metadata":null},{"id":"5057ebb704db441eb08cc4994487cc0d","type":"GO_TERM","name":"RNA polymerase II transcription repressor complex","canonical_id":"go:GO:0090571","description":"\"A protein complex, located in the nucleus, that possesses activity that prevents or downregulates transcription from a RNA polymerase II promoter.\" [GOC:tb]","metadata":null},{"id":"2b8f839e7e004cc2a26046fb74616170","type":"GO_TERM","name":"RNA polymerase II, core complex","canonical_id":"go:GO:0005665","description":"\"RNA polymerase II, one of three nuclear DNA-directed RNA polymerases found in all eukaryotes, is a multisubunit complex; typically it produces mRNAs, snoRNAs, and some of the snRNAs. Two large subunits comprise the most conserved portion including the catalytic site and share similarity with other eukaryotic and bacterial multisubunit RNA polymerases. The largest subunit of RNA polymerase II contains an essential carboxyl-terminal domain (CTD) composed of a variable number of heptapeptide repeats (YSPTSPS). The remainder of the complex is composed of smaller subunits (generally ten or more), some of which are also found in RNA polymerases I and III. Although the core is competent to mediate ribonucleic acid synthesis, it requires additional factors to select the appropriate template.\" [GOC:krc, GOC:mtg_sensu]","metadata":null},{"id":"1aa0030280fa4566a635fe3bb15ef537","type":"GO_TERM","name":"RNA polymerase II, holoenzyme","canonical_id":"go:GO:0016591","description":"\"A nuclear DNA-directed RNA polymerase complex containing an RNA polymerase II core enzyme as well as additional proteins and transcription factor complexes, that are capable of promoter recognition and transcription initiation from an RNA polymerase II promoter in vivo. These additional components may include general transcription factor complexes TFIIA, TFIID, TFIIE, TFIIF, or TFIIH, as well as Mediator, SWI/SNF, GCN5, or SRBs and confer the ability to recognize promoters.\" [GOC:jl, GOC:krc, PMID:16858867, Wikipedia:Rna_polymerase_ii]","metadata":null},{"id":"c0ce047438c240b292dc6819d627f5dd","type":"GO_TERM","name":"RNA polymerase II-specific DNA-binding transcription factor binding","canonical_id":"go:GO:0061629","description":"\"Binding to a sequence-specific DNA binding RNA polymerase II transcription factor, any of the factors that interact selectively and non-covalently with a specific DNA sequence in order to modulate transcription.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"af38fc56ae654af3b0c752c30b125081","type":"GO_TERM","name":"RNA polymerase III assembly","canonical_id":"go:GO:1990115","description":"\"The aggregation, arrangement and bonding together of a set of components to form the eukaryotic RNA polymerase III complex.\" [GOC:rb, PMID:23459708]","metadata":null},{"id":"ab0e8bb4480c454fb8813e84019fe114","type":"GO_TERM","name":"RNA polymerase III cis-regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0000992","description":"\"Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase III. The transcribed region might be contain a single gene or a cistron containing multiple genes.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"42b085d5b4824c9dac92f3e37f190100","type":"GO_TERM","name":"RNA polymerase III complex","canonical_id":"go:GO:0005666","description":"\"RNA polymerase III, one of three nuclear DNA-directed RNA polymerases found in all eukaryotes, is a multisubunit complex; typically it produces 5S rRNA, tRNAs and some of the small nuclear RNAs. Two large subunits comprise the most conserved portion including the catalytic site and share similarity with other eukaryotic and bacterial multisubunit RNA polymerases. The remainder of the complex is composed of smaller subunits (generally ten or more), some of which are also found in RNA polymerase I and others of which are also found in RNA polymerases I and II. Although the core is competent to mediate ribonucleic acid synthesis, it requires additional factors to select the appropriate template.\" [GOC:krc, GOC:mtg_sensu]","metadata":null},{"id":"2fe97b558aa849b8969fa4cf7758e043","type":"GO_TERM","name":"RNA polymerase III core binding","canonical_id":"go:GO:0000994","description":"\"Binding to an RNA polymerase III core enzyme, a multisubunit eukaryotic nuclear RNA polymerase typically composed of seventeen subunits.\" [GOC:txnOH]","metadata":null},{"id":"9ff93c518e5041fc95f3f105222389a7","type":"GO_TERM","name":"RNA polymerase III general transcription initiation factor activity","canonical_id":"go:GO:0000995","description":"\"A general transcription initiation factor activity that contributes to transcription start site selection and transcription initiation of genes transcribed by RNA polymerase III. Factors required for RNA polymerase III transcription initiation include TFIIIA, TFIIIB and TFIIIC. RNA polymerase III transcribes genes encoding short RNAs, including tRNAs, 5S rRNA, U6 snRNA, the short ncRNA component of RNases P, the mitochondrial RNA processing (MRP) RNA, the signal recognition particle SRP RNA, and in higher eukaryotes a number of micro and other small RNAs, though there is some variability across species as to whether a given small noncoding RNA is transcribed by RNA polymerase II or RNA polymerase III.\" [GOC:txnOH-2018, PMID:12381659, PMID:17977614, PMID:20413673, PMID:27068803, PMID:40762516, Wikipedia:RNA_polymerase_III]","metadata":null},{"id":"582b14ca95da4764b28dbb65c96daf12","type":"GO_TERM","name":"RNA polymerase III general transcription initiation factor binding","canonical_id":"go:GO:0001025","description":"\"Binding to an RNA polymerase III transcription factor, a protein required to initiate or regulate transcription by RNA polymerase III.\" [GOC:txnOH]","metadata":null},{"id":"c194944996a74342b719c739c9231924","type":"GO_TERM","name":"RNA polymerase III hybrid type promoter sequence-specific DNA binding","canonical_id":"go:GO:0001039","description":"\"Binding to a sequence of DNA that is a part of a hybrid type promoter that controls transcription by RNA polymerase III (Pol III). A hybrid Pol III promoter contains both regulatory elements both upstream and downstream of the transcription initiation site. An example gene with such a promoter is the S. cerevisiae U6 gene.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"908540fb328b4daeb56e39acf20553d2","type":"GO_TERM","name":"RNA polymerase III preinitiation complex assembly","canonical_id":"go:GO:0070898","description":"\"The formation of a large multiprotein-DNA complex that self-assembles on a tRNA gene through the sequential recruitment of the general initiation factors that compose the preinitiation complex (PIC), (which includes BDP1, BRF1, TBP, TFIIIC in human). The PIC engages RNA polymerase III on its DNA template strand and sparks polymerization of the first few RNA nucleotides.\" [GOC:txnOH, PMID:11387215, PMID:12381659]","metadata":null},{"id":"67f5dadc67b040d39c6f82bf8e753add","type":"GO_TERM","name":"RNA polymerase III promoter clearance","canonical_id":"go:GO:0001110","description":"\"A process that mediates the transition from the initiation to the elongation phases of transcription by RNA polymerase III, generally including a conformational change from the initiation conformation to the elongation conformation. Promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase.\" [GOC:txnOH]","metadata":null},{"id":"ff78d26854854f4c8a215852abad0bfb","type":"GO_TERM","name":"RNA polymerase III transcription regulator complex","canonical_id":"go:GO:0090576","description":"\"A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase III.\" [GOC:tb]","metadata":null},{"id":"aedb349b46644dd9bc139ba48e2b770e","type":"GO_TERM","name":"RNA polymerase III transcription regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0001016","description":"\"Binding to a DNA region that controls the transcription of a gene by RNA polymerase III. Binding may occur as a sequence specific interaction or as an interaction observed only once a factor has been recruited to the DNA by other factors.\" [GOC:txnOH, GOC:vw, PMID:12381659]","metadata":null},{"id":"532d1e88747f4d28a3c958b684ae8825","type":"GO_TERM","name":"RNA polymerase III transcription repressor complex","canonical_id":"go:GO:0090572","description":"\"A protein complex, located in the nucleus, that possesses activity that prevents or downregulates transcription from a RNA polymerase III promoter.\" [GOC:tb]","metadata":null},{"id":"d804d67cc71742ebab1748e01b8e163e","type":"GO_TERM","name":"RNA polymerase III type 1 promoter sequence-specific DNA binding","canonical_id":"go:GO:0001002","description":"\"Binding to a sequence of DNA that is a part of a type 1 promoter that controls transcription by RNA polymerase III. Type 1 promoters are found in 5S rRNA genes, downstream of the transcription start site within the sequence of the mature RNA, and require TFIIIA for recognition.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"b0d0d388f1a641aaa6d369d7dc77222d","type":"GO_TERM","name":"RNA polymerase III type 2 promoter sequence-specific DNA binding","canonical_id":"go:GO:0001003","description":"\"Binding to a sequence of DNA that is a part of a type 2 promoter that controls transcription by RNA polymerase III. Type 2 promoters consist of an A box and a B box downstream of the transcription start site within the sequence within the sequence of the mature RNA. Type 2 promoters are found in many tRNA genes as well as in other small RNAs.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"d6abe52d5f7f4f81b31ba31524b3ca17","type":"GO_TERM","name":"RNA polymerase III type 3 promoter sequence-specific DNA binding","canonical_id":"go:GO:0001006","description":"\"Binding to a sequence of DNA that is a part of a type 3 promoter that controls transcription by RNA polymerase III (Pol III). A type 3 Pol III promoter is composed of elements upstream of the transcription start site, including a TATA box. The human U6 snRNA gene has a type 3 promoter. Type 3 Pol III promoters have not been observed in S. cerevisiae.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"89549877a06d40bd859c5a120c6f0ab7","type":"GO_TERM","name":"RNA polymerase IV complex","canonical_id":"go:GO:0000418","description":"\"RNA polymerase IV is a multisubunit RNA polymerase complex found in the nucleus of plants and involved in accumulation of siRNAs and in DNA methylation-dependent silencing of endogenous repeated sequences. Pol IV is composed of subunits that are paralogous or identical to the 12 subunits of Pol II. The largest and second-largest subunits of Pol IV are the catalytic subunits and share similarity with the corresponding subunits of other eukaryotic and bacterial multisubunit RNA polymerases. The second largest subunit is also found in RNA polymerase V, while the largest subunit is found only in RNAP IV complex.\" [GOC:krc, GOC:mtg_sensu, PMID:15692015, PMID:15766525, PMID:16140984, PMID:19110459]","metadata":null},{"id":"147b58bd6f87400ca93e6fbf002d6f81","type":"GO_TERM","name":"RNA polymerase IV core binding","canonical_id":"go:GO:0001048","description":"\"Binding to RNA polymerase IV core enzyme, a multisubunit eukaryotic nuclear RNA polymerase found in plants and involved in siRNA production.\" [GOC:txnOH, PMID:19110459]","metadata":null},{"id":"37ba4bb73a3e476a82829183fa6e8712","type":"GO_TERM","name":"RNA polymerase IV transcription regulator complex","canonical_id":"go:GO:0090577","description":"\"A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase IV.\" [GOC:tb]","metadata":null},{"id":"6b32e6ef756f4365901a95b98a3089cc","type":"GO_TERM","name":"RNA polymerase IV transcription repressor complex","canonical_id":"go:GO:0090573","description":"\"A protein complex, located in the nucleus, that possesses activity that prevents or downregulates transcription from a RNA polymerase IV promoter.\" [GOC:tb]","metadata":null},{"id":"6a57703e2f73440b8641ae41d6ada880","type":"GO_TERM","name":"RNA polymerase V complex","canonical_id":"go:GO:0000419","description":"\"RNA polymerase V is a multisubunit RNA polymerase complex found in the nucleus of plants and involved in accumulation of siRNAs and in DNA methylation-dependent silencing of endogenous repeated sequences. Pol V is composed of subunits that are paralogous or identical to the 12 subunits of Pol II. Two large subunits comprise the most conserved portion including the catalytic site and share similarity with other eukaryotic and bacterial multisubunit RNA polymerases. The second largest subunit is also found in RNA polymerase IVa, while the largest subunit is found only in the IVa complex and contains an extended C-terminal domain (CTD) that includes multiple repeats of a 16 amino-acid consensus sequence as well as other sequences. The remainder of the complex is composed of smaller subunits.\" [GOC:krc, GOC:mtg_sensu, PMID:16140984, PMID:19110459]","metadata":null},{"id":"a5d92582452b422f841cd8ce2af05219","type":"GO_TERM","name":"RNA polymerase V core binding","canonical_id":"go:GO:0001049","description":"\"Binding to RNA polymerase V core enzyme, a multisubunit eukaryotic nuclear RNA polymerase found in plants and involved in production of noncoding transcripts at target loci for silencing.\" [GOC:txnOH, PMID:19110459]","metadata":null},{"id":"83adbc25a9234044942e46abc024941a","type":"GO_TERM","name":"RNA polymerase V transcription regulator complex","canonical_id":"go:GO:0090578","description":"\"A transcription factor complex that acts at a regulatory region of a gene transcribed by RNA polymerase V.\" [GOC:tb]","metadata":null},{"id":"9f230568067a4c78a3a425d94d33c0fd","type":"GO_TERM","name":"RNA polymerase V transcription repressor complex","canonical_id":"go:GO:0090574","description":"\"A protein complex, located in the nucleus, that possesses activity that prevents or downregulates transcription from a RNA polymerase V promoter.\" [GOC:tb]","metadata":null},{"id":"9336f6431ed944509d62c0f539eafad9","type":"GO_TERM","name":"RNA polymerase activity","canonical_id":"go:GO:0097747","description":"\"Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); the synthesis of RNA from ribonucleotide triphosphates in the presence of a nucleic acid template.\" [GOC:pf]","metadata":null},{"id":"b9e3b71feed04613a113b76a98c68325","type":"GO_TERM","name":"RNA polymerase binding","canonical_id":"go:GO:0070063","description":"\"Binding to an RNA polymerase molecule or complex.\" [GOC:BHF, GOC:mah, GOC:txnOH]","metadata":null},{"id":"6d81bc2e1c604daea472c41424c364be","type":"GO_TERM","name":"RNA polymerase complex","canonical_id":"go:GO:0030880","description":"\"Any complex that possesses RNA polymerase activity; generally comprises a catalytic subunit and one or more additional subunits.\" [GOC:mah]","metadata":null},{"id":"d6494980e826468f91574644eab11e98","type":"GO_TERM","name":"RNA polymerase core enzyme binding","canonical_id":"go:GO:0043175","description":"\"Binding to an RNA polymerase core enzyme, containing a specific subunit composition defined as the core enzyme.\" [GOC:jl, GOC:txnOH]","metadata":null},{"id":"5e014b4fcf704894a3f58fc84a1171b8","type":"GO_TERM","name":"RNA polymerase inhibitor activity","canonical_id":"go:GO:0140870","description":"\"Binds to and stops, prevents or reduces the activity of RNA polymerase.\" [PMID:15300239, PMID:18313387, PMID:31048766]","metadata":null},{"id":"f17043d2599e434da9c225a4f42f6657","type":"GO_TERM","name":"RNA polymerase transcription factor SL1 complex","canonical_id":"go:GO:0005668","description":"\"A RNA polymerase I-specific transcription factor complex that contains the TATA-box-binding protein (TBP) and at least three TBP-associated factors including proteins known in mammals as TAFI110, TAFI63 and TAFI48.\" [PMID:15691654]","metadata":null},{"id":"acf4eff0e20c4cd89f11b0efa2872bca","type":"GO_TERM","name":"RNA processing","canonical_id":"go:GO:0006396","description":"\"Any process involved in the conversion of one or more primary RNA transcripts into one or more mature RNA molecules.\" [GOC:mah]","metadata":null},{"id":"d8791d5777bd4cd490cbca0ff1e2b126","type":"GO_TERM","name":"RNA pseudouridylation guide activity","canonical_id":"go:GO:0030558","description":"\"Specifies the site of pseudouridylation in an RNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"6ae4881ca784428ebf8c9c3129efbe68","type":"GO_TERM","name":"RNA repair","canonical_id":"go:GO:0042245","description":"\"Any process that results in the repair of damaged RNA.\" [PMID:11000254, PMID:11070075, UniProtKB-KW:KW-0692]","metadata":null},{"id":"812c094540d946f887dd0b665afa360e","type":"GO_TERM","name":"RNA replication","canonical_id":"go:GO:0039703","description":"\"The cellular metabolic process in which a cell duplicates one or more molecules of RNA.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"05027ca81436440fa544bf5819181fb6","type":"GO_TERM","name":"RNA sequestering activity","canonical_id":"go:GO:0140610","description":"\"Binding to a specific RNA molecule to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:23334420, PMID:29084823]","metadata":null},{"id":"cab4f38614624653975b28a55cf462a5","type":"GO_TERM","name":"RNA splicing","canonical_id":"go:GO:0008380","description":"\"The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"d1d90b5217bf46f9b82ef2c8dbf24fbc","type":"GO_TERM","name":"RNA splicing, via endonucleolytic cleavage and ligation","canonical_id":"go:GO:0000394","description":"\"Splicing of RNA via recognition of the folded RNA structure that brings the 5' and 3' splice sites into proximity and cleavage of the RNA at both the 3' and 5' splice sites by an endonucleolytic mechanism, followed by ligation of the exons.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"53f1ca001fdd41c39c5b19f9eb7f865f","type":"GO_TERM","name":"RNA splicing, via transesterification reactions","canonical_id":"go:GO:0000375","description":"\"Splicing of RNA via a series of two transesterification reactions.\" [GOC:krc]","metadata":null},{"id":"bc4c89e1040445089d3cd900da65ecc5","type":"GO_TERM","name":"RNA splicing, via transesterification reactions with bulged adenosine as nucleophile","canonical_id":"go:GO:0000377","description":"\"Splicing of RNA via a series of two transesterification reactions with a bulged adenosine residue from the intron branch point as the initiating nucleophile. When the initial RNA for the splicing reaction is a single molecule (cis splicing), the excised intron is released in a lariat structure.\" [GOC:krc, PMID:11377794]","metadata":null},{"id":"f6ee689df43a477693cfc6feffa5df02","type":"GO_TERM","name":"RNA splicing, via transesterification reactions with guanosine as nucleophile","canonical_id":"go:GO:0000376","description":"\"Splicing of RNA via a series of two transesterification reactions with exogenous guanosine as the initiating nucleophile.\" [GOC:krc, PMID:11377794]","metadata":null},{"id":"968d1e90a82440afa0bbfb59f281107c","type":"GO_TERM","name":"RNA stabilization","canonical_id":"go:GO:0043489","description":"\"Prevention of degradation of RNA molecules.\" [GOC:curators]","metadata":null},{"id":"630d0456c81941f7a45fd4eb9b63af82","type":"GO_TERM","name":"RNA stem-loop binding","canonical_id":"go:GO:0035613","description":"\"Binding to a stem-loop in an RNA molecule. An RNA stem-loop is a secondary RNA structure consisting of a double-stranded RNA (dsRNA) stem and a terminal loop.\" [GOC:sart, PMID:16568238, PMID:20455544]","metadata":null},{"id":"f57f8690d4794b84b1a7e1e03d17311b","type":"GO_TERM","name":"RNA strand annealing activity","canonical_id":"go:GO:0033592","description":"\"An activity that facilitates the formation of a complementary double-stranded RNA molecule.\" [GOC:mah, PMID:7543843]","metadata":null},{"id":"160d0f5de2e7439b92e8b8b511d82597","type":"GO_TERM","name":"RNA strand-exchange activity","canonical_id":"go:GO:0034057","description":"\"Facilitates the displacement of one strand of an RNA-RNA duplex and its replacement with a different strand of higher complementarity.\" [GOC:mcc, PMID:9769100]","metadata":null},{"id":"25fb432914034a6a81b98cd95864d752","type":"GO_TERM","name":"RNA surveillance","canonical_id":"go:GO:0071025","description":"\"A process that identifies and degrades defective or aberrant RNAs.\" [GOC:dgf, GOC:krc, PMID:18644474]","metadata":null},{"id":"50798fc567a1438da6dfbe2e8075c23e","type":"GO_TERM","name":"RNA topoisomerase activity","canonical_id":"go:GO:0140226","description":"\"Catalysis of the transient cleavage and passage of individual RNA strands or double helices through one another, resulting a topological transformation in RNA.\" [GOC:lnp, PMID:23912945, PMID:27257063]","metadata":null},{"id":"bc3e998b320242699628899580c3cb0c","type":"GO_TERM","name":"RNA translocase activity","canonical_id":"go:GO:0039630","description":"\"Generating a movement along a single- or double-stranded RNA molecule, driven by ATP hydrolysis.\" [GOC:bm, PMID:22713318]","metadata":null},{"id":"70818e75d9d64f36b6a5251d6c250298","type":"GO_TERM","name":"RNA transmembrane transporter activity","canonical_id":"go:GO:0051033","description":"\"Enables the transfer of RNA, ribonucleic acid, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"7193f1af329c4a11b6ed4dc9b5880cad","type":"GO_TERM","name":"RNA transport","canonical_id":"go:GO:0050658","description":"\"The directed movement of RNA, ribonucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"a9d5397149794bcdb5dc8968cbc39ddf","type":"GO_TERM","name":"RNA trimethylguanosine cap binding","canonical_id":"go:GO:0000341","description":"\"Binding to the trimethylguanosine (m(3)(2,2,7)-GTP) group located at the 5' end of some RNA molecules. Such trimethylated cap structures, generally produced by posttranscriptional modification of a 7-methylguanosine cap, are often found on snRNAs and snoRNAs transcribed by RNA polymerase II, but have also be found on snRNAs transcribed by RNA polymerase III. They have also been found on a subset of the mRNA population in some species, e.g. C. elegans.\" [GOC:krc]","metadata":null},{"id":"1365d1c016b540a18bf8fe2023c5dcbd","type":"GO_TERM","name":"RNA uridine deletion","canonical_id":"go:GO:0070710","description":"\"The modification of an RNA molecule by removal of a uridine nucleotide.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"1b8dc9daa75a4ff59592c2ad31e9ae82","type":"GO_TERM","name":"RNA uridylyltransferase activity","canonical_id":"go:GO:0050265","description":"\"Catalysis of the reaction: UTP + RNA(n) = diphosphate + RNA(n+1).\" [EC:2.7.7.52, MetaCyc:RNA-URIDYLYLTRANSFERASE-RXN]","metadata":null},{"id":"4851ac16924e4aedb8f2f827bd09b2ad","type":"GO_TERM","name":"RNA-(apurinic or apyrimidinic site) endonuclease activity","canonical_id":"go:GO:0052719","description":"\"Catalysis of the hydrolysis of ester linkages immediately 5' to an apurinic/apyrimidinic (AP; also called abasic) site within a ribonucleic acid molecule by creating internal breaks, generating a single-strand break with 5'-ribose phosphate and 3'-hydroxyl ends.\" [PMID:19401441]","metadata":null},{"id":"aac68185ef4d4b6abacfb8fa92d41a2b","type":"GO_TERM","name":"RNA-3'-phosphate cyclase activity","canonical_id":"go:GO:0003963","description":"\"Catalysis of the reaction: ATP + RNA 3'-terminal-phosphate = AMP + diphosphate + RNA terminal-2',3'-cyclic-phosphate.\" [EC:6.5.1.4]","metadata":null},{"id":"85a00a1559834d759a4105e99714a40c","type":"GO_TERM","name":"RNA-DNA hybrid ribonuclease activity","canonical_id":"go:GO:0004523","description":"\"Catalysis of the endonucleolytic cleavage of RNA in RNA-DNA hybrids to 5'-phosphomonoesters.\" [EC:3.1.26.4]","metadata":null},{"id":"8ae38d478f594945b244bd919afc94b3","type":"GO_TERM","name":"RNA-binding transcription regulator activity","canonical_id":"go:GO:0001070","description":"\"A transcription regulator activity that modulates the transcription of specific gene sets via selective and non-covalent binding to a specific RNA sequence. This function is known to occur in phages and viruses, for example the lambda N and the HIV tat proteins are necessary to allow RNA polymerase to read through terminator sequences.\" [GOC:txnOH-2018, PMID:1756726]","metadata":null},{"id":"7d68349b0ee949c89d16e72473dd2b9e","type":"GO_TERM","name":"RNA-directed DNA polymerase activity","canonical_id":"go:GO:0003964","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) = diphosphate + DNA(n+1); RNA-template-directed extension of the 3'-end of a DNA strand by one deoxynucleotide at a time.\" [EC:2.7.7.49]","metadata":null},{"id":"6408fadf2d5d4053a3a78d6290dbc4ac","type":"PROTEIN","name":"RNA-directed RNA polymerase (Hepatitis C virus)","canonical_id":"uniprot:Q96885","description":null,"metadata":null},{"id":"243b5124214349c9aa4356aed5575abb","type":"GO_TERM","name":"RNA-directed RNA polymerase activity","canonical_id":"go:GO:0003968","description":"\"Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); uses an RNA template, i.e. the catalysis of RNA-template-directed extension of the 3'-end of an RNA strand by one nucleotide at a time.\" [EC:2.7.7.48, GOC:mah, GOC:pf]","metadata":null},{"id":"202f267baffa4a02901c38784a70709f","type":"GO_TERM","name":"RNA-directed RNA polymerase complex","canonical_id":"go:GO:0031379","description":"\"A protein complex that possesses RNA-directed RNA polymerase activity.\" [GOC:mah]","metadata":null},{"id":"bc987950ebd14d8bb2ac12d97354a7d8","type":"GO_TERM","name":"RNA-mediated DNA recombination","canonical_id":"go:GO:0042152","description":"\"The reverse transcription of an RNA molecule followed by recombination between the resultant cDNA and its homologous chromosomal allele.\" [GOC:jl, PMID:8380627]","metadata":null},{"id":"a742b92a844e4838bbf925f135865122","type":"GO_TERM","name":"RNA-protein covalent cross-linking","canonical_id":"go:GO:0018144","description":"\"The formation of a covalent cross-link between RNA and a protein.\" [GOC:ma]","metadata":null},{"id":"451289ee466d4845a2cf93c52433abb2","type":"GO_TERM","name":"RNA-templated DNA biosynthetic process","canonical_id":"go:GO:0006278","description":"\"A DNA biosynthetic process that uses RNA as a template for RNA-dependent DNA polymerases (e.g. reverse transcriptase) that synthesize the new strand.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"03b1e8b9e04043b89efac99fe6c2f352","type":"GO_TERM","name":"RNA-templated transcription","canonical_id":"go:GO:0001172","description":"\"The synthesis of an RNA transcript from an RNA template.\" [GOC:txnOH]","metadata":null},{"id":"223f03f44fed4c9db841d675c9c2ae12","type":"GO_TERM","name":"RNA-templated viral transcription","canonical_id":"go:GO:0039696","description":"\"A transcription process that uses viral RNA as a template.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"b45284ddb993413b9d49b727b3e8b984","type":"GENE","name":"RNA18S1","canonical_id":"hgnc:HGNC:44278","description":"RNA, 18S ribosomal 1","metadata":null},{"id":"109e7812c163475da531a554d36d1c3e","type":"GENE","name":"RNA18S2","canonical_id":"hgnc:HGNC:44279","description":"RNA, 18S ribosomal 2","metadata":null},{"id":"83c08279b8d842149519a387788147b7","type":"GENE","name":"RNA18S3","canonical_id":"hgnc:HGNC:44280","description":"RNA, 18S ribosomal 3","metadata":null},{"id":"7cd0947629094b5aa8dd028bc3b7e8de","type":"GENE","name":"RNA18S4","canonical_id":"hgnc:HGNC:44281","description":"RNA, 18S ribosomal 4","metadata":null},{"id":"c76ebbb3bcec4188a5ebdcecf80d89dc","type":"GENE","name":"RNA18S5","canonical_id":"hgnc:HGNC:37657","description":"RNA, 18S ribosomal 5","metadata":{"aliases":["RN18S1"]}},{"id":"6e1ba014fbde4b4eba8305c517b65579","type":"GENE","name":"RNA18SN1","canonical_id":"hgnc:HGNC:53515","description":"RNA, 18S ribosomal N1","metadata":null},{"id":"34b8cb91780041768610ee969fdc7c8f","type":"GENE","name":"RNA18SN2","canonical_id":"hgnc:HGNC:53519","description":"RNA, 18S ribosomal N2","metadata":null},{"id":"0bdcd19d4e6e4c5eb66cc4b122dde077","type":"GENE","name":"RNA18SN3","canonical_id":"hgnc:HGNC:53523","description":"RNA, 18S ribosomal N3","metadata":null},{"id":"4db56006eefe45d99067566811f5103c","type":"GENE","name":"RNA18SN4","canonical_id":"hgnc:HGNC:53528","description":"RNA, 18S ribosomal N4","metadata":null},{"id":"f38f1c36a22a4d01b17d8a898d335958","type":"GENE","name":"RNA18SN5","canonical_id":"hgnc:HGNC:53531","description":"RNA, 18S ribosomal N5","metadata":null},{"id":"f0cbaa57d51941368c8f4fe4ca5cfb7d","type":"GENE","name":"RNA18SP2","canonical_id":"hgnc:HGNC:37658","description":"RNA, 18S ribosomal pseudogene 2","metadata":{"aliases":["RN18S2P"]}},{"id":"8f99df5e3e524c76840e780e291e884e","type":"GENE","name":"RNA18SP3","canonical_id":"hgnc:HGNC:53534","description":"RNA, 18S ribosomal pseudogene 3","metadata":null},{"id":"93da996f76ef4717b1d40e08dbcd58ef","type":"GENE","name":"RNA18SP4","canonical_id":"hgnc:HGNC:53535","description":"RNA, 18S ribosomal pseudogene 4","metadata":null},{"id":"1c231111e65542a8bfb82272b408d2ad","type":"GENE","name":"RNA18SP5","canonical_id":"hgnc:HGNC:53558","description":"RNA, 18S ribosomal pseudogene 5","metadata":null},{"id":"2d8fffaffd4340699706d14cce3ee5cd","type":"GENE","name":"RNA28S1","canonical_id":"hgnc:HGNC:44286","description":"RNA, 28S ribosomal 1","metadata":null},{"id":"0a6457c1c273444b9a80d2627c424bd9","type":"GENE","name":"RNA28S2","canonical_id":"hgnc:HGNC:44287","description":"RNA, 28S ribosomal 2","metadata":null},{"id":"731a5a1245c5431a9674f5629ff8c36b","type":"GENE","name":"RNA28S3","canonical_id":"hgnc:HGNC:44288","description":"RNA, 28S ribosomal 3","metadata":null},{"id":"8782e2e3e3ff4282803282d66b6cc744","type":"GENE","name":"RNA28S4","canonical_id":"hgnc:HGNC:44289","description":"RNA, 28S ribosomal 4","metadata":null},{"id":"d69fcbf909f24b129a3e9381400d5c09","type":"GENE","name":"RNA28S5","canonical_id":"hgnc:HGNC:37659","description":"RNA, 28S ribosomal 5","metadata":{"aliases":["RN28S1"]}},{"id":"3268748faf2a464b8745f46804f2fc9c","type":"GENE","name":"RNA28SN1","canonical_id":"hgnc:HGNC:53516","description":"RNA, 28S ribosomal N1","metadata":null},{"id":"1f96b6668c884c14ab96ec121171b0e9","type":"GENE","name":"RNA28SN2","canonical_id":"hgnc:HGNC:53520","description":"RNA, 28S ribosomal N2","metadata":null},{"id":"45abd528c4014063842e19212dd17e49","type":"GENE","name":"RNA28SN3","canonical_id":"hgnc:HGNC:53524","description":"RNA, 28S ribosomal N3","metadata":null},{"id":"601574772349498aaa5581bf7a4a48b9","type":"GENE","name":"RNA28SN4","canonical_id":"hgnc:HGNC:53527","description":"RNA, 28S ribosomal N4","metadata":null},{"id":"82147c3f61ab4121bc02d4aa30ae802e","type":"GENE","name":"RNA28SN5","canonical_id":"hgnc:HGNC:53532","description":"RNA, 28S ribosomal N5","metadata":null},{"id":"e8f12fdd4d994ed9a91712d98a5fc281","type":"GENE","name":"RNA45S1","canonical_id":"hgnc:HGNC:44274","description":"RNA, 45S pre-ribosomal 1","metadata":null},{"id":"aa48fb443db247b8b0525f05e1f01aaf","type":"GENE","name":"RNA45S2","canonical_id":"hgnc:HGNC:44275","description":"RNA, 45S pre-ribosomal 2","metadata":null},{"id":"4c79bfa1553e43b48a3560c35f5443e1","type":"GENE","name":"RNA45S3","canonical_id":"hgnc:HGNC:44276","description":"RNA, 45S pre-ribosomal 3","metadata":null},{"id":"0322b05482b7428e83f2a72f9365046a","type":"GENE","name":"RNA45S4","canonical_id":"hgnc:HGNC:44277","description":"RNA, 45S pre-ribosomal 4","metadata":null},{"id":"d6c0ae7f154b4c7189e0969af31729e7","type":"GENE","name":"RNA45S5","canonical_id":"hgnc:HGNC:44273","description":"RNA, 45S pre-ribosomal 5","metadata":null},{"id":"e16333c5e43c4081bf5460f1bbcaa8ef","type":"GENE","name":"RNA45SN1","canonical_id":"hgnc:HGNC:53514","description":"RNA, 45S pre-ribosomal N1","metadata":null},{"id":"df29794206364762b5786f532232d3f3","type":"GENE","name":"RNA45SN2","canonical_id":"hgnc:HGNC:53518","description":"RNA, 45S pre-ribosomal N2","metadata":null},{"id":"bb3df06b989645d5a4a4fa6895502352","type":"GENE","name":"RNA45SN3","canonical_id":"hgnc:HGNC:53522","description":"RNA, 45S pre-ribosomal N3","metadata":null},{"id":"1f4334edd69e42b381f892e8f3ec1c18","type":"GENE","name":"RNA45SN4","canonical_id":"hgnc:HGNC:53526","description":"RNA, 45S pre-ribosomal N4","metadata":null},{"id":"9b8183450e194128ba6863e499be24ce","type":"GENE","name":"RNA45SN5","canonical_id":"hgnc:HGNC:53530","description":"RNA, 45S pre-ribosomal N5","metadata":null},{"id":"cfb96a1ce18343fdb0ff3852ee526f6e","type":"GENE","name":"RNA5-8S1","canonical_id":"hgnc:HGNC:44282","description":"RNA, 5.8S ribosomal 1","metadata":null},{"id":"f753d512604f4bea98628fd9c7384181","type":"GENE","name":"RNA5-8S2","canonical_id":"hgnc:HGNC:44283","description":"RNA, 5.8S ribosomal 2","metadata":null},{"id":"23a1a23395b041a883c84f7c81590208","type":"GENE","name":"RNA5-8S3","canonical_id":"hgnc:HGNC:44284","description":"RNA, 5.8S ribosomal 3","metadata":null},{"id":"d86d97749f6342fdb40e6c54088412d4","type":"GENE","name":"RNA5-8S4","canonical_id":"hgnc:HGNC:44285","description":"RNA, 5.8S ribosomal 4","metadata":null},{"id":"4830e8a3b45b4e488a85d5ccf437bb25","type":"GENE","name":"RNA5-8S5","canonical_id":"hgnc:HGNC:37660","description":"RNA, 5.8S ribosomal 5","metadata":{"aliases":["RN5-8S1"]}},{"id":"0291a11e0db244308953b5d0c76e659c","type":"GENE","name":"RNA5-8SN1","canonical_id":"hgnc:HGNC:53517","description":"RNA, 5.8S ribosomal N1","metadata":null},{"id":"17b35ff5fdc64124ac2b8dc994df6215","type":"GENE","name":"RNA5-8SN2","canonical_id":"hgnc:HGNC:53521","description":"RNA, 5.8S ribosomal N2","metadata":{"aliases":["RNA5-8N2"]}},{"id":"4bfd0bf23890424f931c6ba39f4013f6","type":"GENE","name":"RNA5-8SN3","canonical_id":"hgnc:HGNC:53525","description":"RNA, 5.8S ribosomal N3","metadata":null},{"id":"7542da9e961d4a26af54becbf6c61917","type":"GENE","name":"RNA5-8SN4","canonical_id":"hgnc:HGNC:53529","description":"RNA, 5.8S ribosomal N4","metadata":null},{"id":"de64112c87404259b2c0224eafc0a83d","type":"GENE","name":"RNA5-8SN5","canonical_id":"hgnc:HGNC:53533","description":"RNA, 5.8S ribosomal N5","metadata":null},{"id":"9e748ae144da48dcba4e9adc2c6f0fba","type":"GENE","name":"RNA5-8SP10","canonical_id":"hgnc:HGNC:53559","description":"RNA, 5.8S ribosomal pseudogene 10","metadata":null},{"id":"9af72ed4f231485690a3cf56f0e3ad45","type":"GENE","name":"RNA5-8SP2","canonical_id":"hgnc:HGNC:41956","description":"RNA, 5.8S ribosomal pseudogene 2","metadata":{"aliases":["RN5-8S2"]}},{"id":"c81c00dbfcb74bc9bfded99b5dae9e43","type":"GENE","name":"RNA5-8SP3","canonical_id":"hgnc:HGNC:41957","description":"RNA, 5.8S ribosomal pseudogene 3","metadata":{"aliases":["RN5-8S3"]}},{"id":"fdd643a56a8d4653abd4dfe82e21003c","type":"GENE","name":"RNA5-8SP4","canonical_id":"hgnc:HGNC:41958","description":"RNA, 5.8S ribosomal pseudogene 4","metadata":{"aliases":["RN5-8S4"]}},{"id":"d67f53bcc3474e00803ad1737ed77b55","type":"GENE","name":"RNA5-8SP5","canonical_id":"hgnc:HGNC:41959","description":"RNA, 5.8S ribosomal pseudogene 5","metadata":{"aliases":["RN5-8S5"]}},{"id":"9ee5082468714164920c0d9918ef7e43","type":"GENE","name":"RNA5-8SP6","canonical_id":"hgnc:HGNC:41960","description":"RNA, 5.8S ribosomal pseudogene 6","metadata":{"aliases":["RN5-8S6"]}},{"id":"3337a9cdbf9c40af9f7ffb48e3dce25c","type":"GENE","name":"RNA5-8SP7","canonical_id":"hgnc:HGNC:41962","description":"RNA, 5.8S ribosomal pseudogene 7","metadata":{"aliases":["RN5-8S7"]}},{"id":"f4f856caccce432aa7eda02139148045","type":"GENE","name":"RNA5-8SP8","canonical_id":"hgnc:HGNC:53536","description":"RNA, 5.8S ribosomal pseudogene 8","metadata":null},{"id":"7aafa8136efb4981a4fe5a5496e3a65c","type":"GENE","name":"RNA5-8SP9","canonical_id":"hgnc:HGNC:53537","description":"RNA, 5.8S ribosomal pseudogene 9","metadata":null},{"id":"bc14141e310641c99d52c989eb146c61","type":"GENE","name":"RNA5S1","canonical_id":"hgnc:HGNC:34362","description":"RNA, 5S ribosomal 1","metadata":{"aliases":["RN5S1"]}},{"id":"8d63e2cec49c4f228ebe9fcec554d4f6","type":"GENE","name":"RNA5S10","canonical_id":"hgnc:HGNC:34371","description":"RNA, 5S ribosomal 10","metadata":{"aliases":["RN5S10"]}},{"id":"1724a327992047c48e7be33373185fa6","type":"GENE","name":"RNA5S11","canonical_id":"hgnc:HGNC:34372","description":"RNA, 5S ribosomal 11","metadata":{"aliases":["RN5S11"]}},{"id":"006070bb8eb34a7db29fc315db84b596","type":"GENE","name":"RNA5S12","canonical_id":"hgnc:HGNC:34373","description":"RNA, 5S ribosomal 12","metadata":{"aliases":["RN5S12"]}},{"id":"461eb8d8a9244570a40a88e02f95118a","type":"GENE","name":"RNA5S13","canonical_id":"hgnc:HGNC:34374","description":"RNA, 5S ribosomal 13","metadata":{"aliases":["RN5S13"]}},{"id":"5c988e9c390e4cf893fcc96380bf2724","type":"GENE","name":"RNA5S14","canonical_id":"hgnc:HGNC:34375","description":"RNA, 5S ribosomal 14","metadata":{"aliases":["RN5S14"]}},{"id":"4d50180c8b2d4f0aacb667bbb76c69d3","type":"GENE","name":"RNA5S15","canonical_id":"hgnc:HGNC:34376","description":"RNA, 5S ribosomal 15","metadata":{"aliases":["RN5S15"]}},{"id":"52569b27b1704c3aa1c00354f04a3510","type":"GENE","name":"RNA5S16","canonical_id":"hgnc:HGNC:34377","description":"RNA, 5S ribosomal 16","metadata":{"aliases":["RN5S16"]}},{"id":"543143e49b6141289eee7f294f50b1f0","type":"GENE","name":"RNA5S17","canonical_id":"hgnc:HGNC:34378","description":"RNA, 5S ribosomal 17","metadata":{"aliases":["RN5S17"]}},{"id":"fce2d37e41604b4f91a6dce53df1da57","type":"GENE","name":"RNA5S2","canonical_id":"hgnc:HGNC:34363","description":"RNA, 5S ribosomal 2","metadata":{"aliases":["RN5S2"]}},{"id":"9070242146f2496980502d6a9db8100d","type":"GENE","name":"RNA5S3","canonical_id":"hgnc:HGNC:34364","description":"RNA, 5S ribosomal 3","metadata":{"aliases":["RN5S3"]}},{"id":"ff52132acfd24477a8fc2e6e01bdb016","type":"GENE","name":"RNA5S4","canonical_id":"hgnc:HGNC:34365","description":"RNA, 5S ribosomal 4","metadata":{"aliases":["RN5S4"]}},{"id":"d378ca9e063945009a0596ade13a20fe","type":"GENE","name":"RNA5S5","canonical_id":"hgnc:HGNC:34366","description":"RNA, 5S ribosomal 5","metadata":{"aliases":["RN5S5"]}},{"id":"39b893e2e5f349619b825b612492a495","type":"GENE","name":"RNA5S6","canonical_id":"hgnc:HGNC:34367","description":"RNA, 5S ribosomal 6","metadata":{"aliases":["RN5S6"]}},{"id":"1afd1b599e674d3db0c16bf130119efa","type":"GENE","name":"RNA5S7","canonical_id":"hgnc:HGNC:34368","description":"RNA, 5S ribosomal 7","metadata":{"aliases":["RN5S7"]}},{"id":"be5154f0ef5a4648a22022f6f63d03bf","type":"GENE","name":"RNA5S8","canonical_id":"hgnc:HGNC:34369","description":"RNA, 5S ribosomal 8","metadata":{"aliases":["RN5S8"]}},{"id":"38cb88bf4c2a49a6a1125ac934dbd28e","type":"GENE","name":"RNA5S9","canonical_id":"hgnc:HGNC:34370","description":"RNA, 5S ribosomal 9","metadata":{"aliases":["RN5S9"]}},{"id":"d4d2955662364434a2912ad8e64af132","type":"GENE","name":"RNA5SP100","canonical_id":"hgnc:HGNC:42898","description":"RNA, 5S ribosomal pseudogene 100","metadata":{"aliases":["RN5S100"]}},{"id":"e357fffdbd3c49258d357d8f6f37864c","type":"GENE","name":"RNA5SP101","canonical_id":"hgnc:HGNC:42899","description":"RNA, 5S ribosomal pseudogene 101","metadata":{"aliases":["RN5S101"]}},{"id":"a274841828a04a208e53c6ec3b32aade","type":"GENE","name":"RNA5SP102","canonical_id":"hgnc:HGNC:42900","description":"RNA, 5S ribosomal pseudogene 102","metadata":{"aliases":["RN5S102"]}},{"id":"c189213b2a6f458f99bb0f6f0ca27b7e","type":"GENE","name":"RNA5SP103","canonical_id":"hgnc:HGNC:42901","description":"RNA, 5S ribosomal pseudogene 103","metadata":{"aliases":["RN5S103"]}},{"id":"ecb0262c5b0240fa8842139924e695f6","type":"GENE","name":"RNA5SP104","canonical_id":"hgnc:HGNC:42902","description":"RNA, 5S ribosomal pseudogene 104","metadata":{"aliases":["RN5S104"]}},{"id":"e59f818cf3804df98d410a5b7cbe1092","type":"GENE","name":"RNA5SP105","canonical_id":"hgnc:HGNC:42903","description":"RNA, 5S ribosomal pseudogene 105","metadata":{"aliases":["RN5S105"]}},{"id":"35e8c1de4ea6489197234e7b9a1a3516","type":"GENE","name":"RNA5SP106","canonical_id":"hgnc:HGNC:42904","description":"RNA, 5S ribosomal pseudogene 106","metadata":{"aliases":["RN5S106"]}},{"id":"a8d0030f05d14b6ab2fb2131a0fe0ffb","type":"GENE","name":"RNA5SP107","canonical_id":"hgnc:HGNC:42905","description":"RNA, 5S ribosomal pseudogene 107","metadata":{"aliases":["RN5S107"]}},{"id":"9c9f695af1ab4c098f2c5be1e22f5dde","type":"GENE","name":"RNA5SP108","canonical_id":"hgnc:HGNC:42906","description":"RNA, 5S ribosomal pseudogene 108","metadata":{"aliases":["RN5S108"]}},{"id":"cb7bd10d2eb94ee4a497cf6b0af9fbd9","type":"GENE","name":"RNA5SP109","canonical_id":"hgnc:HGNC:42907","description":"RNA, 5S ribosomal pseudogene 109","metadata":{"aliases":["RN5S109"]}},{"id":"f5c9014d5e734336bc8d9c005ae057bb","type":"GENE","name":"RNA5SP110","canonical_id":"hgnc:HGNC:42908","description":"RNA, 5S ribosomal pseudogene 110","metadata":{"aliases":["RN5S110"]}},{"id":"a7d290df18b548a4981e0fefac5be926","type":"GENE","name":"RNA5SP111","canonical_id":"hgnc:HGNC:42909","description":"RNA, 5S ribosomal pseudogene 111","metadata":{"aliases":["RN5S111"]}},{"id":"0f25a2614ecc430da0b60afb22279259","type":"GENE","name":"RNA5SP112","canonical_id":"hgnc:HGNC:42910","description":"RNA, 5S ribosomal pseudogene 112","metadata":{"aliases":["RN5S112"]}},{"id":"9e6d5805b93d4bdc8a6707b997a368b8","type":"GENE","name":"RNA5SP113","canonical_id":"hgnc:HGNC:42911","description":"RNA, 5S ribosomal pseudogene 113","metadata":{"aliases":["RN5S113"]}},{"id":"9e67fe3d65604738adbda492dc91d899","type":"GENE","name":"RNA5SP114","canonical_id":"hgnc:HGNC:42912","description":"RNA, 5S ribosomal pseudogene 114","metadata":{"aliases":["RN5S114"]}},{"id":"a6a3f4f1ff024d48a6d8c55eeffb0be1","type":"GENE","name":"RNA5SP115","canonical_id":"hgnc:HGNC:42913","description":"RNA, 5S ribosomal pseudogene 115","metadata":{"aliases":["RN5S115"]}},{"id":"8a0a6a71f64c44a598eb7b98e8701fca","type":"GENE","name":"RNA5SP116","canonical_id":"hgnc:HGNC:42914","description":"RNA, 5S ribosomal pseudogene 116","metadata":{"aliases":["RN5S116"]}},{"id":"352c2172a91c4a97ad15fd6b80d19f63","type":"GENE","name":"RNA5SP117","canonical_id":"hgnc:HGNC:42915","description":"RNA, 5S ribosomal pseudogene 117","metadata":{"aliases":["RN5S117"]}},{"id":"cce1183ef6524453858840db22ba40f4","type":"GENE","name":"RNA5SP118","canonical_id":"hgnc:HGNC:42916","description":"RNA, 5S ribosomal pseudogene 118","metadata":{"aliases":["RN5S118"]}},{"id":"be49835213ae4525b8411abf06a7269c","type":"GENE","name":"RNA5SP119","canonical_id":"hgnc:HGNC:42917","description":"RNA, 5S ribosomal pseudogene 119","metadata":{"aliases":["RN5S119"]}},{"id":"d7ad4b8d595f44ff8c5aa0cd5f37b81c","type":"GENE","name":"RNA5SP120","canonical_id":"hgnc:HGNC:42918","description":"RNA, 5S ribosomal pseudogene 120","metadata":{"aliases":["RN5S120"]}},{"id":"7f86ef0241b54215825cd6c77245b48f","type":"GENE","name":"RNA5SP121","canonical_id":"hgnc:HGNC:42919","description":"RNA, 5S ribosomal pseudogene 121","metadata":{"aliases":["RN5S121"]}},{"id":"a63f1a757b704f55abb5e3bfddc90011","type":"GENE","name":"RNA5SP122","canonical_id":"hgnc:HGNC:42920","description":"RNA, 5S ribosomal pseudogene 122","metadata":{"aliases":["RN5S122"]}},{"id":"d813d6553b434fb78c1cf1d06b9d9619","type":"GENE","name":"RNA5SP123","canonical_id":"hgnc:HGNC:43023","description":"RNA, 5S ribosomal pseudogene 123","metadata":{"aliases":["RN5S123"]}},{"id":"be02b6035ae742cda544deaef61e1c92","type":"GENE","name":"RNA5SP124","canonical_id":"hgnc:HGNC:43024","description":"RNA, 5S ribosomal pseudogene 124","metadata":{"aliases":["RN5S124"]}},{"id":"4e35d3340b2045b484ce863c4a2bf59c","type":"GENE","name":"RNA5SP125","canonical_id":"hgnc:HGNC:43025","description":"RNA, 5S ribosomal pseudogene 125","metadata":{"aliases":["RN5S125"]}},{"id":"4aa2cdcacc734bfb9cbc33a993e10993","type":"GENE","name":"RNA5SP126","canonical_id":"hgnc:HGNC:43026","description":"RNA, 5S ribosomal pseudogene 126","metadata":{"aliases":["RN5S126"]}},{"id":"5eb027f0b03a4f88a3005d52b2929ff6","type":"GENE","name":"RNA5SP127","canonical_id":"hgnc:HGNC:43027","description":"RNA, 5S ribosomal pseudogene 127","metadata":{"aliases":["RN5S127"]}},{"id":"0004b06db5504352bb527872d1426ea7","type":"GENE","name":"RNA5SP128","canonical_id":"hgnc:HGNC:43028","description":"RNA, 5S ribosomal pseudogene 128","metadata":{"aliases":["RN5S128"]}},{"id":"e4d3f70af0c24b778b03570e589ec1eb","type":"GENE","name":"RNA5SP129","canonical_id":"hgnc:HGNC:43029","description":"RNA, 5S ribosomal pseudogene 129","metadata":{"aliases":["RN5S129"]}},{"id":"f6589a34fad84b0a970c0a580e74cbe9","type":"GENE","name":"RNA5SP130","canonical_id":"hgnc:HGNC:43030","description":"RNA, 5S ribosomal pseudogene 130","metadata":{"aliases":["RN5S130"]}},{"id":"da5f348b1b9b4dbab45b50e6375c2adb","type":"GENE","name":"RNA5SP131","canonical_id":"hgnc:HGNC:43031","description":"RNA, 5S ribosomal pseudogene 131","metadata":{"aliases":["RN5S131"]}},{"id":"30db8af89aa44bd1bc8de8c063ce0166","type":"GENE","name":"RNA5SP132","canonical_id":"hgnc:HGNC:43032","description":"RNA, 5S ribosomal pseudogene 132","metadata":{"aliases":["RN5S132"]}},{"id":"dd8fb09db5ea48fb9bc086be3d0d94a9","type":"GENE","name":"RNA5SP133","canonical_id":"hgnc:HGNC:43033","description":"RNA, 5S ribosomal pseudogene 133","metadata":{"aliases":["RN5S133"]}},{"id":"6a10648fe6704fe5884c5ee002ef4ccb","type":"GENE","name":"RNA5SP134","canonical_id":"hgnc:HGNC:43034","description":"RNA, 5S ribosomal pseudogene 134","metadata":{"aliases":["RN5S134"]}},{"id":"0d5f3bc3d5e34370be48422e1c878064","type":"GENE","name":"RNA5SP135","canonical_id":"hgnc:HGNC:43035","description":"RNA, 5S ribosomal pseudogene 135","metadata":{"aliases":["RN5S135"]}},{"id":"57201991a0a04884b8a5ad585df56479","type":"GENE","name":"RNA5SP136","canonical_id":"hgnc:HGNC:43036","description":"RNA, 5S ribosomal pseudogene 136","metadata":{"aliases":["RN5S136"]}},{"id":"50ca4085ac7c45d1a65a7c125d72d63e","type":"GENE","name":"RNA5SP137","canonical_id":"hgnc:HGNC:43037","description":"RNA, 5S ribosomal pseudogene 137","metadata":{"aliases":["RN5S137"]}},{"id":"6dd89be094e44408881529d91d4d7a65","type":"GENE","name":"RNA5SP138","canonical_id":"hgnc:HGNC:43038","description":"RNA, 5S ribosomal pseudogene 138","metadata":{"aliases":["RN5S138"]}},{"id":"ef015d966614422dbed0a94ba2326eee","type":"GENE","name":"RNA5SP139","canonical_id":"hgnc:HGNC:43039","description":"RNA, 5S ribosomal pseudogene 139","metadata":{"aliases":["RN5S139"]}},{"id":"387afa2ab6d04f518b8e3734fe887ee6","type":"GENE","name":"RNA5SP140","canonical_id":"hgnc:HGNC:43040","description":"RNA, 5S ribosomal pseudogene 140","metadata":{"aliases":["RN5S140"]}},{"id":"eeab3fa1c41e4e9aae1b890afcf2e3c8","type":"GENE","name":"RNA5SP141","canonical_id":"hgnc:HGNC:43041","description":"RNA, 5S ribosomal pseudogene 141","metadata":{"aliases":["RN5S141"]}},{"id":"5060f415daf34846b48f7cf7fb4df166","type":"GENE","name":"RNA5SP142","canonical_id":"hgnc:HGNC:43042","description":"RNA, 5S ribosomal pseudogene 142","metadata":{"aliases":["RN5S142"]}},{"id":"7498e2e3c5ab41e0a0aa3fff02a5d95d","type":"GENE","name":"RNA5SP143","canonical_id":"hgnc:HGNC:43043","description":"RNA, 5S ribosomal pseudogene 143","metadata":{"aliases":["RN5S143"]}},{"id":"98982743563a40ffb222a2f04e544fc4","type":"GENE","name":"RNA5SP144","canonical_id":"hgnc:HGNC:43044","description":"RNA, 5S ribosomal pseudogene 144","metadata":{"aliases":["RN5S144"]}},{"id":"cf098b35dd0c4527a17d9e6b0b0bc71f","type":"GENE","name":"RNA5SP145","canonical_id":"hgnc:HGNC:43045","description":"RNA, 5S ribosomal pseudogene 145","metadata":{"aliases":["RN5S145"]}},{"id":"fef4269fcc454ec8a15c1e1fb9b2e332","type":"GENE","name":"RNA5SP146","canonical_id":"hgnc:HGNC:43046","description":"RNA, 5S ribosomal pseudogene 146","metadata":{"aliases":["RN5S146"]}},{"id":"b872462769c84683b3c3cc576d8066c7","type":"GENE","name":"RNA5SP147","canonical_id":"hgnc:HGNC:43047","description":"RNA, 5S ribosomal pseudogene 147","metadata":{"aliases":["RN5S147"]}},{"id":"1bda840863d54346bb0ff7ab0ce4b24a","type":"GENE","name":"RNA5SP148","canonical_id":"hgnc:HGNC:43048","description":"RNA, 5S ribosomal pseudogene 148","metadata":{"aliases":["RN5S148"]}},{"id":"10f0d450455b42c084aa081bd76c0e28","type":"GENE","name":"RNA5SP149","canonical_id":"hgnc:HGNC:43049","description":"RNA, 5S ribosomal pseudogene 149","metadata":{"aliases":["RN5S149"]}},{"id":"d2b458b2ed5b4a36ac0d7f960e646392","type":"GENE","name":"RNA5SP150","canonical_id":"hgnc:HGNC:43050","description":"RNA, 5S ribosomal pseudogene 150","metadata":{"aliases":["RN5S150"]}},{"id":"730d7a4653f84ee9be69da7be2b95e92","type":"GENE","name":"RNA5SP151","canonical_id":"hgnc:HGNC:43051","description":"RNA, 5S ribosomal pseudogene 151","metadata":{"aliases":["RN5S151"]}},{"id":"ce09e7ef8cca40c19f2f937aaab0fef4","type":"GENE","name":"RNA5SP152","canonical_id":"hgnc:HGNC:43052","description":"RNA, 5S ribosomal pseudogene 152","metadata":{"aliases":["RN5S152"]}},{"id":"f1bf395385d24a48876675eb53deaeac","type":"GENE","name":"RNA5SP153","canonical_id":"hgnc:HGNC:43053","description":"RNA, 5S ribosomal pseudogene 153","metadata":{"aliases":["RN5S153"]}},{"id":"63454a44de32430cb380de7e5dbcb113","type":"GENE","name":"RNA5SP154","canonical_id":"hgnc:HGNC:43054","description":"RNA, 5S ribosomal pseudogene 154","metadata":{"aliases":["RN5S154"]}},{"id":"053ee7e0c7b84280bcf7aad058d785a5","type":"GENE","name":"RNA5SP155","canonical_id":"hgnc:HGNC:43055","description":"RNA, 5S ribosomal pseudogene 155","metadata":{"aliases":["RN5S155"]}},{"id":"4947bf3271f94697aace73a94a98cc85","type":"GENE","name":"RNA5SP156","canonical_id":"hgnc:HGNC:43056","description":"RNA, 5S ribosomal pseudogene 156","metadata":{"aliases":["RN5S156"]}},{"id":"24221d72e8df46e3b0961820b0b4d968","type":"GENE","name":"RNA5SP157","canonical_id":"hgnc:HGNC:43057","description":"RNA, 5S ribosomal pseudogene 157","metadata":{"aliases":["RN5S157"]}},{"id":"e48d80bbedf942a9b59c4408fdc74002","type":"GENE","name":"RNA5SP158","canonical_id":"hgnc:HGNC:43058","description":"RNA, 5S ribosomal pseudogene 158","metadata":{"aliases":["RN5S158"]}},{"id":"7a38e9a7a3f442039678d0aa8cb853fa","type":"GENE","name":"RNA5SP159","canonical_id":"hgnc:HGNC:43059","description":"RNA, 5S ribosomal pseudogene 159","metadata":{"aliases":["RN5S159"]}},{"id":"386c99cf9dfe46149b04129ee585534c","type":"GENE","name":"RNA5SP160","canonical_id":"hgnc:HGNC:43060","description":"RNA, 5S ribosomal pseudogene 160","metadata":{"aliases":["RN5S160"]}},{"id":"7b16fddc044d497198436596c4c4f179","type":"GENE","name":"RNA5SP161","canonical_id":"hgnc:HGNC:43061","description":"RNA, 5S ribosomal pseudogene 161","metadata":{"aliases":["RN5S161"]}},{"id":"e68215f5c16d4841a544ae13b1f52601","type":"GENE","name":"RNA5SP162","canonical_id":"hgnc:HGNC:43062","description":"RNA, 5S ribosomal pseudogene 162","metadata":{"aliases":["RN5S162"]}},{"id":"470189041cdd484089807f46b1203248","type":"GENE","name":"RNA5SP163","canonical_id":"hgnc:HGNC:43063","description":"RNA, 5S ribosomal pseudogene 163","metadata":{"aliases":["RN5S163"]}},{"id":"c7733fb1efb5411ca25796e78468cb35","type":"GENE","name":"RNA5SP164","canonical_id":"hgnc:HGNC:43064","description":"RNA, 5S ribosomal pseudogene 164","metadata":{"aliases":["RN5S164"]}},{"id":"b783833966e44de982749b645aaab51a","type":"GENE","name":"RNA5SP165","canonical_id":"hgnc:HGNC:43065","description":"RNA, 5S ribosomal pseudogene 165","metadata":{"aliases":["RN5S165"]}},{"id":"727df55149324441ab3d405e90242fbf","type":"GENE","name":"RNA5SP166","canonical_id":"hgnc:HGNC:43066","description":"RNA, 5S ribosomal pseudogene 166","metadata":{"aliases":["RN5S166"]}},{"id":"5a98ac28fff7417c9c31def234caaf7f","type":"GENE","name":"RNA5SP167","canonical_id":"hgnc:HGNC:43067","description":"RNA, 5S ribosomal pseudogene 167","metadata":{"aliases":["RN5S167"]}},{"id":"045f379976a54af5919dcf61c4684ad3","type":"GENE","name":"RNA5SP168","canonical_id":"hgnc:HGNC:43068","description":"RNA, 5S ribosomal pseudogene 168","metadata":{"aliases":["RN5S168"]}},{"id":"91dd531b82cf4f4db762f4b2fd54ce62","type":"GENE","name":"RNA5SP169","canonical_id":"hgnc:HGNC:43069","description":"RNA, 5S ribosomal pseudogene 169","metadata":{"aliases":["RN5S169"]}},{"id":"8738f0c1e7724326ae67c3c1d302d1ec","type":"GENE","name":"RNA5SP170","canonical_id":"hgnc:HGNC:43070","description":"RNA, 5S ribosomal pseudogene 170","metadata":{"aliases":["RN5S170"]}},{"id":"1ec42569c4054e3cb1bce8c77944ff01","type":"GENE","name":"RNA5SP171","canonical_id":"hgnc:HGNC:43071","description":"RNA, 5S ribosomal pseudogene 171","metadata":{"aliases":["RN5S171"]}},{"id":"77e9766601044510a18ad6b730649f43","type":"GENE","name":"RNA5SP172","canonical_id":"hgnc:HGNC:43072","description":"RNA, 5S ribosomal pseudogene 172","metadata":{"aliases":["RN5S172"]}},{"id":"2e8024d7e59946a798c2e5b159ec0980","type":"GENE","name":"RNA5SP173","canonical_id":"hgnc:HGNC:43073","description":"RNA, 5S ribosomal pseudogene 173","metadata":{"aliases":["RN5S173"]}},{"id":"f798ab3b981a4338a11cb4c3a79359f4","type":"GENE","name":"RNA5SP174","canonical_id":"hgnc:HGNC:43074","description":"RNA, 5S ribosomal pseudogene 174","metadata":{"aliases":["RN5S174"]}},{"id":"a94da06932be4e6888a8add0250f9f82","type":"GENE","name":"RNA5SP175","canonical_id":"hgnc:HGNC:43075","description":"RNA, 5S ribosomal pseudogene 175","metadata":{"aliases":["RN5S175"]}},{"id":"9fa302a870a048e190ebe46d73ab103c","type":"GENE","name":"RNA5SP176","canonical_id":"hgnc:HGNC:43076","description":"RNA, 5S ribosomal pseudogene 176","metadata":{"aliases":["RN5S176"]}},{"id":"24cd65f5b0fd4963a8f4f9387ef1e34e","type":"GENE","name":"RNA5SP177","canonical_id":"hgnc:HGNC:43077","description":"RNA, 5S ribosomal pseudogene 177","metadata":{"aliases":["RN5S177"]}},{"id":"31b8a22a09fa4d418b4e03f0016b9b91","type":"GENE","name":"RNA5SP178","canonical_id":"hgnc:HGNC:43078","description":"RNA, 5S ribosomal pseudogene 178","metadata":{"aliases":["RN5S178"]}},{"id":"26fbc0decf3646929cc128bf4b57e5ed","type":"GENE","name":"RNA5SP179","canonical_id":"hgnc:HGNC:43079","description":"RNA, 5S ribosomal pseudogene 179","metadata":{"aliases":["RN5S179"]}},{"id":"2e6e68d068044c3193a24e92172c57b5","type":"GENE","name":"RNA5SP18","canonical_id":"hgnc:HGNC:42586","description":"RNA, 5S ribosomal pseudogene 18","metadata":{"aliases":["RN5S18"]}},{"id":"2bee921f3cd647a99eb423808ef32fd9","type":"GENE","name":"RNA5SP180","canonical_id":"hgnc:HGNC:43080","description":"RNA, 5S ribosomal pseudogene 180","metadata":{"aliases":["RN5S180"]}},{"id":"2257fe24207b4151bb9be859d9ac6e87","type":"GENE","name":"RNA5SP181","canonical_id":"hgnc:HGNC:43081","description":"RNA, 5S ribosomal pseudogene 181","metadata":{"aliases":["RN5S181"]}},{"id":"ccfaa8241b854a4d8d44fafadd324cb0","type":"GENE","name":"RNA5SP182","canonical_id":"hgnc:HGNC:43082","description":"RNA, 5S ribosomal pseudogene 182","metadata":{"aliases":["RN5S182"]}},{"id":"a8fb93529fd34d2faf73582313ec9f2c","type":"GENE","name":"RNA5SP183","canonical_id":"hgnc:HGNC:43083","description":"RNA, 5S ribosomal pseudogene 183","metadata":{"aliases":["RN5S183"]}},{"id":"b18100381b3d41e0a04278359152699c","type":"GENE","name":"RNA5SP184","canonical_id":"hgnc:HGNC:43084","description":"RNA, 5S ribosomal pseudogene 184","metadata":{"aliases":["RN5S184"]}},{"id":"0b031ec649f34eedbb1a4a80df67640f","type":"GENE","name":"RNA5SP185","canonical_id":"hgnc:HGNC:43085","description":"RNA, 5S ribosomal pseudogene 185","metadata":{"aliases":["RN5S185"]}},{"id":"77d73df738d84160949756cf3f866779","type":"GENE","name":"RNA5SP186","canonical_id":"hgnc:HGNC:43086","description":"RNA, 5S ribosomal pseudogene 186","metadata":{"aliases":["RN5S186"]}},{"id":"0d4295b257f2410bb980947d52fe9ef1","type":"GENE","name":"RNA5SP187","canonical_id":"hgnc:HGNC:43087","description":"RNA, 5S ribosomal pseudogene 187","metadata":{"aliases":["RN5S187"]}},{"id":"f2079ff2b0c34b2c91428a473f66c096","type":"GENE","name":"RNA5SP188","canonical_id":"hgnc:HGNC:43088","description":"RNA, 5S ribosomal pseudogene 188","metadata":{"aliases":["RN5S188"]}},{"id":"f675898a215840eabde0bffa4e92662f","type":"GENE","name":"RNA5SP189","canonical_id":"hgnc:HGNC:43089","description":"RNA, 5S ribosomal pseudogene 189","metadata":{"aliases":["RN5S189"]}},{"id":"7fc1eea6879d4aa6b71b5f758b2baac4","type":"GENE","name":"RNA5SP19","canonical_id":"hgnc:HGNC:42587","description":"RNA, 5S ribosomal pseudogene 19","metadata":{"aliases":["RN5S19"]}},{"id":"3116f90e6663429b8909fec2c8994581","type":"GENE","name":"RNA5SP190","canonical_id":"hgnc:HGNC:43090","description":"RNA, 5S ribosomal pseudogene 190","metadata":{"aliases":["RN5S190"]}},{"id":"8c74fccdcbe746d7981a87ad1a7f311a","type":"GENE","name":"RNA5SP191","canonical_id":"hgnc:HGNC:43091","description":"RNA, 5S ribosomal pseudogene 191","metadata":{"aliases":["RN5S191"]}},{"id":"520e79fc7ce3499894313097f8cc5a41","type":"GENE","name":"RNA5SP192","canonical_id":"hgnc:HGNC:43092","description":"RNA, 5S ribosomal pseudogene 192","metadata":{"aliases":["RN5S192"]}},{"id":"3c96ade33b344d93aca2f256958e3499","type":"GENE","name":"RNA5SP193","canonical_id":"hgnc:HGNC:43093","description":"RNA, 5S ribosomal pseudogene 193","metadata":{"aliases":["RN5S193"]}},{"id":"44dc60b3266d4bfd83dac7e67b34c3c4","type":"GENE","name":"RNA5SP194","canonical_id":"hgnc:HGNC:43094","description":"RNA, 5S ribosomal pseudogene 194","metadata":{"aliases":["RN5S194"]}},{"id":"3df5682a92e147d4b35ee9f90dbaebb4","type":"GENE","name":"RNA5SP195","canonical_id":"hgnc:HGNC:43095","description":"RNA, 5S ribosomal pseudogene 195","metadata":{"aliases":["RN5S195"]}},{"id":"ba857d4506204d439085098c951885bb","type":"GENE","name":"RNA5SP196","canonical_id":"hgnc:HGNC:43096","description":"RNA, 5S ribosomal pseudogene 196","metadata":{"aliases":["RN5S196"]}},{"id":"6678858201c2482589680ab35a7611a3","type":"GENE","name":"RNA5SP197","canonical_id":"hgnc:HGNC:43097","description":"RNA, 5S ribosomal pseudogene 197","metadata":{"aliases":["RN5S197"]}},{"id":"494ebb1e90ea4a959b2bea598386001a","type":"GENE","name":"RNA5SP198","canonical_id":"hgnc:HGNC:43098","description":"RNA, 5S ribosomal pseudogene 198","metadata":{"aliases":["RN5S198"]}},{"id":"7a0fbfe83bc44a97b1689f7c01e46152","type":"GENE","name":"RNA5SP199","canonical_id":"hgnc:HGNC:43099","description":"RNA, 5S ribosomal pseudogene 199","metadata":{"aliases":["RN5S199"]}},{"id":"c231c78d3b784db6b8a6b20562d4388b","type":"GENE","name":"RNA5SP20","canonical_id":"hgnc:HGNC:42588","description":"RNA, 5S ribosomal pseudogene 20","metadata":{"aliases":["RN5S20"]}},{"id":"c8b644310d0c4f2e90afc18c323956fe","type":"GENE","name":"RNA5SP200","canonical_id":"hgnc:HGNC:43100","description":"RNA, 5S ribosomal pseudogene 200","metadata":{"aliases":["RN5S200"]}},{"id":"4beaf0234f954eaeb63d7cfd78f47af1","type":"GENE","name":"RNA5SP201","canonical_id":"hgnc:HGNC:43101","description":"RNA, 5S ribosomal pseudogene 201","metadata":{"aliases":["RN5S201"]}},{"id":"c93e7a88c3c240b4ab7905bd1370af89","type":"GENE","name":"RNA5SP202","canonical_id":"hgnc:HGNC:43102","description":"RNA, 5S ribosomal pseudogene 202","metadata":{"aliases":["RN5S202"]}},{"id":"1be88d21035b4d269631d4d276ad059f","type":"GENE","name":"RNA5SP203","canonical_id":"hgnc:HGNC:43103","description":"RNA, 5S ribosomal pseudogene 203","metadata":{"aliases":["RN5S203"]}},{"id":"614ee35438234a45bac0aad2f7f0afb3","type":"GENE","name":"RNA5SP204","canonical_id":"hgnc:HGNC:43104","description":"RNA, 5S ribosomal pseudogene 204","metadata":{"aliases":["RN5S204"]}},{"id":"9d476eab5d5d4011bc59a0b064d14292","type":"GENE","name":"RNA5SP205","canonical_id":"hgnc:HGNC:43105","description":"RNA, 5S ribosomal pseudogene 205","metadata":{"aliases":["RN5S205"]}},{"id":"fc943beb47b44ce3b82f4db025952d53","type":"GENE","name":"RNA5SP206","canonical_id":"hgnc:HGNC:43106","description":"RNA, 5S ribosomal pseudogene 206","metadata":{"aliases":["RN5S206"]}},{"id":"5084ab815003467fb165109828e9007b","type":"GENE","name":"RNA5SP207","canonical_id":"hgnc:HGNC:43107","description":"RNA, 5S ribosomal pseudogene 207","metadata":{"aliases":["RN5S207"]}},{"id":"388a52b217e4438896fe3413bd9ecefe","type":"GENE","name":"RNA5SP208","canonical_id":"hgnc:HGNC:43108","description":"RNA, 5S ribosomal pseudogene 208","metadata":{"aliases":["RN5S208"]}},{"id":"6357e91151b14b2d96ba77f1f8b0f704","type":"GENE","name":"RNA5SP209","canonical_id":"hgnc:HGNC:43109","description":"RNA, 5S ribosomal pseudogene 209","metadata":{"aliases":["RN5S209"]}},{"id":"673560960e424038abd0fb7d584f8dbd","type":"GENE","name":"RNA5SP21","canonical_id":"hgnc:HGNC:42589","description":"RNA, 5S ribosomal pseudogene 21","metadata":{"aliases":["RN5S21"]}},{"id":"4222ce155ead4ae7bed0704b632395c1","type":"GENE","name":"RNA5SP210","canonical_id":"hgnc:HGNC:43110","description":"RNA, 5S ribosomal pseudogene 210","metadata":{"aliases":["RN5S210"]}},{"id":"78c1456b521445c7ac9abf3bb76a902d","type":"GENE","name":"RNA5SP211","canonical_id":"hgnc:HGNC:43111","description":"RNA, 5S ribosomal pseudogene 211","metadata":{"aliases":["RN5S211"]}},{"id":"7bcf8be6af2c408182370e00c766aa9c","type":"GENE","name":"RNA5SP212","canonical_id":"hgnc:HGNC:43112","description":"RNA, 5S ribosomal pseudogene 212","metadata":{"aliases":["RN5S212"]}},{"id":"cd6ef5de60a44e5b8c18b33566466e28","type":"GENE","name":"RNA5SP213","canonical_id":"hgnc:HGNC:43113","description":"RNA, 5S ribosomal pseudogene 213","metadata":{"aliases":["RN5S213"]}},{"id":"b56173fe51354877bac675a7b6eacdc7","type":"GENE","name":"RNA5SP214","canonical_id":"hgnc:HGNC:43114","description":"RNA, 5S ribosomal pseudogene 214","metadata":{"aliases":["RN5S214"]}},{"id":"d5e448374f5d4763a5a674a8802ce864","type":"GENE","name":"RNA5SP215","canonical_id":"hgnc:HGNC:43115","description":"RNA, 5S ribosomal pseudogene 215","metadata":{"aliases":["RN5S215"]}},{"id":"bbe835f9a6874cd78449d6a1e1e930a1","type":"GENE","name":"RNA5SP216","canonical_id":"hgnc:HGNC:43116","description":"RNA, 5S ribosomal pseudogene 216","metadata":{"aliases":["RN5S216"]}},{"id":"ab69fb1d04c34961a09b396ef1ea849f","type":"GENE","name":"RNA5SP217","canonical_id":"hgnc:HGNC:43117","description":"RNA, 5S ribosomal pseudogene 217","metadata":{"aliases":["RN5S217"]}},{"id":"e4e5a04152274145ab1d1ac945fa7d57","type":"GENE","name":"RNA5SP218","canonical_id":"hgnc:HGNC:43118","description":"RNA, 5S ribosomal pseudogene 218","metadata":{"aliases":["RN5S218"]}},{"id":"d16c60861280465db5de6c5b932f8b2f","type":"GENE","name":"RNA5SP219","canonical_id":"hgnc:HGNC:43119","description":"RNA, 5S ribosomal pseudogene 219","metadata":{"aliases":["RN5S219"]}},{"id":"00dd3f01ef68411991d150c29c82c555","type":"GENE","name":"RNA5SP22","canonical_id":"hgnc:HGNC:42590","description":"RNA, 5S ribosomal pseudogene 22","metadata":{"aliases":["RN5S22"]}},{"id":"d60b4d6458414113a96fbdaed5402540","type":"GENE","name":"RNA5SP220","canonical_id":"hgnc:HGNC:43120","description":"RNA, 5S ribosomal pseudogene 220","metadata":{"aliases":["RN5S220"]}},{"id":"6f6bb3ec8613425585f5dbba368b7cd4","type":"GENE","name":"RNA5SP221","canonical_id":"hgnc:HGNC:43121","description":"RNA, 5S ribosomal pseudogene 221","metadata":{"aliases":["RN5S221"]}},{"id":"d641b7a803ef473185a5c4fe51251d79","type":"GENE","name":"RNA5SP222","canonical_id":"hgnc:HGNC:43122","description":"RNA, 5S ribosomal pseudogene 222","metadata":{"aliases":["RN5S222"]}},{"id":"5f0b22fb3e7240eebc1821a942142502","type":"GENE","name":"RNA5SP223","canonical_id":"hgnc:HGNC:43123","description":"RNA, 5S ribosomal pseudogene 223","metadata":{"aliases":["RN5S223"]}},{"id":"4ed26c08611b484a8bd333c0712ebc6a","type":"GENE","name":"RNA5SP224","canonical_id":"hgnc:HGNC:43124","description":"RNA, 5S ribosomal pseudogene 224","metadata":{"aliases":["RN5S224"]}},{"id":"f98c4a37f546439ebde2c1c722800d8a","type":"GENE","name":"RNA5SP225","canonical_id":"hgnc:HGNC:43125","description":"RNA, 5S ribosomal pseudogene 225","metadata":{"aliases":["RN5S225"]}},{"id":"53bdb65eb3da4d45abf3c212e85635f5","type":"GENE","name":"RNA5SP226","canonical_id":"hgnc:HGNC:43126","description":"RNA, 5S ribosomal pseudogene 226","metadata":{"aliases":["RN5S226"]}},{"id":"6f73b9af787745f9b9982a2520307543","type":"GENE","name":"RNA5SP227","canonical_id":"hgnc:HGNC:43127","description":"RNA, 5S ribosomal pseudogene 227","metadata":{"aliases":["RN5S227"]}},{"id":"df3b15ee7fcd4771adacf5c5534b8507","type":"GENE","name":"RNA5SP228","canonical_id":"hgnc:HGNC:43128","description":"RNA, 5S ribosomal pseudogene 228","metadata":{"aliases":["RN5S228"]}},{"id":"347a860e59914f26a0e1bd38b3510e64","type":"GENE","name":"RNA5SP229","canonical_id":"hgnc:HGNC:43129","description":"RNA, 5S ribosomal pseudogene 229","metadata":{"aliases":["RN5S229"]}},{"id":"bd26cff79198416c8990fc300cdc96cd","type":"GENE","name":"RNA5SP23","canonical_id":"hgnc:HGNC:42591","description":"RNA, 5S ribosomal pseudogene 23","metadata":{"aliases":["RN5S23"]}},{"id":"705c51eed49541c7bb96d07b0eb208b3","type":"GENE","name":"RNA5SP230","canonical_id":"hgnc:HGNC:43130","description":"RNA, 5S ribosomal pseudogene 230","metadata":{"aliases":["RN5S230"]}},{"id":"666adfc1345d471e87fcc9a162e3d63d","type":"GENE","name":"RNA5SP231","canonical_id":"hgnc:HGNC:43131","description":"RNA, 5S ribosomal pseudogene 231","metadata":{"aliases":["RN5S231"]}},{"id":"f98e4f1cff18487e85917a4c3b7bc762","type":"GENE","name":"RNA5SP232","canonical_id":"hgnc:HGNC:43132","description":"RNA, 5S ribosomal pseudogene 232","metadata":{"aliases":["RN5S232"]}},{"id":"f5adacf43bea48919ea6c4240e25997f","type":"GENE","name":"RNA5SP233","canonical_id":"hgnc:HGNC:43133","description":"RNA, 5S ribosomal pseudogene 233","metadata":{"aliases":["RN5S233"]}},{"id":"08179d7a83b94686a28937a61a793195","type":"GENE","name":"RNA5SP234","canonical_id":"hgnc:HGNC:43134","description":"RNA, 5S ribosomal pseudogene 234","metadata":{"aliases":["RN5S234"]}},{"id":"09ac6d3659614b2c9ee7cfddacbb278e","type":"GENE","name":"RNA5SP235","canonical_id":"hgnc:HGNC:43135","description":"RNA, 5S ribosomal pseudogene 235","metadata":{"aliases":["RN5S235"]}},{"id":"ae2917312a24413c86fc65ae32f739e3","type":"GENE","name":"RNA5SP236","canonical_id":"hgnc:HGNC:43136","description":"RNA, 5S ribosomal pseudogene 236","metadata":{"aliases":["RN5S236"]}},{"id":"a94ed6e56d284e5eb5f044a56a8c931d","type":"GENE","name":"RNA5SP237","canonical_id":"hgnc:HGNC:43137","description":"RNA, 5S ribosomal pseudogene 237","metadata":{"aliases":["RN5S237"]}},{"id":"d4a95abbf3954bdbbdf9200ae380d219","type":"GENE","name":"RNA5SP238","canonical_id":"hgnc:HGNC:43138","description":"RNA, 5S ribosomal pseudogene 238","metadata":{"aliases":["RN5S238"]}},{"id":"830af3a5386b4d84841a69ae45f8e5d8","type":"GENE","name":"RNA5SP239","canonical_id":"hgnc:HGNC:43139","description":"RNA, 5S ribosomal pseudogene 239","metadata":{"aliases":["RN5S239"]}},{"id":"9873406d7eff4d2888b23b0f2e5840a4","type":"GENE","name":"RNA5SP24","canonical_id":"hgnc:HGNC:42600","description":"RNA, 5S ribosomal pseudogene 24","metadata":{"aliases":["RN5S24"]}},{"id":"842437ae346c48d2bdf71b73234fc05c","type":"GENE","name":"RNA5SP240","canonical_id":"hgnc:HGNC:43140","description":"RNA, 5S ribosomal pseudogene 240","metadata":{"aliases":["RN5S240"]}},{"id":"c3f0cefe6d7e46818224f9f652e7cc84","type":"GENE","name":"RNA5SP241","canonical_id":"hgnc:HGNC:43141","description":"RNA, 5S ribosomal pseudogene 241","metadata":{"aliases":["RN5S241"]}},{"id":"db9541383aec456da23bd4392c767a12","type":"GENE","name":"RNA5SP242","canonical_id":"hgnc:HGNC:43142","description":"RNA, 5S ribosomal pseudogene 242","metadata":{"aliases":["RN5S242"]}},{"id":"fa6ec231298c4a27b3a170ef53e7d130","type":"GENE","name":"RNA5SP243","canonical_id":"hgnc:HGNC:43143","description":"RNA, 5S ribosomal pseudogene 243","metadata":{"aliases":["RN5S243"]}},{"id":"066158e7f28b44ddadda63cf79f2e133","type":"GENE","name":"RNA5SP244","canonical_id":"hgnc:HGNC:43144","description":"RNA, 5S ribosomal pseudogene 244","metadata":{"aliases":["RN5S244"]}},{"id":"fd13fda8bf99427bafe029553744ead4","type":"GENE","name":"RNA5SP245","canonical_id":"hgnc:HGNC:43145","description":"RNA, 5S ribosomal pseudogene 245","metadata":{"aliases":["RN5S245"]}},{"id":"24ed1548d9f74f878fe7f6dcd92d6e90","type":"GENE","name":"RNA5SP246","canonical_id":"hgnc:HGNC:43146","description":"RNA, 5S ribosomal pseudogene 246","metadata":{"aliases":["RN5S246"]}},{"id":"dd051adaf90146e99a2b414b5ef64a65","type":"GENE","name":"RNA5SP247","canonical_id":"hgnc:HGNC:43147","description":"RNA, 5S ribosomal pseudogene 247","metadata":{"aliases":["RN5S247"]}},{"id":"e8e8e56b438e42f59a0c0ac07ac052d8","type":"GENE","name":"RNA5SP248","canonical_id":"hgnc:HGNC:43148","description":"RNA, 5S ribosomal pseudogene 248","metadata":{"aliases":["RN5S248"]}},{"id":"421af2406e3545529dd4f000586ba9b2","type":"GENE","name":"RNA5SP249","canonical_id":"hgnc:HGNC:43149","description":"RNA, 5S ribosomal pseudogene 249","metadata":{"aliases":["RN5S249"]}},{"id":"5066cf3a63854199be274b562563b8a7","type":"GENE","name":"RNA5SP25","canonical_id":"hgnc:HGNC:42601","description":"RNA, 5S ribosomal pseudogene 25","metadata":{"aliases":["RN5S25"]}},{"id":"ad67bf169d3345ea87bef86d996e62fd","type":"GENE","name":"RNA5SP250","canonical_id":"hgnc:HGNC:43150","description":"RNA, 5S ribosomal pseudogene 250","metadata":{"aliases":["RN5S250"]}},{"id":"e7a21cf99e68448cb5835455f22fa77a","type":"GENE","name":"RNA5SP251","canonical_id":"hgnc:HGNC:43151","description":"RNA, 5S ribosomal pseudogene 251","metadata":{"aliases":["RN5S251"]}},{"id":"94cb5a73333f4090bf7f3097ee023b6f","type":"GENE","name":"RNA5SP252","canonical_id":"hgnc:HGNC:43152","description":"RNA, 5S ribosomal pseudogene 252","metadata":{"aliases":["RN5S252"]}},{"id":"d46971b484f74f729686e63f9cad33be","type":"GENE","name":"RNA5SP253","canonical_id":"hgnc:HGNC:43153","description":"RNA, 5S ribosomal pseudogene 253","metadata":{"aliases":["RN5S253"]}},{"id":"ec958ed9d3c34ca3a8859c7374ad95da","type":"GENE","name":"RNA5SP254","canonical_id":"hgnc:HGNC:43154","description":"RNA, 5S ribosomal pseudogene 254","metadata":{"aliases":["RN5S254"]}},{"id":"667d16af1394475aafd3b8d2bf6fefa5","type":"GENE","name":"RNA5SP255","canonical_id":"hgnc:HGNC:43155","description":"RNA, 5S ribosomal pseudogene 255","metadata":{"aliases":["RN5S255"]}},{"id":"d3520dd631f249b491df3aae4b1be8ef","type":"GENE","name":"RNA5SP256","canonical_id":"hgnc:HGNC:43156","description":"RNA, 5S ribosomal pseudogene 256","metadata":{"aliases":["RN5S256"]}},{"id":"e1ba6612303742d890e3b0c58f7ce912","type":"GENE","name":"RNA5SP257","canonical_id":"hgnc:HGNC:43157","description":"RNA, 5S ribosomal pseudogene 257","metadata":{"aliases":["RN5S257"]}},{"id":"b3e7d93143ad4f7dafe111092794d3c6","type":"GENE","name":"RNA5SP258","canonical_id":"hgnc:HGNC:43158","description":"RNA, 5S ribosomal pseudogene 258","metadata":{"aliases":["RN5S258"]}},{"id":"f3c41e243a4d476a8d472cdd2e8ffdd7","type":"GENE","name":"RNA5SP259","canonical_id":"hgnc:HGNC:43159","description":"RNA, 5S ribosomal pseudogene 259","metadata":{"aliases":["RN5S259"]}},{"id":"b6d956e443fb41069cefd541fc2435c3","type":"GENE","name":"RNA5SP26","canonical_id":"hgnc:HGNC:42602","description":"RNA, 5S ribosomal pseudogene 26","metadata":{"aliases":["RN5S26"]}},{"id":"253446c470054e829b60276def6f8301","type":"GENE","name":"RNA5SP260","canonical_id":"hgnc:HGNC:43160","description":"RNA, 5S ribosomal pseudogene 260","metadata":{"aliases":["RN5S260"]}},{"id":"f4f048278ab04ea1ba253d04f05ece38","type":"GENE","name":"RNA5SP261","canonical_id":"hgnc:HGNC:43161","description":"RNA, 5S ribosomal pseudogene 261","metadata":{"aliases":["RN5S261"]}},{"id":"0c49ae09840a4b2c9d308b948c0f256b","type":"GENE","name":"RNA5SP262","canonical_id":"hgnc:HGNC:43162","description":"RNA, 5S ribosomal pseudogene 262","metadata":{"aliases":["RN5S262"]}},{"id":"e2ac07f9097c476bb787cff704ba2d6c","type":"GENE","name":"RNA5SP263","canonical_id":"hgnc:HGNC:43163","description":"RNA, 5S ribosomal pseudogene 263","metadata":{"aliases":["RN5S263"]}},{"id":"f1de5aa2bf5644259ad6a3dc002176d7","type":"GENE","name":"RNA5SP264","canonical_id":"hgnc:HGNC:43164","description":"RNA, 5S ribosomal pseudogene 264","metadata":{"aliases":["RN5S264"]}},{"id":"b95651f668a64df2bcbe6f7ad246d817","type":"GENE","name":"RNA5SP265","canonical_id":"hgnc:HGNC:43165","description":"RNA, 5S ribosomal pseudogene 265","metadata":{"aliases":["RN5S265"]}},{"id":"56c9ffc47fd14f909a83346bb112c554","type":"GENE","name":"RNA5SP266","canonical_id":"hgnc:HGNC:43166","description":"RNA, 5S ribosomal pseudogene 266","metadata":{"aliases":["RN5S266"]}},{"id":"ded6d9160bf248a6bc4a4616b7a832fb","type":"GENE","name":"RNA5SP267","canonical_id":"hgnc:HGNC:43167","description":"RNA, 5S ribosomal pseudogene 267","metadata":{"aliases":["RN5S267"]}},{"id":"edc98c0509904944a1c7fb5cefdb3290","type":"GENE","name":"RNA5SP268","canonical_id":"hgnc:HGNC:43168","description":"RNA, 5S ribosomal pseudogene 268","metadata":{"aliases":["RN5S268"]}},{"id":"8c57ee33359d407e850c4340eebff67a","type":"GENE","name":"RNA5SP269","canonical_id":"hgnc:HGNC:43169","description":"RNA, 5S ribosomal pseudogene 269","metadata":{"aliases":["RN5S269"]}},{"id":"ca5922c2623e4f81aaa30caa37955e96","type":"GENE","name":"RNA5SP27","canonical_id":"hgnc:HGNC:42603","description":"RNA, 5S ribosomal pseudogene 27","metadata":{"aliases":["RN5S27"]}},{"id":"2886d40c3eb74ee4bd7686d803c61101","type":"GENE","name":"RNA5SP270","canonical_id":"hgnc:HGNC:43170","description":"RNA, 5S ribosomal pseudogene 270","metadata":{"aliases":["RN5S270"]}},{"id":"4731b02c253b414794d3e3bf5e7c6ff9","type":"GENE","name":"RNA5SP271","canonical_id":"hgnc:HGNC:43171","description":"RNA, 5S ribosomal pseudogene 271","metadata":{"aliases":["RN5S271"]}},{"id":"f51eda47eeee4a019c0131a1c7726f51","type":"GENE","name":"RNA5SP272","canonical_id":"hgnc:HGNC:43172","description":"RNA, 5S ribosomal pseudogene 272","metadata":{"aliases":["RN5S272"]}},{"id":"ce003bfdaaa945a9911f61e0c50e20be","type":"GENE","name":"RNA5SP273","canonical_id":"hgnc:HGNC:43173","description":"RNA, 5S ribosomal pseudogene 273","metadata":{"aliases":["RN5S273"]}},{"id":"631a7e88979b4fb2a74e907ed1cabe4c","type":"GENE","name":"RNA5SP274","canonical_id":"hgnc:HGNC:43174","description":"RNA, 5S ribosomal pseudogene 274","metadata":{"aliases":["RN5S274"]}},{"id":"863e9b7b6aa0408dadcc19c66e1144de","type":"GENE","name":"RNA5SP275","canonical_id":"hgnc:HGNC:43175","description":"RNA, 5S ribosomal pseudogene 275","metadata":{"aliases":["RN5S275"]}},{"id":"7115f9a1087f4672b44a93e67c771f97","type":"GENE","name":"RNA5SP276","canonical_id":"hgnc:HGNC:43176","description":"RNA, 5S ribosomal pseudogene 276","metadata":{"aliases":["RN5S276"]}},{"id":"455cd9f416604cf9a60e6be7e779f838","type":"GENE","name":"RNA5SP277","canonical_id":"hgnc:HGNC:43177","description":"RNA, 5S ribosomal pseudogene 277","metadata":{"aliases":["RN5S277"]}},{"id":"447d858b3ab4460fbb80c4d3a9c5cd46","type":"GENE","name":"RNA5SP278","canonical_id":"hgnc:HGNC:43178","description":"RNA, 5S ribosomal pseudogene 278","metadata":{"aliases":["RN5S278"]}},{"id":"f2c2bcdc6226440fa33390c341f57dad","type":"GENE","name":"RNA5SP279","canonical_id":"hgnc:HGNC:43179","description":"RNA, 5S ribosomal pseudogene 279","metadata":{"aliases":["RN5S279"]}},{"id":"749c1bdbe7334d608056368cc31911ef","type":"GENE","name":"RNA5SP28","canonical_id":"hgnc:HGNC:42604","description":"RNA, 5S ribosomal pseudogene 28","metadata":{"aliases":["RN5S28"]}},{"id":"5f77f92ed8f24685a455e96a9764519e","type":"GENE","name":"RNA5SP280","canonical_id":"hgnc:HGNC:43180","description":"RNA, 5S ribosomal pseudogene 280","metadata":{"aliases":["RN5S280"]}},{"id":"3010f8ee739548ef9ee5efa34e269583","type":"GENE","name":"RNA5SP281","canonical_id":"hgnc:HGNC:43181","description":"RNA, 5S ribosomal pseudogene 281","metadata":{"aliases":["RN5S281"]}},{"id":"f73f75e6ab9f4fe5b8bb1bdb69f6612e","type":"GENE","name":"RNA5SP282","canonical_id":"hgnc:HGNC:43182","description":"RNA, 5S ribosomal pseudogene 282","metadata":{"aliases":["RN5S282"]}},{"id":"70f10647c58045bf802d3af5750a13ae","type":"GENE","name":"RNA5SP283","canonical_id":"hgnc:HGNC:43183","description":"RNA, 5S ribosomal pseudogene 283","metadata":{"aliases":["RN5S283"]}},{"id":"8013ff929e7d4cb2840eef9d34a6c859","type":"GENE","name":"RNA5SP284","canonical_id":"hgnc:HGNC:43184","description":"RNA, 5S ribosomal pseudogene 284","metadata":{"aliases":["RN5S284"]}},{"id":"fb53b4691cc544e0908ba9ee069efdf8","type":"GENE","name":"RNA5SP285","canonical_id":"hgnc:HGNC:43185","description":"RNA, 5S ribosomal pseudogene 285","metadata":{"aliases":["RN5S285"]}},{"id":"cb22b74ca6314b128c0396642f7225f7","type":"GENE","name":"RNA5SP286","canonical_id":"hgnc:HGNC:43186","description":"RNA, 5S ribosomal pseudogene 286","metadata":{"aliases":["RN5S286"]}},{"id":"aacc3e6f29014cd0be2a1e765e6b47f2","type":"GENE","name":"RNA5SP287","canonical_id":"hgnc:HGNC:43187","description":"RNA, 5S ribosomal pseudogene 287","metadata":{"aliases":["RN5S287"]}},{"id":"b9b552b4db6e43f4a4b337ca91467b24","type":"GENE","name":"RNA5SP288","canonical_id":"hgnc:HGNC:43188","description":"RNA, 5S ribosomal pseudogene 288","metadata":{"aliases":["RN5S288"]}},{"id":"6dbf0a9749004bbe9d06ffb2a1a706a2","type":"GENE","name":"RNA5SP289","canonical_id":"hgnc:HGNC:43189","description":"RNA, 5S ribosomal pseudogene 289","metadata":{"aliases":["RN5S289"]}},{"id":"6f406c6d1dcb4fdc88837d95b33f0c3d","type":"GENE","name":"RNA5SP29","canonical_id":"hgnc:HGNC:42605","description":"RNA, 5S ribosomal pseudogene 29","metadata":{"aliases":["RN5S29"]}},{"id":"50fca66ff477434c93cda343921a0445","type":"GENE","name":"RNA5SP290","canonical_id":"hgnc:HGNC:43190","description":"RNA, 5S ribosomal pseudogene 290","metadata":{"aliases":["RN5S290"]}},{"id":"0b4858272864431ea2b906761c1a8698","type":"GENE","name":"RNA5SP291","canonical_id":"hgnc:HGNC:43191","description":"RNA, 5S ribosomal pseudogene 291","metadata":{"aliases":["RN5S291"]}},{"id":"e594244d77a147d8b34d4094d8c897f5","type":"GENE","name":"RNA5SP292","canonical_id":"hgnc:HGNC:43192","description":"RNA, 5S ribosomal pseudogene 292","metadata":{"aliases":["RN5S292"]}},{"id":"227e6665143e4b17a8f8dd75da5997c3","type":"GENE","name":"RNA5SP293","canonical_id":"hgnc:HGNC:43193","description":"RNA, 5S ribosomal pseudogene 293","metadata":{"aliases":["RN5S293"]}},{"id":"a452a627ab0b4f25a87517ff4c95da57","type":"GENE","name":"RNA5SP294","canonical_id":"hgnc:HGNC:43194","description":"RNA, 5S ribosomal pseudogene 294","metadata":{"aliases":["RN5S294"]}},{"id":"e566db933aac477aa3457059d160fe38","type":"GENE","name":"RNA5SP295","canonical_id":"hgnc:HGNC:43195","description":"RNA, 5S ribosomal pseudogene 295","metadata":{"aliases":["RN5S295"]}},{"id":"1d42d8d3d2254a6ea9a2ebdd1405ce52","type":"GENE","name":"RNA5SP296","canonical_id":"hgnc:HGNC:43196","description":"RNA, 5S ribosomal pseudogene 296","metadata":{"aliases":["RN5S296"]}},{"id":"986e157df2ac46dc9db33a4c13841985","type":"GENE","name":"RNA5SP297","canonical_id":"hgnc:HGNC:43197","description":"RNA, 5S ribosomal pseudogene 297","metadata":{"aliases":["RN5S297"]}},{"id":"be132ced906f43ff96eb89a783431f0c","type":"GENE","name":"RNA5SP298","canonical_id":"hgnc:HGNC:43198","description":"RNA, 5S ribosomal pseudogene 298","metadata":{"aliases":["RN5S298"]}},{"id":"7fcd86d8a1804dab8561524994f01ec5","type":"GENE","name":"RNA5SP299","canonical_id":"hgnc:HGNC:43199","description":"RNA, 5S ribosomal pseudogene 299","metadata":{"aliases":["RN5S299"]}},{"id":"f520dee7abd9481398463ddc9fec11dd","type":"GENE","name":"RNA5SP30","canonical_id":"hgnc:HGNC:42606","description":"RNA, 5S ribosomal pseudogene 30","metadata":{"aliases":["RN5S30"]}},{"id":"0039f88c701548578a060562b167e08e","type":"GENE","name":"RNA5SP300","canonical_id":"hgnc:HGNC:43200","description":"RNA, 5S ribosomal pseudogene 300","metadata":{"aliases":["RN5S300"]}},{"id":"279e18ac185b4691b778d2f5aebe5466","type":"GENE","name":"RNA5SP301","canonical_id":"hgnc:HGNC:43201","description":"RNA, 5S ribosomal pseudogene 301","metadata":{"aliases":["RN5S301"]}},{"id":"5d9d3ea6df8042fa9245d497c39ba7af","type":"GENE","name":"RNA5SP302","canonical_id":"hgnc:HGNC:43202","description":"RNA, 5S ribosomal pseudogene 302","metadata":{"aliases":["RN5S302"]}},{"id":"c611b28959ea4c11a9d8e0d1bed82592","type":"GENE","name":"RNA5SP303","canonical_id":"hgnc:HGNC:43203","description":"RNA, 5S ribosomal pseudogene 303","metadata":{"aliases":["RN5S303"]}},{"id":"5140cff56cd1470f86ac38f6d87f88b3","type":"GENE","name":"RNA5SP304","canonical_id":"hgnc:HGNC:43204","description":"RNA, 5S ribosomal pseudogene 304","metadata":{"aliases":["RN5S304"]}},{"id":"710874ca0844481bb8ff384ebfc5a00b","type":"GENE","name":"RNA5SP305","canonical_id":"hgnc:HGNC:43205","description":"RNA, 5S ribosomal pseudogene 305","metadata":{"aliases":["RN5S305"]}},{"id":"5f6d551c7c244750a7316f0c868be057","type":"GENE","name":"RNA5SP306","canonical_id":"hgnc:HGNC:43206","description":"RNA, 5S ribosomal pseudogene 306","metadata":{"aliases":["RN5S306"]}},{"id":"ffd2a580dadb4520a730fe3ff1c34506","type":"GENE","name":"RNA5SP307","canonical_id":"hgnc:HGNC:43207","description":"RNA, 5S ribosomal pseudogene 307","metadata":{"aliases":["RN5S307"]}},{"id":"a7145cc622e44577a8341c26521f6a63","type":"GENE","name":"RNA5SP308","canonical_id":"hgnc:HGNC:43208","description":"RNA, 5S ribosomal pseudogene 308","metadata":{"aliases":["RN5S308"]}},{"id":"59ef715f732e4e289593b300d54aba84","type":"GENE","name":"RNA5SP309","canonical_id":"hgnc:HGNC:43209","description":"RNA, 5S ribosomal pseudogene 309","metadata":{"aliases":["RN5S309"]}},{"id":"3aa11bd4016445c480915bb2234fd660","type":"GENE","name":"RNA5SP31","canonical_id":"hgnc:HGNC:42607","description":"RNA, 5S ribosomal pseudogene 31","metadata":{"aliases":["RN5S31"]}},{"id":"b77e4d0dc946413c882b208e402a2508","type":"GENE","name":"RNA5SP310","canonical_id":"hgnc:HGNC:43210","description":"RNA, 5S ribosomal pseudogene 310","metadata":{"aliases":["RN5S310","RNA5SP316","RN5S316"]}},{"id":"cce39e3bd08d4910b3e39aba45d2f90b","type":"GENE","name":"RNA5SP311","canonical_id":"hgnc:HGNC:43211","description":"RNA, 5S ribosomal pseudogene 311","metadata":{"aliases":["RN5S311","RNA5SP314","RN5S314"]}},{"id":"1c35c5cfc4554f23aa76f5e0d5af594d","type":"GENE","name":"RNA5SP312","canonical_id":"hgnc:HGNC:43212","description":"RNA, 5S ribosomal pseudogene 312","metadata":{"aliases":["RN5S312","RNA5SP313","RN5S313"]}},{"id":"8daf40e2682d4596b21465458131c447","type":"GENE","name":"RNA5SP315","canonical_id":"hgnc:HGNC:43215","description":"RNA, 5S ribosomal pseudogene 315","metadata":{"aliases":["RN5S315"]}},{"id":"2e24946be4ed4c1cadc5199b4e3a1727","type":"GENE","name":"RNA5SP317","canonical_id":"hgnc:HGNC:43217","description":"RNA, 5S ribosomal pseudogene 317","metadata":{"aliases":["RN5S317"]}},{"id":"e23352aeaaaa492a85c777eaa101ecb5","type":"GENE","name":"RNA5SP318","canonical_id":"hgnc:HGNC:43218","description":"RNA, 5S ribosomal pseudogene 318","metadata":{"aliases":["RN5S318"]}},{"id":"66217b18c6664d4ca120e56c4c2bcb41","type":"GENE","name":"RNA5SP319","canonical_id":"hgnc:HGNC:43219","description":"RNA, 5S ribosomal pseudogene 319","metadata":{"aliases":["RN5S319"]}},{"id":"e8a35ae1ed574995a1de85dd37f6b8f0","type":"GENE","name":"RNA5SP320","canonical_id":"hgnc:HGNC:43220","description":"RNA, 5S ribosomal pseudogene 320","metadata":{"aliases":["RN5S320"]}},{"id":"d55f42ddac25471bb553007962fca97e","type":"GENE","name":"RNA5SP321","canonical_id":"hgnc:HGNC:43221","description":"RNA, 5S ribosomal pseudogene 321","metadata":{"aliases":["RN5S321"]}},{"id":"be9157cf2aea44519b7e39104fbc0c1d","type":"GENE","name":"RNA5SP322","canonical_id":"hgnc:HGNC:43222","description":"RNA, 5S ribosomal pseudogene 322","metadata":{"aliases":["RN5S322"]}},{"id":"a34e800865fc4419b6d3eb05a1fde04f","type":"GENE","name":"RNA5SP323","canonical_id":"hgnc:HGNC:43223","description":"RNA, 5S ribosomal pseudogene 323","metadata":{"aliases":["RN5S323"]}},{"id":"85e2c8a6eb764e89b91841d47712bbbf","type":"GENE","name":"RNA5SP324","canonical_id":"hgnc:HGNC:43224","description":"RNA, 5S ribosomal pseudogene 324","metadata":{"aliases":["RN5S324"]}},{"id":"a427374707954824837802bf9786ad58","type":"GENE","name":"RNA5SP325","canonical_id":"hgnc:HGNC:43225","description":"RNA, 5S ribosomal pseudogene 325","metadata":{"aliases":["RN5S325"]}},{"id":"bf392f5c440d415994a0ac9fa1568dd1","type":"GENE","name":"RNA5SP326","canonical_id":"hgnc:HGNC:43226","description":"RNA, 5S ribosomal pseudogene 326","metadata":{"aliases":["RN5S326"]}},{"id":"073b5ccec93f4153b3a6b2f5c2c19d19","type":"GENE","name":"RNA5SP327","canonical_id":"hgnc:HGNC:43227","description":"RNA, 5S ribosomal pseudogene 327","metadata":{"aliases":["RN5S327"]}},{"id":"7cac21680da14ef3b13d34306f50a972","type":"GENE","name":"RNA5SP328","canonical_id":"hgnc:HGNC:43228","description":"RNA, 5S ribosomal pseudogene 328","metadata":{"aliases":["RN5S328"]}},{"id":"d049cc4b3fb9423b978a2fc3adfcebbe","type":"GENE","name":"RNA5SP329","canonical_id":"hgnc:HGNC:43229","description":"RNA, 5S ribosomal pseudogene 329","metadata":{"aliases":["RN5S329"]}},{"id":"0b1033df56b749608968515b95df1595","type":"GENE","name":"RNA5SP33","canonical_id":"hgnc:HGNC:42609","description":"RNA, 5S ribosomal pseudogene 33","metadata":{"aliases":["RN5S33"]}},{"id":"fc7263712d7c40e58a8e3a7e5d371c3d","type":"GENE","name":"RNA5SP330","canonical_id":"hgnc:HGNC:43230","description":"RNA, 5S ribosomal pseudogene 330","metadata":{"aliases":["RN5S330"]}},{"id":"3f6e7a9208cb4b3886c8273b1ebcc916","type":"GENE","name":"RNA5SP331","canonical_id":"hgnc:HGNC:43231","description":"RNA, 5S ribosomal pseudogene 331","metadata":{"aliases":["RN5S331"]}},{"id":"848862d810dd452e905887ef690eeabe","type":"GENE","name":"RNA5SP332","canonical_id":"hgnc:HGNC:43232","description":"RNA, 5S ribosomal pseudogene 332","metadata":{"aliases":["RN5S332"]}},{"id":"335fb539d8cc4842a5cd5d98691799f0","type":"GENE","name":"RNA5SP333","canonical_id":"hgnc:HGNC:43233","description":"RNA, 5S ribosomal pseudogene 333","metadata":{"aliases":["RN5S333"]}},{"id":"24ea2cf874304bf8946553593d54179a","type":"GENE","name":"RNA5SP334","canonical_id":"hgnc:HGNC:43234","description":"RNA, 5S ribosomal pseudogene 334","metadata":{"aliases":["RN5S334"]}},{"id":"d5f3b60fb727442a9ffe51003fc9aecc","type":"GENE","name":"RNA5SP335","canonical_id":"hgnc:HGNC:43235","description":"RNA, 5S ribosomal pseudogene 335","metadata":{"aliases":["RN5S335"]}},{"id":"7e4d97167141447e935607db1558e79c","type":"GENE","name":"RNA5SP336","canonical_id":"hgnc:HGNC:43236","description":"RNA, 5S ribosomal pseudogene 336","metadata":{"aliases":["RN5S336"]}},{"id":"6cb94258989246ec8cbfa4f48e5b630e","type":"GENE","name":"RNA5SP337","canonical_id":"hgnc:HGNC:43237","description":"RNA, 5S ribosomal pseudogene 337","metadata":{"aliases":["RN5S337"]}},{"id":"2c72cd7108154452b25f3b1e55867b04","type":"GENE","name":"RNA5SP338","canonical_id":"hgnc:HGNC:43238","description":"RNA, 5S ribosomal pseudogene 338","metadata":{"aliases":["RN5S338"]}},{"id":"4e0203b7f5344279ae8cd79026b08962","type":"GENE","name":"RNA5SP339","canonical_id":"hgnc:HGNC:43239","description":"RNA, 5S ribosomal pseudogene 339","metadata":{"aliases":["RN5S339"]}},{"id":"691db1e881364a3c9303c99ea9dce51f","type":"GENE","name":"RNA5SP34","canonical_id":"hgnc:HGNC:42610","description":"RNA, 5S ribosomal pseudogene 34","metadata":{"aliases":["RN5S34"]}},{"id":"52fd32a6dfe64022a459468c08c60803","type":"GENE","name":"RNA5SP340","canonical_id":"hgnc:HGNC:43240","description":"RNA, 5S ribosomal pseudogene 340","metadata":{"aliases":["RN5S340"]}},{"id":"4348c6c02cec45b0b67fe9265d6f75d2","type":"GENE","name":"RNA5SP341","canonical_id":"hgnc:HGNC:43241","description":"RNA, 5S ribosomal pseudogene 341","metadata":{"aliases":["RN5S341"]}},{"id":"a6903a0db9c84b90bc3a53ea6fef7726","type":"GENE","name":"RNA5SP342","canonical_id":"hgnc:HGNC:43242","description":"RNA, 5S ribosomal pseudogene 342","metadata":{"aliases":["RN5S342"]}},{"id":"88bb5af63df94133af3195adec1e15b5","type":"GENE","name":"RNA5SP343","canonical_id":"hgnc:HGNC:43243","description":"RNA, 5S ribosomal pseudogene 343","metadata":{"aliases":["RN5S343"]}},{"id":"a38f84d4ef3f459396e04e1e5336753d","type":"GENE","name":"RNA5SP344","canonical_id":"hgnc:HGNC:43244","description":"RNA, 5S ribosomal pseudogene 344","metadata":{"aliases":["RN5S344"]}},{"id":"e82c440b87c34db195f91b0d95a93a0c","type":"GENE","name":"RNA5SP345","canonical_id":"hgnc:HGNC:43245","description":"RNA, 5S ribosomal pseudogene 345","metadata":{"aliases":["RN5S345"]}},{"id":"ff7b1238a7874c399f90f01f7df45a1b","type":"GENE","name":"RNA5SP346","canonical_id":"hgnc:HGNC:43246","description":"RNA, 5S ribosomal pseudogene 346","metadata":{"aliases":["RN5S346"]}},{"id":"8099a9e1815d494394837e1e43ca8969","type":"GENE","name":"RNA5SP347","canonical_id":"hgnc:HGNC:43247","description":"RNA, 5S ribosomal pseudogene 347","metadata":{"aliases":["RN5S347"]}},{"id":"f26ae7e8ff854f6f8f59bc5d13f26262","type":"GENE","name":"RNA5SP348","canonical_id":"hgnc:HGNC:43248","description":"RNA, 5S ribosomal pseudogene 348","metadata":{"aliases":["RN5S348"]}},{"id":"0a92d2fcf9ce4372b35e126079218b82","type":"GENE","name":"RNA5SP349","canonical_id":"hgnc:HGNC:43249","description":"RNA, 5S ribosomal pseudogene 349","metadata":{"aliases":["RN5S349"]}},{"id":"87f7ec348d0d4ddfab6e6f730d6a86ca","type":"GENE","name":"RNA5SP35","canonical_id":"hgnc:HGNC:42611","description":"RNA, 5S ribosomal pseudogene 35","metadata":{"aliases":["RN5S35"]}},{"id":"4bb46cb28e2840cc84975b2fa55e7933","type":"GENE","name":"RNA5SP350","canonical_id":"hgnc:HGNC:43250","description":"RNA, 5S ribosomal pseudogene 350","metadata":{"aliases":["RN5S350"]}},{"id":"b28fee8232fc40cb8f47797b1601f729","type":"GENE","name":"RNA5SP351","canonical_id":"hgnc:HGNC:43251","description":"RNA, 5S ribosomal pseudogene 351","metadata":{"aliases":["RN5S351"]}},{"id":"d58c2878517b4ba78c6b09a39bfa266d","type":"GENE","name":"RNA5SP352","canonical_id":"hgnc:HGNC:43252","description":"RNA, 5S ribosomal pseudogene 352","metadata":{"aliases":["RN5S352"]}},{"id":"73aa1f6653094a6b8ef327cb5827dd53","type":"GENE","name":"RNA5SP353","canonical_id":"hgnc:HGNC:43253","description":"RNA, 5S ribosomal pseudogene 353","metadata":{"aliases":["RN5S353"]}},{"id":"d0d95fdb63434b82a1aff36cea0e3bdd","type":"GENE","name":"RNA5SP354","canonical_id":"hgnc:HGNC:43254","description":"RNA, 5S ribosomal pseudogene 354","metadata":{"aliases":["RN5S354"]}},{"id":"3c60059862d64705b8a374b2b66797ba","type":"GENE","name":"RNA5SP355","canonical_id":"hgnc:HGNC:43255","description":"RNA, 5S ribosomal pseudogene 355","metadata":{"aliases":["RN5S355"]}},{"id":"ddab584f040a4ac286a0870a91b63156","type":"GENE","name":"RNA5SP356","canonical_id":"hgnc:HGNC:43256","description":"RNA, 5S ribosomal pseudogene 356","metadata":{"aliases":["RN5S356"]}},{"id":"acac9b00cf5a489b80c13dbde09b08d2","type":"GENE","name":"RNA5SP357","canonical_id":"hgnc:HGNC:43257","description":"RNA, 5S ribosomal pseudogene 357","metadata":{"aliases":["RN5S357"]}},{"id":"a86d939022cf46e3919d14ce2a4b0033","type":"GENE","name":"RNA5SP358","canonical_id":"hgnc:HGNC:43258","description":"RNA, 5S ribosomal pseudogene 358","metadata":{"aliases":["RN5S358"]}},{"id":"feddbb8a51ff4253bf605b10e573cb23","type":"GENE","name":"RNA5SP359","canonical_id":"hgnc:HGNC:43259","description":"RNA, 5S ribosomal pseudogene 359","metadata":{"aliases":["RN5S359"]}},{"id":"988a284ec9aa4b2aad1a2a3db4223267","type":"GENE","name":"RNA5SP36","canonical_id":"hgnc:HGNC:42612","description":"RNA, 5S ribosomal pseudogene 36","metadata":{"aliases":["RN5S36"]}},{"id":"6224814a930243da9ce9426b699c3d95","type":"GENE","name":"RNA5SP360","canonical_id":"hgnc:HGNC:43260","description":"RNA, 5S ribosomal pseudogene 360","metadata":{"aliases":["RN5S360"]}},{"id":"1398d974c071437fb4f8ca86f40dced4","type":"GENE","name":"RNA5SP361","canonical_id":"hgnc:HGNC:43261","description":"RNA, 5S ribosomal pseudogene 361","metadata":{"aliases":["RN5S361"]}},{"id":"d87d4bb71c4849279f4ce40e7e6720ff","type":"GENE","name":"RNA5SP362","canonical_id":"hgnc:HGNC:43262","description":"RNA, 5S ribosomal pseudogene 362","metadata":{"aliases":["RN5S362"]}},{"id":"9aad6982eafa4ab2b69e49bb135a4151","type":"GENE","name":"RNA5SP363","canonical_id":"hgnc:HGNC:43263","description":"RNA, 5S ribosomal pseudogene 363","metadata":{"aliases":["RN5S363"]}},{"id":"fae39a0eca6644a4a860e7a028c7d31c","type":"GENE","name":"RNA5SP364","canonical_id":"hgnc:HGNC:43264","description":"RNA, 5S ribosomal pseudogene 364","metadata":{"aliases":["RN5S364"]}},{"id":"ce886b8af847497e97c588869d66ec45","type":"GENE","name":"RNA5SP365","canonical_id":"hgnc:HGNC:43265","description":"RNA, 5S ribosomal pseudogene 365","metadata":{"aliases":["RN5S365"]}},{"id":"8396d580a49f4caaac0e8dd5c180e9a4","type":"GENE","name":"RNA5SP366","canonical_id":"hgnc:HGNC:43266","description":"RNA, 5S ribosomal pseudogene 366","metadata":{"aliases":["RN5S366"]}},{"id":"91a29258a12c4496b1d3848428ace9de","type":"GENE","name":"RNA5SP367","canonical_id":"hgnc:HGNC:43267","description":"RNA, 5S ribosomal pseudogene 367","metadata":{"aliases":["RN5S367"]}},{"id":"118d16dae7b3482f8a23d9b681f154a0","type":"GENE","name":"RNA5SP368","canonical_id":"hgnc:HGNC:43268","description":"RNA, 5S ribosomal pseudogene 368","metadata":{"aliases":["RN5S368"]}},{"id":"e97a55b5528145daa7989a6a01e54b85","type":"GENE","name":"RNA5SP369","canonical_id":"hgnc:HGNC:43269","description":"RNA, 5S ribosomal pseudogene 369","metadata":{"aliases":["RN5S369"]}},{"id":"9cd4885db47c4b47a568749348556638","type":"GENE","name":"RNA5SP37","canonical_id":"hgnc:HGNC:42613","description":"RNA, 5S ribosomal pseudogene 37","metadata":{"aliases":["RN5S37"]}},{"id":"f92d40f26c5641188b720c4e4dcef1d5","type":"GENE","name":"RNA5SP370","canonical_id":"hgnc:HGNC:43270","description":"RNA, 5S ribosomal pseudogene 370","metadata":{"aliases":["RN5S370"]}},{"id":"f925d3e9ce664a6e8084921900bfacdb","type":"GENE","name":"RNA5SP371","canonical_id":"hgnc:HGNC:43271","description":"RNA, 5S ribosomal pseudogene 371","metadata":{"aliases":["RN5S371"]}},{"id":"92e5eff9a5b14def8b879b345f29e435","type":"GENE","name":"RNA5SP372","canonical_id":"hgnc:HGNC:43272","description":"RNA, 5S ribosomal pseudogene 372","metadata":{"aliases":["RN5S372"]}},{"id":"8b91767d79d1466ebe8f97a49197f91d","type":"GENE","name":"RNA5SP373","canonical_id":"hgnc:HGNC:43273","description":"RNA, 5S ribosomal pseudogene 373","metadata":{"aliases":["RN5S373"]}},{"id":"d642f2bc0f9a454daf4e85e89b11ff42","type":"GENE","name":"RNA5SP374","canonical_id":"hgnc:HGNC:43274","description":"RNA, 5S ribosomal pseudogene 374","metadata":{"aliases":["RN5S374"]}},{"id":"7c47188c228f4d1e8659d8577f4757d1","type":"GENE","name":"RNA5SP375","canonical_id":"hgnc:HGNC:43275","description":"RNA, 5S ribosomal pseudogene 375","metadata":{"aliases":["RN5S375"]}},{"id":"99e1b4c0572a4ad2aa2351e3584cf022","type":"GENE","name":"RNA5SP376","canonical_id":"hgnc:HGNC:43276","description":"RNA, 5S ribosomal pseudogene 376","metadata":{"aliases":["RN5S376"]}},{"id":"c7eb583a0eb44f49b970a7a5e6bdee48","type":"GENE","name":"RNA5SP377","canonical_id":"hgnc:HGNC:43277","description":"RNA, 5S ribosomal pseudogene 377","metadata":{"aliases":["RN5S377"]}},{"id":"174383a65d844a46b2cc151fb6c8a3f6","type":"GENE","name":"RNA5SP378","canonical_id":"hgnc:HGNC:43278","description":"RNA, 5S ribosomal pseudogene 378","metadata":{"aliases":["RN5S378"]}},{"id":"4763826389de4edd9d90ba46eeab0977","type":"GENE","name":"RNA5SP379","canonical_id":"hgnc:HGNC:43279","description":"RNA, 5S ribosomal pseudogene 379","metadata":{"aliases":["RN5S379"]}},{"id":"a01115ef07c7400790606cf8351f289c","type":"GENE","name":"RNA5SP38","canonical_id":"hgnc:HGNC:42614","description":"RNA, 5S ribosomal pseudogene 38","metadata":{"aliases":["RN5S38"]}},{"id":"0f6f1bbb73fc4160b10ea6ae38cdba79","type":"GENE","name":"RNA5SP380","canonical_id":"hgnc:HGNC:43280","description":"RNA, 5S ribosomal pseudogene 380","metadata":{"aliases":["RN5S380"]}},{"id":"f9e5986443f44549a1fd2c1f4eac003a","type":"GENE","name":"RNA5SP382","canonical_id":"hgnc:HGNC:43282","description":"RNA, 5S ribosomal pseudogene 382","metadata":{"aliases":["RN5S382"]}},{"id":"82beb945c05b41fb98478130c77548d8","type":"GENE","name":"RNA5SP383","canonical_id":"hgnc:HGNC:43283","description":"RNA, 5S ribosomal pseudogene 383","metadata":{"aliases":["RN5S383"]}},{"id":"c8dfada6344b4e75b08340e35c698a80","type":"GENE","name":"RNA5SP384","canonical_id":"hgnc:HGNC:43284","description":"RNA, 5S ribosomal pseudogene 384","metadata":{"aliases":["RN5S384"]}},{"id":"6b778d63bda44602a2bf57bb20472d17","type":"GENE","name":"RNA5SP385","canonical_id":"hgnc:HGNC:43285","description":"RNA, 5S ribosomal pseudogene 385","metadata":{"aliases":["RN5S385"]}},{"id":"cd76359e04bb4f2390673baa61ce859a","type":"GENE","name":"RNA5SP386","canonical_id":"hgnc:HGNC:43286","description":"RNA, 5S ribosomal pseudogene 386","metadata":{"aliases":["RN5S386"]}},{"id":"0aeda67adc1647c58677879bdfecbaf6","type":"GENE","name":"RNA5SP387","canonical_id":"hgnc:HGNC:43287","description":"RNA, 5S ribosomal pseudogene 387","metadata":{"aliases":["RN5S387"]}},{"id":"4897cc9426ac4e38b95453cac6b79d48","type":"GENE","name":"RNA5SP388","canonical_id":"hgnc:HGNC:43288","description":"RNA, 5S ribosomal pseudogene 388","metadata":{"aliases":["RN5S388"]}},{"id":"dc1d522b2b18496184d14d7eb97a38b4","type":"GENE","name":"RNA5SP389","canonical_id":"hgnc:HGNC:43289","description":"RNA, 5S ribosomal pseudogene 389","metadata":{"aliases":["RN5S389"]}},{"id":"f622c729fc13435a975a0aef5ebebebb","type":"GENE","name":"RNA5SP39","canonical_id":"hgnc:HGNC:42615","description":"RNA, 5S ribosomal pseudogene 39","metadata":{"aliases":["RN5S39"]}},{"id":"1364bfe3a7bc4e3199c7716722378665","type":"GENE","name":"RNA5SP390","canonical_id":"hgnc:HGNC:43290","description":"RNA, 5S ribosomal pseudogene 390","metadata":{"aliases":["RN5S390"]}},{"id":"588071ac514f4cf5af36d81a3be537b5","type":"GENE","name":"RNA5SP391","canonical_id":"hgnc:HGNC:43291","description":"RNA, 5S ribosomal pseudogene 391","metadata":{"aliases":["RN5S391"]}},{"id":"64316663641f4bf2a3a2b6aa43755773","type":"GENE","name":"RNA5SP392","canonical_id":"hgnc:HGNC:43292","description":"RNA, 5S ribosomal pseudogene 392","metadata":{"aliases":["RN5S392"]}},{"id":"94b6df62048442ff84b0ae77c90726ad","type":"GENE","name":"RNA5SP393","canonical_id":"hgnc:HGNC:43293","description":"RNA, 5S ribosomal pseudogene 393","metadata":{"aliases":["RN5S393"]}},{"id":"2806001f6c7d4749ab57622621a38150","type":"GENE","name":"RNA5SP394","canonical_id":"hgnc:HGNC:43294","description":"RNA, 5S ribosomal pseudogene 394","metadata":{"aliases":["RN5S394"]}},{"id":"9446efccc20a43e688e345220b8147da","type":"GENE","name":"RNA5SP395","canonical_id":"hgnc:HGNC:43295","description":"RNA, 5S ribosomal pseudogene 395","metadata":{"aliases":["RN5S395"]}},{"id":"259efd94b2e348b0902888d93f0387b5","type":"GENE","name":"RNA5SP396","canonical_id":"hgnc:HGNC:43296","description":"RNA, 5S ribosomal pseudogene 396","metadata":{"aliases":["RN5S396"]}},{"id":"3994bb75bc334a329be4ca375e2e1c6e","type":"GENE","name":"RNA5SP397","canonical_id":"hgnc:HGNC:43297","description":"RNA, 5S ribosomal pseudogene 397","metadata":{"aliases":["RN5S397"]}},{"id":"68ad9e1a88674a97acee290810f22f90","type":"GENE","name":"RNA5SP399","canonical_id":"hgnc:HGNC:43299","description":"RNA, 5S ribosomal pseudogene 399","metadata":{"aliases":["RN5S399"]}},{"id":"f0ce956a206843bba9cf30d373731f5b","type":"GENE","name":"RNA5SP40","canonical_id":"hgnc:HGNC:42816","description":"RNA, 5S ribosomal pseudogene 40","metadata":{"aliases":["RN5S40"]}},{"id":"b10bcf43aaee49d48157d9bf29ca54c4","type":"GENE","name":"RNA5SP400","canonical_id":"hgnc:HGNC:43300","description":"RNA, 5S ribosomal pseudogene 400","metadata":{"aliases":["RN5S400"]}},{"id":"b273a77078814132bc7b9f9ad4334ee3","type":"GENE","name":"RNA5SP401","canonical_id":"hgnc:HGNC:43301","description":"RNA, 5S ribosomal pseudogene 401","metadata":{"aliases":["RN5S401"]}},{"id":"e6d160e897254f7dbff129046eed2afd","type":"GENE","name":"RNA5SP402","canonical_id":"hgnc:HGNC:43302","description":"RNA, 5S ribosomal pseudogene 402","metadata":{"aliases":["RN5S402"]}},{"id":"8e1ee98eb01b41fcb89c4c38f2f598a6","type":"GENE","name":"RNA5SP403","canonical_id":"hgnc:HGNC:43303","description":"RNA, 5S ribosomal pseudogene 403","metadata":{"aliases":["RN5S403"]}},{"id":"fed1240fd2c3462eb7bf5e07e01d3e5e","type":"GENE","name":"RNA5SP404","canonical_id":"hgnc:HGNC:43304","description":"RNA, 5S ribosomal pseudogene 404","metadata":{"aliases":["RN5S404"]}},{"id":"6b966aa33aa64c259fa901ac8d6d6fe7","type":"GENE","name":"RNA5SP405","canonical_id":"hgnc:HGNC:43305","description":"RNA, 5S ribosomal pseudogene 405","metadata":{"aliases":["RN5S405"]}},{"id":"9ec138d132d3474782301bce4c20ff1f","type":"GENE","name":"RNA5SP406","canonical_id":"hgnc:HGNC:43306","description":"RNA, 5S ribosomal pseudogene 406","metadata":{"aliases":["RN5S406"]}},{"id":"73b2156f84bf4e0a839c3459ab80cc79","type":"GENE","name":"RNA5SP407","canonical_id":"hgnc:HGNC:43307","description":"RNA, 5S ribosomal pseudogene 407","metadata":{"aliases":["RN5S407"]}},{"id":"f75e0984407d4a7297e312d28735863a","type":"GENE","name":"RNA5SP408","canonical_id":"hgnc:HGNC:43308","description":"RNA, 5S ribosomal pseudogene 408","metadata":{"aliases":["RN5S408"]}},{"id":"8c16d637bcf44b3697f7d7d811964bc1","type":"GENE","name":"RNA5SP409","canonical_id":"hgnc:HGNC:43309","description":"RNA, 5S ribosomal pseudogene 409","metadata":{"aliases":["RN5S409"]}},{"id":"86b97cd1052242e3922d8de05f85e36e","type":"GENE","name":"RNA5SP41","canonical_id":"hgnc:HGNC:42817","description":"RNA, 5S ribosomal pseudogene 41","metadata":{"aliases":["RN5S41"]}},{"id":"f817b5ecbb2540c1843ae5266215e443","type":"GENE","name":"RNA5SP410","canonical_id":"hgnc:HGNC:43310","description":"RNA, 5S ribosomal pseudogene 410","metadata":{"aliases":["RN5S410"]}},{"id":"c241706d0a614483a613f3ed9c48698b","type":"GENE","name":"RNA5SP411","canonical_id":"hgnc:HGNC:43311","description":"RNA, 5S ribosomal pseudogene 411","metadata":{"aliases":["RN5S411"]}},{"id":"15a69314daa34fba8096bde531a16c36","type":"GENE","name":"RNA5SP412","canonical_id":"hgnc:HGNC:43312","description":"RNA, 5S ribosomal pseudogene 412","metadata":{"aliases":["RN5S412"]}},{"id":"1cee01d6d5e54bd2b2b85548cf5e34b7","type":"GENE","name":"RNA5SP413","canonical_id":"hgnc:HGNC:43313","description":"RNA, 5S ribosomal pseudogene 413","metadata":{"aliases":["RN5S413"]}},{"id":"01286291420543768e611c12d82d6d0b","type":"GENE","name":"RNA5SP414","canonical_id":"hgnc:HGNC:43314","description":"RNA, 5S ribosomal pseudogene 414","metadata":{"aliases":["RN5S414"]}},{"id":"2f2e16c7f3eb4e7ca37189d8872199ba","type":"GENE","name":"RNA5SP415","canonical_id":"hgnc:HGNC:43315","description":"RNA, 5S ribosomal pseudogene 415","metadata":{"aliases":["RN5S415"]}},{"id":"4fc04625505640db939da175f74ffc45","type":"GENE","name":"RNA5SP416","canonical_id":"hgnc:HGNC:43316","description":"RNA, 5S ribosomal pseudogene 416","metadata":{"aliases":["RN5S416"]}},{"id":"7ff4e2e01e5b45f9b7e721cb2142a2c6","type":"GENE","name":"RNA5SP417","canonical_id":"hgnc:HGNC:43317","description":"RNA, 5S ribosomal pseudogene 417","metadata":{"aliases":["RN5S417"]}},{"id":"61ad553a17204d6495d544e72fd315ae","type":"GENE","name":"RNA5SP418","canonical_id":"hgnc:HGNC:43318","description":"RNA, 5S ribosomal pseudogene 418","metadata":{"aliases":["RN5S418"]}},{"id":"620ff530cb5243178d065eb1a4d10a15","type":"GENE","name":"RNA5SP419","canonical_id":"hgnc:HGNC:43319","description":"RNA, 5S ribosomal pseudogene 419","metadata":{"aliases":["RN5S419"]}},{"id":"5e398e79fa5c4dffb473e23c66eaa688","type":"GENE","name":"RNA5SP42","canonical_id":"hgnc:HGNC:42818","description":"RNA, 5S ribosomal pseudogene 42","metadata":{"aliases":["RN5S42"]}},{"id":"e72d5a4388ae4641b9b626059c56dbc9","type":"GENE","name":"RNA5SP420","canonical_id":"hgnc:HGNC:43320","description":"RNA, 5S ribosomal pseudogene 420","metadata":{"aliases":["RN5S420"]}},{"id":"51a1ec6abdd549308cef5cbb52f6ab6b","type":"GENE","name":"RNA5SP421","canonical_id":"hgnc:HGNC:43321","description":"RNA, 5S ribosomal pseudogene 421","metadata":{"aliases":["RN5S421"]}},{"id":"14b470d1458441c3bc2d92a315824c41","type":"GENE","name":"RNA5SP422","canonical_id":"hgnc:HGNC:43322","description":"RNA, 5S ribosomal pseudogene 422","metadata":{"aliases":["RN5S422"]}},{"id":"bf8e80a796cc451b80275cbb2273513b","type":"GENE","name":"RNA5SP423","canonical_id":"hgnc:HGNC:43323","description":"RNA, 5S ribosomal pseudogene 423","metadata":{"aliases":["RN5S423"]}},{"id":"381f07870c814506b405f3b7c89fe831","type":"GENE","name":"RNA5SP424","canonical_id":"hgnc:HGNC:43324","description":"RNA, 5S ribosomal pseudogene 424","metadata":{"aliases":["RN5S424"]}},{"id":"c6be0b5cd4024930814e3003d48b224e","type":"GENE","name":"RNA5SP425","canonical_id":"hgnc:HGNC:43325","description":"RNA, 5S ribosomal pseudogene 425","metadata":{"aliases":["RN5S425"]}},{"id":"192ad89baddb4f6b9c0766de3916ea87","type":"GENE","name":"RNA5SP426","canonical_id":"hgnc:HGNC:43326","description":"RNA, 5S ribosomal pseudogene 426","metadata":{"aliases":["RN5S426"]}},{"id":"eb09ec70972e48789aaca4cf84223345","type":"GENE","name":"RNA5SP427","canonical_id":"hgnc:HGNC:43327","description":"RNA, 5S ribosomal pseudogene 427","metadata":{"aliases":["RN5S427"]}},{"id":"2de2545fb85a4772895edbe61c78a106","type":"GENE","name":"RNA5SP428","canonical_id":"hgnc:HGNC:43328","description":"RNA, 5S ribosomal pseudogene 428","metadata":{"aliases":["RN5S428"]}},{"id":"3c533d3836ec474896bb59767045399c","type":"GENE","name":"RNA5SP429","canonical_id":"hgnc:HGNC:43329","description":"RNA, 5S ribosomal pseudogene 429","metadata":{"aliases":["RN5S429"]}},{"id":"98336b8facb24ffdabc903f36bb10eec","type":"GENE","name":"RNA5SP43","canonical_id":"hgnc:HGNC:42819","description":"RNA, 5S ribosomal pseudogene 43","metadata":{"aliases":["RN5S43"]}},{"id":"8663ba3ce3d54bb888be3eadb40d3ad4","type":"GENE","name":"RNA5SP430","canonical_id":"hgnc:HGNC:43330","description":"RNA, 5S ribosomal pseudogene 430","metadata":{"aliases":["RN5S430"]}},{"id":"2f01094c84d847e7b245c35478258bb5","type":"GENE","name":"RNA5SP431","canonical_id":"hgnc:HGNC:43331","description":"RNA, 5S ribosomal pseudogene 431","metadata":{"aliases":["RN5S431"]}},{"id":"d38ef0b3ad7040bcb594b30a1f9db618","type":"GENE","name":"RNA5SP432","canonical_id":"hgnc:HGNC:43332","description":"RNA, 5S ribosomal pseudogene 432","metadata":{"aliases":["RN5S432"]}},{"id":"a9136e44a9854c45b0e7878ebc4b3ef7","type":"GENE","name":"RNA5SP433","canonical_id":"hgnc:HGNC:43333","description":"RNA, 5S ribosomal pseudogene 433","metadata":{"aliases":["RN5S433"]}},{"id":"558be1f0f36342f399324e8050977c1a","type":"GENE","name":"RNA5SP434","canonical_id":"hgnc:HGNC:43334","description":"RNA, 5S ribosomal pseudogene 434","metadata":{"aliases":["RN5S434"]}},{"id":"0e2f84053a2848c5a69de86ec32a5c22","type":"GENE","name":"RNA5SP435","canonical_id":"hgnc:HGNC:43335","description":"RNA, 5S ribosomal pseudogene 435","metadata":{"aliases":["RN5S435"]}},{"id":"ddc3fcc46c854310adc82ce3de476d0a","type":"GENE","name":"RNA5SP436","canonical_id":"hgnc:HGNC:43336","description":"RNA, 5S ribosomal pseudogene 436","metadata":{"aliases":["RN5S436"]}},{"id":"a843abc5aed34a6ba8da02384603d9dc","type":"GENE","name":"RNA5SP437","canonical_id":"hgnc:HGNC:43337","description":"RNA, 5S ribosomal pseudogene 437","metadata":{"aliases":["RN5S437"]}},{"id":"dc22db9e7c51403e981f450c589e6e5e","type":"GENE","name":"RNA5SP438","canonical_id":"hgnc:HGNC:43338","description":"RNA, 5S ribosomal pseudogene 438","metadata":{"aliases":["RN5S438"]}},{"id":"fb5084501b6b4d9c9432f3a1a10ae2b8","type":"GENE","name":"RNA5SP439","canonical_id":"hgnc:HGNC:43339","description":"RNA, 5S ribosomal pseudogene 439","metadata":{"aliases":["RN5S439"]}},{"id":"a4613421a58347a4958617add6a9bc86","type":"GENE","name":"RNA5SP44","canonical_id":"hgnc:HGNC:42820","description":"RNA, 5S ribosomal pseudogene 44","metadata":{"aliases":["RN5S44"]}},{"id":"9bff8aafd2144e00a6c71764fa0e6616","type":"GENE","name":"RNA5SP440","canonical_id":"hgnc:HGNC:43340","description":"RNA, 5S ribosomal pseudogene 440","metadata":{"aliases":["RN5S440"]}},{"id":"f042f0b1ed98414aa48b9e2838c2ddfd","type":"GENE","name":"RNA5SP441","canonical_id":"hgnc:HGNC:43341","description":"RNA, 5S ribosomal pseudogene 441","metadata":{"aliases":["RN5S441"]}},{"id":"ed9a835c73e74355af545e7dc3b96587","type":"GENE","name":"RNA5SP442","canonical_id":"hgnc:HGNC:43342","description":"RNA, 5S ribosomal pseudogene 442","metadata":{"aliases":["RN5S442"]}},{"id":"86d5afaa74214debb6dea0ff06e6ffe7","type":"GENE","name":"RNA5SP443","canonical_id":"hgnc:HGNC:43343","description":"RNA, 5S ribosomal pseudogene 443","metadata":{"aliases":["RN5S443"]}},{"id":"12840c2e831d478783bef3f73907e4b4","type":"GENE","name":"RNA5SP444","canonical_id":"hgnc:HGNC:43344","description":"RNA, 5S ribosomal pseudogene 444","metadata":{"aliases":["RN5S444"]}},{"id":"dc38c3348f934993b2b27282d24dccbf","type":"GENE","name":"RNA5SP445","canonical_id":"hgnc:HGNC:43345","description":"RNA, 5S ribosomal pseudogene 445","metadata":{"aliases":["RN5S445"]}},{"id":"ec949eb221ea45f3a6b72742e40d164f","type":"GENE","name":"RNA5SP446","canonical_id":"hgnc:HGNC:43346","description":"RNA, 5S ribosomal pseudogene 446","metadata":{"aliases":["RN5S446"]}},{"id":"1347e6682d644bdab026fa7dfe8e8580","type":"GENE","name":"RNA5SP447","canonical_id":"hgnc:HGNC:43347","description":"RNA, 5S ribosomal pseudogene 447","metadata":{"aliases":["RN5S447"]}},{"id":"f06b5cb71d84448eaed64ffa0f25d35a","type":"GENE","name":"RNA5SP448","canonical_id":"hgnc:HGNC:43348","description":"RNA, 5S ribosomal pseudogene 448","metadata":{"aliases":["RN5S448"]}},{"id":"ccf67f9d76144db1ba37ca9bac419259","type":"GENE","name":"RNA5SP449","canonical_id":"hgnc:HGNC:43349","description":"RNA, 5S ribosomal pseudogene 449","metadata":{"aliases":["RN5S449"]}},{"id":"b48bade2a3784b0fa66874ffb72680c1","type":"GENE","name":"RNA5SP45","canonical_id":"hgnc:HGNC:42821","description":"RNA, 5S ribosomal pseudogene 45","metadata":{"aliases":["RN5S45"]}},{"id":"52eb2039db334ae292ea9ab3552c60df","type":"GENE","name":"RNA5SP450","canonical_id":"hgnc:HGNC:43350","description":"RNA, 5S ribosomal pseudogene 450","metadata":{"aliases":["RN5S450"]}},{"id":"247bc98664b64fcc8b98019923f8cc29","type":"GENE","name":"RNA5SP451","canonical_id":"hgnc:HGNC:43351","description":"RNA, 5S ribosomal pseudogene 451","metadata":{"aliases":["RN5S451"]}},{"id":"414382bc7a5249c0be6503426909ad5e","type":"GENE","name":"RNA5SP452","canonical_id":"hgnc:HGNC:43352","description":"RNA, 5S ribosomal pseudogene 452","metadata":{"aliases":["RN5S452"]}},{"id":"c6b3054182294b5fb852fc866303baf9","type":"GENE","name":"RNA5SP453","canonical_id":"hgnc:HGNC:43353","description":"RNA, 5S ribosomal pseudogene 453","metadata":{"aliases":["RN5S453"]}},{"id":"1a7c2c9d72984fa09fbe8f36959fed0d","type":"GENE","name":"RNA5SP454","canonical_id":"hgnc:HGNC:43354","description":"RNA, 5S ribosomal pseudogene 454","metadata":{"aliases":["RN5S454"]}},{"id":"ec57503f0a9b47f792024cbb55b4981d","type":"GENE","name":"RNA5SP455","canonical_id":"hgnc:HGNC:43355","description":"RNA, 5S ribosomal pseudogene 455","metadata":{"aliases":["RN5S455"]}},{"id":"66207343deae42a8b6911b8a7e687d68","type":"GENE","name":"RNA5SP456","canonical_id":"hgnc:HGNC:43356","description":"RNA, 5S ribosomal pseudogene 456","metadata":{"aliases":["RN5S456"]}},{"id":"1b5352b2dbd24278903c8be15e3502d6","type":"GENE","name":"RNA5SP457","canonical_id":"hgnc:HGNC:43357","description":"RNA, 5S ribosomal pseudogene 457","metadata":{"aliases":["RN5S457"]}},{"id":"ce42f94b2b2f4fd780727e654243b83b","type":"GENE","name":"RNA5SP458","canonical_id":"hgnc:HGNC:43358","description":"RNA, 5S ribosomal pseudogene 458","metadata":{"aliases":["RN5S458"]}},{"id":"b6a6866cafe24085a692d0d9ecbdca73","type":"GENE","name":"RNA5SP459","canonical_id":"hgnc:HGNC:43359","description":"RNA, 5S ribosomal pseudogene 459","metadata":{"aliases":["RN5S459"]}},{"id":"e48c9de341dc4c1db71c79ed29214f18","type":"GENE","name":"RNA5SP46","canonical_id":"hgnc:HGNC:42822","description":"RNA, 5S ribosomal pseudogene 46","metadata":{"aliases":["RN5S46"]}},{"id":"2017f916b1324feb8f0d7d09c0a2740f","type":"GENE","name":"RNA5SP460","canonical_id":"hgnc:HGNC:43360","description":"RNA, 5S ribosomal pseudogene 460","metadata":{"aliases":["RN5S460"]}},{"id":"c1637e7fd2f743ac9490f97c33a259b8","type":"GENE","name":"RNA5SP461","canonical_id":"hgnc:HGNC:43361","description":"RNA, 5S ribosomal pseudogene 461","metadata":{"aliases":["RN5S461"]}},{"id":"8f6f6e79a8244b3b9ce7289eea374821","type":"GENE","name":"RNA5SP462","canonical_id":"hgnc:HGNC:43362","description":"RNA, 5S ribosomal pseudogene 462","metadata":{"aliases":["RN5S462"]}},{"id":"fc8a1658ce474473ba2b48b0dbe4f40f","type":"GENE","name":"RNA5SP463","canonical_id":"hgnc:HGNC:43363","description":"RNA, 5S ribosomal pseudogene 463","metadata":{"aliases":["RN5S463"]}},{"id":"b4c77e1244ac451796132f4f570b61f4","type":"GENE","name":"RNA5SP464","canonical_id":"hgnc:HGNC:43364","description":"RNA, 5S ribosomal pseudogene 464","metadata":{"aliases":["RN5S464"]}},{"id":"9f8033ac2dab482b891e8db9d40073dd","type":"GENE","name":"RNA5SP465","canonical_id":"hgnc:HGNC:43365","description":"RNA, 5S ribosomal pseudogene 465","metadata":{"aliases":["RN5S465"]}},{"id":"91d6317ede68415fbdffa862e8b3bc04","type":"GENE","name":"RNA5SP466","canonical_id":"hgnc:HGNC:43366","description":"RNA, 5S ribosomal pseudogene 466","metadata":{"aliases":["RN5S466"]}},{"id":"6bdf71ba21a146158b1947674362b46a","type":"GENE","name":"RNA5SP467","canonical_id":"hgnc:HGNC:43367","description":"RNA, 5S ribosomal pseudogene 467","metadata":{"aliases":["RN5S467"]}},{"id":"59dbdb19e85d4810acdef918f5c5a9d8","type":"GENE","name":"RNA5SP468","canonical_id":"hgnc:HGNC:43368","description":"RNA, 5S ribosomal pseudogene 468","metadata":{"aliases":["RN5S468"]}},{"id":"e1bd4254f48d459bbcb99b0483759eeb","type":"GENE","name":"RNA5SP469","canonical_id":"hgnc:HGNC:43369","description":"RNA, 5S ribosomal pseudogene 469","metadata":{"aliases":["RN5S469"]}},{"id":"dbf538816b2d4fa591e8c8c477f86480","type":"GENE","name":"RNA5SP47","canonical_id":"hgnc:HGNC:42823","description":"RNA, 5S ribosomal pseudogene 47","metadata":{"aliases":["RN5S47"]}},{"id":"e8e89ccb80ce4faab8b6f11682ee6cca","type":"GENE","name":"RNA5SP470","canonical_id":"hgnc:HGNC:43370","description":"RNA, 5S ribosomal pseudogene 470","metadata":{"aliases":["RN5S470"]}},{"id":"a2cbfd4f6640468584201752b3f1cbb3","type":"GENE","name":"RNA5SP471","canonical_id":"hgnc:HGNC:43371","description":"RNA, 5S ribosomal pseudogene 471","metadata":{"aliases":["RN5S471"]}},{"id":"8759d7341110443f8712c611d0abba32","type":"GENE","name":"RNA5SP472","canonical_id":"hgnc:HGNC:43372","description":"RNA, 5S ribosomal pseudogene 472","metadata":{"aliases":["RN5S472"]}},{"id":"1a4858fe6a2344529e571e1586aa3782","type":"GENE","name":"RNA5SP473","canonical_id":"hgnc:HGNC:43373","description":"RNA, 5S ribosomal pseudogene 473","metadata":{"aliases":["RN5S473"]}},{"id":"c45b2c6da56e4bd9a8f3c994e39592e1","type":"GENE","name":"RNA5SP474","canonical_id":"hgnc:HGNC:43374","description":"RNA, 5S ribosomal pseudogene 474","metadata":{"aliases":["RN5S474"]}},{"id":"3e9caae3d690403692497a34982b9c00","type":"GENE","name":"RNA5SP475","canonical_id":"hgnc:HGNC:43375","description":"RNA, 5S ribosomal pseudogene 475","metadata":{"aliases":["RN5S475"]}},{"id":"3997d305c608432e9847a746600d09d5","type":"GENE","name":"RNA5SP476","canonical_id":"hgnc:HGNC:43376","description":"RNA, 5S ribosomal pseudogene 476","metadata":{"aliases":["RN5S476"]}},{"id":"0c89dee660fc4a6d85790aed3a62de17","type":"GENE","name":"RNA5SP477","canonical_id":"hgnc:HGNC:43377","description":"RNA, 5S ribosomal pseudogene 477","metadata":{"aliases":["RN5S477"]}},{"id":"33dba6af39ed4f37b92bc8c0b46e969e","type":"GENE","name":"RNA5SP478","canonical_id":"hgnc:HGNC:43378","description":"RNA, 5S ribosomal pseudogene 478","metadata":{"aliases":["RN5S478"]}},{"id":"c30a543b906a4c788b9cdae7fa31c773","type":"GENE","name":"RNA5SP479","canonical_id":"hgnc:HGNC:43379","description":"RNA, 5S ribosomal pseudogene 479","metadata":{"aliases":["RN5S479"]}},{"id":"aede46b8a0c841dd9d8f1f572ab1f9e6","type":"GENE","name":"RNA5SP48","canonical_id":"hgnc:HGNC:42824","description":"RNA, 5S ribosomal pseudogene 48","metadata":{"aliases":["RN5S48"]}},{"id":"d8346d536e9a441197a08910bacf7a4f","type":"GENE","name":"RNA5SP480","canonical_id":"hgnc:HGNC:43380","description":"RNA, 5S ribosomal pseudogene 480","metadata":{"aliases":["RN5S480"]}},{"id":"751272e742834a4cbaca640cefd5fa97","type":"GENE","name":"RNA5SP481","canonical_id":"hgnc:HGNC:43381","description":"RNA, 5S ribosomal pseudogene 481","metadata":{"aliases":["RN5S481"]}},{"id":"412432b62ffd42c3adc0a081b078f7f4","type":"GENE","name":"RNA5SP482","canonical_id":"hgnc:HGNC:43382","description":"RNA, 5S ribosomal pseudogene 482","metadata":{"aliases":["RN5S482"]}},{"id":"44ffa29e1ebd4aa69fe060edf0cd2ef0","type":"GENE","name":"RNA5SP483","canonical_id":"hgnc:HGNC:43383","description":"RNA, 5S ribosomal pseudogene 483","metadata":{"aliases":["RN5S483"]}},{"id":"42f96e3291c14443b24921af733a5092","type":"GENE","name":"RNA5SP484","canonical_id":"hgnc:HGNC:43384","description":"RNA, 5S ribosomal pseudogene 484","metadata":{"aliases":["RN5S484"]}},{"id":"18e0b88d6370485ba005a07471c4c4ef","type":"GENE","name":"RNA5SP485","canonical_id":"hgnc:HGNC:43385","description":"RNA, 5S ribosomal pseudogene 485","metadata":{"aliases":["RN5S485"]}},{"id":"33592d094f644388b4a79be80ac2bf88","type":"GENE","name":"RNA5SP486","canonical_id":"hgnc:HGNC:43386","description":"RNA, 5S ribosomal pseudogene 486","metadata":{"aliases":["RN5S486"]}},{"id":"07aa18ebd0584a5cb069f9c6881d1908","type":"GENE","name":"RNA5SP487","canonical_id":"hgnc:HGNC:43387","description":"RNA, 5S ribosomal pseudogene 487","metadata":{"aliases":["RN5S487"]}},{"id":"d053f101dd194d94bfbf18cbdd9e8d0b","type":"GENE","name":"RNA5SP488","canonical_id":"hgnc:HGNC:43388","description":"RNA, 5S ribosomal pseudogene 488","metadata":{"aliases":["RN5S488"]}},{"id":"e36e7503675141bc81cc981d4e97656f","type":"GENE","name":"RNA5SP489","canonical_id":"hgnc:HGNC:43389","description":"RNA, 5S ribosomal pseudogene 489","metadata":{"aliases":["RN5S489"]}},{"id":"7c965ff373204028903fed9937043443","type":"GENE","name":"RNA5SP49","canonical_id":"hgnc:HGNC:42825","description":"RNA, 5S ribosomal pseudogene 49","metadata":{"aliases":["RN5S49"]}},{"id":"c78045a7a0b04df0a098761f2d36dbde","type":"GENE","name":"RNA5SP490","canonical_id":"hgnc:HGNC:43390","description":"RNA, 5S ribosomal pseudogene 490","metadata":{"aliases":["RN5S490"]}},{"id":"628f938cb44943068f956894fd1992bb","type":"GENE","name":"RNA5SP491","canonical_id":"hgnc:HGNC:43391","description":"RNA, 5S ribosomal pseudogene 491","metadata":{"aliases":["RN5S491"]}},{"id":"f21c69e3c12e4e7b83da26e2ef2e62bc","type":"GENE","name":"RNA5SP492","canonical_id":"hgnc:HGNC:43392","description":"RNA, 5S ribosomal pseudogene 492","metadata":{"aliases":["RN5S492"]}},{"id":"818d77693115477e88a65499d553d34a","type":"GENE","name":"RNA5SP493","canonical_id":"hgnc:HGNC:43393","description":"RNA, 5S ribosomal pseudogene 493","metadata":{"aliases":["RN5S493"]}},{"id":"ca3894e8ef3a495e92322d21b53cea11","type":"GENE","name":"RNA5SP494","canonical_id":"hgnc:HGNC:43394","description":"RNA, 5S ribosomal pseudogene 494","metadata":{"aliases":["RN5S494"]}},{"id":"710b3bf21bc7498aa837a324720e2913","type":"GENE","name":"RNA5SP495","canonical_id":"hgnc:HGNC:43395","description":"RNA, 5S ribosomal pseudogene 495","metadata":{"aliases":["RN5S495"]}},{"id":"617086fbb6954541bdebc3e28ff312a3","type":"GENE","name":"RNA5SP496","canonical_id":"hgnc:HGNC:43396","description":"RNA, 5S ribosomal pseudogene 496","metadata":{"aliases":["RN5S496"]}},{"id":"780a4c4e290848f4b17c8d6ec2427bdc","type":"GENE","name":"RNA5SP497","canonical_id":"hgnc:HGNC:43397","description":"RNA, 5S ribosomal pseudogene 497","metadata":{"aliases":["RN5S497"]}},{"id":"15892789611f44809ecb7342df69ba25","type":"GENE","name":"RNA5SP498","canonical_id":"hgnc:HGNC:43398","description":"RNA, 5S ribosomal pseudogene 498","metadata":{"aliases":["RN5S498"]}},{"id":"11788adb6cdc4ba1af1f4325e3149857","type":"GENE","name":"RNA5SP499","canonical_id":"hgnc:HGNC:43399","description":"RNA, 5S ribosomal pseudogene 499","metadata":{"aliases":["RN5S499"]}},{"id":"dedc11d0f504447598d200e2b49fab61","type":"GENE","name":"RNA5SP50","canonical_id":"hgnc:HGNC:42827","description":"RNA, 5S ribosomal pseudogene 50","metadata":{"aliases":["RN5S50"]}},{"id":"646dbe37339c45d08e410dc8354715d4","type":"GENE","name":"RNA5SP500","canonical_id":"hgnc:HGNC:43400","description":"RNA, 5S ribosomal pseudogene 500","metadata":{"aliases":["RN5S500"]}},{"id":"0b85829350d548b0aa41e17650f3aac1","type":"GENE","name":"RNA5SP501","canonical_id":"hgnc:HGNC:43401","description":"RNA, 5S ribosomal pseudogene 501","metadata":{"aliases":["RN5S501"]}},{"id":"5f09daa5ccc74a9799feca2bf9c04d3a","type":"GENE","name":"RNA5SP502","canonical_id":"hgnc:HGNC:43402","description":"RNA, 5S ribosomal pseudogene 502","metadata":{"aliases":["RN5S502"]}},{"id":"93cd4080d8b9472bb75ef81bfdf4db79","type":"GENE","name":"RNA5SP503","canonical_id":"hgnc:HGNC:43403","description":"RNA, 5S ribosomal pseudogene 503","metadata":{"aliases":["RN5S503"]}},{"id":"2d66d44d5ce3453c96d3d7574d806812","type":"GENE","name":"RNA5SP504","canonical_id":"hgnc:HGNC:43404","description":"RNA, 5S ribosomal pseudogene 504","metadata":{"aliases":["RN5S504"]}},{"id":"d1da7b9d3d19457c86a2a975b85096fb","type":"GENE","name":"RNA5SP505","canonical_id":"hgnc:HGNC:43405","description":"RNA, 5S ribosomal pseudogene 505","metadata":{"aliases":["RN5S505"]}},{"id":"0d406b872af04bb38cb733c401e83758","type":"GENE","name":"RNA5SP506","canonical_id":"hgnc:HGNC:43406","description":"RNA, 5S ribosomal pseudogene 506","metadata":{"aliases":["RN5S506"]}},{"id":"1ec79db0b34d48318c7b4d43ecbb102d","type":"GENE","name":"RNA5SP507","canonical_id":"hgnc:HGNC:43407","description":"RNA, 5S ribosomal pseudogene 507","metadata":{"aliases":["RN5S507"]}},{"id":"54566743438745918093986ef7c21259","type":"GENE","name":"RNA5SP508","canonical_id":"hgnc:HGNC:43408","description":"RNA, 5S ribosomal pseudogene 508","metadata":{"aliases":["RN5S508"]}},{"id":"680c30173dee4002b452ce7199473433","type":"GENE","name":"RNA5SP509","canonical_id":"hgnc:HGNC:43409","description":"RNA, 5S ribosomal pseudogene 509","metadata":{"aliases":["RN5S509"]}},{"id":"d6d972d6bd1f4c7f91d2ed87fc948855","type":"GENE","name":"RNA5SP51","canonical_id":"hgnc:HGNC:42828","description":"RNA, 5S ribosomal pseudogene 51","metadata":{"aliases":["RN5S51"]}},{"id":"deec80d6a277436bbc2bcc272af1ecaa","type":"GENE","name":"RNA5SP510","canonical_id":"hgnc:HGNC:43410","description":"RNA, 5S ribosomal pseudogene 510","metadata":{"aliases":["RN5S510"]}},{"id":"6196dc38867f448eaa10c002b7b79e68","type":"GENE","name":"RNA5SP511","canonical_id":"hgnc:HGNC:43411","description":"RNA, 5S ribosomal pseudogene 511","metadata":{"aliases":["RN5S511"]}},{"id":"8ab4eebd932942ec965025f68cadc3cf","type":"GENE","name":"RNA5SP512","canonical_id":"hgnc:HGNC:43412","description":"RNA, 5S ribosomal pseudogene 512","metadata":{"aliases":["RN5S512"]}},{"id":"ad80a28a1ea54450925095fb50b6c281","type":"GENE","name":"RNA5SP513","canonical_id":"hgnc:HGNC:43413","description":"RNA, 5S ribosomal pseudogene 513","metadata":{"aliases":["RN5S513"]}},{"id":"2e5494534a864d08be2295c7f1bf693d","type":"GENE","name":"RNA5SP514","canonical_id":"hgnc:HGNC:43414","description":"RNA, 5S ribosomal pseudogene 514","metadata":{"aliases":["RN5S514"]}},{"id":"3b2ca866fc9741a987082511cac602e4","type":"GENE","name":"RNA5SP515","canonical_id":"hgnc:HGNC:43415","description":"RNA, 5S ribosomal pseudogene 515","metadata":{"aliases":["RN5S515"]}},{"id":"88132f3707e24083b469f5ab9772122e","type":"GENE","name":"RNA5SP516","canonical_id":"hgnc:HGNC:43416","description":"RNA, 5S ribosomal pseudogene 516","metadata":{"aliases":["RN5S516"]}},{"id":"f391f022451c4ce791f6f735be4985fb","type":"GENE","name":"RNA5SP517","canonical_id":"hgnc:HGNC:43417","description":"RNA, 5S ribosomal pseudogene 517","metadata":{"aliases":["RN5S517"]}},{"id":"381be62dc91c4baa98de3fc13e3019fb","type":"GENE","name":"RNA5SP518","canonical_id":"hgnc:HGNC:43418","description":"RNA, 5S ribosomal pseudogene 518","metadata":{"aliases":["RN5S518"]}},{"id":"4e24f290e49942dcb3cc4b7f2870690b","type":"GENE","name":"RNA5SP519","canonical_id":"hgnc:HGNC:43419","description":"RNA, 5S ribosomal pseudogene 519","metadata":{"aliases":["RN5S519"]}},{"id":"729ea9ffa75d42be91bdad86fd7ac35b","type":"GENE","name":"RNA5SP52","canonical_id":"hgnc:HGNC:42829","description":"RNA, 5S ribosomal pseudogene 52","metadata":{"aliases":["RN5S52"]}},{"id":"c31d89bec94645518635b05bd0e0dfec","type":"GENE","name":"RNA5SP520","canonical_id":"hgnc:HGNC:43420","description":"RNA, 5S ribosomal pseudogene 520","metadata":{"aliases":["RN5S520"]}},{"id":"56d6318094fd4dcea2afb606c478588e","type":"GENE","name":"RNA5SP521","canonical_id":"hgnc:HGNC:43421","description":"RNA, 5S ribosomal pseudogene 521","metadata":{"aliases":["RN5S521"]}},{"id":"93d49b78d71d478e9d56ebbd9e51123c","type":"GENE","name":"RNA5SP522","canonical_id":"hgnc:HGNC:43422","description":"RNA, 5S ribosomal pseudogene 522","metadata":{"aliases":["RN5S522"]}},{"id":"ffc71da401274a34bc779cbd0fca82d9","type":"GENE","name":"RNA5SP523","canonical_id":"hgnc:HGNC:43423","description":"RNA, 5S ribosomal pseudogene 523","metadata":{"aliases":["RN5S523"]}},{"id":"ac0f6ae602ee4e0d8bc882d976031563","type":"GENE","name":"RNA5SP524","canonical_id":"hgnc:HGNC:53793","description":"RNA, 5S ribosomal pseudogene 524","metadata":null},{"id":"dd96c0d65b214a58a944a81a4fec76a1","type":"GENE","name":"RNA5SP525","canonical_id":"hgnc:HGNC:53794","description":"RNA, 5S ribosomal pseudogene 525","metadata":null},{"id":"f16ecf597520436496a55a707bea592e","type":"GENE","name":"RNA5SP526","canonical_id":"hgnc:HGNC:53795","description":"RNA, 5S ribosomal pseudogene 526","metadata":null},{"id":"a53abb938b5c45d0aca8b12d778758b6","type":"GENE","name":"RNA5SP527","canonical_id":"hgnc:HGNC:53796","description":"RNA, 5S ribosomal pseudogene 527","metadata":null},{"id":"e4b0de03f2954e47857ff56752260855","type":"GENE","name":"RNA5SP528","canonical_id":"hgnc:HGNC:53797","description":"RNA, 5S ribosomal pseudogene 528","metadata":null},{"id":"5e873f6ced78446bbb50170bdf2b3ee8","type":"GENE","name":"RNA5SP529","canonical_id":"hgnc:HGNC:53798","description":"RNA, 5S ribosomal pseudogene 529","metadata":null},{"id":"0b795f60b54f482ebc7c40985fe7d3ce","type":"GENE","name":"RNA5SP53","canonical_id":"hgnc:HGNC:42830","description":"RNA, 5S ribosomal pseudogene 53","metadata":{"aliases":["RN5S53"]}},{"id":"cd86b3ebfae946f9b0cb35062938e653","type":"GENE","name":"RNA5SP530","canonical_id":"hgnc:HGNC:53799","description":"RNA, 5S ribosomal pseudogene 530","metadata":null},{"id":"af0858ac84e5454d99b6a797d858101b","type":"GENE","name":"RNA5SP531","canonical_id":"hgnc:HGNC:53800","description":"RNA, 5S ribosomal pseudogene 531","metadata":null},{"id":"9dc7180d998e4e118757c2289344cd96","type":"GENE","name":"RNA5SP532","canonical_id":"hgnc:HGNC:53801","description":"RNA, 5S ribosomal pseudogene 532","metadata":null},{"id":"6ec2691ec9944b43bb5038a484a73424","type":"GENE","name":"RNA5SP533","canonical_id":"hgnc:HGNC:53802","description":"RNA, 5S ribosomal pseudogene 533","metadata":null},{"id":"fb518b8395694e42898657fb8882d5b0","type":"GENE","name":"RNA5SP534","canonical_id":"hgnc:HGNC:53803","description":"RNA, 5S ribosomal pseudogene 534","metadata":null},{"id":"ebfc6c59443741cc927b7deffd7f113a","type":"GENE","name":"RNA5SP535","canonical_id":"hgnc:HGNC:53804","description":"RNA, 5S ribosomal pseudogene 535","metadata":null},{"id":"c1a33ed4b94045278fb8838bddc33717","type":"GENE","name":"RNA5SP536","canonical_id":"hgnc:HGNC:53805","description":"RNA, 5S ribosomal pseudogene 536","metadata":null},{"id":"9f159d7907c54e8cb33531048a544f13","type":"GENE","name":"RNA5SP54","canonical_id":"hgnc:HGNC:42831","description":"RNA, 5S ribosomal pseudogene 54","metadata":{"aliases":["RN5S54"]}},{"id":"7e7da5e67af042acb63f0ad6e9cbe7d9","type":"GENE","name":"RNA5SP55","canonical_id":"hgnc:HGNC:42832","description":"RNA, 5S ribosomal pseudogene 55","metadata":{"aliases":["RN5S55"]}},{"id":"212bb428cc3949088034dd4a2e760ab2","type":"GENE","name":"RNA5SP56","canonical_id":"hgnc:HGNC:42833","description":"RNA, 5S ribosomal pseudogene 56","metadata":{"aliases":["RN5S56"]}},{"id":"50425dbe444a43088918a74c6505aeed","type":"GENE","name":"RNA5SP57","canonical_id":"hgnc:HGNC:42834","description":"RNA, 5S ribosomal pseudogene 57","metadata":{"aliases":["RN5S57","RNA5SP58","RN5S58"]}},{"id":"8fa3049751e94344a559f7ff246ec255","type":"GENE","name":"RNA5SP59","canonical_id":"hgnc:HGNC:42836","description":"RNA, 5S ribosomal pseudogene 59","metadata":{"aliases":["RN5S59"]}},{"id":"50aaafc67a6b4ee6bf2112b4eed1c883","type":"GENE","name":"RNA5SP60","canonical_id":"hgnc:HGNC:42837","description":"RNA, 5S ribosomal pseudogene 60","metadata":{"aliases":["RN5S60"]}},{"id":"1175cd9f7b3847f78c53f09eb1d74292","type":"GENE","name":"RNA5SP61","canonical_id":"hgnc:HGNC:42838","description":"RNA, 5S ribosomal pseudogene 61","metadata":{"aliases":["RN5S61"]}},{"id":"f6e90ff7e2764ed8b45043d00c9a6529","type":"GENE","name":"RNA5SP62","canonical_id":"hgnc:HGNC:42839","description":"RNA, 5S ribosomal pseudogene 62","metadata":{"aliases":["RN5S62"]}},{"id":"9fb2d232c6d141d4b540746296aab4d7","type":"GENE","name":"RNA5SP63","canonical_id":"hgnc:HGNC:42840","description":"RNA, 5S ribosomal pseudogene 63","metadata":{"aliases":["RN5S63"]}},{"id":"284557a7c1ba42dc812cb8f9e147f2be","type":"GENE","name":"RNA5SP64","canonical_id":"hgnc:HGNC:42841","description":"RNA, 5S ribosomal pseudogene 64","metadata":{"aliases":["RN5S64"]}},{"id":"c020363267f34deb9b18304382e24a4f","type":"GENE","name":"RNA5SP65","canonical_id":"hgnc:HGNC:42842","description":"RNA, 5S ribosomal pseudogene 65","metadata":{"aliases":["RN5S65"]}},{"id":"4ae43a3116da4c12848d79603386aef1","type":"GENE","name":"RNA5SP66","canonical_id":"hgnc:HGNC:42843","description":"RNA, 5S ribosomal pseudogene 66","metadata":{"aliases":["RN5S66"]}},{"id":"b7c59e3fced941c199be361f386fc134","type":"GENE","name":"RNA5SP67","canonical_id":"hgnc:HGNC:42844","description":"RNA, 5S ribosomal pseudogene 67","metadata":{"aliases":["RN5S67"]}},{"id":"25cb0e137b3b40428552bb301f5b7067","type":"GENE","name":"RNA5SP68","canonical_id":"hgnc:HGNC:42845","description":"RNA, 5S ribosomal pseudogene 68","metadata":{"aliases":["RN5S68"]}},{"id":"17fd5e29782247f1b8021c47c9f4a3bc","type":"GENE","name":"RNA5SP69","canonical_id":"hgnc:HGNC:42846","description":"RNA, 5S ribosomal pseudogene 69","metadata":{"aliases":["RN5S69"]}},{"id":"54b3f65570fb43d191f0e74691724541","type":"GENE","name":"RNA5SP70","canonical_id":"hgnc:HGNC:42847","description":"RNA, 5S ribosomal pseudogene 70","metadata":{"aliases":["RN5S70"]}},{"id":"f05eb783771040a69767f45a8c95b165","type":"GENE","name":"RNA5SP71","canonical_id":"hgnc:HGNC:42848","description":"RNA, 5S ribosomal pseudogene 71","metadata":{"aliases":["RN5S71"]}},{"id":"02360dce3c334d4793d2677099621e69","type":"GENE","name":"RNA5SP72","canonical_id":"hgnc:HGNC:42849","description":"RNA, 5S ribosomal pseudogene 72","metadata":{"aliases":["RN5S72"]}},{"id":"287af885f6034e41a9875bdf12a031a3","type":"GENE","name":"RNA5SP73","canonical_id":"hgnc:HGNC:42850","description":"RNA, 5S ribosomal pseudogene 73","metadata":{"aliases":["RN5S73"]}},{"id":"e3000c2eb01849b487eaa95e04d5a2ec","type":"GENE","name":"RNA5SP74","canonical_id":"hgnc:HGNC:42851","description":"RNA, 5S ribosomal pseudogene 74","metadata":{"aliases":["RN5S74"]}},{"id":"214c34f2e7a5424fb3f276a3dc65bc46","type":"GENE","name":"RNA5SP75","canonical_id":"hgnc:HGNC:42852","description":"RNA, 5S ribosomal pseudogene 75","metadata":{"aliases":["RN5S75"]}},{"id":"2123db3b1a9e436b9dd25f6f9b1b85ce","type":"GENE","name":"RNA5SP76","canonical_id":"hgnc:HGNC:42853","description":"RNA, 5S ribosomal pseudogene 76","metadata":{"aliases":["RN5S76"]}},{"id":"1614c93df1d14a32b6206ffa21668a6d","type":"GENE","name":"RNA5SP77","canonical_id":"hgnc:HGNC:42854","description":"RNA, 5S ribosomal pseudogene 77","metadata":{"aliases":["RN5S77"]}},{"id":"707e5a28c72643e2a3e0d0eb029004b9","type":"GENE","name":"RNA5SP78","canonical_id":"hgnc:HGNC:42855","description":"RNA, 5S ribosomal pseudogene 78","metadata":{"aliases":["RN5S78"]}},{"id":"2feaec21d3b3474dbe8267196a0e9e33","type":"GENE","name":"RNA5SP79","canonical_id":"hgnc:HGNC:42856","description":"RNA, 5S ribosomal pseudogene 79","metadata":{"aliases":["RN5S79"]}},{"id":"eec35492566242d98fe6d5441d0fd215","type":"GENE","name":"RNA5SP80","canonical_id":"hgnc:HGNC:42857","description":"RNA, 5S ribosomal pseudogene 80","metadata":{"aliases":["RN5S80"]}},{"id":"3a022a7d3bea4007a14182ca05d9afdd","type":"GENE","name":"RNA5SP82","canonical_id":"hgnc:HGNC:42859","description":"RNA, 5S ribosomal pseudogene 82","metadata":{"aliases":["RN5S82"]}},{"id":"492689b5340e4aa28e938eafc4b8591f","type":"GENE","name":"RNA5SP84","canonical_id":"hgnc:HGNC:42882","description":"RNA, 5S ribosomal pseudogene 84","metadata":{"aliases":["RN5S84"]}},{"id":"45e73d6b41134a85ac0563313c61c08a","type":"GENE","name":"RNA5SP85","canonical_id":"hgnc:HGNC:42883","description":"RNA, 5S ribosomal pseudogene 85","metadata":{"aliases":["RN5S85"]}},{"id":"23f3f3872f7f41f1a69b3fcea96a016e","type":"GENE","name":"RNA5SP86","canonical_id":"hgnc:HGNC:42884","description":"RNA, 5S ribosomal pseudogene 86","metadata":{"aliases":["RN5S86"]}},{"id":"2baea42bd7544bb6b07dce16280a2d72","type":"GENE","name":"RNA5SP87","canonical_id":"hgnc:HGNC:42885","description":"RNA, 5S ribosomal pseudogene 87","metadata":{"aliases":["RN5S87"]}},{"id":"4cfcc42aa5ec4b10bd43669e3dde2398","type":"GENE","name":"RNA5SP88","canonical_id":"hgnc:HGNC:42886","description":"RNA, 5S ribosomal pseudogene 88","metadata":{"aliases":["RN5S88"]}},{"id":"fe4a7b1b65e34aadbe9d046aeb108726","type":"GENE","name":"RNA5SP89","canonical_id":"hgnc:HGNC:42887","description":"RNA, 5S ribosomal pseudogene 89","metadata":{"aliases":["RN5S89"]}},{"id":"4b4f71e6c61049dfa877085ed94dd54e","type":"GENE","name":"RNA5SP90","canonical_id":"hgnc:HGNC:42888","description":"RNA, 5S ribosomal pseudogene 90","metadata":{"aliases":["RN5S90"]}},{"id":"3e5c4120690b4fc2b459ce0146bd6322","type":"GENE","name":"RNA5SP91","canonical_id":"hgnc:HGNC:42889","description":"RNA, 5S ribosomal pseudogene 91","metadata":{"aliases":["RN5S91"]}},{"id":"7cb4c9998ac5413ead1706970b3a19a8","type":"GENE","name":"RNA5SP92","canonical_id":"hgnc:HGNC:42890","description":"RNA, 5S ribosomal pseudogene 92","metadata":{"aliases":["RN5S92"]}},{"id":"153cfea38d4d41a495649025e364a083","type":"GENE","name":"RNA5SP93","canonical_id":"hgnc:HGNC:42891","description":"RNA, 5S ribosomal pseudogene 93","metadata":{"aliases":["RN5S93"]}},{"id":"f1b39116c5f544cbb4140a2b6d0895eb","type":"GENE","name":"RNA5SP94","canonical_id":"hgnc:HGNC:42892","description":"RNA, 5S ribosomal pseudogene 94","metadata":{"aliases":["RN5S94"]}},{"id":"22332d5ef6a348c98d94e9a1055d50ce","type":"GENE","name":"RNA5SP95","canonical_id":"hgnc:HGNC:42893","description":"RNA, 5S ribosomal pseudogene 95","metadata":{"aliases":["RN5S95"]}},{"id":"3a4721ebd636430fbefad6480ebb0d67","type":"GENE","name":"RNA5SP96","canonical_id":"hgnc:HGNC:42894","description":"RNA, 5S ribosomal pseudogene 96","metadata":{"aliases":["RN5S96"]}},{"id":"ed2972f6a8654aee929836a53b761d6f","type":"GENE","name":"RNA5SP97","canonical_id":"hgnc:HGNC:42895","description":"RNA, 5S ribosomal pseudogene 97","metadata":{"aliases":["RN5S97"]}},{"id":"167257cd65ae4c76aabf032dfa20a25d","type":"GENE","name":"RNA5SP98","canonical_id":"hgnc:HGNC:42896","description":"RNA, 5S ribosomal pseudogene 98","metadata":{"aliases":["RN5S98"]}},{"id":"431cb49edf6448f6996bf2b6058397b9","type":"GENE","name":"RNA5SP99","canonical_id":"hgnc:HGNC:42897","description":"RNA, 5S ribosomal pseudogene 99","metadata":{"aliases":["RN5S99"]}},{"id":"d48e31b38eea4ccea57a5d4e1d3c3334","type":"GENE","name":"RNASE1","canonical_id":"hgnc:HGNC:10044","description":"ribonuclease A family member 1, pancreatic","metadata":{"aliases":["RAC1","RNS1"]}},{"id":"b9eafba514db46d48500094436a8d24f","type":"GENE","name":"RNASE10","canonical_id":"hgnc:HGNC:19275","description":"ribonuclease A family member 10 (inactive)","metadata":{"aliases":["RNASE9","RAH1"]}},{"id":"fdb3a45cd44d405682041531a5cc5523","type":"GENE","name":"RNASE11","canonical_id":"hgnc:HGNC:19269","description":"ribonuclease A family member 11 (inactive)","metadata":{"aliases":["RAJ1","C14orf6"]}},{"id":"762d46b42c624205bf8e17204daa7b45","type":"GENE","name":"RNASE11-AS1","canonical_id":"hgnc:HGNC:27381","description":"RNASE11 and RNASE12 antisense RNA 1","metadata":null},{"id":"ca522f3f3b374b3bb5d98d2c074bdb80","type":"GENE","name":"RNASE12","canonical_id":"hgnc:HGNC:24211","description":"ribonuclease A family member 12 (inactive)","metadata":{"aliases":["RAI1"]}},{"id":"0534a3f959e2401f99b30a19d412c83c","type":"GENE","name":"RNASE13","canonical_id":"hgnc:HGNC:25285","description":"ribonuclease A family member 13 (inactive)","metadata":{"aliases":["RAL1"]}},{"id":"51b9858bfd014f6a8a695ac687143340","type":"GENE","name":"RNASE2","canonical_id":"hgnc:HGNC:10045","description":null,"metadata":null},{"id":"e3982da76de344ce9eefbae53808029d","type":"GENE","name":"RNASE2CP","canonical_id":"hgnc:HGNC:55569","description":"ribonuclease A family member 2C, pseudogene","metadata":{"aliases":["ECRP"]}},{"id":"6fd72924ad2c4531bb0518a936dbfea7","type":"GENE","name":"RNASE3","canonical_id":"hgnc:HGNC:10046","description":"ribonuclease A family member 3","metadata":{"aliases":["ECP","RAF1","RNS3"]}},{"id":"77e8fa1b13da42f8965caf7782b215bd","type":"GENE","name":"RNASE4","canonical_id":"hgnc:HGNC:10047","description":"ribonuclease A family member 4","metadata":{"aliases":["RAB1"]}},{"id":"eec35eb29d374ace8b89168a01b2f67d","type":"GENE","name":"RNASE6","canonical_id":"hgnc:HGNC:10048","description":"ribonuclease A family member 6","metadata":{"aliases":["RAD1","RNaseK6","RNS6"]}},{"id":"02588fec7dc64865b800d762e49bb469","type":"GENE","name":"RNASE7","canonical_id":"hgnc:HGNC:19278","description":"ribonuclease A family member 7","metadata":{"aliases":["RAE1"]}},{"id":"2ebde6e7ed9b4d3081d761801d0e9a8e","type":"GENE","name":"RNASE8","canonical_id":"hgnc:HGNC:19277","description":"ribonuclease A family member 8","metadata":{"aliases":["RAE2"]}},{"id":"f91146e1632d40f0be0da78bcd68fa55","type":"GENE","name":"RNASE9","canonical_id":"hgnc:HGNC:20673","description":"ribonuclease A family member 9 (inactive)","metadata":{"aliases":["h461","RAK1"]}},{"id":"29a7a329bb02495ab3c28994d88b377e","type":"GENE","name":"RNASEH1","canonical_id":"hgnc:HGNC:18466","description":"ribonuclease H1","metadata":null},{"id":"c22683559bce4953bd65749ab761e7ff","type":"GENE","name":"RNASEH1-DT","canonical_id":"hgnc:HGNC:49289","description":"RNASEH1 divergent transcript","metadata":{"aliases":["LOC100506054","RNASEH1-AS1"]}},{"id":"a9c1e73569c14e12b0c0c78b7c63735f","type":"GENE","name":"RNASEH1P1","canonical_id":"hgnc:HGNC:10049","description":"ribonuclease H1 pseudogene 1","metadata":{"aliases":["RNH1","RNASEH1"]}},{"id":"93d3bfe5d94248a6a0165ee5d5aca866","type":"GENE","name":"RNASEH1P2","canonical_id":"hgnc:HGNC:18715","description":"ribonuclease H1 pseudogene 2","metadata":null},{"id":"9f39e7a920f0425e8bb3f1fdfe69f3e8","type":"GENE","name":"RNASEH1P3","canonical_id":"hgnc:HGNC:18716","description":"ribonuclease H1 pseudogene 3","metadata":null},{"id":"a139c9bd2a914690bda3659d4173fd49","type":"GENE","name":"RNASEH2A","canonical_id":"hgnc:HGNC:18518","description":"ribonuclease H2 subunit A","metadata":{"aliases":["RNASEHI","RNHIA","RNHL","AGS4"]}},{"id":"f5f2944d41f34ef99b956a72daa93116","type":"GENE","name":"RNASEH2B","canonical_id":"hgnc:HGNC:25671","description":"ribonuclease H2 subunit B","metadata":{"aliases":["FLJ11712","DLEU8","AGS2"]}},{"id":"46a4ebaaf6c64deda2bf257917f6aacd","type":"GENE","name":"RNASEH2B-AS1","canonical_id":"hgnc:HGNC:39967","description":"RNASEH2B antisense RNA 1","metadata":null},{"id":"9e192bca5fc147deb3a6de3d8c935fe4","type":"GENE","name":"RNASEH2C","canonical_id":"hgnc:HGNC:24116","description":"ribonuclease H2 subunit C","metadata":{"aliases":["AYP1","AGS3"]}},{"id":"545a054891294d1cb589830f73bdc590","type":"GENE","name":"RNASEH2CP1","canonical_id":"hgnc:HGNC:24117","description":"ribonuclease H2 subunit C pseudogene 1","metadata":{"aliases":["AYP1p1"]}},{"id":"50d343cee02f467bab602f0906754fd8","type":"GENE","name":"RNASEK","canonical_id":"hgnc:HGNC:33911","description":"ribonuclease K","metadata":{"aliases":["MGC71993"]}},{"id":"b6b9009ce2e24c64ba60e210e8574421","type":"GENE","name":"RNASEK-C17orf49","canonical_id":"hgnc:HGNC:44419","description":"RNASEK-C17orf49 readthrough","metadata":null},{"id":"58cec810e8054dcfa6892990f9b1b5d2","type":"GENE","name":"RNASEL","canonical_id":"hgnc:HGNC:10050","description":null,"metadata":null},{"id":"b3f42a1cc72f4aa0a1b8eb49dea97a35","type":"GENE","name":"RNASET2","canonical_id":"hgnc:HGNC:21686","description":"ribonuclease T2","metadata":{"aliases":["RNASE6PL","FLJ10907","bA514O12.3"]}},{"id":"3e26264728e04b928e90e60f964cba15","type":"GO_TERM","name":"RNAi effector complex","canonical_id":"go:GO:0031332","description":"\"Any protein complex that mediates the effects of small interfering RNAs on gene expression. Most known examples contain one or more members of the Argonaute family of proteins.\" [GOC:mah, PMID:14704433]","metadata":null},{"id":"64a81dc37c064c639e0221010bd1c9c6","type":"GO_TERM","name":"RNAi-mediated antiviral immune response","canonical_id":"go:GO:0009616","description":"\"A post-transcriptional gene silencing pathway mediated by the action of regulatory RNAs that protects against foreign organism invasion by restricting viral replication and dissemination.\" [GOC:jl, PMID:17693253, PMID:21724934, PMID:23686236, PMID:24732439, PMID:31100912]","metadata":null},{"id":"ad92d36f2e714c5c93cd5797ca489749","type":"GO_TERM","name":"RNAi-mediated antiviral immunity against DNA virus","canonical_id":"go:GO:0051215","description":"\"An RNAi-mediated post-transcriptional gene silencing pathway induced by DNA viruses leading to a sequence-specific degradation of target mRNAs or inhibition of translation. In plants, DCL3 is the primary Dicer to detect DNA viruses.\" [PMID:15165191, PMID:17693253, PMID:23151511]","metadata":null},{"id":"c6d3d04ec9f545b9a04a46258a18b2db","type":"GO_TERM","name":"RNAi-mediated antiviral immunity against RNA virus","canonical_id":"go:GO:0051214","description":"\"An RNAi-mediated post-transcriptional gene silencing pathway induced by RNA viruses leading to a sequence-specific degradation of target mRNAs or inhibition of translation. In plants, DCL4 is the primary Dicer to detect RNA viruses.\" [PMID:15165191, PMID:17693253]","metadata":null},{"id":"d08078df97bb4240989614690f20f017","type":"GENE","name":"RND1","canonical_id":"hgnc:HGNC:18314","description":"Rho family GTPase 1","metadata":{"aliases":["Rho6","ARHS","RHOS"]}},{"id":"b5663c26d57f403ab6e33ddb42b9ab0a","type":"GENE","name":"RND2","canonical_id":"hgnc:HGNC:18315","description":"Rho family GTPase 2","metadata":{"aliases":["Rho7","RhoN","ARHN"]}},{"id":"e2e1253afb1841a78249154b83b719e2","type":"GENE","name":"RND3","canonical_id":"hgnc:HGNC:671","description":null,"metadata":null},{"id":"dd7a31afd23248d3aff9e0b03ac8c4e6","type":"GENE","name":"RNF10","canonical_id":"hgnc:HGNC:10055","description":"ring finger protein 10","metadata":{"aliases":["KIAA0262","RIE2"]}},{"id":"3afa2cb13c2d40319f2e07dbabce9fdf","type":"GENE","name":"RNF103","canonical_id":"hgnc:HGNC:12859","description":"ring finger protein 103","metadata":{"aliases":["hkf-1","KF1","ZFP103"]}},{"id":"6df5509c5215463c9224bb38e6f8da32","type":"GENE","name":"RNF103-CHMP3","canonical_id":"hgnc:HGNC:38847","description":"RNF103-CHMP3 readthrough","metadata":{"aliases":["RNF103-VPS24"]}},{"id":"f7678169b4344579844b6d4ba05a389a","type":"GENE","name":"RNF10P1","canonical_id":"hgnc:HGNC:44472","description":"ring finger protein 10 pseudogene 1","metadata":null},{"id":"5dd5aa46699047bda4bf9f288cfff052","type":"GENE","name":"RNF11","canonical_id":"hgnc:HGNC:10056","description":"ring finger protein 11","metadata":{"aliases":["CGI-123","Sid1669p","MGC51169"]}},{"id":"a6b5f36ff9ed4995af354df5659b38b8","type":"GENE","name":"RNF111","canonical_id":"hgnc:HGNC:17384","description":null,"metadata":null},{"id":"7ec12e0ea55d4797a483e90eb3c56264","type":"GENE","name":"RNF112","canonical_id":"hgnc:HGNC:12968","description":"ring finger protein 112","metadata":{"aliases":["BFP","ZNF179"]}},{"id":"10174059088848f7979d6a76350e9822","type":"GENE","name":"RNF112-AS1","canonical_id":"hgnc:HGNC:58560","description":"RNF112 antisense RNA 1","metadata":null},{"id":"67dda8d5ede84dafa3ed3bf953df78b6","type":"GENE","name":"RNF113A","canonical_id":"hgnc:HGNC:12974","description":"ring finger protein 113A","metadata":{"aliases":["RNF113","Cwc24","ZNF183"]}},{"id":"eee5272b883c482d969a4cdd680b7392","type":"GENE","name":"RNF113B","canonical_id":"hgnc:HGNC:17267","description":"ring finger protein 113B","metadata":{"aliases":["RNF161","ZNF183L1"]}},{"id":"75d01f9c0a5a431ebce42fe045653791","type":"GENE","name":"RNF114","canonical_id":"hgnc:HGNC:13094","description":"ring finger protein 114","metadata":{"aliases":["PSORS12","ZNF313"]}},{"id":"7cc84569584e4905b573b6de29f5aa26","type":"GENE","name":"RNF115","canonical_id":"hgnc:HGNC:18154","description":"ring finger protein 115","metadata":{"aliases":["BCA2","Rabring7","CL469780","ZNF364"]}},{"id":"48ef36d3c32849baa63463e87bbe640c","type":"GENE","name":"RNF11P1","canonical_id":"hgnc:HGNC:33988","description":"ring finger protein 11 pseudogene 1","metadata":null},{"id":"c384047c1559433399f051ca35f5eb3a","type":"GENE","name":"RNF11P2","canonical_id":"hgnc:HGNC:16535","description":"ring finger protein 11 pseudogene 2","metadata":{"aliases":["bA280O9.1","RNF11B"]}},{"id":"e7f22c8ed0d9461b87d824a559d6d122","type":"GENE","name":"RNF121","canonical_id":"hgnc:HGNC:21070","description":"ring finger protein 121","metadata":{"aliases":["FLJ11099"]}},{"id":"cae962a5a36e45bebfca6e5fe8af11c4","type":"GENE","name":"RNF122","canonical_id":"hgnc:HGNC:21147","description":"ring finger protein 122","metadata":{"aliases":["FLJ12526"]}},{"id":"ac12105f3c2946dfb142b51055d20a9b","type":"GENE","name":"RNF123","canonical_id":"hgnc:HGNC:21148","description":"ring finger protein 123","metadata":{"aliases":["FLJ12565","KPC1"]}},{"id":"92a4d868e06e48af9dfd3212823e78ce","type":"GENE","name":"RNF125","canonical_id":"hgnc:HGNC:21150","description":"ring finger protein 125","metadata":{"aliases":["FLJ20456"]}},{"id":"a4d33567f4964058a708b07ac839bbba","type":"GENE","name":"RNF126","canonical_id":"hgnc:HGNC:21151","description":"ring finger protein 126","metadata":{"aliases":["FLJ20552"]}},{"id":"f4cd45266e73423397d1a474e8fadb97","type":"GENE","name":"RNF126P1","canonical_id":"hgnc:HGNC:30340","description":"ring finger protein 126 pseudogene 1","metadata":null},{"id":"2547d24efc114524a1b7b0c3750e29df","type":"GENE","name":"RNF128","canonical_id":"hgnc:HGNC:21153","description":"ring finger protein 128","metadata":{"aliases":["FLJ23516","GRAIL"]}},{"id":"37af61cb4e344ee2aa314ced291f1cb0","type":"GENE","name":"RNF13","canonical_id":"hgnc:HGNC:10057","description":"ring finger protein 13","metadata":{"aliases":["RZF"]}},{"id":"3ef0fc4a5ddd4919829bc51dff2b8fc8","type":"GENE","name":"RNF130","canonical_id":"hgnc:HGNC:18280","description":"ring finger protein 130","metadata":{"aliases":["GP","G1RZFP","GOLIATH"]}},{"id":"42fd1b0e2dd14f2a84ecd4d3ca3d6c47","type":"GENE","name":"RNF130-AS1","canonical_id":"hgnc:HGNC:40836","description":"RNF130 antisense RNA 1","metadata":null},{"id":"cc04d5c057cc4ced847a2a6d2d322531","type":"GENE","name":"RNF130-AS2","canonical_id":"hgnc:HGNC:59318","description":"RNF130 antisense RNA 2","metadata":null},{"id":"1d68bf5fdd5b40e9ae2713faa834dd47","type":"GENE","name":"RNF133","canonical_id":"hgnc:HGNC:21154","description":"ring finger protein 133","metadata":null},{"id":"e0f36d58eb0a49d3bf911c549dad2080","type":"GENE","name":"RNF135","canonical_id":"hgnc:HGNC:21158","description":"ring finger protein 135","metadata":{"aliases":["MGC13061"]}},{"id":"a3d5c29fccea4fd28160a5371bd73e5f","type":"GENE","name":"RNF138","canonical_id":"hgnc:HGNC:17765","description":"ring finger protein 138","metadata":{"aliases":["STRIN","NARF"]}},{"id":"81cfe037453c4612b7a82837d49e69d0","type":"GENE","name":"RNF138P1","canonical_id":"hgnc:HGNC:30342","description":"ring finger protein 138 pseudogene 1","metadata":null},{"id":"d09311f4b44f4214a5e044bd8cf1904b","type":"GENE","name":"RNF138P2","canonical_id":"hgnc:HGNC:50775","description":"ring finger protein 138 pseudogene 2","metadata":null},{"id":"8680a3360fda405d894570c8bc207699","type":"GENE","name":"RNF139","canonical_id":"hgnc:HGNC:17023","description":"ring finger protein 139","metadata":{"aliases":["TRC8","RCA1","HRCA1"]}},{"id":"79b7aaec3d074ab79faed28f79f930a2","type":"GENE","name":"RNF139-DT","canonical_id":"hgnc:HGNC:48940","description":"RNF139 divergent transcript","metadata":{"aliases":["RNF139-AS1"]}},{"id":"b556c958f5d24bbea2f3a28d8b9ce32f","type":"GENE","name":"RNF13P1","canonical_id":"hgnc:HGNC:56589","description":"RNF13 pseudogene 1","metadata":null},{"id":"e70c57610c4f4b0783ce1e83ff481a04","type":"GENE","name":"RNF14","canonical_id":"hgnc:HGNC:10058","description":null,"metadata":null},{"id":"afda9059cb2c4feb9d5964b3e45bc748","type":"GENE","name":"RNF14-AS1","canonical_id":"hgnc:HGNC:40505","description":"RNF14 antisense RNA 1","metadata":null},{"id":"4cc9753484324edfabbfb69a6ed04e89","type":"GENE","name":"RNF141","canonical_id":"hgnc:HGNC:21159","description":"ring finger protein 141","metadata":{"aliases":["ZFP26","ZNF230"]}},{"id":"73190cb64ed14d09a9d6892900c40588","type":"GENE","name":"RNF144A","canonical_id":"hgnc:HGNC:20457","description":null,"metadata":null},{"id":"5f9768dcadbb4861b21803bed239a65b","type":"GENE","name":"RNF144B","canonical_id":"hgnc:HGNC:21578","description":"ring finger protein 144B","metadata":{"aliases":["bA528A10.3","P53RFP","IBRDC2"]}},{"id":"14d16340283542ec9cf240793d530187","type":"GENE","name":"RNF144B-AS1","canonical_id":"hgnc:HGNC:59368","description":"RNF144B antisense RNA 1","metadata":null},{"id":"f341a239aab74dfe9254d0d2cdbc3e16","type":"GENE","name":"RNF145","canonical_id":"hgnc:HGNC:20853","description":"ring finger protein 145","metadata":{"aliases":["FLJ31951"]}},{"id":"5c2e018f9a05451e8de7f7b94c5b12e8","type":"GENE","name":"RNF146","canonical_id":"hgnc:HGNC:21336","description":"ring finger protein 146","metadata":{"aliases":["DKFZp434O1427","dactylidin","dJ351K20.1"]}},{"id":"efef14e1db6e41cdb02413f85916691a","type":"GENE","name":"RNF148","canonical_id":"hgnc:HGNC:22411","description":"ring finger protein 148","metadata":{"aliases":["MGC35222"]}},{"id":"524cdd7733b1474584e1ad205a82a054","type":"GENE","name":"RNF149","canonical_id":"hgnc:HGNC:23137","description":"ring finger protein 149","metadata":{"aliases":["FLJ90504"]}},{"id":"2d19b852d60a4938b9fd95c7388c4ddd","type":"GENE","name":"RNF14P1","canonical_id":"hgnc:HGNC:54669","description":"RNF14 pseudogene 1","metadata":null},{"id":"ba6dbf46c72d478194308fcf07b435af","type":"GENE","name":"RNF14P2","canonical_id":"hgnc:HGNC:54670","description":"RNF14 pseudogene 2","metadata":null},{"id":"f679b496b02c46319a791b3c8197cc9e","type":"GENE","name":"RNF14P3","canonical_id":"hgnc:HGNC:54671","description":"RNF14 pseudogene 3","metadata":null},{"id":"39c10aadc42344b6ba7e624df08b4287","type":"GENE","name":"RNF14P4","canonical_id":"hgnc:HGNC:54672","description":"RNF14 pseudogene 4","metadata":null},{"id":"e570e66c647e40abb2ed3482cc1ccf72","type":"GENE","name":"RNF150","canonical_id":"hgnc:HGNC:23138","description":"ring finger protein 150","metadata":{"aliases":["KIAA1214"]}},{"id":"d6e063591bd74c0fb96d3f23d8a5684f","type":"GENE","name":"RNF151","canonical_id":"hgnc:HGNC:23235","description":"ring finger protein 151","metadata":null},{"id":"cb9cadc6d77747b1be093f241df07b41","type":"GENE","name":"RNF152","canonical_id":"hgnc:HGNC:26811","description":"ring finger protein 152","metadata":{"aliases":["FLJ39176"]}},{"id":"f7371fff421041af93e4a851f0dab5e4","type":"GENE","name":"RNF152P1","canonical_id":"hgnc:HGNC:49743","description":"ring finger protein 152 pseudogene 1","metadata":null},{"id":"7492efe17f2543d59e4c1ae2c3bca10d","type":"GENE","name":"RNF157","canonical_id":"hgnc:HGNC:29402","description":"ring finger protein 157","metadata":{"aliases":["KIAA1917"]}},{"id":"8c48f0baff604c198053c67bbaa9efbc","type":"GENE","name":"RNF157-AS1","canonical_id":"hgnc:HGNC:44127","description":"RNF157 antisense RNA 1","metadata":null},{"id":"365c9c2c00cc403fa9f68a9f6c0a835e","type":"GENE","name":"RNF166","canonical_id":"hgnc:HGNC:28856","description":"ring finger protein 166","metadata":{"aliases":["MGC2647","MGC14381"]}},{"id":"e9901c38a1a945b18495c824c5cd6c5d","type":"GENE","name":"RNF167","canonical_id":"hgnc:HGNC:24544","description":"ring finger protein 167","metadata":{"aliases":["DKFZP566H073"]}},{"id":"59ef93fb04ae4a35a0b6802f831f3965","type":"GENE","name":"RNF168","canonical_id":"hgnc:HGNC:26661","description":"ring finger protein 168","metadata":{"aliases":["FLJ35794"]}},{"id":"abf00789b1cf4eefb2650e55322e860a","type":"GENE","name":"RNF169","canonical_id":"hgnc:HGNC:26961","description":"ring finger protein 169","metadata":{"aliases":["KIAA1991"]}},{"id":"ccea762ab6e24963bef0fc259d686e5e","type":"GENE","name":"RNF17","canonical_id":"hgnc:HGNC:10060","description":"ring finger protein 17","metadata":{"aliases":["Mmip-2","SPATA23","FLJ11045","TDRD4"]}},{"id":"47d4d646561a4ac7a2e9d7efa3e70638","type":"GENE","name":"RNF170","canonical_id":"hgnc:HGNC:25358","description":"ring finger protein 170","metadata":{"aliases":["DKFZP564A022","ADSA","SNAX1"]}},{"id":"5e083b7317694f20b8d2ea08390fb1b3","type":"GENE","name":"RNF175","canonical_id":"hgnc:HGNC:27735","description":"ring finger protein 175","metadata":{"aliases":["FLJ34190"]}},{"id":"e3110017775b4edf8af5d2a8a2a3924e","type":"GENE","name":"RNF180","canonical_id":"hgnc:HGNC:27752","description":"ring finger protein 180","metadata":null},{"id":"73a032ca0a814d5b9341e69e558722cf","type":"GENE","name":"RNF180-DT","canonical_id":"hgnc:HGNC:59060","description":"RNF180 divergent transcript","metadata":null},{"id":"feafaf92342b46f28c0810ae4fdee1da","type":"GENE","name":"RNF181","canonical_id":"hgnc:HGNC:28037","description":"ring finger protein 181","metadata":{"aliases":["HSPC238"]}},{"id":"542627233b02451994a635ecd3a2fa85","type":"GENE","name":"RNF182","canonical_id":"hgnc:HGNC:28522","description":"ring finger protein 182","metadata":{"aliases":["MGC33993"]}},{"id":"fc31a0f86199430480544f352b84e108","type":"GENE","name":"RNF183","canonical_id":"hgnc:HGNC:28721","description":"ring finger protein 183","metadata":{"aliases":["MGC4734"]}},{"id":"b2fec545e2a84f9bb14f41308b05b43f","type":"GENE","name":"RNF185","canonical_id":"hgnc:HGNC:26783","description":"ring finger protein 185","metadata":{"aliases":["FLJ38628"]}},{"id":"3b35f66df7684335b152d8b1e2a7689b","type":"GENE","name":"RNF185-AS1","canonical_id":"hgnc:HGNC:41161","description":"RNF185 antisense RNA 1","metadata":null},{"id":"71330b3f43fa48c7bac32039746e5137","type":"GENE","name":"RNF186","canonical_id":"hgnc:HGNC:25978","description":"ring finger protein 186","metadata":{"aliases":["FLJ20225"]}},{"id":"7a4c4709533141cd9144fa98d5849f8c","type":"GENE","name":"RNF186-AS1","canonical_id":"hgnc:HGNC:41127","description":"RNF186 antisense RNA 1","metadata":null},{"id":"321f01409f43437c8f9dc74d68b0217b","type":"GENE","name":"RNF187","canonical_id":"hgnc:HGNC:27146","description":"ring finger protein 187","metadata":{"aliases":["RACO1","RACO-1"]}},{"id":"0c0385ba40a143f4a1ace2a9dd89ac30","type":"GENE","name":"RNF19A","canonical_id":"hgnc:HGNC:13432","description":"ring finger protein 19A, RBR E3 ubiquitin protein ligase","metadata":{"aliases":["dorfin","DKFZp566B1346","RNF19"]}},{"id":"c918be33a4024c808f90db9745071aba","type":"GENE","name":"RNF19B","canonical_id":"hgnc:HGNC:26886","description":"ring finger protein 19B","metadata":{"aliases":["FLJ90005","NKLAM","IBRDC3"]}},{"id":"f82e5a3687344e3995dcdf0eb44598ae","type":"GENE","name":"RNF19BPX","canonical_id":"hgnc:HGNC:38484","description":"ring finger protein 19B pseudogene X-linked","metadata":{"aliases":["RNF19BX"]}},{"id":"e6d0eed0202747ea855b75c591492652","type":"GENE","name":"RNF19BPY","canonical_id":"hgnc:HGNC:38398","description":"ring finger protein 19B pseudogene Y-linked","metadata":null},{"id":"67bf03d1953f421eba05620287f740f0","type":"GENE","name":"RNF2","canonical_id":"hgnc:HGNC:10061","description":null,"metadata":null},{"id":"b481da54e6ce4e3588e34e462c4fb87e","type":"GENE","name":"RNF20","canonical_id":"hgnc:HGNC:10062","description":"ring finger protein 20","metadata":{"aliases":["FLJ20382","FLJ11189","KAIA2779","BRE1A","hBRE1","BRE1"]}},{"id":"270f1600b3394360a7cfc8239ee888c2","type":"GENE","name":"RNF207","canonical_id":"hgnc:HGNC:32947","description":"ring finger protein 207","metadata":{"aliases":["FLJ46380","FLJ32096","C1orf188"]}},{"id":"beefceb778f043808334ffc129c30f42","type":"GENE","name":"RNF207-AS1","canonical_id":"hgnc:HGNC:41286","description":"RNF207 antisense RNA 1","metadata":null},{"id":"5092278fca004ff683f82de67bbae1cb","type":"GENE","name":"RNF208","canonical_id":"hgnc:HGNC:25420","description":"ring finger protein 208","metadata":{"aliases":["DKFZP761H1710"]}},{"id":"505a5b34eb544c58a7fb7d3e349f2bf9","type":"GENE","name":"RNF212","canonical_id":"hgnc:HGNC:27729","description":"ring finger protein 212","metadata":{"aliases":["FLJ38841","LOC285498"]}},{"id":"092fd1f09ead454db196ec720a80e60a","type":"GENE","name":"RNF212-DT","canonical_id":"hgnc:HGNC:58708","description":"RNF212 divergent transcript","metadata":null},{"id":"5c573a8748024466a72c63864fdfe671","type":"GENE","name":"RNF212B","canonical_id":"hgnc:HGNC:20438","description":"ring finger protein 212B","metadata":{"aliases":["C14orf164"]}},{"id":"79d40321327a48c6948ea69762bf041b","type":"GENE","name":"RNF213","canonical_id":"hgnc:HGNC:14539","description":"ring finger protein 213","metadata":{"aliases":["KIAA1554","NET57","ALO17","C17orf27","KIAA1618","MYMY2"]}},{"id":"a2a846b5cb4f47a9981eef7537c67d9c","type":"GENE","name":"RNF213-AS1","canonical_id":"hgnc:HGNC:54402","description":"RNF213 antisense RNA 1","metadata":null},{"id":"e8b6f1684e2f4d9aa55214d14f0fbe5b","type":"GENE","name":"RNF214","canonical_id":"hgnc:HGNC:25335","description":"ring finger protein 214","metadata":{"aliases":["DKFZp547C195"]}},{"id":"b1829fe33ae04b32b7c56cf900f8c9a5","type":"GENE","name":"RNF215","canonical_id":"hgnc:HGNC:33434","description":"ring finger protein 215","metadata":null},{"id":"136f40bcea1d4f5488e53609dda16c30","type":"GENE","name":"RNF216","canonical_id":"hgnc:HGNC:21698","description":"ring finger protein 216","metadata":{"aliases":["TRIAD3","UBCE7IP1","ZIN"]}},{"id":"b9671d4d968546cd891649acda97a413","type":"GENE","name":"RNF216-IT1","canonical_id":"hgnc:HGNC:41463","description":"RNF216 intronic transcript 1","metadata":null},{"id":"6ed03d966e2b48e7ab812918618d77f1","type":"GENE","name":"RNF216P1","canonical_id":"hgnc:HGNC:33610","description":"ring finger protein 216 pseudogene 1","metadata":{"aliases":["RNF216L"]}},{"id":"d9b2eead98764ffdad337528397dd741","type":"GENE","name":"RNF217","canonical_id":"hgnc:HGNC:21487","description":"ring finger protein 217","metadata":{"aliases":["MGC26996","dJ84N20.1","C6orf172","IBRDC1"]}},{"id":"75d3fbaa01df456c94ed208da52cd1f8","type":"GENE","name":"RNF217-AS1","canonical_id":"hgnc:HGNC:50866","description":"RNF217 antisense RNA 1","metadata":{"aliases":["STL"]}},{"id":"219cc5756d084c7eaa6e8c41ac4d46f8","type":"GENE","name":"RNF220","canonical_id":"hgnc:HGNC:25552","description":"ring finger protein 220","metadata":{"aliases":["FLJ10597","C1orf164"]}},{"id":"67467bab81f44a22b49c724d17fc0158","type":"GENE","name":"RNF222","canonical_id":"hgnc:HGNC:34517","description":"ring finger protein 222","metadata":null},{"id":"2882081e2dbf4b0b8df4e0aa9d9fdb7c","type":"GENE","name":"RNF223","canonical_id":"hgnc:HGNC:40020","description":"ring finger protein 223","metadata":null},{"id":"0820c97500ea4fcc9077ba3f9f09fb92","type":"GENE","name":"RNF224","canonical_id":"hgnc:HGNC:41912","description":"ring finger protein 224","metadata":null},{"id":"c479bf197df04c0c9cacb40f6ee7a5bb","type":"GENE","name":"RNF225","canonical_id":"hgnc:HGNC:51249","description":"ring finger protein 225","metadata":null},{"id":"1a9a1ac64f80463995967746ca4458ff","type":"GENE","name":"RNF227","canonical_id":"hgnc:HGNC:27571","description":"ring finger protein 227","metadata":{"aliases":["LINC02581"]}},{"id":"01678cda735b4fd9a149ad7e36fd1761","type":"GENE","name":"RNF228","canonical_id":"hgnc:HGNC:55809","description":"ring finger protein 228","metadata":{"aliases":["AC010980.1"]}},{"id":"510ba9e88cbe45559261368fc2f696f9","type":"GENE","name":"RNF229","canonical_id":"hgnc:HGNC:55810","description":"ring finger protein 229","metadata":null},{"id":"a7abe2d5b1c445ae91ea87edf505fafe","type":"GENE","name":"RNF24","canonical_id":"hgnc:HGNC:13779","description":"ring finger protein 24","metadata":{"aliases":["G1L"]}},{"id":"83db3640bd4d424cab8c6b70d1d6f988","type":"GENE","name":"RNF25","canonical_id":"hgnc:HGNC:14662","description":"ring finger protein 25","metadata":{"aliases":["AO7","FLJ13906"]}},{"id":"6ae1621c51c246e395701cbd2915d3bf","type":"GENE","name":"RNF26","canonical_id":"hgnc:HGNC:14646","description":"ring finger protein 26","metadata":{"aliases":["MGC2642"]}},{"id":"6f9aa18339494ad6a1a8d3abe2d3152e","type":"GENE","name":"RNF26-AS1","canonical_id":"hgnc:HGNC:58408","description":"RNF26 antisense RNA 1","metadata":null},{"id":"b64cbf9f393944c1bfea713ac1b253da","type":"GENE","name":"RNF2P1","canonical_id":"hgnc:HGNC:33987","description":"ring finger protein 2 pseudogene 1","metadata":{"aliases":["RNF2P"]}},{"id":"57e59f2809df42c3b64e3f3a5b5eb512","type":"GENE","name":"RNF31","canonical_id":"hgnc:HGNC:16031","description":"ring finger protein 31","metadata":{"aliases":["ZIBRA","FLJ10111","FLJ23501","HOIP","Paul"]}},{"id":"9c4c6f1d72204a899c848f3762b1de44","type":"GENE","name":"RNF32","canonical_id":"hgnc:HGNC:17118","description":"ring finger protein 32","metadata":{"aliases":["FKSG33","HSD15","LMBR2"]}},{"id":"782d76b10c4e46348910d30207d1fbc3","type":"GENE","name":"RNF32-AS1","canonical_id":"hgnc:HGNC:40798","description":"RNF32 antisense RNA 1","metadata":null},{"id":"fe457776b2e842d081bf0e2a4557890f","type":"GENE","name":"RNF32-DT","canonical_id":"hgnc:HGNC:48971","description":"RNF32 divergent transcript","metadata":{"aliases":["MY040","C7orf13","LINC01006"]}},{"id":"d5115affd4444e54b36ff21459520e27","type":"GENE","name":"RNF34","canonical_id":"hgnc:HGNC:17297","description":"ring finger protein 34","metadata":{"aliases":["RIFF","FLJ21786","RIF"]}},{"id":"8f49f2a422324394a6a5e058ea6f1a84","type":"GENE","name":"RNF38","canonical_id":"hgnc:HGNC:18052","description":"ring finger protein 38","metadata":null},{"id":"fca3f95fbada4fe69845fb0764683e94","type":"GENE","name":"RNF39","canonical_id":"hgnc:HGNC:18064","description":"ring finger protein 39","metadata":{"aliases":["HZFw1","LIRF","FAP216"]}},{"id":"3bc216f7839a4d7d9b87325c91304b3d","type":"GENE","name":"RNF4","canonical_id":"hgnc:HGNC:10067","description":"ring finger protein 4","metadata":{"aliases":["RES4-26","SNURF","SLX5"]}},{"id":"9744d5b42e484a1784e00829455d34a2","type":"GENE","name":"RNF4-DT","canonical_id":"hgnc:HGNC:58712","description":"RNF4 divergent transcript","metadata":null},{"id":"10c974e7599046aea80643024798dc35","type":"GENE","name":"RNF40","canonical_id":"hgnc:HGNC:16867","description":"ring finger protein 40","metadata":{"aliases":["KIAA0661","RBP95","BRE1B","STARING"]}},{"id":"f527cd9c7b4c4c7591f5f18985de48ac","type":"GENE","name":"RNF41","canonical_id":"hgnc:HGNC:18401","description":"ring finger protein 41","metadata":{"aliases":["SBBI03","NRDP1"]}},{"id":"ffcf53621aee4855ac8f10d6a92684cc","type":"GENE","name":"RNF43","canonical_id":"hgnc:HGNC:18505","description":"ring finger protein 43","metadata":{"aliases":["FLJ20315","RNF124","DKFZp781H0392","URCC"]}},{"id":"20a5e618c2864071ad04897cdbaa97d0","type":"GENE","name":"RNF44","canonical_id":"hgnc:HGNC:19180","description":"ring finger protein 44","metadata":{"aliases":["KIAA1100"]}},{"id":"9c0021291b67416db6cf90963393863f","type":"GENE","name":"RNF44-AS1","canonical_id":"hgnc:HGNC:59310","description":"RNF44 antisense RNA 1","metadata":null},{"id":"c46df8b5a7f34c17acc2c4314d13cebc","type":"GENE","name":"RNF4BP","canonical_id":"hgnc:HGNC:58117","description":"ring finger protein 4B, pseudogene","metadata":null},{"id":"1b694236c2af450f823d85562b55876a","type":"GENE","name":"RNF5","canonical_id":"hgnc:HGNC:10068","description":"ring finger protein 5","metadata":{"aliases":["NG2","G16","RING5","RMA1"]}},{"id":"9a9b49427abd40f4a9d46e1e787a8ede","type":"GENE","name":"RNF5P1","canonical_id":"hgnc:HGNC:31053","description":"ring finger protein 5 pseudogene 1","metadata":null},{"id":"80047d356605455784324c2824accbeb","type":"GENE","name":"RNF6","canonical_id":"hgnc:HGNC:10069","description":"ring finger protein 6","metadata":{"aliases":["DKFZp686P0776"]}},{"id":"8a0977ac831c48b1ae39708339833623","type":"GENE","name":"RNF6P1","canonical_id":"hgnc:HGNC:39922","description":"ring finger protein 6 pseudogene 1","metadata":null},{"id":"7faefd0af908450e9c42a7b0ac69efbc","type":"GENE","name":"RNF7","canonical_id":"hgnc:HGNC:10070","description":null,"metadata":null},{"id":"f05d8b411b444c44824e7f6d061fde54","type":"GENE","name":"RNF7P1","canonical_id":"hgnc:HGNC:43425","description":"ring finger protein 7 pseudogene 1","metadata":null},{"id":"4748dc97fda54b4a9c3cea77b99782d5","type":"GENE","name":"RNF8","canonical_id":"hgnc:HGNC:10071","description":null,"metadata":null},{"id":"0f907accc356468ea1f9ab3227d0932c","type":"GENE","name":"RNFT1","canonical_id":"hgnc:HGNC:30206","description":"ring finger protein, transmembrane 1","metadata":{"aliases":["PTD016"]}},{"id":"d713ccd35ca548bd829130176f441b69","type":"GENE","name":"RNFT1-DT","canonical_id":"hgnc:HGNC:51346","description":"RNFT1 divergent transcript","metadata":null},{"id":"6e407a473f2c4dbe8abe0a4d49802ed1","type":"GENE","name":"RNFT1P1","canonical_id":"hgnc:HGNC:44387","description":"ring finger protein, transmembrane 1 pseudogene 1","metadata":null},{"id":"febb06fb4e84433dba2df394c060dcc1","type":"GENE","name":"RNFT1P2","canonical_id":"hgnc:HGNC:44388","description":"ring finger protein, transmembrane 1 pseudogene 2","metadata":null},{"id":"b8caf6c0414b4fab848588f1ccdd0257","type":"GENE","name":"RNFT1P3","canonical_id":"hgnc:HGNC:44389","description":"ring finger protein, transmembrane 1 pseudogene 3","metadata":null},{"id":"164515e687194ea393f0ab2027bfbe31","type":"GENE","name":"RNFT2","canonical_id":"hgnc:HGNC:25905","description":"ring finger protein, transmembrane 2","metadata":{"aliases":["FLJ14627","TMEM118"]}},{"id":"ee70fa4d7f7242fcbd4e8c7048964ece","type":"GENE","name":"RNGTT","canonical_id":"hgnc:HGNC:10073","description":"RNA guanylyltransferase and 5'-phosphatase","metadata":{"aliases":["HCE","HCE1","hCAP"]}},{"id":"10cd8baf485d46a29534632779b86d24","type":"GENE","name":"RNGTTP1","canonical_id":"hgnc:HGNC:39652","description":"RNA guanylyltransferase and 5'-phosphatase pseudogene 1","metadata":null},{"id":"8672a0779b734cd3999911f7e79be548","type":"GENE","name":"RNH1","canonical_id":"hgnc:HGNC:10074","description":"ribonuclease/angiogenin inhibitor 1","metadata":{"aliases":["RAI","RNH"]}},{"id":"7594596d795b4dfab3fcfee00a031234","type":"GENE","name":"RNLS","canonical_id":"hgnc:HGNC:25641","description":"renalase, FAD dependent amine oxidase","metadata":{"aliases":["FLJ11218","renalase","C10orf59"]}},{"id":"b4db3563532a4ea19eeef411e2e4e1f2","type":"GENE","name":"RNMT","canonical_id":"hgnc:HGNC:10075","description":"RNA guanine-7 methyltransferase","metadata":{"aliases":["RG7MT1","N7-MTase"]}},{"id":"51c2229071094f46bce37f4a0a8586d9","type":"GO_TERM","name":"RNP body","canonical_id":"go:GO:0140365","description":"\"A ribonucleoprotein granule located in the cytoplasm of bacteria, minimally containing the RNase E protein and RNA molecules. Bacterial RNP-bodies are similar to eukaryotic P-bodies and stress granules.\" [PMID:30197298]","metadata":null},{"id":"dfa5de78b639495c8299afc310ce230a","type":"GENE","name":"RNPC3","canonical_id":"hgnc:HGNC:18666","description":"RNA binding region (RNP1, RRM) containing 3","metadata":{"aliases":["KIAA1839","FLJ20008","RBM40","SNRNP65"]}},{"id":"70600d2b761947a1aa4fd295d65387f7","type":"GENE","name":"RNPC3-DT","canonical_id":"hgnc:HGNC:55855","description":"RNPC3 divergent transcript","metadata":null},{"id":"e4cd98b972fb46488be8ccfc3a23fc20","type":"GENE","name":"RNPC3P1","canonical_id":"hgnc:HGNC:47036","description":"RNA binding region (RNP1, RRM) containing 3 pseudogene 1","metadata":null},{"id":"9306b6e43a40481d8dcc326a21cc9225","type":"GENE","name":"RNPEP","canonical_id":"hgnc:HGNC:10078","description":"arginyl aminopeptidase","metadata":{"aliases":["APB"]}},{"id":"0088e5ae0e4443d4884267bc8e2a5b4a","type":"GENE","name":"RNPEPL1","canonical_id":"hgnc:HGNC:10079","description":"arginyl aminopeptidase like 1","metadata":null},{"id":"c5de1d63e7974ca5ac4578ffb73504bd","type":"GENE","name":"RNPS1","canonical_id":"hgnc:HGNC:10080","description":"RNA binding protein with serine rich domain 1","metadata":null},{"id":"913d66019efc4dd2bbcf44305b9deb5a","type":"GENE","name":"RNPS1P1","canonical_id":"hgnc:HGNC:39525","description":"RNA binding protein with serine rich domain 1 pseudogene 1","metadata":null},{"id":"c97e3f1c9a9f4cad8d72a0b19d033e60","type":"GENE","name":"RNR1","canonical_id":"hgnc:HGNC:10082","description":"RNA, ribosomal 45S cluster 1","metadata":null},{"id":"70ad04beec4b42cc8a75db3a6ebd77d8","type":"GENE","name":"RNR2","canonical_id":"hgnc:HGNC:10083","description":"RNA, ribosomal 45S cluster 2","metadata":null},{"id":"07e12912e37145d5be4245633363fe6d","type":"GENE","name":"RNR3","canonical_id":"hgnc:HGNC:10084","description":"RNA, ribosomal 45S cluster 3","metadata":null},{"id":"36a104a0f1914805b19b1243e62e5205","type":"GENE","name":"RNR4","canonical_id":"hgnc:HGNC:10085","description":"RNA, ribosomal 45S cluster 4","metadata":null},{"id":"d8ee76feaf2f4074b0a0a48e979a3bc7","type":"GENE","name":"RNR5","canonical_id":"hgnc:HGNC:10086","description":"RNA, ribosomal 45S cluster 5","metadata":null},{"id":"a57253cfc22646779d4712e5a14a8839","type":"GENE","name":"RNU1-1","canonical_id":"hgnc:HGNC:10120","description":"RNA, U1 small nuclear 1","metadata":{"aliases":["Rnu1a1","U1","HU1-1","U1A1","HSD1","RNU1","RNU1G4","RNU1A3","RNU1A"]}},{"id":"aa2ff1c8b8d2418296c23775d332f41f","type":"GENE","name":"RNU1-100P","canonical_id":"hgnc:HGNC:48442","description":"RNA, U1 small nuclear 100, pseudogene","metadata":null},{"id":"5f54e684417c4bf4bc08ba6d1e503124","type":"GENE","name":"RNU1-101P","canonical_id":"hgnc:HGNC:48443","description":"RNA, U1 small nuclear 101, pseudogene","metadata":null},{"id":"e58723a15e7c4f1f95f4cc4ae25b0718","type":"GENE","name":"RNU1-103P","canonical_id":"hgnc:HGNC:48445","description":"RNA, U1 small nuclear 103, pseudogene","metadata":null},{"id":"ba18f51e504e456bbf6301da86ca79ef","type":"GENE","name":"RNU1-104P","canonical_id":"hgnc:HGNC:48446","description":"RNA, U1 small nuclear 104, pseudogene","metadata":null},{"id":"e93e68da15cd4e6db5ca773d7acbb4c0","type":"GENE","name":"RNU1-105P","canonical_id":"hgnc:HGNC:48447","description":"RNA, U1 small nuclear 105, pseudogene","metadata":null},{"id":"79351f925a2d4837a7a37cb70ee7a615","type":"GENE","name":"RNU1-107P","canonical_id":"hgnc:HGNC:48449","description":"RNA, U1 small nuclear 107, pseudogene","metadata":null},{"id":"041210394b9a49c8b636353ddf86c341","type":"GENE","name":"RNU1-108P","canonical_id":"hgnc:HGNC:48450","description":"RNA, U1 small nuclear 108, pseudogene","metadata":null},{"id":"e02ea63da2104a9594364145b10ce2ac","type":"GENE","name":"RNU1-109P","canonical_id":"hgnc:HGNC:48451","description":"RNA, U1 small nuclear 109, pseudogene","metadata":null},{"id":"bafedfe9b4d640d4b3994559d012ad1d","type":"GENE","name":"RNU1-112P","canonical_id":"hgnc:HGNC:48454","description":"RNA, U1 small nuclear 112, pseudogene","metadata":null},{"id":"3ae50897e466483598cfad510fb6411f","type":"GENE","name":"RNU1-114P","canonical_id":"hgnc:HGNC:48456","description":"RNA, U1 small nuclear 114, pseudogene","metadata":null},{"id":"9629f4792cba4d3d8e14d7020a58f733","type":"GENE","name":"RNU1-115P","canonical_id":"hgnc:HGNC:48457","description":"RNA, U1 small nuclear 115, pseudogene","metadata":null},{"id":"db318c99f90f4a728ca1797011fdce91","type":"GENE","name":"RNU1-116P","canonical_id":"hgnc:HGNC:48458","description":"RNA, U1 small nuclear 116, pseudogene","metadata":null},{"id":"88d606c7096449019e54921513e193ad","type":"GENE","name":"RNU1-117P","canonical_id":"hgnc:HGNC:48459","description":"RNA, U1 small nuclear 117, pseudogene","metadata":null},{"id":"c234c66fe4e2486c854ac9bd2a7098cd","type":"GENE","name":"RNU1-119P","canonical_id":"hgnc:HGNC:48461","description":"RNA, U1 small nuclear 119, pseudogene","metadata":null},{"id":"ff112bf2933b47fdb1d1dc659eba4728","type":"GENE","name":"RNU1-11P","canonical_id":"hgnc:HGNC:10137","description":"RNA, U1 small nuclear 11, pseudogene","metadata":{"aliases":["U1P1A","RNU1P1","RNU1P5"]}},{"id":"6d6818d48adf4d17b15c8e509a94ef06","type":"GENE","name":"RNU1-123P","canonical_id":"hgnc:HGNC:48465","description":"RNA, U1 small nuclear 123, pseudogene","metadata":null},{"id":"ec0cf0947b9b4d94a573c1b63d7da217","type":"GENE","name":"RNU1-124P","canonical_id":"hgnc:HGNC:48466","description":"RNA, U1 small nuclear 124, pseudogene","metadata":null},{"id":"739fe0890fb44036844f979fe359bd64","type":"GENE","name":"RNU1-125P","canonical_id":"hgnc:HGNC:48467","description":"RNA, U1 small nuclear 125, pseudogene","metadata":null},{"id":"f38b83c0037245e4b466a05c72891619","type":"GENE","name":"RNU1-128P","canonical_id":"hgnc:HGNC:48470","description":"RNA, U1 small nuclear 128, pseudogene","metadata":null},{"id":"a0fd59b1d6e94dffa13e0caf3071bf41","type":"GENE","name":"RNU1-129P","canonical_id":"hgnc:HGNC:48471","description":"RNA, U1 small nuclear 129, pseudogene","metadata":{"aliases":["RNU1-137P"]}},{"id":"a4533314ee15419b8d37baf77abfd2d6","type":"GENE","name":"RNU1-130P","canonical_id":"hgnc:HGNC:48472","description":"RNA, U1 small nuclear 130, pseudogene","metadata":null},{"id":"d7289180964443c799561797c1db5523","type":"GENE","name":"RNU1-131P","canonical_id":"hgnc:HGNC:48473","description":"RNA, U1 small nuclear 131, pseudogene","metadata":null},{"id":"7408df053bb94783a14ab53097397c50","type":"GENE","name":"RNU1-132P","canonical_id":"hgnc:HGNC:48474","description":"RNA, U1 small nuclear 132, pseudogene","metadata":null},{"id":"4a99897b0d264daba2950bb9c8c51c5c","type":"GENE","name":"RNU1-133P","canonical_id":"hgnc:HGNC:48475","description":"RNA, U1 small nuclear 133, pseudogene","metadata":null},{"id":"1452d25d27d149319ed7fa5b80d4a940","type":"GENE","name":"RNU1-134P","canonical_id":"hgnc:HGNC:48476","description":"RNA, U1 small nuclear 134, pseudogene","metadata":null},{"id":"19c201692be84bd8a2d35008eaf97acc","type":"GENE","name":"RNU1-136P","canonical_id":"hgnc:HGNC:48478","description":"RNA, U1 small nuclear 136, pseudogene","metadata":null},{"id":"a0dca0c99e764bf686c62eb7773df0e0","type":"GENE","name":"RNU1-138P","canonical_id":"hgnc:HGNC:48480","description":"RNA, U1 small nuclear 138, pseudogene","metadata":null},{"id":"5a221af2946e4a30b2ab68fe28256c4d","type":"GENE","name":"RNU1-139P","canonical_id":"hgnc:HGNC:48481","description":"RNA, U1 small nuclear 139, pseudogene","metadata":null},{"id":"c40a5c0e95324ad08eeae673e51553c8","type":"GENE","name":"RNU1-140P","canonical_id":"hgnc:HGNC:48482","description":"RNA, U1 small nuclear 140, pseudogene","metadata":null},{"id":"e011f400a8fb4e55878e8c673e55a2fb","type":"GENE","name":"RNU1-141P","canonical_id":"hgnc:HGNC:48483","description":"RNA, U1 small nuclear 141, pseudogene","metadata":null},{"id":"9ddedb648f2c4a0ab2f0e5dc92e0d3ad","type":"GENE","name":"RNU1-142P","canonical_id":"hgnc:HGNC:48484","description":"RNA, U1 small nuclear 142, pseudogene","metadata":null},{"id":"2080391cfb694dfe813b13afe01458d4","type":"GENE","name":"RNU1-143P","canonical_id":"hgnc:HGNC:48485","description":"RNA, U1 small nuclear 143, pseudogene","metadata":null},{"id":"4fd1ceeeb0f840dd88491370c6a94ff0","type":"GENE","name":"RNU1-146P","canonical_id":"hgnc:HGNC:48488","description":"RNA, U1 small nuclear 146, pseudogene","metadata":null},{"id":"f6b116ae580e4a12917e517ad9d0d9d5","type":"GENE","name":"RNU1-148P","canonical_id":"hgnc:HGNC:48490","description":"RNA, U1 small nuclear 148, pseudogene","metadata":null},{"id":"83c306afb4834de091b7c8726168f09a","type":"GENE","name":"RNU1-149P","canonical_id":"hgnc:HGNC:48491","description":"RNA, U1 small nuclear 149, pseudogene","metadata":null},{"id":"5d99d18aabb54dff9349bb52e65b3baf","type":"GENE","name":"RNU1-14P","canonical_id":"hgnc:HGNC:10139","description":"RNA, U1 small nuclear 14, pseudogene","metadata":{"aliases":["U1P17","RNU1P7"]}},{"id":"985b9f7aaa17493e9f63f2144b38bb16","type":"GENE","name":"RNU1-150P","canonical_id":"hgnc:HGNC:48492","description":"RNA, U1 small nuclear 150, pseudogene","metadata":null},{"id":"76fdfe6ef7304c40bc9fab0a51912032","type":"GENE","name":"RNU1-151P","canonical_id":"hgnc:HGNC:53616","description":"RNA, U1 small nuclear 151, pseudogene","metadata":null},{"id":"031179381f634a83a13d86b4b4eee79c","type":"GENE","name":"RNU1-152P","canonical_id":"hgnc:HGNC:53625","description":"RNA, U1 small nuclear 152, pseudogene","metadata":null},{"id":"e165b547f6d04db6866ac23e4f93f812","type":"GENE","name":"RNU1-153P","canonical_id":"hgnc:HGNC:54435","description":"RNA, U1 small nuclear 153, pseudogene","metadata":null},{"id":"6ae0f8b7324545ed94c131c8b1267cc2","type":"GENE","name":"RNU1-154P","canonical_id":"hgnc:HGNC:54436","description":"RNA, U1 small nuclear 154, pseudogene","metadata":null},{"id":"73f0d7d43e0645b08d42a314ee62e0cd","type":"GENE","name":"RNU1-155P","canonical_id":"hgnc:HGNC:54437","description":"RNA, U1 small nuclear 155 pseudogene","metadata":null},{"id":"720230f7cc24453bb9375539f4fc6952","type":"GENE","name":"RNU1-15P","canonical_id":"hgnc:HGNC:10140","description":"RNA, U1 small nuclear 15, pseudogene","metadata":{"aliases":["U1P11","RNU1P8"]}},{"id":"4d8cef0e97354844bd1a0bc49da1d28b","type":"GENE","name":"RNU1-16P","canonical_id":"hgnc:HGNC:39890","description":"RNA, U1 small nuclear 16, pseudogene","metadata":{"aliases":["U1.64"]}},{"id":"338350e477a64323a6870e1b4e17cad9","type":"GENE","name":"RNU1-17P","canonical_id":"hgnc:HGNC:41943","description":"RNA, U1 small nuclear 17, pseudogene","metadata":null},{"id":"a035f71dd31240c3b1e8bbebfe24fcd0","type":"GENE","name":"RNU1-18P","canonical_id":"hgnc:HGNC:41944","description":"RNA, U1 small nuclear 18, pseudogene","metadata":null},{"id":"2665b29598c54ac5a0fd60cd44ad2eac","type":"GENE","name":"RNU1-19P","canonical_id":"hgnc:HGNC:41945","description":"RNA, U1 small nuclear 19, pseudogene","metadata":null},{"id":"6279be96fa9740fc8353007a8f1ba53e","type":"GENE","name":"RNU1-2","canonical_id":"hgnc:HGNC:10123","description":"RNA, U1 small nuclear 2","metadata":{"aliases":["U1C1","U1C21","RNU1C1","RNU1C2"]}},{"id":"014602b4e50b42179b2654407aca2886","type":"GENE","name":"RNU1-20P","canonical_id":"hgnc:HGNC:41946","description":"RNA, U1 small nuclear 20, pseudogene","metadata":null},{"id":"d6bf6010e7e6460488999a73235280e7","type":"GENE","name":"RNU1-21P","canonical_id":"hgnc:HGNC:41947","description":"RNA, U1 small nuclear 21, pseudogene","metadata":null},{"id":"ed5d708cc6f143ba9bf82e85dc7f675e","type":"GENE","name":"RNU1-22P","canonical_id":"hgnc:HGNC:41963","description":"RNA, U1 small nuclear 22, pseudogene","metadata":null},{"id":"dd54e1dcd6bb412b857fe40de0de28e9","type":"GENE","name":"RNU1-23P","canonical_id":"hgnc:HGNC:41964","description":"RNA, U1 small nuclear 23, pseudogene","metadata":null},{"id":"7928c8923d5148ab8767019908917b5e","type":"GENE","name":"RNU1-24P","canonical_id":"hgnc:HGNC:42504","description":"RNA, U1 small nuclear 24, pseudogene","metadata":{"aliases":["U1.41"]}},{"id":"a7bb4f16c1f7473d8e0e1322c5432d8a","type":"GENE","name":"RNU1-27P","canonical_id":"hgnc:HGNC:37497","description":"RNA, U1 small nuclear 27, pseudogene","metadata":{"aliases":["RNU1-7P"]}},{"id":"7a2a9556d9fe4c89a50518ab6059e001","type":"GENE","name":"RNU1-28P","canonical_id":"hgnc:HGNC:37498","description":"RNA, U1 small nuclear 28, pseudogene","metadata":{"aliases":["RNU1-8","RNU1-8P"]}},{"id":"e19805a507ef4a44b9a90cd8e9a9ca53","type":"GENE","name":"RNU1-29P","canonical_id":"hgnc:HGNC:48371","description":"RNA, U1 small nuclear 29, pseudogene","metadata":null},{"id":"566433238aa5402e9dcaa697d91801b5","type":"GENE","name":"RNU1-3","canonical_id":"hgnc:HGNC:10130","description":"RNA, U1 small nuclear 3","metadata":{"aliases":["HSD4","RNU1G3"]}},{"id":"f88f5b7eeb1d44d5abfd915713722062","type":"GENE","name":"RNU1-30P","canonical_id":"hgnc:HGNC:48372","description":"RNA, U1 small nuclear 30, pseudogene","metadata":null},{"id":"dea1efd2276d41199527549d13ebba1a","type":"GENE","name":"RNU1-31P","canonical_id":"hgnc:HGNC:48373","description":"RNA, U1 small nuclear 31, pseudogene","metadata":null},{"id":"5c1e34c15d6f42299c5f7260b65f9a80","type":"GENE","name":"RNU1-32P","canonical_id":"hgnc:HGNC:48374","description":"RNA, U1 small nuclear 32, pseudogene","metadata":null},{"id":"4afc25e5c07241eea6cd1d3bbec53afb","type":"GENE","name":"RNU1-33P","canonical_id":"hgnc:HGNC:48375","description":"RNA, U1 small nuclear 33, pseudogene","metadata":null},{"id":"85edac9f4c424f9bac7ca927bf522d7f","type":"GENE","name":"RNU1-34P","canonical_id":"hgnc:HGNC:48376","description":"RNA, U1 small nuclear 34, pseudogene","metadata":null},{"id":"12f0f71fe2574133aaa3656cd2c536d5","type":"GENE","name":"RNU1-35P","canonical_id":"hgnc:HGNC:48377","description":"RNA, U1 small nuclear 35, pseudogene","metadata":null},{"id":"32861b588a3e435f9e6fb8ae6aac6530","type":"GENE","name":"RNU1-36P","canonical_id":"hgnc:HGNC:48378","description":"RNA, U1 small nuclear 36, pseudogene","metadata":null},{"id":"3345848e5bd044e792439d564847a35b","type":"GENE","name":"RNU1-38P","canonical_id":"hgnc:HGNC:48380","description":"RNA, U1 small nuclear 38, pseudogene","metadata":null},{"id":"f93b6014e80649af8290d2a4443c4c8c","type":"GENE","name":"RNU1-39P","canonical_id":"hgnc:HGNC:48381","description":"RNA, U1 small nuclear 39, pseudogene","metadata":null},{"id":"800aa2ba2b3e4a96a69ca1495cac67bd","type":"GENE","name":"RNU1-4","canonical_id":"hgnc:HGNC:10128","description":"RNA, U1 small nuclear 4","metadata":{"aliases":["HSD6","U1E2","HSD2","U1D2","HSD5","U1B2","U1F","HSD7","RNU1E2","RNU1G2","RNU1D2","RNU1F1","RNU1G1"]}},{"id":"9be5549a6bcd4010813c06a62bc59268","type":"GENE","name":"RNU1-40P","canonical_id":"hgnc:HGNC:48382","description":"RNA, U1 small nuclear 40, pseudogene","metadata":null},{"id":"6270a755aa1a40b3b3a7f16bb28e5101","type":"GENE","name":"RNU1-41P","canonical_id":"hgnc:HGNC:48383","description":"RNA, U1 small nuclear 41, pseudogene","metadata":null},{"id":"bcb903716e6d48c78acacb42ed1ee453","type":"GENE","name":"RNU1-42P","canonical_id":"hgnc:HGNC:48384","description":"RNA, U1 small nuclear 42, pseudogene","metadata":null},{"id":"7b7246df08354873bf508e80c024812f","type":"GENE","name":"RNU1-43P","canonical_id":"hgnc:HGNC:48385","description":"RNA, U1 small nuclear 43, pseudogene","metadata":null},{"id":"d295ec4b0d8f4038bf78dd6be21ea0f8","type":"GENE","name":"RNU1-44P","canonical_id":"hgnc:HGNC:48386","description":"RNA, U1 small nuclear 44, pseudogene","metadata":null},{"id":"7f780e1e65b24a8588d6bba08983ce5f","type":"GENE","name":"RNU1-45P","canonical_id":"hgnc:HGNC:48387","description":"RNA, U1 small nuclear 45, pseudogene","metadata":null},{"id":"9177859de46f4c9e81b5688be29a4ca7","type":"GENE","name":"RNU1-46P","canonical_id":"hgnc:HGNC:48388","description":"RNA, U1 small nuclear 46, pseudogene","metadata":null},{"id":"5aae5bdf9abb48f49f10fad1c0d9c9bd","type":"GENE","name":"RNU1-47P","canonical_id":"hgnc:HGNC:48389","description":"RNA, U1 small nuclear 47, pseudogene","metadata":null},{"id":"e326d355721a401985898e99051d8d66","type":"GENE","name":"RNU1-48P","canonical_id":"hgnc:HGNC:48390","description":"RNA, U1 small nuclear 48, pseudogene","metadata":null},{"id":"2f1163bffb724ea8b866ed1afbd47450","type":"GENE","name":"RNU1-49P","canonical_id":"hgnc:HGNC:48391","description":"RNA, U1 small nuclear 49, pseudogene","metadata":null},{"id":"a694f9c755cb4c7c9a9f558998e50f87","type":"GENE","name":"RNU1-51P","canonical_id":"hgnc:HGNC:48393","description":"RNA, U1 small nuclear 51, pseudogene","metadata":null},{"id":"97a529f9f9b94c038d3c456c0695425f","type":"GENE","name":"RNU1-52P","canonical_id":"hgnc:HGNC:48394","description":"RNA, U1 small nuclear 52, pseudogene","metadata":null},{"id":"2fb79a7ade2842ceb1320fd8104fed14","type":"GENE","name":"RNU1-54P","canonical_id":"hgnc:HGNC:48396","description":"RNA, U1 small nuclear 54, pseudogene","metadata":null},{"id":"ee0aae0099454cebbda4383c6b4980c8","type":"GENE","name":"RNU1-55P","canonical_id":"hgnc:HGNC:48397","description":"RNA, U1 small nuclear 55, pseudogene","metadata":null},{"id":"64964a96d329471baaf1f39746cf20f0","type":"GENE","name":"RNU1-56P","canonical_id":"hgnc:HGNC:48398","description":"RNA, U1 small nuclear 56, pseudogene","metadata":null},{"id":"420d309788dc4c2eae0e71aa0c7ef501","type":"GENE","name":"RNU1-57P","canonical_id":"hgnc:HGNC:48399","description":"RNA, U1 small nuclear 57, pseudogene","metadata":null},{"id":"baee342f742c4028b441a651c96eb966","type":"GENE","name":"RNU1-58P","canonical_id":"hgnc:HGNC:48400","description":"RNA, U1 small nuclear 58, pseudogene","metadata":null},{"id":"90a4753e528341cd81bbf1896351dc10","type":"GENE","name":"RNU1-5P","canonical_id":"hgnc:HGNC:48304","description":"RNA, U1 small nuclear 5, pseudogene","metadata":{"aliases":["RNU1-5"]}},{"id":"79aecd42cd684355a27015f5618889a9","type":"GENE","name":"RNU1-61P","canonical_id":"hgnc:HGNC:48403","description":"RNA, U1 small nuclear 61, pseudogene","metadata":null},{"id":"b1d4b1aa067f4e6f9faf33ee1ae6e57f","type":"GENE","name":"RNU1-62P","canonical_id":"hgnc:HGNC:48404","description":"RNA, U1 small nuclear 62, pseudogene","metadata":null},{"id":"c523c502ae334a9489123b40ad1dc06d","type":"GENE","name":"RNU1-63P","canonical_id":"hgnc:HGNC:48405","description":"RNA, U1 small nuclear 63, pseudogene","metadata":null},{"id":"a2b34e4cd9ca41ee9ddefe75f2a40207","type":"GENE","name":"RNU1-64P","canonical_id":"hgnc:HGNC:48406","description":"RNA, U1 small nuclear 64, pseudogene","metadata":null},{"id":"6cdb190d744947fdb01202fea57f52c2","type":"GENE","name":"RNU1-65P","canonical_id":"hgnc:HGNC:48407","description":"RNA, U1 small nuclear 65, pseudogene","metadata":null},{"id":"505d5291a33940e69380df7c91548c09","type":"GENE","name":"RNU1-67P","canonical_id":"hgnc:HGNC:48409","description":"RNA, U1 small nuclear 67, pseudogene","metadata":null},{"id":"0b146e2617d94f8faa1ee44ad16da519","type":"GENE","name":"RNU1-68P","canonical_id":"hgnc:HGNC:48410","description":"RNA, U1 small nuclear 68, pseudogene","metadata":null},{"id":"4e5254b8db714a35900bd38d6bc3b6a5","type":"GENE","name":"RNU1-6P","canonical_id":"hgnc:HGNC:48305","description":"RNA, U1 small nuclear 6, pseudogene","metadata":{"aliases":["RNU1-6"]}},{"id":"89d93b5ce2ec40a293234243e5bbe772","type":"GENE","name":"RNU1-70P","canonical_id":"hgnc:HGNC:48412","description":"RNA, U1 small nuclear 70, pseudogene","metadata":null},{"id":"c394f6e59d3642bea571a4b46a0988bb","type":"GENE","name":"RNU1-72P","canonical_id":"hgnc:HGNC:48414","description":"RNA, U1 small nuclear 72, pseudogene","metadata":null},{"id":"4181e36b638943d5ab271997db635d85","type":"GENE","name":"RNU1-73P","canonical_id":"hgnc:HGNC:48415","description":"RNA, U1 small nuclear 73, pseudogene","metadata":null},{"id":"f987e1560ec249c0b6588550ab2105e7","type":"GENE","name":"RNU1-74P","canonical_id":"hgnc:HGNC:48416","description":"RNA, U1 small nuclear 74, pseudogene","metadata":null},{"id":"4e8230bbf529486db9fa4f7d4564215b","type":"GENE","name":"RNU1-75P","canonical_id":"hgnc:HGNC:48417","description":"RNA, U1 small nuclear 75, pseudogene","metadata":null},{"id":"1c2d107740b8428a90b8643a5d8415b6","type":"GENE","name":"RNU1-76P","canonical_id":"hgnc:HGNC:48418","description":"RNA, U1 small nuclear 76, pseudogene","metadata":null},{"id":"15e16a9f35fe4dde9f6ee8e646642dab","type":"GENE","name":"RNU1-77P","canonical_id":"hgnc:HGNC:48419","description":"RNA, U1 small nuclear 77, pseudogene","metadata":null},{"id":"479bcd009f9948a28e8b95952677f203","type":"GENE","name":"RNU1-78P","canonical_id":"hgnc:HGNC:48420","description":"RNA, U1 small nuclear 78, pseudogene","metadata":null},{"id":"f2c875a5ed1548898d35d2cc45b5fca7","type":"GENE","name":"RNU1-79P","canonical_id":"hgnc:HGNC:48421","description":"RNA, U1 small nuclear 79, pseudogene","metadata":null},{"id":"2f84816619f54a3db2c3b02c02c903ad","type":"GENE","name":"RNU1-7P","canonical_id":"hgnc:HGNC:48306","description":"RNA, U1 small nuclear 7, pseudogene","metadata":{"aliases":["RNU1-7"]}},{"id":"cfa81bb7816540b5ac69ef146108a416","type":"GENE","name":"RNU1-80P","canonical_id":"hgnc:HGNC:48422","description":"RNA, U1 small nuclear 80, pseudogene","metadata":null},{"id":"d88fd015ea1d4d98929c2080957c177b","type":"GENE","name":"RNU1-82P","canonical_id":"hgnc:HGNC:48424","description":"RNA, U1 small nuclear 82, pseudogene","metadata":null},{"id":"ce5152d8ba7e4d63a72eee5aaddffd78","type":"GENE","name":"RNU1-83P","canonical_id":"hgnc:HGNC:48425","description":"RNA, U1 small nuclear 83, pseudogene","metadata":null},{"id":"ea62757153624473ac14070e660d0ac9","type":"GENE","name":"RNU1-84P","canonical_id":"hgnc:HGNC:48426","description":"RNA, U1 small nuclear 84, pseudogene","metadata":null},{"id":"b14a7888a55d4457968a9b85b03bb73a","type":"GENE","name":"RNU1-86P","canonical_id":"hgnc:HGNC:48428","description":"RNA, U1 small nuclear 86, pseudogene","metadata":null},{"id":"4dc13ea279494c92be817982eb200fee","type":"GENE","name":"RNU1-88P","canonical_id":"hgnc:HGNC:48430","description":"RNA, U1 small nuclear 88, pseudogene","metadata":null},{"id":"2e94459f6f0642f5a21adf9e911772ee","type":"GENE","name":"RNU1-89P","canonical_id":"hgnc:HGNC:48431","description":"RNA, U1 small nuclear 89, pseudogene","metadata":null},{"id":"458a6de29c1e404babf1aec6a4fcc6df","type":"GENE","name":"RNU1-8P","canonical_id":"hgnc:HGNC:48307","description":"RNA, U1 small nuclear 8, pseudogene","metadata":{"aliases":["RNU1-8"]}},{"id":"e6fd128191514b2ca22ff5ca932bd925","type":"GENE","name":"RNU1-91P","canonical_id":"hgnc:HGNC:48433","description":"RNA, U1 small nuclear 91, pseudogene","metadata":null},{"id":"5eb38f7af8e74c258a598ac19010082e","type":"GENE","name":"RNU1-93P","canonical_id":"hgnc:HGNC:48435","description":"RNA, U1 small nuclear 93, pseudogene","metadata":null},{"id":"52375013505e4a0d8ff633d775c14018","type":"GENE","name":"RNU1-94P","canonical_id":"hgnc:HGNC:48436","description":"RNA, U1 small nuclear 94, pseudogene","metadata":null},{"id":"b436362c08824686a27c75cf38f5d88b","type":"GENE","name":"RNU1-95P","canonical_id":"hgnc:HGNC:48437","description":"RNA, U1 small nuclear 95, pseudogene","metadata":null},{"id":"8f02967264464d938090684b4bcc3f21","type":"GENE","name":"RNU1-96P","canonical_id":"hgnc:HGNC:48438","description":"RNA, U1 small nuclear 96, pseudogene","metadata":null},{"id":"8bd6d32ef28441a49e2f35b80f7e9a5d","type":"GENE","name":"RNU1-97P","canonical_id":"hgnc:HGNC:48439","description":"RNA, U1 small nuclear 97, pseudogene","metadata":null},{"id":"dc9bfa00912b4d6cb5453ea6628e92ce","type":"GENE","name":"RNU1-98P","canonical_id":"hgnc:HGNC:48440","description":"RNA, U1 small nuclear 98, pseudogene","metadata":null},{"id":"6e35e7935bc4482ba06fdf8421c9295a","type":"GENE","name":"RNU105B","canonical_id":"hgnc:HGNC:10103","description":"RNA, U105B small nucleolar","metadata":{"aliases":["E1-2"]}},{"id":"53f709f10287474eb2b97d618c76d75f","type":"GENE","name":"RNU105C","canonical_id":"hgnc:HGNC:10104","description":"RNA, U105C small nucleolar","metadata":{"aliases":["E1-5","E1-6","U105C"]}},{"id":"1bb1e84a8dd14819a6e13e501a18efa9","type":"GENE","name":"RNU11","canonical_id":"hgnc:HGNC:10108","description":"RNA, U11 small nuclear","metadata":{"aliases":["U11","RNU11-1"]}},{"id":"3872e6778f774abfa65a0336d93b6408","type":"GENE","name":"RNU11-2P","canonical_id":"hgnc:HGNC:46942","description":"RNA, U11 small nuclear 2, pseudogene","metadata":null},{"id":"aafcbdb0228b44c583d011cfd59089a5","type":"GENE","name":"RNU11-3P","canonical_id":"hgnc:HGNC:46943","description":"RNA, U11 small nuclear 3, pseudogene","metadata":null},{"id":"5f0d1c3f319141b6b9dec43a0c523f6b","type":"GENE","name":"RNU11-4P","canonical_id":"hgnc:HGNC:46944","description":"RNA, U11 small nuclear 4, pseudogene","metadata":null},{"id":"09cda4a28a0f47fea95eecbdca1f460a","type":"GENE","name":"RNU11-5P","canonical_id":"hgnc:HGNC:46945","description":"RNA, U11 small nuclear 5, pseudogene","metadata":null},{"id":"2fe48a5cf4e34fe888ed1d4e64b2ca77","type":"GENE","name":"RNU11-6P","canonical_id":"hgnc:HGNC:46946","description":"RNA, U11 small nuclear 6, pseudogene","metadata":null},{"id":"f2867d9aab324c2f9b62a63dcd271994","type":"GENE","name":"RNU12","canonical_id":"hgnc:HGNC:19380","description":"RNA, U12 small nuclear","metadata":{"aliases":["RNU12-1","RNU12P"]}},{"id":"5ab2e01432d34c7bb18f75641daa560d","type":"GENE","name":"RNU12-2P","canonical_id":"hgnc:HGNC:10109","description":"RNA, U12 small nuclear 2, pseudogene","metadata":{"aliases":["U12","RNU12","RNU12P"]}},{"id":"802fc82c73d54624827773a0b0d4c580","type":"GENE","name":"RNU2-1","canonical_id":"hgnc:HGNC:10142","description":"RNA, U2 small nuclear 1","metadata":{"aliases":["U2"]}},{"id":"425ca576328a48a88a9b5fe134f9842f","type":"GENE","name":"RNU2-10P","canonical_id":"hgnc:HGNC:48503","description":"RNA, U2 small nuclear 10, pseudogene","metadata":null},{"id":"2eac272d107b40778bc510d049235510","type":"GENE","name":"RNU2-11P","canonical_id":"hgnc:HGNC:48504","description":"RNA, U2 small nuclear 11, pseudogene","metadata":null},{"id":"86373bfc142a4927918bfc6d8c9937bc","type":"GENE","name":"RNU2-12P","canonical_id":"hgnc:HGNC:48505","description":"RNA, U2 small nuclear 12, pseudogene","metadata":null},{"id":"cf97dd55b6ef4211a45022af4fe9d441","type":"GENE","name":"RNU2-13P","canonical_id":"hgnc:HGNC:48506","description":"RNA, U2 small nuclear 13, pseudogene","metadata":null},{"id":"9810de33eb1743eda54cc7dc7e5fc0f9","type":"GENE","name":"RNU2-14P","canonical_id":"hgnc:HGNC:48507","description":"RNA, U2 small nuclear 14, pseudogene","metadata":null},{"id":"49c00a8f77a8453db3456a36482ab09d","type":"GENE","name":"RNU2-15P","canonical_id":"hgnc:HGNC:48508","description":"RNA, U2 small nuclear 15, pseudogene","metadata":null},{"id":"8c394032ac5d426b90b2d81ad5923bad","type":"GENE","name":"RNU2-16P","canonical_id":"hgnc:HGNC:48509","description":"RNA, U2 small nuclear 16, pseudogene","metadata":null},{"id":"e97b6cf31ecd43d79c57df03ad311b2f","type":"GENE","name":"RNU2-17P","canonical_id":"hgnc:HGNC:48510","description":"RNA, U2 small nuclear 17, pseudogene","metadata":null},{"id":"8c186dd0939d410f9520c3d760ad321c","type":"GENE","name":"RNU2-18P","canonical_id":"hgnc:HGNC:48511","description":"RNA, U2 small nuclear 18, pseudogene","metadata":null},{"id":"97ad0a617f2d492484d09278439a55ff","type":"GENE","name":"RNU2-19P","canonical_id":"hgnc:HGNC:48512","description":"RNA, U2 small nuclear 19, pseudogene","metadata":null},{"id":"82884ab9166e47eaaa16f13b98e7c6cc","type":"GENE","name":"RNU2-2","canonical_id":"hgnc:HGNC:10152","description":"RNA, U2 small nuclear 2","metadata":{"aliases":["U2","RNU2B","RNU2-2P"]}},{"id":"ea242da0ff6d4fdba9e6f4b643847d75","type":"GENE","name":"RNU2-20P","canonical_id":"hgnc:HGNC:48513","description":"RNA, U2 small nuclear 20, pseudogene","metadata":null},{"id":"22bc449d3bf3448fbfce4b50ada28bf9","type":"GENE","name":"RNU2-21P","canonical_id":"hgnc:HGNC:48514","description":"RNA, U2 small nuclear 21, pseudogene","metadata":null},{"id":"c93c48eb15dc403884d864a0010bdf4b","type":"GENE","name":"RNU2-22P","canonical_id":"hgnc:HGNC:48515","description":"RNA, U2 small nuclear 22, pseudogene","metadata":null},{"id":"650d5485335341d8905a5ff60935ba0c","type":"GENE","name":"RNU2-23P","canonical_id":"hgnc:HGNC:48516","description":"RNA, U2 small nuclear 23, pseudogene","metadata":null},{"id":"938ef2faa0d54b66b5dc23ee089a7247","type":"GENE","name":"RNU2-24P","canonical_id":"hgnc:HGNC:48517","description":"RNA, U2 small nuclear 24, pseudogene","metadata":null},{"id":"01822743cf93406e9e671813257c693c","type":"GENE","name":"RNU2-25P","canonical_id":"hgnc:HGNC:48518","description":"RNA, U2 small nuclear 25, pseudogene","metadata":null},{"id":"b7110feb1ec64ba48e15f434c67c3e92","type":"GENE","name":"RNU2-26P","canonical_id":"hgnc:HGNC:48519","description":"RNA, U2 small nuclear 26, pseudogene","metadata":null},{"id":"14ad3fc7e57c4f0bafb81ca1ebe3089a","type":"GENE","name":"RNU2-27P","canonical_id":"hgnc:HGNC:48520","description":"RNA, U2 small nuclear 27, pseudogene","metadata":null},{"id":"de6ddfcab3574b3daa3c5cc5d48a3d9f","type":"GENE","name":"RNU2-28P","canonical_id":"hgnc:HGNC:48521","description":"RNA, U2 small nuclear 28, pseudogene","metadata":null},{"id":"98f016a39e7a471f979c9251e62e3bf6","type":"GENE","name":"RNU2-29P","canonical_id":"hgnc:HGNC:48522","description":"RNA, U2 small nuclear 29, pseudogene","metadata":null},{"id":"d66b859297914f11921ebc816b6bbb97","type":"GENE","name":"RNU2-30P","canonical_id":"hgnc:HGNC:48523","description":"RNA, U2 small nuclear 30, pseudogene","metadata":null},{"id":"74b082c2a6b84ac1a34db377ca5d8fee","type":"GENE","name":"RNU2-31P","canonical_id":"hgnc:HGNC:48524","description":"RNA, U2 small nuclear 31, pseudogene","metadata":null},{"id":"97a9b959aece485fb7e847bc2cd7b159","type":"GENE","name":"RNU2-32P","canonical_id":"hgnc:HGNC:48525","description":"RNA, U2 small nuclear 32, pseudogene","metadata":null},{"id":"46bb1ace542f4823a91cfdbb239fd290","type":"GENE","name":"RNU2-33P","canonical_id":"hgnc:HGNC:48526","description":"RNA, U2 small nuclear 33, pseudogene","metadata":null},{"id":"66daf6687d9b45d2b8f05d4b0fc3858b","type":"GENE","name":"RNU2-34P","canonical_id":"hgnc:HGNC:48527","description":"RNA, U2 small nuclear 34, pseudogene","metadata":null},{"id":"39e29dec984848dcb1bdd72f923baf13","type":"GENE","name":"RNU2-35P","canonical_id":"hgnc:HGNC:48528","description":"RNA, U2 small nuclear 35, pseudogene","metadata":null},{"id":"815cd31076c14869b102f9db2ef91058","type":"GENE","name":"RNU2-36P","canonical_id":"hgnc:HGNC:48529","description":"RNA, U2 small nuclear 36, pseudogene","metadata":null},{"id":"1d1d43333be8462f8c935214e09e9a30","type":"GENE","name":"RNU2-37P","canonical_id":"hgnc:HGNC:48530","description":"RNA, U2 small nuclear 37, pseudogene","metadata":null},{"id":"ae4cef84453b415da461c53cacfa09cd","type":"GENE","name":"RNU2-38P","canonical_id":"hgnc:HGNC:48531","description":"RNA, U2 small nuclear 38, pseudogene","metadata":null},{"id":"4b9b2575b2ec4fa38dac60a5ad1e8994","type":"GENE","name":"RNU2-39P","canonical_id":"hgnc:HGNC:48532","description":"RNA, U2 small nuclear 39, pseudogene","metadata":null},{"id":"7b409162bdad4514a4e66b0ce71c722b","type":"GENE","name":"RNU2-3P","canonical_id":"hgnc:HGNC:10153","description":"RNA, U2 small nuclear 3, pseudogene","metadata":{"aliases":["U2","RNU2P1"]}},{"id":"a1443125d44a46ba96aa93726317c1c9","type":"GENE","name":"RNU2-40P","canonical_id":"hgnc:HGNC:48533","description":"RNA, U2 small nuclear 40, pseudogene","metadata":null},{"id":"d5a6f6efb39e4599a33aef5ce9cbcafe","type":"GENE","name":"RNU2-41P","canonical_id":"hgnc:HGNC:48534","description":"RNA, U2 small nuclear 41, pseudogene","metadata":null},{"id":"9f62eefda7d3499b82dacf8418e9edc5","type":"GENE","name":"RNU2-42P","canonical_id":"hgnc:HGNC:48535","description":"RNA, U2 small nuclear 42, pseudogene","metadata":null},{"id":"68c01bfd2fad40d38e19a5890c21bfd1","type":"GENE","name":"RNU2-43P","canonical_id":"hgnc:HGNC:48536","description":"RNA, U2 small nuclear 43, pseudogene","metadata":null},{"id":"1a109bfd656940228914e4bf40f87e15","type":"GENE","name":"RNU2-44P","canonical_id":"hgnc:HGNC:48537","description":"RNA, U2 small nuclear 44, pseudogene","metadata":null},{"id":"b4f20c83a803429aa0322d3386b21be0","type":"GENE","name":"RNU2-45P","canonical_id":"hgnc:HGNC:48538","description":"RNA, U2 small nuclear 45, pseudogene","metadata":null},{"id":"7cb548b501454e9d8849e10a0b6b067b","type":"GENE","name":"RNU2-46P","canonical_id":"hgnc:HGNC:48539","description":"RNA, U2 small nuclear 46, pseudogene","metadata":null},{"id":"4bfc27fd267b4816ba27197763bbe748","type":"GENE","name":"RNU2-47P","canonical_id":"hgnc:HGNC:48540","description":"RNA, U2 small nuclear 47, pseudogene","metadata":null},{"id":"8179c12b8e1b435b8ecd01b5318ca9ad","type":"GENE","name":"RNU2-48P","canonical_id":"hgnc:HGNC:48541","description":"RNA, U2 small nuclear 48, pseudogene","metadata":null},{"id":"96be939940c34972a8ed5f1c047200a8","type":"GENE","name":"RNU2-49P","canonical_id":"hgnc:HGNC:48542","description":"RNA, U2 small nuclear 49, pseudogene","metadata":null},{"id":"bbfb494c93a84993be0c82ceae543b47","type":"GENE","name":"RNU2-4P","canonical_id":"hgnc:HGNC:10154","description":"RNA, U2 small nuclear 4, pseudogene","metadata":{"aliases":["U2","U2/7","RNU2P2"]}},{"id":"aa44a59f1d0348ea96e00997f17bbf93","type":"GENE","name":"RNU2-50P","canonical_id":"hgnc:HGNC:48543","description":"RNA, U2 small nuclear 50, pseudogene","metadata":null},{"id":"e195d9c13f7e46d4889d1e89b548562e","type":"GENE","name":"RNU2-51P","canonical_id":"hgnc:HGNC:48544","description":"RNA, U2 small nuclear 51, pseudogene","metadata":null},{"id":"2b6126f762c8460fab296a9d88f33598","type":"GENE","name":"RNU2-52P","canonical_id":"hgnc:HGNC:48545","description":"RNA, U2 small nuclear 52, pseudogene","metadata":null},{"id":"faef53e9f1dc4680bdcb26cbe1e5882a","type":"GENE","name":"RNU2-53P","canonical_id":"hgnc:HGNC:48546","description":"RNA, U2 small nuclear 53, pseudogene","metadata":null},{"id":"e92fedd1c0fa4ee8aa9de397eb11ee7c","type":"GENE","name":"RNU2-54P","canonical_id":"hgnc:HGNC:48547","description":"RNA, U2 small nuclear 54, pseudogene","metadata":null},{"id":"b43fd666305648e8b29ed186c55a99b9","type":"GENE","name":"RNU2-55P","canonical_id":"hgnc:HGNC:48548","description":"RNA, U2 small nuclear 55, pseudogene","metadata":null},{"id":"2bd1abd3c7bd4af38b53d390363ac842","type":"GENE","name":"RNU2-56P","canonical_id":"hgnc:HGNC:48549","description":"RNA, U2 small nuclear 56, pseudogene","metadata":null},{"id":"272ff29a70b0445f9d6803b60bb99db9","type":"GENE","name":"RNU2-57P","canonical_id":"hgnc:HGNC:48550","description":"RNA, U2 small nuclear 57, pseudogene","metadata":null},{"id":"30d4fb2f6e4642c49d6b802f1bbded4d","type":"GENE","name":"RNU2-58P","canonical_id":"hgnc:HGNC:48551","description":"RNA, U2 small nuclear 58, pseudogene","metadata":null},{"id":"d353de4923c44c6fbf814ff4b0f02222","type":"GENE","name":"RNU2-59P","canonical_id":"hgnc:HGNC:48552","description":"RNA, U2 small nuclear 59, pseudogene","metadata":null},{"id":"948b363a45bb41718df8dbcb33c95d98","type":"GENE","name":"RNU2-5P","canonical_id":"hgnc:HGNC:10155","description":"RNA, U2 small nuclear 5, pseudogene","metadata":{"aliases":["U2","u2.7","RNU2P3"]}},{"id":"32b19f0f6d68424c8026a5d314f5901f","type":"GENE","name":"RNU2-60P","canonical_id":"hgnc:HGNC:48553","description":"RNA, U2 small nuclear 60, pseudogene","metadata":null},{"id":"829e62b95880404da57e6ebe9e0f7d8f","type":"GENE","name":"RNU2-61P","canonical_id":"hgnc:HGNC:48554","description":"RNA, U2 small nuclear 61, pseudogene","metadata":null},{"id":"54f63afdc3e54b15830248f3558bac57","type":"GENE","name":"RNU2-62P","canonical_id":"hgnc:HGNC:48555","description":"RNA, U2 small nuclear 62, pseudogene","metadata":null},{"id":"bd003debb8284d0289db78797fceb7e4","type":"GENE","name":"RNU2-63P","canonical_id":"hgnc:HGNC:48556","description":"RNA, U2 small nuclear 63, pseudogene","metadata":null},{"id":"155a40354f744affbb66d77fc0efd7a9","type":"GENE","name":"RNU2-64P","canonical_id":"hgnc:HGNC:48557","description":"RNA, U2 small nuclear 64, pseudogene","metadata":null},{"id":"baa1f47d021f4624ad1e81fc639e449f","type":"GENE","name":"RNU2-65P","canonical_id":"hgnc:HGNC:48558","description":"RNA, U2 small nuclear 65, pseudogene","metadata":null},{"id":"5fefd42e3a5349dfa212dc1404f785a5","type":"GENE","name":"RNU2-66P","canonical_id":"hgnc:HGNC:48559","description":"RNA, U2 small nuclear 66, pseudogene","metadata":null},{"id":"ff3c125a59c44155b12bc2ee1ae399bf","type":"GENE","name":"RNU2-68P","canonical_id":"hgnc:HGNC:48561","description":"RNA, U2 small nuclear 68, pseudogene","metadata":null},{"id":"3f239bf1705b4bd792ab558cc309f82b","type":"GENE","name":"RNU2-69P","canonical_id":"hgnc:HGNC:48562","description":"RNA, U2 small nuclear 69, pseudogene","metadata":null},{"id":"9bd8e4371de2491d9f1b200a82adb105","type":"GENE","name":"RNU2-6P","canonical_id":"hgnc:HGNC:42506","description":"RNA, U2 small nuclear 6, pseudogene","metadata":null},{"id":"e8c972b051bb489ab414f332fa78d3fb","type":"GENE","name":"RNU2-70P","canonical_id":"hgnc:HGNC:48563","description":"RNA, U2 small nuclear 70, pseudogene","metadata":null},{"id":"4da61f3007154c578a8854c441256c41","type":"GENE","name":"RNU2-71P","canonical_id":"hgnc:HGNC:48564","description":"RNA, U2 small nuclear 71, pseudogene","metadata":null},{"id":"74bcf1dd3d7b4da98277d214d8eec266","type":"GENE","name":"RNU2-72P","canonical_id":"hgnc:HGNC:48565","description":"RNA, U2 small nuclear 72, pseudogene","metadata":null},{"id":"b5c62f90d5974870ac2fd651f173c1e0","type":"GENE","name":"RNU2-7P","canonical_id":"hgnc:HGNC:42505","description":"RNA, U2 small nuclear 7, pseudogene","metadata":null},{"id":"c15fdee637c346f8ad60412c9ba312d0","type":"GENE","name":"RNU2-8P","canonical_id":"hgnc:HGNC:48501","description":"RNA, U2 small nuclear 8, pseudogene","metadata":null},{"id":"0b1ef61efea943048b4ee257c31ab8a1","type":"GENE","name":"RNU2-9P","canonical_id":"hgnc:HGNC:48502","description":"RNA, U2 small nuclear 9, pseudogene","metadata":null},{"id":"571d7bc6c728450b9a2161d11bd2ff26","type":"GENE","name":"RNU4-1","canonical_id":"hgnc:HGNC:10192","description":"RNA, U4 small nuclear 1","metadata":{"aliases":["U4BL","U4","RNU4B2","RNU4A"]}},{"id":"56e3ce83750b4678b2cd92464bdfcd2c","type":"GENE","name":"RNU4-10P","canonical_id":"hgnc:HGNC:42508","description":"RNA, U4 small nuclear 10, pseudogene","metadata":null},{"id":"898b2ead4ffd44caa81eb39c6d1866e7","type":"GENE","name":"RNU4-11P","canonical_id":"hgnc:HGNC:46947","description":"RNA, U4 small nuclear 11, pseudogene","metadata":null},{"id":"f20b1f7bc2914989bb0f990ab1c4fc5e","type":"GENE","name":"RNU4-12P","canonical_id":"hgnc:HGNC:46948","description":"RNA, U4 small nuclear 12, pseudogene","metadata":null},{"id":"a96a9e055dd64628932859e0302cbfb1","type":"GENE","name":"RNU4-13P","canonical_id":"hgnc:HGNC:46949","description":"RNA, U4 small nuclear 13, pseudogene","metadata":null},{"id":"9cdeb5f41fff425f87f4815df1f6045f","type":"GENE","name":"RNU4-14P","canonical_id":"hgnc:HGNC:46950","description":"RNA, U4 small nuclear 14, pseudogene","metadata":null},{"id":"aa32ba16014d4377bb418b290c9cacb2","type":"GENE","name":"RNU4-15P","canonical_id":"hgnc:HGNC:46951","description":"RNA, U4 small nuclear 15, pseudogene","metadata":null},{"id":"b2c114b44a61472182ad1e13b664a8e4","type":"GENE","name":"RNU4-16P","canonical_id":"hgnc:HGNC:46952","description":"RNA, U4 small nuclear 16, pseudogene","metadata":null},{"id":"94465015ec49411bb27cff422c4b2ed9","type":"GENE","name":"RNU4-17P","canonical_id":"hgnc:HGNC:46953","description":"RNA, U4 small nuclear 17, pseudogene","metadata":null},{"id":"bb5b36118578471493eba308750fa7a0","type":"GENE","name":"RNU4-18P","canonical_id":"hgnc:HGNC:46954","description":"RNA, U4 small nuclear 18, pseudogene","metadata":null},{"id":"b664968c312942f18e5f617917ac22d6","type":"GENE","name":"RNU4-2","canonical_id":"hgnc:HGNC:10193","description":"RNA, U4 small nuclear 2","metadata":{"aliases":["U4c","U4b","U4A","RNU4C","RNU4-1B","RNU4B1"]}},{"id":"e58629aba4df45ca8e9dabee0445b144","type":"GENE","name":"RNU4-20P","canonical_id":"hgnc:HGNC:46956","description":"RNA, U4 small nuclear 20, pseudogene","metadata":null},{"id":"deacbf0f089647619a07a70a95fb7b7a","type":"GENE","name":"RNU4-21P","canonical_id":"hgnc:HGNC:46957","description":"RNA, U4 small nuclear 21, pseudogene","metadata":null},{"id":"307d9aaafb0d4c8ba9e2cafeed187a22","type":"GENE","name":"RNU4-22P","canonical_id":"hgnc:HGNC:46958","description":"RNA, U4 small nuclear 22, pseudogene","metadata":null},{"id":"03d452e0b23a4c5f88ad726cd4128efd","type":"GENE","name":"RNU4-23P","canonical_id":"hgnc:HGNC:46959","description":"RNA, U4 small nuclear 23, pseudogene","metadata":null},{"id":"5e6c18997d1b46aaa4efcdde9e21e82b","type":"GENE","name":"RNU4-24P","canonical_id":"hgnc:HGNC:46960","description":"RNA, U4 small nuclear 24, pseudogene","metadata":null},{"id":"494ca30ca1dd420b89bc7ceb074598f0","type":"GENE","name":"RNU4-25P","canonical_id":"hgnc:HGNC:46961","description":"RNA, U4 small nuclear 25, pseudogene","metadata":null},{"id":"2d2923612a3d465fb7ada91f79d8883f","type":"GENE","name":"RNU4-26P","canonical_id":"hgnc:HGNC:46962","description":"RNA, U4 small nuclear 26, pseudogene","metadata":null},{"id":"93cd4e00dc4e4e799c32c7bcb6bfd6d4","type":"GENE","name":"RNU4-27P","canonical_id":"hgnc:HGNC:46963","description":"RNA, U4 small nuclear 27, pseudogene","metadata":null},{"id":"0f874205e1ee4c2ab89a43258c183a69","type":"GENE","name":"RNU4-28P","canonical_id":"hgnc:HGNC:46964","description":"RNA, U4 small nuclear 28, pseudogene","metadata":null},{"id":"1f9b009dd4e44ff2b27f6e74692416f1","type":"GENE","name":"RNU4-29P","canonical_id":"hgnc:HGNC:46965","description":"RNA, U4 small nuclear 29, pseudogene","metadata":null},{"id":"0a4a6c704aeb4cd6b02e54e1e4477999","type":"GENE","name":"RNU4-30P","canonical_id":"hgnc:HGNC:46966","description":"RNA, U4 small nuclear 30, pseudogene","metadata":null},{"id":"7d89f9e9002b45cbbba144f609df7ac6","type":"GENE","name":"RNU4-31P","canonical_id":"hgnc:HGNC:46967","description":"RNA, U4 small nuclear 31, pseudogene","metadata":null},{"id":"81d6805141c54002913a9af42a876ea2","type":"GENE","name":"RNU4-32P","canonical_id":"hgnc:HGNC:46968","description":"RNA, U4 small nuclear 32, pseudogene","metadata":null},{"id":"438e49ddd2a84a3b817aa661243b723d","type":"GENE","name":"RNU4-33P","canonical_id":"hgnc:HGNC:46969","description":"RNA, U4 small nuclear 33, pseudogene","metadata":null},{"id":"09870db1705341c0843502c6b63c2715","type":"GENE","name":"RNU4-34P","canonical_id":"hgnc:HGNC:46970","description":"RNA, U4 small nuclear 34, pseudogene","metadata":null},{"id":"8c0e529d5e7f4dbe9ff52a6e0ef84363","type":"GENE","name":"RNU4-35P","canonical_id":"hgnc:HGNC:46971","description":"RNA, U4 small nuclear 35, pseudogene","metadata":null},{"id":"bb48913ee9384deca3348636d4759eff","type":"GENE","name":"RNU4-36P","canonical_id":"hgnc:HGNC:46972","description":"RNA, U4 small nuclear 36, pseudogene","metadata":null},{"id":"2ee2152306c3478d9eaab9f4f68e321f","type":"GENE","name":"RNU4-37P","canonical_id":"hgnc:HGNC:46973","description":"RNA, U4 small nuclear 37, pseudogene","metadata":null},{"id":"f0e28dd30634474a971893361ee7002d","type":"GENE","name":"RNU4-38P","canonical_id":"hgnc:HGNC:46974","description":"RNA, U4 small nuclear 38, pseudogene","metadata":null},{"id":"d3b781a9f7b3495ea0b8a14d8cc67ac3","type":"GENE","name":"RNU4-39P","canonical_id":"hgnc:HGNC:46975","description":"RNA, U4 small nuclear 39, pseudogene","metadata":null},{"id":"5fe4c8c8b62647d1abc1094dc7a8e41a","type":"GENE","name":"RNU4-3P","canonical_id":"hgnc:HGNC:10196","description":"RNA, U4 small nuclear 3, pseudogene","metadata":{"aliases":["U4","U4/4","RNU4P3"]}},{"id":"43da620287c1410c930a003422c84b4b","type":"GENE","name":"RNU4-40P","canonical_id":"hgnc:HGNC:46976","description":"RNA, U4 small nuclear 40, pseudogene","metadata":null},{"id":"22cffae79fb44a48a4a4ca9a0071317e","type":"GENE","name":"RNU4-41P","canonical_id":"hgnc:HGNC:46977","description":"RNA, U4 small nuclear 41, pseudogene","metadata":null},{"id":"9f099f2e012f4eb4bec9053476a0616f","type":"GENE","name":"RNU4-42P","canonical_id":"hgnc:HGNC:46978","description":"RNA, U4 small nuclear 42, pseudogene","metadata":null},{"id":"368eb8c93009439bb789d5f6e625a59b","type":"GENE","name":"RNU4-43P","canonical_id":"hgnc:HGNC:46979","description":"RNA, U4 small nuclear 43, pseudogene","metadata":null},{"id":"a8455b093d9948b1b785ef11a259618d","type":"GENE","name":"RNU4-44P","canonical_id":"hgnc:HGNC:46980","description":"RNA, U4 small nuclear 44, pseudogene","metadata":null},{"id":"4531c626e7734f869b8629ab64bec3e1","type":"GENE","name":"RNU4-45P","canonical_id":"hgnc:HGNC:46981","description":"RNA, U4 small nuclear 45, pseudogene","metadata":null},{"id":"8800f47d492d461bb27ba4681708f698","type":"GENE","name":"RNU4-46P","canonical_id":"hgnc:HGNC:46982","description":"RNA, U4 small nuclear 46, pseudogene","metadata":null},{"id":"f57c45267e4b432b8cc2d74557e0ef49","type":"GENE","name":"RNU4-47P","canonical_id":"hgnc:HGNC:46983","description":"RNA, U4 small nuclear 47, pseudogene","metadata":null},{"id":"831611260d7d49edb9f12ac18937d2f5","type":"GENE","name":"RNU4-48P","canonical_id":"hgnc:HGNC:46984","description":"RNA, U4 small nuclear 48, pseudogene","metadata":null},{"id":"a1fe12ab78b94d8ea5859ba40daff74d","type":"GENE","name":"RNU4-49P","canonical_id":"hgnc:HGNC:46985","description":"RNA, U4 small nuclear 49, pseudogene","metadata":null},{"id":"0bb52c0900a24a899b8d00788a0ed20b","type":"GENE","name":"RNU4-4P","canonical_id":"hgnc:HGNC:10197","description":"RNA, U4 small nuclear 4, pseudogene","metadata":{"aliases":["U4","U4/5","RNU4P4"]}},{"id":"77a54c753e5544f49be86055a7dbc884","type":"GENE","name":"RNU4-50P","canonical_id":"hgnc:HGNC:46986","description":"RNA, U4 small nuclear 50, pseudogene","metadata":null},{"id":"caf0111d611245c1ae48f47ad436d06d","type":"GENE","name":"RNU4-51P","canonical_id":"hgnc:HGNC:46987","description":"RNA, U4 small nuclear 51, pseudogene","metadata":null},{"id":"4fee2684091e4b86b8ace2e331974725","type":"GENE","name":"RNU4-52P","canonical_id":"hgnc:HGNC:46988","description":"RNA, U4 small nuclear 52, pseudogene","metadata":null},{"id":"5871a6c1e987441594e971325f6102d6","type":"GENE","name":"RNU4-53P","canonical_id":"hgnc:HGNC:46989","description":"RNA, U4 small nuclear 53, pseudogene","metadata":null},{"id":"51e2fd6fb0d04797aefde87c2242e84d","type":"GENE","name":"RNU4-54P","canonical_id":"hgnc:HGNC:46990","description":"RNA, U4 small nuclear 54, pseudogene","metadata":null},{"id":"e2528259dfe74652b60e47e53782f28c","type":"GENE","name":"RNU4-55P","canonical_id":"hgnc:HGNC:46991","description":"RNA, U4 small nuclear 55, pseudogene","metadata":null},{"id":"fead870ab4c2465ea9a03731bd6333a9","type":"GENE","name":"RNU4-56P","canonical_id":"hgnc:HGNC:46992","description":"RNA, U4 small nuclear 56, pseudogene","metadata":null},{"id":"7d31537a0d46401cad8db1a8ae290e9a","type":"GENE","name":"RNU4-57P","canonical_id":"hgnc:HGNC:46993","description":"RNA, U4 small nuclear 57, pseudogene","metadata":null},{"id":"19b85b06b0cd4a4a9a1a34ef1d87c593","type":"GENE","name":"RNU4-58P","canonical_id":"hgnc:HGNC:46994","description":"RNA, U4 small nuclear 58, pseudogene","metadata":null},{"id":"5c08dc2533d2413c993b56f825f2a4e2","type":"GENE","name":"RNU4-59P","canonical_id":"hgnc:HGNC:46995","description":"RNA, U4 small nuclear 59, pseudogene","metadata":null},{"id":"6ddfafa98c134968885e80482e62ee49","type":"GENE","name":"RNU4-5P","canonical_id":"hgnc:HGNC:10198","description":"RNA, U4 small nuclear 5, pseudogene","metadata":{"aliases":["U4","U4/6","RNU4P5"]}},{"id":"108d641d5ac44b27b2dbcee88b36c6e6","type":"GENE","name":"RNU4-60P","canonical_id":"hgnc:HGNC:46996","description":"RNA, U4 small nuclear 60, pseudogene","metadata":null},{"id":"12240ff71c874903ac45ab2557b9c47a","type":"GENE","name":"RNU4-61P","canonical_id":"hgnc:HGNC:46997","description":"RNA, U4 small nuclear 61, pseudogene","metadata":null},{"id":"99a9ca9a3b554948a53d339d1e215dca","type":"GENE","name":"RNU4-62P","canonical_id":"hgnc:HGNC:46998","description":"RNA, U4 small nuclear 62, pseudogene","metadata":null},{"id":"2d672fd8f8d747c8b7132e7d02b999fd","type":"GENE","name":"RNU4-63P","canonical_id":"hgnc:HGNC:46999","description":"RNA, U4 small nuclear 63, pseudogene","metadata":null},{"id":"88a4276734564f578ecadc27d898d457","type":"GENE","name":"RNU4-64P","canonical_id":"hgnc:HGNC:47000","description":"RNA, U4 small nuclear 64, pseudogene","metadata":null},{"id":"64fc373a37854820802a4fe5d4adf974","type":"GENE","name":"RNU4-65P","canonical_id":"hgnc:HGNC:47001","description":"RNA, U4 small nuclear 65, pseudogene","metadata":null},{"id":"b2828f5bdd0940e1ac9b333446b41ded","type":"GENE","name":"RNU4-66P","canonical_id":"hgnc:HGNC:47002","description":"RNA, U4 small nuclear 66, pseudogene","metadata":null},{"id":"1bbda0ad0831440e9b093faeb8387b07","type":"GENE","name":"RNU4-67P","canonical_id":"hgnc:HGNC:47003","description":"RNA, U4 small nuclear 67, pseudogene","metadata":null},{"id":"adc54bef0f914055b1e8f7b4cef973ed","type":"GENE","name":"RNU4-68P","canonical_id":"hgnc:HGNC:47004","description":"RNA, U4 small nuclear 68, pseudogene","metadata":null},{"id":"0aab862afa494296b8acad86cf653861","type":"GENE","name":"RNU4-69P","canonical_id":"hgnc:HGNC:47005","description":"RNA, U4 small nuclear 69, pseudogene","metadata":null},{"id":"65fa7aef5cce4927bf37f0f217719160","type":"GENE","name":"RNU4-6P","canonical_id":"hgnc:HGNC:10199","description":"RNA, U4 small nuclear 6, pseudogene","metadata":{"aliases":["U4","U4/8","RNU4P6"]}},{"id":"f8506c483a414f7cb5a4a560be7f904c","type":"GENE","name":"RNU4-70P","canonical_id":"hgnc:HGNC:47006","description":"RNA, U4 small nuclear 70, pseudogene","metadata":null},{"id":"4d640d4ec12e42e7b8b7d126c16c0bb0","type":"GENE","name":"RNU4-71P","canonical_id":"hgnc:HGNC:47007","description":"RNA, U4 small nuclear 71, pseudogene","metadata":null},{"id":"eb0240ed793042049a3388bd6769d72d","type":"GENE","name":"RNU4-72P","canonical_id":"hgnc:HGNC:47008","description":"RNA, U4 small nuclear 72, pseudogene","metadata":null},{"id":"44a003a42d724ae1b03e0358a9e92bf6","type":"GENE","name":"RNU4-73P","canonical_id":"hgnc:HGNC:47009","description":"RNA, U4 small nuclear 73, pseudogene","metadata":null},{"id":"c080b1fe43884c55a58529a117e9ee8e","type":"GENE","name":"RNU4-74P","canonical_id":"hgnc:HGNC:47010","description":"RNA, U4 small nuclear 74, pseudogene","metadata":null},{"id":"9feaf29894e54e0ca3322b411fb1b3e9","type":"GENE","name":"RNU4-75P","canonical_id":"hgnc:HGNC:47011","description":"RNA, U4 small nuclear 75, pseudogene","metadata":null},{"id":"4a6c5649ead442abb4672593222e5625","type":"GENE","name":"RNU4-76P","canonical_id":"hgnc:HGNC:47012","description":"RNA, U4 small nuclear 76, pseudogene","metadata":null},{"id":"a4fd25853ec442ff88f59d7f1380832e","type":"GENE","name":"RNU4-77P","canonical_id":"hgnc:HGNC:47013","description":"RNA, U4 small nuclear 77, pseudogene","metadata":null},{"id":"f7bfa6d81d9c44c5bffa140d9bbc2f6f","type":"GENE","name":"RNU4-78P","canonical_id":"hgnc:HGNC:47014","description":"RNA, U4 small nuclear 78, pseudogene","metadata":null},{"id":"d62bc7d2bbe34a63a58c706b8bd8d99c","type":"GENE","name":"RNU4-79P","canonical_id":"hgnc:HGNC:47015","description":"RNA, U4 small nuclear 79, pseudogene","metadata":null},{"id":"f320d3d6409a490f84d2aff5e5fe39cd","type":"GENE","name":"RNU4-7P","canonical_id":"hgnc:HGNC:10194","description":"RNA, U4 small nuclear 7, pseudogene","metadata":{"aliases":["U4","U4/7","RNU4P1"]}},{"id":"0b4f1f0c87e843e997ef7747204e3c2f","type":"GENE","name":"RNU4-80P","canonical_id":"hgnc:HGNC:47016","description":"RNA, U4 small nuclear 80, pseudogene","metadata":null},{"id":"cd4a22e40cec40479f72386f265e7e8b","type":"GENE","name":"RNU4-81P","canonical_id":"hgnc:HGNC:47017","description":"RNA, U4 small nuclear 81, pseudogene","metadata":null},{"id":"4a7ee0ee898d4f689ad7b6386193bbd9","type":"GENE","name":"RNU4-82P","canonical_id":"hgnc:HGNC:47018","description":"RNA, U4 small nuclear 82, pseudogene","metadata":null},{"id":"b62363428d2a44de8c55cdad4427ccda","type":"GENE","name":"RNU4-83P","canonical_id":"hgnc:HGNC:47019","description":"RNA, U4 small nuclear 83, pseudogene","metadata":null},{"id":"36b4867288a74b60a7bec3165578a029","type":"GENE","name":"RNU4-84P","canonical_id":"hgnc:HGNC:47020","description":"RNA, U4 small nuclear 84, pseudogene","metadata":null},{"id":"040c5aed1c244bb780d7198606aaceed","type":"GENE","name":"RNU4-85P","canonical_id":"hgnc:HGNC:47021","description":"RNA, U4 small nuclear 85, pseudogene","metadata":null},{"id":"d2fd232187d04fc18da44f9a1ea4d0bc","type":"GENE","name":"RNU4-86P","canonical_id":"hgnc:HGNC:47022","description":"RNA, U4 small nuclear 86, pseudogene","metadata":null},{"id":"3f9fb6e9fbb349fbb9c05742614e4802","type":"GENE","name":"RNU4-87P","canonical_id":"hgnc:HGNC:47023","description":"RNA, U4 small nuclear 87, pseudogene","metadata":null},{"id":"1eb78d8524f243519a5df1fd0fc877b8","type":"GENE","name":"RNU4-88P","canonical_id":"hgnc:HGNC:47024","description":"RNA, U4 small nuclear 88, pseudogene","metadata":null},{"id":"e9c09c1be67047ae9d80bc4582843875","type":"GENE","name":"RNU4-89P","canonical_id":"hgnc:HGNC:47025","description":"RNA, U4 small nuclear 89, pseudogene","metadata":null},{"id":"f4f22402f14f4a3ab8b833ba5f249c5f","type":"GENE","name":"RNU4-8P","canonical_id":"hgnc:HGNC:10195","description":"RNA, U4 small nuclear 8, pseudogene","metadata":{"aliases":["U4","U4/14","RNU4P2"]}},{"id":"154812179fb54daebef7320975140dfb","type":"GENE","name":"RNU4-90P","canonical_id":"hgnc:HGNC:47026","description":"RNA, U4 small nuclear 90, pseudogene","metadata":null},{"id":"bd02b0005dea4da7b1b8802219ce0048","type":"GENE","name":"RNU4-91P","canonical_id":"hgnc:HGNC:47027","description":"RNA, U4 small nuclear 91, pseudogene","metadata":null},{"id":"a7793f7a03cf42ec95ab7ac1b9dfc625","type":"GENE","name":"RNU4-92P","canonical_id":"hgnc:HGNC:47028","description":"RNA, U4 small nuclear 92, pseudogene","metadata":null},{"id":"a69cb130708f4d74931d72fd7ed40fa4","type":"GENE","name":"RNU4-9P","canonical_id":"hgnc:HGNC:42507","description":"RNA, U4 small nuclear 9, pseudogene","metadata":null},{"id":"64ff2a3ce2244e29be4c627985dee13b","type":"GENE","name":"RNU4ATAC","canonical_id":"hgnc:HGNC:34016","description":"RNA, U4atac small nuclear","metadata":{"aliases":["RNU4ATAC1","U4atac"]}},{"id":"6d8a937ea16f4ea28c67d5348c99901d","type":"GENE","name":"RNU4ATAC10P","canonical_id":"hgnc:HGNC:46896","description":"RNA, U4atac small nuclear 10, pseudogene","metadata":null},{"id":"eb592743784f467cb20f202cd10b5960","type":"GENE","name":"RNU4ATAC11P","canonical_id":"hgnc:HGNC:46897","description":"RNA, U4atac small nuclear 11, pseudogene","metadata":null},{"id":"41388681b271436dba219ba5c87f5d57","type":"GENE","name":"RNU4ATAC12P","canonical_id":"hgnc:HGNC:46898","description":"RNA, U4atac small nuclear 12, pseudogene","metadata":null},{"id":"9339bf7d43e6469a8a32f8c053cbf9cf","type":"GENE","name":"RNU4ATAC13P","canonical_id":"hgnc:HGNC:46899","description":"RNA, U4atac small nuclear 13, pseudogene","metadata":null},{"id":"f6c10233c9c84c41876faddbcf45edef","type":"GENE","name":"RNU4ATAC14P","canonical_id":"hgnc:HGNC:46900","description":"RNA, U4atac small nuclear 14, pseudogene","metadata":null},{"id":"21e6a813bb104be796371871b64395e1","type":"GENE","name":"RNU4ATAC15P","canonical_id":"hgnc:HGNC:46901","description":"RNA, U4atac small nuclear 15, pseudogene","metadata":null},{"id":"68fad6cc22ee4924a1c8feadde8d406e","type":"GENE","name":"RNU4ATAC16P","canonical_id":"hgnc:HGNC:46902","description":"RNA, U4atac small nuclear 16, pseudogene","metadata":null},{"id":"c829d6ece0464113a476b29ab590f5b7","type":"GENE","name":"RNU4ATAC17P","canonical_id":"hgnc:HGNC:46903","description":"RNA, U4atac small nuclear 17, pseudogene","metadata":null},{"id":"f28a0a3d26c04d2eaeeeac824b93b138","type":"GENE","name":"RNU4ATAC18P","canonical_id":"hgnc:HGNC:46904","description":"RNA, U4atac small nuclear 18, pseudogene","metadata":null},{"id":"9b223b27f77c44628c521647454c5a04","type":"GENE","name":"RNU4ATAC2P","canonical_id":"hgnc:HGNC:39003","description":"RNA, U4atac small nuclear 2, pseudogene","metadata":null},{"id":"2d5a0e6ac4b94e0990bf3567aff938a9","type":"GENE","name":"RNU4ATAC3P","canonical_id":"hgnc:HGNC:42575","description":"RNA, U4atac small nuclear 3, pseudogene","metadata":null},{"id":"26f425604856462594ab9e055b113196","type":"GENE","name":"RNU4ATAC4P","canonical_id":"hgnc:HGNC:46890","description":"RNA, U4atac small nuclear 4, pseudogene","metadata":null},{"id":"2e2e591ea8424826863134a4942885ca","type":"GENE","name":"RNU4ATAC5P","canonical_id":"hgnc:HGNC:46891","description":"RNA, U4atac small nuclear 5, pseudogene","metadata":null},{"id":"c99902bf80784f11bc24bb4b79fbbeb0","type":"GENE","name":"RNU4ATAC6P","canonical_id":"hgnc:HGNC:46892","description":"RNA, U4atac small nuclear 6, pseudogene","metadata":null},{"id":"450bd51dee824fa28c00b3b8f3b8ee49","type":"GENE","name":"RNU4ATAC7P","canonical_id":"hgnc:HGNC:46893","description":"RNA, U4atac small nuclear 7, pseudogene","metadata":null},{"id":"757f01a313bb447081b95be90a67c12d","type":"GENE","name":"RNU4ATAC8P","canonical_id":"hgnc:HGNC:46894","description":"RNA, U4atac small nuclear 8, pseudogene","metadata":null},{"id":"b35db22c15e3445d8993b70fa33eccd0","type":"GENE","name":"RNU4ATAC9P","canonical_id":"hgnc:HGNC:46895","description":"RNA, U4atac small nuclear 9, pseudogene","metadata":null},{"id":"844b2b7ec0624845bcc9f1078a047f3b","type":"GENE","name":"RNU5A-1","canonical_id":"hgnc:HGNC:10211","description":"RNA, U5A small nuclear 1","metadata":{"aliases":["U5A","U5B1","RNU5C","RNU5A"]}},{"id":"b343f0f922b5417fb630c408c5e30bb2","type":"GENE","name":"RNU5A-2P","canonical_id":"hgnc:HGNC:42515","description":"RNA, U5A small nuclear 2, pseudogene","metadata":null},{"id":"8ecfdae19a45425aa437e943bf62f209","type":"GENE","name":"RNU5A-3P","canonical_id":"hgnc:HGNC:42519","description":"RNA, U5A small nuclear 3, pseudogene","metadata":null},{"id":"4b5c2e75ad4e4daaa6428ee7fa047611","type":"GENE","name":"RNU5A-4P","canonical_id":"hgnc:HGNC:42521","description":"RNA, U5A small nuclear 4, pseudogene","metadata":null},{"id":"d57470fead5845aeb699a3cb4873b914","type":"GENE","name":"RNU5A-5P","canonical_id":"hgnc:HGNC:42525","description":"RNA, U5A small nuclear 5, pseudogene","metadata":null},{"id":"003625e9ef78486199ef782aac89c9a6","type":"GENE","name":"RNU5A-6P","canonical_id":"hgnc:HGNC:42527","description":"RNA, U5A small nuclear 6, pseudogene","metadata":null},{"id":"e00b7dfb54fd4f1a83c5f610ffbda6b6","type":"GENE","name":"RNU5A-7P","canonical_id":"hgnc:HGNC:42529","description":"RNA, U5A small nuclear 7, pseudogene","metadata":null},{"id":"ec80ffba08cd49ef9d4c975daa85ae7d","type":"GENE","name":"RNU5A-8P","canonical_id":"hgnc:HGNC:42530","description":"RNA, U5A small nuclear 8, pseudogene","metadata":null},{"id":"f09a7a151ccf4284b09923cd8f640441","type":"GENE","name":"RNU5B-1","canonical_id":"hgnc:HGNC:10212","description":"RNA, U5B small nuclear 1","metadata":{"aliases":["U5B1","RNU5B"]}},{"id":"535d4f5f471845b49e062f431794f636","type":"GENE","name":"RNU5B-2P","canonical_id":"hgnc:HGNC:34182","description":"RNA, U5B small nuclear 2, pseudogene","metadata":null},{"id":"b66fa61c061c43938b591e7b8dae64eb","type":"GENE","name":"RNU5B-3P","canonical_id":"hgnc:HGNC:34183","description":"RNA, U5B small nuclear 3, pseudogene","metadata":null},{"id":"9ef3bcddb4104b819f9cd646c557c25b","type":"GENE","name":"RNU5B-4P","canonical_id":"hgnc:HGNC:34184","description":"RNA, U5B small nuclear 4, pseudogene","metadata":null},{"id":"0bcebd679236492580912a999db73c13","type":"GENE","name":"RNU5B-5P","canonical_id":"hgnc:HGNC:34185","description":"RNA, U5B small nuclear 5, pseudogene","metadata":null},{"id":"22ee1b61a5694bc7967c5a1f90e9f8cb","type":"GENE","name":"RNU5B-6P","canonical_id":"hgnc:HGNC:34186","description":"RNA, U5B small nuclear 6, pseudogene","metadata":null},{"id":"85ad03158be64b5bbd22b6b89975ea6b","type":"GENE","name":"RNU5D-1","canonical_id":"hgnc:HGNC:10214","description":"RNA, U5D small nuclear 1","metadata":{"aliases":["U5DS","U5DL","RNU5D"]}},{"id":"1c0299b2f4e44cd0b8f7bc3d5d52d7fb","type":"GENE","name":"RNU5D-2P","canonical_id":"hgnc:HGNC:42534","description":"RNA, U5D small nuclear 2, pseudogene","metadata":null},{"id":"067cc749705343649188f55a55d5a156","type":"GENE","name":"RNU5E-1","canonical_id":"hgnc:HGNC:10215","description":"RNA, U5E small nuclear 1","metadata":{"aliases":["U5E","RNU5E"]}},{"id":"8743a8a3b6584a788ae76b47079fcfbe","type":"GENE","name":"RNU5E-10P","canonical_id":"hgnc:HGNC:42533","description":"RNA, U5E small nuclear 10, pseudogene","metadata":null},{"id":"0cf6f9074bf94fbcb4e926e2bca387d7","type":"GENE","name":"RNU5E-2P","canonical_id":"hgnc:HGNC:42511","description":"RNA, U5E small nuclear 2, pseudogene","metadata":null},{"id":"b3e8394ecc4543ba98ac5557ea5f82f3","type":"GENE","name":"RNU5E-3P","canonical_id":"hgnc:HGNC:42512","description":"RNA, U5E small nuclear 3, pseudogene","metadata":null},{"id":"ec7a7e14a093478da1146ea20eb58a7b","type":"GENE","name":"RNU5E-4P","canonical_id":"hgnc:HGNC:42513","description":"RNA, U5E small nuclear 4, pseudogene","metadata":null},{"id":"61f6479e02e54a2580cc69f301d58dac","type":"GENE","name":"RNU5E-5P","canonical_id":"hgnc:HGNC:42520","description":"RNA, U5E small nuclear 5, pseudogene","metadata":null},{"id":"dfce50a7b9cf46cd85d3ba60a8abac49","type":"GENE","name":"RNU5E-6P","canonical_id":"hgnc:HGNC:42522","description":"RNA, U5E small nuclear 6, pseudogene","metadata":null},{"id":"cdfdef2d6a5e440ba95176d4c2a9c542","type":"GENE","name":"RNU5E-7P","canonical_id":"hgnc:HGNC:42526","description":"RNA, U5E small nuclear 7, pseudogene","metadata":null},{"id":"985993e8c48f480cbf7f8b7395cd4cc8","type":"GENE","name":"RNU5E-8P","canonical_id":"hgnc:HGNC:42528","description":"RNA, U5E small nuclear 8, pseudogene","metadata":null},{"id":"f390b8f91e4041018bcf0e37456f8004","type":"GENE","name":"RNU5E-9P","canonical_id":"hgnc:HGNC:42532","description":"RNA, U5E small nuclear 9, pseudogene","metadata":null},{"id":"2d3dffc6ca9545e392aedb7e5eef3d52","type":"GENE","name":"RNU5F-1","canonical_id":"hgnc:HGNC:10216","description":"RNA, U5F small nuclear 1","metadata":{"aliases":["RNU5F"]}},{"id":"43ab00cc618941ab9e53cb96231a41d6","type":"GENE","name":"RNU5F-2P","canonical_id":"hgnc:HGNC:42510","description":"RNA, U5F small nuclear 2, pseudogene","metadata":null},{"id":"84332756271743ad9f5459493094a58b","type":"GENE","name":"RNU5F-3P","canonical_id":"hgnc:HGNC:42514","description":"RNA, U5F small nuclear 3, pseudogene","metadata":null},{"id":"4d5fc7ef613646649f39235b2e1b8ba4","type":"GENE","name":"RNU5F-4P","canonical_id":"hgnc:HGNC:42516","description":"RNA, U5F small nuclear 4, pseudogene","metadata":null},{"id":"2230e120693d4c558189f46f496126b1","type":"GENE","name":"RNU5F-5P","canonical_id":"hgnc:HGNC:42518","description":"RNA, U5F small nuclear 5, pseudogene","metadata":null},{"id":"593866a720b44b3a830b86ccc54d5469","type":"GENE","name":"RNU5F-6P","canonical_id":"hgnc:HGNC:42523","description":"RNA, U5F small nuclear 6, pseudogene","metadata":null},{"id":"7a027fe49df546529e112fe3bfb3cf0e","type":"GENE","name":"RNU5F-7P","canonical_id":"hgnc:HGNC:42524","description":"RNA, U5F small nuclear 7, pseudogene","metadata":null},{"id":"9e9a9d6a009a4ca89a2984087b506b59","type":"GENE","name":"RNU5F-8P","canonical_id":"hgnc:HGNC:42531","description":"RNA, U5F small nuclear 8, pseudogene","metadata":null},{"id":"ec51fe2f12ef4fd095011b51251d3a2f","type":"GENE","name":"RNU6-1","canonical_id":"hgnc:HGNC:10227","description":"RNA, U6 small nuclear 1","metadata":{"aliases":["U6","U6-1","RNU6A"]}},{"id":"fe42e1dfaa6b4ff8a3f0d4c1813d2597","type":"GENE","name":"RNU6-1000P","canonical_id":"hgnc:HGNC:47963","description":"RNA, U6 small nuclear 1000, pseudogene","metadata":null},{"id":"a5e12b4ab6204e93bd225984cfb03c55","type":"GENE","name":"RNU6-1001P","canonical_id":"hgnc:HGNC:47964","description":"RNA, U6 small nuclear 1001, pseudogene","metadata":null},{"id":"a169702d853f48d19e10cf537ffe524e","type":"GENE","name":"RNU6-1003P","canonical_id":"hgnc:HGNC:47966","description":"RNA, U6 small nuclear 1003, pseudogene","metadata":null},{"id":"76030cfdc1d74181b4cea7f14f133e2d","type":"GENE","name":"RNU6-1004P","canonical_id":"hgnc:HGNC:47967","description":"RNA, U6 small nuclear 1004, pseudogene","metadata":null},{"id":"370864cfc0014c36a9355e22bced8406","type":"GENE","name":"RNU6-1005P","canonical_id":"hgnc:HGNC:47968","description":"RNA, U6 small nuclear 1005, pseudogene","metadata":null},{"id":"ab089f5424624a23b29b87b523a016f8","type":"GENE","name":"RNU6-1006P","canonical_id":"hgnc:HGNC:47969","description":"RNA, U6 small nuclear 1006, pseudogene","metadata":null},{"id":"0f6d471bd7f64434a217f13bcff704c3","type":"GENE","name":"RNU6-1007P","canonical_id":"hgnc:HGNC:47970","description":"RNA, U6 small nuclear 1007, pseudogene","metadata":null},{"id":"8a08f556dc8e41ae9027c5cda6b1eab4","type":"GENE","name":"RNU6-1008P","canonical_id":"hgnc:HGNC:47971","description":"RNA, U6 small nuclear 1008, pseudogene","metadata":null},{"id":"ee2697eb4d8b40c68e4b378907b6438f","type":"GENE","name":"RNU6-1009P","canonical_id":"hgnc:HGNC:47972","description":"RNA, U6 small nuclear 1009, pseudogene","metadata":null},{"id":"0f1401e350b04685af21d73ed6ca55a3","type":"GENE","name":"RNU6-100P","canonical_id":"hgnc:HGNC:47063","description":"RNA, U6 small nuclear 100, pseudogene","metadata":null},{"id":"04ed2ad733ca481599f888b058e9b275","type":"GENE","name":"RNU6-1010P","canonical_id":"hgnc:HGNC:47973","description":"RNA, U6 small nuclear 1010, pseudogene","metadata":null},{"id":"a739a285055a4b03869e5d88b1971a70","type":"GENE","name":"RNU6-1011P","canonical_id":"hgnc:HGNC:47974","description":"RNA, U6 small nuclear 1011, pseudogene","metadata":null},{"id":"2c980f1a327e43189f05bb270b8affa0","type":"GENE","name":"RNU6-1012P","canonical_id":"hgnc:HGNC:47975","description":"RNA, U6 small nuclear 1012, pseudogene","metadata":null},{"id":"8a91b79df96648b2b94e03b44da61d24","type":"GENE","name":"RNU6-1013P","canonical_id":"hgnc:HGNC:47976","description":"RNA, U6 small nuclear 1013, pseudogene","metadata":null},{"id":"97637bb0a31946c8bf7d2896f19631ff","type":"GENE","name":"RNU6-1014P","canonical_id":"hgnc:HGNC:47977","description":"RNA, U6 small nuclear 1014, pseudogene","metadata":null},{"id":"ae197e1f8d3840c98261d3c3f8031d30","type":"GENE","name":"RNU6-1015P","canonical_id":"hgnc:HGNC:47978","description":"RNA, U6 small nuclear 1015, pseudogene","metadata":null},{"id":"cc03c2d302364746ac496e12afb75bce","type":"GENE","name":"RNU6-1016P","canonical_id":"hgnc:HGNC:47979","description":"RNA, U6 small nuclear 1016, pseudogene","metadata":null},{"id":"4a3a9eb5eb03458e95efac4f2d8b914a","type":"GENE","name":"RNU6-1017P","canonical_id":"hgnc:HGNC:47980","description":"RNA, U6 small nuclear 1017, pseudogene","metadata":null},{"id":"dbb0a33fb6c44ee386a924dffd89577f","type":"GENE","name":"RNU6-1018P","canonical_id":"hgnc:HGNC:47981","description":"RNA, U6 small nuclear 1018, pseudogene","metadata":null},{"id":"c23b84f082394bafadfc1dfc1d2594c7","type":"GENE","name":"RNU6-1019P","canonical_id":"hgnc:HGNC:47982","description":"RNA, U6 small nuclear 1019, pseudogene","metadata":null},{"id":"7ef6a62af46248ed8a35e140c88c4b32","type":"GENE","name":"RNU6-101P","canonical_id":"hgnc:HGNC:47064","description":"RNA, U6 small nuclear 101, pseudogene","metadata":null},{"id":"1d22eec36d0d47a2ba5182c1bbb9d93d","type":"GENE","name":"RNU6-1020P","canonical_id":"hgnc:HGNC:47983","description":"RNA, U6 small nuclear 1020, pseudogene","metadata":null},{"id":"00a28784b3ad40a5b24e8c560b8a56b1","type":"GENE","name":"RNU6-1021P","canonical_id":"hgnc:HGNC:47984","description":"RNA, U6 small nuclear 1021, pseudogene","metadata":null},{"id":"28cdc28179a0468f92a238e41eb0e05b","type":"GENE","name":"RNU6-1022P","canonical_id":"hgnc:HGNC:47985","description":"RNA, U6 small nuclear 1022, pseudogene","metadata":null},{"id":"51d40ad347f9484db30250a4d4b36ad8","type":"GENE","name":"RNU6-1023P","canonical_id":"hgnc:HGNC:47986","description":"RNA, U6 small nuclear 1023, pseudogene","metadata":null},{"id":"26d12494025d4a87935bcef3a7f67c6e","type":"GENE","name":"RNU6-1024P","canonical_id":"hgnc:HGNC:47987","description":"RNA, U6 small nuclear 1024, pseudogene","metadata":null},{"id":"0a6bdceb8a0c4f0bb28fa42aee2d64f4","type":"GENE","name":"RNU6-1025P","canonical_id":"hgnc:HGNC:47988","description":"RNA, U6 small nuclear 1025, pseudogene","metadata":null},{"id":"4127b59d8e3f482587843802d20a1147","type":"GENE","name":"RNU6-1026P","canonical_id":"hgnc:HGNC:47989","description":"RNA, U6 small nuclear 1026, pseudogene","metadata":null},{"id":"a1f2df0997564716a6515374dda529d5","type":"GENE","name":"RNU6-1027P","canonical_id":"hgnc:HGNC:47990","description":"RNA, U6 small nuclear 1027, pseudogene","metadata":null},{"id":"5ff971447ee147a08e717727180100d2","type":"GENE","name":"RNU6-1028P","canonical_id":"hgnc:HGNC:47991","description":"RNA, U6 small nuclear 1028, pseudogene","metadata":null},{"id":"3310cc8efc2545a1aff8290fd8015055","type":"GENE","name":"RNU6-1029P","canonical_id":"hgnc:HGNC:47992","description":"RNA, U6 small nuclear 1029, pseudogene","metadata":null},{"id":"edab56bb2e4341d9bbf7e825d251d5eb","type":"GENE","name":"RNU6-102P","canonical_id":"hgnc:HGNC:47065","description":"RNA, U6 small nuclear 102, pseudogene","metadata":null},{"id":"e83b58d448c64b739673c7c1dec6ce11","type":"GENE","name":"RNU6-1031P","canonical_id":"hgnc:HGNC:47994","description":"RNA, U6 small nuclear 1031, pseudogene","metadata":null},{"id":"b13eb285ab2f474bb30a1c3a0e667e81","type":"GENE","name":"RNU6-1032P","canonical_id":"hgnc:HGNC:47995","description":"RNA, U6 small nuclear 1032, pseudogene","metadata":null},{"id":"ec453503e3564d6194b0577a99c4372e","type":"GENE","name":"RNU6-1034P","canonical_id":"hgnc:HGNC:47997","description":"RNA, U6 small nuclear 1034, pseudogene","metadata":null},{"id":"bf8e4bae5458440dbb00182952894ff3","type":"GENE","name":"RNU6-1035P","canonical_id":"hgnc:HGNC:47998","description":"RNA, U6 small nuclear 1035, pseudogene","metadata":null},{"id":"6c93710b4b3e416eaaea73066e4cc409","type":"GENE","name":"RNU6-1036P","canonical_id":"hgnc:HGNC:47999","description":"RNA, U6 small nuclear 1036, pseudogene","metadata":null},{"id":"4aa200a764e8493ea924186f0422a043","type":"GENE","name":"RNU6-1037P","canonical_id":"hgnc:HGNC:48000","description":"RNA, U6 small nuclear 1037, pseudogene","metadata":null},{"id":"e9bbb57ec08145cca0907faa2437810a","type":"GENE","name":"RNU6-1038P","canonical_id":"hgnc:HGNC:48001","description":"RNA, U6 small nuclear 1038, pseudogene","metadata":null},{"id":"9dea906545044a8ea6dc16a46b3e95f9","type":"GENE","name":"RNU6-1039P","canonical_id":"hgnc:HGNC:48002","description":"RNA, U6 small nuclear 1039, pseudogene","metadata":null},{"id":"07023995e1e24833b672a1e08c7d04f4","type":"GENE","name":"RNU6-103P","canonical_id":"hgnc:HGNC:47066","description":"RNA, U6 small nuclear 103, pseudogene","metadata":null},{"id":"20c8c526eedb4f50abb22bf3aaf7459e","type":"GENE","name":"RNU6-1040P","canonical_id":"hgnc:HGNC:48003","description":"RNA, U6 small nuclear 1040, pseudogene","metadata":null},{"id":"22a812547e7d4d25819428b83b57bb00","type":"GENE","name":"RNU6-1041P","canonical_id":"hgnc:HGNC:48004","description":"RNA, U6 small nuclear 1041, pseudogene","metadata":null},{"id":"e862182b427e41c29b8f960aac0ba039","type":"GENE","name":"RNU6-1042P","canonical_id":"hgnc:HGNC:48005","description":"RNA, U6 small nuclear 1042, pseudogene","metadata":null},{"id":"558c3313b48b4bd2a0fe24ca6d1a2f19","type":"GENE","name":"RNU6-1043P","canonical_id":"hgnc:HGNC:48006","description":"RNA, U6 small nuclear 1043, pseudogene","metadata":null},{"id":"b2c32547bbcf454ab47ec37221761243","type":"GENE","name":"RNU6-1044P","canonical_id":"hgnc:HGNC:48007","description":"RNA, U6 small nuclear 1044, pseudogene","metadata":null},{"id":"59c38a3cd66d4f6b9134213e5eb10f67","type":"GENE","name":"RNU6-1045P","canonical_id":"hgnc:HGNC:48008","description":"RNA, U6 small nuclear 1045, pseudogene","metadata":null},{"id":"9a3226d2fe304e4c8bf4905ba25aea3b","type":"GENE","name":"RNU6-1046P","canonical_id":"hgnc:HGNC:48009","description":"RNA, U6 small nuclear 1046, pseudogene","metadata":null},{"id":"9913b919daba42cfbe1f39a9e92ff8ec","type":"GENE","name":"RNU6-1047P","canonical_id":"hgnc:HGNC:48010","description":"RNA, U6 small nuclear 1047, pseudogene","metadata":null},{"id":"c148ae7e60924b07b4dcb3bedb4e35e5","type":"GENE","name":"RNU6-1048P","canonical_id":"hgnc:HGNC:48011","description":"RNA, U6 small nuclear 1048, pseudogene","metadata":null},{"id":"8f95d99a89bf4e51a52083fda23d333a","type":"GENE","name":"RNU6-1049P","canonical_id":"hgnc:HGNC:48012","description":"RNA, U6 small nuclear 1049, pseudogene","metadata":null},{"id":"22bb2eb0ba614d92a874d42b63f933a7","type":"GENE","name":"RNU6-104P","canonical_id":"hgnc:HGNC:47067","description":"RNA, U6 small nuclear 104, pseudogene","metadata":null},{"id":"67f22ca79fcf4eae9714bafec405f279","type":"GENE","name":"RNU6-1050P","canonical_id":"hgnc:HGNC:48013","description":"RNA, U6 small nuclear 1050, pseudogene","metadata":null},{"id":"15190ecb21a247888c4e812593c1c6dc","type":"GENE","name":"RNU6-1051P","canonical_id":"hgnc:HGNC:48014","description":"RNA, U6 small nuclear 1051, pseudogene","metadata":null},{"id":"8bb0ebd0b04a4f1f8f80816bab1759c3","type":"GENE","name":"RNU6-1052P","canonical_id":"hgnc:HGNC:48015","description":"RNA, U6 small nuclear 1052, pseudogene","metadata":null},{"id":"90a640295858404c849140b9bc9ee3fc","type":"GENE","name":"RNU6-1053P","canonical_id":"hgnc:HGNC:48016","description":"RNA, U6 small nuclear 1053, pseudogene","metadata":null},{"id":"5e7743fa154744fabab9297a40b29fd9","type":"GENE","name":"RNU6-1054P","canonical_id":"hgnc:HGNC:48017","description":"RNA, U6 small nuclear 1054, pseudogene","metadata":null},{"id":"e0a4227f371a4ab0b5b42990ea80fc0b","type":"GENE","name":"RNU6-1055P","canonical_id":"hgnc:HGNC:48018","description":"RNA, U6 small nuclear 1055, pseudogene","metadata":null},{"id":"b1fc915bb70d40039d77d8cf81fbcb11","type":"GENE","name":"RNU6-1056P","canonical_id":"hgnc:HGNC:48019","description":"RNA, U6 small nuclear 1056, pseudogene","metadata":null},{"id":"543272ccab684b648e4d8898561901c5","type":"GENE","name":"RNU6-1057P","canonical_id":"hgnc:HGNC:48020","description":"RNA, U6 small nuclear 1057, pseudogene","metadata":null},{"id":"6331cc81af654f9c82263ff15fb27cae","type":"GENE","name":"RNU6-1059P","canonical_id":"hgnc:HGNC:48022","description":"RNA, U6 small nuclear 1059, pseudogene","metadata":null},{"id":"b5dfa8a17e8d47c2826c820a884b8df9","type":"GENE","name":"RNU6-105P","canonical_id":"hgnc:HGNC:47068","description":"RNA, U6 small nuclear 105, pseudogene","metadata":null},{"id":"082bf4a646bd409b9ab3b3941e3d5d88","type":"GENE","name":"RNU6-1060P","canonical_id":"hgnc:HGNC:48023","description":"RNA, U6 small nuclear 1060, pseudogene","metadata":null},{"id":"d60e668ffb4d4e28824094e36ca9bcc4","type":"GENE","name":"RNU6-1061P","canonical_id":"hgnc:HGNC:48024","description":"RNA, U6 small nuclear 1061, pseudogene","metadata":null},{"id":"eb4c3f14431d434596fb747cdbb4b381","type":"GENE","name":"RNU6-1062P","canonical_id":"hgnc:HGNC:48025","description":"RNA, U6 small nuclear 1062, pseudogene","metadata":null},{"id":"7ed0b1c6ce4d45e78b5503dca2f129c6","type":"GENE","name":"RNU6-1064P","canonical_id":"hgnc:HGNC:48027","description":"RNA, U6 small nuclear 1064, pseudogene","metadata":null},{"id":"2dc5a025b43e4ecfa222524ca7db7fad","type":"GENE","name":"RNU6-1065P","canonical_id":"hgnc:HGNC:48028","description":"RNA, U6 small nuclear 1065, pseudogene","metadata":null},{"id":"3ffb6950fae445e688937ff91079af35","type":"GENE","name":"RNU6-1066P","canonical_id":"hgnc:HGNC:48029","description":"RNA, U6 small nuclear 1066, pseudogene","metadata":null},{"id":"8e4e8fc0831a4bcaa3e6d852ed12ae27","type":"GENE","name":"RNU6-1067P","canonical_id":"hgnc:HGNC:48030","description":"RNA, U6 small nuclear 1067, pseudogene","metadata":null},{"id":"0bde594fc22a416bafaa3e4228efc103","type":"GENE","name":"RNU6-1068P","canonical_id":"hgnc:HGNC:48031","description":"RNA, U6 small nuclear 1068, pseudogene","metadata":null},{"id":"f4700e433e2d4e45bf095284aac27a03","type":"GENE","name":"RNU6-1069P","canonical_id":"hgnc:HGNC:48032","description":"RNA, U6 small nuclear 1069, pseudogene","metadata":null},{"id":"7ff8d564f9594249ac0ee1543ca3f60f","type":"GENE","name":"RNU6-106P","canonical_id":"hgnc:HGNC:47069","description":"RNA, U6 small nuclear 106, pseudogene","metadata":null},{"id":"b953a5af522540269e63c49998cace0d","type":"GENE","name":"RNU6-1071P","canonical_id":"hgnc:HGNC:48034","description":"RNA, U6 small nuclear 1071, pseudogene","metadata":null},{"id":"57ae0f09498f47dfb03efcbb995d3d64","type":"GENE","name":"RNU6-1072P","canonical_id":"hgnc:HGNC:48035","description":"RNA, U6 small nuclear 1072, pseudogene","metadata":null},{"id":"63319e011e5646908c6ab42a3ce92602","type":"GENE","name":"RNU6-1073P","canonical_id":"hgnc:HGNC:48036","description":"RNA, U6 small nuclear 1073, pseudogene","metadata":null},{"id":"5a6448f267e44040bba229ef34ebd673","type":"GENE","name":"RNU6-1074P","canonical_id":"hgnc:HGNC:48037","description":"RNA, U6 small nuclear 1074, pseudogene","metadata":null},{"id":"a755b61fbdda420daa06cdc17891b8f9","type":"GENE","name":"RNU6-1075P","canonical_id":"hgnc:HGNC:48038","description":"RNA, U6 small nuclear 1075, pseudogene","metadata":null},{"id":"4d3f3b8b5efa40b3843717ccaf1659e8","type":"GENE","name":"RNU6-1076P","canonical_id":"hgnc:HGNC:48039","description":"RNA, U6 small nuclear 1076, pseudogene","metadata":null},{"id":"4744534df58b4cdbbf15a79f7f279db1","type":"GENE","name":"RNU6-1077P","canonical_id":"hgnc:HGNC:48040","description":"RNA, U6 small nuclear 1077, pseudogene","metadata":null},{"id":"5d58b52c32c44f3393f109934f4243ad","type":"GENE","name":"RNU6-1078P","canonical_id":"hgnc:HGNC:48041","description":"RNA, U6 small nuclear 1078, pseudogene","metadata":null},{"id":"d772923573674a0cb9adcea9439b17ce","type":"GENE","name":"RNU6-1079P","canonical_id":"hgnc:HGNC:48042","description":"RNA, U6 small nuclear 1079, pseudogene","metadata":null},{"id":"be75f39a57b7475da116ac29750baacd","type":"GENE","name":"RNU6-107P","canonical_id":"hgnc:HGNC:47070","description":"RNA, U6 small nuclear 107, pseudogene","metadata":null},{"id":"27d3b3f9500445b7a0f043028997fc1d","type":"GENE","name":"RNU6-1080P","canonical_id":"hgnc:HGNC:48043","description":"RNA, U6 small nuclear 1080, pseudogene","metadata":null},{"id":"7713faf9549342d5b6c69bd5f0836372","type":"GENE","name":"RNU6-1081P","canonical_id":"hgnc:HGNC:48044","description":"RNA, U6 small nuclear 1081, pseudogene","metadata":null},{"id":"b99755566de04d98bd3ed3f60abebd7a","type":"GENE","name":"RNU6-1082P","canonical_id":"hgnc:HGNC:48045","description":"RNA, U6 small nuclear 1082, pseudogene","metadata":null},{"id":"ae760b5405674bdda79f11ea3c228a46","type":"GENE","name":"RNU6-1083P","canonical_id":"hgnc:HGNC:48046","description":"RNA, U6 small nuclear 1083, pseudogene","metadata":null},{"id":"2fa14de7cd034eae959f7348fb197f62","type":"GENE","name":"RNU6-1084P","canonical_id":"hgnc:HGNC:48047","description":"RNA, U6 small nuclear 1084, pseudogene","metadata":null},{"id":"d1a36cf17fd5462d916262eaa1108e87","type":"GENE","name":"RNU6-1085P","canonical_id":"hgnc:HGNC:48048","description":"RNA, U6 small nuclear 1085, pseudogene","metadata":null},{"id":"5d76696cdba54898944cf3dbe65cc79c","type":"GENE","name":"RNU6-1086P","canonical_id":"hgnc:HGNC:48049","description":"RNA, U6 small nuclear 1086, pseudogene","metadata":null},{"id":"8d325e61eb2d406b8d52fcc3abce7142","type":"GENE","name":"RNU6-1087P","canonical_id":"hgnc:HGNC:48050","description":"RNA, U6 small nuclear 1087, pseudogene","metadata":null},{"id":"7badba187ec8440cb8b28ba66fdddec6","type":"GENE","name":"RNU6-1088P","canonical_id":"hgnc:HGNC:48051","description":"RNA, U6 small nuclear 1088, pseudogene","metadata":null},{"id":"c4027e18565547f298c4d42d9ad83298","type":"GENE","name":"RNU6-1089P","canonical_id":"hgnc:HGNC:48052","description":"RNA, U6 small nuclear 1089, pseudogene","metadata":null},{"id":"81b5f0ad795644088810b93744aa3237","type":"GENE","name":"RNU6-108P","canonical_id":"hgnc:HGNC:47071","description":"RNA, U6 small nuclear 108, pseudogene","metadata":null},{"id":"5d32fdc10c854598b0045ea2848a9f54","type":"GENE","name":"RNU6-1090P","canonical_id":"hgnc:HGNC:48053","description":"RNA, U6 small nuclear 1090, pseudogene","metadata":null},{"id":"9ec89a2fd2604cca98c5a74d6372dc2d","type":"GENE","name":"RNU6-1091P","canonical_id":"hgnc:HGNC:48054","description":"RNA, U6 small nuclear 1091, pseudogene","metadata":null},{"id":"b8b4c95bd0274482b2a75c9131e7a7b7","type":"GENE","name":"RNU6-1092P","canonical_id":"hgnc:HGNC:48055","description":"RNA, U6 small nuclear 1092, pseudogene","metadata":null},{"id":"10ee4e24972947e7b9a4f5b4a3f04296","type":"GENE","name":"RNU6-1093P","canonical_id":"hgnc:HGNC:48056","description":"RNA, U6 small nuclear 1093, pseudogene","metadata":null},{"id":"d1c43d45a96446a681e26a32551c6f6f","type":"GENE","name":"RNU6-1094P","canonical_id":"hgnc:HGNC:48057","description":"RNA, U6 small nuclear 1094, pseudogene","metadata":null},{"id":"425e48d1e26d4cd69041f68950462e8e","type":"GENE","name":"RNU6-1095P","canonical_id":"hgnc:HGNC:48058","description":"RNA, U6 small nuclear 1095, pseudogene","metadata":null},{"id":"3640d52ef7aa4d168640b6a01e900436","type":"GENE","name":"RNU6-1096P","canonical_id":"hgnc:HGNC:48059","description":"RNA, U6 small nuclear 1096, pseudogene","metadata":null},{"id":"94db61b5225246e3ba9781557a214c77","type":"GENE","name":"RNU6-1097P","canonical_id":"hgnc:HGNC:48060","description":"RNA, U6 small nuclear 1097, pseudogene","metadata":null},{"id":"ae4da0bace8a485a8c06f502a31a4cb8","type":"GENE","name":"RNU6-1098P","canonical_id":"hgnc:HGNC:48061","description":"RNA, U6 small nuclear 1098, pseudogene","metadata":null},{"id":"e5b90d1648e146519bd90d1778551377","type":"GENE","name":"RNU6-1099P","canonical_id":"hgnc:HGNC:48062","description":"RNA, U6 small nuclear 1099, pseudogene","metadata":null},{"id":"b678968d3dd2459b82c23f91a27d0277","type":"GENE","name":"RNU6-109P","canonical_id":"hgnc:HGNC:47072","description":"RNA, U6 small nuclear 109, pseudogene","metadata":null},{"id":"11fc462c53014bd08efdaa1f389479c2","type":"GENE","name":"RNU6-10P","canonical_id":"hgnc:HGNC:34254","description":"RNA, U6 small nuclear 10, pseudogene","metadata":{"aliases":["RNU6-10"]}},{"id":"22c50b14e38442449f0b823b5bea8171","type":"GENE","name":"RNU6-1100P","canonical_id":"hgnc:HGNC:48063","description":"RNA, U6 small nuclear 1100, pseudogene","metadata":null},{"id":"d2bebb5f00384ac0bb4897035e184cea","type":"GENE","name":"RNU6-1101P","canonical_id":"hgnc:HGNC:48064","description":"RNA, U6 small nuclear 1101, pseudogene","metadata":null},{"id":"b6726a55e5234581b7d1aadd0712126a","type":"GENE","name":"RNU6-1102P","canonical_id":"hgnc:HGNC:48065","description":"RNA, U6 small nuclear 1102, pseudogene","metadata":null},{"id":"82c89e7c34ab421ca82b23977b669583","type":"GENE","name":"RNU6-1103P","canonical_id":"hgnc:HGNC:48066","description":"RNA, U6 small nuclear 1103, pseudogene","metadata":null},{"id":"6f9c7491c2a044fface6d5ab20b71074","type":"GENE","name":"RNU6-1104P","canonical_id":"hgnc:HGNC:48067","description":"RNA, U6 small nuclear 1104, pseudogene","metadata":null},{"id":"403181ee2f5e4e4390dbe3be06f0c821","type":"GENE","name":"RNU6-1105P","canonical_id":"hgnc:HGNC:48068","description":"RNA, U6 small nuclear 1105, pseudogene","metadata":null},{"id":"018366c51d09424cb832ad437a8c416e","type":"GENE","name":"RNU6-1106P","canonical_id":"hgnc:HGNC:48069","description":"RNA, U6 small nuclear 1106, pseudogene","metadata":null},{"id":"27107406d4a146b7a49efaa07882c817","type":"GENE","name":"RNU6-1107P","canonical_id":"hgnc:HGNC:48070","description":"RNA, U6 small nuclear 1107, pseudogene","metadata":null},{"id":"7808bef8b0474e0ba275340e8e2340b5","type":"GENE","name":"RNU6-1108P","canonical_id":"hgnc:HGNC:48071","description":"RNA, U6 small nuclear 1108, pseudogene","metadata":null},{"id":"3943adbb57fe4630af0d4a2046841e52","type":"GENE","name":"RNU6-1109P","canonical_id":"hgnc:HGNC:48072","description":"RNA, U6 small nuclear 1109, pseudogene","metadata":null},{"id":"d55d0d3dcd9c4207babe37fc986d278d","type":"GENE","name":"RNU6-110P","canonical_id":"hgnc:HGNC:47073","description":"RNA, U6 small nuclear 110, pseudogene","metadata":null},{"id":"bc4f40610eb341ebac6ef625b9f4e73d","type":"GENE","name":"RNU6-1110P","canonical_id":"hgnc:HGNC:48073","description":"RNA, U6 small nuclear 1110, pseudogene","metadata":null},{"id":"7c7a56ed7ae1423c821f3f439bad90a7","type":"GENE","name":"RNU6-1111P","canonical_id":"hgnc:HGNC:48074","description":"RNA, U6 small nuclear 1111, pseudogene","metadata":null},{"id":"4bb8f5ad3ace4bedbd1586691ce7699a","type":"GENE","name":"RNU6-1112P","canonical_id":"hgnc:HGNC:48075","description":"RNA, U6 small nuclear 1112, pseudogene","metadata":null},{"id":"8a38207a09284bc7b84fa85e98ececd7","type":"GENE","name":"RNU6-1113P","canonical_id":"hgnc:HGNC:48076","description":"RNA, U6 small nuclear 1113, pseudogene","metadata":null},{"id":"e461f34802c245ecaa44e9e7544735fe","type":"GENE","name":"RNU6-1114P","canonical_id":"hgnc:HGNC:48077","description":"RNA, U6 small nuclear 1114, pseudogene","metadata":null},{"id":"238318a0356d45f4996b28d59e4da980","type":"GENE","name":"RNU6-1115P","canonical_id":"hgnc:HGNC:48078","description":"RNA, U6 small nuclear 1115, pseudogene","metadata":null},{"id":"0c4554f5d76e4134b348d13e46a8ca06","type":"GENE","name":"RNU6-1116P","canonical_id":"hgnc:HGNC:48079","description":"RNA, U6 small nuclear 1116, pseudogene","metadata":null},{"id":"f11aa8368c514088a1eaa107631c9fb7","type":"GENE","name":"RNU6-1117P","canonical_id":"hgnc:HGNC:48080","description":"RNA, U6 small nuclear 1117, pseudogene","metadata":null},{"id":"0645d162b49f4bb58fbfed70655bc279","type":"GENE","name":"RNU6-1118P","canonical_id":"hgnc:HGNC:48081","description":"RNA, U6 small nuclear 1118, pseudogene","metadata":null},{"id":"23d039ac16ed4553b0b61e2f50db953e","type":"GENE","name":"RNU6-1119P","canonical_id":"hgnc:HGNC:48082","description":"RNA, U6 small nuclear 1119, pseudogene","metadata":null},{"id":"98e1a32d2dc149e78a0b4983086f5995","type":"GENE","name":"RNU6-111P","canonical_id":"hgnc:HGNC:47074","description":"RNA, U6 small nuclear 111, pseudogene","metadata":null},{"id":"4c275cca6d6e4cca81acdae1ad30845e","type":"GENE","name":"RNU6-1120P","canonical_id":"hgnc:HGNC:48083","description":"RNA, U6 small nuclear 1120, pseudogene","metadata":null},{"id":"d2dbec5b94ce419fa91913a253aa48ef","type":"GENE","name":"RNU6-1121P","canonical_id":"hgnc:HGNC:48084","description":"RNA, U6 small nuclear 1121, pseudogene","metadata":null},{"id":"777953cc9f5d481c818c96fdea13c860","type":"GENE","name":"RNU6-1122P","canonical_id":"hgnc:HGNC:48085","description":"RNA, U6 small nuclear 1122, pseudogene","metadata":null},{"id":"f399a64aec5943f7b250774084290f49","type":"GENE","name":"RNU6-1123P","canonical_id":"hgnc:HGNC:48086","description":"RNA, U6 small nuclear 1123, pseudogene","metadata":null},{"id":"42ceab2e1eb948bf81015d3188fe88c5","type":"GENE","name":"RNU6-1124P","canonical_id":"hgnc:HGNC:48087","description":"RNA, U6 small nuclear 1124, pseudogene","metadata":null},{"id":"0101d419111348609703ad72d2e71f55","type":"GENE","name":"RNU6-1125P","canonical_id":"hgnc:HGNC:48088","description":"RNA, U6 small nuclear 1125, pseudogene","metadata":null},{"id":"22796a016f044f958a35641d93723577","type":"GENE","name":"RNU6-1126P","canonical_id":"hgnc:HGNC:48089","description":"RNA, U6 small nuclear 1126, pseudogene","metadata":null},{"id":"c3e1640ba4d4497289838aa8d9a78daf","type":"GENE","name":"RNU6-1127P","canonical_id":"hgnc:HGNC:48090","description":"RNA, U6 small nuclear 1127, pseudogene","metadata":null},{"id":"981a1dfb266a4e18afdf614e99c7a1c8","type":"GENE","name":"RNU6-1128P","canonical_id":"hgnc:HGNC:48091","description":"RNA, U6 small nuclear 1128, pseudogene","metadata":null},{"id":"bc5adbb38732415e866dffd6167f5ea8","type":"GENE","name":"RNU6-1129P","canonical_id":"hgnc:HGNC:48092","description":"RNA, U6 small nuclear 1129, pseudogene","metadata":null},{"id":"5fb18effb0cd406d81e9e3e4f9feda59","type":"GENE","name":"RNU6-112P","canonical_id":"hgnc:HGNC:47075","description":"RNA, U6 small nuclear 112, pseudogene","metadata":null},{"id":"371dc501a5b84b8d8b6bf8e0f156be49","type":"GENE","name":"RNU6-1130P","canonical_id":"hgnc:HGNC:48093","description":"RNA, U6 small nuclear 1130, pseudogene","metadata":null},{"id":"9fe3b3c3f57a4d558a3174c4d3082e63","type":"GENE","name":"RNU6-1131P","canonical_id":"hgnc:HGNC:48094","description":"RNA, U6 small nuclear 1131, pseudogene","metadata":null},{"id":"9bef09107fe249bfaf37c72bbe1746ce","type":"GENE","name":"RNU6-1132P","canonical_id":"hgnc:HGNC:48095","description":"RNA, U6 small nuclear 1132, pseudogene","metadata":null},{"id":"15ed7e17087448ee926702894f9333df","type":"GENE","name":"RNU6-1133P","canonical_id":"hgnc:HGNC:48096","description":"RNA, U6 small nuclear 1133, pseudogene","metadata":{"aliases":["RNU6-186P"]}},{"id":"a733be4295a540b69909fc652b0a00df","type":"GENE","name":"RNU6-1134P","canonical_id":"hgnc:HGNC:48097","description":"RNA, U6 small nuclear 1134, pseudogene","metadata":null},{"id":"515bfccf634c4d7b89b510ef8ff84b35","type":"GENE","name":"RNU6-1135P","canonical_id":"hgnc:HGNC:48098","description":"RNA, U6 small nuclear 1135, pseudogene","metadata":null},{"id":"826c40f913fd4702b47bba1c822fde90","type":"GENE","name":"RNU6-1136P","canonical_id":"hgnc:HGNC:48099","description":"RNA, U6 small nuclear 1136, pseudogene","metadata":null},{"id":"ef247b89b42c4821b817bb2fcdddf0ae","type":"GENE","name":"RNU6-1137P","canonical_id":"hgnc:HGNC:48100","description":"RNA, U6 small nuclear 1137, pseudogene","metadata":null},{"id":"7b17ee12de28415888826c5c1bae0492","type":"GENE","name":"RNU6-1138P","canonical_id":"hgnc:HGNC:48101","description":"RNA, U6 small nuclear 1138, pseudogene","metadata":null},{"id":"1da6cbc59d104948872371aad3f44d52","type":"GENE","name":"RNU6-1139P","canonical_id":"hgnc:HGNC:48102","description":"RNA, U6 small nuclear 1139, pseudogene","metadata":null},{"id":"3cdfaa5e7e044c60be5cb04474d82dcb","type":"GENE","name":"RNU6-113P","canonical_id":"hgnc:HGNC:47076","description":"RNA, U6 small nuclear 113, pseudogene","metadata":null},{"id":"5916c90f5b4b4b9f906904566110dd18","type":"GENE","name":"RNU6-1140P","canonical_id":"hgnc:HGNC:48103","description":"RNA, U6 small nuclear 1140, pseudogene","metadata":null},{"id":"c9cf5a6dd9794fd2958ff79af0206dfb","type":"GENE","name":"RNU6-1141P","canonical_id":"hgnc:HGNC:48104","description":"RNA, U6 small nuclear 1141, pseudogene","metadata":null},{"id":"09cc73d350a54b6b8d4317d972f0f0bc","type":"GENE","name":"RNU6-1143P","canonical_id":"hgnc:HGNC:48106","description":"RNA, U6 small nuclear 1143, pseudogene","metadata":null},{"id":"66ce3051489e4e1798d5dd0a6a18f9e5","type":"GENE","name":"RNU6-1144P","canonical_id":"hgnc:HGNC:48107","description":"RNA, U6 small nuclear 1144, pseudogene","metadata":null},{"id":"90077e9e1af54f1fac2a7f9ccc267c53","type":"GENE","name":"RNU6-1145P","canonical_id":"hgnc:HGNC:48108","description":"RNA, U6 small nuclear 1145, pseudogene","metadata":null},{"id":"bdd065e7ae6c4f65822823818a46633d","type":"GENE","name":"RNU6-1146P","canonical_id":"hgnc:HGNC:48109","description":"RNA, U6 small nuclear 1146, pseudogene","metadata":null},{"id":"fca42c5a646b41469c23e43942dbd144","type":"GENE","name":"RNU6-1147P","canonical_id":"hgnc:HGNC:48110","description":"RNA, U6 small nuclear 1147, pseudogene","metadata":null},{"id":"7832540d6f274b3d940d25c6e7f67124","type":"GENE","name":"RNU6-1148P","canonical_id":"hgnc:HGNC:48111","description":"RNA, U6 small nuclear 1148, pseudogene","metadata":null},{"id":"ae3c52ad68e64341b4f0960acb9524b6","type":"GENE","name":"RNU6-1149P","canonical_id":"hgnc:HGNC:48112","description":"RNA, U6 small nuclear 1149, pseudogene","metadata":null},{"id":"f2f3a4a5188f4869a0f3af5cfe02f275","type":"GENE","name":"RNU6-114P","canonical_id":"hgnc:HGNC:47077","description":"RNA, U6 small nuclear 114, pseudogene","metadata":null},{"id":"909f959fc1264367a1e4b1fc0aa3ca26","type":"GENE","name":"RNU6-1150P","canonical_id":"hgnc:HGNC:48113","description":"RNA, U6 small nuclear 1150, pseudogene","metadata":null},{"id":"b766db035edc4846ba1bf6b9384bed1c","type":"GENE","name":"RNU6-1151P","canonical_id":"hgnc:HGNC:48114","description":"RNA, U6 small nuclear 1151, pseudogene","metadata":null},{"id":"06d60a36e56541bbb5d1a44c72c38b2f","type":"GENE","name":"RNU6-1152P","canonical_id":"hgnc:HGNC:48115","description":"RNA, U6 small nuclear 1152, pseudogene","metadata":null},{"id":"6b8a962893794bc8b67a7d8ef1c6e88e","type":"GENE","name":"RNU6-1153P","canonical_id":"hgnc:HGNC:48116","description":"RNA, U6 small nuclear 1153, pseudogene","metadata":null},{"id":"c421e3760e8f43a9828d927799f12627","type":"GENE","name":"RNU6-1154P","canonical_id":"hgnc:HGNC:48117","description":"RNA, U6 small nuclear 1154, pseudogene","metadata":null},{"id":"af5030be75ba40f5b3b9ab8565d79591","type":"GENE","name":"RNU6-1155P","canonical_id":"hgnc:HGNC:48118","description":"RNA, U6 small nuclear 1155, pseudogene","metadata":null},{"id":"75a1888c29d346748c053310b805f1f8","type":"GENE","name":"RNU6-1156P","canonical_id":"hgnc:HGNC:48119","description":"RNA, U6 small nuclear 1156, pseudogene","metadata":null},{"id":"e7f6bc975980465c9688b88575a1a277","type":"GENE","name":"RNU6-1157P","canonical_id":"hgnc:HGNC:48120","description":"RNA, U6 small nuclear 1157, pseudogene","metadata":null},{"id":"ce09ed47bb964ba29b23e0de2d66195a","type":"GENE","name":"RNU6-1158P","canonical_id":"hgnc:HGNC:48121","description":"RNA, U6 small nuclear 1158, pseudogene","metadata":null},{"id":"36f1f3b1a53e49eaa864d2cd683df2ad","type":"GENE","name":"RNU6-1159P","canonical_id":"hgnc:HGNC:48122","description":"RNA, U6 small nuclear 1159, pseudogene","metadata":null},{"id":"0b6a978c78274b10a6f7e714d4b23979","type":"GENE","name":"RNU6-115P","canonical_id":"hgnc:HGNC:47078","description":"RNA, U6 small nuclear 115, pseudogene","metadata":null},{"id":"578c23faf1754f799bc262e0405fc614","type":"GENE","name":"RNU6-1160P","canonical_id":"hgnc:HGNC:48123","description":"RNA, U6 small nuclear 1160, pseudogene","metadata":null},{"id":"131f4ddf68d346c1b8658f1388501218","type":"GENE","name":"RNU6-1161P","canonical_id":"hgnc:HGNC:48124","description":"RNA, U6 small nuclear 1161, pseudogene","metadata":null},{"id":"e89d1b901aba4376a79274cb4ccdb7d2","type":"GENE","name":"RNU6-1162P","canonical_id":"hgnc:HGNC:48125","description":"RNA, U6 small nuclear 1162, pseudogene","metadata":null},{"id":"897db99daaf74bc78623d86bb27ead72","type":"GENE","name":"RNU6-1163P","canonical_id":"hgnc:HGNC:48126","description":"RNA, U6 small nuclear 1163, pseudogene","metadata":null},{"id":"3e77e5edc1d04b5abee35012e5d80f0f","type":"GENE","name":"RNU6-1164P","canonical_id":"hgnc:HGNC:48127","description":"RNA, U6 small nuclear 1164, pseudogene","metadata":null},{"id":"5cfca529b71e4756ae67604a0916caeb","type":"GENE","name":"RNU6-1165P","canonical_id":"hgnc:HGNC:48128","description":"RNA, U6 small nuclear 1165, pseudogene","metadata":null},{"id":"e37f65c62b80463b8f0378b925c15d24","type":"GENE","name":"RNU6-1167P","canonical_id":"hgnc:HGNC:48130","description":"RNA, U6 small nuclear 1167, pseudogene","metadata":null},{"id":"923ab63490184258b68c9cf551617201","type":"GENE","name":"RNU6-1168P","canonical_id":"hgnc:HGNC:48131","description":"RNA, U6 small nuclear 1168, pseudogene","metadata":null},{"id":"1107f92718eb4daf8813eb4d8cdda539","type":"GENE","name":"RNU6-1169P","canonical_id":"hgnc:HGNC:48132","description":"RNA, U6 small nuclear 1169, pseudogene","metadata":null},{"id":"5bc75989be09429098dddb5f9c4a71f8","type":"GENE","name":"RNU6-116P","canonical_id":"hgnc:HGNC:47079","description":"RNA, U6 small nuclear 116, pseudogene","metadata":null},{"id":"5219d3c9133748f8afbd8ebf3aa91247","type":"GENE","name":"RNU6-1170P","canonical_id":"hgnc:HGNC:48133","description":"RNA, U6 small nuclear 1170, pseudogene","metadata":null},{"id":"57c3788ad886413ab9578e20af520036","type":"GENE","name":"RNU6-1171P","canonical_id":"hgnc:HGNC:48134","description":"RNA, U6 small nuclear 1171, pseudogene","metadata":null},{"id":"6257f7fb6e244913b53bb5de8b338451","type":"GENE","name":"RNU6-1172P","canonical_id":"hgnc:HGNC:48135","description":"RNA, U6 small nuclear 1172, pseudogene","metadata":null},{"id":"2a97aba7454344809608ddab8f4a0965","type":"GENE","name":"RNU6-1174P","canonical_id":"hgnc:HGNC:48137","description":"RNA, U6 small nuclear 1174, pseudogene","metadata":null},{"id":"fa41a3ecdc6441a28b006351a0ff5f5a","type":"GENE","name":"RNU6-1175P","canonical_id":"hgnc:HGNC:48138","description":"RNA, U6 small nuclear 1175, pseudogene","metadata":null},{"id":"b1980813a85c452e98440500d0f0ac30","type":"GENE","name":"RNU6-1176P","canonical_id":"hgnc:HGNC:48139","description":"RNA, U6 small nuclear 1176, pseudogene","metadata":null},{"id":"7b79f80116274a8db5e3cde0a13e68b4","type":"GENE","name":"RNU6-1177P","canonical_id":"hgnc:HGNC:48140","description":"RNA, U6 small nuclear 1177, pseudogene","metadata":null},{"id":"fb484fe9ced145b5b375f8785996bbee","type":"GENE","name":"RNU6-1178P","canonical_id":"hgnc:HGNC:48141","description":"RNA, U6 small nuclear 1178, pseudogene","metadata":null},{"id":"55d86b6a1c634d8796ed9a5ed5c7d69e","type":"GENE","name":"RNU6-1179P","canonical_id":"hgnc:HGNC:48142","description":"RNA, U6 small nuclear 1179, pseudogene","metadata":null},{"id":"6d28fe63bc5542e1a0b371b89f7001de","type":"GENE","name":"RNU6-117P","canonical_id":"hgnc:HGNC:47080","description":"RNA, U6 small nuclear 117, pseudogene","metadata":null},{"id":"b6ec92dd5088492cb891d3a26795c7d4","type":"GENE","name":"RNU6-1180P","canonical_id":"hgnc:HGNC:48143","description":"RNA, U6 small nuclear 1180, pseudogene","metadata":null},{"id":"300f9699afdf473c9134017dfd5dc04f","type":"GENE","name":"RNU6-1181P","canonical_id":"hgnc:HGNC:48144","description":"RNA, U6 small nuclear 1181, pseudogene","metadata":null},{"id":"a1577f0c495d48bfa8064b49528f6320","type":"GENE","name":"RNU6-1183P","canonical_id":"hgnc:HGNC:48146","description":"RNA, U6 small nuclear 1183, pseudogene","metadata":null},{"id":"43d5623b656548c0a18be32ea1b4eb33","type":"GENE","name":"RNU6-1184P","canonical_id":"hgnc:HGNC:48147","description":"RNA, U6 small nuclear 1184, pseudogene","metadata":null},{"id":"a81564ecaedf47b28397e96a1a991ec7","type":"GENE","name":"RNU6-1186P","canonical_id":"hgnc:HGNC:48149","description":"RNA, U6 small nuclear 1186, pseudogene","metadata":null},{"id":"7834ba6a563b4463930d2160306b1f02","type":"GENE","name":"RNU6-1187P","canonical_id":"hgnc:HGNC:48150","description":"RNA, U6 small nuclear 1187, pseudogene","metadata":null},{"id":"ec5d51441d87491e8bd00befd8e6e966","type":"GENE","name":"RNU6-1188P","canonical_id":"hgnc:HGNC:48151","description":"RNA, U6 small nuclear 1188, pseudogene","metadata":null},{"id":"a8c5609251004ff4b8c1cb7be0d44feb","type":"GENE","name":"RNU6-1189P","canonical_id":"hgnc:HGNC:48152","description":"RNA, U6 small nuclear 1189, pseudogene","metadata":null},{"id":"08bc4992832048f7a8aedb24920bbc71","type":"GENE","name":"RNU6-118P","canonical_id":"hgnc:HGNC:47081","description":"RNA, U6 small nuclear 118, pseudogene","metadata":null},{"id":"799b273919be4b0aaeb31c9ceb6692c0","type":"GENE","name":"RNU6-1190P","canonical_id":"hgnc:HGNC:48153","description":"RNA, U6 small nuclear 1190, pseudogene","metadata":null},{"id":"2c7c12d20116430c8ae5c1cba3c1dd79","type":"GENE","name":"RNU6-1191P","canonical_id":"hgnc:HGNC:48154","description":"RNA, U6 small nuclear 1191, pseudogene","metadata":null},{"id":"e482c8f1af344613953d5e7f975cceea","type":"GENE","name":"RNU6-1192P","canonical_id":"hgnc:HGNC:48155","description":"RNA, U6 small nuclear 1192, pseudogene","metadata":null},{"id":"296407c7869d4c2cb5c93cc96ab442d2","type":"GENE","name":"RNU6-1193P","canonical_id":"hgnc:HGNC:48156","description":"RNA, U6 small nuclear 1193, pseudogene","metadata":null},{"id":"110f7694f85147cca6aa024f5b7d2932","type":"GENE","name":"RNU6-1194P","canonical_id":"hgnc:HGNC:48157","description":"RNA, U6 small nuclear 1194, pseudogene","metadata":null},{"id":"d1b4904566d849b09a27f56380b04e62","type":"GENE","name":"RNU6-1195P","canonical_id":"hgnc:HGNC:48158","description":"RNA, U6 small nuclear 1195, pseudogene","metadata":null},{"id":"73da764e29f74e1a937bb58b7946f9f2","type":"GENE","name":"RNU6-1196P","canonical_id":"hgnc:HGNC:48159","description":"RNA, U6 small nuclear 1196, pseudogene","metadata":null},{"id":"6596570bc77a4d90afbe0f1e78692c4e","type":"GENE","name":"RNU6-1197P","canonical_id":"hgnc:HGNC:48160","description":"RNA, U6 small nuclear 1197, pseudogene","metadata":null},{"id":"f94904cd8da24df78fc99d8defce27d1","type":"GENE","name":"RNU6-1198P","canonical_id":"hgnc:HGNC:48161","description":"RNA, U6 small nuclear 1198, pseudogene","metadata":null},{"id":"90f6eceb51e847d4957f0b360ba13a72","type":"GENE","name":"RNU6-1199P","canonical_id":"hgnc:HGNC:48162","description":"RNA, U6 small nuclear 1199, pseudogene","metadata":null},{"id":"dfeb2c3881b9442ea4884aec4109380b","type":"GENE","name":"RNU6-119P","canonical_id":"hgnc:HGNC:47082","description":"RNA, U6 small nuclear 119, pseudogene","metadata":null},{"id":"e613b2552f114144a5fa4db18b5b6c24","type":"GENE","name":"RNU6-11P","canonical_id":"hgnc:HGNC:34255","description":"RNA, U6 small nuclear 11, pseudogene","metadata":{"aliases":["RNU6-11"]}},{"id":"e2db3c26644b45a0b9d4a6353c9dda17","type":"GENE","name":"RNU6-1200P","canonical_id":"hgnc:HGNC:48163","description":"RNA, U6 small nuclear 1200, pseudogene","metadata":null},{"id":"7776a15e5cff4ab88757854e1c686f5a","type":"GENE","name":"RNU6-1201P","canonical_id":"hgnc:HGNC:48164","description":"RNA, U6 small nuclear 1201, pseudogene","metadata":null},{"id":"a76291a2a1cf4890a0e7c1bf83cc0772","type":"GENE","name":"RNU6-1203P","canonical_id":"hgnc:HGNC:48166","description":"RNA, U6 small nuclear 1203, pseudogene","metadata":null},{"id":"442a9b16097a4781bef1a817fb0b4a77","type":"GENE","name":"RNU6-1204P","canonical_id":"hgnc:HGNC:48167","description":"RNA, U6 small nuclear 1204, pseudogene","metadata":null},{"id":"18536034c0d64d7785984c9f0fff9a48","type":"GENE","name":"RNU6-1205P","canonical_id":"hgnc:HGNC:48168","description":"RNA, U6 small nuclear 1205, pseudogene","metadata":null},{"id":"023f98f490894869a2c0bb5ee03aadd4","type":"GENE","name":"RNU6-1206P","canonical_id":"hgnc:HGNC:48169","description":"RNA, U6 small nuclear 1206, pseudogene","metadata":null},{"id":"5faffb0aff4143df84d821c2ea9c2abe","type":"GENE","name":"RNU6-1207P","canonical_id":"hgnc:HGNC:48170","description":"RNA, U6 small nuclear 1207, pseudogene","metadata":null},{"id":"a3419901ba0f47698f45f0213dd930b8","type":"GENE","name":"RNU6-1208P","canonical_id":"hgnc:HGNC:48171","description":"RNA, U6 small nuclear 1208, pseudogene","metadata":null},{"id":"e62520a66c6d42da959b9b06ab0bcfa2","type":"GENE","name":"RNU6-1209P","canonical_id":"hgnc:HGNC:48172","description":"RNA, U6 small nuclear 1209, pseudogene","metadata":null},{"id":"24747a35d46e4e65bb2285d09ebc2c9e","type":"GENE","name":"RNU6-120P","canonical_id":"hgnc:HGNC:47083","description":"RNA, U6 small nuclear 120, pseudogene","metadata":null},{"id":"f129105910ac4b34adae0543292e201b","type":"GENE","name":"RNU6-1210P","canonical_id":"hgnc:HGNC:48173","description":"RNA, U6 small nuclear 1210, pseudogene","metadata":null},{"id":"074e97a744034627b3cffe2259584e17","type":"GENE","name":"RNU6-1211P","canonical_id":"hgnc:HGNC:48174","description":"RNA, U6 small nuclear 1211, pseudogene","metadata":null},{"id":"1637634677e6439e85ef869b7d4f0f72","type":"GENE","name":"RNU6-1212P","canonical_id":"hgnc:HGNC:48175","description":"RNA, U6 small nuclear 1212, pseudogene","metadata":null},{"id":"c6f62321d0ae490eb16cccb619326bc9","type":"GENE","name":"RNU6-1213P","canonical_id":"hgnc:HGNC:48176","description":"RNA, U6 small nuclear 1213, pseudogene","metadata":null},{"id":"efd5e489ac084884a9aa6a2728dc7c6e","type":"GENE","name":"RNU6-1214P","canonical_id":"hgnc:HGNC:48177","description":"RNA, U6 small nuclear 1214, pseudogene","metadata":null},{"id":"92115744ef144f6ba9e28a38754372f1","type":"GENE","name":"RNU6-1215P","canonical_id":"hgnc:HGNC:48178","description":"RNA, U6 small nuclear 1215, pseudogene","metadata":null},{"id":"94ba6e4760524f899341affd31091449","type":"GENE","name":"RNU6-1216P","canonical_id":"hgnc:HGNC:48179","description":"RNA, U6 small nuclear 1216, pseudogene","metadata":null},{"id":"5aec6a9b08ab4ff188259b22e2930ad3","type":"GENE","name":"RNU6-1217P","canonical_id":"hgnc:HGNC:48180","description":"RNA, U6 small nuclear 1217, pseudogene","metadata":null},{"id":"0eac2322b4c24bb48b07a20a2ea29b90","type":"GENE","name":"RNU6-1218P","canonical_id":"hgnc:HGNC:48181","description":"RNA, U6 small nuclear 1218, pseudogene","metadata":null},{"id":"748f8a186613439cbd57735adad14c93","type":"GENE","name":"RNU6-1219P","canonical_id":"hgnc:HGNC:48182","description":"RNA, U6 small nuclear 1219, pseudogene","metadata":null},{"id":"b70d6a15760846e49eb64e3fa9d96f6a","type":"GENE","name":"RNU6-121P","canonical_id":"hgnc:HGNC:47084","description":"RNA, U6 small nuclear 121, pseudogene","metadata":null},{"id":"1577e3cee614439f836b61425da703bc","type":"GENE","name":"RNU6-1220P","canonical_id":"hgnc:HGNC:48183","description":"RNA, U6 small nuclear 1220, pseudogene","metadata":null},{"id":"f657b09c9ed84b3297edd26faa38b854","type":"GENE","name":"RNU6-1222P","canonical_id":"hgnc:HGNC:48185","description":"RNA, U6 small nuclear 1222, pseudogene","metadata":null},{"id":"474c40b311c64ed0ae9b940cb03a9e69","type":"GENE","name":"RNU6-1223P","canonical_id":"hgnc:HGNC:48186","description":"RNA, U6 small nuclear 1223, pseudogene","metadata":null},{"id":"c5402873326d42579831edb30418575a","type":"GENE","name":"RNU6-1224P","canonical_id":"hgnc:HGNC:48187","description":"RNA, U6 small nuclear 1224, pseudogene","metadata":null},{"id":"653b32efcf9e4a43a642e128557f6bb3","type":"GENE","name":"RNU6-1225P","canonical_id":"hgnc:HGNC:48188","description":"RNA, U6 small nuclear 1225, pseudogene","metadata":null},{"id":"2747440c3a4a460e901fbcd308e49b40","type":"GENE","name":"RNU6-1226P","canonical_id":"hgnc:HGNC:48189","description":"RNA, U6 small nuclear 1226, pseudogene","metadata":null},{"id":"530a1f0c3ed048eda3367986ef07d974","type":"GENE","name":"RNU6-1227P","canonical_id":"hgnc:HGNC:48190","description":"RNA, U6 small nuclear 1227, pseudogene","metadata":null},{"id":"6263c5a138434efda2924ccd1390716f","type":"GENE","name":"RNU6-1228P","canonical_id":"hgnc:HGNC:48191","description":"RNA, U6 small nuclear 1228, pseudogene","metadata":null},{"id":"c1915014608242b6bfbd42d5bd96c631","type":"GENE","name":"RNU6-1229P","canonical_id":"hgnc:HGNC:48192","description":"RNA, U6 small nuclear 1229, pseudogene","metadata":null},{"id":"f7125a707076430d9076a236c8477dd2","type":"GENE","name":"RNU6-122P","canonical_id":"hgnc:HGNC:47085","description":"RNA, U6 small nuclear 122, pseudogene","metadata":null},{"id":"e0ee886d0c7440af8ef12ff09f35eedb","type":"GENE","name":"RNU6-1230P","canonical_id":"hgnc:HGNC:48193","description":"RNA, U6 small nuclear 1230, pseudogene","metadata":null},{"id":"de01f3e1201642669087156dd7fe981b","type":"GENE","name":"RNU6-1231P","canonical_id":"hgnc:HGNC:48194","description":"RNA, U6 small nuclear 1231, pseudogene","metadata":null},{"id":"580fa9d298554b5cbc0ef80a5beaf03d","type":"GENE","name":"RNU6-1232P","canonical_id":"hgnc:HGNC:48195","description":"RNA, U6 small nuclear 1232, pseudogene","metadata":null},{"id":"79638c88d5354e7094096ac016ffd8e7","type":"GENE","name":"RNU6-1233P","canonical_id":"hgnc:HGNC:48196","description":"RNA, U6 small nuclear 1233, pseudogene","metadata":null},{"id":"fe4c87f1a871438da2be4a740917241d","type":"GENE","name":"RNU6-1234P","canonical_id":"hgnc:HGNC:48197","description":"RNA, U6 small nuclear 1234, pseudogene","metadata":null},{"id":"85bc04d0f14f48949e152085261879a6","type":"GENE","name":"RNU6-1235P","canonical_id":"hgnc:HGNC:48198","description":"RNA, U6 small nuclear 1235, pseudogene","metadata":null},{"id":"e6d9291cef9840b294cda0907f97073b","type":"GENE","name":"RNU6-1236P","canonical_id":"hgnc:HGNC:48199","description":"RNA, U6 small nuclear 1236, pseudogene","metadata":null},{"id":"a92b85c25c5049b09d1e588f1051707d","type":"GENE","name":"RNU6-1237P","canonical_id":"hgnc:HGNC:48200","description":"RNA, U6 small nuclear 1237, pseudogene","metadata":null},{"id":"8676711a3c964787bdf2f844ca921880","type":"GENE","name":"RNU6-1238P","canonical_id":"hgnc:HGNC:48201","description":"RNA, U6 small nuclear 1238, pseudogene","metadata":null},{"id":"2f0e2fdcb25944d68297c44c71e4d3db","type":"GENE","name":"RNU6-1239P","canonical_id":"hgnc:HGNC:48202","description":"RNA, U6 small nuclear 1239, pseudogene","metadata":null},{"id":"4206dc32cb8c4730b2e9de1a0c4f30d7","type":"GENE","name":"RNU6-123P","canonical_id":"hgnc:HGNC:47086","description":"RNA, U6 small nuclear 123, pseudogene","metadata":null},{"id":"63b6b7dc6674495eb68465dd44ed8372","type":"GENE","name":"RNU6-1240P","canonical_id":"hgnc:HGNC:48203","description":"RNA, U6 small nuclear 1240, pseudogene","metadata":null},{"id":"4fc0ce25e7e7427cbce9d9e897022334","type":"GENE","name":"RNU6-1241P","canonical_id":"hgnc:HGNC:48204","description":"RNA, U6 small nuclear 1241, pseudogene","metadata":null},{"id":"7d3cd469b6194731ba84fedba58fb760","type":"GENE","name":"RNU6-1242P","canonical_id":"hgnc:HGNC:48205","description":"RNA, U6 small nuclear 1242, pseudogene","metadata":null},{"id":"6d2e4fc07f404a2bba5ebf5bb98fab03","type":"GENE","name":"RNU6-1243P","canonical_id":"hgnc:HGNC:48206","description":"RNA, U6 small nuclear 1243, pseudogene","metadata":null},{"id":"26d1a4462e3f4fcd9cb7433e97636167","type":"GENE","name":"RNU6-1244P","canonical_id":"hgnc:HGNC:48207","description":"RNA, U6 small nuclear 1244, pseudogene","metadata":null},{"id":"970dc9132b8f4f0eba1bf2e112f96854","type":"GENE","name":"RNU6-1245P","canonical_id":"hgnc:HGNC:48208","description":"RNA, U6 small nuclear 1245, pseudogene","metadata":null},{"id":"1e2e21bc29574e00b6c77301f188099c","type":"GENE","name":"RNU6-1246P","canonical_id":"hgnc:HGNC:48209","description":"RNA, U6 small nuclear 1246, pseudogene","metadata":null},{"id":"2d111d329af7418e827c9a497ea9315b","type":"GENE","name":"RNU6-1247P","canonical_id":"hgnc:HGNC:48210","description":"RNA, U6 small nuclear 1247, pseudogene","metadata":null},{"id":"c2528ed02ede4ada9070e0ffecad63f3","type":"GENE","name":"RNU6-1248P","canonical_id":"hgnc:HGNC:48211","description":"RNA, U6 small nuclear 1248, pseudogene","metadata":null},{"id":"79cbe52e199d46ce9f93a4fa007efcff","type":"GENE","name":"RNU6-1249P","canonical_id":"hgnc:HGNC:48212","description":"RNA, U6 small nuclear 1249, pseudogene","metadata":null},{"id":"415a99e24ceb44a590a516d19d60c7af","type":"GENE","name":"RNU6-1250P","canonical_id":"hgnc:HGNC:48213","description":"RNA, U6 small nuclear 1250, pseudogene","metadata":null},{"id":"83c1084b99174129b8170c53b91e36d9","type":"GENE","name":"RNU6-1251P","canonical_id":"hgnc:HGNC:48214","description":"RNA, U6 small nuclear 1251, pseudogene","metadata":null},{"id":"f4a5c3dc4d574af5b2d2e7fec267d97a","type":"GENE","name":"RNU6-1252P","canonical_id":"hgnc:HGNC:48215","description":"RNA, U6 small nuclear 1252, pseudogene","metadata":null},{"id":"8cc164b313cc4f2fa2975991a9ed7d9d","type":"GENE","name":"RNU6-1254P","canonical_id":"hgnc:HGNC:48217","description":"RNA, U6 small nuclear 1254, pseudogene","metadata":null},{"id":"5eff33cb624f4f76bd81faefde0bac55","type":"GENE","name":"RNU6-1255P","canonical_id":"hgnc:HGNC:48218","description":"RNA, U6 small nuclear 1255, pseudogene","metadata":null},{"id":"b3df703f16e64e6c8130acceb566e95e","type":"GENE","name":"RNU6-1256P","canonical_id":"hgnc:HGNC:48219","description":"RNA, U6 small nuclear 1256, pseudogene","metadata":null},{"id":"1804288cea0d43a5a9a8bf2e4d124275","type":"GENE","name":"RNU6-1257P","canonical_id":"hgnc:HGNC:48220","description":"RNA, U6 small nuclear 1257, pseudogene","metadata":null},{"id":"fd823d9996cb474187a54ea90858794c","type":"GENE","name":"RNU6-1258P","canonical_id":"hgnc:HGNC:48221","description":"RNA, U6 small nuclear 1258, pseudogene","metadata":null},{"id":"e1a69f869e7f441ab11be70edb7190a9","type":"GENE","name":"RNU6-125P","canonical_id":"hgnc:HGNC:47088","description":"RNA, U6 small nuclear 125, pseudogene","metadata":null},{"id":"1eede816c91941ddabaf727da79906ce","type":"GENE","name":"RNU6-1260P","canonical_id":"hgnc:HGNC:48223","description":"RNA, U6 small nuclear 1260, pseudogene","metadata":null},{"id":"0a8346373d2847d1a2abc9acfb0a2679","type":"GENE","name":"RNU6-1261P","canonical_id":"hgnc:HGNC:48224","description":"RNA, U6 small nuclear 1261, pseudogene","metadata":null},{"id":"bcf834f7ab0c442b843beaa16d8ec925","type":"GENE","name":"RNU6-1262P","canonical_id":"hgnc:HGNC:48225","description":"RNA, U6 small nuclear 1262, pseudogene","metadata":null},{"id":"911d9dd3bb514e4abbe224deb6b5f3a3","type":"GENE","name":"RNU6-1263P","canonical_id":"hgnc:HGNC:48226","description":"RNA, U6 small nuclear 1263, pseudogene","metadata":null},{"id":"59e9c7a2739c4065bbad13243c5cfb84","type":"GENE","name":"RNU6-1264P","canonical_id":"hgnc:HGNC:48227","description":"RNA, U6 small nuclear 1264, pseudogene","metadata":null},{"id":"3cd2ac6126774e04879c8250caf9a29b","type":"GENE","name":"RNU6-1265P","canonical_id":"hgnc:HGNC:48228","description":"RNA, U6 small nuclear 1265, pseudogene","metadata":null},{"id":"68368a5bd1334409834afe8ccfb16641","type":"GENE","name":"RNU6-1266P","canonical_id":"hgnc:HGNC:48229","description":"RNA, U6 small nuclear 1266, pseudogene","metadata":null},{"id":"84b076ee1c67405db3a62485798f2d19","type":"GENE","name":"RNU6-1267P","canonical_id":"hgnc:HGNC:48230","description":"RNA, U6 small nuclear 1267, pseudogene","metadata":null},{"id":"2d4d2e9f596d4811b32d852d5eacf02a","type":"GENE","name":"RNU6-1268P","canonical_id":"hgnc:HGNC:48231","description":"RNA, U6 small nuclear 1268, pseudogene","metadata":null},{"id":"703800bda659451e84c328be3731183b","type":"GENE","name":"RNU6-1269P","canonical_id":"hgnc:HGNC:48232","description":"RNA, U6 small nuclear 1269, pseudogene","metadata":null},{"id":"1d954495d0d34857a3fc99024741f908","type":"GENE","name":"RNU6-126P","canonical_id":"hgnc:HGNC:47089","description":"RNA, U6 small nuclear 126, pseudogene","metadata":null},{"id":"03005162cc6d4ec98bd418ad3b141658","type":"GENE","name":"RNU6-1270P","canonical_id":"hgnc:HGNC:48233","description":"RNA, U6 small nuclear 1270, pseudogene","metadata":null},{"id":"8fc819c49ac84227934fa57257efb85e","type":"GENE","name":"RNU6-1271P","canonical_id":"hgnc:HGNC:48234","description":"RNA, U6 small nuclear 1271, pseudogene","metadata":null},{"id":"47847a9312e64e58ba55b05070fbcd90","type":"GENE","name":"RNU6-1272P","canonical_id":"hgnc:HGNC:48235","description":"RNA, U6 small nuclear 1272, pseudogene","metadata":null},{"id":"1619c589355345b692de5bfe865eb7df","type":"GENE","name":"RNU6-1273P","canonical_id":"hgnc:HGNC:48236","description":"RNA, U6 small nuclear 1273, pseudogene","metadata":null},{"id":"f496fe60b975488a9316559efe53a20c","type":"GENE","name":"RNU6-1274P","canonical_id":"hgnc:HGNC:48237","description":"RNA, U6 small nuclear 1274, pseudogene","metadata":null},{"id":"f0601079f9ab4517b9e7704bd9413b5f","type":"GENE","name":"RNU6-1275P","canonical_id":"hgnc:HGNC:48238","description":"RNA, U6 small nuclear 1275, pseudogene","metadata":null},{"id":"0fd6428f2a464536a4eed136b2862347","type":"GENE","name":"RNU6-1276P","canonical_id":"hgnc:HGNC:48239","description":"RNA, U6 small nuclear 1276, pseudogene","metadata":null},{"id":"bc11cef9bb4042778da2be7a4cd741ca","type":"GENE","name":"RNU6-1277P","canonical_id":"hgnc:HGNC:48240","description":"RNA, U6 small nuclear 1277, pseudogene","metadata":null},{"id":"29a38d12e9454652913b294e9d5d4e80","type":"GENE","name":"RNU6-1278P","canonical_id":"hgnc:HGNC:48241","description":"RNA, U6 small nuclear 1278, pseudogene","metadata":null},{"id":"9fca503bfcaa405682acb40c6acf9340","type":"GENE","name":"RNU6-1279P","canonical_id":"hgnc:HGNC:48242","description":"RNA, U6 small nuclear 1279, pseudogene","metadata":null},{"id":"c70514259a66486d8e2efc3c5750ac5c","type":"GENE","name":"RNU6-127P","canonical_id":"hgnc:HGNC:47090","description":"RNA, U6 small nuclear 127, pseudogene","metadata":null},{"id":"8e8a6ee28d94451aad9c425fc5816c01","type":"GENE","name":"RNU6-1280P","canonical_id":"hgnc:HGNC:48243","description":"RNA, U6 small nuclear 1280, pseudogene","metadata":null},{"id":"46314cae01f3475fbd88032410dbd254","type":"GENE","name":"RNU6-1281P","canonical_id":"hgnc:HGNC:48244","description":"RNA, U6 small nuclear 1281, pseudogene","metadata":null},{"id":"571d55bb2a794833a84251785a9b9168","type":"GENE","name":"RNU6-1282P","canonical_id":"hgnc:HGNC:48245","description":"RNA, U6 small nuclear 1282, pseudogene","metadata":null},{"id":"115edc26572b4c189a4963ed53fb1f2e","type":"GENE","name":"RNU6-1283P","canonical_id":"hgnc:HGNC:48246","description":"RNA, U6 small nuclear 1283, pseudogene","metadata":null},{"id":"63e0a03bada14a32bf25c908661a3eae","type":"GENE","name":"RNU6-1284P","canonical_id":"hgnc:HGNC:48247","description":"RNA, U6 small nuclear 1284, pseudogene","metadata":null},{"id":"ec5bfae14fae4b3c8f5362b254d0bcbf","type":"GENE","name":"RNU6-1285P","canonical_id":"hgnc:HGNC:48248","description":"RNA, U6 small nuclear 1285, pseudogene","metadata":null},{"id":"5de7cf5d758d4c8bb13ae5eeb4a9245e","type":"GENE","name":"RNU6-1286P","canonical_id":"hgnc:HGNC:48249","description":"RNA, U6 small nuclear 1286, pseudogene","metadata":null},{"id":"15a9bd639418411ba2fdf4a28182254c","type":"GENE","name":"RNU6-1287P","canonical_id":"hgnc:HGNC:48250","description":"RNA, U6 small nuclear 1287, pseudogene","metadata":null},{"id":"f0c45adc1cf345d19c63a0624456e7d2","type":"GENE","name":"RNU6-1288P","canonical_id":"hgnc:HGNC:48251","description":"RNA, U6 small nuclear 1288, pseudogene","metadata":null},{"id":"d46cbe8d691f48c2941fa1a0aa36db1f","type":"GENE","name":"RNU6-1289P","canonical_id":"hgnc:HGNC:48252","description":"RNA, U6 small nuclear 1289, pseudogene","metadata":null},{"id":"2739f16136434aad8c3f6f44abb091bf","type":"GENE","name":"RNU6-128P","canonical_id":"hgnc:HGNC:47091","description":"RNA, U6 small nuclear 128, pseudogene","metadata":null},{"id":"66973d05243b47beb66fcc773fff499d","type":"GENE","name":"RNU6-1290P","canonical_id":"hgnc:HGNC:48253","description":"RNA, U6 small nuclear 1290, pseudogene","metadata":null},{"id":"6e8d617f6274431b8885b5700d940ebc","type":"GENE","name":"RNU6-1291P","canonical_id":"hgnc:HGNC:48254","description":"RNA, U6 small nuclear 1291, pseudogene","metadata":null},{"id":"f59c9ac964384d63b252366f9289a30c","type":"GENE","name":"RNU6-1292P","canonical_id":"hgnc:HGNC:48255","description":"RNA, U6 small nuclear 1292, pseudogene","metadata":null},{"id":"666d4ee7d19c44afb6d14dca906bdd83","type":"GENE","name":"RNU6-1293P","canonical_id":"hgnc:HGNC:48256","description":"RNA, U6 small nuclear 1293, pseudogene","metadata":null},{"id":"83c1cfa1da7445f388393b786fc1bcbd","type":"GENE","name":"RNU6-1294P","canonical_id":"hgnc:HGNC:48257","description":"RNA, U6 small nuclear 1294, pseudogene","metadata":null},{"id":"a775f7921f724d229a90643d2cfa654c","type":"GENE","name":"RNU6-1296P","canonical_id":"hgnc:HGNC:48259","description":"RNA, U6 small nuclear 1296, pseudogene","metadata":null},{"id":"aca28764e9084f3e8622ae5af94a5daf","type":"GENE","name":"RNU6-1297P","canonical_id":"hgnc:HGNC:48260","description":"RNA, U6 small nuclear 1297, pseudogene","metadata":null},{"id":"149c0b65b3474334b8381ae4f1ec75fe","type":"GENE","name":"RNU6-1298P","canonical_id":"hgnc:HGNC:48261","description":"RNA, U6 small nuclear 1298, pseudogene","metadata":null},{"id":"67e5627e84744a039dbbcc3b831cb119","type":"GENE","name":"RNU6-1299P","canonical_id":"hgnc:HGNC:48262","description":"RNA, U6 small nuclear 1299, pseudogene","metadata":null},{"id":"62c8cf575803488d81dda59d84c6f036","type":"GENE","name":"RNU6-129P","canonical_id":"hgnc:HGNC:47092","description":"RNA, U6 small nuclear 129, pseudogene","metadata":null},{"id":"970143eaf1ab4317b6e3dedf41e180c2","type":"GENE","name":"RNU6-12P","canonical_id":"hgnc:HGNC:34256","description":"RNA, U6 small nuclear 12, pseudogene","metadata":{"aliases":["RNU6-12"]}},{"id":"105d1add6fd147c9a5ab56f14c7e829e","type":"GENE","name":"RNU6-1300P","canonical_id":"hgnc:HGNC:48263","description":"RNA, U6 small nuclear 1300, pseudogene","metadata":null},{"id":"ad6258652bef46fb998d0e5af50100bb","type":"GENE","name":"RNU6-1301P","canonical_id":"hgnc:HGNC:48264","description":"RNA, U6 small nuclear 1301, pseudogene","metadata":null},{"id":"c31eb53882444da589d62695aee9b104","type":"GENE","name":"RNU6-1303P","canonical_id":"hgnc:HGNC:48266","description":"RNA, U6 small nuclear 1303, pseudogene","metadata":null},{"id":"8ebdcc758c1f4c38abd4c6807153759f","type":"GENE","name":"RNU6-1304P","canonical_id":"hgnc:HGNC:48267","description":"RNA, U6 small nuclear 1304, pseudogene","metadata":null},{"id":"09f4e06f177b47beab3dc0589b96f0c5","type":"GENE","name":"RNU6-1305P","canonical_id":"hgnc:HGNC:48268","description":"RNA, U6 small nuclear 1305, pseudogene","metadata":null},{"id":"7123fc42b8c648f0b45d5175b848cea1","type":"GENE","name":"RNU6-1306P","canonical_id":"hgnc:HGNC:48269","description":"RNA, U6 small nuclear 1306, pseudogene","metadata":null},{"id":"1826f09f9e2d4a3faa67ec07a2d5d5da","type":"GENE","name":"RNU6-1307P","canonical_id":"hgnc:HGNC:48270","description":"RNA, U6 small nuclear 1307, pseudogene","metadata":null},{"id":"f527bee359f4422c89b735b6195c43d2","type":"GENE","name":"RNU6-1308P","canonical_id":"hgnc:HGNC:48271","description":"RNA, U6 small nuclear 1308, pseudogene","metadata":null},{"id":"900119580d44486f86387e52915925a5","type":"GENE","name":"RNU6-1309P","canonical_id":"hgnc:HGNC:48272","description":"RNA, U6 small nuclear 1309, pseudogene","metadata":null},{"id":"99b5ffa177914f1e88331a06360ddd55","type":"GENE","name":"RNU6-130P","canonical_id":"hgnc:HGNC:47093","description":"RNA, U6 small nuclear 130, pseudogene","metadata":null},{"id":"2ce58c3accd3450e9307e017af29ab4c","type":"GENE","name":"RNU6-1310P","canonical_id":"hgnc:HGNC:48273","description":"RNA, U6 small nuclear 1310, pseudogene","metadata":null},{"id":"e6be9882e3d441daab407caaf915fdb2","type":"GENE","name":"RNU6-1311P","canonical_id":"hgnc:HGNC:48274","description":"RNA, U6 small nuclear 1311, pseudogene","metadata":null},{"id":"057530b43a9f490787a2c00bf1ccab08","type":"GENE","name":"RNU6-1312P","canonical_id":"hgnc:HGNC:48275","description":"RNA, U6 small nuclear 1312, pseudogene","metadata":null},{"id":"143a346231c64c54bb153db64f03c541","type":"GENE","name":"RNU6-1313P","canonical_id":"hgnc:HGNC:48276","description":"RNA, U6 small nuclear 1313, pseudogene","metadata":null},{"id":"d6a091fc62794dbfa2c27037e11b334f","type":"GENE","name":"RNU6-1314P","canonical_id":"hgnc:HGNC:48277","description":"RNA, U6 small nuclear 1314, pseudogene","metadata":null},{"id":"6f3846ff20b546528da7cc68d66cdaea","type":"GENE","name":"RNU6-1315P","canonical_id":"hgnc:HGNC:48278","description":"RNA, U6 small nuclear 1315, pseudogene","metadata":null},{"id":"47684367c2f142a98b785b40df7d24ac","type":"GENE","name":"RNU6-1316P","canonical_id":"hgnc:HGNC:48279","description":"RNA, U6 small nuclear 1316, pseudogene","metadata":null},{"id":"16ff581324054a96a651a1b8ef3eb6cb","type":"GENE","name":"RNU6-1317P","canonical_id":"hgnc:HGNC:48280","description":"RNA, U6 small nuclear 1317, pseudogene","metadata":null},{"id":"2c3b448af05a48258da8aa8096f69950","type":"GENE","name":"RNU6-1318P","canonical_id":"hgnc:HGNC:48281","description":"RNA, U6 small nuclear 1318, pseudogene","metadata":null},{"id":"7834e033210f4c4d85ecd31b162b122e","type":"GENE","name":"RNU6-1319P","canonical_id":"hgnc:HGNC:48282","description":"RNA, U6 small nuclear 1319, pseudogene","metadata":null},{"id":"10c08bf5ff6f4b339868a13ddd91cbaf","type":"GENE","name":"RNU6-131P","canonical_id":"hgnc:HGNC:47094","description":"RNA, U6 small nuclear 131, pseudogene","metadata":null},{"id":"28a81b863e3f48519d494c39157d6025","type":"GENE","name":"RNU6-1320P","canonical_id":"hgnc:HGNC:48283","description":"RNA, U6 small nuclear 1320, pseudogene","metadata":null},{"id":"183298c90f9549eeaa0a172b3a24088e","type":"GENE","name":"RNU6-1321P","canonical_id":"hgnc:HGNC:48284","description":"RNA, U6 small nuclear 1321, pseudogene","metadata":null},{"id":"6e6c677d6172491fb8feef4e43e72d6c","type":"GENE","name":"RNU6-1322P","canonical_id":"hgnc:HGNC:48285","description":"RNA, U6 small nuclear 1322, pseudogene","metadata":null},{"id":"5db0655576d34badaf9ac42ed3cdfea9","type":"GENE","name":"RNU6-1323P","canonical_id":"hgnc:HGNC:48286","description":"RNA, U6 small nuclear 1323, pseudogene","metadata":null},{"id":"c24642ca186640699fc54a15784b6f9b","type":"GENE","name":"RNU6-1324P","canonical_id":"hgnc:HGNC:48287","description":"RNA, U6 small nuclear 1324, pseudogene","metadata":null},{"id":"430c28dc3c304a428abc415e6aeba9c1","type":"GENE","name":"RNU6-1325P","canonical_id":"hgnc:HGNC:48288","description":"RNA, U6 small nuclear 1325, pseudogene","metadata":null},{"id":"fdf970bce5d5427591b8923807c07c25","type":"GENE","name":"RNU6-1326P","canonical_id":"hgnc:HGNC:48289","description":"RNA, U6 small nuclear 1326, pseudogene","metadata":null},{"id":"224d986d756a481c889894673f33f35b","type":"GENE","name":"RNU6-1327P","canonical_id":"hgnc:HGNC:48290","description":"RNA, U6 small nuclear 1327, pseudogene","metadata":null},{"id":"408a9d15b70b4f0097d62deebe51dca4","type":"GENE","name":"RNU6-1328P","canonical_id":"hgnc:HGNC:48291","description":"RNA, U6 small nuclear 1328, pseudogene","metadata":null},{"id":"83196c25e0df454ea0c87d980a57aed6","type":"GENE","name":"RNU6-1329P","canonical_id":"hgnc:HGNC:48292","description":"RNA, U6 small nuclear 1329, pseudogene","metadata":null},{"id":"2d6b014079e343ef871f9c002cff37b0","type":"GENE","name":"RNU6-132P","canonical_id":"hgnc:HGNC:47095","description":"RNA, U6 small nuclear 132, pseudogene","metadata":null},{"id":"fdd41f726c594408b413b4cb6509b50b","type":"GENE","name":"RNU6-1330P","canonical_id":"hgnc:HGNC:48293","description":"RNA, U6 small nuclear 1330, pseudogene","metadata":null},{"id":"34b59ca856b04971b6a9dfcbfcbcb170","type":"GENE","name":"RNU6-1331P","canonical_id":"hgnc:HGNC:48294","description":"RNA, U6 small nuclear 1331, pseudogene","metadata":null},{"id":"babf6f05162d48539818b202089f40b7","type":"GENE","name":"RNU6-1332P","canonical_id":"hgnc:HGNC:48295","description":"RNA, U6 small nuclear 1332, pseudogene","metadata":null},{"id":"27e99cbc5c7341658d951dbe2864c6fe","type":"GENE","name":"RNU6-1333P","canonical_id":"hgnc:HGNC:48296","description":"RNA, U6 small nuclear 1333, pseudogene","metadata":null},{"id":"df08c04cdf6e4bfe99992e641c292e9c","type":"GENE","name":"RNU6-1334P","canonical_id":"hgnc:HGNC:48297","description":"RNA, U6 small nuclear 1334, pseudogene","metadata":null},{"id":"df8917981411484b830373f07e3b3ae2","type":"GENE","name":"RNU6-1335P","canonical_id":"hgnc:HGNC:48298","description":"RNA, U6 small nuclear 1335, pseudogene","metadata":null},{"id":"a304ed3b30274581b93d3ee6f35493a8","type":"GENE","name":"RNU6-1336P","canonical_id":"hgnc:HGNC:48299","description":"RNA, U6 small nuclear 1336, pseudogene","metadata":null},{"id":"952ff1eeb96d4022a4ef5ec278920350","type":"GENE","name":"RNU6-1337P","canonical_id":"hgnc:HGNC:48300","description":"RNA, U6 small nuclear 1337, pseudogene","metadata":null},{"id":"072de290ae454496a2e0466c3521504a","type":"GENE","name":"RNU6-1338P","canonical_id":"hgnc:HGNC:48301","description":"RNA, U6 small nuclear 1338, pseudogene","metadata":null},{"id":"6b99a327c40e4896824de3672d2e4239","type":"GENE","name":"RNU6-1339P","canonical_id":"hgnc:HGNC:48302","description":"RNA, U6 small nuclear 1339, pseudogene","metadata":null},{"id":"61dc4d606be04466ab956839bc6fb595","type":"GENE","name":"RNU6-133P","canonical_id":"hgnc:HGNC:47096","description":"RNA, U6 small nuclear 133, pseudogene","metadata":null},{"id":"ed14288084ab4e898f41ecbd89d2f8c6","type":"GENE","name":"RNU6-1340P","canonical_id":"hgnc:HGNC:48303","description":"RNA, U6 small nuclear 1340, pseudogene","metadata":null},{"id":"17c714a0e0854d2ea95286901d8efdd5","type":"GENE","name":"RNU6-1341P","canonical_id":"hgnc:HGNC:56863","description":"RNA, U6 small nuclear 1341, pseudogene","metadata":null},{"id":"69bcd727b05f4e609cc06380069610ae","type":"GENE","name":"RNU6-1342P","canonical_id":"hgnc:HGNC:56872","description":"RNA, U6 small nuclear 1342, pseudogene","metadata":null},{"id":"bdf247ec3b6043ad8d82f80e6500802e","type":"GENE","name":"RNU6-135P","canonical_id":"hgnc:HGNC:47098","description":"RNA, U6 small nuclear 135, pseudogene","metadata":null},{"id":"bf4254e797e34f688bdc38c16ad6c001","type":"GENE","name":"RNU6-136P","canonical_id":"hgnc:HGNC:47099","description":"RNA, U6 small nuclear 136, pseudogene","metadata":null},{"id":"0457bcb6608a4948b4622ed3ae11eb5d","type":"GENE","name":"RNU6-137P","canonical_id":"hgnc:HGNC:47100","description":"RNA, U6 small nuclear 137, pseudogene","metadata":null},{"id":"8d373b09329e45bd9e8c0c703f16e5d0","type":"GENE","name":"RNU6-138P","canonical_id":"hgnc:HGNC:47101","description":"RNA, U6 small nuclear 138, pseudogene","metadata":null},{"id":"9e16bd74348b4f809c802c5880604df1","type":"GENE","name":"RNU6-139P","canonical_id":"hgnc:HGNC:47102","description":"RNA, U6 small nuclear 139, pseudogene","metadata":null},{"id":"e6c7b7fccc0d499398900bbd19a0588c","type":"GENE","name":"RNU6-13P","canonical_id":"hgnc:HGNC:34257","description":"RNA, U6 small nuclear 13, pseudogene","metadata":{"aliases":["RNU6-13"]}},{"id":"f03d6df863d548a8b02b51486e2ee8f1","type":"GENE","name":"RNU6-140P","canonical_id":"hgnc:HGNC:47103","description":"RNA, U6 small nuclear 140, pseudogene","metadata":null},{"id":"aaade30cf5ae4aa6a2f5a2e61bcc7dd9","type":"GENE","name":"RNU6-141P","canonical_id":"hgnc:HGNC:47104","description":"RNA, U6 small nuclear 141, pseudogene","metadata":null},{"id":"443597cfc12842c1a492174aa1ae50ec","type":"GENE","name":"RNU6-142P","canonical_id":"hgnc:HGNC:47105","description":"RNA, U6 small nuclear 142, pseudogene","metadata":null},{"id":"4f5de6337ee44fc480f7d79456275611","type":"GENE","name":"RNU6-143P","canonical_id":"hgnc:HGNC:47106","description":"RNA, U6 small nuclear 143, pseudogene","metadata":null},{"id":"8cd6cf36c0d24c03b695eb919acc1b7b","type":"GENE","name":"RNU6-144P","canonical_id":"hgnc:HGNC:47107","description":"RNA, U6 small nuclear 144, pseudogene","metadata":null},{"id":"988a3b9a0d0544ca958d2cc8bdc6e219","type":"GENE","name":"RNU6-145P","canonical_id":"hgnc:HGNC:47108","description":"RNA, U6 small nuclear 145, pseudogene","metadata":null},{"id":"d2ff640a8e8644308f1fa29f3a4322c9","type":"GENE","name":"RNU6-146P","canonical_id":"hgnc:HGNC:47109","description":"RNA, U6 small nuclear 146, pseudogene","metadata":null},{"id":"31acebcb575e47248f29684d4e35ba5f","type":"GENE","name":"RNU6-147P","canonical_id":"hgnc:HGNC:47110","description":"RNA, U6 small nuclear 147, pseudogene","metadata":null},{"id":"15a2caebdfbf40bb977e92ba4ad57fc3","type":"GENE","name":"RNU6-148P","canonical_id":"hgnc:HGNC:47111","description":"RNA, U6 small nuclear 148, pseudogene","metadata":null},{"id":"a4a487d214334d7cbbe7ee759aeab195","type":"GENE","name":"RNU6-14P","canonical_id":"hgnc:HGNC:34258","description":"RNA, U6 small nuclear 14, pseudogene","metadata":{"aliases":["RNU6-14"]}},{"id":"9ed1fd38c4a34f0bae2dd6317fa4ad13","type":"GENE","name":"RNU6-150P","canonical_id":"hgnc:HGNC:47113","description":"RNA, U6 small nuclear 150, pseudogene","metadata":null},{"id":"8957be1e760e4085896133abb4e227ba","type":"GENE","name":"RNU6-151P","canonical_id":"hgnc:HGNC:47114","description":"RNA, U6 small nuclear 151, pseudogene","metadata":null},{"id":"3ddee198436c45139639124defa42733","type":"GENE","name":"RNU6-152P","canonical_id":"hgnc:HGNC:47115","description":"RNA, U6 small nuclear 152, pseudogene","metadata":null},{"id":"7b373d8d002140ddb1de1bace485cdd4","type":"GENE","name":"RNU6-153P","canonical_id":"hgnc:HGNC:47116","description":"RNA, U6 small nuclear 153, pseudogene","metadata":null},{"id":"3b619d4cb75b45169db4895b64969d98","type":"GENE","name":"RNU6-154P","canonical_id":"hgnc:HGNC:47117","description":"RNA, U6 small nuclear 154, pseudogene","metadata":null},{"id":"f8798fcdff064c2ea0bd30e9cdf22acf","type":"GENE","name":"RNU6-155P","canonical_id":"hgnc:HGNC:47118","description":"RNA, U6 small nuclear 155, pseudogene","metadata":null},{"id":"7aa12d98f2804dffb2d769ff98065185","type":"GENE","name":"RNU6-156P","canonical_id":"hgnc:HGNC:47119","description":"RNA, U6 small nuclear 156, pseudogene","metadata":null},{"id":"f59713a2626a4f379a78ac429be43527","type":"GENE","name":"RNU6-157P","canonical_id":"hgnc:HGNC:47120","description":"RNA, U6 small nuclear 157, pseudogene","metadata":null},{"id":"85268624201e4960a72819d5ed31b260","type":"GENE","name":"RNU6-158P","canonical_id":"hgnc:HGNC:47121","description":"RNA, U6 small nuclear 158, pseudogene","metadata":null},{"id":"4f2789f2c1624c03811b3c001458985e","type":"GENE","name":"RNU6-159P","canonical_id":"hgnc:HGNC:47122","description":"RNA, U6 small nuclear 159, pseudogene","metadata":null},{"id":"d4b5b16fb6f148e3b73d4291235e78a9","type":"GENE","name":"RNU6-15P","canonical_id":"hgnc:HGNC:34259","description":"RNA, U6 small nuclear 15, pseudogene","metadata":{"aliases":["RNU6-15"]}},{"id":"87c8fee40bf744d099eacd44377ba08f","type":"GENE","name":"RNU6-160P","canonical_id":"hgnc:HGNC:47123","description":"RNA, U6 small nuclear 160, pseudogene","metadata":null},{"id":"97d63c2043774d9da09a2f3b0d99bde3","type":"GENE","name":"RNU6-161P","canonical_id":"hgnc:HGNC:47124","description":"RNA, U6 small nuclear 161, pseudogene","metadata":null},{"id":"167b9eba989046ea84aa129f6e27acc0","type":"GENE","name":"RNU6-162P","canonical_id":"hgnc:HGNC:47125","description":"RNA, U6 small nuclear 162, pseudogene","metadata":null},{"id":"8cbde8fe89484c2d9a8a0225cc51bb8f","type":"GENE","name":"RNU6-163P","canonical_id":"hgnc:HGNC:47126","description":"RNA, U6 small nuclear 163, pseudogene","metadata":null},{"id":"cdb2c505b1954ef9835b74e42c99591b","type":"GENE","name":"RNU6-164P","canonical_id":"hgnc:HGNC:47127","description":"RNA, U6 small nuclear 164, pseudogene","metadata":null},{"id":"bfb3961b76d448de8f33c7f82e90fa0a","type":"GENE","name":"RNU6-165P","canonical_id":"hgnc:HGNC:47128","description":"RNA, U6 small nuclear 165, pseudogene","metadata":null},{"id":"0f5228e5aaab4d5da1231f27cc959ccc","type":"GENE","name":"RNU6-166P","canonical_id":"hgnc:HGNC:47129","description":"RNA, U6 small nuclear 166, pseudogene","metadata":null},{"id":"d5adeef865cb4f0eb511a5290170fb65","type":"GENE","name":"RNU6-167P","canonical_id":"hgnc:HGNC:47130","description":"RNA, U6 small nuclear 167, pseudogene","metadata":null},{"id":"5069c187c8af41558bf05f5efc470d57","type":"GENE","name":"RNU6-168P","canonical_id":"hgnc:HGNC:47131","description":"RNA, U6 small nuclear 168, pseudogene","metadata":null},{"id":"b2dcdb5cf13e472483e25daaf7cb3127","type":"GENE","name":"RNU6-169P","canonical_id":"hgnc:HGNC:47132","description":"RNA, U6 small nuclear 169, pseudogene","metadata":null},{"id":"c0ac4cc26cdd438cba7a979cffa93799","type":"GENE","name":"RNU6-16P","canonical_id":"hgnc:HGNC:34260","description":"RNA, U6 small nuclear 16, pseudogene","metadata":{"aliases":["RNU6-16"]}},{"id":"a5e0023ab6e54cc4a3c25594ef49d84e","type":"GENE","name":"RNU6-170P","canonical_id":"hgnc:HGNC:47133","description":"RNA, U6 small nuclear 170, pseudogene","metadata":null},{"id":"bb9c10ad78d44f40a9e40c53e8407596","type":"GENE","name":"RNU6-171P","canonical_id":"hgnc:HGNC:47134","description":"RNA, U6 small nuclear 171, pseudogene","metadata":null},{"id":"f02f2dd3cfef4417b7329f654e6d0e4e","type":"GENE","name":"RNU6-172P","canonical_id":"hgnc:HGNC:47135","description":"RNA, U6 small nuclear 172, pseudogene","metadata":null},{"id":"4384558e5baa4476a51b6d86a114435f","type":"GENE","name":"RNU6-173P","canonical_id":"hgnc:HGNC:47136","description":"RNA, U6 small nuclear 173, pseudogene","metadata":null},{"id":"270ebcb62cbb4353809f0df13d25ff3b","type":"GENE","name":"RNU6-174P","canonical_id":"hgnc:HGNC:47137","description":"RNA, U6 small nuclear 174, pseudogene","metadata":null},{"id":"c302fe8f154d402dacc2ff25598d34b8","type":"GENE","name":"RNU6-175P","canonical_id":"hgnc:HGNC:47138","description":"RNA, U6 small nuclear 175, pseudogene","metadata":null},{"id":"1ca2ccf1fe7946e3a7540277b7e3533f","type":"GENE","name":"RNU6-176P","canonical_id":"hgnc:HGNC:47139","description":"RNA, U6 small nuclear 176, pseudogene","metadata":null},{"id":"a0f7da3ea0e9464ca474e2aeaf7da8d1","type":"GENE","name":"RNU6-177P","canonical_id":"hgnc:HGNC:47140","description":"RNA, U6 small nuclear 177, pseudogene","metadata":null},{"id":"d3eeb6d4f67342de935450b13b7b039e","type":"GENE","name":"RNU6-178P","canonical_id":"hgnc:HGNC:47141","description":"RNA, U6 small nuclear 178, pseudogene","metadata":null},{"id":"6413ea86c6fc4e8ab2e0694dfbc753dc","type":"GENE","name":"RNU6-179P","canonical_id":"hgnc:HGNC:47142","description":"RNA, U6 small nuclear 179, pseudogene","metadata":null},{"id":"3353de055cfd46dd86e72e8f7c545ee8","type":"GENE","name":"RNU6-17P","canonical_id":"hgnc:HGNC:34261","description":"RNA, U6 small nuclear 17, pseudogene","metadata":{"aliases":["RNU6-17"]}},{"id":"207abff5a44d42c696014e6e0ef3c076","type":"GENE","name":"RNU6-180P","canonical_id":"hgnc:HGNC:47143","description":"RNA, U6 small nuclear 180, pseudogene","metadata":null},{"id":"5cf2d940770644e18cda7ed4dfe0df6d","type":"GENE","name":"RNU6-181P","canonical_id":"hgnc:HGNC:47144","description":"RNA, U6 small nuclear 181, pseudogene","metadata":null},{"id":"81ebf51e6ca24c6188081b576d1468f4","type":"GENE","name":"RNU6-182P","canonical_id":"hgnc:HGNC:47145","description":"RNA, U6 small nuclear 182, pseudogene","metadata":null},{"id":"27f6f4a98acb4014814fcc6ef284aefa","type":"GENE","name":"RNU6-183P","canonical_id":"hgnc:HGNC:47146","description":"RNA, U6 small nuclear 183, pseudogene","metadata":null},{"id":"3bd0d3b14ea24fc085f6d3b168b1d8b9","type":"GENE","name":"RNU6-184P","canonical_id":"hgnc:HGNC:47147","description":"RNA, U6 small nuclear 184, pseudogene","metadata":null},{"id":"811269f0e75f4f9ca9959989c53b103d","type":"GENE","name":"RNU6-185P","canonical_id":"hgnc:HGNC:47148","description":"RNA, U6 small nuclear 185, pseudogene","metadata":null},{"id":"6e74861f1a8b4f9b8442a04672bda7f3","type":"GENE","name":"RNU6-187P","canonical_id":"hgnc:HGNC:47150","description":"RNA, U6 small nuclear 187, pseudogene","metadata":null},{"id":"703b2ac430f74b35a8c85a45d5692880","type":"GENE","name":"RNU6-188P","canonical_id":"hgnc:HGNC:47151","description":"RNA, U6 small nuclear 188, pseudogene","metadata":null},{"id":"dc060b14186d47c58df21bf6fd01e0ee","type":"GENE","name":"RNU6-189P","canonical_id":"hgnc:HGNC:47152","description":"RNA, U6 small nuclear 189, pseudogene","metadata":null},{"id":"6d9962d9001444a7bf3e1fedd86e85ee","type":"GENE","name":"RNU6-18P","canonical_id":"hgnc:HGNC:34262","description":"RNA, U6 small nuclear 18, pseudogene","metadata":{"aliases":["RNU6-18"]}},{"id":"456677ab825c4290a6068c4631cdeb63","type":"GENE","name":"RNU6-190P","canonical_id":"hgnc:HGNC:47153","description":"RNA, U6 small nuclear 190, pseudogene","metadata":null},{"id":"be98ad01fc414a3195cb746f55fa74d7","type":"GENE","name":"RNU6-191P","canonical_id":"hgnc:HGNC:47154","description":"RNA, U6 small nuclear 191, pseudogene","metadata":null},{"id":"bbf656585960484fabaa5cf764799eff","type":"GENE","name":"RNU6-192P","canonical_id":"hgnc:HGNC:47155","description":"RNA, U6 small nuclear 192, pseudogene","metadata":null},{"id":"d1e6d67d3afc4950be80034ffdc42de8","type":"GENE","name":"RNU6-193P","canonical_id":"hgnc:HGNC:47156","description":"RNA, U6 small nuclear 193, pseudogene","metadata":null},{"id":"ed1a689398314ad28036dba0e928d467","type":"GENE","name":"RNU6-194P","canonical_id":"hgnc:HGNC:47157","description":"RNA, U6 small nuclear 194, pseudogene","metadata":null},{"id":"7cc65305c82c4b9f8f79ea5a4bf8b5d5","type":"GENE","name":"RNU6-195P","canonical_id":"hgnc:HGNC:47158","description":"RNA, U6 small nuclear 195, pseudogene","metadata":null},{"id":"d53b65f5130941d5a15e690d4ad18822","type":"GENE","name":"RNU6-196P","canonical_id":"hgnc:HGNC:47159","description":"RNA, U6 small nuclear 196, pseudogene","metadata":null},{"id":"012833c1c6d744279e5122164d08b171","type":"GENE","name":"RNU6-197P","canonical_id":"hgnc:HGNC:47160","description":"RNA, U6 small nuclear 197, pseudogene","metadata":null},{"id":"f58f36a35c0c44e99bfe4c1774b41580","type":"GENE","name":"RNU6-198P","canonical_id":"hgnc:HGNC:47161","description":"RNA, U6 small nuclear 198, pseudogene","metadata":null},{"id":"bc345688105a4848ab2b81b93b3da676","type":"GENE","name":"RNU6-199P","canonical_id":"hgnc:HGNC:47162","description":"RNA, U6 small nuclear 199, pseudogene","metadata":null},{"id":"ff63f63a99b440c8ba0c4754a6792dcd","type":"GENE","name":"RNU6-19P","canonical_id":"hgnc:HGNC:34263","description":"RNA, U6 small nuclear 19, pseudogene","metadata":{"aliases":["RNU6-19"]}},{"id":"63555be7e1bb4997b6228d3e7a8cbd6c","type":"GENE","name":"RNU6-2","canonical_id":"hgnc:HGNC:34270","description":"RNA, U6 small nuclear 2","metadata":{"aliases":["U6-2","RNU6B"]}},{"id":"e96d128e94af4d778ef6fd0ee52d84c2","type":"GENE","name":"RNU6-200P","canonical_id":"hgnc:HGNC:47163","description":"RNA, U6 small nuclear 200, pseudogene","metadata":null},{"id":"7f48467b61d24d70bc14bcce97f9a25a","type":"GENE","name":"RNU6-201P","canonical_id":"hgnc:HGNC:47164","description":"RNA, U6 small nuclear 201, pseudogene","metadata":null},{"id":"c001140945c44f96812453a6b20123a9","type":"GENE","name":"RNU6-202P","canonical_id":"hgnc:HGNC:47165","description":"RNA, U6 small nuclear 202, pseudogene","metadata":null},{"id":"6a11e446185b412e9cbaf59a93ad7425","type":"GENE","name":"RNU6-203P","canonical_id":"hgnc:HGNC:47166","description":"RNA, U6 small nuclear 203, pseudogene","metadata":null},{"id":"25c0d4138c394a1699cb8737d9195a88","type":"GENE","name":"RNU6-204P","canonical_id":"hgnc:HGNC:47167","description":"RNA, U6 small nuclear 204, pseudogene","metadata":null},{"id":"6c01d841088f4127a14dce563742d484","type":"GENE","name":"RNU6-205P","canonical_id":"hgnc:HGNC:47168","description":"RNA, U6 small nuclear 205, pseudogene","metadata":null},{"id":"2094e647c9214852b9e1b6f58cdf3e0d","type":"GENE","name":"RNU6-206P","canonical_id":"hgnc:HGNC:47169","description":"RNA, U6 small nuclear 206, pseudogene","metadata":null},{"id":"aa6860bbbf394ac286bba361a08352bf","type":"GENE","name":"RNU6-207P","canonical_id":"hgnc:HGNC:47170","description":"RNA, U6 small nuclear 207, pseudogene","metadata":null},{"id":"041c9825d0fe4b9fad66c5fc127d31fe","type":"GENE","name":"RNU6-208P","canonical_id":"hgnc:HGNC:47171","description":"RNA, U6 small nuclear 208, pseudogene","metadata":null},{"id":"c8966a47ac9d44579e4216a3b22253a2","type":"GENE","name":"RNU6-209P","canonical_id":"hgnc:HGNC:47172","description":"RNA, U6 small nuclear 209, pseudogene","metadata":null},{"id":"81b8e00f092b402a952aea5b23326af2","type":"GENE","name":"RNU6-20P","canonical_id":"hgnc:HGNC:34264","description":"RNA, U6 small nuclear 20, pseudogene","metadata":{"aliases":["RNU6-20"]}},{"id":"9033f0e50fc14d60a99ece37ec695b88","type":"GENE","name":"RNU6-210P","canonical_id":"hgnc:HGNC:47173","description":"RNA, U6 small nuclear 210, pseudogene","metadata":null},{"id":"2d632b2e5e4347779e259def65aaff26","type":"GENE","name":"RNU6-211P","canonical_id":"hgnc:HGNC:47174","description":"RNA, U6 small nuclear 211, pseudogene","metadata":null},{"id":"0e60e888abd34567a13d610e5337394f","type":"GENE","name":"RNU6-212P","canonical_id":"hgnc:HGNC:47175","description":"RNA, U6 small nuclear 212, pseudogene","metadata":null},{"id":"dc248a92854c4e76bed80d16729d1e79","type":"GENE","name":"RNU6-213P","canonical_id":"hgnc:HGNC:47176","description":"RNA, U6 small nuclear 213, pseudogene","metadata":{"aliases":["RNU6-1033P"]}},{"id":"6db9b7c31bd843c2a92cf284898f1a1d","type":"GENE","name":"RNU6-214P","canonical_id":"hgnc:HGNC:47177","description":"RNA, U6 small nuclear 214, pseudogene","metadata":null},{"id":"15fd2e91dd9d430d875da4498f38df8f","type":"GENE","name":"RNU6-215P","canonical_id":"hgnc:HGNC:47178","description":"RNA, U6 small nuclear 215, pseudogene","metadata":null},{"id":"ea940ba4fc214ca6a968145c56e4a405","type":"GENE","name":"RNU6-216P","canonical_id":"hgnc:HGNC:47179","description":"RNA, U6 small nuclear 216, pseudogene","metadata":null},{"id":"2c206d2fbb9f4ba5a0eb55eb0feb4b6e","type":"GENE","name":"RNU6-217P","canonical_id":"hgnc:HGNC:47180","description":"RNA, U6 small nuclear 217, pseudogene","metadata":null},{"id":"3b273322f6794f0cab95181addfc9067","type":"GENE","name":"RNU6-218P","canonical_id":"hgnc:HGNC:47181","description":"RNA, U6 small nuclear 218, pseudogene","metadata":null},{"id":"56c4ffc1e4174f70b0e9ea221a400a79","type":"GENE","name":"RNU6-219P","canonical_id":"hgnc:HGNC:47182","description":"RNA, U6 small nuclear 219, pseudogene","metadata":null},{"id":"f7fb8852f59a45e2a057bd4cbf55207d","type":"GENE","name":"RNU6-21P","canonical_id":"hgnc:HGNC:34265","description":"RNA, U6 small nuclear 21, pseudogene","metadata":{"aliases":["RNU6-21"]}},{"id":"f64b81337ab7445c9ee3ee31d278cf4a","type":"GENE","name":"RNU6-220P","canonical_id":"hgnc:HGNC:47183","description":"RNA, U6 small nuclear 220, pseudogene","metadata":null},{"id":"a5af99dd762d429db8a42af6f439b50c","type":"GENE","name":"RNU6-221P","canonical_id":"hgnc:HGNC:47184","description":"RNA, U6 small nuclear 221, pseudogene","metadata":null},{"id":"440b201f747c4b18ad8e170ca3d27be5","type":"GENE","name":"RNU6-222P","canonical_id":"hgnc:HGNC:47185","description":"RNA, U6 small nuclear 222, pseudogene","metadata":null},{"id":"9decc2fd214e41f6ab504e59c63abcc2","type":"GENE","name":"RNU6-223P","canonical_id":"hgnc:HGNC:47186","description":"RNA, U6 small nuclear 223, pseudogene","metadata":null},{"id":"1c3f3c688ce1442ab61f7c3c4a958255","type":"GENE","name":"RNU6-224P","canonical_id":"hgnc:HGNC:47187","description":"RNA, U6 small nuclear 224, pseudogene","metadata":null},{"id":"536d2a89e23147c5bb5245aaa5c84bae","type":"GENE","name":"RNU6-225P","canonical_id":"hgnc:HGNC:47188","description":"RNA, U6 small nuclear 225, pseudogene","metadata":null},{"id":"f56519417f2142cea003b9acff8f6c14","type":"GENE","name":"RNU6-226P","canonical_id":"hgnc:HGNC:47189","description":"RNA, U6 small nuclear 226, pseudogene","metadata":null},{"id":"2ed198db362447688c4a28269ab22882","type":"GENE","name":"RNU6-227P","canonical_id":"hgnc:HGNC:47190","description":"RNA, U6 small nuclear 227, pseudogene","metadata":null},{"id":"fc684756cfb54204a8a371288ef7fb08","type":"GENE","name":"RNU6-228P","canonical_id":"hgnc:HGNC:47191","description":"RNA, U6 small nuclear 228, pseudogene","metadata":null},{"id":"6784835f3bec43cdb6c91cf7de9f4c50","type":"GENE","name":"RNU6-229P","canonical_id":"hgnc:HGNC:47192","description":"RNA, U6 small nuclear 229, pseudogene","metadata":null},{"id":"07876f11a604450b984fff6d73415477","type":"GENE","name":"RNU6-22P","canonical_id":"hgnc:HGNC:34266","description":"RNA, U6 small nuclear 22, pseudogene","metadata":{"aliases":["RNU6-22"]}},{"id":"1fd87110fae24789883f67a0e0c252b3","type":"GENE","name":"RNU6-230P","canonical_id":"hgnc:HGNC:47193","description":"RNA, U6 small nuclear 230, pseudogene","metadata":null},{"id":"2afc999faf3a4e2d9a223ae50c8d226d","type":"GENE","name":"RNU6-231P","canonical_id":"hgnc:HGNC:47194","description":"RNA, U6 small nuclear 231, pseudogene","metadata":null},{"id":"ea41ac08222d4d4c834a83eebf8f394a","type":"GENE","name":"RNU6-232P","canonical_id":"hgnc:HGNC:47195","description":"RNA, U6 small nuclear 232, pseudogene","metadata":null},{"id":"1848356bf4a24384a9f705b6efb484e9","type":"GENE","name":"RNU6-233P","canonical_id":"hgnc:HGNC:47196","description":"RNA, U6 small nuclear 233, pseudogene","metadata":null},{"id":"484d4079f544481d9c09b6da3516300a","type":"GENE","name":"RNU6-234P","canonical_id":"hgnc:HGNC:47197","description":"RNA, U6 small nuclear 234, pseudogene","metadata":null},{"id":"37bbbd7d22da4a0baedd838fdbe460d6","type":"GENE","name":"RNU6-235P","canonical_id":"hgnc:HGNC:47198","description":"RNA, U6 small nuclear 235, pseudogene","metadata":null},{"id":"9f683408579d4aa7819344853fa7c44f","type":"GENE","name":"RNU6-236P","canonical_id":"hgnc:HGNC:47199","description":"RNA, U6 small nuclear 236, pseudogene","metadata":null},{"id":"47f8905d43f4462089f47cf0a93a4821","type":"GENE","name":"RNU6-237P","canonical_id":"hgnc:HGNC:47200","description":"RNA, U6 small nuclear 237, pseudogene","metadata":null},{"id":"03011c0c2d1e4be79afe75e7cf110a48","type":"GENE","name":"RNU6-238P","canonical_id":"hgnc:HGNC:47201","description":"RNA, U6 small nuclear 238, pseudogene","metadata":null},{"id":"7a98a5cdae7b480bbb26a6c0693e2798","type":"GENE","name":"RNU6-239P","canonical_id":"hgnc:HGNC:47202","description":"RNA, U6 small nuclear 239, pseudogene","metadata":null},{"id":"11827e866a43437e9b05c528abe40ec5","type":"GENE","name":"RNU6-23P","canonical_id":"hgnc:HGNC:34267","description":"RNA, U6 small nuclear 23, pseudogene","metadata":{"aliases":["RNU6-23"]}},{"id":"ac4c78371bc14cdfb8d141d9502a23d2","type":"GENE","name":"RNU6-240P","canonical_id":"hgnc:HGNC:47203","description":"RNA, U6 small nuclear 240, pseudogene","metadata":null},{"id":"811b1da87c0e4195b7b5cba159066ef1","type":"GENE","name":"RNU6-241P","canonical_id":"hgnc:HGNC:47204","description":"RNA, U6 small nuclear 241, pseudogene","metadata":null},{"id":"f1d1f7792e9d4ce5b6d3306077666741","type":"GENE","name":"RNU6-242P","canonical_id":"hgnc:HGNC:47205","description":"RNA, U6 small nuclear 242, pseudogene","metadata":null},{"id":"dbdce5c73cd24b7d81b70fc79ff82768","type":"GENE","name":"RNU6-243P","canonical_id":"hgnc:HGNC:47206","description":"RNA, U6 small nuclear 243, pseudogene","metadata":null},{"id":"1a5e5e08c27848b79ed956d4976ebdf6","type":"GENE","name":"RNU6-244P","canonical_id":"hgnc:HGNC:47207","description":"RNA, U6 small nuclear 244, pseudogene","metadata":null},{"id":"b358c6e2512c4b60952814b2c6fdf79a","type":"GENE","name":"RNU6-245P","canonical_id":"hgnc:HGNC:47208","description":"RNA, U6 small nuclear 245, pseudogene","metadata":null},{"id":"a7101210e7b14cc5be40cbe147d45281","type":"GENE","name":"RNU6-246P","canonical_id":"hgnc:HGNC:47209","description":"RNA, U6 small nuclear 246, pseudogene","metadata":null},{"id":"3832692f3bb342d6a9e626f24954a443","type":"GENE","name":"RNU6-247P","canonical_id":"hgnc:HGNC:47210","description":"RNA, U6 small nuclear 247, pseudogene","metadata":null},{"id":"7fdc7f484a104cb3a4d2b59af3b10063","type":"GENE","name":"RNU6-248P","canonical_id":"hgnc:HGNC:47211","description":"RNA, U6 small nuclear 248, pseudogene","metadata":null},{"id":"b13ed8e57e6345268add8fde38d60437","type":"GENE","name":"RNU6-249P","canonical_id":"hgnc:HGNC:47212","description":"RNA, U6 small nuclear 249, pseudogene","metadata":null},{"id":"fc3068fb2cd64b71b72ff190abf2faea","type":"GENE","name":"RNU6-24P","canonical_id":"hgnc:HGNC:34268","description":"RNA, U6 small nuclear 24, pseudogene","metadata":{"aliases":["RNU6-24"]}},{"id":"8d107ddba93548b79387b0625962e315","type":"GENE","name":"RNU6-250P","canonical_id":"hgnc:HGNC:47213","description":"RNA, U6 small nuclear 250, pseudogene","metadata":null},{"id":"42e1673b33df467a84257b04e7f162bb","type":"GENE","name":"RNU6-251P","canonical_id":"hgnc:HGNC:47214","description":"RNA, U6 small nuclear 251, pseudogene","metadata":null},{"id":"765c184695e24c69ab74c3eefc562fb2","type":"GENE","name":"RNU6-252P","canonical_id":"hgnc:HGNC:47215","description":"RNA, U6 small nuclear 252, pseudogene","metadata":null},{"id":"43a8d984474e48aba8f4c1a24bb1d0c0","type":"GENE","name":"RNU6-253P","canonical_id":"hgnc:HGNC:47216","description":"RNA, U6 small nuclear 253, pseudogene","metadata":null},{"id":"ded7dd002d8e479db4ea9ee520655b1e","type":"GENE","name":"RNU6-254P","canonical_id":"hgnc:HGNC:47217","description":"RNA, U6 small nuclear 254, pseudogene","metadata":null},{"id":"002c977c28894dc9bf2f964a3237433e","type":"GENE","name":"RNU6-255P","canonical_id":"hgnc:HGNC:47218","description":"RNA, U6 small nuclear 255, pseudogene","metadata":null},{"id":"79470722f07d49c6a3aa37fc4d072cf4","type":"GENE","name":"RNU6-256P","canonical_id":"hgnc:HGNC:47219","description":"RNA, U6 small nuclear 256, pseudogene","metadata":null},{"id":"4a1471021ff9455a9665627a8aebc562","type":"GENE","name":"RNU6-257P","canonical_id":"hgnc:HGNC:47220","description":"RNA, U6 small nuclear 257, pseudogene","metadata":null},{"id":"eb5183fdda9b4d7fad9db84dca10b8e5","type":"GENE","name":"RNU6-258P","canonical_id":"hgnc:HGNC:47221","description":"RNA, U6 small nuclear 258, pseudogene","metadata":null},{"id":"42ca0cd3aa004c6190b90e3a3fd40a80","type":"GENE","name":"RNU6-259P","canonical_id":"hgnc:HGNC:47222","description":"RNA, U6 small nuclear 259, pseudogene","metadata":null},{"id":"ed47dd1c0a244fa4b2302aa65423a6d3","type":"GENE","name":"RNU6-25P","canonical_id":"hgnc:HGNC:34251","description":"RNA, U6 small nuclear 25, pseudogene","metadata":{"aliases":["RNU6-25"]}},{"id":"79a6910b581e4aad89f88800de5af469","type":"GENE","name":"RNU6-260P","canonical_id":"hgnc:HGNC:47223","description":"RNA, U6 small nuclear 260, pseudogene","metadata":null},{"id":"11017999725c45ef89ae7c2fe8be178f","type":"GENE","name":"RNU6-261P","canonical_id":"hgnc:HGNC:47224","description":"RNA, U6 small nuclear 261, pseudogene","metadata":null},{"id":"4aa64eb996574ef4bb2c5e09f61360bf","type":"GENE","name":"RNU6-262P","canonical_id":"hgnc:HGNC:47225","description":"RNA, U6 small nuclear 262, pseudogene","metadata":null},{"id":"3c21b4780458492db0b34053997809e8","type":"GENE","name":"RNU6-263P","canonical_id":"hgnc:HGNC:47226","description":"RNA, U6 small nuclear 263, pseudogene","metadata":null},{"id":"a3d3f528066e4efaa6767f82cc1e4411","type":"GENE","name":"RNU6-264P","canonical_id":"hgnc:HGNC:47227","description":"RNA, U6 small nuclear 264, pseudogene","metadata":null},{"id":"f5d2ef83394e4df392548043d66aa080","type":"GENE","name":"RNU6-266P","canonical_id":"hgnc:HGNC:47229","description":"RNA, U6 small nuclear 266, pseudogene","metadata":null},{"id":"3d3d5f555583439b8cad04f48483ed75","type":"GENE","name":"RNU6-267P","canonical_id":"hgnc:HGNC:47230","description":"RNA, U6 small nuclear 267, pseudogene","metadata":null},{"id":"8c421ba12866468ca02a1a3adfd40536","type":"GENE","name":"RNU6-268P","canonical_id":"hgnc:HGNC:47231","description":"RNA, U6 small nuclear 268, pseudogene","metadata":null},{"id":"c3e89dd2e41b4643b2d8cb40b703ae49","type":"GENE","name":"RNU6-269P","canonical_id":"hgnc:HGNC:47232","description":"RNA, U6 small nuclear 269, pseudogene","metadata":null},{"id":"b99a288ce366428ebaaecd540cba0f2c","type":"GENE","name":"RNU6-26P","canonical_id":"hgnc:HGNC:34252","description":"RNA, U6 small nuclear 26, pseudogene","metadata":{"aliases":["RNU6-26"]}},{"id":"693693e9161b46adaba6c2db74e850a0","type":"GENE","name":"RNU6-270P","canonical_id":"hgnc:HGNC:47233","description":"RNA, U6 small nuclear 270, pseudogene","metadata":null},{"id":"c9a33c07c61f47bcaf639a6ab0d994d5","type":"GENE","name":"RNU6-271P","canonical_id":"hgnc:HGNC:47234","description":"RNA, U6 small nuclear 271, pseudogene","metadata":null},{"id":"63e447df4380412dba2eace0d8602ac8","type":"GENE","name":"RNU6-272P","canonical_id":"hgnc:HGNC:47235","description":"RNA, U6 small nuclear 272, pseudogene","metadata":null},{"id":"d7e9779f19034c83bcce9ce87fc87df5","type":"GENE","name":"RNU6-273P","canonical_id":"hgnc:HGNC:47236","description":"RNA, U6 small nuclear 273, pseudogene","metadata":null},{"id":"ffdb990f5e6a447f9fada8e6d62ba3fb","type":"GENE","name":"RNU6-274P","canonical_id":"hgnc:HGNC:47237","description":"RNA, U6 small nuclear 274, pseudogene","metadata":null},{"id":"cebec67c6f354d369d3c7140a0f53756","type":"GENE","name":"RNU6-275P","canonical_id":"hgnc:HGNC:47238","description":"RNA, U6 small nuclear 275, pseudogene","metadata":null},{"id":"172c485f349b4d988bfd849d378aefa5","type":"GENE","name":"RNU6-276P","canonical_id":"hgnc:HGNC:47239","description":"RNA, U6 small nuclear 276, pseudogene","metadata":null},{"id":"7963fa9580aa4c068b4b02fb41725b8f","type":"GENE","name":"RNU6-277P","canonical_id":"hgnc:HGNC:47240","description":"RNA, U6 small nuclear 277, pseudogene","metadata":null},{"id":"8a91f7d9bbb3404ea9a28cede2c09b01","type":"GENE","name":"RNU6-278P","canonical_id":"hgnc:HGNC:47241","description":"RNA, U6 small nuclear 278, pseudogene","metadata":null},{"id":"b2e32b806bc34e5c84c01250af456998","type":"GENE","name":"RNU6-279P","canonical_id":"hgnc:HGNC:47242","description":"RNA, U6 small nuclear 279, pseudogene","metadata":null},{"id":"faeb8c22d468474bb798714306794f8b","type":"GENE","name":"RNU6-27P","canonical_id":"hgnc:HGNC:34271","description":"RNA, U6 small nuclear 27, pseudogene","metadata":{"aliases":["RNU6-27"]}},{"id":"d36f587812284543979f52c17d264827","type":"GENE","name":"RNU6-280P","canonical_id":"hgnc:HGNC:47243","description":"RNA, U6 small nuclear 280, pseudogene","metadata":{"aliases":["RNU6-1221P"]}},{"id":"0d56a1fdb7d144f7b78ce90aa6d8ad0d","type":"GENE","name":"RNU6-281P","canonical_id":"hgnc:HGNC:47244","description":"RNA, U6 small nuclear 281, pseudogene","metadata":null},{"id":"759191568ef34c1ebc48332dcbb37c57","type":"GENE","name":"RNU6-282P","canonical_id":"hgnc:HGNC:47245","description":"RNA, U6 small nuclear 282, pseudogene","metadata":null},{"id":"579229e4f6bc405dadde7e5d96bfaea5","type":"GENE","name":"RNU6-283P","canonical_id":"hgnc:HGNC:47246","description":"RNA, U6 small nuclear 283, pseudogene","metadata":{"aliases":["RNU6-683P"]}},{"id":"7097078bf58f40f59336a3feddc3dd36","type":"GENE","name":"RNU6-284P","canonical_id":"hgnc:HGNC:47247","description":"RNA, U6 small nuclear 284, pseudogene","metadata":null},{"id":"8fcb01182a1b4be8b149fa01ba3fd958","type":"GENE","name":"RNU6-285P","canonical_id":"hgnc:HGNC:47248","description":"RNA, U6 small nuclear 285, pseudogene","metadata":null},{"id":"99e0ec046bd641e78a64317a8d01a0f2","type":"GENE","name":"RNU6-286P","canonical_id":"hgnc:HGNC:47249","description":"RNA, U6 small nuclear 286, pseudogene","metadata":null},{"id":"b428b5a832044123b7a037bc2d02c2e0","type":"GENE","name":"RNU6-287P","canonical_id":"hgnc:HGNC:47250","description":"RNA, U6 small nuclear 287, pseudogene","metadata":null},{"id":"682a8185b4154c19b0d546baa357aaa1","type":"GENE","name":"RNU6-288P","canonical_id":"hgnc:HGNC:47251","description":"RNA, U6 small nuclear 288, pseudogene","metadata":null},{"id":"5243907835974d6d8a10720b7ac24179","type":"GENE","name":"RNU6-289P","canonical_id":"hgnc:HGNC:47252","description":"RNA, U6 small nuclear 289, pseudogene","metadata":null},{"id":"c932b8d1a5744744a102650c871da382","type":"GENE","name":"RNU6-28P","canonical_id":"hgnc:HGNC:34272","description":"RNA, U6 small nuclear 28, pseudogene","metadata":{"aliases":["RNU6-28"]}},{"id":"35e3a0fd4b2d473c9159f1162b1bdbb7","type":"GENE","name":"RNU6-290P","canonical_id":"hgnc:HGNC:47253","description":"RNA, U6 small nuclear 290, pseudogene","metadata":null},{"id":"cdef1620cbe44524b9d3418c5e9228cc","type":"GENE","name":"RNU6-291P","canonical_id":"hgnc:HGNC:47254","description":"RNA, U6 small nuclear 291, pseudogene","metadata":null},{"id":"1b3571f8d85d4b1f88fcfe01b1fef9d1","type":"GENE","name":"RNU6-293P","canonical_id":"hgnc:HGNC:47256","description":"RNA, U6 small nuclear 293, pseudogene","metadata":null},{"id":"9a70ab13a5354b4eb3262be6d595273d","type":"GENE","name":"RNU6-294P","canonical_id":"hgnc:HGNC:47257","description":"RNA, U6 small nuclear 294, pseudogene","metadata":null},{"id":"ce2e2004d41f41adbacd45a048517e11","type":"GENE","name":"RNU6-295P","canonical_id":"hgnc:HGNC:47258","description":"RNA, U6 small nuclear 295, pseudogene","metadata":null},{"id":"47b6089a0f004dafa0e59edd139d18e6","type":"GENE","name":"RNU6-296P","canonical_id":"hgnc:HGNC:47259","description":"RNA, U6 small nuclear 296, pseudogene","metadata":null},{"id":"8d9d8efa3ad04d1283e968869f849273","type":"GENE","name":"RNU6-297P","canonical_id":"hgnc:HGNC:47260","description":"RNA, U6 small nuclear 297, pseudogene","metadata":null},{"id":"82c31b012ebc42c2ae90f619f845cc18","type":"GENE","name":"RNU6-298P","canonical_id":"hgnc:HGNC:47261","description":"RNA, U6 small nuclear 298, pseudogene","metadata":null},{"id":"df0600971a7746e285a23c7633cf0ac5","type":"GENE","name":"RNU6-299P","canonical_id":"hgnc:HGNC:47262","description":"RNA, U6 small nuclear 299, pseudogene","metadata":null},{"id":"6ac286ce04c34e8dae1bb8ec404f58b1","type":"GENE","name":"RNU6-29P","canonical_id":"hgnc:HGNC:34273","description":"RNA, U6 small nuclear 29, pseudogene","metadata":{"aliases":["RNU6-29"]}},{"id":"19733e23b3e24ca0819c83990c2ae95f","type":"GENE","name":"RNU6-300P","canonical_id":"hgnc:HGNC:47263","description":"RNA, U6 small nuclear 300, pseudogene","metadata":null},{"id":"da314431eb0f428db0355101ff70951c","type":"GENE","name":"RNU6-301P","canonical_id":"hgnc:HGNC:47264","description":"RNA, U6 small nuclear 301, pseudogene","metadata":null},{"id":"93ce47faf2864a10af881f06a139e036","type":"GENE","name":"RNU6-302P","canonical_id":"hgnc:HGNC:47265","description":"RNA, U6 small nuclear 302, pseudogene","metadata":null},{"id":"acf842cef5a445409c638eb07ea7f7f5","type":"GENE","name":"RNU6-303P","canonical_id":"hgnc:HGNC:47266","description":"RNA, U6 small nuclear 303, pseudogene","metadata":null},{"id":"e067fb51dc614e58929575e4527983d1","type":"GENE","name":"RNU6-304P","canonical_id":"hgnc:HGNC:47267","description":"RNA, U6 small nuclear 304, pseudogene","metadata":null},{"id":"039fcf4fe7814fe7adeffbf5ca7d49fe","type":"GENE","name":"RNU6-306P","canonical_id":"hgnc:HGNC:47269","description":"RNA, U6 small nuclear 306, pseudogene","metadata":null},{"id":"72e730d05ef24986bd928949dfcaabd0","type":"GENE","name":"RNU6-307P","canonical_id":"hgnc:HGNC:47270","description":"RNA, U6 small nuclear 307, pseudogene","metadata":null},{"id":"aebf65063bea4fec846aa29d4564ad72","type":"GENE","name":"RNU6-308P","canonical_id":"hgnc:HGNC:47271","description":"RNA, U6 small nuclear 308, pseudogene","metadata":null},{"id":"6f9319473d004c27bbc23f67f1de31b3","type":"GENE","name":"RNU6-309P","canonical_id":"hgnc:HGNC:47272","description":"RNA, U6 small nuclear 309, pseudogene","metadata":null},{"id":"754b3494145141b8b6cfae1463c6045d","type":"GENE","name":"RNU6-30P","canonical_id":"hgnc:HGNC:34274","description":"RNA, U6 small nuclear 30, pseudogene","metadata":{"aliases":["RNU6-30"]}},{"id":"0c92530e218541bfba9236210c1899a1","type":"GENE","name":"RNU6-310P","canonical_id":"hgnc:HGNC:47273","description":"RNA, U6 small nuclear 310, pseudogene","metadata":null},{"id":"ef24ff9c6ae14addadb6f23a0f90a881","type":"GENE","name":"RNU6-311P","canonical_id":"hgnc:HGNC:47274","description":"RNA, U6 small nuclear 311, pseudogene","metadata":null},{"id":"1733f139455746b6b66a395e71688fca","type":"GENE","name":"RNU6-312P","canonical_id":"hgnc:HGNC:47275","description":"RNA, U6 small nuclear 312, pseudogene","metadata":null},{"id":"1648a49edb1a4f40acb415b2f39e8d46","type":"GENE","name":"RNU6-313P","canonical_id":"hgnc:HGNC:47276","description":"RNA, U6 small nuclear 313, pseudogene","metadata":null},{"id":"e88d11eefc6f45bfaa3a2bd159cf5255","type":"GENE","name":"RNU6-314P","canonical_id":"hgnc:HGNC:47277","description":"RNA, U6 small nuclear 314, pseudogene","metadata":null},{"id":"5c183368202e4f679862d6d21a845f01","type":"GENE","name":"RNU6-315P","canonical_id":"hgnc:HGNC:47278","description":"RNA, U6 small nuclear 315, pseudogene","metadata":null},{"id":"5c4e9a89fe3e484694c0b226cd31eafd","type":"GENE","name":"RNU6-316P","canonical_id":"hgnc:HGNC:47279","description":"RNA, U6 small nuclear 316, pseudogene","metadata":null},{"id":"27c21b97d9cb49c7b3451fe0b5b182d5","type":"GENE","name":"RNU6-317P","canonical_id":"hgnc:HGNC:47280","description":"RNA, U6 small nuclear 317, pseudogene","metadata":null},{"id":"13828141225f44eba47114e7430a7e22","type":"GENE","name":"RNU6-318P","canonical_id":"hgnc:HGNC:47281","description":"RNA, U6 small nuclear 318, pseudogene","metadata":{"aliases":["RNU6-1295P"]}},{"id":"4bedb4df60864e07b32c73d997858c14","type":"GENE","name":"RNU6-319P","canonical_id":"hgnc:HGNC:47282","description":"RNA, U6 small nuclear 319, pseudogene","metadata":null},{"id":"5066a18967b74044899ccb64c03f8504","type":"GENE","name":"RNU6-31P","canonical_id":"hgnc:HGNC:34250","description":"RNA, U6 small nuclear 31, pseudogene","metadata":{"aliases":["RNU6-31"]}},{"id":"bbb2f289706d4ad29060bcb8f1976ada","type":"GENE","name":"RNU6-320P","canonical_id":"hgnc:HGNC:47283","description":"RNA, U6 small nuclear 320, pseudogene","metadata":null},{"id":"d94e605654024c75ba0cc71f5f563d3b","type":"GENE","name":"RNU6-321P","canonical_id":"hgnc:HGNC:47284","description":"RNA, U6 small nuclear 321, pseudogene","metadata":null},{"id":"2fc9bf733a77473fadaaf77100213d40","type":"GENE","name":"RNU6-322P","canonical_id":"hgnc:HGNC:47285","description":"RNA, U6 small nuclear 322, pseudogene","metadata":null},{"id":"2256ab9ea65048d586c305d85226dad1","type":"GENE","name":"RNU6-323P","canonical_id":"hgnc:HGNC:47286","description":"RNA, U6 small nuclear 323, pseudogene","metadata":null},{"id":"001b992d07d942be8273bb259ca02114","type":"GENE","name":"RNU6-324P","canonical_id":"hgnc:HGNC:47287","description":"RNA, U6 small nuclear 324, pseudogene","metadata":null},{"id":"d8c50b47d9c14c24a5f29b37ca107137","type":"GENE","name":"RNU6-325P","canonical_id":"hgnc:HGNC:47288","description":"RNA, U6 small nuclear 325, pseudogene","metadata":null},{"id":"ec147f5e54d34371ad881f250cb21a68","type":"GENE","name":"RNU6-326P","canonical_id":"hgnc:HGNC:47289","description":"RNA, U6 small nuclear 326, pseudogene","metadata":null},{"id":"27fead84088d44bb8b40a755bf126f64","type":"GENE","name":"RNU6-327P","canonical_id":"hgnc:HGNC:47290","description":"RNA, U6 small nuclear 327, pseudogene","metadata":null},{"id":"7da37814d4d244feb5e5cbe9858e60aa","type":"GENE","name":"RNU6-328P","canonical_id":"hgnc:HGNC:47291","description":"RNA, U6 small nuclear 328, pseudogene","metadata":null},{"id":"c906c30a2a344baca5c106ec51087cc9","type":"GENE","name":"RNU6-329P","canonical_id":"hgnc:HGNC:47292","description":"RNA, U6 small nuclear 329, pseudogene","metadata":null},{"id":"ef4fc03dbbba4096b032533c050aaf81","type":"GENE","name":"RNU6-32P","canonical_id":"hgnc:HGNC:34276","description":"RNA, U6 small nuclear 32, pseudogene","metadata":{"aliases":["RNU6-32"]}},{"id":"43785d0886db4895803958e1602838c3","type":"GENE","name":"RNU6-330P","canonical_id":"hgnc:HGNC:47293","description":"RNA, U6 small nuclear 330, pseudogene","metadata":null},{"id":"0998387a59c1494b9b7e9f24b1fad58f","type":"GENE","name":"RNU6-331P","canonical_id":"hgnc:HGNC:47294","description":"RNA, U6 small nuclear 331, pseudogene","metadata":null},{"id":"183c0362e6df49edbaf5f9d925c50783","type":"GENE","name":"RNU6-332P","canonical_id":"hgnc:HGNC:47295","description":"RNA, U6 small nuclear 332, pseudogene","metadata":null},{"id":"3c3b20b8cf684c6abbef1d3fd18ae1c2","type":"GENE","name":"RNU6-333P","canonical_id":"hgnc:HGNC:47296","description":"RNA, U6 small nuclear 333, pseudogene","metadata":null},{"id":"340bf52383784e4191554f7ddca63bfc","type":"GENE","name":"RNU6-334P","canonical_id":"hgnc:HGNC:47297","description":"RNA, U6 small nuclear 334, pseudogene","metadata":null},{"id":"70d580e46d944e4782d8ed3320bda5f8","type":"GENE","name":"RNU6-335P","canonical_id":"hgnc:HGNC:47298","description":"RNA, U6 small nuclear 335, pseudogene","metadata":null},{"id":"77751f9b1eea48c2af4684ea80264b46","type":"GENE","name":"RNU6-336P","canonical_id":"hgnc:HGNC:47299","description":"RNA, U6 small nuclear 336, pseudogene","metadata":null},{"id":"0345d6c8c267419b9c0e3a9f38fc2550","type":"GENE","name":"RNU6-337P","canonical_id":"hgnc:HGNC:47300","description":"RNA, U6 small nuclear 337, pseudogene","metadata":null},{"id":"025c21de8d134e53bf291491f352be53","type":"GENE","name":"RNU6-338P","canonical_id":"hgnc:HGNC:47301","description":"RNA, U6 small nuclear 338, pseudogene","metadata":null},{"id":"ae3607185d634de2bb0e35fe9e9adeb0","type":"GENE","name":"RNU6-339P","canonical_id":"hgnc:HGNC:47302","description":"RNA, U6 small nuclear 339, pseudogene","metadata":null},{"id":"5caac0ce69ef42ce922442974cdd6806","type":"GENE","name":"RNU6-33P","canonical_id":"hgnc:HGNC:34277","description":"RNA, U6 small nuclear 33, pseudogene","metadata":{"aliases":["RNU6-33"]}},{"id":"9e82ad19934b4158ba79f89cb25ddae6","type":"GENE","name":"RNU6-340P","canonical_id":"hgnc:HGNC:47303","description":"RNA, U6 small nuclear 340, pseudogene","metadata":null},{"id":"ef010ab1121946119a22a723f1769330","type":"GENE","name":"RNU6-341P","canonical_id":"hgnc:HGNC:47304","description":"RNA, U6 small nuclear 341, pseudogene","metadata":null},{"id":"355d3fdb3ab441a0a6d50bcdd38312f5","type":"GENE","name":"RNU6-342P","canonical_id":"hgnc:HGNC:47305","description":"RNA, U6 small nuclear 342, pseudogene","metadata":null},{"id":"f990ebe666f94fab8090afd7d85c7164","type":"GENE","name":"RNU6-343P","canonical_id":"hgnc:HGNC:47306","description":"RNA, U6 small nuclear 343, pseudogene","metadata":null},{"id":"978160feaa1b4865940fad279a9e9f98","type":"GENE","name":"RNU6-344P","canonical_id":"hgnc:HGNC:47307","description":"RNA, U6 small nuclear 344, pseudogene","metadata":null},{"id":"f9754d23542844f28890bfb69f7374e5","type":"GENE","name":"RNU6-345P","canonical_id":"hgnc:HGNC:47308","description":"RNA, U6 small nuclear 345, pseudogene","metadata":null},{"id":"1c1c148f580f4a6c86b06fc85dd9398d","type":"GENE","name":"RNU6-346P","canonical_id":"hgnc:HGNC:47309","description":"RNA, U6 small nuclear 346, pseudogene","metadata":null},{"id":"cccde67fe96248088b4760b840d1eeb5","type":"GENE","name":"RNU6-347P","canonical_id":"hgnc:HGNC:47310","description":"RNA, U6 small nuclear 347, pseudogene","metadata":null},{"id":"b25480f5a5d645c4a91afc95e85968ab","type":"GENE","name":"RNU6-348P","canonical_id":"hgnc:HGNC:47311","description":"RNA, U6 small nuclear 348, pseudogene","metadata":null},{"id":"9a873501e1484bf395ade4b6adece187","type":"GENE","name":"RNU6-349P","canonical_id":"hgnc:HGNC:47312","description":"RNA, U6 small nuclear 349, pseudogene","metadata":null},{"id":"de0126e113da4181b39d9cc1a0c9add5","type":"GENE","name":"RNU6-34P","canonical_id":"hgnc:HGNC:34278","description":"RNA, U6 small nuclear 34, pseudogene","metadata":{"aliases":["RNU6-34"]}},{"id":"329ddad4f13942aca666f5327399d783","type":"GENE","name":"RNU6-351P","canonical_id":"hgnc:HGNC:47314","description":"RNA, U6 small nuclear 351, pseudogene","metadata":null},{"id":"682148750eda461cabcdfb01775f4834","type":"GENE","name":"RNU6-352P","canonical_id":"hgnc:HGNC:47315","description":"RNA, U6 small nuclear 352, pseudogene","metadata":null},{"id":"d6262d5a1d95460288e9a682bb301ed9","type":"GENE","name":"RNU6-353P","canonical_id":"hgnc:HGNC:47316","description":"RNA, U6 small nuclear 353, pseudogene","metadata":null},{"id":"cb53e345ab5f4aa687737636db873237","type":"GENE","name":"RNU6-354P","canonical_id":"hgnc:HGNC:47317","description":"RNA, U6 small nuclear 354, pseudogene","metadata":null},{"id":"77710253b2c744cbbc1cbbc04fcdea91","type":"GENE","name":"RNU6-355P","canonical_id":"hgnc:HGNC:47318","description":"RNA, U6 small nuclear 355, pseudogene","metadata":null},{"id":"f3c672219a924017af6926b094612894","type":"GENE","name":"RNU6-356P","canonical_id":"hgnc:HGNC:47319","description":"RNA, U6 small nuclear 356, pseudogene","metadata":null},{"id":"3137be23f6384e61b0c72f6f9fcf80fa","type":"GENE","name":"RNU6-358P","canonical_id":"hgnc:HGNC:47321","description":"RNA, U6 small nuclear 358, pseudogene","metadata":null},{"id":"f9bd54b00fa04081a1ecea0e75d82396","type":"GENE","name":"RNU6-359P","canonical_id":"hgnc:HGNC:47322","description":"RNA, U6 small nuclear 359, pseudogene","metadata":null},{"id":"a53988cd7c6442729b9f7355f1097e0f","type":"GENE","name":"RNU6-35P","canonical_id":"hgnc:HGNC:34279","description":"RNA, U6 small nuclear 35, pseudogene","metadata":{"aliases":["RNU6-35"]}},{"id":"e6abac58f2b54fa08ae6797c904e47d5","type":"GENE","name":"RNU6-360P","canonical_id":"hgnc:HGNC:47323","description":"RNA, U6 small nuclear 360, pseudogene","metadata":null},{"id":"e8be0dc10bb04a2e8cf2f773dc0b0062","type":"GENE","name":"RNU6-361P","canonical_id":"hgnc:HGNC:47324","description":"RNA, U6 small nuclear 361, pseudogene","metadata":null},{"id":"e0959fcd17a543048b9b529886b7ab5d","type":"GENE","name":"RNU6-362P","canonical_id":"hgnc:HGNC:47325","description":"RNA, U6 small nuclear 362, pseudogene","metadata":null},{"id":"5c900ca7865e4ef3a8940e42d1e748bc","type":"GENE","name":"RNU6-363P","canonical_id":"hgnc:HGNC:47326","description":"RNA, U6 small nuclear 363, pseudogene","metadata":null},{"id":"6d022f378fca462ca9d16035a9e2d47b","type":"GENE","name":"RNU6-364P","canonical_id":"hgnc:HGNC:47327","description":"RNA, U6 small nuclear 364, pseudogene","metadata":null},{"id":"7501ed7649cb495eaa2a20fec62c172f","type":"GENE","name":"RNU6-365P","canonical_id":"hgnc:HGNC:47328","description":"RNA, U6 small nuclear 365, pseudogene","metadata":null},{"id":"22844a64cdbc4ba3a58995bbf2707077","type":"GENE","name":"RNU6-366P","canonical_id":"hgnc:HGNC:47329","description":"RNA, U6 small nuclear 366, pseudogene","metadata":null},{"id":"50c7947eea9c49929517e0a19b488ff5","type":"GENE","name":"RNU6-367P","canonical_id":"hgnc:HGNC:47330","description":"RNA, U6 small nuclear 367, pseudogene","metadata":null},{"id":"024037baaf0d4a8cb63e505e185acd59","type":"GENE","name":"RNU6-368P","canonical_id":"hgnc:HGNC:47331","description":"RNA, U6 small nuclear 368, pseudogene","metadata":null},{"id":"7dede91dd5094e7fad74aaf683302eb9","type":"GENE","name":"RNU6-369P","canonical_id":"hgnc:HGNC:47332","description":"RNA, U6 small nuclear 369, pseudogene","metadata":null},{"id":"dbdb94a48d37448cad4870804f420a3f","type":"GENE","name":"RNU6-36P","canonical_id":"hgnc:HGNC:34280","description":"RNA, U6 small nuclear 36, pseudogene","metadata":{"aliases":["RNU6-36"]}},{"id":"a5d3f7a6d677484db08391af5215442d","type":"GENE","name":"RNU6-370P","canonical_id":"hgnc:HGNC:47333","description":"RNA, U6 small nuclear 370, pseudogene","metadata":null},{"id":"b4d1fa8241a247448b47d4db2134ca28","type":"GENE","name":"RNU6-371P","canonical_id":"hgnc:HGNC:47334","description":"RNA, U6 small nuclear 371, pseudogene","metadata":null},{"id":"bb1a0c70b9f14e65b72113c436558668","type":"GENE","name":"RNU6-373P","canonical_id":"hgnc:HGNC:47336","description":"RNA, U6 small nuclear 373, pseudogene","metadata":null},{"id":"f102bd4c2f94484a9533bb165daec507","type":"GENE","name":"RNU6-374P","canonical_id":"hgnc:HGNC:47337","description":"RNA, U6 small nuclear 374, pseudogene","metadata":null},{"id":"62d4d2196555401688a95cf6d5173873","type":"GENE","name":"RNU6-375P","canonical_id":"hgnc:HGNC:47338","description":"RNA, U6 small nuclear 375, pseudogene","metadata":null},{"id":"104f25a444fc444db64b4e61181fd910","type":"GENE","name":"RNU6-376P","canonical_id":"hgnc:HGNC:47339","description":"RNA, U6 small nuclear 376, pseudogene","metadata":null},{"id":"8fddd32b76e64180920cd48f1b92a98b","type":"GENE","name":"RNU6-377P","canonical_id":"hgnc:HGNC:47340","description":"RNA, U6 small nuclear 377, pseudogene","metadata":null},{"id":"92d9a05e95894c36b635cf8e02e7e0fa","type":"GENE","name":"RNU6-378P","canonical_id":"hgnc:HGNC:47341","description":"RNA, U6 small nuclear 378, pseudogene","metadata":null},{"id":"303ad13e00f44caaade75cee8ae03901","type":"GENE","name":"RNU6-379P","canonical_id":"hgnc:HGNC:47342","description":"RNA, U6 small nuclear 379, pseudogene","metadata":null},{"id":"0cd9fa8aaa1d4b7686078e5f7e6fdaca","type":"GENE","name":"RNU6-37P","canonical_id":"hgnc:HGNC:34281","description":"RNA, U6 small nuclear 37, pseudogene","metadata":{"aliases":["RNU6-37"]}},{"id":"34f8d608126f49bdac1f8feae0a8d20f","type":"GENE","name":"RNU6-380P","canonical_id":"hgnc:HGNC:47343","description":"RNA, U6 small nuclear 380, pseudogene","metadata":null},{"id":"3d5e2fa79f3f43618e0965ddd11aab3b","type":"GENE","name":"RNU6-381P","canonical_id":"hgnc:HGNC:47344","description":"RNA, U6 small nuclear 381, pseudogene","metadata":null},{"id":"201ecf97728949bcb258d979dc79a9f0","type":"GENE","name":"RNU6-382P","canonical_id":"hgnc:HGNC:47345","description":"RNA, U6 small nuclear 382, pseudogene","metadata":null},{"id":"ca9b568392d7400a9ac338e29e586108","type":"GENE","name":"RNU6-383P","canonical_id":"hgnc:HGNC:47346","description":"RNA, U6 small nuclear 383, pseudogene","metadata":null},{"id":"1ac976fec2b14fd2a5ccd66b7e9576ed","type":"GENE","name":"RNU6-384P","canonical_id":"hgnc:HGNC:47347","description":"RNA, U6 small nuclear 384, pseudogene","metadata":null},{"id":"f283422b37e54fe1bd23378c30bd7bc9","type":"GENE","name":"RNU6-386P","canonical_id":"hgnc:HGNC:47349","description":"RNA, U6 small nuclear 386, pseudogene","metadata":null},{"id":"98c4f5d9521142ce9dd4a408c5876059","type":"GENE","name":"RNU6-387P","canonical_id":"hgnc:HGNC:47350","description":"RNA, U6 small nuclear 387, pseudogene","metadata":null},{"id":"17f4b73c745f42fbbeb77ca72d135ca3","type":"GENE","name":"RNU6-388P","canonical_id":"hgnc:HGNC:47351","description":"RNA, U6 small nuclear 388, pseudogene","metadata":null},{"id":"cc6c0ebed36c47aabcdd8f4748ddae50","type":"GENE","name":"RNU6-389P","canonical_id":"hgnc:HGNC:47352","description":"RNA, U6 small nuclear 389, pseudogene","metadata":null},{"id":"81b0f97cacee47ec99e2f47fb85ddf11","type":"GENE","name":"RNU6-38P","canonical_id":"hgnc:HGNC:34282","description":"RNA, U6 small nuclear 38, pseudogene","metadata":{"aliases":["RNU6-38"]}},{"id":"8e25efba8cad4e43985af8f915569fd3","type":"GENE","name":"RNU6-390P","canonical_id":"hgnc:HGNC:47353","description":"RNA, U6 small nuclear 390, pseudogene","metadata":null},{"id":"5fdfb1db06ea4fb48275ca37cb972294","type":"GENE","name":"RNU6-391P","canonical_id":"hgnc:HGNC:47354","description":"RNA, U6 small nuclear 391, pseudogene","metadata":null},{"id":"36addfbb96424207ad0da944d3348614","type":"GENE","name":"RNU6-392P","canonical_id":"hgnc:HGNC:47355","description":"RNA, U6 small nuclear 392, pseudogene","metadata":null},{"id":"83f9b2aa4f0b4e569e27e2cf7e8a5f02","type":"GENE","name":"RNU6-393P","canonical_id":"hgnc:HGNC:47356","description":"RNA, U6 small nuclear 393, pseudogene","metadata":null},{"id":"65f990dcbc414207a1ce920379cf54fe","type":"GENE","name":"RNU6-394P","canonical_id":"hgnc:HGNC:47357","description":"RNA, U6 small nuclear 394, pseudogene","metadata":null},{"id":"e12bc88eac8241d9a58ced9a0cab809e","type":"GENE","name":"RNU6-395P","canonical_id":"hgnc:HGNC:47358","description":"RNA, U6 small nuclear 395, pseudogene","metadata":null},{"id":"949d8745b6434f789d07c06698639028","type":"GENE","name":"RNU6-396P","canonical_id":"hgnc:HGNC:47359","description":"RNA, U6 small nuclear 396, pseudogene","metadata":null},{"id":"0c33e282324b4c50b5a0e782601e7dc0","type":"GENE","name":"RNU6-397P","canonical_id":"hgnc:HGNC:47360","description":"RNA, U6 small nuclear 397, pseudogene","metadata":null},{"id":"a332b5318894459abc7c1954610ada01","type":"GENE","name":"RNU6-398P","canonical_id":"hgnc:HGNC:47361","description":"RNA, U6 small nuclear 398, pseudogene","metadata":null},{"id":"eebfb6382cf54db099d65b6645c5e5be","type":"GENE","name":"RNU6-399P","canonical_id":"hgnc:HGNC:47362","description":"RNA, U6 small nuclear 399, pseudogene","metadata":null},{"id":"e04f9f69876f4c11b43079ed703b91d3","type":"GENE","name":"RNU6-39P","canonical_id":"hgnc:HGNC:34283","description":"RNA, U6 small nuclear 39, pseudogene","metadata":{"aliases":["RNU6-39"]}},{"id":"a9721b42a9724afc853a2e5a37e241e3","type":"GENE","name":"RNU6-3P","canonical_id":"hgnc:HGNC:34275","description":"RNA, U6 small nuclear 3, pseudogene","metadata":{"aliases":["U6-3","RNU6-3"]}},{"id":"0900ac2a6d6349a89f70e39b5c50e0be","type":"GENE","name":"RNU6-400P","canonical_id":"hgnc:HGNC:47363","description":"RNA, U6 small nuclear 400, pseudogene","metadata":null},{"id":"97d46edf712e4db8ac2c46814ccdc5f9","type":"GENE","name":"RNU6-401P","canonical_id":"hgnc:HGNC:47364","description":"RNA, U6 small nuclear 401, pseudogene","metadata":null},{"id":"628b31557a83426381c179299039a523","type":"GENE","name":"RNU6-402P","canonical_id":"hgnc:HGNC:47365","description":"RNA, U6 small nuclear 402, pseudogene","metadata":null},{"id":"abf487a23536431c8ddb661276a85953","type":"GENE","name":"RNU6-403P","canonical_id":"hgnc:HGNC:47366","description":"RNA, U6 small nuclear 403, pseudogene","metadata":null},{"id":"83ca29c711114917a544924a7bef0bf5","type":"GENE","name":"RNU6-405P","canonical_id":"hgnc:HGNC:47368","description":"RNA, U6 small nuclear 405, pseudogene","metadata":null},{"id":"48943dedc0194a41a2d7f2a86b10477c","type":"GENE","name":"RNU6-406P","canonical_id":"hgnc:HGNC:47369","description":"RNA, U6 small nuclear 406, pseudogene","metadata":null},{"id":"fbc6dce7e57a421180c34eb3b15944d5","type":"GENE","name":"RNU6-407P","canonical_id":"hgnc:HGNC:47370","description":"RNA, U6 small nuclear 407, pseudogene","metadata":null},{"id":"fe0c94d4ea7f445988ca1ef031f226a9","type":"GENE","name":"RNU6-408P","canonical_id":"hgnc:HGNC:47371","description":"RNA, U6 small nuclear 408, pseudogene","metadata":null},{"id":"9b103509ef394b7eadeb685f760f671a","type":"GENE","name":"RNU6-409P","canonical_id":"hgnc:HGNC:47372","description":"RNA, U6 small nuclear 409, pseudogene","metadata":null},{"id":"bf2ca4c3d9344ddc853e9a54850f8e09","type":"GENE","name":"RNU6-40P","canonical_id":"hgnc:HGNC:34248","description":"RNA, U6 small nuclear 40, pseudogene","metadata":{"aliases":["RNU6-40"]}},{"id":"c8683914664d44b197a8bf4cc7978369","type":"GENE","name":"RNU6-410P","canonical_id":"hgnc:HGNC:47373","description":"RNA, U6 small nuclear 410, pseudogene","metadata":null},{"id":"c134bae643d946049830a1cb68b5dad9","type":"GENE","name":"RNU6-411P","canonical_id":"hgnc:HGNC:47374","description":"RNA, U6 small nuclear 411, pseudogene","metadata":null},{"id":"16ccf8f0fbf54ceba8c96ad93a8fba81","type":"GENE","name":"RNU6-412P","canonical_id":"hgnc:HGNC:47375","description":"RNA, U6 small nuclear 412, pseudogene","metadata":null},{"id":"42e9c9d9247f46e5a2d7de28586638a8","type":"GENE","name":"RNU6-413P","canonical_id":"hgnc:HGNC:47376","description":"RNA, U6 small nuclear 413, pseudogene","metadata":null},{"id":"90d0618c879e4e539591dddaf21877a8","type":"GENE","name":"RNU6-414P","canonical_id":"hgnc:HGNC:47377","description":"RNA, U6 small nuclear 414, pseudogene","metadata":null},{"id":"ea779a0dd9d845fdb1b2bce948d6abe9","type":"GENE","name":"RNU6-415P","canonical_id":"hgnc:HGNC:47378","description":"RNA, U6 small nuclear 415, pseudogene","metadata":null},{"id":"194bca2334e245ac84e1d299d57a77f9","type":"GENE","name":"RNU6-416P","canonical_id":"hgnc:HGNC:47379","description":"RNA, U6 small nuclear 416, pseudogene","metadata":null},{"id":"305e7168be1a4d219c954fda8064c720","type":"GENE","name":"RNU6-417P","canonical_id":"hgnc:HGNC:47380","description":"RNA, U6 small nuclear 417, pseudogene","metadata":null},{"id":"3d51a6b48273456392b6994d3eaaa99b","type":"GENE","name":"RNU6-418P","canonical_id":"hgnc:HGNC:47381","description":"RNA, U6 small nuclear 418, pseudogene","metadata":null},{"id":"613ed6df99ba4f64b7fc1917fa47d5c8","type":"GENE","name":"RNU6-419P","canonical_id":"hgnc:HGNC:47382","description":"RNA, U6 small nuclear 419, pseudogene","metadata":null},{"id":"cd94206173f149469d51b43c7091b61d","type":"GENE","name":"RNU6-41P","canonical_id":"hgnc:HGNC:34247","description":"RNA, U6 small nuclear 41, pseudogene","metadata":{"aliases":["RNU6-41"]}},{"id":"c6c25795351f43e1aa2b42daf87715b0","type":"GENE","name":"RNU6-420P","canonical_id":"hgnc:HGNC:47383","description":"RNA, U6 small nuclear 420, pseudogene","metadata":null},{"id":"b5659d30919d4347ba7b538fc15410f9","type":"GENE","name":"RNU6-421P","canonical_id":"hgnc:HGNC:47384","description":"RNA, U6 small nuclear 421, pseudogene","metadata":null},{"id":"8f16b985d80749c8923bc1b62f3d1135","type":"GENE","name":"RNU6-422P","canonical_id":"hgnc:HGNC:47385","description":"RNA, U6 small nuclear 422, pseudogene","metadata":null},{"id":"4ca1e0ff95784d73b65a1d0fe28cd4e2","type":"GENE","name":"RNU6-424P","canonical_id":"hgnc:HGNC:47387","description":"RNA, U6 small nuclear 424, pseudogene","metadata":null},{"id":"c60abae7882542c381751a2940c85b8f","type":"GENE","name":"RNU6-425P","canonical_id":"hgnc:HGNC:47388","description":"RNA, U6 small nuclear 425, pseudogene","metadata":null},{"id":"4b536ae37a65426fb83cae3bf7d51033","type":"GENE","name":"RNU6-426P","canonical_id":"hgnc:HGNC:47389","description":"RNA, U6 small nuclear 426, pseudogene","metadata":null},{"id":"d0651439f7624c27bc082448ee7767be","type":"GENE","name":"RNU6-428P","canonical_id":"hgnc:HGNC:47391","description":"RNA, U6 small nuclear 428, pseudogene","metadata":null},{"id":"1d88b7c95cc94834a3c80b746180ce98","type":"GENE","name":"RNU6-429P","canonical_id":"hgnc:HGNC:47392","description":"RNA, U6 small nuclear 429, pseudogene","metadata":null},{"id":"fbd9a61894304da799e2572c88c5623f","type":"GENE","name":"RNU6-42P","canonical_id":"hgnc:HGNC:34286","description":"RNA, U6 small nuclear 42, pseudogene","metadata":{"aliases":["RNU6-42"]}},{"id":"d1e6aaeb89a1490c882f1704d9c411ee","type":"GENE","name":"RNU6-430P","canonical_id":"hgnc:HGNC:47393","description":"RNA, U6 small nuclear 430, pseudogene","metadata":null},{"id":"a6d5948fcc9a4697b2b3ebc183de69fb","type":"GENE","name":"RNU6-431P","canonical_id":"hgnc:HGNC:47394","description":"RNA, U6 small nuclear 431, pseudogene","metadata":null},{"id":"fb5e4a9b56014a9e8e6a1f6d153f2477","type":"GENE","name":"RNU6-432P","canonical_id":"hgnc:HGNC:47395","description":"RNA, U6 small nuclear 432, pseudogene","metadata":null},{"id":"968d67bc485e45a8946c2355fc7aa747","type":"GENE","name":"RNU6-433P","canonical_id":"hgnc:HGNC:47396","description":"RNA, U6 small nuclear 433, pseudogene","metadata":null},{"id":"1cc1ec87d4254aadaa26073ecab8d908","type":"GENE","name":"RNU6-434P","canonical_id":"hgnc:HGNC:47397","description":"RNA, U6 small nuclear 434, pseudogene","metadata":null},{"id":"f2ac62e9a8904604a02c82c01674c143","type":"GENE","name":"RNU6-435P","canonical_id":"hgnc:HGNC:47398","description":"RNA, U6 small nuclear 435, pseudogene","metadata":null},{"id":"a1dfb79b18e941c494039e0a696c25f6","type":"GENE","name":"RNU6-436P","canonical_id":"hgnc:HGNC:47399","description":"RNA, U6 small nuclear 436, pseudogene","metadata":null},{"id":"2947d3acabed4e9584bdaf4b9e0fa465","type":"GENE","name":"RNU6-437P","canonical_id":"hgnc:HGNC:47400","description":"RNA, U6 small nuclear 437, pseudogene","metadata":null},{"id":"e3b1d3d24c424811a032b2cfe6227abb","type":"GENE","name":"RNU6-438P","canonical_id":"hgnc:HGNC:47401","description":"RNA, U6 small nuclear 438, pseudogene","metadata":null},{"id":"03559b32a0b948cab522c64b3f226bce","type":"GENE","name":"RNU6-439P","canonical_id":"hgnc:HGNC:47402","description":"RNA, U6 small nuclear 439, pseudogene","metadata":null},{"id":"5968edaf386a41b8a888ac5706a60878","type":"GENE","name":"RNU6-43P","canonical_id":"hgnc:HGNC:34287","description":"RNA, U6 small nuclear 43, pseudogene","metadata":{"aliases":["RNU6-43"]}},{"id":"14c907136d624e308acc317e11874476","type":"GENE","name":"RNU6-440P","canonical_id":"hgnc:HGNC:47403","description":"RNA, U6 small nuclear 440, pseudogene","metadata":null},{"id":"fc3380487dcd4f11b1478728096e5a43","type":"GENE","name":"RNU6-441P","canonical_id":"hgnc:HGNC:47404","description":"RNA, U6 small nuclear 441, pseudogene","metadata":null},{"id":"3d4ab45ddfbe460ab4dfc71e6bd180ba","type":"GENE","name":"RNU6-442P","canonical_id":"hgnc:HGNC:47405","description":"RNA, U6 small nuclear 442, pseudogene","metadata":null},{"id":"9b07e783bde9456ca9f538abc87b90b2","type":"GENE","name":"RNU6-443P","canonical_id":"hgnc:HGNC:47406","description":"RNA, U6 small nuclear 443, pseudogene","metadata":null},{"id":"b7d50e03af634629a17216de9ed886e0","type":"GENE","name":"RNU6-444P","canonical_id":"hgnc:HGNC:47407","description":"RNA, U6 small nuclear 444, pseudogene","metadata":null},{"id":"a3231e4c7a9549178cf58f65a11b0011","type":"GENE","name":"RNU6-445P","canonical_id":"hgnc:HGNC:47408","description":"RNA, U6 small nuclear 445, pseudogene","metadata":null},{"id":"4912cc3d5b514485b0a0b14463fef66f","type":"GENE","name":"RNU6-446P","canonical_id":"hgnc:HGNC:47409","description":"RNA, U6 small nuclear 446, pseudogene","metadata":null},{"id":"f0ed5dde6d1e4d1c8603ea6d4164aba5","type":"GENE","name":"RNU6-447P","canonical_id":"hgnc:HGNC:47410","description":"RNA, U6 small nuclear 447, pseudogene","metadata":null},{"id":"3098a7769f6a4da784c1f2f4897e26ef","type":"GENE","name":"RNU6-448P","canonical_id":"hgnc:HGNC:47411","description":"RNA, U6 small nuclear 448, pseudogene","metadata":null},{"id":"e007f82033bd48d0aa6b2fcb70d10305","type":"GENE","name":"RNU6-449P","canonical_id":"hgnc:HGNC:47412","description":"RNA, U6 small nuclear 449, pseudogene","metadata":null},{"id":"737b265e30e746aba5e99d9eaad0d8ef","type":"GENE","name":"RNU6-44P","canonical_id":"hgnc:HGNC:34288","description":"RNA, U6 small nuclear 44, pseudogene","metadata":{"aliases":["RNU6-44"]}},{"id":"9c64ea7e2c9e4b6391803411cfeadba4","type":"GENE","name":"RNU6-450P","canonical_id":"hgnc:HGNC:47413","description":"RNA, U6 small nuclear 450, pseudogene","metadata":null},{"id":"38142d65fdf84ed8ab19ebdc4676f22f","type":"GENE","name":"RNU6-451P","canonical_id":"hgnc:HGNC:47414","description":"RNA, U6 small nuclear 451, pseudogene","metadata":null},{"id":"74e1c290ecc5431096f8d8ea0f8a6954","type":"GENE","name":"RNU6-452P","canonical_id":"hgnc:HGNC:47415","description":"RNA, U6 small nuclear 452, pseudogene","metadata":null},{"id":"d6ed87db867f4fc4b037ad1d70628b7a","type":"GENE","name":"RNU6-453P","canonical_id":"hgnc:HGNC:47416","description":"RNA, U6 small nuclear 453, pseudogene","metadata":null},{"id":"704ee6081c2a463eba9095e7cce7daaa","type":"GENE","name":"RNU6-454P","canonical_id":"hgnc:HGNC:47417","description":"RNA, U6 small nuclear 454, pseudogene","metadata":null},{"id":"16091760298345b195bebe4815d35b0b","type":"GENE","name":"RNU6-455P","canonical_id":"hgnc:HGNC:47418","description":"RNA, U6 small nuclear 455, pseudogene","metadata":null},{"id":"551b64517dff423b83dd8e75fde12178","type":"GENE","name":"RNU6-456P","canonical_id":"hgnc:HGNC:47419","description":"RNA, U6 small nuclear 456, pseudogene","metadata":null},{"id":"7ef1743b6481430196b577ea8b28d63d","type":"GENE","name":"RNU6-457P","canonical_id":"hgnc:HGNC:47420","description":"RNA, U6 small nuclear 457, pseudogene","metadata":null},{"id":"c353debe4c5f4396a600981f0f95c2dd","type":"GENE","name":"RNU6-458P","canonical_id":"hgnc:HGNC:47421","description":"RNA, U6 small nuclear 458, pseudogene","metadata":null},{"id":"fd9361ac0a994fbd9e40339d62f9fb9a","type":"GENE","name":"RNU6-45P","canonical_id":"hgnc:HGNC:34289","description":"RNA, U6 small nuclear 45, pseudogene","metadata":{"aliases":["RNU6-45"]}},{"id":"7e5435dde0d84db7a7e8ae8d9e6e5a15","type":"GENE","name":"RNU6-460P","canonical_id":"hgnc:HGNC:47423","description":"RNA, U6 small nuclear 460, pseudogene","metadata":null},{"id":"f6bd26686f24407f9e56b285f150e02c","type":"GENE","name":"RNU6-461P","canonical_id":"hgnc:HGNC:47424","description":"RNA, U6 small nuclear 461, pseudogene","metadata":null},{"id":"8263c2749f4d49f18359358a82f79520","type":"GENE","name":"RNU6-462P","canonical_id":"hgnc:HGNC:47425","description":"RNA, U6 small nuclear 462, pseudogene","metadata":null},{"id":"c454df8814c14ac2ac6b889ac20f54af","type":"GENE","name":"RNU6-463P","canonical_id":"hgnc:HGNC:47426","description":"RNA, U6 small nuclear 463, pseudogene","metadata":null},{"id":"272ab80f32f44979978601e0275fdbe1","type":"GENE","name":"RNU6-464P","canonical_id":"hgnc:HGNC:47427","description":"RNA, U6 small nuclear 464, pseudogene","metadata":null},{"id":"052b07ab3e664ccfa0d25441e7f5f3dc","type":"GENE","name":"RNU6-465P","canonical_id":"hgnc:HGNC:47428","description":"RNA, U6 small nuclear 465, pseudogene","metadata":null},{"id":"9636091b720742ffa2a43da1943e3003","type":"GENE","name":"RNU6-466P","canonical_id":"hgnc:HGNC:47429","description":"RNA, U6 small nuclear 466, pseudogene","metadata":null},{"id":"f95fad62d04443f69cf035cd5b01a0ae","type":"GENE","name":"RNU6-467P","canonical_id":"hgnc:HGNC:47430","description":"RNA, U6 small nuclear 467, pseudogene","metadata":null},{"id":"64f8deadd93a40e9b8406a640ce0b1a1","type":"GENE","name":"RNU6-468P","canonical_id":"hgnc:HGNC:47431","description":"RNA, U6 small nuclear 468, pseudogene","metadata":null},{"id":"a8b2a867e3ca4b23897f9231f8de21b6","type":"GENE","name":"RNU6-469P","canonical_id":"hgnc:HGNC:47432","description":"RNA, U6 small nuclear 469, pseudogene","metadata":null},{"id":"fbc2f912d03d47a289e520aba255b1e2","type":"GENE","name":"RNU6-46P","canonical_id":"hgnc:HGNC:34290","description":"RNA, U6 small nuclear 46, pseudogene","metadata":{"aliases":["RNU6-46"]}},{"id":"71f8e6a9ece24fa38cfc18765331c3ae","type":"GENE","name":"RNU6-470P","canonical_id":"hgnc:HGNC:47433","description":"RNA, U6 small nuclear 470, pseudogene","metadata":null},{"id":"e8b86c218d524e53ad4e2612ea9e400d","type":"GENE","name":"RNU6-471P","canonical_id":"hgnc:HGNC:47434","description":"RNA, U6 small nuclear 471, pseudogene","metadata":null},{"id":"893709c00f364c0bab2f6a35e16ce30c","type":"GENE","name":"RNU6-472P","canonical_id":"hgnc:HGNC:47435","description":"RNA, U6 small nuclear 472, pseudogene","metadata":null},{"id":"a336c9d1ec2c42c3a2fa9797b3187f8f","type":"GENE","name":"RNU6-473P","canonical_id":"hgnc:HGNC:47436","description":"RNA, U6 small nuclear 473, pseudogene","metadata":null},{"id":"219133de0fcf4f3592a98b9cb11a8d2b","type":"GENE","name":"RNU6-474P","canonical_id":"hgnc:HGNC:47437","description":"RNA, U6 small nuclear 474, pseudogene","metadata":null},{"id":"45da264226854f31be37a23e1d4df087","type":"GENE","name":"RNU6-475P","canonical_id":"hgnc:HGNC:47438","description":"RNA, U6 small nuclear 475, pseudogene","metadata":null},{"id":"0f479dbf61824a94a9955626e162944e","type":"GENE","name":"RNU6-476P","canonical_id":"hgnc:HGNC:47439","description":"RNA, U6 small nuclear 476, pseudogene","metadata":null},{"id":"4e2a44bd115b47db828e356d7dc2bf52","type":"GENE","name":"RNU6-477P","canonical_id":"hgnc:HGNC:47440","description":"RNA, U6 small nuclear 477, pseudogene","metadata":null},{"id":"13ee32108ac94138b3b98a6556856de1","type":"GENE","name":"RNU6-478P","canonical_id":"hgnc:HGNC:47441","description":"RNA, U6 small nuclear 478, pseudogene","metadata":null},{"id":"3d5464a24c5741e2b1056079af11d1ca","type":"GENE","name":"RNU6-479P","canonical_id":"hgnc:HGNC:47442","description":"RNA, U6 small nuclear 479, pseudogene","metadata":null},{"id":"57009d6ddc46420cb19b329cfe0e61b6","type":"GENE","name":"RNU6-47P","canonical_id":"hgnc:HGNC:34291","description":"RNA, U6 small nuclear 47, pseudogene","metadata":{"aliases":["RNU6-47"]}},{"id":"e8cccd049c744d239f277b51265ab1e6","type":"GENE","name":"RNU6-480P","canonical_id":"hgnc:HGNC:47443","description":"RNA, U6 small nuclear 480, pseudogene","metadata":null},{"id":"1f370261a13c41dc9b06a7fde0f5c4a3","type":"GENE","name":"RNU6-481P","canonical_id":"hgnc:HGNC:47444","description":"RNA, U6 small nuclear 481, pseudogene","metadata":null},{"id":"d6523fdb03ec49fc9916cc3b2e8c011d","type":"GENE","name":"RNU6-482P","canonical_id":"hgnc:HGNC:47445","description":"RNA, U6 small nuclear 482, pseudogene","metadata":null},{"id":"5b284dd04fd64d659f8a8fba6313d05b","type":"GENE","name":"RNU6-483P","canonical_id":"hgnc:HGNC:47446","description":"RNA, U6 small nuclear 483, pseudogene","metadata":null},{"id":"43ac33349c0b4edda83548e81dbe5629","type":"GENE","name":"RNU6-484P","canonical_id":"hgnc:HGNC:47447","description":"RNA, U6 small nuclear 484, pseudogene","metadata":null},{"id":"fd6e86fa161e4facaefb5132984f31e8","type":"GENE","name":"RNU6-485P","canonical_id":"hgnc:HGNC:47448","description":"RNA, U6 small nuclear 485, pseudogene","metadata":null},{"id":"5f228bc9a8ad41128d046be24d3bbe6b","type":"GENE","name":"RNU6-486P","canonical_id":"hgnc:HGNC:47449","description":"RNA, U6 small nuclear 486, pseudogene","metadata":null},{"id":"911e43ef69de46f9a6cc01088de4d1ab","type":"GENE","name":"RNU6-487P","canonical_id":"hgnc:HGNC:47450","description":"RNA, U6 small nuclear 487, pseudogene","metadata":null},{"id":"fd4e4eab0a954770920e84daae38f9f6","type":"GENE","name":"RNU6-488P","canonical_id":"hgnc:HGNC:47451","description":"RNA, U6 small nuclear 488, pseudogene","metadata":null},{"id":"bf3190b4977c48cab6271828fbdea04e","type":"GENE","name":"RNU6-489P","canonical_id":"hgnc:HGNC:47452","description":"RNA, U6 small nuclear 489, pseudogene","metadata":null},{"id":"24b58d7149224a8cab2ee47c88855281","type":"GENE","name":"RNU6-48P","canonical_id":"hgnc:HGNC:34292","description":"RNA, U6 small nuclear 48, pseudogene","metadata":{"aliases":["RNU6-48"]}},{"id":"a86da44b13a84aa48be6e4931aa257f9","type":"GENE","name":"RNU6-490P","canonical_id":"hgnc:HGNC:47453","description":"RNA, U6 small nuclear 490, pseudogene","metadata":null},{"id":"7442a1d5c5e34ed98c1e43a502540895","type":"GENE","name":"RNU6-491P","canonical_id":"hgnc:HGNC:47454","description":"RNA, U6 small nuclear 491, pseudogene","metadata":null},{"id":"64da867c9dd24ea2b17fea10a5490a80","type":"GENE","name":"RNU6-492P","canonical_id":"hgnc:HGNC:47455","description":"RNA, U6 small nuclear 492, pseudogene","metadata":null},{"id":"fd14ff4968e941a79d61a53ad83a0b15","type":"GENE","name":"RNU6-493P","canonical_id":"hgnc:HGNC:47456","description":"RNA, U6 small nuclear 493, pseudogene","metadata":null},{"id":"f15a7eba0ebc4bff93c618a24d1ae1b5","type":"GENE","name":"RNU6-494P","canonical_id":"hgnc:HGNC:47457","description":"RNA, U6 small nuclear 494, pseudogene","metadata":null},{"id":"ad2583c01e0c458385060c8199f26061","type":"GENE","name":"RNU6-495P","canonical_id":"hgnc:HGNC:47458","description":"RNA, U6 small nuclear 495, pseudogene","metadata":null},{"id":"d72792ff2e5746258d86cbfd9582600e","type":"GENE","name":"RNU6-496P","canonical_id":"hgnc:HGNC:47459","description":"RNA, U6 small nuclear 496, pseudogene","metadata":null},{"id":"1aff005b45174104898b1016185414ca","type":"GENE","name":"RNU6-497P","canonical_id":"hgnc:HGNC:47460","description":"RNA, U6 small nuclear 497, pseudogene","metadata":null},{"id":"9cb339afc9964b4bac44d5140659972f","type":"GENE","name":"RNU6-498P","canonical_id":"hgnc:HGNC:47461","description":"RNA, U6 small nuclear 498, pseudogene","metadata":null},{"id":"775f61ca257e4022aadfa5d36fd0a562","type":"GENE","name":"RNU6-499P","canonical_id":"hgnc:HGNC:47462","description":"RNA, U6 small nuclear 499, pseudogene","metadata":null},{"id":"063b1b3c2d4e4eda89f1b9665efe0d4d","type":"GENE","name":"RNU6-49P","canonical_id":"hgnc:HGNC:34293","description":"RNA, U6 small nuclear 49, pseudogene","metadata":{"aliases":["RNU6-49"]}},{"id":"888848e89d634ed8861fefab5cb7b176","type":"GENE","name":"RNU6-4P","canonical_id":"hgnc:HGNC:34253","description":"RNA, U6 small nuclear 4, pseudogene","metadata":{"aliases":["U6-4","RNU6-4"]}},{"id":"c16faea9a45a47118b137a45945b46e5","type":"GENE","name":"RNU6-500P","canonical_id":"hgnc:HGNC:47463","description":"RNA, U6 small nuclear 500, pseudogene","metadata":null},{"id":"12e8222b02f14369961628f23e489e6c","type":"GENE","name":"RNU6-501P","canonical_id":"hgnc:HGNC:47464","description":"RNA, U6 small nuclear 501, pseudogene","metadata":null},{"id":"da1380f76ca04d758f233685b3a04d11","type":"GENE","name":"RNU6-502P","canonical_id":"hgnc:HGNC:47465","description":"RNA, U6 small nuclear 502, pseudogene","metadata":null},{"id":"a83d1424ddce428783283944781c0463","type":"GENE","name":"RNU6-503P","canonical_id":"hgnc:HGNC:47466","description":"RNA, U6 small nuclear 503, pseudogene","metadata":null},{"id":"6f2b00e4b89545f083500b4c94f4a279","type":"GENE","name":"RNU6-504P","canonical_id":"hgnc:HGNC:47467","description":"RNA, U6 small nuclear 504, pseudogene","metadata":null},{"id":"bd93c998d5f9476e819f481a8086882f","type":"GENE","name":"RNU6-505P","canonical_id":"hgnc:HGNC:47468","description":"RNA, U6 small nuclear 505, pseudogene","metadata":null},{"id":"9687de749de54e2ebb27131fab9f4ab3","type":"GENE","name":"RNU6-506P","canonical_id":"hgnc:HGNC:47469","description":"RNA, U6 small nuclear 506, pseudogene","metadata":null},{"id":"c4e068ff154f4a43a00dba5aeffe3720","type":"GENE","name":"RNU6-507P","canonical_id":"hgnc:HGNC:47470","description":"RNA, U6 small nuclear 507, pseudogene","metadata":null},{"id":"76eb6eeddd9e4f7892c0335fd70423a9","type":"GENE","name":"RNU6-508P","canonical_id":"hgnc:HGNC:47471","description":"RNA, U6 small nuclear 508, pseudogene","metadata":null},{"id":"62123cf8593c4f6fbb6576eb004eb91f","type":"GENE","name":"RNU6-509P","canonical_id":"hgnc:HGNC:47472","description":"RNA, U6 small nuclear 509, pseudogene","metadata":null},{"id":"97feec3accc241169764f940418d9458","type":"GENE","name":"RNU6-50P","canonical_id":"hgnc:HGNC:10229","description":"RNA, U6 small nuclear 50, pseudogene","metadata":{"aliases":["U6","RNU6P1","RNU6-50"]}},{"id":"aa5b71d22b1d45559d89530c5d97bd07","type":"GENE","name":"RNU6-510P","canonical_id":"hgnc:HGNC:47473","description":"RNA, U6 small nuclear 510, pseudogene","metadata":null},{"id":"ca395939f2b147d496b88389064b9d40","type":"GENE","name":"RNU6-511P","canonical_id":"hgnc:HGNC:47474","description":"RNA, U6 small nuclear 511, pseudogene","metadata":null},{"id":"1733a3b3371d4c2b98f9cc69953be008","type":"GENE","name":"RNU6-512P","canonical_id":"hgnc:HGNC:47475","description":"RNA, U6 small nuclear 512, pseudogene","metadata":null},{"id":"9827b3850e3b44589b4565789229a962","type":"GENE","name":"RNU6-513P","canonical_id":"hgnc:HGNC:47476","description":"RNA, U6 small nuclear 513, pseudogene","metadata":null},{"id":"f94b056e04a542dcb54457502bd31327","type":"GENE","name":"RNU6-514P","canonical_id":"hgnc:HGNC:47477","description":"RNA, U6 small nuclear 514, pseudogene","metadata":null},{"id":"03655043e0294f94bbd402025aa1881e","type":"GENE","name":"RNU6-516P","canonical_id":"hgnc:HGNC:47479","description":"RNA, U6 small nuclear 516, pseudogene","metadata":null},{"id":"9601255747324398b6bd12714a75a6f1","type":"GENE","name":"RNU6-517P","canonical_id":"hgnc:HGNC:47480","description":"RNA, U6 small nuclear 517, pseudogene","metadata":null},{"id":"89ee52f9427c481db71bccf130b1d3a5","type":"GENE","name":"RNU6-518P","canonical_id":"hgnc:HGNC:47481","description":"RNA, U6 small nuclear 518, pseudogene","metadata":null},{"id":"2c233425de8c4f01876f12a26d5b1fe3","type":"GENE","name":"RNU6-519P","canonical_id":"hgnc:HGNC:47482","description":"RNA, U6 small nuclear 519, pseudogene","metadata":null},{"id":"3d3b3d4e16f94e94933307dce65b9d57","type":"GENE","name":"RNU6-520P","canonical_id":"hgnc:HGNC:47483","description":"RNA, U6 small nuclear 520, pseudogene","metadata":null},{"id":"7914f7f193c0474195ea49383b266c59","type":"GENE","name":"RNU6-521P","canonical_id":"hgnc:HGNC:47484","description":"RNA, U6 small nuclear 521, pseudogene","metadata":null},{"id":"67475b1b0bfa47bdb4e011e53871de7a","type":"GENE","name":"RNU6-522P","canonical_id":"hgnc:HGNC:47485","description":"RNA, U6 small nuclear 522, pseudogene","metadata":null},{"id":"3dc482f22c9a488b97cabfa4f7972349","type":"GENE","name":"RNU6-523P","canonical_id":"hgnc:HGNC:47486","description":"RNA, U6 small nuclear 523, pseudogene","metadata":null},{"id":"60209b5c6be24b5aa955647a003eefeb","type":"GENE","name":"RNU6-524P","canonical_id":"hgnc:HGNC:47487","description":"RNA, U6 small nuclear 524, pseudogene","metadata":null},{"id":"74bd150c000143ca87087988cda0abde","type":"GENE","name":"RNU6-525P","canonical_id":"hgnc:HGNC:47488","description":"RNA, U6 small nuclear 525, pseudogene","metadata":null},{"id":"346f257c7a2b4c65a444ab9560e1db12","type":"GENE","name":"RNU6-526P","canonical_id":"hgnc:HGNC:47489","description":"RNA, U6 small nuclear 526, pseudogene","metadata":null},{"id":"60981d6a9fe34f0891f6e077430877a4","type":"GENE","name":"RNU6-527P","canonical_id":"hgnc:HGNC:47490","description":"RNA, U6 small nuclear 527, pseudogene","metadata":null},{"id":"ca4a90f51d314205ab0c78254825f4af","type":"GENE","name":"RNU6-528P","canonical_id":"hgnc:HGNC:47491","description":"RNA, U6 small nuclear 528, pseudogene","metadata":null},{"id":"13944ef3ee9d4e33a34b7815e31ad61a","type":"GENE","name":"RNU6-529P","canonical_id":"hgnc:HGNC:47492","description":"RNA, U6 small nuclear 529, pseudogene","metadata":null},{"id":"6313b30e4cf744c98b94f909d318800a","type":"GENE","name":"RNU6-52P","canonical_id":"hgnc:HGNC:42542","description":"RNA, U6 small nuclear 52, pseudogene","metadata":{"aliases":["RNU6-52"]}},{"id":"d576048aec334039988089706cf426d2","type":"GENE","name":"RNU6-530P","canonical_id":"hgnc:HGNC:47493","description":"RNA, U6 small nuclear 530, pseudogene","metadata":null},{"id":"a966790bb5dd47058294ee0b7bb6a090","type":"GENE","name":"RNU6-531P","canonical_id":"hgnc:HGNC:47494","description":"RNA, U6 small nuclear 531, pseudogene","metadata":null},{"id":"f5ea4863c8914695ac12a1701f961e11","type":"GENE","name":"RNU6-532P","canonical_id":"hgnc:HGNC:47495","description":"RNA, U6 small nuclear 532, pseudogene","metadata":null},{"id":"7880510e7af44a4f9c44e6b9d5e3666c","type":"GENE","name":"RNU6-533P","canonical_id":"hgnc:HGNC:47496","description":"RNA, U6 small nuclear 533, pseudogene","metadata":null},{"id":"e952a9d16f334cefa5256a50acf0aecc","type":"GENE","name":"RNU6-534P","canonical_id":"hgnc:HGNC:47497","description":"RNA, U6 small nuclear 534, pseudogene","metadata":null},{"id":"5af2ea687b5c460082300a8fb7c455cc","type":"GENE","name":"RNU6-535P","canonical_id":"hgnc:HGNC:47498","description":"RNA, U6 small nuclear 535, pseudogene","metadata":null},{"id":"baf66947573f447996cf5dd163910aa9","type":"GENE","name":"RNU6-536P","canonical_id":"hgnc:HGNC:47499","description":"RNA, U6 small nuclear 536, pseudogene","metadata":null},{"id":"50e09119e14b49d6b375defef079dfcb","type":"GENE","name":"RNU6-537P","canonical_id":"hgnc:HGNC:47500","description":"RNA, U6 small nuclear 537, pseudogene","metadata":null},{"id":"35fadfadee8f48a892e75581b77eb4c2","type":"GENE","name":"RNU6-538P","canonical_id":"hgnc:HGNC:47501","description":"RNA, U6 small nuclear 538, pseudogene","metadata":null},{"id":"f18de10d9a6c4272a94cb80b80f2f267","type":"GENE","name":"RNU6-539P","canonical_id":"hgnc:HGNC:47502","description":"RNA, U6 small nuclear 539, pseudogene","metadata":null},{"id":"28e00528de1949b097971610a3305159","type":"GENE","name":"RNU6-53P","canonical_id":"hgnc:HGNC:42543","description":"RNA, U6 small nuclear 53, pseudogene","metadata":{"aliases":["RNU6-53"]}},{"id":"cd52b26bfe864ed586b3641edcfd5ade","type":"GENE","name":"RNU6-540P","canonical_id":"hgnc:HGNC:47503","description":"RNA, U6 small nuclear 540, pseudogene","metadata":null},{"id":"9aa19ee8f38c4a0da666ea55b94def76","type":"GENE","name":"RNU6-541P","canonical_id":"hgnc:HGNC:47504","description":"RNA, U6 small nuclear 541, pseudogene","metadata":null},{"id":"a2cfaa8e70ea469f8ce6fc3fcfa17738","type":"GENE","name":"RNU6-542P","canonical_id":"hgnc:HGNC:47505","description":"RNA, U6 small nuclear 542, pseudogene","metadata":null},{"id":"87d465e447a44db7b16b33eac53facae","type":"GENE","name":"RNU6-543P","canonical_id":"hgnc:HGNC:47506","description":"RNA, U6 small nuclear 543, pseudogene","metadata":null},{"id":"9e19950fb6344e9cb28e9062ff716613","type":"GENE","name":"RNU6-544P","canonical_id":"hgnc:HGNC:47507","description":"RNA, U6 small nuclear 544, pseudogene","metadata":null},{"id":"4054173075014310acdd4a30efcc14d5","type":"GENE","name":"RNU6-545P","canonical_id":"hgnc:HGNC:47508","description":"RNA, U6 small nuclear 545, pseudogene","metadata":{"aliases":["RNU6-292P"]}},{"id":"a337ff3433374d45991f6818b7e16080","type":"GENE","name":"RNU6-546P","canonical_id":"hgnc:HGNC:47509","description":"RNA, U6 small nuclear 546, pseudogene","metadata":null},{"id":"99bcf4b7d39d4da7844976787a663335","type":"GENE","name":"RNU6-547P","canonical_id":"hgnc:HGNC:47510","description":"RNA, U6 small nuclear 547, pseudogene","metadata":null},{"id":"6c5fb4c8dd1b4191a0dea7a2536018ef","type":"GENE","name":"RNU6-548P","canonical_id":"hgnc:HGNC:47511","description":"RNA, U6 small nuclear 548, pseudogene","metadata":null},{"id":"fbd567fe29f547f9939092b011a4500c","type":"GENE","name":"RNU6-549P","canonical_id":"hgnc:HGNC:47512","description":"RNA, U6 small nuclear 549, pseudogene","metadata":null},{"id":"5cf6f4de814a442e9e5b4a6370b4a23f","type":"GENE","name":"RNU6-54P","canonical_id":"hgnc:HGNC:42544","description":"RNA, U6 small nuclear 54, pseudogene","metadata":{"aliases":["RNU6-54"]}},{"id":"ddb7f59a518444a5bc1a7ec0dbd25bd8","type":"GENE","name":"RNU6-550P","canonical_id":"hgnc:HGNC:47513","description":"RNA, U6 small nuclear 550, pseudogene","metadata":null},{"id":"07d4ebd432854cbbaad985961877501f","type":"GENE","name":"RNU6-551P","canonical_id":"hgnc:HGNC:47514","description":"RNA, U6 small nuclear 551, pseudogene","metadata":null},{"id":"786741d4f57f42628b100b69b070b2ba","type":"GENE","name":"RNU6-552P","canonical_id":"hgnc:HGNC:47515","description":"RNA, U6 small nuclear 552, pseudogene","metadata":null},{"id":"af088dcc0aa94735bc4c3182ddfa4103","type":"GENE","name":"RNU6-553P","canonical_id":"hgnc:HGNC:47516","description":"RNA, U6 small nuclear 553, pseudogene","metadata":null},{"id":"b93fec37b8724e90b53a96848f658b6d","type":"GENE","name":"RNU6-554P","canonical_id":"hgnc:HGNC:47517","description":"RNA, U6 small nuclear 554, pseudogene","metadata":null},{"id":"b00fb916e1e7462a908ee3a4097df7ac","type":"GENE","name":"RNU6-555P","canonical_id":"hgnc:HGNC:47518","description":"RNA, U6 small nuclear 555, pseudogene","metadata":null},{"id":"ebce66975dc54a3c93ebda8d91d173d4","type":"GENE","name":"RNU6-556P","canonical_id":"hgnc:HGNC:47519","description":"RNA, U6 small nuclear 556, pseudogene","metadata":null},{"id":"35af4742bb024ced9b30198afcf82838","type":"GENE","name":"RNU6-557P","canonical_id":"hgnc:HGNC:47520","description":"RNA, U6 small nuclear 557, pseudogene","metadata":null},{"id":"c970658a683c453691c41c0c6e981b65","type":"GENE","name":"RNU6-558P","canonical_id":"hgnc:HGNC:47521","description":"RNA, U6 small nuclear 558, pseudogene","metadata":null},{"id":"b77db24f6a5f426e8b509d9e9aeacba7","type":"GENE","name":"RNU6-559P","canonical_id":"hgnc:HGNC:47522","description":"RNA, U6 small nuclear 559, pseudogene","metadata":null},{"id":"9be33bb894aa4bab89e5e80fd4cd09da","type":"GENE","name":"RNU6-55P","canonical_id":"hgnc:HGNC:42545","description":"RNA, U6 small nuclear 55, pseudogene","metadata":{"aliases":["RNU6-55"]}},{"id":"2a821b4f449948a0a88dfa12de052703","type":"GENE","name":"RNU6-560P","canonical_id":"hgnc:HGNC:47523","description":"RNA, U6 small nuclear 560, pseudogene","metadata":null},{"id":"8a953f06940e428b8789cc0afb41ca27","type":"GENE","name":"RNU6-561P","canonical_id":"hgnc:HGNC:47524","description":"RNA, U6 small nuclear 561, pseudogene","metadata":null},{"id":"3f109da20cd947baa387f57f6a833224","type":"GENE","name":"RNU6-562P","canonical_id":"hgnc:HGNC:47525","description":"RNA, U6 small nuclear 562, pseudogene","metadata":null},{"id":"36a9dfa3114342829d00b15b1dc732f7","type":"GENE","name":"RNU6-563P","canonical_id":"hgnc:HGNC:47526","description":"RNA, U6 small nuclear 563, pseudogene","metadata":null},{"id":"dc52fb746ce546acb43dd48be18f42c1","type":"GENE","name":"RNU6-564P","canonical_id":"hgnc:HGNC:47527","description":"RNA, U6 small nuclear 564, pseudogene","metadata":null},{"id":"e9a94851aba1432fac2cbd27631aea94","type":"GENE","name":"RNU6-565P","canonical_id":"hgnc:HGNC:47528","description":"RNA, U6 small nuclear 565, pseudogene","metadata":null},{"id":"671240c2e4634946951c030ba5c06f60","type":"GENE","name":"RNU6-566P","canonical_id":"hgnc:HGNC:47529","description":"RNA, U6 small nuclear 566, pseudogene","metadata":null},{"id":"f7f169d9ca7e47d79e1b7afcaab7c476","type":"GENE","name":"RNU6-567P","canonical_id":"hgnc:HGNC:47530","description":"RNA, U6 small nuclear 567, pseudogene","metadata":null},{"id":"0247ee33e75d44f2980ff694c29edc0b","type":"GENE","name":"RNU6-56P","canonical_id":"hgnc:HGNC:42546","description":"RNA, U6 small nuclear 56, pseudogene","metadata":{"aliases":["RNU6-56"]}},{"id":"a9b6483b2413420690bcc71255d6e1f5","type":"GENE","name":"RNU6-570P","canonical_id":"hgnc:HGNC:47533","description":"RNA, U6 small nuclear 570, pseudogene","metadata":null},{"id":"13247fa252814ef7a5a816d1d53dffd1","type":"GENE","name":"RNU6-571P","canonical_id":"hgnc:HGNC:47534","description":"RNA, U6 small nuclear 571, pseudogene","metadata":null},{"id":"5c06f4623d084bf7905afe99d525f924","type":"GENE","name":"RNU6-572P","canonical_id":"hgnc:HGNC:47535","description":"RNA, U6 small nuclear 572, pseudogene","metadata":null},{"id":"df8d382bbeca47c3b86b2ba5a7a2d514","type":"GENE","name":"RNU6-573P","canonical_id":"hgnc:HGNC:47536","description":"RNA, U6 small nuclear 573, pseudogene","metadata":null},{"id":"c056eb8f51364444b5149228462a3c3a","type":"GENE","name":"RNU6-574P","canonical_id":"hgnc:HGNC:47537","description":"RNA, U6 small nuclear 574, pseudogene","metadata":null},{"id":"48a4f899d33344b9aebbc87937d934ef","type":"GENE","name":"RNU6-575P","canonical_id":"hgnc:HGNC:47538","description":"RNA, U6 small nuclear 575, pseudogene","metadata":null},{"id":"fd21e476320a4d0a9a83f4586bda4860","type":"GENE","name":"RNU6-576P","canonical_id":"hgnc:HGNC:47539","description":"RNA, U6 small nuclear 576, pseudogene","metadata":null},{"id":"33bd172187ae4c538aefb6441b9a0183","type":"GENE","name":"RNU6-577P","canonical_id":"hgnc:HGNC:47540","description":"RNA, U6 small nuclear 577, pseudogene","metadata":null},{"id":"1062557a6bbe4ea692053ff1f01447f2","type":"GENE","name":"RNU6-578P","canonical_id":"hgnc:HGNC:47541","description":"RNA, U6 small nuclear 578, pseudogene","metadata":null},{"id":"5c55584d6750406984cc61e47a19bb6b","type":"GENE","name":"RNU6-579P","canonical_id":"hgnc:HGNC:47542","description":"RNA, U6 small nuclear 579, pseudogene","metadata":null},{"id":"43d73921a6a94743bf5e1e982dc21782","type":"GENE","name":"RNU6-57P","canonical_id":"hgnc:HGNC:42547","description":"RNA, U6 small nuclear 57, pseudogene","metadata":{"aliases":["RNU6-57"]}},{"id":"8dc8b118ef314c0c81c3e32714672f98","type":"GENE","name":"RNU6-580P","canonical_id":"hgnc:HGNC:47543","description":"RNA, U6 small nuclear 580, pseudogene","metadata":null},{"id":"cc4926859ff246678c36bfd39ad20760","type":"GENE","name":"RNU6-581P","canonical_id":"hgnc:HGNC:47544","description":"RNA, U6 small nuclear 581, pseudogene","metadata":null},{"id":"87b1472f7dbd424e8f52e249bfee5b87","type":"GENE","name":"RNU6-582P","canonical_id":"hgnc:HGNC:47545","description":"RNA, U6 small nuclear 582, pseudogene","metadata":null},{"id":"651db30b1c164703928b5e8a14e735f1","type":"GENE","name":"RNU6-583P","canonical_id":"hgnc:HGNC:47546","description":"RNA, U6 small nuclear 583, pseudogene","metadata":null},{"id":"6f97928a20f74a9097595839bdda4f23","type":"GENE","name":"RNU6-584P","canonical_id":"hgnc:HGNC:47547","description":"RNA, U6 small nuclear 584, pseudogene","metadata":null},{"id":"e5974d1b732340ffb1e3ba627c6ff528","type":"GENE","name":"RNU6-586P","canonical_id":"hgnc:HGNC:47549","description":"RNA, U6 small nuclear 586, pseudogene","metadata":null},{"id":"7871df90123642bd9bb6ba7178ddad98","type":"GENE","name":"RNU6-587P","canonical_id":"hgnc:HGNC:47550","description":"RNA, U6 small nuclear 587, pseudogene","metadata":null},{"id":"53a16b2db51c43a79a60b85bf12d32d4","type":"GENE","name":"RNU6-588P","canonical_id":"hgnc:HGNC:47551","description":"RNA, U6 small nuclear 588, pseudogene","metadata":null},{"id":"a767e4344d7642aca99d38d8b61e27a7","type":"GENE","name":"RNU6-589P","canonical_id":"hgnc:HGNC:47552","description":"RNA, U6 small nuclear 589, pseudogene","metadata":null},{"id":"2123aaa747894b47aa14e9b195b4fcd3","type":"GENE","name":"RNU6-58P","canonical_id":"hgnc:HGNC:42548","description":"RNA, U6 small nuclear 58, pseudogene","metadata":{"aliases":["RNU6-58"]}},{"id":"5155378b3a214fe2b0ce27112901fca9","type":"GENE","name":"RNU6-590P","canonical_id":"hgnc:HGNC:47553","description":"RNA, U6 small nuclear 590, pseudogene","metadata":null},{"id":"7bbfe3c311b04c158372914977bf1186","type":"GENE","name":"RNU6-591P","canonical_id":"hgnc:HGNC:47554","description":"RNA, U6 small nuclear 591, pseudogene","metadata":null},{"id":"0428e9ee40f640e98679cbe19aafe36d","type":"GENE","name":"RNU6-592P","canonical_id":"hgnc:HGNC:47555","description":"RNA, U6 small nuclear 592, pseudogene","metadata":null},{"id":"b3fee7c4175348039f3679e1a6067113","type":"GENE","name":"RNU6-593P","canonical_id":"hgnc:HGNC:47556","description":"RNA, U6 small nuclear 593, pseudogene","metadata":null},{"id":"90d9a7e86d2d41f897c07a0029df6621","type":"GENE","name":"RNU6-595P","canonical_id":"hgnc:HGNC:47558","description":"RNA, U6 small nuclear 595, pseudogene","metadata":null},{"id":"4c8f3536a3f747aaab5caaf8862b2075","type":"GENE","name":"RNU6-596P","canonical_id":"hgnc:HGNC:47559","description":"RNA, U6 small nuclear 596, pseudogene","metadata":null},{"id":"97bd515973a44eadb71fd35fee97d42e","type":"GENE","name":"RNU6-597P","canonical_id":"hgnc:HGNC:47560","description":"RNA, U6 small nuclear 597, pseudogene","metadata":null},{"id":"3f96cdc0fd8248ba8d8a04205d29fecb","type":"GENE","name":"RNU6-598P","canonical_id":"hgnc:HGNC:47561","description":"RNA, U6 small nuclear 598, pseudogene","metadata":null},{"id":"574dc9a77c634d1c8db4140f37b64e87","type":"GENE","name":"RNU6-599P","canonical_id":"hgnc:HGNC:47562","description":"RNA, U6 small nuclear 599, pseudogene","metadata":null},{"id":"3b5c9b03496e46c3b11d89e998e5ccdc","type":"GENE","name":"RNU6-59P","canonical_id":"hgnc:HGNC:42549","description":"RNA, U6 small nuclear 59, pseudogene","metadata":{"aliases":["RNU6-59"]}},{"id":"2af56425d6e34c2cb6a586b48a567034","type":"GENE","name":"RNU6-5P","canonical_id":"hgnc:HGNC:34249","description":"RNA, U6 small nuclear 5, pseudogene","metadata":{"aliases":["U6-5","RNU6-5"]}},{"id":"eeddabede8584a04b53991871ecf5367","type":"GENE","name":"RNU6-600P","canonical_id":"hgnc:HGNC:47563","description":"RNA, U6 small nuclear 600, pseudogene","metadata":null},{"id":"59c36ee756b648219b263732d6172ff9","type":"GENE","name":"RNU6-601P","canonical_id":"hgnc:HGNC:47564","description":"RNA, U6 small nuclear 601, pseudogene","metadata":null},{"id":"dc70e93bb892486281e9de2a620882f4","type":"GENE","name":"RNU6-602P","canonical_id":"hgnc:HGNC:47565","description":"RNA, U6 small nuclear 602, pseudogene","metadata":null},{"id":"d2cdee7f344f47d29768c84ffafc17a3","type":"GENE","name":"RNU6-603P","canonical_id":"hgnc:HGNC:47566","description":"RNA, U6 small nuclear 603, pseudogene","metadata":{"aliases":["RNU6-825P"]}},{"id":"6fc0a859684b43b5be662f1cba779a96","type":"GENE","name":"RNU6-604P","canonical_id":"hgnc:HGNC:47567","description":"RNA, U6 small nuclear 604, pseudogene","metadata":null},{"id":"cfce5264371f48f0a9e4a4c3ac61451a","type":"GENE","name":"RNU6-605P","canonical_id":"hgnc:HGNC:47568","description":"RNA, U6 small nuclear 605, pseudogene","metadata":null},{"id":"8bb4dafd14ae4b44bd9dc639b87016d0","type":"GENE","name":"RNU6-606P","canonical_id":"hgnc:HGNC:47569","description":"RNA, U6 small nuclear 606, pseudogene","metadata":null},{"id":"29612e8a362a4b449d8e73c0ef814650","type":"GENE","name":"RNU6-607P","canonical_id":"hgnc:HGNC:47570","description":"RNA, U6 small nuclear 607, pseudogene","metadata":null},{"id":"ac2cac41e2864ad9921b39fc03d7944d","type":"GENE","name":"RNU6-608P","canonical_id":"hgnc:HGNC:47571","description":"RNA, U6 small nuclear 608, pseudogene","metadata":null},{"id":"769423bedbc742a1b38d5ad616465aea","type":"GENE","name":"RNU6-609P","canonical_id":"hgnc:HGNC:47572","description":"RNA, U6 small nuclear 609, pseudogene","metadata":null},{"id":"1ea463fb8c4d434faec78d2ce8f4d0e0","type":"GENE","name":"RNU6-60P","canonical_id":"hgnc:HGNC:42550","description":"RNA, U6 small nuclear 60, pseudogene","metadata":{"aliases":["RNU6-60"]}},{"id":"438a95711c77461d86a0da829781f05b","type":"GENE","name":"RNU6-610P","canonical_id":"hgnc:HGNC:47573","description":"RNA, U6 small nuclear 610, pseudogene","metadata":null},{"id":"66ed4325fbc64127bd66736dd44e0058","type":"GENE","name":"RNU6-611P","canonical_id":"hgnc:HGNC:47574","description":"RNA, U6 small nuclear 611, pseudogene","metadata":null},{"id":"c13feb1bf1fd4cdbbcd9148bf6700f03","type":"GENE","name":"RNU6-612P","canonical_id":"hgnc:HGNC:47575","description":"RNA, U6 small nuclear 612, pseudogene","metadata":null},{"id":"9d68946424564f77995dffaff019ea25","type":"GENE","name":"RNU6-613P","canonical_id":"hgnc:HGNC:47576","description":"RNA, U6 small nuclear 613, pseudogene","metadata":null},{"id":"23e47ff52da9496f91f806f767759e48","type":"GENE","name":"RNU6-614P","canonical_id":"hgnc:HGNC:47577","description":"RNA, U6 small nuclear 614, pseudogene","metadata":null},{"id":"f346f5b6a1004d06b71210f955b6014d","type":"GENE","name":"RNU6-615P","canonical_id":"hgnc:HGNC:47578","description":"RNA, U6 small nuclear 615, pseudogene","metadata":null},{"id":"652fe94d88574ce687a6fa3fbe4bc41f","type":"GENE","name":"RNU6-616P","canonical_id":"hgnc:HGNC:47579","description":"RNA, U6 small nuclear 616, pseudogene","metadata":null},{"id":"315d6d2f8e5a4bf0a5e01a5dfb91ad8e","type":"GENE","name":"RNU6-617P","canonical_id":"hgnc:HGNC:47580","description":"RNA, U6 small nuclear 617, pseudogene","metadata":null},{"id":"4ac05cbcb96e47c1a9f076a1b619be25","type":"GENE","name":"RNU6-618P","canonical_id":"hgnc:HGNC:47581","description":"RNA, U6 small nuclear 618, pseudogene","metadata":null},{"id":"787436ea0f8c45b48ed264be1ec3dc4c","type":"GENE","name":"RNU6-619P","canonical_id":"hgnc:HGNC:47582","description":"RNA, U6 small nuclear 619, pseudogene","metadata":null},{"id":"68322b35dbaa41018895ca7436d01344","type":"GENE","name":"RNU6-61P","canonical_id":"hgnc:HGNC:42551","description":"RNA, U6 small nuclear 61, pseudogene","metadata":{"aliases":["RNU6-61"]}},{"id":"6da4df2ec6724a9293dda9af6df2ba16","type":"GENE","name":"RNU6-620P","canonical_id":"hgnc:HGNC:47583","description":"RNA, U6 small nuclear 620, pseudogene","metadata":null},{"id":"7bc75cdab6cd485f9b949378ce3c2e7e","type":"GENE","name":"RNU6-621P","canonical_id":"hgnc:HGNC:47584","description":"RNA, U6 small nuclear 621, pseudogene","metadata":null},{"id":"dd2c9b84bce44c1593e38a3c913f4993","type":"GENE","name":"RNU6-622P","canonical_id":"hgnc:HGNC:47585","description":"RNA, U6 small nuclear 622, pseudogene","metadata":null},{"id":"f3e8c85a43024b26bcadd2395458ffed","type":"GENE","name":"RNU6-623P","canonical_id":"hgnc:HGNC:47586","description":"RNA, U6 small nuclear 623, pseudogene","metadata":null},{"id":"df16a1e9bef2478383512ecf330441ed","type":"GENE","name":"RNU6-624P","canonical_id":"hgnc:HGNC:47587","description":"RNA, U6 small nuclear 624, pseudogene","metadata":null},{"id":"c0012433be7f45159391704613b71af3","type":"GENE","name":"RNU6-625P","canonical_id":"hgnc:HGNC:47588","description":"RNA, U6 small nuclear 625, pseudogene","metadata":null},{"id":"8b54287725704f28b831bc5bf8e2a155","type":"GENE","name":"RNU6-626P","canonical_id":"hgnc:HGNC:47589","description":"RNA, U6 small nuclear 626, pseudogene","metadata":null},{"id":"00c173f46f704565a82f16e85b7952de","type":"GENE","name":"RNU6-627P","canonical_id":"hgnc:HGNC:47590","description":"RNA, U6 small nuclear 627, pseudogene","metadata":null},{"id":"418bf7c11d8246659ad323ec496d479a","type":"GENE","name":"RNU6-628P","canonical_id":"hgnc:HGNC:47591","description":"RNA, U6 small nuclear 628, pseudogene","metadata":null},{"id":"ab1ba16cd7074f75aa14fce4e8abf739","type":"GENE","name":"RNU6-629P","canonical_id":"hgnc:HGNC:47592","description":"RNA, U6 small nuclear 629, pseudogene","metadata":null},{"id":"e4dcc6574bde4be4856fcb14990c3195","type":"GENE","name":"RNU6-62P","canonical_id":"hgnc:HGNC:42552","description":"RNA, U6 small nuclear 62, pseudogene","metadata":{"aliases":["RNU6-62"]}},{"id":"6dc9152aff3e450499335250c9f7417c","type":"GENE","name":"RNU6-630P","canonical_id":"hgnc:HGNC:47593","description":"RNA, U6 small nuclear 630, pseudogene","metadata":null},{"id":"ec3b6ac2b33b45f393c4fa3e3b106d2f","type":"GENE","name":"RNU6-631P","canonical_id":"hgnc:HGNC:47594","description":"RNA, U6 small nuclear 631, pseudogene","metadata":null},{"id":"e3222dfbd27b4e7db9cb3bf168d1acd0","type":"GENE","name":"RNU6-632P","canonical_id":"hgnc:HGNC:47595","description":"RNA, U6 small nuclear 632, pseudogene","metadata":null},{"id":"bc410f6950db456dae9cce8100940327","type":"GENE","name":"RNU6-633P","canonical_id":"hgnc:HGNC:47596","description":"RNA, U6 small nuclear 633, pseudogene","metadata":null},{"id":"617634410264488987fe9eb194a723b0","type":"GENE","name":"RNU6-634P","canonical_id":"hgnc:HGNC:47597","description":"RNA, U6 small nuclear 634, pseudogene","metadata":null},{"id":"230dcaefd911405f8e6500a7ca39d788","type":"GENE","name":"RNU6-635P","canonical_id":"hgnc:HGNC:47598","description":"RNA, U6 small nuclear 635, pseudogene","metadata":null},{"id":"67d323f40a5d4a08a1e01165be2f8e2a","type":"GENE","name":"RNU6-636P","canonical_id":"hgnc:HGNC:47599","description":"RNA, U6 small nuclear 636, pseudogene","metadata":null},{"id":"40496c1b7ddc48fab5509296f627dc4d","type":"GENE","name":"RNU6-637P","canonical_id":"hgnc:HGNC:47600","description":"RNA, U6 small nuclear 637, pseudogene","metadata":null},{"id":"e3a6222984db46ceb2bd5b82699cbfd7","type":"GENE","name":"RNU6-638P","canonical_id":"hgnc:HGNC:47601","description":"RNA, U6 small nuclear 638, pseudogene","metadata":null},{"id":"ac2c301479f84eec9c8799b97ce09a0f","type":"GENE","name":"RNU6-639P","canonical_id":"hgnc:HGNC:47602","description":"RNA, U6 small nuclear 639, pseudogene","metadata":null},{"id":"3bb4c87f41364aebbe477ba19994412b","type":"GENE","name":"RNU6-63P","canonical_id":"hgnc:HGNC:42553","description":"RNA, U6 small nuclear 63, pseudogene","metadata":{"aliases":["RNU6-63"]}},{"id":"65335f2cae564a5780e7fd45359f43b1","type":"GENE","name":"RNU6-640P","canonical_id":"hgnc:HGNC:47603","description":"RNA, U6 small nuclear 640, pseudogene","metadata":null},{"id":"7b24cb8864a84703902c799024fc0208","type":"GENE","name":"RNU6-641P","canonical_id":"hgnc:HGNC:47604","description":"RNA, U6 small nuclear 641, pseudogene","metadata":null},{"id":"2972066577a24f948e276d1a57d51f3c","type":"GENE","name":"RNU6-642P","canonical_id":"hgnc:HGNC:47605","description":"RNA, U6 small nuclear 642, pseudogene","metadata":null},{"id":"90394759a20d4f908d05c74a913c4ff9","type":"GENE","name":"RNU6-643P","canonical_id":"hgnc:HGNC:47606","description":"RNA, U6 small nuclear 643, pseudogene","metadata":null},{"id":"bd811cde3c81477c88e1e04ba9088e57","type":"GENE","name":"RNU6-644P","canonical_id":"hgnc:HGNC:47607","description":"RNA, U6 small nuclear 644, pseudogene","metadata":null},{"id":"64eb585283874f1d87acaba02e77cebf","type":"GENE","name":"RNU6-645P","canonical_id":"hgnc:HGNC:47608","description":"RNA, U6 small nuclear 645, pseudogene","metadata":null},{"id":"519978c100c4481ba266d71908aecea9","type":"GENE","name":"RNU6-646P","canonical_id":"hgnc:HGNC:47609","description":"RNA, U6 small nuclear 646, pseudogene","metadata":null},{"id":"ecc9183a117d4839a972b12f98231205","type":"GENE","name":"RNU6-647P","canonical_id":"hgnc:HGNC:47610","description":"RNA, U6 small nuclear 647, pseudogene","metadata":null},{"id":"30a2ab8920c84d2bb932e41f0ff35e9e","type":"GENE","name":"RNU6-648P","canonical_id":"hgnc:HGNC:47611","description":"RNA, U6 small nuclear 648, pseudogene","metadata":null},{"id":"8e31f784ecd14173b632f4f4f633e2d9","type":"GENE","name":"RNU6-649P","canonical_id":"hgnc:HGNC:47612","description":"RNA, U6 small nuclear 649, pseudogene","metadata":null},{"id":"aed79f8ba7d346c8b5258c49c0f6643b","type":"GENE","name":"RNU6-64P","canonical_id":"hgnc:HGNC:42554","description":"RNA, U6 small nuclear 64, pseudogene","metadata":{"aliases":["RNU6-64"]}},{"id":"9bd30efbd3194b4f9a8e7dffc2a2e437","type":"GENE","name":"RNU6-650P","canonical_id":"hgnc:HGNC:47613","description":"RNA, U6 small nuclear 650, pseudogene","metadata":null},{"id":"1fa58db4eab04be5b84ab01b97dcbf0b","type":"GENE","name":"RNU6-651P","canonical_id":"hgnc:HGNC:47614","description":"RNA, U6 small nuclear 651, pseudogene","metadata":null},{"id":"f30d495de31647a3b1060231509ec6c9","type":"GENE","name":"RNU6-652P","canonical_id":"hgnc:HGNC:47615","description":"RNA, U6 small nuclear 652, pseudogene","metadata":null},{"id":"9acf8ad022ee47a093e9a8c19b2140f5","type":"GENE","name":"RNU6-653P","canonical_id":"hgnc:HGNC:47616","description":"RNA, U6 small nuclear 653, pseudogene","metadata":null},{"id":"7d7e6daef4844496a80484c51432a391","type":"GENE","name":"RNU6-654P","canonical_id":"hgnc:HGNC:47617","description":"RNA, U6 small nuclear 654, pseudogene","metadata":null},{"id":"76f28e437d334a15b26575ed08d6b1fd","type":"GENE","name":"RNU6-655P","canonical_id":"hgnc:HGNC:47618","description":"RNA, U6 small nuclear 655, pseudogene","metadata":null},{"id":"f1a55c64630349c092dd34d8a3678e39","type":"GENE","name":"RNU6-656P","canonical_id":"hgnc:HGNC:47619","description":"RNA, U6 small nuclear 656, pseudogene","metadata":null},{"id":"1b8f0750e75b4955936b88922f396dd8","type":"GENE","name":"RNU6-657P","canonical_id":"hgnc:HGNC:47620","description":"RNA, U6 small nuclear 657, pseudogene","metadata":null},{"id":"215f46bd98c94ccb83d153f1f36e427e","type":"GENE","name":"RNU6-658P","canonical_id":"hgnc:HGNC:47621","description":"RNA, U6 small nuclear 658, pseudogene","metadata":null},{"id":"6817cc3e982a47dcb3148b10704db06a","type":"GENE","name":"RNU6-659P","canonical_id":"hgnc:HGNC:47622","description":"RNA, U6 small nuclear 659, pseudogene","metadata":null},{"id":"40b76c794e1743409847d625736ad285","type":"GENE","name":"RNU6-65P","canonical_id":"hgnc:HGNC:42555","description":"RNA, U6 small nuclear 65, pseudogene","metadata":{"aliases":["RNU6-65"]}},{"id":"0bb73a00a3724d998cc54d5bec170a04","type":"GENE","name":"RNU6-660P","canonical_id":"hgnc:HGNC:47623","description":"RNA, U6 small nuclear 660, pseudogene","metadata":null},{"id":"005407223f0045d3bf1f283e691a8a82","type":"GENE","name":"RNU6-661P","canonical_id":"hgnc:HGNC:47624","description":"RNA, U6 small nuclear 661, pseudogene","metadata":null},{"id":"49c701995b2a42f8b1949ddb8836a83e","type":"GENE","name":"RNU6-662P","canonical_id":"hgnc:HGNC:47625","description":"RNA, U6 small nuclear 662, pseudogene","metadata":null},{"id":"0095f2fa6a9f470cb541207afa5e3700","type":"GENE","name":"RNU6-663P","canonical_id":"hgnc:HGNC:47626","description":"RNA, U6 small nuclear 663, pseudogene","metadata":null},{"id":"12f7f40ee0b9447b8d158191ac5041d0","type":"GENE","name":"RNU6-664P","canonical_id":"hgnc:HGNC:47627","description":"RNA, U6 small nuclear 664, pseudogene","metadata":null},{"id":"a26d8387b9854f108a292ea0f42451c3","type":"GENE","name":"RNU6-665P","canonical_id":"hgnc:HGNC:47628","description":"RNA, U6 small nuclear 665, pseudogene","metadata":null},{"id":"04f0a073284a471c9a80434a336b12b6","type":"GENE","name":"RNU6-666P","canonical_id":"hgnc:HGNC:47629","description":"RNA, U6 small nuclear 666, pseudogene","metadata":null},{"id":"1feef1f6dfba4e1c97241726c7fb316f","type":"GENE","name":"RNU6-667P","canonical_id":"hgnc:HGNC:47630","description":"RNA, U6 small nuclear 667, pseudogene","metadata":null},{"id":"5090c17300a244239bd317740b0526d9","type":"GENE","name":"RNU6-668P","canonical_id":"hgnc:HGNC:47631","description":"RNA, U6 small nuclear 668, pseudogene","metadata":null},{"id":"228d190065c14356b69753426974ad97","type":"GENE","name":"RNU6-669P","canonical_id":"hgnc:HGNC:47632","description":"RNA, U6 small nuclear 669, pseudogene","metadata":null},{"id":"63da30e3fd6541f5a98ca585a454c7b9","type":"GENE","name":"RNU6-66P","canonical_id":"hgnc:HGNC:42556","description":"RNA, U6 small nuclear 66, pseudogene","metadata":{"aliases":["RNU6-66"]}},{"id":"e88fb103ab0e47d28ad0386776ab6505","type":"GENE","name":"RNU6-670P","canonical_id":"hgnc:HGNC:47633","description":"RNA, U6 small nuclear 670, pseudogene","metadata":null},{"id":"0608ddc856284476b298f274cce58f0f","type":"GENE","name":"RNU6-672P","canonical_id":"hgnc:HGNC:47635","description":"RNA, U6 small nuclear 672, pseudogene","metadata":null},{"id":"e62c2d9e655047a69e0a62ff30ce424d","type":"GENE","name":"RNU6-673P","canonical_id":"hgnc:HGNC:47636","description":"RNA, U6 small nuclear 673, pseudogene","metadata":null},{"id":"0b43bec9b8884b5ba9419b427e1e886d","type":"GENE","name":"RNU6-674P","canonical_id":"hgnc:HGNC:47637","description":"RNA, U6 small nuclear 674, pseudogene","metadata":null},{"id":"7e7598a7bc664987a6b655fc9d144cd2","type":"GENE","name":"RNU6-675P","canonical_id":"hgnc:HGNC:47638","description":"RNA, U6 small nuclear 675, pseudogene","metadata":null},{"id":"7c3d4e874b6a4fe38ab29f967d4a65b9","type":"GENE","name":"RNU6-677P","canonical_id":"hgnc:HGNC:47640","description":"RNA, U6 small nuclear 677, pseudogene","metadata":null},{"id":"403a7a19d06c4b7099e9c5a8ff1e384d","type":"GENE","name":"RNU6-678P","canonical_id":"hgnc:HGNC:47641","description":"RNA, U6 small nuclear 678, pseudogene","metadata":null},{"id":"84256d893e5e402cbe750ec474e59a38","type":"GENE","name":"RNU6-679P","canonical_id":"hgnc:HGNC:47642","description":"RNA, U6 small nuclear 679, pseudogene","metadata":null},{"id":"c9e6dd6979c8420ba97d8c7d51d4d93a","type":"GENE","name":"RNU6-67P","canonical_id":"hgnc:HGNC:42557","description":"RNA, U6 small nuclear 67, pseudogene","metadata":{"aliases":["RNU6-67"]}},{"id":"db243dc5f6274b5395008cfae83c806b","type":"GENE","name":"RNU6-680P","canonical_id":"hgnc:HGNC:47643","description":"RNA, U6 small nuclear 680, pseudogene","metadata":null},{"id":"3b2e2b3475394499ad55ef1b7102eb72","type":"GENE","name":"RNU6-681P","canonical_id":"hgnc:HGNC:47644","description":"RNA, U6 small nuclear 681, pseudogene","metadata":null},{"id":"116b949710524f41804fb308558b338b","type":"GENE","name":"RNU6-682P","canonical_id":"hgnc:HGNC:47645","description":"RNA, U6 small nuclear 682, pseudogene","metadata":null},{"id":"dce2ac5b67354b81a11559d17573db97","type":"GENE","name":"RNU6-684P","canonical_id":"hgnc:HGNC:47647","description":"RNA, U6 small nuclear 684, pseudogene","metadata":null},{"id":"b46639a4dca54a8ebd75b553ff4c0dcf","type":"GENE","name":"RNU6-685P","canonical_id":"hgnc:HGNC:47648","description":"RNA, U6 small nuclear 685, pseudogene","metadata":null},{"id":"28efe2a056134c48afe954be540f25d7","type":"GENE","name":"RNU6-686P","canonical_id":"hgnc:HGNC:47649","description":"RNA, U6 small nuclear 686, pseudogene","metadata":null},{"id":"15c90e923cc844e89bc1d7aecbbfdc3a","type":"GENE","name":"RNU6-687P","canonical_id":"hgnc:HGNC:47650","description":"RNA, U6 small nuclear 687, pseudogene","metadata":null},{"id":"7635f4a175f1402d8c93a7c7261f66f0","type":"GENE","name":"RNU6-689P","canonical_id":"hgnc:HGNC:47652","description":"RNA, U6 small nuclear 689, pseudogene","metadata":null},{"id":"ef7ca09e2c9a4d258bd35ac3e424a4d2","type":"GENE","name":"RNU6-68P","canonical_id":"hgnc:HGNC:42558","description":"RNA, U6 small nuclear 68, pseudogene","metadata":{"aliases":["RNU6-68"]}},{"id":"e11b4faf1f8d43ecb4256fb221ba32f3","type":"GENE","name":"RNU6-690P","canonical_id":"hgnc:HGNC:47653","description":"RNA, U6 small nuclear 690, pseudogene","metadata":null},{"id":"35b6668840274aeb85ad761d820e1bb2","type":"GENE","name":"RNU6-692P","canonical_id":"hgnc:HGNC:47655","description":"RNA, U6 small nuclear 692, pseudogene","metadata":null},{"id":"444e62c06d814312b535e07f346ffe94","type":"GENE","name":"RNU6-693P","canonical_id":"hgnc:HGNC:47656","description":"RNA, U6 small nuclear 693, pseudogene","metadata":null},{"id":"88515d6695e840689240e0b2d7a39d6a","type":"GENE","name":"RNU6-694P","canonical_id":"hgnc:HGNC:47657","description":"RNA, U6 small nuclear 694, pseudogene","metadata":null},{"id":"b18ed597649d4238a82990bf6cbd05b7","type":"GENE","name":"RNU6-695P","canonical_id":"hgnc:HGNC:47658","description":"RNA, U6 small nuclear 695, pseudogene","metadata":null},{"id":"69722fd782384d3f9a2b0aec4a25ac5e","type":"GENE","name":"RNU6-696P","canonical_id":"hgnc:HGNC:47659","description":"RNA, U6 small nuclear 696, pseudogene","metadata":null},{"id":"4e62e24509c14046acc2d196950d16c5","type":"GENE","name":"RNU6-697P","canonical_id":"hgnc:HGNC:47660","description":"RNA, U6 small nuclear 697, pseudogene","metadata":null},{"id":"08ef4169b58b49b6b2ea6d1843daed63","type":"GENE","name":"RNU6-698P","canonical_id":"hgnc:HGNC:47661","description":"RNA, U6 small nuclear 698, pseudogene","metadata":null},{"id":"d1e42cc6ebb74ab28675b2a71e54a1fb","type":"GENE","name":"RNU6-699P","canonical_id":"hgnc:HGNC:47662","description":"RNA, U6 small nuclear 699, pseudogene","metadata":null},{"id":"9c947572f97f44ac8b06d2a8eeb2be95","type":"GENE","name":"RNU6-69P","canonical_id":"hgnc:HGNC:42559","description":"RNA, U6 small nuclear 69, pseudogene","metadata":{"aliases":["RNU6-69"]}},{"id":"99bc628ef51845e596dea62c06995265","type":"GENE","name":"RNU6-6P","canonical_id":"hgnc:HGNC:10228","description":"RNA, U6 small nuclear 6, pseudogene","metadata":{"aliases":["U6-6","RNU6-6"]}},{"id":"1e733e6086ae4620b86553590ea40310","type":"GENE","name":"RNU6-7","canonical_id":"hgnc:HGNC:34284","description":"RNA, U6 small nuclear 7","metadata":{"aliases":["U6-7"]}},{"id":"5fdf60a217d94bf2b0c0b526365237bf","type":"GENE","name":"RNU6-700P","canonical_id":"hgnc:HGNC:47663","description":"RNA, U6 small nuclear 700, pseudogene","metadata":null},{"id":"1cb3a1a2e69546a7bbbaa5b170e3ea6b","type":"GENE","name":"RNU6-701P","canonical_id":"hgnc:HGNC:47664","description":"RNA, U6 small nuclear 701, pseudogene","metadata":null},{"id":"7a83df62ba83462ba4a3d924003f42d3","type":"GENE","name":"RNU6-702P","canonical_id":"hgnc:HGNC:47665","description":"RNA, U6 small nuclear 702, pseudogene","metadata":null},{"id":"702a4cb92bf14020a118d9339e124ee6","type":"GENE","name":"RNU6-703P","canonical_id":"hgnc:HGNC:47666","description":"RNA, U6 small nuclear 703, pseudogene","metadata":null},{"id":"9e9dad2e80dd42bcb1457ac143ed0ec2","type":"GENE","name":"RNU6-704P","canonical_id":"hgnc:HGNC:47667","description":"RNA, U6 small nuclear 704, pseudogene","metadata":null},{"id":"70196f99c23246079d1717dbfe927eee","type":"GENE","name":"RNU6-705P","canonical_id":"hgnc:HGNC:47668","description":"RNA, U6 small nuclear 705, pseudogene","metadata":null},{"id":"c56684caf45842e1ab69800a1713887d","type":"GENE","name":"RNU6-706P","canonical_id":"hgnc:HGNC:47669","description":"RNA, U6 small nuclear 706, pseudogene","metadata":null},{"id":"db17ff9ef19146f68c431b6eeaea966f","type":"GENE","name":"RNU6-707P","canonical_id":"hgnc:HGNC:47670","description":"RNA, U6 small nuclear 707, pseudogene","metadata":null},{"id":"5a635606543b4c6399e5a4401e17c9f9","type":"GENE","name":"RNU6-708P","canonical_id":"hgnc:HGNC:47671","description":"RNA, U6 small nuclear 708, pseudogene","metadata":null},{"id":"ca49f88156b64f05ba8b160b35dbe8b9","type":"GENE","name":"RNU6-709P","canonical_id":"hgnc:HGNC:47672","description":"RNA, U6 small nuclear 709, pseudogene","metadata":null},{"id":"19fb293e704c41bc8733a65561b57f57","type":"GENE","name":"RNU6-70P","canonical_id":"hgnc:HGNC:42560","description":"RNA, U6 small nuclear 70, pseudogene","metadata":{"aliases":["RNU6-70"]}},{"id":"a7eff73337ea49c18e5f88dd4ace23d8","type":"GENE","name":"RNU6-710P","canonical_id":"hgnc:HGNC:47673","description":"RNA, U6 small nuclear 710, pseudogene","metadata":null},{"id":"34b551e632b747c7a27a49d3730226eb","type":"GENE","name":"RNU6-711P","canonical_id":"hgnc:HGNC:47674","description":"RNA, U6 small nuclear 711, pseudogene","metadata":null},{"id":"e86260ce590b4b219795702c8a593438","type":"GENE","name":"RNU6-712P","canonical_id":"hgnc:HGNC:47675","description":"RNA, U6 small nuclear 712, pseudogene","metadata":null},{"id":"24e7b5d193d14c8a8d218f3946c30249","type":"GENE","name":"RNU6-713P","canonical_id":"hgnc:HGNC:47676","description":"RNA, U6 small nuclear 713, pseudogene","metadata":null},{"id":"f9087a3c7a824286a8774776161173a2","type":"GENE","name":"RNU6-714P","canonical_id":"hgnc:HGNC:47677","description":"RNA, U6 small nuclear 714, pseudogene","metadata":null},{"id":"def8312053e4482d8a1823f0e9cdf4f1","type":"GENE","name":"RNU6-715P","canonical_id":"hgnc:HGNC:47678","description":"RNA, U6 small nuclear 715, pseudogene","metadata":null},{"id":"913f1555cec84a86b4149e07b49d306c","type":"GENE","name":"RNU6-716P","canonical_id":"hgnc:HGNC:47679","description":"RNA, U6 small nuclear 716, pseudogene","metadata":null},{"id":"07d8f5685ab34484abbd1d65a76368e6","type":"GENE","name":"RNU6-717P","canonical_id":"hgnc:HGNC:47680","description":"RNA, U6 small nuclear 717, pseudogene","metadata":null},{"id":"1efce8c4e1474076828e11e85cd79927","type":"GENE","name":"RNU6-718P","canonical_id":"hgnc:HGNC:47681","description":"RNA, U6 small nuclear 718, pseudogene","metadata":null},{"id":"e7f73cc7816b455c91941d106a69c6c0","type":"GENE","name":"RNU6-719P","canonical_id":"hgnc:HGNC:47682","description":"RNA, U6 small nuclear 719, pseudogene","metadata":null},{"id":"816f8c13060f45b69b4de760e5b23e8f","type":"GENE","name":"RNU6-71P","canonical_id":"hgnc:HGNC:42561","description":"RNA, U6 small nuclear 71, pseudogene","metadata":{"aliases":["RNU6-71"]}},{"id":"b7720a02193d43728b2f9a8b8a63552e","type":"GENE","name":"RNU6-720P","canonical_id":"hgnc:HGNC:47683","description":"RNA, U6 small nuclear 720, pseudogene","metadata":null},{"id":"b4ee6192ebaa434db6301460918e1d56","type":"GENE","name":"RNU6-721P","canonical_id":"hgnc:HGNC:47684","description":"RNA, U6 small nuclear 721, pseudogene","metadata":null},{"id":"09ce0bfa5f634f5b8cf1402b11c0a433","type":"GENE","name":"RNU6-722P","canonical_id":"hgnc:HGNC:47685","description":"RNA, U6 small nuclear 722, pseudogene","metadata":null},{"id":"f55a0e1dd2da4f73866168a94555fc4f","type":"GENE","name":"RNU6-723P","canonical_id":"hgnc:HGNC:47686","description":"RNA, U6 small nuclear 723, pseudogene","metadata":null},{"id":"d7c9e43a3f774c49a14c39a3d0041363","type":"GENE","name":"RNU6-724P","canonical_id":"hgnc:HGNC:47687","description":"RNA, U6 small nuclear 724, pseudogene","metadata":null},{"id":"998b8c8794424bd9b9a2a30be86a8082","type":"GENE","name":"RNU6-725P","canonical_id":"hgnc:HGNC:47688","description":"RNA, U6 small nuclear 725, pseudogene","metadata":null},{"id":"5b6526deba884b148eaa1996edc4114b","type":"GENE","name":"RNU6-726P","canonical_id":"hgnc:HGNC:47689","description":"RNA, U6 small nuclear 726, pseudogene","metadata":null},{"id":"1aebf7eda3c4442090050f768eca6669","type":"GENE","name":"RNU6-727P","canonical_id":"hgnc:HGNC:47690","description":"RNA, U6 small nuclear 727, pseudogene","metadata":null},{"id":"d5f6d527163849ef8ac1c2045b529127","type":"GENE","name":"RNU6-728P","canonical_id":"hgnc:HGNC:47691","description":"RNA, U6 small nuclear 728, pseudogene","metadata":null},{"id":"1f987c8a8f9e4120a63f491d1a477d8a","type":"GENE","name":"RNU6-729P","canonical_id":"hgnc:HGNC:47692","description":"RNA, U6 small nuclear 729, pseudogene","metadata":null},{"id":"2d98a6e2f56841168dc33a36fd7af942","type":"GENE","name":"RNU6-72P","canonical_id":"hgnc:HGNC:42562","description":"RNA, U6 small nuclear 72, pseudogene","metadata":{"aliases":["RNU6-72"]}},{"id":"17340586e9f74f598ba097aa0ca650bf","type":"GENE","name":"RNU6-730P","canonical_id":"hgnc:HGNC:47693","description":"RNA, U6 small nuclear 730, pseudogene","metadata":null},{"id":"d59865f4f8e14b36aa65757f2eba940d","type":"GENE","name":"RNU6-731P","canonical_id":"hgnc:HGNC:47694","description":"RNA, U6 small nuclear 731, pseudogene","metadata":null},{"id":"376e2cf1165b44b18de13d081d19d28d","type":"GENE","name":"RNU6-732P","canonical_id":"hgnc:HGNC:47695","description":"RNA, U6 small nuclear 732, pseudogene","metadata":null},{"id":"ee442c140065499e8702ccdfe66bb065","type":"GENE","name":"RNU6-733P","canonical_id":"hgnc:HGNC:47696","description":"RNA, U6 small nuclear 733, pseudogene","metadata":null},{"id":"cff2d9cde1a34b78927a93061557ac6e","type":"GENE","name":"RNU6-735P","canonical_id":"hgnc:HGNC:47698","description":"RNA, U6 small nuclear 735, pseudogene","metadata":null},{"id":"77d917e7de854a74b839e143f72560eb","type":"GENE","name":"RNU6-737P","canonical_id":"hgnc:HGNC:47700","description":"RNA, U6 small nuclear 737, pseudogene","metadata":null},{"id":"bcf6c0dc6a50447fb5b4140d774fd199","type":"GENE","name":"RNU6-738P","canonical_id":"hgnc:HGNC:47701","description":"RNA, U6 small nuclear 738, pseudogene","metadata":null},{"id":"22900b86ab98412cb4efaf3048a66b41","type":"GENE","name":"RNU6-739P","canonical_id":"hgnc:HGNC:47702","description":"RNA, U6 small nuclear 739, pseudogene","metadata":null},{"id":"bad0005fdc0a4d00b0702b05ec6e2b75","type":"GENE","name":"RNU6-73P","canonical_id":"hgnc:HGNC:42563","description":"RNA, U6 small nuclear 73, pseudogene","metadata":{"aliases":["RNU6-73"]}},{"id":"00dc1ec9f4114df2923d232d279ffe8c","type":"GENE","name":"RNU6-740P","canonical_id":"hgnc:HGNC:47703","description":"RNA, U6 small nuclear 740, pseudogene","metadata":null},{"id":"4f392187005d48cba6093f18aeb87e90","type":"GENE","name":"RNU6-741P","canonical_id":"hgnc:HGNC:47704","description":"RNA, U6 small nuclear 741, pseudogene","metadata":null},{"id":"55b63d24a3364c24ac28d7a413994ccd","type":"GENE","name":"RNU6-742P","canonical_id":"hgnc:HGNC:47705","description":"RNA, U6 small nuclear 742, pseudogene","metadata":null},{"id":"0e28408ebf8b4ffa9f317faeeeeafca6","type":"GENE","name":"RNU6-743P","canonical_id":"hgnc:HGNC:47706","description":"RNA, U6 small nuclear 743, pseudogene","metadata":null},{"id":"a72d9a81108b4e0db844beca5c6dd568","type":"GENE","name":"RNU6-744P","canonical_id":"hgnc:HGNC:47707","description":"RNA, U6 small nuclear 744, pseudogene","metadata":null},{"id":"168818db63e3470c83ca4f7a0e3b1ff1","type":"GENE","name":"RNU6-745P","canonical_id":"hgnc:HGNC:47708","description":"RNA, U6 small nuclear 745, pseudogene","metadata":null},{"id":"4c0a4c5d1ce241e4a3586bd3b4e5741a","type":"GENE","name":"RNU6-746P","canonical_id":"hgnc:HGNC:47709","description":"RNA, U6 small nuclear 746, pseudogene","metadata":null},{"id":"e5f2126cbdac4d05916bcfb9cd95f1b9","type":"GENE","name":"RNU6-747P","canonical_id":"hgnc:HGNC:47710","description":"RNA, U6 small nuclear 747, pseudogene","metadata":null},{"id":"5c85b57ffab94090be7c5b55dc89fc00","type":"GENE","name":"RNU6-748P","canonical_id":"hgnc:HGNC:47711","description":"RNA, U6 small nuclear 748, pseudogene","metadata":null},{"id":"ce7d3b12df5c4a3ca0fd3f0580e1e795","type":"GENE","name":"RNU6-749P","canonical_id":"hgnc:HGNC:47712","description":"RNA, U6 small nuclear 749, pseudogene","metadata":null},{"id":"44efb84774754749a5e1a0946f422f0d","type":"GENE","name":"RNU6-74P","canonical_id":"hgnc:HGNC:42564","description":"RNA, U6 small nuclear 74, pseudogene","metadata":{"aliases":["RNU6-74"]}},{"id":"780d30fe60114f65a2fb8e77446bda81","type":"GENE","name":"RNU6-750P","canonical_id":"hgnc:HGNC:47713","description":"RNA, U6 small nuclear 750, pseudogene","metadata":null},{"id":"d95f81ae082e4fc489d102d27a1e12be","type":"GENE","name":"RNU6-751P","canonical_id":"hgnc:HGNC:47714","description":"RNA, U6 small nuclear 751, pseudogene","metadata":null},{"id":"b5d1aff5fe9e43e5a31360e683c66668","type":"GENE","name":"RNU6-752P","canonical_id":"hgnc:HGNC:47715","description":"RNA, U6 small nuclear 752, pseudogene","metadata":null},{"id":"edeb50032554442d922eee8cf45a5287","type":"GENE","name":"RNU6-753P","canonical_id":"hgnc:HGNC:47716","description":"RNA, U6 small nuclear 753, pseudogene","metadata":null},{"id":"194aeb35cda24d2fb258f24f1d07f277","type":"GENE","name":"RNU6-754P","canonical_id":"hgnc:HGNC:47717","description":"RNA, U6 small nuclear 754, pseudogene","metadata":null},{"id":"1670a4b5cdc24c30b70e069c947263cd","type":"GENE","name":"RNU6-755P","canonical_id":"hgnc:HGNC:47718","description":"RNA, U6 small nuclear 755, pseudogene","metadata":null},{"id":"34e7acd6ff2149d59f1a241aebb0e85b","type":"GENE","name":"RNU6-756P","canonical_id":"hgnc:HGNC:47719","description":"RNA, U6 small nuclear 756, pseudogene","metadata":null},{"id":"ab511a53cb474912897a63ca57cf1072","type":"GENE","name":"RNU6-757P","canonical_id":"hgnc:HGNC:47720","description":"RNA, U6 small nuclear 757, pseudogene","metadata":null},{"id":"625c34a973fd44c39451a9efa2cd507d","type":"GENE","name":"RNU6-758P","canonical_id":"hgnc:HGNC:47721","description":"RNA, U6 small nuclear 758, pseudogene","metadata":null},{"id":"062a926a90c34b75baab785dbdd5a68a","type":"GENE","name":"RNU6-759P","canonical_id":"hgnc:HGNC:47722","description":"RNA, U6 small nuclear 759, pseudogene","metadata":null},{"id":"c724aef6d2c541999caac4a91e948b61","type":"GENE","name":"RNU6-75P","canonical_id":"hgnc:HGNC:42565","description":"RNA, U6 small nuclear 75, pseudogene","metadata":{"aliases":["RNU6-75"]}},{"id":"4406487f95144de99595e38260c5641a","type":"GENE","name":"RNU6-760P","canonical_id":"hgnc:HGNC:47723","description":"RNA, U6 small nuclear 760, pseudogene","metadata":null},{"id":"4eb47744689d4926aa6e2d8960e0bc9a","type":"GENE","name":"RNU6-761P","canonical_id":"hgnc:HGNC:47724","description":"RNA, U6 small nuclear 761, pseudogene","metadata":null},{"id":"2e99eb8e78e94d4197c382729c8a558f","type":"GENE","name":"RNU6-762P","canonical_id":"hgnc:HGNC:47725","description":"RNA, U6 small nuclear 762, pseudogene","metadata":null},{"id":"4bfa639303c3417ea6b6180882fc6578","type":"GENE","name":"RNU6-763P","canonical_id":"hgnc:HGNC:47726","description":"RNA, U6 small nuclear 763, pseudogene","metadata":null},{"id":"6f0d1fdbb4a84f9f990d0c2f12e26c68","type":"GENE","name":"RNU6-764P","canonical_id":"hgnc:HGNC:47727","description":"RNA, U6 small nuclear 764, pseudogene","metadata":null},{"id":"678f0fbd304c411c9c0db244ed74fd5c","type":"GENE","name":"RNU6-765P","canonical_id":"hgnc:HGNC:47728","description":"RNA, U6 small nuclear 765, pseudogene","metadata":null},{"id":"4725e64d13914fec847f34673b1615d9","type":"GENE","name":"RNU6-766P","canonical_id":"hgnc:HGNC:47729","description":"RNA, U6 small nuclear 766, pseudogene","metadata":null},{"id":"d10d7195a88c4dd6bb8e4a9c571cc89f","type":"GENE","name":"RNU6-767P","canonical_id":"hgnc:HGNC:47730","description":"RNA, U6 small nuclear 767, pseudogene","metadata":null},{"id":"b45c53b069bb46c4b8296547f6a653c1","type":"GENE","name":"RNU6-768P","canonical_id":"hgnc:HGNC:47731","description":"RNA, U6 small nuclear 768, pseudogene","metadata":null},{"id":"6e973c25a0794e4abc6e8a266034cd45","type":"GENE","name":"RNU6-769P","canonical_id":"hgnc:HGNC:47732","description":"RNA, U6 small nuclear 769, pseudogene","metadata":null},{"id":"53191995a56f4eba8d043b614396cb06","type":"GENE","name":"RNU6-76P","canonical_id":"hgnc:HGNC:42566","description":"RNA, U6 small nuclear 76, pseudogene","metadata":{"aliases":["RNU6-76","RNU6-1002P"]}},{"id":"eec4fc5201d84914bbe3516f656adc97","type":"GENE","name":"RNU6-770P","canonical_id":"hgnc:HGNC:47733","description":"RNA, U6 small nuclear 770, pseudogene","metadata":null},{"id":"fde438efec8143e5b41fc149b4cdd1b1","type":"GENE","name":"RNU6-771P","canonical_id":"hgnc:HGNC:47734","description":"RNA, U6 small nuclear 771, pseudogene","metadata":{"aliases":["RNU6-1185P"]}},{"id":"3f65cb8a347845f3a3ded7eaea72dd09","type":"GENE","name":"RNU6-772P","canonical_id":"hgnc:HGNC:47735","description":"RNA, U6 small nuclear 772, pseudogene","metadata":null},{"id":"ace4dc3921d94c4e9066db71af91e0b2","type":"GENE","name":"RNU6-774P","canonical_id":"hgnc:HGNC:47737","description":"RNA, U6 small nuclear 774, pseudogene","metadata":null},{"id":"ea5c0de9a76c4b1f8da4f67d2a2e9531","type":"GENE","name":"RNU6-775P","canonical_id":"hgnc:HGNC:47738","description":"RNA, U6 small nuclear 775, pseudogene","metadata":null},{"id":"041114691db34f95aab26d6344f6744e","type":"GENE","name":"RNU6-776P","canonical_id":"hgnc:HGNC:47739","description":"RNA, U6 small nuclear 776, pseudogene","metadata":null},{"id":"7ad7250fb2f648b9a529fd39b4d4cd11","type":"GENE","name":"RNU6-777P","canonical_id":"hgnc:HGNC:47740","description":"RNA, U6 small nuclear 777, pseudogene","metadata":null},{"id":"627bb5d81c884fda9bdba21f22c2733c","type":"GENE","name":"RNU6-778P","canonical_id":"hgnc:HGNC:47741","description":"RNA, U6 small nuclear 778, pseudogene","metadata":null},{"id":"844db8696d9d4e588dd4712fac9546b2","type":"GENE","name":"RNU6-77P","canonical_id":"hgnc:HGNC:42567","description":"RNA, U6 small nuclear 77, pseudogene","metadata":{"aliases":["RNU6-77"]}},{"id":"736f074b2574444c9d8d34798c1d3e39","type":"GENE","name":"RNU6-780P","canonical_id":"hgnc:HGNC:47743","description":"RNA, U6 small nuclear 780, pseudogene","metadata":null},{"id":"88be104d2ff049d58707c6c5ff5e7570","type":"GENE","name":"RNU6-781P","canonical_id":"hgnc:HGNC:47744","description":"RNA, U6 small nuclear 781, pseudogene","metadata":null},{"id":"58ee7d5e5a2e40b1993d26a45a9d174c","type":"GENE","name":"RNU6-782P","canonical_id":"hgnc:HGNC:47745","description":"RNA, U6 small nuclear 782, pseudogene","metadata":null},{"id":"5dd2624db1e64692b58c898b9aca1f74","type":"GENE","name":"RNU6-783P","canonical_id":"hgnc:HGNC:47746","description":"RNA, U6 small nuclear 783, pseudogene","metadata":null},{"id":"0dce62c4ba41400b86cbefd43a4c15f4","type":"GENE","name":"RNU6-784P","canonical_id":"hgnc:HGNC:47747","description":"RNA, U6 small nuclear 784, pseudogene","metadata":null},{"id":"6ceca13f0f384934a3fd6e23f39554c0","type":"GENE","name":"RNU6-785P","canonical_id":"hgnc:HGNC:47748","description":"RNA, U6 small nuclear 785, pseudogene","metadata":null},{"id":"ee5cf4ee00f54a33a48dadc4a28fe8c5","type":"GENE","name":"RNU6-786P","canonical_id":"hgnc:HGNC:47749","description":"RNA, U6 small nuclear 786, pseudogene","metadata":null},{"id":"fdd7e9726f314bf086b8dad15bbd46be","type":"GENE","name":"RNU6-787P","canonical_id":"hgnc:HGNC:47750","description":"RNA, U6 small nuclear 787, pseudogene","metadata":null},{"id":"e54d6d5615ec4bb9967441ae411f048a","type":"GENE","name":"RNU6-788P","canonical_id":"hgnc:HGNC:47751","description":"RNA, U6 small nuclear 788, pseudogene","metadata":null},{"id":"0562d0c11e2447ec9f3f28c10530b8be","type":"GENE","name":"RNU6-789P","canonical_id":"hgnc:HGNC:47752","description":"RNA, U6 small nuclear 789, pseudogene","metadata":null},{"id":"ecaca6d534a84226bfc2c00fe22d89d5","type":"GENE","name":"RNU6-78P","canonical_id":"hgnc:HGNC:42568","description":"RNA, U6 small nuclear 78, pseudogene","metadata":{"aliases":["RNU6-78"]}},{"id":"ab9a501199c44197a26d34895d644e1f","type":"GENE","name":"RNU6-790P","canonical_id":"hgnc:HGNC:47753","description":"RNA, U6 small nuclear 790, pseudogene","metadata":null},{"id":"6c63db1570134497b632e804ffae0f2a","type":"GENE","name":"RNU6-791P","canonical_id":"hgnc:HGNC:47754","description":"RNA, U6 small nuclear 791, pseudogene","metadata":null},{"id":"c1f3094f0ade4f71bec29657d4b28b3d","type":"GENE","name":"RNU6-792P","canonical_id":"hgnc:HGNC:47755","description":"RNA, U6 small nuclear 792, pseudogene","metadata":null},{"id":"3ed309c4dde04df29b1ad3a720df2562","type":"GENE","name":"RNU6-793P","canonical_id":"hgnc:HGNC:47756","description":"RNA, U6 small nuclear 793, pseudogene","metadata":null},{"id":"0547df3131804402bac227155ee78a90","type":"GENE","name":"RNU6-794P","canonical_id":"hgnc:HGNC:47757","description":"RNA, U6 small nuclear 794, pseudogene","metadata":null},{"id":"f647fe330e2446a3884a02e128d7b3a3","type":"GENE","name":"RNU6-795P","canonical_id":"hgnc:HGNC:47758","description":"RNA, U6 small nuclear 795, pseudogene","metadata":null},{"id":"2469bb66d6d04fdca9e7c29b9e6309f2","type":"GENE","name":"RNU6-796P","canonical_id":"hgnc:HGNC:47759","description":"RNA, U6 small nuclear 796, pseudogene","metadata":null},{"id":"bafd07534dbe48308b44beb40b642e8b","type":"GENE","name":"RNU6-797P","canonical_id":"hgnc:HGNC:47760","description":"RNA, U6 small nuclear 797, pseudogene","metadata":null},{"id":"b259bab1de8e44b08ccf73139afc8de8","type":"GENE","name":"RNU6-798P","canonical_id":"hgnc:HGNC:47761","description":"RNA, U6 small nuclear 798, pseudogene","metadata":null},{"id":"b6bba13445c74b38864f4cfef81fa3be","type":"GENE","name":"RNU6-799P","canonical_id":"hgnc:HGNC:47762","description":"RNA, U6 small nuclear 799, pseudogene","metadata":null},{"id":"5fe8c6ea9dac42f08cd83ccb32b63526","type":"GENE","name":"RNU6-79P","canonical_id":"hgnc:HGNC:42569","description":"RNA, U6 small nuclear 79, pseudogene","metadata":{"aliases":["RNU6-79"]}},{"id":"9aa7f1df83cf490191390b571e948116","type":"GENE","name":"RNU6-8","canonical_id":"hgnc:HGNC:34285","description":"RNA, U6 small nuclear 8","metadata":{"aliases":["U6-8"]}},{"id":"603c9038374a4a589de8bc0e7d7d7ca8","type":"GENE","name":"RNU6-800P","canonical_id":"hgnc:HGNC:47763","description":"RNA, U6 small nuclear 800, pseudogene","metadata":null},{"id":"6fdf57c073fe4f7a86ffa6ef53a772ab","type":"GENE","name":"RNU6-801P","canonical_id":"hgnc:HGNC:47764","description":"RNA, U6 small nuclear 801, pseudogene","metadata":null},{"id":"3145614231d143488b81664d9a4df854","type":"GENE","name":"RNU6-803P","canonical_id":"hgnc:HGNC:47766","description":"RNA, U6 small nuclear 803, pseudogene","metadata":null},{"id":"eec2074ad548459181f0afe32a16ea1d","type":"GENE","name":"RNU6-804P","canonical_id":"hgnc:HGNC:47767","description":"RNA, U6 small nuclear 804, pseudogene","metadata":null},{"id":"58d7a42b91894d43aa0692f72c4fdc3e","type":"GENE","name":"RNU6-805P","canonical_id":"hgnc:HGNC:47768","description":"RNA, U6 small nuclear 805, pseudogene","metadata":null},{"id":"d6182692cfec414e82c9448bfa22558b","type":"GENE","name":"RNU6-806P","canonical_id":"hgnc:HGNC:47769","description":"RNA, U6 small nuclear 806, pseudogene","metadata":null},{"id":"9bdc842eba7747c5b81a10f9122c5886","type":"GENE","name":"RNU6-807P","canonical_id":"hgnc:HGNC:47770","description":"RNA, U6 small nuclear 807, pseudogene","metadata":null},{"id":"8a19f8525a494ec78d95601d6322fe72","type":"GENE","name":"RNU6-808P","canonical_id":"hgnc:HGNC:47771","description":"RNA, U6 small nuclear 808, pseudogene","metadata":null},{"id":"d6c12218e5414c639ca6e69c47b9b2be","type":"GENE","name":"RNU6-809P","canonical_id":"hgnc:HGNC:47772","description":"RNA, U6 small nuclear 809, pseudogene","metadata":null},{"id":"962c13972aaa4e4a92f1c261c06ea847","type":"GENE","name":"RNU6-80P","canonical_id":"hgnc:HGNC:42570","description":"RNA, U6 small nuclear 80, pseudogene","metadata":{"aliases":["RNU6-80"]}},{"id":"bbedbe87d1c64f1d997d2c6dc46e588a","type":"GENE","name":"RNU6-810P","canonical_id":"hgnc:HGNC:47773","description":"RNA, U6 small nuclear 810, pseudogene","metadata":null},{"id":"e92c0bae027a442a81dc2f8aade0cc72","type":"GENE","name":"RNU6-811P","canonical_id":"hgnc:HGNC:47774","description":"RNA, U6 small nuclear 811, pseudogene","metadata":null},{"id":"e2dea8b52d85418bafef38a9ebb20687","type":"GENE","name":"RNU6-812P","canonical_id":"hgnc:HGNC:47775","description":"RNA, U6 small nuclear 812, pseudogene","metadata":null},{"id":"ba84bb71102d4988a61871079a5e77f8","type":"GENE","name":"RNU6-813P","canonical_id":"hgnc:HGNC:47776","description":"RNA, U6 small nuclear 813, pseudogene","metadata":null},{"id":"258f2440dac24d4895f35c27a689eeed","type":"GENE","name":"RNU6-815P","canonical_id":"hgnc:HGNC:47778","description":"RNA, U6 small nuclear 815, pseudogene","metadata":null},{"id":"a8c339cbe175450186726edfed41b2e3","type":"GENE","name":"RNU6-816P","canonical_id":"hgnc:HGNC:47779","description":"RNA, U6 small nuclear 816, pseudogene","metadata":null},{"id":"981de778c2024b818de0d993dbbb8de5","type":"GENE","name":"RNU6-817P","canonical_id":"hgnc:HGNC:47780","description":"RNA, U6 small nuclear 817, pseudogene","metadata":null},{"id":"6276d74ff51d45299a59adafb2e86642","type":"GENE","name":"RNU6-818P","canonical_id":"hgnc:HGNC:47781","description":"RNA, U6 small nuclear 818, pseudogene","metadata":null},{"id":"7d7d5c526bb9479aa7b2404baa4abd9d","type":"GENE","name":"RNU6-819P","canonical_id":"hgnc:HGNC:47782","description":"RNA, U6 small nuclear 819, pseudogene","metadata":null},{"id":"8d21ea3b6bba4f288b7fbda83d173a7a","type":"GENE","name":"RNU6-81P","canonical_id":"hgnc:HGNC:42571","description":"RNA, U6 small nuclear 81, pseudogene","metadata":{"aliases":["RNU6-81"]}},{"id":"60315edfed25495e899da279a3b66e33","type":"GENE","name":"RNU6-820P","canonical_id":"hgnc:HGNC:47783","description":"RNA, U6 small nuclear 820, pseudogene","metadata":null},{"id":"908a697ebc4c42199aece1c11eb08d81","type":"GENE","name":"RNU6-821P","canonical_id":"hgnc:HGNC:47784","description":"RNA, U6 small nuclear 821, pseudogene","metadata":null},{"id":"1ce382c1d1424bbb8c5d6bd216538035","type":"GENE","name":"RNU6-822P","canonical_id":"hgnc:HGNC:47785","description":"RNA, U6 small nuclear 822, pseudogene","metadata":null},{"id":"0a7d3a99e5f944b491bb9e8ab59046c2","type":"GENE","name":"RNU6-823P","canonical_id":"hgnc:HGNC:47786","description":"RNA, U6 small nuclear 823, pseudogene","metadata":null},{"id":"3df77597b99048c99085fac17e641c1b","type":"GENE","name":"RNU6-824P","canonical_id":"hgnc:HGNC:47787","description":"RNA, U6 small nuclear 824, pseudogene","metadata":null},{"id":"05096058fa274a40a32ada31fa8b5811","type":"GENE","name":"RNU6-826P","canonical_id":"hgnc:HGNC:47789","description":"RNA, U6 small nuclear 826, pseudogene","metadata":null},{"id":"9d71bb7b669b41c59bdded294177a525","type":"GENE","name":"RNU6-827P","canonical_id":"hgnc:HGNC:47790","description":"RNA, U6 small nuclear 827, pseudogene","metadata":null},{"id":"1f08407546ce4adb84fce31bf36c0248","type":"GENE","name":"RNU6-828P","canonical_id":"hgnc:HGNC:47791","description":"RNA, U6 small nuclear 828, pseudogene","metadata":null},{"id":"2866c75911e8402d8f7c520009098472","type":"GENE","name":"RNU6-829P","canonical_id":"hgnc:HGNC:47792","description":"RNA, U6 small nuclear 829, pseudogene","metadata":null},{"id":"bea51357680d424388c3d57b2fe2c01d","type":"GENE","name":"RNU6-82P","canonical_id":"hgnc:HGNC:42572","description":"RNA, U6 small nuclear 82, pseudogene","metadata":{"aliases":["RNU6-82"]}},{"id":"2d6bd5176cb140ee8769a9189ba1be39","type":"GENE","name":"RNU6-830P","canonical_id":"hgnc:HGNC:47793","description":"RNA, U6 small nuclear 830, pseudogene","metadata":null},{"id":"269aecdaa9e64b2da490d813edfa2b82","type":"GENE","name":"RNU6-831P","canonical_id":"hgnc:HGNC:47794","description":"RNA, U6 small nuclear 831, pseudogene","metadata":null},{"id":"a9c368bedbb949808927b568c64f437f","type":"GENE","name":"RNU6-832P","canonical_id":"hgnc:HGNC:47795","description":"RNA, U6 small nuclear 832, pseudogene","metadata":null},{"id":"e2800eff6475412abd68a050e843fc80","type":"GENE","name":"RNU6-833P","canonical_id":"hgnc:HGNC:47796","description":"RNA, U6 small nuclear 833, pseudogene","metadata":null},{"id":"c052935420d94d10b0ad6a9df1b6cc43","type":"GENE","name":"RNU6-834P","canonical_id":"hgnc:HGNC:47797","description":"RNA, U6 small nuclear 834, pseudogene","metadata":null},{"id":"609b9bb19a7e40eab428dc62ef47059e","type":"GENE","name":"RNU6-835P","canonical_id":"hgnc:HGNC:47798","description":"RNA, U6 small nuclear 835, pseudogene","metadata":null},{"id":"096ae7e9098641159ea73835246997c4","type":"GENE","name":"RNU6-836P","canonical_id":"hgnc:HGNC:47799","description":"RNA, U6 small nuclear 836, pseudogene","metadata":null},{"id":"e47c80776d804ac4a937ae3a066d3d61","type":"GENE","name":"RNU6-837P","canonical_id":"hgnc:HGNC:47800","description":"RNA, U6 small nuclear 837, pseudogene","metadata":null},{"id":"2509fcbd76024a9b90ec450285226f71","type":"GENE","name":"RNU6-838P","canonical_id":"hgnc:HGNC:47801","description":"RNA, U6 small nuclear 838, pseudogene","metadata":null},{"id":"cf6d34978e164a168859ef313e212742","type":"GENE","name":"RNU6-839P","canonical_id":"hgnc:HGNC:47802","description":"RNA, U6 small nuclear 839, pseudogene","metadata":null},{"id":"a43ed389ba5f4e7d8b40ddce2cb01aac","type":"GENE","name":"RNU6-83P","canonical_id":"hgnc:HGNC:42573","description":"RNA, U6 small nuclear 83, pseudogene","metadata":{"aliases":["RNU6-83"]}},{"id":"a67d660fc4ba43cd9f1c6d47ec615328","type":"GENE","name":"RNU6-840P","canonical_id":"hgnc:HGNC:47803","description":"RNA, U6 small nuclear 840, pseudogene","metadata":null},{"id":"7711b4cf390b4dfe9d538c4b7477e2a5","type":"GENE","name":"RNU6-841P","canonical_id":"hgnc:HGNC:47804","description":"RNA, U6 small nuclear 841, pseudogene","metadata":null},{"id":"ea7dcb1089644ad4bf1a0eab9b6da445","type":"GENE","name":"RNU6-842P","canonical_id":"hgnc:HGNC:47805","description":"RNA, U6 small nuclear 842, pseudogene","metadata":null},{"id":"b2a618a8d1994062b6760c0f23883a56","type":"GENE","name":"RNU6-843P","canonical_id":"hgnc:HGNC:47806","description":"RNA, U6 small nuclear 843, pseudogene","metadata":null},{"id":"ddb11b9cf9c649caa1e49d3d21d3bb81","type":"GENE","name":"RNU6-844P","canonical_id":"hgnc:HGNC:47807","description":"RNA, U6 small nuclear 844, pseudogene","metadata":null},{"id":"77ff13b1f651458fad365f0a96c6de24","type":"GENE","name":"RNU6-845P","canonical_id":"hgnc:HGNC:47808","description":"RNA, U6 small nuclear 845, pseudogene","metadata":null},{"id":"4b6d1542498a4e018c8297e9f6d354b1","type":"GENE","name":"RNU6-847P","canonical_id":"hgnc:HGNC:47810","description":"RNA, U6 small nuclear 847, pseudogene","metadata":null},{"id":"d56ce2de3c754a619624a49fd55a798a","type":"GENE","name":"RNU6-848P","canonical_id":"hgnc:HGNC:47811","description":"RNA, U6 small nuclear 848, pseudogene","metadata":null},{"id":"b93ba1e43ce74e869e311a3011640772","type":"GENE","name":"RNU6-849P","canonical_id":"hgnc:HGNC:47812","description":"RNA, U6 small nuclear 849, pseudogene","metadata":null},{"id":"d6e4fcfd34144e41bde61228655a838d","type":"GENE","name":"RNU6-84P","canonical_id":"hgnc:HGNC:47047","description":"RNA, U6 small nuclear 84, pseudogene","metadata":null},{"id":"ea66d3f636914006b3983f48053d0ce5","type":"GENE","name":"RNU6-850P","canonical_id":"hgnc:HGNC:47813","description":"RNA, U6 small nuclear 850, pseudogene","metadata":{"aliases":["RNU6-1030P"]}},{"id":"ee5dcabb0bb14196b4262d13c9216bb0","type":"GENE","name":"RNU6-851P","canonical_id":"hgnc:HGNC:47814","description":"RNA, U6 small nuclear 851, pseudogene","metadata":null},{"id":"f303377a1b97467fa8eadda771d147b6","type":"GENE","name":"RNU6-853P","canonical_id":"hgnc:HGNC:47816","description":"RNA, U6 small nuclear 853, pseudogene","metadata":null},{"id":"88d4e9fd7ce34832bc415f1998b45904","type":"GENE","name":"RNU6-854P","canonical_id":"hgnc:HGNC:47817","description":"RNA, U6 small nuclear 854, pseudogene","metadata":null},{"id":"fe38000f92fb4b72aeb9e486fe1c96b0","type":"GENE","name":"RNU6-855P","canonical_id":"hgnc:HGNC:47818","description":"RNA, U6 small nuclear 855, pseudogene","metadata":null},{"id":"f4662dd45d624539a815c1b8c1c83771","type":"GENE","name":"RNU6-856P","canonical_id":"hgnc:HGNC:47819","description":"RNA, U6 small nuclear 856, pseudogene","metadata":null},{"id":"5fd0f7e917ee400d824ff523693c6f26","type":"GENE","name":"RNU6-857P","canonical_id":"hgnc:HGNC:47820","description":"RNA, U6 small nuclear 857, pseudogene","metadata":null},{"id":"c9bd6d6cb1a7408f81e2d66ec1e2ea6c","type":"GENE","name":"RNU6-858P","canonical_id":"hgnc:HGNC:47821","description":"RNA, U6 small nuclear 858, pseudogene","metadata":null},{"id":"2d9eb4e8227c4c71b854287302223e90","type":"GENE","name":"RNU6-859P","canonical_id":"hgnc:HGNC:47822","description":"RNA, U6 small nuclear 859, pseudogene","metadata":null},{"id":"8d627fee17924b91b769deaefa4436e1","type":"GENE","name":"RNU6-85P","canonical_id":"hgnc:HGNC:47048","description":"RNA, U6 small nuclear 85, pseudogene","metadata":null},{"id":"04e6815555674608a650c98738c0d04a","type":"GENE","name":"RNU6-860P","canonical_id":"hgnc:HGNC:47823","description":"RNA, U6 small nuclear 860, pseudogene","metadata":null},{"id":"fcd4f814f0c54d75adc90de5f7a44e96","type":"GENE","name":"RNU6-861P","canonical_id":"hgnc:HGNC:47824","description":"RNA, U6 small nuclear 861, pseudogene","metadata":null},{"id":"2845f14666414b3289079b964df107fd","type":"GENE","name":"RNU6-862P","canonical_id":"hgnc:HGNC:47825","description":"RNA, U6 small nuclear 862, pseudogene","metadata":null},{"id":"65614fe2da974fd594da5dba7474c999","type":"GENE","name":"RNU6-863P","canonical_id":"hgnc:HGNC:47826","description":"RNA, U6 small nuclear 863, pseudogene","metadata":null},{"id":"967b0b5472174537bd5bff5a790a0c31","type":"GENE","name":"RNU6-864P","canonical_id":"hgnc:HGNC:47827","description":"RNA, U6 small nuclear 864, pseudogene","metadata":null},{"id":"7f449ca5847d4c74905be0127e33d766","type":"GENE","name":"RNU6-865P","canonical_id":"hgnc:HGNC:47828","description":"RNA, U6 small nuclear 865, pseudogene","metadata":null},{"id":"676576567b214f878d5e64ad3f3666b2","type":"GENE","name":"RNU6-866P","canonical_id":"hgnc:HGNC:47829","description":"RNA, U6 small nuclear 866, pseudogene","metadata":null},{"id":"0abf0a38c98c40f3b083e7b303ec6a16","type":"GENE","name":"RNU6-867P","canonical_id":"hgnc:HGNC:47830","description":"RNA, U6 small nuclear 867, pseudogene","metadata":null},{"id":"71da92bb74264450854594f51f0d753b","type":"GENE","name":"RNU6-869P","canonical_id":"hgnc:HGNC:47832","description":"RNA, U6 small nuclear 869, pseudogene","metadata":null},{"id":"5badbc6a8f5a4dbfb4815e8cd0b38e64","type":"GENE","name":"RNU6-86P","canonical_id":"hgnc:HGNC:47049","description":"RNA, U6 small nuclear 86, pseudogene","metadata":null},{"id":"de71da118d9445cdb40cfde4dd503c8a","type":"GENE","name":"RNU6-871P","canonical_id":"hgnc:HGNC:47834","description":"RNA, U6 small nuclear 871, pseudogene","metadata":null},{"id":"e5066ab193a34e8ba67c03aae855fe0f","type":"GENE","name":"RNU6-873P","canonical_id":"hgnc:HGNC:47836","description":"RNA, U6 small nuclear 873, pseudogene","metadata":null},{"id":"6077c851b1da48c4a2832d0bd49a382e","type":"GENE","name":"RNU6-874P","canonical_id":"hgnc:HGNC:47837","description":"RNA, U6 small nuclear 874, pseudogene","metadata":null},{"id":"7795afa3a6df4221bbe62f0367728c8c","type":"GENE","name":"RNU6-875P","canonical_id":"hgnc:HGNC:47838","description":"RNA, U6 small nuclear 875, pseudogene","metadata":null},{"id":"9528da9c90ee400d99582966a6d6b0fe","type":"GENE","name":"RNU6-876P","canonical_id":"hgnc:HGNC:47839","description":"RNA, U6 small nuclear 876, pseudogene","metadata":null},{"id":"263d51f7a39f465388f603940d95a55e","type":"GENE","name":"RNU6-877P","canonical_id":"hgnc:HGNC:47840","description":"RNA, U6 small nuclear 877, pseudogene","metadata":null},{"id":"9cb26c48195e43b39988af614f70ec73","type":"GENE","name":"RNU6-878P","canonical_id":"hgnc:HGNC:47841","description":"RNA, U6 small nuclear 878, pseudogene","metadata":null},{"id":"ccb6936015564f328839754cdb0ec3fb","type":"GENE","name":"RNU6-879P","canonical_id":"hgnc:HGNC:47842","description":"RNA, U6 small nuclear 879, pseudogene","metadata":null},{"id":"38de451338154967a2a1428466b5072a","type":"GENE","name":"RNU6-87P","canonical_id":"hgnc:HGNC:47050","description":"RNA, U6 small nuclear 87, pseudogene","metadata":null},{"id":"f0b940a147ba4c8bbe78594e04b44b90","type":"GENE","name":"RNU6-880P","canonical_id":"hgnc:HGNC:47843","description":"RNA, U6 small nuclear 880, pseudogene","metadata":null},{"id":"a4d7bb2c05994655b53a60eb02cdeda1","type":"GENE","name":"RNU6-881P","canonical_id":"hgnc:HGNC:47844","description":"RNA, U6 small nuclear 881, pseudogene","metadata":null},{"id":"853eea4736514ed8b03fbb053e9db1f5","type":"GENE","name":"RNU6-882P","canonical_id":"hgnc:HGNC:47845","description":"RNA, U6 small nuclear 882, pseudogene","metadata":null},{"id":"8f569f12b8834f51a517170ab1c43ee1","type":"GENE","name":"RNU6-883P","canonical_id":"hgnc:HGNC:47846","description":"RNA, U6 small nuclear 883, pseudogene","metadata":null},{"id":"78a4d214a6824dfd8a19d7398bba187e","type":"GENE","name":"RNU6-884P","canonical_id":"hgnc:HGNC:47847","description":"RNA, U6 small nuclear 884, pseudogene","metadata":null},{"id":"8d58cd7d43e5456ea600ab040ad9af0c","type":"GENE","name":"RNU6-885P","canonical_id":"hgnc:HGNC:47848","description":"RNA, U6 small nuclear 885, pseudogene","metadata":null},{"id":"7ad197b191f0428895f3d122f1cedc45","type":"GENE","name":"RNU6-886P","canonical_id":"hgnc:HGNC:47849","description":"RNA, U6 small nuclear 886, pseudogene","metadata":null},{"id":"d928b24e450943599a3f429dedbce58c","type":"GENE","name":"RNU6-887P","canonical_id":"hgnc:HGNC:47850","description":"RNA, U6 small nuclear 887, pseudogene","metadata":null},{"id":"df4f9cb96c264a93b23d7ec90aa794ed","type":"GENE","name":"RNU6-888P","canonical_id":"hgnc:HGNC:47851","description":"RNA, U6 small nuclear 888, pseudogene","metadata":null},{"id":"c400a6988b8c43a8a4e58ceece787076","type":"GENE","name":"RNU6-889P","canonical_id":"hgnc:HGNC:47852","description":"RNA, U6 small nuclear 889, pseudogene","metadata":null},{"id":"f08a0f0681d04336addd0282ffe5f902","type":"GENE","name":"RNU6-88P","canonical_id":"hgnc:HGNC:47051","description":"RNA, U6 small nuclear 88, pseudogene","metadata":null},{"id":"d6e0657ab63e48ea83c8fb11bf7fcc18","type":"GENE","name":"RNU6-890P","canonical_id":"hgnc:HGNC:47853","description":"RNA, U6 small nuclear 890, pseudogene","metadata":null},{"id":"2b16fc403c6343eb9746d81fb73df1f6","type":"GENE","name":"RNU6-891P","canonical_id":"hgnc:HGNC:47854","description":"RNA, U6 small nuclear 891, pseudogene","metadata":null},{"id":"335c1ea307d342ddb0b1235fa97a6113","type":"GENE","name":"RNU6-892P","canonical_id":"hgnc:HGNC:47855","description":"RNA, U6 small nuclear 892, pseudogene","metadata":null},{"id":"e9ea4b3b4e4049f8b39a0140b419dd84","type":"GENE","name":"RNU6-893P","canonical_id":"hgnc:HGNC:47856","description":"RNA, U6 small nuclear 893, pseudogene","metadata":null},{"id":"f59f57f628734ecb8d6c940cf9a0daa0","type":"GENE","name":"RNU6-894P","canonical_id":"hgnc:HGNC:47857","description":"RNA, U6 small nuclear 894, pseudogene","metadata":null},{"id":"5902cddc5076428db41110ad98c88f7b","type":"GENE","name":"RNU6-895P","canonical_id":"hgnc:HGNC:47858","description":"RNA, U6 small nuclear 895, pseudogene","metadata":null},{"id":"2b58e6670b8746ffa89a56b00c7bbff6","type":"GENE","name":"RNU6-896P","canonical_id":"hgnc:HGNC:47859","description":"RNA, U6 small nuclear 896, pseudogene","metadata":null},{"id":"2145d420317d4cc09cfcbaa66e2b5504","type":"GENE","name":"RNU6-897P","canonical_id":"hgnc:HGNC:47860","description":"RNA, U6 small nuclear 897, pseudogene","metadata":null},{"id":"2b286227d2b44fbba3b815799aec9e31","type":"GENE","name":"RNU6-898P","canonical_id":"hgnc:HGNC:47861","description":"RNA, U6 small nuclear 898, pseudogene","metadata":null},{"id":"04c2d46b6fd3455db1797972b2e67e62","type":"GENE","name":"RNU6-899P","canonical_id":"hgnc:HGNC:47862","description":"RNA, U6 small nuclear 899, pseudogene","metadata":null},{"id":"fd4e68b1d8df47b7a426622a30dbdcbe","type":"GENE","name":"RNU6-89P","canonical_id":"hgnc:HGNC:47052","description":"RNA, U6 small nuclear 89, pseudogene","metadata":null},{"id":"eb6e5552be6d44bdb4cb928cef1c7f06","type":"GENE","name":"RNU6-9","canonical_id":"hgnc:HGNC:34269","description":"RNA, U6 small nuclear 9","metadata":{"aliases":["U6-9"]}},{"id":"af0fdc0174c645f6a0f8f870ee80fb81","type":"GENE","name":"RNU6-900P","canonical_id":"hgnc:HGNC:47863","description":"RNA, U6 small nuclear 900, pseudogene","metadata":null},{"id":"ca0b257c2389415ab8ae47b6265378c4","type":"GENE","name":"RNU6-901P","canonical_id":"hgnc:HGNC:47864","description":"RNA, U6 small nuclear 901, pseudogene","metadata":null},{"id":"9cd914a2b69f43ef8231fc71b27d487e","type":"GENE","name":"RNU6-902P","canonical_id":"hgnc:HGNC:47865","description":"RNA, U6 small nuclear 902, pseudogene","metadata":null},{"id":"2087a56d48cb47818d909fda61319200","type":"GENE","name":"RNU6-903P","canonical_id":"hgnc:HGNC:47866","description":"RNA, U6 small nuclear 903, pseudogene","metadata":null},{"id":"f51870c5187844d9a295d770cd23caec","type":"GENE","name":"RNU6-904P","canonical_id":"hgnc:HGNC:47867","description":"RNA, U6 small nuclear 904, pseudogene","metadata":null},{"id":"9b5a8f2ec7fe4cfd89c2d141aa1a25d8","type":"GENE","name":"RNU6-905P","canonical_id":"hgnc:HGNC:47868","description":"RNA, U6 small nuclear 905, pseudogene","metadata":null},{"id":"b19eb28a5cbe4199ac419ebf7277e3f7","type":"GENE","name":"RNU6-906P","canonical_id":"hgnc:HGNC:47869","description":"RNA, U6 small nuclear 906, pseudogene","metadata":null},{"id":"86cd2e5e07024ed2aecdce4cc229ef6e","type":"GENE","name":"RNU6-907P","canonical_id":"hgnc:HGNC:47870","description":"RNA, U6 small nuclear 907, pseudogene","metadata":null},{"id":"496c17fb5c4749aa822e17186aa17242","type":"GENE","name":"RNU6-908P","canonical_id":"hgnc:HGNC:47871","description":"RNA, U6 small nuclear 908, pseudogene","metadata":null},{"id":"3494200b5b4f4f8bb4cbcef97d1adc3f","type":"GENE","name":"RNU6-909P","canonical_id":"hgnc:HGNC:47872","description":"RNA, U6 small nuclear 909, pseudogene","metadata":null},{"id":"5b6c9e2576a24ea08e04ed204b2c8422","type":"GENE","name":"RNU6-90P","canonical_id":"hgnc:HGNC:47053","description":"RNA, U6 small nuclear 90, pseudogene","metadata":null},{"id":"f6795126e7bd497ca1fddecde8d4aa88","type":"GENE","name":"RNU6-910P","canonical_id":"hgnc:HGNC:47873","description":"RNA, U6 small nuclear 910, pseudogene","metadata":null},{"id":"41eca53e1548495fa9fe8fa809e0507b","type":"GENE","name":"RNU6-911P","canonical_id":"hgnc:HGNC:47874","description":"RNA, U6 small nuclear 911, pseudogene","metadata":null},{"id":"f104f51943044fbda75807c9c73763e2","type":"GENE","name":"RNU6-912P","canonical_id":"hgnc:HGNC:47875","description":"RNA, U6 small nuclear 912, pseudogene","metadata":null},{"id":"a54d7e0760a748948711ae13d52d396a","type":"GENE","name":"RNU6-913P","canonical_id":"hgnc:HGNC:47876","description":"RNA, U6 small nuclear 913, pseudogene","metadata":null},{"id":"b56a2ca0afa34766951a5a1c96481f27","type":"GENE","name":"RNU6-914P","canonical_id":"hgnc:HGNC:47877","description":"RNA, U6 small nuclear 914, pseudogene","metadata":null},{"id":"fc9310c0649f4ff9bf853dcebdcd9566","type":"GENE","name":"RNU6-915P","canonical_id":"hgnc:HGNC:47878","description":"RNA, U6 small nuclear 915, pseudogene","metadata":null},{"id":"7966abb83b3b433995b252a0e5ae3848","type":"GENE","name":"RNU6-916P","canonical_id":"hgnc:HGNC:47879","description":"RNA, U6 small nuclear 916, pseudogene","metadata":null},{"id":"c6e336e4f90c4c8e96d837a7ae517c01","type":"GENE","name":"RNU6-917P","canonical_id":"hgnc:HGNC:47880","description":"RNA, U6 small nuclear 917, pseudogene","metadata":null},{"id":"65d6d3f37f934cfdb0c14653a60b3611","type":"GENE","name":"RNU6-918P","canonical_id":"hgnc:HGNC:47881","description":"RNA, U6 small nuclear 918, pseudogene","metadata":null},{"id":"d5a5d2907daf45839991d4bbf13983bc","type":"GENE","name":"RNU6-919P","canonical_id":"hgnc:HGNC:47882","description":"RNA, U6 small nuclear 919, pseudogene","metadata":null},{"id":"4460541e4e2e47eab449e1fb29af0524","type":"GENE","name":"RNU6-91P","canonical_id":"hgnc:HGNC:47054","description":"RNA, U6 small nuclear 91, pseudogene","metadata":null},{"id":"5938148c4c7340c4a78e187e25c7b9ef","type":"GENE","name":"RNU6-920P","canonical_id":"hgnc:HGNC:47883","description":"RNA, U6 small nuclear 920, pseudogene","metadata":null},{"id":"67f3c26691184bad816eb63da5ef9041","type":"GENE","name":"RNU6-921P","canonical_id":"hgnc:HGNC:47884","description":"RNA, U6 small nuclear 921, pseudogene","metadata":null},{"id":"4ebc9e23fc574fb78677f1aa8ff932ca","type":"GENE","name":"RNU6-922P","canonical_id":"hgnc:HGNC:47885","description":"RNA, U6 small nuclear 922, pseudogene","metadata":null},{"id":"02b2ea05e752418595cdc82e420e766d","type":"GENE","name":"RNU6-923P","canonical_id":"hgnc:HGNC:47886","description":"RNA, U6 small nuclear 923, pseudogene","metadata":null},{"id":"0392a8a4599b413b95e1c43c40579f35","type":"GENE","name":"RNU6-924P","canonical_id":"hgnc:HGNC:47887","description":"RNA, U6 small nuclear 924, pseudogene","metadata":null},{"id":"58d86240ce974ba49476566c41a6880e","type":"GENE","name":"RNU6-925P","canonical_id":"hgnc:HGNC:47888","description":"RNA, U6 small nuclear 925, pseudogene","metadata":null},{"id":"a96bcc319f5f47e789eabfa32fc09929","type":"GENE","name":"RNU6-926P","canonical_id":"hgnc:HGNC:47889","description":"RNA, U6 small nuclear 926, pseudogene","metadata":null},{"id":"025c8aacad3545fca464627cbb26abd7","type":"GENE","name":"RNU6-927P","canonical_id":"hgnc:HGNC:47890","description":"RNA, U6 small nuclear 927, pseudogene","metadata":null},{"id":"dd2020d8fcba4cbcadc39cfa67dea8e9","type":"GENE","name":"RNU6-928P","canonical_id":"hgnc:HGNC:47891","description":"RNA, U6 small nuclear 928, pseudogene","metadata":null},{"id":"c98aea9e0a464c5e9a96b65d80c60223","type":"GENE","name":"RNU6-929P","canonical_id":"hgnc:HGNC:47892","description":"RNA, U6 small nuclear 929, pseudogene","metadata":null},{"id":"7e8c70f4bcda4b22a0183de38db8673a","type":"GENE","name":"RNU6-92P","canonical_id":"hgnc:HGNC:47055","description":"RNA, U6 small nuclear 92, pseudogene","metadata":null},{"id":"a152c1c21266470680ee6d9af4f2e6f3","type":"GENE","name":"RNU6-930P","canonical_id":"hgnc:HGNC:47893","description":"RNA, U6 small nuclear 930, pseudogene","metadata":{"aliases":["RNU6-1173P"]}},{"id":"f717d23513544e45ae91ad5b049d6a69","type":"GENE","name":"RNU6-931P","canonical_id":"hgnc:HGNC:47894","description":"RNA, U6 small nuclear 931, pseudogene","metadata":null},{"id":"28a9e05ea09a4a868a36e54f17ee0ba7","type":"GENE","name":"RNU6-932P","canonical_id":"hgnc:HGNC:47895","description":"RNA, U6 small nuclear 932, pseudogene","metadata":null},{"id":"9c535b971bef4e0c822d07c632306198","type":"GENE","name":"RNU6-933P","canonical_id":"hgnc:HGNC:47896","description":"RNA, U6 small nuclear 933, pseudogene","metadata":null},{"id":"ede0cfa8d85740f4b9db1503f642918c","type":"GENE","name":"RNU6-934P","canonical_id":"hgnc:HGNC:47897","description":"RNA, U6 small nuclear 934, pseudogene","metadata":null},{"id":"e3cda5680e2a4af9a8c451b067592eab","type":"GENE","name":"RNU6-935P","canonical_id":"hgnc:HGNC:47898","description":"RNA, U6 small nuclear 935, pseudogene","metadata":null},{"id":"5ff3c720941f4f739eba87694e92326f","type":"GENE","name":"RNU6-936P","canonical_id":"hgnc:HGNC:47899","description":"RNA, U6 small nuclear 936, pseudogene","metadata":null},{"id":"b9c8fec6f3b94df88e38693b2099426e","type":"GENE","name":"RNU6-937P","canonical_id":"hgnc:HGNC:47900","description":"RNA, U6 small nuclear 937, pseudogene","metadata":null},{"id":"5b7f8bd6d41e4c45be601d0d17ee9c56","type":"GENE","name":"RNU6-938P","canonical_id":"hgnc:HGNC:47901","description":"RNA, U6 small nuclear 938, pseudogene","metadata":null},{"id":"e913f7f781c64819b9921df412f49bd8","type":"GENE","name":"RNU6-939P","canonical_id":"hgnc:HGNC:47902","description":"RNA, U6 small nuclear 939, pseudogene","metadata":null},{"id":"cea58996f3f84c998f79583e63767e56","type":"GENE","name":"RNU6-940P","canonical_id":"hgnc:HGNC:47903","description":"RNA, U6 small nuclear 940, pseudogene","metadata":null},{"id":"420730ae51444ea99c1c5ff17614787a","type":"GENE","name":"RNU6-941P","canonical_id":"hgnc:HGNC:47904","description":"RNA, U6 small nuclear 941, pseudogene","metadata":null},{"id":"4efec2657b9c403db7309652b8708965","type":"GENE","name":"RNU6-942P","canonical_id":"hgnc:HGNC:47905","description":"RNA, U6 small nuclear 942, pseudogene","metadata":null},{"id":"335397ce8590442cb2aabfd1eae9a73e","type":"GENE","name":"RNU6-943P","canonical_id":"hgnc:HGNC:47906","description":"RNA, U6 small nuclear 943, pseudogene","metadata":null},{"id":"06a84befecc44071ab79c77bb4307e3a","type":"GENE","name":"RNU6-944P","canonical_id":"hgnc:HGNC:47907","description":"RNA, U6 small nuclear 944, pseudogene","metadata":null},{"id":"62a8fe7a8c034c12ab7fbb5072fd343f","type":"GENE","name":"RNU6-945P","canonical_id":"hgnc:HGNC:47908","description":"RNA, U6 small nuclear 945, pseudogene","metadata":null},{"id":"d4c3c00d0fc7428c9f60c80e0ad8cef2","type":"GENE","name":"RNU6-946P","canonical_id":"hgnc:HGNC:47909","description":"RNA, U6 small nuclear 946, pseudogene","metadata":null},{"id":"79acb230d435426a8ce41b89e85d7c41","type":"GENE","name":"RNU6-947P","canonical_id":"hgnc:HGNC:47910","description":"RNA, U6 small nuclear 947, pseudogene","metadata":null},{"id":"c29e3dc3c5194d84af5e0f3307a36e3b","type":"GENE","name":"RNU6-948P","canonical_id":"hgnc:HGNC:47911","description":"RNA, U6 small nuclear 948, pseudogene","metadata":null},{"id":"a1bf356514674092b06b71df2ac17a31","type":"GENE","name":"RNU6-949P","canonical_id":"hgnc:HGNC:47912","description":"RNA, U6 small nuclear 949, pseudogene","metadata":null},{"id":"87f20069d8904381afa07254f86f0bca","type":"GENE","name":"RNU6-94P","canonical_id":"hgnc:HGNC:47057","description":"RNA, U6 small nuclear 94, pseudogene","metadata":null},{"id":"96185c2ef1884f749c26ee96c357d208","type":"GENE","name":"RNU6-950P","canonical_id":"hgnc:HGNC:47913","description":"RNA, U6 small nuclear 950, pseudogene","metadata":null},{"id":"6e61fe5220904d14afe044a0080dc104","type":"GENE","name":"RNU6-951P","canonical_id":"hgnc:HGNC:47914","description":"RNA, U6 small nuclear 951, pseudogene","metadata":null},{"id":"dfcb2288c5cc43a3a537f0205e7a5b8f","type":"GENE","name":"RNU6-952P","canonical_id":"hgnc:HGNC:47915","description":"RNA, U6 small nuclear 952, pseudogene","metadata":null},{"id":"7ad65b649ddd45c28cd682e2d0b4afc4","type":"GENE","name":"RNU6-953P","canonical_id":"hgnc:HGNC:47916","description":"RNA, U6 small nuclear 953, pseudogene","metadata":null},{"id":"92328d94ff0147fd8f96674f017246fb","type":"GENE","name":"RNU6-954P","canonical_id":"hgnc:HGNC:47917","description":"RNA, U6 small nuclear 954, pseudogene","metadata":null},{"id":"9d812f6be400456faf258d29def03aa6","type":"GENE","name":"RNU6-955P","canonical_id":"hgnc:HGNC:47918","description":"RNA, U6 small nuclear 955, pseudogene","metadata":null},{"id":"e47eb38ecec4442ab82cf8745af33a91","type":"GENE","name":"RNU6-956P","canonical_id":"hgnc:HGNC:47919","description":"RNA, U6 small nuclear 956, pseudogene","metadata":null},{"id":"4632c329831c497ba8e86eeed8384aa9","type":"GENE","name":"RNU6-957P","canonical_id":"hgnc:HGNC:47920","description":"RNA, U6 small nuclear 957, pseudogene","metadata":null},{"id":"2e726400064d42c3973e42ecfc17cd0a","type":"GENE","name":"RNU6-958P","canonical_id":"hgnc:HGNC:47921","description":"RNA, U6 small nuclear 958, pseudogene","metadata":null},{"id":"27cfeb37808c4651acbc12f661ecf786","type":"GENE","name":"RNU6-959P","canonical_id":"hgnc:HGNC:47922","description":"RNA, U6 small nuclear 959, pseudogene","metadata":null},{"id":"c16ee67237184da490f306f6b9c1c501","type":"GENE","name":"RNU6-95P","canonical_id":"hgnc:HGNC:47058","description":"RNA, U6 small nuclear 95, pseudogene","metadata":null},{"id":"b76e3b0df71b4835bbc41eb8365ba7d3","type":"GENE","name":"RNU6-960P","canonical_id":"hgnc:HGNC:47923","description":"RNA, U6 small nuclear 960, pseudogene","metadata":null},{"id":"9857079b453346b6accfed6d017515a2","type":"GENE","name":"RNU6-961P","canonical_id":"hgnc:HGNC:47924","description":"RNA, U6 small nuclear 961, pseudogene","metadata":null},{"id":"a333d63383334dd683a18c0183a1cd94","type":"GENE","name":"RNU6-964P","canonical_id":"hgnc:HGNC:47927","description":"RNA, U6 small nuclear 964, pseudogene","metadata":null},{"id":"b12c44ba0aa847caba0139aa7818879a","type":"GENE","name":"RNU6-965P","canonical_id":"hgnc:HGNC:47928","description":"RNA, U6 small nuclear 965, pseudogene","metadata":null},{"id":"92959e1272c447979d38de9f113e9388","type":"GENE","name":"RNU6-966P","canonical_id":"hgnc:HGNC:47929","description":"RNA, U6 small nuclear 966, pseudogene","metadata":null},{"id":"3b5a5f1e8171402d8908c36794c1dfb3","type":"GENE","name":"RNU6-967P","canonical_id":"hgnc:HGNC:47930","description":"RNA, U6 small nuclear 967, pseudogene","metadata":null},{"id":"dab09f0e11aa41578c14514d66855be0","type":"GENE","name":"RNU6-968P","canonical_id":"hgnc:HGNC:47931","description":"RNA, U6 small nuclear 968, pseudogene","metadata":null},{"id":"26929c4d14e64b8a9aad400c71ce1524","type":"GENE","name":"RNU6-969P","canonical_id":"hgnc:HGNC:47932","description":"RNA, U6 small nuclear 969, pseudogene","metadata":null},{"id":"77e50878c1584ee5a2bf2d1e3c28b6e0","type":"GENE","name":"RNU6-970P","canonical_id":"hgnc:HGNC:47933","description":"RNA, U6 small nuclear 970, pseudogene","metadata":null},{"id":"43272a9607554f869ec410c10ab4538a","type":"GENE","name":"RNU6-971P","canonical_id":"hgnc:HGNC:47934","description":"RNA, U6 small nuclear 971, pseudogene","metadata":null},{"id":"7805abd479454e17ba91da3689c113df","type":"GENE","name":"RNU6-972P","canonical_id":"hgnc:HGNC:47935","description":"RNA, U6 small nuclear 972, pseudogene","metadata":null},{"id":"2e04bd99b77e4d37ad6373ceac8cffc6","type":"GENE","name":"RNU6-973P","canonical_id":"hgnc:HGNC:47936","description":"RNA, U6 small nuclear 973, pseudogene","metadata":null},{"id":"f60013b633ca4106a3af3f2dc02c45d8","type":"GENE","name":"RNU6-974P","canonical_id":"hgnc:HGNC:47937","description":"RNA, U6 small nuclear 974, pseudogene","metadata":null},{"id":"61fa30163c2748a6b02629b30eb5c76a","type":"GENE","name":"RNU6-975P","canonical_id":"hgnc:HGNC:47938","description":"RNA, U6 small nuclear 975, pseudogene","metadata":null},{"id":"05e188a7a6b247f6bdb911df1728d002","type":"GENE","name":"RNU6-976P","canonical_id":"hgnc:HGNC:47939","description":"RNA, U6 small nuclear 976, pseudogene","metadata":null},{"id":"829312b75334474c947395ea5bca71d1","type":"GENE","name":"RNU6-977P","canonical_id":"hgnc:HGNC:47940","description":"RNA, U6 small nuclear 977, pseudogene","metadata":null},{"id":"29de6e27822444329e0a61a847638f66","type":"GENE","name":"RNU6-978P","canonical_id":"hgnc:HGNC:47941","description":"RNA, U6 small nuclear 978, pseudogene","metadata":null},{"id":"3519922e8f01437fb059968d2ef9c7cf","type":"GENE","name":"RNU6-979P","canonical_id":"hgnc:HGNC:47942","description":"RNA, U6 small nuclear 979, pseudogene","metadata":null},{"id":"50685f9b4ad6400eaf3cce2121178a83","type":"GENE","name":"RNU6-97P","canonical_id":"hgnc:HGNC:47060","description":"RNA, U6 small nuclear 97, pseudogene","metadata":null},{"id":"3338edceec2a41b9885b251d900ac7d2","type":"GENE","name":"RNU6-980P","canonical_id":"hgnc:HGNC:47943","description":"RNA, U6 small nuclear 980, pseudogene","metadata":null},{"id":"021782a90ebc4d96ae137b5d5c416f45","type":"GENE","name":"RNU6-982P","canonical_id":"hgnc:HGNC:47945","description":"RNA, U6 small nuclear 982, pseudogene","metadata":null},{"id":"ba8c6c4b64cc451eb3754c8fd2d454af","type":"GENE","name":"RNU6-983P","canonical_id":"hgnc:HGNC:47946","description":"RNA, U6 small nuclear 983, pseudogene","metadata":null},{"id":"f1b962e3b0c34a579f48c22db4112e0a","type":"GENE","name":"RNU6-984P","canonical_id":"hgnc:HGNC:47947","description":"RNA, U6 small nuclear 984, pseudogene","metadata":null},{"id":"7e254946da854d789eeb976743514e17","type":"GENE","name":"RNU6-985P","canonical_id":"hgnc:HGNC:47948","description":"RNA, U6 small nuclear 985, pseudogene","metadata":null},{"id":"48ed9e454acd48d4b0ead43ae25de9bc","type":"GENE","name":"RNU6-986P","canonical_id":"hgnc:HGNC:47949","description":"RNA, U6 small nuclear 986, pseudogene","metadata":null},{"id":"133406b0961640ec946dbe43f0abc3c6","type":"GENE","name":"RNU6-987P","canonical_id":"hgnc:HGNC:47950","description":"RNA, U6 small nuclear 987, pseudogene","metadata":null},{"id":"dc0b3d55924f420d98f51eec45cec3e9","type":"GENE","name":"RNU6-988P","canonical_id":"hgnc:HGNC:47951","description":"RNA, U6 small nuclear 988, pseudogene","metadata":null},{"id":"f7030683b0ec4b36a51d7dc9c9658fa2","type":"GENE","name":"RNU6-989P","canonical_id":"hgnc:HGNC:47952","description":"RNA, U6 small nuclear 989, pseudogene","metadata":null},{"id":"8059c489222b440e903f009acd7f1e8f","type":"GENE","name":"RNU6-98P","canonical_id":"hgnc:HGNC:47061","description":"RNA, U6 small nuclear 98, pseudogene","metadata":null},{"id":"bf18b3c3ef8049cba76a259a0abb4cce","type":"GENE","name":"RNU6-990P","canonical_id":"hgnc:HGNC:47953","description":"RNA, U6 small nuclear 990, pseudogene","metadata":null},{"id":"1732bdd711714db6b3025f03e4dfa76a","type":"GENE","name":"RNU6-991P","canonical_id":"hgnc:HGNC:47954","description":"RNA, U6 small nuclear 991, pseudogene","metadata":null},{"id":"613a6b2cc8cb40f186ac71c3270282e1","type":"GENE","name":"RNU6-992P","canonical_id":"hgnc:HGNC:47955","description":"RNA, U6 small nuclear 992, pseudogene","metadata":null},{"id":"4c0c4377cd584bf2bb427001529d6ae3","type":"GENE","name":"RNU6-993P","canonical_id":"hgnc:HGNC:47956","description":"RNA, U6 small nuclear 993, pseudogene","metadata":null},{"id":"f392948f86064be28ad4d914a7cbfb4c","type":"GENE","name":"RNU6-994P","canonical_id":"hgnc:HGNC:47957","description":"RNA, U6 small nuclear 994, pseudogene","metadata":null},{"id":"0c7957008b624747bb5d45cafe7f0bd1","type":"GENE","name":"RNU6-995P","canonical_id":"hgnc:HGNC:47958","description":"RNA, U6 small nuclear 995, pseudogene","metadata":null},{"id":"a7242fc9a52e4ad69e6a0ddb6baaed6f","type":"GENE","name":"RNU6-996P","canonical_id":"hgnc:HGNC:47959","description":"RNA, U6 small nuclear 996, pseudogene","metadata":null},{"id":"8bc949820dc04143bb89595f8a55fb26","type":"GENE","name":"RNU6-997P","canonical_id":"hgnc:HGNC:47960","description":"RNA, U6 small nuclear 997, pseudogene","metadata":null},{"id":"4f414d31db544e999a95d00d7a2ecf3f","type":"GENE","name":"RNU6-998P","canonical_id":"hgnc:HGNC:47961","description":"RNA, U6 small nuclear 998, pseudogene","metadata":null},{"id":"37d481a3e3954a348fdb53121bc92523","type":"GENE","name":"RNU6-999P","canonical_id":"hgnc:HGNC:47962","description":"RNA, U6 small nuclear 999, pseudogene","metadata":null},{"id":"f0e3c09f3605465197794f9b7307ada1","type":"GENE","name":"RNU6-99P","canonical_id":"hgnc:HGNC:47062","description":"RNA, U6 small nuclear 99, pseudogene","metadata":null},{"id":"52fdadde35e24a6aaaa5d39bef32cf59","type":"GENE","name":"RNU6ATAC","canonical_id":"hgnc:HGNC:34017","description":"RNA, U6atac small nuclear","metadata":{"aliases":["RNU6ATAC1"]}},{"id":"72fdefb9db1447a39e3cbf83c6b8b169","type":"GENE","name":"RNU6ATAC10P","canonical_id":"hgnc:HGNC:46909","description":"RNA, U6atac small nuclear 10, pseudogene","metadata":null},{"id":"ae4fc8be09a64671ab81dfcc0afb0cd5","type":"GENE","name":"RNU6ATAC11P","canonical_id":"hgnc:HGNC:46910","description":"RNA, U6atac small nuclear 11, pseudogene","metadata":null},{"id":"0bb5296925c94e289c9975c523dbcbe7","type":"GENE","name":"RNU6ATAC12P","canonical_id":"hgnc:HGNC:46911","description":"RNA, U6atac small nuclear 12, pseudogene","metadata":null},{"id":"d0a209be79114424980e526ecb24eab9","type":"GENE","name":"RNU6ATAC13P","canonical_id":"hgnc:HGNC:46912","description":"RNA, U6atac small nuclear 13, pseudogene","metadata":null},{"id":"1095da3726df4222b87ae3913575172d","type":"GENE","name":"RNU6ATAC14P","canonical_id":"hgnc:HGNC:46913","description":"RNA, U6atac small nuclear 14, pseudogene","metadata":null},{"id":"306806b611ab4a4a82c56f1ac5c6abb9","type":"GENE","name":"RNU6ATAC15P","canonical_id":"hgnc:HGNC:46914","description":"RNA, U6atac small nuclear 15, pseudogene","metadata":null},{"id":"a181e64757204453bd8b8374b8f03628","type":"GENE","name":"RNU6ATAC16P","canonical_id":"hgnc:HGNC:46915","description":"RNA, U6atac small nuclear 16, pseudogene","metadata":null},{"id":"3e5f3316e84a4a86bcb98e72cf761deb","type":"GENE","name":"RNU6ATAC17P","canonical_id":"hgnc:HGNC:46916","description":"RNA, U6atac small nuclear 17, pseudogene","metadata":null},{"id":"53c7376d37094eb088cbde5f0100ba0a","type":"GENE","name":"RNU6ATAC18P","canonical_id":"hgnc:HGNC:46917","description":"RNA, U6atac small nuclear 18, pseudogene","metadata":null},{"id":"5f1263f9a8b5494292fb870ac5afc2d5","type":"GENE","name":"RNU6ATAC19P","canonical_id":"hgnc:HGNC:46918","description":"RNA, U6atac small nuclear 19, pseudogene","metadata":null},{"id":"dd52905ed1614ed0aa183dc80619a54e","type":"GENE","name":"RNU6ATAC20P","canonical_id":"hgnc:HGNC:46919","description":"RNA, U6atac small nuclear 20, pseudogene","metadata":null},{"id":"cc1823e7aea245df94609056d122415e","type":"GENE","name":"RNU6ATAC21P","canonical_id":"hgnc:HGNC:46920","description":"RNA, U6atac small nuclear 21, pseudogene","metadata":null},{"id":"3599ff6d75db4f3eb1fbe5f9b3c4b6ec","type":"GENE","name":"RNU6ATAC22P","canonical_id":"hgnc:HGNC:46921","description":"RNA, U6atac small nuclear 22, pseudogene","metadata":null},{"id":"6ba1113ea079414595eb18eb25dc6c45","type":"GENE","name":"RNU6ATAC23P","canonical_id":"hgnc:HGNC:46922","description":"RNA, U6atac small nuclear 23, pseudogene","metadata":null},{"id":"5c297272cdc14aa694080a543ec730fd","type":"GENE","name":"RNU6ATAC24P","canonical_id":"hgnc:HGNC:46923","description":"RNA, U6atac small nuclear 24, pseudogene","metadata":null},{"id":"3a4e85d23124481ca01be2aaa51d7bc9","type":"GENE","name":"RNU6ATAC25P","canonical_id":"hgnc:HGNC:46924","description":"RNA, U6atac small nuclear 25, pseudogene","metadata":null},{"id":"fb5d5f41556341d0a3203935f697f081","type":"GENE","name":"RNU6ATAC26P","canonical_id":"hgnc:HGNC:46925","description":"RNA, U6atac small nuclear 26, pseudogene","metadata":null},{"id":"961ca074fce8492293d6b0b49cb030a8","type":"GENE","name":"RNU6ATAC27P","canonical_id":"hgnc:HGNC:46926","description":"RNA, U6atac small nuclear 27, pseudogene","metadata":null},{"id":"4cfd1319dc6044028d78f82f592f97e4","type":"GENE","name":"RNU6ATAC28P","canonical_id":"hgnc:HGNC:46927","description":"RNA, U6atac small nuclear 28, pseudogene","metadata":null},{"id":"4bbb9d33697d45df9e999ec4bbac4806","type":"GENE","name":"RNU6ATAC29P","canonical_id":"hgnc:HGNC:46928","description":"RNA, U6atac small nuclear 29, pseudogene","metadata":null},{"id":"5f16012866f044aa8a0f0405d2f2f90e","type":"GENE","name":"RNU6ATAC2P","canonical_id":"hgnc:HGNC:34092","description":"RNA, U6atac small nuclear 2, pseudogene","metadata":null},{"id":"1491c1c8caa04be0a74208c79d81c84b","type":"GENE","name":"RNU6ATAC30P","canonical_id":"hgnc:HGNC:46929","description":"RNA, U6atac small nuclear 30, pseudogene","metadata":null},{"id":"e50c04bcd0d04134b3c21a288d782c8b","type":"GENE","name":"RNU6ATAC31P","canonical_id":"hgnc:HGNC:46930","description":"RNA, U6atac small nuclear 31, pseudogene","metadata":null},{"id":"e465541a170a43a29d176032ff7dfdeb","type":"GENE","name":"RNU6ATAC32P","canonical_id":"hgnc:HGNC:46931","description":"RNA, U6atac small nuclear 32, pseudogene","metadata":null},{"id":"6e30d690fdd14261ba5ef4ae2ad81871","type":"GENE","name":"RNU6ATAC33P","canonical_id":"hgnc:HGNC:46932","description":"RNA, U6atac small nuclear 33, pseudogene","metadata":null},{"id":"2daa190e23da44bf97a68e529edb55ce","type":"GENE","name":"RNU6ATAC34P","canonical_id":"hgnc:HGNC:46933","description":"RNA, U6atac small nuclear 34, pseudogene","metadata":null},{"id":"82ec51954df644288b9caa0a1acf4b3b","type":"GENE","name":"RNU6ATAC35P","canonical_id":"hgnc:HGNC:46934","description":"RNA, U6atac small nuclear 35, pseudogene","metadata":null},{"id":"9f393166dee34dd591bb62fdb5543d82","type":"GENE","name":"RNU6ATAC36P","canonical_id":"hgnc:HGNC:46935","description":"RNA, U6atac small nuclear 36, pseudogene","metadata":null},{"id":"f5378d3339604164abc24846f801bcf9","type":"GENE","name":"RNU6ATAC37P","canonical_id":"hgnc:HGNC:46936","description":"RNA, U6atac small nuclear 37, pseudogene","metadata":null},{"id":"86df03a476104047aed823187e05ed4f","type":"GENE","name":"RNU6ATAC38P","canonical_id":"hgnc:HGNC:46937","description":"RNA, U6atac small nuclear 38, pseudogene","metadata":null},{"id":"2a391ac4924244889499207f052417e0","type":"GENE","name":"RNU6ATAC39P","canonical_id":"hgnc:HGNC:46938","description":"RNA, U6atac small nuclear 39, pseudogene","metadata":null},{"id":"3070e94d007e445591f76f96e6175a85","type":"GENE","name":"RNU6ATAC3P","canonical_id":"hgnc:HGNC:34093","description":"RNA, U6atac small nuclear 3, pseudogene","metadata":null},{"id":"1f944b9df7f643ad927b253f4f713aa0","type":"GENE","name":"RNU6ATAC40P","canonical_id":"hgnc:HGNC:46939","description":"RNA, U6atac small nuclear 40, pseudogene","metadata":null},{"id":"ff356e85a86841f6b64aeb42f0ced8dd","type":"GENE","name":"RNU6ATAC41P","canonical_id":"hgnc:HGNC:46940","description":"RNA, U6atac small nuclear 41, pseudogene","metadata":null},{"id":"567c7940b81a4dc6b275fd65303e8fee","type":"GENE","name":"RNU6ATAC42P","canonical_id":"hgnc:HGNC:46941","description":"RNA, U6atac small nuclear 42, pseudogene","metadata":null},{"id":"6d7362266088436282a6dea332673798","type":"GENE","name":"RNU6ATAC4P","canonical_id":"hgnc:HGNC:34094","description":"RNA, U6atac small nuclear 4, pseudogene","metadata":null},{"id":"833a1912d73f4a2cbf11b569d079645d","type":"GENE","name":"RNU6ATAC5P","canonical_id":"hgnc:HGNC:34095","description":"RNA, U6atac small nuclear 5, pseudogene","metadata":null},{"id":"4c66177262e9401c83ff4d5badcf40ca","type":"GENE","name":"RNU6ATAC6P","canonical_id":"hgnc:HGNC:46905","description":"RNA, U6atac small nuclear 6, pseudogene","metadata":null},{"id":"8e4b466ac52644478949ed8b3341c799","type":"GENE","name":"RNU6ATAC7P","canonical_id":"hgnc:HGNC:46906","description":"RNA, U6atac small nuclear 7, pseudogene","metadata":null},{"id":"1352b0f4276740c7aabb9f3851153ff3","type":"GENE","name":"RNU6ATAC8P","canonical_id":"hgnc:HGNC:46907","description":"RNA, U6atac small nuclear 8, pseudogene","metadata":null},{"id":"15aac967e91b480699e3d068755cac3a","type":"GENE","name":"RNU6ATAC9P","canonical_id":"hgnc:HGNC:46908","description":"RNA, U6atac small nuclear 9, pseudogene","metadata":null},{"id":"d0a34aefa3cb46c79d554fbcc51d60d7","type":"GENE","name":"RNU6V","canonical_id":"hgnc:HGNC:10230","description":"RNA, U6 small nuclear variant sequence with SNRPE pseudogene sequence","metadata":{"aliases":["87U6","LH87"]}},{"id":"eb1889be8a4a4b1eb15c5b5266d17d7a","type":"GENE","name":"RNU7-1","canonical_id":"hgnc:HGNC:34033","description":"RNA, U7 small nuclear 1","metadata":{"aliases":["U7.1","RNU7"]}},{"id":"9180a2e1707b4677ab117a3ca2f38db5","type":"GENE","name":"RNU7-102P","canonical_id":"hgnc:HGNC:45636","description":"RNA, U7 small nuclear 102 pseudogene","metadata":null},{"id":"a403949fc7734e4fb5e6597311b19a1d","type":"GENE","name":"RNU7-103P","canonical_id":"hgnc:HGNC:45637","description":"RNA, U7 small nuclear 103 pseudogene","metadata":null},{"id":"3513374d9ef04f6ebc6004a1bfb18757","type":"GENE","name":"RNU7-104P","canonical_id":"hgnc:HGNC:45638","description":"RNA, U7 small nuclear 104 pseudogene","metadata":null},{"id":"60f458d7b6964ab48bafe2518c722a2b","type":"GENE","name":"RNU7-105P","canonical_id":"hgnc:HGNC:45639","description":"RNA, U7 small nuclear 105 pseudogene","metadata":null},{"id":"23d8a39706fc4807b70c54867dd0c086","type":"GENE","name":"RNU7-106P","canonical_id":"hgnc:HGNC:45640","description":"RNA, U7 small nuclear 106 pseudogene","metadata":null},{"id":"500e964a25c64209b931ba3eb22c1066","type":"GENE","name":"RNU7-107P","canonical_id":"hgnc:HGNC:45641","description":"RNA, U7 small nuclear 107 pseudogene","metadata":null},{"id":"1bbece6c280546eea66b4ec8170f9fe9","type":"GENE","name":"RNU7-10P","canonical_id":"hgnc:HGNC:34106","description":"RNA, U7 small nuclear 10 pseudogene","metadata":{"aliases":["U7.10"]}},{"id":"5fcc83a420ef45df9ef3345217184285","type":"GENE","name":"RNU7-110P","canonical_id":"hgnc:HGNC:45644","description":"RNA, U7 small nuclear 110 pseudogene","metadata":null},{"id":"185317580c834befac3cbfdfecb57468","type":"GENE","name":"RNU7-111P","canonical_id":"hgnc:HGNC:45645","description":"RNA, U7 small nuclear 111 pseudogene","metadata":null},{"id":"9c5bef7bff414aa988fb0f79d3a9ef9a","type":"GENE","name":"RNU7-113P","canonical_id":"hgnc:HGNC:45647","description":"RNA, U7 small nuclear 113 pseudogene","metadata":null},{"id":"59e4a61c371e407eaabfcad5e94037c5","type":"GENE","name":"RNU7-115P","canonical_id":"hgnc:HGNC:45649","description":"RNA, U7 small nuclear 115 pseudogene","metadata":null},{"id":"93a94370a1c942d6aaa996a9d53a6f09","type":"GENE","name":"RNU7-116P","canonical_id":"hgnc:HGNC:45650","description":"RNA, U7 small nuclear 116 pseudogene","metadata":null},{"id":"a39938eb6bd447f29fd164d76d2ac8d2","type":"GENE","name":"RNU7-119P","canonical_id":"hgnc:HGNC:45653","description":"RNA, U7 small nuclear 119 pseudogene","metadata":null},{"id":"a9590a2947814c389d82a17107709e1c","type":"GENE","name":"RNU7-11P","canonical_id":"hgnc:HGNC:34107","description":"RNA, U7 small nuclear 11 pseudogene","metadata":{"aliases":["U7.11"]}},{"id":"a2ae5cbb18604415963b243dd0ca4101","type":"GENE","name":"RNU7-120P","canonical_id":"hgnc:HGNC:45654","description":"RNA, U7 small nuclear 120 pseudogene","metadata":null},{"id":"0e6b8429e9ae4383a8f9e5b4435d4417","type":"GENE","name":"RNU7-121P","canonical_id":"hgnc:HGNC:45655","description":"RNA, U7 small nuclear 121 pseudogene","metadata":null},{"id":"fc9ac339b310456ca87dd9dfc8cbd7d9","type":"GENE","name":"RNU7-123P","canonical_id":"hgnc:HGNC:45657","description":"RNA, U7 small nuclear 123 pseudogene","metadata":null},{"id":"a0d7499377484780b6af88faa4eb3d05","type":"GENE","name":"RNU7-124P","canonical_id":"hgnc:HGNC:45658","description":"RNA, U7 small nuclear 124 pseudogene","metadata":null},{"id":"1fe7ffb35eb74446b44f51c841075352","type":"GENE","name":"RNU7-125P","canonical_id":"hgnc:HGNC:45659","description":"RNA, U7 small nuclear 125 pseudogene","metadata":{"aliases":["RNU7-135P"]}},{"id":"30891f8613e7425c9d6ee6e0a0dbbfd1","type":"GENE","name":"RNU7-126P","canonical_id":"hgnc:HGNC:45660","description":"RNA, U7 small nuclear 126 pseudogene","metadata":null},{"id":"f35aa39ebbbc4ffd940e55ac78b3ed36","type":"GENE","name":"RNU7-127P","canonical_id":"hgnc:HGNC:45661","description":"RNA, U7 small nuclear 127 pseudogene","metadata":null},{"id":"cfa60c6df79c45728a0e364be8762902","type":"GENE","name":"RNU7-128P","canonical_id":"hgnc:HGNC:45662","description":"RNA, U7 small nuclear 128 pseudogene","metadata":null},{"id":"f0f3ba0e0ec44947ac762080bbbc75e9","type":"GENE","name":"RNU7-129P","canonical_id":"hgnc:HGNC:45663","description":"RNA, U7 small nuclear 129 pseudogene","metadata":null},{"id":"0d5d21d00d1e4147a45beb53c837014e","type":"GENE","name":"RNU7-12P","canonical_id":"hgnc:HGNC:34108","description":"RNA, U7 small nuclear 12 pseudogene","metadata":{"aliases":["U7.12","RNU7-100P"]}},{"id":"abdd028e2d9d4126bdd63b7bbb6327f4","type":"GENE","name":"RNU7-130P","canonical_id":"hgnc:HGNC:45664","description":"RNA, U7 small nuclear 130 pseudogene","metadata":null},{"id":"496ba8e2c31646a9bed247c91d72807a","type":"GENE","name":"RNU7-133P","canonical_id":"hgnc:HGNC:45667","description":"RNA, U7 small nuclear 133 pseudogene","metadata":null},{"id":"b3b8d551125846439ecf09e11e345925","type":"GENE","name":"RNU7-134P","canonical_id":"hgnc:HGNC:45668","description":"RNA, U7 small nuclear 134 pseudogene","metadata":null},{"id":"f6f4f9a3c27243a993a72829e834a236","type":"GENE","name":"RNU7-136P","canonical_id":"hgnc:HGNC:45670","description":"RNA, U7 small nuclear 136 pseudogene","metadata":null},{"id":"bb332195863b43a89cf3bc9d9c531948","type":"GENE","name":"RNU7-137P","canonical_id":"hgnc:HGNC:45671","description":"RNA, U7 small nuclear 137 pseudogene","metadata":null},{"id":"3fff75b437944f379ac5860d444a7e7e","type":"GENE","name":"RNU7-138P","canonical_id":"hgnc:HGNC:45672","description":"RNA, U7 small nuclear 138 pseudogene","metadata":null},{"id":"f477698f179c49e580f1b7857fb2b96c","type":"GENE","name":"RNU7-13P","canonical_id":"hgnc:HGNC:34109","description":"RNA, U7 small nuclear 13 pseudogene","metadata":{"aliases":["U7.13"]}},{"id":"bfff2f02fab545d6baf126d835e48926","type":"GENE","name":"RNU7-140P","canonical_id":"hgnc:HGNC:45674","description":"RNA, U7 small nuclear 140 pseudogene","metadata":null},{"id":"364a7f6c281b482c90e547d4cb689a11","type":"GENE","name":"RNU7-141P","canonical_id":"hgnc:HGNC:45675","description":"RNA, U7 small nuclear 141 pseudogene","metadata":null},{"id":"97d4f3b0009c4a18bcc91d74d06fd55e","type":"GENE","name":"RNU7-143P","canonical_id":"hgnc:HGNC:45677","description":"RNA, U7 small nuclear 143 pseudogene","metadata":null},{"id":"a9e37122781e42248afc7460eba0c91b","type":"GENE","name":"RNU7-144P","canonical_id":"hgnc:HGNC:45678","description":"RNA, U7 small nuclear 144 pseudogene","metadata":null},{"id":"fbd051c94c5b4e76a78386d1dcc712b1","type":"GENE","name":"RNU7-147P","canonical_id":"hgnc:HGNC:45681","description":"RNA, U7 small nuclear 147 pseudogene","metadata":null},{"id":"ae7f395c59fd48a298145af069a93c98","type":"GENE","name":"RNU7-148P","canonical_id":"hgnc:HGNC:45682","description":"RNA, U7 small nuclear 148 pseudogene","metadata":null},{"id":"6a02525fedf64fffbc18a10a89551933","type":"GENE","name":"RNU7-149P","canonical_id":"hgnc:HGNC:45683","description":"RNA, U7 small nuclear 149 pseudogene","metadata":null},{"id":"d16ba5c1d7fe434cb979ed7c6f791432","type":"GENE","name":"RNU7-14P","canonical_id":"hgnc:HGNC:34110","description":"RNA, U7 small nuclear 14 pseudogene","metadata":{"aliases":["U7.14"]}},{"id":"b252436eaaf04cd68458f6d2b9a1315e","type":"GENE","name":"RNU7-151P","canonical_id":"hgnc:HGNC:45685","description":"RNA, U7 small nuclear 151 pseudogene","metadata":null},{"id":"27a2f274aebe4876ba2240f29ef8b04c","type":"GENE","name":"RNU7-152P","canonical_id":"hgnc:HGNC:45686","description":"RNA, U7 small nuclear 152 pseudogene","metadata":null},{"id":"70098cf7f80c4ed9a82ae9b71326c9df","type":"GENE","name":"RNU7-153P","canonical_id":"hgnc:HGNC:45687","description":"RNA, U7 small nuclear 153 pseudogene","metadata":null},{"id":"34455772ab964b0b89e9be0b712017fc","type":"GENE","name":"RNU7-154P","canonical_id":"hgnc:HGNC:45688","description":"RNA, U7 small nuclear 154 pseudogene","metadata":null},{"id":"1ae1ea0921bc440794b83b6fc995c114","type":"GENE","name":"RNU7-155P","canonical_id":"hgnc:HGNC:45689","description":"RNA, U7 small nuclear 155 pseudogene","metadata":null},{"id":"143bb62e0b984e54a7edc96b6eec4813","type":"GENE","name":"RNU7-156P","canonical_id":"hgnc:HGNC:45690","description":"RNA, U7 small nuclear 156 pseudogene","metadata":null},{"id":"6f896b66bb65435da4dd0a1a378d3af4","type":"GENE","name":"RNU7-157P","canonical_id":"hgnc:HGNC:45691","description":"RNA, U7 small nuclear 157 pseudogene","metadata":null},{"id":"6cf2694507ea44fcb8e9addbf7eaffc0","type":"GENE","name":"RNU7-159P","canonical_id":"hgnc:HGNC:45693","description":"RNA, U7 small nuclear 159 pseudogene","metadata":null},{"id":"17dba89f782d4e5c82874091e3f97d95","type":"GENE","name":"RNU7-15P","canonical_id":"hgnc:HGNC:34111","description":"RNA, U7 small nuclear 15 pseudogene","metadata":{"aliases":["U7.15"]}},{"id":"7d2fcd663cb44908a100b2514c325076","type":"GENE","name":"RNU7-160P","canonical_id":"hgnc:HGNC:45694","description":"RNA, U7 small nuclear 160 pseudogene","metadata":null},{"id":"13fb879fdcde4deda53b4e32b0654e24","type":"GENE","name":"RNU7-161P","canonical_id":"hgnc:HGNC:45695","description":"RNA, U7 small nuclear 161 pseudogene","metadata":null},{"id":"ae6b50f34ad04197be52a3611fb3cb59","type":"GENE","name":"RNU7-164P","canonical_id":"hgnc:HGNC:45698","description":"RNA, U7 small nuclear 164 pseudogene","metadata":null},{"id":"9cb98f4e9dc84f39b1374528d04f79df","type":"GENE","name":"RNU7-165P","canonical_id":"hgnc:HGNC:45699","description":"RNA, U7 small nuclear 165 pseudogene","metadata":null},{"id":"4c020931acb04f4dbe2bda14c36d802e","type":"GENE","name":"RNU7-167P","canonical_id":"hgnc:HGNC:45701","description":"RNA, U7 small nuclear 167 pseudogene","metadata":null},{"id":"eff493589cc5498391277a30c9517f15","type":"GENE","name":"RNU7-169P","canonical_id":"hgnc:HGNC:45703","description":"RNA, U7 small nuclear 169 pseudogene","metadata":null},{"id":"a9ddee2008dd4742b33d7c73a671c820","type":"GENE","name":"RNU7-16P","canonical_id":"hgnc:HGNC:34112","description":"RNA, U7 small nuclear 16 pseudogene","metadata":{"aliases":["U7.16"]}},{"id":"58429a44a5154f42897f5b4a21319a65","type":"GENE","name":"RNU7-170P","canonical_id":"hgnc:HGNC:45704","description":"RNA, U7 small nuclear 170 pseudogene","metadata":null},{"id":"544a4e330f9f4db9969ee7aca1414f41","type":"GENE","name":"RNU7-171P","canonical_id":"hgnc:HGNC:45705","description":"RNA, U7 small nuclear 171 pseudogene","metadata":null},{"id":"1bc66aac721640a89630429a949f62c8","type":"GENE","name":"RNU7-172P","canonical_id":"hgnc:HGNC:45706","description":"RNA, U7 small nuclear 172 pseudogene","metadata":null},{"id":"8e991487d7eb420bab326abe56981ab6","type":"GENE","name":"RNU7-173P","canonical_id":"hgnc:HGNC:45707","description":"RNA, U7 small nuclear 173 pseudogene","metadata":null},{"id":"dd459d2c8a0f44c59e13da760e8374a4","type":"GENE","name":"RNU7-174P","canonical_id":"hgnc:HGNC:45708","description":"RNA, U7 small nuclear 174 pseudogene","metadata":null},{"id":"839169a94c1b43ffaa7520982d10ddbe","type":"GENE","name":"RNU7-175P","canonical_id":"hgnc:HGNC:45709","description":"RNA, U7 small nuclear 175 pseudogene","metadata":null},{"id":"4b1caeb4c24c4e95bc147b73068073c4","type":"GENE","name":"RNU7-176P","canonical_id":"hgnc:HGNC:45710","description":"RNA, U7 small nuclear 176 pseudogene","metadata":null},{"id":"b5c4037ad528462a844ce61f30b82ec0","type":"GENE","name":"RNU7-179P","canonical_id":"hgnc:HGNC:45713","description":"RNA, U7 small nuclear 179 pseudogene","metadata":null},{"id":"70f60febdc1544a4a58815119f220e2f","type":"GENE","name":"RNU7-17P","canonical_id":"hgnc:HGNC:34113","description":"RNA, U7 small nuclear 17 pseudogene","metadata":{"aliases":["U7.17"]}},{"id":"ba5d289fd6fa4b588365cb1cccefdf82","type":"GENE","name":"RNU7-180P","canonical_id":"hgnc:HGNC:45714","description":"RNA, U7 small nuclear 180 pseudogene","metadata":null},{"id":"01898297e098425783d519c2dc9456c4","type":"GENE","name":"RNU7-181P","canonical_id":"hgnc:HGNC:45715","description":"RNA, U7 small nuclear 181 pseudogene","metadata":null},{"id":"31f35420bd844c5b8ad644bba9824311","type":"GENE","name":"RNU7-182P","canonical_id":"hgnc:HGNC:45716","description":"RNA, U7 small nuclear 182 pseudogene","metadata":null},{"id":"f605b19f873f4c8d90d175955d92a470","type":"GENE","name":"RNU7-183P","canonical_id":"hgnc:HGNC:45717","description":"RNA, U7 small nuclear 183 pseudogene","metadata":null},{"id":"ae0c4a68ba044c9cb8cfe79a92f2be3c","type":"GENE","name":"RNU7-185P","canonical_id":"hgnc:HGNC:45719","description":"RNA, U7 small nuclear 185 pseudogene","metadata":null},{"id":"678d496c46f648688dcc370262d1c617","type":"GENE","name":"RNU7-186P","canonical_id":"hgnc:HGNC:45720","description":"RNA, U7 small nuclear 186 pseudogene","metadata":null},{"id":"8fd02272bc534ab68fcd8043da6d4578","type":"GENE","name":"RNU7-187P","canonical_id":"hgnc:HGNC:45721","description":"RNA, U7 small nuclear 187 pseudogene","metadata":null},{"id":"7d57d353e08f44eeb7a2e53f53a74df5","type":"GENE","name":"RNU7-188P","canonical_id":"hgnc:HGNC:45722","description":"RNA, U7 small nuclear 188 pseudogene","metadata":null},{"id":"89d9fb293c3f430dbb5a5a7e00df33f6","type":"GENE","name":"RNU7-18P","canonical_id":"hgnc:HGNC:34114","description":"RNA, U7 small nuclear 18 pseudogene","metadata":{"aliases":["U7.18","RNU7-142P"]}},{"id":"3169cd090c764e99ae3dbad5b30ebc73","type":"GENE","name":"RNU7-190P","canonical_id":"hgnc:HGNC:45724","description":"RNA, U7 small nuclear 190 pseudogene","metadata":null},{"id":"8fde907f500b42ee814fdbfab02614d6","type":"GENE","name":"RNU7-192P","canonical_id":"hgnc:HGNC:45726","description":"RNA, U7 small nuclear 192 pseudogene","metadata":null},{"id":"98f82ae030c74cbb92ec0fd1aa965d9e","type":"GENE","name":"RNU7-193P","canonical_id":"hgnc:HGNC:45727","description":"RNA, U7 small nuclear 193 pseudogene","metadata":null},{"id":"4f7a6da5416041978aed5f0ce56780ca","type":"GENE","name":"RNU7-194P","canonical_id":"hgnc:HGNC:45728","description":"RNA, U7 small nuclear 194 pseudogene","metadata":null},{"id":"02897a3e0d934693aa70533269b00b78","type":"GENE","name":"RNU7-195P","canonical_id":"hgnc:HGNC:45729","description":"RNA, U7 small nuclear 195 pseudogene","metadata":null},{"id":"b10db6ac8a1d40d9883119b7f17b8e04","type":"GENE","name":"RNU7-196P","canonical_id":"hgnc:HGNC:45730","description":"RNA, U7 small nuclear 196 pseudogene","metadata":null},{"id":"51f79109a7ae4ebba9492511c5864136","type":"GENE","name":"RNU7-197P","canonical_id":"hgnc:HGNC:45731","description":"RNA, U7 small nuclear 197 pseudogene","metadata":null},{"id":"00456f61060a4f568fcf87c1ec96df11","type":"GENE","name":"RNU7-19P","canonical_id":"hgnc:HGNC:34115","description":"RNA, U7 small nuclear 19 pseudogene","metadata":{"aliases":["U7.19"]}},{"id":"e37180c17fe843bcb2ee432c35d6f021","type":"GENE","name":"RNU7-200P","canonical_id":"hgnc:HGNC:45734","description":"RNA, U7 small nuclear 200 pseudogene","metadata":null},{"id":"5fca1d68ad6a48b49fa4ca55d903e304","type":"GENE","name":"RNU7-20P","canonical_id":"hgnc:HGNC:34116","description":"RNA, U7 small nuclear 20 pseudogene","metadata":{"aliases":["U7.20"]}},{"id":"1ae1d1ec6eb6489d8613e2f8c28e8d7e","type":"GENE","name":"RNU7-21P","canonical_id":"hgnc:HGNC:34117","description":"RNA, U7 small nuclear 21 pseudogene","metadata":{"aliases":["U7.21"]}},{"id":"859ec544657c40bba1351cab49443206","type":"GENE","name":"RNU7-22P","canonical_id":"hgnc:HGNC:34118","description":"RNA, U7 small nuclear 22 pseudogene","metadata":{"aliases":["U7.22"]}},{"id":"651dac5d79504545a5bc397be19ce306","type":"GENE","name":"RNU7-23P","canonical_id":"hgnc:HGNC:34119","description":"RNA, U7 small nuclear 23 pseudogene","metadata":{"aliases":["U7.23"]}},{"id":"d910e7fa843b4bcfbb54c91e979bc421","type":"GENE","name":"RNU7-24P","canonical_id":"hgnc:HGNC:34120","description":"RNA, U7 small nuclear 24 pseudogene","metadata":{"aliases":["U7.24","HSU7.25","RNU7P3"]}},{"id":"ed922f12e6c549ed8e128f7940a12b35","type":"GENE","name":"RNU7-25P","canonical_id":"hgnc:HGNC:34121","description":"RNA, U7 small nuclear 25 pseudogene","metadata":{"aliases":["U7.25"]}},{"id":"1cf2799adb65459a8bade13ef5007b3d","type":"GENE","name":"RNU7-26P","canonical_id":"hgnc:HGNC:34122","description":"RNA, U7 small nuclear 26 pseudogene","metadata":{"aliases":["U7.26"]}},{"id":"72ea4c7fa28a432eb8c04d6e5f0f3f2f","type":"GENE","name":"RNU7-27P","canonical_id":"hgnc:HGNC:34123","description":"RNA, U7 small nuclear 27 pseudogene","metadata":{"aliases":["U7.27"]}},{"id":"9a335191095f429d9ed453bda7b6a68a","type":"GENE","name":"RNU7-28P","canonical_id":"hgnc:HGNC:34124","description":"RNA, U7 small nuclear 28 pseudogene","metadata":{"aliases":["U7.28"]}},{"id":"0b581291e5f1480eb13887678e256148","type":"GENE","name":"RNU7-29P","canonical_id":"hgnc:HGNC:34125","description":"RNA, U7 small nuclear 29 pseudogene","metadata":{"aliases":["U7.29"]}},{"id":"f4f987e0bd5d4984bb11b8e9c9219bf4","type":"GENE","name":"RNU7-2P","canonical_id":"hgnc:HGNC:34098","description":"RNA, U7 small nuclear 2 pseudogene","metadata":{"aliases":["U7.2"]}},{"id":"1eb0371867d542769df0e883f4687bfa","type":"GENE","name":"RNU7-30P","canonical_id":"hgnc:HGNC:34126","description":"RNA, U7 small nuclear 30 pseudogene","metadata":{"aliases":["U7.30"]}},{"id":"074d04f4d30c4553bb9368c508bed600","type":"GENE","name":"RNU7-31P","canonical_id":"hgnc:HGNC:34127","description":"RNA, U7 small nuclear 31 pseudogene","metadata":{"aliases":["U7.31"]}},{"id":"898ef77eab3e4087a5c11887a161e052","type":"GENE","name":"RNU7-32P","canonical_id":"hgnc:HGNC:34128","description":"RNA, U7 small nuclear 32 pseudogene","metadata":{"aliases":["U7.32"]}},{"id":"3b1f2860e895491eb8bdf0bb6457eefe","type":"GENE","name":"RNU7-33P","canonical_id":"hgnc:HGNC:34129","description":"RNA, U7 small nuclear 33 pseudogene","metadata":{"aliases":["U7.33"]}},{"id":"6e6befb915584e09acb86b3725b97131","type":"GENE","name":"RNU7-34P","canonical_id":"hgnc:HGNC:34130","description":"RNA, U7 small nuclear 34 pseudogene","metadata":{"aliases":["U7.34"]}},{"id":"b456041a7d5d4295a456255af95b9f12","type":"GENE","name":"RNU7-35P","canonical_id":"hgnc:HGNC:34131","description":"RNA, U7 small nuclear 35 pseudogene","metadata":{"aliases":["U7.35"]}},{"id":"d30f915d155c458db8871c92f3754c9c","type":"GENE","name":"RNU7-36P","canonical_id":"hgnc:HGNC:34132","description":"RNA, U7 small nuclear 36 pseudogene","metadata":{"aliases":["U7.36","RNU7-112P"]}},{"id":"aaaf17477cf144de86d0b91d744c8575","type":"GENE","name":"RNU7-37P","canonical_id":"hgnc:HGNC:34133","description":"RNA, U7 small nuclear 37 pseudogene","metadata":{"aliases":["U7.37"]}},{"id":"578c44d63fe648f2ad0126b96403b1d0","type":"GENE","name":"RNU7-38P","canonical_id":"hgnc:HGNC:34134","description":"RNA, U7 small nuclear 38 pseudogene","metadata":{"aliases":["U7.38"]}},{"id":"96b38d974f8d4f308e3e3ad82430f790","type":"GENE","name":"RNU7-39P","canonical_id":"hgnc:HGNC:34135","description":"RNA, U7 small nuclear 39 pseudogene","metadata":{"aliases":["U7.39"]}},{"id":"8de6cd37d1a04e14af107e32112777de","type":"GENE","name":"RNU7-3P","canonical_id":"hgnc:HGNC:34099","description":"RNA, U7 small nuclear 3 pseudogene","metadata":{"aliases":["U7.3"]}},{"id":"3da1db32eb5241e597027a1f777bca6a","type":"GENE","name":"RNU7-40P","canonical_id":"hgnc:HGNC:34136","description":"RNA, U7 small nuclear 40 pseudogene","metadata":{"aliases":["U7.40"]}},{"id":"8e167e0420b04f46bf855165fdb4c816","type":"GENE","name":"RNU7-41P","canonical_id":"hgnc:HGNC:34137","description":"RNA, U7 small nuclear 41 pseudogene","metadata":{"aliases":["U7.41"]}},{"id":"48283229c2194c169e1a3a66dd9ecfb3","type":"GENE","name":"RNU7-42P","canonical_id":"hgnc:HGNC:34138","description":"RNA, U7 small nuclear 42 pseudogene","metadata":{"aliases":["U7.42"]}},{"id":"6251f0f06ff74656834877fd5045dffd","type":"GENE","name":"RNU7-43P","canonical_id":"hgnc:HGNC:34139","description":"RNA, U7 small nuclear 43 pseudogene","metadata":{"aliases":["U7.43","RNU7-118P"]}},{"id":"fc36cc6c485449768d29f8a04cabee31","type":"GENE","name":"RNU7-44P","canonical_id":"hgnc:HGNC:34140","description":"RNA, U7 small nuclear 44 pseudogene","metadata":{"aliases":["U7.44"]}},{"id":"fadc685df953474bb6084c787e2ea7ec","type":"GENE","name":"RNU7-45P","canonical_id":"hgnc:HGNC:34141","description":"RNA, U7 small nuclear 45 pseudogene","metadata":{"aliases":["U7.45"]}},{"id":"0c545e994a6c4a3dbe1ac3f840d8c7af","type":"GENE","name":"RNU7-46P","canonical_id":"hgnc:HGNC:34142","description":"RNA, U7 small nuclear 46 pseudogene","metadata":{"aliases":["U7.46"]}},{"id":"556b2fcf580744799d6d0c7e87f5bfe9","type":"GENE","name":"RNU7-47P","canonical_id":"hgnc:HGNC:34143","description":"RNA, U7 small nuclear 47 pseudogene","metadata":{"aliases":["U7.47"]}},{"id":"c154c7d8ef2e46ec84e41b26a51e6a9b","type":"GENE","name":"RNU7-48P","canonical_id":"hgnc:HGNC:34144","description":"RNA, U7 small nuclear 48 pseudogene","metadata":{"aliases":["U7.48"]}},{"id":"885dc0c472dc48988390b4fae1d09f51","type":"GENE","name":"RNU7-49P","canonical_id":"hgnc:HGNC:34145","description":"RNA, U7 small nuclear 49 pseudogene","metadata":{"aliases":["U7.49"]}},{"id":"3bcb909b154c4365bf1979ec3d95fac5","type":"GENE","name":"RNU7-4P","canonical_id":"hgnc:HGNC:34100","description":"RNA, U7 small nuclear 4 pseudogene","metadata":{"aliases":["U7.4","RNU7-132P"]}},{"id":"7192ada30b12447281c026b9b6b77a8c","type":"GENE","name":"RNU7-50P","canonical_id":"hgnc:HGNC:34146","description":"RNA, U7 small nuclear 50 pseudogene","metadata":{"aliases":["U7.50"]}},{"id":"666a584d38a54258980c33d9fa139f80","type":"GENE","name":"RNU7-51P","canonical_id":"hgnc:HGNC:34147","description":"RNA, U7 small nuclear 51 pseudogene","metadata":{"aliases":["U7.51"]}},{"id":"320760605ab64d4585857eb4a998d0e7","type":"GENE","name":"RNU7-52P","canonical_id":"hgnc:HGNC:34148","description":"RNA, U7 small nuclear 52 pseudogene","metadata":{"aliases":["U7.52"]}},{"id":"b67817242c7a47b1891706aaa0a80e82","type":"GENE","name":"RNU7-53P","canonical_id":"hgnc:HGNC:34149","description":"RNA, U7 small nuclear 53 pseudogene","metadata":{"aliases":["U7.53"]}},{"id":"1fd8618ac9c14dcabe0e433918281aae","type":"GENE","name":"RNU7-54P","canonical_id":"hgnc:HGNC:34150","description":"RNA, U7 small nuclear 54 pseudogene","metadata":{"aliases":["U7.54"]}},{"id":"dd1f589f5a5247f19c199dbaac81ac3b","type":"GENE","name":"RNU7-55P","canonical_id":"hgnc:HGNC:10239","description":"RNA, U7 small nuclear 55 pseudogene","metadata":{"aliases":["HSU7.36","U7.55","RNU7P4"]}},{"id":"6e979c90fd6d4121b40a6154897dc5cf","type":"GENE","name":"RNU7-56P","canonical_id":"hgnc:HGNC:34152","description":"RNA, U7 small nuclear 56 pseudogene","metadata":{"aliases":["U7.56"]}},{"id":"6796ff1c6e3a493283338ad1d76f2502","type":"GENE","name":"RNU7-57P","canonical_id":"hgnc:HGNC:34153","description":"RNA, U7 small nuclear 57 pseudogene","metadata":{"aliases":["U7.57"]}},{"id":"c8e254b8c80a41638b2db24033e71165","type":"GENE","name":"RNU7-58P","canonical_id":"hgnc:HGNC:34154","description":"RNA, U7 small nuclear 58 pseudogene","metadata":{"aliases":["U7.58"]}},{"id":"96aaeabf4bb24348b572746f4e01b422","type":"GENE","name":"RNU7-59P","canonical_id":"hgnc:HGNC:34155","description":"RNA, U7 small nuclear 59 pseudogene","metadata":{"aliases":["U7.59"]}},{"id":"e277a8f56a8a438ebbb1665602374dfc","type":"GENE","name":"RNU7-5P","canonical_id":"hgnc:HGNC:34101","description":"RNA, U7 small nuclear 5 pseudogene","metadata":{"aliases":["U7.5"]}},{"id":"3d8bf3e768a346fc84685a34f1310975","type":"GENE","name":"RNU7-60P","canonical_id":"hgnc:HGNC:34156","description":"RNA, U7 small nuclear 60 pseudogene","metadata":{"aliases":["U7.60"]}},{"id":"f3ff0c8271ea4fc3b0acf93c88c5d612","type":"GENE","name":"RNU7-61P","canonical_id":"hgnc:HGNC:34157","description":"RNA, U7 small nuclear 61 pseudogene","metadata":{"aliases":["U7.61"]}},{"id":"2f8e50c3b3334409809657c7c261e021","type":"GENE","name":"RNU7-62P","canonical_id":"hgnc:HGNC:34158","description":"RNA, U7 small nuclear 62 pseudogene","metadata":{"aliases":["U7.62"]}},{"id":"2abeb3b1b90d4abb8bc6c06bb8569578","type":"GENE","name":"RNU7-63P","canonical_id":"hgnc:HGNC:34159","description":"RNA, U7 small nuclear 63 pseudogene","metadata":{"aliases":["U7.63"]}},{"id":"db3fd6ff263c425ea6dab622c86a0566","type":"GENE","name":"RNU7-64P","canonical_id":"hgnc:HGNC:34160","description":"RNA, U7 small nuclear 64 pseudogene","metadata":{"aliases":["U7.64"]}},{"id":"f18f17612eed4b619656ea6756f2027e","type":"GENE","name":"RNU7-65P","canonical_id":"hgnc:HGNC:34161","description":"RNA, U7 small nuclear 65 pseudogene","metadata":{"aliases":["U7.65"]}},{"id":"0f5e518ed70041f3987fbf13a170f8e1","type":"GENE","name":"RNU7-66P","canonical_id":"hgnc:HGNC:34162","description":"RNA, U7 small nuclear 66 pseudogene","metadata":{"aliases":["U7.66"]}},{"id":"9752a9313f494702ae0e125774d7b8f5","type":"GENE","name":"RNU7-67P","canonical_id":"hgnc:HGNC:34163","description":"RNA, U7 small nuclear 67 pseudogene","metadata":{"aliases":["U7.67"]}},{"id":"572cfa9f52b448eca405addc9a0948b4","type":"GENE","name":"RNU7-68P","canonical_id":"hgnc:HGNC:10236","description":"RNA, U7 small nuclear 68 pseudogene","metadata":{"aliases":["HSU7.732A","U7.68","RNU7P1"]}},{"id":"d744c037ed7e4d6282f40042163095b8","type":"GENE","name":"RNU7-69P","canonical_id":"hgnc:HGNC:34165","description":"RNA, U7 small nuclear 69 pseudogene","metadata":{"aliases":["U7.69"]}},{"id":"5ba02e8d0d8e4f14bf47ab73c5db81be","type":"GENE","name":"RNU7-6P","canonical_id":"hgnc:HGNC:34102","description":"RNA, U7 small nuclear 6 pseudogene","metadata":{"aliases":["U7.6"]}},{"id":"5c92d550a4aa49108bf0cca9321b489d","type":"GENE","name":"RNU7-70P","canonical_id":"hgnc:HGNC:34166","description":"RNA, U7 small nuclear 70 pseudogene","metadata":{"aliases":["U7.70"]}},{"id":"46a6be25a1c2494584ee8e63a4e3b06b","type":"GENE","name":"RNU7-71P","canonical_id":"hgnc:HGNC:34167","description":"RNA, U7 small nuclear 71 pseudogene","metadata":{"aliases":["U7.71"]}},{"id":"a6742c315ed24223a1e9ea9e4d440a54","type":"GENE","name":"RNU7-72P","canonical_id":"hgnc:HGNC:34168","description":"RNA, U7 small nuclear 72 pseudogene","metadata":{"aliases":["U7.72"]}},{"id":"cfc32290c37b4a9eaf0c903c0d279f3e","type":"GENE","name":"RNU7-73P","canonical_id":"hgnc:HGNC:34169","description":"RNA, U7 small nuclear 73 pseudogene","metadata":{"aliases":["U7.73"]}},{"id":"cffa84d46a6342bcae9b5c7bd6c1754a","type":"GENE","name":"RNU7-74P","canonical_id":"hgnc:HGNC:34170","description":"RNA, U7 small nuclear 74 pseudogene","metadata":{"aliases":["U7.74"]}},{"id":"49939476cc224d8a8f55b2d2feccef66","type":"GENE","name":"RNU7-75P","canonical_id":"hgnc:HGNC:34171","description":"RNA, U7 small nuclear 75 pseudogene","metadata":{"aliases":["U7.75"]}},{"id":"ac893e3107044c388337e6412bd207cd","type":"GENE","name":"RNU7-76P","canonical_id":"hgnc:HGNC:34172","description":"RNA, U7 small nuclear 76 pseudogene","metadata":{"aliases":["U7.76"]}},{"id":"a997a643e06842f78fb3b84a091d4a08","type":"GENE","name":"RNU7-77P","canonical_id":"hgnc:HGNC:34173","description":"RNA, U7 small nuclear 77 pseudogene","metadata":{"aliases":["U7.77"]}},{"id":"e9582c2628f440afb3838dcf860a1bb2","type":"GENE","name":"RNU7-78P","canonical_id":"hgnc:HGNC:34174","description":"RNA, U7 small nuclear 78 pseudogene","metadata":{"aliases":["U7.78"]}},{"id":"0d4215e427f44c359341dd2e430e4c01","type":"GENE","name":"RNU7-79P","canonical_id":"hgnc:HGNC:34175","description":"RNA, U7 small nuclear 79 pseudogene","metadata":{"aliases":["U7.79"]}},{"id":"1fca9ca4a30e4d14897c97e953cc9821","type":"GENE","name":"RNU7-7P","canonical_id":"hgnc:HGNC:34103","description":"RNA, U7 small nuclear 7 pseudogene","metadata":{"aliases":["U7.7"]}},{"id":"8c7208a870b44a29a47566a5e9bd2bb6","type":"GENE","name":"RNU7-80P","canonical_id":"hgnc:HGNC:34176","description":"RNA, U7 small nuclear 80 pseudogene","metadata":{"aliases":["U7.80"]}},{"id":"cfac0a2e163449059f4ef70a5565c8f1","type":"GENE","name":"RNU7-81P","canonical_id":"hgnc:HGNC:34177","description":"RNA, U7 small nuclear 81 pseudogene","metadata":{"aliases":["U7.81"]}},{"id":"4b6ea91fe18344ca9abaf4eaec713ad5","type":"GENE","name":"RNU7-82P","canonical_id":"hgnc:HGNC:34178","description":"RNA, U7 small nuclear 82 pseudogene","metadata":{"aliases":["U7.82","RNU7-163P"]}},{"id":"b2e471aa35e143db99aaac84591c74ba","type":"GENE","name":"RNU7-83P","canonical_id":"hgnc:HGNC:34179","description":"RNA, U7 small nuclear 83 pseudogene","metadata":{"aliases":["U7.83"]}},{"id":"0ddbdc7a71e64ab0ad5ad15d8dc6546d","type":"GENE","name":"RNU7-84P","canonical_id":"hgnc:HGNC:34180","description":"RNA, U7 small nuclear 84 pseudogene","metadata":{"aliases":["U7.84"]}},{"id":"8ddd8b7fd2e74a4e983c63dd292dbd40","type":"GENE","name":"RNU7-85P","canonical_id":"hgnc:HGNC:34181","description":"RNA, U7 small nuclear 85 pseudogene","metadata":{"aliases":["U7.85"]}},{"id":"b644b6185b694c20a43419494cd07d58","type":"GENE","name":"RNU7-86P","canonical_id":"hgnc:HGNC:10237","description":"RNA, U7 small nuclear 86 pseudogene","metadata":{"aliases":["HSU7.7/32B","RNU7P2"]}},{"id":"a78b40f5dd8f4494b7cf0637c9f24709","type":"GENE","name":"RNU7-87P","canonical_id":"hgnc:HGNC:42616","description":"RNA, U7 small nuclear 87 pseudogene","metadata":null},{"id":"5219869ce66646e0b104cf486994c04d","type":"GENE","name":"RNU7-88P","canonical_id":"hgnc:HGNC:42617","description":"RNA, U7 small nuclear 88 pseudogene","metadata":null},{"id":"f2f62ef5a7474cf7a6768b6ba546bc57","type":"GENE","name":"RNU7-89P","canonical_id":"hgnc:HGNC:42618","description":"RNA, U7 small nuclear 89 pseudogene","metadata":null},{"id":"b897faf4714e4516815be9e6e776598b","type":"GENE","name":"RNU7-8P","canonical_id":"hgnc:HGNC:34104","description":"RNA, U7 small nuclear 8 pseudogene","metadata":{"aliases":["U7.8","RNU7-139P"]}},{"id":"f371167e4131415198f81ab5608949b8","type":"GENE","name":"RNU7-90P","canonical_id":"hgnc:HGNC:45624","description":"RNA, U7 small nuclear 90 pseudogene","metadata":null},{"id":"108a1df9e3ad4a3e87c2adafb86f2c4d","type":"GENE","name":"RNU7-92P","canonical_id":"hgnc:HGNC:45626","description":"RNA, U7 small nuclear 92 pseudogene","metadata":null},{"id":"9d59bd830bc14142ab962153ae65d2e5","type":"GENE","name":"RNU7-93P","canonical_id":"hgnc:HGNC:45627","description":"RNA, U7 small nuclear 93 pseudogene","metadata":null},{"id":"b433bf21dce2437e9e30a4486dd8daa2","type":"GENE","name":"RNU7-94P","canonical_id":"hgnc:HGNC:45628","description":"RNA, U7 small nuclear 94 pseudogene","metadata":null},{"id":"be11f99b7fa64f34bc14b6b52547bbf7","type":"GENE","name":"RNU7-95P","canonical_id":"hgnc:HGNC:45629","description":"RNA, U7 small nuclear 95 pseudogene","metadata":null},{"id":"2c738ee79fad41cf9c5e3b254c33c17e","type":"GENE","name":"RNU7-96P","canonical_id":"hgnc:HGNC:45630","description":"RNA, U7 small nuclear 96 pseudogene","metadata":null},{"id":"e736182274f64bf9b9c2ca5f82e95fbc","type":"GENE","name":"RNU7-97P","canonical_id":"hgnc:HGNC:45631","description":"RNA, U7 small nuclear 97 pseudogene","metadata":null},{"id":"2e4a443be5344814b6ef344cbeade722","type":"GENE","name":"RNU7-99P","canonical_id":"hgnc:HGNC:45633","description":"RNA, U7 small nuclear 99 pseudogene","metadata":null},{"id":"82762a7dc0524feea4a560b3d94cf000","type":"GENE","name":"RNU7-9P","canonical_id":"hgnc:HGNC:34105","description":"RNA, U7 small nuclear 9 pseudogene","metadata":{"aliases":["U7.9"]}},{"id":"1708a107b70b4ef297a46df652e6d6b6","type":"GENE","name":"RNVU1-1","canonical_id":"hgnc:HGNC:10133","description":"RNA, variant U1 small nuclear 1","metadata":{"aliases":["vU1.1","U1P14","U1.4","vU1.10","RNU1-53","RNU1P10","RNU1-10P","RNVU1-10"]}},{"id":"7a381fa6256c44ea933ce634cb0155c0","type":"GENE","name":"RNVU1-14","canonical_id":"hgnc:HGNC:48319","description":"RNA, variant U1 small nuclear 14","metadata":{"aliases":["vU1.14","RNU1-37"]}},{"id":"66cac69502bd44dfb3bc90673a5a5415","type":"GENE","name":"RNVU1-15","canonical_id":"hgnc:HGNC:48320","description":"RNA, variant U1 small nuclear 15","metadata":{"aliases":["vU1.15","RNU1-66","vU1.16","RNU1-121","RNVU1-16"]}},{"id":"7611d231ccb640c0ad5e24d83a6e004f","type":"GENE","name":"RNVU1-17","canonical_id":"hgnc:HGNC:48322","description":"RNA, variant U1 small nuclear 17","metadata":{"aliases":["vU1.17","RNU1-127"]}},{"id":"484596802085441a94b7ce5dd54937c1","type":"GENE","name":"RNVU1-18","canonical_id":"hgnc:HGNC:37496","description":"RNA, variant U1 small nuclear 18","metadata":{"aliases":["vU1.18","U1P101","U1P15","U1.15","RNU1P1","RNU1-5","RNU1-25","RNU1-25P"]}},{"id":"416785e0123341238d65394ea023b3de","type":"GENE","name":"RNVU1-19","canonical_id":"hgnc:HGNC:48324","description":"RNA, variant U1 small nuclear 19","metadata":{"aliases":["vU1.19","RNU1-126","vU1.13","RNU1-147","RNVU1-13"]}},{"id":"a594c71866b344d78d92c7c2dcb2ab76","type":"GENE","name":"RNVU1-2","canonical_id":"hgnc:HGNC:48308","description":"RNA, variant U1 small nuclear 2","metadata":{"aliases":["vU1.2","RNU1-71","U1P1","U1.1","vU1.11","U1P2A","RNU1-13P","RNU1P6","RNVU1-11","RNU1P2","RNU1-12P"]}},{"id":"ba348d04ac3c46e6a5de9ba2bb69b281","type":"GENE","name":"RNVU1-20","canonical_id":"hgnc:HGNC:48325","description":"RNA, variant U1 small nuclear 20","metadata":{"aliases":["vU1.20","RNU1-110"]}},{"id":"6f11cd548f6f4ce7b9e2a19399b21799","type":"GENE","name":"RNVU1-21","canonical_id":"hgnc:HGNC:48464","description":"RNA, variant U1 small nuclear 21","metadata":{"aliases":["RNU1-122P"]}},{"id":"8addb65f992e46afa26ab45617d9807d","type":"GENE","name":"RNVU1-22","canonical_id":"hgnc:HGNC:48462","description":"RNA, variant U1 small nuclear 22","metadata":{"aliases":["RNU1-120P"]}},{"id":"0993b6ad0afe4718bf509b744271f213","type":"GENE","name":"RNVU1-23","canonical_id":"hgnc:HGNC:48434","description":"RNA, variant U1 small nuclear 23","metadata":{"aliases":["RNU1-92P"]}},{"id":"0565cfa5d0ad4a17980ec31bf5f8c479","type":"GENE","name":"RNVU1-24","canonical_id":"hgnc:HGNC:48401","description":"RNA, variant U1 small nuclear 24","metadata":{"aliases":["RNU1-59P"]}},{"id":"2ba9a1153e8f479088700ad4c9dfd905","type":"GENE","name":"RNVU1-25","canonical_id":"hgnc:HGNC:54428","description":"RNA, variant U1 small nuclear 25","metadata":null},{"id":"459e27b5c93445b0894919e1dfbd306f","type":"GENE","name":"RNVU1-26","canonical_id":"hgnc:HGNC:54429","description":"RNA, variant U1 small nuclear 26","metadata":null},{"id":"2c35698d010f455e8ed5616cba680801","type":"GENE","name":"RNVU1-27","canonical_id":"hgnc:HGNC:54431","description":"RNA, variant U1 small nuclear 27","metadata":null},{"id":"e305580dbd8342a6acce881fcf6f0a5e","type":"GENE","name":"RNVU1-28","canonical_id":"hgnc:HGNC:54432","description":"RNA, variant U1 small nuclear 28","metadata":null},{"id":"1255dd8e78534123aee40af1670c0ba0","type":"GENE","name":"RNVU1-29","canonical_id":"hgnc:HGNC:54433","description":"RNA, variant U1 small nuclear 29","metadata":null},{"id":"93eb1fa263014b0cb9fcfa22e5e87e04","type":"GENE","name":"RNVU1-2A","canonical_id":"hgnc:HGNC:54430","description":"RNA, variant U1 small nuclear 2A","metadata":{"aliases":["vU1.2a","RNVU1.2a"]}},{"id":"58f050cf871a416fa22ba8b56e1067db","type":"GENE","name":"RNVU1-3","canonical_id":"hgnc:HGNC:48311","description":"RNA, variant U1 small nuclear 3","metadata":{"aliases":["vU1.3","RNU1-113","vU1.12","RNU1-151","RNVU1-12"]}},{"id":"82f1c3eb7be54df8aec01f56e7b75366","type":"GENE","name":"RNVU1-30","canonical_id":"hgnc:HGNC:54434","description":"RNA, variant U1 small nuclear 30","metadata":null},{"id":"31a23514fe8544a282354a30ba7e4b77","type":"GENE","name":"RNVU1-31","canonical_id":"hgnc:HGNC:54448","description":"RNA, variant U1 small nuclear 31","metadata":null},{"id":"6b21250c5b684aa885a47df30c67c09a","type":"GENE","name":"RNVU1-32","canonical_id":"hgnc:HGNC:48448","description":"RNA, variant U1 small nuclear 32","metadata":{"aliases":["U1A4","RNU1-106P"]}},{"id":"b5c219a3048746548d072878dc911255","type":"GENE","name":"RNVU1-33","canonical_id":"hgnc:HGNC:48429","description":"RNA, variant U1 small nuclear 33","metadata":{"aliases":["U1A5","RNU1-87P"]}},{"id":"3a4095227b4b473e98bea9f147122eb9","type":"GENE","name":"RNVU1-34","canonical_id":"hgnc:HGNC:48427","description":"RNA, variant U1 small nuclear 34","metadata":{"aliases":["U1A7","RNU1-85P"]}},{"id":"09050e35985a473cac604964a1c03b1e","type":"GENE","name":"RNVU1-4","canonical_id":"hgnc:HGNC:48312","description":"RNA, variant U1 small nuclear 4","metadata":{"aliases":["vU1.4","RNU1-102","vU1.5","RNU1-50","RNVU1-5"]}},{"id":"fcc73fbabb5f44dca20f4c7e9d68dd77","type":"GENE","name":"RNVU1-6","canonical_id":"hgnc:HGNC:48314","description":"RNA, variant U1 small nuclear 6","metadata":{"aliases":["vU1.6","RNU1-99"]}},{"id":"6ff5251f691b491d916b919691d1135d","type":"GENE","name":"RNVU1-7","canonical_id":"hgnc:HGNC:37500","description":"RNA, variant U1 small nuclear 7","metadata":{"aliases":["vU1.7","vU1.9","RNU1-9","RNU1-9P","RNVU1-9","RNU1-6P","RNU1-26P"]}},{"id":"b81eb5cff7534547826ed85cd3891bdf","type":"GENE","name":"RNVU1-8","canonical_id":"hgnc:HGNC:48315","description":"RNA, variant U1 small nuclear 8","metadata":{"aliases":["vU1.8","RNU1-145"]}},{"id":"ef6fcdfb95a546a1a0b4340f50336978","type":"GENE","name":"RNY1","canonical_id":"hgnc:HGNC:10242","description":"RNA, Ro60-associated Y1","metadata":{"aliases":["hY1"]}},{"id":"b5bf775f65e042ebbe7255bcd0d4effd","type":"GENE","name":"RNY1P1","canonical_id":"hgnc:HGNC:42478","description":"RNY1 pseudogene 1","metadata":null},{"id":"d13b4d583c7548f4a2bab3d8832cd26d","type":"GENE","name":"RNY1P10","canonical_id":"hgnc:HGNC:50873","description":"RNY1 pseudogene 10","metadata":null},{"id":"1f846d964aa842878f048bcd77c41212","type":"GENE","name":"RNY1P11","canonical_id":"hgnc:HGNC:50874","description":"RNY1 pseudogene 11","metadata":null},{"id":"22645c7be84048c69ecd31b2c4e721ad","type":"GENE","name":"RNY1P12","canonical_id":"hgnc:HGNC:50875","description":"RNY1 pseudogene 12","metadata":null},{"id":"3b37aa58dc8643a4994707d0551d8664","type":"GENE","name":"RNY1P13","canonical_id":"hgnc:HGNC:50876","description":"RNY1 pseudogene 13","metadata":null},{"id":"a31fd0cb997a4a5ba522f57cc4cd0a2f","type":"GENE","name":"RNY1P14","canonical_id":"hgnc:HGNC:50877","description":"RNY1 pseudogene 14","metadata":null},{"id":"4e3defe68883483eb2049da37c49f9ae","type":"GENE","name":"RNY1P15","canonical_id":"hgnc:HGNC:50878","description":"RNY1 pseudogene 15","metadata":null},{"id":"ecd01420e1b44a9d98eddbc51e80b61f","type":"GENE","name":"RNY1P16","canonical_id":"hgnc:HGNC:50879","description":"RNY1 pseudogene 16","metadata":null},{"id":"e9a61fddaf534f1c9bc1d5c63b316dee","type":"GENE","name":"RNY1P2","canonical_id":"hgnc:HGNC:42479","description":"RNY1 pseudogene 2","metadata":null},{"id":"9e6391207b184e089f1af7f5427ca7eb","type":"GENE","name":"RNY1P3","canonical_id":"hgnc:HGNC:42480","description":"RNY1 pseudogene 3","metadata":null},{"id":"261d5e224eaa4ce999ed47c6638c1e4c","type":"GENE","name":"RNY1P4","canonical_id":"hgnc:HGNC:42481","description":"RNY1 pseudogene 4","metadata":null},{"id":"75135064f0c74f829e5062254b6deff8","type":"GENE","name":"RNY1P5","canonical_id":"hgnc:HGNC:42482","description":"RNY1 pseudogene 5","metadata":null},{"id":"60baffa894d64084949b8f7192048a57","type":"GENE","name":"RNY1P6","canonical_id":"hgnc:HGNC:42483","description":"RNY1 pseudogene 6","metadata":null},{"id":"1ce10eb3674a4371836c94f1f5eb2879","type":"GENE","name":"RNY1P7","canonical_id":"hgnc:HGNC:42484","description":"RNY1 pseudogene 7","metadata":null},{"id":"bfb1707b30754901b1167e1ba412b1be","type":"GENE","name":"RNY1P8","canonical_id":"hgnc:HGNC:42485","description":"RNY1 pseudogene 8","metadata":null},{"id":"8f3e5f91edc94c0fac8176a46f55da84","type":"GENE","name":"RNY1P9","canonical_id":"hgnc:HGNC:41481","description":"RNY1 pseudogene 9","metadata":{"aliases":["KLHL22-IT1","RNYP1"]}},{"id":"1c9f99df5aac411ea10a8a4291fce560","type":"GENE","name":"RNY3","canonical_id":"hgnc:HGNC:10243","description":"RNA, Ro60-associated Y3","metadata":{"aliases":["hY3"]}},{"id":"e5afac222624463d85ef774c4eaf6434","type":"GENE","name":"RNY3P1","canonical_id":"hgnc:HGNC:42477","description":"RNY3 pseudogene 1","metadata":null},{"id":"889fb736213c42059478360e83415055","type":"GENE","name":"RNY3P10","canonical_id":"hgnc:HGNC:42494","description":"RNY3 pseudogene 10","metadata":null},{"id":"4dfd2bdc50f74703be17576337a5ea6e","type":"GENE","name":"RNY3P11","canonical_id":"hgnc:HGNC:50887","description":"RNY3 pseudogene 11","metadata":null},{"id":"1db7d36050ff4d698072d1ad3d7f199d","type":"GENE","name":"RNY3P12","canonical_id":"hgnc:HGNC:50888","description":"RNY3 pseudogene 12","metadata":null},{"id":"eb71deaed85b4e8c8a65b03ac26e2fe2","type":"GENE","name":"RNY3P13","canonical_id":"hgnc:HGNC:50889","description":"RNY3 pseudogene 13","metadata":null},{"id":"045c0ee41bfd4c678a8a9bac07e5c25c","type":"GENE","name":"RNY3P14","canonical_id":"hgnc:HGNC:50893","description":"RNY3 pseudogene 14","metadata":null},{"id":"6a9e47eb036f4d3ca5b60719dfa2c050","type":"GENE","name":"RNY3P15","canonical_id":"hgnc:HGNC:50890","description":"RNY3 pseudogene 15","metadata":null},{"id":"c3a769aadf984bfc8278ff5c9cd2fe1b","type":"GENE","name":"RNY3P16","canonical_id":"hgnc:HGNC:50891","description":"RNY3 pseudogene 16","metadata":null},{"id":"7ae0019ea30d4400b9d2ada5ce50bfb6","type":"GENE","name":"RNY3P2","canonical_id":"hgnc:HGNC:42486","description":"RNY3 pseudogene 2","metadata":null},{"id":"a50eaa37fcf040468a85e42b37f713b3","type":"GENE","name":"RNY3P3","canonical_id":"hgnc:HGNC:42487","description":"RNY3 pseudogene 3","metadata":null},{"id":"fd2dc796416e4ce3b38299260e096d63","type":"GENE","name":"RNY3P4","canonical_id":"hgnc:HGNC:42488","description":"RNY3 pseudogene 4","metadata":null},{"id":"013a86e53bf84480ba7f3ce82ec12855","type":"GENE","name":"RNY3P5","canonical_id":"hgnc:HGNC:42489","description":"RNY3 pseudogene 5","metadata":null},{"id":"25c4039a650b483986a9c3946a937bed","type":"GENE","name":"RNY3P6","canonical_id":"hgnc:HGNC:42490","description":"RNY3 pseudogene 6","metadata":null},{"id":"1eb1ba87afa94879beff801f62539bec","type":"GENE","name":"RNY3P7","canonical_id":"hgnc:HGNC:42491","description":"RNY3 pseudogene 7","metadata":null},{"id":"beed40f5ee0948f59577c2aa277103c9","type":"GENE","name":"RNY3P8","canonical_id":"hgnc:HGNC:42492","description":"RNY3 pseudogene 8","metadata":null},{"id":"b455f81a7bc94f80867aabf88e76e09f","type":"GENE","name":"RNY3P9","canonical_id":"hgnc:HGNC:42493","description":"RNY3 pseudogene 9","metadata":null},{"id":"081932d2aaa7459c821c4abc6df83b36","type":"GENE","name":"RNY4","canonical_id":"hgnc:HGNC:10244","description":"RNA, Ro60-associated Y4","metadata":{"aliases":["hY4"]}},{"id":"96800030228d43fa9b847a257241c19a","type":"GENE","name":"RNY4P1","canonical_id":"hgnc:HGNC:10245","description":"RNY4 pseudogene 1","metadata":{"aliases":["hY4.B8"]}},{"id":"dea1f7479ba3486bbff588960191b0ba","type":"GENE","name":"RNY4P10","canonical_id":"hgnc:HGNC:34060","description":"RNY4 pseudogene 10","metadata":null},{"id":"7afd3d7772ab4ecc966448ec31f64a5e","type":"GENE","name":"RNY4P11","canonical_id":"hgnc:HGNC:34061","description":"RNY4 pseudogene 11","metadata":null},{"id":"f7519f3c337d48bc80ece3112e7aa270","type":"GENE","name":"RNY4P13","canonical_id":"hgnc:HGNC:34063","description":"RNY4 pseudogene 13","metadata":null},{"id":"d7d57243159d4a40ac76e45dada5909f","type":"GENE","name":"RNY4P14","canonical_id":"hgnc:HGNC:34064","description":"RNY4 pseudogene 14","metadata":null},{"id":"2b4c05b486d74be88669720bf2781856","type":"GENE","name":"RNY4P15","canonical_id":"hgnc:HGNC:34065","description":"RNY4 pseudogene 15","metadata":null},{"id":"6349013bd80c4bc08e93407704b89d01","type":"GENE","name":"RNY4P16","canonical_id":"hgnc:HGNC:34066","description":"RNY4 pseudogene 16","metadata":null},{"id":"dd1f2981b416443cab8f27f391c058ef","type":"GENE","name":"RNY4P17","canonical_id":"hgnc:HGNC:34067","description":"RNY4 pseudogene 17","metadata":null},{"id":"8309a18317174829abfff22e9419b0b0","type":"GENE","name":"RNY4P18","canonical_id":"hgnc:HGNC:34068","description":"RNY4 pseudogene 18","metadata":null},{"id":"763b91cc7dcf4a8e8c9a8c1a9e28a2d0","type":"GENE","name":"RNY4P19","canonical_id":"hgnc:HGNC:34069","description":"RNY4 pseudogene 19","metadata":null},{"id":"44d10777eb9a4acb9cdb6f4c4e3922e6","type":"GENE","name":"RNY4P2","canonical_id":"hgnc:HGNC:10246","description":"RNY4 pseudogene 2","metadata":{"aliases":["hY4.B7"]}},{"id":"654ab278cad446238c0e418efa11405a","type":"GENE","name":"RNY4P20","canonical_id":"hgnc:HGNC:34070","description":"RNY4 pseudogene 20","metadata":null},{"id":"422a0b551a9d4f1f8c000b76a815ac1f","type":"GENE","name":"RNY4P21","canonical_id":"hgnc:HGNC:42471","description":"RNY4 pseudogene 21","metadata":null},{"id":"454fde71ee264775ad71e250217233c0","type":"GENE","name":"RNY4P22","canonical_id":"hgnc:HGNC:42472","description":"RNY4 pseudogene 22","metadata":null},{"id":"5c0bb89e93fb47359dfa5370ada9b28a","type":"GENE","name":"RNY4P23","canonical_id":"hgnc:HGNC:42473","description":"RNY4 pseudogene 23","metadata":null},{"id":"65e527f4f16345f1a610fd728c9dee0d","type":"GENE","name":"RNY4P24","canonical_id":"hgnc:HGNC:42474","description":"RNY4 pseudogene 24","metadata":null},{"id":"c2f3edbbd9d54033b5eb2148b47f13d1","type":"GENE","name":"RNY4P25","canonical_id":"hgnc:HGNC:42475","description":"RNY4 pseudogene 25","metadata":null},{"id":"be2ad9adb32243f2a9aed6c11b115a93","type":"GENE","name":"RNY4P26","canonical_id":"hgnc:HGNC:42476","description":"RNY4 pseudogene 26","metadata":null},{"id":"a19b58e0ae5d4d09801426f12e1ebc5e","type":"GENE","name":"RNY4P27","canonical_id":"hgnc:HGNC:42495","description":"RNY4 pseudogene 27","metadata":null},{"id":"b40c3bc38c834d8f939c7d12d87634d3","type":"GENE","name":"RNY4P28","canonical_id":"hgnc:HGNC:42496","description":"RNY4 pseudogene 28","metadata":null},{"id":"77d5c48cf17c4bbbbe69b1731f4b3f4b","type":"GENE","name":"RNY4P29","canonical_id":"hgnc:HGNC:42497","description":"RNY4 pseudogene 29","metadata":null},{"id":"e238e3f02a304cd1aa840f45dc6e5012","type":"GENE","name":"RNY4P3","canonical_id":"hgnc:HGNC:10247","description":"RNY4 pseudogene 3","metadata":{"aliases":["hY4.F2"]}},{"id":"4a96f5d3e8274895aef310dd58a3d3e5","type":"GENE","name":"RNY4P30","canonical_id":"hgnc:HGNC:42498","description":"RNY4 pseudogene 30","metadata":null},{"id":"1db74f13f7a14bf2a6b556401e57d6fb","type":"GENE","name":"RNY4P31","canonical_id":"hgnc:HGNC:42499","description":"RNY4 pseudogene 31","metadata":null},{"id":"bdaa8885203e4f8ebb09d0128efa1ae3","type":"GENE","name":"RNY4P34","canonical_id":"hgnc:HGNC:50882","description":"RNY4 pseudogene 34","metadata":null},{"id":"e14c1c46792f466da27dfbac812a55c4","type":"GENE","name":"RNY4P36","canonical_id":"hgnc:HGNC:50884","description":"RNY4 pseudogene 36","metadata":null},{"id":"23af6be4b6e148bfa1f853f895c46379","type":"GENE","name":"RNY4P37","canonical_id":"hgnc:HGNC:50885","description":"RNY4 pseudogene 37","metadata":null},{"id":"129fac967ccc42d08aecb88e80027724","type":"GENE","name":"RNY4P4","canonical_id":"hgnc:HGNC:34050","description":"RNY4 pseudogene 4","metadata":null},{"id":"e2a2f390c94848e4a82901089166f16c","type":"GENE","name":"RNY4P5","canonical_id":"hgnc:HGNC:34052","description":"RNY4 pseudogene 5","metadata":null},{"id":"28ae7c99a6204a94aa70cbdf67980984","type":"GENE","name":"RNY4P6","canonical_id":"hgnc:HGNC:34055","description":"RNY4 pseudogene 6","metadata":null},{"id":"fe41a2b739504c478b805bf8119d95a4","type":"GENE","name":"RNY4P7","canonical_id":"hgnc:HGNC:34056","description":"RNY4 pseudogene 7","metadata":null},{"id":"27201becebad408bb7aa43a9ea1af020","type":"GENE","name":"RNY4P8","canonical_id":"hgnc:HGNC:34057","description":"RNY4 pseudogene 8","metadata":null},{"id":"a57b4c7b0aee48df82c9f148753c6e2c","type":"GENE","name":"RNY4P9","canonical_id":"hgnc:HGNC:34058","description":"RNY4 pseudogene 9","metadata":null},{"id":"718e385f69fa4a68a112fc5120025921","type":"GENE","name":"RNY5","canonical_id":"hgnc:HGNC:10248","description":"RNA, Ro60-associated Y5","metadata":{"aliases":["hY5"]}},{"id":"0af2e64d1d964d9ca382e4990cc65e5e","type":"GENE","name":"RNY5P1","canonical_id":"hgnc:HGNC:34082","description":"RNY5 pseudogene 1","metadata":null},{"id":"1e9fedf114964dbe8280354281259fb3","type":"GENE","name":"RNY5P10","canonical_id":"hgnc:HGNC:34091","description":"RNY5 pseudogene 10","metadata":null},{"id":"82187776895441e2b8a3b0ea78074571","type":"GENE","name":"RNY5P2","canonical_id":"hgnc:HGNC:34083","description":"RNY5 pseudogene 2","metadata":null},{"id":"496254ad4380402187bc3ad65bc76557","type":"GENE","name":"RNY5P3","canonical_id":"hgnc:HGNC:34084","description":"RNY5 pseudogene 3","metadata":null},{"id":"35c2487bf53a49509611af7666741a3a","type":"GENE","name":"RNY5P4","canonical_id":"hgnc:HGNC:34085","description":"RNY5 pseudogene 4","metadata":null},{"id":"53988c1d9ab547cf83bd65892291ebf5","type":"GENE","name":"RNY5P5","canonical_id":"hgnc:HGNC:34086","description":"RNY5 pseudogene 5","metadata":null},{"id":"c4498f97531f484b8efe269d1e8b911e","type":"GENE","name":"RNY5P6","canonical_id":"hgnc:HGNC:34087","description":"RNY5 pseudogene 6","metadata":null},{"id":"a93f35d8315142a297da26080ef85ed5","type":"GENE","name":"RNY5P7","canonical_id":"hgnc:HGNC:34088","description":"RNY5 pseudogene 7","metadata":null},{"id":"c3c38141068248e3af206d3cb987526c","type":"GENE","name":"RNY5P8","canonical_id":"hgnc:HGNC:34089","description":"RNY5 pseudogene 8","metadata":null},{"id":"24e393a40b5247ee80af43c7a74a8b7c","type":"GENE","name":"RNY5P9","canonical_id":"hgnc:HGNC:34090","description":"RNY5 pseudogene 9","metadata":null},{"id":"7bc23e34823844fcbc0f3257f2e12d83","type":"TRIAL","name":"RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT01071564","description":"Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma","metadata":null},{"id":"2861d47db4ac41df8b52ec3995814afc","type":"GENE","name":"RO60","canonical_id":"hgnc:HGNC:11313","description":"Ro60, Y RNA binding protein","metadata":{"aliases":["SSA2","TROVE2"]}},{"id":"fedb7c6024074e2faa9923a71dee4cae","type":"TRIAL","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","canonical_id":"clinicaltrials.gov:NCT07413939","description":"HER2-positive Breast Cancer","metadata":null},{"id":"583378ca576a469d8fef4b6af23129da","type":"GENE","name":"ROBO1","canonical_id":"hgnc:HGNC:10249","description":"roundabout guidance receptor 1","metadata":{"aliases":["DUTT1","FLJ21882","SAX3"]}},{"id":"c9bc3aa9afb443f98c33f146ff75a1ac","type":"GENE","name":"ROBO2","canonical_id":"hgnc:HGNC:10250","description":"roundabout guidance receptor 2","metadata":{"aliases":["KIAA1568"]}},{"id":"bf04fc822b8d458197b6e7743612cf1a","type":"GENE","name":"ROBO2P1","canonical_id":"hgnc:HGNC:44386","description":"roundabout guidance receptor 2 pseudogene 1","metadata":null},{"id":"2009ac77b5274476a6bfbb451d27d5b5","type":"GENE","name":"ROBO3","canonical_id":"hgnc:HGNC:13433","description":"roundabout guidance receptor 3","metadata":{"aliases":["RBIG1","FLJ21044","HGPS","HGPPS"]}},{"id":"72980cb511644a09827592fd25090f36","type":"GENE","name":"ROBO4","canonical_id":"hgnc:HGNC:17985","description":"roundabout guidance receptor 4","metadata":{"aliases":["FLJ20798","MRB","ECSM4"]}},{"id":"071f2b5f4b854f7e9493da76627c4428","type":"GENE","name":"ROCK1","canonical_id":"hgnc:HGNC:10251","description":"Rho associated coiled-coil containing protein kinase 1","metadata":{"aliases":["p160ROCK"]}},{"id":"a3260d94530b4590a219682f1c452ac8","type":"GENE","name":"ROCK1P1","canonical_id":"hgnc:HGNC:37832","description":"Rho associated coiled-coil containing protein kinase 1 pseudogene 1","metadata":null},{"id":"5544bebf94434967b430f3cd3f5968ca","type":"GENE","name":"ROCK2","canonical_id":"hgnc:HGNC:10252","description":"Rho associated coiled-coil containing protein kinase 2","metadata":null},{"id":"baacea18c03547a3a0a514ade5cd1626","type":"PROTEIN","name":"ROCK2","canonical_id":"uniprot:O75116","description":null,"metadata":null},{"id":"9fb5734574724ec6bf7b4c9240454a6a","type":"GENE","name":"ROCR","canonical_id":"hgnc:HGNC:52946","description":"regulator of chondrogenesis RNA","metadata":{"aliases":["LINC02095"]}},{"id":"a4787770f35d44c2b20ec43e582b2b4c","type":"GENE","name":"ROGDI","canonical_id":"hgnc:HGNC:29478","description":"rogdi atypical leucine zipper","metadata":{"aliases":["FLJ22386","ROGD1","RAV2"]}},{"id":"78630b66a3c048e3a3d28e66b86ff40a","type":"GENE","name":"ROM1","canonical_id":"hgnc:HGNC:10254","description":"retinal outer segment membrane protein 1","metadata":{"aliases":["TSPAN23","ROM"]}},{"id":"bb51bada3b6b498a97f05f63db6dbc15","type":"GENE","name":"ROMO1","canonical_id":"hgnc:HGNC:16185","description":"reactive oxygen species modulator 1","metadata":{"aliases":["bA353C18.2","MTGMP","C20orf52"]}},{"id":"adaae56363f6449296d8a8133a2b9180","type":"GENE","name":"ROPN1","canonical_id":"hgnc:HGNC:17692","description":"rhophilin associated tail protein 1","metadata":{"aliases":["ODF6","ropporin","ROPN1A","CT91"]}},{"id":"5c2f971f0c0c45e283069c734792ef68","type":"GENE","name":"ROPN1B","canonical_id":"hgnc:HGNC:31927","description":"rhophilin associated tail protein 1B","metadata":null},{"id":"987aa5cf2e55474d803a5acbfaed8f9e","type":"GENE","name":"ROPN1L","canonical_id":"hgnc:HGNC:24060","description":"rhophilin associated tail protein 1 like","metadata":{"aliases":["ASP","FLJ25776","RSPH11","RP11-1C1.7","TCONS_00009352","LINC01513"]}},{"id":"6450494a59664bd58d54eb4902d22703","type":"GENE","name":"ROPN1L-AS1","canonical_id":"hgnc:HGNC:39984","description":"ROPN1L antisense RNA 1","metadata":null},{"id":"87de2da073854509899b7c3b9d01c067","type":"GENE","name":"ROR1","canonical_id":"hgnc:HGNC:10256","description":null,"metadata":null},{"id":"f47d66bcb1074e659ece52d46c750a7f","type":"GENE","name":"ROR1-AS1","canonical_id":"hgnc:HGNC:40508","description":"ROR1 antisense RNA 1","metadata":null},{"id":"67986a2157484843a65d0d7701e5f6b6","type":"GENE","name":"ROR2","canonical_id":"hgnc:HGNC:10257","description":"ROR family WNT receptor 2","metadata":{"aliases":["NTRKR2","BDB","BDB1"]}},{"id":"09856f411285487b9c0d00f59aef9179","type":"GENE","name":"RORA","canonical_id":"hgnc:HGNC:10258","description":null,"metadata":null},{"id":"9d6389aa64634b9795de299b5980a93e","type":"GENE","name":"RORA-AS1","canonical_id":"hgnc:HGNC:51410","description":"RORA antisense RNA 1","metadata":null},{"id":"0a43cd179b604b0bb18ba77d029b71ee","type":"GENE","name":"RORA-AS2","canonical_id":"hgnc:HGNC:51411","description":"RORA antisense RNA 2","metadata":null},{"id":"e64b05b19b1741b1b010f8cb2e48cc9a","type":"GENE","name":"RORA-AS3","canonical_id":"hgnc:HGNC:51412","description":"RORA antisense RNA 3","metadata":null},{"id":"f7c8b9678b3c4ae483ac7210fb856d3e","type":"GENE","name":"RORA-AS4","canonical_id":"hgnc:HGNC:58471","description":"RORA antisense RNA 4","metadata":null},{"id":"cf0811e921d94914bc67c8516e7c5580","type":"GENE","name":"RORB","canonical_id":"hgnc:HGNC:10259","description":"RAR related orphan receptor B","metadata":{"aliases":["RZRB","NR1F2","ROR-BETA","ROR\u03b2","RZR-BETA"]}},{"id":"d24a3b43b5614ef083849e686cae0b06","type":"GENE","name":"RORB-AS1","canonical_id":"hgnc:HGNC:49803","description":"RORB antisense RNA 1","metadata":null},{"id":"cc5e505ffccb4deca17cd7493eeb8823","type":"GENE","name":"RORC","canonical_id":"hgnc:HGNC:10260","description":null,"metadata":null},{"id":"7aabd2292ba1479e83be319049271704","type":"GENE","name":"ROS1","canonical_id":"hgnc:HGNC:10261","description":null,"metadata":null},{"id":"4b8c2317333f457fa637a4c44920c4f7","type":"PROTEIN","name":"ROS1","canonical_id":"uniprot:P08922","description":null,"metadata":null},{"id":"7fa89969538044778c33fb370b997c03","type":"GENE","name":"ROS1","canonical_id":"ensembl:ENSG00000047936","description":null,"metadata":null},{"id":"1457550d3a0c44a8aca24d998d9d8e9a","type":"TRIAL","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07173751","description":"Breast Neoplasms","metadata":null},{"id":"469f9ad19c204af8a9c855845db17ea2","type":"GENE","name":"ROSSALIND","canonical_id":"hgnc:HGNC:52737","description":"reactive oxygen species scavenging lincRNA mitochondrial","metadata":{"aliases":["ROSALIND","LINC01918"]}},{"id":"aa4b919ac1fd46a18a0f388ce26d44d3","type":"TRIAL","name":"RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia","canonical_id":"clinicaltrials.gov:NCT07596485","description":"Trigeminal Neuralgia","metadata":null},{"id":"20ec9fa2efff491884ced1b986a7ca43","type":"GENE","name":"RP1","canonical_id":"hgnc:HGNC:10263","description":null,"metadata":null},{"id":"ad6cabc04cf6478eb4272d618d9c9e13","type":"GENE","name":"RP1L1","canonical_id":"hgnc:HGNC:15946","description":"RP1 like 1","metadata":{"aliases":["DCDC4B"]}},{"id":"df940572b46b43c8898948e2e96edbdf","type":"GENE","name":"RP2","canonical_id":"hgnc:HGNC:10274","description":"RP2 activator of ARL3 GTPase","metadata":{"aliases":["TBCCD2","NME10","NM23-H10"]}},{"id":"afdf5e64732b44c3a054745d20677272","type":"TRIAL","name":"RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy","canonical_id":"clinicaltrials.gov:NCT07218692","description":"Advanced Clear Cell Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8","metadata":null},{"id":"2096c7f3477145fa98a12c880d1a8bae","type":"TRIAL","name":"RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT01490086","description":"Acute Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"668afe328a7a4030a670f89ceb037329","type":"GENE","name":"RP9","canonical_id":"hgnc:HGNC:10288","description":"RP9 pre-mRNA splicing factor","metadata":{"aliases":["PAP-1"]}},{"id":"a1b8254d51d44f80a58d312727097b7a","type":"GENE","name":"RP9P","canonical_id":"hgnc:HGNC:33969","description":"RP9 pseudogene","metadata":null},{"id":"cc42ab41608941a195e0d0ef22db6342","type":"GENE","name":"RPA1","canonical_id":"hgnc:HGNC:10289","description":"replication protein A1","metadata":{"aliases":["REPA1","RPA70","HSSB","RF-A","RP-A"]}},{"id":"9d390586e6d64a42a2154c2b099f10b2","type":"GENE","name":"RPA2","canonical_id":"hgnc:HGNC:10290","description":null,"metadata":null},{"id":"1cf313f780ec41a0abce8bea9645ce52","type":"GENE","name":"RPA2P1","canonical_id":"hgnc:HGNC:19676","description":"replication protein A2 pseudogene 1","metadata":{"aliases":["RPA2P"]}},{"id":"86586d10a7e64a31b2695116a1e74251","type":"GENE","name":"RPA2P2","canonical_id":"hgnc:HGNC:45117","description":"replication protein A2 pseudogene 2","metadata":null},{"id":"8c3d13285c484f719509c8c033616e10","type":"GENE","name":"RPA2P3","canonical_id":"hgnc:HGNC:45118","description":"replication protein A2 pseudogene 3","metadata":null},{"id":"8e1c25c6977a4c45b7b3c9c9b5a7ab8d","type":"GENE","name":"RPA3","canonical_id":"hgnc:HGNC:10291","description":"replication protein A3","metadata":{"aliases":["REPA3"]}},{"id":"496a1fac126442e48f730543eaa343b9","type":"GENE","name":"RPA3P1","canonical_id":"hgnc:HGNC:54790","description":"RPA3 pseudogene 1","metadata":null},{"id":"772934740a114f188af02607194d745b","type":"GENE","name":"RPA3P2","canonical_id":"hgnc:HGNC:54791","description":"RPA3 pseudogene 2","metadata":null},{"id":"7f9d822d5f0742d3ab0ed98e655eb390","type":"GENE","name":"RPA4","canonical_id":"hgnc:HGNC:30305","description":"replication protein A4","metadata":{"aliases":["HSU24186"]}},{"id":"86f32b3264c04102a17fc6416a8458ad","type":"GENE","name":"RPAIN","canonical_id":"hgnc:HGNC:28641","description":"RPA interacting protein","metadata":{"aliases":["MGC4189","RIP","hRIP"]}},{"id":"37cadca04c8d422c9ee7b625a61bf2ec","type":"GENE","name":"RPAP1","canonical_id":"hgnc:HGNC:24567","description":"RNA polymerase II associated protein 1","metadata":{"aliases":["DKFZP727M111","KIAA1403","MGC858","FLJ12732"]}},{"id":"d6087a32ca8847eaa503365f4a41abfb","type":"GENE","name":"RPAP2","canonical_id":"hgnc:HGNC:25791","description":"RNA polymerase II associated protein 2","metadata":{"aliases":["FLJ13150","Rtr1","C1orf82"]}},{"id":"5de549f970904574b7bc06b831aa816d","type":"GENE","name":"RPAP2P1","canonical_id":"hgnc:HGNC:45125","description":"RNA polymerase II associated protein 2 pseudogene 1","metadata":null},{"id":"41d994377d7144619cb86e6160bfcab5","type":"GENE","name":"RPAP3","canonical_id":"hgnc:HGNC:26151","description":"RNA polymerase II associated protein 3","metadata":{"aliases":["FLJ21908","spag","hSpagh","Tah1"]}},{"id":"a0feacd4d003421686acd94b84e1bf80","type":"GENE","name":"RPAP3-DT","canonical_id":"hgnc:HGNC:55477","description":"RPAP3 divergent transcript","metadata":null},{"id":"336934ed833e417ab667618f74d85e44","type":"GO_TERM","name":"RPAP3/R2TP/prefoldin-like complex","canonical_id":"go:GO:1990062","description":"\"A protein complex first characterized in human and comprised of a R2TP module (R2TP complex), a prefoldin-like module (containing both prefoldin-like proteins and canonical prefoldins), WD40 repeat protein Monad/WDR92 and DNA-dependent RNA polymerase subunit RPB5. This complex might have chaperone activity.\" [GOC:pr, PMID:20453924, PMID:21925213, PMID:22418846]","metadata":null},{"id":"94f3461eeee349a48f3f4f4b6fbbd05e","type":"GO_TERM","name":"RPB4-RPB7 complex","canonical_id":"go:GO:1990328","description":"\"A protein complex that cycles between the nucleus where it is part of the RNA polymerase II and the cytoplasmic mRNA processing body where it mediates the two major cytoplasmic mRNA decay pathways.\" [GOC:bhm, PMID:15591044]","metadata":null},{"id":"c533028ea0984335aff5c3ccebef7e9e","type":"GENE","name":"RPE","canonical_id":"hgnc:HGNC:10293","description":"ribulose-5-phosphate-3-epimerase","metadata":null},{"id":"241e4cfb99cd43efab9787576e3419f6","type":"GENE","name":"RPE65","canonical_id":"hgnc:HGNC:10294","description":"retinoid isomerohydrolase RPE65","metadata":{"aliases":["LCA2","rd12","BCO3","RP20"]}},{"id":"769e55cc949d49b8a00a8b6631aa35d8","type":"GENE","name":"RPEL1","canonical_id":"hgnc:HGNC:45241","description":"ribulose-5-phosphate-3-epimerase like 1","metadata":null},{"id":"81a88621075e4e08b0a8a62c582d17b2","type":"GENE","name":"RPEP1","canonical_id":"hgnc:HGNC:44520","description":"ribulose-5-phosphate-3-epimerase pseudogene 1","metadata":null},{"id":"b1badf8673394fbbb7f88c453792aabf","type":"GENE","name":"RPEP2","canonical_id":"hgnc:HGNC:44521","description":"ribulose-5-phosphate-3-epimerase pseudogene 2","metadata":null},{"id":"0c3394bf31d245c2b085bcde2ce49937","type":"GENE","name":"RPEP3","canonical_id":"hgnc:HGNC:44522","description":"ribulose-5-phosphate-3-epimerase pseudogene 3","metadata":null},{"id":"6c2a1e6888f946c086fe405290337ecc","type":"GENE","name":"RPEP4","canonical_id":"hgnc:HGNC:44523","description":"ribulose-5-phosphate-3-epimerase pseudogene 4","metadata":null},{"id":"5cbb50dc0cdb4bcea2fe104dae4af8fc","type":"GENE","name":"RPEP5","canonical_id":"hgnc:HGNC:44524","description":"ribulose-5-phosphate-3-epimerase pseudogene 5","metadata":null},{"id":"f74e7b0e3ca24af38e87c93496bfd2fa","type":"GENE","name":"RPEP6","canonical_id":"hgnc:HGNC:44525","description":"ribulose-5-phosphate-3-epimerase pseudogene 6","metadata":null},{"id":"1b861b65dde643fcbf74720ce61ad9f4","type":"GENE","name":"RPF1","canonical_id":"hgnc:HGNC:30350","description":"ribosome production factor 1 homolog","metadata":{"aliases":["BXDC5"]}},{"id":"7c29b933df75476b99bff10c803c4fc3","type":"GENE","name":"RPF2","canonical_id":"hgnc:HGNC:20870","description":"ribosome production factor 2 homolog","metadata":{"aliases":["FLJ21087","bA397G5.4","BXDC1"]}},{"id":"5986041a585e4b98b573092266f5b912","type":"GENE","name":"RPF2P1","canonical_id":"hgnc:HGNC:16186","description":"ribosome production factor 2 homolog pseudogene 1","metadata":{"aliases":["bA353C18.4","C20orf53","BXDC1P","RPF2P"]}},{"id":"d0b37de0c88046b9b9bd42447b9b80d7","type":"GENE","name":"RPF2P2","canonical_id":"hgnc:HGNC:44015","description":"ribosome production factor 2 homolog pseudogene 2","metadata":null},{"id":"615abe277c09446abdf630adeb56dcc3","type":"GENE","name":"RPGR","canonical_id":"hgnc:HGNC:10295","description":"retinitis pigmentosa GTPase regulator","metadata":{"aliases":["CORDX1","CRD","RP3","RP15","COD1"]}},{"id":"3ced2fab4e1e4df690fc7f7f73fba2e1","type":"GENE","name":"RPGRIP1","canonical_id":"hgnc:HGNC:13436","description":"RPGR interacting protein 1","metadata":{"aliases":["RGI1","LCA6","CORD13","RPGRIP"]}},{"id":"29792176de7b4740b137988a908ac142","type":"GENE","name":"RPGRIP1L","canonical_id":"hgnc:HGNC:29168","description":"RPGRIP1 like","metadata":{"aliases":["KIAA1005","CORS3","JBTS7","MKS5","NPHP8","FTM","PPP1R134"]}},{"id":"cf39f9940be046bd94800bd52c68661c","type":"GENE","name":"RPH3A","canonical_id":"hgnc:HGNC:17056","description":"rabphilin 3A","metadata":{"aliases":["KIAA0985","rabphilin","exophilin-1"]}},{"id":"34b21522f1ef4a8e85efa4ca660d5d88","type":"GENE","name":"RPH3AL","canonical_id":"hgnc:HGNC:10296","description":"rabphilin 3A like (without C2 domains)","metadata":{"aliases":["Noc2"]}},{"id":"0b3cd3c4d6ca4a27bb865fad8a0c6128","type":"GENE","name":"RPH3AL-AS1","canonical_id":"hgnc:HGNC:55345","description":"RPH3AL antisense RNA 1","metadata":{"aliases":["AC129507.1"]}},{"id":"89c92e8dec0f4e73a199773d0547c079","type":"GENE","name":"RPH3AL-AS2","canonical_id":"hgnc:HGNC:56089","description":"RPH3AL antisense RNA 2","metadata":null},{"id":"ec59c10919c44158a21ef0fd172181e4","type":"GENE","name":"RPH3AL-AS3","canonical_id":"hgnc:HGNC:58550","description":"RPH3AL antisense RNA 3","metadata":null},{"id":"9acce355b269483bb9394c5eecfe90d6","type":"GENE","name":"RPIA","canonical_id":"hgnc:HGNC:10297","description":"ribose 5-phosphate isomerase A","metadata":null},{"id":"67f76525f5f2460ca146ecb3afcb441f","type":"GENE","name":"RPIAP1","canonical_id":"hgnc:HGNC:27250","description":"ribose 5-phosphate isomerase A pseudogene 1","metadata":null},{"id":"b270dddb16804fa4ab35b6647ebdfc60","type":"GENE","name":"RPL10","canonical_id":"hgnc:HGNC:10298","description":"ribosomal protein L10","metadata":{"aliases":["NOV","QM","DXS648E","DXS648","FLJ23544","L10","uL16"]}},{"id":"fb6515dd74de4419ac910d46e733584f","type":"GENE","name":"RPL10A","canonical_id":"hgnc:HGNC:10299","description":"ribosomal protein L10a","metadata":{"aliases":["Csa-19","L10A","uL1","NEDD6"]}},{"id":"d7798bb60a3d42b8ba4cd9642f8f049b","type":"GENE","name":"RPL10AP1","canonical_id":"hgnc:HGNC:19813","description":"ribosomal protein L10a pseudogene 1","metadata":null},{"id":"7d2bc36f646d4e1f8314577c42b46960","type":"GENE","name":"RPL10AP10","canonical_id":"hgnc:HGNC:35971","description":"ribosomal protein L10a pseudogene 10","metadata":null},{"id":"49bd90b48fcd427eb3940a3107b3111c","type":"GENE","name":"RPL10AP11","canonical_id":"hgnc:HGNC:35875","description":"ribosomal protein L10a pseudogene 11","metadata":null},{"id":"573425cfda594205b2624888ab9b2845","type":"GENE","name":"RPL10AP12","canonical_id":"hgnc:HGNC:36108","description":"ribosomal protein L10a pseudogene 12","metadata":null},{"id":"65f56ace6deb4dc4aaf7ec709b75cb33","type":"GENE","name":"RPL10AP13","canonical_id":"hgnc:HGNC:36155","description":"ribosomal protein L10a pseudogene 13","metadata":null},{"id":"3eaf315217a44bceb533237b1b159f64","type":"GENE","name":"RPL10AP2","canonical_id":"hgnc:HGNC:31081","description":"ribosomal protein L10a pseudogene 2","metadata":null},{"id":"9923cb6120784ba08ff05040ea24ca0b","type":"GENE","name":"RPL10AP3","canonical_id":"hgnc:HGNC:29803","description":"ribosomal protein L10a pseudogene 3","metadata":{"aliases":["HsT23218"]}},{"id":"fd9938bb7def4bbea62fc80c7f0b26e6","type":"GENE","name":"RPL10AP4","canonical_id":"hgnc:HGNC:35873","description":"ribosomal protein L10a pseudogene 4","metadata":null},{"id":"4c0b9c03c31f4f6389677b079d812cc5","type":"GENE","name":"RPL10AP5","canonical_id":"hgnc:HGNC:36770","description":"ribosomal protein L10a pseudogene 5","metadata":null},{"id":"9caffffc399048beab6de3121184d119","type":"GENE","name":"RPL10AP6","canonical_id":"hgnc:HGNC:36504","description":"ribosomal protein L10a pseudogene 6","metadata":null},{"id":"f9f507a2a4b74d94b879b87cbccde8c5","type":"GENE","name":"RPL10AP7","canonical_id":"hgnc:HGNC:35601","description":"ribosomal protein L10a pseudogene 7","metadata":null},{"id":"48872a216ed94711afae51c71a3baa6f","type":"GENE","name":"RPL10AP8","canonical_id":"hgnc:HGNC:36709","description":"ribosomal protein L10a pseudogene 8","metadata":null},{"id":"478016eb5a954f40b3f90b57be3290c7","type":"GENE","name":"RPL10AP9","canonical_id":"hgnc:HGNC:35947","description":"ribosomal protein L10a pseudogene 9","metadata":null},{"id":"7a3bef2f940c42eaadd6270d022246e2","type":"GENE","name":"RPL10L","canonical_id":"hgnc:HGNC:17976","description":"ribosomal protein L10 like","metadata":null},{"id":"8d5671a7a0e847fa9939b8b2c8395ca0","type":"GENE","name":"RPL10P1","canonical_id":"hgnc:HGNC:10300","description":"ribosomal protein L10 pseudogene 1","metadata":{"aliases":["RPL10P"]}},{"id":"7bed5d49108248efbdf2049185052460","type":"GENE","name":"RPL10P10","canonical_id":"hgnc:HGNC:35486","description":"ribosomal protein L10 pseudogene 10","metadata":null},{"id":"b230620a8b584239b1f7ab8b75abc614","type":"GENE","name":"RPL10P11","canonical_id":"hgnc:HGNC:36565","description":"ribosomal protein L10 pseudogene 11","metadata":null},{"id":"a0eb2ab0c484450a80fa78eb32164f6c","type":"GENE","name":"RPL10P12","canonical_id":"hgnc:HGNC:52345","description":"ribosomal protein L10 pseudogene 12","metadata":null},{"id":"a547774190a44fa9b75c7359f6dd4b7c","type":"GENE","name":"RPL10P13","canonical_id":"hgnc:HGNC:52346","description":"ribosomal protein L10 pseudogene 13","metadata":null},{"id":"88007a7600d642019b921b0d32692631","type":"GENE","name":"RPL10P14","canonical_id":"hgnc:HGNC:43897","description":"ribosomal protein L10 pseudogene 14","metadata":null},{"id":"9c15f0286bf94e7b9f093966d594a33b","type":"GENE","name":"RPL10P15","canonical_id":"hgnc:HGNC:52347","description":"ribosomal protein L10 pseudogene 15","metadata":null},{"id":"ab1f824f4bef44f2ae0de934c37c52bc","type":"GENE","name":"RPL10P16","canonical_id":"hgnc:HGNC:36882","description":"ribosomal protein L10 pseudogene 16","metadata":null},{"id":"f773411005ef4c4d8ba8919060590692","type":"GENE","name":"RPL10P17","canonical_id":"hgnc:HGNC:52348","description":"ribosomal protein L10 pseudogene 17","metadata":null},{"id":"c51db0d32a9f4f599afac15d0ffc3dd3","type":"GENE","name":"RPL10P18","canonical_id":"hgnc:HGNC:52349","description":"ribosomal protein L10 pseudogene 18","metadata":null},{"id":"474abd402cc340009ed172475e70db76","type":"GENE","name":"RPL10P19","canonical_id":"hgnc:HGNC:52350","description":"ribosomal protein L10 pseudogene 19","metadata":null},{"id":"286f9f3d2dea4c109f56c75271a89ce4","type":"GENE","name":"RPL10P2","canonical_id":"hgnc:HGNC:13975","description":"ribosomal protein L10 pseudogene 2","metadata":{"aliases":["RPL10p","bA209A2.1"]}},{"id":"68e6817e22cd4ab1b12af714ba999e47","type":"GENE","name":"RPL10P3","canonical_id":"hgnc:HGNC:23300","description":"ribosomal protein L10 pseudogene 3","metadata":{"aliases":["bA567J2.2"]}},{"id":"16682e528be44acca54feda9818400d4","type":"GENE","name":"RPL10P4","canonical_id":"hgnc:HGNC:52342","description":"ribosomal protein L10 pseudogene 4","metadata":null},{"id":"91561dba95f54c7b9248a222f59b84c8","type":"GENE","name":"RPL10P5","canonical_id":"hgnc:HGNC:35724","description":"ribosomal protein L10 pseudogene 5","metadata":null},{"id":"6902999f4be7456da74e248adf155ca6","type":"GENE","name":"RPL10P6","canonical_id":"hgnc:HGNC:52343","description":"ribosomal protein L10 pseudogene 6","metadata":null},{"id":"cb7da742c95b4fdab4eea8472d68b7c5","type":"GENE","name":"RPL10P7","canonical_id":"hgnc:HGNC:35974","description":"ribosomal protein L10 pseudogene 7","metadata":null},{"id":"ed836a2a64494f6b85a0cfbbf9c126b6","type":"GENE","name":"RPL10P8","canonical_id":"hgnc:HGNC:52344","description":"ribosomal protein L10 pseudogene 8","metadata":null},{"id":"5e126a8ea1ae44d99c846a0277458fbf","type":"GENE","name":"RPL10P9","canonical_id":"hgnc:HGNC:35579","description":"ribosomal protein L10 pseudogene 9","metadata":null},{"id":"ebc02e90da7c4c5da71c21361e57c793","type":"GENE","name":"RPL11","canonical_id":"hgnc:HGNC:10301","description":"ribosomal protein L11","metadata":{"aliases":["L11","uL5"]}},{"id":"46285cd87a7040d48de136f9cb4e81f4","type":"GENE","name":"RPL11P1","canonical_id":"hgnc:HGNC:37021","description":"ribosomal protein L11 pseudogene 1","metadata":null},{"id":"4743bdf3a28140178b7b3ff9b0c8bef4","type":"GENE","name":"RPL11P2","canonical_id":"hgnc:HGNC:36983","description":"ribosomal protein L11 pseudogene 2","metadata":null},{"id":"0d6d0536851e468ea90bc27314418411","type":"GENE","name":"RPL11P3","canonical_id":"hgnc:HGNC:36342","description":"ribosomal protein L11 pseudogene 3","metadata":null},{"id":"289a6b6f843f4e94873e4d3c3ea23da0","type":"GENE","name":"RPL11P4","canonical_id":"hgnc:HGNC:36137","description":"ribosomal protein L11 pseudogene 4","metadata":null},{"id":"302c3cea38994ad389953665fdcf7dbf","type":"GENE","name":"RPL11P5","canonical_id":"hgnc:HGNC:36849","description":"ribosomal protein L11 pseudogene 5","metadata":null},{"id":"afa03b6030924cfea478246b174eabda","type":"GENE","name":"RPL12","canonical_id":"hgnc:HGNC:10302","description":"ribosomal protein L12","metadata":{"aliases":["L12","uL11"]}},{"id":"aaa21efd7a3f43feb520fe3662ca78bf","type":"GENE","name":"RPL12P1","canonical_id":"hgnc:HGNC:13976","description":"ribosomal protein L12 pseudogene 1","metadata":{"aliases":["RPL12-L","dJ570F3.5","CICK0721Q.1"]}},{"id":"2d1d4b9c86ca4d53b11c341a6edf326d","type":"GENE","name":"RPL12P10","canonical_id":"hgnc:HGNC:22583","description":"ribosomal protein L12 pseudogene 10","metadata":{"aliases":["TCAG_1783340"]}},{"id":"94a491f246154b52a2b29e02168792ad","type":"GENE","name":"RPL12P11","canonical_id":"hgnc:HGNC:15835","description":"ribosomal protein L12 pseudogene 11","metadata":{"aliases":["dJ661I20.1","RPL12L2"]}},{"id":"bf21a4da70a5450e91d121e338c739da","type":"GENE","name":"RPL12P12","canonical_id":"hgnc:HGNC:15951","description":"ribosomal protein L12 pseudogene 12","metadata":{"aliases":["dJ999L4.1","RPL12L3"]}},{"id":"00f9cc81e1ac43959e4cec3d0b4ab6b3","type":"GENE","name":"RPL12P13","canonical_id":"hgnc:HGNC:51936","description":"ribosomal protein L12 pseudogene 13","metadata":null},{"id":"d54173280856438995078e53303ea377","type":"GENE","name":"RPL12P14","canonical_id":"hgnc:HGNC:36495","description":"ribosomal protein L12 pseudogene 14","metadata":null},{"id":"6c666bd739ac41109db099e4b5586c0a","type":"GENE","name":"RPL12P15","canonical_id":"hgnc:HGNC:36619","description":"ribosomal protein L12 pseudogene 15","metadata":null},{"id":"826dcbc755cb467380823bab4bd76301","type":"GENE","name":"RPL12P16","canonical_id":"hgnc:HGNC:36926","description":"ribosomal protein L12 pseudogene 16","metadata":null},{"id":"d13ff3af285b4aa5a004702fcd336e81","type":"GENE","name":"RPL12P17","canonical_id":"hgnc:HGNC:36263","description":"ribosomal protein L12 pseudogene 17","metadata":null},{"id":"70f4d8fdfbb04fb78e156a3b3308b89b","type":"GENE","name":"RPL12P18","canonical_id":"hgnc:HGNC:36750","description":"ribosomal protein L12 pseudogene 18","metadata":null},{"id":"291cdd4e9af549adbb0f5462016472a4","type":"GENE","name":"RPL12P19","canonical_id":"hgnc:HGNC:36248","description":"ribosomal protein L12 pseudogene 19","metadata":null},{"id":"c8cb6e22f63341118b2c1a955c37cd2e","type":"GENE","name":"RPL12P2","canonical_id":"hgnc:HGNC:16070","description":"ribosomal protein L12 pseudogene 2","metadata":{"aliases":["dJ441G21.1"]}},{"id":"9d99bd4839844c88b86e43597b7ad702","type":"GENE","name":"RPL12P20","canonical_id":"hgnc:HGNC:36968","description":"ribosomal protein L12 pseudogene 20","metadata":null},{"id":"229028a92ceb409c88432776646856cb","type":"GENE","name":"RPL12P21","canonical_id":"hgnc:HGNC:36845","description":"ribosomal protein L12 pseudogene 21","metadata":null},{"id":"549ff1d881554a62894968cced0b52bc","type":"GENE","name":"RPL12P22","canonical_id":"hgnc:HGNC:35762","description":"ribosomal protein L12 pseudogene 22","metadata":null},{"id":"e663bb462ef64da69baef917c21ea7ce","type":"GENE","name":"RPL12P23","canonical_id":"hgnc:HGNC:36408","description":"ribosomal protein L12 pseudogene 23","metadata":null},{"id":"9f8fbdb2d8b246c5b657c94e1e00f199","type":"GENE","name":"RPL12P24","canonical_id":"hgnc:HGNC:35952","description":"ribosomal protein L12 pseudogene 24","metadata":null},{"id":"ee52d52d81b74645be922344e4e7c19c","type":"GENE","name":"RPL12P25","canonical_id":"hgnc:HGNC:37008","description":"ribosomal protein L12 pseudogene 25","metadata":null},{"id":"e6b37d0c6e0c4002946903e6cd298fe1","type":"GENE","name":"RPL12P26","canonical_id":"hgnc:HGNC:36811","description":"ribosomal protein L12 pseudogene 26","metadata":null},{"id":"6d605863c6c1439aa6ffdd0a0e39299e","type":"GENE","name":"RPL12P27","canonical_id":"hgnc:HGNC:36916","description":"ribosomal protein L12 pseudogene 27","metadata":null},{"id":"06702682fe974c23bd4c8543e96283ec","type":"GENE","name":"RPL12P28","canonical_id":"hgnc:HGNC:36818","description":"ribosomal protein L12 pseudogene 28","metadata":null},{"id":"ac50dad4fb2046dba7bbb75c96dd126b","type":"GENE","name":"RPL12P29","canonical_id":"hgnc:HGNC:35791","description":"ribosomal protein L12 pseudogene 29","metadata":null},{"id":"319f2488039b405393b03dcae9ede348","type":"GENE","name":"RPL12P3","canonical_id":"hgnc:HGNC:16335","description":"ribosomal protein L12 pseudogene 3","metadata":{"aliases":["bA49G10.7"]}},{"id":"8fd7c9b651b246bcb1f900018b1cca35","type":"GENE","name":"RPL12P30","canonical_id":"hgnc:HGNC:35970","description":"ribosomal protein L12 pseudogene 30","metadata":null},{"id":"3bf7b96eb5ea4c1098f3f0fd15b63c1c","type":"GENE","name":"RPL12P31","canonical_id":"hgnc:HGNC:37025","description":"ribosomal protein L12 pseudogene 31","metadata":null},{"id":"bc2b043a055e4310b43f296dadd482cb","type":"GENE","name":"RPL12P32","canonical_id":"hgnc:HGNC:36597","description":"ribosomal protein L12 pseudogene 32","metadata":null},{"id":"25f0239220654317b55dc4d4b186cae2","type":"GENE","name":"RPL12P33","canonical_id":"hgnc:HGNC:35696","description":"ribosomal protein L12 pseudogene 33","metadata":null},{"id":"b244d7f905b847208c9c667ebc152d06","type":"GENE","name":"RPL12P34","canonical_id":"hgnc:HGNC:36168","description":"ribosomal protein L12 pseudogene 34","metadata":null},{"id":"7e634e9619fc479dbeb128a7c03d4626","type":"GENE","name":"RPL12P35","canonical_id":"hgnc:HGNC:35969","description":"ribosomal protein L12 pseudogene 35","metadata":null},{"id":"665a07f5acf84a70987ef76fd47352b8","type":"GENE","name":"RPL12P36","canonical_id":"hgnc:HGNC:36598","description":"ribosomal protein L12 pseudogene 36","metadata":null},{"id":"e761b8061cd0450d8fe9dff7c0e34edf","type":"GENE","name":"RPL12P37","canonical_id":"hgnc:HGNC:35565","description":"ribosomal protein L12 pseudogene 37","metadata":null},{"id":"782f1eaa3f6b4b19a20057bad23dc715","type":"GENE","name":"RPL12P38","canonical_id":"hgnc:HGNC:36838","description":"ribosomal protein L12 pseudogene 38","metadata":null},{"id":"c8d17f25098045cf8b893c88125ff7ec","type":"GENE","name":"RPL12P39","canonical_id":"hgnc:HGNC:35976","description":"ribosomal protein L12 pseudogene 39","metadata":null},{"id":"af4ef23c2719456cbac804dc6ed7dbd4","type":"GENE","name":"RPL12P4","canonical_id":"hgnc:HGNC:16587","description":"ribosomal protein L12 pseudogene 4","metadata":{"aliases":["dJ800C24.1"]}},{"id":"0746ace9777b42d1a577e53003ddff35","type":"GENE","name":"RPL12P40","canonical_id":"hgnc:HGNC:36439","description":"ribosomal protein L12 pseudogene 40","metadata":null},{"id":"8365d257f0f54c5bb73ac9505c5fd79c","type":"GENE","name":"RPL12P41","canonical_id":"hgnc:HGNC:35999","description":"ribosomal protein L12 pseudogene 41","metadata":null},{"id":"eac9b585b7b243d4bbef40c19cabc82f","type":"GENE","name":"RPL12P42","canonical_id":"hgnc:HGNC:36165","description":"ribosomal protein L12 pseudogene 42","metadata":null},{"id":"05fd3c9b330a4892bddb7893d417f438","type":"GENE","name":"RPL12P43","canonical_id":"hgnc:HGNC:35840","description":"ribosomal protein L12 pseudogene 43","metadata":null},{"id":"1f66a22b546c49e9b4e164c45a35f96b","type":"GENE","name":"RPL12P44","canonical_id":"hgnc:HGNC:44603","description":"ribosomal protein L12 pseudogene 44","metadata":null},{"id":"26eba6f7e9054d3695ae44126f4f37be","type":"GENE","name":"RPL12P45","canonical_id":"hgnc:HGNC:51937","description":"ribosomal protein L12 pseudogene 45","metadata":null},{"id":"410510b4089446c6bac292e4914ff644","type":"GENE","name":"RPL12P46","canonical_id":"hgnc:HGNC:51938","description":"ribosomal protein L12 pseudogene 46","metadata":null},{"id":"5621b607cca64b498fe53636f3060ccc","type":"GENE","name":"RPL12P47","canonical_id":"hgnc:HGNC:51939","description":"ribosomal protein L12 pseudogene 47","metadata":null},{"id":"cdbe7416bfcd4ef4a263ec3e56cbfa59","type":"GENE","name":"RPL12P48","canonical_id":"hgnc:HGNC:51940","description":"ribosomal protein L12 pseudogene 48","metadata":null},{"id":"ac04857c7903449b858bf8ce1e916294","type":"GENE","name":"RPL12P49","canonical_id":"hgnc:HGNC:51941","description":"ribosomal protein L12 pseudogene 49","metadata":null},{"id":"f3de584f474746c78cb117fc1bc97ade","type":"GENE","name":"RPL12P5","canonical_id":"hgnc:HGNC:19669","description":"ribosomal protein L12 pseudogene 5","metadata":null},{"id":"a6639ea5008c4351bd85b58012cbda70","type":"GENE","name":"RPL12P50","canonical_id":"hgnc:HGNC:51942","description":"ribosomal protein L12 pseudogene 50","metadata":null},{"id":"696d032b4eb04db0911110376966ee3c","type":"GENE","name":"RPL12P6","canonical_id":"hgnc:HGNC:23538","description":"ribosomal protein L12 pseudogene 6","metadata":null},{"id":"63e00ded256f432c953c66cb72965202","type":"GENE","name":"RPL12P7","canonical_id":"hgnc:HGNC:19782","description":"ribosomal protein L12 pseudogene 7","metadata":null},{"id":"aa9333ec324e4800af1cb07cdd7fac7b","type":"GENE","name":"RPL12P8","canonical_id":"hgnc:HGNC:23735","description":"ribosomal protein L12 pseudogene 8","metadata":{"aliases":["bA57G10.3"]}},{"id":"f896dc51d3c644c49f9f3729ff48b772","type":"GENE","name":"RPL12P9","canonical_id":"hgnc:HGNC:23766","description":"ribosomal protein L12 pseudogene 9","metadata":null},{"id":"21ed20f32d6c45fb9b18c7a15419c41b","type":"GENE","name":"RPL13","canonical_id":"hgnc:HGNC:10303","description":"ribosomal protein L13","metadata":{"aliases":["D16S444E","BBC1","L13","eL13"]}},{"id":"588f5514f4644548ad1253318a9b4b74","type":"GENE","name":"RPL13A","canonical_id":"hgnc:HGNC:10304","description":"ribosomal protein L13a","metadata":{"aliases":["L13A","uL13","TSTA1"]}},{"id":"682b3aa1d1ed4c80b29d3ecea0d49fe9","type":"GENE","name":"RPL13AP","canonical_id":"hgnc:HGNC:13977","description":"ribosomal protein L13a pseudogene","metadata":{"aliases":["dJ271M21.3"]}},{"id":"5015ee9e355e4b128a198c7930951236","type":"GENE","name":"RPL13AP10","canonical_id":"hgnc:HGNC:36864","description":"ribosomal protein L13a pseudogene 10","metadata":null},{"id":"2622cbed31214efcb454fd8442391995","type":"GENE","name":"RPL13AP11","canonical_id":"hgnc:HGNC:36566","description":"ribosomal protein L13a pseudogene 11","metadata":null},{"id":"ad960ccae3284a2b87b2b9579d149d5e","type":"GENE","name":"RPL13AP12","canonical_id":"hgnc:HGNC:35673","description":"ribosomal protein L13a pseudogene 12","metadata":null},{"id":"daf7114a89fd45f3b571d343218aabc7","type":"GENE","name":"RPL13AP13","canonical_id":"hgnc:HGNC:36541","description":"ribosomal protein L13a pseudogene 13","metadata":null},{"id":"4848b010b4874637961a46f46913a1a6","type":"GENE","name":"RPL13AP14","canonical_id":"hgnc:HGNC:36360","description":"ribosomal protein L13a pseudogene 14","metadata":null},{"id":"5fb25674a72045768bb5036521a0364e","type":"GENE","name":"RPL13AP15","canonical_id":"hgnc:HGNC:36883","description":"ribosomal protein L13a pseudogene 15","metadata":null},{"id":"5baaf71635e44560af821c46e436bdbf","type":"GENE","name":"RPL13AP16","canonical_id":"hgnc:HGNC:35722","description":"ribosomal protein L13a pseudogene 16","metadata":null},{"id":"cabe6657b45b40cb909fc147fb5ca9ec","type":"GENE","name":"RPL13AP17","canonical_id":"hgnc:HGNC:36167","description":"ribosomal protein L13a pseudogene 17","metadata":null},{"id":"a3d156d17c0745ddab55adbe27a0fa37","type":"GENE","name":"RPL13AP18","canonical_id":"hgnc:HGNC:36593","description":"ribosomal protein L13a pseudogene 18","metadata":null},{"id":"7b374929b3d14af1b1a98a4df78668a8","type":"GENE","name":"RPL13AP19","canonical_id":"hgnc:HGNC:35855","description":"ribosomal protein L13a pseudogene 19","metadata":null},{"id":"b57e26cc2b854865ac42b9836d4f01ef","type":"GENE","name":"RPL13AP2","canonical_id":"hgnc:HGNC:19675","description":"ribosomal protein L13a pseudogene 2","metadata":null},{"id":"6ab524e45d844a02927e97732662b4f2","type":"GENE","name":"RPL13AP20","canonical_id":"hgnc:HGNC:35709","description":"ribosomal protein L13a pseudogene 20","metadata":{"aliases":["HANR"]}},{"id":"9cce9abc143c4c4793fe900a85afbf8c","type":"GENE","name":"RPL13AP21","canonical_id":"hgnc:HGNC:35654","description":"ribosomal protein L13a pseudogene 21","metadata":null},{"id":"6228d9b6270f41ea893455c9a3382af2","type":"GENE","name":"RPL13AP22","canonical_id":"hgnc:HGNC:35825","description":"ribosomal protein L13a pseudogene 22","metadata":null},{"id":"157f1c4ce204444dad6679d84a426693","type":"GENE","name":"RPL13AP23","canonical_id":"hgnc:HGNC:36498","description":"ribosomal protein L13a pseudogene 23","metadata":null},{"id":"a011fb036c6f4126863c0a9bad4d8b80","type":"GENE","name":"RPL13AP24","canonical_id":"hgnc:HGNC:36209","description":"ribosomal protein L13a pseudogene 24","metadata":null},{"id":"478b5642aa0b452296aee4f3d0aac5f4","type":"GENE","name":"RPL13AP25","canonical_id":"hgnc:HGNC:36981","description":"ribosomal protein L13a pseudogene 25","metadata":null},{"id":"610589b0bb5647e685dffdf26fff22de","type":"GENE","name":"RPL13AP26","canonical_id":"hgnc:HGNC:35492","description":"ribosomal protein L13a pseudogene 26","metadata":null},{"id":"b6ca2b7ae0024fa0b6272e3a03b25d37","type":"GENE","name":"RPL13AP27","canonical_id":"hgnc:HGNC:56393","description":"ribosomal protein L13a pseudogene 27","metadata":null},{"id":"2d1edb2b4cd44a86ae1d0b7f28250dc6","type":"GENE","name":"RPL13AP3","canonical_id":"hgnc:HGNC:23539","description":"ribosomal protein L13a pseudogene 3","metadata":null},{"id":"5e3308ab19fb4222875390bb824328c5","type":"GENE","name":"RPL13AP5","canonical_id":"hgnc:HGNC:23736","description":"ribosomal protein L13a pseudogene 5","metadata":{"aliases":["bA196N24.2"]}},{"id":"21001b563b6049e594bda607263dceab","type":"GENE","name":"RPL13AP6","canonical_id":"hgnc:HGNC:23737","description":"ribosomal protein L13a pseudogene 6","metadata":{"aliases":["bA348N5.5"]}},{"id":"50c901b3f1764ef18430aca7b591b35e","type":"GENE","name":"RPL13AP7","canonical_id":"hgnc:HGNC:23755","description":"ribosomal protein L13a pseudogene 7","metadata":null},{"id":"d3dca7db448b4df8bba66d893075b15e","type":"GENE","name":"RPL13AP8","canonical_id":"hgnc:HGNC:36966","description":"ribosomal protein L13a pseudogene 8","metadata":null},{"id":"49e8432cc1684da0969683a563c35158","type":"GENE","name":"RPL13AP9","canonical_id":"hgnc:HGNC:36341","description":"ribosomal protein L13a pseudogene 9","metadata":null},{"id":"09fb81b5835e4970829bf84bf5cd9910","type":"GENE","name":"RPL13P","canonical_id":"hgnc:HGNC:13978","description":"ribosomal protein L13 pseudogene","metadata":{"aliases":["BBC1p","dJ111M5.1"]}},{"id":"ebfe6fdf40854f9f8b24ccc8634f9847","type":"GENE","name":"RPL13P10","canonical_id":"hgnc:HGNC:35943","description":"ribosomal protein L13 pseudogene 10","metadata":null},{"id":"fca0fd108f8048f88cb40b60c4293f80","type":"GENE","name":"RPL13P11","canonical_id":"hgnc:HGNC:35805","description":"ribosomal protein L13 pseudogene 11","metadata":null},{"id":"bd323660e40d474c80a8930b61e5ab7e","type":"GENE","name":"RPL13P12","canonical_id":"hgnc:HGNC:35701","description":"ribosomal protein L13 pseudogene 12","metadata":null},{"id":"24948b3fa1d84621aedec1c3259aa1da","type":"GENE","name":"RPL13P13","canonical_id":"hgnc:HGNC:36832","description":"ribosomal protein L13 pseudogene 13","metadata":null},{"id":"df768509f1004f84921696ed4458e128","type":"GENE","name":"RPL13P14","canonical_id":"hgnc:HGNC:36387","description":"ribosomal protein L13 pseudogene 14","metadata":null},{"id":"0f233332a72c4d178e5a98881922de90","type":"GENE","name":"RPL13P2","canonical_id":"hgnc:HGNC:16342","description":"ribosomal protein L13 pseudogene 2","metadata":{"aliases":["dJ599F21.2","RPL13P3"]}},{"id":"4645abe2544640fab78e792d7bf91cad","type":"GENE","name":"RPL13P4","canonical_id":"hgnc:HGNC:31027","description":"ribosomal protein L13 pseudogene 4","metadata":{"aliases":["HsT16723"]}},{"id":"828eec54c30b4dae95c00c5ed7d28094","type":"GENE","name":"RPL13P5","canonical_id":"hgnc:HGNC:30363","description":"ribosomal protein L13 pseudogene 5","metadata":{"aliases":["RPL13-2","RPL13L"]}},{"id":"239441ecfdf64ad29c31b1701d798fb4","type":"GENE","name":"RPL13P6","canonical_id":"hgnc:HGNC:19809","description":"ribosomal protein L13 pseudogene 6","metadata":{"aliases":["RPL13AP4"]}},{"id":"be40e7d567964e8e95fc91e7ec1883d0","type":"GENE","name":"RPL13P7","canonical_id":"hgnc:HGNC:35510","description":"ribosomal protein L13 pseudogene 7","metadata":null},{"id":"e43bf29e1874484d80878a25cb99b94d","type":"GENE","name":"RPL13P8","canonical_id":"hgnc:HGNC:35513","description":"ribosomal protein L13 pseudogene 8","metadata":null},{"id":"b253840af08f435690f11261fe28266d","type":"GENE","name":"RPL13P9","canonical_id":"hgnc:HGNC:36587","description":"ribosomal protein L13 pseudogene 9","metadata":null},{"id":"678413fddaad4bc8af7fed769e4169d2","type":"GENE","name":"RPL14","canonical_id":"hgnc:HGNC:10305","description":"ribosomal protein L14","metadata":{"aliases":["L14","hRL14","RL14","CTG-B33","eL14"]}},{"id":"25bef98a062f4441a4ed99cd797a781b","type":"GENE","name":"RPL14P1","canonical_id":"hgnc:HGNC:31384","description":"ribosomal protein L14 pseudogene 1","metadata":{"aliases":["bcm1298","RPL14L"]}},{"id":"58f3dcebd3004e0a9aa19593f2d2a52d","type":"GENE","name":"RPL14P2","canonical_id":"hgnc:HGNC:35962","description":"ribosomal protein L14 pseudogene 2","metadata":null},{"id":"4b09b50f3e754bbf9a3d0aa360514bfc","type":"GENE","name":"RPL14P3","canonical_id":"hgnc:HGNC:36638","description":"ribosomal protein L14 pseudogene 3","metadata":null},{"id":"f594aae991b84515b8ae14e59bf0c81a","type":"GENE","name":"RPL14P4","canonical_id":"hgnc:HGNC:35663","description":"ribosomal protein L14 pseudogene 4","metadata":null},{"id":"7d0dcaeed0d5437e9a011fc0d5c1a380","type":"GENE","name":"RPL14P5","canonical_id":"hgnc:HGNC:37720","description":"ribosomal protein L14 pseudogene 5","metadata":null},{"id":"63d3b15962034b2b990c6f2c201c0133","type":"GENE","name":"RPL14P6","canonical_id":"hgnc:HGNC:54686","description":"RPL14 pseudogene 6","metadata":null},{"id":"8294fff5c5f24c0ab37dbd6922813a6f","type":"GENE","name":"RPL15","canonical_id":"hgnc:HGNC:10306","description":"ribosomal protein L15","metadata":{"aliases":["RPL10","RPLY10","RPYL10","EC45","L15","eL15"]}},{"id":"d7047c261f9b4413b24236b99d9295dc","type":"GENE","name":"RPL15P1","canonical_id":"hgnc:HGNC:16583","description":"ribosomal protein L15 pseudogene 1","metadata":{"aliases":["dJ726N1.3"]}},{"id":"a0c9c2c3b1bb4e1cad5459822681a1f5","type":"GENE","name":"RPL15P11","canonical_id":"hgnc:HGNC:36093","description":"ribosomal protein L15 pseudogene 11","metadata":null},{"id":"2651c760a7634722b99ff25b08b77f12","type":"GENE","name":"RPL15P12","canonical_id":"hgnc:HGNC:35529","description":"ribosomal protein L15 pseudogene 12","metadata":null},{"id":"2b4eda262bdf433aae431eb19b711c77","type":"GENE","name":"RPL15P13","canonical_id":"hgnc:HGNC:35915","description":"ribosomal protein L15 pseudogene 13","metadata":null},{"id":"01e3bbca8c28493282641ddc7657d6b9","type":"GENE","name":"RPL15P14","canonical_id":"hgnc:HGNC:36487","description":"ribosomal protein L15 pseudogene 14","metadata":null},{"id":"5f7cadaacfe0421c8667d92794679fef","type":"GENE","name":"RPL15P15","canonical_id":"hgnc:HGNC:36780","description":"ribosomal protein L15 pseudogene 15","metadata":null},{"id":"acae7e7b6347460eaec17dac60f45f7f","type":"GENE","name":"RPL15P16","canonical_id":"hgnc:HGNC:36067","description":"ribosomal protein L15 pseudogene 16","metadata":null},{"id":"be3d82f96a6c4bdab9b9cc63b58b6205","type":"GENE","name":"RPL15P17","canonical_id":"hgnc:HGNC:36852","description":"ribosomal protein L15 pseudogene 17","metadata":null},{"id":"5f9976cd73d44fab9aa13070bc7c3cb4","type":"GENE","name":"RPL15P18","canonical_id":"hgnc:HGNC:36515","description":"ribosomal protein L15 pseudogene 18","metadata":null},{"id":"f95a5cf62f3141b7b4c835d13b551d26","type":"GENE","name":"RPL15P19","canonical_id":"hgnc:HGNC:56582","description":"RPL15 pseudogene 19","metadata":null},{"id":"e3c43e70580046c3b7c482721137cbd2","type":"GENE","name":"RPL15P2","canonical_id":"hgnc:HGNC:19803","description":"ribosomal protein L15 pseudogene 2","metadata":null},{"id":"ad6ca05acf6d47918d65063fb5e58bee","type":"GENE","name":"RPL15P20","canonical_id":"hgnc:HGNC:36130","description":"ribosomal protein L15 pseudogene 20","metadata":null},{"id":"c418350e3a2947c1b3d64cd276b25b68","type":"GENE","name":"RPL15P21","canonical_id":"hgnc:HGNC:36190","description":"ribosomal protein L15 pseudogene 21","metadata":null},{"id":"f0d659af3c45435a86b5c3d7e48b7151","type":"GENE","name":"RPL15P22","canonical_id":"hgnc:HGNC:36933","description":"ribosomal protein L15 pseudogene 22","metadata":null},{"id":"13eb95e0f2ab41b6a794f8303d8713a8","type":"GENE","name":"RPL15P3","canonical_id":"hgnc:HGNC:21538","description":"ribosomal protein L15 pseudogene 3","metadata":{"aliases":["bA511S14.1"]}},{"id":"56cd33bf197d42e896fb28036f412075","type":"GENE","name":"RPL15P4","canonical_id":"hgnc:HGNC:21663","description":"ribosomal protein L15 pseudogene 4","metadata":{"aliases":["Em:AC006046.2"]}},{"id":"fb16dd503b1d454a83ead302634b3ae1","type":"GENE","name":"RPL15P5","canonical_id":"hgnc:HGNC:35746","description":"ribosomal protein L15 pseudogene 5","metadata":null},{"id":"56540262a79a42d2be5699c0cec084f5","type":"GENE","name":"RPL15P6","canonical_id":"hgnc:HGNC:36185","description":"ribosomal protein L15 pseudogene 6","metadata":null},{"id":"01484094dac042f9bf63ed71cba89085","type":"GENE","name":"RPL15P7","canonical_id":"hgnc:HGNC:36808","description":"ribosomal protein L15 pseudogene 7","metadata":null},{"id":"76e16841559041a6ad72aaef14e7a932","type":"GENE","name":"RPL15P8","canonical_id":"hgnc:HGNC:36390","description":"ribosomal protein L15 pseudogene 8","metadata":null},{"id":"0c1279e65d25440aaf43bb899fd5f420","type":"GENE","name":"RPL15P9","canonical_id":"hgnc:HGNC:36466","description":"ribosomal protein L15 pseudogene 9","metadata":null},{"id":"3df2157ae9eb49adbffb6f2d96f5fdfd","type":"GENE","name":"RPL17","canonical_id":"hgnc:HGNC:10307","description":"ribosomal protein L17","metadata":{"aliases":["rpL23","L17","uL22"]}},{"id":"8ebe4a3bbc8640bcb320683996e5cea1","type":"GENE","name":"RPL17-C18orf32","canonical_id":"hgnc:HGNC:44661","description":"RPL17-C18orf32 readthrough","metadata":null},{"id":"7a4ef1ae7aa7459baf5566ff271de816","type":"GENE","name":"RPL17P1","canonical_id":"hgnc:HGNC:16559","description":"ribosomal protein L17 pseudogene 1","metadata":{"aliases":["dJ1178H5.1"]}},{"id":"3f606e00c0d0486c8da3ef501195b161","type":"GENE","name":"RPL17P10","canonical_id":"hgnc:HGNC:35838","description":"ribosomal protein L17 pseudogene 10","metadata":null},{"id":"7d6a0f6ede334f8db25e3f9b187c4778","type":"GENE","name":"RPL17P11","canonical_id":"hgnc:HGNC:36509","description":"ribosomal protein L17 pseudogene 11","metadata":null},{"id":"5b6a144723284b6f8930799a54be189d","type":"GENE","name":"RPL17P12","canonical_id":"hgnc:HGNC:36779","description":"ribosomal protein L17 pseudogene 12","metadata":null},{"id":"9b31420f94a74f1383905b6811fc1b56","type":"GENE","name":"RPL17P13","canonical_id":"hgnc:HGNC:36378","description":"ribosomal protein L17 pseudogene 13","metadata":null},{"id":"7d0bf0b17fd346e5a37a21aaa2107a41","type":"GENE","name":"RPL17P14","canonical_id":"hgnc:HGNC:35806","description":"ribosomal protein L17 pseudogene 14","metadata":null},{"id":"f57a5d4ddc3c4eeab97eb1f78e14c901","type":"GENE","name":"RPL17P15","canonical_id":"hgnc:HGNC:36889","description":"ribosomal protein L17 pseudogene 15","metadata":null},{"id":"1e1390285c1a400aaf8fdd30f711ce17","type":"GENE","name":"RPL17P16","canonical_id":"hgnc:HGNC:35939","description":"ribosomal protein L17 pseudogene 16","metadata":null},{"id":"576e74ecb1cf46958d48ba55956347f1","type":"GENE","name":"RPL17P17","canonical_id":"hgnc:HGNC:35515","description":"ribosomal protein L17 pseudogene 17","metadata":null},{"id":"3961d73da182436da4677545cb8049a3","type":"GENE","name":"RPL17P18","canonical_id":"hgnc:HGNC:36538","description":"ribosomal protein L17 pseudogene 18","metadata":null},{"id":"8b3cb66a3ff44c8fbc67c33101fe66ac","type":"GENE","name":"RPL17P19","canonical_id":"hgnc:HGNC:36919","description":"ribosomal protein L17 pseudogene 19","metadata":null},{"id":"34e03464231949dea5f4d10a80f69208","type":"GENE","name":"RPL17P2","canonical_id":"hgnc:HGNC:23540","description":"ribosomal protein L17 pseudogene 2","metadata":null},{"id":"6ee1a1cdacc3432c97f2cd76022ba407","type":"GENE","name":"RPL17P20","canonical_id":"hgnc:HGNC:36015","description":"ribosomal protein L17 pseudogene 20","metadata":null},{"id":"d3c2b14de89f4ddc86e9dc9017952777","type":"GENE","name":"RPL17P21","canonical_id":"hgnc:HGNC:36037","description":"ribosomal protein L17 pseudogene 21","metadata":null},{"id":"a1e34ea86ebb4a47ad47bbcc80ad3ef3","type":"GENE","name":"RPL17P22","canonical_id":"hgnc:HGNC:35761","description":"ribosomal protein L17 pseudogene 22","metadata":null},{"id":"d3b5debbd5e3430cb1fa1970cc67851f","type":"GENE","name":"RPL17P23","canonical_id":"hgnc:HGNC:35832","description":"ribosomal protein L17 pseudogene 23","metadata":null},{"id":"3a6ab3612a474ca8b041744a08b82f0e","type":"GENE","name":"RPL17P24","canonical_id":"hgnc:HGNC:36506","description":"ribosomal protein L17 pseudogene 24","metadata":null},{"id":"0483dd2b0a6b4eed933f5d3a7fdd7d84","type":"GENE","name":"RPL17P25","canonical_id":"hgnc:HGNC:36844","description":"ribosomal protein L17 pseudogene 25","metadata":null},{"id":"81e0e342e1814f7f86fb18b723fc9aaa","type":"GENE","name":"RPL17P26","canonical_id":"hgnc:HGNC:35597","description":"ribosomal protein L17 pseudogene 26","metadata":null},{"id":"5b995b944a0b4c37a9286bc1fdf6ab96","type":"GENE","name":"RPL17P27","canonical_id":"hgnc:HGNC:36038","description":"ribosomal protein L17 pseudogene 27","metadata":null},{"id":"4458efd794c84592b0b0ca0df4e57f42","type":"GENE","name":"RPL17P28","canonical_id":"hgnc:HGNC:36055","description":"ribosomal protein L17 pseudogene 28","metadata":{"aliases":["ZAP-IT1","lnc-ZC3HAV1L-1:1"]}},{"id":"fb02a23b81394feabb790865b44b415e","type":"GENE","name":"RPL17P29","canonical_id":"hgnc:HGNC:36510","description":"ribosomal protein L17 pseudogene 29","metadata":null},{"id":"777642aa470449be929f3c5f3ed181c6","type":"GENE","name":"RPL17P3","canonical_id":"hgnc:HGNC:19796","description":"ribosomal protein L17 pseudogene 3","metadata":null},{"id":"3fbcd405e8c74c349fb9f2a05ed91169","type":"GENE","name":"RPL17P30","canonical_id":"hgnc:HGNC:35604","description":"ribosomal protein L17 pseudogene 30","metadata":null},{"id":"e2b8b0594c96469a9c9532e4ad447295","type":"GENE","name":"RPL17P31","canonical_id":"hgnc:HGNC:37036","description":"ribosomal protein L17 pseudogene 31","metadata":null},{"id":"b19377edd7264c3183a6e075505019e0","type":"GENE","name":"RPL17P32","canonical_id":"hgnc:HGNC:36492","description":"ribosomal protein L17 pseudogene 32","metadata":null},{"id":"3f5bbcf61b914f5a9435414e2f46e03a","type":"GENE","name":"RPL17P33","canonical_id":"hgnc:HGNC:36654","description":"ribosomal protein L17 pseudogene 33","metadata":null},{"id":"d4486045fd344a88959d425b519a6f24","type":"GENE","name":"RPL17P34","canonical_id":"hgnc:HGNC:36756","description":"ribosomal protein L17 pseudogene 34","metadata":null},{"id":"a62ce3f282434f6e97530c7b5a24d959","type":"GENE","name":"RPL17P35","canonical_id":"hgnc:HGNC:35819","description":"ribosomal protein L17 pseudogene 35","metadata":null},{"id":"ec26d099438548acbb0ea8ea2a421d8e","type":"GENE","name":"RPL17P36","canonical_id":"hgnc:HGNC:36051","description":"ribosomal protein L17 pseudogene 36","metadata":null},{"id":"45e37874993b4970843b9e1f52466aea","type":"GENE","name":"RPL17P37","canonical_id":"hgnc:HGNC:36854","description":"ribosomal protein L17 pseudogene 37","metadata":null},{"id":"4e56e6c12d70421b90c65d0553d637f1","type":"GENE","name":"RPL17P38","canonical_id":"hgnc:HGNC:36219","description":"ribosomal protein L17 pseudogene 38","metadata":null},{"id":"288160f29a48478cbc72ef44ea11107a","type":"GENE","name":"RPL17P39","canonical_id":"hgnc:HGNC:36427","description":"ribosomal protein L17 pseudogene 39","metadata":null},{"id":"ab5a7cc32e4941c1bfdc8bb077801a92","type":"GENE","name":"RPL17P4","canonical_id":"hgnc:HGNC:19811","description":"ribosomal protein L17 pseudogene 4","metadata":null},{"id":"a23e86eaca12459e9dc09e78d09bfcf6","type":"GENE","name":"RPL17P40","canonical_id":"hgnc:HGNC:36672","description":"ribosomal protein L17 pseudogene 40","metadata":null},{"id":"14e475a86b494692959463150e344ded","type":"GENE","name":"RPL17P41","canonical_id":"hgnc:HGNC:36292","description":"ribosomal protein L17 pseudogene 41","metadata":null},{"id":"3db589d3bcfb448d8f6853700f565152","type":"GENE","name":"RPL17P42","canonical_id":"hgnc:HGNC:36749","description":"ribosomal protein L17 pseudogene 42","metadata":null},{"id":"fe50ec350d774ddab581bbe37fa45131","type":"GENE","name":"RPL17P43","canonical_id":"hgnc:HGNC:35996","description":"ribosomal protein L17 pseudogene 43","metadata":null},{"id":"3fd0115f0ac84a7682324710acda0cb1","type":"GENE","name":"RPL17P44","canonical_id":"hgnc:HGNC:36396","description":"ribosomal protein L17 pseudogene 44","metadata":null},{"id":"e349629aef9947749ebd0fbfdd76b16b","type":"GENE","name":"RPL17P45","canonical_id":"hgnc:HGNC:35618","description":"ribosomal protein L17 pseudogene 45","metadata":null},{"id":"7729aade7fe44515925be3472ffa7d40","type":"GENE","name":"RPL17P46","canonical_id":"hgnc:HGNC:36202","description":"ribosomal protein L17 pseudogene 46","metadata":null},{"id":"53ec7cd1abef4ccfbdcd4df2fdd5b8ba","type":"GENE","name":"RPL17P47","canonical_id":"hgnc:HGNC:36089","description":"ribosomal protein L17 pseudogene 47","metadata":null},{"id":"a1154419d734418d9f918151fe6103bd","type":"GENE","name":"RPL17P48","canonical_id":"hgnc:HGNC:36997","description":"ribosomal protein L17 pseudogene 48","metadata":null},{"id":"762fb85136c24665b6bce3de108a14ea","type":"GENE","name":"RPL17P49","canonical_id":"hgnc:HGNC:37009","description":"ribosomal protein L17 pseudogene 49","metadata":null},{"id":"e037f2fcbbc5451fa67a9ed910fe1f20","type":"GENE","name":"RPL17P5","canonical_id":"hgnc:HGNC:35491","description":"ribosomal protein L17 pseudogene 5","metadata":null},{"id":"c660f80b1717481f819ec34901f675d6","type":"GENE","name":"RPL17P50","canonical_id":"hgnc:HGNC:45098","description":"ribosomal protein L17 pseudogene 50","metadata":null},{"id":"6cbde8522c4d49b2a040e0331ffa3d02","type":"GENE","name":"RPL17P51","canonical_id":"hgnc:HGNC:49100","description":"ribosomal protein L17 pseudogene 51","metadata":null},{"id":"d2480efdee91410a9b2e4d459d9af5e6","type":"GENE","name":"RPL17P52","canonical_id":"hgnc:HGNC:56988","description":"ibosomal protein L17 pseudogene 52","metadata":null},{"id":"e8dd912defc941e5942a19bbf38dd7b0","type":"GENE","name":"RPL17P6","canonical_id":"hgnc:HGNC:36520","description":"ribosomal protein L17 pseudogene 6","metadata":null},{"id":"84149ca92e07460d9c179ad6c604ca8e","type":"GENE","name":"RPL17P7","canonical_id":"hgnc:HGNC:36005","description":"ribosomal protein L17 pseudogene 7","metadata":null},{"id":"4dfc0b6b965c424bb4cdbdcd82e187f4","type":"GENE","name":"RPL17P8","canonical_id":"hgnc:HGNC:35651","description":"ribosomal protein L17 pseudogene 8","metadata":null},{"id":"c4b1118d271841b9b217f6d621e46c14","type":"GENE","name":"RPL17P9","canonical_id":"hgnc:HGNC:36230","description":"ribosomal protein L17 pseudogene 9","metadata":null},{"id":"67c090a4ab0440419e8afe696000fb17","type":"GENE","name":"RPL18","canonical_id":"hgnc:HGNC:10310","description":"ribosomal protein L18","metadata":{"aliases":["L18","eL18"]}},{"id":"3356de6828a145e489dd2ba3290a28c5","type":"GENE","name":"RPL18A","canonical_id":"hgnc:HGNC:10311","description":"ribosomal protein L18a","metadata":{"aliases":["L18A","eL20"]}},{"id":"b03b26327c7d4b3eac1d28515864b35c","type":"GENE","name":"RPL18AP1","canonical_id":"hgnc:HGNC:19778","description":"ribosomal protein L18a pseudogene 1","metadata":null},{"id":"37ee2694f93b43b8a853ba6cc8460005","type":"GENE","name":"RPL18AP10","canonical_id":"hgnc:HGNC:35885","description":"ribosomal protein L18a pseudogene 10","metadata":null},{"id":"8b96f1fb8384483ebb79c1ea19437b73","type":"GENE","name":"RPL18AP11","canonical_id":"hgnc:HGNC:36661","description":"ribosomal protein L18a pseudogene 11","metadata":null},{"id":"456466c206a3451680a4708f4afcce02","type":"GENE","name":"RPL18AP12","canonical_id":"hgnc:HGNC:36991","description":"ribosomal protein L18a pseudogene 12","metadata":null},{"id":"a912af65c7d14be9956bf3f5b01f7ad9","type":"GENE","name":"RPL18AP13","canonical_id":"hgnc:HGNC:36739","description":"ribosomal protein L18a pseudogene 13","metadata":null},{"id":"ec5af4ec0cef4ac78ae01d0cfea9c75a","type":"GENE","name":"RPL18AP14","canonical_id":"hgnc:HGNC:36624","description":"ribosomal protein L18a pseudogene 14","metadata":null},{"id":"6f5f946cd4cb4cc995613fc5ded684e5","type":"GENE","name":"RPL18AP15","canonical_id":"hgnc:HGNC:36010","description":"ribosomal protein L18a pseudogene 15","metadata":null},{"id":"d7b1bdf7d0c745768c60261e3a5e3e96","type":"GENE","name":"RPL18AP16","canonical_id":"hgnc:HGNC:36288","description":"ribosomal protein L18a pseudogene 16","metadata":null},{"id":"eebb97eb3f1045fe9a6083187188c48a","type":"GENE","name":"RPL18AP17","canonical_id":"hgnc:HGNC:39850","description":"ribosomal protein L18a pseudogene 17","metadata":null},{"id":"12efdc5368324335a54e073c9931467f","type":"GENE","name":"RPL18AP2","canonical_id":"hgnc:HGNC:23774","description":"ribosomal protein L18a pseudogene 2","metadata":null},{"id":"539e98fa2ed54ec3b760d8dd8d4271da","type":"GENE","name":"RPL18AP3","canonical_id":"hgnc:HGNC:31387","description":"ribosomal protein L18a pseudogene 3","metadata":{"aliases":["bcm182"]}},{"id":"814abe775673446da449c0df776669c4","type":"GENE","name":"RPL18AP4","canonical_id":"hgnc:HGNC:36556","description":"ribosomal protein L18a pseudogene 4","metadata":null},{"id":"579c606446974cdfada023b0eb4b3eac","type":"GENE","name":"RPL18AP5","canonical_id":"hgnc:HGNC:36777","description":"ribosomal protein L18a pseudogene 5","metadata":null},{"id":"fb7cb64e044342ac951895ec021f0848","type":"GENE","name":"RPL18AP6","canonical_id":"hgnc:HGNC:36266","description":"ribosomal protein L18a pseudogene 6","metadata":null},{"id":"81f4d80f384044fdb863e993557b70a0","type":"GENE","name":"RPL18AP7","canonical_id":"hgnc:HGNC:35607","description":"ribosomal protein L18a pseudogene 7","metadata":null},{"id":"6c9e39a9afe34d3d8e99b4cb007f31f8","type":"GENE","name":"RPL18AP8","canonical_id":"hgnc:HGNC:36984","description":"ribosomal protein L18a pseudogene 8","metadata":null},{"id":"a6b8797f7d384dfd8b7f1021172f862e","type":"GENE","name":"RPL18AP9","canonical_id":"hgnc:HGNC:56413","description":"ribosomal protein L18a pseudogene 9","metadata":null},{"id":"6eb1eda19b2742bd943d21de4fc19499","type":"GENE","name":"RPL18P1","canonical_id":"hgnc:HGNC:19673","description":"ribosomal protein L18 pseudogene 1","metadata":null},{"id":"fd934b16a1df4135bab995015ad5032c","type":"GENE","name":"RPL18P10","canonical_id":"hgnc:HGNC:35957","description":"ribosomal protein L18 pseudogene 10","metadata":null},{"id":"3acf37cd9c424454a8db9f7858c6ae86","type":"GENE","name":"RPL18P11","canonical_id":"hgnc:HGNC:35742","description":"ribosomal protein L18 pseudogene 11","metadata":null},{"id":"6f54e8f185cd4acaa172ae163ed50572","type":"GENE","name":"RPL18P12","canonical_id":"hgnc:HGNC:36115","description":"ribosomal protein L18 pseudogene 12","metadata":null},{"id":"b46f234ad267498fa6590e82450d734d","type":"GENE","name":"RPL18P13","canonical_id":"hgnc:HGNC:35599","description":"ribosomal protein L18 pseudogene 13","metadata":null},{"id":"fe8007fabfa84822aa7afa6d3501631a","type":"GENE","name":"RPL18P2","canonical_id":"hgnc:HGNC:35759","description":"ribosomal protein L18 pseudogene 2","metadata":null},{"id":"b4d65ca885df459a80236c68edc250b6","type":"GENE","name":"RPL18P3","canonical_id":"hgnc:HGNC:35783","description":"ribosomal protein L18 pseudogene 3","metadata":null},{"id":"42f2fc9c292c4368b8a792c022f5c7ac","type":"GENE","name":"RPL18P4","canonical_id":"hgnc:HGNC:36144","description":"ribosomal protein L18 pseudogene 4","metadata":null},{"id":"c9d3adad2fa145b0896b8bd762d92504","type":"GENE","name":"RPL18P5","canonical_id":"hgnc:HGNC:36425","description":"ribosomal protein L18 pseudogene 5","metadata":null},{"id":"a5db833a8f2b4815b021872ea58e3eeb","type":"GENE","name":"RPL18P6","canonical_id":"hgnc:HGNC:35528","description":"ribosomal protein L18 pseudogene 6","metadata":null},{"id":"ca003d6b997d4707a85262071bb74f65","type":"GENE","name":"RPL18P7","canonical_id":"hgnc:HGNC:35936","description":"ribosomal protein L18 pseudogene 7","metadata":null},{"id":"ac52d949e2e0468b8ae45b4f4c50f923","type":"GENE","name":"RPL18P8","canonical_id":"hgnc:HGNC:36878","description":"ribosomal protein L18 pseudogene 8","metadata":null},{"id":"42a3329fb9974b3d84b9b1251e586eb2","type":"GENE","name":"RPL18P9","canonical_id":"hgnc:HGNC:36766","description":"ribosomal protein L18 pseudogene 9","metadata":null},{"id":"5ac979fe6eea4a02b7bb0740eddf0895","type":"GENE","name":"RPL19","canonical_id":"hgnc:HGNC:10312","description":"ribosomal protein L19","metadata":{"aliases":["FLJ27452","MGC71997","DKFZp779D216","L19","eL19"]}},{"id":"a48cd0d2b6ab433a8eb4e87d1932bddd","type":"GENE","name":"RPL19P1","canonical_id":"hgnc:HGNC:16595","description":"ribosomal protein L19 pseudogene 1","metadata":{"aliases":["dJ860F19.2"]}},{"id":"eea0459bc63b4e26873661eb8c4d0976","type":"GENE","name":"RPL19P10","canonical_id":"hgnc:HGNC:36534","description":"ribosomal protein L19 pseudogene 10","metadata":null},{"id":"cc9b1521bce7425dab1327d3b41b77c4","type":"GENE","name":"RPL19P11","canonical_id":"hgnc:HGNC:36953","description":"ribosomal protein L19 pseudogene 11","metadata":null},{"id":"9e72c7031659414393e4c3a620f46a87","type":"GENE","name":"RPL19P12","canonical_id":"hgnc:HGNC:36047","description":"ribosomal protein L19 pseudogene 12","metadata":null},{"id":"936cce2eef2b4c5da229a00e725faf8f","type":"GENE","name":"RPL19P13","canonical_id":"hgnc:HGNC:36879","description":"ribosomal protein L19 pseudogene 13","metadata":null},{"id":"2ca2950d1ac8427387b7dae0403b67b4","type":"GENE","name":"RPL19P14","canonical_id":"hgnc:HGNC:35684","description":"ribosomal protein L19 pseudogene 14","metadata":null},{"id":"4e0185833b6340799091d0e088ad8c37","type":"GENE","name":"RPL19P15","canonical_id":"hgnc:HGNC:35920","description":"ribosomal protein L19 pseudogene 15","metadata":null},{"id":"14f78549dba44490882bfbd6dda987e8","type":"GENE","name":"RPL19P16","canonical_id":"hgnc:HGNC:36596","description":"ribosomal protein L19 pseudogene 16","metadata":null},{"id":"c70c4091e2874642ad04a566d7a643df","type":"GENE","name":"RPL19P17","canonical_id":"hgnc:HGNC:36829","description":"ribosomal protein L19 pseudogene 17","metadata":null},{"id":"11cb6b68532c4fdabddf0843ede3c3ee","type":"GENE","name":"RPL19P18","canonical_id":"hgnc:HGNC:36121","description":"ribosomal protein L19 pseudogene 18","metadata":null},{"id":"827963ecc6c44812ba2bbcff5730b08e","type":"GENE","name":"RPL19P19","canonical_id":"hgnc:HGNC:36194","description":"ribosomal protein L19 pseudogene 19","metadata":null},{"id":"815f6831c6544095b5fe306867e583b5","type":"GENE","name":"RPL19P2","canonical_id":"hgnc:HGNC:29946","description":"ribosomal protein L19 pseudogene 2","metadata":null},{"id":"41b89df9b41b4850800046ebfa1c5161","type":"GENE","name":"RPL19P20","canonical_id":"hgnc:HGNC:35713","description":"ribosomal protein L19 pseudogene 20","metadata":null},{"id":"b50f3c4c890345c1943ec5254b5a5607","type":"GENE","name":"RPL19P21","canonical_id":"hgnc:HGNC:35868","description":"ribosomal protein L19 pseudogene 21","metadata":null},{"id":"64e6342b99244b5585bc8a681dc5d6d9","type":"GENE","name":"RPL19P3","canonical_id":"hgnc:HGNC:36671","description":"ribosomal protein L19 pseudogene 3","metadata":null},{"id":"7a608763562a4706b9de44912a4c9e2b","type":"GENE","name":"RPL19P4","canonical_id":"hgnc:HGNC:36539","description":"ribosomal protein L19 pseudogene 4","metadata":null},{"id":"c097238fbeec42e2a82ef30edf88d13d","type":"GENE","name":"RPL19P5","canonical_id":"hgnc:HGNC:36325","description":"ribosomal protein L19 pseudogene 5","metadata":null},{"id":"f19165cf83ef4786b1b8cf2daebb9bdf","type":"GENE","name":"RPL19P6","canonical_id":"hgnc:HGNC:36795","description":"ribosomal protein L19 pseudogene 6","metadata":null},{"id":"bf6d3050ebf94edb981839191b307619","type":"GENE","name":"RPL19P7","canonical_id":"hgnc:HGNC:36088","description":"ribosomal protein L19 pseudogene 7","metadata":null},{"id":"df9f83bdf7c04f199d9609e7b4c996e0","type":"GENE","name":"RPL19P8","canonical_id":"hgnc:HGNC:36696","description":"ribosomal protein L19 pseudogene 8","metadata":null},{"id":"d623761866f64ceaa77c863f01ab17a0","type":"GENE","name":"RPL19P9","canonical_id":"hgnc:HGNC:35918","description":"ribosomal protein L19 pseudogene 9","metadata":null},{"id":"612175eaaff94b2d8386d9558c5cc1b0","type":"GENE","name":"RPL21","canonical_id":"hgnc:HGNC:10313","description":"ribosomal protein L21","metadata":{"aliases":["L21","FLJ27458","MGC71252","MGC104274","MGC104275","DKFZp686C06101","eL21"]}},{"id":"7f8095cef4f243888ffc38d18e02865d","type":"GENE","name":"RPL21P1","canonical_id":"hgnc:HGNC:10314","description":"ribosomal protein L21 pseudogene 1","metadata":{"aliases":["RPL21P"]}},{"id":"c5d5bc92a1bc4ee685345aa8453b2294","type":"GENE","name":"RPL21P10","canonical_id":"hgnc:HGNC:19795","description":"ribosomal protein L21 pseudogene 10","metadata":null},{"id":"e4c8ae709b8846debed6df72a56e9a95","type":"GENE","name":"RPL21P100","canonical_id":"hgnc:HGNC:36048","description":"ribosomal protein L21 pseudogene 100","metadata":null},{"id":"a430fc1d30db432e8d2cb74cb40c5642","type":"GENE","name":"RPL21P101","canonical_id":"hgnc:HGNC:35733","description":"ribosomal protein L21 pseudogene 101","metadata":null},{"id":"edb23e70b49c4a45bef5cca05b42b063","type":"GENE","name":"RPL21P102","canonical_id":"hgnc:HGNC:36295","description":"ribosomal protein L21 pseudogene 102","metadata":null},{"id":"511ef48720c344fcb66d03b95b89ec18","type":"GENE","name":"RPL21P103","canonical_id":"hgnc:HGNC:36732","description":"ribosomal protein L21 pseudogene 103","metadata":null},{"id":"998adf0e039347868c999129a313cfc9","type":"GENE","name":"RPL21P104","canonical_id":"hgnc:HGNC:36918","description":"ribosomal protein L21 pseudogene 104","metadata":null},{"id":"5934160ba5114a47b032fe864eed9037","type":"GENE","name":"RPL21P105","canonical_id":"hgnc:HGNC:36304","description":"ribosomal protein L21 pseudogene 105","metadata":null},{"id":"02c28fa4dd54436a9580112978b1d945","type":"GENE","name":"RPL21P106","canonical_id":"hgnc:HGNC:36188","description":"ribosomal protein L21 pseudogene 106","metadata":null},{"id":"e38b95e025184cc49a8e3af956aee7b1","type":"GENE","name":"RPL21P107","canonical_id":"hgnc:HGNC:36313","description":"ribosomal protein L21 pseudogene 107","metadata":null},{"id":"63c283d6928a43068c5ce90f70859bec","type":"GENE","name":"RPL21P108","canonical_id":"hgnc:HGNC:35496","description":"ribosomal protein L21 pseudogene 108","metadata":null},{"id":"d1a7528cec6b43e6bdfff2fcdb334ff8","type":"GENE","name":"RPL21P109","canonical_id":"hgnc:HGNC:36388","description":"ribosomal protein L21 pseudogene 109","metadata":null},{"id":"35571d9bc321493ea3a19b344c45254d","type":"GENE","name":"RPL21P11","canonical_id":"hgnc:HGNC:19800","description":"ribosomal protein L21 pseudogene 11","metadata":null},{"id":"b6e150803c944c3aa058fb7516fa1bb2","type":"GENE","name":"RPL21P110","canonical_id":"hgnc:HGNC:35627","description":"ribosomal protein L21 pseudogene 110","metadata":null},{"id":"449b52ec0e974d33a7bdaf2d05865661","type":"GENE","name":"RPL21P111","canonical_id":"hgnc:HGNC:36564","description":"ribosomal protein L21 pseudogene 111","metadata":null},{"id":"0324dc43c00b4f8fa1a6a2b93fff1214","type":"GENE","name":"RPL21P112","canonical_id":"hgnc:HGNC:36526","description":"ribosomal protein L21 pseudogene 112","metadata":null},{"id":"72f6cd598b8a4a26abed91173c1783e0","type":"GENE","name":"RPL21P113","canonical_id":"hgnc:HGNC:36563","description":"ribosomal protein L21 pseudogene 113","metadata":null},{"id":"061ee20bed734393abf6f9cffaff0e9e","type":"GENE","name":"RPL21P114","canonical_id":"hgnc:HGNC:36776","description":"ribosomal protein L21 pseudogene 114","metadata":null},{"id":"bc5329aa79b04526b5aa38a5b5019de5","type":"GENE","name":"RPL21P115","canonical_id":"hgnc:HGNC:35878","description":"ribosomal protein L21 pseudogene 115","metadata":null},{"id":"bf8315d4f4934cd69219cdb34154c1d2","type":"GENE","name":"RPL21P116","canonical_id":"hgnc:HGNC:36101","description":"ribosomal protein L21 pseudogene 116","metadata":null},{"id":"1df64b8005764cf7a0cab4c621a655a6","type":"GENE","name":"RPL21P117","canonical_id":"hgnc:HGNC:35987","description":"ribosomal protein L21 pseudogene 117","metadata":null},{"id":"0aea6024cfc54e8288d9cbd94fc67e8a","type":"GENE","name":"RPL21P118","canonical_id":"hgnc:HGNC:35954","description":"ribosomal protein L21 pseudogene 118","metadata":null},{"id":"788af09db1cf44d5b5d8b4907d699ac2","type":"GENE","name":"RPL21P119","canonical_id":"hgnc:HGNC:35614","description":"ribosomal protein L21 pseudogene 119","metadata":null},{"id":"fe1de69ac9c34d07b7fd6519647b4686","type":"GENE","name":"RPL21P12","canonical_id":"hgnc:HGNC:19810","description":"ribosomal protein L21 pseudogene 12","metadata":null},{"id":"9c8f175496b041b2825ebf2fbf62cc5f","type":"GENE","name":"RPL21P120","canonical_id":"hgnc:HGNC:35743","description":"ribosomal protein L21 pseudogene 120","metadata":null},{"id":"f46602f56fd94fc69e7f07b8571c1d31","type":"GENE","name":"RPL21P121","canonical_id":"hgnc:HGNC:36429","description":"ribosomal protein L21 pseudogene 121","metadata":null},{"id":"a517b3684ab649f692a57b54a734ae16","type":"GENE","name":"RPL21P122","canonical_id":"hgnc:HGNC:36990","description":"ribosomal protein L21 pseudogene 122","metadata":null},{"id":"d88675b922f0440fa29edbec793fa7b5","type":"GENE","name":"RPL21P123","canonical_id":"hgnc:HGNC:35691","description":"ribosomal protein L21 pseudogene 123","metadata":null},{"id":"d6445ab76af14235a95cf32e30adf0bc","type":"GENE","name":"RPL21P124","canonical_id":"hgnc:HGNC:36060","description":"ribosomal protein L21 pseudogene 124","metadata":null},{"id":"ba48a4cc3d9c4bed825fec6d4abf2f8c","type":"GENE","name":"RPL21P125","canonical_id":"hgnc:HGNC:36039","description":"ribosomal protein L21 pseudogene 125","metadata":null},{"id":"f2a02aa4ac9f4b8c8fc10458a2511555","type":"GENE","name":"RPL21P126","canonical_id":"hgnc:HGNC:35959","description":"ribosomal protein L21 pseudogene 126","metadata":null},{"id":"acf33231aea54fefb245f7cb5a0f8df9","type":"GENE","name":"RPL21P127","canonical_id":"hgnc:HGNC:36099","description":"ribosomal protein L21 pseudogene 127","metadata":null},{"id":"0d01106330d54de483b617ecc41d4671","type":"GENE","name":"RPL21P128","canonical_id":"hgnc:HGNC:36311","description":"ribosomal protein L21 pseudogene 128","metadata":null},{"id":"b643214cdea34ab9ade27963597acde6","type":"GENE","name":"RPL21P129","canonical_id":"hgnc:HGNC:36747","description":"ribosomal protein L21 pseudogene 129","metadata":null},{"id":"bf047a3d367d4e5bb55f1dc6f86871ff","type":"GENE","name":"RPL21P13","canonical_id":"hgnc:HGNC:19812","description":"ribosomal protein L21 pseudogene 13","metadata":null},{"id":"fc03ec62579e427b82e9c8f003a135fe","type":"GENE","name":"RPL21P130","canonical_id":"hgnc:HGNC:36453","description":"ribosomal protein L21 pseudogene 130","metadata":null},{"id":"9d563b9e3fa54741b8a2dd8504627968","type":"GENE","name":"RPL21P131","canonical_id":"hgnc:HGNC:36428","description":"ribosomal protein L21 pseudogene 131","metadata":null},{"id":"bf364c5e792a47d38f7ecf44a11037d7","type":"GENE","name":"RPL21P132","canonical_id":"hgnc:HGNC:35865","description":"ribosomal protein L21 pseudogene 132","metadata":null},{"id":"fae23ce9c922425bb8d47fd0ca5917ab","type":"GENE","name":"RPL21P133","canonical_id":"hgnc:HGNC:36003","description":"ribosomal protein L21 pseudogene 133","metadata":null},{"id":"67e3819254604e3099bd7b0600ea3a31","type":"GENE","name":"RPL21P134","canonical_id":"hgnc:HGNC:36006","description":"ribosomal protein L21 pseudogene 134","metadata":null},{"id":"2727a81a0875458a9c8bb2cafc234705","type":"GENE","name":"RPL21P135","canonical_id":"hgnc:HGNC:44539","description":"ribosomal protein L21 pseudogene 135","metadata":null},{"id":"705bd6d1299547a6a516b147b96c6f33","type":"GENE","name":"RPL21P136","canonical_id":"hgnc:HGNC:49854","description":"ribosomal protein L21 pseudogene 136","metadata":null},{"id":"100924d2553a420096f301442d5daa26","type":"GENE","name":"RPL21P137","canonical_id":"hgnc:HGNC:56406","description":"ribosomal protein L21 pseudogene 137","metadata":null},{"id":"b5e78f865dc640a195455367da74c9d6","type":"GENE","name":"RPL21P14","canonical_id":"hgnc:HGNC:31029","description":"ribosomal protein L21 pseudogene 14","metadata":{"aliases":["HsT16795"]}},{"id":"c362baf485e04147bbd212d9fe69bb3f","type":"GENE","name":"RPL21P15","canonical_id":"hgnc:HGNC:31030","description":"ribosomal protein L21 pseudogene 15","metadata":{"aliases":["HsT18206"]}},{"id":"ae9bc506df2e440e963a56c93df00865","type":"GENE","name":"RPL21P16","canonical_id":"hgnc:HGNC:31396","description":"ribosomal protein L21 pseudogene 16","metadata":{"aliases":["Em:AC073587.1"]}},{"id":"5285218dccac4306bb3ad5b46234d9c7","type":"GENE","name":"RPL21P17","canonical_id":"hgnc:HGNC:19416","description":"ribosomal protein L21 pseudogene 17","metadata":null},{"id":"bba31bdd564f4ab1ae1a2552944953be","type":"GENE","name":"RPL21P18","canonical_id":"hgnc:HGNC:28362","description":"ribosomal protein L21 pseudogene 18","metadata":{"aliases":["ENSG00000184796"]}},{"id":"0f867368911147ae994f71217c7c8ac9","type":"GENE","name":"RPL21P19","canonical_id":"hgnc:HGNC:35748","description":"ribosomal protein L21 pseudogene 19","metadata":null},{"id":"df7df872023c4d339f2f1faa54440fd3","type":"GENE","name":"RPL21P2","canonical_id":"hgnc:HGNC:16539","description":"ribosomal protein L21 pseudogene 2","metadata":{"aliases":["bA352D3.1"]}},{"id":"9d02eef3851142b798e6156cfa72b80a","type":"GENE","name":"RPL21P20","canonical_id":"hgnc:HGNC:36582","description":"ribosomal protein L21 pseudogene 20","metadata":null},{"id":"5033fe662ebc4815b60f747a373ae022","type":"GENE","name":"RPL21P21","canonical_id":"hgnc:HGNC:35728","description":"ribosomal protein L21 pseudogene 21","metadata":null},{"id":"4fc623a2116e4bb1b1c57cda45090bb6","type":"GENE","name":"RPL21P22","canonical_id":"hgnc:HGNC:36550","description":"ribosomal protein L21 pseudogene 22","metadata":null},{"id":"e0669f8a000345f5b86dbf4beff2ee85","type":"GENE","name":"RPL21P23","canonical_id":"hgnc:HGNC:36205","description":"ribosomal protein L21 pseudogene 23","metadata":null},{"id":"c23d9539a23c4faab6e9ff3eb56a9690","type":"GENE","name":"RPL21P24","canonical_id":"hgnc:HGNC:35702","description":"ribosomal protein L21 pseudogene 24","metadata":null},{"id":"2b47bc5ddf8d43a8995afae316afdde0","type":"GENE","name":"RPL21P25","canonical_id":"hgnc:HGNC:36785","description":"ribosomal protein L21 pseudogene 25","metadata":null},{"id":"ebe427e27da24e299c8336443a7809d5","type":"GENE","name":"RPL21P26","canonical_id":"hgnc:HGNC:35910","description":"ribosomal protein L21 pseudogene 26","metadata":null},{"id":"29d9763adefb4924813bbff66563f90b","type":"GENE","name":"RPL21P27","canonical_id":"hgnc:HGNC:36371","description":"ribosomal protein L21 pseudogene 27","metadata":null},{"id":"8a8784ceb2224074a60be6bf4ce56d56","type":"GENE","name":"RPL21P28","canonical_id":"hgnc:HGNC:36258","description":"ribosomal protein L21 pseudogene 28","metadata":null},{"id":"2e39c96829dd4dd39d5a9caf29e699cd","type":"GENE","name":"RPL21P29","canonical_id":"hgnc:HGNC:35793","description":"ribosomal protein L21 pseudogene 29","metadata":null},{"id":"350e3c54910346bab29c9ca6ff65987d","type":"GENE","name":"RPL21P3","canonical_id":"hgnc:HGNC:16533","description":"ribosomal protein L21 pseudogene 3","metadata":{"aliases":["bA189K21.4"]}},{"id":"c937debc3c9448e3b6c8dd1fc236cb37","type":"GENE","name":"RPL21P30","canonical_id":"hgnc:HGNC:36091","description":"ribosomal protein L21 pseudogene 30","metadata":null},{"id":"cb09f5b7ec7f4750b8c073bfed210035","type":"GENE","name":"RPL21P31","canonical_id":"hgnc:HGNC:36306","description":"ribosomal protein L21 pseudogene 31","metadata":null},{"id":"60dbf6addb1a4f93b66257cafc4b54e3","type":"GENE","name":"RPL21P32","canonical_id":"hgnc:HGNC:36978","description":"ribosomal protein L21 pseudogene 32","metadata":null},{"id":"48f7b3da2a2045358323df89b669e928","type":"GENE","name":"RPL21P33","canonical_id":"hgnc:HGNC:36686","description":"ribosomal protein L21 pseudogene 33","metadata":null},{"id":"87d13997e64c4474af68d82e51e75e64","type":"GENE","name":"RPL21P34","canonical_id":"hgnc:HGNC:36529","description":"ribosomal protein L21 pseudogene 34","metadata":null},{"id":"8348e9c8ef26491681631eee79bca669","type":"GENE","name":"RPL21P35","canonical_id":"hgnc:HGNC:36900","description":"ribosomal protein L21 pseudogene 35","metadata":null},{"id":"43dd7accce1b4e9bb9aa89993a7fddc1","type":"GENE","name":"RPL21P36","canonical_id":"hgnc:HGNC:36128","description":"ribosomal protein L21 pseudogene 36","metadata":null},{"id":"7ad23dcc84644c0191b8e1e097c66be5","type":"GENE","name":"RPL21P37","canonical_id":"hgnc:HGNC:35704","description":"ribosomal protein L21 pseudogene 37","metadata":null},{"id":"1e45aac366f54a239feefa3c0d372b6a","type":"GENE","name":"RPL21P38","canonical_id":"hgnc:HGNC:36349","description":"ribosomal protein L21 pseudogene 38","metadata":null},{"id":"64361f00bd834a13a118270d39c5d054","type":"GENE","name":"RPL21P39","canonical_id":"hgnc:HGNC:36127","description":"ribosomal protein L21 pseudogene 39","metadata":null},{"id":"80ab97ccfda94855b1acc30200820047","type":"GENE","name":"RPL21P4","canonical_id":"hgnc:HGNC:17959","description":"ribosomal protein L21 pseudogene 4","metadata":null},{"id":"13c01caaf0964dddb6ebd76dff109afc","type":"GENE","name":"RPL21P40","canonical_id":"hgnc:HGNC:36189","description":"ribosomal protein L21 pseudogene 40","metadata":null},{"id":"a1fea53856614a71bb8c049412d7e80b","type":"GENE","name":"RPL21P41","canonical_id":"hgnc:HGNC:36765","description":"ribosomal protein L21 pseudogene 41","metadata":null},{"id":"2115e0746ca543199b91c75127fe467b","type":"GENE","name":"RPL21P42","canonical_id":"hgnc:HGNC:37017","description":"ribosomal protein L21 pseudogene 42","metadata":null},{"id":"074fa56ec19c48178b9f9cad6b22470b","type":"GENE","name":"RPL21P43","canonical_id":"hgnc:HGNC:36008","description":"ribosomal protein L21 pseudogene 43","metadata":null},{"id":"6cc0fe688405417fbb4950de41fc36fe","type":"GENE","name":"RPL21P44","canonical_id":"hgnc:HGNC:33820","description":"ribosomal protein L21 pseudogene 44","metadata":null},{"id":"d7c0b12dd4cb46b285ccc86a957d0ee2","type":"GENE","name":"RPL21P45","canonical_id":"hgnc:HGNC:35983","description":"ribosomal protein L21 pseudogene 45","metadata":null},{"id":"bdb28aab02e84ccfb0ef6d0ac892cd44","type":"GENE","name":"RPL21P46","canonical_id":"hgnc:HGNC:35687","description":"ribosomal protein L21 pseudogene 46","metadata":null},{"id":"5112166b5d3740fa9052720687537fa3","type":"GENE","name":"RPL21P47","canonical_id":"hgnc:HGNC:36711","description":"ribosomal protein L21 pseudogene 47","metadata":null},{"id":"449fafa866114551915af1cb33af2434","type":"GENE","name":"RPL21P48","canonical_id":"hgnc:HGNC:35891","description":"ribosomal protein L21 pseudogene 48","metadata":null},{"id":"9642beae8e3548db8157229765fed422","type":"GENE","name":"RPL21P49","canonical_id":"hgnc:HGNC:35769","description":"ribosomal protein L21 pseudogene 49","metadata":null},{"id":"779ed94cc23a4a1fbf4b57bbf8ca46f8","type":"GENE","name":"RPL21P5","canonical_id":"hgnc:HGNC:23541","description":"ribosomal protein L21 pseudogene 5","metadata":null},{"id":"7094a69639224fd1bb480a839f406084","type":"GENE","name":"RPL21P50","canonical_id":"hgnc:HGNC:36433","description":"ribosomal protein L21 pseudogene 50","metadata":null},{"id":"e3911ca6c75e469fbcda012cd83d09bc","type":"GENE","name":"RPL21P51","canonical_id":"hgnc:HGNC:36081","description":"ribosomal protein L21 pseudogene 51","metadata":null},{"id":"cfc45d0d45094018a57e26622b20e976","type":"GENE","name":"RPL21P52","canonical_id":"hgnc:HGNC:36621","description":"ribosomal protein L21 pseudogene 52","metadata":null},{"id":"0d0646f5510d4921911ef3b94642b35c","type":"GENE","name":"RPL21P53","canonical_id":"hgnc:HGNC:36574","description":"ribosomal protein L21 pseudogene 53","metadata":null},{"id":"9d90928195fa490583569ac48a834e59","type":"GENE","name":"RPL21P54","canonical_id":"hgnc:HGNC:35552","description":"ribosomal protein L21 pseudogene 54","metadata":null},{"id":"ab7641a1a09d4a6eb0e91d8a30e882af","type":"GENE","name":"RPL21P55","canonical_id":"hgnc:HGNC:36434","description":"ribosomal protein L21 pseudogene 55","metadata":null},{"id":"7c6a697052284841ba56185f424ae1ae","type":"GENE","name":"RPL21P56","canonical_id":"hgnc:HGNC:35525","description":"ribosomal protein L21 pseudogene 56","metadata":null},{"id":"85a068c09154468e9ca8fcaeb03c7d4f","type":"GENE","name":"RPL21P57","canonical_id":"hgnc:HGNC:36644","description":"ribosomal protein L21 pseudogene 57","metadata":null},{"id":"ef1c67b16da94c74a6a42384e1f88326","type":"GENE","name":"RPL21P58","canonical_id":"hgnc:HGNC:35755","description":"ribosomal protein L21 pseudogene 58","metadata":null},{"id":"8cda0766363f4868af5b9552fbbd9c38","type":"GENE","name":"RPL21P59","canonical_id":"hgnc:HGNC:36922","description":"ribosomal protein L21 pseudogene 59","metadata":null},{"id":"11ccee03fd364c90998f1467dc7ffa9e","type":"GENE","name":"RPL21P6","canonical_id":"hgnc:HGNC:23542","description":"ribosomal protein L21 pseudogene 6","metadata":null},{"id":"d6dd335ef39b4d999ed8cd5cd36a94ef","type":"GENE","name":"RPL21P60","canonical_id":"hgnc:HGNC:36044","description":"ribosomal protein L21 pseudogene 60","metadata":null},{"id":"0a2daf4a74544ce2ac80c73dc6a836d0","type":"GENE","name":"RPL21P61","canonical_id":"hgnc:HGNC:36712","description":"ribosomal protein L21 pseudogene 61","metadata":null},{"id":"80cc46ba64b6485bbedeb92f2bfadfc9","type":"GENE","name":"RPL21P62","canonical_id":"hgnc:HGNC:36843","description":"ribosomal protein L21 pseudogene 62","metadata":null},{"id":"3aa9f92bc04347edaf81ccd435900910","type":"GENE","name":"RPL21P63","canonical_id":"hgnc:HGNC:35526","description":"ribosomal protein L21 pseudogene 63","metadata":null},{"id":"c5ad4e3a131f40c48da14dd849381f8a","type":"GENE","name":"RPL21P64","canonical_id":"hgnc:HGNC:36259","description":"ribosomal protein L21 pseudogene 64","metadata":null},{"id":"10c2e292838e44fa8bb33ab7d0888a83","type":"GENE","name":"RPL21P65","canonical_id":"hgnc:HGNC:36017","description":"ribosomal protein L21 pseudogene 65","metadata":null},{"id":"44641036bd2649578371f776a679fa92","type":"GENE","name":"RPL21P66","canonical_id":"hgnc:HGNC:36476","description":"ribosomal protein L21 pseudogene 66","metadata":null},{"id":"9d88859a77c34f82831392332c764ba2","type":"GENE","name":"RPL21P67","canonical_id":"hgnc:HGNC:36139","description":"ribosomal protein L21 pseudogene 67","metadata":null},{"id":"02a2d242802344708b170d3c9bc61002","type":"GENE","name":"RPL21P68","canonical_id":"hgnc:HGNC:35720","description":"ribosomal protein L21 pseudogene 68","metadata":null},{"id":"31f8ecf55f0147379bb3b5244ccf06df","type":"GENE","name":"RPL21P69","canonical_id":"hgnc:HGNC:36753","description":"ribosomal protein L21 pseudogene 69","metadata":null},{"id":"5d84a2e6dd7b4d0a9568c5d3da70683b","type":"GENE","name":"RPL21P7","canonical_id":"hgnc:HGNC:19772","description":"ribosomal protein L21 pseudogene 7","metadata":null},{"id":"8b31fdbe4d394600bee5ee02cd044d40","type":"GENE","name":"RPL21P70","canonical_id":"hgnc:HGNC:37024","description":"ribosomal protein L21 pseudogene 70","metadata":null},{"id":"37fa92b64e604e438894d7ce7915c4e6","type":"GENE","name":"RPL21P71","canonical_id":"hgnc:HGNC:36049","description":"ribosomal protein L21 pseudogene 71","metadata":null},{"id":"843ff80d70ca4456b5e6005d82131d69","type":"GENE","name":"RPL21P72","canonical_id":"hgnc:HGNC:37043","description":"ribosomal protein L21 pseudogene 72","metadata":null},{"id":"c2c4a71fef1b4cbb8fe7d419e0ca3356","type":"GENE","name":"RPL21P73","canonical_id":"hgnc:HGNC:36794","description":"ribosomal protein L21 pseudogene 73","metadata":null},{"id":"5212a5215ed04bcf80d98a7c8697b9bb","type":"GENE","name":"RPL21P74","canonical_id":"hgnc:HGNC:35854","description":"ribosomal protein L21 pseudogene 74","metadata":null},{"id":"cce2d0bb1cfe4c27bb17ab13ca2ce663","type":"GENE","name":"RPL21P75","canonical_id":"hgnc:HGNC:36460","description":"ribosomal protein L21 pseudogene 75","metadata":null},{"id":"b85480510fb24ae1aff184ec98e599a3","type":"GENE","name":"RPL21P76","canonical_id":"hgnc:HGNC:37042","description":"ribosomal protein L21 pseudogene 76","metadata":null},{"id":"c209a63fdd5d4716ae29b35bffad8de4","type":"GENE","name":"RPL21P77","canonical_id":"hgnc:HGNC:36186","description":"ribosomal protein L21 pseudogene 77","metadata":null},{"id":"2c7f4c2a370a4486a7bcc52aa8994bf9","type":"GENE","name":"RPL21P78","canonical_id":"hgnc:HGNC:35917","description":"ribosomal protein L21 pseudogene 78","metadata":null},{"id":"f6c8de481c074b67a82db9973219fcd5","type":"GENE","name":"RPL21P79","canonical_id":"hgnc:HGNC:36931","description":"ribosomal protein L21 pseudogene 79","metadata":null},{"id":"433f7d0e7f154ef2aed8f407b778dc51","type":"GENE","name":"RPL21P8","canonical_id":"hgnc:HGNC:19779","description":"ribosomal protein L21 pseudogene 8","metadata":null},{"id":"f3744d00d5044d6d8e34286318e40184","type":"GENE","name":"RPL21P80","canonical_id":"hgnc:HGNC:35697","description":"ribosomal protein L21 pseudogene 80","metadata":null},{"id":"74ee7ee59ce4472592d91441fb55abe5","type":"GENE","name":"RPL21P81","canonical_id":"hgnc:HGNC:35530","description":"ribosomal protein L21 pseudogene 81","metadata":null},{"id":"b15fadcbb2fb4ab7b6e20340837058fa","type":"GENE","name":"RPL21P82","canonical_id":"hgnc:HGNC:36307","description":"ribosomal protein L21 pseudogene 82","metadata":null},{"id":"597222edf5654dc2a96281671b2374d0","type":"GENE","name":"RPL21P83","canonical_id":"hgnc:HGNC:35864","description":"ribosomal protein L21 pseudogene 83","metadata":null},{"id":"715f7ef1c6f24133a4a35bc53fd159c1","type":"GENE","name":"RPL21P84","canonical_id":"hgnc:HGNC:36612","description":"ribosomal protein L21 pseudogene 84","metadata":null},{"id":"6d87cd7746f44819aed503b21b84bd5c","type":"GENE","name":"RPL21P85","canonical_id":"hgnc:HGNC:35694","description":"ribosomal protein L21 pseudogene 85","metadata":null},{"id":"731902823de04da89a6b4d206e263fa5","type":"GENE","name":"RPL21P86","canonical_id":"hgnc:HGNC:37032","description":"ribosomal protein L21 pseudogene 86","metadata":null},{"id":"710389345fb54dcfbf8fc9591ce428cf","type":"GENE","name":"RPL21P87","canonical_id":"hgnc:HGNC:36411","description":"ribosomal protein L21 pseudogene 87","metadata":null},{"id":"f26ff5539fdd437592897102938e3118","type":"GENE","name":"RPL21P88","canonical_id":"hgnc:HGNC:35714","description":"ribosomal protein L21 pseudogene 88","metadata":null},{"id":"97bb374a9a044cbaa4b0526a5702d453","type":"GENE","name":"RPL21P89","canonical_id":"hgnc:HGNC:36474","description":"ribosomal protein L21 pseudogene 89","metadata":null},{"id":"c5fb523852724aacac588cc285eb7267","type":"GENE","name":"RPL21P9","canonical_id":"hgnc:HGNC:19780","description":"ribosomal protein L21 pseudogene 9","metadata":null},{"id":"d2d5dfe52ac0421a8be763c8a0e1554d","type":"GENE","name":"RPL21P90","canonical_id":"hgnc:HGNC:35548","description":"ribosomal protein L21 pseudogene 90","metadata":null},{"id":"d6f09aa2539a4b28b97b37e2c5c156d3","type":"GENE","name":"RPL21P91","canonical_id":"hgnc:HGNC:36450","description":"ribosomal protein L21 pseudogene 91","metadata":null},{"id":"c01523efe0cf4265bcaa4413470c392f","type":"GENE","name":"RPL21P92","canonical_id":"hgnc:HGNC:35606","description":"ribosomal protein L21 pseudogene 92","metadata":null},{"id":"eacfb0a88dd6420f8d0b93e885fd9f23","type":"GENE","name":"RPL21P93","canonical_id":"hgnc:HGNC:35646","description":"ribosomal protein L21 pseudogene 93","metadata":null},{"id":"96ad7dbe8bd24da3815af99305676080","type":"GENE","name":"RPL21P94","canonical_id":"hgnc:HGNC:35568","description":"ribosomal protein L21 pseudogene 94","metadata":null},{"id":"5442522ab642423dae01909f24c02c61","type":"GENE","name":"RPL21P95","canonical_id":"hgnc:HGNC:36097","description":"ribosomal protein L21 pseudogene 95","metadata":null},{"id":"c99857c87f03473081d97e2f75bc0633","type":"GENE","name":"RPL21P96","canonical_id":"hgnc:HGNC:36790","description":"ribosomal protein L21 pseudogene 96","metadata":null},{"id":"58add4b79f8e4b8192140f82a38b09b0","type":"GENE","name":"RPL21P97","canonical_id":"hgnc:HGNC:36223","description":"ribosomal protein L21 pseudogene 97","metadata":null},{"id":"7aa0875773074f09b8c57828dbcc84a9","type":"GENE","name":"RPL21P98","canonical_id":"hgnc:HGNC:36397","description":"ribosomal protein L21 pseudogene 98","metadata":null},{"id":"15a8c234445c4df5a18d7b31d4579f43","type":"GENE","name":"RPL21P99","canonical_id":"hgnc:HGNC:36628","description":"ribosomal protein L21 pseudogene 99","metadata":null},{"id":"2ee0a9f90bd945a2be85dfc40f1b37f5","type":"GENE","name":"RPL22","canonical_id":"hgnc:HGNC:10315","description":"ribosomal protein L22","metadata":{"aliases":["EAP","L22","eL22"]}},{"id":"dc22e332ae3446e3b594beedc3fed1a3","type":"GENE","name":"RPL22L1","canonical_id":"hgnc:HGNC:27610","description":"ribosomal protein L22 like 1","metadata":null},{"id":"3016599982654a6399f8e012b88f7a0e","type":"GENE","name":"RPL22P1","canonical_id":"hgnc:HGNC:17998","description":"ribosomal protein L22 pseudogene 1","metadata":null},{"id":"7aba3275809741c1bcb9837c93965434","type":"GENE","name":"RPL22P10","canonical_id":"hgnc:HGNC:36559","description":"ribosomal protein L22 pseudogene 10","metadata":null},{"id":"84d3e3e3892244e09a806f4c43616a93","type":"GENE","name":"RPL22P11","canonical_id":"hgnc:HGNC:35603","description":"ribosomal protein L22 pseudogene 11","metadata":{"aliases":["RPL22P15"]}},{"id":"1a741737f17e4df7a7457cef7024d8c5","type":"GENE","name":"RPL22P12","canonical_id":"hgnc:HGNC:36345","description":"ribosomal protein L22 pseudogene 12","metadata":null},{"id":"70a732eebb864ae4beff70091a8080e7","type":"GENE","name":"RPL22P13","canonical_id":"hgnc:HGNC:36352","description":"ribosomal protein L22 pseudogene 13","metadata":null},{"id":"6f45da254b054f82b154980710e52dbb","type":"GENE","name":"RPL22P14","canonical_id":"hgnc:HGNC:35990","description":"ribosomal protein L22 pseudogene 14","metadata":null},{"id":"8e72561ec6834051b35cdb459dca18b0","type":"GENE","name":"RPL22P16","canonical_id":"hgnc:HGNC:36536","description":"ribosomal protein L22 pseudogene 16","metadata":null},{"id":"6dce62dafe8042738af41c616e7abdb9","type":"GENE","name":"RPL22P17","canonical_id":"hgnc:HGNC:36985","description":"ribosomal protein L22 pseudogene 17","metadata":null},{"id":"95ad914521d746fe857fb79b500298ff","type":"GENE","name":"RPL22P18","canonical_id":"hgnc:HGNC:36232","description":"ribosomal protein L22 pseudogene 18","metadata":null},{"id":"7903251a3f7844f5a0e961b186c15ed8","type":"GENE","name":"RPL22P19","canonical_id":"hgnc:HGNC:36567","description":"ribosomal protein L22 pseudogene 19","metadata":null},{"id":"5a0bc9d6547140728890faaf581f95c3","type":"GENE","name":"RPL22P2","canonical_id":"hgnc:HGNC:19794","description":"ribosomal protein L22 pseudogene 2","metadata":null},{"id":"7c0e682d163143ef9a56aaac4819d843","type":"GENE","name":"RPL22P20","canonical_id":"hgnc:HGNC:36281","description":"ribosomal protein L22 pseudogene 20","metadata":null},{"id":"9517f879e9284bf9901101315bef4f76","type":"GENE","name":"RPL22P21","canonical_id":"hgnc:HGNC:35547","description":"ribosomal protein L22 pseudogene 21","metadata":null},{"id":"be3fcaa8a14d41da950462f9e294f120","type":"GENE","name":"RPL22P22","canonical_id":"hgnc:HGNC:36109","description":"ribosomal protein L22 pseudogene 22","metadata":null},{"id":"93b4d51bc89d47a1843c4682680dffd7","type":"GENE","name":"RPL22P23","canonical_id":"hgnc:HGNC:53759","description":"ribosomal protein L22 pseudogene 23","metadata":null},{"id":"26d7a3dd52ef4cb68d15e0a3dfeb9390","type":"GENE","name":"RPL22P24","canonical_id":"hgnc:HGNC:53758","description":"ribosomal protein L22 pseudogene 24","metadata":null},{"id":"23066936a49f43839c0c9d93efdcff31","type":"GENE","name":"RPL22P3","canonical_id":"hgnc:HGNC:36804","description":"ribosomal protein L22 pseudogene 3","metadata":null},{"id":"b98801a80cdf4479acf0de8f63cc9b95","type":"GENE","name":"RPL22P4","canonical_id":"hgnc:HGNC:36299","description":"ribosomal protein L22 pseudogene 4","metadata":null},{"id":"a5789b89eede4af8bdb58cd0b2c2d2a3","type":"GENE","name":"RPL22P5","canonical_id":"hgnc:HGNC:37022","description":"ribosomal protein L22 pseudogene 5","metadata":null},{"id":"8d23c61fcb8041ef932c0308ca2e5141","type":"GENE","name":"RPL22P6","canonical_id":"hgnc:HGNC:36473","description":"ribosomal protein L22 pseudogene 6","metadata":null},{"id":"16cea7831e724eb3ba443f7045a39bf5","type":"GENE","name":"RPL22P7","canonical_id":"hgnc:HGNC:35602","description":"ribosomal protein L22 pseudogene 7","metadata":null},{"id":"6190a9ecc4634a4c8f894c963b7e1e06","type":"GENE","name":"RPL22P8","canonical_id":"hgnc:HGNC:36782","description":"ribosomal protein L22 pseudogene 8","metadata":null},{"id":"8b34ac1f9556400d9a646d251ab9972d","type":"GENE","name":"RPL23","canonical_id":"hgnc:HGNC:10316","description":"ribosomal protein L23","metadata":{"aliases":["rpL17","L23","uL14"]}},{"id":"b8f1f221144f4a238e505f2dcc91dc43","type":"GENE","name":"RPL23A","canonical_id":"hgnc:HGNC:10317","description":"ribosomal protein L23a","metadata":{"aliases":["L23A","uL23"]}},{"id":"9725dc3c1d384f458f9ed0d9cb7b6f40","type":"GENE","name":"RPL23AP1","canonical_id":"hgnc:HGNC:10318","description":"ribosomal protein L23a pseudogene 1","metadata":null},{"id":"a891df45a29c47d0bc87059a875bdcb1","type":"GENE","name":"RPL23AP10","canonical_id":"hgnc:HGNC:19804","description":"ribosomal protein L23a pseudogene 10","metadata":null},{"id":"8039a9ac1a4e4fd1b34478cd1ff13a94","type":"GENE","name":"RPL23AP11","canonical_id":"hgnc:HGNC:19808","description":"ribosomal protein L23a pseudogene 11","metadata":null},{"id":"871ee82ecb54405db718d8776f5ac120","type":"GENE","name":"RPL23AP12","canonical_id":"hgnc:HGNC:23840","description":"ribosomal protein L23a pseudogene 12","metadata":null},{"id":"8c0ff011bef241ccb6f708c84362b5b9","type":"GENE","name":"RPL23AP14","canonical_id":"hgnc:HGNC:21007","description":"ribosomal protein L23a pseudogene 14","metadata":null},{"id":"232772a420f9475f9ab5d26889f61528","type":"GENE","name":"RPL23AP15","canonical_id":"hgnc:HGNC:36486","description":"ribosomal protein L23a pseudogene 15","metadata":null},{"id":"7aa193043c1f471a96a1bf2bbd5e4276","type":"GENE","name":"RPL23AP16","canonical_id":"hgnc:HGNC:36652","description":"ribosomal protein L23a pseudogene 16","metadata":null},{"id":"bb5f68a735bc462085b26f7303329ebb","type":"GENE","name":"RPL23AP17","canonical_id":"hgnc:HGNC:35904","description":"ribosomal protein L23a pseudogene 17","metadata":null},{"id":"2dadf00636ca48e891357099c944807c","type":"GENE","name":"RPL23AP18","canonical_id":"hgnc:HGNC:36726","description":"ribosomal protein L23a pseudogene 18","metadata":null},{"id":"1503176007d44e0c9b3378f01c605e90","type":"GENE","name":"RPL23AP19","canonical_id":"hgnc:HGNC:36708","description":"ribosomal protein L23a pseudogene 19","metadata":null},{"id":"e0367f49a9144ba5aa2711b02b0a03ee","type":"GENE","name":"RPL23AP2","canonical_id":"hgnc:HGNC:10319","description":"ribosomal protein L23a pseudogene 2","metadata":null},{"id":"56e1c5cbcb384731b73beee6d04b958f","type":"GENE","name":"RPL23AP20","canonical_id":"hgnc:HGNC:36622","description":"ribosomal protein L23a pseudogene 20","metadata":null},{"id":"34b70e3f6f1340d08bf41805fe2ced58","type":"GENE","name":"RPL23AP21","canonical_id":"hgnc:HGNC:35827","description":"ribosomal protein L23a pseudogene 21","metadata":null},{"id":"25862bac7dfd442db817b3c6aa58ab76","type":"GENE","name":"RPL23AP22","canonical_id":"hgnc:HGNC:35505","description":"ribosomal protein L23a pseudogene 22","metadata":null},{"id":"51da3149def54a1aabac849be4abfb5d","type":"GENE","name":"RPL23AP23","canonical_id":"hgnc:HGNC:36272","description":"ribosomal protein L23a pseudogene 23","metadata":null},{"id":"bd9ef1dc8dc2478c9563da7cdbe88378","type":"GENE","name":"RPL23AP24","canonical_id":"hgnc:HGNC:36176","description":"ribosomal protein L23a pseudogene 24","metadata":null},{"id":"db102646c96d4a3a94e6729a4e97113f","type":"GENE","name":"RPL23AP25","canonical_id":"hgnc:HGNC:35672","description":"ribosomal protein L23a pseudogene 25","metadata":null},{"id":"330a148060364723b1d249156f752d36","type":"GENE","name":"RPL23AP26","canonical_id":"hgnc:HGNC:35592","description":"ribosomal protein L23a pseudogene 26","metadata":null},{"id":"d2f4ca8b20c04808abf136fd780670fd","type":"GENE","name":"RPL23AP27","canonical_id":"hgnc:HGNC:36497","description":"ribosomal protein L23a pseudogene 27","metadata":null},{"id":"c741ccdcd95c43c6890b1960870c8365","type":"GENE","name":"RPL23AP28","canonical_id":"hgnc:HGNC:36727","description":"ribosomal protein L23a pseudogene 28","metadata":null},{"id":"a032e018d69b4226a47aaa490f599c08","type":"GENE","name":"RPL23AP29","canonical_id":"hgnc:HGNC:36355","description":"ribosomal protein L23a pseudogene 29","metadata":null},{"id":"12d3d1c22bda4d2a9fc42ffbff174452","type":"GENE","name":"RPL23AP3","canonical_id":"hgnc:HGNC:10320","description":"ribosomal protein L23a pseudogene 3","metadata":null},{"id":"725316285b5a4ab58e8359493ecbca5f","type":"GENE","name":"RPL23AP30","canonical_id":"hgnc:HGNC:35617","description":"ribosomal protein L23a pseudogene 30","metadata":null},{"id":"adc91e26e62445bcb74634a50e090bb6","type":"GENE","name":"RPL23AP31","canonical_id":"hgnc:HGNC:35777","description":"ribosomal protein L23a pseudogene 31","metadata":null},{"id":"e5e49017ef2b48bb9fc9a4d97eb21a34","type":"GENE","name":"RPL23AP32","canonical_id":"hgnc:HGNC:25345","description":"ribosomal protein L23a pseudogene 32","metadata":{"aliases":["DKFZp547I014"]}},{"id":"907e9c5063dc4200ade63c16840c5a41","type":"GENE","name":"RPL23AP33","canonical_id":"hgnc:HGNC:36946","description":"ribosomal protein L23a pseudogene 33","metadata":null},{"id":"cd257251674e492e950b750f0f28380f","type":"GENE","name":"RPL23AP34","canonical_id":"hgnc:HGNC:36035","description":"ribosomal protein L23a pseudogene 34","metadata":null},{"id":"66ddb06f7198465fb64facc054932339","type":"GENE","name":"RPL23AP35","canonical_id":"hgnc:HGNC:36580","description":"ribosomal protein L23a pseudogene 35","metadata":null},{"id":"33dc3372efbb40b6aedddb203d19de97","type":"GENE","name":"RPL23AP36","canonical_id":"hgnc:HGNC:35685","description":"ribosomal protein L23a pseudogene 36","metadata":null},{"id":"4709cacde7d4490e9058c9b669a8ba08","type":"GENE","name":"RPL23AP37","canonical_id":"hgnc:HGNC:35664","description":"ribosomal protein L23a pseudogene 37","metadata":null},{"id":"79ab0a61d59c4888bc52830ca676f792","type":"GENE","name":"RPL23AP38","canonical_id":"hgnc:HGNC:36351","description":"ribosomal protein L23a pseudogene 38","metadata":null},{"id":"53d13f89fa78496a8dad573d4c15bafb","type":"GENE","name":"RPL23AP39","canonical_id":"hgnc:HGNC:36470","description":"ribosomal protein L23a pseudogene 39","metadata":null},{"id":"f46b873551b14786a889bfccb652d365","type":"GENE","name":"RPL23AP4","canonical_id":"hgnc:HGNC:10321","description":"ribosomal protein L23a pseudogene 4","metadata":null},{"id":"f9ebc02146d4440ca109c270a6b32e9e","type":"GENE","name":"RPL23AP40","canonical_id":"hgnc:HGNC:35587","description":"ribosomal protein L23a pseudogene 40","metadata":null},{"id":"3955e0efe2b7471891ab43c850ecd58c","type":"GENE","name":"RPL23AP41","canonical_id":"hgnc:HGNC:35634","description":"ribosomal protein L23a pseudogene 41","metadata":null},{"id":"259b72ca742f49ed9b7623344d31f2b2","type":"GENE","name":"RPL23AP42","canonical_id":"hgnc:HGNC:35942","description":"ribosomal protein L23a pseudogene 42","metadata":null},{"id":"18a6f8263bc14c45aad450a58c70c3a7","type":"GENE","name":"RPL23AP43","canonical_id":"hgnc:HGNC:35751","description":"ribosomal protein L23a pseudogene 43","metadata":null},{"id":"3b5b4324228241d0b6e72a72715f7b64","type":"GENE","name":"RPL23AP44","canonical_id":"hgnc:HGNC:35955","description":"ribosomal protein L23a pseudogene 44","metadata":null},{"id":"4e0dfdb5a24a4a65b75e8474cfe364b5","type":"GENE","name":"RPL23AP45","canonical_id":"hgnc:HGNC:36896","description":"ribosomal protein L23a pseudogene 45","metadata":null},{"id":"b7e280f53c8541249fb03e56d2cbc225","type":"GENE","name":"RPL23AP46","canonical_id":"hgnc:HGNC:35894","description":"ribosomal protein L23a pseudogene 46","metadata":null},{"id":"a01f541d8e304840a8e52113ee34fdb2","type":"GENE","name":"RPL23AP47","canonical_id":"hgnc:HGNC:36576","description":"ribosomal protein L23a pseudogene 47","metadata":null},{"id":"03229eba103e48309460cf0cf971963e","type":"GENE","name":"RPL23AP48","canonical_id":"hgnc:HGNC:36110","description":"ribosomal protein L23a pseudogene 48","metadata":null},{"id":"eac173090bc14ed5a6ad154250444110","type":"GENE","name":"RPL23AP49","canonical_id":"hgnc:HGNC:35689","description":"ribosomal protein L23a pseudogene 49","metadata":null},{"id":"e88d69c61038496d9f80011f781aeb18","type":"GENE","name":"RPL23AP5","canonical_id":"hgnc:HGNC:14194","description":"ribosomal protein L23a pseudogene 5","metadata":null},{"id":"fb8658c755994570992a72f9e7d5d451","type":"GENE","name":"RPL23AP50","canonical_id":"hgnc:HGNC:35958","description":"ribosomal protein L23a pseudogene 50","metadata":null},{"id":"7026210097b84f0d848cc8b4709c20e8","type":"GENE","name":"RPL23AP51","canonical_id":"hgnc:HGNC:36040","description":"ribosomal protein L23a pseudogene 51","metadata":null},{"id":"77d2a3af7f344c6fa2858d072a2d6fa0","type":"GENE","name":"RPL23AP52","canonical_id":"hgnc:HGNC:36723","description":"ribosomal protein L23a pseudogene 52","metadata":null},{"id":"9d7c68b3a2c743deab902f3349873ec4","type":"GENE","name":"RPL23AP53","canonical_id":"hgnc:HGNC:35921","description":"ribosomal protein L23a pseudogene 53","metadata":null},{"id":"044aa2c9eeb84f70ac62008920e9c760","type":"GENE","name":"RPL23AP54","canonical_id":"hgnc:HGNC:36689","description":"ribosomal protein L23a pseudogene 54","metadata":null},{"id":"ad383732e0974eb19c31b750068727e2","type":"GENE","name":"RPL23AP55","canonical_id":"hgnc:HGNC:35997","description":"ribosomal protein L23a pseudogene 55","metadata":null},{"id":"e139b02e5139499fa0d1ce8353ce5daa","type":"GENE","name":"RPL23AP56","canonical_id":"hgnc:HGNC:35516","description":"ribosomal protein L23a pseudogene 56","metadata":null},{"id":"9adcc99f004c4c7cbb1bf3c305a6b262","type":"GENE","name":"RPL23AP57","canonical_id":"hgnc:HGNC:36971","description":"ribosomal protein L23a pseudogene 57","metadata":null},{"id":"ff7ade8bcf09484095b55680c02bf857","type":"GENE","name":"RPL23AP58","canonical_id":"hgnc:HGNC:36138","description":"ribosomal protein L23a pseudogene 58","metadata":null},{"id":"7f6ff6f9c24b49c8ba2f964abccc9f5b","type":"GENE","name":"RPL23AP59","canonical_id":"hgnc:HGNC:36920","description":"ribosomal protein L23a pseudogene 59","metadata":null},{"id":"e5b8b8bc060a4bf19d85ba7b26a30189","type":"GENE","name":"RPL23AP6","canonical_id":"hgnc:HGNC:16555","description":"ribosomal protein L23a pseudogene 6","metadata":{"aliases":["dJ1068F16.1"]}},{"id":"19822def1e95450bb3a1ea8d9112dc83","type":"GENE","name":"RPL23AP60","canonical_id":"hgnc:HGNC:35966","description":"ribosomal protein L23a pseudogene 60","metadata":null},{"id":"5ce414368837475c99b4472e2dcbae14","type":"GENE","name":"RPL23AP61","canonical_id":"hgnc:HGNC:36016","description":"ribosomal protein L23a pseudogene 61","metadata":null},{"id":"04148ac2e434426589d5645b5eec1061","type":"GENE","name":"RPL23AP62","canonical_id":"hgnc:HGNC:36276","description":"ribosomal protein L23a pseudogene 62","metadata":null},{"id":"da040f2acead4f168895a47b436a0d35","type":"GENE","name":"RPL23AP63","canonical_id":"hgnc:HGNC:35502","description":"ribosomal protein L23a pseudogene 63","metadata":null},{"id":"9595b69946614cc295c9b2580ce924c2","type":"GENE","name":"RPL23AP64","canonical_id":"hgnc:HGNC:36552","description":"ribosomal protein L23a pseudogene 64","metadata":null},{"id":"10e6ea4418a54f6cad6f54c02ba26dd1","type":"GENE","name":"RPL23AP65","canonical_id":"hgnc:HGNC:36289","description":"ribosomal protein L23a pseudogene 65","metadata":null},{"id":"e6c14636cc384fc19dd1429e7755c12e","type":"GENE","name":"RPL23AP66","canonical_id":"hgnc:HGNC:35940","description":"ribosomal protein L23a pseudogene 66","metadata":null},{"id":"9d15491a3f074119b851fabe57e811c2","type":"GENE","name":"RPL23AP67","canonical_id":"hgnc:HGNC:36658","description":"ribosomal protein L23a pseudogene 67","metadata":null},{"id":"428a8ce9ab7a4c9a95cda464963ff975","type":"GENE","name":"RPL23AP68","canonical_id":"hgnc:HGNC:35489","description":"ribosomal protein L23a pseudogene 68","metadata":null},{"id":"6b7823c985c44c4eafa616f67d5592ce","type":"GENE","name":"RPL23AP69","canonical_id":"hgnc:HGNC:36625","description":"ribosomal protein L23a pseudogene 69","metadata":null},{"id":"d2d9a8e23c9b49a7a495ece4f7ea1f52","type":"GENE","name":"RPL23AP7","canonical_id":"hgnc:HGNC:17336","description":"ribosomal protein L23a pseudogene 7","metadata":{"aliases":["RPL23AL1","bA395L14.9"]}},{"id":"29d91383eda6490e9d384f1cf9d8dbcf","type":"GENE","name":"RPL23AP70","canonical_id":"hgnc:HGNC:36030","description":"ribosomal protein L23a pseudogene 70","metadata":null},{"id":"8ff41e00eea64b4e8ab702ad6f74af6d","type":"GENE","name":"RPL23AP71","canonical_id":"hgnc:HGNC:36908","description":"ribosomal protein L23a pseudogene 71","metadata":null},{"id":"919d876d1dac48a4baf08a2ae0616920","type":"GENE","name":"RPL23AP72","canonical_id":"hgnc:HGNC:35736","description":"ribosomal protein L23a pseudogene 72","metadata":null},{"id":"eb56d8871f9747828859fd08b456a094","type":"GENE","name":"RPL23AP73","canonical_id":"hgnc:HGNC:36443","description":"ribosomal protein L23a pseudogene 73","metadata":null},{"id":"b6b858f4d07142a4a0ee1ee158ea473a","type":"GENE","name":"RPL23AP74","canonical_id":"hgnc:HGNC:36148","description":"ribosomal protein L23a pseudogene 74","metadata":null},{"id":"db7a8706eaab4389b3e763f96191057e","type":"GENE","name":"RPL23AP75","canonical_id":"hgnc:HGNC:35975","description":"ribosomal protein L23a pseudogene 75","metadata":null},{"id":"665578676128434ea7ae4d05fc17fabe","type":"GENE","name":"RPL23AP76","canonical_id":"hgnc:HGNC:36555","description":"ribosomal protein L23a pseudogene 76","metadata":null},{"id":"26f80621d5c949d4a19a2fd20c118947","type":"GENE","name":"RPL23AP77","canonical_id":"hgnc:HGNC:36354","description":"ribosomal protein L23a pseudogene 77","metadata":null},{"id":"9d6134fa97ec4a46ba3ac2ac4e6dd488","type":"GENE","name":"RPL23AP78","canonical_id":"hgnc:HGNC:35518","description":"ribosomal protein L23a pseudogene 78","metadata":null},{"id":"790092fd36f84e5393ad60f6b6e2acc1","type":"GENE","name":"RPL23AP79","canonical_id":"hgnc:HGNC:36226","description":"ribosomal protein L23a pseudogene 79","metadata":null},{"id":"5595abcac7ff4271aaa601c21f2a9f02","type":"GENE","name":"RPL23AP8","canonical_id":"hgnc:HGNC:23543","description":"ribosomal protein L23a pseudogene 8","metadata":{"aliases":["RPL23AP9"]}},{"id":"d9c770fb8748458e916803a452f90630","type":"GENE","name":"RPL23AP80","canonical_id":"hgnc:HGNC:36956","description":"ribosomal protein L23a pseudogene 80","metadata":null},{"id":"a2d64b973c86425d971721f3f4b8d421","type":"GENE","name":"RPL23AP81","canonical_id":"hgnc:HGNC:36246","description":"ribosomal protein L23a pseudogene 81","metadata":null},{"id":"116d40d39687413ab9f3e6e882caeccf","type":"GENE","name":"RPL23AP82","canonical_id":"hgnc:HGNC:33730","description":"ribosomal protein L23a pseudogene 82","metadata":{"aliases":["MGC70863"]}},{"id":"58640a9e7a85439d8e6fb9dc9c4862f5","type":"GENE","name":"RPL23AP83","canonical_id":"hgnc:HGNC:35846","description":"ribosomal protein L23a pseudogene 83","metadata":null},{"id":"24602587121040fd9d9084f9a268e08a","type":"GENE","name":"RPL23AP84","canonical_id":"hgnc:HGNC:51575","description":"ribosomal protein L23a pseudogene 84","metadata":null},{"id":"5a9afbf1c0114be8b965ec51ceaa2294","type":"GENE","name":"RPL23AP85","canonical_id":"hgnc:HGNC:51576","description":"ribosomal protein L23a pseudogene 85","metadata":null},{"id":"8a30856d2720401bae1dd730c9ca8de5","type":"GENE","name":"RPL23AP86","canonical_id":"hgnc:HGNC:51577","description":"ribosomal protein L23a pseudogene 86","metadata":null},{"id":"bee3ebd3932a4c0283495e7b9488331e","type":"GENE","name":"RPL23AP87","canonical_id":"hgnc:HGNC:51578","description":"ribosomal protein L23a pseudogene 87","metadata":null},{"id":"afdb22496edf44cfb6db4e7d4d0ddb84","type":"GENE","name":"RPL23AP88","canonical_id":"hgnc:HGNC:51579","description":"ribosomal protein L23a pseudogene 88","metadata":null},{"id":"c0bcef60aadd49bbbe4fec771dbb3060","type":"GENE","name":"RPL23AP89","canonical_id":"hgnc:HGNC:51623","description":"ribosomal protein L23a pseudogene 89","metadata":null},{"id":"c1610fa91b0348e6a4db7f8620b18d35","type":"GENE","name":"RPL23AP90","canonical_id":"hgnc:HGNC:51624","description":"ribosomal protein L23a pseudogene 90","metadata":null},{"id":"dd33794cb39a4b55b7ff68755936df27","type":"GENE","name":"RPL23AP91","canonical_id":"hgnc:HGNC:51625","description":"ribosomal protein L23a pseudogene 91","metadata":null},{"id":"fbc9138eb57e40999a92b37dd2a5d8af","type":"GENE","name":"RPL23AP92","canonical_id":"hgnc:HGNC:51627","description":"ribosomal protein L23a pseudogene 92","metadata":null},{"id":"a14b3c7b0f504cbd9fbf5265f3075456","type":"GENE","name":"RPL23AP93","canonical_id":"hgnc:HGNC:51628","description":"ribosomal protein L23a pseudogene 93","metadata":null},{"id":"5b11b9ad07d84270bc19406bb6845149","type":"GENE","name":"RPL23AP94","canonical_id":"hgnc:HGNC:51629","description":"ribosomal protein L23a pseudogene 94","metadata":null},{"id":"8f3d26d6dd40421caf8019806a3e8f38","type":"GENE","name":"RPL23AP95","canonical_id":"hgnc:HGNC:51630","description":"ribosomal protein L23a pseudogene 95","metadata":null},{"id":"10291e1f535a4240a78768a225e18cce","type":"GENE","name":"RPL23AP96","canonical_id":"hgnc:HGNC:51631","description":"ribosomal protein L23a pseudogene 96","metadata":null},{"id":"5efc65dc265645b5aaeca83a265d3a82","type":"GENE","name":"RPL23AP97","canonical_id":"hgnc:HGNC:51632","description":"ribosomal protein L23a pseudogene 97","metadata":null},{"id":"e5e7df57d02d4bb19b964d60daf2166e","type":"GENE","name":"RPL23P10","canonical_id":"hgnc:HGNC:36177","description":"ribosomal protein L23 pseudogene 10","metadata":null},{"id":"2b87de0d09f44d81bf4bf77630db8a50","type":"GENE","name":"RPL23P11","canonical_id":"hgnc:HGNC:36457","description":"ribosomal protein L23 pseudogene 11","metadata":null},{"id":"56f3ab7f23b84f56a599f05c3df46b20","type":"GENE","name":"RPL23P2","canonical_id":"hgnc:HGNC:10324","description":"ribosomal protein L23 pseudogene 2","metadata":null},{"id":"fb62ecc3310d4301935330aa82114d2a","type":"GENE","name":"RPL23P3","canonical_id":"hgnc:HGNC:35988","description":"ribosomal protein L23 pseudogene 3","metadata":null},{"id":"16bfb56464874ddba9081797e4a27932","type":"GENE","name":"RPL23P4","canonical_id":"hgnc:HGNC:36678","description":"ribosomal protein L23 pseudogene 4","metadata":null},{"id":"04d66b07d7a64dcb8a05200e7a355ee6","type":"GENE","name":"RPL23P5","canonical_id":"hgnc:HGNC:35747","description":"ribosomal protein L23 pseudogene 5","metadata":null},{"id":"792d30857aa24ca9b1a5a886b974e622","type":"GENE","name":"RPL23P6","canonical_id":"hgnc:HGNC:35554","description":"ribosomal protein L23 pseudogene 6","metadata":null},{"id":"25de491c819b40798d9e0f9d7a2808fa","type":"GENE","name":"RPL23P7","canonical_id":"hgnc:HGNC:36215","description":"ribosomal protein L23 pseudogene 7","metadata":null},{"id":"e55e3185871c47559cb3004827945842","type":"GENE","name":"RPL23P8","canonical_id":"hgnc:HGNC:36225","description":"ribosomal protein L23 pseudogene 8","metadata":null},{"id":"7804d8acf7bf40fd820e9ac456829160","type":"GENE","name":"RPL23P9","canonical_id":"hgnc:HGNC:36853","description":"ribosomal protein L23 pseudogene 9","metadata":null},{"id":"0dcf319b3153483fadfaca99fe6538e7","type":"GENE","name":"RPL24","canonical_id":"hgnc:HGNC:10325","description":"ribosomal protein L24","metadata":{"aliases":["L24","eL24"]}},{"id":"e1fb687a7ec240ebada32a4e0636e494","type":"GENE","name":"RPL24P2","canonical_id":"hgnc:HGNC:16597","description":"RPL24 pseudogene 2","metadata":{"aliases":["dJ872K7.2"]}},{"id":"977689549a8d4c0282188339833bc80b","type":"GENE","name":"RPL24P3","canonical_id":"hgnc:HGNC:19784","description":"RPL24 pseudogene 3","metadata":null},{"id":"f8170bac136d4343bbb74ec0a9575764","type":"GENE","name":"RPL24P4","canonical_id":"hgnc:HGNC:21371","description":"RPL24 pseudogene 4","metadata":{"aliases":["dJ125M3.1"]}},{"id":"e84102050a0d422e800e89a468cc2631","type":"GENE","name":"RPL24P5","canonical_id":"hgnc:HGNC:36102","description":"RPL24 pseudogene 5","metadata":null},{"id":"cc5d3f1bfaf44e76acd6f828e59de25a","type":"GENE","name":"RPL24P6","canonical_id":"hgnc:HGNC:36637","description":"RPL24 pseudogene 6","metadata":null},{"id":"e6f8f6f990f34369bc4641c1b8b1aa3d","type":"GENE","name":"RPL24P7","canonical_id":"hgnc:HGNC:36862","description":"RPL24 pseudogene 7","metadata":null},{"id":"737197521bfe48b1895f766257bfb78a","type":"GENE","name":"RPL24P8","canonical_id":"hgnc:HGNC:36409","description":"RPL24 pseudogene 8","metadata":null},{"id":"1bd63824542e45c9bf52a9174b53cbaf","type":"GENE","name":"RPL24P9","canonical_id":"hgnc:HGNC:54886","description":"RPL24 pseudogene 9","metadata":null},{"id":"46d6938f271f42319796cd32dd86d469","type":"GENE","name":"RPL26","canonical_id":"hgnc:HGNC:10327","description":"ribosomal protein L26","metadata":{"aliases":["L26","uL24"]}},{"id":"ae35344125a144bc8aa87fb5452f0c38","type":"GENE","name":"RPL26L1","canonical_id":"hgnc:HGNC:17050","description":"ribosomal protein L26 like 1","metadata":{"aliases":["RPL26P1"]}},{"id":"84feea69319044c888b9a7ed0df6f627","type":"GENE","name":"RPL26L1-AS1","canonical_id":"hgnc:HGNC:55914","description":"RPL26L1 antisense RNA 1","metadata":null},{"id":"856ee02a59d7459c93d3ae16eeb95bcf","type":"GENE","name":"RPL26P10","canonical_id":"hgnc:HGNC:36323","description":"ribosomal protein L26 pseudogene 10","metadata":null},{"id":"a7f646e0931742a7988e727cf985188b","type":"GENE","name":"RPL26P11","canonical_id":"hgnc:HGNC:35768","description":"ribosomal protein L26 pseudogene 11","metadata":null},{"id":"361f9215183943a2bc5464580f45aaee","type":"GENE","name":"RPL26P12","canonical_id":"hgnc:HGNC:36025","description":"ribosomal protein L26 pseudogene 12","metadata":null},{"id":"bab7ea821e1f431ebff26f0e7fd62f6f","type":"GENE","name":"RPL26P13","canonical_id":"hgnc:HGNC:36639","description":"ribosomal protein L26 pseudogene 13","metadata":null},{"id":"89ded43ff32348d39e0f7041d84ffabd","type":"GENE","name":"RPL26P14","canonical_id":"hgnc:HGNC:36184","description":"ribosomal protein L26 pseudogene 14","metadata":null},{"id":"54364e55ffee40c1b3b45ab4a019b7a0","type":"GENE","name":"RPL26P15","canonical_id":"hgnc:HGNC:35512","description":"ribosomal protein L26 pseudogene 15","metadata":null},{"id":"967c0012ce3e4cccbc73dc017b5426ef","type":"GENE","name":"RPL26P16","canonical_id":"hgnc:HGNC:36098","description":"ribosomal protein L26 pseudogene 16","metadata":null},{"id":"d8975ef8d85c4bdaa44a89f3b73e99b8","type":"GENE","name":"RPL26P17","canonical_id":"hgnc:HGNC:35662","description":"ribosomal protein L26 pseudogene 17","metadata":null},{"id":"9cc11b7955f440079978c6b1de9e9ad2","type":"GENE","name":"RPL26P18","canonical_id":"hgnc:HGNC:36579","description":"ribosomal protein L26 pseudogene 18","metadata":null},{"id":"7ae6fceae7c643a4ac3fcdd639e29efe","type":"GENE","name":"RPL26P19","canonical_id":"hgnc:HGNC:36393","description":"ribosomal protein L26 pseudogene 19","metadata":null},{"id":"b8971d2c530d4d94bf8cc83b04883834","type":"GENE","name":"RPL26P2","canonical_id":"hgnc:HGNC:19773","description":"ribosomal protein L26 pseudogene 2","metadata":null},{"id":"f41e989a0f9a4d76b2c7fc709c60e257","type":"GENE","name":"RPL26P20","canonical_id":"hgnc:HGNC:35933","description":"ribosomal protein L26 pseudogene 20","metadata":null},{"id":"123e106e0bff4fd792d43bd07bd54a29","type":"GENE","name":"RPL26P21","canonical_id":"hgnc:HGNC:35497","description":"ribosomal protein L26 pseudogene 21","metadata":null},{"id":"908a41b10f994436b012eb941072124e","type":"GENE","name":"RPL26P22","canonical_id":"hgnc:HGNC:36244","description":"ribosomal protein L26 pseudogene 22","metadata":null},{"id":"648acf019fe8464096b90d209cef6c5e","type":"GENE","name":"RPL26P23","canonical_id":"hgnc:HGNC:36634","description":"ribosomal protein L26 pseudogene 23","metadata":null},{"id":"88b4aaa23d3846cdacf91baa7b6bb2a9","type":"GENE","name":"RPL26P24","canonical_id":"hgnc:HGNC:35774","description":"ribosomal protein L26 pseudogene 24","metadata":null},{"id":"e0f382941c1d447695f8368dc2cb7682","type":"GENE","name":"RPL26P25","canonical_id":"hgnc:HGNC:36383","description":"ribosomal protein L26 pseudogene 25","metadata":null},{"id":"d647b15f2466411ba11549bc55076d21","type":"GENE","name":"RPL26P26","canonical_id":"hgnc:HGNC:35693","description":"ribosomal protein L26 pseudogene 26","metadata":null},{"id":"765d903479694b4fafb5b2ba27c7d9d2","type":"GENE","name":"RPL26P27","canonical_id":"hgnc:HGNC:36735","description":"ribosomal protein L26 pseudogene 27","metadata":null},{"id":"9a3b9f0cc28747dd8241456fe00212d5","type":"GENE","name":"RPL26P28","canonical_id":"hgnc:HGNC:35776","description":"ribosomal protein L26 pseudogene 28","metadata":null},{"id":"dd5a9e80264c4665a7bfe7bcd255b137","type":"GENE","name":"RPL26P29","canonical_id":"hgnc:HGNC:36135","description":"ribosomal protein L26 pseudogene 29","metadata":null},{"id":"f6e34c9e10974ed385628f3efb972554","type":"GENE","name":"RPL26P3","canonical_id":"hgnc:HGNC:19776","description":"ribosomal protein L26 pseudogene 3","metadata":null},{"id":"f009fdd37cf14b90b0065716e2580bca","type":"GENE","name":"RPL26P30","canonical_id":"hgnc:HGNC:36733","description":"ribosomal protein L26 pseudogene 30","metadata":null},{"id":"e8d5476e4dcc4a12aa5a9eda0e5a499b","type":"GENE","name":"RPL26P31","canonical_id":"hgnc:HGNC:36907","description":"ribosomal protein L26 pseudogene 31","metadata":null},{"id":"79e0bf3467534ad4ab973c5754cfa537","type":"GENE","name":"RPL26P32","canonical_id":"hgnc:HGNC:36448","description":"ribosomal protein L26 pseudogene 32","metadata":null},{"id":"9e53ee2d50604f39b62289cb8ad9c09d","type":"GENE","name":"RPL26P33","canonical_id":"hgnc:HGNC:36755","description":"ribosomal protein L26 pseudogene 33","metadata":null},{"id":"d51db1274f724e4bad0e5e8a74ad8b58","type":"GENE","name":"RPL26P34","canonical_id":"hgnc:HGNC:36249","description":"ribosomal protein L26 pseudogene 34","metadata":null},{"id":"8e0f24b68d97444ab17235a6eaf31928","type":"GENE","name":"RPL26P35","canonical_id":"hgnc:HGNC:36278","description":"ribosomal protein L26 pseudogene 35","metadata":null},{"id":"1554f43c7eb44a95aa55efe4093a5798","type":"GENE","name":"RPL26P36","canonical_id":"hgnc:HGNC:36685","description":"ribosomal protein L26 pseudogene 36","metadata":null},{"id":"6fcebbe8603a4463bc99f7d87cf0400e","type":"GENE","name":"RPL26P37","canonical_id":"hgnc:HGNC:36004","description":"ribosomal protein L26 pseudogene 37","metadata":null},{"id":"c949ab3b2c46470c821923d385b72f73","type":"GENE","name":"RPL26P4","canonical_id":"hgnc:HGNC:19807","description":"ribosomal protein L26 pseudogene 4","metadata":null},{"id":"b9f22f813ab446a6b550230b0e416c1b","type":"GENE","name":"RPL26P5","canonical_id":"hgnc:HGNC:31031","description":"ribosomal protein L26 pseudogene 5","metadata":{"aliases":["HsT41398"]}},{"id":"7dc902ec63984cc2a30c7e716c56a69d","type":"GENE","name":"RPL26P6","canonical_id":"hgnc:HGNC:34023","description":"ribosomal protein L26 pseudogene 6","metadata":null},{"id":"8cce7712bb5647aabfde735bd9328280","type":"GENE","name":"RPL26P7","canonical_id":"hgnc:HGNC:37030","description":"ribosomal protein L26 pseudogene 7","metadata":null},{"id":"6eb77719fae44288b04be8f7a852acd7","type":"GENE","name":"RPL26P8","canonical_id":"hgnc:HGNC:36192","description":"ribosomal protein L26 pseudogene 8","metadata":null},{"id":"6dcbb37bd4284cff87f4a10838df1341","type":"GENE","name":"RPL26P9","canonical_id":"hgnc:HGNC:36180","description":"ribosomal protein L26 pseudogene 9","metadata":null},{"id":"e83f86a6e0074a2e8100ed0e61c8add8","type":"GENE","name":"RPL27","canonical_id":"hgnc:HGNC:10328","description":"ribosomal protein L27","metadata":{"aliases":["L27","eL27"]}},{"id":"206b3136cbd045a39019d5e1e3b38d28","type":"GENE","name":"RPL27A","canonical_id":"hgnc:HGNC:10329","description":"ribosomal protein L27a","metadata":{"aliases":["L27A","uL15"]}},{"id":"852d233aadc749f38e0aafeae7392a15","type":"GENE","name":"RPL27AP","canonical_id":"hgnc:HGNC:16250","description":"ribosomal protein L27a pseudogene","metadata":{"aliases":["dJ1028D15.2"]}},{"id":"e2d360e28a574464a4ced608162f9587","type":"GENE","name":"RPL27AP2","canonical_id":"hgnc:HGNC:36238","description":"ribosomal protein L27a pseudogene 2","metadata":null},{"id":"d1cb32f1de6243bdacb38739a240c2ef","type":"GENE","name":"RPL27AP3","canonical_id":"hgnc:HGNC:35553","description":"ribosomal protein L27a pseudogene 3","metadata":null},{"id":"84c84f1e74cf4e39a3afa7df0c1436d8","type":"GENE","name":"RPL27AP4","canonical_id":"hgnc:HGNC:36262","description":"ribosomal protein L27a pseudogene 4","metadata":null},{"id":"8c71cce5311345e0b0200bfcafb66323","type":"GENE","name":"RPL27AP5","canonical_id":"hgnc:HGNC:36420","description":"ribosomal protein L27a pseudogene 5","metadata":null},{"id":"a53567bbe88e4975a472665147fd95aa","type":"GENE","name":"RPL27AP6","canonical_id":"hgnc:HGNC:35977","description":"ribosomal protein L27a pseudogene 6","metadata":null},{"id":"d5721e9a397c4885b645b479a335a2e9","type":"GENE","name":"RPL27AP7","canonical_id":"hgnc:HGNC:36064","description":"ribosomal protein L27a pseudogene 7","metadata":null},{"id":"d8657104aa254546a8f5461e5d5986c1","type":"GENE","name":"RPL27AP8","canonical_id":"hgnc:HGNC:36544","description":"ribosomal protein L27a pseudogene 8","metadata":null},{"id":"cf74c161f2044ff780a80cbfa026bb0e","type":"GENE","name":"RPL27AP9","canonical_id":"hgnc:HGNC:56964","description":"ribosomal protein L27a pseudogene 9","metadata":null},{"id":"79652c537a91496887f14d415dfccc55","type":"GENE","name":"RPL27P1","canonical_id":"hgnc:HGNC:19668","description":"ribosomal protein L27 pseudogene 1","metadata":null},{"id":"cbba0663023b4d019d5c7bfb3fa5d67a","type":"GENE","name":"RPL27P10","canonical_id":"hgnc:HGNC:35494","description":"ribosomal protein L27 pseudogene 10","metadata":null},{"id":"fda9075b1a7942a9b68c48ae0aa6b374","type":"GENE","name":"RPL27P11","canonical_id":"hgnc:HGNC:36533","description":"ribosomal protein L27 pseudogene 11","metadata":null},{"id":"56314323d0c346f9be40a41bf0ad785e","type":"GENE","name":"RPL27P12","canonical_id":"hgnc:HGNC:36736","description":"ribosomal protein L27 pseudogene 12","metadata":null},{"id":"74f730a607bd4423a51eb3ade16d87de","type":"GENE","name":"RPL27P2","canonical_id":"hgnc:HGNC:36948","description":"ribosomal protein L27 pseudogene 2","metadata":null},{"id":"35b4906eaaef4a36a53b80c76268e368","type":"GENE","name":"RPL27P4","canonical_id":"hgnc:HGNC:35503","description":"ribosomal protein L27 pseudogene 4","metadata":null},{"id":"5458b58954b544a99f29134e179bf414","type":"GENE","name":"RPL27P5","canonical_id":"hgnc:HGNC:36120","description":"ribosomal protein L27 pseudogene 5","metadata":null},{"id":"414a66ea3d9c4f118e1510646b716ae9","type":"GENE","name":"RPL27P6","canonical_id":"hgnc:HGNC:36330","description":"ribosomal protein L27 pseudogene 6","metadata":null},{"id":"73188198ff8f49c8bab3badf5c5d7c7a","type":"GENE","name":"RPL27P7","canonical_id":"hgnc:HGNC:36107","description":"ribosomal protein L27 pseudogene 7","metadata":null},{"id":"478989d3d9394b09bf911adf0ea6ec36","type":"GENE","name":"RPL27P8","canonical_id":"hgnc:HGNC:36012","description":"ribosomal protein L27 pseudogene 8","metadata":null},{"id":"037ab285d49c46c6ace3048fce77a5d4","type":"GENE","name":"RPL27P9","canonical_id":"hgnc:HGNC:36874","description":"ribosomal protein L27 pseudogene 9","metadata":null},{"id":"8760595307f1421ea5f7d9c33add6cdc","type":"GENE","name":"RPL28","canonical_id":"hgnc:HGNC:10330","description":"ribosomal protein L28","metadata":{"aliases":["FLJ43307","L28","eL28"]}},{"id":"2c5fa1948255414bb2d859449d40b7c8","type":"GENE","name":"RPL28P1","canonical_id":"hgnc:HGNC:31359","description":"ribosomal protein L28 pseudogene 1","metadata":{"aliases":["bcm2489"]}},{"id":"45d8c0f4138f49428e08838f55dd9f63","type":"GENE","name":"RPL28P2","canonical_id":"hgnc:HGNC:36234","description":"ribosomal protein L28 pseudogene 2","metadata":null},{"id":"11e16ca13eb349abbd028236e36bcfcd","type":"GENE","name":"RPL28P3","canonical_id":"hgnc:HGNC:35973","description":"ribosomal protein L28 pseudogene 3","metadata":null},{"id":"1d7a71d0f73d40ca9db8bbf879cda94e","type":"GENE","name":"RPL28P4","canonical_id":"hgnc:HGNC:36618","description":"ribosomal protein L28 pseudogene 4","metadata":null},{"id":"b25ee20c4be34b5d83e77c8c4ebb09c6","type":"GENE","name":"RPL28P5","canonical_id":"hgnc:HGNC:35766","description":"ribosomal protein L28 pseudogene 5","metadata":null},{"id":"21765157384046a9ab77a52708fe0be1","type":"GENE","name":"RPL28P6","canonical_id":"hgnc:HGNC:56984","description":"ribosomal protein L28 pseudogene 6","metadata":null},{"id":"3f722428ac6d4373a80be718abb69510","type":"GENE","name":"RPL29","canonical_id":"hgnc:HGNC:10331","description":"ribosomal protein L29","metadata":{"aliases":["HIP","HUMRPL29","L29","eL29","RPL29P10"]}},{"id":"31f03ff293e94c92bcfd4a9ca33fb42f","type":"GENE","name":"RPL29P1","canonical_id":"hgnc:HGNC:21593","description":"ribosomal protein L29 pseudogene 1","metadata":{"aliases":["dJ336K20B.2"]}},{"id":"2db63046805542b7bb58323a56a28c22","type":"GENE","name":"RPL29P11","canonical_id":"hgnc:HGNC:36905","description":"ribosomal protein L29 pseudogene 11","metadata":null},{"id":"bf27d4579fa24fe79b56a37562318c2d","type":"GENE","name":"RPL29P12","canonical_id":"hgnc:HGNC:36608","description":"ribosomal protein L29 pseudogene 12","metadata":null},{"id":"9319b670628c480ea824b81181559eba","type":"GENE","name":"RPL29P13","canonical_id":"hgnc:HGNC:36461","description":"ribosomal protein L29 pseudogene 13","metadata":null},{"id":"7bb8e8dd29a4443784aba14c59dc7ff6","type":"GENE","name":"RPL29P14","canonical_id":"hgnc:HGNC:36687","description":"ribosomal protein L29 pseudogene 14","metadata":null},{"id":"e7f32b62d2fd4c80a4b1d08a7b6dbb44","type":"GENE","name":"RPL29P15","canonical_id":"hgnc:HGNC:36159","description":"ribosomal protein L29 pseudogene 15","metadata":null},{"id":"9739257a7ec14d2f8b140d6c67a9ce64","type":"GENE","name":"RPL29P16","canonical_id":"hgnc:HGNC:36898","description":"ribosomal protein L29 pseudogene 16","metadata":null},{"id":"b8256c623bea482a94e7a0ff425a05cf","type":"GENE","name":"RPL29P17","canonical_id":"hgnc:HGNC:36910","description":"ribosomal protein L29 pseudogene 17","metadata":null},{"id":"f66102c9460c4e4c9b4fb2848d56b84f","type":"GENE","name":"RPL29P18","canonical_id":"hgnc:HGNC:36327","description":"ribosomal protein L29 pseudogene 18","metadata":null},{"id":"a812ca5a0c5749c69e64c43ae9575b11","type":"GENE","name":"RPL29P19","canonical_id":"hgnc:HGNC:35508","description":"ribosomal protein L29 pseudogene 19","metadata":null},{"id":"57ffbd92f44741ce952a750e6cf83fd9","type":"GENE","name":"RPL29P2","canonical_id":"hgnc:HGNC:17334","description":"ribosomal protein L29 pseudogene 2","metadata":null},{"id":"fb78e54b05974c1fb012e44a96dbfe99","type":"GENE","name":"RPL29P20","canonical_id":"hgnc:HGNC:36682","description":"ribosomal protein L29 pseudogene 20","metadata":null},{"id":"b0e1431c03324d55827aee6bd56432b9","type":"GENE","name":"RPL29P21","canonical_id":"hgnc:HGNC:36322","description":"ribosomal protein L29 pseudogene 21","metadata":null},{"id":"90cf61b7a9dc42cf954059ea90eddda2","type":"GENE","name":"RPL29P22","canonical_id":"hgnc:HGNC:35675","description":"ribosomal protein L29 pseudogene 22","metadata":null},{"id":"c1224a6d788f4244bef2ef3831c55a2c","type":"GENE","name":"RPL29P23","canonical_id":"hgnc:HGNC:35946","description":"ribosomal protein L29 pseudogene 23","metadata":null},{"id":"2bd8f3d566f641878d197ad33e1b0018","type":"GENE","name":"RPL29P24","canonical_id":"hgnc:HGNC:35616","description":"ribosomal protein L29 pseudogene 24","metadata":null},{"id":"17512505ebaa436f8a3b7048e58c5272","type":"GENE","name":"RPL29P25","canonical_id":"hgnc:HGNC:37039","description":"ribosomal protein L29 pseudogene 25","metadata":null},{"id":"22770a09ba6d4057aa12691d2d899a13","type":"GENE","name":"RPL29P26","canonical_id":"hgnc:HGNC:35717","description":"ribosomal protein L29 pseudogene 26","metadata":null},{"id":"b079503e37f84e64989bbbdb7d396f25","type":"GENE","name":"RPL29P27","canonical_id":"hgnc:HGNC:35551","description":"ribosomal protein L29 pseudogene 27","metadata":null},{"id":"21731386df9e47f08b0456ec64a00560","type":"GENE","name":"RPL29P28","canonical_id":"hgnc:HGNC:36842","description":"ribosomal protein L29 pseudogene 28","metadata":null},{"id":"03e0c09ecb4e4bfa89fbdd257c26f9f5","type":"GENE","name":"RPL29P29","canonical_id":"hgnc:HGNC:36577","description":"ribosomal protein L29 pseudogene 29","metadata":null},{"id":"91a951619e804c65aafafab96bd6e51b","type":"GENE","name":"RPL29P3","canonical_id":"hgnc:HGNC:23565","description":"ribosomal protein L29 pseudogene 3","metadata":null},{"id":"53330311564f48509e25281ac58a3694","type":"GENE","name":"RPL29P30","canonical_id":"hgnc:HGNC:36601","description":"ribosomal protein L29 pseudogene 30","metadata":null},{"id":"6fe5577f32ba46a6853ada383f178bcf","type":"GENE","name":"RPL29P31","canonical_id":"hgnc:HGNC:35944","description":"ribosomal protein L29 pseudogene 31","metadata":{"aliases":["p17","PERMIT"]}},{"id":"e248eb2e55784bb884a15906a6b4c52a","type":"GENE","name":"RPL29P32","canonical_id":"hgnc:HGNC:35834","description":"ribosomal protein L29 pseudogene 32","metadata":null},{"id":"9352fa1120404e17b126a5064c061a12","type":"GENE","name":"RPL29P33","canonical_id":"hgnc:HGNC:36923","description":"ribosomal protein L29 pseudogene 33","metadata":null},{"id":"60ab425c0e254f229788bc4561022c81","type":"GENE","name":"RPL29P34","canonical_id":"hgnc:HGNC:56625","description":"ribosomal protein L29 pseudogene 34","metadata":null},{"id":"3fc31f6a76684b4e9d70267ac5866729","type":"GENE","name":"RPL29P35","canonical_id":"hgnc:HGNC:56961","description":"ribosomal protein L29 pseudogene 35","metadata":null},{"id":"c7cc8ecb9d454429a9da186d907b99f9","type":"GENE","name":"RPL29P4","canonical_id":"hgnc:HGNC:21482","description":"ribosomal protein L29 pseudogene 4","metadata":{"aliases":["bA632C17A.1","RPL29P3"]}},{"id":"23b52cc308f74948b072c055c6ff7918","type":"GENE","name":"RPL29P5","canonical_id":"hgnc:HGNC:36786","description":"ribosomal protein L29 pseudogene 5","metadata":null},{"id":"552a64605727475b86c0604c870457e0","type":"GENE","name":"RPL29P6","canonical_id":"hgnc:HGNC:36627","description":"ribosomal protein L29 pseudogene 6","metadata":null},{"id":"5c734aeea09540309568619ddb18d136","type":"GENE","name":"RPL29P7","canonical_id":"hgnc:HGNC:36859","description":"ribosomal protein L29 pseudogene 7","metadata":null},{"id":"18f031310a184334a92ee605ef91667e","type":"GENE","name":"RPL29P8","canonical_id":"hgnc:HGNC:37026","description":"ribosomal protein L29 pseudogene 8","metadata":null},{"id":"3fcaadd5a759404b98b9124fbcc1e22f","type":"GENE","name":"RPL29P9","canonical_id":"hgnc:HGNC:35729","description":"ribosomal protein L29 pseudogene 9","metadata":null},{"id":"28f17a49d7ab4eccac013873deba3755","type":"GENE","name":"RPL3","canonical_id":"hgnc:HGNC:10332","description":null,"metadata":null},{"id":"6b1b231f642d424f8675de2f7841ea61","type":"GENE","name":"RPL30","canonical_id":"hgnc:HGNC:10333","description":"ribosomal protein L30","metadata":{"aliases":["L30","eL30"]}},{"id":"7728cf311c9b4e0e83a5d3a44eb778e1","type":"GENE","name":"RPL30-AS1","canonical_id":"hgnc:HGNC:56064","description":"RPL30 antisense RNA 1","metadata":{"aliases":["KB-1208A12.3","AP003352.1"]}},{"id":"b3b6806b8d2c4df08f71d5c471de0393","type":"GENE","name":"RPL30P1","canonical_id":"hgnc:HGNC:36642","description":"ribosomal protein L30 pseudogene 1","metadata":null},{"id":"8ff401cfab874663905754390c3ab0ab","type":"GENE","name":"RPL30P10","canonical_id":"hgnc:HGNC:36822","description":"ribosomal protein L30 pseudogene 10","metadata":null},{"id":"bb72c404ad104cc5860e7e333ebad4e7","type":"GENE","name":"RPL30P11","canonical_id":"hgnc:HGNC:36260","description":"ribosomal protein L30 pseudogene 11","metadata":null},{"id":"a880c66689124fdabc75f010eda4d67e","type":"GENE","name":"RPL30P12","canonical_id":"hgnc:HGNC:36909","description":"ribosomal protein L30 pseudogene 12","metadata":null},{"id":"cafa451739244bc9af3d0020d64da840","type":"GENE","name":"RPL30P13","canonical_id":"hgnc:HGNC:36280","description":"ribosomal protein L30 pseudogene 13","metadata":null},{"id":"2f697ccc85904ce3898a3650ec2878ef","type":"GENE","name":"RPL30P14","canonical_id":"hgnc:HGNC:36257","description":"ribosomal protein L30 pseudogene 14","metadata":null},{"id":"3182049a79f54afea276b37276009bb7","type":"GENE","name":"RPL30P15","canonical_id":"hgnc:HGNC:36542","description":"ribosomal protein L30 pseudogene 15","metadata":null},{"id":"5841bb00d1774be28133be556b85c653","type":"GENE","name":"RPL30P16","canonical_id":"hgnc:HGNC:48340","description":"ribosomal protein L30 pseudogene 16","metadata":null},{"id":"cc6462878807436eb5d4148a0cf19b28","type":"GENE","name":"RPL30P2","canonical_id":"hgnc:HGNC:35642","description":"ribosomal protein L30 pseudogene 2","metadata":null},{"id":"4f3861f3fea84c72aafa733f75971316","type":"GENE","name":"RPL30P3","canonical_id":"hgnc:HGNC:36380","description":"ribosomal protein L30 pseudogene 3","metadata":null},{"id":"1bff96c20b4944009267f8dc6b402f73","type":"GENE","name":"RPL30P4","canonical_id":"hgnc:HGNC:35871","description":"ribosomal protein L30 pseudogene 4","metadata":null},{"id":"94291f2e0ab34146b67637db4c5c3015","type":"GENE","name":"RPL30P5","canonical_id":"hgnc:HGNC:36302","description":"ribosomal protein L30 pseudogene 5","metadata":null},{"id":"1ecefd6b011c42259dde0e0ca96ab82e","type":"GENE","name":"RPL30P6","canonical_id":"hgnc:HGNC:37015","description":"ribosomal protein L30 pseudogene 6","metadata":null},{"id":"ed91d7e5dca34ceba37e73c9be8ca8a7","type":"GENE","name":"RPL30P7","canonical_id":"hgnc:HGNC:36402","description":"ribosomal protein L30 pseudogene 7","metadata":null},{"id":"83f13b1f224f481d8607b68be64799bd","type":"GENE","name":"RPL30P8","canonical_id":"hgnc:HGNC:36058","description":"ribosomal protein L30 pseudogene 8","metadata":null},{"id":"eaa5789ada5b4e0f9b563d14ca687616","type":"GENE","name":"RPL30P9","canonical_id":"hgnc:HGNC:35763","description":"ribosomal protein L30 pseudogene 9","metadata":null},{"id":"a621297a25de4120afa67cdecc9a4909","type":"GENE","name":"RPL31","canonical_id":"hgnc:HGNC:10334","description":"ribosomal protein L31","metadata":{"aliases":["L31","eL31"]}},{"id":"8e416eb4814c45b5876e336daf7da98c","type":"GENE","name":"RPL31P1","canonical_id":"hgnc:HGNC:10335","description":"ribosomal protein L31 pseudogene 1","metadata":{"aliases":["RPL31P"]}},{"id":"7c37917728a8461983b49771a0fbb75c","type":"GENE","name":"RPL31P10","canonical_id":"hgnc:HGNC:33180","description":"ribosomal protein L31 pseudogene 10","metadata":null},{"id":"a2c9d3d2c7cd41158b4c6b6ae914d8e9","type":"GENE","name":"RPL31P11","canonical_id":"hgnc:HGNC:35849","description":"ribosomal protein L31 pseudogene 11","metadata":null},{"id":"f15fbdec3a6f4f228c14d32992352d66","type":"GENE","name":"RPL31P12","canonical_id":"hgnc:HGNC:35546","description":"ribosomal protein L31 pseudogene 12","metadata":null},{"id":"98bf3f7b538f4891ac77e24153ce3e93","type":"GENE","name":"RPL31P13","canonical_id":"hgnc:HGNC:35598","description":"ribosomal protein L31 pseudogene 13","metadata":null},{"id":"0a6008d30bf74850990f53ff2151246c","type":"GENE","name":"RPL31P14","canonical_id":"hgnc:HGNC:35477","description":"ribosomal protein L31 pseudogene 14","metadata":null},{"id":"5a99c6a3048946d7b3c5378cb3ec1a6e","type":"GENE","name":"RPL31P15","canonical_id":"hgnc:HGNC:36339","description":"ribosomal protein L31 pseudogene 15","metadata":null},{"id":"9b0a7749e5ec41dca32dafaa42e2513a","type":"GENE","name":"RPL31P16","canonical_id":"hgnc:HGNC:36001","description":"ribosomal protein L31 pseudogene 16","metadata":null},{"id":"d2ff4a388ccf49e3aa262500090003f8","type":"GENE","name":"RPL31P17","canonical_id":"hgnc:HGNC:36995","description":"ribosomal protein L31 pseudogene 17","metadata":null},{"id":"3803f79155e04d0aa2ca7a365ecd8418","type":"GENE","name":"RPL31P18","canonical_id":"hgnc:HGNC:35833","description":"ribosomal protein L31 pseudogene 18","metadata":null},{"id":"0a259c6ccfe149a9a49070ae5e04cddb","type":"GENE","name":"RPL31P19","canonical_id":"hgnc:HGNC:35589","description":"ribosomal protein L31 pseudogene 19","metadata":null},{"id":"d7b0e064ae584680989616c4aa042735","type":"GENE","name":"RPL31P2","canonical_id":"hgnc:HGNC:16575","description":"ribosomal protein L31 pseudogene 2","metadata":{"aliases":["dJ553F4.5"]}},{"id":"13e75e682b794d3899731baff5a00108","type":"GENE","name":"RPL31P20","canonical_id":"hgnc:HGNC:36303","description":"ribosomal protein L31 pseudogene 20","metadata":null},{"id":"afdbfe65fea349f4902f25ea47f483d9","type":"GENE","name":"RPL31P21","canonical_id":"hgnc:HGNC:36245","description":"ribosomal protein L31 pseudogene 21","metadata":null},{"id":"9e042ae3a3574e1890ba659969cb14f1","type":"GENE","name":"RPL31P22","canonical_id":"hgnc:HGNC:36430","description":"ribosomal protein L31 pseudogene 22","metadata":null},{"id":"623814c7bb7d415a8c2134940ab4cba9","type":"GENE","name":"RPL31P23","canonical_id":"hgnc:HGNC:36096","description":"ribosomal protein L31 pseudogene 23","metadata":null},{"id":"8f2e22b175f140c8b7e61b8787c56e8f","type":"GENE","name":"RPL31P24","canonical_id":"hgnc:HGNC:36353","description":"ribosomal protein L31 pseudogene 24","metadata":null},{"id":"79627d40dc2a401480de5aa6e5a6c781","type":"GENE","name":"RPL31P25","canonical_id":"hgnc:HGNC:36698","description":"ribosomal protein L31 pseudogene 25","metadata":null},{"id":"60bd0eec3a5e4ae3b51e23e4817cc2e8","type":"GENE","name":"RPL31P26","canonical_id":"hgnc:HGNC:36063","description":"ribosomal protein L31 pseudogene 26","metadata":null},{"id":"10893d004a7743f3b6da6af04dba8907","type":"GENE","name":"RPL31P27","canonical_id":"hgnc:HGNC:36275","description":"ribosomal protein L31 pseudogene 27","metadata":null},{"id":"0b0b0e3d0d3945358380316b01a16f49","type":"GENE","name":"RPL31P28","canonical_id":"hgnc:HGNC:36253","description":"ribosomal protein L31 pseudogene 28","metadata":null},{"id":"e15ec1412aef4cb2933344c0fef64014","type":"GENE","name":"RPL31P29","canonical_id":"hgnc:HGNC:36647","description":"ribosomal protein L31 pseudogene 29","metadata":null},{"id":"64ef0b10f9a340ba9544e53027117bae","type":"GENE","name":"RPL31P3","canonical_id":"hgnc:HGNC:16549","description":"ribosomal protein L31 pseudogene 3","metadata":{"aliases":["dJ1018D12.4"]}},{"id":"2493a73df429464c9f3f008d2201b68d","type":"GENE","name":"RPL31P30","canonical_id":"hgnc:HGNC:35679","description":"ribosomal protein L31 pseudogene 30","metadata":null},{"id":"50c3328bc08e46f19ef299fc500c901c","type":"GENE","name":"RPL31P31","canonical_id":"hgnc:HGNC:35678","description":"ribosomal protein L31 pseudogene 31","metadata":null},{"id":"1ed6afba48084e30aa376a2595523a5f","type":"GENE","name":"RPL31P32","canonical_id":"hgnc:HGNC:35719","description":"ribosomal protein L31 pseudogene 32","metadata":null},{"id":"5ff39205812444baa967e57da8f23061","type":"GENE","name":"RPL31P33","canonical_id":"hgnc:HGNC:36886","description":"ribosomal protein L31 pseudogene 33","metadata":null},{"id":"ec44cfbea44a4e8697ae7faa53ca9137","type":"GENE","name":"RPL31P34","canonical_id":"hgnc:HGNC:35853","description":"ribosomal protein L31 pseudogene 34","metadata":null},{"id":"a973490eedc848e894c51e13b42d1a12","type":"GENE","name":"RPL31P35","canonical_id":"hgnc:HGNC:36932","description":"ribosomal protein L31 pseudogene 35","metadata":null},{"id":"7243b54b9f8d44478176eb2b7d8563a4","type":"GENE","name":"RPL31P36","canonical_id":"hgnc:HGNC:36676","description":"ribosomal protein L31 pseudogene 36","metadata":null},{"id":"b88c232eb5dc4ed5a449fb2d64e5ab46","type":"GENE","name":"RPL31P37","canonical_id":"hgnc:HGNC:36197","description":"ribosomal protein L31 pseudogene 37","metadata":null},{"id":"d5087b343233411988a0da8e2db3908b","type":"GENE","name":"RPL31P38","canonical_id":"hgnc:HGNC:36834","description":"ribosomal protein L31 pseudogene 38","metadata":null},{"id":"288e850c0bbc48d3aaf2e0c6878f5d8b","type":"GENE","name":"RPL31P39","canonical_id":"hgnc:HGNC:35995","description":"ribosomal protein L31 pseudogene 39","metadata":null},{"id":"41ca06f42fc443698e41ea8fc7e211a6","type":"GENE","name":"RPL31P4","canonical_id":"hgnc:HGNC:23546","description":"ribosomal protein L31 pseudogene 4","metadata":null},{"id":"832cb8ed74394d518ca147732214121d","type":"GENE","name":"RPL31P40","canonical_id":"hgnc:HGNC:36134","description":"ribosomal protein L31 pseudogene 40","metadata":null},{"id":"c56ba121556b4bd685d5dbdc57a15405","type":"GENE","name":"RPL31P41","canonical_id":"hgnc:HGNC:36720","description":"ribosomal protein L31 pseudogene 41","metadata":null},{"id":"22c020624ddf43fda55c49981c8fb2d0","type":"GENE","name":"RPL31P42","canonical_id":"hgnc:HGNC:36930","description":"ribosomal protein L31 pseudogene 42","metadata":null},{"id":"be4164467a424eb3bdf1c0b313fb8797","type":"GENE","name":"RPL31P43","canonical_id":"hgnc:HGNC:36512","description":"ribosomal protein L31 pseudogene 43","metadata":null},{"id":"d643bb982927488d942528406b8bb959","type":"GENE","name":"RPL31P44","canonical_id":"hgnc:HGNC:35523","description":"ribosomal protein L31 pseudogene 44","metadata":null},{"id":"dca160b3e6f24b6cb74cff5284ffaccf","type":"GENE","name":"RPL31P45","canonical_id":"hgnc:HGNC:36796","description":"ribosomal protein L31 pseudogene 45","metadata":null},{"id":"c2a953a4ad9346269c67a175cb5e88ee","type":"GENE","name":"RPL31P46","canonical_id":"hgnc:HGNC:35559","description":"ribosomal protein L31 pseudogene 46","metadata":null},{"id":"0c8a29c6adda4692a2993dca07a9fa92","type":"GENE","name":"RPL31P47","canonical_id":"hgnc:HGNC:36124","description":"ribosomal protein L31 pseudogene 47","metadata":null},{"id":"e004fec7426a4db4a4a52e915671c37b","type":"GENE","name":"RPL31P48","canonical_id":"hgnc:HGNC:36129","description":"ribosomal protein L31 pseudogene 48","metadata":null},{"id":"577b49a6998241a0820b9e859727c3c3","type":"GENE","name":"RPL31P49","canonical_id":"hgnc:HGNC:35909","description":"ribosomal protein L31 pseudogene 49","metadata":null},{"id":"93ba03021a194dc4b126169721a54ce6","type":"GENE","name":"RPL31P5","canonical_id":"hgnc:HGNC:23547","description":"ribosomal protein L31 pseudogene 5","metadata":null},{"id":"2d64fbaad8c641a3b11cfe54aee0aaa9","type":"GENE","name":"RPL31P50","canonical_id":"hgnc:HGNC:36799","description":"ribosomal protein L31 pseudogene 50","metadata":null},{"id":"fd0494ec48314303bfd1bd6469c3cf60","type":"GENE","name":"RPL31P51","canonical_id":"hgnc:HGNC:35600","description":"ribosomal protein L31 pseudogene 51","metadata":null},{"id":"9ef50f2446254280ae6ffa93e3fcb53e","type":"GENE","name":"RPL31P52","canonical_id":"hgnc:HGNC:36607","description":"ribosomal protein L31 pseudogene 52","metadata":null},{"id":"d6f3c96ba3d94edd89078171c4e02b70","type":"GENE","name":"RPL31P53","canonical_id":"hgnc:HGNC:35749","description":"ribosomal protein L31 pseudogene 53","metadata":null},{"id":"dcdf432b62424d29ba656e4810676403","type":"GENE","name":"RPL31P54","canonical_id":"hgnc:HGNC:36077","description":"ribosomal protein L31 pseudogene 54","metadata":null},{"id":"a106a02b0cf04ac58f742e2736cdb7c0","type":"GENE","name":"RPL31P55","canonical_id":"hgnc:HGNC:36982","description":"ribosomal protein L31 pseudogene 55","metadata":null},{"id":"f28c8a1f85d7451abb7a69a790da4d5d","type":"GENE","name":"RPL31P56","canonical_id":"hgnc:HGNC:36336","description":"ribosomal protein L31 pseudogene 56","metadata":null},{"id":"4a2bb8b1ad7143cd887c0b871082aecf","type":"GENE","name":"RPL31P57","canonical_id":"hgnc:HGNC:35703","description":"ribosomal protein L31 pseudogene 57","metadata":null},{"id":"c0f0eba8bc4d4046a03433cfc25dcfb3","type":"GENE","name":"RPL31P58","canonical_id":"hgnc:HGNC:35862","description":"ribosomal protein L31 pseudogene 58","metadata":null},{"id":"864ac9e058964a78ae11910588147f32","type":"GENE","name":"RPL31P59","canonical_id":"hgnc:HGNC:36975","description":"ribosomal protein L31 pseudogene 59","metadata":null},{"id":"6df0adcd209f42cd9f4f2ca7de8cb19c","type":"GENE","name":"RPL31P6","canonical_id":"hgnc:HGNC:31032","description":"ribosomal protein L31 pseudogene 6","metadata":{"aliases":["HsT19508"]}},{"id":"f3189eb770194321be695dbe60ec80cf","type":"GENE","name":"RPL31P60","canonical_id":"hgnc:HGNC:36123","description":"ribosomal protein L31 pseudogene 60","metadata":null},{"id":"9e4db6f55d4d4021924fb6bc2bac0acb","type":"GENE","name":"RPL31P61","canonical_id":"hgnc:HGNC:35635","description":"ribosomal protein L31 pseudogene 61","metadata":null},{"id":"cefb11f29b114000b4e0528a91ca9640","type":"GENE","name":"RPL31P62","canonical_id":"hgnc:HGNC:36569","description":"ribosomal protein L31 pseudogene 62","metadata":null},{"id":"540f71aa8b384fa9b9ba65f36d4a350f","type":"GENE","name":"RPL31P63","canonical_id":"hgnc:HGNC:35666","description":"ribosomal protein L31 pseudogene 63","metadata":null},{"id":"e8c0254bfdbb4860bd499f64e10cd02b","type":"GENE","name":"RPL31P64","canonical_id":"hgnc:HGNC:56627","description":"ribosomal protein L31 pseudogene 64","metadata":null},{"id":"200b653f11584dbcb154818410a6a6c9","type":"GENE","name":"RPL31P7","canonical_id":"hgnc:HGNC:31325","description":"ribosomal protein L31 pseudogene 7","metadata":null},{"id":"42e48a20846c4d0fa3248241b55d5450","type":"GENE","name":"RPL31P8","canonical_id":"hgnc:HGNC:31324","description":"ribosomal protein L31 pseudogene 8","metadata":null},{"id":"bf08f56e9f95418983091d64866a2b13","type":"GENE","name":"RPL31P9","canonical_id":"hgnc:HGNC:31893","description":"ribosomal protein L31 pseudogene 9","metadata":null},{"id":"8de60f52494f45b88a010ca9d8646e71","type":"GENE","name":"RPL32","canonical_id":"hgnc:HGNC:10336","description":"ribosomal protein L32","metadata":{"aliases":["L32","eL32"]}},{"id":"e7116c3a347e46959b6364fe4b3f8a8c","type":"GENE","name":"RPL32P1","canonical_id":"hgnc:HGNC:10339","description":"ribosomal protein L32 pseudogene 1","metadata":{"aliases":["RPL32-L","RPL32P"]}},{"id":"fbae4f0a284544768fc77241e89f9b10","type":"GENE","name":"RPL32P10","canonical_id":"hgnc:HGNC:35641","description":"ribosomal protein L32 pseudogene 10","metadata":null},{"id":"ec4c8959a4f14d53a3f3d627851bb9a2","type":"GENE","name":"RPL32P11","canonical_id":"hgnc:HGNC:35723","description":"ribosomal protein L32 pseudogene 11","metadata":null},{"id":"fc5099b2b67a4d1a9ed40cafe51d375d","type":"GENE","name":"RPL32P12","canonical_id":"hgnc:HGNC:36600","description":"ribosomal protein L32 pseudogene 12","metadata":null},{"id":"9ead3ab75fca4cad94ef46d983548baf","type":"GENE","name":"RPL32P13","canonical_id":"hgnc:HGNC:35950","description":"ribosomal protein L32 pseudogene 13","metadata":null},{"id":"15cf67b12775434e8327349283d2991c","type":"GENE","name":"RPL32P14","canonical_id":"hgnc:HGNC:37038","description":"ribosomal protein L32 pseudogene 14","metadata":null},{"id":"4ffa2bddf73d4ab7abc00f93536ef12c","type":"GENE","name":"RPL32P15","canonical_id":"hgnc:HGNC:36119","description":"ribosomal protein L32 pseudogene 15","metadata":null},{"id":"a0756ce9faeb49549377e9e7b0d3296d","type":"GENE","name":"RPL32P16","canonical_id":"hgnc:HGNC:36086","description":"ribosomal protein L32 pseudogene 16","metadata":null},{"id":"f9a0dd3a45b547ab8145fae7720b8d68","type":"GENE","name":"RPL32P17","canonical_id":"hgnc:HGNC:36251","description":"ribosomal protein L32 pseudogene 17","metadata":null},{"id":"3e010e0b58674464bea0b0e4b53d1c04","type":"GENE","name":"RPL32P18","canonical_id":"hgnc:HGNC:36301","description":"ribosomal protein L32 pseudogene 18","metadata":null},{"id":"e2c70e21b2974923aaffb9f2e42a7a46","type":"GENE","name":"RPL32P19","canonical_id":"hgnc:HGNC:36743","description":"ribosomal protein L32 pseudogene 19","metadata":null},{"id":"780520a6737b47f2b17280fab3e1ee97","type":"GENE","name":"RPL32P2","canonical_id":"hgnc:HGNC:31033","description":"ribosomal protein L32 pseudogene 2","metadata":{"aliases":["HsT20607"]}},{"id":"11fa218b0f254d8387187a1c6542c342","type":"GENE","name":"RPL32P20","canonical_id":"hgnc:HGNC:35934","description":"ribosomal protein L32 pseudogene 20","metadata":null},{"id":"f0296ac9e9e64d6c98a27a40cb70e31c","type":"GENE","name":"RPL32P21","canonical_id":"hgnc:HGNC:36363","description":"ribosomal protein L32 pseudogene 21","metadata":null},{"id":"51390dcaf81c40bbab7459da234f4ab7","type":"GENE","name":"RPL32P22","canonical_id":"hgnc:HGNC:36694","description":"ribosomal protein L32 pseudogene 22","metadata":null},{"id":"621adb158c2646078d1aa5c4e88ec316","type":"GENE","name":"RPL32P23","canonical_id":"hgnc:HGNC:36007","description":"ribosomal protein L32 pseudogene 23","metadata":null},{"id":"29ad11997ac5441f859832436debb2d0","type":"GENE","name":"RPL32P24","canonical_id":"hgnc:HGNC:36722","description":"ribosomal protein L32 pseudogene 24","metadata":null},{"id":"9dbe6368c3d04de8876880312c51f663","type":"GENE","name":"RPL32P25","canonical_id":"hgnc:HGNC:35721","description":"ribosomal protein L32 pseudogene 25","metadata":null},{"id":"34c16cecc3bb40ae93df50a3e74510c0","type":"GENE","name":"RPL32P26","canonical_id":"hgnc:HGNC:36027","description":"ribosomal protein L32 pseudogene 26","metadata":null},{"id":"3541e7f6a4984c54bdbf5c7d0357bf0d","type":"GENE","name":"RPL32P27","canonical_id":"hgnc:HGNC:36924","description":"ribosomal protein L32 pseudogene 27","metadata":null},{"id":"0212d5458c4d4b43bd5647d180487a5d","type":"GENE","name":"RPL32P28","canonical_id":"hgnc:HGNC:36328","description":"ribosomal protein L32 pseudogene 28","metadata":null},{"id":"8ec8dfe15dd24256886919eeb145bbe0","type":"GENE","name":"RPL32P29","canonical_id":"hgnc:HGNC:35771","description":"ribosomal protein L32 pseudogene 29","metadata":null},{"id":"b3d4315f57544f0ba546fcf04ae5a394","type":"GENE","name":"RPL32P3","canonical_id":"hgnc:HGNC:27024","description":"ribosomal protein L32 pseudogene 3","metadata":null},{"id":"5c5f6283847049d0bf33eb4af77e4786","type":"GENE","name":"RPL32P30","canonical_id":"hgnc:HGNC:36729","description":"ribosomal protein L32 pseudogene 30","metadata":null},{"id":"38b3beb2d884421d90d856717eb966ec","type":"GENE","name":"RPL32P31","canonical_id":"hgnc:HGNC:37035","description":"ribosomal protein L32 pseudogene 31","metadata":null},{"id":"f002b1bb886c4c7fa547d2f5c7277855","type":"GENE","name":"RPL32P32","canonical_id":"hgnc:HGNC:36024","description":"ribosomal protein L32 pseudogene 32","metadata":null},{"id":"acd354e5d8824fdba0c75d50c8ad7a48","type":"GENE","name":"RPL32P33","canonical_id":"hgnc:HGNC:36231","description":"ribosomal protein L32 pseudogene 33","metadata":null},{"id":"74308c7ff7254d998c91c1fe8937fd71","type":"GENE","name":"RPL32P34","canonical_id":"hgnc:HGNC:35903","description":"ribosomal protein L32 pseudogene 34","metadata":null},{"id":"6abbad1de07348ebb38b8e23c8e3713d","type":"GENE","name":"RPL32P35","canonical_id":"hgnc:HGNC:36547","description":"ribosomal protein L32 pseudogene 35","metadata":null},{"id":"b723aa8faf42458da4e7baef1493e796","type":"GENE","name":"RPL32P36","canonical_id":"hgnc:HGNC:36613","description":"ribosomal protein L32 pseudogene 36","metadata":null},{"id":"d7c3bb519fa9454bbcaee579ddc17043","type":"GENE","name":"RPL32P37","canonical_id":"hgnc:HGNC:56998","description":"ribosomal protein L32 pseudogene 37","metadata":null},{"id":"34dc5299fa32432bb94fe8c08d023419","type":"GENE","name":"RPL32P4","canonical_id":"hgnc:HGNC:10337","description":"ribosomal protein L32 pseudogene 4","metadata":{"aliases":["RPL32L"]}},{"id":"87b0e21685ed4b19913e887f512d6f33","type":"GENE","name":"RPL32P5","canonical_id":"hgnc:HGNC:10338","description":"ribosomal protein L32 pseudogene 5","metadata":{"aliases":["RPL32L2"]}},{"id":"84b706597a3649468c472e3091f7629f","type":"GENE","name":"RPL32P6","canonical_id":"hgnc:HGNC:36655","description":"ribosomal protein L32 pseudogene 6","metadata":null},{"id":"103de55c532848ba94d83f4da787f064","type":"GENE","name":"RPL32P7","canonical_id":"hgnc:HGNC:35804","description":"ribosomal protein L32 pseudogene 7","metadata":null},{"id":"14a2e31e5e9c4dad9e5a6a36ce072144","type":"GENE","name":"RPL32P8","canonical_id":"hgnc:HGNC:36414","description":"ribosomal protein L32 pseudogene 8","metadata":null},{"id":"609ef8b742b34cd5a2834946ec67361c","type":"GENE","name":"RPL32P9","canonical_id":"hgnc:HGNC:35481","description":"ribosomal protein L32 pseudogene 9","metadata":null},{"id":"cd5b4808ebae4e32ae86155d49845044","type":"GENE","name":"RPL34","canonical_id":"hgnc:HGNC:10340","description":"ribosomal protein L34","metadata":{"aliases":["L34","eL34"]}},{"id":"28b29853beff460a98da8a3168b1c91b","type":"GENE","name":"RPL34-DT","canonical_id":"hgnc:HGNC:26749","description":"RPL34 divergent transcript","metadata":{"aliases":["FLJ37673","RP11-462C24.1","RPL34-AS1"]}},{"id":"9c7d1f2533604dbaa60e203c058b0258","type":"GENE","name":"RPL34P1","canonical_id":"hgnc:HGNC:10341","description":"ribosomal protein L34 pseudogene 1","metadata":null},{"id":"cdd66cbc9cd4405ab5f79e9537b26e5b","type":"GENE","name":"RPL34P10","canonical_id":"hgnc:HGNC:36962","description":"ribosomal protein L34 pseudogene 10","metadata":null},{"id":"2ad4f9e2f8de4cc0a02a71c214dee2e2","type":"GENE","name":"RPL34P11","canonical_id":"hgnc:HGNC:36412","description":"ribosomal protein L34 pseudogene 11","metadata":null},{"id":"b8e58fba88854af697968ecb5e725a2c","type":"GENE","name":"RPL34P12","canonical_id":"hgnc:HGNC:35845","description":"ribosomal protein L34 pseudogene 12","metadata":null},{"id":"ce55b2b221c94e449b2f7425cb9a54f1","type":"GENE","name":"RPL34P13","canonical_id":"hgnc:HGNC:36398","description":"ribosomal protein L34 pseudogene 13","metadata":null},{"id":"018c463af8eb44b3934ffa032e523b97","type":"GENE","name":"RPL34P14","canonical_id":"hgnc:HGNC:35927","description":"ribosomal protein L34 pseudogene 14","metadata":null},{"id":"c8151aceb0de46418d60a355e317532e","type":"GENE","name":"RPL34P15","canonical_id":"hgnc:HGNC:35965","description":"ribosomal protein L34 pseudogene 15","metadata":null},{"id":"dd99743759304228b9049c8474257eae","type":"GENE","name":"RPL34P16","canonical_id":"hgnc:HGNC:37033","description":"ribosomal protein L34 pseudogene 16","metadata":null},{"id":"d8b4d52fd24d49ba8ba5f602f17e0535","type":"GENE","name":"RPL34P17","canonical_id":"hgnc:HGNC:36636","description":"ribosomal protein L34 pseudogene 17","metadata":null},{"id":"c56ad3ecc493419aa4b2b483cc7cc1d4","type":"GENE","name":"RPL34P18","canonical_id":"hgnc:HGNC:35968","description":"ribosomal protein L34 pseudogene 18","metadata":null},{"id":"6a0d81d2871b4cb186b3545ce0bec87d","type":"GENE","name":"RPL34P19","canonical_id":"hgnc:HGNC:36925","description":"ribosomal protein L34 pseudogene 19","metadata":null},{"id":"386c8f7c9d554c0bb8d7b10a9528069c","type":"GENE","name":"RPL34P2","canonical_id":"hgnc:HGNC:10342","description":"ribosomal protein L34 pseudogene 2","metadata":null},{"id":"188ba155e54441468a284a2f6166c3be","type":"GENE","name":"RPL34P20","canonical_id":"hgnc:HGNC:35535","description":"ribosomal protein L34 pseudogene 20","metadata":null},{"id":"9c38988402794bdf96ec62503280f3d8","type":"GENE","name":"RPL34P21","canonical_id":"hgnc:HGNC:35677","description":"ribosomal protein L34 pseudogene 21","metadata":null},{"id":"652dc1b9c274496ebf19339ee650b4d6","type":"GENE","name":"RPL34P22","canonical_id":"hgnc:HGNC:36454","description":"ribosomal protein L34 pseudogene 22","metadata":null},{"id":"fedef63a4aa84346b041177dba47ebc5","type":"GENE","name":"RPL34P23","canonical_id":"hgnc:HGNC:35820","description":"ribosomal protein L34 pseudogene 23","metadata":null},{"id":"7b34348359084718846746022b37b8e0","type":"GENE","name":"RPL34P24","canonical_id":"hgnc:HGNC:36823","description":"ribosomal protein L34 pseudogene 24","metadata":null},{"id":"eee11d7d13cd48fe8f8de5f018cb93d8","type":"GENE","name":"RPL34P25","canonical_id":"hgnc:HGNC:35895","description":"ribosomal protein L34 pseudogene 25","metadata":null},{"id":"8549034237f54f288451fcaebc96e84f","type":"GENE","name":"RPL34P26","canonical_id":"hgnc:HGNC:36100","description":"ribosomal protein L34 pseudogene 26","metadata":null},{"id":"9ceeb22fe63e49568862ac117358de1b","type":"GENE","name":"RPL34P27","canonical_id":"hgnc:HGNC:36369","description":"ribosomal protein L34 pseudogene 27","metadata":null},{"id":"c9a59cb78c534456ba4f6ceddc18966e","type":"GENE","name":"RPL34P28","canonical_id":"hgnc:HGNC:36781","description":"ribosomal protein L34 pseudogene 28","metadata":null},{"id":"6bedb5a55e8d45dea990492585b1f6b2","type":"GENE","name":"RPL34P29","canonical_id":"hgnc:HGNC:35631","description":"ribosomal protein L34 pseudogene 29","metadata":null},{"id":"752de6d7414f48cf838d3ce8b5554fa1","type":"GENE","name":"RPL34P3","canonical_id":"hgnc:HGNC:10343","description":"ribosomal protein L34 pseudogene 3","metadata":null},{"id":"75777f6def9c43d09ef5eb51faae8d27","type":"GENE","name":"RPL34P30","canonical_id":"hgnc:HGNC:36477","description":"ribosomal protein L34 pseudogene 30","metadata":null},{"id":"a258765a40de4f3691e2596179165a9a","type":"GENE","name":"RPL34P31","canonical_id":"hgnc:HGNC:36899","description":"ribosomal protein L34 pseudogene 31","metadata":null},{"id":"344ee2000ab445d9b55aad202fa99805","type":"GENE","name":"RPL34P32","canonical_id":"hgnc:HGNC:36902","description":"ribosomal protein L34 pseudogene 32","metadata":null},{"id":"e99e969d0d7f44778ee21897e477b7b9","type":"GENE","name":"RPL34P33","canonical_id":"hgnc:HGNC:36666","description":"ribosomal protein L34 pseudogene 33","metadata":null},{"id":"46119ee36dd94bf2bc7f2f5c9c64492c","type":"GENE","name":"RPL34P34","canonical_id":"hgnc:HGNC:35848","description":"ribosomal protein L34 pseudogene 34","metadata":null},{"id":"41278018f1114c828fe058b2ccb8dfdd","type":"GENE","name":"RPL34P35","canonical_id":"hgnc:HGNC:35798","description":"ribosomal protein L34 pseudogene 35","metadata":null},{"id":"264e66e519634f588b0d2c3d78c815d6","type":"GENE","name":"RPL34P36","canonical_id":"hgnc:HGNC:55008","description":"RPL34 pseudogene 36","metadata":null},{"id":"ac4504192979457fa1cc67d74d30c88c","type":"GENE","name":"RPL34P4","canonical_id":"hgnc:HGNC:36665","description":"ribosomal protein L34 pseudogene 4","metadata":null},{"id":"16cf4fd0d68a40c0a2f6499149e3d261","type":"GENE","name":"RPL34P5","canonical_id":"hgnc:HGNC:36527","description":"ribosomal protein L34 pseudogene 5","metadata":null},{"id":"fdc00e0354634ab283178d6604eca441","type":"GENE","name":"RPL34P6","canonical_id":"hgnc:HGNC:35810","description":"ribosomal protein L34 pseudogene 6","metadata":null},{"id":"a5f56f30c2cc431ca61dce8df4a991fa","type":"GENE","name":"RPL34P7","canonical_id":"hgnc:HGNC:35575","description":"ribosomal protein L34 pseudogene 7","metadata":null},{"id":"49f6f42db4974dafb2f575fbde63ceb3","type":"GENE","name":"RPL34P8","canonical_id":"hgnc:HGNC:36963","description":"ribosomal protein L34 pseudogene 8","metadata":null},{"id":"b738e9a800054d9482d2dc6521bc6f59","type":"GENE","name":"RPL34P9","canonical_id":"hgnc:HGNC:36771","description":"ribosomal protein L34 pseudogene 9","metadata":null},{"id":"1a26b5be6ce14be1b1302fb85f8973e6","type":"GENE","name":"RPL35","canonical_id":"hgnc:HGNC:10344","description":"ribosomal protein L35","metadata":{"aliases":["L35","uL29"]}},{"id":"391c6256124f411ba898744a900881ea","type":"GENE","name":"RPL35A","canonical_id":"hgnc:HGNC:10345","description":"ribosomal protein L35a","metadata":{"aliases":["L35A","eL33","GIG33"]}},{"id":"eec04531732646388e4eaf7bf234d110","type":"GENE","name":"RPL35AP","canonical_id":"hgnc:HGNC:16546","description":"ribosomal protein L35a pseudogene","metadata":{"aliases":["bA456N23.1"]}},{"id":"6300a5056c604bd08eef785f70a15f2d","type":"GENE","name":"RPL35AP10","canonical_id":"hgnc:HGNC:35905","description":"ribosomal protein L35a pseudogene 10","metadata":null},{"id":"14b9fcfe18414181a9ca2da6e9b7d64c","type":"GENE","name":"RPL35AP11","canonical_id":"hgnc:HGNC:35708","description":"ribosomal protein L35a pseudogene 11","metadata":null},{"id":"4ae0c3eb34634dd89b40fb187b7135b5","type":"GENE","name":"RPL35AP12","canonical_id":"hgnc:HGNC:36068","description":"ribosomal protein L35a pseudogene 12","metadata":null},{"id":"ae5c9f530e09408a964da54319271a6d","type":"GENE","name":"RPL35AP13","canonical_id":"hgnc:HGNC:35916","description":"ribosomal protein L35a pseudogene 13","metadata":null},{"id":"c7b67c0294254d7fb89c4731674eca67","type":"GENE","name":"RPL35AP14","canonical_id":"hgnc:HGNC:36783","description":"ribosomal protein L35a pseudogene 14","metadata":null},{"id":"f42fcf9450634a198bc2054f424b22ef","type":"GENE","name":"RPL35AP15","canonical_id":"hgnc:HGNC:36974","description":"ribosomal protein L35a pseudogene 15","metadata":null},{"id":"26f73ca83b134b4e9d2677d937c4010f","type":"GENE","name":"RPL35AP16","canonical_id":"hgnc:HGNC:35485","description":"ribosomal protein L35a pseudogene 16","metadata":null},{"id":"be22908c8536445081666ffab45c2f65","type":"GENE","name":"RPL35AP17","canonical_id":"hgnc:HGNC:36384","description":"ribosomal protein L35a pseudogene 17","metadata":null},{"id":"ad73de7f08e84371b3c3b36b347c1d75","type":"GENE","name":"RPL35AP18","canonical_id":"hgnc:HGNC:36812","description":"ribosomal protein L35a pseudogene 18","metadata":null},{"id":"2309b2c37f394c9ea85252e1c9b99923","type":"GENE","name":"RPL35AP19","canonical_id":"hgnc:HGNC:36631","description":"ribosomal protein L35a pseudogene 19","metadata":null},{"id":"c264e2e712704567b828a96598a86616","type":"GENE","name":"RPL35AP2","canonical_id":"hgnc:HGNC:19914","description":"ribosomal protein L35a pseudogene 2","metadata":{"aliases":["bA571F15.2"]}},{"id":"ef77001f920f46f49d1d47f09eb8d8ec","type":"GENE","name":"RPL35AP20","canonical_id":"hgnc:HGNC:36053","description":"ribosomal protein L35a pseudogene 20","metadata":null},{"id":"200ae24a9830487497fe0f6728154e7a","type":"GENE","name":"RPL35AP21","canonical_id":"hgnc:HGNC:36814","description":"ribosomal protein L35a pseudogene 21","metadata":null},{"id":"72d640dbfe1a4f60978e13f6c4d75dcc","type":"GENE","name":"RPL35AP22","canonical_id":"hgnc:HGNC:35932","description":"ribosomal protein L35a pseudogene 22","metadata":null},{"id":"2c24c04416c54b13abfd8f55cb37066a","type":"GENE","name":"RPL35AP23","canonical_id":"hgnc:HGNC:36045","description":"ribosomal protein L35a pseudogene 23","metadata":{"aliases":["RPL35AP25"]}},{"id":"6e7271fc61d64d4abf9b753c5491bd5a","type":"GENE","name":"RPL35AP24","canonical_id":"hgnc:HGNC:35544","description":"ribosomal protein L35a pseudogene 24","metadata":null},{"id":"2bbb6fb54c3a46aa87231dae67b8678b","type":"GENE","name":"RPL35AP26","canonical_id":"hgnc:HGNC:36465","description":"ribosomal protein L35a pseudogene 26","metadata":null},{"id":"849866b9c2624732a5e9f7964a370443","type":"GENE","name":"RPL35AP27","canonical_id":"hgnc:HGNC:35979","description":"ribosomal protein L35a pseudogene 27","metadata":null},{"id":"df4137d9c70d4474a654f9ccc47f8a67","type":"GENE","name":"RPL35AP28","canonical_id":"hgnc:HGNC:36480","description":"ribosomal protein L35a pseudogene 28","metadata":null},{"id":"0cb905edc8434981988de9c781233161","type":"GENE","name":"RPL35AP29","canonical_id":"hgnc:HGNC:35569","description":"ribosomal protein L35a pseudogene 29","metadata":null},{"id":"31ce5f5d4ea94e1da7a27953afbd500b","type":"GENE","name":"RPL35AP3","canonical_id":"hgnc:HGNC:21117","description":"ribosomal protein L35a pseudogene 3","metadata":{"aliases":["bA55K22.4"]}},{"id":"e2bc37f13c454ce99caec0451adb02af","type":"GENE","name":"RPL35AP30","canonical_id":"hgnc:HGNC:36751","description":"ribosomal protein L35a pseudogene 30","metadata":null},{"id":"d1e8226ebc044bd383c9403c540689ea","type":"GENE","name":"RPL35AP31","canonical_id":"hgnc:HGNC:36284","description":"ribosomal protein L35a pseudogene 31","metadata":null},{"id":"ea23a16dd084481b81b0d1cbe91554d5","type":"GENE","name":"RPL35AP32","canonical_id":"hgnc:HGNC:36269","description":"ribosomal protein L35a pseudogene 32","metadata":null},{"id":"ce354ba02a3d43e49456d8d501c37baf","type":"GENE","name":"RPL35AP33","canonical_id":"hgnc:HGNC:36950","description":"ribosomal protein L35a pseudogene 33","metadata":null},{"id":"900e2763f57847c3b8ca3bb66f9a18fb","type":"GENE","name":"RPL35AP34","canonical_id":"hgnc:HGNC:36324","description":"ribosomal protein L35a pseudogene 34","metadata":null},{"id":"f3c3738343ba46fd89647c2c332f4ae8","type":"GENE","name":"RPL35AP35","canonical_id":"hgnc:HGNC:36677","description":"ribosomal protein L35a pseudogene 35","metadata":null},{"id":"febc3a8e9fd443ce9998fac634b84758","type":"GENE","name":"RPL35AP36","canonical_id":"hgnc:HGNC:36103","description":"ribosomal protein L35a pseudogene 36","metadata":null},{"id":"7c03a25c75144611a04739f372827622","type":"GENE","name":"RPL35AP37","canonical_id":"hgnc:HGNC:36426","description":"ribosomal protein L35a pseudogene 37","metadata":null},{"id":"60ba0d70143a40088f9281673e43a94c","type":"GENE","name":"RPL35AP38","canonical_id":"hgnc:HGNC:56996","description":"ribosomal protein L35a pseudogene 38","metadata":null},{"id":"c63d8a46918643b0aa0840a8a6ba05e9","type":"GENE","name":"RPL35AP4","canonical_id":"hgnc:HGNC:33460","description":"ribosomal protein L35a pseudogene 4","metadata":{"aliases":["BPG294E21.7","OTTHUMG00000140156"]}},{"id":"8b57aa2dddca48829431fdd816495889","type":"GENE","name":"RPL35AP5","canonical_id":"hgnc:HGNC:35570","description":"ribosomal protein L35a pseudogene 5","metadata":null},{"id":"6a59de0cbf8a4b6cbbd3b4ec093bde9c","type":"GENE","name":"RPL35AP6","canonical_id":"hgnc:HGNC:36793","description":"ribosomal protein L35a pseudogene 6","metadata":null},{"id":"0f259613279e473f828c1350ba6f9198","type":"GENE","name":"RPL35AP7","canonical_id":"hgnc:HGNC:36212","description":"ribosomal protein L35a pseudogene 7","metadata":null},{"id":"4050fd7f2f414b4abd8ab3bdbfd29851","type":"GENE","name":"RPL35AP8","canonical_id":"hgnc:HGNC:36976","description":"ribosomal protein L35a pseudogene 8","metadata":null},{"id":"4249aa96f4064e2781b3bdcffb1d167e","type":"GENE","name":"RPL35AP9","canonical_id":"hgnc:HGNC:35643","description":"ribosomal protein L35a pseudogene 9","metadata":null},{"id":"bc858dd03eae4e5b9d34bc143c936c31","type":"GENE","name":"RPL35P1","canonical_id":"hgnc:HGNC:36695","description":"ribosomal protein L35 pseudogene 1","metadata":null},{"id":"1a19794a2bea468987f184698cc269d3","type":"GENE","name":"RPL35P10","canonical_id":"hgnc:HGNC:56997","description":"ribosomal protein L35 pseudogene 10","metadata":null},{"id":"8d5e9e290c0743bba7b19cd697652692","type":"GENE","name":"RPL35P2","canonical_id":"hgnc:HGNC:35789","description":"ribosomal protein L35 pseudogene 2","metadata":null},{"id":"383a26b4e8844b4798282e143a1f1ec3","type":"GENE","name":"RPL35P3","canonical_id":"hgnc:HGNC:35488","description":"ribosomal protein L35 pseudogene 3","metadata":null},{"id":"65e5e2b9be2b4ebcaca24a3d497451a3","type":"GENE","name":"RPL35P4","canonical_id":"hgnc:HGNC:36285","description":"ribosomal protein L35 pseudogene 4","metadata":null},{"id":"ee80338f749848d7ab40011ecb6d99d5","type":"GENE","name":"RPL35P5","canonical_id":"hgnc:HGNC:36955","description":"ribosomal protein L35 pseudogene 5","metadata":null},{"id":"237f249ae71b4c98a7c09525e25faa58","type":"GENE","name":"RPL35P6","canonical_id":"hgnc:HGNC:35520","description":"ribosomal protein L35 pseudogene 6","metadata":null},{"id":"1c3406bfcc774635996ff3b744d072bd","type":"GENE","name":"RPL35P7","canonical_id":"hgnc:HGNC:35740","description":"ribosomal protein L35 pseudogene 7","metadata":null},{"id":"cc4a4a6cfd0d4a56a41d77ede345bd6a","type":"GENE","name":"RPL35P8","canonical_id":"hgnc:HGNC:36158","description":"ribosomal protein L35 pseudogene 8","metadata":null},{"id":"c487acfe2a794ad5bc0924c53e8d4ef2","type":"GENE","name":"RPL35P9","canonical_id":"hgnc:HGNC:39402","description":"ribosomal protein L35 pseudogene 9","metadata":null},{"id":"955d9910309d4452a0742d7181c36db7","type":"GENE","name":"RPL36","canonical_id":"hgnc:HGNC:13631","description":"ribosomal protein L36","metadata":{"aliases":["DKFZp566B023","L36","eL36"]}},{"id":"1434e4f548924282b74278d18a6a0c31","type":"GENE","name":"RPL36A","canonical_id":"hgnc:HGNC:10359","description":"ribosomal protein L36a","metadata":{"aliases":["L36A","eL42","RPL44"]}},{"id":"9e8334fbb06742f1835e10283b1ad3cc","type":"GENE","name":"RPL36A-HNRNPH2","canonical_id":"hgnc:HGNC:48349","description":"RPL36A-HNRNPH2 readthrough","metadata":null},{"id":"6f36403f1c5f4480a7e554bec6f8fc3c","type":"GENE","name":"RPL36AL","canonical_id":"hgnc:HGNC:10346","description":"ribosomal protein L36a like","metadata":{"aliases":["RPL36A","RPL36AP42"]}},{"id":"00a0684a2fe94b40a7dbea8260a68891","type":"GENE","name":"RPL36AP1","canonical_id":"hgnc:HGNC:23548","description":"ribosomal protein L36a pseudogene 1","metadata":null},{"id":"68f46b64162949c7a468e08b01a3e4c4","type":"GENE","name":"RPL36AP10","canonical_id":"hgnc:HGNC:36175","description":"ribosomal protein L36a pseudogene 10","metadata":null},{"id":"410a604c3d5042e0978fc59f4aa01cac","type":"GENE","name":"RPL36AP11","canonical_id":"hgnc:HGNC:36385","description":"ribosomal protein L36a pseudogene 11","metadata":null},{"id":"4b83e03d733849b69fd3360d68eb98d3","type":"GENE","name":"RPL36AP12","canonical_id":"hgnc:HGNC:35897","description":"ribosomal protein L36a pseudogene 12","metadata":null},{"id":"942b1873a39f449680bb020f13831fa6","type":"GENE","name":"RPL36AP13","canonical_id":"hgnc:HGNC:35877","description":"ribosomal protein L36a pseudogene 13","metadata":null},{"id":"2ca924f05c574c7b9aede0daee6bd9a5","type":"GENE","name":"RPL36AP14","canonical_id":"hgnc:HGNC:36788","description":"ribosomal protein L36a pseudogene 14","metadata":null},{"id":"fc198a287ba24a31b9a4ecee1c03fd11","type":"GENE","name":"RPL36AP15","canonical_id":"hgnc:HGNC:36648","description":"ribosomal protein L36a pseudogene 15","metadata":null},{"id":"f238fb4aea02481e82ab85c38e99cf5a","type":"GENE","name":"RPL36AP16","canonical_id":"hgnc:HGNC:36416","description":"ribosomal protein L36a pseudogene 16","metadata":null},{"id":"20ec21facec14646b39195ae1a81ead0","type":"GENE","name":"RPL36AP17","canonical_id":"hgnc:HGNC:35750","description":"ribosomal protein L36a pseudogene 17","metadata":null},{"id":"38d997b0c6ce40b59043b5ed90e35015","type":"GENE","name":"RPL36AP18","canonical_id":"hgnc:HGNC:35484","description":"ribosomal protein L36a pseudogene 18","metadata":null},{"id":"0089160062764a6db183eb4287377f9c","type":"GENE","name":"RPL36AP19","canonical_id":"hgnc:HGNC:36436","description":"ribosomal protein L36a pseudogene 19","metadata":null},{"id":"a7b3100472ec4758a8be671b5351efcc","type":"GENE","name":"RPL36AP2","canonical_id":"hgnc:HGNC:19777","description":"ribosomal protein L36a pseudogene 2","metadata":null},{"id":"0c6adfeb5b96401c9e817cd8c6aef8b2","type":"GENE","name":"RPL36AP20","canonical_id":"hgnc:HGNC:36250","description":"ribosomal protein L36a pseudogene 20","metadata":null},{"id":"40fefd3289564c8baf512fbcb0d16201","type":"GENE","name":"RPL36AP21","canonical_id":"hgnc:HGNC:37041","description":"ribosomal protein L36a pseudogene 21","metadata":null},{"id":"e783c9286e914464afc3ba2d0bb498b4","type":"GENE","name":"RPL36AP23","canonical_id":"hgnc:HGNC:36002","description":"ribosomal protein L36a pseudogene 23","metadata":null},{"id":"b8aa4164b7564c8896c4cafda04057c8","type":"GENE","name":"RPL36AP24","canonical_id":"hgnc:HGNC:36252","description":"ribosomal protein L36a pseudogene 24","metadata":null},{"id":"0a05bc96a03c479e84c57faea89850cd","type":"GENE","name":"RPL36AP25","canonical_id":"hgnc:HGNC:35926","description":"ribosomal protein L36a pseudogene 25","metadata":null},{"id":"48495654b1b64dd0b54c63bf277de79f","type":"GENE","name":"RPL36AP26","canonical_id":"hgnc:HGNC:36758","description":"ribosomal protein L36a pseudogene 26","metadata":null},{"id":"c8e2dcc0d5ff474eb549056b51df2a77","type":"GENE","name":"RPL36AP27","canonical_id":"hgnc:HGNC:35650","description":"ribosomal protein L36a pseudogene 27","metadata":null},{"id":"2dc1679a9df341a694d2b0722fa4ab02","type":"GENE","name":"RPL36AP28","canonical_id":"hgnc:HGNC:36702","description":"ribosomal protein L36a pseudogene 28","metadata":null},{"id":"eb676a083f034fe39df4c47d29ea0336","type":"GENE","name":"RPL36AP29","canonical_id":"hgnc:HGNC:36897","description":"ribosomal protein L36a pseudogene 29","metadata":null},{"id":"c95c7a9ec14a45369d1f0046340bdd3c","type":"GENE","name":"RPL36AP30","canonical_id":"hgnc:HGNC:36216","description":"ribosomal protein L36a pseudogene 30","metadata":null},{"id":"715620064eae4dcdba1b0655512acb13","type":"GENE","name":"RPL36AP31","canonical_id":"hgnc:HGNC:36066","description":"ribosomal protein L36a pseudogene 31","metadata":null},{"id":"fc5927ec375b43459677bdde15d7e4dd","type":"GENE","name":"RPL36AP32","canonical_id":"hgnc:HGNC:36540","description":"ribosomal protein L36a pseudogene 32","metadata":null},{"id":"f8faeab7cc064f7bb1f68fb6a365d8f7","type":"GENE","name":"RPL36AP33","canonical_id":"hgnc:HGNC:36475","description":"ribosomal protein L36a pseudogene 33","metadata":null},{"id":"18b5dc93568c48a7a6af632ec2bee6cb","type":"GENE","name":"RPL36AP34","canonical_id":"hgnc:HGNC:35882","description":"ribosomal protein L36a pseudogene 34","metadata":null},{"id":"9b52ca81fb574dd782d4ae05b0d33efc","type":"GENE","name":"RPL36AP35","canonical_id":"hgnc:HGNC:35639","description":"ribosomal protein L36a pseudogene 35","metadata":null},{"id":"d58f80479a774dc4b481b189d6131726","type":"GENE","name":"RPL36AP36","canonical_id":"hgnc:HGNC:36326","description":"ribosomal protein L36a pseudogene 36","metadata":null},{"id":"d121bb159d414522b4543d7060aca479","type":"GENE","name":"RPL36AP37","canonical_id":"hgnc:HGNC:36969","description":"ribosomal protein L36a pseudogene 37","metadata":null},{"id":"65f1fe35d5bf4f03aed97cde31fbf8bb","type":"GENE","name":"RPL36AP38","canonical_id":"hgnc:HGNC:35594","description":"ribosomal protein L36a pseudogene 38","metadata":null},{"id":"d7a4bc52b3dd433ea0cb30ae30d1956f","type":"GENE","name":"RPL36AP39","canonical_id":"hgnc:HGNC:36074","description":"ribosomal protein L36a pseudogene 39","metadata":null},{"id":"c384919db482407e9c5af50b5df72ab4","type":"GENE","name":"RPL36AP4","canonical_id":"hgnc:HGNC:19802","description":"ribosomal protein L36a pseudogene 4","metadata":null},{"id":"f1585c766ab1476996ea9714322cd9be","type":"GENE","name":"RPL36AP40","canonical_id":"hgnc:HGNC:36300","description":"ribosomal protein L36a pseudogene 40","metadata":null},{"id":"47f887dc7f9d4e329341a7d85f0aa0ff","type":"GENE","name":"RPL36AP41","canonical_id":"hgnc:HGNC:35813","description":"ribosomal protein L36a pseudogene 41","metadata":null},{"id":"26d8dc7a8f844938a1c6584e03201b1a","type":"GENE","name":"RPL36AP43","canonical_id":"hgnc:HGNC:36791","description":"ribosomal protein L36a pseudogene 43","metadata":null},{"id":"52a3a7808a964fa4ab849790292c9bc3","type":"GENE","name":"RPL36AP44","canonical_id":"hgnc:HGNC:36986","description":"ribosomal protein L36a pseudogene 44","metadata":null},{"id":"db45b1f7af144f7c9d9c7caaf3934789","type":"GENE","name":"RPL36AP45","canonical_id":"hgnc:HGNC:36032","description":"ribosomal protein L36a pseudogene 45","metadata":null},{"id":"1cfd66308f494114be31246410440998","type":"GENE","name":"RPL36AP46","canonical_id":"hgnc:HGNC:35812","description":"ribosomal protein L36a pseudogene 46","metadata":null},{"id":"a784a41e0bc24bf5aad410c7ad385d9e","type":"GENE","name":"RPL36AP47","canonical_id":"hgnc:HGNC:35624","description":"ribosomal protein L36a pseudogene 47","metadata":null},{"id":"1ad61cdc256346519228f0e10f7650f8","type":"GENE","name":"RPL36AP48","canonical_id":"hgnc:HGNC:36721","description":"ribosomal protein L36a pseudogene 48","metadata":null},{"id":"5b8d24dfa92046f4a89cc429a1c8fb91","type":"GENE","name":"RPL36AP49","canonical_id":"hgnc:HGNC:36274","description":"ribosomal protein L36a pseudogene 49","metadata":null},{"id":"ea73a548e3914fcb99251554e291b6d6","type":"GENE","name":"RPL36AP5","canonical_id":"hgnc:HGNC:21258","description":"ribosomal protein L36a pseudogene 5","metadata":{"aliases":["bA256G5.1"]}},{"id":"ceec0bd645fa49e7b19647d8e364cc0b","type":"GENE","name":"RPL36AP50","canonical_id":"hgnc:HGNC:36372","description":"ribosomal protein L36a pseudogene 50","metadata":null},{"id":"289d991f34e04921a5b724e9184f86d5","type":"GENE","name":"RPL36AP51","canonical_id":"hgnc:HGNC:36632","description":"ribosomal protein L36a pseudogene 51","metadata":null},{"id":"44104d6801e94faa8d04a0fe8cebeaca","type":"GENE","name":"RPL36AP52","canonical_id":"hgnc:HGNC:55144","description":"RPL36A pseudogene 52","metadata":null},{"id":"3e13223560204a6081590e10c6557c8e","type":"GENE","name":"RPL36AP53","canonical_id":"hgnc:HGNC:36517","description":"ribosomal protein L36a pseudogene 53","metadata":null},{"id":"94c52a29341749bca9ad2357ab701f26","type":"GENE","name":"RPL36AP54","canonical_id":"hgnc:HGNC:35831","description":"ribosomal protein L36a pseudogene 54","metadata":null},{"id":"8bc16baa7b204e0398880f0b881a33c0","type":"GENE","name":"RPL36AP55","canonical_id":"hgnc:HGNC:44939","description":"ribosomal protein L36a pseudogene 55","metadata":null},{"id":"5651b89e35b94294b97ae1a4f6a7105d","type":"GENE","name":"RPL36AP6","canonical_id":"hgnc:HGNC:23365","description":"ribosomal protein L36a pseudogene 6","metadata":{"aliases":["bA380I20.1"]}},{"id":"613fa6b11de04531aa12e25f97b26ece","type":"GENE","name":"RPL36AP7","canonical_id":"hgnc:HGNC:31328","description":"ribosomal protein L36a pseudogene 7","metadata":null},{"id":"2a64d422a2f7459688f00d46e57d6d0e","type":"GENE","name":"RPL36AP8","canonical_id":"hgnc:HGNC:30973","description":"ribosomal protein L36a pseudogene 8","metadata":null},{"id":"5a8e8d4f9ab343fab3d86eaebdfc4ebd","type":"GENE","name":"RPL36AP9","canonical_id":"hgnc:HGNC:35872","description":"ribosomal protein L36a pseudogene 9","metadata":null},{"id":"2bc629e974944584be3c9c1f8c6f5ade","type":"GENE","name":"RPL36P1","canonical_id":"hgnc:HGNC:16338","description":"ribosomal protein L36 pseudogene 1","metadata":{"aliases":["bA80K6.3"]}},{"id":"4b3f9d2054754b888a2d2adf25692808","type":"GENE","name":"RPL36P10","canonical_id":"hgnc:HGNC:36318","description":"ribosomal protein L36 pseudogene 10","metadata":null},{"id":"a8729c55953541f1bfc3ba6bf4d4163b","type":"GENE","name":"RPL36P11","canonical_id":"hgnc:HGNC:36271","description":"ribosomal protein L36 pseudogene 11","metadata":null},{"id":"20927fc6e9f043a6ac0e8248d9434475","type":"GENE","name":"RPL36P12","canonical_id":"hgnc:HGNC:35590","description":"ribosomal protein L36 pseudogene 12","metadata":null},{"id":"a29c2d12b6a6423bbad72b6c47112f1f","type":"GENE","name":"RPL36P13","canonical_id":"hgnc:HGNC:36941","description":"ribosomal protein L36 pseudogene 13","metadata":null},{"id":"30f368e40ec24b8ca7240a1f2d10a35f","type":"GENE","name":"RPL36P14","canonical_id":"hgnc:HGNC:35734","description":"ribosomal protein L36 pseudogene 14","metadata":null},{"id":"29385f93b76c4d999aea930c8a5ad8fd","type":"GENE","name":"RPL36P15","canonical_id":"hgnc:HGNC:36787","description":"ribosomal protein L36 pseudogene 15","metadata":null},{"id":"ea1b74df4718465686bfa833e8416490","type":"GENE","name":"RPL36P16","canonical_id":"hgnc:HGNC:37010","description":"ribosomal protein L36 pseudogene 16","metadata":null},{"id":"961e40f565c74a86b5d38738fb34c4ce","type":"GENE","name":"RPL36P17","canonical_id":"hgnc:HGNC:35884","description":"ribosomal protein L36 pseudogene 17","metadata":null},{"id":"047723d1751c4746890dc5de3badabc7","type":"GENE","name":"RPL36P18","canonical_id":"hgnc:HGNC:36856","description":"ribosomal protein L36 pseudogene 18","metadata":null},{"id":"82e10ea30bc94d2e981cf46dc73f11d6","type":"GENE","name":"RPL36P19","canonical_id":"hgnc:HGNC:42648","description":"ribosomal protein L36 pseudogene 19","metadata":null},{"id":"173913916adb4f8f92f9e0ed726a03e9","type":"GENE","name":"RPL36P2","canonical_id":"hgnc:HGNC:16570","description":"ribosomal protein L36 pseudogene 2","metadata":{"aliases":["dJ530I15.5"]}},{"id":"89afc1f44d914a1fbd11e090d402a94f","type":"GENE","name":"RPL36P20","canonical_id":"hgnc:HGNC:44564","description":"ribosomal protein L36 pseudogene 20","metadata":null},{"id":"e546befd5ee24237a9ef837e6b28f7a3","type":"GENE","name":"RPL36P3","canonical_id":"hgnc:HGNC:19786","description":"ribosomal protein L36 pseudogene 3","metadata":{"aliases":["RPL36AP3"]}},{"id":"523a5a7fe56643dead02968042b03330","type":"GENE","name":"RPL36P4","canonical_id":"hgnc:HGNC:16569","description":"ribosomal protein L36 pseudogene 4","metadata":{"aliases":["dJ477O4.3"]}},{"id":"a7d3d597647942028c9026367536d9e3","type":"GENE","name":"RPL36P5","canonical_id":"hgnc:HGNC:35567","description":"ribosomal protein L36 pseudogene 5","metadata":null},{"id":"ea47809f3b3748afa26d0fa103f1668d","type":"GENE","name":"RPL36P6","canonical_id":"hgnc:HGNC:36046","description":"ribosomal protein L36 pseudogene 6","metadata":null},{"id":"d7bb69c5f2d24e3d8a3d6045bc14c42a","type":"GENE","name":"RPL36P7","canonical_id":"hgnc:HGNC:35830","description":"ribosomal protein L36 pseudogene 7","metadata":null},{"id":"37b46f8d2572471ea1d1d9fa7745fa86","type":"GENE","name":"RPL36P8","canonical_id":"hgnc:HGNC:36493","description":"ribosomal protein L36 pseudogene 8","metadata":null},{"id":"56601e75cb3c4430896a555e33a6c0da","type":"GENE","name":"RPL36P9","canonical_id":"hgnc:HGNC:36746","description":"ribosomal protein L36 pseudogene 9","metadata":null},{"id":"2e0367a5bdec4b40a97d3f0efb7f9378","type":"GENE","name":"RPL37","canonical_id":"hgnc:HGNC:10347","description":"ribosomal protein L37","metadata":{"aliases":["L37","eL37"]}},{"id":"6b653bc5f5014fb6930bacd32ca1a22b","type":"GENE","name":"RPL37A","canonical_id":"hgnc:HGNC:10348","description":"ribosomal protein L37a","metadata":{"aliases":["L37A","eL43"]}},{"id":"631a8513169840658fcb60e942f3249c","type":"GENE","name":"RPL37A-DT","canonical_id":"hgnc:HGNC:40510","description":"RPL37A divergent transcript","metadata":null},{"id":"ed96863262fb4be1b33a39c06bf93db5","type":"GENE","name":"RPL37AP1","canonical_id":"hgnc:HGNC:16548","description":"ribosomal protein L37a pseudogene 1","metadata":{"aliases":["dJ1013A22.4"]}},{"id":"70660f76b27745fcb9360317c2ec43b3","type":"GENE","name":"RPL37AP2","canonical_id":"hgnc:HGNC:36880","description":"ribosomal protein L37a pseudogene 2","metadata":null},{"id":"a536f352ba5144a69f7e45160f45e4f7","type":"GENE","name":"RPL37AP3","canonical_id":"hgnc:HGNC:36222","description":"ribosomal protein L37a pseudogene 3","metadata":null},{"id":"6a7665e5db274b7b8d2a59597bc3cd57","type":"GENE","name":"RPL37AP4","canonical_id":"hgnc:HGNC:35586","description":"ribosomal protein L37a pseudogene 4","metadata":null},{"id":"e264d0cd4ba241c2b82337081ae0cef3","type":"GENE","name":"RPL37AP5","canonical_id":"hgnc:HGNC:36977","description":"ribosomal protein L37a pseudogene 5","metadata":null},{"id":"bf86ada6a0ee4a829b0c39c5ee809519","type":"GENE","name":"RPL37AP6","canonical_id":"hgnc:HGNC:36824","description":"ribosomal protein L37a pseudogene 6","metadata":null},{"id":"f37f376c760d48cabb317ce99166c0a8","type":"GENE","name":"RPL37AP7","canonical_id":"hgnc:HGNC:35888","description":"ribosomal protein L37a pseudogene 7","metadata":null},{"id":"825ee4acd92846c09f004b1cf57a3546","type":"GENE","name":"RPL37AP8","canonical_id":"hgnc:HGNC:35645","description":"ribosomal protein L37a pseudogene 8","metadata":null},{"id":"8d6e8d4eced343119321b142d959d78e","type":"GENE","name":"RPL37AP9","canonical_id":"hgnc:HGNC:36835","description":"ribosomal protein L37a pseudogene 9","metadata":null},{"id":"2cb088473eec49309f308e4ef1709d40","type":"GENE","name":"RPL37P1","canonical_id":"hgnc:HGNC:16337","description":"ribosomal protein L37 pseudogene 1","metadata":{"aliases":["bA563A22B.2"]}},{"id":"f0d58b009537486c9cca18fd13d4fd0d","type":"GENE","name":"RPL37P10","canonical_id":"hgnc:HGNC:36951","description":"ribosomal protein L37 pseudogene 10","metadata":null},{"id":"935806cdabd1427eadc2d10152f2a94e","type":"GENE","name":"RPL37P11","canonical_id":"hgnc:HGNC:36459","description":"ribosomal protein L37 pseudogene 11","metadata":null},{"id":"5a94c3de08e148d48db76d4f999598de","type":"GENE","name":"RPL37P12","canonical_id":"hgnc:HGNC:36989","description":"ribosomal protein L37 pseudogene 12","metadata":null},{"id":"9b58e0c2e5654153b42dc2143f61948d","type":"GENE","name":"RPL37P13","canonical_id":"hgnc:HGNC:36255","description":"ribosomal protein L37 pseudogene 13","metadata":null},{"id":"2ee2babdc06645d1bee61c3b4f292892","type":"GENE","name":"RPL37P14","canonical_id":"hgnc:HGNC:36871","description":"ribosomal protein L37 pseudogene 14","metadata":null},{"id":"8e8e4615453142ccb9dd191218c06982","type":"GENE","name":"RPL37P15","canonical_id":"hgnc:HGNC:36659","description":"ribosomal protein L37 pseudogene 15","metadata":null},{"id":"cb3b95ffffad4384a1908c7f476c1ddc","type":"GENE","name":"RPL37P16","canonical_id":"hgnc:HGNC:35949","description":"ribosomal protein L37 pseudogene 16","metadata":null},{"id":"9cd49aa0867e4d36b4dae192401c7f0e","type":"GENE","name":"RPL37P17","canonical_id":"hgnc:HGNC:36023","description":"ribosomal protein L37 pseudogene 17","metadata":null},{"id":"0e9377d49598430bbbeb51bd368c5904","type":"GENE","name":"RPL37P18","canonical_id":"hgnc:HGNC:35919","description":"ribosomal protein L37 pseudogene 18","metadata":null},{"id":"c0804648f3f74519a9c461be4109ecad","type":"GENE","name":"RPL37P19","canonical_id":"hgnc:HGNC:35576","description":"ribosomal protein L37 pseudogene 19","metadata":null},{"id":"1d1d2b2422cf4ec38de0ae53adfd800d","type":"GENE","name":"RPL37P2","canonical_id":"hgnc:HGNC:17092","description":"ribosomal protein L37 pseudogene 2","metadata":{"aliases":["PSANK1"]}},{"id":"67d1ea52034f47ec9e62e86030cf1f60","type":"GENE","name":"RPL37P20","canonical_id":"hgnc:HGNC:36562","description":"ribosomal protein L37 pseudogene 20","metadata":null},{"id":"c60eb74010b248bb9f130ffc8bb9965e","type":"GENE","name":"RPL37P21","canonical_id":"hgnc:HGNC:36256","description":"ribosomal protein L37 pseudogene 21","metadata":null},{"id":"c76a9af3030c4f4aa2d47451da3436d7","type":"GENE","name":"RPL37P22","canonical_id":"hgnc:HGNC:37019","description":"ribosomal protein L37 pseudogene 22","metadata":null},{"id":"eabdc5795e6749358eb037ee8ae83201","type":"GENE","name":"RPL37P23","canonical_id":"hgnc:HGNC:37003","description":"ribosomal protein L37 pseudogene 23","metadata":null},{"id":"d100380d3daf442ea3c11ba16449c988","type":"GENE","name":"RPL37P24","canonical_id":"hgnc:HGNC:36201","description":"ribosomal protein L37 pseudogene 24","metadata":null},{"id":"2d6f00d29fc34b2290834589ba9428ce","type":"GENE","name":"RPL37P25","canonical_id":"hgnc:HGNC:49020","description":"ribosomal protein L37 pseudogene 25","metadata":null},{"id":"4ee3d09d0b9340268d69297b2312ad49","type":"GENE","name":"RPL37P3","canonical_id":"hgnc:HGNC:17238","description":"ribosomal protein L37 pseudogene 3","metadata":{"aliases":["RL37P"]}},{"id":"ec6746eaa21d4bf4ac6fdc51a4770cf0","type":"GENE","name":"RPL37P4","canonical_id":"hgnc:HGNC:17239","description":"ribosomal protein L37 pseudogene 4","metadata":{"aliases":["RL37P2"]}},{"id":"252db6165ca1459880bec6effd04587d","type":"GENE","name":"RPL37P5","canonical_id":"hgnc:HGNC:23549","description":"ribosomal protein L37 pseudogene 5","metadata":null},{"id":"2d403ab7cf264a159f7eb1a9aafc4be6","type":"GENE","name":"RPL37P6","canonical_id":"hgnc:HGNC:31080","description":"ribosomal protein L37 pseudogene 6","metadata":null},{"id":"1ad4ff411bd0473e9cc35ef988347614","type":"GENE","name":"RPL37P7","canonical_id":"hgnc:HGNC:36499","description":"ribosomal protein L37 pseudogene 7","metadata":null},{"id":"1996d2f129cd4a27872e6e2aa73a7f58","type":"GENE","name":"RPL37P8","canonical_id":"hgnc:HGNC:36279","description":"ribosomal protein L37 pseudogene 8","metadata":null},{"id":"79586f4de6934c5dabe37801358fa767","type":"GENE","name":"RPL37P9","canonical_id":"hgnc:HGNC:35688","description":"ribosomal protein L37 pseudogene 9","metadata":null},{"id":"bb4798c268ca420f9e278a413203342e","type":"GENE","name":"RPL38","canonical_id":"hgnc:HGNC:10349","description":"ribosomal protein L38","metadata":{"aliases":["L38","eL38"]}},{"id":"4c4591594f4743c38afdf91e60ab75c5","type":"GENE","name":"RPL38P1","canonical_id":"hgnc:HGNC:17093","description":"RPL38 pseudogene 1","metadata":null},{"id":"6c13c9cf1e9448fb8c2170634d574af5","type":"GENE","name":"RPL38P2","canonical_id":"hgnc:HGNC:36620","description":"RPL38 pseudogene 2","metadata":null},{"id":"37aee1db620248dc9017f977c1f0373d","type":"GENE","name":"RPL38P3","canonical_id":"hgnc:HGNC:35980","description":"RPL38 pseudogene 3","metadata":null},{"id":"8c4729f6b1fa4346b39b986365695eec","type":"GENE","name":"RPL38P4","canonical_id":"hgnc:HGNC:48867","description":"RPL38 pseudogene 4","metadata":null},{"id":"f0fa39db55cf44c092636d62edbc868f","type":"GENE","name":"RPL38P5","canonical_id":"hgnc:HGNC:54607","description":"RPL38 pseudogene 5","metadata":null},{"id":"2b745722f4e349a79d3e8fc993deed72","type":"GENE","name":"RPL38P6","canonical_id":"hgnc:HGNC:54608","description":"RPL38 pseudogene 6","metadata":null},{"id":"7130e193ebe344568b55a17e55416e16","type":"GENE","name":"RPL39","canonical_id":"hgnc:HGNC:10350","description":"ribosomal protein L39","metadata":{"aliases":["L39","eL39","RPL39P42"]}},{"id":"886e1e2f10ff484ca8a2fcd3672c68b0","type":"GENE","name":"RPL39L","canonical_id":"hgnc:HGNC:17094","description":"ribosomal protein L39 like","metadata":{"aliases":["RPL39L1"]}},{"id":"bdfdd46dd89448d4bea49a50ae46b74d","type":"GENE","name":"RPL39P","canonical_id":"hgnc:HGNC:16558","description":"ribosomal protein L39 pseudogene","metadata":{"aliases":["dJ1167H4.5"]}},{"id":"6bdb7a02475d48a49c2c5101b4f1932d","type":"GENE","name":"RPL39P10","canonical_id":"hgnc:HGNC:35745","description":"ribosomal protein L39 pseudogene 10","metadata":null},{"id":"068fc938ad4a4212aca13c9290254791","type":"GENE","name":"RPL39P11","canonical_id":"hgnc:HGNC:36798","description":"ribosomal protein L39 pseudogene 11","metadata":null},{"id":"d97319bdb2284609a2a0561cd64af330","type":"GENE","name":"RPL39P12","canonical_id":"hgnc:HGNC:36166","description":"ribosomal protein L39 pseudogene 12","metadata":null},{"id":"eecda9408222464dbe2b7da2900643a5","type":"GENE","name":"RPL39P13","canonical_id":"hgnc:HGNC:36705","description":"ribosomal protein L39 pseudogene 13","metadata":null},{"id":"c4d2b71e697e4c26b14331e37e80e337","type":"GENE","name":"RPL39P14","canonical_id":"hgnc:HGNC:36609","description":"ribosomal protein L39 pseudogene 14","metadata":null},{"id":"61bd09db2f13445fb217a23a7e0fcc9d","type":"GENE","name":"RPL39P15","canonical_id":"hgnc:HGNC:35856","description":"ribosomal protein L39 pseudogene 15","metadata":null},{"id":"c8c852cfa2a8488da459eb68dc055751","type":"GENE","name":"RPL39P16","canonical_id":"hgnc:HGNC:35912","description":"ribosomal protein L39 pseudogene 16","metadata":null},{"id":"8b943377b9e843cdba788d8054f70cfd","type":"GENE","name":"RPL39P17","canonical_id":"hgnc:HGNC:35545","description":"ribosomal protein L39 pseudogene 17","metadata":null},{"id":"3e206cfcb53c416c80508f207e636176","type":"GENE","name":"RPL39P18","canonical_id":"hgnc:HGNC:36111","description":"ribosomal protein L39 pseudogene 18","metadata":null},{"id":"b32b7d28035543d2a9fa38bd1d7858d0","type":"GENE","name":"RPL39P19","canonical_id":"hgnc:HGNC:36346","description":"ribosomal protein L39 pseudogene 19","metadata":null},{"id":"d1bd83d8866d4e4b88210d48d86237e2","type":"GENE","name":"RPL39P2","canonical_id":"hgnc:HGNC:19774","description":"ribosomal protein L39 pseudogene 2","metadata":null},{"id":"3709b5e29602413d89981fd8f34b07c3","type":"GENE","name":"RPL39P20","canonical_id":"hgnc:HGNC:36366","description":"ribosomal protein L39 pseudogene 20","metadata":null},{"id":"bb62c53d76a44ac6a3c7b7345aa70ca2","type":"GENE","name":"RPL39P21","canonical_id":"hgnc:HGNC:36218","description":"ribosomal protein L39 pseudogene 21","metadata":null},{"id":"9741074495db4c0b8d7c0af21cdee17d","type":"GENE","name":"RPL39P22","canonical_id":"hgnc:HGNC:36072","description":"ribosomal protein L39 pseudogene 22","metadata":null},{"id":"a278cf20701f4fa98d7a35c28b8601c7","type":"GENE","name":"RPL39P23","canonical_id":"hgnc:HGNC:36581","description":"ribosomal protein L39 pseudogene 23","metadata":null},{"id":"06ccaea1ad85420696483234086f7667","type":"GENE","name":"RPL39P24","canonical_id":"hgnc:HGNC:36431","description":"ribosomal protein L39 pseudogene 24","metadata":null},{"id":"53d988af037e4b9d9784a715c1c8bc96","type":"GENE","name":"RPL39P25","canonical_id":"hgnc:HGNC:37002","description":"ribosomal protein L39 pseudogene 25","metadata":null},{"id":"9018fed29cb04bf0930b08fcccc5fbd8","type":"GENE","name":"RPL39P26","canonical_id":"hgnc:HGNC:35900","description":"ribosomal protein L39 pseudogene 26","metadata":null},{"id":"49488380dbb34ce999aa8844e0e6786b","type":"GENE","name":"RPL39P27","canonical_id":"hgnc:HGNC:36114","description":"ribosomal protein L39 pseudogene 27","metadata":null},{"id":"c1f71ec36f7d4d4db9402f5bb08bde18","type":"GENE","name":"RPL39P28","canonical_id":"hgnc:HGNC:35619","description":"ribosomal protein L39 pseudogene 28","metadata":null},{"id":"cd86bb46fe1b42e380ae79f8659a8699","type":"GENE","name":"RPL39P29","canonical_id":"hgnc:HGNC:35808","description":"ribosomal protein L39 pseudogene 29","metadata":null},{"id":"d9f2c8b322594ebe883dc5fa337ded47","type":"GENE","name":"RPL39P3","canonical_id":"hgnc:HGNC:21383","description":"ribosomal protein L39 pseudogene 3","metadata":{"aliases":["Em:AC019205.3"]}},{"id":"8be487e717af49c1aaa7af35d79d49b7","type":"GENE","name":"RPL39P30","canonical_id":"hgnc:HGNC:36979","description":"ribosomal protein L39 pseudogene 30","metadata":null},{"id":"561c32d5237e4e738b4faeca5acd9503","type":"GENE","name":"RPL39P31","canonical_id":"hgnc:HGNC:36488","description":"ribosomal protein L39 pseudogene 31","metadata":null},{"id":"9065665ddb8f46fc940f47187427cff2","type":"GENE","name":"RPL39P32","canonical_id":"hgnc:HGNC:36959","description":"ribosomal protein L39 pseudogene 32","metadata":null},{"id":"500ec9f5f25d48c7979c1415dd3f04f6","type":"GENE","name":"RPL39P33","canonical_id":"hgnc:HGNC:36315","description":"ribosomal protein L39 pseudogene 33","metadata":null},{"id":"cbef7f76a5bc4d3db85dc71f39300743","type":"GENE","name":"RPL39P34","canonical_id":"hgnc:HGNC:36528","description":"ribosomal protein L39 pseudogene 34","metadata":null},{"id":"b40e70ebd07a4c5c966187bc47acbdd3","type":"GENE","name":"RPL39P35","canonical_id":"hgnc:HGNC:35815","description":"ribosomal protein L39 pseudogene 35","metadata":null},{"id":"41f039d30fce40f9a3befe167d20157b","type":"GENE","name":"RPL39P36","canonical_id":"hgnc:HGNC:36076","description":"ribosomal protein L39 pseudogene 36","metadata":null},{"id":"8164312f2f2e4710b06d8b6440054bf6","type":"GENE","name":"RPL39P37","canonical_id":"hgnc:HGNC:36282","description":"ribosomal protein L39 pseudogene 37","metadata":null},{"id":"c03f399276894938a4e29a587eab4806","type":"GENE","name":"RPL39P38","canonical_id":"hgnc:HGNC:36935","description":"ribosomal protein L39 pseudogene 38","metadata":null},{"id":"9afb4afac5ff48c28f39347ee50c98d9","type":"GENE","name":"RPL39P39","canonical_id":"hgnc:HGNC:36514","description":"ribosomal protein L39 pseudogene 39","metadata":null},{"id":"b4343c35f3fd4386a57fa71b93214aa4","type":"GENE","name":"RPL39P4","canonical_id":"hgnc:HGNC:31327","description":"ribosomal protein L39 pseudogene 4","metadata":null},{"id":"306230d52adb405e8f1528f5fc51f8f4","type":"GENE","name":"RPL39P40","canonical_id":"hgnc:HGNC:35823","description":"ribosomal protein L39 pseudogene 40","metadata":null},{"id":"cd4b324ed7174ed492f7412ce1c91986","type":"GENE","name":"RPL39P41","canonical_id":"hgnc:HGNC:35941","description":"ribosomal protein L39 pseudogene 41","metadata":null},{"id":"18030d95b96e44bebf8252185426cfef","type":"GENE","name":"RPL39P5","canonical_id":"hgnc:HGNC:26015","description":"ribosomal protein L39 pseudogene 5","metadata":null},{"id":"f0e294216d8747949ea3f3ce90256e31","type":"GENE","name":"RPL39P6","canonical_id":"hgnc:HGNC:35803","description":"ribosomal protein L39 pseudogene 6","metadata":null},{"id":"ee7d1d8b65344726b4476e50bad6d865","type":"GENE","name":"RPL39P7","canonical_id":"hgnc:HGNC:36651","description":"ribosomal protein L39 pseudogene 7","metadata":null},{"id":"b82bb02fc13647caa84cf908eabeed45","type":"GENE","name":"RPL39P8","canonical_id":"hgnc:HGNC:36329","description":"ribosomal protein L39 pseudogene 8","metadata":null},{"id":"bb539acaf66a470caca851142898a24f","type":"GENE","name":"RPL39P9","canonical_id":"hgnc:HGNC:35580","description":"ribosomal protein L39 pseudogene 9","metadata":null},{"id":"9dab43d6c6894657a5bde65dae336cbf","type":"GENE","name":"RPL3L","canonical_id":"hgnc:HGNC:10351","description":"ribosomal protein L3 like","metadata":null},{"id":"b221c1a9d6c843a9840af2c1eb28e123","type":"GENE","name":"RPL3P1","canonical_id":"hgnc:HGNC:10352","description":"ribosomal protein L3 pseudogene 1","metadata":{"aliases":["RPL3P"]}},{"id":"eca595a18ee748f5a5e5236b352bd98a","type":"GENE","name":"RPL3P10","canonical_id":"hgnc:HGNC:36819","description":"ribosomal protein L3 pseudogene 10","metadata":null},{"id":"34af11f403834206a34d5d566e2c7aef","type":"GENE","name":"RPL3P11","canonical_id":"hgnc:HGNC:35521","description":"ribosomal protein L3 pseudogene 11","metadata":null},{"id":"eb29d3b6bbe4498989493a09e3230205","type":"GENE","name":"RPL3P12","canonical_id":"hgnc:HGNC:36298","description":"ribosomal protein L3 pseudogene 12","metadata":null},{"id":"77c629b7a8db46f99e24f9db962c898e","type":"GENE","name":"RPL3P13","canonical_id":"hgnc:HGNC:48494","description":"ribosomal protein L3 pseudogene 13","metadata":null},{"id":"0c05af356d1d4bf4aea6304168ac6c5a","type":"GENE","name":"RPL3P2","canonical_id":"hgnc:HGNC:17834","description":"ribosomal protein L3 pseudogene 2","metadata":{"aliases":["RPL3-Hom"]}},{"id":"d1f1ec625f794226aaae7d52a0ede8eb","type":"GENE","name":"RPL3P3","canonical_id":"hgnc:HGNC:23550","description":"ribosomal protein L3 pseudogene 3","metadata":null},{"id":"0b06b07febfd4e2691107c3bb032dca5","type":"GENE","name":"RPL3P4","canonical_id":"hgnc:HGNC:19805","description":"ribosomal protein L3 pseudogene 4","metadata":null},{"id":"c369e3f2134547e0ae4a025368801b04","type":"GENE","name":"RPL3P5","canonical_id":"hgnc:HGNC:36934","description":"ribosomal protein L3 pseudogene 5","metadata":null},{"id":"71e22dc662194f14a1b7063589babe49","type":"GENE","name":"RPL3P6","canonical_id":"hgnc:HGNC:36395","description":"ribosomal protein L3 pseudogene 6","metadata":null},{"id":"f7dee351511e44089f83f9375bf6885d","type":"GENE","name":"RPL3P7","canonical_id":"hgnc:HGNC:36797","description":"ribosomal protein L3 pseudogene 7","metadata":null},{"id":"f0e6331e55ea44679ba5380970822de0","type":"GENE","name":"RPL3P8","canonical_id":"hgnc:HGNC:35498","description":"ribosomal protein L3 pseudogene 8","metadata":null},{"id":"444644a2f1bc43b4b66880df4b8ec90d","type":"GENE","name":"RPL3P9","canonical_id":"hgnc:HGNC:36839","description":"ribosomal protein L3 pseudogene 9","metadata":null},{"id":"462d148b520b43a3bd5ee46ba552e32d","type":"GENE","name":"RPL4","canonical_id":"hgnc:HGNC:10353","description":"ribosomal protein L4","metadata":{"aliases":["L4","uL4"]}},{"id":"1813860e782342479eaa66a58f8c6533","type":"GENE","name":"RPL41","canonical_id":"hgnc:HGNC:10354","description":"ribosomal protein L41","metadata":{"aliases":["L41","eL41"]}},{"id":"f24548d18d1644e495890b73a9757cab","type":"GENE","name":"RPL41P1","canonical_id":"hgnc:HGNC:10356","description":"ribosomal protein L41 pseudogene 1","metadata":{"aliases":["RPL41L2"]}},{"id":"23b7845d215949ed9b5fa416ae6f0411","type":"GENE","name":"RPL41P2","canonical_id":"hgnc:HGNC:10357","description":"ribosomal protein L41 pseudogene 2","metadata":null},{"id":"771caf7e7fab4244897f33d09a1666b5","type":"GENE","name":"RPL41P3","canonical_id":"hgnc:HGNC:10358","description":"ribosomal protein L41 pseudogene 3","metadata":null},{"id":"2955ba3b3e2a43648a5077ead7bece46","type":"GENE","name":"RPL41P4","canonical_id":"hgnc:HGNC:19788","description":"ribosomal protein L41 pseudogene 4","metadata":null},{"id":"e03db26b5f654e3e857d62022b19454a","type":"GENE","name":"RPL41P5","canonical_id":"hgnc:HGNC:10355","description":"ribosomal protein L41 pseudogene 5","metadata":{"aliases":["RPL41L"]}},{"id":"0708b494cb7446e895868374df440215","type":"GENE","name":"RPL41P6","canonical_id":"hgnc:HGNC:37655","description":"ribosomal protein L41 pseudogene 6","metadata":null},{"id":"b89d808b82f847d7bca669c04edfb385","type":"GENE","name":"RPL41P7","canonical_id":"hgnc:HGNC:37656","description":"ribosomal protein L41 pseudogene 7","metadata":null},{"id":"4cb61a3978304b469eccc054c742e3f5","type":"GENE","name":"RPL4P1","canonical_id":"hgnc:HGNC:23551","description":"ribosomal protein L4 pseudogene 1","metadata":null},{"id":"0678dd2dfba9408dacd7717e80e9b4b0","type":"GENE","name":"RPL4P2","canonical_id":"hgnc:HGNC:36836","description":"ribosomal protein L4 pseudogene 2","metadata":null},{"id":"452d9ce1c95143b5b73c221b459d57a9","type":"GENE","name":"RPL4P3","canonical_id":"hgnc:HGNC:35773","description":"ribosomal protein L4 pseudogene 3","metadata":null},{"id":"39c4d177e6964c89a0e4227960f4471f","type":"GENE","name":"RPL4P4","canonical_id":"hgnc:HGNC:36179","description":"ribosomal protein L4 pseudogene 4","metadata":null},{"id":"b18a609edbcc404a972fdd72ee9e4c04","type":"GENE","name":"RPL4P5","canonical_id":"hgnc:HGNC:35699","description":"ribosomal protein L4 pseudogene 5","metadata":null},{"id":"b179084f6eb44929945d97cba3ebaf24","type":"GENE","name":"RPL4P6","canonical_id":"hgnc:HGNC:35611","description":"ribosomal protein L4 pseudogene 6","metadata":null},{"id":"4aafd95fc6634bfa9cf3ce7aa6b1bdbf","type":"GENE","name":"RPL4P7","canonical_id":"hgnc:HGNC:54598","description":"ribosomal protein L4 pseudogene 7","metadata":null},{"id":"f431ea61c8fa4627bde622ebe8b33957","type":"GENE","name":"RPL5","canonical_id":"hgnc:HGNC:10360","description":"ribosomal protein L5","metadata":{"aliases":["L5","PPP1R135","uL18"]}},{"id":"9ab96f3bcede48cdb59eff3791a1d611","type":"GENE","name":"RPL5P1","canonical_id":"hgnc:HGNC:10361","description":"ribosomal protein L5 pseudogene 1","metadata":null},{"id":"1b12a7eab5554ac89b7734e153ee0404","type":"GENE","name":"RPL5P10","canonical_id":"hgnc:HGNC:36846","description":"ribosomal protein L5 pseudogene 10","metadata":null},{"id":"1045f74b7e88428580ece5a6fb3dd827","type":"GENE","name":"RPL5P11","canonical_id":"hgnc:HGNC:35483","description":"ribosomal protein L5 pseudogene 11","metadata":null},{"id":"d1bd49f1cad04340b5af27723b047703","type":"GENE","name":"RPL5P12","canonical_id":"hgnc:HGNC:36221","description":"ribosomal protein L5 pseudogene 12","metadata":null},{"id":"3b4bf84588454c28ad0a5db4a3905196","type":"GENE","name":"RPL5P13","canonical_id":"hgnc:HGNC:37023","description":"ribosomal protein L5 pseudogene 13","metadata":null},{"id":"cf33f74855e5412b9e2ee85012cfe6a7","type":"GENE","name":"RPL5P14","canonical_id":"hgnc:HGNC:35924","description":"ribosomal protein L5 pseudogene 14","metadata":null},{"id":"d97553d3197746c4968ce251d001bbde","type":"GENE","name":"RPL5P15","canonical_id":"hgnc:HGNC:36769","description":"ribosomal protein L5 pseudogene 15","metadata":null},{"id":"47558baa67ca419894551964341108ad","type":"GENE","name":"RPL5P16","canonical_id":"hgnc:HGNC:36009","description":"ribosomal protein L5 pseudogene 16","metadata":null},{"id":"26ff248eef9d43dc8dd2e7006b475d7e","type":"GENE","name":"RPL5P17","canonical_id":"hgnc:HGNC:36605","description":"ribosomal protein L5 pseudogene 17","metadata":null},{"id":"f148a5b6238d43048c189c52ff36903c","type":"GENE","name":"RPL5P18","canonical_id":"hgnc:HGNC:36640","description":"ribosomal protein L5 pseudogene 18","metadata":null},{"id":"e03090a79100424ca05a6f426b1aefa5","type":"GENE","name":"RPL5P19","canonical_id":"hgnc:HGNC:36604","description":"ribosomal protein L5 pseudogene 19","metadata":null},{"id":"02322b1c77f24952be5ca1c046bdfd4b","type":"GENE","name":"RPL5P2","canonical_id":"hgnc:HGNC:16568","description":"ribosomal protein L5 pseudogene 2","metadata":{"aliases":["dJ461P17.5"]}},{"id":"34abb79e43924a7c9bf36f7ba53882d6","type":"GENE","name":"RPL5P20","canonical_id":"hgnc:HGNC:36660","description":"ribosomal protein L5 pseudogene 20","metadata":null},{"id":"afa05837ac7c4038a955f39bd6cf5bcf","type":"GENE","name":"RPL5P21","canonical_id":"hgnc:HGNC:37029","description":"ribosomal protein L5 pseudogene 21","metadata":null},{"id":"a41c67a8a7854bc9a77ef172901cc040","type":"GENE","name":"RPL5P22","canonical_id":"hgnc:HGNC:35695","description":"ribosomal protein L5 pseudogene 22","metadata":null},{"id":"6f8f3099941044429909b3977a66e891","type":"GENE","name":"RPL5P23","canonical_id":"hgnc:HGNC:36553","description":"ribosomal protein L5 pseudogene 23","metadata":null},{"id":"bfa2cec892424ea5b7a7893cfb28dc50","type":"GENE","name":"RPL5P24","canonical_id":"hgnc:HGNC:35828","description":"ribosomal protein L5 pseudogene 24","metadata":null},{"id":"bcfd4f940f404353ab71d06597528019","type":"GENE","name":"RPL5P25","canonical_id":"hgnc:HGNC:35493","description":"ribosomal protein L5 pseudogene 25","metadata":null},{"id":"fcfdef42613646e69afef3d03c012c2a","type":"GENE","name":"RPL5P26","canonical_id":"hgnc:HGNC:36247","description":"ribosomal protein L5 pseudogene 26","metadata":null},{"id":"7f6ca1fae7b2489b97613361608274d0","type":"GENE","name":"RPL5P27","canonical_id":"hgnc:HGNC:36172","description":"ribosomal protein L5 pseudogene 27","metadata":null},{"id":"f09256466792428587c988002b9a0422","type":"GENE","name":"RPL5P28","canonical_id":"hgnc:HGNC:36827","description":"ribosomal protein L5 pseudogene 28","metadata":null},{"id":"77f69b55eec44a3595327df36c27304f","type":"GENE","name":"RPL5P29","canonical_id":"hgnc:HGNC:36335","description":"ribosomal protein L5 pseudogene 29","metadata":null},{"id":"e9457e50008c4609b356e119ac76423b","type":"GENE","name":"RPL5P3","canonical_id":"hgnc:HGNC:31034","description":"ribosomal protein L5 pseudogene 3","metadata":{"aliases":["HsT18216"]}},{"id":"5775989ea0944963b3c8aa523a836863","type":"GENE","name":"RPL5P30","canonical_id":"hgnc:HGNC:35837","description":"ribosomal protein L5 pseudogene 30","metadata":null},{"id":"1157e6aeca7a46a19e636a73d035e440","type":"GENE","name":"RPL5P31","canonical_id":"hgnc:HGNC:42036","description":"ribosomal protein L5 pseudogene 31","metadata":null},{"id":"ed0b0d3b9f834eb78bc503bb61428631","type":"GENE","name":"RPL5P32","canonical_id":"hgnc:HGNC:36973","description":"ribosomal protein L5 pseudogene 32","metadata":null},{"id":"dcabd2d9da1a4fe5a3864ff8d5f9724d","type":"GENE","name":"RPL5P33","canonical_id":"hgnc:HGNC:36703","description":"ribosomal protein L5 pseudogene 33","metadata":null},{"id":"860d412f7fbb4014adc61d6ac5a0731e","type":"GENE","name":"RPL5P34","canonical_id":"hgnc:HGNC:36463","description":"ribosomal protein L5 pseudogene 34","metadata":null},{"id":"d610b9a829d54482a0742abbbed6ed1b","type":"GENE","name":"RPL5P35","canonical_id":"hgnc:HGNC:36967","description":"ribosomal protein L5 pseudogene 35","metadata":null},{"id":"d95449b25d3f4370abd7220a3778e0b8","type":"GENE","name":"RPL5P4","canonical_id":"hgnc:HGNC:36095","description":"ribosomal protein L5 pseudogene 4","metadata":null},{"id":"f62fd21bb24244c499c84042a6edf553","type":"GENE","name":"RPL5P5","canonical_id":"hgnc:HGNC:35564","description":"ribosomal protein L5 pseudogene 5","metadata":null},{"id":"9f8f6e3c5e49477e9b3fc8ab984045af","type":"GENE","name":"RPL5P6","canonical_id":"hgnc:HGNC:35890","description":"ribosomal protein L5 pseudogene 6","metadata":null},{"id":"edfec848257048d49e77fb815de2a684","type":"GENE","name":"RPL5P7","canonical_id":"hgnc:HGNC:36583","description":"ribosomal protein L5 pseudogene 7","metadata":null},{"id":"231b90d4dec34c05860dcc2bd7199410","type":"GENE","name":"RPL5P8","canonical_id":"hgnc:HGNC:36290","description":"ribosomal protein L5 pseudogene 8","metadata":null},{"id":"891b8e523ed44a78b208b1e251b64fa6","type":"GENE","name":"RPL5P9","canonical_id":"hgnc:HGNC:36557","description":"ribosomal protein L5 pseudogene 9","metadata":null},{"id":"f39cfd2fa17741c1b54b25344d20ab2e","type":"GENE","name":"RPL6","canonical_id":"hgnc:HGNC:10362","description":"ribosomal protein L6","metadata":{"aliases":["TAXREB107","L6","eL6","TXREB1"]}},{"id":"0e3096fdb47c41a0a11955fc71b986bd","type":"GENE","name":"RPL6P1","canonical_id":"hgnc:HGNC:35972","description":"ribosomal protein L6 pseudogene 1","metadata":null},{"id":"02b06ffd3afd46bebdae74375d517734","type":"GENE","name":"RPL6P10","canonical_id":"hgnc:HGNC:36575","description":"ribosomal protein L6 pseudogene 10","metadata":null},{"id":"b6fbbe5c959249b89b1416021dbe723b","type":"GENE","name":"RPL6P11","canonical_id":"hgnc:HGNC:55893","description":"ribosomal protein L6 pseudogene 11","metadata":null},{"id":"c5065e5e62444597a462580124f26fad","type":"GENE","name":"RPL6P12","canonical_id":"hgnc:HGNC:35681","description":"ribosomal protein L6 pseudogene 12","metadata":null},{"id":"92259ef89be24a489a533e3498a03394","type":"GENE","name":"RPL6P13","canonical_id":"hgnc:HGNC:36399","description":"ribosomal protein L6 pseudogene 13","metadata":null},{"id":"d5b13bdc0c8e448a905c8b1485b06827","type":"GENE","name":"RPL6P14","canonical_id":"hgnc:HGNC:35661","description":"ribosomal protein L6 pseudogene 14","metadata":null},{"id":"c698dabc806e44489cdf3cd7c8eb809b","type":"GENE","name":"RPL6P15","canonical_id":"hgnc:HGNC:36903","description":"ribosomal protein L6 pseudogene 15","metadata":null},{"id":"7c58ea8346c644a3a0524dfacc5e584e","type":"GENE","name":"RPL6P16","canonical_id":"hgnc:HGNC:35674","description":"ribosomal protein L6 pseudogene 16","metadata":null},{"id":"69fff5591ec14fe2b7a26069517715ae","type":"GENE","name":"RPL6P17","canonical_id":"hgnc:HGNC:36914","description":"ribosomal protein L6 pseudogene 17","metadata":null},{"id":"846ed294f91a440db8651e3de887edd7","type":"GENE","name":"RPL6P18","canonical_id":"hgnc:HGNC:36911","description":"ribosomal protein L6 pseudogene 18","metadata":null},{"id":"7baf8cf3f14c4c67ae0115a900078f73","type":"GENE","name":"RPL6P19","canonical_id":"hgnc:HGNC:36754","description":"ribosomal protein L6 pseudogene 19","metadata":null},{"id":"7eddea24c2f64d8e88d25a0979e79fdb","type":"GENE","name":"RPL6P2","canonical_id":"hgnc:HGNC:35964","description":"ribosomal protein L6 pseudogene 2","metadata":null},{"id":"85139d2a8e2f494583ddcef124e47b81","type":"GENE","name":"RPL6P20","canonical_id":"hgnc:HGNC:36543","description":"ribosomal protein L6 pseudogene 20","metadata":null},{"id":"d38fb835dadf4da2be3221f3c4988f08","type":"GENE","name":"RPL6P21","canonical_id":"hgnc:HGNC:35994","description":"ribosomal protein L6 pseudogene 21","metadata":null},{"id":"52f57521a48c4a92b174effa4eaacc1b","type":"GENE","name":"RPL6P22","canonical_id":"hgnc:HGNC:36220","description":"ribosomal protein L6 pseudogene 22","metadata":null},{"id":"5c4f35f709f34610af2fc65258c72d29","type":"GENE","name":"RPL6P23","canonical_id":"hgnc:HGNC:55892","description":"ribosomal protein L6 pseudogene 23","metadata":null},{"id":"ebff3886d87b491a98bac042cbcd8b1f","type":"GENE","name":"RPL6P24","canonical_id":"hgnc:HGNC:36343","description":"ribosomal protein L6 pseudogene 24","metadata":null},{"id":"ee764bc663854cc1b6659165a18d01e9","type":"GENE","name":"RPL6P25","canonical_id":"hgnc:HGNC:36840","description":"ribosomal protein L6 pseudogene 25","metadata":null},{"id":"7c0a11360ba5458a8e541a82e63c8973","type":"GENE","name":"RPL6P26","canonical_id":"hgnc:HGNC:36152","description":"ribosomal protein L6 pseudogene 26","metadata":null},{"id":"790ec6bb034845ddaa307b8b81aaaaa7","type":"GENE","name":"RPL6P27","canonical_id":"hgnc:HGNC:36133","description":"ribosomal protein L6 pseudogene 27","metadata":null},{"id":"0a6320085546497cbb41c4c689ce1d15","type":"GENE","name":"RPL6P28","canonical_id":"hgnc:HGNC:36065","description":"ribosomal protein L6 pseudogene 28","metadata":null},{"id":"699a7b7cefc84098a2e1c31c40bd2855","type":"GENE","name":"RPL6P29","canonical_id":"hgnc:HGNC:36382","description":"ribosomal protein L6 pseudogene 29","metadata":null},{"id":"6ce71d29726e4241bdad9f5be4ad4ef0","type":"GENE","name":"RPL6P3","canonical_id":"hgnc:HGNC:35925","description":"ribosomal protein L6 pseudogene 3","metadata":null},{"id":"b04d3dac9e594c0b8f1c6e3624ca0d23","type":"GENE","name":"RPL6P30","canonical_id":"hgnc:HGNC:36171","description":"ribosomal protein L6 pseudogene 30","metadata":null},{"id":"0af35460611d4ec4a8a00d79d8225699","type":"GENE","name":"RPL6P31","canonical_id":"hgnc:HGNC:55890","description":"ribosomal protein L6 pseudogene 31","metadata":null},{"id":"d713415f1ff5475193c346695e61135a","type":"GENE","name":"RPL6P32","canonical_id":"hgnc:HGNC:55891","description":"ribosomal protein L6 pseudogene 32","metadata":null},{"id":"75f47c69b65c43e2a5accbff80c25630","type":"GENE","name":"RPL6P4","canonical_id":"hgnc:HGNC:36344","description":"ribosomal protein L6 pseudogene 4","metadata":null},{"id":"c0009b047d184fc5a37e371d066d1bbd","type":"GENE","name":"RPL6P5","canonical_id":"hgnc:HGNC:36199","description":"ribosomal protein L6 pseudogene 5","metadata":null},{"id":"7b5a6bb6543045d28f5d31db8e00c296","type":"GENE","name":"RPL6P6","canonical_id":"hgnc:HGNC:36673","description":"ribosomal protein L6 pseudogene 6","metadata":null},{"id":"1766456916fb450eb026c5a8c54627e6","type":"GENE","name":"RPL6P7","canonical_id":"hgnc:HGNC:35801","description":"ribosomal protein L6 pseudogene 7","metadata":null},{"id":"649a7fdb9aaf484c9f458562611f0f92","type":"GENE","name":"RPL6P8","canonical_id":"hgnc:HGNC:37044","description":"ribosomal protein L6 pseudogene 8","metadata":null},{"id":"ecdb00a840a84ca8b792c94f580d8354","type":"GENE","name":"RPL6P9","canonical_id":"hgnc:HGNC:36484","description":"ribosomal protein L6 pseudogene 9","metadata":null},{"id":"0e12d405e8cb45d8a88217c51111d2c5","type":"GENE","name":"RPL7","canonical_id":"hgnc:HGNC:10363","description":"ribosomal protein L7","metadata":{"aliases":["humL7-1","L7","uL30"]}},{"id":"7d86182ce5cf45da8c22dc6796942141","type":"GENE","name":"RPL7A","canonical_id":"hgnc:HGNC:10364","description":"ribosomal protein L7a","metadata":{"aliases":["SURF3","TRUP","L7A","eL8"]}},{"id":"94a2ab5abc0744c28308aeca518b5463","type":"GENE","name":"RPL7AP10","canonical_id":"hgnc:HGNC:32433","description":"ribosomal protein L7a pseudogene 10","metadata":{"aliases":["RPL7AP68"]}},{"id":"5c5be5ea1005434cadd3a15b402a656b","type":"GENE","name":"RPL7AP11","canonical_id":"hgnc:HGNC:35242","description":"ribosomal protein L7a pseudogene 11","metadata":null},{"id":"afa53bf772304e93a625994e4e81fa54","type":"GENE","name":"RPL7AP12","canonical_id":"hgnc:HGNC:16562","description":"ribosomal protein L7a pseudogene 12","metadata":{"aliases":["dJ189G13.1","RPL7AL2"]}},{"id":"deeb15df4f03415a8b948f2e1965ee78","type":"GENE","name":"RPL7AP13","canonical_id":"hgnc:HGNC:16565","description":"ribosomal protein L7a pseudogene 13","metadata":{"aliases":["dJ348M17.1","RPL7AL3"]}},{"id":"2ef359ff9f57478e84fec244c8de59e5","type":"GENE","name":"RPL7AP14","canonical_id":"hgnc:HGNC:16590","description":"ribosomal protein L7a pseudogene 14","metadata":{"aliases":["dJ823N20.2","RPL7AL4"]}},{"id":"ada9dcb864d041aa90d448e9982f69e9","type":"GENE","name":"RPL7AP15","canonical_id":"hgnc:HGNC:36873","description":"ribosomal protein L7a pseudogene 15","metadata":null},{"id":"b991d4e72d004254a3bb4b2f8ebdb8a6","type":"GENE","name":"RPL7AP16","canonical_id":"hgnc:HGNC:35898","description":"ribosomal protein L7a pseudogene 16","metadata":null},{"id":"39be9bfd1f1d4f72b28ad3f5f7f05d36","type":"GENE","name":"RPL7AP17","canonical_id":"hgnc:HGNC:36501","description":"ribosomal protein L7a pseudogene 17","metadata":null},{"id":"cb78b4df9a86421381e7d64bd1fafc7c","type":"GENE","name":"RPL7AP18","canonical_id":"hgnc:HGNC:35613","description":"ribosomal protein L7a pseudogene 18","metadata":null},{"id":"f0cc1162e1c24f68ba10e418a3a20182","type":"GENE","name":"RPL7AP19","canonical_id":"hgnc:HGNC:36820","description":"ribosomal protein L7a pseudogene 19","metadata":null},{"id":"da59e767f35840b89592bb8d9f4933f5","type":"GENE","name":"RPL7AP2","canonical_id":"hgnc:HGNC:23552","description":"ribosomal protein L7a pseudogene 2","metadata":null},{"id":"eeba5b5960e24bf89360bf23f98026ed","type":"GENE","name":"RPL7AP20","canonical_id":"hgnc:HGNC:36358","description":"ribosomal protein L7a pseudogene 20","metadata":null},{"id":"c3d2d440598d4518b7cb607ed861ceb5","type":"GENE","name":"RPL7AP21","canonical_id":"hgnc:HGNC:37020","description":"ribosomal protein L7a pseudogene 21","metadata":null},{"id":"11b1238d05ac46128f25080399be659c","type":"GENE","name":"RPL7AP22","canonical_id":"hgnc:HGNC:36592","description":"ribosomal protein L7a pseudogene 22","metadata":null},{"id":"6736185833b84b53af7d8ad7950317e2","type":"GENE","name":"RPL7AP23","canonical_id":"hgnc:HGNC:36884","description":"ribosomal protein L7a pseudogene 23","metadata":null},{"id":"1e9381d9b9aa4064a6b327787219f4da","type":"GENE","name":"RPL7AP24","canonical_id":"hgnc:HGNC:36588","description":"ribosomal protein L7a pseudogene 24","metadata":null},{"id":"91ea0b0d26414d92a5c7c411a75b257d","type":"GENE","name":"RPL7AP25","canonical_id":"hgnc:HGNC:36714","description":"ribosomal protein L7a pseudogene 25","metadata":null},{"id":"f6c94f03474549aeb1b0f04a2ba4cbe6","type":"GENE","name":"RPL7AP26","canonical_id":"hgnc:HGNC:36815","description":"ribosomal protein L7a pseudogene 26","metadata":null},{"id":"47f0ec0336634df4aa6eb7e27c210b16","type":"GENE","name":"RPL7AP27","canonical_id":"hgnc:HGNC:36806","description":"ribosomal protein L7a pseudogene 27","metadata":null},{"id":"5faa706b0c03476db5c90f8b3aae1836","type":"GENE","name":"RPL7AP28","canonical_id":"hgnc:HGNC:35656","description":"ribosomal protein L7a pseudogene 28","metadata":null},{"id":"97d38e02a3304238a35e6bc598648610","type":"GENE","name":"RPL7AP29","canonical_id":"hgnc:HGNC:36394","description":"ribosomal protein L7a pseudogene 29","metadata":null},{"id":"7e67e77a498147019682fec9d5069b43","type":"GENE","name":"RPL7AP3","canonical_id":"hgnc:HGNC:23553","description":"ribosomal protein L7a pseudogene 3","metadata":null},{"id":"0fe37a567600460d866916f4aeec0053","type":"GENE","name":"RPL7AP30","canonical_id":"hgnc:HGNC:35757","description":"ribosomal protein L7a pseudogene 30","metadata":null},{"id":"c0aac805a5504b4eaa3c05c799b980b9","type":"GENE","name":"RPL7AP31","canonical_id":"hgnc:HGNC:36857","description":"ribosomal protein L7a pseudogene 31","metadata":null},{"id":"395fe653998d4d7496bf6870757c7369","type":"GENE","name":"RPL7AP32","canonical_id":"hgnc:HGNC:36415","description":"ribosomal protein L7a pseudogene 32","metadata":null},{"id":"ee4790512b0940d180cdba3a1f6b0d25","type":"GENE","name":"RPL7AP33","canonical_id":"hgnc:HGNC:36679","description":"ribosomal protein L7a pseudogene 33","metadata":null},{"id":"992fff3f53b84c71934c8ff46b213f5b","type":"GENE","name":"RPL7AP34","canonical_id":"hgnc:HGNC:36778","description":"ribosomal protein L7a pseudogene 34","metadata":null},{"id":"177be95edded4b2f9e7839d3126c3453","type":"GENE","name":"RPL7AP35","canonical_id":"hgnc:HGNC:36113","description":"ribosomal protein L7a pseudogene 35","metadata":null},{"id":"34fc61b096f34f7a8aa866e1a00fe622","type":"GENE","name":"RPL7AP36","canonical_id":"hgnc:HGNC:36356","description":"ribosomal protein L7a pseudogene 36","metadata":null},{"id":"34525add3fbd494c9b809bcfe1fa2165","type":"GENE","name":"RPL7AP37","canonical_id":"hgnc:HGNC:36507","description":"ribosomal protein L7a pseudogene 37","metadata":null},{"id":"d0cedc07ffe34436b9870bbdce3f03b1","type":"GENE","name":"RPL7AP38","canonical_id":"hgnc:HGNC:36161","description":"ribosomal protein L7a pseudogene 38","metadata":null},{"id":"23ffd72e672e4b6793f5682f9b504e13","type":"GENE","name":"RPL7AP39","canonical_id":"hgnc:HGNC:35881","description":"ribosomal protein L7a pseudogene 39","metadata":null},{"id":"cad626bba821431ea3f404e284929ca0","type":"GENE","name":"RPL7AP4","canonical_id":"hgnc:HGNC:23554","description":"ribosomal protein L7a pseudogene 4","metadata":null},{"id":"0a14dd1a80954f3ba50b8792fce6ed2e","type":"GENE","name":"RPL7AP40","canonical_id":"hgnc:HGNC:35883","description":"ribosomal protein L7a pseudogene 40","metadata":null},{"id":"bcd3e8fda5ba4cca833abc183b7faf46","type":"GENE","name":"RPL7AP41","canonical_id":"hgnc:HGNC:36403","description":"ribosomal protein L7a pseudogene 41","metadata":null},{"id":"3c3a29cd026a43e0ab4592474af583fe","type":"GENE","name":"RPL7AP42","canonical_id":"hgnc:HGNC:36716","description":"ribosomal protein L7a pseudogene 42","metadata":null},{"id":"c534ab1db10347a6868a513120bd9d78","type":"GENE","name":"RPL7AP43","canonical_id":"hgnc:HGNC:35775","description":"ribosomal protein L7a pseudogene 43","metadata":null},{"id":"454aad2fb67f48cf80690720cae794e0","type":"GENE","name":"RPL7AP44","canonical_id":"hgnc:HGNC:36645","description":"ribosomal protein L7a pseudogene 44","metadata":null},{"id":"58529fccaac5440297c01462c7d8de25","type":"GENE","name":"RPL7AP45","canonical_id":"hgnc:HGNC:35935","description":"ribosomal protein L7a pseudogene 45","metadata":null},{"id":"aa77dc5a5f4b43918124364cd56037b0","type":"GENE","name":"RPL7AP46","canonical_id":"hgnc:HGNC:35698","description":"ribosomal protein L7a pseudogene 46","metadata":null},{"id":"660cc8cc2ee640fbbbbff91dd1e7bbe3","type":"GENE","name":"RPL7AP47","canonical_id":"hgnc:HGNC:36833","description":"ribosomal protein L7a pseudogene 47","metadata":null},{"id":"b2d7b4553d8a4a088d79dc45e51b6710","type":"GENE","name":"RPL7AP48","canonical_id":"hgnc:HGNC:35953","description":"ribosomal protein L7a pseudogene 48","metadata":null},{"id":"e1134dc7cbb24a549758cc43bb3e8ddd","type":"GENE","name":"RPL7AP49","canonical_id":"hgnc:HGNC:35507","description":"ribosomal protein L7a pseudogene 49","metadata":null},{"id":"3c5193cf1d4441f99fef6f0b7afaf81c","type":"GENE","name":"RPL7AP5","canonical_id":"hgnc:HGNC:19781","description":"ribosomal protein L7a pseudogene 5","metadata":null},{"id":"3ec0f7a2abcc426aa84ec63e100f1987","type":"GENE","name":"RPL7AP50","canonical_id":"hgnc:HGNC:36117","description":"ribosomal protein L7a pseudogene 50","metadata":null},{"id":"1990329051464748bf26d9c904608637","type":"GENE","name":"RPL7AP51","canonical_id":"hgnc:HGNC:36826","description":"ribosomal protein L7a pseudogene 51","metadata":null},{"id":"51ab3bfc53434b73a545ac8cd1b7bb54","type":"GENE","name":"RPL7AP52","canonical_id":"hgnc:HGNC:36233","description":"ribosomal protein L7a pseudogene 52","metadata":null},{"id":"437bb9a91e904ccdbeeea3ea2243ba35","type":"GENE","name":"RPL7AP53","canonical_id":"hgnc:HGNC:36392","description":"ribosomal protein L7a pseudogene 53","metadata":null},{"id":"8eeb441b9ec24a48822eaaaf159d80f9","type":"GENE","name":"RPL7AP54","canonical_id":"hgnc:HGNC:36264","description":"ribosomal protein L7a pseudogene 54","metadata":null},{"id":"18a68a0315b646fda5c84acafb1bf056","type":"GENE","name":"RPL7AP55","canonical_id":"hgnc:HGNC:36314","description":"ribosomal protein L7a pseudogene 55","metadata":null},{"id":"2f951c0e760646688c09ec3102412ad7","type":"GENE","name":"RPL7AP56","canonical_id":"hgnc:HGNC:35585","description":"ribosomal protein L7a pseudogene 56","metadata":null},{"id":"0a2a0a9a4ac64869a94b10f205f8e02a","type":"GENE","name":"RPL7AP57","canonical_id":"hgnc:HGNC:36551","description":"ribosomal protein L7a pseudogene 57","metadata":null},{"id":"1a8a570ed4fe454991795a3e6156adf0","type":"GENE","name":"RPL7AP58","canonical_id":"hgnc:HGNC:36586","description":"ribosomal protein L7a pseudogene 58","metadata":null},{"id":"1f3d2a7419274d3c86fbd7367716f971","type":"GENE","name":"RPL7AP6","canonical_id":"hgnc:HGNC:19785","description":"ribosomal protein L7a pseudogene 6","metadata":null},{"id":"6e9f82bc570b4d8c8ff0133b366d5520","type":"GENE","name":"RPL7AP60","canonical_id":"hgnc:HGNC:35859","description":"ribosomal protein L7a pseudogene 60","metadata":null},{"id":"e5b2bd5970b0466594ebb8bd1ebf2413","type":"GENE","name":"RPL7AP61","canonical_id":"hgnc:HGNC:35482","description":"ribosomal protein L7a pseudogene 61","metadata":null},{"id":"46bfaf0358754502add23bfdbbb52ba9","type":"GENE","name":"RPL7AP62","canonical_id":"hgnc:HGNC:36890","description":"ribosomal protein L7a pseudogene 62","metadata":null},{"id":"c47504df8d014aaf9b9e8869f661482b","type":"GENE","name":"RPL7AP63","canonical_id":"hgnc:HGNC:35504","description":"ribosomal protein L7a pseudogene 63","metadata":null},{"id":"e9ceb55d72334533ab42c7c9b98df36e","type":"GENE","name":"RPL7AP64","canonical_id":"hgnc:HGNC:35821","description":"ribosomal protein L7a pseudogene 64","metadata":null},{"id":"b4c54a31e9a04c3d9d52513b29b589fe","type":"GENE","name":"RPL7AP65","canonical_id":"hgnc:HGNC:37031","description":"ribosomal protein L7a pseudogene 65","metadata":null},{"id":"4c213d8978394e868480479dfc746241","type":"GENE","name":"RPL7AP66","canonical_id":"hgnc:HGNC:35682","description":"ribosomal protein L7a pseudogene 66","metadata":null},{"id":"2eb488aaa61a4a9b9051a9c01f7751b2","type":"GENE","name":"RPL7AP67","canonical_id":"hgnc:HGNC:35537","description":"ribosomal protein L7a pseudogene 67","metadata":null},{"id":"b85a1284c4d2404aaba041c573a27dc4","type":"GENE","name":"RPL7AP69","canonical_id":"hgnc:HGNC:36697","description":"ribosomal protein L7a pseudogene 69","metadata":null},{"id":"c513f9d26fb24cab815137a05554ca17","type":"GENE","name":"RPL7AP7","canonical_id":"hgnc:HGNC:21395","description":"ribosomal protein L7a pseudogene 7","metadata":{"aliases":["RPL7B","dJ377H14.2"]}},{"id":"b355c95f04234cb1810dbee4c3e89566","type":"GENE","name":"RPL7AP70","canonical_id":"hgnc:HGNC:36752","description":"ribosomal protein L7a pseudogene 70","metadata":null},{"id":"1e65a34f06f34b40bb62f8083dc53c54","type":"GENE","name":"RPL7AP71","canonical_id":"hgnc:HGNC:35754","description":"ribosomal protein L7a pseudogene 71","metadata":null},{"id":"9567b72bd56745e99559f1665d21bb06","type":"GENE","name":"RPL7AP72","canonical_id":"hgnc:HGNC:36442","description":"ribosomal protein L7a pseudogene 72","metadata":null},{"id":"afc7081a95a04f64afb4738cbe71bc9f","type":"GENE","name":"RPL7AP73","canonical_id":"hgnc:HGNC:41968","description":"ribosomal protein L7a pseudogene 73","metadata":null},{"id":"c659564d6ab7496287a64fc90341618d","type":"GENE","name":"RPL7AP74","canonical_id":"hgnc:HGNC:55897","description":"ribosomal protein L7a pseudogene 74","metadata":null},{"id":"a98ca5aeaaba43c8a737178350feb6f0","type":"GENE","name":"RPL7AP75","canonical_id":"hgnc:HGNC:55898","description":"ribosomal protein L7a pseudogene 75","metadata":null},{"id":"d4c11fccea6e4fa785229314d8c93515","type":"GENE","name":"RPL7AP76","canonical_id":"hgnc:HGNC:55899","description":"ribosomal protein L7a pseudogene 76","metadata":null},{"id":"483dd1452f164b2988ed59c157fadcb8","type":"GENE","name":"RPL7AP77","canonical_id":"hgnc:HGNC:55900","description":"ribosomal protein L7a pseudogene 77","metadata":null},{"id":"1ecf3de669af4958956aca4b084a1731","type":"GENE","name":"RPL7AP78","canonical_id":"hgnc:HGNC:55901","description":"ribosomal protein L7a pseudogene 78","metadata":null},{"id":"9e7d23b2e486498cabd167b54d39515f","type":"GENE","name":"RPL7AP79","canonical_id":"hgnc:HGNC:55902","description":"ribosomal protein L7a pseudogene 79","metadata":null},{"id":"b44ee0961253452281824ce3e6768f2d","type":"GENE","name":"RPL7AP8","canonical_id":"hgnc:HGNC:23738","description":"ribosomal protein L7a pseudogene 8","metadata":{"aliases":["bA141D8.1"]}},{"id":"baf91391d3054ce69a72b10df9c9259e","type":"GENE","name":"RPL7AP80","canonical_id":"hgnc:HGNC:55903","description":"ribosomal protein L7a pseudogene 80","metadata":null},{"id":"9bdfb07257594fb7930712bab9bab014","type":"GENE","name":"RPL7AP81","canonical_id":"hgnc:HGNC:55904","description":"ribosomal protein L7a pseudogene 81","metadata":null},{"id":"53a430c544b44b9a88f62bae1e871b70","type":"GENE","name":"RPL7AP82","canonical_id":"hgnc:HGNC:55905","description":"ribosomal protein L7a pseudogene 82","metadata":null},{"id":"eca1ac405bd043c1919072ec5922b785","type":"GENE","name":"RPL7AP83","canonical_id":"hgnc:HGNC:56412","description":"ribosomal protein L7a pseudogene 83","metadata":null},{"id":"1bdddf0ded684d09a7a8cf5c1f592d0c","type":"GENE","name":"RPL7AP9","canonical_id":"hgnc:HGNC:32398","description":"ribosomal protein L7a pseudogene 9","metadata":{"aliases":["RPL7AP59"]}},{"id":"9a75e09350e4479c99861fcc6c118bd4","type":"GENE","name":"RPL7L1","canonical_id":"hgnc:HGNC:21370","description":"ribosomal protein L7 like 1","metadata":{"aliases":["dJ475N16.4"]}},{"id":"e2acb3b15ecb47d58fc94e1105576d7a","type":"GENE","name":"RPL7L1P1","canonical_id":"hgnc:HGNC:39455","description":"RPL7L1 pseudogene 1","metadata":null},{"id":"9b537c68f5b9411a82f7cdc3fc8d50c7","type":"GENE","name":"RPL7L1P10","canonical_id":"hgnc:HGNC:39492","description":"RPL7L1 pseudogene 10","metadata":null},{"id":"9b430ed3c03c4a2395061b5bca6256bd","type":"GENE","name":"RPL7L1P11","canonical_id":"hgnc:HGNC:39493","description":"RPL7L1 pseudogene 11","metadata":null},{"id":"809e0d8bae3f40dab3ae5e7fc88c41b2","type":"GENE","name":"RPL7L1P12","canonical_id":"hgnc:HGNC:39811","description":"RPL7L1 pseudogene 12","metadata":null},{"id":"a0607edc56744c48bc29bfffa5c8e8b4","type":"GENE","name":"RPL7L1P13","canonical_id":"hgnc:HGNC:44212","description":"RPL7L1 pseudogene 13","metadata":null},{"id":"c405cc7bb19841de9dc8b89dfc276d62","type":"GENE","name":"RPL7L1P14","canonical_id":"hgnc:HGNC:56796","description":"RPL7L1 pseudogene 14","metadata":null},{"id":"bcb682e4d8f54ac2af93dc65b4ac4c23","type":"GENE","name":"RPL7L1P15","canonical_id":"hgnc:HGNC:56797","description":"RPL7L1 pseudogene 15","metadata":null},{"id":"68a9626ae8d94ca58e8f53fa97da7045","type":"GENE","name":"RPL7L1P16","canonical_id":"hgnc:HGNC:56798","description":"RPL7L1 pseudogene 16","metadata":null},{"id":"e1bb262ef02349b98fc4d43f57029dba","type":"GENE","name":"RPL7L1P17","canonical_id":"hgnc:HGNC:56799","description":"RPL7L1 pseudogene 17","metadata":null},{"id":"358afc586ae0478588cc1a1a18e4a418","type":"GENE","name":"RPL7L1P18","canonical_id":"hgnc:HGNC:56800","description":"RPL7L1 pseudogene 18","metadata":null},{"id":"d5d3151814f84f4fa153c4db8a6dd508","type":"GENE","name":"RPL7L1P19","canonical_id":"hgnc:HGNC:56801","description":"RPL7L1 pseudogene 19","metadata":null},{"id":"1148e1187b59420d8b4a8c145dccb216","type":"GENE","name":"RPL7L1P2","canonical_id":"hgnc:HGNC:39484","description":"RPL7L1 pseudogene 2","metadata":null},{"id":"c56bb94e65144ebcb562533c8670458e","type":"GENE","name":"RPL7L1P20","canonical_id":"hgnc:HGNC:56802","description":"RPL7L1 pseudogene 20","metadata":null},{"id":"c999d87e9e0e4fcf9d8970dbdd5f1b18","type":"GENE","name":"RPL7L1P21","canonical_id":"hgnc:HGNC:56803","description":"RPL7L1 pseudogene 21","metadata":null},{"id":"635356444eec4b1f9961adab2e7f3fca","type":"GENE","name":"RPL7L1P22","canonical_id":"hgnc:HGNC:56804","description":"RPL7L1 pseudogene 22","metadata":null},{"id":"9fd472e4d01548ffae809033356601d2","type":"GENE","name":"RPL7L1P3","canonical_id":"hgnc:HGNC:39485","description":"RPL7L1 pseudogene 3","metadata":null},{"id":"b606b6ba8cb248d6a0b5d87e1ea15c87","type":"GENE","name":"RPL7L1P4","canonical_id":"hgnc:HGNC:39486","description":"RPL7L1 pseudogene 4","metadata":null},{"id":"c4c00ad75752435f8dedd0f48da751ad","type":"GENE","name":"RPL7L1P5","canonical_id":"hgnc:HGNC:39487","description":"RPL7L1 pseudogene 5","metadata":null},{"id":"f4d596c7aa2f4878aa5e81e4a25333ca","type":"GENE","name":"RPL7L1P6","canonical_id":"hgnc:HGNC:39488","description":"RPL7L1 pseudogene 6","metadata":null},{"id":"7eec1578762c4404b0d2df6bf055a7aa","type":"GENE","name":"RPL7L1P7","canonical_id":"hgnc:HGNC:39489","description":"RPL7L1 pseudogene 7","metadata":null},{"id":"67d7d9ef079c46b0bfdb5071866a7fbe","type":"GENE","name":"RPL7L1P8","canonical_id":"hgnc:HGNC:39490","description":"RPL7L1 pseudogene 8","metadata":null},{"id":"d8ea3361949f4cafab2af8def88362da","type":"GENE","name":"RPL7L1P9","canonical_id":"hgnc:HGNC:39491","description":"RPL7L1 pseudogene 9","metadata":null},{"id":"4b08057e7f934ff0aed5a6eacc9fb554","type":"GENE","name":"RPL7P1","canonical_id":"hgnc:HGNC:10367","description":"ribosomal protein L7 pseudogene 1","metadata":{"aliases":["RPL17P","RPL7P"]}},{"id":"3c68b8986ed04b3fb6b5dd328c007ebe","type":"GENE","name":"RPL7P10","canonical_id":"hgnc:HGNC:36599","description":"ribosomal protein L7 pseudogene 10","metadata":null},{"id":"b14d9409a00f40929142c3cc59e8f0f4","type":"GENE","name":"RPL7P11","canonical_id":"hgnc:HGNC:35667","description":"ribosomal protein L7 pseudogene 11","metadata":null},{"id":"f8fb43a4621f47eaa54c93ac1dc08a4f","type":"GENE","name":"RPL7P12","canonical_id":"hgnc:HGNC:36611","description":"ribosomal protein L7 pseudogene 12","metadata":null},{"id":"5ad525e243b9465583e18d712513a046","type":"GENE","name":"RPL7P13","canonical_id":"hgnc:HGNC:36861","description":"ribosomal protein L7 pseudogene 13","metadata":null},{"id":"1a59d995f76848be93c2bda46d9e957b","type":"GENE","name":"RPL7P14","canonical_id":"hgnc:HGNC:35984","description":"ribosomal protein L7 pseudogene 14","metadata":null},{"id":"467ae450d62447eab73416a545b9d505","type":"GENE","name":"RPL7P15","canonical_id":"hgnc:HGNC:36740","description":"ribosomal protein L7 pseudogene 15","metadata":null},{"id":"3c2b4b581f254ef6864cb2b5d808cfdb","type":"GENE","name":"RPL7P16","canonical_id":"hgnc:HGNC:36591","description":"ribosomal protein L7 pseudogene 16","metadata":null},{"id":"83f471cad9364663927e258e6828f080","type":"GENE","name":"RPL7P17","canonical_id":"hgnc:HGNC:36116","description":"ribosomal protein L7 pseudogene 17","metadata":null},{"id":"acc9a4b9ec2d48a3b3e330e1dff118e0","type":"GENE","name":"RPL7P18","canonical_id":"hgnc:HGNC:36949","description":"ribosomal protein L7 pseudogene 18","metadata":null},{"id":"ff7cf05b19f54b92967c938025cee25c","type":"GENE","name":"RPL7P19","canonical_id":"hgnc:HGNC:36268","description":"ribosomal protein L7 pseudogene 19","metadata":null},{"id":"669cd5636eca48e884b9fd8a586d2eea","type":"GENE","name":"RPL7P2","canonical_id":"hgnc:HGNC:16336","description":"ribosomal protein L7 pseudogene 2","metadata":{"aliases":["bA550O8.1"]}},{"id":"04de821dd5f84e268da06b7e32bdfb8c","type":"GENE","name":"RPL7P20","canonical_id":"hgnc:HGNC:36013","description":"ribosomal protein L7 pseudogene 20","metadata":null},{"id":"d515f4efa62449b2b3a64f387266060d","type":"GENE","name":"RPL7P21","canonical_id":"hgnc:HGNC:36762","description":"ribosomal protein L7 pseudogene 21","metadata":null},{"id":"0f0bf7bdd3a44dde87a9a036b0c43fc9","type":"GENE","name":"RPL7P22","canonical_id":"hgnc:HGNC:35802","description":"ribosomal protein L7 pseudogene 22","metadata":null},{"id":"8b8fe399b5eb41869490de06cd23f316","type":"GENE","name":"RPL7P23","canonical_id":"hgnc:HGNC:35658","description":"ribosomal protein L7 pseudogene 23","metadata":null},{"id":"849fa41cb233401f8c795814f277272d","type":"GENE","name":"RPL7P24","canonical_id":"hgnc:HGNC:36715","description":"ribosomal protein L7 pseudogene 24","metadata":null},{"id":"43393fa8e2a14a469d8f7b114fe6678d","type":"GENE","name":"RPL7P25","canonical_id":"hgnc:HGNC:36455","description":"ribosomal protein L7 pseudogene 25","metadata":null},{"id":"9ed4bc5957744f9cab9df4d11b74b9e5","type":"GENE","name":"RPL7P26","canonical_id":"hgnc:HGNC:36630","description":"ribosomal protein L7 pseudogene 26","metadata":null},{"id":"f96a58b05f484b1da6d9c196881a2f37","type":"GENE","name":"RPL7P27","canonical_id":"hgnc:HGNC:36649","description":"ribosomal protein L7 pseudogene 27","metadata":null},{"id":"368fb9c44d4b4b819ffb66116ddb0edb","type":"GENE","name":"RPL7P28","canonical_id":"hgnc:HGNC:35899","description":"ribosomal protein L7 pseudogene 28","metadata":null},{"id":"a774c082189e4fa89fb6e85d0085f27c","type":"GENE","name":"RPL7P29","canonical_id":"hgnc:HGNC:35700","description":"ribosomal protein L7 pseudogene 29","metadata":null},{"id":"53a90a3614ad469fa975a5d91b62c457","type":"GENE","name":"RPL7P3","canonical_id":"hgnc:HGNC:16566","description":"ribosomal protein L7 pseudogene 3","metadata":{"aliases":["dJ353C17.2"]}},{"id":"7bce8a604ceb471a82cafef6f618641c","type":"GENE","name":"RPL7P30","canonical_id":"hgnc:HGNC:36151","description":"ribosomal protein L7 pseudogene 30","metadata":null},{"id":"cab362534a2e4d7ea3294533b4249c3f","type":"GENE","name":"RPL7P31","canonical_id":"hgnc:HGNC:36988","description":"ribosomal protein L7 pseudogene 31","metadata":null},{"id":"de1dbf7f93aa4a69a19ff34d159d05e5","type":"GENE","name":"RPL7P32","canonical_id":"hgnc:HGNC:35692","description":"ribosomal protein L7 pseudogene 32","metadata":null},{"id":"8a34922dfaf34b878617994f78bf365f","type":"GENE","name":"RPL7P33","canonical_id":"hgnc:HGNC:35937","description":"ribosomal protein L7 pseudogene 33","metadata":null},{"id":"e6e0e2ded74d44b7b168fa0eac080f82","type":"GENE","name":"RPL7P34","canonical_id":"hgnc:HGNC:36181","description":"ribosomal protein L7 pseudogene 34","metadata":null},{"id":"eaf39a63e6404146a76407985e8dd184","type":"GENE","name":"RPL7P35","canonical_id":"hgnc:HGNC:36153","description":"ribosomal protein L7 pseudogene 35","metadata":null},{"id":"24f3dab7b9a2444094f1cc1f3dd67539","type":"GENE","name":"RPL7P36","canonical_id":"hgnc:HGNC:37045","description":"ribosomal protein L7 pseudogene 36","metadata":null},{"id":"cc2f75aa7f8d477b95daec64d8532f72","type":"GENE","name":"RPL7P37","canonical_id":"hgnc:HGNC:36656","description":"ribosomal protein L7 pseudogene 37","metadata":null},{"id":"90569631d43b43e2a8ff86b601d2535f","type":"GENE","name":"RPL7P38","canonical_id":"hgnc:HGNC:36731","description":"ribosomal protein L7 pseudogene 38","metadata":null},{"id":"603193a4e32e4d32a81f8da0a2e3b11b","type":"GENE","name":"RPL7P39","canonical_id":"hgnc:HGNC:36214","description":"ribosomal protein L7 pseudogene 39","metadata":null},{"id":"ec585fc9b98e4b11b3d764239bcde0e6","type":"GENE","name":"RPL7P4","canonical_id":"hgnc:HGNC:21634","description":"ribosomal protein L7 pseudogene 4","metadata":{"aliases":["Em:AB023049.2"]}},{"id":"6985ddcab16b4f2e847091523466d0a6","type":"GENE","name":"RPL7P40","canonical_id":"hgnc:HGNC:36031","description":"ribosomal protein L7 pseudogene 40","metadata":null},{"id":"bf0f223df53e4e9fbaba81bf77f57f73","type":"GENE","name":"RPL7P41","canonical_id":"hgnc:HGNC:36297","description":"ribosomal protein L7 pseudogene 41","metadata":null},{"id":"612959f13fb34923bd14c255f58041c7","type":"GENE","name":"RPL7P42","canonical_id":"hgnc:HGNC:35543","description":"ribosomal protein L7 pseudogene 42","metadata":null},{"id":"cd7d3880f93847f7902525cd6216d898","type":"GENE","name":"RPL7P43","canonical_id":"hgnc:HGNC:36441","description":"ribosomal protein L7 pseudogene 43","metadata":null},{"id":"f8b6ad999d674abbaba9c343bf9a4139","type":"GENE","name":"RPL7P44","canonical_id":"hgnc:HGNC:36143","description":"ribosomal protein L7 pseudogene 44","metadata":null},{"id":"e08cf29f14a24003a0ac22c86c774ac1","type":"GENE","name":"RPL7P45","canonical_id":"hgnc:HGNC:35522","description":"ribosomal protein L7 pseudogene 45","metadata":null},{"id":"150e6d710cc44dbc8cc152af001e5e91","type":"GENE","name":"RPL7P46","canonical_id":"hgnc:HGNC:36706","description":"ribosomal protein L7 pseudogene 46","metadata":null},{"id":"00bfb40559154e8e9bd44a862459156a","type":"GENE","name":"RPL7P47","canonical_id":"hgnc:HGNC:35913","description":"ribosomal protein L7 pseudogene 47","metadata":null},{"id":"115854f949c549f1bac38d1d1d463d58","type":"GENE","name":"RPL7P48","canonical_id":"hgnc:HGNC:35540","description":"ribosomal protein L7 pseudogene 48","metadata":null},{"id":"8156c39fd6bf47939cdf72242c2831a7","type":"GENE","name":"RPL7P49","canonical_id":"hgnc:HGNC:36912","description":"ribosomal protein L7 pseudogene 49","metadata":null},{"id":"a92d29c965a84e8aade6d7be6e0c07bf","type":"GENE","name":"RPL7P5","canonical_id":"hgnc:HGNC:28886","description":"ribosomal protein L7 pseudogene 5","metadata":null},{"id":"cb431bc6828347a0a0fd7ca96ff84919","type":"GENE","name":"RPL7P50","canonical_id":"hgnc:HGNC:35816","description":"ribosomal protein L7 pseudogene 50","metadata":null},{"id":"0cbefe9f1b7648af998ea522f1adbb52","type":"GENE","name":"RPL7P51","canonical_id":"hgnc:HGNC:36432","description":"ribosomal protein L7 pseudogene 51","metadata":null},{"id":"c1dd573f28e8431891c3e1e5dbfe69dc","type":"GENE","name":"RPL7P52","canonical_id":"hgnc:HGNC:35676","description":"ribosomal protein L7 pseudogene 52","metadata":null},{"id":"881eb487f5324614aede63eb6e876898","type":"GENE","name":"RPL7P53","canonical_id":"hgnc:HGNC:36831","description":"ribosomal protein L7 pseudogene 53","metadata":null},{"id":"b502b426402f40c19421d87c9afd4406","type":"GENE","name":"RPL7P54","canonical_id":"hgnc:HGNC:36817","description":"ribosomal protein L7 pseudogene 54","metadata":null},{"id":"89a8370aca0547c58a6ce3873ae16f1b","type":"GENE","name":"RPL7P55","canonical_id":"hgnc:HGNC:36105","description":"ribosomal protein L7 pseudogene 55","metadata":null},{"id":"975ca8071c794cdd9961883a3bf557ed","type":"GENE","name":"RPL7P56","canonical_id":"hgnc:HGNC:35588","description":"ribosomal protein L7 pseudogene 56","metadata":null},{"id":"d1d2fdebb2c9423082f8b634341e686d","type":"GENE","name":"RPL7P57","canonical_id":"hgnc:HGNC:35901","description":"ribosomal protein L7 pseudogene 57","metadata":null},{"id":"a96ed31ec5f64176a88c8c2ecd248e17","type":"GENE","name":"RPL7P58","canonical_id":"hgnc:HGNC:49214","description":"ribosomal protein L7 pseudogene 58","metadata":null},{"id":"83cda0ed2efa4b53875311ea32838530","type":"GENE","name":"RPL7P59","canonical_id":"hgnc:HGNC:49215","description":"ribosomal protein L7 pseudogene 59","metadata":null},{"id":"89714e58870d417b8761c9b202da26d8","type":"GENE","name":"RPL7P6","canonical_id":"hgnc:HGNC:32430","description":"ribosomal protein L7 pseudogene 6","metadata":null},{"id":"4c80308e90f94b19becc94e9f4d249a1","type":"GENE","name":"RPL7P60","canonical_id":"hgnc:HGNC:49216","description":"ribosomal protein L7 pseudogene 60","metadata":null},{"id":"5e526f2577e6414c9f36b1ccff85b909","type":"GENE","name":"RPL7P61","canonical_id":"hgnc:HGNC:49217","description":"ribosomal protein L7 pseudogene 61","metadata":null},{"id":"a6854e1d94994792a6a847d7b24cf9ca","type":"GENE","name":"RPL7P7","canonical_id":"hgnc:HGNC:36895","description":"ribosomal protein L7 pseudogene 7","metadata":null},{"id":"854d5015c10a4de2a400f23e9efe84cc","type":"GENE","name":"RPL7P8","canonical_id":"hgnc:HGNC:35914","description":"ribosomal protein L7 pseudogene 8","metadata":null},{"id":"24bd2a8b2ecf45a78166e2dd8fc7da74","type":"GENE","name":"RPL7P9","canonical_id":"hgnc:HGNC:37028","description":"ribosomal protein L7 pseudogene 9","metadata":null},{"id":"c4f000c658514c9d83c89b722840d89b","type":"GENE","name":"RPL8","canonical_id":"hgnc:HGNC:10368","description":"ribosomal protein L8","metadata":{"aliases":["L8","uL2"]}},{"id":"44690fba1ff442b2bdbbb0419fc8a1b8","type":"GENE","name":"RPL8P1","canonical_id":"hgnc:HGNC:13980","description":"ribosomal protein L8 pseudogene 1","metadata":{"aliases":["RPL2p","dJ15D7.1","RPL8P"]}},{"id":"359c063f16214b3ab5a2df4c91f9afc7","type":"GENE","name":"RPL8P2","canonical_id":"hgnc:HGNC:17220","description":"ribosomal protein L8 pseudogene 2","metadata":null},{"id":"c4104d3ab3754ab99c44b69337ebe625","type":"GENE","name":"RPL8P3","canonical_id":"hgnc:HGNC:36407","description":"ribosomal protein L8 pseudogene 3","metadata":null},{"id":"d797e08d55554ea9b7380d58af9835fe","type":"GENE","name":"RPL8P4","canonical_id":"hgnc:HGNC:35555","description":"ribosomal protein L8 pseudogene 4","metadata":null},{"id":"642da81198ea4aa48a60f9cbec5eb1f7","type":"GENE","name":"RPL8P5","canonical_id":"hgnc:HGNC:35758","description":"ribosomal protein L8 pseudogene 5","metadata":null},{"id":"2142438533b5408aba39df0206d54538","type":"GENE","name":"RPL9","canonical_id":"hgnc:HGNC:10369","description":"ribosomal protein L9","metadata":{"aliases":["L9","uL6"]}},{"id":"b4c901b72946467bae32852763c2013b","type":"GENE","name":"RPL9P10","canonical_id":"hgnc:HGNC:35686","description":"ribosomal protein L9 pseudogene 10","metadata":null},{"id":"52afadc897294df891098a2247070a70","type":"GENE","name":"RPL9P11","canonical_id":"hgnc:HGNC:35621","description":"ribosomal protein L9 pseudogene 11","metadata":null},{"id":"88e484ba17cb4b89a9949ce04c3d259c","type":"GENE","name":"RPL9P12","canonical_id":"hgnc:HGNC:36728","description":"ribosomal protein L9 pseudogene 12","metadata":null},{"id":"ad94366ad3ac4c18bdf8717560745164","type":"GENE","name":"RPL9P13","canonical_id":"hgnc:HGNC:36558","description":"ribosomal protein L9 pseudogene 13","metadata":null},{"id":"6279808438854838a4ecad9e277bc15b","type":"GENE","name":"RPL9P14","canonical_id":"hgnc:HGNC:36816","description":"ribosomal protein L9 pseudogene 14","metadata":null},{"id":"5df6ceec76434d1bae8ccaea12b9b502","type":"GENE","name":"RPL9P15","canonical_id":"hgnc:HGNC:35539","description":"ribosomal protein L9 pseudogene 15","metadata":null},{"id":"de125851001c47e58053873d7001ca75","type":"GENE","name":"RPL9P16","canonical_id":"hgnc:HGNC:36851","description":"ribosomal protein L9 pseudogene 16","metadata":null},{"id":"b5af042e200f41d3bc7b6af3c9c72659","type":"GENE","name":"RPL9P17","canonical_id":"hgnc:HGNC:36337","description":"ribosomal protein L9 pseudogene 17","metadata":null},{"id":"8b10675153e04492b36d75956ed7e9a8","type":"GENE","name":"RPL9P18","canonical_id":"hgnc:HGNC:36954","description":"ribosomal protein L9 pseudogene 18","metadata":null},{"id":"c44a8bdc3879439d9f47f249a4baef87","type":"GENE","name":"RPL9P19","canonical_id":"hgnc:HGNC:36688","description":"ribosomal protein L9 pseudogene 19","metadata":null},{"id":"3d43d74ad7cc4666847418b9d66c0850","type":"GENE","name":"RPL9P2","canonical_id":"hgnc:HGNC:17049","description":"ribosomal protein L9 pseudogene 2","metadata":null},{"id":"28e1b1e249804c41820442b0a0d1fce0","type":"GENE","name":"RPL9P20","canonical_id":"hgnc:HGNC:36996","description":"ribosomal protein L9 pseudogene 20","metadata":null},{"id":"65ce94a16c6944bc9fe64c670dd657a4","type":"GENE","name":"RPL9P21","canonical_id":"hgnc:HGNC:35886","description":"ribosomal protein L9 pseudogene 21","metadata":null},{"id":"cda1e0daa0c841f6adaa14ede9f2fa08","type":"GENE","name":"RPL9P22","canonical_id":"hgnc:HGNC:36994","description":"ribosomal protein L9 pseudogene 22","metadata":null},{"id":"849fc612081d42528e81fede8f5b9800","type":"GENE","name":"RPL9P23","canonical_id":"hgnc:HGNC:36807","description":"ribosomal protein L9 pseudogene 23","metadata":null},{"id":"de852dcc5c84420da0c1b07e61b1b5aa","type":"GENE","name":"RPL9P24","canonical_id":"hgnc:HGNC:36347","description":"ribosomal protein L9 pseudogene 24","metadata":null},{"id":"e59127bef9fb461da6b5db2d4d74458b","type":"GENE","name":"RPL9P25","canonical_id":"hgnc:HGNC:36112","description":"ribosomal protein L9 pseudogene 25","metadata":null},{"id":"7e3a9c79e1a242b7be6ad96f2933adc1","type":"GENE","name":"RPL9P26","canonical_id":"hgnc:HGNC:35633","description":"ribosomal protein L9 pseudogene 26","metadata":null},{"id":"49012d0417b54f939fa7099d569a4a61","type":"GENE","name":"RPL9P27","canonical_id":"hgnc:HGNC:37012","description":"ribosomal protein L9 pseudogene 27","metadata":null},{"id":"d62ce8bbbc594ff18e99ac34c74eb606","type":"GENE","name":"RPL9P28","canonical_id":"hgnc:HGNC:36445","description":"ribosomal protein L9 pseudogene 28","metadata":null},{"id":"3c6552cbfe5f467fb468b96068b4cc37","type":"GENE","name":"RPL9P29","canonical_id":"hgnc:HGNC:35533","description":"ribosomal protein L9 pseudogene 29","metadata":null},{"id":"a4a0ac1827e54376a3693d3cc5a3a14f","type":"GENE","name":"RPL9P3","canonical_id":"hgnc:HGNC:23555","description":"ribosomal protein L9 pseudogene 3","metadata":null},{"id":"c01ca974809f4bd8b848a0ca86052cd6","type":"GENE","name":"RPL9P30","canonical_id":"hgnc:HGNC:36316","description":"ribosomal protein L9 pseudogene 30","metadata":null},{"id":"45eabd5678114b19bc5e59d1e18c6941","type":"GENE","name":"RPL9P31","canonical_id":"hgnc:HGNC:36617","description":"ribosomal protein L9 pseudogene 31","metadata":null},{"id":"34a6242a8a994dd5a5165fc95ba2b55b","type":"GENE","name":"RPL9P32","canonical_id":"hgnc:HGNC:36418","description":"ribosomal protein L9 pseudogene 32","metadata":null},{"id":"193d6780e62b4293a9e96b31e69ecfd9","type":"GENE","name":"RPL9P33","canonical_id":"hgnc:HGNC:36273","description":"ribosomal protein L9 pseudogene 33","metadata":null},{"id":"8c72f143b5e144fb86635d471e37bd2f","type":"GENE","name":"RPL9P4","canonical_id":"hgnc:HGNC:23556","description":"ribosomal protein L9 pseudogene 4","metadata":null},{"id":"9661d4be64eb45caaf2905cac7df24c0","type":"GENE","name":"RPL9P5","canonical_id":"hgnc:HGNC:23557","description":"ribosomal protein L9 pseudogene 5","metadata":null},{"id":"b96bbc462ee94afd95cd35125e9deb23","type":"GENE","name":"RPL9P6","canonical_id":"hgnc:HGNC:19798","description":"ribosomal protein L9 pseudogene 6","metadata":null},{"id":"d0b893d950a146d3b9f03428c84475df","type":"GENE","name":"RPL9P7","canonical_id":"hgnc:HGNC:30335","description":"ribosomal protein L9 pseudogene 7","metadata":{"aliases":["RPL9P1","RPL9L1"]}},{"id":"aa7403b7f6774016b6555a5fefad9009","type":"GENE","name":"RPL9P8","canonical_id":"hgnc:HGNC:30334","description":"ribosomal protein L9 pseudogene 8","metadata":{"aliases":["RPL9P9"]}},{"id":"946a44a1ce5b47fe926dfbfc51b6a446","type":"GENE","name":"RPLP0","canonical_id":"hgnc:HGNC:10371","description":null,"metadata":null},{"id":"89cb79b8ebca409789b145ae8a0482eb","type":"GENE","name":"RPLP0P1","canonical_id":"hgnc:HGNC:16585","description":"ribosomal protein lateral stalk subunit P0 pseudogene 1","metadata":{"aliases":["dJ777L9.2"]}},{"id":"279aeeb962da4a6a9f70cc1edfce460f","type":"GENE","name":"RPLP0P10","canonical_id":"hgnc:HGNC:35991","description":"ribosomal protein lateral stalk subunit P0 pseudogene 10","metadata":null},{"id":"7e1ce637bacc4479aa243c5b3a28efce","type":"GENE","name":"RPLP0P11","canonical_id":"hgnc:HGNC:36572","description":"ribosomal protein lateral stalk subunit P0 pseudogene 11","metadata":null},{"id":"e2c0d6e80bb44a8788ee243832c92ac0","type":"GENE","name":"RPLP0P12","canonical_id":"hgnc:HGNC:55907","description":"ribosomal protein lateral stalk subunit P0 pseudogene 12","metadata":null},{"id":"d3a1451af8b947feb91d54ad2063146c","type":"GENE","name":"RPLP0P2","canonical_id":"hgnc:HGNC:17960","description":"ribosomal protein lateral stalk subunit P0 pseudogene 2","metadata":null},{"id":"74449d65b8d84faea54cddc9e1b97bfb","type":"GENE","name":"RPLP0P3","canonical_id":"hgnc:HGNC:23558","description":"ribosomal protein lateral stalk subunit P0 pseudogene 3","metadata":null},{"id":"71dcaabe853442f89907b12c09be334b","type":"GENE","name":"RPLP0P4","canonical_id":"hgnc:HGNC:36489","description":"ribosomal protein lateral stalk subunit P0 pseudogene 4","metadata":null},{"id":"56e3bf73b4554385a0c919b1d5f7c158","type":"GENE","name":"RPLP0P5","canonical_id":"hgnc:HGNC:35620","description":"ribosomal protein lateral stalk subunit P0 pseudogene 5","metadata":null},{"id":"4b8e0ee250d04da1814a6ba79357b8b4","type":"GENE","name":"RPLP0P6","canonical_id":"hgnc:HGNC:36404","description":"ribosomal protein lateral stalk subunit P0 pseudogene 6","metadata":null},{"id":"efecc75121ff482eb96216020f3eb2d9","type":"GENE","name":"RPLP0P7","canonical_id":"hgnc:HGNC:36578","description":"ribosomal protein lateral stalk subunit P0 pseudogene 7","metadata":null},{"id":"3790d75ef07c46499a5154d7b71e812b","type":"GENE","name":"RPLP0P8","canonical_id":"hgnc:HGNC:35867","description":"ribosomal protein lateral stalk subunit P0 pseudogene 8","metadata":null},{"id":"8edf5a1d460f4557a05c3bee134db346","type":"GENE","name":"RPLP0P9","canonical_id":"hgnc:HGNC:55906","description":"ribosomal protein lateral stalk subunit P0 pseudogene 9","metadata":null},{"id":"279502118d9544069af84bb43317501a","type":"GENE","name":"RPLP1","canonical_id":"hgnc:HGNC:10372","description":"ribosomal protein lateral stalk subunit P1","metadata":{"aliases":["LP1","P1"]}},{"id":"682be79dcb2b4f6db4aafe50cc0e0d49","type":"GENE","name":"RPLP1P1","canonical_id":"hgnc:HGNC:19793","description":"ribosomal protein lateral stalk subunit P1 pseudogene 1","metadata":null},{"id":"ac4c7a12cc0c46b2aba2413873b9f622","type":"GENE","name":"RPLP1P10","canonical_id":"hgnc:HGNC:35509","description":"ribosomal protein lateral stalk subunit P1 pseudogene 10","metadata":null},{"id":"2e1acd026d644b77ac137ad7d8a8f2fc","type":"GENE","name":"RPLP1P11","canonical_id":"hgnc:HGNC:36196","description":"ribosomal protein lateral stalk subunit P1 pseudogene 11","metadata":null},{"id":"3ec4bb1234d744d29cdb24c1d2ab1c4b","type":"GENE","name":"RPLP1P12","canonical_id":"hgnc:HGNC:36858","description":"ribosomal protein lateral stalk subunit P1 pseudogene 12","metadata":null},{"id":"43d16d0c8da54d508d172bbb7ec476ff","type":"GENE","name":"RPLP1P13","canonical_id":"hgnc:HGNC:41973","description":"ribosomal protein lateral stalk subunit P1 pseudogene 13","metadata":null},{"id":"102c3b0b28f343518495925c4df74967","type":"GENE","name":"RPLP1P2","canonical_id":"hgnc:HGNC:36210","description":"ribosomal protein lateral stalk subunit P1 pseudogene 2","metadata":null},{"id":"fb4fa44389d7472899c054fec8696065","type":"GENE","name":"RPLP1P3","canonical_id":"hgnc:HGNC:36870","description":"ribosomal protein lateral stalk subunit P1 pseudogene 3","metadata":null},{"id":"3fcaa49faf99465e8f36706c093b22b2","type":"GENE","name":"RPLP1P4","canonical_id":"hgnc:HGNC:36939","description":"ribosomal protein lateral stalk subunit P1 pseudogene 4","metadata":null},{"id":"d0b46ee622804dde93e4723c083abe5f","type":"GENE","name":"RPLP1P5","canonical_id":"hgnc:HGNC:35842","description":"ribosomal protein lateral stalk subunit P1 pseudogene 5","metadata":null},{"id":"78035b4da96949888a182e41277b56fc","type":"GENE","name":"RPLP1P6","canonical_id":"hgnc:HGNC:35809","description":"ribosomal protein lateral stalk subunit P1 pseudogene 6","metadata":null},{"id":"aae30e979eee4409874588eb36043f1f","type":"GENE","name":"RPLP1P7","canonical_id":"hgnc:HGNC:36156","description":"ribosomal protein lateral stalk subunit P1 pseudogene 7","metadata":null},{"id":"4b2fa3daad0d467bbd8c75b59b2638c2","type":"GENE","name":"RPLP1P8","canonical_id":"hgnc:HGNC:36104","description":"ribosomal protein lateral stalk subunit P1 pseudogene 8","metadata":null},{"id":"b63555cc8dce46998e572b7f6bf4ca21","type":"GENE","name":"RPLP1P9","canonical_id":"hgnc:HGNC:36069","description":"ribosomal protein lateral stalk subunit P1 pseudogene 9","metadata":null},{"id":"b189ea8cd0684253a7089d6845eedb91","type":"GENE","name":"RPLP2","canonical_id":"hgnc:HGNC:10377","description":"ribosomal protein lateral stalk subunit P2","metadata":{"aliases":["P2","RPP2","MGC71408","LP2","D11S2243E"]}},{"id":"c2cafae1201e4f49a2a97a076f59505e","type":"GENE","name":"RPLP2P1","canonical_id":"hgnc:HGNC:18724","description":"ribosomal protein lateral stalk subunit P2 pseudogene 1","metadata":{"aliases":["dJ408B20.3"]}},{"id":"62f9fcac8473486caf48e0ee70dff8b6","type":"GENE","name":"RPLP2P2","canonical_id":"hgnc:HGNC:36590","description":"ribosomal protein lateral stalk subunit P2 pseudogene 2","metadata":null},{"id":"4d60a1fc59e94b149a698c9e5505e424","type":"GENE","name":"RPLP2P3","canonical_id":"hgnc:HGNC:36494","description":"ribosomal protein lateral stalk subunit P2 pseudogene 3","metadata":null},{"id":"3368c96f84cd466ebd7f7f4f574e40d2","type":"GENE","name":"RPLP2P4","canonical_id":"hgnc:HGNC:36837","description":"ribosomal protein lateral stalk subunit P2 pseudogene 4","metadata":null},{"id":"dc864c3e13674329ab31eedfebeff694","type":"GENE","name":"RPLP2P5","canonical_id":"hgnc:HGNC:35706","description":"ribosomal protein lateral stalk subunit P2 pseudogene 5","metadata":null},{"id":"f34055887267443394e764d0e7bab4e1","type":"GENE","name":"RPN1","canonical_id":"hgnc:HGNC:10381","description":"ribophorin I","metadata":{"aliases":["OST1"]}},{"id":"6954e03383a24b0a803b8a97d71e78c2","type":"GENE","name":"RPN2","canonical_id":"hgnc:HGNC:10382","description":"ribophorin II","metadata":{"aliases":["SWP1","RPNII","RIBIIR","RPN-II"]}},{"id":"ce6f9b4dcc40418daff098ea62e11c9f","type":"GENE","name":"RPP14","canonical_id":"hgnc:HGNC:30327","description":"ribonuclease P/MRP subunit p14","metadata":{"aliases":["P14"]}},{"id":"b5434aeaf0524a26bb78f5a5abb4af01","type":"GENE","name":"RPP21","canonical_id":"hgnc:HGNC:21300","description":"ribonuclease P subunit p21","metadata":{"aliases":["FLJ22638","Em:AB014085.3","C6orf135"]}},{"id":"89dd99cd468f4f69abe1a0c48ef19ff2","type":"GENE","name":"RPP25","canonical_id":"hgnc:HGNC:30361","description":"ribonuclease P/MRP subunit p25","metadata":{"aliases":["FLJ20374"]}},{"id":"9d4210350e8744f4b6ca1accc0e451a2","type":"GENE","name":"RPP25L","canonical_id":"hgnc:HGNC:19909","description":"ribonuclease P/MRP subunit p25 like","metadata":{"aliases":["bA296L22.5","MGC29635","C9orf23"]}},{"id":"66254f4df3f94b1db9195a712038e460","type":"GENE","name":"RPP30","canonical_id":"hgnc:HGNC:17688","description":"ribonuclease P/MRP subunit p30","metadata":{"aliases":["TSG15"]}},{"id":"d66ada6c34b947af9893a939c94e1fc2","type":"GENE","name":"RPP38","canonical_id":"hgnc:HGNC:30329","description":"ribonuclease P/MRP subunit p38","metadata":null},{"id":"d2d3412e21854303b8166a286e298d22","type":"GENE","name":"RPP38-DT","canonical_id":"hgnc:HGNC:28582","description":"RPP38 divergent transcript","metadata":{"aliases":["MGC35468","bA455B2.4","C10orf111"]}},{"id":"9eced89072064bbfb7cf4b1658cf981a","type":"GENE","name":"RPP40","canonical_id":"hgnc:HGNC:20992","description":"ribonuclease P/MRP subunit p40","metadata":{"aliases":["bA428J1.3","RNASEP1"]}},{"id":"38a189d3e883488caa6ea1f316197fb4","type":"GENE","name":"RPP40P1","canonical_id":"hgnc:HGNC:39769","description":"ribonuclease P/MRP subunit p40 pseudogene 1","metadata":null},{"id":"6b3df6b6b101459199037fbd2d0747ce","type":"GENE","name":"RPP40P2","canonical_id":"hgnc:HGNC:39770","description":"ribonuclease P/MRP subunit p40 pseudogene 2","metadata":null},{"id":"1650e5184a014650a90c381389e0085d","type":"GENE","name":"RPPH1","canonical_id":"hgnc:HGNC:19273","description":"ribonuclease P RNA component H1","metadata":{"aliases":["H1RNA","RPPH1-1"]}},{"id":"b20d0305f0b44c7abc53d463b5d27e2f","type":"GENE","name":"RPPH1-2P","canonical_id":"hgnc:HGNC:47029","description":"ribonuclease P RNA component H1, 2 pseudogene","metadata":null},{"id":"38741630aa094347986595fe422a8f1e","type":"GENE","name":"RPPH1-3P","canonical_id":"hgnc:HGNC:47030","description":"ribonuclease P RNA component H1, 3 pseudogene","metadata":null},{"id":"a27548ff3ac1476b8ea0d0063503d157","type":"GENE","name":"RPRD1A","canonical_id":"hgnc:HGNC:25560","description":"regulation of nuclear pre-mRNA domain containing 1A","metadata":{"aliases":["P15RS","FLJ10656","HsT3101"]}},{"id":"10acdc69ac1f4254a7a748b2bd88ab5a","type":"GENE","name":"RPRD1B","canonical_id":"hgnc:HGNC:16209","description":"regulation of nuclear pre-mRNA domain containing 1B","metadata":{"aliases":["dJ1057B20.2","DKFZp434P0735","CREPT","FLJ44520","NET60","Kub5-Hera","K-H","C20orf77"]}},{"id":"e2408b1fedce4bf898bd984f55ff4e39","type":"GENE","name":"RPRD2","canonical_id":"hgnc:HGNC:29039","description":"regulation of nuclear pre-mRNA domain containing 2","metadata":{"aliases":["FLJ32145","HSPC099","KIAA0460"]}},{"id":"51319934b6b145e292d3f8c844d5dfba","type":"GENE","name":"RPRM","canonical_id":"hgnc:HGNC:24201","description":null,"metadata":null},{"id":"b59ed430dd32434783ed4eca8f5f4a61","type":"GENE","name":"RPRML","canonical_id":"hgnc:HGNC:32422","description":"reprimo like","metadata":{"aliases":["MGC43894"]}},{"id":"ad899012ed13475fb0e972839232d28b","type":"GENE","name":"RPS10","canonical_id":"hgnc:HGNC:10383","description":"ribosomal protein S10","metadata":{"aliases":["MGC88819","S10","eS10"]}},{"id":"fdef78bcba1d44778f13d6c1f3233eab","type":"GENE","name":"RPS10-NUDT3","canonical_id":"hgnc:HGNC:49181","description":"RPS10-NUDT3 readthrough","metadata":null},{"id":"519e3d1166a9424c82e022cdeffc938c","type":"GENE","name":"RPS10P1","canonical_id":"hgnc:HGNC:13981","description":"ribosomal protein S10 pseudogene 1","metadata":{"aliases":["RPS10p","dJ34B20.13"]}},{"id":"ebab18c3f9df417ebbe683a0277cbe9c","type":"GENE","name":"RPS10P10","canonical_id":"hgnc:HGNC:37034","description":"ribosomal protein S10 pseudogene 10","metadata":null},{"id":"3bf43f61ea0e42b0b3e7c8efd9f72969","type":"GENE","name":"RPS10P11","canonical_id":"hgnc:HGNC:36775","description":"ribosomal protein S10 pseudogene 11","metadata":null},{"id":"183a51a9385b454d9694ba419efac869","type":"GENE","name":"RPS10P12","canonical_id":"hgnc:HGNC:36662","description":"ribosomal protein S10 pseudogene 12","metadata":null},{"id":"2270d3948ba84dcea147957149cd88b6","type":"GENE","name":"RPS10P13","canonical_id":"hgnc:HGNC:36374","description":"ribosomal protein S10 pseudogene 13","metadata":null},{"id":"aefb5bcef3974a71a08c31f375b78755","type":"GENE","name":"RPS10P14","canonical_id":"hgnc:HGNC:35880","description":"ribosomal protein S10 pseudogene 14","metadata":null},{"id":"6a6fdd07f7784a37acdd5be4b7058b14","type":"GENE","name":"RPS10P15","canonical_id":"hgnc:HGNC:35860","description":"ribosomal protein S10 pseudogene 15","metadata":null},{"id":"ce51fae121a44330b145d736ce9d618a","type":"GENE","name":"RPS10P16","canonical_id":"hgnc:HGNC:36200","description":"ribosomal protein S10 pseudogene 16","metadata":null},{"id":"ad909a65f0b3444daf17e0af6043cc1f","type":"GENE","name":"RPS10P17","canonical_id":"hgnc:HGNC:35562","description":"ribosomal protein S10 pseudogene 17","metadata":null},{"id":"0d6bc6c6ace647b6a133f72897fc4616","type":"GENE","name":"RPS10P18","canonical_id":"hgnc:HGNC:36239","description":"ribosomal protein S10 pseudogene 18","metadata":null},{"id":"2318d63c85f64cf19383d1ad90ce222f","type":"GENE","name":"RPS10P19","canonical_id":"hgnc:HGNC:35907","description":"ribosomal protein S10 pseudogene 19","metadata":null},{"id":"dd29637e0ef44971b7428e6f6fd8409b","type":"GENE","name":"RPS10P2","canonical_id":"hgnc:HGNC:16594","description":"ribosomal protein S10 pseudogene 2","metadata":{"aliases":["dJ858M22.1"]}},{"id":"c377decbba4546e6b3e2b163c8572392","type":"GENE","name":"RPS10P20","canonical_id":"hgnc:HGNC:35829","description":"ribosomal protein S10 pseudogene 20","metadata":null},{"id":"eb35987c14674020971d0de13b5b3476","type":"GENE","name":"RPS10P21","canonical_id":"hgnc:HGNC:35906","description":"ribosomal protein S10 pseudogene 21","metadata":null},{"id":"3eb006f131f5443eb7872e5721e5e65a","type":"GENE","name":"RPS10P22","canonical_id":"hgnc:HGNC:35814","description":"ribosomal protein S10 pseudogene 22","metadata":null},{"id":"e9733b60a7da4c08a52260f5294a0b00","type":"GENE","name":"RPS10P23","canonical_id":"hgnc:HGNC:36657","description":"ribosomal protein S10 pseudogene 23","metadata":null},{"id":"92f95b0d692547b092c67e186b0302ac","type":"GENE","name":"RPS10P24","canonical_id":"hgnc:HGNC:35989","description":"ribosomal protein S10 pseudogene 24","metadata":null},{"id":"c629918ac1ad49e29b1220bb49417ad6","type":"GENE","name":"RPS10P25","canonical_id":"hgnc:HGNC:36532","description":"ribosomal protein S10 pseudogene 25","metadata":null},{"id":"7b6ed0d681224fa8993cfbe6e72bfba7","type":"GENE","name":"RPS10P26","canonical_id":"hgnc:HGNC:36321","description":"ribosomal protein S10 pseudogene 26","metadata":null},{"id":"c425a7e1461747f3a230dc6d0fc26b3e","type":"GENE","name":"RPS10P27","canonical_id":"hgnc:HGNC:36850","description":"ribosomal protein S10 pseudogene 27","metadata":null},{"id":"22ec3cdd5a7745afb552acb52898de76","type":"GENE","name":"RPS10P28","canonical_id":"hgnc:HGNC:35511","description":"ribosomal protein S10 pseudogene 28","metadata":null},{"id":"0cffb36228ab4bd6a3c06d33f7e14dcf","type":"GENE","name":"RPS10P29","canonical_id":"hgnc:HGNC:37120","description":"ribosomal protein S10 pseudogene 29","metadata":null},{"id":"6b5c99bd756344e795917bfbb829a69a","type":"GENE","name":"RPS10P3","canonical_id":"hgnc:HGNC:23684","description":"ribosomal protein S10 pseudogene 3","metadata":null},{"id":"2f8fcefb3e654d8c93832961c53969e6","type":"GENE","name":"RPS10P30","canonical_id":"hgnc:HGNC:35593","description":"ribosomal protein S10 pseudogene 30","metadata":null},{"id":"b908371a786640a6858a77ccdceec1e5","type":"GENE","name":"RPS10P31","canonical_id":"hgnc:HGNC:35998","description":"ribosomal protein S10 pseudogene 31","metadata":null},{"id":"edaacaaeafa2423a849ee8a90d8c0918","type":"GENE","name":"RPS10P4","canonical_id":"hgnc:HGNC:31364","description":"ribosomal protein S10 pseudogene 4","metadata":{"aliases":["bcm1851"]}},{"id":"dae8762ebdaf4b6b9bb8ec36ae0b4644","type":"GENE","name":"RPS10P5","canonical_id":"hgnc:HGNC:15795","description":"ribosomal protein S10 pseudogene 5","metadata":{"aliases":["bA371L19.2","RPS10L"]}},{"id":"8abca8ac69634da4bf9ffd60660b7b19","type":"GENE","name":"RPS10P6","canonical_id":"hgnc:HGNC:35765","description":"ribosomal protein S10 pseudogene 6","metadata":null},{"id":"e37f8d7d39384627b85e640a90580f97","type":"GENE","name":"RPS10P7","canonical_id":"hgnc:HGNC:36423","description":"ribosomal protein S10 pseudogene 7","metadata":{"aliases":["lnc-MCEI"]}},{"id":"712812f2ee4b47378bb1beedbbd378ed","type":"GENE","name":"RPS10P8","canonical_id":"hgnc:HGNC:36606","description":"ribosomal protein S10 pseudogene 8","metadata":null},{"id":"5f023181729649f385a1ce1ceec813e0","type":"GENE","name":"RPS10P9","canonical_id":"hgnc:HGNC:36451","description":"ribosomal protein S10 pseudogene 9","metadata":null},{"id":"948d480ef5f84b6aaad7c5f1193ffb36","type":"GENE","name":"RPS11","canonical_id":"hgnc:HGNC:10384","description":"ribosomal protein S11","metadata":{"aliases":["S11","uS17"]}},{"id":"cf2843495e054af5a9d278ed2c916ccf","type":"GENE","name":"RPS11P1","canonical_id":"hgnc:HGNC:16553","description":"ribosomal protein S11 pseudogene 1","metadata":{"aliases":["dJ1060K6.1"]}},{"id":"e16b2c8ad5b8473a9ff23dd9d027a542","type":"GENE","name":"RPS11P2","canonical_id":"hgnc:HGNC:37007","description":"ribosomal protein S11 pseudogene 2","metadata":null},{"id":"937e0709719f4fabbd039a236328bce0","type":"GENE","name":"RPS11P3","canonical_id":"hgnc:HGNC:35870","description":"ribosomal protein S11 pseudogene 3","metadata":null},{"id":"41c879505c9941b4a48386777e3272e6","type":"GENE","name":"RPS11P4","canonical_id":"hgnc:HGNC:35644","description":"ribosomal protein S11 pseudogene 4","metadata":null},{"id":"19e26308af59422982feddc2803763f9","type":"GENE","name":"RPS11P5","canonical_id":"hgnc:HGNC:36312","description":"ribosomal protein S11 pseudogene 5","metadata":null},{"id":"fbd6261bf8e149da81a0d2ea4bb95af0","type":"GENE","name":"RPS11P6","canonical_id":"hgnc:HGNC:36693","description":"ribosomal protein S11 pseudogene 6","metadata":null},{"id":"3a783408a7d34ff6a481fbb63a9da73b","type":"GENE","name":"RPS11P7","canonical_id":"hgnc:HGNC:36724","description":"ribosomal protein S11 pseudogene 7","metadata":null},{"id":"cc736ec139224d5c84f22a5fcedf1475","type":"GENE","name":"RPS12","canonical_id":"hgnc:HGNC:10385","description":"ribosomal protein S12","metadata":{"aliases":["S12","eS12"]}},{"id":"c6da739b8d9d4f1a810b96d3320dbadd","type":"GENE","name":"RPS12P1","canonical_id":"hgnc:HGNC:19787","description":"ribosomal protein S12 pseudogene 1","metadata":null},{"id":"6353bc5df0864917b5ed9f4c5e09b050","type":"GENE","name":"RPS12P10","canonical_id":"hgnc:HGNC:35824","description":"ribosomal protein S12 pseudogene 10","metadata":null},{"id":"e53c8ec8e9dd4e298c17ad0a545ef183","type":"GENE","name":"RPS12P11","canonical_id":"hgnc:HGNC:36042","description":"ribosomal protein S12 pseudogene 11","metadata":null},{"id":"446f7f972abd419abab8a1338603f41b","type":"GENE","name":"RPS12P12","canonical_id":"hgnc:HGNC:36235","description":"ribosomal protein S12 pseudogene 12","metadata":null},{"id":"c9c36a859b824853873866262a1325c3","type":"GENE","name":"RPS12P13","canonical_id":"hgnc:HGNC:36549","description":"ribosomal protein S12 pseudogene 13","metadata":null},{"id":"22bdd99d29dd4752894510c46d026d85","type":"GENE","name":"RPS12P14","canonical_id":"hgnc:HGNC:35632","description":"ribosomal protein S12 pseudogene 14","metadata":null},{"id":"7c1ef729a8ee4f1b9042effa7b157c1a","type":"GENE","name":"RPS12P15","canonical_id":"hgnc:HGNC:35610","description":"ribosomal protein S12 pseudogene 15","metadata":null},{"id":"ee9839045ae94e1bacc46975be3cfb00","type":"GENE","name":"RPS12P16","canonical_id":"hgnc:HGNC:36595","description":"ribosomal protein S12 pseudogene 16","metadata":null},{"id":"f1a5fbf2937f4e008c90236256630d5c","type":"GENE","name":"RPS12P17","canonical_id":"hgnc:HGNC:35705","description":"ribosomal protein S12 pseudogene 17","metadata":null},{"id":"8542c63eaf38410ea001a85cf3a29805","type":"GENE","name":"RPS12P18","canonical_id":"hgnc:HGNC:36421","description":"ribosomal protein S12 pseudogene 18","metadata":null},{"id":"a4f4ed6cf47140349f29e7ada0baa084","type":"GENE","name":"RPS12P2","canonical_id":"hgnc:HGNC:24221","description":"ribosomal protein S12 pseudogene 2","metadata":{"aliases":["bA40F6.3"]}},{"id":"7a8857eef8ea49e6b3bb006a2f3c38b6","type":"GENE","name":"RPS12P20","canonical_id":"hgnc:HGNC:36187","description":"ribosomal protein S12 pseudogene 20","metadata":null},{"id":"115335a5859a47458db66ccfdcdc719e","type":"GENE","name":"RPS12P21","canonical_id":"hgnc:HGNC:36464","description":"ribosomal protein S12 pseudogene 21","metadata":null},{"id":"4083695e8954419e8c0eaf6d98d204d5","type":"GENE","name":"RPS12P22","canonical_id":"hgnc:HGNC:35671","description":"ribosomal protein S12 pseudogene 22","metadata":null},{"id":"43c47acd7ba9481581f99275f967ff2e","type":"GENE","name":"RPS12P23","canonical_id":"hgnc:HGNC:35573","description":"ribosomal protein S12 pseudogene 23","metadata":null},{"id":"dba02656f45e451ea952c6808b076c11","type":"GENE","name":"RPS12P24","canonical_id":"hgnc:HGNC:35561","description":"ribosomal protein S12 pseudogene 24","metadata":null},{"id":"1dff20c46899471c92e134fc9aa939e7","type":"GENE","name":"RPS12P25","canonical_id":"hgnc:HGNC:36019","description":"ribosomal protein S12 pseudogene 25","metadata":null},{"id":"23a125bfa940477097a4bb55c027c7fb","type":"GENE","name":"RPS12P26","canonical_id":"hgnc:HGNC:36320","description":"ribosomal protein S12 pseudogene 26","metadata":null},{"id":"0aafaf8ce4a64d4d981f4777b765d964","type":"GENE","name":"RPS12P27","canonical_id":"hgnc:HGNC:35892","description":"ribosomal protein S12 pseudogene 27","metadata":null},{"id":"c242d3505e804046991eb84feccf8eb2","type":"GENE","name":"RPS12P28","canonical_id":"hgnc:HGNC:36972","description":"ribosomal protein S12 pseudogene 28","metadata":null},{"id":"a7b97ef09160490cba736e0eed64411e","type":"GENE","name":"RPS12P29","canonical_id":"hgnc:HGNC:36206","description":"ribosomal protein S12 pseudogene 29","metadata":null},{"id":"45c25d0100ea49ee82ca4d322123fd1e","type":"GENE","name":"RPS12P3","canonical_id":"hgnc:HGNC:35500","description":"ribosomal protein S12 pseudogene 3","metadata":null},{"id":"2fede633904b42b58b4f1a0db28572fe","type":"GENE","name":"RPS12P30","canonical_id":"hgnc:HGNC:36813","description":"ribosomal protein S12 pseudogene 30","metadata":null},{"id":"e429b78b9acc47df9b4f43b36593c8b5","type":"GENE","name":"RPS12P31","canonical_id":"hgnc:HGNC:35578","description":"ribosomal protein S12 pseudogene 31","metadata":null},{"id":"7061e3545ac5452fa62c4697afed39e7","type":"GENE","name":"RPS12P32","canonical_id":"hgnc:HGNC:35571","description":"ribosomal protein S12 pseudogene 32","metadata":null},{"id":"319a84730e4540efabac8002eebcc1f2","type":"GENE","name":"RPS12P4","canonical_id":"hgnc:HGNC:35670","description":"ribosomal protein S12 pseudogene 4","metadata":null},{"id":"38f285d8a57a4fcc8f33edcfd9b54920","type":"GENE","name":"RPS12P5","canonical_id":"hgnc:HGNC:36525","description":"ribosomal protein S12 pseudogene 5","metadata":null},{"id":"4d6df6474d0645c283d01868ac3dbfe2","type":"GENE","name":"RPS12P6","canonical_id":"hgnc:HGNC:35790","description":"ribosomal protein S12 pseudogene 6","metadata":null},{"id":"dfa7c43cd43e49e28ce1243f3341f31e","type":"GENE","name":"RPS12P7","canonical_id":"hgnc:HGNC:36699","description":"ribosomal protein S12 pseudogene 7","metadata":null},{"id":"dfb6ba8af79740c2b256bc6a07d89982","type":"GENE","name":"RPS12P8","canonical_id":"hgnc:HGNC:35945","description":"ribosomal protein S12 pseudogene 8","metadata":null},{"id":"a10b961aef8d461bb3bbb2dd9b3bac27","type":"GENE","name":"RPS12P9","canonical_id":"hgnc:HGNC:36719","description":"ribosomal protein S12 pseudogene 9","metadata":null},{"id":"3acdf1e10b08451ba02a477f7d5dca9f","type":"GENE","name":"RPS13","canonical_id":"hgnc:HGNC:10386","description":"ribosomal protein S13","metadata":{"aliases":["S13","uS15"]}},{"id":"9b86c141261c4e1bad9f2d614aebc911","type":"GENE","name":"RPS13P1","canonical_id":"hgnc:HGNC:36309","description":"ribosomal protein S13 pseudogene 1","metadata":null},{"id":"54df862c15364dabb90b33bce000da64","type":"GENE","name":"RPS13P2","canonical_id":"hgnc:HGNC:36364","description":"ribosomal protein S13 pseudogene 2","metadata":null},{"id":"da19d9b0da8a4ae08499bcb5c530beb8","type":"GENE","name":"RPS13P3","canonical_id":"hgnc:HGNC:36866","description":"ribosomal protein S13 pseudogene 3","metadata":null},{"id":"8606cf5c203947468fadff52f2199be2","type":"GENE","name":"RPS13P4","canonical_id":"hgnc:HGNC:35731","description":"ribosomal protein S13 pseudogene 4","metadata":null},{"id":"508339f73cf74c9aa1dc67f56ad31873","type":"GENE","name":"RPS13P5","canonical_id":"hgnc:HGNC:36610","description":"ribosomal protein S13 pseudogene 5","metadata":null},{"id":"24dcdcbb6e544c24953a74302dcac955","type":"GENE","name":"RPS13P6","canonical_id":"hgnc:HGNC:35653","description":"ribosomal protein S13 pseudogene 6","metadata":null},{"id":"78525290e4644121921e043ff883c1f7","type":"GENE","name":"RPS13P7","canonical_id":"hgnc:HGNC:36310","description":"ribosomal protein S13 pseudogene 7","metadata":null},{"id":"17926e7cd0494597951ee646a889a226","type":"GENE","name":"RPS13P8","canonical_id":"hgnc:HGNC:36400","description":"ribosomal protein S13 pseudogene 8","metadata":null},{"id":"cb5f1e80487f43219356d2f571df2dbe","type":"GENE","name":"RPS14","canonical_id":"hgnc:HGNC:10387","description":"ribosomal protein S14","metadata":{"aliases":["EMTB","S14","uS11"]}},{"id":"22ad99671752407ca7b9c965d1a50bce","type":"GENE","name":"RPS14-AS1","canonical_id":"hgnc:HGNC:59281","description":"RPS14 antisense RNA 1","metadata":null},{"id":"b9d48dea409143a79d0a6895f3484800","type":"GENE","name":"RPS14P1","canonical_id":"hgnc:HGNC:35572","description":"ribosomal protein S14 pseudogene 1","metadata":null},{"id":"499195041e474f638b562b0614f7de24","type":"GENE","name":"RPS14P10","canonical_id":"hgnc:HGNC:35517","description":"ribosomal protein S14 pseudogene 10","metadata":null},{"id":"7860d8aa89d242b69343a06f493d1c0d","type":"GENE","name":"RPS14P2","canonical_id":"hgnc:HGNC:36080","description":"ribosomal protein S14 pseudogene 2","metadata":null},{"id":"12f8ae94db614434aa91f7a6727432dc","type":"GENE","name":"RPS14P3","canonical_id":"hgnc:HGNC:35797","description":"ribosomal protein S14 pseudogene 3","metadata":null},{"id":"6f10589e28824584908dde4ce538b2cf","type":"GENE","name":"RPS14P4","canonical_id":"hgnc:HGNC:36419","description":"ribosomal protein S14 pseudogene 4","metadata":null},{"id":"71965f76f9204d77b2200f7a3c1bf0d3","type":"GENE","name":"RPS14P5","canonical_id":"hgnc:HGNC:36087","description":"ribosomal protein S14 pseudogene 5","metadata":null},{"id":"092d7e2fcacc426b8d8e72d3e651e667","type":"GENE","name":"RPS14P6","canonical_id":"hgnc:HGNC:36241","description":"ribosomal protein S14 pseudogene 6","metadata":null},{"id":"ae92e6fb0d7e415f8a1e42a4b550fab5","type":"GENE","name":"RPS14P7","canonical_id":"hgnc:HGNC:36961","description":"ribosomal protein S14 pseudogene 7","metadata":null},{"id":"ae9f3af087e546a3bd0a2baef7603ecb","type":"GENE","name":"RPS14P8","canonical_id":"hgnc:HGNC:37027","description":"ribosomal protein S14 pseudogene 8","metadata":null},{"id":"605113ccdd544976b527789d84767a5d","type":"GENE","name":"RPS14P9","canonical_id":"hgnc:HGNC:36286","description":"ribosomal protein S14 pseudogene 9","metadata":null},{"id":"211edc1332924fd5afdaf68f94e109c2","type":"GENE","name":"RPS15","canonical_id":"hgnc:HGNC:10388","description":"ribosomal protein S15","metadata":{"aliases":["RIG","MGC111130","S15","uS19"]}},{"id":"1b86924ddea64d049241f2770de83a14","type":"GENE","name":"RPS15A","canonical_id":"hgnc:HGNC:10389","description":"ribosomal protein S15a","metadata":{"aliases":["S15A","uS8"]}},{"id":"a119d0a58b894c96bea8b1c3d1a9f5c1","type":"GENE","name":"RPS15AP1","canonical_id":"hgnc:HGNC:16598","description":"ribosomal protein S15a pseudogene 1","metadata":{"aliases":["dJ872K7.6"]}},{"id":"ae64b225817345879790a93c423fb1c7","type":"GENE","name":"RPS15AP10","canonical_id":"hgnc:HGNC:37001","description":"ribosomal protein S15a pseudogene 10","metadata":null},{"id":"a57c545f686c41ff9bc90c01fb46a90c","type":"GENE","name":"RPS15AP11","canonical_id":"hgnc:HGNC:36707","description":"ribosomal protein S15a pseudogene 11","metadata":null},{"id":"6ff7e84bef4f47b9a1406b0b73d146a6","type":"GENE","name":"RPS15AP12","canonical_id":"hgnc:HGNC:36759","description":"ribosomal protein S15a pseudogene 12","metadata":null},{"id":"4a2d91ca4aeb45e1afeaa2aea51d0b1b","type":"GENE","name":"RPS15AP13","canonical_id":"hgnc:HGNC:36774","description":"ribosomal protein S15a pseudogene 13","metadata":null},{"id":"69da94193a4f4109859c9b71ec6958dc","type":"GENE","name":"RPS15AP14","canonical_id":"hgnc:HGNC:36629","description":"ribosomal protein S15a pseudogene 14","metadata":null},{"id":"79f3f0e8d5c9463185c638b55571055f","type":"GENE","name":"RPS15AP15","canonical_id":"hgnc:HGNC:35640","description":"ribosomal protein S15a pseudogene 15","metadata":null},{"id":"26ceead5cdca4841942b912aae0e969b","type":"GENE","name":"RPS15AP16","canonical_id":"hgnc:HGNC:36764","description":"ribosomal protein S15a pseudogene 16","metadata":null},{"id":"9ee7df95b95140c58897cf04e589bd99","type":"GENE","name":"RPS15AP17","canonical_id":"hgnc:HGNC:36888","description":"ribosomal protein S15a pseudogene 17","metadata":null},{"id":"ceb1e8bf451649ff8809573db3318192","type":"GENE","name":"RPS15AP18","canonical_id":"hgnc:HGNC:36524","description":"ribosomal protein S15a pseudogene 18","metadata":null},{"id":"40d6a18ef97f482b85c3e4bcafbc18a9","type":"GENE","name":"RPS15AP19","canonical_id":"hgnc:HGNC:36603","description":"ribosomal protein S15a pseudogene 19","metadata":null},{"id":"49f288c67c474166a2c32ca5fc2d55dc","type":"GENE","name":"RPS15AP2","canonical_id":"hgnc:HGNC:19671","description":"ribosomal protein S15a pseudogene 2","metadata":null},{"id":"3905b00ad738467382a0a7bc175bee57","type":"GENE","name":"RPS15AP20","canonical_id":"hgnc:HGNC:36391","description":"ribosomal protein S15a pseudogene 20","metadata":null},{"id":"4bf3a11a58074674974ba831011d8cf7","type":"GENE","name":"RPS15AP21","canonical_id":"hgnc:HGNC:36142","description":"ribosomal protein S15a pseudogene 21","metadata":null},{"id":"d2f64546e48c4a3a86628a5eb61b4d2a","type":"GENE","name":"RPS15AP22","canonical_id":"hgnc:HGNC:36305","description":"ribosomal protein S15a pseudogene 22","metadata":null},{"id":"560c8386a27d4ab59ec0baaafd44a2fd","type":"GENE","name":"RPS15AP23","canonical_id":"hgnc:HGNC:36718","description":"ribosomal protein S15a pseudogene 23","metadata":null},{"id":"52683dc50d4f42d58ae404e1a35383ed","type":"GENE","name":"RPS15AP24","canonical_id":"hgnc:HGNC:36174","description":"ribosomal protein S15a pseudogene 24","metadata":null},{"id":"77e460129bf940b9b84b818f4ad5befd","type":"GENE","name":"RPS15AP25","canonical_id":"hgnc:HGNC:36848","description":"ribosomal protein S15a pseudogene 25","metadata":null},{"id":"24c90c626ed6426cb82db97295cf4cb5","type":"GENE","name":"RPS15AP26","canonical_id":"hgnc:HGNC:36773","description":"ribosomal protein S15a pseudogene 26","metadata":null},{"id":"525e56ba655f4adaa225a2ace7523470","type":"GENE","name":"RPS15AP27","canonical_id":"hgnc:HGNC:37011","description":"ribosomal protein S15a pseudogene 27","metadata":null},{"id":"2f663ff3e8104008845b50cb77dfb2d7","type":"GENE","name":"RPS15AP28","canonical_id":"hgnc:HGNC:36381","description":"ribosomal protein S15a pseudogene 28","metadata":null},{"id":"2c584c730fc54dc6bdf36aee2858b842","type":"GENE","name":"RPS15AP29","canonical_id":"hgnc:HGNC:35981","description":"ribosomal protein S15a pseudogene 29","metadata":null},{"id":"941917ce82cb491ca9860389870b51c5","type":"GENE","name":"RPS15AP3","canonical_id":"hgnc:HGNC:19674","description":"ribosomal protein S15a pseudogene 3","metadata":null},{"id":"cf910b46f1484067b023e537bba71f10","type":"GENE","name":"RPS15AP30","canonical_id":"hgnc:HGNC:35495","description":"ribosomal protein S15a pseudogene 30","metadata":null},{"id":"495719956b5f45d4b625404ed4d5dfde","type":"GENE","name":"RPS15AP31","canonical_id":"hgnc:HGNC:36960","description":"ribosomal protein S15a pseudogene 31","metadata":null},{"id":"32ebd66fc5104364a0bdd66f6cb864ba","type":"GENE","name":"RPS15AP32","canonical_id":"hgnc:HGNC:35879","description":"ribosomal protein S15a pseudogene 32","metadata":null},{"id":"ee4cc463102a48a5b36aaeda607a592a","type":"GENE","name":"RPS15AP33","canonical_id":"hgnc:HGNC:36178","description":"ribosomal protein S15a pseudogene 33","metadata":null},{"id":"730a04a227a44970addd4aa173f3306d","type":"GENE","name":"RPS15AP34","canonical_id":"hgnc:HGNC:35609","description":"ribosomal protein S15a pseudogene 34","metadata":null},{"id":"13f39f18006d4766a3f1460ec64fa5ca","type":"GENE","name":"RPS15AP35","canonical_id":"hgnc:HGNC:36768","description":"ribosomal protein S15a pseudogene 35","metadata":null},{"id":"3523108387c846bc9a7d8e3a2bed8afe","type":"GENE","name":"RPS15AP36","canonical_id":"hgnc:HGNC:36803","description":"ribosomal protein S15a pseudogene 36","metadata":null},{"id":"c7db9e644cd44f469cb8b9be7632774e","type":"GENE","name":"RPS15AP37","canonical_id":"hgnc:HGNC:36173","description":"ribosomal protein S15a pseudogene 37","metadata":null},{"id":"56e32fc10e384e38b225af28adfbea3f","type":"GENE","name":"RPS15AP38","canonical_id":"hgnc:HGNC:36523","description":"ribosomal protein S15a pseudogene 38","metadata":null},{"id":"cbdffdd3979b4e86b67fb37ce44b8dd5","type":"GENE","name":"RPS15AP39","canonical_id":"hgnc:HGNC:35800","description":"ribosomal protein S15a pseudogene 39","metadata":null},{"id":"36d095a978a44b8ca9b9c448cd352b28","type":"GENE","name":"RPS15AP4","canonical_id":"hgnc:HGNC:23559","description":"ribosomal protein S15a pseudogene 4","metadata":null},{"id":"5a08abcbd3d0429da91dd27ed3a2522d","type":"GENE","name":"RPS15AP40","canonical_id":"hgnc:HGNC:36041","description":"ribosomal protein S15a pseudogene 40","metadata":null},{"id":"3674055f892240869b3fb7c28815adf0","type":"GENE","name":"RPS15AP5","canonical_id":"hgnc:HGNC:23743","description":"ribosomal protein S15a pseudogene 5","metadata":{"aliases":["Em:AC025947.3"]}},{"id":"304f3fa99db74645ae9538c64c6fe71b","type":"GENE","name":"RPS15AP6","canonical_id":"hgnc:HGNC:35657","description":"ribosomal protein S15a pseudogene 6","metadata":null},{"id":"2e90600bb28640609f20ba575ae9dc5e","type":"GENE","name":"RPS15AP7","canonical_id":"hgnc:HGNC:35648","description":"ribosomal protein S15a pseudogene 7","metadata":null},{"id":"6ac913d979a8416a8478f2f64b2c0ca1","type":"GENE","name":"RPS15AP8","canonical_id":"hgnc:HGNC:36887","description":"ribosomal protein S15a pseudogene 8","metadata":null},{"id":"2ec54a688d074a5487835c5e5216bed3","type":"GENE","name":"RPS15AP9","canonical_id":"hgnc:HGNC:36164","description":"ribosomal protein S15a pseudogene 9","metadata":null},{"id":"6ac3987029bb4c35a47a74be5f99566d","type":"GENE","name":"RPS15P1","canonical_id":"hgnc:HGNC:35725","description":"ribosomal protein S15 pseudogene 1","metadata":null},{"id":"33b0eaf1b1df46c29dd0c5c2e437267e","type":"GENE","name":"RPS15P2","canonical_id":"hgnc:HGNC:36033","description":"ribosomal protein S15 pseudogene 2","metadata":null},{"id":"99f739be74ca401fb7493f14903b335b","type":"GENE","name":"RPS15P3","canonical_id":"hgnc:HGNC:35563","description":"ribosomal protein S15 pseudogene 3","metadata":null},{"id":"2a43c6db7d5e499ca487fee34b0d9d03","type":"GENE","name":"RPS15P4","canonical_id":"hgnc:HGNC:35712","description":"ribosomal protein S15 pseudogene 4","metadata":null},{"id":"f5961e4e8fee40ee87c0f570e09f4951","type":"GENE","name":"RPS15P5","canonical_id":"hgnc:HGNC:35536","description":"ribosomal protein S15 pseudogene 5","metadata":null},{"id":"9721b535453d4148bc0154167cc9a57b","type":"GENE","name":"RPS15P6","canonical_id":"hgnc:HGNC:36653","description":"ribosomal protein S15 pseudogene 6","metadata":null},{"id":"e77d9c93c7c24b959dae04b91c105068","type":"GENE","name":"RPS15P7","canonical_id":"hgnc:HGNC:36623","description":"ribosomal protein S15 pseudogene 7","metadata":null},{"id":"17cff74404de4f4d954024ecc85a90e6","type":"GENE","name":"RPS15P8","canonical_id":"hgnc:HGNC:35847","description":"ribosomal protein S15 pseudogene 8","metadata":null},{"id":"9bb5f9650651476bbcb543b10af23051","type":"GENE","name":"RPS15P9","canonical_id":"hgnc:HGNC:36440","description":"ribosomal protein S15 pseudogene 9","metadata":null},{"id":"958db77ac73b4c888ca30db40657a4e0","type":"GENE","name":"RPS16","canonical_id":"hgnc:HGNC:10396","description":"ribosomal protein S16","metadata":{"aliases":["S16","uS9"]}},{"id":"ef3b9e4d70e0442f9eba2669ab786b19","type":"GENE","name":"RPS16P1","canonical_id":"hgnc:HGNC:36462","description":"ribosomal protein S16 pseudogene 1","metadata":null},{"id":"df51e89c0bfa47e9bddb5ae4f2050ec5","type":"GENE","name":"RPS16P10","canonical_id":"hgnc:HGNC:35739","description":"ribosomal protein S16 pseudogene 10","metadata":null},{"id":"35d3304de7bc45febb1ff0e3fe6002c8","type":"GENE","name":"RPS16P2","canonical_id":"hgnc:HGNC:35928","description":"ribosomal protein S16 pseudogene 2","metadata":null},{"id":"b84bd503804b4d2a85568bb795ee5728","type":"GENE","name":"RPS16P3","canonical_id":"hgnc:HGNC:35986","description":"ribosomal protein S16 pseudogene 3","metadata":null},{"id":"8537faaf594245609e2462ec3f70d3d0","type":"GENE","name":"RPS16P4","canonical_id":"hgnc:HGNC:36502","description":"ribosomal protein S16 pseudogene 4","metadata":null},{"id":"b66485133a2f4faf8f9e9cb19eed44e0","type":"GENE","name":"RPS16P5","canonical_id":"hgnc:HGNC:36183","description":"ribosomal protein S16 pseudogene 5","metadata":null},{"id":"9bfe66475bbd466badbfbb09a3c2c1ba","type":"GENE","name":"RPS16P6","canonical_id":"hgnc:HGNC:36741","description":"ribosomal protein S16 pseudogene 6","metadata":null},{"id":"c79d58daaa4e45f6ae4ec66044fe77c3","type":"GENE","name":"RPS16P7","canonical_id":"hgnc:HGNC:36505","description":"ribosomal protein S16 pseudogene 7","metadata":null},{"id":"c2c1030675d84b2089cdf9e9c4d24a54","type":"GENE","name":"RPS16P8","canonical_id":"hgnc:HGNC:35608","description":"ribosomal protein S16 pseudogene 8","metadata":null},{"id":"838072a480e34f07a619fbaf461585f6","type":"GENE","name":"RPS16P9","canonical_id":"hgnc:HGNC:35659","description":"ribosomal protein S16 pseudogene 9","metadata":null},{"id":"adfd467762b0423dbf7bd36145310047","type":"GENE","name":"RPS17","canonical_id":"hgnc:HGNC:10397","description":"ribosomal protein S17","metadata":{"aliases":["RPS17L1","RPS17L2","MGC72007","S17","eS17","RPS17L"]}},{"id":"15f9a69025ff4af48d04b1b95c3ff2cf","type":"GENE","name":"RPS17P1","canonical_id":"hgnc:HGNC:13982","description":"ribosomal protein S17 pseudogene 1","metadata":{"aliases":["RPS17p","dJ994E9.1"]}},{"id":"412d1e165b484f2b983152649e6dfece","type":"GENE","name":"RPS17P10","canonical_id":"hgnc:HGNC:36438","description":"ribosomal protein S17 pseudogene 10","metadata":null},{"id":"bf4b626f305a459ebba9558d8d307013","type":"GENE","name":"RPS17P11","canonical_id":"hgnc:HGNC:36132","description":"ribosomal protein S17 pseudogene 11","metadata":null},{"id":"b9c04005ba5a4938a71687c15d6d4fdb","type":"GENE","name":"RPS17P12","canonical_id":"hgnc:HGNC:35930","description":"ribosomal protein S17 pseudogene 12","metadata":null},{"id":"8e7ceae4110446c5860c145e10218276","type":"GENE","name":"RPS17P13","canonical_id":"hgnc:HGNC:36664","description":"ribosomal protein S17 pseudogene 13","metadata":null},{"id":"9f9889a534e64c2694e5c2314b7883f7","type":"GENE","name":"RPS17P14","canonical_id":"hgnc:HGNC:35534","description":"ribosomal protein S17 pseudogene 14","metadata":null},{"id":"70ecfef6eb2649d883bbca6549578cf0","type":"GENE","name":"RPS17P15","canonical_id":"hgnc:HGNC:35931","description":"ribosomal protein S17 pseudogene 15","metadata":null},{"id":"7d41a3f74a6e4a7c91a8c10156195386","type":"GENE","name":"RPS17P16","canonical_id":"hgnc:HGNC:36821","description":"ribosomal protein S17 pseudogene 16","metadata":null},{"id":"5b30ff2c116b4a9dbc60132726249c78","type":"GENE","name":"RPS17P17","canonical_id":"hgnc:HGNC:35647","description":"ribosomal protein S17 pseudogene 17","metadata":null},{"id":"f3ae01711d604d34a15f482aa10d9596","type":"GENE","name":"RPS17P2","canonical_id":"hgnc:HGNC:10398","description":"ribosomal protein S17 pseudogene 2","metadata":{"aliases":["RPS17L1","RPS17A"]}},{"id":"d5bb362966e244ca9a27a2dec5153a87","type":"GENE","name":"RPS17P3","canonical_id":"hgnc:HGNC:10399","description":"ribosomal protein S17 pseudogene 3","metadata":{"aliases":["RPS17L2","RPS17B"]}},{"id":"8b8f551b7aa84c4d9302876dbfb89534","type":"GENE","name":"RPS17P5","canonical_id":"hgnc:HGNC:21352","description":"ribosomal protein S17 pseudogene 5","metadata":{"aliases":["dJ753D5.2","RPS17L4"]}},{"id":"1eebb4f410214ed4a6888d02f8dc428a","type":"GENE","name":"RPS17P6","canonical_id":"hgnc:HGNC:36945","description":"ribosomal protein S17 pseudogene 6","metadata":null},{"id":"2218b5f431fd4e439d1419d911020679","type":"GENE","name":"RPS17P7","canonical_id":"hgnc:HGNC:35796","description":"ribosomal protein S17 pseudogene 7","metadata":null},{"id":"b6c67f1023f44235a43c5eb74d0417a5","type":"GENE","name":"RPS17P8","canonical_id":"hgnc:HGNC:36772","description":"ribosomal protein S17 pseudogene 8","metadata":null},{"id":"b5a01e9898ed4b91aa8a06db3db00d0f","type":"GENE","name":"RPS17P9","canonical_id":"hgnc:HGNC:36160","description":"ribosomal protein S17 pseudogene 9","metadata":null},{"id":"d132de8ae36f46ca8c6bff9934d39e3b","type":"GENE","name":"RPS18","canonical_id":"hgnc:HGNC:10401","description":"ribosomal protein S18","metadata":{"aliases":["KE3","KE-3","HKE3","S18","uS13","D6S218E"]}},{"id":"7b3d5374426c45ea9c5b3dab9d490030","type":"GENE","name":"RPS18P1","canonical_id":"hgnc:HGNC:16550","description":"ribosomal protein S18 pseudogene 1","metadata":{"aliases":["dJ1022P6.1"]}},{"id":"683d1695296948e5b92f155c206014bb","type":"GENE","name":"RPS18P10","canonical_id":"hgnc:HGNC:35566","description":"ribosomal protein S18 pseudogene 10","metadata":null},{"id":"0b9bffffaadf4d448cdfa1fafbef9d47","type":"GENE","name":"RPS18P11","canonical_id":"hgnc:HGNC:36319","description":"ribosomal protein S18 pseudogene 11","metadata":null},{"id":"ed33c533e86a4605a6a50126168a14c8","type":"GENE","name":"RPS18P12","canonical_id":"hgnc:HGNC:35967","description":"ribosomal protein S18 pseudogene 12","metadata":null},{"id":"0bb5a94370574b32948e3c9496bf6661","type":"GENE","name":"RPS18P13","canonical_id":"hgnc:HGNC:36901","description":"ribosomal protein S18 pseudogene 13","metadata":null},{"id":"7ccf30869f044d3abbf861ae33a8ec07","type":"GENE","name":"RPS18P14","canonical_id":"hgnc:HGNC:36386","description":"ribosomal protein S18 pseudogene 14","metadata":null},{"id":"97bd3148795e4e69a86b4bf9fe96c59f","type":"GENE","name":"RPS18P2","canonical_id":"hgnc:HGNC:19801","description":"ribosomal protein S18 pseudogene 2","metadata":null},{"id":"8854222aef6d49eeb45bbb5e0d44c224","type":"GENE","name":"RPS18P3","canonical_id":"hgnc:HGNC:36198","description":"ribosomal protein S18 pseudogene 3","metadata":null},{"id":"ff5a1c41815e4fd9baa166809a6aff55","type":"GENE","name":"RPS18P4","canonical_id":"hgnc:HGNC:36952","description":"ribosomal protein S18 pseudogene 4","metadata":null},{"id":"80ee2e38a2af4f059854a5ec37bb1028","type":"GENE","name":"RPS18P5","canonical_id":"hgnc:HGNC:36287","description":"ribosomal protein S18 pseudogene 5","metadata":null},{"id":"2c9d8d6705db4ced90bcec39e384ccc5","type":"GENE","name":"RPS18P6","canonical_id":"hgnc:HGNC:36028","description":"ribosomal protein S18 pseudogene 6","metadata":null},{"id":"ad36e3e4837e403caf13982c817c9f4d","type":"GENE","name":"RPS18P7","canonical_id":"hgnc:HGNC:35874","description":"ribosomal protein S18 pseudogene 7","metadata":null},{"id":"56080f58076b49878a81d5fffc085fce","type":"GENE","name":"RPS18P8","canonical_id":"hgnc:HGNC:35956","description":"ribosomal protein S18 pseudogene 8","metadata":null},{"id":"313a7aaa964940e498e8d659f5a5e4de","type":"GENE","name":"RPS18P9","canonical_id":"hgnc:HGNC:36483","description":"ribosomal protein S18 pseudogene 9","metadata":null},{"id":"66597026935548ee9ec7381930b3e4a4","type":"GENE","name":"RPS19","canonical_id":"hgnc:HGNC:10402","description":"ribosomal protein S19","metadata":{"aliases":["S19","eS19","DBA","LOH19CR1"]}},{"id":"6077b8aaa41d4834a349269b8238d05d","type":"GENE","name":"RPS19BP1","canonical_id":"hgnc:HGNC:28749","description":"ribosomal protein S19 binding protein 1","metadata":{"aliases":["AROS","FLJ21770","MGC52010"]}},{"id":"8d39e9c3476c4c0b8906dd8a4fee277d","type":"GENE","name":"RPS19P1","canonical_id":"hgnc:HGNC:16534","description":"ribosomal protein S19 pseudogene 1","metadata":{"aliases":["bA189K21.7"]}},{"id":"fd98a6592fae480f84ba7dc3a6d48811","type":"GENE","name":"RPS19P2","canonical_id":"hgnc:HGNC:17047","description":"ribosomal protein S19 pseudogene 2","metadata":null},{"id":"721b1eced97b4897bbc7818a4f5f72b5","type":"GENE","name":"RPS19P3","canonical_id":"hgnc:HGNC:23560","description":"ribosomal protein S19 pseudogene 3","metadata":null},{"id":"cde5016da5b04c7eafd970ac9ef14286","type":"GENE","name":"RPS19P4","canonical_id":"hgnc:HGNC:35778","description":"ribosomal protein S19 pseudogene 4","metadata":null},{"id":"c67b4b45f8204c47981631c1118b7ad5","type":"GENE","name":"RPS19P5","canonical_id":"hgnc:HGNC:35850","description":"ribosomal protein S19 pseudogene 5","metadata":null},{"id":"5df109e979a34df3811ec413f0a8893b","type":"GENE","name":"RPS19P6","canonical_id":"hgnc:HGNC:36217","description":"ribosomal protein S19 pseudogene 6","metadata":null},{"id":"f412244d1b7b40ddb7c31db679a76c14","type":"GENE","name":"RPS19P7","canonical_id":"hgnc:HGNC:35550","description":"ribosomal protein S19 pseudogene 7","metadata":null},{"id":"f53b465383444ab5b8495216ad61a0e2","type":"GENE","name":"RPS2","canonical_id":"hgnc:HGNC:10404","description":"ribosomal protein S2","metadata":{"aliases":["LLREP3","S2","uS5"]}},{"id":"518c9802d9ea4e26863c7d771d83be30","type":"GENE","name":"RPS20","canonical_id":"hgnc:HGNC:10405","description":"ribosomal protein S20","metadata":{"aliases":["S20","uS10"]}},{"id":"1418056c72304f419d7c6fc05ecb1c6f","type":"GENE","name":"RPS20P1","canonical_id":"hgnc:HGNC:10408","description":"ribosomal protein S20 pseudogene 1","metadata":{"aliases":["RPS20P"]}},{"id":"f5bb9ae65d704fa1a749158db2362686","type":"GENE","name":"RPS20P10","canonical_id":"hgnc:HGNC:36800","description":"ribosomal protein S20 pseudogene 10","metadata":null},{"id":"526b6cb1b0d24a73b781cd0062f07f16","type":"GENE","name":"RPS20P11","canonical_id":"hgnc:HGNC:36084","description":"ribosomal protein S20 pseudogene 11","metadata":null},{"id":"229506c03acb47c1aa0de571ce5eb85d","type":"GENE","name":"RPS20P12","canonical_id":"hgnc:HGNC:36519","description":"ribosomal protein S20 pseudogene 12","metadata":null},{"id":"dffeea691db94c5ebf9b753cc585bfca","type":"GENE","name":"RPS20P13","canonical_id":"hgnc:HGNC:36071","description":"ribosomal protein S20 pseudogene 13","metadata":null},{"id":"48788af06f144073baed2cf271b42c3b","type":"GENE","name":"RPS20P14","canonical_id":"hgnc:HGNC:36692","description":"ribosomal protein S20 pseudogene 14","metadata":null},{"id":"a18e5657c4c44fbaa4163a6245bae64a","type":"GENE","name":"RPS20P15","canonical_id":"hgnc:HGNC:36340","description":"ribosomal protein S20 pseudogene 15","metadata":null},{"id":"a45b35f64fb14affaed3fd8be10bdbc0","type":"GENE","name":"RPS20P16","canonical_id":"hgnc:HGNC:35851","description":"ribosomal protein S20 pseudogene 16","metadata":null},{"id":"83989530337549b1800154f3dd096dc9","type":"GENE","name":"RPS20P17","canonical_id":"hgnc:HGNC:35822","description":"ribosomal protein S20 pseudogene 17","metadata":null},{"id":"a93b14b756324649b05df3ced07e70fb","type":"GENE","name":"RPS20P18","canonical_id":"hgnc:HGNC:36937","description":"ribosomal protein S20 pseudogene 18","metadata":null},{"id":"ab9db388ad3146089a22a19c3bde41fc","type":"GENE","name":"RPS20P19","canonical_id":"hgnc:HGNC:36503","description":"ribosomal protein S20 pseudogene 19","metadata":null},{"id":"523e703a4cc14ab38bbf081adb6237f2","type":"GENE","name":"RPS20P2","canonical_id":"hgnc:HGNC:14195","description":"ribosomal protein S20 pseudogene 2","metadata":null},{"id":"a1e54a97d02f43c79467a5f19943f162","type":"GENE","name":"RPS20P20","canonical_id":"hgnc:HGNC:36674","description":"ribosomal protein S20 pseudogene 20","metadata":null},{"id":"1b3adf46d2084f2eb6ba7708b0458740","type":"GENE","name":"RPS20P21","canonical_id":"hgnc:HGNC:35993","description":"ribosomal protein S20 pseudogene 21","metadata":null},{"id":"2d0439449c534e449663760c332d0e4c","type":"GENE","name":"RPS20P22","canonical_id":"hgnc:HGNC:36379","description":"ribosomal protein S20 pseudogene 22","metadata":null},{"id":"26d9da89edb44db6967508729a733e86","type":"GENE","name":"RPS20P23","canonical_id":"hgnc:HGNC:36146","description":"ribosomal protein S20 pseudogene 23","metadata":null},{"id":"e06e3fb6fbc547c9ab9731ca45b0fe4a","type":"GENE","name":"RPS20P24","canonical_id":"hgnc:HGNC:36283","description":"ribosomal protein S20 pseudogene 24","metadata":null},{"id":"2c3de0a3a81842c08908e43f0b66f02b","type":"GENE","name":"RPS20P25","canonical_id":"hgnc:HGNC:35866","description":"ribosomal protein S20 pseudogene 25","metadata":null},{"id":"ec1de950a4ae4465aec6f233c56ad787","type":"GENE","name":"RPS20P26","canonical_id":"hgnc:HGNC:36980","description":"ribosomal protein S20 pseudogene 26","metadata":null},{"id":"66e8057c7a464607b764c1aacf45758b","type":"GENE","name":"RPS20P27","canonical_id":"hgnc:HGNC:36154","description":"ribosomal protein S20 pseudogene 27","metadata":null},{"id":"c3d47054d567409c9e63ab382caf85e0","type":"GENE","name":"RPS20P28","canonical_id":"hgnc:HGNC:36452","description":"ribosomal protein S20 pseudogene 28","metadata":null},{"id":"7b32e3fd44984fad91aeec7bfe5b2783","type":"GENE","name":"RPS20P29","canonical_id":"hgnc:HGNC:36237","description":"ribosomal protein S20 pseudogene 29","metadata":null},{"id":"f3194fb7b1844287b31ada5affd1f690","type":"GENE","name":"RPS20P3","canonical_id":"hgnc:HGNC:10406","description":"ribosomal protein S20 pseudogene 3","metadata":{"aliases":["RPS20A"]}},{"id":"96b4a41e679641ea94ed768e6f01ff42","type":"GENE","name":"RPS20P30","canonical_id":"hgnc:HGNC:36626","description":"ribosomal protein S20 pseudogene 30","metadata":null},{"id":"e4fc7d0967c0499ca106543bc2ffd2a0","type":"GENE","name":"RPS20P31","canonical_id":"hgnc:HGNC:35767","description":"ribosomal protein S20 pseudogene 31","metadata":null},{"id":"39d829a250ac40e3888cbacd8ac242f3","type":"GENE","name":"RPS20P32","canonical_id":"hgnc:HGNC:36444","description":"ribosomal protein S20 pseudogene 32","metadata":null},{"id":"f641b58f208f4a5ebf9ea9342581e85f","type":"GENE","name":"RPS20P33","canonical_id":"hgnc:HGNC:36725","description":"ribosomal protein S20 pseudogene 33","metadata":null},{"id":"6847de803b924f9c99339c1b48608d2b","type":"GENE","name":"RPS20P34","canonical_id":"hgnc:HGNC:36668","description":"ribosomal protein S20 pseudogene 34","metadata":null},{"id":"2dab1578408641f68a5d87e79751accf","type":"GENE","name":"RPS20P35","canonical_id":"hgnc:HGNC:36929","description":"ribosomal protein S20 pseudogene 35","metadata":null},{"id":"6c8588c55acb4e3e97466ec4adaf6009","type":"GENE","name":"RPS20P4","canonical_id":"hgnc:HGNC:10407","description":"ribosomal protein S20 pseudogene 4","metadata":{"aliases":["RPS20B"]}},{"id":"84d61e156ae54b4291f0cb6c185ad4ec","type":"GENE","name":"RPS20P5","canonical_id":"hgnc:HGNC:36367","description":"ribosomal protein S20 pseudogene 5","metadata":null},{"id":"bdfff4cce9b748df9534d7dbf85e9c30","type":"GENE","name":"RPS20P6","canonical_id":"hgnc:HGNC:35629","description":"ribosomal protein S20 pseudogene 6","metadata":null},{"id":"3e3bd80a25b74edaabe5b61cb31164cd","type":"GENE","name":"RPS20P7","canonical_id":"hgnc:HGNC:35911","description":"ribosomal protein S20 pseudogene 7","metadata":null},{"id":"e1206ed38f0948e69c9409b3449f26ca","type":"GENE","name":"RPS20P8","canonical_id":"hgnc:HGNC:35770","description":"ribosomal protein S20 pseudogene 8","metadata":null},{"id":"ed99cecb51014895bcd85fb26373e977","type":"GENE","name":"RPS20P9","canonical_id":"hgnc:HGNC:36472","description":"ribosomal protein S20 pseudogene 9","metadata":null},{"id":"681396cb5a8a4ebe96dbe6385574f032","type":"GENE","name":"RPS21","canonical_id":"hgnc:HGNC:10409","description":"ribosomal protein S21","metadata":{"aliases":["S21","eS21"]}},{"id":"a06cfbdbe66142edad637d7ead040f4a","type":"GENE","name":"RPS21-DT","canonical_id":"hgnc:HGNC:56740","description":"RPS21 divergent transcript","metadata":{"aliases":["AL121832.2"]}},{"id":"0a3ff13451a7493aa87201a606dce46f","type":"GENE","name":"RPS21P1","canonical_id":"hgnc:HGNC:36401","description":"ribosomal protein S21 pseudogene 1","metadata":null},{"id":"0b86fb11bda84db29aad12d675ef1345","type":"GENE","name":"RPS21P2","canonical_id":"hgnc:HGNC:36191","description":"ribosomal protein S21 pseudogene 2","metadata":null},{"id":"b1a7669289e84ea7a83055a39729cb32","type":"GENE","name":"RPS21P3","canonical_id":"hgnc:HGNC:36847","description":"ribosomal protein S21 pseudogene 3","metadata":null},{"id":"63a5f901ccd840e8a62caf6f8a6bdebe","type":"GENE","name":"RPS21P4","canonical_id":"hgnc:HGNC:35922","description":"ribosomal protein S21 pseudogene 4","metadata":null},{"id":"f94089a0597043bcb7d501e45d5b6bfa","type":"GENE","name":"RPS21P5","canonical_id":"hgnc:HGNC:36359","description":"ribosomal protein S21 pseudogene 5","metadata":null},{"id":"7b0723445aea4d35ba51477fda6a91c5","type":"GENE","name":"RPS21P6","canonical_id":"hgnc:HGNC:36317","description":"ribosomal protein S21 pseudogene 6","metadata":null},{"id":"700449f3ee124896bd3a42ef3f598c76","type":"GENE","name":"RPS21P7","canonical_id":"hgnc:HGNC:35577","description":"ribosomal protein S21 pseudogene 7","metadata":null},{"id":"f1eaf294124a4c90afbeef578a78c66c","type":"GENE","name":"RPS21P8","canonical_id":"hgnc:HGNC:39705","description":"ribosomal protein S21 pseudogene 8","metadata":null},{"id":"8a12d2c4f423465498adce6cdaf79e84","type":"GENE","name":"RPS23","canonical_id":"hgnc:HGNC:10410","description":"ribosomal protein S23","metadata":{"aliases":["S23","uS12"]}},{"id":"07c2ad8146a042ecb72ee61b305c24a4","type":"GENE","name":"RPS23P1","canonical_id":"hgnc:HGNC:16043","description":"ribosomal protein S23 pseudogene 1","metadata":{"aliases":["RPS23RG1"]}},{"id":"882bf7f2640549dc8607921b6748d5d5","type":"GENE","name":"RPS23P10","canonical_id":"hgnc:HGNC:48342","description":"ribosomal protein S23 pseudogene 10","metadata":null},{"id":"96c9de36bf3249f09454ac01ed6a1ccf","type":"GENE","name":"RPS23P2","canonical_id":"hgnc:HGNC:36568","description":"ribosomal protein S23 pseudogene 2","metadata":null},{"id":"f2de035f2b28471cba2eb10d89a8387b","type":"GENE","name":"RPS23P3","canonical_id":"hgnc:HGNC:35499","description":"ribosomal protein S23 pseudogene 3","metadata":null},{"id":"e3b40174b80143b794a9a7e9f6d517a3","type":"GENE","name":"RPS23P4","canonical_id":"hgnc:HGNC:36633","description":"ribosomal protein S23 pseudogene 4","metadata":null},{"id":"96e9b908d2c14913af6121a44658d42b","type":"GENE","name":"RPS23P5","canonical_id":"hgnc:HGNC:35726","description":"ribosomal protein S23 pseudogene 5","metadata":null},{"id":"0217636bd7f140a5b2607d2d2a278f29","type":"GENE","name":"RPS23P6","canonical_id":"hgnc:HGNC:36511","description":"ribosomal protein S23 pseudogene 6","metadata":null},{"id":"97245de92aa94935a6fde175ce802488","type":"GENE","name":"RPS23P7","canonical_id":"hgnc:HGNC:43899","description":"ribosomal protein S23 pseudogene 7","metadata":null},{"id":"c4899e08081e46e7ab02f4ff51218229","type":"GENE","name":"RPS23P8","canonical_id":"hgnc:HGNC:35982","description":"ribosomal protein S23 pseudogene 8","metadata":null},{"id":"918adb5e658942de917b6ea731052dcb","type":"GENE","name":"RPS23P9","canonical_id":"hgnc:HGNC:48341","description":"ribosomal protein S23 pseudogene 9","metadata":null},{"id":"3c9ed06084904c328600d89e54705d59","type":"GENE","name":"RPS24","canonical_id":"hgnc:HGNC:10411","description":"ribosomal protein S24","metadata":{"aliases":["S24","eS24"]}},{"id":"528a376c0de6410abfc0164e342cf25f","type":"GENE","name":"RPS24P1","canonical_id":"hgnc:HGNC:10412","description":"ribosomal protein S24 pseudogene 1","metadata":{"aliases":["RPS24P"]}},{"id":"7870ac87f38c4346bdeeb3d54fabba51","type":"GENE","name":"RPS24P10","canonical_id":"hgnc:HGNC:36554","description":"ribosomal protein S24 pseudogene 10","metadata":null},{"id":"bb9cdf980eb04670857b704657d0c3e1","type":"GENE","name":"RPS24P11","canonical_id":"hgnc:HGNC:36050","description":"ribosomal protein S24 pseudogene 11","metadata":null},{"id":"fd826a7a9b1c44838931897472fa6dc6","type":"GENE","name":"RPS24P12","canonical_id":"hgnc:HGNC:35623","description":"ribosomal protein S24 pseudogene 12","metadata":null},{"id":"1f56fbc167e0480093cee3386db80aa6","type":"GENE","name":"RPS24P13","canonical_id":"hgnc:HGNC:36805","description":"ribosomal protein S24 pseudogene 13","metadata":null},{"id":"153d785953664567ab27d12fa34ed7ae","type":"GENE","name":"RPS24P14","canonical_id":"hgnc:HGNC:35744","description":"ribosomal protein S24 pseudogene 14","metadata":null},{"id":"1de25ad8050d4cd584418cea17402c7e","type":"GENE","name":"RPS24P15","canonical_id":"hgnc:HGNC:35665","description":"ribosomal protein S24 pseudogene 15","metadata":null},{"id":"3cc641c57db64d328aa044d4cb3f877e","type":"GENE","name":"RPS24P16","canonical_id":"hgnc:HGNC:35542","description":"ribosomal protein S24 pseudogene 16","metadata":null},{"id":"6d4224b629ad44f79019b08d38443cbf","type":"GENE","name":"RPS24P17","canonical_id":"hgnc:HGNC:36348","description":"ribosomal protein S24 pseudogene 17","metadata":null},{"id":"b53dffa8fa0c49f085aa5d7bff0ea8c3","type":"GENE","name":"RPS24P18","canonical_id":"hgnc:HGNC:36745","description":"ribosomal protein S24 pseudogene 18","metadata":null},{"id":"8178de7c2e8d409db5cc8baafb69a459","type":"GENE","name":"RPS24P19","canonical_id":"hgnc:HGNC:35683","description":"ribosomal protein S24 pseudogene 19","metadata":null},{"id":"8a2087bee9524cd4b6c6f227a083d945","type":"GENE","name":"RPS24P2","canonical_id":"hgnc:HGNC:19791","description":"ribosomal protein S24 pseudogene 2","metadata":null},{"id":"90475a9996254901b7a042a60401210a","type":"GENE","name":"RPS24P21","canonical_id":"hgnc:HGNC:54883","description":"ribosomal protein S24 pseudogene 21","metadata":null},{"id":"baeec82199e7483d9004746f1319d57f","type":"GENE","name":"RPS24P3","canonical_id":"hgnc:HGNC:19797","description":"ribosomal protein S24 pseudogene 3","metadata":null},{"id":"06d7f83d07704f64a73d90d60404d7eb","type":"GENE","name":"RPS24P4","canonical_id":"hgnc:HGNC:35852","description":"ribosomal protein S24 pseudogene 4","metadata":null},{"id":"22f429b09ae843ee9787f0d31ccada10","type":"GENE","name":"RPS24P5","canonical_id":"hgnc:HGNC:36026","description":"ribosomal protein S24 pseudogene 5","metadata":null},{"id":"fa870a5508d54b90b0ac1f6a41cca2ed","type":"GENE","name":"RPS24P6","canonical_id":"hgnc:HGNC:36240","description":"ribosomal protein S24 pseudogene 6","metadata":null},{"id":"1cbb2b0cc6ce40f1aaa31d89c156395f","type":"GENE","name":"RPS24P7","canonical_id":"hgnc:HGNC:35737","description":"ribosomal protein S24 pseudogene 7","metadata":null},{"id":"6888ceb1c48949bfb2649370f7c7e972","type":"GENE","name":"RPS24P8","canonical_id":"hgnc:HGNC:37016","description":"ribosomal protein S24 pseudogene 8","metadata":null},{"id":"6220d6bb55c14e4a9cc36380200da136","type":"GENE","name":"RPS24P9","canonical_id":"hgnc:HGNC:35711","description":"ribosomal protein S24 pseudogene 9","metadata":null},{"id":"96f6aa59dbb1407ca1ac8fc868da2cc3","type":"GENE","name":"RPS25","canonical_id":"hgnc:HGNC:10413","description":"ribosomal protein S25","metadata":{"aliases":["S25","eS25"]}},{"id":"95d44ebb8e29444cb2c9c2b6c237ea3a","type":"GENE","name":"RPS25P1","canonical_id":"hgnc:HGNC:34027","description":"ribosomal protein S25 pseudogene 1","metadata":null},{"id":"688e6922fc334d05b36ff1c79c4f366f","type":"GENE","name":"RPS25P10","canonical_id":"hgnc:HGNC:36078","description":"ribosomal protein S25 pseudogene 10","metadata":null},{"id":"2787a8187a27433c9c1743d5f5795ecd","type":"GENE","name":"RPS25P2","canonical_id":"hgnc:HGNC:36701","description":"ribosomal protein S25 pseudogene 2","metadata":null},{"id":"30403cdad54b47b58bedf76c0db111b8","type":"GENE","name":"RPS25P3","canonical_id":"hgnc:HGNC:36073","description":"ribosomal protein S25 pseudogene 3","metadata":null},{"id":"9d5416bc625e4a74a2f2cd5360854556","type":"GENE","name":"RPS25P4","canonical_id":"hgnc:HGNC:35669","description":"ribosomal protein S25 pseudogene 4","metadata":null},{"id":"2c12b89e48094590841558ddb1a75a19","type":"GENE","name":"RPS25P5","canonical_id":"hgnc:HGNC:35788","description":"ribosomal protein S25 pseudogene 5","metadata":null},{"id":"dddd6875e94f4ed9ab8a974c38a28e04","type":"GENE","name":"RPS25P6","canonical_id":"hgnc:HGNC:35532","description":"ribosomal protein S25 pseudogene 6","metadata":null},{"id":"3cc7ac06d41541e589b5bd113f667dbc","type":"GENE","name":"RPS25P7","canonical_id":"hgnc:HGNC:36585","description":"ribosomal protein S25 pseudogene 7","metadata":null},{"id":"89b11d2e50f64684bf263f5a0a0282cb","type":"GENE","name":"RPS25P8","canonical_id":"hgnc:HGNC:36075","description":"ribosomal protein S25 pseudogene 8","metadata":null},{"id":"a9c7818717eb46dd961600071ef931cd","type":"GENE","name":"RPS25P9","canonical_id":"hgnc:HGNC:36936","description":"ribosomal protein S25 pseudogene 9","metadata":null},{"id":"09918c1b7e7644d18e503b2a5607721d","type":"GENE","name":"RPS26","canonical_id":"hgnc:HGNC:10414","description":"ribosomal protein S26","metadata":{"aliases":["S26","eS26"]}},{"id":"8994321bea9b4903822c7200460465a6","type":"GENE","name":"RPS26P1","canonical_id":"hgnc:HGNC:10415","description":"ribosomal protein S26 pseudogene 1","metadata":{"aliases":["RPS26P"]}},{"id":"7d9545f622e940a0bb2272cd32885326","type":"GENE","name":"RPS26P10","canonical_id":"hgnc:HGNC:32201","description":"ribosomal protein S26 pseudogene 10","metadata":null},{"id":"5edcf8fb8f6c4a27b9268c9b84e8a8ce","type":"GENE","name":"RPS26P11","canonical_id":"hgnc:HGNC:31817","description":"ribosomal protein S26 pseudogene 11","metadata":{"aliases":["bA366E13.1","RPS26L1"]}},{"id":"4d60551fdabc465a9021e5c4cf691e28","type":"GENE","name":"RPS26P12","canonical_id":"hgnc:HGNC:35487","description":"ribosomal protein S26 pseudogene 12","metadata":null},{"id":"41eee2ebc7164123b405b794debef9b1","type":"GENE","name":"RPS26P13","canonical_id":"hgnc:HGNC:35784","description":"ribosomal protein S26 pseudogene 13","metadata":null},{"id":"c51abf48bf354379bbbde23b039b371b","type":"GENE","name":"RPS26P14","canonical_id":"hgnc:HGNC:36992","description":"ribosomal protein S26 pseudogene 14","metadata":null},{"id":"005905d50aaa4846bf841f4deeb9bb2a","type":"GENE","name":"RPS26P15","canonical_id":"hgnc:HGNC:35680","description":"ribosomal protein S26 pseudogene 15","metadata":null},{"id":"8e7d5daacb164733a160214d932e81bd","type":"GENE","name":"RPS26P16","canonical_id":"hgnc:HGNC:35557","description":"ribosomal protein S26 pseudogene 16","metadata":null},{"id":"de45d58f7ecc4eeea2575eaf8f4e6382","type":"GENE","name":"RPS26P17","canonical_id":"hgnc:HGNC:36681","description":"ribosomal protein S26 pseudogene 17","metadata":null},{"id":"f715ad08569c47f7989163e1cdac0973","type":"GENE","name":"RPS26P18","canonical_id":"hgnc:HGNC:35782","description":"ribosomal protein S26 pseudogene 18","metadata":null},{"id":"2164c0da241648c4b733cf47c09405e5","type":"GENE","name":"RPS26P19","canonical_id":"hgnc:HGNC:36377","description":"ribosomal protein S26 pseudogene 19","metadata":null},{"id":"6b19bfc886544019a055210609630172","type":"GENE","name":"RPS26P2","canonical_id":"hgnc:HGNC:23662","description":"ribosomal protein S26 pseudogene 2","metadata":{"aliases":["bA98O11.1"]}},{"id":"01c998adf9ae45e58b201e1e1b1433d0","type":"GENE","name":"RPS26P20","canonical_id":"hgnc:HGNC:36485","description":"ribosomal protein S26 pseudogene 20","metadata":null},{"id":"67c60efdb27f4a8885b77b16eb8a7810","type":"GENE","name":"RPS26P21","canonical_id":"hgnc:HGNC:36469","description":"ribosomal protein S26 pseudogene 21","metadata":null},{"id":"4318bb123f02412791c8d60a68221331","type":"GENE","name":"RPS26P22","canonical_id":"hgnc:HGNC:36261","description":"ribosomal protein S26 pseudogene 22","metadata":null},{"id":"26c76e01b1aa494c9a22f3650d0ef7b3","type":"GENE","name":"RPS26P23","canonical_id":"hgnc:HGNC:36332","description":"ribosomal protein S26 pseudogene 23","metadata":null},{"id":"390482ee6404420ca26717bdf39300af","type":"GENE","name":"RPS26P24","canonical_id":"hgnc:HGNC:36917","description":"ribosomal protein S26 pseudogene 24","metadata":null},{"id":"8edd899d6f12448da3084689135f0e75","type":"GENE","name":"RPS26P25","canonical_id":"hgnc:HGNC:35730","description":"ribosomal protein S26 pseudogene 25","metadata":null},{"id":"bfbb1e636ea741a8b7179b5fe9f9e523","type":"GENE","name":"RPS26P26","canonical_id":"hgnc:HGNC:36029","description":"ribosomal protein S26 pseudogene 26","metadata":null},{"id":"a7012366a7d646aebd1cf61c36527427","type":"GENE","name":"RPS26P27","canonical_id":"hgnc:HGNC:35636","description":"ribosomal protein S26 pseudogene 27","metadata":null},{"id":"1c98a2b5a36144d18ed58608f1523930","type":"GENE","name":"RPS26P28","canonical_id":"hgnc:HGNC:36149","description":"ribosomal protein S26 pseudogene 28","metadata":null},{"id":"a3ba4866988949ea8f90049ee8dc470c","type":"GENE","name":"RPS26P29","canonical_id":"hgnc:HGNC:36456","description":"ribosomal protein S26 pseudogene 29","metadata":null},{"id":"68b7e50224804ad6bef0ee5f3a69cc15","type":"GENE","name":"RPS26P3","canonical_id":"hgnc:HGNC:23411","description":"ribosomal protein S26 pseudogene 3","metadata":{"aliases":["bA338L20.1"]}},{"id":"88eee3a565e14ff8baeea494b31974b3","type":"GENE","name":"RPS26P30","canonical_id":"hgnc:HGNC:35574","description":"ribosomal protein S26 pseudogene 30","metadata":null},{"id":"29352ce1db3f4535b3f0b607b91bfe65","type":"GENE","name":"RPS26P31","canonical_id":"hgnc:HGNC:36614","description":"ribosomal protein S26 pseudogene 31","metadata":null},{"id":"3791b949d3f642688e18f076986c0ee6","type":"GENE","name":"RPS26P32","canonical_id":"hgnc:HGNC:35753","description":"ribosomal protein S26 pseudogene 32","metadata":null},{"id":"63f60320095b450fab264442884fe92b","type":"GENE","name":"RPS26P33","canonical_id":"hgnc:HGNC:36227","description":"ribosomal protein S26 pseudogene 33","metadata":null},{"id":"d19f7f86b8294d1c805b5d281af37e38","type":"GENE","name":"RPS26P34","canonical_id":"hgnc:HGNC:36894","description":"ribosomal protein S26 pseudogene 34","metadata":null},{"id":"dc83b0a105dd4714b3e058663976c4e4","type":"GENE","name":"RPS26P35","canonical_id":"hgnc:HGNC:36229","description":"ribosomal protein S26 pseudogene 35","metadata":null},{"id":"b6cec4d045a14159a843e59075469c36","type":"GENE","name":"RPS26P36","canonical_id":"hgnc:HGNC:36561","description":"ribosomal protein S26 pseudogene 36","metadata":null},{"id":"d19c566d52024d4f9f18c1318b90a3ac","type":"GENE","name":"RPS26P37","canonical_id":"hgnc:HGNC:36875","description":"ribosomal protein S26 pseudogene 37","metadata":null},{"id":"10b6874f88a6400698efe9770aaea3c2","type":"GENE","name":"RPS26P38","canonical_id":"hgnc:HGNC:36406","description":"ribosomal protein S26 pseudogene 38","metadata":null},{"id":"f6bfa4a438744bf795c6a3817e5fd8a2","type":"GENE","name":"RPS26P39","canonical_id":"hgnc:HGNC:36958","description":"ribosomal protein S26 pseudogene 39","metadata":null},{"id":"f0f4ef1525fd40c5ac871f4019e6ca88","type":"GENE","name":"RPS26P4","canonical_id":"hgnc:HGNC:23775","description":"ribosomal protein S26 pseudogene 4","metadata":null},{"id":"7d7c2fc714114bc0ade874d8102bc1bf","type":"GENE","name":"RPS26P40","canonical_id":"hgnc:HGNC:36906","description":"ribosomal protein S26 pseudogene 40","metadata":null},{"id":"4d1d30b170a4487a85d5c1da4fe8ff72","type":"GENE","name":"RPS26P41","canonical_id":"hgnc:HGNC:36062","description":"ribosomal protein S26 pseudogene 41","metadata":null},{"id":"81b1575bf024490e96b8240da2f46549","type":"GENE","name":"RPS26P42","canonical_id":"hgnc:HGNC:36243","description":"ribosomal protein S26 pseudogene 42","metadata":null},{"id":"382d692a76284f20bb7216d38f61bca2","type":"GENE","name":"RPS26P43","canonical_id":"hgnc:HGNC:36675","description":"ribosomal protein S26 pseudogene 43","metadata":null},{"id":"16f12e673610499dbceb2718955b5cc0","type":"GENE","name":"RPS26P44","canonical_id":"hgnc:HGNC:36927","description":"ribosomal protein S26 pseudogene 44","metadata":null},{"id":"6c51f12834d84539ab2c92ce1e1a54da","type":"GENE","name":"RPS26P45","canonical_id":"hgnc:HGNC:36944","description":"ribosomal protein S26 pseudogene 45","metadata":null},{"id":"50558bf9d9314ab3ae3ef01aa8408cfc","type":"GENE","name":"RPS26P46","canonical_id":"hgnc:HGNC:35807","description":"ribosomal protein S26 pseudogene 46","metadata":null},{"id":"b1b5284d1afe423a97e433649fa0e651","type":"GENE","name":"RPS26P47","canonical_id":"hgnc:HGNC:36368","description":"ribosomal protein S26 pseudogene 47","metadata":null},{"id":"d48e8bf5d62e4687acc96a0f50741adc","type":"GENE","name":"RPS26P48","canonical_id":"hgnc:HGNC:35519","description":"ribosomal protein S26 pseudogene 48","metadata":null},{"id":"de1678e14a9b4968bc5fe0fad45a5c6a","type":"GENE","name":"RPS26P49","canonical_id":"hgnc:HGNC:35514","description":"ribosomal protein S26 pseudogene 49","metadata":null},{"id":"a86678f8836f4e96b571c039ceb7c3a0","type":"GENE","name":"RPS26P5","canonical_id":"hgnc:HGNC:23776","description":"ribosomal protein S26 pseudogene 5","metadata":null},{"id":"ceba2a0853634d1597651ec24cf8b03a","type":"GENE","name":"RPS26P50","canonical_id":"hgnc:HGNC:35615","description":"ribosomal protein S26 pseudogene 50","metadata":null},{"id":"c6a0cc0ad7bf4ebba5b1f22fd657374b","type":"GENE","name":"RPS26P51","canonical_id":"hgnc:HGNC:36254","description":"ribosomal protein S26 pseudogene 51","metadata":null},{"id":"78e035daf0324c88a5e282d5226ee681","type":"GENE","name":"RPS26P52","canonical_id":"hgnc:HGNC:36863","description":"ribosomal protein S26 pseudogene 52","metadata":null},{"id":"136bd0b6d5294e03b9d234e78c9526cd","type":"GENE","name":"RPS26P53","canonical_id":"hgnc:HGNC:35582","description":"ribosomal protein S26 pseudogene 53","metadata":null},{"id":"96849fd7b8e347f5b7fbfd6941b4546f","type":"GENE","name":"RPS26P54","canonical_id":"hgnc:HGNC:36868","description":"ribosomal protein S26 pseudogene 54","metadata":null},{"id":"9c96d8a69e5141538b12f81e27de148a","type":"GENE","name":"RPS26P55","canonical_id":"hgnc:HGNC:36500","description":"ribosomal protein S26 pseudogene 55","metadata":null},{"id":"c8f33e03e82c453280f913d957d6576b","type":"GENE","name":"RPS26P56","canonical_id":"hgnc:HGNC:35858","description":"ribosomal protein S26 pseudogene 56","metadata":null},{"id":"789d0eb93c604e79b66859e915376edd","type":"GENE","name":"RPS26P57","canonical_id":"hgnc:HGNC:36537","description":"ribosomal protein S26 pseudogene 57","metadata":null},{"id":"5177c99fec2d480cb40db2f651c72740","type":"GENE","name":"RPS26P58","canonical_id":"hgnc:HGNC:36571","description":"ribosomal protein S26 pseudogene 58","metadata":null},{"id":"8b96a17f5f664d8b9287b6efb392cd22","type":"GENE","name":"RPS26P59","canonical_id":"hgnc:HGNC:56982","description":"ribosomal protein S26 pseudogene 59","metadata":null},{"id":"746d93aee9c64806aad12f60d23ad9d0","type":"GENE","name":"RPS26P6","canonical_id":"hgnc:HGNC:31090","description":"ribosomal protein S26 pseudogene 6","metadata":null},{"id":"ecdd8d689eb0412fb8b2eb28c92dcc9b","type":"GENE","name":"RPS26P7","canonical_id":"hgnc:HGNC:20077","description":"ribosomal protein S26 pseudogene 7","metadata":{"aliases":["HsT24280"]}},{"id":"232126c570354a4298967f742e82af01","type":"GENE","name":"RPS26P8","canonical_id":"hgnc:HGNC:31329","description":"ribosomal protein S26 pseudogene 8","metadata":null},{"id":"7828bc51c3754bdfbafe3507b9d62794","type":"GENE","name":"RPS26P9","canonical_id":"hgnc:HGNC:31821","description":"ribosomal protein S26 pseudogene 9","metadata":null},{"id":"0c25af63d266449aa0591f18333ff800","type":"GENE","name":"RPS27","canonical_id":"hgnc:HGNC:10416","description":"ribosomal protein S27","metadata":{"aliases":["MPS-1","MPS1","S27","eS27"]}},{"id":"e2eceb65a57e495eb5482eccc8c34da9","type":"GENE","name":"RPS27A","canonical_id":"hgnc:HGNC:10417","description":"ribosomal protein S27a","metadata":{"aliases":["UBCEP80","Uba80","S27A","eS31"]}},{"id":"6ac44c6be0a949469c2124daeba0472a","type":"GENE","name":"RPS27AP1","canonical_id":"hgnc:HGNC:17121","description":"RPS27A pseudogene 1","metadata":{"aliases":["RPS27AP"]}},{"id":"6f38b6bf746b497aa47dbff8881e6485","type":"GENE","name":"RPS27AP10","canonical_id":"hgnc:HGNC:36570","description":"RPS27A pseudogene 10","metadata":null},{"id":"b910c53e635747109fca1f1accc41f52","type":"GENE","name":"RPS27AP11","canonical_id":"hgnc:HGNC:36126","description":"RPS27A pseudogene 11","metadata":null},{"id":"4bf5b67149d242dd94ce0a0cf7c4a492","type":"GENE","name":"RPS27AP12","canonical_id":"hgnc:HGNC:35732","description":"RPS27A pseudogene 12","metadata":null},{"id":"d9051146a4284d96b6891e3974f09445","type":"GENE","name":"RPS27AP13","canonical_id":"hgnc:HGNC:36667","description":"RPS27A pseudogene 13","metadata":null},{"id":"541f3d1c81c642d5bd8fc908288dd536","type":"GENE","name":"RPS27AP14","canonical_id":"hgnc:HGNC:36530","description":"RPS27A pseudogene 14","metadata":null},{"id":"77339d1ae3b2403690f14caaef0f02ee","type":"GENE","name":"RPS27AP15","canonical_id":"hgnc:HGNC:35817","description":"RPS27A pseudogene 15","metadata":null},{"id":"1c86a1d9380440f49fe74c0036af72e2","type":"GENE","name":"RPS27AP16","canonical_id":"hgnc:HGNC:36855","description":"RPS27A pseudogene 16","metadata":null},{"id":"0bfb0ce23e36403f9f128a92ffe5a81f","type":"GENE","name":"RPS27AP17","canonical_id":"hgnc:HGNC:36877","description":"RPS27A pseudogene 17","metadata":null},{"id":"84d9ffc52c33492fb151cc88ef97d43c","type":"GENE","name":"RPS27AP18","canonical_id":"hgnc:HGNC:52299","description":"RPS27A pseudogene 18","metadata":null},{"id":"b5ae2ee5b8b34cce97d06690630f2bc2","type":"GENE","name":"RPS27AP19","canonical_id":"hgnc:HGNC:52298","description":"RPS27A pseudogene 19","metadata":null},{"id":"e8f4bca6704043d8aadfb8e8bb16314f","type":"GENE","name":"RPS27AP2","canonical_id":"hgnc:HGNC:16572","description":"RPS27A pseudogene 2","metadata":{"aliases":["dJ531H16.4","LncRNApcsk2-2:1"]}},{"id":"4d838cc72f7644c5847b28489798bac7","type":"GENE","name":"RPS27AP20","canonical_id":"hgnc:HGNC:54884","description":"RPS27A pseudogene 20","metadata":null},{"id":"9eaa1d2bbe2f402ea2d02889e7ac315d","type":"GENE","name":"RPS27AP3","canonical_id":"hgnc:HGNC:16538","description":"RPS27A pseudogene 3","metadata":{"aliases":["bA332A4.3","RPS27AP"]}},{"id":"5ae0e694b515453f9fb9c3f130608380","type":"GENE","name":"RPS27AP4","canonical_id":"hgnc:HGNC:19775","description":"RPS27A pseudogene 4","metadata":null},{"id":"63557338bd2346989a3c299ee3da6ec4","type":"GENE","name":"RPS27AP5","canonical_id":"hgnc:HGNC:36867","description":"ribosomal protein S27a pseudogene 5","metadata":null},{"id":"e5201a7d09b648e08e92a5f740bb8f72","type":"GENE","name":"RPS27AP6","canonical_id":"hgnc:HGNC:36236","description":"RPS27A pseudogene 6","metadata":null},{"id":"fac54d1cefc44c4d891fde522badaf12","type":"GENE","name":"RPS27AP7","canonical_id":"hgnc:HGNC:35735","description":"RPS27A pseudogene 7","metadata":null},{"id":"6f2722750b00487a849464fb57818706","type":"GENE","name":"RPS27AP8","canonical_id":"hgnc:HGNC:36361","description":"RPS27A pseudogene 8","metadata":null},{"id":"cac0eeaf43e34a6ebf2ed5f926aa0ab6","type":"GENE","name":"RPS27AP9","canonical_id":"hgnc:HGNC:35630","description":"RPS27A pseudogene 9","metadata":null},{"id":"a776deb280ef4eadb67c13aaafdb8def","type":"GENE","name":"RPS27L","canonical_id":"hgnc:HGNC:18476","description":"ribosomal protein S27 like","metadata":null},{"id":"bd88156446164fe8a58fcb9f451c4317","type":"GENE","name":"RPS27P1","canonical_id":"hgnc:HGNC:23740","description":"ribosomal protein S27 pseudogene 1","metadata":{"aliases":["bA108M11.3"]}},{"id":"833b9d05023e4cb0b44cb8b992eec4e8","type":"GENE","name":"RPS27P10","canonical_id":"hgnc:HGNC:35961","description":"ribosomal protein S27 pseudogene 10","metadata":null},{"id":"42e5f9b6298a4b069df0e089857824d9","type":"GENE","name":"RPS27P11","canonical_id":"hgnc:HGNC:36014","description":"ribosomal protein S27 pseudogene 11","metadata":null},{"id":"2d8908d9dc364b97a13154a1f463f673","type":"GENE","name":"RPS27P12","canonical_id":"hgnc:HGNC:35843","description":"ribosomal protein S27 pseudogene 12","metadata":null},{"id":"5679192328cb450ab51e943c840146af","type":"GENE","name":"RPS27P13","canonical_id":"hgnc:HGNC:36203","description":"ribosomal protein S27 pseudogene 13","metadata":null},{"id":"29db9555ea7543cd89248670e96e3d1c","type":"GENE","name":"RPS27P14","canonical_id":"hgnc:HGNC:35923","description":"ribosomal protein S27 pseudogene 14","metadata":null},{"id":"8d571f9e53214872b72a34d35d3ae933","type":"GENE","name":"RPS27P15","canonical_id":"hgnc:HGNC:35863","description":"ribosomal protein S27 pseudogene 15","metadata":null},{"id":"1c51115e8a0542e2ad261809ce27bde8","type":"GENE","name":"RPS27P16","canonical_id":"hgnc:HGNC:36560","description":"ribosomal protein S27 pseudogene 16","metadata":null},{"id":"e2b38bdd34794360a636fd8e5dffb69a","type":"GENE","name":"RPS27P17","canonical_id":"hgnc:HGNC:36291","description":"ribosomal protein S27 pseudogene 17","metadata":null},{"id":"4344884db48845b6b0a33e4f291d4514","type":"GENE","name":"RPS27P18","canonical_id":"hgnc:HGNC:36296","description":"ribosomal protein S27 pseudogene 18","metadata":null},{"id":"d0a9144489564227a016f2e35e04a591","type":"GENE","name":"RPS27P19","canonical_id":"hgnc:HGNC:36094","description":"ribosomal protein S27 pseudogene 19","metadata":null},{"id":"c10b61eb11f045b8aa0f749ba5e5ba07","type":"GENE","name":"RPS27P2","canonical_id":"hgnc:HGNC:31035","description":"ribosomal protein S27 pseudogene 2","metadata":{"aliases":["HsT16324"]}},{"id":"48e2a8a046224de69141f96961cc4646","type":"GENE","name":"RPS27P20","canonical_id":"hgnc:HGNC:36333","description":"ribosomal protein S27 pseudogene 20","metadata":null},{"id":"57e698e2b1e44cbd83539f21fa662ace","type":"GENE","name":"RPS27P21","canonical_id":"hgnc:HGNC:35826","description":"ribosomal protein S27 pseudogene 21","metadata":null},{"id":"afe8dec41611479dafe002eb0da670d9","type":"GENE","name":"RPS27P22","canonical_id":"hgnc:HGNC:36090","description":"ribosomal protein S27 pseudogene 22","metadata":null},{"id":"66360cdd0cd349dab08b2184b022e146","type":"GENE","name":"RPS27P23","canonical_id":"hgnc:HGNC:35716","description":"ribosomal protein S27 pseudogene 23","metadata":null},{"id":"3ae74ba1473c43d6a95cba932242bc15","type":"GENE","name":"RPS27P24","canonical_id":"hgnc:HGNC:37005","description":"ribosomal protein S27 pseudogene 24","metadata":null},{"id":"797d39b7c6964eafaa3a4c201df3b72a","type":"GENE","name":"RPS27P25","canonical_id":"hgnc:HGNC:36020","description":"ribosomal protein S27 pseudogene 25","metadata":null},{"id":"7908b29ba348499c9faceb49539569b7","type":"GENE","name":"RPS27P26","canonical_id":"hgnc:HGNC:36904","description":"ribosomal protein S27 pseudogene 26","metadata":null},{"id":"87e9a5febc1c4e62943ec26cbad33915","type":"GENE","name":"RPS27P27","canonical_id":"hgnc:HGNC:36043","description":"ribosomal protein S27 pseudogene 27","metadata":null},{"id":"897098f8e783435b9700d3fa916df578","type":"GENE","name":"RPS27P28","canonical_id":"hgnc:HGNC:36748","description":"ribosomal protein S27 pseudogene 28","metadata":null},{"id":"0e17aff690444f0c9e5dd851b585c452","type":"GENE","name":"RPS27P29","canonical_id":"hgnc:HGNC:36516","description":"ribosomal protein S27 pseudogene 29","metadata":null},{"id":"2695272743104e6aa452f4a8936aae61","type":"GENE","name":"RPS27P3","canonical_id":"hgnc:HGNC:17445","description":"ribosomal protein S27 pseudogene 3","metadata":null},{"id":"1487a5015f9545ad934394746b13035a","type":"GENE","name":"RPS27P30","canonical_id":"hgnc:HGNC:56416","description":"ribosomal protein S27 pseudogene 30","metadata":null},{"id":"87c0d41dc85a44de94b4b4dd11180977","type":"GENE","name":"RPS27P4","canonical_id":"hgnc:HGNC:16694","description":"ribosomal protein S27 pseudogene 4","metadata":null},{"id":"5e88f427c6a44ccdb4c32dd1d22a2c86","type":"GENE","name":"RPS27P5","canonical_id":"hgnc:HGNC:36734","description":"ribosomal protein S27 pseudogene 5","metadata":null},{"id":"e2fd9267533148878793ebd18a3dd36d","type":"GENE","name":"RPS27P6","canonical_id":"hgnc:HGNC:36163","description":"ribosomal protein S27 pseudogene 6","metadata":null},{"id":"526b277c36de4ae5acb926267cb6be0a","type":"GENE","name":"RPS27P7","canonical_id":"hgnc:HGNC:35622","description":"ribosomal protein S27 pseudogene 7","metadata":null},{"id":"1424552af55c4e6e8a548830b3f54806","type":"GENE","name":"RPS27P8","canonical_id":"hgnc:HGNC:36022","description":"ribosomal protein S27 pseudogene 8","metadata":null},{"id":"5104e36eb0fc498e8954e336e6463b22","type":"GENE","name":"RPS27P9","canonical_id":"hgnc:HGNC:36964","description":"ribosomal protein S27 pseudogene 9","metadata":null},{"id":"a9e7ff0a854b4272b85d5b09860e04bf","type":"GENE","name":"RPS28","canonical_id":"hgnc:HGNC:10418","description":"ribosomal protein S28","metadata":{"aliases":["S28","eS28"]}},{"id":"a8e61801603f450895a14ada5f5c8516","type":"GENE","name":"RPS28P1","canonical_id":"hgnc:HGNC:23561","description":"ribosomal protein S28 pseudogene 1","metadata":null},{"id":"9c3314d073cf4076874001fad11b76e3","type":"GENE","name":"RPS28P2","canonical_id":"hgnc:HGNC:36211","description":"ribosomal protein S28 pseudogene 2","metadata":null},{"id":"83fa94883d934e6b9aeadcb38dd7752a","type":"GENE","name":"RPS28P3","canonical_id":"hgnc:HGNC:36589","description":"ribosomal protein S28 pseudogene 3","metadata":null},{"id":"18bcb1f6e86e480d9fdb2f971076af03","type":"GENE","name":"RPS28P4","canonical_id":"hgnc:HGNC:36208","description":"ribosomal protein S28 pseudogene 4","metadata":null},{"id":"fffde9f592b9475fbfb727f54fc26762","type":"GENE","name":"RPS28P5","canonical_id":"hgnc:HGNC:36802","description":"ribosomal protein S28 pseudogene 5","metadata":null},{"id":"37366dafae1047ba8c87c5fa294209b2","type":"GENE","name":"RPS28P6","canonical_id":"hgnc:HGNC:36085","description":"ribosomal protein S28 pseudogene 6","metadata":null},{"id":"3f3ea1fff1a04adb86f71ef8a3ec4837","type":"GENE","name":"RPS28P7","canonical_id":"hgnc:HGNC:35787","description":"ribosomal protein S28 pseudogene 7","metadata":null},{"id":"6cd008e00ced4012a76f56416c711c09","type":"GENE","name":"RPS28P8","canonical_id":"hgnc:HGNC:36938","description":"ribosomal protein S28 pseudogene 8","metadata":null},{"id":"0385c52e8ee94603bb071700f71988c8","type":"GENE","name":"RPS28P9","canonical_id":"hgnc:HGNC:36193","description":"ribosomal protein S28 pseudogene 9","metadata":null},{"id":"3b8a7112a6f24f2b8d08a7807b95850d","type":"GENE","name":"RPS29","canonical_id":"hgnc:HGNC:10419","description":"ribosomal protein S29","metadata":{"aliases":["S29","uS14"]}},{"id":"b83cf1772a0642f09c2de9e7d28c3c5a","type":"GENE","name":"RPS29P1","canonical_id":"hgnc:HGNC:19783","description":"ribosomal protein S29 pseudogene 1","metadata":null},{"id":"2117d54404704bf5810e0990391ac6f8","type":"GENE","name":"RPS29P10","canonical_id":"hgnc:HGNC:37006","description":"ribosomal protein S29 pseudogene 10","metadata":null},{"id":"cd2e3be9267348118c48022276ad79db","type":"GENE","name":"RPS29P11","canonical_id":"hgnc:HGNC:36413","description":"ribosomal protein S29 pseudogene 11","metadata":null},{"id":"fe217bae9dae4aefb79e559bce4a5433","type":"GENE","name":"RPS29P12","canonical_id":"hgnc:HGNC:36458","description":"ribosomal protein S29 pseudogene 12","metadata":null},{"id":"a73f08b40a0e41e0ad7490bdea211d29","type":"GENE","name":"RPS29P13","canonical_id":"hgnc:HGNC:35818","description":"ribosomal protein S29 pseudogene 13","metadata":null},{"id":"fe1a1ffb6b834ec594ae61bb65f74332","type":"GENE","name":"RPS29P14","canonical_id":"hgnc:HGNC:36471","description":"ribosomal protein S29 pseudogene 14","metadata":null},{"id":"fbf8e1df58164996b614f1d58f9043e8","type":"GENE","name":"RPS29P15","canonical_id":"hgnc:HGNC:35876","description":"ribosomal protein S29 pseudogene 15","metadata":null},{"id":"a3b1741487ae4386b15ba0ae8f2586eb","type":"GENE","name":"RPS29P16","canonical_id":"hgnc:HGNC:35560","description":"ribosomal protein S29 pseudogene 16","metadata":null},{"id":"4a6bd50561a9478aab6810e5f402eedd","type":"GENE","name":"RPS29P17","canonical_id":"hgnc:HGNC:35479","description":"ribosomal protein S29 pseudogene 17","metadata":null},{"id":"e89c599eb169468990ab561f0847cd52","type":"GENE","name":"RPS29P18","canonical_id":"hgnc:HGNC:37004","description":"ribosomal protein S29 pseudogene 18","metadata":null},{"id":"9da4023f7c7248b5a43f5dbbcc05ad49","type":"GENE","name":"RPS29P19","canonical_id":"hgnc:HGNC:36118","description":"ribosomal protein S29 pseudogene 19","metadata":null},{"id":"7d83b7b5a9214caca6ff8a27c792f44c","type":"GENE","name":"RPS29P2","canonical_id":"hgnc:HGNC:31083","description":"ribosomal protein S29 pseudogene 2","metadata":{"aliases":["HsT23291"]}},{"id":"7080d42ded6c4e37a146ca8e1b27aedc","type":"GENE","name":"RPS29P20","canonical_id":"hgnc:HGNC:36491","description":"ribosomal protein S29 pseudogene 20","metadata":null},{"id":"22585994bb7e47c398fcbfbbbb2db5db","type":"GENE","name":"RPS29P21","canonical_id":"hgnc:HGNC:36479","description":"ribosomal protein S29 pseudogene 21","metadata":null},{"id":"329a03d1bfad4a309ea76e18976e291e","type":"GENE","name":"RPS29P22","canonical_id":"hgnc:HGNC:35799","description":"ribosomal protein S29 pseudogene 22","metadata":null},{"id":"6eebba70f26b4723bf9093960736bc42","type":"GENE","name":"RPS29P23","canonical_id":"hgnc:HGNC:35779","description":"ribosomal protein S29 pseudogene 23","metadata":null},{"id":"ee793fe08a00426fabb8a95141fa0102","type":"GENE","name":"RPS29P24","canonical_id":"hgnc:HGNC:35794","description":"ribosomal protein S29 pseudogene 24","metadata":null},{"id":"c4b07ff29fd745309088753f19e617f1","type":"GENE","name":"RPS29P25","canonical_id":"hgnc:HGNC:35649","description":"ribosomal protein S29 pseudogene 25","metadata":null},{"id":"67e91276aebd424e86bf417be13b681f","type":"GENE","name":"RPS29P26","canonical_id":"hgnc:HGNC:36490","description":"ribosomal protein S29 pseudogene 26","metadata":null},{"id":"9d49c17c507a4ebbbc151fa7096110cd","type":"GENE","name":"RPS29P27","canonical_id":"hgnc:HGNC:35836","description":"ribosomal protein S29 pseudogene 27","metadata":null},{"id":"477d4e68b5d0492eb8e93b5c38df9933","type":"GENE","name":"RPS29P28","canonical_id":"hgnc:HGNC:36830","description":"ribosomal protein S29 pseudogene 28","metadata":null},{"id":"0acf84af7a3d49b1ae9c43448ca0d7b4","type":"GENE","name":"RPS29P29","canonical_id":"hgnc:HGNC:52362","description":"ribosomal protein S29 pseudogene 29","metadata":null},{"id":"f9a90de34734452ea9273fbca5638e84","type":"GENE","name":"RPS29P3","canonical_id":"hgnc:HGNC:31363","description":"ribosomal protein S29 pseudogene 3","metadata":{"aliases":["bcm2758"]}},{"id":"37568a11cc294a69acf9c5e1d42ad410","type":"GENE","name":"RPS29P30","canonical_id":"hgnc:HGNC:52363","description":"ribosomal protein S29 pseudogene 30","metadata":null},{"id":"a10edf797e5c40a99083ba6333ea6075","type":"GENE","name":"RPS29P31","canonical_id":"hgnc:HGNC:52364","description":"ribosomal protein S29 pseudogene 31","metadata":null},{"id":"1fc6c145cd784e8b92a017bb785d6b8b","type":"GENE","name":"RPS29P32","canonical_id":"hgnc:HGNC:52365","description":"ribosomal protein S29 pseudogene 32","metadata":null},{"id":"107a05017dac42858ee17f9067567c8a","type":"GENE","name":"RPS29P33","canonical_id":"hgnc:HGNC:52366","description":"ribosomal protein S29 pseudogene 33","metadata":null},{"id":"afcf47064d614277b9249773182d1b43","type":"GENE","name":"RPS29P4","canonical_id":"hgnc:HGNC:35908","description":"ribosomal protein S29 pseudogene 4","metadata":null},{"id":"020f66f481ac4ae9a3e0c1bc6a516f31","type":"GENE","name":"RPS29P5","canonical_id":"hgnc:HGNC:35584","description":"ribosomal protein S29 pseudogene 5","metadata":null},{"id":"2032c481841a4b3bb9878e87a031d314","type":"GENE","name":"RPS29P6","canonical_id":"hgnc:HGNC:35718","description":"ribosomal protein S29 pseudogene 6","metadata":null},{"id":"f8541da9db2447a9a59605f0a31400ef","type":"GENE","name":"RPS29P7","canonical_id":"hgnc:HGNC:36594","description":"ribosomal protein S29 pseudogene 7","metadata":null},{"id":"cd991321b4714c8083cc1ccdb682a779","type":"GENE","name":"RPS29P8","canonical_id":"hgnc:HGNC:36915","description":"ribosomal protein S29 pseudogene 8","metadata":null},{"id":"4da399832b8448889c0cd0bb5a09cce1","type":"GENE","name":"RPS29P9","canonical_id":"hgnc:HGNC:36913","description":"ribosomal protein S29 pseudogene 9","metadata":null},{"id":"c93583bf0e4c4f5296c68f8b0636c576","type":"GENE","name":"RPS2P1","canonical_id":"hgnc:HGNC:16580","description":"ribosomal protein S2 pseudogene 1","metadata":{"aliases":["dJ64K7.1"]}},{"id":"f85c7e86b1154c1183597bb3caa09740","type":"GENE","name":"RPS2P10","canonical_id":"hgnc:HGNC:36892","description":"ribosomal protein S2 pseudogene 10","metadata":null},{"id":"395974c0d7ae477d9dd3df20ae16c7c7","type":"GENE","name":"RPS2P11","canonical_id":"hgnc:HGNC:36350","description":"ribosomal protein S2 pseudogene 11","metadata":null},{"id":"8db40cffb7b0415b9f0861618d5d4d9c","type":"GENE","name":"RPS2P12","canonical_id":"hgnc:HGNC:36546","description":"ribosomal protein S2 pseudogene 12","metadata":null},{"id":"669406421507457fa5645b7942271573","type":"GENE","name":"RPS2P13","canonical_id":"hgnc:HGNC:36021","description":"ribosomal protein S2 pseudogene 13","metadata":null},{"id":"59a32403c1654014b23308ef2336ef36","type":"GENE","name":"RPS2P14","canonical_id":"hgnc:HGNC:36389","description":"ribosomal protein S2 pseudogene 14","metadata":null},{"id":"d31fbb11070d441cb25ddd49dbb9c653","type":"GENE","name":"RPS2P15","canonical_id":"hgnc:HGNC:36468","description":"ribosomal protein S2 pseudogene 15","metadata":null},{"id":"dd7a7de7ba8041feba1a3f1ca3de576b","type":"GENE","name":"RPS2P16","canonical_id":"hgnc:HGNC:36865","description":"ribosomal protein S2 pseudogene 16","metadata":null},{"id":"6e10fba2853346aab0a5431715a6acbf","type":"GENE","name":"RPS2P17","canonical_id":"hgnc:HGNC:35764","description":"ribosomal protein S2 pseudogene 17","metadata":null},{"id":"a641cc18e6b243a89f42f039362c47d0","type":"GENE","name":"RPS2P18","canonical_id":"hgnc:HGNC:36449","description":"ribosomal protein S2 pseudogene 18","metadata":null},{"id":"befdf4e18b6742df888c2fb4b552924f","type":"GENE","name":"RPS2P19","canonical_id":"hgnc:HGNC:35786","description":"ribosomal protein S2 pseudogene 19","metadata":null},{"id":"66d86ff5906e41e6b5e9dd48c8c3a555","type":"GENE","name":"RPS2P2","canonical_id":"hgnc:HGNC:19790","description":"ribosomal protein S2 pseudogene 2","metadata":null},{"id":"127638852bcb4dcf9f9f0a4710d17a5a","type":"GENE","name":"RPS2P20","canonical_id":"hgnc:HGNC:35992","description":"ribosomal protein S2 pseudogene 20","metadata":null},{"id":"681dc1a9a91347e59641f52ae59025d8","type":"GENE","name":"RPS2P21","canonical_id":"hgnc:HGNC:35591","description":"ribosomal protein S2 pseudogene 21","metadata":null},{"id":"8e87e4f52ab54341ab321f34e812ede5","type":"GENE","name":"RPS2P22","canonical_id":"hgnc:HGNC:35506","description":"ribosomal protein S2 pseudogene 22","metadata":null},{"id":"331ce57906aa4bb4ad583620af4d4345","type":"GENE","name":"RPS2P23","canonical_id":"hgnc:HGNC:35760","description":"ribosomal protein S2 pseudogene 23","metadata":null},{"id":"e0828f5dc12a489a9bf06d3c8a12fc09","type":"GENE","name":"RPS2P24","canonical_id":"hgnc:HGNC:35887","description":"ribosomal protein S2 pseudogene 24","metadata":null},{"id":"f2af53bf15e14d9285cd4073ccd78753","type":"GENE","name":"RPS2P25","canonical_id":"hgnc:HGNC:36410","description":"ribosomal protein S2 pseudogene 25","metadata":null},{"id":"5cc1961392c647e0934037a05872396d","type":"GENE","name":"RPS2P26","canonical_id":"hgnc:HGNC:36157","description":"ribosomal protein S2 pseudogene 26","metadata":null},{"id":"e09ce4109dbc46e8b95097096eb3da23","type":"GENE","name":"RPS2P27","canonical_id":"hgnc:HGNC:36876","description":"ribosomal protein S2 pseudogene 27","metadata":null},{"id":"abde827819e04e34ae89b6385511a3f8","type":"GENE","name":"RPS2P28","canonical_id":"hgnc:HGNC:35780","description":"ribosomal protein S2 pseudogene 28","metadata":null},{"id":"0a60b47cd0174112bd9a881952a8f428","type":"GENE","name":"RPS2P29","canonical_id":"hgnc:HGNC:36011","description":"ribosomal protein S2 pseudogene 29","metadata":null},{"id":"66dbe99a881a4541a80e52bae4b0252c","type":"GENE","name":"RPS2P3","canonical_id":"hgnc:HGNC:19806","description":"ribosomal protein S2 pseudogene 3","metadata":null},{"id":"af7a6c93aece43da9745a0bb06dbfda6","type":"GENE","name":"RPS2P30","canonical_id":"hgnc:HGNC:36987","description":"ribosomal protein S2 pseudogene 30","metadata":null},{"id":"608b14a92c2d49be8e7c4c6f9e24dd95","type":"GENE","name":"RPS2P31","canonical_id":"hgnc:HGNC:36965","description":"ribosomal protein S2 pseudogene 31","metadata":null},{"id":"8b374be55224451fa36bada83d479f8b","type":"GENE","name":"RPS2P32","canonical_id":"hgnc:HGNC:30518","description":"ribosomal protein S2 pseudogene 32","metadata":{"aliases":["MGC27348"]}},{"id":"96a12efa2f3d43fa8a5fa202aca5376c","type":"GENE","name":"RPS2P33","canonical_id":"hgnc:HGNC:35549","description":"ribosomal protein S2 pseudogene 33","metadata":null},{"id":"5eca38b9a9954f94bc9db06da39b7c2a","type":"GENE","name":"RPS2P34","canonical_id":"hgnc:HGNC:36370","description":"ribosomal protein S2 pseudogene 34","metadata":null},{"id":"70916d6ca7e049909f868e7c1f9a1c02","type":"GENE","name":"RPS2P35","canonical_id":"hgnc:HGNC:36757","description":"ribosomal protein S2 pseudogene 35","metadata":null},{"id":"cfa7f2d4f7e84cedb4f9979cbffdfbb8","type":"GENE","name":"RPS2P36","canonical_id":"hgnc:HGNC:36784","description":"ribosomal protein S2 pseudogene 36","metadata":null},{"id":"f903165bb51e45bb9f396d6eef169590","type":"GENE","name":"RPS2P37","canonical_id":"hgnc:HGNC:36482","description":"ribosomal protein S2 pseudogene 37","metadata":null},{"id":"a12770f289d94e6ba0c795ab61a44246","type":"GENE","name":"RPS2P38","canonical_id":"hgnc:HGNC:36584","description":"ribosomal protein S2 pseudogene 38","metadata":null},{"id":"f003659046c9479099b6a3736a9aa2b9","type":"GENE","name":"RPS2P39","canonical_id":"hgnc:HGNC:36131","description":"ribosomal protein S2 pseudogene 39","metadata":null},{"id":"9beee3d12d654b8995135b70dc3bba5e","type":"GENE","name":"RPS2P4","canonical_id":"hgnc:HGNC:19814","description":"ribosomal protein S2 pseudogene 4","metadata":null},{"id":"c105f29960fa4a6f82201069c44e40a9","type":"GENE","name":"RPS2P40","canonical_id":"hgnc:HGNC:35541","description":"ribosomal protein S2 pseudogene 40","metadata":null},{"id":"3949f19886154ac580f0fa2bc4722082","type":"GENE","name":"RPS2P41","canonical_id":"hgnc:HGNC:36357","description":"ribosomal protein S2 pseudogene 41","metadata":null},{"id":"6c1d8feac702408f80417620a1d36cc6","type":"GENE","name":"RPS2P42","canonical_id":"hgnc:HGNC:36481","description":"ribosomal protein S2 pseudogene 42","metadata":null},{"id":"cdf8c3fe062a4d7782b745200572b677","type":"GENE","name":"RPS2P43","canonical_id":"hgnc:HGNC:35652","description":"ribosomal protein S2 pseudogene 43","metadata":null},{"id":"cf5f075d0bec41168f6e58b279ebe7b1","type":"GENE","name":"RPS2P44","canonical_id":"hgnc:HGNC:35811","description":"ribosomal protein S2 pseudogene 44","metadata":null},{"id":"6a2a57d18cb54d1681e28be808e053c0","type":"GENE","name":"RPS2P45","canonical_id":"hgnc:HGNC:25709","description":"ribosomal protein S2 pseudogene 45","metadata":{"aliases":["FLJ12331"]}},{"id":"2aeefa80b7454bf9b4a83124571306da","type":"GENE","name":"RPS2P46","canonical_id":"hgnc:HGNC:35839","description":"ribosomal protein S2 pseudogene 46","metadata":null},{"id":"79f05511772c4a0b972857a04eb289e0","type":"GENE","name":"RPS2P47","canonical_id":"hgnc:HGNC:35785","description":"ribosomal protein S2 pseudogene 47","metadata":null},{"id":"252b1ff63c114cc79d588c8cee845866","type":"GENE","name":"RPS2P48","canonical_id":"hgnc:HGNC:35985","description":"ribosomal protein S2 pseudogene 48","metadata":null},{"id":"f914f621767d474bb84b29dd8263f2ba","type":"GENE","name":"RPS2P49","canonical_id":"hgnc:HGNC:36521","description":"ribosomal protein S2 pseudogene 49","metadata":null},{"id":"67b74ee7ad2c408e8de449eae7fd3ea8","type":"GENE","name":"RPS2P5","canonical_id":"hgnc:HGNC:31386","description":"ribosomal protein S2 pseudogene 5","metadata":{"aliases":["bcm384"]}},{"id":"7a7b7f1478ad48f887470f6b971fc7b5","type":"GENE","name":"RPS2P50","canonical_id":"hgnc:HGNC:36034","description":"ribosomal protein S2 pseudogene 50","metadata":null},{"id":"3603f2ed2136472090093b3ca4a0d77a","type":"GENE","name":"RPS2P51","canonical_id":"hgnc:HGNC:36422","description":"ribosomal protein S2 pseudogene 51","metadata":null},{"id":"5b72f4530dc94ec69d566cadd6f82197","type":"GENE","name":"RPS2P52","canonical_id":"hgnc:HGNC:36059","description":"ribosomal protein S2 pseudogene 52","metadata":null},{"id":"0bfac5ead3b14920b22da412e489850b","type":"GENE","name":"RPS2P53","canonical_id":"hgnc:HGNC:36690","description":"ribosomal protein S2 pseudogene 53","metadata":null},{"id":"874bbd13accd4008a745c82143076039","type":"GENE","name":"RPS2P54","canonical_id":"hgnc:HGNC:35835","description":"ribosomal protein S2 pseudogene 54","metadata":null},{"id":"0b9c114fd2094a61a14b43bd6d7f595c","type":"GENE","name":"RPS2P55","canonical_id":"hgnc:HGNC:36140","description":"ribosomal protein S2 pseudogene 55","metadata":null},{"id":"a47e4acc56f343dcbfa73376af2ed1c0","type":"GENE","name":"RPS2P6","canonical_id":"hgnc:HGNC:25485","description":"ribosomal protein S2 pseudogene 6","metadata":null},{"id":"cd8a10dcb50f4c88b5ecd5e64a6ba039","type":"GENE","name":"RPS2P7","canonical_id":"hgnc:HGNC:15838","description":"ribosomal protein S2 pseudogene 7","metadata":{"aliases":["dJ688G8.1","RPS2L1"]}},{"id":"e7470390649e42f5a001c007deb1a92a","type":"GENE","name":"RPS2P8","canonical_id":"hgnc:HGNC:36207","description":"ribosomal protein S2 pseudogene 8","metadata":null},{"id":"db740239d69f45f8a8a45e98832441b5","type":"GENE","name":"RPS2P9","canonical_id":"hgnc:HGNC:36704","description":"ribosomal protein S2 pseudogene 9","metadata":null},{"id":"ec05c01369c04c968fdb9a98d93936e2","type":"GENE","name":"RPS3","canonical_id":"hgnc:HGNC:10420","description":"ribosomal protein S3","metadata":{"aliases":["FLJ26283","FLJ27450","MGC87870","S3","uS3"]}},{"id":"be71a98d6805438b881100326bf10122","type":"GENE","name":"RPS3A","canonical_id":"hgnc:HGNC:10421","description":null,"metadata":null},{"id":"6e180b284f384414bdd15dc7675d9721","type":"GENE","name":"RPS3AP1","canonical_id":"hgnc:HGNC:10422","description":"RPS3A pseudogene 1","metadata":{"aliases":["RPS3AP"]}},{"id":"7608110ca5b44685af100020e28484d1","type":"GENE","name":"RPS3AP10","canonical_id":"hgnc:HGNC:36036","description":"RPS3A pseudogene 10","metadata":null},{"id":"570d4d522ed6457e83dc56dca86204d9","type":"GENE","name":"RPS3AP11","canonical_id":"hgnc:HGNC:36825","description":"RPS3A pseudogene 11","metadata":null},{"id":"a731be834b3941d4b51c6b802460121c","type":"GENE","name":"RPS3AP12","canonical_id":"hgnc:HGNC:35527","description":"RPS3A pseudogene 12","metadata":null},{"id":"49936581997f4a29b39f9c78925b6daf","type":"GENE","name":"RPS3AP13","canonical_id":"hgnc:HGNC:54572","description":"RPS3A pseudogene 13","metadata":null},{"id":"0631dbeaf3744080be37302e48218e2a","type":"GENE","name":"RPS3AP14","canonical_id":"hgnc:HGNC:35715","description":"RPS3A pseudogene 14","metadata":null},{"id":"3fe72dfa4f3748c492212d165aeee7bd","type":"GENE","name":"RPS3AP15","canonical_id":"hgnc:HGNC:35781","description":"RPS3A pseudogene 15","metadata":null},{"id":"72f526670d004a1785e43e0fa2d9d08c","type":"GENE","name":"RPS3AP16","canonical_id":"hgnc:HGNC:36052","description":"RPS3A pseudogene 16","metadata":null},{"id":"929b704f8e9142a68f7851569ae1a54f","type":"GENE","name":"RPS3AP17","canonical_id":"hgnc:HGNC:36083","description":"RPS3A pseudogene 17","metadata":null},{"id":"e5fce1bb74554eabb55b02b30eff2456","type":"GENE","name":"RPS3AP18","canonical_id":"hgnc:HGNC:35893","description":"RPS3A pseudogene 18","metadata":null},{"id":"ee8738ac026343349aa5d7ec7580cb49","type":"GENE","name":"RPS3AP19","canonical_id":"hgnc:HGNC:36467","description":"RPS3A pseudogene 19","metadata":null},{"id":"98523f34323f4529a4cd38a293c07334","type":"GENE","name":"RPS3AP2","canonical_id":"hgnc:HGNC:14196","description":"RPS3A pseudogene 2","metadata":null},{"id":"ad05fc4599274d31aeeecc5ff41524e9","type":"GENE","name":"RPS3AP20","canonical_id":"hgnc:HGNC:36141","description":"RPS3A pseudogene 20","metadata":null},{"id":"723b5091a4e44d79b368fec8141ee70d","type":"GENE","name":"RPS3AP21","canonical_id":"hgnc:HGNC:36841","description":"RPS3A pseudogene 21","metadata":null},{"id":"ee8319db66e74ee290b6c81bbed3dcd4","type":"GENE","name":"RPS3AP22","canonical_id":"hgnc:HGNC:36573","description":"RPS3A pseudogene 22","metadata":null},{"id":"fc960491e1ce446da635d6cf3f39b679","type":"GENE","name":"RPS3AP23","canonical_id":"hgnc:HGNC:36767","description":"RPS3A pseudogene 23","metadata":null},{"id":"244a476f9fd84d17955fba91159348e0","type":"GENE","name":"RPS3AP24","canonical_id":"hgnc:HGNC:36267","description":"RPS3A pseudogene 24","metadata":null},{"id":"075fecb305f646ef90ab5e0c346501d1","type":"GENE","name":"RPS3AP25","canonical_id":"hgnc:HGNC:36801","description":"RPS3A pseudogene 25","metadata":null},{"id":"cfb0fe9777f34aad8654b52e4f785911","type":"GENE","name":"RPS3AP26","canonical_id":"hgnc:HGNC:36513","description":"RPS3A pseudogene 26","metadata":null},{"id":"3a96e592203947e59c57aab2c664b725","type":"GENE","name":"RPS3AP27","canonical_id":"hgnc:HGNC:35978","description":"RPS3A pseudogene 27","metadata":null},{"id":"3c62a8906c6e4d9a9b6a59ec9b7eaed0","type":"GENE","name":"RPS3AP28","canonical_id":"hgnc:HGNC:35738","description":"RPS3A pseudogene 28","metadata":null},{"id":"e955a8f357b84f01a5e321d23bf6ff30","type":"GENE","name":"RPS3AP29","canonical_id":"hgnc:HGNC:35531","description":"RPS3A pseudogene 29","metadata":null},{"id":"c48d55d9a95d4432b9403dc1c8923185","type":"GENE","name":"RPS3AP3","canonical_id":"hgnc:HGNC:16537","description":"RPS3A pseudogene 3","metadata":{"aliases":["bA332A4.2"]}},{"id":"10012f2c0d344a17a330e3c7706c57b5","type":"GENE","name":"RPS3AP30","canonical_id":"hgnc:HGNC:35538","description":"RPS3A pseudogene 30","metadata":null},{"id":"75e0a958f2f34ffcbea5d1fa754db262","type":"GENE","name":"RPS3AP31","canonical_id":"hgnc:HGNC:36860","description":"RPS3A pseudogene 31","metadata":null},{"id":"2fd54fc1c3c0446985f7e54263854dd8","type":"GENE","name":"RPS3AP32","canonical_id":"hgnc:HGNC:36717","description":"RPS3A pseudogene 32","metadata":null},{"id":"9ca70e5128c94ad68b6745d4cddc5a94","type":"GENE","name":"RPS3AP33","canonical_id":"hgnc:HGNC:35476","description":"RPS3A pseudogene 33","metadata":null},{"id":"eb53f78d11bc40ab8abdbdb78b379e3b","type":"GENE","name":"RPS3AP34","canonical_id":"hgnc:HGNC:36293","description":"RPS3A pseudogene 34","metadata":null},{"id":"45c340c102454c11bbc785c8da4ab0fd","type":"GENE","name":"RPS3AP35","canonical_id":"hgnc:HGNC:35902","description":"RPS3A pseudogene 35","metadata":null},{"id":"bb1b3d530f2547a0a314ddcf5e01fcbe","type":"GENE","name":"RPS3AP36","canonical_id":"hgnc:HGNC:35596","description":"RPS3A pseudogene 36","metadata":null},{"id":"3ef05b933d2b4426b82e8d88af659b0f","type":"GENE","name":"RPS3AP37","canonical_id":"hgnc:HGNC:36691","description":"RPS3A pseudogene 37","metadata":null},{"id":"b6a7ebf345404a718d5fdfb9d73a7586","type":"GENE","name":"RPS3AP38","canonical_id":"hgnc:HGNC:36145","description":"RPS3A pseudogene 38","metadata":null},{"id":"3227c33eb1c5474f8324ca468de17761","type":"GENE","name":"RPS3AP39","canonical_id":"hgnc:HGNC:35490","description":"RPS3A pseudogene 39","metadata":null},{"id":"4aec79176c6242c7af6b6193420952b7","type":"GENE","name":"RPS3AP4","canonical_id":"hgnc:HGNC:23562","description":"RPS3A pseudogene 4","metadata":null},{"id":"7f27f8cd9375490e8495e973a4a3f7be","type":"GENE","name":"RPS3AP40","canonical_id":"hgnc:HGNC:35869","description":"RPS3A pseudogene 40","metadata":null},{"id":"d85f515656e04a54841b6ae83d1afc47","type":"GENE","name":"RPS3AP41","canonical_id":"hgnc:HGNC:37000","description":"RPS3A pseudogene 41","metadata":null},{"id":"ab8c7f21374e4ee1af3e40bce2487d19","type":"GENE","name":"RPS3AP42","canonical_id":"hgnc:HGNC:35605","description":"RPS3A pseudogene 42","metadata":null},{"id":"79e885638f7b48ed844ebe56cecc6408","type":"GENE","name":"RPS3AP43","canonical_id":"hgnc:HGNC:36684","description":"RPS3A pseudogene 43","metadata":null},{"id":"e2e903908c194a54a2a32198dd3a392a","type":"GENE","name":"RPS3AP44","canonical_id":"hgnc:HGNC:36761","description":"RPS3A pseudogene 44","metadata":null},{"id":"d466735324ba4b7786fa231875cda621","type":"GENE","name":"RPS3AP46","canonical_id":"hgnc:HGNC:36338","description":"RPS3A pseudogene 46","metadata":null},{"id":"a2aa12b9eda24da98ccbb1f8f8aa4754","type":"GENE","name":"RPS3AP47","canonical_id":"hgnc:HGNC:36744","description":"RPS3A pseudogene 47","metadata":null},{"id":"33cf4b2a47314d6b92caffece765d517","type":"GENE","name":"RPS3AP48","canonical_id":"hgnc:HGNC:36792","description":"RPS3A pseudogene 48","metadata":null},{"id":"4d68ef129b5c4252a1a00683e760a267","type":"GENE","name":"RPS3AP49","canonical_id":"hgnc:HGNC:36810","description":"RPS3A pseudogene 49","metadata":null},{"id":"e718492d4b9b49469ff5d102dfad9b22","type":"GENE","name":"RPS3AP5","canonical_id":"hgnc:HGNC:23744","description":"RPS3A pseudogene 5","metadata":{"aliases":["bA486O22.3"]}},{"id":"7b8c39c4bc444cac9b433b4e850db477","type":"GENE","name":"RPS3AP50","canonical_id":"hgnc:HGNC:37018","description":"RPS3A pseudogene 50","metadata":null},{"id":"c5ac54dc20fd49aeafba4819b405233b","type":"GENE","name":"RPS3AP51","canonical_id":"hgnc:HGNC:35480","description":"RPS3A pseudogene 51","metadata":null},{"id":"fda11d1902ae4663bcd8bd935036ef4f","type":"GENE","name":"RPS3AP52","canonical_id":"hgnc:HGNC:42004","description":"RPS3A pseudogene 52","metadata":null},{"id":"c6cc94dd305d42d8b8ba6408d16ba69c","type":"GENE","name":"RPS3AP53","canonical_id":"hgnc:HGNC:44500","description":"RPS3A pseudogene 53","metadata":null},{"id":"2bedcf2165924310ace3ae938e4c6586","type":"GENE","name":"RPS3AP54","canonical_id":"hgnc:HGNC:49750","description":"RPS3A pseudogene 54","metadata":null},{"id":"04fc277161734cd5a5bb69b2216d45a7","type":"GENE","name":"RPS3AP55","canonical_id":"hgnc:HGNC:56987","description":"RPS3A pseudogene 55","metadata":null},{"id":"caa66b29c4184ba2983838ab3bb83cbe","type":"GENE","name":"RPS3AP6","canonical_id":"hgnc:HGNC:18630","description":"RPS3A pseudogene 6","metadata":null},{"id":"cabf529699cd48bf874e0b8b63794767","type":"GENE","name":"RPS3AP7","canonical_id":"hgnc:HGNC:36376","description":"RPS3A pseudogene 7","metadata":null},{"id":"404450ff15b74be8a70cd625a00f9429","type":"GENE","name":"RPS3AP8","canonical_id":"hgnc:HGNC:35638","description":"RPS3A pseudogene 8","metadata":null},{"id":"cf716c2aa70f474c89dd972f82aa27fd","type":"GENE","name":"RPS3AP9","canonical_id":"hgnc:HGNC:36150","description":"RPS3A pseudogene 9","metadata":null},{"id":"687c1eca958a43d8b84efa3a870301eb","type":"GENE","name":"RPS3P1","canonical_id":"hgnc:HGNC:16579","description":"ribosomal protein S3 pseudogene 1","metadata":{"aliases":["dJ631M13.3"]}},{"id":"ca9e7fac210345b9805ebdfb96a33595","type":"GENE","name":"RPS3P2","canonical_id":"hgnc:HGNC:16603","description":"ribosomal protein S3 pseudogene 2","metadata":{"aliases":["dJ927M24.3"]}},{"id":"9aabda87046543c1a1670f43b25984ae","type":"GENE","name":"RPS3P3","canonical_id":"hgnc:HGNC:36700","description":"ribosomal protein S3 pseudogene 3","metadata":null},{"id":"ed644e53b6914ecc87b62f7214feafee","type":"GENE","name":"RPS3P4","canonical_id":"hgnc:HGNC:36616","description":"ribosomal protein S3 pseudogene 4","metadata":null},{"id":"6001860d85184d42a0072570c0a657f9","type":"GENE","name":"RPS3P5","canonical_id":"hgnc:HGNC:36869","description":"ribosomal protein S3 pseudogene 5","metadata":null},{"id":"9d73a8c2087943cf90d90a4dc5d36574","type":"GENE","name":"RPS3P6","canonical_id":"hgnc:HGNC:36061","description":"ribosomal protein S3 pseudogene 6","metadata":null},{"id":"55bef165731e49ecab8ffe28d42e8414","type":"GENE","name":"RPS3P7","canonical_id":"hgnc:HGNC:36056","description":"ribosomal protein S3 pseudogene 7","metadata":null},{"id":"9d6ef5b816384491a7425cf5d9ee310c","type":"GENE","name":"RPS4X","canonical_id":"hgnc:HGNC:10424","description":"ribosomal protein S4 X-linked","metadata":{"aliases":["DXS306","CCG2","SCAR","SCR10","FLJ40595","RPS4","eS4"]}},{"id":"99294516ef7949d3b4b4c6b5271d11c9","type":"GENE","name":"RPS4XP1","canonical_id":"hgnc:HGNC:32444","description":"ribosomal protein S4X pseudogene 1","metadata":{"aliases":["RPS4P1"]}},{"id":"a963f1e911b943c884778575c6c373cd","type":"GENE","name":"RPS4XP10","canonical_id":"hgnc:HGNC:35741","description":"ribosomal protein S4X pseudogene 10","metadata":{"aliases":["RPS4P10"]}},{"id":"596383adcc3d42168ffe2bec582f2a89","type":"GENE","name":"RPS4XP11","canonical_id":"hgnc:HGNC:37013","description":"ribosomal protein S4X pseudogene 11","metadata":{"aliases":["RPS4P11"]}},{"id":"6e976698794f457aa3338387d5143831","type":"GENE","name":"RPS4XP12","canonical_id":"hgnc:HGNC:35951","description":"ribosomal protein S4X pseudogene 12","metadata":{"aliases":["RPS4P12"]}},{"id":"362bd639a2624d4d9aa7dd619bacf7cd","type":"GENE","name":"RPS4XP13","canonical_id":"hgnc:HGNC:36522","description":"ribosomal protein S4X pseudogene 13","metadata":{"aliases":["RPS4P13"]}},{"id":"401ccbbaa41549b9a741e2efbca340a8","type":"GENE","name":"RPS4XP14","canonical_id":"hgnc:HGNC:36737","description":"ribosomal protein S4X pseudogene 14","metadata":{"aliases":["RPS4P14"]}},{"id":"5bd60e9232d64d5f89ae9474e7f92628","type":"GENE","name":"RPS4XP15","canonical_id":"hgnc:HGNC:36308","description":"ribosomal protein S4X pseudogene 15","metadata":{"aliases":["RPS4P15"]}},{"id":"760cb4db7c81400e9fed3ed413767fa2","type":"GENE","name":"RPS4XP16","canonical_id":"hgnc:HGNC:36365","description":"ribosomal protein S4X pseudogene 16","metadata":{"aliases":["RPS4P16"]}},{"id":"76618458bd044959aee44755ce58fe82","type":"GENE","name":"RPS4XP17","canonical_id":"hgnc:HGNC:36789","description":"ribosomal protein S4X pseudogene 17","metadata":{"aliases":["RPS4P17"]}},{"id":"0aee977ca0054580995ac53cebf76977","type":"GENE","name":"RPS4XP18","canonical_id":"hgnc:HGNC:36170","description":"ribosomal protein S4X pseudogene 18","metadata":{"aliases":["RPS4P18"]}},{"id":"730aa464a99b48988afb9527c8c7a102","type":"GENE","name":"RPS4XP19","canonical_id":"hgnc:HGNC:36872","description":"ribosomal protein S4X pseudogene 19","metadata":{"aliases":["RPS4P19"]}},{"id":"da8ab94e9778425284116ae312446a15","type":"GENE","name":"RPS4XP2","canonical_id":"hgnc:HGNC:16563","description":"ribosomal protein S4X pseudogene 2","metadata":{"aliases":["dJ189G13.2","RPS4L2","RPS4P2"]}},{"id":"d01926caa08a4e66a1cb289d4e255755","type":"GENE","name":"RPS4XP20","canonical_id":"hgnc:HGNC:36437","description":"ribosomal protein S4X pseudogene 20","metadata":{"aliases":["RPS4P20"]}},{"id":"a227b1c727a2493fa92d53b3f4510fc1","type":"GENE","name":"RPS4XP21","canonical_id":"hgnc:HGNC:36228","description":"ribosomal protein S4X pseudogene 21","metadata":{"aliases":["RPS4P21"]}},{"id":"a41072d9215c4165ad0f4356194fe4a5","type":"GENE","name":"RPS4XP22","canonical_id":"hgnc:HGNC:36125","description":"ribosomal protein S4X pseudogene 22","metadata":{"aliases":["RPS4P22"]}},{"id":"121d836b59184c8db7e20a89d0e8ddc9","type":"GENE","name":"RPS4XP23","canonical_id":"hgnc:HGNC:48367","description":"ribosomal protein S4X pseudogene 23","metadata":null},{"id":"006f95aab47345d1b53a6acf3b869614","type":"GENE","name":"RPS4XP3","canonical_id":"hgnc:HGNC:16251","description":"ribosomal protein S4X pseudogene 3","metadata":{"aliases":["dJ843L14.2","RPS4XL","RPS4L","RPS4P3"]}},{"id":"9c16eb14c8254402ab2a747dd132f095","type":"GENE","name":"RPS4XP4","canonical_id":"hgnc:HGNC:36545","description":"ribosomal protein S4X pseudogene 4","metadata":{"aliases":["RPS4P4"]}},{"id":"4568ea9e29e84c7c8c8e268adaf0113b","type":"GENE","name":"RPS4XP5","canonical_id":"hgnc:HGNC:36670","description":"ribosomal protein S4X pseudogene 5","metadata":{"aliases":["RPS4P5"]}},{"id":"7b12428fd67c411c850fd870dd241a62","type":"GENE","name":"RPS4XP6","canonical_id":"hgnc:HGNC:36057","description":"ribosomal protein S4X pseudogene 6","metadata":{"aliases":["RPS4P6"]}},{"id":"85ba7d6a335e44d2ada49c06a87da6b0","type":"GENE","name":"RPS4XP7","canonical_id":"hgnc:HGNC:36885","description":"ribosomal protein S4X pseudogene 7","metadata":{"aliases":["RPS4P7"]}},{"id":"b80679ada857420ea01efe67882d24ba","type":"GENE","name":"RPS4XP8","canonical_id":"hgnc:HGNC:36683","description":"ribosomal protein S4X pseudogene 8","metadata":{"aliases":["RPS4P8"]}},{"id":"b80253956b2d4aaba36c4e6bf1ef9150","type":"GENE","name":"RPS4XP9","canonical_id":"hgnc:HGNC:35792","description":"ribosomal protein S4X pseudogene 9","metadata":{"aliases":["RPS4P9"]}},{"id":"f5d43bd71a354b63840d2c85de28741f","type":"GENE","name":"RPS4Y1","canonical_id":"hgnc:HGNC:10425","description":"ribosomal protein S4 Y-linked 1","metadata":{"aliases":["MGC5070","MGC119100","S4","RPS4Y"]}},{"id":"ad22194f4cd54a25893d8975be984ca9","type":"GENE","name":"RPS4Y1P1","canonical_id":"hgnc:HGNC:36893","description":"RPS4Y1 pseudogene 1","metadata":null},{"id":"19fd06e561864e329f35b13c6108b608","type":"GENE","name":"RPS4Y2","canonical_id":"hgnc:HGNC:18501","description":"ribosomal protein S4 Y-linked 2","metadata":{"aliases":["RPS4Y2P"]}},{"id":"960bb1b7181845319f2458f01473ffaf","type":"GENE","name":"RPS5","canonical_id":"hgnc:HGNC:10426","description":"ribosomal protein S5","metadata":{"aliases":["S5","uS7"]}},{"id":"651ff9306e5a498e9f7862fccc62afd1","type":"GENE","name":"RPS5P1","canonical_id":"hgnc:HGNC:10428","description":"RPS5 pseudogene 1","metadata":null},{"id":"08a4e13b01b349c8b8c3f58e81851846","type":"GENE","name":"RPS5P2","canonical_id":"hgnc:HGNC:17222","description":"RPS5 pseudogene 2","metadata":null},{"id":"2561405493e94106adcb3505d0bb2940","type":"GENE","name":"RPS5P3","canonical_id":"hgnc:HGNC:10427","description":"RPS5 pseudogene 3","metadata":{"aliases":["RPS5L"]}},{"id":"5f36d6f58739472abded356b6498ba5e","type":"GENE","name":"RPS5P4","canonical_id":"hgnc:HGNC:36122","description":"RPS5 pseudogene 4","metadata":null},{"id":"02e426e284bc43ae809ae241eecc9ff6","type":"GENE","name":"RPS5P5","canonical_id":"hgnc:HGNC:35626","description":"RPS5 pseudogene 5","metadata":null},{"id":"9102333138d1471a8d5ca6b93e5f2d8d","type":"GENE","name":"RPS5P6","canonical_id":"hgnc:HGNC:35960","description":"RPS5 pseudogene 6","metadata":null},{"id":"22e56aeaa13d478b9a59db5958339dfa","type":"GENE","name":"RPS5P7","canonical_id":"hgnc:HGNC:36881","description":"RPS5 pseudogene 7","metadata":null},{"id":"8ff26bc2e4074fae8dd0a0f153ca490f","type":"GENE","name":"RPS5P8","canonical_id":"hgnc:HGNC:36531","description":"RPS5 pseudogene 8","metadata":null},{"id":"7343609d98ff4e75879343ee7655137b","type":"GENE","name":"RPS6","canonical_id":"hgnc:HGNC:10429","description":"ribosomal protein S6","metadata":{"aliases":["S6","eS6"]}},{"id":"0882cec417e24aa9a670667fea343030","type":"GENE","name":"RPS6KA1","canonical_id":"hgnc:HGNC:10430","description":"ribosomal protein S6 kinase A1","metadata":{"aliases":["RSK1","HU-1","p90Rsk","MAPKAPK1"]}},{"id":"a5b23316858f4a51bc642ab8e74aa8dd","type":"GENE","name":"RPS6KA2","canonical_id":"hgnc:HGNC:10431","description":"ribosomal protein S6 kinase A2","metadata":{"aliases":["RSK3","HU-2"]}},{"id":"707317a85bd94d9299d35ea4604fece5","type":"GENE","name":"RPS6KA2-AS1","canonical_id":"hgnc:HGNC:40511","description":"RPS6KA2 antisense RNA 1","metadata":null},{"id":"45cb1ed0625541838d2b7197e7dd41dd","type":"GENE","name":"RPS6KA2-IT1","canonical_id":"hgnc:HGNC:41378","description":"RPS6KA2 intronic transcript 1","metadata":null},{"id":"339b117a35ab47c6a3e8bfd2867ba18c","type":"GENE","name":"RPS6KA3","canonical_id":"hgnc:HGNC:10432","description":null,"metadata":null},{"id":"91b605a4ebfb412b92c82188bb8cc521","type":"GENE","name":"RPS6KA4","canonical_id":"hgnc:HGNC:10433","description":"ribosomal protein S6 kinase A4","metadata":{"aliases":["RSK-B","MSK2"]}},{"id":"5c297273df5d4eea8270382327a64886","type":"GENE","name":"RPS6KA5","canonical_id":"hgnc:HGNC:10434","description":"ribosomal protein S6 kinase A5","metadata":{"aliases":["MSK1","RLPK"]}},{"id":"1e6f6cd0a6014a7ba3acdafc5607a8e9","type":"GENE","name":"RPS6KA6","canonical_id":"hgnc:HGNC:10435","description":"ribosomal protein S6 kinase A6","metadata":{"aliases":["RSK4"]}},{"id":"2c3bb47a431349ed9f213272d1f7bcea","type":"GENE","name":"RPS6KB1","canonical_id":"hgnc:HGNC:10436","description":"ribosomal protein S6 kinase B1","metadata":{"aliases":["S6K1","p70(S6K)-alpha","PS6K","S6K","STK14A"]}},{"id":"760b4b8936f44d3d94a2368dfa97a968","type":"GENE","name":"RPS6KB2","canonical_id":"hgnc:HGNC:10437","description":"ribosomal protein S6 kinase B2","metadata":{"aliases":["p70S6Kb","P70-BETA","STK14B","KLS","S6KB","S6Kbeta","S6K\u03b2"]}},{"id":"626eedf9fb144ae7bf1afdd17b8edd3d","type":"GENE","name":"RPS6KB2-AS1","canonical_id":"hgnc:HGNC:53744","description":"RPS6KB2 antisense RNA 1","metadata":{"aliases":["AP003419.16"]}},{"id":"fc92fdb70ba24d65b3e18c5320e59e1c","type":"GENE","name":"RPS6KC1","canonical_id":"hgnc:HGNC:10439","description":"ribosomal protein S6 kinase C1","metadata":{"aliases":["humS6PKh1","RSKL1"]}},{"id":"6b9d4abbc2ac4ac9abbeacd4685b6c7e","type":"GENE","name":"RPS6KL1","canonical_id":"hgnc:HGNC:20222","description":"ribosomal protein S6 kinase like 1","metadata":{"aliases":["MGC11287","RSKL2"]}},{"id":"416769584a2f4780b92cb53720e2fb66","type":"GENE","name":"RPS6P1","canonical_id":"hgnc:HGNC:32478","description":"ribosomal protein S6 pseudogene 1","metadata":null},{"id":"2ebf92cba20b4dd3a0ee6617b3a28e7a","type":"GENE","name":"RPS6P10","canonical_id":"hgnc:HGNC:36730","description":"ribosomal protein S6 pseudogene 10","metadata":null},{"id":"17af3b56f805473b83087a3701e5b23b","type":"GENE","name":"RPS6P11","canonical_id":"hgnc:HGNC:36270","description":"ribosomal protein S6 pseudogene 11","metadata":null},{"id":"299a7f4ebf404d3aa2eb892f5748f74e","type":"GENE","name":"RPS6P12","canonical_id":"hgnc:HGNC:36375","description":"ribosomal protein S6 pseudogene 12","metadata":null},{"id":"6fda8d2e731e4df78d8f520efae28082","type":"GENE","name":"RPS6P13","canonical_id":"hgnc:HGNC:35772","description":"ribosomal protein S6 pseudogene 13","metadata":null},{"id":"d629860e1a994aa699b88a741111be47","type":"GENE","name":"RPS6P14","canonical_id":"hgnc:HGNC:36738","description":"ribosomal protein S6 pseudogene 14","metadata":null},{"id":"6675400fb210442f9dff9ecfceadb863","type":"GENE","name":"RPS6P15","canonical_id":"hgnc:HGNC:36942","description":"ribosomal protein S6 pseudogene 15","metadata":null},{"id":"8080008abb974ff196246db6334dd9b6","type":"GENE","name":"RPS6P16","canonical_id":"hgnc:HGNC:35668","description":"ribosomal protein S6 pseudogene 16","metadata":null},{"id":"825a9bc12ab842b3a807224918d87c21","type":"GENE","name":"RPS6P17","canonical_id":"hgnc:HGNC:36669","description":"ribosomal protein S6 pseudogene 17","metadata":null},{"id":"5a14d40700fb4f548c4ce4895497eca5","type":"GENE","name":"RPS6P18","canonical_id":"hgnc:HGNC:36496","description":"ribosomal protein S6 pseudogene 18","metadata":null},{"id":"f565a73c01354d63adfa6281479cf6a0","type":"GENE","name":"RPS6P19","canonical_id":"hgnc:HGNC:36136","description":"ribosomal protein S6 pseudogene 19","metadata":null},{"id":"b9db8e44cf154fc2a2a1eee096ff10e3","type":"GENE","name":"RPS6P2","canonical_id":"hgnc:HGNC:36446","description":"ribosomal protein S6 pseudogene 2","metadata":null},{"id":"e88149228f254e70a3f20082ba55bc8a","type":"GENE","name":"RPS6P20","canonical_id":"hgnc:HGNC:36940","description":"ribosomal protein S6 pseudogene 20","metadata":null},{"id":"89d2d66629fd43a0b71e4b32e21bcf1c","type":"GENE","name":"RPS6P21","canonical_id":"hgnc:HGNC:36478","description":"ribosomal protein S6 pseudogene 21","metadata":null},{"id":"4e95399af365476e9e2edb957f63bdb0","type":"GENE","name":"RPS6P22","canonical_id":"hgnc:HGNC:35655","description":"ribosomal protein S6 pseudogene 22","metadata":null},{"id":"790f198a63b5429fa5cc202db36768ef","type":"GENE","name":"RPS6P23","canonical_id":"hgnc:HGNC:39581","description":"ribosomal protein S6 pseudogene 23","metadata":null},{"id":"fd736c8ba61545af9e1912523027e2e8","type":"GENE","name":"RPS6P24","canonical_id":"hgnc:HGNC:36070","description":"ribosomal protein S6 pseudogene 24","metadata":null},{"id":"92e383bf3f104ea3bce793d7c53f4a70","type":"GENE","name":"RPS6P25","canonical_id":"hgnc:HGNC:35948","description":"ribosomal protein S6 pseudogene 25","metadata":null},{"id":"b09a09c865464d9fb68586b809808183","type":"GENE","name":"RPS6P26","canonical_id":"hgnc:HGNC:36713","description":"ribosomal protein S6 pseudogene 26","metadata":null},{"id":"2827d30ed104487c966507ab9cbc4fd1","type":"GENE","name":"RPS6P3","canonical_id":"hgnc:HGNC:36943","description":"ribosomal protein S6 pseudogene 3","metadata":null},{"id":"5fdae02f7aef40ad87843e4e43999cf4","type":"GENE","name":"RPS6P4","canonical_id":"hgnc:HGNC:36548","description":"ribosomal protein S6 pseudogene 4","metadata":null},{"id":"daa473c865e8424b9f39abb3b8f73cfb","type":"GENE","name":"RPS6P5","canonical_id":"hgnc:HGNC:36242","description":"ribosomal protein S6 pseudogene 5","metadata":null},{"id":"2c3a304a1ab745c9bef895e9f6ac860f","type":"GENE","name":"RPS6P7","canonical_id":"hgnc:HGNC:36092","description":"ribosomal protein S6 pseudogene 7","metadata":null},{"id":"b5ee0d4c40a6424ca29fef482343b66a","type":"GENE","name":"RPS6P8","canonical_id":"hgnc:HGNC:36999","description":"ribosomal protein S6 pseudogene 8","metadata":null},{"id":"af407943b66e44d4aa7365e99e2717eb","type":"GENE","name":"RPS6P9","canonical_id":"hgnc:HGNC:35938","description":"ribosomal protein S6 pseudogene 9","metadata":null},{"id":"528cb5cf5dcd4975996b86372a5150c0","type":"GENE","name":"RPS7","canonical_id":"hgnc:HGNC:10440","description":"ribosomal protein S7","metadata":{"aliases":["S7","eS7"]}},{"id":"9c4bd2033eb54f32806809854948c92c","type":"GENE","name":"RPS7P1","canonical_id":"hgnc:HGNC:17081","description":"ribosomal protein S7 pseudogene 1","metadata":null},{"id":"8bf34e7b3f1b4bc999d2743ba52a912d","type":"GENE","name":"RPS7P10","canonical_id":"hgnc:HGNC:39903","description":"ribosomal protein S7 pseudogene 10","metadata":null},{"id":"d4b68bf7a4ed4b9dabeb7db801afb612","type":"GENE","name":"RPS7P11","canonical_id":"hgnc:HGNC:35841","description":"ribosomal protein S7 pseudogene 11","metadata":null},{"id":"27da405b512c46ba8d03997a67892666","type":"GENE","name":"RPS7P12","canonical_id":"hgnc:HGNC:36147","description":"ribosomal protein S7 pseudogene 12","metadata":null},{"id":"e848c99218ed4623b20f49ac25e4c4fd","type":"GENE","name":"RPS7P13","canonical_id":"hgnc:HGNC:35756","description":"ribosomal protein S7 pseudogene 13","metadata":null},{"id":"333be2db7f424f4e8ce2cbc34346c73e","type":"GENE","name":"RPS7P14","canonical_id":"hgnc:HGNC:36602","description":"ribosomal protein S7 pseudogene 14","metadata":null},{"id":"001037585bee42e9842566d2105d22d7","type":"GENE","name":"RPS7P15","canonical_id":"hgnc:HGNC:48878","description":"ribosomal protein S7 pseudogene 15","metadata":null},{"id":"e56a585d0aa34e43b966e34852ba0104","type":"GENE","name":"RPS7P2","canonical_id":"hgnc:HGNC:36079","description":"ribosomal protein S7 pseudogene 2","metadata":null},{"id":"e4547feb86074b61af6e4525a2febef9","type":"GENE","name":"RPS7P3","canonical_id":"hgnc:HGNC:36518","description":"ribosomal protein S7 pseudogene 3","metadata":null},{"id":"3d3d984fc7f641aa8b0d32a5454d7841","type":"GENE","name":"RPS7P4","canonical_id":"hgnc:HGNC:36000","description":"ribosomal protein S7 pseudogene 4","metadata":null},{"id":"932ef0b3c4c54c6ab757ac5458f3701f","type":"GENE","name":"RPS7P5","canonical_id":"hgnc:HGNC:37037","description":"ribosomal protein S7 pseudogene 5","metadata":null},{"id":"4f1085e4eb6f495cb8a42b482810883e","type":"GENE","name":"RPS7P6","canonical_id":"hgnc:HGNC:36334","description":"ribosomal protein S7 pseudogene 6","metadata":null},{"id":"37b137815cdf4cfcb48f0537398fd465","type":"GENE","name":"RPS7P7","canonical_id":"hgnc:HGNC:35690","description":"ribosomal protein S7 pseudogene 7","metadata":null},{"id":"5da40e83764d4b8fbeefacbfcfa14c9c","type":"GENE","name":"RPS7P8","canonical_id":"hgnc:HGNC:35710","description":"ribosomal protein S7 pseudogene 8","metadata":null},{"id":"7308d46f33b94c9188b4901a99a662ac","type":"GENE","name":"RPS7P9","canonical_id":"hgnc:HGNC:36998","description":"ribosomal protein S7 pseudogene 9","metadata":null},{"id":"0b5a0adf987a49bbb4191da2c4f61720","type":"GENE","name":"RPS8","canonical_id":"hgnc:HGNC:10441","description":"ribosomal protein S8","metadata":{"aliases":["S8","eS8"]}},{"id":"74cc38266adb49ddad7f91be6d7f61e2","type":"GENE","name":"RPS8P1","canonical_id":"hgnc:HGNC:19789","description":"ribosomal protein S8 pseudogene 1","metadata":null},{"id":"a4111206e6504a22a907f661417b9777","type":"GENE","name":"RPS8P10","canonical_id":"hgnc:HGNC:35628","description":"ribosomal protein S8 pseudogene 10","metadata":null},{"id":"5ad5382f9c804b8e90a6893b61293330","type":"GENE","name":"RPS8P11","canonical_id":"hgnc:HGNC:57005","description":"ribosomal protein S8 pseudogene 11","metadata":null},{"id":"a25487b380b0437d8fecfe90e0658303","type":"GENE","name":"RPS8P3","canonical_id":"hgnc:HGNC:31000","description":"ribosomal protein S8 pseudogene 3","metadata":{"aliases":["HsT2707"]}},{"id":"e2f59896a0724b77b9104e6b9d0f25e6","type":"GENE","name":"RPS8P4","canonical_id":"hgnc:HGNC:17478","description":"ribosomal protein S8 pseudogene 4","metadata":{"aliases":["Em:AC012468.5"]}},{"id":"bf50baa5c1c548cb8561ed79ab9cc9c6","type":"GENE","name":"RPS8P5","canonical_id":"hgnc:HGNC:36417","description":"ribosomal protein S8 pseudogene 5","metadata":null},{"id":"b80d87b7589c44d78f64f8456b6b9db5","type":"GENE","name":"RPS8P6","canonical_id":"hgnc:HGNC:36947","description":"ribosomal protein S8 pseudogene 6","metadata":null},{"id":"152a6fbec92d4731a250ef096ca244be","type":"GENE","name":"RPS8P7","canonical_id":"hgnc:HGNC:35795","description":"ribosomal protein S8 pseudogene 7","metadata":null},{"id":"82d5f9178ad64bdda6afc03691a3e791","type":"GENE","name":"RPS8P8","canonical_id":"hgnc:HGNC:36213","description":"ribosomal protein S8 pseudogene 8","metadata":null},{"id":"311bb17b9aa149b3aa6d0dda3dc2da33","type":"GENE","name":"RPS8P9","canonical_id":"hgnc:HGNC:35524","description":"ribosomal protein S8 pseudogene 9","metadata":null},{"id":"d3f18d1bef014fc686b0b00d2f0d4ec3","type":"GENE","name":"RPS9","canonical_id":"hgnc:HGNC:10442","description":"ribosomal protein S9","metadata":{"aliases":["S9","uS4"]}},{"id":"de04ab9e5fec4676b6e54a672c116f51","type":"GENE","name":"RPS9P1","canonical_id":"hgnc:HGNC:10443","description":"ribosomal protein S9 pseudogene 1","metadata":{"aliases":["RPS9P"]}},{"id":"b6f0f6ce4d1144e897737e3962f32c1d","type":"GENE","name":"RPS9P2","canonical_id":"hgnc:HGNC:19428","description":"ribosomal protein S9 pseudogene 2","metadata":{"aliases":["bA12M9.1"]}},{"id":"85b9f511fe3b4ce8a4b8be00f43094fb","type":"GENE","name":"RPS9P3","canonical_id":"hgnc:HGNC:36635","description":"ribosomal protein S9 pseudogene 3","metadata":null},{"id":"044110fa68964347bb4b271364e9bade","type":"GENE","name":"RPS9P4","canonical_id":"hgnc:HGNC:36710","description":"ribosomal protein S9 pseudogene 4","metadata":null},{"id":"d262c302f4744f4986ca3be9626cbd3d","type":"GENE","name":"RPSA","canonical_id":"hgnc:HGNC:6502","description":"ribosomal protein SA","metadata":{"aliases":["LRP","37LRP","p40","SA","uS2","LAMR1"]}},{"id":"bedee1a690ad4650b67124f654e89ab0","type":"GENE","name":"RPSA2","canonical_id":"hgnc:HGNC:36809","description":"ribosomal protein SA 2","metadata":{"aliases":["RPSAP58"]}},{"id":"5705fd3db3744f2d8e371a1677e27f6a","type":"GENE","name":"RPSAP1","canonical_id":"hgnc:HGNC:16560","description":"ribosomal protein SA pseudogene 1","metadata":{"aliases":["dJ1193N1.1","LAMR1P","LAMR1P1"]}},{"id":"98ad43fae6d645e094e6860173d78340","type":"GENE","name":"RPSAP10","canonical_id":"hgnc:HGNC:31460","description":"ribosomal protein SA pseudogene 10","metadata":{"aliases":["LAMR1P10"]}},{"id":"b596804469c14131ba589dacecbba45d","type":"GENE","name":"RPSAP11","canonical_id":"hgnc:HGNC:6503","description":"ribosomal protein SA pseudogene 11","metadata":{"aliases":["LAMR","LAMRP1","LAMRL1","LAMR1P11"]}},{"id":"520faa7222da425b804152ac3aeb5487","type":"GENE","name":"RPSAP12","canonical_id":"hgnc:HGNC:6504","description":"ribosomal protein SA pseudogene 12","metadata":{"aliases":["LAMRP2","LAMRL2","LAMR1P12"]}},{"id":"473f08e79de9471b8af26a1ebca50a6b","type":"GENE","name":"RPSAP13","canonical_id":"hgnc:HGNC:6505","description":"ribosomal protein SA pseudogene 13","metadata":{"aliases":["LAMRP3","LAMRL3","LAMR1P13"]}},{"id":"00717ce0000347afb53ae8a8f18866d9","type":"GENE","name":"RPSAP14","canonical_id":"hgnc:HGNC:6506","description":"ribosomal protein SA pseudogene 14","metadata":{"aliases":["LAMRP4","LAMRL4","LAMR1P14"]}},{"id":"1f0ca5a5ae834748abe084f50ec1ba50","type":"GENE","name":"RPSAP15","canonical_id":"hgnc:HGNC:31464","description":"ribosomal protein SA pseudogene 15","metadata":{"aliases":["LAMRL5","LAMR1P15"]}},{"id":"efd924fa4af44e1d97d5b9c6d620a579","type":"GENE","name":"RPSAP16","canonical_id":"hgnc:HGNC:35478","description":"ribosomal protein SA pseudogene 16","metadata":null},{"id":"2d384100d95744cea5a7089677f26bff","type":"GENE","name":"RPSAP17","canonical_id":"hgnc:HGNC:35707","description":"ribosomal protein SA pseudogene 17","metadata":null},{"id":"f7aff2957b524886819d9cadc0128b04","type":"GENE","name":"RPSAP18","canonical_id":"hgnc:HGNC:36106","description":"ribosomal protein SA pseudogene 18","metadata":null},{"id":"0dfbff6e03764e51aa82cd72983dd612","type":"GENE","name":"RPSAP19","canonical_id":"hgnc:HGNC:36508","description":"ribosomal protein SA pseudogene 19","metadata":null},{"id":"7670cb7426e147d8b4bdec14d29169e2","type":"GENE","name":"RPSAP2","canonical_id":"hgnc:HGNC:18771","description":"ribosomal protein SA pseudogene 2","metadata":{"aliases":["bA60E24.1","LAMR1P2"]}},{"id":"8fd14545a20a4c749452de9114f9806c","type":"GENE","name":"RPSAP20","canonical_id":"hgnc:HGNC:35595","description":"ribosomal protein SA pseudogene 20","metadata":null},{"id":"75bd3d4802014818b5e385041ff321cc","type":"GENE","name":"RPSAP21","canonical_id":"hgnc:HGNC:36928","description":"ribosomal protein SA pseudogene 21","metadata":null},{"id":"7db8bcf6c3404df583df2c0b3211f5d1","type":"GENE","name":"RPSAP22","canonical_id":"hgnc:HGNC:36435","description":"ribosomal protein SA pseudogene 22","metadata":null},{"id":"c1e296c526cb4c02ab69d1ce6ec60c9f","type":"GENE","name":"RPSAP23","canonical_id":"hgnc:HGNC:36742","description":"ribosomal protein SA pseudogene 23","metadata":null},{"id":"2d88bcf196514103afc2ee5eb3723ee5","type":"GENE","name":"RPSAP24","canonical_id":"hgnc:HGNC:36362","description":"ribosomal protein SA pseudogene 24","metadata":null},{"id":"0e243fef7b8945d99cac73c14b705405","type":"GENE","name":"RPSAP25","canonical_id":"hgnc:HGNC:36405","description":"ribosomal protein SA pseudogene 25","metadata":null},{"id":"dee3c14bef134c64abb84031cbfbbdd2","type":"GENE","name":"RPSAP26","canonical_id":"hgnc:HGNC:36195","description":"ribosomal protein SA pseudogene 26","metadata":null},{"id":"1448bbd1e1484517ac05a29b17c847fd","type":"GENE","name":"RPSAP27","canonical_id":"hgnc:HGNC:36650","description":"ribosomal protein SA pseudogene 27","metadata":null},{"id":"ea7fe4a14e134ff5bbcdfa1f33823de7","type":"GENE","name":"RPSAP28","canonical_id":"hgnc:HGNC:35612","description":"ribosomal protein SA pseudogene 28","metadata":null},{"id":"4d17ad6da81f4479970c96b9d3c86dec","type":"GENE","name":"RPSAP29","canonical_id":"hgnc:HGNC:36680","description":"ribosomal protein SA pseudogene 29","metadata":null},{"id":"c08dd05660ef4c5e958bb9ebb4ad1e04","type":"GENE","name":"RPSAP3","canonical_id":"hgnc:HGNC:19792","description":"ribosomal protein SA pseudogene 3","metadata":{"aliases":["LAMR1P3"]}},{"id":"ddca22f5b3354f94a734f422d989c659","type":"GENE","name":"RPSAP30","canonical_id":"hgnc:HGNC:35861","description":"ribosomal protein SA pseudogene 30","metadata":null},{"id":"f57e7aaceafd4648ac1fd1afe8a3361e","type":"GENE","name":"RPSAP31","canonical_id":"hgnc:HGNC:35558","description":"ribosomal protein SA pseudogene 31","metadata":null},{"id":"22609849ccae49b8acc6d4bfc140a45a","type":"GENE","name":"RPSAP32","canonical_id":"hgnc:HGNC:50310","description":"ribosomal protein SA pseudogene 32","metadata":null},{"id":"dfdfac1653e845e2ae8fb5f390f2d828","type":"GENE","name":"RPSAP33","canonical_id":"hgnc:HGNC:35556","description":"ribosomal protein SA pseudogene 33","metadata":null},{"id":"58b5d9473ca64b3496a703bf27990f46","type":"GENE","name":"RPSAP34","canonical_id":"hgnc:HGNC:36643","description":"ribosomal protein SA pseudogene 34","metadata":null},{"id":"9091391db6e644a3a55ca96ca91ec654","type":"GENE","name":"RPSAP35","canonical_id":"hgnc:HGNC:36447","description":"ribosomal protein SA pseudogene 35","metadata":null},{"id":"148d7b1dd7294536aa022b95ae3d8cb9","type":"GENE","name":"RPSAP36","canonical_id":"hgnc:HGNC:35727","description":"ribosomal protein SA pseudogene 36","metadata":null},{"id":"c188f289ea1545cda60b2d58d0d7dd2e","type":"GENE","name":"RPSAP37","canonical_id":"hgnc:HGNC:35844","description":"ribosomal protein SA pseudogene 37","metadata":null},{"id":"4a947d6e0cd340e8962176c29fcb66ab","type":"GENE","name":"RPSAP38","canonical_id":"hgnc:HGNC:35963","description":"ribosomal protein SA pseudogene 38","metadata":null},{"id":"8a1b03127a824b66b58d634a7b7a6918","type":"GENE","name":"RPSAP39","canonical_id":"hgnc:HGNC:37040","description":"ribosomal protein SA pseudogene 39","metadata":null},{"id":"bd834c7a4b434fdea2a600f896b15792","type":"GENE","name":"RPSAP4","canonical_id":"hgnc:HGNC:20018","description":"ribosomal protein SA pseudogene 4","metadata":{"aliases":["LAMR1P4"]}},{"id":"161191fa157a49c89932b4aa61e9634c","type":"GENE","name":"RPSAP40","canonical_id":"hgnc:HGNC:36828","description":"ribosomal protein SA pseudogene 40","metadata":null},{"id":"8f1946a2a7d3463e8ce1a657b431b666","type":"GENE","name":"RPSAP41","canonical_id":"hgnc:HGNC:36663","description":"ribosomal protein SA pseudogene 41","metadata":null},{"id":"fc7ce4519cf54e1da767bbd00edfb2ab","type":"GENE","name":"RPSAP42","canonical_id":"hgnc:HGNC:36265","description":"ribosomal protein SA pseudogene 42","metadata":null},{"id":"a25ad88e6ed54f28836cd49ca150b1c4","type":"GENE","name":"RPSAP43","canonical_id":"hgnc:HGNC:35501","description":"ribosomal protein SA pseudogene 43","metadata":null},{"id":"5d13a2b24309487691c21e26a3f902c6","type":"GENE","name":"RPSAP44","canonical_id":"hgnc:HGNC:36891","description":"ribosomal protein SA pseudogene 44","metadata":null},{"id":"46f8f61fd4b1413d95631be26e92539f","type":"GENE","name":"RPSAP45","canonical_id":"hgnc:HGNC:35857","description":"ribosomal protein SA pseudogene 45","metadata":null},{"id":"d21a164d59d6451aaf8ebbc691f9d00c","type":"GENE","name":"RPSAP46","canonical_id":"hgnc:HGNC:36082","description":"ribosomal protein SA pseudogene 46","metadata":null},{"id":"376d2809a5514f97bbd4e6ddfa527401","type":"GENE","name":"RPSAP47","canonical_id":"hgnc:HGNC:36162","description":"ribosomal protein SA pseudogene 47","metadata":null},{"id":"bf21a217a35b4ab097a2aa838aa62cd5","type":"GENE","name":"RPSAP48","canonical_id":"hgnc:HGNC:36646","description":"ribosomal protein SA pseudogene 48","metadata":null},{"id":"6d92652f91694d218f052dc5a0f3582b","type":"GENE","name":"RPSAP49","canonical_id":"hgnc:HGNC:35660","description":"ribosomal protein SA pseudogene 49","metadata":null},{"id":"779ef786c49a47a2b359680eaa2ab7ef","type":"GENE","name":"RPSAP5","canonical_id":"hgnc:HGNC:20139","description":"ribosomal protein SA pseudogene 5","metadata":{"aliases":["LAMR1P5"]}},{"id":"9c9e0c8867ac4a27808a41b381fb180e","type":"GENE","name":"RPSAP50","canonical_id":"hgnc:HGNC:35896","description":"ribosomal protein SA pseudogene 50","metadata":null},{"id":"2cc668b45967418c8a0d948103e40ea3","type":"GENE","name":"RPSAP51","canonical_id":"hgnc:HGNC:36224","description":"ribosomal protein SA pseudogene 51","metadata":null},{"id":"2edc2c9c38514307b61666e8f318b2eb","type":"GENE","name":"RPSAP52","canonical_id":"hgnc:HGNC:35752","description":"ribosomal protein SA pseudogene 52","metadata":null},{"id":"5684a4184bd44bd69ad5957e51ae9b39","type":"GENE","name":"RPSAP53","canonical_id":"hgnc:HGNC:36641","description":"ribosomal protein SA pseudogene 53","metadata":null},{"id":"2e2a8a71c32448799c38f447038bd94f","type":"GENE","name":"RPSAP54","canonical_id":"hgnc:HGNC:36373","description":"ribosomal protein SA pseudogene 54","metadata":null},{"id":"795abe32744b44b78bcdc994fffc4f1b","type":"GENE","name":"RPSAP55","canonical_id":"hgnc:HGNC:36921","description":"ribosomal protein SA pseudogene 55","metadata":null},{"id":"4abcd2f18fee43efaf3e2d1aedcc7447","type":"GENE","name":"RPSAP56","canonical_id":"hgnc:HGNC:36018","description":"ribosomal protein SA pseudogene 56","metadata":null},{"id":"d736d9116cb646d9ab88f76561c66882","type":"GENE","name":"RPSAP57","canonical_id":"hgnc:HGNC:35889","description":"ribosomal protein SA pseudogene 57","metadata":null},{"id":"1cb2b2be3c424a98a2c0247f07ac8675","type":"GENE","name":"RPSAP59","canonical_id":"hgnc:HGNC:36957","description":"ribosomal protein SA pseudogene 59","metadata":null},{"id":"86532950e1b648e3a587917e72570311","type":"GENE","name":"RPSAP6","canonical_id":"hgnc:HGNC:31458","description":"ribosomal protein SA pseudogene 6","metadata":{"aliases":["AC022026.3","LAMR1P6"]}},{"id":"6de5eabfc548485b930966ab5aaee278","type":"GENE","name":"RPSAP60","canonical_id":"hgnc:HGNC:36331","description":"ribosomal protein SA pseudogene 60","metadata":null},{"id":"bad60ae485a14eacb782ed7faa13d169","type":"GENE","name":"RPSAP61","canonical_id":"hgnc:HGNC:36760","description":"ribosomal protein SA pseudogene 61","metadata":null},{"id":"532b152b30204061a13798c39c5631e0","type":"GENE","name":"RPSAP62","canonical_id":"hgnc:HGNC:35583","description":"ribosomal protein SA pseudogene 62","metadata":null},{"id":"79ee5877d73b41e994cbb5c31fbf6da9","type":"GENE","name":"RPSAP63","canonical_id":"hgnc:HGNC:35581","description":"ribosomal protein SA pseudogene 63","metadata":null},{"id":"64f067d3e1424b1fb32f53f422f29aaf","type":"GENE","name":"RPSAP64","canonical_id":"hgnc:HGNC:39642","description":"ribosomal protein SA pseudogene 64","metadata":null},{"id":"7f8b559c44b0462aa8b80c4261eb656b","type":"GENE","name":"RPSAP65","canonical_id":"hgnc:HGNC:51914","description":"ribosomal protein SA pseudogene 65","metadata":null},{"id":"4a26314b31864ca197b414351cb5d746","type":"GENE","name":"RPSAP66","canonical_id":"hgnc:HGNC:51916","description":"ribosomal protein SA pseudogene 66","metadata":null},{"id":"29cf936ff30041378381ebc7d5badbe5","type":"GENE","name":"RPSAP67","canonical_id":"hgnc:HGNC:51918","description":"ribosomal protein SA pseudogene 67","metadata":null},{"id":"1d1eadb2fda44675ab382a81b2434991","type":"GENE","name":"RPSAP68","canonical_id":"hgnc:HGNC:51920","description":"ribosomal protein SA pseudogene 68","metadata":null},{"id":"8b6e382940af4b20bbfb8263af1c3c2e","type":"GENE","name":"RPSAP69","canonical_id":"hgnc:HGNC:51922","description":"ribosomal protein SA pseudogene 69","metadata":null},{"id":"2625a27157e44bcc9d2360da8eb1a807","type":"GENE","name":"RPSAP7","canonical_id":"hgnc:HGNC:31461","description":"ribosomal protein SA pseudogene 7","metadata":{"aliases":["LAMR1P7"]}},{"id":"bac8fc7694cf4472aa9929c9427f4c3f","type":"GENE","name":"RPSAP70","canonical_id":"hgnc:HGNC:51923","description":"ribosomal protein SA pseudogene 70","metadata":null},{"id":"cd6d6c76e65e44579d58becb9a41cb0d","type":"GENE","name":"RPSAP71","canonical_id":"hgnc:HGNC:51924","description":"ribosomal protein SA pseudogene 71","metadata":null},{"id":"850c95c57c7a4b2d9615f80e3eba06c4","type":"GENE","name":"RPSAP72","canonical_id":"hgnc:HGNC:51925","description":"ribosomal protein SA pseudogene 72","metadata":null},{"id":"fa5425cf13a740a99455e1d3a8b1023d","type":"GENE","name":"RPSAP73","canonical_id":"hgnc:HGNC:51926","description":"ribosomal protein SA pseudogene 73","metadata":null},{"id":"7e2c9df8cd5d4872a6387127d8037380","type":"GENE","name":"RPSAP74","canonical_id":"hgnc:HGNC:51928","description":"ribosomal protein SA pseudogene 74","metadata":null},{"id":"86ab5c3d34df42e3be537bdde152182c","type":"GENE","name":"RPSAP75","canonical_id":"hgnc:HGNC:51929","description":"ribosomal protein SA pseudogene 75","metadata":null},{"id":"533f64c0871c4aa480f5c6d9070b04f0","type":"GENE","name":"RPSAP76","canonical_id":"hgnc:HGNC:51930","description":"ribosomal protein SA pseudogene 76","metadata":null},{"id":"b4e7263a906348b284a484920d511513","type":"GENE","name":"RPSAP8","canonical_id":"hgnc:HGNC:31462","description":"ribosomal protein SA pseudogene 8","metadata":{"aliases":["LAMR1P8"]}},{"id":"297ea3cf7bb74c73b4ca5c680c03c9d2","type":"GENE","name":"RPSAP9","canonical_id":"hgnc:HGNC:31463","description":"ribosomal protein SA pseudogene 9","metadata":{"aliases":["LAMR1P9"]}},{"id":"0e1bf5a796e34044aebab29bd36d956e","type":"GENE","name":"RPTN","canonical_id":"hgnc:HGNC:26809","description":"repetin","metadata":{"aliases":["FLJ39117"]}},{"id":"0f2ee057b22a45238ce258dfa7f271c0","type":"GENE","name":"RPTOR","canonical_id":"hgnc:HGNC:30287","description":null,"metadata":null},{"id":"c0513afefe8241efa1808606fb9762f7","type":"GENE","name":"RPUSD1","canonical_id":"hgnc:HGNC:14173","description":"RNA pseudouridine synthase domain containing 1","metadata":{"aliases":["RLUCL","MGC19600","C16orf40"]}},{"id":"cf1fabbb752b4317b3f5b0a2a91a6abc","type":"GENE","name":"RPUSD2","canonical_id":"hgnc:HGNC:24180","description":"RNA pseudouridine synthase domain containing 2","metadata":{"aliases":["C18B11","FLJ31409","PUS9","C15orf19"]}},{"id":"0836c4561cf245579378d68135271c46","type":"GENE","name":"RPUSD3","canonical_id":"hgnc:HGNC:28437","description":"RNA pseudouridine synthase D3","metadata":{"aliases":["MGC29784"]}},{"id":"e44ba8f8fe7340ac948a1491cb06388b","type":"GENE","name":"RPUSD4","canonical_id":"hgnc:HGNC:25898","description":"RNA pseudouridine synthase D4","metadata":{"aliases":["FLJ14494"]}},{"id":"e720eb31baff49169e4932415fe7aa41","type":"GO_TERM","name":"RQC complex","canonical_id":"go:GO:1990112","description":"\"A multiprotein complex that forms a stable complex with large ribosomal subunits (60S in eukaryotes and 50S in prokaryotes) containing stalled polypeptides and triggers their degradation (ribosomal quality control). In budding yeast, this complex includes Cdc48p, Rkr1p, Tae2p, Rqc1p, Npl4p and Ufd1p proteins.\" [GOC:rb, PMID:23178123, PMID:23232563]","metadata":null},{"id":"67002e45fddb4fb68399dd6d45d69314","type":"GO_TERM","name":"RQC-trigger complex","canonical_id":"go:GO:0180022","description":"\"A ribosome disassembly complex which dissociates stalled ribsome subunits as part of the ribosome quality control pathway. RQT complex is composed of a RNA helicase-family protein yeast Rqt2 (human ASCC3), a ubiquitin-binding protein yeast Rqt3, (human ASCC2), and Rqt4 (human TRIP4). The human complex has an additional component protein ASCC1 and can act as a transcriptional coactivator by interacting with transcription factors such as NF-kappa B.\" [PMID:12077347, PMID:28757607, PMID:32099016]","metadata":null},{"id":"4358993e3b334836bda7623931756e6e","type":"GENE","name":"RRAD","canonical_id":"hgnc:HGNC:10446","description":"RRAD, Ras related glycolysis inhibitor and calcium channel regulator","metadata":{"aliases":["REM3","RAD"]}},{"id":"b69fe10e0e814403abb82c962ca8e752","type":"GENE","name":"RRAGA","canonical_id":"hgnc:HGNC:16963","description":"Ras related GTP binding A","metadata":{"aliases":["RAGA","FIP-1"]}},{"id":"3cdfe5e073dc493f98e388ef161e1f4d","type":"GENE","name":"RRAGAP1","canonical_id":"hgnc:HGNC:20242","description":"Ras related GTP binding A pseudogene 1","metadata":{"aliases":["RRAGAP"]}},{"id":"f9bd851a752f4f36a1a09cc6f37ebd72","type":"GENE","name":"RRAGAP1-AS1","canonical_id":"hgnc:HGNC:55445","description":"RRAGAP1 antisense RNA 1","metadata":{"aliases":["LINC02302"]}},{"id":"8de77b95a3564866a1d5e0e34528c6b7","type":"GENE","name":"RRAGB","canonical_id":"hgnc:HGNC:19901","description":"Ras related GTP binding B","metadata":null},{"id":"453f58d7ec334b8e826d356751356076","type":"GENE","name":"RRAGC","canonical_id":"hgnc:HGNC:19902","description":"Ras related GTP binding C","metadata":{"aliases":["GTR2","FLJ13311"]}},{"id":"7d52f031210946d2a031a3bdd8035be6","type":"GENE","name":"RRAGC-DT","canonical_id":"hgnc:HGNC:55793","description":"RRAGC divergent transcript","metadata":{"aliases":["LENGA"]}},{"id":"d073f2593993492e97a0f37706b8f6fe","type":"GENE","name":"RRAGD","canonical_id":"hgnc:HGNC:19903","description":"Ras related GTP binding D","metadata":{"aliases":["DKFZP761H171","bA11D8.2.1"]}},{"id":"a663f19731364e72a6afcafdca21ebb0","type":"GENE","name":"RRAS","canonical_id":"hgnc:HGNC:10447","description":"RAS related","metadata":{"aliases":["R-Ras","RRAS1"]}},{"id":"0d79a46cf404413ab3c6f1d012dd75ef","type":"GENE","name":"RRAS2","canonical_id":"hgnc:HGNC:17271","description":null,"metadata":null},{"id":"e0786f0f37f84e1c983fadb106425d9b","type":"GENE","name":"RRAS2P1","canonical_id":"hgnc:HGNC:54561","description":"RRAS2 pseudogene 1","metadata":null},{"id":"ced1e28dd12343edb793867bf6aafddc","type":"GENE","name":"RRAS2P2","canonical_id":"hgnc:HGNC:54562","description":"RRAS2 pseudogene 2","metadata":null},{"id":"64f1722fd9b84e6e87fd4d4b08aa20bf","type":"GENE","name":"RRBP1","canonical_id":"hgnc:HGNC:10448","description":"ribosome binding protein 1","metadata":{"aliases":["ES/130","hES","p180"]}},{"id":"64aad66a60d5462093ab0ab7589a03cd","type":"GENE","name":"RRBP1P1","canonical_id":"hgnc:HGNC:55607","description":"RRBP1 pseudogene 1","metadata":null},{"id":"a8da4ae64a7242a491238779987a35ad","type":"GENE","name":"RRBP1P2","canonical_id":"hgnc:HGNC:55608","description":"RRBP1 pseudogene 2","metadata":null},{"id":"6b5a90a109a74ee498d88cb7960f53cf","type":"GENE","name":"RREB1","canonical_id":"hgnc:HGNC:10449","description":null,"metadata":null},{"id":"caea28ff477e4caca9b2faee70770c0f","type":"GENE","name":"RRH","canonical_id":"hgnc:HGNC:10450","description":"retinal pigment epithelium-derived rhodopsin homolog","metadata":{"aliases":["peropsin"]}},{"id":"6bb4163efea14317a05fe5e7e8cf4f8e","type":"GENE","name":"RRM1","canonical_id":"hgnc:HGNC:10451","description":null,"metadata":null},{"id":"230a6479d8f04fbabf250c2e8273e2a3","type":"PROTEIN","name":"RRM1","canonical_id":"uniprot:P23921","description":null,"metadata":null},{"id":"d1b574bb862a4f6eaaac344a31717b5f","type":"GENE","name":"RRM1-AS1","canonical_id":"hgnc:HGNC:40512","description":"RRM1 antisense RNA 1","metadata":null},{"id":"61b4ecb30ae74a69b4f20ae6e6cc9210","type":"GENE","name":"RRM2","canonical_id":"hgnc:HGNC:10452","description":null,"metadata":null},{"id":"dc39cf3235474a3d9d5a08479a2daa99","type":"GENE","name":"RRM2B","canonical_id":"hgnc:HGNC:17296","description":null,"metadata":null},{"id":"f04f497d8e4c4334b88cda5296215024","type":"GENE","name":"RRM2P2","canonical_id":"hgnc:HGNC:10454","description":"ribonucleotide reductase M2 polypeptide pseudogene 2","metadata":null},{"id":"9ce000c34d7f41f1966d925445f3ef60","type":"GENE","name":"RRM2P3","canonical_id":"hgnc:HGNC:10455","description":"ribonucleotide reductase M2 polypeptide pseudogene 3","metadata":null},{"id":"be48d67b6b38427992d75c7d67501b04","type":"GENE","name":"RRM2P4","canonical_id":"hgnc:HGNC:10456","description":"ribonucleotide reductase M2 polypeptide pseudogene 4","metadata":null},{"id":"638b2469c33a4f38adcddb7e6c3b2a13","type":"GENE","name":"RRN3","canonical_id":"hgnc:HGNC:30346","description":"RNA polymerase I transcription factor RRN3","metadata":{"aliases":["DKFZp566E104","TIF-IA"]}},{"id":"6f846a158d744f659dc828ab3d118d5f","type":"GENE","name":"RRN3P1","canonical_id":"hgnc:HGNC:30548","description":"RRN3 pseudogene 1","metadata":null},{"id":"a23b01a2333345a1844f9e9122cb3461","type":"GENE","name":"RRN3P2","canonical_id":"hgnc:HGNC:37619","description":"RRN3 pseudogene 2","metadata":null},{"id":"8146374ab2424dd9914dc85f1af7261c","type":"GENE","name":"RRN3P3","canonical_id":"hgnc:HGNC:37620","description":"RRN3 pseudogene 3","metadata":null},{"id":"6ee1137638bd48fca8dd9d33aa739fe4","type":"GENE","name":"RRN3P4","canonical_id":"hgnc:HGNC:54536","description":"RRN3 pseudogene 4","metadata":null},{"id":"c416126621504105819323b10556c887","type":"GENE","name":"RRP1","canonical_id":"hgnc:HGNC:18785","description":"ribosomal RNA processing 1","metadata":{"aliases":["NNP-1","Nop52","NOP52","RRP1A","D21S2056E"]}},{"id":"920611629cec41168724c6ca183bf3cb","type":"GENE","name":"RRP12","canonical_id":"hgnc:HGNC:29100","description":"ribosomal RNA processing 12 homolog","metadata":{"aliases":["KIAA0690"]}},{"id":"01318c994f7b4fb1ab5b9abf30d45faa","type":"GENE","name":"RRP15","canonical_id":"hgnc:HGNC:24255","description":"ribosomal RNA processing 15 homolog","metadata":{"aliases":["CGI-115","KIAA0507"]}},{"id":"1ea158cdfc4449129c529dfc66718e80","type":"GENE","name":"RRP1B","canonical_id":"hgnc:HGNC:23818","description":null,"metadata":null},{"id":"214d20926ead44848e6818c5c04f38ca","type":"GENE","name":"RRP36","canonical_id":"hgnc:HGNC:21374","description":"ribosomal RNA processing 36","metadata":{"aliases":["dJ20C7.4","C6orf153"]}},{"id":"954ba145c00d457faf493506ad4b8075","type":"GENE","name":"RRP7A","canonical_id":"hgnc:HGNC:24286","description":"ribosomal RNA processing 7 homolog A","metadata":{"aliases":["CGI-96","Rrp7"]}},{"id":"d8b9e6702fa0477da2e4e4bb3c4eb2c6","type":"GENE","name":"RRP7BP","canonical_id":"hgnc:HGNC:30454","description":"ribosomal RNA processing 7 homolog B, pseudogene","metadata":{"aliases":["dJ222E13.2","RRP7B"]}},{"id":"7ffabd310bc6452286163d7e51ed912f","type":"GENE","name":"RRP8","canonical_id":"hgnc:HGNC:29030","description":"ribosomal RNA processing 8","metadata":{"aliases":["NML","KIAA0409"]}},{"id":"e29f68f4552f493f88f1f89ba6bdd917","type":"GENE","name":"RRP9","canonical_id":"hgnc:HGNC:16829","description":"ribosomal RNA processing 9, U3 small nucleolar RNA binding protein","metadata":{"aliases":["U3-55K","RNU3IP2"]}},{"id":"2c351afbbbc74786aa2162b64a905909","type":"GENE","name":"RRS1","canonical_id":"hgnc:HGNC:17083","description":"regulator of ribosome synthesis 1","metadata":{"aliases":["KIAA0112"]}},{"id":"40b0aa442946413ea0149c63d7e00bcf","type":"GENE","name":"RRS1-DT","canonical_id":"hgnc:HGNC:50465","description":"RRS1 divergent transcript","metadata":{"aliases":["RRS1-AS1"]}},{"id":"4261ccf860704f30bac65a394578d67d","type":"GO_TERM","name":"RS domain binding","canonical_id":"go:GO:0050733","description":"\"Binding to an RS domain of a protein; RS domains are usually highly phosphorylated and characterized by the presence of arginine (R)/serine (S) dipeptides. The RS domain promotes protein-protein interactions and directs subcellular localization and, in certain situations, nucleocytoplasmic shuttling of individual SR proteins. They also play a role in splicing.\" [PMID:11684676, PMID:12215544]","metadata":null},{"id":"3e65f9d461554a298dae1d3aaa745b81","type":"GENE","name":"RS1","canonical_id":"hgnc:HGNC:10457","description":null,"metadata":null},{"id":"7e122408745e43ce8f5a7d7f8251d2a9","type":"GENE","name":"RSAD1","canonical_id":"hgnc:HGNC:25634","description":"radical S-adenosyl methionine domain containing 1","metadata":{"aliases":["FLJ11164","HemW"]}},{"id":"a914dbb21be04d598d5370945e7f5e94","type":"GENE","name":"RSAD2","canonical_id":"hgnc:HGNC:30908","description":"radical S-adenosyl methionine domain containing 2","metadata":{"aliases":["cig5","vig1","Viperin"]}},{"id":"6ba2eed2c9e5481bbfbb5b3426d19ed7","type":"GENE","name":"RSBN1","canonical_id":"hgnc:HGNC:25642","description":"round spermatid basic protein 1","metadata":{"aliases":["FLJ11220","ROSBIN","KDM9"]}},{"id":"efa53cfde23d46f0a8536090fab88c08","type":"GENE","name":"RSBN1L","canonical_id":"hgnc:HGNC:24765","description":"round spermatid basic protein 1 like","metadata":{"aliases":["FLJ42526","FLJ45813","MGC71764"]}},{"id":"da7e3702ba954252ab46ebe809f37158","type":"GO_TERM","name":"RSC-type complex","canonical_id":"go:GO:0016586","description":"\"A SWI/SNF-type complex that contains a bromodomain containing-protein, such as yeast Rsc1 or Rsc4 or mammalian PB1/BAF180. The RSC complex is generally recruited to RNA polymerase III promoters and is specifically recruited to RNA polymerase II promoters by transcriptional activators and repressors; it is also involved in non-homologous end joining.\" [GOC:bhm, PMID:11937489, PMID:12672490, PMID:15870268, PMID:19355820, PMID:8980231]","metadata":null},{"id":"02ba8cf2332e4416b3770b4e4fd75538","type":"GO_TERM","name":"RSF complex","canonical_id":"go:GO:0031213","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (SNF2H in mammals) and an RSF1 homolog. It mediates nucleosome deposition and generates regularly spaced nucleosome arrays. In mammals, RSF is involved in regulation of transcription from RNA polymerase II promoters).\" [GOC:krc, PMID:12972596, PMID:15284901, PMID:16568949, PMID:21810179]","metadata":null},{"id":"1ee6c57311ed480685d409c0ef370bd5","type":"GENE","name":"RSF1","canonical_id":"hgnc:HGNC:18118","description":null,"metadata":null},{"id":"facb11950fb2423486fac2fe3652b26b","type":"GENE","name":"RSF1-IT1","canonical_id":"hgnc:HGNC:41439","description":"RSF1 intronic transcript 1","metadata":null},{"id":"1dccb40923b647c8b403c27a655cbb96","type":"GENE","name":"RSF1-IT2","canonical_id":"hgnc:HGNC:41438","description":"RSF1 intronic transcript 2","metadata":null},{"id":"b7fbce863c7043549dc44b63a13d9974","type":"GENE","name":"RSKR","canonical_id":"hgnc:HGNC:26314","description":"ribosomal protein S6 kinase related","metadata":{"aliases":["FLJ25006","SgK494"]}},{"id":"7ff00076887847e1ada9037284cc34f7","type":"GENE","name":"RSL1D1","canonical_id":"hgnc:HGNC:24534","description":"ribosomal L1 domain containing 1","metadata":{"aliases":["Cic1","PBK1","L12","DKFZP564M182","CSIG","UTP30"]}},{"id":"a8979afb33c44d12a015029f7e02570c","type":"GENE","name":"RSL1D1-DT","canonical_id":"hgnc:HGNC:55337","description":"RSL1D1 divergent transcript","metadata":null},{"id":"cdfac4b6727244df888b1464b07a6536","type":"GENE","name":"RSL24D1","canonical_id":"hgnc:HGNC:18479","description":"ribosomal L24 domain containing 1","metadata":{"aliases":["HRP-L30-iso","L30","RPL24L","RPL24","C15orf15"]}},{"id":"8f32c853e1f740b98e57c2ce7886bfc7","type":"GENE","name":"RSL24D1P1","canonical_id":"hgnc:HGNC:13979","description":"ribosomal L24 domain containing 1 pseudogene 1","metadata":{"aliases":["RPL24p","dJ97D16.2","RPL30BP","RSL24D1P"]}},{"id":"179e34a623c140388fa045a6d6740d9a","type":"GENE","name":"RSL24D1P10","canonical_id":"hgnc:HGNC:37875","description":"ribosomal L24 domain containing 1 pseudogene 10","metadata":null},{"id":"8deb626fb1594f96aa6b36d05b7083e5","type":"GENE","name":"RSL24D1P11","canonical_id":"hgnc:HGNC:37881","description":"ribosomal L24 domain containing 1 pseudogene 11","metadata":null},{"id":"b91cfebcbe9a42c1b36f52d1be04b619","type":"GENE","name":"RSL24D1P2","canonical_id":"hgnc:HGNC:37867","description":"ribosomal L24 domain containing 1 pseudogene 2","metadata":null},{"id":"f6f7caef6f7c44a090a7bfb7d341be6b","type":"GENE","name":"RSL24D1P3","canonical_id":"hgnc:HGNC:37883","description":"ribosomal L24 domain containing 1 pseudogene 3","metadata":null},{"id":"3fef2f880ecd470f8613b1113f90efda","type":"GENE","name":"RSL24D1P4","canonical_id":"hgnc:HGNC:37884","description":"ribosomal L24 domain containing 1 pseudogene 4","metadata":{"aliases":["RSL24D1P19"]}},{"id":"139b92167b1b4e9abc07289241ce9586","type":"GENE","name":"RSL24D1P5","canonical_id":"hgnc:HGNC:37870","description":"ribosomal L24 domain containing 1 pseudogene 5","metadata":null},{"id":"d85a924402d04a698f1c338b9fc40abd","type":"GENE","name":"RSL24D1P6","canonical_id":"hgnc:HGNC:37876","description":"ribosomal L24 domain containing 1 pseudogene 6","metadata":{"aliases":["dJ836N17.3","RPL24P1"]}},{"id":"90b123209b374d2989251900a0cc2e84","type":"GENE","name":"RSL24D1P7","canonical_id":"hgnc:HGNC:37877","description":"ribosomal L24 domain containing 1 pseudogene 7","metadata":null},{"id":"ff59a6afb8164981a081942514b0f365","type":"GENE","name":"RSL24D1P8","canonical_id":"hgnc:HGNC:37873","description":"ribosomal L24 domain containing 1 pseudogene 8","metadata":null},{"id":"eedde5061b6846219b530bd91c13067a","type":"GENE","name":"RSL24D1P9","canonical_id":"hgnc:HGNC:37880","description":"ribosomal L24 domain containing 1 pseudogene 9","metadata":null},{"id":"32ebe4c39df44549bc5f63ca6d1d339a","type":"GO_TERM","name":"RSP5-BUL ubiquitin ligase complex","canonical_id":"go:GO:1990306","description":"\"A ubiquitin ligase complex consisting of RSP5 and BUL components. It polyubiquinates plasma membrane transporters and permeases, required for their endocytosis and subsequent degradation in the vacuole. BUL1 or BUL2, respectively, bind to the target protein, enabling ubiquitylation by Rsp5. Phosphorylation of BUL proteins results in binding to 14-3-3 proteins, protecting the permeases from down-regulation.\" [GOC:bhm, PMID:9931424]","metadata":null},{"id":"7fb60c1e7ae6477a8f436de58162d89b","type":"GENE","name":"RSPH1","canonical_id":"hgnc:HGNC:12371","description":"radial spoke head component 1","metadata":{"aliases":["FLJ32753","RSP44","RSPH10A","CILD24","TSGA2"]}},{"id":"91bbabb50f3941949c67a7dd65bf57ce","type":"GENE","name":"RSPH1-DT","canonical_id":"hgnc:HGNC:55644","description":"RSPH1 divergent transcript","metadata":null},{"id":"52ca3f630a384c819a4c6138c6ef0fdb","type":"GENE","name":"RSPH10B","canonical_id":"hgnc:HGNC:27362","description":"radial spoke head 10 homolog B","metadata":null},{"id":"cc014ab52a8b44e380ee354ff41212b1","type":"GENE","name":"RSPH10B2","canonical_id":"hgnc:HGNC:34385","description":"radial spoke head 10 homolog B2","metadata":null},{"id":"8020d578a262484a8bb533c5aad7a497","type":"GENE","name":"RSPH14","canonical_id":"hgnc:HGNC:13437","description":"radial spoke head 14 homolog","metadata":{"aliases":["RTDR1"]}},{"id":"fb1f9e49dde541958121ef7ad83ddb9c","type":"GENE","name":"RSPH3","canonical_id":"hgnc:HGNC:21054","description":"radial spoke head 3","metadata":{"aliases":["dJ111C20.1","RSP3","RSHL2"]}},{"id":"5a8aa3e3a28a45d8aaba30bc6c0b8897","type":"GENE","name":"RSPH4A","canonical_id":"hgnc:HGNC:21558","description":"radial spoke head component 4A","metadata":{"aliases":["dJ412I7.1","FLJ37974","RSPH6B","CILD11","RSHL3"]}},{"id":"0d937e5b58334397a203956304010415","type":"GENE","name":"RSPH6A","canonical_id":"hgnc:HGNC:14241","description":"radial spoke head 6 homolog A","metadata":{"aliases":["RSP4","RSP6","RSPH4B","RSHL1"]}},{"id":"0ed17f8ceed64207bbfce5ad1dac423d","type":"GENE","name":"RSPH9","canonical_id":"hgnc:HGNC:21057","description":"radial spoke head component 9","metadata":{"aliases":["FLJ30845","CILD12","MRPS18AL1","C6orf206"]}},{"id":"a8461772cc3d4bda85fe9a62b7c2897d","type":"GENE","name":"RSPO1","canonical_id":"hgnc:HGNC:21679","description":"R-spondin 1","metadata":{"aliases":["FLJ40906","RSPONDIN"]}},{"id":"2342fa1c167f4b5eb95fc7399c72e4a9","type":"GENE","name":"RSPO2","canonical_id":"hgnc:HGNC:28583","description":null,"metadata":null},{"id":"131f45493114448e8d314ede2eb4d4eb","type":"GENE","name":"RSPO3","canonical_id":"hgnc:HGNC:20866","description":"R-spondin 3","metadata":{"aliases":["FLJ14440","THSD2"]}},{"id":"cff97a2e22cf4a449a928fcb0440f790","type":"GENE","name":"RSPO4","canonical_id":"hgnc:HGNC:16175","description":"R-spondin 4","metadata":{"aliases":["dJ824F16.3","C20orf182"]}},{"id":"780823061aff420c8a6881cd95b61cbf","type":"GENE","name":"RSPRY1","canonical_id":"hgnc:HGNC:29420","description":"ring finger and SPRY domain containing 1","metadata":{"aliases":["KIAA1972"]}},{"id":"d8e8ab4374b54d62be3cf88a46246393","type":"GENE","name":"RSRC1","canonical_id":"hgnc:HGNC:24152","description":"arginine and serine rich coiled-coil 1","metadata":{"aliases":["MGC12197","BM-011","SRrp53","SFRS21"]}},{"id":"cd5bfee13cde4a34a240ba4938e17685","type":"GENE","name":"RSRC1P1","canonical_id":"hgnc:HGNC:57037","description":"RSRC1 pseudogene 1","metadata":null},{"id":"4fb474680b814f32b775853c90964b0a","type":"GENE","name":"RSRC2","canonical_id":"hgnc:HGNC:30559","description":"arginine and serine rich coiled-coil 2","metadata":{"aliases":["FLJ11021"]}},{"id":"45f2609835f346789870ba3b769bf6b2","type":"GENE","name":"RSRP1","canonical_id":"hgnc:HGNC:25234","description":"arginine and serine rich protein 1","metadata":{"aliases":["DJ465N24.2.1","C1orf63"]}},{"id":"5ea2146356a74679976fcff805b17bbc","type":"GENE","name":"RSU1","canonical_id":"hgnc:HGNC:10464","description":"Ras suppressor protein 1","metadata":{"aliases":["RSP-1","FLJ31034"]}},{"id":"b4f80db8aa814556a28a521a4de3d7a3","type":"GENE","name":"RSU1P1","canonical_id":"hgnc:HGNC:31114","description":"Ras suppressor protein 1 pseudogene 1","metadata":{"aliases":["Y214H10.6"]}},{"id":"c69807a53a43443998d96d583f17f668","type":"GENE","name":"RSU1P2","canonical_id":"hgnc:HGNC:44391","description":"Ras suppressor protein 1 pseudogene 2","metadata":null},{"id":"1d587ce0999142fca69846b41ce3841b","type":"GENE","name":"RSU1P3","canonical_id":"hgnc:HGNC:44392","description":"Ras suppressor protein 1 pseudogene 3","metadata":null},{"id":"9d9a062e87dc4dad81d62071553930b7","type":"TRIAL","name":"RT Plus EGFR-TKI for Wild-type NSCLC","canonical_id":"clinicaltrials.gov:NCT02738983","description":"Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)","metadata":null},{"id":"2ff7aae2c02d4cb585853ea6704b30d4","type":"GENE","name":"RTBDN","canonical_id":"hgnc:HGNC:30310","description":"retbindin","metadata":{"aliases":["FLJ36353"]}},{"id":"cd89dcb768184300b227398233055544","type":"GENE","name":"RTBDN-AS1","canonical_id":"hgnc:HGNC:58174","description":"RTBDN antisense RNA 1","metadata":null},{"id":"884097155a854d02bb8d916a8d63f765","type":"GENE","name":"RTCA","canonical_id":"hgnc:HGNC:17981","description":"RNA 3'-terminal phosphate cyclase","metadata":{"aliases":["RPC","RTC1","RTCD1"]}},{"id":"8fab06d71f3b45b8bf1a8f7c8a8112ab","type":"GENE","name":"RTCA-AS1","canonical_id":"hgnc:HGNC:50573","description":"RTCA antisense RNA 1","metadata":null},{"id":"e4a587c26c6e45c6ad4ecd40050ca25f","type":"GENE","name":"RTCB","canonical_id":"hgnc:HGNC:26935","description":"RNA 2',3'-cyclic phosphate and 5'-OH ligase","metadata":{"aliases":["TSLIG5","HSPC117","FAAP","C22orf28"]}},{"id":"3a7178e5f3334c959a75fba9443546ff","type":"GENE","name":"RTEL1","canonical_id":"hgnc:HGNC:15888","description":"regulator of telomere elongation helicase 1","metadata":{"aliases":["bK3184A7.3","NHL","DKFZP434C013","KIAA1088","RTEL","C20orf41"]}},{"id":"e762120294fa46e2810d4b27228918ad","type":"GENE","name":"RTEL1-TNFRSF6B","canonical_id":"hgnc:HGNC:44095","description":"RTEL1-TNFRSF6B readthrough (NMD candidate)","metadata":null},{"id":"b6218cba48524aa6872b2f3090c1e5b5","type":"GENE","name":"RTEL1P1","canonical_id":"hgnc:HGNC:44213","description":"regulator of telomere elongation helicase 1 pseudogene 1","metadata":null},{"id":"0d4da3a4e2254ccd8c15d5091716798f","type":"GENE","name":"RTF1","canonical_id":"hgnc:HGNC:28996","description":"RTF1 homolog, Paf1/RNA polymerase II complex component","metadata":{"aliases":["KIAA0252"]}},{"id":"50216c7006d04c53a82a3fb657ed6c5b","type":"GENE","name":"RTF2","canonical_id":"hgnc:HGNC:15890","description":"replication termination factor 2","metadata":{"aliases":["HSPC164","CDAO5","C20orf43","RTFDC1"]}},{"id":"dc19d4a5e3d3444999787444adb87b86","type":"GENE","name":"RTKN","canonical_id":"hgnc:HGNC:10466","description":"rhotekin","metadata":{"aliases":["B5","RTKN-1"]}},{"id":"84115e27bda8439bbdab807fb05f928c","type":"GENE","name":"RTKN2","canonical_id":"hgnc:HGNC:19364","description":"rhotekin 2","metadata":{"aliases":["Em:AC024597.2","bA531F24.1","FLJ39352","PLEKHK1"]}},{"id":"db4cf310b9ed497daf65c45856962d08","type":"GENE","name":"RTL1","canonical_id":"hgnc:HGNC:14665","description":"retrotransposon Gag like 1","metadata":{"aliases":["PEG11","MART1","Mar1","SIRH2","HUR1"]}},{"id":"427d45d360704118993cb4a1c73b883b","type":"GENE","name":"RTL10","canonical_id":"hgnc:HGNC:26112","description":"retrotransposon Gag like 10","metadata":{"aliases":["FLJ21125","BOP","C22orf29"]}},{"id":"7e512d378f35455cb11bfe8690ac8947","type":"GENE","name":"RTL3","canonical_id":"hgnc:HGNC:22997","description":"retrotransposon Gag like 3","metadata":{"aliases":["FLJ38865","Mar3","Mart3","ZHC5","SIRH9","ZCCHC5"]}},{"id":"49488e65e6a14bea8afdeff7fc528f16","type":"GENE","name":"RTL4","canonical_id":"hgnc:HGNC:25214","description":"retrotransposon Gag like 4","metadata":{"aliases":["Mart4","Mar4","FLJ46608","SIRH11","ZCCHC16"]}},{"id":"d70a06bf7c1745bb83bd225fb35b2942","type":"GENE","name":"RTL5","canonical_id":"hgnc:HGNC:29430","description":"retrotransposon Gag like 5","metadata":{"aliases":["KIAA2001","Mar5","Mart5","SIRH8","RGAG4"]}},{"id":"829690740ae243b0b4cbbcf008f81b4c","type":"GENE","name":"RTL6","canonical_id":"hgnc:HGNC:13343","description":"retrotransposon Gag like 6","metadata":{"aliases":["dJ1033E15.2","DKFZp761O17121","Mart6","Mar6","SIRH3","LDOC1L"]}},{"id":"7732f029cdc74cc8bac6ad71d1b10f88","type":"GENE","name":"RTL8A","canonical_id":"hgnc:HGNC:24514","description":"retrotransposon Gag like 8A","metadata":{"aliases":["DKFZP564B147","MAR8A","CXX1b","SIRH6","FAM127B"]}},{"id":"4cd5fe5f773e4844a76f4633cf4d30e1","type":"GENE","name":"RTL8B","canonical_id":"hgnc:HGNC:33156","description":"retrotransposon Gag like 8B","metadata":{"aliases":["MAR8B","CXX1c","SIRH4","FAM127C"]}},{"id":"34fa551fd6f54867b7c7c16c460b9e84","type":"GENE","name":"RTL8C","canonical_id":"hgnc:HGNC:2569","description":"retrotransposon Gag like 8C","metadata":{"aliases":["Mart8","Mar8","MAR8C","SIRH5","CXX1","FAM127A"]}},{"id":"33412fb8f38247db8d1f3ce0a35923a3","type":"GENE","name":"RTL9","canonical_id":"hgnc:HGNC:29245","description":"retrotransposon Gag like 9","metadata":{"aliases":["KIAA1318","Mart9","Mar9","SIRH10","RGAG1"]}},{"id":"e3447692825c4fe79100f8696d5a85a3","type":"GENE","name":"RTN1","canonical_id":"hgnc:HGNC:10467","description":"reticulon 1","metadata":{"aliases":["NSP"]}},{"id":"0f375efe37074cb091216657aa6da8a6","type":"GENE","name":"RTN2","canonical_id":"hgnc:HGNC:10468","description":"reticulon 2","metadata":{"aliases":["NSP2","NSPL1","SPG12"]}},{"id":"b7a19af4a39f46d7b87c5dcd13b5f6fa","type":"GENE","name":"RTN3","canonical_id":"hgnc:HGNC:10469","description":null,"metadata":null},{"id":"db5b177d18044a1d8b8136c3a4abfdcd","type":"GENE","name":"RTN3P1","canonical_id":"hgnc:HGNC:19212","description":"reticulon 3 pseudogene 1","metadata":{"aliases":["RTN3PS"]}},{"id":"b9ed51d9b7bd4a90b52a6a4436b100b5","type":"GENE","name":"RTN4","canonical_id":"hgnc:HGNC:14085","description":"reticulon 4","metadata":{"aliases":["NSP-CL","KIAA0886","NOGO","ASY","NOGOA","NOGOB","NOGOC"]}},{"id":"ba88e860ee724b408ebdef7ab7b3d3f7","type":"GENE","name":"RTN4IP1","canonical_id":"hgnc:HGNC:18647","description":"reticulon 4 interacting protein 1","metadata":{"aliases":["Yim1","NIMP"]}},{"id":"0121e2cd2fc54dfca2cd1ce1eaea8e90","type":"GENE","name":"RTN4IP1P1","canonical_id":"hgnc:HGNC:58534","description":"RTN4IP1 pseudogene 1","metadata":null},{"id":"5f339500ff0745699e5dfea61466608d","type":"GENE","name":"RTN4R","canonical_id":"hgnc:HGNC:18601","description":"reticulon 4 receptor","metadata":{"aliases":["NgR1","NgR","NOGOR"]}},{"id":"3a4b2bcca59643d0a068f82c8a9beff7","type":"GENE","name":"RTN4RL1","canonical_id":"hgnc:HGNC:21329","description":"reticulon 4 receptor like 1","metadata":{"aliases":["NGRH2","NgR3","DKFZp547J144"]}},{"id":"210f951600ee482c9a30d70f4d5cc023","type":"GENE","name":"RTN4RL1-AS1","canonical_id":"hgnc:HGNC:58360","description":"RTN4RL1 antisense RNA 1","metadata":null},{"id":"7151bcc936c04c6b90b59f6ef19f933a","type":"GENE","name":"RTN4RL1-AS2","canonical_id":"hgnc:HGNC:58547","description":"RTN4RL1 antisense RNA 2","metadata":null},{"id":"4e1bf9839ce84b78891a4be4ccd1e1ab","type":"GENE","name":"RTN4RL2","canonical_id":"hgnc:HGNC:23053","description":"reticulon 4 receptor like 2","metadata":{"aliases":["NgR2","NGRH1"]}},{"id":"b9889fd1e6d24f4fb5e34727657f812d","type":"GENE","name":"RTP1","canonical_id":"hgnc:HGNC:28580","description":"receptor transporter protein 1","metadata":{"aliases":["MGC35450","Z3CXXC1"]}},{"id":"9c0bb24835264affbf59293c44737cbd","type":"GENE","name":"RTP2","canonical_id":"hgnc:HGNC:32486","description":"receptor transporter protein 2","metadata":{"aliases":["MGC78665","Z3CXXC2"]}},{"id":"b2e991044bd24037b6900993a3498cb9","type":"GENE","name":"RTP3","canonical_id":"hgnc:HGNC:15572","description":"receptor transporter protein 3","metadata":{"aliases":["LTM1","Z3CXXC3","TMEM7"]}},{"id":"8b0d2a93ac9f48d9a4b09521aeef5b87","type":"GENE","name":"RTP4","canonical_id":"hgnc:HGNC:23992","description":"receptor transporter protein 4","metadata":{"aliases":["IFRG28","Z3CXXC4"]}},{"id":"9231c7415c0f41bc8781eab3cf46da30","type":"GENE","name":"RTP5","canonical_id":"hgnc:HGNC:26585","description":"receptor transporter protein 5 (putative)","metadata":{"aliases":["FLJ33590","Z3CXXC5","C2orf85","CXXC11"]}},{"id":"a007af44f1444bdc9f278199c294385c","type":"GENE","name":"RTRAF","canonical_id":"hgnc:HGNC:23169","description":"RNA transcription, translation and transport factor","metadata":{"aliases":["TSLIG4","CGI-99","RLLM1","CLE","CLE7","LCRP369","hCLE1","C14orf166"]}},{"id":"aec379c380d940448ecf5fb6b39eb865","type":"GENE","name":"RTRAFP1","canonical_id":"hgnc:HGNC:54647","description":"RTRAF pseudogene 1","metadata":null},{"id":"07ced2fb398541bb9f0c073d9ef7c0e6","type":"GENE","name":"RTRAFP2","canonical_id":"hgnc:HGNC:54648","description":"RTRAF pseudogene 2","metadata":null},{"id":"4146dc8f07e84f778b955309eb5c625e","type":"GENE","name":"RTTN","canonical_id":"hgnc:HGNC:18654","description":"rotatin","metadata":{"aliases":["DKFZP434G145"]}},{"id":"62c8ec55e0ba489bbc082ec14dd78f0c","type":"GENE","name":"RUBCN","canonical_id":"hgnc:HGNC:28991","description":"rubicon autophagy regulator","metadata":{"aliases":["rubicon","rundataxin","KIAA0226"]}},{"id":"152d3375bfc047ecaf51634262cd79d7","type":"GENE","name":"RUBCNL","canonical_id":"hgnc:HGNC:20420","description":"rubicon like autophagy enhancer","metadata":{"aliases":["FLJ21562","PACER","C13orf18","KIAA0226L"]}},{"id":"62e364fe6dff4101af93800540303a7f","type":"GENE","name":"RUFY1","canonical_id":"hgnc:HGNC:19760","description":"RUN and FYVE domain containing 1","metadata":{"aliases":["FLJ22251","ZFYVE12","RABIP4"]}},{"id":"537bb6f5b3ff4deab70126ff39d9c75c","type":"GENE","name":"RUFY1-AS1","canonical_id":"hgnc:HGNC:40903","description":"RUFY1 antisense RNA 1","metadata":null},{"id":"98a7cf8e34d544fabecd37eb2e192140","type":"GENE","name":"RUFY2","canonical_id":"hgnc:HGNC:19761","description":"RUN and FYVE domain containing 2","metadata":{"aliases":["RABIP4R","FLJ10063","KIAA1537","ZFYVE13"]}},{"id":"f9b29f56101a4c5cb2e1838eb8ccbbcb","type":"GENE","name":"RUFY3","canonical_id":"hgnc:HGNC:30285","description":"RUN and FYVE domain containing 3","metadata":{"aliases":["RIPx","KIAA0871","Singar1","ZFYVE30"]}},{"id":"41074a3773404f7f911a6af49c69ce6b","type":"GENE","name":"RUFY4","canonical_id":"hgnc:HGNC:24804","description":"RUN and FYVE domain containing 4","metadata":{"aliases":["FLJ46536","ZFYVE31"]}},{"id":"ceebf3b8b6c04ca8abd02152ab62dd9b","type":"GENE","name":"RUMY1","canonical_id":"hgnc:HGNC:24044","description":"regulator of UNG2 and MKLN1 interacting yippee protein 1","metadata":{"aliases":["MGC57827","RP11-312O7.1","UGENE","LMPIP","p17","FAM72A"]}},{"id":"4c6ae80e94de4f5da9f6ad04a6c13f76","type":"GENE","name":"RUMY2","canonical_id":"hgnc:HGNC:24805","description":"RUMY family member 2","metadata":{"aliases":["RP11-439A17.6","FAM72B"]}},{"id":"4f51da3664ef4a37894d5b8895c7c62f","type":"GENE","name":"RUMY3","canonical_id":"hgnc:HGNC:30602","description":"RUMY family member 3","metadata":{"aliases":["RP5-998N21.9","FAM72C"]}},{"id":"20e54998c9b34dd1bb78d5e2e5e30405","type":"GENE","name":"RUMY4","canonical_id":"hgnc:HGNC:33593","description":"RUMY family member 4","metadata":{"aliases":["FAM72D"]}},{"id":"57240758acbf4ae6a7997f9278e73603","type":"GENE","name":"RUNDC1","canonical_id":"hgnc:HGNC:25418","description":"RUN domain containing 1","metadata":{"aliases":["DKFZp761H0421"]}},{"id":"47354ba82869450791fa7f93dddc58fb","type":"GENE","name":"RUNDC3A","canonical_id":"hgnc:HGNC:16984","description":"RUN domain containing 3A","metadata":{"aliases":["RPIP8","RAP2IP"]}},{"id":"a441898d008248e597aa0b507d6f1378","type":"GENE","name":"RUNDC3A-AS1","canonical_id":"hgnc:HGNC:51344","description":"RUNDC3A antisense RNA 1","metadata":null},{"id":"281956c5abb94a7daa5cb26c2ad8580e","type":"GENE","name":"RUNDC3B","canonical_id":"hgnc:HGNC:30286","description":"RUN domain containing 3B","metadata":{"aliases":["RPIP9","RPIB9"]}},{"id":"c010f1e741764c26bac09e5521079aa1","type":"GENE","name":"RUNX1","canonical_id":"hgnc:HGNC:10471","description":null,"metadata":null},{"id":"74a436c66a87447c9aa0cd14ce05e523","type":"GENE","name":"RUNX1-AS1","canonical_id":"hgnc:HGNC:56821","description":"RUNX1 antisense RNA 1","metadata":null},{"id":"729d16bbefcf4bd887a3fd341a2c5d21","type":"GENE","name":"RUNX1-AS2","canonical_id":"hgnc:HGNC:58231","description":"RUNX1 antisense RNA 2","metadata":null},{"id":"88cee47b0609411da818c4af9aaea780","type":"GENE","name":"RUNX1-IT1","canonical_id":"hgnc:HGNC:16623","description":"RUNX1 intronic transcript 1","metadata":{"aliases":["FLJ20856","C21orf96"]}},{"id":"934ada0650ae435899f620ba8c1f4be3","type":"GENE","name":"RUNX1T1","canonical_id":"hgnc:HGNC:1535","description":null,"metadata":null},{"id":"a618a6992cee48f9a79102e3123318c7","type":"GENE","name":"RUNX2","canonical_id":"hgnc:HGNC:10472","description":null,"metadata":null},{"id":"c4113f137d6b4a99950c142c3b77ff91","type":"GENE","name":"RUNX2-AS1","canonical_id":"hgnc:HGNC:53512","description":"RUNX2 antisense RNA 1","metadata":null},{"id":"326150fafd2445b3a8c2b8e237c335fd","type":"GENE","name":"RUNX3","canonical_id":"hgnc:HGNC:10473","description":null,"metadata":null},{"id":"a32d49d5f2ad47efaa83e4ff7fe623ba","type":"GENE","name":"RUNX3-AS1","canonical_id":"hgnc:HGNC:40513","description":"RUNX3 antisense RNA 1","metadata":null},{"id":"b20bcbfbef484ccab8340f1ac71c3a7a","type":"GENE","name":"RUSC1","canonical_id":"hgnc:HGNC:17153","description":"RUN and SH3 domain containing 1","metadata":{"aliases":["NESCA"]}},{"id":"1b96b5d9c670425090130e6fd85e2364","type":"GENE","name":"RUSC1-AS1","canonical_id":"hgnc:HGNC:26680","description":"RUSC1 antisense RNA 1","metadata":{"aliases":["FLJ35976","C1orf104"]}},{"id":"16ad4ee0d2f7481c91cdc1a047caed6d","type":"GENE","name":"RUSC2","canonical_id":"hgnc:HGNC:23625","description":"RUN and SH3 domain containing 2","metadata":{"aliases":["KIAA0375"]}},{"id":"7301c7a0e9154160ba077111e15ec0ee","type":"GENE","name":"RUSF1","canonical_id":"hgnc:HGNC:25848","description":"RUS family member 1","metadata":{"aliases":["FLJ13868","C16orf58"]}},{"id":"a7ddad52403d4b429d09d878a3bca86f","type":"GENE","name":"RUSF1-DT","canonical_id":"hgnc:HGNC:56038","description":"RUSF1 divergent transcript","metadata":null},{"id":"b41790b943494144a61647ecce81a6e3","type":"GENE","name":"RUVBL1","canonical_id":"hgnc:HGNC:10474","description":null,"metadata":null},{"id":"56ca54ff94864188bb2cd5b6580cd479","type":"GENE","name":"RUVBL1-AS1","canonical_id":"hgnc:HGNC:40514","description":"RUVBL1 antisense RNA 1","metadata":null},{"id":"da64b3d2afea43f88a28c751e4bc7be4","type":"GENE","name":"RUVBL2","canonical_id":"hgnc:HGNC:10475","description":"RuvB like AAA ATPase 2","metadata":{"aliases":["RVB2","TIP48","TIP49b","Reptin52","ECP51","TIH2","INO80J","Rvb2"]}},{"id":"61c48fc409f74830b8830734db71fda9","type":"GENE","name":"RUVBL2P1","canonical_id":"hgnc:HGNC:55128","description":"RUVBL2 pseudogene 1","metadata":null},{"id":"092c50e8fc4b4c848ab40f9ff15a736f","type":"TRIAL","name":"RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT06397313","description":"Myelofibrosis","metadata":null},{"id":"3007bc1f796f463b845cd7d175dadf24","type":"TRIAL","name":"RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)","canonical_id":"clinicaltrials.gov:NCT05154344","description":"MET Alterations; Non Small Cell Lung Cancer; METex14 Mutations","metadata":null},{"id":"8714e33b8f4c4c31b340f871bf188317","type":"GENE","name":"RWDD1","canonical_id":"hgnc:HGNC:20993","description":"RWD domain containing 1","metadata":{"aliases":["DFRP2","PTD013"]}},{"id":"c908756b5fae4208bcec5226ff57d829","type":"GENE","name":"RWDD1P1","canonical_id":"hgnc:HGNC:31055","description":"RWD domain containing 1 pseudogene 1","metadata":null},{"id":"c6537d914378413494b2d5d84c97d1b5","type":"GENE","name":"RWDD1P3","canonical_id":"hgnc:HGNC:31794","description":"RWD domain containing 1 pseudogene 3","metadata":{"aliases":["RWDD1L1"]}},{"id":"8646e4ebb32a454d95a37a30c772f559","type":"GENE","name":"RWDD2A","canonical_id":"hgnc:HGNC:21385","description":"RWD domain containing 2A","metadata":{"aliases":["MGC13523","dJ747H23.2","RWDD2"]}},{"id":"5b516caed0d847ae9c6ead0be9d82b57","type":"GENE","name":"RWDD2B","canonical_id":"hgnc:HGNC:1302","description":"RWD domain containing 2B","metadata":{"aliases":["GL011","C21orf6"]}},{"id":"5c6847aac852498cb2e13ab4b57fec7f","type":"GENE","name":"RWDD3","canonical_id":"hgnc:HGNC:21393","description":"RWD domain containing 3","metadata":{"aliases":["DKFZP566K023","RSUME"]}},{"id":"d4897b5dbb3d4a14bdc234779e279b22","type":"GENE","name":"RWDD3-DT","canonical_id":"hgnc:HGNC:55839","description":"RWDD3 divergent transcript","metadata":null},{"id":"1e56dc5f3308476b8f9ed29b0a0fd750","type":"GENE","name":"RWDD4","canonical_id":"hgnc:HGNC:23750","description":"RWD domain containing 4","metadata":{"aliases":["MGC10198","FAM28A","RWDD4A"]}},{"id":"bb6478ebd9f4416593f296b57e8288e5","type":"GENE","name":"RWDD4P1","canonical_id":"hgnc:HGNC:23753","description":"RWD domain containing 4 pseudogene 1","metadata":{"aliases":["FAM28BP"]}},{"id":"e9a2a3d554d44ee49a782084f24d3ef1","type":"GENE","name":"RWDD4P2","canonical_id":"hgnc:HGNC:23754","description":"RWD domain containing 4 pseudogene 2","metadata":{"aliases":["FAM28CP"]}},{"id":"6f785c534e2f410da88fb3ac2587fc8e","type":"TRIAL","name":"RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","canonical_id":"clinicaltrials.gov:NCT07301437","description":"Overweight and Obese Adults","metadata":null},{"id":"ef71307f8187406e8c70305d166a88e9","type":"GENE","name":"RXFP1","canonical_id":"hgnc:HGNC:19718","description":"relaxin family peptide receptor 1","metadata":{"aliases":["RXFPR1","LGR7"]}},{"id":"5077766861844491881ecd8d561ec990","type":"GENE","name":"RXFP1-AS1","canonical_id":"hgnc:HGNC:40897","description":"RXFP1 antisense RNA 1","metadata":null},{"id":"4af2ed2ac3c14ec389a40161b16bf142","type":"GENE","name":"RXFP2","canonical_id":"hgnc:HGNC:17318","description":null,"metadata":null},{"id":"534377fc572e4cec8171a80b9df34d17","type":"GENE","name":"RXFP3","canonical_id":"hgnc:HGNC:24883","description":"relaxin family peptide receptor 3","metadata":{"aliases":["SALPR","GPCR135","RXFPR3","RLN3R1"]}},{"id":"66163c74d8024b62ab4243d65372c4dd","type":"GENE","name":"RXFP4","canonical_id":"hgnc:HGNC:14666","description":"relaxin family peptide/INSL5 receptor 4","metadata":{"aliases":["GPCR142","RXFPR4","GPR100","RLN3R2"]}},{"id":"2ad29722ac984754a8028fc9ac1efa7c","type":"GENE","name":"RXRA","canonical_id":"hgnc:HGNC:10477","description":null,"metadata":null},{"id":"d41707db6ff74d178cf55f57118920c1","type":"GENE","name":"RXRB","canonical_id":"hgnc:HGNC:10478","description":"retinoid X receptor beta","metadata":{"aliases":["NR2B2","H-2RIIBP","RCoR-1","RXRbeta","RXR-beta"]}},{"id":"54d479849f7c46898cc00ff709b5bc6d","type":"PROTEIN","name":"RXRB","canonical_id":"uniprot:P28702","description":null,"metadata":null},{"id":"030495a0cd3a46d1a288a856a562e39d","type":"GENE","name":"RXRG","canonical_id":"hgnc:HGNC:10479","description":"retinoid X receptor gamma","metadata":{"aliases":["NR2B3","RXRgamma","RXR-gamma"]}},{"id":"30521dffba7340aa961161d713f645c2","type":"GENE","name":"RXYLT1","canonical_id":"hgnc:HGNC:13530","description":"ribitol xylosyltransferase 1","metadata":{"aliases":["HP10481","TMEM5"]}},{"id":"529b8cd9e5f24f3488857f26b552391d","type":"GENE","name":"RXYLT1-AS1","canonical_id":"hgnc:HGNC:48910","description":"RXYLT1 antisense RNA 1","metadata":{"aliases":["TMEM5-AS1"]}},{"id":"8949aed1e0a148f09c61f7066de1890a","type":"GENE","name":"RYBP","canonical_id":"hgnc:HGNC:10480","description":"RING1 and YY1 binding protein","metadata":{"aliases":["YEAF1","AAP1","DEDAF"]}},{"id":"0516e495f32c47d19baeca2d1569131f","type":"GENE","name":"RYK","canonical_id":"hgnc:HGNC:10481","description":"receptor like tyrosine kinase","metadata":{"aliases":["D3S3195","RYK1","JTK5","JTK5A"]}},{"id":"da1849d179cb4ed0a49ec2647ac0ea35","type":"GENE","name":"RYKP1","canonical_id":"hgnc:HGNC:10482","description":"RYK pseudogene 1","metadata":{"aliases":["JTK5","RYKL1","JTK5B","RYKP"]}},{"id":"f43a46ff13da46b2aebdaea9df6bc1a3","type":"GENE","name":"RYR1","canonical_id":"hgnc:HGNC:10483","description":"ryanodine receptor 1","metadata":{"aliases":["RYR","PPP1R137","MHS","MHS1","CCO"]}},{"id":"507c7f93bc054f608461a108ceb48b18","type":"DISEASE","name":"RYR1-related myopathy","canonical_id":"mondo:0100150","description":null,"metadata":null},{"id":"327c12acce2c4a3186ff2de3a43f9e37","type":"GENE","name":"RYR2","canonical_id":"hgnc:HGNC:10484","description":"ryanodine receptor 2","metadata":{"aliases":["ARVC2","VTSIP","ARVD2"]}},{"id":"646785c673d94db3ba3324625ab61c81","type":"GENE","name":"RYR3","canonical_id":"hgnc:HGNC:10485","description":"ryanodine receptor 3","metadata":null},{"id":"eed64b2ebee34be1bbd565d96cd80b33","type":"GENE","name":"RYR3-AS1","canonical_id":"hgnc:HGNC:58469","description":"RYR3 antisense RNA 1","metadata":null},{"id":"b62bb9eff73f44caacc0e8a68c063ec6","type":"GENE","name":"RYR3-DT","canonical_id":"hgnc:HGNC:51417","description":"RYR3 divergent transcript","metadata":{"aliases":["TCONS_l2_00009005"]}},{"id":"53a0b0eac6694f12aa1238ecc9e1d2f7","type":"GO_TERM","name":"RZZ complex","canonical_id":"go:GO:1990423","description":"\"A kinetochore component required for both meiotic and mitotic spindle assembly checkpoints.\" [PMID:12686595, PMID:15922598, PMID:20462495]","metadata":null},{"id":"f33a89dddfba4859aad8bab06d8b4426","type":"GO_TERM","name":"Rab GDP-dissociation inhibitor activity","canonical_id":"go:GO:0005093","description":"\"Prevents the dissociation of GDP from the small GTPase Rab, thereby preventing GTP from binding.\" [GOC:mah]","metadata":null},{"id":"f397b3123ef94fd995ce5bb549d86e7a","type":"GO_TERM","name":"Rab geranylgeranyltransferase activity","canonical_id":"go:GO:0004663","description":"\"Catalysis of the reaction: 2 geranylgeranyl diphosphate + protein-cysteine = 2 S-geranylgeranyl-protein + 2 diphosphate. This reaction is the formation of two thioether linkages between the C-1 atom of the geranylgeranyl groups and two cysteine residues within the terminal sequence motifs XXCC, XCXC or CCXX. Known substrates include Ras-related GTPases of a single family and the Rab family.\" [EC:2.5.1.60, GOC:mah, PMID:8621375]","metadata":null},{"id":"1c5e7d2256c7455fa10816df55820f00","type":"GO_TERM","name":"Rab protein signal transduction","canonical_id":"go:GO:0032482","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Rab subfamily relays a signal.\" [GOC:mah]","metadata":null},{"id":"6ee7f87b5bb54b858743ef74d492729d","type":"GO_TERM","name":"Rab-protein geranylgeranyltransferase complex","canonical_id":"go:GO:0005968","description":"\"An protein-containing complex which catalyzes of the transfer of a geranyl-geranyl group from geranylgeranyl pyrophosphate to a Rab protein. In mammals it is composed of an alpha and a beta subunit, and associates with an accessory protein Rep (Rab escort protein).\" [GOC:jl, PMID:11886217]","metadata":null},{"id":"fbe798ab4557415dab0a6495219aaf79","type":"TRIAL","name":"Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","canonical_id":"clinicaltrials.gov:NCT00838526","description":"Gastroesophageal Reflux Disease (GERD)","metadata":null},{"id":"76cb715cf7814f1e89c73576ddb10025","type":"DISEASE","name":"Rabson-Mendenhall syndrome","canonical_id":"mondo:0009874","description":null,"metadata":null},{"id":"59f7966072234694ae7392ea7cdddba6","type":"GO_TERM","name":"Rac protein signal transduction","canonical_id":"go:GO:0016601","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Rac subfamily relays a signal.\" [GOC:bf]","metadata":null},{"id":"16714a3c7a7f4862ae841059832b63cf","type":"GO_TERM","name":"Rad17 RFC-like complex","canonical_id":"go:GO:0031389","description":"\"A pentameric protein complex related to replication factor C, which loads a trimeric complex of checkpoint proteins (known as the checkpoint clamp or 9-1-1 complex) onto DNA at damage sites; functions in DNA damage cell cycle checkpoints. In Schizosaccharomyces pombe the subunits are known as Rad17, Rfc2, Rfc3, Rfc4, and Rfc5, while in Saccharomyces cerevisiae the subunits are known as Rad24p, Rfc2p, Rfc3p, Rfc4p, and Rfc5p.\" [PMID:14614842]","metadata":null},{"id":"195b77bd80534468981e5784554153d0","type":"GO_TERM","name":"Rad51B-Rad51C complex","canonical_id":"go:GO:0033066","description":"\"A DNA recombinase mediator complex that contains the Rad51 paralogs RAD51B and RAD51C, or orthologs thereof.\" [GOC:mah, PMID:16093548, PMID:17114795]","metadata":null},{"id":"8bdf4fe3e8d949a19425c3ea5a53dffe","type":"GO_TERM","name":"Rad51B-Rad51C-Rad51D-XRCC2 complex","canonical_id":"go:GO:0033063","description":"\"A DNA recombinase mediator complex that contains the Rad51 paralogs RAD51B, RAD51C, RAD51D, and XRCC2, or orthologs thereof.\" [GOC:mah, PMID:16093548, PMID:17114795]","metadata":null},{"id":"1111798ed3454f6f8ee3c65eba9262ef","type":"GO_TERM","name":"Rad51C-XRCC3 complex","canonical_id":"go:GO:0033065","description":"\"A DNA recombinase mediator complex that contains the Rad51 paralogs RAD51C and XRCC3, or orthologs thereof.\" [GOC:mah, GOC:vw, PMID:12427746, PMID:16093548, PMID:17114795]","metadata":null},{"id":"86085f5c4145447d904f4597216a9f54","type":"GO_TERM","name":"Rad6-Rad18 complex","canonical_id":"go:GO:0097505","description":"\"A ubiquitin ligase complex found to be involved in post-replicative bypass of UV-damaged DNA and UV mutagenesis. In S. cerevisiae, the complex contains the ubiquitin conjugating enzyme Rad6 and Rad18, a protein containing a RING finger motif and a nucleotide binding motif. The yeast Rad6-Rad18 heterodimer has ubiquitin conjugating activity, binds single-stranded DNA, and possesses single-stranded DNA-dependent ATPase activity.\" [GOC:jd, PMID:9287349]","metadata":null},{"id":"9f06012ba03642f9aa49befe34c52076","type":"TRIAL","name":"Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00820248","description":"Head and Neck Cancer","metadata":null},{"id":"bb13cd7cd26540619bce7026a1a296cb","type":"DRUG","name":"Radiation Therapy","canonical_id":"ncit:C15313","description":null,"metadata":null},{"id":"2516ae52608b4d958c47c6782c467af2","type":"TRIAL","name":"Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT00858663","description":"Head and Neck Cancer","metadata":null},{"id":"d15e425e799e4d3592ed3346ca380c98","type":"TRIAL","name":"Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00006386","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"229d99de1792461c914367e6284b6091","type":"TRIAL","name":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","canonical_id":"clinicaltrials.gov:NCT06379087","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"328e9517672843298a1aa83a3e0ee9fc","type":"TRIAL","name":"Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT00023660","description":"Cervical Cancer","metadata":null},{"id":"4bf1fbf09eb746028c07156cf5c726e8","type":"TRIAL","name":"Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01134861","description":"Lung Cancer","metadata":null},{"id":"93a89eca50cc4bc7a2891a4fccf91198","type":"TRIAL","name":"Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00002889","description":"Prostate Cancer","metadata":null},{"id":"ebdf7eeb4cab4859beed7f04572f1d72","type":"TRIAL","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00936390","description":"Prostate Cancer","metadata":null},{"id":"42ca73be78d0418badc1b20fd3177751","type":"TRIAL","name":"Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00002597","description":"Prostate Cancer","metadata":null},{"id":"baabf1ce4e834d8bb61b2de4ce31e656","type":"TRIAL","name":"Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial","canonical_id":"clinicaltrials.gov:NCT03371719","description":"Recurrent Prostate Carcinoma; Stage III Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7","metadata":null},{"id":"ef4a1c444408469abd679303b300cabc","type":"TRIAL","name":"Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00021450","description":"Prostate Cancer","metadata":null},{"id":"ab975733126d4b25a54efad3f9bf4b4b","type":"TRIAL","name":"Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00849082","description":"Prostate Cancer","metadata":null},{"id":"b69a131c5e754449a4cfdaa24849907c","type":"TRIAL","name":"Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT03150836","description":"Bladder Cancer","metadata":null},{"id":"d2f17bed9f6d433693f58c8043649dcf","type":"TRIAL","name":"Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00769548","description":"Prostate Cancer","metadata":null},{"id":"2f8dca14fac9467eb580385d247cfa4e","type":"TRIAL","name":"Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery","canonical_id":"clinicaltrials.gov:NCT01079793","description":"Prostate Cancer","metadata":null},{"id":"47e2d8c6f4574a76bae618cdc0e5659c","type":"TRIAL","name":"Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00096265","description":"Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7","metadata":null},{"id":"4c964df7c4e342d786768531fa3e4d2e","type":"TRIAL","name":"Radiation Therapy in Treating Patients With Glioblastoma","canonical_id":"clinicaltrials.gov:NCT00019058","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"2f28d05c00254d0aa85e5eb4e71a166c","type":"TRIAL","name":"Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","canonical_id":"clinicaltrials.gov:NCT00528866","description":"Prostate Cancer","metadata":null},{"id":"2cdacf2804244f3c9e0d728da17df4ca","type":"TRIAL","name":"Radiation Use During Vemurafenib Treatment","canonical_id":"clinicaltrials.gov:NCT01843738","description":"BRAFV600 Mutation; Stage IV Melanoma","metadata":null},{"id":"2c79b7470f084613a58e92e5a6cdb283","type":"TRIAL","name":"Radio-chemotherapy With or Without Panitumumab (Vectibix\u00ae) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus","canonical_id":"clinicaltrials.gov:NCT01262183","description":"Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus","metadata":null},{"id":"0ad24f2c01914ed3a483732f40b03214","type":"TRIAL","name":"Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC","canonical_id":"clinicaltrials.gov:NCT02187081","description":"HCC","metadata":null},{"id":"36e9cd3eb6744a32946d2e1ab90f699b","type":"TRIAL","name":"Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00005592","description":"Lymphoma","metadata":null},{"id":"9230a4e7f3624995b1a2b7e350510e88","type":"TRIAL","name":"Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00012298","description":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstr\u00f6m Macroglobulinemia","metadata":null},{"id":"07daffe3290942b5aa7475d5e76b5ed8","type":"TRIAL","name":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01476839","description":"Recurrent Adult Hodgkin Lymphoma","metadata":null},{"id":"ee90edb6b37f4f67b0911bbf6caf654f","type":"TRIAL","name":"Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma","canonical_id":"clinicaltrials.gov:NCT00036855","description":"AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma","metadata":null},{"id":"6e410798c96a475493a217fd43224336","type":"TRIAL","name":"Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging","canonical_id":"clinicaltrials.gov:NCT07581769","description":"Hepatocellular Carcinoma (HCC); Downstaging; Liver Resection; Lenvatinib; PD1 Antibody; Transarterial Chemoembolization","metadata":null},{"id":"47765beb03a74cf6a4133a4b2da3a238","type":"TRIAL","name":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","canonical_id":"clinicaltrials.gov:NCT07291401","description":"Rectal Cancer Patients","metadata":null},{"id":"b751fa44897f4e9c8c98cbb607c4f3ac","type":"TRIAL","name":"Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer","canonical_id":"clinicaltrials.gov:NCT01333332","description":"Pancreatic Cancer","metadata":null},{"id":"f331c94d1b954bc3a5a5a147300a16f4","type":"TRIAL","name":"Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT05561634","description":"Basal Cell Carcinoma; Radiotherapy; Complications","metadata":null},{"id":"c02cb7512f934a469fbc5fe59507b2f3","type":"TRIAL","name":"Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC","canonical_id":"clinicaltrials.gov:NCT05085496","description":"Locally Advanced Skin Squamous Cell Carcinoma; Resectable Skin Squamous Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma","metadata":null},{"id":"cb1a5d2de8b341788ec0be9a3a6bbee9","type":"TRIAL","name":"Radiotherapy or Imiquimod in Complex Lentigo Maligna","canonical_id":"clinicaltrials.gov:NCT02394132","description":"Lentigo Maligna","metadata":null},{"id":"d61ce7605004489f927ba24888b0da36","type":"TRIAL","name":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03361735","description":"Prostate Adenocarcinoma","metadata":null},{"id":"1a019a2c3b8249179db5747f3521edcc","type":"TRIAL","name":"Radium-223 in Combination With Enzalutamide","canonical_id":"clinicaltrials.gov:NCT02225704","description":"Prostate Cancer","metadata":null},{"id":"bff7e44e90aa4ed08cc3ad7caa59dd67","type":"DRUG","name":"Radotinib","canonical_id":"mesh:C000606751","description":null,"metadata":null},{"id":"610a7c90847e4f2e93a3c75c1156df3c","type":"GO_TERM","name":"Ragulator complex","canonical_id":"go:GO:0071986","description":"\"A vacuolar membrane-anchored guanine nucleotide exchange factor (GEF) complex for the Rag GTPases (Gtr1-Gtr2 GTPase complex GO:1990131) in TORC1 signaling pathway. In human, Ragulator is comprised of the membrane anchor subunit LAMTOR1 (Meh1p in S. cerevisiae, Lam1 in S. pombe), a GEF subunit LAMTOR2 ( Slm4 in S. cerevisiae , Lam2 in S. pombe ) , LAMTOR3 (no S. cerevisiae ortholog identified, Lam3 in S. pombe) , LAMTOR4 (no S. cerevisiae ortholog identified, Lam4 in S. pombe), and LAMTOR5 (no S. cerevisiae or S. pombe ortholog identified).\" [GOC:vw, PMID:15989961, PMID:16732272, PMID:19177150, PMID:19748353, PMID:20381137, PMID:22980980, PMID:29199950]","metadata":null},{"id":"016e8da66b3c439581b2a4eb2a293ddb","type":"GO_TERM","name":"Ral protein signal transduction","canonical_id":"go:GO:0032484","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the RaI subfamily relays a signal.\" [GOC:mah]","metadata":null},{"id":"b98e63123a944102a243e78a202332a2","type":"TRIAL","name":"Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00031811","description":"Breast Cancer; Menopausal Symptoms; Osteoporosis","metadata":null},{"id":"d5f920ead470431b8b837263bf3f110c","type":"TRIAL","name":"Raloxifene and Rimostil for Perimenopause-Related Depression","canonical_id":"clinicaltrials.gov:NCT00030147","description":"Perimenopausal Depression; Depression","metadata":null},{"id":"62bf533ca1e542e9ade2ce8180e192a8","type":"TRIAL","name":"Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women","canonical_id":"clinicaltrials.gov:NCT01573637","description":"Schizophrenia in Post Menopausal Women","metadata":null},{"id":"74def8a083ae42a2be8ad4ea5f3d5bc0","type":"TRIAL","name":"Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy","canonical_id":"clinicaltrials.gov:NCT00371956","description":"Osteoporosis","metadata":null},{"id":"3e2460c8999e431db2211aade36f819f","type":"TRIAL","name":"Raloxifene for Women With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00368459","description":"Alzheimer Disease","metadata":null},{"id":"aa2cfcf7684c4a50990c18b84e03d9b1","type":"TRIAL","name":"Raloxifene in Preventing Breast Cancer in Premenopausal Women","canonical_id":"clinicaltrials.gov:NCT00019500","description":"Breast Cancer","metadata":null},{"id":"3d4b0e8dce52417db0c29ad60cf88142","type":"TRIAL","name":"Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT00004915","description":"Endometrial Cancer","metadata":null},{"id":"54035c77c5ac4cf699d4d46cd767bda6","type":"TRIAL","name":"Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT01280305","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"1edd23bb74f34fa5bbaa5d331410875b","type":"TRIAL","name":"Raltegravir and Ezetimibe PK Study","canonical_id":"clinicaltrials.gov:NCT00772551","description":"HIV","metadata":null},{"id":"9bf90bc99b2041ebac690129cc74b4e4","type":"TRIAL","name":"Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus","canonical_id":"clinicaltrials.gov:NCT03585530","description":"Esophagus Squamous Cell Carcinoma","metadata":null},{"id":"7e38ab78bacf466cb65fcd6b05cbe8ba","type":"TRIAL","name":"Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT03083613","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"aa4b38ddcff142a58fef3410639d897f","type":"TRIAL","name":"Raltitrexed in HIPEC","canonical_id":"clinicaltrials.gov:NCT04761185","description":"Colorectal Cancer; Raltitrexed; HIPEC","metadata":null},{"id":"026ff71049164f4b94b28c91626d8786","type":"TRIAL","name":"Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed","canonical_id":"clinicaltrials.gov:NCT00004254","description":"Malignant Mesothelioma","metadata":null},{"id":"04321d2a7c8d4e0f8f607d291aabb56e","type":"TRIAL","name":"Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03126071","description":"Advanced Colorectal Cancer","metadata":null},{"id":"f320f8b84ef740259608654aee94fb23","type":"TRIAL","name":"Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension.","canonical_id":"clinicaltrials.gov:NCT06832566","description":"Secondary Adrenal Insufficiency; Hypotension","metadata":null},{"id":"2cbd8e6d51db4b138695996abba88f34","type":"DRUG","name":"Ramatroban","canonical_id":"mesh:C063119","description":null,"metadata":null},{"id":"fe1840206c764c09abad8da77be724fc","type":"TRIAL","name":"Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00462254","description":"Parkinson's Disease","metadata":null},{"id":"fab69bb09ded4022a3b17aeb50a922b4","type":"TRIAL","name":"Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> - Transitional Survey From the Preceding Drug-use Survey -","canonical_id":"clinicaltrials.gov:NCT02153086","description":"Insomnia","metadata":null},{"id":"55a41388b88545509381a5ec83eba19f","type":"TRIAL","name":"Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty","canonical_id":"clinicaltrials.gov:NCT02058992","description":"Insomnia","metadata":null},{"id":"ad8c5861cd7443eba9701517c491ad54","type":"TRIAL","name":"Ramelteon and Citicoline for Delirium","canonical_id":"clinicaltrials.gov:NCT02840591","description":"Delirium","metadata":null},{"id":"3342c757baa44f558b2c80297dad2eb7","type":"TRIAL","name":"Ramelteon for Complex Insomnia in Veterans With PTSD","canonical_id":"clinicaltrials.gov:NCT03265951","description":"Insomnia","metadata":null},{"id":"03a9d949c38b410186ac9c6f38eac4e4","type":"TRIAL","name":"Ramelteon for Insomnia Comorbid With Asthma","canonical_id":"clinicaltrials.gov:NCT00869167","description":"Insomnia; Asthma","metadata":null},{"id":"d12ecdea541c4d179253c35ffcbabfb2","type":"TRIAL","name":"Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety","canonical_id":"clinicaltrials.gov:NCT00746239","description":"Panic Disorder; Insomnia","metadata":null},{"id":"81db045cb74a49269012c6cedd63252b","type":"TRIAL","name":"Ramelteon for Treatment of Insomnia in Cirrhosis","canonical_id":"clinicaltrials.gov:NCT03091738","description":"Cirrhosis","metadata":null},{"id":"8c05ba1f9043485cbaa2f7aa2849b18d","type":"TRIAL","name":"Ramelteon for a Nap Prior to a Night Shift","canonical_id":"clinicaltrials.gov:NCT00595075","description":"Healthy","metadata":null},{"id":"0b4d90868b154e3e90dd350de02f2907","type":"TRIAL","name":"Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00552760","description":"Bipolar Disorder","metadata":null},{"id":"ac3ac8bd005046a591a3e1df54ca85f4","type":"TRIAL","name":"Ramelteon in the Prevention of Post-operative Delirium","canonical_id":"clinicaltrials.gov:NCT02324153","description":"Delirium; Delirium, Dementia, Amnestic, Cognitive Disorders; Delayed Emergence From Anesthesia; Cognitive Disorders","metadata":null},{"id":"a013b39cddd84bdf9eed59d3775b2c12","type":"TRIAL","name":"Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults","canonical_id":"clinicaltrials.gov:NCT03165695","description":"Delirium in Old Age","metadata":null},{"id":"edac985edbf349d3806434143e73db91","type":"TRIAL","name":"Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00828321","description":"Healthy","metadata":null},{"id":"ef19163981e84990a9535b3167301f26","type":"TRIAL","name":"Ramipril Versus Carvedilol in Duchenne and Becker Patients","canonical_id":"clinicaltrials.gov:NCT00819845","description":"Duchenne Muscular Dystrophy; Becker Muscular Dystrophy","metadata":null},{"id":"ccb1798271a7491c987ed469dbd096f1","type":"TRIAL","name":"Ramipril for the Treatment of COVID-19","canonical_id":"clinicaltrials.gov:NCT04366050","description":"COVID-19","metadata":null},{"id":"e31f57386eea4c96890592c0bbea82c0","type":"DRUG","name":"Ramucirumab","canonical_id":"ncit:C70792","description":null,"metadata":null},{"id":"96e6c611ca154f99bedf4b6d7965f761","type":"TRIAL","name":"Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03650764","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"d1c4d4de08a14773a4d108e067b44e90","type":"TRIAL","name":"Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03081143","description":"Advanced Gastric or EGJ Cancer","metadata":null},{"id":"d3835ea91b5b4e7eabfef38f70047ebb","type":"TRIAL","name":"Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France","canonical_id":"clinicaltrials.gov:NCT02307812","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"0ac23c9de57349e6811f99cbee51aa8d","type":"TRIAL","name":"Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)","canonical_id":"clinicaltrials.gov:NCT03921671","description":"Thymic Carcinoma; Thymoma","metadata":null},{"id":"49ad7df97a2e4f75b70013f7c9b981e1","type":"TRIAL","name":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT03971474","description":"Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"d86519775e24430abf3ee8acdc234d51","type":"TRIAL","name":"Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT02520141","description":"Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma","metadata":null},{"id":"a1f5468303434690a5c746cb343fd910","type":"TRIAL","name":"Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00895180","description":"Adult Glioblastoma Multiforme","metadata":null},{"id":"0d9d40168cd74c5d8df54b72792eaaf7","type":"TRIAL","name":"Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC","canonical_id":"clinicaltrials.gov:NCT05007769","description":"Non-small Cell Lung Cancer; Non-small Cell Carcinoma; NSCLC; Non Small Cell Lung Cancer","metadata":null},{"id":"5d56f90686dc48bfa013e6c8ab754a76","type":"TRIAL","name":"Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis","canonical_id":"clinicaltrials.gov:NCT02628951","description":"Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"1f95e33bf85d46479b2a2f60e2a9acab","type":"GO_TERM","name":"Ran protein signal transduction","canonical_id":"go:GO:0031291","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Ran subfamily relays a signal.\" [GOC:mah]","metadata":null},{"id":"7cd681321e3b4c44aa2f05c301d39390","type":"TRIAL","name":"Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00635219","description":"Major Depressive Disorder","metadata":null},{"id":"f826dc77e2554a06a8984e0d24284887","type":"TRIAL","name":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","canonical_id":"clinicaltrials.gov:NCT01140906","description":"Major Depressive Disorder","metadata":null},{"id":"9d6b8bf4fc774fe69a7417d0d7fcf188","type":"TRIAL","name":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT00811252","description":"Major Depressive Disorder","metadata":null},{"id":"7ef7453cbcd644c1a867ce9cf1d0228d","type":"TRIAL","name":"Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","canonical_id":"clinicaltrials.gov:NCT00839423","description":"Major Depressive Disorder","metadata":null},{"id":"ca8a172aa4df44839b630f07d8ee2d46","type":"TRIAL","name":"Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response","canonical_id":"clinicaltrials.gov:NCT01128569","description":"Asthma","metadata":null},{"id":"0f2e16a6a4b74e81821bbe52a46638f6","type":"TRIAL","name":"Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer","canonical_id":"clinicaltrials.gov:NCT05305131","description":"Nasopharyngeal Cancer","metadata":null},{"id":"ba8736a878574a069b5615dc182d814b","type":"TRIAL","name":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins","canonical_id":"clinicaltrials.gov:NCT02135029","description":"Hyperlipidemia","metadata":null},{"id":"a1d6f4f08d3f4bfaa55ccdebc06b047f","type":"TRIAL","name":"Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT05709301","description":"Parkinson Disease; Mild Cognitive Impairment","metadata":null},{"id":"c39b30b563544c3ab756023ae388ab59","type":"TRIAL","name":"Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)","canonical_id":"clinicaltrials.gov:NCT02624063","description":"Hepatitis C, Chronic","metadata":null},{"id":"49ce68ab9bfa4363bcfbfa0905ecb87e","type":"TRIAL","name":"Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis","canonical_id":"clinicaltrials.gov:NCT00330148","description":"Trypanosomiasis, African","metadata":null},{"id":"0c43ad1523dd4f7eabc934f8dc038fc2","type":"TRIAL","name":"Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis","canonical_id":"clinicaltrials.gov:NCT02886299","description":"Fenofibrate/Simvastatin Comparison","metadata":null},{"id":"97548c3d45d146f2a965bc3d22eed65a","type":"TRIAL","name":"Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT00373451","description":"Myocardial Infarction; Coronary Disease","metadata":null},{"id":"252c9d5a28dd4b21a9b3a7cef482b890","type":"TRIAL","name":"Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.","canonical_id":"clinicaltrials.gov:NCT02978040","description":"Coronary Artery Disease; STEMI - ST Elevation Myocardial Infarction","metadata":null},{"id":"45abd669432e4f5b9fda7b11c8247b1d","type":"TRIAL","name":"Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial","canonical_id":"clinicaltrials.gov:NCT06856772","description":"Cardiovascular Diseases (CVD); Drug Effect; Atherosclerosis Cardiovascular Disease","metadata":null},{"id":"f3504d6656424b18b84ff0b037af3315","type":"TRIAL","name":"Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Beh\u00e7et's Syndrome","canonical_id":"clinicaltrials.gov:NCT06780462","description":"Behcet Syndrome","metadata":null},{"id":"395871d2bcba4e6ab06cdfae1a1aa656","type":"TRIAL","name":"Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study","canonical_id":"clinicaltrials.gov:NCT07416968","description":"Overactive Bladder (OAB); Overactive Bladder Syndrome","metadata":null},{"id":"0952a85004534c43b031609bc68bf7d4","type":"TRIAL","name":"Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke","canonical_id":"clinicaltrials.gov:NCT01464788","description":"Ischemic Stroke","metadata":null},{"id":"7faa3521f703416190cfac7c9bc74f1c","type":"TRIAL","name":"Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma","canonical_id":"clinicaltrials.gov:NCT06626620","description":"Acute Exacerbation of Asthma","metadata":null},{"id":"af03c0fcb880437cb7942a02ff5e76e7","type":"TRIAL","name":"Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium","canonical_id":"clinicaltrials.gov:NCT01288404","description":"Pterygium of the Conjunctiva and Cornea","metadata":null},{"id":"0914c4021c6243d3b1b61676d156b494","type":"TRIAL","name":"Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy","canonical_id":"clinicaltrials.gov:NCT01190098","description":"Partial Epilepsy","metadata":null},{"id":"3109cc63447a45159a7893f367516f63","type":"TRIAL","name":"Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension","canonical_id":"clinicaltrials.gov:NCT01456286","description":"Liver Cirrhosis; Portal Hypertension","metadata":null},{"id":"205da7d2800d4303963bfff43ed723e5","type":"TRIAL","name":"Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00450853","description":"Vomiting","metadata":null},{"id":"5ccbcb3a19a64889ba489b7cebe19f97","type":"TRIAL","name":"Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis","canonical_id":"clinicaltrials.gov:NCT04227314","description":"Recurrent Aphtous Stomatitis","metadata":null},{"id":"99400d8cae5943e9ad1cdaf8d0a73c56","type":"TRIAL","name":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","canonical_id":"clinicaltrials.gov:NCT06631287","description":"Long COVID; Sars-CoV-2 Infection; Coronavirus Infections; COVID-19","metadata":null},{"id":"5cbc3b1d128e453cb6abbbcc240cf52e","type":"TRIAL","name":"Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients","canonical_id":"clinicaltrials.gov:NCT00290082","description":"Acute Agitated Patients","metadata":null},{"id":"6e5e1b03993c4496b09c2e78875d82e7","type":"TRIAL","name":"Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial","canonical_id":"clinicaltrials.gov:NCT02330406","description":"Dipeptidyl-Peptidase 4 Inhibitors; LDL Cholesterol; Glycosylated Hemoglobin; Diabetes Mellitus; Coronary Disease","metadata":null},{"id":"13f04ef49bf44697b765050a143693d4","type":"TRIAL","name":"Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine","canonical_id":"clinicaltrials.gov:NCT00474058","description":"Parkinson's Disease","metadata":null},{"id":"a356ff09ad804719b4f84d9682a61101","type":"TRIAL","name":"Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00395915","description":"Schizophrenia","metadata":null},{"id":"5eaae7d3137745b4bdd43833afcdf054","type":"TRIAL","name":"Randomized Gefitinib Trial","canonical_id":"clinicaltrials.gov:NCT00807066","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"6926ea7c7520404da0ac5963bb9c0460","type":"TRIAL","name":"Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment","canonical_id":"clinicaltrials.gov:NCT02548351","description":"Non Alcoholic Steatohepatitis (NASH)","metadata":null},{"id":"0cac1b3461d947c6bfa6243b124df05d","type":"TRIAL","name":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","canonical_id":"clinicaltrials.gov:NCT06878664","description":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","metadata":null},{"id":"2930bad1de7b4354b1b3e40a641ffa11","type":"TRIAL","name":"Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1","canonical_id":"clinicaltrials.gov:NCT04456049","description":"COVID-19 Infection","metadata":null},{"id":"6ba3e372a40549d8845b242547019078","type":"TRIAL","name":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","canonical_id":"clinicaltrials.gov:NCT01059786","description":"Hairy Cell Leukemia","metadata":null},{"id":"fa2fa674f1d64b0cb68a2a7bc7eac1f5","type":"TRIAL","name":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05346848","description":"Prostate Cancer","metadata":null},{"id":"168f64a591414c3c906675f7e7252d36","type":"TRIAL","name":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","canonical_id":"clinicaltrials.gov:NCT04747236","description":"PTCL","metadata":null},{"id":"73f7650a7701471e997dabd7ea49bce4","type":"TRIAL","name":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","canonical_id":"clinicaltrials.gov:NCT03947216","description":"Parkinson Disease","metadata":null},{"id":"1da18b113d8c4ed19cc03b5fbfccc5cc","type":"TRIAL","name":"Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00244842","description":"Psoriasis","metadata":null},{"id":"8b081ef198b9426596937c8c31c61d63","type":"TRIAL","name":"Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00240409","description":"Parkinson Disease","metadata":null},{"id":"5949a2d0502f4ba1b9b1ff7963af1261","type":"TRIAL","name":"Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis","canonical_id":"clinicaltrials.gov:NCT07202598","description":"Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis","metadata":null},{"id":"3c51b7b12aa44f8fa0708e01c34c996b","type":"TRIAL","name":"Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients","canonical_id":"clinicaltrials.gov:NCT00309491","description":"Early-stage Breast Cancer","metadata":null},{"id":"20a29e901eb24642a66e3a16683c2de7","type":"TRIAL","name":"Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00852566","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"945c843082534061ba79d568fa538538","type":"TRIAL","name":"Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01239719","description":"Allergy; Dermatitis","metadata":null},{"id":"86ddfddf62334fb8aae16a7e27adb55d","type":"TRIAL","name":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","canonical_id":"clinicaltrials.gov:NCT04649242","description":"Pediatric Migraine","metadata":null},{"id":"10bde6e37f9843f6ad61ab3b9ba19e5b","type":"TRIAL","name":"Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis","canonical_id":"clinicaltrials.gov:NCT00004403","description":"Epilepsy; Cysticercosis","metadata":null},{"id":"2c451ff54ad14f15a420bf66b3310731","type":"TRIAL","name":"Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00004489","description":"Osteoporosis; Cystic Fibrosis","metadata":null},{"id":"76168e916d184ba2bba25d20ef4f1e7c","type":"TRIAL","name":"Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty","canonical_id":"clinicaltrials.gov:NCT00289601","description":"Angioplasty","metadata":null},{"id":"efb6a15c5033427d8b14d9fc659fc995","type":"TRIAL","name":"Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder","canonical_id":"clinicaltrials.gov:NCT00004834","description":"Panic Disorder","metadata":null},{"id":"1404d088e2f14f14970ffbc5f08bda15","type":"TRIAL","name":"Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC","canonical_id":"clinicaltrials.gov:NCT00880334","description":"Transitional Cell Carcinoma; Bladder Cancer","metadata":null},{"id":"5d2c230353b14e84a230d7d80495a395","type":"TRIAL","name":"Randomized Study of Letrozole and Trilostane for Medical Abortion","canonical_id":"clinicaltrials.gov:NCT01615211","description":"Medical Abortion, Complete or Unspecified, Without Complication","metadata":null},{"id":"87ff633f937140f192c5328ebe9d0d59","type":"TRIAL","name":"Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia","canonical_id":"clinicaltrials.gov:NCT00004399","description":"Pre-eclampsia","metadata":null},{"id":"898c3035a36b403e88346362d92288c1","type":"TRIAL","name":"Randomized Study of Obicetrapib in Combination With Ezetimibe","canonical_id":"clinicaltrials.gov:NCT04770389","description":"Dyslipidemias; High Cholesterol; Hypercholesterolemia","metadata":null},{"id":"c7732e69a8064aa789bf549fedb9f332","type":"TRIAL","name":"Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT00006133","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"e7b118fd25124c67be83f12d2613e6c5","type":"TRIAL","name":"Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT07713914","description":"Pulmonary Arterial Hypertension (PAH)","metadata":null},{"id":"467e8b23fac1474d9b4d8ca27cb1ea2f","type":"TRIAL","name":"Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant","canonical_id":"clinicaltrials.gov:NCT01593215","description":"Type 2 Diabetes","metadata":null},{"id":"04a91112afbb436fad287d104a1dd30a","type":"TRIAL","name":"Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams","canonical_id":"clinicaltrials.gov:NCT00803439","description":"Healthy","metadata":null},{"id":"a8b91d640d8c411eb4b96478c2e6d708","type":"TRIAL","name":"Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up","canonical_id":"clinicaltrials.gov:NCT00563654","description":"Prostatic Hyperplasia; Urinary Retention; Acute Disease","metadata":null},{"id":"40e98bcdeb09479bac54d15b524b80c6","type":"TRIAL","name":"Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control","canonical_id":"clinicaltrials.gov:NCT02025465","description":"Atrial Fibrillation; Atrial Flutter","metadata":null},{"id":"c15f77f001c64d969f136e8f86a30a22","type":"TRIAL","name":"Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis","canonical_id":"clinicaltrials.gov:NCT02929251","description":"Uveitis; Biotherapy","metadata":null},{"id":"8dbe6ac2031e465eb60d9cdd29672236","type":"TRIAL","name":"Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up","canonical_id":"clinicaltrials.gov:NCT00563485","description":"Prostatic Hyperplasia; Urinary Retention","metadata":null},{"id":"f4c5757dc6cf49d0a5d6e34cc66f8183","type":"TRIAL","name":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","canonical_id":"clinicaltrials.gov:NCT06061094","description":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","metadata":null},{"id":"86f89b6608bc435bb741dcdde464c403","type":"TRIAL","name":"Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols","canonical_id":"clinicaltrials.gov:NCT01172418","description":"Transplant; Failure, Kidney","metadata":null},{"id":"59c6a206ccec47498eb9d636fc038176","type":"TRIAL","name":"Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence","canonical_id":"clinicaltrials.gov:NCT00003645","description":"Prostate Cancer","metadata":null},{"id":"e33dc86a36114c1ba68e2046a5c73f6e","type":"TRIAL","name":"Randomized Trial of Fluticasone in Bronchial Premalignancy","canonical_id":"clinicaltrials.gov:NCT00407264","description":"Bronchogenic Carcinoma","metadata":null},{"id":"6b4d8d9abca046ddab7875ad9d1500f9","type":"TRIAL","name":"Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal","canonical_id":"clinicaltrials.gov:NCT02140970","description":"Disorder of Urinary Stent; Ureteral Spasm; Ureteropelvic Junction Obstruction; Urolithiasis","metadata":null},{"id":"46623d66ad624bf798c8d921650eff7f","type":"TRIAL","name":"Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT01499407","description":"ST-elevation Myocardial Infarction","metadata":null},{"id":"79a5e89186004ed3af401037767fb2b1","type":"TRIAL","name":"Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT05294887","description":"Coronary Microvascular Dysfunction; Microvascular Angina; Vasospasm, Coronary; Vasospastic Angina; Prinzmetal Angina; Coronary Artery Disease","metadata":null},{"id":"b7d3c26950634d71ba8d06af2122af2c","type":"TRIAL","name":"Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT00649610","description":"Low Back Pain","metadata":null},{"id":"c38e197cbd934f9b85fe43dde693cd15","type":"TRIAL","name":"Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01027598","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"02cce587438f42e79ba18380212e264e","type":"TRIAL","name":"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT00683592","description":"Major Depressive Disorder","metadata":null},{"id":"4c9c6006371d46b38ad3c87a7b697669","type":"TRIAL","name":"Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management","canonical_id":"clinicaltrials.gov:NCT01584557","description":"Heart Failure","metadata":null},{"id":"0956c258dbbe49d2bf573c136805489e","type":"TRIAL","name":"Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1","canonical_id":"clinicaltrials.gov:NCT00000738","description":"AIDS Dementia Complex; HIV Infections","metadata":null},{"id":"1fec3e80e4c447d892ef7d481753b78b","type":"TRIAL","name":"Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis","canonical_id":"clinicaltrials.gov:NCT01613118","description":"Focal Segmental Glomerulosclerosis","metadata":null},{"id":"5f8cadb2725a4e3983850c0e7b517e9e","type":"TRIAL","name":"Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain","canonical_id":"clinicaltrials.gov:NCT03224403","description":"Post-operative Dental Pain","metadata":null},{"id":"9aa0dff9dffd462d96f28934786f7dc7","type":"TRIAL","name":"Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers","canonical_id":"clinicaltrials.gov:NCT00782327","description":"Marfan Syndrome","metadata":null},{"id":"3621a0602d134b08a32e535026289d6a","type":"TRIAL","name":"Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT00460811","description":"Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"3d6f0b16ffed4633ad5c848e7e2c36dd","type":"TRIAL","name":"Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT07762833","description":"Atopic Dermatitis","metadata":null},{"id":"3c1a5332f1784d1bba494baa45450ff4","type":"TRIAL","name":"Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy","canonical_id":"clinicaltrials.gov:NCT05834738","description":"IgA Nephropathy; Immunoglobulin A Nephropathy","metadata":null},{"id":"76b112b2527e48f18d15f8c3bafebade","type":"TRIAL","name":"Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome","canonical_id":"clinicaltrials.gov:NCT03122652","description":"Multiple Sclerosis","metadata":null},{"id":"b1299682e67149c2b4d557bb817fcb95","type":"TRIAL","name":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","canonical_id":"clinicaltrials.gov:NCT02735707","description":"Community-acquired Pneumonia, Influenza, COVID-19","metadata":null},{"id":"1a66e4c60a494f049c6a40b481c218b6","type":"TRIAL","name":"Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria","canonical_id":"clinicaltrials.gov:NCT00561964","description":"Hypertension","metadata":null},{"id":"4fe68cfcf3a64137ae646fb4c0534458","type":"TRIAL","name":"Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients","canonical_id":"clinicaltrials.gov:NCT00408187","description":"Psoriasis","metadata":null},{"id":"d0ed941e8e1d49e2a35915e21b3523a5","type":"TRIAL","name":"Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy","canonical_id":"clinicaltrials.gov:NCT00746395","description":"Inflammatory Bowel Disease","metadata":null},{"id":"4f1eb96e4e784d169df63b4de5e1fbd7","type":"TRIAL","name":"Randomized\uff0cControlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder","canonical_id":"clinicaltrials.gov:NCT02273154","description":"Major Depression Disorder","metadata":null},{"id":"4aedb741a57f4168b45a9b5e70270848","type":"DRUG","name":"Ranibizumab","canonical_id":"mesh:D000069579","description":null,"metadata":null},{"id":"3a1d3b1dbc1a4ade8de769cf6a629e33","type":"TRIAL","name":"Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth","canonical_id":"clinicaltrials.gov:NCT00685854","description":"Macular Telangiectasia","metadata":null},{"id":"5705e17e5eec4ec0b4a6c70a44a7b936","type":"TRIAL","name":"Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study","canonical_id":"clinicaltrials.gov:NCT02511067","description":"Diabetic Macular Edema","metadata":null},{"id":"c60661be63f54561ae19017d40dc10b5","type":"TRIAL","name":"Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision","canonical_id":"clinicaltrials.gov:NCT01795209","description":"Branch Retinal Vein Occlusion; Macular Edema","metadata":null},{"id":"fb75d661b9b04c198efe33913be7625d","type":"TRIAL","name":"Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial","canonical_id":"clinicaltrials.gov:NCT00378196","description":"Telangiectasia","metadata":null},{"id":"c83bb42a1f5c423aba502f16ae7f0ffa","type":"GO_TERM","name":"Rap protein signal transduction","canonical_id":"go:GO:0032486","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Rap subfamily relays a signal.\" [GOC:mah]","metadata":null},{"id":"d337cd54328e41b680debd1956d43a24","type":"TRIAL","name":"Rapid Acclimatization to Hypoxia at Altitude","canonical_id":"clinicaltrials.gov:NCT01702025","description":"Physiological Function in Low Oxygen Environment","metadata":null},{"id":"ba38dae0d51342948ce21ba3fd12cc56","type":"TRIAL","name":"Rapid Administration Pilot for Infusing Dinutuximab","canonical_id":"clinicaltrials.gov:NCT05421897","description":"Neuroblastoma","metadata":null},{"id":"682adad850c546e19b60ba431d060291","type":"TRIAL","name":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","canonical_id":"clinicaltrials.gov:NCT04449549","description":"Neoplasms","metadata":null},{"id":"f41deb9eeeb54c949a85e0097e1ce62d","type":"TRIAL","name":"Rapid Antidepressant Effects of Yohimbine in Major Depression","canonical_id":"clinicaltrials.gov:NCT00078715","description":"Depression, Involutional; Major Depresssion","metadata":null},{"id":"aee6e2112c584eae8f8203837ede97ee","type":"TRIAL","name":"Rapid Benzodiazepine Detoxification Using Flumazenil - 1","canonical_id":"clinicaltrials.gov:NCT00000246","description":"Substance-Related Disorders","metadata":null},{"id":"bb456d42cf1a4064b57858b95ea34419","type":"TRIAL","name":"Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride","canonical_id":"clinicaltrials.gov:NCT02263547","description":"Teriflunomide Elimination; Healthy Volunteers","metadata":null},{"id":"b0f7132bd8754c3bac061d3ecfc30fb0","type":"TRIAL","name":"Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4","canonical_id":"clinicaltrials.gov:NCT00000301","description":"Cocaine-Related Disorders","metadata":null},{"id":"4852d109ed4a43faa0b871f9626acee1","type":"TRIAL","name":"Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle","canonical_id":"clinicaltrials.gov:NCT00586898","description":"Prostate; Cancer; Hormonal Cycling","metadata":null},{"id":"4ec58687686c4c0baca78cbdc55ee29c","type":"TRIAL","name":"Rapid Initiation of Drug Treatment Engagement","canonical_id":"clinicaltrials.gov:NCT03908437","description":"Opioid-use Disorder; Overdose","metadata":null},{"id":"ffaee1f1eda942fba108da7a3aee7fe7","type":"TRIAL","name":"Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02770014","description":"Epidermal Growth Factor Receptor; Non-Small Cell Lung Cancer","metadata":null},{"id":"548f5bc240674a518854afff3b9b645c","type":"TRIAL","name":"Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination","canonical_id":"clinicaltrials.gov:NCT03743805","description":"Brain Death; Anoxic Brain Injury; Cardiac Arrest; Sedative Intoxication; Narcotic Intoxication","metadata":null},{"id":"30f1b8e2e2cf4bde9d51290fbc978ed7","type":"TRIAL","name":"Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study","canonical_id":"clinicaltrials.gov:NCT01571908","description":"Intubation Conditions","metadata":null},{"id":"5ae0b6cd49964af486dba6785e4779eb","type":"TRIAL","name":"Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates","canonical_id":"clinicaltrials.gov:NCT03590587","description":"Diabetic Macular Edema","metadata":null},{"id":"accb5ac648734eebb1213fa35ebcfd56","type":"TRIAL","name":"Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder","canonical_id":"clinicaltrials.gov:NCT00457899","description":"Schizophrenia; Schizoaffective Disorders; Psychotic Disorders","metadata":null},{"id":"d9b836b8f6884ca99214cd0e4c6d5e12","type":"TRIAL","name":"Rapid Versus Prolonged Inpatient Up-Titration of Captopril","canonical_id":"clinicaltrials.gov:NCT00742040","description":"Heart Disease","metadata":null},{"id":"8ca8835e77364443a9abae14694ea2b2","type":"TRIAL","name":"Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)","canonical_id":"clinicaltrials.gov:NCT07547878","description":"Chronic Kidney Disease; Type 2 Diabetes","metadata":null},{"id":"fa1ca7c1733240909a66d63a50cdefa4","type":"TRIAL","name":"Raptiva in Palm and Sole Psoriasis","canonical_id":"clinicaltrials.gov:NCT00972543","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"f153e9b84e6f4323900ac5f53eabc46b","type":"DISEASE","name":"Rare genetic deafness","canonical_id":"orphanet:96210","description":null,"metadata":null},{"id":"4e4aefbbc1734d5f995cbf54cfc3ad38","type":"GO_TERM","name":"Ras guanyl-nucleotide exchange factor complex","canonical_id":"go:GO:1905742","description":"\"A protein complex which is capable of Ras guanyl-nucleotide exchange factor activity.\" [GO_REF:0000088, GOC:rjd, GOC:TermGenie, PMID:20493808]","metadata":null},{"id":"632189e9e3d04a309cd83a7638a6aa64","type":"GO_TERM","name":"Ras palmitoyltransferase activity","canonical_id":"go:GO:0043849","description":"\"Catalysis of the reaction: palmitoyl-CoA + protein-cysteine = S-palmitoyl protein + CoA, specific for Ras proteins.\" [PMID:16000296]","metadata":null},{"id":"a13160dd1c364873a3a118d9c6c8792c","type":"GO_TERM","name":"Ras protein signal transduction","canonical_id":"go:GO:0007265","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Ras subfamily relays a signal.\" [GOC:bf]","metadata":null},{"id":"844d5aff6cc6462a8fb3a07ae529c2ef","type":"GO_TERM","name":"RasGAP-Fyn-Lyn-Yes complex","canonical_id":"go:GO:0034996","description":"\"A protein complex that consists of a GTPase activator protein (GAP) for Ras and three Src family protein tyrosine kinases, Fyn, Lyn and Yes. The complex is involved in signaling upon platelet activation.\" [PMID:1544885]","metadata":null},{"id":"d81f8e5fbb8246bc96809088f7ccdb21","type":"TRIAL","name":"Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment","canonical_id":"clinicaltrials.gov:NCT02068625","description":"Retinal Detachment","metadata":null},{"id":"a705d79cc5ca4bd7b40add8502ea0aa4","type":"TRIAL","name":"Rasagiline Rescue in Alzheimer's Disease Clinical Trial","canonical_id":"clinicaltrials.gov:NCT02359552","description":"Alzheimer's Disease","metadata":null},{"id":"8421aaedeaed46c1b20641593de53819","type":"TRIAL","name":"Rasagiline Tablets Special Drug Use-Results Survey \"Survey on Long-term Safety\"","canonical_id":"clinicaltrials.gov:NCT03727139","description":"Parkinson's Disease","metadata":null},{"id":"9c7fbae8304c4efea3b3bbcc2bb2383d","type":"TRIAL","name":"Rasagiline and Apathy in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00755027","description":"Parkinson's Disease","metadata":null},{"id":"bf1c94d9bac14ef6abe3db8da12302c2","type":"TRIAL","name":"Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01049984","description":"Parkinson's Disease","metadata":null},{"id":"cb09502f9d074d629cda2068de13c3bf","type":"TRIAL","name":"Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.","canonical_id":"clinicaltrials.gov:NCT00203177","description":"Parkinson's Disease","metadata":null},{"id":"b686bb7b800a45e7a4c19ea6a7dc6bd6","type":"TRIAL","name":"Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn","canonical_id":"clinicaltrials.gov:NCT01055379","description":"Depressive Symptoms; Parkinson's Disease","metadata":null},{"id":"4d1425b4afac45f7b5ade00c154a7ffb","type":"TRIAL","name":"Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China","canonical_id":"clinicaltrials.gov:NCT01556165","description":"Parkinson's Disease","metadata":null},{"id":"f06465c6c2ac4a70879ff6ed4f4c52c6","type":"TRIAL","name":"Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)","canonical_id":"clinicaltrials.gov:NCT01786603","description":"Amyotrophic Lateral Sclerosis (ALS)","metadata":null},{"id":"597d81eb85e54fd58506d3f226a97f1f","type":"TRIAL","name":"Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00492336","description":"Schizophrenia","metadata":null},{"id":"d75c0e8413114bb39ef0b1887970c787","type":"TRIAL","name":"Rasburicase (Fasturtec) Registration Trial","canonical_id":"clinicaltrials.gov:NCT00607152","description":"Hyperuricemia","metadata":null},{"id":"84dde3aa5990489a920c909877e5aff1","type":"TRIAL","name":"Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome","canonical_id":"clinicaltrials.gov:NCT00230178","description":"Tumor Lysis Syndrome; Cancer; Hyperuricemia","metadata":null},{"id":"b5f06c7cadd84ed39b139a9552b45f99","type":"TRIAL","name":"Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT01564277","description":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; de Novo Myelodysplastic Syndromes; Noncontiguous Stage II Adult Burkitt Lymphoma; Previously Trea\u2026","metadata":null},{"id":"afbdb7fdf48c420daea447d565f47e1b","type":"TRIAL","name":"Rash & Diarrhea Prophylaxis With Capivasertib","canonical_id":"clinicaltrials.gov:NCT07426822","description":"Metastatic HR+/HER2- Breast Cancer","metadata":null},{"id":"96c49fd413984147a70166b003dc944f","type":"DISEASE","name":"Rat-Bite Fever","canonical_id":"mesh:D011906","description":null,"metadata":null},{"id":"5798f93bd79e49e09ee660b65e676c69","type":"TRIAL","name":"Rate Control in Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT02251509","description":"Atrial Fibrillation","metadata":null},{"id":"2d5003d5ad0942cd8f1161def73cbf51","type":"TRIAL","name":"Rate Control in Atrial Fibrillation II","canonical_id":"clinicaltrials.gov:NCT02695992","description":"Atrial Fibrillation; Permanent Atrial Fibrillation","metadata":null},{"id":"0db32b077b7d4225876aeadf24b71190","type":"TRIAL","name":"Ravulizumab Outcomes in Polish Patients With aHUS","canonical_id":"clinicaltrials.gov:NCT07399730","description":"Atypical Hemolytic Uremic Syndrome","metadata":null},{"id":"7a684a849d44415abdd4e5b0b1053eec","type":"TRIAL","name":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","canonical_id":"clinicaltrials.gov:NCT03748823","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"0176eefce10c40798d98040ff025caca","type":"TRIAL","name":"Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis","canonical_id":"clinicaltrials.gov:NCT04999020","description":"Dermatomyositis","metadata":null},{"id":"1b44770b7afc484abf6bba78603064d0","type":"TRIAL","name":"Ravulizumab and COVID-19","canonical_id":"clinicaltrials.gov:NCT04570397","description":"Covid19; Thrombotic Microangiopathies; Acute Kidney Injury","metadata":null},{"id":"719305e545a34c68af939039518ae61f","type":"TRIAL","name":"Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab","canonical_id":"clinicaltrials.gov:NCT04320602","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"7732b71c73b544ada008d5bb8e19b750","type":"TRIAL","name":"Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders","canonical_id":"clinicaltrials.gov:NCT06333652","description":"Preeclampsia","metadata":null},{"id":"27bf19ed593144408ede5cec3e194c8d","type":"TRIAL","name":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT04543591","description":"Thrombotic Microangiopathy","metadata":null},{"id":"f54d0ad72dc74384b1e534067ea73731","type":"TRIAL","name":"Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger","canonical_id":"clinicaltrials.gov:NCT04743804","description":"Thrombotic Microangiopathy","metadata":null},{"id":"50d90be4b11d47a7b7f8b5aa45f7d6bd","type":"DISEASE","name":"Raynaud's disease","canonical_id":"mesh:D011928","description":null,"metadata":null},{"id":"a4dc786495e84c5a92bc85c3186f4ac9","type":"GO_TERM","name":"Rb-E2F complex","canonical_id":"go:GO:0035189","description":"\"A multiprotein complex containing a heterodimeric E2F transcription factor and a Retinoblastoma (Rb) family member. This complex is capable of repressing transcription of E2F-regulated genes in order to regulate cell cycle progression.\" [PMID:14616073]","metadata":null},{"id":"44060916f2894f9c9066a2e9c408ff56","type":"TRIAL","name":"Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel","canonical_id":"clinicaltrials.gov:NCT07449299","description":"Emergency Contraception; Contraception; COX-2 Inhibitor","metadata":null},{"id":"bc0ac8d94fc5475490c1cca719e123d2","type":"TRIAL","name":"Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users","canonical_id":"clinicaltrials.gov:NCT01063426","description":"Thrombosis; Prevention; Surgery","metadata":null},{"id":"8f84f934df39480b9f8429d802746140","type":"TRIAL","name":"Re-treatment of Participants With Paget's Disease Using Zoledronic Acid","canonical_id":"clinicaltrials.gov:NCT00740129","description":"Paget's Disease of the Bone","metadata":null},{"id":"eeaea336682e4d328de3f4ce1fbd37a9","type":"TRIAL","name":"Real Life Experience Survey of Dupilumab in the Netherlands","canonical_id":"clinicaltrials.gov:NCT05331755","description":"Severe Asthma","metadata":null},{"id":"ab91bebffb8f455baf5b7ae7a62f0f55","type":"TRIAL","name":"Real Life Study of Biologicals in Patients With Severe CRSwNP","canonical_id":"clinicaltrials.gov:NCT05938972","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"130495af10ab470296fd48c8ceb713a4","type":"TRIAL","name":"Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria","canonical_id":"clinicaltrials.gov:NCT05274633","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"3a0d4f5690224297a9ef334d8c75fa54","type":"TRIAL","name":"Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT06862869","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"5d1f8e65f1a54edb866dcdeeffa05c4a","type":"TRIAL","name":"Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China","canonical_id":"clinicaltrials.gov:NCT07601516","description":"Huntington's Disease; Chorea","metadata":null},{"id":"9713d1330a914f389c6f2ffd1e7b7a33","type":"TRIAL","name":"Real World Effectiveness of Eptinezumab in Participants With Migraine","canonical_id":"clinicaltrials.gov:NCT05284019","description":"Migraine","metadata":null},{"id":"22584c1a54f045aeb0fa0910911a7645","type":"TRIAL","name":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","canonical_id":"clinicaltrials.gov:NCT05701007","description":"Metastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)","metadata":null},{"id":"21b47fd894634fd7a059debec6ef5734","type":"TRIAL","name":"Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)","canonical_id":"clinicaltrials.gov:NCT06439576","description":"Diabetic Macular Edema; Neovascular Age-related Macular Degeneration; Retinal Vein Occlusion","metadata":null},{"id":"cfa275746dbf499ca55e92ff455767f5","type":"TRIAL","name":"Real World Evidence of Fedratinib Effectiveness in MF","canonical_id":"clinicaltrials.gov:NCT05883904","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"d4dd359e14f04d62bfcfa69c2022eccb","type":"TRIAL","name":"Real World Glycemic Effectiveness of Linagliptin","canonical_id":"clinicaltrials.gov:NCT03338803","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"aaaf8a53106d4429b54746ed682889e0","type":"TRIAL","name":"Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","canonical_id":"clinicaltrials.gov:NCT05164263","description":"Type II Diabetes Mellitus; Efficacy, Self; Safety Issues","metadata":null},{"id":"e9ee087d95e148bc9d26938ebbfff297","type":"TRIAL","name":"Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07806604","description":"NSCLC (Non-small Cell Lung Cancer)","metadata":null},{"id":"fab661fa4fd847d39b9d57dbf0685faa","type":"TRIAL","name":"Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT06361589","description":"ALK-positive Non-small Cell Lung Cancer; Real World Study","metadata":null},{"id":"6764cb3cd48d4e2292a1fff7c160d3ba","type":"TRIAL","name":"Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04431791","description":"Colorectal Cancer","metadata":null},{"id":"24efa0dda4874c46a249a33eb390c867","type":"TRIAL","name":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03647592","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"45d05314626346b18abddc9ce3608ac7","type":"TRIAL","name":"Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03646994","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"3c2509af77614935b448b5e2657134ea","type":"TRIAL","name":"Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients","canonical_id":"clinicaltrials.gov:NCT07085117","description":"Thyroid Eye Disease","metadata":null},{"id":"1a8140f04ca947a49c588863fee20cb9","type":"TRIAL","name":"Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT06961331","description":"Metastatic HER2+ Advanced Breast Cancer","metadata":null},{"id":"66f94d8f3971480494691e076d5af3ee","type":"TRIAL","name":"Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT07235527","description":"Age Related Macular Degeneration; Exudative Age-Related Macular Degeneration; Anti Vascular Endothelial Growth Factor","metadata":null},{"id":"669d5da45a914c7f89c4f27b7e48dfda","type":"TRIAL","name":"Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib","canonical_id":"clinicaltrials.gov:NCT05675683","description":"Metastatic Non-Small Cell Lung Cancer","metadata":null},{"id":"d95a94d78d2a4725946cf85602085b0b","type":"TRIAL","name":"Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07442045","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"e6784507fe4e42cab153b40236cc215a","type":"TRIAL","name":"Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma","canonical_id":"clinicaltrials.gov:NCT07828327","description":"Allergic Bronchopulmonary Aspergillosis; ABPA; Severe Eosinophilic Asthma","metadata":null},{"id":"10a3a54640fc449c9849e7cc8b306550","type":"TRIAL","name":"Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data","canonical_id":"clinicaltrials.gov:NCT07821216","description":"Alopecia Areata","metadata":null},{"id":"bd69c6b138c3449eaeb89ce7ea0f6c07","type":"TRIAL","name":"Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis","canonical_id":"clinicaltrials.gov:NCT07757841","description":"Allergic Bronchopulmonary Aspergillosis; Severe Asthma; ABPA","metadata":null},{"id":"22d042a47f75414d91804aa1f86e13ed","type":"TRIAL","name":"Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational Study","canonical_id":"clinicaltrials.gov:NCT07633353","description":"Advanced Upper Tract Urothelial Carcinoma","metadata":null},{"id":"0c9b0ad0a9aa4e50b1c3e43b78c91a16","type":"TRIAL","name":"Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04987931","description":"Breast Cancer","metadata":null},{"id":"d85c75d8342f4a769bac9c36860d6d19","type":"TRIAL","name":"Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea","canonical_id":"clinicaltrials.gov:NCT06258668","description":"Moderate-to-severe Plaque Psoriasis","metadata":null},{"id":"0fe1297dba934d499db52636ea320d52","type":"TRIAL","name":"Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","canonical_id":"clinicaltrials.gov:NCT06802848","description":"Plaque Psoriasis; Psoriatic Arthritis; Scalp Psoriasis; Nail Psoriasis; Palmoplantar Psoriasis; Genital Psoriasis","metadata":null},{"id":"e63e763930fa4e14b03f676ec54934e0","type":"TRIAL","name":"Real-life Treatment Outcomes of Ravulizumab in PNH","canonical_id":"clinicaltrials.gov:NCT06633536","description":"Paroxysmal Nocturnal Haemoglobinuria","metadata":null},{"id":"ff80dbf53d9044d89c09cb32e6841d34","type":"TRIAL","name":"Real-life Use of Niraparib in a Patient Access Program in Norway","canonical_id":"clinicaltrials.gov:NCT04785716","description":"Ovarian Cancer; Peritoneal Cancer","metadata":null},{"id":"7447e7e506fa4719bbe3f4a9912ed60d","type":"TRIAL","name":"Real-life-persistence to Antifibrotic Treatments","canonical_id":"clinicaltrials.gov:NCT06485635","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"d5acbf58109641c996bcabbc4dec82fa","type":"TRIAL","name":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","canonical_id":"clinicaltrials.gov:NCT02625181","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"26c7d561f1414acc8526091cfa3c9aa2","type":"TRIAL","name":"Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist","canonical_id":"clinicaltrials.gov:NCT02687854","description":"Atrial Fibrillation","metadata":null},{"id":"57a93a52ad994073b004f8302405fab2","type":"TRIAL","name":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon","canonical_id":"clinicaltrials.gov:NCT03563937","description":"Atrial Fibrillation","metadata":null},{"id":"1b5e2950b74a4ea8ad45e4a2ddacc747","type":"TRIAL","name":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists","canonical_id":"clinicaltrials.gov:NCT02960880","description":"Atrial Fibrillation","metadata":null},{"id":"caa3c0130f3e47b4a6387a23a06e4cd9","type":"TRIAL","name":"Real-world Data (RWD) of Ramucirumab Plus Paclitaxel","canonical_id":"clinicaltrials.gov:NCT04915807","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"56e249cbb52d47cf9973bae357d9f9dc","type":"TRIAL","name":"Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab","canonical_id":"clinicaltrials.gov:NCT03394586","description":"Ulcerative Colitis; Flare Up, Symptom","metadata":null},{"id":"d9749bf5f1d249688e443f837ad28f46","type":"TRIAL","name":"Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT04974723","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"18f09be556444416a5838680701498eb","type":"TRIAL","name":"Real-world Effectiveness of Combination Therapy in Asthma","canonical_id":"clinicaltrials.gov:NCT01141465","description":"Asthma","metadata":null},{"id":"cd0a7b42ccdf4accb697ac13b25e0c5e","type":"TRIAL","name":"Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases","canonical_id":"clinicaltrials.gov:NCT03606499","description":"Crohn Disease; Colitis, Ulcerative","metadata":null},{"id":"28b38511e42646dc850cb3ceb35f3067","type":"TRIAL","name":"Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07269249","description":"Locally Advanced Rectal Cancer (LARC)","metadata":null},{"id":"70d3c968f3424bd78e813639ce37f187","type":"TRIAL","name":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)","canonical_id":"clinicaltrials.gov:NCT05082415","description":"Age-related Macular Degeneration (AMD)","metadata":null},{"id":"561278be5b054ef2a09cd868d4672775","type":"TRIAL","name":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)","canonical_id":"clinicaltrials.gov:NCT05111743","description":"Age-related Macular Degeneration (AMD)","metadata":null},{"id":"b70c1a93a8474b9b885504dc5b00d8af","type":"TRIAL","name":"Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA)","canonical_id":"clinicaltrials.gov:NCT05989932","description":"Atopic Dermatitis","metadata":null},{"id":"d65719894f75472cb846b102d14e6521","type":"TRIAL","name":"Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.","canonical_id":"clinicaltrials.gov:NCT05375097","description":"Migraine","metadata":null},{"id":"94bc6d3745be4ff9b509fbe91b9532f8","type":"TRIAL","name":"Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy","canonical_id":"clinicaltrials.gov:NCT06902207","description":"Intraocular Inflammation","metadata":null},{"id":"28e8c419ee2c4466b2b7679e11edbb11","type":"TRIAL","name":"Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab","canonical_id":"clinicaltrials.gov:NCT07091695","description":"Melanoma","metadata":null},{"id":"4cef533d1ece480bbe9d0b3f92f8ac98","type":"TRIAL","name":"Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy","canonical_id":"clinicaltrials.gov:NCT05649163","description":"HER2; Advanced Gastric Cancer; Advanced Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumor","metadata":null},{"id":"3553d252369e46078238f9b83a73c52b","type":"TRIAL","name":"Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC","canonical_id":"clinicaltrials.gov:NCT06690541","description":"Lung Cancer, Non-Small Cell","metadata":null},{"id":"2b8a4300268d4aafabd53c6ffa5c8cdf","type":"TRIAL","name":"Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04986371","description":"Epithelial Ovarian Cancer","metadata":null},{"id":"f6deba75a7fc4e0081d1c554f8405ff6","type":"TRIAL","name":"Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07018427","description":"Breast Neoplasms; Triple Negative Breast Cancer; HR+, HER2-, Advanced Breast Cancer; Breast Cancer","metadata":null},{"id":"a1f8f899db5a4fba8a29f2f33df58f83","type":"TRIAL","name":"Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT05883670","description":"Cervical Cancer","metadata":null},{"id":"3f76299ba07c44359d35e16cd07bb61a","type":"TRIAL","name":"Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.","canonical_id":"clinicaltrials.gov:NCT04647110","description":"ALK-positive NSCLC","metadata":null},{"id":"667c7dd2ebab4441b9b2b9814dd986e3","type":"TRIAL","name":"Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy","canonical_id":"clinicaltrials.gov:NCT04176354","description":"Metastatic Breast Cancer","metadata":null},{"id":"9108c45a1ecd4817b91ad8f1ca1933ab","type":"TRIAL","name":"Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England","canonical_id":"clinicaltrials.gov:NCT04637204","description":"Renal Cell Carcinoma","metadata":null},{"id":"aab778a325b74597a7625953e793085b","type":"TRIAL","name":"Realizing Effectiveness Across Continents With Hydroxyurea (REACH)","canonical_id":"clinicaltrials.gov:NCT01966731","description":"Sickle Cell Disease","metadata":null},{"id":"c8f7bf75d47b4707ac2eaea04e49d153","type":"TRIAL","name":"Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT05057481","description":"Autoimmune Hemolytic Anemia; Systemic Lupus Erythematosus","metadata":null},{"id":"06d2cb60f029498eba01e614829679e7","type":"TRIAL","name":"Rebalancing the Serotonergic System in Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT03266939","description":"Cocaine Dependence","metadata":null},{"id":"e641d782b04f4db38c75c60280caf862","type":"TRIAL","name":"Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients","canonical_id":"clinicaltrials.gov:NCT04649697","description":"Rheumatoid Arthritis","metadata":null},{"id":"157661b7bdd44d67b5e9637da844a30c","type":"DRUG","name":"Rebemadlin","canonical_id":"ncit:C74594","description":null,"metadata":null},{"id":"282414d3ec544880a7e340a25845e833","type":"TRIAL","name":"Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00409201","description":"Schizophrenia","metadata":null},{"id":"f77e3058d0914d9e8fda3b4f9afeadec","type":"TRIAL","name":"Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study","canonical_id":"clinicaltrials.gov:NCT00426946","description":"Depression","metadata":null},{"id":"961b41941b744b1a9e95a2b193ef802f","type":"TRIAL","name":"Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01300364","description":"Schizophrenia","metadata":null},{"id":"c92fa084d8fa499f9afd39ebe99b4492","type":"TRIAL","name":"Reboxetine for Sleep Apnoea After ENT Surgery","canonical_id":"clinicaltrials.gov:NCT05978505","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"3e52c38b91b84cb09691f332820da414","type":"GO_TERM","name":"RecFOR complex","canonical_id":"go:GO:0043850","description":"\"A heterotrimeric complex composed of the subunits RecF, RecO and RecR. Mediates the loading of RecA protein specifically onto SSB-coated gapped DNA during DNA repair.\" [PMID:12769856]","metadata":null},{"id":"832a70000f3c4a39acae39f199209a50","type":"GO_TERM","name":"RecQ family helicase-topoisomerase III complex","canonical_id":"go:GO:0031422","description":"\"A complex containing a RecQ family helicase and a topoisomerase III homologue (a member of the topoisomerase type IA subfamily); may also include one or more additional proteins; conserved from E. coli to human.\" [GOC:bhm, GOC:krc, PMID:15889139]","metadata":null},{"id":"b24191ebd90d4f49b6752e73dad4fbeb","type":"TRIAL","name":"Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)","canonical_id":"clinicaltrials.gov:NCT03091400","description":"Memory Disorders; Multiple Sclerosis","metadata":null},{"id":"d5f4d8e6354f4ffdb51ed79464db964b","type":"TRIAL","name":"Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)","canonical_id":"clinicaltrials.gov:NCT01506414","description":"Purpura; Idiopathic Thrombocytopenic Purpura","metadata":null},{"id":"dc5a698134e04fbaa5f3f45361b0204a","type":"TRIAL","name":"Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data","canonical_id":"clinicaltrials.gov:NCT04606264","description":"Perioperative Optimization","metadata":null},{"id":"ab8e397c1cee4df89ef314c73cd45917","type":"TRIAL","name":"Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00367393","description":"Atopic Dermatitis","metadata":null},{"id":"f7cf1d0684af4739b27d8fe44996ceeb","type":"TRIAL","name":"Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","canonical_id":"clinicaltrials.gov:NCT04681430","description":"Corona Virus Infection; SARS-CoV-2 Infection; SARS-CoV-2 PCR Test Positive; SARS-CoV-2 Acute Respiratory Disease","metadata":null},{"id":"9fbe1338e8224571bee1df38a88da497","type":"TRIAL","name":"Rectal Indomethacin vs Intravenous Ketorolac","canonical_id":"clinicaltrials.gov:NCT05664074","description":"Post-ERCP Acute Pancreatitis","metadata":null},{"id":"cf534627aea4457ca75b03bf95549dbf","type":"DISEASE","name":"Rectum Cancer","canonical_id":"doid:1993","description":null,"metadata":null},{"id":"7be6d173a35a4e5e9e4496c553e37250","type":"TRIAL","name":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","canonical_id":"clinicaltrials.gov:NCT06411795","description":"Duodenal Neoplasm; Pancreatic Neoplasm","metadata":null},{"id":"35e7d93fa2784ec0b07ab97a12c028ed","type":"TRIAL","name":"Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency","canonical_id":"clinicaltrials.gov:NCT04231279","description":"Abdominal Pain; Irritable Bowel Syndrome","metadata":null},{"id":"645c5d559ba14620b4abe2ff931e85b2","type":"TRIAL","name":"Recurrent Carotid Stenosis","canonical_id":"clinicaltrials.gov:NCT00000527","description":"Cardiovascular Diseases; Carotid Stenosis; Cerebrovascular Disorders; Heart Diseases; Vascular Diseases","metadata":null},{"id":"fe23315adf5d46b6aabf9257ec4a8225","type":"DISEASE","name":"Recurrent thrombophlebitis","canonical_id":"hp:0004419","description":null,"metadata":null},{"id":"4820ead61b2d4e56bb19cd7cb6ba811c","type":"TRIAL","name":"Red Blood Cell ATP Release and Vascular Function in Humans","canonical_id":"clinicaltrials.gov:NCT03404843","description":"Cardiovascular Diseases","metadata":null},{"id":"51b22154bc7149a28735afd9d4010d93","type":"TRIAL","name":"Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer","canonical_id":"clinicaltrials.gov:NCT02124681","description":"Insulin Resistance","metadata":null},{"id":"40822427ad964fa3917c22bd5fb3f0fc","type":"TRIAL","name":"Reduce Bolus Injection of Bivalirudin","canonical_id":"clinicaltrials.gov:NCT03588611","description":"Acute Coronary Syndrome","metadata":null},{"id":"2947b181e88444268019a43bfb788fb2","type":"TRIAL","name":"Reduce Nonsteroidal Antiinflammatory Drugs Doses for Analgesia After Sternotomy","canonical_id":"clinicaltrials.gov:NCT02180087","description":"Cardiac Surgery; Post-operative Pain","metadata":null},{"id":"91db9ab627bc44d68b7134d5e64d3086","type":"TRIAL","name":"Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism","canonical_id":"clinicaltrials.gov:NCT05512702","description":"Pulmonary Embolism","metadata":null},{"id":"920bf475943245de933b5012064a1a21","type":"TRIAL","name":"Reduced Dose-density of Denosumab for Unresectable GCTB","canonical_id":"clinicaltrials.gov:NCT03620149","description":"Bone Giant Cell Tumor","metadata":null},{"id":"7c3697782ffd4e76829cd598ec1af0c4","type":"TRIAL","name":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00057954","description":"Lymphoma","metadata":null},{"id":"535fd87100d94d6aba215cbef1b00e2d","type":"TRIAL","name":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT00045305","description":"Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms","metadata":null},{"id":"78fd914e46a84996af902e3525dffe00","type":"TRIAL","name":"Reducing Cannabis Overuse With Prazosin","canonical_id":"clinicaltrials.gov:NCT04721353","description":"Cannabis Dependence; Posttraumatic Stress Disorder; Cannabis Use Disorder","metadata":null},{"id":"a4d21449fbdc4a82b8c4ffd65efc6f67","type":"TRIAL","name":"Reducing Pain With Methadone and Ketamine in Liver Transplant","canonical_id":"clinicaltrials.gov:NCT06868589","description":"Liver Transplantation","metadata":null},{"id":"193eab32c45a4ef1ae2ea5e863a85057","type":"TRIAL","name":"Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan","canonical_id":"clinicaltrials.gov:NCT01424319","description":"Chronic Kidney Disease; Diabetic Nephropathy","metadata":null},{"id":"a8e61315b30444c2b67afee8d370237f","type":"TRIAL","name":"Reducing Suicidal Ideation Through Insomnia Treatment","canonical_id":"clinicaltrials.gov:NCT01689909","description":"Insomnia; Depression; Suicidal Ideation","metadata":null},{"id":"b883aee6b3834ae69dd93b11621da643","type":"TRIAL","name":"Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)","canonical_id":"clinicaltrials.gov:NCT02199652","description":"Post Traumatic Stress Disorder; Suicidal Ideation; Nightmares","metadata":null},{"id":"cab9c7de3bff4ca3ae70facadb9cd5cf","type":"TRIAL","name":"Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT01048983","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"81ddbe074d1c4f058b9f40262f11b387","type":"TRIAL","name":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","canonical_id":"clinicaltrials.gov:NCT00806234","description":"Psychotic Disorders","metadata":null},{"id":"3eccd39818c843b08f9f66619fdba3f2","type":"TRIAL","name":"Reducing the Abuse of Opioids in Drug Users","canonical_id":"clinicaltrials.gov:NCT03837860","description":"Opioid Abuse, Unspecified; Opioid Dependence","metadata":null},{"id":"4d29e7d166ac44ebbe89d8789b918aec","type":"TRIAL","name":"Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00821574","description":"Hypertension, Dyslypidaemia","metadata":null},{"id":"366d9375c86f485380fa0de9e9a91006","type":"TRIAL","name":"Reducing the Risk of Drug-Induced QT Interval Lengthening in Women","canonical_id":"clinicaltrials.gov:NCT03834883","description":"Long QT Syndrome; Abnormalities, Drug-Induced","metadata":null},{"id":"091c150108894606b2408199448aa223","type":"TRIAL","name":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT05660135","description":"Hypertension; Dyslipidemias","metadata":null},{"id":"9f5a692416a94350aeee12b883ab338e","type":"TRIAL","name":"Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment","canonical_id":"clinicaltrials.gov:NCT02713776","description":"Enterostomy","metadata":null},{"id":"c7e4f395704a4fae8873818172119c79","type":"TRIAL","name":"Reduction of Bladder Injection Pain With Belladonna Opiate Suppository","canonical_id":"clinicaltrials.gov:NCT02600715","description":"Overactive Bladder; Urinary Urge Incontinence; Urinary Bladder, Neurogenic; Painful Bladder Syndrome","metadata":null},{"id":"fed306fcb3484c4a9c8f0ac1a3238b74","type":"TRIAL","name":"Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine","canonical_id":"clinicaltrials.gov:NCT05053321","description":"Tardive Dyskinesia","metadata":null},{"id":"87ba743280e94638880e032e81cee02e","type":"TRIAL","name":"Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study","canonical_id":"clinicaltrials.gov:NCT01375751","description":"Hypercholesterolemia, Familial","metadata":null},{"id":"a0017c2275bd47bfabaf4f49bfa42d09","type":"TRIAL","name":"Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment","canonical_id":"clinicaltrials.gov:NCT05250752","description":"End Stage Renal Disease; Peritoneal Dialysis Complication","metadata":null},{"id":"b4a840fb533e4e6ca609bfe26350799f","type":"TRIAL","name":"Reduction of Pulmonary Artery Pressure in Patients Subjected to Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01597427","description":"Anesthesia","metadata":null},{"id":"0a2f12304f804730b4fb1489e12b9b9b","type":"DRUG","name":"Refametinib","canonical_id":"ncit:C74059","description":null,"metadata":null},{"id":"34f862449b67458ca0e3d921ebe59695","type":"TRIAL","name":"Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer","canonical_id":"clinicaltrials.gov:NCT02168777","description":"Neoplasms","metadata":null},{"id":"05390ed2427c4ed9873ce271d1402906","type":"TRIAL","name":"Reflux Esophagitis Phase III Study (Initial Treatment)","canonical_id":"clinicaltrials.gov:NCT00633932","description":"Reflux Esophagitis","metadata":null},{"id":"63c85c600f334bba9b594c0dc0a84553","type":"TRIAL","name":"Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging","canonical_id":"clinicaltrials.gov:NCT01021618","description":"Coronary Artery Disease; Myocardial Ischemia","metadata":null},{"id":"d97b8a8920574bd7a3a99d94f1f5be9e","type":"TRIAL","name":"Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System","canonical_id":"clinicaltrials.gov:NCT04521569","description":"Lung Transplant","metadata":null},{"id":"1832e178663b4e119540456d87c3ecf7","type":"TRIAL","name":"Regadenoson Real Time Perfusion Imaging Trial-Optison","canonical_id":"clinicaltrials.gov:NCT01489176","description":"Coronary Artery Disease; Myocardial Perfusion Abnormalities","metadata":null},{"id":"b45fedec9c264b3e810a33ce4a1bacb2","type":"TRIAL","name":"Regadenoson and Adenosine","canonical_id":"clinicaltrials.gov:NCT01809743","description":"Coronary Artery Disease","metadata":null},{"id":"7bb691a23da54380a19fcfd2b1ef961d","type":"TRIAL","name":"Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT02220634","description":"Pulmonary Hypertension","metadata":null},{"id":"3d2a732e65b24febbfd1dad506d46b24","type":"TRIAL","name":"Regeneration in Cervical Degenerative Myelopathy","canonical_id":"clinicaltrials.gov:NCT04631471","description":"Myelopathy; Spinal Cord Diseases","metadata":null},{"id":"d0e8cf20b09d4a609221f5530fc04ad7","type":"TRIAL","name":"Regimen Optimization Study","canonical_id":"clinicaltrials.gov:NCT02137239","description":"Kidney Transplantation","metadata":null},{"id":"25a3b9dd39d44ff8bf4862a8580de7a8","type":"TRIAL","name":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT07173712","description":"Type 2 Diabetes","metadata":null},{"id":"4246261a6d714ea28f7afb6eba7f7d9d","type":"TRIAL","name":"Regional Nasal Block and Dexmedetomidine in Endoscopic Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT05361642","description":"Drug Use","metadata":null},{"id":"325c6e9048824c468a4d3f24524b855b","type":"TRIAL","name":"Regional Tolvaptan Registry","canonical_id":"clinicaltrials.gov:NCT02666651","description":"Decompensated Heart Failure; Hyponatremia","metadata":null},{"id":"95bac67fc49d491185f1a0bb3d19ad3f","type":"TRIAL","name":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","canonical_id":"clinicaltrials.gov:NCT04062097","description":"Intracranial Hemorrhage","metadata":null},{"id":"90d4c2ef74554405bd331ad995bb792c","type":"TRIAL","name":"Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]","canonical_id":"clinicaltrials.gov:NCT00700258","description":"Carcinoma, Renal Cell, Advanced; Lymphoma, Mantle-Cell; Gastrointestinal Stroma Tumors","metadata":null},{"id":"2140f44261fc43038191aa11c59d5f94","type":"TRIAL","name":"Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE\u00ae) in Patients With Duchenne Muscular Dystrophy-SUMMIT","canonical_id":"clinicaltrials.gov:NCT06564974","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"29af2f0e5b034c6fa4ce64db6f267cf5","type":"TRIAL","name":"Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany","canonical_id":"clinicaltrials.gov:NCT01454583","description":"Arterial Hypertension","metadata":null},{"id":"be64cfa603b64868b2ccee05bde8956d","type":"TRIAL","name":"Registry for Migraine - Clinical Core","canonical_id":"clinicaltrials.gov:NCT04603976","description":"Migraine","metadata":null},{"id":"5f17be60a29b4963aac6c1f9784c83d2","type":"TRIAL","name":"Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment","canonical_id":"clinicaltrials.gov:NCT04674020","description":"Migraine; Headache","metadata":null},{"id":"b5ea5234548e4049b884a2b727de3645","type":"TRIAL","name":"Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials","canonical_id":"clinicaltrials.gov:NCT02918539","description":"Alzheimer Disease; Cognition Disorders","metadata":null},{"id":"f74ea5fbc98444b2bc582984e1394deb","type":"TRIAL","name":"Registry of IgA Nephropathy in Chinese Children","canonical_id":"clinicaltrials.gov:NCT03015974","description":"IgA Nephropathy; Proteinuria in Nephrotic Range; Immunosuppressive Treatment","metadata":null},{"id":"69b61fe84cd143fbba5ec53d837f41c9","type":"DRUG","name":"Regorafenib Anhydrous","canonical_id":"ncit:C78204","description":null,"metadata":null},{"id":"be153cac8ddb489ead372d1685b16f98","type":"TRIAL","name":"Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)","canonical_id":"clinicaltrials.gov:NCT04170556","description":"Hepatocellular Carcinoma","metadata":null},{"id":"1cbaf365a5f342e4b0a6f36a40349e34","type":"TRIAL","name":"Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT02383433","description":"Metastatic Pancreatic Adenocarcinoma","metadata":null},{"id":"80226d9d02c34b2aa277b7413ac5e5d2","type":"TRIAL","name":"Regorafenib Post-marketing Surveillance in Japan","canonical_id":"clinicaltrials.gov:NCT01933958","description":"Gastrointestinal Stromal Tumors","metadata":null},{"id":"33b4ab39b09943649bc4e5f028e4d07c","type":"TRIAL","name":"Regorafenib and Cetuximab in Patients With Advanced Malignancy","canonical_id":"clinicaltrials.gov:NCT02095054","description":"Advanced Cancers","metadata":null},{"id":"5f83f741ce164ec5b32a15602f3253b2","type":"TRIAL","name":"Regorafenib for Recurrent Meningioma (MIRAGE Trial)","canonical_id":"clinicaltrials.gov:NCT06275919","description":"Meningioma, Malignant","metadata":null},{"id":"dbbfb9301b7d40d1ac7c1a4a4f68a5e9","type":"TRIAL","name":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04534218","description":"Colo-rectal Cancer; Metastatic Cancer","metadata":null},{"id":"b2d40eb76be248d69291c5cbbb86b096","type":"TRIAL","name":"Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT06454409","description":"Myelodysplastic Syndrome/Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome","metadata":null},{"id":"05849b53138042be9c8a4a1aa78df1cc","type":"TRIAL","name":"Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02023333","description":"Metastatic Colorectal Adenocarcinoma","metadata":null},{"id":"e9d2d9fbe4a74148be65fd6f50371026","type":"TRIAL","name":"Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy","canonical_id":"clinicaltrials.gov:NCT02307500","description":"Pancreas Cancer; Ovarian Cancer; Melanoma; Sarcoma; Thymoma Type B3; Thymoma Type B2; Thymic Carcinoma","metadata":null},{"id":"3afea0bb132344a7b6c0e9006ac66940","type":"TRIAL","name":"Regorafenib in Patients With Refractory Primary Bone Tumors","canonical_id":"clinicaltrials.gov:NCT05395741","description":"Osteosarcoma; Ewing Sarcoma of Bone","metadata":null},{"id":"90a2958e47b847b6ba8afe9502fb250e","type":"TRIAL","name":"Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy","canonical_id":"clinicaltrials.gov:NCT01853319","description":"Colorectal Neoplasms","metadata":null},{"id":"0eb6fb028e5a464d9ac342491c202590","type":"TRIAL","name":"Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7","canonical_id":"clinicaltrials.gov:NCT04777851","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"e7540393f2874346b491caed33ebcbec","type":"TRIAL","name":"Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness","canonical_id":"clinicaltrials.gov:NCT02843685","description":"Sepsis","metadata":null},{"id":"ca81452729b24ae38a6b344e3c3dd06d","type":"TRIAL","name":"Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT04760717","description":"Intracerebral Hemorrhage; Ischemic Stroke; Spironolactone","metadata":null},{"id":"91fa000516cc4c28af68c9504b257f35","type":"TRIAL","name":"Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","canonical_id":"clinicaltrials.gov:NCT05714683","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"65673696932240d8b9b8b6d064966011","type":"TRIAL","name":"Regulatory Post-Marketing Surveillance Study for Brolucizumab","canonical_id":"clinicaltrials.gov:NCT04985487","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"d3fa20f21bfa46009aa94fe914da5f8c","type":"TRIAL","name":"Regulatory T-cells in Psoriasis Patients as Targets for Therapy","canonical_id":"clinicaltrials.gov:NCT01233583","description":"Psoriasis","metadata":null},{"id":"42af36910cc34b6db2f2737f62c7fe16","type":"PROTEIN","name":"Regulatory protein E2","canonical_id":"uniprot:P03120","description":null,"metadata":null},{"id":"5978cccddc094462a95315ab219e2a77","type":"GO_TERM","name":"Rel homology domain binding","canonical_id":"go:GO:0044197","description":"\"Binding to a Rel Homology Domain (RHD) of a protein. The RHD is found in a family of eukaryotic transcription factors, which includes NF-kappaB, Dorsal, Relish and NFAT.\" [InterPro:IPR011539, Wikipedia:Rel_homology_domain]","metadata":null},{"id":"6675a7bfed7844bf9c4a34ecc1065c04","type":"TRIAL","name":"Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food","canonical_id":"clinicaltrials.gov:NCT01189201","description":"Healthy","metadata":null},{"id":"c894a5cb224d46e2aeaa77a26d794fd4","type":"TRIAL","name":"Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00887224","description":"Major Depressive Disorder","metadata":null},{"id":"9a2557cefde849f1954cd835ca507c0f","type":"TRIAL","name":"Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis","canonical_id":"clinicaltrials.gov:NCT03325556","description":"Dementia-related Psychosis","metadata":null},{"id":"f04724d088cb49b6813a5058971eb333","type":"TRIAL","name":"Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)","canonical_id":"clinicaltrials.gov:NCT00660062","description":"Major Depression","metadata":null},{"id":"e8116151c1094a449c4c4cd24c7ae14a","type":"TRIAL","name":"Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01085812","description":"Depression; Major Depressive Disorder","metadata":null},{"id":"203520bc2f1c42e7a8bdc2c53b70cf72","type":"TRIAL","name":"Relapsed and/or Refractory Non-Hodgkin Lymphoma Study","canonical_id":"clinicaltrials.gov:NCT00837174","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"2010c89901944b229df16d37d27aa709","type":"DISEASE","name":"Relapsing Fever","canonical_id":"mesh:D012061","description":null,"metadata":null},{"id":"f9af1d6d93f34b88ae8e780109f5980c","type":"TRIAL","name":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","canonical_id":"clinicaltrials.gov:NCT04410978","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"e61083ae28b449fb8183d726f89231aa","type":"TRIAL","name":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)","canonical_id":"clinicaltrials.gov:NCT04410991","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"6a35d10d064248cc9ad5985ed0896b93","type":"DISEASE","name":"Relapsing remitting multiple sclerosis","canonical_id":"mesh:D020529","description":null,"metadata":null},{"id":"add440c91b7743659021a595242cfe2b","type":"TRIAL","name":"Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)","canonical_id":"clinicaltrials.gov:NCT02759887","description":"Down Syndrome; Alzheimer's Dementia","metadata":null},{"id":"d381eb0e08e14fddaffde2fa8167eaf3","type":"TRIAL","name":"Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine","canonical_id":"clinicaltrials.gov:NCT05890768","description":"Psychosis","metadata":null},{"id":"4bb50f68e3254c218579b0da253dd8af","type":"TRIAL","name":"Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule","canonical_id":"clinicaltrials.gov:NCT01297595","description":"Healthy","metadata":null},{"id":"b0c46a7da6ea477e98da7f6adabb3440","type":"TRIAL","name":"Relative Bioavailability Study of HNC364 Injectable Suspension","canonical_id":"clinicaltrials.gov:NCT06798519","description":"Parkinson&#39;s Disease (PD)","metadata":null},{"id":"6430938ad07248b6950580baba641890","type":"TRIAL","name":"Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00960245","description":"High Blood Pressure; Migraine Headaches; Chest Pain","metadata":null},{"id":"d92ff5d087a442e9b80f4935cd0be16a","type":"TRIAL","name":"Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT02075619","description":"Hypertension","metadata":null},{"id":"ad0df4fd56aa4530bd1c5548550d21cf","type":"TRIAL","name":"Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2","canonical_id":"clinicaltrials.gov:NCT02178059","description":"Healthy Volunteers","metadata":null},{"id":"f9384c59f81b4d80a58cb60bd222a00e","type":"TRIAL","name":"Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1","canonical_id":"clinicaltrials.gov:NCT01146678","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"a5499a12faa7404b8441dbe0b3cb5e80","type":"TRIAL","name":"Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06043739","description":"Bioavailability","metadata":null},{"id":"4c0b55ae2dff47ddae412f96e326321f","type":"TRIAL","name":"Relative Bioavailability of 2 Oral Formulations of Nintedanib","canonical_id":"clinicaltrials.gov:NCT02572752","description":"Healthy","metadata":null},{"id":"1c5e902cbf7046b8843fbdd158c6a1f1","type":"TRIAL","name":"Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02782624","description":"Healthy","metadata":null},{"id":"c6dba79b72474002bccfaa9f04d5be03","type":"TRIAL","name":"Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations","canonical_id":"clinicaltrials.gov:NCT05103891","description":"Melanoma; BRAF V600 Mutation; Unresectable Melanoma; Metastatic Melanoma","metadata":null},{"id":"154db0d7211e40b5b3730f7217a11548","type":"TRIAL","name":"Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02171546","description":"Healthy","metadata":null},{"id":"80acc6e81f8b4d82b17969ab85636e11","type":"TRIAL","name":"Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02171052","description":"Healthy","metadata":null},{"id":"a0a7baeb4e414c278904f8b945d67ac0","type":"TRIAL","name":"Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02260063","description":"Healthy","metadata":null},{"id":"85dab92060d04ec5875253b12018be9c","type":"TRIAL","name":"Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05418348","description":"Aneurysmal Subarachnoid Hemorrhage","metadata":null},{"id":"c01516296a524667b15cd7e0d8fadba3","type":"TRIAL","name":"Relative Bioavailability of NXP001 Compared to Emend\u00ae in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03889366","description":"Healthy","metadata":null},{"id":"118072c1854f4a1fb58d5df946b22f48","type":"TRIAL","name":"Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01301742","description":"Healthy","metadata":null},{"id":"12aa0b3e66ef4eb9a07d9ebba59b5448","type":"TRIAL","name":"Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02171533","description":"Healthy","metadata":null},{"id":"ada310fea831499cac43a935911877a9","type":"TRIAL","name":"Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects","canonical_id":"clinicaltrials.gov:NCT02262793","description":"Healthy","metadata":null},{"id":"df94bfc977e34cc4bb636d5aa4d21be1","type":"TRIAL","name":"Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects","canonical_id":"clinicaltrials.gov:NCT02262572","description":"Healthy","metadata":null},{"id":"e5e0317bf5fe4123a0effd99e5c733f8","type":"TRIAL","name":"Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03021642","description":"Healthy","metadata":null},{"id":"c62cc47b497541bd9d22898375ce373c","type":"TRIAL","name":"Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin","canonical_id":"clinicaltrials.gov:NCT01770392","description":"Healthy","metadata":null},{"id":"ccfe040abf924bafbdb26df3e9759125","type":"TRIAL","name":"Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML","canonical_id":"clinicaltrials.gov:NCT04913922","description":"Acute Myeloid Leukemia","metadata":null},{"id":"c20a34f6f8774bdfb5b12f319462a40e","type":"TRIAL","name":"Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face","canonical_id":"clinicaltrials.gov:NCT01720407","description":"Lentigo Maligna Melanoma (Head or Neck)","metadata":null},{"id":"91b71f2de4784eed8c8b7f8ec8748ba2","type":"TRIAL","name":"Relugolix + Enzalutamide Study in High-Risk Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06130995","description":"Androgen Deprivation Therapy; Locally Advanced Prostate Cancer","metadata":null},{"id":"6e0e46f087064ec8b70d4050cf7aa63e","type":"TRIAL","name":"Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response","canonical_id":"clinicaltrials.gov:NCT07102979","description":"Liver Fibrosis","metadata":null},{"id":"dfa1c7ab1995461b87597c01518655e2","type":"TRIAL","name":"Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training","canonical_id":"clinicaltrials.gov:NCT03272711","description":"Age-related Cognitive Decline","metadata":null},{"id":"13903915a84341e3875cd457e61e84a0","type":"TRIAL","name":"Remediation of Impaired Self-Regulation in Patients With Mild TBI","canonical_id":"clinicaltrials.gov:NCT02260570","description":"Mild Traumatic Brain Injury","metadata":null},{"id":"cfd4ff8aa8b74c599fd4b4561470bc50","type":"TRIAL","name":"Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00818272","description":"Crohn's Disease","metadata":null},{"id":"2275f9bc244d4be99129560aed4ea69f","type":"TRIAL","name":"Remifentanil and Atropine for Intubation in Neonates","canonical_id":"clinicaltrials.gov:NCT00815048","description":"Endotracheal Intubation","metadata":null},{"id":"0ff053505d98471ebce361563ee3a7f5","type":"TRIAL","name":"Remifentanil vs Esmolol During Intubation for Cerebral Aneurysm Coil Embolization","canonical_id":"clinicaltrials.gov:NCT07660861","description":"Cerebral Aneurysm Unruptured; Intracranial Pressure","metadata":null},{"id":"efe0be7c5ad146c19910f472af7f3b2a","type":"TRIAL","name":"Remimazolam-Flumazenil Versus Sevoflurane for Hysteroscopic Day Surgery","canonical_id":"clinicaltrials.gov:NCT07663877","description":"Hysteroscopy; Ambulatory Surgery; General Anesthesia","metadata":null},{"id":"cd5164aa503941b393bdd289a6966637","type":"TRIAL","name":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","canonical_id":"clinicaltrials.gov:NCT02623998","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7b7dc8096c4042bbae3a0b0f7ed08eb7","type":"TRIAL","name":"Remission in Subjects With Crohn's Disease, 1 Year Phase","canonical_id":"clinicaltrials.gov:NCT00055497","description":"Crohn's Disease","metadata":null},{"id":"658e3bc8950445faa04271d058ecf6f8","type":"TRIAL","name":"Remote Treatment of Alcohol Withdrawal","canonical_id":"clinicaltrials.gov:NCT04858490","description":"Alcohol Withdrawal","metadata":null},{"id":"10440c3c1247473094b64e7e01f5446b","type":"TRIAL","name":"Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)","canonical_id":"clinicaltrials.gov:NCT04565392","description":"Covid19","metadata":null},{"id":"85efc0de743643e59ee36bb08edee54f","type":"TRIAL","name":"Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation","canonical_id":"clinicaltrials.gov:NCT05147532","description":"Multiple Sclerosis; Inflammatory Disease","metadata":null},{"id":"e60f5e0ffc714412955b967b57a25479","type":"TRIAL","name":"Renal Denervation in Patients After Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT01901549","description":"Acute Coronary Syndrome; Arterial Hypertension","metadata":null},{"id":"75931d140aad4360831caf58002ee477","type":"TRIAL","name":"Renal Mechanism of SGLT2 Inhibition","canonical_id":"clinicaltrials.gov:NCT05507892","description":"Type 2 Diabetes; Diabetic Kidney Disease","metadata":null},{"id":"fdf7ff3d82f04d87ae4a39109d5ab30a","type":"TRIAL","name":"Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.","canonical_id":"clinicaltrials.gov:NCT04027530","description":"Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Diabetic Nephropathy; Renal Hypoxia; Renoprotection; SGLT2 Inhibitor; Ertugliflozin","metadata":null},{"id":"8146d7ceda2c410981e239fc18e4c734","type":"TRIAL","name":"Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients","canonical_id":"clinicaltrials.gov:NCT00721773","description":"Renal Function Disorder","metadata":null},{"id":"867a89d540234229a3dcfdc75a6c223f","type":"TRIAL","name":"Renal Response to Lower Body Negative Pressure in Pre-hypertensive States","canonical_id":"clinicaltrials.gov:NCT01734096","description":"Hypertension; Obesity; White Coat Hypertension; Resistant Hypertension","metadata":null},{"id":"24bbed5bec1046a097dcbd17aeb20e53","type":"TRIAL","name":"Renal Retention in High Grade Upper Tract Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT05656235","description":"High Grade Urothelial Carcinoma; Bladder Cancer; Urothelial Carcinoma Bladder","metadata":null},{"id":"fabcf4b6002b450b82b439d08b750a00","type":"TRIAL","name":"Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus","canonical_id":"clinicaltrials.gov:NCT04917718","description":"Chronic Kidney Diseases; Heart Transplant","metadata":null},{"id":"8aae2fa0415a4d50829e4173fa8c1e4c","type":"DISEASE","name":"Renal tubular acidosis","canonical_id":"mesh:D000141","description":null,"metadata":null},{"id":"63147a5077ae43ac88d6da367a4ae82c","type":"GO_TERM","name":"Renilla-luciferin 2-monooxygenase activity","canonical_id":"go:GO:0050248","description":"\"Catalysis of the reaction: Renilla luciferin + O2 = oxidized Renilla luciferin + CO2 + light.\" [EC:1.13.12.5]","metadata":null},{"id":"84be47225b804f6ca5237f6ab749db76","type":"GO_TERM","name":"Renilla-luciferin sulfotransferase activity","canonical_id":"go:GO:0050249","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + Renilla luciferin = adenosine 3',5'-diphosphate + H+ + luciferyl sulfate.\" [EC:2.8.2.10, RHEA:20481]","metadata":null},{"id":"cfbde59951594df0ae718c780b8bf429","type":"PROTEIN","name":"Renin","canonical_id":"uniprot:P00797","description":null,"metadata":null},{"id":"4b896fcbc6d04866ba8094bed4bf2348","type":"TRIAL","name":"Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i","canonical_id":"clinicaltrials.gov:NCT00750308","description":"Metabolic Syndrome","metadata":null},{"id":"ed7214f58806416fb896ee4442df92a1","type":"TRIAL","name":"Renin Angiotensin System Study (RASS/B-RASS)","canonical_id":"clinicaltrials.gov:NCT00143949","description":"Type 1 Diabetes","metadata":null},{"id":"7964961782f345e89a9eaf2c54362e27","type":"TRIAL","name":"Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)","canonical_id":"clinicaltrials.gov:NCT03201185","description":"Transcatheter Aortic Valve Replacemen; Angiotensin-Converting Enzyme Inhibitors","metadata":null},{"id":"6723d4bb55a143efb9f3bbd2a345041c","type":"TRIAL","name":"Renohemodynamic Effects of Combined empagliflOzin and LosARtan","canonical_id":"clinicaltrials.gov:NCT04238702","description":"Diabetes Mellitus, Type 2; Diabetic Kidney Disease","metadata":null},{"id":"cd452ffdd4474f5c89dc4682f3041da5","type":"TRIAL","name":"Renoprotection in Early Diabetic Nephropathy in Pima Indians","canonical_id":"clinicaltrials.gov:NCT00340678","description":"Diabetic Nephropathy","metadata":null},{"id":"1899677b6ce6463f86368913e70fb0b7","type":"TRIAL","name":"Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3","canonical_id":"clinicaltrials.gov:NCT05264584","description":"Chronic Kidney Disease stage3; Contrast-induced Nephropathy","metadata":null},{"id":"5db79d27494140698242c71b11c0b979","type":"TRIAL","name":"Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT00311870","description":"Diabetic Nephropathy","metadata":null},{"id":"7b10d960eb8b42ae8b1ca20798438ff9","type":"TRIAL","name":"ReoPro and Retavase to Restore Brain Blood Flow After Stroke","canonical_id":"clinicaltrials.gov:NCT00039832","description":"Cerebrovascular Accident","metadata":null},{"id":"b4295ed3645144dd844cc84585f2b350","type":"TRIAL","name":"Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes","canonical_id":"clinicaltrials.gov:NCT00231192","description":"Diabetes","metadata":null},{"id":"66a48b2bafe44e559c232e79e9c7cafc","type":"TRIAL","name":"Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)","canonical_id":"clinicaltrials.gov:NCT00424177","description":"Purpura, Thrombocytopaenic, Idiopathic","metadata":null},{"id":"ed4c79c109444d098f65e29ab4d9bc16","type":"TRIAL","name":"Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT01773954","description":"Age-Related Macular Degeneration; Macular Degeneration","metadata":null},{"id":"73d942e4c7084e5fb97e5afa72ee97e4","type":"TRIAL","name":"Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data","canonical_id":"clinicaltrials.gov:NCT04736693","description":"Osteoporosis","metadata":null},{"id":"46c338476f9545aba1fef00512dd5343","type":"TRIAL","name":"Replication of the IMPACT COPD Trial in Healthcare Claims Data","canonical_id":"clinicaltrials.gov:NCT05062304","description":"COPD","metadata":null},{"id":"1f263ca4a272432d84cec3b6b7bbdcd1","type":"TRIAL","name":"Replication of the VERO Osteoporosis Trial in Healthcare Claims Data","canonical_id":"clinicaltrials.gov:NCT04879420","description":"Osteoporosis","metadata":null},{"id":"54b84241ee4d41bbaf596ef6f78b1c64","type":"TRIAL","name":"Reproductive Hormonal Alterations in Obesity","canonical_id":"clinicaltrials.gov:NCT01457703","description":"Obesity","metadata":null},{"id":"456c508844f0408d9dd96c16bb9c25c0","type":"TRIAL","name":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT04997811","description":"Myelodysplastic Syndromes (MDS)","metadata":null},{"id":"d7bbde86cb9b4b6c8804cb38008b86ea","type":"TRIAL","name":"Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT04413344","description":"Familial Alzheimer Disease (FAD); PSEN1 Mutation","metadata":null},{"id":"0a81b35f3ce94429900054b91afc59ef","type":"TRIAL","name":"Repurposing Chlorpromazine in the Treatment of Glioblastoma","canonical_id":"clinicaltrials.gov:NCT04224441","description":"Glioblastoma Multiforme; MGMT-Unmethylated Glioblastoma","metadata":null},{"id":"e54f2346e37c4eed9c9713364a2a59cf","type":"TRIAL","name":"Repurposing Mirtazapine in Rett Syndrome","canonical_id":"clinicaltrials.gov:NCT07430046","description":"RETT Syndrome With Proven MECP2 Mutation","metadata":null},{"id":"052f8ab3901447ba91ebcae8197901e5","type":"TRIAL","name":"Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure","canonical_id":"clinicaltrials.gov:NCT01814319","description":"Systolic Heart Failure","metadata":null},{"id":"0c20c835dbed4da588d04a4eb2e34b57","type":"TRIAL","name":"Repurposing Siponimod for Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT06639282","description":"Alzheimer Disease; Mild Alzheimer Disease; MCI With Increased Risk for Alzheimer Disease; Cognitive Impairment, Mild","metadata":null},{"id":"9edc71eabc14414ea556df9f1d7db459","type":"TRIAL","name":"Repurposing of Chlorpromazine in Covid-19 Treatment","canonical_id":"clinicaltrials.gov:NCT04366739","description":"COVID-19","metadata":null},{"id":"09f3f66fe0024222b803d6444304711f","type":"TRIAL","name":"Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer","canonical_id":"clinicaltrials.gov:NCT05433402","description":"Colon Cancer Stage III","metadata":null},{"id":"f5f30e8e2c8045cd9b005ff50e281d37","type":"TRIAL","name":"Rescue Pharmacotherapy for OSA","canonical_id":"clinicaltrials.gov:NCT05293600","description":"Obstructive Sleep Apnea","metadata":null},{"id":"98f68ab414474a819bbb1432917e6395","type":"TRIAL","name":"Research In Viral Eradication of HIV Reservoirs","canonical_id":"clinicaltrials.gov:NCT02336074","description":"HIV","metadata":null},{"id":"e6f5478b5aad4bb2802f1bb9afc70838","type":"TRIAL","name":"Research Investigation of Soy and Estrogen","canonical_id":"clinicaltrials.gov:NCT00997893","description":"Menopause; Hot Flashes","metadata":null},{"id":"9a6221996f2a416abb3e235aca9ca575","type":"TRIAL","name":"Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)","canonical_id":"clinicaltrials.gov:NCT00113945","description":"End Stage Renal Disease","metadata":null},{"id":"cb7c5903fb134743a102da8e420cf9a4","type":"TRIAL","name":"Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT04734210","description":"Dry Eye Disease","metadata":null},{"id":"5f37279e65d7404bb280d3a51bc34757","type":"TRIAL","name":"Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT04916470","description":"Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2","metadata":null},{"id":"b23730601f9340499045331a6a0ea75b","type":"TRIAL","name":"Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity","canonical_id":"clinicaltrials.gov:NCT02140073","description":"GERD","metadata":null},{"id":"4a734cca7915491f9488617c99197943","type":"TRIAL","name":"Research of Intensive Metabolic Intervention Before Pregnancy in PCOS","canonical_id":"clinicaltrials.gov:NCT03383068","description":"PCOS; Impaired Glucose Tolerance","metadata":null},{"id":"d5395c218501411081131d8ddc69c3bb","type":"TRIAL","name":"Research on Translational Outcomes of Alcohol (Project RETRO)","canonical_id":"clinicaltrials.gov:NCT04742348","description":"Alcohol Drinking","metadata":null},{"id":"bfd769b1b12746c9abff9b1d4875259e","type":"TRIAL","name":"Reserpine for the Treatment of Cocaine Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00033033","description":"Cocaine-Related Disorders; Substance-Related Disorders","metadata":null},{"id":"c83006909a714a17a8a8f3c326bf376f","type":"TRIAL","name":"Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo","canonical_id":"clinicaltrials.gov:NCT00283790","description":"Insomnia","metadata":null},{"id":"bea11ea89a3740568e9647119985aff7","type":"TRIAL","name":"Residual Exacerbations With Mepolizumab","canonical_id":"clinicaltrials.gov:NCT04578171","description":"Asthma","metadata":null},{"id":"9135b82417304b7f8fe55fd9cff757ec","type":"TRIAL","name":"Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants","canonical_id":"clinicaltrials.gov:NCT00438230","description":"Deep Vein Thrombosis","metadata":null},{"id":"bbf452e32f394228b90b6fb353fcc1a2","type":"TRIAL","name":"Resistance Training and Amino Pyridine in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT02143167","description":"Multiple Sclerosis","metadata":null},{"id":"9c5294dc645a46a4b81388339f88c109","type":"TRIAL","name":"Resistant Arterial Hypertension Cohort Study","canonical_id":"clinicaltrials.gov:NCT01083017","description":"Hypertension; Essential Hypertension; Resistant Hypertension","metadata":null},{"id":"bdd5d82eee874a9aaa9f33561e0316c3","type":"TRIAL","name":"Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab","canonical_id":"clinicaltrials.gov:NCT03074942","description":"Severe Asthma","metadata":null},{"id":"5d395d535b2f4d15924a1b788d236cc6","type":"TRIAL","name":"Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study","canonical_id":"clinicaltrials.gov:NCT02947945","description":"Asthma","metadata":null},{"id":"402f784c3a664833a710942c412cab57","type":"TRIAL","name":"Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis","canonical_id":"clinicaltrials.gov:NCT01111305","description":"Loiasis","metadata":null},{"id":"bdf967837b84488d9600fac588741920","type":"TRIAL","name":"Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF","canonical_id":"clinicaltrials.gov:NCT02256683","description":"Atrial Fibrillation or Atrial Flutter; Thrombosis of Left Atrial Appendage","metadata":null},{"id":"ccf1578ded7a4ce480255513e1540713","type":"DISEASE","name":"Respiratory Distress Syndrome, Newborn","canonical_id":"mesh:D012127","description":null,"metadata":null},{"id":"fd9f9770de81447d84a94c9b4b65b2aa","type":"TRIAL","name":"Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01854268","description":"Cough","metadata":null},{"id":"c2f6c28a1109495c8c16082afd3672c5","type":"DISEASE","name":"Respiratory Sounds","canonical_id":"mesh:D012135","description":null,"metadata":null},{"id":"d2344b69687149459d845be1c26db95b","type":"DISEASE","name":"Respiratory Tract Infections","canonical_id":"mesh:D012141","description":null,"metadata":null},{"id":"0abd4d22287e4a62b44bad492baf4326","type":"DISEASE","name":"Respiratory syncytial virus infection","canonical_id":"mesh:D018357","description":null,"metadata":null},{"id":"6eff0be557ad4595a333ad86a97a542a","type":"TRIAL","name":"Responding With Evidence and Access for Childhood Headaches","canonical_id":"clinicaltrials.gov:NCT05889624","description":"Headache; Headache Disorders; Headache, Migraine; Migraine; Migraine Disorders; Migraine With Aura; Migraine Without Aura; Chronic Migraine","metadata":null},{"id":"f7a88a168697437583c0b5f73c309e19","type":"TRIAL","name":"Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT02298075","description":"Immune Thrombocytopenia","metadata":null},{"id":"b48c09687e5d4371b21295bb5790fe2b","type":"TRIAL","name":"Response and Remission to Treatment With Anti-IL5/IL5R Antagonists","canonical_id":"clinicaltrials.gov:NCT06348173","description":"Asthma","metadata":null},{"id":"78fc3fc43ec34c4a9777d283f0f15828","type":"TRIAL","name":"Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)","canonical_id":"clinicaltrials.gov:NCT00704769","description":"Rhinitis","metadata":null},{"id":"92cde4656178480a9b7545aa3a456fa2","type":"TRIAL","name":"Response of Topical Capsaicin in Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT00176969","description":"Alopecia Areata","metadata":null},{"id":"c4e29f9078f7434a8c222b6998a8b722","type":"TRIAL","name":"Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas","canonical_id":"clinicaltrials.gov:NCT01620138","description":"Non-functioning Pituitary Adenomas; Prolactinomas","metadata":null},{"id":"36b7e81be76c432fae3855d0cebb4c90","type":"TRIAL","name":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT07419932","description":"Thyroid Cancer; Thyroid Neoplasms","metadata":null},{"id":"6712650701aa41a4bf9e660a8af82bf9","type":"TRIAL","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","canonical_id":"clinicaltrials.gov:NCT02521493","description":"Acute Myeloid Leukemia; Down Syndrome; Myelodysplastic Syndrome; Myeloid Leukemia Associated With Down Syndrome; Myeloproliferative Neoplasm","metadata":null},{"id":"70fa5efef0264808aada1d6a673bb125","type":"TRIAL","name":"Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07126236","description":"Large B Cell Lymphoma","metadata":null},{"id":"743440fcabd64870a1d035600f86003c","type":"TRIAL","name":"Response-based Treatment of High-risk Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT02771743","description":"Newly Diagnosed High Risk Neuroblastoma","metadata":null},{"id":"e00678e40f074d96b9350911e8e1e0d0","type":"TRIAL","name":"Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food","canonical_id":"clinicaltrials.gov:NCT00419692","description":"Restless Legs Syndrome","metadata":null},{"id":"a7062cf46bb54bcf9b1e8bd64ba397d7","type":"DISEASE","name":"Restless Legs Syndrome","canonical_id":"mesh:D012148","description":null,"metadata":null},{"id":"b8ae40dca21a4a608fbd4196e16f61e5","type":"TRIAL","name":"Restoration of Hypoglycemia Awareness With Metoclopramide","canonical_id":"clinicaltrials.gov:NCT03970720","description":"Hypoglycemia Unawareness","metadata":null},{"id":"400f173d5d5d4c7d8fdb34692954de78","type":"TRIAL","name":"Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT07756294","description":"Alzheimer Disease","metadata":null},{"id":"b28f27fcda9f42e8a6620de8a58e550d","type":"TRIAL","name":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","canonical_id":"clinicaltrials.gov:NCT00363480","description":"Asthma","metadata":null},{"id":"9a564ddc24ad44d2a378e9346249109c","type":"DISEASE","name":"Retention of urine","canonical_id":"mesh:D016055","description":null,"metadata":null},{"id":"07a0d514ae6d4a38b04682c9878c434d","type":"TRIAL","name":"Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","canonical_id":"clinicaltrials.gov:NCT07468136","description":"Anaplastic Oligodendroglioma; Astrocytoma, IDH-Mutant, Grade 3; Astrocytoma, IDH-Mutant, Grade 4; Diffuse Astrocytoma; Glioblastoma, IDH-Wildtype; Malignant Glioma","metadata":null},{"id":"a59cb00a3f4442909317253279d890d6","type":"TRIAL","name":"Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy","canonical_id":"clinicaltrials.gov:NCT00232596","description":"Seizures","metadata":null},{"id":"b5d3215bf2354c5aafa9e28bfb8672f5","type":"TRIAL","name":"Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy","canonical_id":"clinicaltrials.gov:NCT00235755","description":"Seizures","metadata":null},{"id":"a7b78e06eb1443f1a24cbaf12dc5b1a1","type":"DISEASE","name":"Retinoblastoma","canonical_id":"mesh:D012175","description":null,"metadata":null},{"id":"c8451252901c4ae99047011b79f6d076","type":"PROTEIN","name":"Retinoic acid receptor RXR-alpha","canonical_id":"uniprot:P19793","description":null,"metadata":null},{"id":"0d5ae37f5d8b42c4af66e56f4523b33a","type":"DRUG","name":"Retinol","canonical_id":"mesh:D014801","description":null,"metadata":null},{"id":"b73f4f69b5934fb7b8757e9e4c48847f","type":"TRIAL","name":"Retisert and Cataract Surgery in Patients With Severe Uveitis","canonical_id":"clinicaltrials.gov:NCT00570830","description":"Intermediate Uveitis; Posterior Uveitis","metadata":null},{"id":"1b9f78f513a7481abac2ad5fdcccf0e9","type":"TRIAL","name":"Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT07814859","description":"Pancreatic Cancer","metadata":null},{"id":"582738f770574ddcb416ac2f425d64e5","type":"TRIAL","name":"Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody","canonical_id":"clinicaltrials.gov:NCT00938041","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"07aa884336fe42c98d7fd08078e01422","type":"TRIAL","name":"Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg\u00ae","canonical_id":"clinicaltrials.gov:NCT03287128","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"d47da72cf857487e87a8b83f5697c683","type":"TRIAL","name":"Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe","canonical_id":"clinicaltrials.gov:NCT01890993","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"38a38888a9524e89b1c0e981ea736122","type":"TRIAL","name":"Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT02645747","description":"Retinal Vein Occlusion","metadata":null},{"id":"e4619f7caa86420ea4512939e9b990cb","type":"TRIAL","name":"Retrospective Evaluation of CML Patients in the National Compassionate Program","canonical_id":"clinicaltrials.gov:NCT02448095","description":"Chronic Myeloid Leukemia; Philadelphia Positive","metadata":null},{"id":"f2b908a38efd4524889cd1fd89c0cd34","type":"TRIAL","name":"Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice","canonical_id":"clinicaltrials.gov:NCT07588750","description":"Obesity & Overweight","metadata":null},{"id":"1066abcae58b468fbb06a42e009f5a48","type":"TRIAL","name":"Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.","canonical_id":"clinicaltrials.gov:NCT05728008","description":"Ulcerative Colitis","metadata":null},{"id":"b24651122be647d2b7d8bcf1500f8375","type":"TRIAL","name":"Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland","canonical_id":"clinicaltrials.gov:NCT05363488","description":"Myeloid Leukemia","metadata":null},{"id":"c09f523422254bada7f21516b297a212","type":"TRIAL","name":"Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012","canonical_id":"clinicaltrials.gov:NCT01056263","description":"Carcinoma, Renal Cell","metadata":null},{"id":"c417aee2dc794935a2376e5a5c1eb888","type":"TRIAL","name":"Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II","canonical_id":"clinicaltrials.gov:NCT01304238","description":"Acute HIT II (Heparin-induced Thrombocytopenia Type II)","metadata":null},{"id":"a0cdf6ec36434651b584f81be404b5c7","type":"TRIAL","name":"Retrospective Study for Identificatiopn of a Link Between Doxycycline and COVID-19 Treatment","canonical_id":"clinicaltrials.gov:NCT05445479","description":"COVID-19","metadata":null},{"id":"857386859fad48e3ad6ee64cf993b0c9","type":"TRIAL","name":"Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)","canonical_id":"clinicaltrials.gov:NCT05263193","description":"Immune-mediated Thrombocytopenic Purpura","metadata":null},{"id":"bfa38fe23e444431980659bca6103e7a","type":"TRIAL","name":"Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome","canonical_id":"clinicaltrials.gov:NCT07150013","description":"Rett Syndrome","metadata":null},{"id":"993e66c66ac34381a77cc2dd8f33afc0","type":"TRIAL","name":"Revascularization Pretreated With Fingolimod in Acute Stroke","canonical_id":"clinicaltrials.gov:NCT04718064","description":"Stroke","metadata":null},{"id":"16d90eb2b585407cb3e09b1aa00204eb","type":"TRIAL","name":"Revefenacin in Acute Respiratory Insufficiency in COPD","canonical_id":"clinicaltrials.gov:NCT04315558","description":"COPD; Acute Respiratory Failure","metadata":null},{"id":"4b7382e70317443b8af0757f2a2f59ba","type":"TRIAL","name":"Reversal Dabigatran Anticoagulant Effect With Idarucizumab","canonical_id":"clinicaltrials.gov:NCT02815670","description":"Hemorrhage","metadata":null},{"id":"ebeef95190b24598821bb205c08c065f","type":"TRIAL","name":"Reversal of Dabigatran Anticoagulant Effect With Idarucizumab","canonical_id":"clinicaltrials.gov:NCT02104947","description":"Hemorrhage","metadata":null},{"id":"39d4f5d1904744e4960b36ef903e3924","type":"TRIAL","name":"Reversal of General Anesthesia With Methylphenidate","canonical_id":"clinicaltrials.gov:NCT02051452","description":"Post Operative Cognitive Dysfunction; Emergence From Anesthesia","metadata":null},{"id":"06798ba9a6d149fc8bff3008951ee440","type":"TRIAL","name":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","canonical_id":"clinicaltrials.gov:NCT05338632","description":"Opioid Induced Respiratory Depression; Chronic Opioid Use","metadata":null},{"id":"12dd2975b2964df896a8b9dd690d1e6a","type":"TRIAL","name":"Reversal of Remimazolam by a Single Dose of Flumazenil","canonical_id":"clinicaltrials.gov:NCT05382806","description":"Flumazenil Adverse Reaction; Ambulatory Surgery; Postoperative Nausea; Remimazolam","metadata":null},{"id":"c6a58f9cb0bd4c0dafd1cc39169e9f02","type":"TRIAL","name":"Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.","canonical_id":"clinicaltrials.gov:NCT03921736","description":"Hypertension; Hyperuricemia; Menopause","metadata":null},{"id":"34552532d7de40f0bcaf3dd42acf2085","type":"PROTEIN","name":"Reverse transcriptase/RNaseH","canonical_id":"uniprot:Q72547","description":null,"metadata":null},{"id":"6e08a860f06a489d93c831276ffabf7e","type":"TRIAL","name":"Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra","canonical_id":"clinicaltrials.gov:NCT02270918","description":"Thrombosis","metadata":null},{"id":"c0107c46ecb2445180a407ce6711573d","type":"TRIAL","name":"Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure","canonical_id":"clinicaltrials.gov:NCT00293150","description":"Diastolic Heart Failure","metadata":null},{"id":"ddb483dea0514f6ca4f19c34db573a08","type":"TRIAL","name":"Reversing Ticagrelor's Effects With Fresh Platelets","canonical_id":"clinicaltrials.gov:NCT02201394","description":"Coronary Artery Disease","metadata":null},{"id":"0beccddd7f5a41e9aa7ffdbb0aaa8fc1","type":"TRIAL","name":"Reversing the Effects of 2% Lidocaine","canonical_id":"clinicaltrials.gov:NCT02861378","description":"Soft Tissue Anaesthesia","metadata":null},{"id":"6e6098fe7f644231a982462c0f34f92a","type":"TRIAL","name":"Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)","canonical_id":"clinicaltrials.gov:NCT00856206","description":"Gout","metadata":null},{"id":"09d408e0f03f494c8bd903c6b9b9c9b4","type":"TRIAL","name":"Revumenib in Combination With 7+3 + Midostaurin in AML","canonical_id":"clinicaltrials.gov:NCT06313437","description":"Acute Myeloid Leukemia; AML, Adult; AML With Gene Mutations; AML; Leukemia","metadata":null},{"id":"77622d0a443a4e368cee0904afbbbca4","type":"TRIAL","name":"Revumenib in Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT07734077","description":"Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"37db04292a5a48d89a191d16f63da844","type":"TRIAL","name":"Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations","canonical_id":"clinicaltrials.gov:NCT02375022","description":"Lung Cancer","metadata":null},{"id":"914826d1ae0c4f329e191f773d554374","type":"DISEASE","name":"Rhabdomyosarcoma","canonical_id":"mesh:D012208","description":null,"metadata":null},{"id":"48dbeb423f5a4ae1a8bd79f226a77f0f","type":"DISEASE","name":"Rhabdomyosarcoma","canonical_id":"doid:3247","description":null,"metadata":null},{"id":"bbee2c2a85854579a439e29cb4f67bcb","type":"DISEASE","name":"Rheumatic Heart Disease","canonical_id":"mesh:D012214","description":null,"metadata":null},{"id":"5fc64be54aa843cb96e86607755c6a83","type":"DISEASE","name":"Rheumatism","canonical_id":"mesh:D012216","description":null,"metadata":null},{"id":"539931ba611b4202aa459ee522493202","type":"TRIAL","name":"Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study","canonical_id":"clinicaltrials.gov:NCT00674362","description":"Rheumatoid Arthritis","metadata":null},{"id":"fc7609b88e9048c094dda7c4c5ca169e","type":"DISEASE","name":"Rheumatoid arthritis","canonical_id":"mesh:D001172","description":null,"metadata":null},{"id":"6e48bb161e7346c5a5802fd262791a2b","type":"DISEASE","name":"Rhinitis","canonical_id":"mesh:D012220","description":null,"metadata":null},{"id":"69b8c69e25f34bd1af1c40ee66a90250","type":"GO_TERM","name":"Rhino-Deadlock-Cutoff Complex","canonical_id":"go:GO:1990469","description":"\"Protein complex found in Drosophila consisting of the gene products of cuff, del and rhi. It regulates the licensing of transcription of dual-strand PIWI interacting RNA (piRNA) source loci by binding to dual-strand-cluster chromatin, probably via the H3K9me3-binding activity of Rhi. Rhi binding brings the putative termination cofactor Cuff in close proximity to the nascent piRNA precursor transcript which it appears to protect from degradation.\" [GOC:bhm, PMID:24906153]","metadata":null},{"id":"cbe78f611b93439c9a3aedfa9bf2f0f9","type":"DISEASE","name":"Rhinoscleroma","canonical_id":"mesh:D012226","description":null,"metadata":null},{"id":"746b7a4abfa5406d8e7927e82276a747","type":"GO_TERM","name":"Rho GDP-dissociation inhibitor activity","canonical_id":"go:GO:0005094","description":"\"Prevents the dissociation of GDP from the small GTPase Rho, thereby preventing GTP from binding.\" [GOC:mah]","metadata":null},{"id":"9868fb1f80c5463c947722db83863e6a","type":"GO_TERM","name":"Rho GDP-dissociation inhibitor binding","canonical_id":"go:GO:0051022","description":"\"Binding to a Rho GDP-dissociation inhibitor protein.\" [GOC:ai]","metadata":null},{"id":"63999274ce7643ae937e789cc68420d2","type":"TRIAL","name":"Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00670202","description":"Carotid Stenosis","metadata":null},{"id":"67b40646969d4f43a3596a1973c8707f","type":"TRIAL","name":"Rho Kinase (ROCK) Inhibitor in Tauopathies - 1","canonical_id":"clinicaltrials.gov:NCT04734379","description":"Progressive Supranuclear Palsy; Corticobasal Syndrome","metadata":null},{"id":"25a7cebb046947d88fe9a2eba3d37931","type":"TRIAL","name":"Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)","canonical_id":"clinicaltrials.gov:NCT05218668","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"7c1bbb096a714ba68aaaa054c8daabb9","type":"GO_TERM","name":"Rho protein signal transduction","canonical_id":"go:GO:0007266","description":"\"An intracellular signaling cassette in which a small monomeric GTPase of the Rho subfamily relays a signal.\" [GOC:bf]","metadata":null},{"id":"4d21b435f90a4dffb9a83d7508505b03","type":"GO_TERM","name":"Rho-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0160221","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of Rho activity. Rho is a family of small (~21 kDa) signaling G proteins that include RhoA, Cdc42, and Rac1.\" [PMID:10836144, PMID:33849392]","metadata":null},{"id":"1b0ab7926252464b9d7ff1a93557b4c5","type":"PROTEIN","name":"Rho-associated protein kinase 1","canonical_id":"uniprot:Q13464","description":null,"metadata":null},{"id":"b9c1fed3de3f494384fc65467808041d","type":"GO_TERM","name":"Rho-dependent protein serine/threonine kinase activity","canonical_id":"go:GO:0072518","description":"\"Rho GTPase-dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein.\" [GOC:ecd, PMID:12778124, PMID:20230755]","metadata":null},{"id":"5bbfb4486ce34281be3f39ed864b2930","type":"TRIAL","name":"Rhofanib\u00ae (Tofacitinib) Safety and Effectiveness Evaluation","canonical_id":"clinicaltrials.gov:NCT07101471","description":"Alopecia Totalis/Universalis; Alopecia Areata(AA)","metadata":null},{"id":"b65ea3a24ee843ab8fbd433df74b3525","type":"TRIAL","name":"Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT05950971","description":"Atrial Fibrillation New Onset; Atrial Fibrillation Paroxysmal","metadata":null},{"id":"89d4629d82aa446c83ff0e18dbf6b268","type":"DRUG","name":"Ribociclib","canonical_id":"ncit:C95701","description":null,"metadata":null},{"id":"24ee57f40ad0407098e8ac2bf116ff1f","type":"TRIAL","name":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT03009201","description":"Advanced Soft Tissue Sarcoma; Locally Advanced Angiosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Malignant Peripheral Nerve Sheath Tumor; Locally Advanced Myxofibrosarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Metastatic Angiosarcoma; Metastatic Epithelioid Sarcoma; Metastatic Fibrosarcoma; Metastatic Liposarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Myxofibrosarcoma; Metastatic Soft Tissue Sarcoma; Metastat\u2026","metadata":null},{"id":"80e056b61b2f4f5b876dae77ab700805","type":"TRIAL","name":"Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors","canonical_id":"clinicaltrials.gov:NCT03387020","description":"CNS Embryonal Tumor, Not Otherwise Specified; Malignant Glioma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma","metadata":null},{"id":"b1635a8769fb48c8847c7d011dc6ba15","type":"TRIAL","name":"Ribociclib and Spartalizumab in R/M HNSCC","canonical_id":"clinicaltrials.gov:NCT04213404","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"6f0797e8843d4f73a2440ecc0fb08c46","type":"TRIAL","name":"Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype","canonical_id":"clinicaltrials.gov:NCT05207709","description":"Metastatic Breast Cancer","metadata":null},{"id":"2a2c940dbf25441fa35709d57fc8080e","type":"TRIAL","name":"Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics","canonical_id":"clinicaltrials.gov:NCT04315233","description":"Metastatic Breast Cancer; Recurrent Ovarian Carcinoma","metadata":null},{"id":"588af7e5b23b4367b33589f910248c3f","type":"TRIAL","name":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05319873","description":"Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; \u2026","metadata":null},{"id":"3a41de98f74b4e6797b100a79c6c6e97","type":"TRIAL","name":"Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC","canonical_id":"clinicaltrials.gov:NCT03905343","description":"Breast Cancer","metadata":null},{"id":"1b1a95b9cdbf4504837ada17ed9623af","type":"DRUG","name":"Riboflavin","canonical_id":"mesh:D012256","description":null,"metadata":null},{"id":"f1395b8b317f4456b591a5ef2903b94f","type":"PROTEIN","name":"Riboflavin kinase","canonical_id":"uniprot:Q969G6","description":null,"metadata":null},{"id":"cbdb85737ee84346b0064b5660674b0c","type":"GO_TERM","name":"Ric1-Rgp1 guanyl-nucleotide exchange factor complex","canonical_id":"go:GO:0034066","description":"\"A protein complex that acts as a nucleotide exchange factor for the GTPase Ypt6p, and is required for fusion of endosome-derived vesicles with the Golgi.\" [GOC:jh, GOC:mah, PMID:10990452]","metadata":null},{"id":"fdea5502117d46a5aca764b1f5f5b583","type":"DISEASE","name":"Richter transformation","canonical_id":"mondo:0002083","description":null,"metadata":null},{"id":"5430ade2d0fd4c40aaa2b817db2d75a5","type":"DISEASE","name":"Rickets","canonical_id":"mesh:D012279","description":null,"metadata":null},{"id":"1bcb3a7549244a79ba4d93917678c16c","type":"DISEASE","name":"Rickettsialpox","canonical_id":"mesh:D000073605","description":null,"metadata":null},{"id":"712c064c528b44b7b36e4fed1a531f4c","type":"DRUG","name":"Ridaforolimus","canonical_id":"ncit:C49061","description":null,"metadata":null},{"id":"283b73988a0d4dd2bb1e9a12937b27df","type":"TRIAL","name":"Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori","canonical_id":"clinicaltrials.gov:NCT04879992","description":"Helicobacter Pylori Infection","metadata":null},{"id":"2c1829d0b4294aa99464f0b91967d822","type":"DRUG","name":"Rifampicin","canonical_id":"mesh:D012293","description":null,"metadata":null},{"id":"9caa35d70e624391a5e342d3cc005d87","type":"TRIAL","name":"Rifampin Drug-Drug Interaction Study With Lurasidone HCl","canonical_id":"clinicaltrials.gov:NCT01082276","description":"Male, Healthy Normal Subjects","metadata":null},{"id":"21c93f14b05949489e17f401910b098f","type":"DRUG","name":"Rifaximin","canonical_id":"mesh:C042734","description":null,"metadata":null},{"id":"3672307aeed7403992ab507c35f00492","type":"TRIAL","name":"Right Ventricular Contractility Reserve Following Repair of Tetralogy of Fallot","canonical_id":"clinicaltrials.gov:NCT00557934","description":"Right Ventricular Dysfunction","metadata":null},{"id":"f5353a0ce9624047aeb6937db00d5300","type":"DISEASE","name":"Rigidity","canonical_id":"hp:0002063","description":null,"metadata":null},{"id":"d8cb5da9584a430bb63d6f724844a1cf","type":"TRIAL","name":"Rilonacept (Arcalyst \u00ae) in the Treatment of Subacromial Bursitis","canonical_id":"clinicaltrials.gov:NCT01830699","description":"Subacromial Bursitis","metadata":null},{"id":"2ce16b7d8d134220be754072b270c726","type":"TRIAL","name":"Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)","canonical_id":"clinicaltrials.gov:NCT01801449","description":"DIRA","metadata":null},{"id":"d910b7790005435b97d9972c911a2323","type":"TRIAL","name":"Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss","canonical_id":"clinicaltrials.gov:NCT02828033","description":"Autoimmune Neurosensory Hearing Loss (ANSHL)","metadata":null},{"id":"02226e5a9e164fff89471c5985812842","type":"TRIAL","name":"Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)","canonical_id":"clinicaltrials.gov:NCT00288704","description":"Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS); Genetic Diseases, Inborn","metadata":null},{"id":"06662893230b405a9356e216ce0bbc00","type":"TRIAL","name":"Rilonacept for Treatment of Familial Mediterranean Fever (FMF)","canonical_id":"clinicaltrials.gov:NCT00582907","description":"Familial Mediterranean Fever","metadata":null},{"id":"e992984a8ae4482883417822d10f10a2","type":"TRIAL","name":"Rilonacept in Diabetes Mellitus Type 1: Safety Study","canonical_id":"clinicaltrials.gov:NCT00962026","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"8a12f163c1494d4980e15fd7407b638d","type":"TRIAL","name":"Rilonacept in Subjects With Cardiac Sarcoidosis","canonical_id":"clinicaltrials.gov:NCT06660732","description":"Cardiac Sarcoidosis","metadata":null},{"id":"691d461c5ceb4694b61d6cc670c44cdb","type":"TRIAL","name":"Rilonacept to Improve Artery Function in Patients With Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00417417","description":"Coronary Artery Disease; Atherosclerosis; Inflammation; Endothelial Dysfunction","metadata":null},{"id":"3fe4896277614b43b6f9d470129f7d17","type":"DRUG","name":"Rilpivirine","canonical_id":"mesh:D000068696","description":null,"metadata":null},{"id":"17b9b4f489fb4c838ed836973fe320ff","type":"DRUG","name":"Riluzole","canonical_id":"mesh:D019782","description":null,"metadata":null},{"id":"c4ff5bae8b1d4ac284b0011f18a3296c","type":"TRIAL","name":"RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment","canonical_id":"clinicaltrials.gov:NCT06409832","description":"Migraine; Migraine With Aura; Migraine Without Aura","metadata":null},{"id":"8efe66d56e234e198334f5bc3ca7122e","type":"TRIAL","name":"Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06999252","description":"Colon Cancer","metadata":null},{"id":"315fcd6e29074689899553574f4ec335","type":"TRIAL","name":"Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL","canonical_id":"clinicaltrials.gov:NCT07613788","description":"Relapsed/Refractory Large B-cell Lymphoma (LBCL)","metadata":null},{"id":"e84fee613230429498c7180a177b5d7d","type":"TRIAL","name":"Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy","canonical_id":"clinicaltrials.gov:NCT07835035","description":"Advanced Urothelial Carcinoma","metadata":null},{"id":"5ac43756b91a45d5a1955e9158aa6dea","type":"TRIAL","name":"Rimegepant in Moderate Plaque-type Psoriasis","canonical_id":"clinicaltrials.gov:NCT04629950","description":"Psoriasis","metadata":null},{"id":"7b7eacbc9271497d84102abc42f68a00","type":"TRIAL","name":"Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07812467","description":"Oral Squamous Cell Carcinoma (OSCC); Oropharyngeal Squamous Cell Carcinoma (OPSCC)","metadata":null},{"id":"a43e00c7b0714454830981b2c039d2c8","type":"DRUG","name":"Rimexolone","canonical_id":"mesh:C013769","description":null,"metadata":null},{"id":"5c14b3834774420c9ed0060c7d5eb220","type":"DRUG","name":"Rimonabant","canonical_id":"mesh:C089032","description":null,"metadata":null},{"id":"f75647b5400a4c378d9fc5dd1f39abdf","type":"TRIAL","name":"Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy","canonical_id":"clinicaltrials.gov:NCT03575130","description":"Fuchs' Endothelial Dystrophy; Fuchs Dystrophy; Corneal Endothelial Dystrophy; Corneal Endothelial Cell Loss; Cornea Guttata","metadata":null},{"id":"0ac74191e5b744fe9e50792c5c12f7b2","type":"TRIAL","name":"Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03478787","description":"Psoriasis","metadata":null},{"id":"26c064c3023f411aa90fe23ea349f7bb","type":"TRIAL","name":"Risankizumab for Fibrostenotic Crohn's Disease Treatment","canonical_id":"clinicaltrials.gov:NCT07177118","description":"Crohn Disease; Crohn Disease and Ulcerative Colitis","metadata":null},{"id":"007c927e0caa40639453f4724b61d341","type":"TRIAL","name":"Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00358176","description":"Osteoporosis Postmenopausal","metadata":null},{"id":"c133837bb4404b978da74a31bacd3702","type":"TRIAL","name":"Risedronate Sodium in Post Menopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00453492","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"3ec73ce90c5a4a2393d3012eb2e9c401","type":"TRIAL","name":"Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT01215890","description":"Crohn's Disease; Low Bone Mineral Density","metadata":null},{"id":"12ac3949332744efb52bf42f5f19651c","type":"TRIAL","name":"Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use","canonical_id":"clinicaltrials.gov:NCT00221299","description":"Osteoporosis","metadata":null},{"id":"7984bb02478342b2b413ed1dcc1054ad","type":"TRIAL","name":"Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00138866","description":"Osteoporosis","metadata":null},{"id":"c22d8cb210f0452fbc6b15deb4b76094","type":"TRIAL","name":"Risedronate in Postmenopausal Women With Low Bone Density","canonical_id":"clinicaltrials.gov:NCT00351091","description":"OSTEOPOROSIS, POSTMENOPAUSAL","metadata":null},{"id":"97e8531b4f644d5ca3b5739191c22cdb","type":"TRIAL","name":"Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00054418","description":"Breast Cancer; Osteoporosis","metadata":null},{"id":"03d035e562b647bea92387a8d013ed8e","type":"TRIAL","name":"Risedronate in the Prevention of Osteoporosis in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00402441","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"0992fad8b6f24ab9bb307bff0771b6ad","type":"TRIAL","name":"Risk Minimisation Study for Diane-35 and Its Generics","canonical_id":"clinicaltrials.gov:NCT02410031","description":"Acne Vulgaris","metadata":null},{"id":"9349aa9a3f3041ee813847ad5a2ec72a","type":"TRIAL","name":"Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics","canonical_id":"clinicaltrials.gov:NCT03641768","description":"Alzheimer Dementia; Posttraumatic Stress Disorder; Traumatic Brain Injury","metadata":null},{"id":"0f6d1ed0d0da4a868d80e22dc7c5e14c","type":"TRIAL","name":"Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","canonical_id":"clinicaltrials.gov:NCT03720613","description":"Opioid-induced Constipation","metadata":null},{"id":"b26fd72247054c8bb9d2227802aea950","type":"TRIAL","name":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT01190930","description":"Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma; Ann Arbor Stage II B Lymphoblastic Lymphoma; Childhood B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Childhood B Lymphoblastic Lymphoma; Down Syndrome; Hypodiploid B Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive","metadata":null},{"id":"929b5fdd340245da980ca425796db22f","type":"TRIAL","name":"Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study","canonical_id":"clinicaltrials.gov:NCT02090296","description":"Sickle Cell Anemia","metadata":null},{"id":"e74c80868b154516a6bc622fa4301613","type":"TRIAL","name":"Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade","canonical_id":"clinicaltrials.gov:NCT01822132","description":"Methamphetamine Abuse; HIV","metadata":null},{"id":"86be2b5949af4c80b8c2abc41ddb8aab","type":"TRIAL","name":"Risperdal Consta for Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00177164","description":"Bipolar I Disorder","metadata":null},{"id":"0f8ea907a2dd4eadbcd7d9801891eede","type":"TRIAL","name":"Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00830349","description":"Healthy","metadata":null},{"id":"e47081342cfb43a9ae204f7afafd7ab5","type":"TRIAL","name":"Risperidone and Desipramine in Alcohol Use and Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01411085","description":"Schizophrenia; Alcoholism; Dual Diagnosis","metadata":null},{"id":"ff78c3f213be4a3786204df996c35db6","type":"TRIAL","name":"Risperidone for the Treatment of Cocaine Dependence - 7","canonical_id":"clinicaltrials.gov:NCT00000342","description":"Cocaine-Related Disorders","metadata":null},{"id":"5d0e115112c34866ba18fc02c7358bf8","type":"TRIAL","name":"Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00273741","description":"Asthenia; Neoplasms","metadata":null},{"id":"0f2281406bdb4ed2ab5ea05b268e9157","type":"TRIAL","name":"Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria","canonical_id":"clinicaltrials.gov:NCT06795373","description":"Chronic Spontaneous Urticaria; CSU","metadata":null},{"id":"22fa944db54b4a0eb6d90e0e635ff7bc","type":"TRIAL","name":"Ritlecitinib in CTCL","canonical_id":"clinicaltrials.gov:NCT05879458","description":"CTCL; Mycosis Fungoides; Sezary Syndrome","metadata":null},{"id":"cffe074e1cbc44cb9955e0cbd858087b","type":"TRIAL","name":"Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy","canonical_id":"clinicaltrials.gov:NCT06373458","description":"Keloid","metadata":null},{"id":"756fa2a102754e168c1da65a5c65233f","type":"DRUG","name":"Ritonavir","canonical_id":"mesh:D019438","description":null,"metadata":null},{"id":"b96c41c758fe4f819040c7107e1d3ef6","type":"TRIAL","name":"RituxiMab INDuction in Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT01095172","description":"Function of Renal Transplant","metadata":null},{"id":"be26e56b2c954198aea4b8185611d758","type":"TRIAL","name":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT07225439","description":"Non Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Follicular Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma","metadata":null},{"id":"26e1b8fec8264234ab3b52bd415dcb7a","type":"TRIAL","name":"Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00225212","description":"Non-Hodgkin's Lymphoma; Diffuse Large Cell Lymphoma; Mantle Cell Lymphoma; Transformed Lymphoma; Other Subtypes of B-cell Lymphoma; Lymphoma","metadata":null},{"id":"f6567f9721c0424fb3f9b93612a6175a","type":"TRIAL","name":"Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","canonical_id":"clinicaltrials.gov:NCT00977977","description":"Nephrotic Syndrome; Proteinuria; Autoimmune Disease; Glomerular Disease; Membranous Glomerulonephritis","metadata":null},{"id":"81ddab7b216e4d619ad7d1672af0c971","type":"TRIAL","name":"Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD","canonical_id":"clinicaltrials.gov:NCT07010302","description":"NMOSD","metadata":null},{"id":"e3bca4b1f20e491bbbf91504687f0cd3","type":"TRIAL","name":"Rituximab and Belimumab for Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT02260934","description":"Lupus Nephritis","metadata":null},{"id":"db4f48bda6df4c91ac5ebc10cdd6360c","type":"TRIAL","name":"Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00983944","description":"Lymphoma","metadata":null},{"id":"1ddb0e3d39154f4bba471a33fbedd94c","type":"TRIAL","name":"Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenstr\u00f6m's Macroglobulinaemia","canonical_id":"clinicaltrials.gov:NCT04061512","description":"Waldenstrom Macroglobulinemia","metadata":null},{"id":"cf2103f7f78941de831e5abeabc4ded4","type":"TRIAL","name":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00110149","description":"Lymphoma","metadata":null},{"id":"a944d7ae9b5b44c7b59710489b9025c8","type":"TRIAL","name":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma","canonical_id":"clinicaltrials.gov:NCT00082836","description":"Lymphoma","metadata":null},{"id":"6a634384fbec4218bc452ab37934d4db","type":"TRIAL","name":"Rituximab as Second Line Treatment for ITP","canonical_id":"clinicaltrials.gov:NCT00344149","description":"Immune Thrombocytopenia (ITP)","metadata":null},{"id":"0d2b3e8f85ea4c16a245a02ddc702da9","type":"TRIAL","name":"Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP","canonical_id":"clinicaltrials.gov:NCT05798156","description":"Lymphoma, Large B-Cell, Diffuse","metadata":null},{"id":"0e46dcbd74cb49438b6937348dbb492e","type":"TRIAL","name":"Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy","canonical_id":"clinicaltrials.gov:NCT00498368","description":"IgA Nephropathy","metadata":null},{"id":"9c908a6881cb47fe867489745928780e","type":"TRIAL","name":"Rituximab in the Treatment of Graves' Disease","canonical_id":"clinicaltrials.gov:NCT00150111","description":"Graves\u00b4 Disease; Thyroid Associated Ophthalmopathy","metadata":null},{"id":"6d450e8ac4ff4153a05410e9a0c7a785","type":"TRIAL","name":"Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells","canonical_id":"clinicaltrials.gov:NCT01097057","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"5385eb78f0bc4e66a2abfcbd97064387","type":"TRIAL","name":"Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00637832","description":"Lymphoma","metadata":null},{"id":"c40fbd2097944a72ab96f52793551c2e","type":"TRIAL","name":"Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00242996","description":"Lymphoma","metadata":null},{"id":"a502c90a375f47ba9c064a797b6d7151","type":"TRIAL","name":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","canonical_id":"clinicaltrials.gov:NCT04978584","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"8d82684a0f6944eb8cf04752802b573f","type":"TRIAL","name":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT01829568","description":"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicu\u2026","metadata":null},{"id":"6e3d06767618477e86e0fed4707f738e","type":"TRIAL","name":"Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00602836","description":"Leukemia; Lymphoma","metadata":null},{"id":"160562e31d28486796c47639435808ea","type":"TRIAL","name":"Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT02281279","description":"B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell\u2026","metadata":null},{"id":"ae73aabc32f44e3db4cd416565570f1f","type":"TRIAL","name":"Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00248534","description":"Lymphoma","metadata":null},{"id":"33de98ba18e5464ab493fdd9da3f4e11","type":"TRIAL","name":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)","canonical_id":"clinicaltrials.gov:NCT02313909","description":"Stroke","metadata":null},{"id":"f774e3fd939440e08fffd66f4abf495a","type":"TRIAL","name":"Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study","canonical_id":"clinicaltrials.gov:NCT04067505","description":"May-Thurner Syndrome","metadata":null},{"id":"8f6b25417b814948814225d7af7c7fd4","type":"TRIAL","name":"Rivaroxaban in Pediatric Patients With DVT","canonical_id":"clinicaltrials.gov:NCT07618988","description":"Pediatric Venous Thromboembolism","metadata":null},{"id":"8008c3fe39004ff28adbe7870c6039c7","type":"TRIAL","name":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome","canonical_id":"clinicaltrials.gov:NCT02157272","description":"Antiphospholipid Syndrome","metadata":null},{"id":"f1b5d9e1704a482cbd9118240f816a42","type":"TRIAL","name":"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03428373","description":"Multiple Myeloma in Relapse; Multiple Myeloma Progression; Multiple Myeloma Stage II; Multiple Myeloma Stage I; Multiple Myeloma With Failed Remission; Multiple Myeloma Stage III","metadata":null},{"id":"dbba2f3eb053420f831ab42610b1434d","type":"TRIAL","name":"Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis","canonical_id":"clinicaltrials.gov:NCT03566303","description":"Prostheses and Implants; Stroke; Valve Heart Disease; Anticoagulants and Bleeding Disorders","metadata":null},{"id":"682e130d6d5f40edb72c0eb45ece7da3","type":"TRIAL","name":"Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)","canonical_id":"clinicaltrials.gov:NCT05883124","description":"Bioequivalence","metadata":null},{"id":"57ddb928dccc41e1ab22ffc00ff8ca5d","type":"TRIAL","name":"Rivastigmine Capsules in Patients With Probable Vascular Dementia","canonical_id":"clinicaltrials.gov:NCT00130338","description":"Vascular Dementia","metadata":null},{"id":"c017b1eba0dc4131aa59e90f3fe08907","type":"TRIAL","name":"Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.","canonical_id":"clinicaltrials.gov:NCT02413554","description":"Delirium","metadata":null},{"id":"fe959ab3a5734b6585b24b1bffbbacd5","type":"TRIAL","name":"Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI","canonical_id":"clinicaltrials.gov:NCT01670526","description":"Traumatic Brain Injury; Cognitive Impairment","metadata":null},{"id":"60f65238580d4c9a880d03bd7ce4acc0","type":"TRIAL","name":"Rivastigmine Study in Adolescents With Down Syndrome","canonical_id":"clinicaltrials.gov:NCT01084135","description":"Down Syndrome","metadata":null},{"id":"ad887577dd0b4aaf94c00cc18cd1e935","type":"TRIAL","name":"Rivastigmine and Huperzine A as Treatments for Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01030692","description":"Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse","metadata":null},{"id":"395200638f1843b3b71017c5d85b6342","type":"TRIAL","name":"Rivastigmine as a Treatment for Methamphetamine Dependence","canonical_id":"clinicaltrials.gov:NCT01073319","description":"Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse","metadata":null},{"id":"0e0d4ad8fa46418f858ac17f6d1a4eba","type":"TRIAL","name":"Rivastigmine for Antimuscarinic Delirium","canonical_id":"clinicaltrials.gov:NCT06382649","description":"Anticholinergic Toxicity","metadata":null},{"id":"11475b2af6c44bbdb00cc08591e83674","type":"TRIAL","name":"Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT00257868","description":"Delirium","metadata":null},{"id":"7824c72848184e86a7bb88162ff58d32","type":"TRIAL","name":"Rivastigmine in Mild Alzheimer's Disease, FMRI Study","canonical_id":"clinicaltrials.gov:NCT00627848","description":"Alzheimer' Disease","metadata":null},{"id":"c9b9aa0041154f49aae15086956636a6","type":"DRUG","name":"Rizatriptan","canonical_id":"mesh:C093622","description":null,"metadata":null},{"id":"75ee79fe953149368e6b4a9ad629516c","type":"TRIAL","name":"Rizatriptan 10 MG RPD in the Treatment of Acute Migraine","canonical_id":"clinicaltrials.gov:NCT01057160","description":"Migraine","metadata":null},{"id":"95ccdbe6eb2c4d33a8660b066e665797","type":"TRIAL","name":"Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)","canonical_id":"clinicaltrials.gov:NCT00898677","description":"Migraine Headache","metadata":null},{"id":"b3444583d43d4bc7862cc6720274330b","type":"TRIAL","name":"Rizatriptan for Episodic Dizziness in Vestibular Migraine","canonical_id":"clinicaltrials.gov:NCT02447991","description":"Vestibular Migraine; Migrainous Vertigo","metadata":null},{"id":"76d8a6d0824b482ea103d61407977155","type":"TRIAL","name":"Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.","canonical_id":"clinicaltrials.gov:NCT00753311","description":"Migraine","metadata":null},{"id":"098ef7a21f61452e88a8c844a9147443","type":"DRUG","name":"Rociletinib","canonical_id":"ncit:C99905","description":null,"metadata":null},{"id":"5403b1bdbda44bf7be9a5e0738258873","type":"DISEASE","name":"Rocky Mountain Spotted Fever","canonical_id":"mesh:D012373","description":null,"metadata":null},{"id":"17700543d85a48b3a3f179e840c449ef","type":"TRIAL","name":"Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)","canonical_id":"clinicaltrials.gov:NCT02410590","description":"Neuromuscular Blockade","metadata":null},{"id":"c7628b9880db438aa23f0b4d525642a0","type":"TRIAL","name":"Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00751179","description":"Neuromuscular Blockade","metadata":null},{"id":"419eb03cafd04e9bbcc34d3159980b19","type":"DRUG","name":"Rofecoxib","canonical_id":"mesh:C116926","description":null,"metadata":null},{"id":"d0c22ddb15994c328e471b34f566fc6d","type":"TRIAL","name":"Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00031863","description":"Colorectal Cancer","metadata":null},{"id":"fa6b11a79a6d4c1793271e80c50d5580","type":"TRIAL","name":"Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy","canonical_id":"clinicaltrials.gov:NCT04684511","description":"Hemophilic Arthropathy","metadata":null},{"id":"36eb7d068bda4082bbc47c35351a8a1f","type":"TRIAL","name":"Rofecoxib and Bupivacaine to Prevent Pain After Third Molar (Wisdom Tooth) Extraction","canonical_id":"clinicaltrials.gov:NCT00050362","description":"Pain; Tooth Extraction","metadata":null},{"id":"4ac41960d2b04b9a8462b39a4c73d514","type":"TRIAL","name":"Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction","canonical_id":"clinicaltrials.gov:NCT00026819","description":"Pain","metadata":null},{"id":"d0ac68951ac5463d882aa1be7017e916","type":"TRIAL","name":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01664624","description":"Type 2 Diabetes","metadata":null},{"id":"3d671df5ff184f5696d22b021a0cfcac","type":"TRIAL","name":"Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02079844","description":"Schizophrenia","metadata":null},{"id":"c80fa4894a4f4982822e9b600f335514","type":"TRIAL","name":"Roflumilast Plus Montelukast in Adults With Severe Asthma","canonical_id":"clinicaltrials.gov:NCT01765192","description":"Asthma","metadata":null},{"id":"7fe9b036006d40b0a78b42b420c98815","type":"TRIAL","name":"Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily","canonical_id":"clinicaltrials.gov:NCT01849341","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"e0a46e96cb03438bb22c1ef21bdd12e3","type":"TRIAL","name":"Roflumilast TMS-EEG Plasticity","canonical_id":"clinicaltrials.gov:NCT04369547","description":"Synaptic Plasticity","metadata":null},{"id":"39959985294145218f8e880d43c49df0","type":"TRIAL","name":"Roflumilast and Cognition","canonical_id":"clinicaltrials.gov:NCT01433666","description":"Dementia","metadata":null},{"id":"265dd6057a154dd68ca06e8cda101e5f","type":"TRIAL","name":"Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02051335","description":"Memory Impairment; Alzheimer's Disease","metadata":null},{"id":"95865c8ee4c24cf3abbc6731f44f44cb","type":"TRIAL","name":"Roflumilast and TMS Motor Plasticity","canonical_id":"clinicaltrials.gov:NCT06457191","description":"Other Conditions of Brain","metadata":null},{"id":"4231c6cb276a4f789691ac60b5517471","type":"TRIAL","name":"Roflumilast in Non-CF Bronchiectasis Study","canonical_id":"clinicaltrials.gov:NCT03428334","description":"Non-cystic Fibrosis Bronchiectasis","metadata":null},{"id":"09291306dc70448497b39747456707b2","type":"TRIAL","name":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT06644183","description":"Leukemia; Relapsed Leukemia; Chronic Lymphocytic Leukemia; Relapsed Cancer; Refractory Leukemia","metadata":null},{"id":"5b9058a60d034164aa3a45ef51a08206","type":"TRIAL","name":"Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL","canonical_id":"clinicaltrials.gov:NCT07847957","description":"Chronic Lymphocytic Leukemia (CLL); Refractory Chronic Lymphocytic Leukemia","metadata":null},{"id":"db845f284a6c4327b317ee68568fd267","type":"GO_TERM","name":"Rohon-Beard neuron differentiation","canonical_id":"go:GO:1905275","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a Rohon-Beard neuron.\" [GO_REF:0000086, GOC:TermGenie, ZFIN:ZDB-PUB-120807-45]","metadata":null},{"id":"a0604335a09f4414bb078385a702220e","type":"TRIAL","name":"Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality","canonical_id":"clinicaltrials.gov:NCT04101474","description":"Treatment Resistant Depression","metadata":null},{"id":"a87d67955a2943409535042b0107f97c","type":"TRIAL","name":"Role Of Sensitivity to neuroEndocrine Systems in Social Decisions","canonical_id":"clinicaltrials.gov:NCT06018727","description":"Borderline Personality Disorder","metadata":null},{"id":"22d06a5c9bd349828c068d87ccbdf99d","type":"TRIAL","name":"Role of Active Deresuscitation After Resuscitation:","canonical_id":"clinicaltrials.gov:NCT06326112","description":"Fluid Overload; Critical Illness; Sepsis; ARDS; Trauma","metadata":null},{"id":"c9c22522aa90486f90a9145c51eeae81","type":"TRIAL","name":"Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.","canonical_id":"clinicaltrials.gov:NCT07224334","description":"Diabetes (DM)","metadata":null},{"id":"11438ee25e704c7fb0bf0df03c1e6aa1","type":"TRIAL","name":"Role of Angiotensin II in Insulin-induced Microvascular Activity","canonical_id":"clinicaltrials.gov:NCT01024543","description":"Insulin Sensitivity; Microcirculation","metadata":null},{"id":"bfa2a20801f742a9a9cf8020a360a4f8","type":"TRIAL","name":"Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone \u2264 1cm","canonical_id":"clinicaltrials.gov:NCT05150899","description":"Renal Colic; Ureter Stone","metadata":null},{"id":"8e26042be36c4dabb093f9df1d248bb9","type":"TRIAL","name":"Role of Bumetanide in Treatment of Autism","canonical_id":"clinicaltrials.gov:NCT04766177","description":"Autism","metadata":null},{"id":"8b4f43972e3e4fd5ab2b274aa0dbb347","type":"TRIAL","name":"Role of Clinical Pharmacists in Epilepsy Management","canonical_id":"clinicaltrials.gov:NCT04967326","description":"Epilepsy","metadata":null},{"id":"9f7dcc84e0bc4b719cc1e3d2fce8a15f","type":"TRIAL","name":"Role of Colchicine as Anti-Inflammatory Therapy in HFpEF","canonical_id":"clinicaltrials.gov:NCT06837623","description":"HFpEF - Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"be4fd53ebca2493082b9dc5e40d4552b","type":"TRIAL","name":"Role of Combination Therapy in Women With Refractory Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT06438861","description":"Overactive Bladder Syndrome","metadata":null},{"id":"3b2e7529a0f24d2391b40884804c1b78","type":"TRIAL","name":"Role of Desloratadine in Reducing Inflammation From Occupational Heat Strain","canonical_id":"clinicaltrials.gov:NCT05446480","description":"Heat Stress, Exertional; Inflammatory Response; Firefighter Personal Protective Equipment","metadata":null},{"id":"09ef064088cf4994b49554a820690cea","type":"TRIAL","name":"Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery","canonical_id":"clinicaltrials.gov:NCT07482540","description":"New Onset; Atrial Fibrillation","metadata":null},{"id":"ae1679f7ccf5493eb05692504e95f845","type":"TRIAL","name":"Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps","canonical_id":"clinicaltrials.gov:NCT05157412","description":"Nasal Polyps; Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"187f37198c1b4711994aa935e90ef7fa","type":"TRIAL","name":"Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00958919","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"347e6d421e194b97b10af696713f81bb","type":"TRIAL","name":"Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)","canonical_id":"clinicaltrials.gov:NCT01100736","description":"Pulmonary Arterial Hypertension; Vasodilation; Vasoconstriction","metadata":null},{"id":"1d5c2da9678a4d9cb20c3c5c7641d49c","type":"TRIAL","name":"Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI","canonical_id":"clinicaltrials.gov:NCT02458469","description":"Spinal Cord Injury; Sleep Disordered Breathing","metadata":null},{"id":"04c7629445be4087857aba26ce31793a","type":"TRIAL","name":"Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).","canonical_id":"clinicaltrials.gov:NCT05365841","description":"Severe Eosinophilic Asthma w/wo CRSwNP","metadata":null},{"id":"d6da12444ac949ce9f1966ad6c41db47","type":"TRIAL","name":"Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease","canonical_id":"clinicaltrials.gov:NCT06168994","description":"Paroxysmal Atrial Fibrillation","metadata":null},{"id":"fcac0347a2394ed5b8ac1616e25af4c6","type":"TRIAL","name":"Role of Fexofenadine in Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT04224428","description":"Diabetic Kidney Disease","metadata":null},{"id":"124aaaa5f97d47f59425d9c57c3d8896","type":"TRIAL","name":"Role of Finerenone in African American Veterans With Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT07155694","description":"Diabetic Kidney Disease","metadata":null},{"id":"3cfeade3ff3a446494393dc2e5074995","type":"TRIAL","name":"Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section","canonical_id":"clinicaltrials.gov:NCT05314257","description":"Granisetron","metadata":null},{"id":"314a97a36407414992754b8f237ac5e8","type":"TRIAL","name":"Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes","canonical_id":"clinicaltrials.gov:NCT02023918","description":"Diabetes; Metabolic Syndrome; Insulin Resistance","metadata":null},{"id":"f006fbb047ac479998b13aae14052ef0","type":"TRIAL","name":"Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01699490","description":"Major Depressive Disorder","metadata":null},{"id":"9ff4f57f70ab4d2888dec2ccd554fc58","type":"TRIAL","name":"Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03441893","description":"Ulcerative Colitis; Ulcerative Colitis Exacerbation; Protozoan Infections; Helminth Infection","metadata":null},{"id":"987b06eb074548708f820a02b274d594","type":"TRIAL","name":"Role of K+ and Ca2+ in Development of Muscle Fatigue","canonical_id":"clinicaltrials.gov:NCT02712658","description":"Skeletal Muscle Fatigue in Humans","metadata":null},{"id":"c4b5bac1ff3547a08e57727a41bb8346","type":"TRIAL","name":"Role of Lung Function for Exercise Capacity in Well-trained Individuals","canonical_id":"clinicaltrials.gov:NCT06077019","description":"Exercise Performance","metadata":null},{"id":"e91f29d88ec24f928af9a8ec274f984d","type":"TRIAL","name":"Role of Menopause in Thermoregulation","canonical_id":"clinicaltrials.gov:NCT06798571","description":"Menopause; Aging","metadata":null},{"id":"2f193ecdff2b4ff78a6a049497030637","type":"TRIAL","name":"Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT","canonical_id":"clinicaltrials.gov:NCT03836937","description":"Non-Alcoholic Fatty Liver Disease","metadata":null},{"id":"56f73ac2f84e4cc3931be3ae99896879","type":"TRIAL","name":"Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients.","canonical_id":"clinicaltrials.gov:NCT07320781","description":"Breast Cancer","metadata":null},{"id":"7e21574220934435affc6da7302364f9","type":"TRIAL","name":"Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women","canonical_id":"clinicaltrials.gov:NCT02968342","description":"Menopause; Sexual Desire Disorder; Hypoactive Sexual Desire Disorder","metadata":null},{"id":"e1d730a852ad440bb275968961fde549","type":"TRIAL","name":"Role of Prophylactic Antiemetics in Women Receiving Intrathecal Morphine and Lipophilic Opioids Added to Bupivacaine for Cesarean Section","canonical_id":"clinicaltrials.gov:NCT06704139","description":"Cesarean Section","metadata":null},{"id":"45b055c1239545858c976d8536f8e717","type":"TRIAL","name":"Role of Roflumilast in Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT05684484","description":"Ulcerative Colitis","metadata":null},{"id":"def5ee2b6eb643f38388a7ee0f8d1507","type":"TRIAL","name":"Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery","canonical_id":"clinicaltrials.gov:NCT03939923","description":"Surgery; Coronary Artery Disease","metadata":null},{"id":"4411263259db4ace906d83368b1d58ed","type":"TRIAL","name":"Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV","canonical_id":"clinicaltrials.gov:NCT02560805","description":"Stress Disorders, Post-Traumatic","metadata":null},{"id":"4eea6b4e5ec046539df9b27a1ced44a6","type":"TRIAL","name":"Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity","canonical_id":"clinicaltrials.gov:NCT03318094","description":"Insulin Resistance; Healthy; Obesity","metadata":null},{"id":"a86a67b39cd04510beda611222b52c47","type":"TRIAL","name":"Role of Triptorelin 0.1 mg as a Luteal Phase Support in Assisted Reproductive Technique After Embryo Transfer : a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT04087408","description":"Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles","metadata":null},{"id":"952ce7e0b36f468580774d2ec20b0975","type":"TRIAL","name":"Role of Uralyt-U in Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT04352153","description":"Uric Acid Stones; Hyperuricemia","metadata":null},{"id":"40e47c72630449c4bb12d69c80a6194a","type":"TRIAL","name":"Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance","canonical_id":"clinicaltrials.gov:NCT02080715","description":"Healthy","metadata":null},{"id":"58e5d5ea55f94712825724c1b9d92849","type":"TRIAL","name":"Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use","canonical_id":"clinicaltrials.gov:NCT02785406","description":"Cocaine Use Disorder; Anxiety","metadata":null},{"id":"146e1041456b42d4b3a793a72a02dc61","type":"TRIAL","name":"Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3K\u03b4 Inhibitor, GS-9820","canonical_id":"clinicaltrials.gov:NCT02739360","description":"Lymphoid Malignancies","metadata":null},{"id":"bb741b659b0d423aae4bacd77053075d","type":"TRIAL","name":"Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study","canonical_id":"clinicaltrials.gov:NCT02584933","description":"ALK Positive Malignancies","metadata":null},{"id":"bfadce42395c4f798d92729a358a1214","type":"TRIAL","name":"Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia","canonical_id":"clinicaltrials.gov:NCT02736955","description":"Tardive Dyskinesia","metadata":null},{"id":"bdb24bf50a1d4faa93277504693670de","type":"TRIAL","name":"Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment","canonical_id":"clinicaltrials.gov:NCT07691970","description":"Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus","metadata":null},{"id":"556c39d0acce44c7b84e74a17dabeef0","type":"TRIAL","name":"Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy","canonical_id":"clinicaltrials.gov:NCT04319198","description":"Metastatic Solid Tumors","metadata":null},{"id":"cda467963ef74e10aa16e86ed3bf402b","type":"DRUG","name":"Romidepsin","canonical_id":"mesh:C087123","description":null,"metadata":null},{"id":"58f4897aa47f4cafb6ebbe1ce13e82fe","type":"TRIAL","name":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT02512497","description":"Cutaneous T-cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/Lymphoma; Peripheral T-Cell Lymphoma","metadata":null},{"id":"1a95a039a18e477b9e4b98b52414fd25","type":"TRIAL","name":"Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL","canonical_id":"clinicaltrials.gov:NCT03355768","description":"Lymphoma, T-Cell, Peripheral","metadata":null},{"id":"13d99961569e4d5081ffb6e0083c0da0","type":"TRIAL","name":"Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01938833","description":"HER2-negative Breast Cancer; Inflammatory Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"833a3e467a9546219d9376fb21fb4b9d","type":"TRIAL","name":"Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01302808","description":"Lung Cancer; Metastatic Cancer","metadata":null},{"id":"0bcbb1ffe8b04e1ea618402e5a96e748","type":"TRIAL","name":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02232516","description":"Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; St\u2026","metadata":null},{"id":"f4e440d70b8d42819319a710dd9a6cd3","type":"TRIAL","name":"Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT04774068","description":"Recurrent Anaplastic Large Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Mycosis Fungoides; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Transformed Mycosis Fungoides; T-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"6b01726fd9d14cc090b2f0e0d1efb6ca","type":"TRIAL","name":"Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors","canonical_id":"clinicaltrials.gov:NCT00084461","description":"Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Regional Gastrointestinal Carcinoid Tumor; Somatostatinoma","metadata":null},{"id":"13282b09966542f1a05b5b6f36cd1191","type":"TRIAL","name":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","canonical_id":"clinicaltrials.gov:NCT01638533","description":"Glioma; Hematopoietic and Lymphoid Cell Neoplasm; Lymphoma; Metastatic Malignant Solid Neoplasm; Neuroendocrine Neoplasm; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Colorectal Carcinoma; Recurrent Head and Neck Carcinoma; Recurrent Lung Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Pancreatic Carcinoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recur\u2026","metadata":null},{"id":"b9323298f55748d8bb28ddc7a47f69d6","type":"TRIAL","name":"Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine","canonical_id":"clinicaltrials.gov:NCT00098813","description":"Recurrent Thyroid Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Papillary Thyroid Cancer","metadata":null},{"id":"c9b86677b0e341118b03b641821250b9","type":"TRIAL","name":"Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00062075","description":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia","metadata":null},{"id":"dec6169c05d14f7eb57473427b9140e9","type":"TRIAL","name":"Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT02203578","description":"Graft Versus Host Disease","metadata":null},{"id":"7c341d7bfe8a481aac92166f018e8ec4","type":"TRIAL","name":"Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT04447027","description":"Cutaneous T-Cell Lymphoma; Mature T-cell Malignancies; Peripheral T-Cell Lymphoma; Relapsed/ Refractory T-cell Malignancies","metadata":null},{"id":"0112e7a9ebb64cfba3ae5a71d91bfa66","type":"TRIAL","name":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01846390","description":"Peripheral T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"7644c377e79348f590b724eb26745e0e","type":"TRIAL","name":"Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","canonical_id":"clinicaltrials.gov:NCT00415532","description":"Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura","metadata":null},{"id":"0952eec3fd6e43aaadae0083d6ee9b46","type":"TRIAL","name":"Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial","canonical_id":"clinicaltrials.gov:NCT06992128","description":"Primary Immune Thrombocytopenia (ITP)","metadata":null},{"id":"9e5f80c3859c45bab5044a10235a1cd7","type":"TRIAL","name":"Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07771881","description":"Thrombocytopenia Chemotherapy Induced","metadata":null},{"id":"fd6dcca2b6c34baab723b31d6991cd36","type":"TRIAL","name":"Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07128576","description":"Solid Tumors","metadata":null},{"id":"5a28710af8084c82969436d6e010bbff","type":"TRIAL","name":"Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT07572084","description":"Aplastic Anemia","metadata":null},{"id":"6ab3329cff8e4467bc9482c645fb9b70","type":"TRIAL","name":"Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT07162519","description":"Cytotoxic Drugs; Romiplostim N01; Breast Cancer","metadata":null},{"id":"04fe614d209e4584871168f105da6028","type":"TRIAL","name":"Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05325593","description":"Primary Immune Thrombocytopenia","metadata":null},{"id":"536ffe51cfbc468e846ee74b449e84f6","type":"TRIAL","name":"Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.","canonical_id":"clinicaltrials.gov:NCT04350164","description":"Wiskott-Aldrich Syndrome","metadata":null},{"id":"7b984e4655f4413295865452e494fde5","type":"TRIAL","name":"Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA","canonical_id":"clinicaltrials.gov:NCT07400341","description":"MDS (Myelodysplastic Syndrome); Aplastic Anemia (AA)","metadata":null},{"id":"64b8a0abc6ce46008580c1cfbc44a357","type":"TRIAL","name":"Romiplostim for Oral TPO-RA Resistant ITP","canonical_id":"clinicaltrials.gov:NCT07612319","description":"Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","metadata":null},{"id":"e8a31b6f386f4792b767488fd7c7d45a","type":"TRIAL","name":"Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT04588194","description":"Immune Thrombocytopenia; Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"e7f5b7f23f034b2e91487d8d32b853bd","type":"TRIAL","name":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","canonical_id":"clinicaltrials.gov:NCT00896532","description":"Low Bone Mineral Density; Postmenopausal Osteoporosis","metadata":null},{"id":"17334dfb68be4bcc83e009c97e708389","type":"TRIAL","name":"Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes","canonical_id":"clinicaltrials.gov:NCT06973109","description":"Osteoporosis, Post-menopausal","metadata":null},{"id":"c3fb6c041aaf434e9ccd0a01721dc79c","type":"TRIAL","name":"Romosozumab Use to Build Skeletal Integrity","canonical_id":"clinicaltrials.gov:NCT05058976","description":"Osteoporosis; Osteoporosis, Postmenopausal; Osteoporosis Fracture","metadata":null},{"id":"6b990ae5d70d4eb581bbfd17dde6e4d4","type":"TRIAL","name":"Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years","canonical_id":"clinicaltrials.gov:NCT07757373","description":"Glucocorticoid-Associated Osteopenia and Osteoporosis","metadata":null},{"id":"88eff985082e4dc2bcf6418bb9bd7b31","type":"TRIAL","name":"Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users","canonical_id":"clinicaltrials.gov:NCT04091243","description":"Glucocorticoid-induced Osteoporosis","metadata":null},{"id":"90d8c7974a3345199c99209e8a26a32a","type":"TRIAL","name":"Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months","canonical_id":"clinicaltrials.gov:NCT06472050","description":"Osteoporosis; Glucocorticoids Toxicity","metadata":null},{"id":"c2ea882514584975a66029afab8d89bc","type":"TRIAL","name":"Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT07283887","description":"Osteoporosis","metadata":null},{"id":"a08f99e10f0f4206a021a454ec1d921e","type":"TRIAL","name":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","canonical_id":"clinicaltrials.gov:NCT06533865","description":"FHA (Functional Hypothalamic Amenorrhea)","metadata":null},{"id":"747c6a838d03433d9991e8d8fd377b18","type":"TRIAL","name":"Romosozumab in Women With Chronic SCI","canonical_id":"clinicaltrials.gov:NCT04708886","description":"Osteoporosis; Bone Loss; Osteopenia, Osteoporosis; Spinal Cord Injuries; Chronic Spinal Paralysis","metadata":null},{"id":"2daa8bff9f6c46b9953044f97de07cba","type":"TRIAL","name":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","canonical_id":"clinicaltrials.gov:NCT04232657","description":"Spinal Cord Injury (=3 Years); Sublesional Bone Loss Secondary to SCI","metadata":null},{"id":"13da85077cdd47ce87ce22621ccceb29","type":"TRIAL","name":"Romosozumab/Denosumab Study for Premenopausal IOP","canonical_id":"clinicaltrials.gov:NCT04800367","description":"Premenopausal Idiopathic Osteoporosis","metadata":null},{"id":"886119d0892d4f2387cef3ae791c85de","type":"TRIAL","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","canonical_id":"clinicaltrials.gov:NCT04285086","description":"Essential Thrombocythemia","metadata":null},{"id":"d918c308c3eb482cbf3389a9c916cd3b","type":"DRUG","name":"Ropinirole","canonical_id":"mesh:C046649","description":null,"metadata":null},{"id":"ee41af72cf0a4b2b902aa92530269a53","type":"TRIAL","name":"Ropinirole 0.25 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00829504","description":"Healthy","metadata":null},{"id":"121b8f1f0655432fa09fa3351bef0355","type":"TRIAL","name":"Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01435915","description":"Parkinson Disease","metadata":null},{"id":"29e244b6c60546bb8015b3d669279078","type":"TRIAL","name":"Ropinirole Tablets In Young Patients With Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00140712","description":"Restless Legs Syndrome","metadata":null},{"id":"04a7b77841034c359c76388ea0eaab8d","type":"TRIAL","name":"Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT00197080","description":"Restless Legs Syndrome","metadata":null},{"id":"d85c4cbf96ae48d1a261be0828f59e2b","type":"TRIAL","name":"Ropinirole in the Treatment of Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT00314821","description":"Bipolar Disorder","metadata":null},{"id":"be5433d369644d14939a69a18e6086bf","type":"TRIAL","name":"Ropivacaine With Clonidine For Pediatric Rectus Sheath Blocks- The Magic Combination","canonical_id":"clinicaltrials.gov:NCT02439281","description":"Postoperative Pain","metadata":null},{"id":"d70082a6b9e44cf0b86b110db039672b","type":"DISEASE","name":"Rosacea","canonical_id":"mesh:D012393","description":null,"metadata":null},{"id":"7cfd4b81590348818ac3afd8f3aa2cae","type":"TRIAL","name":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II","canonical_id":"clinicaltrials.gov:NCT06271772","description":"Bacterial Keratitis","metadata":null},{"id":"4cac5d4cecd7427f8c79013a9e33b816","type":"TRIAL","name":"Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00428090","description":"Alzheimer's Disease","metadata":null},{"id":"017b65c1ce264bf884d094ad9380e828","type":"TRIAL","name":"Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00231387","description":"Non-insulin-dependent Diabetes Mellitus","metadata":null},{"id":"196ffe0d08194f3b92c29611ca0cc59a","type":"TRIAL","name":"Rosiglitazone Effect on Mitochondria and Lipoatrophy","canonical_id":"clinicaltrials.gov:NCT00367744","description":"HIV Infections","metadata":null},{"id":"aa0f7d8df77942f6ae38eabb8304a234","type":"TRIAL","name":"Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia","canonical_id":"clinicaltrials.gov:NCT00369174","description":"Oral Leukoplakia","metadata":null},{"id":"bd35237b524845f8a8c642f92af9b13f","type":"TRIAL","name":"Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance","canonical_id":"clinicaltrials.gov:NCT00733174","description":"Impaired Glucose Tolerance","metadata":null},{"id":"ab7b48c3cbf84bf3878037b55a4a849e","type":"TRIAL","name":"Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution","canonical_id":"clinicaltrials.gov:NCT00025753","description":"HIV Infections; Insulin Resistance","metadata":null},{"id":"b11c03401e3143f48a9a0032b7ebd19b","type":"TRIAL","name":"Rosiglitazone and Insulin Resistance in Renally Impaired Patients","canonical_id":"clinicaltrials.gov:NCT00452166","description":"Chronic Kidney Disease; Insulin Resistance","metadata":null},{"id":"4c0b1f6191d2418880456f7c4b6768c4","type":"TRIAL","name":"Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment","canonical_id":"clinicaltrials.gov:NCT00337350","description":"Schizophrenia","metadata":null},{"id":"cb5e70e8fe6f4606ac3e0b62c9b2f312","type":"TRIAL","name":"Rosiglitazone in Treating Patients With Liposarcoma","canonical_id":"clinicaltrials.gov:NCT00004180","description":"Sarcoma","metadata":null},{"id":"f3d7eeefd8cd43069ff738268bdd6833","type":"TRIAL","name":"Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)","canonical_id":"clinicaltrials.gov:NCT00612066","description":"Cushing's Disease","metadata":null},{"id":"9be471488be24b059edd64ebb241e0b4","type":"TRIAL","name":"Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT00064727","description":"Congestive Heart Failure","metadata":null},{"id":"fa3f2a5ac4c241f6a347323b63dc9be8","type":"DRUG","name":"Rosuvastatin","canonical_id":"mesh:D000068718","description":null,"metadata":null},{"id":"fa2980699fb0403ab41801ef09e7c92d","type":"TRIAL","name":"Rosuvastatin for Preventing Deep Vein Thrombosis","canonical_id":"clinicaltrials.gov:NCT01021488","description":"Deep Vein Thrombosis; Venous; Thrombosis; Prevention","metadata":null},{"id":"6c3ac72e48fd490aad336f111c6798c7","type":"TRIAL","name":"Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)","canonical_id":"clinicaltrials.gov:NCT03504566","description":"Diabetic Nephropathy Type 2","metadata":null},{"id":"0ce7072bf37448f68df6cf32be2c25fb","type":"TRIAL","name":"Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)","canonical_id":"clinicaltrials.gov:NCT01569464","description":"Restless Legs Syndrome","metadata":null},{"id":"316d3bfa344d48a1930b5114ed4599c7","type":"TRIAL","name":"Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT01523301","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"29e0642b1f56477a84b274cdf315dafe","type":"TRIAL","name":"Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT01646255","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"496d34bc6dc74985ad6ce276fdddd1d2","type":"GO_TERM","name":"Roundabout binding","canonical_id":"go:GO:0048495","description":"\"Binding to Roundabout (ROBO) receptor, a transmembrane receptor.\" [GOC:ecd, PMID:10102268, PMID:10197527]","metadata":null},{"id":"b7bc389139e54a7d840860f2679af377","type":"GO_TERM","name":"Roundabout signaling pathway","canonical_id":"go:GO:0035385","description":"\"The series of molecular signals initiated by a SLIT protein binding to a Roundabout (ROBO) family receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:signaling]","metadata":null},{"id":"2a4f872ee9ce44268f91c1c19dc271a0","type":"TRIAL","name":"Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome","canonical_id":"clinicaltrials.gov:NCT05053893","description":"Cardio-Renal Syndrome","metadata":null},{"id":"7bdc7fd7193549878b0ac62856355fcc","type":"DRUG","name":"Roxatidine acetate","canonical_id":"mesh:C053742","description":null,"metadata":null},{"id":"cd5ce7990c874e51829d4660b86bdf21","type":"GO_TERM","name":"Rpd3L complex","canonical_id":"go:GO:0033698","description":"\"A histone deacetylase complex which deacetylates histones preferentially in promoter regions. Composed of a two copies of catalytic histone deacetylase subunit (S. pombe Clr6/ S. cerevisiae Rpd3p), an Sds-3 family protein (S. pombe /S. cerevisiae Sds3(p) ), two copies of SIN3 family co-repressor (S. pombe Pst1/ S. cerevisiae Sin3p, a WD repeat protein/ histone chaperone (S. pombe Prw1/ S. cerevisiae Ume1p), and a zf- PHD finger ( S. pombe Png2/ S. cerevisiae Pho23p), plus 4 additional subunits, and associated factors.\" [GOC:vw, PMID:17450151]","metadata":null},{"id":"85e7b867144d4e32a78946e2ef5cf556","type":"GO_TERM","name":"Rpd3L-Expanded complex","canonical_id":"go:GO:0070210","description":"\"A protein complex that contains a histone deacetylase and is part of the chromatin remodeling machinery. In Saccharomyces cerevisiae this complex contains the Rpd3p, Sin3p, Ume1p, Pho23p, Sap30p, Sds3p, Cti6p, Rxt2p, Rxt3p, Dep1p, Ume6p, Ash1p, Dot6p, Snt1, Sif2p, Set3p, Hos2p, Tos4p and Tod6p proteins.\" [GOC:rb, PMID:19040720]","metadata":null},{"id":"e58a1b36004845c9843c3aaca84ad0aa","type":"GO_TERM","name":"Rpd3S complex","canonical_id":"go:GO:0032221","description":"\"A eukaryotically conserved histone deacetylase complex which deacetylates histones across gene coding regions. Composed of a catalytic histone deacetylase subunit, a chromodomain protein, a SIN3 family co-repressor, and a WD repeat protein (Clr6p, Alp13p, Pst2p, and Prw1p respectively in Schizosaccharomyces; Rpd3p, Sin3p, Ume1p, Rco1p and Eaf3 in Saccharomyces; homologs thereof in other species).\" [GOC:vw, PMID:12773392, PMID:17450151]","metadata":null},{"id":"918cd2593f4f4b9fb8a6bf0084cd570b","type":"DRUG","name":"Rucaparib","canonical_id":"ncit:C137800","description":null,"metadata":null},{"id":"f7605d68ef034453a4b36ac533fab427","type":"TRIAL","name":"Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor","canonical_id":"clinicaltrials.gov:NCT03521037","description":"Neoplasms","metadata":null},{"id":"eb39c4a4dd8547f482a5a5ca30259f3c","type":"TRIAL","name":"Rucaparib Maintenance Therapy in Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT03795272","description":"Cervical Cancer","metadata":null},{"id":"c59dc5785a5b49af92db3937c6710ce1","type":"TRIAL","name":"Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed","canonical_id":"clinicaltrials.gov:NCT07674368","description":"ALK Fusion-positive Non-small Cell Lung Cancer","metadata":null},{"id":"310074697bed4541b74e296bd55d5e7b","type":"TRIAL","name":"Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair","canonical_id":"clinicaltrials.gov:NCT03318445","description":"Solid Tumor, Unspecified, Adult","metadata":null},{"id":"2ad42ed412e34bc9939d79b73ee41124","type":"TRIAL","name":"Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT03572478","description":"Prostate Cancer; Endometrial Cancer","metadata":null},{"id":"5e3b224327f44f049bb871f73706711e","type":"TRIAL","name":"Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03559049","description":"Stage IV Non-small Cell Lung Cancer","metadata":null},{"id":"c2f53c551b464d7c83358aa51f9cc8f4","type":"TRIAL","name":"Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy","canonical_id":"clinicaltrials.gov:NCT03639935","description":"Biliary Tract Cancer","metadata":null},{"id":"b6db4eed3c9d46c28ccc1369e0846bec","type":"TRIAL","name":"Rucaparib in Nonmetastatic prOstAte With BRCAness","canonical_id":"clinicaltrials.gov:NCT03533946","description":"Prostate Cancer","metadata":null},{"id":"db64439fb10c4673a494e809beb40671","type":"TRIAL","name":"Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT03397394","description":"Bladder Cancer; Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Renal Pelvis Carcinoma; Ureter Carcinoma; Urinary Bladder Carcinoma; Urethra Carcinoma; Muscle Invasive Bladder Cancer","metadata":null},{"id":"2d1e42d983f0434c94b8473fe28360ef","type":"TRIAL","name":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT03845296","description":"Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"1c03d75421a24b8aae3a08401b1aec32","type":"TRIAL","name":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT03617679","description":"Metastatic Endometrial Cancer","metadata":null},{"id":"81e5709149c8496fa636722b8a5a67ec","type":"TRIAL","name":"Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00664781","description":"brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer","metadata":null},{"id":"64a22595ff664ebcaed762a25932e2d2","type":"TRIAL","name":"Rupatadine in Patients With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07064707","description":"Ulcerative Colitis","metadata":null},{"id":"9f0a52d90302415db5109e0a7e7a95df","type":"TRIAL","name":"Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT07711262","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"96b58fefed2f41a29d30e8d71adbe368","type":"TRIAL","name":"Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)","canonical_id":"clinicaltrials.gov:NCT00263393","description":"Myocardial Infarction; Angina Pectoris; Cerebrovascular Accidents; Diabetes Mellitus","metadata":null},{"id":"b384798c623a45f889a81b4c4043b37f","type":"TRIAL","name":"Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT00235001","description":"Hypertension","metadata":null},{"id":"3f463e08998040f3a740268f56eb725b","type":"DRUG","name":"Rutin","canonical_id":"mesh:D012431","description":null,"metadata":null},{"id":"def26d6d77d0434a9c674449a8c3a5ba","type":"DRUG","name":"Ruxolitinib","canonical_id":"mesh:C540383","description":null,"metadata":null},{"id":"c1c9ca387fb1466b8de4b7624ca91bf8","type":"TRIAL","name":"Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)","canonical_id":"clinicaltrials.gov:NCT01348490","description":"MPN (Myeloproliferative Neoplasms)","metadata":null},{"id":"058be23ae3414ae4ac855c849c3647e1","type":"TRIAL","name":"Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study","canonical_id":"clinicaltrials.gov:NCT07673640","description":"Non-Segmental Vitiligo (NSV)","metadata":null},{"id":"5fdc5b0912af45fabf43862b44a209b3","type":"TRIAL","name":"Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT01732445","description":"Anemia; Primary Myelofibrosis; Secondary Myelofibrosis","metadata":null},{"id":"7bb0aafc498e4f3bbd26eb21b54f6007","type":"TRIAL","name":"Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD","canonical_id":"clinicaltrials.gov:NCT06233110","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"6ec6101627854cdb9edca745c789d516","type":"TRIAL","name":"Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)","canonical_id":"clinicaltrials.gov:NCT06160791","description":"Hemophagocytic Lymphohistiocytoses","metadata":null},{"id":"625ba2ee144c4491bbab9fcac917049a","type":"TRIAL","name":"Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT04908735","description":"Hematopoietic Stem Cell Transplant (HSCT); Bronchiolitis Obliterans (BO)","metadata":null},{"id":"9d932af2f98846eaa63820f6805373d6","type":"TRIAL","name":"Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT05592015","description":"T-Cell Large Granular Lymphocyte Leukemia","metadata":null},{"id":"2835356b692048ca904578614bb16276","type":"TRIAL","name":"Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","canonical_id":"clinicaltrials.gov:NCT04338958","description":"Covid-19","metadata":null},{"id":"2e955ad55b7e42fcb3e7430c0cbc3410","type":"TRIAL","name":"Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease","canonical_id":"clinicaltrials.gov:NCT07085039","description":"Castleman's Disease (CD); Idiopathic Multicentric Castleman&#39;s Disease","metadata":null},{"id":"a580319c75c346adae39265a93b2bd32","type":"TRIAL","name":"Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors","canonical_id":"clinicaltrials.gov:NCT01751425","description":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission; Minimal Residual Disease; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","metadata":null},{"id":"1b59dc604af3490bbd5f0815d8cf8d30","type":"GO_TERM","name":"Rvs161p-Rvs167p complex","canonical_id":"go:GO:1990528","description":"\"A protein complex that is involved in endocytosis in the yeast S. cerevisiae.\" [GOC:rb, PMID:20610658]","metadata":null},{"id":"0b4ab8fc70f14aec8a89ec23cbfa0e30","type":"PROTEIN","name":"Ryanodine receptor 1","canonical_id":"uniprot:P21817","description":null,"metadata":null},{"id":"2e2f5acc99c941f98ee04f51f80c4cd9","type":"GO_TERM","name":"S bouton","canonical_id":"go:GO:1990027","description":"\"Synaptic bouton found in the ventral horn of the spinal cord. S boutons range in diameter from 0.5 to 8 um and contain spherical synaptic vesicles.\" [NIF_Subcellular:nlx_subcell_100207]","metadata":null},{"id":"6731347dc12b465e85d142b3f2471bc6","type":"GO_TERM","name":"S phase","canonical_id":"go:GO:0051320","description":"\"The cell cycle phase, following G1, during which DNA synthesis takes place.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"3393da42660b46f59d0427be24a389b6","type":"GO_TERM","name":"S-(hydroxymethyl)glutathione dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106322","description":"\"Catalysis of the reaction: S-(hydroxymethyl)glutathione + NAD+ = S-formylglutathione + NADH + H+.\" [RHEA:19985]","metadata":null},{"id":"499a7fd875dd49cabb243d68993b026b","type":"GO_TERM","name":"S-(hydroxymethyl)glutathione dehydrogenase (NADP+) activity","canonical_id":"go:GO:0106321","description":"\"Catalysis of the reaction: S-(hydroxymethyl)glutathione + NADP+ = S-formylglutathione + NADPH + H+.\" [RHEA:19981]","metadata":null},{"id":"f89dda1642684361bd60e05221a1368e","type":"GO_TERM","name":"S-(hydroxymethyl)glutathione dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0051903","description":"\"Catalysis of the reaction: S-(hydroxymethyl)glutathione + NAD(P)+ = S-formylglutathione + NAD(P)H + H+.\" [EC:1.1.1.284]","metadata":null},{"id":"606438a47b35418e9984072c246abfd9","type":"GO_TERM","name":"S-(hydroxymethyl)glutathione synthase activity","canonical_id":"go:GO:0051907","description":"\"Catalysis of the reaction: S-(hydroxymethyl)glutathione = formaldehyde + glutathione.\" [EC:4.4.1.22, RHEA:22488]","metadata":null},{"id":"9ed763f230994b98b5afba2bd12a1363","type":"GO_TERM","name":"S-(hydroxymethyl)mycothiol dehydrogenase activity","canonical_id":"go:GO:0050607","description":"\"Catalysis of the reaction: S-(hydroxymethyl)mycothiol + NAD+ = S-formylmycothiol + NADH + H+.\" [RHEA:28502]","metadata":null},{"id":"7262e32ff8024657bf5b948a9182841f","type":"GO_TERM","name":"S-acetyltransferase activity","canonical_id":"go:GO:0016418","description":"\"Catalysis of the transfer of an acetyl group to a sulfur atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"2715b150b31c46339d016decc14eb602","type":"GO_TERM","name":"S-adenosyl-L-methionine binding","canonical_id":"go:GO:1904047","description":"\"Binding to S-adenosyl-L-methionine.\" [GO_REF:0000067, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:22985361]","metadata":null},{"id":"bfc44931d0354b9d8106db08b25e8395","type":"GO_TERM","name":"S-adenosyl-L-methionine lyase activity","canonical_id":"go:GO:0047625","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine = L-homoserine lactone + S-methyl-5'-thioadenosine.\" [RHEA:21932]","metadata":null},{"id":"66639c8810d744bc8fdc07290d20a60d","type":"GO_TERM","name":"S-adenosyl-L-methionine transmembrane transport","canonical_id":"go:GO:1901962","description":"\"The directed movement of S-adenosyl-L-methionine across a membrane.\" [GOC:TermGenie, PMID:10497160]","metadata":null},{"id":"bc8c0f0bed1e43ce9560f4843e6b4d99","type":"GO_TERM","name":"S-adenosyl-L-methionine transmembrane transporter activity","canonical_id":"go:GO:0000095","description":"\"Enables the transfer of S-adenosylmethionine from one side of a membrane to the other. S-adenosylmethionine is S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.\" [GOC:ai]","metadata":null},{"id":"8407d4e3cb404a178ceca1f79add5a93","type":"GO_TERM","name":"S-adenosyl-L-methionine transport","canonical_id":"go:GO:0015805","description":"\"The directed movement of S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"a55c73d8ca3641a7afdd8ddde73d201a","type":"GO_TERM","name":"S-adenosyl-L-methionine:(S)-corytuberine-N-methyltransferase activity","canonical_id":"go:GO:0102964","description":"\"Catalysis of the reaction: (S)-corytuberine + S-adenosyl-L-methionine = magnoflorine + S-adenosyl-L-homocysteine.\" [RHEA:51524]","metadata":null},{"id":"394dd5c4d28843f7a94bc5da6fed38a3","type":"GO_TERM","name":"S-adenosyl-L-methionine:8-amino-7-oxononanoate transaminase activity","canonical_id":"go:GO:0004015","description":"\"Catalysis of the reaction: (8S)-8-amino-7-oxononanoate + S-adenosyl-L-methionine = S-adenosyl-4-methylsulfanyl-2-oxobutanoate + (7R,8S)-7,8-diammoniononanoate.\" [RHEA:16861]","metadata":null},{"id":"f1f2db2f56ef4ba296e8f0e35c063e67","type":"GO_TERM","name":"S-adenosyl-L-methionine:S-adenosyl-L-homocysteine antiporter activity","canonical_id":"go:GO:0180003","description":"\"Catalysis of the reaction: S-adenosyl-L-homocysteine(out) + S-adenosyl-L-methionine(in) = S-adenosyl-L-homocysteine(in) + S-adenosyl-L-methionine(out).\" [PMID:14674884, PMID:34375635]","metadata":null},{"id":"6adf42636187479b88157032f54b5eaa","type":"GO_TERM","name":"S-adenosyl-L-methionine:benzoic acid carboxyl methyl transferase activity","canonical_id":"go:GO:0080150","description":"\"Catalysis of the reaction: benzoate + S-adenosyl-L-methionine = methylbenzoate + S-adenosyl-L-homocysteine.\" [MetaCyc:RXN-6722, PMID:10852939]","metadata":null},{"id":"24be79f889d843ada2d35f4db2c5de55","type":"GO_TERM","name":"S-adenosylhomocysteine deaminase activity","canonical_id":"go:GO:0050270","description":"\"Catalysis of the reaction: S-adenosyl-L-homocysteine + H2O + H+ = S-inosyl-L-homocysteine + NH4.\" [EC:3.5.4.28, RHEA:20716]","metadata":null},{"id":"5efa3436acf94814a91f64348feef27c","type":"GO_TERM","name":"S-adenosylmethioninamine metabolic process","canonical_id":"go:GO:0046499","description":"\"The chemical reactions and pathways involving S-adenosylmethioninamine, (5-deoxy-5-adenosyl)(3-aminopropyl) methylsulfonium salt.\" [GOC:mah]","metadata":null},{"id":"28330612b52840d19d5c6299f57f050f","type":"GO_TERM","name":"S-adenosylmethionine biosynthetic process","canonical_id":"go:GO:0006556","description":"\"The chemical reactions and pathways resulting in the formation of S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a2520123a75740698e844b2d979fdcb0","type":"GO_TERM","name":"S-adenosylmethionine catabolic process","canonical_id":"go:GO:0050843","description":"\"The chemical reactions and pathways resulting in the breakdown of S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.\" [GOC:ai]","metadata":null},{"id":"8f6037298e0647e3a0fe4da820baa4a1","type":"GO_TERM","name":"S-adenosylmethionine metabolic process","canonical_id":"go:GO:0046500","description":"\"The chemical reactions and pathways involving S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a59ec68f04d543f0a1b44fb2cb39ae4a","type":"GO_TERM","name":"S-adenosylmethionine-dependent methyltransferase activity","canonical_id":"go:GO:0008757","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to a substrate.\" [GOC:mah]","metadata":null},{"id":"98abac3ec3c44605b5d4e3817d750640","type":"GO_TERM","name":"S-adenosylmethionine-homocysteine S-methyltransferase activity","canonical_id":"go:GO:0008898","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + L-homocysteine = S-adenosyl-L-homocysteine + L-methionine.\" [RHEA:21820]","metadata":null},{"id":"ae5e3dfb8d5343b0b096b8e95f371496","type":"GO_TERM","name":"S-adenosylmethionine:tRNA ribosyltransferase-isomerase activity","canonical_id":"go:GO:0051075","description":"\"Catalysis of the reaction: S-adenosylmethionine + 7-(aminomethyl)-7-deazaguanosine-tRNA = adenine + methionine + epoxyqueuosine-tRNA. 7-(aminomethyl)-7-deazaguanosine-tRNA is also known as preQ1-tRNA, and epoxyqueuosine-tRNA as oQ-tRNA.\" [PMID:12731872]","metadata":null},{"id":"d1ad934b14bf4682a827ffe452792331","type":"GO_TERM","name":"S-alkylthiohydroximate lyase activity","canonical_id":"go:GO:0080108","description":"\"Catalysis of the conversion of a S-alkylthiohydroximate to a thiohydroximate.\" [PMID:14871316]","metadata":null},{"id":"da76a071702a404ebc5089d2b0751428","type":"TRIAL","name":"S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension","canonical_id":"clinicaltrials.gov:NCT03226340","description":"Essential Hypertension","metadata":null},{"id":"f3681c136db848c0920d9b1f3a18d412","type":"GO_TERM","name":"S-carboxymethylcysteine synthase activity","canonical_id":"go:GO:0050272","description":"\"Catalysis of the reaction: 3-chloro-L-alanine + thioglycolate = S-carboxymethyl-L-cysteine + chloride + H+.\" [EC:4.5.1.5, RHEA:22868]","metadata":null},{"id":"281397f7996a4b4e9a5cba22da4d74d4","type":"TRIAL","name":"S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet","canonical_id":"clinicaltrials.gov:NCT04505787","description":"Comparative Bioavailability","metadata":null},{"id":"42aa0a9e416d49a1961df03717f6ed71","type":"GO_TERM","name":"S-formylglutathione hydrolase activity","canonical_id":"go:GO:0018738","description":"\"Catalysis of the reaction: S-formylglutathione + H2O = formate + glutathione + H+.\" [EC:3.1.2.12, RHEA:14961]","metadata":null},{"id":"835a2bae80e94fde99e36fda8c19be20","type":"GO_TERM","name":"S-glycoside biosynthetic process","canonical_id":"go:GO:0016144","description":"\"The chemical reactions and pathways resulting in the formation of S-glycosides, any compound in which a glycosyl group has been substituted into a thiol group.\" [ISBN:0198506732]","metadata":null},{"id":"c087c00aaf644b99bf0a3ef11c17e268","type":"GO_TERM","name":"S-glycoside catabolic process","canonical_id":"go:GO:0016145","description":"\"The chemical reactions and pathways resulting in the breakdown of S-glycosides, any compound in which a glycosyl group has been substituted into a thiol group.\" [ISBN:0198506732]","metadata":null},{"id":"a99efc6dc45a4380b18cca027bff0c12","type":"GO_TERM","name":"S-lactaldehyde reductase activity","canonical_id":"go:GO:0052661","description":"\"Catalysis of the reaction: (S)-propane-1,2-diol + NAD+ = (S)-lactaldehyde + NADH + H+.\" [RHEA:15933]","metadata":null},{"id":"668b73ec9b2947958b8b16e4a0bcd688","type":"GO_TERM","name":"S-layer","canonical_id":"go:GO:0030115","description":"\"A crystalline protein layer surrounding some bacteria.\" [GOC:mlg, ISBN:0815108893]","metadata":null},{"id":"514bdc9610234288ab8ddcec3558809e","type":"GO_TERM","name":"S-layer organization","canonical_id":"go:GO:0045232","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an S-layer enveloping the cell. The S-layer is a crystalline protein layer surrounding some bacteria.\" [GOC:ai]","metadata":null},{"id":"f46abf739cea4f269b290fd513825c2e","type":"GO_TERM","name":"S-linalool synthase activity","canonical_id":"go:GO:0034007","description":"\"Catalysis of the reaction: geranyl diphosphate + H2O = (S)-linalool + diphosphate.\" [EC:4.2.3.25, RHEA:24116]","metadata":null},{"id":"ee23255821a84130a6db04e36b429034","type":"GO_TERM","name":"S-malonyltransferase activity","canonical_id":"go:GO:0016419","description":"\"Catalysis of the transfer of a malonyl group to a sulfur atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"596bad42389740eb916fcf2ab1a86b2d","type":"GO_TERM","name":"S-methyl-5-thioadenosine phosphorylase activity","canonical_id":"go:GO:0017061","description":"\"Catalysis of the reaction: 5'-methylthioadenosine + phosphate = adenine + 5-methylthio-D-ribose 1-phosphate.\" [EC:2.4.2.28]","metadata":null},{"id":"534a446395be4060ad32bc4d8ed9c97c","type":"GO_TERM","name":"S-methyl-5-thioribose kinase activity","canonical_id":"go:GO:0046522","description":"\"Catalysis of the reaction: S-methyl-5-thio-D-ribose + ATP = S-methyl-5-thio-alpha-D-ribose 1-phosphate + ADP + 2 H+.\" [EC:2.7.1.100, RHEA:22312]","metadata":null},{"id":"1e22c7a222874f4e8b68f9d734d9bb73","type":"GO_TERM","name":"S-methyl-5-thioribose-1-phosphate isomerase activity","canonical_id":"go:GO:0046523","description":"\"Catalysis of the reaction: S-methyl-5-thio-alpha-D-ribose 1-phosphate = S-methyl-5-thio-D-ribulose 1-phosphate.\" [RHEA:19989]","metadata":null},{"id":"ee63f4b4381c4948a2132869c706eef3","type":"GO_TERM","name":"S-methylmethionine biosynthetic process","canonical_id":"go:GO:0010250","description":"\"The chemical reactions and pathways resulting in the formation of S-methyl-methionine (SMM) from methionine and S-adenosyl-methionine (Ado-Met), catalyzed by methionine S-methyltransferase (MMT). SMM can be reconverted to methionine by donating a methyl group to homocysteine, and concurrent operation of this reaction and that mediated by MMT sets up the SMM cycle.\" [PMID:12692340]","metadata":null},{"id":"436365dbc1684d7194ca046733d01b36","type":"GO_TERM","name":"S-methylmethionine cycle","canonical_id":"go:GO:0033528","description":"\"A cyclic series of interconversions involving S-methyl-L-methionine, S-adenosyl-L-homocysteine, S-adenosyl-L-methionine, L-homocysteine, and L-methionine. Converts the methionine group of adenosylmethionine back to free methionine, and may serve regulate the cellular adenosylmethionine level.\" [GOC:mah, MetaCyc:PWY-5441]","metadata":null},{"id":"ba2819ec5e97418f8e47bb28be092d42","type":"GO_TERM","name":"S-methylmethionine metabolic process","canonical_id":"go:GO:0033477","description":"\"The chemical reactions and pathways involving S-methyl-methionine (SMM). SMM can be converted to methionine by donating a methyl group to homocysteine, and concurrent operation of this reaction and that mediated by MMT sets up the SMM cycle.\" [GOC:mah, PMID:12692340]","metadata":null},{"id":"dc3979528d16477384329b5304ebbc76","type":"GO_TERM","name":"S-methylmethionine transmembrane transporter activity","canonical_id":"go:GO:0000100","description":"\"Enables the transfer of S-methylmethionine from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"5b6a589d2263412b9d7aaad8293fbd16","type":"GO_TERM","name":"S-methylmethionine transport","canonical_id":"go:GO:0015806","description":"\"The directed movement of S-methylmethionine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f293eae99e2d4de7b1bc05d0ce1582bb","type":"GO_TERM","name":"S-methylmethionine-homocysteine S-methyltransferase activity","canonical_id":"go:GO:0061627","description":"\"Catalysis of the reaction: S-methyl-L-methionine + L-homocysteine = 2 L-methionine + H+.\" [RHEA:26337]","metadata":null},{"id":"4ca466af39c045d08f9cb0618fb5c8c7","type":"GO_TERM","name":"S-methyltransferase activity","canonical_id":"go:GO:0008172","description":"\"Catalysis of the transfer of a methyl group to the sulfur atom of an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"138fbf30a5d54304b83755785b318862","type":"GO_TERM","name":"S-nitrosoglutathione binding","canonical_id":"go:GO:0035730","description":"\"Binding to S-nitrosoglutathione, a nitrosothiol considered to be a natural nitric oxide (NO) donor involved in S-nitrosylation, and in the storage and transport of nitric oxide in biological systems.\" [GOC:BHF]","metadata":null},{"id":"c2420d284c0546789d50c7687d5b9fc7","type":"GO_TERM","name":"S-nitrosoglutathione reductase (NADH) activity","canonical_id":"go:GO:0080007","description":"\"Catalysis of the reaction: S-nitrosoglutathione + NADH + H+ = S-(hydroxysulfenamide)glutathione + NAD+.\" [PMID:11260719, PMID:27094420, PMID:30795534]","metadata":null},{"id":"a910e83cbc0b4037b1e30cd21b85ebbd","type":"GO_TERM","name":"S-nitrosoglutathione reductase (NADPH) activity","canonical_id":"go:GO:0160163","description":"\"Catalysis of the reaction: H+ + NADPH + S-nitrosoglutathione = NADP+ + S-(hydroxysulfenamide)glutathione.\" [RHEA:63500]","metadata":null},{"id":"7f3ca248968a4c0699c70e37020c9871","type":"GO_TERM","name":"S-ribosylhomocysteine lyase activity","canonical_id":"go:GO:0043768","description":"\"Catalysis of the reaction: S-(5-deoxy-D-ribos-5-yl)-L-homocysteine = (S)-4,5-dihydroxypentane-2,3-dione + L-homocysteine.\" [RHEA:17753]","metadata":null},{"id":"fb270db318584f5d9d776c7c234c250f","type":"GO_TERM","name":"S-shaped body morphogenesis","canonical_id":"go:GO:0072050","description":"\"The process in which the S-shaped body is generated and organized. The S-shaped body is the successor of the comma-shaped body that contributes to the morphogenesis of the nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"baa4cb4054d643cc8cdf492c83a059b8","type":"GO_TERM","name":"S-succinylglutathione hydrolase activity","canonical_id":"go:GO:0050273","description":"\"Catalysis of the reaction: S-succinylglutathione + H2O = glutathione + H+ + succinate.\" [EC:3.1.2.13, RHEA:16713]","metadata":null},{"id":"a6e6b41a4a234160aacc40265d3a3265","type":"GO_TERM","name":"S-succinyltransferase activity","canonical_id":"go:GO:0016751","description":"\"Catalysis of the transfer of a succinyl group to a sulfur atom on the acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"321d2d1a6af44028a3e218e85df85493","type":"GO_TERM","name":"S-sulfolactate dehydrogenase activity","canonical_id":"go:GO:0102155","description":"\"Catalysis of the reaction: (S)-3-sulfonatolactate + NAD = 3-sulfonatopyruvate(2-) + NADH + H+.\" [EC:1.1.1.310, GOC:pz]","metadata":null},{"id":"296b01aa2a254841bf1e82d32d1cac04","type":"TRIAL","name":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00006721","description":"Lymphoma","metadata":null},{"id":"c302c2034b3a4a62a3c362629316076b","type":"TRIAL","name":"S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00025493","description":"Breast Cancer","metadata":null},{"id":"f1781a18fb4b4b78abbf03c4c6373827","type":"TRIAL","name":"S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00028769","description":"Prostate Cancer","metadata":null},{"id":"17c78abed9e44b25ab1cec3ccf2a180b","type":"TRIAL","name":"S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML","canonical_id":"clinicaltrials.gov:NCT00085709","description":"Leukemia","metadata":null},{"id":"73bb35e182524e45a0fd8511e9e87740","type":"TRIAL","name":"S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00049179","description":"Leukemia","metadata":null},{"id":"2ee967da75c842e58fecb2b578778cb3","type":"TRIAL","name":"S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00087412","description":"Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer","metadata":null},{"id":"fc74ddf24a0143f3b2d31cff39dcd303","type":"TRIAL","name":"S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer","canonical_id":"clinicaltrials.gov:NCT00103324","description":"Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Recurrent Gastric Cancer; Stage III Gastric Cancer; Stage IV Gastric Cancer","metadata":null},{"id":"803457809e1c40fa83352d5390873f40","type":"TRIAL","name":"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT00134056","description":"Metastatic Cancer; Prostate Cancer","metadata":null},{"id":"2d6beb7e152c44f79f3de5b249857f75","type":"TRIAL","name":"S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00107380","description":"Lymphoma","metadata":null},{"id":"5cee3976e8834728a3bac76c4077fa8e","type":"TRIAL","name":"S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00337168","description":"Leukemia","metadata":null},{"id":"8b802563bfd242009b4ad03cd448a52f","type":"TRIAL","name":"S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00551460","description":"Leukemia","metadata":null},{"id":"ec76b0c86b1a4b31a80ea8073cccd12b","type":"TRIAL","name":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","canonical_id":"clinicaltrials.gov:NCT00723658","description":"Lymphoma","metadata":null},{"id":"2e791e1c4f924ce0a889960a0fc89892","type":"TRIAL","name":"S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00937417","description":"Breast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"450d5b06457148cfa98f7be7aac9b5b0","type":"TRIAL","name":"S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00770224","description":"Lymphoma","metadata":null},{"id":"fef44b46762948b6970913baf7a32040","type":"TRIAL","name":"S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00828139","description":"Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer","metadata":null},{"id":"ed9e998191aa42ca8a10dfd22eaf1502","type":"TRIAL","name":"S0820, Adenoma and Second Primary Prevention Trial","canonical_id":"clinicaltrials.gov:NCT01349881","description":"Colorectal Neoplasms","metadata":null},{"id":"03c8a8ce554b4b00bf5bc0cad18ddef6","type":"TRIAL","name":"S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT00872989","description":"Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer","metadata":null},{"id":"aed397fdc94f4823a3d365f26d840636","type":"TRIAL","name":"S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT00945815","description":"Leukemia","metadata":null},{"id":"b9ec139d0aa04fa3abb5741657fd05f3","type":"GO_TERM","name":"S100 protein binding","canonical_id":"go:GO:0044548","description":"\"Binding to a S100 protein. S100 is a small calcium and zinc binding protein produced in astrocytes that is implicated in Alzheimer's disease, Down Syndrome and ALS.\" [GOC:jid]","metadata":null},{"id":"84192a3c1cc44e2b92d0bf5630402c04","type":"TRIAL","name":"S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01359592","description":"Lymphoma","metadata":null},{"id":"aabbfec2faa74a73bd822b5e4aef41c1","type":"GENE","name":"S100A1","canonical_id":"hgnc:HGNC:10486","description":"S100 calcium binding protein A1","metadata":{"aliases":["S100-alpha","S100A"]}},{"id":"87c37fa98cb74a199bb1364e24597d08","type":"GENE","name":"S100A10","canonical_id":"hgnc:HGNC:10487","description":null,"metadata":null},{"id":"061ed623a958480bbf6a8d7da6c00366","type":"GENE","name":"S100A11","canonical_id":"hgnc:HGNC:10488","description":null,"metadata":null},{"id":"b63d38878a154093a9691b77592f5cfd","type":"GENE","name":"S100A11P1","canonical_id":"hgnc:HGNC:10491","description":"S100A11 pseudogene 1","metadata":{"aliases":["S100A14","S100A11P"]}},{"id":"75474151c5624fd6bdd1e1656f732fb7","type":"GENE","name":"S100A11P10","canonical_id":"hgnc:HGNC:54961","description":"S100A11 pseudogene 10","metadata":null},{"id":"3ab4af37ca1b4de48364fc173afeb540","type":"GENE","name":"S100A11P2","canonical_id":"hgnc:HGNC:37840","description":"S100A11 pseudogene 2","metadata":null},{"id":"cbd65873b9d7415d965f000e2ceeaa1e","type":"GENE","name":"S100A11P3","canonical_id":"hgnc:HGNC:37842","description":"S100A11 pseudogene 3","metadata":null},{"id":"3d8bc574ba7443028cf269ec77b7113e","type":"GENE","name":"S100A11P4","canonical_id":"hgnc:HGNC:37841","description":"S100A11 pseudogene 4","metadata":null},{"id":"8249fd396ef44030bbfbcb37c044edd0","type":"GENE","name":"S100A11P5","canonical_id":"hgnc:HGNC:54954","description":"S100A11 pseudogene 5","metadata":null},{"id":"2dd1579d782d4dd28d43e7c9c653fb0f","type":"GENE","name":"S100A11P6","canonical_id":"hgnc:HGNC:54955","description":"S100A11 pseudogene 6","metadata":null},{"id":"d8f9fe9837c7482fba1103806232ad11","type":"GENE","name":"S100A11P7","canonical_id":"hgnc:HGNC:54956","description":"S100A11 pseudogene 7","metadata":null},{"id":"55b155038aa44b42afb67ce4c3a861e9","type":"GENE","name":"S100A11P8","canonical_id":"hgnc:HGNC:54957","description":"S100A11 pseudogene 8","metadata":null},{"id":"8d1e21a6c7e44d9a89995a1b17311a65","type":"GENE","name":"S100A11P9","canonical_id":"hgnc:HGNC:54958","description":"S100A11 pseudogene 9","metadata":null},{"id":"3cf3f1761356403ea5000960c214eba4","type":"GENE","name":"S100A12","canonical_id":"hgnc:HGNC:10489","description":"S100 calcium binding protein A12","metadata":{"aliases":["p6","MRP6","CGRP","CAAF1","CAGC","ENRAGE"]}},{"id":"068e7826fb494bcb880c6eda557e5ef2","type":"GENE","name":"S100A13","canonical_id":"hgnc:HGNC:10490","description":"S100 calcium binding protein A13","metadata":null},{"id":"6efa5ba0eba341b4adc336e8f38e0666","type":"GENE","name":"S100A14","canonical_id":"hgnc:HGNC:18901","description":"S100 calcium binding protein A14","metadata":{"aliases":["S100A15","BCMP84"]}},{"id":"f2183eab55ef42b0bf068fb4c00a1c46","type":"GENE","name":"S100A15A","canonical_id":"hgnc:HGNC:53871","description":"S100 calcium binding protein A15A (pseudogene)","metadata":null},{"id":"83877f47c9f64377b72c0dda351fee81","type":"GENE","name":"S100A16","canonical_id":"hgnc:HGNC:20441","description":"S100 calcium binding protein A16","metadata":{"aliases":["S100F","DT1P1A7","MGC17528"]}},{"id":"e5a932f6259043a7a88238aa0b8be93a","type":"GENE","name":"S100A2","canonical_id":"hgnc:HGNC:10492","description":null,"metadata":null},{"id":"87902adf920c4b16bff8bd6472ad5a91","type":"GENE","name":"S100A3","canonical_id":"hgnc:HGNC:10493","description":"S100 calcium binding protein A3","metadata":{"aliases":["S100E"]}},{"id":"1a3bdf3957654418b0c0225f1c043ca5","type":"GENE","name":"S100A4","canonical_id":"hgnc:HGNC:10494","description":null,"metadata":null},{"id":"1c2693e67cc14426b4f34464862f598c","type":"GENE","name":"S100A5","canonical_id":"hgnc:HGNC:10495","description":"S100 calcium binding protein A5","metadata":{"aliases":["S100D"]}},{"id":"e59da2f359a04c11b4e8e142491bb8e8","type":"GENE","name":"S100A6","canonical_id":"hgnc:HGNC:10496","description":null,"metadata":null},{"id":"24f08d3fe8b04e8aa6cc80d66a57b780","type":"GENE","name":"S100A7","canonical_id":"hgnc:HGNC:10497","description":null,"metadata":null},{"id":"d758c860543a4a04aec592f7f616d575","type":"GENE","name":"S100A7A","canonical_id":"hgnc:HGNC:21657","description":"S100 calcium binding protein A7A","metadata":{"aliases":["S100A7f","S100A15","S100A7L1"]}},{"id":"f21231a994bd4700a9e98091289e59fc","type":"GENE","name":"S100A7L2","canonical_id":"hgnc:HGNC:21655","description":"S100 calcium binding protein A7 like 2","metadata":{"aliases":["s100a7b"]}},{"id":"47afbf3cb4674ef2a2ac4665497c3e71","type":"GENE","name":"S100A7P1","canonical_id":"hgnc:HGNC:21654","description":"S100 calcium binding protein A7 pseudogene 1","metadata":{"aliases":["s100a7d","S100A7L3"]}},{"id":"4ac0de111bad48dd87d283bf8fd503b2","type":"GENE","name":"S100A7P2","canonical_id":"hgnc:HGNC:21656","description":"S100 calcium binding protein A7 pseudogene 2","metadata":{"aliases":["s100a7e","S100A7L4"]}},{"id":"63cf26bedfba4235a6bcf086ccf0716a","type":"GENE","name":"S100A8","canonical_id":"hgnc:HGNC:10498","description":"S100 calcium binding protein A8","metadata":{"aliases":["P8","MRP8","MRP-8","60B8AG","CGLA","S100-A8","CAGA","CFAG"]}},{"id":"48dc94736722451588787fbac5cb6901","type":"GO_TERM","name":"S100A8 complex","canonical_id":"go:GO:1990661","description":"\"A protein complex composed of a S100A8 dimer and capable of binding to toll-like receptor 4 (TLR4).\" [GOC:bhm, PMID:25417112]","metadata":null},{"id":"b8b3f61dccbb4dd29b2a23970e0e7704","type":"GENE","name":"S100A9","canonical_id":"hgnc:HGNC:10499","description":null,"metadata":null},{"id":"788d2be94f5d40ae927665f85a0d3112","type":"GO_TERM","name":"S100A9 complex","canonical_id":"go:GO:1990662","description":"\"A protein complex composed of a S100A9 dimer and capable of binding to toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE) initiating signal transduction through NF-kappa-B pathways. Transports arachidonic acid between the cytosol and the NADPH oxidase complex at the plasma membrane in neutrophils as part of an inflammatory signal cascade leading to an oxidative burst. Complexes with microtubules to increase cell motility.\" [GOC:bhm, PMID:15642721]","metadata":null},{"id":"e61d3439fa3e47daa8ea0e905c4a668d","type":"GENE","name":"S100B","canonical_id":"hgnc:HGNC:10500","description":null,"metadata":null},{"id":"267421d42fff4b779ef3f1d1d17b6635","type":"GENE","name":"S100G","canonical_id":"hgnc:HGNC:1436","description":"S100 calcium binding protein G","metadata":{"aliases":["CABP9K","CABP1","CALB3"]}},{"id":"9f9629f6aa924dadb0acef32e7295bd3","type":"GENE","name":"S100P","canonical_id":"hgnc:HGNC:10504","description":null,"metadata":null},{"id":"5fc3988130694bdba86f149607beaa9f","type":"GENE","name":"S100PBP","canonical_id":"hgnc:HGNC:25768","description":"S100P binding protein","metadata":{"aliases":["FLJ12903","S100PBPR"]}},{"id":"5991eb910ced4ab6891898a7b855db72","type":"GENE","name":"S100Z","canonical_id":"hgnc:HGNC:30367","description":"S100 calcium binding protein Z","metadata":{"aliases":["Gm625","S100-zeta"]}},{"id":"406813bba9b9468c819ec46c5349f836","type":"TRIAL","name":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01674140","description":"Breast Cancer","metadata":null},{"id":"df96247da00041edb6554dafc9a7fd75","type":"TRIAL","name":"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01668719","description":"DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma","metadata":null},{"id":"bf210806f56a4a0f8dfec7ab2fc888fd","type":"TRIAL","name":"S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02164916","description":"Colorectal Cancer","metadata":null},{"id":"1bd67a5b91c64f6d98b0cf3bcbd8f6be","type":"GENE","name":"S1PR1","canonical_id":"hgnc:HGNC:3165","description":null,"metadata":null},{"id":"5b4c16a8709b4b249d8d3a95452f1e8e","type":"PROTEIN","name":"S1PR1","canonical_id":"uniprot:P21453","description":null,"metadata":null},{"id":"2f5f597f98e24147bf293e441e4d3b15","type":"GENE","name":"S1PR1-DT","canonical_id":"hgnc:HGNC:55842","description":"S1PR1 divergent transcript","metadata":{"aliases":["LISPR1"]}},{"id":"1bc23da688c143f096a9dd242178341b","type":"GENE","name":"S1PR2","canonical_id":"hgnc:HGNC:3169","description":"sphingosine-1-phosphate receptor 2","metadata":{"aliases":["Gpcr13","H218","AGR16","EDG5","DFNB68"]}},{"id":"0b1973959e5648acab67f0e8bdc21c7f","type":"GENE","name":"S1PR3","canonical_id":"hgnc:HGNC:3167","description":"sphingosine-1-phosphate receptor 3","metadata":{"aliases":["EDG-3","FLJ37523","bA791O21.3","EDG3","C9orf47","C9orf108"]}},{"id":"6d5cdbe9fa354f15829a3d750d0f5665","type":"GENE","name":"S1PR4","canonical_id":"hgnc:HGNC:3170","description":"sphingosine-1-phosphate receptor 4","metadata":{"aliases":["EDG6"]}},{"id":"a82b7f5cb6954805aa4f8db76543678b","type":"GENE","name":"S1PR5","canonical_id":"hgnc:HGNC:14299","description":"sphingosine-1-phosphate receptor 5","metadata":{"aliases":["Edg-8","EDG8"]}},{"id":"5e18813c57ca4995b57826575d17c1b8","type":"PROTEIN","name":"S1PR5","canonical_id":"uniprot:Q9H228","description":null,"metadata":null},{"id":"4202c5d60e0e4eb7a138151ae91526b1","type":"TRIAL","name":"S90652 in Paediatric Hypertension","canonical_id":"clinicaltrials.gov:NCT00202553","description":"Hypertension","metadata":null},{"id":"aaf759ae281c4a3193e0303669cb4ed7","type":"TRIAL","name":"S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease","canonical_id":"clinicaltrials.gov:NCT00005090","description":"Lymphoma","metadata":null},{"id":"81ef59fa31d04d50875606d199d04eaf","type":"TRIAL","name":"S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00003784","description":"Lymphoma","metadata":null},{"id":"ec256e3278a143db901ff623999e0e01","type":"GO_TERM","name":"SA node cell action potential","canonical_id":"go:GO:0086015","description":"\"An action potential that occurs in a sinoatrial node cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"9b2d0a5b1e4544e2a6110572e2a9ae8f","type":"GO_TERM","name":"SA node cell to atrial cardiac muscle cell communication","canonical_id":"go:GO:0086070","description":"\"The process that mediates interactions between an SA node cardiomyocyte and its surroundings that contributes to the process of the SA node cardiomyocyte communicating with an atrial cardiomyocyte in cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"53a3fc3277e94c409fad11395908f0ee","type":"GO_TERM","name":"SA node cell to atrial cardiac muscle cell communication by electrical coupling","canonical_id":"go:GO:0086021","description":"\"The process that mediates signaling interactions between an SA node cardiomyocyte and an atrial cardiomyocyte by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"88e519fa93b1494bb165ffffe705a8b1","type":"GO_TERM","name":"SA node cell to atrial cardiac muscle cell signaling","canonical_id":"go:GO:0086018","description":"\"Any process that mediates the transfer of information from an SA node cardiomyocyte to an atrial cardiomyocyte.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"2da383d6a23a4510aa7e5586933ed477","type":"GENE","name":"SAA1","canonical_id":"hgnc:HGNC:10513","description":null,"metadata":null},{"id":"5817bdab903d414aad540adf2a3cfa6d","type":"GENE","name":"SAA2","canonical_id":"hgnc:HGNC:10514","description":null,"metadata":null},{"id":"be907f49203d4bdd87d0528ec2de8e58","type":"GENE","name":"SAA2-SAA4","canonical_id":"hgnc:HGNC:39550","description":"SAA2-SAA4 readthrough","metadata":null},{"id":"1e76aef44ad348a7812f443a3a0a2cac","type":"GENE","name":"SAA3P","canonical_id":"hgnc:HGNC:10515","description":"serum amyloid A3, pseudogene","metadata":{"aliases":["SAA3"]}},{"id":"386acbfb422f4a8b99a7b864b70fd236","type":"GENE","name":"SAA4","canonical_id":"hgnc:HGNC:10516","description":"serum amyloid A4, constitutive","metadata":{"aliases":["C-SAA","CSAA"]}},{"id":"c2659b2e8e784110bdf51d27dba83ce0","type":"GENE","name":"SAAL1","canonical_id":"hgnc:HGNC:25158","description":"serum amyloid A like 1","metadata":{"aliases":["FLJ41463","SPACIA1"]}},{"id":"bd258bdee0304c629ba028e36cb4d9bb","type":"TRIAL","name":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","canonical_id":"clinicaltrials.gov:NCT00739674","description":"Hypertension","metadata":null},{"id":"92de1746da0f4bd7bfae8247c869c922","type":"GENE","name":"SAC3D1","canonical_id":"hgnc:HGNC:30179","description":"SAC3 domain containing 1","metadata":{"aliases":["HSU79266","SHD1"]}},{"id":"455b9836a7854536a29a6ce2a07c554d","type":"GENE","name":"SACK1A","canonical_id":"hgnc:HGNC:28210","description":"scaffolding CK1 anchoring protein A","metadata":{"aliases":["MGC14128","BJ-TSA-9","FAM83A"]}},{"id":"699b37da364d4ccfb5048befabea6b68","type":"GENE","name":"SACK1A-AS1","canonical_id":"hgnc:HGNC:48658","description":"SACK1A antisense RNA 1","metadata":{"aliases":["HCCC11","FAM83A-AS1"]}},{"id":"eb9092fec86a45efa36863a2c1612df3","type":"GENE","name":"SACK1A-AS2","canonical_id":"hgnc:HGNC:56225","description":"SACK1A antisense RNA 2","metadata":{"aliases":["AC068228.1","FAM83A-AS2"]}},{"id":"093cd3ecfd884336a9def566625d8bbc","type":"GENE","name":"SACK1B","canonical_id":"hgnc:HGNC:21357","description":"scaffolding CK1 anchoring protein B","metadata":{"aliases":["FLJ30642","C6orf143","FAM83B"]}},{"id":"2e662fe803e549d8aafedb481b68892a","type":"GENE","name":"SACK1C","canonical_id":"hgnc:HGNC:16121","description":"scaffolding CK1 anchoring protein C","metadata":{"aliases":["dJ614O4.7","C20orf128","FAM83C"]}},{"id":"b217e55dee944d6185b45d4cd18c42c9","type":"GENE","name":"SACK1C-AS1","canonical_id":"hgnc:HGNC:16113","description":"SACK1C antisense RNA 1","metadata":{"aliases":["dJ614O4.3","C20orf120","NCRNA00154","FAM83C-AS1"]}},{"id":"57e1ff110df340569834feb8df267cff","type":"GENE","name":"SACK1D","canonical_id":"hgnc:HGNC:16122","description":"scaffolding CK1 anchoring protein D","metadata":{"aliases":["dJ616B8.3","CHICA","C20orf129","FAM83D"]}},{"id":"b1c39839d945483eaf727ba13974f2ad","type":"GENE","name":"SACK1E","canonical_id":"hgnc:HGNC:25972","description":"scaffolding CK1 anchoring protein E","metadata":{"aliases":["FLJ20200","FAM83E"]}},{"id":"3c6c78071a53402e911f73057046c65f","type":"GENE","name":"SACK1F","canonical_id":"hgnc:HGNC:25148","description":"scaffolding CK1 anchoring protein F","metadata":{"aliases":["FAM83F"]}},{"id":"cdcbc15d25df46a9975def8b3e22d10b","type":"GENE","name":"SACK1G","canonical_id":"hgnc:HGNC:32554","description":"scaffolding CK1 anchoring protein G","metadata":{"aliases":["FLJ41564","PAWS1","FAM83G"]}},{"id":"ec39d98284d145349f9f60ef831f5453","type":"GENE","name":"SACK1H","canonical_id":"hgnc:HGNC:24797","description":"scaffolding CK1 anchoring protein H","metadata":{"aliases":["FLJ46072","FAM83H"]}},{"id":"f3d02edffacf45dc9d17562cbabb6116","type":"GENE","name":"SACM1L","canonical_id":"hgnc:HGNC:17059","description":"SAC1 like phosphatidylinositide phosphatase","metadata":{"aliases":["SAC1","KIAA0851"]}},{"id":"f977f1688ac4475085a31f260107f4e8","type":"GENE","name":"SACS","canonical_id":"hgnc:HGNC:10519","description":"sacsin molecular chaperone","metadata":{"aliases":["ARSACS","KIAA0730","DKFZp686B15167","DNAJC29","SPAX6","PPP1R138"]}},{"id":"179daa1074ff4deb8f9df498dd5ca1fd","type":"GENE","name":"SACS-AS1","canonical_id":"hgnc:HGNC:39835","description":"SACS antisense RNA 1","metadata":null},{"id":"e21675dadd874031af5e433ee168e69f","type":"TRIAL","name":"SAD Study in Patients With Parkinson's Disease and Motor Fluctuations","canonical_id":"clinicaltrials.gov:NCT07422675","description":"PARKINSON DISEASE (Disorder); Advanced Parkinson's Disease","metadata":null},{"id":"c3d0e1a87c83430cb043ec4f7d4203a3","type":"GENE","name":"SAE1","canonical_id":"hgnc:HGNC:30660","description":"SUMO1 activating enzyme subunit 1","metadata":{"aliases":["AOS1","FLJ3091","Sua1"]}},{"id":"a228e61c67b04b858b8f61e07f5bb878","type":"GENE","name":"SAE1P1","canonical_id":"hgnc:HGNC:56699","description":"SAE1 pseudogene 1","metadata":null},{"id":"f27aafcd836d48fb97355a51c078b6c4","type":"GENE","name":"SAFB","canonical_id":"hgnc:HGNC:10520","description":"scaffold attachment factor B","metadata":{"aliases":["HET","SAFB1"]}},{"id":"2a5df52243f64f9e948769df649ddbf7","type":"GENE","name":"SAFB2","canonical_id":"hgnc:HGNC:21605","description":"scaffold attachment factor B2","metadata":{"aliases":["KIAA0138"]}},{"id":"30802e4a71fc452e923596ba5d804d97","type":"TRIAL","name":"SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients","canonical_id":"clinicaltrials.gov:NCT00274105","description":"Hypertension; Coronary Arteriosclerosis","metadata":null},{"id":"122f5d0bb1f54feabe80b973d164370c","type":"TRIAL","name":"SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03386162","description":"Breast Cancer, PI3K, Alpelisib","metadata":null},{"id":"bfdb0f9c0be0418899d63ea21f9e6646","type":"GENE","name":"SAG","canonical_id":"hgnc:HGNC:10521","description":"S-antigen visual arrestin","metadata":{"aliases":["ARRESTIN","RP47"]}},{"id":"f81922a3ce8c46a7b2aafbb157d947a4","type":"GO_TERM","name":"SAGA complex","canonical_id":"go:GO:0000124","description":"\"A SAGA-type histone acetyltransferase complex that deubiquitinates H2A and/or H2B. This complex is organized into several functional submodules: a structural core including the activator binding module and consisting of ADA1 or a homolog, members of the SPT and TAF protein families as well as promotor recruitment factor TRRAP/TRA1, a histone acetyltransferase (HAT) module consisting of GCN5/KAT2A or PCAF/KAT2B, ADA2, ADA3/NGG1, and SGF29 or homologues thereof, a histone deubiquitinase (DUB) module consisting of ATXN7/SGF73, ATXN7L3/SGF11, ENY2/SUS1 and USP22/UBP8 or homologues thereof, and in some taxa a splicing module consisting of SF3B3 and SF3B5 or homologues thereof (not in fungi). In budding yeast also contains Spt8 which distinguishes it from SAGA-like (SLIK) complex (GO:0046695).\" [PMID:10637607, PMID:17337012, PMID:19056896, PMID:20838651, PMID:33004486]","metadata":null},{"id":"15ff5a83cdae4a6a9b91940a64244213","type":"GO_TERM","name":"SAGA complex assembly","canonical_id":"go:GO:0036285","description":"\"The aggregation, arrangement and bonding together of a set of components to form a SAGA complex, a SAGA-type histone acetyltransferase complex that contains Spt8 (in budding yeast) or a homolog thereof.\" [GOC:mah, PMID:10637607, PMID:22456315]","metadata":null},{"id":"5a29812b25d94e33bd6d38e7a56032b2","type":"GO_TERM","name":"SAGA complex binding","canonical_id":"go:GO:0062070","description":"\"Binding to a SAGA complex.\" [PMID:27185460]","metadata":null},{"id":"b9160e96ab82445ba82731b48cf52716","type":"GO_TERM","name":"SAGA complex localization to transcription regulatory region","canonical_id":"go:GO:0072742","description":"\"Any process in which a SAGA complex is transported to, or maintained in, a specific location in the transcription regulatory region of a gene.\" [GOC:mah]","metadata":null},{"id":"3ea47d9833014b0fb9a4a548dd31cc69","type":"GO_TERM","name":"SAGA-type complex","canonical_id":"go:GO:0070461","description":"\"A histone acetyltransferase complex that acetylates nucleosomal histones H2B, H3, or H4 and is required for the expression of a subset of Pol II-transcribed genes. This complex includes the acetyltransferases GCN5/KAT2A or PCAF/KAT2B, several proteins of the ADA, SGF and SPT families, and several TBP-associate proteins (TAFs).\" [GOC:mah, PMID:10637607, PMID:17337012]","metadata":null},{"id":"9cc174656fac4651a3ba7a15cfd7d40c","type":"GENE","name":"SAGE1","canonical_id":"hgnc:HGNC:30369","description":"sarcoma antigen 1","metadata":{"aliases":["SAGE","CT14"]}},{"id":"733f4c8694e94ad1b765b09aa20566c1","type":"GENE","name":"SAGE2P","canonical_id":"hgnc:HGNC:51337","description":"sarcoma antigen 2, pseudogene","metadata":null},{"id":"e003922a0ebf4d31ba272320de964574","type":"GENE","name":"SAGE3P","canonical_id":"hgnc:HGNC:51338","description":"sarcoma antigen 3, pseudogene","metadata":null},{"id":"9979cd0bac4842c7a38628555b764292","type":"GENE","name":"SAGE4P","canonical_id":"hgnc:HGNC:51339","description":"sarcoma antigen 4, pseudogene","metadata":null},{"id":"20072aa67d184e468a1e0963e0655ff4","type":"TRIAL","name":"SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00787527","description":"Lymphoma","metadata":null},{"id":"2f7ff9304cd4454aabd8348fbaecdc77","type":"GENE","name":"SAILR","canonical_id":"hgnc:HGNC:52673","description":"survival associated immune regulatory RNA","metadata":{"aliases":["AC079767.4","LINC01857"]}},{"id":"e6cb732db6de431cb6fdad63db5341f9","type":"TRIAL","name":"SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","canonical_id":"clinicaltrials.gov:NCT05782192","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"d2baed9323fc45ffab8dba923ef6df10","type":"TRIAL","name":"SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05160896","description":"Advanced Metastatic Colorectal Cancer","metadata":null},{"id":"b63bf8fabc614020aed7836f8fe0811d","type":"GENE","name":"SALL1","canonical_id":"hgnc:HGNC:10524","description":"spalt like transcription factor 1","metadata":{"aliases":["Hsal1","ZNF794","TBS"]}},{"id":"aced134abe6b46648a0047ef5bd5a188","type":"GENE","name":"SALL1-AS1","canonical_id":"hgnc:HGNC:58539","description":"SALL1 antisense RNA 1","metadata":null},{"id":"9fda8676d7d84b26a4183bdf4341a3f2","type":"GENE","name":"SALL1P1","canonical_id":"hgnc:HGNC:10525","description":"spalt like transcription factor 1 pseudogene 1","metadata":{"aliases":["SALL1P"]}},{"id":"cddd29b5837e41f5820da80626bcf3a4","type":"GENE","name":"SALL2","canonical_id":"hgnc:HGNC:10526","description":null,"metadata":null},{"id":"6e0122ad4c1640f3b903d226ba5c7412","type":"GENE","name":"SALL3","canonical_id":"hgnc:HGNC:10527","description":null,"metadata":null},{"id":"94e1c73b021c413c99eab4a855d347b0","type":"GENE","name":"SALL4","canonical_id":"hgnc:HGNC:15924","description":null,"metadata":null},{"id":"c63f15c759054e5caa26fafc00dd4747","type":"GENE","name":"SALL4P1","canonical_id":"hgnc:HGNC:39818","description":"spalt like transcription factor 4 pseudogene 1","metadata":null},{"id":"06a4cd627bd44d8a8c66ea3c0294830f","type":"GENE","name":"SALL4P2","canonical_id":"hgnc:HGNC:39819","description":"spalt like transcription factor 4 pseudogene 2","metadata":null},{"id":"c53ff8b334e04c6090b44d5bac3bc2b5","type":"GENE","name":"SALL4P3","canonical_id":"hgnc:HGNC:39820","description":"spalt like transcription factor 4 pseudogene 3","metadata":null},{"id":"c5290362ffdb4c9db7fc47dd95bdec9a","type":"GENE","name":"SALL4P4","canonical_id":"hgnc:HGNC:39821","description":"spalt like transcription factor 4 pseudogene 4","metadata":null},{"id":"5798f20275c34cc48c9a8265b4e3f9de","type":"GENE","name":"SALL4P5","canonical_id":"hgnc:HGNC:39822","description":"spalt like transcription factor 4 pseudogene 5","metadata":null},{"id":"02ab7f3081f04503aabdd2af3a003ec0","type":"GENE","name":"SALL4P6","canonical_id":"hgnc:HGNC:39823","description":"spalt like transcription factor 4 pseudogene 6","metadata":null},{"id":"b3ed0619b4724db3b071cfa197c20cea","type":"GENE","name":"SALL4P7","canonical_id":"hgnc:HGNC:43900","description":"spalt like transcription factor 4 pseudogene 7","metadata":null},{"id":"84cef1aaa91c420bb1ff6a03f0d5bf96","type":"GENE","name":"SALRNA1","canonical_id":"hgnc:HGNC:49001","description":"senescence associated long non-coding RNA 1","metadata":{"aliases":["SAL-RNA1","XLOC_023166"]}},{"id":"9ab30816915643a6a171b44e7fca84f7","type":"GENE","name":"SALRNA2","canonical_id":"hgnc:HGNC:49003","description":"senescence associated long non-coding RNA 2","metadata":{"aliases":["SAL-RNA2","XLOC_025931"]}},{"id":"6e36a08d0ee3400389b4ea8fa59bb630","type":"GENE","name":"SALRNA3","canonical_id":"hgnc:HGNC:49002","description":"senescence associated long non-coding RNA 3","metadata":{"aliases":["SAL-RNA3","XLOC_025918"]}},{"id":"5d4bded1cdf843898de688f53a21e49f","type":"GO_TERM","name":"SAM complex","canonical_id":"go:GO:0001401","description":"\"A large complex of the mitochondrial outer membrane that mediates sorting of some imported proteins to the outer membrane and their assembly in the membrane; functions after import of incoming proteins by the mitochondrial outer membrane translocase complex.\" [PMID:12891361]","metadata":null},{"id":"1383145494304c7789138e4f74104c22","type":"GO_TERM","name":"SAM domain binding","canonical_id":"go:GO:0032093","description":"\"Binding to a SAM (Sterile Alpha Motif) domain, which is a 70-amino acid protein sequence that participates in protein-protein, protein-lipid, and protein-RNA interactions and is conserved from lower to higher eukaryotes.\" [GOC:mcc, PMID:16337230]","metadata":null},{"id":"91b703645ba54dd2a67d6831cf41de6c","type":"TRIAL","name":"SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin","canonical_id":"clinicaltrials.gov:NCT00486785","description":"Prostatic Hyperplasia","metadata":null},{"id":"218fb93824314a72a24a7d3158c3955a","type":"GENE","name":"SAMD1","canonical_id":"hgnc:HGNC:17958","description":"sterile alpha motif domain containing 1","metadata":null},{"id":"61793056897b4d81922ff6fb24bbe766","type":"GENE","name":"SAMD10","canonical_id":"hgnc:HGNC:16129","description":"sterile alpha motif domain containing 10","metadata":{"aliases":["C20orf136"]}},{"id":"69274a4788b74793b020212085beb5e0","type":"GENE","name":"SAMD11","canonical_id":"hgnc:HGNC:28706","description":"sterile alpha motif domain containing 11","metadata":{"aliases":["MGC45873"]}},{"id":"a72a684397394499bd48ac523d9f5ad1","type":"GENE","name":"SAMD11P1","canonical_id":"hgnc:HGNC:44473","description":"sterile alpha motif domain containing 11 pseudogene 1","metadata":null},{"id":"24a2584612484e49b921b485de0a3cf7","type":"GENE","name":"SAMD12","canonical_id":"hgnc:HGNC:31750","description":"sterile alpha motif domain containing 12","metadata":{"aliases":["FLJ39458"]}},{"id":"3cd600e89360404ebb18e279cd4d58d4","type":"GENE","name":"SAMD12-AS1","canonical_id":"hgnc:HGNC:30937","description":"SAMD12 antisense RNA 1","metadata":{"aliases":["C8orf26","NCRNA00252"]}},{"id":"bebc74ef21dd44439a43d4334de09beb","type":"GENE","name":"SAMD13","canonical_id":"hgnc:HGNC:24582","description":"sterile alpha motif domain containing 13","metadata":null},{"id":"f1dbe4bca76f48cc976a73f9908e6f10","type":"GENE","name":"SAMD14","canonical_id":"hgnc:HGNC:27312","description":"sterile alpha motif domain containing 14","metadata":{"aliases":["FLJ36890"]}},{"id":"6f3841dce4d24e1d8a635699e3969c59","type":"GENE","name":"SAMD15","canonical_id":"hgnc:HGNC:18631","description":"sterile alpha motif domain containing 15","metadata":{"aliases":["FLJ35963","FAM15A","C14orf174"]}},{"id":"5a19edc9e2894f0c9e5a6da73ee86106","type":"GENE","name":"SAMD3","canonical_id":"hgnc:HGNC:21574","description":"sterile alpha motif domain containing 3","metadata":{"aliases":["bA73O6.2","FLJ34032"]}},{"id":"feeb2f9b18fe4c948a719866c3920604","type":"GENE","name":"SAMD4A","canonical_id":"hgnc:HGNC:23023","description":null,"metadata":null},{"id":"68843d008eec4b56ba360240e68fa65a","type":"GENE","name":"SAMD4A-AS1","canonical_id":"hgnc:HGNC:54803","description":"SAMD4A antisense RNA 1","metadata":{"aliases":["lnc-GCH1-2:3"]}},{"id":"a4b6d9ba5e5c4c4a89c339ae750808bf","type":"GENE","name":"SAMD4B","canonical_id":"hgnc:HGNC:25492","description":"sterile alpha motif domain containing 4B","metadata":{"aliases":["FLJ10211","MGC99832","SMGB","hSmaug2"]}},{"id":"6f2aa1bfd0254993893a4243f7e71790","type":"GENE","name":"SAMD5","canonical_id":"hgnc:HGNC:21180","description":"sterile alpha motif domain containing 5","metadata":{"aliases":["dJ875H10.1"]}},{"id":"2c569dc6dfa04875b5744b4fdcf3cf25","type":"GENE","name":"SAMD7","canonical_id":"hgnc:HGNC:25394","description":"sterile alpha motif domain containing 7","metadata":{"aliases":["DKFZp686E1583"]}},{"id":"dfb0f5fd40c34a3c8d6dcfd6af5779bc","type":"GENE","name":"SAMD8","canonical_id":"hgnc:HGNC:26320","description":"sterile alpha motif domain containing 8","metadata":{"aliases":["FLJ25082","SMSr"]}},{"id":"1517fabddb34441d913c98d8b40bab57","type":"GENE","name":"SAMD9","canonical_id":"hgnc:HGNC:1348","description":"sterile alpha motif domain containing 9","metadata":{"aliases":["KIAA2004","FLJ20073","C7orf5"]}},{"id":"f10b7da88d3d4832a0d33e3f7892f492","type":"GENE","name":"SAMD9L","canonical_id":"hgnc:HGNC:1349","description":"sterile alpha motif domain containing 9 like","metadata":{"aliases":["KIAA2005","FLJ39885","C7orf6"]}},{"id":"59cef47ce4bf4768bdc64583a5a8135c","type":"GENE","name":"SAMHD1","canonical_id":"hgnc:HGNC:15925","description":"SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1","metadata":{"aliases":["SBBI88","Mg11","HDDC1","MOP-5","AGS5"]}},{"id":"dcf8d70f7bc140e09f9cbe131efa0791","type":"GENE","name":"SAMM50","canonical_id":"hgnc:HGNC:24276","description":"SAMM50 sorting and assembly machinery component","metadata":{"aliases":["CGI-51","TRG-3","YNL026W","OMP85","TOB55","SAM50"]}},{"id":"8d27fa23740549e8b5caa43bfe846114","type":"GENE","name":"SAMM50P1","canonical_id":"hgnc:HGNC:49778","description":"SAMM50 sorting and assembly machinery component pseudogene 1","metadata":null},{"id":"11c8135f8d454b02a6452b4cee268218","type":"GENE","name":"SAMMSON","canonical_id":"hgnc:HGNC:49644","description":"survival associated mitochondrial melanoma specific oncogenic non-coding RNA","metadata":{"aliases":["uc.116","LINC01212"]}},{"id":"c2740d74ee2841389007829416f5a677","type":"GENE","name":"SAMSN1","canonical_id":"hgnc:HGNC:10528","description":"SAM domain, SH3 domain and nuclear localization signals 1","metadata":{"aliases":["NASH1","SASH2","SH3D6B","HACS1","SLy2"]}},{"id":"c96a2014f7ee4af7aca5e880de95f641","type":"GENE","name":"SAMSN1-AS1","canonical_id":"hgnc:HGNC:39599","description":"SAMSN1 antisense RNA 1","metadata":null},{"id":"35291a97731549aa899855e3ef9b3683","type":"GENE","name":"SAMTOR","canonical_id":"hgnc:HGNC:26475","description":"S-adenosylmethionine sensor upstream of mTORC1","metadata":{"aliases":["DKFZp762M126","FLJ31818","BMT2","C7orf60"]}},{"id":"32f88c6245ca4dfcb51b8554b3618a6b","type":"GENE","name":"SANBR","canonical_id":"hgnc:HGNC:29387","description":"SANT and BTB domain regulator of CSR","metadata":{"aliases":["KIAA1841"]}},{"id":"f68428ff92864a6fbc5954af0e76ea5a","type":"GENE","name":"SAP130","canonical_id":"hgnc:HGNC:29813","description":"Sin3A associated protein 130","metadata":{"aliases":["FLJ12761"]}},{"id":"6d5e387fe0064c10b1ae37ddb09f52a5","type":"GENE","name":"SAP18","canonical_id":"hgnc:HGNC:10530","description":"Sin3A associated protein 18","metadata":{"aliases":["SAP18p","2HOR0202","MGC27131"]}},{"id":"4294504d23ea46589e614cb35379efbb","type":"GENE","name":"SAP18P1","canonical_id":"hgnc:HGNC:51567","description":"SAP18 pseudogene 1","metadata":null},{"id":"5fe729af293b4169befcd03fff9fe796","type":"GENE","name":"SAP18P2","canonical_id":"hgnc:HGNC:51568","description":"SAP18 pseudogene 2","metadata":null},{"id":"6830a35130b54bc0bbd63f3683370f18","type":"GENE","name":"SAP18P3","canonical_id":"hgnc:HGNC:51569","description":"SAP18 pseudogene 3","metadata":null},{"id":"2a5a1252c7e1479da3307922ab7d5c08","type":"GENE","name":"SAP25","canonical_id":"hgnc:HGNC:41908","description":"Sin3A associated protein 25","metadata":{"aliases":["FLJ00248"]}},{"id":"234653a32c5341869ac6b67bd2e403e2","type":"GENE","name":"SAP30","canonical_id":"hgnc:HGNC:10532","description":null,"metadata":null},{"id":"a91dd886902f473da41c5054dd6cf298","type":"GENE","name":"SAP30-DT","canonical_id":"hgnc:HGNC:54424","description":"SAP30 divergent transcript","metadata":{"aliases":["ENST00000608794","MIRE"]}},{"id":"a343e12672f84366a8fce1fef1dabaa7","type":"GENE","name":"SAP30BP","canonical_id":"hgnc:HGNC:30785","description":"SAP30 binding protein","metadata":{"aliases":["HCNGP","HTRG","HTRP"]}},{"id":"ee09a8f278d34ab2b9550797a2ff7ec6","type":"GENE","name":"SAP30BP-AS1","canonical_id":"hgnc:HGNC:56751","description":"SAP30BP antisense RNA 1","metadata":null},{"id":"dbd507a83da4408296810336a33b9f05","type":"GENE","name":"SAP30L","canonical_id":"hgnc:HGNC:25663","description":"SAP30 like","metadata":{"aliases":["FLJ11526","NS4ATP2"]}},{"id":"4e78a9572c694875a40ea441d3e5407e","type":"GENE","name":"SAP30L-AS1","canonical_id":"hgnc:HGNC:26760","description":"SAP30L and GALNT10 antisense RNA 1","metadata":{"aliases":["FLJ38109","GALNT10-AS1"]}},{"id":"1ed93fac2e5641918e3e6f1f1f0fe6f7","type":"GENE","name":"SAP30P1","canonical_id":"hgnc:HGNC:56560","description":"SAP30 pseudogene 1","metadata":null},{"id":"4dc8436bdfc7429689e05b1244450883","type":"GENE","name":"SAPCD1","canonical_id":"hgnc:HGNC:13938","description":"suppressor APC domain containing 1","metadata":{"aliases":["NG23","C6orf26"]}},{"id":"6d1b68240dd34c70855d4c16067e0229","type":"GENE","name":"SAPCD1-AS1","canonical_id":"hgnc:HGNC:39824","description":"SAPCD1 antisense RNA 1","metadata":{"aliases":["C6orf26-AS1"]}},{"id":"96261c370e2446feb097ad381a5b3c60","type":"GENE","name":"SAPCD2","canonical_id":"hgnc:HGNC:28055","description":"suppressor APC domain containing 2","metadata":{"aliases":["p42.3","C9orf140"]}},{"id":"f5faef64bc9647bcbe63a9101b58d784","type":"GENE","name":"SAPCD2P1","canonical_id":"hgnc:HGNC:51277","description":"suppressor APC domain containing 2 pseudogene 1","metadata":null},{"id":"c5f996e2df504cff8fe78e0fc3b57095","type":"GENE","name":"SAPCD2P2","canonical_id":"hgnc:HGNC:51278","description":"suppressor APC domain containing 2 pseudogene 2","metadata":null},{"id":"dd0d0679bfa54d6291dc1431a1e57afb","type":"GENE","name":"SAPCD2P3","canonical_id":"hgnc:HGNC:51279","description":"suppressor APC domain containing 2 pseudogene 3","metadata":null},{"id":"e0946641c07d4da580a8d544795442d1","type":"GENE","name":"SAPCD2P4","canonical_id":"hgnc:HGNC:51280","description":"suppressor APC domain containing 2 pseudogene 4","metadata":null},{"id":"b2b1ef32481842468e7668fd0cb33eb5","type":"GENE","name":"SAR1A","canonical_id":"hgnc:HGNC:10534","description":"secretion associated Ras related GTPase 1A","metadata":{"aliases":["SAR1","Sara","SARA1"]}},{"id":"892cf972ea9946c993ed1b2dd5a3399f","type":"GENE","name":"SAR1AP1","canonical_id":"hgnc:HGNC:13983","description":"secretion associated Ras related GTPase 1A pseudogene 1","metadata":{"aliases":["hsSARA-p","SARAP1","dJ88J8.3","SARAP","SAR1P1"]}},{"id":"d6273848186c4346907acd15c0d171df","type":"GENE","name":"SAR1AP2","canonical_id":"hgnc:HGNC:20770","description":"secretion associated Ras related GTPase 1A pseudogene 2","metadata":{"aliases":["Em:AC026226.2","SARA1P","SAR1P2"]}},{"id":"bf4b64a2e06540e1a7869fb47fdd07f5","type":"GENE","name":"SAR1AP3","canonical_id":"hgnc:HGNC:32317","description":"secretion associated Ras related GTPase 1A pseudogene 3","metadata":{"aliases":["SAR1P3"]}},{"id":"e771d44f2d464ad3a53a3a1c30238f05","type":"GENE","name":"SAR1AP4","canonical_id":"hgnc:HGNC:37638","description":"secretion associated Ras related GTPase 1A pseudogene 4","metadata":null},{"id":"016beda40590403787863045e1773eb5","type":"GENE","name":"SAR1B","canonical_id":"hgnc:HGNC:10535","description":"secretion associated Ras related GTPase 1B","metadata":{"aliases":["SARA2"]}},{"id":"266c7ddbd76141de8cce813984920704","type":"TRIAL","name":"SAR231893-LPS15497- \"Dupilumab Effect on Sleep in AD Patients\"","canonical_id":"clinicaltrials.gov:NCT04033367","description":"Atopic Dermatitis","metadata":null},{"id":"2f8d46ae604e49478cf417fcacd437ca","type":"TRIAL","name":"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","canonical_id":"clinicaltrials.gov:NCT01749969","description":"Plasma Cell Myeloma","metadata":null},{"id":"bedcd910406c4dadbafd95037e666aaf","type":"GENE","name":"SARAF","canonical_id":"hgnc:HGNC:28789","description":"store-operated calcium entry associated regulatory factor","metadata":{"aliases":["MGC8721","TMEM66"]}},{"id":"d6862c418f044dadb842376e3327c301","type":"GENE","name":"SARDH","canonical_id":"hgnc:HGNC:10536","description":"sarcosine dehydrogenase","metadata":{"aliases":["SDH","DMGDHL1"]}},{"id":"4a0837873fef4fa1b3858a24a45218bb","type":"GENE","name":"SARM1","canonical_id":"hgnc:HGNC:17074","description":"sterile alpha and TIR motif containing 1","metadata":{"aliases":["SARM","SAMD2","KIAA0524"]}},{"id":"edb5b23ba80948c281effb989c3fe832","type":"GENE","name":"SARNP","canonical_id":"hgnc:HGNC:24432","description":"SAP domain containing ribonucleoprotein","metadata":{"aliases":["THO1","Hcc-1","CIP29"]}},{"id":"71f6e99a5296442da9bd4b379d061cb2","type":"PROTEIN","name":"SARS-CoV-2 main protease","canonical_id":"uniprot:P0DTD1","description":null,"metadata":null},{"id":"d0629b56302c48c6997e833e38e24421","type":"GENE","name":"SARS1","canonical_id":"hgnc:HGNC:10537","description":"seryl-tRNA synthetase 1","metadata":{"aliases":["SERS","SARS"]}},{"id":"55b8a8acfdcf406ab7eaafc0e92a7e9c","type":"GENE","name":"SARS2","canonical_id":"hgnc:HGNC:17697","description":"seryl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["FLJ20450","mtSerRS","SerRSmt","SARS","SERS","SYS","SARSM"]}},{"id":"c34a3d64b1724d218870cb0add618814","type":"GENE","name":"SART1","canonical_id":"hgnc:HGNC:10538","description":"spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP","metadata":{"aliases":["Ara1","Snu66","SNRNP110","HAF"]}},{"id":"97ce1e35694c448383784beb1958a945","type":"GENE","name":"SART3","canonical_id":"hgnc:HGNC:16860","description":null,"metadata":null},{"id":"443361669edc45a68dffad8ea83615f0","type":"GO_TERM","name":"SAS acetyltransferase complex","canonical_id":"go:GO:0033255","description":"\"A protein complex that possesses histone acetyltransferase activity and links histone acetylation to the assembly of transcriptionally silent chromatin. In vitro, the complex acetylates lysine 16 of histone H4 and lysine 14 of histone H3, although the latter may not be relevant in vivo. The complex contains a catalytic subunit and at least two other subunits; in Saccharomyces, the catalytic subunit is Sas2p and additional subunits are Sas4p and Sas5p.\" [PMID:11731480, PMID:12626510, PMID:15788653]","metadata":null},{"id":"1926c0653f964a99b17f1f34a765c897","type":"GENE","name":"SASH1","canonical_id":"hgnc:HGNC:19182","description":"SAM and SH3 domain containing 1","metadata":{"aliases":["KIAA0790","dJ323M4.1","SH3D6A"]}},{"id":"3becf8463dc8418c905c98ceef93f489","type":"GENE","name":"SASH3","canonical_id":"hgnc:HGNC:15975","description":"SAM and SH3 domain containing 3","metadata":{"aliases":["SLY","753P9","SH3D6C","HACS2","CXorf9"]}},{"id":"4c8ec54becd345629a69a7929c957cc9","type":"GENE","name":"SASS6","canonical_id":"hgnc:HGNC:25403","description":"SAS-6 centriolar assembly protein","metadata":{"aliases":["DKFZp761A078","SAS-6","FLJ22097","SAS6"]}},{"id":"d3c4e0c5be084e7496a6208fd88434c0","type":"GENE","name":"SAT1","canonical_id":"hgnc:HGNC:10540","description":null,"metadata":null},{"id":"4cb65aa8524e48ab9d6b710b92e5ec07","type":"GENE","name":"SAT1-DT","canonical_id":"hgnc:HGNC:56726","description":"SAT1 divergent transcript","metadata":{"aliases":["lnc-ACOT9-1"]}},{"id":"7ff4c88f20e6489b9f4995acbf6faa2b","type":"GENE","name":"SAT2","canonical_id":"hgnc:HGNC:23160","description":"spermidine/spermine N1-acetyltransferase family member 2","metadata":{"aliases":["SSAT2"]}},{"id":"0b20658b333a48ba9c98d00255154841","type":"GENE","name":"SATB1","canonical_id":"hgnc:HGNC:10541","description":null,"metadata":null},{"id":"e3048ce29d1b48319f7cdd19bdbe4786","type":"GENE","name":"SATB1-AS1","canonical_id":"hgnc:HGNC:50687","description":"SATB1 antisense RNA 1","metadata":{"aliases":["uc.114","uc.113"]}},{"id":"9156678361cb4667b027c9d5fbabf3e6","type":"GENE","name":"SATB2","canonical_id":"hgnc:HGNC:21637","description":null,"metadata":null},{"id":"9b98cab42f28464185af3c8d709809b6","type":"GENE","name":"SATB2-AS1","canonical_id":"hgnc:HGNC:26490","description":"SATB2 antisense RNA 1","metadata":null},{"id":"8d2992dd56f347b28836015de40c7731","type":"GENE","name":"SATL1","canonical_id":"hgnc:HGNC:27992","description":"spermidine/spermine N1-acetyl transferase like 1","metadata":null},{"id":"4117c37c860949b6baf3485258b08983","type":"GENE","name":"SAV1","canonical_id":"hgnc:HGNC:17795","description":"salvador family WW domain containing protein 1","metadata":{"aliases":["WW45","WWP4","salvador"]}},{"id":"d6da5c5bb0e644f9998c072e06524f61","type":"GENE","name":"SAXO1","canonical_id":"hgnc:HGNC:28566","description":"stabilizer of axonemal microtubules 1","metadata":{"aliases":["MGC35182","C9orf138","FAM154A"]}},{"id":"5df9e71cf8e64d148d3509bb8f812839","type":"GENE","name":"SAXO2","canonical_id":"hgnc:HGNC:33727","description":"stabilizer of axonemal microtubules 2","metadata":{"aliases":["DKFZp666G057","FAM154B"]}},{"id":"563a92422c624457ac0ff2eab53ec25b","type":"GENE","name":"SAXO3","canonical_id":"hgnc:HGNC:56771","description":"stabilizer of axonemal microtubules 3","metadata":null},{"id":"b9bb48c7921342fda46fee3ed6c737b3","type":"GENE","name":"SAXO4","canonical_id":"hgnc:HGNC:28869","description":"stabilizer of axonemal microtubules 4","metadata":{"aliases":["IIIG9","FLJ32771","C11orf66","PPP1R32"]}},{"id":"103074a9bcb84c24a139abd4c1418bcf","type":"GENE","name":"SAXO5","canonical_id":"hgnc:HGNC:24745","description":"stabilizer of axonemal microtubules 5","metadata":{"aliases":["FLJ35784","C19orf45","TEX45"]}},{"id":"edaec1211e36420bbd7b5c68575909a7","type":"GENE","name":"SAXO6","canonical_id":"hgnc:HGNC:29917","description":"stabilizer of axonemal microtubules 6","metadata":{"aliases":["MDM1"]}},{"id":"a700e061627c4e088e01ee0a252fe958","type":"GENE","name":"SAYSD1","canonical_id":"hgnc:HGNC:21025","description":"SAYSVFN motif domain containing 1","metadata":{"aliases":["FLJ11101","C6orf64"]}},{"id":"e42d80180fdd42fba39ae63812724936","type":"TRIAL","name":"SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients","canonical_id":"clinicaltrials.gov:NCT03126461","description":"Melanoma; Metastatic Melanoma","metadata":null},{"id":"99663859d6ff4bc7bf4727000c0a83b5","type":"GENE","name":"SBDS","canonical_id":"hgnc:HGNC:19440","description":"SBDS ribosome maturation factor","metadata":{"aliases":["CGI-97","FLJ10917","SDS","SWDS","SDO1"]}},{"id":"1b239353110a453b91f89bd352942300","type":"GENE","name":"SBDSP1","canonical_id":"hgnc:HGNC:21646","description":"SBDS pseudogene 1","metadata":{"aliases":["SBDSP"]}},{"id":"c61a3e30f33d40feb84ad17f073863c4","type":"GO_TERM","name":"SBF transcription complex","canonical_id":"go:GO:0033309","description":"\"A protein complex that binds to the Swi4/6 cell cycle box (SCB) promoter element, consensus sequence CRCGAAA, and activates transcription during the G1/S transition of the cell cycle. In Saccharomyces, the complex contains a heterodimer of the DNA binding protein Swi4p and the activator Swi6p, and is associated with additional proteins known as Whi5p and Msa1p.\" [GOC:mah, PMID:11206552, PMID:15838511, PMID:18160399, PMID:19150335, PMID:7917338]","metadata":null},{"id":"9777821a107b4d39becd8b8027659fb5","type":"GENE","name":"SBF1","canonical_id":"hgnc:HGNC:10542","description":"SET binding factor 1","metadata":{"aliases":["MTMR5","DENND7A"]}},{"id":"394d8ca7f198467ca34e62b7f627d296","type":"GENE","name":"SBF1P1","canonical_id":"hgnc:HGNC:31098","description":"SET binding factor 1 pseudogene 1","metadata":null},{"id":"2f052f205e4540378dc224ba5b51b818","type":"GENE","name":"SBF1P2","canonical_id":"hgnc:HGNC:54552","description":"SBF1 pseudogene 2","metadata":null},{"id":"a555db7068774f2aba6ea5e71134d979","type":"GENE","name":"SBF2","canonical_id":"hgnc:HGNC:2135","description":"SET binding factor 2","metadata":{"aliases":["KIAA1766","MTMR13","DENND7B","CMT4B2"]}},{"id":"97c0ff6603ab47258b21dbfc74f5beba","type":"GENE","name":"SBF2-AS1","canonical_id":"hgnc:HGNC:27438","description":"SBF2 antisense RNA 1","metadata":null},{"id":"fb7ed8e69d3d4e1988cc651f45edb728","type":"GENE","name":"SBK1","canonical_id":"hgnc:HGNC:17699","description":"SH3 domain binding kinase 1","metadata":{"aliases":["Sbk"]}},{"id":"7757b3214dc24a18bb8196d7b303ea7c","type":"GENE","name":"SBK2","canonical_id":"hgnc:HGNC:34416","description":"SH3 domain binding kinase family member 2","metadata":{"aliases":["SGK069"]}},{"id":"3b611797a0874e7abcf33064cea8889c","type":"GENE","name":"SBK3","canonical_id":"hgnc:HGNC:44121","description":"SH3 domain binding kinase family member 3","metadata":{"aliases":["SgK110"]}},{"id":"ec13db014a0748ab861185722c4b43f2","type":"GENE","name":"SBNO1","canonical_id":"hgnc:HGNC:22973","description":"strawberry notch homolog 1","metadata":{"aliases":["MOP3","FLJ10701","FLJ10833","Sno"]}},{"id":"086870021f6049e6b95a0853619d74e9","type":"GENE","name":"SBNO1-AS1","canonical_id":"hgnc:HGNC:54355","description":"SBNO1 antisense RNA 1","metadata":null},{"id":"6dd5a976d19e44c39305f32c9991b733","type":"GENE","name":"SBNO2","canonical_id":"hgnc:HGNC:29158","description":"strawberry notch homolog 2","metadata":{"aliases":["FLJ00173","Stno","Sno","KIAA0963"]}},{"id":"810aef21af6945229c9cda18fbae2384","type":"TRIAL","name":"SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy","canonical_id":"clinicaltrials.gov:NCT05990192","description":"Ovarian Cancer Recurrent","metadata":null},{"id":"de0c4d8761554bcc8aaa7f99d9a02869","type":"TRIAL","name":"SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC","canonical_id":"clinicaltrials.gov:NCT05732662","description":"Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"708528fc63fa403c9b01f8ea4842fc6a","type":"TRIAL","name":"SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT03050554","description":"Early Stage Non-Small Cell Lung Cancer","metadata":null},{"id":"cfc17043c6844a5a9b7a7e219dac01c8","type":"TRIAL","name":"SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC","canonical_id":"clinicaltrials.gov:NCT05747716","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"789159219b1b4a96bc24bd9180934130","type":"TRIAL","name":"SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases","canonical_id":"clinicaltrials.gov:NCT06940921","description":"Advanced Gastric Cancer; Advanced Colorectal Cancer; Advanced Ovarian Cancer; Peritoneal Metastasis","metadata":null},{"id":"ca38faa2abf3498290004f2a410bf12d","type":"GENE","name":"SBSN","canonical_id":"hgnc:HGNC:24950","description":"suprabasin","metadata":{"aliases":["UNQ698","HLAR698"]}},{"id":"189d3592cad9405d9f2213b4178ae19c","type":"GENE","name":"SBSPON","canonical_id":"hgnc:HGNC:30362","description":"somatomedin B and thrombospondin type 1 domain containing","metadata":{"aliases":["RPESP","C8orf84"]}},{"id":"97958af3d4c746de9f522ee93ddb0402","type":"GENE","name":"SC4MOP","canonical_id":"hgnc:HGNC:10546","description":"sterol-C4-methyl oxidase pseudogene","metadata":{"aliases":["DESP4P1"]}},{"id":"529298bbc8b04fb5bbeb12ca4c2e94e4","type":"GENE","name":"SC5D","canonical_id":"hgnc:HGNC:10547","description":"sterol-C5-desaturase","metadata":{"aliases":["SC5DL"]}},{"id":"b470d970bc1946c19a22b470d918989f","type":"GO_TERM","name":"SC5b-7 complex","canonical_id":"go:GO:0034995","description":"\"A protein complex that consist of complement components C5b6 and C7 stably inserted in a cell membrane. Formation of the SC5b-7 complex is the first phase of membrane attack complex assembly.\" [PMID:10090939]","metadata":null},{"id":"4c3f99148603495394b0b0448cfeb922","type":"GENE","name":"SCAANT1","canonical_id":"hgnc:HGNC:43718","description":"SCA7/ATXN7 antisense RNA 1","metadata":{"aliases":["ATXN7-AS1"]}},{"id":"caa722f3abff41659502bbf15b35a364","type":"GENE","name":"SCAF1","canonical_id":"hgnc:HGNC:30403","description":"SR-related CTD associated factor 1","metadata":{"aliases":["SR-A1","FLJ00034"]}},{"id":"dfbf73b240f94bb2b7709e9f0f4765df","type":"GENE","name":"SCAF11","canonical_id":"hgnc:HGNC:10784","description":"SR-related CTD associated factor 11","metadata":{"aliases":["SIP1","SRRP129","CASP11","SFRS2IP","SRSF2IP"]}},{"id":"cf8cc6309c5b4d4bbc8c7d8f6519152e","type":"GENE","name":"SCAF4","canonical_id":"hgnc:HGNC:19304","description":"SR-related CTD associated factor 4","metadata":{"aliases":["KIAA1172","DKFZp434E098","SRA4","SFRS15"]}},{"id":"e6ac2bdf9b334505b2975ddea64dee45","type":"GENE","name":"SCAF8","canonical_id":"hgnc:HGNC:20959","description":"SR-related CTD associated factor 8","metadata":{"aliases":["KIAA1116","RBM16"]}},{"id":"4e864a5c69304a6f8da189652080b8e4","type":"GENE","name":"SCAI","canonical_id":"hgnc:HGNC:26709","description":null,"metadata":null},{"id":"b26b3d7129e148629c8562a5f8aeecd9","type":"TRIAL","name":"SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity","canonical_id":"clinicaltrials.gov:NCT04775082","description":"Obesity","metadata":null},{"id":"7a20e3ce025b42c7a32c3b04afa7bcc3","type":"GENE","name":"SCAMP1","canonical_id":"hgnc:HGNC:10563","description":"secretory carrier membrane protein 1","metadata":{"aliases":["SCAMP37"]}},{"id":"9ea9a81f8d1442d2816c058beb4e09e5","type":"GENE","name":"SCAMP1-AS1","canonical_id":"hgnc:HGNC:50544","description":"SCAMP1 antisense RNA 1","metadata":null},{"id":"88f66a97619346ccb13c821882202022","type":"GENE","name":"SCAMP2","canonical_id":"hgnc:HGNC:10564","description":"secretory carrier membrane protein 2","metadata":null},{"id":"dbdb27aef3f043ff977ee4f3aa1b1ccd","type":"GENE","name":"SCAMP3","canonical_id":"hgnc:HGNC:10565","description":"secretory carrier membrane protein 3","metadata":{"aliases":["C1orf3"]}},{"id":"7386e48bb9704f23bff76a3639e4d2bb","type":"GENE","name":"SCAMP4","canonical_id":"hgnc:HGNC:30385","description":"secretory carrier membrane protein 4","metadata":{"aliases":["FLJ33847"]}},{"id":"c6946e7d39eb45b59bcc2df5390c3235","type":"GENE","name":"SCAMP5","canonical_id":"hgnc:HGNC:30386","description":"secretory carrier membrane protein 5","metadata":{"aliases":["MGC24969"]}},{"id":"025ce7a845cb471da36c158c186a563a","type":"GENE","name":"SCAND1","canonical_id":"hgnc:HGNC:10566","description":null,"metadata":null},{"id":"3d4d28fdb3924385b09749a9a7a2569e","type":"GENE","name":"SCAND2P","canonical_id":"hgnc:HGNC:10567","description":"SCAN domain containing 2 pseudogene","metadata":{"aliases":["SCAND2"]}},{"id":"7874e325bf1f4b9dad14921c3881d383","type":"GENE","name":"SCAND3","canonical_id":"hgnc:HGNC:13851","description":"SCAN domain containing 3","metadata":{"aliases":["ZFP38-L","KIAA1925","FLJ31087","Buster4","FAM200D","ZNF305P2","ZNF452","ZBED9"]}},{"id":"d89bc99feec841ca84119feecc36097a","type":"GENE","name":"SCAND3-AS1","canonical_id":"hgnc:HGNC:55596","description":"SCAND3 antisense RNA 1","metadata":{"aliases":["ZBED9-AS1"]}},{"id":"e06df3332fe74f3d8c541b3d11acccbc","type":"GENE","name":"SCAND3P1","canonical_id":"hgnc:HGNC:42037","description":"SCAND3 pseudogene 1","metadata":{"aliases":["SCAND3P1","ZBED9P1"]}},{"id":"eaa92ba74b4a4c628a24506011a252f2","type":"GENE","name":"SCAP","canonical_id":"hgnc:HGNC:30634","description":"SREBF chaperone","metadata":{"aliases":["KIAA0199"]}},{"id":"39f23989f1db41638bb54bf5a3bce495","type":"GENE","name":"SCAPER","canonical_id":"hgnc:HGNC:13081","description":"S-phase cyclin A associated protein in the ER","metadata":{"aliases":["Zfp291","ZNF291"]}},{"id":"7a16dd0255f94c53b9e04048e730bac1","type":"GO_TERM","name":"SCAR complex","canonical_id":"go:GO:0031209","description":"\"A pentameric complex that includes orthologues of human PIR121, Nap1, Abi, SCAR, and HSPC300 and regulates actin polymerization and/or depolymerization through small GTPase mediated signal transduction.\" [GOC:hla, GOC:pg, PMID:12181570, PMID:24036345, PMID:24630101]","metadata":null},{"id":"02c19fb326df4a36a83617b4bbffefd3","type":"GENE","name":"SCARA3","canonical_id":"hgnc:HGNC:19000","description":"scavenger receptor class A member 3","metadata":{"aliases":["CSR1","CSR","MSLR1","APC7","MSRL1"]}},{"id":"6977e3ab72d44764a44240636dcb10fc","type":"GENE","name":"SCARA5","canonical_id":"hgnc:HGNC:28701","description":"scavenger receptor class A member 5","metadata":{"aliases":["FLJ23907","MGC45780","NET33"]}},{"id":"059961db8e29494991c04f71b782f9de","type":"GENE","name":"SCARB1","canonical_id":"hgnc:HGNC:1664","description":null,"metadata":null},{"id":"3df0dffa5a03423c8e0b7eceed39275b","type":"GENE","name":"SCARB2","canonical_id":"hgnc:HGNC:1665","description":null,"metadata":null},{"id":"60fc3b82817a490a8d7cf2208b570e33","type":"GENE","name":"SCARF1","canonical_id":"hgnc:HGNC:16820","description":null,"metadata":null},{"id":"838a2c142bf349efa0782139d777c434","type":"GENE","name":"SCARF2","canonical_id":"hgnc:HGNC:19869","description":"scavenger receptor class F member 2","metadata":{"aliases":["SREC-II","SREC2","HUMZD58C02"]}},{"id":"9abd3890c5bf4b22a9c620511e727da6","type":"GENE","name":"SCARNA1","canonical_id":"hgnc:HGNC:32555","description":"small Cajal body-specific RNA 1","metadata":{"aliases":["ACA35"]}},{"id":"7ae2f826db7d4c4f87816899807bd3e2","type":"GENE","name":"SCARNA10","canonical_id":"hgnc:HGNC:32567","description":"small Cajal body-specific RNA 10","metadata":{"aliases":["U85","lnc","MBI","52"]}},{"id":"5cab06e23004463fb2450fdb3ff8a34b","type":"GENE","name":"SCARNA11","canonical_id":"hgnc:HGNC:32568","description":"small Cajal body-specific RNA 11","metadata":{"aliases":["ACA57"]}},{"id":"f6635326f2f94244a035ed213c480f87","type":"GENE","name":"SCARNA12","canonical_id":"hgnc:HGNC:32569","description":"small Cajal body-specific RNA 12","metadata":{"aliases":["U89"]}},{"id":"67eaea5267644ba8b1c69608910f3468","type":"GENE","name":"SCARNA13","canonical_id":"hgnc:HGNC:32570","description":"small Cajal body-specific RNA 13","metadata":{"aliases":["U93"]}},{"id":"50d32628e51642da9d636bbbd8b9f562","type":"GENE","name":"SCARNA14","canonical_id":"hgnc:HGNC:32571","description":"small Cajal body-specific RNA 14","metadata":{"aliases":["U100"]}},{"id":"a2f441135f854ed6bcfde9576ee56e38","type":"GENE","name":"SCARNA15","canonical_id":"hgnc:HGNC:32572","description":"small Cajal body-specific RNA 15","metadata":{"aliases":["ACA45"]}},{"id":"d815362ef54e43b2b705056a6f0ec6f3","type":"GENE","name":"SCARNA16","canonical_id":"hgnc:HGNC:32573","description":"small Cajal body-specific RNA 16","metadata":{"aliases":["ACA47"]}},{"id":"1d0890405f3a4962a6f65eab2b26984f","type":"GENE","name":"SCARNA17","canonical_id":"hgnc:HGNC:32574","description":"small Cajal body-specific RNA 17","metadata":{"aliases":["mgU12-22/U4-8","U91"]}},{"id":"99755f82e95f441fbd3568d1ce4c523e","type":"GENE","name":"SCARNA18","canonical_id":"hgnc:HGNC:32559","description":"small Cajal body-specific RNA 18","metadata":{"aliases":["U109","SCARNA18A"]}},{"id":"25ba863e994548ebb2e287dc148a80c4","type":"GENE","name":"SCARNA18B","canonical_id":"hgnc:HGNC:52236","description":"small Cajal body-specific RNA 18B","metadata":null},{"id":"89055400e53c442cbb07e34ff214643c","type":"GENE","name":"SCARNA2","canonical_id":"hgnc:HGNC:32558","description":"small Cajal body-specific RNA 2","metadata":{"aliases":["mgU2-25/61","HBII-382"]}},{"id":"4d5e90a1b9b04a369d6377d963f811dc","type":"GENE","name":"SCARNA20","canonical_id":"hgnc:HGNC:32578","description":"small Cajal body-specific RNA 20","metadata":{"aliases":["ACA66"]}},{"id":"fe6881c151234b57b9738e678b07f4e8","type":"GENE","name":"SCARNA21","canonical_id":"hgnc:HGNC:32579","description":"small Cajal body-specific RNA 21","metadata":{"aliases":["ACA68","SCARNA21A"]}},{"id":"36b78be0db4140f3bd3ab785e3581736","type":"GENE","name":"SCARNA21B","canonical_id":"hgnc:HGNC:52237","description":"small Cajal body-specific RNA 21B","metadata":null},{"id":"7222dc7a0c2f4869a24593f47d6be713","type":"GENE","name":"SCARNA22","canonical_id":"hgnc:HGNC:32580","description":"small Cajal body-specific RNA 22","metadata":{"aliases":["ACA11"]}},{"id":"e90b9cd3c9fd491e91d8b9548982ce13","type":"GENE","name":"SCARNA23","canonical_id":"hgnc:HGNC:32581","description":"small Cajal body-specific RNA 23","metadata":{"aliases":["scaRNA24","ACA12"]}},{"id":"0e2a9adb5dce498b87cf61b55577db47","type":"GENE","name":"SCARNA26A","canonical_id":"hgnc:HGNC:50385","description":"small Cajal body-specific RNA 26A","metadata":null},{"id":"4c41e908a232436889a49170c0062360","type":"GENE","name":"SCARNA26B","canonical_id":"hgnc:HGNC:51394","description":"small Cajal body-specific RNA 26B","metadata":null},{"id":"29bd4e7399704bf99373e1d5f888e3c1","type":"GENE","name":"SCARNA27","canonical_id":"hgnc:HGNC:33614","description":"small Cajal body-specific RNA 27","metadata":null},{"id":"43fec24da7874a8482fdf0108a19ee10","type":"GENE","name":"SCARNA28","canonical_id":"hgnc:HGNC:50388","description":"small Cajal body-specific RNA 28","metadata":{"aliases":["ZL1"]}},{"id":"2e99365215ad442f95322e6b033a4975","type":"GENE","name":"SCARNA3","canonical_id":"hgnc:HGNC:32577","description":"small Cajal body-specific RNA 3","metadata":{"aliases":["scaRNA25","HBI-100"]}},{"id":"5ebcb70cbd9a463c830360eacccf1544","type":"GENE","name":"SCARNA4","canonical_id":"hgnc:HGNC:32560","description":"small Cajal body-specific RNA 4","metadata":{"aliases":["ACA26"]}},{"id":"9621b6b4b7d44e7cb173c7f00dcb7538","type":"GENE","name":"SCARNA5","canonical_id":"hgnc:HGNC:32561","description":"small Cajal body-specific RNA 5","metadata":{"aliases":["U87"]}},{"id":"ba3345a45ff742389fccd8a900b0147e","type":"GENE","name":"SCARNA6","canonical_id":"hgnc:HGNC:32562","description":"small Cajal body-specific RNA 6","metadata":{"aliases":["U88"]}},{"id":"6797be9671ee4ce9ae2dd903bf18dd8f","type":"GENE","name":"SCARNA7","canonical_id":"hgnc:HGNC:32563","description":"small Cajal body-specific RNA 7","metadata":{"aliases":["U90"]}},{"id":"1d8b76ea43f847308dbdd443c4db978b","type":"GENE","name":"SCARNA8","canonical_id":"hgnc:HGNC:32564","description":"small Cajal body-specific RNA 8","metadata":{"aliases":["U92"]}},{"id":"249d762be3b54742a54ec3bfe1ad0d7c","type":"GENE","name":"SCARNA9","canonical_id":"hgnc:HGNC:32566","description":"small Cajal body-specific RNA 9","metadata":{"aliases":["mgU2-19/30","Z32","lncC11orf54-1"]}},{"id":"621b56b78c214a03a15acf2cb0a637d2","type":"GENE","name":"SCARNA9L","canonical_id":"hgnc:HGNC:33559","description":"small Cajal body-specific RNA 9 like","metadata":null},{"id":"103bd43cf0354f48bed03acad4abbd98","type":"GENE","name":"SCART1","canonical_id":"hgnc:HGNC:32411","description":"scavenger receptor family member expressed on T cells 1","metadata":{"aliases":["CD163c-alpha"]}},{"id":"eddfcb5cec6e4669ada0a815c21dfb47","type":"GENE","name":"SCAT1","canonical_id":"hgnc:HGNC:52930","description":"S-phase cancer associated transcript 1","metadata":{"aliases":["CTD-2357A8.3","XLOC_012582","LINC02081"]}},{"id":"aae34471cfcf4efeb5ea50918aa46fc2","type":"GENE","name":"SCAT2","canonical_id":"hgnc:HGNC:53976","description":"S-phase cancer associated transcript 2","metadata":{"aliases":["CBX5-AS1","AC078778.1"]}},{"id":"d68ad6a501c54beebe91d0fc4e2c6cfc","type":"GENE","name":"SCAT8","canonical_id":"hgnc:HGNC:40967","description":"S-phase cancer associated transcript 8","metadata":{"aliases":["EYS-AS1"]}},{"id":"3a0ba21a4e8e4ee3b67ef9172d1c62bd","type":"GENE","name":"SCCPDH","canonical_id":"hgnc:HGNC:24275","description":"saccharopine dehydrogenase (putative)","metadata":{"aliases":["CGI-49","NET11"]}},{"id":"270b67ba22694d818be79ec3ade8a7c2","type":"GENE","name":"SCD","canonical_id":"hgnc:HGNC:10571","description":null,"metadata":null},{"id":"60aafb910a15454eab70354f0c6b2435","type":"GENE","name":"SCD-DT","canonical_id":"hgnc:HGNC:58401","description":"SCD divergent transcript","metadata":{"aliases":["RP11-34D15.2"]}},{"id":"580df943a6ae4871ba7f9ccce443dd54","type":"GENE","name":"SCD5","canonical_id":"hgnc:HGNC:21088","description":null,"metadata":null},{"id":"039a11396c8e44a2831a9ded5a31bd1d","type":"GENE","name":"SCDAL","canonical_id":"hgnc:HGNC:58108","description":"stem cell derived angiogenic lncRNA","metadata":{"aliases":["AC103746.1"]}},{"id":"eaf2d26e376a49f1b241f1cb263336a9","type":"GENE","name":"SCDP1","canonical_id":"hgnc:HGNC:10572","description":"stearoyl-CoA desaturase pseudogene 1","metadata":{"aliases":["SCDP"]}},{"id":"ca05dbc2c43c4bcea4328a2952d1bb14","type":"GENE","name":"SCEL","canonical_id":"hgnc:HGNC:10573","description":"sciellin","metadata":{"aliases":["FLJ21667","MGC22531"]}},{"id":"72eefc86ecde49c0af8c56dfa574067e","type":"GENE","name":"SCEL-AS1","canonical_id":"hgnc:HGNC:39895","description":"SCEL antisense RNA 1","metadata":null},{"id":"f50650a68db4463ea36c0405c4cece64","type":"GO_TERM","name":"SCF complex assembly","canonical_id":"go:GO:0010265","description":"\"The aggregation, arrangement and bonding together of a set of components to form the SKP1-Cullin/Cdc53-F-box protein ubiquitin ligase (SCF) complex.\" [GOC:pz]","metadata":null},{"id":"14d20dcd488f4656a58d1981c7a0c1b7","type":"GO_TERM","name":"SCF complex disassembly in response to cadmium stress","canonical_id":"go:GO:1990171","description":"\"The disaggregation of the SCF ubiquitin ligase complex in response to cadmium stress.\" [GOC:rb, PMID:23000173]","metadata":null},{"id":"87cf3b70ffa24ce09347817d737b5a59","type":"GO_TERM","name":"SCF ubiquitin ligase complex","canonical_id":"go:GO:0019005","description":"\"A ubiquitin ligase complex in which a cullin from the Cul1 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by a Skp1 adaptor and an F-box protein. SCF complexes are involved in targeting proteins for degradation by the proteasome. The best characterized complexes are those from yeast and mammals (with core subunits named Cdc53/Cul1, Rbx1/Hrt1/Roc1).\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"13df5208993f4a73b7d6bb63561e3e2a","type":"GO_TERM","name":"SCF ubiquitin ligase complex binding","canonical_id":"go:GO:1905761","description":"\"Binding to a SCF ubiquitin ligase complex.\" [GOC:dph, GOC:ha, GOC:TermGenie, PMID:19723762]","metadata":null},{"id":"ee7e7d46db7147ee94dee783d026c5cc","type":"GO_TERM","name":"SCF-Cdc4 ubiquitin ligase complex","canonical_id":"go:GO:0097660","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Cdc4 in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:9346238]","metadata":null},{"id":"18b23e8ab4b64656aa3275cc4d0efc5b","type":"GO_TERM","name":"SCF-Ctf13 ubiquitin ligase complex","canonical_id":"go:GO:0097661","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Ctf13 in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:14747994]","metadata":null},{"id":"aec8beb2e5eb4d7eb97d3885557baeef","type":"GO_TERM","name":"SCF-Das1 ubiquitin ligase complex","canonical_id":"go:GO:0097662","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Das1 in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:14747994]","metadata":null},{"id":"6247b41dd97344ebac298e31ab3e4890","type":"GO_TERM","name":"SCF-Dia2/Pof3 ubiquitin ligase complex","canonical_id":"go:GO:0097663","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Dia2 in S. cerevisiae (Pof3 in S. pombe).\" [GOC:jd, GOC:vw, PMID:14747994, PMID:15147268]","metadata":null},{"id":"aa8374cba45e4ed6baf2d8356020330c","type":"GO_TERM","name":"SCF-Grr1/Pof2 ubiquitin ligase complex","canonical_id":"go:GO:0097664","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Grr1 in S. cerevisiae (Pof2 in S. pombe).\" [GOC:jd, GOC:vw, PMID:10213692, PMID:15147268]","metadata":null},{"id":"67773d8458b54008b75efda0fadc6fd1","type":"GO_TERM","name":"SCF-Hrt3/Pof7 ubiquitin ligase complex","canonical_id":"go:GO:0097675","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Hrt3 in S. cerevisiae (Pof7 in S. pombe).\" [GOC:jd, GOC:vw, PMID:14747994, PMID:15147268]","metadata":null},{"id":"5a53c145eeea46aab0ac7d5d89f288b8","type":"GO_TERM","name":"SCF-Mdm30 ubiquitin ligase complex","canonical_id":"go:GO:0097665","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Mdm30 in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:14747994]","metadata":null},{"id":"16e86cad78334c10a56c4a2e3963851a","type":"GO_TERM","name":"SCF-Met30/Pof1 ubiquitin ligase complex","canonical_id":"go:GO:0097666","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Met30 in S. cerevisiae (Pof1 in S pombe).\" [GOC:jd, GOC:vw, PMID:15147268, PMID:9499404]","metadata":null},{"id":"18f451129bcf417cb4e5522b332e60e0","type":"GO_TERM","name":"SCF-Pof5 ubiquitin ligase complex","canonical_id":"go:GO:0097672","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Pof5 in S. pombe (YDR306C in S. cerevisiae).\" [GOC:jd, GOC:vw, PMID:14747994, PMID:15147268]","metadata":null},{"id":"9f2f72d458e14bc5ba6dbb3b5ae51e19","type":"GO_TERM","name":"SCF-Rcy1/Pof6 ubiquitin ligase complex","canonical_id":"go:GO:0097667","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Rcy1 in S. cerevisiae (Pof6 in S. pombe).\" [GOC:jd, GOC:vw, PMID:14747994, PMID:15147268]","metadata":null},{"id":"ac82593694594b7b817a3ba79ef5463e","type":"GO_TERM","name":"SCF-Saf1/Pof9 ubiquitin ligase complex","canonical_id":"go:GO:0097668","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Saf1 in S. cerevisiae (Pof9 in S. pombe).\" [GOC:jd, GOC:vw, PMID:11283612, PMID:15147268]","metadata":null},{"id":"2b2c01f3867e46a6bb81707b1909e958","type":"GO_TERM","name":"SCF-Skp2 ubiquitin ligase complex","canonical_id":"go:GO:0097669","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Skp2 in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:14747994]","metadata":null},{"id":"1bda5ac50f754b7392102cd398f0de4b","type":"GO_TERM","name":"SCF-Ucc1 ubiquitin ligase complex","canonical_id":"go:GO:0097673","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is YLR224W in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:14747994, PMID:25982115]","metadata":null},{"id":"af0738ffcd754d96809adf89541eebb7","type":"GO_TERM","name":"SCF-Ufo1/Pof10 ubiquitin ligase complex","canonical_id":"go:GO:0097670","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is Ufo1 in S. cerevisiae (Pof10 in S. pombe).\" [GOC:jd, GOC:vw, PMID:14747994, PMID:15147268]","metadata":null},{"id":"dcefb9dfbec9430ba4ed39d8f2cd7d82","type":"GO_TERM","name":"SCF-YDR131C ubiquitin ligase complex","canonical_id":"go:GO:0097671","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is YDR131C in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:14747994]","metadata":null},{"id":"741231b5294947eb85f73c7dbb719dd9","type":"GO_TERM","name":"SCF-YLR352W ubiquitin ligase complex","canonical_id":"go:GO:0097674","description":"\"An SCF ubiquitin ligase complex in which the F-box protein is YLR352W in S. cerevisiae.\" [GOC:jd, GOC:vw, PMID:19882662]","metadata":null},{"id":"f78825c466984fe98c819cd1733601f3","type":"GO_TERM","name":"SCF-dependent proteasomal ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0031146","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by an SCF (Skp1/Cul1/F-box protein) complex, and mediated by the proteasome.\" [PMID:15380083]","metadata":null},{"id":"5c944245001a430080aac5addd8ae82a","type":"GENE","name":"SCFD1","canonical_id":"hgnc:HGNC:20726","description":"sec1 family domain containing 1","metadata":{"aliases":["RA410","KIAA0917","STXBP1L2","SLY1","C14orf163"]}},{"id":"6149af79d6884b85a028835803555fb8","type":"GENE","name":"SCFD2","canonical_id":"hgnc:HGNC:30676","description":"sec1 family domain containing 2","metadata":{"aliases":["STXBP1L1","FLJ39514"]}},{"id":"e1cf6daef75b47eab4127197c82408b2","type":"GENE","name":"SCFD2-AS1","canonical_id":"hgnc:HGNC:58243","description":"SCFD2 antisense RNA 1","metadata":null},{"id":"27420a15de054fccb9888a7a6c6f5b9b","type":"GENE","name":"SCFD2-AS2","canonical_id":"hgnc:HGNC:58786","description":"SCFD2 antisense RNA 2","metadata":null},{"id":"2e4820ae6a1d4cf9ae2493bbe945bd72","type":"GENE","name":"SCG2","canonical_id":"hgnc:HGNC:10575","description":"secretogranin II","metadata":{"aliases":["CHGC","SgII","SN"]}},{"id":"629c6510c77a46afb54582e431fe31cd","type":"GENE","name":"SCG3","canonical_id":"hgnc:HGNC:13707","description":null,"metadata":null},{"id":"9bab9f4f4b094c7d9221cddf84d37613","type":"GENE","name":"SCG3-AS1","canonical_id":"hgnc:HGNC:58294","description":"SCG3 antisense RNA 1","metadata":null},{"id":"d1675ee1fe654ce091e066ffc1ced21a","type":"GENE","name":"SCG5","canonical_id":"hgnc:HGNC:10816","description":"secretogranin V","metadata":{"aliases":["7B2","SgV","SGNE1"]}},{"id":"c0579aebf0a541e099e58df5e21c99d1","type":"GENE","name":"SCG5-AS1","canonical_id":"hgnc:HGNC:40524","description":"SCG5 antisense RNA 1","metadata":null},{"id":"99f9d1f616ba49eb9d78c88f4989c22c","type":"GENE","name":"SCGB1A1","canonical_id":"hgnc:HGNC:12523","description":"secretoglobin family 1A member 1","metadata":{"aliases":["CC10","CCSP","CC16","UGB"]}},{"id":"5c33543bb1184805b93fd547e490f727","type":"GENE","name":"SCGB1B1P","canonical_id":"hgnc:HGNC:18392","description":"secretoglobin family 1B member 1, pseudogene","metadata":{"aliases":["Abpa1p"]}},{"id":"c12197b801d347ee940cb98fcf1baa7d","type":"GENE","name":"SCGB1B2P","canonical_id":"hgnc:HGNC:20741","description":"secretoglobin family 1B member 2, pseudogene","metadata":{"aliases":["SCGB4A1P"]}},{"id":"04785b50c54846eea7e1cac082308f0b","type":"GENE","name":"SCGB1B3P","canonical_id":"hgnc:HGNC:20943","description":"secretoglobin family 1B member 3, pseudogene","metadata":{"aliases":["SCGB4A4","SCGB1B3"]}},{"id":"69d422fa0ceb449f83d8f15d83ac309c","type":"GENE","name":"SCGB1C1","canonical_id":"hgnc:HGNC:18394","description":"secretoglobin family 1C member 1","metadata":{"aliases":["RYD5"]}},{"id":"b2de7f7bffdb443ba188018526661945","type":"GENE","name":"SCGB1C2","canonical_id":"hgnc:HGNC:51242","description":"secretoglobin family 1C member 2","metadata":null},{"id":"a103acd3c6584d8981f5d6416baf8f27","type":"GENE","name":"SCGB1D1","canonical_id":"hgnc:HGNC:18395","description":"secretoglobin family 1D member 1","metadata":{"aliases":["LPHA","LIPA","MGC71958"]}},{"id":"2257e9d372a5470f83619dbd1349334d","type":"GENE","name":"SCGB1D2","canonical_id":"hgnc:HGNC:18396","description":"secretoglobin family 1D member 2","metadata":{"aliases":["LPHB","LIPB"]}},{"id":"729e6d899d294e0fb31c0f818268ef26","type":"GENE","name":"SCGB1D4","canonical_id":"hgnc:HGNC:31748","description":"secretoglobin family 1D member 4","metadata":{"aliases":["IIS"]}},{"id":"1fea3b383f79445097f7f818611bf2f2","type":"GENE","name":"SCGB1D5P","canonical_id":"hgnc:HGNC:42735","description":"secretoglobin family 1D member 5, pseudogene","metadata":{"aliases":["SCGB1D1P1"]}},{"id":"1df2eb39901e4571b6b96aa9abf545a8","type":"GENE","name":"SCGB2A1","canonical_id":"hgnc:HGNC:7051","description":"secretoglobin family 2A member 1","metadata":{"aliases":["UGB3","LPHC","MGC71973","MGB2"]}},{"id":"67f19a50c3a747b098a04695821e7457","type":"GENE","name":"SCGB2A2","canonical_id":"hgnc:HGNC:7050","description":"secretoglobin family 2A member 2","metadata":{"aliases":["UGB2","MGC71974","MGB1","PSBP1"]}},{"id":"726cbbf4d03240dcaa979745651ed997","type":"GENE","name":"SCGB2B1P","canonical_id":"hgnc:HGNC:31898","description":"secretoglobin family 2B member 1, pseudogene","metadata":{"aliases":["Abpbg1p"]}},{"id":"03255fe1f0534ae18ab02df268af7ba6","type":"GENE","name":"SCGB2B2","canonical_id":"hgnc:HGNC:27616","description":"secretoglobin family 2B member 2","metadata":{"aliases":["SCGB4A2","SCGBL"]}},{"id":"3407fa0daa554995b2b411b602b42f23","type":"GENE","name":"SCGB2B3P","canonical_id":"hgnc:HGNC:31895","description":"secretoglobin family 2B member 3, pseudogene","metadata":{"aliases":["C2B","SCGB4A3P"]}},{"id":"cfee9cb9e20643368e22467dac6803ae","type":"GENE","name":"SCGB3A1","canonical_id":"hgnc:HGNC:18384","description":"secretoglobin family 3A member 1","metadata":{"aliases":["UGRP2","HIN-1","HIN1","LU105","PnSP-2"]}},{"id":"a7cfc0d6a18440a79d0df88f96e149d2","type":"GENE","name":"SCGB3A1-AS1","canonical_id":"hgnc:HGNC:59320","description":"SCGB3A1 antisense RNA 1","metadata":null},{"id":"cbc130d075624130b1715259ecced2a4","type":"GENE","name":"SCGB3A2","canonical_id":"hgnc:HGNC:18391","description":"secretoglobin family 3A member 2","metadata":{"aliases":["UGRP1","LU103","PNSP1"]}},{"id":"c082b85a58c24b3cabeeae5d45d9f29c","type":"GENE","name":"SCGN","canonical_id":"hgnc:HGNC:16941","description":"secretagogin, EF-hand calcium binding protein","metadata":{"aliases":["SECRET","DJ501N12.8","SEGN","CALBL"]}},{"id":"9fcfdc248d89472ba5c5e91bf1d0b001","type":"TRIAL","name":"SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)","canonical_id":"clinicaltrials.gov:NCT00798213","description":"Leukemia, Myeloid, Acute; Lymphoblastic Leukemia, Acute","metadata":null},{"id":"653ce449ebce45b58bf21616f991eec2","type":"TRIAL","name":"SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)","canonical_id":"clinicaltrials.gov:NCT00871546","description":"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"986ee0362f2946e1b98e36dc92b6a771","type":"GENE","name":"SCHIP1","canonical_id":"hgnc:HGNC:15678","description":"schwannomin interacting protein 1","metadata":{"aliases":["SCHIP-1"]}},{"id":"623863f977534c75ad09d00e65adb5f6","type":"GENE","name":"SCHLAP1","canonical_id":"hgnc:HGNC:48603","description":"SWI/SNF complex antagonist associated with prostate cancer 1","metadata":{"aliases":["PCAT11","LINC00913"]}},{"id":"8e17f0aa06b4468db23d51ff6f1c6abe","type":"TRIAL","name":"SCIL-1Ra in COVID-19 Feasibility & PK/PD","canonical_id":"clinicaltrials.gov:NCT04462757","description":"COVID-19","metadata":null},{"id":"a5aaf2f597494a86991223a2e8f12b46","type":"GENE","name":"SCIMP","canonical_id":"hgnc:HGNC:33504","description":"SLP adaptor and CSK interacting membrane protein","metadata":{"aliases":["DTFT5783","UNQ5783","FLJ32580","MGC163426","MGC163428","C17orf87"]}},{"id":"c29288d7792e4034adbf0d1e44e71195","type":"GENE","name":"SCIN","canonical_id":"hgnc:HGNC:21695","description":"scinderin","metadata":{"aliases":["KIAA1905"]}},{"id":"85e1da42a7bc48368d0374319c4df94e","type":"GENE","name":"SCIRT","canonical_id":"hgnc:HGNC:55341","description":"stem cell inhibitory RNA transcript","metadata":{"aliases":["DATOC-1","AL109615.3"]}},{"id":"db61d1f576594732984a720eafea1202","type":"GENE","name":"SCLT1","canonical_id":"hgnc:HGNC:26406","description":"sodium channel and clathrin linker 1","metadata":{"aliases":["hCAP-1A","FLJ30655"]}},{"id":"58325cc10229455290ca13beb6fee4ec","type":"GENE","name":"SCLY","canonical_id":"hgnc:HGNC:18161","description":"selenocysteine lyase","metadata":{"aliases":["SCL"]}},{"id":"e054883185944c29a160ae437a9fd915","type":"GENE","name":"SCMH1","canonical_id":"hgnc:HGNC:19003","description":"Scm polycomb group protein homolog 1","metadata":{"aliases":["Scml3"]}},{"id":"77941be81bc64781a3b46678d742ea75","type":"GENE","name":"SCMH1-DT","canonical_id":"hgnc:HGNC:55675","description":"SCMH1 divergent transcript","metadata":null},{"id":"660142da828a4328a20fa0f36916003a","type":"GENE","name":"SCML1","canonical_id":"hgnc:HGNC:10580","description":"Scm polycomb group protein like 1","metadata":null},{"id":"9366d2b7479e4255b639fe0897f89959","type":"GENE","name":"SCML2","canonical_id":"hgnc:HGNC:10581","description":"Scm polycomb group protein like 2","metadata":null},{"id":"eb8a4af0088f405a8408dee143e0e9fa","type":"GENE","name":"SCML2P1","canonical_id":"hgnc:HGNC:44329","description":"SCML2 pseudogene 1","metadata":null},{"id":"8574e6e54f0844a5ab250ee1738436f4","type":"GENE","name":"SCML2P2","canonical_id":"hgnc:HGNC:44330","description":"SCML2 pseudogene 2","metadata":null},{"id":"ed22895406fc4796948593ec73b327bf","type":"GENE","name":"SCML4","canonical_id":"hgnc:HGNC:21397","description":"Scm polycomb group protein like 4","metadata":{"aliases":["dJ47M23.1"]}},{"id":"e27224a31a754916a2686a146ad98b22","type":"GENE","name":"SCN10A","canonical_id":"hgnc:HGNC:10582","description":"sodium voltage-gated channel alpha subunit 10","metadata":{"aliases":["Nav1.8","hPN3","SNS","PN3"]}},{"id":"cea30632895a4fd283cec64dad7e1462","type":"GENE","name":"SCN11A","canonical_id":"hgnc:HGNC:10583","description":"sodium voltage-gated channel alpha subunit 11","metadata":{"aliases":["Nav1.9","NaN","SNS-2","SCN12A"]}},{"id":"c312222a8bf04454b4cb52b6d44ddca2","type":"GENE","name":"SCN1A","canonical_id":"hgnc:HGNC:10585","description":"sodium voltage-gated channel alpha subunit 1","metadata":{"aliases":["Nav1.1","GEFSP2","HBSCI","NAC1","SMEI","SCN1","FEB3"]}},{"id":"7986e881bd214a888e6c15a8eecba31c","type":"PROTEIN","name":"SCN1A","canonical_id":"uniprot:P35498","description":null,"metadata":null},{"id":"0295476ec9f04485a11acfbe53277007","type":"GENE","name":"SCN1A-AS1","canonical_id":"hgnc:HGNC:54069","description":"SCN1A and SCN9A antisense RNA 1","metadata":{"aliases":["SCN1ANAT","SCN1A-NAT"]}},{"id":"8b106bf05f7f4a91ab08e8cd40bb59d8","type":"GENE","name":"SCN1B","canonical_id":"hgnc:HGNC:10586","description":"sodium voltage-gated channel beta subunit 1","metadata":null},{"id":"66b7956fa502408398d42206953203d7","type":"GENE","name":"SCN2A","canonical_id":"hgnc:HGNC:10588","description":"sodium voltage-gated channel alpha subunit 2","metadata":{"aliases":["Nav1.2","HBSCII","HBSCI","SCN2A1","SCN2A2"]}},{"id":"f2edd3162d024d2482e770df9853283f","type":"GENE","name":"SCN2B","canonical_id":"hgnc:HGNC:10589","description":"sodium voltage-gated channel beta subunit 2","metadata":null},{"id":"3bf1f3da46384ed69efdd51201b49213","type":"GENE","name":"SCN3A","canonical_id":"hgnc:HGNC:10590","description":"sodium voltage-gated channel alpha subunit 3","metadata":{"aliases":["Nav1.3"]}},{"id":"f6871690fc464b3fbd02c8693b0e58e7","type":"GENE","name":"SCN3B","canonical_id":"hgnc:HGNC:20665","description":"sodium voltage-gated channel beta subunit 3","metadata":{"aliases":["HSA243396","SCNB3"]}},{"id":"19fc6eefb8b74f07b63921da2a1d2aab","type":"GENE","name":"SCN4A","canonical_id":"hgnc:HGNC:10591","description":"sodium voltage-gated channel alpha subunit 4","metadata":{"aliases":["Nav1.4","HYPP","SkM1","HYKPP"]}},{"id":"dc69eb6b7b634859ace56d3826e01ac6","type":"GENE","name":"SCN4B","canonical_id":"hgnc:HGNC:10592","description":"sodium voltage-gated channel beta subunit 4","metadata":{"aliases":["LQT10"]}},{"id":"3c609aa3be6f47608d4e355090fd615f","type":"GENE","name":"SCN5A","canonical_id":"hgnc:HGNC:10593","description":"sodium voltage-gated channel alpha subunit 5","metadata":{"aliases":["Nav1.5","LQT3","HB1","HBBD","PFHB1","IVF","HB2","HH1","SSS1","CDCD2","CMPD2","ICCD","CMD1E"]}},{"id":"eab5a4bc09d849498b8cfc3413bd2c52","type":"GENE","name":"SCN7A","canonical_id":"hgnc:HGNC:10594","description":"sodium voltage-gated channel alpha subunit 7","metadata":{"aliases":["Nav2.1","Nav2.2","NaG","SCN6A"]}},{"id":"73e7d923b9fa466ea3cb369a10f37300","type":"GENE","name":"SCN8A","canonical_id":"hgnc:HGNC:10596","description":"sodium voltage-gated channel alpha subunit 8","metadata":{"aliases":["Nav1.6","NaCh6","PN4","CerIII","CIAT","MED"]}},{"id":"797a23db65a94e8387b9c5543db3585f","type":"GENE","name":"SCN9A","canonical_id":"hgnc:HGNC:10597","description":null,"metadata":null},{"id":"e2a9c62f9ca8413f97a16ebe2973d8e4","type":"GENE","name":"SCNM1","canonical_id":"hgnc:HGNC:23136","description":"sodium channel modifier 1","metadata":{"aliases":["MGC3180"]}},{"id":"b33013220e994b84934977d6e8b9442e","type":"GENE","name":"SCNN1A","canonical_id":"hgnc:HGNC:10599","description":null,"metadata":null},{"id":"a91f6138676d4038a0a0db4a7fc4ee7b","type":"PROTEIN","name":"SCNN1A","canonical_id":"uniprot:P37088","description":null,"metadata":null},{"id":"120b9e77fbea48bbb4fee850416fe056","type":"GENE","name":"SCNN1B","canonical_id":"hgnc:HGNC:10600","description":null,"metadata":null},{"id":"9875827b992e40eeb33d7f3b1616992e","type":"GENE","name":"SCNN1D","canonical_id":"hgnc:HGNC:10601","description":"sodium channel epithelial 1 subunit delta","metadata":{"aliases":["ENaCdelta","dNaCh"]}},{"id":"9a4ebfd7bd0d453fbbdb72e3f614300d","type":"GENE","name":"SCNN1G","canonical_id":"hgnc:HGNC:10602","description":"sodium channel epithelial 1 subunit gamma","metadata":{"aliases":["ENaCgamma","SCNEG"]}},{"id":"381c4966b7f34abeb3096264c3984095","type":"GENE","name":"SCO1","canonical_id":"hgnc:HGNC:10603","description":"synthesis of cytochrome C oxidase 1","metadata":{"aliases":["SCOD1"]}},{"id":"ebd15e200aa04b6e81d2451bbf329d5e","type":"GENE","name":"SCO2","canonical_id":"hgnc:HGNC:10604","description":"synthesis of cytochrome C oxidase 2","metadata":{"aliases":["SCO1L","MYP6"]}},{"id":"c9e2b2dc4d1b40efb7fea680b6975e48","type":"GENE","name":"SCOC","canonical_id":"hgnc:HGNC:20335","description":"short coiled-coil protein","metadata":{"aliases":["HRIHFB2072","SCOCO","UNC-69"]}},{"id":"9431a23b34d64536bdd6b70b9ae8183b","type":"GENE","name":"SCOC-AS1","canonical_id":"hgnc:HGNC:50601","description":"SCOC antisense RNA 1","metadata":null},{"id":"31c09f30a1ee450a889a0d82b9eaa1d4","type":"GENE","name":"SCOCP1","canonical_id":"hgnc:HGNC:20339","description":"short coiled-coil protein pseudogene 1","metadata":null},{"id":"ae24304eec8e460aaf4bb9e1e706fa7e","type":"GENE","name":"SCP2","canonical_id":"hgnc:HGNC:10606","description":"sterol carrier protein 2","metadata":{"aliases":["nsLTP","SCPx","SCP-X"]}},{"id":"b1fdae584298457bae9157c5cbe140d6","type":"GENE","name":"SCP2D1","canonical_id":"hgnc:HGNC:16211","description":"SCP2 sterol binding domain containing 1","metadata":{"aliases":["dJ1068E13.2","HSD22","C20orf79"]}},{"id":"1d4df98e484a4d8883e6f70d377b73c8","type":"GENE","name":"SCP2D1-AS1","canonical_id":"hgnc:HGNC:16210","description":"SCP2D1 antisense RNA 1","metadata":{"aliases":["dJ1068E13.1","C20orf78"]}},{"id":"249ff3c20d5c4830bb1a699cb8374be8","type":"GENE","name":"SCPEP1","canonical_id":"hgnc:HGNC:29507","description":"serine carboxypeptidase 1","metadata":{"aliases":["RISC"]}},{"id":"1b56917fa51a4e25b2ebf6494fa459db","type":"GENE","name":"SCPPPQ1","canonical_id":"hgnc:HGNC:56851","description":"secretory calcium-binding phosphoprotein proline-glutamine rich 1","metadata":null},{"id":"12305d42df70488290b00229bed704f7","type":"GENE","name":"SCREEM1","canonical_id":"hgnc:HGNC:56860","description":"SNAI1 cis-regulatory eRNA expressed in monocytes 1","metadata":null},{"id":"130c2b3b28234e77a91861d41ae605a8","type":"GENE","name":"SCRG1","canonical_id":"hgnc:HGNC:17036","description":"stimulator of chondrogenesis 1","metadata":{"aliases":["SCRG-1","lincSCRG1"]}},{"id":"912ac0cc255f40d39ee6b0071c774ed9","type":"GENE","name":"SCRG1-AS1","canonical_id":"hgnc:HGNC:58912","description":"SCRG1 antisense RNA 1","metadata":null},{"id":"145711c7011748099ffc63bf6e0d7315","type":"GENE","name":"SCRIB","canonical_id":"hgnc:HGNC:30377","description":"scribble planar cell polarity protein","metadata":{"aliases":["KIAA0147","SCRB1","Vartul"]}},{"id":"6ea3147a3c3a4174b979b598107a4930","type":"GENE","name":"SCRN1","canonical_id":"hgnc:HGNC:22192","description":"secernin 1","metadata":{"aliases":["KIAA0193"]}},{"id":"52dabf2076534e1d90cc039d5f986385","type":"GENE","name":"SCRN2","canonical_id":"hgnc:HGNC:30381","description":"secernin 2","metadata":null},{"id":"703fe1c97d5c4a1e88979b00a7f40336","type":"GENE","name":"SCRN3","canonical_id":"hgnc:HGNC:30382","description":"secernin 3","metadata":{"aliases":["FLJ23142"]}},{"id":"0fc7c8717c5a4dbca7b2d6492270fb8b","type":"TRIAL","name":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","canonical_id":"clinicaltrials.gov:NCT06850103","description":"Colorectal Carcinoma; Oligometastases; pMMR; MSS; iTNT","metadata":null},{"id":"983e42df21ce4ebd9c6c656244d8e81b","type":"TRIAL","name":"SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC","canonical_id":"clinicaltrials.gov:NCT07474103","description":"Rectal Cancer, Adenocarcinoma","metadata":null},{"id":"6059a3142f8349cb88a034596026d85f","type":"GENE","name":"SCRT1","canonical_id":"hgnc:HGNC:15950","description":"scratch family transcriptional repressor 1","metadata":{"aliases":["DKFZp547F072","ZNF898"]}},{"id":"13f841b9578c44459991a0b281eb2134","type":"GENE","name":"SCRT2","canonical_id":"hgnc:HGNC:15952","description":"scratch family transcriptional repressor 2","metadata":{"aliases":["ZNF898B"]}},{"id":"d5d8e4867d4f42ac9664719a48af7bcd","type":"GENE","name":"SCT","canonical_id":"hgnc:HGNC:10607","description":null,"metadata":null},{"id":"d3766a1b019a464aa58b1892274f2fa3","type":"TRIAL","name":"SCT Plus Immune Therapy in Average Risk AML/MDS","canonical_id":"clinicaltrials.gov:NCT02117297","description":"Acute Myelogenous Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"be224b1faf7f42c2beeaebad5ceb9a13","type":"TRIAL","name":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07662395","description":"Double Blind","metadata":null},{"id":"3c2801614bfe4e24ae51169faba4076f","type":"GENE","name":"SCTR","canonical_id":"hgnc:HGNC:10608","description":null,"metadata":null},{"id":"798e563ce9a84bde9d633ab827fa176a","type":"PROTEIN","name":"SCTR","canonical_id":"uniprot:P47872","description":null,"metadata":null},{"id":"95cf0396a3da4d9d9d8277454dec2b23","type":"GENE","name":"SCTR-AS1","canonical_id":"hgnc:HGNC:40516","description":"SCTR antisense RNA 1","metadata":null},{"id":"9e746c1a349a4b579e54f4ec823f6171","type":"GENE","name":"SCUBE1","canonical_id":"hgnc:HGNC:13441","description":"signal peptide, CUB domain and EGF like domain containing 1","metadata":null},{"id":"4dc629176b514493a29f9e28917adcf8","type":"GENE","name":"SCUBE1-AS1","canonical_id":"hgnc:HGNC:40635","description":"SCUBE1 antisense RNA 1","metadata":null},{"id":"bc8204ea0050421f844d8dd696dc01b6","type":"GENE","name":"SCUBE1-AS2","canonical_id":"hgnc:HGNC:40633","description":"SCUBE1 antisense RNA 2","metadata":null},{"id":"a2f60058e4f042db8091bfc1614840c0","type":"GENE","name":"SCUBE2","canonical_id":"hgnc:HGNC:30425","description":"signal peptide, CUB domain and EGF like domain containing 2","metadata":{"aliases":["Cegf1","Cegb1","FLJ16792"]}},{"id":"b78b47961d724147b8f25298ff073443","type":"GENE","name":"SCUBE3","canonical_id":"hgnc:HGNC:13655","description":"signal peptide, CUB domain and EGF like domain containing 3","metadata":{"aliases":["FLJ34743","CEGF3"]}},{"id":"e7bafb029496466b8d71f0ba355744bf","type":"GENE","name":"SCUBE3-AS1","canonical_id":"hgnc:HGNC:56671","description":"SCUBE3 antisense RNA 1","metadata":{"aliases":["Z97832.2"]}},{"id":"919e080ec6bf486fae7d7f628e60c4b6","type":"GENE","name":"SCUBE3-DT","canonical_id":"hgnc:HGNC:59386","description":"SCUBE3 divergent transcript","metadata":null},{"id":"71b6fe3a24214d66857d96a9ebcfb88c","type":"GENE","name":"SCX","canonical_id":"hgnc:HGNC:32322","description":"scleraxis bHLH transcription factor","metadata":{"aliases":["bHLHa48","bHLHa41","SCXA","SCXB"]}},{"id":"7e321957bde949c0be4fad92b1d296d1","type":"GENE","name":"SCYGR1","canonical_id":"hgnc:HGNC:34218","description":"small cysteine and glycine repeat containing 1","metadata":{"aliases":["KRTAP28-1"]}},{"id":"6bafc0081bde472299a3c295d3fd23e0","type":"GENE","name":"SCYGR10","canonical_id":"hgnc:HGNC:34221","description":"small cysteine and glycine repeat containing 10 (gene/pseudogene)","metadata":{"aliases":["KRTAP28p2","KRTAP28-10"]}},{"id":"25bed66faa0a44da85c6c3c012e47f21","type":"GENE","name":"SCYGR2","canonical_id":"hgnc:HGNC:34220","description":"small cysteine and glycine repeat containing 2","metadata":{"aliases":["KRTAP28-2"]}},{"id":"3966b9ee148b4882bc5bdefe2d2718c0","type":"GENE","name":"SCYGR3","canonical_id":"hgnc:HGNC:34222","description":"small cysteine and glycine repeat containing 3","metadata":{"aliases":["KRTAP28-3"]}},{"id":"47bbce8a9d08478bab89241b4b9746e1","type":"GENE","name":"SCYGR4","canonical_id":"hgnc:HGNC:34223","description":"small cysteine and glycine repeat containing 4","metadata":{"aliases":["KRTAP28-4"]}},{"id":"172d287466b64478bb09dfebfe0faa00","type":"GENE","name":"SCYGR5","canonical_id":"hgnc:HGNC:34224","description":"small cysteine and glycine repeat containing 5","metadata":{"aliases":["KRTAP28-5"]}},{"id":"ed11371048994fa387818c8c29792043","type":"GENE","name":"SCYGR6","canonical_id":"hgnc:HGNC:34225","description":"small cysteine and glycine repeat containing 6","metadata":{"aliases":["KRTAP28-6"]}},{"id":"73c824cfc6e04ecb9124084b86ee32ba","type":"GENE","name":"SCYGR7","canonical_id":"hgnc:HGNC:34226","description":"small cysteine and glycine repeat containing 7","metadata":{"aliases":["KRTAP28-7"]}},{"id":"3811a89fbc8c46a38bf0f9db6f44c382","type":"GENE","name":"SCYGR8","canonical_id":"hgnc:HGNC:34227","description":"small cysteine and glycine repeat containing 8","metadata":{"aliases":["KRTAP28-8"]}},{"id":"ca761e87184e4032bdb25d6aa7ea63e7","type":"GENE","name":"SCYGR9","canonical_id":"hgnc:HGNC:34219","description":"small cysteine and glycine repeat containing 9 (pseudogene)","metadata":{"aliases":["KRTAP28p1","KRTAP28-9"]}},{"id":"3b10ba7915fe42919845e80a1a298a86","type":"GENE","name":"SCYL1","canonical_id":"hgnc:HGNC:14372","description":"SCY1 like pseudokinase 1","metadata":{"aliases":["HT019","P105","GKLP","NKTL","TAPK","TRAP","TEIF","MGC78454","NTKL"]}},{"id":"97b081f6db0944a8870369f0b9e75500","type":"GENE","name":"SCYL2","canonical_id":"hgnc:HGNC:19286","description":"SCY1 like pseudokinase 2","metadata":{"aliases":["KIAA1360","CVAK104"]}},{"id":"ac337a93424541bd95c4b9487bf21998","type":"GENE","name":"SCYL2P1","canonical_id":"hgnc:HGNC:54685","description":"SCYL2 pseudogene 1","metadata":null},{"id":"3c9943bbfc7041e2a19299b29505df3c","type":"GENE","name":"SCYL3","canonical_id":"hgnc:HGNC:19285","description":"SCY1 like pseudokinase 3","metadata":{"aliases":["PACE-1","PACE1"]}},{"id":"0bb26e53791b49148b0c813a1f88d7ab","type":"GENE","name":"SDAD1","canonical_id":"hgnc:HGNC:25537","description":"SDA1 domain containing 1","metadata":{"aliases":["FLJ10498","Sda1","hSDA"]}},{"id":"fa5c0048105e49cbbedc2cb8c1167cb6","type":"GENE","name":"SDAD1-AS1","canonical_id":"hgnc:HGNC:41106","description":"SDAD1 antisense RNA 1","metadata":null},{"id":"6f72b14dcf4f4948b446aacd50263b6b","type":"GENE","name":"SDAD1P1","canonical_id":"hgnc:HGNC:31403","description":"SDA1 domain containing 1 pseudogene 1","metadata":null},{"id":"ad99095bd00e4303b43bbb252981f524","type":"GENE","name":"SDAD1P2","canonical_id":"hgnc:HGNC:31404","description":"SDA1 domain containing 1 pseudogene 2","metadata":null},{"id":"23d0dbf232064c519710c50b35fbd0d9","type":"GENE","name":"SDAD1P3","canonical_id":"hgnc:HGNC:39260","description":"SDA1 domain containing 1 pseudogene 3","metadata":null},{"id":"853e3be2e0b44a7ba675f2635d1bc832","type":"GENE","name":"SDAD1P4","canonical_id":"hgnc:HGNC:39261","description":"SDA1 domain containing 1 pseudogene 4","metadata":null},{"id":"4de9714f80604ce9aed9daafa96e19cc","type":"GENE","name":"SDC1","canonical_id":"hgnc:HGNC:10658","description":null,"metadata":null},{"id":"a8bdbb6167c34ae1af24be62638577af","type":"GENE","name":"SDC2","canonical_id":"hgnc:HGNC:10659","description":"syndecan 2","metadata":{"aliases":["fibroglycan","SYND2","CD362","HSPG","HSPG1"]}},{"id":"44ec10da66c6449eb932512435d4e72b","type":"GENE","name":"SDC3","canonical_id":"hgnc:HGNC:10660","description":"syndecan 3","metadata":{"aliases":["N-syndecan","SYND3"]}},{"id":"39cefa8b7b4b4ffba8907cdfeb962711","type":"GENE","name":"SDC4","canonical_id":"hgnc:HGNC:10661","description":null,"metadata":null},{"id":"6ff88807bf10469fbc65398fa96bd690","type":"GENE","name":"SDC4P","canonical_id":"hgnc:HGNC:18903","description":"syndecan 4 pseudogene","metadata":null},{"id":"f6a8ffae351548f49ac98495aff5a147","type":"GENE","name":"SDCBP","canonical_id":"hgnc:HGNC:10662","description":"syndecan binding protein","metadata":{"aliases":["SYCL","MDA-9","SDCBP1"]}},{"id":"dfe83091cdaa4618beffc419d0bb8274","type":"GENE","name":"SDCBP2","canonical_id":"hgnc:HGNC:15756","description":"syndecan binding protein 2","metadata":{"aliases":["ST-2","SITAC18"]}},{"id":"85de68f89e9842be9196010d1902ad56","type":"GENE","name":"SDCBP2-AS1","canonical_id":"hgnc:HGNC:44314","description":"SDCBP2 antisense RNA 1","metadata":null},{"id":"4979e387be5e4db0957699acb355ad50","type":"GENE","name":"SDCBP2P1","canonical_id":"hgnc:HGNC:44685","description":"syndecan binding protein 2 pseudogene 1","metadata":null},{"id":"6b589c3f1aab4d0996c7048a6367efa5","type":"GENE","name":"SDCBPP1","canonical_id":"hgnc:HGNC:44684","description":"syndecan binding protein pseudogene 1","metadata":null},{"id":"f73a2f60ca9c4410b363a33b3995a99f","type":"GENE","name":"SDCBPP2","canonical_id":"hgnc:HGNC:44686","description":"syndecan binding protein pseudogene 2","metadata":null},{"id":"f275f22cbee84b0bafe979a1ec92975d","type":"GENE","name":"SDCBPP3","canonical_id":"hgnc:HGNC:44687","description":"syndecan binding protein pseudogene 3","metadata":null},{"id":"622986883a2f4305b7c4541732657ded","type":"GENE","name":"SDCCAG8","canonical_id":"hgnc:HGNC:10671","description":"SHH signaling and ciliogenesis regulator SDCCAG8","metadata":{"aliases":["NY-CO-8","CCCAP","SLSN7","NPHP10","BBS16"]}},{"id":"910b27c3b62642648117cca8e340f5f4","type":"GENE","name":"SDE2","canonical_id":"hgnc:HGNC:26643","description":"spliceosome associated SDE2","metadata":{"aliases":["FLJ35382","C1orf55"]}},{"id":"1d92e7ecf85245999eace6cd933c82e7","type":"GENE","name":"SDF2","canonical_id":"hgnc:HGNC:10675","description":"stromal cell derived factor 2","metadata":null},{"id":"1227be7778ff4d24b7fae0c574893dfb","type":"GENE","name":"SDF2L1","canonical_id":"hgnc:HGNC:10676","description":"stromal cell derived factor 2 like 1","metadata":{"aliases":["AP000553.C22.4","OTTHUMT00000075032"]}},{"id":"6fe9094b9c8e45589bdecc12fad28591","type":"GENE","name":"SDF4","canonical_id":"hgnc:HGNC:24188","description":"stromal cell derived factor 4","metadata":{"aliases":["Cab45"]}},{"id":"4ef206b4f9d849b4a89e09c5f76c2a29","type":"GENE","name":"SDHA","canonical_id":"hgnc:HGNC:10680","description":"succinate dehydrogenase complex flavoprotein subunit A","metadata":{"aliases":["FP","SDHF","SDH2"]}},{"id":"cb2f8ef18fa84752877032bfb3b98a22","type":"GENE","name":"SDHAF1","canonical_id":"hgnc:HGNC:33867","description":"succinate dehydrogenase complex assembly factor 1","metadata":{"aliases":["LYRM8"]}},{"id":"505b6ce9310940dcb803a41036fe8bb1","type":"GENE","name":"SDHAF2","canonical_id":"hgnc:HGNC:26034","description":"succinate dehydrogenase complex assembly factor 2","metadata":{"aliases":["FLJ20487","SDH5","PGL2","C11orf79"]}},{"id":"530f0cf548634e659c704fdfed4a64ab","type":"GENE","name":"SDHAF3","canonical_id":"hgnc:HGNC:21752","description":"succinate dehydrogenase complex assembly factor 3","metadata":{"aliases":["DC11","Sdh7","LYRM10","ACN9"]}},{"id":"ab08551f93b744f5bd041badd1d9557d","type":"GENE","name":"SDHAF4","canonical_id":"hgnc:HGNC:20957","description":"succinate dehydrogenase complex assembly factor 4","metadata":{"aliases":["Sdh8","C6orf57"]}},{"id":"bf9f7237c06643168ddc95bc165b7262","type":"GENE","name":"SDHAP1","canonical_id":"hgnc:HGNC:32455","description":"SDHA pseudogene 1","metadata":{"aliases":["SDHAL1","SDHALP1"]}},{"id":"5ecb9acd3c0e4c3ea1f40385ba5eec8b","type":"GENE","name":"SDHAP2","canonical_id":"hgnc:HGNC:27408","description":"SDHA pseudogene 2","metadata":{"aliases":["SDHAL2","SDHALP2"]}},{"id":"f548194dbc064fa68b2ef44c4fce20f1","type":"GENE","name":"SDHAP3","canonical_id":"hgnc:HGNC:18781","description":"SDHA pseudogene 3","metadata":{"aliases":["SDHAL","SDHACL"]}},{"id":"bfbd5036c5d245f2b9d48bf7116a3108","type":"GENE","name":"SDHAP4","canonical_id":"hgnc:HGNC:55782","description":"SDHA pseudogene 4","metadata":null},{"id":"10c3d5765d8a43b49787e8e35ab767ea","type":"GENE","name":"SDHB","canonical_id":"hgnc:HGNC:10681","description":null,"metadata":null},{"id":"86512923dfb2487cb0159f2d82fa8cb0","type":"GENE","name":"SDHBP1","canonical_id":"hgnc:HGNC:56538","description":"SDHB pseudogene 1","metadata":null},{"id":"c81eb2079cbc42e79ecf15f0f0341ba1","type":"GENE","name":"SDHC","canonical_id":"hgnc:HGNC:10682","description":"succinate dehydrogenase complex subunit C","metadata":{"aliases":["CYB560","cybL","PGL3"]}},{"id":"dda74084eec94d5f80e4ad07141cbbad","type":"GENE","name":"SDHCP1","canonical_id":"hgnc:HGNC:31734","description":"SDHC pseudogene 1","metadata":null},{"id":"7981445cec554adc8245c6fd3cd8685a","type":"GENE","name":"SDHCP2","canonical_id":"hgnc:HGNC:45177","description":"SDHC pseudogene 2","metadata":null},{"id":"cfa6da0799144d91a32c0bf94159ddac","type":"GENE","name":"SDHCP3","canonical_id":"hgnc:HGNC:45178","description":"SDHC pseudogene 3","metadata":null},{"id":"a1c7e2af45494aaeba53b68b65bdb3c4","type":"GENE","name":"SDHCP4","canonical_id":"hgnc:HGNC:45179","description":"SDHC pseudogene 4","metadata":null},{"id":"175a8de2cc24426884f3b983a396e9b5","type":"GENE","name":"SDHCP5","canonical_id":"hgnc:HGNC:57039","description":"SDHC pseudogene 5","metadata":null},{"id":"71a0e9d78d684b49b2dfffc237110efc","type":"GENE","name":"SDHD","canonical_id":"hgnc:HGNC:10683","description":"succinate dehydrogenase complex subunit D","metadata":{"aliases":["cybS","PGL","PGL1"]}},{"id":"77cebf7eb7654d528d1edd200bc47bda","type":"GENE","name":"SDHDP1","canonical_id":"hgnc:HGNC:10684","description":"succinate dehydrogenase complex subunit D pseudogene 1","metadata":null},{"id":"d3a31f0dbb69419fb89bf2cdf86f9dc7","type":"GENE","name":"SDHDP2","canonical_id":"hgnc:HGNC:10685","description":"succinate dehydrogenase complex subunit D pseudogene 2","metadata":null},{"id":"7098e6dee408432a872900a5f6ea84d2","type":"GENE","name":"SDHDP3","canonical_id":"hgnc:HGNC:10686","description":"succinate dehydrogenase complex subunit D pseudogene 3","metadata":null},{"id":"95d65ab87abc451e81a3fa3e191037e1","type":"GENE","name":"SDHDP4","canonical_id":"hgnc:HGNC:10687","description":"succinate dehydrogenase complex subunit D pseudogene 4","metadata":null},{"id":"1427319a5d2d4307b07a272ecd9e55eb","type":"GENE","name":"SDHDP5","canonical_id":"hgnc:HGNC:10688","description":"succinate dehydrogenase complex subunit D pseudogene 5","metadata":null},{"id":"e563b43dfb58401e9dee8f8efa577e80","type":"GENE","name":"SDHDP6","canonical_id":"hgnc:HGNC:10689","description":"succinate dehydrogenase complex subunit D pseudogene 6","metadata":null},{"id":"6817b088322d4ade8eea67fa0a76ce16","type":"GENE","name":"SDHDP7","canonical_id":"hgnc:HGNC:31410","description":"succinate dehydrogenase complex subunit D pseudogene 7","metadata":null},{"id":"d66aed0a382c43ebb1ec9e390a39492b","type":"GENE","name":"SDIM1","canonical_id":"hgnc:HGNC:38749","description":"stress responsive DNAJB4 interacting membrane protein 1","metadata":null},{"id":"3866a6e9196a449b97d8253f886a0d46","type":"GENE","name":"SDK1","canonical_id":"hgnc:HGNC:19307","description":"sidekick cell adhesion molecule 1","metadata":{"aliases":["FLJ31425"]}},{"id":"e5dcdcbbea894cf693bf7178f51f919f","type":"GENE","name":"SDK1-AS1","canonical_id":"hgnc:HGNC:40883","description":"SDK1 antisense RNA 1","metadata":{"aliases":["AC073316.3"]}},{"id":"ceccf01d88d9486b86252992d92eb556","type":"GENE","name":"SDK2","canonical_id":"hgnc:HGNC:19308","description":"sidekick cell adhesion molecule 2","metadata":{"aliases":["FLJ10832","KIAA1514"]}},{"id":"f6de958da26345a2ab7a2ef2794ff3b0","type":"GENE","name":"SDK2-AS1","canonical_id":"hgnc:HGNC:58559","description":"SDK2 antisense RNA 1","metadata":null},{"id":"55d87134aeed4113aa1bc9d987d1c48c","type":"GENE","name":"SDR16C5","canonical_id":"hgnc:HGNC:30311","description":"short chain dehydrogenase/reductase family 16C member 5","metadata":{"aliases":["RDHE2","RDH-E2","EPHD-2"]}},{"id":"7d7abafd8ab6441ca395e8f1395370ae","type":"GENE","name":"SDR16C6P","canonical_id":"hgnc:HGNC:35413","description":"short chain dehydrogenase/reductase family 16C member 6, pseudogene","metadata":{"aliases":["SDR16C6"]}},{"id":"5806659d885b4737b6afa954c2338a18","type":"GENE","name":"SDR39U1","canonical_id":"hgnc:HGNC:20275","description":"short chain dehydrogenase/reductase family 39U member 1","metadata":{"aliases":["HCDI","C14orf124"]}},{"id":"f04bd2ff17c84d0083a04a3a5290bef0","type":"GENE","name":"SDR42E1","canonical_id":"hgnc:HGNC:29834","description":"short chain dehydrogenase/reductase family 42E, member 1","metadata":{"aliases":["HSPC105"]}},{"id":"95bd49c303944a4b917a230593fc5315","type":"GENE","name":"SDR42E1P1","canonical_id":"hgnc:HGNC:50378","description":"short chain dehydrogenase/reductase family 42E, member 1 pseudogene 1","metadata":null},{"id":"ecd250ffc49f4d0f877c8facefc5a8f1","type":"GENE","name":"SDR42E1P2","canonical_id":"hgnc:HGNC:51833","description":"short chain dehydrogenase/reductase family 42E, member 1 pseudogene 2","metadata":null},{"id":"82e56746d7294e4c92bb50b228bef5b2","type":"GENE","name":"SDR42E1P3","canonical_id":"hgnc:HGNC:51834","description":"short chain dehydrogenase/reductase family 42E, member 1 pseudogene 3","metadata":null},{"id":"18894838086144bf8569d5f5238f3f65","type":"GENE","name":"SDR42E1P4","canonical_id":"hgnc:HGNC:51835","description":"short chain dehydrogenase/reductase family 42E, member 1 pseudogene 4","metadata":null},{"id":"beed36f38b73432088c4735b52cbb8ea","type":"GENE","name":"SDR42E1P5","canonical_id":"hgnc:HGNC:51832","description":"short chain dehydrogenase/reductase family 42E, member 1 pseudogene 5","metadata":null},{"id":"957420b669504765a05b68d64f9b0fe6","type":"GENE","name":"SDR42E2","canonical_id":"hgnc:HGNC:35414","description":"short chain dehydrogenase/reductase family 42E, member 2","metadata":null},{"id":"1ca9aeff7c044f568fffbcfd71af3334","type":"GENE","name":"SDR9C7","canonical_id":"hgnc:HGNC:29958","description":"short chain dehydrogenase/reductase family 9C member 7","metadata":{"aliases":["SDR-O","RDHS"]}},{"id":"cf8c8faec64840028c77864ab9a67ab6","type":"GENE","name":"SDS","canonical_id":"hgnc:HGNC:10691","description":"serine dehydratase","metadata":{"aliases":["SDH"]}},{"id":"39847ded520f40dbae54992100ccef1a","type":"GENE","name":"SDSL","canonical_id":"hgnc:HGNC:30404","description":"serine dehydratase like","metadata":{"aliases":["SDS-RS1","cSDH"]}},{"id":"70f0b1bd23b942c2b716137fc0cc6c4a","type":"GENE","name":"SEBOX","canonical_id":"hgnc:HGNC:32942","description":"SEBOX homeobox","metadata":{"aliases":["OG9","OG9X"]}},{"id":"b7f30555c4df4512b8efd156c1f99cb4","type":"GENE","name":"SEC11A","canonical_id":"hgnc:HGNC:17718","description":"SEC11 homolog A, signal peptidase complex subunit","metadata":{"aliases":["SPC18","sid2895","SPCS4A","SEC11L1"]}},{"id":"a0fc87ba795f4a5989ce65da82981955","type":"GENE","name":"SEC11B","canonical_id":"hgnc:HGNC:31884","description":"SEC11 homolog B, signal peptidase complex subunit (pseudogene)","metadata":{"aliases":["SPCS4B","SEC11L2"]}},{"id":"00c243caf74146e7a1ed8beed9720695","type":"GENE","name":"SEC11C","canonical_id":"hgnc:HGNC:23400","description":"SEC11 homolog C, signal peptidase complex subunit","metadata":{"aliases":["SPC21","SPCS4C","SEC11L3"]}},{"id":"f767d188de22412480038dbbdbcab22a","type":"GENE","name":"SEC13","canonical_id":"hgnc:HGNC:10697","description":"SEC13 homolog, nuclear pore and COPII component","metadata":{"aliases":["SEC13R","npp-20","D3S1231E","SEC13L1"]}},{"id":"e025cfbaac094b4d9dcc657a6da32899","type":"GENE","name":"SEC13P1","canonical_id":"hgnc:HGNC:44529","description":"SEC13 homolog, nuclear pore and COPII coat complex component pseudogene 1","metadata":null},{"id":"d74311f5f0e24552b41fafa3fd5d6e1a","type":"GENE","name":"SEC14L1","canonical_id":"hgnc:HGNC:10698","description":"SEC14 like lipid binding 1","metadata":{"aliases":["PRELID4A","SEC14L"]}},{"id":"449258cb9d5d47368fd3a176006c7fe7","type":"GENE","name":"SEC14L1P1","canonical_id":"hgnc:HGNC:44189","description":"SEC14 like 1 pseudogene 1","metadata":null},{"id":"fa112303b36949b1b1593ff63c83db48","type":"GENE","name":"SEC14L2","canonical_id":"hgnc:HGNC:10699","description":null,"metadata":null},{"id":"4c529f5af95f4e5b9a7032142c11e41e","type":"GENE","name":"SEC14L3","canonical_id":"hgnc:HGNC:18655","description":"SEC14 like lipid binding 3","metadata":{"aliases":["TAP2"]}},{"id":"1d095a8968384cd58e24109ded944740","type":"GENE","name":"SEC14L4","canonical_id":"hgnc:HGNC:20627","description":"SEC14 like lipid binding 4","metadata":{"aliases":["TAP3","dJ130H16.5"]}},{"id":"d59417eb59be4ac3a0976055c6bc50e4","type":"GENE","name":"SEC14L5","canonical_id":"hgnc:HGNC:29032","description":"SEC14 like lipid binding 5","metadata":{"aliases":["KIAA0420","PRELID4B"]}},{"id":"fc2144ca79264e669efa9cc0bb2505cb","type":"GENE","name":"SEC14L6","canonical_id":"hgnc:HGNC:40047","description":"SEC14 like lipid binding 6","metadata":null},{"id":"631e27fd64fb4236996073008c17d63c","type":"GENE","name":"SEC16A","canonical_id":"hgnc:HGNC:29006","description":"SEC16 homolog A, endoplasmic reticulum export factor","metadata":{"aliases":["p250","Sec16L","KIAA0310"]}},{"id":"606648ae52aa48adb921d9c7b47a9b4c","type":"GENE","name":"SEC16B","canonical_id":"hgnc:HGNC:30301","description":"SEC16 homolog B, endoplasmic reticulum export factor","metadata":{"aliases":["RGPR-p117","RGPR","Sec16S","LZTR2"]}},{"id":"cee1b739985045e6a7910026a6947e62","type":"GENE","name":"SEC22A","canonical_id":"hgnc:HGNC:20260","description":"SEC22 homolog A, vesicle trafficking protein","metadata":{"aliases":["SEC22L2"]}},{"id":"a1f0983269d6432795c04faafc18ec4b","type":"GENE","name":"SEC22B","canonical_id":"hgnc:HGNC:10700","description":"SEC22 homolog B, vesicle trafficking protein","metadata":{"aliases":["ERS-24","SEC22L1"]}},{"id":"aee90a11169948169d973602b0b6f00d","type":"GENE","name":"SEC22B2P","canonical_id":"hgnc:HGNC:53890","description":"SEC22 homolog B2, pseudogene","metadata":{"aliases":["SEC22B2"]}},{"id":"b67feca1428c431f87ea85ef7aed95d3","type":"GENE","name":"SEC22B3P","canonical_id":"hgnc:HGNC:53891","description":"SEC22 homolog B3, pseudogene","metadata":{"aliases":["SEC22B3"]}},{"id":"0808a284a6f24e83b59f12ce01d5d921","type":"GENE","name":"SEC22B4P","canonical_id":"hgnc:HGNC:53892","description":"SEC22 homolog B4, pseudogene","metadata":null},{"id":"9295dace77484ea4812e424afacd5892","type":"GENE","name":"SEC22C","canonical_id":"hgnc:HGNC:16828","description":"SEC22 homolog C, vesicle trafficking protein","metadata":{"aliases":["MGC13261","MGC5373","SEC22L3"]}},{"id":"c6c131068e5d461987e721f303bb489a","type":"GENE","name":"SEC23A","canonical_id":"hgnc:HGNC:10701","description":"SEC23 homolog A, COPII component","metadata":null},{"id":"1d59c5a8283e4258a8c1950d6730c6d2","type":"GENE","name":"SEC23A-AS1","canonical_id":"hgnc:HGNC:53213","description":"SEC23A antisense RNA 1","metadata":null},{"id":"224f264ab5c849f58c32881e45b4fa46","type":"GENE","name":"SEC23B","canonical_id":"hgnc:HGNC:10702","description":"SEC23 homolog B, COPII component","metadata":{"aliases":["CDA-II","CDAII","HEMPAS","CDAN2"]}},{"id":"b59cefe1da16462cb05991a528479527","type":"GENE","name":"SEC23IP","canonical_id":"hgnc:HGNC:17018","description":"SEC23 interacting protein","metadata":{"aliases":["p125","iPLA1beta","iPLA1\u03b2","p125A"]}},{"id":"f8bf0cfb92cd43629895bb943dbc492a","type":"GENE","name":"SEC24A","canonical_id":"hgnc:HGNC:10703","description":"SEC24 homolog A, COPII component","metadata":null},{"id":"34fe6d300716496ca2a16c5899aaf3f6","type":"GENE","name":"SEC24AP1","canonical_id":"hgnc:HGNC:53767","description":"SEC24 homolog A pseudogene 1","metadata":null},{"id":"2276602348e143eca6352a5207b3b5c7","type":"GENE","name":"SEC24B","canonical_id":"hgnc:HGNC:10704","description":"SEC24 homolog B, COPII component","metadata":null},{"id":"914a4b659b084325b4c9a711d2af9267","type":"GENE","name":"SEC24B-AS1","canonical_id":"hgnc:HGNC:44003","description":"SEC24B antisense RNA 1","metadata":{"aliases":["1/2-SBSRNA4"]}},{"id":"0c63d78662e34144b8ac712590552103","type":"GENE","name":"SEC24C","canonical_id":"hgnc:HGNC:10705","description":"SEC24 homolog C, COPII component","metadata":{"aliases":["KIAA0079"]}},{"id":"1d8fd3cea85c4c17a334a914ceb432f0","type":"GENE","name":"SEC24D","canonical_id":"hgnc:HGNC:10706","description":"SEC24 homolog D, COPII component","metadata":{"aliases":["KIAA0755"]}},{"id":"9d6670c844fc4e99bf07a8a4fccb8e22","type":"GENE","name":"SEC31A","canonical_id":"hgnc:HGNC:17052","description":"SEC31 homolog A, COPII component","metadata":{"aliases":["KIAA0905","ABP125","ABP130","SEC31L1"]}},{"id":"375c0625d60c4cfd91bf2e05c14d202a","type":"GENE","name":"SEC31B","canonical_id":"hgnc:HGNC:23197","description":"SEC31 homolog B, COPII component","metadata":{"aliases":["SEC31B-1","DKFZP434M183","SEC31L2"]}},{"id":"335d1229d18848eba5979b0e3e391a95","type":"GENE","name":"SEC61A1","canonical_id":"hgnc:HGNC:18276","description":"SEC61 translocon subunit alpha 1","metadata":null},{"id":"b534760dc7b54f679ab04f084d992d75","type":"GENE","name":"SEC61A2","canonical_id":"hgnc:HGNC:17702","description":"SEC61 translocon subunit alpha 2","metadata":{"aliases":["FLJ10578"]}},{"id":"5f9a912655fc4f6f88c2401968bda4a3","type":"GENE","name":"SEC61B","canonical_id":"hgnc:HGNC:16993","description":"SEC61 translocon subunit beta","metadata":null},{"id":"303be52b69004cac9f99d740adaead35","type":"GENE","name":"SEC61G","canonical_id":"hgnc:HGNC:18277","description":"SEC61 translocon subunit gamma","metadata":{"aliases":["SSS1"]}},{"id":"76bcb5e4ea4b4174a21cfc6f509868cb","type":"GENE","name":"SEC61G-DT","canonical_id":"hgnc:HGNC:40835","description":"SEC61G divergent transcript","metadata":null},{"id":"0b9ad8bdf56041dbbe7c45fad7651b11","type":"GENE","name":"SEC61GP1","canonical_id":"hgnc:HGNC:54783","description":"SEC61G pseudogene 1","metadata":null},{"id":"eb50b0a518774c64bd29461aff92f94e","type":"GENE","name":"SEC62","canonical_id":"hgnc:HGNC:11846","description":"SEC62 preprotein translocation factor","metadata":{"aliases":["Dtrp1","HTP1","TLOC1"]}},{"id":"ad1e02a3fc1241eca713216d316f70fb","type":"GENE","name":"SEC62-AS1","canonical_id":"hgnc:HGNC:40586","description":"SEC62 antisense RNA 1","metadata":null},{"id":"2fd2587d070a46c9bd37a6e34a86c1c1","type":"GENE","name":"SEC63","canonical_id":"hgnc:HGNC:21082","description":"SEC63 protein translocation regulator","metadata":{"aliases":["SEC63L","PRO2507","ERdj2","DNAJC23"]}},{"id":"f498b8e2acbe4637be93db1e4f0087a6","type":"GENE","name":"SEC63P1","canonical_id":"hgnc:HGNC:41953","description":"SEC63 homolog, protein translocation regulator pseudogene 1","metadata":null},{"id":"90092018be42469b93c63acd783df110","type":"GENE","name":"SEC63P2","canonical_id":"hgnc:HGNC:41954","description":"SEC63 homolog, protein translocation regulator pseudogene 2","metadata":null},{"id":"f1f7c48d42f64ba7a8a757933d30c0dc","type":"GENE","name":"SECISBP2","canonical_id":"hgnc:HGNC:30972","description":"SECIS binding protein 2","metadata":{"aliases":["SBP2"]}},{"id":"009f3860cbb04f49a4cd0f4140147db9","type":"GENE","name":"SECISBP2L","canonical_id":"hgnc:HGNC:28997","description":"SECIS binding protein 2 like","metadata":{"aliases":["KIAA0256"]}},{"id":"d6d547cedff0425ea656f2a1c6e9f7ef","type":"GENE","name":"SECTM1","canonical_id":"hgnc:HGNC:10707","description":"secreted and transmembrane 1","metadata":{"aliases":["K12"]}},{"id":"68925dff76314fab86bbffce8d6a84d6","type":"GENE","name":"SEH1L","canonical_id":"hgnc:HGNC:30379","description":"SEH1 like nucleoporin","metadata":{"aliases":["SEH1A","SEH1B","Seh1","SEC13L"]}},{"id":"257ba9adbef34eeba1cddce0f1c89105","type":"GENE","name":"SEL1L","canonical_id":"hgnc:HGNC:10717","description":"SEL1L adaptor subunit of SYVN1 ubiquitin ligase","metadata":{"aliases":["IBD2","SEL1L1","Hrd3"]}},{"id":"37afecd04d7e411a9b1e9ab0145735cc","type":"GENE","name":"SEL1L2","canonical_id":"hgnc:HGNC:15897","description":"SEL1L2 adaptor subunit of SYVN1 ubiquitin ligase","metadata":{"aliases":["DKFZp434C1826","C20orf50"]}},{"id":"07a52edcec8c45398533595c64adda49","type":"GENE","name":"SEL1L3","canonical_id":"hgnc:HGNC:29108","description":"SEL1L family member 3","metadata":{"aliases":["KIAA0746"]}},{"id":"99f1164acc2e4e54972e2cb26defa71c","type":"GENE","name":"SELE","canonical_id":"hgnc:HGNC:10718","description":null,"metadata":null},{"id":"798a007ef7ce46d7b6810c80817ca497","type":"GENE","name":"SELENBP1","canonical_id":"hgnc:HGNC:10719","description":"selenium binding protein 1","metadata":{"aliases":["hSP56","hSBP","LPSB"]}},{"id":"ebefec2d4b1f41fda78883293b70fcab","type":"GENE","name":"SELENOF","canonical_id":"hgnc:HGNC:17705","description":"selenoprotein F","metadata":{"aliases":["SEP15"]}},{"id":"69a7c3c621f6469196ced5d2c4d0e4d5","type":"GENE","name":"SELENOH","canonical_id":"hgnc:HGNC:18251","description":"selenoprotein H","metadata":{"aliases":["SELH","C11orf31"]}},{"id":"3ecbcc7af2b9490186ee5d5fed8d5390","type":"GENE","name":"SELENOI","canonical_id":"hgnc:HGNC:29361","description":"selenoprotein I","metadata":{"aliases":["KIAA1724","SELI","SEPI","EPT1"]}},{"id":"a4997a1c878a485d82adb73480760465","type":"GENE","name":"SELENOK","canonical_id":"hgnc:HGNC:30394","description":"selenoprotein K","metadata":{"aliases":["SELK"]}},{"id":"be12c14603e541ccbb2c725aef00b916","type":"GENE","name":"SELENOKP1","canonical_id":"hgnc:HGNC:53724","description":"selenoprotein K pseudogene 1","metadata":null},{"id":"4b6247ffae5e48388ba8c04d76fe2d8e","type":"GENE","name":"SELENOKP2","canonical_id":"hgnc:HGNC:53725","description":"selenoprotein K pseudogene 2","metadata":null},{"id":"7b1e025f19b343aebc84c00167f443e8","type":"GENE","name":"SELENOKP3","canonical_id":"hgnc:HGNC:53726","description":"selenoprotein K pseudogene 3","metadata":null},{"id":"2c924ad0624646b29e26dc724e23e988","type":"GENE","name":"SELENOM","canonical_id":"hgnc:HGNC:30397","description":"selenoprotein M","metadata":{"aliases":["SELM","SEPM"]}},{"id":"231a45fcc4d6474ea4a6f83bb68dca3a","type":"GENE","name":"SELENON","canonical_id":"hgnc:HGNC:15999","description":"selenoprotein N","metadata":{"aliases":["SELN","RSS","RSMD1","MDRS1","SEPN1"]}},{"id":"7aa317a1cec54833ad4f2fb3a5568a79","type":"GENE","name":"SELENOO","canonical_id":"hgnc:HGNC:30395","description":"selenoprotein O","metadata":{"aliases":["SELO"]}},{"id":"1bba98bcada64fe4af82131da0cd9f65","type":"GENE","name":"SELENOO-AS1","canonical_id":"hgnc:HGNC:56048","description":"SELENOO antisense RNA 1","metadata":null},{"id":"bd17dffcbfd24dc1b3ee31795269b80e","type":"GENE","name":"SELENOOLP","canonical_id":"hgnc:HGNC:53787","description":"selenoprotein O like, pseudogene","metadata":null},{"id":"6575b430580e4a37ab74d87f34f182f8","type":"GENE","name":"SELENOP","canonical_id":"hgnc:HGNC:10751","description":"selenoprotein P","metadata":{"aliases":["SeP","SELP","SEPP","SEPP1"]}},{"id":"f9d656a32350406fba20f71feafc636f","type":"GENE","name":"SELENOS","canonical_id":"hgnc:HGNC:30396","description":"selenoprotein S","metadata":{"aliases":["SELS","MGC2553","SBBI8","AD-015","SEPS1","VIMP"]}},{"id":"d62bbe4eadb941cba6f801aa21661475","type":"GENE","name":"SELENOT","canonical_id":"hgnc:HGNC:18136","description":"selenoprotein T","metadata":{"aliases":["SELT"]}},{"id":"c0ae15953110493b83a439bc5456f963","type":"GENE","name":"SELENOTP1","canonical_id":"hgnc:HGNC:53722","description":"selenoprotein T pseudogene 1","metadata":null},{"id":"580cb249aba64e4d875bc4b4f58e0c5f","type":"GENE","name":"SELENOTP2","canonical_id":"hgnc:HGNC:53723","description":"selenoprotein T pseudogene 2","metadata":null},{"id":"d3d8c7067a19447abb73d4dc5d9b448b","type":"GENE","name":"SELENOV","canonical_id":"hgnc:HGNC:30399","description":"selenoprotein V","metadata":{"aliases":["SELV"]}},{"id":"fce937937a424348aced47ba14b97a5b","type":"GENE","name":"SELENOW","canonical_id":"hgnc:HGNC:10752","description":"selenoprotein W","metadata":{"aliases":["SELW","SEPW1"]}},{"id":"ede86eaa2c3f4956a3b198706fc3c867","type":"GENE","name":"SELENOWP1","canonical_id":"hgnc:HGNC:10753","description":"selenoprotein W pseudogene 1","metadata":{"aliases":["SEPW1P"]}},{"id":"d7be4cb077244e4c91b9a9d7e453e416","type":"TRIAL","name":"SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT05093608","description":"Hepatocellular Carcinoma","metadata":null},{"id":"a45ca759f1f54129a2fe59f4e4a7577e","type":"GENE","name":"SELL","canonical_id":"hgnc:HGNC:10720","description":null,"metadata":null},{"id":"b10757c3c52442e49c4d8dac51e54513","type":"GENE","name":"SELP","canonical_id":"hgnc:HGNC:10721","description":null,"metadata":null},{"id":"15b58193fc464e9a9cc9ff6683c5a8d3","type":"GENE","name":"SELPLG","canonical_id":"hgnc:HGNC:10722","description":"selectin P ligand","metadata":{"aliases":["PSGL-1","CD162"]}},{"id":"bd4cc30363d44c0fb640c3f0b74c7b47","type":"GENE","name":"SEM1","canonical_id":"hgnc:HGNC:10845","description":"SEM1 26S proteasome subunit","metadata":{"aliases":["DSS1","Shfdg1","ECD","SHSF1","FLJ42280","PSMD15","SHFD1","SHFM1","C7orf76"]}},{"id":"19e1b5d1c401480fa756d39d31666bc7","type":"GENE","name":"SEM1P1","canonical_id":"hgnc:HGNC:24454","description":"SEM1 pseudogene 1","metadata":{"aliases":["DSS1P1","SHFM1P","SHFM1P1"]}},{"id":"3b4deff3ff794b3abba3eb96674f4592","type":"GENE","name":"SEMA3A","canonical_id":"hgnc:HGNC:10723","description":"semaphorin 3A","metadata":{"aliases":["SEMA1","SemD","coll-1","Hsema-I","SEMAD"]}},{"id":"b483e0a638a645379443115115dc1c99","type":"GENE","name":"SEMA3B","canonical_id":"hgnc:HGNC:10724","description":"semaphorin 3B","metadata":{"aliases":["SemA","semaV","LUCA-1","sema5","SEMAA"]}},{"id":"16c6cc7aed714b9a8c18ad5469982c1e","type":"GENE","name":"SEMA3B-AS1","canonical_id":"hgnc:HGNC:49096","description":"SEMA3B antisense RNA 1","metadata":null},{"id":"b6c1841e84764b85bcdb21e305d4706e","type":"GENE","name":"SEMA3C","canonical_id":"hgnc:HGNC:10725","description":"semaphorin 3C","metadata":{"aliases":["SemE","SEMAE"]}},{"id":"2aed1ca88682457b9feac875284cf84c","type":"GENE","name":"SEMA3D","canonical_id":"hgnc:HGNC:10726","description":"semaphorin 3D","metadata":{"aliases":["coll-2","Sema-Z2"]}},{"id":"5388902f6e2f4913b6f1d7a672b1c2a8","type":"GENE","name":"SEMA3E","canonical_id":"hgnc:HGNC:10727","description":"semaphorin 3E","metadata":{"aliases":["M-SemaK","KIAA0331","coll-5","SEMAH"]}},{"id":"284ff85f01a94efaaea85f139feb4c6f","type":"GENE","name":"SEMA3F","canonical_id":"hgnc:HGNC:10728","description":"semaphorin 3F","metadata":{"aliases":["SEMAK","Sema4"]}},{"id":"b99b7f7d6daf4a71baf76d163979f115","type":"GENE","name":"SEMA3F-AS1","canonical_id":"hgnc:HGNC:40518","description":"SEMA3F antisense RNA 1","metadata":{"aliases":["RBM5-AS1"]}},{"id":"cf6593f1a01246219bf614599e184428","type":"GENE","name":"SEMA3G","canonical_id":"hgnc:HGNC:30400","description":"semaphorin 3G","metadata":{"aliases":["FLJ00014","sem2"]}},{"id":"f93252af2d0e460d8ea3c49113110376","type":"GENE","name":"SEMA4A","canonical_id":"hgnc:HGNC:10729","description":"semaphorin 4A","metadata":{"aliases":["SemB","FLJ12287","CORD10","SEMAB"]}},{"id":"344c4d3c3e46433daa290050c12ab5f4","type":"GENE","name":"SEMA4B","canonical_id":"hgnc:HGNC:10730","description":"semaphorin 4B","metadata":{"aliases":["SemC","KIAA1745","MGC131831","SEMAC"]}},{"id":"06625c9b02664f4a8d7c678463c68b83","type":"GENE","name":"SEMA4C","canonical_id":"hgnc:HGNC:10731","description":"semaphorin 4C","metadata":{"aliases":["Semacl1","Semaf","SEMAI"]}},{"id":"4bee5019815b461c9ecfde1fccdd80d2","type":"GENE","name":"SEMA4D","canonical_id":"hgnc:HGNC:10732","description":"semaphorin 4D","metadata":{"aliases":["CD100","coll-4","FLJ39737","SEMAJ","C9orf164"]}},{"id":"f7d7c217a1b04cabaac5c0c1cc940589","type":"GENE","name":"SEMA4F","canonical_id":"hgnc:HGNC:10734","description":"ssemaphorin 4F","metadata":{"aliases":["SEMAW","SEMAM"]}},{"id":"dacb23d1f3a842858fe969a2e3c316b7","type":"GENE","name":"SEMA4G","canonical_id":"hgnc:HGNC:10735","description":"semaphorin 4G","metadata":{"aliases":["FLJ20590","KIAA1619"]}},{"id":"de426a8fb9f247fb8dd5ae6466cd002f","type":"GENE","name":"SEMA5A","canonical_id":"hgnc:HGNC:10736","description":"semaphorin 5A","metadata":{"aliases":["semF","SEMAF"]}},{"id":"ebc5856b393c4688b4f22a9508761154","type":"GENE","name":"SEMA5A-AS1","canonical_id":"hgnc:HGNC:52973","description":"SEMA5A antisense RNA 1","metadata":null},{"id":"2364341af9bd40f18766169cf031e654","type":"GENE","name":"SEMA5A-AS2","canonical_id":"hgnc:HGNC:40519","description":"SEMA5A antisense RNA 2","metadata":null},{"id":"ec885a3bc0c44638be288800efc9954f","type":"GENE","name":"SEMA5A-AS3","canonical_id":"hgnc:HGNC:59000","description":"SEMA5A antisense RNA 3","metadata":null},{"id":"c04b1c0f6afb4c68aa5a17f2168d43ce","type":"GENE","name":"SEMA5A-AS4","canonical_id":"hgnc:HGNC:59001","description":"SEMA5A antisense RNA 4","metadata":null},{"id":"9b185a3c3f2647d6b504be9120d57de5","type":"GENE","name":"SEMA5B","canonical_id":"hgnc:HGNC:10737","description":"semaphorin 5B","metadata":{"aliases":["SemG","KIAA1445","FLJ10372","SEMAG"]}},{"id":"d977b469712840898ed87efdc48e0201","type":"GENE","name":"SEMA6A","canonical_id":"hgnc:HGNC:10738","description":null,"metadata":null},{"id":"2c2fd39460424bf5835ab040d496bdf1","type":"GENE","name":"SEMA6A-AS1","canonical_id":"hgnc:HGNC:51110","description":"SEMA6A antisense RNA 1","metadata":null},{"id":"364fb79bdb7c45dfb93eda2db45d3786","type":"GENE","name":"SEMA6A-AS2","canonical_id":"hgnc:HGNC:52754","description":"SEMA6A antisense RNA 2","metadata":null},{"id":"35a9d3db4de14e758aaafbd93c2c73b5","type":"GENE","name":"SEMA6B","canonical_id":"hgnc:HGNC:10739","description":"semaphorin 6B","metadata":{"aliases":["semaZ","SEMA-VIB","SEM-SEMA-Z","SEMAN"]}},{"id":"f6b1858883aa47ecb547a5e298fe4f55","type":"GENE","name":"SEMA6C","canonical_id":"hgnc:HGNC:10740","description":"semaphorin 6C","metadata":{"aliases":["KIAA1869","Sema-Y"]}},{"id":"34795de4980e402fae33d5fe6dd488fa","type":"GENE","name":"SEMA6D","canonical_id":"hgnc:HGNC:16770","description":"semaphorin 6D","metadata":{"aliases":["KIAA1479","FLJ11598"]}},{"id":"660a33961bfb4bdea3362ff302329f06","type":"GENE","name":"SEMA6D-AS1","canonical_id":"hgnc:HGNC:58081","description":"SEMA6D antisense RNA 1","metadata":{"aliases":["REIR-7"]}},{"id":"03460844eea14c9c9e0d5e46e3526e8d","type":"GENE","name":"SEMA7A","canonical_id":"hgnc:HGNC:10741","description":"semaphorin 7A (JohnMiltonHagen blood group)","metadata":{"aliases":["H-Sema-L","CD108","SEMAL"]}},{"id":"f09f2a5caeec4ed78b988325df1f8590","type":"GENE","name":"SEMG1","canonical_id":"hgnc:HGNC:10742","description":null,"metadata":null},{"id":"d9328d61099e473796a76403ef36cf90","type":"GENE","name":"SEMG2","canonical_id":"hgnc:HGNC:10743","description":"semenogelin 2","metadata":{"aliases":["SGII"]}},{"id":"91955ec76a7a48698cd42129c952e9bd","type":"GENE","name":"SENCR","canonical_id":"hgnc:HGNC:44177","description":"smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA","metadata":{"aliases":["FLI1-AS1"]}},{"id":"fb97708405f64435a30a9052d4d932d5","type":"GENE","name":"SENP1","canonical_id":"hgnc:HGNC:17927","description":"SUMO specific peptidase 1","metadata":null},{"id":"3129b04b5521473aac4fd8597a2a6e5f","type":"GENE","name":"SENP2","canonical_id":"hgnc:HGNC:23116","description":"SUMO specific peptidase 2","metadata":{"aliases":["SMT3IP2","KIAA1331","DKFZp762A2316","AXAM2"]}},{"id":"b661f8bcdb394deca698a3c322e2aae1","type":"GENE","name":"SENP3","canonical_id":"hgnc:HGNC:17862","description":"SUMO specific peptidase 3","metadata":{"aliases":["DKFZP586K0919","SSP3","DKFZp762A152","SMT3IP1","Ulp1"]}},{"id":"ad0b49f0d63748758e18c9f3bfd1faa2","type":"GENE","name":"SENP3-EIF4A1","canonical_id":"hgnc:HGNC:49182","description":"SENP3-EIF4A1 readthrough (NMD candidate)","metadata":null},{"id":"209900559eff428884416c5579c815a1","type":"GENE","name":"SENP5","canonical_id":"hgnc:HGNC:28407","description":"SUMO specific peptidase 5","metadata":{"aliases":["MGC27076"]}},{"id":"fc9e7d0aa5c14fe69d8d0470f3e603ef","type":"GENE","name":"SENP6","canonical_id":"hgnc:HGNC:20944","description":"SUMO specific peptidase 6","metadata":{"aliases":["SUSP1","KIAA0797"]}},{"id":"1a0b808a86e7478997c1bf5cb6277415","type":"GENE","name":"SENP7","canonical_id":"hgnc:HGNC:30402","description":"SUMO specific peptidase 7","metadata":null},{"id":"70f6ce1af8874d818bd558cb6ec6879e","type":"GENE","name":"SENP8","canonical_id":"hgnc:HGNC:22992","description":"SUMO peptidase family member, NEDD8 specific","metadata":{"aliases":["NEDP1","DEN1","HsT17512","PRSC2"]}},{"id":"6c867594cc9f4f759afa3172f0602fbd","type":"TRIAL","name":"SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT00117052","description":"Secondary Hyperparathyroidism; End Stage Renal Disease","metadata":null},{"id":"401934b1189b4a37a22be3878c513178","type":"GENE","name":"SEPHS1","canonical_id":"hgnc:HGNC:19685","description":"selenophosphate synthetase 1","metadata":{"aliases":["SPS","SPS1"]}},{"id":"86270cc29c94465f8e2ed8334e619186","type":"GENE","name":"SEPHS1P1","canonical_id":"hgnc:HGNC:42161","description":"selenophosphate synthetase 1 pseudogene 1","metadata":null},{"id":"4a071fb2d859498597270fee40c54166","type":"GENE","name":"SEPHS1P2","canonical_id":"hgnc:HGNC:42162","description":"selenophosphate synthetase 1 pseudogene 2","metadata":null},{"id":"cd2607e61ecc4be4b78779cd6402a7c4","type":"GENE","name":"SEPHS1P3","canonical_id":"hgnc:HGNC:42163","description":"selenophosphate synthetase 1 pseudogene 3","metadata":null},{"id":"59a4c829799648aabdd01c9490357deb","type":"GENE","name":"SEPHS1P4","canonical_id":"hgnc:HGNC:42169","description":"selenophosphate synthetase 1 pseudogene 4","metadata":null},{"id":"c75d43a21f24416e9aa01195e3d905bc","type":"GENE","name":"SEPHS1P6","canonical_id":"hgnc:HGNC:42168","description":"selenophosphate synthetase 1 pseudogene 6","metadata":null},{"id":"57e07fc8808b47e6b272d10ddcf18aa1","type":"GENE","name":"SEPHS1P7","canonical_id":"hgnc:HGNC:42167","description":"selenophosphate synthetase 1 pseudogene 7","metadata":null},{"id":"368ac01efe2f49f188d767ba443bd9c3","type":"GENE","name":"SEPHS2","canonical_id":"hgnc:HGNC:19686","description":"selenophosphate synthetase 2","metadata":{"aliases":["SPS2","SPS2b"]}},{"id":"fa1a95bbba5d4630b53300b7422858fd","type":"GENE","name":"SEPHS2P1","canonical_id":"hgnc:HGNC:42165","description":"selenophosphate synthetase 2 pseudogene 1","metadata":{"aliases":["SEPHS1P5"]}},{"id":"c2b969c7dbc64869b4f40a745ec65d9c","type":"GENE","name":"SEPSECS","canonical_id":"hgnc:HGNC:30605","description":"Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase","metadata":{"aliases":["SLA/LP","SLA","SLA-p35","SecS"]}},{"id":"a17dc5f1ed8f4a77ac773786889c412e","type":"GENE","name":"SEPSECS-DT","canonical_id":"hgnc:HGNC:27737","description":"SEPSECS divergent transcript","metadata":{"aliases":["SEPSECS-AS1"]}},{"id":"b91a3ecc7daa4d5b83f027f253eff87d","type":"GENE","name":"SEPT7","canonical_id":"hgnc:HGNC:1717","description":null,"metadata":null},{"id":"365f474ab73d45fe96ccfb3de1ff4a76","type":"GENE","name":"SEPTIN1","canonical_id":"hgnc:HGNC:2879","description":"septin 1","metadata":{"aliases":["PNUTL3","Septin-1","DIFF6","SEPT1"]}},{"id":"0af5fd51bb324bb6a4e8092076d670c7","type":"GENE","name":"SEPTIN10","canonical_id":"hgnc:HGNC:14349","description":"septin 10","metadata":{"aliases":["FLJ11619","Septin-10","SEPT10"]}},{"id":"97e4e8eb9dd146fc8d52b4ab42b20547","type":"GENE","name":"SEPTIN10P1","canonical_id":"hgnc:HGNC:40018","description":"septin 10 pseudogene 1","metadata":{"aliases":["SEPT10P1"]}},{"id":"a1979c73abde4600814490a6b0b468b7","type":"GENE","name":"SEPTIN11","canonical_id":"hgnc:HGNC:25589","description":"septin 11","metadata":{"aliases":["FLJ10849","Septin-11","SEPT11"]}},{"id":"b0c80cb73f784255af5ae067414898dc","type":"GENE","name":"SEPTIN11-AS1","canonical_id":"hgnc:HGNC:58825","description":"SEPTIN11 antisense RNA 1","metadata":null},{"id":"d187bf96440f4fc384c2097b9d09be3a","type":"GENE","name":"SEPTIN11-DT","canonical_id":"hgnc:HGNC:58824","description":"SEPTIN11 divergent transcript","metadata":null},{"id":"8bfd94c393d247b8a961169250d5d526","type":"GENE","name":"SEPTIN12","canonical_id":"hgnc:HGNC:26348","description":"septin 12","metadata":{"aliases":["FLJ25410","SEPT12"]}},{"id":"e6f385b85b5a4f978cef991ca8b63656","type":"GENE","name":"SEPTIN14","canonical_id":"hgnc:HGNC:33280","description":"septin 14","metadata":{"aliases":["FLJ44060","Septin-14","SEPT14"]}},{"id":"63043146daf042b98bb86e4dc7a27daa","type":"GENE","name":"SEPTIN14P1","canonical_id":"hgnc:HGNC:51685","description":"septin 14 pseudogene 1","metadata":{"aliases":["SEPT14P1"]}},{"id":"f1c5ed86134644bd9363271542f6672a","type":"GENE","name":"SEPTIN14P10","canonical_id":"hgnc:HGNC:51697","description":"septin 14 pseudogene 10","metadata":{"aliases":["SEPT14P10"]}},{"id":"d08150d530a04488ad1724ecd5133fef","type":"GENE","name":"SEPTIN14P11","canonical_id":"hgnc:HGNC:51698","description":"septin 14 pseudogene 11","metadata":{"aliases":["SEPT14P11"]}},{"id":"f6ae4cff183a4398866e835957c72039","type":"GENE","name":"SEPTIN14P12","canonical_id":"hgnc:HGNC:51699","description":"septin 14 pseudogene 12","metadata":{"aliases":["SEPT14P12"]}},{"id":"b9e5b138446f42e68105f05f6747168e","type":"GENE","name":"SEPTIN14P13","canonical_id":"hgnc:HGNC:51700","description":"septin 14 pseudogene 13","metadata":{"aliases":["SEPT14P13"]}},{"id":"0decc96b08c0410bbe1a1cb822e37936","type":"GENE","name":"SEPTIN14P14","canonical_id":"hgnc:HGNC:51701","description":"septin 14 pseudogene 14","metadata":{"aliases":["SEPT14P14"]}},{"id":"6cf7f2d25ee748588720782c78b20a7c","type":"GENE","name":"SEPTIN14P15","canonical_id":"hgnc:HGNC:51702","description":"septin 14 pseudogene 15","metadata":{"aliases":["SEPT14P15"]}},{"id":"9f7c9a40b4bb4ca6a6e9f3f878003327","type":"GENE","name":"SEPTIN14P16","canonical_id":"hgnc:HGNC:51704","description":"septin 14 pseudogene 16","metadata":{"aliases":["SEPT14P16"]}},{"id":"99e9df6ffa474c7d9296f33a3d09d2af","type":"GENE","name":"SEPTIN14P17","canonical_id":"hgnc:HGNC:51703","description":"septin 14 pseudogene 17","metadata":{"aliases":["SEPT14P17"]}},{"id":"1847cd27425944f39b5c4210169d9f3f","type":"GENE","name":"SEPTIN14P18","canonical_id":"hgnc:HGNC:51705","description":"septin 14 pseudogene 18","metadata":{"aliases":["SEPT14P18"]}},{"id":"28ab04072f074d69942054bab7a864fa","type":"GENE","name":"SEPTIN14P19","canonical_id":"hgnc:HGNC:51707","description":"septin 14 pseudogene 19","metadata":{"aliases":["SEPT14P19"]}},{"id":"b90af66caddf43d09132fa48795209b3","type":"GENE","name":"SEPTIN14P2","canonical_id":"hgnc:HGNC:51686","description":"septin 14 pseudogene 2","metadata":{"aliases":["SEPT14P2"]}},{"id":"d6ddfa5a9f13427aa59a42431ade5a52","type":"GENE","name":"SEPTIN14P20","canonical_id":"hgnc:HGNC:51706","description":"septin 14 pseudogene 20","metadata":{"aliases":["bA476I15.3","RBRP","SEPT14P20","LINC00266-1","C20orf69","NCRNA00266","NCRNA00266-1"]}},{"id":"35e6ae2c36e545a48f54a900df7a338a","type":"GENE","name":"SEPTIN14P21","canonical_id":"hgnc:HGNC:51712","description":"septin 14 pseudogene 21","metadata":{"aliases":["SEPT14P21"]}},{"id":"57d6000f844440e5907fbc188f700178","type":"GENE","name":"SEPTIN14P22","canonical_id":"hgnc:HGNC:51708","description":"septin 14 pseudogene 22","metadata":{"aliases":["SEPT14P22"]}},{"id":"aba34aa1aefa4d7ca86c3f17f7df64eb","type":"GENE","name":"SEPTIN14P23","canonical_id":"hgnc:HGNC:51709","description":"septin 14 pseudogene 23","metadata":{"aliases":["NCRNA00266Y2","SEPT14P23","LINC00266-4P","NCRNA00266D","NCRNA00266-4P"]}},{"id":"bd64b087d00e44fb8c5f0b61aa6138b5","type":"GENE","name":"SEPTIN14P24","canonical_id":"hgnc:HGNC:51710","description":"septin 14 pseudogene 24","metadata":{"aliases":["SEPT14P24"]}},{"id":"2e34fc7da7eb4828b6acdeec938541af","type":"GENE","name":"SEPTIN14P3","canonical_id":"hgnc:HGNC:51687","description":"septin 14 pseudogene 3","metadata":{"aliases":["SEPT14P3"]}},{"id":"e06f7b51abe94b7db8fa56876374cb79","type":"GENE","name":"SEPTIN14P4","canonical_id":"hgnc:HGNC:51688","description":"septin 14 pseudogene 4","metadata":{"aliases":["SEPT14P4"]}},{"id":"ed9507fb2d2147419c8b0ddd687decab","type":"GENE","name":"SEPTIN14P5","canonical_id":"hgnc:HGNC:51689","description":"septin 14 pseudogene 5","metadata":{"aliases":["SEPT14P5"]}},{"id":"c28779c2d9b545c2b7f363e9afa9ef2d","type":"GENE","name":"SEPTIN14P6","canonical_id":"hgnc:HGNC:51690","description":"septin 14 pseudogene 6","metadata":{"aliases":["dJ24O22.2","SEPT14P6","LINC00266-3","C6orf88","NCRNA00266C","NCRNA00266-3"]}},{"id":"e9c8ff4b430d41c2a8e886a85cefdb0c","type":"GENE","name":"SEPTIN14P7","canonical_id":"hgnc:HGNC:51691","description":"septin 14 pseudogene 7","metadata":{"aliases":["SEPT14P7"]}},{"id":"f3953b8549d84edbb025cc949be985b2","type":"GENE","name":"SEPTIN14P8","canonical_id":"hgnc:HGNC:51692","description":"septin 14 pseudogene 8","metadata":{"aliases":["SEPT14P8"]}},{"id":"cc465030a09445aeb9618c8500d4ef65","type":"GENE","name":"SEPTIN2","canonical_id":"hgnc:HGNC:7729","description":"septin 2","metadata":{"aliases":["KIAA0158","hNedd5","Pnutl3","Septin-2","DIFF6","NEDD5","SEPT2"]}},{"id":"a2610d70bbf747baa9aba9244b5a418e","type":"GENE","name":"SEPTIN2P1","canonical_id":"hgnc:HGNC:40017","description":"septin 2 pseudogene 1","metadata":{"aliases":["SEPT2P1"]}},{"id":"8f2b87c8502c4421a1310a194f2f9db1","type":"GENE","name":"SEPTIN3","canonical_id":"hgnc:HGNC:10750","description":"septin 3","metadata":{"aliases":["SEP3","SEPT3"]}},{"id":"48fd0a6669e6468cbb051b536b5a2e57","type":"GENE","name":"SEPTIN4","canonical_id":"hgnc:HGNC:9165","description":"septin 4","metadata":{"aliases":["H5","CE5B3","hucep-7","ARTS","hCDCREL-2","MART","FLJ40121","Septin-4","PNUTL2","C17orf47","SEPT4"]}},{"id":"3ae897a3e7a6436baed3b281edf824aa","type":"GENE","name":"SEPTIN4-AS1","canonical_id":"hgnc:HGNC:51345","description":"SEPTIN4 antisense RNA 1","metadata":{"aliases":["SEPT4-AS1"]}},{"id":"3c15e2aca642423fa20bd1f59be923b3","type":"GENE","name":"SEPTIN5","canonical_id":"hgnc:HGNC:9164","description":"septin 5","metadata":{"aliases":["HCDCREL-1","H5","Septin-5","CDCREL-1","PNUTL1","SEPT5"]}},{"id":"625da64c829d4cd38a530bdbf4c3e058","type":"GENE","name":"SEPTIN6","canonical_id":"hgnc:HGNC:15848","description":"septin 6","metadata":{"aliases":["KIAA0128","SEP2","SEPT2","MGC16619","MGC20339","Septin-6","SEPT6"]}},{"id":"132f5d7ef3ec413cb7105e3c770ccd03","type":"GENE","name":"SEPTIN7-DT","canonical_id":"hgnc:HGNC:51153","description":"SEPTIN7 divergent transcript","metadata":{"aliases":["SEPT7-AS1","SEPTIN7-AS1"]}},{"id":"5d41242b0d704ad18a51e7be93bc538c","type":"GENE","name":"SEPTIN7P1","canonical_id":"hgnc:HGNC:19926","description":"septin 7 pseudogene 1","metadata":{"aliases":["CDC10P","SEPT7P1"]}},{"id":"add3f3345a52444882b6f9d0b9840dce","type":"GENE","name":"SEPTIN7P10","canonical_id":"hgnc:HGNC:55089","description":"septin 7 pseudogene 10","metadata":null},{"id":"814565750daf4f48a59f396a24e2bc85","type":"GENE","name":"SEPTIN7P11","canonical_id":"hgnc:HGNC:55090","description":"septin 7 pseudogene 11","metadata":null},{"id":"dd1f8957078c489bb09fafd5e6dfa761","type":"GENE","name":"SEPTIN7P12","canonical_id":"hgnc:HGNC:55091","description":"septin 7 pseudogene 12","metadata":null},{"id":"28444157263647a7b81377bef5253502","type":"GENE","name":"SEPTIN7P13","canonical_id":"hgnc:HGNC:55092","description":"septin 7 pseudogene 13","metadata":null},{"id":"843d783450e84f1fabfd3baae30dfec9","type":"GENE","name":"SEPTIN7P14","canonical_id":"hgnc:HGNC:44219","description":"septin 7 pseudogene 14","metadata":null},{"id":"8d7e4ed83706464d9b8478c4e2ca78f3","type":"GENE","name":"SEPTIN7P15","canonical_id":"hgnc:HGNC:55096","description":"septin 7 pseudogene 15","metadata":null},{"id":"c5ce97c2dc174289ac30d89aee3e95b0","type":"GENE","name":"SEPTIN7P2","canonical_id":"hgnc:HGNC:32339","description":"septin 7 pseudogene 2","metadata":{"aliases":["DKFZp313J1114","SEPT7B","SEPT13","SEPT7P2"]}},{"id":"fd3d5c94bafc4815b4e931e4aa954c4e","type":"GENE","name":"SEPTIN7P3","canonical_id":"hgnc:HGNC:38038","description":"septin 7 pseudogene 3","metadata":{"aliases":["SEPT7P3"]}},{"id":"43a11ec7832a46099c94a6a65cb7366d","type":"GENE","name":"SEPTIN7P4","canonical_id":"hgnc:HGNC:38039","description":"septin 7 pseudogene 4","metadata":{"aliases":["SEPT7P4"]}},{"id":"d1cd2fd0b73c46fb90ecd479c0a70560","type":"GENE","name":"SEPTIN7P5","canonical_id":"hgnc:HGNC:38041","description":"septin 7 pseudogene 5","metadata":{"aliases":["SEPT7P5"]}},{"id":"c3e9e794f13046e1b6555fa824ebb2c7","type":"GENE","name":"SEPTIN7P6","canonical_id":"hgnc:HGNC:38042","description":"septin 7 pseudogene 6","metadata":{"aliases":["SEPT7P6"]}},{"id":"5a497b818e824bc49e726c7423f4c603","type":"GENE","name":"SEPTIN7P7","canonical_id":"hgnc:HGNC:38043","description":"septin 7 pseudogene 7","metadata":{"aliases":["SEPT7P7"]}},{"id":"7f5da2a5b0194c8887be1cac641d5000","type":"GENE","name":"SEPTIN7P8","canonical_id":"hgnc:HGNC:38044","description":"septin 7 pseudogene 8","metadata":{"aliases":["SEPT7P8"]}},{"id":"130efa90c0494c379a7154f606ca9b17","type":"GENE","name":"SEPTIN7P9","canonical_id":"hgnc:HGNC:30810","description":"septin 7 pseudogene 9","metadata":{"aliases":["bA291L22.2","CDC10L","SEPT7L","SEPT7P9"]}},{"id":"29d4c3adb119429aa50fdd7e1e076bbf","type":"GENE","name":"SEPTIN8","canonical_id":"hgnc:HGNC:16511","description":"septin 8","metadata":{"aliases":["KIAA0202","SEP2","Septin-8","SEPT8"]}},{"id":"30e032d73799449a82bf90179cf12796","type":"GENE","name":"SEPTIN9","canonical_id":"hgnc:HGNC:7323","description":"septin 9","metadata":{"aliases":["MSF1","KIAA0991","PNUTL4","AF17q25","SeptD1","MSF","SEPT9"]}},{"id":"f816618090924177b9d763128c392640","type":"GENE","name":"SEPTIN9-DT","canonical_id":"hgnc:HGNC:52818","description":"SEPTIN9 divergent transcript","metadata":null},{"id":"c8ac9ee637bb4ca4bbc16e23854a6eb1","type":"GENE","name":"SERAC1","canonical_id":"hgnc:HGNC:21061","description":"serine active site containing 1","metadata":{"aliases":["FLJ14917"]}},{"id":"ab89ff24953f4f4eaaba715dbf7d7e06","type":"GENE","name":"SERBP1","canonical_id":"hgnc:HGNC:17860","description":null,"metadata":null},{"id":"5d2b62e5e82e49858a17458beee49e41","type":"GENE","name":"SERBP1P1","canonical_id":"hgnc:HGNC:32247","description":"SERPINE1 mRNA binding protein 1 pseudogene 1","metadata":{"aliases":["SERBP1P"]}},{"id":"a9ea4451afdb4ab198c43d69ed6da48e","type":"GENE","name":"SERBP1P2","canonical_id":"hgnc:HGNC:23967","description":"SERPINE1 mRNA binding protein 1 pseudogene 2","metadata":null},{"id":"2d687545f013404fa1d3ad1e6c8ea3ae","type":"GENE","name":"SERBP1P3","canonical_id":"hgnc:HGNC:44630","description":"SERPINE1 mRNA binding protein 1 pseudogene 3","metadata":null},{"id":"048391122bda4298a2ea5225ce6b4c5a","type":"GENE","name":"SERBP1P4","canonical_id":"hgnc:HGNC:44631","description":"SERPINE1 mRNA binding protein 1 pseudogene 4","metadata":null},{"id":"0a079a8eb7f346aeb88ed714a0d58c6a","type":"GENE","name":"SERBP1P5","canonical_id":"hgnc:HGNC:44632","description":"SERPINE1 mRNA binding protein 1 pseudogene 5","metadata":null},{"id":"94df30fcbd1b405c88b96c34ad359db8","type":"GENE","name":"SERBP1P6","canonical_id":"hgnc:HGNC:44635","description":"SERPINE1 mRNA binding protein 1 pseudogene 6","metadata":null},{"id":"c0d878ba0e064b38a1cc3e36fbd0af6e","type":"TRIAL","name":"SERETIDE Plus Tiotropium Versus Individual Components","canonical_id":"clinicaltrials.gov:NCT00325169","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"fa76924ade1a471291f3da6610a36300","type":"GENE","name":"SERF1A","canonical_id":"hgnc:HGNC:10755","description":"small EDRK-rich factor 1A","metadata":{"aliases":["H4F5","4F5","FAM2A","SMAM1","SERF1"]}},{"id":"fae36db1239d4272b486a04df5365f89","type":"GENE","name":"SERF1AP1","canonical_id":"hgnc:HGNC:44061","description":"small EDRK-rich factor 1A pseudogene 1","metadata":null},{"id":"bc4261b2492d4fabadf3ce8e92508e8c","type":"GENE","name":"SERF1B","canonical_id":"hgnc:HGNC:10756","description":"small EDRK-rich factor 1B","metadata":{"aliases":["FAM2B","H4F5C"]}},{"id":"d1eef29be74c40a684c563bab2759c1e","type":"GENE","name":"SERF2","canonical_id":"hgnc:HGNC:10757","description":"small EDRK-rich factor 2","metadata":{"aliases":["FAM2C","Hero7","4F5REL","H4F5rel","HsT17089"]}},{"id":"b5d9a8f9197c4a49ab1c03da7451ede4","type":"GENE","name":"SERGEF","canonical_id":"hgnc:HGNC:17499","description":"secretion regulating guanine nucleotide exchange factor","metadata":{"aliases":["DelGEF","Gnefr"]}},{"id":"44cd72054ae04bdf8866aa0a08d7a606","type":"GENE","name":"SERHL","canonical_id":"hgnc:HGNC:14408","description":"serine hydrolase like (pseudogene)","metadata":{"aliases":["SERHLP","HS126B42","BK126B4.1","dJ222E13.1"]}},{"id":"b9f3d6fc991a4697b38dc17a03ac7dfc","type":"GENE","name":"SERHL2","canonical_id":"hgnc:HGNC:29446","description":"serine hydrolase like 2","metadata":null},{"id":"97267345c6d84522b3927ce165b6af14","type":"GENE","name":"SERINC1","canonical_id":"hgnc:HGNC:13464","description":"serine incorporator 1","metadata":{"aliases":["TMS-2","TDE1L","KIAA1253","TDE2"]}},{"id":"c570b0cde83e4938bc31875d0103b990","type":"GENE","name":"SERINC2","canonical_id":"hgnc:HGNC:23231","description":"serine incorporator 2","metadata":{"aliases":["FKSG84","PRO0899","TDE2","TDE2L"]}},{"id":"69a51d9a23634e65b3678178bdc34aad","type":"GENE","name":"SERINC3","canonical_id":"hgnc:HGNC:11699","description":"serine incorporator 3","metadata":{"aliases":["DIFF33","TDE","SBBI99","TMS-1","AIGP1","TDE1"]}},{"id":"d4c688c54ade456ebb8a0d90716c2f59","type":"GENE","name":"SERINC4","canonical_id":"hgnc:HGNC:32237","description":"serine incorporator 4","metadata":{"aliases":["FLJ40363"]}},{"id":"e2a237b9c77d43509f6719c66363f648","type":"GENE","name":"SERINC5","canonical_id":"hgnc:HGNC:18825","description":"serine incorporator 5","metadata":{"aliases":["TPO1","C5orf12"]}},{"id":"2ad6ebb308d243b6aa7ea50433d96a13","type":"GENE","name":"SERINC5-AS1","canonical_id":"hgnc:HGNC:59087","description":"SERINC5 antisense RNA 1","metadata":null},{"id":"f0753db1be82480f931a470995159362","type":"GENE","name":"SERP1","canonical_id":"hgnc:HGNC:10759","description":"stress associated endoplasmic reticulum protein 1","metadata":{"aliases":["RAMP4","FLJ43424"]}},{"id":"49abe1cf317c4f30811f88579198d949","type":"GENE","name":"SERP2","canonical_id":"hgnc:HGNC:20607","description":"stress associated endoplasmic reticulum protein family member 2","metadata":{"aliases":["bA269C23.1","C13orf21"]}},{"id":"61afd40a3e994d8194f55f9f3f4f0f7c","type":"GENE","name":"SERPINA1","canonical_id":"hgnc:HGNC:8941","description":"serpin family A member 1","metadata":{"aliases":["AAT","A1A","PI1","alpha-1-antitrypsin","A1AT","alpha1AT","PI"]}},{"id":"c00b91055fac4400bd49c4bcf72f3d62","type":"GENE","name":"SERPINA10","canonical_id":"hgnc:HGNC:15996","description":"serpin family A member 10","metadata":{"aliases":["PZI","ZPI"]}},{"id":"f357905db67b4afcb975a959ce7b7234","type":"GENE","name":"SERPINA11","canonical_id":"hgnc:HGNC:19193","description":"serpin family A member 11","metadata":null},{"id":"a8fafed8ccc2455e8406bb06b5624c4c","type":"GENE","name":"SERPINA12","canonical_id":"hgnc:HGNC:18359","description":"serpin family A member 12","metadata":{"aliases":["OL-64","Vaspin"]}},{"id":"fc0d5fa8fbd64db69359803b81446f7c","type":"GENE","name":"SERPINA13P","canonical_id":"hgnc:HGNC:30909","description":"serpin family A member 13, pseudogene","metadata":{"aliases":["UNQ6121","SERPINA13"]}},{"id":"2ce71958e4fc426484ec5340d2ce07ee","type":"GENE","name":"SERPINA15P","canonical_id":"hgnc:HGNC:44397","description":"serpin family A member 15, pseudogene","metadata":null},{"id":"582e7f871f1f49528ee928ea6ecb461e","type":"GENE","name":"SERPINA2","canonical_id":"hgnc:HGNC:8985","description":"serpin family A member 2 (gene/pseudogene)","metadata":{"aliases":["ATR","ARGS","PIL","SERPINA2P"]}},{"id":"877f0b8c581e400f89168f758884f793","type":"GENE","name":"SERPINA3","canonical_id":"hgnc:HGNC:16","description":null,"metadata":null},{"id":"02f4dd46da7048ab93b03fcf494d4f77","type":"GENE","name":"SERPINA4","canonical_id":"hgnc:HGNC:8948","description":"serpin family A member 4","metadata":{"aliases":["KST","KAL","KLST","PI4"]}},{"id":"9b55a10e0f4c4df185e35e4df6b80887","type":"GENE","name":"SERPINA5","canonical_id":"hgnc:HGNC:8723","description":"serpin family A member 5","metadata":{"aliases":["PAI3","PROCI","PLANH3","PCI"]}},{"id":"c08e3225285b46e5973aa7c434a100ff","type":"GENE","name":"SERPINA6","canonical_id":"hgnc:HGNC:1540","description":"serpin family A member 6","metadata":{"aliases":["CBG"]}},{"id":"f07ec16cab964b6db7558bef925f4980","type":"GENE","name":"SERPINA7","canonical_id":"hgnc:HGNC:11583","description":"serpin family A member 7","metadata":{"aliases":["TBG"]}},{"id":"4c6349e4bb414e488109e4fe98b65480","type":"GENE","name":"SERPINA7P1","canonical_id":"hgnc:HGNC:44398","description":"serpin family A member 7 pseudogene 1","metadata":null},{"id":"bef31306f6ef48878098ef176a354540","type":"GENE","name":"SERPINA9","canonical_id":"hgnc:HGNC:15995","description":"serpin family A member 9","metadata":{"aliases":["SERPINA11b","GCET1"]}},{"id":"f972bf0df61c40a7a4982c2a5ca45cf5","type":"GENE","name":"SERPINB1","canonical_id":"hgnc:HGNC:3311","description":null,"metadata":null},{"id":"56b1fbb1a0d64cb0a4975d595ffe57cc","type":"GENE","name":"SERPINB1-AS1","canonical_id":"hgnc:HGNC:59330","description":"SERPINB1 antisense RNA 1","metadata":null},{"id":"58474ebb49434f9e96ec570f9db1b677","type":"GENE","name":"SERPINB10","canonical_id":"hgnc:HGNC:8942","description":"serpin family B member 10","metadata":{"aliases":["PI10"]}},{"id":"1e7679963d2a4a508582e50e99da3a2f","type":"GENE","name":"SERPINB11","canonical_id":"hgnc:HGNC:14221","description":"serpin family B member 11","metadata":null},{"id":"767388ca86da4b378c68e974b4f0fc0b","type":"GENE","name":"SERPINB12","canonical_id":"hgnc:HGNC:14220","description":"serpin family B member 12","metadata":null},{"id":"35e2d9600f154999874c4d4cb6d5beea","type":"GENE","name":"SERPINB13","canonical_id":"hgnc:HGNC:8944","description":"serpin family B member 13","metadata":{"aliases":["HUR7","PI13"]}},{"id":"9755e76bc4e44a0fb200a1107563d81e","type":"GENE","name":"SERPINB2","canonical_id":"hgnc:HGNC:8584","description":null,"metadata":null},{"id":"6362a136081341838608600a065e4df7","type":"GENE","name":"SERPINB3","canonical_id":"hgnc:HGNC:10569","description":"serpin family B member 3","metadata":{"aliases":["T4-A","HsT1196","SCC","SCCA1"]}},{"id":"d5b230ea86304f3896077d1d196f0a3e","type":"GENE","name":"SERPINB4","canonical_id":"hgnc:HGNC:10570","description":"serpin family B member 4","metadata":{"aliases":["PI11","LEUPIN","SCCA-2","SCCA1","SCCA2"]}},{"id":"7cd8d3a8c8a84b8db625e707adac01ba","type":"GENE","name":"SERPINB5","canonical_id":"hgnc:HGNC:8949","description":null,"metadata":null},{"id":"af386dd2b4ef494689ef4b145a99450c","type":"GENE","name":"SERPINB6","canonical_id":"hgnc:HGNC:8950","description":"serpin family B member 6","metadata":{"aliases":["PTI","CAP","PI6","DFNB91"]}},{"id":"ef9b5d6a2e9c4ee78311e830e2758cb2","type":"GENE","name":"SERPINB7","canonical_id":"hgnc:HGNC:13902","description":"serpin family B member 7","metadata":null},{"id":"0d1f7e4c1b9346d9985309bed7e21f00","type":"GENE","name":"SERPINB8","canonical_id":"hgnc:HGNC:8952","description":"serpin family B member 8","metadata":{"aliases":["CAP2","PI8"]}},{"id":"9983524ea57a49a4ba444dcd339bf250","type":"GENE","name":"SERPINB8P1","canonical_id":"hgnc:HGNC:8953","description":"serpin family B member 8 pseudogene 1","metadata":{"aliases":["PI8L1","SERPINB11","SERPINBP1"]}},{"id":"a25a51e6e7ef42c3bea6e9809de61a43","type":"GENE","name":"SERPINB9","canonical_id":"hgnc:HGNC:8955","description":null,"metadata":null},{"id":"91237d0b5be64589ae0fbad09bd28996","type":"GENE","name":"SERPINB9-AS1","canonical_id":"hgnc:HGNC:56120","description":"SERPINB9 antisense RNA 1","metadata":null},{"id":"c3b42e683bca4bb68863df8372395bd3","type":"GENE","name":"SERPINB9-DT","canonical_id":"hgnc:HGNC:59331","description":"SERPINB9 divergent transcript","metadata":null},{"id":"96984c70331f43cc9023fdea3926a63b","type":"GENE","name":"SERPINB9P1","canonical_id":"hgnc:HGNC:28590","description":"serpin family B member 9 pseudogene 1","metadata":{"aliases":["MGC39372"]}},{"id":"a1c31562bae44fd69b1226cf6a4d7bb2","type":"GENE","name":"SERPINC1","canonical_id":"hgnc:HGNC:775","description":null,"metadata":null},{"id":"1803f9361ada4bc9b695bb200e809e4a","type":"PROTEIN","name":"SERPINC1","canonical_id":"uniprot:P01008","description":null,"metadata":null},{"id":"4e0b59ee46a0417c90f6086c92b01162","type":"GENE","name":"SERPIND1","canonical_id":"hgnc:HGNC:4838","description":"serpin family D member 1","metadata":{"aliases":["HC-II","HLS2","HC2","D22S673","HCF2"]}},{"id":"566233985de04b7290a66276dd08a93b","type":"GENE","name":"SERPINE1","canonical_id":"hgnc:HGNC:8583","description":null,"metadata":null},{"id":"0da9aa8f8800456eb889ac7c550c4f21","type":"GENE","name":"SERPINE2","canonical_id":"hgnc:HGNC:8951","description":"serpin family E member 2","metadata":{"aliases":["PN1","GDN","PNI","nexin","PI7"]}},{"id":"1fce0b772dd54d11976fb77fb45694bb","type":"GENE","name":"SERPINE3","canonical_id":"hgnc:HGNC:24774","description":"serpin family E member 3","metadata":null},{"id":"864fd623c8874fff8c35d1c2204cf458","type":"GENE","name":"SERPINE4P","canonical_id":"hgnc:HGNC:44400","description":"serpin family E member 4, pseudogene","metadata":null},{"id":"90b6794a3e2f4f71900e919c46af67dd","type":"GENE","name":"SERPINF1","canonical_id":"hgnc:HGNC:8824","description":null,"metadata":null},{"id":"d1e7e0c1cb864cf3a8a98f059a3b4837","type":"GENE","name":"SERPINF2","canonical_id":"hgnc:HGNC:9075","description":"serpin family F member 2","metadata":{"aliases":["API","ALPHA-2-PI","A2AP","AAP","alpha2AP","PLI"]}},{"id":"051f72f83a8b4607a13dc86946d2a3f6","type":"GENE","name":"SERPING1","canonical_id":"hgnc:HGNC:1228","description":"serpin family G member 1","metadata":{"aliases":["C1IN","C1-INH","HAE1","HAE2","C1INH","C1NH"]}},{"id":"ee47a13a51ed435a854828e540b68d1e","type":"GENE","name":"SERPINH1","canonical_id":"hgnc:HGNC:1546","description":"serpin family H member 1","metadata":{"aliases":["HSP47","CBP1","CBP2","SERPINH2"]}},{"id":"9dec9942d848495f8aa72a4d5404e180","type":"GENE","name":"SERPINH1P1","canonical_id":"hgnc:HGNC:19917","description":"serpin family H member 1 pseudogene 1","metadata":{"aliases":["bA571F15.6","pshsp47","SERPINHP1"]}},{"id":"6cd1c1f5d96b4d37b08c69f6d5d81edc","type":"GENE","name":"SERPINI1","canonical_id":"hgnc:HGNC:8943","description":"serpin family I member 1","metadata":{"aliases":["PI12"]}},{"id":"6d35b43e63c846f39553e564b4cda688","type":"GENE","name":"SERPINI2","canonical_id":"hgnc:HGNC:8945","description":"serpin family I member 2","metadata":{"aliases":["TSA2004","MEPI","PI14"]}},{"id":"599634ff319043b580fbda1082bdbc5e","type":"GENE","name":"SERTAD1","canonical_id":"hgnc:HGNC:17932","description":null,"metadata":null},{"id":"b9fdd8e08cab49b68a47a937dfd1d9b5","type":"GENE","name":"SERTAD2","canonical_id":"hgnc:HGNC:30784","description":"SERTA domain containing 2","metadata":{"aliases":["TRIP-Br2","KIAA0127","Sei-2"]}},{"id":"056286ffe71d446785fdd7be34ca55aa","type":"GENE","name":"SERTAD2-AS1","canonical_id":"hgnc:HGNC:58178","description":"SERTAD2 antisense RNA 1","metadata":null},{"id":"4e2eb44e41bc44ca9bce1adb471d6f0b","type":"GENE","name":"SERTAD3","canonical_id":"hgnc:HGNC:17931","description":"SERTA domain containing 3","metadata":{"aliases":["RBT1"]}},{"id":"643a3fd597b34273a7debcdbd45b5ab2","type":"GENE","name":"SERTAD3-AS1","canonical_id":"hgnc:HGNC:55281","description":"SERTAD3 antisense RNA 1","metadata":null},{"id":"4c099cfc966b400ea60e2733ce01cecf","type":"GENE","name":"SERTAD4","canonical_id":"hgnc:HGNC:25236","description":"SERTA domain containing 4","metadata":{"aliases":["DJ667H12.2"]}},{"id":"230d81c05dc640d6b5db0139c2b24413","type":"GENE","name":"SERTAD4-AS1","canonical_id":"hgnc:HGNC:32019","description":"SERTAD4 antisense RNA 1","metadata":{"aliases":["C1orf133"]}},{"id":"a2be14358637400ba615066c95b82cb1","type":"GENE","name":"SERTAD4BP","canonical_id":"hgnc:HGNC:44296","description":"SERTA domain containing 4B, pseudogene","metadata":{"aliases":["LINC00643"]}},{"id":"6b38089c6c0f445abaff5176b4580bbb","type":"GENE","name":"SERTM1","canonical_id":"hgnc:HGNC:33792","description":"serine rich and transmembrane domain containing 1","metadata":{"aliases":["C13orf36"]}},{"id":"470b5541379144419f9e68c6cb8c6f3a","type":"GENE","name":"SERTM2","canonical_id":"hgnc:HGNC:48576","description":"serine rich and transmembrane domain containing 2","metadata":{"aliases":["CARDEL","LINC00890"]}},{"id":"4d3d9b8bae6748beb1206ae05e8f56db","type":"GENE","name":"SESN1","canonical_id":"hgnc:HGNC:21595","description":null,"metadata":null},{"id":"594a124ba35549509d0d72c9a418dbb4","type":"GENE","name":"SESN2","canonical_id":"hgnc:HGNC:20746","description":"sestrin 2","metadata":{"aliases":["SES2","DKFZp761M0212","HI95","SEST2"]}},{"id":"fdc32e49ddf742bf893265d7afc25fa7","type":"GENE","name":"SESN3","canonical_id":"hgnc:HGNC:23060","description":null,"metadata":null},{"id":"adbc6be0708f4f5783595dc13c3d6ada","type":"GENE","name":"SESTD1","canonical_id":"hgnc:HGNC:18379","description":"SEC14 and spectrin domain containing 1","metadata":{"aliases":["DKFZp434O0515","Solo"]}},{"id":"63e0ea16d6ee4dd18adc8b810c22281d","type":"GENE","name":"SET","canonical_id":"hgnc:HGNC:10760","description":null,"metadata":null},{"id":"0f2d9844ce8747309bda09214a291a93","type":"GO_TERM","name":"SET domain binding","canonical_id":"go:GO:0070984","description":"\"Binding to a SET domain of a protein. SET domains are named after three Drosophila proteins that contain this domain: Su(var), E(z) and trithorax. SET domains are associated with histone lysine methylation.\" [GOC:sart, Pfam:PF00856, PMID:12575990]","metadata":null},{"id":"a82dfa44d54d421fb5e60ffaa3971be7","type":"GENE","name":"SETBP1","canonical_id":"hgnc:HGNC:15573","description":null,"metadata":null},{"id":"eaa6ceccbf0140cd92a6c1f84da3c5d1","type":"GENE","name":"SETBP1-DT","canonical_id":"hgnc:HGNC:54819","description":"SETBP1 divergent transcript","metadata":null},{"id":"c7c35180bf784654b7db9248783a75d0","type":"GENE","name":"SETD1A","canonical_id":"hgnc:HGNC:29010","description":"SET domain containing 1A, histone lysine methyltransferase","metadata":{"aliases":["KIAA0339","Set1","KMT2F","SET1A"]}},{"id":"a8b2a236dda1404f9147acde5f130164","type":"GENE","name":"SETD1B","canonical_id":"hgnc:HGNC:29187","description":"SET domain containing 1B, histone lysine methyltransferase","metadata":{"aliases":["KIAA1076","Set1B","KMT2G"]}},{"id":"396770cb69764a8ebce339a9f9cb549a","type":"GENE","name":"SETD2","canonical_id":"hgnc:HGNC:18420","description":null,"metadata":null},{"id":"13caf4aecd2d4097baf8b6ea0d822161","type":"GENE","name":"SETD3","canonical_id":"hgnc:HGNC:20493","description":"SET domain containing 3, actin N3(tau)-histidine methyltransferase","metadata":{"aliases":["FLJ23027","C14orf154"]}},{"id":"2ab61298e946415dbc94c9c71f2d7b31","type":"GENE","name":"SETD4","canonical_id":"hgnc:HGNC:1258","description":"SET domain containing 4","metadata":{"aliases":["C21orf27","C21orf18"]}},{"id":"1832d63c0d1341feac600f921bfef9a6","type":"GENE","name":"SETD4-AS1","canonical_id":"hgnc:HGNC:40104","description":"SETD4 antisense RNA 1","metadata":null},{"id":"c99c2ed3432447a4bae5e378945e4efe","type":"GENE","name":"SETD5","canonical_id":"hgnc:HGNC:25566","description":"SET domain containing 5","metadata":{"aliases":["FLJ10707","SETD5A"]}},{"id":"2f1293541c6f435b83a35016eab128ea","type":"GENE","name":"SETD6","canonical_id":"hgnc:HGNC:26116","description":"SET domain containing 6, protein lysine methyltransferase","metadata":{"aliases":["FLJ21148"]}},{"id":"c32cfed84bfb47c3bb24f5b84e7e97b2","type":"GENE","name":"SETD6P1","canonical_id":"hgnc:HGNC:51596","description":"SET domain containing 6 pseudogene 1","metadata":null},{"id":"13f41fbe381a4670a4d86a312412304f","type":"GENE","name":"SETD7","canonical_id":"hgnc:HGNC:30412","description":"SET domain containing 7, histone lysine methyltransferase","metadata":{"aliases":["KIAA1717","SET7","SET7/9","Set9","KMT7"]}},{"id":"00baacd245ec4cdbb00a61f779c64452","type":"GENE","name":"SETD9","canonical_id":"hgnc:HGNC:28508","description":"SET domain containing 9","metadata":{"aliases":["MGC33648","C5orf35"]}},{"id":"0a235de28d7f41eb82013684a91898d2","type":"GENE","name":"SETDB1","canonical_id":"hgnc:HGNC:10761","description":null,"metadata":null},{"id":"a67b6282e0434d11ae06b76cc53bb1e5","type":"GENE","name":"SETDB2","canonical_id":"hgnc:HGNC:20263","description":"SET domain bifurcated histone lysine methyltransferase 2","metadata":{"aliases":["CLLD8","CLLL8","KMT1F","C13orf4"]}},{"id":"bb280f7d584a4d2795f7e77151be12c1","type":"GENE","name":"SETMAR","canonical_id":"hgnc:HGNC:10762","description":"SET and mariner transposase domain methyltransferase","metadata":{"aliases":["metnase"]}},{"id":"93b2110fef5d4e818eaf34a3ca36ecbe","type":"GENE","name":"SETP1","canonical_id":"hgnc:HGNC:19279","description":"SET pseudogene 1","metadata":{"aliases":["SETP","SETP19"]}},{"id":"4a33de62678c4636908e7db5007a3c36","type":"GENE","name":"SETP10","canonical_id":"hgnc:HGNC:42929","description":"SET pseudogene 10","metadata":null},{"id":"bc40b903950a4b5ba7e6bcf85d21a62a","type":"GENE","name":"SETP11","canonical_id":"hgnc:HGNC:42930","description":"SET pseudogene 11","metadata":null},{"id":"dcd40c7ce5f545e78201c83dc810ead9","type":"GENE","name":"SETP12","canonical_id":"hgnc:HGNC:42931","description":"SET pseudogene 12","metadata":null},{"id":"d431036a943f4acca91aca90fd25d108","type":"GENE","name":"SETP14","canonical_id":"hgnc:HGNC:42933","description":"SET pseudogene 14","metadata":null},{"id":"c31f92f0d31541b786b3dcea86960431","type":"GENE","name":"SETP15","canonical_id":"hgnc:HGNC:42934","description":"SET pseudogene 15","metadata":null},{"id":"91168bc15f4748dd8cc59fac4ab71ec5","type":"GENE","name":"SETP16","canonical_id":"hgnc:HGNC:42935","description":"SET pseudogene 16","metadata":null},{"id":"d11b3fbe2aff4728bf2fba4524f17964","type":"GENE","name":"SETP17","canonical_id":"hgnc:HGNC:42936","description":"SET pseudogene 17","metadata":null},{"id":"c644f5ec50e844a2b401d025d3214880","type":"GENE","name":"SETP2","canonical_id":"hgnc:HGNC:20032","description":"SET pseudogene 2","metadata":null},{"id":"7c480085729d4d7ea3b2105fd3ce3330","type":"GENE","name":"SETP20","canonical_id":"hgnc:HGNC:42939","description":"SET pseudogene 20","metadata":null},{"id":"60b2653ee8154c549c3a9a3effa9a878","type":"GENE","name":"SETP21","canonical_id":"hgnc:HGNC:42940","description":"SET pseudogene 21","metadata":null},{"id":"898e5e4ec9ec4c398547ae0c6ea316f0","type":"GENE","name":"SETP22","canonical_id":"hgnc:HGNC:42941","description":"SET pseudogene 22","metadata":null},{"id":"0381c3c1ec104c01bace9e50884162d1","type":"GENE","name":"SETP3","canonical_id":"hgnc:HGNC:31115","description":"SET pseudogene 3","metadata":{"aliases":["SETP13"]}},{"id":"97923bb32a3c4f1598b3bb61e4b520d8","type":"GENE","name":"SETP4","canonical_id":"hgnc:HGNC:42923","description":"SET pseudogene 4","metadata":null},{"id":"ac240039af554729af8e6cdfca0cdd24","type":"GENE","name":"SETP5","canonical_id":"hgnc:HGNC:42924","description":"SET pseudogene 5","metadata":null},{"id":"ef8b8a9c264b432586d5ebabdf94bda0","type":"GENE","name":"SETP6","canonical_id":"hgnc:HGNC:42925","description":"SET pseudogene 6","metadata":null},{"id":"aa33c1bd421b4f62a7b4f5b41ff8ce9d","type":"GENE","name":"SETP7","canonical_id":"hgnc:HGNC:42926","description":"SET pseudogene 7","metadata":null},{"id":"9a1084dc1ee74af1a6286f23950ba868","type":"GENE","name":"SETP8","canonical_id":"hgnc:HGNC:42927","description":"SET pseudogene 8","metadata":null},{"id":"f9a2426670d0410786b483c00273f5ec","type":"GENE","name":"SETP9","canonical_id":"hgnc:HGNC:42928","description":"SET pseudogene 9","metadata":null},{"id":"4a5fbaf58d2447928f7e6cd2b152592f","type":"GENE","name":"SETSIP","canonical_id":"hgnc:HGNC:42937","description":"SET like protein","metadata":{"aliases":["SETP18"]}},{"id":"7598b6ebe6cb45d6b77c4fc3e716dba1","type":"GENE","name":"SETX","canonical_id":"hgnc:HGNC:445","description":"senataxin","metadata":{"aliases":["KIAA0625","AOA2","Sen1","STEX","ALS4","SCAR1"]}},{"id":"2640ad3442214e058458bc45ae240992","type":"GENE","name":"SEZ6","canonical_id":"hgnc:HGNC:15955","description":"seizure related 6 homolog","metadata":null},{"id":"096733fa41ab4f7695afd05c774eafdf","type":"GENE","name":"SEZ6L","canonical_id":"hgnc:HGNC:10763","description":"seizure related 6 homolog like","metadata":{"aliases":["SEZ6L1"]}},{"id":"96eb68e79ad341c492b407aaffb88d5b","type":"GENE","name":"SEZ6L-AS1","canonical_id":"hgnc:HGNC:40521","description":"SEZ6L antisense RNA 1","metadata":null},{"id":"f6aa138c632b4c92ab96f4b34221e8a3","type":"GENE","name":"SEZ6L2","canonical_id":"hgnc:HGNC:30844","description":"seizure related 6 homolog like 2","metadata":{"aliases":["PSK-1","FLJ90517"]}},{"id":"7c942b8a75254ad2980615ab8e72bfec","type":"GENE","name":"SF1","canonical_id":"hgnc:HGNC:12950","description":null,"metadata":null},{"id":"cbf7e15612d34980af477aa1f01a2bd3","type":"GENE","name":"SF1-DT","canonical_id":"hgnc:HGNC:55278","description":"SF1 divergent transcript","metadata":null},{"id":"b2b19ba6fbdc4c1bbf79cb11fe9c925c","type":"GENE","name":"SF3A1","canonical_id":"hgnc:HGNC:10765","description":"splicing factor 3a subunit 1","metadata":{"aliases":["SF3a120","SAP114","PRPF21","Prp21"]}},{"id":"11466ca557354022a6b9454e0599f541","type":"GENE","name":"SF3A2","canonical_id":"hgnc:HGNC:10766","description":"splicing factor 3a subunit 2","metadata":{"aliases":["SF3a66","SAP62","PRPF11","Prp11"]}},{"id":"bc13c4921e0a465e8db69008e7b5ee85","type":"GENE","name":"SF3A2P1","canonical_id":"hgnc:HGNC:56505","description":"SF3A2 pseudogene 1","metadata":null},{"id":"62a0c6441e2a4b5ba5f7c5669bb9a9a7","type":"GENE","name":"SF3A3","canonical_id":"hgnc:HGNC:10767","description":"splicing factor 3a subunit 3","metadata":{"aliases":["SF3a60","SAP61","PRP9","PRPF9"]}},{"id":"b0918f3a036a4991b856becda44559f9","type":"GENE","name":"SF3A3P1","canonical_id":"hgnc:HGNC:16576","description":"splicing factor 3a, subunit 3 pseudogene 1","metadata":{"aliases":["dJ581P3.1","SF3A3P"]}},{"id":"fa70abae240a4b8e9a5e435839ed2851","type":"GENE","name":"SF3A3P2","canonical_id":"hgnc:HGNC:23277","description":"splicing factor 3a, subunit 3 pseudogene 2","metadata":null},{"id":"0da9d189081643b9bed2d72a3d069497","type":"GENE","name":"SF3B1","canonical_id":"hgnc:HGNC:10768","description":null,"metadata":null},{"id":"17bcba57c2b449f28c2639dc0a43c9f6","type":"GENE","name":"SF3B2","canonical_id":"hgnc:HGNC:10769","description":"splicing factor 3b subunit 2","metadata":{"aliases":["SAP145","SF3b1","Cus1","SF3b145"]}},{"id":"fe65132e88d1419a9e7d46cd109fdb19","type":"GENE","name":"SF3B3","canonical_id":"hgnc:HGNC:10770","description":"splicing factor 3b subunit 3","metadata":{"aliases":["SAP130","SF3b130","RSE1","KIAA0017"]}},{"id":"14b1f12ba8354c93a5ed9c904d3182c0","type":"GENE","name":"SF3B4","canonical_id":"hgnc:HGNC:10771","description":"splicing factor 3b subunit 4","metadata":{"aliases":["SAP49","SF3b49","Hsh49"]}},{"id":"3a441d38a21e47978e0b4512b3a7ce7a","type":"GENE","name":"SF3B4P1","canonical_id":"hgnc:HGNC:19821","description":"splicing factor 3b, subunit 4 pseudogene 1","metadata":{"aliases":["SF3B4P"]}},{"id":"b85109ec4ee34cfeb51c90bf11b60f66","type":"GENE","name":"SF3B5","canonical_id":"hgnc:HGNC:21083","description":"splicing factor 3b subunit 5","metadata":{"aliases":["SF3b10","MGC3133","Ysf3"]}},{"id":"3601690b80b44c689c55fe18844b2f84","type":"GENE","name":"SF3B6","canonical_id":"hgnc:HGNC:30096","description":"splicing factor 3b subunit 6","metadata":{"aliases":["P14","SF3B14a","Ht006","CGI-110","SAP14a"]}},{"id":"31fd345a4c4d423e88422cc6ae827b4c","type":"GENE","name":"SFI1","canonical_id":"hgnc:HGNC:29064","description":"SFI1 centrin binding protein","metadata":{"aliases":["KIAA0542","PISD","PPP1R139"]}},{"id":"eb687843b5d14666a49b99967fc30759","type":"GENE","name":"SFMBT1","canonical_id":"hgnc:HGNC:20255","description":"Scm like with four mbt domains 1","metadata":{"aliases":["RU1","DKFZp434L243","SFMBT"]}},{"id":"0840bfc2e945456ebe0e223cbdae6853","type":"GENE","name":"SFMBT2","canonical_id":"hgnc:HGNC:20256","description":"Scm like with four mbt domains 2","metadata":{"aliases":["KIAA1617"]}},{"id":"fab15054ce8547b688dd12384379bafc","type":"GENE","name":"SFN","canonical_id":"hgnc:HGNC:10773","description":null,"metadata":null},{"id":"e5fe6f587aa5487d9ebd5df23ac32927","type":"GENE","name":"SFPQ","canonical_id":"hgnc:HGNC:10774","description":null,"metadata":null},{"id":"8786e1d5efa040918967873fcc3431c2","type":"GENE","name":"SFPQP1","canonical_id":"hgnc:HGNC:10775","description":"splicing factor proline and glutamine rich pseudogene 1","metadata":{"aliases":["SFPQP"]}},{"id":"d872933383684c39a4aaa8756c54e465","type":"GENE","name":"SFR1","canonical_id":"hgnc:HGNC:29574","description":"SWI5 dependent homologous recombination repair protein 1","metadata":{"aliases":["MEI5","bA373N18.1","FLJ41960","C10orf78","MEIR5"]}},{"id":"cc0eb83f3b234b9f8a95a9a1f5b556d3","type":"GENE","name":"SFR1P1","canonical_id":"hgnc:HGNC:51531","description":"SFR1 pseudogene 1","metadata":null},{"id":"dfacd8c1b611473b9026a57ccc828d60","type":"GENE","name":"SFR1P2","canonical_id":"hgnc:HGNC:51532","description":"SFR1 pseudogene 2","metadata":null},{"id":"3b1a6e85b39648868fcbfe56ae340a14","type":"GENE","name":"SFRP1","canonical_id":"hgnc:HGNC:10776","description":null,"metadata":null},{"id":"69b5c73edee34038ba3406f57b8978d9","type":"GENE","name":"SFRP2","canonical_id":"hgnc:HGNC:10777","description":"secreted frizzled related protein 2","metadata":{"aliases":["SARP1","SDF-5","FRP-2"]}},{"id":"db70fd090ae14c599d4f0b480b202ab9","type":"GENE","name":"SFRP4","canonical_id":"hgnc:HGNC:10778","description":"secreted frizzled related protein 4","metadata":{"aliases":["frpHE","FRP-4","FRPHE","FRZB-2"]}},{"id":"ff3edd8be62644348652b23020494134","type":"GENE","name":"SFRP5","canonical_id":"hgnc:HGNC:10779","description":null,"metadata":null},{"id":"0f7545532aa34742a8bb7378762c9da0","type":"GENE","name":"SFSPAT","canonical_id":"hgnc:HGNC:58768","description":"SF1 splicing associated transcript","metadata":{"aliases":["RP11-46H11.3","SPAT"]}},{"id":"e564c9dcaaa940fea6be22b70fdcf298","type":"GENE","name":"SFSWAP","canonical_id":"hgnc:HGNC:10790","description":"splicing factor SWAP","metadata":{"aliases":["SWAP","SFRS8"]}},{"id":"4d0ef81be39140239b7e78c3cd4b49f0","type":"GENE","name":"SFSWAP-AS1","canonical_id":"hgnc:HGNC:58267","description":"SFSWAP antisense RNA 1","metadata":null},{"id":"f0fa48c16336477fa7176fb46e9b7ae0","type":"GENE","name":"SFT2D1","canonical_id":"hgnc:HGNC:21102","description":"SFT2 domain containing 1","metadata":{"aliases":["MGC19825","pRGR1","C6orf83"]}},{"id":"81007fb0b8b3475dbaa57a6b46c27ea6","type":"GENE","name":"SFT2D2","canonical_id":"hgnc:HGNC:25140","description":"SFT2 domain containing 2","metadata":{"aliases":["UNQ512","dJ747L4.C1.2"]}},{"id":"7cc1d75b07f24de4a379ef17096aa994","type":"GENE","name":"SFT2D3","canonical_id":"hgnc:HGNC:28767","description":"SFT2 domain containing 3","metadata":{"aliases":["MGC5391"]}},{"id":"317f15ecad394ea1b59dd46f224427bf","type":"GENE","name":"SFTA1P","canonical_id":"hgnc:HGNC:18383","description":"surfactant associated 1, lncRNA","metadata":{"aliases":["SFTPF"]}},{"id":"449b1487f95a495c8962ffd5f551b468","type":"GENE","name":"SFTA2","canonical_id":"hgnc:HGNC:18386","description":"surfactant associated 2","metadata":{"aliases":["SP-G","SFTPG"]}},{"id":"ad88627fb6794ff0b8814471317738e2","type":"GENE","name":"SFTA2-AS1","canonical_id":"hgnc:HGNC:59379","description":"SFTA2 antisense RNA 1","metadata":null},{"id":"4e9c391eb30844da9e6df8dbf310e867","type":"GENE","name":"SFTA3","canonical_id":"hgnc:HGNC:18387","description":"surfactant associated 3","metadata":{"aliases":["NANCI","SP-H","PAHRF","SFTPH"]}},{"id":"e4f384f5723846a6ad39c520b52cd600","type":"GENE","name":"SFTPA1","canonical_id":"hgnc:HGNC:10798","description":null,"metadata":null},{"id":"16f368687a9f443db933db45d8fe6f26","type":"GENE","name":"SFTPA2","canonical_id":"hgnc:HGNC:10799","description":"surfactant protein A2","metadata":{"aliases":["SP-A2","COLEC5"]}},{"id":"22090f179a1b4db68fc7647313d29842","type":"GENE","name":"SFTPA3P","canonical_id":"hgnc:HGNC:10800","description":"surfactant protein A3, pseudogene","metadata":{"aliases":["COLEC6","SFTPP1","SFTPAP1"]}},{"id":"5f0aeb82bc854b2c96feee045747abf7","type":"GENE","name":"SFTPB","canonical_id":"hgnc:HGNC:10801","description":null,"metadata":null},{"id":"ba6e620cf82b4404b1dab21d2ae8b3f5","type":"GENE","name":"SFTPC","canonical_id":"hgnc:HGNC:10802","description":null,"metadata":null},{"id":"7cad1734b3634acfbb14dc92343317fd","type":"GENE","name":"SFTPD","canonical_id":"hgnc:HGNC:10803","description":null,"metadata":null},{"id":"4cc826cbf6ee4c6b9c6cd88f71bf5b8e","type":"GENE","name":"SFTPD-AS1","canonical_id":"hgnc:HGNC:51589","description":"SFTPD antisense RNA 1","metadata":null},{"id":"f4f8c6afeb184d1584a00673a4ab09e6","type":"GENE","name":"SFXN1","canonical_id":"hgnc:HGNC:16085","description":"sideroflexin 1","metadata":{"aliases":["FLJ12876","SLC56A1"]}},{"id":"c212291916a0486eb0c2038250a4a115","type":"GENE","name":"SFXN2","canonical_id":"hgnc:HGNC:16086","description":"sideroflexin 2","metadata":{"aliases":["SLC56A2"]}},{"id":"f7421440d6a7455ba7e6c86b546c032b","type":"GENE","name":"SFXN3","canonical_id":"hgnc:HGNC:16087","description":"sideroflexin 3","metadata":{"aliases":["SFX3","SLC56A3"]}},{"id":"2c91b77c5df145b9b3d8061377b3f55b","type":"GENE","name":"SFXN4","canonical_id":"hgnc:HGNC:16088","description":"sideroflexin 4","metadata":{"aliases":["SLC56A4"]}},{"id":"57d45e2302044de8bb3a5da4714e6394","type":"GENE","name":"SFXN4P1","canonical_id":"hgnc:HGNC:54574","description":"SFXN4 pseudogene 1","metadata":null},{"id":"9366abb746bc4e988844e1525b2a0078","type":"GENE","name":"SFXN5","canonical_id":"hgnc:HGNC:16073","description":"sideroflexin 5","metadata":{"aliases":["BBG-TCC","SLC56A5"]}},{"id":"ac93f275d7fb47d8bcbad8196dc8da96","type":"GENE","name":"SGCA","canonical_id":"hgnc:HGNC:10805","description":"sarcoglycan alpha","metadata":{"aliases":["SCARMD1","LGMD2D","adhalin","DMDA2","A2","ADL"]}},{"id":"fa21dd9150ed41819190550fe1573024","type":"GENE","name":"SGCB","canonical_id":"hgnc:HGNC:10806","description":"sarcoglycan beta","metadata":{"aliases":["SGC","A3b","LGMD2E"]}},{"id":"e88336adc2c14018a2521767158527a4","type":"GENE","name":"SGCD","canonical_id":"hgnc:HGNC:10807","description":"sarcoglycan delta","metadata":{"aliases":["DAGD","LGMD2F","CMD1L"]}},{"id":"4eccddcfded64e6682903a847cfef397","type":"GENE","name":"SGCD-AS1","canonical_id":"hgnc:HGNC:59288","description":"SGCD antisense RNA 1","metadata":null},{"id":"ed0c5d4479b142c4a92ac0ceabb9ce4c","type":"GENE","name":"SGCD-AS2","canonical_id":"hgnc:HGNC:59289","description":"SGCD antisense RNA 2","metadata":null},{"id":"546c8564b541446db1c0c00393fde055","type":"GENE","name":"SGCE","canonical_id":"hgnc:HGNC:10808","description":"sarcoglycan epsilon","metadata":{"aliases":["DYT11"]}},{"id":"8a6a69f3b1594230b96b85e3ac102972","type":"GENE","name":"SGCEP1","canonical_id":"hgnc:HGNC:54675","description":"SGCE pseudogene 1","metadata":null},{"id":"97f7ae1825d142678956903cf5e1d960","type":"GENE","name":"SGCG","canonical_id":"hgnc:HGNC:10809","description":"sarcoglycan gamma","metadata":{"aliases":["SCARMD2","DAGA4","SCG3","DMDA","TYPE","A4","MGC130048","DMDA1","MAM","LGMD2C"]}},{"id":"79bccbca75c044bf9fb9149eeea4421a","type":"GENE","name":"SGCZ","canonical_id":"hgnc:HGNC:14075","description":"sarcoglycan zeta","metadata":{"aliases":["ZSG1"]}},{"id":"74523ff44f1540ee8c802caf1c425f50","type":"GENE","name":"SGF29","canonical_id":"hgnc:HGNC:25156","description":"SAGA complex associated factor 29","metadata":{"aliases":["FLJ32446","TDRD29","CCDC101"]}},{"id":"6e8efaaca46e4c84b205f45807fd4f5a","type":"GENE","name":"SGF29P1","canonical_id":"hgnc:HGNC:59184","description":"SGF29 pseudogene 1","metadata":null},{"id":"9f445c47442e4867af85772f158dd4a5","type":"GENE","name":"SGF29P2","canonical_id":"hgnc:HGNC:59185","description":"SGF29 pseudogene 2","metadata":null},{"id":"51bda2a631b647d89c485e1dcc16ff46","type":"GENE","name":"SGIP1","canonical_id":"hgnc:HGNC:25412","description":"SH3GL interacting endocytic adaptor 1","metadata":{"aliases":["DKFZp761D221"]}},{"id":"1fee142596f84405a3a4188d6bee9ddd","type":"GENE","name":"SGIP1-AS1","canonical_id":"hgnc:HGNC:59246","description":"SGIP1 antisense RNA 1","metadata":{"aliases":["AL139147.1"]}},{"id":"8d2d8c0bdfa5459983d80cd7223d374c","type":"GENE","name":"SGK1","canonical_id":"hgnc:HGNC:10810","description":null,"metadata":null},{"id":"0e85063a2d8e40a5b0ac319a45f4654e","type":"GENE","name":"SGK2","canonical_id":"hgnc:HGNC:13900","description":"serum/glucocorticoid regulated kinase 2","metadata":null},{"id":"b2da149d3a084a5d8287a9ee59253968","type":"GENE","name":"SGK3","canonical_id":"hgnc:HGNC:10812","description":"serum/glucocorticoid regulated kinase family member 3","metadata":{"aliases":["SGK2","SGKL"]}},{"id":"647b3b88c398473b9ac2027fc58a1c9e","type":"TRIAL","name":"SGLT2 Inhibition and Left Ventricular Mass","canonical_id":"clinicaltrials.gov:NCT02728453","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"84c1a17944d740aba3f75b5702d935b6","type":"TRIAL","name":"SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD","canonical_id":"clinicaltrials.gov:NCT02649465","description":"Non-alcoholic Fatty Liver Disease","metadata":null},{"id":"642bb27256824330aff502abcf0bbdfd","type":"TRIAL","name":"SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes","canonical_id":"clinicaltrials.gov:NCT07614230","description":"Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease; Atherosclerosis","metadata":null},{"id":"8e704ed20871433aa72b42a2c17ea459","type":"TRIAL","name":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT06364930","description":"Chronic Hepatitis B","metadata":null},{"id":"25a4d8028d834fa5ba0c989799acbb88","type":"GENE","name":"SGMS1","canonical_id":"hgnc:HGNC:29799","description":"sphingomyelin synthase 1","metadata":{"aliases":["MOB","MGC17342","SMS1","TMEM23"]}},{"id":"d34d2908874d45238190b4b963489555","type":"GENE","name":"SGMS1-AS1","canonical_id":"hgnc:HGNC:49683","description":"SGMS1 antisense RNA 1","metadata":null},{"id":"27236f48861d4c32b6cd7068ce2f870d","type":"GENE","name":"SGMS2","canonical_id":"hgnc:HGNC:28395","description":"sphingomyelin synthase 2","metadata":{"aliases":["MGC26963","SMS2"]}},{"id":"f69d8b8836b44f1f8698f98e3f3da974","type":"GENE","name":"SGO1","canonical_id":"hgnc:HGNC:25088","description":"shugoshin 1","metadata":{"aliases":["NY-BR-85","SGOL1"]}},{"id":"968b7e97fc6649de9ecd3828f9db9ff0","type":"GENE","name":"SGO1-AS1","canonical_id":"hgnc:HGNC:41081","description":"SGO1 antisense RNA 1","metadata":{"aliases":["SGOL1-AS1"]}},{"id":"695463cb70bc4032bf0e5f1000d67bb4","type":"GENE","name":"SGO1P1","canonical_id":"hgnc:HGNC:50776","description":"shugoshin 1 pseudogene 1","metadata":{"aliases":["SGOL1P1"]}},{"id":"6e4a7f87e4d64eaa96ca96cb6c367902","type":"GENE","name":"SGO1P2","canonical_id":"hgnc:HGNC:50777","description":"shugoshin 1 pseudogene 2","metadata":{"aliases":["SGOL1P2"]}},{"id":"7f048c88e5b24d439f9f93d0dc00f6bc","type":"GENE","name":"SGO2","canonical_id":"hgnc:HGNC:30812","description":"shugoshin 2","metadata":{"aliases":["TRIPIN","FLJ25211","SGOL2"]}},{"id":"84005b150bab426fa033aac43be8a7a8","type":"GENE","name":"SGPL1","canonical_id":"hgnc:HGNC:10817","description":null,"metadata":null},{"id":"931615b01e5b4eb7916f357b524b32e5","type":"GENE","name":"SGPP1","canonical_id":"hgnc:HGNC:17720","description":"sphingosine-1-phosphate phosphatase 1","metadata":null},{"id":"34fb84371cbc4e41a44408d7306a366d","type":"GENE","name":"SGPP2","canonical_id":"hgnc:HGNC:19953","description":"sphingosine-1-phosphate phosphatase 2","metadata":{"aliases":["SPP2","FLJ39004"]}},{"id":"b3bd5969c77c43f09a0cad5b245cacbf","type":"GENE","name":"SGSH","canonical_id":"hgnc:HGNC:10818","description":"N-sulfoglucosamine sulfohydrolase","metadata":{"aliases":["HSS","MPS3A","SFMD"]}},{"id":"7aea3768bb534d79a780492f3aac79fd","type":"GENE","name":"SGSM1","canonical_id":"hgnc:HGNC:29410","description":"small G protein signaling modulator 1","metadata":{"aliases":["KIAA1941","RUTBC2"]}},{"id":"ac05ebc139dd47f591f259c78ea14402","type":"GENE","name":"SGSM2","canonical_id":"hgnc:HGNC:29026","description":"small G protein signaling modulator 2","metadata":{"aliases":["KIAA0397","RUTBC1"]}},{"id":"946b6b13310843af93fee886beb59cf2","type":"GENE","name":"SGSM2-AS1","canonical_id":"hgnc:HGNC:56091","description":"SGSM2 antisense RNA 1","metadata":{"aliases":["RP1-59D14.5"]}},{"id":"b2ea17ddb9664f56bb468663d8483b15","type":"GENE","name":"SGSM3","canonical_id":"hgnc:HGNC:25228","description":"small G protein signaling modulator 3","metadata":{"aliases":["DJ1042K10.2","RUSC3","RabGAP-5","RABGAP5","RUTBC3"]}},{"id":"4d77400cbea74bd486afb270120c6651","type":"GENE","name":"SGSM3-AS1","canonical_id":"hgnc:HGNC:41088","description":"SGSM3 antisense RNA 1","metadata":null},{"id":"df7cf222527f41bdbd67ff7f2ef0d154","type":"GENE","name":"SGTA","canonical_id":"hgnc:HGNC:10819","description":"small glutamine rich tetratricopeptide repeat co-chaperone alpha","metadata":{"aliases":["UBP","SGT1","Vpu","hSGT","alphaSGT","SGT"]}},{"id":"1bb2422981784d48a77c025d752e0961","type":"GENE","name":"SGTB","canonical_id":"hgnc:HGNC:23567","description":"small glutamine rich tetratricopeptide repeat co-chaperone beta","metadata":{"aliases":["Sgt2","FLJ39002"]}},{"id":"2b2b366489b648cfb70a59336d1b8a8f","type":"GO_TERM","name":"SH2 domain binding","canonical_id":"go:GO:0042169","description":"\"Binding to a SH2 domain (Src homology 2) of a protein, a protein domain of about 100 amino-acid residues and belonging to the alpha + beta domain class.\" [GOC:curators, Pfam:PF00017]","metadata":null},{"id":"24694e8788b346e7924e6ff29ba22998","type":"GENE","name":"SH2B1","canonical_id":"hgnc:HGNC:30417","description":"SH2B adaptor protein 1","metadata":{"aliases":["FLJ30542","SH2B"]}},{"id":"500cd48647bf40239a28e4930386d78d","type":"GENE","name":"SH2B2","canonical_id":"hgnc:HGNC:17381","description":"SH2B adaptor protein 2","metadata":{"aliases":["APS"]}},{"id":"ac732d13967d40b08502c0947563d461","type":"GENE","name":"SH2B3","canonical_id":"hgnc:HGNC:29605","description":"SH2B adaptor protein 3","metadata":{"aliases":["LNK","IDDM20"]}},{"id":"de984f557a8a47ebb9d3b370edeb23c5","type":"GENE","name":"SH2D1A","canonical_id":"hgnc:HGNC:10820","description":null,"metadata":null},{"id":"d5c0be39856f418f9ec6728de6d6f3fa","type":"GENE","name":"SH2D1B","canonical_id":"hgnc:HGNC:30416","description":"SH2 domain containing 1B","metadata":{"aliases":["EAT2"]}},{"id":"780674f76adc48ba9d9487dee3b115e9","type":"GENE","name":"SH2D2A","canonical_id":"hgnc:HGNC:10821","description":"SH2 domain containing 2A","metadata":{"aliases":["TSAd","F2771"]}},{"id":"1d658e5afe204ce4aa58da700aa08f97","type":"GENE","name":"SH2D3A","canonical_id":"hgnc:HGNC:16885","description":"SH2 domain containing 3A","metadata":{"aliases":["NSP1"]}},{"id":"279fb96a17cb4ed4a7cdf8d574c6b06b","type":"GENE","name":"SH2D3C","canonical_id":"hgnc:HGNC:16884","description":"SH2 domain containing 3C","metadata":{"aliases":["NSP3"]}},{"id":"29e21d1c517f47ff90a111be4428bf36","type":"GENE","name":"SH2D4A","canonical_id":"hgnc:HGNC:26102","description":"SH2 domain containing 4A","metadata":{"aliases":["FLJ20967","SH2A","PPP1R38"]}},{"id":"81cd320db59f45029327a3cc4fb0842d","type":"GENE","name":"SH2D4B","canonical_id":"hgnc:HGNC:31440","description":"SH2 domain containing 4B","metadata":null},{"id":"d43e87be53b944c5875b793051a49a92","type":"GENE","name":"SH2D5","canonical_id":"hgnc:HGNC:28819","description":"SH2 domain containing 5","metadata":null},{"id":"0da50f27c714450c968cc535e6fdc9b3","type":"GENE","name":"SH2D6","canonical_id":"hgnc:HGNC:30439","description":"SH2 domain containing 6","metadata":{"aliases":["FLJ35993","SLNK"]}},{"id":"09c75379c0a04c0a8933c7ed80209924","type":"GENE","name":"SH2D7","canonical_id":"hgnc:HGNC:34549","description":"SH2 domain containing 7","metadata":{"aliases":["LOC646892"]}},{"id":"93b61d544486481fa5038e95548b1592","type":"GO_TERM","name":"SH3 domain binding","canonical_id":"go:GO:0017124","description":"\"Binding to a SH3 domain (Src homology 3) of a protein, small protein modules containing approximately 50 amino acid residues found in a great variety of intracellular or membrane-associated proteins.\" [GOC:curators, Pfam:PF00018]","metadata":null},{"id":"4af79ec48c4f4e0e9cc78f248a3d643e","type":"GENE","name":"SH3BGR","canonical_id":"hgnc:HGNC:10822","description":"SH3 domain binding glutamate rich protein","metadata":{"aliases":["21-GARP"]}},{"id":"8f605168beb14c29818cd5e3e8d6904b","type":"GENE","name":"SH3BGRL","canonical_id":"hgnc:HGNC:10823","description":"SH3 domain binding glutamate rich protein like","metadata":{"aliases":["MGC117402"]}},{"id":"7bd2b321545141eca7f5d4345c6a5217","type":"GENE","name":"SH3BGRL2","canonical_id":"hgnc:HGNC:15567","description":"SH3 domain binding glutamate rich protein like 2","metadata":null},{"id":"1b28f54e097a4ca089edc6ae1accf292","type":"GENE","name":"SH3BGRL3","canonical_id":"hgnc:HGNC:15568","description":"SH3 domain binding glutamate rich protein like 3","metadata":null},{"id":"02e09cf74af14f72af6058e187551d88","type":"GENE","name":"SH3BP1","canonical_id":"hgnc:HGNC:10824","description":"SH3 domain binding protein 1","metadata":{"aliases":["ARHGAP43"]}},{"id":"4da2fa2581be4b27b45bc1c13653b777","type":"GENE","name":"SH3BP2","canonical_id":"hgnc:HGNC:10825","description":null,"metadata":null},{"id":"c5d611bb14124e919daebdde887720cc","type":"GENE","name":"SH3BP4","canonical_id":"hgnc:HGNC:10826","description":"SH3 domain binding protein 4","metadata":null},{"id":"35b0eb35b79b48589f128e8e18e64f8c","type":"GENE","name":"SH3BP5","canonical_id":"hgnc:HGNC:10827","description":"SH3 domain binding protein 5","metadata":{"aliases":["Sab"]}},{"id":"0d7d65780c774ba3b4230603d4f01253","type":"GENE","name":"SH3BP5-AS1","canonical_id":"hgnc:HGNC:44501","description":"SH3BP5 antisense RNA 1","metadata":null},{"id":"38021432510743e9944ef4ab141de7fb","type":"GENE","name":"SH3BP5L","canonical_id":"hgnc:HGNC:29360","description":"SH3 binding domain protein 5 like","metadata":{"aliases":["KIAA1720"]}},{"id":"831fec762af8425496fdd3574cb920c9","type":"GENE","name":"SH3D19","canonical_id":"hgnc:HGNC:30418","description":"SH3 domain containing 19","metadata":{"aliases":["DKFZp434D0215","EVE1","EBP","Kryn","SH3P19","Eve-1"]}},{"id":"882020cc40824a6a80ca2f1b9a24342f","type":"GENE","name":"SH3D19-AS1","canonical_id":"hgnc:HGNC:58337","description":"SH3D19 antisense RNA 1","metadata":null},{"id":"a56db2945c434164987a4e06f893ce89","type":"GENE","name":"SH3GL1","canonical_id":"hgnc:HGNC:10830","description":"SH3 domain containing GRB2 like 1, endophilin A2","metadata":{"aliases":["SH3P8","SH3D2B","CNSA1","EEN","MGC111371"]}},{"id":"6d76f4298c63473c9ca403f1fa631874","type":"GENE","name":"SH3GL1-AS1","canonical_id":"hgnc:HGNC:58592","description":"SH3GL1 antisense RNA 1","metadata":null},{"id":"e87b30d38f504190a0f3f6ee50d91e52","type":"GENE","name":"SH3GL1P1","canonical_id":"hgnc:HGNC:10835","description":"SH3 domain containing GRB2 like 1, endophilin A2 pseudogene 1","metadata":{"aliases":["CNSA-P1","SH3GLP1"]}},{"id":"f62373dad6a24cb593e1683d243129c0","type":"GENE","name":"SH3GL1P2","canonical_id":"hgnc:HGNC:10836","description":"SH3 domain containing GRB2 like 1, endophilin A2 pseudogene 2","metadata":{"aliases":["CNSA-P2","SH3GLP2"]}},{"id":"3f391cead7084e63b18d28f7f4d18b39","type":"GENE","name":"SH3GL1P3","canonical_id":"hgnc:HGNC:10837","description":"SH3 domain containing GRB2 like 1, endophilin A2 pseudogene 3","metadata":{"aliases":["CNSA-P3","SH3GLP3"]}},{"id":"ac9c8e690ab7402aa3f2fa488fe0dd33","type":"GENE","name":"SH3GL2","canonical_id":"hgnc:HGNC:10831","description":"SH3 domain containing GRB2 like 2, endophilin A1","metadata":{"aliases":["SH3P4","SH3D2A","CNSA2","EEN-B1"]}},{"id":"c3ef573ef00c4e0a90837f5850530112","type":"GENE","name":"SH3GL3","canonical_id":"hgnc:HGNC:10832","description":"SH3 domain containing GRB2 like 3, endophilin A3","metadata":{"aliases":["SH3D2C","SH3P13","CNSA3","EEN-B2","HsT19371"]}},{"id":"a4176e22fb264f258095555724f5a7ab","type":"GENE","name":"SH3GLB1","canonical_id":"hgnc:HGNC:10833","description":"SH3 domain containing GRB2 like, endophilin B1","metadata":{"aliases":["CGI-61","KIAA0491","Bif-1","PPP1R70"]}},{"id":"5d8fc91622d74f85abd45bfb79e1b789","type":"GENE","name":"SH3GLB2","canonical_id":"hgnc:HGNC:10834","description":"SH3 domain containing GRB2 like, endophilin B2","metadata":{"aliases":["KIAA1848"]}},{"id":"1baeb9275adb4ba894b30973722b8b28","type":"GENE","name":"SH3KBP1","canonical_id":"hgnc:HGNC:13867","description":"SH3 domain containing kinase binding protein 1","metadata":{"aliases":["CIN85"]}},{"id":"acd2938035cd48ccaf0e1846dd604ccc","type":"GENE","name":"SH3PXD2A","canonical_id":"hgnc:HGNC:23664","description":"SH3 and PX domains 2A","metadata":{"aliases":["FISH","KIAA0418","SH3MD1"]}},{"id":"817386028ce14a6bb49d4d942b2f7e71","type":"GENE","name":"SH3PXD2A-AS1","canonical_id":"hgnc:HGNC:45242","description":"SH3PXD2A antisense RNA 1","metadata":null},{"id":"04bae70da2ca4057bc25c2a3577deea9","type":"GENE","name":"SH3PXD2B","canonical_id":"hgnc:HGNC:29242","description":"SH3 and PX domains 2B","metadata":{"aliases":["FLJ20831","KIAA1295"]}},{"id":"9b7bb45662564345a3e11a5205536d14","type":"GENE","name":"SH3RF1","canonical_id":"hgnc:HGNC:17650","description":"SH3 domain containing ring finger 1","metadata":{"aliases":["POSH","RNF142","KIAA1494","SH3MD2"]}},{"id":"4db85e2b3ca04d588f9eefb44de887ff","type":"GENE","name":"SH3RF1-AS1","canonical_id":"hgnc:HGNC:58426","description":"SH3RF1 antisense RNA 1","metadata":null},{"id":"234aecbc13cb44938bd050524d14f690","type":"GENE","name":"SH3RF2","canonical_id":"hgnc:HGNC:26299","description":"SH3 domain containing ring finger 2","metadata":{"aliases":["FLJ23654","RNF158","Hepp1","POSHER","PPP1R39"]}},{"id":"eb3701bd0dae40f2a96e3ebee9725274","type":"GENE","name":"SH3RF2-AS1","canonical_id":"hgnc:HGNC:59272","description":"SH3RF2 antisense RNA 1","metadata":null},{"id":"d373e8bd0776467c8a5fb0e8912b882a","type":"GENE","name":"SH3RF3","canonical_id":"hgnc:HGNC:24699","description":"SH3 domain containing ring finger 3","metadata":{"aliases":["FLJ00204","POSH2","SH3MD4"]}},{"id":"ba55771a73eb488c8af658fd619a20e7","type":"GENE","name":"SH3RF3-AS1","canonical_id":"hgnc:HGNC:44168","description":"SH3RF3 antisense RNA 1","metadata":null},{"id":"9e8b68b9e33b4f448b3ea2dbfc6313c6","type":"GENE","name":"SH3TC1","canonical_id":"hgnc:HGNC:26009","description":"SH3 domain and tetratricopeptide repeats 1","metadata":{"aliases":["FLJ20356"]}},{"id":"94ae914862dc4883902b64b9a37a2368","type":"GENE","name":"SH3TC2","canonical_id":"hgnc:HGNC:29427","description":"SH3 domain and tetratricopeptide repeats 2","metadata":{"aliases":["KIAA1985","CMT4C"]}},{"id":"e66aa09a64b94275ac407da8ad6794b7","type":"GENE","name":"SH3TC2-DT","canonical_id":"hgnc:HGNC:52905","description":"SH3TC2 divergent transcript","metadata":null},{"id":"8f15026d5cf4485893ac7abbcace6a15","type":"GENE","name":"SH3YL1","canonical_id":"hgnc:HGNC:29546","description":"SH3 and SYLF domain containing 1","metadata":{"aliases":["Ray","DKFZP586F1318"]}},{"id":"7ab2bc74e57646e4b31717027ffd993d","type":"GENE","name":"SHANK1","canonical_id":"hgnc:HGNC:15474","description":"SH3 and multiple ankyrin repeat domains 1","metadata":{"aliases":["SSTRIP","SPANK-1","synamon"]}},{"id":"54319415e97948e4812a545a478a9c51","type":"GENE","name":"SHANK2","canonical_id":"hgnc:HGNC:14295","description":"SH3 and multiple ankyrin repeat domains 2","metadata":{"aliases":["CTTNBP1","ProSAP1","SHANK","SPANK-3","CORTBP1"]}},{"id":"03b8ca1fa0f442ce848b572a2e6e36ac","type":"GENE","name":"SHANK2-AS1","canonical_id":"hgnc:HGNC:40014","description":"SHANK2 antisense RNA 1","metadata":{"aliases":["SHANK2-AS2"]}},{"id":"5d8998b2220b4998865dcc261b531f93","type":"GENE","name":"SHANK2-AS3","canonical_id":"hgnc:HGNC:25098","description":"SHANK2 antisense RNA 3","metadata":{"aliases":["C11orf76"]}},{"id":"1b2c311200964037beba87d2ddf5adaa","type":"GENE","name":"SHANK3","canonical_id":"hgnc:HGNC:14294","description":"SH3 and multiple ankyrin repeat domains 3","metadata":{"aliases":["SPANK-2","prosap2","KIAA1650","PSAP2"]}},{"id":"aae5cc06d50d4d2ca32c866214ad2c08","type":"TRIAL","name":"SHARE - Symbicort and Health Economics in a Real Life Evaluation","canonical_id":"clinicaltrials.gov:NCT00259766","description":"Asthma","metadata":null},{"id":"f44897e4500347c7a561bdb75b3f3c77","type":"GENE","name":"SHARPIN","canonical_id":"hgnc:HGNC:25321","description":"SHANK associated RH domain interactor","metadata":{"aliases":["DKFZP434N1923","SIPL1"]}},{"id":"569f202e9d3e4e4d8d3f654114cb4410","type":"GENE","name":"SHB","canonical_id":"hgnc:HGNC:10838","description":"SH2 domain containing adaptor protein B","metadata":null},{"id":"d466d86470be4939b44f97286ce779c7","type":"GENE","name":"SHBG","canonical_id":"hgnc:HGNC:10839","description":null,"metadata":null},{"id":"f83de4f138014690ab200047b7c36aa7","type":"GENE","name":"SHC1","canonical_id":"hgnc:HGNC:10840","description":null,"metadata":null},{"id":"c64f4ac49578431c82ea823a003deba6","type":"GENE","name":"SHC1P1","canonical_id":"hgnc:HGNC:10841","description":"SHC adaptor protein 1 pseudogene 1","metadata":null},{"id":"e6ea9f3f3ae348b188e7637d7d0080dc","type":"GENE","name":"SHC1P2","canonical_id":"hgnc:HGNC:10842","description":"SHC adaptor protein 1 pseudogene 2","metadata":{"aliases":["SHCL1"]}},{"id":"7dee7b98072f457598104783aeae246a","type":"GENE","name":"SHC2","canonical_id":"hgnc:HGNC:29869","description":"SHC adaptor protein 2","metadata":{"aliases":["SLI","SCK","SHCB"]}},{"id":"7fe372ad5e54471cb72476c42fdab515","type":"GENE","name":"SHC3","canonical_id":"hgnc:HGNC:18181","description":"SHC adaptor protein 3","metadata":{"aliases":["N-Shc","NSHC","SHCC"]}},{"id":"9a006c30ef864c859dcc7e55473511df","type":"GENE","name":"SHC4","canonical_id":"hgnc:HGNC:16743","description":"SHC adaptor protein 4","metadata":{"aliases":["RaLP","SHCD"]}},{"id":"b74074f6eaa444edb7d1a587b5188525","type":"GENE","name":"SHCBP1","canonical_id":"hgnc:HGNC:29547","description":"SHC binding and spindle associated 1","metadata":{"aliases":["FLJ22009","PAL"]}},{"id":"3163384d5ef148f9972f25a73ec8a6c1","type":"GENE","name":"SHCBP1L","canonical_id":"hgnc:HGNC:16788","description":"SHC binding and spindle associated 1 like","metadata":{"aliases":["C1orf14"]}},{"id":"345689665fef4b878962ec6ed118969f","type":"GENE","name":"SHD","canonical_id":"hgnc:HGNC:30633","description":"Src homology 2 domain containing transforming protein D","metadata":null},{"id":"e0a2d6b770be4109aa8b9d82dedead69","type":"GENE","name":"SHE","canonical_id":"hgnc:HGNC:27004","description":"Src homology 2 domain containing E","metadata":null},{"id":"9d575b508ed545f48e21f498877d534c","type":"GENE","name":"SHF","canonical_id":"hgnc:HGNC:25116","description":"Src homology 2 domain containing F","metadata":null},{"id":"34be1d75464f46cd90ca5fc932618d20","type":"GENE","name":"SHFL","canonical_id":"hgnc:HGNC:25649","description":"shiftless antiviral inhibitor of ribosomal frameshifting","metadata":{"aliases":["FLJ11286","RyDEN","IRAV","SFL","C19orf66"]}},{"id":"f77f3064c2bc418e8562fd646d2cc8e1","type":"GENE","name":"SHH","canonical_id":"hgnc:HGNC:10848","description":null,"metadata":null},{"id":"12424d03b18e426abbbe41b3ab45be0f","type":"GENE","name":"SHISA2","canonical_id":"hgnc:HGNC:20366","description":"shisa family member 2","metadata":{"aliases":["bA398O19.2","PRO28631","WGAR9166","hShisa","C13orf13","TMEM46"]}},{"id":"ae99d9e63eef4eddb52ce156acc99146","type":"GENE","name":"SHISA3","canonical_id":"hgnc:HGNC:25159","description":"shisa family member 3","metadata":{"aliases":["hShisa3"]}},{"id":"c3c666242fba40d497e4edb4f4026cf3","type":"GENE","name":"SHISA4","canonical_id":"hgnc:HGNC:27139","description":"shisa family member 4","metadata":{"aliases":["hShisa4","C1orf40","TMEM58"]}},{"id":"fdd8b813b5554cf1996440872afa2d59","type":"GENE","name":"SHISA5","canonical_id":"hgnc:HGNC:30376","description":"shisa family member 5","metadata":{"aliases":["SCOTIN","hShisa5"]}},{"id":"0370c12f872e470cb4ce28c2cbb9b4b0","type":"GENE","name":"SHISA5P1","canonical_id":"hgnc:HGNC:54937","description":"SHISA5 pseudogene 1","metadata":null},{"id":"c1ab66d9935b4a7cb8a48e1bc29e0833","type":"GENE","name":"SHISA5P2","canonical_id":"hgnc:HGNC:54993","description":"SHISA5 pseudogene 2","metadata":null},{"id":"114d6bc12d70447781311985d8ba540b","type":"GENE","name":"SHISA6","canonical_id":"hgnc:HGNC:34491","description":"shisa family member 6","metadata":{"aliases":["FLJ45455"]}},{"id":"a77e476a2e724c039d5f22a0b34b5421","type":"GENE","name":"SHISA7","canonical_id":"hgnc:HGNC:35409","description":"shisa family member 7","metadata":null},{"id":"1fce856e4e824e88bcf28cbdc5b66f5c","type":"GENE","name":"SHISA8","canonical_id":"hgnc:HGNC:18351","description":"shisa family member 8","metadata":{"aliases":["Orf26","C22orf17"]}},{"id":"885c47e2c38843db93391a26b0d0f2a7","type":"GENE","name":"SHISA9","canonical_id":"hgnc:HGNC:37231","description":"shisa family member 9","metadata":null},{"id":"c1d6c88ea6a240ab87d2e9cd31b6a7e9","type":"GENE","name":"SHISAL1","canonical_id":"hgnc:HGNC:29335","description":"shisa like 1","metadata":{"aliases":["KIAA1644"]}},{"id":"0356ff5cec154e9e92d91162fb9a1bdc","type":"GENE","name":"SHISAL2A","canonical_id":"hgnc:HGNC:28757","description":"shisa like 2A","metadata":{"aliases":["MGC52498","FAM159A"]}},{"id":"94a727e23e624110925b4479793bf1f6","type":"GENE","name":"SHISAL2B","canonical_id":"hgnc:HGNC:34236","description":"shisa like 2B","metadata":{"aliases":["FAM159B"]}},{"id":"bcb287623a4d4b2182dc0570955728a9","type":"GENE","name":"SHKBP1","canonical_id":"hgnc:HGNC:19214","description":"SH3KBP1 binding protein 1","metadata":{"aliases":["PP203","Sb1"]}},{"id":"117ef44da5954c79aa10bc9f42cd0d1a","type":"GENE","name":"SHLD1","canonical_id":"hgnc:HGNC:26318","description":"shieldin complex subunit 1","metadata":{"aliases":["FLJ25067","RINN3","C20orf196"]}},{"id":"5074be9fbb3f4d94a2dad4a9b0c28554","type":"GENE","name":"SHLD2","canonical_id":"hgnc:HGNC:28773","description":"shieldin complex subunit 2","metadata":{"aliases":["MGC5560","bA163M19.1","FAM35A1","RINN2","FAM35A"]}},{"id":"f3248528e4a148a789ee7e69661d5bf5","type":"GENE","name":"SHLD2P1","canonical_id":"hgnc:HGNC:31425","description":"shieldin complex subunit 2 pseudogene 1","metadata":{"aliases":["bA38L15.1","FAM35B","FAM35EP","FAM35BP"]}},{"id":"b05029fbccce4ca6bbdf04f876fb5487","type":"GENE","name":"SHLD2P2","canonical_id":"hgnc:HGNC:31427","description":"shieldin complex subunit 2 pseudogene 2","metadata":{"aliases":["FAM35AP","FAM35A2","FAM35CP"]}},{"id":"eeaf037f685b48b3a7febc19b8f8e2d5","type":"GENE","name":"SHLD2P3","canonical_id":"hgnc:HGNC:34038","description":"shieldin complex subunit 2 pseudogene 3","metadata":{"aliases":["FAM35B2","FAM35DP"]}},{"id":"b25f6155b8774b25bedac6a646f1221b","type":"GENE","name":"SHLD3","canonical_id":"hgnc:HGNC:53826","description":"shieldin complex subunit 3","metadata":{"aliases":["AC008560.1","FLJ26957","CTC-534A2.2","RINN1"]}},{"id":"be3c8b5582de48329fdd26cc3a0f4da6","type":"GENE","name":"SHMT1","canonical_id":"hgnc:HGNC:10850","description":null,"metadata":null},{"id":"df757eb826f2442d966475e4562eaa56","type":"GENE","name":"SHMT1P1","canonical_id":"hgnc:HGNC:10851","description":"SHMT1 pseudogene 1","metadata":{"aliases":["SHMT-ps1","SHMT1P"]}},{"id":"fca284e8313a41049becd01605fea1f3","type":"GENE","name":"SHMT2","canonical_id":"hgnc:HGNC:10852","description":"serine hydroxymethyltransferase 2","metadata":{"aliases":["mSHMT","SHMT"]}},{"id":"e73bcc6896d747c183fbf8fc319259c1","type":"GENE","name":"SHOC1","canonical_id":"hgnc:HGNC:26535","description":"shortage in chiasmata 1","metadata":{"aliases":["FLJ32779","Zip2","MZIP2","C9orf84"]}},{"id":"acee2ac7f99942d2b9f62e00182bae7f","type":"GENE","name":"SHOC2","canonical_id":"hgnc:HGNC:15454","description":"SHOC2 leucine rich repeat scaffold protein","metadata":{"aliases":["KIAA0862","SOC2","SUR-8","SOC-2","SUR8"]}},{"id":"55038376fe5148ed8de301b3eb996550","type":"GENE","name":"SHOX","canonical_id":"hgnc:HGNC:10853","description":null,"metadata":null},{"id":"f52257ac153d47598f683c42c559c1d0","type":"GENE","name":"SHOX2","canonical_id":"hgnc:HGNC:10854","description":null,"metadata":null},{"id":"2e2bb6b8a20746828708e9e5a8a99554","type":"GENE","name":"SHPK","canonical_id":"hgnc:HGNC:1492","description":"sedoheptulokinase","metadata":{"aliases":["SHK","CARKL"]}},{"id":"3ce035714e224f53857e859dcf749656","type":"GENE","name":"SHPRH","canonical_id":"hgnc:HGNC:19336","description":"SNF2 histone linker PHD RING helicase","metadata":{"aliases":["FLJ90837","KIAA2023","bA545I5.2"]}},{"id":"e6b8e40733834464825147d28522816e","type":"GENE","name":"SHQ1","canonical_id":"hgnc:HGNC:25543","description":"SHQ1, H/ACA ribonucleoprotein assembly factor","metadata":{"aliases":["FLJ10539","Shq1p"]}},{"id":"b3427f0e18754c708b77a700071a08a3","type":"GENE","name":"SHQ1P1","canonical_id":"hgnc:HGNC:45013","description":"SHQ1, H/ACA ribonucleoprotein assembly factor pseudogene 1","metadata":null},{"id":"ae305d4043114ee0a9381f26b2743ecd","type":"TRIAL","name":"SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT05020925","description":"Nasopharyngeal Carcinoma","metadata":null},{"id":"d6fad4f135234e5ca88465005296231c","type":"TRIAL","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","canonical_id":"clinicaltrials.gov:NCT06123494","description":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"4e8695deb35544c49c132c3be93b99d9","type":"GO_TERM","name":"SHREC complex","canonical_id":"go:GO:0070824","description":"\"A histone deacetylase complex that contains a core of four proteins -- Clr1, Clr2, Clr3, and Mit1 in fission yeast -- and localizes to all heterochromatic regions in the genome as well as some euchromatic sites. The complex is involved in regulating nucleosome positioning to assemble higher-order chromatin structures.\" [GOC:mah, PMID:17289569]","metadata":null},{"id":"af1ecf659877461e9ecaaddb465dab5e","type":"GO_TERM","name":"SHREC complex localization","canonical_id":"go:GO:0072688","description":"\"Any process in which a SHREC complex is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"2d69aafd77a34b8d859be4d82d944577","type":"GENE","name":"SHROOM1","canonical_id":"hgnc:HGNC:24084","description":"shroom family member 1","metadata":{"aliases":["APXL2","KIAA1960"]}},{"id":"88f7e85fe89d4767b72d681a14485939","type":"GENE","name":"SHROOM2","canonical_id":"hgnc:HGNC:630","description":"shroom family member 2","metadata":{"aliases":["APXL"]}},{"id":"171303c73f6745d9a5adc7d38c756902","type":"GENE","name":"SHROOM2P1","canonical_id":"hgnc:HGNC:631","description":"shroom family member 2 pseudogene 1","metadata":{"aliases":["APXLP"]}},{"id":"7e8ffdaaecf1427092a682513ffc0d5a","type":"GENE","name":"SHROOM3","canonical_id":"hgnc:HGNC:30422","description":"shroom family member 3","metadata":{"aliases":["ShrmL","SHRM","KIAA1481","APXL3"]}},{"id":"a735092761d3408bb07c20d0f76f6bc7","type":"GENE","name":"SHROOM3-AS1","canonical_id":"hgnc:HGNC:41265","description":"SHROOM3 antisense RNA 1","metadata":null},{"id":"c4d13d12c3bc49d38571084e9269e93d","type":"GENE","name":"SHROOM3-AS2","canonical_id":"hgnc:HGNC:58822","description":"SHROOM3 antisense RNA 2","metadata":null},{"id":"838a60d1e5f94545a54440b64e4b416c","type":"GENE","name":"SHROOM4","canonical_id":"hgnc:HGNC:29215","description":"shroom family member 4","metadata":{"aliases":["KIAA1202","Shrm4","SHAP"]}},{"id":"ed6906f6b74b4df8aeaa7a80c98212e8","type":"GENE","name":"SHTN1","canonical_id":"hgnc:HGNC:29319","description":"shootin 1","metadata":{"aliases":["shootin1","shootin-1","KIAA1598"]}},{"id":"71dac1310fe64dae81632a09f7604a64","type":"GENE","name":"SI","canonical_id":"hgnc:HGNC:10856","description":null,"metadata":null},{"id":"ebee882f72594fcea83b5c930557ed6e","type":"GENE","name":"SIAE","canonical_id":"hgnc:HGNC:18187","description":"sialic acid acetylesterase","metadata":{"aliases":["CSE-C","MGC87009","LSE","YSG2"]}},{"id":"035cdac165294529901bfb5937c18c61","type":"GENE","name":"SIAH1","canonical_id":"hgnc:HGNC:10857","description":null,"metadata":null},{"id":"2a913acd6a24484ea91cc1370ba9330f","type":"GENE","name":"SIAH1P1","canonical_id":"hgnc:HGNC:30966","description":"siah E3 ubiquitin protein ligase 1 pseudogene 1","metadata":{"aliases":["SIAH1L"]}},{"id":"2f092416723e424d88af66c637e8f71a","type":"GENE","name":"SIAH2","canonical_id":"hgnc:HGNC:10858","description":"siah E3 ubiquitin protein ligase 2","metadata":null},{"id":"5cea588a242344b196ed9c47cf89e99a","type":"GENE","name":"SIAH2-AS1","canonical_id":"hgnc:HGNC:40526","description":"SIAH2 and CLRN1 antisense RNA 1","metadata":{"aliases":["CLRN1-AS1"]}},{"id":"fa1645f278fd463496892cb22dff4566","type":"GENE","name":"SIAH3","canonical_id":"hgnc:HGNC:30553","description":"siah E3 ubiquitin protein ligase family member 3","metadata":{"aliases":["FLJ39203"]}},{"id":"5ffe6da27df043f8bf840facb2fafb55","type":"GENE","name":"SIDT1","canonical_id":"hgnc:HGNC:25967","description":null,"metadata":null},{"id":"c0e363a124e74b32b728568480eca1ee","type":"GENE","name":"SIDT1-AS1","canonical_id":"hgnc:HGNC:41126","description":"SIDT1 antisense RNA 1","metadata":null},{"id":"0a5d0cfaaeae445baf4a331becf91557","type":"GENE","name":"SIDT2","canonical_id":"hgnc:HGNC:24272","description":"SID1 transmembrane family member 2","metadata":{"aliases":["CGI-40"]}},{"id":"29e3ffe74960469f87f66d0525a7c075","type":"GENE","name":"SIGIRR","canonical_id":"hgnc:HGNC:30575","description":null,"metadata":null},{"id":"e5a4d196d0e84383b1660ede30a78cf3","type":"GENE","name":"SIGLEC1","canonical_id":"hgnc:HGNC:11127","description":"sialic acid binding Ig like lectin 1","metadata":{"aliases":["SIGLEC-1","CD169","FLJ00051","FLJ00055","FLJ00073","FLJ32150","dJ1009E24.1","SN"]}},{"id":"5816e7fe6f774da4b2bb9600b66f0bd2","type":"GENE","name":"SIGLEC10","canonical_id":"hgnc:HGNC:15620","description":"sialic acid binding Ig like lectin 10","metadata":{"aliases":["SIGLEC-10","SLG2","PRO940","MGC126774"]}},{"id":"a0114618b92a4580989d558e4daceaa9","type":"GENE","name":"SIGLEC10-AS1","canonical_id":"hgnc:HGNC:40719","description":"SIGLEC10 antisense RNA 1","metadata":null},{"id":"dbbbbd0085ab4fcf8ff83f9aa4c654fa","type":"GENE","name":"SIGLEC10-AS2","canonical_id":"hgnc:HGNC:40718","description":"SIGLEC10 antisense RNA 2","metadata":{"aliases":["AC008750.1"]}},{"id":"b65690ed158f4b43908017205b5c4fba","type":"GENE","name":"SIGLEC11","canonical_id":"hgnc:HGNC:15622","description":"sialic acid binding Ig like lectin 11","metadata":null},{"id":"307f5ef6f1db4e58a9b57dcb5333ac05","type":"GENE","name":"SIGLEC12","canonical_id":"hgnc:HGNC:15482","description":"sialic acid binding Ig like lectin 12","metadata":{"aliases":["SLG","S2V","Siglec-XII","Siglec-12","Siglec-L1","SIGLECL1"]}},{"id":"54eea4864e55450e8930668bd6402c95","type":"GENE","name":"SIGLEC14","canonical_id":"hgnc:HGNC:32926","description":"sialic acid binding Ig like lectin 14","metadata":null},{"id":"2952f0206ab44c1fb67ed3790ec12989","type":"GENE","name":"SIGLEC15","canonical_id":"hgnc:HGNC:27596","description":"sialic acid binding Ig like lectin 15","metadata":{"aliases":["HsT1361","CD33L3"]}},{"id":"b4676d8596f34934bb948173e1ba980d","type":"GENE","name":"SIGLEC16","canonical_id":"hgnc:HGNC:24851","description":"sialic acid binding Ig like lectin 16 (gene/pseudogene)","metadata":{"aliases":["Siglec-P16","SIGLECP16"]}},{"id":"d90665a4384e4b3fa4812b25f0e00c58","type":"GENE","name":"SIGLEC17P","canonical_id":"hgnc:HGNC:15604","description":"sialic acid binding Ig like lectin 17, pseudogene","metadata":{"aliases":["SIGLECP3"]}},{"id":"aa205657afc5477da389a91e28fd2482","type":"GENE","name":"SIGLEC18P","canonical_id":"hgnc:HGNC:15491","description":"sialic acid binding Ig like lectin 18, pseudogene","metadata":{"aliases":["SIGLECP1"]}},{"id":"20761ba00e35473593b98bfd7d77e957","type":"GENE","name":"SIGLEC20P","canonical_id":"hgnc:HGNC:15609","description":"sialic acid binding Ig like lectin 20, pseudogene","metadata":{"aliases":["SIGLECP4"]}},{"id":"a2f7353125414e5e8f750743213fb02e","type":"GENE","name":"SIGLEC21P","canonical_id":"hgnc:HGNC:15610","description":"sialic acid binding Ig like lectin 21, pseudogene","metadata":{"aliases":["SIGLECP5"]}},{"id":"3df8ec3e6a27413599fffed0694243d9","type":"GENE","name":"SIGLEC22P","canonical_id":"hgnc:HGNC:15611","description":"sialic acid binding Ig like lectin 22, pseudogene","metadata":{"aliases":["SIGLECP6"]}},{"id":"af5e8e1026f74e3395dcc89590f23db7","type":"GENE","name":"SIGLEC24P","canonical_id":"hgnc:HGNC:15613","description":"sialic acid binding Ig like lectin 24, pseudogene","metadata":{"aliases":["SIGLECP8"]}},{"id":"fbc12f40907744038e90fb3a46490f59","type":"GENE","name":"SIGLEC25P","canonical_id":"hgnc:HGNC:15614","description":"sialic acid binding Ig like lectin 25, pseudogene","metadata":{"aliases":["SIGLECP9"]}},{"id":"82bb4b65f2c346c9a4330de73194ebd6","type":"GENE","name":"SIGLEC26P","canonical_id":"hgnc:HGNC:15615","description":"sialic acid binding Ig like lectin 26, pseudogene","metadata":{"aliases":["SIGLECP10"]}},{"id":"f61c716493e44df09d40402b19185022","type":"GENE","name":"SIGLEC27P","canonical_id":"hgnc:HGNC:15617","description":"sialic acid binding Ig like lectin 27, pseudogene","metadata":{"aliases":["SIGLECP11"]}},{"id":"754229da428b4c658026a3c964a2526c","type":"GENE","name":"SIGLEC28P","canonical_id":"hgnc:HGNC:15618","description":"sialic acid binding Ig like lectin 28, pseudogene","metadata":{"aliases":["SIGLECP12"]}},{"id":"6810b12279a54e079ec003b788216978","type":"GENE","name":"SIGLEC29P","canonical_id":"hgnc:HGNC:15619","description":"sialic acid binding Ig like lectin 29, pseudogene","metadata":{"aliases":["SIGLECP13"]}},{"id":"22927c4c151e49bd9a7cc37e669cf3e0","type":"GENE","name":"SIGLEC30P","canonical_id":"hgnc:HGNC:15623","description":"sialic acid binding Ig like lectin 30, pseudogene","metadata":{"aliases":["SIGLECP14"]}},{"id":"032f517121fd4bcface0ea6c1979da9b","type":"GENE","name":"SIGLEC31P","canonical_id":"hgnc:HGNC:16072","description":"sialic acid binding Ig like lectin 31, pseudogene","metadata":{"aliases":["SIGLECP15"]}},{"id":"37e15ed137dd4bf6a0868ed6a097f72b","type":"GENE","name":"SIGLEC5","canonical_id":"hgnc:HGNC:10874","description":"sialic acid binding Ig like lectin 5","metadata":{"aliases":["OB-BP2","SIGLEC-5","CD170","CD33L2"]}},{"id":"97b6d672449b476ab2edcdd3d30d0123","type":"GENE","name":"SIGLEC6","canonical_id":"hgnc:HGNC:10875","description":"sialic acid binding Ig like lectin 6","metadata":{"aliases":["OB-BP1","SIGLEC-6","CD327","CD33L","CD33L1"]}},{"id":"eee5735c6ad64fc383fdbe17de728c9e","type":"GENE","name":"SIGLEC7","canonical_id":"hgnc:HGNC:10876","description":"sialic acid binding Ig like lectin 7","metadata":{"aliases":["SIGLEC-7","p75/AIRM1","QA79","CD328","SIGLEC19P","SIGLECP2"]}},{"id":"155b6717b28748f0a10db7789b3d374a","type":"GENE","name":"SIGLEC8","canonical_id":"hgnc:HGNC:10877","description":"sialic acid binding Ig like lectin 8","metadata":{"aliases":["SIGLEC-8","SAF2","SIGLEC8L","MGC59785"]}},{"id":"42606606bc3841809800788582579831","type":"GENE","name":"SIGLEC9","canonical_id":"hgnc:HGNC:10878","description":"sialic acid binding Ig like lectin 9","metadata":{"aliases":["CD329"]}},{"id":"5c0de56e69b149d190c2225d6b59b5f6","type":"GENE","name":"SIGLECL1","canonical_id":"hgnc:HGNC:26856","description":"SIGLEC family like 1","metadata":{"aliases":["FLJ40235","C19orf75","SIGLEC23P","SIGLECP7"]}},{"id":"b32445fe99454278a8a5769ed924243d","type":"GENE","name":"SIGMAR1","canonical_id":"hgnc:HGNC:8157","description":null,"metadata":null},{"id":"2383912de9284453a224d4aebca3ef7a","type":"PROTEIN","name":"SIGMAR1","canonical_id":"uniprot:Q99720","description":null,"metadata":null},{"id":"a6b86ce1fcca49a8a29b536cefa6f5e8","type":"GENE","name":"SIK1","canonical_id":"hgnc:HGNC:11142","description":"salt inducible kinase 1","metadata":{"aliases":["msk","SNF1LK"]}},{"id":"2834af68d072419fa879fe31b40136a3","type":"GENE","name":"SIK2","canonical_id":"hgnc:HGNC:21680","description":"salt inducible kinase 2","metadata":{"aliases":["KIAA0781","QIK","DKFZp434K1115","LOH11CR1I","SNF1LK2"]}},{"id":"fbd5cee3bb5b495badd589bb549ac8cc","type":"GENE","name":"SIK3","canonical_id":"hgnc:HGNC:29165","description":"SIK family kinase 3","metadata":{"aliases":["FLJ12240","L19","KIAA0999","QSK"]}},{"id":"e2cfcf463438417b9dc90ff79f369d9f","type":"GENE","name":"SIKE1","canonical_id":"hgnc:HGNC:26119","description":"suppressor of IKBKE 1","metadata":{"aliases":["FLJ21168","SIKE"]}},{"id":"756c7400bc5b476dad75a2180935f84e","type":"GENE","name":"SIL1","canonical_id":"hgnc:HGNC:24624","description":"SIL1 nucleotide exchange factor","metadata":{"aliases":["BAP","ULG5","MSS"]}},{"id":"c68e787fd41343cdad0b8b0ba21ea9b4","type":"GENE","name":"SIL1-AS1","canonical_id":"hgnc:HGNC:41056","description":"SIL1 antisense RNA 1","metadata":null},{"id":"9e312c1ec99b4c489bfb887e27d8a409","type":"GENE","name":"SILC1","canonical_id":"hgnc:HGNC:26403","description":"sciatic injury induced lincRNA upregulator of SOX11","metadata":{"aliases":["FLJ30594","LOC150622","LINC01105"]}},{"id":"2e6f05bea9d84fff87e5c23d35d27474","type":"TRIAL","name":"SILtuximab in Viral ARds (SILVAR) Study","canonical_id":"clinicaltrials.gov:NCT04616586","description":"Acute Respiratory Distress Syndrome; Lung Diseases; Pneumonia; Respiratory Tract Infections; Respiratory Tract Disease","metadata":null},{"id":"9c92503b2a9a433ab3e08584c1009595","type":"GENE","name":"SIM1","canonical_id":"hgnc:HGNC:10882","description":"SIM bHLH transcription factor 1","metadata":{"aliases":["bHLHe14"]}},{"id":"67afda6c5c2e426985859eab7c226a3b","type":"GENE","name":"SIM1-AS1","canonical_id":"hgnc:HGNC:40530","description":"SIM1 antisense RNA 1","metadata":null},{"id":"c244026aa79f4e32b9f208354145e326","type":"GENE","name":"SIM2","canonical_id":"hgnc:HGNC:10883","description":null,"metadata":null},{"id":"6a1d18f62f6b43b8839288e6c913da65","type":"GENE","name":"SIMALR","canonical_id":"hgnc:HGNC:53554","description":"suppressor of inflammatory macrophage apoptosis lncRNA","metadata":{"aliases":["LINC02528"]}},{"id":"fd23f472668f4e9da893e634f3d0d9a7","type":"GENE","name":"SIMC1","canonical_id":"hgnc:HGNC:24779","description":"SUMO interacting motifs containing 1","metadata":{"aliases":["FLJ44216","OOMA1","PLEIAD","C5orf25"]}},{"id":"48a7d5ec4f874a9aa6ba5b9b0212b9ea","type":"GENE","name":"SIMC1P1","canonical_id":"hgnc:HGNC:56818","description":"SIMC1 pseudogene 1","metadata":null},{"id":"eef42fdb0a54496080dcc551b74b40c1","type":"GO_TERM","name":"SIN/MEN signaling complex","canonical_id":"go:GO:0160065","description":"\"A protein complex associated with the mitotic spindle pole body during interphase and mitosis and comprises of the proteins of the septation initiation signaling network (SIN) of fission yeast or mitotic exit network (MEN) of budding yeast, organized by two scaffold/adaptor proteins.\" [PMID:21131906, PMID:22525225, PMID:22684255]","metadata":null},{"id":"22a2aac000a640f0bbd0dfc4c76d9657","type":"GO_TERM","name":"SIN/MEN two-component GAP complex","canonical_id":"go:GO:1990334","description":"\"A protein complex that acts as a two-component GTPase-activating protein for the Tem1/Spg1 GTPase, thus regulating a signal transduction cascade (the mitotic exit network, MEN, in budding yeast; the septation initiation network, SIN, in fission yeast), which is required for mitotic exit and cytokinesis. The complex keeps the GTPase inactive until the spindle is properly oriented, thus inhibiting MEN/SIN activation.\" [GOC:bhm, PMID:16449187]","metadata":null},{"id":"31b08db7fbf34a51a01b807feff982bf","type":"GENE","name":"SIN3A","canonical_id":"hgnc:HGNC:19353","description":null,"metadata":null},{"id":"5f22b79261ec4501abc80718c8a2358d","type":"GENE","name":"SIN3B","canonical_id":"hgnc:HGNC:19354","description":"SIN3 transcription regulator family member B","metadata":{"aliases":["KIAA0700"]}},{"id":"ac3c1e439dd44b649535b6047e81eb97","type":"GENE","name":"SINHCAF","canonical_id":"hgnc:HGNC:30702","description":"SIN3-HDAC complex associated factor","metadata":{"aliases":["TERA","C12orf14","FAM60A"]}},{"id":"b852c623d2cb4cfb865a01f36a491347","type":"GENE","name":"SINHCAFP1","canonical_id":"hgnc:HGNC:19052","description":"SINHCAF pseudogene 1","metadata":{"aliases":["HsT2323","FAM60BP"]}},{"id":"4d1201661a7540ebba6190b2123dd09f","type":"GENE","name":"SINHCAFP2","canonical_id":"hgnc:HGNC:31737","description":"SINHCAF pseudogene 2","metadata":{"aliases":["FAM60CP"]}},{"id":"f9f9911733924306a6d037237c96967c","type":"GENE","name":"SINHCAFP3","canonical_id":"hgnc:HGNC:19896","description":"SINHCAF pseudogene 3","metadata":{"aliases":["FAM60DP"]}},{"id":"11b20c1dcf6043eda7240dd310e887d3","type":"GENE","name":"SIPA1","canonical_id":"hgnc:HGNC:10885","description":"signal-induced proliferation-associated 1","metadata":{"aliases":["SPA1"]}},{"id":"1cddc802106a475fa236f50412b47f39","type":"GENE","name":"SIPA1L1","canonical_id":"hgnc:HGNC:20284","description":"signal induced proliferation associated 1 like 1","metadata":{"aliases":["KIAA0440","E6TP1","SPAR1"]}},{"id":"cedfb5d6c63344f2b2a8f3eac4069fb1","type":"GENE","name":"SIPA1L1-AS1","canonical_id":"hgnc:HGNC:55432","description":"SIPA1L1 antisense RNA 1","metadata":null},{"id":"07b86580912449999aa5907dfc4cf4a9","type":"GENE","name":"SIPA1L2","canonical_id":"hgnc:HGNC:23800","description":"signal induced proliferation associated 1 like 2","metadata":{"aliases":["KIAA1389","SPAR2"]}},{"id":"e9e08e06b96f44f9964304b464158876","type":"GENE","name":"SIPA1L3","canonical_id":"hgnc:HGNC:23801","description":"signal induced proliferation associated 1 like 3","metadata":{"aliases":["KIAA0545","SPAR3"]}},{"id":"d68dff8030ee4941ac4cd70d6592802b","type":"GENE","name":"SIRAL1","canonical_id":"hgnc:HGNC:26110","description":"SIR2 antiphage like 1","metadata":{"aliases":["SIRal","FLJ21103","FAM118B"]}},{"id":"9d61943f8550496d8fda20a01ecda015","type":"GENE","name":"SIRAL2","canonical_id":"hgnc:HGNC:1313","description":"SIR2 antiphage like 2","metadata":{"aliases":["SIRal2","FLJ20635","bK268H5.C22.4","C22orf8","FAM118A"]}},{"id":"91c07c96b77d4311b105a6526086fa2c","type":"GENE","name":"SIRLNT","canonical_id":"hgnc:HGNC:53902","description":"SIRT1 regulating lncRNA tumor promoter","metadata":{"aliases":["lncRNA-PRLB"]}},{"id":"d8ed8b875519430081a9e16411239b1f","type":"GENE","name":"SIRPA","canonical_id":"hgnc:HGNC:9662","description":"signal regulatory protein alpha","metadata":{"aliases":["SHPS1","SIRP","MYD-1","BIT","P84","SHPS-1","SIRPalpha","CD172a","SIRPalpha2","MFR","SIRP-ALPHA-1","PTPNS1"]}},{"id":"7b63d229b1874cb6b29fa3e756dc10c8","type":"GENE","name":"SIRPAP1","canonical_id":"hgnc:HGNC:9663","description":"signal regulatory protein alpha pseudogene 1","metadata":{"aliases":["SIRPA2P","PTPNS1L"]}},{"id":"76ce467d62f54d7c9fac78286cce1a3a","type":"GENE","name":"SIRPB1","canonical_id":"hgnc:HGNC:15928","description":"signal regulatory protein beta 1","metadata":{"aliases":["SIRP-BETA-1","CD172b","SIRB1"]}},{"id":"1694a9f9755c432b8f517c021e8ca2e8","type":"GENE","name":"SIRPB2","canonical_id":"hgnc:HGNC:16247","description":"signal regulatory protein beta 2","metadata":{"aliases":["dJ776F14.2","PTPN1L","PTPNS1L3"]}},{"id":"ed6140fd0a6e42dd9247c0b4a5e53132","type":"GENE","name":"SIRPB3P","canonical_id":"hgnc:HGNC:49209","description":"signal regulatory protein beta 3, pseudogene","metadata":null},{"id":"7e9f13f5d6124748823690d697cb2dc4","type":"GENE","name":"SIRPD","canonical_id":"hgnc:HGNC:16248","description":"signal regulatory protein delta","metadata":{"aliases":["dJ576H24.4","PTPNS1L2"]}},{"id":"4da8ea97a2534209b37266f9b6abc9af","type":"GENE","name":"SIRPG","canonical_id":"hgnc:HGNC:15757","description":"signal regulatory protein gamma","metadata":{"aliases":["bA77C3.1","SIRP-B2","SIRPgamma","CD172g","SIRPB2"]}},{"id":"225f6b08f59d43fea765ff4908b9b6df","type":"GENE","name":"SIRPG-AS1","canonical_id":"hgnc:HGNC:51229","description":"SIRPG antisense RNA 1","metadata":null},{"id":"144ffbf6c11344719d65c3b0f32adc8a","type":"GENE","name":"SIRT1","canonical_id":"hgnc:HGNC:14929","description":null,"metadata":null},{"id":"899e4d4d2e0246028ffd70d1186559e1","type":"GENE","name":"SIRT1-AS","canonical_id":"hgnc:HGNC:51912","description":"SIRT1 antisense RNA","metadata":null},{"id":"9de9f7aa1b534265b0a365c5373da035","type":"GENE","name":"SIRT2","canonical_id":"hgnc:HGNC:10886","description":null,"metadata":null},{"id":"1fd7e817e9ed4958870d3beeff1abeeb","type":"GENE","name":"SIRT3","canonical_id":"hgnc:HGNC:14931","description":null,"metadata":null},{"id":"61184ed5082d4b9982b02e542bc80bdf","type":"GENE","name":"SIRT4","canonical_id":"hgnc:HGNC:14932","description":"sirtuin 4","metadata":{"aliases":["SIR2L4"]}},{"id":"b55054fdc50a476eaf434e78482f1e21","type":"GENE","name":"SIRT5","canonical_id":"hgnc:HGNC:14933","description":"sirtuin 5","metadata":null},{"id":"53eebedeadba4b25b83444e0de752ecf","type":"GENE","name":"SIRT5-AS1","canonical_id":"hgnc:HGNC:59355","description":"SIRT5 antisense RNA 1","metadata":null},{"id":"b3941244e65744d8b9ae0916caacfe4f","type":"GENE","name":"SIRT5-AS2","canonical_id":"hgnc:HGNC:59356","description":"SIRT5 antisense RNA 2","metadata":null},{"id":"fda218a7881243bca61b752ceb27528b","type":"GENE","name":"SIRT6","canonical_id":"hgnc:HGNC:14934","description":null,"metadata":null},{"id":"fa6426f553f242988e110dcf1dfcd5a3","type":"GENE","name":"SIRT7","canonical_id":"hgnc:HGNC:14935","description":"sirtuin 7","metadata":null},{"id":"be2e5f62a36d4e50b2dcaee0b96127f0","type":"TRIAL","name":"SISTERS: Spasticity In Stroke Study - Randomized Study","canonical_id":"clinicaltrials.gov:NCT01032239","description":"Severe Spasticity","metadata":null},{"id":"09d2a804493547179307f343c67e19c3","type":"GENE","name":"SIT1","canonical_id":"hgnc:HGNC:17710","description":"signaling threshold regulating transmembrane adaptor 1","metadata":{"aliases":["SIT"]}},{"id":"67fe675505304a139c40d122bb5049c8","type":"GENE","name":"SIVA1","canonical_id":"hgnc:HGNC:17712","description":null,"metadata":null},{"id":"1762ae954bca4c3184b431b9516ac9e4","type":"GENE","name":"SIX1","canonical_id":"hgnc:HGNC:10887","description":null,"metadata":null},{"id":"57b640c8f1864d42bdfe3a17ebd848cc","type":"GENE","name":"SIX2","canonical_id":"hgnc:HGNC:10888","description":"SIX homeobox 2","metadata":null},{"id":"0597e752b23949aabb59d699fa03b272","type":"GENE","name":"SIX3","canonical_id":"hgnc:HGNC:10889","description":null,"metadata":null},{"id":"edd7a152b6f34f3986a64fded9733c05","type":"GENE","name":"SIX3-AS1","canonical_id":"hgnc:HGNC:40532","description":"SIX3 antisense RNA 1","metadata":{"aliases":["SIX3OS"]}},{"id":"94848bef6f8e40769723c67b4c3c67ec","type":"GENE","name":"SIX3-OT1","canonical_id":"hgnc:HGNC:59248","description":"SIX3 overlapping transcript 1","metadata":{"aliases":["AC012354.6"]}},{"id":"e5a8626779aa44a3842c0f9698c9b7a8","type":"GENE","name":"SIX4","canonical_id":"hgnc:HGNC:10890","description":"SIX homeobox 4","metadata":{"aliases":["AREC3"]}},{"id":"d3b8e545d7e743c4b7476826bff1a1ca","type":"GENE","name":"SIX5","canonical_id":"hgnc:HGNC:10891","description":null,"metadata":null},{"id":"a729a2e28eeb4500a83950f3e5dd2259","type":"GENE","name":"SIX6","canonical_id":"hgnc:HGNC:10892","description":null,"metadata":null},{"id":"97f8fca8b3544159852dcbe89849ae66","type":"TRIAL","name":"SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT04923126","description":"Low-Grade Glioma; Recurrent Low-Grade Glioma; Progressive Low-Grade Glioma","metadata":null},{"id":"e4eba328f2694987811ea6cf015465c7","type":"TRIAL","name":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","canonical_id":"clinicaltrials.gov:NCT03434262","description":"Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Ganglioglioma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Pleomorphic Xanthoastrocytoma, Anaplastic; Atypical Teratoid/Rhabdoid Tumor; Brain Cancer; Brain Tumor; Central Nervous System Neoplasms; Choroid Plexus Carcinoma; CNS Embryonal Tumor With Rhabdoid Features; Ganglioneuroblastoma of Central Nervous System; CNS Tumor; Embryonal Tumor of CNS; Ependymoma; Glioblastoma; Glioma; Glioma, Malignant; Medulloblastoma; Medulloblast\u2026","metadata":null},{"id":"312ab86cf8df4130b0d5cdab057d072e","type":"GO_TERM","name":"SKA complex","canonical_id":"go:GO:0170027","description":"\"An outer kinetochore complex involved in the attachment of microtubule ends to the chromosomes during mitosis. In humans, it contains the subunits SKA1, SKA2 and SKA3.\" [PMID:19289083, PMID:22483620]","metadata":null},{"id":"2fb402a6f2fa4469babab8a7d8444206","type":"GENE","name":"SKA1","canonical_id":"hgnc:HGNC:28109","description":"spindle and kinetochore associated complex subunit 1","metadata":{"aliases":["MGC10200","C18orf24"]}},{"id":"8e300c304e094d66a17cb52343d6a0ac","type":"GENE","name":"SKA2","canonical_id":"hgnc:HGNC:28006","description":"spindle and kinetochore associated complex subunit 2","metadata":{"aliases":["FLJ12758","FAM33A"]}},{"id":"41a12e1da7604fdfa0e3dfe4940b7327","type":"GENE","name":"SKA2P1","canonical_id":"hgnc:HGNC:23122","description":"spindle and kinetochore associated complex subunit 2 pseudogene 1","metadata":{"aliases":["Em:AC006313.1","FAM33B","SKA2L"]}},{"id":"6e203338020b41baa247f81f560854d8","type":"GENE","name":"SKA3","canonical_id":"hgnc:HGNC:20262","description":"spindle and kinetochore associated complex subunit 3","metadata":{"aliases":["MGC4832","RAMA1","C13orf3"]}},{"id":"3d86631537e6444dad63e5b9fd054c8f","type":"GENE","name":"SKAP1","canonical_id":"hgnc:HGNC:15605","description":"src kinase associated phosphoprotein 1","metadata":{"aliases":["SKAP55","SCAP1"]}},{"id":"b7d3306923f34cba9fc8054a463de78b","type":"GENE","name":"SKAP1-AS1","canonical_id":"hgnc:HGNC:53166","description":"SKAP1 antisense RNA 1","metadata":{"aliases":["RP11-456D7.1"]}},{"id":"1070b98dd7614d6591661e8f3ec4945f","type":"GENE","name":"SKAP1-AS2","canonical_id":"hgnc:HGNC:55570","description":"SKAP1 antisense RNA 2","metadata":{"aliases":["BTR"]}},{"id":"da4782bd9f1443cc8077c4804fd4785e","type":"GENE","name":"SKAP2","canonical_id":"hgnc:HGNC:15687","description":"src kinase associated phosphoprotein 2","metadata":{"aliases":["RA70","SKAP-HOM","SKAP55R","SAPS","SCAP2"]}},{"id":"f102b9b9e299483b97ddf988068b494c","type":"TRIAL","name":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07109284","description":"ER+HER2- Breast Cancer","metadata":null},{"id":"4d39bf399e1248e59a42021a8d454e16","type":"TRIAL","name":"SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies","canonical_id":"clinicaltrials.gov:NCT07738757","description":"Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies","metadata":null},{"id":"1114d414476048818c7ec5659d2658fd","type":"TRIAL","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05642780","description":"Solid Tumor","metadata":null},{"id":"0c0dbc0471cf49abb061cfd62d62d5d5","type":"GENE","name":"SKI","canonical_id":"hgnc:HGNC:10896","description":null,"metadata":null},{"id":"c2f674c74fe740e0acc307d4d13d9255","type":"GENE","name":"SKIC2","canonical_id":"hgnc:HGNC:10898","description":"SKI2 subunit of superkiller complex","metadata":{"aliases":["HLP","DDX13","SKI2W","170A","SKIV2L1","SKI2","SKIV2","SKIV2L"]}},{"id":"4f937e1f64894491a0398c1f279055da","type":"GENE","name":"SKIC3","canonical_id":"hgnc:HGNC:23639","description":"SKI3 subunit of superkiller complex","metadata":{"aliases":["THES","SKI3","KIAA0372","TTC37"]}},{"id":"e0701015ebc44995a14996a167508385","type":"GENE","name":"SKIC8","canonical_id":"hgnc:HGNC:30300","description":"SKI8 subunit of superkiller complex","metadata":{"aliases":["REC14","SKI8","WDR61"]}},{"id":"48c463aff0334239b3e5fb75da88a788","type":"GENE","name":"SKIDA1","canonical_id":"hgnc:HGNC:32697","description":"SKI/DACH domain containing 1","metadata":{"aliases":["FLJ45187","C10orf140"]}},{"id":"fb16aeca69a849eea3fb5f68c3af8c98","type":"GENE","name":"SKIL","canonical_id":"hgnc:HGNC:10897","description":null,"metadata":null},{"id":"6c55ca52f40841958d40e41c350620c6","type":"GENE","name":"SKINT1L","canonical_id":"hgnc:HGNC:33993","description":"Skint1 like (pseudogene)","metadata":{"aliases":["SKINT1LP","BTN12","SKINTP","SKINTL"]}},{"id":"c78a9140414344119b6c5cf433af029a","type":"GENE","name":"SKOR1","canonical_id":"hgnc:HGNC:21326","description":"SKI family transcriptional corepressor 1","metadata":{"aliases":["CORL1","FUSSEL15","LBXCOR1"]}},{"id":"4a6d0b91cb214ca789cce8f6d2f8849d","type":"GENE","name":"SKOR1-AS1","canonical_id":"hgnc:HGNC:56365","description":"SKOR1 antisense RNA 1","metadata":{"aliases":["AC009292.1"]}},{"id":"0c34c8c131d0439c84fc632ddf9b0ebd","type":"GENE","name":"SKOR2","canonical_id":"hgnc:HGNC:32695","description":"SKI family transcriptional corepressor 2","metadata":{"aliases":["CORL2","FUSSEL18","Fussel-18"]}},{"id":"9bb7154aa5784546a181457165d06f8c","type":"GENE","name":"SKP1","canonical_id":"hgnc:HGNC:10899","description":"S-phase kinase associated protein 1","metadata":{"aliases":["EMC19","OCP2","TCEB1L","MGC34403","OCP-II","p19A","SKP1A"]}},{"id":"2be7607e8a6c4aac9439e40ccd7ee138","type":"GENE","name":"SKP1P1","canonical_id":"hgnc:HGNC:33696","description":"SKP1 pseudogene 1","metadata":{"aliases":["EMC19","OCP2","TCEB1L","TCEB1P"]}},{"id":"882c4bbdb0de48f5909daff6d94beefe","type":"GENE","name":"SKP1P2","canonical_id":"hgnc:HGNC:10900","description":"SKP1 pseudogene 2","metadata":{"aliases":["p19B","SKP1B"]}},{"id":"47cecc5efc774653ab8285854895d10b","type":"GENE","name":"SKP1P3","canonical_id":"hgnc:HGNC:50370","description":"SKP1 pseudogene 3","metadata":null},{"id":"a5d7a31cc36a47b99016a450b18bf542","type":"GENE","name":"SKP1P4","canonical_id":"hgnc:HGNC:56994","description":"SKP1 pseudogene 4","metadata":null},{"id":"7188863b36ba4cf994bdaaa8bd12a9c2","type":"GENE","name":"SKP1P5","canonical_id":"hgnc:HGNC:59073","description":"SKP1 pseudogene 5","metadata":null},{"id":"0a9dd3c27ba545a0a7cd64e3a5c7b4e7","type":"GENE","name":"SKP1P6","canonical_id":"hgnc:HGNC:59072","description":"SKP1 pseudogene 6","metadata":null},{"id":"82ec1bc002274d81bb4e02c0b675edd5","type":"GENE","name":"SKP1P7","canonical_id":"hgnc:HGNC:59074","description":"SKP1 pseudogene 7","metadata":null},{"id":"eeacb8fd19f94789a32b54b803a5a67f","type":"GENE","name":"SKP2","canonical_id":"hgnc:HGNC:10901","description":null,"metadata":null},{"id":"91522e4691a9460687002a92f2345fe8","type":"GENE","name":"SKP2P1","canonical_id":"hgnc:HGNC:55027","description":"SKP2 pseudogene 1","metadata":null},{"id":"517ffecc92974d76a4883a768e5592ab","type":"GO_TERM","name":"SL snRNP","canonical_id":"go:GO:0071024","description":"\"A ribonucleoprotein complex that contains spliced leader (SL) RNA and associated proteins.\" [GOC:krc, ISBN:0879697393]","metadata":null},{"id":"8a9d0e6aa89e493aa9d5c09bcb8f1de0","type":"GENE","name":"SLA","canonical_id":"hgnc:HGNC:10902","description":"Src like adaptor","metadata":{"aliases":["SLA1","SLAP-1","hSLAP","SLAP"]}},{"id":"69bee6907dfe4469a07b0126e717539c","type":"GENE","name":"SLA2","canonical_id":"hgnc:HGNC:17329","description":null,"metadata":null},{"id":"801d91e2846e4eba8ea5b17a4b67c35f","type":"GO_TERM","name":"SLAC complex","canonical_id":"go:GO:0140224","description":"\"A protein complex that regulates Arp2/3 complex-mediated actin nucleation.\" [GOC:lnp, PMID:22973053]","metadata":null},{"id":"239886de6728427a9e607be73181342b","type":"GENE","name":"SLAIN1","canonical_id":"hgnc:HGNC:26387","description":"SLAIN family member 1","metadata":{"aliases":["FLJ30046","C13orf32"]}},{"id":"7bc862da84944e4cbc374c22d2d9d724","type":"GENE","name":"SLAIN2","canonical_id":"hgnc:HGNC:29282","description":"SLAIN family member 2","metadata":{"aliases":["FLJ21611","KIAA1458"]}},{"id":"9931ee5a04a34d4bbae519cb959a3d08","type":"GENE","name":"SLAMF1","canonical_id":"hgnc:HGNC:10903","description":"signaling lymphocytic activation molecule family member 1","metadata":{"aliases":["CD150","IPO-3","IPO3","SLAM"]}},{"id":"2a6448ea3fb74dd093ebbaedfe96f4c6","type":"GENE","name":"SLAMF6","canonical_id":"hgnc:HGNC:21392","description":"SLAM family member 6","metadata":{"aliases":["KALI","NTBA","KALIb","Ly108","SF2000","NTB-A","CD352"]}},{"id":"2de7e146749e4e6f97ac202968207df0","type":"GENE","name":"SLAMF6P1","canonical_id":"hgnc:HGNC:32012","description":"SLAM family member 6 pseudogene 1","metadata":null},{"id":"e7396b668aec415f845e38481ff2bdcd","type":"GENE","name":"SLAMF7","canonical_id":"hgnc:HGNC:21394","description":"SLAM family member 7","metadata":{"aliases":["CRACC","19A","CS1","CD319"]}},{"id":"d81df4de2ea444ec80551787a2354321","type":"PROTEIN","name":"SLAMF7","canonical_id":"uniprot:Q9NQ25","description":null,"metadata":null},{"id":"961bcb1efc214adc8666de693454986c","type":"GENE","name":"SLAMF8","canonical_id":"hgnc:HGNC:21391","description":"SLAM family member 8","metadata":{"aliases":["BLAME","SBBI42","CD353"]}},{"id":"924c1ca488d9455ab769d6cd49f1656d","type":"GENE","name":"SLAMF9","canonical_id":"hgnc:HGNC:18430","description":"SLAM family member 9","metadata":{"aliases":["CD2F-10","CD84-H1","SF2001"]}},{"id":"d4e8081805cc48398d37a1cedafdd72b","type":"GENE","name":"SLBP","canonical_id":"hgnc:HGNC:10904","description":null,"metadata":null},{"id":"fccb0f270e86463f858aeada77d6a6cb","type":"GENE","name":"SLC10A1","canonical_id":"hgnc:HGNC:10905","description":null,"metadata":null},{"id":"61d5eabbea1b459dbdaa7fbd6a1acf1a","type":"GENE","name":"SLC10A2","canonical_id":"hgnc:HGNC:10906","description":null,"metadata":null},{"id":"1420ff12df37447e982d2629b15806df","type":"PROTEIN","name":"SLC10A2","canonical_id":"uniprot:Q12908","description":null,"metadata":null},{"id":"d8d52119632548e78a7ef187c33523ff","type":"GENE","name":"SLC10A3","canonical_id":"hgnc:HGNC:22979","description":"solute carrier family 10 member 3","metadata":{"aliases":["P3","DXS253E"]}},{"id":"1ce79c6f437140ec8f259fad97b8fea6","type":"GENE","name":"SLC10A4","canonical_id":"hgnc:HGNC:22980","description":"solute carrier family 10 member 4","metadata":{"aliases":["MGC29802"]}},{"id":"a96457772ee349418d7ee408e02fa0f2","type":"GENE","name":"SLC10A5","canonical_id":"hgnc:HGNC:22981","description":"solute carrier family 10 member 5","metadata":null},{"id":"9d04e2d5e6494fd5b2a592b9d3848ae4","type":"GENE","name":"SLC10A5P1","canonical_id":"hgnc:HGNC:48930","description":"SLC10A5 pseudogene 1","metadata":null},{"id":"88c24344d1014ce9ab1984b57a493fb4","type":"GENE","name":"SLC10A6","canonical_id":"hgnc:HGNC:30603","description":"solute carrier family 10 member 6","metadata":{"aliases":["SOAT"]}},{"id":"e3961756e20242d0b2987741b4611248","type":"GENE","name":"SLC10A7","canonical_id":"hgnc:HGNC:23088","description":"solute carrier family 10 member 7","metadata":{"aliases":["MGC25043","DKFZp566M114","DKFZp313H0531","DKFZp779O2438","C4orf13"]}},{"id":"a21f8f8c0bdd4e068fb597f07659bcd3","type":"GENE","name":"SLC10A7-AS1","canonical_id":"hgnc:HGNC:58890","description":"SLC10A7 antisense RNA 1","metadata":null},{"id":"09456644be774479aea861fce5246a7c","type":"GENE","name":"SLC11A1","canonical_id":"hgnc:HGNC:10907","description":"solute carrier family 11 member 1","metadata":{"aliases":["LSH","NRAMP","NRAMP1"]}},{"id":"6d3b9a730c924cdb95956814ff3c3b8b","type":"GENE","name":"SLC11A2","canonical_id":"hgnc:HGNC:10908","description":"solute carrier family 11 member 2","metadata":{"aliases":["DCT1","DMT1","DMT-1","FLJ37416","NRAMP2"]}},{"id":"df6d45393f094ab5ad6f051ca000b0b5","type":"GENE","name":"SLC12A1","canonical_id":"hgnc:HGNC:10910","description":"solute carrier family 12 member 1","metadata":{"aliases":["NKCC2","CCC2","BSC1","BSC","BSC-1"]}},{"id":"ab8c8dbaf3c14097acf3bd70a695bfe2","type":"PROTEIN","name":"SLC12A1","canonical_id":"uniprot:Q13621","description":null,"metadata":null},{"id":"c248c5f1439b40c6b24cb8212d9a0a37","type":"GENE","name":"SLC12A2","canonical_id":"hgnc:HGNC:10911","description":"solute carrier family 12 member 2","metadata":{"aliases":["NKCC1","BSC2","BSC-2","PPP1R141","CCC1"]}},{"id":"60294b06d51b46aaaf5a79efaa736671","type":"GENE","name":"SLC12A2-DT","canonical_id":"hgnc:HGNC:49565","description":"SLC12A2 divergent transcript","metadata":{"aliases":["FLJ33630","LINC01184"]}},{"id":"6f6876dd9edc47e1b884ca1432e32ed3","type":"GENE","name":"SLC12A3","canonical_id":"hgnc:HGNC:10912","description":"solute carrier family 12 member 3","metadata":{"aliases":["NCCT","NCC","TSC"]}},{"id":"b753ce70612e4092b6bdf5346be65110","type":"PROTEIN","name":"SLC12A3","canonical_id":"uniprot:P55017","description":null,"metadata":null},{"id":"ba825000376b42d393f6c691fb066158","type":"GENE","name":"SLC12A4","canonical_id":"hgnc:HGNC:10913","description":"solute carrier family 12 member 4","metadata":{"aliases":["KCC1"]}},{"id":"b55024fcc2784bb98d74ca1d1bb42b72","type":"GENE","name":"SLC12A5","canonical_id":"hgnc:HGNC:13818","description":"solute carrier family 12 member 5","metadata":{"aliases":["KIAA1176","KCC2","hKCC2"]}},{"id":"b2e414f9e3bf4784952b165830dd5b6f","type":"GENE","name":"SLC12A5-AS1","canonical_id":"hgnc:HGNC:53143","description":"SLC12A5 and MMP9 antisense RNA 1","metadata":{"aliases":["RP11-465L10.10"]}},{"id":"642faf9f511e49e69245836d80fdb46f","type":"GENE","name":"SLC12A6","canonical_id":"hgnc:HGNC:10914","description":"solute carrier family 12 member 6","metadata":{"aliases":["KCC3A","KCC3B","KCC3","ACCPN"]}},{"id":"9eb600930866412e93c52d558d2e9cdd","type":"GENE","name":"SLC12A7","canonical_id":"hgnc:HGNC:10915","description":"solute carrier family 12 member 7","metadata":{"aliases":["KCC4","DKFZP434F076"]}},{"id":"a2f480dda86443388182bac188cccbfd","type":"GENE","name":"SLC12A7-AS1","canonical_id":"hgnc:HGNC:58989","description":"SLC12A7 antisense RNA 1","metadata":null},{"id":"a4dea9f8b4f74879844e2498cbe5ddb1","type":"GENE","name":"SLC12A8","canonical_id":"hgnc:HGNC:15595","description":"solute carrier family 12 member 8","metadata":{"aliases":["CCC9"]}},{"id":"be0d7ba162c4485bb93b560385efbb0b","type":"GENE","name":"SLC12A9","canonical_id":"hgnc:HGNC:17435","description":"solute carrier family 12 member 9","metadata":{"aliases":["CIP1"]}},{"id":"e89be992b52342d889c6936a85e5939b","type":"GENE","name":"SLC12A9-AS1","canonical_id":"hgnc:HGNC:40807","description":"SLC12A9 antisense RNA 1","metadata":{"aliases":["RP11-126L15.4"]}},{"id":"e8a405dfd6d2410c8aa058314b60055d","type":"GENE","name":"SLC13A1","canonical_id":"hgnc:HGNC:10916","description":"solute carrier family 13 member 1","metadata":{"aliases":["NaSi-1","NAS1"]}},{"id":"95c4e8057f5e4c6dbf8ad3c3914682d1","type":"GENE","name":"SLC13A2","canonical_id":"hgnc:HGNC:10917","description":"solute carrier family 13 member 2","metadata":{"aliases":["NaDC-1"]}},{"id":"17c600d20af444698f740d8c38dc0270","type":"GENE","name":"SLC13A3","canonical_id":"hgnc:HGNC:14430","description":null,"metadata":null},{"id":"fad1ee69fa084e46817826a19e33555e","type":"GENE","name":"SLC13A4","canonical_id":"hgnc:HGNC:15827","description":null,"metadata":null},{"id":"7819fd2357c14a2da52bdead1fff59af","type":"GENE","name":"SLC13A5","canonical_id":"hgnc:HGNC:23089","description":"solute carrier family 13 member 5","metadata":{"aliases":["NACT","INDY","mINDY"]}},{"id":"e9660fd32ae54530bbe9883a3335fa4b","type":"GENE","name":"SLC14A1","canonical_id":"hgnc:HGNC:10918","description":"solute carrier family 14 member 1 (Kidd blood group)","metadata":{"aliases":["HsT1341","RACH1","RACH2","JK"]}},{"id":"0fd27bd8f69444d1b2f8f82d272a3332","type":"GENE","name":"SLC14A2","canonical_id":"hgnc:HGNC:10919","description":"solute carrier family 14 member 2","metadata":{"aliases":["HUT2","UT2"]}},{"id":"3bab2f8347f6462fa7149d11e44947b8","type":"GENE","name":"SLC14A2-AS1","canonical_id":"hgnc:HGNC:51125","description":"SLC14A2 antisense RNA 1","metadata":null},{"id":"074c5c2d181042b6a18c1e4dbfa82315","type":"GENE","name":"SLC15A1","canonical_id":"hgnc:HGNC:10920","description":null,"metadata":null},{"id":"7b31773d2bc94ba299fe2ab61fa6dce2","type":"GENE","name":"SLC15A2","canonical_id":"hgnc:HGNC:10921","description":"solute carrier family 15 member 2","metadata":{"aliases":["PEPT2"]}},{"id":"8ba7262c902c4e129719a96df5af728a","type":"GENE","name":"SLC15A3","canonical_id":"hgnc:HGNC:18068","description":"solute carrier family 15 member 3","metadata":{"aliases":["PHT2","hPTR3"]}},{"id":"ace960c8690c4691aea33a67fbe84de7","type":"GENE","name":"SLC15A4","canonical_id":"hgnc:HGNC:23090","description":"solute carrier family 15 member 4","metadata":{"aliases":["PHT1","PTR4"]}},{"id":"fb1855ec2484459c882df1dfb9d611cb","type":"GENE","name":"SLC15A5","canonical_id":"hgnc:HGNC:33455","description":"solute carrier family 15 member 5","metadata":null},{"id":"4fed19b3c1d742cfa352bd8e63808989","type":"GENE","name":"SLC16A1","canonical_id":"hgnc:HGNC:10922","description":null,"metadata":null},{"id":"e9835d11470f459abc40f726922efcea","type":"GENE","name":"SLC16A1-AS1","canonical_id":"hgnc:HGNC:49445","description":"SLC16A1 antisense RNA 1","metadata":{"aliases":["ENST00000421157.1","LINC01357"]}},{"id":"45d858871d6d440c9d3ee91e3929e8fa","type":"GENE","name":"SLC16A10","canonical_id":"hgnc:HGNC:17027","description":"solute carrier family 16 member 10","metadata":{"aliases":["TAT1","MCT10"]}},{"id":"35622404ac3243dba664d0e3608cd73e","type":"GENE","name":"SLC16A11","canonical_id":"hgnc:HGNC:23093","description":"solute carrier family 16 member 11","metadata":{"aliases":["FLJ90193","MCT11"]}},{"id":"afc5d78f61dd4f1ca7e9686d2b32b605","type":"GENE","name":"SLC16A12","canonical_id":"hgnc:HGNC:23094","description":"solute carrier family 16 member 12","metadata":{"aliases":["MCT12","CRT2"]}},{"id":"046aa150daea4111977d9bc37289a70f","type":"GENE","name":"SLC16A12-AS1","canonical_id":"hgnc:HGNC:51205","description":"SLC16A12 antisense RNA 1","metadata":null},{"id":"189ee82e17634b0a94b8f5cb616845e7","type":"GENE","name":"SLC16A13","canonical_id":"hgnc:HGNC:31037","description":"solute carrier family 16 member 13","metadata":{"aliases":["MCT13"]}},{"id":"e6801ae49bf6496da246f71cdea63976","type":"GENE","name":"SLC16A14","canonical_id":"hgnc:HGNC:26417","description":"solute carrier family 16 member 14","metadata":{"aliases":["FLJ30794","MCT14"]}},{"id":"9559940197684e49b6e27f56449bd8b7","type":"GENE","name":"SLC16A14P1","canonical_id":"hgnc:HGNC:43809","description":"solute carrier family 16 member 14 pseudogene 1","metadata":null},{"id":"dd93b421cfb84c83a55c03d295706168","type":"GENE","name":"SLC16A1P1","canonical_id":"hgnc:HGNC:48931","description":"SLC16A1 pseudogene 1","metadata":null},{"id":"0dd421cd56c146c9a419c54250dc6866","type":"GENE","name":"SLC16A2","canonical_id":"hgnc:HGNC:10923","description":"solute carrier family 16 member 2","metadata":{"aliases":["XPCT","MCT8","MCT7","DXS128E","DXS128","AHDS","MRX22"]}},{"id":"bf5a90243f224fe78b8880f2df0623bc","type":"GENE","name":"SLC16A3","canonical_id":"hgnc:HGNC:10924","description":"solute carrier family 16 member 3","metadata":{"aliases":["MCT3","MCT4"]}},{"id":"c541a3c92a3d4aef97e7c1968e4305b7","type":"GENE","name":"SLC16A4","canonical_id":"hgnc:HGNC:10925","description":"solute carrier family 16 member 4","metadata":{"aliases":["MCT4","MCT5"]}},{"id":"c6a5431e71a94290904cca6197551ce4","type":"GENE","name":"SLC16A5","canonical_id":"hgnc:HGNC:10926","description":"solute carrier family 16 member 5","metadata":{"aliases":["MCT5","MCT6"]}},{"id":"7a9e98078af146a3b09fcf198e583db7","type":"GENE","name":"SLC16A6","canonical_id":"hgnc:HGNC:10927","description":"solute carrier family 16 member 6","metadata":{"aliases":["MCT6","MCT7"]}},{"id":"283151ef2f8941c189b37b4c708bebf7","type":"GENE","name":"SLC16A6P1","canonical_id":"hgnc:HGNC:48932","description":"SLC16A6 pseudogene 1","metadata":null},{"id":"5653abeea1b84698bb47d48c02306060","type":"GENE","name":"SLC16A7","canonical_id":"hgnc:HGNC:10928","description":"solute carrier family 16 member 7","metadata":{"aliases":["MCT2"]}},{"id":"fc9be2629ec7418e99ba6e360dc0e1ac","type":"GENE","name":"SLC16A8","canonical_id":"hgnc:HGNC:16270","description":"solute carrier family 16 member 8","metadata":{"aliases":["MCT3","REMP"]}},{"id":"aaad0ddb836c41289a02263e23bfe453","type":"GENE","name":"SLC16A9","canonical_id":"hgnc:HGNC:23520","description":"solute carrier family 16 member 9","metadata":{"aliases":["FLJ43803","MCT9","C10orf36"]}},{"id":"0e7c5be6c7944ae4807b50940bd6d50c","type":"GENE","name":"SLC17A1","canonical_id":"hgnc:HGNC:10929","description":"solute carrier family 17 member 1","metadata":{"aliases":["NAPI-1","NPT1"]}},{"id":"19abc2dcff2143bd8b0c0154fcd3d8ff","type":"GENE","name":"SLC17A2","canonical_id":"hgnc:HGNC:10930","description":"solute carrier family 17 member 2","metadata":{"aliases":["NPT3"]}},{"id":"2f4a7f4dc9b1413195df8245544d9032","type":"GENE","name":"SLC17A2-AS1","canonical_id":"hgnc:HGNC:59376","description":"SLC17A2 antisense RNA 1","metadata":null},{"id":"7663df367a73488895df51dbdd9c7d43","type":"GENE","name":"SLC17A3","canonical_id":"hgnc:HGNC:10931","description":"solute carrier family 17 member 3","metadata":{"aliases":["NPT4"]}},{"id":"658abac054754bcf95482bdb3a8eeb5f","type":"GENE","name":"SLC17A4","canonical_id":"hgnc:HGNC:10932","description":"solute carrier family 17 member 4","metadata":{"aliases":["KIAA2138"]}},{"id":"c7a3ddbbf8c0494e86ba205aff50502d","type":"GENE","name":"SLC17A5","canonical_id":"hgnc:HGNC:10933","description":"solute carrier family 17 member 5","metadata":{"aliases":["AST","SD","ISSD","NSD","SIALIN","SLD","SIASD"]}},{"id":"81ad4766e3e24e79b72b5b8e266268d3","type":"GENE","name":"SLC17A6","canonical_id":"hgnc:HGNC:16703","description":"solute carrier family 17 member 6","metadata":{"aliases":["DNPI","VGLUT2"]}},{"id":"3058b949e9f04896ba7733ba65e27cb9","type":"GENE","name":"SLC17A6-DT","canonical_id":"hgnc:HGNC:55514","description":"SLC17A6 divergent transcript","metadata":{"aliases":["lncRNA-Glu"]}},{"id":"713832a0d4f5401b970544c61999cc06","type":"GENE","name":"SLC17A7","canonical_id":"hgnc:HGNC:16704","description":"solute carrier family 17 member 7","metadata":{"aliases":["BNPI","VGLUT1"]}},{"id":"383b47e4740c491abacb63f3fa826c17","type":"GENE","name":"SLC17A8","canonical_id":"hgnc:HGNC:20151","description":"solute carrier family 17 member 8","metadata":{"aliases":["VGLUT3","DFNA25"]}},{"id":"4a2f66ba5a614726a1cfc60657298071","type":"GENE","name":"SLC17A9","canonical_id":"hgnc:HGNC:16192","description":"solute carrier family 17 member 9","metadata":{"aliases":["FLJ23412","VNUT","C20orf59"]}},{"id":"68863b8dcc5a438898b8521c98021d6c","type":"GENE","name":"SLC18A1","canonical_id":"hgnc:HGNC:10934","description":"solute carrier family 18 member A1","metadata":{"aliases":["CGAT","VMAT1","VAT1"]}},{"id":"26169e7f10a44fe095c4aa9b223a004a","type":"GENE","name":"SLC18A2","canonical_id":"hgnc:HGNC:10935","description":"solute carrier family 18 member A2","metadata":{"aliases":["SVMT","SVAT","VAT2","VMAT2"]}},{"id":"2fa96dbd559749709d74e62c173d3162","type":"PROTEIN","name":"SLC18A2","canonical_id":"uniprot:Q05940","description":null,"metadata":null},{"id":"4cbcbb6d704b4ce2876ae9188260e093","type":"GENE","name":"SLC18A2-AS1","canonical_id":"hgnc:HGNC:55843","description":"SLC18A2 antisense RNA 1","metadata":null},{"id":"a9a2873afb23494b928af75a7a7ea982","type":"GENE","name":"SLC18A3","canonical_id":"hgnc:HGNC:10936","description":"solute carrier family 18 member A3","metadata":{"aliases":["VACHT"]}},{"id":"d9ced50a7f064d7e962ca62c3aa1b19c","type":"GENE","name":"SLC18B1","canonical_id":"hgnc:HGNC:21573","description":"solute carrier family 18 member B1","metadata":{"aliases":["dJ55C23.6","C6orf192"]}},{"id":"19e6077d884b414fbd14395b249753ed","type":"GENE","name":"SLC19A1","canonical_id":"hgnc:HGNC:10937","description":null,"metadata":null},{"id":"db3844cd7a1348a39820988ffb9cfd0f","type":"GENE","name":"SLC19A2","canonical_id":"hgnc:HGNC:10938","description":null,"metadata":null},{"id":"f3b17817877944b7b4dce8ba76b08940","type":"GENE","name":"SLC19A3","canonical_id":"hgnc:HGNC:16266","description":null,"metadata":null},{"id":"c703a0aedb7b4bbf86abc46c68c1148b","type":"GENE","name":"SLC19A4P","canonical_id":"hgnc:HGNC:25344","description":"solute carrier family 19 member 4, pseudogene","metadata":{"aliases":["DKFZp547H025","C2orf83"]}},{"id":"fe2ae457e4e04976841f05c49b05e6ab","type":"GENE","name":"SLC1A1","canonical_id":"hgnc:HGNC:10939","description":"solute carrier family 1 member 1","metadata":{"aliases":["EAAC1","EAAT3","hEAAC1"]}},{"id":"60032dc8260f404fa666a15b8418bc8c","type":"GENE","name":"SLC1A2","canonical_id":"hgnc:HGNC:10940","description":"solute carrier family 1 member 2","metadata":{"aliases":["GLT-1","GLT1","EAAT2","HBGT"]}},{"id":"685b2f138c3c47338dc422fabdbc4ec2","type":"GENE","name":"SLC1A2-AS1","canonical_id":"hgnc:HGNC:40534","description":"SLC1A2 antisense RNA 1","metadata":null},{"id":"c30c66d034ab4b3c9353e63babcfc58b","type":"GENE","name":"SLC1A2-AS2","canonical_id":"hgnc:HGNC:40535","description":"SLC1A2 antisense RNA 2","metadata":{"aliases":["AC090625.2"]}},{"id":"64452cf63ba44b39a21d10f7a03a5eae","type":"GENE","name":"SLC1A3","canonical_id":"hgnc:HGNC:10941","description":null,"metadata":null},{"id":"a0705cf1a57f4ecb8b0f05243f41a356","type":"GENE","name":"SLC1A3-AS1","canonical_id":"hgnc:HGNC:56374","description":"SLC1A3 antisense RNA 1","metadata":{"aliases":["AC008957.1","CTD-2353F22.1"]}},{"id":"2c192cfcaaf94d18a944957b71b96498","type":"GENE","name":"SLC1A4","canonical_id":"hgnc:HGNC:10942","description":null,"metadata":null},{"id":"f157bbee7117457d9c12f60d0f25478c","type":"GENE","name":"SLC1A5","canonical_id":"hgnc:HGNC:10943","description":"solute carrier family 1 member 5","metadata":{"aliases":["AAAT","ASCT2","RDRC","M7V1"]}},{"id":"edfe8c014b2347d490ef78b556c31c89","type":"GENE","name":"SLC1A6","canonical_id":"hgnc:HGNC:10944","description":"solute carrier family 1 member 6","metadata":{"aliases":["EAAT4"]}},{"id":"233a1e6055bd443bbf1c070ffb331778","type":"GENE","name":"SLC1A7","canonical_id":"hgnc:HGNC:10945","description":"solute carrier family 1 member 7","metadata":{"aliases":["EAAT5"]}},{"id":"0e3a896308c04195b32792d5a00b924d","type":"GENE","name":"SLC20A1","canonical_id":"hgnc:HGNC:10946","description":null,"metadata":null},{"id":"6bcd498b5bdb457eb68b99a90257e7cf","type":"GENE","name":"SLC20A1-DT","canonical_id":"hgnc:HGNC:55651","description":"SLC20A1 divergent transcript","metadata":null},{"id":"50b8231da7d34b9a992b9e0fb6fbecbb","type":"GENE","name":"SLC20A1P1","canonical_id":"hgnc:HGNC:20051","description":"solute carrier family 20 member 1 pseudogene 1","metadata":null},{"id":"ea6dacd798cb47d7ba580c47a6b42cee","type":"GENE","name":"SLC20A1P2","canonical_id":"hgnc:HGNC:42539","description":"solute carrier family 20 member 1 pseudogene 2","metadata":null},{"id":"1b72bd1a02ab43a384f45d3d40a3b07a","type":"GENE","name":"SLC20A1P3","canonical_id":"hgnc:HGNC:42538","description":"solute carrier family 20 member 1 pseudogene 3","metadata":null},{"id":"c6cbf774dfb74b03a6e7634959fa994d","type":"GENE","name":"SLC20A2","canonical_id":"hgnc:HGNC:10947","description":"solute carrier family 20 member 2","metadata":{"aliases":["PiT-2","Glvr-2","Ram-1","PIT2","MLVAR","GLVR2"]}},{"id":"4c7c6594e31d44d5a29b8b1cc20c435e","type":"GENE","name":"SLC22A1","canonical_id":"hgnc:HGNC:10963","description":"solute carrier family 22 member 1","metadata":{"aliases":["OCT1"]}},{"id":"773e5677f77f45a1b35af7c70be8c22e","type":"GENE","name":"SLC22A10","canonical_id":"hgnc:HGNC:18057","description":null,"metadata":null},{"id":"7c3e2c88cd26429a84ff80bed2991c44","type":"GENE","name":"SLC22A11","canonical_id":"hgnc:HGNC:18120","description":"solute carrier family 22 member 11","metadata":{"aliases":["OAT4"]}},{"id":"ac1098743b464bc59a5eac46aa57905d","type":"PROTEIN","name":"SLC22A11","canonical_id":"uniprot:Q9NSA0","description":null,"metadata":null},{"id":"add5a422dc7940a58022f9883162cbc8","type":"GENE","name":"SLC22A12","canonical_id":"hgnc:HGNC:17989","description":"solute carrier family 22 member 12","metadata":{"aliases":["OAT4L","RST","URAT1","hURAT1","UAT"]}},{"id":"bf429471db3040718b11fb29df33fb90","type":"PROTEIN","name":"SLC22A12","canonical_id":"uniprot:Q96S37","description":null,"metadata":null},{"id":"1fff0e4f313a435d94ecd53bc6babda2","type":"GENE","name":"SLC22A13","canonical_id":"hgnc:HGNC:8494","description":"solute carrier family 22 member 13","metadata":{"aliases":["OCTL1","OCTL3","OAT10","ORCTL3"]}},{"id":"84e4ae3962fe4a16a9843bc38fdcef89","type":"GENE","name":"SLC22A14","canonical_id":"hgnc:HGNC:8495","description":"solute carrier family 22 member 14","metadata":{"aliases":["OCTL2","ORCTL4"]}},{"id":"76f7d111859c49e4b04c849cfa52ab6f","type":"GENE","name":"SLC22A15","canonical_id":"hgnc:HGNC:20301","description":"solute carrier family 22 member 15","metadata":{"aliases":["FLIPT1"]}},{"id":"9e6cfc040ce6437db5bb07ef588cc67e","type":"GENE","name":"SLC22A16","canonical_id":"hgnc:HGNC:20302","description":"solute carrier family 22 member 16","metadata":{"aliases":["FLIPT2","CT2","OKB1","OAT6"]}},{"id":"b8cd5a3261cc459980cd777184b25c63","type":"GENE","name":"SLC22A17","canonical_id":"hgnc:HGNC:23095","description":"solute carrier family 22 member 17","metadata":{"aliases":["BOCT","BOIT","NGALR"]}},{"id":"2a0ada2b7c564a3d8e144a3031a8b179","type":"GENE","name":"SLC22A2","canonical_id":"hgnc:HGNC:10966","description":null,"metadata":null},{"id":"733273bf1ce74f9aa8932db89305ba97","type":"GENE","name":"SLC22A20P","canonical_id":"hgnc:HGNC:29867","description":"solute carrier family 22 member 20, pseudogene","metadata":{"aliases":["Oat6","FLJ16331","SLC22A20"]}},{"id":"12cdb4174a864e0bbf2d34368f55fddc","type":"GENE","name":"SLC22A23","canonical_id":"hgnc:HGNC:21106","description":"solute carrier family 22 member 23","metadata":{"aliases":["FLJ22174","C6orf85"]}},{"id":"dcae21eeba584349a2d6da332dcdc590","type":"GENE","name":"SLC22A23-AS1","canonical_id":"hgnc:HGNC:59335","description":"SLC22A23 antisense RNA 1","metadata":null},{"id":"e02019dc345f4935a5bcacdcb5283e3b","type":"GENE","name":"SLC22A23-AS2","canonical_id":"hgnc:HGNC:59336","description":"SLC22A23 antisense RNA 2","metadata":null},{"id":"997fddd39f6c46d2b49646d92d60a200","type":"GENE","name":"SLC22A24","canonical_id":"hgnc:HGNC:28542","description":"solute carrier family 22 member 24","metadata":{"aliases":["MGC34821","NET46"]}},{"id":"c9c74377504140c991c0f5bd8392e0d4","type":"GENE","name":"SLC22A25","canonical_id":"hgnc:HGNC:32935","description":"solute carrier family 22 member 25","metadata":{"aliases":["UST6","HIMTP","MGC120420"]}},{"id":"f7e2d53f73574dab85be34c7c6db84a3","type":"GENE","name":"SLC22A3","canonical_id":"hgnc:HGNC:10967","description":null,"metadata":null},{"id":"b5cd2fa33a2e4616ad5dc4075529331c","type":"GENE","name":"SLC22A31","canonical_id":"hgnc:HGNC:27091","description":"solute carrier family 22 member 31","metadata":null},{"id":"915bd47a8864445eac240d18cc17d8df","type":"GENE","name":"SLC22A4","canonical_id":"hgnc:HGNC:10968","description":null,"metadata":null},{"id":"a23a9995776046b095a4f5232c00fc4f","type":"GENE","name":"SLC22A5","canonical_id":"hgnc:HGNC:10969","description":"solute carrier family 22 member 5","metadata":{"aliases":["OCTN2","SCD","CDSP"]}},{"id":"3e8a1b6a364c4de58eed5bbe61d5480c","type":"GENE","name":"SLC22A6","canonical_id":"hgnc:HGNC:10970","description":null,"metadata":null},{"id":"b09b7758eb2f487c95b5eeb21e2988cc","type":"PROTEIN","name":"SLC22A6","canonical_id":"uniprot:Q4U2R8","description":null,"metadata":null},{"id":"b705db48071c4292870a9f94810c5074","type":"GENE","name":"SLC22A7","canonical_id":"hgnc:HGNC:10971","description":"solute carrier family 22 member 7","metadata":{"aliases":["NLT","OAT2"]}},{"id":"0d4d61dd336a4320a047843aa72645b6","type":"GENE","name":"SLC22A8","canonical_id":"hgnc:HGNC:10972","description":null,"metadata":null},{"id":"4f69eda494f449cd8ac04473a1b1f0a9","type":"PROTEIN","name":"SLC22A8","canonical_id":"uniprot:Q8TCC7","description":null,"metadata":null},{"id":"7496cdd0a6164b1088e9633444b5de07","type":"GENE","name":"SLC22A9","canonical_id":"hgnc:HGNC:16261","description":null,"metadata":null},{"id":"8a6f84ba46f74f9bb6ac1cbc00249c57","type":"GENE","name":"SLC23A1","canonical_id":"hgnc:HGNC:10974","description":"solute carrier family 23 member 1","metadata":{"aliases":["YSPL3","SVCT1","SLC23A2"]}},{"id":"c8853c28cd62448faae4692b88a0b450","type":"GENE","name":"SLC23A2","canonical_id":"hgnc:HGNC:10973","description":"solute carrier family 23 member 2","metadata":{"aliases":["SVCT2","KIAA0238","YSPL2","SLC23A1"]}},{"id":"09239191045748f498a86bc2f8d2650b","type":"GENE","name":"SLC23A3","canonical_id":"hgnc:HGNC:20601","description":"solute carrier family 23 member 3","metadata":{"aliases":["SVCT3","FLJ31168","Yspl1"]}},{"id":"732808349dec41c88e8af6b83853da5c","type":"GENE","name":"SLC23A4P","canonical_id":"hgnc:HGNC:20602","description":"solute carrier family 23 member 4, pseudogene","metadata":{"aliases":["SLC23A4"]}},{"id":"596337bb065746d79173464ad6407ce3","type":"GENE","name":"SLC24A1","canonical_id":"hgnc:HGNC:10975","description":"solute carrier family 24 member 1","metadata":{"aliases":["NCKX1","NCKX","RODX","KIAA0702","HsT17412","CSNB1D"]}},{"id":"9b8273bb3c55484397c83ec2ddc3360c","type":"GENE","name":"SLC24A2","canonical_id":"hgnc:HGNC:10976","description":"solute carrier family 24 member 2","metadata":{"aliases":["NCKX2"]}},{"id":"ea7a2a4691d74648b095f285a810c152","type":"GENE","name":"SLC24A3","canonical_id":"hgnc:HGNC:10977","description":"solute carrier family 24 member 3","metadata":null},{"id":"7dc0c5f965ef4e6caf1d56e98b610e3e","type":"GENE","name":"SLC24A3-AS1","canonical_id":"hgnc:HGNC:40540","description":"SLC24A3 antisense RNA 1","metadata":null},{"id":"05e23d89868c4b63922b2d8ee87b3d69","type":"GENE","name":"SLC24A3-AS2","canonical_id":"hgnc:HGNC:40541","description":"SLC24A3 antisense RNA 2","metadata":null},{"id":"2cc9c5c74fd1430f873e25974a10a2ca","type":"GENE","name":"SLC24A4","canonical_id":"hgnc:HGNC:10978","description":"solute carrier family 24 member 4","metadata":{"aliases":["NCKX4"]}},{"id":"1ed19a6edc3541f180d0dfe0a163a36f","type":"GENE","name":"SLC24A5","canonical_id":"hgnc:HGNC:20611","description":"solute carrier family 24 member 5","metadata":{"aliases":["JSX","OCA6","NCKX5"]}},{"id":"45372752ba96466b8076eead08ebe447","type":"GENE","name":"SLC25A1","canonical_id":"hgnc:HGNC:10979","description":"solute carrier family 25 member 1","metadata":{"aliases":["CTP","CIC","SLC20A3"]}},{"id":"03cde37b292c4b5babfb630ef29594a1","type":"GENE","name":"SLC25A10","canonical_id":"hgnc:HGNC:10980","description":"solute carrier family 25 member 10","metadata":{"aliases":["DIC"]}},{"id":"091ecc533ac34a48887e217f4c7fc82e","type":"GENE","name":"SLC25A11","canonical_id":"hgnc:HGNC:10981","description":"solute carrier family 25 member 11","metadata":{"aliases":["OGC","SLC20A4"]}},{"id":"251645ea0e684579b1fe6d9d2aa59abb","type":"GENE","name":"SLC25A12","canonical_id":"hgnc:HGNC:10982","description":"solute carrier family 25 member 12","metadata":{"aliases":["Aralar","aralar1","AGC1"]}},{"id":"ac397f358eba494dbb970a0ac0675bca","type":"GENE","name":"SLC25A13","canonical_id":"hgnc:HGNC:10983","description":"solute carrier family 25 member 13","metadata":{"aliases":["CITRIN","ARALAR2","CTLN2"]}},{"id":"731b10d509284de8a42c524ba2bf2cca","type":"GENE","name":"SLC25A14","canonical_id":"hgnc:HGNC:10984","description":"solute carrier family 25 member 14","metadata":{"aliases":["BMCP1","UCP5"]}},{"id":"503c2aa2c11a415495d252d44d784a00","type":"GENE","name":"SLC25A14P1","canonical_id":"hgnc:HGNC:43856","description":"solute carrier family 25 member 14 pseudogene 1","metadata":null},{"id":"f63827032f6b4d2b938502e7d35987d7","type":"GENE","name":"SLC25A15","canonical_id":"hgnc:HGNC:10985","description":"solute carrier family 25 member 15","metadata":{"aliases":["ORC1","lnc-HC","D13S327","ORNT1","HHH"]}},{"id":"1048ef4747f9463889e3924a389e1f55","type":"GENE","name":"SLC25A15P1","canonical_id":"hgnc:HGNC:18497","description":"solute carrier family 25 member 15 pseudogene 1","metadata":{"aliases":["SLC25A15PY1","SLC25A15P"]}},{"id":"3258232be2d949c69d5be73ed545a3d2","type":"GENE","name":"SLC25A15P2","canonical_id":"hgnc:HGNC:39843","description":"solute carrier family 25 member 15 pseudogene 2","metadata":null},{"id":"af08980fd1b74d0693637fa1b5aa176e","type":"GENE","name":"SLC25A15P3","canonical_id":"hgnc:HGNC:39844","description":"solute carrier family 25 member 15 pseudogene 3","metadata":null},{"id":"e6c8c0b3f71744e49c7c9b605cb2041e","type":"GENE","name":"SLC25A15P4","canonical_id":"hgnc:HGNC:39845","description":"solute carrier family 25 member 15 pseudogene 4","metadata":null},{"id":"423c47c33607497386a9e5560fbd8382","type":"GENE","name":"SLC25A15P5","canonical_id":"hgnc:HGNC:39846","description":"solute carrier family 25 member 15 pseudogene 5","metadata":null},{"id":"75fc2340a5554391ac5882013d030cf9","type":"GENE","name":"SLC25A16","canonical_id":"hgnc:HGNC:10986","description":"solute carrier family 25 member 16","metadata":{"aliases":["GDA","D10S105E","HGT.1","ML7"]}},{"id":"f51f948b167e4d9488b5a49af589b833","type":"GENE","name":"SLC25A17","canonical_id":"hgnc:HGNC:10987","description":"solute carrier family 25 member 17","metadata":{"aliases":["PMP34"]}},{"id":"707fb58d4fa349aaafccb85748fcbbbd","type":"GENE","name":"SLC25A18","canonical_id":"hgnc:HGNC:10988","description":"solute carrier family 25 member 18","metadata":null},{"id":"5b1c55dc33ac48d1b262740afaaf8c8c","type":"GENE","name":"SLC25A18P1","canonical_id":"hgnc:HGNC:43857","description":"solute carrier family 25 member 18 pseudogene 1","metadata":null},{"id":"262dab685ff243b1bea603fbbc5cdddb","type":"GENE","name":"SLC25A19","canonical_id":"hgnc:HGNC:14409","description":"solute carrier family 25 member 19","metadata":{"aliases":["DNC","MUP1","TPC","MCPHA"]}},{"id":"03b22af86fc040ec9cbbfc4449a17bdc","type":"GENE","name":"SLC25A1P1","canonical_id":"hgnc:HGNC:43845","description":"solute carrier family 25 member 1 pseudogene 1","metadata":null},{"id":"cbd86edba7da461191178c2f05bd7e26","type":"GENE","name":"SLC25A1P2","canonical_id":"hgnc:HGNC:43847","description":"solute carrier family 25 member 1 pseudogene 2","metadata":null},{"id":"324cefb6116d4954acc155a5924fc667","type":"GENE","name":"SLC25A1P3","canonical_id":"hgnc:HGNC:43846","description":"solute carrier family 25 member 1 pseudogene 3","metadata":null},{"id":"0f016f2eb6924bd886edb8600d52eee1","type":"GENE","name":"SLC25A1P4","canonical_id":"hgnc:HGNC:43848","description":"solute carrier family 25 member 1 pseudogene 4","metadata":null},{"id":"4d582ee39a4740d6a0c0ef5817b1f752","type":"GENE","name":"SLC25A1P5","canonical_id":"hgnc:HGNC:43849","description":"solute carrier family 25 member 1 pseudogene 5","metadata":null},{"id":"54e629da9d314d35b4a53472fdf01bd9","type":"GENE","name":"SLC25A2","canonical_id":"hgnc:HGNC:22921","description":"solute carrier family 25 member 2","metadata":{"aliases":["ORNT2"]}},{"id":"fa48efcd07344ce8b5fe810201058d01","type":"GENE","name":"SLC25A20","canonical_id":"hgnc:HGNC:1421","description":null,"metadata":null},{"id":"504b644ce305436db792d99f739b92fb","type":"GENE","name":"SLC25A20P1","canonical_id":"hgnc:HGNC:1422","description":"solute carrier family 25 member 20 pseudogene 1","metadata":{"aliases":["CACTP","SLC25A20P"]}},{"id":"fd7cd79bfdf04c5eb98307f8ea8d7169","type":"GENE","name":"SLC25A21","canonical_id":"hgnc:HGNC:14411","description":"solute carrier family 25 member 21","metadata":{"aliases":["ODC1","ODC"]}},{"id":"ace7bd199afb481bab6ceb6b1a8596e0","type":"GENE","name":"SLC25A21-AS1","canonical_id":"hgnc:HGNC:44298","description":"SLC25A21 antisense RNA 1","metadata":null},{"id":"abb098892543493fb756ca7fa64faf3f","type":"GENE","name":"SLC25A21-AS2","canonical_id":"hgnc:HGNC:58456","description":"SLC25A21 antisense RNA 2","metadata":null},{"id":"4887b8de1129487e9663724e41108b23","type":"GENE","name":"SLC25A22","canonical_id":"hgnc:HGNC:19954","description":"solute carrier family 25 member 22","metadata":{"aliases":["GC1","FLJ13044","NET44","EIEE3","GC-1"]}},{"id":"f404147b139d4b4e91cd43f4951a38d5","type":"GENE","name":"SLC25A23","canonical_id":"hgnc:HGNC:19375","description":"solute carrier family 25 member 23","metadata":{"aliases":["FLJ30339","MGC2615","APC2"]}},{"id":"3e6eec1e5ab5432b9a4ab2b37012eacd","type":"GENE","name":"SLC25A24","canonical_id":"hgnc:HGNC:20662","description":"solute carrier family 25 member 24","metadata":{"aliases":["DKFZp586G0123","APC1","SCAMC1","SCAMC-1"]}},{"id":"b13aa73179b14db298b08fb7e52fc486","type":"GENE","name":"SLC25A24P1","canonical_id":"hgnc:HGNC:48933","description":"SLC25A24 pseudogene 1","metadata":null},{"id":"08852ade213e452781f5c7143cfe8bd3","type":"GENE","name":"SLC25A24P2","canonical_id":"hgnc:HGNC:48934","description":"SLC25A24 pseudogene 2","metadata":null},{"id":"e1b1d1639eb449759c23c6a80dcfcc81","type":"GENE","name":"SLC25A25","canonical_id":"hgnc:HGNC:20663","description":"solute carrier family 25 member 25","metadata":{"aliases":["KIAA1896","PCSCL","MCSC"]}},{"id":"dbb48d59ccc44da0a2f9a5650e982908","type":"GENE","name":"SLC25A25-AS1","canonical_id":"hgnc:HGNC:27844","description":"SLC25A25 antisense RNA 1","metadata":{"aliases":["HRCEG"]}},{"id":"c60afa88fcdc469ebd20ad2e4035a644","type":"GENE","name":"SLC25A26","canonical_id":"hgnc:HGNC:20661","description":"solute carrier family 25 member 26","metadata":{"aliases":["SAMC"]}},{"id":"01d52069a3264a74b1ca4c8dafc1574a","type":"GENE","name":"SLC25A27","canonical_id":"hgnc:HGNC:21065","description":null,"metadata":null},{"id":"390a4bf0691c41fca0bbc077dd5b12c1","type":"GENE","name":"SLC25A28","canonical_id":"hgnc:HGNC:23472","description":"solute carrier family 25 member 28","metadata":{"aliases":["MRS3/4","MRS4L"]}},{"id":"0e9a79651481493085e72d6e331c5c45","type":"GENE","name":"SLC25A28-DT","canonical_id":"hgnc:HGNC:55979","description":"SLC25A28 divergent transcript","metadata":null},{"id":"41c57ab6ca2a492494fa42885f66e4d0","type":"GENE","name":"SLC25A29","canonical_id":"hgnc:HGNC:20116","description":"solute carrier family 25 member 29","metadata":{"aliases":["FLJ38975","C14orf69"]}},{"id":"f3ba4c1cb7f04f4e964cea64e9ab14ae","type":"GENE","name":"SLC25A29-AS1","canonical_id":"hgnc:HGNC:58453","description":"SLC25A29 antisense RNA 1","metadata":null},{"id":"4e7cad75ee8d426a84c4e523a1488313","type":"GENE","name":"SLC25A3","canonical_id":"hgnc:HGNC:10989","description":"solute carrier family 25 member 3","metadata":{"aliases":["PiC","PTP","PHC"]}},{"id":"c2ba80634828483388a4b7704b518a35","type":"GENE","name":"SLC25A30","canonical_id":"hgnc:HGNC:27371","description":"solute carrier family 25 member 30","metadata":null},{"id":"cf0b10e517fe4bd88091158eaae861d6","type":"GENE","name":"SLC25A30-AS1","canonical_id":"hgnc:HGNC:42795","description":"SLC25A30 antisense RNA 1","metadata":null},{"id":"389ddae5c7bb4595b2e16b9f91768e9d","type":"GENE","name":"SLC25A31","canonical_id":"hgnc:HGNC:25319","description":"solute carrier family 25 member 31","metadata":{"aliases":["DKFZP434N1235","ANT4"]}},{"id":"9d2663c5102f4ef4bbd78d137fb1a147","type":"GENE","name":"SLC25A32","canonical_id":"hgnc:HGNC:29683","description":"solute carrier family 25 member 32","metadata":{"aliases":["MFTC"]}},{"id":"8e6f34a6e28a4e10ae8186196d0a8487","type":"GENE","name":"SLC25A33","canonical_id":"hgnc:HGNC:29681","description":"solute carrier family 25 member 33","metadata":{"aliases":["MGC4399","BMSC-MCP","PNC1"]}},{"id":"9f9100727089439fae04ffb376227919","type":"GENE","name":"SLC25A34","canonical_id":"hgnc:HGNC:27653","description":"solute carrier family 25 member 34","metadata":{"aliases":["DKFZp781A10161"]}},{"id":"266cfa1ee60d47a78586cc1971e49621","type":"GENE","name":"SLC25A34-AS1","canonical_id":"hgnc:HGNC:53623","description":"SLC25A34 and TMEM82 antisense RNA 1","metadata":{"aliases":["RP11-169K16.4"]}},{"id":"21f5b71ee7144e77bed3d2d1391835fe","type":"GENE","name":"SLC25A35","canonical_id":"hgnc:HGNC:31921","description":"solute carrier family 25 member 35","metadata":{"aliases":["FLJ40217"]}},{"id":"19b64896146b4bd789215b73e1bfb8c3","type":"GENE","name":"SLC25A36","canonical_id":"hgnc:HGNC:25554","description":"solute carrier family 25 member 36","metadata":{"aliases":["FLJ10618","PNC2"]}},{"id":"5971d4e1daf643889cb65360826b3603","type":"GENE","name":"SLC25A36P1","canonical_id":"hgnc:HGNC:48935","description":"SLC25A36 pseudogene 1","metadata":null},{"id":"a3ac6b93ba724b5c8cf5a051055459dc","type":"GENE","name":"SLC25A37","canonical_id":"hgnc:HGNC:29786","description":"solute carrier family 25 member 37","metadata":{"aliases":["MSCP","MFRN","MFRN1","HT015"]}},{"id":"d593c601451b470292df74a415097aeb","type":"GENE","name":"SLC25A38","canonical_id":"hgnc:HGNC:26054","description":"solute carrier family 25 member 38","metadata":{"aliases":["FLJ20551"]}},{"id":"2147d7bc053448f8be26d896f6203977","type":"GENE","name":"SLC25A38P1","canonical_id":"hgnc:HGNC:43858","description":"SLC25A38 pseudogene 1","metadata":null},{"id":"1de3640927f14d99b13c8ac8c7d2f57a","type":"GENE","name":"SLC25A39","canonical_id":"hgnc:HGNC:24279","description":"solute carrier family 25 member 39","metadata":{"aliases":["FLJ22407","CGI-69"]}},{"id":"45e76432ba3642ee88a57174acf63b16","type":"GENE","name":"SLC25A39P1","canonical_id":"hgnc:HGNC:43859","description":"solute carrier family 25 member 39 pseudogene 1","metadata":null},{"id":"cd4171def72c48f2958f4048b4098901","type":"GENE","name":"SLC25A39P2","canonical_id":"hgnc:HGNC:48936","description":"SLC25A39 pseudogene 2","metadata":null},{"id":"dbfe785d1a574d66bef8a45fb2e35770","type":"GENE","name":"SLC25A3P1","canonical_id":"hgnc:HGNC:26869","description":"solute carrier family 25 member 3 pseudogene 1","metadata":{"aliases":["FLJ40434"]}},{"id":"e7d2629ae71d41519f172f1546e9e5ba","type":"GENE","name":"SLC25A3P2","canonical_id":"hgnc:HGNC:43784","description":"solute carrier family 25 member 3 pseudogene 2","metadata":null},{"id":"6fdedd5d0c564b6fa0d314c32a1b1f77","type":"GENE","name":"SLC25A3P3","canonical_id":"hgnc:HGNC:43785","description":"solute carrier family 25 member 3 pseudogene 3","metadata":null},{"id":"06a60da4e0414cb9a3065d287c7510ab","type":"GENE","name":"SLC25A4","canonical_id":"hgnc:HGNC:10990","description":"solute carrier family 25 member 4","metadata":{"aliases":["T1","AAC1","PEO3","PEO2","ANT1"]}},{"id":"4688e469cf084e6981e6b02c6d842e3d","type":"GENE","name":"SLC25A40","canonical_id":"hgnc:HGNC:29680","description":"solute carrier family 25 member 40","metadata":{"aliases":["MCFP"]}},{"id":"5b6cc2113f22445288fbfac7b29b1a89","type":"GENE","name":"SLC25A41","canonical_id":"hgnc:HGNC:28533","description":"solute carrier family 25 member 41","metadata":{"aliases":["FLJ40442","MGC34725","APC4"]}},{"id":"c482eb4e11bf4e679ecb7bb2bd033c1f","type":"GENE","name":"SLC25A42","canonical_id":"hgnc:HGNC:28380","description":"solute carrier family 25 member 42","metadata":{"aliases":["MGC26694"]}},{"id":"2cf596a7a1ec4d7ab9bdd8bdf1cb3953","type":"GENE","name":"SLC25A43","canonical_id":"hgnc:HGNC:30557","description":"solute carrier family 25 member 43","metadata":null},{"id":"3c7e826c08c54b71b80e9e7171747f2d","type":"GENE","name":"SLC25A44","canonical_id":"hgnc:HGNC:29036","description":"solute carrier family 25 member 44","metadata":{"aliases":["FLJ90431","KIAA0446"]}},{"id":"c527c013e60b4620853a88cbc6305029","type":"GENE","name":"SLC25A45","canonical_id":"hgnc:HGNC:27442","description":"solute carrier family 25 member 45","metadata":null},{"id":"c69d12b421dd41a688e8764b42e0ae94","type":"GENE","name":"SLC25A46","canonical_id":"hgnc:HGNC:25198","description":"solute carrier family 25 member 46","metadata":null},{"id":"af37a3d3d4f14fbf9376d18d81a9490e","type":"GENE","name":"SLC25A47","canonical_id":"hgnc:HGNC:20115","description":"solute carrier family 25 member 47","metadata":{"aliases":["HDCMP","C14orf68"]}},{"id":"d2e38e10ec7549db96cabc9d44d68b06","type":"GENE","name":"SLC25A47P1","canonical_id":"hgnc:HGNC:43860","description":"solute carrier family 25 member 47 pseudogene 1","metadata":null},{"id":"645db4fd674b45c494a812724bebeb7d","type":"GENE","name":"SLC25A48","canonical_id":"hgnc:HGNC:30451","description":"solute carrier family 25 member 48","metadata":{"aliases":["FLJ44862"]}},{"id":"8a20c60be0c7432ba77121f8c2002a6b","type":"GENE","name":"SLC25A48-AS1","canonical_id":"hgnc:HGNC:27965","description":"SLC25A48 antisense RNA 1","metadata":{"aliases":["LINC01959"]}},{"id":"b244b94d85d84aa78349940187e2c480","type":"GENE","name":"SLC25A48-AS2","canonical_id":"hgnc:HGNC:59148","description":"SLC25A48 antisense RNA 2","metadata":null},{"id":"f00a19c757274d4ca7069b9abe2c38f0","type":"GENE","name":"SLC25A5","canonical_id":"hgnc:HGNC:10991","description":"solute carrier family 25 member 5","metadata":{"aliases":["T2","2F1","T3","ANT2"]}},{"id":"167e1fc65c384d9a96c3a7f462e32eac","type":"GENE","name":"SLC25A5-AS1","canonical_id":"hgnc:HGNC:43438","description":"SLC25A5 antisense RNA 1","metadata":null},{"id":"dbec0ed080f4471b802d62032a789225","type":"GENE","name":"SLC25A51","canonical_id":"hgnc:HGNC:23323","description":"solute carrier family 25 member 51","metadata":{"aliases":["MGC14836","CG7943","MCART1"]}},{"id":"c54e4a7881af4935aceb181aafa35f3b","type":"GENE","name":"SLC25A51P1","canonical_id":"hgnc:HGNC:23325","description":"SLC25A51 pseudogene 1","metadata":{"aliases":["bA707M13.1","MCART3P"]}},{"id":"b74def451ce94f88ad9f71d2ad8e4dde","type":"GENE","name":"SLC25A51P2","canonical_id":"hgnc:HGNC:23327","description":"SLC25A51 pseudogene 2","metadata":{"aliases":["MCART4P"]}},{"id":"2de76119056d41b6ab67b762108c9279","type":"GENE","name":"SLC25A51P3","canonical_id":"hgnc:HGNC:31051","description":"SLC25A51 pseudogene 3","metadata":{"aliases":["MCART5P"]}},{"id":"e7e5124f22c94225867cfe1a5f9a8ae0","type":"GENE","name":"SLC25A51P4","canonical_id":"hgnc:HGNC:54321","description":"SLC25A51 pseudogene 4","metadata":null},{"id":"06ac3a4c24d84c688f931b7242ceccbf","type":"GENE","name":"SLC25A52","canonical_id":"hgnc:HGNC:23324","description":"solute carrier family 25 member 52","metadata":{"aliases":["MCART2"]}},{"id":"46c055920be9434dbf1666b6e8cbba54","type":"GENE","name":"SLC25A53","canonical_id":"hgnc:HGNC:31894","description":"solute carrier family 25 member 53","metadata":{"aliases":["MCART6"]}},{"id":"328648374b754ce3858658b9c4645d2d","type":"GENE","name":"SLC25A53P1","canonical_id":"hgnc:HGNC:55040","description":"SLC25A53 pseudogene 1","metadata":null},{"id":"5f2c814a002b4c9b8ce37de3b5985626","type":"GENE","name":"SLC25A5P1","canonical_id":"hgnc:HGNC:19250","description":"solute carrier family 25 member 5 pseudogene 1","metadata":{"aliases":["bK250D10.4","ANTP3"]}},{"id":"76fb91c01f6845a4a2a5f5840aaea9fc","type":"GENE","name":"SLC25A5P2","canonical_id":"hgnc:HGNC:35470","description":"solute carrier family 25 member 5 pseudogene 2","metadata":{"aliases":["LOC344371"]}},{"id":"e9641554a0d64023817706d909fa96b8","type":"GENE","name":"SLC25A5P3","canonical_id":"hgnc:HGNC:507","description":"solute carrier family 25 member 5 pseudogene 3","metadata":{"aliases":["ANTP1"]}},{"id":"36aa8b69408d4967a2d04c240d8c9347","type":"GENE","name":"SLC25A5P4","canonical_id":"hgnc:HGNC:35471","description":"solute carrier family 25 member 5 pseudogene 4","metadata":null},{"id":"a31e956f445745a4973830d5fce7cac7","type":"GENE","name":"SLC25A5P5","canonical_id":"hgnc:HGNC:511","description":"solute carrier family 25 member 5 pseudogene 5","metadata":{"aliases":["TCAG_29001","ANTP5"]}},{"id":"ad137d454cdd4a92b96d65a3b1f121ed","type":"GENE","name":"SLC25A5P6","canonical_id":"hgnc:HGNC:512","description":"solute carrier family 25 member 5 pseudogene 6","metadata":{"aliases":["ANTP6"]}},{"id":"7017b99b5c234ac28b57492e45d44b3a","type":"GENE","name":"SLC25A5P7","canonical_id":"hgnc:HGNC:513","description":"solute carrier family 25 member 5 pseudogene 7","metadata":{"aliases":["ANTP7"]}},{"id":"8b928a812d354d698417c7470c34323e","type":"GENE","name":"SLC25A5P8","canonical_id":"hgnc:HGNC:35469","description":"solute carrier family 25 member 5 pseudogene 8","metadata":null},{"id":"06c0f13a60114865b43a146e8fe4c874","type":"GENE","name":"SLC25A5P9","canonical_id":"hgnc:HGNC:35468","description":"solute carrier family 25 member 5 pseudogene 9","metadata":null},{"id":"12836df9687948208eb056245183be3a","type":"GENE","name":"SLC25A6","canonical_id":"hgnc:HGNC:10992","description":"solute carrier family 25 member 6","metadata":{"aliases":["ANT3Y","MGC17525","ANT3"]}},{"id":"d88cc5e9eb4f4109a82ebf6d5bcdafa4","type":"GENE","name":"SLC25A6P1","canonical_id":"hgnc:HGNC:16554","description":"solute carrier family 25 member 6 pseudogene 1","metadata":{"aliases":["dJ1065O2.2","SLC25A5L"]}},{"id":"b60ffdb439b74b5d893380b8a8b2bfaa","type":"GENE","name":"SLC25A6P2","canonical_id":"hgnc:HGNC:43850","description":"solute carrier family 25 member 6 pseudogene 2","metadata":null},{"id":"3ed10bed4e79413da9eeee1635509ac9","type":"GENE","name":"SLC25A6P3","canonical_id":"hgnc:HGNC:43852","description":"solute carrier family 25 member 6 pseudogene 3","metadata":null},{"id":"9f129651dd8e402cb7cd4a8145501024","type":"GENE","name":"SLC25A6P4","canonical_id":"hgnc:HGNC:43853","description":"solute carrier family 25 member 6 pseudogene 4","metadata":null},{"id":"0a46e0646b904b79b8aa00431b2283cb","type":"GENE","name":"SLC25A6P5","canonical_id":"hgnc:HGNC:43854","description":"solute carrier family 25 member 6 pseudogene 5","metadata":null},{"id":"61258c0987974471874634e5e76cd42b","type":"GENE","name":"SLC25A6P6","canonical_id":"hgnc:HGNC:43855","description":"solute carrier family 25 member 6 pseudogene 6","metadata":null},{"id":"34cd4b1946234580bb8035c5bd6c35be","type":"GENE","name":"SLC26A1","canonical_id":"hgnc:HGNC:10993","description":"solute carrier family 26 member 1","metadata":{"aliases":["SAT-1","EDM4"]}},{"id":"0824422c89d045b19747959f43d1b2a5","type":"GENE","name":"SLC26A10P","canonical_id":"hgnc:HGNC:14470","description":"solute carrier family 26 member 10, pseudogene","metadata":{"aliases":["SLC26A10"]}},{"id":"11940ee747b24cf68323b4cfc1eb0a4f","type":"GENE","name":"SLC26A11","canonical_id":"hgnc:HGNC:14471","description":"solute carrier family 26 member 11","metadata":null},{"id":"787d46143060415486bda5dc8eba0159","type":"GENE","name":"SLC26A2","canonical_id":"hgnc:HGNC:10994","description":"solute carrier family 26 member 2","metadata":{"aliases":["DTDST","DTD"]}},{"id":"7ca199a8f974467d85e5b52bcae0626a","type":"GENE","name":"SLC26A3","canonical_id":"hgnc:HGNC:3018","description":null,"metadata":null},{"id":"8bf733d55013463b85ae1dd88522d433","type":"GENE","name":"SLC26A4","canonical_id":"hgnc:HGNC:8818","description":null,"metadata":null},{"id":"5cc671677d454abd8683f25052edb175","type":"GENE","name":"SLC26A4-AS1","canonical_id":"hgnc:HGNC:22385","description":"SLC26A4 antisense RNA 1","metadata":null},{"id":"7ca9596e92a342ca9b1d58c44435584a","type":"GENE","name":"SLC26A5","canonical_id":"hgnc:HGNC:9359","description":"solute carrier family 26 member 5","metadata":{"aliases":["DFNB61","PRESTIN","PRES"]}},{"id":"b92aae1dd166466fb2499af936110e42","type":"GENE","name":"SLC26A5-AS1","canonical_id":"hgnc:HGNC:55680","description":"SLC26A5 antisense RNA 1","metadata":null},{"id":"be0cab63cf7240c08a718b92f8ec6891","type":"GENE","name":"SLC26A6","canonical_id":"hgnc:HGNC:14472","description":"solute carrier family 26 member 6","metadata":{"aliases":["DKFZp586E1422"]}},{"id":"4733585223064cb59485c629f54e6491","type":"GENE","name":"SLC26A7","canonical_id":"hgnc:HGNC:14467","description":"solute carrier family 26 member 7","metadata":{"aliases":["SUT2"]}},{"id":"6db0eab30b0f4979a8ba8a229aac696c","type":"GENE","name":"SLC26A8","canonical_id":"hgnc:HGNC:14468","description":"solute carrier family 26 member 8","metadata":{"aliases":["TAT1"]}},{"id":"1dbb7b6cd90146928e421bb8254f6c5c","type":"GENE","name":"SLC26A8-AS1","canonical_id":"hgnc:HGNC:59388","description":"SLC26A8 antisense RNA 1","metadata":null},{"id":"cba15b8b9734444b92ce04ffd8db9f04","type":"GENE","name":"SLC26A9","canonical_id":"hgnc:HGNC:14469","description":"solute carrier family 26 member 9","metadata":null},{"id":"6d13bb558bab48a3a0009aa98593d4f4","type":"GENE","name":"SLC26A9-AS1","canonical_id":"hgnc:HGNC:40686","description":"SLC26A9 and RAB7B antisense RNA 1","metadata":null},{"id":"efd3b7631e4a4d1787ed18b87b0c7100","type":"GENE","name":"SLC27A1","canonical_id":"hgnc:HGNC:10995","description":"solute carrier family 27 member 1","metadata":{"aliases":["FATP1","FATP","MGC71751","FLJ00336","ACSVL5"]}},{"id":"f84498e6f21642ac86ceeef89f54c865","type":"GENE","name":"SLC27A2","canonical_id":"hgnc:HGNC:10996","description":"solute carrier family 27 member 2","metadata":{"aliases":["FATP2","hFACVL1","VLACS","VLCS","HsT17226","ACSVL1","FACVL1"]}},{"id":"950d74ff0cc14cb098772f6b173a0ce3","type":"GENE","name":"SLC27A3","canonical_id":"hgnc:HGNC:10997","description":"solute carrier family 27 member 3","metadata":{"aliases":["FATP3","MGC4365","ACSVL3"]}},{"id":"b37c413bcaf943e58e0b0560f5ed8866","type":"GENE","name":"SLC27A4","canonical_id":"hgnc:HGNC:10998","description":"solute carrier family 27 member 4","metadata":{"aliases":["FATP4","ACSVL4","FATP-4"]}},{"id":"74deb3e288094e9a86afe4e6e3dbd802","type":"GENE","name":"SLC27A5","canonical_id":"hgnc:HGNC:10999","description":"solute carrier family 27 member 5","metadata":{"aliases":["FATP5","VLACSR","VLCS-H2","VLCSH2","FACVL3","FLJ22987","ACSVL6","ACSB"]}},{"id":"6a6ae5a4fcb8431dbcc266fd56343bb4","type":"GENE","name":"SLC27A6","canonical_id":"hgnc:HGNC:11000","description":"solute carrier family 27 member 6","metadata":{"aliases":["FATP6","VLCS-H1","FACVL2","ACSVL2"]}},{"id":"0e03b76217824881b1f7846400e42bde","type":"GENE","name":"SLC28A1","canonical_id":"hgnc:HGNC:11001","description":"solute carrier family 28 member 1","metadata":{"aliases":["CNT1"]}},{"id":"03d08fdeeb064db5a18183b8e7f27120","type":"GENE","name":"SLC28A2","canonical_id":"hgnc:HGNC:11002","description":"solute carrier family 28 member 2","metadata":{"aliases":["CNT2","SPNT1","HCNT2","HsT17153"]}},{"id":"8b6e334729d249d08d0f68316af87663","type":"GENE","name":"SLC28A2-AS1","canonical_id":"hgnc:HGNC:55417","description":"SLC28A2 antisense RNA 1","metadata":{"aliases":["AC051619.4"]}},{"id":"ecf029b033f14723a4a63b15241ae143","type":"GENE","name":"SLC28A3","canonical_id":"hgnc:HGNC:16484","description":"solute carrier family 28 member 3","metadata":{"aliases":["CNT3"]}},{"id":"997938c19742435ca4d2fca42cd44bee","type":"GENE","name":"SLC28A3-AS1","canonical_id":"hgnc:HGNC:55460","description":"SLC28A3 regulatory antisense RNA 1","metadata":null},{"id":"daf740f931784529b8591f9ec156a8e0","type":"GENE","name":"SLC29A1","canonical_id":"hgnc:HGNC:11003","description":null,"metadata":null},{"id":"6b67366510184db98b2d7eeed116e83b","type":"PROTEIN","name":"SLC29A1","canonical_id":"uniprot:Q99808","description":null,"metadata":null},{"id":"243f0188f08e4ed691d01680eeb816d6","type":"GENE","name":"SLC29A2","canonical_id":"hgnc:HGNC:11004","description":"solute carrier family 29 member 2","metadata":{"aliases":["DER12","ENT2","HNP36"]}},{"id":"980da01b07bf4f09a6a8473ac69e56a4","type":"GENE","name":"SLC29A3","canonical_id":"hgnc:HGNC:23096","description":"solute carrier family 29 member 3","metadata":{"aliases":["ENT3","FLJ11160","hENT3"]}},{"id":"8182f93f0617455896b71199a725dbc8","type":"GENE","name":"SLC29A4","canonical_id":"hgnc:HGNC:23097","description":"solute carrier family 29 member 4","metadata":{"aliases":["FLJ34923","ENT4"]}},{"id":"8a75c883675f47af92c8d5343c99a0bd","type":"GENE","name":"SLC29A4P1","canonical_id":"hgnc:HGNC:43783","description":"solute carrier family 29 member 4 pseudogene 1","metadata":null},{"id":"4053020ded084bcd9e256315654590ce","type":"GENE","name":"SLC29A4P2","canonical_id":"hgnc:HGNC:43782","description":"solute carrier family 29 member 4 pseudogene 2","metadata":null},{"id":"64ea1be1d8b84613bdf1183bcd9f2e37","type":"GENE","name":"SLC2A1","canonical_id":"hgnc:HGNC:11005","description":null,"metadata":null},{"id":"74af4de80e00484681553e07ec3ef37a","type":"GENE","name":"SLC2A1-DT","canonical_id":"hgnc:HGNC:44187","description":"SLC2A1 divergent transcript","metadata":{"aliases":["SLC2A1-AS1"]}},{"id":"02aaa0dc59924420bf5789432f925b73","type":"GENE","name":"SLC2A10","canonical_id":"hgnc:HGNC:13444","description":"solute carrier family 2 member 10","metadata":{"aliases":["GLUT10","GLUT-10"]}},{"id":"19c46ab80d3f46aa8a8af9b6232f8e94","type":"GENE","name":"SLC2A11","canonical_id":"hgnc:HGNC:14239","description":"solute carrier family 2 member 11","metadata":{"aliases":["GLUT11"]}},{"id":"96ec745c242b441e9be3ebf45f0a5cb5","type":"GENE","name":"SLC2A12","canonical_id":"hgnc:HGNC:18067","description":"solute carrier family 2 member 12","metadata":{"aliases":["GLUT12","GLUT8"]}},{"id":"fceb1351606243858bbbcdca252aac3d","type":"GENE","name":"SLC2A13","canonical_id":"hgnc:HGNC:15956","description":"solute carrier family 2 member 13","metadata":{"aliases":["HMIT"]}},{"id":"ceb471fefa16439b93ba48d07eaa7a6e","type":"GENE","name":"SLC2A13P1","canonical_id":"hgnc:HGNC:48929","description":"SLC2A13 pseudogene 1","metadata":null},{"id":"e4a0df747e5d4ea6bd7619512a7d055c","type":"GENE","name":"SLC2A14","canonical_id":"hgnc:HGNC:18301","description":"solute carrier family 2 member 14","metadata":{"aliases":["GLUT14","SLC2A3P3"]}},{"id":"49ab509c535c420eac29f32900e7fb5f","type":"GENE","name":"SLC2A2","canonical_id":"hgnc:HGNC:11006","description":"solute carrier family 2 member 2","metadata":{"aliases":["GLUT-2","GLUT2"]}},{"id":"ee726423a74f478a8c92a2e91354b916","type":"GENE","name":"SLC2A3","canonical_id":"hgnc:HGNC:11007","description":null,"metadata":null},{"id":"8b4f14186f4b4815bf43e58c7481fdee","type":"GENE","name":"SLC2A3P1","canonical_id":"hgnc:HGNC:11008","description":"solute carrier family 2 member 3 pseudogene 1","metadata":{"aliases":["GLUT6","GLUT3P1","SLC2A3P"]}},{"id":"a6fb936ab4ec4bc2b7fd96ae88e7e52a","type":"GENE","name":"SLC2A3P2","canonical_id":"hgnc:HGNC:31074","description":"solute carrier family 2 member 3 pseudogene 2","metadata":null},{"id":"da4387ce745f499fa310c0308da7a9ff","type":"GENE","name":"SLC2A3P4","canonical_id":"hgnc:HGNC:31076","description":"solute carrier family 2 member 3 pseudogene 4","metadata":null},{"id":"7cdd29b32b91412b980d930a33ad079d","type":"GENE","name":"SLC2A4","canonical_id":"hgnc:HGNC:11009","description":null,"metadata":null},{"id":"dc816386456f4622973f67a5caf6f15a","type":"GENE","name":"SLC2A4RG","canonical_id":"hgnc:HGNC:15930","description":null,"metadata":null},{"id":"5a0f66edca1246789fe602f7202f9926","type":"GENE","name":"SLC2A5","canonical_id":"hgnc:HGNC:11010","description":"solute carrier family 2 member 5","metadata":{"aliases":["GLUT5"]}},{"id":"934126f6222b466083ba5e7e2730f641","type":"GENE","name":"SLC2A6","canonical_id":"hgnc:HGNC:11011","description":"solute carrier family 2 member 6","metadata":{"aliases":["GLUT9","GLUT6","HSA011372"]}},{"id":"3291fc8fbbc74f438191834e9483c1f7","type":"GENE","name":"SLC2A7","canonical_id":"hgnc:HGNC:13445","description":"solute carrier family 2 member 7","metadata":{"aliases":["GLUT7"]}},{"id":"1a6ad137cd42403880a7e9882a773c22","type":"GENE","name":"SLC2A8","canonical_id":"hgnc:HGNC:13812","description":"solute carrier family 2 member 8","metadata":{"aliases":["GLUTX1","GLUT8"]}},{"id":"4232422202a74545aacce5ef48c89ca1","type":"GENE","name":"SLC2A9","canonical_id":"hgnc:HGNC:13446","description":"solute carrier family 2 member 9","metadata":{"aliases":["Glut9","GLUTX","URATv1"]}},{"id":"903644f936024863b3514c96559e39dc","type":"GENE","name":"SLC2A9-AS1","canonical_id":"hgnc:HGNC:40636","description":"SLC2A9 antisense RNA 1","metadata":null},{"id":"4e4c523636b44e40b554759726d6aac6","type":"GENE","name":"SLC2A9-AS2","canonical_id":"hgnc:HGNC:40637","description":"SLC2A9 antisense RNA 2","metadata":null},{"id":"c59df0684bd34688a43d310eb31c960d","type":"GENE","name":"SLC2A9-AS3","canonical_id":"hgnc:HGNC:59109","description":"SLC2A9 antisense RNA 3","metadata":null},{"id":"477d306d04174e6fa5268b3b1b1fd833","type":"GENE","name":"SLC2AXP1","canonical_id":"hgnc:HGNC:31077","description":"solute carrier family 2 pseudogene 1","metadata":null},{"id":"0872b80c03e74a46ba30ea247a664781","type":"GENE","name":"SLC30A1","canonical_id":"hgnc:HGNC:11012","description":"solute carrier family 30 member 1","metadata":{"aliases":["ZRC1","ZNT1"]}},{"id":"47ca96b5075346269dc0cca9f22b2be1","type":"GENE","name":"SLC30A10","canonical_id":"hgnc:HGNC:25355","description":"solute carrier family 30 member 10","metadata":{"aliases":["DKFZp547M236","ZnT-10","ZRC1","ZNT8","ZNT10"]}},{"id":"5d76f94620e44e0980e8ca31d145e57a","type":"GENE","name":"SLC30A2","canonical_id":"hgnc:HGNC:11013","description":"solute carrier family 30 member 2","metadata":{"aliases":["ZNT2"]}},{"id":"ca14670c52ef4598a94074047dab1d18","type":"GENE","name":"SLC30A3","canonical_id":"hgnc:HGNC:11014","description":"solute carrier family 30 member 3","metadata":{"aliases":["ZNT3"]}},{"id":"08e37aeba7824a73936c99aafcc0961b","type":"GENE","name":"SLC30A4","canonical_id":"hgnc:HGNC:11015","description":"solute carrier family 30 member 4","metadata":{"aliases":["ZNT4"]}},{"id":"0ef254e32dab48df9d637ca9c4526ead","type":"GENE","name":"SLC30A4-AS1","canonical_id":"hgnc:HGNC:56661","description":"SLC30A4 antisense RNA 1","metadata":{"aliases":["hLinfRNA4","RP11-519G16.3"]}},{"id":"fb6f542bbdfd4cc8aae785f9142b4a30","type":"GENE","name":"SLC30A5","canonical_id":"hgnc:HGNC:19089","description":"solute carrier family 30 member 5","metadata":{"aliases":["ZTL1","ZnT-5","FLJ12496","FLJ12756","ZNT5","MGC5499","ZNTL1"]}},{"id":"57cae82296e249dbb37be29cf9d53966","type":"GENE","name":"SLC30A6","canonical_id":"hgnc:HGNC:19305","description":"solute carrier family 30 member 6","metadata":{"aliases":["FLJ31101","ZNT6"]}},{"id":"563bf706ec3e4422a5afe8bb2adfb5ec","type":"GENE","name":"SLC30A6-DT","canonical_id":"hgnc:HGNC:55203","description":"SLC30A6 divergent transcript","metadata":null},{"id":"85750399f29e4f6684beb203a2f0967c","type":"GENE","name":"SLC30A6P1","canonical_id":"hgnc:HGNC:54646","description":"SLC30A6 pseudogene 1","metadata":null},{"id":"6b312078df0c4263a723d34e15466794","type":"GENE","name":"SLC30A7","canonical_id":"hgnc:HGNC:19306","description":"solute carrier family 30 member 7","metadata":{"aliases":["ZnTL2","ZNT7"]}},{"id":"a72a592726fd41e1b4cc92200ce93fcf","type":"GENE","name":"SLC30A8","canonical_id":"hgnc:HGNC:20303","description":"solute carrier family 30 member 8","metadata":{"aliases":["ZnT-8","ZNT8"]}},{"id":"1ebf9c474ab74a018e185d30ca0a87d7","type":"GENE","name":"SLC30A9","canonical_id":"hgnc:HGNC:1329","description":"solute carrier family 30 member 9","metadata":{"aliases":["HUEL","ZNT9","GAC63","C4orf1"]}},{"id":"0cb25328bf5a46b8a497c72e6787a49f","type":"GENE","name":"SLC31A1","canonical_id":"hgnc:HGNC:11016","description":null,"metadata":null},{"id":"0eb99ba888174436be3af872a795591e","type":"GENE","name":"SLC31A1P1","canonical_id":"hgnc:HGNC:17124","description":"solute carrier family 31 member 1 pseudogene 1","metadata":{"aliases":["CTR1psi","SLC31A1P"]}},{"id":"98b944e2de58473a8c196d3eddf57ccb","type":"GENE","name":"SLC31A2","canonical_id":"hgnc:HGNC:11017","description":"solute carrier family 31 member 2","metadata":{"aliases":["hCTR2","CTR2","COPT2"]}},{"id":"64f0b5110258400caeb44c18e4428c47","type":"GENE","name":"SLC32A1","canonical_id":"hgnc:HGNC:11018","description":"solute carrier family 32 member 1","metadata":{"aliases":["VGAT","bA122O1.1","VIAAT"]}},{"id":"b78d25eb708d43a8847648e66dafae8b","type":"GENE","name":"SLC33A1","canonical_id":"hgnc:HGNC:95","description":"solute carrier family 33 member 1","metadata":{"aliases":["AT-1","AT1","ACATN","SPG42"]}},{"id":"8550ff9aab07461299f6991bf4d77eee","type":"GENE","name":"SLC33A2","canonical_id":"hgnc:HGNC:25157","description":"solute carrier family 33 member 2","metadata":{"aliases":["MFSD3"]}},{"id":"ac02544fe5c540ec83b442cae24838f7","type":"GENE","name":"SLC34A1","canonical_id":"hgnc:HGNC:11019","description":"solute carrier family 34 member 1","metadata":{"aliases":["NAPI-3","NPTIIa","SLC11","NPT2","SLC17A2"]}},{"id":"ac90ea7f19444c69b9e2fa5b46e276f9","type":"GENE","name":"SLC34A2","canonical_id":"hgnc:HGNC:11020","description":null,"metadata":null},{"id":"fe479039cdd54d6eb15575784dac6153","type":"GENE","name":"SLC34A3","canonical_id":"hgnc:HGNC:20305","description":"solute carrier family 34 member 3","metadata":{"aliases":["NPTIIc","FLJ38680","NaPi-2c","NPT2C"]}},{"id":"85d6771335104eafbf5564896a5bc528","type":"GENE","name":"SLC35A1","canonical_id":"hgnc:HGNC:11021","description":"solute carrier family 35 member A1","metadata":{"aliases":["CMPST","hCST","CMP-Sia-Tr"]}},{"id":"82af62d726c44a03b97fabf549f4484d","type":"GENE","name":"SLC35A2","canonical_id":"hgnc:HGNC:11022","description":"solute carrier family 35 member A2","metadata":{"aliases":["UGAT","UGT","UGT1","UGT2","UGTL","UDP-Gal-Tr","UGALT"]}},{"id":"c0b6a57e327e4d80a644acb2613e9848","type":"GENE","name":"SLC35A3","canonical_id":"hgnc:HGNC:11023","description":"solute carrier family 35 member A3","metadata":null},{"id":"8e475cd20dc046cd91029905e2fdfe07","type":"GENE","name":"SLC35A4","canonical_id":"hgnc:HGNC:20753","description":"solute carrier family 35 member A4","metadata":null},{"id":"d8e42e21b03e442c833004a73dd139da","type":"GENE","name":"SLC35A5","canonical_id":"hgnc:HGNC:20792","description":"solute carrier family 35 member A5","metadata":{"aliases":["FLJ20730"]}},{"id":"b2b1769901a94af7a7a0c757c7f067a1","type":"GENE","name":"SLC35B1","canonical_id":"hgnc:HGNC:20798","description":"solute carrier family 35 member B1","metadata":{"aliases":["UGTREL1","AXER"]}},{"id":"65a760be99c14e498d1eda522158c823","type":"GENE","name":"SLC35B2","canonical_id":"hgnc:HGNC:16872","description":"solute carrier family 35 member B2","metadata":{"aliases":["UGTrel4"]}},{"id":"20ad51edad5c4b21acc92b09a3ba1e61","type":"GENE","name":"SLC35B3","canonical_id":"hgnc:HGNC:21601","description":"solute carrier family 35 member B3","metadata":{"aliases":["CGI-19","dJ453H5.1","PAPST2","C6orf196"]}},{"id":"a918e8e7d8a34fb3be2c3cb4e1cd88a2","type":"GENE","name":"SLC35B3-AS1","canonical_id":"hgnc:HGNC:59343","description":"SLC35B3 antisense RNA 1","metadata":null},{"id":"22f4e8c26803459f9dcfc349f72d4ac9","type":"GENE","name":"SLC35B4","canonical_id":"hgnc:HGNC:20584","description":"solute carrier family 35 member B4","metadata":{"aliases":["FLJ14697","YEA4"]}},{"id":"33199575f2f442d897d2261c0ecc76f0","type":"GENE","name":"SLC35C1","canonical_id":"hgnc:HGNC:20197","description":"solute carrier family 35 member C1","metadata":{"aliases":["FUCT1","FLJ11320"]}},{"id":"cb5d2097cb434438b7d4205e2b70d162","type":"GENE","name":"SLC35C2P1","canonical_id":"hgnc:HGNC:54894","description":"SLC35C2 pseudogene 1","metadata":null},{"id":"1f37d02c79634253b21cbb9a2a56cd3a","type":"GENE","name":"SLC35D1","canonical_id":"hgnc:HGNC:20800","description":"solute carrier family 35 member D1","metadata":{"aliases":["UGTREL7","KIAA0260"]}},{"id":"70489852a7c0452cbb0637872e493d9e","type":"GENE","name":"SLC35D2","canonical_id":"hgnc:HGNC:20799","description":"solute carrier family 35 member D2","metadata":{"aliases":["UGTrel8","SQV7L"]}},{"id":"97337d9ba22a4d8a9582f2b5287c4255","type":"GENE","name":"SLC35D3","canonical_id":"hgnc:HGNC:15621","description":"solute carrier family 35 member D3","metadata":{"aliases":["FRCL1"]}},{"id":"5ed8ce67fe054864a6ec8fcb54276eea","type":"GENE","name":"SLC35D4","canonical_id":"hgnc:HGNC:31723","description":"solute carrier family 35 member D4","metadata":{"aliases":["MGC11386","FLJ44259","C18orf45","TMEM241"]}},{"id":"c5157adf18b644e6b32e9bf59893b20f","type":"GENE","name":"SLC35E1","canonical_id":"hgnc:HGNC:20803","description":"solute carrier family 35 member E1","metadata":{"aliases":["FLJ14251"]}},{"id":"3e300d7b524d4b2db3f231948dbd9f9f","type":"GENE","name":"SLC35E1P1","canonical_id":"hgnc:HGNC:42046","description":"solute carrier family 35 member E1 pseudogene 1","metadata":null},{"id":"02ec0d45423e4c9aae283d4b27c079f2","type":"GENE","name":"SLC35E2A","canonical_id":"hgnc:HGNC:20863","description":"solute carrier family 35 member E2A (pseudogene)","metadata":{"aliases":["KIAA0447","SLC35E2AP","SLC35E2P","SLC35E2"]}},{"id":"e64b6a2d8f9a40b9810004f59b3cac42","type":"GENE","name":"SLC35E2B","canonical_id":"hgnc:HGNC:33941","description":"solute carrier family 35 member E2B","metadata":null},{"id":"1176d26901af49e682d6937499487a52","type":"GENE","name":"SLC35E3","canonical_id":"hgnc:HGNC:20864","description":"solute carrier family 35 member E3","metadata":{"aliases":["BLOV1"]}},{"id":"64ee2f1d0af041758ea3ec72538f5c11","type":"GENE","name":"SLC35E4","canonical_id":"hgnc:HGNC:17058","description":"solute carrier family 35 member E4","metadata":null},{"id":"37faba403b704520b2d62511e3d1fc97","type":"GENE","name":"SLC35F1","canonical_id":"hgnc:HGNC:21483","description":"solute carrier family 35 member F1","metadata":{"aliases":["dJ230I3.1","C6orf169"]}},{"id":"c560446ba0d645388807c3ac17855947","type":"GENE","name":"SLC35F2","canonical_id":"hgnc:HGNC:23615","description":"solute carrier family 35 member F2","metadata":{"aliases":["FLJ13018"]}},{"id":"b9618c3861dd4eb892ddef10cea257d5","type":"GENE","name":"SLC35F3","canonical_id":"hgnc:HGNC:23616","description":"solute carrier family 35 member F3","metadata":{"aliases":["FLJ37712"]}},{"id":"e1e440a17bda484fb986a985c52d3d35","type":"GENE","name":"SLC35F3-AS1","canonical_id":"hgnc:HGNC:41027","description":"SLC35F3 antisense RNA 1","metadata":null},{"id":"32651e649c36460b83a2b86686ae0cf0","type":"GENE","name":"SLC35F4","canonical_id":"hgnc:HGNC:19845","description":"solute carrier family 35 member F4","metadata":{"aliases":["FLJ37712","C14orf36"]}},{"id":"08d174d2b15f4158b2261d01962681fd","type":"GENE","name":"SLC35F4-AS1","canonical_id":"hgnc:HGNC:58292","description":"SLC35F4 antisense RNA 1","metadata":null},{"id":"1be1893b75424daf90cacd1852478bca","type":"GENE","name":"SLC35F5","canonical_id":"hgnc:HGNC:23617","description":"solute carrier family 35 member F5","metadata":{"aliases":["FLJ22004"]}},{"id":"8ffaeecc0b864d059fb340860cb15246","type":"GENE","name":"SLC35F6","canonical_id":"hgnc:HGNC:26055","description":"solute carrier family 35 member F6","metadata":{"aliases":["FLJ20555","ANT2BP","TANGO9","C2orf18"]}},{"id":"5eaad8004fc24ece9eb7961c28046956","type":"GENE","name":"SLC35G1","canonical_id":"hgnc:HGNC:26607","description":"solute carrier family 35 member G1","metadata":{"aliases":["FLJ33990","C10orf60","POST","TMEM20"]}},{"id":"a99c73d5c1134d1bb9d242f22ebdf905","type":"GENE","name":"SLC35G2","canonical_id":"hgnc:HGNC:28480","description":"solute carrier family 35 member G2","metadata":{"aliases":["MGC3295","DKFZp564K2464","TMEM22"]}},{"id":"41366ca138384f0bb1ecbdf6abbf5949","type":"GENE","name":"SLC35G3","canonical_id":"hgnc:HGNC:26848","description":"solute carrier family 35 member G3","metadata":{"aliases":["FLJ40154","TMEM21A","AMAC1"]}},{"id":"409fd9bf9abe4c12871d3f0844a7400e","type":"GENE","name":"SLC35G4","canonical_id":"hgnc:HGNC:31043","description":"solute carrier family 35 member G4","metadata":{"aliases":["AMAC1L1","SLC35G4P"]}},{"id":"077f2508337648c7b0e3254f7a243539","type":"GENE","name":"SLC35G5","canonical_id":"hgnc:HGNC:15546","description":"solute carrier family 35 member G5","metadata":{"aliases":["AMAC","AMAC1L2"]}},{"id":"d36ee30722e94b0baed928b0118efdfb","type":"GENE","name":"SLC35G6","canonical_id":"hgnc:HGNC:31351","description":"solute carrier family 35 member G6","metadata":{"aliases":["TMEM21B","AMAC1L3"]}},{"id":"007e9b3dc298461889bd9b843b05d05b","type":"GENE","name":"SLC35H1","canonical_id":"hgnc:HGNC:17117","description":"solute carrier family 35 member H1","metadata":{"aliases":["CGI-15","bA394O2.1","C20orf5","OVCOV1","SLC35C2"]}},{"id":"8208f0b86c954f27b7dbab548605b231","type":"GENE","name":"SLC36A1","canonical_id":"hgnc:HGNC:18761","description":"solute carrier family 36 member 1","metadata":{"aliases":["LYAAT-1","PAT1","TRAMD3"]}},{"id":"de13ba7cdbc84d11a0708621849786cd","type":"GENE","name":"SLC36A2","canonical_id":"hgnc:HGNC:18762","description":"solute carrier family 36 member 2","metadata":{"aliases":["PAT2","tramdorin","TRAMD1"]}},{"id":"9f0cb04890654260bfe55c45e2cbbb45","type":"GENE","name":"SLC36A3","canonical_id":"hgnc:HGNC:19659","description":"solute carrier family 36 member 3","metadata":{"aliases":["PAT3","TRAMD2","tramdorin2"]}},{"id":"cdf38f0cf0984129bf635ab0afacca14","type":"GENE","name":"SLC36A4","canonical_id":"hgnc:HGNC:19660","description":"solute carrier family 36 member 4","metadata":{"aliases":["PAT4","FLJ38932"]}},{"id":"1bde050b81e343da88fff5828a3bd5e3","type":"GENE","name":"SLC37A1","canonical_id":"hgnc:HGNC:11024","description":"solute carrier family 37 member 1","metadata":{"aliases":["SPX1"]}},{"id":"5213fb915524439d8fd425d71146894e","type":"GENE","name":"SLC37A2","canonical_id":"hgnc:HGNC:20644","description":"solute carrier family 37 member 2","metadata":{"aliases":["FLJ00171","SPX2"]}},{"id":"5d8577b49cb0415486f971b866e70a97","type":"GENE","name":"SLC37A3","canonical_id":"hgnc:HGNC:20651","description":"solute carrier family 37 member 3","metadata":{"aliases":["DKFZp761N0624","SPX3"]}},{"id":"7b124956deac4c07b7d34b061e7d491b","type":"GENE","name":"SLC37A4","canonical_id":"hgnc:HGNC:4061","description":"solute carrier family 37 member 4","metadata":{"aliases":["GSD1b","GSD1c","GSD1d","G6PT","SPX4","G6PT1","G6PT2","G6PT3"]}},{"id":"ce236d4a882b47098d2ce34f0153359a","type":"GENE","name":"SLC38A1","canonical_id":"hgnc:HGNC:13447","description":"solute carrier family 38 member 1","metadata":{"aliases":["ATA1","NAT2","SAT1","SNAT1"]}},{"id":"291a8396598544b1bdf67c995c780095","type":"GENE","name":"SLC38A10","canonical_id":"hgnc:HGNC:28237","description":"solute carrier family 38 member 10","metadata":{"aliases":["MGC15523","PP1744","SNAT10"]}},{"id":"26e6a86bd1c44338be81dbeef183b105","type":"GENE","name":"SLC38A11","canonical_id":"hgnc:HGNC:26836","description":"solute carrier family 38 member 11","metadata":{"aliases":["FLJ39822","AVT2"]}},{"id":"dd2b8a63f5954fe28a11d853fe56bf7f","type":"GENE","name":"SLC38A12","canonical_id":"hgnc:HGNC:25984","description":"solute carrier family 38 member 12","metadata":{"aliases":["FLJ20255","FLJ00021","TMEM104"]}},{"id":"a5557917b7e1466590f4542ae9bad469","type":"GENE","name":"SLC38A2","canonical_id":"hgnc:HGNC:13448","description":"solute carrier family 38 member 2","metadata":{"aliases":["SAT2","ATA2","KIAA1382","SNAT2"]}},{"id":"f7677a9883e047e9aa767f9e72d1200d","type":"GENE","name":"SLC38A2-AS1","canonical_id":"hgnc:HGNC:55454","description":"SLC38A2 antisense RNA 1","metadata":null},{"id":"6e10149d7abb4617ad3e776979d88281","type":"GENE","name":"SLC38A3","canonical_id":"hgnc:HGNC:18044","description":"solute carrier family 38 member 3","metadata":{"aliases":["G17","SN1","SNAT3"]}},{"id":"0b1db5e71a634bc080f065f31cacc978","type":"GENE","name":"SLC38A4","canonical_id":"hgnc:HGNC:14679","description":"solute carrier family 38 member 4","metadata":{"aliases":["PAAT","NAT3","ATA3","SNAT4"]}},{"id":"2369ec41c49c4074ab90b2d6105ee026","type":"GENE","name":"SLC38A4-AS1","canonical_id":"hgnc:HGNC:56178","description":"SLC38A4 antisense RNA 1","metadata":{"aliases":["lncPCED1b"]}},{"id":"e9da53a83bf8462ab6016ae95c2cfabe","type":"GENE","name":"SLC38A5","canonical_id":"hgnc:HGNC:18070","description":"solute carrier family 38 member 5","metadata":{"aliases":["SN2","JM24","SNAT5"]}},{"id":"9815cf86f7844be48e6a5d24e04c32d3","type":"GENE","name":"SLC38A6","canonical_id":"hgnc:HGNC:19863","description":"solute carrier family 38 member 6","metadata":{"aliases":["NAT-1","SNAT6"]}},{"id":"955861027ab84c0d9d9e5a3a9707bdbc","type":"GENE","name":"SLC38A7","canonical_id":"hgnc:HGNC:25582","description":"solute carrier family 38 member 7","metadata":{"aliases":["FLJ10815","SNAT7"]}},{"id":"40d8f85ccdb74ed2a78ef5ce9c181998","type":"GENE","name":"SLC38A8","canonical_id":"hgnc:HGNC:32434","description":"solute carrier family 38 member 8","metadata":{"aliases":["SNAT8"]}},{"id":"48bf586d2b7f4a9486de948c7476de06","type":"GENE","name":"SLC38A9","canonical_id":"hgnc:HGNC:26907","description":"solute carrier family 38 member 9","metadata":{"aliases":["FLJ90709","SNAT9"]}},{"id":"172eef4aa6634712b0918f52381e49a2","type":"GENE","name":"SLC38A9-DT","canonical_id":"hgnc:HGNC:59047","description":"SLC38A9 divergent transcript","metadata":null},{"id":"90dc97f77b874d3789a96ae8a04e153f","type":"GENE","name":"SLC39A1","canonical_id":"hgnc:HGNC:12876","description":null,"metadata":null},{"id":"502ea88138a24f158e9d3fb9a79a5b40","type":"GENE","name":"SLC39A10","canonical_id":"hgnc:HGNC:20861","description":"solute carrier family 39 member 10","metadata":{"aliases":["KIAA1265","FLJ90515","DKFZp564L2123","ZIP10"]}},{"id":"273d8f0d604d42ceb1f7c0bb164556e8","type":"GENE","name":"SLC39A11","canonical_id":"hgnc:HGNC:14463","description":"solute carrier family 39 member 11","metadata":{"aliases":["ZIP11","C17orf26"]}},{"id":"40a57e8087b4479195da602029365db7","type":"GENE","name":"SLC39A12","canonical_id":"hgnc:HGNC:20860","description":"solute carrier family 39 member 12","metadata":{"aliases":["FLJ30499","ZIP12"]}},{"id":"eb7f335dee9f4422b41b3a0b7f957a6f","type":"GENE","name":"SLC39A12-AS1","canonical_id":"hgnc:HGNC:44881","description":"SLC39A12 antisense RNA 1","metadata":null},{"id":"e7c9808619af49deab931ec86f62e697","type":"GENE","name":"SLC39A13","canonical_id":"hgnc:HGNC:20859","description":"solute carrier family 39 member 13","metadata":{"aliases":["FLJ25785","LZT-Hs9","ZIP13","ZIP-13"]}},{"id":"5597b2f0e2de46a39e577b7b5c91380e","type":"GENE","name":"SLC39A13-AS1","canonical_id":"hgnc:HGNC:56351","description":"SLC39A13 antisense RNA 1","metadata":{"aliases":["lnc-SPI1U","LOUP","AC090559.1"]}},{"id":"0ab588ad46c246239da8e1877107a7b7","type":"GENE","name":"SLC39A14","canonical_id":"hgnc:HGNC:20858","description":"solute carrier family 39 member 14","metadata":{"aliases":["KIAA0062","NET34","ZIP14","ZIP-14"]}},{"id":"e58ee6a500114f0785ccbc252d05cd2c","type":"GENE","name":"SLC39A1P1","canonical_id":"hgnc:HGNC:56980","description":"SLC39A1 pseudogene 1","metadata":null},{"id":"9bfa4692664846f9bab7cad04c57bd35","type":"GENE","name":"SLC39A2","canonical_id":"hgnc:HGNC:17127","description":"solute carrier family 39 member 2","metadata":{"aliases":["ZIP2"]}},{"id":"71166976045947f7b33d88b6e1498950","type":"GENE","name":"SLC39A3","canonical_id":"hgnc:HGNC:17128","description":null,"metadata":null},{"id":"d04bc9371ce24c69a66f746845bf98b3","type":"GENE","name":"SLC39A4","canonical_id":"hgnc:HGNC:17129","description":"solute carrier family 39 member 4","metadata":{"aliases":["ZIP4","ZIP-4","AWMS2","AEZ"]}},{"id":"a1add8005de74e7d8a501b9a7bfda199","type":"GENE","name":"SLC39A5","canonical_id":"hgnc:HGNC:20502","description":"solute carrier family 39 member 5","metadata":{"aliases":["ZIP5"]}},{"id":"430841f73b604a09a2782133addbb45f","type":"GENE","name":"SLC39A6","canonical_id":"hgnc:HGNC:18607","description":"solute carrier family 39 member 6","metadata":{"aliases":["LIV-1","ZIP6"]}},{"id":"3fdd36914ce64ea5b6ea363b0e6902a1","type":"GENE","name":"SLC39A7","canonical_id":"hgnc:HGNC:4927","description":"solute carrier family 39 member 7","metadata":{"aliases":["H2-KE4","D6S2244E","KE4","RING5","ZIP7","HKE4"]}},{"id":"2870f69e5df64dbe99d7e4b2cb69b209","type":"GENE","name":"SLC39A8","canonical_id":"hgnc:HGNC:20862","description":null,"metadata":null},{"id":"26819f7426b14d9b9b32453302cfad2d","type":"GENE","name":"SLC39A9","canonical_id":"hgnc:HGNC:20182","description":"solute carrier family 39 member 9","metadata":{"aliases":["FLJ11274","ZIP9"]}},{"id":"d1fd6be869b745fb84125c2b49f4d310","type":"GENE","name":"SLC3A1","canonical_id":"hgnc:HGNC:11025","description":null,"metadata":null},{"id":"cabb1c8378314b15a1e324b05e687b87","type":"GENE","name":"SLC3A2","canonical_id":"hgnc:HGNC:11026","description":null,"metadata":null},{"id":"c4bdfd440ba74718b6c630ce8b99af55","type":"GENE","name":"SLC40A1","canonical_id":"hgnc:HGNC:10909","description":"solute carrier family 40 member 1","metadata":{"aliases":["MTP1","IREG1","FPN1","HFE4","FPN","SLC11A3"]}},{"id":"5b7ed0b437fb4259b212f71b7cbaf676","type":"GENE","name":"SLC41A1","canonical_id":"hgnc:HGNC:19429","description":"solute carrier family 41 member 1","metadata":{"aliases":["MgtE"]}},{"id":"98cd646e49214889869fc8659e43637a","type":"GENE","name":"SLC41A2","canonical_id":"hgnc:HGNC:31045","description":"solute carrier family 41 member 2","metadata":{"aliases":["DKFZP434K0427"]}},{"id":"9a4e4e0630af4f608288eab84cd4f72b","type":"GENE","name":"SLC41A3","canonical_id":"hgnc:HGNC:31046","description":"solute carrier family 41 member 3","metadata":{"aliases":["FLJ20473"]}},{"id":"917095a9a0d448c4a8c5288b5f6ebb59","type":"GENE","name":"SLC41A3-AS1","canonical_id":"hgnc:HGNC:55559","description":"SLC41A3 antisense RNA 1","metadata":null},{"id":"7670f58606714739a85ec78def782903","type":"GENE","name":"SLC43A1","canonical_id":"hgnc:HGNC:9225","description":"solute carrier family 43 member 1","metadata":{"aliases":["R00504","PB39","POV1"]}},{"id":"7bb7cbabebe74409888e5ab66abfa5b0","type":"GENE","name":"SLC43A2","canonical_id":"hgnc:HGNC:23087","description":"solute carrier family 43 member 2","metadata":{"aliases":["MGC34680"]}},{"id":"9856f449de154fa797a304a40fbce328","type":"GENE","name":"SLC43A3","canonical_id":"hgnc:HGNC:17466","description":"solute carrier family 43 member 3","metadata":{"aliases":["SEEEG-1","Eeg1","DKFZp762A227","FOAP-13","PRO1659"]}},{"id":"be5920740c3448949128a9ec9f0f93ad","type":"GENE","name":"SLC44A1","canonical_id":"hgnc:HGNC:18798","description":"solute carrier family 44 member 1","metadata":{"aliases":["CTL1","CHTL1","CD92","CDW92"]}},{"id":"651633eceed541259a845c5fa4cee2f3","type":"GENE","name":"SLC44A2","canonical_id":"hgnc:HGNC:17292","description":"solute carrier family 44 member 2 (CTL2 blood group)","metadata":{"aliases":["HNA-3","CTL2"]}},{"id":"727f3c68c915484da96017d8646b41cf","type":"GENE","name":"SLC44A3","canonical_id":"hgnc:HGNC:28689","description":"solute carrier family 44 member 3","metadata":{"aliases":["MGC45474","CTL3"]}},{"id":"6be34c16486545018c12fb48cbc0030c","type":"GENE","name":"SLC44A3-AS1","canonical_id":"hgnc:HGNC:49057","description":"SLC44A3 antisense RNA 1","metadata":{"aliases":["LINC01057"]}},{"id":"052acde282c84d7aa563307205619e80","type":"GENE","name":"SLC44A3P1","canonical_id":"hgnc:HGNC:54781","description":"SLC44A3 pseudogene 1","metadata":null},{"id":"c77fc15e8ed549c3840ac9c42ff770a6","type":"GENE","name":"SLC44A4","canonical_id":"hgnc:HGNC:13941","description":"solute carrier family 44 member 4","metadata":{"aliases":["NG22","CTL4","FLJ14491","TPPT","DFNA72","C6orf29"]}},{"id":"1484cbd0ced843d9b21c72b518677912","type":"GENE","name":"SLC44A5","canonical_id":"hgnc:HGNC:28524","description":"solute carrier family 44 member 5","metadata":{"aliases":["MGC34032","CTL5"]}},{"id":"f6670f138bc840b99cfb48996c453fc8","type":"GENE","name":"SLC45A1","canonical_id":"hgnc:HGNC:17939","description":"solute carrier family 45 member 1","metadata":{"aliases":["DNB5"]}},{"id":"efed441a64af453a86d5f69568e5a8a8","type":"GENE","name":"SLC45A2","canonical_id":"hgnc:HGNC:16472","description":"solute carrier family 45 member 2","metadata":{"aliases":["AIM-1","OCA4","MATP"]}},{"id":"51cc0f39c35443d9b199f1caf384ca42","type":"GENE","name":"SLC45A3","canonical_id":"hgnc:HGNC:8642","description":"solute carrier family 45 member 3","metadata":{"aliases":["IPCA-6","prostein","IPCA-2","IPCA-8","PCANAP6","PCANAP2","PCANAP8"]}},{"id":"16aeeeada6da4a769cc897d17afe6fd7","type":"GENE","name":"SLC45A4","canonical_id":"hgnc:HGNC:29196","description":"solute carrier family 45 member 4","metadata":{"aliases":["KIAA1126"]}},{"id":"fd037bf35fc84cb4ab801fc4a2666a11","type":"GENE","name":"SLC45A4-AS1","canonical_id":"hgnc:HGNC:56711","description":"SLC45A4 antisense RNA 1","metadata":null},{"id":"82298465b4a142b68783dbe9f1e168ae","type":"GENE","name":"SLC45A4-AS2","canonical_id":"hgnc:HGNC:58259","description":"SLC45A4 antisense RNA 2","metadata":null},{"id":"972c0b7403bf4b368d136e7d979fd5ac","type":"GENE","name":"SLC46A1","canonical_id":"hgnc:HGNC:30521","description":null,"metadata":null},{"id":"28eacd6dd7e74fc19f723f4a9b038fa1","type":"GENE","name":"SLC46A2","canonical_id":"hgnc:HGNC:16055","description":"solute carrier family 46 member 2","metadata":{"aliases":["Ly110","TSCOT"]}},{"id":"5fadf1a5c99e4e8492f263c55d55812b","type":"GENE","name":"SLC46A2-AS1","canonical_id":"hgnc:HGNC:56364","description":"SLC46A2 antisense RNA 1","metadata":{"aliases":["AL139041.1"]}},{"id":"6172c53a726a4815aa1026343464fad4","type":"GENE","name":"SLC46A3","canonical_id":"hgnc:HGNC:27501","description":"solute carrier family 46 member 3","metadata":{"aliases":["DKFZp686A1775","FLJ42613"]}},{"id":"06afad8266d4485bafe439616a144825","type":"GENE","name":"SLC47A1","canonical_id":"hgnc:HGNC:25588","description":"solute carrier family 47 member 1","metadata":{"aliases":["FLJ10847","MATE1"]}},{"id":"8b3f5ab199cb487f9afcae6fd36ab3b5","type":"GENE","name":"SLC47A1P1","canonical_id":"hgnc:HGNC:51849","description":"SLC47A1 pseudogene 1","metadata":null},{"id":"66fe2f142ccd4024be7f092aba697d8b","type":"GENE","name":"SLC47A1P2","canonical_id":"hgnc:HGNC:53866","description":"SLC47A1 pseudogene 2","metadata":null},{"id":"c4cc343618eb4402ad332d7bffb3e40c","type":"GENE","name":"SLC47A2","canonical_id":"hgnc:HGNC:26439","description":"solute carrier family 47 member 2","metadata":{"aliases":["FLJ31196","MATE2","MATE2-K"]}},{"id":"d16baff3de234d8792221d13b5d1bd50","type":"GENE","name":"SLC48A1","canonical_id":"hgnc:HGNC:26035","description":"solute carrier family 48 member 1","metadata":{"aliases":["FLJ20489","hHRG-1","HRG1"]}},{"id":"f92f9e2ea3af4a61b702f2e779279bce","type":"GENE","name":"SLC49A3","canonical_id":"hgnc:HGNC:26177","description":"solute carrier family 49 member 3","metadata":{"aliases":["FLJ22269","LP2561","MFSD7"]}},{"id":"999da89b5bd143dc851cff060edaa3e0","type":"GENE","name":"SLC49A3-AS1","canonical_id":"hgnc:HGNC:58705","description":"SLC49A3 antisense RNA 1","metadata":null},{"id":"fa969e7b3b31493eb09be36d775a21f5","type":"GENE","name":"SLC49A4","canonical_id":"hgnc:HGNC:16628","description":"solute carrier family 49 member 4","metadata":{"aliases":["FLJ14784","RCC4","DIRC2"]}},{"id":"a6295bc419204f12981e36cbc416e83b","type":"GENE","name":"SLC4A1","canonical_id":"hgnc:HGNC:11027","description":"solute carrier family 4 member 1 (Diego blood group)","metadata":{"aliases":["RTA1A","CD233","FR","SW","WR","EMPB3","EPB3","AE1","DI","WD"]}},{"id":"444dc8a064444a8caee4f035d6f5780b","type":"GENE","name":"SLC4A10","canonical_id":"hgnc:HGNC:13811","description":"solute carrier family 4 member 10","metadata":{"aliases":["NBCn2","NCBE"]}},{"id":"8fae39213c1d451ba869eea73dbffe44","type":"GENE","name":"SLC4A11","canonical_id":"hgnc:HGNC:16438","description":"solute carrier family 4 member 11","metadata":{"aliases":["dJ794I6.2","BTR1","NaBC1","FECD4","CHED2","CDPD1"]}},{"id":"d91639dee6454999b757e12db0589987","type":"GENE","name":"SLC4A1AP","canonical_id":"hgnc:HGNC:13813","description":"solute carrier family 4 member 1 adaptor protein","metadata":{"aliases":["kanadaptin","HLC3"]}},{"id":"95519baaf6b84acc82dbd75cf3c6ab39","type":"GENE","name":"SLC4A1APP1","canonical_id":"hgnc:HGNC:49811","description":"solute carrier family 4 member 1 adaptor protein pseudogene 1","metadata":null},{"id":"427405f2916245f68318cc5a4e861daf","type":"GENE","name":"SLC4A1APP2","canonical_id":"hgnc:HGNC:49812","description":"solute carrier family 4 member 1 adaptor protein pseudogene 2","metadata":null},{"id":"cef6a064b66a4032abdd69d1b2345a45","type":"GENE","name":"SLC4A2","canonical_id":"hgnc:HGNC:11028","description":null,"metadata":null},{"id":"891518871af0408bac1bb5055acc8d7a","type":"GENE","name":"SLC4A3","canonical_id":"hgnc:HGNC:11029","description":"solute carrier family 4 member 3","metadata":{"aliases":["AE3","SLC2C"]}},{"id":"d9bbcf5a058a4414a1d954dc73558a2c","type":"GENE","name":"SLC4A4","canonical_id":"hgnc:HGNC:11030","description":"solute carrier family 4 member 4","metadata":{"aliases":["NBC1","HNBC1","NBC2","pNBC","hhNMC","kNBC1","KNBC","NBCe1","SLC4A5"]}},{"id":"51eebb3eb2624f6dba07609e197caf66","type":"GENE","name":"SLC4A4-AS1","canonical_id":"hgnc:HGNC:58809","description":"SLC4A4 antisense RNA 1","metadata":null},{"id":"120d7434340843ae8c7b25b9d97f429d","type":"GENE","name":"SLC4A4-AS2","canonical_id":"hgnc:HGNC:58810","description":"SLC4A4 antisense RNA 2","metadata":null},{"id":"23729b2d982a46dcbcfd2a7daf638ab3","type":"GENE","name":"SLC4A5","canonical_id":"hgnc:HGNC:18168","description":"solute carrier family 4 member 5","metadata":{"aliases":["NBC4"]}},{"id":"7f250065f5124ac0b6809e075ae6909b","type":"GENE","name":"SLC4A7","canonical_id":"hgnc:HGNC:11033","description":"solute carrier family 4 member 7","metadata":{"aliases":["NBC3","SBC2","SLC4A6"]}},{"id":"97dbbd59753d49368f94fe642df95281","type":"GENE","name":"SLC4A8","canonical_id":"hgnc:HGNC:11034","description":"solute carrier family 4 member 8","metadata":{"aliases":["NBC3"]}},{"id":"d51b663a2b4741a488f8bd661b214095","type":"GENE","name":"SLC4A8-AS1","canonical_id":"hgnc:HGNC:55259","description":"SLC4A8 antisense RNA 1","metadata":null},{"id":"089d21ebd6c34a7cbcdbe9aa7d47a099","type":"GENE","name":"SLC4A9","canonical_id":"hgnc:HGNC:11035","description":"solute carrier family 4 member 9","metadata":{"aliases":["AE4"]}},{"id":"dafac7434e1f4b05a9ee720db8623dda","type":"GENE","name":"SLC50A1","canonical_id":"hgnc:HGNC:30657","description":"solute carrier family 50 member 1","metadata":{"aliases":["SCP","RP11-540D14.5","slv","RZPDo834D038D","HsSWEET1","SWEET1","RAG1AP1"]}},{"id":"da61530ef34849f994be5ded8eb3b640","type":"GENE","name":"SLC51A","canonical_id":"hgnc:HGNC:29955","description":"solute carrier family 51 member A","metadata":{"aliases":["OSTalpha","SLC51A1"]}},{"id":"62c0808493624dd9966e7958439201e6","type":"GENE","name":"SLC51B","canonical_id":"hgnc:HGNC:29956","description":"SLC51 subunit beta","metadata":{"aliases":["OSTbeta","SLC51A1BP"]}},{"id":"25ea0cb3eb5249b4b9adc00595b99cfd","type":"GENE","name":"SLC52A1","canonical_id":"hgnc:HGNC:30225","description":"solute carrier family 52 member 1","metadata":{"aliases":["FLJ10060","GPCR42","PAR2","hRFT1","RFVT1","GPR172B"]}},{"id":"0fba27b6ed814dc2bbbd7717552d08cf","type":"GENE","name":"SLC52A2","canonical_id":"hgnc:HGNC:30224","description":"solute carrier family 52 member 2","metadata":{"aliases":["FLJ11856","PAR1","GPCR41","D15Ertd747e","RFVT2","hRFT3","RFT3","HuPAR-1","GPR172A"]}},{"id":"53ccbda8ee3242f79a8b52534a649b1b","type":"GENE","name":"SLC52A3","canonical_id":"hgnc:HGNC:16187","description":"solute carrier family 52 member 3","metadata":{"aliases":["bA371L19.1","hRFT2","RFVT3","RFT2","C20orf54"]}},{"id":"b53ea8a3db6c431bbf15be9904679622","type":"GENE","name":"SLC5A1","canonical_id":"hgnc:HGNC:11036","description":null,"metadata":null},{"id":"4ffe3da04f5649e596cd8208eedfabe2","type":"PROTEIN","name":"SLC5A1","canonical_id":"uniprot:P13866","description":null,"metadata":null},{"id":"7acff97e9c9e4e61a7d21b206c65ab0d","type":"GENE","name":"SLC5A10","canonical_id":"hgnc:HGNC:23155","description":"solute carrier family 5 member 10","metadata":{"aliases":["SGLT5"]}},{"id":"35abd026b637415d94f972e68a71e2d2","type":"GENE","name":"SLC5A11","canonical_id":"hgnc:HGNC:23091","description":"solute carrier family 5 member 11","metadata":{"aliases":["KST1","SMIT2","SGLT6"]}},{"id":"1c91e9a1dcc64766b0b97594bb4b91dd","type":"GENE","name":"SLC5A12","canonical_id":"hgnc:HGNC:28750","description":"solute carrier family 5 member 12","metadata":{"aliases":["MGC52019","SMCT2"]}},{"id":"bfe6edc18b1341c58d7ce3cd6da9261a","type":"GENE","name":"SLC5A2","canonical_id":"hgnc:HGNC:11037","description":"solute carrier family 5 member 2","metadata":{"aliases":["SGLT2"]}},{"id":"3f2a2ba33c524430bb2aa96ac6206cbb","type":"PROTEIN","name":"SLC5A2","canonical_id":"uniprot:P31639","description":null,"metadata":null},{"id":"8eb388e1717e444497e694dbf16a2e6b","type":"GENE","name":"SLC5A3","canonical_id":"hgnc:HGNC:11038","description":"solute carrier family 5 member 3","metadata":{"aliases":["SMIT","SMIT1"]}},{"id":"3f266e44244949e0ade33f35cada1db0","type":"GENE","name":"SLC5A4","canonical_id":"hgnc:HGNC:11039","description":"solute carrier family 5 member 4","metadata":{"aliases":["SAAT1","SGLT3","DJ90G24.4"]}},{"id":"ba06a5f0e0764eb484de1e07c41c7dd0","type":"GENE","name":"SLC5A4-AS1","canonical_id":"hgnc:HGNC:53163","description":"SLC5A4 antisense RNA 1","metadata":{"aliases":["RP1-90G24.10"]}},{"id":"17d4c4d15782449db8095fbc2f00404e","type":"GENE","name":"SLC5A4P1","canonical_id":"hgnc:HGNC:45041","description":"solute carrier family 5 member 4 pseudogene 1","metadata":null},{"id":"f9e8ba4084bb49f2916a78ef46674e7d","type":"GENE","name":"SLC5A5","canonical_id":"hgnc:HGNC:11040","description":null,"metadata":null},{"id":"3af6b53a6b5443f3b18dd643186eade1","type":"GENE","name":"SLC5A6","canonical_id":"hgnc:HGNC:11041","description":"solute carrier family 5 member 6","metadata":{"aliases":["SMVT"]}},{"id":"d363210260ae4cd1882b3de8a3039667","type":"GENE","name":"SLC5A7","canonical_id":"hgnc:HGNC:14025","description":"solute carrier family 5 member 7","metadata":{"aliases":["hCHT","CHT1","ChT"]}},{"id":"ac87332d2eb94c0ba5381a17ba60d1d0","type":"GENE","name":"SLC5A8","canonical_id":"hgnc:HGNC:19119","description":null,"metadata":null},{"id":"73ee648476804ca1aaee1dffc97cafc4","type":"GENE","name":"SLC5A9","canonical_id":"hgnc:HGNC:22146","description":"solute carrier family 5 member 9","metadata":{"aliases":["SGLT4"]}},{"id":"78e3962371ba4480846808f42b7e3f69","type":"GENE","name":"SLC60A1","canonical_id":"hgnc:HGNC:25433","description":"solute carrier family 60 member 1","metadata":{"aliases":["DKFZp761N1114","FLJ34577","UNQ3064","FLJ25004","MFSD4","MFSD4A"]}},{"id":"6c9cb5486be44a8484da80a286b0e657","type":"GENE","name":"SLC60A1-AS1","canonical_id":"hgnc:HGNC:27632","description":"SLC60A1 antisense RNA 1","metadata":{"aliases":["MFSD4A-AS1"]}},{"id":"836139005d7e441ba62e389cb1d73913","type":"GENE","name":"SLC60A2","canonical_id":"hgnc:HGNC:21053","description":"solute carrier family 60 member 2","metadata":{"aliases":["MGC33953","KIAA1919","MFSD4B"]}},{"id":"45a1ae6351064f6ba4258ed038c449ea","type":"GENE","name":"SLC60A2-DT","canonical_id":"hgnc:HGNC:55773","description":"SLC60A2 divergent transcript","metadata":{"aliases":["MFSD4B-DT"]}},{"id":"affc2a4b40244f179904aae8d8df073b","type":"GENE","name":"SLC60A2P1","canonical_id":"hgnc:HGNC:50626","description":"SLC60A2 pseudogene 1","metadata":{"aliases":["MFSD4BP1"]}},{"id":"25d9cdff2a134f4d9fe5ae88be14e2bd","type":"GENE","name":"SLC61A1","canonical_id":"hgnc:HGNC:28156","description":"solute carrier family 61 member 1","metadata":{"aliases":["MGC11308","HsMOT2","MFSD5"]}},{"id":"2811e55e450244be8d09ececd72a5a80","type":"GENE","name":"SLC66A1","canonical_id":"hgnc:HGNC:26001","description":"solute carrier family 66 member 1","metadata":{"aliases":["FLJ20320","LAAT-1","LAAT1","PQLC2"]}},{"id":"77bf73f66d25474ca63db65883108b7a","type":"GENE","name":"SLC66A1LP","canonical_id":"hgnc:HGNC:25146","description":"solute carrier family 66 member 1 like, pseudogene","metadata":{"aliases":["C3orf55","PQLC2L","SLC66A1L"]}},{"id":"75f570a949a14ae99308fc7f2732597a","type":"GENE","name":"SLC66A2","canonical_id":"hgnc:HGNC:26188","description":"solute carrier family 66 member 2","metadata":{"aliases":["FLJ22378","PQLC1"]}},{"id":"2c90980b27fd41bf87aa92297bd1e051","type":"GENE","name":"SLC66A2P1","canonical_id":"hgnc:HGNC:43986","description":"SLC66A2 pseudogene 1","metadata":{"aliases":["PQLC1P1"]}},{"id":"69964c9e3d154b7793c84abcc913e45c","type":"GENE","name":"SLC66A2P2","canonical_id":"hgnc:HGNC:43987","description":"SLC66A2 pseudogene 2","metadata":{"aliases":["PQLC1P2"]}},{"id":"0c21557d8c77461f99b033ca2bf16ff4","type":"GENE","name":"SLC66A3","canonical_id":"hgnc:HGNC:28503","description":"solute carrier family 66 member 3","metadata":{"aliases":["MGC33602","C2orf22","PQLC3"]}},{"id":"6b7a7051a01542a4b90bf20c2ef92d45","type":"GENE","name":"SLC67A1","canonical_id":"hgnc:HGNC:10964","description":"solute carrier family 67 member 1","metadata":{"aliases":["BWR1A","TSSC5","ITM","IMPT1","ORCTL2","BWSCR1A","SLC22A18","SLC22A1L"]}},{"id":"b550c84b63d446d4a147c8c80db73b9b","type":"GENE","name":"SLC67A1-AS","canonical_id":"hgnc:HGNC:10965","description":"SLC67A1 antisense RNA","metadata":{"aliases":["BWR1B","p27-BWR1B","SLC22A18-AS1","BWSCR1B","ORCTL2S","SLC22A1LS","SLC22A18AS"]}},{"id":"b7f82b94099047ba9460a0e07b37fe93","type":"GENE","name":"SLC67A2","canonical_id":"hgnc:HGNC:28158","description":"solute carrier family 67 member 2","metadata":{"aliases":["MGC11332","MFSD9"]}},{"id":"82b2590299084e1f922031e21cb41c4c","type":"GENE","name":"SLC68A1","canonical_id":"hgnc:HGNC:26196","description":"solute carrier family 68 member 1","metadata":{"aliases":["FLJ22529","bA18I14.8","C10orf77","TMEM180","MFSD13A"]}},{"id":"e81b16cc7c844607abd3d2f2b235dfae","type":"GENE","name":"SLC68A2P","canonical_id":"hgnc:HGNC:52163","description":"solute carrier family 68 member 2, pseudogene","metadata":{"aliases":["MFSD13B"]}},{"id":"3eb536e6a71945b5bd1857b86dd2c27b","type":"GENE","name":"SLC6A1","canonical_id":"hgnc:HGNC:11042","description":"solute carrier family 6 member 1","metadata":{"aliases":["GAT1","GABATR","GABATHG","GAT-1","hGAT-1"]}},{"id":"70c732fc09974c30ae7b02888a664077","type":"GENE","name":"SLC6A1-AS1","canonical_id":"hgnc:HGNC:40546","description":"SLC6A1 antisense RNA 1","metadata":null},{"id":"0c1b6fc533264315b388a56311cdaff6","type":"GENE","name":"SLC6A10P","canonical_id":"hgnc:HGNC:11043","description":"solute carrier family 6 member 10, pseudogene","metadata":{"aliases":["CT-2","SLC6A10"]}},{"id":"741da84e898d4f4789373a4a1d4d12de","type":"GENE","name":"SLC6A11","canonical_id":"hgnc:HGNC:11044","description":"solute carrier family 6 member 11","metadata":{"aliases":["GAT3"]}},{"id":"04001b54fb8548ab955cc4264eb761f8","type":"GENE","name":"SLC6A12","canonical_id":"hgnc:HGNC:11045","description":"solute carrier family 6 member 12","metadata":{"aliases":["BGT-1"]}},{"id":"6e199a33830040788106748d5ada1789","type":"GENE","name":"SLC6A12-AS1","canonical_id":"hgnc:HGNC:40548","description":"SLC6A12 antisense RNA 1","metadata":null},{"id":"0f82201b744e423dbc844c0f84b3f07a","type":"GENE","name":"SLC6A13","canonical_id":"hgnc:HGNC:11046","description":"solute carrier family 6 member 13","metadata":{"aliases":["GAT2"]}},{"id":"1022e66fd9b14edab53476ed1769235a","type":"GENE","name":"SLC6A14","canonical_id":"hgnc:HGNC:11047","description":"solute carrier family 6 member 14","metadata":null},{"id":"b551e2f619584d82ad34abe634690b25","type":"GENE","name":"SLC6A14P1","canonical_id":"hgnc:HGNC:54529","description":"SLC6A14 pseudogene 1","metadata":null},{"id":"f6fa3e4ea91c4e5bbb2c476aeb3779aa","type":"GENE","name":"SLC6A14P2","canonical_id":"hgnc:HGNC:54530","description":"SLC6A14 pseudogene 2","metadata":null},{"id":"561b4ed76dd143f49638b28a4c28a9e1","type":"GENE","name":"SLC6A14P3","canonical_id":"hgnc:HGNC:54531","description":"SLC6A14 pseudogene 3","metadata":null},{"id":"416d21c489a0447b8fb74c043e7f39e2","type":"GENE","name":"SLC6A15","canonical_id":"hgnc:HGNC:13621","description":"solute carrier family 6 member 15","metadata":{"aliases":["hv7-3","NTT73","FLJ10316","V7-3","SBAT1"]}},{"id":"b029be183009420a8b813a2cea3ac32f","type":"GENE","name":"SLC6A16","canonical_id":"hgnc:HGNC:13622","description":"solute carrier family 6 member 16","metadata":{"aliases":["NTT5"]}},{"id":"2d1a288624ed49c090c85ce03e90417d","type":"GENE","name":"SLC6A17","canonical_id":"hgnc:HGNC:31399","description":"solute carrier family 6 member 17","metadata":{"aliases":["NTT4"]}},{"id":"3e3f877c7bc041ea9f671ca6cf3b604a","type":"GENE","name":"SLC6A17-AS1","canonical_id":"hgnc:HGNC:41279","description":"SLC6A17 antisense RNA 1","metadata":null},{"id":"5a3f876dda074351ad5421c445704517","type":"GENE","name":"SLC6A18","canonical_id":"hgnc:HGNC:26441","description":"solute carrier family 6 member 18","metadata":{"aliases":["FLJ31236","Xtrp2"]}},{"id":"f113b2e78b3b48e691dd0f9637699c50","type":"GENE","name":"SLC6A19","canonical_id":"hgnc:HGNC:27960","description":"solute carrier family 6 member 19","metadata":{"aliases":["B0AT1"]}},{"id":"298e2c98345c4b9fbe44e336c702a7e8","type":"GENE","name":"SLC6A2","canonical_id":"hgnc:HGNC:11048","description":"solute carrier family 6 member 2","metadata":{"aliases":["NET","NET1","NAT1","SLC6A5"]}},{"id":"1f17d9b6daf44791b782134a8b9c1320","type":"PROTEIN","name":"SLC6A2","canonical_id":"uniprot:P23975","description":null,"metadata":null},{"id":"5c98d2942c954858890b73b492b9106d","type":"GENE","name":"SLC6A20","canonical_id":"hgnc:HGNC:30927","description":"solute carrier family 6 member 20","metadata":{"aliases":["XT3","Xtrp3","SIT1","IMINO"]}},{"id":"a4116e78aa9c465fa734654e89c6d84d","type":"GENE","name":"SLC6A21P","canonical_id":"hgnc:HGNC:31400","description":"solute carrier family 6 member 21, pseudogene","metadata":{"aliases":["SLC6A21"]}},{"id":"eb44fe37794d470c89ba67da71ca3c8c","type":"GENE","name":"SLC6A3","canonical_id":"hgnc:HGNC:11049","description":null,"metadata":null},{"id":"61a359cd64a7418da9357c77f991b493","type":"PROTEIN","name":"SLC6A3","canonical_id":"uniprot:Q01959","description":null,"metadata":null},{"id":"2037993182224543ae5df8b7019daf8f","type":"GENE","name":"SLC6A4","canonical_id":"hgnc:HGNC:11050","description":null,"metadata":null},{"id":"51e10e63db0a42be9d35328755a358d0","type":"PROTEIN","name":"SLC6A4","canonical_id":"uniprot:P31645","description":null,"metadata":null},{"id":"291745ad313140718835d58fe891dfa2","type":"GENE","name":"SLC6A5","canonical_id":"hgnc:HGNC:11051","description":"solute carrier family 6 member 5","metadata":{"aliases":["GLYT2","GlyT-2","NET1"]}},{"id":"8fbee75df612459789b969cff62419bc","type":"GENE","name":"SLC6A6","canonical_id":"hgnc:HGNC:11052","description":null,"metadata":null},{"id":"6275cbd25ac049c795bd096870d242db","type":"GENE","name":"SLC6A6P1","canonical_id":"hgnc:HGNC:11053","description":"solute carrier family 6 member 6 pseudogene 1","metadata":{"aliases":["SLC6A6P"]}},{"id":"32b710f5f25440a6b73b44c90ecc81da","type":"GENE","name":"SLC6A7","canonical_id":"hgnc:HGNC:11054","description":"solute carrier family 6 member 7","metadata":{"aliases":["PROT"]}},{"id":"84473e95c0624803ac5301e77cb37e6b","type":"GENE","name":"SLC6A8","canonical_id":"hgnc:HGNC:11055","description":"solute carrier family 6 member 8","metadata":{"aliases":["CRTR","CT1","CRT","CRT-1","CRT1"]}},{"id":"aaeb7fb8b2834bff8d15db6922023b20","type":"GENE","name":"SLC6A9","canonical_id":"hgnc:HGNC:11056","description":"solute carrier family 6 member 9","metadata":{"aliases":["GLYT1","GlyT-1"]}},{"id":"0f21f067193c4f26ad74dc2c462a89be","type":"GENE","name":"SLC71A1","canonical_id":"hgnc:HGNC:23363","description":"solute carrier family 71 member 1","metadata":{"aliases":["DKFZP564L0864","HIAT1","MFSD14A"]}},{"id":"c4de3b874f404e61b7beb4b397635241","type":"GENE","name":"SLC71A1-AS1","canonical_id":"hgnc:HGNC:58237","description":"SLC71A1 antisense RNA 1","metadata":{"aliases":["MFSD14A-AS1"]}},{"id":"fcd56926f1b549868d508d3efca8a5b9","type":"GENE","name":"SLC71A2","canonical_id":"hgnc:HGNC:23376","description":"solute carrier family 71 member 2","metadata":{"aliases":["FLJ14753","HIATL1","MFSD14B"]}},{"id":"bc4aa968f4504f1da126425c80004908","type":"GENE","name":"SLC71A3P","canonical_id":"hgnc:HGNC:23672","description":"solute carrier family 71 member 3, pseudogene","metadata":{"aliases":["MGC12945","HIATL2","MFSD14C","MFSD14CP"]}},{"id":"a8c320ae5ee84f80ab973d8e976d9629","type":"GENE","name":"SLC75A1","canonical_id":"hgnc:HGNC:16894","description":"solute carrier family 75 member 1","metadata":{"aliases":["IT10C3","TETRAN","SLC75A1","MFSD10"]}},{"id":"f23dd43d4dce4d0286d70a2093242800","type":"GENE","name":"SLC7A1","canonical_id":"hgnc:HGNC:11057","description":null,"metadata":null},{"id":"47cb681172d84bf69b50a39d3a9c10d2","type":"GENE","name":"SLC7A10","canonical_id":"hgnc:HGNC:11058","description":"solute carrier family 7 member 10","metadata":{"aliases":["asc-1"]}},{"id":"8e35082a835346bf9b39fad18ce2d6dc","type":"GENE","name":"SLC7A10-AS1","canonical_id":"hgnc:HGNC:58322","description":"SLC7A10 antisense RNA 1","metadata":null},{"id":"af52742c014d4815b97f622ab0fc1c93","type":"GENE","name":"SLC7A11","canonical_id":"hgnc:HGNC:11059","description":"solute carrier family 7 member 11","metadata":{"aliases":["xCT"]}},{"id":"970084fca09a4f0da64ef3221b7121ef","type":"GENE","name":"SLC7A11-AS1","canonical_id":"hgnc:HGNC:44064","description":"SLC7A11 antisense RNA 1","metadata":{"aliases":["ENST00000512786"]}},{"id":"c1cfb2486715468eb4b135051cf72ced","type":"GENE","name":"SLC7A11-AS2","canonical_id":"hgnc:HGNC:58884","description":"SLC7A11 antisense RNA 2","metadata":null},{"id":"5be1797539df49ca840d960d350a3fb2","type":"GENE","name":"SLC7A13","canonical_id":"hgnc:HGNC:23092","description":"solute carrier family 7 member 13","metadata":{"aliases":["AGT-1","XAT2"]}},{"id":"52ab34de3c564bad9efabe79a57dabc2","type":"GENE","name":"SLC7A14","canonical_id":"hgnc:HGNC:29326","description":"solute carrier family 7 member 14","metadata":{"aliases":["KIAA1613","PPP1R142"]}},{"id":"ea5d320d5c994839a7fdb5bc9cb8416e","type":"GENE","name":"SLC7A14-AS1","canonical_id":"hgnc:HGNC:54092","description":"SLC7A14 antisense RNA 1","metadata":null},{"id":"2b2d7f1c237541ecbb76c2abbd1f03e1","type":"GENE","name":"SLC7A15P","canonical_id":"hgnc:HGNC:32724","description":"solute carrier family 7 member 15, pseudogene","metadata":null},{"id":"0974e4b2156a405299626ed2a12d9821","type":"GENE","name":"SLC7A2","canonical_id":"hgnc:HGNC:11060","description":"solute carrier family 7 member 2","metadata":{"aliases":["CAT-2","HCAT2","SLC7A2A","SLC7A2B","CAT-2A","CAT-2B","ATRC2"]}},{"id":"71946cca16c64c0cb71b7e923f5f7137","type":"GENE","name":"SLC7A2-IT1","canonical_id":"hgnc:HGNC:54925","description":"SLC7A2 intronic transcript 1","metadata":null},{"id":"e2da416938364a03adbc6a5762e774a7","type":"GENE","name":"SLC7A3","canonical_id":"hgnc:HGNC:11061","description":"solute carrier family 7 member 3","metadata":{"aliases":["CAT-3","ATRC3","FLJ14541"]}},{"id":"100b80d99d8943f2bb1d5ca7c28eb5b1","type":"GENE","name":"SLC7A4","canonical_id":"hgnc:HGNC:11062","description":"solute carrier family 7 member 4","metadata":{"aliases":["HCAT3","CAT-4"]}},{"id":"a8ebd2ca5de54ab5ab80607e4b4dd5b9","type":"GENE","name":"SLC7A5","canonical_id":"hgnc:HGNC:11063","description":null,"metadata":null},{"id":"ddcefe85a79142daaa7ea4c5fd36e4ab","type":"GENE","name":"SLC7A5-AS1","canonical_id":"hgnc:HGNC:58301","description":"SLC7A5 antisense RNA 1","metadata":null},{"id":"bdd31d1830dc4677b86664fc41972dd4","type":"GENE","name":"SLC7A5P1","canonical_id":"hgnc:HGNC:29458","description":"solute carrier family 7 member 5 pseudogene 1","metadata":{"aliases":["LAT1-3TM","MLAS"]}},{"id":"3486eab4580941ba8b10e8ea1fcdd3c7","type":"GENE","name":"SLC7A5P2","canonical_id":"hgnc:HGNC:24951","description":"solute carrier family 7 member 5 pseudogene 2","metadata":{"aliases":["IMAA","hLAT1-3TM"]}},{"id":"fd42d20b24884a8f90068e9640932b53","type":"GENE","name":"SLC7A6","canonical_id":"hgnc:HGNC:11064","description":"solute carrier family 7 member 6","metadata":{"aliases":["y+LAT-2","KIAA0245","LAT3","LAT-2"]}},{"id":"9339b4a87e2b43d9ae3f74d1120fbf14","type":"GENE","name":"SLC7A6OS","canonical_id":"hgnc:HGNC:25807","description":"solute carrier family 7 member 6 opposite strand","metadata":{"aliases":["FLJ13291","Iwr1"]}},{"id":"bebe84601a5d4297bc6306e571f1fa8c","type":"GENE","name":"SLC7A7","canonical_id":"hgnc:HGNC:11065","description":"solute carrier family 7 member 7","metadata":{"aliases":["y+LAT-1","Y+LAT1","LPI"]}},{"id":"50ee97ee2367462ebfa7dd4629bd28e0","type":"GENE","name":"SLC7A8","canonical_id":"hgnc:HGNC:11066","description":"solute carrier family 7 member 8","metadata":{"aliases":["LPI-PC1","LAT2"]}},{"id":"303cb6454d054cc89002f1cfc727b925","type":"GENE","name":"SLC7A9","canonical_id":"hgnc:HGNC:11067","description":"solute carrier family 7 member 9","metadata":{"aliases":["BAT1","CSNU3"]}},{"id":"5e6790a8e5cd4fbf980b493bd6f1ed64","type":"GENE","name":"SLC8A1","canonical_id":"hgnc:HGNC:11068","description":"solute carrier family 8 member A1","metadata":{"aliases":["NCX1"]}},{"id":"ea33e991f5634f9baeb0619e9b118080","type":"GENE","name":"SLC8A1-AS1","canonical_id":"hgnc:HGNC:44102","description":"SLC8A1 antisense RNA 1","metadata":null},{"id":"e97e63557c8140c39184a0bf351a06d3","type":"GENE","name":"SLC8A2","canonical_id":"hgnc:HGNC:11069","description":"solute carrier family 8 member A2","metadata":{"aliases":["NCX2","KIAA1087"]}},{"id":"c473a60be99b44bd9b2e22a5f2eb805d","type":"GENE","name":"SLC8A3","canonical_id":"hgnc:HGNC:11070","description":null,"metadata":null},{"id":"10b0fedd456d41648e31aebbd349b8f2","type":"GENE","name":"SLC8B1","canonical_id":"hgnc:HGNC:26175","description":"solute carrier family 8 member B1","metadata":{"aliases":["FLJ22233","NCKX6","NCLX","SLC24A6"]}},{"id":"faa1b94a8a5b4d13826dedd34152fd2d","type":"GENE","name":"SLC9A1","canonical_id":"hgnc:HGNC:11071","description":null,"metadata":null},{"id":"ab3d2fb64a3e48a28f0f401c71ce3629","type":"GENE","name":"SLC9A2","canonical_id":"hgnc:HGNC:11072","description":null,"metadata":null},{"id":"906bb22b2a794f84b662d11fe8acd53a","type":"GENE","name":"SLC9A3","canonical_id":"hgnc:HGNC:11073","description":null,"metadata":null},{"id":"a203a4a2f7ac4b46987e1106d5de1ae4","type":"GENE","name":"SLC9A3-AS1","canonical_id":"hgnc:HGNC:40550","description":"SLC9A3 antisense RNA 1","metadata":{"aliases":["UC011CLY.2"]}},{"id":"ebd0f17a03aa40e0934a786a5017b0b3","type":"GENE","name":"SLC9A3-AS2","canonical_id":"hgnc:HGNC:58987","description":"SLC9A3 antisense RNA 2","metadata":null},{"id":"fb60119b54f24fc2867e205cd3292639","type":"GENE","name":"SLC9A3-OT1","canonical_id":"hgnc:HGNC:24524","description":"SLC9A3 3' UTR overlapping transcript 1","metadata":{"aliases":["PP7080"]}},{"id":"98f22abda427470bb340d13089dc5b8f","type":"GENE","name":"SLC9A3P1","canonical_id":"hgnc:HGNC:11074","description":"solute carrier family 9 member 3 pseudogene 1","metadata":{"aliases":["NHE3P","SLC9A3P","SLC9A3P4"]}},{"id":"78f047bf452746e7ae991cd0df12267b","type":"GENE","name":"SLC9A3P2","canonical_id":"hgnc:HGNC:19325","description":"solute carrier family 9 member 3 pseudogene 2","metadata":null},{"id":"ba4d6cadf7164aff80538d3437c88787","type":"GENE","name":"SLC9A3P3","canonical_id":"hgnc:HGNC:33492","description":"solute carrier family 9 member 3 pseudogene 3","metadata":null},{"id":"144d550e35ae41539a252f061d7c43bd","type":"GENE","name":"SLC9A3R1-AS1","canonical_id":"hgnc:HGNC:55322","description":"SLC9A3R1 antisense RNA 1","metadata":null},{"id":"2fc7510cac0340b9b570c42a727560a0","type":"GENE","name":"SLC9A4","canonical_id":"hgnc:HGNC:11077","description":"solute carrier family 9 member A4","metadata":{"aliases":["NHE4"]}},{"id":"8f1b66736ad8488cbf8677050850aa45","type":"GENE","name":"SLC9A5","canonical_id":"hgnc:HGNC:11078","description":"solute carrier family 9 member A5","metadata":{"aliases":["NHE5"]}},{"id":"40b0590e9d014972bd9bdacd56cc7877","type":"GENE","name":"SLC9A6","canonical_id":"hgnc:HGNC:11079","description":"solute carrier family 9 member A6","metadata":{"aliases":["NHE6","KIAA0267","NHE-6"]}},{"id":"8e689c275da74b0584d48997054d3241","type":"GENE","name":"SLC9A7","canonical_id":"hgnc:HGNC:17123","description":"solute carrier family 9 member A7","metadata":{"aliases":["NHE7","NHE-7"]}},{"id":"a40eb0054c314edbacf2f1f6515f8802","type":"GENE","name":"SLC9A7P1","canonical_id":"hgnc:HGNC:32679","description":"solute carrier family 9 member 7 pseudogene 1","metadata":null},{"id":"b08de02b23fa4a6d97ee38a470c96f3d","type":"GENE","name":"SLC9A8","canonical_id":"hgnc:HGNC:20728","description":"solute carrier family 9 member A8","metadata":{"aliases":["KIAA0939","NHE8"]}},{"id":"924ea0ff868d4903b2d35900197e02de","type":"GENE","name":"SLC9A9","canonical_id":"hgnc:HGNC:20653","description":"solute carrier family 9 member A9","metadata":{"aliases":["FLJ35613","NHE9"]}},{"id":"6e7e01d47dce4d05bbc0342d87f18830","type":"GENE","name":"SLC9A9-AS1","canonical_id":"hgnc:HGNC:40928","description":"SLC9A9 antisense RNA 1","metadata":null},{"id":"10c1908f9c4d4de8b3a518b844993790","type":"GENE","name":"SLC9A9-AS2","canonical_id":"hgnc:HGNC:40929","description":"SLC9A9 antisense RNA 2","metadata":null},{"id":"9747634b89584732ae597940273bc405","type":"GENE","name":"SLC9B1","canonical_id":"hgnc:HGNC:24244","description":"solute carrier family 9 member B1","metadata":{"aliases":["NHA1","NHEDC1"]}},{"id":"129d22c562364e26930069653fd80e8a","type":"GENE","name":"SLC9B1P1","canonical_id":"hgnc:HGNC:37492","description":"solute carrier family 9 member B1 pseudogene 1","metadata":{"aliases":["NHEDC1P1"]}},{"id":"56986399ac614250bb7f8efdc6605805","type":"GENE","name":"SLC9B1P2","canonical_id":"hgnc:HGNC:37493","description":"solute carrier family 9 member B1 pseudogene 2","metadata":{"aliases":["NHEDC1P2"]}},{"id":"573368364e6e4d26be0818d467cfd175","type":"GENE","name":"SLC9B1P3","canonical_id":"hgnc:HGNC:43582","description":"solute carrier family 9 member B1 pseudogene 3","metadata":null},{"id":"8c5d13baecdf46f1a8d9be430e9ba351","type":"GENE","name":"SLC9B1P4","canonical_id":"hgnc:HGNC:43583","description":"solute carrier family 9 member B1 pseudogene 4","metadata":null},{"id":"4c41c97c9947445a968e68bb01142976","type":"GENE","name":"SLC9B1P5","canonical_id":"hgnc:HGNC:43584","description":"solute carrier family 9 member B1 pseudogene 5","metadata":null},{"id":"9bd061dfc03c42ccbb416fbf2248d7b8","type":"GENE","name":"SLC9B2","canonical_id":"hgnc:HGNC:25143","description":"solute carrier family 9 member B2","metadata":{"aliases":["FLJ23984","NHA2","NHEDC2"]}},{"id":"601d9eace8bf4f46a95b9b4c825657ff","type":"GENE","name":"SLC9C1","canonical_id":"hgnc:HGNC:31401","description":"solute carrier family 9 member C1","metadata":{"aliases":["NHE","SLC9A10"]}},{"id":"92e3d64efcb442b5b80512017dffb54a","type":"GENE","name":"SLC9C2","canonical_id":"hgnc:HGNC:28664","description":"solute carrier family 9 member C2 (putative)","metadata":{"aliases":["MGC43026","SLC9A11"]}},{"id":"d7e38fa556874353aac6131dbb8fa06d","type":"GENE","name":"SLC9D1","canonical_id":"hgnc:HGNC:20329","description":"solute carrier family 9 member D1","metadata":{"aliases":["FLJ20623","C13orf11","TMCO3"]}},{"id":"90fb6b833f8e4e65949f93492710ffba","type":"GENE","name":"SLCO1A2","canonical_id":"hgnc:HGNC:10956","description":"solute carrier organic anion transporter family member 1A2","metadata":{"aliases":["OATP","OATP1A2","OATP-A","SLC21A3"]}},{"id":"491740d674664bfc889447f4dfda46b6","type":"GENE","name":"SLCO1B1","canonical_id":"hgnc:HGNC:10959","description":"solute carrier organic anion transporter family member 1B1","metadata":{"aliases":["OATP-C","LST-1","OATP1B1","SLC21A6"]}},{"id":"e20a2a56ec7d4d0b9c967036404034d2","type":"GENE","name":"SLCO1B3","canonical_id":"hgnc:HGNC:10961","description":null,"metadata":null},{"id":"512244fd6f894451ae485987ea6dd2ee","type":"GENE","name":"SLCO1B3-SLCO1B7","canonical_id":"hgnc:HGNC:54403","description":"SLCO1B3-SLCO1B7 readthrough","metadata":{"aliases":["OATP1B3-1B7","LST-3TM12"]}},{"id":"3753bdc4de6a42d9b08b15ad0102d767","type":"GENE","name":"SLCO1B7","canonical_id":"hgnc:HGNC:32934","description":"solute carrier organic anion transporter family member 1B7 (putative)","metadata":{"aliases":["LST3","SLC21A21"]}},{"id":"901e49dec9714e84938121e939814df4","type":"GENE","name":"SLCO1C1","canonical_id":"hgnc:HGNC:13819","description":"solute carrier organic anion transporter family member 1C1","metadata":{"aliases":["OATP-F","OATP1C1","OATP1","SLC21A14"]}},{"id":"0001cf54b9f0454cb92868db9149cbbc","type":"GENE","name":"SLCO2A1","canonical_id":"hgnc:HGNC:10955","description":"solute carrier organic anion transporter family member 2A1","metadata":{"aliases":["PGT","OATP2A1","SLC21A2","MATR1"]}},{"id":"aaf1fe1339e94b988e732fb29b090e72","type":"GENE","name":"SLCO2B1","canonical_id":"hgnc:HGNC:10962","description":"solute carrier organic anion transporter family member 2B1","metadata":{"aliases":["OATP-B","OATP2B1","SLC21A9"]}},{"id":"8e2a23f4ebfa4eb5a0a1e99faaae3cf2","type":"GENE","name":"SLCO3A1","canonical_id":"hgnc:HGNC:10952","description":"solute carrier organic anion transporter family member 3A1","metadata":{"aliases":["OATP-D","OATP3A1","SLC21A11"]}},{"id":"87a7388689d54a38bf80068b7769ced8","type":"GENE","name":"SLCO4A1","canonical_id":"hgnc:HGNC:10953","description":"solute carrier organic anion transporter family member 4A1","metadata":{"aliases":["OATP-E","OATP4A1","SLC21A12"]}},{"id":"f8af053709ff4647b015e1a4952ea43a","type":"GENE","name":"SLCO4A1-AS1","canonical_id":"hgnc:HGNC:40537","description":"SLCO4A1 antisense RNA 1","metadata":{"aliases":["DAMER"]}},{"id":"eb681cf5f0ed4fb490cf6109261ad229","type":"GENE","name":"SLCO4A1-AS2","canonical_id":"hgnc:HGNC:56052","description":"SLCO4A1 antisense RNA 2","metadata":null},{"id":"4e5a3525e51944b4aeacb1a9b6caab91","type":"GENE","name":"SLCO4C1","canonical_id":"hgnc:HGNC:23612","description":null,"metadata":null},{"id":"f0e3ea923bbf488cb54ba3ec668dd634","type":"GENE","name":"SLCO5A1","canonical_id":"hgnc:HGNC:19046","description":"solute carrier organic anion transporter family member 5A1","metadata":{"aliases":["OATPRP4","OATP-J","OATP5A1","SLC21A15"]}},{"id":"682dd4b2cd18463397820bbd755cca69","type":"GENE","name":"SLCO5A1-AS1","canonical_id":"hgnc:HGNC:55595","description":"SLCO5A1 antisense RNA 1","metadata":null},{"id":"1656d41abdf647cc9aeadca8e9ba203f","type":"GENE","name":"SLCO6A1","canonical_id":"hgnc:HGNC:23613","description":"solute carrier organic anion transporter family member 6A1","metadata":{"aliases":["OATP6A1","OATPY","MGC26949","CT48"]}},{"id":"c63300b5a03f483983bf83630e57793a","type":"GENE","name":"SLCO6A1-DT","canonical_id":"hgnc:HGNC:59103","description":"SLCO6A1 divergent transcript","metadata":null},{"id":"7ce638b087e3459c80ef8004bb32a283","type":"GENE","name":"SLEAR","canonical_id":"hgnc:HGNC:54824","description":"STAT1 regulated ILF2 complex interacting lncRNA","metadata":{"aliases":["FLJ42969"]}},{"id":"0162873f163e4e27b2bb1be83238bb84","type":"GENE","name":"SLF1","canonical_id":"hgnc:HGNC:25408","description":"SMC5/6 complex localization factor 1","metadata":{"aliases":["DKFZp761C121","DKFZp564C0469","BRCTx","hNSE5","BRCTD1","ANKRD32"]}},{"id":"d74676b907e346bdad49ec6b1fc775a5","type":"GENE","name":"SLF2","canonical_id":"hgnc:HGNC:17814","description":"SMC5/6 complex localization factor 2","metadata":{"aliases":["FLJ10512","FLJ25012","hNSE6","C10orf6","FAM178A"]}},{"id":"c05e457087624ccaa95b5b1b5eee3ebe","type":"GENE","name":"SLFN11","canonical_id":"hgnc:HGNC:26633","description":"schlafen family member 11","metadata":{"aliases":["FLJ34922"]}},{"id":"329a2ff50a4a49529a3a02d797749527","type":"GENE","name":"SLFN12","canonical_id":"hgnc:HGNC:25500","description":"schlafen family member 12","metadata":{"aliases":["FLJ10260"]}},{"id":"d698acefbda64fdf91b193dacc21b28a","type":"GENE","name":"SLFN12L","canonical_id":"hgnc:HGNC:33920","description":"schlafen family member 12 like","metadata":null},{"id":"53d7d06be11a42b993ad76570e50b7b9","type":"GENE","name":"SLFN13","canonical_id":"hgnc:HGNC:26481","description":"schlafen family member 13","metadata":{"aliases":["FLJ31952"]}},{"id":"fcf3e2a72ed54d12a802f22114ac9c58","type":"GENE","name":"SLFN14","canonical_id":"hgnc:HGNC:32689","description":"schlafen family member 14","metadata":null},{"id":"6c8e411fb50b4c09b5506f1dce0d420d","type":"GENE","name":"SLFN5","canonical_id":"hgnc:HGNC:28286","description":"schlafen family member 5","metadata":{"aliases":["MGC19764"]}},{"id":"0418894b42fa4ee2afe863c2412fa3e8","type":"GENE","name":"SLFNL1","canonical_id":"hgnc:HGNC:26313","description":"schlafen like 1","metadata":{"aliases":["FLJ23878"]}},{"id":"961493e1ec05414a99d6319791fb97d4","type":"GENE","name":"SLFNL1-AS1","canonical_id":"hgnc:HGNC:44126","description":"SLFNL1 antisense RNA 1","metadata":null},{"id":"1cfe434ede1e43d7be61f49832c5398f","type":"GO_TERM","name":"SLIK (SAGA-like) complex","canonical_id":"go:GO:0046695","description":"\"A SAGA-type histone acetyltransferase complex that contains a smaller form of Spt7 (lacking the SPT8 binding region) than the fungal SAGA complex, and consequently lacks Spt8. The complex is involved in the yeast retrograde response pathway, which is important for gene expression changes during mitochondrial dysfunction.\" [PMID:33864814]","metadata":null},{"id":"85c449aa3bcb46fcaeea5c508235be8c","type":"GENE","name":"SLIRP","canonical_id":"hgnc:HGNC:20495","description":"SRA stem-loop interacting RNA binding protein","metadata":{"aliases":["DC50","C14orf156"]}},{"id":"71edbf484cdd42f882c92d487431f5e3","type":"GENE","name":"SLIRP-OT1","canonical_id":"hgnc:HGNC:26385","description":"SLIRP overlapping transcript 1","metadata":{"aliases":["FLJ25976","C14orf178"]}},{"id":"7202900ae97d4e13a6840e986ab1da6c","type":"GENE","name":"SLIRPP1","canonical_id":"hgnc:HGNC:55149","description":"SLIRP. pseudogene 1","metadata":null},{"id":"466463ac99724f3a8b82f76f1d80ab4d","type":"GENE","name":"SLIRPP2","canonical_id":"hgnc:HGNC:55150","description":"SLIRP. pseudogene 2","metadata":null},{"id":"bcd66ec83500420ea8bf3396e6760945","type":"GENE","name":"SLIT1","canonical_id":"hgnc:HGNC:11085","description":"slit guidance ligand 1","metadata":{"aliases":["MEGF4","Slit-1","SLIT3","SLIL1"]}},{"id":"1b0dd21e5f3c473b9f81c0edd2baf637","type":"GENE","name":"SLIT1-AS1","canonical_id":"hgnc:HGNC:51198","description":"SLIT1 antisense RNA 1","metadata":null},{"id":"149151a95bb7499d842715f39417cdd0","type":"GENE","name":"SLIT2","canonical_id":"hgnc:HGNC:11086","description":null,"metadata":null},{"id":"510e8b47ba744348a297c9cf651fa1c6","type":"GENE","name":"SLIT2-AS1","canonical_id":"hgnc:HGNC:58754","description":"SLIT2 antisense RNA 1","metadata":null},{"id":"27888de4134d4f82ba84e5c6e5c14b92","type":"GENE","name":"SLIT2-IT1","canonical_id":"hgnc:HGNC:41383","description":"SLIT2 intronic transcript 1","metadata":null},{"id":"f4cee586efde41ff8daefc4706593d1f","type":"GENE","name":"SLIT3","canonical_id":"hgnc:HGNC:11087","description":"slit guidance ligand 3","metadata":{"aliases":["slit2","MEGF5","SLIT1","Slit-3","SLIL2"]}},{"id":"a449dba904e54f38a986ff434de18052","type":"GENE","name":"SLIT3-AS1","canonical_id":"hgnc:HGNC:40553","description":"SLIT3 antisense RNA 1","metadata":null},{"id":"66b50225ddcc442c9b6a44521ecc57e9","type":"GENE","name":"SLIT3-AS2","canonical_id":"hgnc:HGNC:40551","description":"SLIT3 antisense RNA 2","metadata":null},{"id":"9c571fea552f4b819f6b72104ab03de9","type":"GENE","name":"SLIT3-AS3","canonical_id":"hgnc:HGNC:59299","description":"SLIT3 antisense RNA 3","metadata":null},{"id":"ee2332fd542644edb547654dd1c9656f","type":"GENE","name":"SLITRK1","canonical_id":"hgnc:HGNC:20297","description":"SLIT and NTRK like family member 1","metadata":{"aliases":["KIAA1910","LRRC12"]}},{"id":"1678d62fc7a44fb9b874591c35686399","type":"GENE","name":"SLITRK2","canonical_id":"hgnc:HGNC:13449","description":"SLIT and NTRK like family member 2","metadata":{"aliases":["KIAA1854","CXorf2","SLITL1","TMEM257","CXorf1"]}},{"id":"7f6cc54cd14342ec8c97252772f7f4d8","type":"GENE","name":"SLITRK3","canonical_id":"hgnc:HGNC:23501","description":"SLIT and NTRK like family member 3","metadata":{"aliases":["KIAA0848"]}},{"id":"26de2bc988b84a96a100f47047e0eada","type":"GENE","name":"SLITRK4","canonical_id":"hgnc:HGNC:23502","description":"SLIT and NTRK like family member 4","metadata":{"aliases":["DKFZp547M2010"]}},{"id":"f86d5942488340b19799e2552c528f76","type":"GENE","name":"SLITRK5","canonical_id":"hgnc:HGNC:20295","description":"SLIT and NTRK like family member 5","metadata":{"aliases":["bA364G4.2","KIAA0918","LRRC11"]}},{"id":"af8a5bcb458c4660921d9246805a8383","type":"GENE","name":"SLITRK6","canonical_id":"hgnc:HGNC:23503","description":"SLIT and NTRK like family member 6","metadata":{"aliases":["FLJ22774"]}},{"id":"7e07a767eb84442c8eec5dd0605c6c90","type":"GENE","name":"SLK","canonical_id":"hgnc:HGNC:11088","description":"STE20 like kinase","metadata":{"aliases":["STK2","se20-9","KIAA0204"]}},{"id":"f4840b5cc648451f9b65ca72fd36d67a","type":"GENE","name":"SLMAP","canonical_id":"hgnc:HGNC:16643","description":"sarcolemma associated protein","metadata":{"aliases":["SLAP","KIAA1601"]}},{"id":"73976f7a61c6430d88bc321a5871600e","type":"GENE","name":"SLN","canonical_id":"hgnc:HGNC:11089","description":"sarcolipin","metadata":{"aliases":["MGC12301","MGC125854","MGC125855"]}},{"id":"4b03d510ca1d434f9b9df26bacbdefed","type":"GENE","name":"SLPI","canonical_id":"hgnc:HGNC:11092","description":null,"metadata":null},{"id":"7fb5482e00974891b9dfca36bd30a35e","type":"GENE","name":"SLTM","canonical_id":"hgnc:HGNC:20709","description":"SAFB like transcription modulator","metadata":{"aliases":["Met","FLJ13213"]}},{"id":"538584c9a28f4c6595bc0f9a55f73dd2","type":"GENE","name":"SLU7","canonical_id":"hgnc:HGNC:16939","description":"spliceosome associated SLU7","metadata":{"aliases":["9G8"]}},{"id":"ec5d59a7eb6847919107fd04a231e94b","type":"GENE","name":"SLURP1","canonical_id":"hgnc:HGNC:18746","description":"secreted LY6/PLAUR domain containing 1","metadata":{"aliases":["ARS","ANUP","MDM","ArsB","LY6LS","LY6-MT"]}},{"id":"1de6caed39194beb82c570cb2b111561","type":"GENE","name":"SLURP2","canonical_id":"hgnc:HGNC:25549","description":"secreted LY6/PLAUR domain containing 2","metadata":null},{"id":"6eee31b46ab74f69a88960258a4c80e1","type":"GENE","name":"SLURP2-AS1","canonical_id":"hgnc:HGNC:58427","description":"SLURP2 antisense RNA 1","metadata":null},{"id":"0eb328f23036487c897157436971432c","type":"TRIAL","name":"SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT00335166","description":"Early Stage Parkinson Disease","metadata":null},{"id":"4dd562ca9a974547b1cddff70f192fa9","type":"GENE","name":"SLX1A","canonical_id":"hgnc:HGNC:20922","description":"structure-specific endonuclease subunit SLX1A","metadata":{"aliases":["GIYD1"]}},{"id":"d6b99551416b4917bb03b50cbe1105f2","type":"GENE","name":"SLX1A-SULT1A3","canonical_id":"hgnc:HGNC:44437","description":"SLX1A-SULT1A3 readthrough (NMD candidate)","metadata":null},{"id":"0a11681da36c4eeb8e42cc519c98b222","type":"GENE","name":"SLX1B","canonical_id":"hgnc:HGNC:28748","description":"structure-specific endonuclease subunit SLX1B","metadata":{"aliases":["MGC5178","GIYD2"]}},{"id":"74a068c3015c4afb97433b29d9421211","type":"GENE","name":"SLX1B-SULT1A4","canonical_id":"hgnc:HGNC:48353","description":"SLX1B-SULT1A4 readthrough (NMD candidate)","metadata":null},{"id":"b584ec5817ef4e66a50344141d7c3a28","type":"GENE","name":"SLX4","canonical_id":"hgnc:HGNC:23845","description":"SLX4 structure-specific endonuclease subunit","metadata":{"aliases":["KIAA1784","KIAA1987","FANCP","BTBD12"]}},{"id":"e9f52971aab2424cbbb62a1fbb63b7df","type":"GENE","name":"SLX4IP","canonical_id":"hgnc:HGNC:16225","description":"SLX4 interacting protein","metadata":{"aliases":["dJ1099D15.3","C20orf94"]}},{"id":"2e97e4b9cbb24e8c87dc5d5dfcfca9ed","type":"GENE","name":"SLX9","canonical_id":"hgnc:HGNC:15811","description":"SLX9 ribosome biogenesis factor","metadata":{"aliases":["PRED56","C21orf70","FAM207A"]}},{"id":"1f5eeef2af904f1ba5e8389cf91595ef","type":"GENE","name":"SLX9P1","canonical_id":"hgnc:HGNC:39715","description":"SLX9 pseudogene 1","metadata":{"aliases":["FAM207BP"]}},{"id":"3aef2b70b93046569ac8e8c54dcddff0","type":"GENE","name":"SLX9P2","canonical_id":"hgnc:HGNC:58872","description":"SLX9 pseudogene 2","metadata":null},{"id":"6aed9358bd074983a393525153b943dc","type":"GENE","name":"SLX9P3","canonical_id":"hgnc:HGNC:42676","description":"SLX9 pseudogene 3","metadata":{"aliases":["FAM207CP"]}},{"id":"29653f3e5c51428281b65cd1fe91522b","type":"GO_TERM","name":"SMAD binding","canonical_id":"go:GO:0046332","description":"\"Binding to a SMAD signaling protein.\" [GOC:ai]","metadata":null},{"id":"14b65b261b5243079de38f6092f8c039","type":"GO_TERM","name":"SMAD protein complex","canonical_id":"go:GO:0071141","description":"\"A protein complex that consists of only SMAD proteins; may be homomeric or heteromeric. Heteromeric complexes act as transcription factors while homomeric complexes exist but are transcriptionally inactive. Hetero- versus homotrimerization is largely enthalpy driven.\" [GOC:bhm, GOC:mah, PMID:9670020]","metadata":null},{"id":"658b09cfbf52499898c48395c4441ee6","type":"GO_TERM","name":"SMAD protein signal transduction","canonical_id":"go:GO:0060395","description":"\"An intracellular signaling cassette that starts with the activation of a SMAD protein, leading to the formation of a complex with co-SMADs, which translocates to the nucleus and regulates transcription of specific target genes.\" [GOC:BHF]","metadata":null},{"id":"12dac7a401e14b4786c071164694f184","type":"GENE","name":"SMAD1","canonical_id":"hgnc:HGNC:6767","description":null,"metadata":null},{"id":"b2fd2902b713493894608a108bd59fda","type":"GENE","name":"SMAD1-AS1","canonical_id":"hgnc:HGNC:49379","description":"SMAD1 antisense RNA 1","metadata":{"aliases":["ENST00000513542"]}},{"id":"e82ef4c856ba401883e59ae6bceed2be","type":"GENE","name":"SMAD1-AS2","canonical_id":"hgnc:HGNC:49381","description":"SMAD1 antisense RNA 2","metadata":null},{"id":"78b02f769f6f452294cebb3a2659dc0f","type":"GENE","name":"SMAD2","canonical_id":"hgnc:HGNC:6768","description":null,"metadata":null},{"id":"d7c38794fafd4ef6bcce0b76c26727e0","type":"GENE","name":"SMAD3","canonical_id":"hgnc:HGNC:6769","description":null,"metadata":null},{"id":"57a46950c47e48248e74fb9d784635af","type":"GENE","name":"SMAD3-AS1","canonical_id":"hgnc:HGNC:56692","description":"SMAD3 antisense RNA 1","metadata":{"aliases":["AC012568.1"]}},{"id":"2c663e12a1e1447e898173e8029f5004","type":"GENE","name":"SMAD3-DT","canonical_id":"hgnc:HGNC:56759","description":"SMAD3 divergent transcript","metadata":null},{"id":"1817037d5b9b440f8bb92061102a6c93","type":"GENE","name":"SMAD4","canonical_id":"hgnc:HGNC:6770","description":null,"metadata":null},{"id":"56504ee3b97146289004cb562ee097a2","type":"GENE","name":"SMAD4","canonical_id":"ensembl:ENSG00000141646","description":null,"metadata":null},{"id":"5f50aa1cdd9440868614988eea4e261a","type":"GENE","name":"SMAD5","canonical_id":"hgnc:HGNC:6771","description":"SMAD family member 5","metadata":{"aliases":["Dwfc","JV5-1","MADH5"]}},{"id":"a9be0083043b4861b1ea1aa88d80eb54","type":"GENE","name":"SMAD5-AS1","canonical_id":"hgnc:HGNC:30586","description":"SMAD5 antisense RNA 1","metadata":{"aliases":["DAMS","SMAD5OS"]}},{"id":"168401fe581b4b5faf21f34fc3e96079","type":"GENE","name":"SMAD6","canonical_id":"hgnc:HGNC:6772","description":null,"metadata":null},{"id":"2a2b5f0aad764336aa56538b2c7c34e8","type":"GENE","name":"SMAD7","canonical_id":"hgnc:HGNC:6773","description":null,"metadata":null},{"id":"2aa4baee6a5a4386aacaeaa15993e3a1","type":"GENE","name":"SMAD9","canonical_id":"hgnc:HGNC:6774","description":"SMAD family member 9","metadata":{"aliases":["SMAD8","SMAD8/9","MADH6","MADH9"]}},{"id":"77ffc524efdb4c54a8b45065adc8d525","type":"GENE","name":"SMAD9-IT1","canonical_id":"hgnc:HGNC:39963","description":"SMAD9 intronic transcript 1","metadata":{"aliases":["SMAD9-AS1"]}},{"id":"9b7c27dd4fc14c748779178325e0b881","type":"GENE","name":"SMAGP","canonical_id":"hgnc:HGNC:26918","description":"small cell adhesion glycoprotein","metadata":{"aliases":["MGC149453","MGC149454","hSMAGP"]}},{"id":"85585be07cd54b6d88de44d2f5ccc0aa","type":"GENE","name":"SMANTIS","canonical_id":"hgnc:HGNC:54417","description":"SMARCA4 interacting SWI/SNF chromatin remodeling complex scaffold lncRNA","metadata":{"aliases":["MANTIS","ANXA4-AS","n342419"]}},{"id":"9dfa6db2c34f4b4d942b67deccf8c606","type":"GENE","name":"SMAP1","canonical_id":"hgnc:HGNC:19651","description":"small ArfGAP 1","metadata":{"aliases":["FLJ13159","SMAP-1"]}},{"id":"ead9d39d89584eeebf8a41d4904783ca","type":"GENE","name":"SMAP2","canonical_id":"hgnc:HGNC:25082","description":"small ArfGAP2","metadata":{"aliases":["SMAP1L"]}},{"id":"719c2accac4946109490dbe42fe47c0c","type":"GENE","name":"SMARCA1","canonical_id":"hgnc:HGNC:11097","description":null,"metadata":null},{"id":"14c4ad28ce494bfcb89415402df9dc9b","type":"GENE","name":"SMARCA2","canonical_id":"hgnc:HGNC:11098","description":"SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2","metadata":{"aliases":["BAF190","hSNF2a","hBRM","Sth1p","SNF2LA","BRM","SNF2","SWI2","SNF2L2"]}},{"id":"67cf42c398214f6dbcad184b0bb97559","type":"GENE","name":"SMARCA2-AS1","canonical_id":"hgnc:HGNC:56062","description":"SMARCA2 antisense RNA 1","metadata":null},{"id":"f3b9fe6344df42a0bb7f7f52689d13b7","type":"GENE","name":"SMARCA4","canonical_id":"hgnc:HGNC:11100","description":null,"metadata":null},{"id":"ef3ac4bb90df4babaf8088186603b38f","type":"GENE","name":"SMARCA5","canonical_id":"hgnc:HGNC:11101","description":"SNF2 related chromatin remodeling ATPase 5","metadata":{"aliases":["hSNF2H","hISWI","ISWI"]}},{"id":"345208f922cb460cbe350e197c3d902d","type":"GENE","name":"SMARCA5-AS1","canonical_id":"hgnc:HGNC:39982","description":"SMARCA5 antisense RNA 1","metadata":null},{"id":"ff5f04af275947e58d13e9ed0b2202c6","type":"GENE","name":"SMARCAD1","canonical_id":"hgnc:HGNC:18398","description":"SNF2 related chromatin remodeling ATPase with DExD box 1","metadata":{"aliases":["ETL1","DKFZP762K2015","KIAA1122","DKFZp762K2015","HPGDS-AS1"]}},{"id":"2d29cb9672494658a90d39b808c64e42","type":"GENE","name":"SMARCAD1-DT","canonical_id":"hgnc:HGNC:53364","description":"SMARCAD1 divergent transcript","metadata":null},{"id":"4cd1e18173fc4b13a710426c42b103ab","type":"GENE","name":"SMARCAL1","canonical_id":"hgnc:HGNC:11102","description":"SNF2 related chromatin remodeling annealing helicase 1","metadata":{"aliases":["HHARP","HARP"]}},{"id":"325974215eb04ea790fbafd873764c9e","type":"GENE","name":"SMARCAL1-AS1","canonical_id":"hgnc:HGNC:40555","description":"SMARCAL1 antisense RNA 1","metadata":null},{"id":"645086b785ce4af9844f00cacf711845","type":"GENE","name":"SMARCB1","canonical_id":"hgnc:HGNC:11103","description":null,"metadata":null},{"id":"4e61582007224b3888aadfc809b556b4","type":"GENE","name":"SMARCC1","canonical_id":"hgnc:HGNC:11104","description":"SWI/SNF related BAF chromatin remodeling complex subunit C1","metadata":{"aliases":["BAF155","SRG3","Rsc8","CRACC1"]}},{"id":"30a8a077eff741a4b16c06d91c537dda","type":"GENE","name":"SMARCC2","canonical_id":"hgnc:HGNC:11105","description":"SWI/SNF related BAF chromatin remodeling complex subunit C2","metadata":{"aliases":["BAF170","Rsc8","CRACC2"]}},{"id":"d120fa9fa9744a209039f45eb51d9968","type":"GENE","name":"SMARCD1","canonical_id":"hgnc:HGNC:11106","description":"SWI/SNF related BAF chromatin remodeling complex subunit D1","metadata":{"aliases":["BAF60A","Rsc6p","CRACD1"]}},{"id":"b8396b78eff045438a34636d5d94c708","type":"GENE","name":"SMARCD2","canonical_id":"hgnc:HGNC:11107","description":"SWI/SNF related BAF chromatin remodeling complex subunit D2","metadata":{"aliases":["BAF60B","Rsc6p","CRACD2","PRO2451"]}},{"id":"0f33c79e7d194999a59bb3615d04d2ae","type":"GENE","name":"SMARCD3","canonical_id":"hgnc:HGNC:11108","description":null,"metadata":null},{"id":"7a4cb8fc7dec4d8085f69554cd427b06","type":"GENE","name":"SMARCE1","canonical_id":"hgnc:HGNC:11109","description":"SWI/SNF related BAF chromatin remodeling complex subunit E1","metadata":{"aliases":["BAF57"]}},{"id":"69820148a6f74c3b8eb2f36edd1daa37","type":"GENE","name":"SMARCE1P1","canonical_id":"hgnc:HGNC:39731","description":"SMARCE1 pseudogene 1","metadata":null},{"id":"6cdfc329e79544a680785bef10b05dbb","type":"GENE","name":"SMARCE1P2","canonical_id":"hgnc:HGNC:39732","description":"SMARCE1 pseudogene 2","metadata":null},{"id":"38c59f1e636c440cb7d7329b9335d15c","type":"GENE","name":"SMARCE1P3","canonical_id":"hgnc:HGNC:39733","description":"SMARCE1 pseudogene 3","metadata":null},{"id":"3a2eef28c9a84b3996ec0ce2b93a5ff8","type":"GENE","name":"SMARCE1P4","canonical_id":"hgnc:HGNC:39735","description":"SMARCE1 pseudogene 4","metadata":null},{"id":"4f2509e4724d4d18af83b338dc01933e","type":"GENE","name":"SMARCE1P5","canonical_id":"hgnc:HGNC:39734","description":"SMARCE1 pseudogene 5","metadata":null},{"id":"f8aad3665660448080d60eeab738b85f","type":"GENE","name":"SMARCE1P6","canonical_id":"hgnc:HGNC:39737","description":"SMARCE1 pseudogene 6","metadata":null},{"id":"9a3af1b6506e44a9ab46a0cfe103e745","type":"GENE","name":"SMARCE1P7","canonical_id":"hgnc:HGNC:51208","description":"SMARCE1 pseudogene 7","metadata":null},{"id":"b25f2f48a0c54345bbbc4a7f39e97728","type":"TRIAL","name":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05412082","description":"Locally Advanced Rectal Cancer","metadata":null},{"id":"b196bc67efdd4d00b2d43bc81aa8c9f8","type":"GENE","name":"SMASR","canonical_id":"hgnc:HGNC:53072","description":"SMAD3 associated long non-coding RNA","metadata":{"aliases":["LINC02206"]}},{"id":"a92adc0bc3894c7ebdfd6a4935465749","type":"GENE","name":"SMBD1P","canonical_id":"hgnc:HGNC:53806","description":"somatomedin B domain containing 1, pseudogene","metadata":null},{"id":"836d8a08832c43299e135be07130dfad","type":"GO_TERM","name":"SMC family protein binding","canonical_id":"go:GO:0043221","description":"\"Binding to a protein from the structural maintenance of chromosomes (SMC) family, a group of chromosomal ATPases with a role in mitotic chromosome organization.\" [GOC:jl, GOC:vw, InterPro:IPR024704, PMID:9640531]","metadata":null},{"id":"b4633192e7184c46a60aca3e14036f42","type":"GO_TERM","name":"SMC loading complex","canonical_id":"go:GO:0032116","description":"\"A protein complex required for the loading of a structural maintenance of chromosome (SMC) complex, such as cohesin, condensin or SMC5/SMC6, onto DNA. Appears to be eukaryotically conserved.\" [GOC:curators, GOC:vw, PMID:10882066]","metadata":null},{"id":"eacaf4a36b274221837e758d1b5df30e","type":"TRIAL","name":"SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study","canonical_id":"clinicaltrials.gov:NCT00486369","description":"Osteoarthritis","metadata":null},{"id":"e6fc69f7effe4094955745a956adedad","type":"GENE","name":"SMC1A","canonical_id":"hgnc:HGNC:11111","description":"structural maintenance of chromosomes 1A","metadata":{"aliases":["DXS423E","KIAA0178","SB1.8","Smcb","SMC1L1"]}},{"id":"fcdba984243349ad8bf2a503ba341f55","type":"GENE","name":"SMC1B","canonical_id":"hgnc:HGNC:11112","description":"structural maintenance of chromosomes 1B","metadata":{"aliases":["bK268H5","SMC1L2"]}},{"id":"578139e90ff14a3d980cf082fc36fe91","type":"GENE","name":"SMC2","canonical_id":"hgnc:HGNC:14011","description":"structural maintenance of chromosomes 2","metadata":{"aliases":["hCAP-E","CAP-E","SMC2L1"]}},{"id":"fb9bbe1ac4554ec4909f41b602f1b42b","type":"GENE","name":"SMC2-DT","canonical_id":"hgnc:HGNC:50827","description":"SMC2 divergent transcript","metadata":{"aliases":["SMC2-AS1"]}},{"id":"d3a5feee72f34e2290351d4aa38186c2","type":"GENE","name":"SMC3","canonical_id":"hgnc:HGNC:2468","description":"structural maintenance of chromosomes 3","metadata":{"aliases":["HCAP","BAM","SMC3L1","bamacan","CSPG6"]}},{"id":"85a527208e5444888a6acb28d23cff46","type":"GENE","name":"SMC3P1","canonical_id":"hgnc:HGNC:54642","description":"SMC3 pseudogene 1","metadata":null},{"id":"b26049836af24014a9c94caa6ee0c847","type":"GENE","name":"SMC4","canonical_id":"hgnc:HGNC:14013","description":"structural maintenance of chromosomes 4","metadata":{"aliases":["hCAP-C","CAP-C","SMC4L1"]}},{"id":"ea1068a36be3460ab5cb968ab487179b","type":"GENE","name":"SMC4P1","canonical_id":"hgnc:HGNC:51919","description":"structural maintenance of chromosomes 4 pseudogene 1","metadata":null},{"id":"a97ddee2d2f945b6923e8861e572f000","type":"GENE","name":"SMC5","canonical_id":"hgnc:HGNC:20465","description":"structural maintenance of chromosomes 5","metadata":{"aliases":["KIAA0594","SMC5L1"]}},{"id":"475d24adf5c8476c976c822c7a37f696","type":"GENE","name":"SMC6","canonical_id":"hgnc:HGNC:20466","description":"structural maintenance of chromosomes 6","metadata":{"aliases":["FLJ22116","SMC6L1"]}},{"id":"f1a595e65bb64a2999d898a98b6b6c5b","type":"GENE","name":"SMCHD1","canonical_id":"hgnc:HGNC:29090","description":"structural maintenance of chromosomes flexible hinge domain containing 1","metadata":{"aliases":["KIAA0650","FSHD2"]}},{"id":"3f0cbeac29924101a0624e8994b183db","type":"GENE","name":"SMCO1","canonical_id":"hgnc:HGNC:27407","description":"single-pass membrane protein with coiled-coil domains 1","metadata":{"aliases":["FLJ41923","DKFZp313B0440","C3orf43"]}},{"id":"ac0f4552fc544a6680e845cb8c45b278","type":"GENE","name":"SMCO2","canonical_id":"hgnc:HGNC:34448","description":"single-pass membrane protein with coiled-coil domains 2","metadata":{"aliases":["LOC341346","C12orf70"]}},{"id":"7748eadbbfc04be0a0ffc678ec0cbf4c","type":"GENE","name":"SMCO3","canonical_id":"hgnc:HGNC:34401","description":"single-pass membrane protein with coiled-coil domains 3","metadata":{"aliases":["LOC440087","C12orf69"]}},{"id":"fc21d5c3734144af9245a483ca1ea6b4","type":"GENE","name":"SMCO4","canonical_id":"hgnc:HGNC:24810","description":"single-pass membrane protein with coiled-coil domains 4","metadata":{"aliases":["FN5","C11orf75"]}},{"id":"01d33d5635564f6793f69150b4af76f5","type":"GENE","name":"SMCO4P1","canonical_id":"hgnc:HGNC:49559","description":"single-pass membrane protein with coiled-coil domains 4 pseudogene 1","metadata":null},{"id":"70dbcc1ae9a34ebc9a65eaa6a3881bd3","type":"GENE","name":"SMCP","canonical_id":"hgnc:HGNC:6962","description":"sperm mitochondria associated cysteine rich protein","metadata":{"aliases":["MCSP"]}},{"id":"ff92e3858f8245c7b8ebba36038f0bac","type":"GENE","name":"SMCR2","canonical_id":"hgnc:HGNC:17914","description":"Smith-Magenis syndrome chromosome region, candidate 2","metadata":null},{"id":"18c88bad3cbd4fbdb3a0cb2b19d69f1a","type":"GENE","name":"SMCR5","canonical_id":"hgnc:HGNC:17918","description":"Smith-Magenis syndrome chromosome region, candidate 5","metadata":{"aliases":["NCRNA00034"]}},{"id":"43607af9ce0d4d47b0389fdc9f5bd5bd","type":"GENE","name":"SMCR8","canonical_id":"hgnc:HGNC:17921","description":"SMCR8-C9orf72 complex subunit","metadata":{"aliases":["FLJ34716","DENND8A"]}},{"id":"bf81960e0b2742628f1ae8713c9cc789","type":"GENE","name":"SMDT1","canonical_id":"hgnc:HGNC:25055","description":"single-pass membrane protein with aspartate rich tail 1","metadata":{"aliases":["dJ186O1.1","DDDD","EMRE","C22orf32"]}},{"id":"8650a71c05b84ccfa26deadf6e12a614","type":"GENE","name":"SMG1","canonical_id":"hgnc:HGNC:30045","description":"SMG1 nonsense mediated mRNA decay associated PI3K related kinase","metadata":{"aliases":["LIP","KIAA0421","ATX"]}},{"id":"1c911404b20c41088ccc08f530a00e6d","type":"GENE","name":"SMG1-DT","canonical_id":"hgnc:HGNC:55394","description":"SMG1 divergent transcript","metadata":null},{"id":"1d9af6f69f8e4ed68bca526f84ee07fe","type":"GENE","name":"SMG1P1","canonical_id":"hgnc:HGNC:44186","description":"SMG1 pseudogene 1","metadata":null},{"id":"f0421be542f248778dd9e15e1ac5abf6","type":"GENE","name":"SMG1P2","canonical_id":"hgnc:HGNC:49859","description":"SMG1 pseudogene 2","metadata":null},{"id":"238311d5804f4878a82e07d8db3aa83d","type":"GENE","name":"SMG1P3","canonical_id":"hgnc:HGNC:49860","description":"SMG1 pseudogene 3","metadata":null},{"id":"1d6f6b49c64c4667a8a56e1498ce7d5b","type":"GENE","name":"SMG1P4","canonical_id":"hgnc:HGNC:49861","description":"SMG1 pseudogene 4","metadata":null},{"id":"9ffbbf49b652459293f12fa1030ae025","type":"GENE","name":"SMG1P5","canonical_id":"hgnc:HGNC:49862","description":"SMG1 pseudogene 5","metadata":null},{"id":"dd0d1f9a5d554dc2b20051fae8f9defe","type":"GENE","name":"SMG1P6","canonical_id":"hgnc:HGNC:49863","description":"SMG1 pseudogene 6","metadata":null},{"id":"247bc3b8cd414e1d8efbf35ad9db4b9a","type":"GENE","name":"SMG1P7","canonical_id":"hgnc:HGNC:49864","description":"SMG1 pseudogene 7","metadata":null},{"id":"3ccbf552566d4ae8ba44881dbe789c76","type":"GENE","name":"SMG5","canonical_id":"hgnc:HGNC:24644","description":"SMG5 nonsense mediated mRNA decay factor","metadata":{"aliases":["KIAA1089","LPTS-RP1","LPTSRP1","RP11-54H19.7","SMG-5","EST1B"]}},{"id":"0a30de5bd4ca4e4ea3f8be91a8d457e7","type":"GENE","name":"SMG6","canonical_id":"hgnc:HGNC:17809","description":null,"metadata":null},{"id":"5547460a9abf459f91d885a275bbe932","type":"GENE","name":"SMG6-AS1","canonical_id":"hgnc:HGNC:58200","description":"SMG6 antisense RNA 1","metadata":null},{"id":"f398c65f6cc3462ba509eb46d6e2ab01","type":"GENE","name":"SMG6-IT1","canonical_id":"hgnc:HGNC:1220","description":"SMG6 intronic transcript 1","metadata":{"aliases":["C17orf6"]}},{"id":"50154925646847ceb826b26c518316e5","type":"GENE","name":"SMG7","canonical_id":"hgnc:HGNC:16792","description":"SMG7 nonsense mediated mRNA decay factor","metadata":{"aliases":["KIAA0250","EST1C","SGA56M","SMG-7","C1orf16"]}},{"id":"a8cb7792e6e6452abdf9ab94b9583ad1","type":"GENE","name":"SMG7-AS1","canonical_id":"hgnc:HGNC:24518","description":"SMG7 antisense RNA 1","metadata":{"aliases":["DKFZP564C196"]}},{"id":"aaacab979f7a4e318e6fc6a4b872ae39","type":"GENE","name":"SMG8","canonical_id":"hgnc:HGNC:25551","description":"SMG8 nonsense mediated mRNA decay factor","metadata":{"aliases":["FLJ10587","FLJ23205","C17orf71"]}},{"id":"883c3203439146eb9e1562603b8ff73a","type":"GENE","name":"SMG9","canonical_id":"hgnc:HGNC:25763","description":"SMG9 nonsense mediated mRNA decay factor","metadata":{"aliases":["FLJ12886","C19orf61"]}},{"id":"8794170a9e2547718ea542a606813616","type":"GENE","name":"SMILR","canonical_id":"hgnc:HGNC:51825","description":"smooth muscle induced lncRNA, enhancer of proliferation","metadata":null},{"id":"0457491cd83241b1bd8fb2de2c0800b3","type":"GENE","name":"SMIM1","canonical_id":"hgnc:HGNC:44204","description":"small integral membrane protein 1 (Vel blood group)","metadata":{"aliases":["Vel"]}},{"id":"6a23970ec8d2471fa0c7e984dfe70dba","type":"GENE","name":"SMIM10","canonical_id":"hgnc:HGNC:41913","description":"small integral membrane protein 10","metadata":{"aliases":["CXorf69"]}},{"id":"a7a6b7e53863401fb7bb2cc04afaa970","type":"GENE","name":"SMIM10L1","canonical_id":"hgnc:HGNC:49847","description":"small integral membrane protein 10 like 1","metadata":null},{"id":"c91b939882bf4b6ea7d73c4521a031e0","type":"GENE","name":"SMIM10L2A","canonical_id":"hgnc:HGNC:34499","description":"small integral membrane protein 10 like 2A","metadata":{"aliases":["MGC39606","LED","LINC0086","NCRNA00086","LINC00086"]}},{"id":"d84edceb57d64d518835773429d63bde","type":"GENE","name":"SMIM10L2B","canonical_id":"hgnc:HGNC:34500","description":"small integral membrane protein 10 like 2B","metadata":{"aliases":["RP11-85L21.2","NCRNA00087","LINC00087"]}},{"id":"d1f3c98243694f5a9e6cedf0e391a89d","type":"GENE","name":"SMIM10L2B-AS1","canonical_id":"hgnc:HGNC:53137","description":"SMIM10L2B antisense RNA 1","metadata":{"aliases":["ENST00000453528"]}},{"id":"cd890ceabf2d411c9eb1650b3fdc1fe4","type":"GENE","name":"SMIM10L3","canonical_id":"hgnc:HGNC:56768","description":"small integral membrane protein 10 like 3","metadata":{"aliases":["SAGSIN1"]}},{"id":"10ebc9f7f71543feadd22f8939c7ffc7","type":"GENE","name":"SMIM11","canonical_id":"hgnc:HGNC:1293","description":"small integral membrane protein 11","metadata":{"aliases":["C21orf51","FAM165B","SMIM11A"]}},{"id":"267c2bf1a87a4d5eaa545d00f18beec7","type":"GENE","name":"SMIM11P1","canonical_id":"hgnc:HGNC:21400","description":"SMIM11 pseudogene 1","metadata":{"aliases":["bA33E24.4","C6orf161","FAM165A"]}},{"id":"775b42513ce54d50960e03e8eb0f48a6","type":"GENE","name":"SMIM11P2","canonical_id":"hgnc:HGNC:56407","description":"SMIM11 pseudogene 2","metadata":null},{"id":"0acf989ec7fc4b1aa9c40f8862853e50","type":"GENE","name":"SMIM12","canonical_id":"hgnc:HGNC:25154","description":"small integral membrane protein 12","metadata":{"aliases":["FLJ90372","C1orf212"]}},{"id":"6e4b111a7c2b4f76a0efd97ea9be51fa","type":"GENE","name":"SMIM12P1","canonical_id":"hgnc:HGNC:51598","description":"small integral membrane protein 12 pseudogene 1","metadata":null},{"id":"65d2008401be473989504faaec8a4e98","type":"GENE","name":"SMIM13","canonical_id":"hgnc:HGNC:27356","description":"small integral membrane protein 13","metadata":{"aliases":["C6orf228"]}},{"id":"4174352adcb84af086681fb941f40b53","type":"GENE","name":"SMIM14","canonical_id":"hgnc:HGNC:27321","description":"small integral membrane protein 14","metadata":{"aliases":["FLJ13289","C4orf34"]}},{"id":"a0f1141e1e5f4292a6c72caf63434f3e","type":"GENE","name":"SMIM14-DT","canonical_id":"hgnc:HGNC:53455","description":"SMIM14 divergent transcript","metadata":null},{"id":"5eeb36ee7a7e415bbe58f03e8d20551c","type":"GENE","name":"SMIM15","canonical_id":"hgnc:HGNC:33861","description":"small integral membrane protein 15","metadata":{"aliases":["DKFZP686E2158","C5orf43"]}},{"id":"cd974291c97a48e1802a9dd04b4f756b","type":"GENE","name":"SMIM15-AS1","canonical_id":"hgnc:HGNC:41293","description":"SMIM15 antisense RNA 1","metadata":null},{"id":"08931dde6f504428bd46dca7818c5f9b","type":"GENE","name":"SMIM15P1","canonical_id":"hgnc:HGNC:54940","description":"SMIM15 pseudogene 1","metadata":null},{"id":"a449fd2c1cf64ae89b49020bd0fd0be7","type":"GENE","name":"SMIM15P2","canonical_id":"hgnc:HGNC:54941","description":"SMIM15 pseudogene 2","metadata":null},{"id":"cb6d29e86a174a3e8c8962a2e699a656","type":"GENE","name":"SMIM17","canonical_id":"hgnc:HGNC:27114","description":"small integral membrane protein 17","metadata":null},{"id":"a07e582d38df4b8db7a175cbba41bc09","type":"GENE","name":"SMIM18","canonical_id":"hgnc:HGNC:42973","description":"small integral membrane protein 18","metadata":null},{"id":"d4343a5a1be44010979fc7ee3e1df259","type":"GENE","name":"SMIM19","canonical_id":"hgnc:HGNC:25166","description":"small integral membrane protein 19","metadata":{"aliases":["C8orf40"]}},{"id":"def120731b964936b976a2314965c527","type":"GENE","name":"SMIM2","canonical_id":"hgnc:HGNC:28776","description":"small integral membrane protein 2","metadata":{"aliases":["MGC5590","C13orf44"]}},{"id":"da8540abc2fc47689cd6708bfe4aea4c","type":"GENE","name":"SMIM2-AS1","canonical_id":"hgnc:HGNC:42674","description":"SMIM2 antisense RNA 1","metadata":{"aliases":["C13orf44-AS1"]}},{"id":"bfaae726ea354aa6b56606b39ae5e73d","type":"GENE","name":"SMIM2-IT1","canonical_id":"hgnc:HGNC:41492","description":"SMIM2 intronic transcript 1","metadata":{"aliases":["C13orf44-IT1"]}},{"id":"a5630875896d44ff9b2aedac09242dda","type":"GENE","name":"SMIM20","canonical_id":"hgnc:HGNC:37260","description":"small integral membrane protein 20","metadata":{"aliases":["PNX","MITRAC7","C4orf52"]}},{"id":"b3c430db01894eceac8029d9968f1883","type":"GENE","name":"SMIM20-AS1","canonical_id":"hgnc:HGNC:58755","description":"SMIM20 antisense RNA 1","metadata":null},{"id":"0a4d7cea1bc1417491e8f6f096de6ab9","type":"GENE","name":"SMIM21","canonical_id":"hgnc:HGNC:27598","description":"small integral membrane protein 21","metadata":{"aliases":["C18orf62"]}},{"id":"857070325f2e4d46afd68ff8f8d38383","type":"GENE","name":"SMIM22","canonical_id":"hgnc:HGNC:48329","description":"small integral membrane protein 22","metadata":{"aliases":["CASIMO1"]}},{"id":"2dd0604e4f504fd38117b2f3b21d4f43","type":"GENE","name":"SMIM23","canonical_id":"hgnc:HGNC:34440","description":"small integral membrane protein 23","metadata":{"aliases":["LOC644994","C5orf50"]}},{"id":"5d2c932aabd84e6eb15342edd1c6cc88","type":"GENE","name":"SMIM24","canonical_id":"hgnc:HGNC:37244","description":"small integral membrane protein 24","metadata":{"aliases":["HSPC323","C19orf77"]}},{"id":"fb0f7d9f4d8148b798746144ec85d3f7","type":"GENE","name":"SMIM26","canonical_id":"hgnc:HGNC:43430","description":"small integral membrane protein 26","metadata":{"aliases":["LOC388789","LINC00493"]}},{"id":"9439ed100e784382a3d1682870bd1255","type":"GENE","name":"SMIM28","canonical_id":"hgnc:HGNC:53434","description":"small integral membrane protein 28","metadata":null},{"id":"1cf6aa10c1604c3e9ea55458b6a8a728","type":"GENE","name":"SMIM29","canonical_id":"hgnc:HGNC:1340","description":"small integral membrane protein 29","metadata":{"aliases":["LBH","MGC57858","C6orf1"]}},{"id":"dc8feb043d834292b4536d437543065a","type":"GENE","name":"SMIM29-AS1","canonical_id":"hgnc:HGNC:58176","description":"SMIM29 antisense RNA 1","metadata":null},{"id":"5b1bd999a2f7481eb581c239ed230c3e","type":"GENE","name":"SMIM3","canonical_id":"hgnc:HGNC:30248","description":"small integral membrane protein 3","metadata":{"aliases":["MSTP150","NID67","C5orf62"]}},{"id":"0f57ed59bada47ca95040ffbdd0a3700","type":"GENE","name":"SMIM30","canonical_id":"hgnc:HGNC:48953","description":"small integral membrane protein 30","metadata":{"aliases":["MAVI1","LINC00998"]}},{"id":"40532226b34543dcab5c6e92020f609f","type":"GENE","name":"SMIM31","canonical_id":"hgnc:HGNC:49638","description":"small integral membrane protein 31","metadata":{"aliases":["h.EPR","LINC01207"]}},{"id":"95f3b83433b34fd5825df8f3f6a9cd54","type":"GENE","name":"SMIM32","canonical_id":"hgnc:HGNC:53640","description":"small integral membrane protein 32","metadata":null},{"id":"771c759ee1d242ed94b6f675bc240c34","type":"GENE","name":"SMIM33","canonical_id":"hgnc:HGNC:53645","description":"small integral membrane protein 33","metadata":null},{"id":"1bfb58b52f674e35a2bc1bef56ed0076","type":"GENE","name":"SMIM34","canonical_id":"hgnc:HGNC:39601","description":"small integral membrane protein 34","metadata":{"aliases":["SMIM34A"]}},{"id":"3b061c97713b4e13bd577446600f3707","type":"GENE","name":"SMIM35","canonical_id":"hgnc:HGNC:44179","description":"small integral membrane protein 35","metadata":{"aliases":["TMPRSS4-AS1"]}},{"id":"b59f6b7f03dd447891df307c71854231","type":"GENE","name":"SMIM36","canonical_id":"hgnc:HGNC:53654","description":"small integral membrane protein 36","metadata":null},{"id":"01599bf6e0704f4588ec945fcb6e2062","type":"GENE","name":"SMIM38","canonical_id":"hgnc:HGNC:54074","description":"small integral membrane protein 38","metadata":null},{"id":"4637cdeaca8147b3adea42a85f08c8a3","type":"GENE","name":"SMIM39","canonical_id":"hgnc:HGNC:54076","description":"small integral membrane protein 39","metadata":null},{"id":"bdc388bdee074a0282ba0da9674d185e","type":"GENE","name":"SMIM40","canonical_id":"hgnc:HGNC:54073","description":"small integral membrane protein 40","metadata":null},{"id":"71be1eee0de6420dabb3f07c0c40e18a","type":"GENE","name":"SMIM41","canonical_id":"hgnc:HGNC:54075","description":"small integral membrane protein 41","metadata":null},{"id":"694c62bceebd47d08c4a4f983ac01603","type":"GENE","name":"SMIM41-AS1","canonical_id":"hgnc:HGNC:58285","description":"SMIM41 antisense RNA 1","metadata":null},{"id":"832350f9c7b946cfbf9bb3a6523a1e61","type":"GENE","name":"SMIM42","canonical_id":"hgnc:HGNC:55000","description":"small integral membrane protein 42","metadata":null},{"id":"1dbdbdeff6d144dc9f2989d69de6594a","type":"GENE","name":"SMIM43","canonical_id":"hgnc:HGNC:55077","description":"small integral membrane protein 43","metadata":{"aliases":["NEMEP"]}},{"id":"71d10b9ea1fe4b598329115e20fa50ab","type":"GENE","name":"SMIM44","canonical_id":"hgnc:HGNC:55815","description":"small integral membrane protein 44","metadata":null},{"id":"ccad32c207004f3dbf255202bcf4e466","type":"GENE","name":"SMIM45","canonical_id":"hgnc:HGNC:27930","description":"small integral membrane protein 45","metadata":{"aliases":["LINC00634"]}},{"id":"46791a54637a491b8721abd7fcc6eb61","type":"GENE","name":"SMIM46","canonical_id":"hgnc:HGNC:56307","description":"small integral membrane protein 46","metadata":null},{"id":"beabd4226ab1474a8f7cccbbd42c4254","type":"GENE","name":"SMIM47","canonical_id":"hgnc:HGNC:53452","description":"small integral membrane protein 47","metadata":null},{"id":"6219abccfb0f47d4a889affb47eba923","type":"GENE","name":"SMIM48","canonical_id":"hgnc:HGNC:58752","description":"small integral membrane protein 48","metadata":null},{"id":"17cd79c75ce946f594e0be4fe1a5aa43","type":"GENE","name":"SMIM5","canonical_id":"hgnc:HGNC:40030","description":"small integral membrane protein 5","metadata":{"aliases":["C17orf109"]}},{"id":"06e7058ece494e1f97e53f58cab07d73","type":"GENE","name":"SMIM7","canonical_id":"hgnc:HGNC:28419","description":"small integral membrane protein 7","metadata":{"aliases":["MGC2747","C19orf42"]}},{"id":"7692e7581e404209a3a0fec8788b451f","type":"GENE","name":"SMIM7P1","canonical_id":"hgnc:HGNC:54700","description":"SMIM7 pseudogene 1","metadata":null},{"id":"645f20478fbf46e6b5f6283197c9f392","type":"GENE","name":"SMIM8","canonical_id":"hgnc:HGNC:21401","description":"small integral membrane protein 8","metadata":{"aliases":["DKFZP586E1923","dJ102H19.2","C6orf162"]}},{"id":"ffd55c4957b24c63a6584f59f48e5c24","type":"GENE","name":"SMIM9","canonical_id":"hgnc:HGNC:41915","description":"small integral membrane protein 9","metadata":{"aliases":["CXorf68"]}},{"id":"b9d41f22b2274aca84fa35ee16b0544e","type":"GENE","name":"SMKR1","canonical_id":"hgnc:HGNC:43561","description":"small lysine rich protein 1","metadata":null},{"id":"eea65a676f064ef784e699f18caec54b","type":"GENE","name":"SMLR1","canonical_id":"hgnc:HGNC:44670","description":"small leucine rich protein 1","metadata":null},{"id":"b4ac3bf426154a13b280eea381e8d7ce","type":"GO_TERM","name":"SMN complex","canonical_id":"go:GO:0032797","description":"\"A protein complex that contains the survival motor neuron (SMN) protein and at least eight additional integral components, including the Gemin2-8 and Unrip proteins; the complex is found in the cytoplasm and in nuclear Gems, and is involved in spliceosomal snRNP assembly in the cytoplasm and in pre-mRNA splicing in the nucleus.\" [PMID:16434402, PMID:17023415]","metadata":null},{"id":"b2ef9cb34ef74797bc12057e12682f49","type":"GO_TERM","name":"SMN-Gemin2 complex","canonical_id":"go:GO:0034718","description":"\"A protein complex that contains the survival motor neuron (SMN) protein and Gemin2; may form the stable core of the larger SMN complex.\" [GOC:mah, PMID:17640873]","metadata":null},{"id":"ed74512ddc0a466cbd2792be77eff671","type":"GO_TERM","name":"SMN-Sm protein complex","canonical_id":"go:GO:0034719","description":"\"A protein complex formed by the association of several methylated Sm proteins with the SMN complex; the latter contains the survival motor neuron (SMN) protein and at least eight additional integral components, including the Gemin2-8 and unrip proteins; additional proteins, including galectin-1 and galectin-3, are also found in the SMN-SM complex. The SMN-Sm complex is involved in spliceosomal snRNP assembly in the cytoplasm.\" [GOC:vw, PMID:11522829, PMID:17401408]","metadata":null},{"id":"f749aece74c74d1798b51027129490fe","type":"GENE","name":"SMN1","canonical_id":"hgnc:HGNC:11117","description":null,"metadata":null},{"id":"1ab3a017911c4cde93c126f56c62d38a","type":"GENE","name":"SMN1-AS1","canonical_id":"hgnc:HGNC:58151","description":"SMN1 antisense RNA 1","metadata":{"aliases":["SMN-AS1"]}},{"id":"8d41094132fa43019fb336ff4feaabf7","type":"GENE","name":"SMN2","canonical_id":"hgnc:HGNC:11118","description":"survival of motor neuron 2, centromeric","metadata":{"aliases":["BCD541","SMNC","GEMIN1","TDRD16B"]}},{"id":"2cccd1a5cd624b39a1ad582a2bba8614","type":"GENE","name":"SMN2-AS1","canonical_id":"hgnc:HGNC:53121","description":"SMN2 antisense RNA 1","metadata":{"aliases":["SMN-AS1"]}},{"id":"78a32c0cbed0420c8651f2f337c8f6da","type":"GENE","name":"SMNDC1","canonical_id":"hgnc:HGNC:16900","description":"survival motor neuron domain containing 1","metadata":{"aliases":["SPF30","SMNR","TDRD16C"]}},{"id":"a4e574f4118e460eadb661a725eeceb5","type":"GENE","name":"SMO","canonical_id":"hgnc:HGNC:11119","description":null,"metadata":null},{"id":"d54507ac589346fcba230aacacc51aab","type":"GENE","name":"SMO","canonical_id":"ensembl:ENSG00000128602","description":null,"metadata":null},{"id":"3d783df2c43f48058e22784251abb048","type":"PROTEIN","name":"SMO","canonical_id":"uniprot:Q99835","description":null,"metadata":null},{"id":"7a0b1c0c120f456bb16ae2a142e899a9","type":"GENE","name":"SMOC1","canonical_id":"hgnc:HGNC:20318","description":"SPARC related modular calcium binding 1","metadata":null},{"id":"44d50f311f914d36bf81b20403cf752d","type":"GENE","name":"SMOC2","canonical_id":"hgnc:HGNC:20323","description":"SPARC related modular calcium binding 2","metadata":{"aliases":["SMAP2"]}},{"id":"9c2c3cb6e901487f9dc32533bfdfc656","type":"GENE","name":"SMOX","canonical_id":"hgnc:HGNC:15862","description":"spermine oxidase","metadata":{"aliases":["FLJ20746","dJ779E11.1","PAO","PAOh1","MGC1010","SMO","C20orf16"]}},{"id":"e1fb2f53539f454fb46643fef0c29109","type":"GENE","name":"SMPD1","canonical_id":"hgnc:HGNC:11120","description":null,"metadata":null},{"id":"2647fbc77cb141b5b306dd10caa11005","type":"GENE","name":"SMPD2","canonical_id":"hgnc:HGNC:11121","description":"sphingomyelin phosphodiesterase 2","metadata":{"aliases":["nSMase","ISC1"]}},{"id":"e5134f3f6472490abc6447ea9197dd98","type":"GENE","name":"SMPD3","canonical_id":"hgnc:HGNC:14240","description":"sphingomyelin phosphodiesterase 3","metadata":{"aliases":["NSMASE2"]}},{"id":"9ead825de2e44a95a7d1112638eef248","type":"GENE","name":"SMPD4","canonical_id":"hgnc:HGNC:32949","description":"sphingomyelin phosphodiesterase 4","metadata":{"aliases":["FLJ20297","FLJ20756","nSMase-3","KIAA1418","NSMASE3","NET13"]}},{"id":"24c6009b70394d419b77c475eb2d3011","type":"GENE","name":"SMPD4BP","canonical_id":"hgnc:HGNC:24761","description":"sphingomyelin phosphodiesterase 4B, pseudogene","metadata":null},{"id":"e1f8b616a49641adb8aa57b2b7f100a7","type":"GENE","name":"SMPD4P1","canonical_id":"hgnc:HGNC:39673","description":"sphingomyelin phosphodiesterase 4 pseudogene 1","metadata":null},{"id":"00243a442cf64c8cbab2438cd9858946","type":"GENE","name":"SMPD4P2","canonical_id":"hgnc:HGNC:39674","description":"sphingomyelin phosphodiesterase 4 pseudogene 2","metadata":null},{"id":"06fa38a5cf894cbf8473696960659d90","type":"GENE","name":"SMPD5","canonical_id":"hgnc:HGNC:52275","description":"sphingomyelin phosphodiesterase 5 (pseudogene)","metadata":{"aliases":["SMPD5P","MA-nSMase"]}},{"id":"523be456928346a3838d6f80283f2484","type":"GENE","name":"SMPDL3A","canonical_id":"hgnc:HGNC:17389","description":"sphingomyelin phosphodiesterase acid like 3A","metadata":{"aliases":["FLJ20177","ASM3A","ASML3a","yR36GH4.1"]}},{"id":"a7ddb8eb4575463bb0b7e43cc5aa71bd","type":"GENE","name":"SMPDL3B","canonical_id":"hgnc:HGNC:21416","description":"sphingomyelin phosphodiesterase acid like 3B","metadata":{"aliases":["ASML3B"]}},{"id":"a0886fd1dba44e0698734773cab12fe5","type":"GENE","name":"SMPX","canonical_id":"hgnc:HGNC:11122","description":"small muscle protein X-linked","metadata":{"aliases":["DFNX4","Chisel","Csl","DFN6"]}},{"id":"730b97c5be784d4999461a6e9aec0b6a","type":"GENE","name":"SMR3A","canonical_id":"hgnc:HGNC:19216","description":"submaxillary gland androgen regulated protein 3A","metadata":{"aliases":["PBI","PRL5","PROL5"]}},{"id":"934cd8edf2f54efda900c2d7ad0ef14b","type":"GENE","name":"SMR3A-AS1","canonical_id":"hgnc:HGNC:58805","description":"SMR3A antisense RNA 1","metadata":null},{"id":"b5906628acad4ba692aa413caecca70a","type":"GENE","name":"SMR3B","canonical_id":"hgnc:HGNC:17326","description":"submaxillary gland androgen regulated protein 3B","metadata":{"aliases":["P-B","PRL3","PROL3"]}},{"id":"0f91c4c87d5247dfa2ca87eedd752f2c","type":"GENE","name":"SMS","canonical_id":"hgnc:HGNC:11123","description":"spermine synthase","metadata":{"aliases":["SPMSY","SpS","MRSR","SRS"]}},{"id":"580d7471f8e24d8abae6e9e1889cf89d","type":"GENE","name":"SMSP1","canonical_id":"hgnc:HGNC:54952","description":"SMS pseudogene 1","metadata":null},{"id":"0c3dbe9d20ba4b018069198690fa4ed8","type":"GENE","name":"SMTN","canonical_id":"hgnc:HGNC:11126","description":"smoothelin","metadata":null},{"id":"4b00b5b5939f42758f03aac138c7aa8c","type":"GENE","name":"SMTNL1","canonical_id":"hgnc:HGNC:32394","description":"smoothelin like 1","metadata":{"aliases":["CHASM"]}},{"id":"9bd248c543ae460ab105fb7795db0e2a","type":"GENE","name":"SMTNL2","canonical_id":"hgnc:HGNC:24764","description":"smoothelin like 2","metadata":{"aliases":["FLJ42461"]}},{"id":"874169046b5040049898c814afa1cdee","type":"GENE","name":"SMU1","canonical_id":"hgnc:HGNC:18247","description":"SMU1 DNA replication regulator and spliceosomal factor","metadata":{"aliases":["SMU-1","FLJ10805","BWD","fSAP57"]}},{"id":"2805502bc03a4047aef029b1c23cc123","type":"GENE","name":"SMU1P1","canonical_id":"hgnc:HGNC:54527","description":"SMU1 pseudogene 1","metadata":null},{"id":"2139373579d7489a8f90d9728d309fe7","type":"GENE","name":"SMUG1","canonical_id":"hgnc:HGNC:17148","description":null,"metadata":null},{"id":"08f1367a49314d478699c2a46ad1f9bd","type":"GENE","name":"SMUG1-AS1","canonical_id":"hgnc:HGNC:53307","description":"SMUG1 antisense RNA 1","metadata":null},{"id":"f9ce4666a3b84251898823f00df6ba60","type":"GENE","name":"SMUG1P1","canonical_id":"hgnc:HGNC:49401","description":"single-strand-selective monofunctional uracil-DNA glycosylase 1 pseudogene 1","metadata":null},{"id":"c8c705dd499f4154bb743800819abba0","type":"GENE","name":"SMURF1","canonical_id":"hgnc:HGNC:16807","description":"SMAD specific E3 ubiquitin protein ligase 1","metadata":{"aliases":["KIAA1625"]}},{"id":"40d8c63158434d24968c978cbb93f3e3","type":"GENE","name":"SMURF2","canonical_id":"hgnc:HGNC:16809","description":null,"metadata":null},{"id":"d728221009764947bbb2763028f130b3","type":"GENE","name":"SMURF2P1","canonical_id":"hgnc:HGNC:44402","description":"SMAD specific E3 ubiquitin protein ligase 2 pseudogene 1","metadata":null},{"id":"fb3474268f354ea1bee47537027c444f","type":"GENE","name":"SMYD1","canonical_id":"hgnc:HGNC:20986","description":null,"metadata":null},{"id":"abf0d752e0c04b0f9fad4669ab9af421","type":"GENE","name":"SMYD2","canonical_id":"hgnc:HGNC:20982","description":"SET and MYND domain containing 2","metadata":{"aliases":["HSKM-B","ZMYND14","KMT3C"]}},{"id":"97db7eadcc97449c8e8a7cd7d0506242","type":"GENE","name":"SMYD3","canonical_id":"hgnc:HGNC:15513","description":"SET and MYND domain containing 3","metadata":{"aliases":["KMT3E","ZNFN3A1","ZMYND1"]}},{"id":"8cab5bcbbe4b4f84b845a24528131c16","type":"GENE","name":"SMYD3-AS1","canonical_id":"hgnc:HGNC:40708","description":"SMYD3 antisense RNA 1","metadata":null},{"id":"50e77166a4ef41b9a19c4eb3d057064b","type":"GENE","name":"SMYD3-IT1","canonical_id":"hgnc:HGNC:41406","description":"SMYD3 intronic transcript 1","metadata":null},{"id":"3484ed0e5f8a4e92a057ab48916f46fa","type":"GENE","name":"SMYD4","canonical_id":"hgnc:HGNC:21067","description":"SET and MYND domain containing 4","metadata":{"aliases":["KIAA1936","ZMYND21"]}},{"id":"f67576b6b7ed440c8505a56396db5f79","type":"GENE","name":"SMYD5","canonical_id":"hgnc:HGNC:16258","description":"SMYD family member 5","metadata":{"aliases":["RRG1","NN8-4AG","ZMYND23","RAI15"]}},{"id":"74183e1df4a94423b6727b44de465463","type":"GENE","name":"SNAI1","canonical_id":"hgnc:HGNC:11128","description":null,"metadata":null},{"id":"262280b15a654d5eaa5f7cb7f8b631a3","type":"GENE","name":"SNAI1P1","canonical_id":"hgnc:HGNC:11129","description":"snail family zinc finger 1 pseudogene 1","metadata":{"aliases":["SNAI1L","SNAI1P","SNAI1L1"]}},{"id":"396461a9f85d4e2ba3af63aaf17291c4","type":"GENE","name":"SNAI2","canonical_id":"hgnc:HGNC:11094","description":null,"metadata":null},{"id":"54f737a0eb6f48ec920e9a89e72443ae","type":"GENE","name":"SNAI3","canonical_id":"hgnc:HGNC:18411","description":null,"metadata":null},{"id":"f895aa85715a4198b440edeec81eafe4","type":"GENE","name":"SNAI3-AS1","canonical_id":"hgnc:HGNC:28327","description":"SNAI3 antisense RNA 1","metadata":{"aliases":["MGC23284"]}},{"id":"f10d434a9b154149806d7907e90ce22e","type":"GO_TERM","name":"SNAP receptor activity","canonical_id":"go:GO:0005484","description":"\"Acting as a marker to identify a membrane and interacting selectively with one or more SNAREs on another membrane to mediate membrane fusion.\" [GOC:mah, PMID:14570579]","metadata":null},{"id":"44b21bb53c0b45d4a0f1bb913c40d361","type":"GENE","name":"SNAP23","canonical_id":"hgnc:HGNC:11131","description":"synaptosome associated protein 23","metadata":{"aliases":["SNAP23A","SNAP23B","HsT17016"]}},{"id":"faadc590d99d4e9fb96ade54a3691518","type":"GENE","name":"SNAP23P1","canonical_id":"hgnc:HGNC:16561","description":"synaptosome associated protein 23 pseudogene 1","metadata":{"aliases":["dJ155G6.3","SNAP23P"]}},{"id":"5926d946ec4d4fe3985b3cff160cbc6e","type":"GENE","name":"SNAP25","canonical_id":"hgnc:HGNC:11132","description":null,"metadata":null},{"id":"c7b82371e5d2482499161206d7061edf","type":"GENE","name":"SNAP25-AS1","canonical_id":"hgnc:HGNC:44312","description":"SNAP25 antisense RNA 1","metadata":null},{"id":"58e22a81208f47d1a5ed189647700776","type":"GENE","name":"SNAP29","canonical_id":"hgnc:HGNC:11133","description":"synaptosome associated protein 29","metadata":{"aliases":["SNAP-29","CEDNIK"]}},{"id":"763df9d87a72464da9f44a91d40bdca9","type":"GENE","name":"SNAP47","canonical_id":"hgnc:HGNC:30669","description":"synaptosome associated protein 47","metadata":{"aliases":["SVAP1","SNAP-47","C1orf142"]}},{"id":"dfce350876fc488ca0faea2e273c695a","type":"GENE","name":"SNAP47-AS1","canonical_id":"hgnc:HGNC:41501","description":"SNAP47 antisense RNA 1","metadata":{"aliases":["SNAP47-IT1"]}},{"id":"485fe753599b4f3b99294ab5e611ba7b","type":"GENE","name":"SNAP91","canonical_id":"hgnc:HGNC:14986","description":null,"metadata":null},{"id":"7a233a92798f44f689a8d1c454641980","type":"GENE","name":"SNAPC1","canonical_id":"hgnc:HGNC:11134","description":null,"metadata":null},{"id":"4902832be86742a08586f847be40e6d3","type":"GENE","name":"SNAPC2","canonical_id":"hgnc:HGNC:11135","description":"small nuclear RNA activating complex polypeptide 2","metadata":{"aliases":["SNAP45","PTFdelta"]}},{"id":"ebcd1db647b04e2196df7014b9d83eef","type":"GENE","name":"SNAPC3","canonical_id":"hgnc:HGNC:11136","description":"small nuclear RNA activating complex polypeptide 3","metadata":{"aliases":["SNAP50","PTFbeta","MGC33124","MGC132011"]}},{"id":"81059e3c17e44326ba1976f0ceae6039","type":"GENE","name":"SNAPC4","canonical_id":"hgnc:HGNC:11137","description":"small nuclear RNA activating complex polypeptide 4","metadata":{"aliases":["SNAP190","PTFalpha","FLJ13451"]}},{"id":"3baf8383fd174da39db7d8201f9e9975","type":"GENE","name":"SNAPC5","canonical_id":"hgnc:HGNC:15484","description":"small nuclear RNA activating complex polypeptide 5","metadata":{"aliases":["SNAP19"]}},{"id":"61dfc6ac701d41099ce27b2ea99ed59f","type":"GENE","name":"SNAPC5P1","canonical_id":"hgnc:HGNC:38667","description":"small nuclear RNA activating complex polypeptide 5 pseudogene 1","metadata":null},{"id":"26cafad6e2b2446fa1a1dcc47a914f5c","type":"GENE","name":"SNAPIN","canonical_id":"hgnc:HGNC:17145","description":"SNAP associated protein","metadata":{"aliases":["BLOC1S7","BORCS3","SNAPAP"]}},{"id":"3b8b912558594175beb507d2f3b8234b","type":"GENE","name":"SNAR-A1","canonical_id":"hgnc:HGNC:34304","description":"small NF90 (ILF3) associated RNA A1","metadata":{"aliases":["SNAR-A53113498"]}},{"id":"a3815623eb0a49689b68200d81061365","type":"GENE","name":"SNAR-A10","canonical_id":"hgnc:HGNC:34313","description":"small NF90 (ILF3) associated RNA A10","metadata":{"aliases":["snaR-A55318263"]}},{"id":"f70780ac0d2c495287dccff43c959196","type":"GENE","name":"SNAR-A11","canonical_id":"hgnc:HGNC:34314","description":"small NF90 (ILF3) associated RNA A11","metadata":{"aliases":["snaR-A55323591"]}},{"id":"bdd0dca93f394d6e96d5b9a2b37233ea","type":"GENE","name":"SNAR-A12","canonical_id":"hgnc:HGNC:34315","description":"small NF90 (ILF3) associated RNA A12","metadata":null},{"id":"de8f7fa0f0f24301845bb9396f7cddac","type":"GENE","name":"SNAR-A13","canonical_id":"hgnc:HGNC:34316","description":"small NF90 (ILF3) associated RNA A13","metadata":{"aliases":["snaR-A53139991"]}},{"id":"2e5c88dddce849d185bdf614b584d0f7","type":"GENE","name":"SNAR-A14","canonical_id":"hgnc:HGNC:34338","description":"small NF90 (ILF3) associated RNA A14","metadata":{"aliases":["SNAR-A55293015"]}},{"id":"f0d0d1f3cb2f45c693794a7edd924c22","type":"GENE","name":"SNAR-A2","canonical_id":"hgnc:HGNC:34305","description":"small NF90 (ILF3) associated RNA A2","metadata":{"aliases":["SNAR-A53129250"]}},{"id":"37f4073286d34cbcb3b637e1581a41db","type":"GENE","name":"SNAR-A3","canonical_id":"hgnc:HGNC:34306","description":"small NF90 (ILF3) associated RNA A3","metadata":{"aliases":["snaR-A53118848"]}},{"id":"25cb47ec6130422e8cd9080454165a3c","type":"GENE","name":"SNAR-A4","canonical_id":"hgnc:HGNC:34307","description":"small NF90 (ILF3) associated RNA A4","metadata":{"aliases":["snaR-A55287678"]}},{"id":"6eba8eb3dcd7407195dc5436804273aa","type":"GENE","name":"SNAR-A5","canonical_id":"hgnc:HGNC:34308","description":"small NF90 (ILF3) associated RNA A5","metadata":{"aliases":["snaR-A55296080"]}},{"id":"8839240371254a668c27d4fdc742168f","type":"GENE","name":"SNAR-A6","canonical_id":"hgnc:HGNC:34309","description":"small NF90 (ILF3) associated RNA A6","metadata":{"aliases":["snaR-A55299144"]}},{"id":"0f3c387c617d480ba5ff42e94297d1da","type":"GENE","name":"SNAR-A7","canonical_id":"hgnc:HGNC:34310","description":"small NF90 (ILF3) associated RNA A7","metadata":{"aliases":["snaR-A55302203"]}},{"id":"d21b2cae7c7b45bea562933b1527425a","type":"GENE","name":"SNAR-A8","canonical_id":"hgnc:HGNC:34311","description":"small NF90 (ILF3) associated RNA A8","metadata":{"aliases":["snaR-A55307557"]}},{"id":"2993f67a56214f10a75fffad5eb9265c","type":"GENE","name":"SNAR-A9","canonical_id":"hgnc:HGNC:34312","description":"small NF90 (ILF3) associated RNA A9","metadata":{"aliases":["snaR-A55312909"]}},{"id":"cbb0f4359659466aa76c50f4c0930574","type":"GENE","name":"SNAR-B1","canonical_id":"hgnc:HGNC:34317","description":"small NF90 (ILF3) associated RNA B1","metadata":null},{"id":"418e235074bb44b3b9b0fddee39462ba","type":"GENE","name":"SNAR-B2","canonical_id":"hgnc:HGNC:34318","description":"small NF90 (ILF3) associated RNA B2","metadata":null},{"id":"caabeae9fa4248139ced05d37ab8d303","type":"GENE","name":"SNAR-C1","canonical_id":"hgnc:HGNC:34319","description":"small NF90 (ILF3) associated RNA C1","metadata":null},{"id":"836bbcafd5744b15ac2e33f3a56b106d","type":"GENE","name":"SNAR-C2","canonical_id":"hgnc:HGNC:34320","description":"small NF90 (ILF3) associated RNA C2","metadata":null},{"id":"6ff3921c0efd4b859664748ee034c715","type":"GENE","name":"SNAR-C3","canonical_id":"hgnc:HGNC:34321","description":"small NF90 (ILF3) associated RNA C3","metadata":null},{"id":"81d4467275e146e8938eeba2899953e4","type":"GENE","name":"SNAR-C4","canonical_id":"hgnc:HGNC:34322","description":"small NF90 (ILF3) associated RNA C4","metadata":null},{"id":"670069fd22814091a07a365c6f424778","type":"GENE","name":"SNAR-C5","canonical_id":"hgnc:HGNC:34323","description":"small NF90 (ILF3) associated RNA C5","metadata":null},{"id":"c61b8e58b1464747ab86d8c2f7b540a9","type":"GENE","name":"SNAR-D","canonical_id":"hgnc:HGNC:34324","description":"small NF90 (ILF3) associated RNA D","metadata":null},{"id":"4f5a38b813cc471faa7bf75cc2ff5871","type":"GENE","name":"SNAR-E","canonical_id":"hgnc:HGNC:34325","description":"small NF90 (ILF3) associated RNA E","metadata":null},{"id":"af5dec5f2ba3481dadc68c3b681ca600","type":"GENE","name":"SNAR-F","canonical_id":"hgnc:HGNC:34326","description":"small NF90 (ILF3) associated RNA F","metadata":null},{"id":"2d6401752b1b4e42bce5cdbd31afa9f2","type":"GENE","name":"SNAR-G1","canonical_id":"hgnc:HGNC:34327","description":"small NF90 (ILF3) associated RNA G1","metadata":null},{"id":"d836c0b9519b4fd2a83204be5353483b","type":"GENE","name":"SNAR-G2","canonical_id":"hgnc:HGNC:34328","description":"small NF90 (ILF3) associated RNA G2","metadata":null},{"id":"4afb04289f674c1c8836f1dab6f5b610","type":"GENE","name":"SNAR-H","canonical_id":"hgnc:HGNC:34329","description":"small NF90 (ILF3) associated RNA H","metadata":{"aliases":["snaR-2"]}},{"id":"60932db601bd4851a766e27f54650c8a","type":"GENE","name":"SNAR-I","canonical_id":"hgnc:HGNC:34330","description":"small NF90 (ILF3) associated RNA I","metadata":{"aliases":["snaR-3"]}},{"id":"0f6566cce5604c499b4e538049970eab","type":"GO_TERM","name":"SNARE binding","canonical_id":"go:GO:0000149","description":"\"Binding to a SNARE (soluble N-ethylmaleimide-sensitive factor attached protein receptor) protein.\" [PMID:12642621]","metadata":null},{"id":"a4fda9f1a9bd4bb7b95261e1d925bb44","type":"GO_TERM","name":"SNARE complex","canonical_id":"go:GO:0031201","description":"\"A protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers. One well-characterized example is the neuronal SNARE complex formed of synaptobrevin 2, syntaxin 1a, and SNAP-25.\" [GOC:bhm, GOC:pr, PMID:10872468, PMID:19450911]","metadata":null},{"id":"bd09a7b25cae418c912baf4a3cdaa5a3","type":"GO_TERM","name":"SNARE complex assembly","canonical_id":"go:GO:0035493","description":"\"The aggregation, arrangement and bonding together of a set of components to form a SNARE complex, a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb, PMID:10872468]","metadata":null},{"id":"cf6465fdd5e14c77a33aa193a00c2378","type":"GO_TERM","name":"SNARE complex disassembly","canonical_id":"go:GO:0035494","description":"\"The disaggregation of the SNARE protein complex into its constituent components. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb, PMID:11697877]","metadata":null},{"id":"57851667dbb540dea937e63083ce8d7b","type":"GENE","name":"SNCA","canonical_id":"hgnc:HGNC:11138","description":"synuclein alpha","metadata":{"aliases":["NACP","PD1","PARK1","PARK4"]}},{"id":"f86fcd5f738f4e06a1769ec8e604678f","type":"GENE","name":"SNCA-AS1","canonical_id":"hgnc:HGNC:50600","description":"SNCA antisense RNA 1","metadata":null},{"id":"82fd91a33b1148488f45223e759caf2a","type":"GENE","name":"SNCAIP","canonical_id":"hgnc:HGNC:11139","description":"synuclein alpha interacting protein","metadata":{"aliases":["SYPH1"]}},{"id":"c9fc49d35c764405bb24d6e23bbd1651","type":"GENE","name":"SNCAIP-AS1","canonical_id":"hgnc:HGNC:40559","description":"SNCAIP antisense RNA 1","metadata":null},{"id":"baa9d3c0945b41d8abb68ceeb82dab1d","type":"GENE","name":"SNCAIP-AS2","canonical_id":"hgnc:HGNC:58184","description":"SNCAIP antisense RNA 2","metadata":null},{"id":"e882de68795d4293964c1c9998381695","type":"GENE","name":"SNCAIP-AS3","canonical_id":"hgnc:HGNC:28478","description":"SNCAIP antisense RNA 3","metadata":{"aliases":["MGC32805"]}},{"id":"d7d0f571a1684fa9907375c26bfbc964","type":"GENE","name":"SNCAIP-AS4","canonical_id":"hgnc:HGNC:59121","description":"SNCAIP antisense RNA 4","metadata":null},{"id":"31c1aa7f97854c4f94f7bb8531cbfb34","type":"GENE","name":"SNCB","canonical_id":"hgnc:HGNC:11140","description":null,"metadata":null},{"id":"0bdbbaa66dff4aba955354b778400a3c","type":"GENE","name":"SNCG","canonical_id":"hgnc:HGNC:11141","description":"synuclein gamma","metadata":{"aliases":["BCSG1","SR","persyn"]}},{"id":"55cf1856488545cf8bc87218bf609fc6","type":"GENE","name":"SND1","canonical_id":"hgnc:HGNC:30646","description":null,"metadata":null},{"id":"4f3424e9a22944a8998fda913018c781","type":"GENE","name":"SND1-DT","canonical_id":"hgnc:HGNC:55639","description":"SND1 divergent transcript","metadata":null},{"id":"e6a8977e12de45e6be246495182e7d38","type":"GENE","name":"SND1-IT1","canonical_id":"hgnc:HGNC:24158","description":"SND1 intronic transcript 1","metadata":{"aliases":["NAG8","NSG-X","C7orf54"]}},{"id":"9b2a153927884340a1225973a98f78d0","type":"GENE","name":"SNED1","canonical_id":"hgnc:HGNC:24696","description":"sushi, nidogen and EGF like domains 1","metadata":{"aliases":["FLJ00133","SST3","Snep"]}},{"id":"b038a1fc57b045ea8efdc05b6f04158a","type":"GENE","name":"SNED1-AS1","canonical_id":"hgnc:HGNC:41060","description":"SNED1 antisense RNA 1","metadata":null},{"id":"589b71140559499496ae44e6dca145a4","type":"TRIAL","name":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05594095","description":"Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor; HER2-negative Breast Cancer; Advanced Breast Cancer","metadata":null},{"id":"4ed3e533cda64765aa3a4795287a0614","type":"GENE","name":"SNF8","canonical_id":"hgnc:HGNC:17028","description":null,"metadata":null},{"id":"df90209f3c7048c39c47569e13898a1d","type":"GENE","name":"SNF8P1","canonical_id":"hgnc:HGNC:54702","description":"SNF8 pseudogene 1","metadata":null},{"id":"53c95c29a24a40b996d32facb68ef0dd","type":"GENE","name":"SNHG1","canonical_id":"hgnc:HGNC:32688","description":"small nucleolar RNA host gene 1","metadata":{"aliases":["UHG","NCRNA00057","LINC00057","lncRNA16"]}},{"id":"ae740e82a90044669be7da68302cee03","type":"GENE","name":"SNHG10","canonical_id":"hgnc:HGNC:27510","description":"small nucleolar RNA host gene 10","metadata":{"aliases":["FLJ40557","NCRNA00063","LINC00063","TP53LC16","C14orf62"]}},{"id":"569247cbbf5c4863ad95c55c8ab91f42","type":"GENE","name":"SNHG11","canonical_id":"hgnc:HGNC:25046","description":"small nucleolar RNA host gene 11","metadata":{"aliases":["LINC00101","C20orf198"]}},{"id":"cffc57f52447453b86999d10916a180f","type":"GENE","name":"SNHG12","canonical_id":"hgnc:HGNC:30062","description":"small nucleolar RNA host gene 12","metadata":{"aliases":["PNAS-123","LINC00100","ASLNC04080","C1orf79"]}},{"id":"bfe7ed503eec42b0ae3481ed9a9c7225","type":"GENE","name":"SNHG14","canonical_id":"hgnc:HGNC:37462","description":"small nucleolar RNA host gene 14","metadata":{"aliases":["NCRNA00214","UBE3A-AS","UBE3A-ATS","UBE3A-AS1","IPW"]}},{"id":"c0bed93191aa4f07a501e2184e714955","type":"GENE","name":"SNHG15","canonical_id":"hgnc:HGNC:27797","description":"small nucleolar RNA host gene 15","metadata":{"aliases":["FLJ38860","MYO1GUT","Linc-Myo1g","C7orf40"]}},{"id":"8f6611d560d443d9a5021e4307be516d","type":"GENE","name":"SNHG16","canonical_id":"hgnc:HGNC:44352","description":"small nucleolar RNA host gene 16","metadata":{"aliases":["ncRAN","Nbla12061","Nbla10727","ELNAT1"]}},{"id":"0ec645ecfec844f4b75a6bfcf795d810","type":"GENE","name":"SNHG17","canonical_id":"hgnc:HGNC:48600","description":"small nucleolar RNA host gene 17","metadata":null},{"id":"383b65ed48da49d7945cdea32edcec7c","type":"GENE","name":"SNHG18","canonical_id":"hgnc:HGNC:49007","description":"small nucleolar RNA host gene 18","metadata":null},{"id":"7bbe748fbc5d4b6f849befb5065beee4","type":"GENE","name":"SNHG19","canonical_id":"hgnc:HGNC:49574","description":"small nucleolar RNA host gene 19","metadata":{"aliases":["SNORD60HG"]}},{"id":"91543663d9ca454c849f64fe118f53c1","type":"GENE","name":"SNHG20","canonical_id":"hgnc:HGNC:33099","description":"small nucleolar RNA host gene 20","metadata":{"aliases":["PRO0872","FLJ25582","DKFZp686L05235","SCARNA16HG","C17orf86","NCRNA00338","LINC00338"]}},{"id":"059453846d3a4ce2a6b6fd2b18b1327c","type":"GENE","name":"SNHG21","canonical_id":"hgnc:HGNC:50284","description":"small nucleolar RNA host gene 21","metadata":{"aliases":["SCARNA15HG","FSD2-AS1","RP11-752G15.6"]}},{"id":"d0500a215d2d4c02a5f8df70d9c49dbd","type":"GENE","name":"SNHG22","canonical_id":"hgnc:HGNC:50285","description":"small nucleolar RNA host gene 22","metadata":{"aliases":["SCARNA17HG"]}},{"id":"e0afb54892d048ba8d41eb5e86547db6","type":"GENE","name":"SNHG25","canonical_id":"hgnc:HGNC:51534","description":"small nucleolar RNA host gene 25","metadata":null},{"id":"e71d04952fb949ac997ab39fea97481d","type":"GENE","name":"SNHG26","canonical_id":"hgnc:HGNC:53131","description":"small nucleolar RNA host gene 26","metadata":{"aliases":["AC005682.5"]}},{"id":"9412194e7d8b4a5489136e9ca952520e","type":"GENE","name":"SNHG27","canonical_id":"hgnc:HGNC:53481","description":"small nucleolar RNA host gene 27","metadata":null},{"id":"528fbbf272d5441ca8bc1f4989846029","type":"GENE","name":"SNHG28","canonical_id":"hgnc:HGNC:27647","description":"small nucleolar RNA host gene 28","metadata":{"aliases":["FLJ39187","VSIG8-OT1","C1orf204"]}},{"id":"f70e198a2beb4fe6aa9a515c792188cd","type":"GENE","name":"SNHG29","canonical_id":"hgnc:HGNC:28619","description":"small nucleolar RNA host gene 29","metadata":{"aliases":["ACIL","MGC40157","C17orf45","NCRNA00188","C17orf76-AS1","FAM211A-AS1","LRRC75A-AS1"]}},{"id":"4742f6b890524606ab8c9eec839b5bea","type":"GENE","name":"SNHG3","canonical_id":"hgnc:HGNC:10118","description":"small nucleolar RNA host gene 3","metadata":{"aliases":["U17HG","U17HG-A","NCRNA00014","RNU17D","RNU17C"]}},{"id":"6200228385574c75bbb403429545d886","type":"GENE","name":"SNHG30","canonical_id":"hgnc:HGNC:52836","description":"small nucleolar RNA host gene 30","metadata":{"aliases":["RP11-1094M14.11","LINC02001"]}},{"id":"44e59cb2a6c642279edec0ef1a622d4b","type":"GENE","name":"SNHG31","canonical_id":"hgnc:HGNC:54196","description":"small nucleolar RNA host gene 31","metadata":null},{"id":"fae94a29be7340cfb5799f5b7f438d10","type":"GENE","name":"SNHG32","canonical_id":"hgnc:HGNC:19078","description":"small nucleolar RNA host gene 32","metadata":{"aliases":["D6S57","G8","C6orf48"]}},{"id":"a0aebca5dc02406d874a7021cd26f19e","type":"GENE","name":"SNHG33","canonical_id":"hgnc:HGNC:48575","description":"small nucleolar RNA host gene 33","metadata":{"aliases":["PAINT","LINC00888"]}},{"id":"a808e92b63414d0faaf855932390bbc0","type":"GENE","name":"SNHG34","canonical_id":"hgnc:HGNC:59196","description":"small nucleolar RNA host gene 34","metadata":null},{"id":"63b2d98d89b94cd4b954524124155379","type":"GENE","name":"SNHG35","canonical_id":"hgnc:HGNC:59232","description":"small nucleolar RNA host gene 35","metadata":null},{"id":"344a11f6f2c745d2bbbdac261e42f2f8","type":"GENE","name":"SNHG4","canonical_id":"hgnc:HGNC:32964","description":"small nucleolar RNA host gene 4","metadata":{"aliases":["U19H","NCRNA00059"]}},{"id":"d1ceeb6bb19045a5b2915f2aaf64c19d","type":"GENE","name":"SNHG5","canonical_id":"hgnc:HGNC:21026","description":"small nucleolar RNA host gene 5","metadata":{"aliases":["MGC16362","bA33E24.2","U50HG","NCRNA00044","LINC00044","C6orf160"]}},{"id":"3e072754a64a4a8bba0b8fd881a18b41","type":"GENE","name":"SNHG6","canonical_id":"hgnc:HGNC:32965","description":"small nucleolar RNA host gene 6","metadata":{"aliases":["U87HG","HBII-276HG","NCRNA00058"]}},{"id":"51249d06c5664aa39ddda2d1056d9a98","type":"GENE","name":"SNHG7","canonical_id":"hgnc:HGNC:28254","description":"small nucleolar RNA host gene 7","metadata":{"aliases":["MGC16037","NCRNA00061"]}},{"id":"ff8776851af04696895b2d55c5fa8f15","type":"GENE","name":"SNHG8","canonical_id":"hgnc:HGNC:33098","description":"small nucleolar RNA host gene 8","metadata":{"aliases":["NCRNA00060","LINC00060"]}},{"id":"190db52fec9f4b8fa5a370ccc8d04cc7","type":"GENE","name":"SNHG9","canonical_id":"hgnc:HGNC:33102","description":"small nucleolar RNA host gene 9","metadata":{"aliases":["DKFZp686N06141","NCRNA00062"]}},{"id":"585ae00216f542a88ab66f48d6e317e6","type":"GENE","name":"SNIP1","canonical_id":"hgnc:HGNC:30587","description":null,"metadata":null},{"id":"59631ee3e4f3406d90f159d162b593e7","type":"GENE","name":"SNN","canonical_id":"hgnc:HGNC:11149","description":"stannin","metadata":null},{"id":"5b5c8f7c0c664649809d9de5f0516270","type":"GENE","name":"SNORA1","canonical_id":"hgnc:HGNC:32557","description":"small nucleolar RNA, H/ACA box 1","metadata":{"aliases":["ACA1"]}},{"id":"754e6f514b504b369f93657aba878683","type":"GENE","name":"SNORA10","canonical_id":"hgnc:HGNC:32598","description":"small nucleolar RNA, H/ACA box 10","metadata":{"aliases":["ACA10","SNORA10A"]}},{"id":"ba92222c69c94681aa476323ca63abb1","type":"GENE","name":"SNORA100","canonical_id":"hgnc:HGNC:50404","description":"small nucleolar RNA, H/ACA box 100","metadata":null},{"id":"d67c80ce784b42d98401d6ae245cb137","type":"GENE","name":"SNORA101A","canonical_id":"hgnc:HGNC:50405","description":"small nucleolar RNA, H/ACA box 101A","metadata":null},{"id":"fe5f5edfe9474792bbdecf0707f5d67b","type":"GENE","name":"SNORA101B","canonical_id":"hgnc:HGNC:50406","description":"small nucleolar RNA, H/ACA box 101B","metadata":{"aliases":["ZL4"]}},{"id":"6bf51b723028435f986484f49dd4dfee","type":"GENE","name":"SNORA103","canonical_id":"hgnc:HGNC:51395","description":"small nucleolar RNA, H/ACA box 103","metadata":null},{"id":"34524775d322416e95e7203d3145285f","type":"GENE","name":"SNORA104","canonical_id":"hgnc:HGNC:51396","description":"small nucleolar RNA, H/ACA box 104","metadata":null},{"id":"ca130a86e2f84ce894790a3e2a7e2017","type":"GENE","name":"SNORA105A","canonical_id":"hgnc:HGNC:51397","description":"small nucleolar RNA, H/ACA box 105A","metadata":null},{"id":"2488dd6f5a64421c82891037cb52e3c6","type":"GENE","name":"SNORA105B","canonical_id":"hgnc:HGNC:51398","description":"small nucleolar RNA, H/ACA box 105B","metadata":null},{"id":"e4d84c45353c41cc897fa6ed2a6fdf55","type":"GENE","name":"SNORA105C","canonical_id":"hgnc:HGNC:51399","description":"small nucleolar RNA, H/ACA box 105C","metadata":null},{"id":"05895374269e47f498f09d39226911c3","type":"GENE","name":"SNORA107","canonical_id":"hgnc:HGNC:51400","description":"small nucleolar RNA, H/ACA box 107","metadata":null},{"id":"c5f257c7f3244c0caf875fde0f615d79","type":"GENE","name":"SNORA108","canonical_id":"hgnc:HGNC:51401","description":"small nucleolar RNA, H/ACA box 108","metadata":null},{"id":"4043a40055e84a6e9a5d1978012d9773","type":"GENE","name":"SNORA109","canonical_id":"hgnc:HGNC:51402","description":"small nucleolar RNA, H/ACA box 109","metadata":null},{"id":"a101e816d5924ec2b642c394804cf8c1","type":"GENE","name":"SNORA10B","canonical_id":"hgnc:HGNC:52188","description":"small nucleolar RNA, H/ACA box 10B","metadata":null},{"id":"d162f77cfbe347018f232645183691b6","type":"GENE","name":"SNORA11","canonical_id":"hgnc:HGNC:32599","description":"small nucleolar RNA, H/ACA box 11","metadata":{"aliases":["U107","SNORA11A"]}},{"id":"8e6f972003ec45b6bc90e735549c0f00","type":"GENE","name":"SNORA110","canonical_id":"hgnc:HGNC:51403","description":"small nucleolar RNA, H/ACA box 110","metadata":null},{"id":"71b8f0de0a0d44499f503e627bf39d0a","type":"GENE","name":"SNORA111","canonical_id":"hgnc:HGNC:51404","description":"small nucleolar RNA, H/ACA box 111","metadata":null},{"id":"db4422ce082f447c8c982bd30f769d3b","type":"GENE","name":"SNORA112","canonical_id":"hgnc:HGNC:51850","description":"small nucleolar RNA, H/ACA box 112","metadata":null},{"id":"468a4175d540449b924930f7c9aea855","type":"GENE","name":"SNORA113","canonical_id":"hgnc:HGNC:51851","description":"small nucleolar RNA, H/ACA box 113","metadata":null},{"id":"cd6db4eb70e440b5b532796da040ed3f","type":"GENE","name":"SNORA114","canonical_id":"hgnc:HGNC:51852","description":"small nucleolar RNA, H/ACA box 114","metadata":null},{"id":"6160f3c69b574821bb906eafd502c763","type":"GENE","name":"SNORA115","canonical_id":"hgnc:HGNC:51853","description":"small nucleolar RNA, H/ACA box 115","metadata":null},{"id":"163678cf826742949147077be3457fbb","type":"GENE","name":"SNORA116","canonical_id":"hgnc:HGNC:51854","description":"small nucleolar RNA, H/ACA box 116","metadata":null},{"id":"62ebc7b3738c4ee0ab24d9c63ade6624","type":"GENE","name":"SNORA117","canonical_id":"hgnc:HGNC:51855","description":"small nucleolar RNA, H/ACA box 117","metadata":null},{"id":"dde5eb64a21a4f29aab06a757c2873e1","type":"GENE","name":"SNORA118","canonical_id":"hgnc:HGNC:51856","description":"small nucleolar RNA, H/ACA box 118","metadata":null},{"id":"dbd195127df54c9cadc9bb833a9215d1","type":"GENE","name":"SNORA119","canonical_id":"hgnc:HGNC:51857","description":"small nucleolar RNA, H/ACA box 119","metadata":null},{"id":"ad71b4d0e32b411fb0d263ab3233d8dc","type":"GENE","name":"SNORA11B","canonical_id":"hgnc:HGNC:33620","description":"small nucleolar RNA, H/ACA box 11B","metadata":null},{"id":"15bb7170feb14e889e3119c4c1b128fc","type":"GENE","name":"SNORA11C","canonical_id":"hgnc:HGNC:33621","description":"small nucleolar RNA, H/ACA box 11C","metadata":null},{"id":"7409125194ea40d0bef8c3220a5d32e3","type":"GENE","name":"SNORA11D","canonical_id":"hgnc:HGNC:33622","description":"small nucleolar RNA, H/ACA box 11D","metadata":null},{"id":"bceb987c42b84e049a820487697db4c5","type":"GENE","name":"SNORA11E","canonical_id":"hgnc:HGNC:33623","description":"small nucleolar RNA, H/ACA box 11E","metadata":null},{"id":"29be1cc39a0b4380910a2f172642a021","type":"GENE","name":"SNORA11F","canonical_id":"hgnc:HGNC:52189","description":"small nucleolar RNA, H/ACA box 11F","metadata":null},{"id":"acffb3b3b62b4c8f9cdba5803b2330cc","type":"GENE","name":"SNORA11G","canonical_id":"hgnc:HGNC:52190","description":"small nucleolar RNA, H/ACA box 11G","metadata":null},{"id":"a1d8ce1a837b402ab71ed724b194d3ba","type":"GENE","name":"SNORA12","canonical_id":"hgnc:HGNC:32600","description":"small nucleolar RNA, H/ACA box 12","metadata":{"aliases":["U108"]}},{"id":"bade9a2441a2400e957d6c8b5868ea97","type":"GENE","name":"SNORA120","canonical_id":"hgnc:HGNC:51858","description":"small nucleolar RNA, H/ACA box 120","metadata":null},{"id":"61fd4120adf44245a5127dcd067f177b","type":"GENE","name":"SNORA13","canonical_id":"hgnc:HGNC:32601","description":"small nucleolar RNA, H/ACA box 13","metadata":{"aliases":["ACA13"]}},{"id":"6c531305b703493f8069b166331d8dbc","type":"GENE","name":"SNORA14A","canonical_id":"hgnc:HGNC:32602","description":"small nucleolar RNA, H/ACA box 14A","metadata":{"aliases":["ACA14a"]}},{"id":"9d22e5abe5a246cb94aad02153365f84","type":"GENE","name":"SNORA14B","canonical_id":"hgnc:HGNC:32603","description":"small nucleolar RNA, H/ACA box 14B","metadata":{"aliases":["ACA14b"]}},{"id":"ab9dbf3649894672824581d5c79d5032","type":"GENE","name":"SNORA15","canonical_id":"hgnc:HGNC:32604","description":"small nucleolar RNA, H/ACA box 15","metadata":{"aliases":["ACA15","SNORA15A"]}},{"id":"b332e7a5df7a42c28a94b6a0c54d7565","type":"GENE","name":"SNORA15B-1","canonical_id":"hgnc:HGNC:52191","description":"small nucleolar RNA, H/ACA box 15B-1","metadata":null},{"id":"ecd20b9eadd04db7bbf9d7f9a4018bee","type":"GENE","name":"SNORA15B-2","canonical_id":"hgnc:HGNC:52192","description":"small nucleolar RNA, H/ACA box 15B-2","metadata":{"aliases":["SNORA15C"]}},{"id":"b060a7aa3fdf4f46b93167279ef6add0","type":"GENE","name":"SNORA16A","canonical_id":"hgnc:HGNC:32605","description":"small nucleolar RNA, H/ACA box 16A","metadata":{"aliases":["ACA16"]}},{"id":"20d95ce2a5f647b9adbd712ab29e8cdd","type":"GENE","name":"SNORA16B","canonical_id":"hgnc:HGNC:32606","description":"small nucleolar RNA, H/ACA box 16B","metadata":{"aliases":["U98b"]}},{"id":"e7dcc1c1f62542718e49b336b8e2236c","type":"GENE","name":"SNORA17A","canonical_id":"hgnc:HGNC:32607","description":"small nucleolar RNA, H/ACA box 17A","metadata":{"aliases":["ACA17","SNORA17"]}},{"id":"ef585d88157c430caa173aa1f3d3f44e","type":"GENE","name":"SNORA17B","canonical_id":"hgnc:HGNC:32636","description":"small nucleolar RNA, H/ACA box 17B","metadata":{"aliases":["ACA43","SNORA43"]}},{"id":"eaa7b4c56290496089bd21a61299511b","type":"GENE","name":"SNORA18","canonical_id":"hgnc:HGNC:32608","description":"small nucleolar RNA, H/ACA box 18","metadata":{"aliases":["ACA18"]}},{"id":"ebc98f644eb0473bb4608656b2a6b32f","type":"GENE","name":"SNORA19","canonical_id":"hgnc:HGNC:32609","description":"small nucleolar RNA, H/ACA box 19","metadata":{"aliases":["ACA19"]}},{"id":"4740eff1f0db4462b0a55e6ec0be4daf","type":"GENE","name":"SNORA1B","canonical_id":"hgnc:HGNC:52193","description":"small nucleolar RNA, H/ACA box 1B","metadata":null},{"id":"69199ac1d741447bb2ca19e5d4a979e6","type":"GENE","name":"SNORA20","canonical_id":"hgnc:HGNC:32610","description":"small nucleolar RNA, H/ACA box 20","metadata":{"aliases":["ACA20"]}},{"id":"88b39babdc994b19a1549006b5d403c9","type":"GENE","name":"SNORA20B","canonical_id":"hgnc:HGNC:52194","description":"small nucleolar RNA, H/ACA box 20B","metadata":null},{"id":"5a6ae148be4040c887a2e26563272419","type":"GENE","name":"SNORA21","canonical_id":"hgnc:HGNC:32611","description":"small nucleolar RNA, H/ACA box 21","metadata":{"aliases":["ACA21"]}},{"id":"e7946a2f388d4554a0ec4622c2765747","type":"GENE","name":"SNORA21B","canonical_id":"hgnc:HGNC:52195","description":"small nucleolar RNA, H/ACA box 21B","metadata":null},{"id":"aa81ed0993cb45e18312f9024418aaa1","type":"GENE","name":"SNORA22","canonical_id":"hgnc:HGNC:32612","description":"small nucleolar RNA, H/ACA box 22","metadata":{"aliases":["ACA22","SNORA22A"]}},{"id":"542da07be72e4cf3afc2c583b4701c73","type":"GENE","name":"SNORA22B","canonical_id":"hgnc:HGNC:52196","description":"small nucleolar RNA, H/ACA box 22B","metadata":null},{"id":"bacb71e1150f44bc8a8d1210e6329326","type":"GENE","name":"SNORA22C","canonical_id":"hgnc:HGNC:52197","description":"small nucleolar RNA, H/ACA box 22C","metadata":null},{"id":"03115d5d001243abb70cee36b643257d","type":"GENE","name":"SNORA23","canonical_id":"hgnc:HGNC:32613","description":"small nucleolar RNA, H/ACA box 23","metadata":{"aliases":["ACA23"]}},{"id":"73b029d359314b2cb0240061d681aafa","type":"GENE","name":"SNORA24","canonical_id":"hgnc:HGNC:32614","description":"small nucleolar RNA, H/ACA box 24","metadata":{"aliases":["ACA24","SNORA24A"]}},{"id":"1de1b236705845989dde9e36d77868b2","type":"GENE","name":"SNORA24B","canonical_id":"hgnc:HGNC:52198","description":"small nucleolar RNA, H/ACA box 24B","metadata":null},{"id":"8d4fd834aee14ef5b02520a374a54881","type":"GENE","name":"SNORA25","canonical_id":"hgnc:HGNC:32615","description":"small nucleolar RNA, H/ACA box 25","metadata":{"aliases":["ACA25","SNORA25A"]}},{"id":"02fe749ef06044d2b8490fe949a80674","type":"GENE","name":"SNORA25B","canonical_id":"hgnc:HGNC:52199","description":"small nucleolar RNA, H/ACA box 25B","metadata":null},{"id":"dce77831767b41f1b8a5af232bfc8a6f","type":"GENE","name":"SNORA26","canonical_id":"hgnc:HGNC:32616","description":"small nucleolar RNA, H/ACA box 26","metadata":{"aliases":["HBI-6"]}},{"id":"89b21f006cba4f109d9ab6b7545bade3","type":"GENE","name":"SNORA27","canonical_id":"hgnc:HGNC:32617","description":"small nucleolar RNA, H/ACA box 27","metadata":{"aliases":["ACA27"]}},{"id":"49e1d68c713f411091e743dee3f67dfd","type":"GENE","name":"SNORA28","canonical_id":"hgnc:HGNC:32618","description":"small nucleolar RNA, H/ACA box 28","metadata":{"aliases":["ACA28"]}},{"id":"183c30cdb0ce4632a6f54e9edca4a43f","type":"GENE","name":"SNORA29","canonical_id":"hgnc:HGNC:32619","description":"small nucleolar RNA, H/ACA box 29","metadata":{"aliases":["ACA29"]}},{"id":"f38094ef45ec413e84ce4ba7b7190cda","type":"GENE","name":"SNORA2A","canonical_id":"hgnc:HGNC:32584","description":"small nucleolar RNA, H/ACA box 2A","metadata":{"aliases":["ACA2A"]}},{"id":"183d6f13c8754eac8f9b1c8ef90c5bd9","type":"GENE","name":"SNORA2B","canonical_id":"hgnc:HGNC:32585","description":"small nucleolar RNA, H/ACA box 2B","metadata":{"aliases":["ACA2b"]}},{"id":"9a329bff59f345be80cb100dd033d988","type":"GENE","name":"SNORA2C","canonical_id":"hgnc:HGNC:32624","description":"small nucleolar RNA, H/ACA box 2C","metadata":{"aliases":["ACA34","SNORA34"]}},{"id":"00e657eb68894d97a276c468cda7eb7f","type":"GENE","name":"SNORA30","canonical_id":"hgnc:HGNC:32620","description":"small nucleolar RNA, H/ACA box 30","metadata":{"aliases":["ACA30","SNORA30A"]}},{"id":"7e66eba7d73c4b968a656049f9bbc1b6","type":"GENE","name":"SNORA30B","canonical_id":"hgnc:HGNC:52200","description":"small nucleolar RNA, H/ACA box 30B","metadata":null},{"id":"d20119a8ea074151ab8761ab8a4169b3","type":"GENE","name":"SNORA31","canonical_id":"hgnc:HGNC:32621","description":"small nucleolar RNA, H/ACA box 31","metadata":{"aliases":["ACA31","SNORA31A"]}},{"id":"2f586b8dd6cc4377b74193ed77ae6127","type":"GENE","name":"SNORA31B","canonical_id":"hgnc:HGNC:52201","description":"small nucleolar RNA, H/ACA box 31B","metadata":null},{"id":"189d225ac2c4474d88d02d1ea0cf93c0","type":"GENE","name":"SNORA32","canonical_id":"hgnc:HGNC:32622","description":"small nucleolar RNA, H/ACA box 32","metadata":{"aliases":["ACA32"]}},{"id":"789be015f5714144b66eb5fc62afcf96","type":"GENE","name":"SNORA33","canonical_id":"hgnc:HGNC:32623","description":"small nucleolar RNA, H/ACA box 33","metadata":{"aliases":["ACA33"]}},{"id":"8570acbaadaa404ea07237e3b5f946fb","type":"GENE","name":"SNORA35","canonical_id":"hgnc:HGNC:32625","description":"small nucleolar RNA, H/ACA box 35","metadata":{"aliases":["HBI-36","SNORA35A"]}},{"id":"662a61b8250a4da7881c231d4b85f129","type":"GENE","name":"SNORA35B","canonical_id":"hgnc:HGNC:52202","description":"small nucleolar RNA, H/ACA box 35B","metadata":null},{"id":"e693e227ee0d4902a0954be364aa5c5f","type":"GENE","name":"SNORA36A","canonical_id":"hgnc:HGNC:32628","description":"small nucleolar RNA, H/ACA box 36A","metadata":{"aliases":["ACA36"]}},{"id":"26e4fc0e88c4455e935e9c5760b17b0c","type":"GENE","name":"SNORA36B","canonical_id":"hgnc:HGNC:32629","description":"small nucleolar RNA, H/ACA box 36B","metadata":{"aliases":["ACA36b"]}},{"id":"fadc528f117a4cbb93968abe212321f0","type":"GENE","name":"SNORA36C","canonical_id":"hgnc:HGNC:33616","description":"small nucleolar RNA, H/ACA box 36C","metadata":null},{"id":"bd913e10e6f4416db2c7e722eba5acde","type":"GENE","name":"SNORA37","canonical_id":"hgnc:HGNC:32630","description":"small nucleolar RNA, H/ACA box 37","metadata":{"aliases":["ACA37"]}},{"id":"d6419e314e134277888ce3ca920c4cda","type":"GENE","name":"SNORA38","canonical_id":"hgnc:HGNC:32631","description":"small nucleolar RNA, H/ACA box 38","metadata":{"aliases":["ACA38"]}},{"id":"87f503d22b904a109ee313ddfe2a1b52","type":"GENE","name":"SNORA38B","canonical_id":"hgnc:HGNC:33617","description":"small nucleolar RNA, H/ACA box 38B","metadata":null},{"id":"c27cdb741e6f434e9c9c1428691a6108","type":"GENE","name":"SNORA3A","canonical_id":"hgnc:HGNC:32586","description":"small nucleolar RNA, H/ACA box 3A","metadata":{"aliases":["ACA3","SNORA3","SNORA45A"]}},{"id":"6abc4883165146109e5c20311a58b248","type":"GENE","name":"SNORA3B","canonical_id":"hgnc:HGNC:32638","description":"small nucleolar RNA, H/ACA box 3B","metadata":{"aliases":["ACA3-2","SNORA45","SNORA45B"]}},{"id":"90389b2d8d0e411e8c206f92b5980d77","type":"GENE","name":"SNORA3C","canonical_id":"hgnc:HGNC:52203","description":"small nucleolar RNA, H/ACA box 3C","metadata":null},{"id":"e6b8158c5d4a4da8a9a51a9e51fa2309","type":"GENE","name":"SNORA4","canonical_id":"hgnc:HGNC:32587","description":"small nucleolar RNA, H/ACA box 4","metadata":{"aliases":["ACA4"]}},{"id":"d8bb1abfb184491e8c9b0715e509a64f","type":"GENE","name":"SNORA40","canonical_id":"hgnc:HGNC:32633","description":"small nucleolar RNA, H/ACA box 40","metadata":{"aliases":["ACA40","SNORA40A"]}},{"id":"f5386db4752147ada2e11e1bdabd1f19","type":"GENE","name":"SNORA40B","canonical_id":"hgnc:HGNC:52204","description":"small nucleolar RNA, H/ACA box 40B","metadata":null},{"id":"2f3d77bffa6744d492efaf60587fdf5e","type":"GENE","name":"SNORA40C","canonical_id":"hgnc:HGNC:52205","description":"small nucleolar RNA, H/ACA box 40C","metadata":null},{"id":"73bd8688ac5b41ee8ceb510003da1e82","type":"GENE","name":"SNORA41","canonical_id":"hgnc:HGNC:32634","description":"small nucleolar RNA, H/ACA box 41","metadata":{"aliases":["ACA41","SNORA41A"]}},{"id":"1b3bebeb02944b419d64278862b4dd46","type":"GENE","name":"SNORA41B","canonical_id":"hgnc:HGNC:52206","description":"small nucleolar RNA, H/ACA box 41B","metadata":null},{"id":"c5b8e1d4102546df81a35e976098b792","type":"GENE","name":"SNORA44","canonical_id":"hgnc:HGNC:32637","description":"small nucleolar RNA, H/ACA box 44","metadata":{"aliases":["ACA44"]}},{"id":"ed4e8f62516d41ffa51ed2266f5db14b","type":"GENE","name":"SNORA46","canonical_id":"hgnc:HGNC:32639","description":"small nucleolar RNA, H/ACA box 46","metadata":{"aliases":["ACA46"]}},{"id":"397f6c95f68d424c88c675e03904063f","type":"GENE","name":"SNORA47","canonical_id":"hgnc:HGNC:32640","description":"small nucleolar RNA, H/ACA box 47","metadata":{"aliases":["HBI-115"]}},{"id":"3621aa5ee6d24915956f4770457e3bac","type":"GENE","name":"SNORA48","canonical_id":"hgnc:HGNC:32641","description":"small nucleolar RNA, H/ACA box 48","metadata":{"aliases":["ACA48","SNORA48A"]}},{"id":"a4ad6145a04f4577b915a8093c776362","type":"GENE","name":"SNORA48B","canonical_id":"hgnc:HGNC:52207","description":"small nucleolar RNA, H/ACA box 48B","metadata":null},{"id":"5e38ad38a54443a9b7c1f244ef8e04be","type":"GENE","name":"SNORA49","canonical_id":"hgnc:HGNC:32642","description":"small nucleolar RNA, H/ACA box 49","metadata":{"aliases":["ACA49"]}},{"id":"b0c21c236e714fa799e7c5f8647f2a61","type":"GENE","name":"SNORA50A","canonical_id":"hgnc:HGNC:32643","description":"small nucleolar RNA, H/ACA box 50A","metadata":{"aliases":["ACA50","SNORA50","SNORA76A"]}},{"id":"bd904f284f9c4cd2bc7a09f176ab25fd","type":"GENE","name":"SNORA50B","canonical_id":"hgnc:HGNC:50432","description":"small nucleolar RNA, H/ACA box 50B","metadata":null},{"id":"b2a1962bbaca43b09b3fc310f76952bd","type":"GENE","name":"SNORA50C","canonical_id":"hgnc:HGNC:32662","description":"small nucleolar RNA, H/ACA box 50C","metadata":{"aliases":["ACA62","SNORA76","SNORA76C"]}},{"id":"de3cf1b6daee40d1b89f17a3b19242c8","type":"GENE","name":"SNORA50D","canonical_id":"hgnc:HGNC:50433","description":"small nucleolar RNA, H/ACA box 50D","metadata":null},{"id":"f6b33d45a80c4f3ebfcc41b0d6762496","type":"GENE","name":"SNORA51","canonical_id":"hgnc:HGNC:32644","description":"small nucleolar RNA, H/ACA box 51","metadata":{"aliases":["ACA51"]}},{"id":"8030797c139f42c086e20fcadbebd3b5","type":"GENE","name":"SNORA52","canonical_id":"hgnc:HGNC:32645","description":"small nucleolar RNA, H/ACA box 52","metadata":{"aliases":["ACA52"]}},{"id":"faab00e2b94f4e2a9c023c0098d40a20","type":"GENE","name":"SNORA53","canonical_id":"hgnc:HGNC:32646","description":"small nucleolar RNA, H/ACA box 53","metadata":{"aliases":["ACA53"]}},{"id":"f2b311139f174992b3b9535eb5be7cbc","type":"GENE","name":"SNORA54","canonical_id":"hgnc:HGNC:32647","description":"small nucleolar RNA, H/ACA box 54","metadata":{"aliases":["ACA54"]}},{"id":"52e6705866ee4cc485c6f0d4bde75a5b","type":"GENE","name":"SNORA55","canonical_id":"hgnc:HGNC:32649","description":"small nucleolar RNA, H/ACA box 55","metadata":{"aliases":["ACA55"]}},{"id":"5a3d17e532ee439688af711ef027622e","type":"GENE","name":"SNORA56","canonical_id":"hgnc:HGNC:32650","description":"small nucleolar RNA, H/ACA box 56","metadata":{"aliases":["ACA56"]}},{"id":"61afe5778f8743b6bde365495a80eac0","type":"GENE","name":"SNORA57","canonical_id":"hgnc:HGNC:32651","description":"small nucleolar RNA, H/ACA box 57","metadata":{"aliases":["U99"]}},{"id":"570857cf7e3f47358e3fd26b6377daac","type":"GENE","name":"SNORA58","canonical_id":"hgnc:HGNC:32652","description":"small nucleolar RNA, H/ACA box 58","metadata":{"aliases":["ACA58","SNORA58B"]}},{"id":"e251076bb5d344309de885417a0ac06e","type":"GENE","name":"SNORA58B","canonical_id":"hgnc:HGNC:52208","description":"small nucleolar RNA, H/ACA box 58B","metadata":null},{"id":"b822ce2469ff4164b3c94b2ae201eb79","type":"GENE","name":"SNORA59A","canonical_id":"hgnc:HGNC:32653","description":"small nucleolar RNA, H/ACA box 59A","metadata":{"aliases":["ACA59"]}},{"id":"a44aaf5b7864463ba008d9fda17494cc","type":"GENE","name":"SNORA59B","canonical_id":"hgnc:HGNC:32658","description":"small nucleolar RNA, H/ACA box 59B","metadata":{"aliases":["ACA59"]}},{"id":"0c5d6aa9cbad46299ee15667ad80cb3c","type":"GENE","name":"SNORA5A","canonical_id":"hgnc:HGNC:32588","description":"small nucleolar RNA, H/ACA box 5A","metadata":{"aliases":["ACA5"]}},{"id":"bf9aa9284888405cabd0ccab6736563a","type":"GENE","name":"SNORA5B","canonical_id":"hgnc:HGNC:32589","description":"small nucleolar RNA, H/ACA box 5B","metadata":{"aliases":["ACA5b"]}},{"id":"c65b816ec31645cd8865550e332b3c0b","type":"GENE","name":"SNORA5C","canonical_id":"hgnc:HGNC:32590","description":"small nucleolar RNA, H/ACA box 5C","metadata":{"aliases":["ACA5c"]}},{"id":"544a87650ac9401d9023f6a7e9b59330","type":"GENE","name":"SNORA6","canonical_id":"hgnc:HGNC:32591","description":"small nucleolar RNA, H/ACA box 6","metadata":{"aliases":["ACA6"]}},{"id":"e5fe1f8b6ce94fb6861154eb533af9a7","type":"GENE","name":"SNORA60","canonical_id":"hgnc:HGNC:32654","description":"small nucleolar RNA, H/ACA box 60","metadata":{"aliases":["ACA60"]}},{"id":"40a2b8230ddb4b01b860c4c440227366","type":"GENE","name":"SNORA61","canonical_id":"hgnc:HGNC:32655","description":"small nucleolar RNA, H/ACA box 61","metadata":{"aliases":["ACA61"]}},{"id":"8d03fed363494d998c16e5358a6570db","type":"GENE","name":"SNORA62","canonical_id":"hgnc:HGNC:10107","description":"small nucleolar RNA, H/ACA box 62","metadata":{"aliases":["E2","E2-1","RNE2","RNU108"]}},{"id":"28c76d3938c24dfeb4f935fe3bd5c57f","type":"GENE","name":"SNORA63","canonical_id":"hgnc:HGNC:10106","description":"small nucleolar RNA, H/ACA box 63","metadata":{"aliases":["E3","E3-2","SNORA63A","RNE3","RNU107"]}},{"id":"6accf700c7be4083958a6f6154ef0c35","type":"GENE","name":"SNORA63B","canonical_id":"hgnc:HGNC:52209","description":"small nucleolar RNA, H/ACA box 63B","metadata":null},{"id":"0c66e1d5a07e4e4d91ffc5399c0415cf","type":"GENE","name":"SNORA63C","canonical_id":"hgnc:HGNC:52210","description":"small nucleolar RNA, H/ACA box 63C","metadata":null},{"id":"fc4f6fe9b7f44b60aefea650ad3da2e5","type":"GENE","name":"SNORA63D","canonical_id":"hgnc:HGNC:52211","description":"small nucleolar RNA, H/ACA box 63D","metadata":null},{"id":"d92451d990644716adcd1359027ecbbf","type":"GENE","name":"SNORA63E","canonical_id":"hgnc:HGNC:52212","description":"small nucleolar RNA, H/ACA box 63E","metadata":null},{"id":"fccb92626a294f0999c9787d04e612cd","type":"GENE","name":"SNORA64","canonical_id":"hgnc:HGNC:10221","description":"small nucleolar RNA, H/ACA box 64","metadata":{"aliases":["U64","RNU64"]}},{"id":"4f69fdb309e4489693a53d32470484b1","type":"GENE","name":"SNORA65","canonical_id":"hgnc:HGNC:10222","description":"small nucleolar RNA, H/ACA box 65","metadata":{"aliases":["U65","RNU65"]}},{"id":"1d51df893d17471a83861576236d23ac","type":"GENE","name":"SNORA66","canonical_id":"hgnc:HGNC:10223","description":"small nucleolar RNA, H/ACA box 66","metadata":{"aliases":["U66","RNU66"]}},{"id":"dd78d8c359554241aa48d8418d5afc5d","type":"GENE","name":"SNORA67","canonical_id":"hgnc:HGNC:10224","description":"small nucleolar RNA, H/ACA box 67","metadata":{"aliases":["U67","RNU67"]}},{"id":"7057bd94add048f88ad785507b5672b1","type":"GENE","name":"SNORA68","canonical_id":"hgnc:HGNC:10225","description":"small nucleolar RNA, H/ACA box 68","metadata":{"aliases":["U68","SNORA68A","RNU68"]}},{"id":"f1147be28fdd484c87b66488cd6aac3a","type":"GENE","name":"SNORA68B","canonical_id":"hgnc:HGNC:52213","description":"small nucleolar RNA, H/ACA box 68B","metadata":null},{"id":"83261c2eb3534dbf8c684c21c1fd38aa","type":"GENE","name":"SNORA69","canonical_id":"hgnc:HGNC:10226","description":"small nucleolar RNA, H/ACA box 69","metadata":{"aliases":["U69","RNU69"]}},{"id":"ad5a2777c5214d3f8f85afc8a04fb4c1","type":"GENE","name":"SNORA70","canonical_id":"hgnc:HGNC:10231","description":"small nucleolar RNA, H/ACA box 70","metadata":{"aliases":["U70","DXS648E","RNU70"]}},{"id":"7d211c51e28e445280e57f30c0d18edc","type":"GENE","name":"SNORA70B","canonical_id":"hgnc:HGNC:33618","description":"small nucleolar RNA, H/ACA box 70B","metadata":null},{"id":"deb2270ab10844c98d89208dcac5b832","type":"GENE","name":"SNORA70C","canonical_id":"hgnc:HGNC:33619","description":"small nucleolar RNA, H/ACA box 70C","metadata":null},{"id":"237e622507d44fd0bb45c065eff31cad","type":"GENE","name":"SNORA70D","canonical_id":"hgnc:HGNC:34356","description":"small nucleolar RNA, H/ACA box 70D","metadata":{"aliases":["U70D"]}},{"id":"972d48a658e941918f6ff7d58e4d1ea8","type":"GENE","name":"SNORA70E","canonical_id":"hgnc:HGNC:34357","description":"small nucleolar RNA, H/ACA box 70E","metadata":{"aliases":["U70E"]}},{"id":"b2e0a1d5d8db47f99e4e0861d1eedbf9","type":"GENE","name":"SNORA70F","canonical_id":"hgnc:HGNC:34358","description":"small nucleolar RNA, H/ACA box 70F","metadata":{"aliases":["U70F"]}},{"id":"a6b3c1ced7f740239ed632ab2d931d2f","type":"GENE","name":"SNORA70G","canonical_id":"hgnc:HGNC:34359","description":"small nucleolar RNA, H/ACA box 70G","metadata":{"aliases":["U70G"]}},{"id":"ef63db1e96304aba8af2246cae8bbd1f","type":"GENE","name":"SNORA70H","canonical_id":"hgnc:HGNC:52214","description":"small nucleolar RNA, H/ACA box 70H","metadata":null},{"id":"112355bae86d4b53817bc861766242b6","type":"GENE","name":"SNORA70I","canonical_id":"hgnc:HGNC:52215","description":"small nucleolar RNA, H/ACA box 70I","metadata":null},{"id":"b46296b8e4294638bb5c2f45180b54f5","type":"GENE","name":"SNORA70J","canonical_id":"hgnc:HGNC:52216","description":"small nucleolar RNA, H/ACA box 70J","metadata":null},{"id":"1ff1b48a0e4b4a24aa54bc6c55e97c57","type":"GENE","name":"SNORA71A","canonical_id":"hgnc:HGNC:10232","description":"small nucleolar RNA, H/ACA box 71A","metadata":{"aliases":["U71a","RNU71A"]}},{"id":"d612f0514d254e27b1465ddc1ea181c4","type":"GENE","name":"SNORA71B","canonical_id":"hgnc:HGNC:10233","description":"small nucleolar RNA, H/ACA box 71B","metadata":{"aliases":["U71b","RNU71B"]}},{"id":"05ec0133bc924e358417376fcff4e534","type":"GENE","name":"SNORA71C","canonical_id":"hgnc:HGNC:32656","description":"small nucleolar RNA, H/ACA box 71C","metadata":{"aliases":["U71c"]}},{"id":"e6a7cb2ef9d547f7b5fff595b6cec9c4","type":"GENE","name":"SNORA71D","canonical_id":"hgnc:HGNC:32657","description":"small nucleolar RNA, H/ACA box 71D","metadata":{"aliases":["U71d"]}},{"id":"b4dfabb55bb24a89b97d1f52c9594109","type":"GENE","name":"SNORA71E","canonical_id":"hgnc:HGNC:32632","description":"small nucleolar RNA, H/ACA box 71E","metadata":{"aliases":["ACA39","SNORA39"]}},{"id":"f6347ca7908249e9a19100db32132b85","type":"GENE","name":"SNORA72","canonical_id":"hgnc:HGNC:10234","description":"small nucleolar RNA, H/ACA box 72","metadata":{"aliases":["U72","RNU72"]}},{"id":"e8e6d46e768649b4b2298699ef19700c","type":"GENE","name":"SNORA73A","canonical_id":"hgnc:HGNC:10115","description":"small nucleolar RNA, H/ACA box 73A","metadata":{"aliases":["U17A","E1-7","E1b","E1","RNE1","RNU17A"]}},{"id":"d9353708993143b0bd7b7b82cb0bac41","type":"GENE","name":"SNORA73B","canonical_id":"hgnc:HGNC:10116","description":"small nucleolar RNA, H/ACA box 73B","metadata":{"aliases":["U17B","E1c","RNU17B","RNU105A"]}},{"id":"594dbc30140b4aefac9ab9f2db50e722","type":"GENE","name":"SNORA74A","canonical_id":"hgnc:HGNC:10119","description":"small nucleolar RNA, H/ACA box 74A","metadata":{"aliases":["U19","RNU19"]}},{"id":"e2ba1bee887f4c1a9f018c9a2d165222","type":"GENE","name":"SNORA74B","canonical_id":"hgnc:HGNC:32660","description":"small nucleolar RNA, H/ACA box 74B","metadata":{"aliases":["U19-2"]}},{"id":"80b1ff6c68e94837ac1463375ece7885","type":"GENE","name":"SNORA74C-1","canonical_id":"hgnc:HGNC:52217","description":"small nucleolar RNA, H/ACA box 74C-1","metadata":null},{"id":"7bfc437ac3fb40b7a726b6511c708c50","type":"GENE","name":"SNORA74C-2","canonical_id":"hgnc:HGNC:52218","description":"small nucleolar RNA, H/ACA box 74C-2","metadata":null},{"id":"236741d852df408f8032df17b212b87c","type":"GENE","name":"SNORA74D","canonical_id":"hgnc:HGNC:52219","description":"small nucleolar RNA, H/ACA box 74D","metadata":null},{"id":"1656dce9340041f0a6b6899f4d448065","type":"GENE","name":"SNORA75","canonical_id":"hgnc:HGNC:32661","description":"small nucleolar RNA, H/ACA box 75","metadata":{"aliases":["U23","SNORA75A"]}},{"id":"cce79883032447a3a8e2173e408c7e29","type":"GENE","name":"SNORA75B","canonical_id":"hgnc:HGNC:52220","description":"small nucleolar RNA, H/ACA box 75B","metadata":null},{"id":"01cad42cb48446fa96f324680e72fd75","type":"GENE","name":"SNORA77","canonical_id":"hgnc:HGNC:32663","description":"small nucleolar RNA, H/ACA box 77","metadata":{"aliases":["ACA63","SNORA77A"]}},{"id":"53a0a91e35ab4ea185ce3c7543ef5c65","type":"GENE","name":"SNORA77B","canonical_id":"hgnc:HGNC:52221","description":"small nucleolar RNA, H/ACA box 77B","metadata":null},{"id":"d483ea4903d4445d99aaac64bacf9fc1","type":"GENE","name":"SNORA78","canonical_id":"hgnc:HGNC:32664","description":"small nucleolar RNA, H/ACA box 78","metadata":{"aliases":["ACA64"]}},{"id":"f9962af9b9bb4bbd8381b6688391e3f3","type":"GENE","name":"SNORA79","canonical_id":"hgnc:HGNC:32665","description":"small nucleolar RNA, H/ACA box 79","metadata":{"aliases":["ACA65","SNORA79A"]}},{"id":"3f4854f1529a4da4b0c116cc968e758a","type":"GENE","name":"SNORA79B","canonical_id":"hgnc:HGNC:52222","description":"small nucleolar RNA, H/ACA box 79B","metadata":null},{"id":"fcffc25d5df5458dbcf51b6cd3968f48","type":"GENE","name":"SNORA7A","canonical_id":"hgnc:HGNC:32592","description":"small nucleolar RNA, H/ACA box 7A","metadata":{"aliases":["ACA7"]}},{"id":"dad8aea06a1b45fe9b974eef0b89b0c1","type":"GENE","name":"SNORA7B","canonical_id":"hgnc:HGNC:32593","description":"small nucleolar RNA, H/ACA box 7B","metadata":{"aliases":["ACA7B"]}},{"id":"9855620580e449d9b8eeb8fe1bda32e2","type":"GENE","name":"SNORA8","canonical_id":"hgnc:HGNC:32596","description":"small nucleolar RNA, H/ACA box 8","metadata":{"aliases":["ACA8"]}},{"id":"3ae765fe0a154b53a95d69515a31cac6","type":"GENE","name":"SNORA80A","canonical_id":"hgnc:HGNC:32666","description":"small nucleolar RNA, H/ACA box 80A","metadata":{"aliases":["ACA67","SNORA80"]}},{"id":"f808b57a2d234a5bb9b258234a284fc8","type":"GENE","name":"SNORA80B","canonical_id":"hgnc:HGNC:34355","description":"small nucleolar RNA, H/ACA box 80B","metadata":{"aliases":["ACA67B"]}},{"id":"7298c3a06e924bc89406858f64423633","type":"GENE","name":"SNORA80C","canonical_id":"hgnc:HGNC:50434","description":"small nucleolar RNA, H/ACA box 80C","metadata":null},{"id":"3098a506232e4686ba2a29e4100d7800","type":"GENE","name":"SNORA80D","canonical_id":"hgnc:HGNC:50435","description":"small nucleolar RNA, H/ACA box 80D","metadata":null},{"id":"a10ffaddd02d4889bc12df84ec18cc64","type":"GENE","name":"SNORA80E","canonical_id":"hgnc:HGNC:32635","description":"small nucleolar RNA, H/ACA box 80E","metadata":{"aliases":["ACA42","SNORA42"]}},{"id":"0e29e9d4f11945308712631574bc3825","type":"GENE","name":"SNORA81","canonical_id":"hgnc:HGNC:32667","description":"small nucleolar RNA, H/ACA box 81","metadata":{"aliases":["HBI-61"]}},{"id":"f57363ade80b4ba78bde0fe67fb3aa20","type":"GENE","name":"SNORA84","canonical_id":"hgnc:HGNC:33615","description":"small nucleolar RNA, H/ACA box 84","metadata":null},{"id":"952a327d35234413a84d2c0321c2216a","type":"GENE","name":"SNORA86","canonical_id":"hgnc:HGNC:50390","description":"small nucleolar RNA, H/ACA box 86","metadata":null},{"id":"24dbe2257b7d42ba90803da0e3983795","type":"GENE","name":"SNORA87","canonical_id":"hgnc:HGNC:50391","description":"small nucleolar RNA, H/ACA box 87","metadata":null},{"id":"ac96067de0304f449cc9480687a7aa95","type":"GENE","name":"SNORA88","canonical_id":"hgnc:HGNC:50392","description":"small nucleolar RNA, H/ACA box 88","metadata":null},{"id":"fdfaceb05bb647c1a012b84a7ec362d5","type":"GENE","name":"SNORA89","canonical_id":"hgnc:HGNC:50393","description":"small nucleolar RNA, H/ACA box 89","metadata":null},{"id":"96ff05c7c3724581a2cf7f08a5960868","type":"GENE","name":"SNORA9","canonical_id":"hgnc:HGNC:32597","description":"small nucleolar RNA, H/ACA box 9","metadata":{"aliases":["ACA9","SNORA9A"]}},{"id":"a305567374b443d7b34ab5ccc969321c","type":"GENE","name":"SNORA90","canonical_id":"hgnc:HGNC:50394","description":"small nucleolar RNA, H/ACA box 90","metadata":null},{"id":"297eeb302a794150a226201ab506aec1","type":"GENE","name":"SNORA91","canonical_id":"hgnc:HGNC:50395","description":"small nucleolar RNA, H/ACA box 91","metadata":null},{"id":"3f0e9ad3624a4d789db7ad4c7aa6f5d5","type":"GENE","name":"SNORA92","canonical_id":"hgnc:HGNC:50396","description":"small nucleolar RNA, H/ACA box 92","metadata":null},{"id":"5acdf2597ecb4bbab6cff1fe334c2dc4","type":"GENE","name":"SNORA93","canonical_id":"hgnc:HGNC:50397","description":"small nucleolar RNA, H/ACA box 93","metadata":null},{"id":"664db69309d64d73873ef20b51a6deb3","type":"GENE","name":"SNORA94","canonical_id":"hgnc:HGNC:50398","description":"small nucleolar RNA, H/ACA box 94","metadata":null},{"id":"d705b937e37643179bc5ec92999248d6","type":"GENE","name":"SNORA95","canonical_id":"hgnc:HGNC:50399","description":"small nucleolar RNA, H/ACA box 95","metadata":null},{"id":"1df828dd4b9748dba6f81c37dbf1766b","type":"GENE","name":"SNORA98","canonical_id":"hgnc:HGNC:50402","description":"small nucleolar RNA, H/ACA box 98","metadata":null},{"id":"61f47a4293a940cc9eea3ebd05843852","type":"GENE","name":"SNORA99","canonical_id":"hgnc:HGNC:50403","description":"small nucleolar RNA, H/ACA box 99","metadata":null},{"id":"67102ba1cbc842fbb3c8f3507e22fd78","type":"GENE","name":"SNORA9B","canonical_id":"hgnc:HGNC:52223","description":"small nucleolar RNA, H/ACA box 9B","metadata":null},{"id":"0b40a38cb77c4e5292fb77aa3ba55fba","type":"GENE","name":"SNORC","canonical_id":"hgnc:HGNC:33763","description":"secondary ossification center associated regulator of chondrocyte maturation","metadata":{"aliases":["UNQ830","ASCL830","C2orf82"]}},{"id":"4aa1db2a852e4724a4f916e8252ff82f","type":"GENE","name":"SNORD10","canonical_id":"hgnc:HGNC:32706","description":"small nucleolar RNA, C/D box 10","metadata":{"aliases":["mgU6-77"]}},{"id":"6eaae029eb60413ab6e8e137b1260f31","type":"GENE","name":"SNORD100","canonical_id":"hgnc:HGNC:32763","description":"small nucleolar RNA, C/D box 100","metadata":{"aliases":["HBII-429"]}},{"id":"723d062701fc40938b007ff6b1f8d43a","type":"GENE","name":"SNORD101","canonical_id":"hgnc:HGNC:32764","description":"small nucleolar RNA, C/D box 101","metadata":{"aliases":["U101"]}},{"id":"49788ef9985049d3910fff9ee8bb61c0","type":"GENE","name":"SNORD102","canonical_id":"hgnc:HGNC:10099","description":"small nucleolar RNA, C/D box 102","metadata":{"aliases":["U102","RNU102"]}},{"id":"ba5d56ed9388401c9e3d2bcd3f3a216a","type":"GENE","name":"SNORD103A","canonical_id":"hgnc:HGNC:32766","description":"small nucleolar RNA, C/D box 103A","metadata":{"aliases":["U103"]}},{"id":"b7036b5e409346bea24b06182f0ad9dc","type":"GENE","name":"SNORD103B","canonical_id":"hgnc:HGNC:32767","description":"small nucleolar RNA, C/D box 103B","metadata":{"aliases":["U103B"]}},{"id":"f08bb1e86aa545b68b52fc4fba52567a","type":"GENE","name":"SNORD103C","canonical_id":"hgnc:HGNC:32744","description":"small nucleolar RNA, C/D box 103C","metadata":{"aliases":["HBII-251","SNORD85"]}},{"id":"5c639b757dbe4844a0e43118c4031012","type":"GENE","name":"SNORD104","canonical_id":"hgnc:HGNC:32768","description":"small nucleolar RNA, C/D box 104","metadata":{"aliases":["U104"]}},{"id":"bd21c9b6c6894038ba7d0632ed723cd3","type":"GENE","name":"SNORD105","canonical_id":"hgnc:HGNC:32769","description":"small nucleolar RNA, C/D box 105","metadata":{"aliases":["U105"]}},{"id":"7d8d34aa6dc848eda11afafcab307141","type":"GENE","name":"SNORD105B","canonical_id":"hgnc:HGNC:33572","description":"small nucleolar RNA, C/D box 105B","metadata":null},{"id":"448108d5f53f42c082c55269643dd7dd","type":"GENE","name":"SNORD107","canonical_id":"hgnc:HGNC:32771","description":"small nucleolar RNA, C/D box 107","metadata":{"aliases":["HBII-436"]}},{"id":"fc06454acbde4f119fc779493074f562","type":"GENE","name":"SNORD108","canonical_id":"hgnc:HGNC:32772","description":"small nucleolar RNA, C/D box 108","metadata":{"aliases":["HBII-437"]}},{"id":"e605d3ab52c34ea1bf2a49edbf2ab60e","type":"GENE","name":"SNORD109A","canonical_id":"hgnc:HGNC:32773","description":"small nucleolar RNA, C/D box 109A","metadata":{"aliases":["HBII-438a"]}},{"id":"7be61731f787498d97f9426d45ed83a8","type":"GENE","name":"SNORD109B","canonical_id":"hgnc:HGNC:32774","description":"small nucleolar RNA, C/D box 109B","metadata":{"aliases":["HBII-438b"]}},{"id":"0b53fa8b19774e9c8b1907dbd0d71671","type":"GENE","name":"SNORD11","canonical_id":"hgnc:HGNC:32707","description":"small nucleolar RNA, C/D box 11","metadata":{"aliases":["HBII-95"]}},{"id":"d3c5e7351cc44fce9ddfa1cf4ae05458","type":"GENE","name":"SNORD110","canonical_id":"hgnc:HGNC:32775","description":"small nucleolar RNA, C/D box 110","metadata":{"aliases":["HBII-55"]}},{"id":"320ac55cd4af4968b082e69c9b45c4c0","type":"GENE","name":"SNORD111","canonical_id":"hgnc:HGNC:32776","description":"small nucleolar RNA, C/D box 111","metadata":{"aliases":["HBII-82"]}},{"id":"f05d0149e9c648aebfb689d67d017328","type":"GENE","name":"SNORD111B","canonical_id":"hgnc:HGNC:33579","description":"small nucleolar RNA, C/D box 111B","metadata":{"aliases":["hsa-mir-3647","MIR3647"]}},{"id":"3f4de2fc6d974c64bf8129ce07f3b723","type":"GENE","name":"SNORD112","canonical_id":"hgnc:HGNC:32777","description":"small nucleolar RNA, C/D box 112","metadata":{"aliases":["14q(0)"]}},{"id":"adc2e2b0ff6d4e2989d38c6ba4306749","type":"GENE","name":"SNORD113-1","canonical_id":"hgnc:HGNC:32980","description":"small nucleolar RNA, C/D box 113-1","metadata":{"aliases":["14q(I-1)"]}},{"id":"d84b4d508fe6432486b2bca15daee31c","type":"GENE","name":"SNORD113-2","canonical_id":"hgnc:HGNC:32981","description":"small nucleolar RNA, C/D box 113-2","metadata":{"aliases":["14q(I-2)"]}},{"id":"87927ecc045b441bb348947cbfcfd461","type":"GENE","name":"SNORD113-3","canonical_id":"hgnc:HGNC:32982","description":"small nucleolar RNA, C/D box 113-3","metadata":{"aliases":["14q(I-3)"]}},{"id":"86e120f8f6734ced9f238f15694a22d4","type":"GENE","name":"SNORD113-4","canonical_id":"hgnc:HGNC:32983","description":"small nucleolar RNA, C/D box 113-4","metadata":{"aliases":["14q(I-4)"]}},{"id":"2a70a3ef2cfc49deacd5dd637f36cb70","type":"GENE","name":"SNORD113-5","canonical_id":"hgnc:HGNC:32984","description":"small nucleolar RNA, C/D box 113-5","metadata":{"aliases":["14q(I-5)"]}},{"id":"50760b049249481683fb70c5ae634241","type":"GENE","name":"SNORD113-6","canonical_id":"hgnc:HGNC:32985","description":"small nucleolar RNA, C/D box 113-6","metadata":{"aliases":["14q(I-6)"]}},{"id":"515c6e8061f34abaa4ccb78314b0eb82","type":"GENE","name":"SNORD113-7","canonical_id":"hgnc:HGNC:32986","description":"small nucleolar RNA, C/D box 113-7","metadata":{"aliases":["14q(I-7)"]}},{"id":"a3a64a3417e641248c908de40fffc936","type":"GENE","name":"SNORD113-8","canonical_id":"hgnc:HGNC:32987","description":"small nucleolar RNA, C/D box 113-8","metadata":{"aliases":["14q(I-8)"]}},{"id":"c2521f20eb5c40c08d2d27e6edba1218","type":"GENE","name":"SNORD113-9","canonical_id":"hgnc:HGNC:32988","description":"small nucleolar RNA, C/D box 113-9","metadata":{"aliases":["14q(I-9)"]}},{"id":"5a7d539f8f184f699b37334de8fce2a1","type":"GENE","name":"SNORD114-1","canonical_id":"hgnc:HGNC:32989","description":"small nucleolar RNA, C/D box 114-1","metadata":{"aliases":["14q(II-1)"]}},{"id":"e58856eba6d74e498abe6629cf72b4ef","type":"GENE","name":"SNORD114-10","canonical_id":"hgnc:HGNC:32998","description":"small nucleolar RNA, C/D box 114-10","metadata":{"aliases":["14q(II-10)"]}},{"id":"d849b9805192485ab4feb6c20909ffa9","type":"GENE","name":"SNORD114-11","canonical_id":"hgnc:HGNC:32999","description":"small nucleolar RNA, C/D box 114-11","metadata":{"aliases":["14q(II-11)"]}},{"id":"280655d13300430da97fc9ac449faac3","type":"GENE","name":"SNORD114-12","canonical_id":"hgnc:HGNC:33000","description":"small nucleolar RNA, C/D box 114-12","metadata":{"aliases":["14q(II-12)"]}},{"id":"ae8ed7c46fbe480d88404ae47756d924","type":"GENE","name":"SNORD114-13","canonical_id":"hgnc:HGNC:33001","description":"small nucleolar RNA, C/D box 114-13","metadata":{"aliases":["14q(II-13)"]}},{"id":"5b6fe21d4a84495e8b40278ea82609ee","type":"GENE","name":"SNORD114-14","canonical_id":"hgnc:HGNC:33002","description":"small nucleolar RNA, C/D box 114-14","metadata":{"aliases":["14q(II-14)"]}},{"id":"0b72dab9c78a4f9cb71d72afbc8c9dfc","type":"GENE","name":"SNORD114-15","canonical_id":"hgnc:HGNC:33003","description":"small nucleolar RNA, C/D box 114-15","metadata":{"aliases":["14q(II-15)"]}},{"id":"1e6783ed6ac54cefa566aa44a0bfffaa","type":"GENE","name":"SNORD114-16","canonical_id":"hgnc:HGNC:33004","description":"small nucleolar RNA, C/D box 114-16","metadata":{"aliases":["14q(II-16)"]}},{"id":"018b8b9af6ee4754add814c0e8f234f8","type":"GENE","name":"SNORD114-17","canonical_id":"hgnc:HGNC:33005","description":"small nucleolar RNA, C/D box 114-17","metadata":{"aliases":["14q(II-17)"]}},{"id":"43c61b787615433a854302a889166013","type":"GENE","name":"SNORD114-18","canonical_id":"hgnc:HGNC:33006","description":"small nucleolar RNA, C/D box 114-18","metadata":{"aliases":["14q(II-18)"]}},{"id":"99c2c7f7780f4600af03be5e0c92f8b0","type":"GENE","name":"SNORD114-19","canonical_id":"hgnc:HGNC:33007","description":"small nucleolar RNA, C/D box 114-19","metadata":{"aliases":["14q(II-19)"]}},{"id":"8ba32c8034924ad7be63d8929fab6814","type":"GENE","name":"SNORD114-2","canonical_id":"hgnc:HGNC:32990","description":"small nucleolar RNA, C/D box 114-2","metadata":{"aliases":["14q(II-2)"]}},{"id":"7ce4980056ac44799f370be06dae5a18","type":"GENE","name":"SNORD114-20","canonical_id":"hgnc:HGNC:33008","description":"small nucleolar RNA, C/D box 114-20","metadata":{"aliases":["14q(II-20)"]}},{"id":"3eea1290258546349b382874be4eb9b0","type":"GENE","name":"SNORD114-21","canonical_id":"hgnc:HGNC:33009","description":"small nucleolar RNA, C/D box 114-21","metadata":{"aliases":["14q(II-21)"]}},{"id":"adf96b6e13e2478290d40afee852aa85","type":"GENE","name":"SNORD114-22","canonical_id":"hgnc:HGNC:33010","description":"small nucleolar RNA, C/D box 114-22","metadata":{"aliases":["14q(II-22)"]}},{"id":"525192a5b99a4d4fb557b6bfde26e6ec","type":"GENE","name":"SNORD114-23","canonical_id":"hgnc:HGNC:33011","description":"small nucleolar RNA, C/D box 114-23","metadata":{"aliases":["14q(II-23)"]}},{"id":"a88fa24570bf47c0b8ebf5a4a8034a4d","type":"GENE","name":"SNORD114-24","canonical_id":"hgnc:HGNC:33012","description":"small nucleolar RNA, C/D box 114-24","metadata":{"aliases":["14q(II-24)"]}},{"id":"e16d99c776d7430aa260f7e3f202aa26","type":"GENE","name":"SNORD114-25","canonical_id":"hgnc:HGNC:33013","description":"small nucleolar RNA, C/D box 114-25","metadata":{"aliases":["14q(II-25)"]}},{"id":"82cd2fb529fc457fb206a901ad0122b9","type":"GENE","name":"SNORD114-26","canonical_id":"hgnc:HGNC:33014","description":"small nucleolar RNA, C/D box 114-26","metadata":{"aliases":["14q(II-26)"]}},{"id":"d9e4409658264398a793fab581c0dff0","type":"GENE","name":"SNORD114-27","canonical_id":"hgnc:HGNC:33015","description":"small nucleolar RNA, C/D box 114-27","metadata":{"aliases":["14q(II-27)"]}},{"id":"15be202a702f4b35bb83bf59b59bfc7c","type":"GENE","name":"SNORD114-28","canonical_id":"hgnc:HGNC:33016","description":"small nucleolar RNA, C/D box 114-28","metadata":{"aliases":["14q(II-28)"]}},{"id":"e136a1a3018b46ef8a24d7613961d40e","type":"GENE","name":"SNORD114-29","canonical_id":"hgnc:HGNC:33017","description":"small nucleolar RNA, C/D box 114-29","metadata":{"aliases":["14q(II-29)"]}},{"id":"17413a9fe13041ed9d9e950f36f6a295","type":"GENE","name":"SNORD114-3","canonical_id":"hgnc:HGNC:32991","description":"small nucleolar RNA, C/D box 114-3","metadata":{"aliases":["14q(II-3)"]}},{"id":"fc167937920e49b69c90536f2f608b2b","type":"GENE","name":"SNORD114-30","canonical_id":"hgnc:HGNC:33018","description":"small nucleolar RNA, C/D box 114-30","metadata":{"aliases":["14q(II-30)"]}},{"id":"ab5065f157a945a194733820184ba1e9","type":"GENE","name":"SNORD114-31","canonical_id":"hgnc:HGNC:33019","description":"small nucleolar RNA, C/D box 114-31","metadata":{"aliases":["14q(II-31)"]}},{"id":"357fe490fd31458085675303cc20f4f0","type":"GENE","name":"SNORD114-4","canonical_id":"hgnc:HGNC:32992","description":"small nucleolar RNA, C/D box 114-4","metadata":{"aliases":["14q(II-4)"]}},{"id":"e413d3a760a64d06bb7b6948382e8a83","type":"GENE","name":"SNORD114-5","canonical_id":"hgnc:HGNC:32993","description":"small nucleolar RNA, C/D box 114-5","metadata":{"aliases":["14q(II-5)"]}},{"id":"2018302d7deb4539a79a5954e672c33b","type":"GENE","name":"SNORD114-6","canonical_id":"hgnc:HGNC:32994","description":"small nucleolar RNA, C/D box 114-6","metadata":{"aliases":["14q(II-6)"]}},{"id":"3fb72abdd8ca4a0d92f87cde83c21565","type":"GENE","name":"SNORD114-7","canonical_id":"hgnc:HGNC:32995","description":"small nucleolar RNA, C/D box 114-7","metadata":{"aliases":["14q(II-7)"]}},{"id":"5a41dde85d6648da9892296a0b3e91ee","type":"GENE","name":"SNORD114-8","canonical_id":"hgnc:HGNC:32996","description":"small nucleolar RNA, C/D box 114-8","metadata":{"aliases":["14q(II-8)"]}},{"id":"fa2e526d2ed64118a3c29bc2abed98f6","type":"GENE","name":"SNORD114-9","canonical_id":"hgnc:HGNC:32997","description":"small nucleolar RNA, C/D box 114-9","metadata":{"aliases":["14q(II-9)"]}},{"id":"4bc3b2ba3b8a48b8ad6f3080a4de9d90","type":"GENE","name":"SNORD115-1","canonical_id":"hgnc:HGNC:33020","description":"small nucleolar RNA, C/D box 115-1","metadata":{"aliases":["HBII-52-1"]}},{"id":"9c72e9aad33748f9baa9c0494f4a8aa4","type":"GENE","name":"SNORD115-10","canonical_id":"hgnc:HGNC:33029","description":"small nucleolar RNA, C/D box 115-10","metadata":{"aliases":["HBII-52-10"]}},{"id":"4d1803526c5e40e2a863827d5559a3d0","type":"GENE","name":"SNORD115-11","canonical_id":"hgnc:HGNC:33030","description":"small nucleolar RNA, C/D box 115-11","metadata":{"aliases":["HBII-52-11"]}},{"id":"104f12caba0042159c8b3901d2899b4c","type":"GENE","name":"SNORD115-12","canonical_id":"hgnc:HGNC:33031","description":"small nucleolar RNA, C/D box 115-12","metadata":{"aliases":["HBII-52-12"]}},{"id":"9f11056b519f45299f598f4ef463ed22","type":"GENE","name":"SNORD115-13","canonical_id":"hgnc:HGNC:33032","description":"small nucleolar RNA, C/D box 115-13","metadata":{"aliases":["HBII-52-13"]}},{"id":"e71014445d634e9dbabcc717a4ae6d45","type":"GENE","name":"SNORD115-14","canonical_id":"hgnc:HGNC:33033","description":"small nucleolar RNA, C/D box 115-14","metadata":{"aliases":["HBII-52-14"]}},{"id":"07ae925a39504d4fbc8b2dfec712e3da","type":"GENE","name":"SNORD115-15","canonical_id":"hgnc:HGNC:33034","description":"small nucleolar RNA, C/D box 115-15","metadata":{"aliases":["HBII-52-15"]}},{"id":"8c8b9ce95cb2478883522b9853999b90","type":"GENE","name":"SNORD115-16","canonical_id":"hgnc:HGNC:33035","description":"small nucleolar RNA, C/D box 115-16","metadata":{"aliases":["HBII-52-16"]}},{"id":"82e291431c3c443e9b61c2068c7b4d92","type":"GENE","name":"SNORD115-17","canonical_id":"hgnc:HGNC:33036","description":"small nucleolar RNA, C/D box 115-17","metadata":{"aliases":["HBII-52-17"]}},{"id":"ca9b4992e95f4c50ac26557f5dcf4cae","type":"GENE","name":"SNORD115-18","canonical_id":"hgnc:HGNC:33037","description":"small nucleolar RNA, C/D box 115-18","metadata":{"aliases":["HBII-52-18"]}},{"id":"ed102efb2a704e6da88ffc48343cd0c9","type":"GENE","name":"SNORD115-19","canonical_id":"hgnc:HGNC:33038","description":"small nucleolar RNA, C/D box 115-19","metadata":{"aliases":["HBII-52-19"]}},{"id":"7278e0671d06485ca74345d54090c00e","type":"GENE","name":"SNORD115-2","canonical_id":"hgnc:HGNC:33021","description":"small nucleolar RNA, C/D box 115-2","metadata":{"aliases":["HBII-52-2"]}},{"id":"21b43b7b09154df5970547d8658f3fc4","type":"GENE","name":"SNORD115-20","canonical_id":"hgnc:HGNC:33039","description":"small nucleolar RNA, C/D box 115-20","metadata":{"aliases":["HBII-52-20"]}},{"id":"3be319b0b0d24bad838d09d388a5836e","type":"GENE","name":"SNORD115-21","canonical_id":"hgnc:HGNC:33040","description":"small nucleolar RNA, C/D box 115-21","metadata":{"aliases":["HBII-52-21"]}},{"id":"649817d611e84646b1294a79349ec80d","type":"GENE","name":"SNORD115-22","canonical_id":"hgnc:HGNC:33041","description":"small nucleolar RNA, C/D box 115-22","metadata":{"aliases":["HBII-52-22"]}},{"id":"78ebaf831cf2425b8b6b901324dfbbe4","type":"GENE","name":"SNORD115-23","canonical_id":"hgnc:HGNC:33042","description":"small nucleolar RNA, C/D box 115-23","metadata":{"aliases":["HBII-52-23"]}},{"id":"f3ec99ff98b34b60bdb9667bf35b752e","type":"GENE","name":"SNORD115-24","canonical_id":"hgnc:HGNC:33043","description":"small nucleolar RNA, C/D box 115-24","metadata":{"aliases":["HBII-52-24"]}},{"id":"c810404e1f7c49d28d02b893aa65a997","type":"GENE","name":"SNORD115-25","canonical_id":"hgnc:HGNC:33044","description":"small nucleolar RNA, C/D box 115-25","metadata":{"aliases":["HBII-52-25"]}},{"id":"2f8b96b528594b458b6ee5e2553ddd9d","type":"GENE","name":"SNORD115-26","canonical_id":"hgnc:HGNC:33045","description":"small nucleolar RNA, C/D box 115-26","metadata":{"aliases":["HBII-52-26"]}},{"id":"4343e796a76b4181b9eebb4eb13036ca","type":"GENE","name":"SNORD115-27","canonical_id":"hgnc:HGNC:33046","description":"small nucleolar RNA, C/D box 115-27","metadata":{"aliases":["HBII-52-27"]}},{"id":"c9169c7d442b4cc296d5f1f85d14bd8b","type":"GENE","name":"SNORD115-28","canonical_id":"hgnc:HGNC:33047","description":"small nucleolar RNA, C/D box 115-28","metadata":{"aliases":["HBII-52-28"]}},{"id":"16847a43d8c34704a1a05e02de0d1477","type":"GENE","name":"SNORD115-29","canonical_id":"hgnc:HGNC:33048","description":"small nucleolar RNA, C/D box 115-29","metadata":{"aliases":["HBII-52-29"]}},{"id":"76f54a7cfba54bd891c7f3600bc0de78","type":"GENE","name":"SNORD115-3","canonical_id":"hgnc:HGNC:33022","description":"small nucleolar RNA, C/D box 115-3","metadata":{"aliases":["HBII-52-3"]}},{"id":"dfc87617825e46a69eb6249b218da44d","type":"GENE","name":"SNORD115-30","canonical_id":"hgnc:HGNC:33049","description":"small nucleolar RNA, C/D box 115-30","metadata":{"aliases":["HBII-52-30"]}},{"id":"ed18e7e372664287b8bd93046e22d1c0","type":"GENE","name":"SNORD115-31","canonical_id":"hgnc:HGNC:33050","description":"small nucleolar RNA, C/D box 115-31","metadata":{"aliases":["HBII-52-31"]}},{"id":"d069005ab5b1405f97ee44161254d3f9","type":"GENE","name":"SNORD115-32","canonical_id":"hgnc:HGNC:33051","description":"small nucleolar RNA, C/D box 115-32","metadata":{"aliases":["HBII-52-32"]}},{"id":"7755bb720c31407891c187219c4f1d81","type":"GENE","name":"SNORD115-33","canonical_id":"hgnc:HGNC:33052","description":"small nucleolar RNA, C/D box 115-33","metadata":{"aliases":["HBII-52-33"]}},{"id":"0cd52afc9c0d41159c926d5beec6216e","type":"GENE","name":"SNORD115-34","canonical_id":"hgnc:HGNC:33053","description":"small nucleolar RNA, C/D box 115-34","metadata":{"aliases":["HBII-52-34"]}},{"id":"3a7bead67e164bfdb57556ecfca401aa","type":"GENE","name":"SNORD115-35","canonical_id":"hgnc:HGNC:33054","description":"small nucleolar RNA, C/D box 115-35","metadata":{"aliases":["HBII-52-35"]}},{"id":"9542bbc616c74cd995e09ae0db60c22a","type":"GENE","name":"SNORD115-36","canonical_id":"hgnc:HGNC:33055","description":"small nucleolar RNA, C/D box 115-36","metadata":{"aliases":["HBII-52-36"]}},{"id":"e370b186bc1e426d91ed5e59ee9a22d2","type":"GENE","name":"SNORD115-37","canonical_id":"hgnc:HGNC:33056","description":"small nucleolar RNA, C/D box 115-37","metadata":{"aliases":["HBII-52-37"]}},{"id":"ad7fd9b8e38543afb7bb4560bcfb86c0","type":"GENE","name":"SNORD115-38","canonical_id":"hgnc:HGNC:33057","description":"small nucleolar RNA, C/D box 115-38","metadata":{"aliases":["HBII-52-38"]}},{"id":"768187ba6f10406f8f827f06a6c36cbe","type":"GENE","name":"SNORD115-39","canonical_id":"hgnc:HGNC:33058","description":"small nucleolar RNA, C/D box 115-39","metadata":{"aliases":["HBII-52-39"]}},{"id":"2561b351d7c24bf583dbfe191dac1e04","type":"GENE","name":"SNORD115-4","canonical_id":"hgnc:HGNC:33023","description":"small nucleolar RNA, C/D box 115-4","metadata":{"aliases":["HBII-52-4"]}},{"id":"2810d0b58fc14e49a80a730c67cf60b2","type":"GENE","name":"SNORD115-40","canonical_id":"hgnc:HGNC:33059","description":"small nucleolar RNA, C/D box 115-40","metadata":{"aliases":["HBII-52-40"]}},{"id":"443e2427553a48e8ae90d6edc9294409","type":"GENE","name":"SNORD115-41","canonical_id":"hgnc:HGNC:33060","description":"small nucleolar RNA, C/D box 115-41","metadata":{"aliases":["HBII-52-41"]}},{"id":"aae53cf12a8b474693fc97bd99c9a865","type":"GENE","name":"SNORD115-42","canonical_id":"hgnc:HGNC:33061","description":"small nucleolar RNA, C/D box 115-42","metadata":{"aliases":["HBII-52-42"]}},{"id":"24ce6b6be4c54754a2f12cc8ecb8c19f","type":"GENE","name":"SNORD115-43","canonical_id":"hgnc:HGNC:33062","description":"small nucleolar RNA, C/D box 115-43","metadata":{"aliases":["HBII-52-43"]}},{"id":"02b7f106f71d44dcb980bf2dfc463ff7","type":"GENE","name":"SNORD115-44","canonical_id":"hgnc:HGNC:33063","description":"small nucleolar RNA, C/D box 115-44","metadata":{"aliases":["HBII-52-44"]}},{"id":"8f4659f9f48c4ba386a9b25cf89df926","type":"GENE","name":"SNORD115-45","canonical_id":"hgnc:HGNC:33064","description":"small nucleolar RNA, C/D box 115-45","metadata":{"aliases":["HBII-52-45","SNORD115-48"]}},{"id":"9ffc082294624057b9f967cfa9409445","type":"GENE","name":"SNORD115-46","canonical_id":"hgnc:HGNC:42798","description":"small nucleolar RNA, C/D box 115-46","metadata":{"aliases":["HBII-52-46"]}},{"id":"309a5ddb2e304425a8f47fca8da6a125","type":"GENE","name":"SNORD115-47","canonical_id":"hgnc:HGNC:33065","description":"small nucleolar RNA, C/D box 115-47","metadata":{"aliases":["HBII-52-47"]}},{"id":"3278263f18d44437a3384acdc5086a1b","type":"GENE","name":"SNORD115-48","canonical_id":"hgnc:HGNC:33343","description":"small nucleolar RNA, C/D box 115-48","metadata":{"aliases":["HBII-52-48"]}},{"id":"23f07d2143bd4cdbaef93e633c046381","type":"GENE","name":"SNORD115-5","canonical_id":"hgnc:HGNC:33024","description":"small nucleolar RNA, C/D box 115-5","metadata":{"aliases":["HBII-52-5"]}},{"id":"8fd30ae7c5db4c91b633f3f61bf97d66","type":"GENE","name":"SNORD115-6","canonical_id":"hgnc:HGNC:33025","description":"small nucleolar RNA, C/D box 115-6","metadata":{"aliases":["HBII-52-6"]}},{"id":"7a38e15e41eb4578b6e892e3e879ef52","type":"GENE","name":"SNORD115-7","canonical_id":"hgnc:HGNC:33026","description":"small nucleolar RNA, C/D box 115-7","metadata":{"aliases":["HBII-52-7"]}},{"id":"b4e388f4e2024720991c6bee348ac14e","type":"GENE","name":"SNORD115-8","canonical_id":"hgnc:HGNC:33027","description":"small nucleolar RNA, C/D box 115-8","metadata":{"aliases":["HBII-52-8"]}},{"id":"e554879c385f4a75b29d752aff8d6b1d","type":"GENE","name":"SNORD115-9","canonical_id":"hgnc:HGNC:33028","description":"small nucleolar RNA, C/D box 115-9","metadata":{"aliases":["HBII-52-9"]}},{"id":"dc999795b9ab42948179a4918c149513","type":"GENE","name":"SNORD116-1","canonical_id":"hgnc:HGNC:33067","description":"small nucleolar RNA, C/D box 116-1","metadata":{"aliases":["HBII-85-1"]}},{"id":"c9ee0681c0344b168940d94485e82db5","type":"GENE","name":"SNORD116-10","canonical_id":"hgnc:HGNC:33076","description":"small nucleolar RNA, C/D box 116-10","metadata":{"aliases":["HBII-85-10"]}},{"id":"d2ec41e088d84f81bdc86c9e37c5fb0c","type":"GENE","name":"SNORD116-11","canonical_id":"hgnc:HGNC:33077","description":"small nucleolar RNA, C/D box 116-11","metadata":{"aliases":["HBII-85-11"]}},{"id":"3eff10f440924620954d9a6d708f6ceb","type":"GENE","name":"SNORD116-12","canonical_id":"hgnc:HGNC:33078","description":"small nucleolar RNA, C/D box 116-12","metadata":{"aliases":["HBII-85-12"]}},{"id":"d31a852b1b4c4dbb971512e5dc948deb","type":"GENE","name":"SNORD116-13","canonical_id":"hgnc:HGNC:33079","description":"small nucleolar RNA, C/D box 116-13","metadata":{"aliases":["HBII-85-13"]}},{"id":"91e6fea89619468297d4247824a1755e","type":"GENE","name":"SNORD116-14","canonical_id":"hgnc:HGNC:33080","description":"small nucleolar RNA, C/D box 116-14","metadata":{"aliases":["HBII-85-14"]}},{"id":"9b1adfcf781e4342a0dd326c92a2f6ba","type":"GENE","name":"SNORD116-15","canonical_id":"hgnc:HGNC:33081","description":"small nucleolar RNA, C/D box 116-15","metadata":{"aliases":["HBII-85-15"]}},{"id":"aefb97950ad14168b60d5ef7fb14b7a4","type":"GENE","name":"SNORD116-16","canonical_id":"hgnc:HGNC:33082","description":"small nucleolar RNA, C/D box 116-16","metadata":{"aliases":["HBII-85-16"]}},{"id":"8826948458cc45ff92a11879100408d6","type":"GENE","name":"SNORD116-17","canonical_id":"hgnc:HGNC:33083","description":"small nucleolar RNA, C/D box 116-17","metadata":{"aliases":["HBII-85-17"]}},{"id":"518b54f2cf314520822eafe7c621615c","type":"GENE","name":"SNORD116-18","canonical_id":"hgnc:HGNC:33084","description":"small nucleolar RNA, C/D box 116-18","metadata":{"aliases":["HBII-85-18"]}},{"id":"dfc25840e66a4e25bd7213d38d8d21e6","type":"GENE","name":"SNORD116-19","canonical_id":"hgnc:HGNC:33085","description":"small nucleolar RNA, C/D box 116-19","metadata":{"aliases":["HBII-85-19"]}},{"id":"3dd3b9abc3e84032aac0b0f3bbce0e5f","type":"GENE","name":"SNORD116-2","canonical_id":"hgnc:HGNC:33068","description":"small nucleolar RNA, C/D box 116-2","metadata":{"aliases":["HBII-85-2"]}},{"id":"d6e0d1ed827d4319b8e9bab392163e04","type":"GENE","name":"SNORD116-20","canonical_id":"hgnc:HGNC:33086","description":"small nucleolar RNA, C/D box 116-20","metadata":{"aliases":["HBII-85-20"]}},{"id":"0dcd8af4e9324500a1b51a70e126a977","type":"GENE","name":"SNORD116-21","canonical_id":"hgnc:HGNC:33087","description":"small nucleolar RNA, C/D box 116-21","metadata":{"aliases":["HBII-85-21"]}},{"id":"14e6a02d8241484e84a38d76d248fd07","type":"GENE","name":"SNORD116-22","canonical_id":"hgnc:HGNC:33088","description":"small nucleolar RNA, C/D box 116-22","metadata":{"aliases":["HBII-85-22"]}},{"id":"2c7ae254d3f74ebbaa9a434356814c6a","type":"GENE","name":"SNORD116-23","canonical_id":"hgnc:HGNC:33089","description":"small nucleolar RNA, C/D box 116-23","metadata":{"aliases":["HBII-85-23"]}},{"id":"9bfb459fd32447ac83843dfc2af69e48","type":"GENE","name":"SNORD116-24","canonical_id":"hgnc:HGNC:33090","description":"small nucleolar RNA, C/D box 116-24","metadata":{"aliases":["HBII-85-24"]}},{"id":"c61ae61d498b40d786f64d0fd7c1df47","type":"GENE","name":"SNORD116-25","canonical_id":"hgnc:HGNC:33091","description":"small nucleolar RNA, C/D box 116-25","metadata":{"aliases":["HBII-85-25"]}},{"id":"3c5a8d5a44204ab998b9a0e44205a333","type":"GENE","name":"SNORD116-26","canonical_id":"hgnc:HGNC:33092","description":"small nucleolar RNA, C/D box 116-26","metadata":{"aliases":["HBII-85-26"]}},{"id":"8ddbb1fdb16e459faa806ebe80cf11ea","type":"GENE","name":"SNORD116-27","canonical_id":"hgnc:HGNC:33093","description":"small nucleolar RNA, C/D box 116-27","metadata":{"aliases":["HBII-85-27"]}},{"id":"fca01259c88d4b2eaadfe2c7e61a8d16","type":"GENE","name":"SNORD116-28","canonical_id":"hgnc:HGNC:33347","description":"small nucleolar RNA, C/D box 116-28","metadata":{"aliases":["HBII-85-28"]}},{"id":"7f84f313ec634124aad3edef12ba8bdd","type":"GENE","name":"SNORD116-29","canonical_id":"hgnc:HGNC:33348","description":"small nucleolar RNA, C/D box 116-29","metadata":{"aliases":["HBII-85-29"]}},{"id":"edfdce56737240d6bc1089dea1341baf","type":"GENE","name":"SNORD116-3","canonical_id":"hgnc:HGNC:33069","description":"small nucleolar RNA, C/D box 116-3","metadata":{"aliases":["HBII-85-3"]}},{"id":"3a1b2c6c0ad24f5bbaef60890696f132","type":"GENE","name":"SNORD116-30","canonical_id":"hgnc:HGNC:42797","description":"small nucleolar RNA, C/D box 116-30","metadata":{"aliases":["HBII-85-30"]}},{"id":"b3f5bf0ac2354304aec553329f8a26dc","type":"GENE","name":"SNORD116-4","canonical_id":"hgnc:HGNC:33070","description":"small nucleolar RNA, C/D box 116-4","metadata":{"aliases":["HBII-85-4"]}},{"id":"82b9059a4752436b9b278557d557491b","type":"GENE","name":"SNORD116-5","canonical_id":"hgnc:HGNC:33071","description":"small nucleolar RNA, C/D box 116-5","metadata":{"aliases":["HBII-85-5"]}},{"id":"f8ad9ca180834332878ed9bcc4e213d4","type":"GENE","name":"SNORD116-6","canonical_id":"hgnc:HGNC:33072","description":"small nucleolar RNA, C/D box 116-6","metadata":{"aliases":["HBII-85-6"]}},{"id":"3aac5077deb448ceace67a5dbc6e79a4","type":"GENE","name":"SNORD116-7","canonical_id":"hgnc:HGNC:33073","description":"small nucleolar RNA, C/D box 116-7","metadata":{"aliases":["HBII-85-7"]}},{"id":"983aeb872cec4e16b578442ce07bb089","type":"GENE","name":"SNORD116-8","canonical_id":"hgnc:HGNC:33074","description":"small nucleolar RNA, C/D box 116-8","metadata":{"aliases":["HBII-85-8"]}},{"id":"d84a8538b68f4a62ab5ad3a87998f7b2","type":"GENE","name":"SNORD116-9","canonical_id":"hgnc:HGNC:33075","description":"small nucleolar RNA, C/D box 116-9","metadata":{"aliases":["HBII-85-9"]}},{"id":"16657888f649408db969612bd87607dd","type":"GENE","name":"SNORD117","canonical_id":"hgnc:HGNC:32742","description":"small nucleolar RNA, C/D box 117","metadata":{"aliases":["U83"]}},{"id":"955db71ece0049fea89d1f6c77f2f63d","type":"GENE","name":"SNORD118","canonical_id":"hgnc:HGNC:32952","description":"small nucleolar RNA, C/D box 118","metadata":{"aliases":["U8"]}},{"id":"8af6021e28124751a73ed5b94f78bc41","type":"GENE","name":"SNORD119","canonical_id":"hgnc:HGNC:33558","description":"small nucleolar RNA, C/D box 119","metadata":null},{"id":"3e7df41b2c6549e5974fa754a6b87b93","type":"GENE","name":"SNORD11B","canonical_id":"hgnc:HGNC:33571","description":"small nucleolar RNA, C/D box 11B","metadata":null},{"id":"e46052d05b8a461db74504f6c945afe3","type":"GENE","name":"SNORD12","canonical_id":"hgnc:HGNC:32708","description":"small nucleolar RNA, C/D box 12","metadata":{"aliases":["HBII-99","hsa-mir-1259","MIR1259","MIRN1259"]}},{"id":"2fdee36836bf4d30ab631571ad1a0267","type":"GENE","name":"SNORD121A","canonical_id":"hgnc:HGNC:33560","description":"small nucleolar RNA, C/D box 121A","metadata":null},{"id":"c33b711b51584019b9a59f869730aea0","type":"GENE","name":"SNORD121B","canonical_id":"hgnc:HGNC:33569","description":"small nucleolar RNA, C/D box 121B","metadata":null},{"id":"424210404a024cfb8060ed3d403b0619","type":"GENE","name":"SNORD123","canonical_id":"hgnc:HGNC:33562","description":"small nucleolar RNA, C/D box 123","metadata":null},{"id":"f6eafac5f0244b338f43bbc6708d9d1b","type":"GENE","name":"SNORD124","canonical_id":"hgnc:HGNC:33563","description":"small nucleolar RNA, C/D box 124","metadata":null},{"id":"8249e56e709e4c9d90df45884974c869","type":"GENE","name":"SNORD125","canonical_id":"hgnc:HGNC:33564","description":"small nucleolar RNA, C/D box 125","metadata":null},{"id":"fd560d6664284391a92e6414822be80b","type":"GENE","name":"SNORD126","canonical_id":"hgnc:HGNC:33565","description":"small nucleolar RNA, C/D box 126","metadata":{"aliases":["hsa-mir-1201","MIR1201","MIRN1201"]}},{"id":"3f7e6afb52004f50955b8abe7f813262","type":"GENE","name":"SNORD127","canonical_id":"hgnc:HGNC:33555","description":"small nucleolar RNA, C/D box 127","metadata":null},{"id":"16d754cacdc146b8a0bdac0c434741d7","type":"GENE","name":"SNORD128","canonical_id":"hgnc:HGNC:50409","description":"small nucleolar RNA, C/D box 128","metadata":{"aliases":["ZL43"]}},{"id":"f305cabac72f4f7db7b5aac412518920","type":"GENE","name":"SNORD129","canonical_id":"hgnc:HGNC:50410","description":"small nucleolar RNA, C/D box 129","metadata":null},{"id":"866f44b127e34d0b8ec7428c97fd997b","type":"GENE","name":"SNORD12B","canonical_id":"hgnc:HGNC:33573","description":"small nucleolar RNA, C/D box 12B","metadata":null},{"id":"d3228272311b462198685f96b9492cb2","type":"GENE","name":"SNORD12C","canonical_id":"hgnc:HGNC:10105","description":"small nucleolar RNA, C/D box 12C","metadata":{"aliases":["U106","RNU106","SNORD106"]}},{"id":"2d8b8b3f5bd04efb851659293331ceaa","type":"GENE","name":"SNORD13","canonical_id":"hgnc:HGNC:32711","description":"small nucleolar RNA, C/D box 13","metadata":{"aliases":["U13","RNU13","SNORD13A"]}},{"id":"dbf21c6fc2b34a3097515ea28567e6cf","type":"GENE","name":"SNORD130","canonical_id":"hgnc:HGNC:50411","description":"small nucleolar RNA, C/D box 130","metadata":null},{"id":"3ff65c27bcaf4ec4bcbff2438554e45a","type":"GENE","name":"SNORD131","canonical_id":"hgnc:HGNC:50412","description":"small nucleolar RNA, C/D box 131","metadata":null},{"id":"76ba47c322f543d3919377ce8d10655f","type":"GENE","name":"SNORD132","canonical_id":"hgnc:HGNC:50413","description":"small nucleolar RNA, C/D box 132","metadata":null},{"id":"ca4d6e96e0f84c8a9ea5fd218221398e","type":"GENE","name":"SNORD133","canonical_id":"hgnc:HGNC:50414","description":"small nucleolar RNA, C/D box 133","metadata":{"aliases":["ZL42","ggn68"]}},{"id":"1bd4195f37d04a01985cd12d6ff6a44a","type":"GENE","name":"SNORD134","canonical_id":"hgnc:HGNC:50415","description":"small nucleolar RNA, C/D box 134","metadata":{"aliases":["ZL12"]}},{"id":"2a9465810c1246a7964622c19e024069","type":"GENE","name":"SNORD135","canonical_id":"hgnc:HGNC:50416","description":"small nucleolar RNA, C/D box 135","metadata":{"aliases":["ZL2"]}},{"id":"5a4d8948496d46d3ba9af5cd8d83239d","type":"GENE","name":"SNORD136","canonical_id":"hgnc:HGNC:50417","description":"small nucleolar RNA, C/D box 136","metadata":{"aliases":["ZL26"]}},{"id":"ca751aae0ea749c18fe5209354919e34","type":"GENE","name":"SNORD137","canonical_id":"hgnc:HGNC:50419","description":"small nucleolar RNA, C/D box 137","metadata":null},{"id":"d09184e58e4b41ecb58bc3239422c0e3","type":"GENE","name":"SNORD138","canonical_id":"hgnc:HGNC:50420","description":"small nucleolar RNA, C/D box 138","metadata":{"aliases":["hsa-mir-3607","MIR3607"]}},{"id":"3baaa53c2f274865ae7e53608f6d1cd4","type":"GENE","name":"SNORD139","canonical_id":"hgnc:HGNC:50421","description":"small nucleolar RNA, C/D box 139","metadata":null},{"id":"d5d089892dab461d97321a198597e759","type":"GENE","name":"SNORD13B-1","canonical_id":"hgnc:HGNC:52250","description":"small nucleolar RNA, C/D box 13B-1","metadata":null},{"id":"a15d5723d2c84298a3f602a67dd2e574","type":"GENE","name":"SNORD13B-2","canonical_id":"hgnc:HGNC:52251","description":"small nucleolar RNA, C/D box 13B-2","metadata":null},{"id":"b2b2b4ea04f848a099a4a16377b78b23","type":"GENE","name":"SNORD13C","canonical_id":"hgnc:HGNC:52252","description":"small nucleolar RNA, C/D box 13C","metadata":null},{"id":"bbaa133840f241a39abaa8c3a7e67004","type":"GENE","name":"SNORD13D","canonical_id":"hgnc:HGNC:52253","description":"small nucleolar RNA, C/D box 13D","metadata":null},{"id":"93c2e358762e4728a264e0f5871da12c","type":"GENE","name":"SNORD13E","canonical_id":"hgnc:HGNC:52254","description":"small nucleolar RNA, C/D box 13E","metadata":null},{"id":"85a43155a52d460bae3d999d3df480c5","type":"GENE","name":"SNORD13F","canonical_id":"hgnc:HGNC:52245","description":"small nucleolar RNA, C/D box 13F","metadata":null},{"id":"4d1372dba7b74500a8c8bf09f8ce941a","type":"GENE","name":"SNORD13G","canonical_id":"hgnc:HGNC:52246","description":"small nucleolar RNA, C/D box 13G","metadata":null},{"id":"251d25d29b1041eebe14737aab2e634a","type":"GENE","name":"SNORD13H","canonical_id":"hgnc:HGNC:52247","description":"small nucleolar RNA, C/D box 13H","metadata":null},{"id":"fe251f745cf24c468e7d7bfb98b7adf6","type":"GENE","name":"SNORD13I","canonical_id":"hgnc:HGNC:52248","description":"small nucleolar RNA, C/D box 13I","metadata":null},{"id":"cffdb0dd26cb4ddba43b66c35ef1dd7a","type":"GENE","name":"SNORD13J","canonical_id":"hgnc:HGNC:52249","description":"small nucleolar RNA, C/D box 13J","metadata":{"aliases":["SNORD13P3"]}},{"id":"d3c865e1b3fe406f8554fd6b58ce4ab7","type":"GENE","name":"SNORD13P1","canonical_id":"hgnc:HGNC:10110","description":"small nucleolar RNA, C/D box 13 pseudogene 1","metadata":{"aliases":["U13","U13.32A","RNU13P1"]}},{"id":"81d9ef8f7f1f4d2eb25c23b4ab73be01","type":"GENE","name":"SNORD13P2","canonical_id":"hgnc:HGNC:10111","description":"small nucleolar RNA, C/D box 13 pseudogene 2","metadata":{"aliases":["U13","U13.12A","RNU13P2"]}},{"id":"0c2d89a6caee40faba39e309cb13bd02","type":"GENE","name":"SNORD140","canonical_id":"hgnc:HGNC:51405","description":"small nucleolar RNA, C/D box 140","metadata":null},{"id":"e10f7849234c406d815b57868c4722cf","type":"GENE","name":"SNORD141A","canonical_id":"hgnc:HGNC:51406","description":"small nucleolar RNA, C/D box 141A","metadata":null},{"id":"e5044875c0c34a5e85a8269b77ed24c7","type":"GENE","name":"SNORD141B","canonical_id":"hgnc:HGNC:51407","description":"small nucleolar RNA, C/D box 141B","metadata":null},{"id":"4a531e79162d4ab6af129e5d28e0ac2f","type":"GENE","name":"SNORD142","canonical_id":"hgnc:HGNC:50389","description":"small nucleolar RNA, C/D box 142","metadata":{"aliases":["ZL68","SNORA85","SNORD174"]}},{"id":"08352472232e41e3bf9a9a3b8d21c1c2","type":"GENE","name":"SNORD143","canonical_id":"hgnc:HGNC:50400","description":"small nucleolar RNA, C/D box 143","metadata":{"aliases":["ZL5","SNORA96","SNORD171"]}},{"id":"f60a47c8045343838924b411bd8f070d","type":"GENE","name":"SNORD144","canonical_id":"hgnc:HGNC:50401","description":"small nucleolar RNA, C/D box 144","metadata":{"aliases":["ZL6","SNORA97"]}},{"id":"3c6fc685d3db46e7a9841aac31784e6a","type":"GENE","name":"SNORD145","canonical_id":"hgnc:HGNC:51859","description":"small nucleolar RNA, C/D box 145","metadata":null},{"id":"e02ef8feac584181bfb293f14ecd63b5","type":"GENE","name":"SNORD146","canonical_id":"hgnc:HGNC:51860","description":"small nucleolar RNA, C/D box 146","metadata":null},{"id":"df6440f2f0cd4a998e5341b9c324fa34","type":"GENE","name":"SNORD147","canonical_id":"hgnc:HGNC:51861","description":"small nucleolar RNA, C/D box 147","metadata":null},{"id":"636f698ea2854a51b000e4c2c973e332","type":"GENE","name":"SNORD148","canonical_id":"hgnc:HGNC:51862","description":"small nucleolar RNA, C/D box 148","metadata":null},{"id":"4e33bf1798b0436d99142d35c8d49a5f","type":"GENE","name":"SNORD149","canonical_id":"hgnc:HGNC:51863","description":"small nucleolar RNA, C/D box 149","metadata":null},{"id":"c34d077420c24331877e15b60475195a","type":"GENE","name":"SNORD14A","canonical_id":"hgnc:HGNC:10113","description":"small nucleolar RNA, C/D box 14A","metadata":{"aliases":["U14","RNU14A","RNU14"]}},{"id":"2c7bfb5e2baf4dbeb7e091b410d255d2","type":"GENE","name":"SNORD14B","canonical_id":"hgnc:HGNC:31803","description":"small nucleolar RNA, C/D box 14B","metadata":{"aliases":["U14B","U14","RNU14B"]}},{"id":"7de7dde337d741d996d969e6ab701ac8","type":"GENE","name":"SNORD14C","canonical_id":"hgnc:HGNC:30352","description":"small nucleolar RNA, C/D box 14C","metadata":null},{"id":"cc5d57adde324298ac14035aededa672","type":"GENE","name":"SNORD14D","canonical_id":"hgnc:HGNC:30353","description":"small nucleolar RNA, C/D box 14D","metadata":null},{"id":"f7ffdc5cc55c44fcad3f7cc7676f14fb","type":"GENE","name":"SNORD14E","canonical_id":"hgnc:HGNC:30354","description":"small nucleolar RNA, C/D box 14E","metadata":null},{"id":"9dd7081a9cdc4f12b309d60c5734be6b","type":"GENE","name":"SNORD150","canonical_id":"hgnc:HGNC:51864","description":"small nucleolar RNA, C/D box 150","metadata":null},{"id":"182f3ca2f34a410da4567404a58e4c49","type":"GENE","name":"SNORD151","canonical_id":"hgnc:HGNC:51865","description":"small nucleolar RNA, C/D box 151","metadata":null},{"id":"b9904ecbe2ad4c7faffb9a8c05c6624c","type":"GENE","name":"SNORD152","canonical_id":"hgnc:HGNC:51866","description":"small nucleolar RNA, C/D box 152","metadata":null},{"id":"8bfa26df85ba46a2ac6a1bc445e9ca2f","type":"GENE","name":"SNORD153","canonical_id":"hgnc:HGNC:51867","description":"small nucleolar RNA, C/D box 153","metadata":null},{"id":"9ea17499fa224d0cb1a5eff56c03084d","type":"GENE","name":"SNORD154","canonical_id":"hgnc:HGNC:51868","description":"small nucleolar RNA, C/D box 154","metadata":null},{"id":"6b2139cf08e7404b88a494b1c2891dcb","type":"GENE","name":"SNORD155","canonical_id":"hgnc:HGNC:51869","description":"small nucleolar RNA, C/D box 155","metadata":null},{"id":"47b43aa063d64cd39c147b9841d41e23","type":"GENE","name":"SNORD156","canonical_id":"hgnc:HGNC:51870","description":"small nucleolar RNA, C/D box 156","metadata":null},{"id":"f4b3e99a272d49749e3f752936f62e2f","type":"GENE","name":"SNORD157","canonical_id":"hgnc:HGNC:51871","description":"small nucleolar RNA, C/D box 157","metadata":null},{"id":"04a102fb50da4721b588e0321c44984b","type":"GENE","name":"SNORD158","canonical_id":"hgnc:HGNC:51872","description":"small nucleolar RNA, C/D box 158","metadata":null},{"id":"b6c50f3e3045453c942f1add114f354b","type":"GENE","name":"SNORD159","canonical_id":"hgnc:HGNC:51873","description":"small nucleolar RNA, C/D box 159","metadata":null},{"id":"5621344a21b94b11bb1c521d0174631d","type":"GENE","name":"SNORD15A","canonical_id":"hgnc:HGNC:10114","description":"small nucleolar RNA, C/D box 15A","metadata":{"aliases":["U15A","RNU15A"]}},{"id":"21ca06bff94e40e8ab7384d3c12c53b1","type":"GENE","name":"SNORD15B","canonical_id":"hgnc:HGNC:16649","description":"small nucleolar RNA, C/D box 15B","metadata":{"aliases":["U15B","RNU15B"]}},{"id":"131f84db504448109cdf9b6e2fb080fe","type":"GENE","name":"SNORD16","canonical_id":"hgnc:HGNC:32712","description":"small nucleolar RNA, C/D box 16","metadata":{"aliases":["U16"]}},{"id":"6e030bb7627a4e76a9ed7e226a6e4d7d","type":"GENE","name":"SNORD160","canonical_id":"hgnc:HGNC:51874","description":"small nucleolar RNA, C/D box 160","metadata":null},{"id":"213572cbcb4a4ae8b9633cf408fad52a","type":"GENE","name":"SNORD161","canonical_id":"hgnc:HGNC:51875","description":"small nucleolar RNA, C/D box 161","metadata":null},{"id":"e63283aa3de3465ba07139b35866b6eb","type":"GENE","name":"SNORD162","canonical_id":"hgnc:HGNC:51876","description":"small nucleolar RNA, C/D box 162","metadata":null},{"id":"e1810d537aa245cb915847772e3e0405","type":"GENE","name":"SNORD163","canonical_id":"hgnc:HGNC:51877","description":"small nucleolar RNA, C/D box 163","metadata":null},{"id":"0557a443d98d40b887ca4f333283e03b","type":"GENE","name":"SNORD164","canonical_id":"hgnc:HGNC:51878","description":"small nucleolar RNA, C/D box 164","metadata":null},{"id":"b21b228f4dc3481abb2a49e693383368","type":"GENE","name":"SNORD165","canonical_id":"hgnc:HGNC:51879","description":"small nucleolar RNA, C/D box 165","metadata":null},{"id":"6a4c2d609b344eddbae724fa2bb34e40","type":"GENE","name":"SNORD166","canonical_id":"hgnc:HGNC:51880","description":"small nucleolar RNA, C/D box 166","metadata":null},{"id":"cbbeba8acbb2400cbf92411d7a184019","type":"GENE","name":"SNORD167","canonical_id":"hgnc:HGNC:51881","description":"small nucleolar RNA, C/D box 167","metadata":null},{"id":"49584fc0d6134194a1fec22390eb95d5","type":"GENE","name":"SNORD168","canonical_id":"hgnc:HGNC:51882","description":"small nucleolar RNA, C/D box 168","metadata":null},{"id":"64557decc497463ea095943fe01d3c24","type":"GENE","name":"SNORD169","canonical_id":"hgnc:HGNC:51883","description":"small nucleolar RNA, C/D box 169","metadata":null},{"id":"f37fe474b9fe448384ffe16041f6b42a","type":"GENE","name":"SNORD17","canonical_id":"hgnc:HGNC:32713","description":"small nucleolar RNA, C/D box 17","metadata":{"aliases":["HBI-43"]}},{"id":"ddb3606cca2e4be99ab9a1d502fc2b0b","type":"GENE","name":"SNORD170","canonical_id":"hgnc:HGNC:51884","description":"small nucleolar RNA, C/D box 170","metadata":null},{"id":"a40cc512bbbc4a4b82d73f0d1dee2ea1","type":"GENE","name":"SNORD172","canonical_id":"hgnc:HGNC:51886","description":"small nucleolar RNA, C/D box 172","metadata":null},{"id":"5c68835bb6754990801aba0f123f2c86","type":"GENE","name":"SNORD173","canonical_id":"hgnc:HGNC:51887","description":"small nucleolar RNA, C/D box 173","metadata":null},{"id":"40e26640659841f7a5b274a7da01056a","type":"GENE","name":"SNORD175","canonical_id":"hgnc:HGNC:51889","description":"small nucleolar RNA, C/D box 175","metadata":null},{"id":"7f6c88ddd07148dcabbf5485e6c1515e","type":"GENE","name":"SNORD18A","canonical_id":"hgnc:HGNC:32714","description":"small nucleolar RNA, C/D box 18A","metadata":{"aliases":["U18A"]}},{"id":"3a4a502395ea447890757126e03f8839","type":"GENE","name":"SNORD18B","canonical_id":"hgnc:HGNC:32715","description":"small nucleolar RNA, C/D box 18B","metadata":{"aliases":["U18B"]}},{"id":"1874986ae80f46668ca940915baebb79","type":"GENE","name":"SNORD18C","canonical_id":"hgnc:HGNC:32716","description":"small nucleolar RNA, C/D box 18C","metadata":{"aliases":["U18C"]}},{"id":"9bb8e87c30b94d248d720d1ad086c0d9","type":"GENE","name":"SNORD19","canonical_id":"hgnc:HGNC:32717","description":"small nucleolar RNA, C/D box 19","metadata":{"aliases":["HBII-108"]}},{"id":"d8f57a33ceb74f109c6c2a523f1fb7fb","type":"GENE","name":"SNORD19B","canonical_id":"hgnc:HGNC:33570","description":"small nucleolar RNA, C/D box 19B","metadata":null},{"id":"d9d499d633b34a06b6d9adf06306b576","type":"GENE","name":"SNORD19C","canonical_id":"hgnc:HGNC:52224","description":"small nucleolar RNA, C/D box 19C","metadata":null},{"id":"c0694e0f31f6486890af538dfd439af2","type":"GENE","name":"SNORD1A","canonical_id":"hgnc:HGNC:32556","description":"small nucleolar RNA, C/D box 1A","metadata":{"aliases":["R38A","snR38A"]}},{"id":"136c488568234cf0af06c431c9b69fff","type":"GENE","name":"SNORD1B","canonical_id":"hgnc:HGNC:32676","description":"small nucleolar RNA, C/D box 1B","metadata":{"aliases":["R38B","snR38B"]}},{"id":"aac60668227c4947b134cfaaa9d9c09d","type":"GENE","name":"SNORD1C","canonical_id":"hgnc:HGNC:32677","description":"small nucleolar RNA, C/D box 1C","metadata":{"aliases":["R38C","snR38C"]}},{"id":"4dad4deee7614a4899345fa3b18828e3","type":"GENE","name":"SNORD2","canonical_id":"hgnc:HGNC:32678","description":"small nucleolar RNA, C/D box 2","metadata":{"aliases":["R39B","snR39B"]}},{"id":"833f3fd3259544ef824c9d6ee9a863ca","type":"GENE","name":"SNORD20","canonical_id":"hgnc:HGNC:10143","description":"small nucleolar RNA, C/D box 20","metadata":{"aliases":["U20","RNU20"]}},{"id":"3652cab8803f4c1fbf270c304942d062","type":"GENE","name":"SNORD21","canonical_id":"hgnc:HGNC:10144","description":"small nucleolar RNA, C/D box 21","metadata":{"aliases":["U21","RNU21"]}},{"id":"286d314bb44447ddbef481c936d6e3a4","type":"GENE","name":"SNORD22","canonical_id":"hgnc:HGNC:10145","description":"small nucleolar RNA, C/D box 22","metadata":{"aliases":["U22","RNU22"]}},{"id":"4641c6742f454dd4ae39c6dc38b2ae4b","type":"GENE","name":"SNORD23","canonical_id":"hgnc:HGNC:32718","description":"small nucleolar RNA, C/D box 23","metadata":{"aliases":["HBII-115"]}},{"id":"3edfc5a635f346a4ac253f3adaf680f1","type":"GENE","name":"SNORD24","canonical_id":"hgnc:HGNC:10146","description":"small nucleolar RNA, C/D box 24","metadata":{"aliases":["U24","RNU24"]}},{"id":"8c8c31b1d4524ae3a424d10f00d7edd2","type":"GENE","name":"SNORD25","canonical_id":"hgnc:HGNC:10147","description":"small nucleolar RNA, C/D box 25","metadata":{"aliases":["U25","RNU25"]}},{"id":"c928f14782584ceab36d67796efbf315","type":"GENE","name":"SNORD26","canonical_id":"hgnc:HGNC:10148","description":"small nucleolar RNA, C/D box 26","metadata":{"aliases":["U26","RNU26"]}},{"id":"71df798d5c07468b9fd231a30b2b45c3","type":"GENE","name":"SNORD27","canonical_id":"hgnc:HGNC:10149","description":"small nucleolar RNA, C/D box 27","metadata":{"aliases":["U27","RNU27"]}},{"id":"9370853693764f799279f95553f297fb","type":"GENE","name":"SNORD28","canonical_id":"hgnc:HGNC:10150","description":"small nucleolar RNA, C/D box 28","metadata":{"aliases":["U28","SNORD28A","RNU28"]}},{"id":"7c9ac489bbd8491ab06e1ca72201fc6e","type":"GENE","name":"SNORD28B","canonical_id":"hgnc:HGNC:52225","description":"small nucleolar RNA, C/D box 28B","metadata":null},{"id":"0ab56f315541497a8b72e331dee0bf12","type":"GENE","name":"SNORD29","canonical_id":"hgnc:HGNC:10151","description":"small nucleolar RNA, C/D box 29","metadata":{"aliases":["U29","RNU29"]}},{"id":"b6b92fe849c644b197e5187e5dd083a7","type":"GENE","name":"SNORD30","canonical_id":"hgnc:HGNC:10157","description":"small nucleolar RNA, C/D box 30","metadata":{"aliases":["U30","RNU30"]}},{"id":"c8efb3b25fea4141b69095e6b4a796cb","type":"GENE","name":"SNORD31","canonical_id":"hgnc:HGNC:10158","description":"small nucleolar RNA, C/D box 31","metadata":{"aliases":["U31","SNORD31A","RNU31"]}},{"id":"ed2999f5d8cc49d19b75f8a019be094c","type":"GENE","name":"SNORD31B","canonical_id":"hgnc:HGNC:52226","description":"small nucleolar RNA, C/D box 31B","metadata":null},{"id":"d5dac9e1ce6e45888620c997d73cc6a8","type":"GENE","name":"SNORD32A","canonical_id":"hgnc:HGNC:10159","description":"small nucleolar RNA, C/D box 32A","metadata":{"aliases":["U32","U32A","RNU32"]}},{"id":"d410b45784af45fe9496818dc43210c6","type":"GENE","name":"SNORD32B","canonical_id":"hgnc:HGNC:32719","description":"small nucleolar RNA, C/D box 32B","metadata":{"aliases":["U32B"]}},{"id":"5ce057e9a5244d25ad7f784496b92079","type":"GENE","name":"SNORD33","canonical_id":"hgnc:HGNC:10160","description":"small nucleolar RNA, C/D box 33","metadata":{"aliases":["U33","RNU33"]}},{"id":"75d4924e0fd548449848252d1b51e17d","type":"GENE","name":"SNORD34","canonical_id":"hgnc:HGNC:10161","description":"small nucleolar RNA, C/D box 34","metadata":{"aliases":["U34","RNU34"]}},{"id":"fcd3aa1eb728439a8d706fe58ee39bff","type":"GENE","name":"SNORD35A","canonical_id":"hgnc:HGNC:10162","description":"small nucleolar RNA, C/D box 35A","metadata":{"aliases":["U35","RNU35A","RNU35"]}},{"id":"98ee4d88daf44405a53b932ccefc770c","type":"GENE","name":"SNORD35B","canonical_id":"hgnc:HGNC:17365","description":"small nucleolar RNA, C/D box 35B","metadata":{"aliases":["U35B","RNU35B"]}},{"id":"3f5816587b744859a7fba9b24f45a013","type":"GENE","name":"SNORD36A","canonical_id":"hgnc:HGNC:10163","description":"small nucleolar RNA, C/D box 36A","metadata":{"aliases":["U36a","RNU36A"]}},{"id":"1949720c046f40e0b625fac8e2f2827a","type":"GENE","name":"SNORD36B","canonical_id":"hgnc:HGNC:10164","description":"small nucleolar RNA, C/D box 36B","metadata":{"aliases":["U36b","RNU36B"]}},{"id":"28ac88e3e62743d4b0c158cd2827dd2b","type":"GENE","name":"SNORD36C","canonical_id":"hgnc:HGNC:10165","description":"small nucleolar RNA, C/D box 36C","metadata":{"aliases":["U36c","RNU36C"]}},{"id":"96f64a5e07664c329a3b782d50004e1b","type":"GENE","name":"SNORD37","canonical_id":"hgnc:HGNC:10166","description":"small nucleolar RNA, C/D box 37","metadata":{"aliases":["U37","RNU37"]}},{"id":"1dd5cc0ea8c942ae839ca160df2bc28c","type":"GENE","name":"SNORD38A","canonical_id":"hgnc:HGNC:30355","description":"small nucleolar RNA, C/D box 38A","metadata":{"aliases":["U38A","RNU38A"]}},{"id":"5f2bcb1066bd4632bab6633c6898ee1f","type":"GENE","name":"SNORD38B","canonical_id":"hgnc:HGNC:30356","description":"small nucleolar RNA, C/D box 38B","metadata":{"aliases":["U38B","RNU38B"]}},{"id":"eb0c00e7a5d342d2b321ed868f7f316c","type":"GENE","name":"SNORD38C","canonical_id":"hgnc:HGNC:52227","description":"small nucleolar RNA, C/D box 38C","metadata":null},{"id":"8d29942bf4e548c6892cf34affc8ced7","type":"GENE","name":"SNORD38D","canonical_id":"hgnc:HGNC:52228","description":"small nucleolar RNA, C/D box 38D","metadata":null},{"id":"fb657252e2d54f918f36cfe62ae3eef7","type":"GENE","name":"SNORD3A","canonical_id":"hgnc:HGNC:33189","description":"small nucleolar RNA, C/D box 3A","metadata":{"aliases":["U3","RNU3"]}},{"id":"e89a0b446e29445a9509696e255427c9","type":"GENE","name":"SNORD3B-1","canonical_id":"hgnc:HGNC:10168","description":"small nucleolar RNA, C/D box 3B-1","metadata":{"aliases":["U3a","U3b1","U3b2","RNU3A1"]}},{"id":"8d3c2bf0925448e68d6e3f83efdf797b","type":"GENE","name":"SNORD3B-2","canonical_id":"hgnc:HGNC:33190","description":"small nucleolar RNA, C/D box 3B-2","metadata":{"aliases":["U3-2B","U3b2"]}},{"id":"8994562d1d3543289fc01052ca949837","type":"GENE","name":"SNORD3C","canonical_id":"hgnc:HGNC:33191","description":"small nucleolar RNA, C/D box 3C","metadata":{"aliases":["U3-3","RNU3-3"]}},{"id":"c567dd19cd404bd499827a7084544fc6","type":"GENE","name":"SNORD3D","canonical_id":"hgnc:HGNC:33192","description":"small nucleolar RNA, C/D box 3D","metadata":{"aliases":["U3-4","RNU3-4"]}},{"id":"416efed54d89452da34ba800c784f5b7","type":"GENE","name":"SNORD3E","canonical_id":"hgnc:HGNC:52238","description":"small nucleolar RNA, C/D box 3E","metadata":null},{"id":"2aaef0f8a6e04253b83251f418ba1563","type":"GENE","name":"SNORD3F","canonical_id":"hgnc:HGNC:52239","description":"small nucleolar RNA, C/D box 3F","metadata":{"aliases":["U3","U3.2","SNORD3P2","RNU3P2"]}},{"id":"6938d8e631ca4ee7b18a6d28ab40cb71","type":"GENE","name":"SNORD3G","canonical_id":"hgnc:HGNC:52240","description":"small nucleolar RNA, C/D box 3G","metadata":null},{"id":"051c201738b84326a11386808a88dcdd","type":"GENE","name":"SNORD3H","canonical_id":"hgnc:HGNC:52241","description":"small nucleolar RNA, C/D box 3H","metadata":null},{"id":"301fa3c8e56442b88d9e1e78ffa3cfce","type":"GENE","name":"SNORD3I","canonical_id":"hgnc:HGNC:52242","description":"small nucleolar RNA, C/D box 3I","metadata":null},{"id":"ee542900cd0943c4aafd8419c6d18bdb","type":"GENE","name":"SNORD3J","canonical_id":"hgnc:HGNC:52243","description":"small nucleolar RNA, C/D box 3J","metadata":null},{"id":"0ea2513b003c4f91a10db9145ba19d5e","type":"GENE","name":"SNORD3K","canonical_id":"hgnc:HGNC:52244","description":"small nucleolar RNA, C/D box 3K","metadata":null},{"id":"c13cc5d221854f4795231a6e7dceb31d","type":"GENE","name":"SNORD3P1","canonical_id":"hgnc:HGNC:10175","description":"small nucleolar RNA, C/D box 3 pseudogene 1","metadata":{"aliases":["U3","RNU3P1"]}},{"id":"7572ed95c29645579c6b43417417a6d4","type":"GENE","name":"SNORD3P3","canonical_id":"hgnc:HGNC:10177","description":"small nucleolar RNA, C/D box 3 pseudogene 3","metadata":{"aliases":["U3","U3.5","u3.7","RNU3P3"]}},{"id":"df0b25030e8f4b679b24bb053f6b9b4d","type":"GENE","name":"SNORD3P4","canonical_id":"hgnc:HGNC:10178","description":"small nucleolar RNA, C/D box 3 pseudogene 4","metadata":{"aliases":["U3","U3.6","RNU3P4"]}},{"id":"95a997e076fa44c89ab32769207da302","type":"GENE","name":"SNORD41","canonical_id":"hgnc:HGNC:10179","description":"small nucleolar RNA, C/D box 41","metadata":{"aliases":["U41","RNU41"]}},{"id":"089d5696f72f4fc29578540ba0e1f26d","type":"GENE","name":"SNORD42A","canonical_id":"hgnc:HGNC:10180","description":"small nucleolar RNA, C/D box 42A","metadata":{"aliases":["U42","RNU42A"]}},{"id":"38836fcdb193428397fb0c88de2031d0","type":"GENE","name":"SNORD42B","canonical_id":"hgnc:HGNC:10181","description":"small nucleolar RNA, C/D box 42B","metadata":{"aliases":["U42B","RNU42B"]}},{"id":"f4243cf82105441186581cc7beaa8755","type":"GENE","name":"SNORD43","canonical_id":"hgnc:HGNC:10182","description":"small nucleolar RNA, C/D box 43","metadata":{"aliases":["U43","RNU43"]}},{"id":"6b7cc7eb9f754a059ee158cf1d3ba4f5","type":"GENE","name":"SNORD44","canonical_id":"hgnc:HGNC:10183","description":"small nucleolar RNA, C/D box 44","metadata":{"aliases":["U44","RNU44"]}},{"id":"730fc0f566734554a9be8cd5aa39e8ce","type":"GENE","name":"SNORD45A","canonical_id":"hgnc:HGNC:10184","description":"small nucleolar RNA, C/D box 45A","metadata":{"aliases":["U45a","RNU45A"]}},{"id":"2e06239dcff34c9f969618629c5b9455","type":"GENE","name":"SNORD45B","canonical_id":"hgnc:HGNC:10185","description":"small nucleolar RNA, C/D box 45B","metadata":{"aliases":["U45b","RNU45B"]}},{"id":"1c140f13f3304a859370ee590023e9fc","type":"GENE","name":"SNORD45C","canonical_id":"hgnc:HGNC:32720","description":"small nucleolar RNA, C/D box 45C","metadata":{"aliases":["U45C"]}},{"id":"580b0f8c81064a4a9f9791e1bdff02cc","type":"GENE","name":"SNORD46","canonical_id":"hgnc:HGNC:10186","description":"small nucleolar RNA, C/D box 46","metadata":{"aliases":["U46","U40","RNU46","RNU40"]}},{"id":"ae1ed61ae50b416ca4c0447c5142c399","type":"GENE","name":"SNORD47","canonical_id":"hgnc:HGNC:10187","description":"small nucleolar RNA, C/D box 47","metadata":{"aliases":["U47","RNU47"]}},{"id":"5b350e002f1f455b88d76fe40dfb9742","type":"GENE","name":"SNORD48","canonical_id":"hgnc:HGNC:10188","description":"small nucleolar RNA, C/D box 48","metadata":{"aliases":["U48","RNU48"]}},{"id":"4f4e47ee41a24fb6bc5267f2ac768742","type":"GENE","name":"SNORD49A","canonical_id":"hgnc:HGNC:10189","description":"small nucleolar RNA, C/D box 49A","metadata":{"aliases":["U49","U49A","RNU49"]}},{"id":"1f0d8f3f35584ee9902615c06c21d178","type":"GENE","name":"SNORD49B","canonical_id":"hgnc:HGNC:32721","description":"small nucleolar RNA, C/D box 49B","metadata":{"aliases":["U49B"]}},{"id":"df4c7963f2294e4a9ea3c0aac5a3a6e1","type":"GENE","name":"SNORD4A","canonical_id":"hgnc:HGNC:10097","description":"small nucleolar RNA, C/D box 4A","metadata":{"aliases":["Z17A","mgh18S-121","RNU101A"]}},{"id":"0ba55eae176542b68bcf3cb7ff4b2d43","type":"GENE","name":"SNORD4B","canonical_id":"hgnc:HGNC:10098","description":"small nucleolar RNA, C/D box 4B","metadata":{"aliases":["Z17B","RNU101B"]}},{"id":"7941a2841b2944c79b4ac8bb2f16f097","type":"GENE","name":"SNORD5","canonical_id":"hgnc:HGNC:32702","description":"small nucleolar RNA, C/D box 5","metadata":{"aliases":["mgh28S-2410"]}},{"id":"6194b62d93fd41398dbdc563c08be3ee","type":"GENE","name":"SNORD50A","canonical_id":"hgnc:HGNC:10200","description":"small nucleolar RNA, C/D box 50A","metadata":{"aliases":["U50","RNU50"]}},{"id":"5a3048368db64680935b81c324c619bb","type":"GENE","name":"SNORD50B","canonical_id":"hgnc:HGNC:32722","description":"small nucleolar RNA, C/D box 50B","metadata":{"aliases":["U50B"]}},{"id":"3a37d004863a424e8013c45ae42e2ad2","type":"GENE","name":"SNORD51","canonical_id":"hgnc:HGNC:10201","description":"small nucleolar RNA, C/D box 51","metadata":{"aliases":["U51","RNU51"]}},{"id":"e8f05477607243a3b527adc3ae8a1082","type":"GENE","name":"SNORD52","canonical_id":"hgnc:HGNC:10202","description":"small nucleolar RNA, C/D box 52","metadata":{"aliases":["U52","RNU52"]}},{"id":"8e8ecfc3e6ca4986acc1a3e80cf5639a","type":"GENE","name":"SNORD53","canonical_id":"hgnc:HGNC:10203","description":"small nucleolar RNA, C/D box 53","metadata":{"aliases":["U53","SNORD53A","RNU53"]}},{"id":"938237fcc930439c85e7540568ac5f2a","type":"GENE","name":"SNORD53B","canonical_id":"hgnc:HGNC:52229","description":"small nucleolar RNA, C/D box 53B","metadata":null},{"id":"ca5d9ae8d3e344fcba4b30a0a50de531","type":"GENE","name":"SNORD54","canonical_id":"hgnc:HGNC:10204","description":"small nucleolar RNA, C/D box 54","metadata":{"aliases":["U54","RNU54"]}},{"id":"7d2cb0bdb6524212a86d467a58d98103","type":"GENE","name":"SNORD55","canonical_id":"hgnc:HGNC:10205","description":"small nucleolar RNA, C/D box 55","metadata":{"aliases":["U55","U39","RNU55","RNU39","SNORD39"]}},{"id":"95ab9013116349d0848224fe1b8cae7b","type":"GENE","name":"SNORD56","canonical_id":"hgnc:HGNC:10206","description":"small nucleolar RNA, C/D box 56","metadata":{"aliases":["U56","RNU56"]}},{"id":"1dd7870fc23a4750a8405e706a4f5803","type":"GENE","name":"SNORD56B","canonical_id":"hgnc:HGNC:19771","description":"small nucleolar RNA, C/D box 56B","metadata":{"aliases":["RNU56B"]}},{"id":"d2d437456c004465a65c27457557e0d6","type":"GENE","name":"SNORD57","canonical_id":"hgnc:HGNC:10207","description":"small nucleolar RNA, C/D box 57","metadata":{"aliases":["U57","RNU57"]}},{"id":"91c0bda195bc4555a53124ab81412344","type":"GENE","name":"SNORD58A","canonical_id":"hgnc:HGNC:10208","description":"small nucleolar RNA, C/D box 58A","metadata":{"aliases":["U58a","RNU58A"]}},{"id":"ff31f73e38644290a9f0e2635d063071","type":"GENE","name":"SNORD58B","canonical_id":"hgnc:HGNC:10209","description":"small nucleolar RNA, C/D box 58B","metadata":{"aliases":["U58b","RNU58B"]}},{"id":"57d7d6f8c8af470480f2119124f7eb61","type":"GENE","name":"SNORD58C","canonical_id":"hgnc:HGNC:33613","description":"small nucleolar RNA, C/D box 58C","metadata":null},{"id":"a3137025798e411cbe1bf4487e897c86","type":"GENE","name":"SNORD59A","canonical_id":"hgnc:HGNC:10210","description":"small nucleolar RNA, C/D box 59A","metadata":{"aliases":["U59","RNU59"]}},{"id":"3a80eb6cfacc4781ac7cc36de2949d92","type":"GENE","name":"SNORD59B","canonical_id":"hgnc:HGNC:32723","description":"small nucleolar RNA, C/D box 59B","metadata":{"aliases":["U59B"]}},{"id":"e14bfaf6efe440f185e73e48d7bb3dcf","type":"GENE","name":"SNORD6","canonical_id":"hgnc:HGNC:32703","description":"small nucleolar RNA, C/D box 6","metadata":{"aliases":["mgh28S-2412"]}},{"id":"4b833ff155f14f519be21801814a6050","type":"GENE","name":"SNORD60","canonical_id":"hgnc:HGNC:10217","description":"small nucleolar RNA, C/D box 60","metadata":{"aliases":["U60","RNU60"]}},{"id":"03fee3503b364e17bbed1662a09834a9","type":"GENE","name":"SNORD61","canonical_id":"hgnc:HGNC:10218","description":"small nucleolar RNA, C/D box 61","metadata":{"aliases":["U61","HBII-342","RNU61"]}},{"id":"4be4a18e14fb40d79e514b679f0ea0bd","type":"GENE","name":"SNORD62A","canonical_id":"hgnc:HGNC:10219","description":"small nucleolar RNA, C/D box 62A","metadata":{"aliases":["U62","U62A","RNU62"]}},{"id":"b8fa658d7473408eb1c3b59067d2c0b3","type":"GENE","name":"SNORD62B","canonical_id":"hgnc:HGNC:23031","description":"small nucleolar RNA, C/D box 62B","metadata":{"aliases":["U62","U62B"]}},{"id":"d816c738b8f64f6e9a5e1d5f57b7f195","type":"GENE","name":"SNORD63","canonical_id":"hgnc:HGNC:10220","description":"small nucleolar RNA, C/D box 63","metadata":{"aliases":["U63","SNORD63A","RNU63"]}},{"id":"f68448b7856542cfac4f7f2356c75992","type":"GENE","name":"SNORD63B","canonical_id":"hgnc:HGNC:52230","description":"small nucleolar RNA, C/D box 63B","metadata":null},{"id":"c0218610229e4c05bcc06d39f5a71fa9","type":"GENE","name":"SNORD64","canonical_id":"hgnc:HGNC:32725","description":"small nucleolar RNA, C/D box 64","metadata":{"aliases":["HBII-13"]}},{"id":"c562b8ee978b4cf68122b6b94f698b4a","type":"GENE","name":"SNORD65","canonical_id":"hgnc:HGNC:32726","description":"small nucleolar RNA, C/D box 65","metadata":{"aliases":["HBII-135","SNORD65A"]}},{"id":"68f8c777fbce4c919f15b76fce069d2f","type":"GENE","name":"SNORD65B","canonical_id":"hgnc:HGNC:52231","description":"small nucleolar RNA, C/D box 65B","metadata":null},{"id":"51a5473ca2464d33a54833498036e072","type":"GENE","name":"SNORD65C","canonical_id":"hgnc:HGNC:52232","description":"small nucleolar RNA, C/D box 65C","metadata":null},{"id":"5082785a415d40a893f066af75c31388","type":"GENE","name":"SNORD66","canonical_id":"hgnc:HGNC:32727","description":"small nucleolar RNA, C/D box 66","metadata":{"aliases":["HBII-142"]}},{"id":"14e0b3f8626946edb4652395dd9e08e5","type":"GENE","name":"SNORD67","canonical_id":"hgnc:HGNC:32728","description":"small nucleolar RNA, C/D box 67","metadata":{"aliases":["HBII-166"]}},{"id":"14acbc02296c438199aace0e35843e33","type":"GENE","name":"SNORD68","canonical_id":"hgnc:HGNC:32729","description":"small nucleolar RNA, C/D box 68","metadata":{"aliases":["HBII-202"]}},{"id":"6d395c9eaccb410eb4dafd358df1e18e","type":"GENE","name":"SNORD69","canonical_id":"hgnc:HGNC:32730","description":"small nucleolar RNA, C/D box 69","metadata":{"aliases":["HBII-210"]}},{"id":"54358071222f4c518c87945379caf798","type":"GENE","name":"SNORD7","canonical_id":"hgnc:HGNC:32704","description":"small nucleolar RNA, C/D box 7","metadata":{"aliases":["Z30","mgU6-47"]}},{"id":"c6ab753b2aae4d51a82d7a3ae5b407a5","type":"GENE","name":"SNORD70","canonical_id":"hgnc:HGNC:32731","description":"small nucleolar RNA, C/D box 70","metadata":{"aliases":["HBII-234","SNORD70A"]}},{"id":"c93eb6d350ff45d692200ff1d8bda130","type":"GENE","name":"SNORD70B","canonical_id":"hgnc:HGNC:52233","description":"small nucleolar RNA, C/D box 70B","metadata":null},{"id":"166aa92540c84e1db3974b050e1f38af","type":"GENE","name":"SNORD71","canonical_id":"hgnc:HGNC:32732","description":"small nucleolar RNA, C/D box 71","metadata":{"aliases":["HBII-239","hsa-mir-768","MIRN768"]}},{"id":"845fb7af82fc45269afdde4a752a1eea","type":"GENE","name":"SNORD72","canonical_id":"hgnc:HGNC:32733","description":"small nucleolar RNA, C/D box 72","metadata":{"aliases":["HBII-240"]}},{"id":"131616acf79142d798e8dea2214aa186","type":"GENE","name":"SNORD73A","canonical_id":"hgnc:HGNC:10235","description":"small nucleolar RNA, C/D box 73A","metadata":{"aliases":["U73a","RNU73A","RNU73"]}},{"id":"38c15ada73d7455796dbd39a18f7c87e","type":"GENE","name":"SNORD73B","canonical_id":"hgnc:HGNC:30357","description":"small nucleolar RNA, C/D box 73B","metadata":{"aliases":["U73B","RNU73B"]}},{"id":"fcf81a641c954dd0b9ca411569d02865","type":"GENE","name":"SNORD74","canonical_id":"hgnc:HGNC:32734","description":"small nucleolar RNA, C/D box 74","metadata":{"aliases":["U74","Z18","SNORD74A"]}},{"id":"ba7af73e8e4a48448b32cb904ea9ca2b","type":"GENE","name":"SNORD74B","canonical_id":"hgnc:HGNC:52234","description":"small nucleolar RNA, C/D box 74B","metadata":null},{"id":"0fea732889c84c57871be8822b6ea8c2","type":"GENE","name":"SNORD75","canonical_id":"hgnc:HGNC:32735","description":"small nucleolar RNA, C/D box 75","metadata":{"aliases":["U75"]}},{"id":"e3f048d5432a482f8334ada84139523c","type":"GENE","name":"SNORD76","canonical_id":"hgnc:HGNC:32736","description":"small nucleolar RNA, C/D box 76","metadata":{"aliases":["U76"]}},{"id":"1d5ef3d74ad54c50a76502cdcae14437","type":"GENE","name":"SNORD77","canonical_id":"hgnc:HGNC:32737","description":"small nucleolar RNA, C/D box 77","metadata":{"aliases":["U77","SNORD77A"]}},{"id":"8184f477ccdc41eca74ef96e4213d79a","type":"GENE","name":"SNORD77B","canonical_id":"hgnc:HGNC:52235","description":"small nucleolar RNA, C/D box 77B","metadata":null},{"id":"263543cba1f34bbd937a4d50b4e1a79e","type":"GENE","name":"SNORD78","canonical_id":"hgnc:HGNC:32738","description":"small nucleolar RNA, C/D box 78","metadata":{"aliases":["U78"]}},{"id":"082871d04c664b948d14e3eae2afc7bb","type":"GENE","name":"SNORD79","canonical_id":"hgnc:HGNC:10100","description":"small nucleolar RNA, C/D box 79","metadata":{"aliases":["Z22","U79","RNU103"]}},{"id":"dc71d746b1954fb49571f49b1136a74b","type":"GENE","name":"SNORD8","canonical_id":"hgnc:HGNC:20159","description":"small nucleolar RNA, C/D box 8","metadata":{"aliases":["mgU6-53","RNU6C"]}},{"id":"f41c77bab8c04a938a6ba3b200ca7b01","type":"GENE","name":"SNORD80","canonical_id":"hgnc:HGNC:10096","description":"small nucleolar RNA, C/D box 80","metadata":{"aliases":["Z15","U80","RNU100"]}},{"id":"a93b8736649049d98c7d3a15d09e106e","type":"GENE","name":"SNORD81","canonical_id":"hgnc:HGNC:10101","description":"small nucleolar RNA, C/D box 81","metadata":{"aliases":["Z23","U81","RNU104"]}},{"id":"cdaaeba7b9aa4326a012eb288d4dcbbd","type":"GENE","name":"SNORD82","canonical_id":"hgnc:HGNC:10240","description":"small nucleolar RNA, C/D box 82","metadata":{"aliases":["Z25","U82","RNU82"]}},{"id":"997e7effaec54f939da91d6ddf1ab0b7","type":"GENE","name":"SNORD83A","canonical_id":"hgnc:HGNC:17131","description":"small nucleolar RNA, C/D box 83A","metadata":{"aliases":["U83A","RNU83A"]}},{"id":"0e4bc5d98a8245a0afabd54dd3d67038","type":"GENE","name":"SNORD83B","canonical_id":"hgnc:HGNC:17132","description":"small nucleolar RNA, C/D box 83B","metadata":{"aliases":["U83B","RNU83B"]}},{"id":"849201a0bca04b389296c22d4995a956","type":"GENE","name":"SNORD84","canonical_id":"hgnc:HGNC:32743","description":"small nucleolar RNA, C/D box 84","metadata":{"aliases":["U84"]}},{"id":"12fbf56c8ef940f4892f46ed50e29cd0","type":"GENE","name":"SNORD86","canonical_id":"hgnc:HGNC:32745","description":"small nucleolar RNA, C/D box 86","metadata":{"aliases":["U86"]}},{"id":"5786b7128f78467abff0a968de8a0975","type":"GENE","name":"SNORD87","canonical_id":"hgnc:HGNC:32746","description":"small nucleolar RNA, C/D box 87","metadata":{"aliases":["HBII-276","U87"]}},{"id":"50c45d23c56b47fc9793b9b4db9e2ae6","type":"GENE","name":"SNORD88A","canonical_id":"hgnc:HGNC:32747","description":"small nucleolar RNA, C/D box 88A","metadata":{"aliases":["HBII-180A"]}},{"id":"f0138e35543546ed8ba68e86e8b761ad","type":"GENE","name":"SNORD88B","canonical_id":"hgnc:HGNC:32748","description":"small nucleolar RNA, C/D box 88B","metadata":{"aliases":["HBII-180B"]}},{"id":"2b66da3cd4f64f92a249375596556202","type":"GENE","name":"SNORD88C","canonical_id":"hgnc:HGNC:32749","description":"small nucleolar RNA, C/D box 88C","metadata":{"aliases":["HBII-180C"]}},{"id":"2ab6d7b498a94063b3bd3a353c44ba00","type":"GENE","name":"SNORD89","canonical_id":"hgnc:HGNC:32750","description":"small nucleolar RNA, C/D box 89","metadata":{"aliases":["HBII-289"]}},{"id":"a134330b276545818cb119e2ea882dab","type":"GENE","name":"SNORD9","canonical_id":"hgnc:HGNC:32705","description":"small nucleolar RNA, C/D box 9","metadata":{"aliases":["mgU6-53B"]}},{"id":"53b9868fb7954aeb9bffbe368dd17818","type":"GENE","name":"SNORD90","canonical_id":"hgnc:HGNC:32751","description":"small nucleolar RNA, C/D box 90","metadata":{"aliases":["HBII-295"]}},{"id":"7051f67db92c4af18ac441a253363676","type":"GENE","name":"SNORD91A","canonical_id":"hgnc:HGNC:32752","description":"small nucleolar RNA, C/D box 91A","metadata":{"aliases":["HBII-296a"]}},{"id":"3ed2eed178de4c52a3479125bdaa7d07","type":"GENE","name":"SNORD91B","canonical_id":"hgnc:HGNC:32753","description":"small nucleolar RNA, C/D box 91B","metadata":{"aliases":["HBII-296b"]}},{"id":"b978027a2c2849e6a706dc8189691c5d","type":"GENE","name":"SNORD92","canonical_id":"hgnc:HGNC:32754","description":"small nucleolar RNA, C/D box 92","metadata":{"aliases":["HBII-316"]}},{"id":"bbcb4d5ffd4c4b278c2c1d1a1bd41a03","type":"GENE","name":"SNORD93","canonical_id":"hgnc:HGNC:32755","description":"small nucleolar RNA, C/D box 93","metadata":{"aliases":["HBII-336"]}},{"id":"abde3250a0f147cf95d698f12bc15217","type":"GENE","name":"SNORD94","canonical_id":"hgnc:HGNC:32756","description":"small nucleolar RNA, C/D box 94","metadata":{"aliases":["U94"]}},{"id":"627d792343d34b18b9fd50bffc0c8eac","type":"GENE","name":"SNORD95","canonical_id":"hgnc:HGNC:32757","description":"small nucleolar RNA, C/D box 95","metadata":{"aliases":["U95"]}},{"id":"69c14fd3b6164763b0b21c0087e31624","type":"GENE","name":"SNORD96A","canonical_id":"hgnc:HGNC:32758","description":"small nucleolar RNA, C/D box 96A","metadata":{"aliases":["U96a"]}},{"id":"4cfaff87917c414aa0df8024b43f651e","type":"GENE","name":"SNORD96B","canonical_id":"hgnc:HGNC:32759","description":"small nucleolar RNA, C/D box 96B","metadata":{"aliases":["U96b"]}},{"id":"10060656b3214cb3a25d7fb3374a1b74","type":"GENE","name":"SNORD97","canonical_id":"hgnc:HGNC:32760","description":"small nucleolar RNA, C/D box 97","metadata":{"aliases":["U97"]}},{"id":"9aeb6fd092844ec4bb08cd8aa49a4ffb","type":"GENE","name":"SNORD98","canonical_id":"hgnc:HGNC:32761","description":"small nucleolar RNA, C/D box 98","metadata":{"aliases":["HBII-419"]}},{"id":"59ac54b3978d43ed88107df4333edd8f","type":"GENE","name":"SNORD99","canonical_id":"hgnc:HGNC:32762","description":"small nucleolar RNA, C/D box 99","metadata":{"aliases":["HBII-420"]}},{"id":"3235d33d509a404ea862e319fdf6b3a1","type":"GENE","name":"SNPH","canonical_id":"hgnc:HGNC:15931","description":"syntaphilin","metadata":{"aliases":["bA314N13.5"]}},{"id":"d8a40c23108645efa02fe265aa9646ad","type":"GENE","name":"SNRK","canonical_id":"hgnc:HGNC:30598","description":"SNF related kinase","metadata":{"aliases":["FLJ20224","HSNFRK","KIAA0096"]}},{"id":"921a1a68caeb4bb98cc648e9c10163ba","type":"GENE","name":"SNRK-AS1","canonical_id":"hgnc:HGNC:41269","description":"SNRK antisense RNA 1","metadata":null},{"id":"ec395add56964dcdbd92c87a8f5fffb8","type":"GENE","name":"SNRNP200","canonical_id":"hgnc:HGNC:30859","description":"small nuclear ribonucleoprotein U5 subunit 200","metadata":{"aliases":["U5-200KD","HELIC2","KIAA0788","Brr2","ASCC3L1","RP33"]}},{"id":"8bcd66c2e9b04fd7af6658080f599a9a","type":"GENE","name":"SNRNP25","canonical_id":"hgnc:HGNC:14161","description":"small nuclear ribonucleoprotein U11/U12 subunit 25","metadata":{"aliases":["U11/U12-25K","C16orf33"]}},{"id":"1a91c61ac8354681a8f6c3d694f37ea8","type":"GENE","name":"SNRNP27","canonical_id":"hgnc:HGNC:30240","description":"small nuclear ribonucleoprotein U4/U6.U5 subunit 27","metadata":{"aliases":["RY1","U4/U6.U5-27K"]}},{"id":"a1c5e1ad6f2a4ec5ba71f4623e19137a","type":"GENE","name":"SNRNP35","canonical_id":"hgnc:HGNC:30852","description":"small nuclear ribonucleoprotein U11/U12 subunit 35","metadata":{"aliases":["U1SNRNPBP"]}},{"id":"d4e3eb48149f4df2a60d13ccd4247864","type":"GENE","name":"SNRNP40","canonical_id":"hgnc:HGNC:30857","description":"small nuclear ribonucleoprotein U5 subunit 40","metadata":{"aliases":["PRP8BP","SPF38","PRPF8BP","HPRP8BP","WDR57"]}},{"id":"ec0b6de9b6e046bcb3069f53f9585392","type":"GENE","name":"SNRNP40P1","canonical_id":"hgnc:HGNC:56562","description":"SNRNP40 pseudogene 1","metadata":null},{"id":"5feccf9dbf384ebe9a2eb80f1f801528","type":"GENE","name":"SNRNP48","canonical_id":"hgnc:HGNC:21368","description":"small nuclear ribonucleoprotein U11/U12 subunit 48","metadata":{"aliases":["FLJ32234","dJ512B11.2","dJ336K20B.1","C6orf151"]}},{"id":"de33c805d67a404281aee4d57e0f583a","type":"GENE","name":"SNRNP70","canonical_id":"hgnc:HGNC:11150","description":"small nuclear ribonucleoprotein U1 subunit 70","metadata":{"aliases":["U1-70K","Snp1","RNPU1Z","RPU1","SNRP70"]}},{"id":"1bb20a124d3e4a7b97ae6cb68fce0b57","type":"GENE","name":"SNRPA","canonical_id":"hgnc:HGNC:11151","description":"small nuclear ribonucleoprotein polypeptide A","metadata":{"aliases":["U1A","U1-A","Mud1"]}},{"id":"1f2388c5b3d0467cbbf70a91f31d3d62","type":"GENE","name":"SNRPA1","canonical_id":"hgnc:HGNC:11152","description":"small nuclear ribonucleoprotein polypeptide A'","metadata":{"aliases":["Lea1","U2A'"]}},{"id":"760774736f4e4f8f9b885b2ee20aec86","type":"GENE","name":"SNRPA1-DT","canonical_id":"hgnc:HGNC:55431","description":"SNRPA1 divergent transcript","metadata":null},{"id":"28d14fa5df58483abe58f57383cfe527","type":"GENE","name":"SNRPA1P1","canonical_id":"hgnc:HGNC:54744","description":"SNRPA1 pseudogene 1","metadata":null},{"id":"cd51a72257df4b9380edf5844c404534","type":"GENE","name":"SNRPA1P2","canonical_id":"hgnc:HGNC:56983","description":"SNRPA1 pseudogene 2","metadata":null},{"id":"6fd920c35f5247e184f20d8f12c39c58","type":"GENE","name":"SNRPB","canonical_id":"hgnc:HGNC:11153","description":"small nuclear ribonucleoprotein polypeptides B and B1","metadata":{"aliases":["COD","SmB/SmB'","Sm-B/B'","snRNP-B","SNRPB1"]}},{"id":"e0a9da3c9ac5431a9eb5a9c0319b623b","type":"GENE","name":"SNRPB2","canonical_id":"hgnc:HGNC:11155","description":"small nuclear ribonucleoprotein polypeptide B2","metadata":{"aliases":["Msl1","U2B''"]}},{"id":"b15c028ccdf44cf28bf15e902f96361d","type":"GENE","name":"SNRPB2P1","canonical_id":"hgnc:HGNC:56423","description":"SNRPB2 pseudogene 1","metadata":null},{"id":"22cfaa9ff93942f292b1678f4811fb36","type":"GENE","name":"SNRPBP1","canonical_id":"hgnc:HGNC:38665","description":"small nuclear ribonucleoprotein polypeptides B and B1 pseudogene 1","metadata":null},{"id":"acd4e4713b3d49fd8803f94e5b8098e7","type":"GENE","name":"SNRPC","canonical_id":"hgnc:HGNC:11157","description":"small nuclear ribonucleoprotein polypeptide C","metadata":{"aliases":["U1-C","Yhc1"]}},{"id":"becf22e63c9a4caba7beb032c2bbaf94","type":"GENE","name":"SNRPC-DT","canonical_id":"hgnc:HGNC:59384","description":"SNRPC divergent transcript","metadata":null},{"id":"76f47d6bd17e426083719492a9ffef29","type":"GENE","name":"SNRPCP1","canonical_id":"hgnc:HGNC:49816","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 1","metadata":null},{"id":"c17ac2773cb1401fa989f19e2d28c7c4","type":"GENE","name":"SNRPCP10","canonical_id":"hgnc:HGNC:49825","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 10","metadata":null},{"id":"f6bca1d8bed7467ab9a52bb10979c878","type":"GENE","name":"SNRPCP11","canonical_id":"hgnc:HGNC:49826","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 11","metadata":null},{"id":"ef01085b588f4243bcb400214b483c86","type":"GENE","name":"SNRPCP12","canonical_id":"hgnc:HGNC:49827","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 12","metadata":null},{"id":"5ec97183275e4bb1b67a426ed4fac0d8","type":"GENE","name":"SNRPCP13","canonical_id":"hgnc:HGNC:49828","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 13","metadata":null},{"id":"05bb666458334243b0e1c46354901c83","type":"GENE","name":"SNRPCP14","canonical_id":"hgnc:HGNC:49829","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 14","metadata":null},{"id":"6d862d8d66654ce880b5917c4359733f","type":"GENE","name":"SNRPCP15","canonical_id":"hgnc:HGNC:49830","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 15","metadata":null},{"id":"47d1ba0b1c3e456c9d1c92594cee5c45","type":"GENE","name":"SNRPCP16","canonical_id":"hgnc:HGNC:49831","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 16","metadata":null},{"id":"b9bd0d73ac804ad5aa0a5333f78878ac","type":"GENE","name":"SNRPCP17","canonical_id":"hgnc:HGNC:49832","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 17","metadata":null},{"id":"aafc5a79ed064e04b7246fa90afcb1b1","type":"GENE","name":"SNRPCP18","canonical_id":"hgnc:HGNC:49833","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 18","metadata":null},{"id":"cce77cccfc4c4d9097e24adc6e29158d","type":"GENE","name":"SNRPCP19","canonical_id":"hgnc:HGNC:49834","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 19","metadata":null},{"id":"4ea8af7d09f34caa8d23db598c5f4841","type":"GENE","name":"SNRPCP2","canonical_id":"hgnc:HGNC:49817","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 2","metadata":null},{"id":"2f4f6242d7dc4fca9af03d3e729f7294","type":"GENE","name":"SNRPCP20","canonical_id":"hgnc:HGNC:49835","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 20","metadata":null},{"id":"d1ea41676f0b48fca5964ed0867b421b","type":"GENE","name":"SNRPCP3","canonical_id":"hgnc:HGNC:49818","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 3","metadata":null},{"id":"965a33153f094a6db7ec9951b06a8d5f","type":"GENE","name":"SNRPCP4","canonical_id":"hgnc:HGNC:49819","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 4","metadata":null},{"id":"0655367130c34173ba33080463583c3b","type":"GENE","name":"SNRPCP5","canonical_id":"hgnc:HGNC:49820","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 5","metadata":null},{"id":"7d04ea15d16e435483d1a5a5b55dd56b","type":"GENE","name":"SNRPCP6","canonical_id":"hgnc:HGNC:49821","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 6","metadata":null},{"id":"f40dba4cd5bb467ba53a0a868ed93519","type":"GENE","name":"SNRPCP7","canonical_id":"hgnc:HGNC:49822","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 7","metadata":null},{"id":"011217a5a9014b55ae56619b411878a9","type":"GENE","name":"SNRPCP8","canonical_id":"hgnc:HGNC:49823","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 8","metadata":null},{"id":"0208b07c2bd54d41af80db14801669d3","type":"GENE","name":"SNRPCP9","canonical_id":"hgnc:HGNC:49824","description":"small nuclear ribonucleoprotein polypeptide C pseudogene 9","metadata":null},{"id":"1d7369f3984b4e7187dbe674cc3da155","type":"GENE","name":"SNRPD1","canonical_id":"hgnc:HGNC:11158","description":"small nuclear ribonucleoprotein D1 polypeptide","metadata":{"aliases":["HsT2456","Sm-D1","SNRPD"]}},{"id":"a0e97d5acf244c15b48216e16f24615a","type":"GENE","name":"SNRPD2","canonical_id":"hgnc:HGNC:11159","description":"small nuclear ribonucleoprotein D2 polypeptide","metadata":{"aliases":["Sm-D2","SNRPD1"]}},{"id":"4e747f832d3f4f1798e16e571a581ba6","type":"GENE","name":"SNRPD2P1","canonical_id":"hgnc:HGNC:31459","description":"small nuclear ribonucleoprotein D2 pseudogene 1","metadata":{"aliases":["bA478K7.1","SNRPD2P"]}},{"id":"4dce052d109048b3818e9de447cbbc75","type":"GENE","name":"SNRPD2P2","canonical_id":"hgnc:HGNC:38598","description":"small nuclear ribonucleoprotein D2 pseudogene 2","metadata":null},{"id":"a324514390c746d5a1ae219d9197dee9","type":"GENE","name":"SNRPD3","canonical_id":"hgnc:HGNC:11160","description":"small nuclear ribonucleoprotein D3 polypeptide","metadata":{"aliases":["SMD3","Sm-D3"]}},{"id":"a21fd85a4fb444da9b14f5e2107ef8cd","type":"GENE","name":"SNRPE","canonical_id":"hgnc:HGNC:11161","description":"small nuclear ribonucleoprotein polypeptide E","metadata":{"aliases":["Sm-E"]}},{"id":"dd699b4d23834091b4f84450a6a291b3","type":"GENE","name":"SNRPEP1","canonical_id":"hgnc:HGNC:35244","description":"SNRPE pseudogene 1","metadata":null},{"id":"e8fec8a1d5654333aea2276987515486","type":"GENE","name":"SNRPEP10","canonical_id":"hgnc:HGNC:43575","description":"SNRPE pseudogene 10","metadata":null},{"id":"f9e2841436604d77b4aa94e7d73e7440","type":"GENE","name":"SNRPEP11","canonical_id":"hgnc:HGNC:54746","description":"SNRPE pseudogene 11","metadata":null},{"id":"1f6b4ebe8d47479e83eab80ebf55e784","type":"GENE","name":"SNRPEP2","canonical_id":"hgnc:HGNC:20733","description":"SNRPE pseudogene 2","metadata":{"aliases":["bA390F4.4","SNRPEL1"]}},{"id":"984a736bc57c4415870acdbf9919ac31","type":"GENE","name":"SNRPEP3","canonical_id":"hgnc:HGNC:43445","description":"SNRPE pseudogene 3","metadata":null},{"id":"38768ba2c0124712bc5bbeb605e753c9","type":"GENE","name":"SNRPEP4","canonical_id":"hgnc:HGNC:43446","description":"SNRPE pseudogene 4","metadata":null},{"id":"17407fc2a8284cb99d7945e0e3c60651","type":"GENE","name":"SNRPEP5","canonical_id":"hgnc:HGNC:43447","description":"SNRPE pseudogene 5","metadata":null},{"id":"31e113d3495f41ed993c2762f4fd47b1","type":"GENE","name":"SNRPEP6","canonical_id":"hgnc:HGNC:43571","description":"SNRPE pseudogene 6","metadata":null},{"id":"a24ba034429f43a7ab733b6f46116d3c","type":"GENE","name":"SNRPEP7","canonical_id":"hgnc:HGNC:43572","description":"SNRPE pseudogene 7","metadata":null},{"id":"e3a79dd08ae84666b78450b6f8878a1e","type":"GENE","name":"SNRPEP8","canonical_id":"hgnc:HGNC:43573","description":"SNRPE pseudogene 8","metadata":null},{"id":"22265889d0954ab8ac14556634ff94ca","type":"GENE","name":"SNRPEP9","canonical_id":"hgnc:HGNC:43574","description":"SNRPE pseudogene 9","metadata":null},{"id":"7f30d4ef0e0d49f1aecdee98c1eb93dc","type":"GENE","name":"SNRPF","canonical_id":"hgnc:HGNC:11162","description":"small nuclear ribonucleoprotein polypeptide F","metadata":{"aliases":["Sm-F"]}},{"id":"8c62487105c14a3181c979ab83ddb4ff","type":"GENE","name":"SNRPF-DT","canonical_id":"hgnc:HGNC:55452","description":"SNRPF divergent transcript","metadata":null},{"id":"43eb1ccad96247a68bf1650a4777a743","type":"GENE","name":"SNRPFP1","canonical_id":"hgnc:HGNC:16551","description":"small nuclear ribonucleoprotein polypeptide F pseudogene 1","metadata":{"aliases":["dJ1041C10.2"]}},{"id":"3653180d9a3c4e6289d31154c61c0147","type":"GENE","name":"SNRPFP2","canonical_id":"hgnc:HGNC:39665","description":"small nuclear ribonucleoprotein polypeptide F pseudogene 2","metadata":null},{"id":"5a7a00ae1fdb4ae6b50b72d0df3d44e1","type":"GENE","name":"SNRPFP3","canonical_id":"hgnc:HGNC:39666","description":"small nuclear ribonucleoprotein polypeptide F pseudogene 3","metadata":null},{"id":"fc6d61fa88a34071b8a83045bdd981ce","type":"GENE","name":"SNRPFP4","canonical_id":"hgnc:HGNC:39667","description":"small nuclear ribonucleoprotein polypeptide F pseudogene 4","metadata":null},{"id":"3d55194221b44793a7dd03d07cd6e33d","type":"GENE","name":"SNRPG","canonical_id":"hgnc:HGNC:11163","description":"small nuclear ribonucleoprotein polypeptide G","metadata":{"aliases":["Sm-G"]}},{"id":"fbeb2826f1d048408bd8f7257960d81d","type":"GENE","name":"SNRPGP1","canonical_id":"hgnc:HGNC:20033","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 1","metadata":{"aliases":["SNRPGP"]}},{"id":"96e2391b09ee4bd4b7c7f336c80423a9","type":"GENE","name":"SNRPGP10","canonical_id":"hgnc:HGNC:39329","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 10","metadata":null},{"id":"5defe6b08e3347809d1d20a2b5c402b6","type":"GENE","name":"SNRPGP11","canonical_id":"hgnc:HGNC:39330","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 11","metadata":null},{"id":"eca79f3b4d9e479ea89883a30c1400b4","type":"GENE","name":"SNRPGP12","canonical_id":"hgnc:HGNC:39331","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 12","metadata":null},{"id":"87deb4865bdc4947b362f1c86186a807","type":"GENE","name":"SNRPGP13","canonical_id":"hgnc:HGNC:39332","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 13","metadata":null},{"id":"72f10b43527e49928593ae68e26a1be7","type":"GENE","name":"SNRPGP14","canonical_id":"hgnc:HGNC:42039","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 14","metadata":null},{"id":"da38dbc8dc52458da2c4ae126dd73f36","type":"GENE","name":"SNRPGP15","canonical_id":"hgnc:HGNC:49371","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 15","metadata":null},{"id":"d29217dbd15f4dc1b154c90b8eee8266","type":"GENE","name":"SNRPGP16","canonical_id":"hgnc:HGNC:49373","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 16","metadata":null},{"id":"1aeaf1c4419e468b8feb9c9dfc045c6e","type":"GENE","name":"SNRPGP17","canonical_id":"hgnc:HGNC:49372","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 17","metadata":null},{"id":"e5b1dc3139e44bf3900c690451c49284","type":"GENE","name":"SNRPGP18","canonical_id":"hgnc:HGNC:49374","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 18","metadata":null},{"id":"b617dcba8ab54116be2665febdd5f125","type":"GENE","name":"SNRPGP19","canonical_id":"hgnc:HGNC:49375","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 19","metadata":null},{"id":"9c25573123e14548af728098adfbb7fd","type":"GENE","name":"SNRPGP2","canonical_id":"hgnc:HGNC:30999","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 2","metadata":{"aliases":["HsT2742"]}},{"id":"8165fdf7501640d1b3104df7b6ae90c6","type":"GENE","name":"SNRPGP20","canonical_id":"hgnc:HGNC:49376","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 20","metadata":null},{"id":"198ad8271986486eaedf54b2261d2a77","type":"GENE","name":"SNRPGP3","canonical_id":"hgnc:HGNC:39322","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 3","metadata":null},{"id":"959bb2d0ac3b43b690c276d6d9b099a5","type":"GENE","name":"SNRPGP4","canonical_id":"hgnc:HGNC:39323","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 4","metadata":null},{"id":"843d09cfdf704277ad2e90553cb66c0f","type":"GENE","name":"SNRPGP5","canonical_id":"hgnc:HGNC:39324","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 5","metadata":null},{"id":"503413d6a5774d9f91356e728d071aac","type":"GENE","name":"SNRPGP6","canonical_id":"hgnc:HGNC:39325","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 6","metadata":null},{"id":"1d88fcbc53e14eb986f542249b828eb6","type":"GENE","name":"SNRPGP7","canonical_id":"hgnc:HGNC:39326","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 7","metadata":null},{"id":"bbb54d7a3d8648898a7caf46725d415c","type":"GENE","name":"SNRPGP8","canonical_id":"hgnc:HGNC:39327","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 8","metadata":null},{"id":"251ea47ba1294e82a26b9b3d2f178120","type":"GENE","name":"SNRPGP9","canonical_id":"hgnc:HGNC:39328","description":"small nuclear ribonucleoprotein polypeptide G pseudogene 9","metadata":null},{"id":"c86cc33173de4865979f02f30b55f067","type":"GENE","name":"SNRPN","canonical_id":"hgnc:HGNC:11164","description":null,"metadata":null},{"id":"1292b474c4e9429896c2db9d04d6e6e0","type":"GENE","name":"SNRPNP2","canonical_id":"hgnc:HGNC:56981","description":"SNRPN pseudogene 2","metadata":null},{"id":"04bd58ae99a04ab49ad945db87225c8c","type":"GENE","name":"SNTA1","canonical_id":"hgnc:HGNC:11167","description":"syntrophin alpha 1","metadata":{"aliases":["TACIP1","LQT12","SNT1"]}},{"id":"af34909eaa9646c185e7a321e78658f1","type":"GENE","name":"SNTB1","canonical_id":"hgnc:HGNC:11168","description":"syntrophin beta 1","metadata":{"aliases":["59-DAP","A1B","BSYN2","TIP-43","SNT2","SNT2B1"]}},{"id":"2d4d87d808494144a5b840e5467ecdd5","type":"GENE","name":"SNTB1-AS1","canonical_id":"hgnc:HGNC:58133","description":"SNTB1 antisense RNA 1","metadata":{"aliases":["AC104958.2","GDIL"]}},{"id":"7d93b03ca13344dd81b4f8d2c5cd5054","type":"GENE","name":"SNTB1-AS2","canonical_id":"hgnc:HGNC:58244","description":"SNTB1 antisense RNA 2","metadata":null},{"id":"7d21c9c3e71e4856b4165f72ccad3fc2","type":"GENE","name":"SNTB2","canonical_id":"hgnc:HGNC:11169","description":"syntrophin beta 2","metadata":{"aliases":["EST25263","SNT3","SNT2B2","SNTL","D16S2531E"]}},{"id":"4474518814b34718b76f00d3728212e2","type":"GENE","name":"SNTG1","canonical_id":"hgnc:HGNC:13740","description":"syntrophin gamma 1","metadata":{"aliases":["SYN4","G1SYN"]}},{"id":"ee39ea36f1e9425896a5f26778a52891","type":"GENE","name":"SNTG2","canonical_id":"hgnc:HGNC:13741","description":"syntrophin gamma 2","metadata":{"aliases":["SYN5","G2SYN"]}},{"id":"cad70020096e4409a08eb02938325e4a","type":"GENE","name":"SNTG2-AS1","canonical_id":"hgnc:HGNC:54058","description":"SNTG2 antisense RNA 1","metadata":null},{"id":"922ec9494e9a402ab408f1268ec0cb6a","type":"GENE","name":"SNTN","canonical_id":"hgnc:HGNC:33706","description":"sentan, cilia apical structure protein","metadata":{"aliases":["FLJ44379","S100AL"]}},{"id":"0607293c59354564af2f180c3fe59e7a","type":"GENE","name":"SNU13","canonical_id":"hgnc:HGNC:7819","description":"small nuclear ribonucleoprotein 13","metadata":{"aliases":["FA-1","SPAG12","SNRNP15-5","15.5K","SSFA1","NHP2L1"]}},{"id":"79b4477872ac4e9f9aa45dcdbd5cca0e","type":"GENE","name":"SNUPN","canonical_id":"hgnc:HGNC:14245","description":"snurportin 1","metadata":{"aliases":["SNURPORTIN-1","Snurportin1","RNUT1"]}},{"id":"dc263020a87b433d8a6c05f91b0c5733","type":"GENE","name":"SNURF","canonical_id":"hgnc:HGNC:11171","description":"SNRPN upstream open reading frame","metadata":null},{"id":"e6be7a35e48949119ac99f91f56dd82f","type":"GENE","name":"SNURFL","canonical_id":"hgnc:HGNC:29543","description":"SNRPN upstream open reading frame like (pseudogene)","metadata":{"aliases":["CXorf19"]}},{"id":"d8c06700334d482baa30cf21ae50b651","type":"GENE","name":"SNW1","canonical_id":"hgnc:HGNC:16696","description":null,"metadata":null},{"id":"e6b0de93a9f04b3a8f5985e3ebbacbe2","type":"GENE","name":"SNX1","canonical_id":"hgnc:HGNC:11172","description":"sorting nexin 1","metadata":{"aliases":["SNX1A","MGC8664","HsT17379","Vps5"]}},{"id":"b5db39caa09242fd8bf0c1db3933f4ed","type":"GENE","name":"SNX10","canonical_id":"hgnc:HGNC:14974","description":"sorting nexin 10","metadata":null},{"id":"7a806312ac08434281dc4bb9c1b1f01c","type":"GENE","name":"SNX10-AS1","canonical_id":"hgnc:HGNC:55845","description":"SNX10 antisense RNA 1","metadata":null},{"id":"64c64061b44f4f1482f7d2587df992ec","type":"GENE","name":"SNX11","canonical_id":"hgnc:HGNC:14975","description":"sorting nexin 11","metadata":null},{"id":"8807832330554927a3670349b31d950f","type":"GENE","name":"SNX12","canonical_id":"hgnc:HGNC:14976","description":"sorting nexin 12","metadata":null},{"id":"fa8ed32b1cb4457da90cc7b9a19b1734","type":"GENE","name":"SNX13","canonical_id":"hgnc:HGNC:21335","description":"sorting nexin 13","metadata":{"aliases":["RGS-PX1","KIAA0713"]}},{"id":"92c87f7222144955a9434107e028087c","type":"GENE","name":"SNX14","canonical_id":"hgnc:HGNC:14977","description":"sorting nexin 14","metadata":{"aliases":["RGS-PX2"]}},{"id":"17266b1f5a6a4cafb9fcccf337040d0c","type":"GENE","name":"SNX15","canonical_id":"hgnc:HGNC:14978","description":"sorting nexin 15","metadata":null},{"id":"5b869bb705b04ba980b7b00e764e95ee","type":"GENE","name":"SNX16","canonical_id":"hgnc:HGNC:14980","description":"sorting nexin 16","metadata":null},{"id":"f2debaf06ed04f7abcffb6add3b03fa5","type":"GENE","name":"SNX17","canonical_id":"hgnc:HGNC:14979","description":"sorting nexin 17","metadata":{"aliases":["KIAA0064"]}},{"id":"d573b60c782e47d0a142d76d4b3bfc3c","type":"GENE","name":"SNX18","canonical_id":"hgnc:HGNC:19245","description":"sorting nexin 18","metadata":{"aliases":["SH3PX2","SH3PXD3B","SNAG1"]}},{"id":"b46062c68eca48bf9e1c253882bd944c","type":"GENE","name":"SNX18P10","canonical_id":"hgnc:HGNC:39618","description":"sorting nexin 18 pseudogene 10","metadata":null},{"id":"e5312683a8664e6e8aeb8dcb242293e4","type":"GENE","name":"SNX18P11","canonical_id":"hgnc:HGNC:39619","description":"sorting nexin 18 pseudogene 11","metadata":null},{"id":"5163c36febaa43e5ba1dd33969d339c5","type":"GENE","name":"SNX18P12","canonical_id":"hgnc:HGNC:39620","description":"sorting nexin 18 pseudogene 12","metadata":null},{"id":"711ecd5efadd45dd84602fc5af940bc9","type":"GENE","name":"SNX18P13","canonical_id":"hgnc:HGNC:39621","description":"sorting nexin 18 pseudogene 13","metadata":null},{"id":"6267b0f2bc3141858da4d2e429d78e51","type":"GENE","name":"SNX18P14","canonical_id":"hgnc:HGNC:39622","description":"sorting nexin 18 pseudogene 14","metadata":null},{"id":"e3062634773c43eba72fbed9ddd74213","type":"GENE","name":"SNX18P15","canonical_id":"hgnc:HGNC:39623","description":"sorting nexin 18 pseudogene 15","metadata":null},{"id":"ec89902c8e3a440c94e1fd07f8b09e01","type":"GENE","name":"SNX18P16","canonical_id":"hgnc:HGNC:39624","description":"sorting nexin 18 pseudogene 16","metadata":null},{"id":"0ec48a5b913b4e2b85ce9534b4299602","type":"GENE","name":"SNX18P17","canonical_id":"hgnc:HGNC:39625","description":"sorting nexin 18 pseudogene 17","metadata":null},{"id":"a51856e7b6dd4cb2839649028a2133bd","type":"GENE","name":"SNX18P18","canonical_id":"hgnc:HGNC:39626","description":"sorting nexin 18 pseudogene 18","metadata":null},{"id":"f232793a8e7c4666bc2b44ab2f5c5d11","type":"GENE","name":"SNX18P19","canonical_id":"hgnc:HGNC:39627","description":"sorting nexin 18 pseudogene 19","metadata":null},{"id":"f1acd32610d946499309db58daeacfe4","type":"GENE","name":"SNX18P1Y","canonical_id":"hgnc:HGNC:38442","description":"sorting nexin 18 pseudogene 1, Y-linked","metadata":null},{"id":"84cc8d82eab54c6d9e34be87a034275a","type":"GENE","name":"SNX18P2","canonical_id":"hgnc:HGNC:39610","description":"sorting nexin 18 pseudogene 2","metadata":null},{"id":"4aa4b7d6812b41599442a6f99e585a6b","type":"GENE","name":"SNX18P20","canonical_id":"hgnc:HGNC:39628","description":"sorting nexin 18 pseudogene 20","metadata":null},{"id":"79c54189d0e4415ab2697230ce717146","type":"GENE","name":"SNX18P21","canonical_id":"hgnc:HGNC:39629","description":"sorting nexin 18 pseudogene 21","metadata":null},{"id":"8e85fca934ef4fa898d5681c414235a7","type":"GENE","name":"SNX18P22","canonical_id":"hgnc:HGNC:39630","description":"sorting nexin 18 pseudogene 22","metadata":null},{"id":"bf194f53e6c9430c98194a0e679ab20a","type":"GENE","name":"SNX18P23","canonical_id":"hgnc:HGNC:39631","description":"sorting nexin 18 pseudogene 23","metadata":null},{"id":"eef36bb777c64d448b9ff636d4055445","type":"GENE","name":"SNX18P24","canonical_id":"hgnc:HGNC:39632","description":"sorting nexin 18 pseudogene 24","metadata":null},{"id":"fdb8c60c2bd64a989560116ce8c759df","type":"GENE","name":"SNX18P25","canonical_id":"hgnc:HGNC:39633","description":"sorting nexin 18 pseudogene 25","metadata":null},{"id":"62d56d51c8d7418d876b9f3c852aada4","type":"GENE","name":"SNX18P26","canonical_id":"hgnc:HGNC:39634","description":"sorting nexin 18 pseudogene 26","metadata":null},{"id":"796030e37f6b40ceb647a59cf60e539a","type":"GENE","name":"SNX18P27","canonical_id":"hgnc:HGNC:39635","description":"sorting nexin 18 pseudogene 27","metadata":null},{"id":"22abb3e048f04931bb806ad8320ea928","type":"GENE","name":"SNX18P3","canonical_id":"hgnc:HGNC:39611","description":"sorting nexin 18 pseudogene 3","metadata":null},{"id":"2be0f18692ae4b8588caf655fcea084e","type":"GENE","name":"SNX18P4","canonical_id":"hgnc:HGNC:39612","description":"sorting nexin 18 pseudogene 4","metadata":null},{"id":"756a456e0863495fa86c5047984e1456","type":"GENE","name":"SNX18P5","canonical_id":"hgnc:HGNC:39613","description":"sorting nexin 18 pseudogene 5","metadata":{"aliases":["SNX18P6"]}},{"id":"23b6d97dd17145b6aeeebc2b789e86c7","type":"GENE","name":"SNX18P7","canonical_id":"hgnc:HGNC:39615","description":"sorting nexin 18 pseudogene 7","metadata":null},{"id":"27954a31bdb444a49b206f4640079a8e","type":"GENE","name":"SNX18P8","canonical_id":"hgnc:HGNC:39616","description":"sorting nexin 18 pseudogene 8","metadata":null},{"id":"e0cb3a1daf694a959bd1bccad41db062","type":"GENE","name":"SNX18P9","canonical_id":"hgnc:HGNC:39617","description":"sorting nexin 18 pseudogene 9","metadata":null},{"id":"a1dc4be6fc9044bc88ef4ae7ade7c5ac","type":"GENE","name":"SNX19","canonical_id":"hgnc:HGNC:21532","description":"sorting nexin 19","metadata":{"aliases":["KIAA0254","CHET8"]}},{"id":"d2318094833c4e2ca69ce2f6efaef28b","type":"GENE","name":"SNX19P1","canonical_id":"hgnc:HGNC:16765","description":"sorting nexin 19 pseudogene 1","metadata":{"aliases":["SNX19P"]}},{"id":"00693ca1a2c64367ae326e214f84133a","type":"GENE","name":"SNX19P2","canonical_id":"hgnc:HGNC:38115","description":"sorting nexin 19 pseudogene 2","metadata":null},{"id":"bedf60d140f94bc0b3b379ee31710a7a","type":"GENE","name":"SNX19P3","canonical_id":"hgnc:HGNC:38116","description":"sorting nexin 19 pseudogene 3","metadata":null},{"id":"acffd58854e94c81a09b6604ce424257","type":"GENE","name":"SNX19P4","canonical_id":"hgnc:HGNC:41510","description":"sorting nexin 19 pseudogene 4","metadata":null},{"id":"73a4fbf246734f0da49b789d16ca08cf","type":"GENE","name":"SNX2","canonical_id":"hgnc:HGNC:11173","description":"sorting nexin 2","metadata":null},{"id":"45d34a739ef444ac92db369e8daa88e0","type":"GENE","name":"SNX2-AS1","canonical_id":"hgnc:HGNC:59122","description":"SNX2 antisense RNA 1","metadata":null},{"id":"41cbc1da10f04e20bec3b6aa06cddce5","type":"GENE","name":"SNX20","canonical_id":"hgnc:HGNC:30390","description":"sorting nexin 20","metadata":{"aliases":["SLIC-1","SLIC1"]}},{"id":"9fe0d1f8872245b0a456ea8e7ca9456e","type":"GENE","name":"SNX21","canonical_id":"hgnc:HGNC:16154","description":"sorting nexin family member 21","metadata":{"aliases":["dJ337O18.4","SNX-L","C20orf161"]}},{"id":"4bccdeff94a84965bc9140d76ce03042","type":"GENE","name":"SNX22","canonical_id":"hgnc:HGNC:16315","description":"sorting nexin 22","metadata":{"aliases":["FLJ13952"]}},{"id":"e28c6d55fe9c4c7e9a921aa28d9a8ac5","type":"GENE","name":"SNX24","canonical_id":"hgnc:HGNC:21533","description":"sorting nexin 24","metadata":{"aliases":["SBBI31"]}},{"id":"bb177d349f1e4138902f916c8b0129c9","type":"GENE","name":"SNX25","canonical_id":"hgnc:HGNC:21883","description":"sorting nexin 25","metadata":{"aliases":["SBBI31","LRP2BP-AS1"]}},{"id":"25a8668bd11244aba565692d111ec878","type":"GENE","name":"SNX25P1","canonical_id":"hgnc:HGNC:41509","description":"sorting nexin 25 pseudogene 1","metadata":null},{"id":"a644f4fae7c14779bd99e91d86b6c3ea","type":"GENE","name":"SNX27","canonical_id":"hgnc:HGNC:20073","description":"sorting nexin 27","metadata":{"aliases":["MY014","KIAA0488","MGC20471"]}},{"id":"d451451245424d32bb66a49d00c2992f","type":"GENE","name":"SNX29","canonical_id":"hgnc:HGNC:30542","description":"sorting nexin 29","metadata":{"aliases":["FLJ12363","RUNDC2A"]}},{"id":"7cb6509d70a9432eb4cce58669e00a9c","type":"GENE","name":"SNX29-AS1","canonical_id":"hgnc:HGNC:58483","description":"SNX29 antisense RNA 1","metadata":null},{"id":"476641c2f89e4020acf35fbd94936ebc","type":"GENE","name":"SNX29-AS2","canonical_id":"hgnc:HGNC:58540","description":"SNX29 antisense RNA 2","metadata":null},{"id":"ceb00f8b7ade4f9ba924df6bb663f690","type":"GENE","name":"SNX29-AS3","canonical_id":"hgnc:HGNC:58619","description":"SNX29 antisense RNA 3","metadata":null},{"id":"3d3efac713164e7d85c7eac7ad4b7351","type":"GENE","name":"SNX29P1","canonical_id":"hgnc:HGNC:31913","description":"sorting nexin 29 pseudogene 1","metadata":{"aliases":["RUNDC2B"]}},{"id":"462f641574914623b433cbae887854a9","type":"GENE","name":"SNX29P2","canonical_id":"hgnc:HGNC:31914","description":"sorting nexin 29 pseudogene 2","metadata":{"aliases":["RUNDC2C"]}},{"id":"734748a42b1e45b8899796c3cd34fcbf","type":"GENE","name":"SNX2P1","canonical_id":"hgnc:HGNC:41514","description":"sorting nexin 2 pseudogene 1","metadata":null},{"id":"0ad38f4ba22e45d5ad8267ab18f8582c","type":"GENE","name":"SNX2P2","canonical_id":"hgnc:HGNC:41515","description":"sorting nexin 2 pseudogene 2","metadata":null},{"id":"550b9efeda2c481ca7aae796a5aa6853","type":"GENE","name":"SNX3","canonical_id":"hgnc:HGNC:11174","description":"sorting nexin 3","metadata":{"aliases":["Grd19"]}},{"id":"5d34f2408e9043db8d6ef5c6c8100b23","type":"GENE","name":"SNX30","canonical_id":"hgnc:HGNC:23685","description":"sorting nexin family member 30","metadata":{"aliases":["ATG24A"]}},{"id":"f470bfe4f48a42249e26f2a92ec690a3","type":"GENE","name":"SNX30-DT","canonical_id":"hgnc:HGNC:55835","description":"SNX30 divergent transcript","metadata":null},{"id":"219a8bc1659f4ae6b100fc8dbc8f4a8d","type":"GENE","name":"SNX31","canonical_id":"hgnc:HGNC:28605","description":"sorting nexin 31","metadata":{"aliases":["MGC39715"]}},{"id":"aa42d14f4d99442c96daa76bd3b84f27","type":"GENE","name":"SNX32","canonical_id":"hgnc:HGNC:26423","description":"sorting nexin 32","metadata":{"aliases":["FLJ30934","SNX6B"]}},{"id":"69cb3984357c43fc8c70bf48c7be4f4b","type":"GENE","name":"SNX33","canonical_id":"hgnc:HGNC:28468","description":"sorting nexin 33","metadata":{"aliases":["MGC32065","SH3PXD3C","SNX30","SH3PX3"]}},{"id":"49a6663ac9714c44bc226a0b58688c8d","type":"GENE","name":"SNX33P1","canonical_id":"hgnc:HGNC:48590","description":"sorting nexin 33 pseudogene 1","metadata":null},{"id":"928a66d709254adab28c3e16f78168e7","type":"GENE","name":"SNX3P1X","canonical_id":"hgnc:HGNC:41516","description":"sorting nexin 3 pseudogene 1 X-linked","metadata":null},{"id":"fda1105903b24273a6d3084654e76819","type":"GENE","name":"SNX3P1Y","canonical_id":"hgnc:HGNC:41517","description":"sorting nexin 3 pseudogene 1 Y-linked","metadata":null},{"id":"82f22f82432b44079f0e64c59aa5dd36","type":"GENE","name":"SNX4","canonical_id":"hgnc:HGNC:11175","description":"sorting nexin 4","metadata":{"aliases":["ATG24B"]}},{"id":"359e5382002d42ecba9a89e4f0a638c1","type":"GENE","name":"SNX5","canonical_id":"hgnc:HGNC:14969","description":"sorting nexin 5","metadata":null},{"id":"fdbe60c0456d4eb98a5b428f62f618b9","type":"GENE","name":"SNX5P1","canonical_id":"hgnc:HGNC:41512","description":"sorting nexin 5 pseudogene 1","metadata":null},{"id":"aad70227660247b88e010fa5d6e6d441","type":"GENE","name":"SNX5P2","canonical_id":"hgnc:HGNC:41513","description":"sorting nexin 5 pseudogene 2","metadata":null},{"id":"06184f7c45bb458482643422b988cf72","type":"GENE","name":"SNX6","canonical_id":"hgnc:HGNC:14970","description":"sorting nexin 6","metadata":null},{"id":"b36e18c7b9b54cb1abdbca612a746ff0","type":"GENE","name":"SNX6P1","canonical_id":"hgnc:HGNC:41511","description":"sorting nexin 6 pseudogene 1","metadata":null},{"id":"4fdef9e47fda4c96af360fee6aa25895","type":"GENE","name":"SNX7","canonical_id":"hgnc:HGNC:14971","description":"sorting nexin 7","metadata":null},{"id":"c444467ad60c404eba42302ad6bf084c","type":"GENE","name":"SNX7-DT","canonical_id":"hgnc:HGNC:56892","description":"SNX7 divergent transcript","metadata":{"aliases":["RP11-296E3.2"]}},{"id":"87811f40a7324cb3a4e4462cc31dfad4","type":"GENE","name":"SNX8","canonical_id":"hgnc:HGNC:14972","description":"sorting nexin 8","metadata":{"aliases":["Mvp1"]}},{"id":"2dfc11f276b54db09c90b845bf1e01f3","type":"GENE","name":"SNX9","canonical_id":"hgnc:HGNC:14973","description":"sorting nexin 9","metadata":{"aliases":["SH3PX1","SDP1","SH3PXD3A"]}},{"id":"d5808a8a3377483f82eb650802c88e9c","type":"GENE","name":"SNX9-AS1","canonical_id":"hgnc:HGNC:40699","description":"SNX9 antisense RNA 1","metadata":null},{"id":"0fafcb8d70b5432ab3ce9f0e77653d70","type":"GENE","name":"SOAT1","canonical_id":"hgnc:HGNC:11177","description":"sterol O-acyltransferase 1","metadata":{"aliases":["ACAT","ACAT1","SOAT","STAT"]}},{"id":"8fb659057c8d471e8069db1479e53079","type":"GENE","name":"SOAT2","canonical_id":"hgnc:HGNC:11178","description":"sterol O-acyltransferase 2","metadata":{"aliases":["ACAT2"]}},{"id":"15ade66ffede4b1b94dfcb0a4271a3b8","type":"GENE","name":"SOAT2-AS1","canonical_id":"hgnc:HGNC:59211","description":"SOAT2 antisense RNA 1","metadata":null},{"id":"5a1a0d4753f043b68cd22492e20352a0","type":"GENE","name":"SOBP","canonical_id":"hgnc:HGNC:29256","description":"sine oculis binding protein homolog","metadata":{"aliases":["FLJ10159"]}},{"id":"5500ae4811944253a1249362fe377f58","type":"GENE","name":"SOCAR","canonical_id":"hgnc:HGNC:54421","description":"serous ovarian cancer associated RNA","metadata":null},{"id":"870858a7c03c4222b4755ccf323cc9db","type":"GO_TERM","name":"SOCS family protein binding","canonical_id":"go:GO:0097678","description":"\"Binding to a member of the suppressor of cytokine signaling (SOCS) family of proteins. SOCS represent an important mechanism to extinguish cytokine and growth factor receptor signaling. Individual SOCS proteins are typically induced by specific cytokines and growth factors, thereby generating a negative feedback loop. SOCS proteins have important functions in development and homeostasis, and in disease, particularly tumor suppression and anti-inflammatory functions.\" [GOC:mr, InterPro:IPR028413, PMID:23885323, PMID:24705897]","metadata":null},{"id":"edb63e9f0ad3479da56aa456f42d1e41","type":"GENE","name":"SOCS1","canonical_id":"hgnc:HGNC:19383","description":null,"metadata":null},{"id":"05115ab204664e89b92eb2e440f4f0d9","type":"GENE","name":"SOCS2","canonical_id":"hgnc:HGNC:19382","description":null,"metadata":null},{"id":"501cc26ac09942b1b02d96de123748ba","type":"GENE","name":"SOCS2-AS1","canonical_id":"hgnc:HGNC:27054","description":"SOCS2 antisense RNA 1","metadata":null},{"id":"b9f704dbf51243c0b9740c303490d143","type":"GENE","name":"SOCS2P1","canonical_id":"hgnc:HGNC:16069","description":"suppressor of cytokine signaling 2 pseudogene 1","metadata":null},{"id":"73668a06cd0b423fa7ddbbdbb2b87236","type":"GENE","name":"SOCS2P2","canonical_id":"hgnc:HGNC:19330","description":"suppressor of cytokine signaling 2 pseudogene 2","metadata":null},{"id":"aee56b93f5ac4b12a90dede457b2dc2f","type":"GENE","name":"SOCS3","canonical_id":"hgnc:HGNC:19391","description":null,"metadata":null},{"id":"fbe3a5d77ab542e890220bfd113c7e86","type":"GENE","name":"SOCS3-DT","canonical_id":"hgnc:HGNC:52799","description":"SOCS3 divergent transcript","metadata":null},{"id":"0b8189671a9d4f26bdb8cd2b18a1f7a4","type":"GENE","name":"SOCS4","canonical_id":"hgnc:HGNC:19392","description":"suppressor of cytokine signaling 4","metadata":{"aliases":["SOCS7"]}},{"id":"b1daab59c0f542e99fdfa7b17de55434","type":"GENE","name":"SOCS5","canonical_id":"hgnc:HGNC:16852","description":"suppressor of cytokine signaling 5","metadata":{"aliases":["KIAA0671","SOCS-5","CIS6","CISH6","Cish5"]}},{"id":"5055574d04d743d3aeb187a1c3112dd2","type":"GENE","name":"SOCS5P1","canonical_id":"hgnc:HGNC:44597","description":"suppressor of cytokine signaling 5 pseudogene 1","metadata":null},{"id":"cfed2785f74f418b8258c0d19d2ce1d2","type":"GENE","name":"SOCS5P2","canonical_id":"hgnc:HGNC:44598","description":"suppressor of cytokine signaling 5 pseudogene 2","metadata":null},{"id":"7765af83fe6e4b7ca5ec731daed69ed3","type":"GENE","name":"SOCS5P3","canonical_id":"hgnc:HGNC:44599","description":"suppressor of cytokine signaling 5 pseudogene 3","metadata":null},{"id":"ee4531288be34a63a492400fbc5b2a9a","type":"GENE","name":"SOCS5P4","canonical_id":"hgnc:HGNC:44600","description":"suppressor of cytokine signaling 5 pseudogene 4","metadata":null},{"id":"b91c1f9775044f0bb74cdf6b2ae94c1a","type":"GENE","name":"SOCS5P5","canonical_id":"hgnc:HGNC:44601","description":"suppressor of cytokine signaling 5 pseudogene 5","metadata":null},{"id":"54b57addf091441e97848fea3bdb3a8c","type":"GENE","name":"SOCS6","canonical_id":"hgnc:HGNC:16833","description":"suppressor of cytokine signaling 6","metadata":{"aliases":["CIS4","SSI4","HSPC060","STATI4","STAI4","Cish4","SOCS4"]}},{"id":"a09415a15fb94bafa9d29fb02e7b9d85","type":"GENE","name":"SOCS6P1","canonical_id":"hgnc:HGNC:54990","description":"SOCS6 pseudogene 1","metadata":null},{"id":"7686ad615cbb4882967501771008cc32","type":"GENE","name":"SOCS7","canonical_id":"hgnc:HGNC:29846","description":null,"metadata":null},{"id":"47cb84413f954749a18c2be98d36eec1","type":"GENE","name":"SOD1","canonical_id":"hgnc:HGNC:11179","description":null,"metadata":null},{"id":"0dd29a5f61ce480491a96f91a6e6a836","type":"GO_TERM","name":"SOD1-Bcl-2 complex","canonical_id":"go:GO:0033607","description":"\"A heterodimeric protein complex formed of superoxide dismutase 1 and Bcl-2. Complex formation is thought to link superoxide dismutase to an apoptotic pathway.\" [PMID:15233914, PMID:16790527]","metadata":null},{"id":"5930f40cf9334d3ea869da9b6b1fec89","type":"GENE","name":"SOD1-DT","canonical_id":"hgnc:HGNC:55683","description":"SOD1 divergent transcript","metadata":{"aliases":["AP000253"]}},{"id":"fdc3496ece4747c497a3227604f70629","type":"GO_TERM","name":"SOD1-calcineurin complex","canonical_id":"go:GO:0032517","description":"\"A protein complex formed by the association of superoxide dismutase 1 (SOD1) with calcineurin; complex formation is implicated in activation of calcineurin by SOD1.\" [GOC:mah, PMID:17324120]","metadata":null},{"id":"5e60efb71efb43e68d7ca16cb95167c9","type":"GENE","name":"SOD1P1","canonical_id":"hgnc:HGNC:45134","description":"superoxide dismutase 1 pseudogene 1","metadata":null},{"id":"69b4ccf1087f4781abb81f56de8105b8","type":"GENE","name":"SOD1P2","canonical_id":"hgnc:HGNC:45135","description":"superoxide dismutase 1 pseudogene 2","metadata":null},{"id":"abb9b50ca695440f80aa427ea3b95f96","type":"GENE","name":"SOD1P3","canonical_id":"hgnc:HGNC:45136","description":"superoxide dismutase 1 pseudogene 3","metadata":null},{"id":"4b9c9099a3dd47fcaa67aaae2a35c99b","type":"GENE","name":"SOD2","canonical_id":"hgnc:HGNC:11180","description":null,"metadata":null},{"id":"2733e01821604498ac885abe5f7d019c","type":"GENE","name":"SOD2-OT1","canonical_id":"hgnc:HGNC:53445","description":"SOD2 overlapping transcript 1","metadata":null},{"id":"2b625178c11e4dceae8a7942a2a52c10","type":"GENE","name":"SOD2P1","canonical_id":"hgnc:HGNC:45268","description":"superoxide dismutase 2 pseudogene 1","metadata":null},{"id":"f63d2a709e1b41dea7bf1cfeba71d3a3","type":"GENE","name":"SOD3","canonical_id":"hgnc:HGNC:11181","description":"superoxide dismutase 3","metadata":{"aliases":["EC-SOD"]}},{"id":"77e0a2d9540f44da8c60393b93153322","type":"GENE","name":"SOFU1","canonical_id":"hgnc:HGNC:21750","description":"sperm-oocyte fusion factor 1","metadata":{"aliases":["CTM-1","SOF1","C7orf34","LLCFC1"]}},{"id":"5cb98c41664346b79233aff61a714fdc","type":"GENE","name":"SOHLH1","canonical_id":"hgnc:HGNC:27845","description":"spermatogenesis and oogenesis specific basic helix-loop-helix 1","metadata":{"aliases":["NOHLH","TEB2","bA100C15.3","bHLHe80","SPATA27","C9orf157"]}},{"id":"644a96ba730d491da2d9425132925fcb","type":"GENE","name":"SOHLH2","canonical_id":"hgnc:HGNC:26026","description":"spermatogenesis and oogenesis specific basic helix-loop-helix 2","metadata":{"aliases":["FLJ20449","TEB1","bHLHe81","SPATA28"]}},{"id":"63b3d81ffdcd4da58867f07a5845ca75","type":"TRIAL","name":"SOLIACS: Solian Solution in the Acute Setting","canonical_id":"clinicaltrials.gov:NCT00245674","description":"Schizophrenia","metadata":null},{"id":"45ec57666a824ea8bd016925219c1fa2","type":"TRIAL","name":"SOLIRIS\u00ae (Eculizumab) Treatment of Participants With COVID-19","canonical_id":"clinicaltrials.gov:NCT04355494","description":"COVID-19; Pneumonia, Viral; Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","metadata":null},{"id":"fe5fbe5e80ea4a98828e9279b99a40f9","type":"TRIAL","name":"SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients","canonical_id":"clinicaltrials.gov:NCT00126009","description":"Bipolar Disorder","metadata":null},{"id":"09cf78b36d124b5ba6c28b9995c2fca1","type":"TRIAL","name":"SOLO-Symbicort\u00ae in the Treatment of Persistent Asthma in Adolescents & Adults","canonical_id":"clinicaltrials.gov:NCT00238784","description":"Asthma","metadata":null},{"id":"76fa177d8df34b5da7fd214738f7c7a2","type":"TRIAL","name":"SOM230 Ectopic ACTH-producing Tumors","canonical_id":"clinicaltrials.gov:NCT02780882","description":"Ectopic ACTH Syndrome","metadata":null},{"id":"a4cee851bd9f4e8c9d65c1f295344b4e","type":"TRIAL","name":"SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01329289","description":"Multiple Myeloma in Relapse; Multiple Myeloma","metadata":null},{"id":"3522ceccecc4438387f165928c4681e5","type":"TRIAL","name":"SOMATULINE Autogel 90 mg IN DUMPING SYNDROME","canonical_id":"clinicaltrials.gov:NCT01923649","description":"Dumping Syndrome","metadata":null},{"id":"40267adfa7cb4138b063a506b57a5a0d","type":"GENE","name":"SON","canonical_id":"hgnc:HGNC:11183","description":"SON DNA and RNA binding protein","metadata":{"aliases":["DBP-5","NREBP","KIAA1019","BASS1","FLJ21099","FLJ33914","C21orf50"]}},{"id":"1cb42b80679d4748a093a568c236c390","type":"GENE","name":"SONP1","canonical_id":"hgnc:HGNC:30608","description":"SON pseudogene 1","metadata":null},{"id":"a0aca5b77ca1458ebe079ebf585b8f3c","type":"GENE","name":"SORBS1","canonical_id":"hgnc:HGNC:14565","description":"sorbin and SH3 domain containing 1","metadata":{"aliases":["FLJ12406","CAP","sh3p12","ponsin","KIAA1296","SH3D5"]}},{"id":"c2ede46915bd48c485bf5aab050c6a45","type":"GENE","name":"SORBS2","canonical_id":"hgnc:HGNC:24098","description":"sorbin and SH3 domain containing 2","metadata":{"aliases":["ARGBP2","KIAA0777"]}},{"id":"ea09e49596684ad9b671ddf5d70e86c4","type":"GENE","name":"SORBS2-AS1","canonical_id":"hgnc:HGNC:41039","description":"SORBS2 antisense RNA 1","metadata":{"aliases":["AC093797.1","RP11-301L8.2"]}},{"id":"576f569691b94d439ae8d07633f77766","type":"GENE","name":"SORBS2-AS2","canonical_id":"hgnc:HGNC:58918","description":"SORBS2 antisense RNA 2","metadata":null},{"id":"85178d8e23ff43bba2d3500b678a98ad","type":"GENE","name":"SORBS3","canonical_id":"hgnc:HGNC:30907","description":"sorbin and SH3 domain containing 3","metadata":{"aliases":["SCAM-1","SH3D4","vinexin"]}},{"id":"e869222a2ebe43f588d8686c9137a2eb","type":"GENE","name":"SORCS1","canonical_id":"hgnc:HGNC:16697","description":"sortilin related VPS10 domain containing receptor 1","metadata":null},{"id":"30654ff274ed4a3eaf36bd94a5340c7e","type":"GENE","name":"SORCS2","canonical_id":"hgnc:HGNC:16698","description":"sortilin related VPS10 domain containing receptor 2","metadata":{"aliases":["KIAA1329"]}},{"id":"85452c3a6b7d47dcb61822a11a952235","type":"GENE","name":"SORCS3","canonical_id":"hgnc:HGNC:16699","description":"sortilin related VPS10 domain containing receptor 3","metadata":{"aliases":["KIAA1059","SORCS"]}},{"id":"9ecc540fbf204e779ab42403aab7b153","type":"GENE","name":"SORCS3-AS1","canonical_id":"hgnc:HGNC:45244","description":"SORCS3 antisense RNA 1","metadata":null},{"id":"f54753550130417e99b60135807aa221","type":"GENE","name":"SORD","canonical_id":"hgnc:HGNC:11184","description":"sorbitol dehydrogenase","metadata":{"aliases":["SDH","XDH"]}},{"id":"982b57a2c5e840cd94fd09abd27c60cc","type":"GENE","name":"SORD-AS1","canonical_id":"hgnc:HGNC:58470","description":"SORD antisense RNA 1","metadata":null},{"id":"72452bf78d5c4d979a2928194167f35d","type":"GENE","name":"SORD-AS2","canonical_id":"hgnc:HGNC:58702","description":"SORD antisense RNA 2","metadata":{"aliases":["RP11-109D20.2"]}},{"id":"94831df956e2430890b531c437840bde","type":"GENE","name":"SORD2P","canonical_id":"hgnc:HGNC:49919","description":"sorbitol dehydrogenase 2, pseudogene","metadata":null},{"id":"8a6ce6c139ef422fa175b71810ccf787","type":"GENE","name":"SORL1","canonical_id":"hgnc:HGNC:11185","description":"sortilin related receptor 1","metadata":{"aliases":["gp250","LR11","LRP9","SorLA","SorLA-1","C11orf32"]}},{"id":"a7601e0bafa5406fb9cb92d0d85e4381","type":"GENE","name":"SORL1-AS1","canonical_id":"hgnc:HGNC:55594","description":"SORL1 antisense RNA 1","metadata":{"aliases":["51A"]}},{"id":"521fc9431fba46d79210c775a87d9ac1","type":"GENE","name":"SORT1","canonical_id":"hgnc:HGNC:11186","description":"sortilin 1","metadata":{"aliases":["Gp95","NT3"]}},{"id":"b6b8248b850a46b6b70ee210144a0eac","type":"GO_TERM","name":"SOS response","canonical_id":"go:GO:0009432","description":"\"An error-prone process for repairing damaged microbial DNA.\" [GOC:jl, PMID:16000023]","metadata":null},{"id":"1cb919ee52d047a9b9f1a5341d1711f6","type":"GENE","name":"SOS1","canonical_id":"hgnc:HGNC:11187","description":"SOS Ras/Rac guanine nucleotide exchange factor 1","metadata":{"aliases":["HGF","GF1","GINGF"]}},{"id":"f7462cfb29914d05a7f99142cde35aab","type":"GENE","name":"SOS1-IT1","canonical_id":"hgnc:HGNC:41385","description":"SOS1 intronic transcript 1","metadata":null},{"id":"d53953f32eb54d53b0f3d8d7e1a03703","type":"GENE","name":"SOS2","canonical_id":"hgnc:HGNC:11188","description":"SOS Ras/Rho guanine nucleotide exchange factor 2","metadata":null},{"id":"1a9f31379c6942b3b70bfe11580fb3d2","type":"GO_TERM","name":"SOSS complex","canonical_id":"go:GO:0070876","description":"\"A protein complex that functions downstream of the MRN complex to promote DNA repair and the G2/M checkpoint. The SOSS complex associates with single-stranded DNA at DNA lesions and is composed of SOSS-B (SOSS-B1/OBFC2B or SOSS-B2/OBFC2A), SOSS-A/INTS3 and SOSS-C/C9orf80.\" [PMID:19683501]","metadata":null},{"id":"bc0d46cda05c4815b1afa544654fd6d3","type":"GENE","name":"SOST","canonical_id":"hgnc:HGNC:13771","description":null,"metadata":null},{"id":"85bf91e6ef774a0cb7ec8235fb7cbeca","type":"PROTEIN","name":"SOST","canonical_id":"uniprot:Q9BQB4","description":null,"metadata":null},{"id":"2a30a50c43644c1ba3c06fc144a912a0","type":"GENE","name":"SOSTDC1","canonical_id":"hgnc:HGNC:21748","description":"sclerostin domain containing 1","metadata":{"aliases":["DKFZp564D206","USAG1","DAND7"]}},{"id":"46d5d5b441924cff9d909fb2b8e39d9e","type":"GENE","name":"SOWAHA","canonical_id":"hgnc:HGNC:27033","description":"sosondowah ankyrin repeat domain family member A","metadata":{"aliases":["ANKRD43"]}},{"id":"f62ffb774c0443a3afcdcace10281f3d","type":"GENE","name":"SOWAHB","canonical_id":"hgnc:HGNC:32958","description":"sosondowah ankyrin repeat domain family member B","metadata":{"aliases":["ANKRD56"]}},{"id":"77ccd0559e494b8b8f3a3f83d8c4acd3","type":"GENE","name":"SOWAHB-AS1","canonical_id":"hgnc:HGNC:58823","description":"SOWAHB antisense RNA 1","metadata":null},{"id":"8cf90282868d48f2b03c9b58f187b132","type":"GENE","name":"SOWAHC","canonical_id":"hgnc:HGNC:26149","description":"sosondowah ankyrin repeat domain family member C","metadata":{"aliases":["FLJ21870","C2orf26","ANKRD57"]}},{"id":"4f359c3040ef40e7a2c0385ade061525","type":"GENE","name":"SOWAHCP1","canonical_id":"hgnc:HGNC:37984","description":"SOWAHC pseudogene 1","metadata":{"aliases":["ANKRD57P1"]}},{"id":"1f438acc948d4a3886b78fa66406b62a","type":"GENE","name":"SOWAHCP2","canonical_id":"hgnc:HGNC:54506","description":"SOWAHC pseudogene 2","metadata":null},{"id":"d88ea347400548158f0b51a70ef7d3da","type":"GENE","name":"SOWAHCP3","canonical_id":"hgnc:HGNC:54507","description":"SOWAHC pseudogene 3","metadata":null},{"id":"6b89219aa8874fe091b8e577ae172056","type":"GENE","name":"SOWAHCP4","canonical_id":"hgnc:HGNC:54508","description":"SOWAHC pseudogene 4","metadata":null},{"id":"5a79da06149d43e1b44b6618a7ac8b43","type":"GENE","name":"SOWAHCP5","canonical_id":"hgnc:HGNC:54509","description":"SOWAHC pseudogene 5","metadata":null},{"id":"8c8d321a1296449982cef39137f0071d","type":"GENE","name":"SOWAHD","canonical_id":"hgnc:HGNC:32960","description":"sosondowah ankyrin repeat domain family member D","metadata":{"aliases":["ANKRD58"]}},{"id":"ad06f228a7d24a369a7faf509784d42d","type":"GENE","name":"SOX1","canonical_id":"hgnc:HGNC:11189","description":null,"metadata":null},{"id":"22fc656365304d05b4a8337489b26f43","type":"GENE","name":"SOX1-AS1","canonical_id":"hgnc:HGNC:58968","description":"SOX1 antisense RNA 1","metadata":{"aliases":["uc.357"]}},{"id":"7fb088f18c514974b2d6b074f57a24a3","type":"GENE","name":"SOX1-OT","canonical_id":"hgnc:HGNC:42733","description":"SOX1 overlapping transcript","metadata":{"aliases":["uc.357","LINC00403"]}},{"id":"faa30449c9c74d5591a867d02e71fe82","type":"GENE","name":"SOX10","canonical_id":"hgnc:HGNC:11190","description":null,"metadata":null},{"id":"e3dc85aa20234de38f7d6d32fc387659","type":"GENE","name":"SOX11","canonical_id":"hgnc:HGNC:11191","description":null,"metadata":null},{"id":"e32121fbb9d34016a496dc41d3163998","type":"GENE","name":"SOX12","canonical_id":"hgnc:HGNC:11198","description":"SRY-box transcription factor 12","metadata":{"aliases":["SOX22"]}},{"id":"63abfa23357e4ff8bda2beea4c68fb8d","type":"GENE","name":"SOX13","canonical_id":"hgnc:HGNC:11192","description":"SRY-box transcription factor 13","metadata":{"aliases":["Sox-13","ICA12","MGC117216"]}},{"id":"5a2778ed0b604dcdb90156e7c5a7832a","type":"GENE","name":"SOX14","canonical_id":"hgnc:HGNC:11193","description":null,"metadata":null},{"id":"b8d34ab778e9406d837922a78761fa45","type":"GENE","name":"SOX15","canonical_id":"hgnc:HGNC:11196","description":"SRY-box transcription factor 15","metadata":{"aliases":["SOX27","SOX26","SOX20"]}},{"id":"95a47e22e74c4950ab54dc3086891bfa","type":"GENE","name":"SOX17","canonical_id":"hgnc:HGNC:18122","description":null,"metadata":null},{"id":"57f6bde45f524f3d8495e789a3dbe9d1","type":"GENE","name":"SOX18","canonical_id":"hgnc:HGNC:11194","description":null,"metadata":null},{"id":"991150ac8dff4d2784522adc77cf40f5","type":"GENE","name":"SOX2","canonical_id":"hgnc:HGNC:11195","description":null,"metadata":null},{"id":"6cc66267afa244c7aae90e74412e5c87","type":"GENE","name":"SOX2-OT","canonical_id":"hgnc:HGNC:20209","description":"SOX2 overlapping transcript","metadata":{"aliases":["DKFZp761J1324","NCRNA00043","SOX2OT"]}},{"id":"55d724f32d2c4ce7a936cf97152104b8","type":"GENE","name":"SOX21","canonical_id":"hgnc:HGNC:11197","description":"SRY-box transcription factor 21","metadata":{"aliases":["SOX25"]}},{"id":"7963e32b103945d48f28378626c5ff1a","type":"GENE","name":"SOX21-AS1","canonical_id":"hgnc:HGNC:39807","description":"SOX21 antisense RNA 1","metadata":null},{"id":"1dd0d2e734c24f819ec62c40d20d3862","type":"GENE","name":"SOX3","canonical_id":"hgnc:HGNC:11199","description":null,"metadata":null},{"id":"9c5a3a32f6254c18a2d70620d986d38e","type":"GENE","name":"SOX30","canonical_id":"hgnc:HGNC:30635","description":"SRY-box transcription factor 30","metadata":null},{"id":"87366c16ea9c47d9915a6fedef8c1df5","type":"GENE","name":"SOX30-AS1","canonical_id":"hgnc:HGNC:59291","description":"SOX30 antisense RNA 1","metadata":null},{"id":"629cfd52acaa4a908d52ec0e06b324c0","type":"GENE","name":"SOX30P1","canonical_id":"hgnc:HGNC:35122","description":"SOX30 pseudogene 1","metadata":null},{"id":"83b1de5a5c9c452a9ff9666fdd35aa93","type":"GENE","name":"SOX4","canonical_id":"hgnc:HGNC:11200","description":null,"metadata":null},{"id":"cb2d5575f1564a98af60ae4f8a941dde","type":"GENE","name":"SOX5","canonical_id":"hgnc:HGNC:11201","description":null,"metadata":null},{"id":"014005071ded4c6995d6a3e839362513","type":"GENE","name":"SOX5-AS1","canonical_id":"hgnc:HGNC:53311","description":"SOX5 antisense RNA 1","metadata":null},{"id":"d7ee418bd7cc42fd8639429a0038e931","type":"GENE","name":"SOX5P1","canonical_id":"hgnc:HGNC:11202","description":"SOX5 pseudogene 1","metadata":{"aliases":["SOX29","SOX5P"]}},{"id":"7b20b5d0c1284edfa8bc32a072965522","type":"GENE","name":"SOX6","canonical_id":"hgnc:HGNC:16421","description":null,"metadata":null},{"id":"7224b3c72e0a40e9b6657882cb32e2f2","type":"GENE","name":"SOX7","canonical_id":"hgnc:HGNC:18196","description":null,"metadata":null},{"id":"f28e5ab661584d089c7a1b3a89e31df9","type":"GENE","name":"SOX7-AS1","canonical_id":"hgnc:HGNC:58246","description":"SOX7 antisense RNA 1","metadata":null},{"id":"619647df5eb5448e9887761fb1f1ebd6","type":"GENE","name":"SOX8","canonical_id":"hgnc:HGNC:11203","description":"SRY-box transcription factor 8","metadata":null},{"id":"476b3ee535f9431094e3059b9059fd7f","type":"GENE","name":"SOX9","canonical_id":"hgnc:HGNC:11204","description":null,"metadata":null},{"id":"be729f2367ce4125a5bf83be714ee2bf","type":"GENE","name":"SOX9-AS1","canonical_id":"hgnc:HGNC:49321","description":"SOX9 antisense RNA 1","metadata":{"aliases":["FLJ37644"]}},{"id":"000a98018194404fa8ef1b9aee698ab5","type":"TRIAL","name":"SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir","canonical_id":"clinicaltrials.gov:NCT00002310","description":"Herpes Simplex; HIV Infections","metadata":null},{"id":"c7deb3425f1c4626825807a0a5f7266a","type":"GENE","name":"SP1","canonical_id":"hgnc:HGNC:11205","description":null,"metadata":null},{"id":"746a58f4b591409b9302bd298d2bb946","type":"GENE","name":"SP100","canonical_id":"hgnc:HGNC:11206","description":null,"metadata":null},{"id":"10dd91a4c5704d59b3bf87d9274d9f47","type":"GENE","name":"SP110","canonical_id":"hgnc:HGNC:5401","description":"SP110 nuclear body protein","metadata":{"aliases":["IFI41","IFI75"]}},{"id":"68dffa0e7fbb44d4b7a7190edd53c034","type":"GENE","name":"SP140","canonical_id":"hgnc:HGNC:17133","description":"SP140 nuclear body protein","metadata":{"aliases":["LYSP100-B","LYSP100-A"]}},{"id":"5ae372fcd96743449df84042d29e5e29","type":"GENE","name":"SP140L","canonical_id":"hgnc:HGNC:25105","description":"SP140 like nuclear body protein","metadata":null},{"id":"717f831fea5a41a5bc5f866395d81f93","type":"GENE","name":"SP2","canonical_id":"hgnc:HGNC:11207","description":null,"metadata":null},{"id":"8d7881e3138c48c2a73384f7cc80c802","type":"GENE","name":"SP2-AS1","canonical_id":"hgnc:HGNC:51341","description":"SP2 antisense RNA 1","metadata":{"aliases":["SP2-DT"]}},{"id":"e718d6b36fbc480d92ee10409e12202c","type":"GENE","name":"SP3","canonical_id":"hgnc:HGNC:11208","description":null,"metadata":null},{"id":"1371682a38e64a0ab3b289aeb90c96cb","type":"GENE","name":"SP3P","canonical_id":"hgnc:HGNC:35430","description":"Sp3 transcription factor pseudogene","metadata":null},{"id":"765424cac97742ee9b150d751d3232e6","type":"GENE","name":"SP4","canonical_id":"hgnc:HGNC:11209","description":null,"metadata":null},{"id":"4d33020d878b424e9d9068d5de6deb83","type":"GENE","name":"SP5","canonical_id":"hgnc:HGNC:14529","description":"Sp5 transcription factor","metadata":null},{"id":"5dcaadc42dab4f3b96bd6282f9ec21e7","type":"GENE","name":"SP6","canonical_id":"hgnc:HGNC:14530","description":"Sp6 transcription factor","metadata":{"aliases":["KLF14","Epfn"]}},{"id":"335562e68a98480b9fa5a12d7399724e","type":"GENE","name":"SP7","canonical_id":"hgnc:HGNC:17321","description":null,"metadata":null},{"id":"aba0fc6fa04f42959d1275affa11c781","type":"GENE","name":"SP8","canonical_id":"hgnc:HGNC:19196","description":"Sp8 transcription factor","metadata":null},{"id":"b781571a3d5e4ebf8ab7a622ddae1ecb","type":"GENE","name":"SP9","canonical_id":"hgnc:HGNC:30690","description":"Sp9 transcription factor","metadata":{"aliases":["ZNF990"]}},{"id":"6da48582857b4116af97154a2c459bff","type":"GENE","name":"SPA17","canonical_id":"hgnc:HGNC:11210","description":"sperm autoantigenic protein 17","metadata":{"aliases":["SP17","CT22"]}},{"id":"7965b1aff5ed4aebb732fd405304b8c8","type":"GENE","name":"SPA17P1","canonical_id":"hgnc:HGNC:23224","description":"sperm autoantigenic protein 17 pseudogene 1","metadata":{"aliases":["Sp17-2"]}},{"id":"125cdf6461054482b50b18f1bc844af9","type":"GENE","name":"SPAAR","canonical_id":"hgnc:HGNC:27244","description":"small regulatory polypeptide of amino acid response","metadata":{"aliases":["SPAR","LINC00961"]}},{"id":"0eceb286b4ba4db9ad99bcbff95af1f4","type":"GENE","name":"SPACA1","canonical_id":"hgnc:HGNC:14967","description":"sperm acrosome associated 1","metadata":{"aliases":["SAMP32"]}},{"id":"18ee3cfcb1504f06b2a514d02f9a4894","type":"GENE","name":"SPACA3","canonical_id":"hgnc:HGNC:16260","description":"sperm acrosome associated 3","metadata":{"aliases":["ALLP17","SLLP1","LYC3","LYZL3","CT54"]}},{"id":"66af8298a07b4e8fa46c5a2d36d94fdb","type":"GENE","name":"SPACA4","canonical_id":"hgnc:HGNC:16441","description":"sperm acrosome associated 4","metadata":{"aliases":["SAMP14"]}},{"id":"0f73e6c1fdd54c3cacaf791a3c7265f1","type":"GENE","name":"SPACA5","canonical_id":"hgnc:HGNC:31353","description":"sperm acrosome associated 5","metadata":{"aliases":["SLLP2","LYZL5","LYC5","UNQ6288","dJ54B20.3","PNPK6288"]}},{"id":"be0281f9dc8143a3863bc8293c6b0ba1","type":"GENE","name":"SPACA5B","canonical_id":"hgnc:HGNC:19142","description":"sperm acrosome associated 5B","metadata":{"aliases":["LYZL5B"]}},{"id":"8d2980d2a691422a9f002fabb6a41c58","type":"GENE","name":"SPACA6","canonical_id":"hgnc:HGNC:27113","description":"sperm acrosome associated 6","metadata":{"aliases":["LET7EH","NCRNA00085","LINC00085","SPACA6P"]}},{"id":"fb5c000d0fd0482d940a39cc79d3a704","type":"GENE","name":"SPACA6-AS1","canonical_id":"hgnc:HGNC:49383","description":"SPACA6 antisense RNA 1","metadata":{"aliases":["LINC01129","SPACA6P-AS"]}},{"id":"4de69b2743d24fc39208fe8ee16fbce8","type":"GENE","name":"SPACA7","canonical_id":"hgnc:HGNC:29575","description":"sperm acrosome associated 7","metadata":{"aliases":["C13orf28"]}},{"id":"0b08f230d52c471b8a8ff714993b5157","type":"GENE","name":"SPACA7BP","canonical_id":"hgnc:HGNC:55609","description":"SPACA7 family member B, pseudogene","metadata":{"aliases":["GC14"]}},{"id":"aa07fa7c74e04ada8594492eb93cbef6","type":"GENE","name":"SPACA9","canonical_id":"hgnc:HGNC:1367","description":"sperm acrosome associated 9","metadata":{"aliases":["Mast","C9orf9"]}},{"id":"69c383f420ff402ca1b0c298bd193566","type":"GENE","name":"SPACDR","canonical_id":"hgnc:HGNC:22135","description":"sperm acrosome developmental regulator","metadata":{"aliases":["IMAGE:4839025","C7orf61"]}},{"id":"c6267651ba1f495eb0d364f5810a9ba3","type":"GENE","name":"SPADH","canonical_id":"hgnc:HGNC:55808","description":"spermadhesin family member","metadata":null},{"id":"26eac32bc7d44224aee08a05a5b28127","type":"GENE","name":"SPAG1","canonical_id":"hgnc:HGNC:11212","description":"sperm associated antigen 1","metadata":{"aliases":["SP75","FLJ32920","HSD-3.8","TPIS","CT140","CILD28","DNAAF13"]}},{"id":"ef28463898f942c1ba1f91d97f06de20","type":"GENE","name":"SPAG11A","canonical_id":"hgnc:HGNC:33342","description":"sperm associated antigen 11A","metadata":{"aliases":["HE2","EDDM2A"]}},{"id":"ef1133610f664ac0a1c54e959fba506e","type":"GENE","name":"SPAG11B","canonical_id":"hgnc:HGNC:14534","description":"sperm associated antigen 11B","metadata":{"aliases":["HE2","EP2","EP2C","EP2D","EDDM2B"]}},{"id":"f5ae241bbf90422c9ae843990a25beb5","type":"GENE","name":"SPAG16","canonical_id":"hgnc:HGNC:23225","description":"sperm associated antigen 16","metadata":{"aliases":["PF20","FLJ22724","DKFZp666P1710","WDR29"]}},{"id":"be21a0eef97045f8b896a10f22e2d5a6","type":"GENE","name":"SPAG16-DT","canonical_id":"hgnc:HGNC:52674","description":"SPAG16 divergent transcript","metadata":null},{"id":"8c4e713969ea41b3b4ec1bf8c5ac8c95","type":"GENE","name":"SPAG17","canonical_id":"hgnc:HGNC:26620","description":"sperm associated antigen 17","metadata":{"aliases":["FLJ34497","PF6","RP4-776P7.2","CT143"]}},{"id":"251311cbc8774b99bf9f60974df9e163","type":"GENE","name":"SPAG4","canonical_id":"hgnc:HGNC:11214","description":"sperm associated antigen 4","metadata":{"aliases":["SUN4","CT127"]}},{"id":"b569199e7b01487ebf8caa648a08cd0a","type":"GENE","name":"SPAG5","canonical_id":"hgnc:HGNC:13452","description":"sperm associated antigen 5","metadata":{"aliases":["DEEPEST","MAP126","hMAP126"]}},{"id":"08f561401ecf416495fd89345abd5014","type":"GENE","name":"SPAG5-AS1","canonical_id":"hgnc:HGNC:41140","description":"SPAG5 antisense RNA 1","metadata":null},{"id":"4d36bc27975c4bee89cd211381fd1082","type":"GENE","name":"SPAG6","canonical_id":"hgnc:HGNC:11215","description":null,"metadata":null},{"id":"4f470265d03d47ecb2b00d384eddf1d8","type":"GENE","name":"SPAG7","canonical_id":"hgnc:HGNC:11216","description":"sperm associated antigen 7","metadata":{"aliases":["FSA-1","ACRP","MGC20134"]}},{"id":"aaf81ade2c6644868dee60b320a82e33","type":"GENE","name":"SPAG8","canonical_id":"hgnc:HGNC:14105","description":"sperm associated antigen 8","metadata":{"aliases":["hSMP-1","HSD-1","BS-84","SPAG3","CT142"]}},{"id":"e54cc7e6c971498c8ba35b4de0101639","type":"GENE","name":"SPAG9","canonical_id":"hgnc:HGNC:14524","description":"sperm associated antigen 9","metadata":{"aliases":["HSS","SYD1","KIAA0516","MGC14967","MGC74461","MGC117291","JLP","PHET","HLC4","FLJ13450","FLJ14006","FLJ26141","FLJ34602","CT89","JIP4","JIP-4","PIG6"]}},{"id":"a007754ac5e84425b8841f25fd3de9ce","type":"TRIAL","name":"SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective","canonical_id":"clinicaltrials.gov:NCT06373601","description":"Coronary Artery Disease; Stenosis Coronary; Coronary Artery Lesion; Percutaneous Coronary Intervention","metadata":null},{"id":"fa070e47d1664777b085eac46a9a2d68","type":"GENE","name":"SPAM1","canonical_id":"hgnc:HGNC:11217","description":"sperm adhesion molecule 1","metadata":{"aliases":["HYAL5","PH-20","SPAG15"]}},{"id":"e961bc8db2d6417aaac0c7ffa3903d80","type":"GENE","name":"SPANXA1","canonical_id":"hgnc:HGNC:11218","description":"sperm protein associated with the nucleus, X-linked, family member A1","metadata":{"aliases":["NAP-X","SPAN-Xa","SPAN-Xb","CT11.1","SPANX"]}},{"id":"4b94e27caa984eec80129b6494767c20","type":"GENE","name":"SPANXA2","canonical_id":"hgnc:HGNC:14328","description":"SPANX family member A2","metadata":{"aliases":["SPANX"]}},{"id":"4e51fd4782504201b6939ba14f5db61d","type":"GENE","name":"SPANXA2-OT1","canonical_id":"hgnc:HGNC:31683","description":"SPANXA2 overlapping transcript 1","metadata":{"aliases":["FLJ36186","CXorf18"]}},{"id":"2512a3159b354dcbb207132d4a77079e","type":"GENE","name":"SPANXB1","canonical_id":"hgnc:HGNC:14329","description":"SPANX family member B1","metadata":{"aliases":["CT11.2","SPANXB2","SPANXF1","SPANXF2"]}},{"id":"7c005fbe7fca4a7688105b0fd6bdbae1","type":"GENE","name":"SPANXC","canonical_id":"hgnc:HGNC:14331","description":"SPANX family member C","metadata":{"aliases":["CTp11","CT11.3"]}},{"id":"95d02a0899a94366a6e8ae757192083f","type":"GENE","name":"SPANXD","canonical_id":"hgnc:HGNC:14332","description":"SPANX family member D","metadata":{"aliases":["CT11.4","SPANXE"]}},{"id":"404de2b406fd4bcbb488bf3bbc36622a","type":"GENE","name":"SPANXN1","canonical_id":"hgnc:HGNC:33174","description":"SPANX family member N1","metadata":{"aliases":["SPANX-N1","CT11.6"]}},{"id":"69f69dd63f944b31a6ae836085f0ac03","type":"GENE","name":"SPANXN2","canonical_id":"hgnc:HGNC:33175","description":"SPANX family member N2","metadata":{"aliases":["SPANX-N2","CT11.7"]}},{"id":"50756fdd286a4ba3bb260b48d2b4f0ae","type":"GENE","name":"SPANXN3","canonical_id":"hgnc:HGNC:33176","description":"SPANX family member N3","metadata":{"aliases":["SPANX-N3","CT11.8"]}},{"id":"89f7986378c14cf5bd89391497f5a94d","type":"GENE","name":"SPANXN4","canonical_id":"hgnc:HGNC:33177","description":"SPANX family member N4","metadata":{"aliases":["SPANX-N4","CT11.9"]}},{"id":"918ecc0faaaa41b79d1f4bdc8994e02b","type":"GENE","name":"SPANXN5","canonical_id":"hgnc:HGNC:33178","description":"SPANX family member N5","metadata":{"aliases":["SPANX-N5","CT11.10"]}},{"id":"6ba99d81c7404c999c0b88a1a9fc743d","type":"GENE","name":"SPARC","canonical_id":"hgnc:HGNC:11219","description":null,"metadata":null},{"id":"ddb0f922c4b54985a45041d7c9057cad","type":"GENE","name":"SPARCL1","canonical_id":"hgnc:HGNC:11220","description":"SPARC like 1","metadata":{"aliases":["MAST9"]}},{"id":"ac375611280e443d9825af670fd52a1e","type":"GENE","name":"SPARCL1-AS1","canonical_id":"hgnc:HGNC:58842","description":"SPARCL1 antisense RNA 1","metadata":null},{"id":"0dac51d6005c4a6a8a6fb55a9cf0e5fc","type":"GENE","name":"SPART","canonical_id":"hgnc:HGNC:18514","description":null,"metadata":null},{"id":"07b42451b6fa480c8ffec941934dfe3e","type":"GENE","name":"SPART-AS1","canonical_id":"hgnc:HGNC:39933","description":"SPART antisense RNA 1","metadata":{"aliases":["C13orf43","SPG20OS","SPG20-AS1"]}},{"id":"115cad0b19234cc19230e54d59d5f54a","type":"GENE","name":"SPAST","canonical_id":"hgnc:HGNC:11233","description":null,"metadata":null},{"id":"7ede98da12394229af45a564ee132436","type":"GENE","name":"SPATA1","canonical_id":"hgnc:HGNC:14682","description":"spermatogenesis associated 1","metadata":{"aliases":["SP-2"]}},{"id":"d0bdbb1bfe3a4f05b035cfb77d1f4480","type":"GENE","name":"SPATA12","canonical_id":"hgnc:HGNC:23221","description":"spermatogenesis associated 12","metadata":null},{"id":"c277426dec42426eb977eb8659e43c87","type":"GENE","name":"SPATA13","canonical_id":"hgnc:HGNC:23222","description":"spermatogenesis associated 13","metadata":{"aliases":["FLJ31208","ARHGEF29","ASEF2"]}},{"id":"7f65341d30044a14a271a62098bad6a0","type":"GENE","name":"SPATA13-AS1","canonical_id":"hgnc:HGNC:39905","description":"SPATA13 antisense RNA 1","metadata":null},{"id":"e4922079b20d448884df54549ec5da35","type":"GENE","name":"SPATA16","canonical_id":"hgnc:HGNC:29935","description":"spermatogenesis associated 16","metadata":{"aliases":["NYD-SP12"]}},{"id":"e21d02c4c0ec4db88c9be7cd117635f1","type":"GENE","name":"SPATA17","canonical_id":"hgnc:HGNC:25184","description":"spermatogenesis associated 17","metadata":{"aliases":["IQCH","MOT17","FAP305","CFAP305"]}},{"id":"03103c68c48c4fff965fc21c8cadb116","type":"GENE","name":"SPATA17-AS1","canonical_id":"hgnc:HGNC:41086","description":"SPATA17 antisense RNA 1","metadata":null},{"id":"08b73c4b3da04a5796b8352ef8651954","type":"GENE","name":"SPATA18","canonical_id":"hgnc:HGNC:29579","description":"spermatogenesis associated 18","metadata":{"aliases":["FLJ32906"]}},{"id":"b2fd25c0a68c4249a4d6dadf1eb7c3ab","type":"GENE","name":"SPATA19","canonical_id":"hgnc:HGNC:30614","description":"spermatogenesis associated 19","metadata":{"aliases":["FLJ25851","spergen1","SPAS1","CT132"]}},{"id":"5bff0a601a254b00bf795eff047cc5d0","type":"GENE","name":"SPATA2","canonical_id":"hgnc:HGNC:14681","description":"spermatogenesis associated 2","metadata":{"aliases":["KIAA0757","PD1","tamo","PPP1R145"]}},{"id":"1293926f0e68470da85d01b6d4a88eb1","type":"GENE","name":"SPATA20","canonical_id":"hgnc:HGNC:26125","description":"spermatogenesis associated 20","metadata":{"aliases":["FLJ21347","SSP411","Tisp78"]}},{"id":"3cd3bf5bbbc94a62bd64426e0aca4b4a","type":"GENE","name":"SPATA20P1","canonical_id":"hgnc:HGNC:39636","description":"spermatogenesis associated 20 pseudogene 1","metadata":null},{"id":"03c038ecc9314663bbaaee0eb4cf8ca9","type":"GENE","name":"SPATA21","canonical_id":"hgnc:HGNC:28026","description":"spermatogenesis associated 21","metadata":{"aliases":["spergen-2","spergen2"]}},{"id":"1453dccba1a6454195ab111cc0feefa0","type":"GENE","name":"SPATA22","canonical_id":"hgnc:HGNC:30705","description":"spermatogenesis associated 22","metadata":{"aliases":["NYD-SP20"]}},{"id":"8029c4982334474f8549166e1a30128e","type":"GENE","name":"SPATA24","canonical_id":"hgnc:HGNC:27322","description":"spermatogenesis associated 24","metadata":{"aliases":["T6441","CCDC161"]}},{"id":"87f2dcf87e194798b358d070a0a0ba54","type":"GENE","name":"SPATA25","canonical_id":"hgnc:HGNC:16158","description":"spermatogenesis associated 25","metadata":{"aliases":["dJ337O18.8","TSG23","C20orf165"]}},{"id":"c173e693057644abbe1ff07b100afca7","type":"GENE","name":"SPATA2L","canonical_id":"hgnc:HGNC:28393","description":"spermatogenesis associated 2 like","metadata":{"aliases":["MGC26885","tamo","C16orf76"]}},{"id":"648b554be80b452aa440b9b19a7b7afc","type":"GENE","name":"SPATA2P1","canonical_id":"hgnc:HGNC:39446","description":"spermatogenesis associated 2 pseudogene 1","metadata":null},{"id":"7edf0bb79b754719ae92dd097386f384","type":"GENE","name":"SPATA3","canonical_id":"hgnc:HGNC:17884","description":"spermatogenesis associated 3","metadata":{"aliases":["TSARG1"]}},{"id":"52e32aa656f34d8d965b6d2ac59e52a6","type":"GENE","name":"SPATA3-AS1","canonical_id":"hgnc:HGNC:28013","description":"SPATA3 antisense RNA 1","metadata":null},{"id":"d3997ee4806d414891c7776b3acdd8c4","type":"GENE","name":"SPATA31A1","canonical_id":"hgnc:HGNC:23394","description":"SPATA31 subfamily A member 1","metadata":{"aliases":["DKFZP434B204","C9orf36A","C9orf36","FAM75A1","SPATA31A2","FAM75A2"]}},{"id":"bcf5b17050e043c6bd8db4573c4d0ef2","type":"GENE","name":"SPATA31A3","canonical_id":"hgnc:HGNC:32003","description":"SPATA31 subfamily A member 3","metadata":{"aliases":["OTTHUMG00000013164","DKFZp434B204","FAM75A3"]}},{"id":"f3ff8f2d0b704d6faa439b56533be254","type":"GENE","name":"SPATA31A5","canonical_id":"hgnc:HGNC:32005","description":"SPATA31 subfamily A member 5","metadata":{"aliases":["OTTHUMG00000013204","FAM75A5"]}},{"id":"807d4ec6110e401ba7198f58976ca25e","type":"GENE","name":"SPATA31A6","canonical_id":"hgnc:HGNC:32006","description":"SPATA31 subfamily A member 6","metadata":{"aliases":["OTTHUMG00000013224","FAM75A6"]}},{"id":"a7806bedfd7f4952a6dcca7ae1a5aedd","type":"GENE","name":"SPATA31A7","canonical_id":"hgnc:HGNC:32007","description":"SPATA31 subfamily A member 7","metadata":{"aliases":["FAM75A7","SPATA31A4","FAM75A4"]}},{"id":"1f48936e02de48cbbbfd02ab43be1a05","type":"GENE","name":"SPATA31B1P","canonical_id":"hgnc:HGNC:31411","description":"SPATA31 subfamily B member 1, pseudogene","metadata":{"aliases":["bA388B24.2","C9orf36B","FAM75B","SPATA31B1"]}},{"id":"cc12c85d6fc84f96870b379aa906519f","type":"GENE","name":"SPATA31B2P","canonical_id":"hgnc:HGNC:55745","description":"SPATA31 subfamily B member 2, pseudogene","metadata":null},{"id":"fc061dcf97254432835485d956c4e810","type":"GENE","name":"SPATA31C1","canonical_id":"hgnc:HGNC:27846","description":"SPATA31 subfamily C member 1","metadata":{"aliases":["FLJ36055","FAM75C1"]}},{"id":"0abbafa6f64045ef97ea2d9117e42a96","type":"GENE","name":"SPATA31C2","canonical_id":"hgnc:HGNC:24508","description":"SPATA31 subfamily C member 2","metadata":{"aliases":["DKFZP434M131","FAM75C2"]}},{"id":"43e9eafcb3b4420f8f7a90d102d49c18","type":"GENE","name":"SPATA31D1","canonical_id":"hgnc:HGNC:37283","description":"SPATA31 subfamily D member 1","metadata":{"aliases":["FLJ46321","FAM75D1"]}},{"id":"3d63668a01ae4fbeb883ebe9c7f4206c","type":"GENE","name":"SPATA31D2P","canonical_id":"hgnc:HGNC:38607","description":"SPATA31 subfamily D member 2, pseudogene","metadata":{"aliases":["FAM75D2P"]}},{"id":"5b73fef2bc714c238f0ee23a7b921637","type":"GENE","name":"SPATA31D3","canonical_id":"hgnc:HGNC:38603","description":"SPATA31 subfamily D member 3","metadata":{"aliases":["FLJ44082","FAM75D3"]}},{"id":"2347be77dc24494f8fdf74a0f2c163ce","type":"GENE","name":"SPATA31D4","canonical_id":"hgnc:HGNC:38601","description":"SPATA31 subfamily D member 4","metadata":{"aliases":["FLJ43859","FAM75D4"]}},{"id":"5b1b8103464f4570ae34158f1e66d069","type":"GENE","name":"SPATA31D5P","canonical_id":"hgnc:HGNC:38602","description":"SPATA31 subfamily D member 5, pseudogene","metadata":{"aliases":["FLJ43950","FAM75D5P","FAM75D5"]}},{"id":"9e96a7d4c9714859a8c5d4fe4f8dbdbd","type":"GENE","name":"SPATA31E1","canonical_id":"hgnc:HGNC:26672","description":"SPATA31 subfamily E member 1","metadata":{"aliases":["FLJ35866","C9orf79","FAM75E1"]}},{"id":"59bec86663f0447fa01ff865255b87f0","type":"GENE","name":"SPATA31E2P","canonical_id":"hgnc:HGNC:43827","description":"SPATA31 subfamily E member 2, pseudogene","metadata":{"aliases":["FAM75E2P"]}},{"id":"c450094f10b1488fba49f05f1bd060b5","type":"GENE","name":"SPATA31E3P","canonical_id":"hgnc:HGNC:43828","description":"SPATA31 subfamily E member 3, pseudogene","metadata":{"aliases":["FAM75E3P"]}},{"id":"4d8abb39a69f47e785cabc5c7ebffe7e","type":"GENE","name":"SPATA31F1","canonical_id":"hgnc:HGNC:41911","description":"SPATA31 subfamily F member 1","metadata":{"aliases":["C9orf144B","FAM205A"]}},{"id":"32235992a12c463c8f7a5a2a87543685","type":"GENE","name":"SPATA31F2P","canonical_id":"hgnc:HGNC:24504","description":"SPATA31 subfamily F member 2, pseudogene","metadata":{"aliases":["DKFZp434J193","C9orf144A","C9orf144","FAM205B","FAM205BP"]}},{"id":"2bc1568a37da43f7849ea5a6d7824658","type":"GENE","name":"SPATA31F3","canonical_id":"hgnc:HGNC:42673","description":"SPATA31 subfamily F member 3","metadata":{"aliases":["FAM205CP","FAM205C"]}},{"id":"517e6f9e5b5f4929ba22ae036396aa0f","type":"GENE","name":"SPATA31G1","canonical_id":"hgnc:HGNC:31418","description":"SPATA31 subfamily G member 1","metadata":{"aliases":["MGC41945","C9orf131"]}},{"id":"f9e32f67fbe34a2abd2b9923ebf27b80","type":"GENE","name":"SPATA31H1","canonical_id":"hgnc:HGNC:25275","description":"SPATA31 subfamily H member 1","metadata":{"aliases":["DKFZp434G118","C2orf16"]}},{"id":"220ed8e1d6a44869a15f6a3743c99d85","type":"GENE","name":"SPATA31J1","canonical_id":"hgnc:HGNC:27753","description":"SPATA31 subfamily J member 1","metadata":{"aliases":["C5orf60"]}},{"id":"f396f2c4b55040ffb987d381ceaf36c2","type":"GENE","name":"SPATA32","canonical_id":"hgnc:HGNC:26349","description":"spermatogenesis associated 32","metadata":{"aliases":["FLJ25414","AEP2","VAD1.2","C17orf46","TEX34"]}},{"id":"4f4c8978f0f0467fa9f7ccb493a82b12","type":"GENE","name":"SPATA33","canonical_id":"hgnc:HGNC:26463","description":"spermatogenesis associated 33","metadata":{"aliases":["FLJ31606","C16orf55"]}},{"id":"3bfcff843c3c4a9585886972024076d5","type":"GENE","name":"SPATA4","canonical_id":"hgnc:HGNC:17333","description":"spermatogenesis associated 4","metadata":{"aliases":["TSARG2","SPEF1B","FAP178","CFAP178"]}},{"id":"6472532ca3e14ee4b40a61fb36ea7ea3","type":"GENE","name":"SPATA41","canonical_id":"hgnc:HGNC:48613","description":"spermatogenesis associated 41","metadata":{"aliases":["FLJ42289","HSD47"]}},{"id":"c191c99731394eb99ccd3ce083d63e4a","type":"GENE","name":"SPATA42","canonical_id":"hgnc:HGNC:41198","description":"spermatogenesis associated 42","metadata":{"aliases":["SRG7","AKNAD1-AS1"]}},{"id":"0a17ab9c7bd345118b4acf27285aa754","type":"GENE","name":"SPATA45","canonical_id":"hgnc:HGNC:33709","description":"spermatogenesis associated 45","metadata":{"aliases":["LOC149643","C1orf227"]}},{"id":"78f7a5eb16884defb78e5cd0d11e5f0d","type":"GENE","name":"SPATA46","canonical_id":"hgnc:HGNC:27648","description":"spermatogenesis associated 46","metadata":{"aliases":["TEKT2BP2","C1orf111"]}},{"id":"8a4e5f07d4d44f06b0e84c58d093fed9","type":"GENE","name":"SPATA6","canonical_id":"hgnc:HGNC:18309","description":"spermatogenesis associated 6","metadata":{"aliases":["SRF1","FLJ10007","SRF-1"]}},{"id":"459c4b7a85d94a3f87763606f333ad6e","type":"GENE","name":"SPATA6L","canonical_id":"hgnc:HGNC:25472","description":"spermatogenesis associated 6 like","metadata":{"aliases":["FLJ10058","C9orf68"]}},{"id":"efa331028d454534a4c14c94ffef8579","type":"GENE","name":"SPATA7","canonical_id":"hgnc:HGNC:20423","description":"spermatogenesis associated 7","metadata":{"aliases":["HSD3","LCA3"]}},{"id":"79b85102650f4f3b9df07d6c804b1aee","type":"GENE","name":"SPATA8","canonical_id":"hgnc:HGNC:28676","description":"spermatogenesis associated 8","metadata":{"aliases":["MGC44294","SRG8"]}},{"id":"5369de155dae42f495a3883f68175c88","type":"GENE","name":"SPATA8-AS1","canonical_id":"hgnc:HGNC:48627","description":"SPATA8 antisense RNA 1","metadata":null},{"id":"2ca4296652c647b2b1ca678ddd1374f5","type":"GENE","name":"SPATA9","canonical_id":"hgnc:HGNC:22988","description":"spermatogenesis associated 9","metadata":{"aliases":["NYD-SP16","FLJ35906"]}},{"id":"d2820ca36bcd409c8325471f95253e69","type":"GENE","name":"SPATC1","canonical_id":"hgnc:HGNC:30510","description":"spermatogenesis and centriole associated 1","metadata":{"aliases":["MGC61633","SPATA15","SPERIOLIN"]}},{"id":"66c58da29f9a439dadda9e2258e21bbc","type":"GENE","name":"SPATC1L","canonical_id":"hgnc:HGNC:1298","description":"spermatogenesis and centriole associated 1 like","metadata":{"aliases":["C21orf56"]}},{"id":"dd7b16c70d5c4a0887077c9568683293","type":"GENE","name":"SPATS1","canonical_id":"hgnc:HGNC:22957","description":"spermatogenesis associated serine rich 1","metadata":{"aliases":["SPATA8","FLJ25442","SRSP1"]}},{"id":"67ce3b941f27434c9145965dbfb6c46a","type":"GENE","name":"SPATS2","canonical_id":"hgnc:HGNC:18650","description":"spermatogenesis associated serine rich 2","metadata":{"aliases":["SPATA10","SCR59","FLJ13117"]}},{"id":"a1fea99a186045cf916e1ef4e9e96ef9","type":"GENE","name":"SPATS2L","canonical_id":"hgnc:HGNC:24574","description":"spermatogenesis associated serine rich 2 like","metadata":{"aliases":["DNAPTP6","SGNP"]}},{"id":"34ae8310e6354a389115166a8340a384","type":"GENE","name":"SPC24","canonical_id":"hgnc:HGNC:26913","description":"SPC24 component of NDC80 kinetochore complex","metadata":{"aliases":["FLJ90806","SPBC24"]}},{"id":"5df75f24f51545d2971375223eaf8e43","type":"GENE","name":"SPC25","canonical_id":"hgnc:HGNC:24031","description":"SPC25 component of NDC80 kinetochore complex","metadata":{"aliases":["MGC22228","AD024","SPBC25"]}},{"id":"6a43e2e982fe4387834b836d22016bf5","type":"GENE","name":"SPCS1","canonical_id":"hgnc:HGNC:23401","description":"signal peptidase complex subunit 1","metadata":{"aliases":["SPC12","HSPC033","YJR010C-A","SPC1"]}},{"id":"72e50874c563402b95d493678482ca0b","type":"GENE","name":"SPCS2","canonical_id":"hgnc:HGNC:28962","description":"signal peptidase complex subunit 2","metadata":{"aliases":["KIAA0102"]}},{"id":"b5ade02958a4426e97c96d82f5f3bf26","type":"GENE","name":"SPCS2P1","canonical_id":"hgnc:HGNC:31885","description":"signal peptidase complex subunit 2 pseudogene 1","metadata":{"aliases":["SPCS2P"]}},{"id":"98195f47809b4fccadd48a7931073325","type":"GENE","name":"SPCS2P2","canonical_id":"hgnc:HGNC:45235","description":"signal peptidase complex subunit 2 pseudogene 2","metadata":null},{"id":"104682090db84aa9afc6fc7ac801d5a1","type":"GENE","name":"SPCS2P3","canonical_id":"hgnc:HGNC:45236","description":"signal peptidase complex subunit 2 pseudogene 3","metadata":null},{"id":"9e75344d215a4e8faa5e26838de6010b","type":"GENE","name":"SPCS2P4","canonical_id":"hgnc:HGNC:45237","description":"signal peptidase complex subunit 2 pseudogene 4","metadata":null},{"id":"9af3fcddec5642d29c3f2b359e8b9a8a","type":"GENE","name":"SPCS3","canonical_id":"hgnc:HGNC:26212","description":"signal peptidase complex subunit 3","metadata":{"aliases":["FLJ22649","SPC22/23","SPC3","YLR066W","PRO3567"]}},{"id":"1e88acc1882c4f4593bd125f53671ab4","type":"GENE","name":"SPCS3-AS1","canonical_id":"hgnc:HGNC:54818","description":"SPCS3 antisense RNA 1","metadata":null},{"id":"8e5aefbb981f44f09b912a6da8a0b9f2","type":"GENE","name":"SPDEF","canonical_id":"hgnc:HGNC:17257","description":null,"metadata":null},{"id":"60b28e945500407b8a29caf3edc37e4a","type":"GENE","name":"SPDL1","canonical_id":"hgnc:HGNC:26010","description":"spindle apparatus coiled-coil protein 1","metadata":{"aliases":["FLJ20364","hSpindly","CCDC99"]}},{"id":"8d4ebd79eb7542768acbb4163ecf1fa3","type":"GENE","name":"SPDL1-DT","canonical_id":"hgnc:HGNC:59300","description":"SPDL1 divergent transcript","metadata":null},{"id":"b75733f256064480a6d739583c416b74","type":"GENE","name":"SPDYA","canonical_id":"hgnc:HGNC:30613","description":"speedy/RINGO cell cycle regulator family member A","metadata":{"aliases":["SPY1","Ringo3","SPDY1"]}},{"id":"f4c641baa84543d584fae957fdea1034","type":"GENE","name":"SPDYC","canonical_id":"hgnc:HGNC:32681","description":"speedy/RINGO cell cycle regulator family member C","metadata":{"aliases":["Ringo2"]}},{"id":"f070ec4994c648939390140d6cfb87d7","type":"GENE","name":"SPDYE1","canonical_id":"hgnc:HGNC:16408","description":"speedy/RINGO cell cycle regulator family member E1","metadata":{"aliases":["Ringo1","SPDYE","WBSCR19"]}},{"id":"230232b0b61f4f55bd3045cdf6eb2a1b","type":"GENE","name":"SPDYE1-AS1","canonical_id":"hgnc:HGNC:56874","description":"SPDYE1 and UBE2D4 antisense RNA 1","metadata":{"aliases":["RASA4CP-POLR2J4-UPK3BL3P-RASA4EP"]}},{"id":"30d2784899cd4fd7bc4a06bc973a177c","type":"GENE","name":"SPDYE10","canonical_id":"hgnc:HGNC:51506","description":"speedy/RINGO cell cycle regulator family member E10","metadata":{"aliases":["SPDYE10P"]}},{"id":"7329d5a5624a4af5b761a726fa06da39","type":"GENE","name":"SPDYE11","canonical_id":"hgnc:HGNC:51507","description":"speedy/RINGO cell cycle regulator family member E11","metadata":null},{"id":"c31008d430c7415bba9becd07da36b8c","type":"GENE","name":"SPDYE12","canonical_id":"hgnc:HGNC:51508","description":"speedy/RINGO cell cycle regulator family member E12","metadata":{"aliases":["SPDYE12P"]}},{"id":"b4750957f8124aa684d34675c41a89f9","type":"GENE","name":"SPDYE13","canonical_id":"hgnc:HGNC:51509","description":"speedy/RINGO cell cycle regulator family member E13","metadata":{"aliases":["SPDYE13P"]}},{"id":"d5f9d1c8fc50467c86a3466022b8abc3","type":"GENE","name":"SPDYE14","canonical_id":"hgnc:HGNC:51510","description":"speedy/RINGO cell cycle regulator family member E14","metadata":{"aliases":["SPDYE14P"]}},{"id":"756c27a581bc4de1951065137c2a3a98","type":"GENE","name":"SPDYE15","canonical_id":"hgnc:HGNC:51511","description":"speedy/RINGO cell cycle regulator family member E15","metadata":{"aliases":["SPDYE15P"]}},{"id":"b2ec115c1d0148c78c71bf3a83f69b71","type":"GENE","name":"SPDYE16","canonical_id":"hgnc:HGNC:51512","description":"speedy/RINGO cell cycle regulator family member E16","metadata":null},{"id":"5eee29c8e3f741c1be095802123daacf","type":"GENE","name":"SPDYE17","canonical_id":"hgnc:HGNC:51513","description":"speedy/RINGO cell cycle regulator family member E17","metadata":null},{"id":"66ee3641c97e49ff9abb53aee36f57f4","type":"GENE","name":"SPDYE18","canonical_id":"hgnc:HGNC:51514","description":"speedy/RINGO cell cycle regulator family member E18","metadata":null},{"id":"0804f79f04a64da48e429097fc56a9cb","type":"GENE","name":"SPDYE19P","canonical_id":"hgnc:HGNC:51515","description":"speedy/RINGO cell cycle regulator family member E19, pseudogene","metadata":null},{"id":"793208faa12c4e58bc9f529c0c740a51","type":"GENE","name":"SPDYE2","canonical_id":"hgnc:HGNC:33841","description":"speedy/RINGO cell cycle regulator family member E2","metadata":{"aliases":["MGC119295"]}},{"id":"c982593f396c4de89cdc60d97fb1c865","type":"GENE","name":"SPDYE20P","canonical_id":"hgnc:HGNC:51516","description":"speedy/RINGO cell cycle regulator family member E20, pseudogene","metadata":null},{"id":"159f420194a0448fa3ed48ede8c285c9","type":"GENE","name":"SPDYE21","canonical_id":"hgnc:HGNC:51517","description":"speedy/RINGO cell cycle regulator family member E21","metadata":{"aliases":["SPDYE21P"]}},{"id":"48578be609dc4b45904e681c1b806d23","type":"GENE","name":"SPDYE22P","canonical_id":"hgnc:HGNC:51518","description":"speedy/RINGO cell cycle regulator family member E22, pseudogene","metadata":null},{"id":"4082f26f90e74a689700fa8e5db8e2ff","type":"GENE","name":"SPDYE2B","canonical_id":"hgnc:HGNC:48334","description":"speedy/RINGO cell cycle regulator family member E2B","metadata":null},{"id":"c6e361a1a13f4d7e97b35d09185c3208","type":"GENE","name":"SPDYE3","canonical_id":"hgnc:HGNC:35462","description":"speedy/RINGO cell cycle regulator family member E3","metadata":null},{"id":"a9a74ca5447a446da3b79eec5a1edd33","type":"GENE","name":"SPDYE4","canonical_id":"hgnc:HGNC:35463","description":"speedy/RINGO cell cycle regulator family member E4","metadata":null},{"id":"53166430cb5144b78cd49ac550ce03fe","type":"GENE","name":"SPDYE5","canonical_id":"hgnc:HGNC:35464","description":"speedy/RINGO cell cycle regulator family member E5","metadata":null},{"id":"310fb9c316514f02a79f4f1f333f35b8","type":"GENE","name":"SPDYE6","canonical_id":"hgnc:HGNC:35465","description":"speedy/RINGO cell cycle regulator family member E6","metadata":null},{"id":"7980a4225ddd400e8273b49e0a8e98e6","type":"GENE","name":"SPDYE7P","canonical_id":"hgnc:HGNC:35466","description":"speedy/RINGO cell cycle regulator family member E7, pseudogene","metadata":null},{"id":"116538a7bfa047b9b58a359c7abdd90f","type":"GENE","name":"SPDYE8","canonical_id":"hgnc:HGNC:33771","description":"speedy/RINGO cell cycle regulator family member E8","metadata":{"aliases":["SPDYE8P"]}},{"id":"413456f483e74599b927bfdb01600378","type":"GENE","name":"SPDYE9","canonical_id":"hgnc:HGNC:45034","description":"speedy/RINGO cell cycle regulator family member E9","metadata":{"aliases":["SPDYE9P"]}},{"id":"5aae6b098a724be5a7efe3d995c0cf65","type":"GENE","name":"SPECC1","canonical_id":"hgnc:HGNC:30615","description":"sperm antigen with calponin homology and coiled-coil domains 1","metadata":{"aliases":["HCMOGT-1","FLJ36955","NSP","CYTSB"]}},{"id":"2b0ab6c02f334f5380f34fe988695ffc","type":"GENE","name":"SPECC1-DT","canonical_id":"hgnc:HGNC:55376","description":"SPECC1 divergent transcript","metadata":null},{"id":"a2aed4818ca64169b5990cd3afb8a44d","type":"GENE","name":"SPECC1L","canonical_id":"hgnc:HGNC:29022","description":"sperm antigen with calponin homology and coiled-coil domains 1 like","metadata":{"aliases":["KIAA0376","CYTSA"]}},{"id":"a48a1ab505f04a54bcce0d10b5c0c0cf","type":"GENE","name":"SPECC1L-ADORA2A","canonical_id":"hgnc:HGNC:49185","description":"SPECC1L-ADORA2A readthrough (NMD candidate)","metadata":null},{"id":"fbf32ff59c6d432ba435d5867af18df8","type":"GENE","name":"SPECC1P1","canonical_id":"hgnc:HGNC:53867","description":"SPECC1 pseudogene 1","metadata":null},{"id":"2684efc3ffef4f6fa868bdeb35c3a822","type":"GENE","name":"SPECC1P2","canonical_id":"hgnc:HGNC:53868","description":"SPECC1 pseudogene 2","metadata":null},{"id":"ce78d9d674ba4efd88d137369dd17316","type":"GENE","name":"SPEF1","canonical_id":"hgnc:HGNC:15874","description":"sperm flagellar and cilia associated 1","metadata":{"aliases":["DKFZP434I114","SPEF1A","CLAMP","C20orf28"]}},{"id":"53373029f67f45688b8790630fcaa892","type":"GENE","name":"SPEF2","canonical_id":"hgnc:HGNC:26293","description":"sperm flagellar and cilia associated 2","metadata":{"aliases":["KPL2","FLJ23577","CT122"]}},{"id":"e03c8e354d9440c5851b64cf79269fbf","type":"GENE","name":"SPEG","canonical_id":"hgnc:HGNC:16901","description":"striated muscle enriched protein kinase","metadata":{"aliases":["MGC12676","KIAA1297","SPEGalpha","SPEGbeta","BPEG","MYLK6","APEG1"]}},{"id":"508e559058c941e69edf8e724c26c25b","type":"GENE","name":"SPEGNB","canonical_id":"hgnc:HGNC:51251","description":"SPEG neighbor","metadata":null},{"id":"9c0d1700ca474ec0a3e26d05050bc766","type":"GENE","name":"SPEM1","canonical_id":"hgnc:HGNC:32429","description":"spermatid maturation 1","metadata":{"aliases":["FLJ40081","C17orf83"]}},{"id":"d6266185201f49b18b32d8268f39a072","type":"GENE","name":"SPEM2","canonical_id":"hgnc:HGNC:27315","description":"SPEM family member 2","metadata":{"aliases":["C17orf74"]}},{"id":"de33218761d94c52b58e5544ff69dc38","type":"GENE","name":"SPEM3","canonical_id":"hgnc:HGNC:53651","description":"SPEM family member 3","metadata":null},{"id":"0bed475d2a614579b35e281bb696728f","type":"GENE","name":"SPEN","canonical_id":"hgnc:HGNC:17575","description":null,"metadata":null},{"id":"4ce4279de9f242b78ace3da3ae1fc7b1","type":"GENE","name":"SPEN-AS1","canonical_id":"hgnc:HGNC:55937","description":"SPEN antisense RNA 1","metadata":{"aliases":["FLJ37453"]}},{"id":"beb8eaa13a8e4ec5b0eddf7a88babaf0","type":"GENE","name":"SPESP1","canonical_id":"hgnc:HGNC:15570","description":"sperm equatorial segment protein 1","metadata":{"aliases":["SP-ESP"]}},{"id":"bb58e9f3bb0b451180de739dc835c5f6","type":"TRIAL","name":"SPG Block for Acute Pediatric Migraine","canonical_id":"clinicaltrials.gov:NCT03984045","description":"Migraine in Children; Sphenopalatine Neuralgia; Migraine in Adolescence","metadata":null},{"id":"8a1071d03ea44c489a65739c0711e748","type":"GENE","name":"SPG11","canonical_id":"hgnc:HGNC:11226","description":"SPG11 vesicle trafficking associated, spatacsin","metadata":{"aliases":["FLJ21439","KIAA1840","ALS5"]}},{"id":"f3f1d9b0e99b4b1dbde5ea00fc16331f","type":"GENE","name":"SPG21","canonical_id":"hgnc:HGNC:20373","description":"SPG21 abhydrolase domain containing, maspardin","metadata":{"aliases":["ACP33","GL010","BM-019","MAST","ABHD21"]}},{"id":"df05d250360d43de8f363e8bde77bded","type":"GENE","name":"SPG7","canonical_id":"hgnc:HGNC:11237","description":"SPG7 matrix AAA peptidase subunit, paraplegin","metadata":{"aliases":["CAR","SPG5C","CMAR"]}},{"id":"8bffcd8d993f449cb1c4767e6b7184ae","type":"GENE","name":"SPHK1","canonical_id":"hgnc:HGNC:11240","description":null,"metadata":null},{"id":"bb2a29cdbe5d4226beb9f2478395f9ba","type":"GENE","name":"SPHK2","canonical_id":"hgnc:HGNC:18859","description":"sphingosine kinase 2","metadata":null},{"id":"ef59c557627e4befbf16ba122d5f9de4","type":"GENE","name":"SPHKAP","canonical_id":"hgnc:HGNC:30619","description":"SPHK1 interactor, AKAP domain containing","metadata":{"aliases":["SKIP"]}},{"id":"bcc240d28b57456c9ffb1881d9ed2317","type":"TRIAL","name":"SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide","canonical_id":"clinicaltrials.gov:NCT02953340","description":"Neutropenia; Breast Cancer","metadata":null},{"id":"b6c7f168071b46b7b04cb9183eb1257b","type":"GENE","name":"SPI1","canonical_id":"hgnc:HGNC:11241","description":null,"metadata":null},{"id":"b0fb2603409643d985c2e0e8a8b87be8","type":"GENE","name":"SPIB","canonical_id":"hgnc:HGNC:11242","description":null,"metadata":null},{"id":"793fe9f6d64746e0abecd227c49fc8da","type":"GENE","name":"SPIC","canonical_id":"hgnc:HGNC:29549","description":null,"metadata":null},{"id":"db0eb0bd16f045c0be1a8bdb070ce510","type":"GENE","name":"SPICE1","canonical_id":"hgnc:HGNC:25083","description":"spindle and centriole associated protein 1","metadata":{"aliases":["SPICE","CCDC52"]}},{"id":"45df947802574063bb8531059d19a750","type":"GENE","name":"SPICE1-CFAP44","canonical_id":"hgnc:HGNC:58084","description":"SPICE1-CFAP44 readthrough (NMD candidate)","metadata":null},{"id":"eb40916696eb4dfca315d3a4d2c974fc","type":"GENE","name":"SPICP1","canonical_id":"hgnc:HGNC:56809","description":"Spi-C transcription factor pseudogene 1","metadata":null},{"id":"ef12ab3ff24a47149b67ec4ed1a5c4c8","type":"GENE","name":"SPICP2","canonical_id":"hgnc:HGNC:56810","description":"Spi-C transcription factor pseudogene 2","metadata":null},{"id":"f3d57ddd542b4d3e835b75b57052be5e","type":"GENE","name":"SPICP3","canonical_id":"hgnc:HGNC:56811","description":"Spi-C transcription factor pseudogene 3","metadata":null},{"id":"251f858742e149b899861867629764d5","type":"GENE","name":"SPICP4","canonical_id":"hgnc:HGNC:56812","description":"Spi-C transcription factor pseudogene 4","metadata":null},{"id":"38048615f6b9457082d95b2fc31005c0","type":"GENE","name":"SPICP5","canonical_id":"hgnc:HGNC:56813","description":"Spi-C transcription factor pseudogene 5","metadata":null},{"id":"660409419c7f4881ad3a754124907ad8","type":"GENE","name":"SPIDR","canonical_id":"hgnc:HGNC:28971","description":"scaffold protein involved in DNA repair","metadata":{"aliases":["KIAA0146"]}},{"id":"76db4834e168417da31b33e93504cc72","type":"GENE","name":"SPIN1","canonical_id":"hgnc:HGNC:11243","description":"spindlin 1","metadata":{"aliases":["TDRD24","SPIN"]}},{"id":"0efceebf21d84409aec130feeb8a0109","type":"GENE","name":"SPIN2A","canonical_id":"hgnc:HGNC:20694","description":"spindlin family member 2A","metadata":{"aliases":["DXF34","TDRD25","SPIN2"]}},{"id":"9e79d4fcf2b3433197c2bf5a7b8e884c","type":"GENE","name":"SPIN2B","canonical_id":"hgnc:HGNC:33147","description":"spindlin family member 2B","metadata":{"aliases":["SPIN-2","TDRD26"]}},{"id":"212dd7c398fb49f7adac067f37dd24a9","type":"GENE","name":"SPIN2P1","canonical_id":"hgnc:HGNC:54967","description":"SPIN2 family pseudogene 1","metadata":null},{"id":"1bc15877abc34a97891a80da22ef22f6","type":"GENE","name":"SPIN3","canonical_id":"hgnc:HGNC:27272","description":"spindlin family member 3","metadata":{"aliases":["TDRD27"]}},{"id":"3004559bfe1c490eb69a35f338a22b87","type":"GENE","name":"SPIN4","canonical_id":"hgnc:HGNC:27040","description":"spindlin family member 4","metadata":{"aliases":["FLJ44984","TDRD28"]}},{"id":"bc45e08d76284ac0883715cc724c2c10","type":"GENE","name":"SPIN4-AS1","canonical_id":"hgnc:HGNC:41177","description":"SPIN4 antisense RNA 1","metadata":null},{"id":"50f2f2cfd8424b47b5bdacd2f1285cad","type":"GENE","name":"SPINDOC","canonical_id":"hgnc:HGNC:25115","description":"spindlin interactor and repressor of chromatin binding","metadata":{"aliases":["SPIN-DOC","C11orf84"]}},{"id":"6fd98aef5f784026b8d2c6a664764f0b","type":"GENE","name":"SPINK1","canonical_id":"hgnc:HGNC:11244","description":"serine peptidase inhibitor Kazal type 1","metadata":{"aliases":["Spink3","PCTT","PSTI","TATI"]}},{"id":"39418487cbcb4b9a904fef807d48d7e5","type":"GENE","name":"SPINK13","canonical_id":"hgnc:HGNC:27200","description":"serine peptidase inhibitor Kazal type 13","metadata":{"aliases":["SPINK5L3","LiESP6","HESPINTOR","MGC149260"]}},{"id":"24d1c0ec972d45689182f91d0db35493","type":"GENE","name":"SPINK14","canonical_id":"hgnc:HGNC:33825","description":"serine peptidase inhibitor Kazal type 14 (putative)","metadata":{"aliases":["SPINK5L2"]}},{"id":"6195313d8bfd49b9b174cd426d6cbf86","type":"GENE","name":"SPINK2","canonical_id":"hgnc:HGNC:11245","description":"serine peptidase inhibitor Kazal type 2","metadata":{"aliases":["HUSI-II"]}},{"id":"64bc02db087b4d5797cc2833b015430a","type":"GENE","name":"SPINK4","canonical_id":"hgnc:HGNC:16646","description":null,"metadata":null},{"id":"14f711eca6d34453a64472618c281d46","type":"GENE","name":"SPINK5","canonical_id":"hgnc:HGNC:15464","description":"serine peptidase inhibitor Kazal type 5","metadata":{"aliases":["VAKTI","LEKTI","LETKI","NETS","NS","FLJ21544","FLJ97536","FLJ97596","FLJ99794","DKFZp686K19184"]}},{"id":"f3606b5d9813463aafa271755bf052fe","type":"GENE","name":"SPINK6","canonical_id":"hgnc:HGNC:29486","description":"serine peptidase inhibitor Kazal type 6","metadata":{"aliases":["MGC21394","UNQ844","BUSI2"]}},{"id":"b693ac9eec004edc9e8197f8468565b5","type":"GENE","name":"SPINK7","canonical_id":"hgnc:HGNC:24643","description":"serine peptidase inhibitor Kazal type 7","metadata":{"aliases":["ECG2","ECRG2"]}},{"id":"0d7a17fa0e744c8abf9dc632bc13398f","type":"GENE","name":"SPINK8","canonical_id":"hgnc:HGNC:33160","description":"serine peptidase inhibitor Kazal type 8 (putative)","metadata":null},{"id":"845238f1fcf343b6b2cbfdffd0355da3","type":"GENE","name":"SPINK9","canonical_id":"hgnc:HGNC:32951","description":"serine peptidase inhibitor Kazal type 9","metadata":null},{"id":"36f35a7c48e44b658254f455ebbc4cdb","type":"GENE","name":"SPINT1","canonical_id":"hgnc:HGNC:11246","description":"serine peptidase inhibitor, Kunitz type 1","metadata":{"aliases":["HAI","HAI-1","MANSC2"]}},{"id":"3cd11cf8536e4a35b15d531e27919459","type":"GENE","name":"SPINT1-AS1","canonical_id":"hgnc:HGNC:53162","description":"SPINT1 antisense RNA 1","metadata":{"aliases":["RP11-532F12.5"]}},{"id":"5d8282180b4e4a1f98017b60205d6084","type":"GENE","name":"SPINT2","canonical_id":"hgnc:HGNC:11247","description":"serine peptidase inhibitor, Kunitz type 2","metadata":{"aliases":["Kop","HAI-2","HAI2"]}},{"id":"397ca51c5652405cb1b1608900e4c69e","type":"GENE","name":"SPINT3","canonical_id":"hgnc:HGNC:11248","description":"serine peptidase inhibitor, Kunitz type 3","metadata":{"aliases":["HKIB9"]}},{"id":"b2f7d4763ae24dada7701f095ebda6a7","type":"GENE","name":"SPINT4","canonical_id":"hgnc:HGNC:16130","description":"serine peptidase inhibitor, Kunitz type 4","metadata":{"aliases":["dJ601O1.1","C20orf137"]}},{"id":"f5efb1c15b074de789e400b1219ee06b","type":"GENE","name":"SPINT5P","canonical_id":"hgnc:HGNC:16161","description":"serine peptidase inhibitor, Kunitz type 5, pseudogene","metadata":{"aliases":["dJ447F3.6","C20orf168"]}},{"id":"23c49d676eac40718250414d75d5005a","type":"GENE","name":"SPIRE1","canonical_id":"hgnc:HGNC:30622","description":"spire type actin nucleation factor 1","metadata":{"aliases":["spir-1","KIAA1135"]}},{"id":"89a33308a2f8444d89abf095a2084b2a","type":"GENE","name":"SPIRE2","canonical_id":"hgnc:HGNC:30623","description":"spire type actin nucleation factor 2","metadata":{"aliases":["spir-2","KIAA1832"]}},{"id":"d126cef8c85048b696aebbe0a3e9e8a9","type":"GENE","name":"SPMAP1","canonical_id":"hgnc:HGNC:34492","description":"sperm microtubule associated protein 1","metadata":{"aliases":["LOC388381","C17orf98"]}},{"id":"9476e602344a417eaa959cac2bcfad81","type":"GENE","name":"SPMAP2","canonical_id":"hgnc:HGNC:13706","description":"sperm microtubule associated protein 2","metadata":{"aliases":["CT56","THEG1","THEG"]}},{"id":"8e41f83b99e44922b78e7a616696e282","type":"GENE","name":"SPMAP2L","canonical_id":"hgnc:HGNC:43771","description":"sperm microtubule associated protein 2 like","metadata":{"aliases":["THEGL"]}},{"id":"ae7e0de7ea1549e58d17812600a72aed","type":"GENE","name":"SPMAP2L-DT","canonical_id":"hgnc:HGNC:58796","description":"SPMAP2L divergent transcript","metadata":null},{"id":"0940f7f15daa4d03a2b32a87e5268f3b","type":"GENE","name":"SPMIP1","canonical_id":"hgnc:HGNC:52392","description":"sperm microtubule inner protein 1","metadata":{"aliases":["ATP6V1FNB"]}},{"id":"46198bc950d9487b828452a1ff1f153d","type":"GENE","name":"SPMIP10","canonical_id":"hgnc:HGNC:33767","description":"sperm microtubule inner protein 10","metadata":{"aliases":["MGC163367","MGC163369","FLJ27505","Tseg7","C5orf48","TEX43"]}},{"id":"5fce4edec0154ee2b9dc50b2e84f913a","type":"GENE","name":"SPMIP11","canonical_id":"hgnc:HGNC:48628","description":"sperm microtubule inner protein 11","metadata":{"aliases":["LINC00935","TEX49"]}},{"id":"eda1b60ea48545c49e29d8a56654e3c2","type":"GENE","name":"SPMIP1BP","canonical_id":"hgnc:HGNC:55169","description":"sperm microtubule inner protein 1B, pseudogene","metadata":{"aliases":["Gm45521P"]}},{"id":"110c4f0fde5549c493619ac8100ffc61","type":"GENE","name":"SPMIP2","canonical_id":"hgnc:HGNC:26342","description":"sperm microtubule inner protein 2","metadata":{"aliases":["FLJ25371","C4orf45"]}},{"id":"af99b0f8c28341429042ca66e122429e","type":"GENE","name":"SPMIP3","canonical_id":"hgnc:HGNC:30435","description":"sperm microtubule inner protein 3","metadata":{"aliases":["C1orf100"]}},{"id":"30ef93ed4fff4dd0ab0390dc82a60936","type":"GENE","name":"SPMIP3P1","canonical_id":"hgnc:HGNC:56415","description":"SPMIP3 pseudogene 1","metadata":{"aliases":["C1orf100P1"]}},{"id":"dc7f0a39a6b3491b9abcb641ce94b92a","type":"GENE","name":"SPMIP4","canonical_id":"hgnc:HGNC:21722","description":"sperm microtubule inner protein 4","metadata":{"aliases":["C7orf31"]}},{"id":"d0f2792b620c42f9b482c06733577305","type":"GENE","name":"SPMIP5","canonical_id":"hgnc:HGNC:28500","description":"sperm microtubule inner protein 5","metadata":{"aliases":["MGC33547","Em:AC016825.4","C10orf82"]}},{"id":"63633b9b46cc480eb4697c38b96afe8b","type":"GENE","name":"SPMIP6","canonical_id":"hgnc:HGNC:19919","description":"sperm microtubule inner protein 6","metadata":{"aliases":["bA573M23.4","NYD-SP22","MGC32921","MGC33614","CBE1","SMRP1","C9orf24"]}},{"id":"2af2ea49cd374e52a7551d9171bee17f","type":"GENE","name":"SPMIP7","canonical_id":"hgnc:HGNC:22564","description":"sperm microtubule inner protein 7","metadata":{"aliases":["C7orf72","SPATA48"]}},{"id":"6e3a51e04058476e9bd477284765f0a2","type":"GENE","name":"SPMIP8","canonical_id":"hgnc:HGNC:33745","description":"sperm microtubule inner protein 8","metadata":{"aliases":["TEPP"]}},{"id":"dfdcb7150e844526b0d9ea8fb542cd96","type":"GENE","name":"SPMIP9","canonical_id":"hgnc:HGNC:26341","description":"sperm microtubule inner protein 9","metadata":{"aliases":["FLJ25369","TSC21","C2orf51","TEX37"]}},{"id":"60f6d4630f28493983d80b8b0248f201","type":"GENE","name":"SPN","canonical_id":"hgnc:HGNC:11249","description":null,"metadata":null},{"id":"68d8883925f34ac3b13d64398c0a0eb8","type":"GENE","name":"SPNS1","canonical_id":"hgnc:HGNC:30621","description":"SPNS lysolipid transporter 1, lysophospholipid","metadata":{"aliases":["HSpin1","nrs","SPINL","PP2030","SPIN1","LAT","SLC63A1"]}},{"id":"1a4f03cf653c4e65bfa2f5e85512c3d9","type":"GENE","name":"SPNS2","canonical_id":"hgnc:HGNC:26992","description":"SPNS lysolipid transporter 2, sphingosine-1-phosphate","metadata":{"aliases":["SLC63A2"]}},{"id":"840acbe9f40f4f67bcf73ff06fe9d538","type":"GENE","name":"SPNS2-AS1","canonical_id":"hgnc:HGNC:55787","description":"SPNS2 antisense RNA 1","metadata":null},{"id":"732a4c9d06094531adb256de89d81309","type":"GENE","name":"SPNS3","canonical_id":"hgnc:HGNC:28433","description":"SPNS lysolipid transporter 3, sphingosine-1-phosphate (putative)","metadata":{"aliases":["MGC29671","SLC63A3"]}},{"id":"3b8929dc45054788bc8f335c8b25d3b1","type":"GENE","name":"SPO11","canonical_id":"hgnc:HGNC:11250","description":"SPO11 initiator of meiotic double strand breaks","metadata":{"aliases":["CT35","SPATA43","TOPVIA","TOPOVIA"]}},{"id":"b68a08ecf4da413595bd820c4b1b4fcf","type":"GENE","name":"SPOCD1","canonical_id":"hgnc:HGNC:26338","description":"SPOC domain containing 1","metadata":{"aliases":["FLJ25348","PPP1R146"]}},{"id":"1559f57f20b94738be0e7ddf1e5d4109","type":"GENE","name":"SPOCK1","canonical_id":"hgnc:HGNC:11251","description":"SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1","metadata":{"aliases":["testican-1","TIC1","SPOCK"]}},{"id":"d814d9fdcaa34d4c8934c3367fda38b5","type":"GENE","name":"SPOCK1-AS1","canonical_id":"hgnc:HGNC:59149","description":"SPOCK1 antisense RNA 1","metadata":null},{"id":"9ebb6fb966674e6bb6d4c4a4c8508f7e","type":"GENE","name":"SPOCK2","canonical_id":"hgnc:HGNC:13564","description":"SPARC (osteonectin), cwcv and kazal like domains proteoglycan 2","metadata":{"aliases":["KIAA0275","testican-2"]}},{"id":"83f75706d5964b8499b1208ea87c60f5","type":"GENE","name":"SPOCK3","canonical_id":"hgnc:HGNC:13565","description":"SPARC (osteonectin), cwcv and kazal like domains proteoglycan 3","metadata":{"aliases":["testican-3"]}},{"id":"1ffb14fd7a284ad2a470bc31675b0d82","type":"GENE","name":"SPOCK3-AS1","canonical_id":"hgnc:HGNC:58906","description":"SPOCK3 antisense RNA 1","metadata":null},{"id":"c2dbca4c622140aca91e216e41b73542","type":"GENE","name":"SPON1","canonical_id":"hgnc:HGNC:11252","description":"spondin 1","metadata":{"aliases":["KIAA0762","f-spondin"]}},{"id":"210339971fc745119fec6c3e9eaf1992","type":"GENE","name":"SPON1-AS1","canonical_id":"hgnc:HGNC:53117","description":"SPON1 antisense RNA 1","metadata":{"aliases":["RP11-21","L19.1"]}},{"id":"eddf3dc10ae6400f9b5e113c758c0aaa","type":"GENE","name":"SPON2","canonical_id":"hgnc:HGNC:11253","description":"spondin 2","metadata":{"aliases":["DIL1"]}},{"id":"968e99f2a9d941bba9dd78c482717d49","type":"GENE","name":"SPON2-AS1","canonical_id":"hgnc:HGNC:58121","description":"SPON2 antisense RNA 1","metadata":{"aliases":["LINC-AC092535.5","AC092535.4"]}},{"id":"2b0824eb1ea6434eacdf2b606e4003eb","type":"GENE","name":"SPOP","canonical_id":"hgnc:HGNC:11254","description":"speckle type BTB/POZ protein","metadata":{"aliases":["TEF2","BTBD32"]}},{"id":"60da6811c1bb482f89cff279af2e6dd5","type":"GENE","name":"SPOPL","canonical_id":"hgnc:HGNC:27934","description":"speckle type BTB/POZ protein like","metadata":{"aliases":["BTBD33"]}},{"id":"41312744f0484e99aa41c2a7028e9dc0","type":"GENE","name":"SPOPL-DT","canonical_id":"hgnc:HGNC:55802","description":"SPOPL divergent transcript","metadata":null},{"id":"8a3a174ddef7466bb860ae93b164dc90","type":"GENE","name":"SPOPLP1","canonical_id":"hgnc:HGNC:56791","description":"SPOPL pseudogene 1","metadata":null},{"id":"71e591cdd68349c1a5b357a97c2c2b8f","type":"GENE","name":"SPOPLP2","canonical_id":"hgnc:HGNC:56792","description":"SPOPL pseudogene 2","metadata":null},{"id":"2ec91693367146e4a53b3b26cc3c4b30","type":"GENE","name":"SPOPLP3","canonical_id":"hgnc:HGNC:56793","description":"SPOPL pseudogene 3","metadata":null},{"id":"cb514c80fabf4f31a2ed069a8452083e","type":"GENE","name":"SPOUT1","canonical_id":"hgnc:HGNC:26933","description":"SPOUT domain containing methyltransferase 1","metadata":{"aliases":["HSPC109","CENP-32","C9orf114"]}},{"id":"1650d924daa44bd396a37700e97b57ec","type":"GENE","name":"SPP1","canonical_id":"hgnc:HGNC:11255","description":null,"metadata":null},{"id":"8419b38fd03a41b4aff2df9e4eb2cb3b","type":"TRIAL","name":"SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction","canonical_id":"clinicaltrials.gov:NCT00299832","description":"Hypertension","metadata":null},{"id":"21a5fec8b319476c8a7a84eebb7b2914","type":"TRIAL","name":"SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00299806","description":"Hypertension","metadata":null},{"id":"68ca696f3f154dde979dce5dc78deb38","type":"GENE","name":"SPP2","canonical_id":"hgnc:HGNC:11256","description":"secreted phosphoprotein 2","metadata":{"aliases":["SPP24"]}},{"id":"1fec72c50aa941729e145968fa5554a6","type":"GENE","name":"SPPL2A","canonical_id":"hgnc:HGNC:30227","description":"signal peptide peptidase like 2A","metadata":{"aliases":["IMP3","PSL2"]}},{"id":"63978049602a48958d78f8aaaf97dd77","type":"GENE","name":"SPPL2B","canonical_id":"hgnc:HGNC:30627","description":"signal peptide peptidase like 2B","metadata":{"aliases":["IMP4","PSL1","KIAA1532"]}},{"id":"00632b58f35344a191a3cc518a084119","type":"GENE","name":"SPPL2C","canonical_id":"hgnc:HGNC:28902","description":"signal peptide peptidase like 2C","metadata":{"aliases":["IMP5"]}},{"id":"d87c28bb3d8f4faabd77ce4031c7608c","type":"GENE","name":"SPPL3","canonical_id":"hgnc:HGNC:30424","description":"signal peptide peptidase like 3","metadata":{"aliases":["IMP2","PSL4","MGC90402","MGC126674","MGC126676","DKFZP586C1324"]}},{"id":"e153956d65334c0fa8884de81bc01d30","type":"GENE","name":"SPPL3P1","canonical_id":"hgnc:HGNC:59235","description":"SPPL3 pseudogene 1","metadata":null},{"id":"1016a7e7adf94de59141c461e3abad52","type":"GENE","name":"SPR","canonical_id":"hgnc:HGNC:11257","description":"sepiapterin reductase","metadata":{"aliases":["SDR38C1"]}},{"id":"2b78c603741243a7bc0a8bb04fac864d","type":"GENE","name":"SPRED1","canonical_id":"hgnc:HGNC:20249","description":"sprouty related EVH1 domain containing 1","metadata":{"aliases":["FLJ33903","PPP1R147","SPRED-1"]}},{"id":"6258c8ab50154b3ca8fadaf87363873a","type":"GENE","name":"SPRED2","canonical_id":"hgnc:HGNC:17722","description":"sprouty related EVH1 domain containing 2","metadata":{"aliases":["Spred-2","FLJ21897","FLJ31917"]}},{"id":"9d38f816d23c4e62bc8f549cb1645039","type":"GENE","name":"SPRED3","canonical_id":"hgnc:HGNC:31041","description":"sprouty related EVH1 domain containing 3","metadata":null},{"id":"d596356ee9c74672b71c9ed4f62f7c74","type":"GENE","name":"SPRING1","canonical_id":"hgnc:HGNC:26128","description":"SREBF pathway regulator in golgi 1","metadata":{"aliases":["FLJ21415","SPRING","POST1","LUR1","C12orf49"]}},{"id":"f6864593d13b4441b705b59907b3809e","type":"GENE","name":"SPRING1P1","canonical_id":"hgnc:HGNC:44986","description":"SPRING1 pseudogene 1","metadata":null},{"id":"716ffac5458b474890348ab6c1d43781","type":"GENE","name":"SPRING1P2","canonical_id":"hgnc:HGNC:55130","description":"SPRING1 pseudogene 2","metadata":null},{"id":"710e7f1dfe744d0cb12bec54abc3a147","type":"GENE","name":"SPRING1P3","canonical_id":"hgnc:HGNC:56328","description":"SPRING1 pseudogene 3","metadata":null},{"id":"952b112d31b64a8bbe34137b33471fb4","type":"GENE","name":"SPRN","canonical_id":"hgnc:HGNC:16871","description":"shadow of prion protein","metadata":{"aliases":["Shadoo","bA108K14.1","FLJ41197"]}},{"id":"fbd8ff89623b46b6b526c6b6624506a1","type":"GENE","name":"SPRNP1","canonical_id":"hgnc:HGNC:37819","description":"shadow of prion protein pseudogene 1","metadata":{"aliases":["FLJ44653"]}},{"id":"0f61215bfdaa46448b9bb54287062c0e","type":"GENE","name":"SPRR1A","canonical_id":"hgnc:HGNC:11259","description":null,"metadata":null},{"id":"a38dd5592deb4785b82630f342c372d5","type":"GENE","name":"SPRR1B","canonical_id":"hgnc:HGNC:11260","description":null,"metadata":null},{"id":"9c61185156e54a7caacfa640b3f6cc0b","type":"GENE","name":"SPRR2A","canonical_id":"hgnc:HGNC:11261","description":null,"metadata":null},{"id":"656f35a9a63145b3ba797d55703d27e1","type":"GENE","name":"SPRR2B","canonical_id":"hgnc:HGNC:11262","description":"small proline rich protein 2B","metadata":null},{"id":"7322f1b1425f4d978362bc1250ac9740","type":"GENE","name":"SPRR2C","canonical_id":"hgnc:HGNC:11263","description":"small proline rich protein 2C (pseudogene)","metadata":null},{"id":"8926f671994342ebbf68542ad574be20","type":"GENE","name":"SPRR2D","canonical_id":"hgnc:HGNC:11264","description":"small proline rich protein 2D","metadata":null},{"id":"62aa6ae0f72f421b919fdeac1ded1482","type":"GENE","name":"SPRR2E","canonical_id":"hgnc:HGNC:11265","description":"small proline rich protein 2E","metadata":null},{"id":"49febd04282b4786a2b243594823d4bf","type":"GENE","name":"SPRR2F","canonical_id":"hgnc:HGNC:11266","description":"small proline rich protein 2F","metadata":null},{"id":"2989e6cda1d0468a9c546b43ae9e66aa","type":"GENE","name":"SPRR2G","canonical_id":"hgnc:HGNC:11267","description":"small proline rich protein 2G","metadata":null},{"id":"39d1e8e2a0a9413580539a277f002534","type":"GENE","name":"SPRR3","canonical_id":"hgnc:HGNC:11268","description":null,"metadata":null},{"id":"dad8ee68a6664af6bb5c4c4710f3b5db","type":"GENE","name":"SPRR4","canonical_id":"hgnc:HGNC:23173","description":"small proline rich protein 4","metadata":null},{"id":"0db5409f45a646c492adc4a23f060041","type":"GENE","name":"SPRR5","canonical_id":"hgnc:HGNC:53428","description":"small proline rich protein 5","metadata":null},{"id":"eb39e0d141444015a5d7aae4aebccca0","type":"GENE","name":"SPRTN","canonical_id":"hgnc:HGNC:25356","description":"SprT-like N-terminal domain","metadata":{"aliases":["DKFZP547N043","Spartan","DVC1","C1orf124"]}},{"id":"f1f4fedf34bb4f8886ea469225c3068a","type":"GENE","name":"SPRY1","canonical_id":"hgnc:HGNC:11269","description":null,"metadata":null},{"id":"fbe058b2d2e74a6791e2a79189834f51","type":"GENE","name":"SPRY2","canonical_id":"hgnc:HGNC:11270","description":null,"metadata":null},{"id":"dbcd41ce76b3403dabd2029f613c8dc8","type":"GENE","name":"SPRY3","canonical_id":"hgnc:HGNC:11271","description":"sprouty RTK signaling antagonist 3","metadata":{"aliases":["HSPRY3"]}},{"id":"b271f51ebb6f4caab6216abbec536b61","type":"GENE","name":"SPRY4","canonical_id":"hgnc:HGNC:15533","description":"sprouty RTK signaling antagonist 4","metadata":null},{"id":"50f8fbc94ccc48c1b0126bcc75f850f9","type":"GENE","name":"SPRY4-AS1","canonical_id":"hgnc:HGNC:53465","description":"SPRY4 antisense RNA 1","metadata":{"aliases":["THCAT68","AC005592.2","LINC01844"]}},{"id":"374ee2aebffe49a58147cce02e4f7ea6","type":"GENE","name":"SPRY4-IT1","canonical_id":"hgnc:HGNC:42394","description":"SPRY4 intronic transcript 1","metadata":{"aliases":["SPRIGHTLY"]}},{"id":"d77cda39d20546ddb8597df1af7d4221","type":"GENE","name":"SPRYD3","canonical_id":"hgnc:HGNC:25920","description":"SPRY domain containing 3","metadata":{"aliases":["FLJ14800"]}},{"id":"76d71f2f2fc6468792551d8caa05d063","type":"GENE","name":"SPRYD4","canonical_id":"hgnc:HGNC:27468","description":"SPRY domain containing 4","metadata":{"aliases":["DKFZp686N0877"]}},{"id":"42a736db10ae472392583338e37f32aa","type":"GENE","name":"SPRYD7","canonical_id":"hgnc:HGNC:14297","description":"SPRY domain containing 7","metadata":{"aliases":["CLLD6","C13orf1"]}},{"id":"806eadff27364ae7adfb5fb776aae299","type":"GENE","name":"SPRYD7P1","canonical_id":"hgnc:HGNC:52300","description":"SPRY domain containing 7 pseudogene 1","metadata":null},{"id":"a93ce9dbabf44ff6875c880713cd455b","type":"GENE","name":"SPSB1","canonical_id":"hgnc:HGNC:30628","description":"splA/ryanodine receptor domain and SOCS box containing 1","metadata":{"aliases":["SSB-1"]}},{"id":"b8a69658e3284a8d8d13b91dd457fa1a","type":"GENE","name":"SPSB2","canonical_id":"hgnc:HGNC:29522","description":"splA/ryanodine receptor domain and SOCS box containing 2","metadata":{"aliases":["GRCC9","SSB-2"]}},{"id":"cdfdffdd15c14724943daff205aa5ebd","type":"GENE","name":"SPSB3","canonical_id":"hgnc:HGNC:30629","description":"splA/ryanodine receptor domain and SOCS box containing 3","metadata":{"aliases":["SSB-3","C16orf31"]}},{"id":"e9f5afa6ae1b4ab09aba90f4e323a4f7","type":"GENE","name":"SPSB4","canonical_id":"hgnc:HGNC:30630","description":"splA/ryanodine receptor domain and SOCS box containing 4","metadata":{"aliases":["SSB-4"]}},{"id":"2a7f1e3769624d8a9fbee807c10f4468","type":"GENE","name":"SPTA1","canonical_id":"hgnc:HGNC:11272","description":"spectrin alpha, erythrocytic 1","metadata":{"aliases":["EL2"]}},{"id":"a99f168afdf34c41a5593e81388dcf0d","type":"GENE","name":"SPTAN1","canonical_id":"hgnc:HGNC:11273","description":"spectrin alpha, non-erythrocytic 1","metadata":null},{"id":"d4c18fea8afb41d5ad60b6d6738a2ef3","type":"GENE","name":"SPTB","canonical_id":"hgnc:HGNC:11274","description":"spectrin beta, erythrocytic","metadata":null},{"id":"80ae4009dd224d449ef0b14d0aee625d","type":"GENE","name":"SPTBN1","canonical_id":"hgnc:HGNC:11275","description":"spectrin beta, non-erythrocytic 1","metadata":null},{"id":"68a6643dbee84684b4c4a96413dabea2","type":"GENE","name":"SPTBN1-AS1","canonical_id":"hgnc:HGNC:40562","description":"SPTBN1 antisense RNA 1","metadata":{"aliases":["SPTBN1-AS2"]}},{"id":"5a0c7d22dadf4e309f13ba7b9666385b","type":"GENE","name":"SPTBN1-AS2","canonical_id":"hgnc:HGNC:40563","description":"SPTBN1 antisense RNA 2","metadata":null},{"id":"9df3e0bdcf474757a17ab686fe1b0b43","type":"GENE","name":"SPTBN2","canonical_id":"hgnc:HGNC:11276","description":"spectrin beta, non-erythrocytic 2","metadata":{"aliases":["SCA5"]}},{"id":"988036d207c44901b8349faf5a19ca03","type":"GENE","name":"SPTBN4","canonical_id":"hgnc:HGNC:14896","description":"spectrin beta, non-erythrocytic 4","metadata":{"aliases":["SPTBN3","KIAA1642"]}},{"id":"3f62800329a64bef99a81b39d28f6581","type":"GENE","name":"SPTBN5","canonical_id":"hgnc:HGNC:15680","description":"spectrin beta, non-erythrocytic 5","metadata":{"aliases":["HUSPECV","BSPECV","HUBSPECV"]}},{"id":"d513077429104fe49003e489b3b1560a","type":"GENE","name":"SPTLC1","canonical_id":"hgnc:HGNC:11277","description":"serine palmitoyltransferase long chain base subunit 1","metadata":{"aliases":["LCB1","SPTI","HSAN1","hLCB1","HSN1"]}},{"id":"856f9b19a87f449da22a4e9276256268","type":"GENE","name":"SPTLC1P1","canonical_id":"hgnc:HGNC:39668","description":"serine palmitoyltransferase long chain base subunit 1 pseudogene 1","metadata":null},{"id":"4b7d834a623f4fbaae951342b656a330","type":"GENE","name":"SPTLC1P2","canonical_id":"hgnc:HGNC:39669","description":"serine palmitoyltransferase long chain base subunit 1 pseudogene 2","metadata":null},{"id":"a1d19251bf264dc384a750b4f12675ad","type":"GENE","name":"SPTLC1P3","canonical_id":"hgnc:HGNC:39670","description":"serine palmitoyltransferase long chain base subunit 1 pseudogene 3","metadata":null},{"id":"73b33f10e1704d72860433ee8ddd81dc","type":"GENE","name":"SPTLC1P4","canonical_id":"hgnc:HGNC:39671","description":"serine palmitoyltransferase long chain base subunit 1 pseudogene 4","metadata":null},{"id":"bfcd73ab44a541a5b731692481100a20","type":"GENE","name":"SPTLC1P5","canonical_id":"hgnc:HGNC:39672","description":"serine palmitoyltransferase long chain base subunit 1 pseudogene 5","metadata":null},{"id":"2232a1674590499abfff7366e5dca642","type":"GENE","name":"SPTLC2","canonical_id":"hgnc:HGNC:11278","description":"serine palmitoyltransferase long chain base subunit 2","metadata":{"aliases":["KIAA0526","LCB2","LCB2A","hLCB2a"]}},{"id":"ab7afbdc7aac439d85642a645dd3f59d","type":"GENE","name":"SPTLC3","canonical_id":"hgnc:HGNC:16253","description":"serine palmitoyltransferase long chain base subunit 3","metadata":{"aliases":["LCB2B","FLJ11112","hLCB2b","C20orf38","SPTLC2L"]}},{"id":"f7144c1eaca6435b86f9d5a05f37a56e","type":"GENE","name":"SPTSSA","canonical_id":"hgnc:HGNC:20361","description":"serine palmitoyltransferase small subunit A","metadata":{"aliases":["ssSPTa","C14orf147"]}},{"id":"73b39937b44d4a15840a617d8491a313","type":"GENE","name":"SPTSSB","canonical_id":"hgnc:HGNC:24045","description":"serine palmitoyltransferase small subunit B","metadata":{"aliases":["ADMP","ssSPTb","C3orf57"]}},{"id":"39dbb64df32244d0aedc740cdd56f146","type":"GENE","name":"SPTY2D1","canonical_id":"hgnc:HGNC:26818","description":"SPT2 chromatin protein domain containing 1","metadata":{"aliases":["FLJ39441","DKFZp686I068","Spt2"]}},{"id":"5f3a151e992142d89818e077946ad8e7","type":"GENE","name":"SPX","canonical_id":"hgnc:HGNC:28139","description":"spexin hormone","metadata":{"aliases":["MGC10946","NPQ","spexin","SPX1","C12orf39"]}},{"id":"8e7b3dab9cd341fe9554a18518684725","type":"GENE","name":"SPZ1","canonical_id":"hgnc:HGNC:30721","description":"spermatogenic leucine zipper 1","metadata":{"aliases":["NYD-TSP1","FLJ25709","PPP1R148"]}},{"id":"b8d6a29b90ec4e00b52cd2762f6f1043","type":"GENE","name":"SQLE","canonical_id":"hgnc:HGNC:11279","description":"squalene epoxidase","metadata":null},{"id":"4d42693fa8e8463ab4dfe38671d84424","type":"GENE","name":"SQLE-DT","canonical_id":"hgnc:HGNC:55534","description":"SQLE divergent transcript","metadata":{"aliases":["lnc030"]}},{"id":"25aa97423d2c4536a5b051d2b4f118d7","type":"GENE","name":"SQOR","canonical_id":"hgnc:HGNC:20390","description":"sulfide quinone oxidoreductase","metadata":{"aliases":["CGI-44","SQR","SQRDL"]}},{"id":"b0f1acf0e80b4d5d8a24d9eb9345965c","type":"GENE","name":"SQSTM1","canonical_id":"hgnc:HGNC:11280","description":null,"metadata":null},{"id":"6fbadab8f04449389d8568dc188cd87e","type":"GENE","name":"SQSTM1P1","canonical_id":"hgnc:HGNC:49099","description":"sequestosome 1 pseudogene 1","metadata":null},{"id":"c0759cef71c84e3f98082399cbe3bc84","type":"GENE","name":"SRA1","canonical_id":"hgnc:HGNC:11281","description":"steroid receptor RNA activator 1","metadata":{"aliases":["SRA","STRAA1"]}},{"id":"3d2093acc59a48f18ffc47f0217c9452","type":"GENE","name":"SRARP","canonical_id":"hgnc:HGNC:28339","description":"steroid receptor associated and regulated protein","metadata":{"aliases":["MGC24047","ERRF","C1orf64"]}},{"id":"2406e22ac80d48e592e09fc6987bf531","type":"GENE","name":"SRBD1","canonical_id":"hgnc:HGNC:25521","description":"S1 RNA binding domain 1","metadata":{"aliases":["FLJ10379"]}},{"id":"cfb60592c41249b1803ace69af3f9b2a","type":"GENE","name":"SRC","canonical_id":"hgnc:HGNC:11283","description":null,"metadata":null},{"id":"078602724df44be488e8c3b624aa84a1","type":"GENE","name":"SRC","canonical_id":"ensembl:ENSG00000197122","description":null,"metadata":null},{"id":"8c951d8fe5174897a49c378841bc8951","type":"PROTEIN","name":"SRC","canonical_id":"uniprot:P12931","description":null,"metadata":null},{"id":"4d5d9a1eccf042cfa47e6c2c2b157d1f","type":"GENE","name":"SRCAP","canonical_id":"hgnc:HGNC:16974","description":null,"metadata":null},{"id":"f51badc239f0490f8ee90850aa9fbf9f","type":"GENE","name":"SRCAP-AS1","canonical_id":"hgnc:HGNC:55348","description":"SRCAP antisense RNA 1","metadata":null},{"id":"bbb22f2076f94656a682d5e5de66245a","type":"GENE","name":"SRCIN1","canonical_id":"hgnc:HGNC:29506","description":"SRC kinase signaling inhibitor 1","metadata":{"aliases":["SNIP","p140Cap","KIAA1684"]}},{"id":"2cb787215b614b87ace48bbb2cc9afb3","type":"GENE","name":"SRD5A1","canonical_id":"hgnc:HGNC:11284","description":"steroid 5 alpha-reductase 1","metadata":null},{"id":"c934c950eaae490698a8461d4a3b74bd","type":"GENE","name":"SRD5A1P1","canonical_id":"hgnc:HGNC:11286","description":"steroid 5 alpha-reductase 1 pseudogene 1","metadata":{"aliases":["SRD5AP1"]}},{"id":"fdb0cec0a03f4156b2d1cf5c66b06e63","type":"GENE","name":"SRD5A2","canonical_id":"hgnc:HGNC:11285","description":"steroid 5 alpha-reductase 2","metadata":null},{"id":"b8ed86433b3b47b99a6af467aa10e1b6","type":"PROTEIN","name":"SRD5A2","canonical_id":"uniprot:P31213","description":null,"metadata":null},{"id":"e495aa04dcd44f85a8c73376f7e409a6","type":"GENE","name":"SRD5A2P1","canonical_id":"hgnc:HGNC:55160","description":"SRD5A2 pseudogene 1","metadata":null},{"id":"1e50eac770c44d3291cb5d18b6f8c14e","type":"GENE","name":"SRD5A3","canonical_id":"hgnc:HGNC:25812","description":null,"metadata":null},{"id":"153c28d10a6c4ad5885b65ec4360b933","type":"GENE","name":"SRD5A3-AS1","canonical_id":"hgnc:HGNC:44138","description":"SRD5A3 antisense RNA 1","metadata":null},{"id":"9fa2cc9f3b9a4f0d9b47502fecaadbd0","type":"GENE","name":"SRD5A3P1","canonical_id":"hgnc:HGNC:49243","description":"steroid 5 alpha-reductase 3 pseudogene 1","metadata":null},{"id":"8921b9a4355d4f25ad3d8b32dc1fb539","type":"GENE","name":"SREBF1","canonical_id":"hgnc:HGNC:11289","description":null,"metadata":null},{"id":"fc39ce37454a410cbc89af3997205730","type":"GENE","name":"SREBF2","canonical_id":"hgnc:HGNC:11290","description":null,"metadata":null},{"id":"4adec79aa0f74cbb87644e05f5101d85","type":"GENE","name":"SREBF2-AS1","canonical_id":"hgnc:HGNC:53953","description":"SREBF2 antisense RNA 1","metadata":{"aliases":["RP5","821D11.7"]}},{"id":"c329e233e56c4a6f9f22905c0bda3a1c","type":"GO_TERM","name":"SREBP signaling pathway","canonical_id":"go:GO:0032933","description":"\"The series of molecular signals from the endoplasmic reticulum to the nucleus generated as a consequence of decreased levels of one or more sterols (and in some yeast, changes in oxygen levels) and which proceeds through activation of a sterol response element binding transcription factor (SREBP) to result in up-regulation of target gene transcription.\" [GOC:bf, GOC:mah, GOC:signaling, GOC:vw, PMID:12923525, PMID:22017871]","metadata":null},{"id":"fbb035e8a10e434d8ef08f382e7370f5","type":"GO_TERM","name":"SREBP-SCAP complex","canonical_id":"go:GO:0032936","description":"\"A protein complex formed by the association of sterol regulatory element binding protein (SREBP) and SREBP-cleavage-activating protein (SCAP) in the ER membrane; in the absence of sterols, the SREBP-SCAP complex is packaged into COPII vesicles and travels to the Golgi apparatus to be processed.\" [PMID:12923525]","metadata":null},{"id":"7aa9ffcbf1b145a5926224b8d1109ed3","type":"GO_TERM","name":"SREBP-SCAP complex retention in endoplasmic reticulum","canonical_id":"go:GO:0036316","description":"\"Any process in which the SREBP-SCAP complex is maintained in the endoplasmic reticulum and prevented from moving elsewhere. The SREBP-SCAP complex is formed by the association of sterol regulatory element binding protein (SREBP) and SREBP-cleavage-activating protein (SCAP). In the absence of sterols, the SREBP-SCAP complex is packaged into COPII vesicles and travels to the Golgi apparatus to be processed. In the presence of sterols, the complex binds ER-resident proteins such as INSIG, which retain the complex in the ER.\" [GOC:bf, PMID:16525117]","metadata":null},{"id":"f69006c7a0c4442fabb393d249c08ce6","type":"GO_TERM","name":"SREBP-SCAP-Insig complex","canonical_id":"go:GO:0032937","description":"\"A protein complex formed by the association of sterol regulatory element binding protein (SREBP), SREBP-cleavage-activating protein (SCAP), and an Insig protein (Insig-1 or Insig-2) in the ER membrane.\" [PMID:12923525]","metadata":null},{"id":"4da80d563bc04ee393660d50f087e8d9","type":"GENE","name":"SREK1","canonical_id":"hgnc:HGNC:17882","description":"splicing regulatory glutamic acid and lysine rich protein 1","metadata":{"aliases":["DKFZp564B176","SRrp86","SRrp508","SFRS12"]}},{"id":"7d8eeb947df4406bb62bfd1e6a6cca4f","type":"GENE","name":"SREK1IP1","canonical_id":"hgnc:HGNC:26716","description":"SREK1 interacting protein 1","metadata":{"aliases":["FLJ36754","P18SRP","SFRS12IP1"]}},{"id":"8c452e61686749a6b0721d8db2a8679e","type":"GENE","name":"SREK1IP1P1","canonical_id":"hgnc:HGNC:54504","description":"SREK1IP1 pseudogene 1","metadata":null},{"id":"f9d91b29e92c4292a30e41c468767897","type":"GENE","name":"SREK1IP1P2","canonical_id":"hgnc:HGNC:54505","description":"SREK1IP1 pseudogene 2","metadata":null},{"id":"40f3b242de4340759887e398d4fbadf5","type":"GENE","name":"SRF","canonical_id":"hgnc:HGNC:11291","description":null,"metadata":null},{"id":"8d3bf22fd4224eee931cec6a68933c7a","type":"GENE","name":"SRF-AS1","canonical_id":"hgnc:HGNC:59410","description":"SRF antisense RNA 1","metadata":null},{"id":"8de85b748db44026ae261f220f6b764a","type":"GO_TERM","name":"SRF-myogenin-E12 complex","canonical_id":"go:GO:0070514","description":"\"A transcription factor complex that contains the serum response factor (SRF) and the basic helix-loop-helix proteins myogenin and E12, and is involved in activating transcription of muscle-specific genes.\" [PMID:8617811]","metadata":null},{"id":"45b4f860ec704b0591d4c82850a8f08b","type":"GENE","name":"SRFBP1","canonical_id":"hgnc:HGNC:26333","description":"serum response factor binding protein 1","metadata":{"aliases":["FLJ25286","p49","STRAP","BUD22","Rlb1"]}},{"id":"6706eab705ab43fc9e4629940638873b","type":"GENE","name":"SRGAP1","canonical_id":"hgnc:HGNC:17382","description":"SLIT-ROBO Rho GTPase activating protein 1","metadata":{"aliases":["KIAA1304","ARHGAP13"]}},{"id":"90f280ed631c4c1ca806dd9c1fc25d95","type":"GENE","name":"SRGAP1-AS1","canonical_id":"hgnc:HGNC:59221","description":"SRGAP1 antisense RNA 1","metadata":null},{"id":"9b90e7ad9d984c14b3a2e76fa05c271d","type":"GENE","name":"SRGAP2","canonical_id":"hgnc:HGNC:19751","description":"SLIT-ROBO Rho GTPase activating protein 2","metadata":{"aliases":["KIAA0456","ARHGAP34","SRGAP2A","FNBP2"]}},{"id":"954d865914774f1e9254ef7dd0c9ba90","type":"GENE","name":"SRGAP2-AS1","canonical_id":"hgnc:HGNC:40902","description":"SRGAP2 antisense RNA 1","metadata":null},{"id":"4a0275cda8ef42e59d1bbd8c64befb37","type":"GENE","name":"SRGAP2B","canonical_id":"hgnc:HGNC:35237","description":"SLIT-ROBO Rho GTPase activating protein 2B","metadata":{"aliases":["SRGAP2P2"]}},{"id":"d4480cc76020474cb0796f2b2105c047","type":"GENE","name":"SRGAP2C","canonical_id":"hgnc:HGNC:30584","description":"SLIT-ROBO Rho GTPase activating protein 2C","metadata":{"aliases":["SRGAP2P1"]}},{"id":"3d944dfff58f439e88de6085c49834ba","type":"GENE","name":"SRGAP2D","canonical_id":"hgnc:HGNC:43932","description":"SLIT-ROBO Rho GTPase activating protein 2D (pseudogene)","metadata":null},{"id":"260af3c301ed4ae28138d75f43ef5b39","type":"GENE","name":"SRGAP3","canonical_id":"hgnc:HGNC:19744","description":"SLIT-ROBO Rho GTPase activating protein 3","metadata":{"aliases":["KIAA0411","MEGAP","WRP","ARHGAP14","SRGAP2"]}},{"id":"5ee5ace300cc4a238ce75f7d404dc9de","type":"GENE","name":"SRGAP3-AS1","canonical_id":"hgnc:HGNC:40898","description":"SRGAP3 antisense RNA 1","metadata":null},{"id":"642f6f00755843cb9ed744ab3d92eb26","type":"GENE","name":"SRGAP3-AS2","canonical_id":"hgnc:HGNC:40899","description":"SRGAP3 antisense RNA 2","metadata":null},{"id":"1d5bac90768a4f3e8f7941266d84f2a8","type":"GENE","name":"SRGAP3-AS3","canonical_id":"hgnc:HGNC:40900","description":"SRGAP3 antisense RNA 3","metadata":null},{"id":"85d7324336184f75aa2be6610c5b0298","type":"GENE","name":"SRGAP3-AS4","canonical_id":"hgnc:HGNC:42434","description":"SRGAP3 antisense RNA 4","metadata":null},{"id":"049a3e31c07943d790385c1928d68600","type":"GENE","name":"SRGN","canonical_id":"hgnc:HGNC:9361","description":"serglycin","metadata":{"aliases":["PPG","PRG","PRG1"]}},{"id":"504e27eccd2f4c3e817671ee26d11096","type":"GENE","name":"SRGNP1","canonical_id":"hgnc:HGNC:49107","description":"serglycin pseudogene 1","metadata":null},{"id":"b2e4625328094dcabd75dc6c2add600a","type":"GENE","name":"SRI","canonical_id":"hgnc:HGNC:11292","description":"sorcin","metadata":null},{"id":"bc591a122eaf4b66905a0334d555583c","type":"GENE","name":"SRI-AS1","canonical_id":"hgnc:HGNC:40564","description":"SRI antisense RNA 1","metadata":null},{"id":"cd4db4185ee84b65b7e2e44626def268","type":"GENE","name":"SRIP1","canonical_id":"hgnc:HGNC:11293","description":"sorcin pseudogene 1","metadata":{"aliases":["SRIL"]}},{"id":"3600fa9e755645c1be59693d157fed9e","type":"GENE","name":"SRIP2","canonical_id":"hgnc:HGNC:38734","description":"sorcin pseudogene 2","metadata":null},{"id":"836f772a012e461dac8ed456e945e86e","type":"GENE","name":"SRIP3","canonical_id":"hgnc:HGNC:38735","description":"sorcin pseudogene 3","metadata":null},{"id":"820267e8d524453f886c5c837c02f7e5","type":"GENE","name":"SRL","canonical_id":"hgnc:HGNC:11295","description":"sarcalumenin","metadata":{"aliases":["SAR"]}},{"id":"d40affd362b04657a9183ab578bdc0ea","type":"GENE","name":"SRM","canonical_id":"hgnc:HGNC:11296","description":"spermidine synthase","metadata":{"aliases":["SPS1","SRML1"]}},{"id":"c70ebae8317446a4811e4cdae8cdd128","type":"GENE","name":"SRMP1","canonical_id":"hgnc:HGNC:16552","description":"SRM pseudogene 1","metadata":{"aliases":["dJ1057D4.1"]}},{"id":"286cf4288fd1492ebf97aafa754c246a","type":"GENE","name":"SRMP2","canonical_id":"hgnc:HGNC:20034","description":"SRM pseudogene 2","metadata":null},{"id":"4af8e4f94bff4ceea8b0bdf68d1154d2","type":"GENE","name":"SRMP3","canonical_id":"hgnc:HGNC:54681","description":"SRM pseudogene 3","metadata":null},{"id":"b4accc3205c34655b5c138dfe2157e77","type":"GENE","name":"SRMS","canonical_id":"hgnc:HGNC:11298","description":"src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites","metadata":{"aliases":["SRM","dJ697K14.1","PTK70","C20orf148"]}},{"id":"901ea580969c489b8188a104646b576b","type":"GO_TERM","name":"SRP-dependent cotranslational protein targeting to membrane","canonical_id":"go:GO:0006614","description":"\"The targeting of proteins to a membrane that occurs during translation and is dependent upon two key components, the signal-recognition particle (SRP) and the SRP receptor. SRP is a cytosolic particle that transiently binds to the endoplasmic reticulum (ER) signal sequence in a nascent protein, to the large ribosomal unit, and to the SRP receptor in the ER membrane.\" [ISBN:0716731363]","metadata":null},{"id":"900d0cbd648d40529059f2b5a905e11d","type":"GO_TERM","name":"SRP-dependent cotranslational protein targeting to membrane, docking","canonical_id":"go:GO:0006615","description":"\"The process in which an SRP-bound ribosome forms a complex with the SRP receptor in the ER membrane, allowing the ribosome to bind to the membrane, during cotranslational membrane targeting.\" [ISBN:0815316194]","metadata":null},{"id":"20efc9ca3339475e882e98f3a9d1a777","type":"GO_TERM","name":"SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition","canonical_id":"go:GO:0006617","description":"\"The process in which SRP binds to the signal peptide in a nascent protein, causing protein elongation to pause, during cotranslational membrane targeting.\" [ISBN:0815316194]","metadata":null},{"id":"1a009ef33bb045028759251e03903fab","type":"GO_TERM","name":"SRP-dependent cotranslational protein targeting to membrane, translocation","canonical_id":"go:GO:0006616","description":"\"The process during cotranslational membrane targeting wherein proteins move across a membrane. SRP and its receptor initiate the transfer of the nascent chain across the endoplasmic reticulum (ER) membrane; they then dissociate from the chain, which is transferred to a set of transmembrane proteins, collectively called the translocon. Once the nascent chain translocon complex is assembled, the elongating chain passes directly from the large ribosomal subunit into the centers of the translocon, a protein-lined channel within the membrane. The growing chain is never exposed to the cytosol and does not fold until it reaches the ER lumen.\" [ISBN:0716731363]","metadata":null},{"id":"9b3ce0f80e26449faa275720ed12d5eb","type":"GENE","name":"SRP14","canonical_id":"hgnc:HGNC:11299","description":"signal recognition particle 14","metadata":{"aliases":["ALURBP","MGC14326"]}},{"id":"408acd472894460cacab6f83e5c14035","type":"GENE","name":"SRP14-DT","canonical_id":"hgnc:HGNC:48619","description":"SRP14 divergent transcript","metadata":{"aliases":["SRP14-AS1"]}},{"id":"86f64430843c4b68a5387b2316da3ba2","type":"GENE","name":"SRP14P1","canonical_id":"hgnc:HGNC:33181","description":"SRP14 pseudogene 1","metadata":null},{"id":"13b68f0a511f424fb012c08ed6be68ed","type":"GENE","name":"SRP14P2","canonical_id":"hgnc:HGNC:53768","description":"SRP14 pseudogene 2","metadata":null},{"id":"8d41617bb2c54d9f9cb096d103ecf1e2","type":"GENE","name":"SRP14P3","canonical_id":"hgnc:HGNC:53769","description":"SRP14 pseudogene 3","metadata":null},{"id":"4c768ed4ff3d4f7abf25220c669bc9eb","type":"GENE","name":"SRP14P4","canonical_id":"hgnc:HGNC:53770","description":"SRP14 pseudogene 4","metadata":null},{"id":"5f4c9c7478184d088a07326bce300359","type":"GENE","name":"SRP14P5","canonical_id":"hgnc:HGNC:56569","description":"SRP14 pseudogene 5","metadata":null},{"id":"f64142ac560d402a874df7ba52fba05b","type":"GENE","name":"SRP19","canonical_id":"hgnc:HGNC:11300","description":"signal recognition particle 19","metadata":null},{"id":"ec01d15696374ed094ffe0ad4b719886","type":"GENE","name":"SRP54","canonical_id":"hgnc:HGNC:11301","description":"signal recognition particle 54","metadata":null},{"id":"695d0d518d864e9794a71724201c7e5f","type":"GENE","name":"SRP54-AS1","canonical_id":"hgnc:HGNC:50643","description":"SRP54 antisense RNA 1","metadata":null},{"id":"96fd6b1b92694897907aea8d5dd0462b","type":"GENE","name":"SRP68","canonical_id":"hgnc:HGNC:11302","description":"signal recognition particle 68","metadata":null},{"id":"77ad2332081e471e8feeaf8f0f52f6c0","type":"GENE","name":"SRP68P1","canonical_id":"hgnc:HGNC:30427","description":"signal recognition particle 68 pseudogene 1","metadata":{"aliases":["SRPSMCR"]}},{"id":"3f58b5d4c4204ed6aa73994e54505714","type":"GENE","name":"SRP68P2","canonical_id":"hgnc:HGNC:30426","description":"signal recognition particle 68 pseudogene 2","metadata":{"aliases":["SRPSMCR"]}},{"id":"5c7344bb67fd4f3083461f1f54dd3455","type":"GENE","name":"SRP68P3","canonical_id":"hgnc:HGNC:30428","description":"signal recognition particle 68 pseudogene 3","metadata":{"aliases":["SRPSMCR"]}},{"id":"59391b302d2943edbead5e48056859ce","type":"GENE","name":"SRP72","canonical_id":"hgnc:HGNC:11303","description":"signal recognition particle 72","metadata":null},{"id":"3dddd032978a4362a78b2fd52b53fb59","type":"GENE","name":"SRP72P1","canonical_id":"hgnc:HGNC:31095","description":"signal recognition particle 72 pseudogene 1","metadata":null},{"id":"73c9abadda78495da177bf0a54879735","type":"GENE","name":"SRP72P2","canonical_id":"hgnc:HGNC:31096","description":"signal recognition particle 72 pseudogene 2","metadata":{"aliases":["dJ274L14.2"]}},{"id":"38b9019fb62a46cd95e00f2e0fda2064","type":"GENE","name":"SRP9","canonical_id":"hgnc:HGNC:11304","description":"signal recognition particle 9","metadata":null},{"id":"7d12cc61a42a45798cb58eaffb5f94b0","type":"GENE","name":"SRP9P1","canonical_id":"hgnc:HGNC:23402","description":"signal recognition particle 9 pseudogene 1","metadata":{"aliases":["SRP9L1"]}},{"id":"b25481b50804422d8f7fa1cc36a18d08","type":"GENE","name":"SRPK1","canonical_id":"hgnc:HGNC:11305","description":"SRSF protein kinase 1","metadata":{"aliases":["SFRSK1"]}},{"id":"66ba6a35f70a4accb15f6a5f3b223507","type":"GENE","name":"SRPK2","canonical_id":"hgnc:HGNC:11306","description":"SRSF protein kinase 2","metadata":{"aliases":["SFRSK2"]}},{"id":"57eb9aa5a26748259b48a8d03aa7b4e3","type":"GENE","name":"SRPK2-AS1","canonical_id":"hgnc:HGNC:40565","description":"SRPK2 antisense RNA 1","metadata":null},{"id":"d31532cf7c3745e3a29f1f55ef1142e1","type":"GENE","name":"SRPK2P1","canonical_id":"hgnc:HGNC:30303","description":"SRPK2 pseudogene 1","metadata":{"aliases":["SRPK2ps","SRPK2P"]}},{"id":"f12138fc441f428f956c9602a90c4ec1","type":"GENE","name":"SRPK3","canonical_id":"hgnc:HGNC:11402","description":"SRSF protein kinase 3","metadata":{"aliases":["MSSK1","STK23"]}},{"id":"c7e66ce57a0f4e95b4394d15017a2bcc","type":"GENE","name":"SRPRA","canonical_id":"hgnc:HGNC:11307","description":"SRP receptor subunit alpha","metadata":{"aliases":["SRP-alpha","Sralpha","SR-alpha","SRPR"]}},{"id":"21e0074879044da188d160ff7a852275","type":"GENE","name":"SRPRB","canonical_id":"hgnc:HGNC:24085","description":"SRP receptor subunit beta","metadata":{"aliases":["APMCF1","SR-beta"]}},{"id":"e716588ad8a04b9e9a2c689e100cdd54","type":"GENE","name":"SRPX","canonical_id":"hgnc:HGNC:11309","description":null,"metadata":null},{"id":"4ac61df2a2f8453d8fce7b0a150bf103","type":"GENE","name":"SRPX2","canonical_id":"hgnc:HGNC:30668","description":null,"metadata":null},{"id":"32001302dad5458cadc111a2cb91deca","type":"GENE","name":"SRR","canonical_id":"hgnc:HGNC:14398","description":null,"metadata":null},{"id":"fd77c23c352a479f8ef08d0b51437e64","type":"GENE","name":"SRRD","canonical_id":"hgnc:HGNC:33910","description":"SRR1 domain containing","metadata":{"aliases":["HC/HCC","SRR1L"]}},{"id":"c168322af77147fcaef3be61b73dc273","type":"GENE","name":"SRRM1","canonical_id":"hgnc:HGNC:16638","description":"serine and arginine repetitive matrix 1","metadata":{"aliases":["SRM160","POP101","MGC39488"]}},{"id":"676cd24043324700ae14a16a6797e8a6","type":"GENE","name":"SRRM1P1","canonical_id":"hgnc:HGNC:31861","description":"serine/arginine repetitive matrix 1 pseudogene 1","metadata":{"aliases":["SRRM1L","SRRM1P"]}},{"id":"92e9450a47b545598cf05389003ef7b1","type":"GENE","name":"SRRM1P2","canonical_id":"hgnc:HGNC:38163","description":"serine/arginine repetitive matrix 1 pseudogene 2","metadata":null},{"id":"1088a689f6b7444e97f39bbad30ad3ac","type":"GENE","name":"SRRM1P3","canonical_id":"hgnc:HGNC:38164","description":"serine/arginine repetitive matrix 1 pseudogene 3","metadata":null},{"id":"673466df59164e4c87c1d08ef748874a","type":"GENE","name":"SRRM2","canonical_id":"hgnc:HGNC:16639","description":"serine/arginine repetitive matrix 2","metadata":{"aliases":["SRm300","SRL300","KIAA0324","Cwc21"]}},{"id":"00a7013720b047ab990dda6ff2f63b24","type":"GENE","name":"SRRM2-AS1","canonical_id":"hgnc:HGNC:44162","description":"SRRM2 antisense RNA 1","metadata":null},{"id":"e4672bfc049840afabcac03f53a61fe5","type":"GENE","name":"SRRM3","canonical_id":"hgnc:HGNC:26729","description":"serine/arginine repetitive matrix 3","metadata":{"aliases":["FLJ37078"]}},{"id":"f9484d9edda44b918a2cc02b668351d7","type":"GENE","name":"SRRM4","canonical_id":"hgnc:HGNC:29389","description":"serine/arginine repetitive matrix 4","metadata":{"aliases":["nSR100","KIAA1853"]}},{"id":"b851dff414794e0a9c1385f22aabb522","type":"GENE","name":"SRRM4-AS1","canonical_id":"hgnc:HGNC:58442","description":"SRRM4 antisense RNA 1","metadata":null},{"id":"12b7370e01ac4f6abe109359c8b2a9c7","type":"GENE","name":"SRRM5","canonical_id":"hgnc:HGNC:37248","description":"serine/arginine repetitive matrix 5","metadata":null},{"id":"53d30443d4a64b848d3f0733c7e8f152","type":"GENE","name":"SRRT","canonical_id":"hgnc:HGNC:24101","description":"serrate, RNA effector molecule","metadata":{"aliases":["Asr2","serrate","ARS2"]}},{"id":"fc8cdd2964ce4c94aa9d85d9b138fb35","type":"GENE","name":"SRSF1","canonical_id":"hgnc:HGNC:10780","description":null,"metadata":null},{"id":"6fcfaf79e1264c36bb5493b2e9b8dfb7","type":"GENE","name":"SRSF10","canonical_id":"hgnc:HGNC:16713","description":"serine and arginine rich splicing factor 10","metadata":{"aliases":["TASR1","TASR2","SRp38","SRrp40","SFRS13","PPP1R149","FUSIP2","FUSIP1","SFRS13A"]}},{"id":"ab04fcd1d296494d86778db215732399","type":"GENE","name":"SRSF10P1","canonical_id":"hgnc:HGNC:31002","description":"serine and arginine rich splicing factor 10 pseudogene 1","metadata":{"aliases":["HsT2687","FUSIP1P","SFRS13AP1"]}},{"id":"e8dbbc5efd2942948b2208f576775b9c","type":"GENE","name":"SRSF10P2","canonical_id":"hgnc:HGNC:24823","description":"serine and arginine rich splicing factor 10 pseudogene 2","metadata":{"aliases":["FUSIP1P2","SFRS13AP2"]}},{"id":"49787de6362544db89a9bb10ef072e02","type":"GENE","name":"SRSF11","canonical_id":"hgnc:HGNC:10782","description":"serine and arginine rich splicing factor 11","metadata":{"aliases":["p54","NET2","SFRS11"]}},{"id":"57e645791c6b4c2c914111231ed86ebe","type":"GENE","name":"SRSF11P1","canonical_id":"hgnc:HGNC:49884","description":"serine and arginine rich splicing factor 11 pseudogene 1","metadata":null},{"id":"f2622f4580234a9c8ec867b919c82c9d","type":"GENE","name":"SRSF12","canonical_id":"hgnc:HGNC:21220","description":"serine and arginine rich splicing factor 12","metadata":{"aliases":["SRrp35","SFRS19","SFRS13B"]}},{"id":"2432f47f4bb54ff08f037cd323d6772c","type":"GENE","name":"SRSF1P1","canonical_id":"hgnc:HGNC:39417","description":"serine and arginine rich splicing factor 1 pseudogene 1","metadata":null},{"id":"e7ca3b44d52a40c29e931c4c1084daea","type":"GENE","name":"SRSF2","canonical_id":"hgnc:HGNC:10783","description":"serine and arginine rich splicing factor 2","metadata":{"aliases":["SC-35","SC35","PR264","SFRS2A","SFRS2"]}},{"id":"6842284ebf894b0fb2514f24a632fef6","type":"GENE","name":"SRSF2P1","canonical_id":"hgnc:HGNC:54922","description":"SRSF2 pseudogene 1","metadata":null},{"id":"84cc4784238b49d3b572de15ead9830b","type":"GENE","name":"SRSF3","canonical_id":"hgnc:HGNC:10785","description":"serine and arginine rich splicing factor 3","metadata":{"aliases":["SRp20","SFRS3"]}},{"id":"ddde20de3f56424ebe1ea25cfe2a4795","type":"GENE","name":"SRSF3P1","canonical_id":"hgnc:HGNC:54691","description":"SRSF3 pseudogene 1","metadata":null},{"id":"f5d289c0b5b04c0885d7acd530f1fada","type":"GENE","name":"SRSF3P2","canonical_id":"hgnc:HGNC:54692","description":"SRSF3 pseudogene 2","metadata":null},{"id":"bc0cdb04822c41458408d3f4e54c41f2","type":"GENE","name":"SRSF3P4","canonical_id":"hgnc:HGNC:54693","description":"SRSF3 pseudogene 4","metadata":null},{"id":"3b38cb85b528475a9a2e5d2769ae39e6","type":"GENE","name":"SRSF3P5","canonical_id":"hgnc:HGNC:54694","description":"SRSF3 pseudogene 5","metadata":null},{"id":"000c4c5fe696436c91f9df3f18e54faa","type":"GENE","name":"SRSF3P6","canonical_id":"hgnc:HGNC:54695","description":"SRSF3 pseudogene 6","metadata":null},{"id":"69389a52076a4b9495fc565202d72613","type":"GENE","name":"SRSF4","canonical_id":"hgnc:HGNC:10786","description":"serine and arginine rich splicing factor 4","metadata":{"aliases":["SRP75","SFRS4"]}},{"id":"a08af7bca54a4f058646615a92cbad9b","type":"GENE","name":"SRSF5","canonical_id":"hgnc:HGNC:10787","description":"serine and arginine rich splicing factor 5","metadata":{"aliases":["SRP40","HRS","SFRS5"]}},{"id":"30044a9b48b84d2bb8e8c6cf459854ba","type":"GENE","name":"SRSF6","canonical_id":"hgnc:HGNC:10788","description":"serine and arginine rich splicing factor 6","metadata":{"aliases":["SRP55","B52","SFRS6"]}},{"id":"8ab168bfed5f48558c4ea0aa8e04c624","type":"GENE","name":"SRSF6P1","canonical_id":"hgnc:HGNC:54946","description":"SRSF6 pseudogene 1","metadata":null},{"id":"7ac2921033e948fe93d7b7f5fdcc3696","type":"GENE","name":"SRSF6P2","canonical_id":"hgnc:HGNC:54947","description":"SRSF6 pseudogene 2","metadata":null},{"id":"3e067176857d4582852e958f134a2344","type":"GENE","name":"SRSF7","canonical_id":"hgnc:HGNC:10789","description":"serine and arginine rich splicing factor 7","metadata":{"aliases":["9G8","ZCRB2","HSSG1","AAG3","RBM37","ZCCHC20","SFRS7"]}},{"id":"387e1a29207f443e86f318356b4973e2","type":"GENE","name":"SRSF8","canonical_id":"hgnc:HGNC:16988","description":"serine and arginine rich splicing factor 8","metadata":{"aliases":["SRP46","SFRS2B"]}},{"id":"313f359b72074801a00724c6727b123d","type":"GENE","name":"SRSF8BP","canonical_id":"hgnc:HGNC:55910","description":"serine and arginine rich splicing factor 8B, pseudogene","metadata":null},{"id":"8c253425dc6b4c2abe5d2420adaf6183","type":"GENE","name":"SRSF8CP","canonical_id":"hgnc:HGNC:55911","description":"serine and arginine rich splicing factor 8C, pseudogene","metadata":null},{"id":"6e24908ff6f248f8aecd57c0649c23aa","type":"GENE","name":"SRSF9","canonical_id":"hgnc:HGNC:10791","description":"serine and arginine rich splicing factor 9","metadata":{"aliases":["SRp30c","SFRS9"]}},{"id":"3256da72461844c2ac1c5224fd9a9996","type":"GENE","name":"SRSF9P1","canonical_id":"hgnc:HGNC:10792","description":"serine and arginine rich splicing factor 9 pseudogene 1","metadata":{"aliases":["SFRS9P1"]}},{"id":"2dcc504427804d8d81eae9463cf2c413","type":"GENE","name":"SRXN1","canonical_id":"hgnc:HGNC:16132","description":"sulfiredoxin 1","metadata":{"aliases":["Npn3","Srx","SRX1","YKL086W","dJ850E9.2","C20orf139"]}},{"id":"0978569cd55e474280b61726d8ffa0e4","type":"GENE","name":"SRXN1P1","canonical_id":"hgnc:HGNC:58622","description":"SRXN1 pseudogene 1","metadata":null},{"id":"a206aff59ba746b68fa93fc431981932","type":"GENE","name":"SRXN1P2","canonical_id":"hgnc:HGNC:58623","description":"SRXN1 pseudogene 2","metadata":null},{"id":"8362646fbae84f11968c6722835cae4c","type":"GENE","name":"SRY","canonical_id":"hgnc:HGNC:11311","description":null,"metadata":null},{"id":"9239c7d99b45423cb01c31af4ecd6ea5","type":"GENE","name":"SS18","canonical_id":"hgnc:HGNC:11340","description":"SS18 subunit of BAF chromatin remodeling complex","metadata":{"aliases":["SYT","SMARCL1","SSXT"]}},{"id":"0a091287f283426bba0068d7594139e6","type":"GENE","name":"SS18L1","canonical_id":"hgnc:HGNC:15592","description":"SS18L1 subunit of BAF chromatin remodeling complex","metadata":{"aliases":["KIAA0693","CREST","SMARCL2"]}},{"id":"30556431184f4515937430c5397807b6","type":"GENE","name":"SS18L2","canonical_id":"hgnc:HGNC:15593","description":"SS18 like 2","metadata":{"aliases":["KIAA-iso"]}},{"id":"2fe513fe55f54626810ec9d20f9bb221","type":"GENE","name":"SS18L2P1","canonical_id":"hgnc:HGNC:44965","description":"SS18 like 2 pseudogene 1","metadata":null},{"id":"309dbb47a46b453d91188eb9f537d93e","type":"GENE","name":"SS18L2P2","canonical_id":"hgnc:HGNC:44966","description":"SS18 like 2 pseudogene 2","metadata":null},{"id":"ff5c220a23d64bc6a38218c022df082d","type":"TRIAL","name":"SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","canonical_id":"clinicaltrials.gov:NCT01362790","description":"Mesothelioma; Adenocarcinoma of Lung; Pancreatic Neoplasms","metadata":null},{"id":"daf8c5e5e6ab41508a8aba383ab9d905","type":"GENE","name":"SSB","canonical_id":"hgnc:HGNC:11316","description":null,"metadata":null},{"id":"417855f34da94afaa7ba7e1d8e693dc5","type":"GENE","name":"SSBL2P","canonical_id":"hgnc:HGNC:54972","description":"small RNA binding exonuclease protection factor La like 2, pseudogene","metadata":null},{"id":"175828054dfe4619adef70f49a88fcb4","type":"GENE","name":"SSBL3P","canonical_id":"hgnc:HGNC:54984","description":"small RNA binding exonuclease protection factor La like 3, pseudogene","metadata":null},{"id":"300de0db3efd4578bfe8195bb9975a57","type":"GENE","name":"SSBL4P","canonical_id":"hgnc:HGNC:54985","description":"small RNA binding exonuclease protection factor La like 4, pseudogene","metadata":null},{"id":"60b56404ed8c49c0800f8f1f3cefbf0b","type":"GENE","name":"SSBL5P","canonical_id":"hgnc:HGNC:54986","description":"small RNA binding exonuclease protection factor La like 5, pseudogene","metadata":null},{"id":"0c13e10762324267a31a2c35dc183f00","type":"GENE","name":"SSBL6P","canonical_id":"hgnc:HGNC:56574","description":"small RNA binding exonuclease protection factor La like 6, pseudogene","metadata":null},{"id":"91bb54a6d18b45cc8e80edd976f88e11","type":"GENE","name":"SSBP1","canonical_id":"hgnc:HGNC:11317","description":"single stranded DNA binding protein 1","metadata":{"aliases":["SSBP","mtSSB"]}},{"id":"a972725c22f94fb9a5afe09bbb28c899","type":"GENE","name":"SSBP1P1","canonical_id":"hgnc:HGNC:58624","description":"SSBP1 pseudogene 1","metadata":null},{"id":"c3061155f4f5429194ef8967eaf63250","type":"GENE","name":"SSBP1P2","canonical_id":"hgnc:HGNC:58625","description":"SSBP1 pseudogene 2","metadata":null},{"id":"5467380457774a8586f922871e031a76","type":"GENE","name":"SSBP1P3","canonical_id":"hgnc:HGNC:58626","description":"SSBP1 pseudogene 3","metadata":null},{"id":"163d7cced5204b9793eca47300f46ef6","type":"GENE","name":"SSBP1P4","canonical_id":"hgnc:HGNC:58627","description":"SSBP1 pseudogene 4","metadata":null},{"id":"f92465b22ca34022b77982a6b43b0e34","type":"GENE","name":"SSBP2","canonical_id":"hgnc:HGNC:15831","description":"single stranded DNA binding protein 2","metadata":{"aliases":["HSPC116"]}},{"id":"e669755ab96844d1ba7a47c1dcfdbdfe","type":"GENE","name":"SSBP2-AS1","canonical_id":"hgnc:HGNC:59090","description":"SSBP2 antisense RNA 1","metadata":null},{"id":"2007e4ec47a14585ac2ce674f5e9b5a9","type":"GENE","name":"SSBP3","canonical_id":"hgnc:HGNC:15674","description":"single stranded DNA binding protein 3","metadata":{"aliases":["CSDP","SSDP","FLJ10355","SSDP1"]}},{"id":"409e14be69db4f0f9f1384f912ec0a6b","type":"GENE","name":"SSBP3-AS1","canonical_id":"hgnc:HGNC:32328","description":"SSBP3 antisense RNA 1","metadata":{"aliases":["MSTP128","C1orf191"]}},{"id":"fc9036ff35574a479281817d40133237","type":"GENE","name":"SSBP3-AS2","canonical_id":"hgnc:HGNC:40721","description":"SSBP3 antisense RNA 2","metadata":null},{"id":"1801863229404ebc86b668395051c866","type":"GENE","name":"SSBP3P1","canonical_id":"hgnc:HGNC:54577","description":"SSBP3 pseudogene 1","metadata":{"aliases":["SSBL3P1"]}},{"id":"618f287440314a318c8bbfd05098cf2e","type":"GENE","name":"SSBP3P2","canonical_id":"hgnc:HGNC:54579","description":"SSBP3 pseudogene 2","metadata":null},{"id":"939497d602a24d68877ced877162770c","type":"GENE","name":"SSBP3P3","canonical_id":"hgnc:HGNC:56966","description":"SSBP3 pseudogene 3","metadata":null},{"id":"465875a7e92b45ec9120daf3f68dd00b","type":"GENE","name":"SSBP3P4","canonical_id":"hgnc:HGNC:56967","description":"SSBP3 pseudogene 4","metadata":null},{"id":"39c3027db06f44a287f49cb190ca0da5","type":"GENE","name":"SSBP3P5","canonical_id":"hgnc:HGNC:56968","description":"SSBP3 pseudogene 5","metadata":null},{"id":"f7ca2b81efa748da95b823e79a13a30e","type":"GENE","name":"SSBP3P6","canonical_id":"hgnc:HGNC:56969","description":"SSBP3 pseudogene 6","metadata":null},{"id":"4d3fba6229ae49b0b288bf1d067645b1","type":"GENE","name":"SSBP4","canonical_id":"hgnc:HGNC:15676","description":"single stranded DNA binding protein 4","metadata":null},{"id":"b5fcb1499f4e422ca9be655d8d0042b2","type":"GENE","name":"SSC4D","canonical_id":"hgnc:HGNC:14461","description":"scavenger receptor cysteine rich family member with 4 domains","metadata":{"aliases":["SRCRB-S4D","S4D-SRCRB","SRCRB4D"]}},{"id":"9847c69dc1e043f5b12ece3f63aaa2c6","type":"GENE","name":"SSC5D","canonical_id":"hgnc:HGNC:26641","description":"scavenger receptor cysteine rich family member with 5 domains","metadata":{"aliases":["FLJ35258","S5D-SRCRB"]}},{"id":"f4722ab77ded4dca81894222418cf9be","type":"GENE","name":"SSH1","canonical_id":"hgnc:HGNC:30579","description":"slingshot protein phosphatase 1","metadata":{"aliases":["KIAA1298","SSH1L"]}},{"id":"0a7f32d93bd04767bdc45fa20a409d03","type":"GENE","name":"SSH2","canonical_id":"hgnc:HGNC:30580","description":"slingshot protein phosphatase 2","metadata":{"aliases":["KIAA1725"]}},{"id":"2f563e3f627e42a69a6e32051bee1feb","type":"GENE","name":"SSH2-AS1","canonical_id":"hgnc:HGNC:58555","description":"SSH2 antisense RNA 1","metadata":null},{"id":"54761421b952442a8d8b8acd5b469956","type":"GENE","name":"SSH3","canonical_id":"hgnc:HGNC:30581","description":"slingshot protein phosphatase 3","metadata":{"aliases":["FLJ20515","FLJ10928"]}},{"id":"d63017a694124de185247a05a62fefd8","type":"GENE","name":"SSMEM1","canonical_id":"hgnc:HGNC:29580","description":"serine rich single-pass membrane protein 1","metadata":{"aliases":["FLJ40316","C7orf45"]}},{"id":"13bf56a51d07405d8c641244d01586c4","type":"GENE","name":"SSNA1","canonical_id":"hgnc:HGNC:11321","description":"SS nuclear autoantigen 1","metadata":{"aliases":["NA14","N14"]}},{"id":"8143178318ba4a33ae88c55b7885934d","type":"GENE","name":"SSPN","canonical_id":"hgnc:HGNC:11322","description":null,"metadata":null},{"id":"b9a4797933364ea2a0554b581806c09d","type":"GENE","name":"SSPN-AS1","canonical_id":"hgnc:HGNC:56072","description":"SSPN antisense RNA 1","metadata":{"aliases":["ITPR2-AS1"]}},{"id":"c077569a920a40c5a4f1603ec1496f09","type":"GENE","name":"SSPOP","canonical_id":"hgnc:HGNC:21998","description":"SCO-spondin, pseudogene","metadata":{"aliases":["SCO-spondin","KIAA0543","FLJ36112","SSPO"]}},{"id":"64c2bb18054a4ca6846a1f6053f703ef","type":"GENE","name":"SSR1","canonical_id":"hgnc:HGNC:11323","description":"signal sequence receptor subunit 1","metadata":{"aliases":["TRAPA"]}},{"id":"733abff1a112414cb88518387170ed9f","type":"GENE","name":"SSR1-AS1","canonical_id":"hgnc:HGNC:40566","description":"SSR1 antisense RNA 1","metadata":null},{"id":"d0f451baca2b490a97601c7cacd7a3ce","type":"GENE","name":"SSR1P1","canonical_id":"hgnc:HGNC:39273","description":"signal sequence receptor subunit 1 pseudogene 1","metadata":null},{"id":"85b11a9eed9c4ff082468b9b2c48bfd7","type":"GENE","name":"SSR1P2","canonical_id":"hgnc:HGNC:39274","description":"signal sequence receptor subunit 1 pseudogene 2","metadata":null},{"id":"a384e155ab3148de9c51e551d483f1c5","type":"GENE","name":"SSR2","canonical_id":"hgnc:HGNC:11324","description":"signal sequence receptor subunit 2","metadata":{"aliases":["TLAP","TRAPB"]}},{"id":"c79ea852bf8e44bfa52e3c914225f7e6","type":"GENE","name":"SSR3","canonical_id":"hgnc:HGNC:11325","description":"signal sequence receptor subunit 3","metadata":{"aliases":["TRAPG"]}},{"id":"607b3e681f1b46a5bf52debe792211d7","type":"GENE","name":"SSR4","canonical_id":"hgnc:HGNC:11326","description":"signal sequence receptor subunit 4","metadata":{"aliases":["TRAPD"]}},{"id":"49e2e5b59fa748f7ab3ac6fea858a6c0","type":"GENE","name":"SSR4P1","canonical_id":"hgnc:HGNC:23131","description":"signal sequence receptor subunit 4 pseudogene 1","metadata":{"aliases":["PRED90","MGC10960","PRED57","C21orf122"]}},{"id":"54702b8db00d495da39a0cfce4a04179","type":"TRIAL","name":"SSRI and Buprenorphine","canonical_id":"clinicaltrials.gov:NCT00475878","description":"Opiate Dependence; Depression","metadata":null},{"id":"ad163995acda4c0bb2360d93265769f9","type":"GENE","name":"SSRP1","canonical_id":"hgnc:HGNC:11327","description":"structure specific recognition protein 1","metadata":{"aliases":["FACT80"]}},{"id":"75f1aed7156d473db12e6daddbca98dd","type":"GENE","name":"SST","canonical_id":"hgnc:HGNC:11329","description":"somatostatin","metadata":{"aliases":["SMST","SST1"]}},{"id":"7f398254464746b6a7c41fad620f664a","type":"GENE","name":"SSTR1","canonical_id":"hgnc:HGNC:11330","description":null,"metadata":null},{"id":"b5babe51215d444da49e0d3d1dbb1b53","type":"GENE","name":"SSTR2","canonical_id":"hgnc:HGNC:11331","description":null,"metadata":null},{"id":"913372cd24964aa68bfde7931ca985d3","type":"PROTEIN","name":"SSTR2","canonical_id":"uniprot:P30874","description":null,"metadata":null},{"id":"3b6707454f89455d9abaf9d2e06aba6f","type":"GENE","name":"SSTR3","canonical_id":"hgnc:HGNC:11332","description":"somatostatin receptor 3","metadata":null},{"id":"cb71249138b941aabfc0cb6ea6a13a76","type":"PROTEIN","name":"SSTR3","canonical_id":"uniprot:P32745","description":null,"metadata":null},{"id":"4a23aa4f7a2846a9b720c105726621be","type":"GENE","name":"SSTR4","canonical_id":"hgnc:HGNC:11333","description":"somatostatin receptor 4","metadata":null},{"id":"a5e9cbf71b7e498fa55a2dcc6db12e37","type":"GENE","name":"SSTR5","canonical_id":"hgnc:HGNC:11334","description":"somatostatin receptor 5","metadata":null},{"id":"c7438e0d419e47c3b014abe11a5cf139","type":"PROTEIN","name":"SSTR5","canonical_id":"uniprot:P35346","description":null,"metadata":null},{"id":"edaaa386bc2f4bab9720abfd0e6071e1","type":"GENE","name":"SSTR5-AS1","canonical_id":"hgnc:HGNC:26502","description":"SSTR5 antisense RNA 1","metadata":null},{"id":"b8604bc6486f4689b01d85b008463167","type":"GENE","name":"SSU72","canonical_id":"hgnc:HGNC:25016","description":"SSU72 homolog, RNA polymerase II CTD phosphatase","metadata":{"aliases":["HSPC182"]}},{"id":"25f586109bae4b43b1b33e47239db894","type":"GENE","name":"SSU72-AS1","canonical_id":"hgnc:HGNC:57014","description":"SSU72 antisense RNA 1","metadata":null},{"id":"adfbb3750fa140fc932543a056488092","type":"GENE","name":"SSU72L1","canonical_id":"hgnc:HGNC:43626","description":"SSU72 like 1","metadata":{"aliases":["SSU72P7"]}},{"id":"426eb0e8207e47058ed6fc2faffb7dc8","type":"GENE","name":"SSU72L2","canonical_id":"hgnc:HGNC:43621","description":"SSU72 like 2","metadata":{"aliases":["SSU72P2"]}},{"id":"808021361e52417aa10b2bfc351132e2","type":"GENE","name":"SSU72L3","canonical_id":"hgnc:HGNC:43622","description":"SSU72 like 3","metadata":{"aliases":["SSU72P3"]}},{"id":"946493a20f3a464cb0e34c9352643f4e","type":"GENE","name":"SSU72L4","canonical_id":"hgnc:HGNC:43623","description":"SSU72 like 4","metadata":{"aliases":["SSU72P4"]}},{"id":"3883dc0b946246009650279570d9fc8a","type":"GENE","name":"SSU72L5","canonical_id":"hgnc:HGNC:43624","description":"SSU72 like 5","metadata":{"aliases":["SSU72P5"]}},{"id":"9f1776e905d74091bcc57d7fae30d171","type":"GENE","name":"SSU72L6","canonical_id":"hgnc:HGNC:43627","description":"SSU72 like 6","metadata":{"aliases":["SSU72P8"]}},{"id":"afe30ea293044b74bd8d33759109ba61","type":"GENE","name":"SSU72P1","canonical_id":"hgnc:HGNC:43620","description":"SSU72 pseudogene 1","metadata":null},{"id":"a2c0323838fd4deca9f75209f554cce9","type":"GENE","name":"SSU72P6","canonical_id":"hgnc:HGNC:43625","description":"SSU72 pseudogene 6","metadata":null},{"id":"4e7b4e96c4a440c79e2ad4473b291371","type":"GENE","name":"SSUH2","canonical_id":"hgnc:HGNC:24809","description":"ssu-2 homolog","metadata":{"aliases":["fls485","ssu-2","C3orf32"]}},{"id":"9f57ad07d06348ee8747f80512c5f9fa","type":"GENE","name":"SSX1","canonical_id":"hgnc:HGNC:11335","description":"SSX family member 1","metadata":{"aliases":["CT5.1"]}},{"id":"cdd72279c15441038b9ca2d9ccadb7ea","type":"GENE","name":"SSX11P","canonical_id":"hgnc:HGNC:30637","description":"SSX family member 11, pseudogene","metadata":{"aliases":["psiSSX1","SSXP1"]}},{"id":"d4d72e9f2f1146feba420748aff204ce","type":"GENE","name":"SSX13P","canonical_id":"hgnc:HGNC:30640","description":"SSX family member 13, pseudogene","metadata":{"aliases":["psiSSX3","SSXP3"]}},{"id":"f433125b56ac48d7bc5de5bd12558bf3","type":"GENE","name":"SSX14P","canonical_id":"hgnc:HGNC:30641","description":"SSX family member 14, pseudogene","metadata":{"aliases":["psiSSX4","SSX10","SSXP4"]}},{"id":"0dea6160e95b4eefbe634e5e021d1c4e","type":"GENE","name":"SSX15P","canonical_id":"hgnc:HGNC:30642","description":"SSX family member 15, pseudogene","metadata":{"aliases":["psiSSX5","SSXP5"]}},{"id":"e776b38c1af44e37999cc03e3fec2b08","type":"GENE","name":"SSX16P","canonical_id":"hgnc:HGNC:30643","description":"SSX family member 16, pseudogene","metadata":{"aliases":["psiSSX6","SSXP6"]}},{"id":"4afd1a5fec0b4f6b9bfe49150f56d322","type":"GENE","name":"SSX17P","canonical_id":"hgnc:HGNC:30644","description":"SSX family member 17, pseudogene","metadata":{"aliases":["psiSSX7","SSXP7"]}},{"id":"338808a15e514f519de452d9bf657e7d","type":"GENE","name":"SSX18P","canonical_id":"hgnc:HGNC:56827","description":"SSX family member 18, pseudogene","metadata":{"aliases":["psiSSX8"]}},{"id":"6f8abe8c16094f099dedfe2fff9a4ec3","type":"GENE","name":"SSX19P","canonical_id":"hgnc:HGNC:30645","description":"SSX family member 19, pseudogene","metadata":{"aliases":["psiSSX9","SSXP9"]}},{"id":"61c8c7dc58594348a78fec81102d2380","type":"GENE","name":"SSX2","canonical_id":"hgnc:HGNC:11336","description":null,"metadata":null},{"id":"7d4832041d3d4df3a5f929567572fe84","type":"GENE","name":"SSX20P","canonical_id":"hgnc:HGNC:56825","description":"SSX family member 20, pseudogene","metadata":null},{"id":"821c2029c0ba49be93278dc65978386f","type":"GENE","name":"SSX21P","canonical_id":"hgnc:HGNC:56826","description":"SSX family member 21, pseudogene","metadata":null},{"id":"0fbb0d66b0bd44e2a28b81de52b0b12a","type":"GENE","name":"SSX2B","canonical_id":"hgnc:HGNC:22263","description":"SSX family member 2B","metadata":{"aliases":["CT5.2b"]}},{"id":"064542c9dc394f54930f1fde3ccd17a3","type":"GENE","name":"SSX2IP","canonical_id":"hgnc:HGNC:16509","description":"SSX family member 2 interacting protein","metadata":{"aliases":["hMsd1"]}},{"id":"2d6130640fb14c1d81299fd19c23a78c","type":"GENE","name":"SSX2IPP1","canonical_id":"hgnc:HGNC:56463","description":"SSX2IP pseudogene 1","metadata":null},{"id":"e683591fad2f4efe9d60216163407749","type":"GENE","name":"SSX3","canonical_id":"hgnc:HGNC:11337","description":"SSX family member 3","metadata":{"aliases":["CT5.3"]}},{"id":"95b3d3bdba5945368514a05cd1f112e8","type":"GENE","name":"SSX4","canonical_id":"hgnc:HGNC:11338","description":"SSX family member 4","metadata":{"aliases":["CT5.4"]}},{"id":"fc3f0c138f0743ed948fca7804bf1444","type":"GENE","name":"SSX4B","canonical_id":"hgnc:HGNC:16880","description":"SSX family member 4B","metadata":{"aliases":["OTTHUMT00000056510"]}},{"id":"dbd1814111c142c880bd7ac8dba178b0","type":"GENE","name":"SSX5","canonical_id":"hgnc:HGNC:11339","description":"SSX family member 5","metadata":null},{"id":"6e2a6182530146e18ff8c17e9cfcd628","type":"GENE","name":"SSX6P","canonical_id":"hgnc:HGNC:19652","description":"SSX family member 6, pseudogene","metadata":{"aliases":["psiSSX2","SSXP2","SSX6"]}},{"id":"9dea6da981b64afeb45ee8472601340c","type":"GENE","name":"SSX7","canonical_id":"hgnc:HGNC:19653","description":"SSX family member 7","metadata":null},{"id":"31d7bae6877d42aa964ae42e80734707","type":"GENE","name":"SSX8P","canonical_id":"hgnc:HGNC:19654","description":"SSX family member 8, pseudogene","metadata":{"aliases":["SSX8"]}},{"id":"1c65fe011643473488e14bea1fe2b9bc","type":"GENE","name":"SSX9P","canonical_id":"hgnc:HGNC:19655","description":"SSX family member 9, pseudogene","metadata":{"aliases":["SSX9"]}},{"id":"d42ab279283240e79bc844fdfcaf8c4d","type":"GENE","name":"SSXP10","canonical_id":"hgnc:HGNC:30638","description":"SSX family pseudogene 10","metadata":{"aliases":["psiSSX10"]}},{"id":"7a9ae5e8ba544831a234ac87fac0c52a","type":"GENE","name":"ST13","canonical_id":"hgnc:HGNC:11343","description":"ST13 Hsp70 interacting protein","metadata":{"aliases":["SNC6","HSPABP1","HIP","P48","FAM10A1"]}},{"id":"6b8be7de32de4f328cafab8338500131","type":"GENE","name":"ST13P1","canonical_id":"hgnc:HGNC:38715","description":"ST13, Hsp70 interacting protein pseudogene 1","metadata":null},{"id":"6ee9f5c945f04cf7987b5addaedb5a02","type":"GENE","name":"ST13P10","canonical_id":"hgnc:HGNC:38745","description":"ST13, Hsp70 interacting protein pseudogene 10","metadata":null},{"id":"36a24409117e477dbd79f95d633b7d4f","type":"GENE","name":"ST13P11","canonical_id":"hgnc:HGNC:38746","description":"ST13, Hsp70 interacting protein pseudogene 11","metadata":null},{"id":"77d15cfbde2348c8be65c64cbe5ccc6a","type":"GENE","name":"ST13P12","canonical_id":"hgnc:HGNC:38787","description":"ST13, Hsp70 interacting protein pseudogene 12","metadata":null},{"id":"25c64aae719d4346bc7ae17f97749b16","type":"GENE","name":"ST13P13","canonical_id":"hgnc:HGNC:38788","description":"ST13, Hsp70 interacting protein pseudogene 13","metadata":null},{"id":"6511c866f9be400daed82f093b64a770","type":"GENE","name":"ST13P14","canonical_id":"hgnc:HGNC:38849","description":"ST13, Hsp70 interacting protein pseudogene 14","metadata":null},{"id":"9132eb9f7dc142ee98bd3646a532bde2","type":"GENE","name":"ST13P15","canonical_id":"hgnc:HGNC:38850","description":"ST13, Hsp70 interacting protein pseudogene 15","metadata":null},{"id":"ae46f059cbf745cf817f9644232ca7c4","type":"GENE","name":"ST13P16","canonical_id":"hgnc:HGNC:38851","description":"ST13, Hsp70 interacting protein pseudogene 16","metadata":null},{"id":"beae4bc4f41e4c3281edbe6dd2292250","type":"GENE","name":"ST13P17","canonical_id":"hgnc:HGNC:38859","description":"ST13, Hsp70 interacting protein pseudogene 17","metadata":null},{"id":"86d5e0ff53e34fd49939d49d4bd52774","type":"GENE","name":"ST13P18","canonical_id":"hgnc:HGNC:38861","description":"ST13, Hsp70 interacting protein pseudogene 18","metadata":null},{"id":"d994d798af824a2b8a29ea350584ce42","type":"GENE","name":"ST13P19","canonical_id":"hgnc:HGNC:38862","description":"ST13, Hsp70 interacting protein pseudogene 19","metadata":null},{"id":"34cd9c8e6e794b6896187acb2c6120ec","type":"GENE","name":"ST13P2","canonical_id":"hgnc:HGNC:38716","description":"ST13, Hsp70 interacting protein pseudogene 2","metadata":null},{"id":"47ae433e80c94ec983cfc0e131fbd097","type":"GENE","name":"ST13P20","canonical_id":"hgnc:HGNC:38863","description":"ST13, Hsp70 interacting protein pseudogene 20","metadata":null},{"id":"5ada0f526027416592240701cb620669","type":"GENE","name":"ST13P21","canonical_id":"hgnc:HGNC:38864","description":"ST13, Hsp70 interacting protein pseudogene 21","metadata":null},{"id":"4c1646c0b509483bb868ce604b187217","type":"GENE","name":"ST13P22","canonical_id":"hgnc:HGNC:38865","description":"ST13, Hsp70 interacting protein pseudogene 22","metadata":null},{"id":"244662d9d52e493fabd383a51d43cd83","type":"GENE","name":"ST13P3","canonical_id":"hgnc:HGNC:18552","description":"ST13, Hsp70 interacting protein pseudogene 3","metadata":{"aliases":["FAM10A3P","FAM10A3"]}},{"id":"1a55cc624bd744f9902a7b527736f881","type":"GENE","name":"ST13P4","canonical_id":"hgnc:HGNC:18487","description":"ST13, Hsp70 interacting protein pseudogene 4","metadata":{"aliases":["FAM10A4P","FAM10A4"]}},{"id":"39e4072d3f4540518097f91ea0e614be","type":"GENE","name":"ST13P5","canonical_id":"hgnc:HGNC:18556","description":"ST13, Hsp70 interacting protein pseudogene 5","metadata":{"aliases":["FAM10A5"]}},{"id":"73b00afaf6e3436e95482d19c92d1b99","type":"GENE","name":"ST13P6","canonical_id":"hgnc:HGNC:18557","description":"ST13, Hsp70 interacting protein pseudogene 6","metadata":{"aliases":["FAM10A6P","FAM10A6"]}},{"id":"44dcca84616848f4976ab512e8a60b28","type":"GENE","name":"ST13P7","canonical_id":"hgnc:HGNC:18558","description":"ST13, Hsp70 interacting protein pseudogene 7","metadata":{"aliases":["FAM10A7P","FAM10A7"]}},{"id":"9d3de8634cd349bb96b7c090b9fb66e2","type":"GENE","name":"ST13P8","canonical_id":"hgnc:HGNC:38743","description":"ST13, Hsp70 interacting protein pseudogene 8","metadata":null},{"id":"96724e6609fd401fb21c8b3af543849a","type":"GENE","name":"ST13P9","canonical_id":"hgnc:HGNC:38744","description":"ST13, Hsp70 interacting protein pseudogene 9","metadata":null},{"id":"02a15a42ca8547f8bb0e123ef39faa4d","type":"GENE","name":"ST14","canonical_id":"hgnc:HGNC:11344","description":"ST14 transmembrane serine protease matriptase","metadata":{"aliases":["SNC19","HAI","MT-SP1","TMPRSS14","CAP3","PRSS14"]}},{"id":"c2ab065a4fde4a41a6afde0c1414acb6","type":"GENE","name":"ST18","canonical_id":"hgnc:HGNC:18695","description":"ST18 C2H2C-type zinc finger transcription factor","metadata":{"aliases":["KIAA0535","ZC2HC10","NZF3","NZF-3","ZC2H2C3","ZNF387"]}},{"id":"4617149a2aad48c5aaa8af734c4e88a3","type":"GENE","name":"ST18-AS1","canonical_id":"hgnc:HGNC:58430","description":"ST18 antisense RNA 1","metadata":null},{"id":"b42f674cfd554233874b704449200e1d","type":"GENE","name":"ST18-AS2","canonical_id":"hgnc:HGNC:58433","description":"ST18 antisense RNA 2","metadata":null},{"id":"acca6f52c72d49d490f49d2e687dd915","type":"GENE","name":"ST18-AS3","canonical_id":"hgnc:HGNC:58615","description":"ST18 antisense RNA 3","metadata":null},{"id":"75cf7d85654e429180be2099d1ec0fed","type":"GENE","name":"ST20","canonical_id":"hgnc:HGNC:33520","description":"suppressor of tumorigenicity 20","metadata":{"aliases":["HCCS-1"]}},{"id":"8f477b27c75542db82747a07dfae9d0c","type":"GENE","name":"ST20-AS1","canonical_id":"hgnc:HGNC:27521","description":"ST20 antisense RNA 1","metadata":{"aliases":["FLJ33788","C15orf37"]}},{"id":"ab2e604d521f43f0b225a49f443a9da0","type":"GENE","name":"ST20-MTHFS","canonical_id":"hgnc:HGNC:44655","description":"ST20-MTHFS readthrough","metadata":null},{"id":"948e445880734979ab9724ee5b960359","type":"GENE","name":"ST3GAL1","canonical_id":"hgnc:HGNC:10862","description":null,"metadata":null},{"id":"032e3768c9184ebd8090af3c7e44e353","type":"GENE","name":"ST3GAL1-DT","canonical_id":"hgnc:HGNC:55372","description":"ST3GAL1 divergent transcript","metadata":null},{"id":"4c919e5b6558417aa6d3fae614d0693b","type":"GENE","name":"ST3GAL1P1","canonical_id":"hgnc:HGNC:45174","description":"ST3GAL1 pseudogene 1","metadata":null},{"id":"4f9b6ffd3f0448b0b263b8e300039b2c","type":"GENE","name":"ST3GAL2","canonical_id":"hgnc:HGNC:10863","description":"ST3 beta-galactoside alpha-2,3-sialyltransferase 2","metadata":{"aliases":["ST3GALII","ST3GalA.2","SIAT4B"]}},{"id":"8bb973e3368343129104698c59e07459","type":"GENE","name":"ST3GAL3","canonical_id":"hgnc:HGNC:10866","description":null,"metadata":null},{"id":"57be3a0acb0e4e5cbcd41dd681db022e","type":"GENE","name":"ST3GAL3-AS1","canonical_id":"hgnc:HGNC:40529","description":"ST3GAL3 antisense RNA 1","metadata":null},{"id":"89c2d249e35f43ef9656bfb7890801b5","type":"GENE","name":"ST3GAL4","canonical_id":"hgnc:HGNC:10864","description":null,"metadata":null},{"id":"30870a6399524050b095347758e631fb","type":"GENE","name":"ST3GAL5","canonical_id":"hgnc:HGNC:10872","description":null,"metadata":null},{"id":"263729f491664dbbadeb4d104a02f7bf","type":"GENE","name":"ST3GAL5-AS1","canonical_id":"hgnc:HGNC:51129","description":"ST3GAL5 antisense RNA 1","metadata":null},{"id":"87a898f026b247b39c65fcd47245a617","type":"GENE","name":"ST3GAL5P1","canonical_id":"hgnc:HGNC:45175","description":"ST3GAL5 pseudogene 1","metadata":null},{"id":"65126b5f3e1542b697d8bc87a66a349a","type":"GENE","name":"ST3GAL6","canonical_id":"hgnc:HGNC:18080","description":"ST3 beta-galactoside alpha-2,3-sialyltransferase 6","metadata":{"aliases":["ST3GALVI","SIAT10"]}},{"id":"8b3645c1431040d081b3c9091c2c1729","type":"GENE","name":"ST3GAL6-AS1","canonical_id":"hgnc:HGNC:40828","description":"ST3GAL6 antisense RNA 1","metadata":null},{"id":"8a6a9b631fa644d6ad5c6879d4cce213","type":"GENE","name":"ST6GAL1","canonical_id":"hgnc:HGNC:10860","description":null,"metadata":null},{"id":"fd9c458ce2b948fcbffd91393614dba2","type":"GENE","name":"ST6GAL2","canonical_id":"hgnc:HGNC:10861","description":"ST6 beta-galactoside alpha-2,6-sialyltransferase 2","metadata":{"aliases":["KIAA1877","St6GalII","SIAT2"]}},{"id":"02c18fafd9874b7480684e34519e6c2c","type":"GENE","name":"ST6GAL2-IT1","canonical_id":"hgnc:HGNC:41380","description":"ST6GAL2 intronic transcript 1","metadata":null},{"id":"a9cea6f8f5164280af9d07dda54c1114","type":"GENE","name":"ST6GALNAC1","canonical_id":"hgnc:HGNC:23614","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1","metadata":{"aliases":["ST6GalNAcI","SIAT7A"]}},{"id":"eeec52852c0e4c7f8086d4ec7b5ae29d","type":"GENE","name":"ST6GALNAC2","canonical_id":"hgnc:HGNC:10867","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2","metadata":{"aliases":["ST6GalNAII","STHM","SIAT7","SIAT7B","SIATL1"]}},{"id":"6ddc284a1bab4de8a572f2bf812c9b53","type":"GENE","name":"ST6GALNAC2P1","canonical_id":"hgnc:HGNC:45160","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 pseudogene 1","metadata":null},{"id":"d223ceab8bac4c768ef7bbbcfd9657c4","type":"GENE","name":"ST6GALNAC3","canonical_id":"hgnc:HGNC:19343","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3","metadata":{"aliases":["SIAT7C"]}},{"id":"022174508fab46bd955a2e48d3b95477","type":"GENE","name":"ST6GALNAC4","canonical_id":"hgnc:HGNC:17846","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4","metadata":{"aliases":["ST6GALNACIV","SIAT3C","SIAT7D"]}},{"id":"35563086778446058055299da983959c","type":"GENE","name":"ST6GALNAC4P1","canonical_id":"hgnc:HGNC:39660","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 pseudogene 1","metadata":null},{"id":"7a6f67fad01e4f4db7df73b4065cd978","type":"GENE","name":"ST6GALNAC5","canonical_id":"hgnc:HGNC:19342","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5","metadata":{"aliases":["MGC3184","ST6GalNAcV","SIAT7E"]}},{"id":"08d82e06393649a6af9d5a56f765c617","type":"GENE","name":"ST6GALNAC6","canonical_id":"hgnc:HGNC:23364","description":"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6","metadata":{"aliases":["ST6GALNACVI","SIAT7F"]}},{"id":"65bad3f71c704afd8fa5bfc86ddd89b8","type":"GENE","name":"ST7","canonical_id":"hgnc:HGNC:11351","description":"suppression of tumorigenicity 7","metadata":{"aliases":["TSG7","SEN4","ETS7q","HELG","RAY1","FAM4A","FAM4A1"]}},{"id":"e190dd231c9445b6924b01e788bed7bf","type":"GENE","name":"ST7-AS1","canonical_id":"hgnc:HGNC:16000","description":"ST7 antisense RNA 1","metadata":{"aliases":["ST7AS1","ST7OT1"]}},{"id":"5cb405598f2c418b826e4bb99e51e16a","type":"GENE","name":"ST7-AS2","canonical_id":"hgnc:HGNC:16044","description":"ST7 antisense RNA 2","metadata":{"aliases":["ST7AS2","ST7OT2"]}},{"id":"5a45aee3e77349ceb2907fa2a4c7e636","type":"GENE","name":"ST7-OT3","canonical_id":"hgnc:HGNC:16045","description":"ST7 overlapping transcript 3","metadata":{"aliases":["NCRNA00026","ST7OT3"]}},{"id":"8ce64b9eefd24d20853929b3f41d4ae7","type":"GENE","name":"ST7-OT4","canonical_id":"hgnc:HGNC:18835","description":"ST7 overlapping transcript 4","metadata":{"aliases":["NCRNA00042","ST7OT4"]}},{"id":"d4b76567fbc446bb98c4f550a1644198","type":"GENE","name":"ST7L","canonical_id":"hgnc:HGNC:18441","description":"suppression of tumorigenicity 7 like","metadata":{"aliases":["FLJ20284","STLR","ST7R","FAM4B"]}},{"id":"7482438945ca455895508cb31f0dd239","type":"GENE","name":"ST8SIA1","canonical_id":"hgnc:HGNC:10869","description":"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1","metadata":{"aliases":["SIAT8","SIAT8A"]}},{"id":"36bfd15a3ae04b0ba4dbc72a13236c6d","type":"GENE","name":"ST8SIA2","canonical_id":"hgnc:HGNC:10870","description":"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2","metadata":{"aliases":["STX","ST8SIA-II","HsT19690","SIAT8B"]}},{"id":"6b640145ec08496cb5088cf83a0d5c13","type":"GENE","name":"ST8SIA3","canonical_id":"hgnc:HGNC:14269","description":"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3","metadata":{"aliases":["SIAT8C"]}},{"id":"0728aaf16f6b47afad904724728def0b","type":"GENE","name":"ST8SIA4","canonical_id":"hgnc:HGNC:10871","description":"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4","metadata":{"aliases":["PST","PST1","SIAT8D"]}},{"id":"0dd8286413db48868c6ed2f84961c3df","type":"GENE","name":"ST8SIA4-DT","canonical_id":"hgnc:HGNC:59102","description":"ST8SIA4 divergent transcript","metadata":null},{"id":"ae891886e5a7407bb653db3a6b8754ce","type":"GENE","name":"ST8SIA5","canonical_id":"hgnc:HGNC:17827","description":"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5","metadata":{"aliases":["SIAT8E"]}},{"id":"1b50aadb31604609b077d0b18498fea5","type":"GENE","name":"ST8SIA5-DT","canonical_id":"hgnc:HGNC:55267","description":"ST8SIA5 divergent transcript","metadata":null},{"id":"c520cb1ac1f14344a47919ce0e287e98","type":"GENE","name":"ST8SIA6","canonical_id":"hgnc:HGNC:23317","description":"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6","metadata":{"aliases":["SIAT8F"]}},{"id":"afa188060ebe42b3984d71dfadf88e5a","type":"GENE","name":"ST8SIA6-AS1","canonical_id":"hgnc:HGNC:44880","description":"ST8SIA6 antisense RNA 1","metadata":{"aliases":["APAL"]}},{"id":"cd573a10735c475780f8c81af43b3adb","type":"GENE","name":"STAB1","canonical_id":"hgnc:HGNC:18628","description":"stabilin 1","metadata":{"aliases":["KIAA0246","STAB-1","FEEL-1","CLEVER-1","FELE-1","FEX1","SCARH2"]}},{"id":"c7f6c543ae4841d7b711f092e2d96fb0","type":"GENE","name":"STAB2","canonical_id":"hgnc:HGNC:18629","description":"stabilin 2","metadata":{"aliases":["DKFZP434E0321","FELL","STAB-2","HARE","FEEL-2","SCARH1"]}},{"id":"fdbd26bc340e486fb46d885006a48c45","type":"GENE","name":"STAB2-AS1","canonical_id":"hgnc:HGNC:58447","description":"STAB2 antisense RNA 1","metadata":null},{"id":"f6565dc886dd4151a2cac6b6289c6d76","type":"GENE","name":"STAC","canonical_id":"hgnc:HGNC:11353","description":"SH3 and cysteine rich domain","metadata":{"aliases":["STAC1"]}},{"id":"5c7f5a601068470fa7e920a0e5f1b7f4","type":"GENE","name":"STAC2","canonical_id":"hgnc:HGNC:23990","description":"SH3 and cysteine rich domain 2","metadata":{"aliases":["24b2"]}},{"id":"f2f3073a3bd540baa5c56692fda26379","type":"GENE","name":"STAC3","canonical_id":"hgnc:HGNC:28423","description":"SH3 and cysteine rich domain 3","metadata":{"aliases":["MGC2793"]}},{"id":"a231f1c5dcae4321a4de97b8e9c7e05a","type":"GENE","name":"STAG1","canonical_id":"hgnc:HGNC:11354","description":"STAG1 cohesin complex component","metadata":{"aliases":["SA-1","SCC3A","SA1"]}},{"id":"9ab436fe0802442dbae657dc2bdb276e","type":"GENE","name":"STAG1-DT","canonical_id":"hgnc:HGNC:55350","description":"STAG1 divergent transcript","metadata":null},{"id":"066030b388684c24819025800c0e6726","type":"GENE","name":"STAG2","canonical_id":"hgnc:HGNC:11355","description":"STAG2 cohesin complex component","metadata":{"aliases":["SA-2","SCC3B","SA2"]}},{"id":"7d3bde9ab63d412da12389e8b39feb25","type":"GENE","name":"STAG2-AS1","canonical_id":"hgnc:HGNC:55727","description":"STAG2 antisense RNA 1","metadata":null},{"id":"946e46f6f0db49af9cdf3606bd8b3e95","type":"GENE","name":"STAG3","canonical_id":"hgnc:HGNC:11356","description":"STAG3 cohesin complex component","metadata":{"aliases":["SA3"]}},{"id":"e9df3220e498483f8a3e04c2bd26edac","type":"GENE","name":"STAG3L1","canonical_id":"hgnc:HGNC:33852","description":"STAG3 cohesin complex component like 1 (pseudogene)","metadata":{"aliases":["DKFZP434A0131","STAG3L1P"]}},{"id":"e172daea5419403c838e6bb382ddd727","type":"GENE","name":"STAG3L2","canonical_id":"hgnc:HGNC:33886","description":"STAG3 cohesin complex component like 2 (pseudogene)","metadata":{"aliases":["MGC131759","STAG3L2P"]}},{"id":"b016fea3d9424eb98393f7b52ecc6d74","type":"GENE","name":"STAG3L3","canonical_id":"hgnc:HGNC:33845","description":"STAG3 cohesin complex component like 3 (pseudogene)","metadata":{"aliases":["STAG3L3P"]}},{"id":"b37e41ac4055428299225bff1f339c36","type":"GENE","name":"STAG3L4","canonical_id":"hgnc:HGNC:33887","description":"STAG3 cohesin complex component like 4 (pseudogene)","metadata":{"aliases":["FLJ13195","STAG3L4P"]}},{"id":"60c299b568004401b6ba8d57fcdc7d78","type":"GENE","name":"STAG3L5P","canonical_id":"hgnc:HGNC:48896","description":"STAG3 cohesin complex component like 5, pseudogene","metadata":null},{"id":"f5b2b17c58674dbd9cf69109ced747fc","type":"GENE","name":"STAG3L5P-PVRIG2P-PILRB","canonical_id":"hgnc:HGNC:48898","description":"STAG3L5P-PVRIG2P-PILRB readthrough","metadata":null},{"id":"18f3659db1524a38adda9debf79b60c3","type":"GENE","name":"STAM","canonical_id":"hgnc:HGNC:11357","description":"signal transducing adaptor molecule","metadata":{"aliases":["STAM1"]}},{"id":"ad668e02e1d44f5fb8d9860777b3983c","type":"GENE","name":"STAM-AS2","canonical_id":"hgnc:HGNC:58362","description":"STAM antisense RNA 2","metadata":null},{"id":"10ac4e5782754e46bacba343435473df","type":"GENE","name":"STAM-DT","canonical_id":"hgnc:HGNC:49568","description":"STAM divergent transcript","metadata":{"aliases":["locus3182","STAM-AS1"]}},{"id":"f8a88cd691014bedaa42125a4c6a468d","type":"GENE","name":"STAM2","canonical_id":"hgnc:HGNC:11358","description":"signal transducing adaptor molecule 2","metadata":{"aliases":["Hbp"]}},{"id":"f9954e40f0a34540b5b58c054e6106f0","type":"GENE","name":"STAMBP","canonical_id":"hgnc:HGNC:16950","description":"STAM binding protein","metadata":{"aliases":["AMSH"]}},{"id":"a710faa2e75f4cb8b484c05c2c826ce9","type":"GENE","name":"STAMBPL1","canonical_id":"hgnc:HGNC:24105","description":"STAM binding protein like 1","metadata":{"aliases":["AMSH-LP","KIAA1373","AMSH-FP","FLJ31524","ALMalpha","bA399O19.2"]}},{"id":"5d5d0eb21d2a4078943ce8556fb17fbc","type":"GENE","name":"STAP1","canonical_id":"hgnc:HGNC:24133","description":"signal transducing adaptor family member 1","metadata":{"aliases":["STAP-1","BRDG1"]}},{"id":"5b9025ef6a7b4d3e9869e57ab63d0450","type":"GENE","name":"STAP2","canonical_id":"hgnc:HGNC:30430","description":"signal transducing adaptor family member 2","metadata":{"aliases":["STAP-2","BKS"]}},{"id":"bbe3e9d212aa4ebe85c6817531581da4","type":"GENE","name":"STAR","canonical_id":"hgnc:HGNC:11359","description":null,"metadata":null},{"id":"d405682617ed44d1959962a06a5a317f","type":"GENE","name":"STARD10","canonical_id":"hgnc:HGNC:10666","description":"StAR related lipid transfer domain containing 10","metadata":{"aliases":["NY-CO-28","CGI-52","PCTP2","SDCCAG28"]}},{"id":"a49a11c1c0274dec8d50316e2d40e053","type":"GENE","name":"STARD13","canonical_id":"hgnc:HGNC:19164","description":"StAR related lipid transfer domain containing 13","metadata":{"aliases":["GT650","DLC2","ARHGAP37","LINC00464"]}},{"id":"e2fed9a6b8c44b88a385305aa2ef9035","type":"GENE","name":"STARD13-AS","canonical_id":"hgnc:HGNC:40873","description":"STARD13 antisense RNA","metadata":{"aliases":["STARD13-AS2"]}},{"id":"7b6abd2bf4b643608122944ee1cf9fc7","type":"GENE","name":"STARD13-IT1","canonical_id":"hgnc:HGNC:41453","description":"STARD13 intronic transcript 1","metadata":null},{"id":"19adf713f9d74dc2ac172fa53935ec8a","type":"GENE","name":"STARD3","canonical_id":"hgnc:HGNC:17579","description":null,"metadata":null},{"id":"1a8fc93d722249f088080890043b87a1","type":"GENE","name":"STARD3NL","canonical_id":"hgnc:HGNC:19169","description":"STARD3 N-terminal like","metadata":{"aliases":["MENTHO","MGC3251"]}},{"id":"1fdd691f4ba044f29e3a9c54dfaf01d2","type":"GENE","name":"STARD4","canonical_id":"hgnc:HGNC:18058","description":null,"metadata":null},{"id":"24452cd3def449afa73df3b7585e386a","type":"GENE","name":"STARD4-AS1","canonical_id":"hgnc:HGNC:44117","description":"STARD4 antisense RNA 1","metadata":null},{"id":"5d71a31004824180ae7ffb516ff2e1cb","type":"GENE","name":"STARD5","canonical_id":"hgnc:HGNC:18065","description":"StAR related lipid transfer domain containing 5","metadata":{"aliases":["MGC10327"]}},{"id":"aca33f98411d4f7c9723bd9bfcef3825","type":"GENE","name":"STARD6","canonical_id":"hgnc:HGNC:18066","description":"StAR related lipid transfer domain containing 6","metadata":null},{"id":"3779b7e2a1164c789db411770e18c4c7","type":"GENE","name":"STARD7","canonical_id":"hgnc:HGNC:18063","description":null,"metadata":null},{"id":"07368101348a474980f3700bf22bd835","type":"GENE","name":"STARD7-AS1","canonical_id":"hgnc:HGNC:40827","description":"STARD7 antisense RNA 1","metadata":null},{"id":"ede60653cc174a6db62b038903c1f765","type":"GENE","name":"STARD8","canonical_id":"hgnc:HGNC:19161","description":"StAR related lipid transfer domain containing 8","metadata":{"aliases":["KIAA0189","ARHGAP38"]}},{"id":"147d9e15e8e3453dab28ae5549e12590","type":"GENE","name":"STARD9","canonical_id":"hgnc:HGNC:19162","description":"StAR related lipid transfer domain containing 9","metadata":{"aliases":["KIAA1300","KIF16A"]}},{"id":"64b6db668cfa483bb63f4585944345bc","type":"GENE","name":"STARP1","canonical_id":"hgnc:HGNC:11360","description":"steroidogenic acute regulatory protein pseudogene 1","metadata":{"aliases":["STARD1P1"]}},{"id":"efb034ecd8e94d738c3207abeb0e9c50","type":"GO_TERM","name":"STAT family protein binding","canonical_id":"go:GO:0097677","description":"\"Binding to a member of the signal transducers and activators of transcription (STAT) protein family. STATs are, as the name indicates, both signal transducers and transcription factors. STATs are activated by cytokines and some growth factors and thus control important biological processes including cell growth, cell differentiation, apoptosis and immune responses.\" [GOC:mr, InterPro:IPR001217, PMID:21447371, PMID:24470978]","metadata":null},{"id":"ec5d9e2e06af41d28b1513969a28ffac","type":"GENE","name":"STAT1","canonical_id":"hgnc:HGNC:11362","description":null,"metadata":null},{"id":"f15d3b64b9b7466b9798ea91d115f8d3","type":"GENE","name":"STAT2","canonical_id":"hgnc:HGNC:11363","description":null,"metadata":null},{"id":"79b7226f139c4646a2582d9572f73608","type":"GENE","name":"STAT3","canonical_id":"hgnc:HGNC:11364","description":null,"metadata":null},{"id":"1661672e4be24740bb6b5378799e06e9","type":"GENE","name":"STAT3","canonical_id":"ensembl:ENSG00000168610","description":null,"metadata":null},{"id":"cb48747dc5ea4f32b06c74e91b8cd997","type":"GENE","name":"STAT4","canonical_id":"hgnc:HGNC:11365","description":null,"metadata":null},{"id":"ee211201cb074609962f0394a81d2532","type":"GENE","name":"STAT4-AS1","canonical_id":"hgnc:HGNC:55764","description":"STAT4 antisense RNA 1","metadata":null},{"id":"295990dbe7124e26ad0620850c110b3b","type":"GENE","name":"STAT5A","canonical_id":"hgnc:HGNC:11366","description":null,"metadata":null},{"id":"9bcb303bd9b84f2396b2f7cedd5789d7","type":"GENE","name":"STAT5B","canonical_id":"hgnc:HGNC:11367","description":null,"metadata":null},{"id":"0fb2227a83a74659b495347df771bd29","type":"GENE","name":"STAT6","canonical_id":"hgnc:HGNC:11368","description":null,"metadata":null},{"id":"290361c3abaf47789a7bbc8e09c1bd84","type":"GENE","name":"STATH","canonical_id":"hgnc:HGNC:11369","description":"statherin","metadata":{"aliases":["STR"]}},{"id":"44edcff9aaee4debb7a91437bc7e9eaf","type":"GENE","name":"STAU1","canonical_id":"hgnc:HGNC:11370","description":"staufen double-stranded RNA binding protein 1","metadata":{"aliases":["PPP1R150","STAU"]}},{"id":"1d52dcfcc2a94560bc8bd4a890bb6ae2","type":"GENE","name":"STAU2","canonical_id":"hgnc:HGNC:11371","description":"staufen double-stranded RNA binding protein 2","metadata":{"aliases":["39K2"]}},{"id":"6b64d5d514c34aefa760c967bd8857c3","type":"GENE","name":"STAU2-AS1","canonical_id":"hgnc:HGNC:44101","description":"STAU2 antisense RNA 1","metadata":null},{"id":"eed4ae38980f4ef1bbd5e63b7c20c2e6","type":"GENE","name":"STAU2P1","canonical_id":"hgnc:HGNC:55011","description":"STAU2 pseudogene 1","metadata":null},{"id":"09449acabf2f434cb6046e10a092bd5e","type":"GENE","name":"STBD1","canonical_id":"hgnc:HGNC:24854","description":"starch binding domain 1","metadata":{"aliases":["FLJ41801","GENX-3414"]}},{"id":"3c3858437f0d428f989e79cb9f61fdf7","type":"GENE","name":"STBD1P1","canonical_id":"hgnc:HGNC:56805","description":"STBD1 pseudogene 1","metadata":null},{"id":"0fa68dd356a34a8796786f6d8a37ca46","type":"GENE","name":"STC1","canonical_id":"hgnc:HGNC:11373","description":"stanniocalcin 1","metadata":{"aliases":["STC"]}},{"id":"6db5f91717834d3281e65b5f06e8e3e0","type":"GENE","name":"STC2","canonical_id":"hgnc:HGNC:11374","description":"stanniocalcin 2","metadata":{"aliases":["STC-2"]}},{"id":"bd18cbcc4c7b4e178d41c09b7c8bab1d","type":"GENE","name":"STC2-DT","canonical_id":"hgnc:HGNC:59308","description":"STC2 divergent transcript","metadata":null},{"id":"534c1638dac5428487ae93bb2245d195","type":"GENE","name":"STEAP1","canonical_id":"hgnc:HGNC:11378","description":"STEAP family member 1","metadata":{"aliases":["PRSS24","STEAP"]}},{"id":"28595e76b04a4841bf1a8888101dcc52","type":"GENE","name":"STEAP1B","canonical_id":"hgnc:HGNC:41907","description":"STEAP family member 1B","metadata":null},{"id":"7c1c14cb28264740a7bd450e0e25a191","type":"GENE","name":"STEAP1B-AS1","canonical_id":"hgnc:HGNC:56137","description":"STEAP1B antisense RNA 1","metadata":null},{"id":"bc7f6e9dbdb342d282d7d2c752275b78","type":"GENE","name":"STEAP1B-AS2","canonical_id":"hgnc:HGNC:56643","description":"STEAP1B antisense RNA 2","metadata":{"aliases":["MRF"]}},{"id":"6fc91b0905e34db38fd0e408cc9c7126","type":"GENE","name":"STEAP2","canonical_id":"hgnc:HGNC:17885","description":"STEAP2 metalloreductase","metadata":{"aliases":["IPCA-1","STAMP1","STMP","PCANAP1"]}},{"id":"acd2ab1ab9874d9f86736e579c6ab8ca","type":"GENE","name":"STEAP2-AS1","canonical_id":"hgnc:HGNC:40820","description":"STEAP2 antisense RNA 1","metadata":null},{"id":"18b14cef244d46baaec82bafb77864d7","type":"GENE","name":"STEAP3","canonical_id":"hgnc:HGNC:24592","description":"STEAP3 metalloreductase","metadata":{"aliases":["TSAP6","dudlin-2","STMP3"]}},{"id":"db7d627a1bd54abcbc471a258403856f","type":"GENE","name":"STEAP3-AS1","canonical_id":"hgnc:HGNC:41053","description":"STEAP3 antisense RNA 1","metadata":null},{"id":"24342ae124d44cc181e7636c0c49a91c","type":"GENE","name":"STEAP4","canonical_id":"hgnc:HGNC:21923","description":"STEAP4 metalloreductase","metadata":{"aliases":["FLJ23153","TIARP","STAMP2","SchLAH","TNFAIP9"]}},{"id":"8550272c69f644789b9e7ec639dda6d2","type":"GENE","name":"STEEP1","canonical_id":"hgnc:HGNC:26239","description":"STING1 ER exit protein 1","metadata":{"aliases":["FLJ22965","CXorf56"]}},{"id":"36004279366a4113a49e222eaab186e0","type":"GENE","name":"STEEP1P1","canonical_id":"hgnc:HGNC:59153","description":"STEEP1 pseudogene 1","metadata":null},{"id":"a64f0ccab0204ae29cb9086aa9019bfc","type":"TRIAL","name":"STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE","canonical_id":"clinicaltrials.gov:NCT07341022","description":"Sickle Cell Disease","metadata":null},{"id":"c76b32e2e7894123806eb98950d2938b","type":"TRIAL","name":"STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","canonical_id":"clinicaltrials.gov:NCT03548935","description":"Metabolism and Nutrition Disorder; Overweight or Obesity","metadata":null},{"id":"7e3868ab3bb0458e8bfb6f98a1a76c55","type":"TRIAL","name":"STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01367665","description":"Basal Cell Carcinoma","metadata":null},{"id":"cd33e051463a4bcc9dec5ce43fe4727c","type":"GENE","name":"STH","canonical_id":"hgnc:HGNC:18839","description":"saitohin","metadata":{"aliases":["MAPTIT"]}},{"id":"73aeaac1ffd64025ac202a47f8f47d4e","type":"TRIAL","name":"STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00015834","description":"Blastic Phase Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Relapsing Chronic Myelogenous Leukemia","metadata":null},{"id":"c6898cd6cdeb4b2a9dd5865c151b71d7","type":"GENE","name":"STIL","canonical_id":"hgnc:HGNC:10879","description":"STIL centriolar assembly protein","metadata":{"aliases":["MCPH7","SIL"]}},{"id":"ef993da932bc4225b9dc3d9110e1a943","type":"GENE","name":"STIM1","canonical_id":"hgnc:HGNC:11386","description":null,"metadata":null},{"id":"53c56bb1609c4171bd5d4288ad9d9498","type":"GENE","name":"STIM1-AS1","canonical_id":"hgnc:HGNC:40568","description":"STIM1 antisense RNA 1","metadata":null},{"id":"55cc4ac319904a58a0bb8794c4bf3024","type":"GENE","name":"STIM2","canonical_id":"hgnc:HGNC:19205","description":"stromal interaction molecule 2","metadata":null},{"id":"6004da3c7f81445aa2ee72482a530f9c","type":"GENE","name":"STIM2-AS1","canonical_id":"hgnc:HGNC:40879","description":"STIM2 antisense RNA 1","metadata":null},{"id":"635e0b6139e443b3ab32afb28a6b94f9","type":"GENE","name":"STIMATE","canonical_id":"hgnc:HGNC:30526","description":"STIM activating enhancer","metadata":{"aliases":["MGC52022","TMEM110"]}},{"id":"6b69513b04b64582a62b67ff135b305a","type":"GENE","name":"STIMATE-MUSTN1","canonical_id":"hgnc:HGNC:38834","description":"STIMATE-MUSTN1 readthrough","metadata":{"aliases":["TMEM110-MUSTN1"]}},{"id":"6ab52e15052541569c7719fa12196706","type":"GO_TERM","name":"STING complex","canonical_id":"go:GO:1990231","description":"\"A protein dimer containing two STING monomers. It binds cyclic purine di-nucleotides. Activation of the sting complex by 2',5'-3'-5'-cyclic GMP-AMP activates nuclear transcription factor kB (NF-kB) and interferon regulatory factor 3 (IRF3) which then induce transcription of the genes encoding type I IFN and cytokines active in the innate immune response.\" [GOC:bhm, PMID:22705373, PMID:23706668, PMID:23910378]","metadata":null},{"id":"63697f748c91417b9ee785bb0703c8cb","type":"GENE","name":"STING1","canonical_id":"hgnc:HGNC:27962","description":"stimulator of interferon response cGAMP interactor 1","metadata":{"aliases":["FLJ38577","NET23","ERIS","MPYS","STING","MITA","TMEM173"]}},{"id":"bb515406e98b4741b4cee2c1c9cea8f7","type":"GENE","name":"STIP1","canonical_id":"hgnc:HGNC:11387","description":null,"metadata":null},{"id":"e2447483c4fd4df79ca17a9dad531e9a","type":"GENE","name":"STIP1P1","canonical_id":"hgnc:HGNC:49552","description":"stress induced phosphoprotein 1 pseudogene 1","metadata":null},{"id":"8c0f83f51f214ee4a30569f7fdbc85b3","type":"GENE","name":"STIP1P2","canonical_id":"hgnc:HGNC:49553","description":"stress induced phosphoprotein 1 pseudogene 2","metadata":null},{"id":"dccd40853cb0467c9297cc6dc74d71a3","type":"GENE","name":"STIP1P3","canonical_id":"hgnc:HGNC:49554","description":"stress induced phosphoprotein 1 pseudogene 3","metadata":null},{"id":"0ca3c2c9c9144c10ae1e86e3d07d565c","type":"TRIAL","name":"STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)","canonical_id":"clinicaltrials.gov:NCT00637078","description":"Hypertension; Hypercholesterolemia","metadata":null},{"id":"93a6ef4c18e24368aa46b8c0c0ba349a","type":"GENE","name":"STK10","canonical_id":"hgnc:HGNC:11388","description":"serine/threonine kinase 10","metadata":{"aliases":["LOK","PRO2729"]}},{"id":"64fd108ccaca40b2863044da36d94b5e","type":"GENE","name":"STK10-AS1","canonical_id":"hgnc:HGNC:59306","description":"STK10 antisense RNA 1","metadata":null},{"id":"a6636994dbf94a609b8fde87bd731c80","type":"GENE","name":"STK11","canonical_id":"hgnc:HGNC:11389","description":null,"metadata":null},{"id":"d1d4c90034a9449f93eb39e6774a4883","type":"GENE","name":"STK11IP","canonical_id":"hgnc:HGNC:19184","description":"serine/threonine kinase 11 interacting protein","metadata":{"aliases":["LIP1","KIAA1898","LKB1IP","STK11IP1"]}},{"id":"fadd42a63c904640937553df5a6d9db4","type":"GENE","name":"STK16","canonical_id":"hgnc:HGNC:11394","description":"serine/threonine kinase 16","metadata":{"aliases":["MPSK1","PKL12","MPSK"]}},{"id":"73942083114a4b44b6ef7cd5b440025e","type":"GENE","name":"STK16P1","canonical_id":"hgnc:HGNC:19283","description":"serine/threonine kinase 16 pseudogene 1","metadata":{"aliases":["STK16P"]}},{"id":"98f14d4b48424d21bdc4758d1b990b4c","type":"GENE","name":"STK17A","canonical_id":"hgnc:HGNC:11395","description":"serine/threonine kinase 17a","metadata":{"aliases":["DRAK1"]}},{"id":"bac53419713a453d96cdf6ea0002c733","type":"GENE","name":"STK17B","canonical_id":"hgnc:HGNC:11396","description":"serine/threonine kinase 17b","metadata":{"aliases":["DRAK2"]}},{"id":"bda059155ea04ce9941396a85185c0ea","type":"GENE","name":"STK24","canonical_id":"hgnc:HGNC:11403","description":"serine/threonine kinase 24","metadata":{"aliases":["MST-3","MST3","MST3B","STK3","STE20"]}},{"id":"07fe43ffe28941b6b3d22b97c0db935c","type":"GENE","name":"STK24-AS1","canonical_id":"hgnc:HGNC:39935","description":"STK24 antisense RNA 1","metadata":null},{"id":"e65b3aa6a8a143b990ea31cebaccf2ae","type":"GENE","name":"STK24P1","canonical_id":"hgnc:HGNC:50360","description":"serine/threonine kinase 24 pseudogene 1","metadata":null},{"id":"f3645a3c251b4fb6a40e4bb8e1e9dfde","type":"GENE","name":"STK25","canonical_id":"hgnc:HGNC:11404","description":"serine/threonine kinase 25","metadata":{"aliases":["SOK1","YSK1"]}},{"id":"ecdb366f66d94479a85a738fd25a5cca","type":"GENE","name":"STK25P1","canonical_id":"hgnc:HGNC:50361","description":"serine/threonine kinase 25 pseudogene 1","metadata":null},{"id":"b518774fce9f439ba00e2f59ca710910","type":"GENE","name":"STK26","canonical_id":"hgnc:HGNC:18174","description":"serine/threonine kinase 26","metadata":{"aliases":["MST4","MASK"]}},{"id":"c5503ed745ef4fc4ab7ca22003495c1b","type":"GENE","name":"STK3","canonical_id":"hgnc:HGNC:11406","description":"serine/threonine kinase 3","metadata":{"aliases":["MST2","KRS1"]}},{"id":"d238d049835649e79f3fec44fc5359d0","type":"GENE","name":"STK31","canonical_id":"hgnc:HGNC:11407","description":"serine/threonine kinase 31","metadata":{"aliases":["TDRD8","SgK396"]}},{"id":"ad079c000c7c4960bfdb4ad52e4e47d9","type":"GENE","name":"STK32A","canonical_id":"hgnc:HGNC:28317","description":"serine/threonine kinase 32A","metadata":{"aliases":["MGC22688","YANK1"]}},{"id":"3195273d786f4309b21004aebaed133a","type":"GENE","name":"STK32A-AS1","canonical_id":"hgnc:HGNC:53468","description":"STK32A antisense RNA 1","metadata":{"aliases":["CTC-255N20"]}},{"id":"fe93995b42a24b538898b9dd592ead3f","type":"GENE","name":"STK32B","canonical_id":"hgnc:HGNC:14217","description":"serine/threonine kinase 32B","metadata":{"aliases":["STKG6","YANK2","STK32","HSA250839"]}},{"id":"5a2d46536c1740d6a0f959f6222d0b01","type":"GENE","name":"STK32B-AS1","canonical_id":"hgnc:HGNC:58720","description":"STK32B antisense RNA 1","metadata":null},{"id":"8feee6e493a44853941d46dfeb1315e0","type":"GENE","name":"STK32B-DT","canonical_id":"hgnc:HGNC:58719","description":"STK32B divergent transcript","metadata":null},{"id":"37eb4c6b3f794d6e95ff2b74ef16b161","type":"GENE","name":"STK32C","canonical_id":"hgnc:HGNC:21332","description":"serine/threonine kinase 32C","metadata":{"aliases":["PKE","MGC23665","YANK3"]}},{"id":"0a3113b5e3264aaa909180e5a8ff9138","type":"GENE","name":"STK33","canonical_id":"hgnc:HGNC:14568","description":"serine/threonine kinase 33","metadata":null},{"id":"3d86cc99293c41b1b1a59a761bdc01c0","type":"GENE","name":"STK33P1","canonical_id":"hgnc:HGNC:26871","description":"serine/threonine kinase 33 pseudogene 1","metadata":{"aliases":["STK33ps","STK33P"]}},{"id":"84a02ca56a774a469e92c228c4307ee0","type":"GENE","name":"STK35","canonical_id":"hgnc:HGNC:16254","description":"serine/threonine kinase 35","metadata":{"aliases":["bA550O8.2","CLIK1","STK35L1"]}},{"id":"01455c698f1b44daa27d216566d0cb0b","type":"GENE","name":"STK36","canonical_id":"hgnc:HGNC:17209","description":"serine/threonine kinase 36","metadata":{"aliases":["KIAA1278","FU"]}},{"id":"77dc15c73e5642a18b1566bcaeff40c9","type":"GENE","name":"STK38","canonical_id":"hgnc:HGNC:17847","description":"serine/threonine kinase 38","metadata":{"aliases":["NDR","NDR1"]}},{"id":"f54dfdad58b1473683aa6e928040fbe8","type":"GENE","name":"STK38L","canonical_id":"hgnc:HGNC:17848","description":"serine/threonine kinase 38 like","metadata":{"aliases":["KIAA0965","NDR2"]}},{"id":"2d0c9d01b66c46a7865d15b148f7bd03","type":"GENE","name":"STK39","canonical_id":"hgnc:HGNC:17717","description":null,"metadata":null},{"id":"73c881b720d249f3adf68fd6f7738bb7","type":"GENE","name":"STK4","canonical_id":"hgnc:HGNC:11408","description":"serine/threonine kinase 4","metadata":{"aliases":["MST1","KRS2","YSK3"]}},{"id":"86965f6945a2436a8af0f328bc4828b2","type":"GENE","name":"STK4-DT","canonical_id":"hgnc:HGNC:43811","description":"STK4 divergent transcript","metadata":{"aliases":["STK4-AS1"]}},{"id":"9b1d7ffe9f334df0b05a06cc9e1dadca","type":"GENE","name":"STK40","canonical_id":"hgnc:HGNC:21373","description":"serine/threonine kinase 40","metadata":{"aliases":["MGC4796","SgK495","SHIK"]}},{"id":"1f9bdff8bc514667b1c323581dcbe4b3","type":"GENE","name":"STKLD1","canonical_id":"hgnc:HGNC:28669","description":"serine/threonine kinase like domain containing 1","metadata":{"aliases":["MGC43306","SGK071","C9orf96"]}},{"id":"4681d744b3c3448ba72554c42b4a49e0","type":"GENE","name":"STMN1","canonical_id":"hgnc:HGNC:6510","description":null,"metadata":null},{"id":"809401e6829243b6bc0475542326c7f6","type":"GENE","name":"STMN1P1","canonical_id":"hgnc:HGNC:44062","description":"stathmin 1 pseudogene 1","metadata":null},{"id":"2e353fe8f4e2426c9b8e582799b1c636","type":"GENE","name":"STMN1P2","canonical_id":"hgnc:HGNC:44063","description":"stathmin 1 pseudogene 2","metadata":null},{"id":"09309b5ae2ec44c2b79e48e41f17ba2a","type":"GENE","name":"STMN2","canonical_id":"hgnc:HGNC:10577","description":null,"metadata":null},{"id":"9f586912d41e49c2b8158d3f42a17507","type":"GENE","name":"STMN3","canonical_id":"hgnc:HGNC:15926","description":"stathmin 3","metadata":{"aliases":["SCLIP"]}},{"id":"8809f26208ef4a4a845abc900df6f1aa","type":"GENE","name":"STMN3P1","canonical_id":"hgnc:HGNC:56985","description":"STMN3 pseudogene 1","metadata":null},{"id":"5c8c09486bb24040aa6ca99cef6d063b","type":"GENE","name":"STMN4","canonical_id":"hgnc:HGNC:16078","description":"stathmin 4","metadata":{"aliases":["RB3"]}},{"id":"193b5668d60f4f6abc4f73c455c5da93","type":"GENE","name":"STMND1","canonical_id":"hgnc:HGNC:44668","description":"stathmin domain containing 1","metadata":{"aliases":["FLJ23152"]}},{"id":"dee6bd045e0347d9b467b8c11a393804","type":"GENE","name":"STMP1","canonical_id":"hgnc:HGNC:41909","description":"short transmembrane mitochondrial protein 1","metadata":{"aliases":["PL-5283","Mm47","Mtlbn","C7orf73"]}},{"id":"59d3a1bf95be4087a189e28d8ef3a448","type":"GENE","name":"STMP1P1","canonical_id":"hgnc:HGNC:58522","description":"STMP1 pseudogene 1","metadata":null},{"id":"484ffad1c1584296ba8fc1a80c5f7364","type":"GENE","name":"STMP1P2","canonical_id":"hgnc:HGNC:58523","description":"STMP1 pseudogene 2","metadata":null},{"id":"e2f517df6f7548318192bedcee7b6169","type":"GENE","name":"STN1","canonical_id":"hgnc:HGNC:26200","description":"STN1 subunit of CST complex","metadata":{"aliases":["FLJ22559","bA541N10.2","OBFC1"]}},{"id":"97186aa666ed43d5babcc1d55a5fd8e9","type":"GENE","name":"STOM","canonical_id":"hgnc:HGNC:3383","description":"stomatin","metadata":{"aliases":["BND7","EPB7","EPB72"]}},{"id":"f19e96aec056473e8af1ea78cfeed103","type":"GENE","name":"STOML1","canonical_id":"hgnc:HGNC:14560","description":"stomatin like 1","metadata":{"aliases":["hUNC-24","SLP-1","STORP","FLJ36370"]}},{"id":"abff31d3c7cc4a29923140d07157dc6d","type":"GENE","name":"STOML2","canonical_id":"hgnc:HGNC:14559","description":"stomatin like 2","metadata":{"aliases":["SLP-2","HSPC108"]}},{"id":"1b8f0b07030349a6b913281d70de9400","type":"GENE","name":"STOML3","canonical_id":"hgnc:HGNC:19420","description":"stomatin like 3","metadata":{"aliases":["SRO","Epb7.2l"]}},{"id":"b3c08099ddd54517b34538cdc45d049d","type":"GENE","name":"STON1","canonical_id":"hgnc:HGNC:17003","description":"stonin 1","metadata":{"aliases":["SBLF","stoned-b1"]}},{"id":"4b9dfba4915a44c1b5bf954b7b4498f1","type":"GENE","name":"STON1-GTF2A1L","canonical_id":"hgnc:HGNC:30651","description":"STON1-GTF2A1L readthrough","metadata":{"aliases":["SALF"]}},{"id":"b1f88e3efba14707aa76513165c34789","type":"GENE","name":"STON2","canonical_id":"hgnc:HGNC:30652","description":"stonin 2","metadata":{"aliases":["STNB2","STN2"]}},{"id":"d8e58cdf3fbc4292af471fac5e9cae5f","type":"TRIAL","name":"STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19","canonical_id":"clinicaltrials.gov:NCT04817332","description":"Covid19","metadata":null},{"id":"75a46c04d4c84f3f961b21ed15e57d7a","type":"GENE","name":"STOX1","canonical_id":"hgnc:HGNC:23508","description":"storkhead box 1","metadata":{"aliases":["FLJ25162","C10orf24"]}},{"id":"9144cddc0d1744f1a2e7b2a06ee7baa3","type":"GENE","name":"STOX2","canonical_id":"hgnc:HGNC:25450","description":"storkhead box 2","metadata":{"aliases":["DKFZp762K222"]}},{"id":"a545a43f43e7454ebf6679817694822e","type":"GENE","name":"STPG1","canonical_id":"hgnc:HGNC:28070","description":"sperm tail PG-rich repeat containing 1","metadata":{"aliases":["FLJ33340","MAPO2","C1orf201"]}},{"id":"f26a1cd1fad744ffb6088ee515507f4f","type":"GENE","name":"STPG2","canonical_id":"hgnc:HGNC:28712","description":"sperm tail PG-rich repeat containing 2","metadata":{"aliases":["MGC46496","C4orf37"]}},{"id":"c1ce6476155544589da44076de4e3f24","type":"GENE","name":"STPG2-AS1","canonical_id":"hgnc:HGNC:41209","description":"STPG2 antisense RNA 1","metadata":null},{"id":"948a4601427b4e45ae48986e2ecbefca","type":"GENE","name":"STPG3","canonical_id":"hgnc:HGNC:37285","description":"sperm-tail PG-rich repeat containing 3","metadata":{"aliases":["FLJ40246","C9orf173"]}},{"id":"dfd9ce00e7dd463ca5dbdb246eccb586","type":"GENE","name":"STPG3-AS1","canonical_id":"hgnc:HGNC:51176","description":"STPG3 antisense RNA 1","metadata":{"aliases":["C9orf173-AS1"]}},{"id":"fb7a4714df724df48e40310b99e3337d","type":"GENE","name":"STPG4","canonical_id":"hgnc:HGNC:26850","description":"sperm-tail PG-rich repeat containing 4","metadata":{"aliases":["FLJ40172","C2orf61"]}},{"id":"6d5224825ebf40819f6f2f94a434e490","type":"GENE","name":"STRA6","canonical_id":"hgnc:HGNC:30650","description":"signaling receptor and transporter of retinol STRA6","metadata":{"aliases":["SLC69A1","FLJ12541"]}},{"id":"c10b798fb7534288af72447a4f27f258","type":"GENE","name":"STRA6LP","canonical_id":"hgnc:HGNC:53830","description":"STRA6 like, pseudogene","metadata":null},{"id":"a56ff9fda7e5466e998059c094ebac75","type":"GENE","name":"STRA8","canonical_id":"hgnc:HGNC:30653","description":"stimulated by retinoic acid 8","metadata":null},{"id":"e7548fec1db64cd8be4e4e318acfdbc6","type":"GENE","name":"STRADA","canonical_id":"hgnc:HGNC:30172","description":"STE20 related adaptor alpha","metadata":{"aliases":["STLK5","NY-BR-96","LYK5","Stlk","STRAD"]}},{"id":"1554323c01f74692a7031baf2679b7f6","type":"GENE","name":"STRADB","canonical_id":"hgnc:HGNC:13205","description":"STE20 related adaptor beta","metadata":{"aliases":["STLK6","CALS-21","PAPK","ILPIPA","ILPIP","ALS2CR2"]}},{"id":"39bc4672d2224389854a9600d3d16884","type":"GENE","name":"STRADBP1","canonical_id":"hgnc:HGNC:22478","description":"STE20-related kinase adaptor beta pseudogene 1","metadata":{"aliases":["STLK6ps1","ALS2CR2P1"]}},{"id":"7b04c3aa33d246d88175503238b90162","type":"GENE","name":"STRAP","canonical_id":"hgnc:HGNC:30796","description":"serine/threonine kinase receptor associated protein","metadata":{"aliases":["UNRIP","pt-wd","MAWD"]}},{"id":"b7672c987da94528a5b2ffcf1f842b4b","type":"GENE","name":"STRBP","canonical_id":"hgnc:HGNC:16462","description":"spermatid perinuclear RNA binding protein","metadata":{"aliases":["FLJ11307","SPNR","ILF3L"]}},{"id":"4eafb82c49154098abd126b1a765831a","type":"GENE","name":"STRC","canonical_id":"hgnc:HGNC:16035","description":"stereocilin","metadata":{"aliases":["DFNB16"]}},{"id":"e43958606565451eac6c7c912eec5f3d","type":"GENE","name":"STRCP1","canonical_id":"hgnc:HGNC:33915","description":"stereocilin pseudogene 1","metadata":{"aliases":["STRCP"]}},{"id":"853bbdee92ed4a559a7f252aad13e5d9","type":"TRIAL","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07213570","description":"Colorectal Cancer Metastatic","metadata":null},{"id":"38f382ea24b3445eb3cb2959cbf403f2","type":"GENE","name":"STRIP1","canonical_id":"hgnc:HGNC:25916","description":"striatin interacting protein 1","metadata":{"aliases":["FLJ14743","KIAA1761","FAR11A","FAM40A"]}},{"id":"042414f18ebe4cd0aab511a1c6c8d9bc","type":"GENE","name":"STRIP2","canonical_id":"hgnc:HGNC:22209","description":"striatin interacting protein 2","metadata":{"aliases":["KIAA1170","FAR11B","FAM40B"]}},{"id":"ec0128b2008f4dcbabdb4e27eb5e3a2f","type":"GENE","name":"STRIT1","canonical_id":"hgnc:HGNC:52297","description":"small transmembrane regulator of ion transport 1","metadata":{"aliases":["DWORF"]}},{"id":"779f509a22a440ecb367c3c63051ea6c","type":"GENE","name":"STRN","canonical_id":"hgnc:HGNC:11424","description":"striatin","metadata":{"aliases":["PPP2R6A","STRN1"]}},{"id":"650abddad7444c1696a93e484af40e86","type":"GENE","name":"STRN3","canonical_id":"hgnc:HGNC:15720","description":"striatin 3","metadata":{"aliases":["SG2NA","PPP2R6B","S/G2NA"]}},{"id":"19326d79d5834ace976e5b2317f9879b","type":"GENE","name":"STRN4","canonical_id":"hgnc:HGNC:15721","description":"striatin 4","metadata":{"aliases":["ZIN","PPP2R6C"]}},{"id":"f825efe0ea44431b99cd414fdd610aaf","type":"GENE","name":"STS","canonical_id":"hgnc:HGNC:11425","description":null,"metadata":null},{"id":"c460b933c9884fb5a60b3415a2f58062","type":"GENE","name":"STSP1","canonical_id":"hgnc:HGNC:11426","description":"steroid sulfatase (microsomal) pseudogene 1","metadata":{"aliases":["STS-Y","STSP"]}},{"id":"b2e1c82c69664eb788807cf870280d39","type":"GENE","name":"STT3A","canonical_id":"hgnc:HGNC:6172","description":"STT3 oligosaccharyltransferase complex catalytic subunit A","metadata":{"aliases":["TMC","MGC9042","STT3-A","ITM1"]}},{"id":"5b72d768bc59400baee6b40ef579fdc0","type":"GENE","name":"STT3A-AS1","canonical_id":"hgnc:HGNC:44585","description":"STT3A antisense RNA 1","metadata":null},{"id":"2e274a58741a4188ab9578c6d3c55145","type":"GENE","name":"STT3B","canonical_id":"hgnc:HGNC:30611","description":"STT3 oligosaccharyltransferase complex catalytic subunit B","metadata":{"aliases":["SIMP","FLJ90106","STT3-B"]}},{"id":"3761e11d96874f9c8844185fef352f42","type":"GENE","name":"STUB1","canonical_id":"hgnc:HGNC:11427","description":"STIP1 homology and U-box containing protein 1","metadata":{"aliases":["UBOX1","CHIP","SDCCAG7","HSPABP2","NY-CO-7"]}},{"id":"992b50b230f9476cbe3402aff3900133","type":"GENE","name":"STUB1-DT","canonical_id":"hgnc:HGNC:54519","description":"STUB1 divergent transcript","metadata":{"aliases":["LA16c-313D11.9","LINC02867"]}},{"id":"73fc38fedbb14b27ac1761416db87d98","type":"GENE","name":"STUB1P1","canonical_id":"hgnc:HGNC:54743","description":"STUB1 pseudogene 1","metadata":null},{"id":"77041445b9684cdb82b1cac0bd2ae87e","type":"GENE","name":"STUM","canonical_id":"hgnc:HGNC:30491","description":"stum, mechanosensory transduction mediator homolog","metadata":{"aliases":["DKFZp761P211","C1orf95"]}},{"id":"bd54652c19b6486c9057460881fcbaff","type":"GENE","name":"STX10","canonical_id":"hgnc:HGNC:11428","description":"syntaxin 10","metadata":{"aliases":["hsyn10","SYN10"]}},{"id":"52e173a54245455d9c5ecd63edcb6490","type":"GENE","name":"STX11","canonical_id":"hgnc:HGNC:11429","description":"syntaxin 11","metadata":null},{"id":"97891df2dc334bd3a1ce0deb907aeb6e","type":"GENE","name":"STX12","canonical_id":"hgnc:HGNC:11430","description":"syntaxin 12","metadata":{"aliases":["STX13","STX14"]}},{"id":"366dfa2073014d99980cd0f5ce85ca1f","type":"GENE","name":"STX16","canonical_id":"hgnc:HGNC:11431","description":"syntaxin 16","metadata":{"aliases":["hsyn16","SYN16","SYN-16"]}},{"id":"dd0b52e938bb4f63b94e84768231d9f2","type":"GENE","name":"STX16-NPEPL1","canonical_id":"hgnc:HGNC:41993","description":"STX16-NPEPL1 readthrough (NMD candidate)","metadata":null},{"id":"3263862c411248768830df44f3d98df8","type":"GENE","name":"STX17","canonical_id":"hgnc:HGNC:11432","description":"syntaxin 17","metadata":{"aliases":["FLJ20651"]}},{"id":"d4cdc6ecf0374804889474db6ae5c70f","type":"GENE","name":"STX18","canonical_id":"hgnc:HGNC:15942","description":"syntaxin 18","metadata":{"aliases":["Ufe1"]}},{"id":"94ed6a4a3eb44ca58ca66bbe6108754e","type":"GENE","name":"STX18-AS1","canonical_id":"hgnc:HGNC:48877","description":"STX18 antisense RNA 1","metadata":null},{"id":"ee54f8e87bd04c43a2c49108070029cb","type":"GENE","name":"STX18-IT1","canonical_id":"hgnc:HGNC:41415","description":"STX18 intronic transcript 1","metadata":null},{"id":"5f2764325383404794528a0464e88e20","type":"GENE","name":"STX18P1","canonical_id":"hgnc:HGNC:43995","description":"syntaxin 18 pseudogene 1","metadata":null},{"id":"e143979eb7e94f66abe2972df772aff2","type":"GENE","name":"STX19","canonical_id":"hgnc:HGNC:19300","description":"syntaxin 19","metadata":{"aliases":["MGC21382"]}},{"id":"20956f2756fb4bbf8040631fee6c2a5c","type":"GENE","name":"STX1A","canonical_id":"hgnc:HGNC:11433","description":"syntaxin 1A","metadata":{"aliases":["HPC-1","p35-1","STX1"]}},{"id":"d0b39ac4e9284599b4ffa41162696b44","type":"GENE","name":"STX1B","canonical_id":"hgnc:HGNC:18539","description":"syntaxin 1B","metadata":{"aliases":["STX1B1","STX1B2"]}},{"id":"b212cdb6df734f2fae9cb2eb5da7eabb","type":"GENE","name":"STX2","canonical_id":"hgnc:HGNC:3403","description":"syntaxin 2","metadata":{"aliases":["EPM","STX2B","STX2C","STX2A","EPIM"]}},{"id":"e3bf4aa9c82c4488af26a7028db29df9","type":"GENE","name":"STX3","canonical_id":"hgnc:HGNC:11438","description":"syntaxin 3","metadata":{"aliases":["STX3A"]}},{"id":"57c5a8fe14bb47d99fe565582253f627","type":"GENE","name":"STX4","canonical_id":"hgnc:HGNC:11439","description":"syntaxin 4","metadata":{"aliases":["p35-2","STX4A"]}},{"id":"9546e3265a28418faa57a579bd9a4ef4","type":"GENE","name":"STX5","canonical_id":"hgnc:HGNC:11440","description":"syntaxin 5","metadata":{"aliases":["SED5","STX5A"]}},{"id":"4dd05663aea848c19f8fdbc1baa19b84","type":"GENE","name":"STX5-DT","canonical_id":"hgnc:HGNC:55488","description":"STX5 divergent transcript","metadata":null},{"id":"54ab61f27a3a43d3b02663bbe0bf50c9","type":"GENE","name":"STX6","canonical_id":"hgnc:HGNC:11441","description":"syntaxin 6","metadata":null},{"id":"6310cb1b229f45c7b9786a089193a44f","type":"GENE","name":"STX7","canonical_id":"hgnc:HGNC:11442","description":"syntaxin 7","metadata":null},{"id":"f3e9be3f7f924e88aecd0558d55a447f","type":"GENE","name":"STX8","canonical_id":"hgnc:HGNC:11443","description":"syntaxin 8","metadata":{"aliases":["CARB"]}},{"id":"8ea1c437678745f79afb7a0ed2b92091","type":"GENE","name":"STX8P1","canonical_id":"hgnc:HGNC:49855","description":"syntaxin 8 pseudogene 1","metadata":null},{"id":"9e469ebd8f5a4fdb8d77eae3427bb8f4","type":"GENE","name":"STXBP1","canonical_id":"hgnc:HGNC:11444","description":"syntaxin binding protein 1","metadata":{"aliases":["hUNC18","MUNC18-1","UNC18","rbSec1","nSec1"]}},{"id":"9ce2c217fdc04b3a88041ffd54521844","type":"GENE","name":"STXBP2","canonical_id":"hgnc:HGNC:11445","description":"syntaxin binding protein 2","metadata":{"aliases":["UNC18B","Hunc18b","Unc18-2","MUNC18-2"]}},{"id":"ff261d4b4bdb44249b349835457d080a","type":"GENE","name":"STXBP3","canonical_id":"hgnc:HGNC:11446","description":"syntaxin binding protein 3","metadata":{"aliases":["UNC-18C"]}},{"id":"76a6c91264ba43da88bbb0dcec4ea3ff","type":"GENE","name":"STXBP4","canonical_id":"hgnc:HGNC:19694","description":"syntaxin binding protein 4","metadata":{"aliases":["Synip","MGC50337"]}},{"id":"98dd801ebcc648d68ce5a50ed0dd0746","type":"GENE","name":"STXBP5","canonical_id":"hgnc:HGNC:19665","description":"syntaxin binding protein 5","metadata":{"aliases":["tomosyn","LLGL3","tomosyn-1"]}},{"id":"1a1f4e1f4e9b441baa5b3dc28aabd23e","type":"GENE","name":"STXBP5-AS1","canonical_id":"hgnc:HGNC:44183","description":"STXBP5 antisense RNA 1","metadata":null},{"id":"906bfff745974633991beb2ab268a7ec","type":"GENE","name":"STXBP5L","canonical_id":"hgnc:HGNC:30757","description":"syntaxin binding protein 5L","metadata":{"aliases":["KIAA1006","LLGL4","tomosyn-2"]}},{"id":"6a4b95485f54483fbfccdffeacaa7093","type":"GENE","name":"STXBP6","canonical_id":"hgnc:HGNC:19666","description":"syntaxin binding protein 6","metadata":{"aliases":["amisyn","HSPC156"]}},{"id":"1f8581bb90454250820a1a4dde9f24f4","type":"GENE","name":"STYK1","canonical_id":"hgnc:HGNC:18889","description":"STY kinase 1","metadata":{"aliases":["SuRTK106","DKFZp761P1010","NOK"]}},{"id":"dd238fb49a234918ab20c4a7f155e793","type":"GENE","name":"STYX","canonical_id":"hgnc:HGNC:11447","description":"serine/threonine/tyrosine interacting protein","metadata":null},{"id":"0ec91309296b4f0e95edb749e08571d5","type":"GENE","name":"STYXL1","canonical_id":"hgnc:HGNC:18165","description":"serine/threonine/tyrosine interacting like 1","metadata":{"aliases":["MK-STYX","DUSP24"]}},{"id":"3957f18f924f4a78978f34d058809a13","type":"GENE","name":"STYXL2","canonical_id":"hgnc:HGNC:25034","description":"serine/threonine/tyrosine interacting like 2","metadata":{"aliases":["DUSP27"]}},{"id":"d7332d4208114ee89c227d006ac0ffcb","type":"TRIAL","name":"STunning in Acute Myocardial Infarction - BAS","canonical_id":"clinicaltrials.gov:NCT06562582","description":"Myocardial Infarct","metadata":null},{"id":"5dddafd6860f4bc1a946c90a60283243","type":"TRIAL","name":"SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00003293","description":"Brain and Central Nervous System Tumors","metadata":null},{"id":"2cebb9e4d97146298de2550887769c73","type":"GENE","name":"SUB1","canonical_id":"hgnc:HGNC:19985","description":"SUB1 regulator of transcription","metadata":{"aliases":["PC4","p15","p14"]}},{"id":"64b6d664bd7b42828d5cfc8dbb72e905","type":"GENE","name":"SUB1P1","canonical_id":"hgnc:HGNC:32300","description":"SUB1 pseudogene 1","metadata":null},{"id":"e7b86e18713d42d6bd119073475ee079","type":"GENE","name":"SUB1P2","canonical_id":"hgnc:HGNC:43992","description":"SUB1 pseudogene 2","metadata":null},{"id":"52e5e50b145b480fb4b38fafc7ba3a3e","type":"GENE","name":"SUB1P3","canonical_id":"hgnc:HGNC:43993","description":"SUB1 pseudogene 3","metadata":null},{"id":"91eabb5d89bc49d990eae42ec5f32761","type":"GENE","name":"SUB1P4","canonical_id":"hgnc:HGNC:43994","description":"SUB1 pseudogene 4","metadata":null},{"id":"66d593fc868a4d4e91513f5bb7f634a4","type":"GENE","name":"SUCLA2","canonical_id":"hgnc:HGNC:11448","description":"succinate-CoA ligase ADP-forming subunit beta","metadata":{"aliases":["LINC00444"]}},{"id":"653e879ce8144c56a9e057ffb5960c58","type":"GENE","name":"SUCLA2-AS1","canonical_id":"hgnc:HGNC:39965","description":"SUCLA2 antisense RNA 1","metadata":null},{"id":"d09b0edb00f540a4b630734d7770c2dc","type":"GENE","name":"SUCLA2P1","canonical_id":"hgnc:HGNC:21632","description":"SUCLA2 pseudogene 1","metadata":{"aliases":["Em:AB014080.4","SUCLA2P"]}},{"id":"65137c6b30b44017920c20e5d0c1d51a","type":"GENE","name":"SUCLA2P2","canonical_id":"hgnc:HGNC:38102","description":"SUCLA2 pseudogene 2","metadata":null},{"id":"1149b494bfb64e1f82f302bfd7b0034c","type":"GENE","name":"SUCLA2P3","canonical_id":"hgnc:HGNC:38103","description":"SUCLA2 pseudogene 3","metadata":null},{"id":"1fde7625bc20498dac26b074c56392c3","type":"GENE","name":"SUCLG1","canonical_id":"hgnc:HGNC:11449","description":"succinate-CoA ligase GDP/ADP-forming subunit alpha","metadata":null},{"id":"b51899f9bdda4aa799e8a3e19d61af15","type":"GENE","name":"SUCLG2","canonical_id":"hgnc:HGNC:11450","description":"succinate-CoA ligase GDP-forming subunit beta","metadata":null},{"id":"e79c7854e35b4081825677eb73b2d675","type":"GENE","name":"SUCLG2-DT","canonical_id":"hgnc:HGNC:49643","description":"SUCLG2 divergent transcript","metadata":{"aliases":["SUCLG2-AS1"]}},{"id":"0f08fee730dd48be8f58de9e5090944f","type":"GENE","name":"SUCLG2P1","canonical_id":"hgnc:HGNC:43996","description":"SUCLG2 pseudogene 1","metadata":null},{"id":"65a1223970214859b1ec76c803b608fe","type":"GENE","name":"SUCLG2P2","canonical_id":"hgnc:HGNC:43997","description":"SUCLG2 pseudogene 2","metadata":null},{"id":"dd22ab3ce3594953a8aee9af4bac737b","type":"GENE","name":"SUCLG2P3","canonical_id":"hgnc:HGNC:43998","description":"SUCLG2 pseudogene 3","metadata":null},{"id":"e24e252c799f416e80f7790d96a05039","type":"GENE","name":"SUCLG2P4","canonical_id":"hgnc:HGNC:43999","description":"SUCLG2 pseudogene 4","metadata":null},{"id":"d6d4faaa463d44deb80686e071126a1f","type":"GENE","name":"SUCNR1","canonical_id":"hgnc:HGNC:4542","description":"succinate receptor 1","metadata":{"aliases":["GPR91"]}},{"id":"75b2341ff908437c8504426e31653b7d","type":"GENE","name":"SUCO","canonical_id":"hgnc:HGNC:1240","description":"SUN domain containing ossification factor","metadata":{"aliases":["CH1","SLP1","OPT","C1orf9"]}},{"id":"13956042765c435b90b57ab047a16dd1","type":"GENE","name":"SUDS3","canonical_id":"hgnc:HGNC:29545","description":"SIN3A corepressor complex component SDS3","metadata":{"aliases":["SDS3","FLJ00052","SAP45"]}},{"id":"3960bcaddbf247acbd8e265a2bcd3e20","type":"GENE","name":"SUDS3P1","canonical_id":"hgnc:HGNC:44000","description":"SDS3 homolog, SIN3A corepressor complex component pseudogene 1","metadata":null},{"id":"32812ab138934b00a394eda0eb53c645","type":"GENE","name":"SUFU","canonical_id":"hgnc:HGNC:16466","description":"SUFU negative regulator of hedgehog signaling","metadata":{"aliases":["SUFUH","SUFUXL","PRO1280"]}},{"id":"0b9a6d236580453683948fc37951fa11","type":"GENE","name":"SUGCT","canonical_id":"hgnc:HGNC:16001","description":"succinyl-CoA:glutarate-CoA transferase","metadata":{"aliases":["FLJ11808","ORF19","DERP13","C7orf10"]}},{"id":"865c9f3b77c147e6936cface81f4d641","type":"GENE","name":"SUGCT-AS1","canonical_id":"hgnc:HGNC:40745","description":"SUGCT antisense RNA 1","metadata":null},{"id":"b5b642ccabb04f43bf734c8973272f62","type":"GENE","name":"SUGP1","canonical_id":"hgnc:HGNC:18643","description":null,"metadata":null},{"id":"a48b5b12dae04389ae3d9fde4de314df","type":"GENE","name":"SUGP2","canonical_id":"hgnc:HGNC:18641","description":"SURP and G-patch domain containing 2","metadata":{"aliases":["KIAA0365","SFRS14"]}},{"id":"cbbcc194a8434326b78750f5294ebf60","type":"GENE","name":"SUGT1","canonical_id":"hgnc:HGNC:16987","description":"SGT1 assembly cochaperone of MIS12 kinetochore complex","metadata":{"aliases":["SGT1"]}},{"id":"7ee97d6c3f4d443bbfe64d23715726f7","type":"GENE","name":"SUGT1-DT","canonical_id":"hgnc:HGNC:54809","description":"SUGT1 divergent transcript","metadata":null},{"id":"fa1f082a2e9b495aadffbf407c5b8173","type":"GENE","name":"SUGT1P1","canonical_id":"hgnc:HGNC:19384","description":"SUGT1 pseudogene 1","metadata":{"aliases":["bA255A11.1","SGT1P","MGC15151","SUGT1P"]}},{"id":"9b1924f007b54d70b4fa7ff333ccce1a","type":"GENE","name":"SUGT1P2","canonical_id":"hgnc:HGNC:31377","description":"SUGT1 pseudogene 2","metadata":null},{"id":"9f221afc85a94b2eb096ef4d528053c3","type":"GENE","name":"SUGT1P3","canonical_id":"hgnc:HGNC:20513","description":"SUGT1 pseudogene 3","metadata":{"aliases":["SUGT1L1"]}},{"id":"df1635cc069743b8af760ddae86e8091","type":"GENE","name":"SUGT1P4","canonical_id":"hgnc:HGNC:53832","description":"SUGT1 pseudogene 4","metadata":null},{"id":"e5ed2b3c019f440b897ec0b76887761e","type":"GENE","name":"SUGT1P4-STRA6LP","canonical_id":"hgnc:HGNC:53834","description":"SUGT1P4-STRA6LP readthrough","metadata":null},{"id":"20dc6df0862449268979d4e6bea2750c","type":"GENE","name":"SUGT1P4-STRA6LP-CCDC180","canonical_id":"hgnc:HGNC:53835","description":"SUGT1P4-STRA6LP-CCDC180 readthrough","metadata":null},{"id":"1f32f1162a4a4b2ba7589d378c241be3","type":"GENE","name":"SULF1","canonical_id":"hgnc:HGNC:20391","description":"sulfatase 1","metadata":{"aliases":["KIAA1077","SULF-1","hSulf-1"]}},{"id":"1d4398d610b1442e8c498be8eaf09b48","type":"GENE","name":"SULF2","canonical_id":"hgnc:HGNC:20392","description":"sulfatase 2","metadata":{"aliases":["KIAA1247","HSULF-2","SULF-2"]}},{"id":"f32c325d3f8c47f1945aff105bb9a1d3","type":"GENE","name":"SULT1A1","canonical_id":"hgnc:HGNC:11453","description":"sulfotransferase family 1A member 1","metadata":{"aliases":["P-PST","STP","STP1"]}},{"id":"7fa89725b65745eeb33c93afb7fa827d","type":"GENE","name":"SULT1A2","canonical_id":"hgnc:HGNC:11454","description":"sulfotransferase family 1A member 2","metadata":{"aliases":["HAST4","STP2"]}},{"id":"a76dd1a38d1841ea83ff4cc14fdc75fa","type":"GENE","name":"SULT1A3","canonical_id":"hgnc:HGNC:11455","description":"sulfotransferase family 1A member 3","metadata":{"aliases":["TL-PST","STM"]}},{"id":"6650ee638b37450199bf4d76cc51846e","type":"GENE","name":"SULT1A4","canonical_id":"hgnc:HGNC:30004","description":"sulfotransferase family 1A member 4","metadata":null},{"id":"f11a71576db74744ae83955bbdf726ee","type":"GENE","name":"SULT1B1","canonical_id":"hgnc:HGNC:17845","description":"sulfotransferase family 1B member 1","metadata":{"aliases":["ST1B2"]}},{"id":"d40ad62b4b984fbcb44747adf706d039","type":"GENE","name":"SULT1C2","canonical_id":"hgnc:HGNC:11456","description":"sulfotransferase family 1C member 2","metadata":{"aliases":["ST1C1","SULT1C1"]}},{"id":"b9ef58859b6b4bdda0eb72e48d580f40","type":"GENE","name":"SULT1C2P2","canonical_id":"hgnc:HGNC:51595","description":"sulfotransferase family, cytosolic, 1C, member 2 pseudogene 2","metadata":null},{"id":"519d8fedb05941a587958ed22de825d1","type":"GENE","name":"SULT1C3","canonical_id":"hgnc:HGNC:33543","description":"sulfotransferase family 1C member 3","metadata":null},{"id":"94325e66a1d24a41adeb421ab0b7c483","type":"GENE","name":"SULT1C4","canonical_id":"hgnc:HGNC:11457","description":"sulfotransferase family 1C member 4","metadata":{"aliases":["SULT1C","SULT1C2"]}},{"id":"5ee8f7e3d278474fa5bab8fc09ce5f43","type":"GENE","name":"SULT1C5P","canonical_id":"hgnc:HGNC:33545","description":"sulfotransferase family 1C member 5, pseudogene","metadata":{"aliases":["SULT1C1P","SULT1C2P1"]}},{"id":"8e6b952ff21946f8a151fd51fb5f5861","type":"GENE","name":"SULT1D1P","canonical_id":"hgnc:HGNC:30659","description":"sulfotransferase family 1D member 1, pseudogene","metadata":{"aliases":["SULT1D1"]}},{"id":"d8c9eb165f7f4903a09806ffb7a292eb","type":"GENE","name":"SULT1D1P2","canonical_id":"hgnc:HGNC:56583","description":"sulfotransferase family 1D member 1 pseudogene 2","metadata":null},{"id":"d34b479623dd4cc5b5a95938feda83c8","type":"GENE","name":"SULT1E1","canonical_id":"hgnc:HGNC:11377","description":null,"metadata":null},{"id":"7bc31119f6d8461486ceca58f8cffd4f","type":"GENE","name":"SULT2A1","canonical_id":"hgnc:HGNC:11458","description":null,"metadata":null},{"id":"b0d28f56757344c896fbbf0cefb9982a","type":"GENE","name":"SULT2B1","canonical_id":"hgnc:HGNC:11459","description":"sulfotransferase family 2B member 1","metadata":{"aliases":["HSST2"]}},{"id":"ba8b8490551b4ef4907141bcbfae805e","type":"GENE","name":"SULT4A1","canonical_id":"hgnc:HGNC:14903","description":"sulfotransferase family 4A member 1","metadata":{"aliases":["SULTX3","hBR-STL-1"]}},{"id":"c5e4f92b81094656ba37301191685a97","type":"GENE","name":"SULT6B1","canonical_id":"hgnc:HGNC:33433","description":"sulfotransferase family 6B member 1","metadata":null},{"id":"d98d10606346407ca9373d92477004e8","type":"GENE","name":"SULT6B2P","canonical_id":"hgnc:HGNC:53737","description":"sulfotransferase family 6B member 2, pseudogene","metadata":null},{"id":"d592c71575b84a07990e3d1b228a932e","type":"GENE","name":"SUMF1","canonical_id":"hgnc:HGNC:20376","description":"sulfatase modifying factor 1","metadata":{"aliases":["FGE","UNQ3037"]}},{"id":"65c9a9c045c54092bc6e25622408bed7","type":"GENE","name":"SUMF2","canonical_id":"hgnc:HGNC:20415","description":"sulfatase modifying factor 2","metadata":{"aliases":["DKFZp566I1024"]}},{"id":"187b356c5ba64b95bdd9aa1fee83f8c0","type":"GO_TERM","name":"SUMO activating enzyme activity","canonical_id":"go:GO:0019948","description":"\"Catalysis of the activation of the proteolytically processed small ubiquitin-related modifier SUMO, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:rn, PMID:10187858, PMID:11265250]","metadata":null},{"id":"997bb4d4d1c348c98c837a7b04edf818","type":"GO_TERM","name":"SUMO activating enzyme complex","canonical_id":"go:GO:0031510","description":"\"A conserved heterodimeric complex with SUMO activating enzyme activity.\" [PMID:15601841]","metadata":null},{"id":"669427e3e1d84d3ebdd01f5a10df2bf1","type":"GO_TERM","name":"SUMO binding","canonical_id":"go:GO:0032183","description":"\"Binding to the small ubiquitin-like protein SUMO.\" [GOC:mah]","metadata":null},{"id":"8b302e16285e4babb79b8832def92aac","type":"GO_TERM","name":"SUMO conjugating enzyme activity","canonical_id":"go:GO:0061656","description":"\"Isoenergetic transfer of SUMO from one protein to another via the reaction X-SUMO + Y = Y-SUMO + X, where both the X-SUMO and Y-SUMO linkages are thioester bonds between the C-terminal amino acid of SUMO and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"27d67320641e41a19061b23e8045485b","type":"GO_TERM","name":"SUMO ligase activity","canonical_id":"go:GO:0061665","description":"\"Catalysis of the transfer of SUMO to a substrate protein via the reaction X-SUMO + S = X + S-SUMO, where X is either an E2 or E3 enzyme, the X-SUMO linkage is a thioester bond, and the S-SUMO linkage is an isopeptide bond between the C-terminal amino acid of SUMO and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"f739cc2efe0d43c8a975370efd63ddc6","type":"GO_TERM","name":"SUMO ligase complex","canonical_id":"go:GO:0106068","description":"\"A protein ligase complex that enables protein sumoylation. Consists of a SUMO-protein transferase and other proteins that may confer substrate specificity of the complex.\" [PMID:16847351]","metadata":null},{"id":"ab00101c665143de8ab575190ec50c3d","type":"GO_TERM","name":"SUMO ligase regulator activity","canonical_id":"go:GO:0180016","description":"\"Binds to and modulates the activity of a SUMO ligase.\" [PMID:19363481, PMID:33446573]","metadata":null},{"id":"7caf218c37b34f63a8945ba90d802fab","type":"GO_TERM","name":"SUMO polymer binding","canonical_id":"go:GO:0032184","description":"\"Binding to a polymer of the small ubiquitin-like protein SUMO.\" [GOC:mah]","metadata":null},{"id":"ae15ce3f63864b7eb31dfd16510c9443","type":"GO_TERM","name":"SUMO transferase activity","canonical_id":"go:GO:0019789","description":"\"Catalysis of the transfer of SUMO from one protein to another via the reaction X-SUMO + Y = Y-SUMO + X, where both X-SUMO and Y-SUMO are covalent linkages.\" [GOC:rn, PMID:11031248, PMID:11265250]","metadata":null},{"id":"beecdeadf0634f7ba4feba2b425c5595","type":"GO_TERM","name":"SUMO-modified protein reader activity","canonical_id":"go:GO:0140037","description":"\"A molecular adaptor that recognizes and binds a target protein containing a SUMO modification and that brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.\" [PMID:26060076]","metadata":null},{"id":"426ae9573d464895b842f1708dc6858e","type":"GO_TERM","name":"SUMO-specific endopeptidase activity","canonical_id":"go:GO:0070139","description":"\"Catalysis of the hydrolysis of peptide bonds between an alpha-carboxyl group and an alpha-amino group within the small conjugating protein SUMO.\" [GOC:mah]","metadata":null},{"id":"4d1edfba3a704e328e74fdefc839c26e","type":"GO_TERM","name":"SUMO-targeted ubiquitin ligase complex","canonical_id":"go:GO:0033768","description":"\"A nuclear ubiquitin ligase complex that specifically targets SUMOylated proteins; the complex is formed of homodimers or heterodimers of RNF4 family ubiquitin ligases and is conserved in eukaryotes.\" [GOC:vw, PMID:17762864, PMID:17762865]","metadata":null},{"id":"37cc249947134c8e9bc1178b8b016738","type":"GO_TERM","name":"SUMO-ubiquitin ligase activity","canonical_id":"go:GO:0140082","description":"\"Isoenergetic transfer of SUMO from one protein to an existing ubiquitin chain via the reaction X-ubiquitin + Y-ubiquitin = Y-ubiquitin-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.\" [PMID:28552615]","metadata":null},{"id":"8eacf216de484322ae579a801e2a11c9","type":"GENE","name":"SUMO1","canonical_id":"hgnc:HGNC:12502","description":null,"metadata":null},{"id":"e6e2d1fa7e694b16a9f19e5f6c1763ae","type":"GENE","name":"SUMO1P1","canonical_id":"hgnc:HGNC:33148","description":"SUMO1 pseudogene 1","metadata":{"aliases":["PIC1L","UBL2","UBL6"]}},{"id":"1789ac1fd7d24512bf8378bbd4685b61","type":"GENE","name":"SUMO1P2","canonical_id":"hgnc:HGNC:33149","description":"SUMO1 pseudogene 2","metadata":null},{"id":"92cb004a5aee4e7d8a430b79f3e56fc7","type":"GENE","name":"SUMO1P3","canonical_id":"hgnc:HGNC:33150","description":"SUMO1 pseudogene 3","metadata":null},{"id":"da5f5d28ccc3483c9009416e422a92c2","type":"GENE","name":"SUMO1P4","canonical_id":"hgnc:HGNC:33151","description":"SUMO1 pseudogene 4","metadata":null},{"id":"44290cf85ab04eb1903232b731a9eb9b","type":"GENE","name":"SUMO1P5","canonical_id":"hgnc:HGNC:33152","description":"SUMO1 pseudogene 5","metadata":null},{"id":"da83296defae409daf066a2374e0edbd","type":"GENE","name":"SUMO2","canonical_id":"hgnc:HGNC:11125","description":null,"metadata":null},{"id":"df2aa6043d4046498cb70a64e91f328c","type":"GENE","name":"SUMO2P1","canonical_id":"hgnc:HGNC:13985","description":"SUMO2 pseudogene 1","metadata":{"aliases":["SMT3Bp","dJ271M21","SMT3H2P","SUMO2P"]}},{"id":"4ad7b9c70e1b46bb81edefa3e4d7d70c","type":"GENE","name":"SUMO2P10","canonical_id":"hgnc:HGNC:49348","description":"SUMO2 pseudogene 10","metadata":null},{"id":"1d93ad370c454692ae126cc280c76690","type":"GENE","name":"SUMO2P11","canonical_id":"hgnc:HGNC:49349","description":"SUMO2 pseudogene 11","metadata":null},{"id":"483ce6ca6a03446cbcb0d175289972cd","type":"GENE","name":"SUMO2P12","canonical_id":"hgnc:HGNC:49350","description":"SUMO2 pseudogene 12","metadata":null},{"id":"311dddb6785746cf82c8ce895ff1b302","type":"GENE","name":"SUMO2P13","canonical_id":"hgnc:HGNC:49351","description":"SUMO2 pseudogene 13","metadata":null},{"id":"087a16bac48d48a5875a4c28e3859ec8","type":"GENE","name":"SUMO2P14","canonical_id":"hgnc:HGNC:49352","description":"SUMO2 pseudogene 14","metadata":null},{"id":"62f26832e61b496485056c866eb21704","type":"GENE","name":"SUMO2P15","canonical_id":"hgnc:HGNC:49353","description":"SUMO2 pseudogene 15","metadata":null},{"id":"19f30318254a41249d334c047c1a2320","type":"GENE","name":"SUMO2P16","canonical_id":"hgnc:HGNC:49354","description":"SUMO2 pseudogene 16","metadata":null},{"id":"7a9db1c1142e42c3b5c82bfc1ac38330","type":"GENE","name":"SUMO2P17","canonical_id":"hgnc:HGNC:49358","description":"SUMO2 pseudogene 17","metadata":null},{"id":"251882deaf93468bbe260eb268e30d05","type":"GENE","name":"SUMO2P18","canonical_id":"hgnc:HGNC:49356","description":"SUMO2 pseudogene 18","metadata":null},{"id":"a9face85ab78456d80c5aedd93d090d7","type":"GENE","name":"SUMO2P19","canonical_id":"hgnc:HGNC:49357","description":"SUMO2 pseudogene 19","metadata":null},{"id":"db766ef1054f481ea97c76bc4a09c49c","type":"GENE","name":"SUMO2P2","canonical_id":"hgnc:HGNC:39012","description":"SUMO2 pseudogene 2","metadata":null},{"id":"6f495f19c5a843ce876a105bd9e87063","type":"GENE","name":"SUMO2P20","canonical_id":"hgnc:HGNC:49355","description":"SUMO2 pseudogene 20","metadata":null},{"id":"cd865b89c110462f99b864be640b6363","type":"GENE","name":"SUMO2P21","canonical_id":"hgnc:HGNC:55054","description":"SUMO2 pseudogene 21","metadata":null},{"id":"5c02fc93380047a6bbf75440aa496c62","type":"GENE","name":"SUMO2P3","canonical_id":"hgnc:HGNC:39013","description":"SUMO2 pseudogene 3","metadata":null},{"id":"60a01eb7c78244c3b6d080a72f2bf926","type":"GENE","name":"SUMO2P4","canonical_id":"hgnc:HGNC:39014","description":"SUMO2 pseudogene 4","metadata":null},{"id":"f420293176d347b4a35d91cfea2b3dc5","type":"GENE","name":"SUMO2P5","canonical_id":"hgnc:HGNC:39015","description":"SUMO2 pseudogene 5","metadata":null},{"id":"0c13d8e417fd4b409a8448e220478930","type":"GENE","name":"SUMO2P6","canonical_id":"hgnc:HGNC:39016","description":"SUMO2 pseudogene 6","metadata":null},{"id":"20c41c48ee974c6a9b1eaf6ebe8a2550","type":"GENE","name":"SUMO2P7","canonical_id":"hgnc:HGNC:39017","description":"SUMO2 pseudogene 7","metadata":null},{"id":"2af78534a5974ae4b976e201b1f89d92","type":"GENE","name":"SUMO2P8","canonical_id":"hgnc:HGNC:39018","description":"SUMO2 pseudogene 8","metadata":null},{"id":"c359b8331b4e4e56a97f6b7705d8c434","type":"GENE","name":"SUMO3","canonical_id":"hgnc:HGNC:11124","description":"small ubiquitin like modifier 3","metadata":{"aliases":["SMT3A","SMT3H1"]}},{"id":"c7392e685d274678a52bbc6c68f873cd","type":"GENE","name":"SUMO4","canonical_id":"hgnc:HGNC:21181","description":"small ubiquitin like modifier 4","metadata":{"aliases":["dJ281H8.4","SMT3H4","IDDM5"]}},{"id":"e9256ab68f82488d9ebb8ba166d9825d","type":"GENE","name":"SUN1","canonical_id":"hgnc:HGNC:18587","description":"Sad1 and UNC84 domain containing 1","metadata":{"aliases":["KIAA0810","FLJ12407","UNC84A"]}},{"id":"70be47a2817443038177ede8cd41c870","type":"GENE","name":"SUN2","canonical_id":"hgnc:HGNC:14210","description":"Sad1 and UNC84 domain containing 2","metadata":{"aliases":["UNC84B"]}},{"id":"44cc2f4511dd44c9912f52d2703548bb","type":"GENE","name":"SUN3","canonical_id":"hgnc:HGNC:22429","description":"Sad1 and UNC84 domain containing 3","metadata":{"aliases":["MGC33329","SUNC1"]}},{"id":"262538f6a9fa45bfb70ba46cc9b4d95d","type":"GENE","name":"SUN5","canonical_id":"hgnc:HGNC:16252","description":"Sad1 and UNC84 domain containing 5","metadata":{"aliases":["dJ726C3.1","TSARG4","SPAG4L"]}},{"id":"f1b4416dceca4cb28687926b8c91d1ce","type":"GENE","name":"SUNO1","canonical_id":"hgnc:HGNC:55385","description":"S-phase upregulated non-coding 1","metadata":null},{"id":"70c2a465de784f2d8b74432196834917","type":"GENE","name":"SUOX","canonical_id":"hgnc:HGNC:11460","description":"sulfite oxidase","metadata":null},{"id":"71650742a0304560ad9e739e6664c96e","type":"TRIAL","name":"SUPRAME-ACTengine\u00ae IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","canonical_id":"clinicaltrials.gov:NCT06743126","description":"Melanoma, Cutaneous Malignant","metadata":null},{"id":"367c68b87ce3467f922564594adc21e3","type":"GENE","name":"SUPT16H","canonical_id":"hgnc:HGNC:11465","description":"SPT16 homolog, facilitates chromatin remodeling subunit","metadata":{"aliases":["FACT","FACTP140","SPT16/CDC68","FLJ14010","FLJ10857","CDC68"]}},{"id":"68f689d16f784689856b0c2a500578aa","type":"GENE","name":"SUPT16HP1","canonical_id":"hgnc:HGNC:31388","description":"SPT16 homolog, facilitates chromatin remodeling subunit pseudogene 1","metadata":{"aliases":["bcm670","SUPT16HP"]}},{"id":"be452c9931094437a4ed5896639407b3","type":"GENE","name":"SUPT20H","canonical_id":"hgnc:HGNC:20596","description":"SPT20 homolog, SAGA complex component","metadata":{"aliases":["SPT20","bA421P11.4","P38IP","C13orf19","FAM48A"]}},{"id":"afb27542936044fcad30659f157c69aa","type":"GENE","name":"SUPT20HL1","canonical_id":"hgnc:HGNC:30773","description":"SUPT20H like 1","metadata":{"aliases":["SPT20L","FAM48B1"]}},{"id":"0471a7e444b047acbafeb200e7aec3be","type":"GENE","name":"SUPT20HL2","canonical_id":"hgnc:HGNC:31797","description":"SUPT20H like 2","metadata":{"aliases":["FAM48B2"]}},{"id":"de6469a58a7d4a928c7323e27bac6675","type":"GENE","name":"SUPT3H","canonical_id":"hgnc:HGNC:11466","description":null,"metadata":null},{"id":"3637d075fef64fe1a268e9dfea54af8d","type":"GENE","name":"SUPT3H-AS1","canonical_id":"hgnc:HGNC:59417","description":"SUPT3H antisense RNA 1","metadata":null},{"id":"0cd94b9492794fb2b794acbc3b245e75","type":"GENE","name":"SUPT4H1","canonical_id":"hgnc:HGNC:11467","description":"SPT4 homolog, DSIF elongation factor subunit","metadata":{"aliases":["SPT4H","Spt4","Supt4a","SUPT4H"]}},{"id":"28cbb798699f476f8aa44eeaa2d2dce8","type":"GENE","name":"SUPT4H1P1","canonical_id":"hgnc:HGNC:33981","description":"SPT4 homolog, DSIF elongation factor subunit pseudogene","metadata":{"aliases":["SUPT4H1P"]}},{"id":"97786e40bd9449c1b2bdc15955aa216a","type":"GENE","name":"SUPT4H1P2","canonical_id":"hgnc:HGNC:50823","description":"SPT4 homolog, DSIF elongation factor subunit pseudogene 2","metadata":null},{"id":"bfd15bf5d51245fe9b119c0be88cb8a4","type":"GENE","name":"SUPT5H","canonical_id":"hgnc:HGNC:11469","description":"SPT5 homolog, DSIF elongation factor subunit","metadata":{"aliases":["SPT5H","SPT5","FLJ34157"]}},{"id":"2b70c4e7d30e4a09996ae0178b29222f","type":"GENE","name":"SUPT6H","canonical_id":"hgnc:HGNC:11470","description":"SPT6 homolog, histone chaperone and transcription elongation factor","metadata":{"aliases":["KIAA0162","SPT6H"]}},{"id":"c8623a7c1c774325b7ae2b2237a11396","type":"GENE","name":"SUPT7L","canonical_id":"hgnc:HGNC:30632","description":"SPT7 like, STAGA complex subunit gamma","metadata":{"aliases":["STAF65gamma","KIAA0764","SPT7L","STAF65"]}},{"id":"6db2fbcc3ba94223a5e9f987036c9c75","type":"GENE","name":"SUPV3L1","canonical_id":"hgnc:HGNC:11471","description":"Suv3 like RNA helicase","metadata":{"aliases":["SUV3"]}},{"id":"eb0527f3adc842479ad867eee42f67e7","type":"GENE","name":"SURF1","canonical_id":"hgnc:HGNC:11474","description":null,"metadata":null},{"id":"34b6502918b04a82b7c6dd78aa40f0e3","type":"GENE","name":"SURF2","canonical_id":"hgnc:HGNC:11475","description":null,"metadata":null},{"id":"f16b4ff62ff0445e93507deb6fb0793e","type":"GENE","name":"SURF4","canonical_id":"hgnc:HGNC:11476","description":"surfeit 4","metadata":{"aliases":["ERV29","FLJ22993","MGC102753"]}},{"id":"1d05f84d13914394ab00c76163adfee7","type":"GENE","name":"SURF6","canonical_id":"hgnc:HGNC:11478","description":"surfeit 6","metadata":{"aliases":["FLJ30322","RRP14"]}},{"id":"0a2d229a241443289d9598755f373dfa","type":"GENE","name":"SURF6P1","canonical_id":"hgnc:HGNC:37722","description":"surfeit 6 pseudogene 1","metadata":null},{"id":"fea16a1521da448ab79f6e5c1b3c041e","type":"GENE","name":"SURMIR","canonical_id":"hgnc:HGNC:59156","description":"SLC35A4 uORF mitochondrial inner membrane regulator","metadata":{"aliases":["STREMI","altSLC35A4","SLC35A4-URF","SLC35A4-uORF","uSLC35A4","SLC35A4-MP","STREMI"]}},{"id":"fbb93eead48f478886f7ad12f75056e1","type":"GENE","name":"SUSD1","canonical_id":"hgnc:HGNC:25413","description":"sushi domain containing 1","metadata":{"aliases":["DKFZP761E1824"]}},{"id":"b92a51a5dc554d24857a233a9bdb149b","type":"GENE","name":"SUSD2","canonical_id":"hgnc:HGNC:30667","description":"sushi domain containing 2","metadata":{"aliases":["BK65A6.2","FLJ22778","W5C5"]}},{"id":"b30fee6328f649ac80d8e204476f8707","type":"GENE","name":"SUSD2P1","canonical_id":"hgnc:HGNC:33889","description":"sushi domain containing 2 pseudogene 1","metadata":null},{"id":"d9fc1dccefc34a9d8974e851f9b1311c","type":"GENE","name":"SUSD2P2","canonical_id":"hgnc:HGNC:35197","description":"sushi domain containing 2 pseudogene 2","metadata":null},{"id":"cea9e8c7addc462fb5f378c1e6a7daf8","type":"GENE","name":"SUSD3","canonical_id":"hgnc:HGNC:28391","description":"sushi domain containing 3","metadata":{"aliases":["MGC26847"]}},{"id":"b1ec489eac3f44908812aae4e9c2bb65","type":"GENE","name":"SUSD4","canonical_id":"hgnc:HGNC:25470","description":"sushi domain containing 4","metadata":{"aliases":["FLJ10052"]}},{"id":"4a39baeb17484b7d8273aa88d3496256","type":"GENE","name":"SUSD5","canonical_id":"hgnc:HGNC:29061","description":"sushi domain containing 5","metadata":{"aliases":["KIAA0527"]}},{"id":"99825b87efbd4f30a74c3333234cea2e","type":"GENE","name":"SUSD6","canonical_id":"hgnc:HGNC:19956","description":"sushi domain containing 6","metadata":{"aliases":["KIAA0247"]}},{"id":"76299944b47843c88e33ca1a02c75829","type":"TRIAL","name":"SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT00535379","description":"Glioblastoma Multiforme","metadata":null},{"id":"4a30dcaa7d79448b834a3609da5fc0e2","type":"GENE","name":"SUV39H1","canonical_id":"hgnc:HGNC:11479","description":"SUV39H1 histone lysine methyltransferase","metadata":{"aliases":["KMT1A","SUV39H"]}},{"id":"b2af75fc272f4e51afe247780aa8716f","type":"GENE","name":"SUV39H2","canonical_id":"hgnc:HGNC:17287","description":"SUV39H2 histone lysine methyltransferase","metadata":{"aliases":["FLJ23414","KMT1B"]}},{"id":"8adb9e759e594eca82b5ee63080e1bbe","type":"GENE","name":"SUV39H2-DT","canonical_id":"hgnc:HGNC:55188","description":"SUV39H2 divergent transcript","metadata":null},{"id":"bf2dc850f157464d89fffc8dda2c9296","type":"TRIAL","name":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","canonical_id":"clinicaltrials.gov:NCT02580305","description":"Alzheimer's Disease","metadata":null},{"id":"d2f066e8911045a7999a0c5c47f94959","type":"GENE","name":"SUZ12","canonical_id":"hgnc:HGNC:17101","description":null,"metadata":null},{"id":"1666d5748aec4a8288a6fb0eec5be8d1","type":"GENE","name":"SUZ12P1","canonical_id":"hgnc:HGNC:32421","description":"SUZ12 pseudogene 1","metadata":{"aliases":["SUZ12P"]}},{"id":"98252e7c30bc4c329200d1ff846b97c9","type":"GENE","name":"SUZ12P2","canonical_id":"hgnc:HGNC:43872","description":"SUZ12 pseudogene 2","metadata":null},{"id":"ad11a279ef014655adb9d2fc5febe11d","type":"GENE","name":"SV2A","canonical_id":"hgnc:HGNC:20566","description":"synaptic vesicle glycoprotein 2A","metadata":{"aliases":["SV2","KIAA0736","SLC22B1"]}},{"id":"f0f20ced11df41a6a0ed8e3a7b72c824","type":"PROTEIN","name":"SV2A","canonical_id":"uniprot:Q7L0J3","description":null,"metadata":null},{"id":"7c5ee19e235f45048f2bd0e039a7c527","type":"GENE","name":"SV2B","canonical_id":"hgnc:HGNC:16874","description":"synaptic vesicle glycoprotein 2B","metadata":{"aliases":["KIAA0735","HsT19680","SLC22B2"]}},{"id":"8de1fa896af04cd8b29efb3b1680459f","type":"GENE","name":"SV2C","canonical_id":"hgnc:HGNC:30670","description":"synaptic vesicle glycoprotein 2C","metadata":{"aliases":["SLC22B3"]}},{"id":"5cd327c0d9294778b681bc8f5df5ac42","type":"GENE","name":"SV2C-AS1","canonical_id":"hgnc:HGNC:55583","description":"SV2C antisense RNA 1","metadata":null},{"id":"377d42a8de314b25bd154258ceb37d90","type":"GENE","name":"SV2C-AS2","canonical_id":"hgnc:HGNC:58251","description":"SV2C antisense RNA 2","metadata":null},{"id":"2db728f4a0024c789586d3d717a3f930","type":"GENE","name":"SVBP","canonical_id":"hgnc:HGNC:29204","description":"small vasohibin binding protein","metadata":{"aliases":["MGC45441","CCDC23"]}},{"id":"c9d354c9eb144e5f93ec8708278b0bdb","type":"GENE","name":"SVEP1","canonical_id":"hgnc:HGNC:15985","description":"sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1","metadata":{"aliases":["bA427L11.3","POLYDOM","FLJ13529","C9orf13"]}},{"id":"c9fbc0eb83d94ab4bf81270dea2a70eb","type":"GENE","name":"SVIL","canonical_id":"hgnc:HGNC:11480","description":"supervillin","metadata":null},{"id":"f4dd949ff3e64eaabdccf057d25fdb7b","type":"GENE","name":"SVIL-AS1","canonical_id":"hgnc:HGNC:51219","description":"SVIL antisense RNA 1","metadata":{"aliases":["RP11-534G20.3"]}},{"id":"e4b17b4381aa4b129d11168472aec727","type":"GENE","name":"SVIL2P","canonical_id":"hgnc:HGNC:44959","description":"supervillin family member 2, pseudogene","metadata":{"aliases":["SVILP1"]}},{"id":"e9834cb85584460e94699c0862968001","type":"GENE","name":"SVIP","canonical_id":"hgnc:HGNC:25238","description":"small VCP interacting protein","metadata":{"aliases":["DKFZp313A2432"]}},{"id":"9b20f892eb244e68b5044e345f2a5d4f","type":"GENE","name":"SVOP","canonical_id":"hgnc:HGNC:25417","description":"SV2 related protein","metadata":{"aliases":["DKFZp761H039","SLC22B4"]}},{"id":"6af4f23e31724f32a12809285bb56fea","type":"GENE","name":"SVOPL","canonical_id":"hgnc:HGNC:27034","description":"SVOP like","metadata":{"aliases":["MGC46715","SLC22B5"]}},{"id":"9cf8d6c03c4a402ab0e15f006fc6f258","type":"GENE","name":"SWAP70","canonical_id":"hgnc:HGNC:17070","description":"switching B cell complex subunit SWAP70","metadata":{"aliases":["KIAA0640","SWAP-70"]}},{"id":"67b4883888ea4939b4a3325f12463a93","type":"GO_TERM","name":"SWI/SNF complex","canonical_id":"go:GO:0016514","description":"\"A SWI/SNF-type complex that contains 8 to 14 proteins, including both conserved (core) and nonconserved components; contains the ATPase product of the yeast SNF2 or mammalian SMARCA4/BAF190A/BRG1 gene, or an ortholog thereof.\" [GOC:bhm, PMID:12672490]","metadata":null},{"id":"375309c544cc43f1bec6512d1ed31e59","type":"GO_TERM","name":"SWI/SNF superfamily-type complex","canonical_id":"go:GO:0070603","description":"\"A protein complex that contains an ortholog of the Saccharomyces ATPase Swi2/Snf2 as one of the catalytic subunit components (ATPase) and mediates assembly of nucleosomes, changes to the spacing or structure of nucleosomes, or some combination of those activities in a manner that requires ATP.\" [GOC:bhm, GOC:krc, GOC:mah, PMID:16155938]","metadata":null},{"id":"dab6c7dcc08747258c64b08caea59c82","type":"GENE","name":"SWI5","canonical_id":"hgnc:HGNC:31412","description":"SWI5 homologous recombination repair protein","metadata":{"aliases":["bA395P17.9","SAE3","C9orf119"]}},{"id":"807516b55cfd4d5cb4fcbb7ead6e01ff","type":"GENE","name":"SWINGN","canonical_id":"hgnc:HGNC:43709","description":"SWI/SNF complex interacting GAS6 enhancer non-coding RNA","metadata":{"aliases":["LINC00565"]}},{"id":"b4d49ca65df34cc4b36b83bce0d44bb0","type":"TRIAL","name":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","canonical_id":"clinicaltrials.gov:NCT01295151","description":"Rheumatoid Arthritis","metadata":null},{"id":"20fed0d8a5fb425ebccf83feb566d551","type":"TRIAL","name":"SWITCH: Apixaban vs Vitamin K in HM3","canonical_id":"clinicaltrials.gov:NCT07471139","description":"LVAD (Left Ventricular Assist Device) Thrombosis; Heart Failure; Bleeding; Thrombosis; Artery; Stroke; Heart Transplant","metadata":null},{"id":"43465cae863a40f4a3ce957f68b20b99","type":"TRIAL","name":"SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00002651","description":"Prostate Cancer","metadata":null},{"id":"45cfc6da2c984cdc94d6cb1462891e6d","type":"TRIAL","name":"SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00004031","description":"Lymphoma","metadata":null},{"id":"ae7c0948b09e42e0bea958c754f71f27","type":"GENE","name":"SWSAP1","canonical_id":"hgnc:HGNC:26638","description":"SWIM-type zinc finger 7 associated protein 1","metadata":{"aliases":["FLJ35119","ZSWIM7AP1","SWS1AP1","C19orf39"]}},{"id":"a7d7eddd8c394de1a65b724ba8504ba8","type":"GENE","name":"SWT1","canonical_id":"hgnc:HGNC:16785","description":"SWT1 RNA endoribonuclease homolog","metadata":{"aliases":["FLJ20121","HsSwt1","C1orf26"]}},{"id":"05a405d8c2a24d6fa86ab751b4cefcce","type":"GENE","name":"SYAP1","canonical_id":"hgnc:HGNC:16273","description":"synapse associated protein 1","metadata":{"aliases":["FLJ14495","PRO3113"]}},{"id":"e7be1fa18cd34df1983c1d9458891337","type":"GENE","name":"SYBU","canonical_id":"hgnc:HGNC:26011","description":"syntabulin","metadata":{"aliases":["FLJ20366","GOLSYN","KIAA1472","OCSYN","SNPHL"]}},{"id":"57ca0e351a3f44ebbbd265175f0f0b70","type":"GENE","name":"SYBU-AS1","canonical_id":"hgnc:HGNC:55741","description":"SYBU antisense RNA 1","metadata":{"aliases":["AC079061.1"]}},{"id":"35570fba32ac4ad988d70fe0c1a37b47","type":"GENE","name":"SYCE1","canonical_id":"hgnc:HGNC:28852","description":"synaptonemal complex central element protein 1","metadata":{"aliases":["bA108K14.6","CT76","C10orf94"]}},{"id":"5eff1a75322944e4a3a933c45dda9b14","type":"GENE","name":"SYCE1L","canonical_id":"hgnc:HGNC:37236","description":"synaptonemal complex central element protein 1 like","metadata":{"aliases":["MRP2"]}},{"id":"160fbb07c6b24757b5b292415db05261","type":"GENE","name":"SYCE2","canonical_id":"hgnc:HGNC:27411","description":"synaptonemal complex central element protein 2","metadata":{"aliases":["CESC1"]}},{"id":"d61a103f854049ffbd381cccd5d87099","type":"GENE","name":"SYCE3","canonical_id":"hgnc:HGNC:35245","description":"synaptonemal complex central element protein 3","metadata":{"aliases":["C22orf41"]}},{"id":"fbf2e261a632442b86af3a903786450b","type":"GENE","name":"SYCN","canonical_id":"hgnc:HGNC:18442","description":"syncollin","metadata":{"aliases":["SYL","FLJ27441","INSSA1"]}},{"id":"9f554235fdc443f9a34eca05d37dc8a5","type":"GENE","name":"SYCP1","canonical_id":"hgnc:HGNC:11487","description":"synaptonemal complex protein 1","metadata":{"aliases":["HOM-TES-14","SCP1","CT8"]}},{"id":"d098962f00164758af813bd0c11f159a","type":"GENE","name":"SYCP2","canonical_id":"hgnc:HGNC:11490","description":"synaptonemal complex protein 2","metadata":{"aliases":["SCP2"]}},{"id":"4abb6f28686f4f839e91432f43082564","type":"GENE","name":"SYCP2L","canonical_id":"hgnc:HGNC:21537","description":"synaptonemal complex protein 2 like","metadata":{"aliases":["dJ62D2.1","NO145","C6orf177"]}},{"id":"255153f7359144dbb367834083676e67","type":"GENE","name":"SYCP3","canonical_id":"hgnc:HGNC:18130","description":"synaptonemal complex protein 3","metadata":null},{"id":"95dae15bd51c42bfa63a5d8dcecf3f97","type":"GENE","name":"SYDE1","canonical_id":"hgnc:HGNC:25824","description":"synapse defective Rho GTPase activating protein 1","metadata":{"aliases":["7h3","FLJ13511","SYD1"]}},{"id":"0a83556ea97e465f9c797b9bcab88172","type":"GENE","name":"SYDE2","canonical_id":"hgnc:HGNC:25841","description":"synapse defective Rho GTPase homolog 2","metadata":{"aliases":["FLJ13815"]}},{"id":"f4b44d90285746caa7b0faa80b144fa2","type":"GENE","name":"SYF2","canonical_id":"hgnc:HGNC:19824","description":"SYF2 pre-mRNA splicing factor","metadata":{"aliases":["p29","DKFZp564O2082","NTC31","fSAP29","CBPIN"]}},{"id":"2c6e4a4ca88b4eb18b8c7b9f88cbd5f9","type":"GENE","name":"SYF2P1","canonical_id":"hgnc:HGNC:19925","description":"SYF2 pre-mRNA splicing factor pseudogene 1","metadata":{"aliases":["CBPINP","SYF2P"]}},{"id":"a77ca37e36804eb2a893e9db39cd8180","type":"GENE","name":"SYF2P2","canonical_id":"hgnc:HGNC:38139","description":"SYF2 pre-mRNA splicing factor pseudogene 2","metadata":null},{"id":"80c559eea66a4e459aa95d81670bf5a6","type":"TRIAL","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07662811","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"5da2c888d6524ee1af4a83d729e5c881","type":"GENE","name":"SYK","canonical_id":"hgnc:HGNC:11491","description":null,"metadata":null},{"id":"3249480abd604afcaeac1f4c61ed8484","type":"TRIAL","name":"SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT04762160","description":"Follicular Lymphoma","metadata":null},{"id":"4d267bb394e141bebcf79a36357278cb","type":"GENE","name":"SYMPK","canonical_id":"hgnc:HGNC:22935","description":null,"metadata":null},{"id":"7124f82829334559adfce54d44f25dae","type":"GENE","name":"SYMPK-AS1","canonical_id":"hgnc:HGNC:58331","description":"SYMPK antisense RNA 1","metadata":null},{"id":"837d0197724d4344bb00685ca968b9ce","type":"GENE","name":"SYN1","canonical_id":"hgnc:HGNC:11494","description":null,"metadata":null},{"id":"a3e7bdc62e0a422bac4fe035e94028e6","type":"GENE","name":"SYN2","canonical_id":"hgnc:HGNC:11495","description":null,"metadata":null},{"id":"fe36905c79374ef890927b174c31e6c0","type":"GENE","name":"SYN3","canonical_id":"hgnc:HGNC:11496","description":"synapsin III","metadata":null},{"id":"43031b5956524c28b4247c2a306c23d6","type":"GENE","name":"SYN3-AS1","canonical_id":"hgnc:HGNC:40569","description":"SYN3 antisense RNA 1","metadata":null},{"id":"4b8a0d7a22084758be3e62838935f7b9","type":"GENE","name":"SYNAGE","canonical_id":"hgnc:HGNC:56730","description":"synapse stability regulating cerebellar lncRNA","metadata":null},{"id":"477e80fe15984985ac6d2ad0e6e80e63","type":"GENE","name":"SYNC","canonical_id":"hgnc:HGNC:28897","description":"syncoilin, intermediate filament protein","metadata":{"aliases":["SYNCOILIN","SYNC1"]}},{"id":"6c563bc0d45d4a5b9a847944d708e044","type":"GENE","name":"SYNCRIP","canonical_id":"hgnc:HGNC:16918","description":"synaptotagmin binding cytoplasmic RNA interacting protein","metadata":{"aliases":["NSAP1","GRY-RBP","dJ3J17.2","HNRPQ1","hnRNP-Q","HNRNPQ"]}},{"id":"0020130d3b404ef2ac349a4103a4e32b","type":"GENE","name":"SYNCRIPP1","canonical_id":"hgnc:HGNC:56945","description":"SYNCRIP pseudogene 1","metadata":null},{"id":"948b4ae200c54dbf9fbf7ff367029285","type":"GENE","name":"SYNDIG1","canonical_id":"hgnc:HGNC:15885","description":"synapse differentiation inducing 1","metadata":{"aliases":["FLJ14220","IFITMD5","DSPC2","C20orf39","TMEM90B"]}},{"id":"d55e606633594ce7ae393b16e517054b","type":"GENE","name":"SYNDIG1L","canonical_id":"hgnc:HGNC:32388","description":"synapse differentiation inducing 1 like","metadata":{"aliases":["capucin","IFITMD4","DSPC1","SynDIG2","TMEM90A"]}},{"id":"7aeaa802e4914213b218f79c751eaa94","type":"GENE","name":"SYNE1","canonical_id":"hgnc:HGNC:17089","description":"spectrin repeat containing nuclear envelope protein 1","metadata":{"aliases":["SYNE-1B","KIAA0796","8B","Nesprin-1","enaptin","MYNE1","CPG2","dJ45H2.2","SCAR8","ARCA1","Nesp1","C6orf98"]}},{"id":"aff9d43f89e040e6a48f0833fe9579b9","type":"GENE","name":"SYNE1-AS1","canonical_id":"hgnc:HGNC:40793","description":"SYNE1 antisense RNA 1","metadata":null},{"id":"49bdd16a411f4e81a9ea505536e1f42a","type":"GENE","name":"SYNE1-AS2","canonical_id":"hgnc:HGNC:40794","description":"SYNE1 antisense RNA 2","metadata":null},{"id":"183a93c703f74051aa5b567e2e4785bb","type":"GENE","name":"SYNE2","canonical_id":"hgnc:HGNC:17084","description":"spectrin repeat containing nuclear envelope protein 2","metadata":{"aliases":["SYNE-2","DKFZP434H2235","Nesprin-2","NUANCE","NUA","KIAA1011","Nesp2"]}},{"id":"f10fa596b2204280be39b434bef2b7b2","type":"GENE","name":"SYNE3","canonical_id":"hgnc:HGNC:19861","description":"spectrin repeat containing nuclear envelope family member 3","metadata":{"aliases":["FLJ25605","NET53","Nesprin-3","Nesp3","C14orf49","LINC00341","C14orf139","NCRNA00341"]}},{"id":"3746f5c5ef8b42c885628151d4a3f864","type":"GENE","name":"SYNE3-AS1","canonical_id":"hgnc:HGNC:56940","description":"SYNE3 antisense RNA 1","metadata":{"aliases":["AL133467.1"]}},{"id":"669f1e4a81eb46e692b921e64114db2e","type":"GENE","name":"SYNE4","canonical_id":"hgnc:HGNC:26703","description":"spectrin repeat containing nuclear envelope family member 4","metadata":{"aliases":["FLJ36445","Nesprin-4","Nesp4","C19orf46","DFNB76"]}},{"id":"02cefa818edf44eeaa921f84ae213602","type":"GENE","name":"SYNGAP1","canonical_id":"hgnc:HGNC:11497","description":"synaptic Ras GTPase activating protein 1","metadata":{"aliases":["SYNGAP","RASA5","KIAA1938"]}},{"id":"44041aba9d6b4675aca3a2af6ba9abc6","type":"GENE","name":"SYNGAP1-AS1","canonical_id":"hgnc:HGNC:53831","description":"SYNGAP1 antisense RNA 1","metadata":{"aliases":["SYNGAP1-AS"]}},{"id":"7a3d0d0408574f519b3d1a59d1094e26","type":"GENE","name":"SYNGR1","canonical_id":"hgnc:HGNC:11498","description":"synaptogyrin 1","metadata":null},{"id":"64e35134b00b47a49fe8ce2c7dd02aaa","type":"GENE","name":"SYNGR2","canonical_id":"hgnc:HGNC:11499","description":"synaptogyrin 2","metadata":null},{"id":"b8f819583554420e8f981fb966c42d37","type":"GENE","name":"SYNGR2P1","canonical_id":"hgnc:HGNC:11500","description":"synaptogyrin 2 pseudogene 1","metadata":{"aliases":["SYNGR2P"]}},{"id":"fb2da3650f784d1cb6caa539673a6a44","type":"GENE","name":"SYNGR2P2","canonical_id":"hgnc:HGNC:33947","description":"synaptogyrin 2 pseudogene 2","metadata":null},{"id":"9e238ec1b0d64bcb9ec911aa3e43bf17","type":"GENE","name":"SYNGR3","canonical_id":"hgnc:HGNC:11501","description":"synaptogyrin 3","metadata":null},{"id":"9d404fd28db94aacbad8fedcb057e393","type":"GENE","name":"SYNGR4","canonical_id":"hgnc:HGNC:11502","description":"synaptogyrin 4","metadata":null},{"id":"d7d99126909b4a38aae8963036795f9d","type":"GENE","name":"SYNJ1","canonical_id":"hgnc:HGNC:11503","description":"synaptojanin 1","metadata":{"aliases":["INPP5G","PARK20"]}},{"id":"cf374acaa1e04a8d95ec6f124a3f8b03","type":"GENE","name":"SYNJ2","canonical_id":"hgnc:HGNC:11504","description":"synaptojanin 2","metadata":{"aliases":["INPP5H"]}},{"id":"cda22392ecca42859f62ddf266fd6b75","type":"GENE","name":"SYNJ2-IT1","canonical_id":"hgnc:HGNC:41387","description":"SYNJ2 intronic transcript 1","metadata":null},{"id":"5c09515ddfe54f08b1bee1b965d95df7","type":"GENE","name":"SYNJ2BP","canonical_id":"hgnc:HGNC:18955","description":"synaptojanin 2 binding protein","metadata":{"aliases":["Arip2"]}},{"id":"5d24e420ff2948ab954f510ada56f041","type":"GENE","name":"SYNJ2BP-COX16","canonical_id":"hgnc:HGNC:48350","description":"SYNJ2BP-COX16 readthrough","metadata":null},{"id":"b58059bfbe42422eab7807a5e3ad318c","type":"GENE","name":"SYNM","canonical_id":"hgnc:HGNC:24466","description":"synemin","metadata":{"aliases":["KIAA0353","SYN","DMN"]}},{"id":"5a020d5c674647fa9ef334bdc19888e2","type":"GENE","name":"SYNM-AS1","canonical_id":"hgnc:HGNC:55421","description":"SYNM antisense RNA 1","metadata":null},{"id":"84a0f4fc676044c79d11dffb8fab6af1","type":"GENE","name":"SYNM-AS2","canonical_id":"hgnc:HGNC:56228","description":"SYNM antisense RNA 2","metadata":{"aliases":["TP53LC11"]}},{"id":"f610095cf2c94e649f04571e014cb9ad","type":"GENE","name":"SYNPO","canonical_id":"hgnc:HGNC:30672","description":"synaptopodin","metadata":{"aliases":["KIAA1029","SYNPO1"]}},{"id":"4bdb47246fdd43869388ab86a938c1e0","type":"GENE","name":"SYNPO-AS1","canonical_id":"hgnc:HGNC:41270","description":"SYNPO antisense RNA 1","metadata":null},{"id":"4daffe7931a448319860254418648e3c","type":"GENE","name":"SYNPO-AS2","canonical_id":"hgnc:HGNC:59282","description":"SYNPO antisense RNA 2","metadata":null},{"id":"6cc3879c86204f6ebf7ce02277c117e2","type":"GENE","name":"SYNPO2","canonical_id":"hgnc:HGNC:17732","description":"synaptopodin 2","metadata":{"aliases":["MYOPODIN"]}},{"id":"82f1bf34f2c94d71b34ac9486cb26b56","type":"GENE","name":"SYNPO2-AS1","canonical_id":"hgnc:HGNC:58370","description":"SYNPO2 antisense RNA 1","metadata":null},{"id":"61ed1e104e134799b152f9da5eb6d4b0","type":"GENE","name":"SYNPO2L","canonical_id":"hgnc:HGNC:23532","description":"synaptopodin 2 like","metadata":{"aliases":["FLJ12921"]}},{"id":"93f1e4811d6a40df8d02ff97a36ece86","type":"GENE","name":"SYNPO2L-AS1","canonical_id":"hgnc:HGNC:55242","description":"SYNPO2L antisense RNA 1","metadata":null},{"id":"18df93d86d964ebfa2e9b2d4e8ffd9a5","type":"GENE","name":"SYNPR","canonical_id":"hgnc:HGNC:16507","description":"synaptoporin","metadata":{"aliases":["MGC26651","SPO"]}},{"id":"efb1cdc1644e4c419d3e2745cd8c2ab8","type":"GENE","name":"SYNPR-AS1","canonical_id":"hgnc:HGNC:40774","description":"SYNPR antisense RNA 1","metadata":{"aliases":["LncFASA"]}},{"id":"187b2f32ba2447eb84fe92ccb30cc2af","type":"GENE","name":"SYNRG","canonical_id":"hgnc:HGNC:557","description":"synergin gamma","metadata":{"aliases":["SYNG","MGC104959","AP1GBP1"]}},{"id":"3f5f54665bb04bd19771ce4b75dbb991","type":"GENE","name":"SYP","canonical_id":"hgnc:HGNC:11506","description":null,"metadata":null},{"id":"76a668ea9a1e4bcf840e6a0a5476c376","type":"GENE","name":"SYP-AS1","canonical_id":"hgnc:HGNC:40571","description":"SYP antisense RNA 1","metadata":null},{"id":"dd2e85fe5c084b0eb27d1ddb16afc266","type":"GENE","name":"SYPL1","canonical_id":"hgnc:HGNC:11507","description":"synaptophysin like 1","metadata":{"aliases":["SYPL"]}},{"id":"64dcc89429c3471fa4ecb765ffdacf2b","type":"GENE","name":"SYPL1P1","canonical_id":"hgnc:HGNC:53546","description":"synaptophysin like 1 pseudogene 1","metadata":null},{"id":"455d85b800404f898f7104c5dcebe9f3","type":"GENE","name":"SYPL1P2","canonical_id":"hgnc:HGNC:53547","description":"synaptophysin like 1 pseudogene 2","metadata":null},{"id":"be31becf9c8c492cba8070c93514a661","type":"GENE","name":"SYPL2","canonical_id":"hgnc:HGNC:27638","description":"synaptophysin like 2","metadata":{"aliases":["Mg29"]}},{"id":"6530f785e42c417b9e98c6b54c7c8e19","type":"GENE","name":"SYS1","canonical_id":"hgnc:HGNC:16162","description":"SYS1 golgi trafficking protein","metadata":{"aliases":["dJ453C12.4","C20orf169"]}},{"id":"039d087caac140b890ea8d821949e0c8","type":"GENE","name":"SYS1-DBNDD2","canonical_id":"hgnc:HGNC:33535","description":"SYS1-DBNDD2 readthrough (NMD candidate)","metadata":null},{"id":"d1fc4237833b4c5ca57a40ab0fcd80ea","type":"TRIAL","name":"SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT07374549","description":"Advanced Urothelial Carcinoma","metadata":null},{"id":"d3ae9aa0aaaa4d6682aa52c47831860b","type":"TRIAL","name":"SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07622225","description":"Advanced Solid Tumors","metadata":null},{"id":"d3e90f06dff943779009001b75801a35","type":"TRIAL","name":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07254585","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"7bc069e8311b466388312f2fb7162f28","type":"TRIAL","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC\uff08SYNSTAR 04\uff09","canonical_id":"clinicaltrials.gov:NCT07633873","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"ae90c96de1fd47aaae95309a6c45fc65","type":"GENE","name":"SYT1","canonical_id":"hgnc:HGNC:11509","description":"synaptotagmin 1","metadata":{"aliases":["P65","SYT","SVP65"]}},{"id":"4e5c72cf626148838fc812cae953db89","type":"GENE","name":"SYT1-AS1","canonical_id":"hgnc:HGNC:58105","description":"SYT1 antisense RNA 1","metadata":{"aliases":["AC027288.3"]}},{"id":"f555f4f07c0e476ea55e6e88537841a0","type":"GENE","name":"SYT10","canonical_id":"hgnc:HGNC:19266","description":"synaptotagmin 10","metadata":null},{"id":"e11598f7ce3647f285c91bdb8af533a5","type":"GENE","name":"SYT11","canonical_id":"hgnc:HGNC:19239","description":"synaptotagmin 11","metadata":{"aliases":["KIAA0080","MGC10881","MGC17226","DKFZp781D015"]}},{"id":"5cc474ff8f0745e698003899888c1791","type":"GENE","name":"SYT12","canonical_id":"hgnc:HGNC:18381","description":"synaptotagmin 12","metadata":{"aliases":["SRG1"]}},{"id":"785d5cac08714a50a3f0d5ef32ec5c54","type":"GENE","name":"SYT13","canonical_id":"hgnc:HGNC:14962","description":"synaptotagmin 13","metadata":{"aliases":["KIAA1427"]}},{"id":"6ea71a2c622c40b3ad6b38bb758e4505","type":"GENE","name":"SYT13-AS1","canonical_id":"hgnc:HGNC:58435","description":"SYT13 antisense RNA 1","metadata":null},{"id":"eaf3470a050a47f8adb42200070bc4a5","type":"GENE","name":"SYT14","canonical_id":"hgnc:HGNC:23143","description":"synaptotagmin 14","metadata":{"aliases":["sytXIV","FLJ34198"]}},{"id":"a99c5c7e2b944de6bffc0dee42553e5a","type":"GENE","name":"SYT14P1","canonical_id":"hgnc:HGNC:33429","description":"synaptotagmin 14 pseudogene 1","metadata":{"aliases":["SYTDEP","CHR415SYT","SYT14L"]}},{"id":"b6dc2a371bfb48c5bf4a3a33fb00cabc","type":"GENE","name":"SYT15","canonical_id":"hgnc:HGNC:17167","description":"synaptotagmin 15","metadata":{"aliases":["CHR10SYT"]}},{"id":"aeb49abc4ea44b09b72cd0ecbb26cdb8","type":"GENE","name":"SYT15-AS1","canonical_id":"hgnc:HGNC:56167","description":"SYT15 antisense RNA 1","metadata":null},{"id":"4071a6d85b9a48d9844076eb98f05cf6","type":"GENE","name":"SYT15B","canonical_id":"hgnc:HGNC:51487","description":"synaptotagmin 15B","metadata":null},{"id":"4647957de5454d95b2e7c5b1ca87f229","type":"GENE","name":"SYT16","canonical_id":"hgnc:HGNC:23142","description":"synaptotagmin 16","metadata":{"aliases":["yt14r","CHR14SYT","Strep14","SYT14L"]}},{"id":"911311e2f7b64a7cbf4391142f4b3fa0","type":"GENE","name":"SYT17","canonical_id":"hgnc:HGNC:24119","description":"synaptotagmin 17","metadata":{"aliases":["Syt-17"]}},{"id":"93eface154a945af9ced298cf7e118dd","type":"GENE","name":"SYT2","canonical_id":"hgnc:HGNC:11510","description":"synaptotagmin 2","metadata":null},{"id":"eb24b22034404c4f93588d703f1048a0","type":"GENE","name":"SYT2-AS1","canonical_id":"hgnc:HGNC:40572","description":"SYT2 antisense RNA 1","metadata":{"aliases":["RP11-569A11.1"]}},{"id":"fb80437204584d8eb16a2bfcc7264d65","type":"GENE","name":"SYT3","canonical_id":"hgnc:HGNC:11511","description":"synaptotagmin 3","metadata":null},{"id":"bfc7b5bd46b04137968d5ef3537298a6","type":"GENE","name":"SYT4","canonical_id":"hgnc:HGNC:11512","description":"synaptotagmin 4","metadata":{"aliases":["KIAA1342","HsT1192"]}},{"id":"b46e3c42b8944165bfd7a94f9750ddf7","type":"GENE","name":"SYT5","canonical_id":"hgnc:HGNC:11513","description":"synaptotagmin 5","metadata":null},{"id":"a93753ef21f24c689a4266da16bc5ee7","type":"GENE","name":"SYT6","canonical_id":"hgnc:HGNC:18638","description":"synaptotagmin 6","metadata":null},{"id":"b7f53455e74f48c5bc92273c9ca94680","type":"GENE","name":"SYT7","canonical_id":"hgnc:HGNC:11514","description":"synaptotagmin 7","metadata":{"aliases":["IPCA-7","SYT-VII","MGC150517","PCANAP7"]}},{"id":"f6f22e4c0d2d4bf09fcf081ed89d2bd0","type":"GENE","name":"SYT8","canonical_id":"hgnc:HGNC:19264","description":"synaptotagmin 8","metadata":{"aliases":["DKFZp434K0322"]}},{"id":"dfa1c8c318974757a900677a908e36f2","type":"GENE","name":"SYT9","canonical_id":"hgnc:HGNC:19265","description":"synaptotagmin 9","metadata":null},{"id":"5e5ca016da804207b67164baac4007fa","type":"GENE","name":"SYT9-AS1","canonical_id":"hgnc:HGNC:56173","description":"SYT9 antisense RNA 1","metadata":null},{"id":"335a7365b5274fdd8dc8992b46b20ffe","type":"GENE","name":"SYTL1","canonical_id":"hgnc:HGNC:15584","description":"synaptotagmin like 1","metadata":{"aliases":["SLP1","JFC1","FLJ14996","exophilin-7"]}},{"id":"1e1d9ba1974a44f98e9f118efaa18f14","type":"GENE","name":"SYTL2","canonical_id":"hgnc:HGNC:15585","description":"synaptotagmin like 2","metadata":{"aliases":["FLJ20163","FLJ21219","KIAA1597","exophilin-4","CHR11SYT","SLP2","SGA72M","MGC102768","PPP1R151"]}},{"id":"a1b9030e32d44060bfe6afa2332378a2","type":"GENE","name":"SYTL3","canonical_id":"hgnc:HGNC:15587","description":"synaptotagmin like 3","metadata":{"aliases":["SLP3","exophilin-6"]}},{"id":"f0e5bb211659434ba252f616c72c329a","type":"GENE","name":"SYTL4","canonical_id":"hgnc:HGNC:15588","description":null,"metadata":null},{"id":"6f0afddc24134fe8805b9963c23d0801","type":"GENE","name":"SYTL5","canonical_id":"hgnc:HGNC:15589","description":"synaptotagmin like 5","metadata":{"aliases":["Slp5"]}},{"id":"8ba70a36cad44da9bbfb1e8e5d7990d4","type":"GENE","name":"SYVN1","canonical_id":"hgnc:HGNC:20738","description":"synoviolin 1","metadata":{"aliases":["HRD1","DER3"]}},{"id":"b85986cc9c84457293e75027c89af625","type":"GENE","name":"SZRD1","canonical_id":"hgnc:HGNC:30232","description":"SUZ RNA binding domain containing 1","metadata":{"aliases":["DKFZp566C0424","C1orf144"]}},{"id":"a8b627e8940649e689396b9aea0d0237","type":"GENE","name":"SZRD1P1","canonical_id":"hgnc:HGNC:56315","description":"SZRD1 pseudogene 1","metadata":null},{"id":"d8e4cc36088b4e579ba8c801e6ecc8fe","type":"GENE","name":"SZT2","canonical_id":"hgnc:HGNC:29040","description":"SZT2 subunit of KICSTOR complex","metadata":{"aliases":["FLJ10387","SZT2B","RP11-506B15.1","FLJ34502","SZT2A","KICS1","C1orf84","KIAA0467"]}},{"id":"324b18c45ec443d594f4d6e5ebb22670","type":"GENE","name":"SZT2-AS1","canonical_id":"hgnc:HGNC:41225","description":"SZT2 antisense RNA 1","metadata":null},{"id":"8b1ab598ec6142cc9682eb780d2c71b2","type":"TRIAL","name":"Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients","canonical_id":"clinicaltrials.gov:NCT01266291","description":"Complex Partial Seizures","metadata":null},{"id":"cd1ec13ca7d74b4ca1f985fdb47c7e0e","type":"TRIAL","name":"Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","canonical_id":"clinicaltrials.gov:NCT07139366","description":"Gastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer; Peptic Ulcer","metadata":null},{"id":"5f43f925c8a643e8a5209a7185181447","type":"TRIAL","name":"Saci Nivo Rela for TNBC","canonical_id":"clinicaltrials.gov:NCT06963905","description":"Metastatic Triple-negative Breast Cancer","metadata":null},{"id":"766f53b0299341608fa6e0f259971558","type":"TRIAL","name":"Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases","canonical_id":"clinicaltrials.gov:NCT06462079","description":"Brain Metastasis","metadata":null},{"id":"8ff719cd37884652989224d38e6b58ac","type":"TRIAL","name":"Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy","canonical_id":"clinicaltrials.gov:NCT07504588","description":"Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma","metadata":null},{"id":"234f8d54aa0a4f888117edfb14b2302d","type":"TRIAL","name":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","canonical_id":"clinicaltrials.gov:NCT06401824","description":"NSCLC Stage IV; Brain Metastases, Adult","metadata":null},{"id":"9d1c697f2f7349a09ea1dea1b8022dd2","type":"TRIAL","name":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","canonical_id":"clinicaltrials.gov:NCT06865677","description":"Recurrent Platinum Resistant Epithelial Ovarian Carcinoma; Recurrent Epithelial Endometrial Carcinoma; Recurrent Epithelial Cervical Carcinoma","metadata":null},{"id":"af055c0224f047f399f9568e35acdb0b","type":"TRIAL","name":"Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)","canonical_id":"clinicaltrials.gov:NCT06923826","description":"Salivary Gland Cancer; Thyroid Cancer","metadata":null},{"id":"8049615c421c4bbfb1e1091f9ae52547","type":"TRIAL","name":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT05226117","description":"Urothelial Carcinoma","metadata":null},{"id":"7f2a147dfe4e40099e2352be234235ae","type":"TRIAL","name":"Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07701681","description":"ESCC; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma (ESCC); GC/GEJC","metadata":null},{"id":"8e443867971843df85244cff5b7345d7","type":"TRIAL","name":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07153965","description":"Triple Negative Breast Cancer (TNBC); PD-L1 Positive","metadata":null},{"id":"65d70deb70194304bea47c8ec9a5a5e4","type":"TRIAL","name":"Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)","canonical_id":"clinicaltrials.gov:NCT07179783","description":"Prostate Cancer (Adenocarcinoma); Prostate Cancer Metastatic Castration-Resistant; Prostate Adenocarcinoma With Neuroendocrine Differentiation","metadata":null},{"id":"f789ebe6e89e4da495a4b1e6f02ad1ed","type":"TRIAL","name":"Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery","canonical_id":"clinicaltrials.gov:NCT02539693","description":"Pilonidal Sinus","metadata":null},{"id":"f478d3c1f8f348fab5548326b2542dc4","type":"DRUG","name":"Sacrosidase","canonical_id":"mesh:D043324","description":null,"metadata":null},{"id":"86500149c22d4b479cbf6c47674f3f63","type":"TRIAL","name":"Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT07853625","description":"Hypertension; Left Ventricular Diastolic Dysfunction; Essential (Primary) Hypertension","metadata":null},{"id":"05c0273354c942b1ba2c862f1c99d155","type":"GO_TERM","name":"Sad1-Kms1 LINC complex","canonical_id":"go:GO:1990612","description":"\"A LINC complex implicated in the connection of DNA double strand breaks to the cytoskeleton during DNA double-strand break repair.\" [GOC:vw, PMID:24943839, PMID:24947240]","metadata":null},{"id":"ecc8b447dde64acf928bc7b3ee5ff9a8","type":"DISEASE","name":"Saethre-Chotzen syndrome","canonical_id":"mondo:0007042","description":null,"metadata":null},{"id":"dbccd5edc671453696fb9757f3d7fe68","type":"TRIAL","name":"Safe Accelerated Venetoclax Escalation in CLL","canonical_id":"clinicaltrials.gov:NCT04843904","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"c215a70c8f5949e188af838d17b848ab","type":"TRIAL","name":"Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel","canonical_id":"clinicaltrials.gov:NCT04862585","description":"Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; \u2026","metadata":null},{"id":"ee3ffe90a2214c6bb5c647de4a9a3d52","type":"TRIAL","name":"Safest Choice of Antihypertensive Regimen for Postpartum Hypertension","canonical_id":"clinicaltrials.gov:NCT05551104","description":"Postpartum Complication; Maternal Hypertension; High Blood Pressure","metadata":null},{"id":"829f44b73c3144be87b8c609aeb490fe","type":"TRIAL","name":"Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption","canonical_id":"clinicaltrials.gov:NCT06840652","description":"Alcoholic Cirrhosis; Alcohol Abstinence; Alcohol Withdrawal; Medication Toxicity; Medication Adherence","metadata":null},{"id":"01a318f463da48528704525e0cf0951e","type":"TRIAL","name":"Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill","canonical_id":"clinicaltrials.gov:NCT00045799","description":"Upper Gastrointestinal Bleeding","metadata":null},{"id":"9ed0c0a61a984ddd90419c0d8854a99f","type":"TRIAL","name":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00597753","description":"Chronic Renal Failure; Chronic Kidney Disease; Anemia","metadata":null},{"id":"489d65516e43478689b03afc52ebe3aa","type":"TRIAL","name":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00597584","description":"Chronic Renal Failure; Chronic Kidney Disease; Anemia","metadata":null},{"id":"f706752d8e9541b48ea48f0565e44747","type":"TRIAL","name":"Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA","canonical_id":"clinicaltrials.gov:NCT00680043","description":"Anemia; Chronic Renal Failure; Chronic Kidney Disease","metadata":null},{"id":"4f61aac81213426aaf73f400e2191c10","type":"TRIAL","name":"Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","canonical_id":"clinicaltrials.gov:NCT00598273","description":"Chronic Renal Failure; Chronic Kidney Disease; Anemia","metadata":null},{"id":"63d3dd4824a74c56869ccb885452ed35","type":"TRIAL","name":"Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults","canonical_id":"clinicaltrials.gov:NCT05114486","description":"Presbyopia","metadata":null},{"id":"6e3c37a376a847e6bcbd2fcfacbe2acf","type":"TRIAL","name":"Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT01439867","description":"Chronic Kidney Disease; Hyperparathyroidism, Secondary","metadata":null},{"id":"a16f61bc38634c0eb6e330acff163d53","type":"TRIAL","name":"Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression","canonical_id":"clinicaltrials.gov:NCT01078298","description":"Smoking Cessation; Depression","metadata":null},{"id":"67a7843ed90347c99dac83cdd00ff3bc","type":"TRIAL","name":"Safety And Efficacy Of Bosutinib","canonical_id":"clinicaltrials.gov:NCT02501330","description":"Chronic Myelogenous Leukemia","metadata":null},{"id":"9bf108418ce54c02b0f36e2f621182cc","type":"TRIAL","name":"Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT00640432","description":"Low Back Pain","metadata":null},{"id":"41e050f6ef824be1add15e3cb7941390","type":"TRIAL","name":"Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19","canonical_id":"clinicaltrials.gov:NCT04342156","description":"Coronavirus Infection; Hydroxychloroquine Adverse Reaction","metadata":null},{"id":"42eed61624784f16b33121527a1cce3f","type":"TRIAL","name":"Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity","canonical_id":"clinicaltrials.gov:NCT00441428","description":"Overactive Bladder; Detrusor Underactivity","metadata":null},{"id":"ef2bafe0d5d84da9b86762d315662aa9","type":"TRIAL","name":"Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors","canonical_id":"clinicaltrials.gov:NCT02228382","description":"Previously Treated PH + CML","metadata":null},{"id":"286fe17f536c48139672e0102f5f15ba","type":"TRIAL","name":"Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy","canonical_id":"clinicaltrials.gov:NCT01758640","description":"Anticoagulation in Pregnancy","metadata":null},{"id":"dec3552ee361400a8d50e4dec2a9a8fa","type":"TRIAL","name":"Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)","canonical_id":"clinicaltrials.gov:NCT01124877","description":"Bipolar Disorder","metadata":null},{"id":"17f5d50d4cc4468594cccfdb199dd9ee","type":"TRIAL","name":"Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01960179","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"8ec08ea856fe4348ad5e86b11804752d","type":"TRIAL","name":"Safety Assessment for Sotalol Protocol in Outpatient Unit","canonical_id":"clinicaltrials.gov:NCT05418036","description":"Supraventricular Arrhythmia; Ventricular Arrythmia; Proarrhythmia; Antiarrhythmic Drug Adverse Reaction","metadata":null},{"id":"ffb8d3e95653430c9c641798298a3d95","type":"TRIAL","name":"Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan","canonical_id":"clinicaltrials.gov:NCT02941367","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"e2e3c8d7f4144fcc9d6ff552fe6db2b7","type":"TRIAL","name":"Safety Evaluation of Aminophylline and Methazolamide","canonical_id":"clinicaltrials.gov:NCT01587027","description":"Mountain Sickness","metadata":null},{"id":"8874790eceee40939d143d3f6213834e","type":"TRIAL","name":"Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT00185315","description":"Hypertension, Pulmonary","metadata":null},{"id":"93122a99b283488ca19c1732c593aa9c","type":"TRIAL","name":"Safety Interaction Trial Ibudilast and Methamphetamine","canonical_id":"clinicaltrials.gov:NCT01217970","description":"Methamphetamine-dependence; Substance Abuse","metadata":null},{"id":"30dc471b939442329e8cb835cc614756","type":"TRIAL","name":"Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT03568929","description":"Follicular Non-Hodgkin's Lymphoma Refractory","metadata":null},{"id":"6c5deee044d24e8b87ad0437856cc1f0","type":"TRIAL","name":"Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT01423058","description":"Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"f9b5b7343fa246d68ab20dbd5575abd2","type":"TRIAL","name":"Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00709098","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"61a4c190370a438581fd7fcdcd42af48","type":"TRIAL","name":"Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT00388427","description":"Malignant Solid Tumour","metadata":null},{"id":"a20128f71a9348879f6ba3f2242545ef","type":"TRIAL","name":"Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab","canonical_id":"clinicaltrials.gov:NCT03992729","description":"Pregnancy Related","metadata":null},{"id":"4ba7799142f34118b96d9b0602df2e41","type":"TRIAL","name":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00807859","description":"Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors","metadata":null},{"id":"b209aa23468f4b118ea59b78a59e673a","type":"TRIAL","name":"Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies","canonical_id":"clinicaltrials.gov:NCT00660920","description":"Chronic Myelogenous Leukemia; Hematologic Malignancies","metadata":null},{"id":"cc26fd8406bb443aa284fa6cc845dcdc","type":"TRIAL","name":"Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00883675","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"e99f4c5937044503be191a5ff55d2b57","type":"TRIAL","name":"Safety Study of Afatinib for Brain Cancer","canonical_id":"clinicaltrials.gov:NCT02423525","description":"Brain Cancer","metadata":null},{"id":"9756b0f5215c49aeb69beab47d1fabfc","type":"TRIAL","name":"Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor","canonical_id":"clinicaltrials.gov:NCT01750580","description":"CANCER, NOS","metadata":null},{"id":"96cf6e55cb7748f8beccdc27209fd07b","type":"TRIAL","name":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","canonical_id":"clinicaltrials.gov:NCT00491166","description":"Diabetic Macular Edema","metadata":null},{"id":"37305440a13a494fa04afa862f54bf54","type":"TRIAL","name":"Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)","canonical_id":"clinicaltrials.gov:NCT00953771","description":"Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"4d7eb2345e0c404c8490486f8d21a577","type":"TRIAL","name":"Safety Study of Dantrolene in Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT01024972","description":"Subarachnoid Hemorrhage; Cerebral Vasospasm","metadata":null},{"id":"c43176665ad941a5a2836ee1bb28ac0a","type":"TRIAL","name":"Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT00964548","description":"Cerebral Vasospasm After Subarachnoid Hemorrhage","metadata":null},{"id":"4f62ef9c556e48a09617f467b7490d7b","type":"TRIAL","name":"Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis","canonical_id":"clinicaltrials.gov:NCT00913133","description":"Thrombosis","metadata":null},{"id":"d3febe0a0e624b9b97b541a966887c37","type":"TRIAL","name":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT02169609","description":"Neuroblastoma; Neoplasm, Residual; Effects of Immunotherapy","metadata":null},{"id":"c7c9424824104929a0da46827e4fe116","type":"TRIAL","name":"Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00928590","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"043809a7667346ef828de903a26d1bdd","type":"TRIAL","name":"Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome","canonical_id":"clinicaltrials.gov:NCT00208026","description":"Netherton Syndrome","metadata":null},{"id":"20cf94dfa3f44e67bbf993eef88e9c42","type":"TRIAL","name":"Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)","canonical_id":"clinicaltrials.gov:NCT01481220","description":"Myelodysplastic Syndrome; Thrombocytopenia","metadata":null},{"id":"fef1ed5ee52349a89f807155aca1b99e","type":"TRIAL","name":"Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01597193","description":"Breast Cancer","metadata":null},{"id":"61ef052248614d96a59970c8c1c46e92","type":"TRIAL","name":"Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01292174","description":"Prevention of Infection With HIV-1","metadata":null},{"id":"9543bb944bda4232ad8fece9f5744745","type":"TRIAL","name":"Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721","canonical_id":"clinicaltrials.gov:NCT02682407","description":"IgAN; LN; MN; C3G","metadata":null},{"id":"daf6dc2055d44e0c9c055a19d63958cd","type":"TRIAL","name":"Safety Study of Levocetirizine and Fexofenadine","canonical_id":"clinicaltrials.gov:NCT01586091","description":"Pruritus; Chronic Urticaria; Allergic Rhinitis","metadata":null},{"id":"f0747d03de714a5dac08c534b9e73232","type":"TRIAL","name":"Safety Study of Lifitegrast to Treat Dry Eye","canonical_id":"clinicaltrials.gov:NCT01636206","description":"Dry Eye Disease","metadata":null},{"id":"35d34ce4d66c440fae3e8504219f811f","type":"TRIAL","name":"Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant","canonical_id":"clinicaltrials.gov:NCT01491919","description":"Hypertension","metadata":null},{"id":"17f52d0148c94fd69183cb5afb93f56e","type":"TRIAL","name":"Safety Study of MGAH22 in HER2-positive Carcinomas","canonical_id":"clinicaltrials.gov:NCT01148849","description":"Breast Cancer; Gastric Cancer","metadata":null},{"id":"58c240001770409b9537043b5d552260","type":"TRIAL","name":"Safety Study of Maraviroc's Effect on Human Osteoclasts","canonical_id":"clinicaltrials.gov:NCT01428986","description":"HIV Infections; AIDS","metadata":null},{"id":"c99867bedbcd475e92d555d999bb231c","type":"TRIAL","name":"Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02445586","description":"Breast Cancer","metadata":null},{"id":"afb35f55bd854e39a602a98e5eb17e88","type":"TRIAL","name":"Safety Study of Remsima\u00ae (Infliximab) in Rheumatoid Arthritis Patients in Jordan","canonical_id":"clinicaltrials.gov:NCT03348046","description":"Rheumatoid Arthritis","metadata":null},{"id":"00d9eae8bba94537bf1bbb7f95601680","type":"TRIAL","name":"Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia","canonical_id":"clinicaltrials.gov:NCT01481610","description":"Kidney Failure, Chronic; Arthralgia","metadata":null},{"id":"64c714dff131442285a4849b0624c142","type":"TRIAL","name":"Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02667496","description":"Dementia Alzheimer's Type","metadata":null},{"id":"fcd21084618c4e5eb2ff8549758ee4f2","type":"TRIAL","name":"Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites","canonical_id":"clinicaltrials.gov:NCT01065246","description":"Malignant Ascites Due to Epithelial Carcinoma","metadata":null},{"id":"4b6c60903025493cb7c4a58b9f5f7800","type":"TRIAL","name":"Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","canonical_id":"clinicaltrials.gov:NCT00856583","description":"Schizophrenia","metadata":null},{"id":"0b9a127f39774aa3a0c2e51de6dcc3b4","type":"TRIAL","name":"Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception","canonical_id":"clinicaltrials.gov:NCT01218789","description":"Non 24 Hour Sleep Wake Disorder","metadata":null},{"id":"64e18cfd08354859b902d83aae2a3de7","type":"TRIAL","name":"Safety Study of Tezepelumab (AMG 157) in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT00972179","description":"Healthy Volunteers","metadata":null},{"id":"db7112084c474d8da29d7ef55d321aeb","type":"TRIAL","name":"Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT02096289","description":"Acute Myeloid Leukemia","metadata":null},{"id":"11e0dd31b1604a36ae561ff18d33252f","type":"TRIAL","name":"Safety Study of Zileuton Injection in Patients With Asthma","canonical_id":"clinicaltrials.gov:NCT00299065","description":"Asthma","metadata":null},{"id":"0deb5460cc8a428c8ebc886fca0667d6","type":"TRIAL","name":"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT00889252","description":"Allergic Conjunctivitis","metadata":null},{"id":"5338b078c3f7497eb8893d7024043a31","type":"TRIAL","name":"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT00569777","description":"Allergic Conjunctivitis","metadata":null},{"id":"a33ade3f8d8441dba69ecfcc8b0185b7","type":"TRIAL","name":"Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00763438","description":"Schizophrenia","metadata":null},{"id":"3141e60a1ab64be6b7d648d00ab48dfb","type":"TRIAL","name":"Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT00216294","description":"Obsessive Compulsive Disorder (OCD)","metadata":null},{"id":"160816f8408044d38ed04b66ab307b66","type":"TRIAL","name":"Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis","canonical_id":"clinicaltrials.gov:NCT01086410","description":"Asthma","metadata":null},{"id":"b399ced45bc54c46ac16aae91c5f921e","type":"TRIAL","name":"Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01378429","description":"Perennial Allergic Rhinitis; PAR","metadata":null},{"id":"88bd121b6462448b9bc626f575defe85","type":"TRIAL","name":"Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls","canonical_id":"clinicaltrials.gov:NCT02014064","description":"Continuous Methamphetamine Dependence; Methamphetamine Dependence in Remission","metadata":null},{"id":"708af7b624c24259affbff9b387e4916","type":"TRIAL","name":"Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)","canonical_id":"clinicaltrials.gov:NCT00505232","description":"Mantle Cell Lymphoma","metadata":null},{"id":"730ced2a9cf14164968a18695cf4d3a8","type":"TRIAL","name":"Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00239291","description":"Non-Metastatic Prostate Cancer","metadata":null},{"id":"52309be6c8d54998afbc12d0f3888132","type":"TRIAL","name":"Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD","canonical_id":"clinicaltrials.gov:NCT00894179","description":"Coronary Artery Disease","metadata":null},{"id":"51ed0eeaae7b4e3c874bf37c90ef4035","type":"TRIAL","name":"Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris","canonical_id":"clinicaltrials.gov:NCT07487948","description":"Central Centrifugal Cicatricial Alopecia; Lichen Planopilaris","metadata":null},{"id":"8d9fd11c2c1148dfb29df461fd681192","type":"TRIAL","name":"Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01802970","description":"Metastatic Breast Cancer","metadata":null},{"id":"ff5799273fe245228c4d84d387dbffc0","type":"TRIAL","name":"Safety and Clinical Activity of Itolizumab in aGVHD","canonical_id":"clinicaltrials.gov:NCT05823675","description":"Acute Graft Versus Host Disease","metadata":null},{"id":"bdf6c99cb46341538b6e86677f79c886","type":"TRIAL","name":"Safety and Comfort of AL-4943A Ophthalmic Solution","canonical_id":"clinicaltrials.gov:NCT01326858","description":"Allergic Conjunctivitis","metadata":null},{"id":"e5aea3b4e02e4314848213438f80e793","type":"TRIAL","name":"Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women","canonical_id":"clinicaltrials.gov:NCT02403401","description":"Contraception","metadata":null},{"id":"78a18dd3b19c499988cd8614a03676b5","type":"TRIAL","name":"Safety and Dose Finding Study of Xigris in Hemodialysis Patients","canonical_id":"clinicaltrials.gov:NCT01227187","description":"End Stage Renal Disease","metadata":null},{"id":"1f3b19db81724ce49538f44535c55f66","type":"TRIAL","name":"Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)","canonical_id":"clinicaltrials.gov:NCT00605176","description":"Actinic Keratoses","metadata":null},{"id":"fe582eadf3e8428ca248ffe833b997db","type":"TRIAL","name":"Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)","canonical_id":"clinicaltrials.gov:NCT00603798","description":"Actinic Keratosis","metadata":null},{"id":"32de16238cc54dd3a01aafe088cd9581","type":"TRIAL","name":"Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea","canonical_id":"clinicaltrials.gov:NCT00547898","description":"HIV Associated Diarrhea","metadata":null},{"id":"6166f95c2ac74bab92e98dd5e01600f5","type":"TRIAL","name":"Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)","canonical_id":"clinicaltrials.gov:NCT00163514","description":"Perennial Allergic Rhinitis; Allergic Rhinitis; Hay Fever","metadata":null},{"id":"3b77cd3544654ce4b1e21c589e979c9b","type":"TRIAL","name":"Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT00133107","description":"Lichen Planus, Oral","metadata":null},{"id":"9ce836bf3bd74259892a96ec6fcc6e47","type":"TRIAL","name":"Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT05611528","description":"Homozygous Familial Hypercholesterolemia","metadata":null},{"id":"b31178d6e59e436d9479723895124a3e","type":"TRIAL","name":"Safety and Effectiveness of Generic Fingolimod (Sphingomod\u00ae, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt","canonical_id":"clinicaltrials.gov:NCT05423769","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"61a620e3d542455386734f8a06c35728","type":"TRIAL","name":"Safety and Effectiveness of Juv\u00e9derm\u00ae Volbella With Lidocaine Versus Restylane-L\u00ae for Lip Volume Enhancement","canonical_id":"clinicaltrials.gov:NCT01579305","description":"Lip Volume Enhancement","metadata":null},{"id":"787c32ab50d64338809516fe11a31a60","type":"TRIAL","name":"Safety and Effectiveness of Nintedanib in Korean Patients","canonical_id":"clinicaltrials.gov:NCT04525547","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"41a9a18ce60147ccb7b02563d3d041d5","type":"TRIAL","name":"Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03959540","description":"Parkinson Disease","metadata":null},{"id":"5a1290e0b37e4c079f3b06e8576f789b","type":"TRIAL","name":"Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults","canonical_id":"clinicaltrials.gov:NCT00534495","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"b86b6eb31eb449d9bc27ae458f616a01","type":"TRIAL","name":"Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke","canonical_id":"clinicaltrials.gov:NCT00307203","description":"Tobacco-Use Disorder; Schizophrenia; Psychotic Disorders","metadata":null},{"id":"b0ae0c3e3fe14f488723549d6d2bfbd5","type":"TRIAL","name":"Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia","canonical_id":"clinicaltrials.gov:NCT06771323","description":"Cervical Dystonia","metadata":null},{"id":"5469969e7de845b2bb65f8b13965bde5","type":"TRIAL","name":"Safety and Effectiveness of a Combination Anti-HIV Drug Treatment","canonical_id":"clinicaltrials.gov:NCT00005018","description":"HIV Infections","metadata":null},{"id":"0b1fa08c0287460aa513b5fa8953b8da","type":"TRIAL","name":"Safety and Effectiveness of the Selegiline \"Patch\" for Decreased Mental Function in HIV Patients","canonical_id":"clinicaltrials.gov:NCT00013585","description":"Cognition Disorders; HIV Infections","metadata":null},{"id":"b1e4374cfe3341968f90c76b5e26885a","type":"TRIAL","name":"Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging","canonical_id":"clinicaltrials.gov:NCT04946383","description":"Aging","metadata":null},{"id":"d4e5641b8c884a7295fe5440fb769c11","type":"TRIAL","name":"Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study","canonical_id":"clinicaltrials.gov:NCT05685550","description":"Progression Free Survival(PFS)","metadata":null},{"id":"4b13ec5e0b9349c68e3315c949ea0e03","type":"TRIAL","name":"Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06866548","description":"mCRPC","metadata":null},{"id":"6c16b3d19004432b904ae0bc6a9d1dfb","type":"TRIAL","name":"Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients","canonical_id":"clinicaltrials.gov:NCT04793399","description":"Chronic Phase-Chronic Myeloid Leukemia","metadata":null},{"id":"2ba979fa57ce41f1bf1807b8ba474ace","type":"TRIAL","name":"Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder","canonical_id":"clinicaltrials.gov:NCT01192568","description":"Overactive Detrusor; Neurogenic Bladder","metadata":null},{"id":"de8ba2f6a4464a39956eb3bdbe323baa","type":"TRIAL","name":"Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01051349","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"e1567cf39126489883d7fb5704f38a39","type":"TRIAL","name":"Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00870740","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"733ead4b184a4b7ea70ebebbf3d0c552","type":"TRIAL","name":"Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis","canonical_id":"clinicaltrials.gov:NCT03452228","description":"Severe Hypertriglyceridemia (sHTG)","metadata":null},{"id":"68ab59365f184260844d00da92b653c9","type":"TRIAL","name":"Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.","canonical_id":"clinicaltrials.gov:NCT00314210","description":"Anxiety Disorders","metadata":null},{"id":"5015dc01bc5e4589b74bef22a4b6f30e","type":"TRIAL","name":"Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne","canonical_id":"clinicaltrials.gov:NCT00722761","description":"Acne Vulgaris","metadata":null},{"id":"f25921ccd89542eba8b271a73dfcbfee","type":"TRIAL","name":"Safety and Efficacy Study BRIMOCHOL\u2122 PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia","canonical_id":"clinicaltrials.gov:NCT05270863","description":"Presbyopia","metadata":null},{"id":"71b8abb2834249aca9f7b10fec5d3738","type":"TRIAL","name":"Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT02014363","description":"Major Depressive Disorder","metadata":null},{"id":"cc78a8f1989d4b6da74190013a0c6d03","type":"TRIAL","name":"Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT00352833","description":"Gastric Cancer; Gastric Adenocarcinoma","metadata":null},{"id":"5d770d0c91114c91abff0f536b79f879","type":"TRIAL","name":"Safety and Efficacy Study in Adult Subjects With Acute Migraines","canonical_id":"clinicaltrials.gov:NCT03235479","description":"Migraine, With or Without Aura","metadata":null},{"id":"10c96f7da3ee4928a4802852ccc4893f","type":"TRIAL","name":"Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer","canonical_id":"clinicaltrials.gov:NCT02713529","description":"Pancreatic Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer","metadata":null},{"id":"6d94b7945a0946eab5fa34e754c19327","type":"TRIAL","name":"Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age","canonical_id":"clinicaltrials.gov:NCT01156792","description":"Asthma","metadata":null},{"id":"4aede884024f4e64aee4410e421f508b","type":"TRIAL","name":"Safety and Efficacy Study of BCD-021 Compared to Lucentis\u00ae in Patients With Neovascular Wet Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT02036723","description":"Wet Age-related Macular Degeneration","metadata":null},{"id":"2a132944fd0d48e6b8d93e407e099ea2","type":"TRIAL","name":"Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00061516","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"806fd5dc269d4c259f1a383264914f0e","type":"TRIAL","name":"Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00061542","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"0a8010781cbd4f3d8b5f652b54317e1f","type":"TRIAL","name":"Safety and Efficacy Study of BRIMOCHOL\u2122 PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","canonical_id":"clinicaltrials.gov:NCT05135286","description":"Presbyopia","metadata":null},{"id":"2a045349c1b24028b0e8af2f126bbb66","type":"TRIAL","name":"Safety and Efficacy Study of BRIMOCHOL\u2122, BRIMOCHOL\u2122 F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","canonical_id":"clinicaltrials.gov:NCT04774237","description":"Presbyopia","metadata":null},{"id":"f54833a88beb4715a0431a3050650833","type":"TRIAL","name":"Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00651859","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"ad86b55fe3004c598d96be774c57a0ee","type":"TRIAL","name":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","canonical_id":"clinicaltrials.gov:NCT00907426","description":"Hypotrichosis","metadata":null},{"id":"5426b9009c7f462fbd0b187f29e84170","type":"TRIAL","name":"Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)","canonical_id":"clinicaltrials.gov:NCT00716742","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"67e07a8dff49478fa369c87edd06b4a9","type":"TRIAL","name":"Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00332059","description":"Ocular Hypertension","metadata":null},{"id":"6b683c01c342403a819a89dfd451655f","type":"TRIAL","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00377429","description":"Ovarian Cancer","metadata":null},{"id":"d64425704ae1472cad162d9e0c4b2df9","type":"TRIAL","name":"Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina","canonical_id":"clinicaltrials.gov:NCT02094469","description":"Vasospastic Angina","metadata":null},{"id":"a3d6d4432b0947609049d7947240a8bf","type":"TRIAL","name":"Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne","canonical_id":"clinicaltrials.gov:NCT00713609","description":"Acne Vulgaris","metadata":null},{"id":"163bd306b48349bdabe0eedc1c23be35","type":"TRIAL","name":"Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00390221","description":"Relapsing-Remitting Multiple Sclerosis","metadata":null},{"id":"bbc04d263a1348e39fe5d6d63b122900","type":"TRIAL","name":"Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin","canonical_id":"clinicaltrials.gov:NCT00998686","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d7bf246abbc54ae1a140d7f9165e4678","type":"TRIAL","name":"Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients","canonical_id":"clinicaltrials.gov:NCT01192399","description":"Paroxysmal Nocturnal Hemoglobinuria","metadata":null},{"id":"2fc66910147e4191b9ac8ac0f7ca1f3e","type":"TRIAL","name":"Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma","canonical_id":"clinicaltrials.gov:NCT00485576","description":"Allergic Asthma","metadata":null},{"id":"486ca21996fc404798d61527ca88d941","type":"TRIAL","name":"Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01664923","description":"Prostate Cancer","metadata":null},{"id":"77340ab5af5d4120a02806ece25706f0","type":"TRIAL","name":"Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01889238","description":"Advanced, Androgen Receptor Positive Triple Negative Breast Cancer","metadata":null},{"id":"6197c527a3074e3aa4878cfdc51b898f","type":"TRIAL","name":"Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)","canonical_id":"clinicaltrials.gov:NCT00564421","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"f42c679f6ad94d3cbdee5e4501f43ca7","type":"TRIAL","name":"Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)","canonical_id":"clinicaltrials.gov:NCT00251823","description":"Myocardial Infarction","metadata":null},{"id":"6eb8afc38bcb43daa7949b622b2b1a42","type":"TRIAL","name":"Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects","canonical_id":"clinicaltrials.gov:NCT00091741","description":"HIV Infection","metadata":null},{"id":"9b9211cfef584434a610b4368b7b1652","type":"TRIAL","name":"Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma\uff08FACT\uff09","canonical_id":"clinicaltrials.gov:NCT02390947","description":"Colorectal Cancer Metastatic; Colorectal Cancer Recurrent","metadata":null},{"id":"5128bfe6f7df48ad839ecd4387dea6c5","type":"TRIAL","name":"Safety and Efficacy Study of Fingolimod in Taiwanese Adults (\u2265 20years) With Relapsing Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04480853","description":"Multiple Sclerosis","metadata":null},{"id":"1935509dfc8f462a8e723c9d39395ba3","type":"TRIAL","name":"Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)","canonical_id":"clinicaltrials.gov:NCT01855711","description":"Irritable Colon","metadata":null},{"id":"e561c2632a77476eb08ec76ab5a6d374","type":"TRIAL","name":"Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration","canonical_id":"clinicaltrials.gov:NCT01709721","description":"Management of Chronic Pain","metadata":null},{"id":"10ecb6c4d01540bab95aec127abfde3c","type":"TRIAL","name":"Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00484874","description":"Hodgkin's Disease","metadata":null},{"id":"1c99d85183bc40c593ceae7c66a93344","type":"TRIAL","name":"Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients","canonical_id":"clinicaltrials.gov:NCT01040780","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"af67f096a5dc41088f02fb0e7e92367a","type":"TRIAL","name":"Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma","canonical_id":"clinicaltrials.gov:NCT01306643","description":"Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"8c449e712e69470da31320b703f64cdd","type":"TRIAL","name":"Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT01656980","description":"Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Glioblastoma","metadata":null},{"id":"1adce611e27b42499352e22307a5fd39","type":"TRIAL","name":"Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00381368","description":"Breast Cancer","metadata":null},{"id":"3e74e88557164cc3bf52f098930cd929","type":"TRIAL","name":"Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00992992","description":"Lymphoma, Mantle-Cell","metadata":null},{"id":"917fa4c289a44277b9ea057cb15a2467","type":"TRIAL","name":"Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC","canonical_id":"clinicaltrials.gov:NCT06519721","description":"Hepatocellular Carcinoma","metadata":null},{"id":"0d861ee4ebcc4c1585b751633013dfad","type":"TRIAL","name":"Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03684694","description":"Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma","metadata":null},{"id":"2eb4da869c0146009801affa48339647","type":"TRIAL","name":"Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures","canonical_id":"clinicaltrials.gov:NCT02389621","description":"Chronic Liver Disease; Thrombocytopenia","metadata":null},{"id":"2d5e90e32e764492a332dd8251f6b7a6","type":"TRIAL","name":"Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT00071487","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"714c59d6a6e244bb97bb40e235833c32","type":"TRIAL","name":"Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT00761137","description":"Sialorrhea Secondary to Parkinson's Disease","metadata":null},{"id":"e8b645eefda647c4a9676124e2fee0ad","type":"TRIAL","name":"Safety and Efficacy Study of NV-101 in Dental Patients","canonical_id":"clinicaltrials.gov:NCT00154167","description":"Soft Tissue Anesthesia (Numbness)","metadata":null},{"id":"cfb8c482c0454f17a6afb1ab3c38ceb9","type":"TRIAL","name":"Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01222143","description":"Acute Myeloid Leukemia","metadata":null},{"id":"302fc66e5b5a4b59bf365341e5c88924","type":"TRIAL","name":"Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome","canonical_id":"clinicaltrials.gov:NCT03205995","description":"Thrombotic Microangiopathies; Atypical Hemolytic Uremic Syndrome","metadata":null},{"id":"b1b4cdd9d54c4d079490af7607271f99","type":"TRIAL","name":"Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions","canonical_id":"clinicaltrials.gov:NCT00491894","description":"Cerebral Palsy; Neurological Conditions; Mental Retardation; Sialorrhea","metadata":null},{"id":"8010aa8bf2804021b6e820c4b8b0d753","type":"TRIAL","name":"Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain","canonical_id":"clinicaltrials.gov:NCT01648699","description":"Pain","metadata":null},{"id":"7088328872eb4076832234fae576caa2","type":"TRIAL","name":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","canonical_id":"clinicaltrials.gov:NCT03820986","description":"Malignant Melanoma","metadata":null},{"id":"17ba575f70154cc79253a2c8649aced8","type":"TRIAL","name":"Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00756002","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"e7ac9c27cd204753b06df1263a1f5f00","type":"TRIAL","name":"Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis","canonical_id":"clinicaltrials.gov:NCT03920293","description":"Generalized Myasthenia Gravis","metadata":null},{"id":"fe4639d04475430aa897530ffefe3709","type":"TRIAL","name":"Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT01444417","description":"Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura; Immune Thrombocytopenia","metadata":null},{"id":"601013395ce24308979bade6f0b25fdf","type":"TRIAL","name":"Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","canonical_id":"clinicaltrials.gov:NCT01421498","description":"Keratoconjunctivitis Sicca; Dry Eye Disease","metadata":null},{"id":"fa924cb97f4d40d39b42cd530b9159f4","type":"TRIAL","name":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","canonical_id":"clinicaltrials.gov:NCT02078648","description":"Adult Brain Glioblastoma; Glioblastoma Multiforme","metadata":null},{"id":"62ffca7a82b94f27a793939005e160bc","type":"TRIAL","name":"Safety and Efficacy Study of Sitaxentan Sodium (Thelin\u2122) in Patients With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00080457","description":"Pulmonary Hypertension","metadata":null},{"id":"0698df1904824b6099f52641331f72ab","type":"TRIAL","name":"Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT07738952","description":"Neuromyelitis Optica Spectrum Disorder Attack","metadata":null},{"id":"2ca8d4e0b9234a239642551450f1197c","type":"TRIAL","name":"Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT06776432","description":"Sleep Apnea","metadata":null},{"id":"b39ec88be4104b19a0b30042a1495b10","type":"TRIAL","name":"Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control","canonical_id":"clinicaltrials.gov:NCT03242252","description":"Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 3","metadata":null},{"id":"ccfc4e4a1877465d8efcbfa5b7b1fa64","type":"TRIAL","name":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","canonical_id":"clinicaltrials.gov:NCT01097629","description":"Primary Insomnia","metadata":null},{"id":"8931858c18714cca82d31f9d94cf239e","type":"TRIAL","name":"Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT00081458","description":"Short Bowel Syndrome","metadata":null},{"id":"081638296efb493c82eea9e8c1e35444","type":"TRIAL","name":"Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)","canonical_id":"clinicaltrials.gov:NCT00172185","description":"Short Bowel Syndrome","metadata":null},{"id":"64f2770375a14cefb385cbe294256a9f","type":"TRIAL","name":"Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02737891","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"1b4cfdbd2f3f44d981aa72c660bf2e7d","type":"TRIAL","name":"Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT00198445","description":"Postoperative Complications; Cataract","metadata":null},{"id":"22487d65440546d68dcdc72ebe155af5","type":"TRIAL","name":"Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma","canonical_id":"clinicaltrials.gov:NCT01943422","description":"Melanoma","metadata":null},{"id":"036f9aa8e55e45148e25851c912ac578","type":"TRIAL","name":"Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence","canonical_id":"clinicaltrials.gov:NCT00730522","description":"Methamphetamine Dependence","metadata":null},{"id":"b15b00e68ff84764b07f3297af09db96","type":"TRIAL","name":"Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00290914","description":"Major Depressive Disorder","metadata":null},{"id":"78584896ce274c47970b3cc67548d282","type":"TRIAL","name":"Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation","canonical_id":"clinicaltrials.gov:NCT01586845","description":"Renal Transplantation","metadata":null},{"id":"829fa26753da4e8993fb2eb4525eac3d","type":"TRIAL","name":"Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT00057356","description":"Chronic Heart Failure","metadata":null},{"id":"e97c98d454474b00ba489689d12c1792","type":"TRIAL","name":"Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer","canonical_id":"clinicaltrials.gov:NCT00541281","description":"Hormone Resistant Prostate Cancer; Metastatic Prostate Cancer","metadata":null},{"id":"c4abfa62e4f843fd9997f4b52564fbf1","type":"TRIAL","name":"Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma","canonical_id":"clinicaltrials.gov:NCT00317044","description":"Asthma; GERD","metadata":null},{"id":"660128027a044a69a46e29bfc910072f","type":"TRIAL","name":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","canonical_id":"clinicaltrials.gov:NCT00103740","description":"Paget's Disease of Bone","metadata":null},{"id":"a61a7f896901462080f7043f95b06ae2","type":"TRIAL","name":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","canonical_id":"clinicaltrials.gov:NCT00051636","description":"Paget's Disease of Bone","metadata":null},{"id":"2c47e1937a604cb0b318298d02c47d04","type":"TRIAL","name":"Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT04574362","description":"Acute Migraine","metadata":null},{"id":"9d7e87de684a4d719f5a495630035f17","type":"TRIAL","name":"Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita","canonical_id":"clinicaltrials.gov:NCT01001598","description":"Fanconi Anemia; Dyskeratosis Congenita","metadata":null},{"id":"4db62a0c1d324180861ce3d6d82bd671","type":"TRIAL","name":"Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)","canonical_id":"clinicaltrials.gov:NCT01915823","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"642622c7e70d4d86ac21888a29e04968","type":"TRIAL","name":"Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01279083","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"bd9c434471144e088cfb7595fd72d796","type":"TRIAL","name":"Safety and Efficacy in Adult Subjects With Acute Migraines","canonical_id":"clinicaltrials.gov:NCT03237845","description":"Migraine, With or Without Aura","metadata":null},{"id":"1007cd55c74042ddab2442a174922a71","type":"TRIAL","name":"Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)","canonical_id":"clinicaltrials.gov:NCT01817530","description":"Heavy Uterine Bleeding; Uterine Fibroids","metadata":null},{"id":"51cf9e0f29644d0f90a221c0e39f5652","type":"TRIAL","name":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","canonical_id":"clinicaltrials.gov:NCT06349759","description":"Mesopic Vision; Night Vision Loss","metadata":null},{"id":"08d05659d59e43918407e9dc7b5dc559","type":"TRIAL","name":"Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants","canonical_id":"clinicaltrials.gov:NCT05133050","description":"Alport Syndrome","metadata":null},{"id":"d4233d532b68426fae1d2421b21d4353","type":"TRIAL","name":"Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00072839","description":"Crohn's Disease","metadata":null},{"id":"3a0c58aa191a4e8f85d715c0ddb0146e","type":"TRIAL","name":"Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008","canonical_id":"clinicaltrials.gov:NCT00308438","description":"Crohn's Disease","metadata":null},{"id":"22f86b9806494cc697f4b63831eec5b2","type":"TRIAL","name":"Safety and Efficacy of AR1005 in Patients with Lewy Body Disease","canonical_id":"clinicaltrials.gov:NCT06537076","description":"Lewy Body Dementia","metadata":null},{"id":"96302197803b46c291a24ea667ef8f9d","type":"TRIAL","name":"Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT03916081","description":"Atopic Dermatitis","metadata":null},{"id":"7867b9df83c64199a12f3710c3d12757","type":"TRIAL","name":"Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF","canonical_id":"clinicaltrials.gov:NCT00607750","description":"Age-Related Macular Degeneration","metadata":null},{"id":"98dd48e68d954811af8a7caad187ac5f","type":"TRIAL","name":"Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00414206","description":"Macular Degeneration","metadata":null},{"id":"f23e1bada200430bbe2bfd67ce593d11","type":"TRIAL","name":"Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)","canonical_id":"clinicaltrials.gov:NCT03512262","description":"Osteoporosis; Osteoporosis, Age-Related; Osteoporosis Localized to Spine; Age Related Osteoporosis; Osteoporosis Senile; Osteoporosis of Vertebrae","metadata":null},{"id":"7778c4e773a540c885657477bd9408aa","type":"TRIAL","name":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","canonical_id":"clinicaltrials.gov:NCT03464136","description":"Crohn Disease","metadata":null},{"id":"60850115d6d841fda3daa63e73f50ba7","type":"TRIAL","name":"Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT00195689","description":"Psoriatic Arthritis","metadata":null},{"id":"becc0c91217d4b98b7f4f31542f94c30","type":"TRIAL","name":"Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00259857","description":"Osteoporosis","metadata":null},{"id":"59cdd3d5606b45fca513cc7196d0c274","type":"TRIAL","name":"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg","canonical_id":"clinicaltrials.gov:NCT00529451","description":"Hypertension","metadata":null},{"id":"d972e7a7812f4dc492536b87d69e5375","type":"TRIAL","name":"Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age","canonical_id":"clinicaltrials.gov:NCT01150357","description":"Hypertension","metadata":null},{"id":"da948355c74c463a92ae38311785c3bd","type":"TRIAL","name":"Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome","canonical_id":"clinicaltrials.gov:NCT05926505","description":"Post-Acute COVID-19 Syndrome; Post-Acute COVID-19; Long COVID","metadata":null},{"id":"e9a9ce02dc534689808116a7d436157b","type":"TRIAL","name":"Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 \u03bcg/Kgevery 8 Hours for Three Consecutive Days After Surgery.","canonical_id":"clinicaltrials.gov:NCT07514637","description":"Patients Who Undergo Pancreaticoduodenectomy","metadata":null},{"id":"a7836a253dab48bb8e8eaea014c26037","type":"TRIAL","name":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT04916093","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"c7c96e8de5304f6daaed1d154319a110","type":"TRIAL","name":"Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00250679","description":"Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema","metadata":null},{"id":"13446933096f4ac195e8db0dfbacf3c9","type":"TRIAL","name":"Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO","canonical_id":"clinicaltrials.gov:NCT04925167","description":"Respiratory Failure","metadata":null},{"id":"06faaf8c94a64c1787f9a1fc5cc669c1","type":"TRIAL","name":"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months","canonical_id":"clinicaltrials.gov:NCT04826198","description":"Ovarian Cancer","metadata":null},{"id":"165887f333d14ad085c0d3bb283596f1","type":"TRIAL","name":"Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure","canonical_id":"clinicaltrials.gov:NCT00038662","description":"Prostatic Neoplasms","metadata":null},{"id":"67df2b6ff8c8413d991eb2de63527885","type":"TRIAL","name":"Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT00362115","description":"Hypertension","metadata":null},{"id":"cbe8d7ee19cc47c7ad30308824025f97","type":"TRIAL","name":"Safety and Efficacy of BFH772 in Psoriasis Patients","canonical_id":"clinicaltrials.gov:NCT00987870","description":"Psoriasis; Arthritis","metadata":null},{"id":"00fff1e0eb134a31a906bcf8205d1f50","type":"TRIAL","name":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders","canonical_id":"clinicaltrials.gov:NCT05262517","description":"Temporomandibular Disorders (TMD)","metadata":null},{"id":"9f0b2a67d1884ad880a60dbe94ede01b","type":"TRIAL","name":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis","canonical_id":"clinicaltrials.gov:NCT05248997","description":"Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps","metadata":null},{"id":"6744200a30db42de866402a0b6de20c5","type":"TRIAL","name":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","canonical_id":"clinicaltrials.gov:NCT00793624","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"8007fd821af04439a202a04b0b194576","type":"TRIAL","name":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II","canonical_id":"clinicaltrials.gov:NCT00796653","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"b4426b54d0c14d5994cb1e73f8c940ef","type":"TRIAL","name":"Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00719264","description":"Carcinoma; Adenocarcinoma; Renal Cell; Nephroid Carcinoma; Hypernephroid","metadata":null},{"id":"19214cb7cd48425e998b723892680c5e","type":"TRIAL","name":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","canonical_id":"clinicaltrials.gov:NCT02769481","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d106d3fdda2d4e6090c357a2be78ee8e","type":"TRIAL","name":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","canonical_id":"clinicaltrials.gov:NCT03259789","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"f181ad2463334ef6b0f296d0009d7f69","type":"TRIAL","name":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","canonical_id":"clinicaltrials.gov:NCT03115112","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"92409159a60d4730889b62d241d98c7f","type":"TRIAL","name":"Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT02715258","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"866767af47fb4923bd4ba5d18b899c61","type":"TRIAL","name":"Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT03557658","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"93ec2e92c19d49e8be2861d0a99ac30b","type":"TRIAL","name":"Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment","canonical_id":"clinicaltrials.gov:NCT02836873","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"613d29b053244211b102f2b70e681acd","type":"TRIAL","name":"Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00541242","description":"Ocular Hypertension; Glaucoma","metadata":null},{"id":"d62d88daedc64a96abe9e94fc54a17f5","type":"TRIAL","name":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","canonical_id":"clinicaltrials.gov:NCT00693420","description":"Eyelashes","metadata":null},{"id":"559b2194775a4c728b6b7113e5a2f7b4","type":"TRIAL","name":"Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children","canonical_id":"clinicaltrials.gov:NCT01023841","description":"Eyelash Hypotrichosis; Alopecia Areata","metadata":null},{"id":"10d5d115583843549dcd8d284c86c60e","type":"TRIAL","name":"Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI","canonical_id":"clinicaltrials.gov:NCT04475835","description":"STEMI With Multivessel Coronary Disease","metadata":null},{"id":"a8dfed7400bb4917a0accfe2930fce27","type":"TRIAL","name":"Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation","canonical_id":"clinicaltrials.gov:NCT03965208","description":"Extracorporeal Membrane Oxygenation Complication; Anticoagulants","metadata":null},{"id":"e9b33239f2714ee4962cc1f1a5529bd5","type":"TRIAL","name":"Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain","canonical_id":"clinicaltrials.gov:NCT00312195","description":"Chronic Non-malignant Pain","metadata":null},{"id":"5be9c655c244494ebc51c320ad3a123e","type":"TRIAL","name":"Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)","canonical_id":"clinicaltrials.gov:NCT05499026","description":"Cerebrotendinous Xanthomatoses","metadata":null},{"id":"d6102a44404a472dbd1c82ce9532e0ab","type":"TRIAL","name":"Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07076823","description":"Colorectal Cancer; SGLT-2 Inhibitor","metadata":null},{"id":"17f9517b3b56425d9008d737f4948854","type":"TRIAL","name":"Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1\u2265 50%","canonical_id":"clinicaltrials.gov:NCT04139317","description":"Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"e6f14508c5344c548e7f791a58083478","type":"TRIAL","name":"Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen","canonical_id":"clinicaltrials.gov:NCT00638807","description":"Osteoarthritis, Knee","metadata":null},{"id":"3793cf653bde4bff90cdf44321494b44","type":"TRIAL","name":"Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT01191450","description":"Arterial Hypertension","metadata":null},{"id":"ea010d8a744949b0ad33bb995119dd1d","type":"TRIAL","name":"Safety and Efficacy of Chlorthalidone in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT03325114","description":"Type 1 Diabetes Mellitus; Hypercalciuria","metadata":null},{"id":"58ed44e2911b4d60a1bb3a8d41825e28","type":"TRIAL","name":"Safety and Efficacy of Chronic Hypnotic Use","canonical_id":"clinicaltrials.gov:NCT01006525","description":"Primary Insomnia","metadata":null},{"id":"c8b6c1f7f6404407b953db62fb352981","type":"TRIAL","name":"Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)","canonical_id":"clinicaltrials.gov:NCT00305487","description":"Hay Fever; Seasonal Allergic Rhinitis","metadata":null},{"id":"719d86dcdfc247e4bd0bc59c380ef51d","type":"TRIAL","name":"Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial","canonical_id":"clinicaltrials.gov:NCT07225387","description":"Lupus Nephritis","metadata":null},{"id":"9463578d14e04c43b12e1603337bc45a","type":"TRIAL","name":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01606007","description":"Type 2 Diabetes","metadata":null},{"id":"8f24ff7e3c774d93bc6d962b65915df5","type":"TRIAL","name":"Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients","canonical_id":"clinicaltrials.gov:NCT00684164","description":"Hyponatremia","metadata":null},{"id":"f7cbd5562b5847d78d374f98fbaba4fd","type":"TRIAL","name":"Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)","canonical_id":"clinicaltrials.gov:NCT00843986","description":"Hyponatremia; Acute Decompensated Heart Failure","metadata":null},{"id":"e90859356dd1447f9797fc2981f68ad3","type":"TRIAL","name":"Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)","canonical_id":"clinicaltrials.gov:NCT06904872","description":"Short Bowel Syndrome; Malabsorption Syndromes; Short Gut Syndrome; Post-Op Complication; Functional Gastrointestinal Disorders","metadata":null},{"id":"b4daf93be3d740599ee10cd536b4d0eb","type":"TRIAL","name":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients","canonical_id":"clinicaltrials.gov:NCT01016912","description":"Hepatitis C Infection","metadata":null},{"id":"8a79bfd54e2349369dce14ad984c23d7","type":"TRIAL","name":"Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03746652","description":"Multiple Myeloma","metadata":null},{"id":"6e7c3107e394415284bf71a7e5cc8db2","type":"TRIAL","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","canonical_id":"clinicaltrials.gov:NCT00434148","description":"Cushing's Disease","metadata":null},{"id":"13ba3676c4d64ac68e069d288b079372","type":"TRIAL","name":"Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01099774","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"1f81b91253af4e28b95b1786fc10432c","type":"TRIAL","name":"Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis","canonical_id":"clinicaltrials.gov:NCT01201798","description":"Endogenous Anterior Uveitis","metadata":null},{"id":"769206cbac4d49be874450ac37c02076","type":"TRIAL","name":"Safety and Efficacy of Eculizumab in High-risk TA-TMA","canonical_id":"clinicaltrials.gov:NCT07707687","description":"Transplant-Associated Thrombotic Microangiopathy (TA-TMA)","metadata":null},{"id":"6e3b811d057b4f3e99f20dbcaeb32cb5","type":"TRIAL","name":"Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)","canonical_id":"clinicaltrials.gov:NCT01997229","description":"Refractory Generalized Myasthenia Gravis","metadata":null},{"id":"1f40db206cda43c5a8ad83d84d94c5dd","type":"TRIAL","name":"Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids","canonical_id":"clinicaltrials.gov:NCT01441635","description":"Heavy Uterine Bleeding; Uterine Fibroids","metadata":null},{"id":"4e6fb43b24374b37a901f7d5b6c875c3","type":"TRIAL","name":"Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs","canonical_id":"clinicaltrials.gov:NCT00634985","description":"Migraine","metadata":null},{"id":"60b4853f2ec245cd9553ee49fe9c0c50","type":"TRIAL","name":"Safety and Efficacy of Eltrombopag at Escalated Doses","canonical_id":"clinicaltrials.gov:NCT01880047","description":"Immune Thrombocytopenia; Platelet Disorder","metadata":null},{"id":"d5ab858bcd3e4e198991c6b6d25b82f8","type":"TRIAL","name":"Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05206656","description":"Metastatic Breast Cancer","metadata":null},{"id":"4c39366ebdeb45c688d14d9bd8d3e198","type":"TRIAL","name":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","canonical_id":"clinicaltrials.gov:NCT02036515","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"c33deb2b5fa64294b20f663f1b0c5a29","type":"TRIAL","name":"Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT01554163","description":"Osteoarthritis of the Knee","metadata":null},{"id":"a7a960c216874a07bf47f3372210abb9","type":"TRIAL","name":"Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02447302","description":"Ulcerative Colitis","metadata":null},{"id":"1fbe70a64b6249d882346cfc286e0b38","type":"TRIAL","name":"Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT02662569","description":"Diabetes, Hyperlipidemia, Mixed Dyslipidemia","metadata":null},{"id":"5fe9485c383f4af79b96f1808d1a21fc","type":"TRIAL","name":"Safety and Efficacy of Evolocumab in Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT05697185","description":"Ischemic Stroke, Acute","metadata":null},{"id":"47eb4891920d41ccad9e19ceeda91d47","type":"TRIAL","name":"Safety and Efficacy of Faricimab in Patients With NPDR","canonical_id":"clinicaltrials.gov:NCT05681884","description":"Non-Proliferative Diabetic Retinopathy","metadata":null},{"id":"2ba5d1b022c9450782d7b5cbd22b59a2","type":"TRIAL","name":"Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.","canonical_id":"clinicaltrials.gov:NCT07585526","description":"MASLD; Chronic Kidney Diseases","metadata":null},{"id":"cbc6fff84718428bbb70d7f56d99204a","type":"TRIAL","name":"Safety and Efficacy of Fingolimod in MS Patients in China","canonical_id":"clinicaltrials.gov:NCT01941004","description":"Multiple Sclerosis (Relapsing Remitting)","metadata":null},{"id":"fe23ebda28d9471d8cdf5b3fa1025c77","type":"TRIAL","name":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01892722","description":"Multiple Sclerosis","metadata":null},{"id":"2993c2d1b0694e308ad9adc053bfd87d","type":"TRIAL","name":"Safety and Efficacy of Firmagon\u00ae (Degarelix) for Injection","canonical_id":"clinicaltrials.gov:NCT02886598","description":"Prostate Cancer","metadata":null},{"id":"1cc04a7d50474ee9a9b8b6961c14ab30","type":"TRIAL","name":"Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy","canonical_id":"clinicaltrials.gov:NCT00468871","description":"Non-infectious Uveitis","metadata":null},{"id":"2d75cd11102e483aa95663fcd2ebf981","type":"TRIAL","name":"Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL","canonical_id":"clinicaltrials.gov:NCT04334408","description":"Cadasil; Migraine","metadata":null},{"id":"cc46205b776b45b786acdfd01de8be13","type":"TRIAL","name":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06685276","description":"Colorectal Cancer Metastatic","metadata":null},{"id":"372d5d302901459a8f24f0d87fab2cc9","type":"TRIAL","name":"Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT07392346","description":"Gastric Cancer Adenocarcinoma Metastatic","metadata":null},{"id":"fb0fb6a55a8a42c897b02c55059d94c9","type":"TRIAL","name":"Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride","canonical_id":"clinicaltrials.gov:NCT01233622","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"e66283c9f118469db59d9cb7130f184e","type":"TRIAL","name":"Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism","canonical_id":"clinicaltrials.gov:NCT03284463","description":"Acute Stroke","metadata":null},{"id":"1d0fd5a71d5d4dfea11232c3ad2c86c0","type":"TRIAL","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06771622","description":"Solid Cancer","metadata":null},{"id":"375b9e33413f4ac3b968efaf559e6484","type":"TRIAL","name":"Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01393106","description":"Hodgkin Lymphoma","metadata":null},{"id":"5bb2f0e2a11f4caba0d196ee174165f3","type":"TRIAL","name":"Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00219726","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"72a16e704c6b4f7590a6ed55c5da3a28","type":"TRIAL","name":"Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses","canonical_id":"clinicaltrials.gov:NCT00175643","description":"Actinic Keratoses","metadata":null},{"id":"bedd92a39cb840eaa36f76308916b551","type":"TRIAL","name":"Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT02866695","description":"Actinic Keratosis","metadata":null},{"id":"6f8607face2345c98d1621ec13fa7a76","type":"TRIAL","name":"Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT01820260","description":"Actinic Keratosis","metadata":null},{"id":"9377d38f9a8a478d90cc6d4c724862e4","type":"TRIAL","name":"Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00453414","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"fa6de5d0fd78404099ef36b4484110cd","type":"TRIAL","name":"Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE","canonical_id":"clinicaltrials.gov:NCT02630316","description":"Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema","metadata":null},{"id":"c2321691448041a28b26888b36f18cf1","type":"TRIAL","name":"Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT00576459","description":"Diabetic Macular Edema","metadata":null},{"id":"0a63791e1fab4e468009628223b91901","type":"TRIAL","name":"Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19","canonical_id":"clinicaltrials.gov:NCT04551755","description":"Covid19","metadata":null},{"id":"57111c8f5d0148f19751bc4aaf83f4c1","type":"TRIAL","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","canonical_id":"clinicaltrials.gov:NCT04502394","description":"Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma","metadata":null},{"id":"27121c5374f347c59354c8f3a239f1c5","type":"TRIAL","name":"Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study","canonical_id":"clinicaltrials.gov:NCT06874192","description":"Statin Adverse Reaction","metadata":null},{"id":"76c45cf95c1c43aab4fedbb5e1438cc3","type":"TRIAL","name":"Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures","canonical_id":"clinicaltrials.gov:NCT02408549","description":"Epilepsy","metadata":null},{"id":"09afa09ddb014f1c80658e094656c0fe","type":"TRIAL","name":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01254305","description":"Major Depressive Disorder","metadata":null},{"id":"fdc66c27565b446ab33fd05bd38358b8","type":"TRIAL","name":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00969150","description":"Major Depressive Disorder","metadata":null},{"id":"3d84cc45dc324582970c1bd54a245ecb","type":"TRIAL","name":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00969709","description":"Major Depressive Disorder","metadata":null},{"id":"f0d99d17ff4443029918ce0ff0f57696","type":"TRIAL","name":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01034462","description":"Major Depressive Disorder","metadata":null},{"id":"c58849659055434188748ea8404739df","type":"TRIAL","name":"Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01377194","description":"Major Depressive Disorder","metadata":null},{"id":"cc57e54c46374421817c7d22595f92bb","type":"TRIAL","name":"Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT02431806","description":"Major Depressive Disorder","metadata":null},{"id":"c1d7eb5515164f59977c40ccb0394787","type":"TRIAL","name":"Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating","canonical_id":"clinicaltrials.gov:NCT01642914","description":"Chronic Constipation; Constipation","metadata":null},{"id":"802ba634e67140aaba5eff65495f6252","type":"TRIAL","name":"Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment","canonical_id":"clinicaltrials.gov:NCT01087502","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"5b606610919f41b6906f69241f7bbf2c","type":"TRIAL","name":"Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone","canonical_id":"clinicaltrials.gov:NCT01512108","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"6acddea1461547f781958abdba112e66","type":"TRIAL","name":"Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study","canonical_id":"clinicaltrials.gov:NCT02974387","description":"Must be PRK Candidate","metadata":null},{"id":"fd9a60a4b74b43198fea79a6b6dd82d9","type":"TRIAL","name":"Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting","canonical_id":"clinicaltrials.gov:NCT03195673","description":"Carotid Artery Stenosis","metadata":null},{"id":"422b927851ad41f28b2d31b003a979d1","type":"TRIAL","name":"Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS","canonical_id":"clinicaltrials.gov:NCT02415803","description":"Non ST Segment Elevation Acute Coronary Syndrome","metadata":null},{"id":"04ec08971c9d48e9aad9e3741067ceae","type":"TRIAL","name":"Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO","canonical_id":"clinicaltrials.gov:NCT07499037","description":"Pneumonia; Heart Failure","metadata":null},{"id":"0038bd80b9da412e824a4634a77a8eef","type":"TRIAL","name":"Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation","canonical_id":"clinicaltrials.gov:NCT00452335","description":"Constipation","metadata":null},{"id":"b263c748c21148fdad2c740c59f0aa37","type":"TRIAL","name":"Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain","canonical_id":"clinicaltrials.gov:NCT00170898","description":"Musculoskeletal Pain","metadata":null},{"id":"f269f46eccf245609d96197bff8bcc94","type":"TRIAL","name":"Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension","canonical_id":"clinicaltrials.gov:NCT00267176","description":"Osteoarthritis; Controlled Hypertension","metadata":null},{"id":"28879fc813254790ad7085ee600eb4d6","type":"TRIAL","name":"Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome","canonical_id":"clinicaltrials.gov:NCT02180516","description":"Arthritis, Rheumatoid","metadata":null},{"id":"59f38d4f86a64fdea58ea0bf17236e2f","type":"TRIAL","name":"Safety and Efficacy of Miglustat in Chinese NPC Patients","canonical_id":"clinicaltrials.gov:NCT03910621","description":"Niemann-Pick Disease, Type C","metadata":null},{"id":"dc3de60822b846cbb4646e99179a6ec8","type":"TRIAL","name":"Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01328002","description":"Primary Fibromyalgia","metadata":null},{"id":"00b11b5ee7214ab5973f26d05803b88e","type":"TRIAL","name":"Safety and Efficacy of Mobic\u00ae Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions","canonical_id":"clinicaltrials.gov:NCT02184052","description":"Arthritis, Rheumatoid","metadata":null},{"id":"c8faf813d5e648f8995573fb6f002257","type":"TRIAL","name":"Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia","canonical_id":"clinicaltrials.gov:NCT01998828","description":"Polycythemia Vera; Essential Thrombocythemia","metadata":null},{"id":"1eb38d73dd224e9082b27bcf70e12cbe","type":"TRIAL","name":"Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome","canonical_id":"clinicaltrials.gov:NCT03530293","description":"Tourette Syndrome","metadata":null},{"id":"898f8c2f6d154a8fbd58bcc20b3a2486","type":"TRIAL","name":"Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00811941","description":"Alcohol Dependence","metadata":null},{"id":"70c43f362c8c42ad8b019acfd4c7b886","type":"TRIAL","name":"Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00030966","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"5fa68ca8a7fa443d908959ef1973e5fc","type":"TRIAL","name":"Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00055536","description":"Crohn's Disease","metadata":null},{"id":"03526c5a2aa04f62896ba627cb05f793","type":"TRIAL","name":"Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00032786","description":"Crohn's Disease","metadata":null},{"id":"74dea2b5497042ae94082fe94a682d37","type":"TRIAL","name":"Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients","canonical_id":"clinicaltrials.gov:NCT01275196","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"698b5f976c9d4243b38f748ef7ab8f08","type":"TRIAL","name":"Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica","canonical_id":"clinicaltrials.gov:NCT01816334","description":"Sciatica","metadata":null},{"id":"4550a31b37aa4575843f3afa77e2aa47","type":"TRIAL","name":"Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00097071","description":"Diabetes; Diabetes Mellitus, Type 1","metadata":null},{"id":"7026a62c4f0e4f7e8dc2cc2c470ceeac","type":"TRIAL","name":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","canonical_id":"clinicaltrials.gov:NCT04638660","description":"Dim Light Vision Disturbances","metadata":null},{"id":"1820c1f5d67f44a1a1268e050a65c9a6","type":"TRIAL","name":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis","canonical_id":"clinicaltrials.gov:NCT04620213","description":"Mydriasis; Dilation","metadata":null},{"id":"5d0dc6ba192f4605b75edeb56decb8a6","type":"TRIAL","name":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)","canonical_id":"clinicaltrials.gov:NCT05134974","description":"Mydriasis; Dilation","metadata":null},{"id":"a969f834ae1b4648bc3c7c239c334684","type":"TRIAL","name":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","canonical_id":"clinicaltrials.gov:NCT05646719","description":"Presbyopia","metadata":null},{"id":"69e6cf82a3864bd6b249ca109158f2ba","type":"TRIAL","name":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","canonical_id":"clinicaltrials.gov:NCT04675151","description":"Presbyopia","metadata":null},{"id":"0e15da3af7ae463187db79f7e1e36dfa","type":"TRIAL","name":"Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis","canonical_id":"clinicaltrials.gov:NCT00979615","description":"Vasomotor Rhinitis","metadata":null},{"id":"ad9ca098d7a2457a8716d2db9a17202a","type":"TRIAL","name":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma","canonical_id":"clinicaltrials.gov:NCT03960866","description":"Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"ee7841e466c448c1a0d93045f0473e6f","type":"TRIAL","name":"Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis","canonical_id":"clinicaltrials.gov:NCT04024891","description":"Mydriasis; Dilation","metadata":null},{"id":"8d118ce3f59f4c10942b5db3b955b1e4","type":"TRIAL","name":"Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT05567406","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"6c0bd55ef32240369a654608ef9d71d8","type":"TRIAL","name":"Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT04556734","description":"Alopecia Areata","metadata":null},{"id":"0a90b647989649faa1a7470b1e2614e8","type":"TRIAL","name":"Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00041717","description":"Spinal Cord Injury; Muscle Spasticity","metadata":null},{"id":"551ee9b1d3d94c449909946ec176692a","type":"TRIAL","name":"Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT01683838","description":"Spinal Cord Injury; Muscle Spasticity","metadata":null},{"id":"eb46b607c7244e5e9e83bac284f5b265","type":"TRIAL","name":"Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT02663895","description":"Systemic Sclerosis; Calcinosis","metadata":null},{"id":"c5f078ae5db54e4c9718e5009d25549c","type":"TRIAL","name":"Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved","canonical_id":"clinicaltrials.gov:NCT02530320","description":"Oligodendroglioma; Oligoastrocytoma","metadata":null},{"id":"4d1e055d54ee429bb9e0d077d082798d","type":"TRIAL","name":"Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","canonical_id":"clinicaltrials.gov:NCT07282509","description":"Advanced Hepatocellular Carcinoma (HCC)","metadata":null},{"id":"bb2cc5f6b8f141ab878774e2723d3c98","type":"TRIAL","name":"Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT00828295","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"5969b222ca1e4bfc9e7fbfe8d80ec255","type":"TRIAL","name":"Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)","canonical_id":"clinicaltrials.gov:NCT01020487","description":"Chronic Kidney Disease Stage 3 and 4","metadata":null},{"id":"8170e0962cdc47079a00736fa1d834b9","type":"TRIAL","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","canonical_id":"clinicaltrials.gov:NCT00600886","description":"Acromegaly","metadata":null},{"id":"d802dc86bc35473a9a8bcc0c1f7f8030","type":"TRIAL","name":"Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)","canonical_id":"clinicaltrials.gov:NCT00724295","description":"Hepatitis C, Chronic; Hepatitis C","metadata":null},{"id":"e811d74dd88e45c4b42c63e98d1b0524","type":"TRIAL","name":"Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.","canonical_id":"clinicaltrials.gov:NCT00752609","description":"Anemia","metadata":null},{"id":"aeef6e5d3e0e4a9986fa3e4f92b28561","type":"TRIAL","name":"Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","canonical_id":"clinicaltrials.gov:NCT00598442","description":"Chronic Renal Failure; Chronic Kidney Disease; Anemia","metadata":null},{"id":"da93a6ee224b484f8ebe3c192bd34733","type":"TRIAL","name":"Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess","canonical_id":"clinicaltrials.gov:NCT03882034","description":"Pituitary Disease","metadata":null},{"id":"f21385a1f7e043be91b500fe1748fafa","type":"TRIAL","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","canonical_id":"clinicaltrials.gov:NCT03407144","description":"Hodgkin Lymphoma","metadata":null},{"id":"434c45b8471d4c1d9900abaec13fff75","type":"TRIAL","name":"Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT00571662","description":"Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplastic Syndromes; Multiple Myeloma; Non-Hodgkins Lymphoma; Hodgkins Disease; Peripheral T-cell Lymphoma","metadata":null},{"id":"f911ee9db83849a1a44b78c4139c3073","type":"TRIAL","name":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","canonical_id":"clinicaltrials.gov:NCT03751631","description":"Mydriasis","metadata":null},{"id":"3a860baab2c9464c85040fef91b6e3ba","type":"TRIAL","name":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","canonical_id":"clinicaltrials.gov:NCT03751098","description":"Mydriasis","metadata":null},{"id":"2fc15cfc5a7d40b2955ff07cfb6f92df","type":"TRIAL","name":"Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT05119920","description":"Dry Eye Disease; Kerato Conjunctivitis Sicca","metadata":null},{"id":"efa737b05942486c9840ab385223ceaf","type":"TRIAL","name":"Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia","canonical_id":"clinicaltrials.gov:NCT05124275","description":"Presbyopia","metadata":null},{"id":"1ab960d48d964f1497725b2d592e4cbb","type":"TRIAL","name":"Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression","canonical_id":"clinicaltrials.gov:NCT03482882","description":"Treatment of Depression in Adults With Parkinson's Disease (PD)","metadata":null},{"id":"904d206124d6454381327e6d8e2e70e1","type":"TRIAL","name":"Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification","canonical_id":"clinicaltrials.gov:NCT00124709","description":"Atopic Dermatitis","metadata":null},{"id":"ddc68d978aad42df9f4ce5736270c559","type":"TRIAL","name":"Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca","canonical_id":"clinicaltrials.gov:NCT00128245","description":"Keratoconjunctivitis Sicca","metadata":null},{"id":"d31f01c69ec44b5ab2dc3cffd3267f19","type":"TRIAL","name":"Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1","canonical_id":"clinicaltrials.gov:NCT04886518","description":"Myotonic Dystrophy 1; Excessive Daytime Sleepiness","metadata":null},{"id":"d7ec40a92310461c9a7ce9d2c0a7c9c2","type":"TRIAL","name":"Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","canonical_id":"clinicaltrials.gov:NCT04070443","description":"Philadelphia Chromosome Positive CML; BCR-ABL Positive Chronic Myelogenous Leukemia","metadata":null},{"id":"4e7bdec83831407f87b56d0e79c4bd1f","type":"TRIAL","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03934372","description":"Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphocytic Leukemia; Leukemia; Lymphoma; Solid Tumors","metadata":null},{"id":"051d7633f2bc4cb68bcb82b65f46678c","type":"TRIAL","name":"Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China","canonical_id":"clinicaltrials.gov:NCT03358212","description":"Giant Cell Tumor of Bone","metadata":null},{"id":"6a9adc4d532b4bf3b3793a279c2521dc","type":"TRIAL","name":"Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)","canonical_id":"clinicaltrials.gov:NCT06611592","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"8ad99926a48a4ae88a260ffd651f61f5","type":"TRIAL","name":"Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02172573","description":"Parkinson Disease","metadata":null},{"id":"d6f6c083284843898cd03c5d3794c05b","type":"TRIAL","name":"Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature","canonical_id":"clinicaltrials.gov:NCT02014454","description":"Retinopathy of Prematurity","metadata":null},{"id":"c3497fdee96c4020be52b77273518de8","type":"TRIAL","name":"Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH","canonical_id":"clinicaltrials.gov:NCT01260129","description":"Benign Prostatic Hypertrophy","metadata":null},{"id":"10a9db5284e74323bdff7cc224ea1f67","type":"TRIAL","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","canonical_id":"clinicaltrials.gov:NCT03793478","description":"Acute Myeloid Leukemia","metadata":null},{"id":"fcf49c62a1fd41eb84b82cc856084ee8","type":"TRIAL","name":"Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00755495","description":"Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"5ab223f172224c959f434b5c57a7057c","type":"TRIAL","name":"Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00237497","description":"Balance","metadata":null},{"id":"12d1811723cf4cd99e99dbb956239c48","type":"TRIAL","name":"Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.","canonical_id":"clinicaltrials.gov:NCT00671294","description":"Chronic Insomnia","metadata":null},{"id":"a9013e80f2b542a78ec1cbb3a049fd0b","type":"TRIAL","name":"Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00366119","description":"Essential Hypertension","metadata":null},{"id":"59e7dfea69824bb294d81a11c43fa527","type":"TRIAL","name":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT01131585","description":"Visual Impairment Due to Diabetic Macular Edema","metadata":null},{"id":"6d37c9ead3e844dcae14206f2071f9fc","type":"TRIAL","name":"Safety and Efficacy of Rasagiline in Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT01192503","description":"Restless Legs Syndrome","metadata":null},{"id":"5c396250d4c74298a6f1a8b4db7ab4bf","type":"TRIAL","name":"Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir","canonical_id":"clinicaltrials.gov:NCT02092116","description":"HIV I Infection","metadata":null},{"id":"46f82f19c6574003903e760df6b4c6d2","type":"TRIAL","name":"Safety and Efficacy of Ruxolitinib for COVID-19","canonical_id":"clinicaltrials.gov:NCT04348071","description":"COVID-19","metadata":null},{"id":"8419518212c24fa8af4866acebea25d1","type":"TRIAL","name":"Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial","canonical_id":"clinicaltrials.gov:NCT07840456","description":"Carcinoma, Squamous Cell of Head and Neck HNSCC","metadata":null},{"id":"9eb30ca65194490985959efd01ad38e6","type":"TRIAL","name":"Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT00151736","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"100d615dc5de4ba1b2d171815ea9e5f8","type":"TRIAL","name":"Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)","canonical_id":"clinicaltrials.gov:NCT00293111","description":"Multiple Myeloma","metadata":null},{"id":"0426a3c1f10f468a8febed302cc37e2b","type":"TRIAL","name":"Safety and Efficacy of SIMBRINZA\u00ae BID as an Adjunctive to DUOTRAV\u00ae","canonical_id":"clinicaltrials.gov:NCT02730871","description":"Open-angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"028b2fa4e43d40abb01c8aeef9fb969f","type":"TRIAL","name":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","canonical_id":"clinicaltrials.gov:NCT00152009","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"42618cef7df04f33b5318336e1e60855","type":"TRIAL","name":"Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.","canonical_id":"clinicaltrials.gov:NCT06682611","description":"Unresectable Locally Advanced or Metastatic Solid Tumors","metadata":null},{"id":"299a208086e74164bf9d32836f586d72","type":"TRIAL","name":"Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","canonical_id":"clinicaltrials.gov:NCT00757588","description":"Type 2 Diabetes","metadata":null},{"id":"d5a6e8a3eaa04c64aa6caed7283f6060","type":"TRIAL","name":"Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient","canonical_id":"clinicaltrials.gov:NCT02182895","description":"Diabetes Mellitus","metadata":null},{"id":"803f6127d170491abdc592f8bae4f952","type":"TRIAL","name":"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis","canonical_id":"clinicaltrials.gov:NCT01358578","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"fda5db7e1778431bb654880c5b8e33b6","type":"TRIAL","name":"Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT02581826","description":"Premature Ejaculation","metadata":null},{"id":"0843f653bddf429bb1418be291e7658c","type":"TRIAL","name":"Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00034307","description":"Pulmonary Hypertension","metadata":null},{"id":"65501035a0d849928f3f831c86d9f9eb","type":"TRIAL","name":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","canonical_id":"clinicaltrials.gov:NCT02992457","description":"Hepatitis C","metadata":null},{"id":"a910f3918a5046d391e24b0ca8e9c9bb","type":"TRIAL","name":"Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01742208","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"b63714728c92484495bdd41d39bb6281","type":"TRIAL","name":"Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis","canonical_id":"clinicaltrials.gov:NCT03770273","description":"Indolent Systemic Mastocytosis","metadata":null},{"id":"8511dee5a19c4ec886ab89143f310970","type":"TRIAL","name":"Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)","canonical_id":"clinicaltrials.gov:NCT02166346","description":"Transverse Myelitis; Neuromyelitis Optica; Idiopathic Transverse Myelitis; Myelitis NOS","metadata":null},{"id":"b565c537baf7499cb43b0b43cc01a2ea","type":"TRIAL","name":"Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)","canonical_id":"clinicaltrials.gov:NCT02750306","description":"Sleep Initiation and Maintenance Disorders; Alzheimer Disease","metadata":null},{"id":"7bd3031ae2a640d28b85dbf10ee7a7ff","type":"TRIAL","name":"Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD","canonical_id":"clinicaltrials.gov:NCT00485875","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"1be1b4abc1c6469fa39954c35c5962bf","type":"TRIAL","name":"Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas","canonical_id":"clinicaltrials.gov:NCT00660335","description":"Pancreatitis","metadata":null},{"id":"901356b69b814e28a7ce668aab70caa1","type":"TRIAL","name":"Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02135445","description":"Prostate Cancer","metadata":null},{"id":"64bbe81f5514490aa798ddd2bf90c22d","type":"TRIAL","name":"Safety and Efficacy of TD0025 (Rocket1h) for Treatment of Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT02798159","description":"Erectile Dysfunction","metadata":null},{"id":"b6f137e37a164761a2adc5563e9afedb","type":"TRIAL","name":"Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100","canonical_id":"clinicaltrials.gov:NCT06065462","description":"Ovarian Clear Cell Carcinoma","metadata":null},{"id":"46314d55f0784465b474bf6b2e485a60","type":"TRIAL","name":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00829049","description":"Acne Vulgaris","metadata":null},{"id":"1d532febf069417cb5e9527349743291","type":"TRIAL","name":"Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03770000","description":"T Cell Lymphoma","metadata":null},{"id":"64ee93f6a2794d40a9c1dcfde5dd9ef5","type":"TRIAL","name":"Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses","canonical_id":"clinicaltrials.gov:NCT01487096","description":"Multiple Sclerosis","metadata":null},{"id":"59b23a5528114f128f874d12a58bd993","type":"TRIAL","name":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","canonical_id":"clinicaltrials.gov:NCT04631601","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"f8a9990491ee48d68be8e90caab36a32","type":"TRIAL","name":"Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management","canonical_id":"clinicaltrials.gov:NCT02094963","description":"Acute Coronary Syndrome; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Angina Pectoris","metadata":null},{"id":"e35e26738bc847b5be5c34736e48bd1b","type":"TRIAL","name":"Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT04630288","description":"Acute Coronary Syndromes","metadata":null},{"id":"6a4c4a665d9740a5a5f64ba49b04c7b3","type":"TRIAL","name":"Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT03786081","description":"Cervical Cancer","metadata":null},{"id":"e628e4c3daf64fb6b4c0c1cc6b8cbae0","type":"TRIAL","name":"Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial","canonical_id":"clinicaltrials.gov:NCT03738956","description":"Axial Spondyloarthritis","metadata":null},{"id":"a98df7eb82e048c4b2baac12e7338d95","type":"TRIAL","name":"Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation","canonical_id":"clinicaltrials.gov:NCT01481974","description":"Ischemia Reperfusion Injury","metadata":null},{"id":"613bf8a22aa44e12a26a7dfdd07f6c31","type":"TRIAL","name":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01216943","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"91ec1c6507ef47c6a40da07ce0d32285","type":"TRIAL","name":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT01241240","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"1f59e6cf08614b73bcb55d9e124a393a","type":"TRIAL","name":"Safety and Efficacy of Two Dosages of Diractin\u00ae in Osteoarthritis (OA)","canonical_id":"clinicaltrials.gov:NCT00716547","description":"Osteoarthritis of the Knee","metadata":null},{"id":"a9ffbe3d9af94e2fb4b3316925505165","type":"TRIAL","name":"Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT02547922","description":"Lupus Nephritis","metadata":null},{"id":"b53900543d82422cad9eeb1f730e7f6b","type":"TRIAL","name":"Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.","canonical_id":"clinicaltrials.gov:NCT00409760","description":"Hypertension","metadata":null},{"id":"8184029c31aa45c9bdd3850fb938a93b","type":"TRIAL","name":"Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT00396656","description":"Hypertension","metadata":null},{"id":"1edd490e31b745f0828701c6c7e7b720","type":"TRIAL","name":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","canonical_id":"clinicaltrials.gov:NCT00704405","description":"Hepatitis C, Chronic","metadata":null},{"id":"7c90b87fd71b4ec9ad90bdc0d03d0d8e","type":"TRIAL","name":"Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01878292","description":"Major Depressive Disorder","metadata":null},{"id":"5324b5d6e2904665ad2037e0e52ebc56","type":"TRIAL","name":"Safety and Efficacy of Vilazodone in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01473381","description":"Major Depressive Disorder","metadata":null},{"id":"c9d128814d51473191e305016f051f16","type":"TRIAL","name":"Safety and Efficacy of Vilazodone in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01573598","description":"Major Depressive Disorder","metadata":null},{"id":"5ed31a863ac44b458a41b7b1b404cf50","type":"TRIAL","name":"Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)","canonical_id":"clinicaltrials.gov:NCT02372799","description":"Major Depressive Disorder","metadata":null},{"id":"69af4938a8cb45d792bdb2684b3f088a","type":"TRIAL","name":"Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01153009","description":"Depressive Disorder, Major","metadata":null},{"id":"30c1b847bc9245a796df751016873808","type":"TRIAL","name":"Safety and Efficacy of Xalkori ROS1","canonical_id":"clinicaltrials.gov:NCT03375242","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"9c3adccdd83743b69fbdd68c123a8812","type":"TRIAL","name":"Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases","canonical_id":"clinicaltrials.gov:NCT00001723","description":"Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome","metadata":null},{"id":"b5da3c9b133346bb86ee284b35cf5212","type":"TRIAL","name":"Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT02745392","description":"Acute Migraine","metadata":null},{"id":"1b115c05e23c4e2eadf755b5c5065386","type":"TRIAL","name":"Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)","canonical_id":"clinicaltrials.gov:NCT00048516","description":"Renal Insufficiency, Chronic","metadata":null},{"id":"af6adecd0c204adaaf4d0bf418bc04a0","type":"TRIAL","name":"Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00057343","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"c72dec5595a64857af80d5d607b593a8","type":"TRIAL","name":"Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)","canonical_id":"clinicaltrials.gov:NCT00257166","description":"Bipolar Disorder","metadata":null},{"id":"e7c071dfdb474261bfaca9ec0fe44045","type":"TRIAL","name":"Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.","canonical_id":"clinicaltrials.gov:NCT00034203","description":"Rheumatoid Arthritis","metadata":null},{"id":"9923d62072c4437683bf59d46c99bf1a","type":"TRIAL","name":"Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis","canonical_id":"clinicaltrials.gov:NCT00309621","description":"Hand Dermatoses","metadata":null},{"id":"e310838c3ff741d4a475446fe50b95f9","type":"TRIAL","name":"Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT00758784","description":"Dry Eye Disease","metadata":null},{"id":"c8eceacfc7d64bc49c2e3e2eccee0704","type":"TRIAL","name":"Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure","canonical_id":"clinicaltrials.gov:NCT01647932","description":"Heart Failure","metadata":null},{"id":"faf82297d51d4b1c8ab2415be2d752fa","type":"TRIAL","name":"Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT02983617","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"e69da0b90a7f40c68459c6ed2bc75c96","type":"TRIAL","name":"Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department","canonical_id":"clinicaltrials.gov:NCT03051243","description":"DM2","metadata":null},{"id":"273220076e494cb78dee70e3f92512e8","type":"TRIAL","name":"Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement","canonical_id":"clinicaltrials.gov:NCT01598662","description":"Contraception","metadata":null},{"id":"8fd2058c7f824e83aa717caebf88df79","type":"TRIAL","name":"Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO","canonical_id":"clinicaltrials.gov:NCT05226442","description":"Extracorporeal Membrane Oxygenation Complication; Anticoagulants and Bleeding Disorders","metadata":null},{"id":"0e456e6f13954029806c62c628648eca","type":"TRIAL","name":"Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke","canonical_id":"clinicaltrials.gov:NCT02448069","description":"Stroke; Cerebral Ischemia","metadata":null},{"id":"b7b3f0042106408f9306ff37745ce08a","type":"TRIAL","name":"Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy","canonical_id":"clinicaltrials.gov:NCT05469009","description":"Mild Cognitive Impairment; Alzheimer Disease 1","metadata":null},{"id":"44f450fb70e84116957559a018894bd4","type":"TRIAL","name":"Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone","canonical_id":"clinicaltrials.gov:NCT01367587","description":"Healthy Volunteers","metadata":null},{"id":"6215631393c746be96be52a77763a0a4","type":"TRIAL","name":"Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients","canonical_id":"clinicaltrials.gov:NCT00651703","description":"Malignant Melanoma","metadata":null},{"id":"d05ae02c0c114a2b89c176f370d95d32","type":"TRIAL","name":"Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART","canonical_id":"clinicaltrials.gov:NCT03787095","description":"HIV Infections","metadata":null},{"id":"1047be2235304d099f7ae9c9c7396bae","type":"TRIAL","name":"Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)","canonical_id":"clinicaltrials.gov:NCT00280566","description":"Bipolar Mania; Bipolar Disorder","metadata":null},{"id":"51f0b34b52b64bc68db7cb004b056df0","type":"TRIAL","name":"Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study","canonical_id":"clinicaltrials.gov:NCT04801966","description":"Cancer","metadata":null},{"id":"5f0754fbba2745d3bf9ee2b2a8bca838","type":"TRIAL","name":"Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01431404","description":"Healthy","metadata":null},{"id":"60bff2dc9951418e85461784aeae5f80","type":"TRIAL","name":"Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment","canonical_id":"clinicaltrials.gov:NCT01140607","description":"Neoplasm Malignant","metadata":null},{"id":"b198db49c4cf40c7a9975fb6c1af98f7","type":"TRIAL","name":"Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT05503511","description":"Epilepsy; Alzheimer Disease; Epilepsy Intractable","metadata":null},{"id":"9616ab5696884918b91719024ec37323","type":"TRIAL","name":"Safety and Pharmacokinetic Study of Sublingual Flumazenil (CRLS035) in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01655914","description":"Insomnia","metadata":null},{"id":"263ac7cbf50349d39df565e29aef1d51","type":"TRIAL","name":"Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02609945","description":"Migraine","metadata":null},{"id":"bf42c3fd28ab4f769aed1dabe725b8ae","type":"TRIAL","name":"Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis","canonical_id":"clinicaltrials.gov:NCT00808223","description":"Psoriasis","metadata":null},{"id":"76e86edd8bbe4a429dcc7cc339643969","type":"TRIAL","name":"Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids","canonical_id":"clinicaltrials.gov:NCT05588323","description":"Opioid-Induced Constipation (OIC)","metadata":null},{"id":"16d89051341347e0aaba851ac44adb21","type":"TRIAL","name":"Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia","canonical_id":"clinicaltrials.gov:NCT01189279","description":"Alopecia; Alopecia, Androgenetic; Baldness","metadata":null},{"id":"f36f788776134b37871a1807c95023c0","type":"TRIAL","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","canonical_id":"clinicaltrials.gov:NCT05222555","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"6571dc437f274421af2df9fa5b8deb8a","type":"TRIAL","name":"Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT03233139","description":"Advanced Malignancies","metadata":null},{"id":"fe3e108a14e94c4cbd2e47c5ca080ac3","type":"TRIAL","name":"Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring","canonical_id":"clinicaltrials.gov:NCT01363037","description":"HIV Infections","metadata":null},{"id":"eba45e719f52435e901b33ee21898eee","type":"TRIAL","name":"Safety and Pharmacokinetics of Probucol and Cilostazol","canonical_id":"clinicaltrials.gov:NCT00549978","description":"Healthy","metadata":null},{"id":"854cdad9a38e4823973b4b1999e971e7","type":"TRIAL","name":"Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT02507388","description":"Neovascular Age-Related Macular Degeneration","metadata":null},{"id":"42bd66aa2ea4458c8afe5dd4a47a137a","type":"TRIAL","name":"Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination","canonical_id":"clinicaltrials.gov:NCT01973868","description":"Neoplasms","metadata":null},{"id":"232c09fa3c7e4f4da630d32c0793cf4f","type":"TRIAL","name":"Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years","canonical_id":"clinicaltrials.gov:NCT01596400","description":"Chemotherapy Induced Nausea and Vomiting","metadata":null},{"id":"7eea74f2d7334363acbb11b7087f911d","type":"TRIAL","name":"Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00097747","description":"Anemia; Chronic Kidney Disease; Chronic Renal Failure; Cancer","metadata":null},{"id":"c8f8426e759b46599d5c017c298af3dd","type":"TRIAL","name":"Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)","canonical_id":"clinicaltrials.gov:NCT00394160","description":"Bronchiolitis","metadata":null},{"id":"b48719bc412a4ac89230a1509b486e16","type":"TRIAL","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","canonical_id":"clinicaltrials.gov:NCT07463235","description":"Prolactinoma; Prolactin Excess","metadata":null},{"id":"2314cec9b7474f88ba0357c5e12084e4","type":"TRIAL","name":"Safety and Preliminary Clinical Activity of Itolizumab in ARDS","canonical_id":"clinicaltrials.gov:NCT05978544","description":"Acute Respiratory Distress Syndrome","metadata":null},{"id":"d44108f2a02e44df9ceb29e2bf67173c","type":"TRIAL","name":"Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis","canonical_id":"clinicaltrials.gov:NCT05986162","description":"Dermatomyositis, Adult Type","metadata":null},{"id":"fc9a93a5b8d443c9ba387ce7715f3001","type":"TRIAL","name":"Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.","canonical_id":"clinicaltrials.gov:NCT07364344","description":"Acute Ischemic Stroke","metadata":null},{"id":"c290f09f3cbb4a5da3f0315046023c82","type":"TRIAL","name":"Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat","canonical_id":"clinicaltrials.gov:NCT04750759","description":"Covid19","metadata":null},{"id":"5ca8df3f5b0a43278c2ce8289cb133ef","type":"TRIAL","name":"Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients","canonical_id":"clinicaltrials.gov:NCT01114737","description":"Phenylketonuria","metadata":null},{"id":"5e628dccfcf14b1b814389e1b882911d","type":"TRIAL","name":"Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01909466","description":"Schizophrenia; Mental Disorder; Nervous System Diseases","metadata":null},{"id":"771e5c4f347d45b5ad16950a4cd2a94c","type":"TRIAL","name":"Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention","canonical_id":"clinicaltrials.gov:NCT05207865","description":"Migraine; Episodic Migraine; Phonophobia; Photophobia","metadata":null},{"id":"509c70c91a9b4538842e46c3104b1de6","type":"TRIAL","name":"Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT03428360","description":"Epilepsy","metadata":null},{"id":"3bf1a81cd5224ea58b46504f54d8dc0c","type":"TRIAL","name":"Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT01893190","description":"Ruptured Cerebral Aneurysm; Ruptured Berry Aneurysm","metadata":null},{"id":"99f87d3c5d94402290174352c77f4e38","type":"TRIAL","name":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","canonical_id":"clinicaltrials.gov:NCT03885921","description":"Hypercholesterolemia","metadata":null},{"id":"10b3588634ed446fb2aaba8bcec52d67","type":"TRIAL","name":"Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02242747","description":"Actinic Keratosis","metadata":null},{"id":"82c8e04a51e84c3a8de28cfb766df08b","type":"TRIAL","name":"Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome","canonical_id":"clinicaltrials.gov:NCT02879578","description":"Tourette Syndrome","metadata":null},{"id":"a69bf9ad4ab24da49be877df9addfee9","type":"TRIAL","name":"Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT03768531","description":"Resectable Biliary Tract Cancer","metadata":null},{"id":"43a4da0bd024441090096c7c18e6b863","type":"TRIAL","name":"Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)","canonical_id":"clinicaltrials.gov:NCT02598193","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"779b2213b60648dfaa813389286f657b","type":"TRIAL","name":"Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04190628","description":"Advanced Solid Tumor; BRAF V600 Mutation","metadata":null},{"id":"d7659caaa8454e68a69d3b2b94be76bc","type":"TRIAL","name":"Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT01437540","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"960ac528d41e42e2bf004d813ee01f75","type":"TRIAL","name":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00996281","description":"Essential Hypertension","metadata":null},{"id":"a41fd7e1de4347fdb010a884924328fe","type":"TRIAL","name":"Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)","canonical_id":"clinicaltrials.gov:NCT00261287","description":"Hay Fever; Perennial Allergic Rhinitis","metadata":null},{"id":"11dd42b3d8604c8092ac139ee1d27b05","type":"TRIAL","name":"Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)","canonical_id":"clinicaltrials.gov:NCT00314509","description":"Asthma","metadata":null},{"id":"930b777360a54fd09735718dbd89216c","type":"TRIAL","name":"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients","canonical_id":"clinicaltrials.gov:NCT03623243","description":"Multiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis","metadata":null},{"id":"28c5bedfaea4456d8fe9d9cde97d3b30","type":"TRIAL","name":"Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea","canonical_id":"clinicaltrials.gov:NCT01374490","description":"HIV Enteropathy; Diarrhea With HIV","metadata":null},{"id":"c63771e7fd9143ffb64ea5c03004b07a","type":"TRIAL","name":"Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy","canonical_id":"clinicaltrials.gov:NCT01468350","description":"Cerebral Palsy (CP)","metadata":null},{"id":"811b94d87e3e45b8be78ea05ce480bf0","type":"TRIAL","name":"Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus","canonical_id":"clinicaltrials.gov:NCT06593392","description":"Pruritus; Chronic Kidney Diseases","metadata":null},{"id":"60547e3b6f54474eb40810974be9f7d2","type":"TRIAL","name":"Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01497262","description":"Multiple Sclerosis","metadata":null},{"id":"80628c1b256f4329adccff8478113c7d","type":"TRIAL","name":"Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches","canonical_id":"clinicaltrials.gov:NCT01035983","description":"Migraine","metadata":null},{"id":"0b275150ef53498ba25a2b7c2fcc41b7","type":"TRIAL","name":"Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor","canonical_id":"clinicaltrials.gov:NCT04174677","description":"Highly Sensitized Patients on Waiting List for Kidney Transplantation","metadata":null},{"id":"e3e9c238e0174535a21b68da013fd109","type":"TRIAL","name":"Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","canonical_id":"clinicaltrials.gov:NCT01405508","description":"Epilepsy","metadata":null},{"id":"0897c7b500ab4d8b8b942e9317b0d6cb","type":"TRIAL","name":"Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids","canonical_id":"clinicaltrials.gov:NCT03197623","description":"Osteopenia; Osteoporosis; Osteonecrosis","metadata":null},{"id":"47f987565436411e89fb0c985abaa219","type":"TRIAL","name":"Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01507285","description":"Diabetes; Diabetes Mellitus, Type 2; Healthy","metadata":null},{"id":"2913f3c752184c33b32b832cbc27409a","type":"TRIAL","name":"Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01615978","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"5505dc8a068f4314ac8753b5722273ff","type":"TRIAL","name":"Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01940965","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"964b8ec14594422097a4399f56e7ad64","type":"TRIAL","name":"Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)","canonical_id":"clinicaltrials.gov:NCT00410748","description":"Pain; Analgesics, Opioid","metadata":null},{"id":"7d0201b369d54057a6dc169b4d7ba579","type":"TRIAL","name":"Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)","canonical_id":"clinicaltrials.gov:NCT01025843","description":"Hypertension","metadata":null},{"id":"38af57e546d2407297f9b26aad2fc6e7","type":"TRIAL","name":"Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma","canonical_id":"clinicaltrials.gov:NCT00546143","description":"Asthma","metadata":null},{"id":"b6b12e77ffc1457e86da237cc590a40e","type":"TRIAL","name":"Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients","canonical_id":"clinicaltrials.gov:NCT00482508","description":"Asthma","metadata":null},{"id":"92bfc4d8d87c496db9df68c7f5779286","type":"TRIAL","name":"Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","canonical_id":"clinicaltrials.gov:NCT01727713","description":"Tourette's Disorder; Tic Disorder","metadata":null},{"id":"4cc1a157ea9640b080949fff2c8253c9","type":"TRIAL","name":"Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients","canonical_id":"clinicaltrials.gov:NCT01003678","description":"Myelodysplastic Syndrome","metadata":null},{"id":"c57beb2127554907935ef43209adb6ef","type":"TRIAL","name":"Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT01535443","description":"Inflammation; Cataract","metadata":null},{"id":"7858e605e17d412e986d2e8ae50ba9f4","type":"TRIAL","name":"Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs","canonical_id":"clinicaltrials.gov:NCT01263353","description":"Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System","metadata":null},{"id":"fff2b4325cf04ce996d30d4799d3e012","type":"TRIAL","name":"Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00504959","description":"Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration (AMD)","metadata":null},{"id":"761ea393056944a1ad72be6d6d6d7515","type":"TRIAL","name":"Safety and Tolerability of Repeat Courses of IM Alefacept","canonical_id":"clinicaltrials.gov:NCT00233662","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"76ea27c124fc4121a3dfb75c938e7bce","type":"TRIAL","name":"Safety and Tolerability of Repeat Courses of IM Alefacept","canonical_id":"clinicaltrials.gov:NCT00794807","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"7664475e3bbf4ae58733ac1ef59c71ec","type":"TRIAL","name":"Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)","canonical_id":"clinicaltrials.gov:NCT01045772","description":"Muckle-Wells Syndrome; Schnitzler Syndrome","metadata":null},{"id":"1f8571486757421d960dc224f0653a2d","type":"TRIAL","name":"Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00305903","description":"Alzheimer's Disease","metadata":null},{"id":"8cb46d53da394d0fbc32823d10e0d914","type":"TRIAL","name":"Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.","canonical_id":"clinicaltrials.gov:NCT00151944","description":"Colitis, Ulcerative","metadata":null},{"id":"190b7fef79d74299acafbac813e0d498","type":"TRIAL","name":"Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00151996","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"3cb78c22d0774b43b2139b23d0524c32","type":"TRIAL","name":"Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age","canonical_id":"clinicaltrials.gov:NCT01365481","description":"Hypertension; Chronic Kidney Disease","metadata":null},{"id":"750a2c81b3ce41cc9d1e12a6d9f15937","type":"TRIAL","name":"Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study","canonical_id":"clinicaltrials.gov:NCT01152996","description":"Depressive Disorder, Major","metadata":null},{"id":"294d58bceb61496898864fda6f79f404","type":"TRIAL","name":"Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks","canonical_id":"clinicaltrials.gov:NCT00000670","description":"HIV Infections","metadata":null},{"id":"93db7a7746274d7493ba0e0a199e1780","type":"TRIAL","name":"Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00854620","description":"Carcinoma, Renal Cell; Kidney Disease; Kidney Cancer","metadata":null},{"id":"1e8d04a29d8245d086cb99cfef01dc59","type":"TRIAL","name":"Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01071889","description":"Healthy","metadata":null},{"id":"f8c85f005d44426d81a399534326fef1","type":"TRIAL","name":"Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair\u00ae (Montelukast Sodium)to Treat Asthma","canonical_id":"clinicaltrials.gov:NCT02029313","description":"Asthma and Allergic Rhinitis","metadata":null},{"id":"7681661ce154490cbbdd0c557eeffe9d","type":"TRIAL","name":"Safety of \"Ticagrelor+ Warfarin\"in Comparison With \"Clopidogrel+Aspirin+Warfarin\"","canonical_id":"clinicaltrials.gov:NCT02206815","description":"Atrial Fibrillation; Coronary Artery Disease","metadata":null},{"id":"97ed08bd2e91458b88f11796885709e9","type":"TRIAL","name":"Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT00101907","description":"Lung Cancer; Pancreatic Cancer; Esophageal Cancer","metadata":null},{"id":"071c384b37324d7ab58ebf79a3ae6f1d","type":"TRIAL","name":"Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy","canonical_id":"clinicaltrials.gov:NCT00949351","description":"Type 2 Diabetes With Nephropathy","metadata":null},{"id":"7bb2bff214444aa09131e6c16c0e90e0","type":"TRIAL","name":"Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00723736","description":"Rhinitis; Urticaria","metadata":null},{"id":"3d85adcb454b4eb080240ec11179ef78","type":"TRIAL","name":"Safety of Argatroban Infusion in Conduction Disturbances","canonical_id":"clinicaltrials.gov:NCT05740371","description":"Stable Coronary Artery Disease (CAD); Unstable Angina (Troponin Negative)","metadata":null},{"id":"46778c1d6ac44edba8f56c2a8f801be3","type":"TRIAL","name":"Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR","canonical_id":"clinicaltrials.gov:NCT01880840","description":"Allergic Rhinitis","metadata":null},{"id":"972aa90652644da5a8199c85a0ff5b38","type":"TRIAL","name":"Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase","canonical_id":"clinicaltrials.gov:NCT01141283","description":"Osteoarthritis","metadata":null},{"id":"916a2b435aad481ca701bfa86ea1079a","type":"TRIAL","name":"Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)","canonical_id":"clinicaltrials.gov:NCT04097561","description":"Idiopathic CD4 Lymphopenia","metadata":null},{"id":"3c58fecec3824b07af79676ffa5c87e3","type":"TRIAL","name":"Safety of Bosentan in Type II Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT04068272","description":"Diabetes Mellitus","metadata":null},{"id":"f0046f021f40409cb7396690e2590bcd","type":"TRIAL","name":"Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)","canonical_id":"clinicaltrials.gov:NCT00163488","description":"Perennial Allergic Rhinitis; Allergic Rhinitis; Hay Fever","metadata":null},{"id":"70327be79d8645efba15887cc5e3bae7","type":"TRIAL","name":"Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT01279096","description":"Acute Lymphoid Leukemia Relapse; Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant","metadata":null},{"id":"64369418196847e0a54fee4979fcd565","type":"TRIAL","name":"Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)","canonical_id":"clinicaltrials.gov:NCT00757562","description":"Chronic Idiopathic Urticaria; Atopy","metadata":null},{"id":"ec54ec15563f47deb15fb436d36489b6","type":"TRIAL","name":"Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency","canonical_id":"clinicaltrials.gov:NCT00630708","description":"Renal Insufficiency, Chronic","metadata":null},{"id":"01185f432a564751b2e217f4ae7de57f","type":"TRIAL","name":"Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)","canonical_id":"clinicaltrials.gov:NCT01327638","description":"Spondylarthropathies; Spondylitis, Ankylosing","metadata":null},{"id":"441f6cfef0224e87bbe57b4b504c2891","type":"TRIAL","name":"Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas","canonical_id":"clinicaltrials.gov:NCT02115074","description":"Glioma","metadata":null},{"id":"d2792470232c4baa860080fea6d32e73","type":"TRIAL","name":"Safety of Fondaparinux as Post Partum Thromboprophylaxis","canonical_id":"clinicaltrials.gov:NCT04447378","description":"Thromboembolism in the Puerperium","metadata":null},{"id":"a85099f5fddc4ceda87d44c3e8861111","type":"TRIAL","name":"Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients","canonical_id":"clinicaltrials.gov:NCT00493896","description":"Venous Thromboembolism","metadata":null},{"id":"9bf63b5311c44fe69a463614c30b76f9","type":"TRIAL","name":"Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)","canonical_id":"clinicaltrials.gov:NCT02527798","description":"Bronchopulmonary Dysplasia","metadata":null},{"id":"bbc3e79a041f43d98cb3cceb882c65bd","type":"TRIAL","name":"Safety of High-dose Tirofiban During Coronary Angioplasty","canonical_id":"clinicaltrials.gov:NCT00566891","description":"Coronary Artery Disease","metadata":null},{"id":"5bd586ef038e4fb7984304e677091a9a","type":"TRIAL","name":"Safety of Ibritumomab Tiuxetan (Zevalin\u00ae) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","canonical_id":"clinicaltrials.gov:NCT00607854","description":"Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma","metadata":null},{"id":"2398c49c70da4e41a7c9392ef75a3e3e","type":"TRIAL","name":"Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm","canonical_id":"clinicaltrials.gov:NCT03517670","description":"Cerebral Vasospasm; Subarachnoid Hemorrhage","metadata":null},{"id":"326553d05cdb446a877b40c69fc4335e","type":"TRIAL","name":"Safety of Lumiracoxib in Patients With Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT00637949","description":"Osteoarthritis","metadata":null},{"id":"1525ff3653764d278e9bcf00f1f7408f","type":"TRIAL","name":"Safety of Nintedanib in Real World in China","canonical_id":"clinicaltrials.gov:NCT05676112","description":"Pulmonary Fibrosis","metadata":null},{"id":"5e1505c5a45541948735eefe9bc527e1","type":"TRIAL","name":"Safety of Ramelteon in Elderly Subjects","canonical_id":"clinicaltrials.gov:NCT00568789","description":"Insomnia","metadata":null},{"id":"909400104b484fe2b9b9ea701bc32f97","type":"TRIAL","name":"Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00316992","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"a14a420f541f4bbd87426337b50766dc","type":"TRIAL","name":"Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00672802","description":"Chronic Obstructive Pulmonary Disease; COPD","metadata":null},{"id":"bbcc3114a3aa499fafbc41e314d4960d","type":"TRIAL","name":"Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT00672061","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"9389cc3595e24694906c18d5ff8632c3","type":"TRIAL","name":"Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06291116","description":"Kidney Diseases","metadata":null},{"id":"aa60a52ad30f42ae8dfc8e7d192cfbdf","type":"TRIAL","name":"Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00109291","description":"Anemia; Chronic Kidney Disease; Chronic Renal Failure","metadata":null},{"id":"c9c200f7e980437795e5b80f45245fb0","type":"TRIAL","name":"Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness","canonical_id":"clinicaltrials.gov:NCT00672139","description":"Opioid-Induced Constipation","metadata":null},{"id":"ae2b08e6e4364f3399f00c6a9e3bb74c","type":"TRIAL","name":"Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00428389","description":"Alzheimer's Disease","metadata":null},{"id":"d8dfb5924cc042ffb21a78791b6cfae9","type":"TRIAL","name":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","canonical_id":"clinicaltrials.gov:NCT04798287","description":"Rheumatoid Arthritis","metadata":null},{"id":"f9f4b35be4a94615af45c885dabeecad","type":"TRIAL","name":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome","canonical_id":"clinicaltrials.gov:NCT04496960","description":"Sjogren's Syndrome","metadata":null},{"id":"76d32010b0e34b3d822c5d5065be771e","type":"TRIAL","name":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT02535689","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"c40d0edf3c774a3bb4b010e15ff9763f","type":"TRIAL","name":"Safety of Tranexamic Acid in Reducing Bleeding in Adults Undergoing Spinal Surgery","canonical_id":"clinicaltrials.gov:NCT00444470","description":"Spine Surgery","metadata":null},{"id":"bcafb91c268844e68bfbcbb24cb0aeab","type":"TRIAL","name":"Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.","canonical_id":"clinicaltrials.gov:NCT04694677","description":"Myoma","metadata":null},{"id":"9b301d37431e42948a35be6cb9798f70","type":"TRIAL","name":"Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.","canonical_id":"clinicaltrials.gov:NCT01130688","description":"Chronic Myelogenous Leukemia","metadata":null},{"id":"5d71af1891144420b1b9be4453b77e1a","type":"TRIAL","name":"Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT06585384","description":"Alzheimer Disease","metadata":null},{"id":"440ceb0bb97c4cbd883fd34224f35e9e","type":"TRIAL","name":"Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)","canonical_id":"clinicaltrials.gov:NCT04054193","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"1d6d9543e97a4293a63ea11620791186","type":"TRIAL","name":"Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency","canonical_id":"clinicaltrials.gov:NCT04138251","description":"Glycogen Storage Disease Type I; Glucose 6 Phosphatase Deficiency","metadata":null},{"id":"0fbd489032ca4ef6a6033be4a01ae16c","type":"TRIAL","name":"Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)","canonical_id":"clinicaltrials.gov:NCT01244230","description":"Atopic Dermatitis","metadata":null},{"id":"30a50a8bda1b44669eecdc704b9721dc","type":"TRIAL","name":"Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT03571516","description":"Short Bowel Syndrome","metadata":null},{"id":"f0aebe94f1b84e6f8c3e35f36463656c","type":"TRIAL","name":"Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT00051662","description":"Psoriatic Arthritis","metadata":null},{"id":"2df4624b2fe0445bbf94246c7df42ce9","type":"TRIAL","name":"Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01844115","description":"Generalized Anxiety Disorder","metadata":null},{"id":"afcd533b3e2147938ed02722a980443f","type":"TRIAL","name":"Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01629966","description":"Generalized Anxiety Disorder","metadata":null},{"id":"eeb0f89dbccc405db54e9d349cf2ca89","type":"TRIAL","name":"Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL","canonical_id":"clinicaltrials.gov:NCT00520208","description":"Acute Promyelocytic Leukemia","metadata":null},{"id":"6f56db8bf484447f907be06dc96716a2","type":"TRIAL","name":"Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms","canonical_id":"clinicaltrials.gov:NCT00487708","description":"NALP3 Mutation","metadata":null},{"id":"1a5b3ce5c7964c459d53d1cba7ed11f9","type":"TRIAL","name":"Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT01473394","description":"Major Depressive Disorder","metadata":null},{"id":"f7ce5bc6eade42298fc2523e4cda3d11","type":"TRIAL","name":"Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH","canonical_id":"clinicaltrials.gov:NCT00439946","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"e3cd3c8ed94e4ec384f498a7ee2ffc14","type":"TRIAL","name":"Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients","canonical_id":"clinicaltrials.gov:NCT00228436","description":"Anemia; Chronic Kidney Disease; Chronic Renal Failure","metadata":null},{"id":"d0d88b97f8cd4fb9a60ed35cb89fbb63","type":"TRIAL","name":"Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT03826485","description":"Healthy","metadata":null},{"id":"edfabdb26d6f4866a17551a0f666c623","type":"TRIAL","name":"Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants","canonical_id":"clinicaltrials.gov:NCT05644626","description":"Solid Tumors","metadata":null},{"id":"10d924a93c5545cd945e4569389c927e","type":"TRIAL","name":"Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients \u22656 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)","canonical_id":"clinicaltrials.gov:NCT03346434","description":"Dermatitis, Atopic","metadata":null},{"id":"48782ce249714db3bf962b2120eb503f","type":"TRIAL","name":"Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT07136389","description":"Systemic Lupus Erthematosus","metadata":null},{"id":"cafa8865d0a3464cbcc959399b6d315c","type":"TRIAL","name":"Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)","canonical_id":"clinicaltrials.gov:NCT02964273","description":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","metadata":null},{"id":"ee8b64a95095402cb4fdebd477a2ae35","type":"TRIAL","name":"Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05494762","description":"Solid Tumor","metadata":null},{"id":"fcbb706e2bea42de88a9fc8db17759bf","type":"TRIAL","name":"Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT03774771","description":"Primary Hyperparathyroidism","metadata":null},{"id":"078283361b1240fe9131db2318e04eb5","type":"TRIAL","name":"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT03637764","description":"Neoplasm","metadata":null},{"id":"a74da7908fcb4a8e9fdbd20ec0cd63dc","type":"TRIAL","name":"Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01982942","description":"Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive","metadata":null},{"id":"c8b3d32ab6994fa893ded33cf82c4b8e","type":"TRIAL","name":"Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine","canonical_id":"clinicaltrials.gov:NCT04179474","description":"Migraine","metadata":null},{"id":"312a22f215c542e8a2e2f9fe1e24cb2b","type":"TRIAL","name":"Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00055367","description":"Crohn's Disease","metadata":null},{"id":"a6e28747797e4d24badc47141ad70854","type":"TRIAL","name":"Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients","canonical_id":"clinicaltrials.gov:NCT01730404","description":"COPD","metadata":null},{"id":"5cfc5aea7f9a4d7db0e0e4ff12561a1d","type":"TRIAL","name":"Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients","canonical_id":"clinicaltrials.gov:NCT00170833","description":"Renal Transplantation","metadata":null},{"id":"f75928ddcc464dfe9c1d6bd3fd253d59","type":"TRIAL","name":"Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03828799","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"111c89c7a3bb4687aceead9c3a86b416","type":"TRIAL","name":"Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01968460","description":"Parkinson's Disease","metadata":null},{"id":"1b3569b1b109456f94b07640914353f6","type":"TRIAL","name":"Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression","canonical_id":"clinicaltrials.gov:NCT00285766","description":"Major Depression","metadata":null},{"id":"3ae2081fd62c46d2a2cffede1cb49ffb","type":"TRIAL","name":"Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure","canonical_id":"clinicaltrials.gov:NCT03292653","description":"Cardiac Failure Aggravated","metadata":null},{"id":"572089ff307e4b69976ce2011a0cd4d5","type":"TRIAL","name":"Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.","canonical_id":"clinicaltrials.gov:NCT00568503","description":"COPD","metadata":null},{"id":"6a9b0b4b997948bdb6c3e537426da48f","type":"TRIAL","name":"Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT03595189","description":"Dose Finding Study","metadata":null},{"id":"2690cc92b909488e90de8a01d8d892a9","type":"TRIAL","name":"Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02218034","description":"Acne Vulgaris","metadata":null},{"id":"01ac795ceff247278856c841ab4fc47f","type":"TRIAL","name":"Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00996892","description":"Solid Tumors","metadata":null},{"id":"2a5747e86ff84cfc8ffec7b5def6453c","type":"TRIAL","name":"Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT05045781","description":"Healthy","metadata":null},{"id":"bbad7e58b32d4f489c0e72b7167f5ae5","type":"TRIAL","name":"Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06902090","description":"Pain","metadata":null},{"id":"b579e54f1836479ab35e3a0aa70c3f69","type":"TRIAL","name":"Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01181973","description":"Bioavailability","metadata":null},{"id":"699bab979d484bdab527300321405f76","type":"TRIAL","name":"Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT05931575","description":"Idiopathic Parkinson\u00b4s Disease","metadata":null},{"id":"cf70aeaad0694ea1a7a29b6f60d352f1","type":"TRIAL","name":"Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)","canonical_id":"clinicaltrials.gov:NCT01081158","description":"Hepatitis C, Chronic","metadata":null},{"id":"35d6516a117646b3a069856950373ad2","type":"TRIAL","name":"Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044","canonical_id":"clinicaltrials.gov:NCT01419470","description":"Premature Ejaculation","metadata":null},{"id":"4940d68931234e0b8120d995bf5a922a","type":"TRIAL","name":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01688089","description":"Healthy","metadata":null},{"id":"14fdfd586ea844c6b6b8d83dfb90058f","type":"TRIAL","name":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01840423","description":"Healthy","metadata":null},{"id":"79543a7c995846cf9a3e2d60864ff9f3","type":"TRIAL","name":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib","canonical_id":"clinicaltrials.gov:NCT05555823","description":"Healthy","metadata":null},{"id":"6a330be9208e4ea2909d1158f4de0679","type":"TRIAL","name":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT07554495","description":"Polyarticular Course Juvenile Idiopathic Arthritis","metadata":null},{"id":"c33ea30d8fbf4e79adb4aa01fe89e801","type":"TRIAL","name":"Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers","canonical_id":"clinicaltrials.gov:NCT04781322","description":"Alcohol Associated Liver Disease; Heavy Drinking Behavior","metadata":null},{"id":"cf744bcb5dd74da19b5ea66844bc7d63","type":"TRIAL","name":"Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)","canonical_id":"clinicaltrials.gov:NCT03776058","description":"Primary Hyperparathyroidism","metadata":null},{"id":"fc28639e6a704636a0f7a7280a0eef57","type":"TRIAL","name":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","canonical_id":"clinicaltrials.gov:NCT02476006","description":"Hypercholesterolemia","metadata":null},{"id":"22ba63ffac6d4759940cf57b7ad2bf43","type":"TRIAL","name":"Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00203138","description":"Parkinson's Disease","metadata":null},{"id":"0b1d7611ba9d473ca081639b62a8e51b","type":"TRIAL","name":"Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1","canonical_id":"clinicaltrials.gov:NCT02485080","description":"PT-NANBH","metadata":null},{"id":"6229892cbf3b4ddb869b66b7381cca6d","type":"TRIAL","name":"Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate","canonical_id":"clinicaltrials.gov:NCT02885181","description":"Rheumatoid Arthritis","metadata":null},{"id":"f83354845daf49a8afdba89d5b9287f6","type":"TRIAL","name":"Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)","canonical_id":"clinicaltrials.gov:NCT01505634","description":"Urinary Tract Infections; Pyelonephritis","metadata":null},{"id":"7b135647a2e24017a000865c9135f65f","type":"TRIAL","name":"Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome","canonical_id":"clinicaltrials.gov:NCT03325010","description":"Tourette Syndrome","metadata":null},{"id":"f5caa557c29f4e6bbec38a771a45a711","type":"TRIAL","name":"Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD","canonical_id":"clinicaltrials.gov:NCT05614115","description":"End-stage Kidney Disease; Kidney Disease, Chronic; Dialysis; Diabetic; Non-diabetic; Kidney Dysfunction; Kidney Failure; Hemodialysis","metadata":null},{"id":"935df87d494a40f1adaf2522e0daff51","type":"TRIAL","name":"Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02281409","description":"Advanced Solid Tumors; Metastatic Solid Tumors","metadata":null},{"id":"46f6ee640c9c4e11a9992020cf25011e","type":"TRIAL","name":"Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT06253546","description":"Schizophrenia","metadata":null},{"id":"77d701fc58d141b88727ca0c7dbb8c1a","type":"TRIAL","name":"Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01974258","description":"Neoplasms","metadata":null},{"id":"7ebc1d407785490ca28cf3fd07ddb06e","type":"TRIAL","name":"Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)","canonical_id":"clinicaltrials.gov:NCT00612105","description":"Postherpetic Neuralgia","metadata":null},{"id":"b6c35ec6252649b1996d7993546d2691","type":"TRIAL","name":"Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients","canonical_id":"clinicaltrials.gov:NCT01399008","description":"Gout","metadata":null},{"id":"5bb65e43c08b4707a778168418728b69","type":"TRIAL","name":"Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT00333918","description":"Pain; Inflammation","metadata":null},{"id":"1b64965bda024ea7aaa7b28072d44cda","type":"TRIAL","name":"Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT00387517","description":"Hypertension","metadata":null},{"id":"2265e0f3916b49bb93c9401921d8afe6","type":"TRIAL","name":"Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00404820","description":"Osteoporosis","metadata":null},{"id":"bce3c0f81fef4114a0c2c7a7a75cd680","type":"TRIAL","name":"Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH","canonical_id":"clinicaltrials.gov:NCT02893826","description":"Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"69511f2b991c4f5faa3bf3bd4aedc8b7","type":"DRUG","name":"Safinamide","canonical_id":"mesh:C092797","description":null,"metadata":null},{"id":"a6de15910db54fd697723c848de4fa78","type":"TRIAL","name":"Safinamide Renal Impairment Trial","canonical_id":"clinicaltrials.gov:NCT01374113","description":"Renal Impairment","metadata":null},{"id":"accedc3f5fd94edcb7d6be135c29e49f","type":"TRIAL","name":"Safinamide Steady State Interaction With Rosuvastatin","canonical_id":"clinicaltrials.gov:NCT03216304","description":"Healthy","metadata":null},{"id":"e34a9cae4bfb499992c675225265c6be","type":"TRIAL","name":"Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist","canonical_id":"clinicaltrials.gov:NCT00643045","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"d89e514ddb8e406286c2721a2096400a","type":"TRIAL","name":"Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)","canonical_id":"clinicaltrials.gov:NCT00642889","description":"Parkinson's Disease","metadata":null},{"id":"6b88ecbadbd54667a81115343d12dd6c","type":"TRIAL","name":"Safinamide for Levodopa-induced Dyskinesia (PD-LID)","canonical_id":"clinicaltrials.gov:NCT03987750","description":"Dyskinesia, Drug-Induced; Parkinson Disease","metadata":null},{"id":"832c76c1de1e439bb21ab208def138cd","type":"TRIAL","name":"Safinamide for Multiple System Atrophy (MSA)","canonical_id":"clinicaltrials.gov:NCT03753763","description":"Multiple System Atrophy","metadata":null},{"id":"d4e98a39de0c4e3da9db8be8c3501926","type":"TRIAL","name":"Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects","canonical_id":"clinicaltrials.gov:NCT01113320","description":"Parkinson's Disease","metadata":null},{"id":"6d9e63c0c468408783263c4974a69c07","type":"TRIAL","name":"Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations","canonical_id":"clinicaltrials.gov:NCT07761936","description":"PARKINSON DISEASE (Disorder); Pain; Pain Management; Parkinson Disease (PD)","metadata":null},{"id":"ef87aa302ba74f118f817cda5beec46b","type":"TRIAL","name":"Sagene 2014 - Parkinson's Disease and Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT02225548","description":"Parkinson's Disease; Erectile Dysfunction","metadata":null},{"id":"a25abcaf87a84d5ab1da90b1ddc59272","type":"TRIAL","name":"Sahastara Remedy Extract Capsule in Primary Osteoarthritis of Clinical Trial Phase II","canonical_id":"clinicaltrials.gov:NCT04591795","description":"Osteoarthritis","metadata":null},{"id":"4f2346790daf4d029309312cd97ac7bb","type":"DRUG","name":"Salbutamol","canonical_id":"mesh:D000420","description":null,"metadata":null},{"id":"7ea47d8f73284fecb8834da21f9e2bde","type":"DRUG","name":"Salirasib","canonical_id":"ncit:C71146","description":null,"metadata":null},{"id":"64124a623b634f18b5d01754c3af19bd","type":"TRIAL","name":"Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis","canonical_id":"clinicaltrials.gov:NCT01389401","description":"Gastroesophageal Reflux Disease (GERD); Chronic Laryngitis","metadata":null},{"id":"6059a10390af4e44ad4f07d0fc2de977","type":"TRIAL","name":"Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients","canonical_id":"clinicaltrials.gov:NCT03083834","description":"Adrenal Insufficiency; Adrenal Cancer","metadata":null},{"id":"dc01f9924405467ab4b726a26882bd59","type":"DISEASE","name":"Salivary Gland Cancer","canonical_id":"doid:8850","description":null,"metadata":null},{"id":"a2dcbba856c34e32bd713e39d1a20b1f","type":"DISEASE","name":"Salivary Gland Carcinoma","canonical_id":"doid:0050904","description":null,"metadata":null},{"id":"b0c0b9c942a34ff99edf35db96196fa9","type":"TRIAL","name":"Salivary Interactions With Chemosensations","canonical_id":"clinicaltrials.gov:NCT03883880","description":"Diet, Food Choice, Taste","metadata":null},{"id":"01acf9213f2841b6ac824e199f57d92e","type":"DISEASE","name":"Salmonella infection","canonical_id":"mesh:D012480","description":null,"metadata":null},{"id":"adcab42dc04a46f690890bb53adf490c","type":"DISEASE","name":"Salpingitis","canonical_id":"mesh:D012488","description":null,"metadata":null},{"id":"59b77181f22644c699d025c0b44d5a14","type":"TRIAL","name":"Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT01393808","description":"Type 2 Diabetes","metadata":null},{"id":"0276e96de3b3406eb171d3fe09a72dea","type":"TRIAL","name":"Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain","canonical_id":"clinicaltrials.gov:NCT00482378","description":"Multiple Myeloma and Plasma Cell Neoplasm; Pain","metadata":null},{"id":"e2e6e85a3c16428689c42878f51d644e","type":"TRIAL","name":"Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)","canonical_id":"clinicaltrials.gov:NCT01852604","description":"Chronic Hepatitis C Virus","metadata":null},{"id":"785aa97cbc9549edbea134d2715aac02","type":"TRIAL","name":"Same Day Oral EC and Implant Initiation","canonical_id":"clinicaltrials.gov:NCT04678817","description":"Contraception","metadata":null},{"id":"6abddcc128ec46d784eb6d3bbb218fd7","type":"TRIAL","name":"Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH","canonical_id":"clinicaltrials.gov:NCT04790175","description":"Antidiuretic Hormone, Inappropriate Secretion","metadata":null},{"id":"67cb55eed6654b87bad72515fc0001a8","type":"TRIAL","name":"Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial","canonical_id":"clinicaltrials.gov:NCT01178827","description":"Overactive Bladder","metadata":null},{"id":"84882ed0b299490aacac93d64275558e","type":"DRUG","name":"Sapanisertib","canonical_id":"ncit:C90548","description":null,"metadata":null},{"id":"743f3673d350499587ce719ab63bc802","type":"TRIAL","name":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT02159989","description":"Advanced Malignant Solid Neoplasm; Fibrolamellar Carcinoma; Metastatic Malignant Solid Neoplasm; Ovarian Carcinoma; Pancreatic Neuroendocrine Tumor; Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm","metadata":null},{"id":"90ca5323463f46cca0d751396078cb80","type":"TRIAL","name":"Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy","canonical_id":"clinicaltrials.gov:NCT02756364","description":"Breast Neoplasms","metadata":null},{"id":"5120e6573abb4a33a814a8ebaeab532a","type":"TRIAL","name":"Saphnelo Use in Females of Child-bearing Potential","canonical_id":"clinicaltrials.gov:NCT07431775","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"2bcabdd8ebfb43af94844bb10e19f574","type":"TRIAL","name":"Sapropterin Expanded Access Program","canonical_id":"clinicaltrials.gov:NCT00484991","description":"Phenylketonuria","metadata":null},{"id":"49d8f17c238f426894c9a2dcb5faffd4","type":"TRIAL","name":"Sapropterin as a Treatment for Autistic Disorder","canonical_id":"clinicaltrials.gov:NCT00850070","description":"Autistic Disorder","metadata":null},{"id":"cadd88e83aaa475da5cb1c1ecb84f7de","type":"TRIAL","name":"Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria","canonical_id":"clinicaltrials.gov:NCT01977820","description":"Phenylketonuria","metadata":null},{"id":"4c77ccc52e6547dc81771127375b433c","type":"DISEASE","name":"Sarcoidosis","canonical_id":"mesh:D012507","description":null,"metadata":null},{"id":"779fb2a4d386420a97bfb37e880edd5c","type":"DISEASE","name":"Sarcoma","canonical_id":"doid:1115","description":null,"metadata":null},{"id":"c8a58599a634421192bb7cac36fa5dc3","type":"DISEASE","name":"Sarcoma of soft tissue","canonical_id":"mesh:D012509","description":null,"metadata":null},{"id":"6fad602c5e3a4119829437abcc8bc861","type":"DISEASE","name":"Sarilumab","canonical_id":"mesh:C000592401","description":null,"metadata":null},{"id":"ab290ec98ed248d2a1816c9c35b79746","type":"TRIAL","name":"Sarilumab COVID-19","canonical_id":"clinicaltrials.gov:NCT04327388","description":"Corona Virus Infection","metadata":null},{"id":"e8c6de8dcc1446fc9204b9f7ce74d336","type":"TRIAL","name":"Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica","canonical_id":"clinicaltrials.gov:NCT07286214","description":"Polymyalgia Rheumatica","metadata":null},{"id":"7b8856b2bcd14ddfb2f633dbe092a431","type":"TRIAL","name":"Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19","canonical_id":"clinicaltrials.gov:NCT04661527","description":"COVID-19 Drug Treatment","metadata":null},{"id":"40689cf9d2d14b078d8de79eb590ba5d","type":"TRIAL","name":"Sarilumab for Patients With Moderate COVID-19 Disease","canonical_id":"clinicaltrials.gov:NCT04359901","description":"COVID","metadata":null},{"id":"d61cc48553b948c5b29efd4fbb2386aa","type":"TRIAL","name":"Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis","canonical_id":"clinicaltrials.gov:NCT04008069","description":"Sarcoidosis","metadata":null},{"id":"8dc42c9209214071ac280e1b033fb0d6","type":"TRIAL","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06380751","description":"Advanced Breast Cancer","metadata":null},{"id":"1d810d48c88d4b778952ba5a9f721c7f","type":"TRIAL","name":"Satisfaction and Compliance of Risedronate in PMO","canonical_id":"clinicaltrials.gov:NCT00549965","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"8c2f270681b841d6b6c9c18312d13a5e","type":"TRIAL","name":"Satisfaction of Patients With Erectile Dysfunction With the Use of Sildenafil Oral Suspension Compared to Orodispersible Tablets","canonical_id":"clinicaltrials.gov:NCT07676617","description":"Erectile Dysfunction; Erectile Dysfunction (ED)","metadata":null},{"id":"fb44c693a317411fa50cea65787fecd8","type":"TRIAL","name":"Satisfaction of Patients With the Chosen Method of Inhibition of Lactation","canonical_id":"clinicaltrials.gov:NCT04038749","description":"Lactation Suppressed","metadata":null},{"id":"132112906a1e4ff188a77ecd775fc8d4","type":"TRIAL","name":"Satralizumab in Aneurysmal Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT05727657","description":"Aneurysmal Subarachnoid Hemorrhage; Delayed Cerebral Ischemia","metadata":null},{"id":"e0c4f7d12ae948358aad1c4ad32d41b0","type":"TRIAL","name":"Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)","canonical_id":"clinicaltrials.gov:NCT05679570","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"d7ee1250ad1e4abc9c46ac37ec805e61","type":"TRIAL","name":"Savella in Treatment for Provoked Vestibulodynia","canonical_id":"clinicaltrials.gov:NCT01304589","description":"Vestibulodynia; Vulvodynia","metadata":null},{"id":"3087f761ff154a4ebde1e996cd6bec65","type":"TRIAL","name":"Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan","canonical_id":"clinicaltrials.gov:NCT00791830","description":"Kidney Failure, Chronic","metadata":null},{"id":"5355a86ccefa4dba9094e47542724c26","type":"TRIAL","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","canonical_id":"clinicaltrials.gov:NCT03091192","description":"Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Urologic Neoplasms; Kidney Diseases; Neoplasms by Site; Enzyme Inhibitors; Protein Kinase Inhibitors","metadata":null},{"id":"9fed28a7c9cf4c1682b15a38e4e8e2fd","type":"TRIAL","name":"Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis","canonical_id":"clinicaltrials.gov:NCT02022007","description":"Polycystic Ovary Syndrome; Disorder of Glucose Regulation","metadata":null},{"id":"ab6c1372fb0f4860802cf39a8e863502","type":"TRIAL","name":"Saxagliptin and Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT01552018","description":"Coronary Artery Disease; Diabetes Mellitus Type 2","metadata":null},{"id":"7d8a5f591a3d44e1ac9effdbc58a5d39","type":"TRIAL","name":"Scalp Cooling in MBC","canonical_id":"clinicaltrials.gov:NCT04986579","description":"Metastatic Breast Cancer; Chemotherapy-induced Alopecia","metadata":null},{"id":"d4d66747764b4395a7d8fac5edf827ce","type":"DISEASE","name":"Scalp Dermatoses","canonical_id":"mesh:D012536","description":null,"metadata":null},{"id":"fdbf4077bc034e9dadf316fb69bb0c1b","type":"DISEASE","name":"Scarlet fever","canonical_id":"mesh:D012541","description":null,"metadata":null},{"id":"f5ae0fd662ee46a6ac18f466e358ba8b","type":"GO_TERM","name":"Scc2-Scc4 cohesin loading complex","canonical_id":"go:GO:0090694","description":"\"A eukaryotically conserved heterodimeric protein complex (comprising adherin and the chromatid cohesion factor MAU2/Scc4/Ssl3) required for the loading of a cohesin, complex onto DNA.\" [GOC:vw, PMID:24291789]","metadata":null},{"id":"feb4b4b4b7924db883517fcc2480a51e","type":"GO_TERM","name":"Schaffer axon collateral","canonical_id":"go:GO:1990021","description":"\"Part of axon of a CA3 pyramidal neuron that projects to hippocampal area CA1.\" [NIF_Subcellular:nlx_subcell_20090511]","metadata":null},{"id":"a40c00fd45d34273bb0f4aa306f82bfd","type":"GO_TERM","name":"Schaffer collateral - CA1 synapse","canonical_id":"go:GO:0098685","description":"\"A synapse between the Schaffer collateral axon of a CA3 pyramidal cell and a CA1 pyramidal cell.\" [PMID:16399689]","metadata":null},{"id":"87881ea2fb0e4268b6effbaf4af07b20","type":"DISEASE","name":"Schistosomiasis","canonical_id":"mesh:D012552","description":null,"metadata":null},{"id":"c2093c7a8c3f443a8068db9ec83dcaa1","type":"DISEASE","name":"Schizophrenia","canonical_id":"mesh:D012559","description":null,"metadata":null},{"id":"647fff2a77154522b2a83770bbd7472e","type":"TRIAL","name":"Schizophrenia Trial of Aripiprazole","canonical_id":"clinicaltrials.gov:NCT00237913","description":"Schizophrenia","metadata":null},{"id":"dae355bd185046febc25c48e6a186551","type":"GO_TERM","name":"Schmidt-Lanterman incisure","canonical_id":"go:GO:0043220","description":"\"Regions within compact myelin in which the cytoplasmic faces of the enveloping myelin sheath are not tightly juxtaposed, and include cytoplasm from the cell responsible for making the myelin. Schmidt-Lanterman incisures occur in the compact myelin internode, while lateral loops are analogous structures found in the paranodal region adjacent to the nodes of Ranvier.\" [GOC:dgh]","metadata":null},{"id":"5979890baa9349b5b41d85d64e2b9dd1","type":"GO_TERM","name":"Schwann cell chemotaxis","canonical_id":"go:GO:1990751","description":"\"The directed movement of a Schwann cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [PMID:16203995]","metadata":null},{"id":"67db2e22ca84477ab0a58ed980ea57b6","type":"GO_TERM","name":"Schwann cell development","canonical_id":"go:GO:0014044","description":"\"The process aimed at the progression of a Schwann cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. Schwann cells are found in the peripheral nervous system, where they insulate neurons and axons, and regulate the environment in which neurons function.\" [GOC:dgh, GOC:ef]","metadata":null},{"id":"86e1f34618f24f9084b5e927a225d5cc","type":"GO_TERM","name":"Schwann cell differentiation","canonical_id":"go:GO:0014037","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a Schwann cell. Schwann cells are found in the peripheral nervous system, where they insulate neurons and axons, and regulate the environment in which neurons function.\" [GOC:ef]","metadata":null},{"id":"d6fff943d17b459385488f6ec459fbf9","type":"GO_TERM","name":"Schwann cell microvillus","canonical_id":"go:GO:0097454","description":"\"Small finger-like extension of a Schwann cell that contacts the nodal membrane.\" [NIF_Subcellular:sao1890444066, PMID:15988042]","metadata":null},{"id":"f096e952c38248e8b4faa1de4aa95030","type":"GO_TERM","name":"Schwann cell migration","canonical_id":"go:GO:0036135","description":"\"The orderly movement of a Schwann cell from one site to another. A Schwann cell is a glial cell that ensheathes axons of neuron in the peripheral nervous system and is necessary for their maintenance and function.\" [CL:0002573, PMID:20335460]","metadata":null},{"id":"fde219c64baf47d8adc5cbed1d5409b1","type":"GO_TERM","name":"Schwann cell proliferation","canonical_id":"go:GO:0014010","description":"\"The multiplication or reproduction of Schwann cells, resulting in the expansion of their population. Schwann cells are a type of glial cell in the peripheral nervous system.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"de925595245c4e239af6201e910f7f7b","type":"TRIAL","name":"Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet","canonical_id":"clinicaltrials.gov:NCT05614648","description":"Lumbosacral Radiculopathy","metadata":null},{"id":"a7f19916f84f4e5396b5c9ec8a78b987","type":"TRIAL","name":"Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children","canonical_id":"clinicaltrials.gov:NCT04996485","description":"Congenital Ichthyosis","metadata":null},{"id":"545588dacbb64051948b5b0f7c2bf693","type":"TRIAL","name":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT07388758","description":"Nasopharyngeal Carcinoma (NPC)","metadata":null},{"id":"5a1e8e8c0fda46b5ba8456f86f608e1d","type":"DISEASE","name":"Scleroderma, Localized","canonical_id":"mesh:D012594","description":null,"metadata":null},{"id":"6addfb086e8645258c12f645c661cd44","type":"DRUG","name":"Scopolamine","canonical_id":"mesh:D012601","description":null,"metadata":null},{"id":"3375d372a1ff4c5e8ccab65021b9fa85","type":"TRIAL","name":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06314334","description":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","metadata":null},{"id":"cdc9655c60f14f55b6d0bd483be7ab1d","type":"TRIAL","name":"Screening Trial for Pain Relief in Schwannomatosis (STARFISH)","canonical_id":"clinicaltrials.gov:NCT05684692","description":"Schwannomatosis; Schwannomas; Pain, Chronic","metadata":null},{"id":"fdcd5e1b1e5540b28a74e6396b46e9a2","type":"TRIAL","name":"Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease","canonical_id":"clinicaltrials.gov:NCT03793114","description":"Primary Adrenal Insufficiency","metadata":null},{"id":"a853a982400846eca65a1b86924e87ce","type":"TRIAL","name":"Screening for Colorectal Cancer in Average and High Risk Population","canonical_id":"clinicaltrials.gov:NCT04017845","description":"Colorectal Neoplasms; Colorectal Cancer; Adenomatous Polyp of Colon","metadata":null},{"id":"4de031fc7dab426aacad4bcc9f476383","type":"GO_TERM","name":"Scrib-APC complex","canonical_id":"go:GO:0034749","description":"\"A protein complex that contains the Scribble protein (a cell polarity determinant) and the tumor suppressor protein adenomatous polyposis coli (APC); may be involved in the control of cell proliferation.\" [PMID:16611247]","metadata":null},{"id":"40913f4c2d7c4975b7f6ac3f98cb81c6","type":"GO_TERM","name":"Scrib-APC-beta-catenin complex","canonical_id":"go:GO:0034750","description":"\"A protein complex that contains the Scribble protein (a cell polarity determinant), the tumor suppressor protein adenomatous polyposis coli (APC), and beta-catenin; may be involved in the control of cell proliferation.\" [PMID:16611247]","metadata":null},{"id":"e81be8e0a72f46ab94fc666cc01ed392","type":"DISEASE","name":"Scrotum Paget's Disease","canonical_id":"doid:3444","description":null,"metadata":null},{"id":"224f8df77919404389def2d2b1350b77","type":"DISEASE","name":"Scrub Typhus","canonical_id":"mesh:D012612","description":null,"metadata":null},{"id":"9af53ac570d745868de77483d3a7a07a","type":"TRIAL","name":"Scrub Typhus Antibiotic Resistance Trial","canonical_id":"clinicaltrials.gov:NCT03083197","description":"Scrub Typhus","metadata":null},{"id":"97fb6fa1e1c747468aee2f8dcfc8e1e5","type":"GO_TERM","name":"Se-methyltransferase activity","canonical_id":"go:GO:0051995","description":"\"Catalysis of the transfer of a methyl group to the selenium atom of an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"4d3059e4b87f47ecb3b09b7bc43ef178","type":"TRIAL","name":"Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human","canonical_id":"clinicaltrials.gov:NCT02129621","description":"Cardiovascular Diseases","metadata":null},{"id":"1b732a79048145548d26af1a5eab9cf4","type":"DISEASE","name":"Seasonal affective disorder","canonical_id":"mesh:D016574","description":null,"metadata":null},{"id":"91d8fbdbb9af46e3bc49639fb242eb02","type":"DISEASE","name":"Seasonal allergic rhinitis","canonical_id":"mesh:D006255","description":null,"metadata":null},{"id":"1d6868e7ec59493999af707fd085e0dd","type":"DISEASE","name":"Seborrheic dermatitis","canonical_id":"mesh:D012628","description":null,"metadata":null},{"id":"0df2596332d7409a92b30b12f79b6658","type":"GO_TERM","name":"Sec61 translocon complex","canonical_id":"go:GO:0005784","description":"\"A translocon complex that contains a core heterotrimer of conserved alpha, beta and gamma subunits, and may contain additional proteins (translocon-associated proteins or TRAPs); in budding yeast the core proteins are Sec61p, Sbh1p, and Sss1p. The Sec61 translocon complex functions in cotranslational and posttranslational translocation events.\" [GOC:mah, PMID:18166647, PMID:32820719, PMID:33960686]","metadata":null},{"id":"1cc8520442ed434b8fad0e46210249d8","type":"GO_TERM","name":"Sec61 translocon complex binding","canonical_id":"go:GO:0106138","description":"\"Binding to a Sec61 translocon complex.\" [GOC:pga, PMID:9792704]","metadata":null},{"id":"0b732250a38e4584989cd693dab10a29","type":"GO_TERM","name":"Sec62/Sec63 complex","canonical_id":"go:GO:0031207","description":"\"A protein complex involved in the posttranslational targeting of proteins to the ER. In yeast, it is a tetrameric complex consisting of Sec62p, Sec63p, Sec71p and Sec72p.\" [PMID:12518317, PMID:14617809]","metadata":null},{"id":"c7873c97162a452fa7a4c81643211382","type":"DRUG","name":"Secbutabarbital","canonical_id":"mesh:C084833","description":null,"metadata":null},{"id":"3687bc9e7e7d451e87a9273102dc76d0","type":"DRUG","name":"Secnidazole","canonical_id":"mesh:C016724","description":null,"metadata":null},{"id":"e9e60c28c30c4e1aa474065688e0d98a","type":"TRIAL","name":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT02684708","description":"Classical Hodgkin Lymphoma","metadata":null},{"id":"cfee775fb46f4356971dc34ec98471db","type":"TRIAL","name":"Second-Line Treatments for Anovulatory Infertility in PCOS Patients","canonical_id":"clinicaltrials.gov:NCT00558077","description":"Polycystic Ovary Syndrome; Infertility; Anovulation","metadata":null},{"id":"e20bf6efe983471b8854232803c1f7c6","type":"TRIAL","name":"Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00684216","description":"Breast Cancer","metadata":null},{"id":"9b1d267d7000468b8ba3396bb7ce0a17","type":"TRIAL","name":"Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy","canonical_id":"clinicaltrials.gov:NCT05585580","description":"Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"2db07119c85541729073254f0f5a5574","type":"TRIAL","name":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","canonical_id":"clinicaltrials.gov:NCT05323955","description":"Brain Metastases; Human Epidermal Growth Factor 2 Positive Carcinoma of Breast; Advanced Breast Cancer","metadata":null},{"id":"a13225d18cc44fe492b2e7407d1f9f49","type":"TRIAL","name":"Secondary Prophylaxis After Variceal Bleeding in Non-Responders","canonical_id":"clinicaltrials.gov:NCT00450164","description":"Gastrointestinal Hemorrhage; Portal Hypertension; Cirrhosis","metadata":null},{"id":"49be14c2370d43c68390b2c6558735ab","type":"DISEASE","name":"Secondary hyperparathyroidism","canonical_id":"mesh:D006962","description":null,"metadata":null},{"id":"7b86f799a6d9444dab00b40e000005d1","type":"DISEASE","name":"Secondary malignant neoplasm of female breast","canonical_id":"mesh:D001943","description":null,"metadata":null},{"id":"c16594130ba34955912c67a3270ccff4","type":"TRIAL","name":"Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT00587132","description":"Pancreatic Cancer","metadata":null},{"id":"111990c5f3b849cbb7fe134c2dcc0e84","type":"TRIAL","name":"Secretin Activates Human Brown Fat and Induces Satiation.","canonical_id":"clinicaltrials.gov:NCT03290846","description":"Obesity","metadata":null},{"id":"758cd22d497c4a8eace20e59c42f299e","type":"TRIAL","name":"Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population","canonical_id":"clinicaltrials.gov:NCT00621283","description":"Acute Recurrent Pancreatitis; Chronic Pancreatitis","metadata":null},{"id":"fa96d16c7d9c45cf87374321b4582004","type":"TRIAL","name":"Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas","canonical_id":"clinicaltrials.gov:NCT00621556","description":"Intraductal Papillary Mucinous Neoplasms","metadata":null},{"id":"5718bf5b402849a2a04c0d8418d603c5","type":"TRIAL","name":"Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis","canonical_id":"clinicaltrials.gov:NCT00620919","description":"Chronic Pancreatitis","metadata":null},{"id":"a39a160ebc0645d29c1ad697d4d2f095","type":"TRIAL","name":"Secretin Infusion for Pain Due to Chronic Pancreatitis","canonical_id":"clinicaltrials.gov:NCT01265875","description":"Chronic Pancreatitis","metadata":null},{"id":"5b7699cba5154890af41da44a2f0abcf","type":"TRIAL","name":"Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection","canonical_id":"clinicaltrials.gov:NCT02160808","description":"Injury of Body of Pancreas","metadata":null},{"id":"57b6f1fdb5d84c408a1c83aa26d8e1f9","type":"TRIAL","name":"Secretin for Acute Pancreatitis","canonical_id":"clinicaltrials.gov:NCT03686618","description":"Pancreatitis, Acute","metadata":null},{"id":"688d4ee0a4134074a388de864df81c31","type":"TRIAL","name":"Secretin for the Treatment of Autism","canonical_id":"clinicaltrials.gov:NCT00065962","description":"Autism","metadata":null},{"id":"b168200bad4249ed86d0cf5d9064d8be","type":"TRIAL","name":"Secretin in Ex-situ Liver Perfusion","canonical_id":"clinicaltrials.gov:NCT07651748","description":"Liver Transplantation","metadata":null},{"id":"270b4baab1564afaaeb3bce587263737","type":"TRIAL","name":"Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity","canonical_id":"clinicaltrials.gov:NCT01371240","description":"Pancreas Cancer","metadata":null},{"id":"196f097dd78d4cb592ed905fc667e4ab","type":"TRIAL","name":"Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients","canonical_id":"clinicaltrials.gov:NCT01094561","description":"Pancreatic Cancer","metadata":null},{"id":"eeac72999eaf4fe491c2a6add1a650d8","type":"TRIAL","name":"Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery","canonical_id":"clinicaltrials.gov:NCT01094535","description":"Pancreatic Cancer","metadata":null},{"id":"bef878f2bdee462b8ebdef5ea8dbdbab","type":"TRIAL","name":"Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection","canonical_id":"clinicaltrials.gov:NCT01094626","description":"Pancreatic Cancer; Intraductal Papillary Mucinous Neoplasm","metadata":null},{"id":"727c0d826331440bbb7bfb3fc21aba27","type":"TRIAL","name":"Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNF\u03b1 Agents.","canonical_id":"clinicaltrials.gov:NCT01770379","description":"Rheumatoid Arthritis","metadata":null},{"id":"8139014a188940348df06f72a291e903","type":"TRIAL","name":"Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)","canonical_id":"clinicaltrials.gov:NCT03791060","description":"Necrobiosis Lipoidica Diabeticorum","metadata":null},{"id":"7081a810245646728d32a98392dc6ef3","type":"TRIAL","name":"Secukinumab for Treatment of Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02594098","description":"Atopic Dermatitis","metadata":null},{"id":"0d1898e467ff4a53bcdc69d3b8c245ab","type":"TRIAL","name":"Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial","canonical_id":"clinicaltrials.gov:NCT00596414","description":"Cirrhosis; Chronic Hepatitis; Anxiety","metadata":null},{"id":"6b58af7f459149fd9aa29c6448133d7a","type":"TRIAL","name":"Sedation and Nursing Management in EEG Recording in Children","canonical_id":"clinicaltrials.gov:NCT05492812","description":"Electroencephalography; Melatonin; Chloral Hydrate; Hydroxyzine; Sleep Deprivation","metadata":null},{"id":"9cbfdbfba76f4dd881a471b583b52a6b","type":"TRIAL","name":"Sedation in Patients Undergoing GIT Endoscopy","canonical_id":"clinicaltrials.gov:NCT05880459","description":"Sedation for Patients Undergoing GIT Endoscopy","metadata":null},{"id":"f5164650164a423caf08124a42078c29","type":"GO_TERM","name":"Seh1-associated complex","canonical_id":"go:GO:0035859","description":"\"A GTPase-activating protein (GAP) complex that regulates TORC1 signaling by interacting with the Rag GTPase. In S. cerevisiae the complex contains Seh1p, Sec13p, Npr2p, Npr3p, Iml1p, Mtc5p, Rtc1p, and Sea4p.\" [GOC:jh, PMID:21454883, PMID:23974112]","metadata":null},{"id":"d981f66fc7504ce4a9bef8365b218aa7","type":"DISEASE","name":"Seizure","canonical_id":"hp:0001250","description":null,"metadata":null},{"id":"03de905f55a04d7f9096dc8601440461","type":"TRIAL","name":"Seizure Prophylaxis in Patients With Glioma or Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT03436433","description":"Glioma; Glioma of Brain; Brain Tumor","metadata":null},{"id":"04ef15b9300344b1b4013e51044bed1f","type":"TRIAL","name":"Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).","canonical_id":"clinicaltrials.gov:NCT07305363","description":"Liver Transplant; Complications; Ischemic Cholangiopathy","metadata":null},{"id":"62f7fa50d76e4521b9e3858467899274","type":"TRIAL","name":"Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis","canonical_id":"clinicaltrials.gov:NCT06051617","description":"Primary Biliary Cholangitis","metadata":null},{"id":"96bfc8e0c99f4cfd88bcf3cea916c807","type":"TRIAL","name":"Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","canonical_id":"clinicaltrials.gov:NCT02015728","description":"Recurrent Childhood Brain Tumor","metadata":null},{"id":"52bf5b3d0c5e4e24acca9d184c4b4ad7","type":"TRIAL","name":"Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT00165048","description":"Cancer of Stomach","metadata":null},{"id":"852caee85b5643f3873aaadf1806cafb","type":"TRIAL","name":"Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging \u2265 T2N1) - A Multi-Centre Prospective Randomised Controlled Trial","canonical_id":"clinicaltrials.gov:NCT00164892","description":"Cancer of Stomach","metadata":null},{"id":"7d7f4f56367745578bd29191391a4529","type":"TRIAL","name":"Selective Estrogen Modulation and Melatonin in Early COVID-19","canonical_id":"clinicaltrials.gov:NCT04531748","description":"Covid19","metadata":null},{"id":"1249fc1b04124cd685b673b42a73b8a5","type":"TRIAL","name":"Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?","canonical_id":"clinicaltrials.gov:NCT01481883","description":"Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder","metadata":null},{"id":"4b2ae5f5800741eea2d00e4450ff875f","type":"TRIAL","name":"Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00361543","description":"Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder","metadata":null},{"id":"e95a67f71a98411f9890340f151dfe43","type":"TRIAL","name":"Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors","canonical_id":"clinicaltrials.gov:NCT03382834","description":"HIV Infections","metadata":null},{"id":"48190a29ee4e4e0484762621c6d003b4","type":"TRIAL","name":"Selegiline Patch for Treatment of Nicotine Dependence","canonical_id":"clinicaltrials.gov:NCT01330030","description":"Tobacco Use Disorder","metadata":null},{"id":"8bdac1375cd948f9b5f763dbb3aa8178","type":"TRIAL","name":"Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00032929","description":"Cocaine-Related Disorders","metadata":null},{"id":"14a3a82ffdc547f985f06ddd57366ce4","type":"TRIAL","name":"Selegiline and Reward Processing","canonical_id":"clinicaltrials.gov:NCT04130087","description":"Healthy","metadata":null},{"id":"3c333dc8aacd47a583a064f8a191b9b4","type":"TRIAL","name":"Selegiline for Smoking Cessation - 1","canonical_id":"clinicaltrials.gov:NCT00439413","description":"Nicotine Dependence","metadata":null},{"id":"28fd2603574c465fb27cd2ed6edb87c2","type":"TRIAL","name":"Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04870372","description":"Parkinson Disease","metadata":null},{"id":"e3c6b0aad2bb49e289831bfa555a7e3f","type":"TRIAL","name":"Selegiline in Outpatient Treatment for Cocaine Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00000336","description":"Cocaine-Related Disorders","metadata":null},{"id":"b0db1ac68a8947fbbf5f0cacb7f0ccc7","type":"TRIAL","name":"Selegiline in Treatment of Cocaine Dependence - 2","canonical_id":"clinicaltrials.gov:NCT00000188","description":"Cocaine-Related Disorders","metadata":null},{"id":"38aea76f529e448ab02b558dfbaed990","type":"DRUG","name":"Selenium sulfide","canonical_id":"mesh:C025698","description":null,"metadata":null},{"id":"690e3aa3b72f4d85ad70b11d3d5c1c4c","type":"TRIAL","name":"Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00736645","description":"Prostate Cancer","metadata":null},{"id":"a7d0087e5a624f54b8fbe444cb240581","type":"TRIAL","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","canonical_id":"clinicaltrials.gov:NCT05035745","description":"Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers","metadata":null},{"id":"747a24f5c0364a50ae453050f462bd43","type":"TRIAL","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT02343042","description":"Multiple Myeloma","metadata":null},{"id":"08294737e7974f73b8162b635f18f95e","type":"TRIAL","name":"Selinexor and Pacritinib in JAK Inhibitor-na\u00efve MF Patients With Cytopenias","canonical_id":"clinicaltrials.gov:NCT07447817","description":"Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"9fc8b695c9f44f2b92a1a28ca575a7de","type":"TRIAL","name":"Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma","canonical_id":"clinicaltrials.gov:NCT03880123","description":"Liposarcoma; Malignant Peripheral Nerve Sheath Tumors; Alveolar Soft Part Sarcoma; Ewing Sarcoma; Sarcoma","metadata":null},{"id":"8ee29455f39c42418cca572f677b0711","type":"TRIAL","name":"Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement","canonical_id":"clinicaltrials.gov:NCT05478993","description":"Multiple Myeloma","metadata":null},{"id":"3d3815d4796b40e99c537fe311d30f0a","type":"DRUG","name":"Selumetinib","canonical_id":"ncit:C66939","description":null,"metadata":null},{"id":"e00bfbee50fe4e1c8e0dd606786c64bd","type":"TRIAL","name":"Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)","canonical_id":"clinicaltrials.gov:NCT01974752","description":"Metastatic; Uveal Melanoma","metadata":null},{"id":"1580313d51174b4b968e01480f68966b","type":"TRIAL","name":"Selumetinib Paediatric NF1 Japan Study","canonical_id":"clinicaltrials.gov:NCT04495127","description":"Neurofibromatosis Type 1","metadata":null},{"id":"f654bd9f29814ee5b0928722264cf4eb","type":"TRIAL","name":"Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer","canonical_id":"clinicaltrials.gov:NCT00551070","description":"Borderline Ovarian Serous Tumor; Low Grade Ovarian Serous Adenocarcinoma; Micropapillary Serous Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor","metadata":null},{"id":"1f86826dc750417eac4f6853cd6dc452","type":"TRIAL","name":"Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT01859182","description":"Adenocarcinoma of the Gallbladder; Adenocarcinoma With Squamous Metaplasia of the Gallbladder; Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Localized Unresectable Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Stage II Gallbladder Cancer; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbladder Cancer; Stage IVA G\u2026","metadata":null},{"id":"93463ac177804ab58150e41cf79e5545","type":"TRIAL","name":"Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib","canonical_id":"clinicaltrials.gov:NCT01519427","description":"Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma","metadata":null},{"id":"fb264fc0e3ba4e0bb4cd2318b4574c49","type":"TRIAL","name":"Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01658943","description":"Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer","metadata":null},{"id":"8bedfc92c2dc4e858461e00d680b9acd","type":"TRIAL","name":"Selumetinib and Azacitidine in High Risk Chronic Blood Cancers","canonical_id":"clinicaltrials.gov:NCT03326310","description":"Chronic Myeloid Leukemia; Myelofibroses","metadata":null},{"id":"8ff7013fed994b20bf55cba2d143e9f9","type":"TRIAL","name":"Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01217450","description":"Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"db23f10f1cc1488bbb427ffe12fa354f","type":"TRIAL","name":"Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT01061749","description":"Adult Solid Neoplasm","metadata":null},{"id":"74b59e98613e4902abe4a2c79e1e62ca","type":"TRIAL","name":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02188264","description":"Recurrent Colorectal Carcinoma; Solid Neoplasm; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7","metadata":null},{"id":"5c10aee1e7e7461192dac6e2be4881b6","type":"TRIAL","name":"Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01222689","description":"Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer","metadata":null},{"id":"54d12ebf68b54276a01b13be5b590bb4","type":"TRIAL","name":"Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02503358","description":"Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7","metadata":null},{"id":"c4a378bbdc3d441fa44bde389880fac9","type":"TRIAL","name":"Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phase\u2161, Double-Blinded, Placebo-Controlled Study","canonical_id":"clinicaltrials.gov:NCT05825365","description":"Neurofibromatosis Type 1; Plexiform Neurofibromas; Post-operative","metadata":null},{"id":"d69a6b11c1e048f387a8a712c115deb4","type":"TRIAL","name":"Selumetinib in Combination With Gefitinib in NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT02025114","description":"Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"c4b49a912ad04924bc7a4c361af8bd42","type":"TRIAL","name":"Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT02337530","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"7ad943f27a7249a298e2c339134d7579","type":"TRIAL","name":"Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00553332","description":"Liver and Intrahepatic Biliary Tract Cancer; Recurrent Extrahepatic Bile Duct Cancer; Unresectable Extrahepatic Bile Duct Cancer","metadata":null},{"id":"f7bc5a44f0824e5b93ec87b85d4ade6f","type":"TRIAL","name":"Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma","canonical_id":"clinicaltrials.gov:NCT02839720","description":"Cutaneous Neurofibroma; Neurofibromatosis Type 1; Optic Nerve Glioma","metadata":null},{"id":"0532aa3bfa3c45e0bac00e211ceb0344","type":"TRIAL","name":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT07082270","description":"Recurrent Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"066196ccf359453382179225d7c838f9","type":"TRIAL","name":"Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)","canonical_id":"clinicaltrials.gov:NCT07223983","description":"Alcohol Use Disorder; Weight Loss; Bariatric Surgery Patients","metadata":null},{"id":"0b48e783ec27445c96ba1010a6b818b7","type":"TRIAL","name":"Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)","canonical_id":"clinicaltrials.gov:NCT07859150","description":"Morbid Obesity","metadata":null},{"id":"0b133994cb2d4977bb51694e3792b63d","type":"TRIAL","name":"Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT07281196","description":"Sleep Apnea Syndrome (OSAS)","metadata":null},{"id":"08f8f297648a4839866cf2313daec410","type":"TRIAL","name":"Semaglutide Use in Acute Pulmonary Embolism","canonical_id":"clinicaltrials.gov:NCT06118203","description":"Pulmonary Embolism","metadata":null},{"id":"9b5d32e982274bf48b4d7c4e5f4f7fb8","type":"TRIAL","name":"Semaglutide and Intestinal Iron Absorption","canonical_id":"clinicaltrials.gov:NCT06629688","description":"Diabetes Mellitus Type 2; Iron Absorption","metadata":null},{"id":"acda60c1c72c46f78a81ae8c3ea0d110","type":"TRIAL","name":"Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients","canonical_id":"clinicaltrials.gov:NCT04885634","description":"Atrial Fibrillation; Overweight and Obesity","metadata":null},{"id":"0fcf3e72ed2c4cdf83e015d3848ae755","type":"TRIAL","name":"Semaglutide in Youth With Autism Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT07770152","description":"Autism Spectrum Disorder; Obesity","metadata":null},{"id":"398fd7549cf14e89afe25d4392a8333a","type":"TRIAL","name":"Senescence in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02848131","description":"Chronic Kidney Disease","metadata":null},{"id":"a5e855e684ab4d9094e5bf60c5a5c597","type":"DRUG","name":"Sennosides","canonical_id":"mesh:D012676","description":null,"metadata":null},{"id":"0cdae1cd3e774941b4c7f9f3878dceab","type":"TRIAL","name":"Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00807534","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"bf6cf59a3554429abaa27aac005d9be8","type":"TRIAL","name":"Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents","canonical_id":"clinicaltrials.gov:NCT02822937","description":"Healthy","metadata":null},{"id":"d8155636df1b486bb82b2a354c8bf342","type":"TRIAL","name":"Sensor and Electronic Health Records (EHR) Integration Pilot Study","canonical_id":"clinicaltrials.gov:NCT03357341","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"8746166e17a94826ac1be632a9b80c6f","type":"TRIAL","name":"Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain","canonical_id":"clinicaltrials.gov:NCT03537612","description":"Scoliosis","metadata":null},{"id":"da30d8adbff44576a0a7c5d67d1cb5d1","type":"GO_TERM","name":"Sep-tRNA:Cys-tRNA synthase activity","canonical_id":"go:GO:0043766","description":"\"Catalysis of the reaction: H+ + hydrogen sulfide + O-phospho-L-seryl-tRNA(Cys) = L-cysteinyl-tRNA(Cys) + phosphate.\" [PMID:15790858, PMID:16380427, PMID:17110438, RHEA:25686]","metadata":null},{"id":"2cebbd8c1f5f4f73994d2ef6c30b3f65","type":"DISEASE","name":"Sepsis","canonical_id":"hp:0100806","description":null,"metadata":null},{"id":"09aecd433dc0401eaebe1cb1e24ce258","type":"DISEASE","name":"Sepsis of the newborn","canonical_id":"mesh:D000071074","description":null,"metadata":null},{"id":"13eed14a94cc434294563ecdab4e12df","type":"GO_TERM","name":"SeqA-DNA complex","canonical_id":"go:GO:1990097","description":"\"A protein-DNA complex that contains an oligomer of SeqA bound to GATC sites in methylated or newly-synthesized, hemi-methylated double-stranded DNA, with preference for the latter. Binding of SeqA to hemimethylated DNA sequesters oriC, prevents re-methylation of DNA by Dam and in turn stops premature re-initiation of replication during one replication cycle.\" [GOC:bhm, PMID:12379844, PMID:15933720, PMID:23149570]","metadata":null},{"id":"bc28c11485c14ae79d15d26727b9610b","type":"TRIAL","name":"Sequence Towards Remission in Depression","canonical_id":"clinicaltrials.gov:NCT01628783","description":"Depression","metadata":null},{"id":"0ba28f36b3694b28983607acf6a0f12c","type":"TRIAL","name":"Sequenced Therapies for Comorbid and Primary Insomnias","canonical_id":"clinicaltrials.gov:NCT01651442","description":"Insomnia Comorbid to Psychiatric Disorder; Primary Insomnia","metadata":null},{"id":"f0f8571d1ce54213814a2421e269bbab","type":"TRIAL","name":"Sequenced Treatment Alternatives to Relieve Depression (STAR*D)","canonical_id":"clinicaltrials.gov:NCT00021528","description":"Depression","metadata":null},{"id":"04147dee641a46758c87fad031d0b6cd","type":"TRIAL","name":"Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04450836","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"a3e8968c2f9f4dd796fbb89c29751121","type":"TRIAL","name":"Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial","canonical_id":"clinicaltrials.gov:NCT05188742","description":"Overactive Bladder Syndrome","metadata":null},{"id":"1e631cd84e2d4ba39e0c4ecc06dd5171","type":"TRIAL","name":"Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)","canonical_id":"clinicaltrials.gov:NCT00587873","description":"Hodgkin's Disease","metadata":null},{"id":"f84cdb5805ff424395b00544be491d04","type":"TRIAL","name":"Sequential Belimumab and T-cell Based Therapy in SLE","canonical_id":"clinicaltrials.gov:NCT04447053","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"dfc9e695ead04108b39d2ff78d911537","type":"TRIAL","name":"Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00002680","description":"Breast Cancer","metadata":null},{"id":"21a8461d47b448fe95e74ccc4e5d30eb","type":"TRIAL","name":"Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02103257","description":"EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma","metadata":null},{"id":"4a9214d003324d2081137a854d66fc43","type":"TRIAL","name":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT06433635","description":"Bipolar I Disorder; Depression","metadata":null},{"id":"7f4a2301db4d4eea9d0080991ab24f96","type":"TRIAL","name":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","canonical_id":"clinicaltrials.gov:NCT03510325","description":"Schizophrenia","metadata":null},{"id":"5c1d1fe6377b45baaaf7ce860190e35d","type":"TRIAL","name":"Sequential Nephron Blockade in Acute Heart Failure","canonical_id":"clinicaltrials.gov:NCT04163588","description":"Acute Heart Failure","metadata":null},{"id":"eedb262284a24c629ebce3ce835ec66d","type":"TRIAL","name":"Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT02832973","description":"Hypertension Resistant to Conventional Therapy","metadata":null},{"id":"166e66bf654d44c39604939842b39136","type":"TRIAL","name":"Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B","canonical_id":"clinicaltrials.gov:NCT07809165","description":"Chronic Hepatitis B","metadata":null},{"id":"9816345b6b0640bfb0e7b9a3db0beb13","type":"TRIAL","name":"Sequential Therapies After Osteoanabolic Treatment","canonical_id":"clinicaltrials.gov:NCT06164795","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"bf4c818d700e4f6e932d26a1c1a284df","type":"TRIAL","name":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","canonical_id":"clinicaltrials.gov:NCT02974010","description":"Bipolar Depression; Suicidal Ideas; Suicidal Ideation; Suicide, Attempted","metadata":null},{"id":"a7fcde943fa343c9b84a00156d0b81b5","type":"TRIAL","name":"Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression","canonical_id":"clinicaltrials.gov:NCT00296686","description":"Major Depression","metadata":null},{"id":"164f73235a2545cf971ee972092084fe","type":"TRIAL","name":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","canonical_id":"clinicaltrials.gov:NCT04722848","description":"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); ALL, Adult; Philadelphia-Positive ALL","metadata":null},{"id":"8462e7136ff143429f5d701605a2c632","type":"TRIAL","name":"Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD","canonical_id":"clinicaltrials.gov:NCT07772609","description":"Osteoporosis in Post-menopausal Women","metadata":null},{"id":"40b892bdb8b540bd964e93baf56ea96f","type":"TRIAL","name":"Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)","canonical_id":"clinicaltrials.gov:NCT00365456","description":"Osteoporosis","metadata":null},{"id":"5c05ec0045994892ab31fee32d8d3d55","type":"TRIAL","name":"Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine","canonical_id":"clinicaltrials.gov:NCT05042635","description":"Plaque Psoriasis","metadata":null},{"id":"c0107444366844bbb26c558a8540c613","type":"TRIAL","name":"Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00035256","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"48187fdd880f4c0bb3f3e07528f91b62","type":"TRIAL","name":"Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT02194556","description":"EGFR Positive Non-small Cell Lung Cancer; Adenocarcinoma","metadata":null},{"id":"cf8c1b66db8a4a00902c722f714d86ce","type":"GO_TERM","name":"Ser(Gly)-tRNA(Ala) hydrolase activity","canonical_id":"go:GO:0043908","description":"\"Catalysis of the hydrolysis of misacylated Ser-tRNA(Ala) and Gly-tRNA(Ala).\" [GOC:jl, PMID:14663147]","metadata":null},{"id":"c22f94ac3f7242a4bf2947c562fc7519","type":"GO_TERM","name":"Ser-tRNA(Ala) deacylase activity","canonical_id":"go:GO:0002196","description":"\"Catalysis of the hydrolysis of misacylated Ser-tRNA(Ala).\" [GOC:hjd, PMID:21285375]","metadata":null},{"id":"3843ea8f29e84bf7b21f88a4ce79eb83","type":"TRIAL","name":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","canonical_id":"clinicaltrials.gov:NCT03878524","description":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hemato\u2026","metadata":null},{"id":"060a546a5b6f413fa9aba52376e705fc","type":"DRUG","name":"Serine","canonical_id":"mesh:D012694","description":null,"metadata":null},{"id":"214d056963bb4212a955274ba01714b7","type":"TRIAL","name":"Serine and Fenofibrate Study in Patients With MacTel Type 2","canonical_id":"clinicaltrials.gov:NCT04907084","description":"Macular Telangiectasia Type 2","metadata":null},{"id":"2abffe5dfea34f60b5d8b09bf772702e","type":"DRUG","name":"Sermorelin","canonical_id":"mesh:D017337","description":null,"metadata":null},{"id":"f47d6fd1b9bb4122a2efc3fd2c9c8b3f","type":"TRIAL","name":"Seroquel on Glucose Metabolism","canonical_id":"clinicaltrials.gov:NCT00214578","description":"Schizophrenia","metadata":null},{"id":"60e8ef9d6a8840fc8cd4cd69fd65c1f2","type":"TRIAL","name":"Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04239339","description":"Healthy","metadata":null},{"id":"97b9dd2430b74734af2ceddf2ef884f3","type":"TRIAL","name":"Serotonergic Pharmacotherapy for Agitation of Dementia","canonical_id":"clinicaltrials.gov:NCT00009204","description":"Dementia; Alzheimer Disease; Dementia, Vascular","metadata":null},{"id":"b0a4828eab464be284d9a4ef5b73c2bf","type":"TRIAL","name":"Serotonin 1A Agonists and Cognition in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00178971","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"1c3e129603de422e88053ba8954ee6f5","type":"TRIAL","name":"Serotonin Receptor Blockers in Ischemic Mitral Regurgitation","canonical_id":"clinicaltrials.gov:NCT05469165","description":"Ischemic Mitral Regurgitation","metadata":null},{"id":"c519b01134f5467eb70201d4cb79ae63","type":"TRIAL","name":"Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT02767999","description":"Stroke","metadata":null},{"id":"4dc77948c7d8415c8efeee7019b86568","type":"TRIAL","name":"Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression","canonical_id":"clinicaltrials.gov:NCT02132286","description":"Major Depressive Disorder","metadata":null},{"id":"0421466019404d30ad6efbde1c6ab1f8","type":"TRIAL","name":"Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response","canonical_id":"clinicaltrials.gov:NCT00456430","description":"Depression","metadata":null},{"id":"5a0629b69f9a434f9a43f21645a23280","type":"TRIAL","name":"Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT02320240","description":"Depression; Acute Kidney Injury","metadata":null},{"id":"7909998e179842a9a3bb95e150398e10","type":"TRIAL","name":"Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06860529","description":"HR+/HER2- Breast Cancer","metadata":null},{"id":"63140ea1ee27400d81fbf022cd813c98","type":"TRIAL","name":"Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05882513","description":"NSCLC; Neoadjuvant Therapy","metadata":null},{"id":"05a19b203496428bbe4b4a3ef4c15b2a","type":"TRIAL","name":"Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07064876","description":"Early Lung Cancer","metadata":null},{"id":"b47201178b6e4db7898b3f8c1a022b09","type":"TRIAL","name":"Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma","canonical_id":"clinicaltrials.gov:NCT07177443","description":"Locally Advanced Nasopharyngeal Carcinoma","metadata":null},{"id":"8054e731190d4267a6a1ed9163a408d4","type":"TRIAL","name":"Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06388135","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"a69295ad29d34b92894989bc110b5b6e","type":"TRIAL","name":"Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS \u2265 50%","canonical_id":"clinicaltrials.gov:NCT07596121","description":"NSCLC (Non-small Cell Lung Cancer)","metadata":null},{"id":"00ba5f42608f4897b0d58d073b6b8f7f","type":"TRIAL","name":"Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06394661","description":"Breast Cancer","metadata":null},{"id":"e824f8c2cc2d4a6dad94fd985904d157","type":"TRIAL","name":"Serplulimab for Locally Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT07340489","description":"Cervical Cancer","metadata":null},{"id":"9618ac9cea89447cbf72378e9c17c7fe","type":"TRIAL","name":"Serratus Intercostal Plane Block,New Analgesia in Supraumbilical Surgery","canonical_id":"clinicaltrials.gov:NCT04282291","description":"Postoperative Pain; Analgesia; Local Anaesthetic; Abdominal Injury","metadata":null},{"id":"e789046d3b904e6a8cf3550d2b79642b","type":"TRIAL","name":"Sertindole in Asian Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00864045","description":"Schizophrenia","metadata":null},{"id":"4037d12f2e2e4aa989cd0088c3205e4c","type":"GO_TERM","name":"Sertoli cell apoptotic process","canonical_id":"go:GO:1902484","description":"\"Any apoptotic process in a Sertoli cell.\" [GOC:ic, GOC:TermGenie, PMID:17761895]","metadata":null},{"id":"6c9c1f86241a4548a8f6f3ecbb001beb","type":"GO_TERM","name":"Sertoli cell barrier remodeling","canonical_id":"go:GO:0061843","description":"\"The tissue remodeling process by which the Sertoli cell barrier is temporarily disrupted and reorganized to accommodate the transit of preleptotene spermatocytes at stage VIII of the epithelial cycle.\" [PMID:20534520, PMID:24467744]","metadata":null},{"id":"ef5127bc451146158eee4210c4b57865","type":"GO_TERM","name":"Sertoli cell development","canonical_id":"go:GO:0060009","description":"\"The process whose specific outcome is the progression of a Sertoli cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a Sertoli cell fate.\" [GOC:dph]","metadata":null},{"id":"2773a47898ca44389b60494b819fb1e3","type":"GO_TERM","name":"Sertoli cell differentiation","canonical_id":"go:GO:0060008","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a Sertoli cell. A Sertoli cell is a supporting cell projecting inward from the basement membrane of seminiferous tubules.\" [GOC:dph]","metadata":null},{"id":"ec5a1168a0cc49cd904e6c421d3dd70d","type":"GO_TERM","name":"Sertoli cell fate commitment","canonical_id":"go:GO:0060010","description":"\"The process in which the cellular identity of Sertoli cells is acquired and determined.\" [GOC:dph]","metadata":null},{"id":"ebe21df91a094de7bfe24b31d84b4fe4","type":"GO_TERM","name":"Sertoli cell proliferation","canonical_id":"go:GO:0060011","description":"\"The multiplication or reproduction of Sertoli cells, resulting in the expansion of the Sertoli cell population. A Sertoli cell is a supporting cell projecting inward from the basement membrane of seminiferous tubules.\" [GOC:dph]","metadata":null},{"id":"6b95245c45ad4639a2bbe6e840dd0933","type":"TRIAL","name":"Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT04963257","description":"OCD","metadata":null},{"id":"c3f5bdeaacf74166bfca661cae61b2ac","type":"TRIAL","name":"Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression","canonical_id":"clinicaltrials.gov:NCT07645157","description":"Major Depressive Disorder (MDD); Probiotic Intervention","metadata":null},{"id":"7678f10cbcbf47eca0dfc0bb6c5c70a2","type":"TRIAL","name":"Serum Concentration of Tranexamic Acid After Topical Administration in Massive Weight Loss Skin Reducing Surgery","canonical_id":"clinicaltrials.gov:NCT03101124","description":"Surgical Wound; Bleeding","metadata":null},{"id":"04e8114ce86444cc897d2f6dd8dc3955","type":"TRIAL","name":"Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study","canonical_id":"clinicaltrials.gov:NCT04806230","description":"Pharmacokinetics; Antidepressive Agents; Pregnancy","metadata":null},{"id":"c06f5132aada4940b8fdbcb1706a9ee0","type":"DISEASE","name":"Serum Sickness","canonical_id":"mesh:D012713","description":null,"metadata":null},{"id":"a814d51e7ec8483c8b8af63a29aca756","type":"TRIAL","name":"Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab","canonical_id":"clinicaltrials.gov:NCT03115255","description":"Infant, Premature, Diseases","metadata":null},{"id":"86fe7e8af2dc44a09a1646a851758761","type":"TRIAL","name":"Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT05446493","description":"Erectile Dysfunction; Erectile Dysfunction With Diabetes Mellitus","metadata":null},{"id":"224fbc8786274287a53b9e1326c7584e","type":"GO_TERM","name":"Set1C/COMPASS complex","canonical_id":"go:GO:0048188","description":"\"A conserved protein complex that catalyzes methylation of histone H3. In Saccharomyces the complex contains Shg1p, Sdc1p, Swd1p, Swd2p, Swd3p, Spp1p, Bre2p, and the trithorax-related Set1p; in mammals it contains the catalytic subunit (SETD1A or SETD1B), WDR5, WDR82, RBBP5, ASH2L/ASH2, CXXC1/CFP1, HCFC1 and DPY30.\" [PMID:11687631, PMID:11742990, PMID:11805083, PMID:12488447, PMID:18508253, PMID:18838538]","metadata":null},{"id":"d29e4a07e9cd472f97d22d230dc7f674","type":"GO_TERM","name":"Set3 complex","canonical_id":"go:GO:0034967","description":"\"A histone deacetylase complex that is involved in transcriptional regulation. In S. cerevisiae, this complex consists of Set3p, Snt1p, Hos4p, Sif2p, Cpr1p, Hos2p, and Hst1p.\" [GOC:ds, PMID:11711434]","metadata":null},{"id":"59a5966693134b2881275ed7ab38f7de","type":"DRUG","name":"Sevabertinib","canonical_id":"ncit:C185187","description":null,"metadata":null},{"id":"f29a22326bc346c78674c4fdc8b24b98","type":"TRIAL","name":"Severe Hepatitis Intervention With Emapalumab for Liver Disease","canonical_id":"clinicaltrials.gov:NCT07744919","description":"Hepatitis","metadata":null},{"id":"08697a8f4d1d40c2898455ab3081a579","type":"TRIAL","name":"Sex Difference in Preemptive Analgesic Effects With Flurbiprofen Axetil on Postoperative Pain and Sleep Quality","canonical_id":"clinicaltrials.gov:NCT04627779","description":"Preemptive Analgesia; Sex Difference; Flurbiprofen Axetil; Postoperative Pain; Postoperative Sleep Quality","metadata":null},{"id":"4a33d914d12e42d48a90c9c2a25fb328","type":"TRIAL","name":"Sex Differences in Sympathetic Vascular Reactivity at High Altitude","canonical_id":"clinicaltrials.gov:NCT05525416","description":"Vasodilation; Vasoconstriction","metadata":null},{"id":"3cfbe40b665c491eabd8c74d1f8e13be","type":"TRIAL","name":"Sex Disparities in Hypoxic Vasodilation and Impact of Obesity","canonical_id":"clinicaltrials.gov:NCT05219799","description":"Obesity; Vasodilation; Healthy","metadata":null},{"id":"0c769adae50f4425919f5c5b1c846d15","type":"TRIAL","name":"Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial","canonical_id":"clinicaltrials.gov:NCT04944836","description":"Rotator Cuff Tears","metadata":null},{"id":"a85fb30512e64fca8d6584e0fbcd5c33","type":"TRIAL","name":"Sex Steroids and the Serotonin Transporter","canonical_id":"clinicaltrials.gov:NCT01065220","description":"Transsexualism","metadata":null},{"id":"da53fa05388d46ebbf0451839989f127","type":"DISEASE","name":"Sexual Dysfunctions, Psychological","canonical_id":"mesh:D020018","description":null,"metadata":null},{"id":"2fecd8b440fc49e0b6b0586171cb7a4c","type":"TRIAL","name":"Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin","canonical_id":"clinicaltrials.gov:NCT00401661","description":"Prostatic Hyperplasia","metadata":null},{"id":"0bc77f5426fe47ab82e90a2b1a34bff9","type":"DISEASE","name":"Sezary syndrome","canonical_id":"mondo:0017844","description":null,"metadata":null},{"id":"20428a209b864ff88cffaa89e06fde37","type":"GO_TERM","name":"Shc-EGFR complex","canonical_id":"go:GO:0070435","description":"\"A protein complex that contains the epidermal growth factor receptor (EGFR) and the adaptor protein Shc, and is involved in linking EGFR activation to the p21-Ras pathway.\" [GOC:mah, PMID:7798267]","metadata":null},{"id":"378a94f1b3ea404f83849aeb3f494d9c","type":"GO_TERM","name":"Shc-Grb2-Sos complex","canonical_id":"go:GO:0070619","description":"\"A protein complex that contains Grb2, the adaptor protein Shc and the guanine nucleotide exchange factor Sos (or an ortholog thereof, such as mSos1), and is involved in linking EGFR activation to the p21-Ras pathway.\" [GOC:mah, PMID:7970708, PMID:8940013]","metadata":null},{"id":"1663cb6606514cd98e307a44b50dd905","type":"TRIAL","name":"Shifting Pain Modulation From Pro-to Anti-nociceptive","canonical_id":"clinicaltrials.gov:NCT02672202","description":"Post-operative Chronic Pain","metadata":null},{"id":"def415085af748d2950b98130ed397dc","type":"DISEASE","name":"Shigellosis","canonical_id":"mesh:D004405","description":null,"metadata":null},{"id":"5c8234f78b39456ba21347df4fc7d47f","type":"TRIAL","name":"Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition","canonical_id":"clinicaltrials.gov:NCT02682381","description":"Short Bowel Syndrome","metadata":null},{"id":"335c803c0ce64076b72c3460bf90b1d2","type":"TRIAL","name":"Short Bowel Syndrome and Teduglutide Versus Placebo","canonical_id":"clinicaltrials.gov:NCT02099084","description":"Short Bowel Syndrome","metadata":null},{"id":"491c9346ff8d49f481fb7853429cad2e","type":"TRIAL","name":"Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06487429","description":"Gastric Cancer","metadata":null},{"id":"2ed145bcbfb74234aa613dc16f98293c","type":"TRIAL","name":"Short Term Rescue Study of Olanzapine","canonical_id":"clinicaltrials.gov:NCT00186017","description":"Bipolar Disorder","metadata":null},{"id":"0ebca1e3564d4238868575ea15d638c5","type":"TRIAL","name":"Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00706004","description":"Constipation; Cystic Fibrosis","metadata":null},{"id":"bdb1ea6ab5c249bd983e11645e1c010f","type":"TRIAL","name":"Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT02417896","description":"Acute Kidney Injuries; Kidney Injuries, Acute; Kidney Injury, Acute; Acute Renal Injury; Acute Renal Injuries","metadata":null},{"id":"c9627e03d43d491ba9851aab51fe7b38","type":"TRIAL","name":"Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO","canonical_id":"clinicaltrials.gov:NCT02149329","description":"Febrile Neutropenia; Hematological Malignancy","metadata":null},{"id":"c51f629aa164415bb3223778f29c2b41","type":"TRIAL","name":"Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.","canonical_id":"clinicaltrials.gov:NCT02849782","description":"Multiple Sclerosis","metadata":null},{"id":"51a1eba1c6364cb9ad77d9903e83913e","type":"TRIAL","name":"Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis","canonical_id":"clinicaltrials.gov:NCT03534284","description":"Insomnia; End Stage Renal Disease","metadata":null},{"id":"1cc46e4bf19c43bc9be74392be004d45","type":"DISEASE","name":"Short bowel syndrome","canonical_id":"mesh:D012778","description":null,"metadata":null},{"id":"e23224e1743e4a0286ad45ef53f25cf4","type":"DISEASE","name":"Short stature","canonical_id":"hp:0004322","description":null,"metadata":null},{"id":"b3720b955a5e4ad2bc5025bb1bfb2963","type":"TRIAL","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","canonical_id":"clinicaltrials.gov:NCT06542588","description":"Rectal Cancer","metadata":null},{"id":"ba7149bc2a5743efbc4def5169b02f82","type":"TRIAL","name":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT07080684","description":"Chronic Coronary Syndrome","metadata":null},{"id":"4916fd8c9e1a45e39c40e54eb88ffdcc","type":"TRIAL","name":"Short-Term Outcomes of Early Administration of Colchicine in Non-ST Segment Elevation Myocardial Infarction Patients Treated With Drug-Eluting Stents.","canonical_id":"clinicaltrials.gov:NCT07143136","description":"Non ST-Segment Elevation Myocardial Infarction","metadata":null},{"id":"01ee9190cf004e2a9809c5ec56629ee2","type":"TRIAL","name":"Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)","canonical_id":"clinicaltrials.gov:NCT05732493","description":"Locally Advanced Colon Cancer","metadata":null},{"id":"38c91ddef5684ec0b59f28b064da01c6","type":"TRIAL","name":"Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05891561","description":"Breast Cancer","metadata":null},{"id":"c6038468e0ef473ab8385e892a9d2221","type":"TRIAL","name":"Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03747978","description":"Diabetes Mellitus, Type 2; Hypertension","metadata":null},{"id":"100b99de52bc43ba98f90272c323193b","type":"TRIAL","name":"Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)","canonical_id":"clinicaltrials.gov:NCT03591757","description":"Transthyretin Amyloidosis; Amyloidosis, Leptomeningeal, Transthyretin-Related","metadata":null},{"id":"361e44d943c24becbd9c9145c1a45520","type":"TRIAL","name":"Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty","canonical_id":"clinicaltrials.gov:NCT02148848","description":"Osteoporotic Fractures; Femoral Neck Fracture","metadata":null},{"id":"bcb35142cc284760b62b80f0583c518e","type":"TRIAL","name":"Shortened Aggrastat\u00ae Versus Integrilin in Percutaneous Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT01522417","description":"Myocardial Infarction; Acute Coronary Syndromes; Unstable Angina","metadata":null},{"id":"d7e7633e0fc345c383882b84e5a4ea3f","type":"TRIAL","name":"Shortened LSD Intervention for Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT07503002","description":"Major Depression Moderate; Major Depression Severe; Major Depression","metadata":null},{"id":"b07c349930eb425bba9dacf4c62bcb11","type":"GO_TERM","name":"Shu complex","canonical_id":"go:GO:0097196","description":"\"A protein complex involved in error-free DNA post-replication repair (PRR). In Saccharomyces cerevisiae the complex contains Csm2p, Psy3p, Shu1p, and Shu2p.\" [GOC:jh, PMID:15654096, PMID:19496932]","metadata":null},{"id":"5811eb42191648129d0eaf9c89e8175a","type":"TRIAL","name":"Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients","canonical_id":"clinicaltrials.gov:NCT00729963","description":"Obstructive Sleep Apnea; Obesity; Hypertension","metadata":null},{"id":"7ff02bb048ae456c941486618303bb48","type":"TRIAL","name":"Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates","canonical_id":"clinicaltrials.gov:NCT00037752","description":"Cardiovascular Diseases; Heart Diseases; Obesity","metadata":null},{"id":"5ad9c15c895248e1a0e5600ed2c2e0ee","type":"TRIAL","name":"Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients","canonical_id":"clinicaltrials.gov:NCT00941382","description":"Obesity","metadata":null},{"id":"5920da44729146969746c9db69a6168e","type":"GO_TERM","name":"Sid2-Mob1 complex","canonical_id":"go:GO:0034973","description":"\"A protein complex that contains a protein kinase (Sid2 in S. pombe) and its regulatory subunit (Mob1). The Sid2p-Mob1p kinase complex is a component of the septation initiation network in fission yeast (called the mitotic exit network in S. cerevisiae) and is required for cytokinesis. The analogous complex in S. cerevisiae is called Dbf2p-Mob1p complex.\" [GOC:vw, PMID:10837231, PMID:15060149]","metadata":null},{"id":"1839a8e0220944928b6bb384fc7cf2f7","type":"TRIAL","name":"Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT07317115","description":"Obesity (Disorder); Obesity & Overweight; Type 2 Diabetes (T2DM)","metadata":null},{"id":"e7833bf036894e64a436a797b99ecd9f","type":"TRIAL","name":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","canonical_id":"clinicaltrials.gov:NCT03458221","description":"Recurrent Ovarian Cancer; Signal Transduction Pathway Deregulation; Therapy-Associated Cancer","metadata":null},{"id":"643ec2fa033a472c84b859985b15a7e8","type":"TRIAL","name":"Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion","canonical_id":"clinicaltrials.gov:NCT01246011","description":"Coronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 Antibody","metadata":null},{"id":"f1b2e942706e4c86b4bd7b4382f07b82","type":"TRIAL","name":"Sildenafil Citrate Therapy for Oligohydramnios","canonical_id":"clinicaltrials.gov:NCT02372487","description":"Pregnancy Complication","metadata":null},{"id":"385ad217c3ef4b128c1a1a793298efb4","type":"TRIAL","name":"Sildenafil Effect After Ovulation Induction","canonical_id":"clinicaltrials.gov:NCT02890238","description":"Infertility","metadata":null},{"id":"afe5a2b557f64e2cb37fbe8b86075778","type":"TRIAL","name":"Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.","canonical_id":"clinicaltrials.gov:NCT01762475","description":"Traumatic Brain Injury; Post-concussive Syndrome","metadata":null},{"id":"261adba9d076461fbc0f583db590052f","type":"TRIAL","name":"Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01481350","description":"Pulmonary Hypertension","metadata":null},{"id":"10af5762c65340d28fd0babf15726d77","type":"TRIAL","name":"Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH","canonical_id":"clinicaltrials.gov:NCT01726049","description":"Heart Failure, Diastolic; Pulmonary Hypertension","metadata":null},{"id":"320dd9990ed847219760b5b59049cb2b","type":"TRIAL","name":"Sildenafil in Hemodialysis Patients With Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT03763045","description":"Pulmonary Hypertension; Hemodialysis Complication","metadata":null},{"id":"fd24c5ee20a34f608f787fa513de540e","type":"TRIAL","name":"Sildenofil in Persistent Pulmonary Hypertension in Newborns","canonical_id":"clinicaltrials.gov:NCT01558466","description":"Persistent Fetal Circulation Syndrome","metadata":null},{"id":"90d0cbd076634b56ade0c3091f834f6e","type":"DRUG","name":"Silodosin","canonical_id":"mesh:C095285","description":null,"metadata":null},{"id":"ce695330d18c4f1c862b1e2a3cdb02c5","type":"TRIAL","name":"Silodosin Versus Tamsulosin for Treatment of Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT02369744","description":"Ureteral Calculus; Ureterolithiasis; Ureteral Stone","metadata":null},{"id":"c7d6f5b847b5426eac6399f4174f795f","type":"TRIAL","name":"Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07614321","description":"Multiple Sclerosis; Lower Urinary Track Symptoms","metadata":null},{"id":"c3e5ce663fd242a2b712ea35b88c00e8","type":"TRIAL","name":"Silodosin in Facilitating Flexible Uretroscopy","canonical_id":"clinicaltrials.gov:NCT07068087","description":"Stone Ureter; Stone, Kidney","metadata":null},{"id":"bdb63f1bb798473b8d0529859a1da438","type":"TRIAL","name":"Silodosin in Management of Lower Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT06381206","description":"Stone, Kidney","metadata":null},{"id":"727201aa1e924fdfb78d01d0cea46246","type":"TRIAL","name":"Silodosin in Retrograde Intrarenal Surgery","canonical_id":"clinicaltrials.gov:NCT05921370","description":"Urolithiasis","metadata":null},{"id":"0b011fc2db524e27a0ae7a6f7e6d1a0f","type":"TRIAL","name":"Silodosin vs Placebo in the Treatment of Female LUTS","canonical_id":"clinicaltrials.gov:NCT06114979","description":"Lower Urinary Tract Symptoms","metadata":null},{"id":"daedc44a25fb4c92ad5c58c602d5cd8a","type":"TRIAL","name":"Silodosin vs Tamsulosin as MET","canonical_id":"clinicaltrials.gov:NCT05570084","description":"Stone, Urinary","metadata":null},{"id":"e518d8195cfc4e05b4dad26ad4fdd57a","type":"TRIAL","name":"Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial","canonical_id":"clinicaltrials.gov:NCT07467343","description":"Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms","metadata":null},{"id":"67ba3bf8ea7c4b10a6c20b6b74724442","type":"TRIAL","name":"Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones","canonical_id":"clinicaltrials.gov:NCT05789732","description":"Lower Ureteric Stones; Medical Expulsive Therapy; Tadalafil; Silodosin","metadata":null},{"id":"d14cd9cc4124407eb95717a27b306787","type":"DRUG","name":"Siltuximab","canonical_id":"mesh:C504234","description":null,"metadata":null},{"id":"76dc925b119a4bc589730fc3bdbc9b1c","type":"TRIAL","name":"Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease","canonical_id":"clinicaltrials.gov:NCT04838860","description":"Idiopathic Multicentric Castleman's Disease","metadata":null},{"id":"b06bb28551d5419299ecb1fc0f223220","type":"TRIAL","name":"Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04191421","description":"Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8","metadata":null},{"id":"cd0244aab861425ca5e1e2da0b5768dd","type":"TRIAL","name":"Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM","canonical_id":"clinicaltrials.gov:NCT06352866","description":"Multiple Myeloma; Cytokine Release Syndrome; Refractory Multiple Myeloma; Immune Effector Cell Associated Neurotoxicity Syndrome","metadata":null},{"id":"9b47e803ab424bcba7b3d90bbbad85ef","type":"TRIAL","name":"Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT05665725","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"2945fd0a1e7b43aaa5c65d1fb93b48a0","type":"TRIAL","name":"Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial","canonical_id":"clinicaltrials.gov:NCT06470971","description":"Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm","metadata":null},{"id":"ae4df7eb34b845079c967927072c7ef3","type":"TRIAL","name":"Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)","canonical_id":"clinicaltrials.gov:NCT05316116","description":"Large Granular Lymphocyte Leukemia","metadata":null},{"id":"8bb5ec22be954db6b455aaeb0df0ba31","type":"TRIAL","name":"Siltuximab in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02796859","description":"Schizophrenia; Psychotic Disorders","metadata":null},{"id":"3f1332665a0945b0981205abbba861d1","type":"TRIAL","name":"Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT02805868","description":"Myelofibrosis; Polycythemia Vera; Primary Myelofibrosis; Thrombocytopenia","metadata":null},{"id":"aa4b8fd6643c475ca131eb894d286234","type":"TRIAL","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","canonical_id":"clinicaltrials.gov:NCT03315026","description":"Multiple Myeloma; AL Amyloidosis","metadata":null},{"id":"533acc9e00ae4f88910abbaa4d63fa45","type":"TRIAL","name":"Silver Nitrate Versus Topical Steroid For Umbilical Granuloma","canonical_id":"clinicaltrials.gov:NCT06363539","description":"Umbilical Granuloma","metadata":null},{"id":"da8e135e94e44427943d50ae0e9fff52","type":"TRIAL","name":"Similarities and Differences of Biological Therapies for Severe Asthma.","canonical_id":"clinicaltrials.gov:NCT04665141","description":"Asthma","metadata":null},{"id":"09d82c62205b4c2fa6007eaf70f8f73d","type":"DISEASE","name":"Simple goiter","canonical_id":"mesh:D006043","description":null,"metadata":null},{"id":"31f7eee608a84a0e8db4ab4256484138","type":"DISEASE","name":"Simple partial seizure","canonical_id":"mesh:D004828","description":null,"metadata":null},{"id":"c8c3b0c128374afc88ff89f93d68432e","type":"DRUG","name":"Simvastatin","canonical_id":"mesh:D019821","description":null,"metadata":null},{"id":"9814c6f4c0ed4ad49cd24cc62ff9d23a","type":"TRIAL","name":"Simvastatin For Intracerebral Hemorrhage Study","canonical_id":"clinicaltrials.gov:NCT00718328","description":"Intracerebral Hemorrhage","metadata":null},{"id":"d43e2c38d1104a97a0b2399f3787c785","type":"TRIAL","name":"Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","canonical_id":"clinicaltrials.gov:NCT02390843","description":"Retinoblastoma; Clear Cell Sarcoma; Renal Cell Carcinoma; Rhabdoid Tumor; Wilms Tumor; Hepatoblastoma; Neuroblastoma; Germ Cell Tumors; Ewings Sarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Osteosarcoma; Rhabdomyosarcoma","metadata":null},{"id":"1777729785a34dc9b59e19fde63c5dd4","type":"TRIAL","name":"Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment","canonical_id":"clinicaltrials.gov:NCT00819403","description":"Metabolic Syndrome","metadata":null},{"id":"37f09995d0804ce9a8600873b260a0c4","type":"TRIAL","name":"Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT02015988","description":"Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Hypertriglyceridemia","metadata":null},{"id":"27e6b3b1c6c94967a5357c2ecd241359","type":"TRIAL","name":"Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01110785","description":"Colorectal Cancer","metadata":null},{"id":"b273623b53e34306afc94c7e397c91cd","type":"TRIAL","name":"Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02787590","description":"Parkinson Disease","metadata":null},{"id":"47249736578c4beea98a17a148d0014b","type":"TRIAL","name":"Simvastatin for Treating Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00947323","description":"Erectile Dysfunction; Vascular Disease Detected; C Reactive Protein","metadata":null},{"id":"7787a162557944698f697bd4ec1d92b8","type":"TRIAL","name":"Simvastatin in Patients With Septic Shock","canonical_id":"clinicaltrials.gov:NCT00450840","description":"Septic Shock","metadata":null},{"id":"48faf41280bf4ce095db3848fe310331","type":"TRIAL","name":"Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo","canonical_id":"clinicaltrials.gov:NCT00668343","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"f72ba5cf9aa54814ab07799b9d5f2325","type":"GO_TERM","name":"Sin3-type complex","canonical_id":"go:GO:0070822","description":"\"Any of a number of evolutionarily conserved histone deacetylase complexes (HDACs) containing a core consisting of a paired amphipathic helix motif protein (e.g. Sin3p in S. cerevisiae, Pst1 in S. pombe or Sin3A in mammals) at least one class I histone deacetylase (e.g. Rpd3p in S. cerevisiae, Clr6 in S. pombe, or HDAC1 and HDAC2 in mammals), and at least one WD40 repeat protein (e.g. Ume1p in S. cerevisiae, Prw1 in S. pombe, or RbAp46 and RbAp48 in mammals). These complexes also contain a variable number of other proteins that direct histone binding, DNA binding, or add other functionality to the complex.\" [PMID:15565322, PMID:18292778]","metadata":null},{"id":"753b8b2cd3b4403e92f39012de622198","type":"TRIAL","name":"Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis","canonical_id":"clinicaltrials.gov:NCT03929068","description":"Amyotrophic Lateral Sclerosis; Motor Neuron Disease","metadata":null},{"id":"f0ca592051e54fcaa51e14b040b27a93","type":"TRIAL","name":"Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy","canonical_id":"clinicaltrials.gov:NCT01200589","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"6834c74789d94cf6837729377c8de868","type":"TRIAL","name":"Single Arm Romiplostim to Prevent CIT","canonical_id":"clinicaltrials.gov:NCT07048249","description":"Ewings Sarcoma; Chemotherapy Induced Thrombocytopenia","metadata":null},{"id":"9df30646debc46f58c1451d58a2ca98f","type":"TRIAL","name":"Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606","canonical_id":"clinicaltrials.gov:NCT04041648","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"a29b0442fd954bedaecaafe10bd176b5","type":"TRIAL","name":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","canonical_id":"clinicaltrials.gov:NCT02232087","description":"Healthy","metadata":null},{"id":"8088704ef56f4602a995fc07af475c78","type":"TRIAL","name":"Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct","canonical_id":"clinicaltrials.gov:NCT05677282","description":"Diarrhoea;Acute; Diarrhea Travelers","metadata":null},{"id":"e2b394322be8475b9c0cd47357b17fb6","type":"TRIAL","name":"Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT01229280","description":"Bioequivalency","metadata":null},{"id":"ef528d6f8e3d4177b7a4f97e8d4c131a","type":"TRIAL","name":"Single Dose Bronchodilatory Study in Asthma","canonical_id":"clinicaltrials.gov:NCT01805687","description":"Asthma","metadata":null},{"id":"9b95151458a0413293992ef264851a7e","type":"TRIAL","name":"Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.","canonical_id":"clinicaltrials.gov:NCT03136666","description":"Clinical Pharmacology","metadata":null},{"id":"14419c3ed0204bd68fb926de40552dbd","type":"TRIAL","name":"Single Dose Pharmacokinetics of Egalet\u00ae Hydrocodone","canonical_id":"clinicaltrials.gov:NCT00802087","description":"Pain","metadata":null},{"id":"ade833a18e2849fe96448bcaf838dad5","type":"TRIAL","name":"Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays","canonical_id":"clinicaltrials.gov:NCT01190852","description":"Allergic Rhinitis","metadata":null},{"id":"4dbc0c6c677a4d418fda3f78e449f5f8","type":"TRIAL","name":"Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays","canonical_id":"clinicaltrials.gov:NCT01194622","description":"Allergic Rhinitis","metadata":null},{"id":"ab9650fc3bff4b3fb87bffc43393cfe7","type":"TRIAL","name":"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01490658","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"cf4bf848ace14dfda3e2a935b3ee6742","type":"TRIAL","name":"Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients","canonical_id":"clinicaltrials.gov:NCT00571194","description":"End Stage Renal Disease","metadata":null},{"id":"317643bf89b44d3e8b6cd302172874cd","type":"TRIAL","name":"Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate","canonical_id":"clinicaltrials.gov:NCT01199029","description":"Healthy","metadata":null},{"id":"a5f6fb664e5c46928ed9651221887d3a","type":"TRIAL","name":"Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances","canonical_id":"clinicaltrials.gov:NCT04004507","description":"Decrease in Night Vision; Disturbance; Vision, Loss","metadata":null},{"id":"7ea30b386a0a4bbeba5a2fb3994678d1","type":"TRIAL","name":"Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age","canonical_id":"clinicaltrials.gov:NCT02022956","description":"Pharmacokinetics in Obese Adolescents","metadata":null},{"id":"fcb7b52d994741a68886d5c50824b1f4","type":"TRIAL","name":"Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)","canonical_id":"clinicaltrials.gov:NCT06500793","description":"Pharmacokinetics; Healthy Volunteer","metadata":null},{"id":"f62f24abf2c1498aafdb7bca37d6cbf6","type":"TRIAL","name":"Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant","canonical_id":"clinicaltrials.gov:NCT06372483","description":"Coagulation Disorder","metadata":null},{"id":"35b384c5aa264b4b837f3e94c03a98a8","type":"TRIAL","name":"Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT01227811","description":"Bioequivalency","metadata":null},{"id":"337a2166849f4740bccffc342b1a18af","type":"TRIAL","name":"Single Dose Versus Double Dose Tamsulosin 0.4 and Solifenacin 5 in Management of Stent Related Symptoms","canonical_id":"clinicaltrials.gov:NCT06955533","description":"Stent Related Symptoms","metadata":null},{"id":"ee794e143dd24d76bde78cd8d7913129","type":"TRIAL","name":"Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation","canonical_id":"clinicaltrials.gov:NCT00120432","description":"Eye Diseases","metadata":null},{"id":"a466397c0ec74288bf3ff3f1148ca279","type":"TRIAL","name":"Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention","canonical_id":"clinicaltrials.gov:NCT04364321","description":"Recurrent Febrile Convulsion","metadata":null},{"id":"a5e5698fed764164bef2700632931ba0","type":"TRIAL","name":"Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments","canonical_id":"clinicaltrials.gov:NCT06124677","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"771519afcb6445e696c7bcca287db80e","type":"TRIAL","name":"Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab","canonical_id":"clinicaltrials.gov:NCT04247906","description":"Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)","metadata":null},{"id":"7ebe029c497547b5b839736f7f0edfb9","type":"TRIAL","name":"Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT02434718","description":"Alzheimer's Disease","metadata":null},{"id":"27093d80cbca4279aef0be080289932f","type":"TRIAL","name":"Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis","canonical_id":"clinicaltrials.gov:NCT01828086","description":"Chronic Plaque-type Psoriasis","metadata":null},{"id":"674430c9a09f458fa21ce69676e73b3e","type":"TRIAL","name":"Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07629999","description":"Healthy Volunteers","metadata":null},{"id":"50f2c4af6ca34cef854dd29f4eda1d52","type":"TRIAL","name":"Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)","canonical_id":"clinicaltrials.gov:NCT02406066","description":"Cocaine Use Disorder; Tobacco Use Disorder","metadata":null},{"id":"7705915720614727a2c41cea15796a2c","type":"TRIAL","name":"Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib","canonical_id":"clinicaltrials.gov:NCT02226172","description":"Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"5817930dc37c41dd946141e6747e0dda","type":"TRIAL","name":"Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205","canonical_id":"clinicaltrials.gov:NCT01247922","description":"Ependymoma","metadata":null},{"id":"07da6c11f4604a0989f17892b8e37be0","type":"TRIAL","name":"Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02450149","description":"Refractory Solid Tumors","metadata":null},{"id":"c296c13ad91e426381262ed6490bbf45","type":"TRIAL","name":"Single-dose Linaclotide for Capsule Endoscopy Preparation","canonical_id":"clinicaltrials.gov:NCT02465385","description":"Crohn's; Ulcerative Colitis; Gastrointestinal Bleeding","metadata":null},{"id":"73a0a1ee57bd4dd9b9131968802b1c56","type":"TRIAL","name":"Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT03184168","description":"Healthy Volunteers","metadata":null},{"id":"424913e5bc70457781e0bfd6823ffb81","type":"TRIAL","name":"Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity","canonical_id":"clinicaltrials.gov:NCT02372318","description":"Alcoholism","metadata":null},{"id":"54ec668861334dacb1547f634e985753","type":"TRIAL","name":"Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations","canonical_id":"clinicaltrials.gov:NCT02070796","description":"Healthy","metadata":null},{"id":"509cce72e6054fd18367120382d98467","type":"TRIAL","name":"Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma","canonical_id":"clinicaltrials.gov:NCT05502991","description":"Glioblastoma","metadata":null},{"id":"8ea3b82824e34309adcc09337f8f1e90","type":"TRIAL","name":"Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04213170","description":"Brain Metastases; Non Small Cell Lung Cancer; Sintilimab; Bevacizumab","metadata":null},{"id":"5da5364577e74a3da62edd429f69b1ad","type":"TRIAL","name":"Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study","canonical_id":"clinicaltrials.gov:NCT06848569","description":"Classical Hodgkin Lymphoma","metadata":null},{"id":"0c342d73c9b64b3a8e703a910316829d","type":"TRIAL","name":"Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07781072","description":"Locally Advanced Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"a0123e58ba90440c925e6fc05eab1919","type":"TRIAL","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT07831993","description":"Biliary Tract Cancer","metadata":null},{"id":"9a065def21674d42baeffe034c5d22bb","type":"TRIAL","name":"Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06793956","description":"Extranodal Natural Killer/T Cell Lymphoma","metadata":null},{"id":"8fd6fa02596e49f8bc9c3a379c216e5d","type":"TRIAL","name":"Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT04140318","description":"Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma","metadata":null},{"id":"a0a2121afcc74de4bfc5960fb3c32727","type":"TRIAL","name":"Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL","canonical_id":"clinicaltrials.gov:NCT04994210","description":"Safety and Efficacy","metadata":null},{"id":"f4f781ce8b1f4c46a4f63b4e00767db4","type":"TRIAL","name":"Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT03629925","description":"Squamous NSCLC","metadata":null},{"id":"fbf12209337645aea3c6d1a576e4d9ae","type":"TRIAL","name":"Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization","canonical_id":"clinicaltrials.gov:NCT04065737","description":"Oral Cavity Cancer; Mouth Neoplasm; Precancerous Conditions","metadata":null},{"id":"c0a1a2786d5a443dbb1e77b9cacdb461","type":"DISEASE","name":"Sinusitis","canonical_id":"mesh:D012852","description":null,"metadata":null},{"id":"d49990d2d3eb4745ae804b1c6ac7af76","type":"DRUG","name":"Sirolimus","canonical_id":"mesh:D020123","description":null,"metadata":null},{"id":"e02a9cc99bf142a1820eb660fcf145f5","type":"DRUG","name":"Sirolimus","canonical_id":"ncit:C1212","description":null,"metadata":null},{"id":"e43bac473eb64089bcb898cf58f9070f","type":"TRIAL","name":"Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease","canonical_id":"clinicaltrials.gov:NCT04511234","description":"Peripheral Artery Disease; Atherosclerosis; Arterial Disease","metadata":null},{"id":"0ab698ce4e79474c8082eac45e4088a1","type":"TRIAL","name":"Sirolimus in COVID-19 Phase 1","canonical_id":"clinicaltrials.gov:NCT04371640","description":"SARS-CoV-2; Covid-19","metadata":null},{"id":"e09c2bfc7b3742b292ec273688c18f7f","type":"TRIAL","name":"Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT01266057","description":"Advanced Cancers","metadata":null},{"id":"a4d7e11bcadb40b696658a41120dca5e","type":"TRIAL","name":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","canonical_id":"clinicaltrials.gov:NCT00885352","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"70ff9f45992642e692573a2992a79c6f","type":"TRIAL","name":"Sitagliptin Dose Determination Study","canonical_id":"clinicaltrials.gov:NCT01530178","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"916beb646f564369a20a48c356379f42","type":"TRIAL","name":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","canonical_id":"clinicaltrials.gov:NCT02741687","description":"Hyperglycemia","metadata":null},{"id":"f19aa1e1731247e29469bed10def6eb0","type":"TRIAL","name":"Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS","canonical_id":"clinicaltrials.gov:NCT06587698","description":"Polycystic Ovarian Syndrome","metadata":null},{"id":"2944e4d346d147369830f0a8cceb505c","type":"DRUG","name":"Sitaxentan","canonical_id":"mesh:C106276","description":null,"metadata":null},{"id":"473d50bb48c14b44b08182382a174648","type":"TRIAL","name":"Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)","canonical_id":"clinicaltrials.gov:NCT00795639","description":"Pulmonary Arterial Hypertension; Pulmonary Hypertension","metadata":null},{"id":"051bc6b759154adfbc35123fee367703","type":"TRIAL","name":"Sitaxsentan in Proteinuric Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT00817037","description":"Chronic Kidney Disease; Proteinuria; Blood Pressure","metadata":null},{"id":"dc5f219601e74cc7acb4fccfc95a6b0b","type":"DISEASE","name":"Sitosterolemia","canonical_id":"mesh:C537345","description":null,"metadata":null},{"id":"543e9729416e47dbb41c8e304bab01b2","type":"TRIAL","name":"Sitosterolemia Extension Study (0653-003)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092807","description":"Lipid Metabolism, Inborn Errors; Heart Disease","metadata":null},{"id":"a9a4c3b5b14d4720acc12c575fcfd967","type":"DRUG","name":"Sivelestat","canonical_id":"mesh:C069195","description":null,"metadata":null},{"id":"da8c5dcf5c2844109645e6cd96b308b6","type":"TRIAL","name":"Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion","canonical_id":"clinicaltrials.gov:NCT07552610","description":"Acute Ischemic Stroke; Large Vessel Occlusion; Thrombectomy; Neutrophil Extracellular Trap Formation","metadata":null},{"id":"e641b437e32345baa84e99517eba2b24","type":"TRIAL","name":"Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection","canonical_id":"clinicaltrials.gov:NCT07156656","description":"Type A Aortic Dissection; Organ Failure, Multiple","metadata":null},{"id":"f0b24c02f889414bb3d32cc720cdec97","type":"TRIAL","name":"Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19","canonical_id":"clinicaltrials.gov:NCT05697016","description":"Respiratory Infection Virus; Respiratory Failure","metadata":null},{"id":"ca16175e11fb4f499a6c074b9658c8aa","type":"DISEASE","name":"Sjogren syndrome","canonical_id":"mondo:0010030","description":null,"metadata":null},{"id":"ae7bc3484c344431a4644b370f360d1d","type":"DISEASE","name":"Sjogren's Syndrome","canonical_id":"mesh:D012859","description":null,"metadata":null},{"id":"e50bc27c24a34985b30d8042227bcceb","type":"GO_TERM","name":"Ski complex","canonical_id":"go:GO:0055087","description":"\"A protein complex that regulates RNA degradation by the exosome complex. In Saccharomyces the complex has a heterotetrameric stoichiometry consisting of one copy each of Ski2p and Ski3 and two copies of Ski8p.\" [GOC:mcc, PMID:10744028, PMID:15703439, PMID:16043509, PMID:18042677]","metadata":null},{"id":"69d2d8edd62943ba9be16e99cf47a357","type":"DISEASE","name":"Skin Melanoma","canonical_id":"doid:8923","description":null,"metadata":null},{"id":"6ca2304a842347218d6eeba3c0276ec3","type":"TISSUE","name":"Skin Not Sun Exposed Suprapubic","canonical_id":"uberon:UBERON:0036149","description":null,"metadata":null},{"id":"d949e8efe2f64380ad28fed2691a45f1","type":"TRIAL","name":"Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01874860","description":"Colorectal Cancer; Head and Neck Cancer","metadata":null},{"id":"a0acb7a9e2a946c0b760ff9c5e73629d","type":"TISSUE","name":"Skin Sun Exposed Lower leg","canonical_id":"uberon:UBERON:0004264","description":null,"metadata":null},{"id":"43f705f1130341029e280d67adfa156a","type":"DISEASE","name":"Skin ulcer","canonical_id":"hp:0200042","description":null,"metadata":null},{"id":"80866d12381a401381ba19ea375cf435","type":"DISEASE","name":"Skin ulcer","canonical_id":"mesh:D012883","description":null,"metadata":null},{"id":"e19ea04c04a94c05a5fbd12b57ae87f2","type":"GO_TERM","name":"Skp1-protein-hydroxyproline N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0033830","description":"\"Catalysis of the reaction: UDP-N-acetylglucosamine + Skp1-protein-hydroxyproline = UDP + Skp1-protein-O-(N-acetyl-D-glucosaminyl)hydroxyproline.\" [EC:2.4.1.229]","metadata":null},{"id":"27a7845bd5d744da925c80e13bdb61d7","type":"TRIAL","name":"Sleep Apnea: Mechanism and Cerebrovascular Consequences","canonical_id":"clinicaltrials.gov:NCT00108602","description":"Sleep Apnea, Obstructive; Stroke","metadata":null},{"id":"632c1d8df4ac451582cbbf133fbee6b9","type":"TRIAL","name":"Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01519882","description":"Advanced Idiopathic Parkinson's Disease","metadata":null},{"id":"386aed789ca34f67885b0dc01c86d96b","type":"TRIAL","name":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","canonical_id":"clinicaltrials.gov:NCT07494084","description":"Shift Work Schedule; Circadian Rhythm; Insulin Resistance; Circadian Misalignment","metadata":null},{"id":"7ab4568c5e114224883f71d3aa7f2f38","type":"TRIAL","name":"Sleep Quality and Amyloid-Beta Kinetics","canonical_id":"clinicaltrials.gov:NCT03077620","description":"Amyloid-beta","metadata":null},{"id":"b88018e596ee4bc5b1482071eaa44c73","type":"TRIAL","name":"Sleep Quality, Cognitive Performance, and Computerized Cognitive Training","canonical_id":"clinicaltrials.gov:NCT06328140","description":"Bipolar Disorder; Major Depressive Disorder; Psychosis","metadata":null},{"id":"312692740d974544b316cc9d626b981c","type":"TRIAL","name":"Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR","canonical_id":"clinicaltrials.gov:NCT00393042","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"46c4a7e5bbbb453ea21e190fc34cdbd4","type":"GO_TERM","name":"Slit-Robo signaling complex","canonical_id":"go:GO:0071666","description":"\"A protein-carbohydrate complex that consists of a transmembrane roundabout (Robo) receptor, an extracellular Slit ligand and heparin/heparan sulfate.\" [GOC:sart, PMID:17062560, PMID:18359766]","metadata":null},{"id":"d8901f40eb7946de9f7ed9f46956ca66","type":"TRIAL","name":"Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD","canonical_id":"clinicaltrials.gov:NCT07132398","description":"Neuromyelitis Optica (NMO); Neuromyelitis Optica Spectrum Disorders (NMOSD)","metadata":null},{"id":"aea35acfb55b4811a23141230b578ef0","type":"GO_TERM","name":"Slx1-Slx4 complex","canonical_id":"go:GO:0033557","description":"\"A heterodimeric protein complex that possesses an endonuclease activity that specifically cleaves certain types of branched DNA structures; because such structures often form during the replication ribosomal DNA (rDNA) repeats, the complex plays a role in the maintenance of rDNA. The subunits are known as Slx1 and Slx 4 in budding and fission yeasts, and are conserved in eukaryotes.\" [PMID:14528010, PMID:16467377]","metadata":null},{"id":"1ebbb8362ff44d84a44deb644450602b","type":"GO_TERM","name":"Sm-like protein family complex","canonical_id":"go:GO:0120114","description":"\"A protein complex containing members of the Like-Sm family of proteins, which includes both the Sm proteins and the Lsm proteins, and which generally form hexameric or heptameric ring structures which bind to RNA. While some of these ring complexes may form independently of RNA, many only form in association with their target RNA. In addition to Lsm-family proteins, many of these complexes contain additional protein members. Members of this family of complexes include the snRNPs which comprise the majority of the spliceosome. Others are involved in the 5' to 3' degradation pathways of mRNAs in the cytoplasm and of unspliced transcripts in the nucleus, as well as other diverse roles.\" [GOC:bhm, GOC:krc, PMID:19121818, PMID:27627834]","metadata":null},{"id":"0f17d6adb6ca42f78456fec022f345a7","type":"GO_TERM","name":"SmD-containing SMN-Sm protein complex","canonical_id":"go:GO:0034730","description":"\"An SMN-Sm protein complex formed by the association of the methylated Sm proteins B/B', D1, D2, D3, E, F, and G with the SMN complex.\" [PMID:12975319, PMID:17401408]","metadata":null},{"id":"3750744f9ade49d98d793d410f4750ad","type":"TISSUE","name":"Small Intestine Terminal Ileum","canonical_id":"uberon:UBERON:0001211","description":null,"metadata":null},{"id":"cb51e0bf32274429a5adf03583917984","type":"TRIAL","name":"Small Particle Steroids in Refractory Asthma","canonical_id":"clinicaltrials.gov:NCT01171365","description":"Asthma","metadata":null},{"id":"6525d43afa774b2ca1cbc1615c0f1ae0","type":"TRIAL","name":"Small Trial of Alendronate Impact on the Reservoir of HIV","canonical_id":"clinicaltrials.gov:NCT07216794","description":"HIV","metadata":null},{"id":"4d47d0a608f340d8a7a29b303de0f400","type":"DISEASE","name":"Small cell carcinoma of lung","canonical_id":"mesh:D055752","description":null,"metadata":null},{"id":"c4ca3ecece91407390f3f3e3bd8b6aaa","type":"GO_TERM","name":"Smc5-Smc6 complex","canonical_id":"go:GO:0030915","description":"\"A conserved complex that contains a heterodimer of SMC proteins (Smc5p and Smc6p, or homologs thereof) and several other proteins, and is involved in DNA repair and maintaining cell cycle arrest following DNA damage. In S. cerevisiae, this is an octameric complex called Mms21-Smc5-Smc6 complex, with at least five of its subunits conserved in fission yeast and humans.\" [GOC:rb, PMID:14701739, PMID:15738391, PMID:27373152]","metadata":null},{"id":"8937bd191c7a495c92fe810eb8dcd74a","type":"TRIAL","name":"Smell Changes & Efficacy of Nasal Theophylline","canonical_id":"clinicaltrials.gov:NCT03990766","description":"Olfactory Disorder; Anosmia; Viral Infection; Theophylline Causing Adverse Effects in Therapeutic Use; Smell Disorder","metadata":null},{"id":"6361f3b78a264c6584d43796beb93b26","type":"TRIAL","name":"Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)","canonical_id":"clinicaltrials.gov:NCT05947643","description":"COVID-19","metadata":null},{"id":"b7103874ab2542b89db26dac6225cd60","type":"TRIAL","name":"Smell in Covid-19 and Efficacy of Nasal Theophylline","canonical_id":"clinicaltrials.gov:NCT04789499","description":"Covid19; Anosmia; Olfactory Disorder; Covid-19 Pandemic; SARS-CoV-2 Infection; Hyposmia; Ageusia; Hypogeusia","metadata":null},{"id":"68939749bff44cf6b3471d9983181a6f","type":"TRIAL","name":"Smoking Cessation Intervention for Thoracic Patients","canonical_id":"clinicaltrials.gov:NCT00580398","description":"Lung Cancer","metadata":null},{"id":"2700e5d3de8548da81b991bd05565cdf","type":"TRIAL","name":"Smoking Cessation Study In Healthy Adolescent Smokers","canonical_id":"clinicaltrials.gov:NCT01312909","description":"Smoking Cessation","metadata":null},{"id":"04845cc5c07f40089481ec4f9c53f2fa","type":"TRIAL","name":"Smoking Cessation for People Living With HIV/AIDS","canonical_id":"clinicaltrials.gov:NCT01965405","description":"HIV; AIDS; Nicotine Dependence","metadata":null},{"id":"36123e3c8bac4eeeb397053d2db4b23e","type":"TRIAL","name":"Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).","canonical_id":"clinicaltrials.gov:NCT00285012","description":"Smoking Cessation","metadata":null},{"id":"bf12c014bae84db48c79d525e7e9c014","type":"GO_TERM","name":"Smp focus","canonical_id":"go:GO:0062238","description":"\"A DNA-binding ribonucleoprotein complex that contains a lncRNA complementary to the bound chromosomal locus and is involved in the tethering homologous chromosomes together during chromosome pairing at meiotic prophase I.\" [PMID:22582262, PMID:31811152]","metadata":null},{"id":"976fb6b737d34a01afb3e9fd1475eb42","type":"DISEASE","name":"Sneezing","canonical_id":"mesh:D012912","description":null,"metadata":null},{"id":"4d0181bbc79f4e99934b117a9d147f54","type":"GO_TERM","name":"Snt2C complex","canonical_id":"go:GO:0070211","description":"\"A histone deacetylase complex that is part of the chromatin remodeling machinery. In Saccharomyces cerevisiae this complex contains Snt2p, Ecm5p and Rpd3p.\" [GOC:rb, PMID:19040720]","metadata":null},{"id":"4c2c8d6478bb448393fd2feb0508776c","type":"TRIAL","name":"So-Lo-Mo Intervention Applied to the Smoking Cessation Process","canonical_id":"clinicaltrials.gov:NCT03553173","description":"Smoking Cessation; Health Behavior; Lifestyle-related Condition","metadata":null},{"id":"45fb9ada57e24abe97dfdaed6c0b592b","type":"TRIAL","name":"Social Decision Making in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04249544","description":"Parkinson Disease","metadata":null},{"id":"4edf577bf569463faaa14da3788b71d7","type":"DISEASE","name":"Social phobia","canonical_id":"mesh:D000072861","description":null,"metadata":null},{"id":"616f08bd83d2403f8de325cf16762257","type":"TRIAL","name":"Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT06433050","description":"Hypertrophic Cardiomyopathy Without Obstruction","metadata":null},{"id":"258e33986d6441119feffbe3461c197a","type":"TRIAL","name":"Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -","canonical_id":"clinicaltrials.gov:NCT02106455","description":"Osseous Paget's Disease","metadata":null},{"id":"b896bf555d924c50894fe84f29fd98ee","type":"TRIAL","name":"Sodium Sivelestat With Mechanical Thrombectomy for Acute Stroke: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT07196605","description":"Acute Ischemic Stroke; Neutrophil Extracellular Traps Formation; Large Vessel Occlusion; Thrombectomy","metadata":null},{"id":"e0b6c6f8bf02429bb534571a397954f9","type":"PROTEIN","name":"Sodium channel protein","canonical_id":"uniprot:Q2VKV7","description":null,"metadata":null},{"id":"ce209ae63a764f24a2fc9e3d53e6447c","type":"PROTEIN","name":"Sodium channel protein type 10 subunit alpha","canonical_id":"uniprot:Q9Y5Y9","description":null,"metadata":null},{"id":"7a7c37cffee745d8b9fd617c215df2c4","type":"PROTEIN","name":"Sodium channel protein type 4 subunit alpha","canonical_id":"uniprot:P35499","description":null,"metadata":null},{"id":"5b99c1b009d5472c94db25477ac1f978","type":"PROTEIN","name":"Sodium channel protein type 5 subunit alpha","canonical_id":"uniprot:Q14524","description":null,"metadata":null},{"id":"e6e9423fd47248848eccb32e746ca6e5","type":"PROTEIN","name":"Sodium channel protein type 9 subunit alpha","canonical_id":"uniprot:Q15858","description":null,"metadata":null},{"id":"1ae6cb5d8cbb4a559637b04e606146cd","type":"DRUG","name":"Sodium citrate","canonical_id":"mesh:D000077559","description":null,"metadata":null},{"id":"1b070714ed8c4f15bcb291a15539bd76","type":"DRUG","name":"Sodium oxybate","canonical_id":"mesh:D012978","description":null,"metadata":null},{"id":"c1fb6d818b3d442b98087b03ce11d207","type":"DRUG","name":"Sodium phosphate","canonical_id":"mesh:C018279","description":null,"metadata":null},{"id":"b6ecaf9bf3c648699f8d140904ce34e4","type":"TRIAL","name":"Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention","canonical_id":"clinicaltrials.gov:NCT04778787","description":"Congestive Heart Failure","metadata":null},{"id":"53ab58fef1e74d9b9685df5144255891","type":"DRUG","name":"Sofalcone","canonical_id":"mesh:C035032","description":null,"metadata":null},{"id":"b34bfc0a5ac54ddc8012032c62bc621a","type":"TRIAL","name":"Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV","canonical_id":"clinicaltrials.gov:NCT03069001","description":"HCV","metadata":null},{"id":"992e67b34a3a47eb9e49bb0f99260e3d","type":"TRIAL","name":"Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients","canonical_id":"clinicaltrials.gov:NCT02702739","description":"Liver Cirrhosis","metadata":null},{"id":"9a83c2c5c78c4d6bba743b67e9ae2142","type":"TRIAL","name":"Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01530373","description":"Hot Flashes; Breast Cancer","metadata":null},{"id":"e6470af76f7a4b70add0f920f2d655f8","type":"TRIAL","name":"Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency","canonical_id":"clinicaltrials.gov:NCT00979472","description":"Urinary Bladder, Overactive; Overactive Bladder","metadata":null},{"id":"add37fc9179741b0897c485c8c703949","type":"TRIAL","name":"Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction","canonical_id":"clinicaltrials.gov:NCT00507455","description":"Lower Urinary Tract Symptoms; Bladder Outlet Obstruction","metadata":null},{"id":"91f2e43c78454659862396efd3496009","type":"TRIAL","name":"Soluble CD23 Expression in Asthma Patients Treated With OMA","canonical_id":"clinicaltrials.gov:NCT00226200","description":"Asthma","metadata":null},{"id":"945d31b534434913aa553f597363fa31","type":"TRIAL","name":"Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01128192","description":"Hyperglycemia","metadata":null},{"id":"be7fa7356366427185b52b0607f2a666","type":"TRIAL","name":"Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)","canonical_id":"clinicaltrials.gov:NCT01354405","description":"Polycystic Liver Disease","metadata":null},{"id":"58d73bae3044405799680422078ebf38","type":"PROTEIN","name":"Somatostatin receptor type 1","canonical_id":"uniprot:P30872","description":null,"metadata":null},{"id":"ff096050060b497d8c1ade28059c98d5","type":"TRIAL","name":"Somato\u00ae (Phytomelatonin) Versus Synthetic Melatonin and Placebo on Sleep Quality","canonical_id":"clinicaltrials.gov:NCT07669766","description":"Sleep","metadata":null},{"id":"9ee1609003944fee901c25f518412af2","type":"DRUG","name":"Somatrem","canonical_id":"mesh:C447442","description":null,"metadata":null},{"id":"773fded9b4e94dcd9e4a9890e7e62988","type":"TRIAL","name":"Somatuline Autogel Preference and Health Economy Study","canonical_id":"clinicaltrials.gov:NCT00681187","description":"Neuroendocrine Tumour With Carcinoid Symptoms","metadata":null},{"id":"6b622b62cf1b44c59480c1cd7a468c63","type":"TRIAL","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","canonical_id":"clinicaltrials.gov:NCT07431281","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer","metadata":null},{"id":"fa9c47b154b54f5b954ba52030328a37","type":"TRIAL","name":"Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02086552","description":"Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma","metadata":null},{"id":"1597f3ff4cd641edabebaaf371458359","type":"TRIAL","name":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04007744","description":"Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Gastric Adenocarcinoma; Metastatic\u2026","metadata":null},{"id":"9531e459baa94d6da652cefcee1a88f8","type":"TRIAL","name":"Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China","canonical_id":"clinicaltrials.gov:NCT06880848","description":"Carcinoma, Basal Cell (BCC)","metadata":null},{"id":"c979fe22338e44148b19c0105fcce478","type":"TRIAL","name":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04821284","description":"Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"7daed7001cf244baa3e47c2b7db55a8f","type":"TRIAL","name":"Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07774234","description":"Large B-Cell Lymphoma (LBCL); High-grade B-cell Lymphoma","metadata":null},{"id":"5d1bfa09d69f41469c5e439cff72e323","type":"TRIAL","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06561048","description":"Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Systemic Anaplastic Large Cell Lymphoma; Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell","metadata":null},{"id":"6e3d62a1fde94a7193ab93b59668858c","type":"DRUG","name":"Sorafenib","canonical_id":"mesh:C471405","description":null,"metadata":null},{"id":"18de1d7b09614303bb9e642ccd724460","type":"DRUG","name":"Sorafenib","canonical_id":"ncit:C61948","description":null,"metadata":null},{"id":"bddccec610744838b650600eb903c3a6","type":"TRIAL","name":"Sorafenib + mFOLFOX for Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01775501","description":"Hepatocellular Cancer","metadata":null},{"id":"d0ea6aed1d294a5999e9847792e875ca","type":"TRIAL","name":"Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC","canonical_id":"clinicaltrials.gov:NCT02774187","description":"Hepatocellular Carcinoma","metadata":null},{"id":"abecc7c12d20435fa5cac2118382650c","type":"TRIAL","name":"Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","canonical_id":"clinicaltrials.gov:NCT00335764","description":"Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor","metadata":null},{"id":"6e2a7545fbdf40c19a7864338082acb1","type":"TRIAL","name":"Sorafenib Drug Drug Interaction Study in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02332031","description":"Drug Interactions","metadata":null},{"id":"b67dae784af745379ea615ab63084c0a","type":"TRIAL","name":"Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00096395","description":"Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer","metadata":null},{"id":"612dff3f6d984ac5856143d9a688629a","type":"TRIAL","name":"Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE","canonical_id":"clinicaltrials.gov:NCT01187212","description":"Malignant Neoplasm of Stomach; Effects of Chemotherapy","metadata":null},{"id":"a02b2e7446c648f7b215258c50755e46","type":"TRIAL","name":"Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT00589420","description":"Prostate Cancer","metadata":null},{"id":"3bb98fb210574bd38683ca56acb92137","type":"TRIAL","name":"Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT00768937","description":"Hepatocellular Carcinoma","metadata":null},{"id":"b6ca55cebc7044f5b3afbd921127bd24","type":"TRIAL","name":"Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00828074","description":"Breast Cancer","metadata":null},{"id":"eb161485a3bc4c9a9792badb2604c530","type":"TRIAL","name":"Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer","canonical_id":"clinicaltrials.gov:NCT01075113","description":"Liver Cancer","metadata":null},{"id":"87bfb240a3fb4cbba6c1d8ade15ffde5","type":"TRIAL","name":"Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)","canonical_id":"clinicaltrials.gov:NCT00692770","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"d9501e6690b246eab71d0de8516e50d1","type":"TRIAL","name":"Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer","canonical_id":"clinicaltrials.gov:NCT00917462","description":"Esophageal Cancer; Gastroesophageal Junction Cancer","metadata":null},{"id":"660122fc3d0f42218e9ad3c48d8c7f47","type":"TRIAL","name":"Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT01932385","description":"Liver Cancer","metadata":null},{"id":"430dfe3e1bba4cc8abe20b635bd14932","type":"TRIAL","name":"Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00405366","description":"Kidney Cancer","metadata":null},{"id":"6ce813f3058c4ec5b832e57e7541a72c","type":"TRIAL","name":"Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT00874874","description":"Sarcoma","metadata":null},{"id":"6abfc3e75cc149f185eea7960b3d55a4","type":"TRIAL","name":"Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium","canonical_id":"clinicaltrials.gov:NCT00112905","description":"Adenocarcinoma of the Bladder; Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Squamous Cell Carcinoma of the Bladder; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated Wi\u2026","metadata":null},{"id":"bbb4d8fa665249d3bc473ef0b06c1606","type":"TRIAL","name":"Sorafenib-induced Hand- Foot Skin Reaction Treatment","canonical_id":"clinicaltrials.gov:NCT00667589","description":"Hand-foot Skin Reaction; Rash","metadata":null},{"id":"3df37de5586f447d942565fd94ee22c2","type":"TRIAL","name":"Sotagliflozin Bioequivalence Study","canonical_id":"clinicaltrials.gov:NCT03211195","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"fbff9ac8f2fd495dad27a1b46b7057c3","type":"TRIAL","name":"Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT03909451","description":"Diabetes Mellitus","metadata":null},{"id":"8b888895b2254cfe9293c1dde54e42bd","type":"TRIAL","name":"Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity","canonical_id":"clinicaltrials.gov:NCT07572175","description":"Anthracycline-induced Cardiotoxicity; Lymphoma; Chemotherapy; Cardiotoxicity","metadata":null},{"id":"19751f95093b48738339e9d29c509dde","type":"TRIAL","name":"Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients","canonical_id":"clinicaltrials.gov:NCT05562063","description":"Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"a832ff4f35784ffbad21d050f341d2cc","type":"TRIAL","name":"Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT06435156","description":"Type 1 Diabetes; Heart Failure","metadata":null},{"id":"8336a12b57f44ecc8912b19174698583","type":"TRIAL","name":"Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06217302","description":"Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure","metadata":null},{"id":"2c3ccc8d4c2046dbaef8ea891a932383","type":"DRUG","name":"Sotalol","canonical_id":"mesh:D013015","description":null,"metadata":null},{"id":"1f7b5613386b45d39dc80da9acb91012","type":"DRUG","name":"Sotorasib","canonical_id":"ncit:C154287","description":null,"metadata":null},{"id":"90033bde18a74bfbaab822728faeec67","type":"TRIAL","name":"South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)","canonical_id":"clinicaltrials.gov:NCT07753616","description":"Diabetic Macular Edema","metadata":null},{"id":"bfc52f4f8a7b4708995a49d27ce81d31","type":"TRIAL","name":"South Korean Pitavastatin Heart Failure Study","canonical_id":"clinicaltrials.gov:NCT00701285","description":"Chronic Heart Failure","metadata":null},{"id":"7310fe7cdea8499bb25aeab14397387b","type":"TRIAL","name":"Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.","canonical_id":"clinicaltrials.gov:NCT04285866","description":"Small Cell Lung Cancer (SCLC)","metadata":null},{"id":"0284ce1f5a5443698c02bdd55072b5d3","type":"DRUG","name":"Sparfloxacin","canonical_id":"mesh:C061363","description":null,"metadata":null},{"id":"03cac283969f497b8aaa2b22b3d48022","type":"TRIAL","name":"Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria","canonical_id":"clinicaltrials.gov:NCT07224776","description":"Proteinuric Renal Disease; Proteinuric Kidney Disease; Proteinuria; Proteinuria in Nephrotic Range","metadata":null},{"id":"2c63261167a045e3af07da339b125db8","type":"TRIAL","name":"Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis","canonical_id":"clinicaltrials.gov:NCT07219121","description":"Proteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis; Kidney Transplant","metadata":null},{"id":"e5c27a7b8d264e8f8c27e4b6f88bf8ca","type":"DISEASE","name":"Spasm","canonical_id":"mesh:D013035","description":null,"metadata":null},{"id":"c0ee1bbb724f497b8cca1135dc49f5c7","type":"DISEASE","name":"Spasms, Infantile","canonical_id":"mesh:D013036","description":null,"metadata":null},{"id":"131a2583ce7d4d959cf806ad4d5ddb7b","type":"DISEASE","name":"Spasticity","canonical_id":"hp:0001257","description":null,"metadata":null},{"id":"2a4a77a88d884f00a8614f61b0d449aa","type":"DISEASE","name":"Spasticity","canonical_id":"mesh:D009128","description":null,"metadata":null},{"id":"5d289b25cefd4a1db31ff32d1962c3d7","type":"TRIAL","name":"Special Access for the Use of Voclosporin for Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT01236287","description":"Immunosuppression; Transplantation, Kidney","metadata":null},{"id":"be3e3fe6e2c84df0b6f0aa29db5b8334","type":"TRIAL","name":"Special Drug Use Investigation (Retrospective) for Arixtra\u00ae (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)","canonical_id":"clinicaltrials.gov:NCT01428544","description":"Ataxia","metadata":null},{"id":"0dcae62d26e54855abac07b44f8f2e1b","type":"TRIAL","name":"Special Drug Use Investigation for AMERGE\u00ae Tablet (Long-term)","canonical_id":"clinicaltrials.gov:NCT01332383","description":"Migraine Disorders","metadata":null},{"id":"e59be7b7fc3e4645907ac3eb2d910231","type":"TRIAL","name":"Special Drug Use Investigation for Arixtra\u00ae (Fondaparinux) Venous Thromboembolism Treatment","canonical_id":"clinicaltrials.gov:NCT01428531","description":"Ataxia","metadata":null},{"id":"1395ba9b24364c1ab1089c19c0fe09d2","type":"TRIAL","name":"Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)","canonical_id":"clinicaltrials.gov:NCT01371461","description":"Mental Disorders","metadata":null},{"id":"0d589c33421f4b22ad65a7d6d7f2a5c2","type":"TRIAL","name":"Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)","canonical_id":"clinicaltrials.gov:NCT01376128","description":"Panic Disorder","metadata":null},{"id":"92d5b8e1db1f44c289241670c2cd9af1","type":"TRIAL","name":"Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion \"Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma\"","canonical_id":"clinicaltrials.gov:NCT04213209","description":"Peripheral T Cell Lymphoma; Pediatric Hodgkin Lymphoma","metadata":null},{"id":"055fb4add6ac4543839eed5114ddb1db","type":"TRIAL","name":"Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]","canonical_id":"clinicaltrials.gov:NCT03824561","description":"Ulcerative Colitis","metadata":null},{"id":"df65f46d0a0a4b49b63ec4ad76f57d2b","type":"TRIAL","name":"Specificity of Dyspnoea Relief With Inhaled Furosemide","canonical_id":"clinicaltrials.gov:NCT02881866","description":"Dyspnea","metadata":null},{"id":"857ccdd81bf8467d8cad44915bd23ee7","type":"TRIAL","name":"Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients","canonical_id":"clinicaltrials.gov:NCT02479399","description":"Type 2 Diabetes","metadata":null},{"id":"8d5530bdd8194be78e35ebc16938ccec","type":"TRIAL","name":"Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use","canonical_id":"clinicaltrials.gov:NCT05342493","description":"Migraine Disorders","metadata":null},{"id":"1c1dea51e49d4d4bb5d32fb6f87267e5","type":"TRIAL","name":"Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)","canonical_id":"clinicaltrials.gov:NCT04812379","description":"Bipolar Disorder I","metadata":null},{"id":"508267d1fadc4399bdeab731be19f817","type":"TRIAL","name":"Specifying and Treating Anxiety in Autism Research","canonical_id":"clinicaltrials.gov:NCT03279471","description":"Autism Spectrum Disorder; Anxiety","metadata":null},{"id":"38fd2848136545259f0f0d153bafb8d5","type":"DRUG","name":"Spectinomycin","canonical_id":"mesh:D000198","description":null,"metadata":null},{"id":"a6f24a3c653645e5bbac97332f25d9d7","type":"GO_TERM","name":"Spemann organizer formation","canonical_id":"go:GO:0060061","description":"\"Formation of the specialized region on the dorsalmost side of the embryo that acts as the main signaling center establishing the vertebrate body plan.\" [GOC:bf, GOC:dph]","metadata":null},{"id":"cefe356cf3754893be260fce30278ea8","type":"GO_TERM","name":"Spemann organizer formation at the anterior end of the primitive streak","canonical_id":"go:GO:0060064","description":"\"Formation of the specialized region at the anterior end of the primitive streak of the embryo that acts as the main signaling center establishing the body plan.\" [GOC:dph, PMID:9442883]","metadata":null},{"id":"a80f3b531b454be591cfc3a69bfd8144","type":"GO_TERM","name":"Spemann organizer formation at the dorsal lip of the blastopore","canonical_id":"go:GO:0060062","description":"\"Formation of the specialized region at the dorsal lip of the blatopore of the embryo that acts as the main signaling center establishing the vertebrate body plan.\" [GOC:dph, PMID:9442883]","metadata":null},{"id":"33bccec5ecc04acdb245187b5e09b4af","type":"GO_TERM","name":"Spemann organizer formation at the embryonic shield","canonical_id":"go:GO:0060063","description":"\"Formation of the specialized region of the embryonic shield of the embryo that acts as the main signaling center establishing the teleost body plan.\" [GOC:dph, PMID:9442883]","metadata":null},{"id":"092909ee215443b9aea3e5f254a3dedb","type":"TRIAL","name":"Spinal Cord Neuromodulation for Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT02313194","description":"Cervical Spinal Cord Injury; Tetraparesis; Tetraplegia","metadata":null},{"id":"61c8f8b3692e476a88aed242b89ce3e6","type":"TRIAL","name":"Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT06577155","description":"Total Hip Arthroplasty; Analgesia","metadata":null},{"id":"b6182d31c67c41f2a67a61766d232eb6","type":"TRIAL","name":"Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery","canonical_id":"clinicaltrials.gov:NCT02647047","description":"Secondary Malignant Neoplasm of Liver; Liver Diseases; Liver Neoplasms","metadata":null},{"id":"e5e1b92e42a9498d83bb666e2c75073c","type":"TRIAL","name":"Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.","canonical_id":"clinicaltrials.gov:NCT02996591","description":"Nerve Block; General Anesthesia; Spinal Anesthesia; Pain; Postoperative Nausea and Vomiting","metadata":null},{"id":"6feaf536ae6d41f987f5df3e375d2a9e","type":"TRIAL","name":"Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT03464292","description":"Fibromyalgia; Pain","metadata":null},{"id":"126d52bce94d409c9abc01e65948a2a8","type":"DISEASE","name":"Spinal muscular atrophy","canonical_id":"mesh:D009134","description":null,"metadata":null},{"id":"c3ab4d18be9d4bfa95c1b29126111f52","type":"DISEASE","name":"Spindle Cell Rhabdomyosarcoma","canonical_id":"doid:3260","description":null,"metadata":null},{"id":"bd912d521baa4fff8f4f2eac690e6f7f","type":"DRUG","name":"Spirapril","canonical_id":"mesh:C052555","description":null,"metadata":null},{"id":"ab55559afd144d618b97dea780a29fce","type":"TRIAL","name":"Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00240656","description":"Hypertension, Pulmonary","metadata":null},{"id":"a03ef36f04b14efe80ccc6386791c005","type":"TRIAL","name":"Spironolactone Improved Children With Gene Mutations Related to NCOR","canonical_id":"clinicaltrials.gov:NCT06678685","description":"NCOR Gene Mutations; Spironolactone; ASD","metadata":null},{"id":"aecfc83838044f36983405b12728e1ed","type":"TRIAL","name":"Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT01021943","description":"Kidney Transplant","metadata":null},{"id":"86fc84fa446c45f8825857d019ba994e","type":"TRIAL","name":"Spironolactone and XPB-1 Integrity in the TFIIH Complex","canonical_id":"clinicaltrials.gov:NCT07415811","description":"HIV","metadata":null},{"id":"f0172dc67bbf4ede9af2c7de3e738bbd","type":"TRIAL","name":"Spironolactone for Paroxysmal Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT00689598","description":"Atrial Fibrillation","metadata":null},{"id":"0ca7faa5551a4f8e8ff27b833571f201","type":"TRIAL","name":"Spironolactone in Alcohol Use Disorder (SAUD)","canonical_id":"clinicaltrials.gov:NCT05807139","description":"Alcohol Use Disorder","metadata":null},{"id":"895aa00b87f045768278db5cdae01be4","type":"TRIAL","name":"Spironolactone in CKD Enabled by Chlorthalidone: PILOT","canonical_id":"clinicaltrials.gov:NCT05222191","description":"Renal Insufficiency; Chronic Hypertension","metadata":null},{"id":"c156e40923e04e05be23c8d35b055339","type":"TRIAL","name":"Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics","canonical_id":"clinicaltrials.gov:NCT00276289","description":"Idiopathic Hypercalciuria; Hypokalemia Caused by Thiazide Diuretics","metadata":null},{"id":"c4a6b6c5495640ffa17221942e0b4239","type":"TISSUE","name":"Spleen","canonical_id":"uberon:UBERON:0002106","description":null,"metadata":null},{"id":"7f063b4e29b94c8892a5f3e6585ad7f4","type":"DISEASE","name":"Splenomegaly","canonical_id":"hp:0001744","description":null,"metadata":null},{"id":"961911b5a31c42eba4982750a5051d45","type":"TRIAL","name":"Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy","canonical_id":"clinicaltrials.gov:NCT00611442","description":"Bowel Preparation for Colonoscopy","metadata":null},{"id":"8678e7cfd46649dc8b92d4504f18b66b","type":"TRIAL","name":"Spondylitis Trial of Apremilast for Better Rheumatic Therapy","canonical_id":"clinicaltrials.gov:NCT00944658","description":"Ankylosing Spondylitis","metadata":null},{"id":"81597ac4f3bd41399f68fa9fdf288431","type":"TRIAL","name":"Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus","canonical_id":"clinicaltrials.gov:NCT02539459","description":"Sporadic Angiomyolipomas (AMLs)","metadata":null},{"id":"e745bf18392a47ef952873cf5ca52ebc","type":"TRIAL","name":"Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast","canonical_id":"clinicaltrials.gov:NCT00947453","description":"Asthma","metadata":null},{"id":"ca404e50398d4e4b95da45ee73fe8a9f","type":"PROTEIN","name":"Squalene monooxygenase","canonical_id":"uniprot:Q14534","description":null,"metadata":null},{"id":"d238366eeeb44b1187ffdd097e1bf066","type":"PROTEIN","name":"Squalene monooxygenase (Candida albicans)","canonical_id":"uniprot:Q92206","description":null,"metadata":null},{"id":"e9d2d99b3b5a481cbf8c0ab9962ebefd","type":"DISEASE","name":"Squamous cell carcinoma","canonical_id":"mesh:D002294","description":null,"metadata":null},{"id":"21f1a322fdd14378aac0c48f5afa97f0","type":"GO_TERM","name":"Ssh1 translocon complex","canonical_id":"go:GO:0071261","description":"\"A translocon complex that contains a core heterotrimer of alpha, beta and gamma subunits, and may contain additional proteins (translocon-associated proteins or TRAPs); in budding yeast the core proteins are Ssh1p, Sbh2p, and Sss1p. The Ssh1 translocon complex is involved in the cotranslational pathway of protein transport across the ER membrane, and recognizes proteins bearing strongly hydrophobic signal sequences.\" [GOC:mah, PMID:12134063, PMID:8612571]","metadata":null},{"id":"38f42150c48f4c18afec964a5aae3669","type":"GO_TERM","name":"SsuD-SsuE complex","canonical_id":"go:GO:1990200","description":"\"A protein complex containing an alkanesulfonate monooxygenase subunit (SsuD tetramer in E.coli) and a flavin oxidoreductase subunit (SsuE dimer in E.coli). Involved in the utilization of alkanesulfonates as sulfur sources under conditions of sulfate or cysteine starvation.\" [GOC:bhm, PMID:16997955]","metadata":null},{"id":"7b9a54d87e084a7fa911799fbf98cdb0","type":"TRIAL","name":"St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene","canonical_id":"clinicaltrials.gov:NCT03278886","description":"HIV Infection; Alcohol Use; Pain","metadata":null},{"id":"17e5f993cbac4a8b9cd01afb2df31f66","type":"TRIAL","name":"StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis","canonical_id":"clinicaltrials.gov:NCT03882177","description":"Tuberculosis; Pulmonary Tuberculosis","metadata":null},{"id":"bd0de2e06500441f85441ea4eee0c530","type":"TRIAL","name":"StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT06785727","description":"Ischemic Stroke; Transient Ischemic Attack","metadata":null},{"id":"aa8c755750de46969875c4656716f58b","type":"TRIAL","name":"Staccato Loxapine Multidose PK","canonical_id":"clinicaltrials.gov:NCT00555412","description":"Volunteers on Chronic, Stable Antipsychotic Regimens","metadata":null},{"id":"73bc840f74934da791c4644b876134e9","type":"TRIAL","name":"Staccato Loxapine PK in Smokers and Nonsmokers","canonical_id":"clinicaltrials.gov:NCT00873769","description":"Smoking, Cigarette","metadata":null},{"id":"6ba3bb5afbb1438b9198788b2dd80c8d","type":"TRIAL","name":"Staccato Loxapine Pulmonary Safety in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00789360","description":"Healthy","metadata":null},{"id":"0acadb3e964e46ce94869de6cd7dcb63","type":"TRIAL","name":"Staccato Loxapine Pulmonary Safety in Patients With Asthma","canonical_id":"clinicaltrials.gov:NCT00890175","description":"Asthma","metadata":null},{"id":"52f5b122b12f477cb832c62b0de28b82","type":"TRIAL","name":"Staccato Loxapine Pulmonary Safety in Patients With COPD","canonical_id":"clinicaltrials.gov:NCT00889837","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"a4e0c86f8ea447298b60d7750797f603","type":"TRIAL","name":"Staccato Loxapine Single Dose PK","canonical_id":"clinicaltrials.gov:NCT00444028","description":"Schizophrenia","metadata":null},{"id":"f0b1ea15d9de465089274bf50717a58a","type":"TRIAL","name":"Staccato Loxapine Thorough QT/QTc Study","canonical_id":"clinicaltrials.gov:NCT00874237","description":"Thorough QT/QTc Study","metadata":null},{"id":"6f59ffe3072a48c0a2718c4d8238f6e6","type":"TRIAL","name":"Staccato Loxapine in Agitated Patients With Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00721955","description":"Bipolar I Disorder","metadata":null},{"id":"1a61ce5688e149f19cc510d33b55f04e","type":"TRIAL","name":"Staccato Loxapine in Agitated Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00628589","description":"Patients With Schizophrenia and Acute Agitation","metadata":null},{"id":"a44d475df040459ba22597014d399de5","type":"TRIAL","name":"Staccato Loxapine in Agitation (Proof of Concept)","canonical_id":"clinicaltrials.gov:NCT00369577","description":"Schizophrenia","metadata":null},{"id":"cb0afb619dc7478eb0ed2b437a65efd6","type":"TRIAL","name":"Staccato Loxapine in Migraine (Out Patient)","canonical_id":"clinicaltrials.gov:NCT00825500","description":"Migraine Headache","metadata":null},{"id":"da53412ec8d84179bb2742944744ece8","type":"TRIAL","name":"Staccato Loxapine in Migraine (in Clinic)","canonical_id":"clinicaltrials.gov:NCT00489476","description":"Migraine","metadata":null},{"id":"31b345334d534d83ba85bc56dad9ff57","type":"TRIAL","name":"Staccato Prochlorperazine Single Dose PK Study","canonical_id":"clinicaltrials.gov:NCT00610727","description":"Migraine","metadata":null},{"id":"9a7341c62c544cf4b287c4874c17d11b","type":"TRIAL","name":"Staccato Prochlorperazine Thorough QT/QTc","canonical_id":"clinicaltrials.gov:NCT00543062","description":"Cardiotoxicity","metadata":null},{"id":"9be313cdbbeb4308b61696b938c57173","type":"TRIAL","name":"Staccato Prochlorperazine in Migraine (in Clinic)","canonical_id":"clinicaltrials.gov:NCT00610428","description":"Migraine Headache, With or Without Aura","metadata":null},{"id":"c248272d2aa74e65a31e7b0e1c0d4caf","type":"TRIAL","name":"StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study","canonical_id":"clinicaltrials.gov:NCT02082054","description":"Rhinitis, Seasonal, Allergic","metadata":null},{"id":"b3be4e677b124e2facd624ddc6c5d079","type":"TRIAL","name":"Stalevo in Early Wearing-Off Patients","canonical_id":"clinicaltrials.gov:NCT00125567","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"9d8a3984520c43229086e9701f3d77ca","type":"TRIAL","name":"Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)","canonical_id":"clinicaltrials.gov:NCT01575795","description":"ST-elevation Myocardial Infarction","metadata":null},{"id":"378ea3d556dc4741bc27cf6265c940f1","type":"TRIAL","name":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","canonical_id":"clinicaltrials.gov:NCT07106034","description":"Advanced Colorectal Cancer","metadata":null},{"id":"b406ac1eaef44b31814458d35c729334","type":"TRIAL","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03678025","description":"Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"c002fdc8ac7d4ca2b5ed03def0e6df17","type":"TRIAL","name":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","canonical_id":"clinicaltrials.gov:NCT01167725","description":"Colorectal Cancer","metadata":null},{"id":"bf21a59c6dff4f43875a6aabc6c132a8","type":"TRIAL","name":"Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction","canonical_id":"clinicaltrials.gov:NCT07815379","description":"BPH (Benign Prostatic Hyperplasia)","metadata":null},{"id":"daba6361b1514338969faf7c3d187f2c","type":"TRIAL","name":"Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML","canonical_id":"clinicaltrials.gov:NCT01883362","description":"Acute Myeloid Leukemia","metadata":null},{"id":"de4988f795e7418f9a75f005f7efac8a","type":"TRIAL","name":"Standardised Drug Provocation Testing in Perioperative Hypersensitivity","canonical_id":"clinicaltrials.gov:NCT06065137","description":"Allergic Reaction; Hypersensitivity; Perioperative Complication; Anaphylaxis; Anaphylactic Reaction; Immediate Hypersensitivity; Hypersensitivity, Drug","metadata":null},{"id":"8dd1bfa3b1b14b25af478076f16979e3","type":"TRIAL","name":"Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT02335281","description":"Inflammatory Bowel Disease; Ulcerative Colitis; Crohn's Disease","metadata":null},{"id":"a8eb29173236413f97b02944a39005fd","type":"TRIAL","name":"Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00148746","description":"Moderate to Severe Atopic Dermatitis","metadata":null},{"id":"4dd61571f85c4544b3d4e428aa7273eb","type":"DISEASE","name":"Staphylococcal Skin Infections","canonical_id":"mesh:D013207","description":null,"metadata":null},{"id":"1c353a240eea4c03b73edc8a759cbf9a","type":"DISEASE","name":"Staphylococcal pneumonia","canonical_id":"mesh:D011023","description":null,"metadata":null},{"id":"995fc450a2644e1f861cd15dae959c8b","type":"DISEASE","name":"Stargardt's disease","canonical_id":"mesh:D000080362","description":null,"metadata":null},{"id":"315dbe5304de4e1c8a0d10fe9b44160d","type":"TRIAL","name":"Start or STop Anticoagulants Randomised Trial (SoSTART)","canonical_id":"clinicaltrials.gov:NCT03153150","description":"Intracranial Hemorrhages; Intracranial Hemorrhage, Hypertensive; Subarachnoid Hemorrhage; Subdural Hematoma; Intraventricular Hemorrhage; Atrial Fibrillation; Atrial Flutter; Small Vessel Cerebrovascular Disease; Microhaemorrhage","metadata":null},{"id":"92b3f095c260410daedcb50d37d54ac9","type":"TRIAL","name":"Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients","canonical_id":"clinicaltrials.gov:NCT03611699","description":"COPD","metadata":null},{"id":"8a553d52179d4961b15e8f4386f722ea","type":"TRIAL","name":"Statin Distribution","canonical_id":"clinicaltrials.gov:NCT02360826","description":"Drug Distribution","metadata":null},{"id":"f21fdd5468e14ab6872709faa2f5976f","type":"TRIAL","name":"Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation","canonical_id":"clinicaltrials.gov:NCT05251129","description":"Vasculopathy","metadata":null},{"id":"ed48a96d0f9e45428a3eb12be2e22675","type":"TRIAL","name":"Statin Therapy In Patients With Vasospastic Angina","canonical_id":"clinicaltrials.gov:NCT02790528","description":"Angina Pectoris, Variant; Statins, HMG-CoA","metadata":null},{"id":"25a35af263f24111a7fdb82c7bab7e59","type":"TRIAL","name":"Statin Therapy in Asymptomatic Aortic Stenosis","canonical_id":"clinicaltrials.gov:NCT00176410","description":"Aortic Valve Stenosis","metadata":null},{"id":"e02a67ced6b54785bfe45c8d2d48466e","type":"TRIAL","name":"Statin Therapy in Patients With Early Stage ADPKD","canonical_id":"clinicaltrials.gov:NCT03273413","description":"ADPKD; Autosomal Dominant Polycystic Kidney","metadata":null},{"id":"c7bb80f59e6d48f19071c58789db5c0c","type":"TRIAL","name":"Statin Use in Abdominal Aortic Aneurysm Repair","canonical_id":"clinicaltrials.gov:NCT01062802","description":"Abdominal Aortic Aneurysm","metadata":null},{"id":"aeb35cd1103d4ca7b849d2cf5ce8b998","type":"TRIAL","name":"Statins and the Urinary Proteome","canonical_id":"clinicaltrials.gov:NCT00464503","description":"Statin Induced Proteinuria","metadata":null},{"id":"e221e53a3c8948d3aa0554938200f09f","type":"TRIAL","name":"Statins in Proteinuric Nephropathies","canonical_id":"clinicaltrials.gov:NCT00199927","description":"Chronic Nephropathy; Proteinuria; Hypertension","metadata":null},{"id":"e7954aecd4f54661a8734233988a96a2","type":"TRIAL","name":"Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis","canonical_id":"clinicaltrials.gov:NCT02079974","description":"Endometriosis","metadata":null},{"id":"cb19164909b54d3ea8c9eae98ee199db","type":"TRIAL","name":"Status Migrainosus - Differentiating Between Responders and Non-responders","canonical_id":"clinicaltrials.gov:NCT03066544","description":"Migraine","metadata":null},{"id":"a9f01541bd994115a0a78fe9df6bb277","type":"DISEASE","name":"Status epilepticus","canonical_id":"mesh:D013226","description":null,"metadata":null},{"id":"4cff739e33314921b9bddf9d5183e98b","type":"GO_TERM","name":"Ste12p-Dig1p-Dig2p complex","canonical_id":"go:GO:1990526","description":"\"A multiprotein complex that is involved in the transcription regulation of mating genes in the yeast S. cerevisiae.\" [GOC:rb, PMID:16782869]","metadata":null},{"id":"3706fd585a554b05b282c9ebb0323fe4","type":"TRIAL","name":"Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02215005","description":"Healthy","metadata":null},{"id":"c0a862cdebb6411086084324acc720f5","type":"TRIAL","name":"Stellate Ganglion Block as Adjuvant Therapy to ca Channel Blocker","canonical_id":"clinicaltrials.gov:NCT04100824","description":"Subarachnoid Hemorrhage","metadata":null},{"id":"fa1f0b54d7c1445f9ae7c6e7aec05126","type":"TRIAL","name":"Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.","canonical_id":"clinicaltrials.gov:NCT02006225","description":"Autologous Stem Cell Transplantation","metadata":null},{"id":"0c1693c4548044c59214f4575565ab22","type":"TRIAL","name":"Stem Cell Recruitment in Osteoporosis Therapy","canonical_id":"clinicaltrials.gov:NCT01656629","description":"Low Bone Density","metadata":null},{"id":"4183791540164a32909f1d5ed24104f2","type":"TRIAL","name":"Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01234129","description":"Multiple Myeloma","metadata":null},{"id":"0ffe590ea8e14b78b8fbd0234d06f5f2","type":"TRIAL","name":"Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)","canonical_id":"clinicaltrials.gov:NCT05707442","description":"Idiopathic Intracranial Hypotension; Venous Sinus Stenosis","metadata":null},{"id":"cf4c949988e044008262e43d9c16f2e6","type":"TRIAL","name":"Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction","canonical_id":"clinicaltrials.gov:NCT02684305","description":"Induction of Labor","metadata":null},{"id":"b55d915ea32547b8990dcb1dfd216530","type":"TRIAL","name":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","canonical_id":"clinicaltrials.gov:NCT06378866","description":"Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma","metadata":null},{"id":"5f974fac94f24cbfaf6f6fb0a4c270ba","type":"TRIAL","name":"Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04641078","description":"Prostate Cancer; Prostate Cancer Recurrent; Prostate Cancer Metastatic; Metastatic Cancer; Oligometastasis","metadata":null},{"id":"6411cab004ff4fb69825ac439493aeea","type":"PROTEIN","name":"Steroid 17-alpha-hydroxylase/17,20 lyase","canonical_id":"uniprot:P05093","description":null,"metadata":null},{"id":"36e0b19c3ba44029ac4e8a48ba25d5bc","type":"TRIAL","name":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","canonical_id":"clinicaltrials.gov:NCT00141037","description":"Kidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation; Renal Transplant","metadata":null},{"id":"2638d56d28914fb9a684be1787ee9dec","type":"TRIAL","name":"Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00351052","description":"Atopic Dermatitis","metadata":null},{"id":"7a9675a442564ac485f8a3aa85b7e5da","type":"TRIAL","name":"Steroids In Eosinophil Negative Asthma","canonical_id":"clinicaltrials.gov:NCT02066298","description":"Asthma","metadata":null},{"id":"ec9655f8eb0e42798951f1e7877d1b5c","type":"TRIAL","name":"Steroids and Cross-linking for Ulcer Treatment","canonical_id":"clinicaltrials.gov:NCT04097730","description":"Keratitis Bacterial","metadata":null},{"id":"842dd75c7736478797280251fa98d27f","type":"TRIAL","name":"Steroids for Early Treatment of Radiation Retinopathy","canonical_id":"clinicaltrials.gov:NCT03238157","description":"Radiation Retinopathy","metadata":null},{"id":"48bb94f4673648cfa0c89758c456a549","type":"TRIAL","name":"Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy","canonical_id":"clinicaltrials.gov:NCT02652884","description":"Transient Hypoparathyroidism","metadata":null},{"id":"1293e4710d89406b91812ca02e9188a5","type":"PROTEIN","name":"Sterol 14-alpha demethylase","canonical_id":"uniprot:B8N2C8","description":null,"metadata":null},{"id":"b105d336c1d64eeb96455b5a8e16f0d1","type":"PROTEIN","name":"Sterol 14-alpha demethylase CYP51C","canonical_id":"uniprot:I1S2M5","description":null,"metadata":null},{"id":"f0211717ea1a4086b24e1ca3d9885b44","type":"PROTEIN","name":"Sterol 26-hydroxylase, mitochondrial","canonical_id":"uniprot:Q02318","description":null,"metadata":null},{"id":"d925aba9584a46c7a097674bd970a05f","type":"DISEASE","name":"Stevens-Johnson syndrome","canonical_id":"mondo:0018229","description":null,"metadata":null},{"id":"3847d32d690f4cadb725122fb88d06d1","type":"DISEASE","name":"Stevens-Johnson syndrome","canonical_id":"mesh:D013262","description":null,"metadata":null},{"id":"91fffda2c60f499692e034f463acf13f","type":"TRIAL","name":"Stigma and Efficacy of Zhizhu Kuanzhong Capsules","canonical_id":"clinicaltrials.gov:NCT05107999","description":"Functional Gastrointestinal Disorders; Dyspepsia; Psychosomatic Disorder","metadata":null},{"id":"8c8706f9e913465c8e3db26ff1d127f2","type":"TRIAL","name":"Stimulant Effects on Brain Activity","canonical_id":"clinicaltrials.gov:NCT02453698","description":"Healthy Volunteers","metadata":null},{"id":"fd699f7d83a1487ba5f68e0a0e03b54a","type":"TRIAL","name":"Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD","canonical_id":"clinicaltrials.gov:NCT04577417","description":"Attention Deficit Hyperactivity Disorder; Attention Deficit Disorder; Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"d696ff481c58406ea45e339de12dba0f","type":"TRIAL","name":"Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT05241249","description":"Pancreas Cancer","metadata":null},{"id":"2cd5bd3c30eb4f5d9daeb15e3dd67e34","type":"TISSUE","name":"Stomach","canonical_id":"uberon:UBERON:0000945","description":null,"metadata":null},{"id":"013f032cf25a490585a170878168b599","type":"DISEASE","name":"Stomach Cancer","canonical_id":"doid:10534","description":null,"metadata":null},{"id":"902c9b00d45b4bfe880b60dd58f1d483","type":"DISEASE","name":"Stomach Carcinoma","canonical_id":"doid:5517","description":null,"metadata":null},{"id":"4f79159505db4b8b8570411932a29512","type":"DISEASE","name":"Stomach Ulcer","canonical_id":"mesh:D013276","description":null,"metadata":null},{"id":"42bbd4fa212b4f6abff438ab129912f9","type":"DISEASE","name":"Stomatitis, Aphthous","canonical_id":"mesh:D013281","description":null,"metadata":null},{"id":"d1d2bb7263114e47ae0afdcda318d55f","type":"TRIAL","name":"Stone Clearance in Patients With Upper Ureteric Stones Using Extracorporeal Shock Wave Lithotripsy Compared With Extracorporeal Shock Wave Lithotripsy Combined With Tamsulosin Therapy","canonical_id":"clinicaltrials.gov:NCT05725122","description":"Renal Stone","metadata":null},{"id":"b27998a49f9e4cfeb7c5ab9ee645dc23","type":"TRIAL","name":"Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis","canonical_id":"clinicaltrials.gov:NCT01617798","description":"Respiratory Failure; Volume Overload; Hypernatremia","metadata":null},{"id":"51fb6e1023b448b3a04e659b3401160f","type":"TRIAL","name":"Stop Retinal Ganglion Cell Dysfunction Study","canonical_id":"clinicaltrials.gov:NCT02390284","description":"Glaucoma","metadata":null},{"id":"46de9af12e7e4046810ffa085ab0659d","type":"TRIAL","name":"StrataPATH\u2122 (Precision Indications for Approved Therapies)","canonical_id":"clinicaltrials.gov:NCT05097599","description":"Cancer; Advanced Solid Tumor","metadata":null},{"id":"793ef5d7962f4c008e36337d01288bae","type":"TRIAL","name":"Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis","canonical_id":"clinicaltrials.gov:NCT03987711","description":"Atrial Fibrillation; End Stage Renal Failure on Dialysis","metadata":null},{"id":"d9fc9e9da7014d27a102af8f87a65f31","type":"TRIAL","name":"Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation","canonical_id":"clinicaltrials.gov:NCT02136875","description":"COPD; Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"3c97e1b1a5e24e648737ce5f759367c2","type":"TRIAL","name":"Strategy to Improve Adherence of Roflumilast","canonical_id":"clinicaltrials.gov:NCT02018432","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"6006d0d2376042a09887c8cb9dac6277","type":"TRIAL","name":"Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients","canonical_id":"clinicaltrials.gov:NCT01819441","description":"Cerebral Small Vessel Diseases","metadata":null},{"id":"649e6123911749878580c31afb901f11","type":"TRIAL","name":"Stratified Pharmacological Approaches for Regulating Circuit-Level Effects","canonical_id":"clinicaltrials.gov:NCT07022405","description":"Depression - Major Depressive Disorder","metadata":null},{"id":"789e76bc855b41e3a78b7e7e3d83bd5e","type":"DISEASE","name":"Streptococcal tonsillitis","canonical_id":"mesh:D014069","description":null,"metadata":null},{"id":"9b89611df1ce4242bb95d747a5b8cd76","type":"DISEASE","name":"Streptococcus pyogenes infection","canonical_id":"mesh:D013290","description":null,"metadata":null},{"id":"82d83cebd3f44106bb82e67e685d6f7a","type":"DRUG","name":"Streptomycin","canonical_id":"mesh:D013307","description":null,"metadata":null},{"id":"bd1cc2347c6a4491b75c99f0b9af3ce4","type":"TRIAL","name":"Stress & Premenstrual Symptoms Study","canonical_id":"clinicaltrials.gov:NCT02777372","description":"PMDD; Stress; Mood","metadata":null},{"id":"b82e4200a3564a158695fd23ba149252","type":"TRIAL","name":"Stress & Social Cognition in BPD (part 2)","canonical_id":"clinicaltrials.gov:NCT05310253","description":"Borderline Personality Disorder","metadata":null},{"id":"084d6f2bd14f4abebf8514d84232c93e","type":"TRIAL","name":"Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures","canonical_id":"clinicaltrials.gov:NCT01673087","description":"Stress","metadata":null},{"id":"d01faa75c62c4ec4afcceae02e7a97e6","type":"TRIAL","name":"Stress CT Perfusion in Patients With Chest Pain","canonical_id":"clinicaltrials.gov:NCT01969916","description":"Coronary Artery Disease","metadata":null},{"id":"78edcce719274ef18e04a0065860f82d","type":"TRIAL","name":"Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction","canonical_id":"clinicaltrials.gov:NCT02597543","description":"Heart Transplant; Acute Graft Rejection; Chronic Graft Rejection","metadata":null},{"id":"31c75d9fa4b14c37923c0ee58d47fc40","type":"TRIAL","name":"Stress Echocardiography Study With Regadenoson","canonical_id":"clinicaltrials.gov:NCT00907764","description":"Heart Disease; Coronary Artery Disease","metadata":null},{"id":"bd8e2dc4b7474534ab9e97ba1e3f76e7","type":"TRIAL","name":"Stress Testing and Cardiac Magnetic Resonance","canonical_id":"clinicaltrials.gov:NCT00871260","description":"Coronary Disease","metadata":null},{"id":"f6c3b90fdbba4f739c8a52bb689e8dac","type":"TRIAL","name":"Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease","canonical_id":"clinicaltrials.gov:NCT03667703","description":"Congenital Heart Disease; Upper Gastrointestinal Bleeding; Stress Ulcer; Infection","metadata":null},{"id":"4b8d9856a6a14dabbc0417f4ef32dd38","type":"TRIAL","name":"Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","canonical_id":"clinicaltrials.gov:NCT02157376","description":"Stress Ulcer Prophylaxis","metadata":null},{"id":"eafb0f47f584438899545f84e17dc6ac","type":"TRIAL","name":"Stress and Medication Effects on Cocaine Cue Reactivity","canonical_id":"clinicaltrials.gov:NCT00613015","description":"Cocaine Related Disorders","metadata":null},{"id":"35d22393de294a5ba1a9a3b8a8d58fe5","type":"TRIAL","name":"Stress and Treatment Response in Puerto Rican Children With Asthma","canonical_id":"clinicaltrials.gov:NCT03134755","description":"Asthma in Children","metadata":null},{"id":"a2447c6ba8654bce96c1e8acae3de0a4","type":"TRIAL","name":"Stress and the Nervous System","canonical_id":"clinicaltrials.gov:NCT02339506","description":"Autonomic Nervous System; Baroreflex; Stress, Physiological","metadata":null},{"id":"58f9bad0cd0748478a0c45118e533661","type":"DISEASE","name":"Stress urinary incontinence","canonical_id":"hp:0010992","description":null,"metadata":null},{"id":"05d383e4d43f4eb6a4375dac9b06ed98","type":"TRIAL","name":"Strict IGF-1 Control in Acromegaly","canonical_id":"clinicaltrials.gov:NCT02952885","description":"Acromegaly","metadata":null},{"id":"f16b9b8d1ff44aa584c49ab2cd79a32f","type":"TRIAL","name":"Stroke Prevention With Abciximab in Carotid Endarterectomy","canonical_id":"clinicaltrials.gov:NCT00178451","description":"Carotid Stenosis","metadata":null},{"id":"c530fd2fc73a4e84bb58cdce9df783e3","type":"TRIAL","name":"Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT05679024","description":"Chronic Kidney Diseases; Atrial Fibrillation; Stroke; Intracerebral Hemorrhage; Major Bleed; Cardiovascular Complication; Death; Kidney Transplant; Complications; Thromboses, Venous","metadata":null},{"id":"8d81bed8cc5145d68c12c9cb97de844d","type":"DISEASE","name":"Strongyloidiasis","canonical_id":"mesh:D013322","description":null,"metadata":null},{"id":"9f969d4997c34c2d9d23ab28fb22e0f1","type":"TRIAL","name":"Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects","canonical_id":"clinicaltrials.gov:NCT00135577","description":"Cancer; Bowel Dysfunction","metadata":null},{"id":"2ca4600f14714029bc3e19b4f8013f14","type":"TRIAL","name":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","canonical_id":"clinicaltrials.gov:NCT05890352","description":"Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Non-Hodgkin Lymphoma","metadata":null},{"id":"a118f10bbd5540b7bca6f6db368c6a94","type":"TRIAL","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT06158841","description":"Multiple Myeloma","metadata":null},{"id":"37b15d0c2be04b1b9c9cd5c280343edb","type":"TRIAL","name":"Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)","canonical_id":"clinicaltrials.gov:NCT04980833","description":"PIK3CA-related Overgrowth Spectrum (PROS)","metadata":null},{"id":"360742e1810a44e5ad500926156aff4d","type":"TRIAL","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04544189","description":"Breast Neoplasms","metadata":null},{"id":"14ebdece3e714f5f8be1a3907d42c07e","type":"TRIAL","name":"Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy","canonical_id":"clinicaltrials.gov:NCT05666804","description":"Macular Polypoidal Choroidal Vasculopathy (PCV)","metadata":null},{"id":"01cdfb524bde41e7b62ee2646853dfe4","type":"TRIAL","name":"Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00755521","description":"Fibromyalgia","metadata":null},{"id":"35a9b79bcc07425c8f908d56f4fa2847","type":"TRIAL","name":"Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00784823","description":"Multiple Myeloma","metadata":null},{"id":"0218750d497b4b41a33c7f257c6353ff","type":"TRIAL","name":"Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT06485947","description":"Neuroblastoma","metadata":null},{"id":"1025d5f3e19d4f12ad5b947c891444dc","type":"TRIAL","name":"Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT00498745","description":"Healthy","metadata":null},{"id":"92a90b0749724090838cb3e399d96a8f","type":"TRIAL","name":"Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT01251107","description":"Hodgkin Lymphoma","metadata":null},{"id":"7549458beae042b4ac9e9870a55e3d07","type":"TRIAL","name":"Study Comparing Adapalene Gel 0.3% to Differin\u00ae and Both to a Placebo Control in Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02411942","description":"Acne Vulgaris","metadata":null},{"id":"00df01f8d5d4487292252da2dfd33766","type":"TRIAL","name":"Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo\u00ae and Both to a Placebo Control in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT01742637","description":"Acne Vulgaris","metadata":null},{"id":"68aca07cf8064ac5b0d4eb1b90682211","type":"TRIAL","name":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","canonical_id":"clinicaltrials.gov:NCT07152184","description":"Patient With Schizophrenia Spectrum Disorder; NLM Classification WM 203, Psychology:Schizophrenic Psychology; Schizophrenia Spectrum and Other Psychotic Disorders","metadata":null},{"id":"46740aa977cd472085f614fe65e172c1","type":"TRIAL","name":"Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00383422","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"9351ffa1066a44b4b359c7c5448f245a","type":"TRIAL","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06792253","description":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"a53408606cc5408ebcc228dc0e3776df","type":"TRIAL","name":"Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT07836530","description":"Hepatocellular Carcinoma; Liver Cancer","metadata":null},{"id":"991b042845a04d46986a341fae8b6d28","type":"TRIAL","name":"Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO","canonical_id":"clinicaltrials.gov:NCT03318393","description":"Extracorporeal Membrane Oxygenation Complication; Pediatric ALL; Anticoagulants","metadata":null},{"id":"1f47d2bf944b4134a973d70666b9d310","type":"TRIAL","name":"Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases","canonical_id":"clinicaltrials.gov:NCT03520231","description":"Urothelial Carcinoma; Kidney Cancer; Ureter Cancer; Bladder Cancer","metadata":null},{"id":"6fa9dcffb5414052a3087841ae57c261","type":"TRIAL","name":"Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery","canonical_id":"clinicaltrials.gov:NCT00329433","description":"Deep Venous Thrombosis","metadata":null},{"id":"b4f5c2cff3894a8383366e7d797da8a9","type":"TRIAL","name":"Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC","canonical_id":"clinicaltrials.gov:NCT02835924","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"cacc12ea66314799a7643844e4f623ee","type":"TRIAL","name":"Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT01056289","description":"Major Depressive Disorder","metadata":null},{"id":"f3235d2aeb444d6fb509fff8a53e020f","type":"TRIAL","name":"Study Comparing Emergency Contraception Effectiveness in Women Who Weight \u2265 80 kg","canonical_id":"clinicaltrials.gov:NCT03537768","description":"Contraception","metadata":null},{"id":"ac980f8e42164db19c1dbc76cf1f8d2b","type":"TRIAL","name":"Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","canonical_id":"clinicaltrials.gov:NCT00422227","description":"Rheumatoid Arthritis","metadata":null},{"id":"7e77e5cbf51948758ae67ed44d4c24d8","type":"TRIAL","name":"Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00565409","description":"Arthritis, Rheumatoid","metadata":null},{"id":"64b98bfff7004eef977115a9d4eb3a4c","type":"TRIAL","name":"Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens","canonical_id":"clinicaltrials.gov:NCT00550303","description":"Healthy","metadata":null},{"id":"8ee232f84e2c4c488a62b63118c90f7a","type":"TRIAL","name":"Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT00562965","description":"Lymphoma, Follicular","metadata":null},{"id":"4ad3be21c67349bcbb0c0afc78bf6976","type":"TRIAL","name":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","canonical_id":"clinicaltrials.gov:NCT04524611","description":"Crohn's Disease (CD)","metadata":null},{"id":"29e5aa0e49344a55afa89e0d85b5fd8b","type":"TRIAL","name":"Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT00088582","description":"Acromegaly","metadata":null},{"id":"31c0eb84963e4eccbd179701c3b51294","type":"TRIAL","name":"Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00344110","description":"Hypertension","metadata":null},{"id":"807c61e4f1cd4506b8462ed520fe197d","type":"TRIAL","name":"Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT02278887","description":"Metastatic Melanoma","metadata":null},{"id":"6e8839f6828c4dd6abd7eabc0036fbab","type":"TRIAL","name":"Study Comparing Tapinarof Cream 1% To VTAMA \u00ae (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT06742957","description":"Plaque Type Psorisis","metadata":null},{"id":"78a9446f169b492380b222e476d2e719","type":"TRIAL","name":"Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT03359525","description":"Tranexamic Acid Adverse Reaction","metadata":null},{"id":"abe77a8322b946f985b87efb82d0194f","type":"TRIAL","name":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF \u00ae (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT05550337","description":"Acne Vulgaris","metadata":null},{"id":"e9189a53811b4b618e712c8fc3256ec4","type":"TRIAL","name":"Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01080365","description":"Healthy","metadata":null},{"id":"8fff685490614afe95f9fb706377daff","type":"TRIAL","name":"Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients","canonical_id":"clinicaltrials.gov:NCT00261820","description":"Graft Rejection; Kidney Failure; Kidney Transplantation","metadata":null},{"id":"7d442f43d06045c9831572aa1afe1502","type":"TRIAL","name":"Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women","canonical_id":"clinicaltrials.gov:NCT00319163","description":"Healthy","metadata":null},{"id":"92c487e1757949afaef1a6bd575a4059","type":"TRIAL","name":"Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT01528163","description":"Squamous Cell Carcinoma of the Head and Neck","metadata":null},{"id":"387f00b1ef7d45e8a34f9b4d762c665c","type":"TRIAL","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","canonical_id":"clinicaltrials.gov:NCT04632758","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"91b03d08cda74445a7b46a3740cfcc9d","type":"TRIAL","name":"Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity","canonical_id":"clinicaltrials.gov:NCT03931317","description":"OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension","metadata":null},{"id":"5e58a12773dd413d88dc592a20cf0691","type":"TRIAL","name":"Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00710580","description":"Moderate to Severe Plaque Psoriasis","metadata":null},{"id":"fa6686f61b364f00b337320a8af31583","type":"TRIAL","name":"Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua\u2122) in Patients With Type 2 Diabetes Mellitus (T2DM)","canonical_id":"clinicaltrials.gov:NCT03767543","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"8e48b2240c4d46aa8578e11f753847f9","type":"TRIAL","name":"Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00136851","description":"Hypertension","metadata":null},{"id":"4db980531f964c4aa4fa4a9ac94ab336","type":"TRIAL","name":"Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women","canonical_id":"clinicaltrials.gov:NCT02112903","description":"Healthy Women","metadata":null},{"id":"02f048ca0ce94636b89043371ef133d5","type":"TRIAL","name":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","canonical_id":"clinicaltrials.gov:NCT00035555","description":"Graft Rejection; Kidney Transplantation; Renal Transplantation","metadata":null},{"id":"8cc58a32b8d64a44b9c1e5bfe4011c46","type":"TRIAL","name":"Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine","canonical_id":"clinicaltrials.gov:NCT01393522","description":"Chronic Migraine","metadata":null},{"id":"56980dcef61a45b8816ca0a4367d470e","type":"TRIAL","name":"Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain","canonical_id":"clinicaltrials.gov:NCT01098747","description":"Pain","metadata":null},{"id":"3fbf02ad3dfa47b099c58874450f8b4a","type":"TRIAL","name":"Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00777530","description":"Breast Cancer; Tumors; Leukemia","metadata":null},{"id":"7180dc1407b4443fb59435b424b2b155","type":"TRIAL","name":"Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00205777","description":"Osteoporosis","metadata":null},{"id":"9dd0e2d7da4946bd9f4f18e1e68e6838","type":"TRIAL","name":"Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.","canonical_id":"clinicaltrials.gov:NCT00238745","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"ba0705a1f9ec487683096da4d223b48e","type":"TRIAL","name":"Study Evaluating Bazedoxifene/CE in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00550433","description":"Postmenopause","metadata":null},{"id":"3b444bc503bd42d49eda832760eb3ac6","type":"TRIAL","name":"Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause","canonical_id":"clinicaltrials.gov:NCT00234819","description":"Vasomotor Symptoms Associated With Menopause","metadata":null},{"id":"7c62ddc9c3ba4cd294843a3dabf777b5","type":"TRIAL","name":"Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause","canonical_id":"clinicaltrials.gov:NCT00238732","description":"Vaginal Atrophy","metadata":null},{"id":"3e49e71af05d4f8d959f844dae3908b6","type":"TRIAL","name":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00464789","description":"Menopause","metadata":null},{"id":"c35036166dd24976afa63217834e6860","type":"TRIAL","name":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00242710","description":"Endometrial Hyperplasia; Osteoporosis","metadata":null},{"id":"9d6fe88ce0b245f8ae0ada468c1c6377","type":"TRIAL","name":"Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00465075","description":"Healthy","metadata":null},{"id":"340d774922834d5e93c76ec2183f1259","type":"TRIAL","name":"Study Evaluating Betrixaban in Pediatric Participants","canonical_id":"clinicaltrials.gov:NCT03346083","description":"VTE Prophylaxis","metadata":null},{"id":"6aea233784b742c6a99e4554a99f4d11","type":"TRIAL","name":"Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00793546","description":"Advanced Breast Cancer","metadata":null},{"id":"b3c8c711660d46428dce2ad4cfe8ada3","type":"TRIAL","name":"Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00880009","description":"Breast Cancer","metadata":null},{"id":"5f4b6cc4081147858172115c74afc18b","type":"TRIAL","name":"Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00073749","description":"Lymphoma, B-Cell","metadata":null},{"id":"4cd3080d209743e89c7336c5d7a2cff9","type":"TRIAL","name":"Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat\u00ae (Lacosamide) in Combination Therapy","canonical_id":"clinicaltrials.gov:NCT01673282","description":"Focal Epilepsy With and Without Secondary Generalization","metadata":null},{"id":"aeaf6daf04e04f4b8cd2959f0ea806d4","type":"TRIAL","name":"Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT01055496","description":"Lymphoma, B-Cell","metadata":null},{"id":"9b1ede1875184ffcb2b49c90b98b54cf","type":"TRIAL","name":"Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00837837","description":"Allergic Reactions","metadata":null},{"id":"7a0d051c847947e69c2a2a97f08c6dd6","type":"TRIAL","name":"Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder","canonical_id":"clinicaltrials.gov:NCT00128934","description":"Menstruation Disturbances; Premenstrual Syndrome","metadata":null},{"id":"63e919f397bb48129a0645d701f19139","type":"TRIAL","name":"Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome","canonical_id":"clinicaltrials.gov:NCT00424892","description":"Fibromyalgia","metadata":null},{"id":"dfa39dd87c134cb8b7aa09d76f7d2b8b","type":"TRIAL","name":"Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00087737","description":"Major Depressive Disorder","metadata":null},{"id":"d2d898101a2943a39eb32ee30fab564e","type":"TRIAL","name":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00798707","description":"Major Depressive Disorder","metadata":null},{"id":"2ed5711873ba4b15a7cbdcf315dfb9b5","type":"TRIAL","name":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00406640","description":"Depression; Depressive Disorder; Depressive Disorder, Major","metadata":null},{"id":"5b941ddebe04431e8ddd1731806e7499","type":"TRIAL","name":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00863798","description":"Major Depressive Disorder","metadata":null},{"id":"e19fb9d034dd4b859ad0fe2c9e8f5613","type":"TRIAL","name":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00619619","description":"Depression; Major Depressive Disorder","metadata":null},{"id":"5eda405ba884455d8ffb45323e1f421d","type":"TRIAL","name":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT01432457","description":"Major Depressive Disorder","metadata":null},{"id":"3e2df6f23de24e04985147b9f06551c6","type":"TRIAL","name":"Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma","canonical_id":"clinicaltrials.gov:NCT02598570","description":"Lymphoma","metadata":null},{"id":"fc5611bb01844741820ef33ce82805b9","type":"TRIAL","name":"Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy","canonical_id":"clinicaltrials.gov:NCT04816214","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"d7dd490244024d38bce09c1d5e0a1ac1","type":"TRIAL","name":"Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00300781","description":"Breast Neoplasms; Neoplasms","metadata":null},{"id":"bf422d20adcc491ca0d4c2925eb58f3a","type":"TRIAL","name":"Study Evaluating HKI-272 Administered to Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00366600","description":"Healthy","metadata":null},{"id":"3415341b63ee4c33ab3b1fcbfe24512c","type":"TRIAL","name":"Study Evaluating HKI-272 in Tumors","canonical_id":"clinicaltrials.gov:NCT00146172","description":"Breast Neoplasms","metadata":null},{"id":"81a7d44f70a84a2483749930b2ec4a0f","type":"TRIAL","name":"Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus","canonical_id":"clinicaltrials.gov:NCT00387309","description":"Post Operative Bowel Dysfunction","metadata":null},{"id":"d2590ac74d9c48bfb0e4a051e274582d","type":"TRIAL","name":"Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma","canonical_id":"clinicaltrials.gov:NCT00868608","description":"Lymphoma","metadata":null},{"id":"1f95e855e5a4407d8f764b620db9754e","type":"TRIAL","name":"Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00867087","description":"Lymphoma, B-Cell","metadata":null},{"id":"8b3cc7ea45a34450a0ec18ab0b166b35","type":"TRIAL","name":"Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01363297","description":"Acute Lymphocytic Leukemia","metadata":null},{"id":"1a1b2a49c94246b8b6d60a27325cc0eb","type":"TRIAL","name":"Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT00299494","description":"B-Cell Lymphoma","metadata":null},{"id":"e34a37363afc4122a6d7d2eaecf858c9","type":"TRIAL","name":"Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT00831415","description":"Major Depressive Disorder","metadata":null},{"id":"c195ce9ff4d646718e68c064955f4ad6","type":"TRIAL","name":"Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation","canonical_id":"clinicaltrials.gov:NCT00804141","description":"Constipation","metadata":null},{"id":"6c3bf24e2015454aafebf754be17af10","type":"TRIAL","name":"Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT03979066","description":"Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"92c0b76e15ab457898775e88dc2f17eb","type":"TRIAL","name":"Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab","canonical_id":"clinicaltrials.gov:NCT03212651","description":"Bladder Cancer","metadata":null},{"id":"40f74b98b64e496eb06072aa01918277","type":"TRIAL","name":"Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00706030","description":"Breast Cancer; Advanced Malignant Solid Tumors","metadata":null},{"id":"33091d77012d4825ab2bc5b355313a7a","type":"TRIAL","name":"Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00915018","description":"Breast Cancer","metadata":null},{"id":"e2420fced99e45fba1468b01d32a1e89","type":"TRIAL","name":"Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00777101","description":"Advanced Breast Cancer; Breast Cancer","metadata":null},{"id":"fd3fd7d8fe684e8386f148ba093b0f67","type":"TRIAL","name":"Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT00550212","description":"Healthy","metadata":null},{"id":"b743e00b2474489e926d4bfce9c1e14f","type":"TRIAL","name":"Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain","canonical_id":"clinicaltrials.gov:NCT00547586","description":"Constipation","metadata":null},{"id":"f86b5387368e419cabcd8e53c9d93509","type":"TRIAL","name":"Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00706225","description":"Postmenopause","metadata":null},{"id":"2ad31f5a24664949ac5a1bfddc8ce699","type":"TRIAL","name":"Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered","canonical_id":"clinicaltrials.gov:NCT00966966","description":"Healthy","metadata":null},{"id":"7f2603a00034416d941413c792d6f958","type":"TRIAL","name":"Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients","canonical_id":"clinicaltrials.gov:NCT01727024","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"bffb2113d163483395b153aa351bb6b4","type":"TRIAL","name":"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01058005","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"0b31efaa1d6d4644aa0f7c3c4c479790","type":"TRIAL","name":"Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00195260","description":"Neoplasms","metadata":null},{"id":"447b1f61d328406aaf815943a1ec267b","type":"TRIAL","name":"Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias","canonical_id":"clinicaltrials.gov:NCT00811070","description":"Chronic Myelogenous Leukemia","metadata":null},{"id":"d82c7056a1e84966b60529401e87f582","type":"TRIAL","name":"Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias","canonical_id":"clinicaltrials.gov:NCT00261846","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"798cc33503624ac9919204ed63f4652c","type":"TRIAL","name":"Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00319254","description":"Breast Neoplasms; Neoplasm Metastasis","metadata":null},{"id":"0e1eabcd35484b41994b367c9e64f49b","type":"TRIAL","name":"Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors","canonical_id":"clinicaltrials.gov:NCT00088595","description":"Carcinoid Tumors","metadata":null},{"id":"b38d9c353d6d4b4e90fa3ccd50e3c33d","type":"TRIAL","name":"Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects","canonical_id":"clinicaltrials.gov:NCT00858754","description":"Opioid-Induced Constipation","metadata":null},{"id":"27d2b042291e40b1a9f0b1047d3ca3ca","type":"TRIAL","name":"Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00675688","description":"Endometrial Hyperplasia; Osteoporosis","metadata":null},{"id":"1d2f3eed9f9745fd96b5f5e5c98db9e7","type":"TRIAL","name":"Study Evaluating Sirolimus in Kidney Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00195273","description":"Graft vs Host Disease; Kidney Transplantation","metadata":null},{"id":"9bbd10a8463344ef8d5bda3bb4bf359a","type":"TRIAL","name":"Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain","canonical_id":"clinicaltrials.gov:NCT00529087","description":"Constipation","metadata":null},{"id":"f22e75bafd5d42dbbc2002423d12edbf","type":"TRIAL","name":"Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness","canonical_id":"clinicaltrials.gov:NCT00672477","description":"Opioid-Induced Constipation","metadata":null},{"id":"8682fafcd9b04d7498b2b81b79c1323f","type":"TRIAL","name":"Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.","canonical_id":"clinicaltrials.gov:NCT00036218","description":"Parkinson Disease","metadata":null},{"id":"c48e9ad5421749dc9e710bb479014b21","type":"TRIAL","name":"Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00481169","description":"Osteoporosis","metadata":null},{"id":"cde06dbe84b44215bda310c2919de807","type":"TRIAL","name":"Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib","canonical_id":"clinicaltrials.gov:NCT00932464","description":"Healthy","metadata":null},{"id":"a6b837e3cb3f4ed0ac43d5db4a951cf6","type":"TRIAL","name":"Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus","canonical_id":"clinicaltrials.gov:NCT00502242","description":"Kidney Transplant","metadata":null},{"id":"c967aa5e148d460eb60db15ebbbb4f28","type":"TRIAL","name":"Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00808132","description":"Menopause; Osteoporosis","metadata":null},{"id":"5b87c064ea914c82ae05b9793823ab54","type":"TRIAL","name":"Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT00886743","description":"Severe Thrombocytopenia","metadata":null},{"id":"51bc405e734342f7a08c10212800a946","type":"TRIAL","name":"Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection","canonical_id":"clinicaltrials.gov:NCT01035346","description":"Infection","metadata":null},{"id":"7e6e4d39f6e943bd81e6370647420882","type":"TRIAL","name":"Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use","canonical_id":"clinicaltrials.gov:NCT00717093","description":"Tobacco Use Cessation","metadata":null},{"id":"4f41fa20e0f048efab0e9d2e1fb3240f","type":"TRIAL","name":"Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease","canonical_id":"clinicaltrials.gov:NCT00781430","description":"Hepatic Insufficiency","metadata":null},{"id":"c569af9bd41a48b89b3d1842883261b4","type":"TRIAL","name":"Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00759837","description":"Breast Cancer; Leukemia, Myeloid, Chronic","metadata":null},{"id":"7244804c64c0468f96cc20577ab8818d","type":"TRIAL","name":"Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin","canonical_id":"clinicaltrials.gov:NCT00860223","description":"Healthy","metadata":null},{"id":"58d31c6db6d9492fa441496491a1d69f","type":"TRIAL","name":"Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib","canonical_id":"clinicaltrials.gov:NCT00864487","description":"Healthy Subjects","metadata":null},{"id":"f1f2fa2853604f05b77aa4a56b5097e5","type":"TRIAL","name":"Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women","canonical_id":"clinicaltrials.gov:NCT00683800","description":"Vasomotor Symptoms","metadata":null},{"id":"865c8ce6cb054d759d68a131b852cef1","type":"TRIAL","name":"Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab","canonical_id":"clinicaltrials.gov:NCT00724971","description":"Lymphoma, B-Cell","metadata":null},{"id":"fc5e03bfe1b441849d57d65ec6407dc2","type":"TRIAL","name":"Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone","canonical_id":"clinicaltrials.gov:NCT00406315","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"d608659b2e0b4782be0521c28130389a","type":"TRIAL","name":"Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution","canonical_id":"clinicaltrials.gov:NCT00367536","description":"Postmenopause","metadata":null},{"id":"bea58f6b03594d23abb22a0b7261412a","type":"TRIAL","name":"Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia","canonical_id":"clinicaltrials.gov:NCT00080496","description":"Bacterial Pneumonia","metadata":null},{"id":"dd1021b32b2b4edaae06a81aa7177249","type":"TRIAL","name":"Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06123468","description":"Esophagogastric Adenocarcinoma","metadata":null},{"id":"6dcd4a11938649388063b1bdacf2c604","type":"TRIAL","name":"Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)","canonical_id":"clinicaltrials.gov:NCT01007448","description":"Refractory Cutaneous T-cell Lymphoma","metadata":null},{"id":"50092023d73f4936aa7f3acb4a30c3cf","type":"TRIAL","name":"Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)","canonical_id":"clinicaltrials.gov:NCT00814060","description":"Healthy Subjects","metadata":null},{"id":"7cbf2f9dbbb744edb40781845de466bb","type":"TRIAL","name":"Study Evaluating Venlafaxine ER in Patients With Panic Disorder","canonical_id":"clinicaltrials.gov:NCT00044772","description":"Panic Disorder","metadata":null},{"id":"4ad7d3e7556644129e237e7f72cdfadc","type":"TRIAL","name":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01323621","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"f0cbf3cdc0ce4d76a48788f4600b3689","type":"TRIAL","name":"Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis","canonical_id":"clinicaltrials.gov:NCT02443103","description":"Bone Cancer; Metastasis","metadata":null},{"id":"9f6a46832be94990b9ad2b296c603cb4","type":"TRIAL","name":"Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00640601","description":"Schizophrenia","metadata":null},{"id":"f3f9fa25199f4e1288a4459202f590f5","type":"TRIAL","name":"Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","canonical_id":"clinicaltrials.gov:NCT01957150","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"2100a44972344167bfc6aa6a6b02fb79","type":"TRIAL","name":"Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT04829773","description":"Fibrodysplasia Ossificans Progressiva","metadata":null},{"id":"daba950b23ca49e183155973b0bc243b","type":"TRIAL","name":"Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib","canonical_id":"clinicaltrials.gov:NCT00700687","description":"Healthy","metadata":null},{"id":"096bb21f11da4849abbebf9d26e80aff","type":"TRIAL","name":"Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00366652","description":"Depression; Depressive Disorder; Depressive Disorder, Major","metadata":null},{"id":"b4655a288f5647f38c61214394d5fe19","type":"TRIAL","name":"Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00329147","description":"Depression","metadata":null},{"id":"e555c28ca3154b08a42fe4f53cb99f06","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00300378","description":"Depressive Disorder, Major","metadata":null},{"id":"560fd6d9d42b45b39b223d2f404567ed","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00658177","description":"Erectile Dysfunction","metadata":null},{"id":"e549e83d010b49b1a452a868e7d70168","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )","canonical_id":"clinicaltrials.gov:NCT01569295","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"ed34d227be4441cc95fef327d9706729","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","canonical_id":"clinicaltrials.gov:NCT03869190","description":"Urothelial Carcinoma; Bladder Cancer","metadata":null},{"id":"805085fc8995432d8f1ebdde0adc9805","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis","canonical_id":"clinicaltrials.gov:NCT03439254","description":"Compensated Cirrhosis; Nonalcoholic Steatohepatitis","metadata":null},{"id":"3a0b110ed30e4d0f8b4e5d58faaec227","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00551876","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"0cf1645593eb4f1687b0afab118f596b","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation","canonical_id":"clinicaltrials.gov:NCT00936884","description":"Constipation","metadata":null},{"id":"2328296beab746b89080baf72b9d9c4e","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy","canonical_id":"clinicaltrials.gov:NCT02967510","description":"Vaginal Atrophy","metadata":null},{"id":"61a69fed4d7449558ee11e07c9a81aec","type":"TRIAL","name":"Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg\u00ae) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.","canonical_id":"clinicaltrials.gov:NCT07463768","description":"Acute Myeloid Leukemia","metadata":null},{"id":"a3aca502eb6d42c6988e17284e719f36","type":"TRIAL","name":"Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan","canonical_id":"clinicaltrials.gov:NCT00503503","description":"Rheumatoid Arthritis","metadata":null},{"id":"5bb32c0e9a8a40ac8ec62b09fcca584b","type":"TRIAL","name":"Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC","canonical_id":"clinicaltrials.gov:NCT04313504","description":"Head and Neck Cancer","metadata":null},{"id":"a477e1b892154f76be24b9c4028a45fd","type":"TRIAL","name":"Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil","canonical_id":"clinicaltrials.gov:NCT00661297","description":"Erectile Dysfunction","metadata":null},{"id":"0336061560724dcea0a111bcb3d00114","type":"TRIAL","name":"Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02090101","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"68559f8ead2e48f4ba31d4ede22186f8","type":"TRIAL","name":"Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00727064","description":"Healthy","metadata":null},{"id":"dd74011db9364ebfbe9f1f710d7f85b7","type":"TRIAL","name":"Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine","canonical_id":"clinicaltrials.gov:NCT00500721","description":"Healthy","metadata":null},{"id":"028ab7e7009e408e8e3d2eef774c5889","type":"TRIAL","name":"Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women","canonical_id":"clinicaltrials.gov:NCT00384072","description":"Postmenopause; Osteoporosis","metadata":null},{"id":"bdbedc76c8ad4d8db717ed644f78cc93","type":"TRIAL","name":"Study Evaluating the Safety and Efficacy of CLONICEL\u00ae to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT00556959","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"eaf88831b7254d57a1f7a6646a309d93","type":"TRIAL","name":"Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan","canonical_id":"clinicaltrials.gov:NCT00503139","description":"Rheumatoid Arthritis","metadata":null},{"id":"b898a575f8c14dd18142fa574adfea31","type":"TRIAL","name":"Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","canonical_id":"clinicaltrials.gov:NCT01727700","description":"Tourette's Disorder; Tic Disorder","metadata":null},{"id":"bfae317e77bf47aab8b5e5e44c2dd02b","type":"TRIAL","name":"Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00037583","description":"Acute Myeloid Leukemia","metadata":null},{"id":"675f9c9e45504af786b9b96fdd2f4677","type":"TRIAL","name":"Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT07741643","description":"HNSCC,Larynx, Pharynx and Oral Cavity; Squamous Cell Carcinoma; Head and Neck Cancer; Head and Neck Surgery","metadata":null},{"id":"be9fc593ce5e44e5bf7a5021b66aa84f","type":"TRIAL","name":"Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks","canonical_id":"clinicaltrials.gov:NCT00682019","description":"Erectile Dysfunction","metadata":null},{"id":"29c2e36d9bf2490fa9c28e8cf9f6f29f","type":"TRIAL","name":"Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)","canonical_id":"clinicaltrials.gov:NCT00440427","description":"Depressive Disorder, Major","metadata":null},{"id":"c83564df9b07499bbc8ebdde93e4f0fb","type":"TRIAL","name":"Study Examining Repeat Dosing of OROS\u00ae Methylphenidate (CONCERTA\u00ae) and Immediate Release Methylphenidate in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT00302393","description":"Healthy","metadata":null},{"id":"05e3a9786e654d0bacecd77fed06f9ba","type":"TRIAL","name":"Study Exploring the Supportive Effect of Acarbose in Weight Management","canonical_id":"clinicaltrials.gov:NCT05934110","description":"Overweight or Obesity","metadata":null},{"id":"17af36b670044c43a7f880cfc744f89e","type":"TRIAL","name":"Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)","canonical_id":"clinicaltrials.gov:NCT02349633","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"9955ac67ff4f41cd924a97f5aa6c343d","type":"TRIAL","name":"Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib","canonical_id":"clinicaltrials.gov:NCT00526669","description":"Neoplasms, Gastrointestinal Tract","metadata":null},{"id":"dcf168061b8f4ebcb126243a644f7875","type":"TRIAL","name":"Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics","canonical_id":"clinicaltrials.gov:NCT01134042","description":"Asthma","metadata":null},{"id":"2485f6f55c7545a1b0f92a3ba50ec21e","type":"TRIAL","name":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","canonical_id":"clinicaltrials.gov:NCT03603795","description":"Acute Myeloid Leukemia","metadata":null},{"id":"b66dd7c966374d2ea5610a1da3b60c6a","type":"TRIAL","name":"Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy","canonical_id":"clinicaltrials.gov:NCT00067457","description":"Irritable Colon; Irritable Bowel Syndrome (IBS)","metadata":null},{"id":"d415bb41a8a64942ba8726d988136519","type":"TRIAL","name":"Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00764738","description":"Neovascular Age Related Macular Degeneration","metadata":null},{"id":"cfb81ab1205e4024b0ed500a6c57d47a","type":"TRIAL","name":"Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil","canonical_id":"clinicaltrials.gov:NCT00796666","description":"Pulmonary Arterial Hypertension; Pulmonary Hypertension","metadata":null},{"id":"8535d6fcaf524ad3b14279d64d67b1e4","type":"TRIAL","name":"Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients","canonical_id":"clinicaltrials.gov:NCT00097032","description":"Bipolar Disorder","metadata":null},{"id":"b1e307cfa5d14acb80ef4d2ff9483d12","type":"TRIAL","name":"Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery","canonical_id":"clinicaltrials.gov:NCT00424255","description":"Neoplasms, Head and Neck","metadata":null},{"id":"a144b06954084a77ae6a171bc67cbe41","type":"TRIAL","name":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","canonical_id":"clinicaltrials.gov:NCT00296491","description":"Asthma","metadata":null},{"id":"82b3c96a3b3a498fa150e019e573e1fb","type":"TRIAL","name":"Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication","canonical_id":"clinicaltrials.gov:NCT00101998","description":"Constipation; Bowel Dysfunction","metadata":null},{"id":"c25fd924f1724fc1888c71d26d5a0242","type":"TRIAL","name":"Study Of Angiomax In Infants Under Six Months With Thrombosis","canonical_id":"clinicaltrials.gov:NCT00043277","description":"Thrombosis","metadata":null},{"id":"9b7e171a71c44ba59e659984049c7374","type":"TRIAL","name":"Study Of Asthma In Patients Of African Descent","canonical_id":"clinicaltrials.gov:NCT00102765","description":"Asthma","metadata":null},{"id":"d0e8c96121de48d48f28d4b8efbf41ee","type":"TRIAL","name":"Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00959946","description":"Advanced Breast Cancer (Parts 1 and 2); Advanced Pancreatic Cancer (Part 1); Advanced Colorectal Cancer (Part 1); Advanced Cholangiocarcinoma (Part 1); Advanced Glioblastoma Multiforme (Part 1)","metadata":null},{"id":"ceea936b73764d5986ee74b4a7abd9a9","type":"TRIAL","name":"Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00372996","description":"Breast Neoplasms","metadata":null},{"id":"b07d72da6c264a1a8d59f1d2b87bd755","type":"TRIAL","name":"Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00729833","description":"Advanced Cancer; Advanced Solid Tumors","metadata":null},{"id":"a42687acf77240e6a711d91e8ea34a30","type":"TRIAL","name":"Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.","canonical_id":"clinicaltrials.gov:NCT00174239","description":"Parkinson Disease","metadata":null},{"id":"1e12228b4079474eaaf6c26a48b32694","type":"TRIAL","name":"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis","canonical_id":"clinicaltrials.gov:NCT00141102","description":"Osteoarthritis; Arthritis, Rheumatoid","metadata":null},{"id":"5b28782afa9141b2843b25e75f0d90f6","type":"TRIAL","name":"Study Of Diabetic Nephropathy With Atrasentan","canonical_id":"clinicaltrials.gov:NCT01858532","description":"Diabetic Nephropathy","metadata":null},{"id":"ff06e8e40ca24f87a0c1b5fcdb9b8bfc","type":"TRIAL","name":"Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium","canonical_id":"clinicaltrials.gov:NCT02866370","description":"Ovarian Clear Cell Carcinoma; Endometrial Clear Cell Carcinoma","metadata":null},{"id":"b5cb187533bc4bdd976422cfbbc95256","type":"TRIAL","name":"Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain","canonical_id":"clinicaltrials.gov:NCT04333576","description":"Endometriosis","metadata":null},{"id":"731a1874b327404d8bfe7fc9cd91d222","type":"TRIAL","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03709680","description":"Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma","metadata":null},{"id":"15310b238b544f85a3cd9e8d41baa5d9","type":"TRIAL","name":"Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms","canonical_id":"clinicaltrials.gov:NCT00479778","description":"Postmenopause","metadata":null},{"id":"69d18ad712d244bf862cea6246ec4890","type":"TRIAL","name":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","canonical_id":"clinicaltrials.gov:NCT01059825","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"6a1b1ab154ca4cf59e83589cc9e1e249","type":"TRIAL","name":"Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan","canonical_id":"clinicaltrials.gov:NCT00356603","description":"Migraine Disorders","metadata":null},{"id":"2b281dfe197746f4bbdce71c43ad731e","type":"TRIAL","name":"Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT00555672","description":"Stomach Neoplasms","metadata":null},{"id":"f70dffb0566049929f117a28f7c46287","type":"TRIAL","name":"Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT00555620","description":"Stomach Neoplasms","metadata":null},{"id":"fe0c984fcf7d4bc8a5c759cb5700ac01","type":"TRIAL","name":"Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma","canonical_id":"clinicaltrials.gov:NCT00843037","description":"Paraganglioma; Pheochromocytoma","metadata":null},{"id":"2269f04512d9405cabde985b20eef88a","type":"TRIAL","name":"Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT00553696","description":"Stomach Neoplasms","metadata":null},{"id":"f341e051cd044887b94f3c0a12d8f574","type":"TRIAL","name":"Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT01710046","description":"Plaque Psoriasis","metadata":null},{"id":"f0ec93b2aa3047a28db7454cc964bdb4","type":"TRIAL","name":"Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks","canonical_id":"clinicaltrials.gov:NCT00240617","description":"Migraine Disorders","metadata":null},{"id":"1b542a3957904bf19ccf89bb3c7c4df2","type":"TRIAL","name":"Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL","canonical_id":"clinicaltrials.gov:NCT00041288","description":"Leukemia; Lymphoma","metadata":null},{"id":"7223d72b9a1b4f1486de961e86af83c2","type":"TRIAL","name":"Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults","canonical_id":"clinicaltrials.gov:NCT01884922","description":"Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas","metadata":null},{"id":"03ec16dabc2a4a07b46b7117430d0744","type":"TRIAL","name":"Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy","canonical_id":"clinicaltrials.gov:NCT00067561","description":"Irritable Colon; Irritable Bowel Syndrome (IBS)","metadata":null},{"id":"fd444c1d1d0b4a9ebd19c462e196016f","type":"TRIAL","name":"Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina","canonical_id":"clinicaltrials.gov:NCT00225342","description":"Angina Pectoris; Diabetes Mellitus, Type 2","metadata":null},{"id":"5b4eb324270a45beafcdbc9638b16ec7","type":"TRIAL","name":"Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety","canonical_id":"clinicaltrials.gov:NCT00796510","description":"Pulmonary Arterial Hypertension; Pulmonary Hypertension","metadata":null},{"id":"e7fcbeeb846b4ed4ade113cbaf0f5ab5","type":"TRIAL","name":"Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)","canonical_id":"clinicaltrials.gov:NCT06600178","description":"Angina Patients With Non-obstructive Coronary Artery Disease; Coronary Microvascular Disease; Coronary Microvascular Dysfunction (CMD)","metadata":null},{"id":"91c5ac8eab0847a28e6878a3035ddca6","type":"TRIAL","name":"Study To Assess FRacTure Healing With SclerosTin Antibody - Hip","canonical_id":"clinicaltrials.gov:NCT01081678","description":"Fracture Healing","metadata":null},{"id":"dbb21951366843e4905df43482df8351","type":"TRIAL","name":"Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT03802487","description":"Type 2 Diabetes Mellitus; Healthy Subjects","metadata":null},{"id":"0dec10e0f29848e5a283f3336b91d9f5","type":"TRIAL","name":"Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00395707","description":"Macular Degeneration","metadata":null},{"id":"0aec38bee0834d2cbe494593200e502c","type":"TRIAL","name":"Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)","canonical_id":"clinicaltrials.gov:NCT01114568","description":"Healthy","metadata":null},{"id":"ccbdca0f4d4b4e148c0c7ee8c347e445","type":"TRIAL","name":"Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT01189461","description":"Anti- VGF Inhibitor; Diabetic Macular Edema; Diabetic Retinopathy","metadata":null},{"id":"14ace1add32d4e28b0f31b333ba18dff","type":"TRIAL","name":"Study Trial of Dexamethasone Use for Alleviation of Symptoms After Scleral Buckle Eye Surgery","canonical_id":"clinicaltrials.gov:NCT01326585","description":"Retinal Detachment","metadata":null},{"id":"69bc6ad548c549aa8a2c2aaae05891b1","type":"TRIAL","name":"Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)","canonical_id":"clinicaltrials.gov:NCT00659503","description":"Rhinitis, Allergic, Seasonal; Hay Fever","metadata":null},{"id":"6451863cee2d4c5494ab1ef475fc6921","type":"TRIAL","name":"Study Utilizing Rilonacept in Gout Exacerbations","canonical_id":"clinicaltrials.gov:NCT00855920","description":"Acute Gout Flare","metadata":null},{"id":"b2028474c35b41b0a4700e3575794c30","type":"TRIAL","name":"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT02982694","description":"MSI; ColoRectal Cancer; Chemotherapy; Resistance, APC","metadata":null},{"id":"93644702d6d847cba75d49fcd3693fff","type":"TRIAL","name":"Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT01956149","description":"Gastric Cancer","metadata":null},{"id":"a021446c4c84424dbb2f49c5982e72c0","type":"TRIAL","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","canonical_id":"clinicaltrials.gov:NCT06904235","description":"Nausea and Vomiting Chemotherapy-Induced; Nausea Post Chemotherapy","metadata":null},{"id":"33417651ad25402aa95b6079ee6bfa12","type":"TRIAL","name":"Study With Improved Solubility Pazopanib","canonical_id":"clinicaltrials.gov:NCT02810756","description":"Pharmacokinetics of Pazopanib","metadata":null},{"id":"2a8cefa9af7f47a399eb1719a4dbcfa7","type":"TRIAL","name":"Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations","canonical_id":"clinicaltrials.gov:NCT05222165","description":"Advanced Solid Tumor; CNS Tumor; Recurrent WHO Grade II Glioma","metadata":null},{"id":"27e54e6e6c8e431aa0cc43545050e8c2","type":"TRIAL","name":"Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01018758","description":"Chemotherapy-Induced Nausea and Vomiting; Non Hodgkin's Lymphoma","metadata":null},{"id":"2aa8e76a67364c749010d2235e323fe7","type":"TRIAL","name":"Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects","canonical_id":"clinicaltrials.gov:NCT00258141","description":"Allergy","metadata":null},{"id":"296b24accb4c454ca654f792159cf3c2","type":"TRIAL","name":"Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.","canonical_id":"clinicaltrials.gov:NCT05029297","description":"Diabetic Neuropathy, Painful","metadata":null},{"id":"87b3adc64a624419988e177a2cef9f37","type":"TRIAL","name":"Study for Evaluating Different Methods of Measuring Depression Treatment Response","canonical_id":"clinicaltrials.gov:NCT00406952","description":"Depressive Disorder, Major","metadata":null},{"id":"78d6613e830e4e8b9f6b760023318713","type":"TRIAL","name":"Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)","canonical_id":"clinicaltrials.gov:NCT07247786","description":"Non Small Cell Lung Cancer; Respiratory Tract Neoplasm","metadata":null},{"id":"12a9323c72424d08b82a6da85198f9f2","type":"TRIAL","name":"Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01032486","description":"Parkinson's Disease","metadata":null},{"id":"04f15f2d3ab943c49cecdef81da2d4e6","type":"TRIAL","name":"Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients","canonical_id":"clinicaltrials.gov:NCT00042432","description":"Secondary Hyperparathyroidism; Chronic Renal Insufficiency","metadata":null},{"id":"df8a0dca42944e7b8151f1fe9be37d02","type":"TRIAL","name":"Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination","canonical_id":"clinicaltrials.gov:NCT02655029","description":"Adherence to Medication Regime; Hypertensive Disease","metadata":null},{"id":"edf08cb443744c3b8bd0e6a351a0ddd2","type":"TRIAL","name":"Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)","canonical_id":"clinicaltrials.gov:NCT00405964","description":"Allergic Rhinitis","metadata":null},{"id":"0bf7066037b34997b730eb46e2222f2a","type":"TRIAL","name":"Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias","canonical_id":"clinicaltrials.gov:NCT02921477","description":"Mild Cognitive Impairment; Dementia","metadata":null},{"id":"39a4fba8a95a4cc1881464b79d149a9a","type":"TRIAL","name":"Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.","canonical_id":"clinicaltrials.gov:NCT04069234","description":"Diabetes Mellitus; Microvascular Coronary Artery Disease","metadata":null},{"id":"f37af0450e51441194c5563e77260e1e","type":"TRIAL","name":"Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group","canonical_id":"clinicaltrials.gov:NCT00836654","description":"EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast); Malignant Ascites","metadata":null},{"id":"6bb3dabb7ac643f78048fcdea8948768","type":"TRIAL","name":"Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium","canonical_id":"clinicaltrials.gov:NCT03682497","description":"Heart Failure","metadata":null},{"id":"a2cbe11e7f1f4c19895a8206155e97fa","type":"TRIAL","name":"Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s","canonical_id":"clinicaltrials.gov:NCT03457597","description":"Healthy","metadata":null},{"id":"71fcb35545c847c0bb55a75317b6f8b0","type":"TRIAL","name":"Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects","canonical_id":"clinicaltrials.gov:NCT01607034","description":"Healthy Volunteers","metadata":null},{"id":"1ae349bf8f6a47e2aa67dd996ec078ef","type":"TRIAL","name":"Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib","canonical_id":"clinicaltrials.gov:NCT01561781","description":"Healthy Volunteers","metadata":null},{"id":"717d62da08d24d40b29ee45eda01409f","type":"TRIAL","name":"Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol","canonical_id":"clinicaltrials.gov:NCT01594619","description":"Drug Induced Constipation","metadata":null},{"id":"72b0c536d3b146c2af0154ebc3f47682","type":"TRIAL","name":"Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.","canonical_id":"clinicaltrials.gov:NCT00881894","description":"Healthy","metadata":null},{"id":"baa86a701f044840b457d00b1e5530ae","type":"TRIAL","name":"Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body","canonical_id":"clinicaltrials.gov:NCT01059903","description":"Healthy Volunteers","metadata":null},{"id":"2c9f98e12fa64a98abfb0d319119ab72","type":"TRIAL","name":"Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body","canonical_id":"clinicaltrials.gov:NCT00957944","description":"Healthy Volunteers","metadata":null},{"id":"c5baed6ae39b4626a70f368405708f46","type":"TRIAL","name":"Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support","canonical_id":"clinicaltrials.gov:NCT02980666","description":"Short Bowel Syndrome","metadata":null},{"id":"72c04b737eab4241b285258379ee4d5c","type":"TRIAL","name":"Study in Participants With Acute Migraines Headaches","canonical_id":"clinicaltrials.gov:NCT00804973","description":"Migraine Headache","metadata":null},{"id":"0c7208f0f17e4e9188193cffee400ab2","type":"TRIAL","name":"Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","canonical_id":"clinicaltrials.gov:NCT03156621","description":"Homozygous Familial Hypercholesterolemia","metadata":null},{"id":"a4c28d7d646e4c3aaad360fa9fcf3273","type":"TRIAL","name":"Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib","canonical_id":"clinicaltrials.gov:NCT00473486","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"b7024d6faeee40ac9aeff6e81924e368","type":"TRIAL","name":"Study in Patients With COPD","canonical_id":"clinicaltrials.gov:NCT00215423","description":"COPD; Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"da2d4f50f76647c1a63ce92926eccd49","type":"TRIAL","name":"Study in Patients With Chronic Leukemia","canonical_id":"clinicaltrials.gov:NCT03807479","description":"Leukemia, Myeloid, Chronic-Phase","metadata":null},{"id":"23da0258c8fc4db4a2ca5af1883b7d80","type":"TRIAL","name":"Study in Pediatric Subjects With Epilepsy","canonical_id":"clinicaltrials.gov:NCT01494584","description":"Epilepsy","metadata":null},{"id":"26d9dd060af34d2b96aafbc4302c1c7a","type":"TRIAL","name":"Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma","canonical_id":"clinicaltrials.gov:NCT02227108","description":"B-Cell Pediatric ALL","metadata":null},{"id":"4312f7f23fd64731bd56200946ac6ea6","type":"TRIAL","name":"Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01455025","description":"Acute Myeloid Leukemia","metadata":null},{"id":"20c9bc02a097450a84859558e007feae","type":"TRIAL","name":"Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03176238","description":"Post Menopausal Breast Cancer","metadata":null},{"id":"900463908f904646bec5b98ef0519663","type":"TRIAL","name":"Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma","canonical_id":"clinicaltrials.gov:NCT02141100","description":"Non-Hodgkin Lymphoma","metadata":null},{"id":"d881512851904ae98eb2c320e6e39b29","type":"TRIAL","name":"Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBF\u03b2::MYH11(+) AML","canonical_id":"clinicaltrials.gov:NCT06429098","description":"Acute Myeloid Leukemia","metadata":null},{"id":"4d76482c99954a759dd3e4f45ec2a8a0","type":"TRIAL","name":"Study of ABO2102 in KRAS-Mutated Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07455617","description":"Advanced / Metastatic Solid Tumor","metadata":null},{"id":"6d6b1c2337af4d439f79b25f4023be4c","type":"TRIAL","name":"Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01241214","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"de4f10549a9a49ddaa7d278a6d16db42","type":"TRIAL","name":"Study of ALXN1210 in Complement Inhibitor Treatment-Na\u00efve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","canonical_id":"clinicaltrials.gov:NCT02949128","description":"Atypical Hemolytic Uremic Syndrome (aHUS)","metadata":null},{"id":"cf4c963aa8924965a94da8f0982bfc1b","type":"TRIAL","name":"Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04526210","description":"Wilson Disease","metadata":null},{"id":"a90a9603ffc7485ba756a63ef635a7e6","type":"TRIAL","name":"Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT00694590","description":"Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)","metadata":null},{"id":"1d8d072317fb481da1b9dfde06478485","type":"TRIAL","name":"Study of AMG531(Romiplostim) in Patients With Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT03957694","description":"Aplastic Anemia","metadata":null},{"id":"adf0174e07ba4c98be5514331f848209","type":"TRIAL","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07287917","description":"Melanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer","metadata":null},{"id":"122d997bb4564d7a90fb8c135e26b803","type":"TRIAL","name":"Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation","canonical_id":"clinicaltrials.gov:NCT01983761","description":"Blood And Marrow Transplantation; Leukemia; Lymphoma; Transplantation Infection; Myelodysplastic Syndrome (MDS); Non-Hodgkin's Lymphoma (NHL); Hodgkin's Lymphoma","metadata":null},{"id":"c16e0cd5a4894efebe1b9e12fb42c19f","type":"TRIAL","name":"Study of AT-527 in Subjects With Normal and Impaired Renal Function","canonical_id":"clinicaltrials.gov:NCT05618314","description":"Healthy Volunteer; Renal Impairment","metadata":null},{"id":"76814b317ed345bd9e072239ba7087f3","type":"TRIAL","name":"Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT00284141","description":"Pulmonary Diseases; Neoplasms, Lung","metadata":null},{"id":"b7b572821745420993144c7497af5dbf","type":"TRIAL","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05867251","description":"Advanced Solid Tumor; HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer; CCNE1 Amplification; Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"ff9a7557159a42ce8746af24b63847b0","type":"TRIAL","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","canonical_id":"clinicaltrials.gov:NCT07764978","description":"Newly Diagnosed Multiple Myeloma","metadata":null},{"id":"2d7be84d5b704f2b94fb0ff6e0d92f7b","type":"TRIAL","name":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT03616587","description":"ER+ HER2- Advanced Breast Cancer","metadata":null},{"id":"d2ecc77878fd44cfa8860c9f29040016","type":"TRIAL","name":"Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels","canonical_id":"clinicaltrials.gov:NCT02867020","description":"Prostate Cancer","metadata":null},{"id":"461ee09363b04e6b95cca1d4ab68f34b","type":"TRIAL","name":"Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01845792","description":"Prostate Cancer","metadata":null},{"id":"5f69e6e5a45240cd881b70de51a7119a","type":"TRIAL","name":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04262154","description":"Metastatic Prostate Cancer","metadata":null},{"id":"6c376142caf24fb190511bd0bacab76e","type":"TRIAL","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","canonical_id":"clinicaltrials.gov:NCT05952024","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"cb447dc8259d480aab647f9ca66179fe","type":"TRIAL","name":"Study of Acalabrutinib and Tafasitamab in MZL Patients","canonical_id":"clinicaltrials.gov:NCT04646395","description":"Marginal Zone Lymphoma","metadata":null},{"id":"2747f5c8187d4039b87af1db929be29b","type":"TRIAL","name":"Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT03011671","description":"Malignant Glioma of Brain","metadata":null},{"id":"78e2e2c94ecf46219f18aa9e499aceef","type":"TRIAL","name":"Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01908140","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"d6c62e6c733642bc986a13b5e08d52bc","type":"TRIAL","name":"Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00409617","description":"Crohn's Disease","metadata":null},{"id":"b84fc63ccdba46229471042e35744e3d","type":"TRIAL","name":"Study of Adalimumab in Patients With Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT00939003","description":"Axial Spondyloarthritis","metadata":null},{"id":"4966cf1d608b4960a8a9a4c92d417845","type":"TRIAL","name":"Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)","canonical_id":"clinicaltrials.gov:NCT00617305","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"0f95e3a6f4df4362937d729c419c8867","type":"TRIAL","name":"Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT00997009","description":"Cervical Cancer","metadata":null},{"id":"79bd6d8c20ff4e48baa74e24d4662a8b","type":"TRIAL","name":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03969004","description":"Cutaneous Squamous Cell Carcinoma","metadata":null},{"id":"9725aa529b7c4780918f9cc6ecbc6f99","type":"TRIAL","name":"Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density","canonical_id":"clinicaltrials.gov:NCT00145704","description":"Osteopenia","metadata":null},{"id":"69f76a11546e48669a0aef5557534991","type":"TRIAL","name":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","canonical_id":"clinicaltrials.gov:NCT01730053","description":"Hypercholesterolemia","metadata":null},{"id":"654dd2713ebc415cac3e80c5c626bd61","type":"TRIAL","name":"Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","canonical_id":"clinicaltrials.gov:NCT02326220","description":"Heterozygous Familial Hypercholesterolemia","metadata":null},{"id":"bcf484f261044414bf2a30179a4d43b4","type":"TRIAL","name":"Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","canonical_id":"clinicaltrials.gov:NCT01709500","description":"Heterozygous Familial Hypercholesterolemia","metadata":null},{"id":"f378accfb9a74640b1a23cd9b45950c2","type":"TRIAL","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","canonical_id":"clinicaltrials.gov:NCT04208178","description":"Advanced HER2+Breast Cancer","metadata":null},{"id":"3cebb5c0d384461cb8c1882c0a0f0db2","type":"TRIAL","name":"Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus","canonical_id":"clinicaltrials.gov:NCT00388479","description":"Ileus","metadata":null},{"id":"f3a0ce7cc9774cf897cc23572a188300","type":"TRIAL","name":"Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus","canonical_id":"clinicaltrials.gov:NCT00388258","description":"Ileus","metadata":null},{"id":"8f74bca3e37b48afb06aac4cd3b60422","type":"TRIAL","name":"Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus","canonical_id":"clinicaltrials.gov:NCT00205842","description":"Ileus","metadata":null},{"id":"90c035d7536e46b38dbc7dea521d8069","type":"TRIAL","name":"Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus","canonical_id":"clinicaltrials.gov:NCT00388401","description":"Ileus","metadata":null},{"id":"6ce6ca7ce1cc48b4a74d258f506545d5","type":"TRIAL","name":"Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT01093885","description":"Systemic Sclerosis; Scleroderma","metadata":null},{"id":"f8ef4b8c849c4ecd8980934ebd03ea5f","type":"TRIAL","name":"Study of Ambrisentan in Participants With Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT00777920","description":"Pulmonary Hypertension","metadata":null},{"id":"f0005b822e254328978d4d12dfb5dbd6","type":"TRIAL","name":"Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension","canonical_id":"clinicaltrials.gov:NCT01308983","description":"Prehypertension","metadata":null},{"id":"8844dd2ae2a34ca19637b0a0ac3cb398","type":"TRIAL","name":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02609776","description":"Non-Small-Cell Lung Cancer","metadata":null},{"id":"d9623ffec47749559b27b865dee98a3a","type":"TRIAL","name":"Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC","canonical_id":"clinicaltrials.gov:NCT03736837","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"8ed56ad519ae4902b104179b8e19bc87","type":"TRIAL","name":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT03636685","description":"NSCLC; Adenocarcinoma; Squamous Cell Carcinoma","metadata":null},{"id":"4831b46a5c32453f99fe70e44ed830bc","type":"TRIAL","name":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","canonical_id":"clinicaltrials.gov:NCT02735239","description":"Esophageal Cancer","metadata":null},{"id":"647dd77a5e424d96be088de249fc3281","type":"TRIAL","name":"Study of Antidepressants in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00086190","description":"Parkinson Disease; Depression","metadata":null},{"id":"eaf0cf61258a4195b41bd44a98b8559f","type":"TRIAL","name":"Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT01150331","description":"Status; Epilepticus, Tonic-clonic","metadata":null},{"id":"510d4ae6b79745a09ac87bb6346078f2","type":"TRIAL","name":"Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","canonical_id":"clinicaltrials.gov:NCT00371683","description":"Deep Vein Thrombosis; Pulmonary Embolism","metadata":null},{"id":"2b9fa25417164834ae5b532dd78838c9","type":"TRIAL","name":"Study of Apremilast in Atopic or Contact Dermatitis","canonical_id":"clinicaltrials.gov:NCT00931242","description":"Atopic Dermatitis; Allergic Contact Dermatitis","metadata":null},{"id":"fc67701714b34b3bbc07735dee3eac05","type":"TRIAL","name":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","canonical_id":"clinicaltrials.gov:NCT00080444","description":"Vomiting","metadata":null},{"id":"56bb7e86b637439faa30e29af11d58b0","type":"TRIAL","name":"Study of Aripiprazole in Patients With Acute Bipolar Mania","canonical_id":"clinicaltrials.gov:NCT00097266","description":"Bipolar Disorder","metadata":null},{"id":"7e701f00ed1e45d0a9d2113c4367b3ce","type":"TRIAL","name":"Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders","canonical_id":"clinicaltrials.gov:NCT00870727","description":"Pervasive Developmental Disorder","metadata":null},{"id":"b859f972ddf74065a0b766bb22610cfc","type":"TRIAL","name":"Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy","canonical_id":"clinicaltrials.gov:NCT00539942","description":"Venous Thrombosis","metadata":null},{"id":"390851575ff44c8eb30c7b0f4cd10f73","type":"TRIAL","name":"Study of Ascending Levels of Tolvaptan in Hyponatremia","canonical_id":"clinicaltrials.gov:NCT00201994","description":"Hyponatremia","metadata":null},{"id":"52eb01c68ce64f83bef62a2b4118454d","type":"TRIAL","name":"Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)","canonical_id":"clinicaltrials.gov:NCT00281320","description":"Psychosis","metadata":null},{"id":"1e3824ada1234f6d939bd66cf5d7601c","type":"TRIAL","name":"Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01431053","description":"Breast Neoplasms","metadata":null},{"id":"cc5715e308444eb0a3a5e562dfa51c80","type":"TRIAL","name":"Study of Association of Anti-inflammatory and Anti-rheumatic","canonical_id":"clinicaltrials.gov:NCT02448199","description":"Osteoarthritis","metadata":null},{"id":"713d61da8a4840419c0a09fe3adbf1dd","type":"TRIAL","name":"Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD","canonical_id":"clinicaltrials.gov:NCT00585910","description":"ADHD; Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"eb53632e4da449bfbb38ce5ca96514e7","type":"TRIAL","name":"Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes","canonical_id":"clinicaltrials.gov:NCT00191633","description":"Attention-Deficit/Hyperactivity Disorder","metadata":null},{"id":"d226e8502c144ffbbb16407ca2e2e4e5","type":"TRIAL","name":"Study of Atorvastatin Dose Dependent Reduction of Proteinuria","canonical_id":"clinicaltrials.gov:NCT00768638","description":"Chronic Kidney Disease","metadata":null},{"id":"15c80b2e6f3f489abae1e25710932e96","type":"TRIAL","name":"Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00036556","description":"Prostatic Neoplasms","metadata":null},{"id":"741c494002824f7fa390b85ddedcf7d1","type":"TRIAL","name":"Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children","canonical_id":"clinicaltrials.gov:NCT06697522","description":"Myopia","metadata":null},{"id":"bd703a01e35141f9bd23d3bd17f6e629","type":"TRIAL","name":"Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage","canonical_id":"clinicaltrials.gov:NCT00890656","description":"Acute Lymphoblastic Leukemia","metadata":null},{"id":"72cdc614f273440a856189f428b880b0","type":"TRIAL","name":"Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)","canonical_id":"clinicaltrials.gov:NCT06424717","description":"Urothelial Carcinoma","metadata":null},{"id":"dcd5cf9cddf24364b899ef8190437abe","type":"TRIAL","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05371093","description":"Relapsed/Refractory Follicular Lymphoma","metadata":null},{"id":"d791f110c6984bd8b1411e006185b650","type":"TRIAL","name":"Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma","canonical_id":"clinicaltrials.gov:NCT03839498","description":"Pheochromocytoma; Paraganglioma","metadata":null},{"id":"b48f15f72f184464b8c704050b4b348b","type":"TRIAL","name":"Study of Axitinib and Temsirolimus in Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01529138","description":"Cancer","metadata":null},{"id":"0b19d275d0ed495089a305c5fec7f128","type":"TRIAL","name":"Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma","canonical_id":"clinicaltrials.gov:NCT02859012","description":"Recurrent ACC, metastaticACC, Unreaectable ACC","metadata":null},{"id":"9eef166ddf9e4255a37080e89b379166","type":"TRIAL","name":"Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic","canonical_id":"clinicaltrials.gov:NCT01519284","description":"Parkinson Disease","metadata":null},{"id":"9a3788e664d643b49041cdc6cfb08db4","type":"TRIAL","name":"Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant","canonical_id":"clinicaltrials.gov:NCT00114777","description":"Renal Transplantation","metadata":null},{"id":"da4a9f40b17b472a96776d8a7cc77530","type":"TRIAL","name":"Study of Belimumab Administered Subcutaneously to Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01583530","description":"Healthy","metadata":null},{"id":"c1bcdbb367984998adc2e18664077b24","type":"TRIAL","name":"Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06516887","description":"Advanced Lung Adenocarcinoma","metadata":null},{"id":"2ef50d86b345477ab2c8b7581ec051e6","type":"TRIAL","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","canonical_id":"clinicaltrials.gov:NCT05588388","description":"Extensive-stage Small-cell Lung Cancer; Liver Metastases","metadata":null},{"id":"d2761ebbf2e548ddab2969052e8a2034","type":"TRIAL","name":"Study of Bexarotene in Patients With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00316030","description":"AML; Acute Myeloid Leukemia","metadata":null},{"id":"d2873e5df2a14abc8b8d0648e9e540c8","type":"TRIAL","name":"Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy","canonical_id":"clinicaltrials.gov:NCT00490490","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"e74d1f0712fc45158e84e77f2aab2d07","type":"TRIAL","name":"Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00972855","description":"Healthy","metadata":null},{"id":"88557d9788b644a7a7782453bec78915","type":"TRIAL","name":"Study of Bile Acids in Patients With Peroxisomal Disorders","canonical_id":"clinicaltrials.gov:NCT00004442","description":"Infantile Refsum's Disease; Zellweger Syndrome; Bifunctional Enzyme Deficiency; Adrenoleukodystrophy","metadata":null},{"id":"2d66000d20914476b22f0ff4905f5096","type":"TRIAL","name":"Study of Bimatoprost Gel on Eyelash Growth","canonical_id":"clinicaltrials.gov:NCT01200251","description":"Madarosis; Hypotrichosis","metadata":null},{"id":"f50b256d359c45ba9f1087bafc9d040b","type":"TRIAL","name":"Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis","canonical_id":"clinicaltrials.gov:NCT00958035","description":"Hypotrichosis","metadata":null},{"id":"23c8b00a98a74a13b551fc791172c860","type":"TRIAL","name":"Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG","canonical_id":"clinicaltrials.gov:NCT03973918","description":"High Grade Glioma; BRAF V600E; BRAF V600K; Anaplastic Astrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Gliosarcoma; Glioblastoma","metadata":null},{"id":"dbf3ade59e4d432eb363dffb26ff9c50","type":"TRIAL","name":"Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01478048","description":"Multiple Myeloma","metadata":null},{"id":"bbf3b4e59c3747329ffd38e89f800daa","type":"TRIAL","name":"Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM","canonical_id":"clinicaltrials.gov:NCT02375555","description":"Multiple Myeloma","metadata":null},{"id":"2a2ef43cb66242e0bec19d8a6a120ab6","type":"TRIAL","name":"Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT03128411","description":"Leukemia, Chronic Myelogenous","metadata":null},{"id":"0c8c9fc0fc7a4b37a0e71a7b5442f4b7","type":"TRIAL","name":"Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01874054","description":"Hodgkin Disease","metadata":null},{"id":"d4e726953ce8452aa4b4d85f19e9e3ab","type":"TRIAL","name":"Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas","canonical_id":"clinicaltrials.gov:NCT04334174","description":"T Cell Lymphoma","metadata":null},{"id":"381c9af29bf24151b38d1bebab86742d","type":"TRIAL","name":"Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)","canonical_id":"clinicaltrials.gov:NCT04880434","description":"Relapsed/Refractory Mantle Cell Lymphoma","metadata":null},{"id":"5ae4ba61838e4085bb7f320f2ae3cbbf","type":"TRIAL","name":"Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients","canonical_id":"clinicaltrials.gov:NCT01151904","description":"Glaucoma, Angle-Closure","metadata":null},{"id":"ffe93a9d5c7c4a4b9804494db98911d9","type":"TRIAL","name":"Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00372827","description":"Primary Open-angle Glaucoma; Ocular Hypertension; Pigment Dispersion Glaucoma","metadata":null},{"id":"8f040ec2b7354276921b237d1a953587","type":"TRIAL","name":"Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT04264819","description":"Neovascular Age-Related Macular Degeneration","metadata":null},{"id":"137b75a3df44484291f8eab3df63603f","type":"TRIAL","name":"Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.","canonical_id":"clinicaltrials.gov:NCT00588406","description":"Asthma","metadata":null},{"id":"d7730bc261b74ed0b0a4429779bca8f7","type":"TRIAL","name":"Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)","canonical_id":"clinicaltrials.gov:NCT02304367","description":"Tumor Induced Osteomalacia (TIO); Epidermal Nevus Syndrome (ENS)","metadata":null},{"id":"897ed15196c1402c81e39026068554ec","type":"TRIAL","name":"Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT01641159","description":"Cocaine Dependence","metadata":null},{"id":"ee5490e27768484fa0ded940497d4511","type":"TRIAL","name":"Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer","canonical_id":"clinicaltrials.gov:NCT04289779","description":"Bladder Cancer","metadata":null},{"id":"66fc243756ea4ff39a79e0f81e98fccc","type":"TRIAL","name":"Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03875313","description":"Solid Tumor; Clear Cell Renal Cell Carcinoma; TNBC - Triple-Negative Breast Cancer; Colorectal Cancer; CRC; RCC; ccRCC","metadata":null},{"id":"8ec7c25b163e40a2b952e6b3c06b1d68","type":"TRIAL","name":"Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00161590","description":"T-Cell Lymphoma; Lymphoma, Non-Hodgkin's","metadata":null},{"id":"c67ccf554ead411aa91a18dc60bdef59","type":"TRIAL","name":"Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT05014776","description":"Pancreatic Cancer","metadata":null},{"id":"8af9aa38d03c40ef8c959d244ff70afc","type":"TRIAL","name":"Study of CRx-191 to Assess Activity in Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00557739","description":"Plaque Psoriasis","metadata":null},{"id":"40ccddc9857545ce92bae5c94bed68d9","type":"TRIAL","name":"Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes","canonical_id":"clinicaltrials.gov:NCT00506298","description":"Type 2 Diabetes","metadata":null},{"id":"87d67431a1984f95bec1186c6f45ce03","type":"TRIAL","name":"Study of CS-3150 in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT02890173","description":"Essential Hypertension","metadata":null},{"id":"1725cc4e1ebc480a819f2dfd5d9a6532","type":"TRIAL","name":"Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01649635","description":"Prostate Cancer","metadata":null},{"id":"04587488f7744de789d6802019d43ecb","type":"TRIAL","name":"Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes","canonical_id":"clinicaltrials.gov:NCT01693549","description":"Breast Cancer","metadata":null},{"id":"065a0cf844e741cbb1036f9bac3e3f88","type":"TRIAL","name":"Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers","canonical_id":"clinicaltrials.gov:NCT01535859","description":"Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"0a0116b0052d4afbbec799e6367854a1","type":"TRIAL","name":"Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor","canonical_id":"clinicaltrials.gov:NCT00889525","description":"Cushing's Disease; Corticotroph Adenoma","metadata":null},{"id":"19e11894f143411d8383fa8a22dd3e1f","type":"TRIAL","name":"Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01522443","description":"Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms","metadata":null},{"id":"6d883839b23c4c4eb44a28f4225f7c5a","type":"TRIAL","name":"Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib","canonical_id":"clinicaltrials.gov:NCT01908426","description":"Hepatocellular Carcinoma","metadata":null},{"id":"1e77ea79b065483e82570c397b54c3a9","type":"TRIAL","name":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04963283","description":"Colorectal Adenocarcinoma; Colon Cancer; Colon Adenocarcinoma; Rectum Cancer; Rectal Cancer; Rectal Adenocarcinoma; Colorectal Cancer","metadata":null},{"id":"866c641269fb4ab592bd96f60167068d","type":"TRIAL","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06202313","description":"Triple Negative Breast Cancer","metadata":null},{"id":"dae914cb37fa41279258e2a54a17d078","type":"TRIAL","name":"Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases","canonical_id":"clinicaltrials.gov:NCT05812534","description":"Non Small Cell Lung Cancer; Brain Metastases","metadata":null},{"id":"48269e18db284d31ad47523a50bb8b34","type":"TRIAL","name":"Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma","canonical_id":"clinicaltrials.gov:NCT05930665","description":"Pleural Mesothelioma","metadata":null},{"id":"f6f9cfcb3fe6489c8a7337aecb53c3c5","type":"TRIAL","name":"Study of Canakinumab in Patients With Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT05467800","description":"Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; ET-MF; Post-polycythemia Vera Related Myelofibrosis; PV-MF","metadata":null},{"id":"5c3d44df9f694582b8c039069ab18bed","type":"TRIAL","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","canonical_id":"clinicaltrials.gov:NCT05348577","description":"Prostate Cancer","metadata":null},{"id":"9eb1ea49c42146959edeb921a14ad2b9","type":"TRIAL","name":"Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT05008055","description":"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","metadata":null},{"id":"ed86327475c240dea30b4dec0d665996","type":"TRIAL","name":"Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","canonical_id":"clinicaltrials.gov:NCT04427072","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"fab0e48f16f1424aafd3548ef49fa09b","type":"TRIAL","name":"Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03647488","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"2b945ba7f5bd4a7f9d092bb0b0d4df77","type":"TRIAL","name":"Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations","canonical_id":"clinicaltrials.gov:NCT04323436","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"3ea3665850414413abb694f649009c1c","type":"TRIAL","name":"Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","canonical_id":"clinicaltrials.gov:NCT04677595","description":"Non-Small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"64c94f464b224d719ff9a09b97829937","type":"TRIAL","name":"Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.","canonical_id":"clinicaltrials.gov:NCT05110196","description":"Non-Small Cell Lung Carcinoma","metadata":null},{"id":"287254f65bf245719b78a8c88d984645","type":"TRIAL","name":"Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma","canonical_id":"clinicaltrials.gov:NCT01276717","description":"Lymphoma","metadata":null},{"id":"aecf2b115b814920a8f1867a8ff63417","type":"TRIAL","name":"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","canonical_id":"clinicaltrials.gov:NCT03158688","description":"Relapsed Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"e2bc79a2a5994774bb2700dfb3923daa","type":"TRIAL","name":"Study of Cetuximab to Treat Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT00699881","description":"Gastric Cancer","metadata":null},{"id":"c7a559ebc46d474697d4d0c2a4783def","type":"TRIAL","name":"Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)","canonical_id":"clinicaltrials.gov:NCT01431521","description":"Non-alcoholic Fatty Liver Disease","metadata":null},{"id":"e6316ec3964d412ab316afdac979650e","type":"TRIAL","name":"Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT05799469","description":"Locally Advanced Cervical Cancer","metadata":null},{"id":"619140ac08f24e398add41da278b728a","type":"TRIAL","name":"Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02272127","description":"NSCLC","metadata":null},{"id":"aac1717cf0cb4236a95f4f5835c45742","type":"TRIAL","name":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","canonical_id":"clinicaltrials.gov:NCT04747912","description":"Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia; ph+ Acute Lymphoblastic Leukemia","metadata":null},{"id":"fb68da4fe1434c7295c2d1838ff3b281","type":"TRIAL","name":"Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab","canonical_id":"clinicaltrials.gov:NCT03369574","description":"Chronic Rhinosinusitis (Diagnosis); Asthma; Nasal Polyps","metadata":null},{"id":"2cb49b6f411d449e9afbd99942598309","type":"TRIAL","name":"Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","canonical_id":"clinicaltrials.gov:NCT00823875","description":"Atherosclerosis Cerebral Infarction","metadata":null},{"id":"1b8e9e6e0795491293498472514819ce","type":"TRIAL","name":"Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker","canonical_id":"clinicaltrials.gov:NCT00823849","description":"Type 2 Diabetes Mellitus; Arteriosclerosis Obliterans","metadata":null},{"id":"f958378dd4a448c2bc489496fd77439b","type":"TRIAL","name":"Study of Cingal\u2122 for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide","canonical_id":"clinicaltrials.gov:NCT03191903","description":"Knee Osteoarthritis","metadata":null},{"id":"1aeec24578d64074918df03a14d77cc6","type":"TRIAL","name":"Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes","canonical_id":"clinicaltrials.gov:NCT01302106","description":"Myelodysplastic Syndromes","metadata":null},{"id":"adbae78fabbc42e396550b21bce1261f","type":"TRIAL","name":"Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02476123","description":"Solid Tumor","metadata":null},{"id":"dbd87da608cc4d64b64016699bc2adf8","type":"TRIAL","name":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT04214418","description":"Gastrointestinal Cancer","metadata":null},{"id":"356781dcd0084ca4a9fb4cd82d289be8","type":"TRIAL","name":"Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)","canonical_id":"clinicaltrials.gov:NCT06028321","description":"Cachexia","metadata":null},{"id":"b7e8b5d36dbe4a409d56020a0045955a","type":"TRIAL","name":"Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia","canonical_id":"clinicaltrials.gov:NCT00709215","description":"Refractory TdT-Positive Leukemia","metadata":null},{"id":"a1f7143b71e04cc7ad79fbbf063a2c52","type":"TRIAL","name":"Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma","canonical_id":"clinicaltrials.gov:NCT03778073","description":"B-cell Non Hodgkin Lymphoma; Richter's Transformation","metadata":null},{"id":"5a530fea78b14b2aac062d1306f2b1d2","type":"TRIAL","name":"Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT03193918","description":"Esophagogastric Adenocarcinoma","metadata":null},{"id":"b7fc82c649654296a3f51eb1a8c8a743","type":"TRIAL","name":"Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML","canonical_id":"clinicaltrials.gov:NCT03258931","description":"Newly Diagnosed FLT3 Mutated AML","metadata":null},{"id":"3ea7a8341abf4d8bb4fd547b592aaf83","type":"TRIAL","name":"Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome","canonical_id":"clinicaltrials.gov:NCT01171378","description":"Richter's Syndrome","metadata":null},{"id":"740f98bf7b4145de9050526a1cc7a4e3","type":"TRIAL","name":"Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab","canonical_id":"clinicaltrials.gov:NCT06447376","description":"Non-Hodgkin Lymphoma; Cytokine Release Syndrome","metadata":null},{"id":"9a0b0d17261542d98203bcd28bc93435","type":"TRIAL","name":"Study of DF1001 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04143711","description":"Solid Tumor, Adult","metadata":null},{"id":"d65b67cace474d0c9d939a2221bf5159","type":"TRIAL","name":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03851614","description":"Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma","metadata":null},{"id":"221031c9cdd147fea03b7329a5e0e722","type":"TRIAL","name":"Study of DS-7080a for the Treatment of Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT02530918","description":"Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema","metadata":null},{"id":"0346d71654af40d6bb56dcc40629bac5","type":"TRIAL","name":"Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus","canonical_id":"clinicaltrials.gov:NCT01628692","description":"Hepatitis C Virus","metadata":null},{"id":"8c02284b423c4a218ec3caaee67a958b","type":"TRIAL","name":"Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity","canonical_id":"clinicaltrials.gov:NCT00845338","description":"Multiple Sclerosis; Overactive Detrusor","metadata":null},{"id":"b84ca6b52c6e4fab96f1c2f1e8b10514","type":"TRIAL","name":"Study of Dasatinib (BMS-354825) in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00339144","description":"Tumors","metadata":null},{"id":"9f0944a9aac848418d580639f679afbb","type":"TRIAL","name":"Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia","canonical_id":"clinicaltrials.gov:NCT05419050","description":"Fibrous Dysplasia","metadata":null},{"id":"e92bb89dfae5424a9934e55b380a8eef","type":"TRIAL","name":"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00321620","description":"Bone Metastases","metadata":null},{"id":"a90cb48e6cb7480eaac14d3d941f1497","type":"TRIAL","name":"Study of Desvenlafaxine in Treating Major Depressive Disorder.","canonical_id":"clinicaltrials.gov:NCT04364997","description":"Major Depressive Disorder","metadata":null},{"id":"7b2a0d1ca6884184aad158c66f514cfa","type":"TRIAL","name":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","canonical_id":"clinicaltrials.gov:NCT01659658","description":"Relapsed or Refractory Systemic Light Chain Amyloidosis","metadata":null},{"id":"475bff20a5234bd48f7d4ca23cc3f803","type":"TRIAL","name":"Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation","canonical_id":"clinicaltrials.gov:NCT00406341","description":"Inflammation","metadata":null},{"id":"21f990e078ac4f8c89185bee7d64bf6c","type":"TRIAL","name":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation","canonical_id":"clinicaltrials.gov:NCT00407225","description":"Inflammation","metadata":null},{"id":"8a4df5f8ee80453bbf9963ad63dd9fb1","type":"TRIAL","name":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation","canonical_id":"clinicaltrials.gov:NCT00406497","description":"Inflammation","metadata":null},{"id":"c09153f0654f4b719bacc81bd289a2f8","type":"TRIAL","name":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis","canonical_id":"clinicaltrials.gov:NCT00407056","description":"Uveitis; Panuveitis","metadata":null},{"id":"4b86af826c0544bf91ce637bbcbc9660","type":"TRIAL","name":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis","canonical_id":"clinicaltrials.gov:NCT00405496","description":"Anterior Uveitis","metadata":null},{"id":"58ec6045bd404ec28ee2ad006d91dc83","type":"TRIAL","name":"Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis","canonical_id":"clinicaltrials.gov:NCT00406887","description":"Anterior Uveitis; Panuveitis","metadata":null},{"id":"26358f5eb84c41df9cbc761a55f30f11","type":"TRIAL","name":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)","canonical_id":"clinicaltrials.gov:NCT00616070","description":"Inflammation","metadata":null},{"id":"8ca5632225ea4ce58584f0668491484d","type":"TRIAL","name":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)","canonical_id":"clinicaltrials.gov:NCT00616993","description":"Inflammation","metadata":null},{"id":"bf5407680a6841639362acf2b4516453","type":"TRIAL","name":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)","canonical_id":"clinicaltrials.gov:NCT00429923","description":"Inflammation","metadata":null},{"id":"a5aa5a8d587e45d0bc276f7d948dd385","type":"TRIAL","name":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)","canonical_id":"clinicaltrials.gov:NCT00430092","description":"Inflammation","metadata":null},{"id":"d50d69f4b5164700918ed1588c24f7a6","type":"TRIAL","name":"Study of Difluprednate in the Treatment of Uveitis","canonical_id":"clinicaltrials.gov:NCT00501579","description":"Uveitis","metadata":null},{"id":"c96710b8e1ce4e5188f34dd63adb13b6","type":"TRIAL","name":"Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.","canonical_id":"clinicaltrials.gov:NCT01244334","description":"Cataracts; Corneal Edema; Retinal Structural Change, Deposit and Degeneration; Visual Acuity Reduced Transiently","metadata":null},{"id":"be8ac15caf4b4f86967c121db370bd99","type":"TRIAL","name":"Study of Drug Therapy for Pediatric Heart Failure","canonical_id":"clinicaltrials.gov:NCT06039540","description":"Heart Failure Congenital","metadata":null},{"id":"3025d717cbe84035bc4ced7655ba8ff1","type":"TRIAL","name":"Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT06064539","description":"Multiple Sclerosis","metadata":null},{"id":"2e94fcb7a6fc40e38855534ca0a6eaf7","type":"TRIAL","name":"Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01859988","description":"Atopic Dermatitis","metadata":null},{"id":"9adaec0bd1444de988ec972db1edc3e4","type":"TRIAL","name":"Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer","canonical_id":"clinicaltrials.gov:NCT03428126","description":"Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon Cancer","metadata":null},{"id":"394275ab9d7c46d18ffe656417321c4d","type":"TRIAL","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","canonical_id":"clinicaltrials.gov:NCT03164616","description":"Non Small Cell Lung Cancer NSCLC","metadata":null},{"id":"e177bd242bb14816bc25c69405d00a85","type":"TRIAL","name":"Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy","canonical_id":"clinicaltrials.gov:NCT03703297","description":"Small Cell Lung Cancer","metadata":null},{"id":"ff933c0b288143d680022dd77b896842","type":"TRIAL","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","canonical_id":"clinicaltrials.gov:NCT02542293","description":"Non Small Cell Lung Carcinoma NSCLC","metadata":null},{"id":"1efba7076f5d4a6d867e7fd83017e887","type":"TRIAL","name":"Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT02204982","description":"Follicular Lymphoma","metadata":null},{"id":"1c888db1cf8e4e7eaa09a64ff502f2a6","type":"TRIAL","name":"Study of E7389 for Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00965523","description":"Breast Cancer","metadata":null},{"id":"c042715c51284f14946ef2d5ca867335","type":"TRIAL","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06726148","description":"Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Extensive-stage Small Cell Lung Cancer","metadata":null},{"id":"22c0b911375c4df9b869b5009305dd27","type":"TRIAL","name":"Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT02790632","description":"Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"1613398f8d094a3abc636ef451d0c81c","type":"TRIAL","name":"Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC","canonical_id":"clinicaltrials.gov:NCT03333343","description":"EGFR-mutant Non-small Cell Lung Cancer","metadata":null},{"id":"c015e555257343249ed2d071548bab15","type":"TRIAL","name":"Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05060432","description":"Advanced Cancer; Lung Cancer; Head and Neck Cancer; Melanoma","metadata":null},{"id":"be5d6519380a441facaba9ba3e451385","type":"TRIAL","name":"Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis","canonical_id":"clinicaltrials.gov:NCT04128579","description":"Lupus Erythematosus; Lupus Nephritis","metadata":null},{"id":"e5b804a602274c96b5f7594335f9ecc9","type":"TRIAL","name":"Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT07570966","description":"Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC)","metadata":null},{"id":"50ba3c385f364b11a8cb3d6697e8fe20","type":"TRIAL","name":"Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00726466","description":"Age Related Macular Degeneration; AMD; CNV","metadata":null},{"id":"52a05b831bd54d3fa9474a7cb2bf5c52","type":"TRIAL","name":"Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics","canonical_id":"clinicaltrials.gov:NCT01654120","description":"Diabetes Mellitus, Type II","metadata":null},{"id":"3aadf78f683942db8f92065b82ab5c9b","type":"TRIAL","name":"Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury","canonical_id":"clinicaltrials.gov:NCT00580970","description":"Prostate Cancer","metadata":null},{"id":"282811a54526481c9be025e0e5628039","type":"TRIAL","name":"Study of Effects of Preoperative Oral Domperidone on Gastric Residual Volume After Clear Fluid Ingestion in Patients Scheduled for Elective Surgeries","canonical_id":"clinicaltrials.gov:NCT05570292","description":"Gastric Residual Volume","metadata":null},{"id":"3ac6ac8cb15b4c268d8370096910b4f6","type":"TRIAL","name":"Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia","canonical_id":"clinicaltrials.gov:NCT00478192","description":"Hyponatremia","metadata":null},{"id":"eba5c7c226c841d7a05f42dfdd251d2f","type":"TRIAL","name":"Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients","canonical_id":"clinicaltrials.gov:NCT03333109","description":"Episodic Migraine","metadata":null},{"id":"473f3d666be74367b8b30d778cd33adb","type":"TRIAL","name":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.","canonical_id":"clinicaltrials.gov:NCT03578367","description":"CML; Chronic Myelogenous Leukemia; Leukemia, Myeloid Chronic; Hematologic Diseases","metadata":null},{"id":"476df10f6a88429d91fd867db77ff9b3","type":"TRIAL","name":"Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility","canonical_id":"clinicaltrials.gov:NCT01902290","description":"Asthma","metadata":null},{"id":"8b3709e68a99428e8a5aedffde995250","type":"TRIAL","name":"Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT02429882","description":"Axial Spondyloarthritis","metadata":null},{"id":"00a98619e7a447a5892d2cdd7a9e3714","type":"TRIAL","name":"Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT02024646","description":"Psoriatic Arthritis","metadata":null},{"id":"5ccd418f0276479c9f9b9b7509064e26","type":"TRIAL","name":"Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT04278417","description":"Proliferative Diabetic Retinopathy","metadata":null},{"id":"2d5191f024dc4d91a8d9f125b49a851d","type":"TRIAL","name":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT04047472","description":"Neovascular Age-Related Macular Degeneration","metadata":null},{"id":"fab12d19049944e38b6d532bc4a929c2","type":"TRIAL","name":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT03481634","description":"Diabetic Macular Edema","metadata":null},{"id":"f199d4da69984c4a812ab878987fdc7b","type":"TRIAL","name":"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","canonical_id":"clinicaltrials.gov:NCT04362813","description":"Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia","metadata":null},{"id":"b94cf169efe442c5a0b99d6194fb01c2","type":"TRIAL","name":"Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA","canonical_id":"clinicaltrials.gov:NCT02396212","description":"Systemic Juvenile Idiopathic Arthritis","metadata":null},{"id":"e3e431731c654475bbaf55255addc3d4","type":"TRIAL","name":"Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers","canonical_id":"clinicaltrials.gov:NCT02059291","description":"Hereditary Periodic Fevers","metadata":null},{"id":"09b0c8be276d4951b64f071f611adcde","type":"TRIAL","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors","canonical_id":"clinicaltrials.gov:NCT02684058","description":"Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-f\u2026","metadata":null},{"id":"a2810e97e0754996899acd729da945ed","type":"TRIAL","name":"Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence","canonical_id":"clinicaltrials.gov:NCT04797000","description":"Myelodysplastic Syndromes","metadata":null},{"id":"a506a28a8a4042c3bc4d86ebcb559d6a","type":"TRIAL","name":"Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients","canonical_id":"clinicaltrials.gov:NCT03867201","description":"Migraine","metadata":null},{"id":"62e079656490423d9f060cbb42fa0bf3","type":"TRIAL","name":"Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT04708782","description":"Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease","metadata":null},{"id":"0de225b2ecd34f9eb346c66cb0414451","type":"TRIAL","name":"Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy","canonical_id":"clinicaltrials.gov:NCT01625494","description":"Hypertension","metadata":null},{"id":"9c7121085dbf4ea095167587d4cd6136","type":"TRIAL","name":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05429502","description":"Neuroblastoma","metadata":null},{"id":"a355b6f4319444b6a1159c165b090d3a","type":"TRIAL","name":"Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03589885","description":"Plaque Psoriasis","metadata":null},{"id":"71fbd9ca47024785ab2344531dcf25f5","type":"TRIAL","name":"Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis","canonical_id":"clinicaltrials.gov:NCT02750592","description":"Ankylosing Spondylitis","metadata":null},{"id":"dd36a23efc9d4b18bde2bbcff09f6161","type":"TRIAL","name":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","canonical_id":"clinicaltrials.gov:NCT04558918","description":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","metadata":null},{"id":"e1ffb9658c2b4560a996f2e26ca75785","type":"TRIAL","name":"Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)","canonical_id":"clinicaltrials.gov:NCT03713632","description":"Hidradenitis Suppurativa","metadata":null},{"id":"efe76586026c424c866f1276d5c655d9","type":"TRIAL","name":"Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00731120","description":"Generalized Anxiety Disorder","metadata":null},{"id":"4dfa09cdcf7943339547b16dbc00e502","type":"TRIAL","name":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","canonical_id":"clinicaltrials.gov:NCT03106779","description":"Chronic Myelogenous Leukemia","metadata":null},{"id":"1450891494624874820fcf1e1c2e9b6d","type":"TRIAL","name":"Study of Efficacy of Ramelteon in Adults With Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT00671125","description":"Chronic Insomnia","metadata":null},{"id":"91400aaa305b4b49b170c1b72991b4ee","type":"TRIAL","name":"Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT02029495","description":"Psoriatic Arthritis","metadata":null},{"id":"5f8d068ba21a4760979ef9b5bebf56fa","type":"TRIAL","name":"Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment","canonical_id":"clinicaltrials.gov:NCT03200717","description":"Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma","metadata":null},{"id":"c35881d2ab044444b4a2697a1f2611d3","type":"TRIAL","name":"Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function","canonical_id":"clinicaltrials.gov:NCT01393964","description":"Multiple Myeloma","metadata":null},{"id":"dc3e860c324048ec9f8fe956bbc951e4","type":"TRIAL","name":"Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01547299","description":"Prostate Cancer","metadata":null},{"id":"f0915a148c6a4320b7d7ada14d6eca7f","type":"TRIAL","name":"Study of Epirubicin (Pharmorubicin\u00ae), Carboplatin (Paraplatin\u00ae) and Capecitabine (Xeloda\u00ae) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates","canonical_id":"clinicaltrials.gov:NCT00130936","description":"Gastric Cancer; Esophageal Cancer; Tumors","metadata":null},{"id":"105857fd05ce449289aeb774498b9eb7","type":"TRIAL","name":"Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel\u00ae 1% in Subjects With Mild to Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02791308","description":"Atopic Dermatitis","metadata":null},{"id":"8723917a68d043f99d20a30c02d97098","type":"TRIAL","name":"Study of Eribulin in Children With Cancer to Determine Safety","canonical_id":"clinicaltrials.gov:NCT02082626","description":"Pediatric Cancer; Solid Tumors; Lymphoma","metadata":null},{"id":"b2bdbf4a7bb44df4812b01d0b8be0c42","type":"TRIAL","name":"Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment","canonical_id":"clinicaltrials.gov:NCT00840125","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"fcdb3140eefb48a7b716042822089b50","type":"TRIAL","name":"Study of Erlotinib in Combination With Dasatinib","canonical_id":"clinicaltrials.gov:NCT00895128","description":"Advanced Cancer","metadata":null},{"id":"b4fe2fafa29c410b957e92083efcd0d4","type":"TRIAL","name":"Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT03146416","description":"Healthy Volunteers","metadata":null},{"id":"e55007f5e979483e80d8eeed56946e95","type":"TRIAL","name":"Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT03175367","description":"Hypercholesterolemia","metadata":null},{"id":"4a01b9468bce4c9188ad600bd19e8805","type":"TRIAL","name":"Study of Evobrutinib in Participants With RMS (evolutionRMS 1)","canonical_id":"clinicaltrials.gov:NCT04338022","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"43ce404b18f2426ea252d1560d1e6349","type":"TRIAL","name":"Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients","canonical_id":"clinicaltrials.gov:NCT01602198","description":"Mild Cognitive Disorder; Mild Cognitive Impairment","metadata":null},{"id":"bb15a194cd79420ab2199da838413378","type":"TRIAL","name":"Study of Experimental Models of Pain and Inflammation.","canonical_id":"clinicaltrials.gov:NCT01097902","description":"Pain; Inflammation","metadata":null},{"id":"219f0610fac14e9791f0b6646e961850","type":"TRIAL","name":"Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT04757532","description":"Healthy Volunteers","metadata":null},{"id":"90b5a5f01e40440e9b27cb906db4a2e7","type":"TRIAL","name":"Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00116220","description":"Prostate Cancer","metadata":null},{"id":"aff53a149cd6440baf31943c97165063","type":"TRIAL","name":"Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092573","description":"Hypercholesterolemia; Hypertriglyceridemia","metadata":null},{"id":"9f79bcdf30964e31ab317cb2581d5742","type":"TRIAL","name":"Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01328379","description":"Multiple Sclerosis","metadata":null},{"id":"6b1be7e3a21e4c08b22c987d5ed9a648","type":"TRIAL","name":"Study of Fat Malabsorption by Lipiblock Versus Xenical","canonical_id":"clinicaltrials.gov:NCT01170806","description":"Obesity","metadata":null},{"id":"0ab68b790d5e4f75bf54ed5615c0a40a","type":"TRIAL","name":"Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure","canonical_id":"clinicaltrials.gov:NCT01472692","description":"Prehypertension; Gout; Pulse Wave Velocity; Hypertension; 24 Hour Blood Pressure","metadata":null},{"id":"cac944122c664690a48c3eca3d02ed1f","type":"TRIAL","name":"Study of Fibromyalgia Treated With Milnacipran","canonical_id":"clinicaltrials.gov:NCT01125423","description":"Fibromyalgia","metadata":null},{"id":"51bd122a86c14ccd8805ff779b5a78c6","type":"TRIAL","name":"Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)","canonical_id":"clinicaltrials.gov:NCT03898180","description":"Urothelial Carcinoma","metadata":null},{"id":"9501c8b734a54a569c476382853748fe","type":"TRIAL","name":"Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01126112","description":"Colorectal Cancer","metadata":null},{"id":"0805dad31e6f412cab232ebee6106de4","type":"TRIAL","name":"Study of Fluoxetine in Patients With Depersonalization Disorder","canonical_id":"clinicaltrials.gov:NCT00004446","description":"Depersonalization Disorder","metadata":null},{"id":"afb6039914e84e1e92a0315e2222f128","type":"TRIAL","name":"Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00821301","description":"Multiple Myeloma","metadata":null},{"id":"0f3e9f3002bc43b0bba63e2a4eae1411","type":"TRIAL","name":"Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)","canonical_id":"clinicaltrials.gov:NCT01724879","description":"Philadelphia Positive Acute Lymphoblastic Leukemia","metadata":null},{"id":"39385f4e04694624ab33ee425cdce1c8","type":"TRIAL","name":"Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT03684967","description":"Lung Cancer","metadata":null},{"id":"d04927c4808c4d0691925289d5d79eee","type":"TRIAL","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT06584032","description":"Advanced Endometrial Cancer","metadata":null},{"id":"f90c166a245a4f5980ae155f0d9878ca","type":"TRIAL","name":"Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06115733","description":"Colorectal Carcinoma","metadata":null},{"id":"85d5043e97f14906963941a109e1e95a","type":"TRIAL","name":"Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy","canonical_id":"clinicaltrials.gov:NCT01442090","description":"Renal Cell Carcinoma","metadata":null},{"id":"9d6e4020cd6d4e79b848bcba1aa97706","type":"TRIAL","name":"Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06167317","description":"Advanced Solid Tumors","metadata":null},{"id":"d6f673b1e5544f949e9de814f469af29","type":"TRIAL","name":"Study of GSK3511294 in Healthy Chinese Participants","canonical_id":"clinicaltrials.gov:NCT05140200","description":"Asthma","metadata":null},{"id":"6506a7d57e0a4bd182ec9a0bbcb8cd58","type":"TRIAL","name":"Study of GemOx and Vandetanib in Advanced Solid Malignancy","canonical_id":"clinicaltrials.gov:NCT00660725","description":"Advanced Incurable Solid Malignancy","metadata":null},{"id":"3b33f864323a43ccb776eae84f1cf2ee","type":"TRIAL","name":"Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01453153","description":"Stage IV Pancreatic Cancer","metadata":null},{"id":"b00b0ebd69744a43bf4a39bdc554dff1","type":"TRIAL","name":"Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT02896101","description":"Atopic Dermatitis","metadata":null},{"id":"def08409f47d467d9b39476466491cec","type":"TRIAL","name":"Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study","canonical_id":"clinicaltrials.gov:NCT02362880","description":"Alzheimer Disease","metadata":null},{"id":"419510a7196f4c1a98c8c56c5a17c663","type":"TRIAL","name":"Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus","canonical_id":"clinicaltrials.gov:NCT00004360","description":"Diabetes Insipidus, Nephrogenic","metadata":null},{"id":"ddfbaad138f2428d8517ee544d88f11b","type":"TRIAL","name":"Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance","canonical_id":"clinicaltrials.gov:NCT05470504","description":"Insulin Receptor Mutation; Partial Lipodystrophy","metadata":null},{"id":"5003ecd814874c75889ade7487d62386","type":"TRIAL","name":"Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05338502","description":"Healthy","metadata":null},{"id":"ab50172d53594dfaab1ad6b4318abdc4","type":"TRIAL","name":"Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC","canonical_id":"clinicaltrials.gov:NCT05195294","description":"Hepatocellular Carcinoma; Liver Cancer, Adult; Liver Cell Carcinoma","metadata":null},{"id":"e9c03552d50f42f29b9974b2e702bc1d","type":"TRIAL","name":"Study of Heart and Renal Protection","canonical_id":"clinicaltrials.gov:NCT00125593","description":"Kidney Disease, Chronic","metadata":null},{"id":"e2a36b28a6304f99b9fece9a608cdcd4","type":"TRIAL","name":"Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients","canonical_id":"clinicaltrials.gov:NCT02238457","description":"Heart Failure","metadata":null},{"id":"9bbbeb22f09745e5b5d315d56a20ec1c","type":"TRIAL","name":"Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate","canonical_id":"clinicaltrials.gov:NCT01950520","description":"Healthy Volunteers","metadata":null},{"id":"82c322ba7a03431495b7a4bef4f56cc8","type":"TRIAL","name":"Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)","canonical_id":"clinicaltrials.gov:NCT04937907","description":"Alport Syndrome, X-Linked","metadata":null},{"id":"952e657c643f48dba06d00145c60bdc5","type":"TRIAL","name":"Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology","canonical_id":"clinicaltrials.gov:NCT03330028","description":"Diseases of Oesophagus Stomach and Duodenum","metadata":null},{"id":"9d3bee899b2f4806b576c331c043949d","type":"TRIAL","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","canonical_id":"clinicaltrials.gov:NCT03947385","description":"Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors","metadata":null},{"id":"5d151ef4b5c54bf5b3bd66ac9c4c884d","type":"TRIAL","name":"Study of IMC-11F8 in Participants With Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00835185","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"3e69b08ecb8b4b019a6a8d2131ef43eb","type":"TRIAL","name":"Study of INCB053914 in Subjects With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT02587598","description":"Solid Tumors","metadata":null},{"id":"5a54a78d33dc4a37a3a180c8f4800dc3","type":"TRIAL","name":"Study of INCB123667 in Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05238922","description":"Solid Tumors","metadata":null},{"id":"4e119eaec12f40288e93eead645b9963","type":"TRIAL","name":"Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)","canonical_id":"clinicaltrials.gov:NCT00570765","description":"Liver Cirrhosis, Biliary","metadata":null},{"id":"e3a7c966f8f14ae69a71b74a8bf2bba6","type":"TRIAL","name":"Study of ISA247 (Voclosporin) in De Novo Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00270634","description":"Kidney Diseases","metadata":null},{"id":"2c37813ba9164656b2a9eca3a0a646d7","type":"TRIAL","name":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","canonical_id":"clinicaltrials.gov:NCT05272826","description":"Multiple Myeloma","metadata":null},{"id":"6d882f5c0d3a47f98e64148905d71d42","type":"TRIAL","name":"Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT02538614","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"5baa783384be4efd86f6ad8e69a943f6","type":"TRIAL","name":"Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02275299","description":"Rheumatoid Arthritis","metadata":null},{"id":"9b7981a9e70b4bd58e8b60792dcbc181","type":"TRIAL","name":"Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma","canonical_id":"clinicaltrials.gov:NCT01175109","description":"Chordoma","metadata":null},{"id":"e6386357192c4a6bad5676fcbafc17e6","type":"TRIAL","name":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","canonical_id":"clinicaltrials.gov:NCT04585815","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"86c562b50df84bfbbfbb9a21da02617a","type":"TRIAL","name":"Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation","canonical_id":"clinicaltrials.gov:NCT02535286","description":"Chronic Lymphocytic Leukemia; Richter Syndrome","metadata":null},{"id":"04b5a6fdce424947a33e48518bec65e5","type":"TRIAL","name":"Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)","canonical_id":"clinicaltrials.gov:NCT05795244","description":"Endometrial Neoplasms; Endometrial Cancer","metadata":null},{"id":"ab7bee72f6094e999d91e6a4549d6af3","type":"TRIAL","name":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04165772","description":"Rectal Adenocarcinoma; Clinical Stage: Stage II (T3-4, N-); Stage III (Any T, N+); Solid Tumor; Solid Tumor, Adult","metadata":null},{"id":"167bdd45c245456b9674690092c5b557","type":"TRIAL","name":"Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients","canonical_id":"clinicaltrials.gov:NCT02654041","description":"Glioblastoma Multiforme (GBM)","metadata":null},{"id":"90b9289ecd8143ce8eb8f0fb0ded7cd9","type":"TRIAL","name":"Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT05549258","description":"Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"8042fea84daf48928ba9a128c09d3a90","type":"TRIAL","name":"Study of Infigratinib in Children With Achondroplasia","canonical_id":"clinicaltrials.gov:NCT04265651","description":"Achondroplasia","metadata":null},{"id":"92550dbecd344693954d3e3c183317f2","type":"TRIAL","name":"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04504331","description":"Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer","metadata":null},{"id":"73ee2ce38d5042c2bb3e3c7c938b35f3","type":"TRIAL","name":"Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery","canonical_id":"clinicaltrials.gov:NCT01310751","description":"Pulmonary Hypertension","metadata":null},{"id":"3d929e027ffb45f3a70778209bfb1fec","type":"TRIAL","name":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT02969837","description":"Multiple Myeloma","metadata":null},{"id":"a899fdcb2aec4bca8c8e55a74ed4bd78","type":"TRIAL","name":"Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04892017","description":"Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor","metadata":null},{"id":"39f68a35b3d04c9e86c5f87f232d72fc","type":"TRIAL","name":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","canonical_id":"clinicaltrials.gov:NCT06039592","description":"Congenital Mitral Insufficiency","metadata":null},{"id":"11bb10c65ff843f1a3dce081f5e5ba65","type":"TRIAL","name":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","canonical_id":"clinicaltrials.gov:NCT06037434","description":"Congenital Mitral Insufficiency","metadata":null},{"id":"f59db01c27644c5a9c2c03f546451abc","type":"TRIAL","name":"Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.","canonical_id":"clinicaltrials.gov:NCT04774926","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"e2a5018f0a20444ca2740d72a7ebc560","type":"TRIAL","name":"Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma","canonical_id":"clinicaltrials.gov:NCT01535989","description":"B-cell Lymphoma Refractory","metadata":null},{"id":"432a8eb4559e43298082e59d07d900a5","type":"TRIAL","name":"Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL","canonical_id":"clinicaltrials.gov:NCT06863259","description":"B-cell Acute Lymphoblastic Leukemia","metadata":null},{"id":"cbf7b7cc362b419ba7fb3b173da50485","type":"TRIAL","name":"Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po","canonical_id":"clinicaltrials.gov:NCT00206050","description":"Healthy","metadata":null},{"id":"e0dbfb09bf884d358363138614e831d0","type":"TRIAL","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06585410","description":"Cutaneous Squamous Cell Carcinoma (CSCC)","metadata":null},{"id":"c023a40774424fba8e75dbbd2f3a1b2d","type":"TRIAL","name":"Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures","canonical_id":"clinicaltrials.gov:NCT00594945","description":"Epilepsy","metadata":null},{"id":"68b777cdf0b54a70a1e73253385a1758","type":"TRIAL","name":"Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)","canonical_id":"clinicaltrials.gov:NCT00401375","description":"Post-Operative Ileus (POI)","metadata":null},{"id":"f17cc6634b5c4b7e8a961225a7c8ab45","type":"TRIAL","name":"Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00921661","description":"Colorectal Neoplasms; Neoplasm Metastasis","metadata":null},{"id":"db849299d1204332a976400e473264eb","type":"TRIAL","name":"Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients","canonical_id":"clinicaltrials.gov:NCT05546359","description":"Nausea and Vomiting, Postoperative","metadata":null},{"id":"d8b64b439ed84c068ea9a19a0bf4739e","type":"TRIAL","name":"Study of Intravenous Erenumab in Patients With Status Migrainosus","canonical_id":"clinicaltrials.gov:NCT04920331","description":"Status Migrainosus","metadata":null},{"id":"e81d91435c84448db590987ff54f7b78","type":"TRIAL","name":"Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00494533","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"d81827e5f7134a22b11cc0f6fbb3aaf9","type":"TRIAL","name":"Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein","canonical_id":"clinicaltrials.gov:NCT06093503","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"69d8fcbba49e459db06e0e0d1113c708","type":"TRIAL","name":"Study of Intravitreal Aflibercept Injection (IAI; EYLEA\u00ae; BAY86-5321) in Patients With Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT01363440","description":"Diabetic Macular Edema","metadata":null},{"id":"fd36b1a1b5e949379ed308387fe0083c","type":"TRIAL","name":"Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology","canonical_id":"clinicaltrials.gov:NCT00950755","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"6722b93cf9e64786931fa46ac23cfd2e","type":"TRIAL","name":"Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab","canonical_id":"clinicaltrials.gov:NCT00996593","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"02316ee675ee4306a631b8c35bdbab7e","type":"TRIAL","name":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT07131345","description":"Malignant Mesothelioma; Mesothelioma","metadata":null},{"id":"05efd52eafb64f42b91b32c75716aaf0","type":"TRIAL","name":"Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy","canonical_id":"clinicaltrials.gov:NCT02847091","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"177427a012464b348eed315b7620ae59","type":"TRIAL","name":"Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00130702","description":"Myelogenous Leukemia, Acute","metadata":null},{"id":"8428a8737a124941974207af0449a61b","type":"TRIAL","name":"Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01018966","description":"Solid Tumors","metadata":null},{"id":"514d5c0dceaf4442951e614ae9b4b0b1","type":"TRIAL","name":"Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT03547700","description":"Lymphoma, T-Cell, Peripheral","metadata":null},{"id":"b62386846b9b440782589a83e6a50fc0","type":"TRIAL","name":"Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies","canonical_id":"clinicaltrials.gov:NCT03082677","description":"Myeloid Hematologic Malignancy; Lymphoid Hematologic Malignancy","metadata":null},{"id":"59ac4bab28e54adebe4f91775e934ddf","type":"TRIAL","name":"Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03073200","description":"Plaque Psoriasis","metadata":null},{"id":"9891f19212e54a1d9f2785b37ace0c31","type":"TRIAL","name":"Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)","canonical_id":"clinicaltrials.gov:NCT05519449","description":"Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer","metadata":null},{"id":"f8a7a99001564432b3de09517fe9757e","type":"TRIAL","name":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05132075","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"1c0ccfd6a5f04cd28c7216ad08202881","type":"TRIAL","name":"Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia","canonical_id":"clinicaltrials.gov:NCT03822507","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"8af8af7d69334c71a6a7605b97a47f45","type":"TRIAL","name":"Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)","canonical_id":"clinicaltrials.gov:NCT02163577","description":"X-linked Hypophosphatemia","metadata":null},{"id":"fdf494814068423f92f93e8ad27c141c","type":"TRIAL","name":"Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)","canonical_id":"clinicaltrials.gov:NCT02526160","description":"X-linked Hypophosphatemia","metadata":null},{"id":"c6c0df127afa48daa258cc69c809193e","type":"TRIAL","name":"Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)","canonical_id":"clinicaltrials.gov:NCT01611142","description":"Peripheral T-Cell Lymphoma","metadata":null},{"id":"0d9552c12ee14d7393833fc1f3ad125c","type":"TRIAL","name":"Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL","canonical_id":"clinicaltrials.gov:NCT01728805","description":"Cutaneous T-Cell Lymphoma","metadata":null},{"id":"20ed29afcfab455ca75c5433ce9ae3b6","type":"TRIAL","name":"Study of Kuvan Treatment in Adults With GTPCH Deficiency","canonical_id":"clinicaltrials.gov:NCT01425528","description":"GTP Cyclohydrolase Deficiency","metadata":null},{"id":"450ae9635f3c4ba99175332aacc23c72","type":"TRIAL","name":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT07207954","description":"Rheumatoid Arthritis","metadata":null},{"id":"b45e43df10e64f54ba1dbd85722133b4","type":"TRIAL","name":"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT01719380","description":"Colorectal Cancer","metadata":null},{"id":"58fedd0da0da4bb8be38b2b16858b50a","type":"TRIAL","name":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","canonical_id":"clinicaltrials.gov:NCT04666038","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"1bee4dc63ba84ac2a27feadbc37a8e9a","type":"TRIAL","name":"Study of LP-184 in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05933265","description":"Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancreatic Adenocarcinoma; DDR Gene Mutation","metadata":null},{"id":"23f4518f51564647a63ff5169f73c79b","type":"TRIAL","name":"Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).","canonical_id":"clinicaltrials.gov:NCT05906732","description":"Long QT Syndrome","metadata":null},{"id":"7120521a64a64d74b0315b222b7d425f","type":"TRIAL","name":"Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects","canonical_id":"clinicaltrials.gov:NCT03401671","description":"Healthy Volunteers","metadata":null},{"id":"f41a7d1c8f654f54941d5efdb1b62cac","type":"TRIAL","name":"Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET","canonical_id":"clinicaltrials.gov:NCT03083210","description":"Neuroendocrine Tumors","metadata":null},{"id":"3c96e9df00d7407bb770550bef051322","type":"TRIAL","name":"Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres","canonical_id":"clinicaltrials.gov:NCT02859064","description":"Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors","metadata":null},{"id":"462b633aac724813b8517f09855eb7c0","type":"TRIAL","name":"Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","canonical_id":"clinicaltrials.gov:NCT03001557","description":"Irregular Sleep-Wake Rhythm Disorder","metadata":null},{"id":"31595325cf904293b8b8fd82bf4a794c","type":"TRIAL","name":"Study of Lemborexant-Alcohol Interaction in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03483636","description":"Healthy Subjects","metadata":null},{"id":"c3e487c5e06f46d1bdbbd55815487e75","type":"TRIAL","name":"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT01923168","description":"Breast Cancer","metadata":null},{"id":"e82ad6b5c0074576aec352293879d0f6","type":"TRIAL","name":"Study of Long-term Peg Intron vs. Colchicine in Non-responders.","canonical_id":"clinicaltrials.gov:NCT00179413","description":"Hepatitis C Virus; Advanced Fibrosis; Cirrhosis","metadata":null},{"id":"382d65c3aec3408a9230b1b1f00fb241","type":"TRIAL","name":"Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma","canonical_id":"clinicaltrials.gov:NCT02392039","description":"Lymphoma","metadata":null},{"id":"6388e3e921714b2cbc03a8463c3843d2","type":"TRIAL","name":"Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04362072","description":"Carcinoma; Non-Small-Cell Lung","metadata":null},{"id":"2ba166853cfe47d99050adaac7d47f8d","type":"TRIAL","name":"Study of Lorlatinib in ROS1 Rearranged NSCLC","canonical_id":"clinicaltrials.gov:NCT03612154","description":"Nonsmall Cell Lung Cancer","metadata":null},{"id":"494aeb7a050c4fe5b8dd9346f610bc06","type":"TRIAL","name":"Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction","canonical_id":"clinicaltrials.gov:NCT00818701","description":"Congestive Heart Failure; Renal Dysfunction","metadata":null},{"id":"c77b5afbc2f54e979147d347b0c00fdd","type":"TRIAL","name":"Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","canonical_id":"clinicaltrials.gov:NCT01953328","description":"Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events","metadata":null},{"id":"dacc674f2d194c7e96c18a85527cda3d","type":"TRIAL","name":"Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy","canonical_id":"clinicaltrials.gov:NCT07781293","description":"Major Depressive Disorder (MDD); Major Depressive Disorder With Psychotic Features","metadata":null},{"id":"bf7fc89aa87d4fb7a4428777634dc07e","type":"TRIAL","name":"Study of Lyme Neuroborreliosis","canonical_id":"clinicaltrials.gov:NCT01635530","description":"Lyme Neuroborreliosis","metadata":null},{"id":"cd41ba0fd64e48bf8adb6a20df60ad33","type":"TRIAL","name":"Study of M4344 in Combination With Niraparib","canonical_id":"clinicaltrials.gov:NCT04655183","description":"Advanced Solid Tumor; Breast Cancer","metadata":null},{"id":"cdaa5d1d994349eaaf7bf6ebb944b0b1","type":"TRIAL","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT02516241","description":"Urothelial Cancer","metadata":null},{"id":"0f613d73fc384ec3b11c4b52d039e5d2","type":"TRIAL","name":"Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)","canonical_id":"clinicaltrials.gov:NCT00442338","description":"Asthma","metadata":null},{"id":"7dba5b1406b448ca9a536120aff8db97","type":"TRIAL","name":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","canonical_id":"clinicaltrials.gov:NCT01437111","description":"Osteoporosis","metadata":null},{"id":"683a3bcd184e44399cedd42fe467d6d1","type":"TRIAL","name":"Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)","canonical_id":"clinicaltrials.gov:NCT03364049","description":"Solid Neoplasms","metadata":null},{"id":"cb0fbee93f34460ba908ee7452a6743c","type":"TRIAL","name":"Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)","canonical_id":"clinicaltrials.gov:NCT03745989","description":"Solid Tumors","metadata":null},{"id":"9c7871a013e0495a8fa8efe735cae733","type":"TRIAL","name":"Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00092196","description":"Nausea; Vomiting; Breast Neoplasms","metadata":null},{"id":"497f5cca1e21459aa9e37cf16ae85cd5","type":"TRIAL","name":"Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT07122401","description":"Secondary Hyperparathyroidism, Chronic Kidney Disease","metadata":null},{"id":"f3e55cab96254ee793ae7301270131bd","type":"TRIAL","name":"Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00660179","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"f092e7f806fd42e990c552c24f4da61b","type":"TRIAL","name":"Study of Meloxicam Capsules to Treat Osteoarthritis Pain","canonical_id":"clinicaltrials.gov:NCT01787188","description":"Osteoarthritis","metadata":null},{"id":"eb3b8647c87b46ea9e9a641a92da14c6","type":"TRIAL","name":"Study of Metastatic Ocular Melanoma","canonical_id":"clinicaltrials.gov:NCT00168870","description":"Ocular Melanoma","metadata":null},{"id":"00d765abea9d410784828837b970708e","type":"TRIAL","name":"Study of Methylnaltrexone (MNTX) for the Relief of Constipation","canonical_id":"clinicaltrials.gov:NCT00402038","description":"Advance Illness Patients With OIC","metadata":null},{"id":"a6157b8905224c9ea632f3d0ff988088","type":"TRIAL","name":"Study of Methylnaltrexone in Opioid-Induced Constipation Patients","canonical_id":"clinicaltrials.gov:NCT02574819","description":"Opioid-induced Constipation","metadata":null},{"id":"9e83867f6ffd4f6888a660dfaee843e8","type":"TRIAL","name":"Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)","canonical_id":"clinicaltrials.gov:NCT00914095","description":"Parkinson's Disease; Gait Disorders, Neurologic; Dementia","metadata":null},{"id":"f0924871b1274145bae3f97ed7ec49d6","type":"TRIAL","name":"Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI","canonical_id":"clinicaltrials.gov:NCT06376630","description":"Myocardial Infarction; Coronary Stenosis; Coronary Microvascular Dysfunction","metadata":null},{"id":"8993f463c3bc4a9291518a95f5eee5bc","type":"TRIAL","name":"Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00797797","description":"Fibromyalgia","metadata":null},{"id":"1f7eae26023b4f8f9a4381a0adc7d33e","type":"TRIAL","name":"Study of Milnacipran for the Treatment of Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00314249","description":"Fibromyalgia","metadata":null},{"id":"66df5f08f7ad4e90a4aa0f6f0548a561","type":"TRIAL","name":"Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01077375","description":"Fibromyalgia","metadata":null},{"id":"3fe9a1f644a3430e9af21e015bb58892","type":"TRIAL","name":"Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years","canonical_id":"clinicaltrials.gov:NCT01195714","description":"Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma","metadata":null},{"id":"8fa02d4b64104b9fadd6d4f8cdb7cf8a","type":"TRIAL","name":"Study of Mirtazapine for Agitation in Dementia","canonical_id":"clinicaltrials.gov:NCT03031184","description":"Dementia","metadata":null},{"id":"22a18b88bc1243e9ac3436fd6a81d89c","type":"TRIAL","name":"Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02358473","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"b9d7e7929b5e42279fa9e26639f2f96c","type":"TRIAL","name":"Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02301130","description":"Advanced Solid Tumors","metadata":null},{"id":"1195928a2c0848378ec7c33efb28d90f","type":"TRIAL","name":"Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02705105","description":"Solid Tumor; Cancer; Carcinoma; Hepatocellular Carcinoma; HCC","metadata":null},{"id":"cf0f6debe9d84b929b9001995f56dc57","type":"TRIAL","name":"Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05996185","description":"T Cell Lymphoma; T-cell Lymphoma","metadata":null},{"id":"69d7ffe413c94c79bc41c34af06fa47b","type":"TRIAL","name":"Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis","canonical_id":"clinicaltrials.gov:NCT06517875","description":"Primary Myelofibrosis; Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","metadata":null},{"id":"384407cdd1174e6292b309438df6aba2","type":"TRIAL","name":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","canonical_id":"clinicaltrials.gov:NCT00379288","description":"Asthma","metadata":null},{"id":"50902cb9135c4e0c8a8d3edc9d22de3e","type":"TRIAL","name":"Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera","canonical_id":"clinicaltrials.gov:NCT02410278","description":"Multiple Sclerosis","metadata":null},{"id":"8bf569bab1bd43caa3be1545fda2159c","type":"TRIAL","name":"Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)","canonical_id":"clinicaltrials.gov:NCT01891981","description":"Leukemia","metadata":null},{"id":"95337c9754874174951cf054fcc82a45","type":"TRIAL","name":"Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","canonical_id":"clinicaltrials.gov:NCT04590586","description":"COVID-19","metadata":null},{"id":"14b01f87eb4a49f582b6eba2537acb9e","type":"TRIAL","name":"Study of Multiple Doses of Saxagliptin (BMS-477118)","canonical_id":"clinicaltrials.gov:NCT00950599","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"8841e0c48844476d99d08fb1f08d3ab5","type":"TRIAL","name":"Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies","canonical_id":"clinicaltrials.gov:NCT07511972","description":"CRC","metadata":null},{"id":"135debb965494c3bb8878b2aaf75f29d","type":"TRIAL","name":"Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)","canonical_id":"clinicaltrials.gov:NCT00916942","description":"Postherpetic Neuralgia","metadata":null},{"id":"a503d511e2c940889a9799191a8fa5e7","type":"TRIAL","name":"Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy","canonical_id":"clinicaltrials.gov:NCT00085761","description":"HIV Infections; Peripheral Nervous System Diseases; Pain","metadata":null},{"id":"549ff07326744d478aaadb49c48b6ace","type":"TRIAL","name":"Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures","canonical_id":"clinicaltrials.gov:NCT00309361","description":"Anesthesia, Dental","metadata":null},{"id":"e1bf8233d60b43928b3e56488766823b","type":"TRIAL","name":"Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures","canonical_id":"clinicaltrials.gov:NCT00309335","description":"Anesthesia, Dental","metadata":null},{"id":"69c29dc6272e4ccaaf9f30340079661f","type":"TRIAL","name":"Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures","canonical_id":"clinicaltrials.gov:NCT00309322","description":"Anesthesia, Dental","metadata":null},{"id":"1891dc84564c43359f6cc36b9d5c8a18","type":"TRIAL","name":"Study of NXP900 With Lorlatinib in ALK+ Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07784959","description":"ALK Positive; ALK Positive Non-small Cell Lung Cancer; NSCLC; ALK+ Non-Small-Cell Lung Carcinoma","metadata":null},{"id":"e16e55e5a25b460d8fe312d0530d9cd2","type":"TRIAL","name":"Study of Nalbuphine ER in Participants With Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT04020016","description":"Hepatic Impairment","metadata":null},{"id":"1b3c134dc0aa43dc872a44610043030a","type":"TRIAL","name":"Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis","canonical_id":"clinicaltrials.gov:NCT02174419","description":"Prurigo Nodularis; Nodularis Prurigo; Prurigo; Pruritus","metadata":null},{"id":"c2e646ba717a48dc945ed192b88ab4a1","type":"TRIAL","name":"Study of Nasonex\u00ae for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)","canonical_id":"clinicaltrials.gov:NCT00378378","description":"Nasal Polyps","metadata":null},{"id":"b31197d60f164ee49dc6e7dadb5c2f72","type":"TRIAL","name":"Study of Natalizumab in Relapsed/Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00675428","description":"Multiple Myeloma","metadata":null},{"id":"1f71446ae13f4620a06e1d4971a76f14","type":"TRIAL","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","canonical_id":"clinicaltrials.gov:NCT07011654","description":"Metastatic Triple-Negative Breast Cancer","metadata":null},{"id":"6ea860e3d111480db7635bdfc9b5cad1","type":"TRIAL","name":"Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT06356155","description":"Urothelial Carcinoma","metadata":null},{"id":"2281aca041ad4a16a5c7210179ef4671","type":"TRIAL","name":"Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status","canonical_id":"clinicaltrials.gov:NCT03457896","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"5456990d29954b78b3ba4f7d127749cb","type":"TRIAL","name":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03642067","description":"Microsatellite Stable (MSS) Colorectal Adenocarcinomas; Colorectal Adenocarcinoma","metadata":null},{"id":"2935ffe2c7ab4ed685dcabcba7c20371","type":"TRIAL","name":"Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy","canonical_id":"clinicaltrials.gov:NCT04085250","description":"Stage III Non-small-cell Lung Cancer","metadata":null},{"id":"37ceb502ee984df898cd2b65102407d6","type":"TRIAL","name":"Study of Non Inferiority Bi-Profenid\u00ae 200mg Versus Bi-Profenid\u00ae 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)","canonical_id":"clinicaltrials.gov:NCT00810121","description":"Pain","metadata":null},{"id":"b8f9925009bd4af69f155bc977837d9c","type":"TRIAL","name":"Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT05430230","description":"Osteoarthritis, Knee","metadata":null},{"id":"67a3fa7e7c7e4d85b12e721099b37531","type":"TRIAL","name":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC","canonical_id":"clinicaltrials.gov:NCT05239468","description":"Primary Biliary Cholangitis","metadata":null},{"id":"db2c565579c748e7b363f80f3b2f8d8e","type":"TRIAL","name":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","canonical_id":"clinicaltrials.gov:NCT04594694","description":"Primary Biliary Cholangitis","metadata":null},{"id":"4e49c907981f4b2983026c13a0518ccb","type":"TRIAL","name":"Study of ONO-1078 in Patients With Chronic Sinusitis","canonical_id":"clinicaltrials.gov:NCT00410735","description":"Chronic Sinusitis","metadata":null},{"id":"4d348d57d242410d9f1c395d3d8264c7","type":"TRIAL","name":"Study of ORIC-101 in Combination With Enzalutamide","canonical_id":"clinicaltrials.gov:NCT04033328","description":"Prostatic Neoplasms","metadata":null},{"id":"76f75d0462e0496d89320891239d50a6","type":"TRIAL","name":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT05413421","description":"Metastatic Prostate Cancer","metadata":null},{"id":"8ca5d4685ae34e2e9070e8582e635615","type":"TRIAL","name":"Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT03633227","description":"Liver Cirrhosis, Biliary","metadata":null},{"id":"df7c2e13c8a244bd89b6c5ff9704f58c","type":"TRIAL","name":"Study of Obeticholic Acid\uff08OCA\uff09 Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)","canonical_id":"clinicaltrials.gov:NCT04956328","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"c21889115f9c4daebabdfe6be9b0d19a","type":"TRIAL","name":"Study of Olaparib (Lynparza\u2122) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","canonical_id":"clinicaltrials.gov:NCT02987543","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"7b46f9d61fbc4ae4a3f43468dfbda626","type":"TRIAL","name":"Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT00914524","description":"Chronic Glomerulonephritis; Diabetic Nephropathy","metadata":null},{"id":"86ad312a563345f7b1b924e2cb5ef8f9","type":"TRIAL","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","canonical_id":"clinicaltrials.gov:NCT06423911","description":"Chronic Myeloid Leukemia; CML; CML, Chronic Phase","metadata":null},{"id":"89838cbd4aa347bb8cab2c5cc9c0452c","type":"TRIAL","name":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","canonical_id":"clinicaltrials.gov:NCT04901702","description":"Recurrent Solid Tumor; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Wilms Tumor; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Ne\u2026","metadata":null},{"id":"16713b38d3c244818f9e5a1e98b6ce9c","type":"TRIAL","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","canonical_id":"clinicaltrials.gov:NCT06136624","description":"Prostate Cancer Metastatic","metadata":null},{"id":"0158dde6195a4f0180ec9dc70ad68f48","type":"TRIAL","name":"Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00306969","description":"Cutaneous T-Cell Lymphoma","metadata":null},{"id":"f76806aa704f4a798681d6018eeb37c4","type":"TRIAL","name":"Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies","canonical_id":"clinicaltrials.gov:NCT02638909","description":"Colorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Adenocarcinoma","metadata":null},{"id":"ca222d2f01d0464fb02585bd6bd8d78a","type":"TRIAL","name":"Study of Oral Fampridine-SR in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00127530","description":"Multiple Sclerosis","metadata":null},{"id":"025fb8fa66a548d3b6d4f505573964f9","type":"TRIAL","name":"Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00932698","description":"Relapsed and Refractory Multiple Myeloma","metadata":null},{"id":"49f8dec07cdd40bea9b36ffd5cb4c9ba","type":"TRIAL","name":"Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00087867","description":"Multiple Myeloma","metadata":null},{"id":"8de2565e903f4f1ca0edeff4a3404966","type":"TRIAL","name":"Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00098358","description":"Acne Vulgaris","metadata":null},{"id":"dc04f39b89fe40109ff2b6f2f7499de5","type":"TRIAL","name":"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","canonical_id":"clinicaltrials.gov:NCT02414139","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"3ff630e5549a4c1597243d337bc71d7b","type":"TRIAL","name":"Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT03909334","description":"Non Small Cell Lung Cancer; EGFR Gene Mutation; Advanced Cancer; Metastatic Cancer","metadata":null},{"id":"f3a7f82e01b341d4a87730237b20cf6d","type":"TRIAL","name":"Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome","canonical_id":"clinicaltrials.gov:NCT00317395","description":"Coronary Disease","metadata":null},{"id":"6be744cf91f64d3d849273ef89efd683","type":"TRIAL","name":"Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT00057681","description":"Bipolar Disorder","metadata":null},{"id":"4123a306458f492e943ce7a805d850e0","type":"TRIAL","name":"Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)","canonical_id":"clinicaltrials.gov:NCT02294058","description":"Multiple Sclerosis","metadata":null},{"id":"e55c618c53cb41db8643db13c16b0914","type":"TRIAL","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","canonical_id":"clinicaltrials.gov:NCT06760637","description":"Breast Cancer","metadata":null},{"id":"0289573e2c9142d5b3de7684731fb7b9","type":"TRIAL","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04606446","description":"Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer","metadata":null},{"id":"d20cbeabf6d84dbb92b4135363fe0a00","type":"TRIAL","name":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03711058","description":"Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor; Microsatellite Stable (MSS) Colon Cancer","metadata":null},{"id":"d30e9d65026f4385abf334e559633341","type":"TRIAL","name":"Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world","canonical_id":"clinicaltrials.gov:NCT05022342","description":"Breast Cancer","metadata":null},{"id":"ec130ed80df944b69496abe8882ebcab","type":"TRIAL","name":"Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04969497","description":"Migraine","metadata":null},{"id":"b609a4cf4c954040a0f178278f5fc0b6","type":"TRIAL","name":"Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00693004","description":"Alzheimer's Disease","metadata":null},{"id":"cfa7cedcc7e74161bce892f08a721991","type":"TRIAL","name":"Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)","canonical_id":"clinicaltrials.gov:NCT02920450","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"142b799cc29b4ec8a01dc134e2312d6c","type":"TRIAL","name":"Study of Palbociclib in MLL-rearranged Acute Leukemias","canonical_id":"clinicaltrials.gov:NCT02310243","description":"Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia","metadata":null},{"id":"cabb0be65fc342fa99e78b04e1ac37f8","type":"TRIAL","name":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT02356159","description":"Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma","metadata":null},{"id":"c9245e74001143c6bf68de0da91f9f5d","type":"TRIAL","name":"Study of Panitumumab in the Treatment of Carcinoid Syndrome","canonical_id":"clinicaltrials.gov:NCT01172717","description":"Carcinoid Syndrome","metadata":null},{"id":"d802e443488a4b74b0f88ce813389f10","type":"TRIAL","name":"Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease","canonical_id":"clinicaltrials.gov:NCT00446082","description":"Carcinoid Tumor; Acromegaly","metadata":null},{"id":"ca9acd32cde64553bcb24277be3d2594","type":"TRIAL","name":"Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)","canonical_id":"clinicaltrials.gov:NCT01253161","description":"Neuroendocrine Tumors; Carcinoid Tumors","metadata":null},{"id":"596ac5a5200b421680b4e37a1e69cd8c","type":"TRIAL","name":"Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.","canonical_id":"clinicaltrials.gov:NCT04033991","description":"Carcinoma; Renal Cell","metadata":null},{"id":"509105329d7e49049bd48b50df80e726","type":"TRIAL","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","canonical_id":"clinicaltrials.gov:NCT06686394","description":"Breast Neoplasms; Breast Cancer","metadata":null},{"id":"f0a208956f1443c49d3dc1cc9ebf0c95","type":"TRIAL","name":"Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor","canonical_id":"clinicaltrials.gov:NCT01099540","description":"Neuroendocrine Tumor","metadata":null},{"id":"874db9c6e85a46b280b95b391ec1f659","type":"TRIAL","name":"Study of Pazopanib and Ixabepilone in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01012362","description":"Breast Cancer; Lung Cancer; Colon Cancer; Pancreatic Cancer; Head and Neck Cancer; Kidney Cancer; Sarcoma; Hepatocellular Cancer","metadata":null},{"id":"36334475aaf44a83905854fa84eb5a7d","type":"TRIAL","name":"Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00866528","description":"Lung Cancer, Non-Small Cell","metadata":null},{"id":"487c5d786408419691e7e31abd8763e4","type":"TRIAL","name":"Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma","canonical_id":"clinicaltrials.gov:NCT01506596","description":"Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma","metadata":null},{"id":"2c788a0c08664964a6a58e1e68848add","type":"TRIAL","name":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","canonical_id":"clinicaltrials.gov:NCT03834493","description":"Prostatic Neoplasms","metadata":null},{"id":"dae6d8f1497f4d98a283f7c6f1eea106","type":"TRIAL","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","canonical_id":"clinicaltrials.gov:NCT04210115","description":"Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adenocarcinoma (EAC)","metadata":null},{"id":"3690df6144ae475f80172bc55cd87d1e","type":"TRIAL","name":"Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL","canonical_id":"clinicaltrials.gov:NCT03240211","description":"PTCL; CTCL","metadata":null},{"id":"09543325602d41e0aa5ed4736e75256a","type":"TRIAL","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","canonical_id":"clinicaltrials.gov:NCT04380636","description":"Lung Neoplasms; Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"2bd1f1b4f09647978d83434296290d9d","type":"TRIAL","name":"Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)","canonical_id":"clinicaltrials.gov:NCT02853305","description":"Urothelial Carcinoma Associated 1 RNA, Human","metadata":null},{"id":"81d1d3be68ee47c5bb5dbf40e77bd649","type":"TRIAL","name":"Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)","canonical_id":"clinicaltrials.gov:NCT06266338","description":"Cervix Cancer; Cervical Cancer","metadata":null},{"id":"4374016aa6a345d1a52c0f610e1e7574","type":"TRIAL","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT04786964","description":"Metastatic Non-squamous Non Small Cell Lung Cancer","metadata":null},{"id":"11f7f9132ae84a88b5209d1fe0a4a262","type":"TRIAL","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","canonical_id":"clinicaltrials.gov:NCT05855200","description":"Colonic Neoplasms; Neoplasms, Colon","metadata":null},{"id":"a2617379bafd40478eb7475ce02d6bf5","type":"TRIAL","name":"Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)","canonical_id":"clinicaltrials.gov:NCT07629700","description":"Urothelial Carcinoma (UC); Peripheral Nerve Disease","metadata":null},{"id":"ed9e71197fb24bdaa136adcec289ad17","type":"TRIAL","name":"Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02734433","description":"Advanced Solid Tumors","metadata":null},{"id":"c99b9035ae3e4256869729e0b6752105","type":"TRIAL","name":"Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04223635","description":"Moderate Hepatic Impairment","metadata":null},{"id":"f8ae116a933e4b498b48da46b0b41d1f","type":"TRIAL","name":"Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease","canonical_id":"clinicaltrials.gov:NCT03491215","description":"Acute Graft Versus Host Disease","metadata":null},{"id":"223285e8875c4d24b74ddfc52ece45d5","type":"TRIAL","name":"Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide","canonical_id":"clinicaltrials.gov:NCT01366365","description":"Healthy Adults","metadata":null},{"id":"083529046bca4116a1ee27c3e15174d2","type":"TRIAL","name":"Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006","canonical_id":"clinicaltrials.gov:NCT00332189","description":"Phenylketonuria","metadata":null},{"id":"9481748bd8984211a76a79c47bac16f2","type":"TRIAL","name":"Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet","canonical_id":"clinicaltrials.gov:NCT00272792","description":"Phenylketonurias","metadata":null},{"id":"128134429e0244e3be4232a25a9cee09","type":"TRIAL","name":"Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.","canonical_id":"clinicaltrials.gov:NCT01292551","description":"Hypoplastic Left Heart Syndrome; Tricuspid Atresia; Other Specified Congenital Anomalies of Heart","metadata":null},{"id":"ed34b9a34144401d967bc0263b1c3771","type":"TRIAL","name":"Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas","canonical_id":"clinicaltrials.gov:NCT01140568","description":"Glioma","metadata":null},{"id":"5d9445b98cc94cc984ad20c5288e63ae","type":"TRIAL","name":"Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04005716","description":"Small Cell Lung Cancer","metadata":null},{"id":"14ed5a66d5594c3894aa26e6af0087a0","type":"TRIAL","name":"Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00990054","description":"Acute Myeloid Leukemia","metadata":null},{"id":"5885ed042aba411eb7a18b65972c4099","type":"TRIAL","name":"Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT00901225","description":"Multiple Myeloma; Non-Hodgkins Lymphoma; Hodgkins Disease","metadata":null},{"id":"f5a2b520bc734ec0bb39bd8a0ea12d1a","type":"TRIAL","name":"Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody \uff08PPR\uff09 in Third or Later Line Therapy of DLBCL","canonical_id":"clinicaltrials.gov:NCT06832228","description":"Diffuse Large B-cell Lymphoma (DLBCL)","metadata":null},{"id":"b77cd6c8ba164922a4296a08c5c513ab","type":"TRIAL","name":"Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma","canonical_id":"clinicaltrials.gov:NCT01979276","description":"Multiple Myeloma","metadata":null},{"id":"5db74bc64b154b96aaf7575009823513","type":"TRIAL","name":"Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide","canonical_id":"clinicaltrials.gov:NCT04989140","description":"Multiple Myeloma","metadata":null},{"id":"c7916e3a50fc472ca464c0fe59d4dd65","type":"TRIAL","name":"Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients","canonical_id":"clinicaltrials.gov:NCT03690115","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"7e87459e0d584dbfaf0afe3e164e6640","type":"TRIAL","name":"Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers","canonical_id":"clinicaltrials.gov:NCT01935336","description":"Adenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer","metadata":null},{"id":"a984b17c37e9497fbbc1909af8726ad3","type":"TRIAL","name":"Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)","canonical_id":"clinicaltrials.gov:NCT02662985","description":"Psoriatic Arthritis","metadata":null},{"id":"3e3963d38f5541b99475e943f3e2fa77","type":"TRIAL","name":"Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies","canonical_id":"clinicaltrials.gov:NCT00481871","description":"Relapsed or Refractory Lymphoproliferative Malignancies; Hodgkin's Lymphoma; Peripheral T-cell Lymphoma; B-cell Lymphoma; Waldenstrom's Macroglobulinemia","metadata":null},{"id":"fb7b734304a0412a9c924d310722f8b1","type":"TRIAL","name":"Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)","canonical_id":"clinicaltrials.gov:NCT01183065","description":"Head and Neck Cancer","metadata":null},{"id":"ebeafebf3f5944fba4448e59f984bdc2","type":"TRIAL","name":"Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00364923","description":"Peripheral T-cell Lymphoma","metadata":null},{"id":"4e93753ec6654db88e0e900dd109b42c","type":"TRIAL","name":"Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01118624","description":"Breast Cancer; Breast Tumors; Neoplasms, Breast; Cancer of the Breast; Human Mammary Carcinoma","metadata":null},{"id":"e3879a076f1b482580b8d4a3e441b6f9","type":"TRIAL","name":"Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00554827","description":"Cutaneous T-cell Lymphoma","metadata":null},{"id":"918dd9e7f31b4cc590cb8cf21c342339","type":"TRIAL","name":"Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder","canonical_id":"clinicaltrials.gov:NCT00722553","description":"Carcinoma, Transitional Cell; Bladder Cancer; Bladder Neoplasm","metadata":null},{"id":"3e118589852b4bba9a3faf20e3ff1920","type":"TRIAL","name":"Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00998946","description":"Lymphoma, B-Cell","metadata":null},{"id":"70b12965b5204e1e88b87b46995ea687","type":"TRIAL","name":"Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment","canonical_id":"clinicaltrials.gov:NCT00606502","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"4f41531436e345028cd04257fab83e31","type":"TRIAL","name":"Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients","canonical_id":"clinicaltrials.gov:NCT02946671","description":"Gastric Cancer; Esophageal Cancer; Lung Cancer; Renal Cancer; Oral Cancer","metadata":null},{"id":"8d431d27b2984bafa30b5862221ac27f","type":"TRIAL","name":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","canonical_id":"clinicaltrials.gov:NCT06692491","description":"Rare Tumour","metadata":null},{"id":"b251cc1ac4b142ecae80078cd0eeb35d","type":"TRIAL","name":"Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy","canonical_id":"clinicaltrials.gov:NCT05198245","description":"Migraine","metadata":null},{"id":"2895fbc5abf9418498cb422c02afe474","type":"TRIAL","name":"Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection","canonical_id":"clinicaltrials.gov:NCT01025180","description":"Severe Sepsis","metadata":null},{"id":"8f82341143ef4a3c9019f159a9f52000","type":"TRIAL","name":"Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02294786","description":"Cancer","metadata":null},{"id":"18dff5e4470840b0be17bc79ee3e7020","type":"TRIAL","name":"Study of Quetiapine Treatment for Cannabis Dependence","canonical_id":"clinicaltrials.gov:NCT00954681","description":"Cannabis Dependence","metadata":null},{"id":"0d7fc886d4814127bb5a7b9f276e9003","type":"TRIAL","name":"Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT03723681","description":"Acute Myeloid Leukemia (AML)","metadata":null},{"id":"7697fe0a0229444fad31fb79a7bc357e","type":"TRIAL","name":"Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT02834390","description":"Acute Myeloid Leukemia","metadata":null},{"id":"6d3ed9c1c09f4622b4e6cd21daa190dc","type":"TRIAL","name":"Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT02383212","description":"Advanced Cancer; Advanced Malignancies","metadata":null},{"id":"9bfcf3cfb16347bd96d5fe27463e9536","type":"TRIAL","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","canonical_id":"clinicaltrials.gov:NCT03564340","description":"Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial Cancer; Endometrial Cancer; Low-grade Serous Ovarian Cancer","metadata":null},{"id":"7c17cf7688a84871bcafd8794f09ccad","type":"TRIAL","name":"Study of RP-3500, Camonsertib, in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04497116","description":"Advanced Solid Tumor","metadata":null},{"id":"1321f0314ae34e14ba612cbefed3ad5c","type":"TRIAL","name":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","canonical_id":"clinicaltrials.gov:NCT05477576","description":"GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET","metadata":null},{"id":"696939ce36df49f1add315167fa76438","type":"TRIAL","name":"Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone\u00ae 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT01536561","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"a3da17f491484bc784a32c87300cee24","type":"TRIAL","name":"Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00288561","description":"Age-Related Macular Degeneration (ARMD)","metadata":null},{"id":"da8b24bbc06f46f189dc648d1f79fd2b","type":"TRIAL","name":"Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis","canonical_id":"clinicaltrials.gov:NCT01879241","description":"Amyotrophic Lateral Sclerosis","metadata":null},{"id":"7791644da1744a4f8807fc33b665edf5","type":"TRIAL","name":"Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","canonical_id":"clinicaltrials.gov:NCT03131219","description":"Atypical Hemolytic Uremic Syndrome (aHUS)","metadata":null},{"id":"53900460dfb34b898f64e57c3a34bffd","type":"TRIAL","name":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","canonical_id":"clinicaltrials.gov:NCT06291376","description":"Immunoglobulin A Nephropathy; IgAN","metadata":null},{"id":"f66393c17fa54ddcb31b1faa32debbdc","type":"TRIAL","name":"Study of Ravulizumab in Pediatric Participants With HSCT-TMA","canonical_id":"clinicaltrials.gov:NCT04557735","description":"Thrombotic Microangiopathy","metadata":null},{"id":"1b290258cda4457598be292de805f15e","type":"TRIAL","name":"Study of Ravulizumab in Pediatric Participants With Primary IgAN","canonical_id":"clinicaltrials.gov:NCT07024563","description":"IgAN; IgAVN; Immunoglobulin A Nephropathy; Immunoglobulin A Vasculitis Associated Nephritis; Henoch-schonlein Purpura Nephritis; IgA Vasculitis","metadata":null},{"id":"e0bb5484059c4040a1277b46fbebe031","type":"TRIAL","name":"Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","canonical_id":"clinicaltrials.gov:NCT04564339","description":"Lupus Nephritis; Immunoglobulin A Nephropathy","metadata":null},{"id":"ca7f1efe90d644fd9e15f31228bc6266","type":"TRIAL","name":"Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant","canonical_id":"clinicaltrials.gov:NCT03116997","description":"Surgery","metadata":null},{"id":"816427b63d9a4ed68ae0c8494caaf16b","type":"TRIAL","name":"Study of Regorafenib in Patients With Advanced Myeloid Malignancies","canonical_id":"clinicaltrials.gov:NCT03042689","description":"Acute Myeloid Leukemia","metadata":null},{"id":"719229255f12498c8470a9a89f4bdf1d","type":"TRIAL","name":"Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils","canonical_id":"clinicaltrials.gov:NCT02452190","description":"Asthma","metadata":null},{"id":"93fc7486e41c4d7ca1a04a45da9fd0d6","type":"TRIAL","name":"Study of Respiratory Depression When Using a Hydromorphone Pain Protocol","canonical_id":"clinicaltrials.gov:NCT01784991","description":"Pain; Respiratory Depression","metadata":null},{"id":"023833cc633541e5836b8a8a69160cf3","type":"TRIAL","name":"Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures","canonical_id":"clinicaltrials.gov:NCT01227902","description":"Epilepsy","metadata":null},{"id":"e7d541e4a98746faa056a9288ea616c1","type":"TRIAL","name":"Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05996107","description":"Breast Cancer","metadata":null},{"id":"cfab47dc65524c3dace6d24a111754e5","type":"TRIAL","name":"Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.","canonical_id":"clinicaltrials.gov:NCT02732119","description":"Breast Cancer","metadata":null},{"id":"6de932ff6df04e27aef28cc0ec06636f","type":"TRIAL","name":"Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant","canonical_id":"clinicaltrials.gov:NCT05843253","description":"High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV Glioma; Diffuse Hemispheric Glioma, H3 G34-Mutant","metadata":null},{"id":"78f9072602cc4cb8af77b0636be4d947","type":"TRIAL","name":"Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01900496","description":"Lymphoma","metadata":null},{"id":"c93fe48e037f460fa6556c27484c359a","type":"TRIAL","name":"Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia","canonical_id":"clinicaltrials.gov:NCT00767091","description":"Parkinson's Disease; Apathy; no Dementia","metadata":null},{"id":"068497e98ca44dc0aace47cf30238b7e","type":"TRIAL","name":"Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops","canonical_id":"clinicaltrials.gov:NCT01306266","description":"Chronic Post-traumatic Headache","metadata":null},{"id":"247b620917084de6ae0ab28b3060bc59","type":"TRIAL","name":"Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC","canonical_id":"clinicaltrials.gov:NCT00385606","description":"Advanced Non-small Cell Lung Cancer","metadata":null},{"id":"159f23708043463b9285d7fe9c13b524","type":"TRIAL","name":"Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03458546","description":"Lymphoma, B-Cell","metadata":null},{"id":"d4e98b506900437fb207d3c2c4bd04e3","type":"TRIAL","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03362177","description":"Chemotherapy-induced Thrombocytopenia","metadata":null},{"id":"8791f5d2992448e38404bc62413b99a9","type":"TRIAL","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.","canonical_id":"clinicaltrials.gov:NCT03343847","description":"Chemotherapy-induced Thrombocytopenia","metadata":null},{"id":"65bab6f9437248ccb60d877a8cb7bd98","type":"TRIAL","name":"Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT02773290","description":"Aplastic Anemia","metadata":null},{"id":"e76822caf3ed499094cfa3812e930c35","type":"TRIAL","name":"Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis","canonical_id":"clinicaltrials.gov:NCT01833754","description":"Osteoporosis","metadata":null},{"id":"405e1bdc6f2e455ba5c07f370a2a6395","type":"TRIAL","name":"Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing","canonical_id":"clinicaltrials.gov:NCT00907296","description":"Fracture Healing","metadata":null},{"id":"e03f5c88f38c481880d7fa270c7fe3f1","type":"TRIAL","name":"Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients","canonical_id":"clinicaltrials.gov:NCT01340651","description":"Myelofibrosis","metadata":null},{"id":"097ad810eafd4e91985596ac01da9633","type":"TRIAL","name":"Study of Ruxolitinib Cream in Children With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05034822","description":"Atopic Dermatitis","metadata":null},{"id":"585c44418c764942b6c06b9fc88fe8f2","type":"TRIAL","name":"Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)","canonical_id":"clinicaltrials.gov:NCT02117479","description":"Pancreatic Cancer","metadata":null},{"id":"9f85965f94d343ff961172f81c8c0768","type":"TRIAL","name":"Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04807777","description":"Advanced Cutaneous Squamous Cell Carcinoma","metadata":null},{"id":"f9a0096ad58943ec87a44cd8d6fbc1d1","type":"TRIAL","name":"Study of SA+X in the Treatment of Newly Diagnosed AML","canonical_id":"clinicaltrials.gov:NCT07548710","description":"Acute Myeloid Leukemia","metadata":null},{"id":"f948c9af00ba4ec4b7f4b66709d7670d","type":"TRIAL","name":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","canonical_id":"clinicaltrials.gov:NCT05379972","description":"Gastric Cancer; GastroEsophageal Cancer","metadata":null},{"id":"ccc3bd31ae1a42818da54298563f830c","type":"TRIAL","name":"Study of SDX in Patients With Idiopathic Hypersomnia (IH)","canonical_id":"clinicaltrials.gov:NCT05668754","description":"Idiopathic Hypersomnia","metadata":null},{"id":"b34d5d4024e24e72a8b0b9b69366d3b4","type":"TRIAL","name":"Study of SHP620 (Maribavir) in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02775240","description":"Cytomegalovirus (CMV)","metadata":null},{"id":"ae0a1e72e910419d89bdf057f4377455","type":"TRIAL","name":"Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06686745","description":"Advanced Solid Tumors","metadata":null},{"id":"2a8fed0da2354c4193d0c4bfc9fc579e","type":"TRIAL","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06081959","description":"Metastatic Breast Cancer","metadata":null},{"id":"9733a2fbc03f4d4f989b98e0236d464c","type":"TRIAL","name":"Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00711269","description":"Schizophrenia","metadata":null},{"id":"a64ce5c9330b49ef922ad8a6379d8b38","type":"TRIAL","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06228053","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"d7eb2880f0044cd8a3a063b1e07abf9c","type":"TRIAL","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT05089734","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"c5a0a815e1f34ec0a336204a23f11cf4","type":"TRIAL","name":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","canonical_id":"clinicaltrials.gov:NCT04527991","description":"Locally Advanced or Metastatic Unresectable Urothelial Cancer","metadata":null},{"id":"5dcd33bd729e4a7288147db5ca1d258d","type":"TRIAL","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)","canonical_id":"clinicaltrials.gov:NCT06486441","description":"Endometrial Cancer","metadata":null},{"id":"91d05febb6b1472e854a8480fe7a9770","type":"TRIAL","name":"Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment","canonical_id":"clinicaltrials.gov:NCT04617522","description":"Advanced or Metastatic Solid Tumor; Liver Failure","metadata":null},{"id":"0a4928246b9d447d8cc1e0c859772288","type":"TRIAL","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03964727","description":"Metastatic Solid Tumor","metadata":null},{"id":"5364282916304f13918427087a9af769","type":"TRIAL","name":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","canonical_id":"clinicaltrials.gov:NCT01631552","description":"Gastric Adenocarcinoma; Esophageal Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Ovarian Epithelial Cancer; Carcinoma Breast Stage IV; Hormone-refractory Prostate Cancer; Head and Neck Cancers- Squamous Cell; Renal Cell Cancer; Urinary Bladder Neoplasms; Cervical Cancer; Endometrial Cancer; Glioblastoma Multiforme; Triple Negative Breast Cancer; Pancreatic Cancer","metadata":null},{"id":"335dc874340848fe94c49529c6636f4f","type":"TRIAL","name":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03901339","description":"Metastatic Breast Cancer","metadata":null},{"id":"6e044376ebbe41a78f708836e83217ab","type":"TRIAL","name":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05382286","description":"Triple Negative Breast Cancer; PD-L1 Positive","metadata":null},{"id":"42c8ad015f5b40c8adab53327f062a29","type":"TRIAL","name":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","canonical_id":"clinicaltrials.gov:NCT05633654","description":"Triple Negative Breast Cancer","metadata":null},{"id":"60948893142946aab57517ed56b1c5b9","type":"TRIAL","name":"Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC","canonical_id":"clinicaltrials.gov:NCT07438600","description":"NSCLC (Non-small Cell Lung Cancer)","metadata":null},{"id":"c31c191386164f43ac25ed42b7d59fc8","type":"TRIAL","name":"Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction","canonical_id":"clinicaltrials.gov:NCT04128891","description":"Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"b5ed8531e4754e76aa714f39996746dc","type":"TRIAL","name":"Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)","canonical_id":"clinicaltrials.gov:NCT01096667","description":"Diabetes Mellitus, Type 2; Hypertension","metadata":null},{"id":"910551cb2a2d43d68a5b38298d08747d","type":"TRIAL","name":"Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL","canonical_id":"clinicaltrials.gov:NCT02603445","description":"Follicular Lymphoma, Mantle Cell Lymphoma","metadata":null},{"id":"ff456b3331414763b511776384f06a9c","type":"TRIAL","name":"Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)","canonical_id":"clinicaltrials.gov:NCT05200481","description":"Non Small Cell Lung Cancer; ALK Gene Mutation","metadata":null},{"id":"7f7fe5346cf144af81df739ee0e37b3d","type":"TRIAL","name":"Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections","canonical_id":"clinicaltrials.gov:NCT03710564","description":"Age-Related Macular Degeneration","metadata":null},{"id":"d75d90e73cc9443cbe1b183f2e20c4ba","type":"TRIAL","name":"Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD","canonical_id":"clinicaltrials.gov:NCT03386474","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"d56defe4654f41d1a7a016414ed74b67","type":"TRIAL","name":"Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02393625","description":"ALK-positive NSCLC","metadata":null},{"id":"09f077307dd0431d92bc042ade01f225","type":"TRIAL","name":"Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT02335944","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"e0e1ed73de8a458d8e274c2e3fd2a5d3","type":"TRIAL","name":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","canonical_id":"clinicaltrials.gov:NCT04884035","description":"Lymphoma, B-Cell","metadata":null},{"id":"e9d5f2bc5d8d47e795c4c043168ca7f1","type":"TRIAL","name":"Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT02292550","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"be0bb1fc9c834b91b06a88be5a4cfd63","type":"TRIAL","name":"Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).","canonical_id":"clinicaltrials.gov:NCT03742349","description":"Triple Negative Breast Cancer (TNBC)","metadata":null},{"id":"70674bfe113b49498ac7ac8f593c4dd9","type":"TRIAL","name":"Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients","canonical_id":"clinicaltrials.gov:NCT00228020","description":"Pediatric Kidney Transplantation","metadata":null},{"id":"f328ce83f1c2427dad704370225ac397","type":"TRIAL","name":"Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab","canonical_id":"clinicaltrials.gov:NCT00933335","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"10d69b2ff1354202b186dcc30036efae","type":"TRIAL","name":"Study of Salmeterol (SN408D) for Adult Asthma","canonical_id":"clinicaltrials.gov:NCT00950794","description":"Asthma; Bronchial Asthma","metadata":null},{"id":"ea22d01ef08d48bb9237dfc87aedbb12","type":"TRIAL","name":"Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events","canonical_id":"clinicaltrials.gov:NCT07836101","description":"Any Advanced Solid Tumors","metadata":null},{"id":"ec32fad1081d4bd38f3d3b5f5f6af244","type":"TRIAL","name":"Study of Secukinumab Compared to Fumaderm\u00ae in Adults With Moderate to Severe Psoriasis.","canonical_id":"clinicaltrials.gov:NCT02474082","description":"Psoriasis","metadata":null},{"id":"6a334b3c700e4440baf378b3641ca1e8","type":"TRIAL","name":"Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis","canonical_id":"clinicaltrials.gov:NCT07841977","description":"Primary Biliary Cholangitis","metadata":null},{"id":"0d9dc1e534d14d368c43b8bde0aa4519","type":"TRIAL","name":"Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)","canonical_id":"clinicaltrials.gov:NCT03301506","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"4a3e664aa4d74afe801009e34e0f236d","type":"TRIAL","name":"Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.","canonical_id":"clinicaltrials.gov:NCT01336634","description":"Cancer","metadata":null},{"id":"8e1e94fd7600429fb92d6e6976f61d5a","type":"TRIAL","name":"Study of Self or Clinic Administration of DepoProvera","canonical_id":"clinicaltrials.gov:NCT01019369","description":"Contraception","metadata":null},{"id":"9e1a94523f034d90a103e0a2e928ff3c","type":"TRIAL","name":"Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05975944","description":"Extensive-stage Small Cell Lung Cancer","metadata":null},{"id":"620fcc29f7764cd5a992d151e6488595","type":"TRIAL","name":"Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT07479979","description":"Relapse Multiple Myeloma; Refractory Multiple Myeloma","metadata":null},{"id":"905f66fa86504d43b95f264d0ae47ff8","type":"TRIAL","name":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT04607772","description":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"ae74a27317184f3e8a49470f1615e7ff","type":"TRIAL","name":"Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)","canonical_id":"clinicaltrials.gov:NCT03833427","description":"Advanced/Metastatic Solid Tumors","metadata":null},{"id":"ebca13d6c78b4f62a87256a22de2337a","type":"TRIAL","name":"Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)","canonical_id":"clinicaltrials.gov:NCT02717884","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"5b870551289d43d5b5a53179f6a957ab","type":"TRIAL","name":"Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH","canonical_id":"clinicaltrials.gov:NCT00588536","description":"Langerhans Cell Histiocytosis","metadata":null},{"id":"8a6b60ca88a64286989223b8e46d6522","type":"TRIAL","name":"Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00142506","description":"Prostate Cancer; Erectile Dysfunction","metadata":null},{"id":"400d57f9d81e4e79a396cf4a92f4c52c","type":"TRIAL","name":"Study of Silodosin to Facilitate Passage of Urinary Stones","canonical_id":"clinicaltrials.gov:NCT01144949","description":"Ureteral Calculi; Kidney Stones; Urolithiasis","metadata":null},{"id":"85d30f4e185c4c2fa5b0a21d8354b96a","type":"TRIAL","name":"Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT02468557","description":"Previously Untreated Pancreatic Ductal Adenocarcinoma; Relapsed/Refractory Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"7062172cb8284ae288184e01016d4e5b","type":"TRIAL","name":"Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan","canonical_id":"clinicaltrials.gov:NCT00219375","description":"Acute Lung Injury; Systemic Inflammatory Response Syndrome","metadata":null},{"id":"93f87da1985f4f9d877cccee87f63acf","type":"TRIAL","name":"Study of Sivelestat Sodium in OPCABG","canonical_id":"clinicaltrials.gov:NCT07118930","description":"Coronary Heart Disease; Coronary Artery Disease; Coronary Arterial Disease (CAD)","metadata":null},{"id":"33f8bc6caec8428d93d506fac9f27ae4","type":"TRIAL","name":"Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT01265576","description":"HCC","metadata":null},{"id":"f9bf744eb95f4271be778244c7c4afab","type":"TRIAL","name":"Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases","canonical_id":"clinicaltrials.gov:NCT05003986","description":"Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis; Alport Syndrome","metadata":null},{"id":"57af08ae5a2048cd8b184854b73aacb2","type":"TRIAL","name":"Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)","canonical_id":"clinicaltrials.gov:NCT03493685","description":"Focal Segmental Glomerulosclerosis","metadata":null},{"id":"94fedecef1344188a39fc9e578a395ff","type":"TRIAL","name":"Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","canonical_id":"clinicaltrials.gov:NCT07617324","description":"Seasonal Allergic Rhinitis (SAR)","metadata":null},{"id":"929ea838416d4019ba88870f3fb2a3eb","type":"TRIAL","name":"Study of Stapokibart Injection in Patients With Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT06525597","description":"Allergic Rhinitis","metadata":null},{"id":"e1f8b985711a4d34900ac0d4ac349413","type":"TRIAL","name":"Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT07210554","description":"Bullous Pemphigoid (BP)","metadata":null},{"id":"0baf2f770d5a4555b58fbec444c63a58","type":"TRIAL","name":"Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen","canonical_id":"clinicaltrials.gov:NCT00556452","description":"Leukemia; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome","metadata":null},{"id":"04f0e5df6f9e4d769f1dc87be1d0cc9f","type":"TRIAL","name":"Study of Stroke Related Edema Treatments","canonical_id":"clinicaltrials.gov:NCT01954290","description":"Acute Cerebrovascular Accident; Cerebral Edema","metadata":null},{"id":"fe651d397ce2412eb72c06daa2bf5f8a","type":"TRIAL","name":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","canonical_id":"clinicaltrials.gov:NCT04052880","description":"Newly Diagnosed Multiple Myeloma","metadata":null},{"id":"621c41b2a9b345fe904ccc183fff2072","type":"TRIAL","name":"Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement","canonical_id":"clinicaltrials.gov:NCT04713592","description":"Psoriasis","metadata":null},{"id":"ba80f45c634240398189f5a2bee55be3","type":"TRIAL","name":"Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)","canonical_id":"clinicaltrials.gov:NCT04179032","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"f4dd5c7f18ec40f4a83ccd16ea104460","type":"TRIAL","name":"Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures","canonical_id":"clinicaltrials.gov:NCT00640146","description":"Opioid-induced Constipation","metadata":null},{"id":"778676fee9224a849c42cc1a53be36e2","type":"TRIAL","name":"Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy","canonical_id":"clinicaltrials.gov:NCT04908475","description":"Psoriasis","metadata":null},{"id":"7051a35386644a97809a4d2db21d99eb","type":"TRIAL","name":"Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00272662","description":"Chemotherapy Induced Anemia; Cancer","metadata":null},{"id":"c6261bdd9707442b94529dacb890214b","type":"TRIAL","name":"Study of Sutent\u00ae/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas","canonical_id":"clinicaltrials.gov:NCT01402817","description":"Neurofibromatosis; NF1; Plexiform Neurofibromas","metadata":null},{"id":"b33d1eddf4744aabb253bb8c03c0143a","type":"TRIAL","name":"Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT07423429","description":"Exudative Age-Related Macular Degeneration","metadata":null},{"id":"3a7a9f4a8b204e80a4e0b61a91afda57","type":"TRIAL","name":"Study of TCP-ATRA for Adult Patients With AML and MDS","canonical_id":"clinicaltrials.gov:NCT02273102","description":"Acute Myelogenous Leukemia; Myelodysplastic Syndromes; Leukemia","metadata":null},{"id":"c4531df7355a4e4c9719fc4ee0d28546","type":"TRIAL","name":"Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies","canonical_id":"clinicaltrials.gov:NCT03671590","description":"Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia","metadata":null},{"id":"b627283dade6489a99ffce98cfc3f4f5","type":"TRIAL","name":"Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT04806035","description":"CLL; SLL; Richter's Transformation; Indolent Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Aggressive Lymphoma; DLBCL; Mediastinal Large B-cell Lymphoma; MCL","metadata":null},{"id":"0dd0e68c4ce34d46b5cc641bb506e2e4","type":"TRIAL","name":"Study of TG-1801 in Subjects With B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03804996","description":"B-Cell Lymphoma","metadata":null},{"id":"7c7598050b864519a90cb93776753adf","type":"TRIAL","name":"Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT03986073","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"6e657e55cae04a3ca772a543d62ccdc8","type":"TRIAL","name":"Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology","canonical_id":"clinicaltrials.gov:NCT05206955","description":"Fontan Palliation","metadata":null},{"id":"6ced28977ae04412ade64254649af241","type":"TRIAL","name":"Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older","canonical_id":"clinicaltrials.gov:NCT04974216","description":"DLBCL","metadata":null},{"id":"1f9dde1f8ed14fef949dadf4af6d66a8","type":"TRIAL","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","canonical_id":"clinicaltrials.gov:NCT04821622","description":"Prostate Cancer","metadata":null},{"id":"abdaceadf16640b1886ce46ab05c7d21","type":"TRIAL","name":"Study of Tamibarotene in Patients With ADPKD","canonical_id":"clinicaltrials.gov:NCT06289998","description":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","metadata":null},{"id":"8dd08c57cc9549b2a7c1622658193c48","type":"TRIAL","name":"Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00003906","description":"Breast Cancer","metadata":null},{"id":"23fb98eb7f8a49da88b3cece9022776e","type":"TRIAL","name":"Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00125359","description":"Carcinoma, Non-small-cell Lung","metadata":null},{"id":"ceed100df68649f7a6977f85e6a0db34","type":"TRIAL","name":"Study of Tarceva and Targretin in Stage I-II Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00125372","description":"Carcinoma, Non-small-cell Lung","metadata":null},{"id":"733e308b3ac44985997ce601d260d433","type":"TRIAL","name":"Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis","canonical_id":"clinicaltrials.gov:NCT06865105","description":"Psoriatic Arthritis","metadata":null},{"id":"b6148af9a0434f928acce695996f8b90","type":"TRIAL","name":"Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT06548542","description":"Crohn's Disease","metadata":null},{"id":"5a5f9470bfbf48b08048571037caa08e","type":"TRIAL","name":"Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT06475989","description":"Refractory Differentiated Thyroid Gland Carcinoma","metadata":null},{"id":"c3426d5d8c1443a49cbdf9b8c7fa7a21","type":"TRIAL","name":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","canonical_id":"clinicaltrials.gov:NCT01897571","description":"B-cell Lymphomas (Phase 1); Advanced Solid Tumors (Phase 1); Diffuse Large B-cell Lymphoma (Phase 2); Follicular Lymphoma (Phase 2); Transformed Follicular Lymphoma; Primary Mediastinal Large B-Cell Lymphoma","metadata":null},{"id":"50f49df1fcf940639813f2e06a47dad4","type":"TRIAL","name":"Study of Tazemetostat in Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT05983965","description":"T-cell Lymphoma","metadata":null},{"id":"54224d6a6f6943118c56f623d3531e0c","type":"TRIAL","name":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","canonical_id":"clinicaltrials.gov:NCT02889523","description":"Lymphoma; DLBCL; Follicular Lymphoma","metadata":null},{"id":"fdc20033d3c34277b0e3e89834f0ccdc","type":"TRIAL","name":"Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation","canonical_id":"clinicaltrials.gov:NCT03456726","description":"Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","metadata":null},{"id":"b38f1d62c5f2488cbb26ddd3252ed468","type":"TRIAL","name":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT05572229","description":"Multiple Myeloma","metadata":null},{"id":"5b87ad9b0b854a2e91ecf906f4e26500","type":"TRIAL","name":"Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects","canonical_id":"clinicaltrials.gov:NCT00798967","description":"Short Bowel Syndrome","metadata":null},{"id":"89b49855c3e2487cad7249d5df401a50","type":"TRIAL","name":"Study of Teduglutide in Japanese Participants With Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT03663582","description":"Short Bowel Syndrome","metadata":null},{"id":"44c5fc6bc95e4e1c838a8005cfe50213","type":"TRIAL","name":"Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)","canonical_id":"clinicaltrials.gov:NCT00442936","description":"Migraine","metadata":null},{"id":"2f4bd521a25c4d1d8dcc97f02c3c2039","type":"TRIAL","name":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03539536","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"0ca94fe55b88483b94c822c7ef9834ec","type":"TRIAL","name":"Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)","canonical_id":"clinicaltrials.gov:NCT04515394","description":"Colorectal Neoplasms","metadata":null},{"id":"5c8ff09d5bfa4455bfa4a8e1a258eadb","type":"TRIAL","name":"Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT00134563","description":"Multiple Sclerosis","metadata":null},{"id":"2194808208d6495486176053e6ded470","type":"TRIAL","name":"Study of Teriparatide in Stress Fracture Healing","canonical_id":"clinicaltrials.gov:NCT04196855","description":"Stress Fracture; Parathyroid Hormone","metadata":null},{"id":"e0dff7ca6582481fb6efbe497c32ff28","type":"TRIAL","name":"Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin","canonical_id":"clinicaltrials.gov:NCT06406426","description":"Gastric / Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"4831c13844d946b985ed614171fe5269","type":"TRIAL","name":"Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin","canonical_id":"clinicaltrials.gov:NCT06030934","description":"Gastric / Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"2bd38eb537e54784a3434324be2b8de1","type":"TRIAL","name":"Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT00087581","description":"Kidney Transplantation","metadata":null},{"id":"034207d9103a44d597fd4d3dc06fc8f4","type":"TRIAL","name":"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)","canonical_id":"clinicaltrials.gov:NCT04947319","description":"Refractory Primary Central Nervous System Lymphoma; Primary CNS Lymphoma","metadata":null},{"id":"a32b9d4013374a3386b7a5722c3372aa","type":"TRIAL","name":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","canonical_id":"clinicaltrials.gov:NCT00398463","description":"Angioplasty, Transluminal, Percutaneous Coronary","metadata":null},{"id":"81826f23f1a246fd900915329e4dc371","type":"TRIAL","name":"Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers","canonical_id":"clinicaltrials.gov:NCT00660153","description":"Colorectal Cancer; Gastrointestinal Cancer","metadata":null},{"id":"666df9ee4f934f01bd189a5be9086cb5","type":"TRIAL","name":"Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients","canonical_id":"clinicaltrials.gov:NCT01258712","description":"Rheumatoid Arthritis (RA)","metadata":null},{"id":"a0eb0daf1b0a4591993510e5add169de","type":"TRIAL","name":"Study of Tofacitinib in Refractory Dermatomyositis","canonical_id":"clinicaltrials.gov:NCT03002649","description":"Dermatomyositis","metadata":null},{"id":"6b77f67eff4f4b5ca25c82ae87eb30cd","type":"TRIAL","name":"Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma","canonical_id":"clinicaltrials.gov:NCT03501368","description":"Melanoma; Unresectable Melanoma; Advanced Melanoma","metadata":null},{"id":"af151dd8d13a41aaa416708098d55c41","type":"TRIAL","name":"Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT00995618","description":"Gout; Hyperuricemia","metadata":null},{"id":"ce71cc7659c343c580cc30b826e8bf5e","type":"TRIAL","name":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","canonical_id":"clinicaltrials.gov:NCT01652664","description":"Pediatric Glaucoma; Elevated IOP in Pediatric Patients; Ocular Hypertension in Pediatric Patients","metadata":null},{"id":"9b77c13dbc6b4480a8411b29592f0815","type":"TRIAL","name":"Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia","canonical_id":"clinicaltrials.gov:NCT01348542","description":"Insomnia","metadata":null},{"id":"ae4bc0a59af945db871f42e3c3dd1fae","type":"TRIAL","name":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","canonical_id":"clinicaltrials.gov:NCT03107793","description":"Crohn Disease","metadata":null},{"id":"661f3c4fedeb4111984817147da3729b","type":"TRIAL","name":"Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis","canonical_id":"clinicaltrials.gov:NCT06526104","description":"Hepatocellular Carcinoma; Cirrhosis, Liver","metadata":null},{"id":"0090d805750d4c1aa5efae83e3dafcc3","type":"TRIAL","name":"Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation","canonical_id":"clinicaltrials.gov:NCT04856904","description":"Acne Vulgaris","metadata":null},{"id":"5b590881d4684027be038a48fb46b2b0","type":"TRIAL","name":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05748834","description":"Breast Cancer","metadata":null},{"id":"1f068c2b33fa4d42900e47067779a68b","type":"TRIAL","name":"Study of U101 for Bladder Pain and/or Urgency","canonical_id":"clinicaltrials.gov:NCT00256542","description":"Pelvic Pain; Interstitial Cystitis; Bladder Diseases","metadata":null},{"id":"5df02ea8f74e4af7bb51c2ce93b01eb4","type":"TRIAL","name":"Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07389590","description":"Multiple Sclerosis","metadata":null},{"id":"54522e0faaba4ce0906888cbb8daa253","type":"TRIAL","name":"Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects","canonical_id":"clinicaltrials.gov:NCT02634437","description":"Renal Function","metadata":null},{"id":"17028e08f4624f90aa551fb1e18e7f50","type":"TRIAL","name":"Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab","canonical_id":"clinicaltrials.gov:NCT00062894","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"994ad857e38f4bd2b5a9cb8b3ef7188f","type":"TRIAL","name":"Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis","canonical_id":"clinicaltrials.gov:NCT00004705","description":"Cystic Fibrosis","metadata":null},{"id":"5fc537bacbc64a3b842e7065910e96ff","type":"TRIAL","name":"Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching","canonical_id":"clinicaltrials.gov:NCT01825655","description":"Pruritus","metadata":null},{"id":"9b9051a57f704dc88ef02f6bebd36118","type":"TRIAL","name":"Study of VESIcare\u00ae In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life","canonical_id":"clinicaltrials.gov:NCT00573508","description":"Urinary Bladder, Overactive","metadata":null},{"id":"5a6f9de62af949a7ad42b35687303798","type":"TRIAL","name":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT05371054","description":"Lymphoma; Non-Hodgkin Lymphoma; NHL; Hematologic Malignancies; Lymphoid Malignancies","metadata":null},{"id":"684bde053b4a4a7dbbdbc52a3417c9c4","type":"TRIAL","name":"Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00687297","description":"Lung Cancer; Non Small Cell Lung Cancer","metadata":null},{"id":"2c86513ecdae410fa6d4637faacdedb7","type":"TRIAL","name":"Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT00783692","description":"Crohn's Disease","metadata":null},{"id":"f868b07c7ad540ea888eaf772b65d1d1","type":"TRIAL","name":"Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT01224171","description":"Crohn's Disease","metadata":null},{"id":"169672d8c02f4e8f9dc5f4c6598a5786","type":"TRIAL","name":"Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer","canonical_id":"clinicaltrials.gov:NCT00106262","description":"Cervical Cancer","metadata":null},{"id":"c5a60a8846ba4a4bbe3df3473dd07d66","type":"TRIAL","name":"Study of Vemurafenib, Carboplatin, and Paclitaxel","canonical_id":"clinicaltrials.gov:NCT01636622","description":"Advanced Cancers","metadata":null},{"id":"7a4a623f5e4c4ba792937220670d80f2","type":"TRIAL","name":"Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03844815","description":"Acute Myeloid Leukemia","metadata":null},{"id":"2434b3ea50fe42f3abb4d589c7a263d0","type":"TRIAL","name":"Study of Vilazodone to Treat Social Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01712321","description":"Social Anxiety Disorder","metadata":null},{"id":"e7fc9fce8a2e44bdb40a97f4468aa272","type":"TRIAL","name":"Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults","canonical_id":"clinicaltrials.gov:NCT01887522","description":"Refractory Low-grade Gliomas; Recurrent Low-grade Gliomas","metadata":null},{"id":"2cc1d42b5a4d47c4b6501b34a1531550","type":"TRIAL","name":"Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function","canonical_id":"clinicaltrials.gov:NCT01320722","description":"Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity","metadata":null},{"id":"8dfababf441141ca98e44800544f3336","type":"TRIAL","name":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","canonical_id":"clinicaltrials.gov:NCT05484622","description":"Astrocytoma; Oligodendroglioma","metadata":null},{"id":"44eea5b892a045538c2d5a4d1f2bcc13","type":"TRIAL","name":"Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma","canonical_id":"clinicaltrials.gov:NCT01879085","description":"Sarcoma","metadata":null},{"id":"1fddbab7fcb44ea8b07c45d247670492","type":"TRIAL","name":"Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00081887","description":"Chronic Lymphocytic Leukemia; Leukemia","metadata":null},{"id":"3a14fe5bd6534b6c968131f3bac35d50","type":"TRIAL","name":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","canonical_id":"clinicaltrials.gov:NCT04925284","description":"Non Small Cell Lung Cancer; Cervical Cancer; SCCHN; Pancreatic Cancer; Esophageal SCC; Metastatic Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Hormone Receptor-positive Breast Cancer; Epithelial Ovarian Cancer; Endometrial Cancer; Tissue Factor-Expressing Solid Tumors","metadata":null},{"id":"a7082cc6aeca4457b21ea46052c7d190","type":"TRIAL","name":"Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen","canonical_id":"clinicaltrials.gov:NCT01042925","description":"Breast Cancer; Breast Neoplasms","metadata":null},{"id":"2a8b9d86d4404be3905923832d29a5fb","type":"TRIAL","name":"Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT05176483","description":"Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC); Solid Tumor; Hepatocellular Carcinoma (HCC); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Head and Neck Squamous Cell Carcinoma (HNSCC); Clear Cell Renal Cell Carcinoma (ccRCC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Drug-Drug Interaction (DDI)","metadata":null},{"id":"d940541498d648a4a0b3aea6470b99f9","type":"TRIAL","name":"Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women","canonical_id":"clinicaltrials.gov:NCT00322348","description":"Advanced Breast Cancer","metadata":null},{"id":"fd8caa2c8460472e83ec9dcd68247b97","type":"TRIAL","name":"Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT00966992","description":"Uterine Cervical Neoplasms","metadata":null},{"id":"d78295f1e59d4c448aaa3a1e0e0f45a0","type":"TRIAL","name":"Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures","canonical_id":"clinicaltrials.gov:NCT00143442","description":"Pain","metadata":null},{"id":"7fa79ddcea7c45acb977ea81e275a130","type":"TRIAL","name":"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.","canonical_id":"clinicaltrials.gov:NCT01520909","description":"Idiopathic Thrombocytopenic Purpura","metadata":null},{"id":"94aa7a37aecb4be3a270948ea9bee25d","type":"TRIAL","name":"Study of a Novel Antipsychotic ITI-007 in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT01499563","description":"Schizophrenia","metadata":null},{"id":"fb6e2eb1d20c430488a9157024b59a97","type":"TRIAL","name":"Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01172925","description":"NSCLC; Dyspnea","metadata":null},{"id":"0bb776d4d83f4913be3f2df7f0f2a26a","type":"TRIAL","name":"Study of a \u03b11A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)","canonical_id":"clinicaltrials.gov:NCT01259531","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"567cd9ca51fa4ff5ae50bdcf1ff5cb40","type":"TRIAL","name":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","canonical_id":"clinicaltrials.gov:NCT04092673","description":"Solid Tumor, Adult","metadata":null},{"id":"44c895a71cc6408dbbbeb2e1927e970b","type":"TRIAL","name":"Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH","canonical_id":"clinicaltrials.gov:NCT03920072","description":"X-linked Hypophosphatemia","metadata":null},{"id":"cd566f923b694853b1fb44f0fba74a17","type":"TRIAL","name":"Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib","canonical_id":"clinicaltrials.gov:NCT02357732","description":"Metastatic Melanoma","metadata":null},{"id":"576de5afec2849eb83edef781b474262","type":"TRIAL","name":"Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury","canonical_id":"clinicaltrials.gov:NCT00006270","description":"Brain Injury; Craniocerebral Trauma","metadata":null},{"id":"5aeb2401da4643afbb20798b5bdfac77","type":"TRIAL","name":"Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)","canonical_id":"clinicaltrials.gov:NCT00945035","description":"Pain","metadata":null},{"id":"5458f11a1ca84d1e982110a99691eba6","type":"TRIAL","name":"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03065062","description":"Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer","metadata":null},{"id":"bab1249f38a540efbad61cc571041086","type":"TRIAL","name":"Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder","canonical_id":"clinicaltrials.gov:NCT06398158","description":"Neuromyelitis Optica","metadata":null},{"id":"daf1e4ad21b047e69c131fe32bcdff00","type":"TRIAL","name":"Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma","canonical_id":"clinicaltrials.gov:NCT05526989","description":"Penile Carcinoma","metadata":null},{"id":"9a7db76062ab4672b24d4dfabd3c4fea","type":"TRIAL","name":"Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT00894803","description":"Ischemic Stroke; Stroke; Brain Infarction","metadata":null},{"id":"af6286ffacb44ce89c735a0b191905b9","type":"TRIAL","name":"Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)","canonical_id":"clinicaltrials.gov:NCT01977456","description":"Stroke; Brain Infarction","metadata":null},{"id":"1a8e7c1fd7dc46b4a0eaecfb43e0501e","type":"TRIAL","name":"Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma","canonical_id":"clinicaltrials.gov:NCT03878719","description":"Melanoma","metadata":null},{"id":"6c44ec0a40aa48b4a8af7739e17d3b08","type":"TRIAL","name":"Study of the Combination of CM082 With Everolimus in Patients With mRCC","canonical_id":"clinicaltrials.gov:NCT02577458","description":"Renal Cell Carcinoma Recurrent","metadata":null},{"id":"e1c94e5842d5439589815f57c5f0ac4d","type":"TRIAL","name":"Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent\u00ae Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT02260011","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"1ee0862464bc42dea8a6e9b1688d4464","type":"TRIAL","name":"Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception","canonical_id":"clinicaltrials.gov:NCT01963962","description":"Emergency Contraception","metadata":null},{"id":"a15cbea16f3d4332a2074cd5992c7855","type":"TRIAL","name":"Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00115076","description":"Psoriasis","metadata":null},{"id":"7976b576f60c41b485cc40d004f476d0","type":"TRIAL","name":"Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma","canonical_id":"clinicaltrials.gov:NCT02860286","description":"Mesothelioma; BAP1 Loss of Function","metadata":null},{"id":"f853dfcac56043e78f9ca3a4af040308","type":"TRIAL","name":"Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression","canonical_id":"clinicaltrials.gov:NCT03126188","description":"Depressive Episode","metadata":null},{"id":"a46e88748c42418e9bd30d9abd11f74a","type":"TRIAL","name":"Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00904176","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"69f6a15d0f1f4eeeb85864eb050051d5","type":"TRIAL","name":"Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages","canonical_id":"clinicaltrials.gov:NCT00763997","description":"Platelet Aggregation","metadata":null},{"id":"359de0915fad4ce5aa9a6e9606fac0a5","type":"TRIAL","name":"Study of the Effect of Dosing on Clozapine Levels","canonical_id":"clinicaltrials.gov:NCT02286206","description":"Psychotic Disorders; Schizophrenia","metadata":null},{"id":"88f7260011a543c390799e3363771332","type":"TRIAL","name":"Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01708798","description":"Breast Cancer","metadata":null},{"id":"3849f56d68d241a896ef373efdf95414","type":"TRIAL","name":"Study of the Effect of Food on the Pharmacokinetics of Mirabegron","canonical_id":"clinicaltrials.gov:NCT00939757","description":"Healthy; Pharmacokinetics of Mirabegron","metadata":null},{"id":"5193e368b3274ef390c2e6f50535c30b","type":"TRIAL","name":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","canonical_id":"clinicaltrials.gov:NCT01615874","description":"Asthma","metadata":null},{"id":"8961c47da4ff4b7c931374b107cb6bf0","type":"TRIAL","name":"Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma","canonical_id":"clinicaltrials.gov:NCT01248065","description":"Asthma","metadata":null},{"id":"e0a3582c6ee34b899d16f89854021194","type":"TRIAL","name":"Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)","canonical_id":"clinicaltrials.gov:NCT00817076","description":"Dermatitis, Atopic","metadata":null},{"id":"8cafec043e224249af5e5e4072fd6a83","type":"TRIAL","name":"Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet","canonical_id":"clinicaltrials.gov:NCT05978206","description":"Sarcopenia","metadata":null},{"id":"4ec9c2bd358f4a35bac40083a852bfba","type":"TRIAL","name":"Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia","canonical_id":"clinicaltrials.gov:NCT05859698","description":"Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Tardive Dyskinesia","metadata":null},{"id":"613987f924014c7d9aaa884ed66b52d0","type":"TRIAL","name":"Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","canonical_id":"clinicaltrials.gov:NCT01033825","description":"Perennial Allergic Rhinitis","metadata":null},{"id":"87d98c59331d463e923cdd282b8c869b","type":"TRIAL","name":"Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00129181","description":"Parkinson Disease; Parkinsonian Syndrome","metadata":null},{"id":"07fa2ba2c7434a9f81c9d0b97ee4e27c","type":"TRIAL","name":"Study of the Effects of Mecamylamine and Varenicline in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00455650","description":"Cognition in Schizophrenia","metadata":null},{"id":"ddc36276aff2438292f216967cd3e809","type":"TRIAL","name":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","canonical_id":"clinicaltrials.gov:NCT01730040","description":"Hypercholesterolemia","metadata":null},{"id":"f4ed503a361e435eb6cae89b4cfddee4","type":"TRIAL","name":"Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo","canonical_id":"clinicaltrials.gov:NCT00134368","description":"Vitiligo","metadata":null},{"id":"694a0c5328b84f0ab8dca9f9ec10211e","type":"TRIAL","name":"Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","canonical_id":"clinicaltrials.gov:NCT05943535","description":"Progressive Pulmonary Fibrosis; Interstitial Lung Disease","metadata":null},{"id":"0dff30e66d00448cbfe49128aee52dcd","type":"TRIAL","name":"Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)","canonical_id":"clinicaltrials.gov:NCT02783729","description":"Insomnia","metadata":null},{"id":"f51810e688c44460919a43e073def710","type":"TRIAL","name":"Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01647971","description":"Non-Hodgkins Lymphoma; B-cell Lymphoma; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Primary Central Nervous System Lymphoma","metadata":null},{"id":"12f686d08de848cba877276b98404bf9","type":"TRIAL","name":"Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT02510794","description":"Macular Degeneration","metadata":null},{"id":"9a4009c9c83c437dbeb0ae3e803c4330","type":"TRIAL","name":"Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT03020199","description":"Plaque Psoriasis","metadata":null},{"id":"594553617dab4915865e2c546e3e1b39","type":"TRIAL","name":"Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas","canonical_id":"clinicaltrials.gov:NCT03732495","description":"Thyroid Cancer Metastatic","metadata":null},{"id":"45035cea3b3b4b6295875a34d0b8e094","type":"TRIAL","name":"Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT02136888","description":"Healthy","metadata":null},{"id":"b55a0003253c47c9bb62289ec88edf62","type":"TRIAL","name":"Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01873950","description":"Drug-induced Surface ECG Changes","metadata":null},{"id":"00f8badcf045496ebd31f2da65df347f","type":"TRIAL","name":"Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy","canonical_id":"clinicaltrials.gov:NCT00577863","description":"Osteoporosis","metadata":null},{"id":"7f3793983ab44238bfae64c5466f695b","type":"TRIAL","name":"Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients","canonical_id":"clinicaltrials.gov:NCT01712997","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"d9a4b6aba25a4934a1ffa3affbaee2e6","type":"TRIAL","name":"Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension","canonical_id":"clinicaltrials.gov:NCT00300079","description":"Primary Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"0d8340960055454dbdcf8b30c31fbdbd","type":"TRIAL","name":"Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture","canonical_id":"clinicaltrials.gov:NCT05866029","description":"Osteoporotic Fractures","metadata":null},{"id":"0bc7d8f1c7a6425b852c92537a4d9332","type":"TRIAL","name":"Study of the Medication Prazosin for Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00762710","description":"Alcoholism","metadata":null},{"id":"ac050a1fe55c44c79c2b47fc18134703","type":"TRIAL","name":"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant","canonical_id":"clinicaltrials.gov:NCT03439046","description":"Breast Cancer","metadata":null},{"id":"0238deaaac3446f580b7da4f875a96b9","type":"TRIAL","name":"Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT02776215","description":"Circadian Rhythm Sleep Disorders; Non-24 Hour Sleep-Wake Disorder; Autism Spectrum Disorder; Smith-Magenis Syndrome","metadata":null},{"id":"bb256ea49cc6491498799a323d34674c","type":"TRIAL","name":"Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX","canonical_id":"clinicaltrials.gov:NCT01367483","description":"Healthy Male Volunteers","metadata":null},{"id":"dd6e9565c5924842984c2ac38a33ca1f","type":"TRIAL","name":"Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia","canonical_id":"clinicaltrials.gov:NCT07243483","description":"Acute Myeloid Leukemia","metadata":null},{"id":"81be7898133642be962f8de9615beb1b","type":"TRIAL","name":"Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)","canonical_id":"clinicaltrials.gov:NCT00482612","description":"Insomnia","metadata":null},{"id":"ec13ba27294948439d258f0b2d5ab7f9","type":"TRIAL","name":"Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT04446351","description":"Neoplasms","metadata":null},{"id":"a6a26ad6324e4380a85edcf1755c8fe0","type":"TRIAL","name":"Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia","canonical_id":"clinicaltrials.gov:NCT00609544","description":"Chronic Kidney Disease; Anemia","metadata":null},{"id":"50e5252f9532448b9db427785348ddfd","type":"TRIAL","name":"Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares","canonical_id":"clinicaltrials.gov:NCT00610363","description":"Gout","metadata":null},{"id":"10041cae2ec54d51bfdc9ac3ec95000b","type":"TRIAL","name":"Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy","canonical_id":"clinicaltrials.gov:NCT00646178","description":"Arthritis; Psoriatic","metadata":null},{"id":"894540c5bd764463861b00fa973dd0e7","type":"TRIAL","name":"Study of the Safety and Efficacy of Conivaptan (Vaprisol\u00ae) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT00930202","description":"Severe Traumatic Brain Injury","metadata":null},{"id":"c9d828fef5644ad28a73f583b7cdde02","type":"TRIAL","name":"Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00369434","description":"Menopause; Vasomotor System","metadata":null},{"id":"e283f55f3b764e73b0b709a773aadc2a","type":"TRIAL","name":"Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome","canonical_id":"clinicaltrials.gov:NCT03951077","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"ae1c46406cf64db6aa7cb64be36993e6","type":"TRIAL","name":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT01692301","description":"Hypertension","metadata":null},{"id":"11848ecbfe014bcb8469381184005df7","type":"TRIAL","name":"Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares","canonical_id":"clinicaltrials.gov:NCT01459796","description":"Gout","metadata":null},{"id":"49093e62564c422fad2b94c029f6f53b","type":"TRIAL","name":"Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT03954236","description":"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease","metadata":null},{"id":"101f192c397e4d1fac827ed8a384996f","type":"TRIAL","name":"Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive","canonical_id":"clinicaltrials.gov:NCT03296098","description":"Contraception; Healthy Female","metadata":null},{"id":"44298ccab61149b3a1226556c157bb37","type":"TRIAL","name":"Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03905148","description":"Solid Tumor, Adult","metadata":null},{"id":"6a2a79818ec440fa91c229cee5aa8594","type":"TRIAL","name":"Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01199822","description":"Malignancy; Metastasis","metadata":null},{"id":"5274f360a8a44b4ea5d58bcb28f14bb5","type":"TRIAL","name":"Study of the Safety of Trogarzo\u2122 Administered as an Undiluted \"IV Push\" or an Intramuscular Injection","canonical_id":"clinicaltrials.gov:NCT03913195","description":"HIV-1-infection","metadata":null},{"id":"1658387edc16442b8ecfd39eac6fd7ad","type":"TRIAL","name":"Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)","canonical_id":"clinicaltrials.gov:NCT02750618","description":"X-Linked Hypophosphatemia","metadata":null},{"id":"3d6c680f5cec469d90a8478034c1815a","type":"TRIAL","name":"Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)","canonical_id":"clinicaltrials.gov:NCT00215670","description":"Age-Related Macular Degeneration","metadata":null},{"id":"2f520b8e38c6411d96d06b63a8fe3812","type":"TRIAL","name":"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","canonical_id":"clinicaltrials.gov:NCT01506271","description":"Intra-abdominal Infections","metadata":null},{"id":"5ee52ca35b4c495e97846dfd6cd2798a","type":"TRIAL","name":"Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01363063","description":"Healthy Volunteers","metadata":null},{"id":"e6bf0d45a8f84dd5a6f447be7c5a5932","type":"TRIAL","name":"Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)","canonical_id":"clinicaltrials.gov:NCT01448304","description":"Hypercholesterolemia","metadata":null},{"id":"2837604e06484b62a766885e6bbdcf90","type":"TRIAL","name":"Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites","canonical_id":"clinicaltrials.gov:NCT00326885","description":"Malignant Ascites","metadata":null},{"id":"99b15be798944de780bc6b3330d5fdba","type":"TRIAL","name":"Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy","canonical_id":"clinicaltrials.gov:NCT07746882","description":"Stroke; Acute Ischemic Stroke","metadata":null},{"id":"5a1f807351514e9f8321478b9019bd9c","type":"TRIAL","name":"Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension","canonical_id":"clinicaltrials.gov:NCT01425242","description":"Hypertension; Abdominal Aortic Aneurysm","metadata":null},{"id":"acb821ca28c44d15b4e6e19b447f7de1","type":"TRIAL","name":"Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets","canonical_id":"clinicaltrials.gov:NCT04275492","description":"Parkinson's Disease","metadata":null},{"id":"95262cd5ca094ff3a71701e1977ebc1a","type":"TRIAL","name":"Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)","canonical_id":"clinicaltrials.gov:NCT00907478","description":"Thrombocytopenia; Idiopathic Thrombocytopenic Purpura","metadata":null},{"id":"7e17992402cb49e596b862fc572d10fe","type":"TRIAL","name":"Study on Children Henoch-Sch\u00f6nlein Purpura Nephritis With TCM Multistep Treatment","canonical_id":"clinicaltrials.gov:NCT03591471","description":"Henoch-Sch\u00f6nlein Purpura Nephritis","metadata":null},{"id":"99860f36f1ce452ca62b4912e65eebd9","type":"TRIAL","name":"Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy","canonical_id":"clinicaltrials.gov:NCT01475318","description":"Complete Abortion","metadata":null},{"id":"b084401b93eb4166926a92720e1c3e75","type":"TRIAL","name":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","canonical_id":"clinicaltrials.gov:NCT06093672","description":"Polycythemia Vera","metadata":null},{"id":"4aa43c79e84a4d8a9f18b0e827e65e72","type":"TRIAL","name":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02918968","description":"Prostate Cancer","metadata":null},{"id":"70116ba609a14bdcb4de6c285078f7fa","type":"TRIAL","name":"Study on Exploring the Effect of DPP-4 Inhibitors on \u03b2-cell Function by Using the Two-step Hyperglycemic Clamp","canonical_id":"clinicaltrials.gov:NCT02386943","description":"Type 2 Diabetes","metadata":null},{"id":"e07327d4680547c6a90d77f090a146c7","type":"TRIAL","name":"Study on Gynecological Laparoscopy Under Total Intravenous Anesthesia","canonical_id":"clinicaltrials.gov:NCT06524596","description":"Butorphanol","metadata":null},{"id":"fc3ca2e6f31a4b2e9459e81a111f026f","type":"TRIAL","name":"Study on Hibernation-like Therapy Based on Mechanical Thrombectomy","canonical_id":"clinicaltrials.gov:NCT06663631","description":"Acute Ischemic Stroke","metadata":null},{"id":"74a6f89c43e34330b820295055cae5c5","type":"TRIAL","name":"Study on Lixisenatide and Counterregulation to Hypoglycemia","canonical_id":"clinicaltrials.gov:NCT02020629","description":"Type 2 Diabetes","metadata":null},{"id":"a93125edc50a422d9605c52dba2803b5","type":"TRIAL","name":"Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00759460","description":"Schizophrenia","metadata":null},{"id":"c0b4b2f2c7ce4db8af578231ed8482c5","type":"TRIAL","name":"Study on Opioid-free Anesthesia Protocol With S-ketamine and Propofol","canonical_id":"clinicaltrials.gov:NCT05242081","description":"Opioid Use, Unspecified; S-ketamine","metadata":null},{"id":"ccfced6920ad4f6b8812e4dddfa02bbc","type":"TRIAL","name":"Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation","canonical_id":"clinicaltrials.gov:NCT05138029","description":"Diabetic Retinopathy","metadata":null},{"id":"0bdb2a63fe694807b72733e5809d65fb","type":"TRIAL","name":"Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)","canonical_id":"clinicaltrials.gov:NCT00508924","description":"Coronary Artery Disease; Angina, Unstable","metadata":null},{"id":"d1ae7b1fbc894a41a5443455c161d2a5","type":"TRIAL","name":"Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients","canonical_id":"clinicaltrials.gov:NCT05213221","description":"Advanced Hepatocellular Carcinoma","metadata":null},{"id":"feaf90e3c58a4bd9b1212fc1b158b9b0","type":"TRIAL","name":"Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction","canonical_id":"clinicaltrials.gov:NCT05310968","description":"Branch Atheromatous Disease","metadata":null},{"id":"e5bf9265b5424f18909e218671036492","type":"TRIAL","name":"Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.","canonical_id":"clinicaltrials.gov:NCT04794127","description":"Liposarcoma, Myxoid; Liposarcoma, Dedifferentiated; Liposarcoma, Round Cell","metadata":null},{"id":"8a31fd34d6d2469b8dbaee32c77a3d54","type":"TRIAL","name":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07471776","description":"Metastatic Breast Cancer ( HER2 Negative)","metadata":null},{"id":"fb1cf520ce584956ad842f34199458cc","type":"TRIAL","name":"Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test","canonical_id":"clinicaltrials.gov:NCT07691801","description":"Primary Aldosteronism","metadata":null},{"id":"f339a1abbf1c45cb8bb9835d8709cf7b","type":"TRIAL","name":"Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body","canonical_id":"clinicaltrials.gov:NCT06066112","description":"Bioequivalence; Schizophrenia","metadata":null},{"id":"b54ee887270f4cfe992c4283a41c54cd","type":"TRIAL","name":"Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion","canonical_id":"clinicaltrials.gov:NCT07738055","description":"Potentially Resectable Hepatocellular Carcinoma","metadata":null},{"id":"f4bb061d12ce4b3cac9a4658f4deecbd","type":"TRIAL","name":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","canonical_id":"clinicaltrials.gov:NCT05976893","description":"ASCVD; Atherosclerotic Cardiovascular Disease; Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor; Cancer","metadata":null},{"id":"21c0c6f33c3d41b783a67f52667f9107","type":"TRIAL","name":"Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib","canonical_id":"clinicaltrials.gov:NCT07742384","description":"Healthy Adult Participants","metadata":null},{"id":"c0c4b1ff77944e88bd689e9ca343c67d","type":"TRIAL","name":"Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles","canonical_id":"clinicaltrials.gov:NCT02230371","description":"Myofascial Pain; Temporomandibular Disorders","metadata":null},{"id":"2435a0c50a8a4b7eb529f987efd2522b","type":"TRIAL","name":"Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients","canonical_id":"clinicaltrials.gov:NCT02943473","description":"High Risk Smoldering Multiple Myeloma","metadata":null},{"id":"b9ff783f2f4f41ff8b0100823103a0a6","type":"TRIAL","name":"Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.","canonical_id":"clinicaltrials.gov:NCT02970669","description":"Heart Failure, Reduced Ejection Fraction","metadata":null},{"id":"dc7a9ce1edac48e2ae2d4efd00fc7278","type":"TRIAL","name":"Study on the Efficacy and Safety of QLM1016 in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT06799559","description":"Schizophrenia","metadata":null},{"id":"c82b9e0d0fd742d7aabf4aa00392e5da","type":"TRIAL","name":"Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout","canonical_id":"clinicaltrials.gov:NCT06653686","description":"Refractory Gout","metadata":null},{"id":"f18e712f4750472880a94f0344da39b2","type":"TRIAL","name":"Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT04533724","description":"Negative Symptom; Schizophrenia; Amisulpride; Gut Microbiomes","metadata":null},{"id":"db0b5bc3e2e5494da60a47cda1c85ec7","type":"TRIAL","name":"Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases","canonical_id":"clinicaltrials.gov:NCT06953843","description":"NSCLC Stage IV Without EGFR/ALK Mutation","metadata":null},{"id":"4568a03c57f44e869aeb89a340bb61f8","type":"TRIAL","name":"Study on the Safety of Abatacept in Relapsing Polychondritis","canonical_id":"clinicaltrials.gov:NCT01272856","description":"Relapsing Polychondritis","metadata":null},{"id":"8b0c5d8831aa440ebc9217d851f7a9b5","type":"TRIAL","name":"Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06467786","description":"Small Cell Lung Cancer","metadata":null},{"id":"bcb6ef8755ec44f3bc1dbfe2689f2c3e","type":"TRIAL","name":"Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT07678931","description":"Seasonal Allergic Rhinitis (SAR)","metadata":null},{"id":"32cff32288e249aba7c9082f856cd38f","type":"TRIAL","name":"Study on the Treatment of Prurigo Nodularis With Stapokibart Injection","canonical_id":"clinicaltrials.gov:NCT06424470","description":"Prurigo Nodularis","metadata":null},{"id":"c936d004aa0145c6978efb4dab95c24a","type":"TRIAL","name":"Study on the Use of Sarilumab in Patients With COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04386239","description":"COVID19","metadata":null},{"id":"9d22e8be0a8d468e9fbec97fa4bd5f1c","type":"TRIAL","name":"Study the Impact of Statins in Septic Shock","canonical_id":"clinicaltrials.gov:NCT02681653","description":"Septic Shock","metadata":null},{"id":"10a9746c43c44cb1a17038fcfb9f413d","type":"TRIAL","name":"Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe","canonical_id":"clinicaltrials.gov:NCT05405985","description":"Healthy Volunteers","metadata":null},{"id":"3ab81f4be0c541b9accc4f304e84fcd8","type":"TRIAL","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","canonical_id":"clinicaltrials.gov:NCT03040973","description":"Advanced Solid Tumors Which Are cMET-dependent","metadata":null},{"id":"e7af84fca5ed4796ad4035e3988186c4","type":"TRIAL","name":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","canonical_id":"clinicaltrials.gov:NCT06084481","description":"Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer","metadata":null},{"id":"558a960a4c5e497d86bf333eaaf01f0e","type":"TRIAL","name":"Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.","canonical_id":"clinicaltrials.gov:NCT05782907","description":"Ulcerative Colitis","metadata":null},{"id":"4da3abc4774d482db9ee3f37e0b6c60a","type":"TRIAL","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT05814627","description":"Rheumatoid Arthritis","metadata":null},{"id":"9ffb73d40d804d6d9c89d1b3a29744be","type":"TRIAL","name":"Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression","canonical_id":"clinicaltrials.gov:NCT02229825","description":"Depressive Disorder, Major","metadata":null},{"id":"170f44bdd5ea49c7859ecff2091ae802","type":"TRIAL","name":"Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927","canonical_id":"clinicaltrials.gov:NCT02230033","description":"Healthy","metadata":null},{"id":"bbd3beb3712e415bb5c0ffc44e82bb7f","type":"TRIAL","name":"Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07220252","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"ee52db5857a6476bae3c326b41ea7cdf","type":"TRIAL","name":"Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients","canonical_id":"clinicaltrials.gov:NCT03022097","description":"COPD","metadata":null},{"id":"f2bd7c79e6ed4bf2aa470920772d5d38","type":"TRIAL","name":"Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","canonical_id":"clinicaltrials.gov:NCT01151423","description":"Acquired Thrombotic Thrombocytopenic Purpura","metadata":null},{"id":"10b986b5c2db41d28e2aa105d9ff8633","type":"TRIAL","name":"Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.","canonical_id":"clinicaltrials.gov:NCT02876900","description":"Schizophrenia","metadata":null},{"id":"e4130838e8b8409990f0591d8bc721c7","type":"TRIAL","name":"Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction","canonical_id":"clinicaltrials.gov:NCT02275338","description":"Intestinal Obstruction","metadata":null},{"id":"bbf2bb0837674e938d44cc18ca1b0790","type":"TRIAL","name":"Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.","canonical_id":"clinicaltrials.gov:NCT01397994","description":"Chronic Stable Angina","metadata":null},{"id":"07c37735d0c54b1aaf06a006fcb58264","type":"TRIAL","name":"Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria","canonical_id":"clinicaltrials.gov:NCT01605487","description":"Cold Contact Urticaria","metadata":null},{"id":"9205e9e376f24d96b59506662117cffa","type":"TRIAL","name":"Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin","canonical_id":"clinicaltrials.gov:NCT02393599","description":"Cocaine Abuse","metadata":null},{"id":"239ad0609bf64deca35163b9b360da82","type":"TRIAL","name":"Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sj\u00f6gren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT04186871","description":"Autoimmune Disorder; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Primary Sj\u00f6gren's Syndrome","metadata":null},{"id":"34887b92d93b4ef3b57ad2a1517b50df","type":"TRIAL","name":"Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.","canonical_id":"clinicaltrials.gov:NCT00423748","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"63b37c5f79a14fd7847d440547a0b6d9","type":"TRIAL","name":"Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above","canonical_id":"clinicaltrials.gov:NCT05720455","description":"Rhinitis Allergic","metadata":null},{"id":"c0969abf53804db0affbb43ed032c96e","type":"TRIAL","name":"Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome","canonical_id":"clinicaltrials.gov:NCT03100942","description":"Sjogren's Syndrome","metadata":null},{"id":"d24fd2db4e0e4587b99d2cb6086bfd18","type":"TRIAL","name":"Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT07681076","description":"Healthy Volunteers","metadata":null},{"id":"831c7bb85a124018887ca5b114264ee9","type":"TRIAL","name":"Study to Assess Safety and Tolerability of Multiple Doses of EO2002","canonical_id":"clinicaltrials.gov:NCT05636579","description":"Corneal Edema; Corneal Endothelial Dystrophy; Endothelial Dysfunction; Fuchs Dystrophy; Fuchs' Endothelial Dystrophy; Bullous Keratopathy; Pseudophakic Bullous Keratopathy; Corneal Edema Pseudophakic","metadata":null},{"id":"0918484a94dd4e09810b97c0e5f3e248","type":"TRIAL","name":"Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo","canonical_id":"clinicaltrials.gov:NCT07524946","description":"Acne Vulgaris","metadata":null},{"id":"fa37e37bf6004ed9a3f527362d7b2d6c","type":"TRIAL","name":"Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT01484184","description":"Spinal Cord Injury","metadata":null},{"id":"d0cbf51a5c344d6dbfefb13b6aae5e85","type":"TRIAL","name":"Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects","canonical_id":"clinicaltrials.gov:NCT04762355","description":"Dry Eye Disease","metadata":null},{"id":"2847c35f3c86453b88181ea09c543f60","type":"TRIAL","name":"Study to Assess Sarilumab in Halting Progression of Morphea","canonical_id":"clinicaltrials.gov:NCT03679845","description":"Morphea, Plaque Form","metadata":null},{"id":"1db4fe515a3b492fae73003ec2194d1d","type":"TRIAL","name":"Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)","canonical_id":"clinicaltrials.gov:NCT04650152","description":"Hypertriglyceridemia; Metabolic Syndrome","metadata":null},{"id":"848f98ec7be44eabad773d2bffcd8932","type":"TRIAL","name":"Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT03828448","description":"Follicular Lymphoma; Small Lymphocytic Lymphoma","metadata":null},{"id":"b6aa778076454d478572409d5eea79c8","type":"TRIAL","name":"Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02689167","description":"Kidney Neoplasms; Metastatic Renal Cell Cancer","metadata":null},{"id":"241add61ae1a47f2a010dc2906e263fd","type":"TRIAL","name":"Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02929342","description":"Healthy Volunteers","metadata":null},{"id":"3bf254103b584ecab41d6cbbae4f77ec","type":"TRIAL","name":"Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule","canonical_id":"clinicaltrials.gov:NCT04768985","description":"Bioequivalence","metadata":null},{"id":"0749711c4e8747fb80ca094ea53b379f","type":"TRIAL","name":"Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule","canonical_id":"clinicaltrials.gov:NCT02877225","description":"Healthy","metadata":null},{"id":"92c47efcbe3a4bae9a2a7e15215fb411","type":"TRIAL","name":"Study to Assess the Effect Of Alosetron On Mucosal Blood Flow","canonical_id":"clinicaltrials.gov:NCT00370032","description":"Irritable Colon","metadata":null},{"id":"fdd39e7e606a4dc08373d4de825113ba","type":"TRIAL","name":"Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04470778","description":"Healthy Participants","metadata":null},{"id":"2ec8ac468c65433b8a8395310d1b6946","type":"TRIAL","name":"Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04944771","description":"Solid and Hematological Malignancies","metadata":null},{"id":"d50da2b4958e4e339e63c456c618db97","type":"TRIAL","name":"Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range","canonical_id":"clinicaltrials.gov:NCT02181322","description":"Healthy","metadata":null},{"id":"bc76ec7a635542568f8e2639b628669f","type":"TRIAL","name":"Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT02050802","description":"Healthy","metadata":null},{"id":"3d7aeb0c2f6e48a7a290e03f5e2dd8f4","type":"TRIAL","name":"Study to Assess the Effect of Osimertinib (TAGRISSO\u2122 ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC","canonical_id":"clinicaltrials.gov:NCT02908750","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"47fd5c4d9155467a9c8a2ff90aa61d1a","type":"TRIAL","name":"Study to Assess the Effect of Pharmacokinetics/Pharmacodynamics (PK/PD) Interaction After co-Administration of Cilostazol With Ginkgo Biloba or Placebo","canonical_id":"clinicaltrials.gov:NCT00689858","description":"Healthy","metadata":null},{"id":"8cb2d545980d44208fe01d1c4d435fd9","type":"TRIAL","name":"Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06740825","description":"Healthy Subjects","metadata":null},{"id":"0aa0c653a6564bd3a20d3004d9db20c0","type":"TRIAL","name":"Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain","canonical_id":"clinicaltrials.gov:NCT01054820","description":"Acute Back Strain","metadata":null},{"id":"b429ddc612da4c48bc7085c67a5b2719","type":"TRIAL","name":"Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT07271186","description":"Diabetic Kidney Disease (DKD)","metadata":null},{"id":"8d44996473e3448d9f4149cbae8785a2","type":"TRIAL","name":"Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02228239","description":"Healthy","metadata":null},{"id":"de0b96feb4f9441e87a23b88a7df87af","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)","canonical_id":"clinicaltrials.gov:NCT04005352","description":"Age-related Macular Degeneration","metadata":null},{"id":"d7084d6f5da04937bcdb526811d601c2","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis","canonical_id":"clinicaltrials.gov:NCT03312751","description":"Primary Hemophagocytic Lymphohistiocytosis","metadata":null},{"id":"7176cd92d159448091bca226c01b492b","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Lanreotide Autogel\u00ae in Chinese Participants With GEP-NETs","canonical_id":"clinicaltrials.gov:NCT04852679","description":"Gastroenteropancreatic Neuroendocrine Tumor","metadata":null},{"id":"051a0026a4c94d9ba81216c605b6f46b","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","canonical_id":"clinicaltrials.gov:NCT04501666","description":"Prurigo Nodularis","metadata":null},{"id":"ea86f00342694eafbb0099de551ad133","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)","canonical_id":"clinicaltrials.gov:NCT04282109","description":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"e3eee6f19ff940a9b2af60c1de4b9135","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma","canonical_id":"clinicaltrials.gov:NCT01912872","description":"Severe IgE-mediated Asthma","metadata":null},{"id":"c2a7551c2289405586bb9bbf945d50b0","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis","canonical_id":"clinicaltrials.gov:NCT03737110","description":"Recurrent Pericarditis","metadata":null},{"id":"f840b7434624432c80d1dc74a27a1bc8","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females","canonical_id":"clinicaltrials.gov:NCT00796289","description":"Infertility","metadata":null},{"id":"50ba2425f7a6459c936bac2951daa091","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","canonical_id":"clinicaltrials.gov:NCT02793583","description":"Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma","metadata":null},{"id":"369b787dfe6d41c2b2e7f4a3d619b8d5","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax","canonical_id":"clinicaltrials.gov:NCT04016805","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"923c62fffe874fc5b1eaf7dc942d731a","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","canonical_id":"clinicaltrials.gov:NCT03801525","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"a066f55239624525bef3811c9c6ae5b8","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)","canonical_id":"clinicaltrials.gov:NCT03277248","description":"Relapsing Multiple Sclerosis (RMS)","metadata":null},{"id":"92dcbd52bd1b4e1dbd3a8ee779101ab7","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )","canonical_id":"clinicaltrials.gov:NCT03277261","description":"Relapsing Multiple Sclerosis (RMS)","metadata":null},{"id":"7d3342d4d5734b399ed79941af7392f1","type":"TRIAL","name":"Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT03364231","description":"Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia; Non Follicular Indolent Non-Hodgkin Lymphoma","metadata":null},{"id":"9a5dc4595e444243a1fa053064b52769","type":"TRIAL","name":"Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children","canonical_id":"clinicaltrials.gov:NCT02235428","description":"Asthma","metadata":null},{"id":"86df9757d37b42a38fa68014f97c9ce8","type":"TRIAL","name":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN","canonical_id":"clinicaltrials.gov:NCT07498335","description":"Berger Disease; Bergers Disease; IgA Nephropathy; Immunoglobulin A Nephropathy; Primary IgAN; Nephritis IgA Type, Nephropathy IgA Type","metadata":null},{"id":"647bb189364843eb860caa2463e8638c","type":"TRIAL","name":"Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy","canonical_id":"clinicaltrials.gov:NCT05206513","description":"Dyskinesia; Cerebral Palsy","metadata":null},{"id":"c6205265b1574e00be91a8a64444b4b5","type":"TRIAL","name":"Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID","canonical_id":"clinicaltrials.gov:NCT00235053","description":"Asthma; Candidiasis, Oral; Voice Disorders","metadata":null},{"id":"3537cd8b68674606b08a307ab8a7bf9a","type":"TRIAL","name":"Study to Assess the Influence of Three Different \u03b1-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02266537","description":"Healthy","metadata":null},{"id":"804955d2528547eab3878208fcceaea3","type":"TRIAL","name":"Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT02457559","description":"Relapsed/Refractory B-cell Malignancies","metadata":null},{"id":"ae58d5daa5fb4619b70b776815941b1e","type":"TRIAL","name":"Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy","canonical_id":"clinicaltrials.gov:NCT00464776","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"6c05b88caf844e0ba0fc2f21f9e3064e","type":"TRIAL","name":"Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03451110","description":"Healthy Subjects","metadata":null},{"id":"522477575f164ff286cd5eafdcee665f","type":"TRIAL","name":"Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)","canonical_id":"clinicaltrials.gov:NCT01376232","description":"Anaemia","metadata":null},{"id":"e1537a5666d442aaba0ef4676b5ccbc8","type":"TRIAL","name":"Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)","canonical_id":"clinicaltrials.gov:NCT03059303","description":"Healthy","metadata":null},{"id":"fa357a3147c94b39a4bae8114ba1ecdb","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry","canonical_id":"clinicaltrials.gov:NCT01646385","description":"Rheumatoid Arthritis","metadata":null},{"id":"b1ef950a390a41618e37e2c77eb5252c","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)","canonical_id":"clinicaltrials.gov:NCT01462370","description":"Dysmenorrhea","metadata":null},{"id":"ca8a91c3bfa94ec1963228a608e654cb","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands","canonical_id":"clinicaltrials.gov:NCT00115154","description":"Keratosis","metadata":null},{"id":"b4cd465e97374442934dd035bfeb3b2e","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa","canonical_id":"clinicaltrials.gov:NCT00795574","description":"Hidradenitis Suppurativa","metadata":null},{"id":"d276db641cec4f30ac2634cfee337164","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.","canonical_id":"clinicaltrials.gov:NCT03379727","description":"Acute Myeloid Leukemia","metadata":null},{"id":"dc43b09e0cc44ae1ae776bf078b6201a","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC","canonical_id":"clinicaltrials.gov:NCT02941926","description":"Breast Cancer","metadata":null},{"id":"ed0226e80c4145de8d70bbb82c542b9f","type":"TRIAL","name":"Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT05969223","description":"Genital Psoriasis; Scalp Psoriasis","metadata":null},{"id":"99bcecb597d64e87868216edeb1b9ef3","type":"TRIAL","name":"Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment","canonical_id":"clinicaltrials.gov:NCT01571999","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"3e4e284c8d184695a8b6dd96d4bca138","type":"TRIAL","name":"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","canonical_id":"clinicaltrials.gov:NCT01639040","description":"Atopic Dermatitis","metadata":null},{"id":"da41413731bd42dfadefd9359743574e","type":"TRIAL","name":"Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers","canonical_id":"clinicaltrials.gov:NCT02846142","description":"Healthy Volunteer","metadata":null},{"id":"0cb3d62fb49a4ecca9837a6a3404bdc5","type":"TRIAL","name":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age","canonical_id":"clinicaltrials.gov:NCT04188964","description":"X-linked Hypophosphatemia (XLH)","metadata":null},{"id":"f6b01099108544e5b67def81fb8fe4fc","type":"TRIAL","name":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","canonical_id":"clinicaltrials.gov:NCT01500278","description":"Rheumatoid Arthritis","metadata":null},{"id":"f2136a3e353a47c0a646c93ea3d52652","type":"TRIAL","name":"Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)","canonical_id":"clinicaltrials.gov:NCT07688980","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"ab8a70aa6c994f378eedb8d523c11da2","type":"TRIAL","name":"Study to Characterize the Effect of Heparin on Palifermin Activity","canonical_id":"clinicaltrials.gov:NCT01163097","description":"Oral Mucositis","metadata":null},{"id":"27cce7a6f19f4c51b520afc5b6b115fd","type":"TRIAL","name":"Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)","canonical_id":"clinicaltrials.gov:NCT00690612","description":"Hypertension","metadata":null},{"id":"949b417af79842199e9cabc196017421","type":"TRIAL","name":"Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed","canonical_id":"clinicaltrials.gov:NCT04307940","description":"Pain","metadata":null},{"id":"5b9e5944d6c34f62b08048909725ed18","type":"TRIAL","name":"Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants","canonical_id":"clinicaltrials.gov:NCT04991571","description":"Chronic Kidney Disease","metadata":null},{"id":"d05e2710ebf945fc9686ee42f0ac59cf","type":"TRIAL","name":"Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations","canonical_id":"clinicaltrials.gov:NCT01338896","description":"Parkinson's Disease","metadata":null},{"id":"77f8f233922a454ba880992259e4ca34","type":"TRIAL","name":"Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT01693289","description":"Focus of Study","metadata":null},{"id":"bbbacfbc26254151aaf2aa874c22305c","type":"TRIAL","name":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","canonical_id":"clinicaltrials.gov:NCT04529226","description":"Psychosis; Intellectual Disability","metadata":null},{"id":"c11095395ec04237a7914d6a745990da","type":"TRIAL","name":"Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function","canonical_id":"clinicaltrials.gov:NCT00887627","description":"Kidney Diseases; Hyponatremia","metadata":null},{"id":"4a53ff6886ef4cce98344064caa2fcdd","type":"TRIAL","name":"Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function","canonical_id":"clinicaltrials.gov:NCT00851227","description":"Liver Disease; Hyponatremia","metadata":null},{"id":"120b8bba28444d6e9b947851ae17b761","type":"TRIAL","name":"Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00413426","description":"Healthy","metadata":null},{"id":"bfb05cba3651488a93d9b293ccec1193","type":"TRIAL","name":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","canonical_id":"clinicaltrials.gov:NCT03272477","description":"Breast Neoplasms","metadata":null},{"id":"0fba25d1758d4018939d3dcb3bfca9a6","type":"TRIAL","name":"Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382","canonical_id":"clinicaltrials.gov:NCT03347968","description":"Healthy Volunteers","metadata":null},{"id":"7c25db4ccb3f4fca99165def6ed39dd5","type":"TRIAL","name":"Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT07200986","description":"Healthy Participants","metadata":null},{"id":"5ea6562e96d443358179ab39acaf37ee","type":"TRIAL","name":"Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf\u00ae PR Capsules in Stable Kidney Transplant Patients.","canonical_id":"clinicaltrials.gov:NCT03978494","description":"Kidney Transplant","metadata":null},{"id":"80b14934fd154599b95893beaf8aaf60","type":"TRIAL","name":"Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product","canonical_id":"clinicaltrials.gov:NCT05288075","description":"Healthy Volunteers","metadata":null},{"id":"44a9032c8d584a0f8b51dc0b2f3bee7e","type":"TRIAL","name":"Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04987203","description":"Renal Cell Carcinoma","metadata":null},{"id":"fce5a672cb5d46c4b42ca44602e7a64b","type":"TRIAL","name":"Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol","canonical_id":"clinicaltrials.gov:NCT00754039","description":"Hypercholesterolemia; Hyperlipidemia, Familial Combined","metadata":null},{"id":"5abcf5bc71f344c6bc80aac5e7dd1a1b","type":"TRIAL","name":"Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs","canonical_id":"clinicaltrials.gov:NCT03312517","description":"Insomnia","metadata":null},{"id":"a31dbd43272c47c9b742ac207c3ae457","type":"TRIAL","name":"Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse","canonical_id":"clinicaltrials.gov:NCT01986998","description":"Multiple Sclerosis","metadata":null},{"id":"2bdfbdf6a0f448d9abf3e376df022274","type":"TRIAL","name":"Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily","canonical_id":"clinicaltrials.gov:NCT00986245","description":"Parkinson Disease","metadata":null},{"id":"701063480a3a4d0a90cf4a520ac983d0","type":"TRIAL","name":"Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States","canonical_id":"clinicaltrials.gov:NCT00143026","description":"Parkinson's Disease","metadata":null},{"id":"8de6ad3a460c4166a8578d528ee4857e","type":"TRIAL","name":"Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects","canonical_id":"clinicaltrials.gov:NCT04511611","description":"Clinical Pharmacology","metadata":null},{"id":"305b87409c804aadbb095da5306036f2","type":"TRIAL","name":"Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany","canonical_id":"clinicaltrials.gov:NCT04444804","description":"Venous Thromboembolism","metadata":null},{"id":"b8551dacb3fc4931b8b16ab189e9b9e2","type":"TRIAL","name":"Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT00257686","description":"Hypercholesterolemia or Combined Dyslipidemia","metadata":null},{"id":"ae46cf4da7594f9eb4f8e344d45d6543","type":"TRIAL","name":"Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin","canonical_id":"clinicaltrials.gov:NCT00309777","description":"Hypercholesterolemia; Dyslipidemia","metadata":null},{"id":"ca731a054b3d45e6aada3aeb0f76e31c","type":"TRIAL","name":"Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","canonical_id":"clinicaltrials.gov:NCT02571777","description":"Asthma","metadata":null},{"id":"81f4c7842a814b6595dd8015818704dd","type":"TRIAL","name":"Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT05887843","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"efc73fd5ab404be1a3aef5da0827a503","type":"TRIAL","name":"Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects","canonical_id":"clinicaltrials.gov:NCT04829786","description":"FOP","metadata":null},{"id":"a9e21c22f4b7422da07f0672e54e5b28","type":"TRIAL","name":"Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants","canonical_id":"clinicaltrials.gov:NCT07726914","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"f83886df6cb4493d91c385b59bc185bc","type":"TRIAL","name":"Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs","canonical_id":"clinicaltrials.gov:NCT02548286","description":"Hypertension","metadata":null},{"id":"1c68f5c5f1b24107983b411ec06b7ee7","type":"TRIAL","name":"Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED","canonical_id":"clinicaltrials.gov:NCT00492635","description":"Erectile Dysfunction; Sexual Dysfunction, Physiological","metadata":null},{"id":"0fbc6dcdd9044e6a90df03f9b5ac77aa","type":"TRIAL","name":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel","canonical_id":"clinicaltrials.gov:NCT01891864","description":"Chronic Stable Plaque Psoriasis","metadata":null},{"id":"c93a201561e14af7a788d0ed0ca59d61","type":"TRIAL","name":"Study to Determine Effective Dosing of Fondaparinux in Obese Persons","canonical_id":"clinicaltrials.gov:NCT00346879","description":"Morbid Obesity","metadata":null},{"id":"36ca68d0eb1644f48668435836ab1c44","type":"TRIAL","name":"Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy","canonical_id":"clinicaltrials.gov:NCT03352076","description":"Endometriosis","metadata":null},{"id":"84d3318acee642f6975807f7a4f38773","type":"TRIAL","name":"Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib","canonical_id":"clinicaltrials.gov:NCT06717100","description":"Drug Interactions","metadata":null},{"id":"ab4624fe8da146938e5f18917f5516df","type":"TRIAL","name":"Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection","canonical_id":"clinicaltrials.gov:NCT00547352","description":"Impotence","metadata":null},{"id":"e05d8d9b93594737be727b15108e09b1","type":"TRIAL","name":"Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency","canonical_id":"clinicaltrials.gov:NCT02860507","description":"Neuromuscular Blockade","metadata":null},{"id":"0efe92a916774d0989bce9be9bff193e","type":"TRIAL","name":"Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment","canonical_id":"clinicaltrials.gov:NCT01298323","description":"Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer","metadata":null},{"id":"eae25ad16cd34917b0924521de2c2c8f","type":"TRIAL","name":"Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00721474","description":"Healthy Subjects","metadata":null},{"id":"9fa295c325ed42109ea5ece29a195ad5","type":"TRIAL","name":"Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","canonical_id":"clinicaltrials.gov:NCT03633617","description":"Eosinophilic Esophagitis","metadata":null},{"id":"91f7e3ce64c64e12ad56aa11d5e87a35","type":"TRIAL","name":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01631214","description":"Postmenopausal Women With Osteoporosis","metadata":null},{"id":"dc3bd70ea6fc4ff7abf8574909d11c96","type":"TRIAL","name":"Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly","canonical_id":"clinicaltrials.gov:NCT02396953","description":"Acromegaly","metadata":null},{"id":"182fd6d0b8ba4cbaa55fba7962f9bcf1","type":"TRIAL","name":"Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination","canonical_id":"clinicaltrials.gov:NCT02064504","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"4055088ee4bc4aa98a3c3dc1c08f71e8","type":"TRIAL","name":"Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)","canonical_id":"clinicaltrials.gov:NCT00941863","description":"Carcinoma","metadata":null},{"id":"30da98c7dce24e538535f40ece89b1fa","type":"TRIAL","name":"Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate","canonical_id":"clinicaltrials.gov:NCT00551564","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"b38bab8fc273415eb71f62f8e31ff005","type":"TRIAL","name":"Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi","canonical_id":"clinicaltrials.gov:NCT05126342","description":"Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Primary Peritoneal Cancer","metadata":null},{"id":"970b983ecce042c392ba5cb7e77f8fef","type":"TRIAL","name":"Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation","canonical_id":"clinicaltrials.gov:NCT03072589","description":"Lung Transplant","metadata":null},{"id":"1f0f89d6c10b4891a03857b87e318610","type":"TRIAL","name":"Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo","canonical_id":"clinicaltrials.gov:NCT04927975","description":"Non-Segmental Vitiligo","metadata":null},{"id":"ae013a7e027a46bfbbc52efb5065df64","type":"TRIAL","name":"Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977","canonical_id":"clinicaltrials.gov:NCT04862286","description":"Psoriasis","metadata":null},{"id":"5c281d02b49b409fba339a60b628394f","type":"TRIAL","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","canonical_id":"clinicaltrials.gov:NCT05822752","description":"Hepatocellular Carcinoma","metadata":null},{"id":"0443ed0fc23f4bf9be62ba7b65078074","type":"TRIAL","name":"Study to Evaluate Broadlumab vs Placebo and Ustekinumab","canonical_id":"clinicaltrials.gov:NCT02786732","description":"Psoriasis","metadata":null},{"id":"58a454b010fa45a0b541d46f9fa31dfa","type":"TRIAL","name":"Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine","canonical_id":"clinicaltrials.gov:NCT02016261","description":"Recurrent Depressive Disorder","metadata":null},{"id":"f97d429a58e3419f865aa21088003f5a","type":"TRIAL","name":"Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females","canonical_id":"clinicaltrials.gov:NCT00745901","description":"Contraception","metadata":null},{"id":"98516866b5d44e1a91efefc4c4618ce6","type":"TRIAL","name":"Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib","canonical_id":"clinicaltrials.gov:NCT04526704","description":"Tenosynovial Giant Cell Tumor","metadata":null},{"id":"1952fb0b52fa42d6be8c84534e79447c","type":"TRIAL","name":"Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)","canonical_id":"clinicaltrials.gov:NCT01813513","description":"Chronic Hepatitis C Infection","metadata":null},{"id":"9c505c1c9d2341d295c87f443f4f19b8","type":"TRIAL","name":"Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01766050","description":"Transplant Rejection","metadata":null},{"id":"d15d97e9f36c40b58e7837833f208a65","type":"TRIAL","name":"Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass","canonical_id":"clinicaltrials.gov:NCT01604057","description":"Osteoporosis; Osteopenia","metadata":null},{"id":"9ea7351a1d2846c6abf3abbec521edbe","type":"TRIAL","name":"Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease","canonical_id":"clinicaltrials.gov:NCT02581124","description":"Anemia of Chronic Kidney Disease","metadata":null},{"id":"1fd7e6940b4148c88f4334afe15c94fd","type":"TRIAL","name":"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03296800","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"5ecd52995108433e81b3cee8efbe7e63","type":"TRIAL","name":"Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids","canonical_id":"clinicaltrials.gov:NCT02449473","description":"Asthma","metadata":null},{"id":"3f12fbd7b7cf46afa7aa4f59f63751b9","type":"TRIAL","name":"Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients","canonical_id":"clinicaltrials.gov:NCT02105948","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"d0ee7099ddd646fa9e26a5b712d4ddc5","type":"TRIAL","name":"Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)","canonical_id":"clinicaltrials.gov:NCT03055234","description":"Pulmonary Hypertension Associated With Sickle Cell Disease","metadata":null},{"id":"b7219b258fee4886b9b176d8f5cdd7d1","type":"TRIAL","name":"Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta","canonical_id":"clinicaltrials.gov:NCT05972551","description":"Osteogenesis Imperfecta","metadata":null},{"id":"0d48bb52857142bca73968ff6b30acaa","type":"TRIAL","name":"Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04659382","description":"Metastatic Colorectal Cancer; pMMR; MSS; Immune Checkpoint Inhibitor; Internal Radiotherapy","metadata":null},{"id":"c5e8a8cc80fe44d6ac057eb2811eb96b","type":"TRIAL","name":"Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","canonical_id":"clinicaltrials.gov:NCT05274815","description":"Asthma","metadata":null},{"id":"8448b541e248412da372fa126724632f","type":"TRIAL","name":"Study to Evaluate Efficacy of Micardis\u00ae (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring","canonical_id":"clinicaltrials.gov:NCT02242318","description":"Hypertension","metadata":null},{"id":"8df807b7164c43d5a41fa94f95e0b8be","type":"TRIAL","name":"Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients","canonical_id":"clinicaltrials.gov:NCT02796261","description":"Anaplastic Astrocytoma; Recurrent Anaplastic Astrocytoma","metadata":null},{"id":"685b1d0684b9479a962a6d50f15ad732","type":"TRIAL","name":"Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT01232400","description":"Subarachnoid Hemorrhage","metadata":null},{"id":"c97ecf456f70499c9d9fd25c0386e4a2","type":"TRIAL","name":"Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT03038880","description":"Neovascularization, Choroidal; Macular Degeneration, Age-Related","metadata":null},{"id":"3f6305ff55384aa38b052fee9815438c","type":"TRIAL","name":"Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT\u00ae Triple Action in Healthy Volunteers With Sleep Disorders","canonical_id":"clinicaltrials.gov:NCT03514732","description":"Sleep Disorder (Healthy Volunteers)","metadata":null},{"id":"2e235986793a4ae9a26168af2e85f14f","type":"TRIAL","name":"Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab","canonical_id":"clinicaltrials.gov:NCT00891930","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"760a9a3a0c2940beaa8e4d6aa5b473c8","type":"TRIAL","name":"Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response","canonical_id":"clinicaltrials.gov:NCT01043874","description":"Philadelphia Chromosome Positive; Chronic Myelogenous Leukemia in Chronic Phase","metadata":null},{"id":"d7b1607f72de4145968b7bdda6616721","type":"TRIAL","name":"Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT04608344","description":"Rheumatoid Arthritis","metadata":null},{"id":"6f3470445d1e482db70f593bab207cf8","type":"TRIAL","name":"Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause","canonical_id":"clinicaltrials.gov:NCT02638337","description":"Vaginal Dryness","metadata":null},{"id":"f98ce89c75354cdd964fabefbf527dba","type":"TRIAL","name":"Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02684318","description":"Advanced Cancer; Ovarian Cancer; Endometrial Cancer; Breast Cancer","metadata":null},{"id":"cea15c9054f8455485bcf61295fadf46","type":"TRIAL","name":"Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT00094861","description":"Dysphagia; Non-Small Cell Lung Cancer; Lung Cancer","metadata":null},{"id":"646602619953429fb4678c34c2163ca1","type":"TRIAL","name":"Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta","canonical_id":"clinicaltrials.gov:NCT04545554","description":"Osteogenesis Imperfecta","metadata":null},{"id":"951c44ec0d5b4d60a578ffeb3d35728a","type":"TRIAL","name":"Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine","canonical_id":"clinicaltrials.gov:NCT04164758","description":"Parkinson's Disease","metadata":null},{"id":"b007518c0c304b8b807bac787eea3a34","type":"TRIAL","name":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","canonical_id":"clinicaltrials.gov:NCT03199053","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"0d2b60abfb674372995876a09b11c216","type":"TRIAL","name":"Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome","canonical_id":"clinicaltrials.gov:NCT02101138","description":"Hypereosinophilic Syndrome","metadata":null},{"id":"0cb307b00e1540ec840498e1173f8e39","type":"TRIAL","name":"Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT02905006","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"68b414c6cd544f9b8fd387c67a06faa9","type":"TRIAL","name":"Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)","canonical_id":"clinicaltrials.gov:NCT03134222","description":"Cutaneous Lupus Erythematosus","metadata":null},{"id":"10a9a290cbfa44e3aacbfdc0356c479a","type":"TRIAL","name":"Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT02626026","description":"Rheumatoid Arthritis","metadata":null},{"id":"d8f60cd098fb4955b2e710be7472937b","type":"TRIAL","name":"Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi","canonical_id":"clinicaltrials.gov:NCT02639910","description":"Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"daedef79d24441f1a486abf88dcfc58a","type":"TRIAL","name":"Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab","canonical_id":"clinicaltrials.gov:NCT05877963","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"4a35164e48514a7281356caf7c552df5","type":"TRIAL","name":"Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis","canonical_id":"clinicaltrials.gov:NCT00828464","description":"Hand Dermatosis","metadata":null},{"id":"22dd1ad59c73475e80d025b47d5862e2","type":"TRIAL","name":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","canonical_id":"clinicaltrials.gov:NCT03382977","description":"Glioblastoma Multiforme","metadata":null},{"id":"ce35ac1005474a18ba7401d8d4c16da7","type":"TRIAL","name":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease","canonical_id":"clinicaltrials.gov:NCT02436135","description":"Myelofibrosis","metadata":null},{"id":"e9d9cbcde46444c8a5a8669637a3e02d","type":"TRIAL","name":"Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT02242045","description":"Chronic Lymphocytic Leukemia; Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia); Marginal Zone Lymphoma","metadata":null},{"id":"69ec94494b7d4eac9e611ed15753baac","type":"TRIAL","name":"Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function","canonical_id":"clinicaltrials.gov:NCT02647918","description":"Renal Impairment; Healthy","metadata":null},{"id":"4b41bda4e2d64e65ae59cc0de69b5b6a","type":"TRIAL","name":"Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT03347279","description":"Asthma","metadata":null},{"id":"74ef5a66433747cc87bb1373ad4b54ca","type":"TRIAL","name":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","canonical_id":"clinicaltrials.gov:NCT04833855","description":"Chronic Spontaneous Urticaria","metadata":null},{"id":"2df7cfc680b44688a9ddd8cccb53b65b","type":"TRIAL","name":"Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma","canonical_id":"clinicaltrials.gov:NCT03927157","description":"Asthma","metadata":null},{"id":"90486d799142486e9e651252adfb6909","type":"TRIAL","name":"Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)","canonical_id":"clinicaltrials.gov:NCT03688074","description":"Asthma; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases","metadata":null},{"id":"c8955a73999040f9962468e6922b478b","type":"TRIAL","name":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04882163","description":"Lymphoma, B-Cell","metadata":null},{"id":"36383b84a27741d9acec08d329a1dfbb","type":"TRIAL","name":"Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction","canonical_id":"clinicaltrials.gov:NCT00245258","description":"Impotence","metadata":null},{"id":"20fbe62e79bc4630b68709e2496ee610","type":"TRIAL","name":"Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder","canonical_id":"clinicaltrials.gov:NCT05303064","description":"Schizophrenia; Bipolar I Disorder","metadata":null},{"id":"c6fe254127684ff89842bbd4f9c106cb","type":"TRIAL","name":"Study to Evaluate an Aflibercept (EYLEA\u00ae) Prefilled Syringe","canonical_id":"clinicaltrials.gov:NCT03767738","description":"Chorioretinal Vascular Disease","metadata":null},{"id":"54520d24ea6a4e90b32e6038da296438","type":"TRIAL","name":"Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.","canonical_id":"clinicaltrials.gov:NCT04936984","description":"Osteoporosis","metadata":null},{"id":"6e3c43f27e1a4096841b24c1e6f12edd","type":"TRIAL","name":"Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.","canonical_id":"clinicaltrials.gov:NCT04663464","description":"Healthy Volunteers","metadata":null},{"id":"063f6c09335e4ffca7f4f957263c4488","type":"TRIAL","name":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","canonical_id":"clinicaltrials.gov:NCT04601441","description":"Metastatic Castration-sensitive Prostate Cancer","metadata":null},{"id":"09fc8c6db0f2449da0e30c4fb0305bb3","type":"TRIAL","name":"Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline","canonical_id":"clinicaltrials.gov:NCT02115256","description":"External Cephalic Version","metadata":null},{"id":"99571185c446495f9c8a8a70bda730d2","type":"TRIAL","name":"Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users","canonical_id":"clinicaltrials.gov:NCT03657355","description":"Healthy Recreational Drug Users","metadata":null},{"id":"40fdd1eae74747b5888e240a7e351c19","type":"TRIAL","name":"Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01056276","description":"Multiple Myeloma","metadata":null},{"id":"d189c15e239148f3a678f53e988aa005","type":"TRIAL","name":"Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose","canonical_id":"clinicaltrials.gov:NCT01869686","description":"Healthy Volunteer","metadata":null},{"id":"2383ddcab8664e56808760b9225abfb4","type":"TRIAL","name":"Study to Evaluate the Effect Single and Multiple Oral Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT02256878","description":"Healthy","metadata":null},{"id":"4c1e93f076864a0c9d1e418b664ebdb4","type":"TRIAL","name":"Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder","canonical_id":"clinicaltrials.gov:NCT02350309","description":"Insomnia Disorder","metadata":null},{"id":"4d41cde2a54b4f2bbcdb26b52026f30f","type":"TRIAL","name":"Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02979548","description":"Chemotherapy Induced Vomiting; Acute Myeloid Leukemia","metadata":null},{"id":"8971bc3df5464388bd43082ade4ad284","type":"TRIAL","name":"Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT03036124","description":"Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","metadata":null},{"id":"0b6f75758c104436893d599c8a0e3b85","type":"TRIAL","name":"Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02947711","description":"Healthy Subjects","metadata":null},{"id":"d9ad3c8e50a0489aa8a6b048c8eb30f4","type":"TRIAL","name":"Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan","canonical_id":"clinicaltrials.gov:NCT02741310","description":"Healthy Subjects","metadata":null},{"id":"31f173b8a8594c67aaf511444c27a5ca","type":"TRIAL","name":"Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis","canonical_id":"clinicaltrials.gov:NCT03926195","description":"Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Non-Radiographical Axial Spondyloarthritis","metadata":null},{"id":"e7c720d5f2bd4aee972b7d7571bf1689","type":"TRIAL","name":"Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects","canonical_id":"clinicaltrials.gov:NCT02583451","description":"Healthy Participants","metadata":null},{"id":"81cda90c699847bbb9dc357cd3c4f283","type":"TRIAL","name":"Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03439943","description":"Parkinson Disease","metadata":null},{"id":"52773c521269426d834be27b1b2ad9c8","type":"TRIAL","name":"Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02256813","description":"Healthy","metadata":null},{"id":"24aae0dcc4974471b910efbaef8c1af3","type":"TRIAL","name":"Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide","canonical_id":"clinicaltrials.gov:NCT05097716","description":"Healthy Volunteers","metadata":null},{"id":"cca385875f7241e387612f839813f1f0","type":"TRIAL","name":"Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02745912","description":"Healthy Subjects","metadata":null},{"id":"05d6ae041d5f47e78c54cf172ee7f054","type":"TRIAL","name":"Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma","canonical_id":"clinicaltrials.gov:NCT00267202","description":"Allergic Asthma","metadata":null},{"id":"7a01d548f56f456e9dea5e6fe16e1af0","type":"TRIAL","name":"Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006","canonical_id":"clinicaltrials.gov:NCT00119639","description":"Kidney Diseases","metadata":null},{"id":"73ab31bec90245a187a8ccdaafe420e9","type":"TRIAL","name":"Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.","canonical_id":"clinicaltrials.gov:NCT00720577","description":"Peripheral Arterial Disease","metadata":null},{"id":"9256215262eb42b698aa63fd2e31eea2","type":"TRIAL","name":"Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02169713","description":"Healthy Subjects; Pharmacokinetics; Drug-Drug Interaction (DDI)","metadata":null},{"id":"dea8c28744f543de9449c02ca812abd3","type":"TRIAL","name":"Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers","canonical_id":"clinicaltrials.gov:NCT02030535","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"c95438d69d244b2ca4b77d12ac1fe3ee","type":"TRIAL","name":"Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT06408259","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"9a0b1e043d1e446eb95cc5904d9e751c","type":"TRIAL","name":"Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants","canonical_id":"clinicaltrials.gov:NCT02816853","description":"Healthy","metadata":null},{"id":"ffc0a0f2b845479d99c57c8e9410206d","type":"TRIAL","name":"Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00950820","description":"Colorectal Neoplasms","metadata":null},{"id":"e322ed1bf4794532b1596f304016bd44","type":"TRIAL","name":"Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00889343","description":"Colorectal Neoplasms","metadata":null},{"id":"f3ef0dc2737c4028af1b0f12f596acbf","type":"TRIAL","name":"Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)","canonical_id":"clinicaltrials.gov:NCT02609048","description":"Primary Biliary Cirrhosis (PBC)","metadata":null},{"id":"5ae373f291c34b18af5d2fe6addb420b","type":"TRIAL","name":"Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02820298","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"8d979ba88cf54fe39d5997ab6422404c","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)","canonical_id":"clinicaltrials.gov:NCT03018340","description":"Adjunctive Treatment of Major Depressive Disorder","metadata":null},{"id":"45761cd80a0040249206ef04a1a703ae","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Belviq XR\u00ae in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years","canonical_id":"clinicaltrials.gov:NCT03338296","description":"Obesity","metadata":null},{"id":"1115d1fbc4c147b9a473e0434af60a2f","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor","canonical_id":"clinicaltrials.gov:NCT04346381","description":"Solid Tumor","metadata":null},{"id":"c817719d11de404ca980e582870be4c1","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT05038449","description":"Covid19; Colchicine","metadata":null},{"id":"e09e651efa3543eea1abeecf50cd891b","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07133308","description":"Alopecia Areata","metadata":null},{"id":"38d3d24a38694c4da76b8277bd92ea5d","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT07617597","description":"Alopecia Areata","metadata":null},{"id":"9157a2a88cbc42fc9c8a36ce31e4691e","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","canonical_id":"clinicaltrials.gov:NCT01952574","description":"Migraine","metadata":null},{"id":"11f00d56006f4dbf8bc48b126f278dde","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","canonical_id":"clinicaltrials.gov:NCT02456740","description":"Migraine","metadata":null},{"id":"e6c7e61fd38c46d6a4840c87da5a3593","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02481050","description":"Breast Cancer","metadata":null},{"id":"2c0380b72192434eb8616445991cbf39","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","canonical_id":"clinicaltrials.gov:NCT04586023","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"a3a65d25e588450a9777010974141ff6","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis","canonical_id":"clinicaltrials.gov:NCT03207815","description":"Noninfectious Uveitis","metadata":null},{"id":"7b4e2b9e2e1c46eb9d0312b2e080876c","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy","canonical_id":"clinicaltrials.gov:NCT04483687","description":"Ankylosing Spondylitis","metadata":null},{"id":"9c5d8e44972c4eb89d3d359f7ca25b37","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy","canonical_id":"clinicaltrials.gov:NCT04115748","description":"Psoriatic Arthritis","metadata":null},{"id":"08b1e44aafb54585ad34fa1529c528e7","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy","canonical_id":"clinicaltrials.gov:NCT04115839","description":"Psoriatic Arthritis","metadata":null},{"id":"e9f8af991887448b8ec92c49ddbfe854","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT03077412","description":"Fistulizing Crohn's Disease","metadata":null},{"id":"542bad8d118f44a08a1bb89002c946ca","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)","canonical_id":"clinicaltrials.gov:NCT03046056","description":"Small Bowel Crohn's Disease","metadata":null},{"id":"d95528f387534e3fab41e4ef6dbf5ca2","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","canonical_id":"clinicaltrials.gov:NCT01985334","description":"COPD","metadata":null},{"id":"8179b56534b04e9b937a89d4a744d03e","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","canonical_id":"clinicaltrials.gov:NCT03894046","description":"Acinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia; Colistin Resistant ABC","metadata":null},{"id":"ec82e0d9534d403f985588be0b6195a7","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT06495918","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"b3b08bfe456944e886d3f41b0d680b47","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment","canonical_id":"clinicaltrials.gov:NCT03011450","description":"Severe Hypertriglyceridemia","metadata":null},{"id":"9c9be0303a0741d286906470eea36fdd","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT04699461","description":"Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma","metadata":null},{"id":"759a442d43d049ea90fadbb6f77d34bf","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma\u00ae) in Early HER2-positive Breast Cancer in Routine Clinical Practice","canonical_id":"clinicaltrials.gov:NCT06907082","description":"Breast Cancer","metadata":null},{"id":"dd7907ba0ac34e4f9775b37e34b041f1","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04018027","description":"Pruritus; Atopic Dermatitis","metadata":null},{"id":"20a0e810a2014c83af1d34ce25bc536e","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)","canonical_id":"clinicaltrials.gov:NCT04706975","description":"Pruritus; Notalgia Paresthetica","metadata":null},{"id":"e737ff2337d349a897c5a9ba10fdc6c1","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05387707","description":"Pruritus; Atopic Dermatitis","metadata":null},{"id":"45dd24a97b7d4a5095dac56758464c77","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica","canonical_id":"clinicaltrials.gov:NCT05978063","description":"Pruritus; Notalgia Paresthetica","metadata":null},{"id":"0fa6ed9fc0cb4b99b9435eafe779e320","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia","canonical_id":"clinicaltrials.gov:NCT03004469","description":"Alopecia, Androgenetic","metadata":null},{"id":"26c12b72bfa349f7860c9def505fe7e3","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)","canonical_id":"clinicaltrials.gov:NCT02853331","description":"Renal Cell Carcinoma","metadata":null},{"id":"c37f978bce5f4cc49aec3be3ed16e477","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT07686081","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"081aba4d847748b493881505eb2aea46","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma","canonical_id":"clinicaltrials.gov:NCT01508936","description":"Eosinophilic Asthma","metadata":null},{"id":"2ce5dfe2be6c422b8be3069c143d11e2","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","canonical_id":"clinicaltrials.gov:NCT01278342","description":"Acromegaly","metadata":null},{"id":"4d63e31e4f0d4f2cafefd06cf50fd979","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1","canonical_id":"clinicaltrials.gov:NCT06222827","description":"Facioscapulohumeral Muscular Dystrophy 1","metadata":null},{"id":"2df40aa7a20942ca8bfe0977bae28c62","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","canonical_id":"clinicaltrials.gov:NCT02284893","description":"Type 2 Diabetes","metadata":null},{"id":"0cac183d1feb457a92216e4b4427f277","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes","canonical_id":"clinicaltrials.gov:NCT05979415","description":"Parkinson Disease","metadata":null},{"id":"abdf5ea86a664669a54dd06d89c73b4a","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy","canonical_id":"clinicaltrials.gov:NCT00859001","description":"Follicular Lymphoma","metadata":null},{"id":"72df1846000d4da08b294c9c2bfa2ae5","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT06041529","description":"Essential Hypertension","metadata":null},{"id":"3ab6dc6c888c43479081639945defabb","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT06282549","description":"Essential Hypertension","metadata":null},{"id":"6f4a1ebfa6f943a18e2699b495f1ddcb","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma","canonical_id":"clinicaltrials.gov:NCT03406078","description":"Asthma","metadata":null},{"id":"924e3be1e0e741dc88971b4b01ac8ce2","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","canonical_id":"clinicaltrials.gov:NCT04345445","description":"COVID-19","metadata":null},{"id":"ed05ac2157164c909bbec0fc51faaa4b","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT01108341","description":"Non-Hodgkin's Lymphoma (NHL)","metadata":null},{"id":"e3615c3257c5410398265a6084db8fe2","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT03806127","description":"Irritable Bowel Syndrome","metadata":null},{"id":"7e371a2251a2449d83285fbb6e172a2e","type":"TRIAL","name":"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","canonical_id":"clinicaltrials.gov:NCT01926782","description":"Hypercholesterolemia","metadata":null},{"id":"5f3fbab20bda4f75be9ae22e9e0f79fd","type":"TRIAL","name":"Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder","canonical_id":"clinicaltrials.gov:NCT03187769","description":"Schizophrenia; Schizophreniform Disorders; Bipolar I Disorder","metadata":null},{"id":"4454cd0b608342299ee71196d299586f","type":"TRIAL","name":"Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints","canonical_id":"clinicaltrials.gov:NCT00296894","description":"Erosive Osteo-Arthritis","metadata":null},{"id":"e46711d33e1c4945a2e14ce0c161db96","type":"TRIAL","name":"Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis","canonical_id":"clinicaltrials.gov:NCT00301002","description":"Psoriasis; Palmoplantaris Pustulosis; Pustular Psoriasis of Palms and Soles; Pustulosis Palmaris et Plantaris; Pustulosis of Palms and Soles","metadata":null},{"id":"ac1cbb087fbf40ba8a11d3fad4cdc8f8","type":"TRIAL","name":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03635021","description":"Colorectal Cancer","metadata":null},{"id":"73f901fc53c946b8aa1a24825ae052a2","type":"TRIAL","name":"Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy","canonical_id":"clinicaltrials.gov:NCT01631994","description":"Gastric Transit Time","metadata":null},{"id":"6a386671d44b43d0afeab1879148d19c","type":"TRIAL","name":"Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer","canonical_id":"clinicaltrials.gov:NCT01038154","description":"Esophageal Cancer; Stomach Cancer","metadata":null},{"id":"b4fbbf1f8e8b4017ae1a25af06b568aa","type":"TRIAL","name":"Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery","canonical_id":"clinicaltrials.gov:NCT00763685","description":"Pain","metadata":null},{"id":"b5319d98652b4e5f8c2707136806db7c","type":"TRIAL","name":"Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow","canonical_id":"clinicaltrials.gov:NCT01525043","description":"Epicondylitis of the Elbow","metadata":null},{"id":"72f03eb1e2c54f0d8cd416da4a170be0","type":"TRIAL","name":"Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT02191397","description":"Depressive Disorder, Major","metadata":null},{"id":"cbbd2d8b598f4e1c900179bbf484fb57","type":"TRIAL","name":"Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)","canonical_id":"clinicaltrials.gov:NCT03902080","description":"Overactive Bladder","metadata":null},{"id":"2bfb6b178ca94b618d40c5f2d5442146","type":"TRIAL","name":"Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT05987423","description":"Thyroid Eye Disease; TED","metadata":null},{"id":"40e184746790416b9a3d265c36bd2326","type":"TRIAL","name":"Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria","canonical_id":"clinicaltrials.gov:NCT04827589","description":"Chronic Spontaneous Urticaria","metadata":null},{"id":"a52851f12b804a188648bc27a84af274","type":"TRIAL","name":"Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia","canonical_id":"clinicaltrials.gov:NCT05654870","description":"Schizophrenia","metadata":null},{"id":"deac257ba9694b6ab9ed1461277fe00a","type":"TRIAL","name":"Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients","canonical_id":"clinicaltrials.gov:NCT01767493","description":"Multiple Sclerosis","metadata":null},{"id":"6f59327f539a4a8cb5e329cd881098ea","type":"TRIAL","name":"Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis","canonical_id":"clinicaltrials.gov:NCT00493324","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"1ce3ac9909b840ee9ff2427b0321f8d0","type":"TRIAL","name":"Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson\u00b4s Subject Symptoms Management","canonical_id":"clinicaltrials.gov:NCT03103919","description":"Parkinson\u00b4s Disease","metadata":null},{"id":"39d5f99b71d4441a821a0545b5fe545c","type":"TRIAL","name":"Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00770900","description":"Asthma","metadata":null},{"id":"03bb31ecc793415fb578e53605fff9ba","type":"TRIAL","name":"Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)","canonical_id":"clinicaltrials.gov:NCT04654312","description":"Photosensitivity","metadata":null},{"id":"03b4671fd64c4df98d35f1b3c2d7106f","type":"TRIAL","name":"Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain","canonical_id":"clinicaltrials.gov:NCT01760954","description":"Endometriosis","metadata":null},{"id":"f6be513e90f845469bb4f5a07f06e650","type":"TRIAL","name":"Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time","canonical_id":"clinicaltrials.gov:NCT01223365","description":"Chronic Pain","metadata":null},{"id":"60e33562e14447a6b34bedc9bc8820cb","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)","canonical_id":"clinicaltrials.gov:NCT04366726","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"9fed6a73cde4443dbe5c2e833f664195","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment","canonical_id":"clinicaltrials.gov:NCT07036133","description":"Advanced Solid Tumors; Hematologic Malignancies","metadata":null},{"id":"0f4e0c30fe534bb29363d24f1dc2dde1","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03440424","description":"Hepatic Impairment","metadata":null},{"id":"6d4202d2b5b24518b44dec4bfe229810","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment","canonical_id":"clinicaltrials.gov:NCT03443063","description":"Renal Impairment","metadata":null},{"id":"b9113e1826f5415e984c4dec0b6371e3","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension","canonical_id":"clinicaltrials.gov:NCT05562362","description":"Healthy Subjects","metadata":null},{"id":"25dc3fb2ea58438da19fcdf1c9a119dc","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety","canonical_id":"clinicaltrials.gov:NCT01820143","description":"Healthy; Pharmacokinetics; Pharmacodynamics; Ilaprazole","metadata":null},{"id":"d92e8d27e70940e9a68b7ecdb9f31ae3","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD","canonical_id":"clinicaltrials.gov:NCT07222553","description":"Immunoglobulin G4-related Disease","metadata":null},{"id":"58e2036a2cb84327b6e9bd201df3133f","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT01675024","description":"Healthy","metadata":null},{"id":"2361a598025a4943908615e2ef54be8b","type":"TRIAL","name":"Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03369002","description":"Hepatic Impairment","metadata":null},{"id":"8c8ce559f0464b309c6e88919e1ab6b1","type":"TRIAL","name":"Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00930865","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"bc76f73efc43479790ca7867f7b80878","type":"TRIAL","name":"Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants","canonical_id":"clinicaltrials.gov:NCT04978298","description":"Healthy Volunteers","metadata":null},{"id":"415dc4148d3c47119e8f17bfabc96e36","type":"TRIAL","name":"Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)","canonical_id":"clinicaltrials.gov:NCT04160546","description":"Chronic Myeloid Leukemia, Chronic Phase","metadata":null},{"id":"e9a9614cceae4ab9bc2f46a34d28356a","type":"TRIAL","name":"Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users","canonical_id":"clinicaltrials.gov:NCT01987739","description":"Abuse Potential Study","metadata":null},{"id":"9befa987c5de4ac8b5bfbc3ed340229b","type":"TRIAL","name":"Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT05567029","description":"Healthy Volunteers","metadata":null},{"id":"ac6429f2f96d40ceb0cc32536fe50f57","type":"TRIAL","name":"Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT03471871","description":"Obstructive Sleep Apnea; Healthy Subjects","metadata":null},{"id":"8c215cdd514749fe9f8a2f2b349cfc69","type":"TRIAL","name":"Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin\u2122 Treatment in Subjects With Phenylketonuria","canonical_id":"clinicaltrials.gov:NCT00104260","description":"Phenylketonurias","metadata":null},{"id":"9fa4ae25a29c415db37b5a799af2539e","type":"TRIAL","name":"Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy","canonical_id":"clinicaltrials.gov:NCT04975555","description":"Cytokine Release Syndrome; ICANS; Lymphoma, Non-Hodgkin; Multiple Myeloma; Acute Lymphoblastic Leukemia","metadata":null},{"id":"b41eefa211974e038ac711f8493f5f8d","type":"TRIAL","name":"Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals","canonical_id":"clinicaltrials.gov:NCT02616874","description":"HIV","metadata":null},{"id":"68dadbf0d7f94f7181e960f52c544684","type":"TRIAL","name":"Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)","canonical_id":"clinicaltrials.gov:NCT05269966","description":"Neovascular Age-related Macular Degeneration (nAMD)","metadata":null},{"id":"21c04aa88f574b949bc1dc33df88091d","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT00832585","description":"Atopic Dermatitis","metadata":null},{"id":"6445ae3515984670b683816d4687561a","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)","canonical_id":"clinicaltrials.gov:NCT03285711","description":"Lupus Membranous Nephropathy","metadata":null},{"id":"ef4353f8eb4842ac82b72bea87aead62","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT00880490","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"93f99124945f4d7e83e811dae91280a2","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain","canonical_id":"clinicaltrials.gov:NCT01122030","description":"Opioid Induced Bowel Dysfunction","metadata":null},{"id":"17ee6ed32a364867b9ad39435f4a19d1","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT05102149","description":"Type 2 Diabetes Mellitus (T2DM)","metadata":null},{"id":"552d84d3cf3a49a3be2bab34202ae7bd","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin","canonical_id":"clinicaltrials.gov:NCT01214577","description":"Photo-damage","metadata":null},{"id":"a93065aa1b534bfaaa8d5f3b710aa60b","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis","canonical_id":"clinicaltrials.gov:NCT01214564","description":"Seborrheic Keratosis","metadata":null},{"id":"3afafe4c4bd04767995d9ec4d77ba80b","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Phenoptin\u2122 in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels","canonical_id":"clinicaltrials.gov:NCT00104247","description":"Phenylketonurias","metadata":null},{"id":"3f4ebbcbddd34d089155eef0cd8aeec7","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT05751629","description":"Ovarian Neoplasm","metadata":null},{"id":"3ff531c7535448c0bf294a00bc8e078b","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","canonical_id":"clinicaltrials.gov:NCT05429268","description":"Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"7e8d5eb9630a4316b9c5390de9fab42e","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma","canonical_id":"clinicaltrials.gov:NCT06561321","description":"Palmoplantar Keratoderma","metadata":null},{"id":"64523f143c4c4223920489e4c7eae272","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT02065622","description":"Ulcerative Colitis (UC)","metadata":null},{"id":"5121ece2a9b84e0b922e515af1c23dd9","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT07680946","description":"Schizophrenia","metadata":null},{"id":"5ed9f54b6fad40b68f4affdac6cb7ff7","type":"TRIAL","name":"Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT02968563","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"3a102dfc221e4c36a23ce1083fc416b4","type":"TRIAL","name":"Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients","canonical_id":"clinicaltrials.gov:NCT00203164","description":"Parkinson's Disease","metadata":null},{"id":"c8e8535adf5a4042a9b902c04dd05615","type":"TRIAL","name":"Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL","canonical_id":"clinicaltrials.gov:NCT01659255","description":"Non Hodgkins Lymphoma; Chronic Lymphocytic Leukaemia","metadata":null},{"id":"5ff033206e2c4184b035cb9f10ade0b5","type":"TRIAL","name":"Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","canonical_id":"clinicaltrials.gov:NCT01803321","description":"Systemic Juvenile Idiopathic Arthritis","metadata":null},{"id":"4623b1bef07440ce948cfc86e58c7dfb","type":"TRIAL","name":"Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT00783432","description":"Chronic Allergic Rhinitis; Nonallergic Rhinitis","metadata":null},{"id":"3ea2579e11b44544af85c4dbec43116b","type":"TRIAL","name":"Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT06132035","description":"Age-related Wet Macular Degeneration","metadata":null},{"id":"a37c14757d3e4f02adf676adfececf17","type":"TRIAL","name":"Study to Evaluate the Safety of Colchicine","canonical_id":"clinicaltrials.gov:NCT05335148","description":"Radiation Therapy","metadata":null},{"id":"486385aaf3c5430c9fd820c249fbbd07","type":"TRIAL","name":"Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00162851","description":"B-CLL","metadata":null},{"id":"2a53d43efef34eb782f23d40146c69b7","type":"TRIAL","name":"Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)","canonical_id":"clinicaltrials.gov:NCT02340819","description":"Short Bowel Syndrome","metadata":null},{"id":"2c1b2e22b7cf43768d4252d2d8a32cf6","type":"TRIAL","name":"Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00771030","description":"Rheumatoid Arthritis","metadata":null},{"id":"4c2ef72845a84b61bfaa29a27b4f79ee","type":"TRIAL","name":"Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02028780","description":"Healthy","metadata":null},{"id":"5ce83dadb7e84fb1acb2a64aca87cf53","type":"TRIAL","name":"Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.","canonical_id":"clinicaltrials.gov:NCT05931484","description":"Parkinson Disease","metadata":null},{"id":"b3f5e0a7bd6e4a7991906bc41b0b5715","type":"TRIAL","name":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05162131","description":"Healthy","metadata":null},{"id":"6dfc6f9069c64c4db40e24fa3963a080","type":"TRIAL","name":"Study to Evaluate the Safety, Tolerability, and PK of Pacritinib","canonical_id":"clinicaltrials.gov:NCT05552183","description":"Hepatic Impairment","metadata":null},{"id":"827772fb92ca438995563e43aa059ca3","type":"TRIAL","name":"Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo","canonical_id":"clinicaltrials.gov:NCT02097147","description":"Healthy","metadata":null},{"id":"bd7b2c52419045b09145f4f2e3711bdb","type":"TRIAL","name":"Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease","canonical_id":"clinicaltrials.gov:NCT03201445","description":"Inflammatory Bowel Disease","metadata":null},{"id":"51cb1f3135a84ed3836192cc80a17564","type":"TRIAL","name":"Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients","canonical_id":"clinicaltrials.gov:NCT02244229","description":"Prostatic Hyperplasia","metadata":null},{"id":"d28514248b694248bfe86f8f128fa0cf","type":"TRIAL","name":"Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis","canonical_id":"clinicaltrials.gov:NCT02037347","description":"Toxic Epidermal Necrolysis; Stevens-Johnson Syndrome","metadata":null},{"id":"2a1e939e0b4544809a774a7c1979c94c","type":"TRIAL","name":"Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.","canonical_id":"clinicaltrials.gov:NCT00557128","description":"Hypertension","metadata":null},{"id":"b3a153753c1d4c13b84354efd601575d","type":"TRIAL","name":"Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)","canonical_id":"clinicaltrials.gov:NCT00708903","description":"Breast Cancer","metadata":null},{"id":"170743bdc4d54c20a0da0422078391db","type":"TRIAL","name":"Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects","canonical_id":"clinicaltrials.gov:NCT00645255","description":"Obesity; Weight Loss","metadata":null},{"id":"6d08efc5287146c5ba854dcede7319fe","type":"TRIAL","name":"Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)","canonical_id":"clinicaltrials.gov:NCT02992132","description":"Agitation and Aggression in Alzheimer's Disease","metadata":null},{"id":"b320ebacea79441f93585c50a2056cf9","type":"TRIAL","name":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","canonical_id":"clinicaltrials.gov:NCT02688985","description":"Relapsing Multiple Sclerorsis; Multiple Sclerosis, Primary Progressive","metadata":null},{"id":"44bad4074fb14802b2e655a4e5dd7411","type":"TRIAL","name":"Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT04264637","description":"Allergic Rhinitis","metadata":null},{"id":"d3cf4f860981442eae1d54d13d017431","type":"TRIAL","name":"Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon","canonical_id":"clinicaltrials.gov:NCT00586287","description":"Pulmonary Embolism; Atrial Fibrillation; Hip Replacement Postoperative; Knee Replacement Postoperative","metadata":null},{"id":"eb0e767b61c74e2bbce18660c3730847","type":"TRIAL","name":"Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb","canonical_id":"clinicaltrials.gov:NCT04614246","description":"Endometriosis","metadata":null},{"id":"ee54dee4461f4b83b62b5312c79f1c31","type":"TRIAL","name":"Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.","canonical_id":"clinicaltrials.gov:NCT00549510","description":"Hypertension","metadata":null},{"id":"0527765f4ac94cf4b29fccf7401f199d","type":"TRIAL","name":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01088048","description":"Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma","metadata":null},{"id":"2fcef8fdef0e4f8eaf8f2f74b581577b","type":"TRIAL","name":"Study to Investigate Lacosamide as Add-on Therapy in Subjects \u22654 Years to <17 Years of Age With Partial Onset Seizures","canonical_id":"clinicaltrials.gov:NCT01921205","description":"Epilepsy","metadata":null},{"id":"c95ff8302350443389ec36518f3e90ba","type":"TRIAL","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05725200","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"fc5cf93abc9645829a7b1ed299bec3e1","type":"TRIAL","name":"Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.","canonical_id":"clinicaltrials.gov:NCT02710890","description":"Epilepsy","metadata":null},{"id":"453706b64f36405cb04f51ea74de3d55","type":"TRIAL","name":"Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects","canonical_id":"clinicaltrials.gov:NCT02068235","description":"Healthy","metadata":null},{"id":"77663de1e3f34c1b80c474982d6376b8","type":"TRIAL","name":"Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386","canonical_id":"clinicaltrials.gov:NCT00672646","description":"Pain","metadata":null},{"id":"2b5f221ed00a4885921eb2b6c345215a","type":"TRIAL","name":"Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT00306137","description":"Blood Loss, Surgical","metadata":null},{"id":"aafd249625a5456eac080d6d63aaa0dd","type":"TRIAL","name":"Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05891119","description":"Atopic Dermatitis","metadata":null},{"id":"2afc9e837e624e62bb823ebf2d535ada","type":"TRIAL","name":"Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","canonical_id":"clinicaltrials.gov:NCT04394351","description":"Eosinophilic Esophagitis (EoE)","metadata":null},{"id":"27d4f881ef5e4e058a5757dc5b15a025","type":"TRIAL","name":"Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2","canonical_id":"clinicaltrials.gov:NCT04700046","description":"Myotonic Dystrophy Type 1 and Type 2","metadata":null},{"id":"e27f4c43276e474f8fb3f8b5fc974bcc","type":"TRIAL","name":"Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00657033","description":"Erectile Dysfunction","metadata":null},{"id":"e4306e0c9b4a4c14bf25d646b9d214e1","type":"TRIAL","name":"Study to Investigate the Efficacy of Symbicort\u00ae SMART.","canonical_id":"clinicaltrials.gov:NCT00839800","description":"Asthma","metadata":null},{"id":"542d808124c54dbba11ad8e17f473557","type":"TRIAL","name":"Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)","canonical_id":"clinicaltrials.gov:NCT06709339","description":"Polypoidal Choroidal Vasculopathy","metadata":null},{"id":"9556e63e2f734d2fb5ad94141c9e35b0","type":"TRIAL","name":"Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide","canonical_id":"clinicaltrials.gov:NCT01403376","description":"Multiple Sclerosis","metadata":null},{"id":"653fed7954b7452596befb9a6d2df3f1","type":"TRIAL","name":"Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants","canonical_id":"clinicaltrials.gov:NCT02824315","description":"Healthy","metadata":null},{"id":"df57330ef3a041cf93a374f6b09870a2","type":"TRIAL","name":"Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State","canonical_id":"clinicaltrials.gov:NCT03086356","description":"Healthy Volunteers","metadata":null},{"id":"efae71f5e716404f9b0a04c0ad1626c6","type":"TRIAL","name":"Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.","canonical_id":"clinicaltrials.gov:NCT04731298","description":"Graft Failure","metadata":null},{"id":"b97289a2d56b476696ea984081ed619a","type":"TRIAL","name":"Study to Investigate the Safety and Efficacy of High Dose of Symbicort\u00ae SMART in Japanese Patients","canonical_id":"clinicaltrials.gov:NCT00837967","description":"Asthma","metadata":null},{"id":"27fcba56762d49cd89b7c8d45d507e23","type":"TRIAL","name":"Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension","canonical_id":"clinicaltrials.gov:NCT06585163","description":"Healthy; PK Drug-drug Interaction Study","metadata":null},{"id":"046778409cb94fe1b36c4fadcdb2542a","type":"TRIAL","name":"Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.","canonical_id":"clinicaltrials.gov:NCT00333944","description":"Acute Organophosphorus Pesticide Poisoning","metadata":null},{"id":"600b5141b5d245518287e8adfe504569","type":"TRIAL","name":"Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)","canonical_id":"clinicaltrials.gov:NCT06222034","description":"Juvenile Idiopathic Arthritis","metadata":null},{"id":"3e5e2d0b4fc740c1bf6a393482586e77","type":"TRIAL","name":"Study to Prevent Cartilage Damage Following Acute Knee Injury.","canonical_id":"clinicaltrials.gov:NCT00332254","description":"Knee Injury","metadata":null},{"id":"36d3ad130ea04cef8906be2cecb03ee5","type":"TRIAL","name":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","canonical_id":"clinicaltrials.gov:NCT00516737","description":"Migraine","metadata":null},{"id":"43d37d24893a40a0a1fa93de918b1113","type":"TRIAL","name":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)","canonical_id":"clinicaltrials.gov:NCT00111709","description":"Migraine","metadata":null},{"id":"5f6a2d3e4ad34592a2c10445a1e8c72d","type":"TRIAL","name":"Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)","canonical_id":"clinicaltrials.gov:NCT00111722","description":"Migraine","metadata":null},{"id":"5a0e057b3f9442beb046ea22349d8c5e","type":"TRIAL","name":"Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea","canonical_id":"clinicaltrials.gov:NCT00250458","description":"Migraine","metadata":null},{"id":"af497cd1bc1c4aa08959cb512537d0c4","type":"TRIAL","name":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)","canonical_id":"clinicaltrials.gov:NCT00092963","description":"Migraine","metadata":null},{"id":"1ae75d356a7d47cf9d8b3284b122caf3","type":"TRIAL","name":"Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)","canonical_id":"clinicaltrials.gov:NCT00095004","description":"Migraine","metadata":null},{"id":"5a8b3e5da1914f95a72ccab9aa81911d","type":"TRIAL","name":"Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors","canonical_id":"clinicaltrials.gov:NCT06663072","description":"Metastatic Pancreatic Neuroendocrine Tumor","metadata":null},{"id":"f1363a2e7187471baecd9d8425849933","type":"TRIAL","name":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","canonical_id":"clinicaltrials.gov:NCT06169124","description":"Adult Ovarian Granulosa Cell Tumor","metadata":null},{"id":"dd1cd19df2a64f8e88ee8161872281fa","type":"TRIAL","name":"Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar","canonical_id":"clinicaltrials.gov:NCT00475332","description":"Non-Hodgkin's Lymphoma; Follicular Lymphoma","metadata":null},{"id":"4311d3c0a4444c8fb9e653742d9227cf","type":"TRIAL","name":"Studying the Effects of Sibutramine on Eating Behavior","canonical_id":"clinicaltrials.gov:NCT01170364","description":"Obesity","metadata":null},{"id":"dce4cf30f16240bc8f83d11ea9f837ac","type":"TRIAL","name":"Studying the Role of Brain Molecules for Decision Making","canonical_id":"clinicaltrials.gov:NCT04384562","description":"Decision Making; Healthy","metadata":null},{"id":"18b1cc33f4814f279cf9089ab52e8661","type":"TRIAL","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","canonical_id":"clinicaltrials.gov:NCT07217184","description":"Multiple Myeloma","metadata":null},{"id":"8bc4ab6dc2da4e538a2139c707920fb5","type":"TRIAL","name":"Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT03596957","description":"Autosomal Dominant Polycystic Kidney","metadata":null},{"id":"6f03348536114787b37d8899522101bd","type":"DISEASE","name":"Subarachnoid intracranial hemorrhage","canonical_id":"mesh:D013345","description":null,"metadata":null},{"id":"afc8d2d3819b4552bb0b324e755cc874","type":"TRIAL","name":"Subclinical Cardiovascular Disease in Psoriatic Disease","canonical_id":"clinicaltrials.gov:NCT03228017","description":"Cardiovascular Diseases; Myocardial Infarction; Atherosclerotic Cardiovascular Disease; Thrombotic Vascular Disease","metadata":null},{"id":"4c3d35e542324b82a44be4e6e33b9260","type":"TRIAL","name":"Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06190158","description":"Type 2 Diabetes; Chronic Kidney Diseases","metadata":null},{"id":"a8610a11210e4881946086c5908f514c","type":"TRIAL","name":"Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)","canonical_id":"clinicaltrials.gov:NCT04786158","description":"Progressive Supranuclear Palsy; Corticobasal Degeneration","metadata":null},{"id":"711c58e889c243d28724b5d393189943","type":"TRIAL","name":"Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05340309","description":"Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"24ed872b8a2446ea9db78ab2582e6184","type":"TRIAL","name":"Subcutaneous Calcitonin in Acute Herpes Zoster","canonical_id":"clinicaltrials.gov:NCT07655804","description":"Calcitonin; Subcutaneous; Acute Herpes Zoster","metadata":null},{"id":"bcf09bc1a283444290bf21afe5bf9ed6","type":"TRIAL","name":"Subcutaneous Infliximab After A Previous Intravenous Dose Optimization","canonical_id":"clinicaltrials.gov:NCT06113913","description":"Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis","metadata":null},{"id":"305cfe861a894671aaaf9dd5596997f8","type":"TRIAL","name":"Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention","canonical_id":"clinicaltrials.gov:NCT03852524","description":"Postoperative Ileus","metadata":null},{"id":"6a4ac4b11e7c4d9b9becfc739ad593f4","type":"TRIAL","name":"Subcutaneous Pharmacokinetics of Belatacept","canonical_id":"clinicaltrials.gov:NCT00569803","description":"Transplantation","metadata":null},{"id":"80f9fc0e216841c1a132b8752fe54481","type":"TRIAL","name":"Subcutaneous Route and Pharmacology of Metoclopramide","canonical_id":"clinicaltrials.gov:NCT02466984","description":"Nausea; Vomiting","metadata":null},{"id":"f8a7d45bbb8542e1a9f4a0e06bb74f13","type":"TRIAL","name":"Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19","canonical_id":"clinicaltrials.gov:NCT07196306","description":"COVID; COVID-19; Corona Virus Infection","metadata":null},{"id":"bf64cf1abcee4f0294bd754bc033a0c2","type":"TRIAL","name":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema","canonical_id":"clinicaltrials.gov:NCT00097695","description":"Angioedema","metadata":null},{"id":"66e72051d21e4f829cb66d37b1c9f9cb","type":"TRIAL","name":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)","canonical_id":"clinicaltrials.gov:NCT00500656","description":"Hereditary Angioedema","metadata":null},{"id":"4f92b878ff0144619286229c25e019e1","type":"TRIAL","name":"Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT00045006","description":"Cancer","metadata":null},{"id":"155f54745be9456baee9a79f0376e9c9","type":"TRIAL","name":"Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy","canonical_id":"clinicaltrials.gov:NCT00005634","description":"Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"8ac6a96b633e4c4fb8a72cd5d9b828fe","type":"TRIAL","name":"Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00138177","description":"Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"3139f0c1ef5344d59b5c1de654eb03a0","type":"TRIAL","name":"Subfoveal Choroidal Thickness After Surgery for Age-related Cataracts","canonical_id":"clinicaltrials.gov:NCT02895074","description":"Cataract","metadata":null},{"id":"9ae839ca0b3b4838a72282b3c68d0dd4","type":"TRIAL","name":"Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy","canonical_id":"clinicaltrials.gov:NCT06173245","description":"Subfoveal Choroidal Thickness; Intravitreal; Ranibizumab; Visual Acuity; Diabetic Retinopathy","metadata":null},{"id":"aefc46ef00e844b9a5a995612484eb67","type":"TRIAL","name":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne","canonical_id":"clinicaltrials.gov:NCT02932267","description":"Acne Vulgaris","metadata":null},{"id":"81131c51d4374d5d911012fa004de3fd","type":"TRIAL","name":"Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.","canonical_id":"clinicaltrials.gov:NCT00414102","description":"Chronic Insomnia","metadata":null},{"id":"e51bb603197c4a5bb91e13cffe11d759","type":"TRIAL","name":"Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study","canonical_id":"clinicaltrials.gov:NCT03057938","description":"Subjective Cognitive Decline","metadata":null},{"id":"e99888cec6cc4618a0405c0ccb51ff35","type":"TRIAL","name":"Sublingual Apomorphine in Refractory Restless Legs Syndrome","canonical_id":"clinicaltrials.gov:NCT05529095","description":"Restless Legs Syndrome","metadata":null},{"id":"373293ae20df47fd8417c695f6b070fe","type":"TRIAL","name":"Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope","canonical_id":"clinicaltrials.gov:NCT03080350","description":"Acute Pain Due to Trauma","metadata":null},{"id":"9be61866b3a141f49d6ec30805e5be73","type":"TRIAL","name":"Sublingual vs IV Atropine Bioavailability Study","canonical_id":"clinicaltrials.gov:NCT04290039","description":"Toxic Effect of Organophosphate and Carbamate Insecticides","metadata":null},{"id":"135cbb3cec22483a8ad0bdd377ae7b8d","type":"TRIAL","name":"Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1","canonical_id":"clinicaltrials.gov:NCT00078117","description":"Opioid-Related Disorders","metadata":null},{"id":"f3f2b972fc154383ac8383547f57c51c","type":"TRIAL","name":"Subretinal Macugen\u00ae for Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT00788177","description":"Age-related Macular Degeneration","metadata":null},{"id":"317b2f92af04423f9de7c464d5378e4c","type":"TRIAL","name":"Substance Dependent Teens - Impact of Treating Depression Study 1 - 1","canonical_id":"clinicaltrials.gov:NCT00061113","description":"Alcohol-Related Disorders; Marijuana Abuse; Substance-Related Disorders","metadata":null},{"id":"b5f543d173db41ac9af28e9d0ea695ae","type":"TRIAL","name":"Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02810743","description":"Breast Cancer","metadata":null},{"id":"b2af0e8716134ece98cbecd11b784b5b","type":"TRIAL","name":"Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting","canonical_id":"clinicaltrials.gov:NCT02500095","description":"Healthy","metadata":null},{"id":"7e2f060b1b7f4a9db69c7fbbaadeda84","type":"TRIAL","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","canonical_id":"clinicaltrials.gov:NCT06353386","description":"Prostatic Neoplasms, Castration-Resistant","metadata":null},{"id":"5583dd5aa3fd42d9b6683645d6226ece","type":"TRIAL","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","canonical_id":"clinicaltrials.gov:NCT06445972","description":"Gastroesophageal Junction; Gastroesophageal Adenocarcinoma; Esophageal Neoplasms; Esophageal Cancer","metadata":null},{"id":"f55f5b3711d841409e77d189102a9f39","type":"TRIAL","name":"Subtenon and Intravenous Dexmedetomidine Effect on Patients Undergoing Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT04668456","description":"Acute Postoperative Pain","metadata":null},{"id":"6f8938d1e23144fe91bba4631d17f5f7","type":"TRIAL","name":"Success of External Cephalic Version Study","canonical_id":"clinicaltrials.gov:NCT03106753","description":"External Cephalic Version","metadata":null},{"id":"4ec4e8f3625c4116b12f1711452e5b6d","type":"TRIAL","name":"Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation","canonical_id":"clinicaltrials.gov:NCT01120366","description":"Rheumatoid Arthritis","metadata":null},{"id":"59e3dbbaf49b41999c283b29ae9cc801","type":"PROTEIN","name":"Succinate-semialdehyde dehydrogenase, mitochondrial","canonical_id":"uniprot:P51649","description":null,"metadata":null},{"id":"057d2b544b2e4d2bbcb88b3a7dfe4dac","type":"DRUG","name":"Succinic acid","canonical_id":"mesh:D019802","description":null,"metadata":null},{"id":"037c11dfccc64142b5f5ec427040d45c","type":"TRIAL","name":"Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care","canonical_id":"clinicaltrials.gov:NCT00355368","description":"Intubation","metadata":null},{"id":"a71242aea8ed47cb8447c1d5326bf52a","type":"TRIAL","name":"Succinylcholine vs Rocuronium for Prehospital Emergency Intubation","canonical_id":"clinicaltrials.gov:NCT02000674","description":"Coma; Major Trauma; Respiratory Distress; Shock","metadata":null},{"id":"7ee3ec4f0f344f25a784a9dfe7aecd7b","type":"DISEASE","name":"Sucrase-isomaltase deficiency","canonical_id":"mesh:C538139","description":null,"metadata":null},{"id":"04ab890a4b884a9496b34355e1afd8db","type":"DRUG","name":"Sufentanil","canonical_id":"mesh:D017409","description":null,"metadata":null},{"id":"d7beff3ce42d4b23b03bc7dcf2081254","type":"TRIAL","name":"Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular","canonical_id":"clinicaltrials.gov:NCT03322657","description":"Neuromuscular Blockade; Anesthesia","metadata":null},{"id":"db243381dde745a18680d0f1d93da79d","type":"TRIAL","name":"Sugammadex v.s. Neostigmine/Glycopyrrolate","canonical_id":"clinicaltrials.gov:NCT06398899","description":"Head and Neck Surgery; Chronic Sinusitis; Chronic Otitis Media; Laryngeal Disease","metadata":null},{"id":"b311d5f8cc9d4a37ad11120f70815608","type":"TRIAL","name":"Suitability of Nitisinone in Alkaptonuria 2","canonical_id":"clinicaltrials.gov:NCT01916382","description":"Alkaptonuria","metadata":null},{"id":"6e3f402274a74111b8ccd5b3e23bb1c7","type":"DRUG","name":"Sulfadiazine silver","canonical_id":"mesh:D012837","description":null,"metadata":null},{"id":"e3a294b031e848779fdabc8f17cb2202","type":"DRUG","name":"Sulfamethizole","canonical_id":"mesh:D013419","description":null,"metadata":null},{"id":"05dfca8e090b452f8d9a64e29d1d3671","type":"DRUG","name":"Sulfamethoxazole","canonical_id":"mesh:D013420","description":null,"metadata":null},{"id":"9190e5d0b7ce45988aed55cc3fc359a9","type":"TRIAL","name":"Sulfamethoxazole Drug Interaction Study With MMX\u00ae Mesalazine/Mesalamine","canonical_id":"clinicaltrials.gov:NCT01469637","description":"Healthy","metadata":null},{"id":"b496c583ed504a6489745cea2638c4ab","type":"DRUG","name":"Sulfanilamide","canonical_id":"mesh:C036944","description":null,"metadata":null},{"id":"bcb2b5c6997641e093f352ff53d8fb39","type":"DRUG","name":"Sulfapyridine","canonical_id":"mesh:D013427","description":null,"metadata":null},{"id":"9d1bd230163147b7b6ac5e2c10f2b3b9","type":"DRUG","name":"Sulfinpyrazone","canonical_id":"mesh:D013442","description":null,"metadata":null},{"id":"890cdbd6d49c4b159b4d61dd70f7785e","type":"DRUG","name":"Sulindac","canonical_id":"mesh:D013467","description":null,"metadata":null},{"id":"87659b42c5cb4d14a7696a911ff4ce74","type":"DRUG","name":"Sulindac","canonical_id":"ncit:C850","description":null,"metadata":null},{"id":"c934873063804eac943d37f65c68f033","type":"TRIAL","name":"Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults","canonical_id":"clinicaltrials.gov:NCT03357614","description":"Complicated Urinary Tract Infections","metadata":null},{"id":"bdff78d9096943659b1d1889496875db","type":"TRIAL","name":"Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study","canonical_id":"clinicaltrials.gov:NCT02201602","description":"Diabetes","metadata":null},{"id":"6f9261156ee8463cbef7c66950418e0b","type":"TRIAL","name":"Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric","canonical_id":"clinicaltrials.gov:NCT02749747","description":"Menopausal Syndrome; Hot Flashes","metadata":null},{"id":"c1fb3fcca9914615b3cafa446e638443","type":"TRIAL","name":"Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00847405","description":"Healthy","metadata":null},{"id":"92da5f85576c47979f25e0e6e6cf2224","type":"TRIAL","name":"Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00846885","description":"Healthy","metadata":null},{"id":"612418b53a0c4673a43caee7d2cdab31","type":"TRIAL","name":"Sumatriptan and Naratriptan Pregnancy Registry","canonical_id":"clinicaltrials.gov:NCT01059604","description":"Migraine Disorders","metadata":null},{"id":"78afa897e8bc48af88543a26e13d4bed","type":"TRIAL","name":"Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT03035630","description":"Clear-cell Renal Cell Carcinoma; RCC; Kidney Cancer; Clear-cell Kidney Carcinoma","metadata":null},{"id":"3ba42a01e8f54409b7756c7febc69572","type":"TRIAL","name":"Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer","canonical_id":"clinicaltrials.gov:NCT00787787","description":"Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer","metadata":null},{"id":"8b06b4438d2a413b84b32a8a37a1ef80","type":"TRIAL","name":"Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00693992","description":"Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7","metadata":null},{"id":"d874e6a679624891bd07bfbb8fa451fe","type":"TRIAL","name":"Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma","canonical_id":"clinicaltrials.gov:NCT00521092","description":"AIDS-related Kaposi Sarcoma; Classic Kaposi Sarcoma","metadata":null},{"id":"93fd06a5031b417abcf5dbc50cd5895b","type":"TRIAL","name":"Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT00388037","description":"Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; St\u2026","metadata":null},{"id":"29a06db5f0404084bef5d6955fdc5b74","type":"TRIAL","name":"Sunitinib for Advanced Thymus Cancer Following Earlier Treatment","canonical_id":"clinicaltrials.gov:NCT01621568","description":"Thymoma; Thymus Neoplasms","metadata":null},{"id":"dc653138093a42a18a151720518cd3ac","type":"TRIAL","name":"Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas","canonical_id":"clinicaltrials.gov:NCT00474994","description":"Adult Malignant Fibrous Histiocytoma of Bone; Desmoid Tumor; Endometrial Cancer; Ovarian Cancer; Sarcoma; Small Intestine Cancer","metadata":null},{"id":"659ef48279d14772beb05e677dadb2da","type":"TRIAL","name":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","canonical_id":"clinicaltrials.gov:NCT01391962","description":"Sarcoma, Alveolar Soft Part","metadata":null},{"id":"01be3d89fbde4c59a1df3e89df28bbab","type":"TRIAL","name":"Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00616122","description":"Breast Cancer","metadata":null},{"id":"3c5a580c6b6d4745b24e9aeaebe610a8","type":"DRUG","name":"Sunvozertinib","canonical_id":"ncit:C167205","description":null,"metadata":null},{"id":"40c2b54c12bf4375bfae401a9497fe64","type":"TRIAL","name":"SuperB Trial: SUrgical Versus PERcutaneous Bypass","canonical_id":"clinicaltrials.gov:NCT01220245","description":"Cardiovascular Diseases","metadata":null},{"id":"f76de6b6767a4afca265a0c4db9fb882","type":"TRIAL","name":"Superficial Cervical Plexus Block With Dexmedetomidine Versus Without Adjuvant in Thyroid Surgery","canonical_id":"clinicaltrials.gov:NCT07274670","description":"Thyroid Cancer; Goiter; Hyperthyroidism","metadata":null},{"id":"d19bbf4f48404d4e8f82c63fd2518cd5","type":"TRIAL","name":"Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux","canonical_id":"clinicaltrials.gov:NCT01499953","description":"Superficial Vein Thrombosis","metadata":null},{"id":"2cf10ab6ba3e48e7a1c119aba67a139c","type":"TRIAL","name":"Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response","canonical_id":"clinicaltrials.gov:NCT02823106","description":"Ischemic Stroke","metadata":null},{"id":"43439f2791c942c5a725aa29778058b3","type":"TRIAL","name":"Supracondylar Distal Femur Fractures and Abaloparatide","canonical_id":"clinicaltrials.gov:NCT04626141","description":"Femoral Fractures","metadata":null},{"id":"73b43ae82acc464591a48bbdfe3986af","type":"TRIAL","name":"Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy","canonical_id":"clinicaltrials.gov:NCT01917149","description":"Dilated Cardiomyopathy","metadata":null},{"id":"cb070f10ac924cd5b60569290145b4d9","type":"TRIAL","name":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","canonical_id":"clinicaltrials.gov:NCT07142551","description":"Metastatic Castration-resistant Prostate Cancer","metadata":null},{"id":"e41901ed765d4adc825839edf0f01a72","type":"DRUG","name":"Suramin","canonical_id":"mesh:D013498","description":null,"metadata":null},{"id":"ef222e639b3544d2a71de29869e48a4c","type":"TRIAL","name":"Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT05200260","description":"Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma","metadata":null},{"id":"ca17c63a1a934855917324459c8ff12e","type":"TRIAL","name":"Surgery for Relapsed Ovarian Cancer in Precision","canonical_id":"clinicaltrials.gov:NCT06602063","description":"Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma","metadata":null},{"id":"74ec007460a74af6a53822bcdfca41d9","type":"TRIAL","name":"Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen","canonical_id":"clinicaltrials.gov:NCT01334957","description":"Pain","metadata":null},{"id":"aaf2c4e83f5745fbb0f05cba985b4493","type":"TRIAL","name":"Surgical vs. Medical Abortion on Sexual Function After Early Pregnancy Loss","canonical_id":"clinicaltrials.gov:NCT07646275","description":"Early Pregnancy Loss; Abortion, Spontaneous; Miscarriage; Pregnancy, Unwanted","metadata":null},{"id":"c8e3bccabed848eb8c8d82a9e1344958","type":"TRIAL","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","canonical_id":"clinicaltrials.gov:NCT06531291","description":"ESCC; Biliary Tract Cancer; Gastric Cancer; Pancreas Cancer","metadata":null},{"id":"0e43c8369df243f795b2a862de8a46dc","type":"TRIAL","name":"Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06092645","description":"Bile Duct Adenocarcinoma","metadata":null},{"id":"d213e2229e8d4f30be15fb1bacf904fc","type":"TRIAL","name":"Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients","canonical_id":"clinicaltrials.gov:NCT05722977","description":"Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients","metadata":null},{"id":"a4be0bda381d434f8c8e00c5e1e48d6e","type":"TRIAL","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","canonical_id":"clinicaltrials.gov:NCT05988372","description":"Locally Advanced Pancreatic Cancer","metadata":null},{"id":"4dcf910f35414e61a65af92b839978af","type":"TRIAL","name":"Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05100069","description":"Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"7d1ef9002dc04839a51774f88b4b1eac","type":"TRIAL","name":"Survey on the Pharmacy Follow-up of Alli Purchasers","canonical_id":"clinicaltrials.gov:NCT01387243","description":"Overweight","metadata":null},{"id":"482717dea46b464fb4b77c9babaa50eb","type":"TRIAL","name":"Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)","canonical_id":"clinicaltrials.gov:NCT04724629","description":"Covid19","metadata":null},{"id":"74bdc27e2309474ead82533a35238eb2","type":"TRIAL","name":"Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","canonical_id":"clinicaltrials.gov:NCT02129699","description":"Lung Cancer Non-small Cell Stage IV","metadata":null},{"id":"e39eaf58a0204cc58144f75bc0e5be7f","type":"TRIAL","name":"Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism","canonical_id":"clinicaltrials.gov:NCT00754442","description":"Secondary Hyperparathyroidism","metadata":null},{"id":"d5e20a4c4e444116b5577101bdeacb33","type":"TRIAL","name":"Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT00786253","description":"Erectile Dysfunction","metadata":null},{"id":"e1f2dc7fe8ef42f2a8943f4feeba11d7","type":"TRIAL","name":"Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C","canonical_id":"clinicaltrials.gov:NCT01639547","description":"Chronic Hepatitis C","metadata":null},{"id":"d599edb619e7480b9170b0a2069f560b","type":"TRIAL","name":"Sutent Rechallenge In mRCC Patients","canonical_id":"clinicaltrials.gov:NCT01827254","description":"Metastatic Renal Cell Carcinoma","metadata":null},{"id":"9b69f8ac919f4b878315588265f6d2a7","type":"TRIAL","name":"Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer","canonical_id":"clinicaltrials.gov:NCT00463060","description":"Cancer","metadata":null},{"id":"ed6e6c669b7f46c086fd54014f1129fb","type":"TRIAL","name":"Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan","canonical_id":"clinicaltrials.gov:NCT05132127","description":"Cold Agglutinin Disease","metadata":null},{"id":"3a79b8176b24461ba27c4d29ce12ad64","type":"TRIAL","name":"Suvorexant 3 - PE-PC","canonical_id":"clinicaltrials.gov:NCT07686731","description":"PTSD - Post Traumatic Stress Disorder; Insomnia; TBI (Traumatic Brain Injury)","metadata":null},{"id":"4f01fee6ea6a4a8984802db057baa530","type":"TRIAL","name":"Suvorexant and Alcohol","canonical_id":"clinicaltrials.gov:NCT06326684","description":"Alcohol Use Disorder","metadata":null},{"id":"74783536c0bc40caa8793889fd2f7f28","type":"TRIAL","name":"Suvorexant and Cocaine","canonical_id":"clinicaltrials.gov:NCT03937986","description":"Cocaine Use Disorder","metadata":null},{"id":"9e3e50700d9244dfad26a63d14862a57","type":"TRIAL","name":"Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder","canonical_id":"clinicaltrials.gov:NCT02849548","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"75d804b0e10648bdbd811f66eb8349fe","type":"TRIAL","name":"Suvorexant and Sleep/Delirium in ICU Patients","canonical_id":"clinicaltrials.gov:NCT04092894","description":"Insomnia; Sleep Fragmentation; Sleep Initiation and Maintenance Disorders; Postoperative Delirium","metadata":null},{"id":"5b1b93781a4d4a808e3334f787a1754d","type":"TRIAL","name":"Suvorexant and Trauma Related Insomnia","canonical_id":"clinicaltrials.gov:NCT02704754","description":"Insomnia; Posttraumatic Stress Disorder","metadata":null},{"id":"f53bfd139e544cc49558b788a820b809","type":"TRIAL","name":"Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl","canonical_id":"clinicaltrials.gov:NCT05145764","description":"Suvorexant; Placebo; Opioid Use Disorder","metadata":null},{"id":"f3e8bbd5a6534580bdb976a0a2d20bdc","type":"TRIAL","name":"Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06834386","description":"Advanced Malignant Solid Neoplasm; Delirium; Hematopoietic and Lymphatic System Neoplasm; Insomnia","metadata":null},{"id":"87de4d16c42a46ffa423dc7209761197","type":"TRIAL","name":"Suvorexant for Opioid/Stimulant Co-use","canonical_id":"clinicaltrials.gov:NCT05546515","description":"Opioid Use Disorder; Stimulant Use Disorder","metadata":null},{"id":"3bd18fbedffc4bb6a2eb1382d0ff4173","type":"TRIAL","name":"Suvorexant for Treatment of AUD and PTSD","canonical_id":"clinicaltrials.gov:NCT06679062","description":"Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD); Insomnia","metadata":null},{"id":"f10f6cc39304421c97db3cf6ec1a57f3","type":"TRIAL","name":"Suvorexant in Insomnia Co-morbid With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT02684136","description":"Insomnia; Fibromyalgia","metadata":null},{"id":"35a94aa29c154961aafad521d8204804","type":"TRIAL","name":"Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT03897062","description":"Insomnia; Alcohol Use Disorder","metadata":null},{"id":"105f688a351f44ea896a7abc7e035dd3","type":"TRIAL","name":"Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03818581","description":"Type 2 Diabetes Mellitus; Insomnia; Sleep Disorder; Inflammation","metadata":null},{"id":"a8ba3b338a56410687902726850ba170","type":"TRIAL","name":"Suvorexant to Reduce Symptoms of Nicotine Use","canonical_id":"clinicaltrials.gov:NCT04234997","description":"Smoking Cessation","metadata":null},{"id":"097bc690e0884a09af25c34ea24bb2a3","type":"TRIAL","name":"Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress","canonical_id":"clinicaltrials.gov:NCT03642028","description":"Sleep Initiation and Maintenance Disorders; Stress Disorders, Posttraumatic","metadata":null},{"id":"2f3222821dea411e9f2832d1a3ddb3d2","type":"TRIAL","name":"Swedish Cardiac And Renal Failure Study-1","canonical_id":"clinicaltrials.gov:NCT07029503","description":"HFrEF - Heart Failure With Reduced Ejection Fraction; Chronic Kidney Disease","metadata":null},{"id":"4183d9de46c24ed79ad51b6fe106584b","type":"GO_TERM","name":"Swi5-Sfr1 complex","canonical_id":"go:GO:0032798","description":"\"A conserved DNA recombinase mediator complex that contains two Swi5 monomers and one Sfr1 monomer in Schizosaccharomyces, or orthologs thereof (e.g. Sae3p and Mei5p in Saccharomyces).\" [PMID:15620352, PMID:16921379]","metadata":null},{"id":"c1ba33803b984444a8105c74ce8d0633","type":"GO_TERM","name":"Swi5-Sfr1 complex binding","canonical_id":"go:GO:1905334","description":"\"Binding to a Swi5-Sfr1 complex.\" [GOC:TermGenie, PMID:16921379]","metadata":null},{"id":"9dbd33c36be9463898006b1c5d1cef7b","type":"GO_TERM","name":"Swi5-Swi2 complex","canonical_id":"go:GO:0034974","description":"\"A protein complex involved that contains proteins known in Schizosaccharomyces as Swi5 monomers and Swi2, and is involved in mating type switching.\" [PMID:14663140]","metadata":null},{"id":"7850452ce83b4e9da0f51aaa7abac37f","type":"TRIAL","name":"Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study","canonical_id":"clinicaltrials.gov:NCT04895202","description":"Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity","metadata":null},{"id":"531ad37db2244fab8d541e1fb63fab2d","type":"TRIAL","name":"Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide","canonical_id":"clinicaltrials.gov:NCT00745433","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"3b8c70eb89384bb38e7081ede10c6efc","type":"TRIAL","name":"Switch Study of Existing Atypical Antipsychotics to Bifeprunox","canonical_id":"clinicaltrials.gov:NCT00347425","description":"Schizophrenia and Schizoaffective Disorder","metadata":null},{"id":"b8ec3db2b8be4f6aa8863b4a4b852b7d","type":"TRIAL","name":"Switch to Ofatumumab and Level of Immunoglobulins","canonical_id":"clinicaltrials.gov:NCT07625800","description":"Multiple Sclerosis","metadata":null},{"id":"f8b52fc52d3e48408d05e9db272042fa","type":"TRIAL","name":"Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)","canonical_id":"clinicaltrials.gov:NCT00796705","description":"Rheumatoid Arthritis","metadata":null},{"id":"b139ef356eb048efb504dbe074ea336e","type":"TRIAL","name":"Switching From Adalimumab to Infliximab","canonical_id":"clinicaltrials.gov:NCT01338740","description":"Crohn's Disease","metadata":null},{"id":"a9d0a9dcdfd2435d9b1eca3f52a5f5e4","type":"TRIAL","name":"Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors","canonical_id":"clinicaltrials.gov:NCT06691191","description":"Coronary Artery Disease","metadata":null},{"id":"0ada6b34ce8a46949508987b5ef060fd","type":"TRIAL","name":"Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone","canonical_id":"clinicaltrials.gov:NCT02015546","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"60ec5df07d7940be9e1658d351be9e79","type":"TRIAL","name":"Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT02090400","description":"Osteoporosis, Postmenopausal","metadata":null},{"id":"5a1938bbdaa54b5ab187d9c007f0c797","type":"TRIAL","name":"Switching From Preserved to Preserved-free Treatments for Glaucoma.","canonical_id":"clinicaltrials.gov:NCT01433900","description":"Glaucoma","metadata":null},{"id":"9b385414ce604af38e65ffa8fd91357e","type":"TRIAL","name":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression\uff08SMART-I)","canonical_id":"clinicaltrials.gov:NCT07011693","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"4f7417d83a334d939a2fed8a6b8c7a97","type":"TRIAL","name":"Switching Medication to Treat Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00044655","description":"Schizophrenia","metadata":null},{"id":"3d5dd5c4f1cc4a4c9cc041ec599ca949","type":"TRIAL","name":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","canonical_id":"clinicaltrials.gov:NCT06231121","description":"Neovascular Age-related Macular Degeneration","metadata":null},{"id":"0b65cfa6649c42cd8124c284e4743c7a","type":"GO_TERM","name":"Swr1 complex","canonical_id":"go:GO:0000812","description":"\"A multisubunit protein complex that is involved in chromatin remodeling. It is required for the incorporation of the histone variant H2AZ into chromatin. In S. cerevisiae, the complex contains Swr1p, a Swi2/Snf2-related ATPase, and 12 additional subunits.\" [GOC:rb, PMID:14645854, PMID:14690608, PMID:19355820]","metadata":null},{"id":"89662b968f01462f8ed2aa17952819e2","type":"TRIAL","name":"Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01253473","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"5e446f51c9fc48e58abc1a1ecb8e9d11","type":"TRIAL","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","canonical_id":"clinicaltrials.gov:NCT07421700","description":"Urothelial Cancer; Advanced/Metastatic Urothelial Cancer; Urothelial Carcinoma","metadata":null},{"id":"3d45d8bafdce4182b3565396dabacc3a","type":"TRIAL","name":"Sympathetic Nerve Activity in Renal Failure","canonical_id":"clinicaltrials.gov:NCT00892892","description":"Chronic Kidney Disease; Hypertension","metadata":null},{"id":"a02dceb1762d40aabab40aa4e32464ea","type":"TRIAL","name":"Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences","canonical_id":"clinicaltrials.gov:NCT05997732","description":"Vasoconstriction; Vasodilation","metadata":null},{"id":"574f372b4f024dcdb0899f2f6c3c617c","type":"TRIAL","name":"Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms","canonical_id":"clinicaltrials.gov:NCT06787066","description":"Menopause","metadata":null},{"id":"618505beb4454b2599afdcbf71eea042","type":"TRIAL","name":"Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation","canonical_id":"clinicaltrials.gov:NCT02311569","description":"Myeloproliferative Neoplasm; Primary Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera","metadata":null},{"id":"37288c03d963413e907d55f57dd7e692","type":"TRIAL","name":"Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT04855617","description":"Multiple Sclerosis","metadata":null},{"id":"6d79be3639e94b0a81bf81435f075435","type":"TRIAL","name":"Symptomatic Management of Lyme Arthritis","canonical_id":"clinicaltrials.gov:NCT04038346","description":"Lyme Arthritis; Lyme Disease; Arthritis","metadata":null},{"id":"829e5e942d0141c9a8d6dfab9c846381","type":"TRIAL","name":"Symptomatic Therapy for Patients With Huntington's Disease","canonical_id":"clinicaltrials.gov:NCT04071639","description":"Huntington Disease","metadata":null},{"id":"003acc1b19684d8287eb279e3e58539a","type":"TRIAL","name":"Symptomatic Treatment of Acute Gastroenteritis","canonical_id":"clinicaltrials.gov:NCT01257672","description":"Gastroenteritis; Vomiting; Acute Gastroenteritis","metadata":null},{"id":"dc9f45a80d5848ed80523cfd7ad98861","type":"TRIAL","name":"Synaptic Imaging and Network Activity in Treatment Resistant Depression","canonical_id":"clinicaltrials.gov:NCT05870501","description":"Depressive Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Bipolar Disorder; Bipolar Disorder I; Bipolar Disorder II; Mood Disorders; Anhedonia","metadata":null},{"id":"56dea690e8014c379c8c60f41bf7e01f","type":"TRIAL","name":"Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression","canonical_id":"clinicaltrials.gov:NCT07560878","description":"Major Depression","metadata":null},{"id":"84be00a0be924831b4391078af555e5f","type":"TRIAL","name":"Synergetic B-cell Immodulation in SLE","canonical_id":"clinicaltrials.gov:NCT02284984","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"115afb2bd8324e25b7eb1a1bff29b1bb","type":"TRIAL","name":"Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)","canonical_id":"clinicaltrials.gov:NCT01031667","description":"Therapy","metadata":null},{"id":"b1b1bea4240d427bab29c4b51104dd78","type":"TRIAL","name":"Synergistic Effect of Vedolizumab and Pentoxifylline","canonical_id":"clinicaltrials.gov:NCT02953275","description":"Crohn Disease","metadata":null},{"id":"d0108f0b18564f0798c8f0ff6a321a90","type":"TRIAL","name":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06468280","description":"Gastric Cancer; GastroEsophageal Cancer","metadata":null},{"id":"60b359e58cce40c3afed5233fd7c11ec","type":"TRIAL","name":"Synergistic Enteral Regimen for Treatment of the Gangliosidoses","canonical_id":"clinicaltrials.gov:NCT02030015","description":"GM1 Gangliosidoses; GM2 Gangliosidoses; Tay-Sachs Disease; Sandhoff Disease","metadata":null},{"id":"d10b16f34bfb4fe2945177a05d46f4c3","type":"DISEASE","name":"Synovitis","canonical_id":"mesh:D013585","description":null,"metadata":null},{"id":"f7dc9dad585b4e86b6a8cb0acdd51c2a","type":"TRIAL","name":"Synthetic Human Secretin in Children With Autism","canonical_id":"clinicaltrials.gov:NCT00036244","description":"Autism","metadata":null},{"id":"6cc7e5114cf440948f6c8b8881117183","type":"TRIAL","name":"Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction","canonical_id":"clinicaltrials.gov:NCT00036231","description":"Autism","metadata":null},{"id":"4f1b5f9df80a47e4aa05692f57e70c98","type":"GO_TERM","name":"Syp1 complex","canonical_id":"go:GO:1990252","description":"\"A protein complex that contributes to the endocytic process and bud growth in yeast. It is involved in the precise timing of actin assembly during endocytosis.\" [GOC:bhm, PMID:19713939]","metadata":null},{"id":"35f5d9c6d123463cadd27adcad38be8d","type":"DISEASE","name":"Syphilis","canonical_id":"mesh:D013587","description":null,"metadata":null},{"id":"8db8a49067034bec8bc4a56da8a3b572","type":"DISEASE","name":"Syphilis, Congenital","canonical_id":"mesh:D013590","description":null,"metadata":null},{"id":"c2bf2f15408b4a92a29273dffa15ded0","type":"DISEASE","name":"Syphilis, Latent","canonical_id":"mesh:D013592","description":null,"metadata":null},{"id":"73f745f8e2b34e259699a012c7771247","type":"DISEASE","name":"Syphilis, secondary","canonical_id":"mesh:C536773","description":null,"metadata":null},{"id":"96435aeafd0b44f2b60ebf5b8c47edbd","type":"DISEASE","name":"Syphilis, tertiary","canonical_id":"mesh:C536774","description":null,"metadata":null},{"id":"46a7daa186654fc59babcec84a539a8c","type":"TRIAL","name":"Systematic Review and Meta-Analysis of Multaq\u00ae for Safety in Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT05279833","description":"Atrial Fibrillation","metadata":null},{"id":"84e699d77bc346bba89110ab31f09df0","type":"TRIAL","name":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","canonical_id":"clinicaltrials.gov:NCT01587339","description":"Epilepsy","metadata":null},{"id":"2f8931a423314a04bfdf95f13971c7be","type":"TRIAL","name":"Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","canonical_id":"clinicaltrials.gov:NCT00012558","description":"Bipolar Disorder","metadata":null},{"id":"44e2ef786c0f4b83a70c21b24b600f47","type":"TRIAL","name":"Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00361283","description":"Inflammation","metadata":null},{"id":"b9784e3c8f0847cb8751f744bab63c01","type":"TRIAL","name":"Systemic Nalbuphine Versus Intravenous Regional Anesthesia","canonical_id":"clinicaltrials.gov:NCT03150732","description":"Postoperative Pain","metadata":null},{"id":"27c19b1adee740428f45de3717e52b34","type":"TRIAL","name":"Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan\u00ae 0.01% Eye Drops in 40 Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT05729594","description":"Healthy Volunteers","metadata":null},{"id":"583f570bb0a841b6ad7a026f5e65613b","type":"TRIAL","name":"Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas","canonical_id":"clinicaltrials.gov:NCT04651049","description":"Infantile Haemangiomas","metadata":null},{"id":"169b3a88c5344662b5cbc2bd28e5dbb4","type":"TRIAL","name":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","canonical_id":"clinicaltrials.gov:NCT06726421","description":"Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic","metadata":null},{"id":"5a363139ec684dfb8d60600fbb10ebde","type":"TRIAL","name":"Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor","canonical_id":"clinicaltrials.gov:NCT01603212","description":"Melanoma","metadata":null},{"id":"0c42fba7c48b4525bcaa6a33f5fe9551","type":"DISEASE","name":"Systemic lupus erythematosus","canonical_id":"mesh:D008180","description":null,"metadata":null},{"id":"a06611a8f98c47bea4146e95dbbf6268","type":"DISEASE","name":"Systemic mast cell disease","canonical_id":"mesh:D034721","description":null,"metadata":null},{"id":"6baeb3edd5d545839dd6d5b62434c19c","type":"TRIAL","name":"Systolic Hypertension in Europe Placebo-Controlled Trial","canonical_id":"clinicaltrials.gov:NCT02088450","description":"Isolated Systolic Hypertension","metadata":null},{"id":"b510279a4c934020827e5d0cbd270b75","type":"TRIAL","name":"Systolic Hypertension in the Elderly Program (SHEP)","canonical_id":"clinicaltrials.gov:NCT00000514","description":"Cardiovascular Diseases; Cerebrovascular Disorders; Heart Diseases; Hypertension","metadata":null},{"id":"795e20eb65a849888ecc994fde0bf298","type":"TRIAL","name":"Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)","canonical_id":"clinicaltrials.gov:NCT00000499","description":"Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases","metadata":null},{"id":"e547fd0ac98d48d0b577779af3a4fc01","type":"GO_TERM","name":"T cell activation","canonical_id":"go:GO:0042110","description":"\"The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"6342c834c5b54548a7cc5753d9a09065","type":"GO_TERM","name":"T cell activation involved in immune response","canonical_id":"go:GO:0002286","description":"\"The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"fdf1f32a60b34f159ee9eec427f26340","type":"GO_TERM","name":"T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell","canonical_id":"go:GO:0002291","description":"\"The change in morphology and behavior of a mature or immature T cell resulting from exposure to an antigen for which its T cell receptor is specific bound to an MHC molecule on an antigen presenting cell, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"511f6854b59c43569b92e62b003af499","type":"GO_TERM","name":"T cell aggregation","canonical_id":"go:GO:0070489","description":"\"The adhesion of one T cell to one or more other T cells via adhesion molecules.\" [GOC:sl, PMID:12972508]","metadata":null},{"id":"a29fcccfa4194327aec7d23a74c228ef","type":"GO_TERM","name":"T cell anergy","canonical_id":"go:GO:0002870","description":"\"Any process contributing to anergy in T cells, a state of functional inactivation which is part of T cell tolerance induction.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b0f4c8ccf67c42efb097f2d7a38a3683","type":"GO_TERM","name":"T cell antigen processing and presentation","canonical_id":"go:GO:0002457","description":"\"The process in which a T cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, PMID:11417857, PMID:15120183]","metadata":null},{"id":"508c666ad7a0452d94528cda8ea99a65","type":"GO_TERM","name":"T cell apoptotic process","canonical_id":"go:GO:0070231","description":"\"Any apoptotic process in a T cell, a type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex.\" [CL:0000084, GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"ce9be8b92eb54ae391f8c39f196abc9a","type":"GO_TERM","name":"T cell chemotaxis","canonical_id":"go:GO:0010818","description":"\"The directed movement of a T cell in response to an external stimulus. A T cell is a type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6ec3abc4e32741a4acebfc098bf305f1","type":"GO_TERM","name":"T cell costimulation","canonical_id":"go:GO:0031295","description":"\"The process of providing, via surface-bound receptor-ligand pairs, a second, antigen-independent, signal in addition to that provided by the T cell receptor to augment T cell activation.\" [ISBN:0781735149]","metadata":null},{"id":"101f5ff7e4974afa85668037bd5c05d5","type":"GO_TERM","name":"T cell cytokine production","canonical_id":"go:GO:0002369","description":"\"Any process that contributes to cytokine production by a T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"45240ea8870c41eda83a93dd93e6a140","type":"GO_TERM","name":"T cell differentiation","canonical_id":"go:GO:0030217","description":"\"The process in which a precursor cell type acquires characteristics of a more mature T-cell. A T cell is a type of lymphocyte whose definin characteristic is the expression of a T cell receptor complex.\" [GO_REF:0000022, GOC:jid, GOC:mah]","metadata":null},{"id":"46f38f3649da42be805f01f2a27f7807","type":"GO_TERM","name":"T cell differentiation in thymus","canonical_id":"go:GO:0033077","description":"\"The process in which a precursor cell type acquires the specialized features of a T cell via a differentiation pathway dependent upon transit through the thymus.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"e67240cc8b6d4c979e7503df9358f09e","type":"GO_TERM","name":"T cell differentiation involved in immune response","canonical_id":"go:GO:0002292","description":"\"The process in which an antigenically naive T cell acquires the specialized features of an effector, regulatory, or memory T cell as part of an immune response. Effector T cells include cells which provide T cell help or exhibit cytotoxicity towards other cells.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"41a4052bb44849c7a97b0c6278516498","type":"GO_TERM","name":"T cell extravasation","canonical_id":"go:GO:0072683","description":"\"The migration of a T cell from the blood vessels into the surrounding tissue.\" [CL:0000084, GOC:BHF, GOC:mah]","metadata":null},{"id":"e88e7e6c1c2949b3840d57bf756c64f9","type":"GO_TERM","name":"T cell homeostasis","canonical_id":"go:GO:0043029","description":"\"The process of regulating the proliferation and elimination of T cells such that the total number of T cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"d4368b0c73ab4027afd3f3ee2a70855b","type":"GO_TERM","name":"T cell homeostatic proliferation","canonical_id":"go:GO:0001777","description":"\"The non-specific expansion of T cell populations within a whole or part of an organism to reach to a total number of T cells which will then remain stable over time in the absence of an external stimulus.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"cdd2b848e83c4a60aade0d9c21ae3e1a","type":"GO_TERM","name":"T cell inhibitory signaling pathway","canonical_id":"go:GO:0002770","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of a T cell capable of inhibiting an immune effector process contributing to an immune response.\" [GOC:add, PMID:15258309]","metadata":null},{"id":"c1ca4d3554fd4952b5aea6e506a8a386","type":"GO_TERM","name":"T cell lineage commitment","canonical_id":"go:GO:0002360","description":"\"The process in which a lymphoid progenitor cell becomes committed to becoming any type of T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"06a2e703a86846218d71a929484b4981","type":"GO_TERM","name":"T cell meandering migration","canonical_id":"go:GO:0120117","description":"\"The random-like motility observed for T cells in lymph nodes which enhances surveillance of antigens presented by major histocompatibility complex (MHC) molecules on antigen presenting cells (APCs).\" [GOC:add, GOC:krc, PMID:25083865]","metadata":null},{"id":"1a6fa9af684343e99d83327b03ee8c15","type":"GO_TERM","name":"T cell mediated cytotoxicity","canonical_id":"go:GO:0001913","description":"\"The directed killing of a target cell by a T cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors.\" [GOC:add, GOC:pr, ISBN:0781735149, PMID:11911826]","metadata":null},{"id":"c048079d74b44bdab3e902d02e3ab0c9","type":"GO_TERM","name":"T cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002419","description":"\"The directed killing of a tumor cell by a T cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"7b8e3daf4c3c4ac781f2eafe8faa0191","type":"GO_TERM","name":"T cell mediated immune response to tumor cell","canonical_id":"go:GO:0002424","description":"\"An immune response mediated by a T cell triggered in response to the presence of a tumor cell.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"3e17ba3ccbe643f9b12a827366e89365","type":"GO_TERM","name":"T cell mediated immunity","canonical_id":"go:GO:0002456","description":"\"Any process involved in the carrying out of an immune response by a T cell.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"1a907660983d441e84de9633135fd5de","type":"GO_TERM","name":"T cell migration","canonical_id":"go:GO:0072678","description":"\"The movement of a T cell within or between different tissues and organs of the body.\" [CL:0000084, GOC:BHF, GOC:mah]","metadata":null},{"id":"15dfe7f68c4a43daa92da9f6ee2f878d","type":"GO_TERM","name":"T cell proliferation","canonical_id":"go:GO:0042098","description":"\"The expansion of a T cell population by cell division. Follows T cell activation.\" [GOC:jl]","metadata":null},{"id":"f8e4333d8fcb4ec6b0ba8c53a0cdca6e","type":"GO_TERM","name":"T cell proliferation involved in immune response","canonical_id":"go:GO:0002309","description":"\"The expansion of a T cell population by cell division as part of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7018028d2c514db28ffbfa791178fe79","type":"GO_TERM","name":"T cell receptor V(D)J recombination","canonical_id":"go:GO:0033153","description":"\"The process in which T cell receptor V, D, and J, or V and J gene segments, depending on the specific locus, are recombined within a single locus utilizing the conserved heptamer and nonomer recombination signal sequences (RSS).\" [GOC:add, ISBN:0781700221]","metadata":null},{"id":"b546499cd55241988bb53e41a17d3d9d","type":"GO_TERM","name":"T cell receptor binding","canonical_id":"go:GO:0042608","description":"\"Binding to a T cell receptor, the antigen-recognizing receptor on the surface of T cells.\" [GOC:jl]","metadata":null},{"id":"7581f307be814da2b3d417d95065c9ad","type":"GO_TERM","name":"T cell receptor complex","canonical_id":"go:GO:0042101","description":"\"A protein complex that contains a disulfide-linked heterodimer of T cell receptor (TCR) chains, which are members of the immunoglobulin superfamily, and mediates antigen recognition, ultimately resulting in T cell activation. The TCR heterodimer is associated with the CD3 complex, which consists of the nonpolymorphic polypeptides gamma, delta, epsilon, zeta, and, in some cases, eta (an RNA splice variant of zeta) or Fc epsilon chains.\" [GOC:mah, ISBN:0781735149]","metadata":null},{"id":"fb09c7d39f0d478e91b4da979c931637","type":"GO_TERM","name":"T cell receptor signaling pathway","canonical_id":"go:GO:0050852","description":"\"The series of molecular signals initiated by the cross-linking of an antigen receptor on a T cell.\" [GOC:add]","metadata":null},{"id":"31ede76d19f54f32a7515b91930470b9","type":"GO_TERM","name":"T cell secretory granule organization","canonical_id":"go:GO:0033371","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a secretory granule in a T cell. A secretory granule is a small subcellular vesicle, surrounded by a membrane, that is formed from the Golgi apparatus and contains a highly concentrated protein destined for secretion.\" [GOC:mah]","metadata":null},{"id":"e260fe1f0e5449e6a734430956e966fa","type":"GO_TERM","name":"T cell selection","canonical_id":"go:GO:0045058","description":"\"The process in which T cells that express T cell receptors that are restricted by self MHC protein complexes and tolerant to self antigens are selected for further maturation.\" [ISBN:0781735149, PMID:12414722]","metadata":null},{"id":"a7d45571c4e8453ab92684578232126a","type":"GO_TERM","name":"T cell tolerance induction","canonical_id":"go:GO:0002517","description":"\"A process involving any mechanism for tolerance induction in T cells.\" [GOC:jal, ISBN:0781735149, PMID:16551263]","metadata":null},{"id":"e224f879fd4548ad89bb5053f2680d0f","type":"GO_TERM","name":"T cell tolerance induction in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002403","description":"\"Tolerance induction taking place in the mucosal-associated lymphoid tissue (MALT) mediated by T cells.\" [GOC:jal, ISBN:0781735149, PMID:16551263]","metadata":null},{"id":"f0d196d68d32442f85715312c7e358c8","type":"GO_TERM","name":"T cell tolerance induction to tumor cell","canonical_id":"go:GO:0002411","description":"\"A process of tolerance induction dependent on T cells which leads to immunological tolerance of a tumor.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"7e3d72f87e2e4e88a81213ca4ad2b4f2","type":"GO_TERM","name":"T follicular helper cell differentiation","canonical_id":"go:GO:0061470","description":"\"The process in which a relatively unspecialized T cell acquires specialized features of a mature T follicular helper cell.\" [GOC:dph, PMID:21572431]","metadata":null},{"id":"e6518931c5d745d1b09f28fdb516e403","type":"DISEASE","name":"T-B+ severe combined immunodeficiency","canonical_id":"mondo:0044200","description":null,"metadata":null},{"id":"7f2d1c3ef45544ae8985189aeacf389d","type":"DISEASE","name":"T-B+ severe combined immunodeficiency due to JAK3 deficiency","canonical_id":"mondo:0010938","description":null,"metadata":null},{"id":"87026fe824f54a3fb5ec522e27e81a65","type":"DISEASE","name":"T-B- severe combined immunodeficiency","canonical_id":"mondo:0017855","description":null,"metadata":null},{"id":"dbb25e79768842a38ba2c7c81a17e143","type":"TRIAL","name":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","canonical_id":"clinicaltrials.gov:NCT03653338","description":"Sickle Cell Anemia; Beta-thalassemia Major; Diamond-blackfan Anemia","metadata":null},{"id":"7020168398114ce5ad7b3cf213e00dbf","type":"TRIAL","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06045767","description":"Non-small Cell Lung Cancer Metastatic","metadata":null},{"id":"413d2efc2fb3475688dfa4d833d3bd8f","type":"TRIAL","name":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","canonical_id":"clinicaltrials.gov:NCT04457596","description":"Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma; Anatomic Stage I Breast Cancer AJCC v8","metadata":null},{"id":"a9e48c176b1d422a98665826f15bc42e","type":"TRIAL","name":"T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA","canonical_id":"clinicaltrials.gov:NCT02326974","description":"HER-2 Positive Breast Cancer; Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer","metadata":null},{"id":"d5a15c74d25e4cf8bd3eba1be3db65cf","type":"TRIAL","name":"T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd","canonical_id":"clinicaltrials.gov:NCT07683754","description":"Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive; HR Positive","metadata":null},{"id":"c0933936c76d44e48189485dd7d6edba","type":"TRIAL","name":"T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer","canonical_id":"clinicaltrials.gov:NCT00602693","description":"Leukemia; Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm; Myelodysplastic Syndromes","metadata":null},{"id":"fe8540375e3040e4a5abb4be8e3753d4","type":"GO_TERM","name":"T-bar","canonical_id":"go:GO:0098986","description":"\"A T-shaped presynpatic density. These are common in arhropod central nervous systems.\" [GOC:dos, PMID:26780543]","metadata":null},{"id":"1562596f13424f00aab3a7dac1972f23","type":"TRIAL","name":"T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04611126","description":"Metastatic Ovarian Cancer; Metastatic Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"cf4cba3c1bda4d8594b128316cd381a9","type":"DISEASE","name":"T-cell acute lymphoblastic leukemia","canonical_id":"mondo:0004963","description":null,"metadata":null},{"id":"e0dafb6191e84c529efc3f0b25bc287c","type":"DISEASE","name":"T-cell acute lymphoblastic leukemia","canonical_id":"mesh:D054218","description":null,"metadata":null},{"id":"37b475ec77e644e3bfeb7f32667f5dbd","type":"DISEASE","name":"T-cell non-Hodgkin lymphoma","canonical_id":"mondo:0015760","description":null,"metadata":null},{"id":"fcd921eba1664027aabfca54eb6d7de6","type":"GO_TERM","name":"T-helper 1 cell activation","canonical_id":"go:GO:0035711","description":"\"The change in morphology and behavior of a T-helper 1 cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [CL:0000545, GOC:BHF]","metadata":null},{"id":"147fa01baded479daef5920a155155e8","type":"GO_TERM","name":"T-helper 1 cell chemotaxis","canonical_id":"go:GO:0035706","description":"\"The directed movement of a T-helper 1 cell in response to an external stimulus.\" [CL:0000545, GOC:BHF]","metadata":null},{"id":"5143dea1d4314fc6a81f9ba2f615555e","type":"GO_TERM","name":"T-helper 1 cell cytokine production","canonical_id":"go:GO:0035744","description":"\"Any process that contributes to cytokine production by a T-helper 1 cell.\" [CL:0000545, GOC:BHF]","metadata":null},{"id":"001fb79eb93145b1b23ee09a8b66fedf","type":"GO_TERM","name":"T-helper 1 cell diapedesis","canonical_id":"go:GO:0035688","description":"\"The passage of a T-helper 1 cell between the tight junctions of endothelial cells lining blood vessels, typically the fourth and final step of cellular extravasation. A T-helper 1 cell is a CD4-positive, alpha-beta T cell that has the phenotype T-bet-positive and produces interferon-gamma.\" [CL:0000545, GOC:BHF, PMID:10477596]","metadata":null},{"id":"40f511130ba54e569d5e032de99ec9b2","type":"GO_TERM","name":"T-helper 1 cell differentiation","canonical_id":"go:GO:0045063","description":"\"The process in which a relatively unspecialized T cell acquires the specialized features of a T-helper 1 (Th1) cell. A Th1 cell is a CD4-positive, alpha-beta T cell that has the phenotype T-bet-positive and produces interferon-gamma.\" [CL:0000545, GOC:ebc]","metadata":null},{"id":"768dec3737af48aea53fe4b991b1c0b2","type":"GO_TERM","name":"T-helper 1 cell extravasation","canonical_id":"go:GO:0035687","description":"\"The migration of a T-helper 1 cell from the blood vessels into the surrounding tissue. A T-helper 1 cell is a CD4-positive, alpha-beta T cell that has the phenotype T-bet-positive and produces interferon-gamma.\" [CL:0000545, GOC:BHF]","metadata":null},{"id":"5f1621655bdc4076b1eb25564a23ae14","type":"GO_TERM","name":"T-helper 1 cell lineage commitment","canonical_id":"go:GO:0002296","description":"\"The process in which a CD4-positive, alpha-beta T cell becomes committed to becoming a T-helper 1 cell, a CD4-positive, alpha-beta T cell specialized to promote immunological processes often associated with resistance to intracellular bacteria, fungi, and protozoa, and pathological conditions such as arthritis.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d0acb10435be4e4383c5a2045632e467","type":"GO_TERM","name":"T-helper 1 type immune response","canonical_id":"go:GO:0042088","description":"\"An immune response which is associated with resistance to intracellular bacteria, fungi, and protozoa, and pathological conditions such as arthritis, and which is typically orchestrated by the production of particular cytokines by T-helper 1 cells, most notably interferon-gamma, IL-2, and lymphotoxin.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"e654051cd0d0415abf829442ae05b199","type":"GO_TERM","name":"T-helper 17 cell chemotaxis","canonical_id":"go:GO:0035705","description":"\"The directed movement of a T-helper 17 cell in response to an external stimulus.\" [CL:0000899, GOC:BHF]","metadata":null},{"id":"9b1dce8430a04196ac9cc30a3b51686a","type":"GO_TERM","name":"T-helper 17 cell differentiation","canonical_id":"go:GO:0072539","description":"\"The process in which a relatively unspecialized T cell acquires the specialized features of a T-helper 17 (Th17) cell. A Th17 cell is a CD4-positive, alpha-beta T cell with the phenotype RORgamma-t-positive that produces IL-17.\" [CL:0000899, GOC:BHF, GOC:ebc]","metadata":null},{"id":"82b38ad8374f44aeb9e00a16b77dd940","type":"GO_TERM","name":"T-helper 17 cell extravasation","canonical_id":"go:GO:0035699","description":"\"The migration of a T-helper 17 cell from the blood vessels into the surrounding tissue.\" [CL:0000899, GOC:BHF]","metadata":null},{"id":"173401ca91064d078825f129ea7bf6a8","type":"GO_TERM","name":"T-helper 17 cell lineage commitment","canonical_id":"go:GO:0072540","description":"\"The process in which a CD4-positive, alpha-beta T cell becomes committed to becoming a T-helper 17 cell, a CD4-positive, alpha-beta T cell with the phenotype RORgamma-t-positive that produces IL-17.\" [CL:0000899, GOC:BHF, GOC:ebc]","metadata":null},{"id":"8e9c3170574b41eab4de69b28d279c4f","type":"GO_TERM","name":"T-helper 17 type immune response","canonical_id":"go:GO:0072538","description":"\"An immune response which is associated with resistance to intracellular bacteria with a key role in inflammation and tissue injury. This immune response is associated with pathological autoimmune conditions such as multiple sclerosis, arthritis and psoriasis which is typically orchestrated by the production of particular cytokines by T-helper 17 cells, most notably interleukin-17, IL-21 and IL-22.\" [GOC:BHF, GOC:ebc]","metadata":null},{"id":"cec9ebc613224da081aad99673c2062a","type":"GO_TERM","name":"T-helper 2 cell activation","canonical_id":"go:GO:0035712","description":"\"The change in morphology and behavior of a T helper 2 cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [CL:0000546, GOC:BHF]","metadata":null},{"id":"5d7fc66ebef94964b7e3a5210f20566e","type":"GO_TERM","name":"T-helper 2 cell chemotaxis","canonical_id":"go:GO:0035707","description":"\"The directed movement of a T-helper 2 cell in response to an external stimulus.\" [CL:0000546, GOC:BHF]","metadata":null},{"id":"9ffa55546c29419f9cbe5ef1db1e846b","type":"GO_TERM","name":"T-helper 2 cell cytokine production","canonical_id":"go:GO:0035745","description":"\"Any process that contributes to cytokine production by a T-helper 2 cell.\" [CL:0000546, GOC:BHF]","metadata":null},{"id":"a31b4df2904a48399ec988ddb63fc273","type":"GO_TERM","name":"T-helper 2 cell differentiation","canonical_id":"go:GO:0045064","description":"\"The process in which a relatively unspecialized T cell acquires specialized features of a T-helper 2 (Th2) cell. A Th2 cell is a CD4-positive, alpha-beta T cell that has the phenotype GATA-3-positive and produces interleukin-4.\" [CL:0000546, GOC:ebc]","metadata":null},{"id":"8a2669b4bccd423d92816216c9dbccb0","type":"GO_TERM","name":"T-helper 2 cell lineage commitment","canonical_id":"go:GO:0002297","description":"\"The process in which a CD4-positive, alpha-beta T cell becomes committed to becoming a T-helper 2 cell, a CD4-positive, alpha-beta T cell specialized to promote immunological processes often associated with resistance to extracellular organisms such as helminths, enhanced production of particular antibody isotypes, and pathological conditions such as allergy.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b3347fff52bf4d86824064533159580f","type":"GO_TERM","name":"T-helper cell differentiation","canonical_id":"go:GO:0042093","description":"\"The process in which a relatively unspecialized thymocyte acquires specialized features of a T-helper cell.\" [GOC:ebc]","metadata":null},{"id":"5ac32be6fdda4e509aa7fd839ccf3ee9","type":"GO_TERM","name":"T-helper cell lineage commitment","canonical_id":"go:GO:0002295","description":"\"The process in which a CD4-positive, alpha-beta T cell becomes committed to becoming a T-helper cell, a CD4-positive, alpha-beta T cell specialized to promote various immunological processes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"261fed1665fb4beb922c52bd2780defd","type":"GO_TERM","name":"T-tubule","canonical_id":"go:GO:0030315","description":"\"Invagination of the plasma membrane of a muscle cell that extends inward from the cell surface around each myofibril. The ends of T-tubules make contact with the sarcoplasmic reticulum membrane.\" [GOC:mtg_muscle, ISBN:0815316194]","metadata":null},{"id":"737b004ff7ce4307993bd1a37e2e3548","type":"GO_TERM","name":"T-tubule organization","canonical_id":"go:GO:0033292","description":"\"A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of the T-tubule. A T-tubule is an invagination of the plasma membrane of a muscle cell that extends inward from the cell surface around each myofibril.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"f2a4f8293e154d81b521b559b5431583","type":"GO_TERM","name":"T/G mismatch-specific endonuclease activity","canonical_id":"go:GO:0043765","description":"\"Catalysis of the repair of T/G mismatches arising from deamination of 5-methylcytosine in DNA by nicking double-stranded DNA within the sequence CT(AT)GN or NT(AT)GG next to the mismatched thymidine residue. The incision is mismatch-dependent and strand-specific, in favor of the G-containing strand. The incision serves as a starting point for subsequent excision repair by DNA polymerase I, which excises thymidine and reinserts cytidine.\" [PMID:17651368]","metadata":null},{"id":"22166fb937e943c49b286c5169ed5c81","type":"TRIAL","name":"T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT00939653","description":"Relapsed Acute Myelogenous Leukemia","metadata":null},{"id":"afcb57221dae4b3697b8b85803a42791","type":"DRUG","name":"T4","canonical_id":"gtopdb:2635","description":null,"metadata":null},{"id":"1e645077b25c4f6c9569dbe04611190b","type":"GO_TERM","name":"T=1 icosahedral viral capsid","canonical_id":"go:GO:0039615","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=1 symmetry. The T=1 capsid is composed of 12 pentameric capsomeres.\" [VZ:1057]","metadata":null},{"id":"6566c17e79504e43b01314b8046a21aa","type":"GO_TERM","name":"T=13 icosahedral viral capsid","canonical_id":"go:GO:0039621","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=13 symmetry. The T=13 capsid is composed of 12 pentameric and 120 hexameric capsomeres.\" [VZ:260]","metadata":null},{"id":"db81d1bbd5c74005a217c4b4c7e82040","type":"GO_TERM","name":"T=147 icosahedral capsid","canonical_id":"go:GO:0039627","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=147 symmetry. T=147 icosahedral capsid is composed of 12 pentameric and 1460 hexameric capsomeres for a total of 8820 capsid proteins.\" [GOC:plm, UniProtKB-KW:KW-0167]","metadata":null},{"id":"fed1aa1d5e484c41933aee79aee4f09e","type":"GO_TERM","name":"T=16 icosahedral viral capsid","canonical_id":"go:GO:0039622","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=16 symmetry. The T=16 capsid is composed of 12 pentameric and 150 hexameric capsomeres.\" [VZ:807]","metadata":null},{"id":"6653afcd4a124e678a471f8fe71f9b6d","type":"GO_TERM","name":"T=169 icosahedral viral capsid","canonical_id":"go:GO:0039628","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=169 symmetry. T=169 icosahedral capsid is composed of 12 pentameric and 1680 hexameric capsomeres for a total of 10140 capsid proteins.\" [GOC:plm, VZ:10117]","metadata":null},{"id":"c090e252747a4d16b2eef92066f1044a","type":"GO_TERM","name":"T=2 icosahedral viral capsid","canonical_id":"go:GO:0039616","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=2 symmetry. The T=2 capsid is composed of 12 pentameric dimers.\" [VZ:838]","metadata":null},{"id":"5bc9b0bcb0ac48b9a466982f420cc36c","type":"GO_TERM","name":"T=21/pseudo21 icosahedral capsid","canonical_id":"go:GO:0160169","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=21 or pseudo T=21 symmetry.\" [VZ:833]","metadata":null},{"id":"520fe1864d98425fb7c3d32ded984c38","type":"GO_TERM","name":"T=219 icosahedral capsid","canonical_id":"go:GO:0039629","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=219 symmetry. T=219 icosahedral capsid is composed of 12 pentameric and 2180 hexameric capsomeres for a total of 13140 capsid proteins.\" [GOC:plm, UniProtKB-KW:KW-1151]","metadata":null},{"id":"a4cb34875dc24150a16df2f56644beb3","type":"GO_TERM","name":"T=25 icosahedral viral capsid","canonical_id":"go:GO:0039623","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=25 symmetry. The T=25 capsid is composed of 12 pentameric and 240 hexameric capsomeres.\" [VZ:810]","metadata":null},{"id":"36796ff377614718be41946e2be0fc30","type":"GO_TERM","name":"T=27/pseudo27 icosahedral capsid","canonical_id":"go:GO:0160170","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=27 or pseudo T=27 symmetry.\" [VZ:1556]","metadata":null},{"id":"46fc9ec5aeee4f53a39b302d77a1be01","type":"GO_TERM","name":"T=28 icosahedral capsid","canonical_id":"go:GO:0160171","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=28 symmetry.\" [VZ:6057]","metadata":null},{"id":"b2e1c441ef76411da5b4bbf048ee17bf","type":"GO_TERM","name":"T=3 icosahedral viral capsid","canonical_id":"go:GO:0039617","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=3 symmetry. The T=3 capsid is composed of 12 pentameric and 20 hexameric capsomeres.\" [VZ:806]","metadata":null},{"id":"41d909dce1bd4982907d4ad0ef530067","type":"GO_TERM","name":"T=31/pseudo31 icosahedral capsid","canonical_id":"go:GO:0160172","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=31 or pseudo T=31 symmetry.\" [VZ:7036]","metadata":null},{"id":"df0e5c12fb024effadba10ec1ce41071","type":"GO_TERM","name":"T=4 icosahedral viral capsid","canonical_id":"go:GO:0039619","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=4 symmetry. The T=4 capsid is composed of 12 pentameric and 30 hexameric capsomeres.\" [VZ:808]","metadata":null},{"id":"7a901017a1a243a3833c67ef57c34721","type":"GO_TERM","name":"T=7 icosahedral viral capsid","canonical_id":"go:GO:0039620","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=7 symmetry. The T=7 capsid is composed of 12 pentameric and 60 hexameric capsomeres.\" [VZ:804]","metadata":null},{"id":"9fb9a61e5d474302af9ceb1b9f5ac3c5","type":"GO_TERM","name":"T=9 icosahedral viral capsid","canonical_id":"go:GO:0160168","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with T=9 symmetry. The T=9 capsid is composed of 12 pentameric and 80 hexameric capsomeres.\" [PMID:37138077]","metadata":null},{"id":"8a3700689aea4337bfb6c0716df6cba3","type":"GO_TERM","name":"T=pseudo3 icosahedral viral capsid","canonical_id":"go:GO:0039618","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles where the subunits (capsomeres) are arranged to form an icosahedron with pseudo T=3 symmetry. The T=pseudo3 capsid is composed of 12 pentameric and 20 hexameric capsomeres.\" [VZ:809]","metadata":null},{"id":"eff2ad13fc654528aaa3e868a392814b","type":"GENE","name":"TAAR1","canonical_id":"hgnc:HGNC:17734","description":"trace amine associated receptor 1","metadata":{"aliases":["TAR1","TA1","TRAR1"]}},{"id":"fe563723ee014cca976f863a6d8de7f2","type":"GENE","name":"TAAR2","canonical_id":"hgnc:HGNC:4514","description":"trace amine associated receptor 2","metadata":{"aliases":["GPR58"]}},{"id":"03ef1cb20d8348d4969d01e33ef8ae58","type":"GENE","name":"TAAR3P","canonical_id":"hgnc:HGNC:4513","description":"trace amine associated receptor 3, pseudogene","metadata":{"aliases":["GPR57","TAAR3"]}},{"id":"0640690069f14d7e9aa8b6f40ecda895","type":"GENE","name":"TAAR4P","canonical_id":"hgnc:HGNC:31924","description":"trace amine associated receptor 4, pseudogene","metadata":null},{"id":"8f92759fd3c04ce2bbc31370742962f9","type":"GENE","name":"TAAR5","canonical_id":"hgnc:HGNC:30236","description":"trace amine associated receptor 5","metadata":{"aliases":["PNR"]}},{"id":"539c82f255c04e26948a6610461e2c79","type":"GENE","name":"TAAR6","canonical_id":"hgnc:HGNC:20978","description":"trace amine associated receptor 6","metadata":{"aliases":["TA4","TRAR4"]}},{"id":"5d15be4bab7a40a3a24cb87abad50794","type":"GENE","name":"TAAR7P","canonical_id":"hgnc:HGNC:31925","description":"trace amine associated receptor 7, pseudogene","metadata":null},{"id":"65f6d7e1cb7f4d8882e8f9e303a0d54c","type":"GENE","name":"TAAR8","canonical_id":"hgnc:HGNC:14964","description":"trace amine associated receptor 8","metadata":{"aliases":["TA5","TAR5","GPR102","TRAR5"]}},{"id":"25023eb103334127b8b5572d7fad9be1","type":"GENE","name":"TAAR9","canonical_id":"hgnc:HGNC:20977","description":"trace amine associated receptor 9","metadata":{"aliases":["TA3","TAR3","TRAR3"]}},{"id":"551b0fa6fb9345f29e0b73033f6bb9af","type":"GENE","name":"TAB1","canonical_id":"hgnc:HGNC:18157","description":"TGF-beta activated kinase 1 (MAP3K7) binding protein 1","metadata":{"aliases":["MAP3K7IP1"]}},{"id":"9ce87bff607744ae8e6568c1fad570b6","type":"GENE","name":"TAB2","canonical_id":"hgnc:HGNC:17075","description":"TGF-beta activated kinase 1 (MAP3K7) binding protein 2","metadata":{"aliases":["KIAA0733","MAP3K7IP2"]}},{"id":"36920235f00a47aab5464a0c41685a5e","type":"GENE","name":"TAB2-AS1","canonical_id":"hgnc:HGNC:53508","description":"TAB2 antisense RNA 1","metadata":null},{"id":"dfe7b9ba0e8f41f1ad5790613ed813d0","type":"GENE","name":"TAB3","canonical_id":"hgnc:HGNC:30681","description":"TGF-beta activated kinase 1 (MAP3K7) binding protein 3","metadata":{"aliases":["MAP3K7IP3"]}},{"id":"bc192ce1eb324502b5be552e554b7576","type":"GENE","name":"TAB3-AS1","canonical_id":"hgnc:HGNC:20176","description":"TAB3 antisense RNA 1","metadata":{"aliases":["OTTHUMG00000021331","CXorf29"]}},{"id":"91d56cc27aa34bc2a108b881f72fe33c","type":"GENE","name":"TAB3-AS2","canonical_id":"hgnc:HGNC:40013","description":"TAB3 antisense RNA 2","metadata":null},{"id":"86d57e8c3cc14c45969a9241a978ca0f","type":"GENE","name":"TAB3P1","canonical_id":"hgnc:HGNC:37723","description":"TGF-beta activated kinase 1/MAP3K7 binding protein 3 pseudogene 1","metadata":null},{"id":"420f453fc57e4ba4b25f1b884ecbd036","type":"GENE","name":"TAC1","canonical_id":"hgnc:HGNC:11517","description":null,"metadata":null},{"id":"3fdb1204fca44666afb6772422f46c65","type":"GENE","name":"TAC3","canonical_id":"hgnc:HGNC:11521","description":null,"metadata":null},{"id":"a665b93941384a16997605496b3f0747","type":"GENE","name":"TAC4","canonical_id":"hgnc:HGNC:16641","description":"tachykinin precursor 4","metadata":{"aliases":["HK-1","Pptc","PPT-C"]}},{"id":"07f773d4a99e48b3ae0f90515bba8603","type":"GENE","name":"TAC4-AS1","canonical_id":"hgnc:HGNC:58214","description":"TAC4 antisense RNA 1","metadata":null},{"id":"04d6919bc7a84575b5e813dc9e6600d5","type":"GO_TERM","name":"TACC/TOG complex","canonical_id":"go:GO:0070850","description":"\"A protein complex that contains the transforming acidic coiled coil (TACC) protein and the TOG protein (Mia1p/Alp7p and Alp14, respectively, in fission yeast), and is involved in microtubule array remodeling as cells progress through the cell cycle. The TACC/TOG complex is conserved in eukaryotes, associates with microtubules, and shuttles between the nucleus and the cytoplasm during interphase.\" [GOC:mah, GOC:vw, PMID:19606211]","metadata":null},{"id":"abaaa7f2272946bda2fe3329af5f663a","type":"GENE","name":"TACC1","canonical_id":"hgnc:HGNC:11522","description":"transforming acidic coiled-coil containing protein 1","metadata":null},{"id":"1654c75e219148ff93e1bb7902ab1b43","type":"GENE","name":"TACC1P1","canonical_id":"hgnc:HGNC:44974","description":"transforming acidic coiled-coil containing protein 1 pseudogene 1","metadata":null},{"id":"c1117364433342ffb5670b61e9de649e","type":"GENE","name":"TACC2","canonical_id":"hgnc:HGNC:11523","description":"transforming acidic coiled-coil containing protein 2","metadata":{"aliases":["AZU-1","ECTACC"]}},{"id":"56144a68dba0441d94f8248ffa4884dc","type":"GENE","name":"TACC3","canonical_id":"hgnc:HGNC:11524","description":"transforming acidic coiled-coil containing protein 3","metadata":{"aliases":["ERIC1","ERIC-1","maskin","Tacc4"]}},{"id":"d916182a7fdf47cf87268c601d3dade7","type":"TRIAL","name":"TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT04988945","description":"HCC","metadata":null},{"id":"3d376738f99147549832932424ba4e43","type":"TRIAL","name":"TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC","canonical_id":"clinicaltrials.gov:NCT05250843","description":"Hepatocellular Carcinoma","metadata":null},{"id":"77d9f4ba57664914893b64425f2ad226","type":"GENE","name":"TACO1","canonical_id":"hgnc:HGNC:24316","description":"translational activator of cytochrome c oxidase I","metadata":{"aliases":["CCDC44"]}},{"id":"e77c50bfabcf46bd8baea171cdc1191f","type":"GENE","name":"TACR1","canonical_id":"hgnc:HGNC:11526","description":"tachykinin receptor 1","metadata":{"aliases":["SPR","NK1R","NKIR","TAC1R"]}},{"id":"158b047cd90a475ca3d36bf012b13aee","type":"PROTEIN","name":"TACR1","canonical_id":"uniprot:P25103","description":null,"metadata":null},{"id":"061e17ac56a84833b0d740d8bb2cb954","type":"GENE","name":"TACR1-AS1","canonical_id":"hgnc:HGNC:58209","description":"TACR1 antisense RNA 1","metadata":null},{"id":"a41a0bb5322e44ba9dbe017dd076b496","type":"GENE","name":"TACR2","canonical_id":"hgnc:HGNC:11527","description":"tachykinin receptor 2","metadata":{"aliases":["SKR","NK2R","TAC2R","NKNAR"]}},{"id":"9775c8689a104a5fa31a8a3fafcb19cc","type":"GENE","name":"TACR3","canonical_id":"hgnc:HGNC:11528","description":"tachykinin receptor 3","metadata":{"aliases":["NK3R","NKR","TAC3R"]}},{"id":"24012a3116c942dbbb948cbc2ae53e9f","type":"PROTEIN","name":"TACR3","canonical_id":"uniprot:P29371","description":null,"metadata":null},{"id":"ded63119edb4499da062e91e820f253a","type":"GENE","name":"TACR3-AS1","canonical_id":"hgnc:HGNC:55593","description":"TACR3 antisense RNA 1","metadata":{"aliases":["RP11-297P16.3"]}},{"id":"6ee3361775c444838e9d3b3926cd3b2a","type":"GENE","name":"TACSTD2","canonical_id":"hgnc:HGNC:11530","description":"tumor associated calcium signal transducer 2","metadata":{"aliases":["TROP2","GA733-1","EGP-1","M1S1"]}},{"id":"f885b6dd2c7047e5964f6c40fa8ee092","type":"PROTEIN","name":"TACSTD2","canonical_id":"uniprot:P09758","description":null,"metadata":null},{"id":"85c5584bbb014535b721e9573a3c0523","type":"GENE","name":"TADA1","canonical_id":"hgnc:HGNC:30631","description":"transcriptional adaptor 1","metadata":{"aliases":["STAF42","ADA1","hADA1","HFI1","TADA1L"]}},{"id":"8718e67ba71d4bbd8683af5b55281eef","type":"GENE","name":"TADA2A","canonical_id":"hgnc:HGNC:11531","description":"transcriptional adaptor 2A","metadata":{"aliases":["ADA2","hADA2","ADA2A","TADA2L"]}},{"id":"d513d3fb72e74a55b77c58699a0ccd71","type":"GENE","name":"TADA2B","canonical_id":"hgnc:HGNC:30781","description":"transcriptional adaptor 2B","metadata":{"aliases":["MGC21874"]}},{"id":"58da949e290e4dca8c54a0d77a8ea72c","type":"GENE","name":"TADA3","canonical_id":"hgnc:HGNC:19422","description":"transcriptional adaptor 3","metadata":{"aliases":["FLJ20221","FLJ21329","ADA3","hADA3","NGG1","TADA3L"]}},{"id":"5aab1002065c4f77b82a6abc069e59b7","type":"GENE","name":"TAF1","canonical_id":"hgnc:HGNC:11535","description":null,"metadata":null},{"id":"4fbe4cc5c23b4a5aa056859449424775","type":"GENE","name":"TAF10","canonical_id":"hgnc:HGNC:11543","description":"TATA-box binding protein associated factor 10","metadata":{"aliases":["TAFII30","TAF2H","TAF2A"]}},{"id":"d7aa9ef5ae9b488ca73e6034a4c56943","type":"GENE","name":"TAF11","canonical_id":"hgnc:HGNC:11544","description":"TATA-box binding protein associated factor 11","metadata":{"aliases":["TAFII28","TAF2I"]}},{"id":"e1ce80380d1a4f979dc9cff9a9f3ed6c","type":"GENE","name":"TAF11L1","canonical_id":"hgnc:HGNC:53838","description":"TATA-box binding protein associated factor 11 like 1 (pseudogene)","metadata":null},{"id":"7e6b6141a7bb42fab0a37f30f26579bd","type":"GENE","name":"TAF11L10","canonical_id":"hgnc:HGNC:53853","description":"TATA-box binding protein associated factor 11 like 10","metadata":null},{"id":"1108d322083e48858e2b4b964d73592c","type":"GENE","name":"TAF11L11","canonical_id":"hgnc:HGNC:53854","description":"TATA-box binding protein associated factor 11 like 11","metadata":null},{"id":"69385ed5719b4e3f97cc9c3b64f11d79","type":"GENE","name":"TAF11L12","canonical_id":"hgnc:HGNC:53855","description":"TATA-box binding protein associated factor 11 like 12","metadata":null},{"id":"54626e66537041ce84b2341bd8b38798","type":"GENE","name":"TAF11L13","canonical_id":"hgnc:HGNC:53856","description":"TATA-box binding protein associated factor 11 like 13","metadata":null},{"id":"006df6e4eb934332bb8ccbf71525040d","type":"GENE","name":"TAF11L14","canonical_id":"hgnc:HGNC:53857","description":"TATA-box binding protein associated factor 11 like 14","metadata":null},{"id":"b500d30b58ca4102b4426f1572889dd0","type":"GENE","name":"TAF11L2","canonical_id":"hgnc:HGNC:53845","description":"TATA-box binding protein associated factor 11 like 2","metadata":null},{"id":"696d4139c5eb43f7ba1565ccabaa02e4","type":"GENE","name":"TAF11L3","canonical_id":"hgnc:HGNC:53846","description":"TATA-box binding protein associated factor 11 like 3","metadata":null},{"id":"7f966a132e3a4c35a068238bea835aa6","type":"GENE","name":"TAF11L4","canonical_id":"hgnc:HGNC:53847","description":"TATA-box binding protein associated factor 11 like 4","metadata":null},{"id":"7151d838fa624ec28d75707daad41397","type":"GENE","name":"TAF11L5","canonical_id":"hgnc:HGNC:53848","description":"TATA-box binding protein associated factor 11 like 5","metadata":null},{"id":"458a111134ed4f2ab07a4d2c314a7095","type":"GENE","name":"TAF11L6","canonical_id":"hgnc:HGNC:53849","description":"TATA-box binding protein associated factor 11 like 6","metadata":null},{"id":"e2d1897091104af9b744a8af48506e4f","type":"GENE","name":"TAF11L7","canonical_id":"hgnc:HGNC:53850","description":"TATA-box binding protein associated factor 11 like 7","metadata":null},{"id":"9281c36f2e28432990115b06343b19b9","type":"GENE","name":"TAF11L8","canonical_id":"hgnc:HGNC:53851","description":"TATA-box binding protein associated factor 11 like 8","metadata":null},{"id":"25be1f4581b7454dbd3e2dc5bbf32bde","type":"GENE","name":"TAF11L9","canonical_id":"hgnc:HGNC:53852","description":"TATA-box binding protein associated factor 11 like 9","metadata":null},{"id":"d791256fb5f04f26b8fcd31afe390d85","type":"GENE","name":"TAF12","canonical_id":"hgnc:HGNC:11545","description":null,"metadata":null},{"id":"e60af29969cd48ab9b43cb2ef3d62529","type":"GENE","name":"TAF12-DT","canonical_id":"hgnc:HGNC:52502","description":"TAF12 divergent transcript","metadata":{"aliases":["LINC01715"]}},{"id":"73c5f5f69a1e4ee49154966d3b4d5dbe","type":"GENE","name":"TAF13","canonical_id":"hgnc:HGNC:11546","description":"TATA-box binding protein associated factor 13","metadata":{"aliases":["TAFII18","TAF2K"]}},{"id":"a63418d58dcc494d925bbc71a098bb0c","type":"GENE","name":"TAF13P1","canonical_id":"hgnc:HGNC:18699","description":"TATA-box binding protein associated factor 13 pseudogene 1","metadata":{"aliases":["TAF13P"]}},{"id":"28ecf114e0474e75be921741ba0cd806","type":"GENE","name":"TAF13P2","canonical_id":"hgnc:HGNC:38161","description":"TATA-box binding protein associated factor 13 pseudogene 2","metadata":null},{"id":"0827a0e107664117b4c3d8817a26294a","type":"GENE","name":"TAF15","canonical_id":"hgnc:HGNC:11547","description":"TATA-box binding protein associated factor 15","metadata":{"aliases":["hTAFII68","RBP56","Npl3","TAF2N"]}},{"id":"239df33fdec54465bf0c18306f357dde","type":"GENE","name":"TAF1A","canonical_id":"hgnc:HGNC:11532","description":null,"metadata":null},{"id":"aa98d3e46dc24deeae1f7b457e98f9cc","type":"GENE","name":"TAF1A-AS1","canonical_id":"hgnc:HGNC:40573","description":"TAF1A antisense RNA 1","metadata":null},{"id":"eaefbce844cc4c95b7794b5d0f4398b7","type":"GENE","name":"TAF1B","canonical_id":"hgnc:HGNC:11533","description":null,"metadata":null},{"id":"86832f37d1ac4c849a288a760c9acb4c","type":"GENE","name":"TAF1C","canonical_id":"hgnc:HGNC:11534","description":"TATA-box binding protein associated factor, RNA polymerase I subunit C","metadata":{"aliases":["TAFI110","TAFI95","SL1","MGC:39976"]}},{"id":"8cf4d0b7853940abb952f296f0e8c617","type":"GENE","name":"TAF1D","canonical_id":"hgnc:HGNC:28759","description":"TATA-box binding protein associated factor, RNA polymerase I subunit D","metadata":{"aliases":["MGC5306","TAF(I)41","JOSD3"]}},{"id":"152bc9a13eea46ce8f2845916e74798e","type":"GENE","name":"TAF1L","canonical_id":"hgnc:HGNC:18056","description":"TATA-box binding protein associated factor 1 like","metadata":null},{"id":"f0c3c7a4ae024bd9a1e6b931161cff5f","type":"GENE","name":"TAF2","canonical_id":"hgnc:HGNC:11536","description":"TATA-box binding protein associated factor 2","metadata":{"aliases":["TAFII150","CIF150","TAF2B"]}},{"id":"e3c942577a3e4a7aa3a0ff596c9888de","type":"GENE","name":"TAF3","canonical_id":"hgnc:HGNC:17303","description":"TATA-box binding protein associated factor 3","metadata":{"aliases":["TAF140","TAFII140"]}},{"id":"8fa2bd160b2e4851bd372078b33e2c1d","type":"GENE","name":"TAF4","canonical_id":"hgnc:HGNC:11537","description":null,"metadata":null},{"id":"5e92d3f8cd524fdf91958d0b6945c37e","type":"GENE","name":"TAF4B","canonical_id":"hgnc:HGNC:11538","description":"TATA-box binding protein associated factor 4b","metadata":{"aliases":["TAFII105","TAF2C2"]}},{"id":"4826ce162ea845b3973c74e2740fbb5d","type":"GO_TERM","name":"TAF4B-containing transcription factor TFIID complex","canonical_id":"go:GO:0070556","description":"\"A transcription factor TFIID complex that contains the TBP-associated factor TAF4B (also known as TAFII105 in human), a cell-type-specific variant of TAF4.\" [GOC:mah, PMID:8858156]","metadata":null},{"id":"0780258387714c2b9fa6be472c9899f7","type":"GENE","name":"TAF5","canonical_id":"hgnc:HGNC:11539","description":null,"metadata":null},{"id":"5ed66c49099e461fb39bf8a1ddaa206b","type":"GENE","name":"TAF5L","canonical_id":"hgnc:HGNC:17304","description":"TATA-box binding protein associated factor 5 like","metadata":{"aliases":["PAF65B"]}},{"id":"7a3255d3ae5f4aa89baf46e001ad614f","type":"GENE","name":"TAF5LP1","canonical_id":"hgnc:HGNC:24115","description":"TATA-box binding protein associated factor 5 like pseudogene 1","metadata":{"aliases":["HsT33855","TAF5LP"]}},{"id":"11ada69d9c054a099fbd0b41659a4084","type":"GENE","name":"TAF6","canonical_id":"hgnc:HGNC:11540","description":"TATA-box binding protein associated factor 6","metadata":{"aliases":["TAFII70","TAFII80","MGC:8964","TAFII85","TAF2E"]}},{"id":"ce9772cb7c0f4678a2df87a12b990b49","type":"GENE","name":"TAF6L","canonical_id":"hgnc:HGNC:17305","description":"TATA-box binding protein associated factor 6 like","metadata":{"aliases":["PAF65A"]}},{"id":"15d40d2a05514b48a801262cb518e42a","type":"GENE","name":"TAF7","canonical_id":"hgnc:HGNC:11541","description":null,"metadata":null},{"id":"d103f492deeb4238b5af8682921dfc0a","type":"GENE","name":"TAF7L","canonical_id":"hgnc:HGNC:11548","description":"TATA-box binding protein associated factor 7 like","metadata":{"aliases":["CT40","TAF2Q"]}},{"id":"0f650625bf4c46a094eb2b02eef10a1b","type":"GENE","name":"TAF8","canonical_id":"hgnc:HGNC:17300","description":"TATA-box binding protein associated factor 8","metadata":{"aliases":["FLJ32821","TAF(II)43","TBN"]}},{"id":"302f75a32ad14ac298a451849133d488","type":"GENE","name":"TAF9","canonical_id":"hgnc:HGNC:11542","description":"TATA-box binding protein associated factor 9","metadata":{"aliases":["TAFII31","TAFII32","TAFIID32","MGC5067","CGI-137","MGC1603","MGC3647","AD-004","TAF2G"]}},{"id":"eecc1795213941a7befad0d2a4a6cd74","type":"GENE","name":"TAF9B","canonical_id":"hgnc:HGNC:17306","description":"TATA-box binding protein associated factor 9b","metadata":{"aliases":["TAFII31L","DN-7","DN7","TFIID-31","TAF9L"]}},{"id":"c7504a764ec841a69cef67c572361f52","type":"GENE","name":"TAF9BP1","canonical_id":"hgnc:HGNC:30687","description":"TATA-box binding protein associated factor 9b pseudogene 1","metadata":null},{"id":"8698d1441d6d4862b196c277105a56fb","type":"GENE","name":"TAF9BP2","canonical_id":"hgnc:HGNC:38836","description":"TATA-box binding protein associated factor 9b pseudogene 2","metadata":null},{"id":"3e62248158934511b4ad92f7b1e4e4fb","type":"GENE","name":"TAF9P1","canonical_id":"hgnc:HGNC:31743","description":"TATA-box binding protein associated factor 9 pseudogene 1","metadata":null},{"id":"c02f4fb465124092a439852b8b27657f","type":"GENE","name":"TAF9P2","canonical_id":"hgnc:HGNC:31744","description":"TATA-box binding protein associated factor 9 pseudogene 2","metadata":null},{"id":"7d15ff886bb543188af70d72b5195528","type":"GENE","name":"TAF9P3","canonical_id":"hgnc:HGNC:30678","description":"TATA-box binding protein associated factor 9 pseudogene 3","metadata":{"aliases":["TAF2GL"]}},{"id":"860b8eedf0cf49f681887915bf0d0d0f","type":"GENE","name":"TAFA1","canonical_id":"hgnc:HGNC:21587","description":"TAFA chemokine like family member 1","metadata":{"aliases":["TAFA-1","FAM19A1"]}},{"id":"8f0799eb594842a1ab1904909c609f1c","type":"GENE","name":"TAFA2","canonical_id":"hgnc:HGNC:21589","description":"TAFA chemokine like family member 2","metadata":{"aliases":["TAFA-2","FAM19A2"]}},{"id":"9ebf21037a4b409bb11569e262e1b828","type":"GENE","name":"TAFA3","canonical_id":"hgnc:HGNC:21590","description":"TAFA chemokine like family member 3","metadata":{"aliases":["TAFA-3","FAM19A3"]}},{"id":"74ddfcb471ec47daa04f8768d8a55fb6","type":"GENE","name":"TAFA4","canonical_id":"hgnc:HGNC:21591","description":"TAFA chemokine like family member 4","metadata":{"aliases":["TAFA-4","FAM19A4"]}},{"id":"f9a270c7394441f9bd64d3fd03eb405b","type":"GENE","name":"TAFA5","canonical_id":"hgnc:HGNC:21592","description":"TAFA chemokine like family member 5","metadata":{"aliases":["TAFA-5","FAM19A5"]}},{"id":"29993903b9a54f78a79c8b703457ec4f","type":"GENE","name":"TAFA5-AS1","canonical_id":"hgnc:HGNC:27673","description":"TAFA5 antisense RNA 1","metadata":null},{"id":"92a35b45e4034bddbae48ee0f95bf3e1","type":"GENE","name":"TAFAZZIN","canonical_id":"hgnc:HGNC:11577","description":"tafazzin, phospholipid-lysophospholipid transacylase","metadata":{"aliases":["BTHS","G4.5","TAZ1","CMD3A","EFE2","EFE","TAZ"]}},{"id":"6e2e08f2ff344c5b8212f1da0cfd721e","type":"GENE","name":"TAGAP","canonical_id":"hgnc:HGNC:15669","description":"T cell activation RhoGTPase activating protein","metadata":{"aliases":["FLJ32631","IDDM21","ARHGAP47"]}},{"id":"e7358b5ff7304e31bc95721019616bf1","type":"GENE","name":"TAGAP-AS1","canonical_id":"hgnc:HGNC:55239","description":"TAGAP antisense RNA 1","metadata":null},{"id":"c9bdbddaa4ea47c5842a434f760800e4","type":"GENE","name":"TAGLN","canonical_id":"hgnc:HGNC:11553","description":null,"metadata":null},{"id":"da7322fae8fb4a43bf8ee3e19f2452c1","type":"GENE","name":"TAGLN2","canonical_id":"hgnc:HGNC:11554","description":"transgelin 2","metadata":{"aliases":["KIAA0120","HA1756"]}},{"id":"7053c59c797a4528a937bc09966c32b7","type":"GENE","name":"TAGLN2P1","canonical_id":"hgnc:HGNC:21739","description":"transgelin 2 pseudogene 1","metadata":null},{"id":"78a3811a1ef643759852d52dd2311136","type":"GENE","name":"TAGLN2P2","canonical_id":"hgnc:HGNC:31039","description":"transgelin 2 pseudogene 2","metadata":null},{"id":"2cafa35943a547c8848b3a0594a308bd","type":"GENE","name":"TAGLN3","canonical_id":"hgnc:HGNC:29868","description":"transgelin 3","metadata":{"aliases":["NP25","NP22"]}},{"id":"04502a90809c4d879bd21f6121aa7195","type":"GENE","name":"TAL1","canonical_id":"hgnc:HGNC:11556","description":null,"metadata":null},{"id":"822dc87f1f054712b01c42346d0214ee","type":"GENE","name":"TAL2","canonical_id":"hgnc:HGNC:11557","description":"TAL bHLH transcription factor 2","metadata":{"aliases":["bHLHa19"]}},{"id":"57c40d9252cd47178ac34e7cacdfb5ba","type":"GENE","name":"TALAM1","canonical_id":"hgnc:HGNC:54476","description":"TALAM1 transcript, MALAT1 antisense RNA","metadata":null},{"id":"087586ce0a2440489335f56205f9eb4a","type":"TRIAL","name":"TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03964532","description":"Breast Cancer","metadata":null},{"id":"67de2740f12c4050881a98f4d5a7e256","type":"GENE","name":"TALDO1","canonical_id":"hgnc:HGNC:11559","description":null,"metadata":null},{"id":"4ddbdf98bb6e4a95a5d502796666584b","type":"GENE","name":"TALDO1P1","canonical_id":"hgnc:HGNC:11560","description":"transaldolase 1 pseudogene 1","metadata":{"aliases":["TAL-H","TALDO","TALDOP1"]}},{"id":"075939051bbf4d1196158fce92653e30","type":"TRIAL","name":"TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT04678362","description":"Urothelial Carcinoma","metadata":null},{"id":"4b1ec54dc10247299a79201bcc2d6d20","type":"GO_TERM","name":"TAM protein secretion complex","canonical_id":"go:GO:0097347","description":"\"A heterooligomeric protein complex that spans the bacterial periplasm and enables the secretion of adhesin proteins in Gram-negative bacteria. In Citrobacter rodentium, Salmonella enterica and Escherichia coli, the TAM complex consists of an Omp85-family protein, TamA, in the outer membrane and TamB in the inner membrane.\" [GOC:am, PMID:22466966]","metadata":null},{"id":"9de708d5fa774598bdd5d530d25e32cc","type":"GENE","name":"TAMALIN","canonical_id":"hgnc:HGNC:18707","description":"trafficking regulator and scaffold protein tamalin","metadata":{"aliases":["GRASP"]}},{"id":"690ba66746d54b3fbca9238f0707dd7b","type":"GENE","name":"TAMALIN-AS1","canonical_id":"hgnc:HGNC:32680","description":"TAMALIN antisense RNA 1","metadata":{"aliases":["GRASPOS","GRASP-AS1"]}},{"id":"a2da846061444ffe9d4a0c35e95f4ed9","type":"TRIAL","name":"TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02879136","description":"Parkinson's Disease, Idiopathic","metadata":null},{"id":"f492d34f4b6a453e93a220257c8336b0","type":"GENE","name":"TAMM41","canonical_id":"hgnc:HGNC:25187","description":"TAM41 mitochondrial translocator assembly and maintenance homolog","metadata":{"aliases":["MGC16471","DKFZp434E0519","C3orf31"]}},{"id":"3e432da4291e4e98b439f733228ec1cc","type":"GENE","name":"TANAR","canonical_id":"hgnc:HGNC:56695","description":"TWIST1 associated long noncoding RNA regulated by androgen receptor","metadata":null},{"id":"d06eef5530464880b89c1fae8bd2ac4a","type":"GENE","name":"TANC1","canonical_id":"hgnc:HGNC:29364","description":"tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1","metadata":{"aliases":["KIAA1728","ROLSB"]}},{"id":"9e4bbf7e5fee4c4b86bbaafcdce1cc35","type":"GENE","name":"TANC2","canonical_id":"hgnc:HGNC:30212","description":"tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2","metadata":{"aliases":["DKFZP564D166","FLJ10215","FLJ11824","KIAA1148","KIAA1636","rols","ROLSA"]}},{"id":"9b7af58bda9648cda9880f143b421911","type":"GENE","name":"TANGO2","canonical_id":"hgnc:HGNC:25439","description":"transport and golgi organization 2 homolog","metadata":{"aliases":["DKFZp761P1121","C22orf25"]}},{"id":"c685a5d43c124aff957456b71949b093","type":"GENE","name":"TANGO2-AS1","canonical_id":"hgnc:HGNC:41096","description":"TANGO2 antisense RNA 1","metadata":null},{"id":"9f26df702ff746c8966c47cda8f09ad0","type":"GENE","name":"TANGO6","canonical_id":"hgnc:HGNC:25749","description":"transport and golgi organization 6 homolog","metadata":{"aliases":["FLJ12688","KIAA1746","TMCO7"]}},{"id":"a722c4b166314edeaaf675da8217acc0","type":"GENE","name":"TANK","canonical_id":"hgnc:HGNC:11562","description":"TRAF family member associated NFKB activator","metadata":{"aliases":["I-TRAF","TRAF2"]}},{"id":"ca1cc4b3acb24334a3bccb2181152912","type":"GENE","name":"TANK-AS1","canonical_id":"hgnc:HGNC:40575","description":"TANK antisense RNA 1","metadata":null},{"id":"b3fa04f5667041b5be1469e3435d956d","type":"GENE","name":"TAOK1","canonical_id":"hgnc:HGNC:29259","description":"TAO kinase 1","metadata":{"aliases":["KIAA1361","MARKK","PSK2","MAP3K16","FLJ14314","TAO1","hTAOK1","hKFC-B"]}},{"id":"418c5887ff924e8fbceee9920a79f7ff","type":"GENE","name":"TAOK2","canonical_id":"hgnc:HGNC:16835","description":"TAO kinase 2","metadata":{"aliases":["TAO1","KIAA0881","PSK","PSK1","TAO2","MAP3K17","hKFC-C","PSK-1","PSK1-BETA","Tao2beta"]}},{"id":"d9e45330e1ec4d4c80469f58579196c9","type":"GENE","name":"TAOK3","canonical_id":"hgnc:HGNC:18133","description":"TAO kinase 3","metadata":{"aliases":["JIK","DPK","MAP3K18"]}},{"id":"11445aeea7a748489805a99cc38b44c3","type":"TRIAL","name":"TAP Block , Intrathecal Morphine Or Their Combination For Post Operative Analgesia Following TAH","canonical_id":"clinicaltrials.gov:NCT06882369","description":"Post-operative Pain Management","metadata":null},{"id":"fbe6ebf072a64aaa85cbb1580995e410","type":"TRIAL","name":"TAP Versus Thoracic Epidural in Major Abdominal Resections","canonical_id":"clinicaltrials.gov:NCT02197988","description":"Malignant Neoplasm of Abdomen; Surgery","metadata":null},{"id":"283fba8d7b384743ac04a3c74c613926","type":"GO_TERM","name":"TAP binding","canonical_id":"go:GO:0046977","description":"\"Binding to TAP protein, transporter associated with antigen processing protein. TAP protein is a heterodimeric peptide transporter consisting of the subunits TAP1 and TAP2.\" [PMID:11133832]","metadata":null},{"id":"b5294e5de456417392d6b78867216512","type":"GO_TERM","name":"TAP complex","canonical_id":"go:GO:0042825","description":"\"A heterodimer composed of the subunits TAP1 and TAP2 (transporter associated with antigen presentation). Functions in the transport of antigenic peptides from the cytosol to the lumen of the endoplasmic reticulum.\" [GOC:jl, PMID:10618487, PMID:10631934]","metadata":null},{"id":"782e118f5aba4e4885b3e4dd67a1cc57","type":"GO_TERM","name":"TAP complex binding","canonical_id":"go:GO:0062061","description":"\"Binding to a TAP complex.\" [PMID:17947644]","metadata":null},{"id":"35d7d8c98e0d48ecb9a805baf9a43868","type":"GENE","name":"TAP1","canonical_id":"hgnc:HGNC:43","description":null,"metadata":null},{"id":"cd6deba146434ecd80ffea14f8e910a1","type":"GO_TERM","name":"TAP1 binding","canonical_id":"go:GO:0046978","description":"\"Binding to the TAP1 subunit of TAP (transporter associated with antigen processing) protein.\" [PMID:11133832]","metadata":null},{"id":"a48da3774b34463a8af1fb08ae383cc1","type":"GENE","name":"TAP2","canonical_id":"hgnc:HGNC:44","description":null,"metadata":null},{"id":"818d228ac8094f9b8811d33982c6794c","type":"GO_TERM","name":"TAP2 binding","canonical_id":"go:GO:0046979","description":"\"Binding to the TAP2 subunit of TAP (transporter associated with antigen processing) protein.\" [PMID:11133832]","metadata":null},{"id":"87fd7466c0ba4d4abbd0dbad404c5843","type":"GENE","name":"TAPBP","canonical_id":"hgnc:HGNC:11566","description":null,"metadata":null},{"id":"885120cbbf0d4fcd8c944543cffab441","type":"GENE","name":"TAPBPL","canonical_id":"hgnc:HGNC:30683","description":"TAP binding protein like","metadata":{"aliases":["TAPBP-R","FLJ10143","TAPBPR"]}},{"id":"ce9c4b5dbd044065875faf145564ec2a","type":"GENE","name":"TAPT1","canonical_id":"hgnc:HGNC:26887","description":"transmembrane anterior posterior transformation 1","metadata":{"aliases":["FLJ90013"]}},{"id":"68d5983058aa46ae9c641ae85eec8845","type":"GENE","name":"TAPT1-AS1","canonical_id":"hgnc:HGNC:26832","description":"TAPT1 antisense RNA 1","metadata":{"aliases":["FLJ39653"]}},{"id":"deaad96e075a4381889907210daa3f8c","type":"TRIAL","name":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","canonical_id":"clinicaltrials.gov:NCT02693535","description":"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors","metadata":null},{"id":"1943d8b2535049728e1ff8d2ae0dc010","type":"GENE","name":"TARBP1","canonical_id":"hgnc:HGNC:11568","description":"tRNA guanosine 2 -O-methyltransferase TARBP1","metadata":{"aliases":["TRP-185","TRM3","TRMT3"]}},{"id":"282707d26219460fbc565c2abd23a920","type":"GENE","name":"TARBP2","canonical_id":"hgnc:HGNC:11569","description":"TARBP2 subunit of RISC loading complex","metadata":{"aliases":["Trbp"]}},{"id":"ef15a170afb0402a93e788e7a06333ac","type":"GENE","name":"TARBP2P1","canonical_id":"hgnc:HGNC:11570","description":"TARBP2 pseudogene 1","metadata":{"aliases":["TRBP","TARBP2P"]}},{"id":"c6bfdd78d62e454d985410e3a3ca3a04","type":"GENE","name":"TARDBP","canonical_id":"hgnc:HGNC:11571","description":"TAR DNA binding protein","metadata":{"aliases":["TDP-43","ALS10"]}},{"id":"c1ca3c7b7a83428a982fec811ad4b1f9","type":"GENE","name":"TARDBPP1","canonical_id":"hgnc:HGNC:16536","description":"TARDBP pseudogene 1","metadata":{"aliases":["bA318P23.1","TARDBPL"]}},{"id":"0372572a755f46cd8c17a11e27baa6f6","type":"GENE","name":"TARDBPP2","canonical_id":"hgnc:HGNC:39848","description":"TARDBP pseudogene 2","metadata":null},{"id":"0d8bd82342b0476d9893ff0abd83d554","type":"GENE","name":"TARDBPP3","canonical_id":"hgnc:HGNC:55122","description":"TARDBP pseudogene 3","metadata":null},{"id":"f1a81063b8b3459a98b09fb1aaf5dab8","type":"GENE","name":"TARDBPP4","canonical_id":"hgnc:HGNC:55123","description":"TARDBP pseudogene 4","metadata":null},{"id":"659b9d665a8f45d4ba605ba52e73bd14","type":"GENE","name":"TARDBPP5","canonical_id":"hgnc:HGNC:55124","description":"TARDBP pseudogene 5","metadata":null},{"id":"9d7d092e89cf4b79bae18ebd387b0dee","type":"GENE","name":"TARID","canonical_id":"hgnc:HGNC:50506","description":"TCF21 antisense RNA inducing promoter demethylation","metadata":{"aliases":["EYA4-AS1"]}},{"id":"d7d6bd97070c4367b8a588015657f065","type":"GENE","name":"TARM1","canonical_id":"hgnc:HGNC:37250","description":"T cell-interacting, activating receptor on myeloid cells 1","metadata":null},{"id":"2d6bbb3bb18a4bfbb544488191401ba1","type":"GENE","name":"TARS1","canonical_id":"hgnc:HGNC:11572","description":"threonyl-tRNA synthetase 1","metadata":{"aliases":["TARS"]}},{"id":"9abe69d01f7e46959aee3fd9b80b2e3d","type":"GENE","name":"TARS1-DT","canonical_id":"hgnc:HGNC:55565","description":"TARS1 divergent transcript","metadata":null},{"id":"2711093b417b4ad9a8e089abf1573b97","type":"GENE","name":"TARS2","canonical_id":"hgnc:HGNC:30740","description":"threonyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["FLJ12528","TARSL1"]}},{"id":"78a1ba6a25214acd8a6344871931b9fc","type":"GENE","name":"TARS2P1","canonical_id":"hgnc:HGNC:43712","description":"TARS2 pseudogene 1","metadata":null},{"id":"0f2a5cb833b14bccb0a1cfe703f2fe14","type":"GENE","name":"TARS3","canonical_id":"hgnc:HGNC:24728","description":"threonyl-tRNA synthetase 3","metadata":{"aliases":["FLJ25005","ThrRS-L","TARSL2"]}},{"id":"6f5602cd820e4a5db36a43e4717ba96b","type":"TRIAL","name":"TART - Troglitazone Atherosclerosis Regression Trial","canonical_id":"clinicaltrials.gov:NCT00116545","description":"Atherosclerosis; Diabetes Mellitus","metadata":null},{"id":"8c395ffd235f4439be29667bdfcfc44b","type":"TRIAL","name":"TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05993702","description":"TAS 102; Regorafenib; Fruquintinib; Gastrointestinal Tumours","metadata":null},{"id":"be63abec525f4a0b8e14dcb06a1b4b6e","type":"GENE","name":"TAS1R1","canonical_id":"hgnc:HGNC:14448","description":"taste 1 receptor member 1","metadata":{"aliases":["T1R1","TR1","GPR70"]}},{"id":"067ce4c02de24ce49021f9646b88edd9","type":"GENE","name":"TAS1R2","canonical_id":"hgnc:HGNC:14905","description":"taste 1 receptor member 2","metadata":{"aliases":["T1R2","TR2","GPR71"]}},{"id":"452b79cb3b58491ab74807c3594f93f6","type":"GENE","name":"TAS1R3","canonical_id":"hgnc:HGNC:15661","description":"taste 1 receptor member 3","metadata":{"aliases":["T1R3"]}},{"id":"0b82f2f012964d7887ad78a74fb83fdf","type":"GENE","name":"TAS2R1","canonical_id":"hgnc:HGNC:14909","description":"taste 2 receptor member 1","metadata":{"aliases":["T2R1","TRB7"]}},{"id":"ae2a56014d6e403282b51ae0847d9133","type":"GENE","name":"TAS2R10","canonical_id":"hgnc:HGNC:14918","description":"taste 2 receptor member 10","metadata":{"aliases":["T2R10","TRB2"]}},{"id":"2c50e34c9a1347faa40384942dcef2da","type":"GENE","name":"TAS2R12P","canonical_id":"hgnc:HGNC:19103","description":"taste 2 receptor member 12, pseudogene","metadata":{"aliases":["T2R12","TAS2R12"]}},{"id":"512fccb7aa3c4f8a8e5fd676a1c3d5c5","type":"GENE","name":"TAS2R13","canonical_id":"hgnc:HGNC:14919","description":"taste 2 receptor member 13","metadata":{"aliases":["T2R13","TRB3"]}},{"id":"c1d4fe19d010481391141e99e4a5afaf","type":"GENE","name":"TAS2R14","canonical_id":"hgnc:HGNC:14920","description":"taste 2 receptor member 14","metadata":{"aliases":["T2R14","TRB1"]}},{"id":"944ea52d8e684bb1ab77c096757338e1","type":"GENE","name":"TAS2R15P","canonical_id":"hgnc:HGNC:19106","description":"taste 2 receptor member 15, pseudogene","metadata":{"aliases":["T2R15","PS8","TAS2R15"]}},{"id":"2996d6135d17459c8d0815baec3566c1","type":"GENE","name":"TAS2R16","canonical_id":"hgnc:HGNC:14921","description":"taste 2 receptor member 16","metadata":{"aliases":["T2R16"]}},{"id":"4ba0fce91f3b4d0e97d24ef6d9ae5e7d","type":"GENE","name":"TAS2R18P","canonical_id":"hgnc:HGNC:19107","description":"taste 2 receptor member 18, pseudogene","metadata":{"aliases":["T2R18","TAS2R65","TAS2R65P","TAS2R18"]}},{"id":"7f469b6770594079a2cb019c89a665bc","type":"GENE","name":"TAS2R19","canonical_id":"hgnc:HGNC:19108","description":"taste 2 receptor member 19","metadata":{"aliases":["T2R19","T2R23","TAS2R48","TAS2R23"]}},{"id":"04f666438ff64d65b319c0d73168e334","type":"GENE","name":"TAS2R2","canonical_id":"hgnc:HGNC:20615","description":"taste 2 receptor member 2 (gene/pseudogene)","metadata":{"aliases":["T2R02","T2R2","TAS2R2P"]}},{"id":"1fb1fa3672fe4faca7496ad987e29d58","type":"GENE","name":"TAS2R20","canonical_id":"hgnc:HGNC:19109","description":"taste 2 receptor member 20","metadata":{"aliases":["T2R20","T2R56","TAS2R49"]}},{"id":"3915874251ec40448784d54aebecec14","type":"GENE","name":"TAS2R22P","canonical_id":"hgnc:HGNC:19110","description":"taste 2 receptor member 22, pseudogene","metadata":{"aliases":["T2R22","TAS2R22"]}},{"id":"f110887bf2254f658098afd0924d64e6","type":"GENE","name":"TAS2R3","canonical_id":"hgnc:HGNC:14910","description":"taste 2 receptor member 3","metadata":{"aliases":["T2R3"]}},{"id":"9ddc2cf11e714e9f9a94488d83570df4","type":"GENE","name":"TAS2R30","canonical_id":"hgnc:HGNC:19112","description":"taste 2 receptor member 30","metadata":{"aliases":["T2R30","TAS2R47"]}},{"id":"588f2bcde3bd412f8aeb4f74568d5797","type":"GENE","name":"TAS2R31","canonical_id":"hgnc:HGNC:19113","description":"taste 2 receptor member 31","metadata":{"aliases":["T2R31","T2R53","TAS2R44"]}},{"id":"0c47c277d6cc4f5fadfaf9b68cd862a0","type":"GENE","name":"TAS2R33","canonical_id":"hgnc:HGNC:19114","description":"taste 2 receptor member 33","metadata":{"aliases":["T2R33"]}},{"id":"30402d3c1549449e80270b353d6482bd","type":"GENE","name":"TAS2R36","canonical_id":"hgnc:HGNC:19115","description":"taste 2 receptor member 36","metadata":{"aliases":["T2R36"]}},{"id":"023a2cfef9de43c98131f5c0ec61b53a","type":"GENE","name":"TAS2R37P","canonical_id":"hgnc:HGNC:19116","description":"taste 2 receptor member 37, pseudogene","metadata":{"aliases":["T2R37","TAS2R37"]}},{"id":"36be3ce080684b7c8cadd928001b7af8","type":"GENE","name":"TAS2R38","canonical_id":"hgnc:HGNC:9584","description":"taste 2 receptor member 38","metadata":{"aliases":["T2R61","PTC"]}},{"id":"25fbf59b39d7487ea8521fca011075cd","type":"GENE","name":"TAS2R39","canonical_id":"hgnc:HGNC:18886","description":"taste 2 receptor member 39","metadata":null},{"id":"54d97071b2944c9c9507790a8fd9331e","type":"GENE","name":"TAS2R4","canonical_id":"hgnc:HGNC:14911","description":"taste 2 receptor member 4","metadata":{"aliases":["T2R4"]}},{"id":"3037d0aae3674edb99658ff46bab633b","type":"GENE","name":"TAS2R40","canonical_id":"hgnc:HGNC:18885","description":"taste 2 receptor member 40","metadata":{"aliases":["GPR60"]}},{"id":"22ee39c0d87441059ce7dd781df7699c","type":"GENE","name":"TAS2R41","canonical_id":"hgnc:HGNC:18883","description":"taste 2 receptor member 41","metadata":{"aliases":["T2R59"]}},{"id":"0c6fa860d6884749b2864d3d549ef3d1","type":"GENE","name":"TAS2R42","canonical_id":"hgnc:HGNC:18888","description":"taste 2 receptor member 42","metadata":{"aliases":["T2R24","T2R55","hT2R55","TAS2R55"]}},{"id":"a4ccc4df1cc642f786c3ce6b7f2c8915","type":"GENE","name":"TAS2R43","canonical_id":"hgnc:HGNC:18875","description":"taste 2 receptor member 43","metadata":{"aliases":["T2R52"]}},{"id":"f282063a3392439c8acd9946995702c9","type":"GENE","name":"TAS2R45","canonical_id":"hgnc:HGNC:18876","description":"taste 2 receptor member 45","metadata":{"aliases":["ZG24P","GPR59"]}},{"id":"34dd11a7c17a44dc8ef0b1b1b6e6bea3","type":"GENE","name":"TAS2R46","canonical_id":"hgnc:HGNC:18877","description":"taste 2 receptor member 46","metadata":{"aliases":["T2R54"]}},{"id":"c9a1446a00e44969a6c567d44dbf7913","type":"GENE","name":"TAS2R5","canonical_id":"hgnc:HGNC:14912","description":"taste 2 receptor member 5","metadata":{"aliases":["T2R5"]}},{"id":"6e6ec225671a41df8d20565eab62118b","type":"GENE","name":"TAS2R50","canonical_id":"hgnc:HGNC:18882","description":"taste 2 receptor member 50","metadata":{"aliases":["T2R51"]}},{"id":"21c33795ee3e42d398a5c190aac683d0","type":"GENE","name":"TAS2R60","canonical_id":"hgnc:HGNC:20639","description":"taste 2 receptor member 60","metadata":{"aliases":["T2R60"]}},{"id":"83fa132a7b1d465d8793b188a2c54128","type":"GENE","name":"TAS2R62P","canonical_id":"hgnc:HGNC:20640","description":"taste 2 receptor member 62, pseudogene","metadata":{"aliases":["T2R62","TAS2R62"]}},{"id":"d9f6f1725bdb4156ace583f393352f35","type":"GENE","name":"TAS2R63P","canonical_id":"hgnc:HGNC:20641","description":"taste 2 receptor member 63, pseudogene","metadata":null},{"id":"57ca2b4a5c1042fc866de416bbcb89a8","type":"GENE","name":"TAS2R64P","canonical_id":"hgnc:HGNC:20642","description":"taste 2 receptor member 64, pseudogene","metadata":{"aliases":["T2R64","T2R64P"]}},{"id":"0a4d58285abc4f3f92e1be984d8bff7d","type":"GENE","name":"TAS2R67P","canonical_id":"hgnc:HGNC:43898","description":"taste 2 receptor member 67, pseudogene","metadata":null},{"id":"c988e1f94a834e1f996a2664c4b77fc7","type":"GENE","name":"TAS2R68P","canonical_id":"hgnc:HGNC:43905","description":"taste 2 receptor member 68, pseudogene","metadata":{"aliases":["T2R68P","PS7"]}},{"id":"c532dea982b84ff79e8df4e869304ee6","type":"GENE","name":"TAS2R6P","canonical_id":"hgnc:HGNC:20616","description":"taste 2 receptor member 6, pseudogene","metadata":{"aliases":["T2R06","T2R6","TAS2R6"]}},{"id":"cb1bd0a101704424b378637c1b62a412","type":"GENE","name":"TAS2R7","canonical_id":"hgnc:HGNC:14913","description":"taste 2 receptor member 7","metadata":{"aliases":["T2R7","TRB4"]}},{"id":"926ed811af7e4f80ad05402dbd15bca9","type":"GENE","name":"TAS2R8","canonical_id":"hgnc:HGNC:14915","description":"taste 2 receptor member 8","metadata":{"aliases":["T2R8","TRB5"]}},{"id":"f7c74cc1c225455d96132bb39ea04303","type":"GENE","name":"TAS2R9","canonical_id":"hgnc:HGNC:14917","description":"taste 2 receptor member 9","metadata":{"aliases":["T2R9","TRB6"]}},{"id":"781b0f3bcd5a47ddae251474c1478007","type":"GENE","name":"TASL","canonical_id":"hgnc:HGNC:25667","description":"TLR adaptor interacting with endolysosomal SLC15A4","metadata":{"aliases":["FLJ11577","CXorf21"]}},{"id":"8b18e29d25054f9ba62236ea30311b5b","type":"GENE","name":"TASOR","canonical_id":"hgnc:HGNC:30314","description":"transcription activation suppressor","metadata":{"aliases":["se89-1","RAP140","KIAA1105","TASOR1","C3orf63","FAM208A"]}},{"id":"04452f27d4ca4e6fa714a4e1c9099647","type":"GENE","name":"TASOR2","canonical_id":"hgnc:HGNC:23484","description":"transcription activation suppressor family member 2","metadata":{"aliases":["FLJ20360","bA318E3.2","KIAA2006","C10orf18","FAM208B"]}},{"id":"97cf5e6a5d1846e2aaac3253b5aec677","type":"GENE","name":"TASP1","canonical_id":"hgnc:HGNC:15859","description":"taspase 1","metadata":{"aliases":["FLJ20212","dJ585I14.2","C20orf13"]}},{"id":"6e7f8c74eb284c15b502a562c3eb57fa","type":"GENE","name":"TAT","canonical_id":"hgnc:HGNC:11573","description":null,"metadata":null},{"id":"135af38ddeaf40e1afe2749884bdf276","type":"GO_TERM","name":"TAT protein transport complex","canonical_id":"go:GO:0033281","description":"\"A complex of three proteins integral to the cytoplasmic membrane of bacteria and membranes of organelles derived from bacteria (chloroplasts and mitochondria) involved in membrane transport of folded proteins.\" [GOC:pamgo_curators]","metadata":null},{"id":"e07fc892dd924c4b8ff4cd979a02c4cf","type":"GENE","name":"TAT-AS1","canonical_id":"hgnc:HGNC:51369","description":"TAT antisense RNA 1","metadata":null},{"id":"e2b015da564748bda57082ffc6670717","type":"GENE","name":"TATDN1","canonical_id":"hgnc:HGNC:24220","description":"TatD DNase domain containing 1","metadata":{"aliases":["CDA11"]}},{"id":"bc0387fb1ecb4dbc870959a8af911e0f","type":"GENE","name":"TATDN1P1","canonical_id":"hgnc:HGNC:45058","description":"TatD DNase domain containing 1 pseudogene 1","metadata":null},{"id":"b0942c9f133749fba167f84583c537a1","type":"GENE","name":"TATDN2","canonical_id":"hgnc:HGNC:28988","description":"TatD DNase domain containing 2","metadata":{"aliases":["KIAA0218"]}},{"id":"f96c60b02b5940e8b0333ca74268c7a0","type":"GENE","name":"TATDN2P1","canonical_id":"hgnc:HGNC:39254","description":"TatD DNase domain containing 2 pseudogene 1","metadata":null},{"id":"8640e06702ef4ec9a5910506ebc5cabf","type":"GENE","name":"TATDN2P2","canonical_id":"hgnc:HGNC:39255","description":"TatD DNase domain containing 2 pseudogene 2","metadata":null},{"id":"7fa8d83a1d0841cd9330549bcac7c96c","type":"GENE","name":"TATDN2P3","canonical_id":"hgnc:HGNC:39256","description":"TatD DNase domain containing 2 pseudogene 3","metadata":null},{"id":"708c3ed00ebf43dfaae4b7d16ddb7ae1","type":"GENE","name":"TATDN3","canonical_id":"hgnc:HGNC:27010","description":"TatD DNase domain containing 3","metadata":null},{"id":"3fb62d91ee264e43a3c78d42e8d9f331","type":"GENE","name":"TAX1BP1","canonical_id":"hgnc:HGNC:11575","description":"Tax1 binding protein 1","metadata":{"aliases":["TXBP151","CALCOCO3"]}},{"id":"f2cb7f84f7744092bb51457be6d3b0bc","type":"GENE","name":"TAX1BP1-AS1","canonical_id":"hgnc:HGNC:40576","description":"TAX1BP1 antisense RNA 1","metadata":null},{"id":"459b373b1fbd4ddc8f13aef4443cb1ea","type":"GENE","name":"TAX1BP3","canonical_id":"hgnc:HGNC:30684","description":"Tax1 binding protein 3","metadata":{"aliases":["TIP-1"]}},{"id":"185a2499953c4175b23375e516addfaa","type":"GENE","name":"TBATA","canonical_id":"hgnc:HGNC:23511","description":"thymus, brain and testes associated","metadata":{"aliases":["FLJ32820","spatial","C10orf27"]}},{"id":"dcdb0a88741b431980e7b9cd1027e191","type":"GENE","name":"TBC1D1","canonical_id":"hgnc:HGNC:11578","description":"TBC1 domain family member 1","metadata":{"aliases":["TBC","TBC1","KIAA1108"]}},{"id":"e1f0d181d4384cbcb220b31494fe399a","type":"GENE","name":"TBC1D1-AS1","canonical_id":"hgnc:HGNC:58759","description":"TBC1D1 antisense RNA 1","metadata":null},{"id":"95d93dcf1f0743f988c533643d4fd5ee","type":"GENE","name":"TBC1D10A","canonical_id":"hgnc:HGNC:23609","description":"TBC1 domain family member 10A","metadata":{"aliases":["EPI64","AC004997.C22.2","TBC1D10"]}},{"id":"c4dd163df3944dc4a06e85ca0c504401","type":"GENE","name":"TBC1D10B","canonical_id":"hgnc:HGNC:24510","description":"TBC1 domain family member 10B","metadata":{"aliases":["DKFZP434P1750","Rab27A-GAPbeta","FLJ13130","EPI64B"]}},{"id":"7a49a73daeda4b10ae1b0d83b5b23f09","type":"GENE","name":"TBC1D10C","canonical_id":"hgnc:HGNC:24702","description":"TBC1 domain family member 10C","metadata":{"aliases":["FLJ00332","Carabin","EPI64C"]}},{"id":"9bbf013392964281a8b7eb7fdf27bb68","type":"GENE","name":"TBC1D12","canonical_id":"hgnc:HGNC:29082","description":"TBC1 domain family member 12","metadata":{"aliases":["KIAA0608"]}},{"id":"c9be9eebbc374611906ff869d3710658","type":"GENE","name":"TBC1D13","canonical_id":"hgnc:HGNC:25571","description":"TBC1 domain family member 13","metadata":{"aliases":["FLJ10743"]}},{"id":"649b7230f4a342c8abd4f3133e75e2e6","type":"GENE","name":"TBC1D14","canonical_id":"hgnc:HGNC:29246","description":"TBC1 domain family member 14","metadata":{"aliases":["KIAA1322"]}},{"id":"4bd10d4329cf4381a8031224499507a9","type":"GENE","name":"TBC1D15","canonical_id":"hgnc:HGNC:25694","description":"TBC1 domain family member 15","metadata":{"aliases":["FLJ12085","DKFZp761D0223"]}},{"id":"9be81d58eb724138963c1e9670ed2220","type":"GENE","name":"TBC1D16","canonical_id":"hgnc:HGNC:28356","description":"TBC1 domain family member 16","metadata":{"aliases":["MGC25062","FLJ20748"]}},{"id":"8fda88400afc45b48d80f48013b92c08","type":"GENE","name":"TBC1D17","canonical_id":"hgnc:HGNC:25699","description":"TBC1 domain family member 17","metadata":{"aliases":["FLJ12168"]}},{"id":"01dcdab352ab4188be1b73d777cf6f32","type":"GENE","name":"TBC1D19","canonical_id":"hgnc:HGNC:25624","description":"TBC1 domain family member 19","metadata":{"aliases":["FLJ11082"]}},{"id":"f5bf04ad228d4de4858eb67456193e58","type":"GENE","name":"TBC1D2","canonical_id":"hgnc:HGNC:18026","description":"TBC1 domain family member 2","metadata":{"aliases":["PARIS1","TBC1D2A","Armus"]}},{"id":"8a50e85ff86840e68c6a8e38578815ec","type":"GENE","name":"TBC1D20","canonical_id":"hgnc:HGNC:16133","description":"TBC1 domain family member 20","metadata":{"aliases":["dJ852M4.2","C20orf140"]}},{"id":"10c19dee4e8641969ef0c0d24f974827","type":"GENE","name":"TBC1D21","canonical_id":"hgnc:HGNC:28536","description":"TBC1 domain family member 21","metadata":{"aliases":["MGC34741","MgcRabGAP"]}},{"id":"26edbe3bf85c467d9be6d7732da19d1a","type":"GENE","name":"TBC1D22A","canonical_id":"hgnc:HGNC:1309","description":null,"metadata":null},{"id":"71874cda5e374266ba6f07734aca1d9f","type":"GENE","name":"TBC1D22A-AS1","canonical_id":"hgnc:HGNC:51221","description":"TBC1D22A antisense RNA 1","metadata":null},{"id":"c94f3e3991b245b18efff82c4f2a5f7d","type":"GENE","name":"TBC1D22B","canonical_id":"hgnc:HGNC:21602","description":"TBC1 domain family member 22B","metadata":{"aliases":["FLJ20337","dJ744I24.2","C6orf197"]}},{"id":"d7c05cca2cc24eb395400934b98af461","type":"GENE","name":"TBC1D22B-AS1","canonical_id":"hgnc:HGNC:59394","description":"TBC1D22B antisense RNA 1","metadata":null},{"id":"54dcb37cded5429c983e98c843ca13a0","type":"GENE","name":"TBC1D23","canonical_id":"hgnc:HGNC:25622","description":"TBC1 domain family member 23","metadata":{"aliases":["FLJ11046"]}},{"id":"67297abd22284d218f7e78119e0e055b","type":"GENE","name":"TBC1D24","canonical_id":"hgnc:HGNC:29203","description":"TBC1 domain family member 24","metadata":{"aliases":["KIAA1171","TLDC6","DFNA65","DFNB86"]}},{"id":"7151385158c447d68e8e372edaba4be2","type":"GENE","name":"TBC1D25","canonical_id":"hgnc:HGNC:8092","description":"TBC1 domain family member 25","metadata":{"aliases":["OATL1"]}},{"id":"3d7c7640cbdb4a3397bb229c47860548","type":"GENE","name":"TBC1D26","canonical_id":"hgnc:HGNC:28745","description":"TBC1 domain family member 26","metadata":{"aliases":["MGC51025"]}},{"id":"0bdb4f66c1b5443cb95531ffc3803cab","type":"GENE","name":"TBC1D26-AS1","canonical_id":"hgnc:HGNC:41211","description":"TBC1D26 antisense RNA 1","metadata":null},{"id":"901b0a14c1554513812eb29f0adf11dc","type":"GENE","name":"TBC1D27P","canonical_id":"hgnc:HGNC:28104","description":"TBC1 domain family member 27, pseudogene","metadata":{"aliases":["TBC1D27"]}},{"id":"50c97cd2e96042b4a26bbd2fd1b8f50b","type":"GENE","name":"TBC1D28","canonical_id":"hgnc:HGNC:26858","description":"TBC1 domain family member 28","metadata":{"aliases":["FLJ40244"]}},{"id":"a8a7335ae1294a16b2426cf120d60dea","type":"GENE","name":"TBC1D29P","canonical_id":"hgnc:HGNC:24509","description":"TBC1 domain family member 29, pseudogene","metadata":{"aliases":["DKFZP434O047","TBC1D29"]}},{"id":"f8ead9e5d8f84733a0e2d0d0ae2ee471","type":"GENE","name":"TBC1D2B","canonical_id":"hgnc:HGNC:29183","description":"TBC1 domain family member 2B","metadata":{"aliases":["KIAA1055"]}},{"id":"3a869d0306f04f8f88fa3af41121bc3c","type":"GENE","name":"TBC1D3","canonical_id":"hgnc:HGNC:19031","description":"TBC1 domain family member 3","metadata":{"aliases":["TBC1D3A","DKFZp434P2235","PRC17"]}},{"id":"beebcab0d04e4528b4606dceaa80d92c","type":"GENE","name":"TBC1D30","canonical_id":"hgnc:HGNC:29164","description":"TBC1 domain family member 30","metadata":{"aliases":["KIAA0984"]}},{"id":"dbe5b32b9d9144fc9a1f30585308372b","type":"GENE","name":"TBC1D31","canonical_id":"hgnc:HGNC:30888","description":"TBC1 domain family member 31","metadata":{"aliases":["MGC21654","Gm85","WDR67"]}},{"id":"3fb32782707e444aba80ca8ea824e3fe","type":"GENE","name":"TBC1D32","canonical_id":"hgnc:HGNC:21485","description":"TBC1 domain family member 32","metadata":{"aliases":["FLJ30899","dJ310J6.1","FLJ34235","bA57L9.1","BROMI","C6orf171","C6orf170"]}},{"id":"bcc9e7cf2c7e478fa9f7e3fa53137842","type":"GENE","name":"TBC1D3B","canonical_id":"hgnc:HGNC:27011","description":"TBC1 domain family member 3B","metadata":{"aliases":["PRC17","TBC1D3I"]}},{"id":"7de326e332a840ceb25161c383aa4de7","type":"GENE","name":"TBC1D3C","canonical_id":"hgnc:HGNC:24889","description":"TBC1 domain family member 3C","metadata":{"aliases":["MGC44903"]}},{"id":"ed169086464948088b9e7f4d9646e554","type":"GENE","name":"TBC1D3D","canonical_id":"hgnc:HGNC:28944","description":"TBC1 domain family member 3D","metadata":null},{"id":"68941b63fc5b4353a22009622e611798","type":"GENE","name":"TBC1D3E","canonical_id":"hgnc:HGNC:27071","description":"TBC1 domain family member 3E","metadata":null},{"id":"894bb290dada45628aa402782ad6cf89","type":"GENE","name":"TBC1D3F","canonical_id":"hgnc:HGNC:18257","description":"TBC1 domain family member 3F","metadata":null},{"id":"55e347cb809c49ae8f47962a8ac00d83","type":"GENE","name":"TBC1D3G","canonical_id":"hgnc:HGNC:29860","description":"TBC1 domain family member 3G","metadata":null},{"id":"8cdafc893ec948a3bcd8b8bc86447870","type":"GENE","name":"TBC1D3H","canonical_id":"hgnc:HGNC:30708","description":"TBC1 domain family member 3H","metadata":null},{"id":"a4a07b5022a94de3ac15c0d74831d9e2","type":"GENE","name":"TBC1D3I","canonical_id":"hgnc:HGNC:32709","description":"TBC1 domain family member 3I","metadata":null},{"id":"dbc48aa0e60943cc9f98cf3744367568","type":"GENE","name":"TBC1D3JP","canonical_id":"hgnc:HGNC:51247","description":"TBC1 domain family member 3J, pseudogene","metadata":{"aliases":["TBC1D3J"]}},{"id":"bfcae4ef0f9c47079c6c6e58eed50056","type":"GENE","name":"TBC1D3K","canonical_id":"hgnc:HGNC:51245","description":"TBC1 domain family member 3K","metadata":null},{"id":"a71a97b0dede4a92a9a7836c7e8ef53d","type":"GENE","name":"TBC1D3L","canonical_id":"hgnc:HGNC:51246","description":"TBC1 domain family member 3L","metadata":null},{"id":"b1e0f325611a4d3fa0fb9376bd5ce115","type":"GENE","name":"TBC1D3P1","canonical_id":"hgnc:HGNC:27445","description":"TBC1 domain family member 3 pseudogene 1","metadata":null},{"id":"028d6a8671ae4472aca94dd34ecd8194","type":"GENE","name":"TBC1D3P1-DHX40P1","canonical_id":"hgnc:HGNC:42362","description":"TBC1D3P1-DHX40P1 readthrough, transcribed pseudogene","metadata":null},{"id":"f5a69bccc7a14f0b98018415d056709d","type":"GENE","name":"TBC1D3P2","canonical_id":"hgnc:HGNC:27783","description":"TBC1 domain family member 3 pseudogene 2","metadata":null},{"id":"5406ec677ada4937830c7fd6d254ad0f","type":"GENE","name":"TBC1D3P3","canonical_id":"hgnc:HGNC:32408","description":"TBC1 domain family member 3 pseudogene 3","metadata":{"aliases":["USP6P1"]}},{"id":"2c9086f2dd2547c89e1dd86e1138051e","type":"GENE","name":"TBC1D3P4","canonical_id":"hgnc:HGNC:32409","description":"TBC1 domain family member 3 pseudogene 4","metadata":{"aliases":["USP6P2"]}},{"id":"48609b203cdf497b89a727b01de188b0","type":"GENE","name":"TBC1D3P5","canonical_id":"hgnc:HGNC:43567","description":"TBC1 domain family member 3 pseudogene 5","metadata":null},{"id":"b3218a1796044fe0bae095cefade47c1","type":"GENE","name":"TBC1D3P6","canonical_id":"hgnc:HGNC:43568","description":"TBC1 domain family member 3 pseudogene 6","metadata":null},{"id":"f82cf89c6ee54e949cdf0923a482b1ab","type":"GENE","name":"TBC1D3P7","canonical_id":"hgnc:HGNC:43569","description":"TBC1 domain family member 3 pseudogene 7","metadata":null},{"id":"97a41ebdc8cb4dc4b4c068fd25e60e65","type":"GENE","name":"TBC1D4","canonical_id":"hgnc:HGNC:19165","description":"TBC1 domain family member 4","metadata":{"aliases":["KIAA0603","AS160","DKFZp779C0666"]}},{"id":"6c8de0c30fe346119f1e993969fe4fb3","type":"GENE","name":"TBC1D5","canonical_id":"hgnc:HGNC:19166","description":"TBC1 domain family member 5","metadata":{"aliases":["KIAA0210"]}},{"id":"ad44873652c7405da95fea9a0e27ad3d","type":"GENE","name":"TBC1D7","canonical_id":"hgnc:HGNC:21066","description":"TBC1 domain family member 7","metadata":{"aliases":["dJ257A7.3","FLJ32666","TBC7"]}},{"id":"8851dc48ad21403f85e3922960117e90","type":"GENE","name":"TBC1D7-DT","canonical_id":"hgnc:HGNC:59353","description":"TBC1D7 divergent transcript","metadata":null},{"id":"af9b051ea8ea4b36b0a8a493b97bdbc8","type":"GENE","name":"TBC1D8","canonical_id":"hgnc:HGNC:17791","description":"TBC1 domain family member 8","metadata":{"aliases":["HBLP1","VRP","AD3","GRAMD8"]}},{"id":"f39a50a6893741ea8336c1f1a41a79e7","type":"GENE","name":"TBC1D8-AS1","canonical_id":"hgnc:HGNC:52782","description":"TBC1D8 antisense RNA 1","metadata":null},{"id":"4fc32cec958148b98fc0876a79592aba","type":"GENE","name":"TBC1D8B","canonical_id":"hgnc:HGNC:24715","description":"TBC1 domain family member 8B","metadata":{"aliases":["FLJ20298","RP11-321G1.1","GRAMD8B"]}},{"id":"8bfe4c13b588456489be89bb884e635e","type":"GENE","name":"TBC1D9","canonical_id":"hgnc:HGNC:21710","description":"TBC1 domain family member 9","metadata":{"aliases":["KIAA0882","MDR1","GRAMD9"]}},{"id":"fc793e9028ea44169cf4cf13ff58876a","type":"GENE","name":"TBC1D9-AS1","canonical_id":"hgnc:HGNC:58411","description":"TBC1D9 antisense RNA 1","metadata":null},{"id":"e398b1845a3b4efdac1b3c2e0223f895","type":"GENE","name":"TBC1D9-AS2","canonical_id":"hgnc:HGNC:58700","description":"TBC1D9 antisense RNA 2","metadata":{"aliases":["TBC1D9-AS2"]}},{"id":"8e276000988d454ebee9f8a622c5cfb9","type":"GENE","name":"TBC1D9B","canonical_id":"hgnc:HGNC:29097","description":"TBC1 domain family member 9B","metadata":{"aliases":["KIAA0676","GRAMD9B"]}},{"id":"699a91ae3a3e4650acfe59bca9611ae9","type":"GENE","name":"TBCA","canonical_id":"hgnc:HGNC:11579","description":"tubulin folding cofactor A","metadata":null},{"id":"bf55e9c9857b402a9e7844d6d0c01657","type":"GENE","name":"TBCAP1","canonical_id":"hgnc:HGNC:42630","description":"tubulin folding cofactor A pseudogene 1","metadata":null},{"id":"76504c8d789f45a8ae89b0f767d6a320","type":"GENE","name":"TBCAP2","canonical_id":"hgnc:HGNC:42631","description":"tubulin folding cofactor A pseudogene 2","metadata":null},{"id":"aaee7d08633b43d2a465f14b139de336","type":"GENE","name":"TBCAP3","canonical_id":"hgnc:HGNC:42632","description":"tubulin folding cofactor A pseudogene 3","metadata":null},{"id":"f8ff4773e94940e18dbef5934f275493","type":"GENE","name":"TBCB","canonical_id":"hgnc:HGNC:1989","description":"tubulin folding cofactor B","metadata":{"aliases":["CG22","CKAPI","CKAP1"]}},{"id":"966af22c179748e29be635ed728a53ba","type":"GENE","name":"TBCC","canonical_id":"hgnc:HGNC:11580","description":"tubulin folding cofactor C","metadata":{"aliases":["CFC"]}},{"id":"a148000f5c4042df93d181087da2cc00","type":"GENE","name":"TBCCD1","canonical_id":"hgnc:HGNC:25546","description":"TBCC domain containing 1","metadata":{"aliases":["FLJ10560"]}},{"id":"4922e6fda28a478399c273bfd3657150","type":"GENE","name":"TBCD","canonical_id":"hgnc:HGNC:11581","description":"tubulin folding cofactor D","metadata":null},{"id":"da15aaab2d6340b2936df9dd498464bf","type":"GENE","name":"TBCE","canonical_id":"hgnc:HGNC:11582","description":"tubulin folding cofactor E","metadata":{"aliases":["KCS1","pac2","KCS","HRD"]}},{"id":"777b4431450c4e73aded716e7a5be877","type":"GENE","name":"TBCEL","canonical_id":"hgnc:HGNC:28115","description":"tubulin folding cofactor E like","metadata":{"aliases":["MGC10233","LRRC35"]}},{"id":"6c8ca1f7940b4acfbd5657a7ebce54c5","type":"GENE","name":"TBCEL-TECTA","canonical_id":"hgnc:HGNC:54857","description":"TBCEL-TECTA readthrough","metadata":null},{"id":"ae05d42da09f44b0b13fedd3ee0d8c38","type":"GENE","name":"TBCK","canonical_id":"hgnc:HGNC:28261","description":"TBC1 domain containing kinase","metadata":{"aliases":["MGC16169","HSPC302","Fy-1","FERRY1"]}},{"id":"7bf7f6ff1da046eb84bcc80bc4f5b9d7","type":"GENE","name":"TBILA","canonical_id":"hgnc:HGNC:53943","description":"TGF-beta induced lncRNA","metadata":null},{"id":"52169be09ee241b195f448fb7522a8eb","type":"GENE","name":"TBK1","canonical_id":"hgnc:HGNC:11584","description":"TANK binding kinase 1","metadata":{"aliases":["NAK"]}},{"id":"1f2a98d286a244718a19c4023b6d9e6a","type":"GO_TERM","name":"TBK1-IKKE-DDX3 complex","canonical_id":"go:GO:0039658","description":"\"A protein complex containing TBK1 (TANK-binding kinase 1), IKBKE (I-Kappa-B kinase epsilon/IKKE/IKK-epsilon) and the DEAD box family RNA helicase DDX3.\" [PMID:18636090, VZ:719]","metadata":null},{"id":"bb76d72a8a73491c8a8abd0dcdc14ecc","type":"GENE","name":"TBKBP1","canonical_id":"hgnc:HGNC:30140","description":"TBK1 binding protein 1","metadata":{"aliases":["ProSAPiP2","KIAA0775"]}},{"id":"c2915717110945d0a322c46b9f684edd","type":"GENE","name":"TBL1X","canonical_id":"hgnc:HGNC:11585","description":null,"metadata":null},{"id":"e6981e09c43047b187727d85286fd170","type":"GENE","name":"TBL1XR1","canonical_id":"hgnc:HGNC:29529","description":"TBL1X/Y related 1","metadata":{"aliases":["IRA1","FLJ12894","TBLR1","C21","DC42"]}},{"id":"7901023d960d46dd88f35aa3c4d073e1","type":"GENE","name":"TBL1XR1-AS1","canonical_id":"hgnc:HGNC:41243","description":"TBL1XR1 antisense RNA 1","metadata":null},{"id":"7d5a2cce6ed446aebcb0cc6f4b0d48f3","type":"GENE","name":"TBL1Y","canonical_id":"hgnc:HGNC:18502","description":"transducin beta like 1 Y-linked","metadata":{"aliases":["TBL1"]}},{"id":"bae5e6c051b6402a974733bec1935b28","type":"GENE","name":"TBL1YP1","canonical_id":"hgnc:HGNC:23979","description":"transducin beta like 1 Y-linked pseudogene 1","metadata":null},{"id":"5b303776d97349459a32c5ea913a6bab","type":"GENE","name":"TBL2","canonical_id":"hgnc:HGNC:11586","description":"transducin beta like 2","metadata":{"aliases":["WS-betaTRP","WBSCR13","DKFZP43N024"]}},{"id":"e84fc290415a4b6ca08a47742b59e06a","type":"GENE","name":"TBL3","canonical_id":"hgnc:HGNC:11587","description":"transducin beta like 3","metadata":{"aliases":["SAZD","UTP13"]}},{"id":"54b42a05728847c79ecf80efd48e0b84","type":"GENE","name":"TBL3-DT","canonical_id":"hgnc:HGNC:59247","description":"TBL3 divergent transcript","metadata":{"aliases":["AC005363.2"]}},{"id":"4a455af777c0409b8b7e70bc718b9745","type":"GENE","name":"TBP","canonical_id":"hgnc:HGNC:11588","description":null,"metadata":null},{"id":"58f9c0b600664e71b4e77006e56088a5","type":"GO_TERM","name":"TBP-class protein binding","canonical_id":"go:GO:0017025","description":"\"Binding to a member of the class of TATA-binding proteins (TBP), including any of the TBP-related factors (TRFs).\" [GOC:jl, GOC:txnOH, PMID:1509519, PMID:16858867]","metadata":null},{"id":"e1fe793c35174eb58279892a15f7f486","type":"GENE","name":"TBPL1","canonical_id":"hgnc:HGNC:11589","description":null,"metadata":null},{"id":"71c1b89cedc14124898d6558b401cfe7","type":"GENE","name":"TBPL1P1","canonical_id":"hgnc:HGNC:56577","description":"TBPL1 pseudogene 1","metadata":null},{"id":"704e45ce5917419989211d46fa1d86c3","type":"GENE","name":"TBPL2","canonical_id":"hgnc:HGNC:19841","description":"TATA-box binding protein like 2","metadata":{"aliases":["TRF3","TBP2"]}},{"id":"363c4a72226c4ec8a429cfaaf7c15746","type":"GENE","name":"TBR1","canonical_id":"hgnc:HGNC:11590","description":null,"metadata":null},{"id":"209d6d2591614701b1efc9e683bed37e","type":"GENE","name":"TBX1","canonical_id":"hgnc:HGNC:11592","description":"T-box transcription factor 1","metadata":{"aliases":["CATCH22","VCF"]}},{"id":"7b9858f2521c49358783fc8ce1efb3c0","type":"GENE","name":"TBX10","canonical_id":"hgnc:HGNC:11593","description":"T-box transcription factor 10","metadata":{"aliases":["TBX13","TBX7"]}},{"id":"4c1efbd998214a1fb1e3fbce3ee3d37d","type":"GENE","name":"TBX15","canonical_id":"hgnc:HGNC:11594","description":"T-box transcription factor 15","metadata":{"aliases":["TBX14"]}},{"id":"082747fe4eb5431883d12297a2d62d6b","type":"GENE","name":"TBX18","canonical_id":"hgnc:HGNC:11595","description":null,"metadata":null},{"id":"8a9ed04da8ec4f26b0a8ba56b7782d28","type":"GENE","name":"TBX18-AS1","canonical_id":"hgnc:HGNC:52256","description":"TBX18 antisense RNA 1","metadata":null},{"id":"7b47b6bf3023444999cea1dbd976bdb3","type":"GENE","name":"TBX19","canonical_id":"hgnc:HGNC:11596","description":"T-box transcription factor 19","metadata":{"aliases":["dj747L4.1","TPIT"]}},{"id":"e928aacd6806458f8e970e1e0a5c61f0","type":"GENE","name":"TBX2","canonical_id":"hgnc:HGNC:11597","description":null,"metadata":null},{"id":"945f793874304a528b1d01b2834996a8","type":"GENE","name":"TBX2-AS1","canonical_id":"hgnc:HGNC:50355","description":"TBX2 antisense RNA 1","metadata":null},{"id":"7eb473146a6d4b0cb4090d4e52108362","type":"GENE","name":"TBX20","canonical_id":"hgnc:HGNC:11598","description":null,"metadata":null},{"id":"66cc1f5d6d17487dbe42fba44f9ef83b","type":"GENE","name":"TBX21","canonical_id":"hgnc:HGNC:11599","description":null,"metadata":null},{"id":"5b89751bfe014c52874a91b22a46173d","type":"GENE","name":"TBX22","canonical_id":"hgnc:HGNC:11600","description":"T-box transcription factor 22","metadata":{"aliases":["CPX","CLPA"]}},{"id":"35a72d76830442609c9cd985850a213c","type":"GENE","name":"TBX23P","canonical_id":"hgnc:HGNC:11601","description":"T-box transcription factor 23, pseudogene","metadata":{"aliases":["TBX23"]}},{"id":"f61ec3720d31499386cd98b3dfbdd48a","type":"GENE","name":"TBX3","canonical_id":"hgnc:HGNC:11602","description":null,"metadata":null},{"id":"08fce454304c450cb5aae02d4204330c","type":"GENE","name":"TBX3-AS1","canonical_id":"hgnc:HGNC:55471","description":"TBX3 antisense RNA 1","metadata":null},{"id":"dec5928df9d74179bc58b537764fef44","type":"GENE","name":"TBX4","canonical_id":"hgnc:HGNC:11603","description":null,"metadata":null},{"id":"e0003da9db214a85bd2131f69d8f47c3","type":"GENE","name":"TBX5","canonical_id":"hgnc:HGNC:11604","description":null,"metadata":null},{"id":"b631b00ce8bd4c79b42cd0ea3b49e616","type":"GENE","name":"TBX5-AS1","canonical_id":"hgnc:HGNC:27402","description":"TBX5 antisense RNA 1","metadata":null},{"id":"c0f67a9f68af4c30aa44a7ffeff4b794","type":"GENE","name":"TBX6","canonical_id":"hgnc:HGNC:11605","description":"T-box transcription factor 6","metadata":null},{"id":"8d8d5f80d61842ddb4b8fb1cf9eb89d1","type":"GENE","name":"TBXA2R","canonical_id":"hgnc:HGNC:11608","description":null,"metadata":null},{"id":"b826ddf4c4fc4b97bc6db32903f9965f","type":"GENE","name":"TBXAS1","canonical_id":"hgnc:HGNC:11609","description":null,"metadata":null},{"id":"a3292c16688b4dbb8d4e016275bd3923","type":"GENE","name":"TBXT","canonical_id":"hgnc:HGNC:11515","description":null,"metadata":null},{"id":"b570c48d6a8149c09b407b3b912196ad","type":"GENE","name":"TC2N","canonical_id":"hgnc:HGNC:19859","description":"tandem C2 domains, nuclear","metadata":{"aliases":["FLJ36557","Tac2-N","C2CD1","C14orf47","MTAC2D1"]}},{"id":"e89293221d53455daf1972152b593135","type":"GENE","name":"TCAF1","canonical_id":"hgnc:HGNC:22201","description":"TRPM8 channel associated factor 1","metadata":{"aliases":["KIAA0738","GATD9A","FAM115A"]}},{"id":"50d75b8961234575b44ecbce84ebe2c4","type":"GENE","name":"TCAF1P1","canonical_id":"hgnc:HGNC:33604","description":"TRPM8 channel associated factor 1 pseudogene 1","metadata":{"aliases":["FAM115B"]}},{"id":"07ec6bd3c28a4bd096118a7e1bbfde12","type":"GENE","name":"TCAF2","canonical_id":"hgnc:HGNC:26878","description":"TRPM8 channel associated factor 2","metadata":{"aliases":["FLJ40722","GATD9B","FAM139A","FAM115C"]}},{"id":"386e3bc662fd49f392032d85c78bacb3","type":"GENE","name":"TCAF2C","canonical_id":"hgnc:HGNC:53641","description":"TRPM8 channel associated factor 2C","metadata":null},{"id":"36fc8884882b4abab4b5c8880a97348a","type":"GENE","name":"TCAF2P1","canonical_id":"hgnc:HGNC:33603","description":"TRPM8 channel associated factor 2 pseudogene 1","metadata":{"aliases":["FLJ40722-like","TCAF2BP","FAM139B","FAM115D"]}},{"id":"264d965b7b0e46e98ca4d293b961eae5","type":"GENE","name":"TCAIM","canonical_id":"hgnc:HGNC:25241","description":"T cell activation inhibitor, mitochondrial","metadata":{"aliases":["DKFZp313N0621","TOAG-1","C3orf23"]}},{"id":"2687bf80b17b4d65be7cab0159df68af","type":"GENE","name":"TCAM1P","canonical_id":"hgnc:HGNC:30707","description":"testicular cell adhesion molecule 1, pseudogene","metadata":{"aliases":["TCAM1"]}},{"id":"673e76d616e646189055d2701461f4eb","type":"GENE","name":"TCAP","canonical_id":"hgnc:HGNC:11610","description":"titin-cap","metadata":{"aliases":["T-cap","TELE","telethonin","CMD1N","LGMD2G"]}},{"id":"01ded97e86a340aeadf2b6bf18bd33fe","type":"GENE","name":"TCEA1","canonical_id":"hgnc:HGNC:11612","description":"transcription elongation factor A1","metadata":{"aliases":["SII","TF2S","TFIIS","TCEA","GTF2S"]}},{"id":"0164937f4e724bab8d619717fe29140e","type":"GENE","name":"TCEA1P1","canonical_id":"hgnc:HGNC:11613","description":"transcription elongation factor A1 pseudogene 1","metadata":{"aliases":["GTF2SP","TCEA1P"]}},{"id":"104e73fc8ce04bdca2f50fc511f0cc3f","type":"GENE","name":"TCEA1P2","canonical_id":"hgnc:HGNC:29891","description":"transcription elongation factor A1 pseudogene 2","metadata":{"aliases":["TCEA1"]}},{"id":"b0b76bfadbf546be9496443f983532b3","type":"GENE","name":"TCEA1P3","canonical_id":"hgnc:HGNC:30569","description":"transcription elongation factor A1 pseudogene 3","metadata":null},{"id":"6d64b8986f7e4d7b95489785ca18a536","type":"GENE","name":"TCEA1P4","canonical_id":"hgnc:HGNC:31091","description":"transcription elongation factor A1 pseudogene 4","metadata":null},{"id":"a74a07300d584580845bd7361d42a82f","type":"GENE","name":"TCEA2","canonical_id":"hgnc:HGNC:11614","description":"transcription elongation factor A2","metadata":{"aliases":["TFIIS"]}},{"id":"ff14f11536a046afb7a0b21290ae7545","type":"GENE","name":"TCEA3","canonical_id":"hgnc:HGNC:11615","description":"transcription elongation factor A3","metadata":{"aliases":["TFIIS.H"]}},{"id":"e0104346b8cb4b5e98e79ff7a10067fd","type":"GENE","name":"TCEAL1","canonical_id":"hgnc:HGNC:11616","description":null,"metadata":null},{"id":"cd6798f2da124e47bd579dca8179f5dd","type":"GENE","name":"TCEAL2","canonical_id":"hgnc:HGNC:29818","description":"transcription elongation factor A like 2","metadata":{"aliases":["my048","MY0876G05","WEX1"]}},{"id":"f138b53cb4b84acf9c9e6f92b10539ca","type":"GENE","name":"TCEAL3","canonical_id":"hgnc:HGNC:28247","description":"transcription elongation factor A like 3","metadata":{"aliases":["MGC15737","WEX8"]}},{"id":"b72b5c710f0f467dad9c4b79fbdec54b","type":"GENE","name":"TCEAL3-AS1","canonical_id":"hgnc:HGNC:41191","description":"TCEAL3 antisense RNA 1","metadata":null},{"id":"8a708945dd814a4cae1d6d6c15d4a7a2","type":"GENE","name":"TCEAL4","canonical_id":"hgnc:HGNC:26121","description":"transcription elongation factor A like 4","metadata":{"aliases":["FLJ21174","WEX7"]}},{"id":"63fedb8eb865429cb7ca92fe836cf4cd","type":"GENE","name":"TCEAL4P1","canonical_id":"hgnc:HGNC:39582","description":"transcription elongation factor A like 4 pseudogene 1","metadata":null},{"id":"92e9c391485f4e8badcfe0d0e6d1650f","type":"GENE","name":"TCEAL5","canonical_id":"hgnc:HGNC:22282","description":"transcription elongation factor A like 5","metadata":{"aliases":["WEX4"]}},{"id":"976f468a14954493a31b8f18550a19d2","type":"GENE","name":"TCEAL6","canonical_id":"hgnc:HGNC:24553","description":"transcription elongation factor A like 6","metadata":{"aliases":["WEX2"]}},{"id":"6e58f7db89b0477ab39eceaf4f0202a6","type":"GENE","name":"TCEAL7","canonical_id":"hgnc:HGNC:28336","description":"transcription elongation factor A like 7","metadata":{"aliases":["MGC23947","WEX5"]}},{"id":"a915223539314a94a4597ccec97ee078","type":"GENE","name":"TCEAL8","canonical_id":"hgnc:HGNC:28683","description":"transcription elongation factor A like 8","metadata":{"aliases":["MGC45400","WEX3"]}},{"id":"0bda9de9729a4afcab8f13a71275def5","type":"GENE","name":"TCEAL8P1","canonical_id":"hgnc:HGNC:45245","description":"TCEAL8 pseudogene 1","metadata":null},{"id":"938e3723506b4ae9aeaa42839240d80f","type":"GENE","name":"TCEAL9","canonical_id":"hgnc:HGNC:30084","description":"transcription elongation factor A like 9","metadata":{"aliases":["DKFZp313K1940","WEX6","WBP5"]}},{"id":"cd2a2bdcbfa642cfa50874c84d416bac","type":"GENE","name":"TCEAL9P1","canonical_id":"hgnc:HGNC:56943","description":"TCEAL9 pseudogene 1","metadata":null},{"id":"25ce3bad9553464ba2fd485f27d3afaf","type":"GENE","name":"TCEANC","canonical_id":"hgnc:HGNC:28277","description":"transcription elongation factor A N-terminal and central domain containing","metadata":{"aliases":["MGC17403","TCEANC1"]}},{"id":"b2d7f44458f441afb19fa4d6ea72fa31","type":"GENE","name":"TCEANC2","canonical_id":"hgnc:HGNC:26494","description":"transcription elongation factor A N-terminal and central domain containing 2","metadata":{"aliases":["FLJ32112","C1orf83"]}},{"id":"8a1bb71aaf1647cb8c3a667b79027993","type":"GENE","name":"TCERG1","canonical_id":"hgnc:HGNC:15630","description":null,"metadata":null},{"id":"348339f4e4794798be606ca56f0eb1ab","type":"GENE","name":"TCERG1L","canonical_id":"hgnc:HGNC:23533","description":"transcription elongation regulator 1 like","metadata":{"aliases":["FLJ38950"]}},{"id":"77e3a1c47d844121b67b661cdd472cd5","type":"GENE","name":"TCERG1L-AS1","canonical_id":"hgnc:HGNC:49532","description":"TCERG1L antisense RNA 1","metadata":null},{"id":"137681f6569f4218ace5287e015536e1","type":"GENE","name":"TCERG1P1","canonical_id":"hgnc:HGNC:55056","description":"TCERG1 pseudogene 1","metadata":null},{"id":"39efc69e6d4e48878a80d647c568efb7","type":"GENE","name":"TCERG1P2","canonical_id":"hgnc:HGNC:55057","description":"TCERG1 pseudogene 2","metadata":null},{"id":"4a2218d229d74b069182afb30d68bc63","type":"GENE","name":"TCF12","canonical_id":"hgnc:HGNC:11623","description":null,"metadata":null},{"id":"1663df2f1e334ffe9864ea9a0b28ad3b","type":"GENE","name":"TCF12-DT","canonical_id":"hgnc:HGNC:27078","description":"TCF12 divergent transcript","metadata":null},{"id":"c2dfb53b18044cbdbe534a64b1d0506c","type":"GENE","name":"TCF15","canonical_id":"hgnc:HGNC:11627","description":"transcription factor 15","metadata":{"aliases":["EC2","PARAXIS","bHLHa40"]}},{"id":"3774835f72d245d682756cba88c03cb8","type":"GENE","name":"TCF19","canonical_id":"hgnc:HGNC:11629","description":null,"metadata":null},{"id":"99e3ff1b76fc4436a9df9e0ff4bdcd66","type":"GENE","name":"TCF20","canonical_id":"hgnc:HGNC:11631","description":"transcription factor 20","metadata":{"aliases":["AR1","SPBP"]}},{"id":"9e5e6baf1a1540a3b1cc4052f602ead0","type":"GENE","name":"TCF21","canonical_id":"hgnc:HGNC:11632","description":"transcription factor 21","metadata":{"aliases":["POD1","bHLHa23"]}},{"id":"33180ebe40a247259943215a5513f5ef","type":"GENE","name":"TCF23","canonical_id":"hgnc:HGNC:18602","description":"transcription factor 23","metadata":{"aliases":["OUT","bHLHa24"]}},{"id":"eb7f7a97a886405aa96ddcdb6bda69dc","type":"GENE","name":"TCF24","canonical_id":"hgnc:HGNC:32275","description":"transcription factor 24","metadata":{"aliases":["bHLHa25"]}},{"id":"2698aff0b6564b708e990dfdd55a376f","type":"GENE","name":"TCF25","canonical_id":"hgnc:HGNC:29181","description":"TCF25 ribosome quality control complex subunit","metadata":{"aliases":["Nulp1","KIAA1049"]}},{"id":"448357d9801a4fa3bb792810e7d38f93","type":"GENE","name":"TCF3","canonical_id":"hgnc:HGNC:11633","description":null,"metadata":null},{"id":"3db01cc20de740979528e952fb228ac3","type":"GENE","name":"TCF3P1","canonical_id":"hgnc:HGNC:49742","description":"transcription factor 3 pseudogene 1","metadata":null},{"id":"4f69306c31164b7290b7379711d94914","type":"GENE","name":"TCF4","canonical_id":"hgnc:HGNC:11634","description":null,"metadata":null},{"id":"cd6b81c5b6254446b3a3694a35e3155c","type":"GENE","name":"TCF4-AS1","canonical_id":"hgnc:HGNC:51642","description":"TCF4 antisense RNA 1","metadata":{"aliases":["MIR4529HG"]}},{"id":"2c851de42caa4291a7bb9813f9f50c61","type":"GENE","name":"TCF4-AS2","canonical_id":"hgnc:HGNC:51643","description":"TCF4 antisense RNA 2","metadata":null},{"id":"fbb9cccf5687482289a0528157e1b4db","type":"GENE","name":"TCF7","canonical_id":"hgnc:HGNC:11639","description":null,"metadata":null},{"id":"7c90f229bd224f7abfae280d86c6d07a","type":"GENE","name":"TCF7L1","canonical_id":"hgnc:HGNC:11640","description":"transcription factor 7 like 1","metadata":{"aliases":["TCF3"]}},{"id":"2f5c712bb94a4b19856bc5b5e4501a24","type":"GENE","name":"TCF7L1-IT1","canonical_id":"hgnc:HGNC:41388","description":"TCF7L1 intronic transcript 1","metadata":null},{"id":"a06e1ac242fc434cb923fd56634144b2","type":"GENE","name":"TCF7L2","canonical_id":"hgnc:HGNC:11641","description":null,"metadata":null},{"id":"9d363ab6cf814ed8bb4cbf34eeeaccce","type":"GENE","name":"TCFL5","canonical_id":"hgnc:HGNC:11646","description":null,"metadata":null},{"id":"d587350a0b57465a9017d5e65cb8692f","type":"GENE","name":"TCHH","canonical_id":"hgnc:HGNC:11791","description":"trichohyalin","metadata":{"aliases":["THH"]}},{"id":"da00c0b92a4c45299dfc0c03af1d94f2","type":"GENE","name":"TCHHL1","canonical_id":"hgnc:HGNC:31796","description":"trichohyalin like 1","metadata":{"aliases":["S100A17","THHL1"]}},{"id":"7eb0c6ff5f99421f88ed0cda225c5d4a","type":"GENE","name":"TCHP","canonical_id":"hgnc:HGNC:28135","description":"trichoplein keratin filament binding","metadata":{"aliases":["MGC10854","TpMs"]}},{"id":"6e2752f8bc5a4d0b9b3407f87c365a23","type":"GENE","name":"TCIM","canonical_id":"hgnc:HGNC:1357","description":"transcriptional and immune response regulator","metadata":{"aliases":["TC-1","hTC-1","TC1","C8orf4"]}},{"id":"016c88c3cecc4de3a5d8ce88d65ec0aa","type":"GENE","name":"TCIRG1","canonical_id":"hgnc:HGNC:11647","description":"T cell immune regulator 1, ATPase H+ transporting V0 subunit a3","metadata":{"aliases":["TIRC7","OC-116","OC116","ATP6N1C","Atp6i","a3","ATP6V0A3"]}},{"id":"9c22c2ac7e6f4325a69fabf42dc6af36","type":"GENE","name":"TCL1A","canonical_id":"hgnc:HGNC:11648","description":"TCL1 family AKT coactivator A","metadata":{"aliases":["TCL1"]}},{"id":"f4e45877224a4ba3b2fb30f2d144e7ea","type":"GENE","name":"TCL1B","canonical_id":"hgnc:HGNC:11649","description":"TCL1 family AKT coactivator B","metadata":{"aliases":["TML1"]}},{"id":"67184ff625334f64b986fee86c8df5ac","type":"GENE","name":"TCL6","canonical_id":"hgnc:HGNC:13463","description":"T cell leukemia/lymphoma 6","metadata":{"aliases":["TCL6e1","TNG2","TNG1","TCL6148"]}},{"id":"ee80471f31734a77a9cf96bdd135e61e","type":"GENE","name":"TCN1","canonical_id":"hgnc:HGNC:11652","description":"transcobalamin 1","metadata":{"aliases":["TCI","TC1"]}},{"id":"f6c7fc94a981424dbdedb63df94b38d4","type":"GENE","name":"TCN2","canonical_id":"hgnc:HGNC:11653","description":null,"metadata":null},{"id":"1a9366b45f654eef93cc27b13a63b965","type":"GENE","name":"TCOF1","canonical_id":"hgnc:HGNC:11654","description":"treacle ribosome biogenesis factor 1","metadata":{"aliases":["treacle","TCS"]}},{"id":"8b8de065fdc64f03ab6273c64f4e2ac4","type":"GENE","name":"TCP1","canonical_id":"hgnc:HGNC:11655","description":"t-complex 1","metadata":{"aliases":["D6S230E","CCT1","Ccta"]}},{"id":"a06ed523ca6e4df9bf4017b238c9e64f","type":"GENE","name":"TCP10L","canonical_id":"hgnc:HGNC:11657","description":"t-complex 10 like","metadata":{"aliases":["PRED77"]}},{"id":"4a7a06c399e84a808794abaca066d3d9","type":"GENE","name":"TCP10L2","canonical_id":"hgnc:HGNC:21254","description":"t-complex 10 like 2 (pseudogene)","metadata":{"aliases":["bA517H2.3"]}},{"id":"5eb8cfbb9c8b45d1bf6489de463bb7f5","type":"GENE","name":"TCP10L3","canonical_id":"hgnc:HGNC:11656","description":"t-complex 10 like 3 (pseudogene)","metadata":{"aliases":["TCP10"]}},{"id":"dfe46c6245084a8bbfb64d1ef06a2269","type":"GENE","name":"TCP11","canonical_id":"hgnc:HGNC:11658","description":"t-complex 11","metadata":{"aliases":["KIAA0229","FPPR","D6S230E"]}},{"id":"b2c805372fc5401caba358aa3d7949fe","type":"GENE","name":"TCP11L1","canonical_id":"hgnc:HGNC:25655","description":"t-complex 11 like 1","metadata":{"aliases":["FLJ11336"]}},{"id":"57c30c67800240dfb3d986fea12e64ff","type":"GENE","name":"TCP11L2","canonical_id":"hgnc:HGNC:28627","description":"t-complex 11 like 2","metadata":{"aliases":["MGC40368"]}},{"id":"a7c55cfc8361463586efdacf9e18dc6d","type":"GENE","name":"TCP11X1","canonical_id":"hgnc:HGNC:48369","description":"t-complex 11 family, X-linked 1","metadata":null},{"id":"f2794b56c2b845ed9b3857a9ec9858b5","type":"GENE","name":"TCP11X2","canonical_id":"hgnc:HGNC:48335","description":"t-complex 11 family, X-linked 2","metadata":null},{"id":"1c3b20009fa74a68bbcb507b4e638e38","type":"GENE","name":"TCP11X3P","canonical_id":"hgnc:HGNC:48370","description":"t-complex 11 family, X-linked 3, pseudogene","metadata":null},{"id":"d0c82501776f4b609f754bd370315b93","type":"GENE","name":"TCP1P1","canonical_id":"hgnc:HGNC:11659","description":"t-complex 1 pseudogene 1","metadata":{"aliases":["TCP1L1"]}},{"id":"938a8736e7c448618fcd2044f12567af","type":"GENE","name":"TCP1P2","canonical_id":"hgnc:HGNC:11660","description":"t-complex 1 pseudogene 2","metadata":{"aliases":["TCP1L2"]}},{"id":"8650629125fa4a91a3c4d6314c7f9b45","type":"GENE","name":"TCP1P3","canonical_id":"hgnc:HGNC:21630","description":"t-complex 1 pseudogene 3","metadata":{"aliases":["TCP1L3"]}},{"id":"20ba6ba356be43ebb3866fa87e92d415","type":"GO_TERM","name":"TCR signalosome","canonical_id":"go:GO:0036398","description":"\"A multi-protein complex containing at least the T-cell receptor complex and the LAT (linker for activation of T cells) scaffold protein. Also contains a variety of signaling proteins including co-receptors, kinases, phosphatases and adaptors such as CD8. Connects events on the plasma membrane to distal signaling cascades to ultimately modulate T cell biology.\" [GOC:krc, PMID:17534068, PMID:20107804, PMID:22426112]","metadata":null},{"id":"9bd0ad4931904ec098f8c6682cdfeb6c","type":"GO_TERM","name":"TCR signalosome assembly","canonical_id":"go:GO:0036399","description":"\"The aggregation, arrangement and bonding together of a set of components to form a TCR signalosome.\" [GOC:krc, PMID:22426112]","metadata":null},{"id":"a1b1d502b8a84f1583a4768275af7ed9","type":"GENE","name":"TCTA","canonical_id":"hgnc:HGNC:11692","description":"T cell leukemia translocation altered","metadata":null},{"id":"38c3a84ced5b49459a3e9d3cb45f95be","type":"GENE","name":"TCTN1","canonical_id":"hgnc:HGNC:26113","description":"tectonic family member 1","metadata":{"aliases":["FLJ21127","TECT1","JBTS13"]}},{"id":"0f0a84c01b5b434893502925095b9613","type":"GENE","name":"TCTN2","canonical_id":"hgnc:HGNC:25774","description":"tectonic family member 2","metadata":{"aliases":["FLJ12975","TECT2","MKS8","JBTS24","C12orf38"]}},{"id":"e7978bd49bff413aab2011a39b503f4c","type":"GENE","name":"TCTN3","canonical_id":"hgnc:HGNC:24519","description":"tectonic family member 3","metadata":{"aliases":["DKFZP564D116","TECT3","JBTS18","C10orf61"]}},{"id":"fb7f4ec214f046d8b847e6efa57fcf62","type":"TRIAL","name":"TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT02538016","description":"Cystinuria","metadata":null},{"id":"56ea451cead4442ebd51e8fe7742bdc6","type":"GENE","name":"TDG","canonical_id":"hgnc:HGNC:11700","description":null,"metadata":null},{"id":"060d75857fb04667a1d8aa4901c3a0ed","type":"GENE","name":"TDGF1","canonical_id":"hgnc:HGNC:11701","description":null,"metadata":null},{"id":"e51309f719f749ee948ef2b0ed978ee2","type":"GENE","name":"TDGP1","canonical_id":"hgnc:HGNC:49891","description":"thymine-DNA glycosylase pseudogene 1","metadata":null},{"id":"e3fbaafcb080454e9db022713f32cd14","type":"GENE","name":"TDH","canonical_id":"hgnc:HGNC:15547","description":"L-threonine dehydrogenase (pseudogene)","metadata":{"aliases":["TDHP","FLJ25033","SDR14E1P"]}},{"id":"36c2ccf7b2d041f684336b36980b76db","type":"GENE","name":"TDH-AS1","canonical_id":"hgnc:HGNC:55510","description":"TDH antisense RNA 1","metadata":{"aliases":["AF131216.3"]}},{"id":"67ab82da163c4c1287e688f96781838c","type":"GENE","name":"TDO2","canonical_id":"hgnc:HGNC:11708","description":null,"metadata":null},{"id":"b670dfb77639436493825e638a3911ec","type":"GO_TERM","name":"TDP biosynthetic process","canonical_id":"go:GO:0006232","description":"\"The chemical reactions and pathways resulting in the formation of TDP, ribosylthymine diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"e116fcf428374d9ea8ae1472d2a5d9de","type":"GO_TERM","name":"TDP catabolic process","canonical_id":"go:GO:0006245","description":"\"The chemical reactions and pathways resulting in the breakdown of TDP, ribosylthymine diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"9cbb8b7ef434451c9ec97f783aed54e9","type":"GO_TERM","name":"TDP metabolic process","canonical_id":"go:GO:0046043","description":"\"The chemical reactions and pathways involving TDP, ribosylthymine diphosphate.\" [GOC:curators]","metadata":null},{"id":"8fb778dd08b64444a6de43c568ce5d8b","type":"GENE","name":"TDP1","canonical_id":"hgnc:HGNC:18884","description":"tyrosyl-DNA phosphodiesterase 1","metadata":{"aliases":["FLJ11090","SCAN1"]}},{"id":"9f6d73666d214fc9992f4db207cae113","type":"GENE","name":"TDP2","canonical_id":"hgnc:HGNC:17768","description":"tyrosyl-DNA phosphodiesterase 2","metadata":{"aliases":["TTRAP"]}},{"id":"1805bed905954c0ebf785f30682828ff","type":"GENE","name":"TDRD1","canonical_id":"hgnc:HGNC:11712","description":null,"metadata":null},{"id":"7b3d5e1c26d64cce8f4024a89adc0f76","type":"GENE","name":"TDRD10","canonical_id":"hgnc:HGNC:25316","description":"tudor domain containing 10","metadata":{"aliases":["DKFZp434M202"]}},{"id":"b35d9dfb07594745b1bfc4557a33a822","type":"GENE","name":"TDRD12","canonical_id":"hgnc:HGNC:25044","description":"tudor domain containing 12","metadata":{"aliases":["ECAT8","FLJ13072"]}},{"id":"e0cdc4ef03f24d4b88d9ee9da36cb8bd","type":"GENE","name":"TDRD15","canonical_id":"hgnc:HGNC:45037","description":"tudor domain containing 15","metadata":null},{"id":"9ed6f6a7c68a4a638bbff767ed2880ad","type":"GENE","name":"TDRD3","canonical_id":"hgnc:HGNC:20612","description":"tudor domain containing 3","metadata":{"aliases":["FLJ21007"]}},{"id":"24a2536def734ee3a969bec031f75715","type":"GENE","name":"TDRD5","canonical_id":"hgnc:HGNC:20614","description":"tudor domain containing 5","metadata":{"aliases":["FLJ34823","TUDOR3"]}},{"id":"32dd58f550424391bf1cf07ec146c6d5","type":"GENE","name":"TDRD6","canonical_id":"hgnc:HGNC:21339","description":"tudor domain containing 6","metadata":{"aliases":["NY-CO-45","bA446F17.4","CT41.2","SPATA36"]}},{"id":"2531b07b0dd64c27966a4b2f3e59e12c","type":"GENE","name":"TDRD6-AS1","canonical_id":"hgnc:HGNC:56119","description":"TDRD6 and SLC25A27 antisense RNA 1","metadata":null},{"id":"7487bfa441364353b29a94e9cf4bebe2","type":"GENE","name":"TDRD7","canonical_id":"hgnc:HGNC:30831","description":"tudor domain containing 7","metadata":{"aliases":["PCTAIRE2BP"]}},{"id":"d1c189e026a24374afa5a267fab71130","type":"GENE","name":"TDRD9","canonical_id":"hgnc:HGNC:20122","description":"tudor domain containing 9","metadata":{"aliases":["DKFZp434N0820","FLJ36164","NET54","C14orf75"]}},{"id":"684120df6826482fa180d3b839067100","type":"GENE","name":"TDRG1","canonical_id":"hgnc:HGNC:43642","description":"testis development regulator, piRNA precursor","metadata":{"aliases":["LINC00532","lincRNA-NR_024015"]}},{"id":"aa6d0a89495144899c1a112ac2591737","type":"GENE","name":"TDRKH","canonical_id":"hgnc:HGNC:11713","description":"tudor and KH domain containing","metadata":{"aliases":["TDRD2"]}},{"id":"3a9e704d0d584ed69ff27a64b60c1ad6","type":"GENE","name":"TDRKH-AS1","canonical_id":"hgnc:HGNC:40578","description":"TDRKH antisense RNA 1","metadata":{"aliases":["RP11-98D18.9"]}},{"id":"9bd44452c8374f2ca90c41f0ad7222d5","type":"GENE","name":"TDRP","canonical_id":"hgnc:HGNC:26951","description":"testis development related protein","metadata":{"aliases":["INM01","TDRP1","TDRP2","C8orf42"]}},{"id":"63fef72e65e94e20ac33b8903e54da70","type":"GO_TERM","name":"TEAD-YAP complex","canonical_id":"go:GO:0140552","description":"\"A transcription factor complex that is composed of the one DNA binding protein of the TEAD family and the transcriptional coactivator YAP.\" [GOC:mah, PMID:11358867]","metadata":null},{"id":"229284a5d9254c64892fd1c9eedcbeb1","type":"GENE","name":"TEAD1","canonical_id":"hgnc:HGNC:11714","description":null,"metadata":null},{"id":"77ddcf1eb7884ac195ee347462fdd7b9","type":"GENE","name":"TEAD1-AS1","canonical_id":"hgnc:HGNC:58346","description":"TEAD1 antisense RNA 1","metadata":null},{"id":"12d07bb5c5aa4efd872e66ec8b6ca21f","type":"GENE","name":"TEAD2","canonical_id":"hgnc:HGNC:11715","description":"TEA domain transcription factor 2","metadata":{"aliases":["TEF-4","ETF","TEF4"]}},{"id":"f4d130a41be74bb9b710b0af7eb46639","type":"GENE","name":"TEAD2-AS1","canonical_id":"hgnc:HGNC:58682","description":"TEAD2 antisense RNA 1","metadata":null},{"id":"ab2d97aad9664ad98c3bf21988681e84","type":"GENE","name":"TEAD3","canonical_id":"hgnc:HGNC:11716","description":"TEA domain transcription factor 3","metadata":{"aliases":["TEF-5","ETFR-1","TEAD5"]}},{"id":"3761c192cc8e4f4c94d737c79bab2335","type":"GENE","name":"TEAD4","canonical_id":"hgnc:HGNC:11717","description":null,"metadata":null},{"id":"e30f8ac8e39848d2a128a1fb6068d813","type":"TRIAL","name":"TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib","canonical_id":"clinicaltrials.gov:NCT04173585","description":"Acute Myeloid Leukemia","metadata":null},{"id":"afdbddf96b7946b6b9cb37ea225cb36b","type":"TRIAL","name":"TEAPOT Study Multisite","canonical_id":"clinicaltrials.gov:NCT07565753","description":"Hemorrhage, Surgical; Tonsillar Bleeding","metadata":null},{"id":"4cf93eaad39d4c9e94c52c684c8bfe30","type":"GENE","name":"TEC","canonical_id":"hgnc:HGNC:11719","description":"tec protein tyrosine kinase","metadata":{"aliases":["PSCTK4"]}},{"id":"398eee8ddd00428e9769006800b39de8","type":"GENE","name":"TEC-AS1","canonical_id":"hgnc:HGNC:58783","description":"TEC antisense RNA 1","metadata":null},{"id":"74285e519c0f46cc8933604a30f1069c","type":"GENE","name":"TEC-DT","canonical_id":"hgnc:HGNC:58784","description":"TEC divergent transcript","metadata":null},{"id":"8ef87a881e534c5bacf9a8eff745e90d","type":"GENE","name":"TECPR1","canonical_id":"hgnc:HGNC:22214","description":"tectonin beta-propeller repeat containing 1","metadata":{"aliases":["DKFZP434B0335","FLJ23419","FLJ90593","KIAA1358"]}},{"id":"cb9f03e2b96a4098875f39aea1dad83c","type":"GENE","name":"TECPR2","canonical_id":"hgnc:HGNC:19957","description":"tectonin beta-propeller repeat containing 2","metadata":{"aliases":["KIAA0329"]}},{"id":"d35fddd3b130440fbc0e1ae65c9555e8","type":"GENE","name":"TECR","canonical_id":"hgnc:HGNC:4551","description":"trans-2,3-enoyl-CoA reductase","metadata":{"aliases":["TER","MRT14","SC2","GPSN2"]}},{"id":"7b0c2fc3fb294069b9b9983cbe1f5cb8","type":"GENE","name":"TECRL","canonical_id":"hgnc:HGNC:27365","description":"trans-2,3-enoyl-CoA reductase like","metadata":{"aliases":["GPSN2L","SRD5A2L2","DKFZp313D0829","DKFZp313B2333","TERL"]}},{"id":"92bd4b2459e04de489f539c8a5cf2e4b","type":"GENE","name":"TECRP1","canonical_id":"hgnc:HGNC:44050","description":"trans-2,3-enoyl-CoA reductase pseudogene 1","metadata":null},{"id":"d8d5cd8e891a4dd9ae00061c3aff18d8","type":"GENE","name":"TECRP2","canonical_id":"hgnc:HGNC:44051","description":"trans-2,3-enoyl-CoA reductase pseudogene 2","metadata":null},{"id":"d28f278f4a7d484fa3e8e1c9d90312de","type":"GENE","name":"TECTA","canonical_id":"hgnc:HGNC:11720","description":"tectorin alpha","metadata":{"aliases":["DFNA12","DFNA8","DFNB21"]}},{"id":"2c3311c2eeaf4360a9e89485943c4ba9","type":"GENE","name":"TECTB","canonical_id":"hgnc:HGNC:11721","description":"tectorin beta","metadata":null},{"id":"7172479265bd447eb2d59368391df5d2","type":"GENE","name":"TEDAR","canonical_id":"hgnc:HGNC:31825","description":"terminal epidermal differentiation associated RNA","metadata":{"aliases":["XP33","C1orf46","NCRNA00302","LINC00302"]}},{"id":"c761b682d48247a2beccd817f870720b","type":"GENE","name":"TEDC1","canonical_id":"hgnc:HGNC:20127","description":"tubulin epsilon and delta complex 1","metadata":{"aliases":["C14orf80"]}},{"id":"2be32eed2db44665828ec055f7ce2084","type":"GENE","name":"TEDC2","canonical_id":"hgnc:HGNC:25849","description":"tubulin epsilon and delta complex 2","metadata":{"aliases":["FLJ13909","C16orf59"]}},{"id":"fd59dc5d50114282970e8dc402e2b302","type":"GENE","name":"TEDC2-AS1","canonical_id":"hgnc:HGNC:55403","description":"TEDC2 antisense RNA 1","metadata":null},{"id":"e2d6214bed04435982546c8e5145dce1","type":"GENE","name":"TEDDM1","canonical_id":"hgnc:HGNC:30233","description":"transmembrane epididymal protein 1","metadata":{"aliases":["HE9","Epdd1","TMEM45C","EDDM9"]}},{"id":"2a1ccaf322614b42bc2fe7cd75c2e7a6","type":"GENE","name":"TEDDM2P","canonical_id":"hgnc:HGNC:42447","description":"transmembrane epididymal protein 2, pseudogene","metadata":{"aliases":["TEDDM1P1"]}},{"id":"657d5d34017741e3a4ffc9bcafbedda0","type":"GENE","name":"TEDDM3P","canonical_id":"hgnc:HGNC:56610","description":"transmembrane epididymal protein 3, pseudogene","metadata":null},{"id":"680e0d5986704d9a8da3e485a36aa242","type":"TRIAL","name":"TED_ORG: Study on Short Bowel Syndrome","canonical_id":"clinicaltrials.gov:NCT07400783","description":"Short Bowel Syndrome (SBS)","metadata":null},{"id":"b370679718b54c54bc53c0f3da0b2781","type":"GENE","name":"TEF","canonical_id":"hgnc:HGNC:11722","description":null,"metadata":null},{"id":"97b42535d61744ad904fdc6645f3e4ec","type":"GENE","name":"TEFM","canonical_id":"hgnc:HGNC:26223","description":"transcription elongation factor, mitochondrial","metadata":{"aliases":["FLJ22729","C17orf42"]}},{"id":"7936866cbd3e4f299292eaa6a56a4301","type":"GENE","name":"TEK","canonical_id":"hgnc:HGNC:11724","description":null,"metadata":null},{"id":"33874ce78b5f42a68735ce2a2d9b1073","type":"PROTEIN","name":"TEK","canonical_id":"uniprot:Q02763","description":null,"metadata":null},{"id":"8275fbd88fb84b1eac452ebfc3d23ee7","type":"GENE","name":"TEKT1","canonical_id":"hgnc:HGNC:15534","description":"tektin 1","metadata":null},{"id":"10236ca27a294683805d9e9e2639a381","type":"GENE","name":"TEKT2","canonical_id":"hgnc:HGNC:11725","description":"tektin 2","metadata":{"aliases":["TEKTB1"]}},{"id":"61e20ece20b34cd087942377952950c5","type":"GENE","name":"TEKT3","canonical_id":"hgnc:HGNC:14293","description":"tektin 3","metadata":{"aliases":["FLJ32828"]}},{"id":"70b11ed79506441ab6483bc1d2b7b2ac","type":"GENE","name":"TEKT4","canonical_id":"hgnc:HGNC:31012","description":"tektin 4","metadata":{"aliases":["MGC27019"]}},{"id":"88d1c6ae4b5c4e2aa6ce13ba5aa311a7","type":"GENE","name":"TEKT4P1","canonical_id":"hgnc:HGNC:37711","description":"tektin 4 pseudogene 1","metadata":null},{"id":"7a7fed2e8b9a45daa19983a3ff6d09ff","type":"GENE","name":"TEKT4P2","canonical_id":"hgnc:HGNC:40046","description":"tektin 4 pseudogene 2","metadata":{"aliases":["MAFIPL"]}},{"id":"5d64a57d1bed4eb881ae753837c8b9dd","type":"GENE","name":"TEKT4P3","canonical_id":"hgnc:HGNC:42330","description":"tektin 4 pseudogene 3","metadata":null},{"id":"bc3519b57b3e49a9ba86e5452adabb0e","type":"GENE","name":"TEKT5","canonical_id":"hgnc:HGNC:26554","description":"tektin 5","metadata":{"aliases":["FLJ32871","CT149"]}},{"id":"48225f80f8c74a36bc0b5778c6acd4bf","type":"GENE","name":"TEKTIP1","canonical_id":"hgnc:HGNC:34496","description":"tektin bundle interacting protein 1","metadata":{"aliases":["LOC100128569","C19orf71"]}},{"id":"9238ee42ad534906991dc3dc955cd4d3","type":"GENE","name":"TEKTL1","canonical_id":"hgnc:HGNC:26866","description":"tektin like 1","metadata":{"aliases":["FLJ40365","CCDC105"]}},{"id":"10e31845adb543af9ab9513ceac44ea2","type":"GENE","name":"TELO2","canonical_id":"hgnc:HGNC:29099","description":"telomere maintenance 2","metadata":{"aliases":["KIAA0683","hCLK2","TEL2"]}},{"id":"5c31a0973a954771bfdde47ef3cfd104","type":"GENE","name":"TEN1","canonical_id":"hgnc:HGNC:37242","description":"TEN1 subunit of CST complex","metadata":{"aliases":["FLJ39785","C17orf106"]}},{"id":"730cb18033b94e9c876351c782199cba","type":"GENE","name":"TEN1-CDK3","canonical_id":"hgnc:HGNC:44420","description":"TEN1-CDK3 readthrough (NMD candidate)","metadata":null},{"id":"35349b91e14e410ea6d6f155cdb9aa7e","type":"GENE","name":"TENM1","canonical_id":"hgnc:HGNC:8117","description":"teneurin transmembrane protein 1","metadata":{"aliases":["TEN-M1","TEN1","ODZ3","TNM","ODZ1"]}},{"id":"d7406006e9504b0ebb946e780d773bb8","type":"GENE","name":"TENM2","canonical_id":"hgnc:HGNC:29943","description":"teneurin transmembrane protein 2","metadata":{"aliases":["KIAA1127","Ten-M2","TEN2","ODZ2"]}},{"id":"bcbd0fda0e3b412687990883cdc824f7","type":"GENE","name":"TENM2-AS1","canonical_id":"hgnc:HGNC:56066","description":"TENM2 antisense RNA 1","metadata":null},{"id":"2a2d339ed44f427d9388289436ed00bf","type":"GENE","name":"TENM2-AS2","canonical_id":"hgnc:HGNC:58260","description":"TENM2 antisense RNA 2","metadata":null},{"id":"777fd8ccf73d4532995e8ffd5eb852fe","type":"GENE","name":"TENM2-AS3","canonical_id":"hgnc:HGNC:58261","description":"TENM2 antisense RNA 3","metadata":null},{"id":"26c4b93f942b49c390b59d20433d7ad2","type":"GENE","name":"TENM2-AS4","canonical_id":"hgnc:HGNC:58432","description":"TENM2 antisense RNA 4","metadata":null},{"id":"f4ae010089284c3f8b467cb5b9f2b4bc","type":"GENE","name":"TENM3","canonical_id":"hgnc:HGNC:29944","description":"teneurin transmembrane protein 3","metadata":{"aliases":["Ten-M3","KIAA1455","TEN3","ODZ3"]}},{"id":"aa6636f799864611bc38b2facc04c101","type":"GENE","name":"TENM3-AS1","canonical_id":"hgnc:HGNC:28076","description":"TENM3 antisense RNA 1","metadata":{"aliases":["TENM3-AS2"]}},{"id":"40404023054740629bb1c461fa798992","type":"GENE","name":"TENM3-AS3","canonical_id":"hgnc:HGNC:58915","description":"TENM3 antisense RNA 3","metadata":null},{"id":"5e86e3f461054fa882e4b77c14bbe276","type":"GENE","name":"TENM4","canonical_id":"hgnc:HGNC:29945","description":"teneurin transmembrane protein 4","metadata":{"aliases":["KIAA1302","Ten-M4","TEN4","DOC4","ODZ4"]}},{"id":"4dacb783ca96426985f5b182ceee7613","type":"GENE","name":"TENM4-AS1","canonical_id":"hgnc:HGNC:58189","description":"TENM4 antisense RNA 1","metadata":null},{"id":"24bb8531fe1f45ff834bf0de249313e9","type":"GENE","name":"TENT2","canonical_id":"hgnc:HGNC:26776","description":"terminal nucleotidyltransferase 2","metadata":{"aliases":["FLJ38499","GLD2","TUT2","PAPD4"]}},{"id":"22666efdf63f4a4d8a520565a27ea28e","type":"GENE","name":"TENT2-AS1","canonical_id":"hgnc:HGNC:59085","description":"TENT2 antisense RNA 1","metadata":null},{"id":"b2df267d24ac42aea11543bbc8f646bf","type":"GENE","name":"TENT4A","canonical_id":"hgnc:HGNC:16705","description":"terminal nucleotidyltransferase 4A","metadata":{"aliases":["POLK","TRF4","LAK-1","TRF4-1","POLS","PAPD7"]}},{"id":"3c7dea38ed4348058ad57bb7b2ce55ea","type":"GENE","name":"TENT4B","canonical_id":"hgnc:HGNC:30758","description":"terminal nucleotidyltransferase 4B","metadata":{"aliases":["TRF4-2","TUT3","PAPD5"]}},{"id":"c5383425c038480e9c5fdbefa55ecd62","type":"GENE","name":"TENT5A","canonical_id":"hgnc:HGNC:18345","description":"terminal nucleotidyltransferase 5A","metadata":{"aliases":["FLJ20037","C6orf37","FAM46A"]}},{"id":"403b969fd001450b8853987e7deeea25","type":"GENE","name":"TENT5B","canonical_id":"hgnc:HGNC:28273","description":"terminal nucleotidyltransferase 5B","metadata":{"aliases":["MGC16491","FAM46B"]}},{"id":"81c60d21c5844daba0bdc01274e08807","type":"GENE","name":"TENT5C","canonical_id":"hgnc:HGNC:24712","description":"terminal nucleotidyltransferase 5C","metadata":{"aliases":["FLJ20202","FAM46C"]}},{"id":"54cf386d05ed495f925c2f8a07d3eaa3","type":"GENE","name":"TENT5C-DT","canonical_id":"hgnc:HGNC:55656","description":"TENT5C divergent transcript","metadata":null},{"id":"b39b91d1f91147f0a7738bdfbccc754d","type":"GENE","name":"TENT5D","canonical_id":"hgnc:HGNC:28399","description":"terminal nucleotidyltransferase 5D","metadata":{"aliases":["MGC26999","CT1.26","CT112","FAM46D"]}},{"id":"9952c5e6a2df4eaba503d49d12d4bfff","type":"GENE","name":"TEP1","canonical_id":"hgnc:HGNC:11726","description":"telomerase associated protein 1","metadata":{"aliases":["TP1","TLP1","VAULT2","p240","TROVE1"]}},{"id":"4949c21a2f084080ad76cf11ae506286","type":"TRIAL","name":"TEPEZZA\u00ae (Teprotumumab-trbw) Post-Marketing Requirement Study","canonical_id":"clinicaltrials.gov:NCT05002998","description":"Thyroid Eye Disease","metadata":null},{"id":"5714efbb966f406c9753f0a86027ccd9","type":"GENE","name":"TEPSIN","canonical_id":"hgnc:HGNC:26458","description":"TEPSIN adaptor related protein complex 4 accessory protein","metadata":{"aliases":["FLJ31528","C17orf56","ENTHD2"]}},{"id":"52f774730c7a407893a4ce371bf60816","type":"GENE","name":"TEPSIN-AS1","canonical_id":"hgnc:HGNC:58197","description":"TEPSIN antisense RNA 1","metadata":null},{"id":"84220f5d92634481b0b46191529b2cf1","type":"GENE","name":"TERB1","canonical_id":"hgnc:HGNC:26675","description":"telomere repeat binding bouquet formation protein 1","metadata":{"aliases":["FLJ35894","CCDC79"]}},{"id":"80f947c070ab4119bf95eef924bbdec4","type":"GENE","name":"TERB2","canonical_id":"hgnc:HGNC:28520","description":"telomere repeat binding bouquet formation protein 2","metadata":{"aliases":["MGC33951","C15orf43"]}},{"id":"5d8c9649be8c4184b4dd2ece1cadf52f","type":"GENE","name":"TERC","canonical_id":"hgnc:HGNC:11727","description":"telomerase RNA component","metadata":{"aliases":["TR","hTR","TRC3","SCARNA19","TER"]}},{"id":"235c459aca0c4ec59f51ba33e93faa3a","type":"GENE","name":"TERF1","canonical_id":"hgnc:HGNC:11728","description":null,"metadata":null},{"id":"6e37637d4c0e4ef3a3d54d722b9a8935","type":"GENE","name":"TERF1P1","canonical_id":"hgnc:HGNC:16733","description":"TERF1 pseudogene 1","metadata":{"aliases":["TERF1P"]}},{"id":"9df4a9b1b4e847f49087550f8fcf6460","type":"GENE","name":"TERF1P2","canonical_id":"hgnc:HGNC:38110","description":"TERF1 pseudogene 2","metadata":null},{"id":"d9f2fe1dac094e25a7138529fafa3588","type":"GENE","name":"TERF1P3","canonical_id":"hgnc:HGNC:38499","description":"TERF1 pseudogene 3","metadata":null},{"id":"e05dc787e4b8412382591993f8dafca7","type":"GENE","name":"TERF1P4","canonical_id":"hgnc:HGNC:38500","description":"TERF1 pseudogene 4","metadata":null},{"id":"63f5037711fa49b1a022dd02e88766cc","type":"GENE","name":"TERF1P5","canonical_id":"hgnc:HGNC:39686","description":"TERF1 pseudogene 5","metadata":null},{"id":"1198f5d6e8fa46e38af6e65317d6a630","type":"GENE","name":"TERF1P6","canonical_id":"hgnc:HGNC:54602","description":"TERF1 pseudogene 6","metadata":null},{"id":"3043716b5c394fc2a4bdc195055be70a","type":"GENE","name":"TERF1P7","canonical_id":"hgnc:HGNC:54603","description":"TERF1 pseudogene 7","metadata":null},{"id":"3fbe4da2e523425294c61197f3ca0088","type":"GENE","name":"TERF2","canonical_id":"hgnc:HGNC:11729","description":null,"metadata":null},{"id":"2e080fd38ad7439089843d171dcad8b1","type":"GENE","name":"TERF2IP","canonical_id":"hgnc:HGNC:19246","description":"TERF2 interacting protein","metadata":{"aliases":["RAP1"]}},{"id":"a2d165cae1fd4cfd9a747a20d15d3f4a","type":"GENE","name":"TERF2IPP1","canonical_id":"hgnc:HGNC:19258","description":"TERF2 interacting protein pseudogene 1","metadata":null},{"id":"9cdb5ec43d3946ba80b44013dc23a4b2","type":"GENE","name":"TERLR1","canonical_id":"hgnc:HGNC:52952","description":"TERT regulating lncRNA 1","metadata":{"aliases":["BC032469"]}},{"id":"a960c96cf16a4f8ea1354ac970cd9862","type":"GENE","name":"TERT","canonical_id":"hgnc:HGNC:11730","description":null,"metadata":null},{"id":"213eb709deb54883a789710c43eadbe0","type":"GENE","name":"TERT-AS1","canonical_id":"hgnc:HGNC:58990","description":"TERT antisense RNA 1","metadata":null},{"id":"d4887c99336f4bd8a58f46e00f3e64c7","type":"GENE","name":"TERT-DT","canonical_id":"hgnc:HGNC:53844","description":"TERT divergent transcript","metadata":{"aliases":["hTAPAS"]}},{"id":"495b854628b5467aa46285bf9c749000","type":"GO_TERM","name":"TERT-RMRP complex","canonical_id":"go:GO:1990572","description":"\"A ribonucleoprotein complex that has RNA-directed RNA polymerase (RdRP) activity, and is composed of telomerase reverse transcriptase (TERT) and the non-coding RNA component of mitochondrial RNA processing endoribonuclease (RMRP).\" [GOC:bf, GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:19701182]","metadata":null},{"id":"113446a7b37444a6bab9f16fffefb5e9","type":"GENE","name":"TES","canonical_id":"hgnc:HGNC:14620","description":"testin LIM domain protein","metadata":{"aliases":["DKFZP586B2022","TESS-2","TESTIN"]}},{"id":"f10f439146034348ae8004742129ae24","type":"GENE","name":"TESC","canonical_id":"hgnc:HGNC:26065","description":"tescalcin","metadata":{"aliases":["TSC","FLJ20607","CHP3"]}},{"id":"ec196a48821f4c1c9eda30ea25b1140c","type":"GENE","name":"TESC-AS1","canonical_id":"hgnc:HGNC:51142","description":"TESC antisense RNA 1","metadata":null},{"id":"295c237b9cf3429aadc1f36f898774db","type":"GENE","name":"TESHL","canonical_id":"hgnc:HGNC:52740","description":"testicular germ cell expressed HSF2 interacting lncRNA","metadata":{"aliases":["DIRC3-AS1","LINC01921"]}},{"id":"c18076fa30264a01b273ee4a5765cde4","type":"GENE","name":"TESK1","canonical_id":"hgnc:HGNC:11731","description":"testis associated actin remodelling kinase 1","metadata":null},{"id":"472a58183df14235b4446b8cc13d020a","type":"GENE","name":"TESK2","canonical_id":"hgnc:HGNC:11732","description":"testis associated actin remodelling kinase 2","metadata":null},{"id":"b6f4b71ad8634d67a2aea821a46c9c24","type":"GENE","name":"TESMIN","canonical_id":"hgnc:HGNC:7446","description":"testis expressed metallothionein like protein","metadata":{"aliases":["CXCDC2","MTL5"]}},{"id":"7ec468f4fc6d40f49d31e26fbb2ac16c","type":"GENE","name":"TESPA1","canonical_id":"hgnc:HGNC:29109","description":"thymocyte expressed, positive selection associated 1","metadata":{"aliases":["ITPRID3","KIAA0748"]}},{"id":"84b1ebef153c46bbb37b16f448dda041","type":"GENE","name":"TESPA1-AS1","canonical_id":"hgnc:HGNC:59217","description":"TESPA1 antisense RNA 1","metadata":null},{"id":"baeb86904414490b8aa982fa8fe07b8f","type":"GENE","name":"TET1","canonical_id":"hgnc:HGNC:29484","description":"tet methylcytosine dioxygenase 1","metadata":{"aliases":["LCX","KIAA1676","bA119F7.1","CXXC6"]}},{"id":"4ff3dec88b4c4450b2ee27a0b926c616","type":"GENE","name":"TET1P1","canonical_id":"hgnc:HGNC:33586","description":"tet methylcytosine dioxygenase 1 pseudogene 1","metadata":{"aliases":["CXXC6P1"]}},{"id":"af415517c01c4f39ae479cb3e3a75630","type":"GENE","name":"TET2","canonical_id":"hgnc:HGNC:25941","description":"tet methylcytosine dioxygenase 2","metadata":{"aliases":["FLJ20032","KIAA1546"]}},{"id":"5e941671b4954ec991cffd09c0c93e61","type":"GENE","name":"TET2-AS1","canonical_id":"hgnc:HGNC:41125","description":"TET2 antisense RNA 1","metadata":null},{"id":"6a07c30a37c545ccbf02f06410d0eef7","type":"GENE","name":"TET3","canonical_id":"hgnc:HGNC:28313","description":"tet methylcytosine dioxygenase 3","metadata":{"aliases":["MGC22014","hCG_40738"]}},{"id":"98ebd21661c54d3fa1e4ce1b830d08ac","type":"GENE","name":"TEX10","canonical_id":"hgnc:HGNC:25988","description":"testis expressed 10","metadata":{"aliases":["FLJ20287","bA208F1.2","Ipi1"]}},{"id":"3185b2c690e5418ba63fa10faaf9591b","type":"GENE","name":"TEX101","canonical_id":"hgnc:HGNC:30722","description":"testis expressed 101","metadata":{"aliases":["MGC4766","SGRG","CT131","SPATA44","TES101RP"]}},{"id":"4a4a26e69e6f45d3b0fce095463009c9","type":"GENE","name":"TEX101P1","canonical_id":"hgnc:HGNC:55030","description":"TEX101 pseudogene 1","metadata":null},{"id":"9ef2396083e84f74b93c13f995657f97","type":"GENE","name":"TEX11","canonical_id":"hgnc:HGNC:11733","description":"testis expressed 11","metadata":{"aliases":["TSGA3","TGC1","ZIP4","ZIP4H","MZIP4","Spo22"]}},{"id":"4fc458724642414587e70ea5d7cf5bcd","type":"GENE","name":"TEX12","canonical_id":"hgnc:HGNC:11734","description":"testis expressed 12","metadata":null},{"id":"e5f9bf6cb5c04a78b69bb6727b012ede","type":"GENE","name":"TEX12-AS1","canonical_id":"hgnc:HGNC:58436","description":"TEX12 antisense RNA 1","metadata":null},{"id":"a62cb78ec2d94f9090272eaf29a1c95c","type":"GENE","name":"TEX13A","canonical_id":"hgnc:HGNC:11735","description":"testis expressed 13A","metadata":null},{"id":"f0870e786683496e99e44146c4aa7e48","type":"GENE","name":"TEX13B","canonical_id":"hgnc:HGNC:11736","description":"testis expressed 13B","metadata":{"aliases":["TSGA5","TGC3B"]}},{"id":"fa34a095e28b486e87bbeff89cae5f3b","type":"GENE","name":"TEX13C","canonical_id":"hgnc:HGNC:52277","description":"TEX13 family member C","metadata":null},{"id":"161aa7adf8844f2ab2e5d89dbd6b0952","type":"GENE","name":"TEX13D","canonical_id":"hgnc:HGNC:52278","description":"TEX13 family member D","metadata":null},{"id":"f554d434741d4edbb04e60d11e93c8c9","type":"GENE","name":"TEX14","canonical_id":"hgnc:HGNC:11737","description":"testis expressed 14, intercellular bridge forming factor","metadata":{"aliases":["CT113","SgK307"]}},{"id":"ef1f98dcb55441048daaf495440df0a3","type":"GENE","name":"TEX14BP","canonical_id":"hgnc:HGNC:51268","description":"testis expressed 14B, pseudogene","metadata":{"aliases":["LNCGM1082","LINC01529"]}},{"id":"e4d7dcd896b84e1eb6405399b379d05f","type":"GENE","name":"TEX15","canonical_id":"hgnc:HGNC:11738","description":"testis expressed 15, meiosis and synapsis associated","metadata":{"aliases":["CT42"]}},{"id":"60c4aca7ce634d0ca96233750794ef0d","type":"GENE","name":"TEX16P","canonical_id":"hgnc:HGNC:37957","description":"testis expressed 16, pseudogene","metadata":null},{"id":"57d2f3b549d9452e8311ac7211cb1fdb","type":"GENE","name":"TEX19","canonical_id":"hgnc:HGNC:33802","description":"testis expressed 19","metadata":{"aliases":["FLJ35767"]}},{"id":"3e03fd90bb7446babe9886c743648d8f","type":"GENE","name":"TEX2","canonical_id":"hgnc:HGNC:30884","description":"testis expressed 2","metadata":{"aliases":["HT008","TMEM96","KIAA1738"]}},{"id":"c5808abf9c2842268f01db774138897f","type":"GENE","name":"TEX21P","canonical_id":"hgnc:HGNC:35455","description":"testis expressed 21, pseudogene","metadata":null},{"id":"973cc1aebd174363bc29ab1d29610316","type":"GENE","name":"TEX22","canonical_id":"hgnc:HGNC:40026","description":"testis expressed 22","metadata":null},{"id":"cfeb19a9475240428968a3130fe70d40","type":"GENE","name":"TEX26","canonical_id":"hgnc:HGNC:28622","description":"testis expressed 26","metadata":{"aliases":["MGC40178","C13orf26"]}},{"id":"7a701bc17bb94f629fdab980dae3c063","type":"GENE","name":"TEX26-AS1","canonical_id":"hgnc:HGNC:42784","description":"TEX26 antisense RNA 1","metadata":{"aliases":["LINC00447"]}},{"id":"e130a3900b9e4ac4aa9f371f469edcfe","type":"GENE","name":"TEX26-AS2","canonical_id":"hgnc:HGNC:58403","description":"TEX26 antisense RNA 2","metadata":null},{"id":"9d400a275bc6425d90216ff6bcf201dc","type":"GENE","name":"TEX261","canonical_id":"hgnc:HGNC:30712","description":"testis expressed 261","metadata":{"aliases":["MGC32043","TEG-261"]}},{"id":"a60b67a67834420eac82f86535f65b36","type":"GENE","name":"TEX264","canonical_id":"hgnc:HGNC:30247","description":"testis expressed 264, ER-phagy receptor","metadata":{"aliases":["ZSIG11","FLJ13935"]}},{"id":"c2ec64d17d124d2d9de225f2961bf345","type":"GENE","name":"TEX264P1","canonical_id":"hgnc:HGNC:59177","description":"TEX264 pseudogene 1","metadata":null},{"id":"c7bcc75dac5843948930ededa0eedc6a","type":"GENE","name":"TEX28","canonical_id":"hgnc:HGNC:2563","description":"testis expressed 28","metadata":{"aliases":["fTEX","CXorf2"]}},{"id":"3a6560684b6e44128c8a2aac00e57384","type":"GENE","name":"TEX28P1","canonical_id":"hgnc:HGNC:33356","description":"TEX28 pseudogene 1","metadata":{"aliases":["pTEX"]}},{"id":"674d8940931a438ca4bd405998f57dbe","type":"GENE","name":"TEX28P2","canonical_id":"hgnc:HGNC:33357","description":"TEX28 pseudogene 2","metadata":{"aliases":["pTEX","CXorf2B"]}},{"id":"6eebfce8fb28415bbc2fa0242cea24bc","type":"GENE","name":"TEX28P3","canonical_id":"hgnc:HGNC:55924","description":"TEX28 pseudogene 3","metadata":null},{"id":"686611f639644e048af846af6252ac86","type":"GENE","name":"TEX29","canonical_id":"hgnc:HGNC:20370","description":"testis expressed 29","metadata":{"aliases":["bA474D23.1","MGC35169","C13orf16"]}},{"id":"8fd06c7c1e5e447c83cc3a52e178434b","type":"GENE","name":"TEX30","canonical_id":"hgnc:HGNC:25188","description":"testis expressed 30","metadata":{"aliases":["C13orf27"]}},{"id":"e5dbcf9a16c14e349a9613327d784071","type":"GENE","name":"TEX35","canonical_id":"hgnc:HGNC:25366","description":"testis expressed 35","metadata":{"aliases":["DKFZP564J047","TSC24","C1orf49"]}},{"id":"8fb4cc434d3e4731ac68d8070a48bf46","type":"GENE","name":"TEX36","canonical_id":"hgnc:HGNC:31653","description":"testis expressed 36","metadata":{"aliases":["bA383C5.1","C10orf122"]}},{"id":"ff6a2969f7984117944e7a62bf3cd480","type":"GENE","name":"TEX36-AS1","canonical_id":"hgnc:HGNC:49500","description":"TEX36 antisense RNA 1","metadata":null},{"id":"7026bbbd1e5a41a4bb4d0fb55f08b457","type":"GENE","name":"TEX38","canonical_id":"hgnc:HGNC:29589","description":"testis expressed 38","metadata":{"aliases":["LOC374973","THEG4","C1orf223","ATPAF1-AS1"]}},{"id":"9cfd5c6f687643feb06a023f4e9bd57e","type":"GENE","name":"TEX41","canonical_id":"hgnc:HGNC:48667","description":"testis expressed 41","metadata":{"aliases":["DKFZp686O1327","LINC00953"]}},{"id":"409d675384884ef3a1309e9253aee525","type":"GENE","name":"TEX44","canonical_id":"hgnc:HGNC:28563","description":"testis expressed 44","metadata":{"aliases":["MGC35154","C2orf57"]}},{"id":"6ce4dfc8d82c4883825947192dbf5078","type":"GENE","name":"TEX46","canonical_id":"hgnc:HGNC:44651","description":"testis expressed 46","metadata":{"aliases":["C1orf234"]}},{"id":"bb1992f7a1514bb184afd9f2c87532c4","type":"GENE","name":"TEX47","canonical_id":"hgnc:HGNC:22402","description":"testis expressed 47","metadata":{"aliases":["MGC26647","DYBLUF","C7orf62"]}},{"id":"903383a00ee54b32ae7fe0c9ef3076cf","type":"GENE","name":"TEX48","canonical_id":"hgnc:HGNC:52393","description":"testis expressed 48","metadata":null},{"id":"441897d0478d4d2aa4ebf9df8544d204","type":"GENE","name":"TEX50","canonical_id":"hgnc:HGNC:52382","description":"testis expressed 50","metadata":null},{"id":"039acb7771c149dea0c7e3920a545ff6","type":"GENE","name":"TEX51","canonical_id":"hgnc:HGNC:52387","description":"testis expressed 51","metadata":null},{"id":"a39a85fae84a496cbf144ecba742ec71","type":"GENE","name":"TEX52","canonical_id":"hgnc:HGNC:53643","description":"testis expressed 52","metadata":null},{"id":"70411d9ac9d6403493ab3d9b3b227724","type":"GENE","name":"TEX53","canonical_id":"hgnc:HGNC:53655","description":"testis expressed 53","metadata":null},{"id":"4dc7a4e695fe4d55aad203341fd021e8","type":"GENE","name":"TEX54","canonical_id":"hgnc:HGNC:53729","description":"testis expressed 54","metadata":null},{"id":"4b6400919b6d47c4b5ace26d8fa382c4","type":"GENE","name":"TEX55","canonical_id":"hgnc:HGNC:26553","description":"testis expressed 55","metadata":{"aliases":["FLJ32859","TSCPA","C3orf30"]}},{"id":"ca60f0726dda4be19eb98042094d9447","type":"GENE","name":"TEX56P","canonical_id":"hgnc:HGNC:21620","description":"testis expressed 56, pseudogene","metadata":{"aliases":["dJ1013A10.5","C6orf201"]}},{"id":"f045b882317f429fbcd44d3d38bc5e2f","type":"GENE","name":"TEX9","canonical_id":"hgnc:HGNC:29585","description":"testis expressed 9","metadata":null},{"id":"dda69bedf22e4bc99c097346a6c9242e","type":"GENE","name":"TF","canonical_id":"hgnc:HGNC:11740","description":null,"metadata":null},{"id":"ee60577b8a8949a5b1ef60901f0b215b","type":"GENE","name":"TFAM","canonical_id":"hgnc:HGNC:11741","description":null,"metadata":null},{"id":"dc640e602f9049918fec3c55a2c0d97a","type":"GENE","name":"TFAMP1","canonical_id":"hgnc:HGNC:11636","description":"transcription factor A, mitochondrial pseudogene 1","metadata":{"aliases":["MTTF1","TCF6L1"]}},{"id":"ae128e39986a4e0fb6767fef89c53e43","type":"GENE","name":"TFAMP2","canonical_id":"hgnc:HGNC:11638","description":"transcription factor A, mitochondrial pseudogene 2","metadata":{"aliases":["MTTF1","TCF6L3"]}},{"id":"3ee793dc28884dbdbea6e430c09b7cc7","type":"GENE","name":"TFAP2A","canonical_id":"hgnc:HGNC:11742","description":null,"metadata":null},{"id":"00e7fc23ad504ba59857b5b07900d31e","type":"GENE","name":"TFAP2A-AS1","canonical_id":"hgnc:HGNC:40579","description":"TFAP2A antisense RNA 1","metadata":null},{"id":"d65f07c4c3874ed982293a0896cec735","type":"GENE","name":"TFAP2A-AS2","canonical_id":"hgnc:HGNC:52289","description":"TFAP2A antisense RNA 2","metadata":{"aliases":["HIPSTR"]}},{"id":"e8c775af82f14968b3618cac20ed794e","type":"GENE","name":"TFAP2B","canonical_id":"hgnc:HGNC:11743","description":null,"metadata":null},{"id":"4dd2d170300c45888f015a810f4190a1","type":"GENE","name":"TFAP2C","canonical_id":"hgnc:HGNC:11744","description":null,"metadata":null},{"id":"bede81af3b6d416ba4a5b37e22b10724","type":"GENE","name":"TFAP2D","canonical_id":"hgnc:HGNC:15581","description":"transcription factor AP-2 delta","metadata":{"aliases":["AP-2delta","TFAP2BL1"]}},{"id":"8c38611eb71b4f3eb64e859de0ef5408","type":"GENE","name":"TFAP2E","canonical_id":"hgnc:HGNC:30774","description":"transcription factor AP-2 epsilon","metadata":{"aliases":["AP2E","AP-2epsilon"]}},{"id":"51e89b247f9048649c5c4321c2a8d5a6","type":"GENE","name":"TFAP2E-AS1","canonical_id":"hgnc:HGNC:41274","description":"TFAP2E antisense RNA 1","metadata":null},{"id":"42d1717402bb412fa7ac28bb0fdbe5f9","type":"GENE","name":"TFAP4","canonical_id":"hgnc:HGNC:11745","description":null,"metadata":null},{"id":"78ce4f07c72c47318e43e0ed471eefe8","type":"GENE","name":"TFB1M","canonical_id":"hgnc:HGNC:17037","description":"transcription factor B1, mitochondrial","metadata":{"aliases":["mtTFB","CGI-75"]}},{"id":"8c26b990899948c08de9b2ace93f9a2d","type":"GENE","name":"TFB2M","canonical_id":"hgnc:HGNC:18559","description":"transcription factor B2, mitochondrial","metadata":{"aliases":["FLJ23182","FLJ22661","Hkp1"]}},{"id":"23adf35e788744489f5e288621b454c2","type":"GENE","name":"TFB2MP1","canonical_id":"hgnc:HGNC:56898","description":"TFB2M pseudogene 1","metadata":null},{"id":"050ff1f3a37242389ebd07c900e4b122","type":"GENE","name":"TFCP2","canonical_id":"hgnc:HGNC:11748","description":null,"metadata":null},{"id":"22ce5b5ddb884a1b9c8d15034e672d39","type":"GENE","name":"TFCP2L1","canonical_id":"hgnc:HGNC:17925","description":null,"metadata":null},{"id":"0e968ad01d764373a873401b27e01d76","type":"GENE","name":"TFCP2L6P","canonical_id":"hgnc:HGNC:59198","description":"transcription factor CP2 like 6, pseudogene","metadata":null},{"id":"cbe52c5fcb564ba6a45a4e27171ee93e","type":"GENE","name":"TFDP1","canonical_id":"hgnc:HGNC:11749","description":null,"metadata":null},{"id":"b2244f88a65b482c8204cb3fcb089539","type":"GENE","name":"TFDP1P1","canonical_id":"hgnc:HGNC:11750","description":"TFDP1 pseudogene 1","metadata":{"aliases":["TFDP1P"]}},{"id":"1ced968bcc864796b647173d077acd7f","type":"GENE","name":"TFDP1P2","canonical_id":"hgnc:HGNC:54930","description":"TFDP1 pseudogene 2","metadata":null},{"id":"71f3e95132464cee81689026b1ec9ed1","type":"GENE","name":"TFDP1P3","canonical_id":"hgnc:HGNC:54931","description":"TFDP1 pseudogene 3","metadata":null},{"id":"c51d3081d4114c55ad18e0537f432b07","type":"GENE","name":"TFDP2","canonical_id":"hgnc:HGNC:11751","description":"transcription factor Dp-2","metadata":{"aliases":["Dp-2"]}},{"id":"1b1237ccf42c47048df85750c1806015","type":"GENE","name":"TFDP3","canonical_id":"hgnc:HGNC:24603","description":null,"metadata":null},{"id":"bb6c555025084520b59b10066a5f28c0","type":"GENE","name":"TFE3","canonical_id":"hgnc:HGNC:11752","description":null,"metadata":null},{"id":"a8a12c7ce0504be4913978912604e7c3","type":"GENE","name":"TFEB","canonical_id":"hgnc:HGNC:11753","description":null,"metadata":null},{"id":"18fc603a32fa4d999668233313149974","type":"GENE","name":"TFEB-AS1","canonical_id":"hgnc:HGNC:40580","description":"TFEB antisense RNA 1","metadata":null},{"id":"96dce30e69c748f994b9db3a0140ff54","type":"GENE","name":"TFEC","canonical_id":"hgnc:HGNC:11754","description":"transcription factor EC","metadata":{"aliases":["TCFEC","TFECL","bHLHe34"]}},{"id":"dc83a322ba1940008e21624241b8f0fd","type":"GENE","name":"TFF1","canonical_id":"hgnc:HGNC:11755","description":null,"metadata":null},{"id":"097432be418b4b92ad4a6b2730a1f0d6","type":"GENE","name":"TFF2","canonical_id":"hgnc:HGNC:11756","description":null,"metadata":null},{"id":"2d20d7751e3646049a2e7b4bbb3c4dba","type":"GENE","name":"TFF3","canonical_id":"hgnc:HGNC:11757","description":null,"metadata":null},{"id":"4904f51c825947e6a61372ac6bb5f11d","type":"GENE","name":"TFG","canonical_id":"hgnc:HGNC:11758","description":"trafficking from ER to golgi regulator","metadata":{"aliases":["TF6","FLJ36137","SPG57"]}},{"id":"f4f071974bd6422a87348c314c6ea50d","type":"GENE","name":"TFGP1","canonical_id":"hgnc:HGNC:55068","description":"TFG pseudogene 1","metadata":null},{"id":"f4c114eecf66479d8e9edd9f196151e6","type":"GO_TERM","name":"TFIIA-class transcription factor complex binding","canonical_id":"go:GO:0001092","description":"\"Binding to a general RNA polymerase II transcription factor belonging to the TFIIA complex, one of the complexes involved in formation of the preinitiation complex (PIC) by RNA polymerase II and defined as a basal or general transcription factor.\" [GOC:krc, PMID:16858867]","metadata":null},{"id":"2423d0ead59a43ac9be813e05e2a20d3","type":"GO_TERM","name":"TFIIB-class transcription factor binding","canonical_id":"go:GO:0001093","description":"\"Binding to a general RNA polymerase II transcription factor of the TFIIB class, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.\" [GOC:krc, PMID:16858867]","metadata":null},{"id":"d4e4e422df004db8892df505174438f3","type":"GO_TERM","name":"TFIID-class transcription factor complex binding","canonical_id":"go:GO:0001094","description":"\"Binding to a general RNA polymerase II transcription factor belonging to the TFIID complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.\" [GOC:krc, PMID:16858867]","metadata":null},{"id":"6df96848fdbd433eb73c643e933ea45d","type":"GO_TERM","name":"TFIIE-class transcription factor complex binding","canonical_id":"go:GO:0001095","description":"\"Binding to a general RNA polymerase II transcription factor belonging to the TFIIE complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.\" [GOC:krc, PMID:16858867]","metadata":null},{"id":"509f175b73944bd1bd0ea03cb6f53312","type":"GO_TERM","name":"TFIIF-class transcription factor complex binding","canonical_id":"go:GO:0001096","description":"\"Binding to a general RNA polymerase II transcription factor belonging to the TFIIF complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.\" [GOC:krc, PMID:16858867]","metadata":null},{"id":"596572225fb74a588bafcac12b60a580","type":"GO_TERM","name":"TFIIH-class transcription factor complex binding","canonical_id":"go:GO:0001097","description":"\"Binding to a general RNA polymerase II transcription factor belonging to the TFIIH complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.\" [GOC:krc, PMID:16858867]","metadata":null},{"id":"1b36c9491a914d27935c7fb10bb74aef","type":"GO_TERM","name":"TFIIIA-class transcription factor binding","canonical_id":"go:GO:0001155","description":"\"Binding to an RNA polymerase III transcription factor of the TFIIIA class, one of the factors involved in formation of the preinitiation complex (PIC) at RNA polymerase III promoters.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"d87c051c0cf44318906076c1e99ad6d6","type":"GO_TERM","name":"TFIIIB-class transcription factor complex binding","canonical_id":"go:GO:0001154","description":"\"Binding to a general RNA polymerase III transcription factor belonging to the TFIIB complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase III.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"f062ed24c05243db979c9a79bbda4392","type":"GO_TERM","name":"TFIIIC-TOP1-SUB1 complex","canonical_id":"go:GO:0034740","description":"\"A protein complex that contains TFIIIC, topoisomerase 1, and Sub1/PC4. Characterized in human, the complex is involved in regulating transcription from RNA polymerase III (Pol III) promoters. Topoisomerase 1 and Sub1 enhance the accuracy of transcription termination, and promote reinitiation by Pol III.\" [PMID:9660958]","metadata":null},{"id":"6bb751ec63bd4c40a0a635079fe43897","type":"GO_TERM","name":"TFIIIC-class transcription factor complex binding","canonical_id":"go:GO:0001156","description":"\"Binding to a general RNA polymerase III transcription factor belonging to the TFIIC complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase III.\" [GOC:txnOH, PMID:12381659]","metadata":null},{"id":"483051d0763b4777a51f6054eadfa58f","type":"GENE","name":"TFIP11","canonical_id":"hgnc:HGNC:17165","description":"tuftelin interacting protein 11","metadata":{"aliases":["TIP39","DKFZP434B194","Spp382"]}},{"id":"2aa97d525ca44a11a7d14d15764cc881","type":"GENE","name":"TFIP11-DT","canonical_id":"hgnc:HGNC:55374","description":"TFIP11 divergent transcript","metadata":null},{"id":"0a8aa7b6d43e480bbb35193fc7ed44e0","type":"GENE","name":"TFPI","canonical_id":"hgnc:HGNC:11760","description":"tissue factor pathway inhibitor","metadata":{"aliases":["EPI","TFI","TFPI1","LACI"]}},{"id":"5f91fbbd333b46aeb481f0fca7be8ba9","type":"GENE","name":"TFPI2","canonical_id":"hgnc:HGNC:11761","description":null,"metadata":null},{"id":"c3d48e6771504714bd91d64289c2372b","type":"GENE","name":"TFPI2-DT","canonical_id":"hgnc:HGNC:40581","description":"TFPI2 divergent transcript","metadata":null},{"id":"3a8d0de9dab74e3698658be86393c5cc","type":"GENE","name":"TFPT","canonical_id":"hgnc:HGNC:13630","description":null,"metadata":null},{"id":"1a6cb593c6fa46acbf758bcaedc79d57","type":"GENE","name":"TFR2","canonical_id":"hgnc:HGNC:11762","description":"transferrin receptor 2","metadata":{"aliases":["HFE3","TFRC2"]}},{"id":"0a84a241565549868e2a37cd443f1aad","type":"GENE","name":"TFRC","canonical_id":"hgnc:HGNC:11763","description":null,"metadata":null},{"id":"977adcd92eff492fb17840848d258699","type":"GENE","name":"TG","canonical_id":"hgnc:HGNC:11764","description":null,"metadata":null},{"id":"f08fd1593fb540f8a9cae64351d8291c","type":"GENE","name":"TGDS","canonical_id":"hgnc:HGNC:20324","description":"TDP-glucose 4,6-dehydratase","metadata":{"aliases":["TDPGD","SDR2E1"]}},{"id":"e38f599ea41d4d94807e715727205122","type":"GENE","name":"TGFA","canonical_id":"hgnc:HGNC:11765","description":null,"metadata":null},{"id":"c8f5c3693eb54fb08f2022f36b23fe86","type":"GENE","name":"TGFA-IT1","canonical_id":"hgnc:HGNC:41389","description":"TGFA intronic transcript 1","metadata":null},{"id":"dd940cfd59164a758a93b8388acfbc13","type":"GENE","name":"TGFB1","canonical_id":"hgnc:HGNC:11766","description":null,"metadata":null},{"id":"197580f96e534c78804b4466bc8b990a","type":"GENE","name":"TGFB1I1","canonical_id":"hgnc:HGNC:11767","description":"transforming growth factor beta 1 induced transcript 1","metadata":{"aliases":["Hic-5","TSC-5","ARA55","HIC-5"]}},{"id":"74496dfdf0be4264b9e1970b75b268e8","type":"GENE","name":"TGFB2","canonical_id":"hgnc:HGNC:11768","description":null,"metadata":null},{"id":"42038a9587c545eaaff5223d686b5154","type":"GENE","name":"TGFB2-AS1","canonical_id":"hgnc:HGNC:50628","description":"TGFB2 antisense RNA 1","metadata":null},{"id":"31c4c31da75249d69bfb525806d3677d","type":"GENE","name":"TGFB2-OT1","canonical_id":"hgnc:HGNC:50629","description":"TGFB2 overlapping transcript 1","metadata":{"aliases":["FLJ11812"]}},{"id":"adf5b4c86b624f01a0f8792316822af3","type":"GENE","name":"TGFB3","canonical_id":"hgnc:HGNC:11769","description":null,"metadata":null},{"id":"959687447b924ee883e195288a88cafc","type":"GENE","name":"TGFB3-AS1","canonical_id":"hgnc:HGNC:53144","description":"TGFB3 antisense RNA 1","metadata":{"aliases":["ENST00000553732"]}},{"id":"43d1c47206964f0e8b0431837d4e6418","type":"GENE","name":"TGFBI","canonical_id":"hgnc:HGNC:11771","description":null,"metadata":null},{"id":"e676b7bdcf0b49d984054e1cd2d43a4e","type":"GENE","name":"TGFBR1","canonical_id":"hgnc:HGNC:11772","description":null,"metadata":null},{"id":"4a8abc7ede784b0b9f4987e6d2b0d092","type":"GENE","name":"TGFBR1P1","canonical_id":"hgnc:HGNC:56999","description":"TGFBR1 pseudogene 1","metadata":null},{"id":"24c37677d129491e90f01e40ab3922c4","type":"GENE","name":"TGFBR2","canonical_id":"hgnc:HGNC:11773","description":null,"metadata":null},{"id":"0df65d51d824407fb40be774b83c6f13","type":"GENE","name":"TGFBR3","canonical_id":"hgnc:HGNC:11774","description":null,"metadata":null},{"id":"a79099a99e2149ddadf3bc00f3fd8587","type":"GENE","name":"TGFBR3L","canonical_id":"hgnc:HGNC:44152","description":"transforming growth factor beta receptor 3 like","metadata":{"aliases":["GEMP"]}},{"id":"a7257300eb76435f9414ad2d20e5f191","type":"GENE","name":"TGFBRAP1","canonical_id":"hgnc:HGNC:16836","description":"transforming growth factor beta receptor associated protein 1","metadata":{"aliases":["TRAP-1","TRAP1","VPS3"]}},{"id":"a4adcb1064054591bef9f8eb62357f71","type":"GENE","name":"TGFBRAP1-AS1","canonical_id":"hgnc:HGNC:56908","description":"TGFBRAP1 antisense RNA 1","metadata":{"aliases":["AC012360.1"]}},{"id":"e3acc17193b9407585fcdd3cf6828b1d","type":"GENE","name":"TGIF1","canonical_id":"hgnc:HGNC:11776","description":null,"metadata":null},{"id":"9a4126038b8543c4880a28553a1f225f","type":"GENE","name":"TGIF1P1","canonical_id":"hgnc:HGNC:30730","description":"TGFB induced factor homeobox 1 pseudogene 1","metadata":null},{"id":"fc43449034c84bf7b89da417f28c62e1","type":"GENE","name":"TGIF2","canonical_id":"hgnc:HGNC:15764","description":null,"metadata":null},{"id":"e27300ae25f241dd9864f7deb16ab7e3","type":"GENE","name":"TGIF2-RAB5IF","canonical_id":"hgnc:HGNC:44664","description":"TGIF2-RAB5IF readthrough","metadata":{"aliases":["TGIF2-C20orf24"]}},{"id":"3badb47141594ad7b1ec8853fb17a6ae","type":"GENE","name":"TGIF2LX","canonical_id":"hgnc:HGNC:18570","description":"TGFB induced factor homeobox 2 like X-linked","metadata":null},{"id":"b5a909b62a7b43a38677e35c2594e477","type":"GENE","name":"TGIF2LY","canonical_id":"hgnc:HGNC:18569","description":"TGFB induced factor homeobox 2 like Y-linked","metadata":null},{"id":"aeef69eba3fd454196fa01b80460a83b","type":"GENE","name":"TGIF2P1","canonical_id":"hgnc:HGNC:33317","description":"TGFB induced factor homeobox 2 pseudogene 1","metadata":null},{"id":"df06ddc685a047f5a4f4d109243ea3a4","type":"GENE","name":"TGILR","canonical_id":"hgnc:HGNC:58116","description":"TGF-beta induced TARBP2 interacting lncRNA","metadata":{"aliases":["AL590004.3","RP1-140K8.5"]}},{"id":"e5f029f06f084afe983c992ac1402cfe","type":"GENE","name":"TGM1","canonical_id":"hgnc:HGNC:11777","description":"transglutaminase 1","metadata":{"aliases":["TGASE","TGK","LI","LI1","ICR2"]}},{"id":"a2c28ed4616b401a8a346198c8636f99","type":"GENE","name":"TGM2","canonical_id":"hgnc:HGNC:11778","description":"transglutaminase 2","metadata":{"aliases":["TGC","TG2"]}},{"id":"6c8bc3a8e54b4ce690e4afdc49db7526","type":"GENE","name":"TGM3","canonical_id":"hgnc:HGNC:11779","description":"transglutaminase 3","metadata":{"aliases":["TGE"]}},{"id":"b42fa29cfb114601b891ebcc1099b178","type":"GENE","name":"TGM4","canonical_id":"hgnc:HGNC:11780","description":null,"metadata":null},{"id":"5a5fde2b8e8640e6aa774e491564ed7b","type":"GENE","name":"TGM5","canonical_id":"hgnc:HGNC:11781","description":"transglutaminase 5","metadata":{"aliases":["TGX","TGMX"]}},{"id":"9e44a2dbcb3b4b16916c9678c513b3a9","type":"GENE","name":"TGM6","canonical_id":"hgnc:HGNC:16255","description":"transglutaminase 6","metadata":{"aliases":["dJ734P14.3","TGY","SCA35","TGM3L"]}},{"id":"6246b642e8f4428f909ae0669c9bdb20","type":"GENE","name":"TGM7","canonical_id":"hgnc:HGNC:30790","description":"transglutaminase 7","metadata":{"aliases":["TGMZ"]}},{"id":"7d000224e45c4e23af4d858bb83622a3","type":"GENE","name":"TGOLN2","canonical_id":"hgnc:HGNC:15450","description":"trans-golgi network protein 2","metadata":{"aliases":["TGN51","TGN46","TGN48","TGN38","TTGN2"]}},{"id":"a89fd4fb6a3c4a1a87fa269e0a47bd07","type":"TRIAL","name":"TGR-1202 (Umbralisib) in Treatment Na\u00efve Patients With Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT04163718","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"26fbccbfaa424e2a91932c99a1e9d17b","type":"TRIAL","name":"TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT02874404","description":"Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"dc69296411b74fa083621494874abc5b","type":"TRIAL","name":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT06082635","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"e9d39124ed7b47dfad329b81b2a67eed","type":"GENE","name":"TGS1","canonical_id":"hgnc:HGNC:17843","description":"trimethylguanosine synthase 1","metadata":{"aliases":["PIMT","NCOA6IP"]}},{"id":"7ffbc822f59a47f9ae45cf6587500141","type":"GENE","name":"TH","canonical_id":"hgnc:HGNC:11782","description":null,"metadata":null},{"id":"5b6988fc8aa44ab4a2de7bca24bd432c","type":"DISEASE","name":"TH-deficient dopa-responsive dystonia","canonical_id":"mondo:0011551","description":null,"metadata":null},{"id":"3928d68b1b1d4f619f4e0882ccb86db9","type":"TRIAL","name":"TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis","canonical_id":"clinicaltrials.gov:NCT06733519","description":"Pruritus; Primary Biliary Cholangitis","metadata":null},{"id":"04352043d42f4beb9054428e33445c65","type":"GENE","name":"TH2LCRR","canonical_id":"hgnc:HGNC:40495","description":"T helper type 2 locus control region associated RNA","metadata":{"aliases":["TH2-LCR"]}},{"id":"63dc5a69d32f4d0c8b064fc0c29aade5","type":"TRIAL","name":"TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy","canonical_id":"clinicaltrials.gov:NCT00608023","description":"Lipodystrophy; HIV Infections","metadata":null},{"id":"390c3e09dda74959b70ad98d74133292","type":"GENE","name":"THA1P","canonical_id":"hgnc:HGNC:18004","description":"threonine aldolase 1, pseudogene","metadata":{"aliases":["GLY1"]}},{"id":"7170dc4bad8640c1acb49b861a4c3486","type":"GENE","name":"THADA","canonical_id":"hgnc:HGNC:19217","description":"THADA armadillo repeat containing","metadata":{"aliases":["FLJ21877","KIAA1767","GITA","ARMC13","Trm732"]}},{"id":"0fc21166d9b4424f873ba60219468a92","type":"GENE","name":"THAP1","canonical_id":"hgnc:HGNC:20856","description":"THAP domain containing 1","metadata":{"aliases":["FLJ10477","4833431A01Rik","DYT6"]}},{"id":"3e7e94a155ed4e9a8df372323f354456","type":"GENE","name":"THAP10","canonical_id":"hgnc:HGNC:23193","description":"THAP domain containing 10","metadata":null},{"id":"1dfa9f7d9f1d4ebcb864f588ccb3ad94","type":"GENE","name":"THAP11","canonical_id":"hgnc:HGNC:23194","description":"THAP domain containing 11","metadata":{"aliases":["HRIHFB2206","CTG-B45d","CTG-B43a","RONIN"]}},{"id":"1e484338182c4df9a8f7339319e90357","type":"GENE","name":"THAP12","canonical_id":"hgnc:HGNC:9440","description":"THAP domain containing 12","metadata":{"aliases":["P52rIPK","DAP4","THAP0","PRKRIR"]}},{"id":"309421d17eec40289eabba767bf89bb1","type":"GENE","name":"THAP12P1","canonical_id":"hgnc:HGNC:39563","description":"THAP domain containing 12 pseudogene 1","metadata":{"aliases":["PRKRIRP1"]}},{"id":"78d3557f501945859ad997f4472dbfc4","type":"GENE","name":"THAP12P10","canonical_id":"hgnc:HGNC:39741","description":"THAP domain containing 12 pseudogene 10","metadata":{"aliases":["PRKRIRP10"]}},{"id":"28186964a2cc4166abb088d234121088","type":"GENE","name":"THAP12P2","canonical_id":"hgnc:HGNC:39566","description":"THAP domain containing 12 pseudogene 2","metadata":{"aliases":["PRKRIRP2"]}},{"id":"d7414ce30ee6424aaa9b31c66915749c","type":"GENE","name":"THAP12P3","canonical_id":"hgnc:HGNC:39567","description":"THAP domain containing 12 pseudogene 3","metadata":{"aliases":["PRKRIRP3"]}},{"id":"5bea20a0c97d43c1b52bd2e9ed7970e6","type":"GENE","name":"THAP12P4","canonical_id":"hgnc:HGNC:39568","description":"THAP domain containing 12 pseudogene 4","metadata":{"aliases":["PRKRIRP4"]}},{"id":"daee174e15be4aeeb527f0606f0ff24e","type":"GENE","name":"THAP12P5","canonical_id":"hgnc:HGNC:39569","description":"THAP domain containing 12 pseudogene 5","metadata":{"aliases":["PRKRIRP5"]}},{"id":"72339e3e65714a069aded58a5ecd91f4","type":"GENE","name":"THAP12P6","canonical_id":"hgnc:HGNC:39570","description":"THAP domain containing 12 pseudogene 6","metadata":{"aliases":["PRKRIRP6"]}},{"id":"d7c43b8e6b584a948e1356fb2db1b34c","type":"GENE","name":"THAP12P7","canonical_id":"hgnc:HGNC:39574","description":"THAP domain containing 12 pseudogene 7","metadata":{"aliases":["PRKRIRP7"]}},{"id":"770f0f39d5c848819c6ff6de1b135a67","type":"GENE","name":"THAP12P8","canonical_id":"hgnc:HGNC:39572","description":"THAP domain containing 12 pseudogene 8","metadata":{"aliases":["PRKRIRP8"]}},{"id":"9511e959dbb34270aa07302cfa5c8c31","type":"GENE","name":"THAP12P9","canonical_id":"hgnc:HGNC:39573","description":"THAP domain containing 12 pseudogene 9","metadata":{"aliases":["PRKRIRP9"]}},{"id":"b3b759e2b9ef4ca0aefcac98cace90d8","type":"GENE","name":"THAP2","canonical_id":"hgnc:HGNC:20854","description":"THAP domain containing 2","metadata":{"aliases":["DKFZP564I0422"]}},{"id":"72357760d6fb40d08fcca8b2740dc552","type":"GENE","name":"THAP3","canonical_id":"hgnc:HGNC:20855","description":"THAP domain containing 3","metadata":null},{"id":"9bb1dd1c6be04edca89a1386ad2938bf","type":"GENE","name":"THAP3P1","canonical_id":"hgnc:HGNC:56895","description":"THAP3 pseudogene 1","metadata":null},{"id":"7691441d954d4ace8b870ce587322279","type":"GENE","name":"THAP4","canonical_id":"hgnc:HGNC:23187","description":"THAP domain containing 4","metadata":{"aliases":["CGI-36","Nb(III)"]}},{"id":"c4236ce95b1c4e65afd1884894408ca2","type":"GENE","name":"THAP5","canonical_id":"hgnc:HGNC:23188","description":"THAP domain containing 5","metadata":{"aliases":["DKFZp313O1132"]}},{"id":"95b787980d934ec3aad1615976452b03","type":"GENE","name":"THAP5P1","canonical_id":"hgnc:HGNC:22340","description":"THAP domain containing 5 pseudogene 1","metadata":null},{"id":"55f38eb785d243bbbfb35f33fb6cac69","type":"GENE","name":"THAP5P2","canonical_id":"hgnc:HGNC:44502","description":"THAP domain containing 5 pseudogene 2","metadata":null},{"id":"1e9761e4da1143e5a8ee49da99abd29b","type":"GENE","name":"THAP6","canonical_id":"hgnc:HGNC:23189","description":"THAP domain containing 6","metadata":{"aliases":["MGC30052"]}},{"id":"f637790b1b474f1c93353193aa62d059","type":"GENE","name":"THAP6-AS1","canonical_id":"hgnc:HGNC:58818","description":"THAP6 antisense RNA 1","metadata":null},{"id":"d583fcabb5a547918f32e81e254df220","type":"GENE","name":"THAP7","canonical_id":"hgnc:HGNC:23190","description":"THAP domain containing 7","metadata":{"aliases":["MGC10963"]}},{"id":"ad237cd3b9914a6e9dfd8beec35278a5","type":"GENE","name":"THAP7-AS1","canonical_id":"hgnc:HGNC:41013","description":"THAP7 antisense RNA 1","metadata":null},{"id":"743d703a275a4ade84f9d1714ea8dca6","type":"GENE","name":"THAP8","canonical_id":"hgnc:HGNC:23191","description":"THAP domain containing 8","metadata":{"aliases":["FLJ32891"]}},{"id":"2881f97f1a16414cbfecd3549dcb80ba","type":"GENE","name":"THAP9","canonical_id":"hgnc:HGNC:23192","description":"THAP domain containing 9","metadata":{"aliases":["FLJ34093"]}},{"id":"aee54bcdb3c34d02a02f00615e76b0c9","type":"GENE","name":"THAP9-AS1","canonical_id":"hgnc:HGNC:44172","description":"THAP9 antisense RNA 1","metadata":null},{"id":"668cc7b29a7c479aa988139e3f9bfcf0","type":"GENE","name":"THBD","canonical_id":"hgnc:HGNC:11784","description":null,"metadata":null},{"id":"30c4098684e4405a8f915f05dbe601cf","type":"GENE","name":"THBS1","canonical_id":"hgnc:HGNC:11785","description":null,"metadata":null},{"id":"41e6a14fb69a45ea947d3a3d69eae29c","type":"GENE","name":"THBS1-AS1","canonical_id":"hgnc:HGNC:55224","description":"THBS1 antisense RNA 1","metadata":null},{"id":"8af253b8dce64b928153e3307050cc0f","type":"GENE","name":"THBS1-IT1","canonical_id":"hgnc:HGNC:55225","description":"THBS1 intronic transcript 1","metadata":{"aliases":["TBULC"]}},{"id":"1c274da60f39497d81c8e7d7f3c53f71","type":"GENE","name":"THBS2","canonical_id":"hgnc:HGNC:11786","description":null,"metadata":null},{"id":"de824967f6204968b6f0d3ff3cd50759","type":"GENE","name":"THBS2-AS1","canonical_id":"hgnc:HGNC:56059","description":"THBS2 antisense RNA 1","metadata":null},{"id":"56a2a928e0034dc592136c1d4238c4c6","type":"GENE","name":"THBS3","canonical_id":"hgnc:HGNC:11787","description":"thrombospondin 3","metadata":null},{"id":"d0527ddea48d40ce88270d65f626301d","type":"GENE","name":"THBS3-AS1","canonical_id":"hgnc:HGNC:40582","description":"THBS3 antisense RNA 1","metadata":null},{"id":"99f18a0fb88f491ea7934f8a3e47c5a3","type":"GENE","name":"THBS4","canonical_id":"hgnc:HGNC:11788","description":"thrombospondin 4","metadata":null},{"id":"be862c3a34eb416ea069059c4c137713","type":"GENE","name":"THBS4-AS1","canonical_id":"hgnc:HGNC:40583","description":"THBS4 antisense RNA 1","metadata":null},{"id":"6a5a71a0a3ef4a0ba0ad576b05a259cf","type":"GENE","name":"THEM4","canonical_id":"hgnc:HGNC:17947","description":"thioesterase superfamily member 4","metadata":{"aliases":["CTMP"]}},{"id":"93a7e333e8fa4cc9ad760c4e08c4ee49","type":"GENE","name":"THEM4P1","canonical_id":"hgnc:HGNC:32692","description":"thioesterase superfamily member 4 pseudogene 1","metadata":null},{"id":"5b3d26cfbab2475888a2c133bef9dd99","type":"GENE","name":"THEM5","canonical_id":"hgnc:HGNC:26755","description":"thioesterase superfamily member 5","metadata":{"aliases":["FLJ37964"]}},{"id":"2242c28bddbd47f9889a6f82c20ec82f","type":"GENE","name":"THEM6","canonical_id":"hgnc:HGNC:29656","description":"thioesterase superfamily member 6","metadata":{"aliases":["DSCD75","C8orf55"]}},{"id":"af0c0948ef2a4bb28a429c71f7107adf","type":"GENE","name":"THEM7P","canonical_id":"hgnc:HGNC:50386","description":"thioesterase superfamily member 7, pseudogene","metadata":{"aliases":["uc.329","RP1-65P5.1"]}},{"id":"1db985ce8cfa451ab8efac814d0633de","type":"GENE","name":"THEMIS","canonical_id":"hgnc:HGNC:21569","description":"thymocyte selection associated","metadata":{"aliases":["bA325O24.4","FLJ40584","bA325O24.3","THEMIS1","C6orf207","C6orf190","TSEPA"]}},{"id":"5e26007b67e84343bd36615cc8a6c07b","type":"GENE","name":"THEMIS2","canonical_id":"hgnc:HGNC:16839","description":"thymocyte selection associated family member 2","metadata":{"aliases":["ICB-1","Icb-1","C1orf38"]}},{"id":"8502b27865034103995fa5a9e4e02caa","type":"GENE","name":"THEMIS3P","canonical_id":"hgnc:HGNC:49196","description":"thymocyte selection associated family member 3, pseudogene","metadata":null},{"id":"4b945295a6c14b70b93027eaceb86f9d","type":"GENE","name":"THG1L","canonical_id":"hgnc:HGNC:26053","description":"tRNA-histidine guanylyltransferase 1 like","metadata":{"aliases":["ICF45","FLJ11601","FLJ20546","IHG-1","hTHG1"]}},{"id":"78da9fda59d24b19a8bf9ff95d3b65c6","type":"GENE","name":"THG1L-AS1","canonical_id":"hgnc:HGNC:59292","description":"THG1L antisense RNA 1","metadata":null},{"id":"616ea9bb4fa64c0892bcaee37d3634c1","type":"TRIAL","name":"THINC-it Vortioxetine - Sensitivity to Change","canonical_id":"clinicaltrials.gov:NCT03053362","description":"Major Depressive Disorder; Cognitive Change","metadata":null},{"id":"bded3220c8aa4720969e0d45c86386b3","type":"GENE","name":"THNSL1","canonical_id":"hgnc:HGNC:26160","description":"threonine synthase like 1","metadata":{"aliases":["FLJ22002","TSH1"]}},{"id":"114e7d43e5034c548e6abc63f51ba67a","type":"GENE","name":"THNSL2","canonical_id":"hgnc:HGNC:25602","description":"threonine synthase like 2","metadata":{"aliases":["FLJ10916","TSH2","SOFAT"]}},{"id":"4191a7f88bd741c19c41f287625fbeb6","type":"GO_TERM","name":"THO complex","canonical_id":"go:GO:0000347","description":"\"The THO complex is a nuclear complex that is required for transcription elongation through genes containing tandemly repeated DNA sequences. The THO complex is also part of the TREX (TRanscription EXport) complex that is involved in coupling transcription to export of mRNAs to the cytoplasm. In S. cerevisiae, it is composed of four subunits: Hpr1p, Tho2p, Thp1p, and Mft1p, while the human complex is composed of 7 subunits.\" [GOC:krc, PMID:11060033, PMID:11979277, PMID:16983072]","metadata":null},{"id":"a975713b28904793b5b018f599764809","type":"GO_TERM","name":"THO complex part of transcription export complex","canonical_id":"go:GO:0000445","description":"\"The THO complex when it is part of the TREX (TRanscription EXport) complex that is involved in coupling transcription to export of mRNAs to the cytoplasm. In S. cerevisiae, it is composed of four subunits: Hpr1, Tho2, Thp1, and Mft1, while the human complex is composed of 7 subunits.\" [GOC:krc, PMID:11060033, PMID:11979277, PMID:16983072]","metadata":null},{"id":"a6393132ed7b4e94bb2a7541d48a1547","type":"GENE","name":"THOC1","canonical_id":"hgnc:HGNC:19070","description":"THO complex subunit 1","metadata":{"aliases":["P84","HPR1"]}},{"id":"c7acfa8d15524abca77dc61cd96d49e5","type":"GENE","name":"THOC1-DT","canonical_id":"hgnc:HGNC:55334","description":"THOC1 divergent transcript","metadata":null},{"id":"c1d654efdda24a2fa64188fcf392ff90","type":"GENE","name":"THOC2","canonical_id":"hgnc:HGNC:19073","description":"THO complex subunit 2","metadata":{"aliases":["THO2","dJ506G2.1","CXorf3","MRX12","MRX35"]}},{"id":"dceb6e29e4984098b00f665210d8cd5a","type":"GENE","name":"THOC3","canonical_id":"hgnc:HGNC:19072","description":"THO complex subunit 3","metadata":{"aliases":["TEX1","MGC5469"]}},{"id":"78225787373b4c538fb31518e9aaa4b7","type":"GENE","name":"THOC3-AS1","canonical_id":"hgnc:HGNC:40866","description":"THOC3 antisense RNA 1","metadata":null},{"id":"65752002337b445da460dd38107c8fb7","type":"GENE","name":"THOC5","canonical_id":"hgnc:HGNC:19074","description":"THO complex subunit 5","metadata":{"aliases":["PK1.3","KIAA0983","Fmip","fSAP79","C22orf19"]}},{"id":"643e23c7aad6442ab298d2f2a17b0754","type":"GENE","name":"THOC6","canonical_id":"hgnc:HGNC:28369","description":"THO complex subunit 6","metadata":{"aliases":["MGC2655","fSAP35","WDR58"]}},{"id":"597447532a8a459fad4af7797e79cfa2","type":"GENE","name":"THOC7","canonical_id":"hgnc:HGNC:29874","description":"THO complex subunit 7","metadata":{"aliases":["NIF3L1BP1","FLJ23445","fSAP24"]}},{"id":"2661dd500f3a4a5d9c1f34fb772a492a","type":"GENE","name":"THOC7-AS1","canonical_id":"hgnc:HGNC:41249","description":"THOC7 antisense RNA 1","metadata":null},{"id":"6adb71a5bc2749e6a4c1215803226dba","type":"GENE","name":"THOP1","canonical_id":"hgnc:HGNC:11793","description":"thimet oligopeptidase 1","metadata":null},{"id":"7b3bbe9a90134786942d0a8306e02fce","type":"GENE","name":"THORLNC","canonical_id":"hgnc:HGNC:53788","description":"testis associated oncogenic lncRNA","metadata":{"aliases":["THOR"]}},{"id":"d1b24068065143478d66cd5bf15ec92d","type":"GO_TERM","name":"THPH synthase activity","canonical_id":"go:GO:0106265","description":"\"Catalysis of the reaction: 3 H+ + hexanoyl-CoA + 3 malonyl-CoA = 2,4,6-trihydroxyphenylhexan-1-one + 3 CO2 + 4 CoA.\" [PMID:9446571, RHEA:64352]","metadata":null},{"id":"02bdd2154eea4797ac8d5cbb1f0e6203","type":"GENE","name":"THPO","canonical_id":"hgnc:HGNC:11795","description":"thrombopoietin","metadata":{"aliases":["TPO","MPLLG","MGDF"]}},{"id":"c32dbcd2b1ac49719ceb0a793b4f73f5","type":"GENE","name":"THRA","canonical_id":"hgnc:HGNC:11796","description":null,"metadata":null},{"id":"575d3fda4e7b41199a5836aedde9e202","type":"PROTEIN","name":"THRA","canonical_id":"uniprot:P10827","description":null,"metadata":null},{"id":"55be53729b43403ca25e21c82537aa6f","type":"GENE","name":"THRAP3","canonical_id":"hgnc:HGNC:22964","description":"thyroid hormone receptor associated protein 3","metadata":{"aliases":["TRAP150","BCLAF2"]}},{"id":"f133aab497ed4eaf83b5c8d9390a29b8","type":"GENE","name":"THRAP3P1","canonical_id":"hgnc:HGNC:32386","description":"THRAP3 pseudogene 1","metadata":{"aliases":["THRAP3L"]}},{"id":"256d11c7a7c64e978d765f3a52fde238","type":"GENE","name":"THRAP3P2","canonical_id":"hgnc:HGNC:54830","description":"THRAP3 pseudogene 2","metadata":null},{"id":"b8f595b11be54c999171760d2493538e","type":"GENE","name":"THRAP3P3","canonical_id":"hgnc:HGNC:54834","description":"THRAP3 pseudogene 3","metadata":null},{"id":"11ccdc4ee8e641d7bd1c9ccf637f0bb7","type":"GENE","name":"THRB","canonical_id":"hgnc:HGNC:11799","description":null,"metadata":null},{"id":"fb4ca96f8bdb4962b2e7e7438fc610e2","type":"GENE","name":"THRB-AS1","canonical_id":"hgnc:HGNC:44515","description":"THRB antisense RNA 1","metadata":null},{"id":"4ef1253bf4ca4e2298d63569152dcf38","type":"GENE","name":"THRB-AS2","canonical_id":"hgnc:HGNC:54854","description":"THRB antisense RNA 2","metadata":null},{"id":"d9086217246d42179d205bbab4c5ad60","type":"GENE","name":"THRB-IT1","canonical_id":"hgnc:HGNC:41390","description":"THRB intronic transcript 1","metadata":null},{"id":"c7412cf43cf94c69ad14c7c2ac5f7d14","type":"GENE","name":"THRIL","canonical_id":"hgnc:HGNC:49503","description":"TNF and HNRNPL related immunoregulatory long non-coding RNA","metadata":{"aliases":["Linc1992","TCONS_00020260","BRI3BP-AS1"]}},{"id":"c43b564804dd4a4793d53826e9bb32a4","type":"GENE","name":"THRSP","canonical_id":"hgnc:HGNC:11800","description":null,"metadata":null},{"id":"ef26b3142246445da2fa45c83050a5da","type":"TRIAL","name":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","canonical_id":"clinicaltrials.gov:NCT05735639","description":"Venous Thromboembolism; Varicose Veins","metadata":null},{"id":"c92d150baa5b44caa8b9c4dff7d38a36","type":"GENE","name":"THSD1","canonical_id":"hgnc:HGNC:17754","description":"thrombospondin type 1 domain containing 1","metadata":{"aliases":["TMTSP"]}},{"id":"e551fc24deb240da900ebe1c9e13f065","type":"GENE","name":"THSD1P1","canonical_id":"hgnc:HGNC:31375","description":"thrombospondin type 1 domain containing 1 pseudogene 1","metadata":{"aliases":["THSD1P"]}},{"id":"1b779dd9f21c4796b970755cb83f2716","type":"GENE","name":"THSD4","canonical_id":"hgnc:HGNC:25835","description":"thrombospondin type 1 domain containing 4","metadata":{"aliases":["FVSY9334","PRO34005","FLJ13710","ADAMTSL6"]}},{"id":"823dab6a66fa4610a300d0e552b39696","type":"GENE","name":"THSD4-AS1","canonical_id":"hgnc:HGNC:51420","description":"THSD4 antisense RNA 1","metadata":null},{"id":"01d3f33bb6dc4330be1539c5ffb140d4","type":"GENE","name":"THSD4-AS2","canonical_id":"hgnc:HGNC:51421","description":"THSD4 antisense RNA 2","metadata":null},{"id":"679461e952f540ef86b672129ff93ecf","type":"GENE","name":"THSD7A","canonical_id":"hgnc:HGNC:22207","description":"thrombospondin type 1 domain containing 7A","metadata":{"aliases":["KIAA0960"]}},{"id":"bff758fe5995494e8d7bdf769b8272da","type":"GENE","name":"THSD7B","canonical_id":"hgnc:HGNC:29348","description":"thrombospondin type 1 domain containing 7B","metadata":{"aliases":["KIAA1679"]}},{"id":"6a8c57123c49484c93ea9cf4d72ba644","type":"GENE","name":"THSD8","canonical_id":"hgnc:HGNC:53785","description":"thrombospondin type 1 domain containing 8","metadata":null},{"id":"d1694ad484494e25ad14eb3a306f9ab1","type":"GENE","name":"THTPA","canonical_id":"hgnc:HGNC:18987","description":"thiamine triphosphatase","metadata":{"aliases":["THTPASE"]}},{"id":"2b2d7033d3884506a141b47b8757930d","type":"GENE","name":"THUMPD1","canonical_id":"hgnc:HGNC:23807","description":"THUMP domain 1 NAT10 acetyltransferase adaptor ","metadata":{"aliases":["FLJ20274","Tan1"]}},{"id":"ca9e2618328543d6bc5fbd05c38018a0","type":"GENE","name":"THUMPD1P1","canonical_id":"hgnc:HGNC:23808","description":"THUMP domain containing 1 pseudogene 1","metadata":null},{"id":"89c1df09d49541b7b8445dca7e2690d8","type":"GENE","name":"THUMPD2","canonical_id":"hgnc:HGNC:14890","description":"THUMP domain 2 tRNA and snRNA guanosine methyltransferase","metadata":{"aliases":["MGC2454","C2orf8"]}},{"id":"117936160e2a444a8a905f7731c7977f","type":"GENE","name":"THUMPD3","canonical_id":"hgnc:HGNC:24493","description":"THUMP domain 3 tRNA guanosine methyltransferase","metadata":{"aliases":["DKFZP434F091"]}},{"id":"dbe8ea6d2c3e46cd9bb42666e22792cd","type":"GENE","name":"THUMPD3-AS1","canonical_id":"hgnc:HGNC:44478","description":"THUMPD3 antisense RNA 1","metadata":{"aliases":["SETD5-AS1"]}},{"id":"5f1f3010c6564de882ebe001e0916943","type":"GENE","name":"THUMPD3P1","canonical_id":"hgnc:HGNC:50793","description":"THUMP domain containing 3 pseudogene 1","metadata":null},{"id":"63be1c002de442948560781ab57b026a","type":"GENE","name":"THY1","canonical_id":"hgnc:HGNC:11801","description":null,"metadata":null},{"id":"d754ef5f19914fe9b3772bf7dfcbca77","type":"GENE","name":"THY1-AS1","canonical_id":"hgnc:HGNC:54852","description":"THY1 antisense RNA 1","metadata":{"aliases":["RP11-334E6.12"]}},{"id":"b2163a65202a497b845388c66c8fa377","type":"GENE","name":"THYN1","canonical_id":"hgnc:HGNC:29560","description":"thymocyte nuclear protein 1","metadata":{"aliases":["THY28"]}},{"id":"cf46363314af4d66b25c0e1661f4b836","type":"GENE","name":"TIA1","canonical_id":"hgnc:HGNC:11802","description":"TIA1 cytotoxic granule associated RNA binding protein","metadata":{"aliases":["TIA-1"]}},{"id":"7587567d8c6045d083fd3575cccbc5fc","type":"GENE","name":"TIAL1","canonical_id":"hgnc:HGNC:11804","description":null,"metadata":null},{"id":"42ccf4eb95724eb3b8817cfd9c9eec47","type":"GENE","name":"TIAL1P1","canonical_id":"hgnc:HGNC:56933","description":"TIAL1 pseudogene","metadata":null},{"id":"0a044e4b7dd849cfa6e5bc23948ce753","type":"GENE","name":"TIALD","canonical_id":"hgnc:HGNC:56938","description":"transcript inducer of AURKA lysosomal degradation","metadata":{"aliases":["AC079360.1"]}},{"id":"6f79701aa4b7444e8da56ac4217fc4b0","type":"GENE","name":"TIAM1","canonical_id":"hgnc:HGNC:11805","description":"TIAM Rac1 associated GEF 1","metadata":null},{"id":"f36f26f524d3485eb907158ee4567025","type":"GENE","name":"TIAM1-AS1","canonical_id":"hgnc:HGNC:54361","description":"TIAM1 antisense RNA 1","metadata":null},{"id":"28c030d6f9df47c498c72878a45681fc","type":"GENE","name":"TIAM2","canonical_id":"hgnc:HGNC:11806","description":"TIAM Rac1 associated GEF 2","metadata":{"aliases":["STEF"]}},{"id":"08de543bb083458c8fd2795cd9dd6fb7","type":"GENE","name":"TICAM1","canonical_id":"hgnc:HGNC:18348","description":null,"metadata":null},{"id":"368dcbe181a94b6db5f65f50c9090e1b","type":"GENE","name":"TICAM2","canonical_id":"hgnc:HGNC:21354","description":"TIR domain containing adaptor molecule 2","metadata":{"aliases":["TRAM","TICAM-2","TIRP"]}},{"id":"e59f07028f494441a71ea08c588688e1","type":"GENE","name":"TICAM2-AS1","canonical_id":"hgnc:HGNC:55575","description":"TICAM2 antisense RNA 1","metadata":null},{"id":"795954cb6f094998a51cdc296f4d0679","type":"GENE","name":"TICRR","canonical_id":"hgnc:HGNC:28704","description":"TOPBP1 interacting checkpoint and replication regulator","metadata":{"aliases":["MGC45866","FLJ41618","Treslin","SLD3","C15orf42"]}},{"id":"a803bcc7e65e4c8ea78ef940980ab70e","type":"GENE","name":"TIE1","canonical_id":"hgnc:HGNC:11809","description":"tyrosine kinase with immunoglobulin like and EGF like domains 1","metadata":{"aliases":["JTK14","TIE"]}},{"id":"9e87a8f3714146d5a5619cf7c499ae8e","type":"GENE","name":"TIFA","canonical_id":"hgnc:HGNC:19075","description":"TRAF interacting protein with forkhead associated domain","metadata":{"aliases":["MGC20791","T2BP","T6BP","TIFAA"]}},{"id":"f5bcd2eb269c4b5c916230eef45fa21c","type":"GENE","name":"TIFAB","canonical_id":"hgnc:HGNC:34024","description":"TIFA inhibitor","metadata":null},{"id":"b09b6afae53049d69f598a0b5d155164","type":"GENE","name":"TIFAB-AS1","canonical_id":"hgnc:HGNC:41047","description":"TIFAB antisense RNA 1","metadata":null},{"id":"acab6791dbc94aa49bea910a84fe7ebe","type":"GENE","name":"TIGAR","canonical_id":"hgnc:HGNC:1185","description":"TP53 induced glycolysis regulatory phosphatase","metadata":{"aliases":["C12orf5"]}},{"id":"04749015e7cc48999f3a8bcad004d863","type":"GENE","name":"TIGD1","canonical_id":"hgnc:HGNC:14523","description":"tigger transposable element derived 1","metadata":{"aliases":["EEYORE"]}},{"id":"21e46489532c4d929a1761b8a5668926","type":"GENE","name":"TIGD2","canonical_id":"hgnc:HGNC:18333","description":"tigger transposable element derived 2","metadata":null},{"id":"e6e69a739a5d4fbf9386cd58a7ea5f37","type":"GENE","name":"TIGD3","canonical_id":"hgnc:HGNC:18334","description":"tigger transposable element derived 3","metadata":null},{"id":"62e47b2feba340e0b7e72863f2e9180a","type":"GENE","name":"TIGD4","canonical_id":"hgnc:HGNC:18335","description":"tigger transposable element derived 4","metadata":null},{"id":"6264e6cc80aa49488c62c6b60360ebe5","type":"GENE","name":"TIGD5","canonical_id":"hgnc:HGNC:18336","description":"tigger transposable element derived 5","metadata":{"aliases":["FLJ14926"]}},{"id":"630f77fa83dd4cc6a64bf26bd5490a30","type":"GENE","name":"TIGD6","canonical_id":"hgnc:HGNC:18332","description":"tigger transposable element derived 6","metadata":{"aliases":["DKFZp761E2110"]}},{"id":"5b4b26bd3e574ba785a38f17cb902874","type":"GENE","name":"TIGD7","canonical_id":"hgnc:HGNC:18331","description":"tigger transposable element derived 7","metadata":{"aliases":["Sancho"]}},{"id":"1c7ae7c0a5954c97a1cd941617a33932","type":"GENE","name":"TIGIT","canonical_id":"hgnc:HGNC:26838","description":"T cell immunoreceptor with Ig and ITIM domains","metadata":{"aliases":["FLJ39873","DKFZp667A205","VSIG9","VSTM3"]}},{"id":"7d8ea460f41c4171a8ac04d35c4d8eed","type":"GENE","name":"TILAM","canonical_id":"hgnc:HGNC:52795","description":"TGF-beta induced lncRNA activating myofibroblasts","metadata":{"aliases":["LINC01969"]}},{"id":"ec98843402474bfeac8f1bf5a244651a","type":"GENE","name":"TILRLS","canonical_id":"hgnc:HGNC:53077","description":"TCL1A interacting lncRNA, retroperitoneal liposarcoma associated","metadata":{"aliases":["PILRLS"]}},{"id":"12cc2a0f610a4857a78d2f6b25e7d5bc","type":"GO_TERM","name":"TIM22 mitochondrial import inner membrane insertion complex","canonical_id":"go:GO:0042721","description":"\"A multi-subunit complex embedded in the mitochondrial inner membrane that mediates the inner membrane insertion of multi-transmembrane spanning proteins that contain internal targeting elements. In yeast cells, TIM22 is a 300-kDa complex, consisting of four membrane integral subunits, Tim22, Tim54, Tim18 and Sdh3, and a peripheral chaperone complex consisting of the small TIM proteins, Tim9-Tim10-Tim12.\" [PMID:12191765, PMID:27554484]","metadata":null},{"id":"49823def79e84f10b5b123ebb693fb60","type":"GO_TERM","name":"TIM23 mitochondrial import inner membrane translocase complex","canonical_id":"go:GO:0005744","description":"\"The protein transport machinery of the mitochondrial inner membrane that typically transports proteins that possess a matrix-targeting N-terminal presequence. The TIM23 complex contains three essential Tim proteins: Tim17 and Tim23 are thought to build a preprotein translocation channel while Tim44 interacts transiently with the matrix heat-shock protein Hsp70 to form an ATP-driven import motor.\" [PMID:27554484, PMID:8851659]","metadata":null},{"id":"8609c3eb4a914a7b841cd867e71bdcb8","type":"GENE","name":"TIMCC","canonical_id":"hgnc:HGNC:25911","description":"TIM double twin CX3C motif chaperone","metadata":{"aliases":["FLJ14668","FAM136A"]}},{"id":"37f841cc3b4f4375adea9d188180da90","type":"GENE","name":"TIMCCP1","canonical_id":"hgnc:HGNC:21110","description":"TIMCC pseudogene 1","metadata":{"aliases":["dJ40E16.3","C6orf87","FAM136B","FAM136BP"]}},{"id":"4fc908fe228f4780ade3bebc1cff0565","type":"GENE","name":"TIMCCP2","canonical_id":"hgnc:HGNC:55496","description":"TIMCC pseudogene 2","metadata":{"aliases":["FAM136CP"]}},{"id":"a6ba0d91d85542e3bd364748db9b4fe5","type":"GENE","name":"TIMCCP3","canonical_id":"hgnc:HGNC:55497","description":"TIMCC pseudogene 3","metadata":{"aliases":["FAM136DP"]}},{"id":"61aaad22519f4c768c42639539d2ac12","type":"GENE","name":"TIMCCP4","canonical_id":"hgnc:HGNC:55498","description":"TIMCC pseudogene 4","metadata":{"aliases":["FAM136EP"]}},{"id":"d21060d5edba4c64bb1c56f6f0e833bc","type":"GENE","name":"TIMCCP5","canonical_id":"hgnc:HGNC:55499","description":"TIMCC pseudogene 5","metadata":{"aliases":["FAM136FP"]}},{"id":"a55ec912990f450da72a6f33ca5fcfb6","type":"GENE","name":"TIMCCP6","canonical_id":"hgnc:HGNC:55500","description":"TIMCC pseudogene 6","metadata":{"aliases":["FAM136GP"]}},{"id":"8df689b9740f48f2a8b13b4614ec1c01","type":"GENE","name":"TIMD4","canonical_id":"hgnc:HGNC:25132","description":"T cell immunoglobulin and mucin domain containing 4","metadata":{"aliases":["TIM4"]}},{"id":"715872aeab1a4af4be7d416e02905bc9","type":"TRIAL","name":"TIME in Immunotherapy Combined With nCRT for Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT05507112","description":"Locally Advanced Rectal Cancer","metadata":null},{"id":"fa17dbf536c54affaea79e621ed2dd4d","type":"GENE","name":"TIMELESS","canonical_id":"hgnc:HGNC:11813","description":"timeless circadian regulator","metadata":{"aliases":["hTIM","TIM","TIM1"]}},{"id":"054be4cdaf27499d814d0b88618051d2","type":"GENE","name":"TIMM10","canonical_id":"hgnc:HGNC:11814","description":"translocase of inner mitochondrial membrane 10","metadata":{"aliases":["TIM10","TIM10A","TIMM10A"]}},{"id":"020c98218e8046638a6c363d3886774f","type":"GENE","name":"TIMM10B","canonical_id":"hgnc:HGNC:4022","description":"translocase of inner mitochondrial membrane 10B","metadata":{"aliases":["Tim9b","TIM10B","FXC1"]}},{"id":"b6a1babe96d04dbe8b0c78fcc5fa5477","type":"GENE","name":"TIMM13","canonical_id":"hgnc:HGNC:11816","description":"translocase of inner mitochondrial membrane 13","metadata":{"aliases":["Tim13","TIMM13B"]}},{"id":"4ed6102f9ee2435ab82693be38f170c2","type":"GENE","name":"TIMM17A","canonical_id":"hgnc:HGNC:17315","description":"translocase of inner mitochondrial membrane 17A","metadata":{"aliases":["TIM17","TIM17A"]}},{"id":"0b69a7fc522c4477b8c519e23f03a63a","type":"GENE","name":"TIMM17B","canonical_id":"hgnc:HGNC:17310","description":"translocase of inner mitochondrial membrane 17B","metadata":{"aliases":["DXS9822","JM3"]}},{"id":"7064b314f798452bb3dc53ea864de8d9","type":"GENE","name":"TIMM17BP1","canonical_id":"hgnc:HGNC:49865","description":"translocase of inner mitochondrial membrane 17B pseudogene 1","metadata":null},{"id":"a38b55831efd4114b7f4fa95ded81fee","type":"GENE","name":"TIMM21","canonical_id":"hgnc:HGNC:25010","description":"translocase of inner mitochondrial membrane 21","metadata":{"aliases":["HSPC154","TIM21","C18orf55"]}},{"id":"fd39bede63fb434fa1811559e47772da","type":"GENE","name":"TIMM22","canonical_id":"hgnc:HGNC:17317","description":"translocase of inner mitochondrial membrane 22","metadata":{"aliases":["TIM22","TEX4"]}},{"id":"4956d95c565a4301bd09f12d1a36de88","type":"GENE","name":"TIMM23","canonical_id":"hgnc:HGNC:17312","description":"translocase of inner mitochondrial membrane 23","metadata":{"aliases":["TIM23"]}},{"id":"3c5732bdbbf445bf8a759f56e7321ace","type":"GENE","name":"TIMM23B","canonical_id":"hgnc:HGNC:23581","description":"translocase of inner mitochondrial membrane 23 homolog B","metadata":{"aliases":["bA592B15.7"]}},{"id":"85a8038724e142dabfe3e664445bd2f5","type":"GENE","name":"TIMM23B-AGAP6","canonical_id":"hgnc:HGNC:45009","description":"TIMM23B-AGAP6 readthrough (NMD candidate)","metadata":{"aliases":["LINC00843"]}},{"id":"b3cccb7fb8714303a79092ec4ed92d49","type":"GENE","name":"TIMM29","canonical_id":"hgnc:HGNC:25152","description":"translocase of inner mitochondrial membrane 29","metadata":{"aliases":["TIM29","C19orf52"]}},{"id":"7febcfa8f9a84790b4240662d3a52df1","type":"GENE","name":"TIMM44","canonical_id":"hgnc:HGNC:17316","description":"translocase of inner mitochondrial membrane 44","metadata":{"aliases":["TIM44"]}},{"id":"ea3d52c99aa243a68b0540d0f7f0d620","type":"GENE","name":"TIMM50","canonical_id":"hgnc:HGNC:23656","description":"translocase of inner mitochondrial membrane 50","metadata":{"aliases":["TIM50L","TIM50"]}},{"id":"fa0cd632c6dd48429a805f2f1b9377d9","type":"GENE","name":"TIMM8A","canonical_id":"hgnc:HGNC:11817","description":"translocase of inner mitochondrial membrane 8A","metadata":{"aliases":["DDP","MTS","DFN1"]}},{"id":"963fd165424d41e684def8dd8c2477d1","type":"GENE","name":"TIMM8AP1","canonical_id":"hgnc:HGNC:17802","description":"translocase of inner mitochondrial membrane 8A pseudogene 1","metadata":{"aliases":["DDPP","TIMM8AP"]}},{"id":"88ca8dcfcb5a463bbccb95420af6e392","type":"GENE","name":"TIMM8B","canonical_id":"hgnc:HGNC:11818","description":"translocase of inner mitochondrial membrane 8 homolog B","metadata":{"aliases":["TIM8B","DDP2","FLJ21744","MGC102866","MGC117373"]}},{"id":"6a853f88113f49b6aaa52aeda9bae1ed","type":"GENE","name":"TIMM8BP1","canonical_id":"hgnc:HGNC:39211","description":"translocase of inner mitochondrial membrane 8B pseudogene 1","metadata":null},{"id":"c8f4bec8fcd1463b85ed00772f76379b","type":"GENE","name":"TIMM8BP2","canonical_id":"hgnc:HGNC:39212","description":"translocase of inner mitochondrial membrane 8B pseudogene 2","metadata":null},{"id":"4a4291595dad4cb896315208fbd845cc","type":"GENE","name":"TIMM9","canonical_id":"hgnc:HGNC:11819","description":"translocase of inner mitochondrial membrane 9","metadata":{"aliases":["TIM9A"]}},{"id":"cd219cb6c7304d7bb61a7bb211dd603e","type":"GENE","name":"TIMM9P1","canonical_id":"hgnc:HGNC:39928","description":"TIMM9 pseudogene 1","metadata":null},{"id":"9c71e775bbad470389acc5e80db6aa1b","type":"GENE","name":"TIMM9P2","canonical_id":"hgnc:HGNC:39929","description":"TIMM9 pseudogene 2","metadata":null},{"id":"15adfeefe9864ceda32021e215d79088","type":"GENE","name":"TIMM9P3","canonical_id":"hgnc:HGNC:39930","description":"TIMM9 pseudogene 3","metadata":null},{"id":"45a1e51a598843c09e87c22dfdbe0e32","type":"GENE","name":"TIMMDC1","canonical_id":"hgnc:HGNC:1321","description":"translocase of inner mitochondrial membrane domain containing 1","metadata":{"aliases":["FLJ22597","C3orf1"]}},{"id":"03dea8cf2df245e79656a2613c51153a","type":"GENE","name":"TIMMDC1-DT","canonical_id":"hgnc:HGNC:55207","description":"TIMMDC1 divergent transcript","metadata":{"aliases":["AC073352.1"]}},{"id":"33887007236c4ee7a9a690df750eec62","type":"GO_TERM","name":"TIMP family protein binding","canonical_id":"go:GO:0098769","description":"\"Binding to a member of the Tissue inhibitors of metalloproteinases (TIMPs) family. TIMPs are endogenous protein regulators of the matrix metalloproteinase (MMPs) family.\" [PMID:22078297]","metadata":null},{"id":"1b671e05cd0a47008fa547d31b41eb92","type":"GENE","name":"TIMP1","canonical_id":"hgnc:HGNC:11820","description":null,"metadata":null},{"id":"2442fd358656469f994a4b8312910231","type":"GENE","name":"TIMP2","canonical_id":"hgnc:HGNC:11821","description":null,"metadata":null},{"id":"d81bd2536af243598e9cadfcd3c9fe2b","type":"GENE","name":"TIMP3","canonical_id":"hgnc:HGNC:11822","description":null,"metadata":null},{"id":"39f7a92bb00f491c871fbba756a9763b","type":"GENE","name":"TIMP4","canonical_id":"hgnc:HGNC:11823","description":"TIMP metallopeptidase inhibitor 4","metadata":null},{"id":"cb71f8de5f664c4fa0776e69d27f4cd2","type":"GENE","name":"TINAG","canonical_id":"hgnc:HGNC:14599","description":"tubulointerstitial nephritis antigen","metadata":null},{"id":"660ed3bd3e0745d797fe295d0906c1b8","type":"GENE","name":"TINAG-AS1","canonical_id":"hgnc:HGNC:40691","description":"TINAG antisense RNA 1","metadata":null},{"id":"0b3d7404da0b4562a23523058d3ace53","type":"GENE","name":"TINAGL1","canonical_id":"hgnc:HGNC:19168","description":"tubulointerstitial nephritis antigen like 1","metadata":{"aliases":["P3ECSL","LIECG3","ARG1","TINAGRP","LCN7"]}},{"id":"43162599a1324283a5b23a3173902add","type":"GENE","name":"TINCR","canonical_id":"hgnc:HGNC:14607","description":"TINCR ubiquitin domain containing","metadata":{"aliases":["FLJ90734","NCRNA00036","LINC00036","onco-lncRNA-16","TUBL","PLAC2"]}},{"id":"274650a7f84f4c03ac4f890518f6900a","type":"GENE","name":"TINF2","canonical_id":"hgnc:HGNC:11824","description":null,"metadata":null},{"id":"64cc4028840b4829a41c46691a6e9e69","type":"GO_TERM","name":"TINTIN complex","canonical_id":"go:GO:1990453","description":"\"A protein complex involved in the disassembly and subsequent reassembly of nucleosomes. It associates with the coding region of transcriptionally active genes where it interacts with the RNA polymerase II and affects its processivity during co-transcriptional RNA processing and maturation. It exists as a functionally independent part of the NuA4 complex.\" [GOC:bhm, PMID:24843044, PMID:36190236]","metadata":null},{"id":"aa360dd7f18f4d16a6f5649cf084c6c1","type":"GENE","name":"TIPARP","canonical_id":"hgnc:HGNC:23696","description":"TCDD inducible poly(ADP-ribose) polymerase","metadata":{"aliases":["DKFZP434J214","DKFZp686N0351","DDF1","PARP7","PARP-7","PARP-1","pART14","RM1","ARTD14"]}},{"id":"d91e20530d9340f6853495ee69463302","type":"GENE","name":"TIPARP-AS1","canonical_id":"hgnc:HGNC:41028","description":"TIPARP antisense RNA 1","metadata":null},{"id":"496a5280f0484e22bfb490e7e7930a93","type":"GENE","name":"TIPE1","canonical_id":"hgnc:HGNC:28279","description":"TNF alpha induced protein 8 like 1","metadata":{"aliases":["MGC17791","TNFAIP8L1"]}},{"id":"2be044d38a4e4fada6b6537cad4b167c","type":"GENE","name":"TIPE2","canonical_id":"hgnc:HGNC:26277","description":"TNF alpha induced protein 8 like 2","metadata":{"aliases":["FLJ23467","TNFAIP8L2"]}},{"id":"87ead7ccbbdb44fc9d2dabe270d902d7","type":"GENE","name":"TIPE3","canonical_id":"hgnc:HGNC:20620","description":"TNF alpha induced protein 8 like 3","metadata":{"aliases":["FLJ41287","TNFAIP8L3"]}},{"id":"ab7514b495ad443d8204a757adeb0fef","type":"GENE","name":"TIPIN","canonical_id":"hgnc:HGNC:30750","description":"TIMELESS interacting protein","metadata":{"aliases":["FLJ20516"]}},{"id":"228bb7d7cf864ecf95c07f4dd95464a1","type":"GENE","name":"TIPINP1","canonical_id":"hgnc:HGNC:54963","description":"TIPIN pseudogene 1","metadata":null},{"id":"83230c91eb3846b69a095a842e2daaff","type":"GENE","name":"TIPINP2","canonical_id":"hgnc:HGNC:56789","description":"TIPIN pseudogene 2","metadata":null},{"id":"ecec5d1b6022456580034e28bb7f71c8","type":"GENE","name":"TIPRL","canonical_id":"hgnc:HGNC:30231","description":"TOR signaling pathway regulator","metadata":{"aliases":["MGC3794","dJ69E11.3","TIP41","TIPRL1"]}},{"id":"3460e387074c4b608a033f1a4496a9f6","type":"TRIAL","name":"TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study","canonical_id":"clinicaltrials.gov:NCT05882370","description":"Hepatocellular Carcinoma","metadata":null},{"id":"c521c1b296f8496385d83340c1f5c520","type":"TRIAL","name":"TIPS or Anticoagulation in Portal Vein Thrombosis","canonical_id":"clinicaltrials.gov:NCT03422419","description":"Thrombosis Portal Vein","metadata":null},{"id":"fb4fc6dc681f4946aa5fe6ddd6a95e8d","type":"GO_TERM","name":"TIR domain binding","canonical_id":"go:GO:0070976","description":"\"Binding to a Toll-Interleukin receptor (TIR) domain of a protein. The TIR domain is an intracellular 200 residue domain that is found in the Toll protein, the interleukin-1 receptor (IL-1R), and MyD88; it contains three highly-conserved regions, and mediates protein-protein interactions between the Toll-like receptors (TLRs) and signal-transduction components.\" [GOC:mah, InterPro:IPR000157]","metadata":null},{"id":"7bd5e42b25ea4bef885e99a1802bf354","type":"GENE","name":"TIRAP","canonical_id":"hgnc:HGNC:17192","description":"TIR domain containing adaptor protein","metadata":{"aliases":["Mal","wyatt"]}},{"id":"1e7b287835734acbafc9a9ef406fe7a8","type":"GENE","name":"TIRAP-AS1","canonical_id":"hgnc:HGNC:56069","description":"TIRAP antisense RNA 1","metadata":null},{"id":"f4de2444052e4f4ca94065b5b6153c7e","type":"GO_TERM","name":"TIRAP-dependent toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0035665","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like receptor 4 where the TIRAP/MAL adaptor mediates transduction of the signal. Toll-like 4 receptors are pattern recognition receptors that bind bacterial lipopolysaccharide (LPS) to initiate an innate immune response.\" [GOC:BHF, PMID:12447441]","metadata":null},{"id":"d73d12e41e6643a6abf6a6cb160a5e1a","type":"GO_TERM","name":"TIRAP-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0035664","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like receptor where the TIRAP/MAL adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate an innate immune response.\" [GOC:BHF, PMID:11526399, PMID:11544529, PMID:12447442]","metadata":null},{"id":"02dff15e721841178c0bb0ddbc340b44","type":"GO_TERM","name":"TIS granule","canonical_id":"go:GO:0140363","description":"\"A ribonucleoprotein granule located in the cytoplasm that is formed by the RNA-binding protein TIS11B and RNA molecules, enriched in membrane protein-encoding mRNAs with multiple AU-rich elements. TIS granules are reticular meshworks intertwined with the endoplasmic reticulum (ER).\" [PMID:30449617, PMID:30479375, Wikipedia:TIGER_domain]","metadata":null},{"id":"885be9d362dc4c248654ffc4efe2ab98","type":"GENE","name":"TJAP1","canonical_id":"hgnc:HGNC:17949","description":"tight junction associated protein 1","metadata":{"aliases":["PILT","TJP4"]}},{"id":"2dd2759e2e0046018ea729a8f46de7ab","type":"GENE","name":"TJAP1P1","canonical_id":"hgnc:HGNC:55129","description":"TJAP1 pseudogene 1","metadata":null},{"id":"4c1650052797450fb80ee8c825ca1bf8","type":"GENE","name":"TJP1","canonical_id":"hgnc:HGNC:11827","description":null,"metadata":null},{"id":"101e4f7f2e134705ad61fa1b68f9c8ee","type":"GENE","name":"TJP1P1","canonical_id":"hgnc:HGNC:14167","description":"tight junction protein 1 pseudogene 1","metadata":{"aliases":["TJP1P"]}},{"id":"89ced1dff5b5448492c1860bec87f144","type":"GENE","name":"TJP2","canonical_id":"hgnc:HGNC:11828","description":"tight junction protein 2","metadata":{"aliases":["ZO-2","X104","ZO2","DFNA51"]}},{"id":"9d9dc35c2ed849849de104251ad007df","type":"GENE","name":"TJP3","canonical_id":"hgnc:HGNC:11829","description":"tight junction protein 3","metadata":{"aliases":["ZO-3"]}},{"id":"7a042d57069341c2ab83cfb7fc249b7d","type":"GENE","name":"TK1","canonical_id":"hgnc:HGNC:11830","description":null,"metadata":null},{"id":"ccdfad0a648b4ecf9f51a3b73fdecfb7","type":"GENE","name":"TK2","canonical_id":"hgnc:HGNC:11831","description":"thymidine kinase 2","metadata":{"aliases":["SCA31"]}},{"id":"40a4703fe7ce48e09ddf184a2b037d8a","type":"GENE","name":"TKFC","canonical_id":"hgnc:HGNC:24552","description":"triokinase and FMN cyclase","metadata":{"aliases":["DKFZP586B1621","NET45","DAK"]}},{"id":"c03fc88039b948faa3ebea99030b360d","type":"GENE","name":"TKT","canonical_id":"hgnc:HGNC:11834","description":"transketolase","metadata":null},{"id":"b8fc48d26787481a91352846e49d711c","type":"GENE","name":"TKTL1","canonical_id":"hgnc:HGNC:11835","description":"transketolase like 1","metadata":{"aliases":["TKR","TKT2"]}},{"id":"fba9621357bd47efb0e1f4ff0e1e6b69","type":"GENE","name":"TKTL2","canonical_id":"hgnc:HGNC:25313","description":"transketolase like 2","metadata":{"aliases":["FLJ32975","DKFZP434L1717"]}},{"id":"effb921cb63149a0bac21dbed379e000","type":"GENE","name":"TLCD1","canonical_id":"hgnc:HGNC:25177","description":"TLC domain containing 1","metadata":null},{"id":"2bcac46b59a34defbd698b7fc2d9c3fd","type":"GENE","name":"TLCD2","canonical_id":"hgnc:HGNC:33522","description":"TLC domain containing 2","metadata":null},{"id":"a2cd64812fdb471a9fb07617c043413e","type":"GENE","name":"TLCD3B","canonical_id":"hgnc:HGNC:25295","description":"TLC domain containing 3B","metadata":{"aliases":["DKFZP434I2117","FAM57B"]}},{"id":"a685190f18ba4b9ea7b93a3c8a68ba4c","type":"GENE","name":"TLCD4","canonical_id":"hgnc:HGNC:26477","description":"TLC domain containing 4","metadata":{"aliases":["FLJ31842","TMEM56"]}},{"id":"9539f631c77749ed838bbffe67d87908","type":"GENE","name":"TLCD4-RWDD3","canonical_id":"hgnc:HGNC:49388","description":"TLCD4-RWDD3 readthrough","metadata":{"aliases":["TMEM56-RWDD3"]}},{"id":"14024c7af024419688928ac59d963128","type":"GENE","name":"TLCD5","canonical_id":"hgnc:HGNC:28280","description":"TLC domain containing 5","metadata":{"aliases":["MGC17839","TMEM136"]}},{"id":"fb27f63400c34878a61732d472d58a9c","type":"GENE","name":"TLDC2","canonical_id":"hgnc:HGNC:16112","description":"TBC/LysM-associated domain containing 2","metadata":{"aliases":["dJ132F21.2","C20orf118"]}},{"id":"7fb9bf05aa3247959fc3536d1945c20e","type":"GENE","name":"TLE1","canonical_id":"hgnc:HGNC:11837","description":null,"metadata":null},{"id":"249db8e4346f4cae9c643a22372441f9","type":"GENE","name":"TLE1-DT","canonical_id":"hgnc:HGNC:55701","description":"TLE1 divergent transcript","metadata":null},{"id":"be0c33df81304efebb23f1f6c3c31e8c","type":"GENE","name":"TLE1P1","canonical_id":"hgnc:HGNC:39438","description":"TLE family member 1 pseudogene 1","metadata":null},{"id":"14cd17b3b8504ef9bf93d928ee0c49f2","type":"GENE","name":"TLE2","canonical_id":"hgnc:HGNC:11838","description":"TLE family member 2, transcriptional corepressor","metadata":{"aliases":["ESG2","GRG2","ESG","FLJ41188"]}},{"id":"a9739a34aef7491292eff62c861ea5ea","type":"GENE","name":"TLE3","canonical_id":"hgnc:HGNC:11839","description":null,"metadata":null},{"id":"153f3b1b0b7f416dab5a2cd6399ff339","type":"GENE","name":"TLE4","canonical_id":"hgnc:HGNC:11840","description":"TLE family member 4, transcriptional corepressor","metadata":{"aliases":["E(spl)","ESG","GRG4"]}},{"id":"64301e86ed90467cad6ccdeb0384f38b","type":"GENE","name":"TLE6","canonical_id":"hgnc:HGNC:30788","description":"TLE family member 6, subcortical maternal complex member","metadata":{"aliases":["FLJ14009","GRG6"]}},{"id":"fc1cf53d45314b36aac62a0f9cca1661","type":"GENE","name":"TLE7","canonical_id":"hgnc:HGNC:53648","description":"TLE family member 7","metadata":null},{"id":"94d3c117ebaa405b90681acad432aaed","type":"GENE","name":"TLK1","canonical_id":"hgnc:HGNC:11841","description":"tousled like kinase 1","metadata":{"aliases":["KIAA0137","PKU-BETA"]}},{"id":"a7175e13c3b04dc981ae92bf4dd83943","type":"GENE","name":"TLK1P1","canonical_id":"hgnc:HGNC:28608","description":"tousled like kinase 1 pseudogene 1","metadata":{"aliases":["TLK1ps","TLK1P"]}},{"id":"88c8053e2aeb4859adf345c91ae2277f","type":"GENE","name":"TLK2","canonical_id":"hgnc:HGNC:11842","description":"tousled like kinase 2","metadata":{"aliases":["PKU-ALPHA","MGC44450"]}},{"id":"487f812230f349c2ae9381e8161e0e12","type":"GENE","name":"TLK2P1","canonical_id":"hgnc:HGNC:18048","description":"tousled like kinase 2 pseudogene 1","metadata":{"aliases":["TLK2ps1"]}},{"id":"d067c9f99649421bae00ccaa386ed481","type":"GENE","name":"TLK2P2","canonical_id":"hgnc:HGNC:22227","description":"tousled like kinase 2 pseudogene 2","metadata":{"aliases":["TLK2ps2"]}},{"id":"cd2701d8e50e4eebb3c9525099711075","type":"GENE","name":"TLL1","canonical_id":"hgnc:HGNC:11843","description":"tolloid like 1","metadata":null},{"id":"6ad790f6b6ae4901a4e161062a839c96","type":"GENE","name":"TLL2","canonical_id":"hgnc:HGNC:11844","description":"tolloid like 2","metadata":null},{"id":"cc4f959095944a90abe7da4773951832","type":"GENE","name":"TLN1","canonical_id":"hgnc:HGNC:11845","description":"talin 1","metadata":{"aliases":["ILWEQ","TLN"]}},{"id":"b0f87fca5b2d417fb1dfb1d816cbc2a9","type":"GENE","name":"TLN2","canonical_id":"hgnc:HGNC:15447","description":"talin 2","metadata":{"aliases":["KIAA0320","ILWEQ"]}},{"id":"9bad8dda76654ed095f115d011849dab","type":"GENE","name":"TLNRD1","canonical_id":"hgnc:HGNC:13519","description":"talin rod domain containing 1","metadata":{"aliases":["MGC99595","MESDC1"]}},{"id":"a237eae9551f4a5b8fd63b42e4b671e6","type":"GENE","name":"TLR1","canonical_id":"hgnc:HGNC:11847","description":"toll like receptor 1","metadata":{"aliases":["rsc786","KIAA0012","CD281"]}},{"id":"e0ba1efc7b1c466f9a93fa590bd90f24","type":"GENE","name":"TLR10","canonical_id":"hgnc:HGNC:15634","description":null,"metadata":null},{"id":"de81f0c722d94dbc94bb26ff5e36875a","type":"GENE","name":"TLR12P","canonical_id":"hgnc:HGNC:31754","description":"toll like receptor 12, pseudogene","metadata":null},{"id":"6d0c6e6d13524b0f97d3c0ea5835278a","type":"GENE","name":"TLR2","canonical_id":"hgnc:HGNC:11848","description":null,"metadata":null},{"id":"27e18e1c95bb4fa1a3a1a5f75da75dcb","type":"GENE","name":"TLR2P1","canonical_id":"hgnc:HGNC:59192","description":"TLR2 pseudogene 1","metadata":null},{"id":"cee11f55881e407f836b038c8545c46a","type":"GENE","name":"TLR3","canonical_id":"hgnc:HGNC:11849","description":null,"metadata":null},{"id":"e6f997984757410fb15ab957669a7e7c","type":"GENE","name":"TLR4","canonical_id":"hgnc:HGNC:11850","description":null,"metadata":null},{"id":"20a744dcdb9443519bdfa5f7c6cb3f3b","type":"GENE","name":"TLR5","canonical_id":"hgnc:HGNC:11851","description":"toll like receptor 5","metadata":{"aliases":["TIL3","FLJ10052","MGC126430","MGC126431","SLEB1"]}},{"id":"abf4a8317db448efba487ac99ba65ea3","type":"GENE","name":"TLR6","canonical_id":"hgnc:HGNC:16711","description":null,"metadata":null},{"id":"9ff0c0dd969a4758b23b50ac28c6ce87","type":"GENE","name":"TLR7","canonical_id":"hgnc:HGNC:15631","description":null,"metadata":null},{"id":"82bc2ead8c65421180b12354b42f390e","type":"PROTEIN","name":"TLR7","canonical_id":"uniprot:Q9NYK1","description":null,"metadata":null},{"id":"cd891e2b833b4d5588dc58dfc91615bf","type":"GENE","name":"TLR8","canonical_id":"hgnc:HGNC:15632","description":"toll like receptor 8","metadata":{"aliases":["CD288","hTLR8"]}},{"id":"19f9d94149964c4096dd55ed75625a5b","type":"GENE","name":"TLR8-AS1","canonical_id":"hgnc:HGNC:40720","description":"TLR8 antisense RNA 1","metadata":null},{"id":"e6cf983b499943eaab0c4d24d0f3c245","type":"GENE","name":"TLR9","canonical_id":"hgnc:HGNC:15633","description":null,"metadata":null},{"id":"002b5c394a494e1fb4955bc277bb2097","type":"TRIAL","name":"TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT02927964","description":"Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma","metadata":null},{"id":"29cdca7a5691427bac2c0f1f47e5dfba","type":"GENE","name":"TLX1","canonical_id":"hgnc:HGNC:5056","description":null,"metadata":null},{"id":"641faa87826648a9b1b8c78243298a08","type":"GENE","name":"TLX1NB","canonical_id":"hgnc:HGNC:37183","description":"TLX1 neighbor","metadata":{"aliases":["TD1","TDI","APT-B7"]}},{"id":"7435cb227eca4fabba1fe9f06c6652ed","type":"GENE","name":"TLX2","canonical_id":"hgnc:HGNC:5057","description":null,"metadata":null},{"id":"7815de3bfe464deeb9d1a5c68e26cd88","type":"GENE","name":"TLX3","canonical_id":"hgnc:HGNC:13532","description":"T cell leukemia homeobox 3","metadata":{"aliases":["RNX","HOX11L2"]}},{"id":"cbe78b696a3242dfba06287f3f1b2cd1","type":"GENE","name":"TLX3-AS1","canonical_id":"hgnc:HGNC:59303","description":"TLX3 antisense RNA 1","metadata":null},{"id":"5409381d71724beca18fb90f9a815d86","type":"GENE","name":"TM2D1","canonical_id":"hgnc:HGNC:24142","description":"TM2 domain containing 1","metadata":{"aliases":["BBP"]}},{"id":"cd2cb538a2a049e1ab8cb2afe9cb803c","type":"GENE","name":"TM2D2","canonical_id":"hgnc:HGNC:24127","description":"TM2 domain containing 2","metadata":{"aliases":["BLP1"]}},{"id":"d4d4ed4ed14e4026a2aff9a3b0d249e9","type":"GENE","name":"TM2D3","canonical_id":"hgnc:HGNC:24128","description":"TM2 domain containing 3","metadata":{"aliases":["BLP2","FLJ22604"]}},{"id":"c75e0e39210e4abc8980fe565c5ac22f","type":"GENE","name":"TM4SF1","canonical_id":"hgnc:HGNC:11853","description":null,"metadata":null},{"id":"a38a9dcea5b74ceea35176b29b3cf1b4","type":"GENE","name":"TM4SF1-AS1","canonical_id":"hgnc:HGNC:40587","description":"TM4SF1 antisense RNA 1","metadata":null},{"id":"54d40ba4d1da498091ba152f205e3801","type":"GENE","name":"TM4SF18","canonical_id":"hgnc:HGNC:25181","description":"transmembrane 4 L six family member 18","metadata":{"aliases":["L6D"]}},{"id":"b39181cb30f24976aa17db91923ae56e","type":"GENE","name":"TM4SF18-AS1","canonical_id":"hgnc:HGNC:56678","description":"TM4SF18 antisense RNA 1","metadata":{"aliases":["AC093001.1"]}},{"id":"dfcf1c63ddc14df4bbe99f2c704aa565","type":"GENE","name":"TM4SF19","canonical_id":"hgnc:HGNC:25167","description":"transmembrane 4 L six family member 19","metadata":null},{"id":"1632c14ad1a448089668a647fefe0fb7","type":"GENE","name":"TM4SF19-AS1","canonical_id":"hgnc:HGNC:41085","description":"TM4SF19 antisense RNA 1","metadata":null},{"id":"8754ba2be1ad442095a8f20d5a72e234","type":"GENE","name":"TM4SF19-DYNLT2B","canonical_id":"hgnc:HGNC:49190","description":"TM4SF19-DYNLT2B readthrough (NMD candidate)","metadata":{"aliases":["TM4SF19-TCTEX1D2"]}},{"id":"963aae7bb6b44fb68d0257026eb64be8","type":"GENE","name":"TM4SF20","canonical_id":"hgnc:HGNC:26230","description":"transmembrane 4 L six family member 20","metadata":{"aliases":["FLJ22800","TCCE518"]}},{"id":"caef77eb9554480e8479715042137608","type":"GENE","name":"TM4SF4","canonical_id":"hgnc:HGNC:11856","description":"transmembrane 4 L six family member 4","metadata":{"aliases":["il-TMP"]}},{"id":"eb74e1259324484793b98bef767b377e","type":"GENE","name":"TM4SF5","canonical_id":"hgnc:HGNC:11857","description":"transmembrane 4 L six family member 5","metadata":null},{"id":"dd8f6fc67d124013b1c0745a077a9bae","type":"GENE","name":"TM6SF1","canonical_id":"hgnc:HGNC:11860","description":"transmembrane 6 superfamily member 1","metadata":null},{"id":"e5bf237b42824c51b5ffe293972a064e","type":"GENE","name":"TM6SF2","canonical_id":"hgnc:HGNC:11861","description":"transmembrane 6 superfamily member 2","metadata":{"aliases":["Lpr4"]}},{"id":"308c425db31c414caa04747a8d9c13a6","type":"GENE","name":"TM7SF2","canonical_id":"hgnc:HGNC:11863","description":"transmembrane 7 superfamily member 2","metadata":{"aliases":["C14SR","ANG1","DHCR14A","NET47"]}},{"id":"cb1a3acd516b4e77b15cf4154606efd9","type":"GENE","name":"TM7SF3","canonical_id":"hgnc:HGNC:23049","description":"transmembrane 7 superfamily member 3","metadata":null},{"id":"ad9fa41e5bfb42e9a74a783865d68e04","type":"GENE","name":"TM7SF3-AS1","canonical_id":"hgnc:HGNC:58075","description":"TM7SF3 antisense RNA 1","metadata":{"aliases":["AC024896.1"]}},{"id":"6ba7b9ee0425429b8c94bae09304a0ae","type":"GENE","name":"TM9SF1","canonical_id":"hgnc:HGNC:11864","description":"transmembrane 9 superfamily member 1","metadata":{"aliases":["MP70","HMP70"]}},{"id":"c8827108928d4152a8d65117c4d90f79","type":"GENE","name":"TM9SF2","canonical_id":"hgnc:HGNC:11865","description":"transmembrane 9 superfamily member 2","metadata":{"aliases":["P76","Lnc-PCIR"]}},{"id":"b7c10c718ab54334916178e491c57a02","type":"GENE","name":"TM9SF3","canonical_id":"hgnc:HGNC:21529","description":"transmembrane 9 superfamily member 3","metadata":{"aliases":["SMBP"]}},{"id":"a8785b8ed34840f3bdcedc50adb6182e","type":"GENE","name":"TM9SF4","canonical_id":"hgnc:HGNC:30797","description":"transmembrane 9 superfamily member 4","metadata":{"aliases":["KIAA0255","dJ836N17.2"]}},{"id":"8dfb8d6a805a436f9bb7908ce7ec7d5e","type":"GENE","name":"TM9SF5P","canonical_id":"hgnc:HGNC:55623","description":"transmembrane 9 superfamily member 5, pseudogene","metadata":null},{"id":"53c1e94e7a5a4871babd81af7d813557","type":"GENE","name":"TMA16","canonical_id":"hgnc:HGNC:25638","description":"translation machinery associated 16 homolog","metadata":{"aliases":["FLJ11184","C4orf43"]}},{"id":"7a6a577b0a6d40b5af934a6dd8e47f7b","type":"GENE","name":"TMA16-AS1","canonical_id":"hgnc:HGNC:58904","description":"TMA16 antisense RNA 1","metadata":null},{"id":"d7d756c86d8a4809a204b79bc7936b35","type":"GENE","name":"TMA16P1","canonical_id":"hgnc:HGNC:43780","description":"translation machinery associated 16 homolog pseudogene 1","metadata":null},{"id":"a77ae89ca87d45138910534e7903a37b","type":"GENE","name":"TMA16P2","canonical_id":"hgnc:HGNC:43781","description":"translation machinery associated 16 homolog pseudogene 2","metadata":null},{"id":"bed360b311c94c18bf50d05060967f15","type":"GENE","name":"TMA7","canonical_id":"hgnc:HGNC:26932","description":"translation machinery associated 7 homolog","metadata":{"aliases":["HSPC016","CCDC72"]}},{"id":"1a6f3eea5ae34b7aacaf3e0a9e8979d0","type":"GENE","name":"TMA7B","canonical_id":"hgnc:HGNC:53893","description":"translation machinery associated 7 homolog B","metadata":null},{"id":"5902841fd4b64a0c82df9dc32530cde0","type":"GENE","name":"TMBIM1","canonical_id":"hgnc:HGNC:23410","description":"transmembrane BAX inhibitor motif containing 1","metadata":{"aliases":["PP1201","RECS1","LFG3"]}},{"id":"e72a8e816b5e4565afc4a1c63bb9c0ac","type":"GENE","name":"TMBIM4","canonical_id":"hgnc:HGNC:24257","description":"transmembrane BAX inhibitor motif containing 4","metadata":{"aliases":["CGI-119","S1R","ZPRO","LFG4","GAAP"]}},{"id":"91c3fa0b677d43e2a4cb7e22423ae558","type":"GENE","name":"TMBIM6","canonical_id":"hgnc:HGNC:11723","description":"transmembrane BAX inhibitor motif containing 6","metadata":{"aliases":["BI-1","BAXI1","TEGT"]}},{"id":"04c97eb3370e438face82fc153d583ef","type":"GENE","name":"TMBIM7P","canonical_id":"hgnc:HGNC:49212","description":"transmembrane BAX inhibitor motif containing 7, pseudogene","metadata":null},{"id":"9920fea5aa95490db14f7f1b2e58b494","type":"GENE","name":"TMC1","canonical_id":"hgnc:HGNC:16513","description":"transmembrane channel like 1","metadata":{"aliases":["DFNA36","DFNB7","DFNB11"]}},{"id":"b6496bf11e6a406b984a6c45c39fb5dc","type":"GENE","name":"TMC2","canonical_id":"hgnc:HGNC:16527","description":"transmembrane channel like 2","metadata":{"aliases":["dJ686C3.3","C20orf145"]}},{"id":"600208c6414f4127b7c9738ebb914941","type":"GENE","name":"TMC3","canonical_id":"hgnc:HGNC:22995","description":"transmembrane channel like 3","metadata":null},{"id":"72bb1d5b7a054befb47039fa8ea92a78","type":"GENE","name":"TMC3-AS1","canonical_id":"hgnc:HGNC:51424","description":"TMC3 antisense RNA 1","metadata":null},{"id":"2528055154744d9789883846573ba2aa","type":"GENE","name":"TMC4","canonical_id":"hgnc:HGNC:22998","description":"transmembrane channel like 4","metadata":null},{"id":"99d988b5ea2b4e8596957993e5818444","type":"GENE","name":"TMC5","canonical_id":"hgnc:HGNC:22999","description":"transmembrane channel like 5","metadata":{"aliases":["FLJ13593"]}},{"id":"2fd315f4b9fa44bfaef2de5ccd94114a","type":"GENE","name":"TMC5-AS1","canonical_id":"hgnc:HGNC:58394","description":"TMC5 antisense RNA 1","metadata":null},{"id":"abd4111681bf4a29bfdc7e08debea732","type":"GENE","name":"TMC6","canonical_id":"hgnc:HGNC:18021","description":"transmembrane channel like 6","metadata":{"aliases":["LAK-4P","EVIN1","EVER1","TNRC6C-AS1"]}},{"id":"ece14c3c9af44fdda4ba0133854b0156","type":"GENE","name":"TMC7","canonical_id":"hgnc:HGNC:23000","description":"transmembrane channel like 7","metadata":{"aliases":["FLJ21240"]}},{"id":"a02d96dabe6e412ba1b4a7e375edffa9","type":"GENE","name":"TMC8","canonical_id":"hgnc:HGNC:20474","description":"transmembrane channel like 8","metadata":{"aliases":["EVIN2","EVER2"]}},{"id":"74d8ad1e5ede4caba01983ec729af52a","type":"GENE","name":"TMCC1","canonical_id":"hgnc:HGNC:29116","description":"transmembrane and coiled-coil domain family 1","metadata":{"aliases":["KIAA0779"]}},{"id":"135e4a0a648849219014dc81b6649dad","type":"GENE","name":"TMCC1-DT","canonical_id":"hgnc:HGNC:49060","description":"TMCC1 divergent transcript","metadata":{"aliases":["TMCC1-AS1"]}},{"id":"4677010fe335466f88ee14a52c81c871","type":"GENE","name":"TMCC1P1","canonical_id":"hgnc:HGNC:31901","description":"transmembrane and coiled-coil domain family 1 pseudogene 1","metadata":{"aliases":["TMCC1P"]}},{"id":"c6fed0465cdb41f7828dd7fc91506046","type":"GENE","name":"TMCC2","canonical_id":"hgnc:HGNC:24239","description":"transmembrane and coiled-coil domain family 2","metadata":{"aliases":["HUCEP11","FLJ38497"]}},{"id":"9a3f6c9935564bdabfc5b15338380075","type":"GENE","name":"TMCC2-AS1","canonical_id":"hgnc:HGNC:41042","description":"TMCC2 antisense RNA 1","metadata":null},{"id":"b11f9d7ecc884896aeb85aa6a2a76218","type":"GENE","name":"TMCC3","canonical_id":"hgnc:HGNC:29199","description":"transmembrane and coiled-coil domain family 3","metadata":{"aliases":["KIAA1145"]}},{"id":"07cf85556aea4dc089590136ea563d60","type":"GENE","name":"TMCO1","canonical_id":"hgnc:HGNC:18188","description":"transmembrane and coiled-coil domains 1","metadata":{"aliases":["HP10122","TMCC4"]}},{"id":"3e41b1b3c98a4d1681caef03d40020ac","type":"GENE","name":"TMCO1-AS1","canonical_id":"hgnc:HGNC:54046","description":"TMCO1 antisense RNA 1","metadata":null},{"id":"aa7d25e7ccbd4194909fdea16291c6f3","type":"GENE","name":"TMCO2","canonical_id":"hgnc:HGNC:23312","description":"transmembrane and coiled-coil domains 2","metadata":{"aliases":["dJ39G22.2"]}},{"id":"d1955abc8a4c4d028f4d583bba18e1bd","type":"GENE","name":"TMCO4","canonical_id":"hgnc:HGNC:27393","description":"transmembrane and coiled-coil domains 4","metadata":{"aliases":["DKFZp686C23231"]}},{"id":"0f5a716ca86947fe982174d9d12bb61d","type":"GENE","name":"TMCO5A","canonical_id":"hgnc:HGNC:28558","description":"transmembrane and coiled-coil domains 5A","metadata":{"aliases":["MGC35118","TMCO5"]}},{"id":"8e2055b5eaa748339ed94226eb0f62b3","type":"GENE","name":"TMCO5B","canonical_id":"hgnc:HGNC:34243","description":"transmembrane and coiled-coil domains 5B (pseudogene)","metadata":{"aliases":["TMCO5BP"]}},{"id":"7dab923ee9ab4922ae21f575a4a4cd69","type":"GENE","name":"TMCO6","canonical_id":"hgnc:HGNC:28814","description":"transmembrane and coiled-coil domains 6","metadata":{"aliases":["FLJ39769","PRO1580"]}},{"id":"0e840949753e4e89adc964708a10dc26","type":"GENE","name":"TMDD1","canonical_id":"hgnc:HGNC:53646","description":"transmembrane and death domain 1","metadata":{"aliases":["hCG1648055","C12orf81"]}},{"id":"3a96e395a1134e69906a968c69f86b66","type":"GENE","name":"TMED1","canonical_id":"hgnc:HGNC:17291","description":"transmembrane p24 trafficking protein 1","metadata":{"aliases":["ST2L","MGC1270","IL1RL1LG","Il1rl1l","p24gamma1","p24g1"]}},{"id":"b31cca65cf754013b096593bbe7488c7","type":"GENE","name":"TMED10","canonical_id":"hgnc:HGNC:16998","description":"transmembrane p24 trafficking protein 10","metadata":{"aliases":["TMP21","P24(DELTA)","p24d1","p24delta1","p23"]}},{"id":"7f70fa3f1a324a0598286caae7098a3a","type":"GENE","name":"TMED10P1","canonical_id":"hgnc:HGNC:30754","description":"transmembrane p24 trafficking protein 10 pseudogene 1","metadata":{"aliases":["Tmp21-II","TMED10P"]}},{"id":"51d65b9146574409bed4b135858f0b18","type":"GENE","name":"TMED10P2","canonical_id":"hgnc:HGNC:38105","description":"transmembrane p24 trafficking protein 10 pseudogene 2","metadata":null},{"id":"5d12e94c4254491b95aafb3d1c73e9b9","type":"GENE","name":"TMED11P","canonical_id":"hgnc:HGNC:35401","description":"transmembrane p24 trafficking protein 11, pseudogene","metadata":{"aliases":["p24alpha1","p24a1"]}},{"id":"eecd99923f794fbaba3fc41809695b1b","type":"GENE","name":"TMED2","canonical_id":"hgnc:HGNC:16996","description":"transmembrane p24 trafficking protein 2","metadata":{"aliases":["RNP24","P24A","p24beta1","p24b1"]}},{"id":"5e794f7b4dde4057aed6793a1d8134f3","type":"GENE","name":"TMED2-DT","canonical_id":"hgnc:HGNC:53346","description":"TMED2 divergent transcript","metadata":null},{"id":"d99fb33647d7423a9b11441f37a362c6","type":"GENE","name":"TMED2P1","canonical_id":"hgnc:HGNC:56425","description":"TMED2 pseudogene 1","metadata":null},{"id":"6f4ccb27da754e138aba099b637d06f0","type":"GENE","name":"TMED3","canonical_id":"hgnc:HGNC:28889","description":"transmembrane p24 trafficking protein 3","metadata":{"aliases":["p24B","p24gamma4","p24g4","C15orf22"]}},{"id":"1c8e415beab3495bb191e99467830286","type":"GENE","name":"TMED4","canonical_id":"hgnc:HGNC:22301","description":"transmembrane p24 trafficking protein 4","metadata":{"aliases":["HNLF","p24alpha3","p24a3"]}},{"id":"b1cfd4c7fd3f4040a3ae0904cf93d9c4","type":"GENE","name":"TMED5","canonical_id":"hgnc:HGNC:24251","description":"transmembrane p24 trafficking protein 5","metadata":{"aliases":["CGI-100","p24g2","p24gamma2"]}},{"id":"b814fd7cfa314bd39ddb6d020ba0b369","type":"GENE","name":"TMED6","canonical_id":"hgnc:HGNC:28331","description":"transmembrane p24 trafficking protein 6","metadata":{"aliases":["MGC23911","p24gamma5","p24g5"]}},{"id":"2000eb7703be42e7bfc516475f1003aa","type":"GENE","name":"TMED7","canonical_id":"hgnc:HGNC:24253","description":"transmembrane p24 trafficking protein 7","metadata":{"aliases":["CGI-109","FLJ90481","p24gamma3","p24g3"]}},{"id":"98667d7b4421472f83b4625fd200b173","type":"GENE","name":"TMED7-TICAM2","canonical_id":"hgnc:HGNC:33945","description":"TMED7-TICAM2 readthrough","metadata":null},{"id":"faa4c216aa9841a880355c9cc1e459cd","type":"GENE","name":"TMED8","canonical_id":"hgnc:HGNC:18633","description":"transmembrane p24 trafficking protein family member 8","metadata":{"aliases":["FAM15B"]}},{"id":"12e1fd01b0d84ffb8214f1261676719f","type":"GENE","name":"TMED9","canonical_id":"hgnc:HGNC:24878","description":"transmembrane p24 trafficking protein 9","metadata":{"aliases":["HSGP25L2G","p24alpha2","p24a2"]}},{"id":"841b894236004159bf8262a967d432d2","type":"GENE","name":"TMEFF1","canonical_id":"hgnc:HGNC:11866","description":"transmembrane protein with EGF like and two follistatin like domains 1","metadata":{"aliases":["H7365","CT120.1","C9orf2"]}},{"id":"79ec77fdb7c541e59f0984749e01b896","type":"GENE","name":"TMEFF2","canonical_id":"hgnc:HGNC:11867","description":"transmembrane protein with EGF like and two follistatin like domains 2","metadata":{"aliases":["TENB2","HPP1","TR","TPEF","CT120.2"]}},{"id":"ebbeeeb87a8040c5ac22a7026c6acc89","type":"GENE","name":"TMEM100","canonical_id":"hgnc:HGNC:25607","description":"transmembrane protein 100","metadata":{"aliases":["FLJ10970","FLJ37856"]}},{"id":"83c8700937d74c2daed33a0e81051dda","type":"GENE","name":"TMEM101","canonical_id":"hgnc:HGNC:28653","description":"transmembrane protein 101","metadata":{"aliases":["MGC4251","FLJ23987"]}},{"id":"c204f1d65cf24df7bd970a61ad2fe956","type":"GENE","name":"TMEM102","canonical_id":"hgnc:HGNC:26722","description":"transmembrane protein 102","metadata":{"aliases":["FLJ36878","CBAP","D2B"]}},{"id":"53d8777d79e5463e8ae174fd25febe6e","type":"GENE","name":"TMEM105","canonical_id":"hgnc:HGNC:26794","description":"TMEM105 long non-coding RNA","metadata":{"aliases":["FLJ38792"]}},{"id":"6dd93c3940ae466fa1a7e5ac96a9c55c","type":"GENE","name":"TMEM106A","canonical_id":"hgnc:HGNC:28288","description":"transmembrane protein 106A","metadata":{"aliases":["MGC20235"]}},{"id":"f8e10b8212ea4a22abc81ec71eb15174","type":"GENE","name":"TMEM106B","canonical_id":"hgnc:HGNC:22407","description":"transmembrane protein 106B","metadata":{"aliases":["MGC33727","FLJ11273"]}},{"id":"9a87496efc3142bd8f2499a832e224b4","type":"GENE","name":"TMEM106C","canonical_id":"hgnc:HGNC:28775","description":"transmembrane protein 106C","metadata":{"aliases":["MGC5576"]}},{"id":"adc641aee79e45409f57b76ff6f5234e","type":"GENE","name":"TMEM107","canonical_id":"hgnc:HGNC:28128","description":"transmembrane protein 107","metadata":{"aliases":["MGC10744","JBTS29","MKS13"]}},{"id":"7d1f9f64664b40488bd5da5c81b86ea9","type":"GENE","name":"TMEM108","canonical_id":"hgnc:HGNC:28451","description":"transmembrane protein 108","metadata":{"aliases":["RTLN","MGC3040","CT124"]}},{"id":"3e7a74c4ecde479084b09b0ee33bc016","type":"GENE","name":"TMEM108-AS1","canonical_id":"hgnc:HGNC:50307","description":"TMEM108 antisense RNA 1","metadata":null},{"id":"0941e8f8a83c4ecbb0913f5fa8340f0e","type":"GENE","name":"TMEM109","canonical_id":"hgnc:HGNC:28771","description":"transmembrane protein 109","metadata":{"aliases":["MGC5508","SND3","hSND3","Mg23"]}},{"id":"eba704dbb97c46e38ef4b198d9c23fa2","type":"GENE","name":"TMEM109-DT","canonical_id":"hgnc:HGNC:55487","description":"TMEM109 divergent transcript","metadata":null},{"id":"3b7bbf5e2bf14519bcda58d750fafd8d","type":"GENE","name":"TMEM11","canonical_id":"hgnc:HGNC:16823","description":"transmembrane protein 11","metadata":{"aliases":["PMI","PM1","C17orf35"]}},{"id":"89afc3d7b49c4ed1b7f58e988e5beb1c","type":"GENE","name":"TMEM11-DT","canonical_id":"hgnc:HGNC:55671","description":"TMEM11 divergent transcript","metadata":null},{"id":"7a5fe01311664374bd3cca2a55a67d7f","type":"GENE","name":"TMEM114","canonical_id":"hgnc:HGNC:33227","description":"transmembrane protein 114","metadata":null},{"id":"677a838bd3624ef5bc35c0890fea7635","type":"GENE","name":"TMEM115","canonical_id":"hgnc:HGNC:30055","description":"transmembrane protein 115","metadata":{"aliases":["PL6"]}},{"id":"8ca4cf81affe4677b3132134de60f0a1","type":"GENE","name":"TMEM116","canonical_id":"hgnc:HGNC:25084","description":"transmembrane protein 116","metadata":{"aliases":["FLJ90167"]}},{"id":"7a7bd37ddf284257b7a28d116afc6fa2","type":"GENE","name":"TMEM117","canonical_id":"hgnc:HGNC:25308","description":"transmembrane protein 117","metadata":{"aliases":["DKFZp434K2435"]}},{"id":"b7ee63b275a54cafb57dabfa4349c057","type":"GENE","name":"TMEM119","canonical_id":"hgnc:HGNC:27884","description":"transmembrane protein 119","metadata":{"aliases":["OBIF"]}},{"id":"874c0f78e6ec4981990a787d65f6b835","type":"GENE","name":"TMEM120A","canonical_id":"hgnc:HGNC:21697","description":"transmembrane protein 120A","metadata":{"aliases":["TMPIT","NET29","TACAN"]}},{"id":"cf3b088708454bc69c30177498282c21","type":"GENE","name":"TMEM120B","canonical_id":"hgnc:HGNC:32008","description":"transmembrane protein 120B","metadata":null},{"id":"7ae3100f48b04ca9ad7b7b4ab0b1394e","type":"GENE","name":"TMEM121","canonical_id":"hgnc:HGNC:20511","description":"transmembrane protein 121","metadata":{"aliases":["MGC4659","hole","hhole","TMEM121A"]}},{"id":"3282780152284e66a895043b64018ca3","type":"GENE","name":"TMEM121B","canonical_id":"hgnc:HGNC:1844","description":"transmembrane protein 121B","metadata":{"aliases":["CECR6"]}},{"id":"f8b091fc4fc64c588667b0493f6d0fa6","type":"GENE","name":"TMEM123","canonical_id":"hgnc:HGNC:30138","description":"transmembrane protein 123","metadata":{"aliases":["PORIMIN","KCT3"]}},{"id":"804764d5d416462b9d518c6918dbef75","type":"GENE","name":"TMEM123-DT","canonical_id":"hgnc:HGNC:55502","description":"TMEM123 divergent transcript","metadata":null},{"id":"9661ee4211e543f28063761f8c74ad87","type":"GENE","name":"TMEM125","canonical_id":"hgnc:HGNC:28275","description":"transmembrane protein 125","metadata":{"aliases":["MGC17299"]}},{"id":"3bde5fae5349404597996fa747a96c7e","type":"GENE","name":"TMEM126A","canonical_id":"hgnc:HGNC:25382","description":"transmembrane protein 126A","metadata":{"aliases":["DKFZp586C1924","OPA7"]}},{"id":"65916be31139404cbe320a9c9ee98f01","type":"GENE","name":"TMEM126B","canonical_id":"hgnc:HGNC:30883","description":"transmembrane protein 126B","metadata":{"aliases":["HT007"]}},{"id":"3f08b415ea064f5ca2d9ca17d403f2fc","type":"GENE","name":"TMEM127","canonical_id":"hgnc:HGNC:26038","description":"transmembrane protein 127","metadata":{"aliases":["FLJ20507","FLJ22257"]}},{"id":"0025bf1c7f464bc2af4e9f715f5e283f","type":"GENE","name":"TMEM128","canonical_id":"hgnc:HGNC:28201","description":"transmembrane protein 128","metadata":{"aliases":["MGC13159"]}},{"id":"1c7b8a01da644444a9824dc033796d13","type":"GENE","name":"TMEM128-DT","canonical_id":"hgnc:HGNC:58718","description":"TMEM128 divergent transcript","metadata":null},{"id":"30a9bf6a155e464b8f44d397cfa36468","type":"GENE","name":"TMEM129","canonical_id":"hgnc:HGNC:25137","description":"transmembrane protein 129, E3 ubiquitin ligase","metadata":{"aliases":["D4S2561E"]}},{"id":"a270a511496f4eb0a08e57b1dc055e94","type":"GENE","name":"TMEM130","canonical_id":"hgnc:HGNC:25429","description":"transmembrane protein 130","metadata":{"aliases":["DKFZp761L1417","FLJ42643"]}},{"id":"49e379dcae434eef8e2ad22ee41abdde","type":"GENE","name":"TMEM131","canonical_id":"hgnc:HGNC:30366","description":"transmembrane protein 131","metadata":{"aliases":["CC28","YR-23","RW1","KIAA0257","PRO1048"]}},{"id":"cb37f16cdb9648909afa00ccea11c2dc","type":"GENE","name":"TMEM131L","canonical_id":"hgnc:HGNC:29146","description":"transmembrane 131 like","metadata":{"aliases":["DKFZp586H1322","KIAA0922"]}},{"id":"b21b68c5cd504586b967875be8bdfd70","type":"GENE","name":"TMEM131L-AS1","canonical_id":"hgnc:HGNC:58899","description":"TMEM131L antisense RNA 1","metadata":null},{"id":"adf02df92eea4831b192fa4b51e95641","type":"GENE","name":"TMEM132A","canonical_id":"hgnc:HGNC:31092","description":"transmembrane protein 132A","metadata":{"aliases":["GBP","FLJ20539","HSPA5BP1"]}},{"id":"887e40c2470942edaad2d3d3eba98dfd","type":"GENE","name":"TMEM132B","canonical_id":"hgnc:HGNC:29397","description":"transmembrane protein 132B","metadata":{"aliases":["KIAA1906","KIAA1786"]}},{"id":"4bc81e52dca0413fb49621e08bb28518","type":"GENE","name":"TMEM132C","canonical_id":"hgnc:HGNC:25436","description":"transmembrane protein 132C","metadata":{"aliases":["DKFZp761O2018","PPP1R152"]}},{"id":"ef2e42dfccc146ec85b06512c3e5a23c","type":"GENE","name":"TMEM132D","canonical_id":"hgnc:HGNC:29411","description":"transmembrane protein 132D","metadata":{"aliases":["KIAA1944","MOLT","PPP1R153"]}},{"id":"ac1726f2c4454d39ab650d7e1e7aac5e","type":"GENE","name":"TMEM132D-AS1","canonical_id":"hgnc:HGNC:27466","description":"TMEM132D antisense RNA 1","metadata":{"aliases":["LOC283352","RP11-669N7.2"]}},{"id":"3fc22f1872974efab446392693bbd227","type":"GENE","name":"TMEM132D-AS2","canonical_id":"hgnc:HGNC:53324","description":"TMEM132D antisense RNA 2","metadata":null},{"id":"1277ecbec92e43f4b65b2181715fb650","type":"GENE","name":"TMEM132E","canonical_id":"hgnc:HGNC:26991","description":"transmembrane protein 132E","metadata":{"aliases":["DFNB99"]}},{"id":"6f26ce634e2e42fc957cd7b5a83fc115","type":"GENE","name":"TMEM132E-DT","canonical_id":"hgnc:HGNC:34412","description":"TMEM132E divergent transcript","metadata":{"aliases":["FLJ44815","C17orf102"]}},{"id":"b8cf619b893247cdafe2b86a4bd1e354","type":"GENE","name":"TMEM134","canonical_id":"hgnc:HGNC:26142","description":"transmembrane protein 134","metadata":{"aliases":["FLJ21749"]}},{"id":"c6005e811f2b47eab38fec89c0edd42d","type":"GENE","name":"TMEM135","canonical_id":"hgnc:HGNC:26167","description":"transmembrane protein 135","metadata":{"aliases":["FLJ22104","PMP52"]}},{"id":"308ddf45041146ccb1b866b8debe2b21","type":"GENE","name":"TMEM138","canonical_id":"hgnc:HGNC:26944","description":"transmembrane protein 138","metadata":{"aliases":["HSPC196","JBTS16"]}},{"id":"111b994fd19d4deab05169c8d7695579","type":"GENE","name":"TMEM139","canonical_id":"hgnc:HGNC:22058","description":"transmembrane protein 139","metadata":{"aliases":["FLJ90586"]}},{"id":"f003ebc6a1304aff89d983673c298fe1","type":"GENE","name":"TMEM139-AS1","canonical_id":"hgnc:HGNC:40988","description":"TMEM139 antisense RNA 1","metadata":null},{"id":"db744aebbe814d49a2c3d126f43f3dd3","type":"GENE","name":"TMEM140","canonical_id":"hgnc:HGNC:21870","description":"transmembrane protein 140","metadata":{"aliases":["FLJ11000"]}},{"id":"34110b818b744dc5a41039bbe70eac49","type":"GENE","name":"TMEM141","canonical_id":"hgnc:HGNC:28211","description":"transmembrane protein 141","metadata":{"aliases":["MGC14141"]}},{"id":"f0efa64bafee4e289e84be8e2f823f26","type":"GENE","name":"TMEM143","canonical_id":"hgnc:HGNC:25603","description":"transmembrane protein 143","metadata":{"aliases":["FLJ10922"]}},{"id":"9275de58ab7c41ffb995aba2b633c2de","type":"GENE","name":"TMEM144","canonical_id":"hgnc:HGNC:25633","description":"transmembrane protein 144","metadata":{"aliases":["FLJ11155","SLC35G7"]}},{"id":"98c1e548268b4257afac752b8492622d","type":"GENE","name":"TMEM145","canonical_id":"hgnc:HGNC:26912","description":"transmembrane protein 145","metadata":{"aliases":["FLJ90805"]}},{"id":"a742e3c9b8544bc6a52eff340e0c76c9","type":"GENE","name":"TMEM147","canonical_id":"hgnc:HGNC:30414","description":"transmembrane protein 147","metadata":{"aliases":["NIFIE14","MGC1936"]}},{"id":"ba075bab3cec45d9913da526b2b9e0f8","type":"GENE","name":"TMEM147-AS1","canonical_id":"hgnc:HGNC:51273","description":"TMEM147 antisense RNA 1","metadata":null},{"id":"9ef1d16aec764f2baf273230758f9a05","type":"GENE","name":"TMEM14A","canonical_id":"hgnc:HGNC:21076","description":"transmembrane protein 14A","metadata":{"aliases":["PTD011","C6orf73"]}},{"id":"747ba55bbc2448b792e9f5246aabf80b","type":"GENE","name":"TMEM14B","canonical_id":"hgnc:HGNC:21384","description":"transmembrane protein 14B","metadata":{"aliases":["MGC1223"]}},{"id":"c0ce752fda7249b98a15c88b57f8da34","type":"GENE","name":"TMEM14B-DT","canonical_id":"hgnc:HGNC:55230","description":"TMEM14B divergent transcript","metadata":null},{"id":"baf8a8edf0eb43b9b72c6a5317aa9335","type":"GENE","name":"TMEM14C","canonical_id":"hgnc:HGNC:20952","description":"transmembrane protein 14C","metadata":{"aliases":["HSPC194","bA421M1.6","NET26","C6orf53"]}},{"id":"0049d953fa2a4f99bc77571577c42463","type":"GENE","name":"TMEM14DP","canonical_id":"hgnc:HGNC:15660","description":"transmembrane protein 14D, pseudogene","metadata":{"aliases":["bA524O24.3","TMEM14D"]}},{"id":"ed222b8a0cc2456ba1f234966d733c40","type":"GENE","name":"TMEM14EP","canonical_id":"hgnc:HGNC:34386","description":"transmembrane protein 14E, pseudogene","metadata":{"aliases":["TMEM14E"]}},{"id":"8b420e90b3fb4fd89d1273548f55a3b8","type":"GENE","name":"TMEM150A","canonical_id":"hgnc:HGNC:24677","description":"transmembrane protein 150A","metadata":{"aliases":["DRAM5","TM6P1","FLJ90024","TTN1","TMEM150"]}},{"id":"bd1b989b30084327a32a1388e87fb22e","type":"GENE","name":"TMEM150B","canonical_id":"hgnc:HGNC:34415","description":"transmembrane protein 150B","metadata":{"aliases":["TTN2","DRAM3","TMEM224"]}},{"id":"7fcb8766082a458e99d6d2639aaa46c4","type":"GENE","name":"TMEM150C","canonical_id":"hgnc:HGNC:37263","description":"transmembrane protein 150C","metadata":{"aliases":["DRAM4","FLJ12993","TTN3"]}},{"id":"0f82c80ca1784354a4c4daf4cdebb5ee","type":"GENE","name":"TMEM150C-AS1","canonical_id":"hgnc:HGNC:58837","description":"TMEM150C antisense RNA 1","metadata":null},{"id":"53527cf78ab743109011cab84640406f","type":"GENE","name":"TMEM151A","canonical_id":"hgnc:HGNC:28497","description":"transmembrane protein 151A","metadata":{"aliases":["MGC33486","TMEM151"]}},{"id":"b5943b2337fc4967a4c4ab6fd54aa79d","type":"GENE","name":"TMEM151B","canonical_id":"hgnc:HGNC:21315","description":"transmembrane protein 151B","metadata":{"aliases":["bA444E17.5","C6orf137","TMEM193"]}},{"id":"4a884e9840414158aafe9b92dc30305d","type":"GENE","name":"TMEM154","canonical_id":"hgnc:HGNC:26489","description":"transmembrane protein 154","metadata":{"aliases":["FLJ32028"]}},{"id":"b403eb30832443fa810fbb89423a7407","type":"GENE","name":"TMEM154-AS1","canonical_id":"hgnc:HGNC:58413","description":"TMEM154 antisense RNA 1","metadata":null},{"id":"a1e81a0242df4d0c8dbf33a4397d2047","type":"GENE","name":"TMEM154-AS2","canonical_id":"hgnc:HGNC:58896","description":"TMEM154 antisense RNA 2","metadata":null},{"id":"0a0858094dda466a8c0266555a1f2457","type":"GENE","name":"TMEM156","canonical_id":"hgnc:HGNC:26260","description":"transmembrane protein 156","metadata":{"aliases":["FLJ23235"]}},{"id":"343bac37d4a348f0bde909b118c1bbf4","type":"GENE","name":"TMEM158","canonical_id":"hgnc:HGNC:30293","description":null,"metadata":null},{"id":"6d4c350a01214d0781107df890650b69","type":"GENE","name":"TMEM160","canonical_id":"hgnc:HGNC:26042","description":"transmembrane protein 160","metadata":{"aliases":["FLJ20512"]}},{"id":"33a80b3012b94d1e8e801a80a54131cf","type":"GENE","name":"TMEM161A","canonical_id":"hgnc:HGNC:26020","description":"transmembrane protein 161A","metadata":{"aliases":["FLJ39645","FLJ20422"]}},{"id":"f3bf53cd8041401b8ddedde8d13df83e","type":"GENE","name":"TMEM161B","canonical_id":"hgnc:HGNC:28483","description":"transmembrane protein 161B","metadata":{"aliases":["MGC33214"]}},{"id":"2fc7a0e0964b4b77b699101bd7516a6d","type":"GENE","name":"TMEM161B-DT","canonical_id":"hgnc:HGNC:43839","description":"TMEM161B divergent transcript","metadata":{"aliases":["uc.165","linc-POLR3G-8","TMEM161B-AS1"]}},{"id":"d85b25cc2dc945f2bfc551efa079a042","type":"GENE","name":"TMEM161BP1","canonical_id":"hgnc:HGNC:44973","description":"transmembrane protein 161B pseudogene 1","metadata":null},{"id":"ed7eea44f23a452fa9310d6cd6608068","type":"GENE","name":"TMEM163","canonical_id":"hgnc:HGNC:25380","description":"transmembrane protein 163","metadata":{"aliases":["DKFZP566N034","SV31","SLC30A11"]}},{"id":"3d4393c319aa443297305228578e7a64","type":"GENE","name":"TMEM164","canonical_id":"hgnc:HGNC:26217","description":"transmembrane protein 164","metadata":{"aliases":["FLJ22679","RP13-360B22.2"]}},{"id":"b08a98b1a9e04119acf54a268d00e7a1","type":"GENE","name":"TMEM165","canonical_id":"hgnc:HGNC:30760","description":"transmembrane protein 165","metadata":{"aliases":["TMPT27","TPARL","GDT1","SLC64A1"]}},{"id":"eb47cffde2804e8e8df797afd39db3a9","type":"GENE","name":"TMEM167A","canonical_id":"hgnc:HGNC:28330","description":"transmembrane protein 167A","metadata":{"aliases":["FLJ30508","MGC23909","kish","TMEM167"]}},{"id":"183c76035aee4922a0250c60dcee0012","type":"GENE","name":"TMEM167AP1","canonical_id":"hgnc:HGNC:23956","description":"transmembrane protein 167A pseudogene 1","metadata":null},{"id":"73e647dc35334f23ae3e08f489afd1a5","type":"GENE","name":"TMEM167AP2","canonical_id":"hgnc:HGNC:55999","description":"TMEM167A pseudogene 2","metadata":null},{"id":"5400d0d2368d41a29b752d4afea040ff","type":"GENE","name":"TMEM167B","canonical_id":"hgnc:HGNC:30187","description":"transmembrane protein 167B","metadata":{"aliases":["AD-020","FLJ90710","C1orf119"]}},{"id":"18413dcfefdd4172ad977985fee3b8e6","type":"GENE","name":"TMEM167B-DT","canonical_id":"hgnc:HGNC:55076","description":"TMEM167B divergent transcript","metadata":null},{"id":"d9f66629ae34434891f6b49b4558a5c2","type":"GENE","name":"TMEM168","canonical_id":"hgnc:HGNC:25826","description":"transmembrane protein 168","metadata":{"aliases":["DKFZp564C012","FLJ13576"]}},{"id":"1710724400d244f5b232ac05dca276ab","type":"GENE","name":"TMEM169","canonical_id":"hgnc:HGNC:25130","description":"transmembrane protein 169","metadata":{"aliases":["FLJ34263"]}},{"id":"4d93020833794c3f8f03bceaef9aeb6d","type":"GENE","name":"TMEM17","canonical_id":"hgnc:HGNC:26623","description":"transmembrane protein 17","metadata":{"aliases":["FLJ34583"]}},{"id":"a9a50bf4c7714698ba62c8c4efbd662d","type":"GENE","name":"TMEM170A","canonical_id":"hgnc:HGNC:29577","description":"transmembrane protein 170A","metadata":{"aliases":["FLJ37611","TMEM170"]}},{"id":"708a8086d6ca4e5bb94cde4bd6303966","type":"GENE","name":"TMEM170B","canonical_id":"hgnc:HGNC:34244","description":"transmembrane protein 170B","metadata":null},{"id":"6cd0dd92051f4410a61a678662d75d3f","type":"GENE","name":"TMEM171","canonical_id":"hgnc:HGNC:27031","description":"transmembrane protein 171","metadata":{"aliases":["PRP2"]}},{"id":"677040bcef3d49d4a73341737ff8a7fe","type":"GENE","name":"TMEM174","canonical_id":"hgnc:HGNC:28187","description":"transmembrane protein 174","metadata":{"aliases":["MGC13034","FLJ31268"]}},{"id":"12b313dcadda480aa3f154600a7e17ba","type":"GENE","name":"TMEM175","canonical_id":"hgnc:HGNC:28709","description":"transmembrane protein 175","metadata":{"aliases":["MGC4618"]}},{"id":"fb090daaadea4ae4b61ab4b850e6c4ff","type":"GENE","name":"TMEM176A","canonical_id":"hgnc:HGNC:24930","description":"transmembrane protein 176A","metadata":{"aliases":["HCA112","MS4B1"]}},{"id":"aa44c7c2863b479bbbc7fba16b59c8db","type":"GENE","name":"TMEM176B","canonical_id":"hgnc:HGNC:29596","description":"transmembrane protein 176B","metadata":{"aliases":["LR8","MS4B2"]}},{"id":"dfd0bc50d1fc42429e13610e6900c064","type":"GENE","name":"TMEM177","canonical_id":"hgnc:HGNC:28143","description":"transmembrane protein 177","metadata":{"aliases":["MGC10993"]}},{"id":"bd732edbb267484ba500d9ad0075848b","type":"GENE","name":"TMEM178A","canonical_id":"hgnc:HGNC:28517","description":"transmembrane protein 178A","metadata":{"aliases":["MGC33926","TMEM178"]}},{"id":"e4ae7456c0824c8d9ee252bf9f1d02f3","type":"GENE","name":"TMEM178B","canonical_id":"hgnc:HGNC:44112","description":"transmembrane protein 178B","metadata":{"aliases":["DKFZp547G036"]}},{"id":"44299ef3189641369fce4de55c50998b","type":"GENE","name":"TMEM179","canonical_id":"hgnc:HGNC:20137","description":"transmembrane protein 179","metadata":{"aliases":["FLJ42486","TMEM179A","C14orf90"]}},{"id":"5540940480404c6a9370eae029e3011c","type":"GENE","name":"TMEM179B","canonical_id":"hgnc:HGNC:33744","description":"transmembrane protein 179B","metadata":null},{"id":"1f73a5b123a6432094024b36cef30f45","type":"GENE","name":"TMEM18","canonical_id":"hgnc:HGNC:25257","description":"transmembrane protein 18","metadata":{"aliases":["DKFZp434C1714","lncND"]}},{"id":"6de1ce918e8a4bcca94fbed99192f39b","type":"GENE","name":"TMEM18-DT","canonical_id":"hgnc:HGNC:54481","description":"TMEM18 divergent transcript","metadata":{"aliases":["AC092159.2"]}},{"id":"71443c28ca8348b0a8a953c049db7f57","type":"GENE","name":"TMEM181","canonical_id":"hgnc:HGNC:20958","description":"transmembrane protein 181","metadata":{"aliases":["KIAA1423","GPR178"]}},{"id":"790c84515a5f44e3b558e8afa36a5b2d","type":"GENE","name":"TMEM182","canonical_id":"hgnc:HGNC:26391","description":"transmembrane protein 182","metadata":{"aliases":["FLJ30294"]}},{"id":"1b4f97d568914d84996276c578458429","type":"GENE","name":"TMEM183A","canonical_id":"hgnc:HGNC:20173","description":"transmembrane protein 183A","metadata":{"aliases":["C1orf37"]}},{"id":"ac377e7a37664038aeb941ac7852cca9","type":"GENE","name":"TMEM183AP1","canonical_id":"hgnc:HGNC:33458","description":"TMEM183A pseudogene 1","metadata":{"aliases":["BPG126D10.10","OTTHUMG00000086663"]}},{"id":"b6c3f9ba00d545baa3ccc604d33b18c5","type":"GENE","name":"TMEM183AP2","canonical_id":"hgnc:HGNC:56453","description":"TMEM183A pseudogene 2","metadata":null},{"id":"96b0733d1185402c8d43c00a775a6ccc","type":"GENE","name":"TMEM183AP3","canonical_id":"hgnc:HGNC:56454","description":"TMEM183A pseudogene 3","metadata":null},{"id":"b02317c8017b4acbbf22fb71432a624c","type":"GENE","name":"TMEM183AP4","canonical_id":"hgnc:HGNC:56455","description":"TMEM183A pseudogene 4","metadata":null},{"id":"f4a69c5bf47445759c3404e6cec4478a","type":"GENE","name":"TMEM183AP5","canonical_id":"hgnc:HGNC:56456","description":"TMEM183A pseudogene 5","metadata":null},{"id":"eab3c95e25934680b56db50d40a0cc7e","type":"GENE","name":"TMEM183AP6","canonical_id":"hgnc:HGNC:56457","description":"TMEM183A pseudogene 6","metadata":null},{"id":"c9f78ef6a2cc4047a3e4494faa846ca2","type":"GENE","name":"TMEM183BP","canonical_id":"hgnc:HGNC:33205","description":"transmembrane protein 183B, pseudogene","metadata":{"aliases":["C1orf37-DUP","TMEM183B"]}},{"id":"8b21b6e79cab4bfb9c4dd7d27302c04c","type":"GENE","name":"TMEM184A","canonical_id":"hgnc:HGNC:28797","description":"transmembrane protein 184A","metadata":{"aliases":["MGC9712","SDMG1","SLC51C1"]}},{"id":"48a0b57b2fdb44068eb7b62078cd68e9","type":"GENE","name":"TMEM184B","canonical_id":"hgnc:HGNC:1310","description":"transmembrane protein 184B","metadata":{"aliases":["HS5O6A","DKFZP586A1024","FM08","SLC51C2","C22orf5"]}},{"id":"94e3ac1cccee4b759088b6d70acd79e3","type":"GENE","name":"TMEM184B-AS1","canonical_id":"hgnc:HGNC:56716","description":"TMEM184B antisense RNA 1","metadata":{"aliases":["RP1-5O6.5","RP1"]}},{"id":"4e7014c1ab2145409a93a07976e4944f","type":"GENE","name":"TMEM184C","canonical_id":"hgnc:HGNC:25587","description":"transmembrane protein 184C","metadata":{"aliases":["FLJ10846","SLC51C3","TMEM34"]}},{"id":"251eb9d8c5914db6aa70eae8c3e538e9","type":"GENE","name":"TMEM184C-DT","canonical_id":"hgnc:HGNC:55544","description":"TMEM184C divergent transcript","metadata":{"aliases":["loc105377478"]}},{"id":"130954c3c0784895a86f15e69d5569b0","type":"GENE","name":"TMEM184CP1","canonical_id":"hgnc:HGNC:55010","description":"TMEM184C pseudogene 1","metadata":null},{"id":"526ab1f21225495d99193e4f7e975858","type":"GENE","name":"TMEM185A","canonical_id":"hgnc:HGNC:17125","description":"transmembrane protein 185A","metadata":{"aliases":["CXorf13","FAM11A","FRAXF"]}},{"id":"126bb3c52ffb4a23ad74e8821e2790a1","type":"GENE","name":"TMEM185AP1","canonical_id":"hgnc:HGNC:31717","description":"transmembrane protein 185A pseudogene 1","metadata":{"aliases":["TMEM185AL"]}},{"id":"fc03a9abb15e4e47b919e09ae18390ec","type":"GENE","name":"TMEM185B","canonical_id":"hgnc:HGNC:18896","description":"transmembrane protein 185B","metadata":{"aliases":["FLJ20979","FAM11B"]}},{"id":"2257938068c04a208bb234409c2e698a","type":"GENE","name":"TMEM186","canonical_id":"hgnc:HGNC:24530","description":"transmembrane protein 186","metadata":{"aliases":["DKFZP564K2062","C16orf51"]}},{"id":"122329819bca4a518721a7128d1ce223","type":"GENE","name":"TMEM187","canonical_id":"hgnc:HGNC:13705","description":"transmembrane protein 187","metadata":{"aliases":["ITBA1","DXS9878E","CXorf12"]}},{"id":"46fdf2e02d0f4addb2406f1b9604035a","type":"GENE","name":"TMEM190","canonical_id":"hgnc:HGNC:29632","description":"transmembrane protein 190","metadata":{"aliases":["MDAC1"]}},{"id":"4cfdc63676104f2f9842ac864342178a","type":"GENE","name":"TMEM191A","canonical_id":"hgnc:HGNC:25317","description":"transmembrane protein 191A (pseudogene)","metadata":{"aliases":["DKFZp434N035","TMEM191AP"]}},{"id":"1bc082aefdd34849ba6f6ebdd8c14daa","type":"GENE","name":"TMEM191B","canonical_id":"hgnc:HGNC:33600","description":"transmembrane protein 191B","metadata":null},{"id":"5d2dd0519c4249ad973945aeabeed99c","type":"GENE","name":"TMEM191C","canonical_id":"hgnc:HGNC:33601","description":"transmembrane protein 191C","metadata":null},{"id":"ddcf221d1df0426dabef00bf2b48eedd","type":"GENE","name":"TMEM192","canonical_id":"hgnc:HGNC:26775","description":"transmembrane protein 192","metadata":{"aliases":["FLJ38482"]}},{"id":"02a5c6a3f58740f69649b461c20bacd1","type":"GENE","name":"TMEM196","canonical_id":"hgnc:HGNC:22431","description":"transmembrane protein 196","metadata":{"aliases":["MGC42090"]}},{"id":"11046da541a041feb7513613cda4e43f","type":"GENE","name":"TMEM198","canonical_id":"hgnc:HGNC:33704","description":"transmembrane protein 198","metadata":{"aliases":["MGC99813","TMEM198A"]}},{"id":"a91c9cc428d34f5c9877a2252aeb8d85","type":"GENE","name":"TMEM198B","canonical_id":"hgnc:HGNC:43629","description":"transmembrane protein 198B (pseudogene)","metadata":null},{"id":"45005f15323e42d28eee473e62d98754","type":"GENE","name":"TMEM200A","canonical_id":"hgnc:HGNC:21075","description":"transmembrane protein 200A","metadata":{"aliases":["TTMC","KIAA1913"]}},{"id":"1efff652c7b641bc8f78d531bb8ced75","type":"GENE","name":"TMEM200B","canonical_id":"hgnc:HGNC:33785","description":"transmembrane protein 200B","metadata":{"aliases":["TTMB"]}},{"id":"12dc824ad5ff4934bda8205b98927494","type":"GENE","name":"TMEM200C","canonical_id":"hgnc:HGNC:37208","description":"transmembrane protein 200C","metadata":{"aliases":["TTMA"]}},{"id":"5845c40e3adb4673a144cdb2e2157062","type":"GENE","name":"TMEM201","canonical_id":"hgnc:HGNC:33719","description":"transmembrane protein 201","metadata":{"aliases":["RP13-15M17.2","NET5","Ima1","SAMP1"]}},{"id":"eadc9222306f4e2cb7de472d207ffa60","type":"GENE","name":"TMEM202","canonical_id":"hgnc:HGNC:33733","description":"transmembrane protein 202","metadata":{"aliases":["FLJ27523"]}},{"id":"64c474c10a5b461d98de25e163c87288","type":"GENE","name":"TMEM202-AS1","canonical_id":"hgnc:HGNC:53265","description":"TMEM202 antisense RNA 1","metadata":null},{"id":"4e7d910d74f449529f0f55dd97cb8cef","type":"GENE","name":"TMEM203","canonical_id":"hgnc:HGNC:28217","description":"transmembrane protein 203","metadata":{"aliases":["MGC14327","HBEBP1"]}},{"id":"98ac4093a5424e1486ffd9fd8f7b51f1","type":"GENE","name":"TMEM204","canonical_id":"hgnc:HGNC:14158","description":"transmembrane protein 204","metadata":{"aliases":["FLJ20898","CLP24","C16orf30"]}},{"id":"56cb5387b92644d2bd1a2a585f9184d7","type":"GENE","name":"TMEM205","canonical_id":"hgnc:HGNC:29631","description":"transmembrane protein 205","metadata":{"aliases":["UNQ501","MBC3205"]}},{"id":"a2a3832278004b91b6d17375137dff28","type":"GENE","name":"TMEM207","canonical_id":"hgnc:HGNC:33705","description":"transmembrane protein 207","metadata":null},{"id":"0857b101205843968e5133b05c400807","type":"GENE","name":"TMEM208","canonical_id":"hgnc:HGNC:25015","description":"transmembrane protein 208","metadata":{"aliases":["HSPC171","hSND2","SND2"]}},{"id":"21d71f94e33a4a88a6b0a2dfb7f06b37","type":"GENE","name":"TMEM209","canonical_id":"hgnc:HGNC:21898","description":"transmembrane protein 209","metadata":{"aliases":["FLJ14803","NET31"]}},{"id":"97030f90cdb447c7a73c6bec3618ae20","type":"GENE","name":"TMEM210","canonical_id":"hgnc:HGNC:34059","description":"transmembrane protein 210","metadata":null},{"id":"c0c7e52feaf74caa9aaff817fd492d55","type":"GENE","name":"TMEM212","canonical_id":"hgnc:HGNC:34295","description":"transmembrane protein 212","metadata":{"aliases":["FLJ23172"]}},{"id":"dc5ec70e01294746bbe49839ffb940ab","type":"GENE","name":"TMEM212-AS1","canonical_id":"hgnc:HGNC:41939","description":"TMEM212 antisense RNA 1","metadata":null},{"id":"7f5956a3644e483db32613c9ed696990","type":"GENE","name":"TMEM212-IT1","canonical_id":"hgnc:HGNC:41505","description":"TMEM212 intronic transcript 1","metadata":null},{"id":"fdc0cef6af094d27aef33a46219e660b","type":"GENE","name":"TMEM213","canonical_id":"hgnc:HGNC:27220","description":"transmembrane protein 213","metadata":null},{"id":"70d1ab696744411f802bf663a470338b","type":"GENE","name":"TMEM214","canonical_id":"hgnc:HGNC:25983","description":"transmembrane protein 214","metadata":{"aliases":["FLJ20254"]}},{"id":"b39913d7bf78408a8e9ce6d93b61eb6c","type":"GENE","name":"TMEM215","canonical_id":"hgnc:HGNC:33816","description":"transmembrane protein 215","metadata":null},{"id":"9a4ee015748345b6a82403a661706ed9","type":"GENE","name":"TMEM216","canonical_id":"hgnc:HGNC:25018","description":"transmembrane protein 216","metadata":{"aliases":["MGC13379","HSPC244","JBTS2","CORS2","MKS2"]}},{"id":"de6af2d8178946ac94091f4ef641e9c6","type":"GENE","name":"TMEM217","canonical_id":"hgnc:HGNC:21238","description":"transmembrane protein 217","metadata":{"aliases":["dJ355M6.2","C6orf128"]}},{"id":"6d01da2807da4abe8695cb45381b3cf5","type":"GENE","name":"TMEM217B","canonical_id":"hgnc:HGNC:55922","description":"transmembrane protein 217B","metadata":null},{"id":"94d4378b95834c8ca2796e1002406619","type":"GENE","name":"TMEM218","canonical_id":"hgnc:HGNC:27344","description":"transmembrane protein 218","metadata":null},{"id":"ec68503211bc45dfa7f88cb4645dc7f1","type":"GENE","name":"TMEM219","canonical_id":"hgnc:HGNC:25201","description":"transmembrane protein 219","metadata":{"aliases":["IGFBP-3R"]}},{"id":"b60fc31254a34f18a05cfdafdb229c1f","type":"GENE","name":"TMEM220","canonical_id":"hgnc:HGNC:33757","description":"transmembrane protein 220","metadata":null},{"id":"03a609873ec4453b8fab4fce16e3f92f","type":"GENE","name":"TMEM220-AS1","canonical_id":"hgnc:HGNC:44357","description":"TMEM220 antisense RNA 1","metadata":null},{"id":"c323ff5a115943aaa96095647ed10e4a","type":"GENE","name":"TMEM221","canonical_id":"hgnc:HGNC:21943","description":"transmembrane protein 221","metadata":{"aliases":["Jiraiya"]}},{"id":"36d19a51f3be450f9fba54d1e57c8bea","type":"GENE","name":"TMEM222","canonical_id":"hgnc:HGNC:25363","description":"transmembrane protein 222","metadata":{"aliases":["DKFZP564D0478","C1orf160"]}},{"id":"6e4f4d88755147b7ba8624b3c1587a6e","type":"GENE","name":"TMEM223","canonical_id":"hgnc:HGNC:28464","description":"transmembrane protein 223","metadata":{"aliases":["MGC3196","Mrx15"]}},{"id":"001e18b10b6140508b2ba44d810edcc3","type":"GENE","name":"TMEM225","canonical_id":"hgnc:HGNC:32390","description":"transmembrane protein 225","metadata":{"aliases":["PMP22CD","PPP1R154","SPATA47"]}},{"id":"2637d219f62548d099288effef06adac","type":"GENE","name":"TMEM225B","canonical_id":"hgnc:HGNC:53075","description":"transmembrane protein 225B","metadata":null},{"id":"10228cd7aacd45f4ab0514326bf94aa6","type":"GENE","name":"TMEM229A","canonical_id":"hgnc:HGNC:37279","description":"transmembrane protein 229A","metadata":null},{"id":"e28ac5dda65e4cc19aa142facdb6988e","type":"GENE","name":"TMEM229B","canonical_id":"hgnc:HGNC:20130","description":"transmembrane protein 229B","metadata":{"aliases":["FLJ33387","C14orf83"]}},{"id":"5bacb4ac8d834e279a1827bbafb6e25f","type":"GENE","name":"TMEM229BP1","canonical_id":"hgnc:HGNC:56580","description":"TMEM229B pseudogene 1","metadata":null},{"id":"d1500e56bd394a5d8480f152c41df44f","type":"GENE","name":"TMEM230","canonical_id":"hgnc:HGNC:15876","description":"transmembrane protein 230","metadata":{"aliases":["HSPC274","C20orf30"]}},{"id":"1e2bae6870a54e8695e8e0fc8f8fa447","type":"GENE","name":"TMEM230P1","canonical_id":"hgnc:HGNC:55043","description":"TMEM230 pseudogene 1","metadata":null},{"id":"c8816515856c4bfd8592d478936f9ea7","type":"GENE","name":"TMEM230P2","canonical_id":"hgnc:HGNC:55044","description":"TMEM230 pseudogene 2","metadata":null},{"id":"6a9581bedf364d07a3a49c799497145f","type":"GENE","name":"TMEM231","canonical_id":"hgnc:HGNC:37234","description":"transmembrane protein 231","metadata":{"aliases":["FLJ22167","ALYE870","PRO1886","JBTS20","MKS11"]}},{"id":"153bd111602a47b4aa4b837f1ff205ef","type":"GENE","name":"TMEM231P1","canonical_id":"hgnc:HGNC:53870","description":"TMEM231 pseudogene 1","metadata":null},{"id":"f4fdbf127acb47b0a4626d547cd1e50c","type":"GENE","name":"TMEM232","canonical_id":"hgnc:HGNC:37270","description":"transmembrane protein 232","metadata":{"aliases":["FLJ43080"]}},{"id":"e398016cf6f34c8fbc31a869edb5f40f","type":"GENE","name":"TMEM233","canonical_id":"hgnc:HGNC:37219","description":"transmembrane protein 233","metadata":{"aliases":["IFITMD2","DSPB2"]}},{"id":"8a5dbb64b80349af84fb15f9b5006231","type":"GENE","name":"TMEM234","canonical_id":"hgnc:HGNC:28837","description":"transmembrane protein 234","metadata":{"aliases":["RP4-622L5","dJ622L5.7","FLJ90779","C1orf91"]}},{"id":"1032ee14564a4c2c883f8d54f73ffc43","type":"GENE","name":"TMEM235","canonical_id":"hgnc:HGNC:27563","description":"transmembrane protein 235","metadata":null},{"id":"ddead15eccbe4eb8bd7546eb05b7fd1f","type":"GENE","name":"TMEM236","canonical_id":"hgnc:HGNC:23473","description":"transmembrane protein 236","metadata":{"aliases":["bA16O1.2","bA162I21.2","FAM23B","FAM23A"]}},{"id":"9b755d60d5db423db2e045be29841161","type":"GENE","name":"TMEM237","canonical_id":"hgnc:HGNC:14432","description":"transmembrane protein 237","metadata":{"aliases":["JBTS14","ALS2CR4"]}},{"id":"23af76e0277d43b6bb4fd2a1153df672","type":"GENE","name":"TMEM238","canonical_id":"hgnc:HGNC:40042","description":"transmembrane protein 238","metadata":null},{"id":"eb4a2929844548aea15d6b7da4e26db4","type":"GENE","name":"TMEM238L","canonical_id":"hgnc:HGNC:44356","description":"transmembrane protein 238 like","metadata":{"aliases":["FORCP","LINC00675"]}},{"id":"204a3d5896cb4457a89ab1ff916f3726","type":"GENE","name":"TMEM239","canonical_id":"hgnc:HGNC:40044","description":"transmembrane protein 239","metadata":null},{"id":"e01fefd35758409d8fe2a842e0792312","type":"GENE","name":"TMEM240","canonical_id":"hgnc:HGNC:25186","description":"transmembrane protein 240","metadata":{"aliases":["C1orf70","SCA21"]}},{"id":"2e1a30dd262d459690b574db9d779a3c","type":"GO_TERM","name":"TMEM240-body","canonical_id":"go:GO:0160045","description":"\"A multilamellar subcellular structure formed in the cytoplasm of developing neuron, composed of Tmem240 and Emd proteins.\" [PMID:32535204]","metadata":null},{"id":"7ec41a71f3674dac8ec3af877159d06d","type":"GENE","name":"TMEM242","canonical_id":"hgnc:HGNC:17206","description":"transmembrane protein 242","metadata":{"aliases":["BM033","C6orf35"]}},{"id":"91fc08101024449ab96ddd63ff2d7e83","type":"GENE","name":"TMEM242-DT","canonical_id":"hgnc:HGNC:55260","description":"TMEM242 divergent transcript","metadata":null},{"id":"33a95772eb234071be0eeb5a491c0024","type":"GENE","name":"TMEM243","canonical_id":"hgnc:HGNC:21707","description":"transmembrane protein 243","metadata":{"aliases":["MGC4175","MM-TRAG","C7orf23"]}},{"id":"f93bd06f342e4d12a34dc0e03af9ce12","type":"GENE","name":"TMEM244","canonical_id":"hgnc:HGNC:21571","description":"transmembrane protein 244","metadata":{"aliases":["bA174C7.4","C6orf191"]}},{"id":"e7a337585f1345d9847beb024da8b7a9","type":"GENE","name":"TMEM245","canonical_id":"hgnc:HGNC:1363","description":"transmembrane protein 245","metadata":{"aliases":["CG-2","C9orf5"]}},{"id":"66b6689e3177403ab94d88732dfae665","type":"GENE","name":"TMEM246-AS1","canonical_id":"hgnc:HGNC:51191","description":"TMEM246 antisense RNA 1","metadata":null},{"id":"09091877fcdd4c249102cb869bda46ef","type":"GENE","name":"TMEM247","canonical_id":"hgnc:HGNC:42967","description":"transmembrane protein 247","metadata":null},{"id":"7a8f8a4c22bf400aa42e7bc76b8edc1d","type":"GENE","name":"TMEM248","canonical_id":"hgnc:HGNC:25476","description":"transmembrane protein 248","metadata":{"aliases":["FLJ10099","FLJ13090","C7orf42"]}},{"id":"5cc82d7440c84b82b7f5a10b15703473","type":"GENE","name":"TMEM248P1","canonical_id":"hgnc:HGNC:44053","description":"transmembrane protein 248 pseudogene 1","metadata":null},{"id":"99e018a5511448bc990f0ab0afbe7937","type":"GENE","name":"TMEM25","canonical_id":"hgnc:HGNC:25890","description":"transmembrane protein 25","metadata":{"aliases":["FLJ14399"]}},{"id":"21325dcb24864fa9b8ef765b1bd84465","type":"GENE","name":"TMEM250","canonical_id":"hgnc:HGNC:31009","description":"transmembrane protein 250","metadata":{"aliases":["bA83N9.1","C9orf69"]}},{"id":"5ad137e197cf430eb074c68f30cd1c92","type":"GENE","name":"TMEM252","canonical_id":"hgnc:HGNC:28537","description":"transmembrane protein 252","metadata":{"aliases":["MGC34760","C9orf71"]}},{"id":"88ce1b63672d4bc197524c04930012c5","type":"GENE","name":"TMEM252-DT","canonical_id":"hgnc:HGNC:54377","description":"TMEM252 divergent transcript","metadata":null},{"id":"3780f48ec88a48238b353f5ddf7f6bee","type":"GENE","name":"TMEM253","canonical_id":"hgnc:HGNC:32545","description":"transmembrane protein 253","metadata":{"aliases":["NCRNA00220","C14orf95","C14orf176"]}},{"id":"05eef8c85aa8478bac900eeb1579703a","type":"GENE","name":"TMEM254","canonical_id":"hgnc:HGNC:25804","description":"transmembrane protein 254","metadata":{"aliases":["FLJ13263","bA369J21.6","C10orf57"]}},{"id":"5a32209a919f46dfbcaed0e61e433067","type":"GENE","name":"TMEM254-AS1","canonical_id":"hgnc:HGNC:27340","description":"TMEM254 antisense RNA 1","metadata":{"aliases":["CPHX"]}},{"id":"b39a7c51d1d24ab8bcfcd4a7c458deaa","type":"GENE","name":"TMEM255A","canonical_id":"hgnc:HGNC:26086","description":"transmembrane protein 255A","metadata":{"aliases":["FLJ20716","FAM70A"]}},{"id":"6a016165ef5041168e75d14b131b388a","type":"GENE","name":"TMEM255B","canonical_id":"hgnc:HGNC:28297","description":"transmembrane protein 255B","metadata":{"aliases":["MGC20579","FAM70B"]}},{"id":"25482b9d1f6c4415b4f1c5b2deceb89b","type":"GENE","name":"TMEM256","canonical_id":"hgnc:HGNC:28618","description":"transmembrane protein 256","metadata":{"aliases":["MGC40107","C17orf61"]}},{"id":"85cf0e5895864e22a385f4bc61a1ccfc","type":"GENE","name":"TMEM256-PLSCR3","canonical_id":"hgnc:HGNC:49186","description":"TMEM256-PLSCR3 readthrough (NMD candidate)","metadata":null},{"id":"b8a666f283e14e0da8e0d0d5ce950f00","type":"GENE","name":"TMEM256P1","canonical_id":"hgnc:HGNC:45087","description":"transmembrane protein 256 pseudogene 1","metadata":null},{"id":"24eedd6c880a47d5ae38688aab41c44a","type":"GENE","name":"TMEM256P2","canonical_id":"hgnc:HGNC:45088","description":"transmembrane protein 256 pseudogene 2","metadata":null},{"id":"0309a976ff934276b85156ad6a628d3b","type":"GENE","name":"TMEM258","canonical_id":"hgnc:HGNC:1164","description":"transmembrane protein 258","metadata":{"aliases":["Kuduk","Kud","C11orf10"]}},{"id":"160f8bfc3e2b42a99bd3587e9099d128","type":"GENE","name":"TMEM258P1","canonical_id":"hgnc:HGNC:56321","description":"TMEM258 pseudogene 1","metadata":null},{"id":"6ea835a82e5d4870af54783ed83a640a","type":"GENE","name":"TMEM258P2","canonical_id":"hgnc:HGNC:56322","description":"TMEM258 pseudogene 2","metadata":null},{"id":"84e5ba2621e64fcab6d631b0cc968fb6","type":"GENE","name":"TMEM259","canonical_id":"hgnc:HGNC:17039","description":"transmembrane protein 259","metadata":{"aliases":["MGC4022","ASBABP1","MBRL","C19orf6"]}},{"id":"ff2e076fbdea49ffad5a0f4835cd56f7","type":"GENE","name":"TMEM26","canonical_id":"hgnc:HGNC:28550","description":"transmembrane protein 26","metadata":{"aliases":["MGC35010","Em:AC068892.1"]}},{"id":"dc05c9e8d15e482e9d69bb82053d26f0","type":"GENE","name":"TMEM26-AS1","canonical_id":"hgnc:HGNC:51209","description":"TMEM26 antisense RNA 1","metadata":null},{"id":"f4d6c3ce910d4cb68a153259782a23f3","type":"GENE","name":"TMEM260","canonical_id":"hgnc:HGNC:20185","description":"transmembrane protein 260","metadata":{"aliases":["FLJ20392","C14orf101"]}},{"id":"d9f07e51c9dc4ee19e9a50486b06f1fe","type":"GENE","name":"TMEM263","canonical_id":"hgnc:HGNC:28281","description":"transmembrane protein 263","metadata":{"aliases":["MGC17943","C12orf23"]}},{"id":"1a4cfbea893f4d04b34486bad32e7b68","type":"GENE","name":"TMEM263-DT","canonical_id":"hgnc:HGNC:55395","description":"TMEM263 divergent transcript","metadata":null},{"id":"2d75cf28a21d425b9c8b82389299a083","type":"GENE","name":"TMEM265","canonical_id":"hgnc:HGNC:51241","description":"transmembrane protein 265","metadata":null},{"id":"96d657259752432996107109a132eb8a","type":"GENE","name":"TMEM266","canonical_id":"hgnc:HGNC:26763","description":"transmembrane protein 266","metadata":{"aliases":["FLJ38190","C15orf27"]}},{"id":"b7e2385532604f438dfe393d03a95a1d","type":"GENE","name":"TMEM267","canonical_id":"hgnc:HGNC:26139","description":"transmembrane protein 267","metadata":{"aliases":["FLJ21657","C5orf28"]}},{"id":"21bf477fd0c84aefb76ae39296a23689","type":"GENE","name":"TMEM268","canonical_id":"hgnc:HGNC:24513","description":"transmembrane protein 268","metadata":{"aliases":["DKFZp547P234","FLJ38045","C9orf91"]}},{"id":"afa282d7fba24bd9a1a7e5acbd6b31d2","type":"GENE","name":"TMEM269","canonical_id":"hgnc:HGNC:52381","description":"transmembrane protein 269","metadata":null},{"id":"0841018ba0f946a9b4a7c9f73dd26a50","type":"GENE","name":"TMEM269-DT","canonical_id":"hgnc:HGNC:54423","description":"TMEM269 divergent transcript","metadata":{"aliases":["C1orf50-AS1"]}},{"id":"38481b84f581406cb8ece5c07456dd3f","type":"GENE","name":"TMEM270","canonical_id":"hgnc:HGNC:23018","description":"transmembrane protein 270","metadata":{"aliases":["MGC26719","WBSCR28"]}},{"id":"9a069a8cf886426880cbc9d5ab92f61d","type":"GENE","name":"TMEM271","canonical_id":"hgnc:HGNC:53639","description":"transmembrane protein 271","metadata":null},{"id":"affc839ab69243168ba0a90ed3e566fe","type":"GENE","name":"TMEM272","canonical_id":"hgnc:HGNC:26737","description":"transmembrane protein 272","metadata":{"aliases":["FLJ37307","NCRNA00282","LINC00282"]}},{"id":"6b0d94c2929d413186c296974e2b3d06","type":"GENE","name":"TMEM273","canonical_id":"hgnc:HGNC:27274","description":"transmembrane protein 273","metadata":{"aliases":["Em:AC084727.5","C10orf128"]}},{"id":"52b8d3b0c4fb4f979b7991e7b9a1ae85","type":"GENE","name":"TMEM274P","canonical_id":"hgnc:HGNC:53732","description":"transmembrane protein 274, pseudogene","metadata":null},{"id":"01cf9c1512d44026bbe9c753825eb317","type":"GENE","name":"TMEM275","canonical_id":"hgnc:HGNC:53938","description":"transmembrane protein 275","metadata":null},{"id":"06fa2ef120f94c8781f6455d1f997425","type":"GENE","name":"TMEM276","canonical_id":"hgnc:HGNC:56235","description":"transmembrane protein 276","metadata":null},{"id":"e4fcdb62933b4cfba65a53d7ac39c311","type":"GENE","name":"TMEM276-ZFTRAF1","canonical_id":"hgnc:HGNC:56752","description":"TMEM276-ZFTRAF1 readthrough","metadata":null},{"id":"b41d02beb65445ea9417d39d2eab9eda","type":"GENE","name":"TMEM277P","canonical_id":"hgnc:HGNC:25050","description":"transmembrane protein 277, pseudogene","metadata":{"aliases":["MGC45922","LINC01869"]}},{"id":"142f0a042a0b46f38825b7da4d37d7a0","type":"GENE","name":"TMEM278","canonical_id":"hgnc:HGNC:37099","description":"transmembrane protein 278","metadata":{"aliases":["TMEM88B"]}},{"id":"4a9f985338e046c7a4cc7ed413243fa4","type":"GENE","name":"TMEM30A-DT","canonical_id":"hgnc:HGNC:48985","description":"TMEM30A divergent transcript","metadata":null},{"id":"47034d6e00674bd687f8f9289477818f","type":"GENE","name":"TMEM30BP1","canonical_id":"hgnc:HGNC:55058","description":"TMEM30B pseudogene 1","metadata":null},{"id":"dc9e68cb70204cb29514620a33e61aa2","type":"GENE","name":"TMEM31","canonical_id":"hgnc:HGNC:28601","description":"transmembrane protein 31","metadata":{"aliases":["MGC39655"]}},{"id":"513daabce541425ba02b877f844f6c24","type":"GENE","name":"TMEM33","canonical_id":"hgnc:HGNC:25541","description":"transmembrane protein 33","metadata":{"aliases":["FLJ10525","Pom33"]}},{"id":"9220b67b85484457834b8697463f441e","type":"GENE","name":"TMEM33-DT","canonical_id":"hgnc:HGNC:58779","description":"TMEM33 divergent transcript","metadata":null},{"id":"f1eb357cd9474393b31dc2d461dfc2ea","type":"GENE","name":"TMEM35A","canonical_id":"hgnc:HGNC:25864","description":"transmembrane protein 35A","metadata":{"aliases":["FLJ14084","TUF-1","NACHO","TMEM35"]}},{"id":"2c680a5634ed413eaf1cc65a238b5152","type":"GENE","name":"TMEM35B","canonical_id":"hgnc:HGNC:40021","description":"transmembrane protein 35B","metadata":{"aliases":["ZMYM6NB"]}},{"id":"0dfa8b3b753f4584a219284199b595f2","type":"GENE","name":"TMEM37","canonical_id":"hgnc:HGNC:18216","description":"transmembrane protein 37","metadata":{"aliases":["PR1","PR"]}},{"id":"52fc4a5659004bf981c60ef2cdf2b9d0","type":"GENE","name":"TMEM38A","canonical_id":"hgnc:HGNC:28462","description":"transmembrane protein 38A","metadata":{"aliases":["MGC3169","TRIC-A"]}},{"id":"cc330129c92e4ca9aa573f0a4e16dada","type":"GENE","name":"TMEM38B","canonical_id":"hgnc:HGNC:25535","description":"transmembrane protein 38B","metadata":{"aliases":["FLJ10493","bA219P18.1","D4Ertd89e","TRIC-B","C9orf87"]}},{"id":"497f4de876534b939eaabc82d60e3ed5","type":"GENE","name":"TMEM38BP1","canonical_id":"hgnc:HGNC:56587","description":"TMEM38B pseudogene 1","metadata":null},{"id":"ea7aa12b628e425cbfc61832892510f2","type":"GENE","name":"TMEM39A","canonical_id":"hgnc:HGNC:25600","description":"transmembrane protein 39A","metadata":{"aliases":["FLJ10902","SUSR2"]}},{"id":"f750bb4e7837428cb6f7600205848f03","type":"GENE","name":"TMEM39B","canonical_id":"hgnc:HGNC:25510","description":"transmembrane protein 39B","metadata":{"aliases":["FLJ10315"]}},{"id":"84dd40c04bb04e2ebd98aba2f9314fdc","type":"GENE","name":"TMEM40","canonical_id":"hgnc:HGNC:25620","description":"transmembrane protein 40","metadata":{"aliases":["FLJ11036"]}},{"id":"f8f20594ca9940da8aec94f84cdb1852","type":"GENE","name":"TMEM41A","canonical_id":"hgnc:HGNC:30544","description":"transmembrane protein 41A","metadata":{"aliases":["MGC15397"]}},{"id":"350367babda949aab05a550ca61a864d","type":"GENE","name":"TMEM41A-DT","canonical_id":"hgnc:HGNC:58335","description":"TMEM41A divergent transcript","metadata":{"aliases":["lnc-MAP3K13-3:1"]}},{"id":"6490900c149b4948b05ebb5d4d32ed54","type":"GENE","name":"TMEM41B","canonical_id":"hgnc:HGNC:28948","description":"transmembrane protein 41B","metadata":{"aliases":["KIAA0033"]}},{"id":"66b277e1cea7428eb38e830b298ee598","type":"GENE","name":"TMEM42","canonical_id":"hgnc:HGNC:28444","description":"transmembrane protein 42","metadata":{"aliases":["MGC29956"]}},{"id":"0d712dadd00d4136b4c015d0b4f169fb","type":"GENE","name":"TMEM43","canonical_id":"hgnc:HGNC:28472","description":"transmembrane protein 43","metadata":{"aliases":["MGC3222","DKFZp586G1919","LUMA","ARVD5"]}},{"id":"1eeb34d8af814e3fb5f765b13ab78865","type":"GENE","name":"TMEM44","canonical_id":"hgnc:HGNC:25120","description":"transmembrane protein 44","metadata":{"aliases":["DKFZp686O18124"]}},{"id":"6134fc844c9e40a48a7f4cd3a4c9d7f7","type":"GENE","name":"TMEM44-AS1","canonical_id":"hgnc:HGNC:44272","description":"TMEM44 antisense RNA 1","metadata":null},{"id":"a3f03b38fc254c4591dd51cefac6d398","type":"GENE","name":"TMEM44-AS2","canonical_id":"hgnc:HGNC:41082","description":"TMEM44 antisense RNA 2","metadata":null},{"id":"6a5f957a27714de1a16d2398268ccc60","type":"GENE","name":"TMEM45A","canonical_id":"hgnc:HGNC:25480","description":"transmembrane protein 45A","metadata":{"aliases":["FLJ10134","DERP7"]}},{"id":"d3e477dae29e4cbcb375bc6d58c77d51","type":"GENE","name":"TMEM45B","canonical_id":"hgnc:HGNC:25194","description":"transmembrane protein 45B","metadata":{"aliases":["BC016153","FLJ40787"]}},{"id":"48873a97afc046f99d11d9be679dcfe1","type":"GENE","name":"TMEM47","canonical_id":"hgnc:HGNC:18515","description":"transmembrane protein 47","metadata":{"aliases":["BCMP1","DKFZP761J17121","DKFZp564E153","VAB-9","TM4SF10"]}},{"id":"e7eff7ae5baa4b4fa17a1732b9a071fc","type":"GENE","name":"TMEM50A","canonical_id":"hgnc:HGNC:30590","description":"transmembrane protein 50A","metadata":{"aliases":["SMP1"]}},{"id":"9409e2427a184cd5bc8a55ab991f85df","type":"GENE","name":"TMEM50B","canonical_id":"hgnc:HGNC:1280","description":"transmembrane protein 50B","metadata":{"aliases":["C21orf4"]}},{"id":"16c1f9c7adc344649c2228df03bf1d7e","type":"GENE","name":"TMEM51","canonical_id":"hgnc:HGNC:25488","description":"transmembrane protein 51","metadata":{"aliases":["FLJ10199","C1orf72"]}},{"id":"41755f1ff40c4f9c8a1e77d0ede2c5ec","type":"GENE","name":"TMEM51-AS1","canonical_id":"hgnc:HGNC:26301","description":"TMEM51 antisense RNA 1","metadata":{"aliases":["FLJ23703","C1orf126"]}},{"id":"5ad454538ad04e458149c14c3bac7a55","type":"GENE","name":"TMEM51-AS2","canonical_id":"hgnc:HGNC:32332","description":"TMEM51 antisense RNA 2","metadata":{"aliases":["C1orf195"]}},{"id":"67a7109a469d4516a0d1b8b897bb8478","type":"GENE","name":"TMEM52","canonical_id":"hgnc:HGNC:27916","description":"transmembrane protein 52","metadata":null},{"id":"f9162b4d20d841599efc66ddb644b09b","type":"GENE","name":"TMEM52B","canonical_id":"hgnc:HGNC:26438","description":"transmembrane protein 52B","metadata":{"aliases":["FLJ31166","C12orf59"]}},{"id":"66d65011d94641b3ba48b95fedd9d178","type":"GENE","name":"TMEM53","canonical_id":"hgnc:HGNC:26186","description":"transmembrane protein 53","metadata":{"aliases":["FLJ22353","NET4"]}},{"id":"cb58ecb573dd4a84b9ff0c202d93deed","type":"GENE","name":"TMEM54","canonical_id":"hgnc:HGNC:24143","description":"transmembrane protein 54","metadata":{"aliases":["CAC-1","BCLP"]}},{"id":"e78780ca153947ab992ffddab29a896b","type":"GENE","name":"TMEM59","canonical_id":"hgnc:HGNC:1239","description":"transmembrane protein 59","metadata":{"aliases":["HSPC001","C1orf8"]}},{"id":"809e042e5abe4ab58805a6e3f0bd39b1","type":"GENE","name":"TMEM59L","canonical_id":"hgnc:HGNC:13237","description":"transmembrane protein 59 like","metadata":{"aliases":["BSMAP","C19orf4"]}},{"id":"fbbc46fd31344bdd83356c8fef8b5dc5","type":"GENE","name":"TMEM60","canonical_id":"hgnc:HGNC:21754","description":"transmembrane protein 60","metadata":{"aliases":["DC32","C7orf35"]}},{"id":"118639a363b6489c994db47b2ea67552","type":"GENE","name":"TMEM61","canonical_id":"hgnc:HGNC:27296","description":"transmembrane protein 61","metadata":null},{"id":"1403ad5291a044e2b0f20e18bcf8422e","type":"GENE","name":"TMEM62","canonical_id":"hgnc:HGNC:26269","description":"transmembrane protein 62","metadata":{"aliases":["FLJ23375"]}},{"id":"8dea621458884fb8a81e5c2d08538933","type":"GENE","name":"TMEM63A","canonical_id":"hgnc:HGNC:29118","description":"transmembrane protein 63A","metadata":{"aliases":["KIAA0792"]}},{"id":"2eacfe16c7eb48999cfa62e38c90011f","type":"GENE","name":"TMEM63B","canonical_id":"hgnc:HGNC:17735","description":"transmembrane protein 63B","metadata":{"aliases":["DKFZp434P0531","dJ421H19.2","C6orf110"]}},{"id":"d72527d13e734e0ca4dd002132d0d13a","type":"GENE","name":"TMEM63B-AS1","canonical_id":"hgnc:HGNC:59414","description":"TMEM63B antisense RNA 1","metadata":null},{"id":"4d840933382a41d790d2ea6de4799aa6","type":"GENE","name":"TMEM63C","canonical_id":"hgnc:HGNC:23787","description":"transmembrane protein 63C","metadata":{"aliases":["DKFZp434P0111","CSC1","hsCSC1","C14orf171"]}},{"id":"b0fdb4becefc469da693a0ac46591eb3","type":"GENE","name":"TMEM64","canonical_id":"hgnc:HGNC:25441","description":"transmembrane protein 64","metadata":{"aliases":["DKFZp762C1112"]}},{"id":"b8b49b68a1644d43b7833ca70dfac901","type":"GENE","name":"TMEM65","canonical_id":"hgnc:HGNC:25203","description":"transmembrane protein 65","metadata":null},{"id":"c7f9fc2980a84c979b8417a4cfa151a7","type":"GENE","name":"TMEM67","canonical_id":"hgnc:HGNC:28396","description":"transmembrane protein 67","metadata":{"aliases":["MGC26979","JBTS6","NPHP11","MKS3"]}},{"id":"3409ceded3ee49f0b7c7a59e0a205987","type":"GENE","name":"TMEM68","canonical_id":"hgnc:HGNC:26510","description":"transmembrane protein 68","metadata":{"aliases":["FLJ32370","DIESL"]}},{"id":"3c4b217d370b49a590b3d3611962815b","type":"GENE","name":"TMEM69","canonical_id":"hgnc:HGNC:28035","description":"transmembrane protein 69","metadata":{"aliases":["FLJ21029","C1orf154"]}},{"id":"e6563cebdb234c5fa0dbba08ccebd3da","type":"GENE","name":"TMEM69P1","canonical_id":"hgnc:HGNC:56807","description":"TMEM69 pseudogene 1","metadata":null},{"id":"cad896518f0241bfbfa7c6c990d8e4b7","type":"GENE","name":"TMEM69P2","canonical_id":"hgnc:HGNC:56808","description":"TMEM69 pseudogene 2","metadata":null},{"id":"b15127ae133a4fe989de2e7d0ecdc885","type":"GENE","name":"TMEM70","canonical_id":"hgnc:HGNC:26050","description":"transmembrane protein 70","metadata":{"aliases":["MC5DN2","FLJ20533"]}},{"id":"04687e675f7b4970ac0e2cd852100086","type":"GENE","name":"TMEM71","canonical_id":"hgnc:HGNC:26572","description":null,"metadata":null},{"id":"49dc243dae9d4cfa890c852a944eb23b","type":"GENE","name":"TMEM72","canonical_id":"hgnc:HGNC:31658","description":"transmembrane protein 72","metadata":{"aliases":["bA285G1.3","KSP37","C10orf127"]}},{"id":"daa31ad4503b4efd98ba962a999ff844","type":"GENE","name":"TMEM72-AS1","canonical_id":"hgnc:HGNC:27349","description":"TMEM72 antisense RNA 1","metadata":null},{"id":"a88968a4b285426eb1ad9e39babba728","type":"GENE","name":"TMEM74","canonical_id":"hgnc:HGNC:26409","description":"transmembrane protein 74","metadata":{"aliases":["FLJ30668","NET36"]}},{"id":"061d5e171898476c9b3efab6cbb90837","type":"GENE","name":"TMEM74B","canonical_id":"hgnc:HGNC:15893","description":"transmembrane protein 74B","metadata":{"aliases":["FLJ11190","C20orf46"]}},{"id":"bb9a8f1397a446ce95864ab47f2b3ecf","type":"GENE","name":"TMEM78","canonical_id":"hgnc:HGNC:32307","description":"transmembrane protein 78","metadata":{"aliases":["FLJ40168"]}},{"id":"934477a04c8c4b328956185e977410e3","type":"GENE","name":"TMEM79","canonical_id":"hgnc:HGNC:28196","description":"transmembrane protein 79","metadata":{"aliases":["MGC13102","FLJ16057","FLJ32254","MATT"]}},{"id":"57cdc705ecc346aaa1c27febfc0c8fbf","type":"GENE","name":"TMEM80","canonical_id":"hgnc:HGNC:27453","description":"transmembrane protein 80","metadata":{"aliases":["FLJ38216"]}},{"id":"ad51c7d8a10447fa97fd7b8fef91eb96","type":"GENE","name":"TMEM81","canonical_id":"hgnc:HGNC:32349","description":"transmembrane protein 81","metadata":{"aliases":["UNQ2788","MGC75217","HC3107","KVLA2788"]}},{"id":"e4abc5abfd494c8fb5070a279101729f","type":"GENE","name":"TMEM82","canonical_id":"hgnc:HGNC:32350","description":"transmembrane protein 82","metadata":null},{"id":"c9fefe12146e4b378ceb56e6c6074883","type":"GENE","name":"TMEM86A","canonical_id":"hgnc:HGNC:26890","description":"transmembrane protein 86A","metadata":{"aliases":["FLJ90119"]}},{"id":"0eb5b8b7207f484db146bcaef332b246","type":"GENE","name":"TMEM86B","canonical_id":"hgnc:HGNC:28448","description":"transmembrane protein 86B","metadata":{"aliases":["MGC30208"]}},{"id":"81756c0d9d8742b29fcdf82afcfba188","type":"GENE","name":"TMEM87A","canonical_id":"hgnc:HGNC:24522","description":"transmembrane protein 87A","metadata":{"aliases":["DKFZP564G2022","ELKIN1"]}},{"id":"8abefe118ed34fe983f7b5af30c79807","type":"GENE","name":"TMEM87B","canonical_id":"hgnc:HGNC:25913","description":"transmembrane protein 87B","metadata":{"aliases":["FLJ14681"]}},{"id":"c58baa4c99e0464c9d219d99d5dbf9a2","type":"GENE","name":"TMEM88","canonical_id":"hgnc:HGNC:32371","description":"transmembrane protein 88","metadata":{"aliases":["MGC71744","FLJ20025"]}},{"id":"72d1e94a3d7f40168af9cdf9311b3efc","type":"GENE","name":"TMEM89","canonical_id":"hgnc:HGNC:32372","description":"transmembrane protein 89","metadata":null},{"id":"1c759f0419df49778db7c4d71fbed751","type":"GENE","name":"TMEM8B","canonical_id":"hgnc:HGNC:21427","description":"transmembrane protein 8B","metadata":{"aliases":["NAG-5","NGX6","NGX6a","FP588","C9orf127","LINC00950"]}},{"id":"2f02bbfe0c4141bd9b36f5181443f63b","type":"GENE","name":"TMEM9","canonical_id":"hgnc:HGNC:18823","description":"transmembrane protein 9","metadata":{"aliases":["TMEM9A"]}},{"id":"b9fa37d41fee447498f6dee3cd5de18e","type":"GENE","name":"TMEM91","canonical_id":"hgnc:HGNC:32393","description":"transmembrane protein 91","metadata":{"aliases":["FLJ27310","IFITMD6","DSPC3","SynDIG3"]}},{"id":"f39c7ff50f70448186f311fb428b95fc","type":"GENE","name":"TMEM92","canonical_id":"hgnc:HGNC:26579","description":"transmembrane protein 92","metadata":{"aliases":["FLJ33318"]}},{"id":"b55ef869bc6645328fcae2ebeda2233f","type":"GENE","name":"TMEM92-AS1","canonical_id":"hgnc:HGNC:50442","description":"TMEM92 antisense RNA 1","metadata":{"aliases":["RP11-893F2.9","lncRNA-508851","TCONS_00025237"]}},{"id":"5e042466e89346c0aa477427336efe6c","type":"GENE","name":"TMEM94","canonical_id":"hgnc:HGNC:28983","description":"transmembrane protein 94","metadata":{"aliases":["ERMA","KIAA0195"]}},{"id":"251a4b954a1841768effb2fe2a5c7946","type":"GENE","name":"TMEM95","canonical_id":"hgnc:HGNC:27898","description":"transmembrane protein 95","metadata":{"aliases":["MGC129793","UNQ9390"]}},{"id":"322d53098df24d3381c1730a1c5092df","type":"GENE","name":"TMEM97","canonical_id":"hgnc:HGNC:28106","description":"transmembrane protein 97","metadata":{"aliases":["S2R","sigma2R","sigma(2)R","MAC30","\u03c32R"]}},{"id":"d5dac89bf5ed42a1a6b10274c40d6dd1","type":"GENE","name":"TMEM97P1","canonical_id":"hgnc:HGNC:39640","description":"transmembrane protein 97 pseudogene 1","metadata":null},{"id":"6e56b95ac0c54d3da7387b61eb453962","type":"GENE","name":"TMEM97P2","canonical_id":"hgnc:HGNC:39641","description":"transmembrane protein 97 pseudogene 2","metadata":null},{"id":"d36ba9d01dea4f4285ac3043f16f7e2c","type":"GENE","name":"TMEM98","canonical_id":"hgnc:HGNC:24529","description":"transmembrane protein 98","metadata":{"aliases":["DKFZP564K1964"]}},{"id":"18688c87119d41dba15e79a5bb989b1b","type":"GENE","name":"TMEM98P1","canonical_id":"hgnc:HGNC:58644","description":"TMEM98 pseudogene 1","metadata":null},{"id":"2a0ebc50d4ff4bb8b4fcdd5ad13dbb01","type":"GENE","name":"TMEM98P2","canonical_id":"hgnc:HGNC:58645","description":"TMEM98 pseudogene 2","metadata":null},{"id":"19c140336a2143449b393bb14a794e38","type":"GENE","name":"TMEM9B","canonical_id":"hgnc:HGNC:1168","description":"TMEM9 domain family member B","metadata":{"aliases":["C11orf15"]}},{"id":"c19283f4bc354c5eb2f2fb825a2dfee4","type":"GENE","name":"TMEM9B-AS1","canonical_id":"hgnc:HGNC:19230","description":"TMEM9B antisense RNA 1","metadata":{"aliases":["C11orf18"]}},{"id":"b54aceefc379445a909b7b80a3e04f43","type":"GENE","name":"TMF1","canonical_id":"hgnc:HGNC:11870","description":"TATA element modulatory factor 1","metadata":{"aliases":["ARA160","TMF"]}},{"id":"94e0f8af86104a22b1a0226156fe51ae","type":"GENE","name":"TMF1P1","canonical_id":"hgnc:HGNC:51353","description":"TATA element modulatory factor 1 pseudogene 1","metadata":null},{"id":"d993e9b795904ee391f15719d788f768","type":"GENE","name":"TMIE","canonical_id":"hgnc:HGNC:30800","description":"transmembrane inner ear","metadata":{"aliases":["DFNB6"]}},{"id":"746d8013a19248c59c9caea345d20e13","type":"GENE","name":"TMIGD1","canonical_id":"hgnc:HGNC:32431","description":"transmembrane and immunoglobulin domain containing 1","metadata":{"aliases":["UNQ9372","TMIGD"]}},{"id":"a01d6dac299e494b922cda03a054161b","type":"GENE","name":"TMIGD2","canonical_id":"hgnc:HGNC:28324","description":"transmembrane and immunoglobulin domain containing 2","metadata":{"aliases":["MGC23244","CD28H","IGPR-1"]}},{"id":"6f78a6b2baab4276902547a628c4e853","type":"GENE","name":"TMIGD3","canonical_id":"hgnc:HGNC:51375","description":"transmembrane and immunoglobulin domain containing 3","metadata":{"aliases":["AD026"]}},{"id":"2cea4600970a468f9f97c421d8d41bc4","type":"GENE","name":"TMLHE","canonical_id":"hgnc:HGNC:18308","description":"trimethyllysine hydroxylase, epsilon","metadata":{"aliases":["TMLH","FLJ10727","BBOX2","XAP130"]}},{"id":"8ee6757a4a0b45dd8b509e6a27aa37ea","type":"GENE","name":"TMLHE-AS1","canonical_id":"hgnc:HGNC:44261","description":"TMLHE antisense RNA 1","metadata":null},{"id":"9d08dea6b1ea47f095a3d4ae2e7502a6","type":"GENE","name":"TMLHEP1","canonical_id":"hgnc:HGNC:55622","description":"TMLHE pseudogene 1","metadata":null},{"id":"832c9ce6705a45d49aef2d534c3e0256","type":"GENE","name":"TMOD1","canonical_id":"hgnc:HGNC:11871","description":"tropomodulin 1","metadata":{"aliases":["ETMOD","D9S57E","TMOD"]}},{"id":"74a85e21cb0d41399aa1e4dbbff6c544","type":"GENE","name":"TMOD1-AS1","canonical_id":"hgnc:HGNC:58361","description":"TMOD1 antisense RNA 1","metadata":null},{"id":"4b3fa62f411c42eeb02aaf9936232430","type":"GENE","name":"TMOD2","canonical_id":"hgnc:HGNC:11872","description":"tropomodulin 2","metadata":{"aliases":["NTMOD"]}},{"id":"09922fa960684ab986eece7e6d38192e","type":"GENE","name":"TMOD3","canonical_id":"hgnc:HGNC:11873","description":"tropomodulin 3","metadata":{"aliases":["UTMOD"]}},{"id":"1a56ac51f68d4e789f7463e9323a26a1","type":"GENE","name":"TMOD4","canonical_id":"hgnc:HGNC:11874","description":"tropomodulin 4","metadata":{"aliases":["Sk-Tmod"]}},{"id":"9995773500ba42e28c986e964116a39b","type":"GO_TERM","name":"TMP biosynthetic process","canonical_id":"go:GO:0006230","description":"\"The chemical reactions and pathways resulting in the formation of TMP, ribosylthymine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"d3d891f87f2e40c9b00b3425318b8a2a","type":"GO_TERM","name":"TMP catabolic process","canonical_id":"go:GO:0046045","description":"\"The chemical reactions and pathways resulting in the breakdown of TMP, ribosylthymine monophosphate.\" [GOC:curators]","metadata":null},{"id":"8131622b046d4bbc97e8bed998e588b6","type":"GO_TERM","name":"TMP metabolic process","canonical_id":"go:GO:0046044","description":"\"The chemical reactions and pathways involving TMP, ribosylthymine monophosphate.\" [GOC:curators]","metadata":null},{"id":"9dbd546f4dd24859b0eddff236af2875","type":"GENE","name":"TMPO","canonical_id":"hgnc:HGNC:11875","description":null,"metadata":null},{"id":"07fac8a9fda945b38a72a5cc139c7505","type":"GENE","name":"TMPO-AS1","canonical_id":"hgnc:HGNC:44158","description":"TMPO antisense RNA 1","metadata":null},{"id":"ef8bb3e76eb84c3987a93d46cef15183","type":"GENE","name":"TMPOP1","canonical_id":"hgnc:HGNC:21364","description":"thymopoietin pseudogene 1","metadata":{"aliases":["Em:AB014080.3","TMPOL1"]}},{"id":"ca8833d5ec8448d4ab9b68ef8c92ddc4","type":"GENE","name":"TMPOP2","canonical_id":"hgnc:HGNC:50860","description":"thymopoietin pseudogene 2","metadata":null},{"id":"5d4de843a1624dc787dd985a0d818c7f","type":"GENE","name":"TMPPE","canonical_id":"hgnc:HGNC:33865","description":"transmembrane protein with metallophosphoesterase domain","metadata":{"aliases":["FLJ45032"]}},{"id":"f592cf4dfe5b4e3981bc2bfa1c614057","type":"GENE","name":"TMPRSS11A","canonical_id":"hgnc:HGNC:27954","description":"transmembrane serine protease 11A","metadata":{"aliases":["ECRG1","HATL1","HESP"]}},{"id":"ad2b8077869b468cb1d563fbf187a4e3","type":"GENE","name":"TMPRSS11B","canonical_id":"hgnc:HGNC:25398","description":"transmembrane serine protease 11B","metadata":{"aliases":["HATL5"]}},{"id":"62bc0301121f4106ae8f599f3d1ff430","type":"GENE","name":"TMPRSS11BNL","canonical_id":"hgnc:HGNC:37262","description":"TMPRSS11B N-terminal like (pseudogene)","metadata":{"aliases":["FLJ41562"]}},{"id":"724dbe7be8274121880ab191d96f9be3","type":"GENE","name":"TMPRSS11CP","canonical_id":"hgnc:HGNC:31934","description":"transmembrane serine protease 11C, pseudogene","metadata":null},{"id":"a5f0152c9cc14297873cead2b86c33ae","type":"GENE","name":"TMPRSS11D","canonical_id":"hgnc:HGNC:24059","description":"transmembrane serine protease 11D","metadata":{"aliases":["HAT","ASP"]}},{"id":"32ee3b5182f4444284fabc94f7237cfa","type":"GENE","name":"TMPRSS11E","canonical_id":"hgnc:HGNC:24465","description":"transmembrane serine protease 11E","metadata":{"aliases":["DESC1","TMPRSS11E2"]}},{"id":"df808de665e94c669200a37eb09e4d3f","type":"GENE","name":"TMPRSS11F","canonical_id":"hgnc:HGNC:29994","description":"transmembrane serine protease 11F","metadata":{"aliases":["FLJ16046","HATL4"]}},{"id":"5d12cb3c33a2463cb6bede729dd28201","type":"GENE","name":"TMPRSS11GP","canonical_id":"hgnc:HGNC:42983","description":"transmembrane serine protease 11G, pseudogene","metadata":null},{"id":"4c8fcc94d29540338a07ccc5894b5e05","type":"GENE","name":"TMPRSS12","canonical_id":"hgnc:HGNC:28779","description":"transmembrane serine protease 12","metadata":{"aliases":["MGC57341","CT151"]}},{"id":"4f3a9d68e0fe4fb180aa867f5e94d039","type":"GENE","name":"TMPRSS13","canonical_id":"hgnc:HGNC:29808","description":"transmembrane serine protease 13","metadata":{"aliases":["MSPL","MSPS","TMPRSS11"]}},{"id":"5279a70454d147c6894b89fcafff09c7","type":"GENE","name":"TMPRSS15","canonical_id":"hgnc:HGNC:9490","description":"transmembrane serine protease 15","metadata":{"aliases":["ENTK","MGC133046","PRSS7"]}},{"id":"66ae855fbef44d1484d87cdb443e9545","type":"GENE","name":"TMPRSS2","canonical_id":"hgnc:HGNC:11876","description":null,"metadata":null},{"id":"12df406ca52047d2831987668450470c","type":"GENE","name":"TMPRSS3","canonical_id":"hgnc:HGNC:11877","description":"transmembrane serine protease 3","metadata":{"aliases":["DFNB10","DFNB8"]}},{"id":"63b65a8f7fd144f2b9b61accf94cf02a","type":"GENE","name":"TMPRSS4","canonical_id":"hgnc:HGNC:11878","description":"transmembrane serine protease 4","metadata":{"aliases":["TMPRSS3","MT-SP2","CAP2"]}},{"id":"b4c9408275e54cbf9fd20843dc5ec4af","type":"GENE","name":"TMPRSS5","canonical_id":"hgnc:HGNC:14908","description":"transmembrane serine protease 5","metadata":{"aliases":["MGC141886","MGC148044"]}},{"id":"4a339a257ef04314b60b5c7d39fe3c89","type":"GENE","name":"TMPRSS6","canonical_id":"hgnc:HGNC:16517","description":"transmembrane serine protease 6","metadata":{"aliases":["FLJ30744","MT2"]}},{"id":"1c76266adf274572b93941d74630e0d0","type":"GENE","name":"TMPRSS6-AS1","canonical_id":"hgnc:HGNC:40775","description":"TMPRSS6 antisense RNA 1","metadata":null},{"id":"6e9e936d41fe41b381c2f60f5f95a551","type":"GENE","name":"TMPRSS7","canonical_id":"hgnc:HGNC:30846","description":"transmembrane serine protease 7","metadata":null},{"id":"19c1ad7cae724dbfb378edfb9bb93e74","type":"GENE","name":"TMPRSS9","canonical_id":"hgnc:HGNC:30079","description":"transmembrane serine protease 9","metadata":null},{"id":"c0e6ebb2215e47a28ec2ee9dfa7140fb","type":"TRIAL","name":"TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT01172509","description":"Autism","metadata":null},{"id":"f036205ee4a84f9d8e0f8158a12821a6","type":"GENE","name":"TMSB10","canonical_id":"hgnc:HGNC:11879","description":"thymosin beta 10","metadata":{"aliases":["TB10"]}},{"id":"6a75ae1de9d44c309350a8e5a02de1fc","type":"GENE","name":"TMSB10P1","canonical_id":"hgnc:HGNC:41949","description":"thymosin beta 10 pseudogene 1","metadata":null},{"id":"e54c4f59d63b4a43be9279410e49b593","type":"GENE","name":"TMSB10P2","canonical_id":"hgnc:HGNC:41950","description":"thymosin beta 10 pseudogene 2","metadata":null},{"id":"97ca50b6470c4a158b3130bfc6f4ad8f","type":"GENE","name":"TMSB15A","canonical_id":"hgnc:HGNC:30744","description":"thymosin beta 15A","metadata":{"aliases":["TMSNB","TMSL8"]}},{"id":"f13d6a5be5514cf693c2b37f38f0e815","type":"GENE","name":"TMSB15B","canonical_id":"hgnc:HGNC:28612","description":"thymosin beta 15B","metadata":{"aliases":["MGC39900"]}},{"id":"765650a9bc9f4b5ea080e0f0ffe9548a","type":"GENE","name":"TMSB15B-AS1","canonical_id":"hgnc:HGNC:53858","description":"TMSB15B antisense RNA 1","metadata":null},{"id":"cd308dc167914c46a3bac31270e97184","type":"GENE","name":"TMSB15C","canonical_id":"hgnc:HGNC:55173","description":"thymosin beta 15C","metadata":null},{"id":"8dd191091f784ef7b9146bda16a7c01d","type":"GENE","name":"TMSB4X","canonical_id":"hgnc:HGNC:11881","description":"thymosin beta 4 X-linked","metadata":{"aliases":["TB4X","TMSB4"]}},{"id":"14760c1c58cf4ab1bb58cf024d73071f","type":"GENE","name":"TMSB4XP1","canonical_id":"hgnc:HGNC:11883","description":"TMSB4X pseudogene 1","metadata":{"aliases":["TMSL1"]}},{"id":"5d9486d7b0e94a11961a913681b52403","type":"GENE","name":"TMSB4XP2","canonical_id":"hgnc:HGNC:11884","description":"TMSB4X pseudogene 2","metadata":{"aliases":["TMSL2"]}},{"id":"3ab3afba3ed248efa51aed3ded22ba9d","type":"GENE","name":"TMSB4XP3","canonical_id":"hgnc:HGNC:38587","description":"TMSB4X pseudogene 3","metadata":null},{"id":"68442c679f744265885fc3fa40ce4bf2","type":"GENE","name":"TMSB4XP4","canonical_id":"hgnc:HGNC:11886","description":"TMSB4X pseudogene 4","metadata":{"aliases":["TMSL4"]}},{"id":"61841bbd03464548bc1ddc690f9d5d6c","type":"GENE","name":"TMSB4XP5","canonical_id":"hgnc:HGNC:11887","description":"TMSB4X pseudogene 5","metadata":{"aliases":["TMSL5"]}},{"id":"56f5d5e264134ea199896aa95556357c","type":"GENE","name":"TMSB4XP6","canonical_id":"hgnc:HGNC:11888","description":"TMSB4X pseudogene 6","metadata":{"aliases":["dJ1071L10.1","TMSB4L","TMSL6"]}},{"id":"914dd95032274fa6a0bb7832f22720db","type":"GENE","name":"TMSB4XP7","canonical_id":"hgnc:HGNC:11889","description":"TMSB4X pseudogene 7","metadata":{"aliases":["TMSL7"]}},{"id":"1719c139dd634004a784ae40b2af1ffa","type":"GENE","name":"TMSB4XP8","canonical_id":"hgnc:HGNC:11885","description":"TMSB4X pseudogene 8","metadata":{"aliases":["TMSL3"]}},{"id":"dafab615fed043daac78c71f4ab952dc","type":"GENE","name":"TMSB4Y","canonical_id":"hgnc:HGNC:11882","description":"thymosin beta 4 Y-linked","metadata":{"aliases":["TB4Y"]}},{"id":"545903b863d346648d1eb61ec1ae722d","type":"GENE","name":"TMT1A","canonical_id":"hgnc:HGNC:24550","description":"thiol methyltransferase 1A","metadata":{"aliases":["DKFZP586A0522","METTL7A"]}},{"id":"60be78803efa4bf4b86c0af31fb74b81","type":"GENE","name":"TMT1AP1","canonical_id":"hgnc:HGNC:48874","description":"thiol methyltransferase 1A pseudogene 1","metadata":{"aliases":["METTL7AP1"]}},{"id":"a432933131da4c1aa04685994c99e7e2","type":"GENE","name":"TMT1B","canonical_id":"hgnc:HGNC:28276","description":"thiol methyltransferase 1B","metadata":{"aliases":["MGC17301","ALDI","METTL7B"]}},{"id":"a4471ca8ff1e4b0bb14e62a1fec5cab0","type":"GENE","name":"TMTC1","canonical_id":"hgnc:HGNC:24099","description":"transmembrane O-mannosyltransferase targeting cadherins 1","metadata":{"aliases":["ARG99","OLF","FLJ31400","FLJ41625"]}},{"id":"d92fab1d333745f39b49b1a24127aabe","type":"GENE","name":"TMTC2","canonical_id":"hgnc:HGNC:25440","description":"transmembrane O-mannosyltransferase targeting cadherins 2","metadata":{"aliases":["DKFZp762A217"]}},{"id":"f6a5e5ff412b49bbaaa46ae3dac40461","type":"GENE","name":"TMTC3","canonical_id":"hgnc:HGNC:26899","description":"transmembrane O-mannosyltransferase targeting cadherins 3","metadata":{"aliases":["FLJ90492","SMILE"]}},{"id":"48c1cd8f12944771adc69d6ee162541f","type":"GENE","name":"TMTC4","canonical_id":"hgnc:HGNC:25904","description":"transmembrane O-mannosyltransferase targeting cadherins 4","metadata":{"aliases":["FLJ14624","FLJ22153"]}},{"id":"2b2952f2771842a69e5c63849d6ecd8d","type":"GENE","name":"TMUB1","canonical_id":"hgnc:HGNC:21709","description":"transmembrane and ubiquitin like domain containing 1","metadata":{"aliases":["SB144","HOPS","C7orf21"]}},{"id":"9198d7d0bc4c4d18a30c1bccc421b782","type":"GENE","name":"TMUB2","canonical_id":"hgnc:HGNC:28459","description":"transmembrane and ubiquitin like domain containing 2","metadata":{"aliases":["MGC3123"]}},{"id":"a15b830bbc3f4e97b5089d5901fccb88","type":"GENE","name":"TMX1","canonical_id":"hgnc:HGNC:15487","description":"thioredoxin related transmembrane protein 1","metadata":{"aliases":["TMX","PDIA11","TXNDC","TXNDC1"]}},{"id":"39c71e9415154ec88f09dbba7907827a","type":"GENE","name":"TMX1P1","canonical_id":"hgnc:HGNC:56777","description":"TMX1 pseudogene 1","metadata":null},{"id":"7a648410935446cc96d6a8d448c9e9ad","type":"GENE","name":"TMX1P2","canonical_id":"hgnc:HGNC:56778","description":"TMX1 pseudogene 2","metadata":null},{"id":"945eb52feace47d6924ad8425748c6f8","type":"GENE","name":"TMX2","canonical_id":"hgnc:HGNC:30739","description":"thioredoxin related transmembrane protein 2","metadata":{"aliases":["PDIA12","TXNDC14"]}},{"id":"5e2a538cdaae4b268983459bb9497c0f","type":"GENE","name":"TMX2-CTNND1","canonical_id":"hgnc:HGNC:41992","description":"TMX2-CTNND1 readthrough (NMD candidate)","metadata":null},{"id":"53af85ff3822441693fb94670d709c01","type":"GENE","name":"TMX2P1","canonical_id":"hgnc:HGNC:49916","description":"thioredoxin related transmembrane protein 2 pseudogene 1","metadata":null},{"id":"5062b27e28ef47bdad4042e587b68ac6","type":"GENE","name":"TMX3","canonical_id":"hgnc:HGNC:24718","description":"thioredoxin related transmembrane protein 3","metadata":{"aliases":["FLJ20793","KIAA1830","PDIA13","TXNDC10"]}},{"id":"e5503ba61ee1432fa96ff4e93e46250e","type":"GENE","name":"TMX4","canonical_id":"hgnc:HGNC:25237","description":"thioredoxin related transmembrane protein 4","metadata":{"aliases":["DJ971N18.2","KIAA1162","PDIA14","TXNDC13"]}},{"id":"1c28309490174700900d93e9921acb7f","type":"GENE","name":"TMX4-AS1","canonical_id":"hgnc:HGNC:55788","description":"TMX4 antisense RNA 1","metadata":null},{"id":"1237bf0563744853a825963de58ccdf3","type":"GENE","name":"TMZR1","canonical_id":"hgnc:HGNC:58351","description":"temozolomide resistance associated STAT3 regulator 1","metadata":null},{"id":"268b662802864f048bfdf47c8947e9fc","type":"GENE","name":"TNC","canonical_id":"hgnc:HGNC:5318","description":null,"metadata":null},{"id":"4ca55ef23a8f49e1bae53ed36d08be9d","type":"GENE","name":"TNF","canonical_id":"hgnc:HGNC:11892","description":null,"metadata":null},{"id":"35001e1e830d46f787bd7c4767695e2f","type":"PROTEIN","name":"TNF","canonical_id":"uniprot:P01375","description":null,"metadata":null},{"id":"6b6650da796243afac9d6e0092f784c7","type":"DRUG","name":"TNF receptor-associated periodic fever syndrome (TRAPS)","canonical_id":"mesh:C536657","description":null,"metadata":null},{"id":"6805d1c9f72d4c12a2787630187780ab","type":"TRIAL","name":"TNF-Alpha Inhibition for Treatment of Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00203320","description":"Alzheimer's Disease","metadata":null},{"id":"d221ddbdd41c4443aafda85212467257","type":"GENE","name":"TNFAIP1","canonical_id":"hgnc:HGNC:11894","description":"TNF alpha induced protein 1","metadata":{"aliases":["B61","B12","MGC2317","BTBD34","EDP1"]}},{"id":"f22d35cff9f24fa9a15a8f03546efe6b","type":"GENE","name":"TNFAIP2","canonical_id":"hgnc:HGNC:11895","description":"TNF alpha induced protein 2","metadata":{"aliases":["B94","EXOC3L3"]}},{"id":"5b15b5183c664c07b93229bfb1444577","type":"GENE","name":"TNFAIP3","canonical_id":"hgnc:HGNC:11896","description":null,"metadata":null},{"id":"d965758f95ca43299c380143c71cd8d2","type":"GENE","name":"TNFAIP6","canonical_id":"hgnc:HGNC:11898","description":null,"metadata":null},{"id":"cf51b29561ee40ebb75f31c7bb6de243","type":"GENE","name":"TNFAIP8","canonical_id":"hgnc:HGNC:17260","description":"TNF alpha induced protein 8","metadata":{"aliases":["GG2-1","MDC-3.13","SCC-S2"]}},{"id":"d0d10ed393714491b3368912eba2f2f0","type":"GENE","name":"TNFAIP8-AS1","canonical_id":"hgnc:HGNC:59119","description":"TNFAIP8 antisense RNA 1","metadata":null},{"id":"888b565479c44fe7ad1d0d2f1bdcc5f8","type":"GENE","name":"TNFRSF10A","canonical_id":"hgnc:HGNC:11904","description":null,"metadata":null},{"id":"b750fd228a8f4812a9d3f45fa5e6f0dc","type":"GENE","name":"TNFRSF10A-AS1","canonical_id":"hgnc:HGNC:53164","description":"TNFRSF10A antisense RNA 1","metadata":{"aliases":["RP11-1149O23.2"]}},{"id":"f9f56e60d4294e2e8ffa914cd08fdca6","type":"GENE","name":"TNFRSF10A-DT","canonical_id":"hgnc:HGNC:52647","description":"TNFRSF10A divergent transcript","metadata":{"aliases":["LOC389641","PLACT1"]}},{"id":"fe91bc509dc543669d93c783a5bfb854","type":"GENE","name":"TNFRSF10B","canonical_id":"hgnc:HGNC:11905","description":null,"metadata":null},{"id":"0727511378ae46aaa0ddf96f440c055a","type":"GENE","name":"TNFRSF10B-AS1","canonical_id":"hgnc:HGNC:27809","description":"TNFRSF10B antisense RNA 1","metadata":{"aliases":["DR5-AS"]}},{"id":"ba756dc8f7644a09807c6bd8bf4d7ec0","type":"GENE","name":"TNFRSF10C","canonical_id":"hgnc:HGNC:11906","description":"TNF receptor superfamily member 10c","metadata":{"aliases":["DcR1","TRAILR3","LIT","TRID","CD263"]}},{"id":"f948603396ae49fdb56d97ab4548ac2b","type":"GENE","name":"TNFRSF10D","canonical_id":"hgnc:HGNC:11907","description":"TNF receptor superfamily member 10d","metadata":{"aliases":["DcR2","TRUNDD","TRAILR4","CD264"]}},{"id":"aef4c679c9934ef3a8df6f7cc7f4bb58","type":"GENE","name":"TNFRSF11A","canonical_id":"hgnc:HGNC:11908","description":null,"metadata":null},{"id":"ac0d7b6a2adf4f9c9728327c90cbe9e6","type":"GENE","name":"TNFRSF11B","canonical_id":"hgnc:HGNC:11909","description":null,"metadata":null},{"id":"964da563f74f416bada27299c1449400","type":"GENE","name":"TNFRSF12A","canonical_id":"hgnc:HGNC:18152","description":null,"metadata":null},{"id":"653ae5747e064396a45237513356b71b","type":"GENE","name":"TNFRSF13B","canonical_id":"hgnc:HGNC:18153","description":"TNF receptor superfamily member 13B","metadata":{"aliases":["TACI","CD267","IGAD2"]}},{"id":"c1ee12655adb4cd58bd414d92a7467c1","type":"GENE","name":"TNFRSF13C","canonical_id":"hgnc:HGNC:17755","description":null,"metadata":null},{"id":"07d6c6cae79a4c3fa4fa1d097bcf127b","type":"GENE","name":"TNFRSF14","canonical_id":"hgnc:HGNC:11912","description":"TNF receptor superfamily member 14","metadata":{"aliases":["HVEM","ATAR","TR2","LIGHTR","HVEA","CD270"]}},{"id":"ee225a777c204090a55ab8913af07960","type":"GENE","name":"TNFRSF14-AS1","canonical_id":"hgnc:HGNC:26966","description":"TNFRSF14 antisense RNA 1","metadata":{"aliases":["ENST00000416860.2"]}},{"id":"4ecd1a98235a471eab6458e353f12ac3","type":"GENE","name":"TNFRSF17","canonical_id":"hgnc:HGNC:11913","description":null,"metadata":null},{"id":"3c416bacc3004d67add77d3c8a1aaaaa","type":"GENE","name":"TNFRSF18","canonical_id":"hgnc:HGNC:11914","description":"TNF receptor superfamily member 18","metadata":{"aliases":["AITR","GITR","CD357"]}},{"id":"96a24a37b32e4827b2c7e22574484935","type":"GENE","name":"TNFRSF19","canonical_id":"hgnc:HGNC:11915","description":"TNF receptor superfamily member 19","metadata":{"aliases":["TAJ-alpha","TROY","TAJ","TRADE"]}},{"id":"eab0d957e3a8439eb04636769c790a65","type":"GENE","name":"TNFRSF1A","canonical_id":"hgnc:HGNC:11916","description":"TNF receptor superfamily member 1A","metadata":{"aliases":["TNF-R","TNFAR","TNFR60","TNF-R-I","CD120a","TNF-R55","TNFR1"]}},{"id":"27d4eb0a6132452fa27c6d4055638805","type":"GENE","name":"TNFRSF1B","canonical_id":"hgnc:HGNC:11917","description":null,"metadata":null},{"id":"dfc09694c45c40d4a8ddec9aa5b529be","type":"GENE","name":"TNFRSF21","canonical_id":"hgnc:HGNC:13469","description":null,"metadata":null},{"id":"9e76334e58584e16921a9dcae81f369c","type":"GENE","name":"TNFRSF21-DT","canonical_id":"hgnc:HGNC:59420","description":"TNFRSF21 divergent transcript","metadata":null},{"id":"1f9200f33d0846d5836cfea227812597","type":"GENE","name":"TNFRSF25","canonical_id":"hgnc:HGNC:11910","description":"TNF receptor superfamily member 25","metadata":{"aliases":["DR3","TRAMP","WSL-1","LARD","WSL-LR","DDR3","TR3","APO-3","TNFRSF12"]}},{"id":"bbc75a190bb5442987897f9686d4da87","type":"GENE","name":"TNFRSF4","canonical_id":"hgnc:HGNC:11918","description":"TNF receptor superfamily member 4","metadata":{"aliases":["ACT35","OX40","CD134","TXGP1L"]}},{"id":"cc4a5380571a4e35a83d24719c9965fd","type":"GENE","name":"TNFRSF6B","canonical_id":"hgnc:HGNC:11921","description":"TNF receptor superfamily member 6b","metadata":{"aliases":["DcR3","DCR3","TR6","M68"]}},{"id":"5ea66584bf1a412d9b865050059475fa","type":"GENE","name":"TNFRSF8","canonical_id":"hgnc:HGNC:11923","description":"TNF receptor superfamily member 8","metadata":{"aliases":["KI-1","CD30","D1S166E"]}},{"id":"bf9a982c31f14930881c7dce8ef98e3c","type":"PROTEIN","name":"TNFRSF8","canonical_id":"uniprot:P28908","description":null,"metadata":null},{"id":"2f924bcc0c3846b2a27af37ac361bd35","type":"GENE","name":"TNFRSF9","canonical_id":"hgnc:HGNC:11924","description":null,"metadata":null},{"id":"ecb8745f615b4dc3bd06137734254a89","type":"GENE","name":"TNFSF10","canonical_id":"hgnc:HGNC:11925","description":null,"metadata":null},{"id":"7d55045fdaad4387a420e79a7e69a3aa","type":"GENE","name":"TNFSF11","canonical_id":"hgnc:HGNC:11926","description":null,"metadata":null},{"id":"2fce5859f13f4cf885d68d3b81cf01ed","type":"PROTEIN","name":"TNFSF11","canonical_id":"uniprot:O14788","description":null,"metadata":null},{"id":"5ebb4ed4da754fdeb7f03a1cd863a206","type":"GO_TERM","name":"TNFSF11 binding","canonical_id":"go:GO:0038057","description":"\"Binding to tumor necrosis factor ligand superfamily member 11 (TNFSF11), a member of the tumor necrosis factor (TNF) cytokine family.\" [GOC:cjm]","metadata":null},{"id":"769395a85d3d4da7a8503a25364b416c","type":"GENE","name":"TNFSF12","canonical_id":"hgnc:HGNC:11927","description":"TNF superfamily member 12","metadata":{"aliases":["TWEAK","DR3LG","APO3L","TNF12"]}},{"id":"540bba26204246bfb5e3bf0a2ae7061e","type":"GENE","name":"TNFSF12-TNFSF13","canonical_id":"hgnc:HGNC:33537","description":"TNFSF12-TNFSF13 readthrough","metadata":{"aliases":["TWE-PRIL"]}},{"id":"8a501aa600004c989bf418ff4c23e84f","type":"GENE","name":"TNFSF13","canonical_id":"hgnc:HGNC:11928","description":"TNF superfamily member 13","metadata":{"aliases":["APRIL","CD256"]}},{"id":"5fbea13dd5fb490e86612cd10c5577d4","type":"GENE","name":"TNFSF13B","canonical_id":"hgnc:HGNC:11929","description":null,"metadata":null},{"id":"5d5b50e1bc9146dda38652a8b5ea6590","type":"PROTEIN","name":"TNFSF13B","canonical_id":"uniprot:Q9Y275","description":null,"metadata":null},{"id":"2b646c8cbe734088be5303682570ce21","type":"GENE","name":"TNFSF14","canonical_id":"hgnc:HGNC:11930","description":null,"metadata":null},{"id":"dfeab85a5d524627acd03abbdea3a412","type":"GENE","name":"TNFSF15","canonical_id":"hgnc:HGNC:11931","description":"TNF superfamily member 15","metadata":{"aliases":["TL1","VEGI","TL1A","VEGI192A","MGC129934","MGC129935"]}},{"id":"b9aad3d470c24d5498bb25d606bcc5ee","type":"GENE","name":"TNFSF18","canonical_id":"hgnc:HGNC:11932","description":"TNF superfamily member 18","metadata":{"aliases":["AITRL","TL6","hGITRL"]}},{"id":"9bff45e1be9e4ca48f6e26c7deded6c1","type":"GENE","name":"TNFSF4","canonical_id":"hgnc:HGNC:11934","description":null,"metadata":null},{"id":"d7c655d472354348a9a3e7186155bd0d","type":"GENE","name":"TNFSF8","canonical_id":"hgnc:HGNC:11938","description":"TNF superfamily member 8","metadata":{"aliases":["CD153","CD30LG"]}},{"id":"d0d54455329640eaa6aa6644077bcadc","type":"GENE","name":"TNFSF9","canonical_id":"hgnc:HGNC:11939","description":"TNF superfamily member 9","metadata":{"aliases":["4-1BB-L","4-1BBL","CD137L"]}},{"id":"8d8f1db51aa14088b7e4edac2b85444b","type":"GENE","name":"TNIK","canonical_id":"hgnc:HGNC:30765","description":"TRAF2 and NCK interacting kinase","metadata":{"aliases":["MAP4K7","KIAA0551"]}},{"id":"984e9c82411e4f3eba29f877529d5f00","type":"GENE","name":"TNIP1","canonical_id":"hgnc:HGNC:16903","description":"TNFAIP3 interacting protein 1","metadata":{"aliases":["NAF1","KIAA0113","ABIN-1","VAN"]}},{"id":"1e19b28d9a1d4ae2aaee078d800bdd47","type":"GENE","name":"TNIP2","canonical_id":"hgnc:HGNC:19118","description":"TNFAIP3 interacting protein 2","metadata":{"aliases":["ABIN-2","MGC4289","KLIP","FLIP1","ABIN2"]}},{"id":"9e9d2ca7c2f649939696214c8f986d8d","type":"GENE","name":"TNIP2P1","canonical_id":"hgnc:HGNC:54936","description":"TNIP2 pseudogene 1","metadata":null},{"id":"f3b643eef5ad47f69c80384b34d07bdd","type":"GENE","name":"TNIP3","canonical_id":"hgnc:HGNC:19315","description":null,"metadata":null},{"id":"67d7825f6bb04713a03e3da6c7ee896f","type":"GENE","name":"TNK1","canonical_id":"hgnc:HGNC:11940","description":"tyrosine kinase non receptor 1","metadata":{"aliases":["KOS1"]}},{"id":"ed4e8c5a4bda4e10bee4ec2b33f86619","type":"GENE","name":"TNK2","canonical_id":"hgnc:HGNC:19297","description":"tyrosine kinase non receptor 2","metadata":{"aliases":["p21cdc42Hs","ACK","ACK1"]}},{"id":"22e56a82ae62416381fc4d589b655edf","type":"GENE","name":"TNK2-AS1","canonical_id":"hgnc:HGNC:49093","description":"TNK2 antisense RNA 1","metadata":null},{"id":"1b50ae10185b4710bd88693c2c9b9782","type":"GENE","name":"TNKS","canonical_id":"hgnc:HGNC:11941","description":"tankyrase","metadata":{"aliases":["TIN1","TINF1","TNKS1","PARP-5a","PARP5A","pART5","ARTD5"]}},{"id":"32979132445944bb930aae4996778371","type":"GENE","name":"TNKS2","canonical_id":"hgnc:HGNC:15677","description":"tankyrase 2","metadata":{"aliases":["TNKL","TANK2","PARP-5b","PARP-5c","PARP5B","PARP5C","pART6","ARTD6"]}},{"id":"eefbab1200db4da1a6483535f2b9ab0a","type":"GENE","name":"TNKS2-DT","canonical_id":"hgnc:HGNC:45173","description":"TNKS2 divergent transcript","metadata":{"aliases":["TNKS2-AS1"]}},{"id":"1cdf05b92a4e4b8398ddbe142e357f47","type":"GENE","name":"TNMD","canonical_id":"hgnc:HGNC:17757","description":"tenomodulin","metadata":{"aliases":["myodulin","ChM1L","tendin","TEM","BRICD4"]}},{"id":"247a0970144b4cd4815b94851ee57734","type":"GENE","name":"TNN","canonical_id":"hgnc:HGNC:22942","description":"tenascin N","metadata":{"aliases":["TNW"]}},{"id":"3e5f114158e34dc3a1123d32e95c9540","type":"GENE","name":"TNNC1","canonical_id":"hgnc:HGNC:11943","description":"troponin C1, slow skeletal and cardiac type","metadata":{"aliases":["TNNC"]}},{"id":"9535664eb78448d7940c676302e06bdc","type":"GENE","name":"TNNC2","canonical_id":"hgnc:HGNC:11944","description":"troponin C2, fast skeletal type","metadata":{"aliases":["FAP85","CFAP85"]}},{"id":"4b3f20d6b1234e74937319a05aab2ecb","type":"GENE","name":"TNNI1","canonical_id":"hgnc:HGNC:11945","description":"troponin I1, slow skeletal type","metadata":{"aliases":["ssTnI"]}},{"id":"1f9bef00a08c46a1b50c02984c215ce1","type":"GENE","name":"TNNI2","canonical_id":"hgnc:HGNC:11946","description":"troponin I2, fast skeletal type","metadata":{"aliases":["FSSV","DA2B","fsTnI","AMCD2B"]}},{"id":"39647c9f12f440aca729288565da1db0","type":"GENE","name":"TNNI3","canonical_id":"hgnc:HGNC:11947","description":null,"metadata":null},{"id":"74f50d18cdf44716b94f231ef9cee81f","type":"GENE","name":"TNNI3K","canonical_id":"hgnc:HGNC:19661","description":"TNNI3 interacting kinase","metadata":{"aliases":["CARK"]}},{"id":"7f9b00eb9fe142a6882e6a8d94f6afa9","type":"GENE","name":"TNNT1","canonical_id":"hgnc:HGNC:11948","description":"troponin T1, slow skeletal type","metadata":{"aliases":["ANM","STNT","TNT","TNTS","FLJ98147","MGC104241","NEM5"]}},{"id":"d8ef985033864458b194286a9889af56","type":"GENE","name":"TNNT2","canonical_id":"hgnc:HGNC:11949","description":"troponin T2, cardiac type","metadata":{"aliases":["CMPD2","CMH2","CMD1D"]}},{"id":"f180d0b796e841e98f2fca6be4d00dc5","type":"GENE","name":"TNNT3","canonical_id":"hgnc:HGNC:11950","description":"troponin T3, fast skeletal type","metadata":{"aliases":["AMCD2B","DA2B","FSSV","DKFZp779M2348"]}},{"id":"c280179677754787a9cb2c3f0425c7b5","type":"GENE","name":"TNP1","canonical_id":"hgnc:HGNC:11951","description":"transition protein 1","metadata":null},{"id":"379de5f27e414819bc88a2bae9e1416a","type":"GENE","name":"TNP2","canonical_id":"hgnc:HGNC:11952","description":"transition protein 2","metadata":{"aliases":["TP2"]}},{"id":"552417077872487d80dd610313c76690","type":"GENE","name":"TNPO1","canonical_id":"hgnc:HGNC:6401","description":null,"metadata":null},{"id":"1fed0666fe6049798db2be6fb05eafe9","type":"GENE","name":"TNPO1-DT","canonical_id":"hgnc:HGNC:40328","description":"TNPO1 divergent transcript","metadata":{"aliases":["LINC02056"]}},{"id":"3ca6f4276bb5437a839df76ad3e8a563","type":"GENE","name":"TNPO1P1","canonical_id":"hgnc:HGNC:45120","description":"transportin 1 pseudogene 1","metadata":null},{"id":"4a6a275bf8a9486f8686e97c7746a6ef","type":"GENE","name":"TNPO1P2","canonical_id":"hgnc:HGNC:45121","description":"transportin 1 pseudogene 2","metadata":null},{"id":"0c7c14efd8394af58356357554e0b983","type":"GENE","name":"TNPO1P3","canonical_id":"hgnc:HGNC:50718","description":"transportin 1 pseudogene 3","metadata":null},{"id":"06e554ae04d44622b714180be6073dcd","type":"GENE","name":"TNPO2","canonical_id":"hgnc:HGNC:19998","description":"transportin 2","metadata":{"aliases":["IPO3","KPNB2B","FLJ12155","TRN2"]}},{"id":"2c2db6de8f2d4cdb9d9ddd288486d55d","type":"GENE","name":"TNPO3","canonical_id":"hgnc:HGNC:17103","description":"transportin 3","metadata":{"aliases":["TRN-SR","MTR10A","TRN-SR2","IPO12","LGMD1F"]}},{"id":"4b712ea6c4b542a195e04d253c7f7b0d","type":"GENE","name":"TNPO3P1","canonical_id":"hgnc:HGNC:55053","description":"TNPO3 pseudogene 1","metadata":null},{"id":"e499b74455394645bee6de93a5a90165","type":"GENE","name":"TNPO3P2","canonical_id":"hgnc:HGNC:56932","description":"TNPO3 pseudogene 2","metadata":null},{"id":"d83070449f014962a897fb5794829ee8","type":"GENE","name":"TNR","canonical_id":"hgnc:HGNC:11953","description":"tenascin R","metadata":null},{"id":"099665380e8847c9a7b674083749ab8c","type":"GENE","name":"TNR-IT1","canonical_id":"hgnc:HGNC:41391","description":"TNR intronic transcript 1","metadata":null},{"id":"58578c07a2b742068b01b4794fa33bd8","type":"GENE","name":"TNRC17","canonical_id":"hgnc:HGNC:11961","description":"trinucleotide repeat containing 17","metadata":{"aliases":["CAGL234"]}},{"id":"a0844c0fa14d45bcaa6db256ce72a046","type":"GENE","name":"TNRC18","canonical_id":"hgnc:HGNC:11962","description":"trinucleotide repeat containing 18","metadata":{"aliases":["CAGL79","TNRC18A","KIAA1856"]}},{"id":"f4d981ee2959428a9ba6940cdb153b67","type":"GENE","name":"TNRC18-AS1","canonical_id":"hgnc:HGNC:58212","description":"TNRC18 antisense RNA 1","metadata":null},{"id":"18f9dbedb0d94e53ad17b854f1fe7eee","type":"GENE","name":"TNRC18P1","canonical_id":"hgnc:HGNC:43881","description":"trinucleotide repeat containing 18 pseudogene 1","metadata":null},{"id":"786202bab5a743dcaca9b3375419e048","type":"GENE","name":"TNRC18P2","canonical_id":"hgnc:HGNC:34014","description":"trinucleotide repeat containing 18 pseudogene 2","metadata":{"aliases":["TNRC18B"]}},{"id":"3bd58b80de514feeb57554c2b2fa997d","type":"GENE","name":"TNRC18P3","canonical_id":"hgnc:HGNC:34015","description":"trinucleotide repeat containing 18 pseudogene 3","metadata":{"aliases":["TNRC18C"]}},{"id":"38ea72bd8f0e49c7a6d7c966c41af6e6","type":"GENE","name":"TNRC6A","canonical_id":"hgnc:HGNC:11969","description":"trinucleotide repeat containing adaptor 6A","metadata":{"aliases":["CAGH26","KIAA1460","GW182","TNRC6"]}},{"id":"dbede980e35d4761a3f64ea8df592065","type":"GENE","name":"TNRC6B","canonical_id":"hgnc:HGNC:29190","description":"trinucleotide repeat containing adaptor 6B","metadata":{"aliases":["KIAA1093"]}},{"id":"780a605349ec4ca29eb48db321a64e77","type":"GENE","name":"TNRC6B-DT","canonical_id":"hgnc:HGNC:55373","description":"TNRC6B divergent transcript","metadata":null},{"id":"98ad4562494846e1a18f28acede8bad2","type":"GENE","name":"TNRC6C","canonical_id":"hgnc:HGNC:29318","description":"trinucleotide repeat containing adaptor 6C","metadata":{"aliases":["KIAA1582","FLJ20015"]}},{"id":"1a50109e37b04bfaa1445fc9e06781e8","type":"GENE","name":"TNS1","canonical_id":"hgnc:HGNC:11973","description":"tensin 1","metadata":{"aliases":["DKFZp586K0617","PPP1R155","TNS","MXRA6"]}},{"id":"8e9fdc9a1ea84c0db25f5ea27a6afb71","type":"GENE","name":"TNS1-AS1","canonical_id":"hgnc:HGNC:40589","description":"TNS1 antisense RNA 1","metadata":null},{"id":"1674e832fe9b41f59dc68a9fd2ab0c6f","type":"GENE","name":"TNS2","canonical_id":"hgnc:HGNC:19737","description":"tensin 2","metadata":{"aliases":["KIAA1075","C1-TEN","TENC1"]}},{"id":"7534df4ce93a43e8823079dd5a9963f8","type":"GENE","name":"TNS2-AS1","canonical_id":"hgnc:HGNC:27464","description":"TNS2 antisense RNA 1","metadata":{"aliases":["RP11-983P16.4"]}},{"id":"ab03e06005a3462ba7928c00e688b8fd","type":"GENE","name":"TNS3","canonical_id":"hgnc:HGNC:21616","description":"tensin 3","metadata":{"aliases":["TEM6","H_NH0549I23.2","FLJ13732","TENS1"]}},{"id":"55d83694cecc45a3936157b4b90e8171","type":"GENE","name":"TNS4","canonical_id":"hgnc:HGNC:24352","description":"tensin 4","metadata":{"aliases":["CTEN"]}},{"id":"6d8a905185de42b3bdcdda3f41958a57","type":"GENE","name":"TNXA","canonical_id":"hgnc:HGNC:11975","description":"tenascin XA (pseudogene)","metadata":{"aliases":["XA","D6S103E","HXBL","TNX"]}},{"id":"dbfeb25b2c3d48d78a74f2cd23d1d911","type":"GENE","name":"TNXB","canonical_id":"hgnc:HGNC:11976","description":"tenascin XB","metadata":{"aliases":["TNXBS","XBS","XB","HXBL","TN-X","TNX","TNXB1","TNXB2"]}},{"id":"459146abfa4c45fbbb091ff0df73bd4d","type":"GENE","name":"TNXB-AS1","canonical_id":"hgnc:HGNC:59380","description":"TNXB antisense RNA 1","metadata":null},{"id":"1ce4db56f462460e9ae76f2b909111f1","type":"GENE","name":"TNXB-AS2","canonical_id":"hgnc:HGNC:59381","description":"TNXB antisense RNA 2","metadata":null},{"id":"d6772665a79445f2b92bb3d1d49e1423","type":"TRIAL","name":"TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE","canonical_id":"clinicaltrials.gov:NCT04413617","description":"Rheumatoid Arthritis","metadata":null},{"id":"eb120dacbfd845e6bcf44e3bd477621f","type":"TRIAL","name":"TO Compare the Triple Drug Therapy and Dual Therapy .","canonical_id":"clinicaltrials.gov:NCT02075242","description":"HEPATITIS","metadata":null},{"id":"2603c454d38b492584797cef96578a61","type":"GENE","name":"TOB1","canonical_id":"hgnc:HGNC:11979","description":null,"metadata":null},{"id":"a76783a19c5f493b97de9928778bb0a3","type":"GENE","name":"TOB1-AS1","canonical_id":"hgnc:HGNC:44340","description":"TOB1 antisense RNA 1","metadata":null},{"id":"04d2a58a3dd7456ab2fd323be55e4cd3","type":"GENE","name":"TOB2","canonical_id":"hgnc:HGNC:11980","description":"transducer of ERBB2, 2","metadata":{"aliases":["TOBL","TOB4","bK223H9","APRO5","TROB2"]}},{"id":"63453b7d57cd4af3aa14f5e33ad7ec25","type":"GENE","name":"TOB2P1","canonical_id":"hgnc:HGNC:13986","description":"transducer of ERBB2, 2 pseudogene 1","metadata":{"aliases":["TOB4p","p373c6.3","TOB2P"]}},{"id":"c96f8a38f03240ee8f53c3c2c2f991be","type":"GO_TERM","name":"TOC-TIC supercomplex I","canonical_id":"go:GO:0061927","description":"\"The protein transport macromolecular complex of the chloroplast membrane that interacts with the precursor proteins and contains components of both the outer membrane and inner membrane complexes containing at least Toc75, Toc159, Toc34 and Tic110.\" [PMID:28745032]","metadata":null},{"id":"894a720c23f645aba326c97bd54ec90d","type":"GENE","name":"TODL","canonical_id":"hgnc:HGNC:56636","description":"transcript overexpressed in dedifferentiated liposarcoma","metadata":null},{"id":"03dbb093c78c4748b1f78e69370edc84","type":"GENE","name":"TOE1","canonical_id":"hgnc:HGNC:15954","description":null,"metadata":null},{"id":"13870cfbeddc4114bf3f6786cd0a81b7","type":"TRIAL","name":"TOFAcitinib in SARS-CoV2 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04332042","description":"SARS-COv2 Related Interstitial Pneumonia","metadata":null},{"id":"7f0c16332468484e82b7d99b223a3ef1","type":"TRIAL","name":"TOFO Insulin Combination Trial","canonical_id":"clinicaltrials.gov:NCT02201004","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"ffb7f5f978f1403eaf672a29bcce3d57","type":"GENE","name":"TOGARAM1","canonical_id":"hgnc:HGNC:19959","description":"TOG array regulator of axonemal microtubules 1","metadata":{"aliases":["Crescerin-1","crescerin","KIAA0423","FAM179B"]}},{"id":"1be21344a8f74b68bde85833312374c9","type":"GENE","name":"TOGARAM2","canonical_id":"hgnc:HGNC:33715","description":"TOG array regulator of axonemal microtubules 2","metadata":{"aliases":["FLJ43249","LOC165186","Crescerin-2","FAM179A"]}},{"id":"bb5fc555e2b64d8b87c2367c277966bd","type":"TRIAL","name":"TOLERA: Tolerance Enhancement in RA","canonical_id":"clinicaltrials.gov:NCT04120831","description":"Rheumatoid Arthritis","metadata":null},{"id":"e6bd688156b8472e808120bd89228cb9","type":"GENE","name":"TOLLIP","canonical_id":"hgnc:HGNC:16476","description":"toll interacting protein","metadata":{"aliases":["IL-1RAcPIP"]}},{"id":"df2a4115182642f5b69e5ffc4e0ad8f2","type":"GENE","name":"TOLLIP-DT","canonical_id":"hgnc:HGNC:27403","description":"TOLLIP divergent transcript","metadata":{"aliases":["TOLLIP-AS1"]}},{"id":"cda03be57a4648e0aa0b83f415d7cc4a","type":"GO_TERM","name":"TOM complex","canonical_id":"go:GO:0140596","description":"\"A large mitochondrial outer membrane translocase complex that mediates transport of proteins into mitochondrial compartments. TOM transports beta-barrel precursors across the outer membrane and the sorting and assembly machinery (SAM complex) inserts them into the target membrane.\" [PMID:33035511]","metadata":null},{"id":"e4f0f80cdd5143f98914a005b7b82e7d","type":"GO_TERM","name":"TOM-TIM22-mediated mitochondrial inner membrane protein insertion","canonical_id":"go:GO:7770061","description":"\"The import of multipass-membrane proteins from the cytosol and their insertion into the mitochondrial inner membrane, supported by tiny-tim chaperones.\" [PMID:36931257]","metadata":null},{"id":"dfe20780c0f046fd93e50c7c51661ff3","type":"GO_TERM","name":"TOM-TIM23-SORT-mediated protein insertion into the mitochondrial inner membrane","canonical_id":"go:GO:7770060","description":"\"The import of proteins from the cytosol across the outer mitochondrial membrane and laterally inserted into the inner membrane. Typically acting on single-pass transmembrane proteins with an N-terminal targeting sequence and an internal hydrophobic stop-transfer sequence which targets them for lateral insertion.\" [PMID:36931257]","metadata":null},{"id":"e72de0611be3453985b2362c3b43d285","type":"GENE","name":"TOM1","canonical_id":"hgnc:HGNC:11982","description":"target of myb1 membrane trafficking protein","metadata":null},{"id":"485759c56b06406e9e5678af4cfc7b75","type":"GENE","name":"TOM1L1","canonical_id":"hgnc:HGNC:11983","description":"target of myb1 like 1 membrane trafficking protein","metadata":{"aliases":["SRCASM"]}},{"id":"613346a1902f40fe925edc214379517b","type":"GENE","name":"TOM1L2","canonical_id":"hgnc:HGNC:11984","description":"target of myb1 like 2 membrane trafficking protein","metadata":null},{"id":"62fab65a9ae84fe3af3ec5707cb7bbc7","type":"GENE","name":"TOM1L2-AS1","canonical_id":"hgnc:HGNC:58399","description":"TOM1L2 antisense RNA 1","metadata":null},{"id":"8b8f505052274c64a8e25f076fcdc5d1","type":"GENE","name":"TOMM20","canonical_id":"hgnc:HGNC:20947","description":"translocase of outer mitochondrial membrane 20","metadata":{"aliases":["KIAA0016","TOM20","MOM19","MAS20"]}},{"id":"a9202777ee144c1fa92ddd522d475290","type":"GENE","name":"TOMM20L","canonical_id":"hgnc:HGNC:33752","description":"translocase of outer mitochondrial membrane 20 like","metadata":{"aliases":["UNQ9438"]}},{"id":"01af7dad626a4f89b3b7352ab1bb1511","type":"GENE","name":"TOMM20L-DT","canonical_id":"hgnc:HGNC:55443","description":"TOMM20L divergent transcript","metadata":null},{"id":"17e00279d38e4bc098e41ef4483d74ff","type":"GENE","name":"TOMM20P1","canonical_id":"hgnc:HGNC:50518","description":"TOMM20 pseudogene 1","metadata":null},{"id":"b1748ef37ee04b8daf6cdce0a62f9098","type":"GENE","name":"TOMM20P2","canonical_id":"hgnc:HGNC:50519","description":"TOMM20 pseudogene 2","metadata":null},{"id":"a7cb866a6b514b918cf3863f38b5c708","type":"GENE","name":"TOMM20P3","canonical_id":"hgnc:HGNC:50520","description":"TOMM20 pseudogene 3","metadata":null},{"id":"e8f544dc6cf943869640090cc9ff56cc","type":"GENE","name":"TOMM20P4","canonical_id":"hgnc:HGNC:50522","description":"TOMM20 pseudogene 4","metadata":null},{"id":"d00e92debd1a4ba49152bbfd29b2e187","type":"GENE","name":"TOMM22","canonical_id":"hgnc:HGNC:18002","description":"translocase of outer mitochondrial membrane 22","metadata":{"aliases":["TOM22"]}},{"id":"bac8acf0c92b4ee894009f2b983f5936","type":"GENE","name":"TOMM22-DT","canonical_id":"hgnc:HGNC:56758","description":"TOMM22 divergent transcript","metadata":{"aliases":["lnc408"]}},{"id":"c0e41525723f444c8dcc672895b814fc","type":"GENE","name":"TOMM22P1","canonical_id":"hgnc:HGNC:38736","description":"TOMM22 pseudogene 1","metadata":null},{"id":"cc322218b6e3456585560ff1f5e4dcb8","type":"GENE","name":"TOMM22P2","canonical_id":"hgnc:HGNC:38737","description":"TOMM22 pseudogene 2","metadata":null},{"id":"83bb5f982ca244068903c5fd19abe07a","type":"GENE","name":"TOMM22P3","canonical_id":"hgnc:HGNC:38739","description":"TOMM22 pseudogene 3","metadata":null},{"id":"2a5564906e124683b0944affa48153a1","type":"GENE","name":"TOMM22P4","canonical_id":"hgnc:HGNC:38740","description":"TOMM22 pseudogene 4","metadata":null},{"id":"7152c9c9476b4254b7e869a13850b543","type":"GENE","name":"TOMM22P5","canonical_id":"hgnc:HGNC:38741","description":"TOMM22 pseudogene 5","metadata":null},{"id":"4e4defdfa9c44ce1b1184fa045619791","type":"GENE","name":"TOMM22P6","canonical_id":"hgnc:HGNC:38742","description":"TOMM22 pseudogene 6","metadata":null},{"id":"9a7610ec38514999bed89ba18fea1423","type":"GENE","name":"TOMM34","canonical_id":"hgnc:HGNC:15746","description":null,"metadata":null},{"id":"d8fe2592d04e43dc9c6552bc72244955","type":"GENE","name":"TOMM40","canonical_id":"hgnc:HGNC:18001","description":"translocase of outer mitochondrial membrane 40","metadata":{"aliases":["PEREC1","D19S1177E","C19orf1","TOM40","PER-EC1"]}},{"id":"b028abf4af894f57a09f439284d57b01","type":"GENE","name":"TOMM40L","canonical_id":"hgnc:HGNC:25756","description":"translocase of outer mitochondrial membrane 40 like","metadata":{"aliases":["FLJ12770","TOMM40B"]}},{"id":"77adc968869a47829d2e7ee5214111ae","type":"GENE","name":"TOMM40P1","canonical_id":"hgnc:HGNC:54623","description":"TOMM40 pseudogene 1","metadata":null},{"id":"51a63f4cd6874a4bb6275e791873cd9f","type":"GENE","name":"TOMM40P2","canonical_id":"hgnc:HGNC:54624","description":"TOMM40 pseudogene 2","metadata":null},{"id":"bb69d165b7b04454b52661d652f71bd9","type":"GENE","name":"TOMM40P3","canonical_id":"hgnc:HGNC:54632","description":"TOMM40 pseudogene 3","metadata":null},{"id":"cba470a3261a4ef4b14798d3a0ffed87","type":"GENE","name":"TOMM40P4","canonical_id":"hgnc:HGNC:54633","description":"TOMM40 pseudogene 4","metadata":null},{"id":"b5e9fed59fe24f5ebbdbbfde5ee5784c","type":"GENE","name":"TOMM5","canonical_id":"hgnc:HGNC:31369","description":"translocase of outer mitochondrial membrane 5","metadata":{"aliases":["bA613M10.3","Tom5","C9orf105"]}},{"id":"51512b8d078648eea53ab61c051bb499","type":"GENE","name":"TOMM5P1","canonical_id":"hgnc:HGNC:56896","description":"TOMM5 pseudogene 1","metadata":null},{"id":"8ed7460b5f17444485f9b70c0dcdea12","type":"GENE","name":"TOMM6","canonical_id":"hgnc:HGNC:34528","description":"translocase of outer mitochondrial membrane 6","metadata":{"aliases":["OBTP","Tom6"]}},{"id":"b740e21cac004b879ead08c83e7ca749","type":"GENE","name":"TOMM6P1","canonical_id":"hgnc:HGNC:58628","description":"TOMM6 pseudogene 1","metadata":null},{"id":"203ae12588234d2ebe4f6cfbdc1fce89","type":"GENE","name":"TOMM6P2","canonical_id":"hgnc:HGNC:58629","description":"TOMM6 pseudogene 2","metadata":null},{"id":"70b429a205da4780800c86866321ef13","type":"GENE","name":"TOMM6P3","canonical_id":"hgnc:HGNC:58630","description":"TOMM6 pseudogene 3","metadata":null},{"id":"6d93086042c549589f39da0523e57399","type":"GENE","name":"TOMM6P4","canonical_id":"hgnc:HGNC:58631","description":"TOMM6 pseudogene 4","metadata":null},{"id":"0530e3fd531e493ba2f9d02b93e57afd","type":"GENE","name":"TOMM7","canonical_id":"hgnc:HGNC:21648","description":"translocase of outer mitochondrial membrane 7","metadata":{"aliases":["Tom7"]}},{"id":"ff9cdea4ae82464fad3bf7fada96aad8","type":"GENE","name":"TOMM70","canonical_id":"hgnc:HGNC:11985","description":null,"metadata":null},{"id":"25f44b9b3dcc41a395d9b82e57682af5","type":"GENE","name":"TOMT","canonical_id":"hgnc:HGNC:55527","description":"transmembrane O-methyltransferase","metadata":{"aliases":["COMT2"]}},{"id":"b1be10ec173647e9bc8fe07518553ce8","type":"GENE","name":"TONSL","canonical_id":"hgnc:HGNC:7801","description":"tonsoku like, DNA repair protein","metadata":{"aliases":["IKBR","NFKBIL2"]}},{"id":"a5f4b3c7900246c5a08c9914f41dad47","type":"GENE","name":"TONSL-AS1","canonical_id":"hgnc:HGNC:51556","description":"TONSL antisense RNA 1","metadata":null},{"id":"68a79bf211f846279e46323995787832","type":"TRIAL","name":"TOP 2301: Neoadjuvant Chemo for NSCLC","canonical_id":"clinicaltrials.gov:NCT06385262","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"40efe642b0054ca4a8ca754f0f4e4049","type":"GENE","name":"TOP1","canonical_id":"hgnc:HGNC:11986","description":null,"metadata":null},{"id":"f79a6b96b25244bd813f423b13bf6088","type":"PROTEIN","name":"TOP1","canonical_id":"uniprot:P11387","description":null,"metadata":null},{"id":"4bd732f3084744f78881db8258360246","type":"GENE","name":"TOP1MT","canonical_id":"hgnc:HGNC:29787","description":null,"metadata":null},{"id":"e2d14bd3aefe42c5a059384c7bb4e502","type":"GENE","name":"TOP1P1","canonical_id":"hgnc:HGNC:11987","description":"DNA topoisomerase I pseudogene 1","metadata":null},{"id":"a0c6af8915d645918f5424a88aca14b5","type":"GENE","name":"TOP1P2","canonical_id":"hgnc:HGNC:11988","description":"DNA topoisomerase I pseudogene 2","metadata":null},{"id":"b8fa354df8b547f1b86c5bd17c0b3978","type":"GENE","name":"TOP2A","canonical_id":"hgnc:HGNC:11989","description":null,"metadata":null},{"id":"59842dc3adc34236a9f34812a089a4d5","type":"PROTEIN","name":"TOP2A","canonical_id":"uniprot:P11388","description":null,"metadata":null},{"id":"3169ab2bbb9146fbb3819ea4daa1b8d8","type":"GENE","name":"TOP2B","canonical_id":"hgnc:HGNC:11990","description":null,"metadata":null},{"id":"890cdc4540ae4e2280f740b64d495d4b","type":"GENE","name":"TOP3A","canonical_id":"hgnc:HGNC:11992","description":null,"metadata":null},{"id":"725291c4957849de8b0c00bcc7cd6b23","type":"GENE","name":"TOP3B","canonical_id":"hgnc:HGNC:11993","description":"DNA topoisomerase III beta","metadata":null},{"id":"c57ba02ba2614731ba4b70079711a3fa","type":"GENE","name":"TOP3BP1","canonical_id":"hgnc:HGNC:11994","description":"DNA topoisomerase III beta pseudogene 1","metadata":{"aliases":["TOP3B2"]}},{"id":"80c3347ed7384d5dae2a9333413dfa48","type":"GENE","name":"TOP6BL","canonical_id":"hgnc:HGNC:26197","description":"TOP6B like initiator of meiotic double strand breaks","metadata":{"aliases":["FLJ22531","TOPOVIBL","C11orf80"]}},{"id":"87ac8c4b928e47108f01acb606466434","type":"GENE","name":"TOPAZ1","canonical_id":"hgnc:HGNC:24746","description":"testis and ovary specific TOPAZ 1","metadata":{"aliases":["FLJ36157","C3orf77"]}},{"id":"2d34278630f04f809ee74c8d23fbd925","type":"TRIAL","name":"TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases","canonical_id":"clinicaltrials.gov:NCT04512261","description":"Breast Cancer; Brain Metastases; HER2-positive Breast Cancer; CNS Disease","metadata":null},{"id":"c3421d4da5024f2abbda6867b76ae8c7","type":"GENE","name":"TOPBP1","canonical_id":"hgnc:HGNC:17008","description":null,"metadata":null},{"id":"f6c088e8a3a249a7bd4be738cfa52478","type":"GENE","name":"TOPORS","canonical_id":"hgnc:HGNC:21653","description":"TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase","metadata":{"aliases":["TP53BPL","LUN","RP31"]}},{"id":"2efa3378f03e411e98b6d3eee0656a3e","type":"GENE","name":"TOPORSLP","canonical_id":"hgnc:HGNC:50276","description":"topoisomerase I binding, arginine and serine rich like, pseudogene","metadata":{"aliases":["TOPORSLP1"]}},{"id":"ea7a11ff9302435ea0d8b50d825a824c","type":"GO_TERM","name":"TOR complex","canonical_id":"go:GO:0038201","description":"\"A protein complex that contains at least TOR (target of rapamycin) in complex with other signaling components. Mediates the phosphorylation and activation of downstream signaling components including PKB (AKT) or S6K.\" [Wikipedia:MTORC1, Wikipedia:MTORC2]","metadata":null},{"id":"31206c1e038641c1973d78f136fd2925","type":"GO_TERM","name":"TOR signaling","canonical_id":"go:GO:0031929","description":"\"The series of molecular signals mediated by TOR (Target of rapamycin) proteins, members of the phosphoinositide (PI) 3-kinase related kinase (PIKK) family that act as serine/threonine kinases in response to nutrient availability or growth factors.\" [PMID:12372295]","metadata":null},{"id":"25f19c5d3cd14bea900282dd3053ec7b","type":"GENE","name":"TOR1A","canonical_id":"hgnc:HGNC:3098","description":"torsin family 1 member A","metadata":{"aliases":["DQ2","DYT1"]}},{"id":"1139dab6099d4d77b9ba9e145d309d92","type":"GENE","name":"TOR1AIP1","canonical_id":"hgnc:HGNC:29456","description":"torsin 1A interacting protein 1","metadata":{"aliases":["LAP1B","FLJ13142","LAP1","LAP1C"]}},{"id":"a05c362371dd4fc3b572b2532bea2858","type":"GENE","name":"TOR1AIP2","canonical_id":"hgnc:HGNC:24055","description":"torsin 1A interacting protein 2","metadata":{"aliases":["LULL1","NET9","IFRG15"]}},{"id":"cd188353ea73443cb10235f17ed66ee5","type":"GENE","name":"TOR1B","canonical_id":"hgnc:HGNC:11995","description":"torsin family 1 member B","metadata":{"aliases":["DQ1","MGC4386"]}},{"id":"05a8220b5d6e4352852909a45325c80e","type":"GENE","name":"TOR1BP1","canonical_id":"hgnc:HGNC:54599","description":"TOR1B pseudogene 1","metadata":null},{"id":"1cef915e06d14aad958f27608cf80f3c","type":"GENE","name":"TOR2A","canonical_id":"hgnc:HGNC:11996","description":"torsin family 2 member A","metadata":{"aliases":["FLJ14771","TORP1"]}},{"id":"2e06172f19564eff8d13863d62baca63","type":"GENE","name":"TOR3A","canonical_id":"hgnc:HGNC:11997","description":"torsin family 3 member A","metadata":{"aliases":["FLJ22345","ADIR2","ADIR"]}},{"id":"1d51418d8bfc42e0845c678a31256ff0","type":"GENE","name":"TOR4A","canonical_id":"hgnc:HGNC:25981","description":"torsin family 4 member A","metadata":{"aliases":["FLJ20245","C9orf167"]}},{"id":"6fb437e01e3f4d1daa2527d511d4bd90","type":"GO_TERM","name":"TORC1 complex","canonical_id":"go:GO:0031931","description":"\"A protein complex that contains at least TOR (target of rapamycin) and Raptor (regulatory-associated protein of TOR), or orthologs of, in complex with other signaling components. Mediates the phosphorylation and activation of S6K. In Saccharomyces, the complex contains Kog1p, Lst8p, Tco89p, and either Tor1p or Tor2p.\" [GOC:jh, PMID:15780592, PMID:16469695, PMID:21548787]","metadata":null},{"id":"e2c369d9a4ce4be5b978ccdb090c4845","type":"GO_TERM","name":"TORC1 complex assembly","canonical_id":"go:GO:1905669","description":"\"The aggregation, arrangement and bonding together of a set of components to form a TORC1 complex.\" [GO_REF:0000079, GOC:kmv, GOC:TermGenie, PMID:21952218]","metadata":null},{"id":"e1b30673f06c440b86bcea3d4698a84d","type":"GO_TERM","name":"TORC1 signaling","canonical_id":"go:GO:0038202","description":"\"A series of intracellular molecular signals mediated by TORC1; TOR (target of rapamycin) in complex with at least Raptor (regulatory-associated protein of TOR), or orthologs of, and other signaling components.\" [GOC:lb]","metadata":null},{"id":"984c01495e9544c3ad7cc5266908dceb","type":"GO_TERM","name":"TORC2 complex","canonical_id":"go:GO:0031932","description":"\"A protein complex that contains at least TOR (target of rapamycin) and Rictor (rapamycin-insensitive companion of TOR), or orthologs of, in complex with other signaling components. Mediates the phosphorylation and activation of PKB (also called AKT). In Saccharomyces, the complex contains Avo1p, Avo2p, Tsc11p, Lst8p, Bit61p, Slm1p, Slm2p, and Tor2p.\" [GOC:bf, GOC:jh, PMID:14736892, PMID:15780592, PMID:16469695, PMID:21548787]","metadata":null},{"id":"c73d37458d8c4098abd5b2c86e367bbf","type":"GO_TERM","name":"TORC2 complex binding","canonical_id":"go:GO:1904841","description":"\"Binding to a TORC2 complex.\" [GOC:TermGenie, PMID:20660630]","metadata":null},{"id":"3a02f1fde98746168eb6719f5008fa05","type":"GO_TERM","name":"TORC2 complex disassembly","canonical_id":"go:GO:1905670","description":"\"The disaggregation of a TORC2 complex into its constituent components.\" [GO_REF:0000079, GOC:kmv, GOC:TermGenie, PMID:21952218]","metadata":null},{"id":"737eaabf75a9482cba8a8b664740d889","type":"GO_TERM","name":"TORC2 signaling","canonical_id":"go:GO:0038203","description":"\"A series of intracellular molecular signals mediated by TORC2; TOR (rapamycin-insensitive companion of TOR) in complex with at least Rictor (regulatory-associated protein of TOR), or orthologs of, and other signaling components.\" [GOC:lb]","metadata":null},{"id":"dfce27cc32b44f1093ae3222b63833ca","type":"TRIAL","name":"TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Na\u00efve to RoActemra/Actemra Treatment","canonical_id":"clinicaltrials.gov:NCT02031471","description":"Rheumatoid Arthritis","metadata":null},{"id":"51d6c430320c4f7ab913f93893b0bee5","type":"GENE","name":"TOX","canonical_id":"hgnc:HGNC:18988","description":"thymocyte selection associated high mobility group box","metadata":{"aliases":["KIAA0808","TOX1"]}},{"id":"59f5d6169453459694d80a6c61e354d1","type":"GENE","name":"TOX-DT","canonical_id":"hgnc:HGNC:55935","description":"TOX divergent transcript","metadata":null},{"id":"9ec0ba494cc44383943788be82103b6f","type":"GENE","name":"TOX2","canonical_id":"hgnc:HGNC:16095","description":"TOX high mobility group box family member 2","metadata":{"aliases":["dJ1108D11.2","GCX-1","C20orf100"]}},{"id":"0026b00dfa744ccd9cf160b559828ef8","type":"GENE","name":"TOX3","canonical_id":"hgnc:HGNC:11972","description":"TOX high mobility group box family member 3","metadata":{"aliases":["CAGF9","TNRC9"]}},{"id":"19652ee0146240118a96e2dd589493bd","type":"GENE","name":"TOX4","canonical_id":"hgnc:HGNC:20161","description":"TOX high mobility group box family member 4","metadata":{"aliases":["LCP1","C14orf92","KIAA0737"]}},{"id":"e2cec7f399d34aa59b599128c155d3d8","type":"GENE","name":"TOX4P1","canonical_id":"hgnc:HGNC:44009","description":"TOX high mobility group box family member 4 pseudogene 1","metadata":null},{"id":"e97c8e0e6f4f4e2982b656018354df53","type":"GENE","name":"TP53","canonical_id":"hgnc:HGNC:11998","description":null,"metadata":null},{"id":"c88b4b6c0eda4f4c983e699730744bb9","type":"GENE","name":"TP53","canonical_id":"ensembl:ENSG00000141510","description":null,"metadata":null},{"id":"ff53da32f03a4f409bab5d7331c1d090","type":"BIOMARKER","name":"TP53 A161T","canonical_id":"civic:1088","description":null,"metadata":null},{"id":"ca7c386071d04c0bb78d8f621f08a04c","type":"BIOMARKER","name":"TP53 A276V","canonical_id":"civic:1024","description":null,"metadata":null},{"id":"8ecd336cd9034e27ac906e1ec0dca6d9","type":"BIOMARKER","name":"TP53 ALTERATION","canonical_id":"civic:1281","description":null,"metadata":null},{"id":"2df6f03e6842401f8a0ebaa508e0a658","type":"BIOMARKER","name":"TP53 C124R","canonical_id":"civic:3981","description":null,"metadata":null},{"id":"2d8b716dc5a34b5d9b5499b7902d652c","type":"BIOMARKER","name":"TP53 C135W","canonical_id":"civic:898","description":null,"metadata":null},{"id":"23d2caf6ca4a4821b2721712e4fefc8b","type":"BIOMARKER","name":"TP53 C238Y","canonical_id":"civic:2517","description":null,"metadata":null},{"id":"fe23228c34a844c787a8be587e54f646","type":"BIOMARKER","name":"TP53 C242F","canonical_id":"civic:1036","description":null,"metadata":null},{"id":"5a67236ef31d42388424987a711bf875","type":"BIOMARKER","name":"TP53 C242S","canonical_id":"civic:1037","description":null,"metadata":null},{"id":"43fc1a19ca3245f8971f036ebf72b072","type":"BIOMARKER","name":"TP53 C242Y","canonical_id":"civic:1038","description":null,"metadata":null},{"id":"1ea71426a50c4083849daa3de843e3e7","type":"BIOMARKER","name":"TP53 CONSERVED DOMAIN MUT","canonical_id":"civic:1274","description":null,"metadata":null},{"id":"e7f42f1e86054405bef8a1554d954458","type":"BIOMARKER","name":"TP53 D259V","canonical_id":"civic:3269","description":null,"metadata":null},{"id":"a0ed68d2d3c745e6b799190a2e2320f2","type":"BIOMARKER","name":"TP53 D281E","canonical_id":"civic:1018","description":null,"metadata":null},{"id":"c6cc0f73cab2439e878bc8157723694b","type":"BIOMARKER","name":"TP53 D281N","canonical_id":"civic:3660","description":null,"metadata":null},{"id":"390f37c202c94d579f909c5a4e78825c","type":"BIOMARKER","name":"TP53 DNA Binding Domain Mutation","canonical_id":"civic:238","description":null,"metadata":null},{"id":"5bbe7a889fb04adca440c5903843657a","type":"BIOMARKER","name":"TP53 Deleterious Mutation","canonical_id":"civic:221","description":null,"metadata":null},{"id":"4b6c65512110412aaf1aa9c7aa04db25","type":"BIOMARKER","name":"TP53 E224K","canonical_id":"civic:3648","description":null,"metadata":null},{"id":"bcbb9aec6d6e4282be2c480a815a55b2","type":"BIOMARKER","name":"TP53 E258K","canonical_id":"civic:3640","description":null,"metadata":null},{"id":"9f6e91607bff413eafe2736e4cc3cf85","type":"BIOMARKER","name":"TP53 E285K","canonical_id":"civic:1017","description":null,"metadata":null},{"id":"82319f81ee264ea49f41cabc8147e847","type":"BIOMARKER","name":"TP53 E286K","canonical_id":"civic:889","description":null,"metadata":null},{"id":"785dc3327bcc47fba895ea33dffed6fd","type":"BIOMARKER","name":"TP53 E68G","canonical_id":"civic:3974","description":null,"metadata":null},{"id":"f93c734d051d4e958eb8cd2433797b0f","type":"BIOMARKER","name":"TP53 F270S","canonical_id":"civic:1027","description":null,"metadata":null},{"id":"0935805b1b694771858d7e81ce9846aa","type":"BIOMARKER","name":"TP53 G154S","canonical_id":"civic:3287","description":null,"metadata":null},{"id":"c6dcaae5f92347ae9a2b73f7667c25d6","type":"BIOMARKER","name":"TP53 G244S","canonical_id":"civic:1034","description":null,"metadata":null},{"id":"6e715ece3ec9464c8daa4e0512a95b98","type":"BIOMARKER","name":"TP53 G245D","canonical_id":"civic:1010","description":null,"metadata":null},{"id":"b0e4898f2cca410c9ab94ce9d9073b5a","type":"BIOMARKER","name":"TP53 G245S","canonical_id":"civic:853","description":null,"metadata":null},{"id":"654028837334455db96ff95be2a255b3","type":"BIOMARKER","name":"TP53 G262D","canonical_id":"civic:3641","description":null,"metadata":null},{"id":"007735bea1934acab99f8f06bc19c198","type":"BIOMARKER","name":"TP53 G266E","canonical_id":"civic:3642","description":null,"metadata":null},{"id":"37f183bdef364ae0a6c8653d1b7d90b2","type":"BIOMARKER","name":"TP53 G266R","canonical_id":"civic:1029","description":null,"metadata":null},{"id":"3e8f0066b7ba4090a5d96419262eef14","type":"BIOMARKER","name":"TP53 G266V","canonical_id":"civic:3990","description":null,"metadata":null},{"id":"b6d2d72d98744a70a323beea2f14fe36","type":"BIOMARKER","name":"TP53 G279E","canonical_id":"civic:3659","description":null,"metadata":null},{"id":"693dcdfb9d4147e98b9a5cade9911065","type":"BIOMARKER","name":"TP53 H115Y","canonical_id":"civic:3980","description":null,"metadata":null},{"id":"86d54362c0a74e46a7c5e80d2cff4bfd","type":"BIOMARKER","name":"TP53 H168Y","canonical_id":"civic:3651","description":null,"metadata":null},{"id":"36e9d59b32314786824bfbe09332987d","type":"BIOMARKER","name":"TP53 H178P","canonical_id":"civic:3971","description":null,"metadata":null},{"id":"3a20ca1a9c944baba7d940758ce9255c","type":"BIOMARKER","name":"TP53 H179R","canonical_id":"civic:1056","description":null,"metadata":null},{"id":"70a9794f0c504186a94931eb60ae31e5","type":"BIOMARKER","name":"TP53 H179Y","canonical_id":"civic:1057","description":null,"metadata":null},{"id":"973d925a9de04f34aa50bb22254a5a0f","type":"BIOMARKER","name":"TP53 I162F","canonical_id":"civic:3636","description":null,"metadata":null},{"id":"d4f0d83f4b56453999f2167899137585","type":"BIOMARKER","name":"TP53 R175H OR TP53 H193R","canonical_id":"civic:5817","description":null,"metadata":null},{"id":"b6e67dd623f04972a384a30329e41838","type":"BIOMARKER","name":"TP53 R273C OR TP53 G245S OR TP53 R213*","canonical_id":"civic:5814","description":null,"metadata":null},{"id":"cebfbbed7d1542509ab36bbb5c8e3de8","type":"GENE","name":"TP53AIP1","canonical_id":"hgnc:HGNC:29984","description":"tumor protein p53 regulated apoptosis inducing protein 1","metadata":{"aliases":["p53AIP1"]}},{"id":"736c11a8104848b59dfca387dcd29d8d","type":"GENE","name":"TP53BP1","canonical_id":"hgnc:HGNC:11999","description":null,"metadata":null},{"id":"6929f5e57001442888b53c2c58cb9599","type":"GENE","name":"TP53BP2","canonical_id":"hgnc:HGNC:12000","description":null,"metadata":null},{"id":"feb5234cfd25487a9a319298ea63de3c","type":"GENE","name":"TP53BP2P1","canonical_id":"hgnc:HGNC:16328","description":"tumor protein p53 binding protein 2 pseudogene 1","metadata":{"aliases":["PPP1R13AP"]}},{"id":"c3521f24f889406ca6b1ec9cb011e07b","type":"GENE","name":"TP53COR1","canonical_id":"hgnc:HGNC:43652","description":"tumor protein p53 pathway corepressor 1","metadata":{"aliases":["linc-p21","lincRNA-p21","Trp53cor1"]}},{"id":"3ec09cf001f749fca359fd01f1d38e69","type":"GENE","name":"TP53I11","canonical_id":"hgnc:HGNC:16842","description":"tumor protein p53 inducible protein 11","metadata":{"aliases":["PIG11"]}},{"id":"746f55b051fe4c65b503852259f9cc5c","type":"GENE","name":"TP53I13","canonical_id":"hgnc:HGNC:25102","description":"tumor protein p53 inducible protein 13","metadata":{"aliases":["DSCP1"]}},{"id":"745439d36c9744f8992de867039f00b7","type":"GENE","name":"TP53I3","canonical_id":"hgnc:HGNC:19373","description":null,"metadata":null},{"id":"6285f0dbd62b46119452d84c9e371bb7","type":"GENE","name":"TP53INP1","canonical_id":"hgnc:HGNC:18022","description":null,"metadata":null},{"id":"92f57ad0e0a5467187b020849f94a454","type":"GENE","name":"TP53INP2","canonical_id":"hgnc:HGNC:16104","description":"tumor protein p53 inducible nuclear protein 2","metadata":{"aliases":["FLJ21759","FLJ23500","DKFZp434B2411","DKFZp434O0827","dJ1181N3.1","PINH","DOR","C20orf110"]}},{"id":"23344865faf2454bb0eb8a9f61e59d70","type":"GENE","name":"TP53RK","canonical_id":"hgnc:HGNC:16197","description":"TP53 regulating kinase","metadata":{"aliases":["dJ101A2.2","prpk","Nori-2p","BUD32","TPRKB","C20orf64"]}},{"id":"b3c52cc23cc241b3b6f053afcd1a17c7","type":"GENE","name":"TP53RK-DT","canonical_id":"hgnc:HGNC:55243","description":"TP53RK divergent transcript","metadata":null},{"id":"8d41ca68049b42fbb24ebfbb673384da","type":"GENE","name":"TP53TG1","canonical_id":"hgnc:HGNC:17026","description":"TP53 target 1","metadata":{"aliases":["H_RG012D21.9","LINC00096","TP53LC12","TP53AP1"]}},{"id":"460b8fbafa5e42fbafe854151582d354","type":"GENE","name":"TP53TG3","canonical_id":"hgnc:HGNC:30759","description":"TP53 target 3","metadata":{"aliases":["P53TG3","TP53TG3A"]}},{"id":"cab6d9b3d05f44969adca563453820bf","type":"GENE","name":"TP53TG3B","canonical_id":"hgnc:HGNC:37202","description":"TP53 target 3B","metadata":null},{"id":"413e15863bf84b8ea8c349a8aadd7903","type":"GENE","name":"TP53TG3C","canonical_id":"hgnc:HGNC:42962","description":"TP53 target 3C","metadata":null},{"id":"83352b329b164736b1304fd771b617de","type":"GENE","name":"TP53TG3D","canonical_id":"hgnc:HGNC:44657","description":"TP53 target 3D","metadata":null},{"id":"f588aa8ff8d64f24a166aa1902409e8a","type":"GENE","name":"TP53TG3E","canonical_id":"hgnc:HGNC:51816","description":"TP53 target 3 family member E","metadata":null},{"id":"05b60d97028a45e4ac1533c14b11829c","type":"GENE","name":"TP53TG3F","canonical_id":"hgnc:HGNC:51817","description":"TP53 target 3 family member F","metadata":null},{"id":"8f0f3cd34b6f4847b9a62d7d13de90b8","type":"GENE","name":"TP53TG3GP","canonical_id":"hgnc:HGNC:51818","description":"TP53 target 3 family member G, pseudogene","metadata":null},{"id":"31d8aea459c54435a292e9e9b1534b36","type":"GENE","name":"TP53TG3HP","canonical_id":"hgnc:HGNC:51819","description":"TP53 target 3 family member H, pseudogene","metadata":null},{"id":"68480c8229f74d8e990f5e67d38b6fe2","type":"GENE","name":"TP53TG5","canonical_id":"hgnc:HGNC:15856","description":"TP53 target 5","metadata":{"aliases":["CLG01","dJ453C12.5","C20orf10"]}},{"id":"aa64c53e89d64567afa9ca85a890e2ae","type":"GENE","name":"TP63","canonical_id":"hgnc:HGNC:15979","description":null,"metadata":null},{"id":"4c8b60083e8441f8b85fc0b7ab29ad28","type":"GENE","name":"TP73","canonical_id":"hgnc:HGNC:12003","description":null,"metadata":null},{"id":"4d3e9953099948e3bf6a5afbf8ff3f6b","type":"GENE","name":"TP73-AS2","canonical_id":"hgnc:HGNC:40591","description":"TP73 antisense RNA 2","metadata":{"aliases":["RP5-1092A11.2"]}},{"id":"7af45102a67a4dffa9e72f6b9ccd9616","type":"GENE","name":"TP73-AS3","canonical_id":"hgnc:HGNC:40590","description":"TP73 antisense RNA 3","metadata":null},{"id":"cd251b38b61640a9a72d10082690ad20","type":"GENE","name":"TPBG","canonical_id":"hgnc:HGNC:12004","description":"trophoblast glycoprotein","metadata":{"aliases":["5T4-AG","5T4"]}},{"id":"c875de1c6a2e46b889fa6362009ac3f7","type":"GENE","name":"TPBGL","canonical_id":"hgnc:HGNC:44159","description":"trophoblast glycoprotein like","metadata":null},{"id":"aaa743839a664b468601d4f68774e26e","type":"GENE","name":"TPBGL-AS1","canonical_id":"hgnc:HGNC:55506","description":"TPBGL antisense RNA 1","metadata":null},{"id":"1dde002e5e944dc2ac8c432bb28a472a","type":"GENE","name":"TPCN1","canonical_id":"hgnc:HGNC:18182","description":"two pore segment channel 1","metadata":{"aliases":["KIAA1169","FLJ20612","TPC1"]}},{"id":"8075a36f28684e53b6f7031361ae7329","type":"GENE","name":"TPCN2","canonical_id":"hgnc:HGNC:20820","description":"two pore segment channel 2","metadata":{"aliases":["TPC2"]}},{"id":"d7220bf04fa04f5ea0853a84c786b915","type":"GENE","name":"TPD52","canonical_id":"hgnc:HGNC:12005","description":"tumor protein D52","metadata":{"aliases":["D52","hD52","N8L"]}},{"id":"3d84b032e5634b2591514818e50d6a92","type":"GENE","name":"TPD52L1","canonical_id":"hgnc:HGNC:12006","description":"TPD52 like 1","metadata":{"aliases":["D53","hD53","TPD53"]}},{"id":"8f1793cc11fc4b2b8d2bcc1b38521fc7","type":"GENE","name":"TPD52L2","canonical_id":"hgnc:HGNC:12007","description":"TPD52 like 2","metadata":{"aliases":["D54","hD54","TPD54"]}},{"id":"5483c59f873d46ca8956afd3f146c49f","type":"GENE","name":"TPD52L3","canonical_id":"hgnc:HGNC:23382","description":"TPD52 like 3","metadata":{"aliases":["NYD-SP25","D55","TPD55"]}},{"id":"c9a1f9ec40b84e13b6bfdc4c2151a803","type":"TRIAL","name":"TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07502872","description":"Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Lymphoma; Lymphoma, B-Cell","metadata":null},{"id":"6057745c2e4c45debf00ac990b7da2d7","type":"GENE","name":"TPGS1","canonical_id":"hgnc:HGNC:25058","description":"tubulin polyglutamylase complex subunit 1","metadata":{"aliases":["GTRGEO22","PGs1","C19orf20"]}},{"id":"32501e9a1cba44c68a88938a62ce73a3","type":"GENE","name":"TPGS2","canonical_id":"hgnc:HGNC:24561","description":"tubulin polyglutamylase complex subunit 2","metadata":{"aliases":["DKFZP586M1523","HsT3006","PGs2","C18orf10"]}},{"id":"27870fc161e848a5aa2ae82bebcc447c","type":"GENE","name":"TPH1","canonical_id":"hgnc:HGNC:12008","description":null,"metadata":null},{"id":"5c3d16fbd9644e59a525e86712d3e44d","type":"GENE","name":"TPH2","canonical_id":"hgnc:HGNC:20692","description":null,"metadata":null},{"id":"04e8c15a4c434652abbef313fa6355cc","type":"TRIAL","name":"TPI 287 in Breast Cancer Metastatic to the Brain","canonical_id":"clinicaltrials.gov:NCT01332630","description":"Breast Cancer","metadata":null},{"id":"9ce7dc2fce7e4decb2707172ef831578","type":"GENE","name":"TPI1","canonical_id":"hgnc:HGNC:12009","description":"triosephosphate isomerase 1","metadata":null},{"id":"318e4f096ad0484ea21436bc81d980fb","type":"GENE","name":"TPI1P1","canonical_id":"hgnc:HGNC:35449","description":"triosephosphate isomerase 1 pseudogene 1","metadata":null},{"id":"015b16e9396f4baa947b4974089db2f1","type":"GENE","name":"TPI1P2","canonical_id":"hgnc:HGNC:38069","description":"triosephosphate isomerase 1 pseudogene 2","metadata":null},{"id":"101f00bf7713467e9bacd7a65796a4ab","type":"GENE","name":"TPI1P3","canonical_id":"hgnc:HGNC:38070","description":"triosephosphate isomerase 1 pseudogene 3","metadata":null},{"id":"53d0d81faf6d4dc4874634fb352911da","type":"GENE","name":"TPI1P4","canonical_id":"hgnc:HGNC:38071","description":"triosephosphate isomerase 1 pseudogene 4","metadata":null},{"id":"37b23a749c02482ba5d9ff5a327bb75a","type":"GENE","name":"TPK1","canonical_id":"hgnc:HGNC:17358","description":"thiamin pyrophosphokinase 1","metadata":{"aliases":["HTPK1","PP20"]}},{"id":"c6249498eac746f4a665ba3aeef008d7","type":"GENE","name":"TPL1","canonical_id":"hgnc:HGNC:58473","description":"triple negative breast cancer promoting lncRNA 1","metadata":null},{"id":"02d1025270f5450b8d3e884b1180f0a0","type":"GENE","name":"TPM1","canonical_id":"hgnc:HGNC:12010","description":"tropomyosin 1","metadata":{"aliases":["C15orf13","CMH3"]}},{"id":"218617fc91024ee3982fcc303a2618d8","type":"GENE","name":"TPM1-AS","canonical_id":"hgnc:HGNC:53635","description":"TPM1 antisense RNA","metadata":{"aliases":["TPM1-AS1"]}},{"id":"0f68d93154a849e0ab2aa38528f36011","type":"GENE","name":"TPM2","canonical_id":"hgnc:HGNC:12011","description":"tropomyosin 2","metadata":{"aliases":["DA1","NEM4","AMCD1"]}},{"id":"b77f52846b244bb1973721f87a816b21","type":"GENE","name":"TPM2P1","canonical_id":"hgnc:HGNC:55137","description":"TPM2 pseudogene 1","metadata":null},{"id":"6a29482531584e0491d9dafd4789c20c","type":"GENE","name":"TPM3","canonical_id":"hgnc:HGNC:12012","description":"tropomyosin 3","metadata":{"aliases":["TRK","NEM1"]}},{"id":"49945d80915945d0a670f159a93a44f3","type":"GENE","name":"TPM3P1","canonical_id":"hgnc:HGNC:16350","description":"tropomyosin 3 pseudogene 1","metadata":{"aliases":["TPM3L2"]}},{"id":"2394b79de29e4e54afe51e2c32a0590f","type":"GENE","name":"TPM3P2","canonical_id":"hgnc:HGNC:16556","description":"tropomyosin 3 pseudogene 2","metadata":{"aliases":["dJ1125A11.2","TPM5P"]}},{"id":"9b138fd5632c49e9b03526d37f5fb185","type":"GENE","name":"TPM3P3","canonical_id":"hgnc:HGNC:39166","description":"tropomyosin 3 pseudogene 3","metadata":null},{"id":"e74d86ffd479479eb56caf2cb15e2169","type":"GENE","name":"TPM3P4","canonical_id":"hgnc:HGNC:39167","description":"tropomyosin 3 pseudogene 4","metadata":null},{"id":"ebd8b39bd2f94a2984033670c16086e6","type":"GENE","name":"TPM3P5","canonical_id":"hgnc:HGNC:39168","description":"tropomyosin 3 pseudogene 5","metadata":null},{"id":"fda0e6fc56de43579eb0f5531bc5ef48","type":"GENE","name":"TPM3P6","canonical_id":"hgnc:HGNC:39169","description":"tropomyosin 3 pseudogene 6","metadata":null},{"id":"cc905bc462214b3fa107b064bfe7de2d","type":"GENE","name":"TPM3P7","canonical_id":"hgnc:HGNC:39170","description":"tropomyosin 3 pseudogene 7","metadata":null},{"id":"4ae5307ef2104be6be23398b7b918231","type":"GENE","name":"TPM3P8","canonical_id":"hgnc:HGNC:39171","description":"tropomyosin 3 pseudogene 8","metadata":null},{"id":"afac8611a5c8419890983377dc6defa1","type":"GENE","name":"TPM3P9","canonical_id":"hgnc:HGNC:44142","description":"tropomyosin 3 pseudogene 9","metadata":null},{"id":"d5e8de88168548d59e2048e12386fbeb","type":"GENE","name":"TPM4","canonical_id":"hgnc:HGNC:12013","description":"tropomyosin 4","metadata":null},{"id":"1395e70480dc4375874cf1c43824cdd4","type":"GENE","name":"TPM4P1","canonical_id":"hgnc:HGNC:45234","description":"TPM4 pseudogene 1","metadata":null},{"id":"0f07c3a773f54b3dad678561d3ce4447","type":"GENE","name":"TPM4P2","canonical_id":"hgnc:HGNC:56401","description":"TPM4 pseudogene 2","metadata":null},{"id":"da31b0b25898405e8823b33b0781c27e","type":"GENE","name":"TPM4P3","canonical_id":"hgnc:HGNC:56402","description":"TPM4 pseudogene 3","metadata":null},{"id":"20111e84900d46a8afde4da2d121f6af","type":"GENE","name":"TPMT","canonical_id":"hgnc:HGNC:12014","description":null,"metadata":null},{"id":"6577890e4466425285816592d00576f4","type":"GENE","name":"TPMT-AS1","canonical_id":"hgnc:HGNC:59366","description":"TPMT antisense RNA 1","metadata":null},{"id":"e161a3c9b6174ddcbc6be7a18af4e32a","type":"GENE","name":"TPMTP1","canonical_id":"hgnc:HGNC:17490","description":"thiopurine S-methyltransferase pseudogene 1","metadata":null},{"id":"48ece1b8708f435b9d704c19460a9a64","type":"GENE","name":"TPMTP2","canonical_id":"hgnc:HGNC:44565","description":"thiopurine S-methyltransferase pseudogene 2","metadata":null},{"id":"630715decce944fca1358761f70016e1","type":"GENE","name":"TPMTP3","canonical_id":"hgnc:HGNC:44566","description":"thiopurine S-methyltransferase pseudogene 3","metadata":null},{"id":"a14f34b49840443f8f2ff78fc7501019","type":"GENE","name":"TPMTP4","canonical_id":"hgnc:HGNC:44567","description":"thiopurine S-methyltransferase pseudogene 4","metadata":null},{"id":"1b86798744564d0e91528c708acdbd42","type":"GENE","name":"TPO","canonical_id":"hgnc:HGNC:12015","description":null,"metadata":null},{"id":"7f5315e4cea848f3be3cb2aa13d36e63","type":"PROTEIN","name":"TPO","canonical_id":"uniprot:P07202","description":null,"metadata":null},{"id":"6541f02cf1af4995be6879b4f7239719","type":"GENE","name":"TPP1","canonical_id":"hgnc:HGNC:2073","description":"tripeptidyl peptidase 1","metadata":{"aliases":["LPIC","TPP-1","CLN2","SCAR7"]}},{"id":"8073a691f0ec47e08503ea7f43b5f9bb","type":"GENE","name":"TPP2","canonical_id":"hgnc:HGNC:12016","description":"tripeptidyl peptidase 2","metadata":{"aliases":["TPPII"]}},{"id":"485ba368abbc4dc680f98ab8994056ac","type":"GENE","name":"TPPP","canonical_id":"hgnc:HGNC:24164","description":"tubulin polymerization promoting protein","metadata":{"aliases":["p25alpha","TPPP1","p25","TPPP/p25"]}},{"id":"c8518f30395244adb6d84601d9e8b324","type":"GENE","name":"TPPP-AS1","canonical_id":"hgnc:HGNC:58988","description":"TPPP antisense RNA 1","metadata":null},{"id":"ec76a4ad845d44b587e267afaaef012d","type":"GENE","name":"TPPP2","canonical_id":"hgnc:HGNC:19293","description":"tubulin polymerization promoting protein family member 2","metadata":{"aliases":["p25beta","p18","CT152","C14orf8"]}},{"id":"6f786e2093c947aca1ac97f36b9ede25","type":"GENE","name":"TPPP3","canonical_id":"hgnc:HGNC:24162","description":"tubulin polymerization promoting protein family member 3","metadata":{"aliases":["CGI-38","p25gamma","p20"]}},{"id":"eb714b80696146d984837abcfa133cf8","type":"GENE","name":"TPR","canonical_id":"hgnc:HGNC:12017","description":"translocated promoter region, nuclear basket protein","metadata":null},{"id":"f1fbc12393814ae9b00f813d2c08a553","type":"GO_TERM","name":"TPR domain binding","canonical_id":"go:GO:0030911","description":"\"Binding to a tetratricopeptide repeat (TPR) domain of a protein, the consensus sequence of which is defined by a pattern of small and large hydrophobic amino acids and a structure composed of helices.\" [GOC:mah]","metadata":null},{"id":"6a2492866b3840a8b8d2b8e0545fd030","type":"GENE","name":"TPRA1","canonical_id":"hgnc:HGNC:30413","description":"transmembrane protein adipocyte associated 1","metadata":{"aliases":["TPRA40","FLJ32197","TMEM227","GPR175"]}},{"id":"9cd31c4f9eb0454db5921e6d0444217e","type":"GENE","name":"TPRG1","canonical_id":"hgnc:HGNC:24759","description":"tumor protein p63 regulated 1","metadata":{"aliases":["FLJ41238","FLJ43694","FAM79B"]}},{"id":"0c50f3cbfb6f476095f87cdfacc11c36","type":"GENE","name":"TPRG1-AS1","canonical_id":"hgnc:HGNC:42391","description":"TPRG1 antisense RNA 1","metadata":null},{"id":"ed287093450e4b8d82ab9b7fb0bce294","type":"GENE","name":"TPRG1-AS2","canonical_id":"hgnc:HGNC:41062","description":"TPRG1 antisense RNA 2","metadata":null},{"id":"a9848321410b477d9f2f9272d699722d","type":"GENE","name":"TPRG1L","canonical_id":"hgnc:HGNC:27007","description":"tumor protein p63 regulated 1 like","metadata":{"aliases":["RP11-46F15.3","FLJ21811","TPRGL","SVAP30","h-Mover","FAM79A"]}},{"id":"f260ccbfccc141a6b5d30a0656937be9","type":"GENE","name":"TPRG1LP1","canonical_id":"hgnc:HGNC:52353","description":"tumor protein p63 regulated 1 like pseudogene 1","metadata":null},{"id":"1337e157c78c44e1b56069947fdc8c4c","type":"GENE","name":"TPRKB","canonical_id":"hgnc:HGNC:24259","description":"TP53RK binding protein","metadata":{"aliases":["CGI-121","CGI121"]}},{"id":"56bd86d5a1354f57be8ccdc9c23b51ba","type":"GENE","name":"TPRKBP1","canonical_id":"hgnc:HGNC:44943","description":"TP53RK binding protein pseudogene 1","metadata":null},{"id":"6b5a609e37b6474391428e1740e3a6f3","type":"GENE","name":"TPRKBP2","canonical_id":"hgnc:HGNC:44944","description":"TP53RK binding protein pseudogene 2","metadata":null},{"id":"a1abda4109484fc5b85799fc7bc73a6a","type":"GENE","name":"TPRN","canonical_id":"hgnc:HGNC:26894","description":"taperin","metadata":{"aliases":["FLJ90254","C9orf75","DFNB79"]}},{"id":"f11f1f0b134c47eeb558565d078f7f3e","type":"GENE","name":"TPRX1","canonical_id":"hgnc:HGNC:32174","description":"tetrapeptide repeat homeobox 1","metadata":{"aliases":["FLJ40321"]}},{"id":"c915edc4202247c284412be1762927bf","type":"GENE","name":"TPRX1P1","canonical_id":"hgnc:HGNC:32176","description":"tetrapeptide repeat homeobox 1 pseudogene 1","metadata":null},{"id":"20101abe16854402b8aa5adc0af0e936","type":"GENE","name":"TPRX2","canonical_id":"hgnc:HGNC:32175","description":"tetrapeptide repeat homeobox 2","metadata":{"aliases":["TPRX2P1","TPRX2P"]}},{"id":"70e11eb7facc4d448d21ce5612baa3f1","type":"GENE","name":"TPRXL","canonical_id":"hgnc:HGNC:32178","description":"tetrapeptide repeat homeobox like (pseudogene)","metadata":{"aliases":["FLJ35107","TPRX3P"]}},{"id":"0b7a2ec424d44181b59d7e2de7689223","type":"GENE","name":"TPSAB1","canonical_id":"hgnc:HGNC:12019","description":"tryptase alpha/beta 1","metadata":{"aliases":["TPSB1","TPS1","TPS2"]}},{"id":"61ebb35e5b5e4c258fd1fc412432cbf0","type":"GENE","name":"TPSB2","canonical_id":"hgnc:HGNC:14120","description":"tryptase beta 2","metadata":null},{"id":"3058a6d63aa049da843490d0927d6ba1","type":"GENE","name":"TPSD1","canonical_id":"hgnc:HGNC:14118","description":"tryptase delta 1","metadata":null},{"id":"fe82b04b3ea54c73a0eae14963dc7377","type":"GENE","name":"TPSG1","canonical_id":"hgnc:HGNC:14134","description":"tryptase gamma 1","metadata":{"aliases":["TMT","PRSS31"]}},{"id":"3a8e632033104d7e8544e0853511a7ff","type":"GENE","name":"TPSP1","canonical_id":"hgnc:HGNC:14182","description":"tryptase pseudogene 1","metadata":null},{"id":"d677dcef98194804adda3c3001e96c8a","type":"GENE","name":"TPSP2","canonical_id":"hgnc:HGNC:14136","description":"tryptase pseudogene 2","metadata":{"aliases":["Mastin"]}},{"id":"bc218acc3b754336b82109a061741cf3","type":"GENE","name":"TPST1","canonical_id":"hgnc:HGNC:12020","description":"tyrosylprotein sulfotransferase 1","metadata":{"aliases":["TANGO13A"]}},{"id":"628d7e6fb09145b7b9d52f23e7483a11","type":"GENE","name":"TPST2","canonical_id":"hgnc:HGNC:12021","description":"tyrosylprotein sulfotransferase 2","metadata":{"aliases":["TANGO13B"]}},{"id":"138d845d84eb41149f83913a4f398bcd","type":"GENE","name":"TPST2P1","canonical_id":"hgnc:HGNC:44425","description":"tyrosylprotein sulfotransferase 2 pseudogene 1","metadata":null},{"id":"709f7c9c5c0745669a106ea5a3c13597","type":"GENE","name":"TPT1","canonical_id":"hgnc:HGNC:12022","description":null,"metadata":null},{"id":"44eb66cf4c0a4633b19df07c60b5efcd","type":"GENE","name":"TPT1-AS1","canonical_id":"hgnc:HGNC:43686","description":"TPT1 antisense RNA 1","metadata":null},{"id":"43fb95bb16b545269277c78e5b3a48d0","type":"GENE","name":"TPT1P1","canonical_id":"hgnc:HGNC:16742","description":"TPT1 pseudogene 1","metadata":{"aliases":["TPT1P"]}},{"id":"5b6dcfe8e12c4dcea5f3f8eacd578f88","type":"GENE","name":"TPT1P10","canonical_id":"hgnc:HGNC:49301","description":"TPT1 pseudogene 10","metadata":null},{"id":"569ebe338e26484b9b8c70f934916607","type":"GENE","name":"TPT1P11","canonical_id":"hgnc:HGNC:49302","description":"TPT1 pseudogene 11","metadata":null},{"id":"3d250f88e20a4b919cf04f1eb6f5256c","type":"GENE","name":"TPT1P12","canonical_id":"hgnc:HGNC:49303","description":"TPT1 pseudogene 12","metadata":null},{"id":"0070f2a3c9f240f88b1e22a10e537d18","type":"GENE","name":"TPT1P13","canonical_id":"hgnc:HGNC:49304","description":"TPT1 pseudogene 13","metadata":null},{"id":"2f9a500d6c1f4ae9830e1e9a11ff25ca","type":"GENE","name":"TPT1P14","canonical_id":"hgnc:HGNC:49305","description":"TPT1 pseudogene 14","metadata":null},{"id":"feaf88bab8df4e9aaab177ed60c4883f","type":"GENE","name":"TPT1P15","canonical_id":"hgnc:HGNC:55881","description":"TPT1 pseudogene 15","metadata":null},{"id":"04a473c2ef8a4f84b3840d0bfba99d90","type":"GENE","name":"TPT1P2","canonical_id":"hgnc:HGNC:49294","description":"TPT1 pseudogene 2","metadata":null},{"id":"34830e3b06164e79b53b83300b29c34e","type":"GENE","name":"TPT1P3","canonical_id":"hgnc:HGNC:49295","description":"TPT1 pseudogene 3","metadata":null},{"id":"cd6eb3e4e5eb467581e9608356d97095","type":"GENE","name":"TPT1P4","canonical_id":"hgnc:HGNC:49298","description":"TPT1 pseudogene 4","metadata":null},{"id":"2747cb2aef784e7d9210cfe4a6d084fd","type":"GENE","name":"TPT1P5","canonical_id":"hgnc:HGNC:49296","description":"TPT1 pseudogene 5","metadata":null},{"id":"e1544401309f44c19d6fd7fe1f2bb680","type":"GENE","name":"TPT1P6","canonical_id":"hgnc:HGNC:49297","description":"TPT1 pseudogene 6","metadata":null},{"id":"e0fe70262f134c59909e002a262c760f","type":"GENE","name":"TPT1P7","canonical_id":"hgnc:HGNC:49300","description":"TPT1 pseudogene 7","metadata":null},{"id":"71693f8d4fa6462c80861a5e2c9bce4d","type":"GENE","name":"TPT1P8","canonical_id":"hgnc:HGNC:24088","description":"TPT1 pseudogene 8","metadata":{"aliases":["FKSG2"]}},{"id":"121c64de665d496c82a4e189e5d4b814","type":"GENE","name":"TPT1P9","canonical_id":"hgnc:HGNC:49299","description":"TPT1 pseudogene 9","metadata":null},{"id":"72ad2d9838be44b3b1ca60a45f3a3296","type":"GENE","name":"TPTE","canonical_id":"hgnc:HGNC:12023","description":"transmembrane phosphatase with tensin homology","metadata":{"aliases":["PTEN2","CT44","TPTE1"]}},{"id":"8d37213d8e4f4752a3ddda14ddebe0fb","type":"GENE","name":"TPTE2","canonical_id":"hgnc:HGNC:17299","description":"transmembrane phosphoinositide 3-phosphatase and tensin homolog 2","metadata":{"aliases":["TPIP"]}},{"id":"4df2242f61114e898c5e431e3c507176","type":"GENE","name":"TPTE2-AS1","canonical_id":"hgnc:HGNC:42668","description":"TPTE2 antisense RNA 1","metadata":{"aliases":["LINC00350"]}},{"id":"1e5fc19743f34b0d9c7c855ee495322c","type":"GENE","name":"TPTE2P1","canonical_id":"hgnc:HGNC:35196","description":"TPTE2 pseudogene 1","metadata":null},{"id":"156e77db8be249b6a3c7aa03af040a40","type":"GENE","name":"TPTE2P2","canonical_id":"hgnc:HGNC:38076","description":"TPTE2 pseudogene 2","metadata":null},{"id":"7d19d3d8074040fd9668ea3ff8b4e39d","type":"GENE","name":"TPTE2P3","canonical_id":"hgnc:HGNC:27345","description":"TPTE2 pseudogene 3","metadata":null},{"id":"b0fdfbfc9e63415d82f4c6b92a4628fa","type":"GENE","name":"TPTE2P4","canonical_id":"hgnc:HGNC:38077","description":"TPTE2 pseudogene 4","metadata":null},{"id":"70ab88e31a3c4db0a057bb6fadcc75f6","type":"GENE","name":"TPTE2P5","canonical_id":"hgnc:HGNC:42356","description":"TPTE2 pseudogene 5","metadata":null},{"id":"81b1f24bd2254be2aea50651dc574fe3","type":"GENE","name":"TPTE2P6","canonical_id":"hgnc:HGNC:42644","description":"TPTE2 pseudogene 6","metadata":null},{"id":"564f192ee06d496d8a3e11413d122438","type":"GENE","name":"TPTE2P7","canonical_id":"hgnc:HGNC:56459","description":"TPTE2 pseudogene 7","metadata":null},{"id":"6e12300f908d468987e323f579d96ba4","type":"GENE","name":"TPTEP1","canonical_id":"hgnc:HGNC:43648","description":"TPTE pseudogene 1","metadata":{"aliases":["psiTPTE22"]}},{"id":"0a20594624f649ef84093099cf5e155d","type":"GENE","name":"TPTEP2","canonical_id":"hgnc:HGNC:53828","description":"TPTE pseudogene 2","metadata":{"aliases":["Z98749.2"]}},{"id":"bb69832bc08145f3ab33c12e7d27d69a","type":"GENE","name":"TPTEP2-CSNK1E","canonical_id":"hgnc:HGNC:53829","description":"TPTEP2-CSNK1E readthrough","metadata":null},{"id":"1b89f7f0fa334106af5609b4b1b8f17b","type":"GENE","name":"TPX2","canonical_id":"hgnc:HGNC:1249","description":"TPX2 microtubule nucleation factor","metadata":{"aliases":["p100","DIL-2","HCA519","FLS353","C20orf2","C20orf1"]}},{"id":"d34ef54fea1543f58ff5d63d91a2149e","type":"GENE","name":"TRA","canonical_id":"hgnc:HGNC:12027","description":null,"metadata":null},{"id":"da17db58274a48b391acc123413c3a92","type":"GENE","name":"TRA-AGC1-1","canonical_id":"hgnc:HGNC:34914","description":"tRNA-Ala (anticodon AGC) 1-1","metadata":{"aliases":["tRNA-Ala-AGC-1-1","TRNAA34"]}},{"id":"9f1f9ed230d0428cb94815cdaf771ff5","type":"GENE","name":"TRA-AGC10-1","canonical_id":"hgnc:HGNC:34690","description":"tRNA-Ala (anticodon AGC) 10-1","metadata":{"aliases":["tRNA-Ala-AGC-10-1","TRNAA18"]}},{"id":"8f46ed08d036438aa794f861b22f8f3e","type":"GENE","name":"TRA-AGC11-1","canonical_id":"hgnc:HGNC:33253","description":"tRNA-Ala (anticodon AGC) 11-1","metadata":{"aliases":["tRNA-Ala-AGC-11-1","TRNAA2"]}},{"id":"cae3f70addaa4d509af121dcfca2bbeb","type":"GENE","name":"TRA-AGC12-1","canonical_id":"hgnc:HGNC:34937","description":"tRNA-Ala (anticodon AGC) 12-1","metadata":{"aliases":["tRNA-Ala-AGC-12-1","TRNAA37"]}},{"id":"582c8bfad54d4abcba0e116a3164399c","type":"GENE","name":"TRA-AGC12-2","canonical_id":"hgnc:HGNC:34894","description":"tRNA-Ala (anticodon AGC) 12-2","metadata":{"aliases":["tRNA-Ala-AGC-12-2","TRNAA31"]}},{"id":"84b6f3235fa24a529f7283d9e0630973","type":"GENE","name":"TRA-AGC12-3","canonical_id":"hgnc:HGNC:34667","description":"tRNA-Ala (anticodon AGC) 12-3","metadata":{"aliases":["tRNA-Ala-AGC-12-3","TRNAA14"]}},{"id":"ac31f666ab334915b9a8067b34964251","type":"GENE","name":"TRA-AGC13-1","canonical_id":"hgnc:HGNC:34980","description":"tRNA-Ala (anticodon AGC) 13-1","metadata":{"aliases":["tRNA-Ala-AGC-13-1","TRNAA41"]}},{"id":"a7577c74f4b8407fb404c2982df170e3","type":"GENE","name":"TRA-AGC13-2","canonical_id":"hgnc:HGNC:34619","description":"tRNA-Ala (anticodon AGC) 13-2","metadata":{"aliases":["tRNA-Ala-AGC-13-2","TRNAA9"]}},{"id":"2930877a02f441c2ae4c295c1b86238e","type":"GENE","name":"TRA-AGC13-3","canonical_id":"hgnc:HGNC:54208","description":"tRNA-Ala (anticodon AGC) 13-3","metadata":{"aliases":["tRNA-Ala-AGC-13-3"]}},{"id":"87c6162dea7648e9a5dcd20af6099000","type":"GENE","name":"TRA-AGC14-1","canonical_id":"hgnc:HGNC:34926","description":"tRNA-Ala (anticodon AGC) 14-1","metadata":{"aliases":["tRNA-Ala-AGC-14-1","TRNAA36"]}},{"id":"ef39157cd406484bb9e5fc09e80ac57e","type":"GENE","name":"TRA-AGC14-2","canonical_id":"hgnc:HGNC:54706","description":"tRNA-Ala (anticodon AGC) 14-2","metadata":{"aliases":["tRNA-Ala-AGC-14-2"]}},{"id":"6e334883f1b248cf85c8dc2054cfa480","type":"GENE","name":"TRA-AGC15-1","canonical_id":"hgnc:HGNC:34679","description":"tRNA-Ala (anticodon AGC) 15-1","metadata":{"aliases":["tRNA-Ala-AGC-15-1","TRNAA17"]}},{"id":"cde762b3d5374e96a6c3705488c2c483","type":"GENE","name":"TRA-AGC16-1","canonical_id":"hgnc:HGNC:34879","description":"tRNA-Ala (anticodon AGC) 16-1","metadata":{"aliases":["tRNA-Ala-AGC-16-1","TRNAA30"]}},{"id":"9782d5ac9bac4a6e92d237d248c48384","type":"GENE","name":"TRA-AGC17-1","canonical_id":"hgnc:HGNC:34921","description":"tRNA-Ala (AGC) 17-1","metadata":{"aliases":["tRNA-Ala-AGC-17-1","TRNAA35"]}},{"id":"10aee9a7769a4f9c8c358ad3e2312485","type":"GENE","name":"TRA-AGC18-1","canonical_id":"hgnc:HGNC:34909","description":"tRNA-Ala (AGC) 18-1","metadata":{"aliases":["tRNA-Ala-AGC-18-1","TRNAA33"]}},{"id":"95c32fc15e644edab3e1efeecafa61ba","type":"GENE","name":"TRA-AGC18-2","canonical_id":"hgnc:HGNC:34775","description":"tRNA-Ala (AGC) 18-2","metadata":{"aliases":["tRNA-Ala-AGC-18-2","TRNAA22"]}},{"id":"301245f7bfb84b1388787bc4cb89b900","type":"GENE","name":"TRA-AGC19-1","canonical_id":"hgnc:HGNC:34809","description":"tRNA-Ala (AGC) 19-1","metadata":{"aliases":["tRNA-Ala-AGC-19-1","TRNAA24"]}},{"id":"d6f630bdae4540f1a09afe474fd9e26b","type":"GENE","name":"TRA-AGC2-1","canonical_id":"hgnc:HGNC:34654","description":"tRNA-Ala (anticodon AGC) 2-1","metadata":{"aliases":["tRNA-Ala-AGC-2-1","TRNAA13"]}},{"id":"1e99f04fc7a948afac7e5b7eb7820643","type":"GENE","name":"TRA-AGC2-2","canonical_id":"hgnc:HGNC:34861","description":"tRNA-Ala (anticodon AGC) 2-2","metadata":{"aliases":["tRNA-Ala-AGC-2-2","TRNAA27"]}},{"id":"2d497b411fd046609327d0ea38387ca2","type":"GENE","name":"TRA-AGC20-1","canonical_id":"hgnc:HGNC:34678","description":"tRNA-Ala (AGC) 20-1","metadata":{"aliases":["tRNA-Ala-AGC-20-1","TRNAA16"]}},{"id":"d02a961e20054123a98838a8823b7993","type":"GENE","name":"TRA-AGC21-1","canonical_id":"hgnc:HGNC:34755","description":"tRNA-Ala (AGC) 21-1","metadata":{"aliases":["tRNA-Ala-AGC-21-1","TRNAA21"]}},{"id":"2cf994e1a7f8475da18d24d7f3ef7638","type":"GENE","name":"TRA-AGC22-1","canonical_id":"hgnc:HGNC:35004","description":"tRNA-Ala (anticodon AGC) 22-1","metadata":{"aliases":["tRNA-Ala-AGC-22-1","TRNAA43"]}},{"id":"7cd6dc9c2c204b6d9387aa57111f5dcb","type":"GENE","name":"TRA-AGC23-1","canonical_id":"hgnc:HGNC:35040","description":"tRNA-Ala (anticodon AGC) 23-1","metadata":{"aliases":["tRNA-Ala-AGC-23-1","TRNAA44P"]}},{"id":"d3bdcdf59e5745b09c86d3b956cf2d73","type":"GENE","name":"TRA-AGC24-1","canonical_id":"hgnc:HGNC:54707","description":"tRNA-Ala (anticodon AGC) 24-1","metadata":{"aliases":["tRNA-Ala-AGC-24-1"]}},{"id":"a6ac40ac9f6f456dafd2d8e9e528a8fa","type":"GENE","name":"TRA-AGC3-1","canonical_id":"hgnc:HGNC:34865","description":"tRNA-Ala (anticodon AGC) 3-1","metadata":{"aliases":["tRNA-Ala-AGC-3-1","TRNAA28"]}},{"id":"cf4d042126f74734ad853da533481722","type":"GENE","name":"TRA-AGC4-1","canonical_id":"hgnc:HGNC:34605","description":"tRNA-Ala (anticodon AGC) 4-1","metadata":{"aliases":["tRNA-Ala-AGC-4-1","TRNAA7"]}},{"id":"ebeacb9412bb4750b8db5827ec514c56","type":"GENE","name":"TRA-AGC5-1","canonical_id":"hgnc:HGNC:34606","description":"tRNA-Ala (anticodon AGC) 5-1","metadata":{"aliases":["tRNA-Ala-AGC-5-1","TRNAA8"]}},{"id":"1f3fa52ec76e462f8b97108a3a144a01","type":"GENE","name":"TRA-AGC6-1","canonical_id":"hgnc:HGNC:34601","description":"tRNA-Ala (anticodon AGC) 6-1","metadata":{"aliases":["tRNA-Ala-AGC-6-1","TRNAA6"]}},{"id":"1f1f018e3ed04c9aab2108b9b31e7c66","type":"GENE","name":"TRA-AGC7-1","canonical_id":"hgnc:HGNC:34653","description":"tRNA-Ala (anticodon AGC) 7-1","metadata":{"aliases":["tRNA-Ala-AGC-7-1","TRNAA12"]}},{"id":"67e150a6ed7c4e89ae8ba453fffb9932","type":"GENE","name":"TRA-AGC8-1","canonical_id":"hgnc:HGNC:33254","description":"tRNA-Ala (anticodon AGC) 8-1","metadata":{"aliases":["tRNA-Ala-AGC-8-1","TRNAA3"]}},{"id":"12663364b2f3435b98a9d6ba643ff2a2","type":"GENE","name":"TRA-AGC8-2","canonical_id":"hgnc:HGNC:34966","description":"tRNA-Ala (anticodon AGC) 8-2","metadata":{"aliases":["tRNA-Ala-AGC-8-2","TRNAA39"]}},{"id":"f0357ecb340348e98af8e33fc9f916cd","type":"GENE","name":"TRA-AGC9-1","canonical_id":"hgnc:HGNC:34718","description":"tRNA-Ala (anticodon AGC) 9-1","metadata":{"aliases":["tRNA-Ala-AGC-9-1","TRNAA20"]}},{"id":"0033c43d898f41fa96e16306ed008938","type":"GENE","name":"TRA-AGC9-2","canonical_id":"hgnc:HGNC:34992","description":"tRNA-Ala (anticodon AGC) 9-2","metadata":{"aliases":["tRNA-Ala-AGC-9-2","TRNAA42"]}},{"id":"dbb90795c74c4b9d913fbe6bf1f4c3d7","type":"GENE","name":"TRA-CGC1-1","canonical_id":"hgnc:HGNC:34875","description":"tRNA-Ala (anticodon CGC) 1-1","metadata":{"aliases":["tRNA-Ala-CGC-1-1","TRNAA29"]}},{"id":"b550613d343d4b3aaeb969a31d05a61e","type":"GENE","name":"TRA-CGC2-1","canonical_id":"hgnc:HGNC:34969","description":"tRNA-Ala (anticodon CGC) 2-1","metadata":{"aliases":["tRNA-Ala-CGC-2-1","TRNAA40"]}},{"id":"40d6afd5a2e44e7793b5c930f1e4c16f","type":"GENE","name":"TRA-CGC3-1","canonical_id":"hgnc:HGNC:34580","description":"tRNA-Ala (anticodon CGC) 3-1","metadata":{"aliases":["tRNA-Ala-CGC-3-1","TRNAA4"]}},{"id":"00510fd560c1412fba686cad125a96c2","type":"GENE","name":"TRA-CGC4-1","canonical_id":"hgnc:HGNC:34592","description":"tRNA-Ala (anticodon CGC) 4-1","metadata":{"aliases":["tRNA-Ala-CGC-4-1","TRNAA5"]}},{"id":"bc88fe7734324a0cbb0c0136a238b297","type":"GENE","name":"TRA-CGC5-1","canonical_id":"hgnc:HGNC:34963","description":"tRNA-Ala (CGC) 5-1","metadata":{"aliases":["tRNA-Ala-CGC-5-1","TRNAA38"]}},{"id":"b1218829b4df4771a6d21091d8f18765","type":"GENE","name":"TRA-TGC1-1","canonical_id":"hgnc:HGNC:34711","description":"tRNA-Ala (anticodon TGC) 1-1","metadata":{"aliases":["tRNA-Ala-TGC-1-1","TRNAA19"]}},{"id":"1f656d4654094a51ace2788273c09336","type":"GENE","name":"TRA-TGC10-1","canonical_id":"hgnc:HGNC:35041","description":"tRNA-Ala (TGC) 10-1","metadata":{"aliases":["tRNA-Ala-TGC-10-1","TRNAA45P"]}},{"id":"89ca516f4d71443ba458fce565e229ff","type":"GENE","name":"TRA-TGC2-1","canonical_id":"hgnc:HGNC:34676","description":"tRNA-Ala (anticodon TGC) 2-1","metadata":{"aliases":["tRNA-Ala-TGC-2-1","TRNAA15"]}},{"id":"237af523a3ec4ff6ad4874848cb50945","type":"GENE","name":"TRA-TGC3-1","canonical_id":"hgnc:HGNC:34846","description":"tRNA-Ala (anticodon TGC) 3-1","metadata":{"aliases":["tRNA-Ala-TGC-3-1","TRNAA26","TRA-TGC3-2"]}},{"id":"d8b48744c83148b0bd13d97a2c754135","type":"GENE","name":"TRA-TGC3-2","canonical_id":"hgnc:HGNC:34795","description":"tRNA-Ala (anticodon TGC) 3-2","metadata":{"aliases":["tRNA-Ala-TGC-3-2","TRNAA23","TRA-TGC3-1"]}},{"id":"61e590cfab9c4cdbb3739e404ec97c56","type":"GENE","name":"TRA-TGC4-1","canonical_id":"hgnc:HGNC:34907","description":"tRNA-Ala (anticodon TGC) 4-1","metadata":{"aliases":["tRNA-Ala-TGC-4-1","TRNAA32"]}},{"id":"1dbbe722e7f54544a43e2185b38fdb8a","type":"GENE","name":"TRA-TGC5-1","canonical_id":"hgnc:HGNC:34625","description":"tRNA-Ala (anticodon TGC) 5-1","metadata":{"aliases":["tRNA-Ala-TGC-5-1","TRNAA10"]}},{"id":"95eeaa873b5b48999d0128306322b0f9","type":"GENE","name":"TRA-TGC6-1","canonical_id":"hgnc:HGNC:34642","description":"tRNA-Ala (anticodon TGC) 6-1","metadata":{"aliases":["tRNA-Ala-TGC-6-1","TRNAA11"]}},{"id":"6efd7f0d663344cfb5d7b9dd0c71a96a","type":"GENE","name":"TRA-TGC7-1","canonical_id":"hgnc:HGNC:12098","description":"tRNA-Ala (anticodon TGC) 7-1","metadata":{"aliases":["tRNA-Ala-TGC-7-1","TRAN","TRNAA1"]}},{"id":"1e805f904abe41c598ab5fcd33a07980","type":"GENE","name":"TRA-TGC8-1","canonical_id":"hgnc:HGNC:34819","description":"tRNA-Ala (TGC) 8-1","metadata":{"aliases":["tRNA-Ala-TGC-8-1","TRNAA25"]}},{"id":"f9d8a748fcbf48f4bb7c044bab2b2274","type":"GENE","name":"TRA-TGC9-1","canonical_id":"hgnc:HGNC:35106","description":"tRNA-Ala (anticodon TGC) 9-1","metadata":{"aliases":["tRNA-Ala-TGC-9-1","TRNAA46P"]}},{"id":"392ad891639d479981ce3af1509f25fc","type":"GENE","name":"TRA2A","canonical_id":"hgnc:HGNC:16645","description":"transformer 2 alpha homolog","metadata":{"aliases":["htra-2-alpha","AWMS1"]}},{"id":"3db6018752c741cea43dbec9652a1824","type":"GENE","name":"TRA2B","canonical_id":"hgnc:HGNC:10781","description":"transformer 2 beta homolog","metadata":{"aliases":["Htra2-beta","PPP1R156","SFRS10"]}},{"id":"f6611c4e13d945d989285e63a0b071f8","type":"GENE","name":"TRABD","canonical_id":"hgnc:HGNC:28805","description":"TraB domain containing","metadata":{"aliases":["PP2447"]}},{"id":"a1e5be7536b1454581d3050fc312955c","type":"GENE","name":"TRABD-AS1","canonical_id":"hgnc:HGNC:56049","description":"TRABD antisense RNA 1","metadata":null},{"id":"78316c2ccf77454cadf621e82baaf214","type":"GENE","name":"TRABD2A","canonical_id":"hgnc:HGNC:27013","description":"TraB domain containing 2A","metadata":{"aliases":["TIKI1","C2orf89"]}},{"id":"35819854d3f64290b27de3f3841c65da","type":"GENE","name":"TRABD2B","canonical_id":"hgnc:HGNC:44200","description":"TraB domain containing 2B","metadata":{"aliases":["TIKI2"]}},{"id":"719cb9200c70479bb259ea7b7f1626f7","type":"GENE","name":"TRABD2B-AS1","canonical_id":"hgnc:HGNC:58355","description":"TRABD2B antisense RNA 1","metadata":null},{"id":"af725f554f344e4b950430a8283e828e","type":"GENE","name":"TRAC","canonical_id":"hgnc:HGNC:12029","description":"T cell receptor alpha constant","metadata":null},{"id":"361287ac8e874b98ba121de28af0f111","type":"GENE","name":"TRADD","canonical_id":"hgnc:HGNC:12030","description":"TNFRSF1A associated via death domain","metadata":{"aliases":["Hs.89862"]}},{"id":"98fb82890b8a472a84db0705fd53dcc7","type":"GENE","name":"TRAF1","canonical_id":"hgnc:HGNC:12031","description":null,"metadata":null},{"id":"ad77565923a84cf1911b9631ad6bd9ce","type":"GENE","name":"TRAF2","canonical_id":"hgnc:HGNC:12032","description":null,"metadata":null},{"id":"5b5ccefd6b8842b18ca6d897be729d20","type":"GO_TERM","name":"TRAF2-GSTP1 complex","canonical_id":"go:GO:0097057","description":"\"A protein complex comprising tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) and glutathione S-transferase pi 1 (GSTP1). This complex is thought to disrupt the TNF signaling cascade, thus down-regulating inflammatory responses.\" [GOC:BHF, PMID:16636664]","metadata":null},{"id":"8fe9325ee52f4295ac79367b89905708","type":"GENE","name":"TRAF3","canonical_id":"hgnc:HGNC:12033","description":"TNF receptor associated factor 3","metadata":{"aliases":["CAP-1","CD40bp","CRAF1","LAP1","RNF118"]}},{"id":"c324efc73ba749e7b644ee002f728b3d","type":"GENE","name":"TRAF3IP2","canonical_id":"hgnc:HGNC:1343","description":"TRAF3 interacting protein 2","metadata":{"aliases":["DKFZP586G0522","ACT1","CIKS","C6orf4","C6orf5","C6orf6","C6orf2"]}},{"id":"d3e9500bf5bb40808109dc2d7ad7490e","type":"GENE","name":"TRAF3IP2-AS1","canonical_id":"hgnc:HGNC:40005","description":"TRAF3IP2 antisense RNA 1","metadata":{"aliases":["C6UAS","BetaFAAR","TRAF3IP2-AS2","C6orf3","NCRNA00248"]}},{"id":"37408a2e888a45e5a03f4b41ecf03789","type":"GENE","name":"TRAF3IP3","canonical_id":"hgnc:HGNC:30766","description":"TRAF3 interacting protein 3","metadata":{"aliases":["T3JAM"]}},{"id":"fe09ca1b6cca4d60af0e2047bf0eb2a9","type":"GENE","name":"TRAF4","canonical_id":"hgnc:HGNC:12034","description":"TNF receptor associated factor 4","metadata":{"aliases":["CART1","MLN62","RNF83"]}},{"id":"166fd822880b4e60951875dd64129481","type":"GENE","name":"TRAF5","canonical_id":"hgnc:HGNC:12035","description":"TNF receptor associated factor 5","metadata":{"aliases":["RNF84"]}},{"id":"37eb3fdf94174fc086ad1275e99c1ddf","type":"GENE","name":"TRAF6","canonical_id":"hgnc:HGNC:12036","description":null,"metadata":null},{"id":"1b68992df2894677b689326dae03c94a","type":"GENE","name":"TRAF6P1","canonical_id":"hgnc:HGNC:45032","description":"TNF receptor associated factor 6 pseudogene 1","metadata":null},{"id":"a28fd0c483724d788959a83f50f0c769","type":"GENE","name":"TRAF7","canonical_id":"hgnc:HGNC:20456","description":"TNF receptor associated factor 7","metadata":{"aliases":["RNF119","DKFZp586I021","MGC7807","RFWD1"]}},{"id":"7522857d71f942feadd805578aa8dcb1","type":"GENE","name":"TRAFD1","canonical_id":"hgnc:HGNC:24808","description":"TRAF-type zinc finger domain containing 1","metadata":{"aliases":["FLN29"]}},{"id":"5dd4c9219b8f4a5c84b1d51a423776ab","type":"GO_TERM","name":"TRAIL binding","canonical_id":"go:GO:0045569","description":"\"Binding to TRAIL (TNF-related apoptosis inducing ligand), a member of the tumor necrosis factor ligand family that rapidly induces apoptosis in a variety of transformed cell lines.\" [GOC:curators, PMID:9082980]","metadata":null},{"id":"67d11d9fb0b64733af7e1b52dffca742","type":"GO_TERM","name":"TRAIL death-inducing signaling complex","canonical_id":"go:GO:0031266","description":"\"A protein complex formed upon binding of TRAIL to its ligand. The complex includes FADD/Mort1 and procaspase-8 addition to the ligand-bound receptor.\" [PMID:12628743, PMID:12655293]","metadata":null},{"id":"da20cff315744a1f89a688198a579594","type":"GO_TERM","name":"TRAIL death-inducing signaling complex assembly","canonical_id":"go:GO:1903074","description":"\"The aggregation, arrangement and bonding together of a set of components to form a TRAIL death-inducing signaling complex.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21785459]","metadata":null},{"id":"14e44c16797e40e98003195b1ec07026","type":"GO_TERM","name":"TRAIL production","canonical_id":"go:GO:0032639","description":"\"The appearance of TRAIL due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:9311998]","metadata":null},{"id":"3e77fd2d15cb4ca29182a495cd1f6c50","type":"GO_TERM","name":"TRAIL receptor activity","canonical_id":"go:GO:0036463","description":"\"Combining with the ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and transmitting the signal from one side of the plasma membrane to the other to initiate apoptotic cell death.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"a5591b6dfa87463198c3d34277dc6cac","type":"GO_TERM","name":"TRAIL-activated apoptotic signaling pathway","canonical_id":"go:GO:0036462","description":"\"An extrinsic apoptotic signaling pathway initiated by the binding of the ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) to a death receptor on the cell surface.\" [GOC:bf, GOC:PARL, PMID:21785459]","metadata":null},{"id":"43985762d130454db5394e60831adaf7","type":"GENE","name":"TRAIP","canonical_id":"hgnc:HGNC:30764","description":"TRAF interacting protein","metadata":{"aliases":["TRIP","RNF206"]}},{"id":"dd59c960ba8d41e98349bd648d4d0d53","type":"GENE","name":"TRAJ1","canonical_id":"hgnc:HGNC:12037","description":"T cell receptor alpha joining 1 (non-functional)","metadata":null},{"id":"e9cdd0a3cab64426b5d47170990672e1","type":"GENE","name":"TRAJ10","canonical_id":"hgnc:HGNC:12038","description":"T cell receptor alpha joining 10","metadata":null},{"id":"57f545d29eda4d86b46544763e597e7d","type":"GENE","name":"TRAJ11","canonical_id":"hgnc:HGNC:12039","description":"T cell receptor alpha joining 11","metadata":null},{"id":"2242b8658a694f8fb448ab5375d18a9a","type":"GENE","name":"TRAJ12","canonical_id":"hgnc:HGNC:12040","description":"T cell receptor alpha joining 12","metadata":null},{"id":"bfd21915d0f74203a6e94bcc76461649","type":"GENE","name":"TRAJ13","canonical_id":"hgnc:HGNC:12041","description":"T cell receptor alpha joining 13","metadata":null},{"id":"fbdb8391832c4e59994d707a1a0f6e37","type":"GENE","name":"TRAJ14","canonical_id":"hgnc:HGNC:12042","description":"T cell receptor alpha joining 14","metadata":null},{"id":"425d6a4b03b7443b8705cf4f248ba2c7","type":"GENE","name":"TRAJ15","canonical_id":"hgnc:HGNC:12043","description":"T cell receptor alpha joining 15","metadata":null},{"id":"b87af709232743bea82e9d8882e36812","type":"GENE","name":"TRAJ16","canonical_id":"hgnc:HGNC:12044","description":"T cell receptor alpha joining 16","metadata":null},{"id":"7cde7c864dd14c7db4184115b42406c9","type":"GENE","name":"TRAJ17","canonical_id":"hgnc:HGNC:12045","description":"T cell receptor alpha joining 17","metadata":null},{"id":"b17ee3b083014f4e9167f55868acb377","type":"GENE","name":"TRAJ18","canonical_id":"hgnc:HGNC:12046","description":"T cell receptor alpha joining 18","metadata":null},{"id":"3064e736a2624703b425221936e286f1","type":"GENE","name":"TRAJ19","canonical_id":"hgnc:HGNC:12047","description":"T cell receptor alpha joining 19 (non-functional)","metadata":null},{"id":"e8d63b9373e343bcb914d473104f4c98","type":"GENE","name":"TRAJ2","canonical_id":"hgnc:HGNC:12048","description":"T cell receptor alpha joining 2 (non-functional)","metadata":null},{"id":"5ebfcfd7c5a049ed92d6f456f167c782","type":"GENE","name":"TRAJ20","canonical_id":"hgnc:HGNC:12049","description":"T cell receptor alpha joining 20","metadata":null},{"id":"a1d9ddc54d0c45149307dfcaee61afbc","type":"GENE","name":"TRAJ21","canonical_id":"hgnc:HGNC:12050","description":"T cell receptor alpha joining 21","metadata":null},{"id":"c7cb1b0814dd4f05862b8dd074f65a3e","type":"GENE","name":"TRAJ22","canonical_id":"hgnc:HGNC:12051","description":"T cell receptor alpha joining 22","metadata":null},{"id":"664788c9a47e4a459bb599f2a33694ea","type":"GENE","name":"TRAJ23","canonical_id":"hgnc:HGNC:12052","description":"T cell receptor alpha joining 23","metadata":null},{"id":"8847edd5dc0945bd96a3d9711c4bf8dd","type":"GENE","name":"TRAJ24","canonical_id":"hgnc:HGNC:12053","description":"T cell receptor alpha joining 24","metadata":null},{"id":"df6ce8a489b840edb9034709ebc5523e","type":"GENE","name":"TRAJ25","canonical_id":"hgnc:HGNC:12054","description":"T cell receptor alpha joining 25 (non-functional)","metadata":null},{"id":"d99bf082b04444a5b41e1dd5facbde33","type":"GENE","name":"TRAJ26","canonical_id":"hgnc:HGNC:12055","description":"T cell receptor alpha joining 26","metadata":null},{"id":"09f4a982000544dc8b9e909dab7f74b8","type":"GENE","name":"TRAJ27","canonical_id":"hgnc:HGNC:12056","description":"T cell receptor alpha joining 27","metadata":null},{"id":"86844d042fff4616a92a040c216a9346","type":"GENE","name":"TRAJ28","canonical_id":"hgnc:HGNC:12057","description":"T cell receptor alpha joining 28","metadata":null},{"id":"04f7ce6f763d48f5a0d5a5e988ec5c7a","type":"GENE","name":"TRAJ29","canonical_id":"hgnc:HGNC:12058","description":"T cell receptor alpha joining 29","metadata":null},{"id":"887dbfe6effc412996b8d556976e03a1","type":"GENE","name":"TRAJ3","canonical_id":"hgnc:HGNC:12059","description":"T cell receptor alpha joining 3","metadata":null},{"id":"acc928caa0e74938bce1465b3a82fb1e","type":"GENE","name":"TRAJ30","canonical_id":"hgnc:HGNC:12060","description":"T cell receptor alpha joining 30","metadata":null},{"id":"c375116074ea4c0c97460e066c870a79","type":"GENE","name":"TRAJ31","canonical_id":"hgnc:HGNC:12061","description":"T cell receptor alpha joining 31","metadata":null},{"id":"b2d592d0f50641768b124c1cdea421de","type":"GENE","name":"TRAJ32","canonical_id":"hgnc:HGNC:12062","description":"T cell receptor alpha joining 32","metadata":null},{"id":"ffa4120be00f44f0993cbb96806c5aaf","type":"GENE","name":"TRAJ33","canonical_id":"hgnc:HGNC:12063","description":"T cell receptor alpha joining 33","metadata":null},{"id":"54ccea6c18024660971ec290514e8add","type":"GENE","name":"TRAJ34","canonical_id":"hgnc:HGNC:12064","description":"T cell receptor alpha joining 34","metadata":null},{"id":"38d78170f9a649329540b54ca991e866","type":"GENE","name":"TRAJ35","canonical_id":"hgnc:HGNC:12065","description":"T cell receptor alpha joining 35 (non-functional)","metadata":null},{"id":"964096913ae74043841da21d044b04b4","type":"GENE","name":"TRAJ36","canonical_id":"hgnc:HGNC:12066","description":"T cell receptor alpha joining 36","metadata":null},{"id":"db3e8762d4cc4d2687447d9c43d0cb46","type":"GENE","name":"TRAJ37","canonical_id":"hgnc:HGNC:12067","description":"T cell receptor alpha joining 37","metadata":null},{"id":"11427a0e98bc480392631a803247a37e","type":"GENE","name":"TRAJ38","canonical_id":"hgnc:HGNC:12068","description":"T cell receptor alpha joining 38","metadata":null},{"id":"dd620efc1aef41eb8218df4055c9bd81","type":"GENE","name":"TRAJ39","canonical_id":"hgnc:HGNC:12069","description":"T cell receptor alpha joining 39","metadata":null},{"id":"31996b86bbf6400d92bda3ddd1a5dc65","type":"GENE","name":"TRAJ4","canonical_id":"hgnc:HGNC:12070","description":"T cell receptor alpha joining 4","metadata":null},{"id":"dc7be567ff1c4bae891280cab12aa169","type":"GENE","name":"TRAJ40","canonical_id":"hgnc:HGNC:12071","description":"T cell receptor alpha joining 40","metadata":null},{"id":"ea586350713547c49164452c42861e63","type":"GENE","name":"TRAJ41","canonical_id":"hgnc:HGNC:12072","description":"T cell receptor alpha joining 41","metadata":null},{"id":"f9f015d3ad404e1f8fb085731b95c0bd","type":"GENE","name":"TRAJ42","canonical_id":"hgnc:HGNC:12073","description":"T cell receptor alpha joining 42","metadata":null},{"id":"65a2e84a0d114988a067b7561a672ef1","type":"GENE","name":"TRAJ43","canonical_id":"hgnc:HGNC:12074","description":"T cell receptor alpha joining 43","metadata":null},{"id":"38b655dda0ba42bb801cceda6040615c","type":"GENE","name":"TRAJ44","canonical_id":"hgnc:HGNC:12075","description":"T cell receptor alpha joining 44","metadata":null},{"id":"e15cb2327bc8464f9a2d36705554277f","type":"GENE","name":"TRAJ45","canonical_id":"hgnc:HGNC:12076","description":"T cell receptor alpha joining 45","metadata":null},{"id":"e39218809ede43fc92608c4862bbb881","type":"GENE","name":"TRAJ46","canonical_id":"hgnc:HGNC:12077","description":"T cell receptor alpha joining 46","metadata":null},{"id":"6289f277eceb4955b46f8a3e744621aa","type":"GENE","name":"TRAJ47","canonical_id":"hgnc:HGNC:12078","description":"T cell receptor alpha joining 47","metadata":null},{"id":"93af0314a60643c89bc994ec6549f4aa","type":"GENE","name":"TRAJ48","canonical_id":"hgnc:HGNC:12079","description":"T cell receptor alpha joining 48","metadata":null},{"id":"af3af40844e640348d498cf476b82b08","type":"GENE","name":"TRAJ49","canonical_id":"hgnc:HGNC:12080","description":"T cell receptor alpha joining 49","metadata":null},{"id":"1782d50f82ea47dabe96e5220951ee79","type":"GENE","name":"TRAJ5","canonical_id":"hgnc:HGNC:12081","description":"T cell receptor alpha joining 5","metadata":null},{"id":"607b71c529e74884a6275141c0e0c0aa","type":"GENE","name":"TRAJ50","canonical_id":"hgnc:HGNC:12082","description":"T cell receptor alpha joining 50","metadata":null},{"id":"aa28bb75f1d345fc94cc60b5466b18da","type":"GENE","name":"TRAJ51","canonical_id":"hgnc:HGNC:12083","description":"T cell receptor alpha joining 51 (pseudogene)","metadata":null},{"id":"35cc8376a72c4226869d1cd488e3fd82","type":"GENE","name":"TRAJ52","canonical_id":"hgnc:HGNC:12084","description":"T cell receptor alpha joining 52","metadata":null},{"id":"9a90feca1be14f8583f2bd30a8ec52b6","type":"GENE","name":"TRAJ53","canonical_id":"hgnc:HGNC:12085","description":"T cell receptor alpha joining 53","metadata":null},{"id":"997de4d8b5ac4343a88ff15193bfed6f","type":"GENE","name":"TRAJ54","canonical_id":"hgnc:HGNC:12086","description":"T cell receptor alpha joining 54","metadata":null},{"id":"d5ebf160ee6a496e9c55d60ddf19b981","type":"GENE","name":"TRAJ55","canonical_id":"hgnc:HGNC:12087","description":"T cell receptor alpha joining 55 (pseudogene)","metadata":null},{"id":"82402d87d789472fa1e1ae505f03834e","type":"GENE","name":"TRAJ56","canonical_id":"hgnc:HGNC:12088","description":"T cell receptor alpha joining 56","metadata":null},{"id":"0e50964ade3f4806a048346d0ead7e1f","type":"GENE","name":"TRAJ57","canonical_id":"hgnc:HGNC:12089","description":"T cell receptor alpha joining 57","metadata":null},{"id":"96193b1122814cb0873c4473f6a847a7","type":"GENE","name":"TRAJ58","canonical_id":"hgnc:HGNC:12090","description":"T cell receptor alpha joining 58 (non-functional)","metadata":null},{"id":"34367b2d35ef4043b7ace73de9e6cb84","type":"GENE","name":"TRAJ59","canonical_id":"hgnc:HGNC:12091","description":"T cell receptor alpha joining 59 (non-functional)","metadata":null},{"id":"fed7df1bdf9e4a8b81f7bf1092c856aa","type":"GENE","name":"TRAJ6","canonical_id":"hgnc:HGNC:12092","description":"T cell receptor alpha joining 6","metadata":null},{"id":"5b7856221f884a07b72d3e2975e14768","type":"GENE","name":"TRAJ60","canonical_id":"hgnc:HGNC:12093","description":"T cell receptor alpha joining 60 (pseudogene)","metadata":null},{"id":"580ea99d1e704047b7f18da7a84648ee","type":"GENE","name":"TRAJ61","canonical_id":"hgnc:HGNC:12094","description":"T cell receptor alpha joining 61 (non-functional)","metadata":null},{"id":"f43e21a0fc9944a194c0b1e68cc0bdce","type":"GENE","name":"TRAJ7","canonical_id":"hgnc:HGNC:12095","description":"T cell receptor alpha joining 7","metadata":null},{"id":"10bcfb365949425ea787d2efa8aaf352","type":"GENE","name":"TRAJ8","canonical_id":"hgnc:HGNC:12096","description":"T cell receptor alpha joining 8","metadata":null},{"id":"c99060193a3b49759a06901a180a9d82","type":"GENE","name":"TRAJ9","canonical_id":"hgnc:HGNC:12097","description":"T cell receptor alpha joining 9","metadata":null},{"id":"1c511132c62848a880f2f742ee68f6f8","type":"GENE","name":"TRAK1","canonical_id":"hgnc:HGNC:29947","description":"trafficking kinesin protein 1","metadata":{"aliases":["OIP106","KIAA1042","MILT1"]}},{"id":"34bbbd64c7184a4a9ab70ca23e4f91a1","type":"GENE","name":"TRAK2","canonical_id":"hgnc:HGNC:13206","description":"trafficking kinesin protein 2","metadata":{"aliases":["CALS-C","KIAA0549","GRIF-1","OIP98","MILT2","ALS2CR3"]}},{"id":"c9a58a6ad62b44eaa526cd388feb2693","type":"GO_TERM","name":"TRAM-dependent toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0035669","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like receptor 4 where the TRAM adaptor mediates transduction of the signal. Toll-like 4 receptors are pattern recognition receptors that bind bacterial lipopolysaccharide (LPS) to initiate an innate immune response.\" [GOC:BHF, PMID:14556004, PMID:18297073]","metadata":null},{"id":"a11a27c8007347ab8e7868b9b6334efe","type":"GO_TERM","name":"TRAM-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0035668","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like receptor where the TRAM adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate an innate immune response.\" [GOC:BHF, PMID:14556004]","metadata":null},{"id":"ccf8f758fb9449348403d10a752ca1a6","type":"GENE","name":"TRAM1","canonical_id":"hgnc:HGNC:20568","description":"translocation associated membrane protein 1","metadata":{"aliases":["TRAM","TRAMP"]}},{"id":"0e5b0f925ecd460796321205b198e851","type":"GENE","name":"TRAM1L1","canonical_id":"hgnc:HGNC:28371","description":"translocation associated membrane protein 1 like 1","metadata":{"aliases":["MGC26568"]}},{"id":"cde8aea578d647d9a0d9618f65313d06","type":"GENE","name":"TRAM1L1-AS1","canonical_id":"hgnc:HGNC:58876","description":"TRAM1L1 antisense RNA 1","metadata":null},{"id":"1589bd76d6f34f2d82b1b0f61e35d8e9","type":"GENE","name":"TRAM2","canonical_id":"hgnc:HGNC:16855","description":"translocation associated membrane protein 2","metadata":{"aliases":["KIAA0057"]}},{"id":"3584c173da744e99902260dda17e9ad3","type":"GENE","name":"TRAM2-AS1","canonical_id":"hgnc:HGNC:48663","description":"TRAM2 antisense RNA 1","metadata":null},{"id":"4d5d7abc35e04cb4878577811d8f4b70","type":"GO_TERM","name":"TRAMP complex","canonical_id":"go:GO:0031499","description":"\"A multiprotein complex having distributive polyadenylation activity of a variety of RNA substrates including hypomodified and incorrectly folded tRNAs, pre-snRNAs, pre-snoRNAs, incorrectly spliced or processed pre-mRNAs, cryptic unstable transcripts (CUTs), pre-rRNAs and rRNA fragments released as part of rRNA processing. In S. cerevisiae, the complex consists of either Pap2 (also known as Trf4) or Trf5, Air1 or Air2, and Mtr4, and is involved in RNA 3'-end processing and in RNA surveillance and quality control.\" [PMID:15173578, PMID:15828860, PMID:15935758, PMID:15935759, PMID:16373491, PMID:16374505, PMID:16431988, PMID:16973437, PMID:17410208, PMID:17652137]","metadata":null},{"id":"fa460135496d441f865a9473da70cdb7","type":"GO_TERM","name":"TRAMP-dependent tRNA surveillance pathway","canonical_id":"go:GO:0071038","description":"\"A nuclear tRNA surveillance pathway, dependent on the TRAMP exosome adaptor and the nuclear exosome.\" [GOC:vw, PMID:35901126]","metadata":null},{"id":"7c15eb2bbeb24eadbee0a7b173d323b7","type":"GENE","name":"TRANK1","canonical_id":"hgnc:HGNC:29011","description":"tetratricopeptide repeat and ankyrin repeat containing 1","metadata":{"aliases":["LBA1","KIAA0342"]}},{"id":"91661b9e2c2143c1a2aba24fa43b2213","type":"GENE","name":"TRAP1","canonical_id":"hgnc:HGNC:16264","description":"TNF receptor associated protein 1","metadata":{"aliases":["HSP75","HSP90L"]}},{"id":"14a7fdc2b30d4221ac0fe23cb52dae13","type":"GO_TERM","name":"TRAPP complex","canonical_id":"go:GO:0030008","description":"\"A large complex that acts as a tethering factor involved in transporting vesicles from the ER through the Golgi to the plasma membrane. A TRAPP (transport protein particle) complex has a core set of proteins which are joined by specific subunits depending on the cellular component where a given TRAPP complex is active.\" [GOC:bhm, GOC:vw, PMID:22669257]","metadata":null},{"id":"e1d82080f0b54362a3967059dbf2e104","type":"GENE","name":"TRAPPC1","canonical_id":"hgnc:HGNC:19894","description":"trafficking protein particle complex subunit 1","metadata":{"aliases":["MUM2","BET5"]}},{"id":"fdc9aa304b614c52ba7fc993ea13dea7","type":"GENE","name":"TRAPPC10","canonical_id":"hgnc:HGNC:11868","description":"trafficking protein particle complex subunit 10","metadata":{"aliases":["EHOC-1","TRS130","TMEM1"]}},{"id":"62adf0de4572483ca9f9f702bc046276","type":"GENE","name":"TRAPPC11","canonical_id":"hgnc:HGNC:25751","description":"trafficking protein particle complex subunit 11","metadata":{"aliases":["FLJ12716","gry","foigr","C4orf41"]}},{"id":"cfdb54d75d614106aba065bd9e9e352d","type":"GENE","name":"TRAPPC12","canonical_id":"hgnc:HGNC:24284","description":"trafficking protein particle complex subunit 12","metadata":{"aliases":["CGI-87","TTC-15","TTC15"]}},{"id":"ec48e8471b044aa9b9ea8fc81af80d83","type":"GENE","name":"TRAPPC12-AS1","canonical_id":"hgnc:HGNC:41046","description":"TRAPPC12 antisense RNA 1","metadata":null},{"id":"7a621853769e49eda849897a53e73b0f","type":"GENE","name":"TRAPPC13","canonical_id":"hgnc:HGNC:25828","description":"trafficking protein particle complex subunit 13","metadata":{"aliases":["FLJ13611","MGC48585","C5orf44"]}},{"id":"852b635c82cc4a28946f2abb7e961e71","type":"GENE","name":"TRAPPC13P1","canonical_id":"hgnc:HGNC:50347","description":"trafficking protein particle complex 13 pseudogene 1","metadata":null},{"id":"cfb35d8fc6c74fd9a9ad1f639d7abeb3","type":"GENE","name":"TRAPPC14","canonical_id":"hgnc:HGNC:25604","description":"trafficking protein particle complex subunit 14","metadata":{"aliases":["FLJ10925","C7orf43","MAP11"]}},{"id":"c413e14be86c46ccb96bf4adbf52966c","type":"GENE","name":"TRAPPC2","canonical_id":"hgnc:HGNC:23068","description":"trafficking protein particle complex subunit 2","metadata":{"aliases":["TRS20","SEDT","MIP-2A","ZNF547L","hYP38334","SEDL"]}},{"id":"f658f62ea4d94898be105649c977adc7","type":"GENE","name":"TRAPPC2B","canonical_id":"hgnc:HGNC:10710","description":"trafficking protein particle complex subunit 2B","metadata":{"aliases":["SEDLP1","MIP-2A","SEDLP","TRAPPC2P1"]}},{"id":"79053fce4ac94aeda95ea3a6b434cdcf","type":"GENE","name":"TRAPPC2L","canonical_id":"hgnc:HGNC:30887","description":"trafficking protein particle complex subunit 2L","metadata":{"aliases":["HSPC176"]}},{"id":"c3efc25ca66b47a4b9a72c77f6747729","type":"GENE","name":"TRAPPC2LP1","canonical_id":"hgnc:HGNC:54982","description":"TRAPPC2L pseudogene 1","metadata":null},{"id":"acabf465662b41668d25d47169ddeebb","type":"GENE","name":"TRAPPC2P10","canonical_id":"hgnc:HGNC:37732","description":"trafficking protein particle complex 2 pseudogene 10","metadata":{"aliases":["TRAPPC2P5B"]}},{"id":"16ca468431d44c0e8c931d12ab9b68f6","type":"GENE","name":"TRAPPC2P2","canonical_id":"hgnc:HGNC:10711","description":"trafficking protein particle complex 2 pseudogene 2","metadata":{"aliases":["SEDLP2"]}},{"id":"afa8a87028ef46538861c767973909ad","type":"GENE","name":"TRAPPC2P3","canonical_id":"hgnc:HGNC:10712","description":"trafficking protein particle complex 2 pseudogene 3","metadata":{"aliases":["SEDLP3"]}},{"id":"2b8eafe9c37b4353a9d97473abe4c1a3","type":"GENE","name":"TRAPPC2P4","canonical_id":"hgnc:HGNC:10713","description":"trafficking protein particle complex 2 pseudogene 4","metadata":{"aliases":["SEDLP4"]}},{"id":"f038779370c44c5187b2b1df1f8e7156","type":"GENE","name":"TRAPPC2P5","canonical_id":"hgnc:HGNC:10714","description":"trafficking protein particle complex 2 pseudogene 5","metadata":{"aliases":["SEDLP5"]}},{"id":"d51214b14af24b1e94e71882c0c5e32f","type":"GENE","name":"TRAPPC2P6","canonical_id":"hgnc:HGNC:10715","description":"trafficking protein particle complex 2 pseudogene 6","metadata":{"aliases":["SEDLP6"]}},{"id":"947d617dabc84aec85bf2be6c4573084","type":"GENE","name":"TRAPPC2P7","canonical_id":"hgnc:HGNC:10716","description":"trafficking protein particle complex 2 pseudogene 7","metadata":{"aliases":["SEDLP7"]}},{"id":"fc0aef4d448f442bbbe5b49c796c569c","type":"GENE","name":"TRAPPC2P8","canonical_id":"hgnc:HGNC:37731","description":"trafficking protein particle complex 2 pseudogene 8","metadata":{"aliases":["TRAPPC2P3B"]}},{"id":"9ab470ff7b8e4d00ae37c87e7e065d86","type":"GENE","name":"TRAPPC2P9","canonical_id":"hgnc:HGNC:37733","description":"trafficking protein particle complex 2 pseudogene 9","metadata":{"aliases":["TRAPPC2P4B"]}},{"id":"410375cd29b446949db6ca07373d3bc9","type":"GENE","name":"TRAPPC3","canonical_id":"hgnc:HGNC:19942","description":"trafficking protein particle complex subunit 3","metadata":{"aliases":["BET3"]}},{"id":"b31078cdf67c451a9ef522cdb90ef8c9","type":"GENE","name":"TRAPPC3L","canonical_id":"hgnc:HGNC:21090","description":"trafficking protein particle complex subunit 3L","metadata":{"aliases":["bA259P20.2","FLJ11180","BET3L"]}},{"id":"88254f609ce240ea830513161fe8b257","type":"GENE","name":"TRAPPC4","canonical_id":"hgnc:HGNC:19943","description":"trafficking protein particle complex subunit 4","metadata":{"aliases":["TRS23","SBDN","PTD009"]}},{"id":"1d05d266ed3e46d6929b6bb0120128b5","type":"GENE","name":"TRAPPC5","canonical_id":"hgnc:HGNC:23067","description":"trafficking protein particle complex subunit 5","metadata":{"aliases":["MGC52424","TRS31"]}},{"id":"f8a2aae137504fa28fa7068c3ced4a4d","type":"GENE","name":"TRAPPC6A","canonical_id":"hgnc:HGNC:23069","description":"trafficking protein particle complex subunit 6A","metadata":{"aliases":["TRS33","MGC2650","HSPC289"]}},{"id":"c0d8fbf3432a403d95a9d3c4b1d2ae8f","type":"GENE","name":"TRAPPC6B","canonical_id":"hgnc:HGNC:23066","description":"trafficking protein particle complex subunit 6B","metadata":null},{"id":"149c3476ba1b4a028e6d4ad7a6e2c76b","type":"GENE","name":"TRAPPC8","canonical_id":"hgnc:HGNC:29169","description":"trafficking protein particle complex subunit 8","metadata":{"aliases":["HsT2706","TRS85","GSG1","KIAA1012"]}},{"id":"5ffb08feea7b4d8e840a925eadcb35d8","type":"GENE","name":"TRAPPC9","canonical_id":"hgnc:HGNC:30832","description":"trafficking protein particle complex subunit 9","metadata":{"aliases":["IKBKBBP","NIBP","KIAA1882","T1","TRS120","MRT13"]}},{"id":"9621d6db639c44feac12f3079203fd54","type":"GO_TERM","name":"TRAPPI protein complex","canonical_id":"go:GO:1990070","description":"\"A complex that tethers COPII vesicles at ER-Golgi intermediate compartment. Its role in this part of the vesicular transport may start at the ER exit sites. Binds to a component of the COPII coat. In yeast it includes the following subunits: Bet3 (as homodimer), Bet5, Trs20, Trs23, Trs31, Trs33 which are regarded as the core subunits of all TRAPP complexes in yeast.\" [GOC:bhm, PMID:20375281, PMID:22669257]","metadata":null},{"id":"b538eb127b404d90ac13ba5cad860246","type":"GO_TERM","name":"TRAPPII protein complex","canonical_id":"go:GO:1990071","description":"\"A complex that mediates intra-Golgi traffic, Golgi exit, endosome-to-Golgi traffic, and the trafficking of autophagy proteins from Golgi to the phagophore assembly site. Binds to a component of the COPI coat. In yeast it includes the following subunits: Bet3 (as homodimer), Bet5, Tca17, Trs20, Trs23, Trs31, Trs33, Trs65, Trs120, Trs130. The whole complex is thought to dimerize with itself.\" [GOC:bhm, PMID:20375281, PMID:22669257]","metadata":null},{"id":"09ba3d65bb5544fb8d29e53c2d02bafc","type":"GO_TERM","name":"TRAPPIII protein complex","canonical_id":"go:GO:1990072","description":"\"A complex that functions in anterograde transport at the Golgi and also regulates autophagy. In yeast it includes at least the following subunits: Bet3 (as homodimer), Bet5, Trs20, Trs23, Trs31, Trs33, Trs85. TRAPPIII may include further, as yet undescribed, proteins.\" [GOC:bhm, PMID:20375281, PMID:22669257]","metadata":null},{"id":"8b49b28babc147cfa760067268a4ce46","type":"GENE","name":"TRARG1","canonical_id":"hgnc:HGNC:29592","description":"trafficking regulator of GLUT4 (SLC2A4) 1 (gene/pseudogene)","metadata":{"aliases":["LOST1","IFITMD3","BEC-1","DSPB1","TUSC5"]}},{"id":"44c77b97ce064152bcfad59db1c469cd","type":"GENE","name":"TRAT1","canonical_id":"hgnc:HGNC:30698","description":"T cell receptor associated transmembrane adaptor 1","metadata":{"aliases":["HSPC062","TRIM","TCRIM"]}},{"id":"9f819628e1d74be8b8dd6a5513094f0f","type":"TRIAL","name":"TRAUMA HELP: Healing and Analgesia With Propranolol","canonical_id":"clinicaltrials.gov:NCT01007084","description":"Trauma","metadata":null},{"id":"f9aa8f5088b54eb4aae85bd6b764f979","type":"GENE","name":"TRAV1-1","canonical_id":"hgnc:HGNC:12101","description":"T cell receptor alpha variable 1-1","metadata":{"aliases":["TRAV11","TCRAV1S1","TCRAV7S1"]}},{"id":"b171ad808e1b498d85586bdac09c9d5e","type":"GENE","name":"TRAV1-2","canonical_id":"hgnc:HGNC:12102","description":"T cell receptor alpha variable 1-2","metadata":null},{"id":"30748c3db13949908fcd24b95120c838","type":"GENE","name":"TRAV10","canonical_id":"hgnc:HGNC:12103","description":"T cell receptor alpha variable 10","metadata":{"aliases":["TCRAV10S1","TCRAV24S1"]}},{"id":"64ddfe420470413f9b91c050133c2605","type":"GENE","name":"TRAV11","canonical_id":"hgnc:HGNC:12104","description":"T cell receptor alpha variable 11 (pseudogene)","metadata":null},{"id":"7d6636bf70e242c69c33b2e23efdfe3c","type":"GENE","name":"TRAV12-1","canonical_id":"hgnc:HGNC:12105","description":"T cell receptor alpha variable 12-1","metadata":null},{"id":"069581e284734fd98bdf4cc7a8b7dcd4","type":"GENE","name":"TRAV12-2","canonical_id":"hgnc:HGNC:12106","description":"T cell receptor alpha variable 12-2","metadata":null},{"id":"71650b263bdb45ffb1b2a3d105ce65a2","type":"GENE","name":"TRAV12-3","canonical_id":"hgnc:HGNC:12107","description":"T cell receptor alpha variable 12-3","metadata":{"aliases":["TRAV123","TCRAV2S2","TCRAV12S3"]}},{"id":"5293b39d5c9f47d19479ccbfc79685b3","type":"GENE","name":"TRAV13-1","canonical_id":"hgnc:HGNC:12108","description":"T cell receptor alpha variable 13-1","metadata":null},{"id":"c8c6d06ce06d4dbb9cff1616a3dc277d","type":"GENE","name":"TRAV13-2","canonical_id":"hgnc:HGNC:12109","description":"T cell receptor alpha variable 13-2","metadata":null},{"id":"425f87aa55044f34b06403a242c6fc76","type":"GENE","name":"TRAV14DV4","canonical_id":"hgnc:HGNC:12110","description":"T cell receptor alpha variable 14/delta variable 4","metadata":{"aliases":["TRAV14/DV4","TCRAV6S1-hDV104S1","hADV14S1"]}},{"id":"c6e81de2cc884c038f4ba22cf9a97944","type":"GENE","name":"TRAV15","canonical_id":"hgnc:HGNC:12111","description":"T cell receptor alpha variable 15 (pseudogene)","metadata":{"aliases":["TCRAV15S1"]}},{"id":"25e9f41347da4809b165a8962ce38d0d","type":"GENE","name":"TRAV16","canonical_id":"hgnc:HGNC:12112","description":"T cell receptor alpha variable 16","metadata":{"aliases":["TCRAV16S1","TCRAV9S1"]}},{"id":"a733c1597afb492b8723b3a2ec63c0a7","type":"GENE","name":"TRAV17","canonical_id":"hgnc:HGNC:12113","description":"T cell receptor alpha variable 17","metadata":{"aliases":["TCRAV17S1","TCRAV3S1"]}},{"id":"fb8fede7a8ce467a95a3c629d38c4afa","type":"GENE","name":"TRAV18","canonical_id":"hgnc:HGNC:12114","description":"T cell receptor alpha variable 18","metadata":{"aliases":["TCRAV18S1"]}},{"id":"8c98a9513aa2420d8850963a6da3f0fc","type":"GENE","name":"TRAV19","canonical_id":"hgnc:HGNC:12115","description":"T cell receptor alpha variable 19","metadata":{"aliases":["TCRAV12S1","TCRAV19S1"]}},{"id":"4f54d5eeefdf4a1e9f157b402a14bb1a","type":"GENE","name":"TRAV2","canonical_id":"hgnc:HGNC:12116","description":"T cell receptor alpha variable 2","metadata":null},{"id":"648182a0725b4526936d68802fd578b1","type":"GENE","name":"TRAV20","canonical_id":"hgnc:HGNC:12117","description":"T cell receptor alpha variable 20","metadata":null},{"id":"a0d23c945c314562ae6404cec8245d09","type":"GENE","name":"TRAV21","canonical_id":"hgnc:HGNC:12118","description":"T cell receptor alpha variable 21","metadata":null},{"id":"d5434d86fcfb450faae5f2b7607c01fa","type":"GENE","name":"TRAV22","canonical_id":"hgnc:HGNC:12119","description":"T cell receptor alpha variable 22","metadata":{"aliases":["TCRAV13S1","TCRAV22S1"]}},{"id":"a72c98d6b49a4c32ac36e43cacca09cc","type":"GENE","name":"TRAV23DV6","canonical_id":"hgnc:HGNC:12120","description":"T cell receptor alpha variable 23/delta variable 6","metadata":{"aliases":["TRAV23/DV6","TCRAV17S1"]}},{"id":"cc488f48137b419ebbb2b4fc909b3d30","type":"GENE","name":"TRAV24","canonical_id":"hgnc:HGNC:12121","description":"T cell receptor alpha variable 24","metadata":null},{"id":"22df03fc856748afa34732cb31ee721d","type":"GENE","name":"TRAV25","canonical_id":"hgnc:HGNC:12122","description":"T cell receptor alpha variable 25","metadata":{"aliases":["TCRAV25S1","TCRAV32S1"]}},{"id":"021b9ced45734279b45481cd9e4e9282","type":"GENE","name":"TRAV26-1","canonical_id":"hgnc:HGNC:12123","description":"T cell receptor alpha variable 26-1","metadata":null},{"id":"7f825620783b4f4aa35d0dec1424f16d","type":"GENE","name":"TRAV26-2","canonical_id":"hgnc:HGNC:12124","description":"T cell receptor alpha variable 26-2","metadata":{"aliases":["TRAV262","TCRAV4S1","TCRAV26S2"]}},{"id":"63d25fb7111248708af0e79f736104df","type":"GENE","name":"TRAV27","canonical_id":"hgnc:HGNC:12125","description":"T cell receptor alpha variable 27","metadata":null},{"id":"5d0b61ad92fb4f6684f5dd89a66dde2c","type":"GENE","name":"TRAV28","canonical_id":"hgnc:HGNC:12126","description":"T cell receptor alpha variable 28 (pseudogene)","metadata":null},{"id":"47ac4706798c432db6c2bd4b0467dd9d","type":"GENE","name":"TRAV29DV5","canonical_id":"hgnc:HGNC:12127","description":"T cell receptor alpha variable 29/delta variable 5","metadata":{"aliases":["TRAV29/DV5"]}},{"id":"3c3cfeb0facc4d698ed39eeb1b5844d4","type":"GENE","name":"TRAV3","canonical_id":"hgnc:HGNC:12128","description":"T cell receptor alpha variable 3","metadata":null},{"id":"59834729694e4e2dbff3bf618c5ae28d","type":"GENE","name":"TRAV30","canonical_id":"hgnc:HGNC:12129","description":"T cell receptor alpha variable 30","metadata":null},{"id":"b5d24ef5300d4759a7d4c4bf9dc320b2","type":"GENE","name":"TRAV31","canonical_id":"hgnc:HGNC:12130","description":"T cell receptor alpha variable 31 (pseudogene)","metadata":{"aliases":["TCRAV31S1"]}},{"id":"2d360cd645154732803a62921e384d85","type":"GENE","name":"TRAV32","canonical_id":"hgnc:HGNC:12131","description":"T cell receptor alpha variable 32 (pseudogene)","metadata":null},{"id":"1ce719c530514d31bd072ee025f955e1","type":"GENE","name":"TRAV33","canonical_id":"hgnc:HGNC:12132","description":"T cell receptor alpha variable 33 (pseudogene)","metadata":{"aliases":["C14orf12"]}},{"id":"f51407132ffa4f27b9c0bffcf7354573","type":"GENE","name":"TRAV34","canonical_id":"hgnc:HGNC:12133","description":"T cell receptor alpha variable 34","metadata":{"aliases":["TCRAV26S1","TCRAV34S1"]}},{"id":"1112068acc6d43aea0f36ecea8feb419","type":"GENE","name":"TRAV35","canonical_id":"hgnc:HGNC:12134","description":"T cell receptor alpha variable 35","metadata":{"aliases":["TCRAV25S1","TCRAV35S1"]}},{"id":"7b7b826af9f445bcbc4b0464cac5277f","type":"GENE","name":"TRAV36DV7","canonical_id":"hgnc:HGNC:12135","description":"T cell receptor alpha variable 36/delta variable 7","metadata":{"aliases":["TRAV36/DV7"]}},{"id":"af150dbe9f6d471ea65f3171e7809b2f","type":"GENE","name":"TRAV37","canonical_id":"hgnc:HGNC:12136","description":"T cell receptor alpha variable 37 (pseudogene)","metadata":null},{"id":"80e9d07d81d94c99a7b3f630c0fed008","type":"GENE","name":"TRAV38-1","canonical_id":"hgnc:HGNC:12137","description":"T cell receptor alpha variable 38-1","metadata":{"aliases":["TRAV381","TCRAV14S2","TCRAV38S1"]}},{"id":"707f989a99bb4251948cafbc6df1699e","type":"GENE","name":"TRAV38-2DV8","canonical_id":"hgnc:HGNC:12138","description":"T cell receptor alpha variable 38-2/delta variable 8","metadata":{"aliases":["TRAV38-2/DV8","TRAV382DV8","TCRAV14S1","hADV38S2"]}},{"id":"825cf6f51a274ecf837ad4d0e33b7443","type":"GENE","name":"TRAV39","canonical_id":"hgnc:HGNC:12139","description":"T cell receptor alpha variable 39","metadata":{"aliases":["TCRAV27S1","TCRAV39S1"]}},{"id":"e88a5b4fa07e45e9af817ec7bde46993","type":"GENE","name":"TRAV4","canonical_id":"hgnc:HGNC:12140","description":"T cell receptor alpha variable 4","metadata":{"aliases":["TCRAV20S1","TCRAV4S1"]}},{"id":"7d8ba59606b240e092fc83c6438325ac","type":"GENE","name":"TRAV40","canonical_id":"hgnc:HGNC:12141","description":"T cell receptor alpha variable 40","metadata":{"aliases":["TCRAV31S1","TCRAV40S1"]}},{"id":"8a9416ab5ef5436d9fefc124babb66a4","type":"GENE","name":"TRAV41","canonical_id":"hgnc:HGNC:12142","description":"T cell receptor alpha variable 41","metadata":{"aliases":["TCRAV19S1","TCRAV41S1"]}},{"id":"d79be80087e6409aa1527df4fa8286e3","type":"GENE","name":"TRAV5","canonical_id":"hgnc:HGNC:12143","description":"T cell receptor alpha variable 5","metadata":null},{"id":"234a1171201a4c72a16d7ef95398729f","type":"GENE","name":"TRAV6","canonical_id":"hgnc:HGNC:12144","description":"T cell receptor alpha variable 6","metadata":{"aliases":["TCRAV5S1"]}},{"id":"278822295b0441e591693daaa53b7968","type":"GENE","name":"TRAV7","canonical_id":"hgnc:HGNC:12145","description":"T cell receptor alpha variable 7","metadata":null},{"id":"e239c8c5342b45f3a9fbb2911ccc53bb","type":"GENE","name":"TRAV8-1","canonical_id":"hgnc:HGNC:12146","description":"T cell receptor alpha variable 8-1","metadata":null},{"id":"49629769f3a8428c9d7875231a9446d1","type":"GENE","name":"TRAV8-2","canonical_id":"hgnc:HGNC:12147","description":"T cell receptor alpha variable 8-2","metadata":null},{"id":"074bd3c585b64c32a66372c4fa11535a","type":"GENE","name":"TRAV8-3","canonical_id":"hgnc:HGNC:12148","description":"T cell receptor alpha variable 8-3","metadata":null},{"id":"ab286f6e9f2e45039144a453179ebb01","type":"GENE","name":"TRAV8-4","canonical_id":"hgnc:HGNC:12149","description":"T cell receptor alpha variable 8-4","metadata":null},{"id":"8aa1f0f8b00f4e5da70c91b098539ea8","type":"GENE","name":"TRAV8-5","canonical_id":"hgnc:HGNC:12150","description":"T cell receptor alpha variable 8-5 (pseudogene)","metadata":{"aliases":["TRAV85","TCRAV8S5"]}},{"id":"1a9f4745ae2b4fc398bb3d71c7d4b435","type":"GENE","name":"TRAV8-6","canonical_id":"hgnc:HGNC:12151","description":"T cell receptor alpha variable 8-6","metadata":null},{"id":"cb3a0ed4f4334e9d972a6c8306b1a79d","type":"GENE","name":"TRAV8-7","canonical_id":"hgnc:HGNC:12152","description":"T cell receptor alpha variable 8-7 (pseudogene)","metadata":null},{"id":"7a0417eafe9f411baa19ca55fa7832fa","type":"GENE","name":"TRAV9-1","canonical_id":"hgnc:HGNC:12153","description":"T cell receptor alpha variable 9-1","metadata":null},{"id":"fa57263d21ea4b0789ebb1499d8bfb9d","type":"GENE","name":"TRAV9-2","canonical_id":"hgnc:HGNC:12154","description":"T cell receptor alpha variable 9-2","metadata":null},{"id":"ee22879d0d544d8981b9dd9f693890a8","type":"GENE","name":"TRB","canonical_id":"hgnc:HGNC:12155","description":null,"metadata":null},{"id":"89a7682f2c9d4933a9a7c51155174d82","type":"GENE","name":"TRBC1","canonical_id":"hgnc:HGNC:12156","description":"T cell receptor beta constant 1","metadata":{"aliases":["TCRBC1","BV05S1J2.2"]}},{"id":"4f911213ee864504aee6525ac6cd611e","type":"GENE","name":"TRBC2","canonical_id":"hgnc:HGNC:12157","description":"T cell receptor beta constant 2","metadata":{"aliases":["TCRBC2"]}},{"id":"2b226adaf4b4495a9669f79cb5487ae0","type":"GENE","name":"TRBD1","canonical_id":"hgnc:HGNC:12158","description":"T cell receptor beta diversity 1","metadata":{"aliases":["TCRBD1"]}},{"id":"abf50ad7273a47e8a7170e6621435c9b","type":"GENE","name":"TRBD2","canonical_id":"hgnc:HGNC:12159","description":"T cell receptor beta diversity 2","metadata":{"aliases":["TCRBD2"]}},{"id":"0844833e144f4eae966378c100f0890b","type":"GENE","name":"TRBJ1-1","canonical_id":"hgnc:HGNC:12162","description":"T cell receptor beta joining 1-1","metadata":{"aliases":["TRBJ11","TCRBJ1S1"]}},{"id":"b63944f1274f431da8f12143a6480d7a","type":"GENE","name":"TRBJ1-2","canonical_id":"hgnc:HGNC:12163","description":"T cell receptor beta joining 1-2","metadata":{"aliases":["TRBJ12","TCRBJ1S2"]}},{"id":"ad23ac98ee284b399785de2233cf9dc0","type":"GENE","name":"TRBJ1-3","canonical_id":"hgnc:HGNC:12164","description":"T cell receptor beta joining 1-3","metadata":{"aliases":["TRBJ13","TCRBJ1S3"]}},{"id":"7f88d9ae574b45a494a3b4cbac2ad796","type":"GENE","name":"TRBJ1-4","canonical_id":"hgnc:HGNC:12165","description":"T cell receptor beta joining 1-4","metadata":{"aliases":["TRBJ14","TCRBJ1S4"]}},{"id":"8edd365bdea84522b67d97cfc42eb3d8","type":"GENE","name":"TRBJ1-5","canonical_id":"hgnc:HGNC:12166","description":"T cell receptor beta joining 1-5","metadata":{"aliases":["TRBJ15","TCRBJ1S5"]}},{"id":"644e616b99af46ffad5b562370fb08fd","type":"GENE","name":"TRBJ1-6","canonical_id":"hgnc:HGNC:12167","description":"T cell receptor beta joining 1-6","metadata":{"aliases":["TRBJ16","TCRBJ1S6"]}},{"id":"87f38c8a45264d4e8dfc48d3fdbbd0b5","type":"GENE","name":"TRBJ2-1","canonical_id":"hgnc:HGNC:12168","description":"T cell receptor beta joining 2-1","metadata":{"aliases":["TRBJ21","TCRBJ2S1"]}},{"id":"ba57e223ad944567884e80c1292ceb63","type":"GENE","name":"TRBJ2-2","canonical_id":"hgnc:HGNC:12169","description":"T cell receptor beta joining 2-2","metadata":{"aliases":["TRBJ22","TCRBJ2S2"]}},{"id":"93e8833db7784ecdbe68d04c77fcd3b5","type":"GENE","name":"TRBJ2-2P","canonical_id":"hgnc:HGNC:12170","description":"T cell receptor beta joining 2-2P (non-functional)","metadata":{"aliases":["TRBJ22P"]}},{"id":"7c7bb0d856e244d694219b8470bd309f","type":"GENE","name":"TRBJ2-3","canonical_id":"hgnc:HGNC:12171","description":"T cell receptor beta joining 2-3","metadata":{"aliases":["TRBJ23","TCRBJ2S3"]}},{"id":"b87fe54fbf9a44aab8688268e4e16d5e","type":"GENE","name":"TRBJ2-4","canonical_id":"hgnc:HGNC:12172","description":"T cell receptor beta joining 2-4","metadata":{"aliases":["TRBJ24","TCRBJ2S4"]}},{"id":"cec84165d4f846559f498693543a84f3","type":"GENE","name":"TRBJ2-5","canonical_id":"hgnc:HGNC:12173","description":"T cell receptor beta joining 2-5","metadata":{"aliases":["TRBJ25","TCRBJ2S5"]}},{"id":"b51b9307103a402891b31a3117b0acfa","type":"GENE","name":"TRBJ2-6","canonical_id":"hgnc:HGNC:12174","description":"T cell receptor beta joining 2-6","metadata":{"aliases":["TRBJ26","TCRBJ2S6"]}},{"id":"80b4baeac0c24390afb188e95354fb45","type":"GENE","name":"TRBJ2-7","canonical_id":"hgnc:HGNC:12175","description":"T cell receptor beta joining 2-7","metadata":{"aliases":["TRBJ27","TCRBJ2S7"]}},{"id":"67ee8ffd7c7848ad8937e7dfd77a5e97","type":"GENE","name":"TRBV1","canonical_id":"hgnc:HGNC:12176","description":"T cell receptor beta variable 1 (pseudogene)","metadata":{"aliases":["TCRBV27S1P","TCRBV1S1P"]}},{"id":"779a744e37214fdbbb1e4014a478bba9","type":"GENE","name":"TRBV10-1","canonical_id":"hgnc:HGNC:12177","description":"T cell receptor beta variable 10-1","metadata":{"aliases":["TRBV101","TCRBV10S1","TCRBV12S2A1T","TCRBV12S2"]}},{"id":"e27a516512be48bfa4cb941f812b16ef","type":"GENE","name":"TRBV10-2","canonical_id":"hgnc:HGNC:12178","description":"T cell receptor beta variable 10-2","metadata":{"aliases":["TRBV102","TCRBV10S2","TCRBV12S3"]}},{"id":"6ae0930934644946a935a44634a42114","type":"GENE","name":"TRBV10-3","canonical_id":"hgnc:HGNC:12179","description":"T cell receptor beta variable 10-3","metadata":{"aliases":["TRBV103","TCRBV10S3","TCRBV12S1A1N2"]}},{"id":"bdd0163d8c274d56b6c70f9444cf8847","type":"GENE","name":"TRBV11-1","canonical_id":"hgnc:HGNC:12180","description":"T cell receptor beta variable 11-1","metadata":{"aliases":["TRBV111","TCRBV11S1","TCRBV21S1"]}},{"id":"bbc3243f7cdc4989ba644713727af8f6","type":"GENE","name":"TRBV11-2","canonical_id":"hgnc:HGNC:12181","description":"T cell receptor beta variable 11-2","metadata":{"aliases":["TRBV112","TCRBV11S2","TCRBV21S3A2N2T"]}},{"id":"0578fc05a2fc495c93ee2f8295db1348","type":"GENE","name":"TRBV11-3","canonical_id":"hgnc:HGNC:12182","description":"T cell receptor beta variable 11-3","metadata":{"aliases":["TRBV113","TCRBV11S3","TCRBV21S2A2"]}},{"id":"62aaf22e0c2c420ea118651cb682b095","type":"GENE","name":"TRBV12-1","canonical_id":"hgnc:HGNC:12183","description":"T cell receptor beta variable 12-1 (pseudogene)","metadata":{"aliases":["TRBV121","TCRBV12S1","TCRBV8S4P"]}},{"id":"fc18bb6ceab646faabe8eb2624d9e280","type":"GENE","name":"TRBV12-2","canonical_id":"hgnc:HGNC:12184","description":"T cell receptor beta variable 12-2 (pseudogene)","metadata":{"aliases":["TRBV122","TCRBV12S2","TCRBV8S5P"]}},{"id":"5f8ea62530af437e8fc51555437d7ce6","type":"GENE","name":"TRBV12-3","canonical_id":"hgnc:HGNC:12185","description":"T cell receptor beta variable 12-3","metadata":{"aliases":["TRBV123","TCRBV12S3","TCRBV8S1"]}},{"id":"8f16d56bafc044d0a67bc75c0ca5156b","type":"GENE","name":"TRBV12-4","canonical_id":"hgnc:HGNC:12186","description":"T cell receptor beta variable 12-4","metadata":{"aliases":["TRBV124","TCRBV12S4","TCRBV8S2A1T"]}},{"id":"82a435c381c846f6aea085e95346db3d","type":"GENE","name":"TRBV12-5","canonical_id":"hgnc:HGNC:12187","description":"T cell receptor beta variable 12-5","metadata":{"aliases":["TRBV125","TCRBV12S5","TCRBV8S3"]}},{"id":"b9c6014a652f4a1f8540bb365bf02a70","type":"GENE","name":"TRBV13","canonical_id":"hgnc:HGNC:12188","description":"T cell receptor beta variable 13","metadata":{"aliases":["TCRBV13S1","TCRBV23S1A2T"]}},{"id":"e88cbe46e2b84e5580f8b38d75179dce","type":"GENE","name":"TRBV14","canonical_id":"hgnc:HGNC:12189","description":"T cell receptor beta variable 14","metadata":{"aliases":["TCRBV14S1","TCRBV16S1A1N1"]}},{"id":"bc149bfe289746279fd5583d00e88505","type":"GENE","name":"TRBV15","canonical_id":"hgnc:HGNC:12190","description":"T cell receptor beta variable 15","metadata":{"aliases":["TCRBV15S1","TCRBV24S1A3T"]}},{"id":"96011d27ee054b76a6e572f029bc6c17","type":"GENE","name":"TRBV16","canonical_id":"hgnc:HGNC:12191","description":"T cell receptor beta variable 16","metadata":{"aliases":["TCRBV16S1","TCRBV25S1A2PT"]}},{"id":"8bf2c9aabb804b3784479e4fd66eebfa","type":"GENE","name":"TRBV17","canonical_id":"hgnc:HGNC:12192","description":"T cell receptor beta variable 17 (non-functional)","metadata":{"aliases":["TCRBV17S1","TCRBV26S1P"]}},{"id":"5f33ed42bdfb4e41b22c01a73c80654c","type":"GENE","name":"TRBV18","canonical_id":"hgnc:HGNC:12193","description":"T cell receptor beta variable 18","metadata":{"aliases":["TCRBV18S1"]}},{"id":"71a9eeefaba74c28a7eb521fc1f02951","type":"GENE","name":"TRBV19","canonical_id":"hgnc:HGNC:12194","description":"T cell receptor beta variable 19","metadata":{"aliases":["TCRBV17S1A1T","TCRBV19S1"]}},{"id":"d830a2f9079e4ec89dd8bae1940f4f77","type":"GENE","name":"TRBV2","canonical_id":"hgnc:HGNC:12195","description":"T cell receptor beta variable 2","metadata":{"aliases":["TCRBV22S1A2N1T","TCRBV2S1"]}},{"id":"bbc422a5d1b84b60a4771439c372e88f","type":"GENE","name":"TRBV20-1","canonical_id":"hgnc:HGNC:12196","description":"T cell receptor beta variable 20-1","metadata":{"aliases":["TRBV201","TCRBV20S1","TCRBV2S1"]}},{"id":"c175d2a957704aa8ad413f2c2d6d1826","type":"GENE","name":"TRBV20OR9-2","canonical_id":"hgnc:HGNC:12197","description":"T cell receptor beta variable 20/OR9-2 (non-functional)","metadata":{"aliases":["TRBV20/OR9-2","TCRBV20S2","TCRBV2S2O","TCRBV2O"]}},{"id":"338e34a1d57e4b6cb94946ca7fc371a8","type":"GENE","name":"TRBV21-1","canonical_id":"hgnc:HGNC:12198","description":"T cell receptor beta variable 21-1 (pseudogene)","metadata":{"aliases":["TRBV211","TCRBV10S1P","TCRBV21S1"]}},{"id":"996157d046e249c3b1579869dfdae3f1","type":"GENE","name":"TRBV21OR9-2","canonical_id":"hgnc:HGNC:12199","description":"T cell receptor beta variable 21/OR9-2 (pseudogene)","metadata":{"aliases":["TRBV21/OR9-2","TCRBV10S2O","TCRBV21S2","TCRBV10O"]}},{"id":"66f24a7aa8f145c7896aa20517489a30","type":"GENE","name":"TRBV22-1","canonical_id":"hgnc:HGNC:12200","description":"T cell receptor beta variable 22-1 (pseudogene)","metadata":{"aliases":["TCRBV22S1","TCRBV29S1P","TRBV22"]}},{"id":"b08399c2867545739d654c64d34ebfa8","type":"GENE","name":"TRBV22OR9-2","canonical_id":"hgnc:HGNC:18740","description":"T cell receptor beta variable 22/OR9-2 (pseudogene)","metadata":{"aliases":["TCRBV29S2O","TCRBV22S2","TRBV22/OR9-2"]}},{"id":"d020ad13bd904594a8ea619e28fc0226","type":"GENE","name":"TRBV23-1","canonical_id":"hgnc:HGNC:12201","description":"T cell receptor beta variable 23-1 (non-functional)","metadata":{"aliases":["TRBV231","TCRBV19S1P","TCRBV23S1"]}},{"id":"fb9de42e4a644b8db3e50f678761cca2","type":"GENE","name":"TRBV23OR9-2","canonical_id":"hgnc:HGNC:12202","description":"T cell receptor beta variable 23/OR9-2 (pseudogene)","metadata":{"aliases":["TRBV23/OR9-2","TRBV23OR92","TCRBV19S2O","TCRBV23S2"]}},{"id":"272ef2a58d0a4a959f4ab33bf30abe50","type":"GENE","name":"TRBV24-1","canonical_id":"hgnc:HGNC:12203","description":"T cell receptor beta variable 24-1","metadata":{"aliases":["TRBV241","TCRBV15S1","TCRBV24S1"]}},{"id":"6e2571abe28c4f38a38ecaa5be52da34","type":"GENE","name":"TRBV24OR9-2","canonical_id":"hgnc:HGNC:12204","description":"T cell receptor beta variable 24/OR9-2 (pseudogene)","metadata":{"aliases":["TRBV24/OR9-2","TCRBV15S2O","TCRBV24S2","TCRBV15O"]}},{"id":"a813f2e19fc54e708bf5e73049f192bb","type":"GENE","name":"TRBV25-1","canonical_id":"hgnc:HGNC:12205","description":"T cell receptor beta variable 25-1","metadata":{"aliases":["TRBV251","TCRBV11S1A1T","TCRBV25S1"]}},{"id":"c5bded12820842acbb2db69b2eb110f2","type":"GENE","name":"TRBV25OR9-2","canonical_id":"hgnc:HGNC:12206","description":"T cell receptor beta variable 25/OR9-2 (pseudogene)","metadata":{"aliases":["TRBV25/OR9-2","TCRBV11S2O","TCRBV25S2","TCRBV11O"]}},{"id":"552e813bb8be4660beb3db4d2dd100fe","type":"GENE","name":"TRBV26","canonical_id":"hgnc:HGNC:12207","description":"T cell receptor beta variable 26 (pseudogene)","metadata":{"aliases":["TCRBV26S1","TCRBV28S1P"]}},{"id":"c2b5c4ea17f141cf93f6077719ded7de","type":"GENE","name":"TRBV26OR9-2","canonical_id":"hgnc:HGNC:15485","description":"T cell receptor beta variable 26/OR9-2 (pseudogene)","metadata":{"aliases":["TRBV26/OR9-2","TCRBV28S2O","TCRBV28S2","TCRBV26S2"]}},{"id":"568058c954da4a8ca9ead7d3524613bf","type":"GENE","name":"TRBV27","canonical_id":"hgnc:HGNC:12208","description":"T cell receptor beta variable 27","metadata":{"aliases":["TCRBV14S1","TCRBV27S1"]}},{"id":"e1b4d3b605c44127af784f7d36c48a99","type":"GENE","name":"TRBV28","canonical_id":"hgnc:HGNC:12209","description":"T cell receptor beta variable 28","metadata":{"aliases":["TCRBV28S1","TCRBV3S1"]}},{"id":"3cb48738e2e04de6871ffe4d6b71a0c1","type":"GENE","name":"TRBV29-1","canonical_id":"hgnc:HGNC:12210","description":"T cell receptor beta variable 29-1","metadata":{"aliases":["TRBV291","TCRBV29S1","TCRBV4S1A1T"]}},{"id":"e639a006e08748ada86555fad113bf78","type":"GENE","name":"TRBV29OR9-2","canonical_id":"hgnc:HGNC:12211","description":"T cell receptor beta variable 29/OR9-2 (non-functional)","metadata":{"aliases":["TRBV29/OR9-2","TCRBV29S2","TCRBV4S2O","TCRBV4O"]}},{"id":"5dd21fc066c242af949fe84bb6093de4","type":"GENE","name":"TRBV3-1","canonical_id":"hgnc:HGNC:12212","description":"T cell receptor beta variable 3-1","metadata":{"aliases":["TRBV31","TCRBV3S1","TCRBV9S1A1T"]}},{"id":"f37f59385e74493bbacc7fa843380966","type":"GENE","name":"TRBV3-2","canonical_id":"hgnc:HGNC:12213","description":"T cell receptor beta variable 3-2 (pseudogene)","metadata":{"aliases":["TRBV32","TCRBV3S2","TCRBV9S2A2PT"]}},{"id":"26070e62c091443086eac1145ba75672","type":"GENE","name":"TRBV30","canonical_id":"hgnc:HGNC:12214","description":"T cell receptor beta variable 30","metadata":{"aliases":["TCRBV20S1A1N2","TCRBV30S1"]}},{"id":"e6bb3ea6899b4b569a9d1cf888299988","type":"GENE","name":"TRBV4-1","canonical_id":"hgnc:HGNC:12215","description":"T cell receptor beta variable 4-1","metadata":{"aliases":["TRBV41","TCRBV4S1","TCRBV7S1A1N2T","BV07S1J2.7"]}},{"id":"b823ab51fd6a4443a5cb2de6be22f0cc","type":"GENE","name":"TRBV4-2","canonical_id":"hgnc:HGNC:12216","description":"T cell receptor beta variable 4-2","metadata":{"aliases":["TRBV42","TCRBV4S2","TCRBV7S3A2T"]}},{"id":"d363ff0bebda45b2ab68f3e9531229b8","type":"GENE","name":"TRBV4-3","canonical_id":"hgnc:HGNC:12217","description":"T cell receptor beta variable 4-3","metadata":{"aliases":["TRBV43","TCRBV4S3","TCRBV7S2A1N4T"]}},{"id":"9caef4af671349b8937306486324ed24","type":"GENE","name":"TRBV5-1","canonical_id":"hgnc:HGNC:12218","description":"T cell receptor beta variable 5-1","metadata":{"aliases":["TRBV51","TCRBV5S1","TCRBV5S1A1T"]}},{"id":"053828f40e3e4b1093ddce9b2c817332","type":"GENE","name":"TRBV5-2","canonical_id":"hgnc:HGNC:12219","description":"T cell receptor beta variable 5-2 (pseudogene)","metadata":{"aliases":["TRBV52","TCRBV31S1","TCRBV5S2P"]}},{"id":"d357e7b90e9543aea80c7bbcb308f1ce","type":"GENE","name":"TRBV5-3","canonical_id":"hgnc:HGNC:12220","description":"T cell receptor beta variable 5-3 (non-functional)","metadata":{"aliases":["TRBV53","TCRBV5S3","TCRBV5S5P"]}},{"id":"dea60e590d6f4c20843f86374c0a63e8","type":"GENE","name":"TRBV5-4","canonical_id":"hgnc:HGNC:12221","description":"T cell receptor beta variable 5-4","metadata":{"aliases":["TRBV54","TCRBV5S4","TCRBV5S6A3N2T"]}},{"id":"413d135bbf704634a2190fbb04cd7de4","type":"GENE","name":"TRBV5-5","canonical_id":"hgnc:HGNC:12222","description":"T cell receptor beta variable 5-5","metadata":{"aliases":["TRBV55","TCRBV5S3A2T","TCRBV5S5"]}},{"id":"e85cf02e544041c1bc1e38ae7a7ea86e","type":"GENE","name":"TRBV5-6","canonical_id":"hgnc:HGNC:12223","description":"T cell receptor beta variable 5-6","metadata":{"aliases":["TRBV56","TCRBV5S2","TCRBV5S6"]}},{"id":"5f49a130c10748fcbbebb100976d4853","type":"GENE","name":"TRBV5-7","canonical_id":"hgnc:HGNC:12224","description":"T cell receptor beta variable 5-7 (non-functional)","metadata":{"aliases":["TRBV57","TCRBV5S7","TCRBV5S7P"]}},{"id":"f811e335b16044d89758edf99b56406d","type":"GENE","name":"TRBV5-8","canonical_id":"hgnc:HGNC:12225","description":"T cell receptor beta variable 5-8","metadata":{"aliases":["TRBV58","TCRBV5S4A2T","TCRBV5S8"]}},{"id":"294653f158694c39adcacfce78f772c8","type":"GENE","name":"TRBV6-1","canonical_id":"hgnc:HGNC:12226","description":"T cell receptor beta variable 6-1","metadata":{"aliases":["TRBV61","TCRBV13S3","TCRBV6S1"]}},{"id":"6015d48c6e814ee1910a105cd1bbd2c2","type":"GENE","name":"TRBV6-2","canonical_id":"hgnc:HGNC:12227","description":"T cell receptor beta variable 6-2","metadata":{"aliases":["TRBV62","TCRBV13S2A1T","TCRBV6S2"]}},{"id":"82a6320311d9460ba7424b61e01e190f","type":"GENE","name":"TRBV6-3","canonical_id":"hgnc:HGNC:12228","description":"T cell receptor beta variable 6-3","metadata":{"aliases":["TRBV63","TCRBV13S9/13S2A1T","TCRBV6S3"]}},{"id":"cdc22cb7ba824416b80b89d80c32e431","type":"GENE","name":"TRBV6-4","canonical_id":"hgnc:HGNC:12229","description":"T cell receptor beta variable 6-4","metadata":{"aliases":["TRBV64","TCRBV13S5","TCRBV6S4"]}},{"id":"88f7fa353a0c453e902f54f53defd11b","type":"GENE","name":"TRBV6-5","canonical_id":"hgnc:HGNC:12230","description":"T cell receptor beta variable 6-5","metadata":{"aliases":["TRBV65","TCRBV13S1","TCRBV6S5"]}},{"id":"5c9ab9e20d01407da7657e8675fd2708","type":"GENE","name":"TRBV6-6","canonical_id":"hgnc:HGNC:12231","description":"T cell receptor beta variable 6-6","metadata":{"aliases":["TRBV66","TCRBV13S6A2T","TCRBV6S6"]}},{"id":"765ec1dd13b24167ad707f2bd61d6a04","type":"GENE","name":"TRBV6-7","canonical_id":"hgnc:HGNC:12232","description":"T cell receptor beta variable 6-7 (non-functional)","metadata":{"aliases":["TRBV67","TCRBV13S8P","TCRBV6S7"]}},{"id":"cb68a54094c2463492ad0657183b9c7e","type":"GENE","name":"TRBV6-8","canonical_id":"hgnc:HGNC:12233","description":"T cell receptor beta variable 6-8","metadata":{"aliases":["TRBV68","TCRBV13S7P","TCRBV6S8"]}},{"id":"9086b4548d99446aaecbcf276fc66756","type":"GENE","name":"TRBV6-9","canonical_id":"hgnc:HGNC:12234","description":"T cell receptor beta variable 6-9","metadata":{"aliases":["TRBV69","TCRBV13S4","TCRBV6S9"]}},{"id":"e0184167aa6245b28073fa0916effd93","type":"GENE","name":"TRBV7-1","canonical_id":"hgnc:HGNC:12235","description":"T cell receptor beta variable 7-1 (non-functional)","metadata":{"aliases":["TRBV71","TCRBV6S7P","TCRBV7S1"]}},{"id":"3cb84d43b297453aba6d0fe5c435df71","type":"GENE","name":"TRBV7-2","canonical_id":"hgnc:HGNC:12236","description":"T cell receptor beta variable 7-2","metadata":{"aliases":["TRBV72","TCRBV6S5A1N1","TCRBV7S2"]}},{"id":"a09933e25dc8420bbfb3d356bc7f7a94","type":"GENE","name":"TRBV7-3","canonical_id":"hgnc:HGNC:12237","description":"T cell receptor beta variable 7-3","metadata":{"aliases":["TRBV73","TCRBV6S1A1N1","TCRBV7S3"]}},{"id":"02a26d70b10c40a09d728be51648525d","type":"GENE","name":"TRBV7-4","canonical_id":"hgnc:HGNC:12238","description":"T cell receptor beta variable 7-4","metadata":{"aliases":["TRBV74","TCRBV6S8A2T","TCRBV7S4"]}},{"id":"c86c205f23fc47638787ce80578b8f43","type":"GENE","name":"TRBV7-5","canonical_id":"hgnc:HGNC:12239","description":"T cell receptor beta variable 7-5 (pseudogene)","metadata":{"aliases":["TRBV75","TCRBV6S9P","TCRBV7S5"]}},{"id":"a45e35aec37546ccb4e2f4592ad0e6fc","type":"GENE","name":"TRBV7-6","canonical_id":"hgnc:HGNC:12240","description":"T cell receptor beta variable 7-6","metadata":{"aliases":["TRBV76","TCRBV6S3A1N1T","TCRBV7S6"]}},{"id":"82585a7ea3b04c6b8acd91fb816063e8","type":"GENE","name":"TRBV7-7","canonical_id":"hgnc:HGNC:12241","description":"T cell receptor beta variable 7-7","metadata":{"aliases":["TRBV77","TCRBV6S6A2T","TCRBV7S7"]}},{"id":"760661893a0b4484b3acaf207ded0440","type":"GENE","name":"TRBV7-8","canonical_id":"hgnc:HGNC:12242","description":"T cell receptor beta variable 7-8","metadata":{"aliases":["TRBV78","TCRBV6S2A1N1T","TCRBV7S8"]}},{"id":"8ac3e4b8927d457e86c456e7e1404c2c","type":"GENE","name":"TRBV7-9","canonical_id":"hgnc:HGNC:12243","description":"T cell receptor beta variable 7-9","metadata":{"aliases":["TRBV79","TCRBV6S4A1","TCRBV7S9"]}},{"id":"5d576b27310549278c159dce21688946","type":"GENE","name":"TRBV8-1","canonical_id":"hgnc:HGNC:12244","description":"T cell receptor beta variable 8-1 (pseudogene)","metadata":{"aliases":["TRBV81","TCRBV30S1P","TCRBV8S1P"]}},{"id":"c667ecdea1dd46ada40dfc47def0db5e","type":"GENE","name":"TRBV8-2","canonical_id":"hgnc:HGNC:12245","description":"T cell receptor beta variable 8-2 (pseudogene)","metadata":{"aliases":["TRBV82","TCRBV32S1P"]}},{"id":"a25e4acfaff440f29a1d389076886557","type":"GENE","name":"TRBV9","canonical_id":"hgnc:HGNC:12246","description":"T cell receptor beta variable 9","metadata":{"aliases":["TCRBV1S1A1N1","TCRBV9S1"]}},{"id":"4431c03097f94d3ba9b605f81ec4b5fd","type":"GENE","name":"TRBVA","canonical_id":"hgnc:HGNC:12247","description":"T cell receptor beta variable A (pseudogene)","metadata":{"aliases":["TCRBV33S1"]}},{"id":"cfd775c346a8413a87a242049d6264dd","type":"GENE","name":"TRBVAOR9-2","canonical_id":"hgnc:HGNC:18741","description":"T cell receptor beta variable A/OR9-2 (pseudogene)","metadata":{"aliases":["TRBVA/OR9-2","TCRBV33S2"]}},{"id":"a78434250c274390aae9f95593f35600","type":"GENE","name":"TRBVB","canonical_id":"hgnc:HGNC:12248","description":"T cell receptor beta variable B (pseudogene)","metadata":{"aliases":["TCRBV34S1"]}},{"id":"499be873aeee4845827f2562323e37b7","type":"GENE","name":"TRBVC","canonical_id":"hgnc:HGNC:50321","description":"T cell receptor beta variable C (pseudogene)","metadata":null},{"id":"04b66a05f9bd4c1bb237254a6b08221f","type":"GO_TERM","name":"TRC complex","canonical_id":"go:GO:0072380","description":"\"A protein complex found in yeast that contains GET4, MDY2 (GET5), SGT2, and at least two heat shock proteins, HSP104 and YBR137W. The TRC complex transfers tail-anchored (TA) proteins to GET3 for targeting to the endoplasmic reticulum membrane.\" [GOC:mah, PMID:20850366, PMID:23142665]","metadata":null},{"id":"d32b1a060dc847b9a3631adcbb3036d0","type":"GENE","name":"TRC-ACA1-1","canonical_id":"hgnc:HGNC:35083","description":"tRNA-Cys (anticodon ACA) 1-1","metadata":{"aliases":["tRNA-Cys-ACA-1-1","TRNAC32P"]}},{"id":"d8751c6f154f4024a77ed75afa84d01e","type":"GENE","name":"TRC-GCA1-1","canonical_id":"hgnc:HGNC:34706","description":"tRNA-Cys (anticodon GCA) 1-1","metadata":{"aliases":["tRNA-Cys-GCA-1-1","TRNAC10"]}},{"id":"64f1f6e21f58499692d1f66be8cb0385","type":"GENE","name":"TRC-GCA10-1","canonical_id":"hgnc:HGNC:34871","description":"tRNA-Cys (anticodon GCA) 10-1","metadata":{"aliases":["tRNA-Cys-GCA-10-1","TRNAC21"]}},{"id":"d1cbeeac2eb740d2a84ca34f329c1833","type":"GENE","name":"TRC-GCA11-1","canonical_id":"hgnc:HGNC:34566","description":"tRNA-Cys (anticodon GCA) 11-1","metadata":{"aliases":["tRNA-Cys-GCA-11-1","TRNAC2"]}},{"id":"b5b456340ef74ad9a8e09ef67c125f6c","type":"GENE","name":"TRC-GCA12-1","canonical_id":"hgnc:HGNC:34634","description":"tRNA-Cys (anticodon GCA) 12-1","metadata":{"aliases":["tRNA-Cys-GCA-12-1","TRNAC6"]}},{"id":"22b250cc8e98446d8863d37dbbe130da","type":"GENE","name":"TRC-GCA13-1","canonical_id":"hgnc:HGNC:34925","description":"tRNA-Cys (anticodon GCA) 13-1","metadata":{"aliases":["tRNA-Cys-GCA-13-1","TRNAC23"]}},{"id":"cea07e040fee4c8baa6894b94a0ef645","type":"GENE","name":"TRC-GCA14-1","canonical_id":"hgnc:HGNC:35005","description":"tRNA-Cys (anticodon GCA) 14-1","metadata":{"aliases":["tRNA-Cys-GCA-14-1","TRNAC30"]}},{"id":"6d9ef36cff7b43b6975473f8a9e2429c","type":"GENE","name":"TRC-GCA15-1","canonical_id":"hgnc:HGNC:34830","description":"tRNA-Cys (anticodon GCA) 15-1","metadata":{"aliases":["tRNA-Cys-GCA-15-1","TRNAC19"]}},{"id":"c07a3e3496a84794ae7583163bfa6497","type":"GENE","name":"TRC-GCA16-1","canonical_id":"hgnc:HGNC:34708","description":"tRNA-Cys (anticodon GCA) 16-1","metadata":{"aliases":["tRNA-Cys-GCA-16-1","TRNAC11"]}},{"id":"3a846230719447dca15287b5fd7b1a70","type":"GENE","name":"TRC-GCA17-1","canonical_id":"hgnc:HGNC:34855","description":"tRNA-Cys (anticodon GCA) 17-1","metadata":{"aliases":["tRNA-Cys-GCA-17-1","TRNAC20"]}},{"id":"a8f1e64d0dd749b2af362ec0a288faf3","type":"GENE","name":"TRC-GCA18-1","canonical_id":"hgnc:HGNC:34608","description":"tRNA-Cys (anticodon GCA) 18-1","metadata":{"aliases":["tRNA-Cys-GCA-18-1","TRNAC4"]}},{"id":"6409c93333ad41428c07f05f53aab260","type":"GENE","name":"TRC-GCA19-1","canonical_id":"hgnc:HGNC:34739","description":"tRNA-Cys (anticodon GCA) 19-1","metadata":{"aliases":["tRNA-Cys-GCA-19-1","TRNAC13"]}},{"id":"139ab4d12ea64cdfbe2bdeb99302d24b","type":"GENE","name":"TRC-GCA2-1","canonical_id":"hgnc:HGNC:34760","description":"tRNA-Cys (anticodon GCA) 2-1","metadata":{"aliases":["tRNA-Cys-GCA-2-1","TRNAC16","TRC-GCA2-4"]}},{"id":"077e8aea2de54187a41c6f6fa27de7e7","type":"GENE","name":"TRC-GCA2-2","canonical_id":"hgnc:HGNC:34611","description":"tRNA-Cys (anticodon GCA) 2-2","metadata":{"aliases":["tRNA-Cys-GCA-2-2","TRNAC5","TRC-GCA2-1"]}},{"id":"45ddf2b3f5014925b8abcf6c998335a6","type":"GENE","name":"TRC-GCA2-3","canonical_id":"hgnc:HGNC:34666","description":"tRNA-Cys (anticodon GCA) 2-3","metadata":{"aliases":["tRNA-Cys-GCA-2-3","TRNAC9","TRC-GCA2-2"]}},{"id":"cad3bb8d23ca42f99942f5316db51cf6","type":"GENE","name":"TRC-GCA2-4","canonical_id":"hgnc:HGNC:34983","description":"tRNA-Cys (anticodon GCA) 2-4","metadata":{"aliases":["tRNA-Cys-GCA-2-4","TRNAC29","TRC-GCA2-3"]}},{"id":"e02b88919bf24735a7d255c9bb87ccbd","type":"GENE","name":"TRC-GCA20-1","canonical_id":"hgnc:HGNC:34923","description":"tRNA-Cys (anticodon GCA) 20-1","metadata":{"aliases":["tRNA-Cys-GCA-20-1","TRNAC22"]}},{"id":"6a68777e198a4b43ba593cd66a500956","type":"GENE","name":"TRC-GCA21-1","canonical_id":"hgnc:HGNC:34943","description":"tRNA-Cys (anticodon GCA) 21-1","metadata":{"aliases":["tRNA-Cys-GCA-21-1","TRNAC25"]}},{"id":"e60cc285e8dd4f4a83118883b723ec3b","type":"GENE","name":"TRC-GCA22-1","canonical_id":"hgnc:HGNC:34588","description":"tRNA-Cys (anticodon GCA) 22-1","metadata":{"aliases":["tRNA-Cys-GCA-22-1","TRNAC3"]}},{"id":"989eaaf112cf4238b08cece7a22767ce","type":"GENE","name":"TRC-GCA23-1","canonical_id":"hgnc:HGNC:34757","description":"tRNA-Cys (anticodon GCA) 23-1","metadata":{"aliases":["tRNA-Cys-GCA-23-1","TRNAC15"]}},{"id":"c0189bc145ce4280af4d315be499e79e","type":"GENE","name":"TRC-GCA24-1","canonical_id":"hgnc:HGNC:12250","description":"tRNA-Cys (GCA) 24-1","metadata":{"aliases":["tRNA-Cys-GCA-24-1","TRC","TRNAC1"]}},{"id":"7dd32f6be5024ed68516e71e6b10f007","type":"GENE","name":"TRC-GCA25-1","canonical_id":"hgnc:HGNC:35017","description":"tRNA-Cys (anticodon GCA) 25-1","metadata":{"aliases":["tRNA-Cys-GCA-25-1","TRNAC31P"]}},{"id":"2bb665131549479388ed96acfc5c70c9","type":"GENE","name":"TRC-GCA3-1","canonical_id":"hgnc:HGNC:34658","description":"tRNA-Cys (anticodon GCA) 3-1","metadata":{"aliases":["tRNA-Cys-GCA-3-1","TRNAC8"]}},{"id":"85a1368247a844fc90d8394e87b044b8","type":"GENE","name":"TRC-GCA4-1","canonical_id":"hgnc:HGNC:34650","description":"tRNA-Cys (anticodon GCA) 4-1","metadata":{"aliases":["tRNA-Cys-GCA-4-1","TRNAC7"]}},{"id":"833d52f81ff44849bb9f3a7471ca14ae","type":"GENE","name":"TRC-GCA5-1","canonical_id":"hgnc:HGNC:34717","description":"tRNA-Cys (anticodon GCA) 5-1","metadata":{"aliases":["tRNA-Cys-GCA-5-1","TRNAC12"]}},{"id":"a827b0c0ceb84431b6502520f191c768","type":"GENE","name":"TRC-GCA6-1","canonical_id":"hgnc:HGNC:34741","description":"tRNA-Cys (anticodon GCA) 6-1","metadata":{"aliases":["tRNA-Cys-GCA-6-1","TRNAC14"]}},{"id":"d661106ad4c84acfb79f51e64c814481","type":"GENE","name":"TRC-GCA7-1","canonical_id":"hgnc:HGNC:38575","description":"tRNA-Cys (anticodon GCA) 7-1","metadata":{"aliases":["tRNA-Cys-GCA-7-1","TRNAC33"]}},{"id":"0760d3313f984dcd8a1c867150c05412","type":"GENE","name":"TRC-GCA8-1","canonical_id":"hgnc:HGNC:34927","description":"tRNA-Cys (anticodon GCA) 8-1","metadata":{"aliases":["tRNA-Cys-GCA-8-1","TRNAC24"]}},{"id":"17f8e80c42d24bd59553346b1b0c1b8f","type":"GENE","name":"TRC-GCA9-1","canonical_id":"hgnc:HGNC:34813","description":"tRNA-Cys (anticodon GCA) 9-1","metadata":{"aliases":["tRNA-Cys-GCA-9-1","TRNAC18"]}},{"id":"46939b4a921c46ef8ff1f989a8246df7","type":"GENE","name":"TRC-GCA9-2","canonical_id":"hgnc:HGNC:34982","description":"tRNA-Cys (anticodon GCA) 9-2","metadata":{"aliases":["tRNA-Cys-GCA-9-2","TRNAC28"]}},{"id":"b3688c93d3c840f69ce1130f47e8b33d","type":"GENE","name":"TRC-GCA9-3","canonical_id":"hgnc:HGNC:34944","description":"tRNA-Cys (anticodon GCA) 9-3","metadata":{"aliases":["tRNA-Cys-GCA-9-3","TRNAC26"]}},{"id":"f6ed6d366a424033926b7dfcb3dcd668","type":"GENE","name":"TRC-GCA9-4","canonical_id":"hgnc:HGNC:34947","description":"tRNA-Cys (anticodon GCA) 9-4","metadata":{"aliases":["tRNA-Cys-GCA-9-4","TRNAC27"]}},{"id":"ac5d031555234474b86fa5cec9d731ee","type":"TRIAL","name":"TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas","canonical_id":"clinicaltrials.gov:NCT01851369","description":"Lymphomas; Solid Tumors; NSCLC; Metastatic Colon Carcinoma; Granulosa Cell Ovarian Cancer","metadata":null},{"id":"f61a779fe9ea40bab390e9d87f98c602","type":"GENE","name":"TRCG1P","canonical_id":"hgnc:HGNC:53112","description":"taste receptor cell gene 1, pseudogene","metadata":null},{"id":"1c9f6d16be1648bf92b18d87a4f5e0fb","type":"GENE","name":"TRCR1","canonical_id":"hgnc:HGNC:55388","description":"TBC1D22A divergent RNA CLOCK regulator 1","metadata":{"aliases":["TBC1D22A-DT"]}},{"id":"230458410c9d4543bb71425ef7b5e05c","type":"GENE","name":"TRD","canonical_id":"hgnc:HGNC:12252","description":"T cell receptor delta locus","metadata":{"aliases":["TCRDV1","TCRD","TRD@"]}},{"id":"131a26afb9494232bc3ffd8c4fcc7c57","type":"GENE","name":"TRD-AS1","canonical_id":"hgnc:HGNC:56197","description":"TRD antisense RNA 1","metadata":null},{"id":"9073fe3a74ef4a2eb68d194a405ff4d8","type":"GENE","name":"TRD-GTC1-1","canonical_id":"hgnc:HGNC:34770","description":"tRNA-Asp (anticodon GTC) 1-1","metadata":{"aliases":["tRNA-Asp-GTC-1-1","TRNAD10"]}},{"id":"8cc87a9d439b44c992da9e94f4c7a0ff","type":"GENE","name":"TRD-GTC10-1","canonical_id":"hgnc:HGNC:35070","description":"tRNA-Asp (GTC) 10-1","metadata":{"aliases":["tRNA-Asp-GTC-10-1","TRNAD20P"]}},{"id":"6ca4273ca6d545898f256d2e46d89c5b","type":"GENE","name":"TRD-GTC2-1","canonical_id":"hgnc:HGNC:34981","description":"tRNA-Asp (anticodon GTC) 2-1","metadata":{"aliases":["tRNA-Asp-GTC-2-1","TRNAD18"]}},{"id":"d5299eadfd7c4a45abc0b17b7544b781","type":"GENE","name":"TRD-GTC2-10","canonical_id":"hgnc:HGNC:34915","description":"tRNA-Asp (anticodon GTC) 2-10","metadata":{"aliases":["tRNA-Asp-GTC-2-10","TRNAD16","TRD-GTC2-8"]}},{"id":"1b1e06c589c74cd5934f224f3c551617","type":"GENE","name":"TRD-GTC2-11","canonical_id":"hgnc:HGNC:34951","description":"tRNA-Asp (anticodon GTC) 2-11","metadata":{"aliases":["tRNA-Asp-GTC-2-11","TRNAD17","TRD-GTC2-9"]}},{"id":"2deff7b44bf04dbe999e8f7ce587b14f","type":"GENE","name":"TRD-GTC2-2","canonical_id":"hgnc:HGNC:34798","description":"tRNA-Asp (anticodon GTC) 2-2","metadata":{"aliases":["tRNA-Asp-GTC-2-2","TRNAD11"]}},{"id":"8e491a43241b4aa78532c9eb659d1609","type":"GENE","name":"TRD-GTC2-3","canonical_id":"hgnc:HGNC:34856","description":"tRNA-Asp (anticodon GTC) 2-3","metadata":{"aliases":["tRNA-Asp-GTC-2-3","TRNAD13"]}},{"id":"a691c388fe6f4d93aa60124da8ae11ee","type":"GENE","name":"TRD-GTC2-4","canonical_id":"hgnc:HGNC:34696","description":"tRNA-Asp (anticodon GTC) 2-4","metadata":{"aliases":["tRNA-Asp-GTC-2-4","TRNAD6"]}},{"id":"63de89adfa0b42b2b2a452d81599c4b5","type":"GENE","name":"TRD-GTC2-5","canonical_id":"hgnc:HGNC:34682","description":"tRNA-Asp (anticodon GTC) 2-5","metadata":{"aliases":["tRNA-Asp-GTC-2-5","TRNAD5"]}},{"id":"d484f79220b04bdc9d9aa90f87663741","type":"GENE","name":"TRD-GTC2-6","canonical_id":"hgnc:HGNC:34720","description":"tRNA-Asp (anticodon GTC) 2-6","metadata":{"aliases":["tRNA-Asp-GTC-2-6","TRNAD8","TRD-GTC2-10"]}},{"id":"c218567609f34bf2b93fa5fa29879af2","type":"GENE","name":"TRD-GTC2-7","canonical_id":"hgnc:HGNC:34858","description":"tRNA-Asp (anticodon GTC) 2-7","metadata":{"aliases":["tRNA-Asp-GTC-2-7","TRNAD14","TRD-GTC2-11"]}},{"id":"0ae9edf329af4938bce5041c568f7b4a","type":"GENE","name":"TRD-GTC2-8","canonical_id":"hgnc:HGNC:34802","description":"tRNA-Asp (anticodon GTC) 2-8","metadata":{"aliases":["tRNA-Asp-GTC-2-8","TRNAD12","TRD-GTC2-6"]}},{"id":"9b99213cc3684324aa5ba64bea3f0f66","type":"GENE","name":"TRD-GTC2-9","canonical_id":"hgnc:HGNC:34911","description":"tRNA-Asp (anticodon GTC) 2-9","metadata":{"aliases":["tRNA-Asp-GTC-2-9","TRNAD15","TRD-GTC2-7"]}},{"id":"583f41c8935d4752b54e418d4338977e","type":"GENE","name":"TRD-GTC3-1","canonical_id":"hgnc:HGNC:34763","description":"tRNA-Asp (anticodon GTC) 3-1","metadata":{"aliases":["tRNA-Asp-GTC-3-1","TRNAD9"]}},{"id":"e6b5e507cfff4d37ab6179b0662fda77","type":"GENE","name":"TRD-GTC4-1","canonical_id":"hgnc:HGNC:34551","description":"tRNA-Asp (GTC) 4-1","metadata":{"aliases":["tRNA-Asp-GTC-4-1","TRNAD2"]}},{"id":"183290288f55473e8e7abe2dbafe746f","type":"GENE","name":"TRD-GTC5-1","canonical_id":"hgnc:HGNC:34620","description":"tRNA-Asp (GTC) 5-1","metadata":{"aliases":["tRNA-Asp-GTC-5-1","TRNAD3"]}},{"id":"4ffdd73c636f4944a2da3217fdc514bd","type":"GENE","name":"TRD-GTC6-1","canonical_id":"hgnc:HGNC:34712","description":"tRNA-Asp (GTC) 6-1","metadata":{"aliases":["tRNA-Asp-GTC-6-1","TRNAD7"]}},{"id":"cc24f53257204a3ba96cb22441162226","type":"GENE","name":"TRD-GTC7-1","canonical_id":"hgnc:HGNC:34647","description":"tRNA-Asp (GTC) 7-1","metadata":{"aliases":["tRNA-Asp-GTC-7-1","TRNAD4"]}},{"id":"4abe0a2adb5846959646377ac61c86f7","type":"GENE","name":"TRD-GTC8-1","canonical_id":"hgnc:HGNC:35000","description":"tRNA-Asp (GTC) 8-1","metadata":{"aliases":["tRNA-Asp-GTC-8-1","TRNAD19"]}},{"id":"2a4da605673e4cf684f9b387fdd3bebb","type":"GENE","name":"TRD-GTC9-1","canonical_id":"hgnc:HGNC:12251","description":"tRNA-Asp (anticodon GTC) 9-1","metadata":{"aliases":["tRNA-Asp-GTC-9-1","TRD","TRNAD1"]}},{"id":"91f5a59c9c354b2c98645f949d604d9e","type":"GENE","name":"TRDC","canonical_id":"hgnc:HGNC:12253","description":"T cell receptor delta constant","metadata":null},{"id":"0c19e5a04f814433b8015bfe661eb97a","type":"GENE","name":"TRDD1","canonical_id":"hgnc:HGNC:12254","description":"T cell receptor delta diversity 1","metadata":null},{"id":"bbebc86c0b384827a915ecd2f9de6dbf","type":"GENE","name":"TRDD2","canonical_id":"hgnc:HGNC:12255","description":"T cell receptor delta diversity 2","metadata":null},{"id":"9377fcec9e4d4208baf2caf99ea02285","type":"GENE","name":"TRDD3","canonical_id":"hgnc:HGNC:12256","description":"T cell receptor delta diversity 3","metadata":null},{"id":"4eb14fa0360948e18d717886b4cd0ccc","type":"GENE","name":"TRDJ1","canonical_id":"hgnc:HGNC:12257","description":"T cell receptor delta joining 1","metadata":null},{"id":"a8dd18bd6fab4968927a60d0ac420775","type":"GENE","name":"TRDJ2","canonical_id":"hgnc:HGNC:12258","description":"T cell receptor delta joining 2","metadata":null},{"id":"efddf6fc8dae426d8dc1a999e3682653","type":"GENE","name":"TRDJ3","canonical_id":"hgnc:HGNC:12259","description":"T cell receptor delta joining 3","metadata":null},{"id":"a063642537ee48cd96247d65230626c4","type":"GENE","name":"TRDJ4","canonical_id":"hgnc:HGNC:12260","description":"T cell receptor delta joining 4","metadata":null},{"id":"341bcb8bde9d4b7e9bc89b8a7fc4c7a3","type":"GENE","name":"TRDMT1","canonical_id":"hgnc:HGNC:2977","description":"tRNA aspartic acid methyltransferase 1","metadata":{"aliases":["RNMT1","DNMT2"]}},{"id":"21b928cd2fd84deb89f239e1b00757dd","type":"GENE","name":"TRDN","canonical_id":"hgnc:HGNC:12261","description":"triadin","metadata":{"aliases":["TRISK"]}},{"id":"b24269763bc948e6a390ed40a628c202","type":"GENE","name":"TRDN-AS1","canonical_id":"hgnc:HGNC:40592","description":"TRDN antisense RNA 1","metadata":{"aliases":["HRAT13"]}},{"id":"2e5115b672084e78ae7aecf9bd77d679","type":"GENE","name":"TRDV1","canonical_id":"hgnc:HGNC:12262","description":"T cell receptor delta variable 1","metadata":{"aliases":["hDV101S1"]}},{"id":"b166059ab6514788a1178cd555e1bbc1","type":"GENE","name":"TRDV2","canonical_id":"hgnc:HGNC:12263","description":"T cell receptor delta variable 2","metadata":{"aliases":["hDV102S1","MGC117421"]}},{"id":"0aa480840ab84726a28cf047cde484ea","type":"GENE","name":"TRDV3","canonical_id":"hgnc:HGNC:12264","description":"T cell receptor delta variable 3","metadata":{"aliases":["hDV103S1"]}},{"id":"7145e0c464fd46519aea59de937cddd2","type":"GENE","name":"TRE-CTC1-1","canonical_id":"hgnc:HGNC:34952","description":"tRNA-Glu (anticodon CTC) 1-1","metadata":{"aliases":["tRNA-Glu-CTC-1-1","TRNAE21"]}},{"id":"af877a63471a428aab11509fcb4db3c2","type":"GENE","name":"TRE-CTC1-2","canonical_id":"hgnc:HGNC:34651","description":"tRNA-Glu (anticodon CTC) 1-2","metadata":{"aliases":["tRNA-Glu-CTC-1-2","TRNAE13"]}},{"id":"fcda7b0cefdc43a4b498239dc75b38de","type":"GENE","name":"TRE-CTC1-3","canonical_id":"hgnc:HGNC:34953","description":"tRNA-Glu (anticodon CTC) 1-3","metadata":{"aliases":["tRNA-Glu-CTC-1-3","TRNAE22"]}},{"id":"2006182a8f9c4916981860f1120f2bc4","type":"GENE","name":"TRE-CTC1-4","canonical_id":"hgnc:HGNC:34822","description":"tRNA-Glu (anticodon CTC) 1-4","metadata":{"aliases":["tRNA-Glu-CTC-1-4","TRNAE18"]}},{"id":"0e98c9f6354f4ce7908f4ddcea72640b","type":"GENE","name":"TRE-CTC1-5","canonical_id":"hgnc:HGNC:34576","description":"tRNA-Glu (anticodon CTC) 1-5","metadata":{"aliases":["tRNA-Glu-CTC-1-5","TRNAE5"]}},{"id":"e0fb7990137e4ba9996fbe0bfa9cc379","type":"GENE","name":"TRE-CTC1-6","canonical_id":"hgnc:HGNC:34583","description":"tRNA-Glu (anticodon CTC) 1-6","metadata":{"aliases":["tRNA-Glu-CTC-1-6","TRNAE6"]}},{"id":"b6325f6dd4294e738073f7cedf722602","type":"GENE","name":"TRE-CTC1-7","canonical_id":"hgnc:HGNC:34832","description":"tRNA-Glu (anticodon CTC) 1-7","metadata":{"aliases":["tRNA-Glu-CTC-1-7","TRNAE19"]}},{"id":"7ff179f3a01d469c9fe3042f44c55d6b","type":"GENE","name":"TRE-CTC10-1","canonical_id":"hgnc:HGNC:35109","description":"tRNA-Glu (CTC) 10-1","metadata":{"aliases":["tRNA-Glu-CTC-10-1","TRNAE43P"]}},{"id":"a68149e8f7224393be607a7da9983c2e","type":"GENE","name":"TRE-CTC11-1","canonical_id":"hgnc:HGNC:35061","description":"tRNA-Glu (CTC) 11-1","metadata":{"aliases":["tRNA-Glu-CTC-11-1","TRNAE35P"]}},{"id":"c64ce2204a054f88b913a41d69c42a48","type":"GENE","name":"TRE-CTC12-1","canonical_id":"hgnc:HGNC:35010","description":"tRNA-Glu (CTC) 12-1","metadata":{"aliases":["tRNA-Glu-CTC-12-1","TRNAE27P"]}},{"id":"f4f256b67eca4205b739b3671f7f3d92","type":"GENE","name":"TRE-CTC13-1","canonical_id":"hgnc:HGNC:35031","description":"tRNA-Glu (CTC) 13-1","metadata":{"aliases":["tRNA-Glu-CTC-13-1","TRNAE31P"]}},{"id":"a13e09da3bcd4401bf4aaac9306cabee","type":"GENE","name":"TRE-CTC14-1","canonical_id":"hgnc:HGNC:35020","description":"tRNA-Glu (CTC) 14-1","metadata":{"aliases":["tRNA-Glu-CTC-14-1","TRNAE28P"]}},{"id":"655234272d8f4e23a0969317eec4fb1a","type":"GENE","name":"TRE-CTC15-1","canonical_id":"hgnc:HGNC:35104","description":"tRNA-Glu (CTC) 15-1","metadata":{"aliases":["tRNA-Glu-CTC-15-1","TRNAE41P"]}},{"id":"e6acdb9fc9414adab64cd06bf9f0d6f8","type":"GENE","name":"TRE-CTC16-1","canonical_id":"hgnc:HGNC:35105","description":"tRNA-Glu (anticodon CTC) 16-1","metadata":{"aliases":["tRNA-Glu-CTC-16-1","TRNAE42P"]}},{"id":"5a4c256f80684a729d58ab420563905e","type":"GENE","name":"TRE-CTC17-1","canonical_id":"hgnc:HGNC:34675","description":"tRNA-Glu (CTC) 17-1","metadata":{"aliases":["tRNA-Glu-CTC-17-1","TRNAE14"]}},{"id":"251ed65b8a2d474daa7e6b866f2e531e","type":"GENE","name":"TRE-CTC18-1","canonical_id":"hgnc:HGNC:35067","description":"tRNA-Glu (CTC) 18-1","metadata":{"aliases":["tRNA-Glu-CTC-18-1","TRNAE37P"]}},{"id":"1c186fceb5bf443b9c1f8e05fea9941a","type":"GENE","name":"TRE-CTC2-1","canonical_id":"hgnc:HGNC:34978","description":"tRNA-Glu (anticodon CTC) 2-1","metadata":{"aliases":["tRNA-Glu-CTC-2-1","TRNAE24"]}},{"id":"6d98bb938cf54ceba3688e724b411227","type":"GENE","name":"TRE-CTC3-1","canonical_id":"hgnc:HGNC:34564","description":"tRNA-Glu (CTC) 3-1","metadata":{"aliases":["tRNA-Glu-CTC-3-1","TRNAE4"]}},{"id":"8087b2c8f334446f8ad92c50fda544f9","type":"GENE","name":"TRE-CTC4-1","canonical_id":"hgnc:HGNC:35081","description":"tRNA-Glu (CTC) 4-1","metadata":{"aliases":["tRNA-Glu-CTC-4-1","TRNAE39P"]}},{"id":"6b58e140be19405d836b233962f3fd7e","type":"GENE","name":"TRE-CTC5-1","canonical_id":"hgnc:HGNC:34799","description":"tRNA-Glu (CTC) 5-1","metadata":{"aliases":["tRNA-Glu-CTC-5-1","TRNAE17"]}},{"id":"b460e7c3de2943f4b7cbf16556a12873","type":"GENE","name":"TRE-CTC6-1","canonical_id":"hgnc:HGNC:34986","description":"tRNA-Glu (anticodon CTC) 6-1","metadata":{"aliases":["tRNA-Glu-CTC-6-1","TRNAE25"]}},{"id":"0d11ccf47b604425aaa15559404963f0","type":"GENE","name":"TRE-CTC7-1","canonical_id":"hgnc:HGNC:35065","description":"tRNA-Glu (anticodon CTC) 7-1","metadata":{"aliases":["tRNA-Glu-CTC-7-1","TRNAE36P"]}},{"id":"b8c82fcd0e9c49848e336513b1b78c9b","type":"GENE","name":"TRE-CTC8-1","canonical_id":"hgnc:HGNC:34603","description":"tRNA-Glu (CTC) 8-1","metadata":{"aliases":["tRNA-Glu-CTC-8-1","TRNAE9"]}},{"id":"fa25fa4c0c58415196de18502d9b518f","type":"GENE","name":"TRE-CTC9-1","canonical_id":"hgnc:HGNC:35069","description":"tRNA-Glu (CTC) 9-1","metadata":{"aliases":["tRNA-Glu-CTC-9-1","TRNAE38P"]}},{"id":"6fabb04e7539497fbea83ed35910cc59","type":"GENE","name":"TRE-TTC1-1","canonical_id":"hgnc:HGNC:34987","description":"tRNA-Glu (anticodon TTC) 1-1","metadata":{"aliases":["tRNA-Glu-TTC-1-1","TRNAE26","TRE-TTC1-2"]}},{"id":"09d87c4bce2f47e59f8ecb022b7f436a","type":"GENE","name":"TRE-TTC1-2","canonical_id":"hgnc:HGNC:34901","description":"tRNA-Glu (anticodon TTC) 1-2","metadata":{"aliases":["tRNA-Glu-TTC-1-2","TRNAE20","TRE-TTC1-1"]}},{"id":"593f43f3697a40e2b333afcad73f43fd","type":"GENE","name":"TRE-TTC10-1","canonical_id":"hgnc:HGNC:35025","description":"tRNA-Glu (anticodon TTC) 10-1","metadata":{"aliases":["tRNA-Glu-TTC-10-1","TRNAE29P"]}},{"id":"86bd18c05513431f986c43579b66fbb4","type":"GENE","name":"TRE-TTC11-1","canonical_id":"hgnc:HGNC:34691","description":"tRNA-Glu (anticodon TTC) 11-1","metadata":{"aliases":["tRNA-Glu-TTC-11-1","TRNAE15"]}},{"id":"b5516bab8dc24ba79d98bf0a27ae3f28","type":"GENE","name":"TRE-TTC12-1","canonical_id":"hgnc:HGNC:34557","description":"tRNA-Glu (anticodon TTC) 12-1","metadata":{"aliases":["tRNA-Glu-TTC-12-1","TRNAE3"]}},{"id":"04a11ab52e524ffc8bfe3de12ccf724d","type":"GENE","name":"TRE-TTC13-1","canonical_id":"hgnc:HGNC:34613","description":"tRNA-Glu (anticodon TTC) 13-1","metadata":{"aliases":["tRNA-Glu-TTC-13-1","TRNAE10"]}},{"id":"234361e3766c48a1a486a4c9ce4d105e","type":"GENE","name":"TRE-TTC14-1","canonical_id":"hgnc:HGNC:35058","description":"tRNA-Glu (anticodon TTC) 14-1","metadata":{"aliases":["tRNA-Glu-TTC-14-1","TRNAE34P"]}},{"id":"980ca4b4b7714b78b3a3d42bd651620c","type":"GENE","name":"TRE-TTC15-1","canonical_id":"hgnc:HGNC:35057","description":"tRNA-Glu (TTC) 15-1","metadata":{"aliases":["tRNA-Glu-TTC-15-1","TRNAE33P"]}},{"id":"21ae2c9f6f2f41bbb307f197a08e438c","type":"GENE","name":"TRE-TTC16-1","canonical_id":"hgnc:HGNC:34773","description":"tRNA-Glu (TTC) 16-1","metadata":{"aliases":["tRNA-Glu-TTC-16-1","TRNAE16"]}},{"id":"6a727408d7af4898bbc4d9c5a632caf2","type":"GENE","name":"TRE-TTC2-1","canonical_id":"hgnc:HGNC:34589","description":"tRNA-Glu (anticodon TTC) 2-1","metadata":{"aliases":["tRNA-Glu-TTC-2-1","TRNAE7"]}},{"id":"3a584accae484eddaa03d785c83dca7d","type":"GENE","name":"TRE-TTC2-2","canonical_id":"hgnc:HGNC:34622","description":"tRNA-Glu (anticodon TTC) 2-2","metadata":{"aliases":["tRNA-Glu-TTC-2-2","TRNAE11"]}},{"id":"7260b551069f4333acd65d6db8a2ac6e","type":"GENE","name":"TRE-TTC3-1","canonical_id":"hgnc:HGNC:12265","description":"tRNA-Glu (anticodon TTC) 3-1","metadata":{"aliases":["tRNA-Glu-TTC-3-1","TRE","TRNAE1"]}},{"id":"f4f0b72b974c496a9805bb696dd526e0","type":"GENE","name":"TRE-TTC4-1","canonical_id":"hgnc:HGNC:38581","description":"tRNA-Glu (anticodon TTC) 4-1","metadata":{"aliases":["tRNA-Glu-TTC-4-1","TRNAE44"]}},{"id":"0a873445fc6e41a8818b449491bcb669","type":"GENE","name":"TRE-TTC4-2","canonical_id":"hgnc:HGNC:34976","description":"tRNA-Glu (anticodon TTC) 4-2","metadata":{"aliases":["tRNA-Glu-TTC-4-2","TRNAE23"]}},{"id":"93e51c2fd3d34620bdc8a739192fbcc5","type":"GENE","name":"TRE-TTC5-1","canonical_id":"hgnc:HGNC:34590","description":"tRNA-Glu (TTC) 5-1","metadata":{"aliases":["tRNA-Glu-TTC-5-1","TRNAE8"]}},{"id":"e0b743f3375241aca9b82a243cf5ac55","type":"GENE","name":"TRE-TTC6-1","canonical_id":"hgnc:HGNC:35037","description":"tRNA-Glu (anticodon TTC) 6-1","metadata":{"aliases":["tRNA-Glu-TTC-6-1","TRNAE32P"]}},{"id":"408d3a67d45a479d8642277576229119","type":"GENE","name":"TRE-TTC7-1","canonical_id":"hgnc:HGNC:35028","description":"tRNA-Glu (anticodon TTC) 7-1","metadata":{"aliases":["tRNA-Glu-TTC-7-1","TRNAE30P"]}},{"id":"549efc44b9444593814479e4d7b1d1ef","type":"GENE","name":"TRE-TTC8-1","canonical_id":"hgnc:HGNC:34627","description":"tRNA-Glu (anticodon TTC) 8-1","metadata":{"aliases":["tRNA-Glu-TTC-8-1","TRNAE12"]}},{"id":"33c9a95a78c0476fbae7ef836ca442f7","type":"GENE","name":"TRE-TTC8-2","canonical_id":"hgnc:HGNC:54204","description":"tRNA-Glu (TTC) 8-2","metadata":{"aliases":["tRNA-Glu-TTC-8-2"]}},{"id":"77ba15fd2f3c4c55b70d54f7543b091b","type":"GENE","name":"TRE-TTC9-1","canonical_id":"hgnc:HGNC:35093","description":"tRNA-Glu (anticodon TTC) 9-1","metadata":{"aliases":["tRNA-Glu-TTC-9-1","TRNAE40P"]}},{"id":"59633170beec4b9ebab7fff6ef11c0d1","type":"TRIAL","name":"TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting","canonical_id":"clinicaltrials.gov:NCT03639558","description":"Psychiatric Emergency; Aggression; Agitation","metadata":null},{"id":"2adbee6706074d64b4737dad6f8be220","type":"GENE","name":"TREH","canonical_id":"hgnc:HGNC:12266","description":"trehalase","metadata":{"aliases":["TRE","TREA","MGC129621"]}},{"id":"47506259db4240b8909c286389c58b5d","type":"GENE","name":"TREHP1","canonical_id":"hgnc:HGNC:51907","description":"trehalase pseudogene 1","metadata":null},{"id":"b57e7b9804c6409cb5e50df92ca6b4a0","type":"GENE","name":"TREM1","canonical_id":"hgnc:HGNC:17760","description":"triggering receptor expressed on myeloid cells 1","metadata":{"aliases":["TREM-1","CD354"]}},{"id":"7034ab024b2c49acbfcb613d70d36fa2","type":"GENE","name":"TREM2","canonical_id":"hgnc:HGNC:17761","description":"triggering receptor expressed on myeloid cells 2","metadata":{"aliases":["TREM-2","Trem2a","Trem2b","Trem2c"]}},{"id":"9e80169d79a546ad8c0914e429378dfe","type":"GENE","name":"TREML1","canonical_id":"hgnc:HGNC:20434","description":"triggering receptor expressed on myeloid cells like 1","metadata":{"aliases":["TLT1","dJ238O23.3"]}},{"id":"7d31c6f8e2574e7dafffa6d235e171f7","type":"GENE","name":"TREML1-AS1","canonical_id":"hgnc:HGNC:59400","description":"TREML1 and TREM2 antisense RNA 1","metadata":null},{"id":"9efc3dc1a9c9484ca6b792860ca53c2f","type":"GENE","name":"TREML2","canonical_id":"hgnc:HGNC:21092","description":"triggering receptor expressed on myeloid cells like 2","metadata":{"aliases":["FLJ13693","TLT2","dJ238O23.1","C6orf76"]}},{"id":"f5400671ebd94650979953a9a72e1124","type":"GENE","name":"TREML2-AS1","canonical_id":"hgnc:HGNC:59401","description":"TREML2 antisense RNA 1","metadata":null},{"id":"e3530f0205244cf59b4ca0c1243d2c22","type":"GENE","name":"TREML3P","canonical_id":"hgnc:HGNC:30806","description":"triggering receptor expressed on myeloid cells like 3, pseudogene","metadata":{"aliases":["TLT3","TREML3"]}},{"id":"f80a335125284397b60cc28bb5d514c4","type":"GENE","name":"TREML4","canonical_id":"hgnc:HGNC:30807","description":"triggering receptor expressed on myeloid cells like 4","metadata":{"aliases":["TLT4"]}},{"id":"b62dad2b3e5a47c89230f704bb23dd04","type":"GENE","name":"TREML5P","canonical_id":"hgnc:HGNC:30808","description":"triggering receptor expressed on myeloid cells like 5, pseudogene","metadata":{"aliases":["TLT5","TREML2P","TREML2P1"]}},{"id":"e912d6937bd44dd0a6c4715e201787f2","type":"GENE","name":"TRERF1","canonical_id":"hgnc:HGNC:18273","description":null,"metadata":null},{"id":"da08e624345c4476be8ba16563009462","type":"GENE","name":"TRERF1-DT","canonical_id":"hgnc:HGNC:59405","description":"TRERF1 divergent transcript","metadata":null},{"id":"3bef02784bf74a7db758013cca0043c4","type":"GENE","name":"TRERNA1","canonical_id":"hgnc:HGNC:44307","description":"translation regulatory long non-coding RNA 1","metadata":{"aliases":["MEF","treRNA","ncRNA-a7","LINC00651"]}},{"id":"451610c259864ea8b91d7c751779b661","type":"GENE","name":"TREX1","canonical_id":"hgnc:HGNC:12269","description":"three prime repair exonuclease 1","metadata":{"aliases":["DRN3","AGS1"]}},{"id":"f3b1ee4ccb9447598f79ae6f1c64c086","type":"GENE","name":"TREX2","canonical_id":"hgnc:HGNC:12270","description":"three prime repair exonuclease 2","metadata":null},{"id":"35f4005ff4f140c5ac6f156c9cd1286a","type":"TRIAL","name":"TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine","canonical_id":"clinicaltrials.gov:NCT00385008","description":"Migraine Disorders","metadata":null},{"id":"3d308572ec9b425b8d88b91929a6bdfe","type":"GENE","name":"TRF-GAA1-1","canonical_id":"hgnc:HGNC:34699","description":"tRNA-Phe (anticodon GAA) 1-1","metadata":{"aliases":["tRNA-Phe-GAA-1-1","TRNAF3","TRF-GAA1-5"]}},{"id":"65f7b30044fa443b98320490f7b81c93","type":"GENE","name":"TRF-GAA1-2","canonical_id":"hgnc:HGNC:34817","description":"tRNA-Phe (anticodon GAA) 1-2","metadata":{"aliases":["tRNA-Phe-GAA-1-2","TRNAF7","TRF-GAA1-6"]}},{"id":"5ec6b6ab5b3a44c3bfe8bb06fc281739","type":"GENE","name":"TRF-GAA1-3","canonical_id":"hgnc:HGNC:34984","description":"tRNA-Phe (anticodon GAA) 1-3","metadata":{"aliases":["tRNA-Phe-GAA-1-3","TRNAF11","TRF-GAA1-1"]}},{"id":"38bc991e41e544028756fd7fa81ca915","type":"GENE","name":"TRF-GAA1-4","canonical_id":"hgnc:HGNC:33259","description":"tRNA-Phe (anticodon GAA) 1-4","metadata":{"aliases":["tRNA-Phe-GAA-1-4","TRNAF2","TRF-GAA1-2"]}},{"id":"ee5d74b36b86426bb7a07757630cf59b","type":"GENE","name":"TRF-GAA1-5","canonical_id":"hgnc:HGNC:34814","description":"tRNA-Phe (anticodon GAA) 1-5","metadata":{"aliases":["tRNA-Phe-GAA-1-5","TRNAF6","TRF-GAA1-3"]}},{"id":"e04db0de917149d986b2c10fe8630ba1","type":"GENE","name":"TRF-GAA1-6","canonical_id":"hgnc:HGNC:34873","description":"tRNA-Phe (anticodon GAA) 1-6","metadata":{"aliases":["tRNA-Phe-GAA-1-6","TRNAF10","TRF-GAA1-4"]}},{"id":"d9e2f3be238e4bf08eb1c42e5b4fe38f","type":"GENE","name":"TRF-GAA10-1","canonical_id":"hgnc:HGNC:35072","description":"tRNA-Phe (anticodon GAA) 10-1","metadata":{"aliases":["tRNA-Phe-GAA-10-1","TRNAF16P"]}},{"id":"c425fc11e3fc4d4abab91e79a3d863d8","type":"GENE","name":"TRF-GAA11-1","canonical_id":"hgnc:HGNC:35045","description":"tRNA-Phe (anticodon GAA) 11-1","metadata":{"aliases":["tRNA-Phe-GAA-11-1","TRNAF15P"]}},{"id":"8fdae1f22c9246f0b41416dd7e511a75","type":"GENE","name":"TRF-GAA12-1","canonical_id":"hgnc:HGNC:35044","description":"tRNA-Phe (anticodon GAA) 12-1","metadata":{"aliases":["tRNA-Phe-GAA-12-1","TRNAF14P"]}},{"id":"5741e8b3f47049b4afb02b56f4bc48ae","type":"GENE","name":"TRF-GAA2-1","canonical_id":"hgnc:HGNC:33255","description":"tRNA-Phe (anticodon GAA) 2-1","metadata":{"aliases":["tRNA-Phe-GAA-2-1","TRNAF1"]}},{"id":"2563bb8359cf4c17a6ce22b4a85bc864","type":"GENE","name":"TRF-GAA3-1","canonical_id":"hgnc:HGNC:34732","description":"tRNA-Phe (anticodon GAA) 3-1","metadata":{"aliases":["tRNA-Phe-GAA-3-1","TRNAF5"]}},{"id":"cd12eaa4f9204dc9abc2bd7e8253724e","type":"GENE","name":"TRF-GAA4-1","canonical_id":"hgnc:HGNC:34859","description":"tRNA-Phe (anticodon GAA) 4-1","metadata":{"aliases":["tRNA-Phe-GAA-4-1","TRNAF9"]}},{"id":"7bf04caa48954e1b84df113cafe8634a","type":"GENE","name":"TRF-GAA5-1","canonical_id":"hgnc:HGNC:34707","description":"tRNA-Phe (anticodon GAA) 5-1","metadata":{"aliases":["tRNA-Phe-GAA-5-1","TRNAF4"]}},{"id":"528d535a8c9247f28d8becfd33fbd192","type":"GENE","name":"TRF-GAA6-1","canonical_id":"hgnc:HGNC:34825","description":"tRNA-Phe (anticodon GAA) 6-1","metadata":{"aliases":["tRNA-Phe-GAA-6-1","TRNAF8"]}},{"id":"8ac92a810d734a1dac2ef756f9960f45","type":"GENE","name":"TRF-GAA7-1","canonical_id":"hgnc:HGNC:34990","description":"tRNA-Phe (anticodon GAA) 7-1","metadata":{"aliases":["tRNA-Phe-GAA-7-1","TRNAF12"]}},{"id":"646bf44e29804809bc2c5efa577f69a0","type":"GENE","name":"TRF-GAA8-1","canonical_id":"hgnc:HGNC:35016","description":"tRNA-Phe (anticodon GAA) 8-1","metadata":{"aliases":["tRNA-Phe-GAA-8-1","TRNAF13P"]}},{"id":"309e9e99ab6345a79715c53b986b3cda","type":"GENE","name":"TRF-GAA9-1","canonical_id":"hgnc:HGNC:35110","description":"tRNA-Phe (anticodon GAA) 9-1","metadata":{"aliases":["tRNA-Phe-GAA-9-1","TRNAF17P"]}},{"id":"66d403520ade4f63ab1d761c355b05da","type":"GENE","name":"TRG","canonical_id":"hgnc:HGNC:12271","description":"T cell receptor gamma locus","metadata":{"aliases":["TCRG","TRG@"]}},{"id":"2c2e3ce16dad4162a067189a66b11324","type":"GENE","name":"TRG-AS1","canonical_id":"hgnc:HGNC:48974","description":"TRG antisense RNA 1","metadata":null},{"id":"ea406536650b4cb4bdd6231967dc74d5","type":"GENE","name":"TRG-CCC1-1","canonical_id":"hgnc:HGNC:38580","description":"tRNA-Gly (anticodon CCC) 1-1","metadata":{"aliases":["tRNA-Gly-CCC-1-1","TRNAG37"]}},{"id":"12a87584511a4911873e2ab62cfb5306","type":"GENE","name":"TRG-CCC1-2","canonical_id":"hgnc:HGNC:34864","description":"tRNA-Gly (anticodon CCC) 1-2","metadata":{"aliases":["tRNA-Gly-CCC-1-2","TRNAG28"]}},{"id":"4dba454dbcff466c9fd2268a1e6daea5","type":"GENE","name":"TRG-CCC2-1","canonical_id":"hgnc:HGNC:34794","description":"tRNA-Gly (anticodon CCC) 2-1","metadata":{"aliases":["tRNA-Gly-CCC-2-1","TRNAG22","TRG-CCC2-2"]}},{"id":"ed74b1a7dac246868f7b3960c69d1850","type":"GENE","name":"TRG-CCC2-2","canonical_id":"hgnc:HGNC:14183","description":"tRNA-Gly (anticodon CCC) 2-2","metadata":{"aliases":["tRNA-Gly-CCC-2-2","TRG4","TRNAG4","TRG-CCC2-1"]}},{"id":"5cf4e15c924f4b809d3e95d6792a5029","type":"GENE","name":"TRG-CCC3-1","canonical_id":"hgnc:HGNC:34841","description":"tRNA-Gly (anticodon CCC) 3-1","metadata":{"aliases":["tRNA-Gly-CCC-3-1","TRNAG26"]}},{"id":"1ba9ce6e62bb4e3fa71f085e382de5c1","type":"GENE","name":"TRG-CCC4-1","canonical_id":"hgnc:HGNC:35059","description":"tRNA-Gly (CCC) 4-1","metadata":{"aliases":["tRNA-Gly-CCC-4-1","TRNAV35P","TRNAG36"]}},{"id":"9ec6c3e445b74cb381a12ca32f77de29","type":"GENE","name":"TRG-CCC5-1","canonical_id":"hgnc:HGNC:34604","description":"tRNA-Gly (CCC) 5-1","metadata":{"aliases":["tRNA-Gly-CCC-5-1","TRNAG10"]}},{"id":"dacded5210a843208e6584fd1a6b2fae","type":"GENE","name":"TRG-CCC6-1","canonical_id":"hgnc:HGNC:35073","description":"tRNA-Gly (CCC) 6-1","metadata":{"aliases":["tRNA-Gly-CCC-6-1","TRNAG34P"]}},{"id":"6e5c23a05745438eaa449c1077bd9928","type":"GENE","name":"TRG-CCC7-1","canonical_id":"hgnc:HGNC:35030","description":"tRNA-Gly (CCC) 7-1","metadata":{"aliases":["tRNA-Gly-CCC-7-1","TRNAG32P"]}},{"id":"6c737264e1b443de851ec114d3c0325e","type":"GENE","name":"TRG-CCC8-1","canonical_id":"hgnc:HGNC:50798","description":"tRNA-Gly (anticodon CCC) 8-1","metadata":{"aliases":["tRNA-Gly-CCC-8-1"]}},{"id":"8e1c904848934ae18f7b13bd13f99f88","type":"GENE","name":"TRG-GCC1-1","canonical_id":"hgnc:HGNC:34934","description":"tRNA-Gly (anticodon GCC) 1-1","metadata":{"aliases":["tRNA-Gly-GCC-1-1","TRNAG30"]}},{"id":"5f1736a5ca8e4e5bb2b6424dd1193c2b","type":"GENE","name":"TRG-GCC1-2","canonical_id":"hgnc:HGNC:34815","description":"tRNA-Gly (anticodon GCC) 1-2","metadata":{"aliases":["tRNA-Gly-GCC-1-2","TRNAG23"]}},{"id":"1ca6a7b54c4b4980b504ad799bfec0fc","type":"GENE","name":"TRG-GCC1-3","canonical_id":"hgnc:HGNC:34793","description":"tRNA-Gly (anticodon GCC) 1-3","metadata":{"aliases":["tRNA-Gly-GCC-1-3","TRNAG21"]}},{"id":"3586ef67447844a88a4b5f7d7b48f51d","type":"GENE","name":"TRG-GCC1-4","canonical_id":"hgnc:HGNC:34722","description":"tRNA-Gly (anticodon GCC) 1-4","metadata":{"aliases":["tRNA-Gly-GCC-1-4","TRNAG15"]}},{"id":"e9d45c0b3bee4377821cd24ab7696740","type":"GENE","name":"TRG-GCC1-5","canonical_id":"hgnc:HGNC:34850","description":"tRNA-Gly (anticodon GCC) 1-5","metadata":{"aliases":["tRNA-Gly-GCC-1-5","TRNAG27"]}},{"id":"906da50111b645f1abf9ddf22e3c029e","type":"GENE","name":"TRG-GCC2-1","canonical_id":"hgnc:HGNC:34948","description":"tRNA-Gly (anticodon GCC) 2-1","metadata":{"aliases":["tRNA-Gly-GCC-2-1","TRNAG31"]}},{"id":"82a37d860cb3453e9dcf00c449961b68","type":"GENE","name":"TRG-GCC2-2","canonical_id":"hgnc:HGNC:34771","description":"tRNA-Gly (anticodon GCC) 2-2","metadata":{"aliases":["tRNA-Gly-GCC-2-2","TRNAG19","TRG-GCC2-5"]}},{"id":"42c2eed28625444a9d050c3344ae7a25","type":"GENE","name":"TRG-GCC2-3","canonical_id":"hgnc:HGNC:34881","description":"tRNA-Gly (anticodon GCC) 2-3","metadata":{"aliases":["tRNA-Gly-GCC-2-3","TRNAG29","TRG-GCC2-6"]}},{"id":"c986a0f52f4f4c269ce23a749004f701","type":"GENE","name":"TRG-GCC2-4","canonical_id":"hgnc:HGNC:34533","description":"tRNA-Gly (anticodon GCC) 2-4","metadata":{"aliases":["tRNA-Gly-GCC-2-4","TRNAG6","TRG-GCC2-2"]}},{"id":"739fa6451cdb4e8e9e2440f0cbb53d4d","type":"GENE","name":"TRG-GCC2-5","canonical_id":"hgnc:HGNC:34725","description":"tRNA-Gly (anticodon GCC) 2-5","metadata":{"aliases":["tRNA-Gly-GCC-2-5","TRNAG16","TRG-GCC2-3"]}},{"id":"fe0401af596d42799c9c27d6d628873b","type":"GENE","name":"TRG-GCC2-6","canonical_id":"hgnc:HGNC:12273","description":"tRNA-Gly (anticodon GCC) 2-6","metadata":{"aliases":["tRNA-Gly-GCC-2-6","TRG2","TRNAG2","TRG-GCC2-4"]}},{"id":"8e1bca403066480493053ad6fa4ab808","type":"GENE","name":"TRG-GCC3-1","canonical_id":"hgnc:HGNC:12282","description":"tRNA-Gly (anticodon GCC) 3-1","metadata":{"aliases":["tRNA-Gly-GCC-3-1","TRGL1","TRG5","TRNAG5"]}},{"id":"2fa0e57522e4436d98f321650fa3d766","type":"GENE","name":"TRG-GCC4-1","canonical_id":"hgnc:HGNC:34838","description":"tRNA-Gly (anticodon GCC) 4-1","metadata":{"aliases":["tRNA-Gly-GCC-4-1","TRNAG25"]}},{"id":"a12286a0181042c69bf810f9a22fd264","type":"GENE","name":"TRG-GCC5-1","canonical_id":"hgnc:HGNC:34783","description":"tRNA-Gly (anticodon GCC) 5-1","metadata":{"aliases":["tRNA-Gly-GCC-5-1","TRNAG20"]}},{"id":"fb66ac5a4e6e415185734400301ca312","type":"GENE","name":"TRG-GCC6-1","canonical_id":"hgnc:HGNC:34641","description":"tRNA-Gly (GCC) 6-1","metadata":{"aliases":["tRNA-Gly-GCC-6-1","TRNAG12"]}},{"id":"04cfacd0544d4dc694422ed955aa9c0d","type":"GENE","name":"TRG-TCC1-1","canonical_id":"hgnc:HGNC:12274","description":"tRNA-Gly (anticodon TCC) 1-1","metadata":{"aliases":["tRNA-Gly-TCC-1-1","TRG3","TRNAG3"]}},{"id":"2a02746fa2a54141869fadfa0f1587fe","type":"GENE","name":"TRG-TCC2-1","canonical_id":"hgnc:HGNC:34623","description":"tRNA-Gly (anticodon TCC) 2-1","metadata":{"aliases":["tRNA-Gly-TCC-2-1","TRNAG11"]}},{"id":"2af2c3dc426146c5b7278b6d0cbda0b8","type":"GENE","name":"TRG-TCC2-2","canonical_id":"hgnc:HGNC:34823","description":"tRNA-Gly (anticodon TCC) 2-2","metadata":{"aliases":["tRNA-Gly-TCC-2-2","TRNAG24"]}},{"id":"50712fd4b79b485e9d908ca30af8ecf6","type":"GENE","name":"TRG-TCC2-3","canonical_id":"hgnc:HGNC:34703","description":"tRNA-Gly (anticodon TCC) 2-3","metadata":{"aliases":["tRNA-Gly-TCC-2-3","TRNAG13"]}},{"id":"ddd8e056286d4f33adad8f940d38f608","type":"GENE","name":"TRG-TCC2-4","canonical_id":"hgnc:HGNC:34751","description":"tRNA-Gly (anticodon TCC) 2-4","metadata":{"aliases":["tRNA-Gly-TCC-2-4","TRNAG17"]}},{"id":"3ed8ff667baf49de998b92db6fd4a32e","type":"GENE","name":"TRG-TCC2-5","canonical_id":"hgnc:HGNC:34598","description":"tRNA-Gly (anticodon TCC) 2-5","metadata":{"aliases":["tRNA-Gly-TCC-2-5","TRNAG9"]}},{"id":"c95f796834f24a2f9e358d5b45cc9864","type":"GENE","name":"TRG-TCC2-6","canonical_id":"hgnc:HGNC:34570","description":"tRNA-Gly (anticodon TCC) 2-6","metadata":{"aliases":["tRNA-Gly-TCC-2-6","TRNAG8"]}},{"id":"48eeeea73c224f76bf20df673b04baab","type":"GENE","name":"TRG-TCC3-1","canonical_id":"hgnc:HGNC:34769","description":"tRNA-Gly (anticodon TCC) 3-1","metadata":{"aliases":["tRNA-Gly-TCC-3-1","TRNAG18"]}},{"id":"a27f1c0169884f47827c7f69b9f2c993","type":"GENE","name":"TRG-TCC4-1","canonical_id":"hgnc:HGNC:34554","description":"tRNA-Gly (anticodon TCC) 4-1","metadata":{"aliases":["tRNA-Gly-TCC-4-1","TRNAG7"]}},{"id":"e28970afbf5444fcb73c7feb72e0796a","type":"GENE","name":"TRG-TCC5-1","canonical_id":"hgnc:HGNC:35032","description":"tRNA-Gly (anticodon TCC) 5-1","metadata":{"aliases":["tRNA-Gly-TCC-5-1","TRNAG33P"]}},{"id":"cf48db1cd8a24c74a0cf290a85f4935d","type":"GENE","name":"TRG-TCC6-1","canonical_id":"hgnc:HGNC:35086","description":"tRNA-Gly (anticodon TCC) 6-1","metadata":{"aliases":["tRNA-Gly-TCC-6-1","TRNAG35P"]}},{"id":"b811dd5de6834882ae86b10c3bf23bc7","type":"GENE","name":"TRGC1","canonical_id":"hgnc:HGNC:12275","description":"T cell receptor gamma constant 1","metadata":{"aliases":["C1","TCRGC1"]}},{"id":"b74f8e53b59e4ebda43f7515f3cc29fe","type":"GENE","name":"TRGC2","canonical_id":"hgnc:HGNC:12276","description":"T cell receptor gamma constant 2","metadata":{"aliases":["TRGC2(2X)","TRGC2(3X)","TCRGC2"]}},{"id":"a4b802731ce34f019a222e8387e14ab1","type":"GENE","name":"TRGJ1","canonical_id":"hgnc:HGNC:12277","description":"T cell receptor gamma joining 1","metadata":{"aliases":["J1","TCRGJ1"]}},{"id":"970e9aa6571243ec8dc487b03334f9c7","type":"GENE","name":"TRGJ2","canonical_id":"hgnc:HGNC:12278","description":"T cell receptor gamma joining 2","metadata":{"aliases":["J2","TCRGJ2"]}},{"id":"28df6b82a48049edbe8f30e4c7922f7e","type":"GENE","name":"TRGJP","canonical_id":"hgnc:HGNC:12279","description":"T cell receptor gamma joining P","metadata":{"aliases":["JP","TCRGJP"]}},{"id":"5a25ac706a244082af3fc5789d2c634b","type":"GENE","name":"TRGJP1","canonical_id":"hgnc:HGNC:12280","description":"T cell receptor gamma joining P1","metadata":{"aliases":["JP1","TCRGJP1"]}},{"id":"d56ac6591ea245149c0b101bfb0bce0e","type":"GENE","name":"TRGJP2","canonical_id":"hgnc:HGNC:12281","description":"T cell receptor gamma joining P2","metadata":{"aliases":["JP2","TCRGJP2"]}},{"id":"69ee29f0fbe5405c94aac354871e3bd1","type":"GENE","name":"TRGV1","canonical_id":"hgnc:HGNC:12284","description":"T cell receptor gamma variable 1 (non-functional)","metadata":{"aliases":["V1S1P","TCRGV1"]}},{"id":"c83050135ae142be9699f2f10b0930cf","type":"GENE","name":"TRGV10","canonical_id":"hgnc:HGNC:12285","description":"T cell receptor gamma variable 10 (non-functional)","metadata":{"aliases":["V3P","TCRGV10"]}},{"id":"41981c7c824b4e6ca70c6e7237faae09","type":"GENE","name":"TRGV11","canonical_id":"hgnc:HGNC:12286","description":"T cell receptor gamma variable 11 (non-functional)","metadata":{"aliases":["V4P","TCRGV11"]}},{"id":"47db7737067a40c79f9925c112d69790","type":"GENE","name":"TRGV2","canonical_id":"hgnc:HGNC:12287","description":"T cell receptor gamma variable 2","metadata":{"aliases":["VIS2","TCRGV2"]}},{"id":"987d8825284d444ebe24de3c254e20ee","type":"GENE","name":"TRGV3","canonical_id":"hgnc:HGNC:12288","description":"T cell receptor gamma variable 3","metadata":{"aliases":["V1S3","TCRGV3"]}},{"id":"fdba955647b944b1b10974b26980bc8a","type":"GENE","name":"TRGV4","canonical_id":"hgnc:HGNC:12289","description":"T cell receptor gamma variable 4","metadata":{"aliases":["V1S4","TCRGV4"]}},{"id":"1067349aa3da44af83c3936c8485fac5","type":"GENE","name":"TRGV5","canonical_id":"hgnc:HGNC:12290","description":"T cell receptor gamma variable 5","metadata":{"aliases":["V1S5","TCRGV5"]}},{"id":"e970465c74ed49e5814087b14b22422a","type":"GENE","name":"TRGV5P","canonical_id":"hgnc:HGNC:12291","description":"T cell receptor gamma variable 5P (pseudogene)","metadata":{"aliases":["V1S5P","TCRGV5P"]}},{"id":"9574caa526b44f599e2033a9fdcf72fa","type":"GENE","name":"TRGV6","canonical_id":"hgnc:HGNC:12292","description":"T cell receptor gamma variable 6 (pseudogene)","metadata":{"aliases":["V1S5P","TCRGV5P","TCRGV6"]}},{"id":"6202fdab188f4eb39b677a26663ac10e","type":"GENE","name":"TRGV7","canonical_id":"hgnc:HGNC:12293","description":"T cell receptor gamma variable 7 (pseudogene)","metadata":{"aliases":["V1S7P","TCRGV7"]}},{"id":"2dbde6bc648e4743a71811f4f20f1e04","type":"GENE","name":"TRGV8","canonical_id":"hgnc:HGNC:12294","description":"T cell receptor gamma variable 8","metadata":{"aliases":["V1S8","TCRGV8"]}},{"id":"ccf46d958f76477eb9452867e6376355","type":"GENE","name":"TRGV9","canonical_id":"hgnc:HGNC:12295","description":"T cell receptor gamma variable 9","metadata":{"aliases":["V2","TCRGV9"]}},{"id":"7d6337812cba43958a1bbd93aa4e6fb4","type":"GENE","name":"TRGVA","canonical_id":"hgnc:HGNC:12296","description":"T cell receptor gamma variable A (pseudogene)","metadata":{"aliases":["V5P","TCRGVA"]}},{"id":"272df16748534d2c9a3cd565162af7b7","type":"GENE","name":"TRGVB","canonical_id":"hgnc:HGNC:12297","description":"T cell receptor gamma variable B (pseudogene)","metadata":{"aliases":["V6P","TCRGVB"]}},{"id":"481af006ed57471c83463ebb7789449a","type":"GENE","name":"TRH","canonical_id":"hgnc:HGNC:12298","description":null,"metadata":null},{"id":"942a17518cc4497cb1367c1fd7f54339","type":"DRUG","name":"TRH","canonical_id":"gtopdb:2139","description":null,"metadata":null},{"id":"7fbd52af6eaf48e09fa67b2afa6ce0b6","type":"GENE","name":"TRH-GTG1-1","canonical_id":"hgnc:HGNC:34535","description":"tRNA-His (anticodon GTG) 1-1","metadata":{"aliases":["tRNA-His-GTG-1-1","TRNAH4"]}},{"id":"68dc6233b7c34065b8037ac4a41b2e13","type":"GENE","name":"TRH-GTG1-2","canonical_id":"hgnc:HGNC:34902","description":"tRNA-His (anticodon GTG) 1-2","metadata":{"aliases":["tRNA-His-GTG-1-2","TRNAH10"]}},{"id":"e3ab7137369a498cb5ead19a0a0163bf","type":"GENE","name":"TRH-GTG1-3","canonical_id":"hgnc:HGNC:34874","description":"tRNA-His (anticodon GTG) 1-3","metadata":{"aliases":["tRNA-His-GTG-1-3","TRNAH9"]}},{"id":"e4793664997d497088bb1d76af073ff9","type":"GENE","name":"TRH-GTG1-4","canonical_id":"hgnc:HGNC:34736","description":"tRNA-His (anticodon GTG) 1-4","metadata":{"aliases":["tRNA-His-GTG-1-4","TRNAH7"]}},{"id":"ee948a188efc4792bd868609b6cdf225","type":"GENE","name":"TRH-GTG1-5","canonical_id":"hgnc:HGNC:34538","description":"tRNA-His (anticodon GTG) 1-5","metadata":{"aliases":["tRNA-His-GTG-1-5","TRNAH3","TRH-GTG1-8"]}},{"id":"47fdda2c85844700825a9c33082d4046","type":"GENE","name":"TRH-GTG1-6","canonical_id":"hgnc:HGNC:33260","description":"tRNA-His (anticodon GTG) 1-6","metadata":{"aliases":["tRNA-His-GTG-1-6","TRNAH5","TRH-GTG1-9"]}},{"id":"2aaf366f002744a3bca3f03a12fc89e9","type":"GENE","name":"TRH-GTG1-7","canonical_id":"hgnc:HGNC:34536","description":"tRNA-His (anticodon GTG) 1-7","metadata":{"aliases":["tRNA-His-GTG-1-7","TRNAH1","TRH-GTG1-5"]}},{"id":"14e8d3ff9bee41b0b7a469d5298b79bb","type":"GENE","name":"TRH-GTG1-8","canonical_id":"hgnc:HGNC:34537","description":"tRNA-His (anticodon GTG) 1-8","metadata":{"aliases":["tRNA-His-GTG-1-8","TRNAH2","TRH-GTG1-6"]}},{"id":"8023e9b7ea0d47e4b4f093676b14ea16","type":"GENE","name":"TRH-GTG1-9","canonical_id":"hgnc:HGNC:34624","description":"tRNA-His (anticodon GTG) 1-9","metadata":{"aliases":["tRNA-His-GTG-1-9","TRNAH6","TRH-GTG1-7"]}},{"id":"bd80ab80a75f46f6a11eeb7ea1f7f132","type":"GENE","name":"TRH-GTG2-1","canonical_id":"hgnc:HGNC:34918","description":"tRNA-His (GTG) 2-1","metadata":{"aliases":["tRNA-His-GTG-2-1","TRNAH11"]}},{"id":"b8ee38b7e0ee4d2ea4ce9b399805d940","type":"GENE","name":"TRH-GTG3-1","canonical_id":"hgnc:HGNC:34805","description":"tRNA-His (anticodon GTG) 3-1","metadata":{"aliases":["tRNA-His-GTG-3-1","TRNAH8"]}},{"id":"db04b9f9baa443f883505fc3d4a39269","type":"GENE","name":"TRHDE","canonical_id":"hgnc:HGNC:30748","description":"thyrotropin releasing hormone degrading enzyme","metadata":{"aliases":["PGPEP2","TRH-DE","PAP-II"]}},{"id":"60fc586509e244eeaa1d815e270e5167","type":"GENE","name":"TRHDE-AS1","canonical_id":"hgnc:HGNC:27471","description":"TRHDE antisense RNA 1","metadata":null},{"id":"c212d87212d1467086f3c1b96a618f54","type":"GENE","name":"TRHR","canonical_id":"hgnc:HGNC:12299","description":"thyrotropin releasing hormone receptor","metadata":null},{"id":"3a4549c50f8c4f8db05ecc605983a676","type":"GENE","name":"TRI-AAT1-1","canonical_id":"hgnc:HGNC:34812","description":"tRNA-Ile (anticodon AAT) 1-1","metadata":{"aliases":["tRNA-Ile-AAT-1-1","TRNAI12"]}},{"id":"2caee811f9914a22b2278061ddc58012","type":"GENE","name":"TRI-AAT10-1","canonical_id":"hgnc:HGNC:35034","description":"tRNA-Ile (anticodon AAT) 10-1","metadata":{"aliases":["tRNA-Ile-AAT-10-1","TRNAI28P"]}},{"id":"55b177bf0ac947e0bb730c6f1b70489c","type":"GENE","name":"TRI-AAT11-1","canonical_id":"hgnc:HGNC:35047","description":"tRNA-Ile (anticodon AAT) 11-1","metadata":{"aliases":["tRNA-Ile-AAT-11-1","TRNAI29P"]}},{"id":"d33989f1488140749a6a0bd2b427a3b7","type":"GENE","name":"TRI-AAT12-1","canonical_id":"hgnc:HGNC:35054","description":"tRNA-Ile (anticodon AAT) 12-1","metadata":{"aliases":["tRNA-Ile-AAT-12-1","TRNAI30P"]}},{"id":"1224ec70495e4ac5875c69893fe990e3","type":"GENE","name":"TRI-AAT2-1","canonical_id":"hgnc:HGNC:34630","description":"tRNA-Ile (anticodon AAT) 2-1","metadata":{"aliases":["tRNA-Ile-AAT-2-1","TRNAI4"]}},{"id":"678d68b01d2e4e688e281552df9dbbb4","type":"GENE","name":"TRI-AAT3-1","canonical_id":"hgnc:HGNC:34776","description":"tRNA-Ile (anticodon AAT) 3-1","metadata":{"aliases":["tRNA-Ile-AAT-3-1","TRNAI11"]}},{"id":"bd1360c83bfd4c92b7a8f6c2dc9553d6","type":"GENE","name":"TRI-AAT4-1","canonical_id":"hgnc:HGNC:34961","description":"tRNA-Ile (anticodon AAT) 4-1","metadata":{"aliases":["tRNA-Ile-AAT-4-1","TRNAI24"]}},{"id":"2b69527ff98c4eec989437d343cac6dc","type":"GENE","name":"TRI-AAT5-1","canonical_id":"hgnc:HGNC:34715","description":"tRNA-Ile (anticodon AAT) 5-1","metadata":{"aliases":["tRNA-Ile-AAT-5-1","TRNAI9","TRI-AAT5-3"]}},{"id":"df67c2eae5ac446f8e97a7561146f077","type":"GENE","name":"TRI-AAT5-2","canonical_id":"hgnc:HGNC:34904","description":"tRNA-Ile (anticodon AAT) 5-2","metadata":{"aliases":["tRNA-Ile-AAT-5-2","TRNAI20","TRI-AAT5-4"]}},{"id":"29cbedf4e33649938ab591dba5c8df13","type":"GENE","name":"TRI-AAT5-3","canonical_id":"hgnc:HGNC:34877","description":"tRNA-Ile (anticodon AAT) 5-3","metadata":{"aliases":["tRNA-Ile-AAT-5-3","TRNAI17","TRI-AAT5-5"]}},{"id":"a4f7c9485cdf4bc5aa41cac17469acd9","type":"GENE","name":"TRI-AAT5-4","canonical_id":"hgnc:HGNC:34839","description":"tRNA-Ile (anticodon AAT) 5-4","metadata":{"aliases":["tRNA-Ile-AAT-5-4","TRNAI15","TRI-AAT5-1"]}},{"id":"076c7ed068334f75acafd3115a6aa72c","type":"GENE","name":"TRI-AAT5-5","canonical_id":"hgnc:HGNC:34955","description":"tRNA-Ile (anticodon AAT) 5-5","metadata":{"aliases":["tRNA-Ile-AAT-5-5","TRNAI23","TRI-AAT5-2"]}},{"id":"23c1037985f240d49e2bd899cc96acba","type":"GENE","name":"TRI-AAT6-1","canonical_id":"hgnc:HGNC:34940","description":"tRNA-Ile (anticodon AAT) 6-1","metadata":{"aliases":["tRNA-Ile-AAT-6-1","TRNAI22"]}},{"id":"3ff72549789d4db0b352183fd861ef60","type":"GENE","name":"TRI-AAT7-1","canonical_id":"hgnc:HGNC:34710","description":"tRNA-Ile (anticodon AAT) 7-1","metadata":{"aliases":["tRNA-Ile-AAT-7-1","TRNAI8"]}},{"id":"d830b8bf65c94c6fbbee4905f2bbed11","type":"GENE","name":"TRI-AAT7-2","canonical_id":"hgnc:HGNC:34970","description":"tRNA-Ile (anticodon AAT) 7-2","metadata":{"aliases":["tRNA-Ile-AAT-7-2","TRNAI25"]}},{"id":"09a4ed63d2b6446eafaaa2c85ae736e8","type":"GENE","name":"TRI-AAT8-1","canonical_id":"hgnc:HGNC:34656","description":"tRNA-Ile (anticodon AAT) 8-1","metadata":{"aliases":["tRNA-Ile-AAT-8-1","TRNAI5"]}},{"id":"72b612c031854879adb01f31699e652d","type":"GENE","name":"TRI-AAT9-1","canonical_id":"hgnc:HGNC:12300","description":"tRNA-Ile (anticodon AAT) 9-1","metadata":{"aliases":["tRNA-Ile-AAT-9-1","TRI","TRNAI1"]}},{"id":"0f8a9f8fab794829966868c39076e35c","type":"GENE","name":"TRI-GAT1-1","canonical_id":"hgnc:HGNC:34694","description":"tRNA-Ile (anticodon GAT) 1-1","metadata":{"aliases":["tRNA-Ile-GAT-1-1","TRNAI7"]}},{"id":"b24649c8ccac4b4187b900284a5aab76","type":"GENE","name":"TRI-GAT1-2","canonical_id":"hgnc:HGNC:34609","description":"tRNA-Ile (anticodon GAT) 1-2","metadata":{"aliases":["tRNA-Ile-GAT-1-2","TRNAI3"]}},{"id":"4b4500c8c5b94ce99fdeab943f6727ec","type":"GENE","name":"TRI-GAT1-3","canonical_id":"hgnc:HGNC:34996","description":"tRNA-Ile (anticodon GAT) 1-3","metadata":{"aliases":["tRNA-Ile-GAT-1-3","TRNAI26"]}},{"id":"b5be076a7e7b400581d3d79682b1b1f6","type":"GENE","name":"TRI-TAT1-1","canonical_id":"hgnc:HGNC:34891","description":"tRNA-Ile (anticodon TAT) 1-1","metadata":{"aliases":["tRNA-Ile-TAT-1-1","TRNAI18"]}},{"id":"97046c4adf0549a6bff3863d7e3effd5","type":"GENE","name":"TRI-TAT2-1","canonical_id":"hgnc:HGNC:34828","description":"tRNA-Ile (anticodon TAT) 2-1","metadata":{"aliases":["tRNA-Ile-TAT-2-1","TRNAI13"]}},{"id":"ce4d9eef4c5947378d244a335dbb04a8","type":"GENE","name":"TRI-TAT2-2","canonical_id":"hgnc:HGNC:34587","description":"tRNA-Ile (anticodon TAT) 2-2","metadata":{"aliases":["tRNA-Ile-TAT-2-2","TRNAI2"]}},{"id":"63b397364a5d4affb24d1e9dbfaabe9a","type":"GENE","name":"TRI-TAT2-3","canonical_id":"hgnc:HGNC:34693","description":"tRNA-Ile (anticodon TAT) 2-3","metadata":{"aliases":["tRNA-Ile-TAT-2-3","TRNAI6"]}},{"id":"4b130375e1c54e9cb4ca0ddb6fc96506","type":"GENE","name":"TRI-TAT3-1","canonical_id":"hgnc:HGNC:34916","description":"tRNA-Ile (anticodon TAT) 3-1","metadata":{"aliases":["tRNA-Ile-TAT-3-1","TRNAI21"]}},{"id":"ff32491349b24ae8957e4d6da175edb2","type":"GENE","name":"TRIAP1","canonical_id":"hgnc:HGNC:26937","description":"TP53 regulated inhibitor of apoptosis 1","metadata":{"aliases":["P53CSV","WF-1","HSPC132","p53CSV","MDM35"]}},{"id":"1d84b0e30faa41e483584470c544256f","type":"GENE","name":"TRIAP1P1","canonical_id":"hgnc:HGNC:31659","description":"TP53 regulated inhibitor of apoptosis 1 pseudogene 1","metadata":{"aliases":["bA748L13.4","C10orf135"]}},{"id":"72d8552220954d6f939ccd0e021d2dfd","type":"GENE","name":"TRIB1","canonical_id":"hgnc:HGNC:16891","description":"tribbles pseudokinase 1","metadata":{"aliases":["C8FW","GIG2","TRB1"]}},{"id":"ff058b86aa5742809dfa9575297a979c","type":"GENE","name":"TRIB1AL","canonical_id":"hgnc:HGNC:56762","description":"TRIB1 associated lncRNA","metadata":{"aliases":["TRIBAL"]}},{"id":"92f858f51824410da37ec2d2955cc383","type":"GENE","name":"TRIB2","canonical_id":"hgnc:HGNC:30809","description":null,"metadata":null},{"id":"1170399e9d934aceb2064bf3fd4650c1","type":"GENE","name":"TRIB3","canonical_id":"hgnc:HGNC:16228","description":null,"metadata":null},{"id":"cfdf288533ea4447b8997dad405b4b6e","type":"GO_TERM","name":"TRIBOA-glucoside methyltransferase activity","canonical_id":"go:GO:0102718","description":"\"Catalysis of the reaction: TRIBOA-beta-D-glucoside + S-adenosyl-L-methionine = (2R)-DIMBOA glucoside + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.241, GOC:pz]","metadata":null},{"id":"4567f00ca8a1412aa6e7630b113e64e3","type":"GENE","name":"TRIDDENT","canonical_id":"hgnc:HGNC:54406","description":"TRIM28 interacting DNA damage repair enhancing non-coding transcript","metadata":{"aliases":["RP11-462G12.2","TRIDENT","LINC02861"]}},{"id":"86524c5575754670b71bcb3569c4a36f","type":"GO_TERM","name":"TRIF-dependent toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0035667","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like 4 receptor where the TRIF adaptor mediates transduction of the signal. Toll-like 4 receptors are pattern recognition receptors that bind bacterial lipopolysaccharide (LPS) to initiate an innate immune response.\" [GOC:BHF, PMID:18641322, PMID:20511708]","metadata":null},{"id":"6fd7ecaff3ad4a4caf7237304e2a68a2","type":"GO_TERM","name":"TRIF-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0035666","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like receptor where the TRIF adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate an innate immune response.\" [GOC:BHF, PMID:12855817]","metadata":null},{"id":"2a9528252352494dbed4e59cda6c09f4","type":"GENE","name":"TRIL","canonical_id":"hgnc:HGNC:22200","description":"TLR4 interactor with leucine rich repeats","metadata":{"aliases":["KIAA0644"]}},{"id":"bfaf0cef185e4ff681b4a48745bd6b84","type":"GENE","name":"TRIM10","canonical_id":"hgnc:HGNC:10072","description":"tripartite motif containing 10","metadata":{"aliases":["RFB30","HERF1","RNF9"]}},{"id":"e65c717c137e48989c677bb34e6977b6","type":"GENE","name":"TRIM11","canonical_id":"hgnc:HGNC:16281","description":"tripartite motif containing 11","metadata":{"aliases":["RNF92","BIA1"]}},{"id":"8b5b35165668430688a4c7329d097c7f","type":"GENE","name":"TRIM11-AS1","canonical_id":"hgnc:HGNC:58336","description":"TRIM11 antisense RNA 1","metadata":null},{"id":"a4d839490af94f2e97b08b3e69a181d5","type":"GENE","name":"TRIM13","canonical_id":"hgnc:HGNC:9976","description":"tripartite motif containing 13","metadata":{"aliases":["Leu5","RNF77","DLEU5","RFP2"]}},{"id":"4fc8ba760e2844be9a6f46090e1736aa","type":"GENE","name":"TRIM14","canonical_id":"hgnc:HGNC:16283","description":"tripartite motif containing 14","metadata":{"aliases":["KIAA0129"]}},{"id":"39157f1eb548473eb999cabd5cd1e060","type":"GENE","name":"TRIM15","canonical_id":"hgnc:HGNC:16284","description":"tripartite motif containing 15","metadata":{"aliases":["ZNFB7","RNF93","ZNF178"]}},{"id":"ea0f1ba559ba41b5803d9c9611bc3a39","type":"GENE","name":"TRIM16","canonical_id":"hgnc:HGNC:17241","description":null,"metadata":null},{"id":"60a388ed516f40c2b3ee6379db18ffc6","type":"GENE","name":"TRIM16L","canonical_id":"hgnc:HGNC:32670","description":"tripartite motif containing 16 like (pseudogene)","metadata":{"aliases":["TRIM70"]}},{"id":"966c5af2b6d945a490ef4c9d1b12f9d3","type":"GENE","name":"TRIM17","canonical_id":"hgnc:HGNC:13430","description":"tripartite motif containing 17","metadata":{"aliases":["terf","RBCC","RNF16"]}},{"id":"339b283c8f7849da8ae5a1145375f515","type":"GENE","name":"TRIM2","canonical_id":"hgnc:HGNC:15974","description":"tripartite motif containing 2","metadata":{"aliases":["KIAA0517","RNF86","CMT2R"]}},{"id":"65529844b97c4bdd83f43590b0c7af5b","type":"GENE","name":"TRIM2-AS1","canonical_id":"hgnc:HGNC:58898","description":"TRIM2 antisense RNA 1","metadata":null},{"id":"72c157532c3d41f4baaf151f80d5217a","type":"GENE","name":"TRIM21","canonical_id":"hgnc:HGNC:11312","description":null,"metadata":null},{"id":"a55845d3c07d46e0b854692a057cc374","type":"GENE","name":"TRIM22","canonical_id":"hgnc:HGNC:16379","description":null,"metadata":null},{"id":"304273641701461eaa3cb17b99be8a54","type":"GENE","name":"TRIM23","canonical_id":"hgnc:HGNC:660","description":"tripartite motif containing 23","metadata":{"aliases":["ARD1","RNF46","ARFD1"]}},{"id":"ed2f262542ec4e2383df98d4567ffcf2","type":"GENE","name":"TRIM24","canonical_id":"hgnc:HGNC:11812","description":"tripartite motif containing 24","metadata":{"aliases":["hTIF1","Tif1a","RNF82","TIF1A","TIF1"]}},{"id":"d20e935b339e4371b7343e1f8d0f4d64","type":"GENE","name":"TRIM25","canonical_id":"hgnc:HGNC:12932","description":null,"metadata":null},{"id":"2ff9bdc1a1ac46cb9fad979808e40df2","type":"GENE","name":"TRIM26","canonical_id":"hgnc:HGNC:12962","description":"tripartite motif containing 26","metadata":{"aliases":["RNF95","ZNF173"]}},{"id":"0761853974bd4ca38d3e658ed2e80f44","type":"GENE","name":"TRIM26BP","canonical_id":"hgnc:HGNC:31338","description":"tripartite motif containing 26B, pseudogene","metadata":{"aliases":["Em:AB023053.1","TRIM26P1","TRIM26P"]}},{"id":"c37549fc069c4f359b359d37e288312d","type":"GENE","name":"TRIM27","canonical_id":"hgnc:HGNC:9975","description":"tripartite motif containing 27","metadata":{"aliases":["RNF76","RFP"]}},{"id":"0808da590c2a4b86baf4fc4ba97ec8c0","type":"GENE","name":"TRIM28","canonical_id":"hgnc:HGNC:16384","description":null,"metadata":null},{"id":"64cf42048ebb48c0909aeca4eac7b69a","type":"GENE","name":"TRIM29","canonical_id":"hgnc:HGNC:17274","description":"tripartite motif containing 29","metadata":{"aliases":["ATDC","FLJ36085"]}},{"id":"be5d8f9104224b3f913fe09517649c87","type":"GENE","name":"TRIM3","canonical_id":"hgnc:HGNC:10064","description":"tripartite motif containing 3","metadata":{"aliases":["HAC1","BERP","RNF97","RNF22"]}},{"id":"2638a581cb654130af64a6182470abfe","type":"GENE","name":"TRIM31","canonical_id":"hgnc:HGNC:16289","description":"tripartite motif containing 31","metadata":{"aliases":["RNF","HCGI","C6orf13","HCG1"]}},{"id":"44078a35274d477c851b7a1f6448aac4","type":"GENE","name":"TRIM31-AS1","canonical_id":"hgnc:HGNC:39761","description":"TRIM31 antisense RNA 1","metadata":null},{"id":"fd05efe2c7d9477ab3abc7ecf59460f7","type":"GENE","name":"TRIM32","canonical_id":"hgnc:HGNC:16380","description":"tripartite motif containing 32","metadata":{"aliases":["HT2A","TATIP","BBS11","LGMD2H"]}},{"id":"bed2247e0edb467182e4f6ec5f65f7ec","type":"GENE","name":"TRIM33","canonical_id":"hgnc:HGNC:16290","description":"tripartite motif containing 33","metadata":{"aliases":["TIF1GAMMA","FLJ11429","KIAA1113","TIFGAMMA","RFG7","TF1G","TIF1G","PTC7"]}},{"id":"b03fe36e34c94027b86308f54799108e","type":"GENE","name":"TRIM34","canonical_id":"hgnc:HGNC:10063","description":"tripartite motif containing 34","metadata":{"aliases":["RNF21"]}},{"id":"5b1a7b29121042989c134992dcadbffd","type":"GENE","name":"TRIM35","canonical_id":"hgnc:HGNC:16285","description":"tripartite motif containing 35","metadata":{"aliases":["KIAA1098","MAIR","HLS5"]}},{"id":"49ca7c74d00146fbb9596f6c90a25ab8","type":"GENE","name":"TRIM36","canonical_id":"hgnc:HGNC:16280","description":"tripartite motif containing 36","metadata":{"aliases":["RBCC728","RNF98","HAPRIN"]}},{"id":"b7113671f87945eab845444447945029","type":"GENE","name":"TRIM36-IT1","canonical_id":"hgnc:HGNC:41422","description":"TRIM36 intronic transcript 1","metadata":null},{"id":"0441120aa6ba41e196871e02e4b1f86b","type":"GENE","name":"TRIM37","canonical_id":"hgnc:HGNC:7523","description":"tripartite motif containing 37","metadata":{"aliases":["KIAA0898","POB1","TEF3","MUL"]}},{"id":"fb7203f69584400c88fd9b6f3ba6cd26","type":"GENE","name":"TRIM38","canonical_id":"hgnc:HGNC:10059","description":"tripartite motif containing 38","metadata":{"aliases":["RORET","RNF15"]}},{"id":"4ffc35294b544f6f9f06336021eea633","type":"GENE","name":"TRIM39","canonical_id":"hgnc:HGNC:10065","description":"tripartite motif containing 39","metadata":{"aliases":["RNF23"]}},{"id":"4f88b26b2616418e8fb700f08e98b270","type":"GENE","name":"TRIM39-RPP21","canonical_id":"hgnc:HGNC:38845","description":"TRIM39-RPP21 readthrough","metadata":null},{"id":"4d0c569e429e4f0e97fd8ae52384bf7b","type":"GENE","name":"TRIM4","canonical_id":"hgnc:HGNC:16275","description":"tripartite motif containing 4","metadata":{"aliases":["RNF87"]}},{"id":"e39968b471834f18a8f8e1ffd5115de8","type":"GENE","name":"TRIM40","canonical_id":"hgnc:HGNC:18736","description":"tripartite motif containing 40","metadata":{"aliases":["RNF35"]}},{"id":"b91c1eb4f0b64f6185b0c07ce402d537","type":"GENE","name":"TRIM41","canonical_id":"hgnc:HGNC:19013","description":"tripartite motif containing 41","metadata":{"aliases":["MGC1127","RINCK"]}},{"id":"2dd538a240ee428a85f57698de97c262","type":"GENE","name":"TRIM41-AS1","canonical_id":"hgnc:HGNC:40863","description":"TRIM41 antisense RNA 1","metadata":null},{"id":"27b4b6cb19f54fd68c19fa80760190f2","type":"GENE","name":"TRIM42","canonical_id":"hgnc:HGNC:19014","description":"tripartite motif containing 42","metadata":{"aliases":["FLJ40097","PPP1R40","T4A1"]}},{"id":"a77f43aaf70444d18629bf6c9a2dc308","type":"GENE","name":"TRIM43","canonical_id":"hgnc:HGNC:19015","description":"tripartite motif containing 43","metadata":{"aliases":["TRIM43A"]}},{"id":"c6796f3a5f264201b0821c338a483d2d","type":"GENE","name":"TRIM43B","canonical_id":"hgnc:HGNC:37146","description":"tripartite motif containing 43B","metadata":null},{"id":"95e4b61a9d3442a4b299944e9dc27de4","type":"GENE","name":"TRIM43CP","canonical_id":"hgnc:HGNC:43981","description":"tripartite motif containing 43C, pseudogene","metadata":null},{"id":"db939f886b084d86b8062b01da577bbc","type":"GENE","name":"TRIM44","canonical_id":"hgnc:HGNC:19016","description":"TRIM family member 44","metadata":{"aliases":["DIPB","MC7"]}},{"id":"513834b3c7d9420cb9f298ec196ff3a8","type":"GENE","name":"TRIM45","canonical_id":"hgnc:HGNC:19018","description":"tripartite motif containing 45","metadata":{"aliases":["FLJ13181","RNF99"]}},{"id":"91cf7e8c95d74ca29cfaebd3c9da13ae","type":"GENE","name":"TRIM46","canonical_id":"hgnc:HGNC:19019","description":"tripartite motif containing 46","metadata":{"aliases":["FLJ23229","TRIFIC"]}},{"id":"c363438553d54501bc35a33123a9268b","type":"GENE","name":"TRIM47","canonical_id":"hgnc:HGNC:19020","description":"tripartite motif containing 47","metadata":{"aliases":["GOA","RNF100"]}},{"id":"eba9fc18cd4b478d847815426626c929","type":"GENE","name":"TRIM48","canonical_id":"hgnc:HGNC:19021","description":"tripartite motif containing 48","metadata":{"aliases":["RNF101"]}},{"id":"3eaa23aa34e74c14b45ddcce3ddc48c5","type":"GENE","name":"TRIM49","canonical_id":"hgnc:HGNC:13431","description":"tripartite motif containing 49","metadata":{"aliases":["TRIM49A","RNF18"]}},{"id":"b887070055554d4b933fe99d95936a3b","type":"GENE","name":"TRIM49B","canonical_id":"hgnc:HGNC:42955","description":"tripartite motif containing 49B","metadata":null},{"id":"d8ee15e61884418ab70110cadb882762","type":"GENE","name":"TRIM49C","canonical_id":"hgnc:HGNC:38877","description":"tripartite motif containing 49C","metadata":{"aliases":["TRIM49L2"]}},{"id":"a0e3245673d94551865afac9e1690190","type":"GENE","name":"TRIM49D1","canonical_id":"hgnc:HGNC:43973","description":"tripartite motif containing 49D1","metadata":{"aliases":["TRIM49D","TRIM49DP","TRIM49D1P"]}},{"id":"8a4ec03ac7d841c8b57b08277dcfcff2","type":"GENE","name":"TRIM49D2","canonical_id":"hgnc:HGNC:37217","description":"tripartite motif containing 49D2","metadata":{"aliases":["TRIM49L","TRIM49L1","TRIM49D2P"]}},{"id":"175c749517a2452bb7ce93419656eef3","type":"GENE","name":"TRIM5","canonical_id":"hgnc:HGNC:16276","description":"tripartite motif containing 5","metadata":{"aliases":["RNF88","TRIM5alpha"]}},{"id":"1cf8937ab2f44dc5b4ab5cf6f77a69a0","type":"GENE","name":"TRIM50","canonical_id":"hgnc:HGNC:19017","description":"tripartite motif containing 50","metadata":{"aliases":["FLJ32804","TRIM50A"]}},{"id":"34df4d9524f047f49f4d2c3b6446d342","type":"GENE","name":"TRIM51","canonical_id":"hgnc:HGNC:19023","description":"tripartite motif-containing 51","metadata":{"aliases":["TRIM51A","SPRYD5"]}},{"id":"5810ecdb8d8c4b4b9192867085930410","type":"GENE","name":"TRIM51BP","canonical_id":"hgnc:HGNC:37145","description":"tripartite motif-containing 51B, pseudogene","metadata":{"aliases":["SPRYD5P","SPRYD5P1"]}},{"id":"0ce955ae01a3404e878a2a220bdab671","type":"GENE","name":"TRIM51CP","canonical_id":"hgnc:HGNC:43968","description":"tripartite motif-containing 51C, pseudogene","metadata":null},{"id":"ee86a9ed30a14dcaa58cdbf119e9956a","type":"GENE","name":"TRIM51DP","canonical_id":"hgnc:HGNC:43969","description":"tripartite motif-containing 51D, pseudogene","metadata":null},{"id":"839e8e619fe54e0892aa253ad4ab750c","type":"GENE","name":"TRIM51EP","canonical_id":"hgnc:HGNC:43970","description":"tripartite motif-containing 51E, pseudogene","metadata":null},{"id":"385c5c38156c4eddbe5c11efec283f7b","type":"GENE","name":"TRIM51FP","canonical_id":"hgnc:HGNC:43966","description":"tripartite motif-containing 51F, pseudogene","metadata":null},{"id":"c5bcf9a350aa408e91cba235dfca9d5b","type":"GENE","name":"TRIM51G","canonical_id":"hgnc:HGNC:43972","description":"tripartite motif-containing 51G","metadata":{"aliases":["TRIM51GP"]}},{"id":"94eb31b1c6b34eb595566acb11068571","type":"GENE","name":"TRIM51HP","canonical_id":"hgnc:HGNC:43977","description":"tripartite motif-containing 51H, pseudogene","metadata":null},{"id":"f1a7531a59f443608c4f29472c0f5ae0","type":"GENE","name":"TRIM51JP","canonical_id":"hgnc:HGNC:43978","description":"tripartite motif-containing 51J, pseudogene","metadata":null},{"id":"afc69d4f3ebe4a27a09ff1062e64f61e","type":"GENE","name":"TRIM52","canonical_id":"hgnc:HGNC:19024","description":"tripartite motif containing 52","metadata":{"aliases":["RNF102"]}},{"id":"fb257f4fdbde414d91d5891af66985a5","type":"GENE","name":"TRIM52-AS1","canonical_id":"hgnc:HGNC:49006","description":"TRIM52 antisense RNA 1","metadata":null},{"id":"0344acfa5b064e5db8defa8dc38b541a","type":"GENE","name":"TRIM53AP","canonical_id":"hgnc:HGNC:19025","description":"tripartite motif containing 53A, pseudogene","metadata":{"aliases":["TRIM53","TRIM53P"]}},{"id":"81aa187a17964a4ebbe1cde208fefa75","type":"GENE","name":"TRIM53BP","canonical_id":"hgnc:HGNC:37144","description":"tripartite motif containing 53B, pseudogene","metadata":{"aliases":["TRIM53L","TRIM53B","TRIM80P"]}},{"id":"32b01ff97f6442cfa338c0be7c3c50dd","type":"GENE","name":"TRIM53CP","canonical_id":"hgnc:HGNC:43979","description":"tripartite motif containing 53C, pseudogene","metadata":null},{"id":"ab47eef9134440fabf0e745e5245f627","type":"GENE","name":"TRIM54","canonical_id":"hgnc:HGNC:16008","description":"tripartite motif containing 54","metadata":{"aliases":["MURF","MURF-3","RNF30"]}},{"id":"8fa8216eb4034d2fb3dacc821dfa76c3","type":"GENE","name":"TRIM55","canonical_id":"hgnc:HGNC:14215","description":"tripartite motif containing 55","metadata":{"aliases":["MURF-2","RNF29"]}},{"id":"0a2897c7d0dc43b79f19bc4cb0e6eb8d","type":"GENE","name":"TRIM56","canonical_id":"hgnc:HGNC:19028","description":"tripartite motif containing 56","metadata":{"aliases":["RNF109"]}},{"id":"6764b368fc7c42b7bb598ea3417b8733","type":"GENE","name":"TRIM58","canonical_id":"hgnc:HGNC:24150","description":"tripartite motif containing 58","metadata":{"aliases":["BIA2"]}},{"id":"f611e66570c343e5a52f5ef70be88908","type":"GENE","name":"TRIM59","canonical_id":"hgnc:HGNC:30834","description":"tripartite motif containing 59","metadata":{"aliases":["TSBF1","Mrf1","RNF104","TRIM57"]}},{"id":"3b12b4d6a56a480a8ba43d17f12acf83","type":"GENE","name":"TRIM59-IFT80","canonical_id":"hgnc:HGNC:56756","description":"TRIM59-IFT80 readthrough (NMD candidate)","metadata":null},{"id":"2032ab97b9274ef98e41cda1ea9c17cd","type":"GENE","name":"TRIM6","canonical_id":"hgnc:HGNC:16277","description":"tripartite motif containing 6","metadata":{"aliases":["RNF89"]}},{"id":"7a7368c6394e4efab2aebb1a5d9e09ea","type":"GENE","name":"TRIM6-TRIM34","canonical_id":"hgnc:HGNC:33440","description":"TRIM6-TRIM34 readthrough","metadata":null},{"id":"81e817a9e3aa470bbeb7f4c8b85dc39a","type":"GENE","name":"TRIM60","canonical_id":"hgnc:HGNC:21162","description":"tripartite motif containing 60","metadata":{"aliases":["FLJ35882","RNF129","RNF33"]}},{"id":"840ae3b311df48848f63aeb17cf0107e","type":"GENE","name":"TRIM60P10Y","canonical_id":"hgnc:HGNC:38462","description":"tripartite motif containing 60 pseudogene 10, Y-linked","metadata":{"aliases":["TRIM60P10","TRIM60PY10"]}},{"id":"5d84b881b8f4499ab6d791e2fe9abc58","type":"GENE","name":"TRIM60P11Y","canonical_id":"hgnc:HGNC:38463","description":"tripartite motif containing 60 pseudogene 11, Y-linked","metadata":{"aliases":["TRIM60P11","TRIM60PY11"]}},{"id":"24fed088fb584135b1d5422c85337d69","type":"GENE","name":"TRIM60P12Y","canonical_id":"hgnc:HGNC:38465","description":"tripartite motif containing 60 pseudogene 12, Y-linked","metadata":{"aliases":["TRIM60P12","TRIM60PY12"]}},{"id":"8c4ec706084945d0b6fb8a2d41a87d10","type":"GENE","name":"TRIM60P13","canonical_id":"hgnc:HGNC:38485","description":"tripartite motif containing 60 pseudogene 13","metadata":null},{"id":"e82e5d72dbb644399d7ca66bd994eae4","type":"GENE","name":"TRIM60P14","canonical_id":"hgnc:HGNC:38486","description":"tripartite motif containing 60 pseudogene 14","metadata":null},{"id":"7dc6e66d53f34eaa88247f86c713d16a","type":"GENE","name":"TRIM60P15","canonical_id":"hgnc:HGNC:38487","description":"tripartite motif containing 60 pseudogene 15","metadata":null},{"id":"8803531227d34bd8bc882de5cc77c87e","type":"GENE","name":"TRIM60P16","canonical_id":"hgnc:HGNC:38488","description":"tripartite motif containing 60 pseudogene 16","metadata":null},{"id":"234a3717abf541c8965e9f623941d986","type":"GENE","name":"TRIM60P17","canonical_id":"hgnc:HGNC:38489","description":"tripartite motif containing 60 pseudogene 17","metadata":null},{"id":"3d44361abde2415185d592256b7039cd","type":"GENE","name":"TRIM60P18","canonical_id":"hgnc:HGNC:38490","description":"tripartite motif containing 60 pseudogene 18","metadata":null},{"id":"0b34f8b933b2444088e876c5e7c211bc","type":"GENE","name":"TRIM60P19","canonical_id":"hgnc:HGNC:42010","description":"tripartite motif containing 60 pseudogene 19","metadata":null},{"id":"b3d5d34cb85d4184983b9b7dd1a17ac0","type":"GENE","name":"TRIM60P1Y","canonical_id":"hgnc:HGNC:38403","description":"tripartite motif containing 60 pseudogene 1, Y-linked","metadata":{"aliases":["TRIM60P1","TRIM60PY1"]}},{"id":"217a3393dfef47f9b991c444334193e7","type":"GENE","name":"TRIM60P2Y","canonical_id":"hgnc:HGNC:38405","description":"tripartite motif containing 60 pseudogene 2, Y-linked","metadata":{"aliases":["TRIM60P2","TRIM60PY2"]}},{"id":"63b30c85124f48e39f55f81bfbe0a905","type":"GENE","name":"TRIM60P3Y","canonical_id":"hgnc:HGNC:38409","description":"tripartite motif containing 60 pseudogene 3, Y-linked","metadata":{"aliases":["TRIM60P3","TRIM60PY3"]}},{"id":"720746bc6d4d4c299a1260960129dccc","type":"GENE","name":"TRIM60P4Y","canonical_id":"hgnc:HGNC:38425","description":"tripartite motif containing 60 pseudogene 4, Y-linked","metadata":{"aliases":["TRIM60P4","TRIM60PY4"]}},{"id":"252cc0f06b414465b868f1152403240c","type":"GENE","name":"TRIM60P5Y","canonical_id":"hgnc:HGNC:38430","description":"tripartite motif containing 60 pseudogene 5, Y-linked","metadata":{"aliases":["TRIM60P5","TRIM60PY5"]}},{"id":"ee322ab643e04286851de807d041ee00","type":"GENE","name":"TRIM60P6Y","canonical_id":"hgnc:HGNC:38432","description":"tripartite motif containing 60 pseudogene 6, Y-linked","metadata":{"aliases":["TRIM60P6","TRIM60PY6"]}},{"id":"8f836aa7394845b4978c11ec092fbb88","type":"GENE","name":"TRIM60P7Y","canonical_id":"hgnc:HGNC:38433","description":"tripartite motif containing 60 pseudogene 7, Y-linked","metadata":{"aliases":["TRIM60P7","TRIM60PY7"]}},{"id":"1aed373acc404559aef71a76134af182","type":"GENE","name":"TRIM60P8Y","canonical_id":"hgnc:HGNC:38458","description":"tripartite motif containing 60 pseudogene 8, Y-linked","metadata":{"aliases":["TRIM60P8","TRIM60PY8"]}},{"id":"3a1205238b564c129d59e6da1091107a","type":"GENE","name":"TRIM60P9Y","canonical_id":"hgnc:HGNC:38459","description":"tripartite motif containing 60 pseudogene 9, Y-linked","metadata":{"aliases":["TRIM60P9","TRIM60PY9"]}},{"id":"56e7273e573a4e8d924be81219807098","type":"GENE","name":"TRIM61","canonical_id":"hgnc:HGNC:24339","description":"tripartite motif containing 61","metadata":{"aliases":["RNF35"]}},{"id":"aaea7ecc7dac415299b506b1883f23d4","type":"GENE","name":"TRIM62","canonical_id":"hgnc:HGNC:25574","description":"tripartite motif containing 62","metadata":{"aliases":["FLJ10759","DEAR1"]}},{"id":"915c601955694d81a275f91d1d664aa0","type":"GENE","name":"TRIM63","canonical_id":"hgnc:HGNC:16007","description":"tripartite motif containing 63","metadata":{"aliases":["MURF-1","IRF","SMRZ","RNF28"]}},{"id":"94d448e4b15b4f9fbce6c748c8e8cb1b","type":"GENE","name":"TRIM64","canonical_id":"hgnc:HGNC:14663","description":"tripartite motif containing 64","metadata":{"aliases":["TRIM64A","C11orf28"]}},{"id":"ece579ae2cb84626abd4d43624d0d313","type":"GENE","name":"TRIM64B","canonical_id":"hgnc:HGNC:37147","description":"tripartite motif containing 64B","metadata":null},{"id":"4ce1cd506ab54d4ca72eb52d43cc8ad6","type":"GENE","name":"TRIM64C","canonical_id":"hgnc:HGNC:37148","description":"tripartite motif containing 64C","metadata":null},{"id":"7a49dc4ee81f4aa483c1ae2a1bf999ff","type":"GENE","name":"TRIM64DP","canonical_id":"hgnc:HGNC:43974","description":"tripartite motif containing 64D, pseudogene","metadata":null},{"id":"54ef7c816bd44ab984855d630c8b33cf","type":"GENE","name":"TRIM64EP","canonical_id":"hgnc:HGNC:43975","description":"tripartite motif containing 64E, pseudogene","metadata":null},{"id":"02d1786a8beb4c3ca13308fd1560bf02","type":"GENE","name":"TRIM64FP","canonical_id":"hgnc:HGNC:43976","description":"tripartite motif containing 64F, pseudogene","metadata":null},{"id":"02d439f311814203b4a812b015874dce","type":"GENE","name":"TRIM64GP","canonical_id":"hgnc:HGNC:58552","description":"tripartite motif containing 64G, pseudogene","metadata":null},{"id":"f81ab9408be24a75806c165e79a24bd0","type":"GENE","name":"TRIM64HP","canonical_id":"hgnc:HGNC:50291","description":"tripartite motif containing 64H, pseudogene","metadata":null},{"id":"1c87888639884506a3bbf3b41db9f38f","type":"GENE","name":"TRIM64JP","canonical_id":"hgnc:HGNC:50292","description":"tripartite motif containing 64J, pseudogene","metadata":null},{"id":"50136be34e2f4b3fb520bea41b5cfa77","type":"GENE","name":"TRIM65","canonical_id":"hgnc:HGNC:27316","description":"tripartite motif containing 65","metadata":null},{"id":"d048e0173d564b28b85c4a919eba3e28","type":"GENE","name":"TRIM66","canonical_id":"hgnc:HGNC:29005","description":"tripartite motif containing 66","metadata":{"aliases":["KIAA0298","TIF1D","C11orf29"]}},{"id":"8a72ac6a9a124306b9eed6e640613be7","type":"GENE","name":"TRIM67","canonical_id":"hgnc:HGNC:31859","description":"tripartite motif containing 67","metadata":{"aliases":["TNL"]}},{"id":"a06202e35aef47779a37a645e733e064","type":"GENE","name":"TRIM67-AS1","canonical_id":"hgnc:HGNC:41282","description":"TRIM67 antisense RNA 1","metadata":null},{"id":"d1f4595a81164f61aabf466c675ce5e2","type":"GENE","name":"TRIM68","canonical_id":"hgnc:HGNC:21161","description":"tripartite motif containing 68","metadata":{"aliases":["SS-56","FLJ10369","RNF137"]}},{"id":"1abe58c0c3974c59a0fb449079019ae6","type":"GENE","name":"TRIM69","canonical_id":"hgnc:HGNC:17857","description":"tripartite motif containing 69","metadata":{"aliases":["Trif","TRIMLESS","RNF36"]}},{"id":"cb68d0d91d1e4365b7df84ecb9955938","type":"GENE","name":"TRIM7","canonical_id":"hgnc:HGNC:16278","description":"tripartite motif containing 7","metadata":{"aliases":["RNF90","GNIP"]}},{"id":"817a4dc7d33b4ea7a6651b1df54053b5","type":"GENE","name":"TRIM7-AS1","canonical_id":"hgnc:HGNC:40764","description":"TRIM7 antisense RNA 1","metadata":null},{"id":"e5e9cc242edc41d4947b8695f118e1b4","type":"GENE","name":"TRIM7-AS2","canonical_id":"hgnc:HGNC:56031","description":"TRIM7 antisense RNA 2","metadata":{"aliases":["CTC-338M12.5"]}},{"id":"a2a5618695c04cef86594d38a3e02377","type":"GENE","name":"TRIM71","canonical_id":"hgnc:HGNC:32669","description":"tripartite motif containing 71","metadata":{"aliases":["LIN41","LIN-41"]}},{"id":"cddff38566e04c17b7535e15a48cb4bb","type":"GENE","name":"TRIM72","canonical_id":"hgnc:HGNC:32671","description":"tripartite motif containing 72","metadata":{"aliases":["MG53"]}},{"id":"bb12d0efdcf549319df1b225de8cb3a8","type":"GENE","name":"TRIM73","canonical_id":"hgnc:HGNC:18162","description":"tripartite motif containing 73","metadata":{"aliases":["TRIM50B"]}},{"id":"8e6394b8adde4aa58cb5cd02f2b94278","type":"GENE","name":"TRIM74","canonical_id":"hgnc:HGNC:17453","description":"tripartite motif containing 74","metadata":{"aliases":["MGC45440","TRIM50C"]}},{"id":"52cb1379930749a4af13768c36e1c362","type":"GENE","name":"TRIM75","canonical_id":"hgnc:HGNC:32686","description":"tripartite motif containing 75","metadata":{"aliases":["TRIM75P"]}},{"id":"e4add53081d849c8a0da43ff476917cf","type":"GENE","name":"TRIM77","canonical_id":"hgnc:HGNC:34228","description":"tripartite motif containing 77","metadata":{"aliases":["TRIM77P"]}},{"id":"24fc0e20ffdd4ec9ae34fdb67803377e","type":"GENE","name":"TRIM77BP","canonical_id":"hgnc:HGNC:43980","description":"tripartite motif containing 77B, pseudogene","metadata":null},{"id":"c5ee3c35451a424dbc61a6a9f94a2d34","type":"GENE","name":"TRIM8","canonical_id":"hgnc:HGNC:15579","description":"tripartite motif containing 8","metadata":{"aliases":["GERP","RNF27"]}},{"id":"da94a39461664c85bfec52143654a568","type":"GENE","name":"TRIM8-DT","canonical_id":"hgnc:HGNC:55573","description":"TRIM8 divergent transcript","metadata":null},{"id":"1fdc2a2050d443c99ea9f8ccdeda023b","type":"GENE","name":"TRIM80P","canonical_id":"hgnc:HGNC:51490","description":"tripartite motif containing 80, pseudogene","metadata":{"aliases":["TRIM47LP"]}},{"id":"452c90a0a15a43709f86e44174578584","type":"GENE","name":"TRIM9","canonical_id":"hgnc:HGNC:16288","description":"tripartite motif containing 9","metadata":{"aliases":["SPRING","RNF91"]}},{"id":"18676e7c1c5f43e7bd14a0c60a87c0fd","type":"TRIAL","name":"TRIMBOW\u00ae and RELVAR\u00ae on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","canonical_id":"clinicaltrials.gov:NCT04671355","description":"COPD","metadata":null},{"id":"cafd00df2753409b980f055659442a04","type":"GENE","name":"TRIML1","canonical_id":"hgnc:HGNC:26698","description":"tripartite motif family like 1","metadata":{"aliases":["FLJ36180","RNF209"]}},{"id":"916a8f3fa90b4cd1b625cb8905d089c3","type":"GENE","name":"TRIML2","canonical_id":"hgnc:HGNC:26378","description":"tripartite motif family like 2","metadata":{"aliases":["FLJ25801","SPRYD6"]}},{"id":"b8fedcbc90174f1b9a2626fd3101756b","type":"GENE","name":"TRINGS","canonical_id":"hgnc:HGNC:53614","description":"TP53 regulated inhibitor of necrosis under glucose starvation","metadata":null},{"id":"9fdb14bd1ab343d6a24f0ba02473c31d","type":"GENE","name":"TRIO","canonical_id":"hgnc:HGNC:12303","description":"trio Rho guanine nucleotide exchange factor","metadata":{"aliases":["ARHGEF23"]}},{"id":"14f2554b0848443dbcae1b72456c274f","type":"GENE","name":"TRIO-AS1","canonical_id":"hgnc:HGNC:59004","description":"TRIO antisense RNA 1","metadata":null},{"id":"efab51eb76a24b9e9eee3320912239df","type":"GENE","name":"TRIOBP","canonical_id":"hgnc:HGNC:17009","description":"TRIO and F-actin binding protein","metadata":{"aliases":["HRIHFB2122","KIAA1662","Tara","TAP68","DFNB28"]}},{"id":"455fce6d0c5a409aa9183ae396aec04e","type":"GENE","name":"TRIP10","canonical_id":"hgnc:HGNC:12304","description":"thyroid hormone receptor interactor 10","metadata":{"aliases":["STP","HSTP","CIP4","STOT"]}},{"id":"fb18bb1645cd4fb88cfc41d8db466c5c","type":"GENE","name":"TRIP10-AS1","canonical_id":"hgnc:HGNC:58603","description":"TRIP10 antisense RNA 1","metadata":null},{"id":"08287ece9be646c0a761958829292176","type":"GENE","name":"TRIP11","canonical_id":"hgnc:HGNC:12305","description":"thyroid hormone receptor interactor 11","metadata":{"aliases":["CEV14","Trip230","GMAP-210","GMAP210"]}},{"id":"0a77da15590643f792e2dc810bc4f4fd","type":"GENE","name":"TRIP12","canonical_id":"hgnc:HGNC:12306","description":"thyroid hormone receptor interactor 12","metadata":{"aliases":["KIAA0045","ULF","TRIPC"]}},{"id":"b2dc1589be4544d1a59361264955b9c6","type":"GENE","name":"TRIP13","canonical_id":"hgnc:HGNC:12307","description":"thyroid hormone receptor interactor 13","metadata":{"aliases":["16E1BP"]}},{"id":"caa113529a824c7ea45fd403c5e8aecd","type":"GENE","name":"TRIP4","canonical_id":"hgnc:HGNC:12310","description":"thyroid hormone receptor interactor 4","metadata":{"aliases":["HsT17391","ZC2HC5","ASC-1"]}},{"id":"09ac58c83c6240ca985abbe43f34e353","type":"GENE","name":"TRIP6","canonical_id":"hgnc:HGNC:12311","description":null,"metadata":null},{"id":"741f5941115c452c91c22f217277c19a","type":"GENE","name":"TRIQK","canonical_id":"hgnc:HGNC:27828","description":"triple QxxK/R motif containing","metadata":{"aliases":["DKFZp779L1068","PRO0845","LOC286144","C8orf83"]}},{"id":"4f91887ae9f1487eb4ea983e1d0028f8","type":"GENE","name":"TRIQK-AS1","canonical_id":"hgnc:HGNC:58428","description":"TRIQK antisense RNA 1","metadata":null},{"id":"242bbdfdbc724b69b9c38c7a59fd1f97","type":"GENE","name":"TRIR","canonical_id":"hgnc:HGNC:28424","description":"telomerase RNA component interacting RNase","metadata":{"aliases":["MGC2803","fSAP18","TERCIR","C19orf43"]}},{"id":"a7f98485cc144689952a156cd1fb8278","type":"GENE","name":"TRIT1","canonical_id":"hgnc:HGNC:20286","description":"tRNA isopentenyltransferase 1","metadata":{"aliases":["FLJ20061","IPT"]}},{"id":"e726a7e9f67b4c25b9684203beb2f1b4","type":"GENE","name":"TRK-CTT1-1","canonical_id":"hgnc:HGNC:34668","description":"tRNA-Lys (anticodon CTT) 1-1","metadata":{"aliases":["tRNA-Lys-CTT-1-1","TRNAK13"]}},{"id":"6c04e99ec2a84b8d950ed6042a5e9c55","type":"GENE","name":"TRK-CTT1-2","canonical_id":"hgnc:HGNC:34572","description":"tRNA-Lys (anticodon CTT) 1-2","metadata":{"aliases":["tRNA-Lys-CTT-1-2","TRNAK6"]}},{"id":"1ef36d69483842d6befbdec4765ed307","type":"GENE","name":"TRK-CTT10-1","canonical_id":"hgnc:HGNC:34935","description":"tRNA-Lys (anticodon CTT) 10-1","metadata":{"aliases":["tRNA-Lys-CTT-10-1","TRNAK30"]}},{"id":"cc109c0fe5524c11a2d42e6b93a3bf2e","type":"GENE","name":"TRK-CTT11-1","canonical_id":"hgnc:HGNC:34878","description":"tRNA-Lys (anticodon CTT) 11-1","metadata":{"aliases":["tRNA-Lys-CTT-11-1","TRNAK28"]}},{"id":"a1e13c236bcb4240877f17cf20d42f50","type":"GENE","name":"TRK-CTT12-1","canonical_id":"hgnc:HGNC:35036","description":"tRNA-Lys (anticodon CTT) 12-1","metadata":{"aliases":["tRNA-Lys-CTT-12-1","TRNAK36P"]}},{"id":"0a5056a933c94171948745fad21d0be5","type":"GENE","name":"TRK-CTT13-1","canonical_id":"hgnc:HGNC:35009","description":"tRNA-Lys (anticodon CTT) 13-1","metadata":{"aliases":["tRNA-Lys-CTT-13-1","TRNAK35P"]}},{"id":"34ba78a7c46146219a756584f5f2a7f4","type":"GENE","name":"TRK-CTT14-1","canonical_id":"hgnc:HGNC:35039","description":"tRNA-Lys (anticodon CTT) 14-1","metadata":{"aliases":["tRNA-Lys-CTT-14-1","TRNAK37P"]}},{"id":"afe767b6c4394d419ecd6931267e3da5","type":"GENE","name":"TRK-CTT15-1","canonical_id":"hgnc:HGNC:34556","description":"tRNA-Lys (anticodon CTT) 15-1","metadata":{"aliases":["tRNA-Lys-CTT-15-1","TRNAK5"]}},{"id":"95c52492de4b40c58a25a5db3bae8101","type":"GENE","name":"TRK-CTT16-1","canonical_id":"hgnc:HGNC:35113","description":"tRNA-Lys (anticodon CTT) 16-1","metadata":{"aliases":["tRNA-Lys-CTT-16-1","TRNAK42P"]}},{"id":"03d5162876b246e08c707689c68e3ad4","type":"GENE","name":"TRK-CTT2-1","canonical_id":"hgnc:HGNC:34761","description":"tRNA-Lys (anticodon CTT) 2-1","metadata":{"aliases":["tRNA-Lys-CTT-2-1","TRNAK20"]}},{"id":"7c388346e50747f7a700cf46db7fbac5","type":"GENE","name":"TRK-CTT2-2","canonical_id":"hgnc:HGNC:34967","description":"tRNA-Lys (anticodon CTT) 2-2","metadata":{"aliases":["tRNA-Lys-CTT-2-2","TRNAK33","TRK-CTT2-3"]}},{"id":"6c43324164f847b599b1aa7ebaffd117","type":"GENE","name":"TRK-CTT2-3","canonical_id":"hgnc:HGNC:33199","description":"tRNA-Lys (anticodon CTT) 2-3","metadata":{"aliases":["tRNA-Lys-CTT-2-3","TRK2","TRNAK2","TRK-CTT2-4"]}},{"id":"b23bb4036b4a4e8791db0f195683483a","type":"GENE","name":"TRK-CTT2-4","canonical_id":"hgnc:HGNC:34671","description":"tRNA-Lys (anticodon CTT) 2-4","metadata":{"aliases":["tRNA-Lys-CTT-2-4","TRNAK14","TRK-CTT2-5"]}},{"id":"7672f16cd466429384ec36ab48bd3f8d","type":"GENE","name":"TRK-CTT2-5","canonical_id":"hgnc:HGNC:34848","description":"tRNA-Lys (anticodon CTT) 2-5","metadata":{"aliases":["tRNA-Lys-CTT-2-5","TRNAK26","TRK-CTT2-2"]}},{"id":"702721f865cd48478b1a90708d8c6a07","type":"GENE","name":"TRK-CTT3-1","canonical_id":"hgnc:HGNC:34681","description":"tRNA-Lys (anticodon CTT) 3-1","metadata":{"aliases":["tRNA-Lys-CTT-3-1","TRNAK15"]}},{"id":"a0b6d1c191d942398a4a617629b3da01","type":"GENE","name":"TRK-CTT4-1","canonical_id":"hgnc:HGNC:34621","description":"tRNA-Lys (anticodon CTT) 4-1","metadata":{"aliases":["tRNA-Lys-CTT-4-1","TRNAK9"]}},{"id":"e668b2df95f74a85b30f4d3c83c15492","type":"GENE","name":"TRK-CTT5-1","canonical_id":"hgnc:HGNC:34772","description":"tRNA-Lys (anticodon CTT) 5-1","metadata":{"aliases":["tRNA-Lys-CTT-5-1","TRNAK21"]}},{"id":"dc9218cbfd414ecbaf432137bae9a0f9","type":"GENE","name":"TRK-CTT6-1","canonical_id":"hgnc:HGNC:34552","description":"tRNA-Lys (CTT) 6-1","metadata":{"aliases":["tRNA-Lys-CTT-6-1","TRNAK4"]}},{"id":"4cd2288785c74629bc7507cc31387078","type":"GENE","name":"TRK-CTT7-1","canonical_id":"hgnc:HGNC:35098","description":"tRNA-Lys (anticodon CTT) 7-1","metadata":{"aliases":["tRNA-Lys-CTT-7-1","TRNAL48","TRNAQ49P"]}},{"id":"a29ad1a9c190489ca9ee37bb97a2bb5c","type":"GENE","name":"TRK-CTT8-1","canonical_id":"hgnc:HGNC:34807","description":"tRNA-Lys (anticodon CTT) 8-1","metadata":{"aliases":["tRNA-Lys-CTT-8-1","TRNAK24"]}},{"id":"4d96909efb38421bb6b5c6cbb8f75a71","type":"GENE","name":"TRK-CTT9-1","canonical_id":"hgnc:HGNC:34742","description":"tRNA-Lys (anticodon CTT) 9-1","metadata":{"aliases":["tRNA-Lys-CTT-9-1","TRNAK18"]}},{"id":"b89067d9d58949fb939f6e9f1b55eb12","type":"GENE","name":"TRK-TTT1-1","canonical_id":"hgnc:HGNC:34687","description":"tRNA-Lys (anticodon TTT) 1-1","metadata":{"aliases":["tRNA-Lys-TTT-1-1","TRNAK17"]}},{"id":"3e5e4a2581b54188a91bf0308b605437","type":"GENE","name":"TRK-TTT10-1","canonical_id":"hgnc:HGNC:35053","description":"tRNA-Lys (anticodon TTT) 10-1","metadata":{"aliases":["tRNA-Lys-TTT-10-1","TRNAK38P"]}},{"id":"873d9ad8b84a4fd08f552b0a4baacb51","type":"GENE","name":"TRK-TTT11-1","canonical_id":"hgnc:HGNC:34665","description":"tRNA-Lys (anticodon TTT) 11-1","metadata":{"aliases":["tRNA-Lys-TTT-11-1","TRNAK12"]}},{"id":"541457499d6b4717ae7935f93da7058d","type":"GENE","name":"TRK-TTT12-1","canonical_id":"hgnc:HGNC:34610","description":"tRNA-Lys (anticodon TTT) 12-1","metadata":{"aliases":["tRNA-Lys-TTT-12-1","TRNAK7"]}},{"id":"0bd643f400d349d0a4ae3a91e0321a3d","type":"GENE","name":"TRK-TTT13-1","canonical_id":"hgnc:HGNC:35116","description":"tRNA-Lys (anticodon TTT) 13-1","metadata":{"aliases":["tRNA-Lys-TTT-13-1","TRNAK43P"]}},{"id":"9cb5be3824cf46aca1248c4d9f65aa8b","type":"GENE","name":"TRK-TTT14-1","canonical_id":"hgnc:HGNC:35089","description":"tRNA-Lys (TTT) 14-1","metadata":{"aliases":["tRNA-Lys-TTT-14-1","TRNAK40P"]}},{"id":"c8df824a9c9348db9dd2bd57cfe953fe","type":"GENE","name":"TRK-TTT15-1","canonical_id":"hgnc:HGNC:35079","description":"tRNA-Lys (anticodon TTT) 15-1","metadata":{"aliases":["tRNA-Lys-TTT-15-1","TRNAK39P"]}},{"id":"0578033fcde34f7db1a83df1a35a1016","type":"GENE","name":"TRK-TTT16-1","canonical_id":"hgnc:HGNC:34960","description":"tRNA-Lys (TTT) 16-1","metadata":{"aliases":["tRNA-Lys-TTT-16-1","TRNAK32"]}},{"id":"1befceabfa5141ff8a128a333aaae65e","type":"GENE","name":"TRK-TTT17-1","canonical_id":"hgnc:HGNC:35094","description":"tRNA-Lys (TTT) 17-1","metadata":{"aliases":["tRNA-Lys-TTT-17-1","TRNAK41P"]}},{"id":"97baba65189944f0bc362a191792f98d","type":"GENE","name":"TRK-TTT2-1","canonical_id":"hgnc:HGNC:34860","description":"tRNA-Lys (anticodon TTT) 2-1","metadata":{"aliases":["tRNA-Lys-TTT-2-1","TRNAK27"]}},{"id":"d3519cace98d4c159fdd38d21e04e545","type":"GENE","name":"TRK-TTT3-1","canonical_id":"hgnc:HGNC:34684","description":"tRNA-Lys (anticodon TTT) 3-1","metadata":{"aliases":["tRNA-Lys-TTT-3-1","TRNAK16"]}},{"id":"acb36132dda14c8982ec8561f03e554d","type":"GENE","name":"TRK-TTT3-2","canonical_id":"hgnc:HGNC:34994","description":"tRNA-Lys (anticodon TTT) 3-2","metadata":{"aliases":["tRNA-Lys-TTT-3-2","TRNAK34"]}},{"id":"555a530305d548bf92f657ef84a272f6","type":"GENE","name":"TRK-TTT3-3","canonical_id":"hgnc:HGNC:34797","description":"tRNA-Lys (anticodon TTT) 3-3","metadata":{"aliases":["tRNA-Lys-TTT-3-3","TRNAK22","TRK-TTT3-5"]}},{"id":"0f2c1c1832c449168a31211b104a050a","type":"GENE","name":"TRK-TTT3-4","canonical_id":"hgnc:HGNC:33256","description":"tRNA-Lys (anticodon TTT) 3-4","metadata":{"aliases":["tRNA-Lys-TTT-3-4","TRNAK3","TRK-TTT3-3"]}},{"id":"5867b275466846aa91f7d243e5b3e600","type":"GENE","name":"TRK-TTT3-5","canonical_id":"hgnc:HGNC:12314","description":"tRNA-Lys (anticodon TTT) 3-5","metadata":{"aliases":["tRNA-Lys-TTT-3-5","TRK1","TRNAK1","TRK-TTT3-4"]}},{"id":"0b371d908fcf43fb88b8cba88efb2325","type":"GENE","name":"TRK-TTT4-1","canonical_id":"hgnc:HGNC:34612","description":"tRNA-Lys (anticodon TTT) 4-1","metadata":{"aliases":["tRNA-Lys-TTT-4-1","TRNAK8"]}},{"id":"c7d7b8a74dfa422ab7cb9bbdf3b39000","type":"GENE","name":"TRK-TTT5-1","canonical_id":"hgnc:HGNC:34801","description":"tRNA-Lys (anticodon TTT) 5-1","metadata":{"aliases":["tRNA-Lys-TTT-5-1","TRNAK23"]}},{"id":"4dae5d81024d428ca4019fb871df423a","type":"GENE","name":"TRK-TTT6-1","canonical_id":"hgnc:HGNC:34745","description":"tRNA-Lys (anticodon TTT) 6-1","metadata":{"aliases":["tRNA-Lys-TTT-6-1","TRNAK19"]}},{"id":"7774007b52384a3cb591007736320316","type":"GENE","name":"TRK-TTT7-1","canonical_id":"hgnc:HGNC:34900","description":"tRNA-Lys (anticodon TTT) 7-1","metadata":{"aliases":["tRNA-Lys-TTT-7-1","TRNAK29"]}},{"id":"ca63c7ba467248ddab9923600da8606a","type":"GENE","name":"TRK-TTT8-1","canonical_id":"hgnc:HGNC:34659","description":"tRNA-Lys (TTT) 8-1","metadata":{"aliases":["tRNA-Lys-TTT-8-1","TRNAK11"]}},{"id":"778e6ea1e63a4af9ae3939efd8357ed1","type":"GENE","name":"TRK-TTT9-1","canonical_id":"hgnc:HGNC:34958","description":"tRNA-Lys (TTT) 9-1","metadata":{"aliases":["tRNA-Lys-TTT-9-1","TRNAK31"]}},{"id":"c9bc2eaadcc84960aae4274909cc62a5","type":"GENE","name":"TRL-AAG1-1","canonical_id":"hgnc:HGNC:34930","description":"tRNA-Leu (anticodon AAG) 1-1","metadata":{"aliases":["tRNA-Leu-AAG-1-1","TRNAL34"]}},{"id":"e3d054a576eb423899afd83f02282872","type":"GENE","name":"TRL-AAG1-2","canonical_id":"hgnc:HGNC:34836","description":"tRNA-Leu (anticodon AAG) 1-2","metadata":{"aliases":["tRNA-Leu-AAG-1-2","TRNAL24"]}},{"id":"15591a2edf174ee89c9e1d5c33b39f1b","type":"GENE","name":"TRL-AAG1-3","canonical_id":"hgnc:HGNC:34561","description":"tRNA-Leu (anticodon AAG) 1-3","metadata":{"aliases":["tRNA-Leu-AAG-1-3","TRNAL4"]}},{"id":"8e61cbc4744742ffb3500288432b29e6","type":"GENE","name":"TRL-AAG2-1","canonical_id":"hgnc:HGNC:34895","description":"tRNA-Leu (anticodon AAG) 2-1","metadata":{"aliases":["tRNA-Leu-AAG-2-1","TRNAL32","TRL-AAG2-3"]}},{"id":"786c72ba8fe54b5bacf6f0ff84ad5681","type":"GENE","name":"TRL-AAG2-2","canonical_id":"hgnc:HGNC:34765","description":"tRNA-Leu (anticodon AAG) 2-2","metadata":{"aliases":["tRNA-Leu-AAG-2-2","TRNAL20","TRL-AAG2-4"]}},{"id":"6c9f651e2832451896d3414bd916feed","type":"GENE","name":"TRL-AAG2-3","canonical_id":"hgnc:HGNC:12315","description":"tRNA-Leu (anticodon AAG) 2-3","metadata":{"aliases":["tRNA-Leu-AAG-2-3","TRNP1","TRL1","TRNAL1","TRL-AAG2-1"]}},{"id":"de7e9c661a754f8a9f2a5f1961dc3b35","type":"GENE","name":"TRL-AAG2-4","canonical_id":"hgnc:HGNC:34857","description":"tRNA-Leu (anticodon AAG) 2-4","metadata":{"aliases":["tRNA-Leu-AAG-2-4","TRNAL27","TRL-AAG2-2"]}},{"id":"2720f086181f480bb440a2c8c5927fae","type":"GENE","name":"TRL-AAG3-1","canonical_id":"hgnc:HGNC:34731","description":"tRNA-Leu (anticodon AAG) 3-1","metadata":{"aliases":["tRNA-Leu-AAG-3-1","TRNAL17"]}},{"id":"77e8754f189445c7b15d4a08d1ada351","type":"GENE","name":"TRL-AAG4-1","canonical_id":"hgnc:HGNC:34680","description":"tRNA-Leu (anticodon AAG) 4-1","metadata":{"aliases":["tRNA-Leu-AAG-4-1","TRNAL12"]}},{"id":"d27d527749214dcd9806bf9201662ab9","type":"GENE","name":"TRL-AAG5-1","canonical_id":"hgnc:HGNC:34602","description":"tRNA-Leu (AAG) 5-1","metadata":{"aliases":["tRNA-Leu-AAG-5-1","TRNAL9"]}},{"id":"46266ca354624e00ac615fda526f1217","type":"GENE","name":"TRL-AAG6-1","canonical_id":"hgnc:HGNC:34998","description":"tRNA-Leu (anticodon AAG) 6-1","metadata":{"aliases":["tRNA-Leu-AAG-6-1","TRNAL39"]}},{"id":"57815b900f754c47acc954f18975f13a","type":"GENE","name":"TRL-AAG7-1","canonical_id":"hgnc:HGNC:35068","description":"tRNA-Leu (anticodon AAG) 7-1","metadata":{"aliases":["tRNA-Leu-AAG-7-1","TRNAL43P"]}},{"id":"6dc2237704694806934492ee0708f763","type":"GENE","name":"TRL-AAG8-1","canonical_id":"hgnc:HGNC:34917","description":"tRNA-Leu (AAG) 8-1","metadata":{"aliases":["tRNA-Leu-AAG-8-1","TRNAL33"]}},{"id":"c7af54bf331d438a9e978c64439eee7d","type":"GENE","name":"TRL-CAA1-1","canonical_id":"hgnc:HGNC:38583","description":"tRNA-Leu (anticodon CAA) 1-1","metadata":{"aliases":["tRNA-Leu-CAA-1-1","TRNAL49"]}},{"id":"f28ccb96e04148dfa006f3c50deef096","type":"GENE","name":"TRL-CAA1-2","canonical_id":"hgnc:HGNC:34800","description":"tRNA-Leu (anticodon CAA) 1-2","metadata":{"aliases":["tRNA-Leu-CAA-1-2","TRNAL22"]}},{"id":"f2c73fbb4dc04af39468c48988ff1703","type":"GENE","name":"TRL-CAA2-1","canonical_id":"hgnc:HGNC:34867","description":"tRNA-Leu (anticodon CAA) 2-1","metadata":{"aliases":["tRNA-Leu-CAA-2-1","TRNAL28"]}},{"id":"ff3005705db24dd997fd28f7beec3add","type":"GENE","name":"TRL-CAA3-1","canonical_id":"hgnc:HGNC:34597","description":"tRNA-Leu (anticodon CAA) 3-1","metadata":{"aliases":["tRNA-Leu-CAA-3-1","TRNAL8"]}},{"id":"acccf6decc4c49d0ad9b05f64550e21e","type":"GENE","name":"TRL-CAA4-1","canonical_id":"hgnc:HGNC:34762","description":"tRNA-Leu (anticodon CAA) 4-1","metadata":{"aliases":["tRNA-Leu-CAA-4-1","TRNAL19"]}},{"id":"842251149e2844f882e0c1ea7bc0f7cf","type":"GENE","name":"TRL-CAA5-1","canonical_id":"hgnc:HGNC:34938","description":"tRNA-Leu (CAA) 5-1","metadata":{"aliases":["tRNA-Leu-CAA-5-1","TRNAL36"]}},{"id":"03be2e3350714c84818b1077cf7f7ff8","type":"GENE","name":"TRL-CAA6-1","canonical_id":"hgnc:HGNC:34560","description":"tRNA-Leu (anticodon CAA) 6-1","metadata":{"aliases":["tRNA-Leu-CAA-6-1","TRNAL3"]}},{"id":"44964553d3e84721bd26a382c9cda53f","type":"GENE","name":"TRL-CAA7-1","canonical_id":"hgnc:HGNC:35074","description":"tRNA-Leu (CAA) 7-1","metadata":{"aliases":["tRNA-Leu-CAA-7-1","TRNAL44P"]}},{"id":"4f1a69994a994593a2663be6866ace5b","type":"GENE","name":"TRL-CAG1-1","canonical_id":"hgnc:HGNC:34962","description":"tRNA-Leu (anticodon CAG) 1-1","metadata":{"aliases":["tRNA-Leu-CAG-1-1","TRNAL38"]}},{"id":"99fea4181c1c413eae6d202c45a8c6f8","type":"GENE","name":"TRL-CAG1-2","canonical_id":"hgnc:HGNC:34568","description":"tRNA-Leu (anticodon CAG) 1-2","metadata":{"aliases":["tRNA-Leu-CAG-1-2","TRNAL5"]}},{"id":"59ea9bc97594470a93e2540dbeeff50d","type":"GENE","name":"TRL-CAG1-3","canonical_id":"hgnc:HGNC:34883","description":"tRNA-Leu (anticodon CAG) 1-3","metadata":{"aliases":["tRNA-Leu-CAG-1-3","TRNAL30"]}},{"id":"275a82d3eb594fd19bf8b9904b686db9","type":"GENE","name":"TRL-CAG1-4","canonical_id":"hgnc:HGNC:34932","description":"tRNA-Leu (anticodon CAG) 1-4","metadata":{"aliases":["tRNA-Leu-CAG-1-4","TRNAL35"]}},{"id":"a6c87ff792be409e9c26413ad4854913","type":"GENE","name":"TRL-CAG1-5","canonical_id":"hgnc:HGNC:34701","description":"tRNA-Leu (anticodon CAG) 1-5","metadata":{"aliases":["tRNA-Leu-CAG-1-5","TRNAL14"]}},{"id":"53196e98ffc3496684e8807ce4b02a99","type":"GENE","name":"TRL-CAG1-6","canonical_id":"hgnc:HGNC:34577","description":"tRNA-Leu (anticodon CAG) 1-6","metadata":{"aliases":["tRNA-Leu-CAG-1-6","TRNAL6"]}},{"id":"a1a4bf8b4e2846aa8fee65c7f2c33555","type":"GENE","name":"TRL-CAG1-7","canonical_id":"hgnc:HGNC:34854","description":"tRNA-Leu (anticodon CAG) 1-7","metadata":{"aliases":["tRNA-Leu-CAG-1-7","TRNAL26"]}},{"id":"cff00cc2d392450c8de535ad7cdcc09b","type":"GENE","name":"TRL-CAG2-1","canonical_id":"hgnc:HGNC:34692","description":"tRNA-Leu (anticodon CAG) 2-1","metadata":{"aliases":["tRNA-Leu-CAG-2-1","TRNAL13"]}},{"id":"0966655da6e94bab9113079f0ca625ef","type":"GENE","name":"TRL-CAG2-2","canonical_id":"hgnc:HGNC:34649","description":"tRNA-Leu (anticodon CAG) 2-2","metadata":{"aliases":["tRNA-Leu-CAG-2-2","TRNAL11"]}},{"id":"a3d5dc2a6e8c4024a9abe85f0fb18639","type":"GENE","name":"TRL-CAG3-1","canonical_id":"hgnc:HGNC:34767","description":"tRNA-Leu (CAG) 3-1","metadata":{"aliases":["tRNA-Leu-CAG-3-1","TRNAL21"]}},{"id":"f5bc3c3261554bd69e14b339336795af","type":"GENE","name":"TRL-TAA1-1","canonical_id":"hgnc:HGNC:34880","description":"tRNA-Leu (anticodon TAA) 1-1","metadata":{"aliases":["tRNA-Leu-TAA-1-1","TRNAL29"]}},{"id":"2f144ac66b82400382faa8fec9beb4ea","type":"GENE","name":"TRL-TAA2-1","canonical_id":"hgnc:HGNC:34726","description":"tRNA-Leu (anticodon TAA) 2-1","metadata":{"aliases":["tRNA-Leu-TAA-2-1","TRNAL16"]}},{"id":"fa3b5b696a6548dc982641596e2f8018","type":"GENE","name":"TRL-TAA3-1","canonical_id":"hgnc:HGNC:34803","description":"tRNA-Leu (anticodon TAA) 3-1","metadata":{"aliases":["tRNA-Leu-TAA-3-1","TRNAL23"]}},{"id":"0a95bff7c4a846cb909f7a58dea4c814","type":"GENE","name":"TRL-TAA4-1","canonical_id":"hgnc:HGNC:34626","description":"tRNA-Leu (anticodon TAA) 4-1","metadata":{"aliases":["tRNA-Leu-TAA-4-1","TRNAL10"]}},{"id":"9cc8da0812a84807abf8f3cbfd6778d3","type":"GENE","name":"TRL-TAA5-1","canonical_id":"hgnc:HGNC:34737","description":"tRNA-Leu (anticodon TAA) 5-1","metadata":{"aliases":["tRNA-Leu-TAA-5-1","TRNAL18"]}},{"id":"fd82930fc86a47f8bc9a30c8328b7f0b","type":"GENE","name":"TRL-TAG1-1","canonical_id":"hgnc:HGNC:12316","description":"tRNA-Leu (anticodon TAG) 1-1","metadata":{"aliases":["tRNA-Leu-TAG-1-1","TRL2","TRNAL2"]}},{"id":"dc7373be48de403ca29ee25da26d158e","type":"GENE","name":"TRL-TAG2-1","canonical_id":"hgnc:HGNC:34713","description":"tRNA-Leu (anticodon TAG) 2-1","metadata":{"aliases":["tRNA-Leu-TAG-2-1","TRNAL15"]}},{"id":"33ab0084bb6a4c739f555aecff47137a","type":"GENE","name":"TRL-TAG3-1","canonical_id":"hgnc:HGNC:34591","description":"tRNA-Leu (anticodon TAG) 3-1","metadata":{"aliases":["tRNA-Leu-TAG-3-1","TRNAL7"]}},{"id":"9325012f99ff43efa4aa75c9c6b8ca99","type":"GENE","name":"TRL-TAG4-1","canonical_id":"hgnc:HGNC:35011","description":"tRNA-Leu (anticodon TAG) 4-1","metadata":{"aliases":["tRNA-Leu-TAG-4-1","TRNAL40P"]}},{"id":"fec4c231ead043028f1d5d4417519bf3","type":"GENE","name":"TRM-CAT1-1","canonical_id":"hgnc:HGNC:34764","description":"tRNA-Met (anticodon CAT) 1-1","metadata":{"aliases":["tRNA-Met-CAT-1-1","TRNAM11"]}},{"id":"fee3f7202d52409f80a65dd186aedf0b","type":"GENE","name":"TRM-CAT2-1","canonical_id":"hgnc:HGNC:34697","description":"tRNA-Met (anticodon CAT) 2-1","metadata":{"aliases":["tRNA-Met-CAT-2-1","TRNAM9"]}},{"id":"17df1551e3ea4447953d09dac2b529d7","type":"GENE","name":"TRM-CAT3-1","canonical_id":"hgnc:HGNC:34779","description":"tRNA-Met (anticodon CAT) 3-1","metadata":{"aliases":["tRNA-Met-CAT-3-1","TRNAM12"]}},{"id":"8c89ad15243c4660bf1d951c93b530af","type":"GENE","name":"TRM-CAT3-2","canonical_id":"hgnc:HGNC:34673","description":"tRNA-Met (anticodon CAT) 3-2","metadata":{"aliases":["tRNA-Met-CAT-3-2","TRNAM8"]}},{"id":"b8ae26c3003b4094a4e9459c13c8ecf3","type":"GENE","name":"TRM-CAT4-1","canonical_id":"hgnc:HGNC:34661","description":"tRNA-Met (anticodon CAT) 4-1","metadata":{"aliases":["tRNA-Met-CAT-4-1","TRNAM7"]}},{"id":"e750cfaaf387423c9692068210100fc5","type":"GENE","name":"TRM-CAT4-2","canonical_id":"hgnc:HGNC:34922","description":"tRNA-Met (anticodon CAT) 4-2","metadata":{"aliases":["tRNA-Met-CAT-4-2","TRNAM19"]}},{"id":"a57be7fd1f1942ce8e3feb15cc5f0466","type":"GENE","name":"TRM-CAT4-3","canonical_id":"hgnc:HGNC:34959","description":"tRNA-Met (anticodon CAT) 4-3","metadata":{"aliases":["tRNA-Met-CAT-4-3","TRNAM20"]}},{"id":"348baface21644f4901731d758a12326","type":"GENE","name":"TRM-CAT5-1","canonical_id":"hgnc:HGNC:34869","description":"tRNA-Met (anticodon CAT) 5-1","metadata":{"aliases":["tRNA-Met-CAT-5-1","TRNAM16"]}},{"id":"9deda5303fcd4118ac8977c2c17a69f8","type":"GENE","name":"TRM-CAT5-2","canonical_id":"hgnc:HGNC:54713","description":"tRNA-Met (anticodon CAT) 5-2","metadata":{"aliases":["tRNA-Met-CAT-5-2"]}},{"id":"7dedec62d7224598b4d12960fc32eca0","type":"GENE","name":"TRM-CAT6-1","canonical_id":"hgnc:HGNC:34789","description":"tRNA-Met (anticodon CAT) 6-1","metadata":{"aliases":["tRNA-Met-CAT-6-1","TRNAM13"]}},{"id":"a91c064ac85e451a9ff2b641bdce0fa7","type":"GENE","name":"TRM-CAT7-1","canonical_id":"hgnc:HGNC:34645","description":"tRNA-Met (anticodon CAT) 7-1","metadata":{"aliases":["tRNA-Met-CAT-7-1","TRNAM5"]}},{"id":"22d11d0cc47a40509362686cd1f39918","type":"GENE","name":"TRMO","canonical_id":"hgnc:HGNC:30967","description":"tRNA methyltransferase O","metadata":{"aliases":["HSPC219","C9orf156"]}},{"id":"5b78c41dd870428e8e8175787660117a","type":"GENE","name":"TRMT1","canonical_id":"hgnc:HGNC:25980","description":"tRNA methyltransferase 1","metadata":{"aliases":["FLJ20244","TRM1"]}},{"id":"d084fec557dd4077931f50b721854239","type":"GENE","name":"TRMT10A","canonical_id":"hgnc:HGNC:28403","description":"tRNA methyltransferase 10A","metadata":{"aliases":["MGC27034","TRM10","RG9MTD2"]}},{"id":"67514d1fcb3b4a4e98ef2794ee76f2a5","type":"GENE","name":"TRMT10B","canonical_id":"hgnc:HGNC:26454","description":"tRNA methyltransferase 10B","metadata":{"aliases":["FLJ31455","bA3J10.9","RG9MTD3"]}},{"id":"36f8eb3c6c4c4844a37b221ff291725e","type":"GENE","name":"TRMT10BP1","canonical_id":"hgnc:HGNC:52409","description":"tRNA methyltransferase 10B pseudogene 1","metadata":null},{"id":"8ceb8c7f98e848e88e381da00b3ca0ee","type":"GENE","name":"TRMT10C","canonical_id":"hgnc:HGNC:26022","description":"tRNA methyltransferase 10C, mitochondrial RNase P subunit","metadata":{"aliases":["FLJ20432","MRPP1","RG9MTD1"]}},{"id":"41d9fec74c8d454889e95ed13be887e6","type":"GENE","name":"TRMT11","canonical_id":"hgnc:HGNC:21080","description":"tRNA methyltransferase 11","metadata":{"aliases":["MDS024","dJ187J11.2","TRM11","TRMT11-1","C6orf75"]}},{"id":"67c362f627214fdb881add4e7948925e","type":"GENE","name":"TRMT112","canonical_id":"hgnc:HGNC:26940","description":"tRNA methyltransferase activator subunit 11-2","metadata":{"aliases":["HSPC152","HSPC170","TRM112","TRMT11-2","hTrm112"]}},{"id":"53e1f9788b254b7d85091ab2f0559420","type":"GENE","name":"TRMT112P1","canonical_id":"hgnc:HGNC:44020","description":"tRNA methyltransferase subunit 11-2 pseudogene 1","metadata":null},{"id":"ff9421f99704442aa980febe556091fb","type":"GENE","name":"TRMT112P2","canonical_id":"hgnc:HGNC:44021","description":"tRNA methyltransferase subunit 11-2 pseudogene 2","metadata":null},{"id":"8cf0e308d1ee4ad98dd1b293cad0045b","type":"GENE","name":"TRMT112P3","canonical_id":"hgnc:HGNC:44022","description":"tRNA methyltransferase subunit 11-2 pseudogene 3","metadata":null},{"id":"71b0950daf7b4be2b6871a0e86319735","type":"GENE","name":"TRMT112P4","canonical_id":"hgnc:HGNC:44023","description":"tRNA methyltransferase subunit 11-2 pseudogene 4","metadata":null},{"id":"4c454dbcb29a4e9aa54b84ea94e27bfa","type":"GENE","name":"TRMT112P5","canonical_id":"hgnc:HGNC:44024","description":"tRNA methyltransferase subunit 11-2 pseudogene 5","metadata":null},{"id":"3e6b440f09384e4786ba191898c72c8d","type":"GENE","name":"TRMT112P6","canonical_id":"hgnc:HGNC:44025","description":"tRNA methyltransferase subunit 11-2 pseudogene 6","metadata":null},{"id":"835ed44e5bb143659bb2dce587fb9faa","type":"GENE","name":"TRMT112P7","canonical_id":"hgnc:HGNC:44026","description":"tRNA methyltransferase subunit 11-2 pseudogene 7","metadata":null},{"id":"ec75daeaaf95406096e86782f801bffe","type":"GENE","name":"TRMT112P8","canonical_id":"hgnc:HGNC:56991","description":"tRNA methyltransferase subunit 11-2 pseudogene 8","metadata":null},{"id":"6cf7df6d2c7242a9bd6f47cb2dcca215","type":"GENE","name":"TRMT13","canonical_id":"hgnc:HGNC:25502","description":"tRNA methyltransferase 13","metadata":{"aliases":["FLJ10287","FLJ11219","hTrmt13","CCDC76"]}},{"id":"2511d39ea584471da51521541719e7c5","type":"GENE","name":"TRMT1L","canonical_id":"hgnc:HGNC:16782","description":"tRNA methyltransferase 1L","metadata":{"aliases":["C1orf25"]}},{"id":"5e83d55648ab4a46be9ede03eee925c2","type":"GENE","name":"TRMT1P1","canonical_id":"hgnc:HGNC:55145","description":"TRMT1 pseudogene 1","metadata":null},{"id":"145905752d104d2193830ce5fb30c618","type":"GENE","name":"TRMT2A","canonical_id":"hgnc:HGNC:24974","description":"tRNA methyltransferase 2A","metadata":{"aliases":["HTF9C"]}},{"id":"f37fe770c0484490b37e7fdd496f59b1","type":"GENE","name":"TRMT2B","canonical_id":"hgnc:HGNC:25748","description":"tRNA methyltransferase 2B","metadata":{"aliases":["FLJ12687","CXorf34"]}},{"id":"6d11b73111724c4591fca6b1dd8cbf21","type":"GENE","name":"TRMT2B-AS1","canonical_id":"hgnc:HGNC:41116","description":"TRMT2B antisense RNA 1","metadata":null},{"id":"c687cf2ac6114414aa47e22089098b5f","type":"GENE","name":"TRMT44","canonical_id":"hgnc:HGNC:26653","description":"tRNA methyltransferase 44 homolog","metadata":{"aliases":["FLJ35725","TRM44","C4orf23","METTL19"]}},{"id":"2516e04cf3b9489bbd2181d9111bb805","type":"GENE","name":"TRMT44-AS1","canonical_id":"hgnc:HGNC:58729","description":"TRMT44 antisense RNA 1","metadata":null},{"id":"3190c4a510fc4f73a5214fa211833b86","type":"GENE","name":"TRMT5","canonical_id":"hgnc:HGNC:23141","description":"tRNA methyltransferase 5","metadata":{"aliases":["TRM5","KIAA1393"]}},{"id":"9ec247d56e5d4a1ca0ad5c066d375956","type":"GENE","name":"TRMT6","canonical_id":"hgnc:HGNC:20900","description":"tRNA methyltransferase 6 non-catalytic subunit","metadata":{"aliases":["GCD10","MGC5029","Gcd10p","CGI-09"]}},{"id":"61760fc3754d412eb199cec9f40c12b5","type":"GENE","name":"TRMT61A","canonical_id":"hgnc:HGNC:23790","description":"tRNA methyltransferase 61A","metadata":{"aliases":["FLJ40452","GCD14","Gcd14p","hTRM61","C14orf172"]}},{"id":"73b2554f909a440eb879a624641702a4","type":"GENE","name":"TRMT61A-DT","canonical_id":"hgnc:HGNC:56082","description":"TRMT61A divergent transcript","metadata":null},{"id":"4762c068dc84451cbab7f140f2ed16a5","type":"GENE","name":"TRMT61B","canonical_id":"hgnc:HGNC:26070","description":"tRNA methyltransferase 61B","metadata":{"aliases":["FLJ20628"]}},{"id":"1fcf5996a2cc4e5b8b5751b193d58816","type":"GENE","name":"TRMT9B","canonical_id":"hgnc:HGNC:26725","description":"tRNA methyltransferase 9B (putative)","metadata":{"aliases":["FLJ36980","TRM9L","hTRM9L","C8orf79","KIAA1456"]}},{"id":"be8d4ed13e7548889ba627ca3b5f5149","type":"GENE","name":"TRMU","canonical_id":"hgnc:HGNC:25481","description":"tRNA mitochondrial 2-thiouridylase","metadata":{"aliases":["FLJ10140","MTO2","MTU1","TRMT"]}},{"id":"933dad6af9a74dcbb6599f03a7fbef09","type":"GENE","name":"TRN-ATT1-1","canonical_id":"hgnc:HGNC:34887","description":"tRNA-Asn (ATT) 1-1","metadata":{"aliases":["tRNA-Asn-ATT-1-1","TRNAN26"]}},{"id":"e97f8d9863d9442aaf29e55149dcb6ad","type":"GENE","name":"TRN-ATT1-2","canonical_id":"hgnc:HGNC:50812","description":"tRNA-Asn (ATT) 1-2","metadata":{"aliases":["tRNA-Asn-ATT-1-2"]}},{"id":"591ceea62c864f57b3c761c3da2c5cc1","type":"GENE","name":"TRN-GTT1-1","canonical_id":"hgnc:HGNC:34688","description":"tRNA-Asn (anticodon GTT) 1-1","metadata":{"aliases":["tRNA-Asn-GTT-1-1","TRNAN14"]}},{"id":"ad2a4de76a76428186fd5c7c401ddc65","type":"GENE","name":"TRN-GTT10-1","canonical_id":"hgnc:HGNC:35092","description":"tRNA-Asn (anticodon GTT) 10-1","metadata":{"aliases":["tRNA-Asn-GTT-10-1","TRNAN35P","TRNAN35"]}},{"id":"7ca8581a1ded4ad49978ab7588b7713b","type":"GENE","name":"TRN-GTT11-1","canonical_id":"hgnc:HGNC:34669","description":"tRNA-Asn (anticodon GTT) 11-1","metadata":{"aliases":["tRNA-Asn-GTT-11-1","TRNAN13"]}},{"id":"5fe8b3e0cd6e402ab5ffab00e72f143f","type":"GENE","name":"TRN-GTT11-2","canonical_id":"hgnc:HGNC:34820","description":"tRNA-Asn (anticodon GTT) 11-2","metadata":{"aliases":["tRNA-Asn-GTT-11-2","TRNAN22"]}},{"id":"951fc5efeb8945eaa8de62c669c2c82b","type":"GENE","name":"TRN-GTT12-1","canonical_id":"hgnc:HGNC:34924","description":"tRNA-Asn (anticodon GTT) 12-1","metadata":{"aliases":["tRNA-Asn-GTT-12-1","TRNAN29"]}},{"id":"3ebca20072af480080c5bd479c7558b3","type":"GENE","name":"TRN-GTT13-1","canonical_id":"hgnc:HGNC:34746","description":"tRNA-Asn (GTT) 13-1","metadata":{"aliases":["tRNA-Asn-GTT-13-1","TRNAN18"]}},{"id":"fd49a58250e649d0b98aba9f6fc9105f","type":"GENE","name":"TRN-GTT14-1","canonical_id":"hgnc:HGNC:34553","description":"tRNA-Asn (GTT) 14-1","metadata":{"aliases":["tRNA-Asn-GTT-14-1","TRNAN4"]}},{"id":"d91b5789592f4819934a13d53e414c0a","type":"GENE","name":"TRN-GTT15-1","canonical_id":"hgnc:HGNC:34796","description":"tRNA-Asn (GTT) 15-1","metadata":{"aliases":["tRNA-Asn-GTT-15-1","TRNAN21"]}},{"id":"6bbdaef192ee45a4abcfa563624b809b","type":"GENE","name":"TRN-GTT15-2","canonical_id":"hgnc:HGNC:54203","description":"tRNA-Asn (GTT) 15-2","metadata":{"aliases":["tRNA-Asn-GTT-15-2"]}},{"id":"7eb1566226a2402d9c89682d763f48fb","type":"GENE","name":"TRN-GTT16-1","canonical_id":"hgnc:HGNC:34628","description":"tRNA-Asn (GTT) 16-1","metadata":{"aliases":["tRNA-Asn-GTT-16-1","TRNAN9"]}},{"id":"dba3ad5f7e5148079b744ae3c28d40a4","type":"GENE","name":"TRN-GTT16-2","canonical_id":"hgnc:HGNC:34834","description":"tRNA-Asn (GTT) 16-2","metadata":{"aliases":["tRNA-Asn-GTT-16-2","TRNAN24"]}},{"id":"bba1bc4f260041728c93d3d30f058833","type":"GENE","name":"TRN-GTT16-3","canonical_id":"hgnc:HGNC:34639","description":"tRNA-Asn (GTT) 16-3","metadata":{"aliases":["tRNA-Asn-GTT-16-3","TRNAN10"]}},{"id":"ecd8059ae386441da1383c7a00befc29","type":"GENE","name":"TRN-GTT16-4","canonical_id":"hgnc:HGNC:34727","description":"tRNA-Asn (GTT) 16-4","metadata":{"aliases":["tRNA-Asn-GTT-16-4","TRNAN16"]}},{"id":"5952c35c7cbb43359f322a178dc78591","type":"GENE","name":"TRN-GTT16-5","canonical_id":"hgnc:HGNC:34906","description":"tRNA-Asn (anticodon GTT) 16-5","metadata":{"aliases":["tRNA-Asn-GTT-16-5","TRNAN28"]}},{"id":"eee4264010874fb8b7a0f6c2f93f0ce2","type":"GENE","name":"TRN-GTT17-1","canonical_id":"hgnc:HGNC:34657","description":"tRNA-Asn (GTT) 17-1","metadata":{"aliases":["tRNA-Asn-GTT-17-1","TRNAN12"]}},{"id":"fcfa86b217ec48ba94e4f1756ca2c9d8","type":"GENE","name":"TRN-GTT18-1","canonical_id":"hgnc:HGNC:50799","description":"tRNA-Asn (GTT) 18-1","metadata":{"aliases":["tRNA-Asn-GTT-18-1"]}},{"id":"47c2a515d7ef4ac9a1e06e77c638b70d","type":"GENE","name":"TRN-GTT19-1","canonical_id":"hgnc:HGNC:34949","description":"tRNA-Asn (GTT) 19-1","metadata":{"aliases":["tRNA-Asn-GTT-19-1","TRNAN30"]}},{"id":"cec9a3ce810b40298a8b8553b273e400","type":"GENE","name":"TRN-GTT19-2","canonical_id":"hgnc:HGNC:54205","description":"tRNA-Asn (GTT) 19-2","metadata":{"aliases":["tRNA-Asn-GTT-19-2"]}},{"id":"d465842371f74bb6b199194390de2483","type":"GENE","name":"TRN-GTT2-1","canonical_id":"hgnc:HGNC:12324","description":"tRNA-Asn (anticodon GTT) 2-1","metadata":{"aliases":["tRNA-Asn-GTT-2-1","RNN","TRN","TRN1","TRNAN1"]}},{"id":"261ddfe4d8c94900bada607fbdc849ef","type":"GENE","name":"TRN-GTT2-2","canonical_id":"hgnc:HGNC:34971","description":"tRNA-Asn (anticodon GTT) 2-2","metadata":{"aliases":["tRNA-Asn-GTT-2-2","TRNAN32"]}},{"id":"2664a005af044e19855fe8b9436b104b","type":"GENE","name":"TRN-GTT2-3","canonical_id":"hgnc:HGNC:34643","description":"tRNA-Asn (anticodon GTT) 2-3","metadata":{"aliases":["tRNA-Asn-GTT-2-3","TRNAN11"]}},{"id":"f872c28e0125441e899aab440ad7fe8d","type":"GENE","name":"TRN-GTT2-4","canonical_id":"hgnc:HGNC:34595","description":"tRNA-Asn (anticodon GTT) 2-4","metadata":{"aliases":["tRNA-Asn-GTT-2-4","TRNAN7"]}},{"id":"583553b34b6d4487828ffed7471badb8","type":"GENE","name":"TRN-GTT2-5","canonical_id":"hgnc:HGNC:34738","description":"tRNA-Asn (anticodon GTT) 2-5","metadata":{"aliases":["tRNA-Asn-GTT-2-5","TRNAN17"]}},{"id":"b9ac08d417374f1bba46ffabe0c6dc35","type":"GENE","name":"TRN-GTT2-6","canonical_id":"hgnc:HGNC:34758","description":"tRNA-Asn (anticodon GTT) 2-6","metadata":{"aliases":["tRNA-Asn-GTT-2-6","TRNAN20"]}},{"id":"fcfe7a3a61594c2f912ae230aaf6a44b","type":"GENE","name":"TRN-GTT2-7","canonical_id":"hgnc:HGNC:54714","description":"tRNA-Asn (anticodon GTT) 2-7","metadata":{"aliases":["tRNA-Asn-GTT-2-7"]}},{"id":"cbc9b182030a41168d8d6e59fff20af3","type":"GENE","name":"TRN-GTT2-8","canonical_id":"hgnc:HGNC:54715","description":"tRNA-Asn (anticodon GTT) 2-8","metadata":{"aliases":["tRNA-Asn-GTT-2-8"]}},{"id":"fc593ca500a3412bb7785f9d8ef42763","type":"GENE","name":"TRN-GTT20-1","canonical_id":"hgnc:HGNC:34829","description":"tRNA-Asn (GTT) 20-1","metadata":{"aliases":["tRNA-Asn-GTT-20-1","TRNAN23"]}},{"id":"125933208ffa418580e97ac6d9f3808c","type":"GENE","name":"TRN-GTT21-1","canonical_id":"hgnc:HGNC:38584","description":"tRNA-Asn (anticodon GTT) 21-1","metadata":{"aliases":["tRNA-Asn-GTT-21-1","TRNAN38"]}},{"id":"2bd557060961466caa521a23530f09e5","type":"GENE","name":"TRN-GTT22-1","canonical_id":"hgnc:HGNC:35111","description":"tRNA-Asn (anticodon GTT) 22-1","metadata":{"aliases":["tRNA-Asn-GTT-22-1","TRNAN36P"]}},{"id":"50855ddd2fd34513b66fd9a0bded37d8","type":"GENE","name":"TRN-GTT23-1","canonical_id":"hgnc:HGNC:35064","description":"tRNA-Asn (anticodon GTT) 23-1","metadata":{"aliases":["tRNA-Asn-GTT-23-1","TRNAN34P"]}},{"id":"1d10d45660a844e6a1f891d018926d90","type":"GENE","name":"TRN-GTT24-1","canonical_id":"hgnc:HGNC:54716","description":"tRNA-Asn (anticodon GTT) 24-1","metadata":{"aliases":["tRNA-Asn-GTT-24-1"]}},{"id":"dbf28ec5e3c1438d8072fc6e82dfd0b8","type":"GENE","name":"TRN-GTT25-1","canonical_id":"hgnc:HGNC:54717","description":"tRNA-Asn (anticodon GTT) 25-1","metadata":{"aliases":["tRNA-Asn-GTT-25-1"]}},{"id":"1ab7db705caf49daa73315a8b70e5b41","type":"GENE","name":"TRN-GTT26-1","canonical_id":"hgnc:HGNC:54718","description":"tRNA-Asn (anticodon GTT) 26-1","metadata":{"aliases":["tRNA-Asn-GTT-26-1"]}},{"id":"67547afb829648a3a9528dbfc1e6b901","type":"GENE","name":"TRN-GTT27-1","canonical_id":"hgnc:HGNC:54719","description":"tRNA-Asn (anticodon GTT) 27-1","metadata":{"aliases":["tRNA-Asn-GTT-27-1"]}},{"id":"4f6cda4ebe034d75ba367335a6be46e7","type":"GENE","name":"TRN-GTT3-1","canonical_id":"hgnc:HGNC:34890","description":"tRNA-Asn (anticodon GTT) 3-1","metadata":{"aliases":["tRNA-Asn-GTT-3-1","TRNAN27"]}},{"id":"da85c593b34f42b788e9839d8a0b6ea9","type":"GENE","name":"TRN-GTT3-2","canonical_id":"hgnc:HGNC:34689","description":"tRNA-Asn (GTT) 3-2","metadata":{"aliases":["tRNA-Asn-GTT-3-2","TRNAN15"]}},{"id":"8cdc2ed8f2504ab39ad880eaabc65476","type":"GENE","name":"TRN-GTT4-1","canonical_id":"hgnc:HGNC:33197","description":"tRNA-Asn (anticodon GTT) 4-1","metadata":{"aliases":["tRNA-Asn-GTT-4-1","TRN2","TRNAN2"]}},{"id":"8580384d540c41e39761e5fd03b27500","type":"GENE","name":"TRN-GTT5-1","canonical_id":"hgnc:HGNC:38582","description":"tRNA-Asn (anticodon GTT) 5-1","metadata":{"aliases":["tRNA-Asn-GTT-5-1","TRNAN37"]}},{"id":"3846e28f356446d0b1bd94c1ffbbed8d","type":"GENE","name":"TRN-GTT6-1","canonical_id":"hgnc:HGNC:33198","description":"tRNA-Asn (anticodon GTT) 6-1","metadata":{"aliases":["tRNA-Asn-GTT-6-1","TRN3","TRNAN3"]}},{"id":"453ec46c6aa7442eb61aee1af569d1a7","type":"GENE","name":"TRN-GTT7-1","canonical_id":"hgnc:HGNC:34562","description":"tRNA-Asn (anticodon GTT) 7-1","metadata":{"aliases":["tRNA-Asn-GTT-7-1","TRNAN5"]}},{"id":"fa297e766cbc452297f4c8729067c47f","type":"GENE","name":"TRN-GTT8-1","canonical_id":"hgnc:HGNC:34618","description":"tRNA-Asn (anticodon GTT) 8-1","metadata":{"aliases":["tRNA-Asn-GTT-8-1","TRNAN8"]}},{"id":"4e18c43e943f43c49a354cc94f9daf63","type":"GENE","name":"TRN-GTT9-1","canonical_id":"hgnc:HGNC:34870","description":"tRNA-Asn (anticodon GTT) 9-1","metadata":{"aliases":["tRNA-Asn-GTT-9-1","TRNAN25"]}},{"id":"ed1b5c61897044c59cf85c255bb10692","type":"GENE","name":"TRN-GTT9-2","canonical_id":"hgnc:HGNC:34756","description":"tRNA-Asn (anticodon GTT) 9-2","metadata":{"aliases":["tRNA-Asn-GTT-9-2","TRNAN19"]}},{"id":"bd6598caa9744cc28a73f7aca9e7ccf1","type":"GENE","name":"TRNAU1AP","canonical_id":"hgnc:HGNC:30813","description":"tRNA selenocysteine 1 associated protein 1","metadata":{"aliases":["SECP43","FLJ20503","TRSPAP1"]}},{"id":"8514b3253c3749e8adadf60f017b057a","type":"GENE","name":"TRNP1","canonical_id":"hgnc:HGNC:34348","description":"TMF1 regulated nuclear protein 1","metadata":{"aliases":["TRNP","C1orf225"]}},{"id":"b620ffef2fdc46689bcf8369794e51ad","type":"GENE","name":"TRNT1","canonical_id":"hgnc:HGNC:17341","description":"tRNA nucleotidyl transferase 1","metadata":{"aliases":["MtCCA","CGI-47","CCA1"]}},{"id":"6eff22f08043494b9494773ca0ba2521","type":"GENE","name":"TRNT1P1","canonical_id":"hgnc:HGNC:56781","description":"TRNT1 pseudogene 1","metadata":null},{"id":"1042132f7cb84bada1e878620b987c1a","type":"GENE","name":"TRNT1P2","canonical_id":"hgnc:HGNC:56782","description":"TRNT1 pseudogene 2","metadata":null},{"id":"720930f933ce4a368222114f479f3e9d","type":"GENE","name":"TRO","canonical_id":"hgnc:HGNC:12326","description":"trophinin","metadata":{"aliases":["MAGE-D3","KIAA1114","MAGED3"]}},{"id":"729a3c82e5724177a73599aae9d2bb20","type":"GENE","name":"TROAP","canonical_id":"hgnc:HGNC:12327","description":"trophinin associated protein","metadata":{"aliases":["TASTIN"]}},{"id":"fa4dd993dd2a4313993eaa2efc796a61","type":"GENE","name":"TROAP-AS1","canonical_id":"hgnc:HGNC:55453","description":"TROAP and PRPH antisense RNA 1","metadata":null},{"id":"8319dc3d957f4075bc9c61acc60634c1","type":"GENE","name":"TRP-AGG1-1","canonical_id":"hgnc:HGNC:34579","description":"tRNA-Pro (anticodon AGG) 1-1","metadata":{"aliases":["tRNA-Pro-AGG-1-1","TRNAP5"]}},{"id":"80042479759c4f93be3ec0055595ce69","type":"GENE","name":"TRP-AGG2-1","canonical_id":"hgnc:HGNC:34578","description":"tRNA-Pro (anticodon AGG) 2-1","metadata":{"aliases":["tRNA-Pro-AGG-2-1","TRNAP4"]}},{"id":"7f5d36bd13b149189f2108d24cb5a7e5","type":"GENE","name":"TRP-AGG2-2","canonical_id":"hgnc:HGNC:34786","description":"tRNA-Pro (anticodon AGG) 2-2","metadata":{"aliases":["tRNA-Pro-AGG-2-2","TRNAP13","TRP-AGG2-7"]}},{"id":"a80152d6136949c09b07830a1abb02d6","type":"GENE","name":"TRP-AGG2-3","canonical_id":"hgnc:HGNC:34840","description":"tRNA-Pro (anticodon AGG) 2-3","metadata":{"aliases":["tRNA-Pro-AGG-2-3","TRNAP15","TRP-AGG2-8"]}},{"id":"fdef8269da264bdf8a09f3f5c9727115","type":"GENE","name":"TRP-AGG2-4","canonical_id":"hgnc:HGNC:34631","description":"tRNA-Pro (anticodon AGG) 2-4","metadata":{"aliases":["tRNA-Pro-AGG-2-4","TRNAP6","TRP-AGG2-2"]}},{"id":"886a0303762f467ca7e9ab1d454459a6","type":"GENE","name":"TRP-AGG2-5","canonical_id":"hgnc:HGNC:12330","description":"tRNA-Pro (anticodon AGG) 2-5","metadata":{"aliases":["tRNA-Pro-AGG-2-5","TRNP1","TRP1","TRNAP1","TRP-AGG2-3"]}},{"id":"de8ea2dd40c6431d8a3a5d0a18a6e81d","type":"GENE","name":"TRP-AGG2-6","canonical_id":"hgnc:HGNC:12331","description":"tRNA-Pro (anticodon AGG) 2-6","metadata":{"aliases":["tRNA-Pro-AGG-2-6","TRNP1","TRP2","TRNAP2","TRP-AGG2-4"]}},{"id":"5a27fe5a4a69418092541c4cf1daf747","type":"GENE","name":"TRP-AGG2-7","canonical_id":"hgnc:HGNC:34698","description":"tRNA-Pro (anticodon AGG) 2-7","metadata":{"aliases":["tRNA-Pro-AGG-2-7","TRNAP9","TRP-AGG2-5"]}},{"id":"60dbe62745f14dd69ab4f5ca869d914c","type":"GENE","name":"TRP-AGG2-8","canonical_id":"hgnc:HGNC:34862","description":"tRNA-Pro (anticodon AGG) 2-8","metadata":{"aliases":["tRNA-Pro-AGG-2-8","TRNAP18","TRP-AGG2-6"]}},{"id":"dc4495785a154d388d28e5afa75fdd53","type":"GENE","name":"TRP-AGG3-1","canonical_id":"hgnc:HGNC:34929","description":"tRNA-Pro (AGG) 3-1","metadata":{"aliases":["tRNA-Pro-AGG-3-1","TRNAP20"]}},{"id":"24f430300a374d4a80b1fdcee80edeaa","type":"GENE","name":"TRP-AGG4-1","canonical_id":"hgnc:HGNC:35107","description":"tRNA-Pro (anticodon AGG) 4-1","metadata":{"aliases":["tRNA-Pro-AGG-4-1","TRNAP28P"]}},{"id":"4654561c4715410ca076c89af0f0121d","type":"GENE","name":"TRP-AGG5-1","canonical_id":"hgnc:HGNC:35055","description":"tRNA-Pro (anticodon AGG) 5-1","metadata":{"aliases":["tRNA-Pro-AGG-5-1","TRNAP25P"]}},{"id":"59ccea2dfb634c38bcb7b99910ea180c","type":"GENE","name":"TRP-AGG6-1","canonical_id":"hgnc:HGNC:35049","description":"tRNA-Pro (anticodon AGG) 6-1","metadata":{"aliases":["tRNA-Pro-AGG-6-1","TRNAP24P"]}},{"id":"843ab163618a4d45886d0b0ae7fd3e9d","type":"GENE","name":"TRP-CGG1-1","canonical_id":"hgnc:HGNC:34774","description":"tRNA-Pro (anticodon CGG) 1-1","metadata":{"aliases":["tRNA-Pro-CGG-1-1","TRNAP11"]}},{"id":"fdb09e6c992a4144bb157ff5fb63642d","type":"GENE","name":"TRP-CGG1-2","canonical_id":"hgnc:HGNC:34784","description":"tRNA-Pro (anticodon CGG) 1-2","metadata":{"aliases":["tRNA-Pro-CGG-1-2","TRNAP12"]}},{"id":"1a7306fcb0984064b920a7a7adccbf8f","type":"GENE","name":"TRP-CGG1-3","canonical_id":"hgnc:HGNC:34686","description":"tRNA-Pro (anticodon CGG) 1-3","metadata":{"aliases":["tRNA-Pro-CGG-1-3","TRNAP8"]}},{"id":"2a7f593e67204825ae19c5e29a15a385","type":"GENE","name":"TRP-CGG2-1","canonical_id":"hgnc:HGNC:34734","description":"tRNA-Pro (anticodon CGG) 2-1","metadata":{"aliases":["tRNA-Pro-CGG-2-1","TRNAP10"]}},{"id":"e27410b0ade1448e884ccf5533ed9592","type":"GENE","name":"TRP-GGG1-1","canonical_id":"hgnc:HGNC:35026","description":"tRNA-Pro (GGG) 1-1","metadata":{"aliases":["tRNA-Pro-GGG-1-1","TRNAP22P"]}},{"id":"f466577c20234396b3c0958564b7e980","type":"GENE","name":"TRP-TGG1-1","canonical_id":"hgnc:HGNC:34852","description":"tRNA-Pro (anticodon TGG) 1-1","metadata":{"aliases":["tRNA-Pro-TGG-1-1","TRNAP17"]}},{"id":"46d6c8afdd8b4e0d9eb9fac1f774222f","type":"GENE","name":"TRP-TGG2-1","canonical_id":"hgnc:HGNC:34787","description":"tRNA-Pro (anticodon TGG) 2-1","metadata":{"aliases":["tRNA-Pro-TGG-2-1","TRNAP14"]}},{"id":"11300dc0cbac4a50b00d49a3a024f738","type":"GENE","name":"TRP-TGG3-1","canonical_id":"hgnc:HGNC:12332","description":"tRNA-Pro (anticodon TGG) 3-1","metadata":{"aliases":["tRNA-Pro-TGG-3-1","TRP3","TRNAP3","TRP-TGG3-5"]}},{"id":"0e24b1949f8c4d7faab71e09a879e496","type":"GENE","name":"TRP-TGG3-2","canonical_id":"hgnc:HGNC:34648","description":"tRNA-Pro (anticodon TGG) 3-2","metadata":{"aliases":["tRNA-Pro-TGG-3-2","TRNAP7","TRP-TGG3-1"]}},{"id":"c3bf0759c2df4714aa41f8119e43e03e","type":"GENE","name":"TRP-TGG3-3","canonical_id":"hgnc:HGNC:34903","description":"tRNA-Pro (anticodon TGG) 3-3","metadata":{"aliases":["tRNA-Pro-TGG-3-3","TRNAP19","TRP-TGG3-2"]}},{"id":"e2b5ae03d99344dfae84c80ab7b67a50","type":"GENE","name":"TRP-TGG3-4","canonical_id":"hgnc:HGNC:34956","description":"tRNA-Pro (anticodon TGG) 3-4","metadata":{"aliases":["tRNA-Pro-TGG-3-4","TRNAP21","TRP-TGG3-3"]}},{"id":"eede293680ad42698e28bb978374219b","type":"GENE","name":"TRP-TGG3-5","canonical_id":"hgnc:HGNC:34847","description":"tRNA-Pro (anticodon TGG) 3-5","metadata":{"aliases":["tRNA-Pro-TGG-3-5","TRNAP16","TRP-TGG3-4"]}},{"id":"b9e539851ac6457ab90bb51129eb5c56","type":"GENE","name":"TRP-TGG4-1","canonical_id":"hgnc:HGNC:35056","description":"tRNA-Pro (anticodon TGG) 4-1","metadata":{"aliases":["tRNA-Pro-TGG-4-1","TRNAP26P"]}},{"id":"f58e8ed858c847c48cd8485206a811bf","type":"GENE","name":"TRP-TGG5-1","canonical_id":"hgnc:HGNC:35090","description":"tRNA-Pro (anticodon TGG) 5-1","metadata":{"aliases":["tRNA-Pro-TGG-5-1","TRNAP27P"]}},{"id":"921d9fe1c1f34f08af3727e35ee6f961","type":"GENE","name":"TRPA1","canonical_id":"hgnc:HGNC:497","description":"transient receptor potential cation channel subfamily A member 1","metadata":{"aliases":["ANKTM1"]}},{"id":"00edebb6efe3419587f74bcd7dc09e13","type":"PROTEIN","name":"TRPA1","canonical_id":"uniprot:O75762","description":null,"metadata":null},{"id":"063463ae32af455eb8c64ed5244fb5ca","type":"GENE","name":"TRPA2P","canonical_id":"hgnc:HGNC:57045","description":"transient receptor potential cation channel subfamily A member 2, pseudogene","metadata":null},{"id":"e78ef053d4274b0e816a4d081e630e34","type":"GENE","name":"TRPC1","canonical_id":"hgnc:HGNC:12333","description":null,"metadata":null},{"id":"8a491f430dcc4831a8344817b07d2160","type":"GENE","name":"TRPC2","canonical_id":"hgnc:HGNC:12334","description":"transient receptor potential cation channel subfamily C member 2 (pseudogene)","metadata":{"aliases":["TRPC2P"]}},{"id":"00c737b820304a9cb8c04e7949ec0c80","type":"GENE","name":"TRPC3","canonical_id":"hgnc:HGNC:12335","description":"transient receptor potential cation channel subfamily C member 3","metadata":null},{"id":"2612f31ccadf4396ae2e0a5b110867e3","type":"GENE","name":"TRPC3-AS1","canonical_id":"hgnc:HGNC:58881","description":"TRPC3 antisense RNA 1","metadata":null},{"id":"d06075fd361f4e218dd033382a50240c","type":"GENE","name":"TRPC4","canonical_id":"hgnc:HGNC:12336","description":"transient receptor potential cation channel subfamily C member 4","metadata":{"aliases":["HTRP4","TRP4"]}},{"id":"84e3891be8d640678849d3d921945330","type":"GENE","name":"TRPC4AP","canonical_id":"hgnc:HGNC:16181","description":"transient receptor potential cation channel subfamily C member 4 associated protein","metadata":{"aliases":["DKFZP727M231","DKFZp586C1223","dJ756N5.2","TRRP4AP","PPP1R158","C20orf188"]}},{"id":"e2dfe8528bac44f9b7c89b1600a23f2e","type":"GENE","name":"TRPC5","canonical_id":"hgnc:HGNC:12337","description":"transient receptor potential cation channel subfamily C member 5","metadata":{"aliases":["PPP1R159"]}},{"id":"564a65f2325c47668eaaa50dc075b10f","type":"GENE","name":"TRPC5OS","canonical_id":"hgnc:HGNC:40593","description":"TRPC5 opposite strand","metadata":{"aliases":["TRPC5-AS1"]}},{"id":"9ca7c475bbd9471da99be248126923da","type":"GENE","name":"TRPC6","canonical_id":"hgnc:HGNC:12338","description":"transient receptor potential cation channel subfamily C member 6","metadata":{"aliases":["TRP6","FSGS2"]}},{"id":"7a81bae3373542848140220b123b2a7c","type":"GENE","name":"TRPC6P1","canonical_id":"hgnc:HGNC:23270","description":"TRPC6 pseudogene 1","metadata":{"aliases":["TRPC6L","TRPC6P"]}},{"id":"c4a36402acd44600813bea683f2b6ef5","type":"GENE","name":"TRPC6P10","canonical_id":"hgnc:HGNC:55951","description":"TRPC6 pseudogene 10","metadata":null},{"id":"4b77de2c59d147fba1fc11c573ca1a20","type":"GENE","name":"TRPC6P2","canonical_id":"hgnc:HGNC:55943","description":"TRPC6 pseudogene 2","metadata":null},{"id":"ec12d57395a94e62939a390031a77f36","type":"GENE","name":"TRPC6P3","canonical_id":"hgnc:HGNC:55944","description":"TRPC6 pseudogene 3","metadata":null},{"id":"54557d14ae6b412a96f5b3cb7530ec56","type":"GENE","name":"TRPC6P4","canonical_id":"hgnc:HGNC:55945","description":"TRPC6 pseudogene 4","metadata":null},{"id":"8861169a9a7a42baa86956b8fa477043","type":"GENE","name":"TRPC6P5","canonical_id":"hgnc:HGNC:55946","description":"TRPC6 pseudogene 5","metadata":null},{"id":"a4cbbb84da904706b31a1168a897406f","type":"GENE","name":"TRPC6P6","canonical_id":"hgnc:HGNC:55947","description":"TRPC6 pseudogene 6","metadata":null},{"id":"247bb87d11294dcba77f1aa0939ecc45","type":"GENE","name":"TRPC6P7","canonical_id":"hgnc:HGNC:55948","description":"TRPC6 pseudogene 7","metadata":null},{"id":"3804ed7360cc44dda47165262e39a4d2","type":"GENE","name":"TRPC6P8","canonical_id":"hgnc:HGNC:55949","description":"TRPC6 pseudogene 8","metadata":null},{"id":"30c5a621c4d44d229497d4d0cab1e914","type":"GENE","name":"TRPC6P9","canonical_id":"hgnc:HGNC:55950","description":"TRPC6 pseudogene 9","metadata":null},{"id":"64fec648e3b64e20835ed17dd043c3b9","type":"GENE","name":"TRPC7","canonical_id":"hgnc:HGNC:20754","description":"transient receptor potential cation channel subfamily C member 7","metadata":null},{"id":"607415b6875e4863b3183197cffd48c1","type":"GENE","name":"TRPC7-AS1","canonical_id":"hgnc:HGNC:40936","description":"TRPC7 antisense RNA 1","metadata":null},{"id":"5a73794031004bfaa20dfe159eecada3","type":"GENE","name":"TRPC7-AS2","canonical_id":"hgnc:HGNC:40937","description":"TRPC7 antisense RNA 2","metadata":null},{"id":"291ad93578e047f482a2858cadcb7d41","type":"GENE","name":"TRPM1","canonical_id":"hgnc:HGNC:7146","description":null,"metadata":null},{"id":"b639d04dd8a54f01bbc5722458bf0c9b","type":"GENE","name":"TRPM1-AS1","canonical_id":"hgnc:HGNC:58477","description":"TRPM1 antisense RNA 1","metadata":null},{"id":"8a5321a0598f4d1d9cd36efa4c8336da","type":"GENE","name":"TRPM2","canonical_id":"hgnc:HGNC:12339","description":"transient receptor potential cation channel subfamily M member 2","metadata":{"aliases":["KNP3","LTRPC2","NUDT9L1","NUDT9H","EREG1","TRPC7"]}},{"id":"3aa83b3d1a4a441f96481d96b67e0ebc","type":"GENE","name":"TRPM2-AS","canonical_id":"hgnc:HGNC:50758","description":"TRPM2 antisense RNA","metadata":{"aliases":["TRPM2-AS1"]}},{"id":"c18cdcd21f484c65ad3723f1d1963fc9","type":"GENE","name":"TRPM3","canonical_id":"hgnc:HGNC:17992","description":"transient receptor potential cation channel subfamily M member 3","metadata":{"aliases":["KIAA1616","LTRPC3","GON-2"]}},{"id":"d84b612c8709446c92f2ef465118be56","type":"GENE","name":"TRPM4","canonical_id":"hgnc:HGNC:17993","description":"transient receptor potential cation channel subfamily M member 4","metadata":{"aliases":["FLJ20041"]}},{"id":"4ce838b040294e1ca3d3bd542232ad6f","type":"GENE","name":"TRPM5","canonical_id":"hgnc:HGNC:14323","description":"transient receptor potential cation channel subfamily M member 5","metadata":{"aliases":["LTRPC5","MTR1"]}},{"id":"64de859a44304a989b7105f51131eab0","type":"GENE","name":"TRPM6","canonical_id":"hgnc:HGNC:17995","description":"transient receptor potential cation channel subfamily M member 6","metadata":{"aliases":["CHAK2","FLJ22628","HOMG","HSH"]}},{"id":"3b05a42dd70e4f0da722e7b7a6e2df4b","type":"GENE","name":"TRPM7","canonical_id":"hgnc:HGNC:17994","description":"transient receptor potential cation channel subfamily M member 7","metadata":{"aliases":["CHAK1","LTRPC7","TRP-PLIK"]}},{"id":"7da0ee2d8d73422f8c3722db4e9355df","type":"GENE","name":"TRPM8","canonical_id":"hgnc:HGNC:17961","description":"transient receptor potential cation channel subfamily M member 8","metadata":null},{"id":"3782966bda7c4ccab4a4714699647fdd","type":"PROTEIN","name":"TRPM8","canonical_id":"uniprot:Q7Z2W7","description":null,"metadata":null},{"id":"544c1f7c0e144df08bb7d7d2176d2a66","type":"GENE","name":"TRPS1","canonical_id":"hgnc:HGNC:12340","description":null,"metadata":null},{"id":"82044e212fe6418b84c91ee43f2fa528","type":"GENE","name":"TRPS1-AS1","canonical_id":"hgnc:HGNC:56224","description":"TRPS1 antisense RNA 1","metadata":{"aliases":["AF178030.2"]}},{"id":"15b5596614e449f5b6c4b98614072e7b","type":"GENE","name":"TRPT1","canonical_id":"hgnc:HGNC:20316","description":"tRNA phosphotransferase 1","metadata":{"aliases":["MGC11134"]}},{"id":"7a69c46cfe1b455ea51c3cc09f2d63e9","type":"GENE","name":"TRPV1","canonical_id":"hgnc:HGNC:12716","description":"transient receptor potential cation channel subfamily V member 1","metadata":{"aliases":["VR1"]}},{"id":"f6d6205ff2d24159a79398c30841f45c","type":"PROTEIN","name":"TRPV1","canonical_id":"uniprot:Q8NER1","description":null,"metadata":null},{"id":"180ef01278fa43018f76e6170e8bd963","type":"GENE","name":"TRPV2","canonical_id":"hgnc:HGNC:18082","description":"transient receptor potential cation channel subfamily V member 2","metadata":{"aliases":["VRL","VRL-1","VRL1"]}},{"id":"52fc1b14d063454c8d0d67f403641675","type":"TRIAL","name":"TRPV2 Agonists in the Fontan Circulation","canonical_id":"clinicaltrials.gov:NCT03965351","description":"Fontan","metadata":null},{"id":"cad1f28cb6f24a86a067fc89be889165","type":"GENE","name":"TRPV3","canonical_id":"hgnc:HGNC:18084","description":"transient receptor potential cation channel subfamily V member 3","metadata":{"aliases":["VRL3"]}},{"id":"dac7f594d1f544c881e539802f148c66","type":"GENE","name":"TRPV4","canonical_id":"hgnc:HGNC:18083","description":"transient receptor potential cation channel subfamily V member 4","metadata":{"aliases":["OTRPC4","TRP12","VROAC","VRL-2","VR-OAC","CMT2C"]}},{"id":"eac281794b46463ab1dafb3b4990f3a8","type":"GENE","name":"TRPV5","canonical_id":"hgnc:HGNC:3145","description":"transient receptor potential cation channel subfamily V member 5","metadata":{"aliases":["CaT2","ECAC1"]}},{"id":"e5ec0c92f6d44be685f3831bbd6726af","type":"GENE","name":"TRPV6","canonical_id":"hgnc:HGNC:14006","description":null,"metadata":null},{"id":"8c45a7c2a5174858b78b1d079dd13bb2","type":"GENE","name":"TRQ-CTG1-1","canonical_id":"hgnc:HGNC:34853","description":"tRNA-Gln (anticodon CTG) 1-1","metadata":{"aliases":["tRNA-Gln-CTG-1-1","TRNAQ22","TRQ-CTG1-3"]}},{"id":"9b20ef0f46dd47c89e3e889b0573d163","type":"GENE","name":"TRQ-CTG1-2","canonical_id":"hgnc:HGNC:34752","description":"tRNA-Gln (anticodon CTG) 1-2","metadata":{"aliases":["tRNA-Gln-CTG-1-2","TRNAQ16","TRQ-CTG1-4"]}},{"id":"b4aae080148f4c1ab7bd06b697173b1e","type":"GENE","name":"TRQ-CTG1-3","canonical_id":"hgnc:HGNC:34683","description":"tRNA-Gln (anticodon CTG) 1-3","metadata":{"aliases":["tRNA-Gln-CTG-1-3","TRNAQ11","TRQ-CTG1-5"]}},{"id":"c0767c24f8da4930aaf7cf40675b5a7f","type":"GENE","name":"TRQ-CTG1-4","canonical_id":"hgnc:HGNC:34884","description":"tRNA-Gln (anticodon CTG) 1-4","metadata":{"aliases":["tRNA-Gln-CTG-1-4","TRNAQ24","TRQ-CTG1-1"]}},{"id":"50df2b5a2a8a4c2e8e7b439a647acfa6","type":"GENE","name":"TRQ-CTG1-5","canonical_id":"hgnc:HGNC:12341","description":"tRNA-Gln (anticodon CTG) 1-5","metadata":{"aliases":["tRNA-Gln-CTG-1-5","TRQ1","TRNAQ1","TRQ-CTG1-2"]}},{"id":"a4a17b6daae344f7bc752a0b75ba5432","type":"GENE","name":"TRQ-CTG10-1","canonical_id":"hgnc:HGNC:34889","description":"tRNA-Gln (CTG) 10-1","metadata":{"aliases":["tRNA-Gln-CTG-10-1","TRNAQ26"]}},{"id":"ea6d07e80fb24c5e8361f0849bc6a6e2","type":"GENE","name":"TRQ-CTG11-1","canonical_id":"hgnc:HGNC:35023","description":"tRNA-Gln (anticodon CTG) 11-1","metadata":{"aliases":["tRNA-Gln-CTG-11-1","TRNAQ37P"]}},{"id":"914c338dd8bd4eb0815dcd91e8e95759","type":"GENE","name":"TRQ-CTG12-1","canonical_id":"hgnc:HGNC:34957","description":"tRNA-Gln (anticodon CTG) 12-1","metadata":{"aliases":["tRNA-Gln-CTG-12-1","TRNAQ30"]}},{"id":"2b2c7c7aae5d49918d21ad2d0557c2bf","type":"GENE","name":"TRQ-CTG13-1","canonical_id":"hgnc:HGNC:35115","description":"tRNA-Gln (anticodon CTG) 13-1","metadata":{"aliases":["tRNA-Gln-CTG-13-1","TRNAQ53P"]}},{"id":"1f3188865d9a45959b3db3be4208c592","type":"GENE","name":"TRQ-CTG14-1","canonical_id":"hgnc:HGNC:38574","description":"tRNA-Gln (anticodon CTG) 14-1","metadata":{"aliases":["tRNA-Gln-CTG-14-1","TRNAQ55"]}},{"id":"3b790004c57d4ac4ac7e62fe74065a34","type":"GENE","name":"TRQ-CTG15-1","canonical_id":"hgnc:HGNC:34575","description":"tRNA-Gln (anticodon CTG) 15-1","metadata":{"aliases":["tRNA-Gln-CTG-15-1","TRNAQ6"]}},{"id":"dbc9c501fa0440798287ed289b02d122","type":"GENE","name":"TRQ-CTG16-1","canonical_id":"hgnc:HGNC:35078","description":"tRNA-Gln (anticodon CTG) 16-1","metadata":{"aliases":["tRNA-Gln-CTG-16-1","TRNAQ44P"]}},{"id":"4c59a743acec48b39d2a3e051ddc2c9d","type":"GENE","name":"TRQ-CTG17-1","canonical_id":"hgnc:HGNC:34868","description":"tRNA-Gln (anticodon CTG) 17-1","metadata":{"aliases":["tRNA-Gln-CTG-17-1","TRNAQ23"]}},{"id":"c84b3ad99e324c6495f7675367b6d532","type":"GENE","name":"TRQ-CTG18-1","canonical_id":"hgnc:HGNC:34919","description":"tRNA-Gln (anticodon CTG) 18-1","metadata":{"aliases":["tRNA-Gln-CTG-18","TRNAQ28"]}},{"id":"631890344a414cce8b69fb07c75bdee3","type":"GENE","name":"TRQ-CTG2-1","canonical_id":"hgnc:HGNC:34831","description":"tRNA-Gln (anticodon CTG) 2-1","metadata":{"aliases":["tRNA-Gln-CTG-2-1","TRNAQ21"]}},{"id":"8e4dc2f6cdf540db989c2076853802b9","type":"GENE","name":"TRQ-CTG3-1","canonical_id":"hgnc:HGNC:34954","description":"tRNA-Gln (anticodon CTG) 3-1","metadata":{"aliases":["tRNA-Gln-CTG-3-1","TRNAQ29"]}},{"id":"32f6afb0217f4f0abbced9e862e017bd","type":"GENE","name":"TRQ-CTG3-2","canonical_id":"hgnc:HGNC:34702","description":"tRNA-Gln (anticodon CTG) 3-2","metadata":{"aliases":["tRNA-Gln-CTG-3-2","TRNAQ13"]}},{"id":"9262c5894713499888ccaabb667692e9","type":"GENE","name":"TRQ-CTG4-1","canonical_id":"hgnc:HGNC:34615","description":"tRNA-Gln (anticodon CTG) 4-1","metadata":{"aliases":["tRNA-Gln-CTG-4-1","TRNAQ8"]}},{"id":"7a4eaa12228e4622a5dbe7323e1d85c4","type":"GENE","name":"TRQ-CTG4-2","canonical_id":"hgnc:HGNC:34824","description":"tRNA-Gln (anticodon CTG) 4-2","metadata":{"aliases":["tRNA-Gln-CTG-4-2","TRNAQ20"]}},{"id":"0401cde404304018a08c2fa2fa06fd52","type":"GENE","name":"TRQ-CTG5-1","canonical_id":"hgnc:HGNC:34896","description":"tRNA-Gln (anticodon CTG) 5-1","metadata":{"aliases":["tRNA-Gln-CTG-5-1","TRNAQ27"]}},{"id":"5a66464e98ec4ccd87a4fd57a633ca16","type":"GENE","name":"TRQ-CTG6-1","canonical_id":"hgnc:HGNC:34777","description":"tRNA-Gln (anticodon CTG) 6-1","metadata":{"aliases":["tRNA-Gln-CTG-6-1","TRNAQ17"]}},{"id":"44c442905a93474ca6a09cb55ebe40fc","type":"GENE","name":"TRQ-CTG7-1","canonical_id":"hgnc:HGNC:34555","description":"tRNA-Gln (anticodon CTG) 7-1","metadata":{"aliases":["tRNA-Gln-CTG-7-1","TRNAQ3"]}},{"id":"ceaad4cfa6d44434b3ea8a0a9005dac3","type":"GENE","name":"TRQ-CTG8-1","canonical_id":"hgnc:HGNC:34780","description":"tRNA-Gln (CTG) 8-1","metadata":{"aliases":["tRNA-Gln-CTG-8-1","TRNAQ19"]}},{"id":"476d2977e3f74650af2b7292db576fe9","type":"GENE","name":"TRQ-CTG8-2","canonical_id":"hgnc:HGNC:34716","description":"tRNA-Gln (CTG) 8-2","metadata":{"aliases":["tRNA-Gln-CTG-8-2","TRNAQ14"]}},{"id":"7d4ec0b8510f4377b6156e879e69f7fd","type":"GENE","name":"TRQ-CTG8-3","canonical_id":"hgnc:HGNC:54206","description":"tRNA-Gln (CTG) 8-3","metadata":{"aliases":["tRNA-Gln-CTG-8-3"]}},{"id":"a40774e1ebb34c2ead9ddc1a41bf1d29","type":"GENE","name":"TRQ-CTG9-1","canonical_id":"hgnc:HGNC:35108","description":"tRNA-Gln (anticodon CTG) 9-1","metadata":{"aliases":["tRNA-Gln-CTG-9-1","TRNAQ51P"]}},{"id":"26f3e27f1f204902bdb343742d0f0d50","type":"GENE","name":"TRQ-TTG1-1","canonical_id":"hgnc:HGNC:12342","description":"tRNA-Gln (anticodon TTG) 1-1","metadata":{"aliases":["tRNA-Gln-TTG-1-1","TRQ2","TRNAQ2"]}},{"id":"38890e2f3ee3443e80505839a4e8848a","type":"GENE","name":"TRQ-TTG10-1","canonical_id":"hgnc:HGNC:34569","description":"tRNA-Gln (anticodon TTG) 10-1","metadata":{"aliases":["tRNA-Gln-TTG-10-1","TRNAQ5"]}},{"id":"c618c967d5824a479ec2c4455fcfdc51","type":"GENE","name":"TRQ-TTG2-1","canonical_id":"hgnc:HGNC:34700","description":"tRNA-Gln (anticodon TTG) 2-1","metadata":{"aliases":["tRNA-Gln-TTG-2-1","TRNAQ12"]}},{"id":"b55153e4559f4cb2b7a582b12a51063a","type":"GENE","name":"TRQ-TTG3-1","canonical_id":"hgnc:HGNC:34888","description":"tRNA-Gln (anticodon TTG) 3-1","metadata":{"aliases":["tRNA-Gln-TTG-3-1","TRNAQ25"]}},{"id":"991d566ffd444933b77849e95ccd9eac","type":"GENE","name":"TRQ-TTG3-2","canonical_id":"hgnc:HGNC:34748","description":"tRNA-Gln (anticodon TTG) 3-2","metadata":{"aliases":["tRNA-Gln-TTG-3-2","TRNAQ15"]}},{"id":"e653ae1f37274317bdebfac5ac94c422","type":"GENE","name":"TRQ-TTG3-3","canonical_id":"hgnc:HGNC:34633","description":"tRNA-Gln (anticodon TTG) 3-3","metadata":{"aliases":["tRNA-Gln-TTG-3-3","TRNAQ10"]}},{"id":"d69f69602b604e95a6eb13bc9d2213da","type":"GENE","name":"TRQ-TTG4-1","canonical_id":"hgnc:HGNC:34991","description":"tRNA-Gln (anticodon TTG) 4-1","metadata":{"aliases":["tRNA-Gln-TTG-4-1","TRNAQ32"]}},{"id":"573fac7b362a4935ad4b99d83e2050ba","type":"GENE","name":"TRQ-TTG5-1","canonical_id":"hgnc:HGNC:35046","description":"tRNA-Gln (anticodon TTG) 5-1","metadata":{"aliases":["tRNA-Gln-TTG-5-1","TRNAQ39P"]}},{"id":"166b85d9e91547eda60cde758f36a984","type":"GENE","name":"TRQ-TTG6-1","canonical_id":"hgnc:HGNC:34585","description":"tRNA-Gln (anticodon TTG) 6-1","metadata":{"aliases":["tRNA-Gln-TTG-6-1","TRNAQ7"]}},{"id":"317be254d6be4e568db62e11547182c0","type":"GENE","name":"TRQ-TTG7-1","canonical_id":"hgnc:HGNC:35014","description":"tRNA-Gln (anticodon TTG) 7-1","metadata":{"aliases":["tRNA-Gln-TTG-7-1","TRNAQ33P"]}},{"id":"9ed035b50903497c9b807cfff3674e30","type":"GENE","name":"TRQ-TTG8-1","canonical_id":"hgnc:HGNC:35080","description":"tRNA-Gln (anticodon TTG) 8-1","metadata":{"aliases":["tRNA-Gln-TTG-8-1","TRNAQ45P"]}},{"id":"45f945a255e7423b8d36703f92cfdc15","type":"GENE","name":"TRQ-TTG9-1","canonical_id":"hgnc:HGNC:35084","description":"tRNA-Gln (anticodon TTG) 9-1","metadata":{"aliases":["tRNA-Gln-TTG-9-1","TRNAQ46P"]}},{"id":"c957ddcd266c4d56a1a779e0a38f6ac3","type":"GENE","name":"TRR-ACG1-1","canonical_id":"hgnc:HGNC:34964","description":"tRNA-Arg (anticodon ACG) 1-1","metadata":{"aliases":["tRNA-Arg-ACG-1-1","TRNAR26","TRR-ACG1-2"]}},{"id":"f531de396c794656986af74b76cad270","type":"GENE","name":"TRR-ACG1-2","canonical_id":"hgnc:HGNC:12344","description":"tRNA-Arg (anticodon ACG) 1-2","metadata":{"aliases":["tRNA-Arg-ACG-1-2","TRR2","TRNAR2","TRR-ACG1-3"]}},{"id":"d98c50ed7a904b62a3b06eaa569d370f","type":"GENE","name":"TRR-ACG1-3","canonical_id":"hgnc:HGNC:34806","description":"tRNA-Arg (anticodon ACG) 1-3","metadata":{"aliases":["tRNA-Arg-ACG-1-3","TRNAR21","TRR-ACG1-1"]}},{"id":"c4ffd61bfaac460b8ca74220d774ab69","type":"GENE","name":"TRR-ACG2-1","canonical_id":"hgnc:HGNC:34664","description":"tRNA-Arg (anticodon ACG) 2-1","metadata":{"aliases":["tRNA-Arg-ACG-2-1","TRNAR11"]}},{"id":"5f97a9bb01b04927805675a15e56ef97","type":"GENE","name":"TRR-ACG2-2","canonical_id":"hgnc:HGNC:34729","description":"tRNA-Arg (anticodon ACG) 2-2","metadata":{"aliases":["tRNA-Arg-ACG-2-2","TRNAR17"]}},{"id":"d3fd54bfe7614ff980b61bc6c7579e1f","type":"GENE","name":"TRR-ACG2-3","canonical_id":"hgnc:HGNC:34660","description":"tRNA-Arg (anticodon ACG) 2-3","metadata":{"aliases":["tRNA-Arg-ACG-2-3","TRNAR10"]}},{"id":"272052669d9f48d7a43116ab7aa049fa","type":"GENE","name":"TRR-ACG2-4","canonical_id":"hgnc:HGNC:34997","description":"tRNA-Arg (anticodon ACG) 2-4","metadata":{"aliases":["tRNA-Arg-ACG-2-4","TRNAR29"]}},{"id":"11a756d086ad486daf87fd1903659e9b","type":"GENE","name":"TRR-CCG1-1","canonical_id":"hgnc:HGNC:34933","description":"tRNA-Arg (anticodon CCG) 1-1","metadata":{"aliases":["tRNA-Arg-CCG-1-1","TRNAR24","TRR-CCG1-2"]}},{"id":"c016365531f5465eb0d6ac759a179c77","type":"GENE","name":"TRR-CCG1-2","canonical_id":"hgnc:HGNC:34644","description":"tRNA-Arg (anticodon CCG) 1-2","metadata":{"aliases":["tRNA-Arg-CCG-1-2","TRNAR9","TRR-CCG1-3"]}},{"id":"67c201d57a5d49ee82699962ab36ab5c","type":"GENE","name":"TRR-CCG1-3","canonical_id":"hgnc:HGNC:34735","description":"tRNA-Arg (anticodon CCG) 1-3","metadata":{"aliases":["tRNA-Arg-CCG-1-3","TRNAR19","TRR-CCG1-1"]}},{"id":"68b5aa25427a4eb7b3b29a69d0d3867f","type":"GENE","name":"TRR-CCG2-1","canonical_id":"hgnc:HGNC:12346","description":"tRNA-Arg (anticodon CCG) 2-1","metadata":{"aliases":["tRNA-Arg-CCG-2-1","TRR4","TRNAR4"]}},{"id":"59ea40e32f0340f1a491d3a2ec5e348d","type":"GENE","name":"TRR-CCT1-1","canonical_id":"hgnc:HGNC:34638","description":"tRNA-Arg (anticodon CCT) 1-1","metadata":{"aliases":["tRNA-Arg-CCT-1-1","TRNAR8"]}},{"id":"cb0478ce94c3420ea5116556329e7edb","type":"GENE","name":"TRR-CCT2-1","canonical_id":"hgnc:HGNC:34744","description":"tRNA-Arg (anticodon CCT) 2-1","metadata":{"aliases":["tRNA-Arg-CCT-2-1","TRNAR20"]}},{"id":"68c5e2ce893e43d4a7654344b002a018","type":"GENE","name":"TRR-CCT3-1","canonical_id":"hgnc:HGNC:34730","description":"tRNA-Arg (anticodon CCT) 3-1","metadata":{"aliases":["tRNA-Arg-CCT-3-1","TRNAR18"]}},{"id":"7ea80f17b4444383909f26e165594833","type":"GENE","name":"TRR-CCT4-1","canonical_id":"hgnc:HGNC:34975","description":"tRNA-Arg (anticodon CCT) 4-1","metadata":{"aliases":["tRNA-Arg-CCT-4-1","TRNAR27"]}},{"id":"902287cc920a407fbf23940518b9ac66","type":"GENE","name":"TRR-CCT5-1","canonical_id":"hgnc:HGNC:34833","description":"tRNA-Arg (anticodon CCT) 5-1","metadata":{"aliases":["tRNA-Arg-CCT-5-1","TRNAR23"]}},{"id":"58d4f0df156e49bdbf77fc8b5f6bec70","type":"GENE","name":"TRR-CCT6-1","canonical_id":"hgnc:HGNC:35096","description":"tRNA-Arg (anticodon CCT) 6-1","metadata":{"aliases":["tRNA-Arg-CCT-6-1","TRNAR33P"]}},{"id":"8f07afdb7eee46b4a237db0fba277ebe","type":"GENE","name":"TRR-CCT6-2","canonical_id":"hgnc:HGNC:35019","description":"tRNA-Arg (anticodon CCT) 6-2","metadata":{"aliases":["tRNA-Arg-CCT-6-2","TRNAR31P"]}},{"id":"aec19f9a4e8d489ca77d8422c2e4d944","type":"GENE","name":"TRR-CCT7-1","canonical_id":"hgnc:HGNC:35013","description":"tRNA-Arg (anticodon CCT) 7-1","metadata":{"aliases":["tRNA-Arg-CCT-7-1","TRNAR30P"]}},{"id":"7bb970e0886d43bf9ea37a1d062e3000","type":"GENE","name":"TRR-CCT8-1","canonical_id":"hgnc:HGNC:35077","description":"tRNA-Arg (anticodon CCT) 8-1","metadata":{"aliases":["tRNA-Arg-CCT-8-1","TRNAR32P"]}},{"id":"617363e4cd2d44caa5a124c55b622366","type":"GENE","name":"TRR-CCT9-1","canonical_id":"hgnc:HGNC:35114","description":"tRNA-Arg (anticodon CCT) 9-1","metadata":{"aliases":["tRNA-Arg-CCT-9-1","TRNAR34P"]}},{"id":"8911669f4e474e86a49714e92da878e9","type":"GENE","name":"TRR-TCG1-1","canonical_id":"hgnc:HGNC:34827","description":"tRNA-Arg (anticodon TCG) 1-1","metadata":{"aliases":["tRNA-Arg-TCG-1-1","TRNAR22"]}},{"id":"9a4397ef1ce64653aba8e69833ccb0f4","type":"GENE","name":"TRR-TCG2-1","canonical_id":"hgnc:HGNC:34979","description":"tRNA-Arg (anticodon TCG) 2-1","metadata":{"aliases":["tRNA-Arg-TCG-2-1","TRNAR28"]}},{"id":"7906839896da4c13b7be13a3708b174c","type":"GENE","name":"TRR-TCG3-1","canonical_id":"hgnc:HGNC:34939","description":"tRNA-Arg (anticodon TCG) 3-1","metadata":{"aliases":["tRNA-Arg-TCG-3-1","TRNAR25"]}},{"id":"97ee4f88c8b9482893c3758d62c9768c","type":"GENE","name":"TRR-TCG4-1","canonical_id":"hgnc:HGNC:12345","description":"tRNA-Arg (anticodon TCG) 4-1","metadata":{"aliases":["tRNA-Arg-TCG-4-1","TRR3","TRNAR3"]}},{"id":"917f675731fa4751a333933fe9f6a9da","type":"GENE","name":"TRR-TCG5-1","canonical_id":"hgnc:HGNC:34593","description":"tRNA-Arg (anticodon TCG) 5-1","metadata":{"aliases":["tRNA-Arg-TCG-5-1","TRNAR7"]}},{"id":"4da6a169be964ea097b81016a3121dd1","type":"GENE","name":"TRR-TCG6-1","canonical_id":"hgnc:HGNC:34584","description":"tRNA-Arg (anticodon TCG) 6-1","metadata":{"aliases":["tRNA-Arg-TCG-6-1","TRNAR6"]}},{"id":"7e69d15e4a6d4b788901912e0f648733","type":"GENE","name":"TRR-TCT1-1","canonical_id":"hgnc:HGNC:34695","description":"tRNA-Arg (anticodon TCT) 1-1","metadata":{"aliases":["tRNA-Arg-TCT-1-1","TRNAR15"]}},{"id":"fc57d1b98d5d4cb98af8de237db33981","type":"GENE","name":"TRR-TCT2-1","canonical_id":"hgnc:HGNC:12343","description":"tRNA-Arg (anticodon TCT) 2-1","metadata":{"aliases":["tRNA-Arg-TCT-2-1","TRR1","TRNAR1"]}},{"id":"039fe2d9ccbe45b0b1578bb63b36c213","type":"GENE","name":"TRR-TCT3-1","canonical_id":"hgnc:HGNC:34670","description":"tRNA-Arg (anticodon TCT) 3-1","metadata":{"aliases":["tRNA-Arg-TCT-3-1","TRNAR12","TRR-TCT3-2"]}},{"id":"94648aa3368949b881075be592f775b6","type":"GENE","name":"TRR-TCT3-2","canonical_id":"hgnc:HGNC:34677","description":"tRNA-Arg (anticodon TCT) 3-2","metadata":{"aliases":["tRNA-Arg-TCT-3-2","TRNAR14","TRR-TCT3-1"]}},{"id":"293e159fa7354345ab2923fe4cbf327b","type":"GENE","name":"TRR-TCT4-1","canonical_id":"hgnc:HGNC:34728","description":"tRNA-Arg (anticodon TCT) 4-1","metadata":{"aliases":["tRNA-Arg-TCT-4-1","TRNAR16"]}},{"id":"2bbb672d15da48d39625acf7579e1cab","type":"GENE","name":"TRR-TCT5-1","canonical_id":"hgnc:HGNC:34571","description":"tRNA-Arg (anticodon TCT) 5-1","metadata":{"aliases":["tRNA-Arg-TCT-5-1","TRNAR5"]}},{"id":"8bcc380fa1a04ff997dd68d4cf9bc6a7","type":"GENE","name":"TRRAP","canonical_id":"hgnc:HGNC:12347","description":null,"metadata":null},{"id":"0a7c50e337fc48b3aaa94ed55befbe31","type":"GENE","name":"TRS-ACT1-1","canonical_id":"hgnc:HGNC:35102","description":"tRNA-Ser (anticodon ACT) 1-1","metadata":{"aliases":["tRNA-Ser-ACT-1-1","TRNAS32P"]}},{"id":"c7f104758df24167868a79062fd6aeb4","type":"GENE","name":"TRS-AGA1-1","canonical_id":"hgnc:HGNC:34920","description":"tRNA-Ser (anticodon AGA) 1-1","metadata":{"aliases":["tRNA-Ser-AGA-1-1","TRNAS24"]}},{"id":"fb3dbf5c6826436899e22cd4005985c5","type":"GENE","name":"TRS-AGA2-1","canonical_id":"hgnc:HGNC:34950","description":"tRNA-Ser (anticodon AGA) 2-1","metadata":{"aliases":["tRNA-Ser-AGA-2-1","TRNAS25","TRS-AGA2-2"]}},{"id":"3154d92f800d4ce9a2e5095ef64373aa","type":"GENE","name":"TRS-AGA2-2","canonical_id":"hgnc:HGNC:34637","description":"tRNA-Ser (anticodon AGA) 2-2","metadata":{"aliases":["tRNA-Ser-AGA-2-2","TRNAS10","TRS-AGA2-3"]}},{"id":"4c0df61d6bf7450f8601c9406cbda7a5","type":"GENE","name":"TRS-AGA2-3","canonical_id":"hgnc:HGNC:16293","description":"tRNA-Ser (anticodon AGA) 2-3","metadata":{"aliases":["TRNS","tRNA-Ser-AGA-2-3","TRS2","TRNAS2","TRS-AGA2-4"]}},{"id":"011e3f75c118476698c6d611c583f53f","type":"GENE","name":"TRS-AGA2-4","canonical_id":"hgnc:HGNC:34810","description":"tRNA-Ser (anticodon AGA) 2-4","metadata":{"aliases":["tRNA-Ser-AGA-2-4","TRNAS19","TRS-AGA2-5"]}},{"id":"4ce3bcf343234acc81dd5d546ba45a95","type":"GENE","name":"TRS-AGA2-5","canonical_id":"hgnc:HGNC:34811","description":"tRNA-Ser (anticodon AGA) 2-5","metadata":{"aliases":["tRNA-Ser-AGA-2-5","TRNAS20","TRS-AGA2-6"]}},{"id":"d4eaee4fda854eb98c116cf0241e9e6d","type":"GENE","name":"TRS-AGA2-6","canonical_id":"hgnc:HGNC:34747","description":"tRNA-Ser (anticodon AGA) 2-6","metadata":{"aliases":["tRNA-Ser-AGA-2-6","TRNAS14","TRS-AGA2-1"]}},{"id":"b17cc636eb4841b88d5866f9c81f3228","type":"GENE","name":"TRS-AGA3-1","canonical_id":"hgnc:HGNC:33201","description":"tRNA-Ser (anticodon AGA) 3-1","metadata":{"aliases":["tRNA-Ser-AGA-3-1","TRS4","TRNAS4"]}},{"id":"d1b0c6e931bd434b85a7043e63803d12","type":"GENE","name":"TRS-AGA4-1","canonical_id":"hgnc:HGNC:34629","description":"tRNA-Ser (anticodon AGA) 4-1","metadata":{"aliases":["tRNA-Ser-AGA-4-1","TRNAS9"]}},{"id":"512cb7cd309e49e6b333ec860e476003","type":"GENE","name":"TRS-AGA5-1","canonical_id":"hgnc:HGNC:35001","description":"tRNA-Ser (AGA) 5-1","metadata":{"aliases":["tRNA-Ser-AGA-5-1","TRNAS28"]}},{"id":"39a209047df54527a4e576c44132a3a4","type":"GENE","name":"TRS-AGA6-1","canonical_id":"hgnc:HGNC:34989","description":"tRNA-Ser (AGA) 6-1","metadata":{"aliases":["tRNA-Ser-AGA-6-1","TRNAS26"]}},{"id":"cfb2860f6c384948aa596e12014e105f","type":"GENE","name":"TRS-AGA7-1","canonical_id":"hgnc:HGNC:35060","description":"tRNA-Ser (anticodon AGA) 7-1","metadata":{"aliases":["tRNA-Ser-AGA-7-1","TRNAS29P"]}},{"id":"e13f4456a058450388e5b85ef8533968","type":"GENE","name":"TRS-CGA1-1","canonical_id":"hgnc:HGNC:34596","description":"tRNA-Ser (anticodon CGA) 1-1","metadata":{"aliases":["tRNA-Ser-CGA-1-1","TRNAS6"]}},{"id":"50bbbea26ad04f5a833e7cd3c095c4cc","type":"GENE","name":"TRS-CGA2-1","canonical_id":"hgnc:HGNC:34600","description":"tRNA-Ser (anticodon CGA) 2-1","metadata":{"aliases":["tRNA-Ser-CGA-2-1","TRNAS7"]}},{"id":"3e54035d32464c1480bc65c5ec44e1df","type":"GENE","name":"TRS-CGA3-1","canonical_id":"hgnc:HGNC:34768","description":"tRNA-Ser (anticodon CGA) 3-1","metadata":{"aliases":["tRNA-Ser-CGA-3-1","TRNAS15"]}},{"id":"f8e447044d734d359725efd264d73fa8","type":"GENE","name":"TRS-CGA4-1","canonical_id":"hgnc:HGNC:34714","description":"tRNA-Ser (anticodon CGA) 4-1","metadata":{"aliases":["tRNA-Ser-CGA-4-1","TRNAS11"]}},{"id":"5f7eea1e6d9944f5a595d38d442008be","type":"GENE","name":"TRS-GCT1-1","canonical_id":"hgnc:HGNC:34719","description":"tRNA-Ser (anticodon GCT) 1-1","metadata":{"aliases":["tRNA-Ser-GCT-1-1","TRNAS12"]}},{"id":"07d09c1132de430b9277947f30aa00ff","type":"GENE","name":"TRS-GCT2-1","canonical_id":"hgnc:HGNC:34559","description":"tRNA-Ser (anticodon GCT) 2-1","metadata":{"aliases":["tRNA-Ser-GCT-2-1","TRNAS5"]}},{"id":"b8f782c483954351bdddc13ea8e5c0ab","type":"GENE","name":"TRS-GCT3-1","canonical_id":"hgnc:HGNC:34851","description":"tRNA-Ser (anticodon GCT) 3-1","metadata":{"aliases":["tRNA-Ser-GCT-3-1","TRNAS22"]}},{"id":"ba9745389948420c93504e8aa0775a0b","type":"GENE","name":"TRS-GCT4-1","canonical_id":"hgnc:HGNC:34788","description":"tRNA-Ser (anticodon GCT) 4-1","metadata":{"aliases":["tRNA-Ser-GCT-4-1","TRNAS17","TRS-GCT4-3"]}},{"id":"7395ad780b494c42bb255091867d0b26","type":"GENE","name":"TRS-GCT4-2","canonical_id":"hgnc:HGNC:34792","description":"tRNA-Ser (anticodon GCT) 4-2","metadata":{"aliases":["tRNA-Ser-GCT-4-2","TRNAS18","TRS-GCT4-1"]}},{"id":"69ecd9bb92e74897acc9ed965d23bdc9","type":"GENE","name":"TRS-GCT4-3","canonical_id":"hgnc:HGNC:34898","description":"tRNA-Ser (anticodon GCT) 4-3","metadata":{"aliases":["tRNA-Ser-GCT-4-3","TRNAS23","TRS-GCT4-2"]}},{"id":"ea54000077fa439b90aafe71abffe517","type":"GENE","name":"TRS-GCT5-1","canonical_id":"hgnc:HGNC:34721","description":"tRNA-Ser (anticodon GCT) 5-1","metadata":{"aliases":["tRNA-Ser-GCT-5-1","TRNAS13"]}},{"id":"9bf3914bed3a430aab923bce4e3d48d2","type":"GENE","name":"TRS-GCT6-1","canonical_id":"hgnc:HGNC:34781","description":"tRNA-Ser (anticodon GCT) 6-1","metadata":{"aliases":["tRNA-Ser-GCT-6-1","TRNAS16"]}},{"id":"987683c0e4534ff385f35c6e468d25b7","type":"GENE","name":"TRS-TGA1-1","canonical_id":"hgnc:HGNC:34845","description":"tRNA-Ser (anticodon TGA) 1-1","metadata":{"aliases":["tRNA-Ser-TGA-1-1","TRNAS21"]}},{"id":"fcb729b579024bdda916a07b89563d5b","type":"GENE","name":"TRS-TGA2-1","canonical_id":"hgnc:HGNC:16292","description":"tRNA-Ser (anticodon TGA) 2-1","metadata":{"aliases":["tRNA-Ser-TGA-2-1","TRS1","TRNAS1"]}},{"id":"ba9d30a646ba4e70a48e926c37c9ac50","type":"GENE","name":"TRS-TGA3-1","canonical_id":"hgnc:HGNC:34999","description":"tRNA-Ser (anticodon TGA) 3-1","metadata":{"aliases":["tRNA-Ser-TGA-3-1","TRNAS27"]}},{"id":"d691dea0482f447bb860634081fe52d3","type":"GENE","name":"TRS-TGA4-1","canonical_id":"hgnc:HGNC:16294","description":"tRNA-Ser (anticodon TGA) 4-1","metadata":{"aliases":["tRNA-Ser-TGA-4-1","TRS3","TRNAS3"]}},{"id":"b20898b6cf584cb7a91cc8876e449aa6","type":"GENE","name":"TRSUP-CTA1-1","canonical_id":"hgnc:HGNC:34995","description":"tRNA suppressor (anticodon CTA) 1-1","metadata":{"aliases":["tRNA-Sup-CTA-1-1","TRNASUP3"]}},{"id":"291ed76ce29b412e82b91e3f17eda5f6","type":"GENE","name":"TRSUP-CTA2-1","canonical_id":"hgnc:HGNC:35012","description":"tRNA suppressor (anticodon CTA) 2-1","metadata":{"aliases":["tRNA-Sup-CTA-2-1","TRNASUP4P"]}},{"id":"d6073f59245049dbb49df772d6ef8843","type":"GENE","name":"TRSUP-CTA3-1","canonical_id":"hgnc:HGNC:35043","description":"tRNA suppressor (anticodon CTA) 3-1","metadata":{"aliases":["tRNA-Sup-CTA-3-1","TRNASUP6P"]}},{"id":"6db3a18da61342c29b75154a284a2e13","type":"GENE","name":"TRSUP-TTA1-1","canonical_id":"hgnc:HGNC:34640","description":"tRNA suppressor (TTA) 1-1","metadata":{"aliases":["tRNA-Sup-TTA-1-1","TRNASUP1"]}},{"id":"53d6355a0fe74beba207eb3fcbb59820","type":"GENE","name":"TRSUP-TTA2-1","canonical_id":"hgnc:HGNC:34897","description":"tRNA suppressor (anticodon TTA) 2-1","metadata":{"aliases":["tRNA-Sup-TTA-2-1","TRNASUP2"]}},{"id":"b8006a52549240dbb59a78e95fc38ba5","type":"GENE","name":"TRSUP-TTA3-1","canonical_id":"hgnc:HGNC:35024","description":"tRNA suppressor (anticodon TTA) 3-1","metadata":{"aliases":["tRNA-Sup-TTA-3-1","TRNASUP5P"]}},{"id":"6cd24e6ea2a244ce90e11ae5de4ff817","type":"GENE","name":"TRT-AGT1-1","canonical_id":"hgnc:HGNC:34750","description":"tRNA-Thr (anticodon AGT) 1-1","metadata":{"aliases":["tRNA-Thr-AGT-1-1","TRNAT8"]}},{"id":"638a3e70d7214dfaa038c06907c80fdf","type":"GENE","name":"TRT-AGT1-2","canonical_id":"hgnc:HGNC:34785","description":"tRNA-Thr (anticodon AGT) 1-2","metadata":{"aliases":["tRNA-Thr-AGT-1-2","TRNAT9"]}},{"id":"ac103e400daf4cd18ec3428b8d0b63f4","type":"GENE","name":"TRT-AGT1-3","canonical_id":"hgnc:HGNC:34563","description":"tRNA-Thr (anticodon AGT) 1-3","metadata":{"aliases":["tRNA-Thr-AGT-1-3","TRNAT4"]}},{"id":"ec0789f75753400caed042695456ce18","type":"GENE","name":"TRT-AGT2-1","canonical_id":"hgnc:HGNC:34886","description":"tRNA-Thr (anticodon AGT) 2-1","metadata":{"aliases":["tRNA-Thr-AGT-2-1","TRNAT14"]}},{"id":"69ce2089260d419a9821dab91e2ac65e","type":"GENE","name":"TRT-AGT2-2","canonical_id":"hgnc:HGNC:34908","description":"tRNA-Thr (anticodon AGT) 2-2","metadata":{"aliases":["tRNA-Thr-AGT-2-2","TRNAT15"]}},{"id":"95faa6ef79de4e91ba54daa0e8fbc86a","type":"GENE","name":"TRT-AGT3-1","canonical_id":"hgnc:HGNC:35003","description":"trRNA-Thr (anticodon AGT) 3-1","metadata":{"aliases":["tRNA-Thr-AGT-3-1","TRNAT21"]}},{"id":"5128b35df61a4579af83af610be9de69","type":"GENE","name":"TRT-AGT4-1","canonical_id":"hgnc:HGNC:34942","description":"tRNA-Thr (anticodon AGT) 4-1","metadata":{"aliases":["tRNA-Thr-AGT-4-1","TRNAT18","TRT-AGT5-1"]}},{"id":"96f4fbab85d242028e50867d3108060d","type":"GENE","name":"TRT-AGT5-1","canonical_id":"hgnc:HGNC:35008","description":"tRNA-Thr (anticodon AGT) 5-1","metadata":{"aliases":["tRNA-Thr-AGT-5-1","TRNAT22","TRT-AGT4-1"]}},{"id":"a4df8ec3925144e880e481ef0ab3753d","type":"GENE","name":"TRT-AGT6-1","canonical_id":"hgnc:HGNC:34705","description":"tRNA-Thr (anticodon AGT) 6-1","metadata":{"aliases":["tRNA-Thr-AGT-6-1","TRNAT7"]}},{"id":"aa7938256dfb4fa699821bcb7dab8225","type":"GENE","name":"TRT-AGT7-1","canonical_id":"hgnc:HGNC:12352","description":"tRNA-Thr (AGT) 7-1","metadata":{"aliases":["tRNA-Thr-AGT-7-1","TRT3","TRNAT3"]}},{"id":"b804ec0cb3bf4b209378f249e37fd486","type":"GENE","name":"TRT-CGT1-1","canonical_id":"hgnc:HGNC:34594","description":"tRNA-Thr (anticodon CGT) 1-1","metadata":{"aliases":["tRNA-Thr-CGT-1-1","TRNAT5"]}},{"id":"c00a1ad0868048188302086335a08a19","type":"GENE","name":"TRT-CGT2-1","canonical_id":"hgnc:HGNC:34646","description":"tRNA-Thr (anticodon CGT) 2-1","metadata":{"aliases":["tRNA-Thr-CGT-2-1","TRNAT6"]}},{"id":"70e0d0647fa243fe9f2d67e725e8feba","type":"GENE","name":"TRT-CGT3-1","canonical_id":"hgnc:HGNC:34928","description":"tRNA-Thr (anticodon CGT) 3-1","metadata":{"aliases":["tRNA-Thr-CGT-3-1","TRNAT17"]}},{"id":"82055d48c7de43a79d9263cd60f4b1c2","type":"GENE","name":"TRT-CGT4-1","canonical_id":"hgnc:HGNC:34808","description":"tRNA-Thr (anticodon CGT) 4-1","metadata":{"aliases":["tRNA-Thr-CGT-4-1","TRNAT10"]}},{"id":"ac06c0715c654f4f8be1ab702084dfa3","type":"GENE","name":"TRT-CGT5-1","canonical_id":"hgnc:HGNC:34866","description":"tRNA-Thr (anticodon CGT) 5-1","metadata":{"aliases":["tRNA-Thr-CGT-5-1","TRNAT13"]}},{"id":"6f0d51943c2a4bf3a9bfd339cb856151","type":"GENE","name":"TRT-CGT6-1","canonical_id":"hgnc:HGNC:34821","description":"tRNA-Thr (anticodon CGT) 6-1","metadata":{"aliases":["tRNA-Thr-CGT-6-1","TRNAT11"]}},{"id":"42fabbc8063b44c6b101caad02cdf9a7","type":"GENE","name":"TRT-TGT1-1","canonical_id":"hgnc:HGNC:34912","description":"tRNA-Thr (anticodon TGT) 1-1","metadata":{"aliases":["tRNA-Thr-TGT-1-1","TRNAT16"]}},{"id":"c8783bc8c3044133adaadf37f1bc2baa","type":"GENE","name":"TRT-TGT2-1","canonical_id":"hgnc:HGNC:34946","description":"tRNA-Thr (anticodon TGT) 2-1","metadata":{"aliases":["tRNA-Thr-TGT-2-1","TRNAT19"]}},{"id":"8564c05808b8451d88ad208bec240bd0","type":"GENE","name":"TRT-TGT3-1","canonical_id":"hgnc:HGNC:12351","description":"tRNA-Thr (anticodon TGT) 3-1","metadata":{"aliases":["tRNA-Thr-TGT-3-1","TRT2","TRNAT2"]}},{"id":"9d9c1d33edd341d3bb2678770b2222f1","type":"GENE","name":"TRT-TGT4-1","canonical_id":"hgnc:HGNC:34988","description":"tRNA-Thr (anticodon TGT) 4-1","metadata":{"aliases":["tRNA-Thr-TGT-4-1","TRNAT20"]}},{"id":"a8e6534a73234c35829282a19d2eda48","type":"GENE","name":"TRT-TGT5-1","canonical_id":"hgnc:HGNC:34826","description":"tRNA-Thr (anticodon TGT) 5-1","metadata":{"aliases":["tRNA-Thr-TGT-5-1","TRNAT12"]}},{"id":"a1b8d66650074693863a3e6cab3f52e7","type":"GENE","name":"TRT-TGT6-1","canonical_id":"hgnc:HGNC:12350","description":"tRNA-Thr (anticodon TGT) 6-1","metadata":{"aliases":["tRNA-Thr-TGT-6-1","TRT1","TRNAT1"]}},{"id":"3fda1f0064164b5284fe6e3bb739bfc0","type":"GENE","name":"TRU-TCA1-1","canonical_id":"hgnc:HGNC:12348","description":"tRNA-SeC (anticodon TCA) 1-1","metadata":{"aliases":["tRNA(Sec)","tRNA-SeC-TCA-1-1","TRSP","TRNAU1"]}},{"id":"9a0073a0a9554e1aafe9fdaf9234562a","type":"GENE","name":"TRU-TCA2-1","canonical_id":"hgnc:HGNC:12349","description":"tRNA-SeC (anticodon TCA) 2-1","metadata":{"aliases":["TRSP2","tRNA-SeC-TCA-2-1","TRSPP1","TRNAU2"]}},{"id":"e2733d71dc6443968378da444ee5c397","type":"GENE","name":"TRU-TCA3-1","canonical_id":"hgnc:HGNC:34525","description":"tRNA-SeC (TCA) 3-1","metadata":{"aliases":["tRNA-SeC-TCA-3-1","TRNAU3"]}},{"id":"e803344efe524e639082b08dbd97631c","type":"GENE","name":"TRUB1","canonical_id":"hgnc:HGNC:16060","description":"TruB pseudouridine synthase family member 1","metadata":{"aliases":["PUS4"]}},{"id":"65688b3fe43c405c99603343dfbf3fd8","type":"GENE","name":"TRUB2","canonical_id":"hgnc:HGNC:17170","description":"TruB pseudouridine synthase family member 2","metadata":{"aliases":["CLONE24922"]}},{"id":"9613379aef8844baafb63c40cbb8f041","type":"GENE","name":"TRUND-NNN1-1","canonical_id":"hgnc:HGNC:50813","description":"tRNA-undetermined (NNN) 1-1","metadata":{"aliases":["tRNA-Und-NNN-1-1"]}},{"id":"5e84cfac7dca40c6810003c208d6a50d","type":"GENE","name":"TRUND-NNN10-1","canonical_id":"hgnc:HGNC:50822","description":"tRNA-undetermined (NNN) 10-1","metadata":null},{"id":"b0a7be01123e4fa5b177f9a0f3adedd9","type":"GENE","name":"TRUND-NNN2-1","canonical_id":"hgnc:HGNC:50814","description":"tRNA-undetermined (NNN) 2-1","metadata":{"aliases":["tRNA-Und-NNN-2-1"]}},{"id":"875346d7d45e4c0d9635e2b2d1475c83","type":"GENE","name":"TRUND-NNN3-1","canonical_id":"hgnc:HGNC:50815","description":"tRNA-undetermined (NNN) 3-1","metadata":{"aliases":["tRNA-Und-NNN-3-1"]}},{"id":"3f51bdc9a7e14d0eacd3f63a27cede9d","type":"GENE","name":"TRUND-NNN4-1","canonical_id":"hgnc:HGNC:50816","description":"tRNA-undetermined (NNN) 4-1","metadata":{"aliases":["tRNA-Und-NNN-4-1"]}},{"id":"e09cb902124b454ea6dda7297bf0cf6b","type":"GENE","name":"TRUND-NNN5-1","canonical_id":"hgnc:HGNC:50817","description":"tRNA-undetermined (NNN) 5-1","metadata":{"aliases":["tRNA-Und-NNN-5-1"]}},{"id":"925e25f3826b4522bb5f29b9b8f46407","type":"GENE","name":"TRUND-NNN6-1","canonical_id":"hgnc:HGNC:50818","description":"tRNA-undetermined (NNN) 6-1","metadata":null},{"id":"2bf6baf0227f493d83abf085ad5edb82","type":"GENE","name":"TRUND-NNN7-1","canonical_id":"hgnc:HGNC:50819","description":"tRNA-undetermined (NNN) 7-1","metadata":null},{"id":"08d5bb7e290c4e9c9ffea18773fc8d9f","type":"GENE","name":"TRUND-NNN8-1","canonical_id":"hgnc:HGNC:50820","description":"tRNA-undetermined (NNN) 8-1","metadata":null},{"id":"cf41e1dd5e664042a8a870c035092e4e","type":"GENE","name":"TRUND-NNN9-1","canonical_id":"hgnc:HGNC:50821","description":"tRNA-undetermined (NNN) 9-1","metadata":null},{"id":"6b2c9ea8874f46f5a962b3178ca3d9fb","type":"TRIAL","name":"TRUST Study: Raptiva \u00ae in Hand & Foot Psoriasis","canonical_id":"clinicaltrials.gov:NCT00739882","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"c490c71c2aed4e629cf24700696ed3da","type":"GENE","name":"TRV-AAC1-1","canonical_id":"hgnc:HGNC:34885","description":"tRNA-Val (anticodon AAC) 1-1","metadata":{"aliases":["tRNA-Val-AAC-1-1","TRNAV24"]}},{"id":"66ff2cc4ccdc4876853d7d3b70c2eb6f","type":"GENE","name":"TRV-AAC1-2","canonical_id":"hgnc:HGNC:34542","description":"tRNA-Val (anticodon AAC) 1-2","metadata":{"aliases":["tRNA-Val-AAC-1-2","TRNAV5"]}},{"id":"aba74b311f924e0db3e72d5603662326","type":"GENE","name":"TRV-AAC1-3","canonical_id":"hgnc:HGNC:12355","description":"tRNA-Val (anticodon AAC) 1-3","metadata":{"aliases":["tRNA-Val-AAC-1-3","TRV3","TRNAV3"]}},{"id":"737db8ef258f4c77951d78a47baf5260","type":"GENE","name":"TRV-AAC1-4","canonical_id":"hgnc:HGNC:12353","description":"tRNA-Val (anticodon AAC) 1-4","metadata":{"aliases":["tRNA-Val-AAC-1-4","TRV","TRV1","TRNAV1"]}},{"id":"76fbe12998484f93809986d1fb0a0e52","type":"GENE","name":"TRV-AAC1-5","canonical_id":"hgnc:HGNC:33246","description":"tRNA-Val (anticodon AAC) 1-5","metadata":{"aliases":["HtV1","tRNA-Val-AAC-1-5","TRV7","TRNAV7"]}},{"id":"10f98e0f620444e08c8be854ecda4c11","type":"GENE","name":"TRV-AAC2-1","canonical_id":"hgnc:HGNC:34543","description":"tRNA-Val (anticodon AAC) 2-1","metadata":{"aliases":["tRNA-Val-AAC-2-1","TRNAV10"]}},{"id":"e9ce32c979ce48ef8918edeb9b1f47c7","type":"GENE","name":"TRV-AAC3-1","canonical_id":"hgnc:HGNC:33247","description":"tRNA-Val (anticodon AAC) 3-1","metadata":{"aliases":["HtV2","tRNA-Val-AAC-3-1","TRV8","TRNAV8"]}},{"id":"268b43097c2d4a54b4c7d5ed34595a91","type":"GENE","name":"TRV-AAC4-1","canonical_id":"hgnc:HGNC:34723","description":"tRNA-Val (anticodon AAC) 4-1","metadata":{"aliases":["tRNA-Val-AAC-4-1","TRNAV17"]}},{"id":"a5605914876f4488a4f0e186d297d958","type":"GENE","name":"TRV-AAC5-1","canonical_id":"hgnc:HGNC:34573","description":"tRNA-Val (anticodon AAC) 5-1","metadata":{"aliases":["tRNA-Val-AAC-5-1","TRNAV12"]}},{"id":"a3befec6b82040b789a549844d618d52","type":"GENE","name":"TRV-AAC6-1","canonical_id":"hgnc:HGNC:34740","description":"tRNA-Val (anticodon AAC) 6-1","metadata":{"aliases":["tRNA-Val-AAC-6-1","TRNAV18"]}},{"id":"e26e2dad7aba478094a0e190716fdd5c","type":"GENE","name":"TRV-AAC7-1","canonical_id":"hgnc:HGNC:34973","description":"tRNA-Val (AAC) 7-1","metadata":{"aliases":["tRNA-Val-AAC-7-1","TRNAV30"]}},{"id":"3b2b16bc62904dc7af49b1262e5dbd91","type":"GENE","name":"TRV-CAC1-1","canonical_id":"hgnc:HGNC:34941","description":"tRNA-Val (anticodon CAC) 1-1","metadata":{"aliases":["tRNA-Val-CAC-1-1","TRNAV29"]}},{"id":"de476c76216245c39806e78132415734","type":"GENE","name":"TRV-CAC1-2","canonical_id":"hgnc:HGNC:12354","description":"tRNA-Val (anticodon CAC) 1-2","metadata":{"aliases":["tRNA-Val-CAC-1-2","TRV2","TRNAV2"]}},{"id":"816bffbd92b247439563d996b2747112","type":"GENE","name":"TRV-CAC1-3","canonical_id":"hgnc:HGNC:33248","description":"tRNA-Val (anticodon CAC) 1-3","metadata":{"aliases":["HtV3","tRNA-Val-CAC-1-3","TRV9","TRNAV9"]}},{"id":"a6d328077b684266a9ff3efff6d5b41e","type":"GENE","name":"TRV-CAC1-4","canonical_id":"hgnc:HGNC:34541","description":"tRNA-Val (anticodon CAC) 1-4","metadata":{"aliases":["tRNA-Val-CAC-1-4","TRNAV4"]}},{"id":"b3c4a974877742b7a155caa31959302f","type":"GENE","name":"TRV-CAC1-5","canonical_id":"hgnc:HGNC:33245","description":"tRNA-Val (anticodon CAC) 1-5","metadata":{"aliases":["tRNA-Val-CAC-1-5","TRV6","TRNAV6"]}},{"id":"7566ce251fe7493aa236679127bde50b","type":"GENE","name":"TRV-CAC1-6","canonical_id":"hgnc:HGNC:34790","description":"tRNA-Val (anticodon CAC) 1-6","metadata":{"aliases":["tRNA-Val-CAC-1-6","TRNAV21"]}},{"id":"3dca8f4e799746e98236a59a67fecd54","type":"GENE","name":"TRV-CAC1-7","canonical_id":"hgnc:HGNC:54846","description":"tRNA-Val (anticodon CAC) 1-7","metadata":{"aliases":["tRNA-Val-CAC-1-7"]}},{"id":"1c010ab0b29a430093f0c393c385eaa2","type":"GENE","name":"TRV-CAC10-1","canonical_id":"hgnc:HGNC:38576","description":"tRNA-Val (CAC) 10-1","metadata":{"aliases":["tRNA-Val-CAC-10-1","TRNAV38"]}},{"id":"0c92e51a210d41ad9d60b9337d5c8192","type":"GENE","name":"TRV-CAC11-1","canonical_id":"hgnc:HGNC:38578","description":"tRNA-Val (anticodon CAC) 11-1","metadata":{"aliases":["tRNA-Val-CAC-11-1","TRNAV39"]}},{"id":"9682f3337e9c4dd1bc99e978dd079bea","type":"GENE","name":"TRV-CAC11-2","canonical_id":"hgnc:HGNC:35052","description":"tRNA-Val (anticodon CAC) 11-2","metadata":{"aliases":["tRNA-Val-CAC-11-2","TRNAV34P"]}},{"id":"493dc8786caf43a3be98e046e2beb350","type":"GENE","name":"TRV-CAC12-1","canonical_id":"hgnc:HGNC:34632","description":"tRNA-Val (anticodon CAC) 12-1","metadata":{"aliases":["tRNA-Val-CAC-12-1","TRNAV14"]}},{"id":"610a82c2b8e141dda990e3bf72861703","type":"GENE","name":"TRV-CAC13-1","canonical_id":"hgnc:HGNC:35075","description":"tRNA-Val (CAC) 13-1","metadata":{"aliases":["tRNA-Val-CAC-13-1","TRNAV36P"]}},{"id":"0da7c0916d2e43839ace7d87690408a4","type":"GENE","name":"TRV-CAC14-1","canonical_id":"hgnc:HGNC:35050","description":"tRNA-Val (anticodon CAC) 14-1","metadata":{"aliases":["tRNA-Val-CAC-14-1","TRNAV33P"]}},{"id":"2100d28ec4ca4f0c9b47cdd1972cbff2","type":"GENE","name":"TRV-CAC2-1","canonical_id":"hgnc:HGNC:34931","description":"tRNA-Val (anticodon CAC) 2-1","metadata":{"aliases":["tRNA-Val-CAC-2-1","TRNAV27"]}},{"id":"d0ad3b6ad4cc46c49ebc719540bed4d3","type":"GENE","name":"TRV-CAC3-1","canonical_id":"hgnc:HGNC:34985","description":"tRNA-Val (anticodon CAC) 3-1","metadata":{"aliases":["tRNA-Val-CAC-3-1","TRNAV32"]}},{"id":"bcdca5b1d22444cabd968c9d22c00135","type":"GENE","name":"TRV-CAC4-1","canonical_id":"hgnc:HGNC:34893","description":"tRNA-Val (anticodon CAC) 4-1","metadata":{"aliases":["tRNA-Val-CAC-4-1","TRNAV25"]}},{"id":"2721249724b14b9080ccc2b34654fd94","type":"GENE","name":"TRV-CAC5-1","canonical_id":"hgnc:HGNC:34791","description":"tRNA-Val (anticodon CAC) 5-1","metadata":{"aliases":["tRNA-Val-CAC-5-1","TRNAV22"]}},{"id":"2ef3a345539041bca4f3a370bcd1f6ff","type":"GENE","name":"TRV-CAC6-1","canonical_id":"hgnc:HGNC:34936","description":"tRNA-Val (anticodon CAC) 6-1","metadata":{"aliases":["tRNA-Val-CAC-6-1","TRNAV28"]}},{"id":"1c76f7da45e6483881d02e5af56d7a39","type":"GENE","name":"TRV-CAC7-1","canonical_id":"hgnc:HGNC:34662","description":"tRNA-Val (CAC) 7-1","metadata":{"aliases":["tRNA-Val-CAC-7-1","TRNAV15"]}},{"id":"a9def15b8f354c0280593882a8777078","type":"GENE","name":"TRV-CAC8-1","canonical_id":"hgnc:HGNC:34704","description":"tRNA-Val (CAC) 8-1","metadata":{"aliases":["tRNA-Val-CAC-8-1","TRNAV16"]}},{"id":"d48842dcfcaf4f77a89f60e9b0e5fdbb","type":"GENE","name":"TRV-CAC9-1","canonical_id":"hgnc:HGNC:34759","description":"tRNA-Val (anticodon CAC) 9-1","metadata":{"aliases":["tRNA-Val-CAC-9-1","TRNAV20"]}},{"id":"c63d08080ca8432d9d501a443d0d6ca1","type":"GENE","name":"TRV-TAC1-1","canonical_id":"hgnc:HGNC:34544","description":"tRNA-Val (anticodon TAC) 1-1","metadata":{"aliases":["tRNA-Val-TAC-1-1","TRNAV11"]}},{"id":"11895f65a97e4d60a7a64e4d5f37c507","type":"GENE","name":"TRV-TAC1-2","canonical_id":"hgnc:HGNC:34754","description":"tRNA-Val (anticodon TAC) 1-2","metadata":{"aliases":["tRNA-Val-TAC-1-2","TRNAV19"]}},{"id":"35868bd5413f4c388597217edcf8ce91","type":"GENE","name":"TRV-TAC2-1","canonical_id":"hgnc:HGNC:34849","description":"tRNA-Val (anticodon TAC) 2-1","metadata":{"aliases":["tRNA-Val-TAC-2-1","TRNAV23"]}},{"id":"f1a8d39b9eaf4d00ab6cba1612d32fb9","type":"GENE","name":"TRV-TAC3-1","canonical_id":"hgnc:HGNC:34910","description":"tRNA-Val (anticodon TAC) 3-1","metadata":{"aliases":["tRNA-Val-TAC-3-1","TRNAV26"]}},{"id":"595811f34ba1479ca7ad4d14d09c96c0","type":"GENE","name":"TRV-TAC4-1","canonical_id":"hgnc:HGNC:34977","description":"tRNA-Val (anticodon TAC) 4-1","metadata":{"aliases":["tRNA-Val-TAC-4-1","TRNAV31"]}},{"id":"532086902f6a4b67aebefe81266c2e01","type":"GENE","name":"TRW-CCA1-1","canonical_id":"hgnc:HGNC:34685","description":"tRNA-Trp (anticodon CCA) 1-1","metadata":{"aliases":["tRNA-Trp-CCA-1-1","TRNAW4"]}},{"id":"3eb8e70910524f78a52947fbb8d60fd9","type":"GENE","name":"TRW-CCA2-1","canonical_id":"hgnc:HGNC:34766","description":"tRNA-Trp (anticodon CCA) 2-1","metadata":{"aliases":["tRNA-Trp-CCA-2-1","TRNAW7"]}},{"id":"4e2d4cf3d9d440e989c30ec187bd8992","type":"GENE","name":"TRW-CCA3-1","canonical_id":"hgnc:HGNC:35006","description":"tRNA-Trp (anticodon CCA) 3-1","metadata":{"aliases":["tRNA-Trp-CCA-3-1","TRNAW9","TRW-CCA3-2"]}},{"id":"23fa57064e534fcb990ccfcdc687435f","type":"GENE","name":"TRW-CCA3-2","canonical_id":"hgnc:HGNC:34607","description":"tRNA-Trp (anticodon CCA) 3-2","metadata":{"aliases":["tRNA-Trp-CCA-3-2","TRNAW2","TRW-CCA3-3"]}},{"id":"3771b9be1972477b92678f7d62c49df7","type":"GENE","name":"TRW-CCA3-3","canonical_id":"hgnc:HGNC:34674","description":"tRNA-Trp (anticodon CCA) 3-3","metadata":{"aliases":["tRNA-Trp-CCA-3-3","TRNAW3","TRW-CCA3-1"]}},{"id":"b4d6dbf655b94681b49dc8e8952bc09c","type":"GENE","name":"TRW-CCA4-1","canonical_id":"hgnc:HGNC:34733","description":"tRNA-Trp (anticodon CCA) 4-1","metadata":{"aliases":["tRNA-Trp-CCA-4-1","TRNAW5"]}},{"id":"41f0cdbdc1cd46ae960dd849b0993756","type":"GENE","name":"TRW-CCA5-1","canonical_id":"hgnc:HGNC:34753","description":"tRNA-Trp (anticodon CCA) 5-1","metadata":{"aliases":["tRNA-Trp-CCA-5-1","TRNAW6"]}},{"id":"e57ab808c463445a927d8f1e68086a74","type":"GENE","name":"TRW-CCA6-1","canonical_id":"hgnc:HGNC:34876","description":"tRNA-Trp (anticodon CCA) 6-1","metadata":{"aliases":["tRNA-Trp-CCA-6-1","TRNAW8"]}},{"id":"8dc01b81080741c1b13887da5bd14f27","type":"GENE","name":"TRX-CAT1-1","canonical_id":"hgnc:HGNC:34574","description":"tRNA-iMet (anticodon CAT) 1-1","metadata":{"aliases":["tRNA-iMet-CAT-1-1","TRNAM3"]}},{"id":"6387358ce38d4454abe37c07f2e6b115","type":"GENE","name":"TRX-CAT1-2","canonical_id":"hgnc:HGNC:12318","description":"tRNA-iMet (anticodon CAT) 1-2","metadata":{"aliases":["tRNA-iMet-CAT-1-2","TRM1","TRNAMI2","TRM2","TRMI2","TRNAM1","TRX-CAT1-3"]}},{"id":"a6af2251751b49249e7ca03098ef986f","type":"GENE","name":"TRX-CAT1-3","canonical_id":"hgnc:HGNC:34655","description":"tRNA-iMet (anticodon CAT) 1-3","metadata":{"aliases":["tRNA-iMet-CAT-1-3","TRNAM6","TRX-CAT1-4"]}},{"id":"ed3b0168dfb343b3a566bf7f67c66dd3","type":"GENE","name":"TRX-CAT1-4","canonical_id":"hgnc:HGNC:34599","description":"tRNA-iMet (anticodon CAT) 1-4","metadata":{"aliases":["tRNA-iMet-CAT-1-4","TRNAM4","TRX-CAT1-5"]}},{"id":"0c8df29cb8e147e7b0b66556eec6f70a","type":"GENE","name":"TRX-CAT1-5","canonical_id":"hgnc:HGNC:34913","description":"tRNA-iMet (anticodon CAT) 1-5","metadata":{"aliases":["tRNA-iMet-CAT-1-5","TRNAM18","TRX-CAT1-6"]}},{"id":"868a5a30d82c4a7391da841a55cf7c59","type":"GENE","name":"TRX-CAT1-6","canonical_id":"hgnc:HGNC:34863","description":"tRNA-iMet (anticodon CAT) 1-6","metadata":{"aliases":["tRNA-iMet-CAT-1-6","TRNAM15","TRX-CAT1-7"]}},{"id":"e59a4bb8de0f41f4868c39a3a4d2ddf6","type":"GENE","name":"TRX-CAT1-7","canonical_id":"hgnc:HGNC:34882","description":"tRNA-iMet (anticodon CAT) 1-7","metadata":{"aliases":["tRNA-iMet-CAT-1-7","TRNAM17","TRX-CAT1-8"]}},{"id":"967fe338ad334099bebb9c3b1efd1800","type":"GENE","name":"TRX-CAT1-8","canonical_id":"hgnc:HGNC:34818","description":"tRNA-iMet (anticodon CAT) 1-8","metadata":{"aliases":["tRNA-iMet-CAT-1-8","TRNAM14","TRX-CAT1-2"]}},{"id":"aef27f822b924c79bcedebcb7335f9bc","type":"GENE","name":"TRX-CAT2-1","canonical_id":"hgnc:HGNC:12322","description":"tRNA-iMet (anticodon CAT) 2-1","metadata":{"aliases":["tRNA-iMet-CAT-2-1","TRM1","TRMI1","TRNAMI1","TRNAM2"]}},{"id":"8cb5e61ee40b45ef84599cb2e3e64343","type":"GENE","name":"TRX-CAT3-1","canonical_id":"hgnc:HGNC:34749","description":"tRNA-iMet (anticodon CAT) 3-1","metadata":{"aliases":["tRNA-iMet-CAT-3-1","TRNAM10"]}},{"id":"a94e921cf54342b69de2752157b9d512","type":"GENE","name":"TRY-ATA1-1","canonical_id":"hgnc:HGNC:34816","description":"tRNA-Tyr (anticodon ATA) 1-1","metadata":{"aliases":["tRNA-Tyr-ATA-1-1","TRNAY9"]}},{"id":"c189559eb6eb41899c408bc8b82dd820","type":"GENE","name":"TRY-GTA1-1","canonical_id":"hgnc:HGNC:34835","description":"tRNA-Tyr (anticodon GTA) 1-1","metadata":{"aliases":["tRNA-Tyr-GTA-1-1","TRNAY10"]}},{"id":"def5162c13db46a7be54a4aea0540ced","type":"GENE","name":"TRY-GTA10-1","canonical_id":"hgnc:HGNC:34842","description":"tRNA-Tyr (GTA) 10-1","metadata":{"aliases":["tRNA-Tyr-GTA-10-1","TRNAY11"]}},{"id":"0c60e53b2ced4cad8f3e19cfc084ffff","type":"GENE","name":"TRY-GTA11-1","canonical_id":"hgnc:HGNC:35082","description":"tRNA-Tyr (anticodon GTA) 11-1","metadata":{"aliases":["tRNA-Tyr-GTA-11-1","TRNAY17P"]}},{"id":"d9446c6f28f647718579517eaf537680","type":"GENE","name":"TRY-GTA12-1","canonical_id":"hgnc:HGNC:35071","description":"tRNA-Tyr (anticodon GTA) 12-1","metadata":{"aliases":["tRNA-Tyr-GTA-12-1","TRNAY16P"]}},{"id":"fa88a9b3922949989646a0902f1e8828","type":"GENE","name":"TRY-GTA2-1","canonical_id":"hgnc:HGNC:34581","description":"tRNA-Tyr (anticodon GTA) 2-1","metadata":{"aliases":["tRNA-Tyr-GTA-2-1","TRNAY4"]}},{"id":"c25ad9a5012c4887b14382bf2c873d42","type":"GENE","name":"TRY-GTA3-1","canonical_id":"hgnc:HGNC:34724","description":"tRNA-Tyr (anticodon GTA) 3-1","metadata":{"aliases":["tRNA-Tyr-GTA-3-1","TRNAY7"]}},{"id":"5a1021799bdf47839bd038182179dbbf","type":"GENE","name":"TRY-GTA4-1","canonical_id":"hgnc:HGNC:34974","description":"tRNA-Tyr (anticodon GTA) 4-1","metadata":{"aliases":["tRNA-Tyr-GTA-4-1","TRNAY13"]}},{"id":"61e7cf9dac5d4d309baf83186cdf14b7","type":"GENE","name":"TRY-GTA5-1","canonical_id":"hgnc:HGNC:35007","description":"tRNA-Tyr (anticodon GTA) 5-1","metadata":{"aliases":["tRNA-Tyr-GTA-5-1","TRNAY15","TRY-GTA5-4"]}},{"id":"eda1850b0a5e4300b8136b2a99f437ac","type":"GENE","name":"TRY-GTA5-2","canonical_id":"hgnc:HGNC:34663","description":"tRNA-Tyr (anticodon GTA) 5-2","metadata":{"aliases":["tRNA-Tyr-GTA-5-2","TRNAY6","TRY-GTA5-5"]}},{"id":"0472af70fc07457694c8bf3d23db64b8","type":"GENE","name":"TRY-GTA5-3","canonical_id":"hgnc:HGNC:34993","description":"tRNA-Tyr (anticodon GTA) 5-3","metadata":{"aliases":["tRNA-Tyr-GTA-5-3","TRNAY14","TRY-GTA5-1"]}},{"id":"7abf87a689b04a5495c6c7f58da86999","type":"GENE","name":"TRY-GTA5-4","canonical_id":"hgnc:HGNC:33250","description":"tRNA-Tyr (anticodon GTA) 5-4","metadata":{"aliases":["tRNA-Tyr-GTA-5-4","TRNAY2","TRY-GTA5-2"]}},{"id":"b9899c1a031244d986bb291e874e0776","type":"GENE","name":"TRY-GTA5-5","canonical_id":"hgnc:HGNC:34558","description":"tRNA-Tyr (anticodon GTA) 5-5","metadata":{"aliases":["tRNA-Tyr-GTA-5-5","TRNAY3","TRY-GTA5-3"]}},{"id":"15504bbb7a9a4cd197f6a3d033c45b92","type":"GENE","name":"TRY-GTA6-1","canonical_id":"hgnc:HGNC:34782","description":"tRNA-Tyr (anticodon GTA) 6-1","metadata":{"aliases":["tRNA-Tyr-GTA-6-1","TRNAY8"]}},{"id":"3d1ccc571201444c96ef5aa70c65c970","type":"GENE","name":"TRY-GTA7-1","canonical_id":"hgnc:HGNC:33249","description":"tRNA-Tyr (anticodon GTA) 7-1","metadata":{"aliases":["tRNA-Tyr-GTA-7-1","TRNAY1"]}},{"id":"6895246bb5894cc89f881ce1b7a331ee","type":"GENE","name":"TRY-GTA8-1","canonical_id":"hgnc:HGNC:34905","description":"tRNA-Tyr (anticodon GTA) 8-1","metadata":{"aliases":["tRNA-Tyr-GTA-8-1","TRNAY12"]}},{"id":"51c889b4b506401499e22581c13f44a3","type":"GENE","name":"TRY-GTA9-1","canonical_id":"hgnc:HGNC:34616","description":"tRNA-Tyr (anticodon GTA) 9-1","metadata":{"aliases":["tRNA-Tyr-GTA-9-1","TRNAY5"]}},{"id":"1662fc5cc9a94e8fb312280d7c855606","type":"TRIAL","name":"TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.","canonical_id":"clinicaltrials.gov:NCT01711658","description":"Non-HPV Locally Advanced Head and Neck Cancer","metadata":null},{"id":"29ec76bcad3945c7b1713dcc441157d0","type":"GENE","name":"TSACC","canonical_id":"hgnc:HGNC:30636","description":"TSSK6 activating cochaperone","metadata":{"aliases":["SSTK-IP","SIP","C1orf182"]}},{"id":"7e80e5cfe0794723bf6a5d0f73403191","type":"GENE","name":"TSBP1","canonical_id":"hgnc:HGNC:13922","description":"testis expressed basic protein 1","metadata":{"aliases":["TSBP","C6orf10"]}},{"id":"54ccf61a846140e5b913d32762a1d378","type":"GENE","name":"TSBP1-AS1","canonical_id":"hgnc:HGNC:39756","description":"TSBP1 and BTNL2 antisense RNA 1","metadata":{"aliases":["XXbac-BPG154L12.4"]}},{"id":"7670fde5920b45b6acc42f5e6b149d55","type":"GENE","name":"TSC1","canonical_id":"hgnc:HGNC:12362","description":null,"metadata":null},{"id":"fdbd47078b674480b0105f9ccb4c757c","type":"GO_TERM","name":"TSC1-TSC2 complex","canonical_id":"go:GO:0033596","description":"\"A protein complex consisting of at least tumerin and hamartin; its formation may regulate hamartin homomultimer formation. The complex acts as a GTPase activating protein (GAP) for the small GTPase (Rheb), and inhibits the TOR signaling pathway.\" [PMID:10585443, PMID:17121544, PMID:9580671]","metadata":null},{"id":"8e6a857744e34508ac8ac9bef26ef9bb","type":"GO_TERM","name":"TSC1-TSC2 complex binding","canonical_id":"go:GO:0062078","description":"\"Binding to a TSC1-TSC2 complex.\" [PMID:28561066]","metadata":null},{"id":"e2db0154b52744c0935cb5acbdee88cd","type":"GENE","name":"TSC2","canonical_id":"hgnc:HGNC:12363","description":null,"metadata":null},{"id":"8915bd90ac174ea2b26d884d75e1ea64","type":"GENE","name":"TSC22D1","canonical_id":"hgnc:HGNC:16826","description":null,"metadata":null},{"id":"256050a3f7644e2db1d466d2743288cb","type":"GENE","name":"TSC22D1-AS1","canonical_id":"hgnc:HGNC:43684","description":"TSC22D1 antisense RNA 1","metadata":{"aliases":["LINC00407"]}},{"id":"ee4c5ec095994e41b1d1d106fbdbd65d","type":"GENE","name":"TSC22D2","canonical_id":"hgnc:HGNC:29095","description":"TSC22 domain family member 2","metadata":{"aliases":["KIAA0669","TILZ4a","TILZ4b","TILZ4c"]}},{"id":"a6630a34202d4ee19ebadafeeaa2eb35","type":"GENE","name":"TSC22D3","canonical_id":"hgnc:HGNC:3051","description":null,"metadata":null},{"id":"36ecc946e76a4ce8860ac014a2a42b4c","type":"GENE","name":"TSC22D4","canonical_id":"hgnc:HGNC:21696","description":"TSC22 domain family member 4","metadata":{"aliases":["THG-1","TILZ2"]}},{"id":"1a6fae16543b4b8e9ee31c9b742f5944","type":"GENE","name":"TSEN15","canonical_id":"hgnc:HGNC:16791","description":"tRNA splicing endonuclease subunit 15","metadata":{"aliases":["C1orf19"]}},{"id":"a7a65939454c4d05adbb89e179b5df32","type":"GENE","name":"TSEN15P1","canonical_id":"hgnc:HGNC:43962","description":"tRNA splicing endonuclease subunit 15 pseudogene 1","metadata":null},{"id":"5a549eead0f5448c828b799629218dfc","type":"GENE","name":"TSEN15P2","canonical_id":"hgnc:HGNC:43963","description":"tRNA splicing endonuclease subunit 15 pseudogene 2","metadata":null},{"id":"48a76dfc8a3c4b43a57949e1079ef352","type":"GENE","name":"TSEN15P3","canonical_id":"hgnc:HGNC:43964","description":"tRNA splicing endonuclease subunit 15 pseudogene 3","metadata":null},{"id":"62362a5ec2884cc5a63a41307dbcf056","type":"GENE","name":"TSEN2","canonical_id":"hgnc:HGNC:28422","description":"tRNA splicing endonuclease subunit 2","metadata":{"aliases":["SEN2","SEN2L","MGC2776"]}},{"id":"d8254149f5f244e785d05bfc4899057e","type":"GENE","name":"TSEN2P1","canonical_id":"hgnc:HGNC:43965","description":"tRNA splicing endonuclease subunit 2 pseudogene 1","metadata":null},{"id":"b370f3fb39b44db5b4f3dc222b02249e","type":"GENE","name":"TSEN34","canonical_id":"hgnc:HGNC:15506","description":"tRNA splicing endonuclease subunit 34","metadata":{"aliases":["SEN34","SEN34L","LENG5"]}},{"id":"99e25d7e28d8404daa450a2b063ac87f","type":"GENE","name":"TSEN54","canonical_id":"hgnc:HGNC:27561","description":"tRNA splicing endonuclease subunit 54","metadata":{"aliases":["SEN54","SEN54L"]}},{"id":"766a528262824a218d423fe481635b5b","type":"GENE","name":"TSFM","canonical_id":"hgnc:HGNC:12367","description":"Ts translation elongation factor, mitochondrial","metadata":{"aliases":["EF-Tsmt","EF-TS"]}},{"id":"1c92f6408e6849659ae78daa23f0903b","type":"GENE","name":"TSG101","canonical_id":"hgnc:HGNC:15971","description":null,"metadata":null},{"id":"212a2af18efd47a3a47830393778378c","type":"GENE","name":"TSGA10","canonical_id":"hgnc:HGNC:14927","description":"testis specific 10","metadata":{"aliases":["CEP4L","CT79"]}},{"id":"08584545f0034eb6b255e0bd4f842031","type":"GENE","name":"TSGA10IP","canonical_id":"hgnc:HGNC:26555","description":"testis specific 10 interacting protein","metadata":{"aliases":["FLJ32880","FAM161C"]}},{"id":"e0ed7cb52fcc49a3989ce65d91fa934e","type":"GENE","name":"TSGA13","canonical_id":"hgnc:HGNC:12369","description":"testis specific 13","metadata":null},{"id":"aa072e56ba6c4658b2e75e55c4c13132","type":"DRUG","name":"TSH","canonical_id":"gtopdb:3920","description":null,"metadata":null},{"id":"411af5a4ea2141cd923d7322e90904b0","type":"DRUG","name":"TSH","canonical_id":"chembl:CHEMBL1201532","description":null,"metadata":null},{"id":"5c9b97d8c4004a48b7e035e880db7679","type":"GENE","name":"TSHB","canonical_id":"hgnc:HGNC:12372","description":null,"metadata":null},{"id":"606f60c550f8427d972f8bfc3bb860d5","type":"GENE","name":"TSHR","canonical_id":"hgnc:HGNC:12373","description":null,"metadata":null},{"id":"22d05bf89adb44ec91efea4da3438bac","type":"PROTEIN","name":"TSHR","canonical_id":"uniprot:P16473","description":null,"metadata":null},{"id":"a244be69a36148348e2cceb006fa4762","type":"GENE","name":"TSHR-AS1","canonical_id":"hgnc:HGNC:58172","description":"TSHR antisense RNA 1","metadata":null},{"id":"6de4e358d89e4fe4b609022886dc0812","type":"GENE","name":"TSHZ1","canonical_id":"hgnc:HGNC:10669","description":"teashirt zinc finger homeobox 1","metadata":{"aliases":["NY-CO-33","TSH1","SDCCAG33"]}},{"id":"7f219b6526b94f2181269db22d2840d7","type":"GENE","name":"TSHZ2","canonical_id":"hgnc:HGNC:13010","description":"teashirt zinc finger homeobox 2","metadata":{"aliases":["ZABC2","OVC10-2","TSH2","C20orf17","ZNF218"]}},{"id":"6259323a157a495db981225dbeff7b0b","type":"GENE","name":"TSHZ2-AS1","canonical_id":"hgnc:HGNC:58099","description":"TSHZ2 antisense RNA 1","metadata":null},{"id":"7fd980a548be4037ac7e377675686d11","type":"GENE","name":"TSHZ3","canonical_id":"hgnc:HGNC:30700","description":"teashirt zinc finger homeobox 3","metadata":{"aliases":["KIAA1474","TSH3","ZNF537"]}},{"id":"22ab5e6024664c578244b6f930735105","type":"GENE","name":"TSHZ3-AS1","canonical_id":"hgnc:HGNC:55288","description":"TSHZ3 antisense RNA 1","metadata":null},{"id":"54f06b7a218249dd81e5cee533e55421","type":"GENE","name":"TSIX","canonical_id":"hgnc:HGNC:12377","description":null,"metadata":null},{"id":"fbc6cb26e008481280c7d6daf274c685","type":"GENE","name":"TSKS","canonical_id":"hgnc:HGNC:30719","description":"testis specific serine kinase substrate","metadata":{"aliases":["TSSKS","PPP1R161"]}},{"id":"826570c8746747d0b67838bb7742cc0a","type":"GENE","name":"TSKU","canonical_id":"hgnc:HGNC:28850","description":"tsukushi, small leucine rich proteoglycan","metadata":{"aliases":["E2IG4","TSK","LRRC54"]}},{"id":"cbdfb44b14084b0fa31420bc4c3f1625","type":"GENE","name":"TSKU-AS1","canonical_id":"hgnc:HGNC:55509","description":"TSKU antisense RNA 1","metadata":null},{"id":"dabe57510cae4e0184f4251c5a5d2174","type":"GENE","name":"TSLIG1","canonical_id":"hgnc:HGNC:24094","description":"tRNA splicing ligase complex subunit 1","metadata":{"aliases":["ARCH","ZBTB8OS"]}},{"id":"e33cee020cee4bfb89733460f8ce9dfc","type":"GENE","name":"TSLIG2","canonical_id":"hgnc:HGNC:28772","description":"tRNA splicing ligase complex subunit 2","metadata":{"aliases":["MGC5509","asw","C2orf49"]}},{"id":"aaa736f71f27463f9f5597c5c6c96a3f","type":"GENE","name":"TSLIG3A","canonical_id":"hgnc:HGNC:24520","description":"tRNA splicing ligase complex subunit 3A","metadata":{"aliases":["DKFZP564F0522","FAM98A"]}},{"id":"2d4ed2ed2b4f48a58706c798fee5cd73","type":"GENE","name":"TSLIG3B","canonical_id":"hgnc:HGNC:26773","description":"tRNA splicing ligase complex subunit 3B","metadata":{"aliases":["FLJ38426","FAM98B"]}},{"id":"74f7d0d788994eb3b0ad4bb6186135f0","type":"GENE","name":"TSLIG3C","canonical_id":"hgnc:HGNC:27119","description":"tRNA splicing ligase complex subunit 3C","metadata":{"aliases":["FLJ44669","FAM98C"]}},{"id":"860c53d4b88d43e2be1800f808c4bcd7","type":"GENE","name":"TSLP","canonical_id":"hgnc:HGNC:30743","description":null,"metadata":null},{"id":"23fc7521ab3046169311a2c98e453af2","type":"PROTEIN","name":"TSLP","canonical_id":"uniprot:Q969D9","description":null,"metadata":null},{"id":"f71e2117272e40e1b654c931117c1493","type":"GENE","name":"TSN","canonical_id":"hgnc:HGNC:12379","description":"translin","metadata":{"aliases":["TRSLN","BCLF-1","REHF-1"]}},{"id":"b54f07bd7afa4a2e9d562dfbd663a6d2","type":"GENE","name":"TSNARE1","canonical_id":"hgnc:HGNC:26437","description":"t-SNARE domain containing 1","metadata":{"aliases":["FLJ31164"]}},{"id":"38e2e013edea4881b4ffc6df45efbec6","type":"GENE","name":"TSNAX","canonical_id":"hgnc:HGNC:12380","description":"translin associated factor X","metadata":{"aliases":["TRAX","C3PO"]}},{"id":"65ee16cc708b4b03af0dd48f69b9601d","type":"GENE","name":"TSNAX-DISC1","canonical_id":"hgnc:HGNC:49177","description":"TSNAX-DISC1 readthrough (NMD candidate)","metadata":null},{"id":"7b61e9a162fc4864b36f03c12ccc814b","type":"GENE","name":"TSNAXIP1","canonical_id":"hgnc:HGNC:18586","description":"translin associated factor X interacting protein 1","metadata":{"aliases":["TXI1"]}},{"id":"626496dd98f745c2b1762b4e8c4bc843","type":"GENE","name":"TSPAN1","canonical_id":"hgnc:HGNC:20657","description":"tetraspanin 1","metadata":{"aliases":["TSPAN-1","NET-1"]}},{"id":"718977f0fae640beb1e9a3abafc26fa1","type":"GENE","name":"TSPAN10","canonical_id":"hgnc:HGNC:29942","description":"tetraspanin 10","metadata":{"aliases":["OCSP"]}},{"id":"90bdb2bbaa1947a697c1883b15bc6bcc","type":"GENE","name":"TSPAN11","canonical_id":"hgnc:HGNC:30795","description":"tetraspanin 11","metadata":null},{"id":"47620003ab1c47dc9403f958abbe8b5f","type":"GENE","name":"TSPAN11-AS1","canonical_id":"hgnc:HGNC:56687","description":"TSPAN11 antisense RNA 1","metadata":null},{"id":"e28ae8776d3b40c1b202fc313362d4c4","type":"GENE","name":"TSPAN12","canonical_id":"hgnc:HGNC:21641","description":"tetraspanin 12","metadata":{"aliases":["NET-2","TM4SF12"]}},{"id":"68f7ac5b826c49bfacb05b4210e11ce7","type":"GENE","name":"TSPAN13","canonical_id":"hgnc:HGNC:21643","description":"tetraspanin 13","metadata":{"aliases":["NET-6","TM4SF13"]}},{"id":"d5c9768a5cf4451dad9add2db13e4007","type":"GENE","name":"TSPAN14","canonical_id":"hgnc:HGNC:23303","description":"tetraspanin 14","metadata":{"aliases":["DC-TM4F2","MGC11352","TM4SF14"]}},{"id":"9a98386310f4484b97966988fc4e2640","type":"GENE","name":"TSPAN14-AS1","canonical_id":"hgnc:HGNC:55833","description":"TSPAN14 antisense RNA 1","metadata":null},{"id":"4a8909748775482780bf37d338912bc1","type":"GENE","name":"TSPAN15","canonical_id":"hgnc:HGNC:23298","description":"tetraspanin 15","metadata":{"aliases":["NET-7","TM4SF15"]}},{"id":"294a94b173e7496eb71b09804e1925d3","type":"GENE","name":"TSPAN16","canonical_id":"hgnc:HGNC:30725","description":"tetraspanin 16","metadata":{"aliases":["TM4-B","TM-8","TM4SF16"]}},{"id":"c9b99b4b70524b2e8d17954cda94854c","type":"GENE","name":"TSPAN16-AS1","canonical_id":"hgnc:HGNC:58319","description":"TSPAN16 antisense RNA 1","metadata":{"aliases":["HSPC102"]}},{"id":"3819d3c271a041acbf489fdf0e9b1f70","type":"GENE","name":"TSPAN17","canonical_id":"hgnc:HGNC:13594","description":"tetraspanin 17","metadata":{"aliases":["FBX23","FBXO23","TM4SF17"]}},{"id":"02be9ce38578413096145a62d60c51c6","type":"GENE","name":"TSPAN18","canonical_id":"hgnc:HGNC:20660","description":"tetraspanin 18","metadata":{"aliases":["TSPAN"]}},{"id":"85cf71d782cd4e869abc834419555950","type":"GENE","name":"TSPAN18-AS1","canonical_id":"hgnc:HGNC:54221","description":"TSPAN18 antisense RNA 1","metadata":null},{"id":"29533ed6ab2b4482b3b17db3d7d0d9fe","type":"GENE","name":"TSPAN19","canonical_id":"hgnc:HGNC:31886","description":"tetraspanin 19","metadata":null},{"id":"64b1e91bca7c40d2b52dde04385e05dc","type":"GENE","name":"TSPAN2","canonical_id":"hgnc:HGNC:20659","description":"tetraspanin 2","metadata":{"aliases":["TSPAN-2","TSN2","FLJ12082"]}},{"id":"8394dc43eb2f499697bb9c9dc2cced19","type":"GENE","name":"TSPAN3","canonical_id":"hgnc:HGNC:17752","description":"tetraspanin 3","metadata":{"aliases":["TM4-A","TSPAN-3","TM4SF8"]}},{"id":"124339fddca24854ba0d07ba15eddd10","type":"GENE","name":"TSPAN31","canonical_id":"hgnc:HGNC:10539","description":"tetraspanin 31","metadata":{"aliases":["SAS"]}},{"id":"2bdc7b0349c24d7985fab5caee71e3e0","type":"GENE","name":"TSPAN32","canonical_id":"hgnc:HGNC:13410","description":"tetraspanin 32","metadata":{"aliases":["TSSC6","PHEMX"]}},{"id":"34af367cdfbf4d7c9ee21038faf3e5b1","type":"GENE","name":"TSPAN33","canonical_id":"hgnc:HGNC:28743","description":"tetraspanin 33","metadata":{"aliases":["MGC50844","Penumbra"]}},{"id":"5e5b00ca238945cf93dc420c0a658b14","type":"GENE","name":"TSPAN4","canonical_id":"hgnc:HGNC:11859","description":"tetraspanin 4","metadata":{"aliases":["NAG-2","TSPAN-4","TETRASPAN","TM4SF7"]}},{"id":"82053088860e4900aaff586ae081abb7","type":"GENE","name":"TSPAN5","canonical_id":"hgnc:HGNC:17753","description":"tetraspanin 5","metadata":{"aliases":["Tspan-5","NET-4","TM4SF9"]}},{"id":"594cf1b050be4774ae837aa4303a932f","type":"GENE","name":"TSPAN5-AS1","canonical_id":"hgnc:HGNC:40817","description":"TSPAN5 antisense RNA 1","metadata":null},{"id":"e09574a38a0d4e76b59d1d908f57d697","type":"GENE","name":"TSPAN5-DT","canonical_id":"hgnc:HGNC:55389","description":"TSPAN5 divergent transcript","metadata":null},{"id":"3c28badbeb444511865449b8b3288448","type":"GENE","name":"TSPAN6","canonical_id":"hgnc:HGNC:11858","description":"tetraspanin 6","metadata":{"aliases":["T245","TSPAN-6","TM4SF6"]}},{"id":"4c9b9555bb6e4f549f055cdb0f7b73ac","type":"GENE","name":"TSPAN7","canonical_id":"hgnc:HGNC:11854","description":"tetraspanin 7","metadata":{"aliases":["DXS1692E","TALLA-1","A15","CD231","MXS1","TM4SF2","MRX58"]}},{"id":"b97c18d7a9ad4d1381162907e1244840","type":"GENE","name":"TSPAN8","canonical_id":"hgnc:HGNC:11855","description":"tetraspanin 8","metadata":{"aliases":["CO-029","TM4SF3"]}},{"id":"892ba3fd89d44c45b18c8d9b390584c3","type":"GENE","name":"TSPAN9","canonical_id":"hgnc:HGNC:21640","description":"tetraspanin 9","metadata":{"aliases":["NET-5"]}},{"id":"48ee209ee0f3406c96e8dd5ee7fc1263","type":"GENE","name":"TSPAN9-IT1","canonical_id":"hgnc:HGNC:41462","description":"TSPAN9 intronic transcript 1","metadata":null},{"id":"c61f2ccde176402caee99ccde8b8f2b7","type":"GENE","name":"TSPEAR","canonical_id":"hgnc:HGNC:1268","description":"thrombospondin type laminin G domain and EAR repeats","metadata":{"aliases":["MGC11251","TSP-EAR","C21orf29","DFNB98"]}},{"id":"0c6e6ba4c4c74c6b95daa57a935dc218","type":"GENE","name":"TSPEAR-AS1","canonical_id":"hgnc:HGNC:1271","description":"TSPEAR antisense RNA 1","metadata":{"aliases":["C21orf90","TSPEAR-AS2"]}},{"id":"14ccfa0af99940c384b7ce68daa82115","type":"GENE","name":"TSPO","canonical_id":"hgnc:HGNC:1158","description":"translocator protein","metadata":{"aliases":["PBR","MBR","PKBS","mDRC","DBI","IBP","pk18","TSPO1","BZRP"]}},{"id":"4de22053ddb541c8a8ca791356d1ea3c","type":"GENE","name":"TSPO2","canonical_id":"hgnc:HGNC:21256","description":"translocator protein 2","metadata":{"aliases":["dJ34B21.2","BZRPL1"]}},{"id":"199b58bdfc8848e098341b3f2f7130a2","type":"GENE","name":"TSPOAP1","canonical_id":"hgnc:HGNC:16831","description":"TSPO associated protein 1","metadata":{"aliases":["PRAX-1","KIAA0612","RIM-BP1","RIMBP1","BZRAP1"]}},{"id":"de95b92b66fa4ef3a0592711643bdad9","type":"GENE","name":"TSPOAP1-AS1","canonical_id":"hgnc:HGNC:44148","description":"TSPOAP1, SUPT4H1 and RNF43 antisense RNA 1","metadata":{"aliases":["BZRAP1-AS1"]}},{"id":"e31a78439f424a8a87d30b3fbba96d19","type":"GENE","name":"TSPY1","canonical_id":"hgnc:HGNC:12381","description":"testis specific protein Y-linked 1","metadata":{"aliases":["CT78","TSPY"]}},{"id":"043adc12dd69414f9a3d0a796759521e","type":"GENE","name":"TSPY10","canonical_id":"hgnc:HGNC:37473","description":"testis specific protein Y-linked 10","metadata":null},{"id":"7b66652d50694956990084037a3cc9af","type":"GENE","name":"TSPY11P","canonical_id":"hgnc:HGNC:23903","description":"testis specific protein Y-linked 11, pseudogene","metadata":{"aliases":["TSPYP1"]}},{"id":"270cd57d34604b79937baf40e5d73a1a","type":"GENE","name":"TSPY12P","canonical_id":"hgnc:HGNC:23904","description":"testis specific protein Y-linked 12, pseudogene","metadata":{"aliases":["TSPYP2"]}},{"id":"30d5dfa81c1547fbae461ebd9188f8f9","type":"GENE","name":"TSPY13P","canonical_id":"hgnc:HGNC:23905","description":"testis specific protein Y-linked 13, pseudogene","metadata":{"aliases":["TSPYP3"]}},{"id":"96b12ee1db0a41e082eabe87ecf2af18","type":"GENE","name":"TSPY14P","canonical_id":"hgnc:HGNC:23906","description":"testis specific protein Y-linked 14, pseudogene","metadata":{"aliases":["TSPYP4"]}},{"id":"c702e53f4d2c47c785eaf6f20322a567","type":"GENE","name":"TSPY15P","canonical_id":"hgnc:HGNC:37474","description":"testis specific protein Y-linked 15, pseudogene","metadata":null},{"id":"c80b0a76f2f247f08212cc87f64bbd2f","type":"GENE","name":"TSPY16P","canonical_id":"hgnc:HGNC:37712","description":"testis specific protein Y-linked 16, pseudogene","metadata":null},{"id":"014ef6839d1f4a4aaa34053028160663","type":"GENE","name":"TSPY17P","canonical_id":"hgnc:HGNC:37713","description":"testis specific protein Y-linked 17, pseudogene","metadata":null},{"id":"0f064e50c65c4b1bb928aa21297e6f3c","type":"GENE","name":"TSPY18P","canonical_id":"hgnc:HGNC:37725","description":"testis specific protein Y-linked 18, pseudogene","metadata":null},{"id":"0e3b38b73e354612b3af07d9aac4bef3","type":"GENE","name":"TSPY19P","canonical_id":"hgnc:HGNC:37998","description":"testis specific protein Y-linked 19, pseudogene","metadata":null},{"id":"d2e7d8e880044908abbc02c106a0dd3b","type":"GENE","name":"TSPY2","canonical_id":"hgnc:HGNC:23924","description":"testis specific protein Y-linked 2","metadata":{"aliases":["TSPYQ1"]}},{"id":"fa3910ccac7040c1bc76bf766d82252a","type":"GENE","name":"TSPY20P","canonical_id":"hgnc:HGNC:38093","description":"testis specific protein Y-linked 20, pseudogene","metadata":null},{"id":"207ba7fd5ef443eeba28337414031128","type":"GENE","name":"TSPY21P","canonical_id":"hgnc:HGNC:38101","description":"testis specific protein Y-linked 21, pseudogene","metadata":null},{"id":"f2941b10f0b840e7bde1837d8018cc5f","type":"GENE","name":"TSPY22P","canonical_id":"hgnc:HGNC:38522","description":"testis specific protein Y-linked 22, pseudogene","metadata":null},{"id":"889edfa8f5cf402c85baeb86b0168db6","type":"GENE","name":"TSPY23P","canonical_id":"hgnc:HGNC:38594","description":"testis specific protein Y-linked 23, pseudogene","metadata":null},{"id":"209cd75debec4446bd8fd2e613b6b137","type":"GENE","name":"TSPY24P","canonical_id":"hgnc:HGNC:38725","description":"testis specific protein Y-linked 24, pseudogene","metadata":null},{"id":"0182ee81cd4844b2bc98a41a1e5cd372","type":"GENE","name":"TSPY25P","canonical_id":"hgnc:HGNC:38726","description":"testis specific protein Y-linked 25, pseudogene","metadata":null},{"id":"ca0b8c5d9b36433f89bcae35737c283f","type":"GENE","name":"TSPY26P","canonical_id":"hgnc:HGNC:16256","description":"testis specific protein Y-linked 26, pseudogene","metadata":{"aliases":["bA392M18.1","TSPYL3"]}},{"id":"ee5b91b2ab254ed4a83ad755ae8fa519","type":"GENE","name":"TSPY3","canonical_id":"hgnc:HGNC:33876","description":"testis specific protein Y-linked 3","metadata":{"aliases":["CT78"]}},{"id":"fb283ead698f480298519bbf00eb7c29","type":"GENE","name":"TSPY4","canonical_id":"hgnc:HGNC:37287","description":"testis specific protein Y-linked 4","metadata":null},{"id":"466ff7b41d4b4a1abeb1101540592f86","type":"GENE","name":"TSPY5P","canonical_id":"hgnc:HGNC:23907","description":"testis specific protein Y-linked 5, pseudogene","metadata":{"aliases":["TSPYP5"]}},{"id":"cb72027c6a22471a97419eb516fe7085","type":"GENE","name":"TSPY6P","canonical_id":"hgnc:HGNC:34039","description":"testis specific protein Y-linked 6, pseudogene","metadata":{"aliases":["TSPYP6"]}},{"id":"fd06b92cad9c41cfad57d4c699a55b0e","type":"GENE","name":"TSPY7P","canonical_id":"hgnc:HGNC:34040","description":"testis specific protein Y-linked 7, pseudogene","metadata":{"aliases":["TSPYP7"]}},{"id":"30c529b6e8b84835aaa547bc3b3e2930","type":"GENE","name":"TSPY8","canonical_id":"hgnc:HGNC:37471","description":"testis specific protein Y-linked 8","metadata":null},{"id":"31e6483645804b82aef0a3fa7fbef0df","type":"GENE","name":"TSPY9","canonical_id":"hgnc:HGNC:37472","description":"testis specific protein Y-linked 9","metadata":{"aliases":["TSPY9P"]}},{"id":"cd970dbe410a4b8dba12fe3fe548f8b9","type":"GENE","name":"TSPYL1","canonical_id":"hgnc:HGNC:12382","description":"TSPY like 1","metadata":{"aliases":["TSPYL"]}},{"id":"f16b3a2fbb704ef2a9e1d9597e007a1e","type":"GENE","name":"TSPYL2","canonical_id":"hgnc:HGNC:24358","description":"TSPY like 2","metadata":{"aliases":["SE20-4","HRIHFB2216","CTCL","DENTT","CDA1","CINAP","TSPX"]}},{"id":"97d3eb44383342d09bb333b387fe7462","type":"GENE","name":"TSPYL4","canonical_id":"hgnc:HGNC:21559","description":"TSPY like 4","metadata":{"aliases":["dJ486I3.2","KIAA0721"]}},{"id":"760e6403d875418696540fccd500e9c6","type":"GENE","name":"TSPYL5","canonical_id":"hgnc:HGNC:29367","description":"TSPY like 5","metadata":{"aliases":["KIAA1750"]}},{"id":"25d3fed1cf514562832c93419c7c157c","type":"GENE","name":"TSPYL6","canonical_id":"hgnc:HGNC:14521","description":"TSPY like 6","metadata":null},{"id":"f14ac0d4186b47d1968a7d56fc1e5298","type":"GENE","name":"TSR1","canonical_id":"hgnc:HGNC:25542","description":"TSR1 ribosome maturation factor","metadata":{"aliases":["FLJ10534"]}},{"id":"8d960c3cf64f433394b27d7984ee7d48","type":"GENE","name":"TSR2","canonical_id":"hgnc:HGNC:25455","description":"TSR2 ribosome maturation factor","metadata":{"aliases":["DT1P1A10","RP1-112K5.2","WGG1"]}},{"id":"1cbab1f673e1424cbb976ba8fdbd6efe","type":"GENE","name":"TSR3","canonical_id":"hgnc:HGNC:14175","description":"TSR3 ribosome maturation factor","metadata":{"aliases":["MGC24381","C16orf42"]}},{"id":"1ac5e3daddb7493ea82f0a8d07bcd639","type":"GENE","name":"TSSC2","canonical_id":"hgnc:HGNC:12384","description":"tumor suppressing subtransferable candidate 2 (pseudogene)","metadata":null},{"id":"e4c5ca6bf1494f94846d88ec006c58f7","type":"GENE","name":"TSSC4","canonical_id":"hgnc:HGNC:12386","description":"tumor suppressing subtransferable candidate 4","metadata":null},{"id":"4c18c9d432414c099811ba7cfc4a6603","type":"GENE","name":"TSSK1A","canonical_id":"hgnc:HGNC:11400","description":"testis specific serine kinase 1A (pseudogene)","metadata":{"aliases":["TSSK1","SPOGA1","TSSK1AP","STK22A","TSSK7P"]}},{"id":"b6abfbc719fe48b9bfab00d72e82e232","type":"GENE","name":"TSSK1B","canonical_id":"hgnc:HGNC:14968","description":"testis specific serine kinase 1B","metadata":{"aliases":["SPOGA4","FKSG81","STK22D","TSSK1"]}},{"id":"9ca429be83274fc99bd71db02784c9ee","type":"GENE","name":"TSSK2","canonical_id":"hgnc:HGNC:11401","description":"testis specific serine kinase 2","metadata":{"aliases":["SPOGA2","FLJ38613","STK22B"]}},{"id":"9bfd543f6e7d41f69aae40f158c2b178","type":"GENE","name":"TSSK3","canonical_id":"hgnc:HGNC:15473","description":"testis specific serine kinase 3","metadata":{"aliases":["SPOGA3","STK22C"]}},{"id":"8e37b447a31149fc8e8aeb3b93d6345c","type":"GENE","name":"TSSK4","canonical_id":"hgnc:HGNC:19825","description":"testis specific serine kinase 4","metadata":{"aliases":["C14orf20","STK22E"]}},{"id":"49b117aa19c3452486e8474775c897f0","type":"GENE","name":"TSSK5P","canonical_id":"hgnc:HGNC:31931","description":"testis specific serine kinase 5, pseudogene","metadata":{"aliases":["TSSKps1","TSSK5P2","TSSK5P1"]}},{"id":"b03eb56f57064699acb8b9707d8e2914","type":"GENE","name":"TSSK6","canonical_id":"hgnc:HGNC:30410","description":"testis specific serine kinase 6","metadata":{"aliases":["SSTK","FLJ24002","CT72"]}},{"id":"12be2413dd4c4e63bb7f6acb2664dcb3","type":"GENE","name":"TST","canonical_id":"hgnc:HGNC:12388","description":"thiosulfate sulfurtransferase","metadata":{"aliases":["RDS"]}},{"id":"405cb410ae83439787f6f20640219bda","type":"GENE","name":"TSTD1","canonical_id":"hgnc:HGNC:35410","description":"thiosulfate sulfurtransferase like domain containing 1","metadata":{"aliases":["KAT"]}},{"id":"c690ef63eac84f5b82e05573220fe9a1","type":"GENE","name":"TSTD2","canonical_id":"hgnc:HGNC:30087","description":"thiosulfate sulfurtransferase like domain containing 2","metadata":{"aliases":["PP4189","C9orf97"]}},{"id":"d9b4c07fa87943f0bfe1da6dc36a80ff","type":"GENE","name":"TSTD3P","canonical_id":"hgnc:HGNC:40910","description":"thiosulfate sulfurtransferase like domain containing 3, pseudogene","metadata":{"aliases":["TSTD3"]}},{"id":"44e2feaabbb84e26a6a8df0f81099ca5","type":"GENE","name":"TTBK1","canonical_id":"hgnc:HGNC:19140","description":"tau tubulin kinase 1","metadata":{"aliases":["KIAA1855"]}},{"id":"c68a6c60942846599bacf1d33f086679","type":"GENE","name":"TTBK2","canonical_id":"hgnc:HGNC:19141","description":"tau tubulin kinase 2","metadata":{"aliases":["KIAA0847","SCA11"]}},{"id":"18abe5bda3d643778fff5f99ee6c8a1a","type":"GENE","name":"TTBK2-AS1","canonical_id":"hgnc:HGNC:55598","description":"TTBK2 antisense RNA 1","metadata":null},{"id":"43c2c3d3dc424d768b47eb57d12a7e82","type":"GENE","name":"TTC1","canonical_id":"hgnc:HGNC:12391","description":"tetratricopeptide repeat domain 1","metadata":{"aliases":["TPR1"]}},{"id":"fdc98cc52fef495a8b7a0d6ba0948d23","type":"GENE","name":"TTC12","canonical_id":"hgnc:HGNC:23700","description":"tetratricopeptide repeat domain 12","metadata":{"aliases":["FLJ13859","FLJ20535","TPARM"]}},{"id":"912b234afd8547f783e7d2f2bafba668","type":"GENE","name":"TTC12-DT","canonical_id":"hgnc:HGNC:55508","description":"TTC12 divergent transcript","metadata":null},{"id":"75d34f9b12004e16867ffca23ab18673","type":"GENE","name":"TTC13","canonical_id":"hgnc:HGNC:26204","description":"tetratricopeptide repeat domain 13","metadata":{"aliases":["FLJ22584"]}},{"id":"20b0f705bfea42b293259044b3b6206e","type":"GENE","name":"TTC14","canonical_id":"hgnc:HGNC:24697","description":"tetratricopeptide repeat domain 14","metadata":{"aliases":["FLJ00166","KIAA1980"]}},{"id":"5ced211305d54403bff2c8eccf0eb57d","type":"GENE","name":"TTC14-DT","canonical_id":"hgnc:HGNC:52912","description":"TTC14 divergent transcript","metadata":null},{"id":"4b0d559778cd42ab8c39c4a88cec53bb","type":"GENE","name":"TTC16","canonical_id":"hgnc:HGNC:26536","description":"tetratricopeptide repeat domain 16","metadata":{"aliases":["FLJ32780"]}},{"id":"87e4997790444480bde306da47f8f287","type":"GENE","name":"TTC17","canonical_id":"hgnc:HGNC:25596","description":"tetratricopeptide repeat domain 17","metadata":{"aliases":["FLJ10890"]}},{"id":"c52bd3ded7534725b1d51268faa73238","type":"GENE","name":"TTC19","canonical_id":"hgnc:HGNC:26006","description":"tetratricopeptide repeat domain 19","metadata":{"aliases":["FLJ20343","MGC19520"]}},{"id":"46f8a262d6334f0099544cdfc90cbb05","type":"GENE","name":"TTC21A","canonical_id":"hgnc:HGNC:30761","description":"tetratricopeptide repeat domain 21A","metadata":{"aliases":["STI2","IFT139A","Thm2"]}},{"id":"86a70c7d8f6b4d459b78870bceed66f3","type":"GENE","name":"TTC21B","canonical_id":"hgnc:HGNC:25660","description":"tetratricopeptide repeat domain 21B","metadata":{"aliases":["FLJ11457","JBTS11","NPHP12","IFT139B","THM1","FAP60","FLA17","IFT139","CFAP60"]}},{"id":"0ed06de0a66748c0a93e5cacbb339a34","type":"GENE","name":"TTC21B-AS1","canonical_id":"hgnc:HGNC:41115","description":"TTC21B antisense RNA 1","metadata":null},{"id":"71aefef7c267484aa58b3b43ab7a6fc3","type":"GENE","name":"TTC22","canonical_id":"hgnc:HGNC:26067","description":"tetratricopeptide repeat domain 22","metadata":{"aliases":["FLJ20619"]}},{"id":"065aca44cb204d68945ef751d5137079","type":"GENE","name":"TTC23","canonical_id":"hgnc:HGNC:25730","description":"tetratricopeptide repeat domain 23","metadata":{"aliases":["FLJ12572","HCC-8"]}},{"id":"d5f167a96ea249d4b36e8efb95e433d4","type":"GENE","name":"TTC23-AS1","canonical_id":"hgnc:HGNC:56675","description":"TTC23 antisense RNA 1","metadata":{"aliases":["AC036108.3"]}},{"id":"950dfef6e7c347878cb660d45948579c","type":"GENE","name":"TTC23L","canonical_id":"hgnc:HGNC:26355","description":"tetratricopeptide repeat domain 23 like","metadata":{"aliases":["FLJ25439"]}},{"id":"f2567bd0eec340f483a5dba32cf84152","type":"GENE","name":"TTC23L-AS1","canonical_id":"hgnc:HGNC:55215","description":"TTC23L antisense RNA 1","metadata":null},{"id":"a830fbb103b94e70b3d902ec0c0f9503","type":"GENE","name":"TTC24","canonical_id":"hgnc:HGNC:32348","description":"tetratricopeptide repeat domain 24","metadata":null},{"id":"3b03e364464043e9b009c2f68a01d1af","type":"GENE","name":"TTC27","canonical_id":"hgnc:HGNC:25986","description":"tetratricopeptide repeat domain 27","metadata":{"aliases":["FLJ20272"]}},{"id":"f6e0ad0687b94c6eae5dfb98d3abf087","type":"GENE","name":"TTC28","canonical_id":"hgnc:HGNC:29179","description":"tetratricopeptide repeat domain 28","metadata":{"aliases":["KIAA1043"]}},{"id":"6750cb23ccbd4970b4edace39415c96b","type":"GENE","name":"TTC28-AS1","canonical_id":"hgnc:HGNC:29336","description":"TTC28 antisense RNA 1","metadata":{"aliases":["KIAA1648","TTC28AS","TTC28-AS"]}},{"id":"60ade6d973fc40c4a1a58321279401f4","type":"GENE","name":"TTC29","canonical_id":"hgnc:HGNC:29936","description":"tetratricopeptide repeat domain 29","metadata":{"aliases":["NYD-SP14"]}},{"id":"36d5e48c3afe47ad9c8b516863ccdd2e","type":"GENE","name":"TTC29-AS1","canonical_id":"hgnc:HGNC:58415","description":"TTC29 antisense RNA 1","metadata":null},{"id":"39544bf4e47f470b99b3175c1704fa81","type":"GENE","name":"TTC3","canonical_id":"hgnc:HGNC:12393","description":"tetratricopeptide repeat domain 3","metadata":{"aliases":["TPRD","TPRDI","DCRR1","TPRDII","TPRDIII","RNF105"]}},{"id":"0ee0a2238447434b83e74b11df972649","type":"GENE","name":"TTC3-AS1","canonical_id":"hgnc:HGNC:40595","description":"TTC3 antisense RNA 1","metadata":null},{"id":"43c7cb0f91cc48f088666532f7a38a70","type":"GENE","name":"TTC31","canonical_id":"hgnc:HGNC:25759","description":"tetratricopeptide repeat domain 31","metadata":{"aliases":["FLJ12788"]}},{"id":"1c5b58c171bc4d66b4fd3e893a65b1cf","type":"GENE","name":"TTC32","canonical_id":"hgnc:HGNC:32954","description":"tetratricopeptide repeat domain 32","metadata":null},{"id":"9ed7abf2a5e64f2d97f940ef3b3ad32d","type":"GENE","name":"TTC32-DT","canonical_id":"hgnc:HGNC:55236","description":"TTC32 divergent transcript","metadata":null},{"id":"9734c0f0a95f4537a3be3da35050b879","type":"GENE","name":"TTC33","canonical_id":"hgnc:HGNC:29959","description":"tetratricopeptide repeat domain 33","metadata":{"aliases":["OSRF"]}},{"id":"2def1e60fd934e7d992200a6ccdd1473","type":"GENE","name":"TTC34","canonical_id":"hgnc:HGNC:34297","description":"tetratricopeptide repeat domain 34","metadata":null},{"id":"0ddf809d81c9440eaab68e719c078c87","type":"GENE","name":"TTC36","canonical_id":"hgnc:HGNC:33708","description":"tetratricopeptide repeat domain 36","metadata":{"aliases":["HBP21"]}},{"id":"9b9c369f352a47c2b19ab83eb0754510","type":"GENE","name":"TTC36-AS1","canonical_id":"hgnc:HGNC:55495","description":"TTC36 and KMT2A antisense RNA 1","metadata":null},{"id":"3cd95cc579bb4ec7b52573690226b4e0","type":"GENE","name":"TTC38","canonical_id":"hgnc:HGNC:26082","description":"tetratricopeptide repeat domain 38","metadata":{"aliases":["FLJ20699"]}},{"id":"396116812e14449e95786560ba7eed12","type":"GENE","name":"TTC39A","canonical_id":"hgnc:HGNC:18657","description":"tetratricopeptide repeat domain 39A","metadata":{"aliases":["KIAA0452","DEME-6","C1orf34"]}},{"id":"e88a1fd70e2d4bfebdd1f58bed2e7711","type":"GENE","name":"TTC39A-AS1","canonical_id":"hgnc:HGNC:40851","description":"TTC39A antisense RNA 1","metadata":{"aliases":["lincRNA-EPS"]}},{"id":"b2d2cd218d484c21b82ae05d320996bd","type":"GENE","name":"TTC39B","canonical_id":"hgnc:HGNC:23704","description":"tetratricopeptide repeat domain 39B","metadata":{"aliases":["FLJ33868","C9orf52"]}},{"id":"4a4e582f2e014e1fba24b560a904736a","type":"GENE","name":"TTC39C","canonical_id":"hgnc:HGNC:26595","description":"tetratricopeptide repeat domain 39C","metadata":{"aliases":["FLJ33761","HsT2697","C18orf17"]}},{"id":"0bfb7342ef6c44b191d3c1e7d085e208","type":"GENE","name":"TTC39C-AS1","canonical_id":"hgnc:HGNC:51321","description":"TTC39C antisense RNA 1","metadata":null},{"id":"859d4cd03a164904943e021201b960da","type":"GENE","name":"TTC39CP1","canonical_id":"hgnc:HGNC:44019","description":"tetratricopeptide repeat domain 39C pseudogene 1","metadata":null},{"id":"d25fb9cc4ed8432b972f24d3b29ca416","type":"GENE","name":"TTC39DP","canonical_id":"hgnc:HGNC:35451","description":"tetratricopeptide repeat domain 39D, pseudogene","metadata":null},{"id":"ad204609f44e4475a254ca454cff9417","type":"GENE","name":"TTC3P1","canonical_id":"hgnc:HGNC:23318","description":"tetratricopeptide repeat domain 3 pseudogene 1","metadata":{"aliases":["RNF105L","TTC3L"]}},{"id":"670b8fe7d8344e7fb35d67ecdc1f6bff","type":"GENE","name":"TTC4","canonical_id":"hgnc:HGNC:12394","description":"tetratricopeptide repeat domain 4","metadata":{"aliases":["MGC5097","FLJ41930","CNS1"]}},{"id":"715e8f80316b445c859070f82c789945","type":"GENE","name":"TTC41P","canonical_id":"hgnc:HGNC:49210","description":"tetratricopeptide repeat domain 41, pseudogene","metadata":{"aliases":["GNNP"]}},{"id":"5aa61eb10bad41868d718cf735032575","type":"GENE","name":"TTC4P1","canonical_id":"hgnc:HGNC:12395","description":"tetratricopeptide repeat domain 4 pseudogene 1","metadata":{"aliases":["TTC4P"]}},{"id":"9a59d89fec8e4b8885b65d5f17d3fe8c","type":"GENE","name":"TTC5","canonical_id":"hgnc:HGNC:19274","description":"tetratricopeptide repeat domain 5","metadata":{"aliases":["Strap"]}},{"id":"8d0590595e0047348ce5c2ce2ffa758a","type":"GENE","name":"TTC6","canonical_id":"hgnc:HGNC:19739","description":"tetratricopeptide repeat domain 6","metadata":{"aliases":["NCRNA00291","C14orf25"]}},{"id":"c91c31db5d23453faba95c0ce320b5f0","type":"GENE","name":"TTC7A","canonical_id":"hgnc:HGNC:19750","description":"tetratricopeptide repeat domain 7A","metadata":{"aliases":["KIAA1140","TTC7"]}},{"id":"ec954dd0117b4cfba06e7cf58a6db15e","type":"GENE","name":"TTC7B","canonical_id":"hgnc:HGNC:19858","description":"tetratricopeptide repeat domain 7B","metadata":{"aliases":["TTC7L1"]}},{"id":"ad1d0012be2746c5aaf593ff38f32775","type":"GENE","name":"TTC7B-AS1","canonical_id":"hgnc:HGNC:56196","description":"TTC7B antisense RNA 1","metadata":null},{"id":"51806be31bc44331bad3f13480a40be3","type":"GENE","name":"TTC7B-AS2","canonical_id":"hgnc:HGNC:58457","description":"TTC7B antisense RNA 2","metadata":null},{"id":"b977eddbb4e04d27baf3d58337ea9617","type":"GENE","name":"TTC7B-AS3","canonical_id":"hgnc:HGNC:58462","description":"TTC7B antisense RNA 3","metadata":null},{"id":"f5107ca3f7c2430ead7d8d0aafa5ffe5","type":"GENE","name":"TTC8","canonical_id":"hgnc:HGNC:20087","description":"tetratricopeptide repeat domain 8","metadata":{"aliases":["BBS8","RP51"]}},{"id":"7c8a864b80b24bb3bcf638fc8a78554b","type":"GENE","name":"TTC9","canonical_id":"hgnc:HGNC:20267","description":"tetratricopeptide repeat domain 9","metadata":{"aliases":["KIAA0227","TTC9A"]}},{"id":"165146962fc14957b6df6c98f6414076","type":"GENE","name":"TTC9-DT","canonical_id":"hgnc:HGNC:53243","description":"TTC9 divergent transcript","metadata":null},{"id":"d601e8ddc0644ffe925b280b810ee086","type":"GENE","name":"TTC9B","canonical_id":"hgnc:HGNC:26395","description":"tetratricopeptide repeat domain 9B","metadata":{"aliases":["FLJ30373"]}},{"id":"1bd8cc18adb14299b75eb51c21e056e2","type":"GENE","name":"TTC9C","canonical_id":"hgnc:HGNC:28432","description":"tetratricopeptide repeat domain 9C","metadata":{"aliases":["MGC29649"]}},{"id":"3bbb73ad4d6e4284ad7fce0c46827c8d","type":"GENE","name":"TTF1","canonical_id":"hgnc:HGNC:12397","description":"transcription termination factor 1","metadata":null},{"id":"2b53bcf7765647118c63b29fdc60afb5","type":"GENE","name":"TTF2","canonical_id":"hgnc:HGNC:12398","description":null,"metadata":null},{"id":"3dfe5218313a436fb6fe543252fa50f4","type":"GENE","name":"TTI1","canonical_id":"hgnc:HGNC:29029","description":"TELO2 interacting protein 1","metadata":{"aliases":["smg-10","KIAA0406"]}},{"id":"0f237ac553ba4e2987bf74a8cabaa961","type":"GENE","name":"TTI2","canonical_id":"hgnc:HGNC:26262","description":"TELO2 interacting protein 2","metadata":{"aliases":["FLJ23263","C8orf41"]}},{"id":"9df1b4dfb7ac4da2b2b45a62e1ad158d","type":"GENE","name":"TTK","canonical_id":"hgnc:HGNC:12401","description":null,"metadata":null},{"id":"01e18f0d983840c68710251f153f901d","type":"GENE","name":"TTL","canonical_id":"hgnc:HGNC:21586","description":"tubulin tyrosine ligase","metadata":{"aliases":["MGC46235"]}},{"id":"77e02da43f154f41b468049fe4ed8fba","type":"GENE","name":"TTLL1","canonical_id":"hgnc:HGNC:1312","description":"TTL family tubulin polyglutamylase complex subunit L1","metadata":{"aliases":["PGs3","TPGS3","C22orf7"]}},{"id":"cedd0c95bd224eb6ba7883b25fd6951f","type":"GENE","name":"TTLL1-AS1","canonical_id":"hgnc:HGNC:40111","description":"TTLL1 antisense RNA 1","metadata":null},{"id":"ad6dec79d71a4cf2bbc0614f433d7275","type":"GENE","name":"TTLL10","canonical_id":"hgnc:HGNC:26693","description":"tubulin tyrosine ligase like 10","metadata":{"aliases":["FLJ36119","TTLL5"]}},{"id":"27ed2c18ad194111880e524cacceb5ff","type":"GENE","name":"TTLL10-AS1","canonical_id":"hgnc:HGNC:41159","description":"TTLL10 antisense RNA 1","metadata":null},{"id":"986c56757f884a42a968729a3dc1065f","type":"GENE","name":"TTLL11","canonical_id":"hgnc:HGNC:18113","description":"tubulin tyrosine ligase like 11","metadata":{"aliases":["bA244O19.1","C9orf20","TTLL11-IT1","C9orf148"]}},{"id":"d8b817cdec98495eb7a6b1df31c24490","type":"GENE","name":"TTLL12","canonical_id":"hgnc:HGNC:28974","description":"tubulin tyrosine ligase like 12","metadata":{"aliases":["KIAA0153"]}},{"id":"6d3607e339bd429991ce13c723e4b022","type":"GENE","name":"TTLL13","canonical_id":"hgnc:HGNC:32484","description":"tubulin tyrosine ligase like 13","metadata":{"aliases":["FLJ46079","MGC33417","TTLL13P"]}},{"id":"1aa03e667b9e43488b421b4788885d1d","type":"GENE","name":"TTLL2","canonical_id":"hgnc:HGNC:21211","description":"tubulin tyrosine ligase like 2","metadata":{"aliases":["NYD-TSPG","dJ366N23.3","C6orf104"]}},{"id":"6593290541674a7795533794564ea0fb","type":"GENE","name":"TTLL3","canonical_id":"hgnc:HGNC:24483","description":"tubulin tyrosine ligase like 3","metadata":{"aliases":["DKFZP434B103","HOTTL"]}},{"id":"cec53ff12a864d8b83a2b525aca81723","type":"GENE","name":"TTLL4","canonical_id":"hgnc:HGNC:28976","description":"tubulin tyrosine ligase like 4","metadata":{"aliases":["KIAA0173"]}},{"id":"8533f12111134271863df59f8180dc4d","type":"GENE","name":"TTLL5","canonical_id":"hgnc:HGNC:19963","description":"tubulin tyrosine ligase like 5","metadata":{"aliases":["STAMP","KIAA0998"]}},{"id":"055c0268f3294511bce367dc475eb65e","type":"GENE","name":"TTLL6","canonical_id":"hgnc:HGNC:26664","description":"tubulin tyrosine ligase like 6","metadata":{"aliases":["FLJ35808"]}},{"id":"9e3ca31a6007411099db295db8cf72bc","type":"GENE","name":"TTLL7","canonical_id":"hgnc:HGNC:26242","description":"tubulin tyrosine ligase like 7","metadata":{"aliases":["FLJ23033"]}},{"id":"531404442c654397bf4b260992275c1b","type":"GENE","name":"TTLL7-IT1","canonical_id":"hgnc:HGNC:41486","description":"TTLL7 intronic transcript 1","metadata":null},{"id":"de4b39e227f3466da2be441e6f3a84c2","type":"GENE","name":"TTLL8","canonical_id":"hgnc:HGNC:34000","description":"tubulin tyrosine ligase like 8","metadata":null},{"id":"d7710f874f3249ab9004341b77832ed6","type":"GENE","name":"TTLL9","canonical_id":"hgnc:HGNC:16118","description":"tubulin tyrosine ligase like 9","metadata":{"aliases":["dJ310O13.1","C20orf125"]}},{"id":"5a8fb426cbee4f199edea39512c49f02","type":"GENE","name":"TTN","canonical_id":"hgnc:HGNC:12403","description":"titin","metadata":{"aliases":["CMPD4","FLJ32040","TMD","CMH9","LGMD2J","MYLK5","CMD1G"]}},{"id":"f79523fd8f35438baf07ea2a30cca30f","type":"GENE","name":"TTN-AS1","canonical_id":"hgnc:HGNC:44124","description":"TTN antisense RNA 1","metadata":null},{"id":"fa87983becbe4cac9ae4e9b5634d7577","type":"GO_TERM","name":"TTP biosynthetic process","canonical_id":"go:GO:0006234","description":"\"The chemical reactions and pathways resulting in the formation of TTP, ribosylthymine triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"27bb36bb1dc4436a9609dc8db5a3c6ca","type":"GO_TERM","name":"TTP catabolic process","canonical_id":"go:GO:0046047","description":"\"The chemical reactions and pathways resulting in the breakdown of TTP, ribosylthymine triphosphate.\" [GOC:curators]","metadata":null},{"id":"649409860097424f82533eab507f7a02","type":"GO_TERM","name":"TTP metabolic process","canonical_id":"go:GO:0046046","description":"\"The chemical reactions and pathways involving TTP, ribosylthymine triphosphate.\" [GOC:curators]","metadata":null},{"id":"557f73d0195544d7bb972e4eb27ce106","type":"GENE","name":"TTPA","canonical_id":"hgnc:HGNC:12404","description":"alpha tocopherol transfer protein","metadata":{"aliases":["AVED"]}},{"id":"538327302efc4283ae6558c42e679c87","type":"GENE","name":"TTPAL","canonical_id":"hgnc:HGNC:16114","description":"alpha tocopherol transfer protein like","metadata":{"aliases":["dJ179M20.3","C20orf121"]}},{"id":"2b334888b97948218670ef99058abfaa","type":"GO_TERM","name":"TTPase activity","canonical_id":"go:GO:0050339","description":"\"Catalysis of the reaction: dTTP + H2O = dTDP + H+ + phosphate.\" [RHEA:19013]","metadata":null},{"id":"4aebffbeaa8d44c58790cf77a7a6d46e","type":"GENE","name":"TTR","canonical_id":"hgnc:HGNC:12405","description":"transthyretin","metadata":{"aliases":["HsT2651","CTS","PALB","CTS1"]}},{"id":"f6fdfcc2aae648e6a51ccf227310c1e0","type":"GO_TERM","name":"TTT Hsp90 cochaperone complex","canonical_id":"go:GO:0110078","description":"\"A Hsp90 cochaperone complex acting as an adapter between Hps90 and its substrates, members of the PIKK kinase family.\" [PMID:20810650, PMID:22505622, PMID:28827813, PMID:34233195]","metadata":null},{"id":"ff1310127c0c456f84fe4dbabeeb02f8","type":"GENE","name":"TTTY1","canonical_id":"hgnc:HGNC:14022","description":"testis expressed transcript, Y-linked 1","metadata":{"aliases":["TTY1","NCRNA00033","LINC00033"]}},{"id":"47f4aaf190ad4513ba847552a0b8dc3f","type":"GENE","name":"TTTY10","canonical_id":"hgnc:HGNC:18491","description":"testis expressed transcript, Y-linked 10","metadata":{"aliases":["NCRNA00133","lnc-KDM5D-4"]}},{"id":"9b82b00610394139ab12f351e69728c8","type":"GENE","name":"TTTY11","canonical_id":"hgnc:HGNC:18492","description":"testis expressed transcript, Y-linked 11","metadata":{"aliases":["TTY11","NCRNA00134"]}},{"id":"990234b62d994bcbbdd041515dbc9adb","type":"GENE","name":"TTTY12","canonical_id":"hgnc:HGNC:18493","description":"testis expressed transcript, Y-linked 12","metadata":{"aliases":["TTY11","NCRNA00135"]}},{"id":"7b7c93d4056c41bab1c07a2789109932","type":"GENE","name":"TTTY13","canonical_id":"hgnc:HGNC:18494","description":"testis expressed transcript, Y-linked 13","metadata":{"aliases":["TTY13","NCRNA00136"]}},{"id":"82343e093a344f25bcad4e22b931ee88","type":"GENE","name":"TTTY14","canonical_id":"hgnc:HGNC:18495","description":"testis expressed transcript, Y-linked 14","metadata":{"aliases":["TTY14","NCRNA00137","PRO2834","NCRNA00185","CYorf14"]}},{"id":"0f2d5431f43f46c09331124af9d53223","type":"GENE","name":"TTTY15","canonical_id":"hgnc:HGNC:18567","description":"testis expressed transcript, Y-linked 15","metadata":{"aliases":["DKFZP434I143","NCRNA00138"]}},{"id":"09ea2b4d71494916b41a3ba0424b22dd","type":"GENE","name":"TTTY16","canonical_id":"hgnc:HGNC:18840","description":"testis expressed transcript, Y-linked 16","metadata":{"aliases":["NCRNA00139"]}},{"id":"64949a31f9c84056998a1ef3812e9cd6","type":"GENE","name":"TTTY17A","canonical_id":"hgnc:HGNC:18841","description":"testis expressed transcript, Y-linked 17A","metadata":{"aliases":["NCRNA00140","TTTY17"]}},{"id":"8f542e0d99ab476eb188bb63ada75027","type":"GENE","name":"TTTY17B","canonical_id":"hgnc:HGNC:31889","description":"testis expressed transcript, Y-linked 17B","metadata":{"aliases":["NCRNA00141"]}},{"id":"4f4eac60f21e45abbc8110511d3051be","type":"GENE","name":"TTTY17C","canonical_id":"hgnc:HGNC:31890","description":"testis expressed transcript, Y-linked 17C","metadata":{"aliases":["NCRNA00142"]}},{"id":"6e54695f9a9548b5be3a6f64834871f1","type":"GENE","name":"TTTY18","canonical_id":"hgnc:HGNC:18842","description":"testis expressed transcript, Y-linked 18","metadata":{"aliases":["NCRNA00143"]}},{"id":"2b6d1ca4da704856958a451116c41fa1","type":"GENE","name":"TTTY19","canonical_id":"hgnc:HGNC:18843","description":"testis expressed transcript, Y-linked 19","metadata":{"aliases":["NCRNA00144"]}},{"id":"9b6ff40130484a82872659947eda6503","type":"GENE","name":"TTTY1B","canonical_id":"hgnc:HGNC:37981","description":"testis expressed transcript, Y-linked 1B","metadata":null},{"id":"977856d6c1664e28b8a909718704d798","type":"GENE","name":"TTTY2","canonical_id":"hgnc:HGNC:14023","description":"testis expressed transcript, Y-linked 2","metadata":{"aliases":["TTY2","lINC00109"]}},{"id":"255c979556664918874d6307c5070c1f","type":"GENE","name":"TTTY20","canonical_id":"hgnc:HGNC:18844","description":"testis expressed transcript, Y-linked 20","metadata":{"aliases":["NCRNA00145"]}},{"id":"1b6f9873fba14550be0a48a52838d84c","type":"GENE","name":"TTTY22","canonical_id":"hgnc:HGNC:18846","description":"testis expressed transcript, Y-linked 22","metadata":{"aliases":["NCRNA00147"]}},{"id":"03ad483eba0d48d881ec95d39dd3023c","type":"GENE","name":"TTTY23","canonical_id":"hgnc:HGNC:18847","description":"testis expressed transcript, Y-linked 23","metadata":{"aliases":["NCRNA00148"]}},{"id":"76bebc24034c49c0bcb84022172c6580","type":"GENE","name":"TTTY23B","canonical_id":"hgnc:HGNC:37983","description":"testis expressed transcript, Y-linked 23B","metadata":null},{"id":"3e7846e3668f4bc086eed34621126cb4","type":"GENE","name":"TTTY24P","canonical_id":"hgnc:HGNC:38521","description":"testis expressed transcript, Y-linked 24, pseudogene","metadata":null},{"id":"991adce00df040789e4593b3871cde1c","type":"GENE","name":"TTTY25P","canonical_id":"hgnc:HGNC:38524","description":"testis expressed transcript, Y-linked 25, pseudogene","metadata":null},{"id":"701f53eea9fe49f29866c9d0d09b6249","type":"GENE","name":"TTTY26P","canonical_id":"hgnc:HGNC:38528","description":"testis expressed transcript, Y-linked 26, pseudogene","metadata":null},{"id":"4bb1671d1fe048b68685e3af178459bd","type":"GENE","name":"TTTY27P","canonical_id":"hgnc:HGNC:38527","description":"testis expressed transcript, Y-linked 27, pseudogene","metadata":null},{"id":"b7665575121e4f3ab0bbdf57dd0aef0f","type":"GENE","name":"TTTY28P","canonical_id":"hgnc:HGNC:38534","description":"testis expressed transcript, Y-linked 28, pseudogene","metadata":null},{"id":"a7b96926fa4845d1aa306a346fe989bf","type":"GENE","name":"TTTY29P","canonical_id":"hgnc:HGNC:38547","description":"testis expressed transcript, Y-linked 29, pseudogene","metadata":null},{"id":"45ea204904b545b6afef4ce9c1a1316b","type":"GENE","name":"TTTY2B","canonical_id":"hgnc:HGNC:37982","description":"testis expressed transcript, Y-linked 2B","metadata":null},{"id":"f1198df9fc29433ea6212ec84d8170c5","type":"GENE","name":"TTTY3","canonical_id":"hgnc:HGNC:16480","description":"testis expressed transcript, Y-linked 3","metadata":{"aliases":["TTY3","TTTY3A","LINC00121"]}},{"id":"1eec0b52d4804bca862907f3ebe299f6","type":"GENE","name":"TTTY30P","canonical_id":"hgnc:HGNC:38604","description":"testis expressed transcript, Y-linked 30, pseudogene","metadata":null},{"id":"cac9e9daa46243788d91087ed8d0d781","type":"GENE","name":"TTTY31P","canonical_id":"hgnc:HGNC:38711","description":"testis expressed transcript, Y-linked 31, pseudogene","metadata":null},{"id":"66a3dfd100274dd9bd2d808dd58d7629","type":"GENE","name":"TTTY3B","canonical_id":"hgnc:HGNC:31888","description":"testis expressed transcript, Y-linked 3B","metadata":{"aliases":["LNCRNA00122"]}},{"id":"ea2653f8435c4fed99c1a1b7952d958b","type":"GENE","name":"TTTY4","canonical_id":"hgnc:HGNC:16481","description":"testis expressed transcript, Y-linked 4","metadata":{"aliases":["TTY4","TTTY4A","LINC00123"]}},{"id":"2710d78985594c6ea6e4a65437cfda35","type":"GENE","name":"TTTY4B","canonical_id":"hgnc:HGNC:31891","description":"testis expressed transcript, Y-linked 4B","metadata":{"aliases":["LINC00124"]}},{"id":"e0de220a0e4947b9aa3123ab6611089a","type":"GENE","name":"TTTY4C","canonical_id":"hgnc:HGNC:31892","description":"testis expressed transcript, Y-linked 4C","metadata":{"aliases":["LINC00125"]}},{"id":"da86f6b343f14990a98bff5e8601ed98","type":"GENE","name":"TTTY5","canonical_id":"hgnc:HGNC:16482","description":"testis expressed transcript, Y-linked 5","metadata":{"aliases":["TTY5","LINC00126"]}},{"id":"fb67bd56fa0e49d5988b0fd6912881d8","type":"GENE","name":"TTTY6","canonical_id":"hgnc:HGNC:16483","description":"testis expressed transcript, Y-linked 6","metadata":{"aliases":["TTY6","TTTY6A","LINC00127"]}},{"id":"2136aa48a1b34626820817340e00d4b6","type":"GENE","name":"TTTY6B","canonical_id":"hgnc:HGNC:31887","description":"testis expressed transcript, Y-linked 6B","metadata":{"aliases":["LINC00128"]}},{"id":"b5bdf0f8046041408575f22906302b9a","type":"GENE","name":"TTTY7","canonical_id":"hgnc:HGNC:18488","description":"testis expressed transcript, Y-linked 7","metadata":{"aliases":["LINC00129","TTTY7A","TTTY21B"]}},{"id":"d59ba99a12d3451a8dc331f243456903","type":"GENE","name":"TTTY7B","canonical_id":"hgnc:HGNC:37463","description":"testis expressed transcript, Y-linked 7B","metadata":{"aliases":["NCRNA00215","TTTY21"]}},{"id":"4811f3e42a574b869a5995bca0ff2f29","type":"GENE","name":"TTTY8","canonical_id":"hgnc:HGNC:18489","description":"testis expressed transcript, Y-linked 8","metadata":{"aliases":["TTY8","NCRNA00130","LINC00130"]}},{"id":"8c4b2ec56e284e90a00cd36b3416e52e","type":"GENE","name":"TTTY8B","canonical_id":"hgnc:HGNC:37622","description":"testis expressed transcript, Y-linked 8B","metadata":{"aliases":["NCRNA00217"]}},{"id":"39d3b1bfba7b491fb998bbfe010e217a","type":"GENE","name":"TTTY9A","canonical_id":"hgnc:HGNC:18490","description":"testis expressed transcript, Y-linked 9A","metadata":{"aliases":["TTY9","NCRNA00131","TTTY9"]}},{"id":"4ad6f4ababa24f819d87b3e735777891","type":"GENE","name":"TTTY9B","canonical_id":"hgnc:HGNC:32425","description":"testis expressed transcript, Y-linked 9B","metadata":{"aliases":["NCRNA00132"]}},{"id":"6a0b0f7854804878b8aa1acd3a7b0623","type":"GENE","name":"TTYH1","canonical_id":"hgnc:HGNC:13476","description":"tweety family member 1","metadata":null},{"id":"0811b72b1c1d44ff9e2c66a5c2307c52","type":"GENE","name":"TTYH2","canonical_id":"hgnc:HGNC:13877","description":"tweety family member 2","metadata":{"aliases":["C17orf29"]}},{"id":"bf237db4dbb54ff4a7a84fe29c8c1b0f","type":"GENE","name":"TTYH3","canonical_id":"hgnc:HGNC:22222","description":"tweety family member 3","metadata":{"aliases":["KIAA1691"]}},{"id":"23af828e31fc41ee8c880501b47fa76c","type":"GENE","name":"TUB","canonical_id":"hgnc:HGNC:12406","description":"TUB bipartite transcription factor","metadata":{"aliases":["rd5"]}},{"id":"e64976c473464ab89b1932c901123e9c","type":"GENE","name":"TUB-AS1","canonical_id":"hgnc:HGNC:51120","description":"TUB antisense RNA 1","metadata":null},{"id":"db3ca7d7d0c041d4a63fd66d30f5f92a","type":"GENE","name":"TUBA1A","canonical_id":"hgnc:HGNC:20766","description":"tubulin alpha 1a","metadata":{"aliases":["TUBA3","B-ALPHA-1","FLJ25113"]}},{"id":"b6e0cd9eb04c41349cc48467ac03acf4","type":"GENE","name":"TUBA1B","canonical_id":"hgnc:HGNC:18809","description":null,"metadata":null},{"id":"fa87cc93463f47aa95c7414b836b45c2","type":"GENE","name":"TUBA1B-AS1","canonical_id":"hgnc:HGNC:56356","description":"TUBA1B antisense RNA 1","metadata":{"aliases":["RP11-386G11.10"]}},{"id":"4d8bf8898abf455782166aef9286585e","type":"GENE","name":"TUBA1C","canonical_id":"hgnc:HGNC:20768","description":"tubulin alpha 1c","metadata":{"aliases":["MGC14580","MGC10851","bcm948","TUBA6"]}},{"id":"72cba14d4533450ebc4919b3e3815f88","type":"GENE","name":"TUBA1C-AS1","canonical_id":"hgnc:HGNC:58452","description":"TUBA1C antisense RNA 1","metadata":null},{"id":"b9d84fa4064240839c73fb81b313de45","type":"GENE","name":"TUBA3C","canonical_id":"hgnc:HGNC:12408","description":"tubulin alpha 3c","metadata":{"aliases":["bA408E5.3","TUBA2"]}},{"id":"c954d721beb64d58883f51bfd34d0582","type":"GENE","name":"TUBA3C-DT","canonical_id":"hgnc:HGNC:58850","description":"TUBA3C divergent transcript","metadata":null},{"id":"db1244c585cf4ed1951cc44ab0fcc991","type":"GENE","name":"TUBA3D","canonical_id":"hgnc:HGNC:24071","description":"tubulin alpha 3d","metadata":{"aliases":["H2-ALPHA"]}},{"id":"a593f2662bcc4cdab971a5307e730b5b","type":"GENE","name":"TUBA3E","canonical_id":"hgnc:HGNC:20765","description":"tubulin alpha 3e","metadata":null},{"id":"0dc9a805630e4e0592b6437d9e31cebe","type":"GENE","name":"TUBA3GP","canonical_id":"hgnc:HGNC:44096","description":"tubulin alpha 3g pseudogene","metadata":null},{"id":"3bfb6b02e4a54846a35c87e1cffcd023","type":"GENE","name":"TUBA4A","canonical_id":"hgnc:HGNC:12407","description":"tubulin alpha 4a","metadata":{"aliases":["FLJ30169","H2-ALPHA","TUBA1"]}},{"id":"d8eb018a106c45a1924a9aaa3ba59d8d","type":"GENE","name":"TUBA4B","canonical_id":"hgnc:HGNC:18637","description":"tubulin alpha 4b","metadata":{"aliases":["FLJ13940","TUBA4"]}},{"id":"777da442f8aa4fe19b650a24a0dcf225","type":"GENE","name":"TUBA5P","canonical_id":"hgnc:HGNC:54799","description":"tubulin alpha 5, pseudogene","metadata":{"aliases":["RP11-480I12.5","TUBAP5"]}},{"id":"ab2a59a942374f7ba7f89902b17a7077","type":"GENE","name":"TUBA8","canonical_id":"hgnc:HGNC:12410","description":"tubulin alpha 8","metadata":{"aliases":["TUBAL2"]}},{"id":"ce1b8375060c447a84519333701139a5","type":"GENE","name":"TUBAL3","canonical_id":"hgnc:HGNC:23534","description":"tubulin alpha like 3","metadata":{"aliases":["FLJ21665"]}},{"id":"343fdb0259654cb0a6ac6da6e1db3d8f","type":"GENE","name":"TUBAP1","canonical_id":"hgnc:HGNC:12411","description":"tubulin alpha pseudogene 1","metadata":{"aliases":["TUBAP"]}},{"id":"96a71b14e7ff42f299bfdb210b6249d1","type":"GENE","name":"TUBAP10","canonical_id":"hgnc:HGNC:54877","description":"tubulin alpha pseudogene 10","metadata":null},{"id":"f337f70650584637be2f5f5074194401","type":"GENE","name":"TUBAP11","canonical_id":"hgnc:HGNC:54878","description":"tubulin alpha pseudogene 11","metadata":null},{"id":"dde8b90a26074f6a8d8bdd5375a93fe8","type":"GENE","name":"TUBAP12","canonical_id":"hgnc:HGNC:54879","description":"tubulin alpha pseudogene 12","metadata":null},{"id":"1ee5cae501e148039c5f237b487ed83d","type":"GENE","name":"TUBAP13","canonical_id":"hgnc:HGNC:54880","description":"tubulin alpha pseudogene 13","metadata":null},{"id":"4969435f4d654dc68315ac5f9ab867ec","type":"GENE","name":"TUBAP14","canonical_id":"hgnc:HGNC:54881","description":"tubulin alpha pseudogene 14","metadata":null},{"id":"7502eda4d1224b178f62a9aa797e9322","type":"GENE","name":"TUBAP15","canonical_id":"hgnc:HGNC:54882","description":"tubulin alpha pseudogene 15","metadata":null},{"id":"aa07e265c3fd462095f5632491a6ac95","type":"GENE","name":"TUBAP2","canonical_id":"hgnc:HGNC:14531","description":"tubulin alpha pseudogene 2","metadata":null},{"id":"482acf8003c64a2783f59b0783ff801b","type":"GENE","name":"TUBAP3","canonical_id":"hgnc:HGNC:44568","description":"tubulin alpha pseudogene 3","metadata":{"aliases":["TUBA8P1"]}},{"id":"3193a09e659046e48db6e6789d97afdd","type":"GENE","name":"TUBAP4","canonical_id":"hgnc:HGNC:44569","description":"tubulin alpha pseudogene 4","metadata":{"aliases":["TUBA8P2"]}},{"id":"db2ddf70a6da477eb130a46133fbf72f","type":"GENE","name":"TUBAP6","canonical_id":"hgnc:HGNC:54873","description":"tubulin alpha pseudogene 6","metadata":null},{"id":"c594e25f283a4721b08f6d62a8676a0e","type":"GENE","name":"TUBAP7","canonical_id":"hgnc:HGNC:54874","description":"tubulin alpha pseudogene 7","metadata":null},{"id":"dc29086c78ec4bdeb73fb870b8ac886e","type":"GENE","name":"TUBAP8","canonical_id":"hgnc:HGNC:54875","description":"tubulin alpha pseudogene 8","metadata":null},{"id":"57cafae8acb3460db0875f4502fa03d0","type":"GENE","name":"TUBAP9","canonical_id":"hgnc:HGNC:54876","description":"tubulin alpha pseudogene 9","metadata":null},{"id":"8be688dba4774663909179d9e353a3b4","type":"GENE","name":"TUBB","canonical_id":"hgnc:HGNC:20778","description":"tubulin beta class I","metadata":{"aliases":["OK/SW-cl.56","MGC16435","M40","Tubb5"]}},{"id":"6a454276bf78449e8e586a1665b24a89","type":"GENE","name":"TUBB1","canonical_id":"hgnc:HGNC:16257","description":"tubulin beta 1 class VI","metadata":{"aliases":["dJ543J19.4"]}},{"id":"591ebaf7e2ed40bf8cfda18ac1d8a606","type":"GENE","name":"TUBB1P1","canonical_id":"hgnc:HGNC:23982","description":"tubulin beta 1 class VI pseudogene 1","metadata":null},{"id":"98e07241dda34812b9bf5472f8fad529","type":"GENE","name":"TUBB1P2","canonical_id":"hgnc:HGNC:23981","description":"tubulin beta 1 class VI pseudogene 2","metadata":null},{"id":"1a4a04eab0a5491cac3f2fd33847f034","type":"GENE","name":"TUBB2A","canonical_id":"hgnc:HGNC:12412","description":"tubulin beta 2A class IIa","metadata":{"aliases":["dJ40E16.7","TUBB","TUBB2"]}},{"id":"b3915720fafa415ba9258c20a42589c1","type":"GENE","name":"TUBB2A-DT","canonical_id":"hgnc:HGNC:59333","description":"TUBB2A divergent transcript","metadata":null},{"id":"45e7a7e296ea4adf856053837ab3d958","type":"GENE","name":"TUBB2B","canonical_id":"hgnc:HGNC:30829","description":"tubulin beta 2B class IIb","metadata":{"aliases":["MGC8685","DKFZp566F223","bA506K6.1"]}},{"id":"7a12554d43f4420e9f79635db9e52312","type":"GENE","name":"TUBB2BP1","canonical_id":"hgnc:HGNC:42332","description":"tubulin beta 2B class IIb pseudogene 1","metadata":null},{"id":"45bee42e473f4089956bc105426d6ed8","type":"GENE","name":"TUBB3","canonical_id":"hgnc:HGNC:20772","description":null,"metadata":null},{"id":"477e0a31b45e41e4a2611e65edf06a9e","type":"GENE","name":"TUBB3P1","canonical_id":"hgnc:HGNC:42339","description":"tubulin beta 3 class III pseudogene 1","metadata":null},{"id":"3765c5d0be524acfac1d47e8f7d99168","type":"GENE","name":"TUBB3P2","canonical_id":"hgnc:HGNC:42181","description":"tubulin beta 3 class III pseudogene 2","metadata":null},{"id":"6453e85d8a3446b7a7d3550d74bddee2","type":"GENE","name":"TUBB4A","canonical_id":"hgnc:HGNC:20774","description":"tubulin beta 4A class IVa","metadata":{"aliases":["beta-5","TUBB4","DYT4"]}},{"id":"d7489e09469243f480d41a9c15c62f11","type":"GENE","name":"TUBB4AP1","canonical_id":"hgnc:HGNC:42340","description":"tubulin beta 4A class IVa pseudogene 1","metadata":null},{"id":"8f855aa526404ad9a587ab3f316d94cd","type":"GENE","name":"TUBB4B","canonical_id":"hgnc:HGNC:20771","description":"tubulin beta 4B class IVb","metadata":{"aliases":["Beta2","TUBB2C"]}},{"id":"45cbe58249c04b4a88a5222d984edeb7","type":"PROTEIN","name":"TUBB4B","canonical_id":"uniprot:P68371","description":null,"metadata":null},{"id":"4c8f0beb4b7b4f29af29644c9ae333d9","type":"GENE","name":"TUBB4BP1","canonical_id":"hgnc:HGNC:42180","description":"TUBB4B pseudogene 1","metadata":null},{"id":"c069c82cfec847558734360262c0f6be","type":"GENE","name":"TUBB4BP2","canonical_id":"hgnc:HGNC:42183","description":"TUBB4B pseudogene 2","metadata":null},{"id":"591ccc226675498e987232e2ccd68c22","type":"GENE","name":"TUBB4BP3","canonical_id":"hgnc:HGNC:42331","description":"TUBB4B pseudogene 3","metadata":null},{"id":"d94860a9873a4cf699c1308be9543069","type":"GENE","name":"TUBB4BP4","canonical_id":"hgnc:HGNC:42333","description":"TUBB4B pseudogene 4","metadata":null},{"id":"ea4d5d73041a406d80494a44cff0800d","type":"GENE","name":"TUBB4BP5","canonical_id":"hgnc:HGNC:42335","description":"TUBB4B pseudogene 5","metadata":null},{"id":"a9e225642bbb48fca1daac1de6d0ba83","type":"GENE","name":"TUBB4BP6","canonical_id":"hgnc:HGNC:42336","description":"TUBB4B pseudogene 6","metadata":null},{"id":"15c43595b18c4eaaa4817afe2d57162c","type":"GENE","name":"TUBB4BP7","canonical_id":"hgnc:HGNC:42337","description":"TUBB4B pseudogene 7","metadata":null},{"id":"b626fa17566b43739f057f646d90376a","type":"GENE","name":"TUBB4BP8","canonical_id":"hgnc:HGNC:55021","description":"TUBB4B pseudogene 8","metadata":null},{"id":"f16ac5c7b7dd44fd8d07fad0ba4231f8","type":"GENE","name":"TUBB6","canonical_id":"hgnc:HGNC:20776","description":"tubulin beta 6 class V","metadata":{"aliases":["MGC4083","HsT1601"]}},{"id":"87d6f230f730420fa5c18617df58af35","type":"GENE","name":"TUBB6P1","canonical_id":"hgnc:HGNC:42342","description":"tubulin beta 6 class V pseudogene 1","metadata":null},{"id":"d3ed7bc8fc134d89b37e2fafb77f9e7a","type":"GENE","name":"TUBB7P","canonical_id":"hgnc:HGNC:12413","description":"tubulin beta 7 pseudogene","metadata":{"aliases":["TUBB4Q"]}},{"id":"978f44c82e57415ca4066a191f952e1b","type":"GENE","name":"TUBB8","canonical_id":"hgnc:HGNC:20773","description":"tubulin beta 8 class VIII","metadata":{"aliases":["bA631M21.2"]}},{"id":"007f66eed2524d89a178a5883a6f94e9","type":"GENE","name":"TUBB8B","canonical_id":"hgnc:HGNC:24983","description":"tubulin beta 8B","metadata":{"aliases":["TUBB8P12"]}},{"id":"a6a3bd0295e943ff8d15a035b5ab9c35","type":"GENE","name":"TUBB8P1","canonical_id":"hgnc:HGNC:42182","description":"tubulin beta 8 class VIII pseudogene 1","metadata":null},{"id":"dccc217d1ae94ff1868c12e51a454338","type":"GENE","name":"TUBB8P10","canonical_id":"hgnc:HGNC:42348","description":"tubulin beta 8 class VIII pseudogene 10","metadata":null},{"id":"7cf276fa30094e768b25bdf5ecb76f84","type":"GENE","name":"TUBB8P11","canonical_id":"hgnc:HGNC:32337","description":"tubulin beta 8 class VIII pseudogene 11","metadata":null},{"id":"b86074f870314f1a8fb8b867d4e0730c","type":"GENE","name":"TUBB8P2","canonical_id":"hgnc:HGNC:42334","description":"tubulin beta 8 class VIII pseudogene 2","metadata":null},{"id":"64d97dc75e234b2d9d3109db4dc83373","type":"GENE","name":"TUBB8P3","canonical_id":"hgnc:HGNC:42338","description":"tubulin beta 8 class VIII pseudogene 3","metadata":null},{"id":"4d59ef5175e14d60b8782de7819c66bf","type":"GENE","name":"TUBB8P4","canonical_id":"hgnc:HGNC:42185","description":"tubulin beta 8 class VIII pseudogene 4","metadata":null},{"id":"98c37a9aaf7d4efaa7e5dbf891e9d59f","type":"GENE","name":"TUBB8P5","canonical_id":"hgnc:HGNC:42186","description":"tubulin beta 8 class VIII pseudogene 5","metadata":null},{"id":"54eb1f5c16b1437498b58d0c741ad551","type":"GENE","name":"TUBB8P6","canonical_id":"hgnc:HGNC:42343","description":"tubulin beta 8 class VIII pseudogene 6","metadata":null},{"id":"a76fe754c81d4d81a46a7673cb682a19","type":"GENE","name":"TUBB8P7","canonical_id":"hgnc:HGNC:42345","description":"tubulin beta 8 class VIII pseudogene 7","metadata":null},{"id":"3825ffa93dd84ccaab8350e77532ef2a","type":"GENE","name":"TUBB8P8","canonical_id":"hgnc:HGNC:42346","description":"tubulin beta 8 class VIII pseudogene 8","metadata":null},{"id":"a614af6ba95d4698a8c2feba143e8a5f","type":"GENE","name":"TUBB8P9","canonical_id":"hgnc:HGNC:42347","description":"tubulin beta 8 class VIII pseudogene 9","metadata":null},{"id":"ef45c06214ce4be3b619fe845c7c92ae","type":"GENE","name":"TUBBP1","canonical_id":"hgnc:HGNC:12414","description":"tubulin beta pseudogene 1","metadata":null},{"id":"2fa98509e8174d239567fc4eaeeaadb5","type":"GENE","name":"TUBBP10","canonical_id":"hgnc:HGNC:42344","description":"tubulin beta class I pseudogene 10","metadata":null},{"id":"03d9d81475ad47c3a1c67015639f4601","type":"GENE","name":"TUBBP11","canonical_id":"hgnc:HGNC:42184","description":"tubulin beta class I pseudogene 11","metadata":null},{"id":"786fbfe61f7c41b8aa7bdc0607067089","type":"GENE","name":"TUBBP2","canonical_id":"hgnc:HGNC:12415","description":"tubulin beta pseudogene 2","metadata":null},{"id":"d63e2beaf493445a81e923715dfcd466","type":"GENE","name":"TUBBP3","canonical_id":"hgnc:HGNC:18192","description":"tubulin beta pseudogene 3","metadata":null},{"id":"da67f180cafb4997b9b1e27edabcb2dd","type":"GENE","name":"TUBBP4","canonical_id":"hgnc:HGNC:19913","description":"tubulin beta pseudogene 4","metadata":{"aliases":["bA537H15.5"]}},{"id":"4ce521e812c842748f542065dd0c40f4","type":"GENE","name":"TUBBP5","canonical_id":"hgnc:HGNC:23674","description":"tubulin beta pseudogene 5","metadata":null},{"id":"0e428b7c2d914fcfbde228fd50607439","type":"GENE","name":"TUBBP6","canonical_id":"hgnc:HGNC:42175","description":"tubulin beta class I pseudogene 6","metadata":null},{"id":"f8bde35491394f08bcce0f31bdc846e5","type":"GENE","name":"TUBBP7","canonical_id":"hgnc:HGNC:42176","description":"tubulin beta class I pseudogene 7","metadata":null},{"id":"3c986effed5e4ac5a52a222612737d12","type":"GENE","name":"TUBBP8","canonical_id":"hgnc:HGNC:42179","description":"tubulin beta class I pseudogene 8","metadata":null},{"id":"02b96136173f4173bebebb3ddec9b529","type":"GENE","name":"TUBBP9","canonical_id":"hgnc:HGNC:42178","description":"tubulin beta class I pseudogene 9","metadata":null},{"id":"74f257f858c743ab84beda4df21f631c","type":"GENE","name":"TUBD1","canonical_id":"hgnc:HGNC:16811","description":"tubulin delta 1","metadata":{"aliases":["FLJ12709","TUBD"]}},{"id":"34e91fa9cb914aee82764f5d62fd539d","type":"GENE","name":"TUBE1","canonical_id":"hgnc:HGNC:20775","description":"tubulin epsilon 1","metadata":{"aliases":["dJ142L7.2","FLJ22589","TUBE"]}},{"id":"d2eeb28d81f74163b5e668ef45e72c95","type":"GENE","name":"TUBG1","canonical_id":"hgnc:HGNC:12417","description":"tubulin gamma 1","metadata":{"aliases":["TUBGCP1","TUBG"]}},{"id":"67b5fc7153cf491e9a3cedb2a0292234","type":"GENE","name":"TUBG1P","canonical_id":"hgnc:HGNC:12418","description":"tubulin gamma 1 pseudogene","metadata":null},{"id":"34be27c9d8e842fca5e0afec5703d9cf","type":"GENE","name":"TUBG2","canonical_id":"hgnc:HGNC:12419","description":"tubulin gamma 2","metadata":null},{"id":"98b3a0784deb49c880023add54eac648","type":"GENE","name":"TUBGCP2","canonical_id":"hgnc:HGNC:18599","description":"tubulin gamma complex component 2","metadata":{"aliases":["GCP2","Spc97p","SPBC97","hGCP2","ALP4"]}},{"id":"9e6f37672a6e477f8d3c7301ffb88e02","type":"GENE","name":"TUBGCP3","canonical_id":"hgnc:HGNC:18598","description":"tubulin gamma complex component 3","metadata":{"aliases":["GCP3","Spc98p","SPBC98"]}},{"id":"d85ca4828bbc4950ae5ee623dc21d71e","type":"GENE","name":"TUBGCP4","canonical_id":"hgnc:HGNC:16691","description":"tubulin gamma complex component 4","metadata":{"aliases":["76P","FLJ14797","GCP4"]}},{"id":"442d464f7e0f416fa95802bcbab955d2","type":"GENE","name":"TUBGCP5","canonical_id":"hgnc:HGNC:18600","description":"tubulin gamma complex component 5","metadata":{"aliases":["GCP5","KIAA1899"]}},{"id":"d1e9d889935d4ef29fe88abe172f8a4b","type":"GENE","name":"TUBGCP6","canonical_id":"hgnc:HGNC:18127","description":"tubulin gamma complex component 6","metadata":{"aliases":["GCP6","KIAA1669","DJ402G11.6"]}},{"id":"10d467e1372d467aae19cfda33e90874","type":"GENE","name":"TUFM","canonical_id":"hgnc:HGNC:12420","description":"Tu translation elongation factor, mitochondrial","metadata":{"aliases":["EFTu","EF-TuMT","EFTU"]}},{"id":"d45f56e487f049399ef877dec9b0edcb","type":"GENE","name":"TUFMP1","canonical_id":"hgnc:HGNC:12421","description":"Tu translation elongation factor, mitochondrial pseudogene 1","metadata":{"aliases":["TUFML"]}},{"id":"11d915eb02ee4978b49d6884c93ca7d0","type":"GENE","name":"TUFT1","canonical_id":"hgnc:HGNC:12422","description":"tuftelin 1","metadata":null},{"id":"83c03a15318d4fb48b120ef45bfd5b49","type":"GENE","name":"TUG1","canonical_id":"hgnc:HGNC:26066","description":"taurine up-regulated 1","metadata":{"aliases":["FLJ20618","NCRNA00080","LINC00080"]}},{"id":"d8c72e2316f441648f8a7cb9e71abdca","type":"GENE","name":"TULP1","canonical_id":"hgnc:HGNC:12423","description":"TUB like protein 1","metadata":{"aliases":["TUBL1","LCA15","RP14"]}},{"id":"97afc4d7ac484472b5f2a414c5c1d910","type":"GENE","name":"TULP2","canonical_id":"hgnc:HGNC:12424","description":"TUB like protein 2","metadata":{"aliases":["TUBL2","CT65"]}},{"id":"8c3b8c4f3c76460aac41106183269242","type":"GENE","name":"TULP3","canonical_id":"hgnc:HGNC:12425","description":"TUB like protein 3","metadata":{"aliases":["TUBL3"]}},{"id":"274b4075fccc4d4eb243fcef7dca5a11","type":"GENE","name":"TULP3P1","canonical_id":"hgnc:HGNC:39262","description":"TUB like protein 3 pseudogene 1","metadata":null},{"id":"640116a10833406894fdaea7129dddeb","type":"GENE","name":"TULP4","canonical_id":"hgnc:HGNC:15530","description":"TUB like protein 4","metadata":{"aliases":["TUSP","KIAA1397"]}},{"id":"4ec45fff58a04da6bb5eef3e989fdd79","type":"GENE","name":"TUNAR","canonical_id":"hgnc:HGNC:44088","description":"transmembrane neural differentiation associated intracellular calcium regulator","metadata":{"aliases":["BNLN","TUNA","pTUNAR","HI-LNC78","LINC00617"]}},{"id":"c605d2dbd3fe4186898b124a8c426d40","type":"GENE","name":"TUSC1","canonical_id":"hgnc:HGNC:31010","description":"tumor suppressor candidate 1","metadata":{"aliases":["TSG-9","CCDC89B"]}},{"id":"85f4622239014b038d8dc0e596e09c83","type":"GENE","name":"TUSC2","canonical_id":"hgnc:HGNC:17034","description":"tumor suppressor 2, mitochondrial calcium regulator","metadata":{"aliases":["FUS1","PAP","C3orf11","PDAP2"]}},{"id":"74e845382adf418d8ce4b5e7a8f7398a","type":"GENE","name":"TUSC2P1","canonical_id":"hgnc:HGNC:23963","description":"TUSC2 pseudogene 1","metadata":{"aliases":["TUSC2P"]}},{"id":"e549711e8d6a4055aca7dffc9faa7b99","type":"GENE","name":"TUSC2P2","canonical_id":"hgnc:HGNC:53818","description":"TUSC2 pseudogene 2","metadata":null},{"id":"1262cfd14b3e44a7bec682e809ec48ea","type":"GENE","name":"TUSC3","canonical_id":"hgnc:HGNC:30242","description":"tumor suppressor candidate 3","metadata":{"aliases":["MGC13453","N33","OST3A","MRT7","MagT2","SLC58A2","MRT22"]}},{"id":"b45e14fdab3646cb8fd423bb1a786dc0","type":"GENE","name":"TUSC7","canonical_id":"hgnc:HGNC:27701","description":"tumor suppressor candidate 7","metadata":{"aliases":["LINC00902","LOC285194","NCRNA00295","LSAMP-AS3"]}},{"id":"5e3aca0aa3fd4332b075136c75460c57","type":"GENE","name":"TUSC8","canonical_id":"hgnc:HGNC:49111","description":"tumor suppressor candidate 8","metadata":{"aliases":["XLOC_010588","LINC01071"]}},{"id":"2f7d660330044cc295694a5f0a8e8c24","type":"GENE","name":"TUT1","canonical_id":"hgnc:HGNC:26184","description":"terminal uridylyl transferase 1, U6 snRNA-specific","metadata":{"aliases":["FLJ22347","FLJ22267","FLJ21850","PAPD2","TUTase","TENT1","RBM21"]}},{"id":"7c73338402004cc0a8ace90edcbd2afd","type":"GENE","name":"TUT4","canonical_id":"hgnc:HGNC:28981","description":"terminal uridylyl transferase 4","metadata":{"aliases":["KIAA0191","PAPD3","TENT3A","ZCCHC11"]}},{"id":"882d2a987880414db9421fbbb70beced","type":"GENE","name":"TUT7","canonical_id":"hgnc:HGNC:25817","description":"terminal uridylyl transferase 7","metadata":{"aliases":["KIAA1711","FLJ13409","PAPD6","TENT3B","ZCCHC6"]}},{"id":"44d3d7efbf7044c683e3563a27379c81","type":"GENE","name":"TVP23A","canonical_id":"hgnc:HGNC:20398","description":"trans-golgi network vesicle protein 23 homolog A","metadata":{"aliases":["YDR084C","FAM18A"]}},{"id":"8c6212fe695040fa8d40b68d7f31bf10","type":"GENE","name":"TVP23B","canonical_id":"hgnc:HGNC:20399","description":"trans-golgi network vesicle protein 23 homolog B","metadata":{"aliases":["CGI-148","YDR084C","FAM18B","FAM18B1"]}},{"id":"8dc08b7f719f4709aab1e0e652e3172b","type":"GENE","name":"TVP23BP1","canonical_id":"hgnc:HGNC:31127","description":"TVP23B pseudogene 1","metadata":{"aliases":["FAM18B3P"]}},{"id":"db765ad6109c41eaa6804b00c2e1a4e4","type":"GENE","name":"TVP23BP2","canonical_id":"hgnc:HGNC:38869","description":"TVP23B pseudogene 2","metadata":{"aliases":["FAM18B4P"]}},{"id":"a1c16c7c139a4a829b92f571608cc204","type":"GENE","name":"TVP23BP3","canonical_id":"hgnc:HGNC:56942","description":"TVP23B pseudogene 3","metadata":null},{"id":"ea23829e7ee3487c88a1ba5bdf69f4fd","type":"GENE","name":"TVP23C","canonical_id":"hgnc:HGNC:30453","description":"trans-golgi network vesicle protein 23 homolog C","metadata":{"aliases":["MGC8763","FAM18B2"]}},{"id":"93e1defa853b432caa961e983e83f077","type":"GENE","name":"TVP23C-CDRT4","canonical_id":"hgnc:HGNC:42961","description":"TVP23C-CDRT4 readthrough","metadata":{"aliases":["FAM18B2-CDRT4"]}},{"id":"272013e11e3945aaa1ebfa7fd8351eae","type":"GENE","name":"TVP23CP1","canonical_id":"hgnc:HGNC:44646","description":"TVP23C pseudogene 1","metadata":null},{"id":"e3ce3f1901da49879480d2dd25ab21f4","type":"GENE","name":"TVP23CP2","canonical_id":"hgnc:HGNC:44647","description":"TVP23C pseudogene 2","metadata":null},{"id":"ac677d8edcab44aabfa5e598c844b70e","type":"GENE","name":"TVP23CP3","canonical_id":"hgnc:HGNC:56608","description":"TVP23C pseudogene 3","metadata":null},{"id":"ad1f8e2ff140442f86907ea04357ad82","type":"GENE","name":"TWF1","canonical_id":"hgnc:HGNC:9620","description":"twinfilin actin binding protein 1","metadata":{"aliases":["A6","PTK9"]}},{"id":"1bc08819149f49998c03d68d7ea153cc","type":"GENE","name":"TWF1P1","canonical_id":"hgnc:HGNC:21736","description":"twinfilin 1 pseudogene 1","metadata":{"aliases":["A6ps1","PTK9P1"]}},{"id":"84ba8b738fe04fbdbb4355aad492cdf0","type":"GENE","name":"TWF1P2","canonical_id":"hgnc:HGNC:21737","description":"twinfilin 1 pseudogene 2","metadata":{"aliases":["A6ps2","PTK9P2"]}},{"id":"73b63746e1df4c67a57d330eef8c1140","type":"GENE","name":"TWF2","canonical_id":"hgnc:HGNC:9621","description":"twinfilin actin binding protein 2","metadata":{"aliases":["A6RP","A6r","PTK9L"]}},{"id":"450d1f06f7b74df7894138df9f372a8f","type":"GENE","name":"TWF2-DT","canonical_id":"hgnc:HGNC:55619","description":"TWF2 divergent transcript","metadata":null},{"id":"1cae35b9a8d843259c965ee61dbba482","type":"TRIAL","name":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","canonical_id":"clinicaltrials.gov:NCT04392479","description":"Cancer Colorectal; Metastasis","metadata":null},{"id":"6aced8ce3a564bf3af895a562fb8afbb","type":"GENE","name":"TWIST1","canonical_id":"hgnc:HGNC:12428","description":null,"metadata":null},{"id":"815f2517f6f84d85aa10138ab51242fc","type":"GENE","name":"TWIST2","canonical_id":"hgnc:HGNC:20670","description":null,"metadata":null},{"id":"7bce94f2c3cc4d35ab92cc52447b1f04","type":"GENE","name":"TWNK","canonical_id":"hgnc:HGNC:1160","description":"twinkle mtDNA helicase","metadata":{"aliases":["PEO","PEO1","TWINKLE","FLJ21832","TWINL","IOSCA","C10orf2"]}},{"id":"e60ca4b370ea45a896ff9ffe2ebabb7d","type":"GENE","name":"TWSG1","canonical_id":"hgnc:HGNC:12429","description":"twisted gastrulation BMP signaling modulator 1","metadata":{"aliases":["TSG"]}},{"id":"96668d312f854f638cfd059ca1249bee","type":"GENE","name":"TWSG1-DT","canonical_id":"hgnc:HGNC:55329","description":"TWSG1 divergent transcript","metadata":null},{"id":"a14737768db34cbf870e5262bd226922","type":"GENE","name":"TXK","canonical_id":"hgnc:HGNC:12434","description":"TXK tyrosine kinase","metadata":{"aliases":["TKL","PSCTK5","BTKL","RLK","PTK4"]}},{"id":"4c75d713a33b44258cbc94fb2c256d5a","type":"GENE","name":"TXLNA","canonical_id":"hgnc:HGNC:30685","description":"taxilin alpha","metadata":{"aliases":["DKFZp451J0118","IL-14","IL14"]}},{"id":"fb7562a8a4ef4adaa5a87c19ed0a66cb","type":"GENE","name":"TXLNB","canonical_id":"hgnc:HGNC:21617","description":"taxilin beta","metadata":{"aliases":["DKFZp451A175","MDP77","dJ522B19.2","C6orf198"]}},{"id":"e4a2dbea61e4412490860bc081f116c4","type":"GENE","name":"TXLNG","canonical_id":"hgnc:HGNC:18578","description":"taxilin gamma","metadata":{"aliases":["FLJ11209","LSR5","FIAT","MGC126621","MGC126625","TXLNGX","CXorf15"]}},{"id":"2bc28b1c27b946b3aa0f6a1978ac046b","type":"GENE","name":"TXLNGY","canonical_id":"hgnc:HGNC:18473","description":"taxilin gamma Y-linked (pseudogene)","metadata":{"aliases":["CYorf15A","CYorf15B","TXLNG2P"]}},{"id":"23206784718b471cb934b1bd65b8754a","type":"GENE","name":"TXN","canonical_id":"hgnc:HGNC:12435","description":null,"metadata":null},{"id":"7a8967a70bae48ffb539c6a9a423334b","type":"GENE","name":"TXN2","canonical_id":"hgnc:HGNC:17772","description":null,"metadata":null},{"id":"a4341214f6a94de3b826d8d6f5511052","type":"GENE","name":"TXN2P1","canonical_id":"hgnc:HGNC:54554","description":"TXN2 pseudogene 1","metadata":null},{"id":"4285a6183ab4493aa77bc4efec57c03f","type":"GENE","name":"TXNDC11","canonical_id":"hgnc:HGNC:28030","description":"thioredoxin domain containing 11","metadata":{"aliases":["EFP1"]}},{"id":"e193d1ecb4184f608bd1c71bf2a54700","type":"GENE","name":"TXNDC11-AS1","canonical_id":"hgnc:HGNC:56375","description":"TXNDC11 antisense RNA 1","metadata":{"aliases":["AC007613.1"]}},{"id":"104dd5a183ec432eba5145eed5edd93d","type":"GENE","name":"TXNDC12","canonical_id":"hgnc:HGNC:24626","description":"thioredoxin domain containing 12","metadata":{"aliases":["TLP19","ERP18","ERP19","hAG-1","AGR1","PDIA16"]}},{"id":"10b15e20beb347538260923369b52703","type":"GENE","name":"TXNDC12-AS1","canonical_id":"hgnc:HGNC:30008","description":"TXNDC12 antisense RNA 1","metadata":null},{"id":"daaadb30227048c9bc374963e76309dd","type":"GENE","name":"TXNDC15","canonical_id":"hgnc:HGNC:20652","description":"thioredoxin domain containing 15","metadata":{"aliases":["TMX5","FLJ22625","2310047H23Rik","C5orf14"]}},{"id":"9cb0197393cd451bbf74b2ea167825b1","type":"GENE","name":"TXNDC15-AS1","canonical_id":"hgnc:HGNC:59147","description":"TXNDC15 antisense RNA 1","metadata":null},{"id":"3a48224316884be48f00d8fa7bf956d9","type":"GENE","name":"TXNDC16","canonical_id":"hgnc:HGNC:19965","description":"thioredoxin domain containing 16","metadata":{"aliases":["KIAA1344"]}},{"id":"de5815daf2754a4881e2fe471e1a02bd","type":"GENE","name":"TXNDC17","canonical_id":"hgnc:HGNC:28218","description":"thioredoxin domain containing 17","metadata":{"aliases":["MGC14353","TRP14","TXNL5"]}},{"id":"200cd479b9bd4d96afaa06612e68bc80","type":"GENE","name":"TXNDC2","canonical_id":"hgnc:HGNC:16470","description":"thioredoxin domain containing 2","metadata":{"aliases":["SPTRX1"]}},{"id":"e00e102aef0c4b3a9ff00948d73991a5","type":"GENE","name":"TXNDC5","canonical_id":"hgnc:HGNC:21073","description":"thioredoxin domain containing 5","metadata":{"aliases":["MGC3178","FLJ21353","FLJ90810","EndoPDI","Hcc-2","ERp46","PDIA15"]}},{"id":"485db1f1ec0a475ab9e4f03c42a3b691","type":"GENE","name":"TXNDC8","canonical_id":"hgnc:HGNC:31454","description":"thioredoxin domain containing 8","metadata":{"aliases":["bA427L11.2","TRX6","SPTRX-3"]}},{"id":"6c15cb59ec82440dbaf9cf064cd15ed9","type":"GENE","name":"TXNDC9","canonical_id":"hgnc:HGNC:24110","description":"thioredoxin domain containing 9","metadata":{"aliases":["APACD"]}},{"id":"d33d611339254b4694b5b61f46beec7d","type":"GENE","name":"TXNIP","canonical_id":"hgnc:HGNC:16952","description":null,"metadata":null},{"id":"74f6abf33a844c7292993ad3eae8dbbd","type":"GENE","name":"TXNL1","canonical_id":"hgnc:HGNC:12436","description":"thioredoxin like 1","metadata":{"aliases":["Txl","TRP32","TXNL"]}},{"id":"c86a444d7b434293a052e8de516c7c74","type":"GENE","name":"TXNL1P1","canonical_id":"hgnc:HGNC:39459","description":"thioredoxin like 1 pseudogene 1","metadata":null},{"id":"9ca70d580a704290a17303b7f96720b6","type":"GENE","name":"TXNL4A","canonical_id":"hgnc:HGNC:30551","description":"thioredoxin like 4A","metadata":{"aliases":["U5-15kD","DIM1","HsT161","DIB1","SNRNP15","TXNL4"]}},{"id":"8799bb0853ff4719be1388d9ffc127b9","type":"GENE","name":"TXNL4AP1","canonical_id":"hgnc:HGNC:54569","description":"TXNL4A pseudogene 1","metadata":null},{"id":"aa5731eed6f248dca738f751e245bd7f","type":"GENE","name":"TXNL4B","canonical_id":"hgnc:HGNC:26041","description":"thioredoxin like 4B","metadata":{"aliases":["FLJ20511","DLP","Dim2"]}},{"id":"b404c0b0afb340179ecc3388c1903627","type":"GENE","name":"TXNP1","canonical_id":"hgnc:HGNC:49481","description":"thioredoxin pseudogene 1","metadata":null},{"id":"1ea05d1c047f4ea3887ae1611721c7b4","type":"GENE","name":"TXNP2","canonical_id":"hgnc:HGNC:49482","description":"thioredoxin pseudogene 2","metadata":null},{"id":"de318d085e534119ab4171462154a280","type":"GENE","name":"TXNP3","canonical_id":"hgnc:HGNC:49483","description":"thioredoxin pseudogene 3","metadata":null},{"id":"d9443569c5aa429da820d5cd46a71f7d","type":"GENE","name":"TXNP4","canonical_id":"hgnc:HGNC:49484","description":"thioredoxin pseudogene 4","metadata":null},{"id":"b30e7e9f5b1f4ce09c02d1954b4e059e","type":"GENE","name":"TXNP5","canonical_id":"hgnc:HGNC:49485","description":"thioredoxin pseudogene 5","metadata":null},{"id":"2c9d6d65e8be470297d5ff7bae016f40","type":"GENE","name":"TXNP6","canonical_id":"hgnc:HGNC:49486","description":"thioredoxin pseudogene 6","metadata":null},{"id":"45298a1f50e64bef91044b2bf9f90694","type":"GENE","name":"TXNP7","canonical_id":"hgnc:HGNC:49487","description":"thioredoxin pseudogene 7","metadata":null},{"id":"06472097c46c49dc87a4d485d9c88b41","type":"GENE","name":"TXNRD1","canonical_id":"hgnc:HGNC:12437","description":null,"metadata":null},{"id":"94868134d37d488eb7bee302f654bcee","type":"GENE","name":"TXNRD1-AS1","canonical_id":"hgnc:HGNC:58280","description":"TXNRD1 antisense RNA 1","metadata":null},{"id":"429b7f25fa5b4346acdacc8ab297aa00","type":"GENE","name":"TXNRD2","canonical_id":"hgnc:HGNC:18155","description":"thioredoxin reductase 2","metadata":{"aliases":["TR","TRXR2","TR3","SELZ","TXNR2"]}},{"id":"1032ce0160c84e2cb04a0e8c595a68ec","type":"GENE","name":"TXNRD3","canonical_id":"hgnc:HGNC:20667","description":"thioredoxin reductase 3","metadata":{"aliases":["TR2","TRXR3","TGR","TR2IT1","TXNRD3NT1","TXNR3","TXNRD3NB","TXNRD3IT1"]}},{"id":"eaf8fa345e204f0ba9d09caa516e641a","type":"GENE","name":"TYK2","canonical_id":"hgnc:HGNC:12440","description":null,"metadata":null},{"id":"eca811b2c0034a01b252f4804e2b5a8f","type":"PROTEIN","name":"TYK2","canonical_id":"uniprot:P29597","description":null,"metadata":null},{"id":"98c9df002ba7453ab88edd09687ab0f3","type":"GENE","name":"TYMP","canonical_id":"hgnc:HGNC:3148","description":null,"metadata":null},{"id":"fa425ec66868421e879b615caa48a79c","type":"GENE","name":"TYMS","canonical_id":"hgnc:HGNC:12441","description":null,"metadata":null},{"id":"cc5e96b80a1b4a309bcdd97262adf2ad","type":"PROTEIN","name":"TYMS","canonical_id":"uniprot:P04818","description":null,"metadata":null},{"id":"69bf3545de9544c78144592be52ea60a","type":"GENE","name":"TYMSOS","canonical_id":"hgnc:HGNC:29553","description":"TYMS opposite strand RNA","metadata":{"aliases":["C18orf56"]}},{"id":"2705e7a4e94d41a6839036acc8a66d70","type":"GENE","name":"TYMSP1","canonical_id":"hgnc:HGNC:52351","description":"thymidylate synthetase pseudogene 1","metadata":null},{"id":"392259d71dd04e8a996739ab8bcc190e","type":"GENE","name":"TYMSP2","canonical_id":"hgnc:HGNC:52352","description":"thymidylate synthetase pseudogene 2","metadata":null},{"id":"312437129a9f47d4a2ffafda4e4643c6","type":"GENE","name":"TYR","canonical_id":"hgnc:HGNC:12442","description":null,"metadata":null},{"id":"769daa7e0dd749779d979eec1356e50a","type":"GENE","name":"TYRL","canonical_id":"hgnc:HGNC:12443","description":"tyrosinase like (pseudogene)","metadata":null},{"id":"64c63f0e6a96428b8fb4971009bcbfd4","type":"GENE","name":"TYRO3","canonical_id":"hgnc:HGNC:12446","description":"TYRO3 protein tyrosine kinase","metadata":{"aliases":["Dtk","Brt","Tif","Sky","Etk-2","Rek","RSE"]}},{"id":"30bcc67bd6f240ac8f788bf50873a266","type":"GENE","name":"TYRO3P","canonical_id":"hgnc:HGNC:12447","description":"TYRO3P protein tyrosine kinase pseudogene","metadata":null},{"id":"660134610811409c83dbb48d26d0f413","type":"GENE","name":"TYROBP","canonical_id":"hgnc:HGNC:12449","description":"transmembrane immune signaling adaptor TYROBP","metadata":{"aliases":["DAP12","PLO-SL","KARAP","PLOSL"]}},{"id":"7abb1924282c4c3e81110fca874c7a8d","type":"GENE","name":"TYRP1","canonical_id":"hgnc:HGNC:12450","description":null,"metadata":null},{"id":"42c51e81967e473688f5c68f1163c290","type":"GENE","name":"TYSND1","canonical_id":"hgnc:HGNC:28531","description":"trypsin like peroxisomal matrix peptidase 1","metadata":{"aliases":["MGC34695","NET41"]}},{"id":"37bf7e92f5904ce582cc113a9747f439","type":"GENE","name":"TYW1","canonical_id":"hgnc:HGNC:25598","description":"tRNA-yW synthesizing protein 1 homolog","metadata":{"aliases":["FLJ10900","MGC23001","MGC60291","YPL207W","TYW1A","RSAFD1"]}},{"id":"c00d2574d2c448959533efb62cd8e97b","type":"GENE","name":"TYW1B","canonical_id":"hgnc:HGNC:33908","description":"tRNA-yW synthesizing protein 1 homolog B","metadata":{"aliases":["RSAFD2","MGC87315","NCRNA00069","LINC00069"]}},{"id":"1d124f75532744dab8021a1b7245729f","type":"GENE","name":"TYW1P1","canonical_id":"hgnc:HGNC:41905","description":"tRNA-yW synthesizing protein 1 homolog pseudogene 1","metadata":null},{"id":"eb2a32f5ddab4dc380f9b261071ff815","type":"GENE","name":"TYW2","canonical_id":"hgnc:HGNC:26091","description":"tRNA wybutosine-synthesizing protein 2","metadata":{"aliases":["FLJ20772","Trm12","TYW2","TRMT12"]}},{"id":"e1998b0257ba43d99021ed330c899f2a","type":"GENE","name":"TYW3","canonical_id":"hgnc:HGNC:24757","description":"tRNA-yW synthesizing protein 3 homolog","metadata":{"aliases":["FLJ40918","C1orf171"]}},{"id":"db64394392264170a6126d1318cb198c","type":"GENE","name":"TYW5","canonical_id":"hgnc:HGNC:26754","description":"tRNA-yW synthesizing protein 5","metadata":{"aliases":["FLJ37953","C2orf60"]}},{"id":"f44dd86413bd4d12a886f8d7f7e21a4e","type":"GENE","name":"TZMP1","canonical_id":"hgnc:HGNC:31420","description":"transition zone microprotein 1","metadata":{"aliases":["C9orf133","TOPORS-AS1","SMIM27"]}},{"id":"ddeac0d82ece476c8d4b35dddbadbc65","type":"DISEASE","name":"Tachyarrhythmia","canonical_id":"mesh:D013610","description":null,"metadata":null},{"id":"c94265aff4294708a1252f72bf0e49c6","type":"DISEASE","name":"Tachycardia, Supraventricular","canonical_id":"mesh:D013617","description":null,"metadata":null},{"id":"6742c9f7c05a4d10b0c184906a98a4d6","type":"DRUG","name":"Tacrine","canonical_id":"mesh:D013619","description":null,"metadata":null},{"id":"2fa946f0c85e49b9a496f4730e6d7840","type":"TRIAL","name":"Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT01406522","description":"Cocaine Dependence","metadata":null},{"id":"bf388f8fdff346c4b27110db025b0da3","type":"DRUG","name":"Tacrolimus","canonical_id":"mesh:D016559","description":null,"metadata":null},{"id":"00b034bf1a6b4caa814e448dd5521864","type":"TRIAL","name":"Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients","canonical_id":"clinicaltrials.gov:NCT00347048","description":"Ulcerative Colitis","metadata":null},{"id":"a1fdb190c88547e1b08169d5017de11e","type":"TRIAL","name":"Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure","canonical_id":"clinicaltrials.gov:NCT06235892","description":"Organ Grafts","metadata":null},{"id":"b65e8fafb59c49fea7f7507bdabe2bd2","type":"TRIAL","name":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT01713400","description":"Graft vs. Host Disease","metadata":null},{"id":"c70a4ab946364da68d3fc38335b6d79b","type":"TRIAL","name":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","canonical_id":"clinicaltrials.gov:NCT00928018","description":"Non-hodgkin Lymphoma; Hodgkin Lymphoma","metadata":null},{"id":"502f4f83743d42efb27448e0c81b4b36","type":"TRIAL","name":"Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate","canonical_id":"clinicaltrials.gov:NCT07466030","description":"BPH (Benign Prostatic Hyperplasia)","metadata":null},{"id":"027a0f39a1834c5eb985908948ee35f1","type":"TRIAL","name":"Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention","canonical_id":"clinicaltrials.gov:NCT01060969","description":"Pulmonary Edema; Cerebral Edema","metadata":null},{"id":"aa419e6ea6a940f1ab70509175cc9a91","type":"TRIAL","name":"Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT03993353","description":"Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Carcinoma; Head and Neck Cancer Stage III; Head and Neck Cancer Stage IV; Head and Neck Cancer Metastatic; Cancer; Cancer of Esophagus; Cancer, Metastatic; Cancer of Head and Neck; Cancer of Mouth; Cancer of Neck","metadata":null},{"id":"446e7907fc484896b7eb84298bcfc87c","type":"TRIAL","name":"Tadalafil and Sildenafil for Duchenne Muscular Dystrophy","canonical_id":"clinicaltrials.gov:NCT01359670","description":"Duchenne Muscular Dystrophy","metadata":null},{"id":"4669badeedbe49389f2265662c1c55d2","type":"TRIAL","name":"Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia","canonical_id":"clinicaltrials.gov:NCT00538564","description":"Sickle Cell Anemia; Priapism","metadata":null},{"id":"03a4f7b202f644fca02fd8727cfe4d8d","type":"TRIAL","name":"Tadalafil for the Treatment of Raynaud's","canonical_id":"clinicaltrials.gov:NCT00822354","description":"Raynaud","metadata":null},{"id":"1f0799cc43014e2bac81a67375b19f60","type":"TRIAL","name":"Tadalafil in Becker Muscular Dystrophy","canonical_id":"clinicaltrials.gov:NCT01070511","description":"Becker Muscular Dystrophy","metadata":null},{"id":"6100e95696044befb90ebfe84efb841c","type":"TRIAL","name":"Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy","canonical_id":"clinicaltrials.gov:NCT00931528","description":"Prostate Cancer; Sexual Dysfunction","metadata":null},{"id":"83ad9c59ebdf49dcba3c8ee191bd5b32","type":"TRIAL","name":"Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia","canonical_id":"clinicaltrials.gov:NCT05366218","description":"ALL, Childhood B-Cell; Acute Lymphoid Leukemia Relapse; Acute Lymphocytic Leukemia Refractory","metadata":null},{"id":"8d96b135032d4cb9b7a085912fe56be0","type":"TRIAL","name":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","canonical_id":"clinicaltrials.gov:NCT04824092","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"62925c5b183d47efaf2c3ac4cbfaa4ac","type":"TRIAL","name":"Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma","canonical_id":"clinicaltrials.gov:NCT05351593","description":"CNS Lymphoma; Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma","metadata":null},{"id":"56c7e7c69daf4e199b178e194dee0cd9","type":"TRIAL","name":"Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT07582159","description":"Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma","metadata":null},{"id":"ec39aff8815847cd94faa8151e7cdf6f","type":"TRIAL","name":"Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05821088","description":"Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Cutaneous Diffuse\u2026","metadata":null},{"id":"e52b9a50a6ee43ea93bb78c01be93634","type":"TRIAL","name":"Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym","canonical_id":"clinicaltrials.gov:NCT06760156","description":"Large B-cell Lymphoma","metadata":null},{"id":"4c3024669199447798665017aa41cb93","type":"TRIAL","name":"Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder","canonical_id":"clinicaltrials.gov:NCT05786040","description":"Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder; Polymorphic Post-Transplant Lymphoproliferative Disorder","metadata":null},{"id":"6945db561f8b4d43a574d8cb52c90cf8","type":"TRIAL","name":"Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT07731789","description":"Classic Follicular Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma","metadata":null},{"id":"5bf565fdce6e457ea69adebbe132670f","type":"TRIAL","name":"Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study","canonical_id":"clinicaltrials.gov:NCT05718869","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"85ddec2bfc9f4dfe92be1496e655b3ac","type":"TRIAL","name":"Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT05943496","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"3a9a71183ffd445f80e845ad9ffe34f5","type":"TRIAL","name":"Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05910801","description":"Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma","metadata":null},{"id":"a52c3c733f2540a2b41ee03919231be3","type":"TRIAL","name":"Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT05455697","description":"Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma","metadata":null},{"id":"3da4b9dab9fc467982714d1a309363d4","type":"DRUG","name":"Tafluprost","canonical_id":"mesh:C485333","description":null,"metadata":null},{"id":"8e65ff4672d64ecdab2af42cfae75d4f","type":"TRIAL","name":"Tafluprost Preservative Free Switch Study","canonical_id":"clinicaltrials.gov:NCT04654611","description":"Glaucoma; Primary Open Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"dcdd8742aa494d12915bcf26a823cb54","type":"TRIAL","name":"Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","canonical_id":"clinicaltrials.gov:NCT01306461","description":"Ocular Hypertension; Open-angle Glaucoma","metadata":null},{"id":"e88a592fb4b64075a879a07b1ef834f9","type":"TRIAL","name":"Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies","canonical_id":"clinicaltrials.gov:NCT01292460","description":"Ocular Hypertension; Open-angle Glaucoma","metadata":null},{"id":"732e9311ee5a4eda93fa97091901fdb0","type":"TRIAL","name":"Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT01475552","description":"Diabetes Mellitus","metadata":null},{"id":"ea66fb9c49374f948d32c95c400f345d","type":"TRIAL","name":"Tailored Sonidegib Schedule After Complete Response in BCC","canonical_id":"clinicaltrials.gov:NCT04806646","description":"Locally Advanced Basal Cell Carcinoma","metadata":null},{"id":"0a96ce8aef64405e8354b0e828a87f13","type":"TRIAL","name":"Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy","canonical_id":"clinicaltrials.gov:NCT03708848","description":"Helicobacter Pylori Infection","metadata":null},{"id":"8952d687a9af4d8cb099c8ef73a65bf9","type":"TRIAL","name":"Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients","canonical_id":"clinicaltrials.gov:NCT03114995","description":"Non-ST Elevation Myocardial Infarction","metadata":null},{"id":"fd67b303dbb8429e8e9aa7adc627c6b9","type":"TRIAL","name":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","canonical_id":"clinicaltrials.gov:NCT05681702","description":"Coronary Artery Disease","metadata":null},{"id":"730bd0ffbf384358a4dd6b5a3718c300","type":"TRIAL","name":"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT03283384","description":"Breast Neoplasms","metadata":null},{"id":"7ad68797962542df95ff4b4aec168865","type":"TRIAL","name":"Takayasu Arteritis Clinical Trial in China","canonical_id":"clinicaltrials.gov:NCT02981979","description":"Takayasu Arteritis","metadata":null},{"id":"27b1e0d965654c02b962bce842602a39","type":"DRUG","name":"Talaporfin","canonical_id":"mesh:C053434","description":null,"metadata":null},{"id":"63e901a0e0b74c07ba076bd7f3cb09a9","type":"DRUG","name":"Talazoparib","canonical_id":"ncit:C95733","description":null,"metadata":null},{"id":"114b8a40facf45d896e2a2c750b9aa1f","type":"TRIAL","name":"Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd","canonical_id":"clinicaltrials.gov:NCT04740190","description":"Recurrent Glioma; Recurrent Glioblastoma; Poly ADP Ribose Polymerase (PARP) Inhibitor; PTEN Gene Inactivation; IDH Mutation","metadata":null},{"id":"2ef580ccbaec4a4dbb73625914ea1a87","type":"TRIAL","name":"Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02282345","description":"Breast Adenocarcinoma; Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; HER2/Neu Negative; Invasive Breast Carcinoma","metadata":null},{"id":"a0a557e34b5d451a8499adb723341930","type":"TRIAL","name":"Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT06582628","description":"Metastatic Prostate Cancer","metadata":null},{"id":"6e2a99310cb64e46afe18dcacbef0ea9","type":"TRIAL","name":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04734730","description":"Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"84e5ea9789cd44b78782f0dd23d6edc3","type":"TRIAL","name":"Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04068831","description":"Metastatic Renal Cell Carcinoma; Fumarate Hydratase Deficient Renal Cell Carcinoma; Succinate Dehydrogenase Deficient Renal Cell Carcinoma","metadata":null},{"id":"f614af9991fc4799b930d33dc98ec670","type":"TRIAL","name":"Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04207190","description":"Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"23ab64e198ce4e88bb57854f483d025b","type":"TRIAL","name":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","canonical_id":"clinicaltrials.gov:NCT04693468","description":"Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm","metadata":null},{"id":"ac493b8e499044b69610cf2e34dd9f8a","type":"TRIAL","name":"Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies","canonical_id":"clinicaltrials.gov:NCT02116777","description":"Adult Solid Neoplasm; Childhood Solid Neoplasm; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Malignant Solid Neoplasm; Refractory Central Nervous System Neoplasm","metadata":null},{"id":"c5bd74db88eb4a458c743bc52758ceb6","type":"TRIAL","name":"Talazoparib and Thoracic RT for ES-SCLC","canonical_id":"clinicaltrials.gov:NCT04170946","description":"Lung Cancer; Small-Cell Lung Cancer","metadata":null},{"id":"38cb1ebaf15c484fbd68703afad16a30","type":"TRIAL","name":"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04703920","description":"Metastatic Breast Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Ovarian Carcinoma; Metastic or Unresectable Pancreatic Adenocarcinoma","metadata":null},{"id":"4610c38a9779412289d934c554a10f65","type":"DRUG","name":"Taliglucerase alfa","canonical_id":"mesh:C582473","description":null,"metadata":null},{"id":"5cd6b30870a94ecfa7d76abadef7725c","type":"DRUG","name":"Talinolol","canonical_id":"mesh:C011550","description":null,"metadata":null},{"id":"94b952b311684fcba856e55bb44160f6","type":"TRIAL","name":"Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT04797780","description":"Myelodysplastic Syndromes","metadata":null},{"id":"c2150da9d4414e7c97d18e2a4415cdde","type":"TRIAL","name":"Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT04905407","description":"Acute Myeloid Leukemia","metadata":null},{"id":"0ba5f0365e4947029a1d0796edfb1f8a","type":"TRIAL","name":"Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00985530","description":"Acute Promyelocytic Leukemia","metadata":null},{"id":"56bb4ded940a41bb8011ea17e3f6b992","type":"DRUG","name":"Tamoxifen","canonical_id":"mesh:D013629","description":null,"metadata":null},{"id":"10e37325c4c94b3bbef040344fb0978f","type":"DRUG","name":"Tamoxifen","canonical_id":"ncit:C62078","description":null,"metadata":null},{"id":"10facd4537c44ab5bf5780a6475e99a8","type":"TRIAL","name":"Tamoxifen Citrate in Patients With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00963209","description":"Breast Cancer","metadata":null},{"id":"b056316c2c2e492386828912d7b337d5","type":"TRIAL","name":"Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF","canonical_id":"clinicaltrials.gov:NCT02690870","description":"Infertility","metadata":null},{"id":"8a69b32401e244a6bb5f15cdee382055","type":"TRIAL","name":"Tamoxifen in Treating Women With High-Risk Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00002542","description":"Breast Cancer","metadata":null},{"id":"edd58f4904fb473a95df75545717c54b","type":"DRUG","name":"Tamsulosin","canonical_id":"mesh:C088482","description":null,"metadata":null},{"id":"6c10d2defcca4608b5f9e2e369005d76","type":"TRIAL","name":"Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention","canonical_id":"clinicaltrials.gov:NCT07650968","description":"Acute Urinary Retention; Benign Prostatic Hyperplasia","metadata":null},{"id":"4c0b5562069f4eb9b53166c4d28b2aaa","type":"TRIAL","name":"Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT01149746","description":"Healthy","metadata":null},{"id":"696fdc871aa14dc886ecde8af8e895e0","type":"TRIAL","name":"Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy","canonical_id":"clinicaltrials.gov:NCT03614052","description":"Ureterolithiasis; Ureteral Calculi; Urolithiasis","metadata":null},{"id":"d681b272bdef48a09e12884f2fdc54b1","type":"TRIAL","name":"Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair","canonical_id":"clinicaltrials.gov:NCT04434378","description":"Post Operative Urinary Retention","metadata":null},{"id":"8f9d76688fbf46cabd6004af69388cca","type":"TRIAL","name":"Tandem Auto-Allo Transplant for Lymphoma","canonical_id":"clinicaltrials.gov:NCT01181271","description":"Diffuse, Large B-Cell, Lymphoma; Lymphoma, Low-Grade; T-Cell Lymphoma; Mantle-Cell Lymphoma; Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic","metadata":null},{"id":"845243e043dd4e1aac913f12bf3f6503","type":"TRIAL","name":"Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study","canonical_id":"clinicaltrials.gov:NCT05492695","description":"Migraine","metadata":null},{"id":"7369f370cf4148e1a73333c3ad456675","type":"TRIAL","name":"Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02040883","description":"Schizophrenia","metadata":null},{"id":"3fb19c35f5ca46448e49ed823d78f63a","type":"DRUG","name":"Tanespimycin","canonical_id":"ncit:C37899","description":null,"metadata":null},{"id":"d8bc658967394b6fadb10e801c728307","type":"GO_TERM","name":"Tapasin-ERp57 complex","canonical_id":"go:GO:0061779","description":"\"Subunit of the MHC class I peptide loading complex (GO:0042824) (=PLC) involved in the assembly of the heavy-chain-beta2-microglobulin dimers of the MHC class I molecules that fold with eight to ten residue peptides in the endoplasmic reticulum. Required for the inhibition of the reduction of the disulfide bonds of the heavy chains and the assembly and stabilization of the PLC, suggesting it may play a structural rather than a catalytic role.\" [GOC:bhm, GOC:dph, Intact:EBI-11896237, Intact:EBI-9013963, PMID:17603487]","metadata":null},{"id":"71ba8ef728ed40eb8cea8760637d3faa","type":"DRUG","name":"Tapentadol","canonical_id":"mesh:C523979","description":null,"metadata":null},{"id":"091c08d5ac254a6aab2ecfbb081006b6","type":"TRIAL","name":"Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.","canonical_id":"clinicaltrials.gov:NCT01838616","description":"Back Pain; Low Back Pain; Neuropathic Pain","metadata":null},{"id":"9d3189880aba43d68a1368e8a882f306","type":"TRIAL","name":"Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT04718116","description":"Postoperative Pain; Surgery; Pain, Postoperative; Pain, Acute; Pain, Chronic; Pain, Procedural; Pain, Neuropathic; Analgesia","metadata":null},{"id":"59389d45d4694227837f7a944e77101c","type":"TRIAL","name":"Tapentadol in Chronic Malignant Tumour Related Pain","canonical_id":"clinicaltrials.gov:NCT01264887","description":"Cancer; Chronic Pain; Pain","metadata":null},{"id":"8e578068c2114c9aa4bddc68f9da727d","type":"TRIAL","name":"Tapentadol vs Pregabalin for Postoperative Pain in Lower Limb Surgery","canonical_id":"clinicaltrials.gov:NCT07587645","description":"Acute Postoperative Pain; Lower Limb Surgery","metadata":null},{"id":"76250e9b6c6e43d0bddfe1b3c20996d7","type":"TRIAL","name":"Tapentadol vs Tramadol in Arthroscopic Rotator Cuff Repair","canonical_id":"clinicaltrials.gov:NCT07779473","description":"Arthroscopic Rotator Cuff Repair (ARCR); Postoperative Pain; Chronic Pain","metadata":null},{"id":"c345e13a9ea949aa8e803fcad97f4fef","type":"TRIAL","name":"Tapinarof for Cutaneous Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT06661213","description":"Cutaneous Lupus Erythematosus","metadata":null},{"id":"abdbd2bb8a6c4c448fc564f6ac2f2957","type":"TRIAL","name":"Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults","canonical_id":"clinicaltrials.gov:NCT05014568","description":"Atopic Dermatitis","metadata":null},{"id":"d6471bd1485d456b9b413f376a4e403a","type":"TRIAL","name":"Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)","canonical_id":"clinicaltrials.gov:NCT05032859","description":"Atopic Dermatitis","metadata":null},{"id":"cdd714a2e41f47299b4514b67c4c60a2","type":"TRIAL","name":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)","canonical_id":"clinicaltrials.gov:NCT03956355","description":"Plaque Psoriasis","metadata":null},{"id":"496a1e320aca4256adec68d776f5272f","type":"TRIAL","name":"Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)","canonical_id":"clinicaltrials.gov:NCT03983980","description":"Plaque Psoriasis","metadata":null},{"id":"5d223330607944f6bd19cb52d8d10117","type":"TRIAL","name":"Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects","canonical_id":"clinicaltrials.gov:NCT05172726","description":"Plaque Psoriasis","metadata":null},{"id":"486a8a38b72448d28b195aee8ead7b52","type":"TRIAL","name":"Tardive Dyskinesia and Cognitive Function","canonical_id":"clinicaltrials.gov:NCT00926965","description":"Tardive Dyskinesia; Neurocognitive Function","metadata":null},{"id":"44766367c8f34a7a8e866253d5dbcce7","type":"DISEASE","name":"Tardive dyskinesia","canonical_id":"mesh:D000071057","description":null,"metadata":null},{"id":"fc5561ede11d4dd4a4cbbfa3c97139f6","type":"TRIAL","name":"Target Engagement of Terazosin in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT04551040","description":"Healthy","metadata":null},{"id":"5d50be69a446421bb00b5ebc5152796a","type":"TRIAL","name":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","canonical_id":"clinicaltrials.gov:NCT06504160","description":"Atopic Dermatitis","metadata":null},{"id":"bd538acc5fca43499409ac00110aa0b9","type":"TRIAL","name":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT04005690","description":"Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"bb448887c2c44fa1966387f5911d5ad8","type":"TRIAL","name":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","canonical_id":"clinicaltrials.gov:NCT02465060","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate C\u2026","metadata":null},{"id":"5e1899aaca134079b4aaf8c49174e1c8","type":"TRIAL","name":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","canonical_id":"clinicaltrials.gov:NCT05564377","description":"Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Pe\u2026","metadata":null},{"id":"a7c4768e6d794562b25fb43a821eb0e6","type":"TRIAL","name":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","canonical_id":"clinicaltrials.gov:NCT03155620","description":"Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuro\u2026","metadata":null},{"id":"0a15a07f147743138c2b86de1de99b41","type":"TRIAL","name":"Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy","canonical_id":"clinicaltrials.gov:NCT00939523","description":"Pituitary Adenomas; Prolactinomas","metadata":null},{"id":"bbce58f449eb4ebaa60d1ca364ce9e0a","type":"TRIAL","name":"Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT01620216","description":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"361e01add0d7407dabfb910f08fb4b67","type":"TRIAL","name":"Targeted Therapy of Bronchiolitis Obliterans Syndrome","canonical_id":"clinicaltrials.gov:NCT01307462","description":"Bronchiolitis Obliterans","metadata":null},{"id":"b7d604c389624e0b92ce57d5600a46c2","type":"TRIAL","name":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03737994","description":"Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8","metadata":null},{"id":"0cd8c4a78a0449af96ec6d3875fc7ed0","type":"TRIAL","name":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT06116682","description":"Lung Non-Small Cell Carcinoma","metadata":null},{"id":"781cfbc0b5394155b4892187eac43ac3","type":"TRIAL","name":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT06031688","description":"Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"23c19b29f8754b5c9803b55b3269d307","type":"TRIAL","name":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","canonical_id":"clinicaltrials.gov:NCT06632977","description":"Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"699d9313fbec4b59b9dfe084c0487db6","type":"TRIAL","name":"Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D","canonical_id":"clinicaltrials.gov:NCT05847413","description":"Type 1 Diabetes","metadata":null},{"id":"ffc259e59e774f8fa767b33e96503a89","type":"TRIAL","name":"Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone","canonical_id":"clinicaltrials.gov:NCT05282550","description":"AMCI - Amnestic Mild Cognitive Impairment; Sleep Disturbance","metadata":null},{"id":"98de98bd58d04e169dccfe1a77312573","type":"TRIAL","name":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab","canonical_id":"clinicaltrials.gov:NCT01275287","description":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","metadata":null},{"id":"815a36464357436ea9885ddd7c654386","type":"TRIAL","name":"Targeting IL-17A for Treatment-Resistant Depression","canonical_id":"clinicaltrials.gov:NCT04979910","description":"Major Depressive Disorder","metadata":null},{"id":"c6abb14a9c1245e88100f5ba4f4b403a","type":"TRIAL","name":"Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction","canonical_id":"clinicaltrials.gov:NCT07538336","description":"Lung Transplant","metadata":null},{"id":"38230defc2ec45b48d074c63b04d1adb","type":"TRIAL","name":"Targeting Leukotrienes in Kidney Disease","canonical_id":"clinicaltrials.gov:NCT05362474","description":"Diabetic Kidney Disease","metadata":null},{"id":"288af487239d4fa7a8fd073ad71bafd1","type":"TRIAL","name":"Targeting Orexin to Treat Nicotine Dependence","canonical_id":"clinicaltrials.gov:NCT03999099","description":"Nicotine Dependence","metadata":null},{"id":"af867b236b3840aa98a543e7fc81ac11","type":"TRIAL","name":"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","canonical_id":"clinicaltrials.gov:NCT03109288","description":"Multiple Sclerosis","metadata":null},{"id":"384abb323d1c48d6887f2cca4cc2f75d","type":"TRIAL","name":"Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)","canonical_id":"clinicaltrials.gov:NCT03787680","description":"Prostate Cancer","metadata":null},{"id":"bb15f913bd3749588a4997d88f358195","type":"TRIAL","name":"Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL","canonical_id":"clinicaltrials.gov:NCT03398252","description":"Alcohol Use Disorder","metadata":null},{"id":"5116641610c6439cb31b4bdff736873a","type":"TRIAL","name":"Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease","canonical_id":"clinicaltrials.gov:NCT05007678","description":"COVID-19","metadata":null},{"id":"ea4fefc40c9f4391adc5b0d2195b240a","type":"TRIAL","name":"Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT00069160","description":"Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms; Renal Neoplasms","metadata":null},{"id":"ac06e9cb1f04436e89f42c5abcd1bfbe","type":"TRIAL","name":"Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)","canonical_id":"clinicaltrials.gov:NCT00234858","description":"Hypertension; Metabolic Syndrome","metadata":null},{"id":"d6d50e53379c4c3583690baca6bb2653","type":"TRIAL","name":"Tarka\u00ae vs. Lotrel\u00ae in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)","canonical_id":"clinicaltrials.gov:NCT00234871","description":"Hypertension; Diabetes; Proteinuria","metadata":null},{"id":"7901420f2a284b4c9e45b49d1fcb45c6","type":"DRUG","name":"Taselisib","canonical_id":"ncit:C116876","description":null,"metadata":null},{"id":"305376cd67d14f5c94ea141c6481fbf4","type":"TRIAL","name":"Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT02457910","description":"Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma","metadata":null},{"id":"9070ec5618d34dbb9468ce6f343b17db","type":"TRIAL","name":"Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception","canonical_id":"clinicaltrials.gov:NCT01429116","description":"Non-24-Hour Sleep-Wake Disorder","metadata":null},{"id":"bc77aaa0ee624f6ba0c23b435218bff4","type":"TRIAL","name":"Taste Assessment of Ozanimod","canonical_id":"clinicaltrials.gov:NCT05001152","description":"Healthy Volunteers","metadata":null},{"id":"8ab938a897004aeb8a52d9abb44974d3","type":"TRIAL","name":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)","canonical_id":"clinicaltrials.gov:NCT00794794","description":"Allergic Rhinitis","metadata":null},{"id":"3d143fee3563491c85d5f234633cb493","type":"TRIAL","name":"Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)","canonical_id":"clinicaltrials.gov:NCT00794378","description":"Allergic Rhinitis","metadata":null},{"id":"32f260e492e246d8a1b5f8b16675cca0","type":"TRIAL","name":"Taste and Palatability of Orfadin Suspension","canonical_id":"clinicaltrials.gov:NCT01734889","description":"Hereditary Tyrosinemia, Type I","metadata":null},{"id":"e2933ea84c6547b18ecb4e08856489bf","type":"GO_TERM","name":"Tat protein binding","canonical_id":"go:GO:0030957","description":"\"Binding to Tat, a viral transactivating regulatory protein from the human immunodeficiency virus, or the equivalent protein from another virus.\" [GOC:mah, PMID:9094689]","metadata":null},{"id":"cf650b93b1984fa58da220ac2d6e2bec","type":"DRUG","name":"Tavaborole","canonical_id":"mesh:C512998","description":null,"metadata":null},{"id":"06c1c13ed4894962b2ba4928b5bc626e","type":"DRUG","name":"Taxane Compound","canonical_id":"ncit:C1490","description":null,"metadata":null},{"id":"2a81bb3164fe4d5cb9a75944600181db","type":"TRIAL","name":"Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne","canonical_id":"clinicaltrials.gov:NCT05704114","description":"Acne Vulgaris; Post Inflammatory Hyperpigmentation; Post Inflammatory Pigmentation Change; Erythema; Skin Scarring","metadata":null},{"id":"94eacebe64754489b86f81650054375d","type":"TRIAL","name":"Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study","canonical_id":"clinicaltrials.gov:NCT00779896","description":"Cutaneous T-Cell Lymphoma","metadata":null},{"id":"e9db686ab4fc4c818032129b97ef21ea","type":"TRIAL","name":"Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT02721173","description":"Acne Vulgaris","metadata":null},{"id":"0f49b93a58c9495ea31e0ab6f5cedc19","type":"TRIAL","name":"Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma","canonical_id":"clinicaltrials.gov:NCT04225429","description":"Epithelioid Sarcoma","metadata":null},{"id":"9f87ba0932144212a0b99f78065a0ffb","type":"TRIAL","name":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT03874455","description":"Epithelioid Sarcoma (Ex-US Only); Spindle Cell Sarcoma; Sinonasal Carcinoma; Small Cell Carcinoma of the Ovary Hypercalcemic Type; Thoracic Sarcoma; Poorly Differentiated Chordoma; ATRT; Malignant Rhabdoid Tumor of Kidney; Malignant Rhabdoid Tumor of Ovary; Malignant Rhabdoid Tumor; Myxoid Spindle Cell Sarcoma; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Chondrosarcoma; Renal Cell Carcinoma; Myoepithelial Carcinoma; Synovial Sarcoma; Renal Medullary Carcinoma; Malignant Mesothelioma; D\u2026","metadata":null},{"id":"20c2599ac5a14332b92e3a69dc1dd7ab","type":"TRIAL","name":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06692452","description":"Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","metadata":null},{"id":"1ecf6c0b9f55417c84e3693180900619","type":"TRIAL","name":"Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05994235","description":"Follicular Lymphoma","metadata":null},{"id":"3e2e179e8c8a4925a28d60df5dc7ecea","type":"TRIAL","name":"Tazemetostat and Palbociclib With CPX-351for R/R AML","canonical_id":"clinicaltrials.gov:NCT05627232","description":"Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia","metadata":null},{"id":"e29623ef5aa64e64b69ff9e4a66b08c7","type":"TRIAL","name":"Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04624113","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"0d1d3e582c3540588eec38547dc0fa18","type":"TRIAL","name":"Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT05618366","description":"Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma; Follicular Lymphoma","metadata":null},{"id":"ffd5a663cb134098ad2ffc13b092f7e3","type":"TRIAL","name":"Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT05018975","description":"COVID-19 Acute Respiratory Distress Syndrome; Cytokine Release Syndrome","metadata":null},{"id":"d800f95ad4624d7090caa2c78d55da09","type":"TRIAL","name":"Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05467943","description":"Relapsed/Refractory Follicular Lymphoma With EZH2","metadata":null},{"id":"cf590146b9fd4902b91d8d709b2e21e2","type":"TRIAL","name":"Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma","canonical_id":"clinicaltrials.gov:NCT04204941","description":"Advanced Soft-tissue Sarcoma; Advanced Epithelioid Sarcoma","metadata":null},{"id":"5ef6d0ff135648a7841772f1f2b55908","type":"TRIAL","name":"Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05152459","description":"Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma","metadata":null},{"id":"2228017b71df40d9bc1afa1bf8bd39d8","type":"TRIAL","name":"Tazemetostat in Malignant Peripheral Nerve Sheath Tumors","canonical_id":"clinicaltrials.gov:NCT04917042","description":"Peripheral Nerve Sheath Tumor","metadata":null},{"id":"0606a0ad7529495690ca24c8f9e546dc","type":"TRIAL","name":"Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction","canonical_id":"clinicaltrials.gov:NCT03217253","description":"Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma; Metastatic Malignant Solid Neoplasm; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Unresectable Solid Neoplasm","metadata":null},{"id":"a85e0795684c424ba941a3db4cb087e5","type":"TRIAL","name":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT03348631","description":"Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma","metadata":null},{"id":"8bbbebc0e457421f89e326c4aab75cdd","type":"TRIAL","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT03213665","description":"Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Low Grade Glioma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Hodgkin Lymphoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recur\u2026","metadata":null},{"id":"cfd6170f1bc94e7a9ec5161b45a5aac8","type":"TRIAL","name":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","canonical_id":"clinicaltrials.gov:NCT05407441","description":"Atypical Teratoid Rhabdoid Tumor; INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors; SMARCA4-deficient Primary CNS Malignant Tumors; Malignant Rhabdoid Tumor (MRT); Rhabdoid Tumor of the Kidney (RTK); Epithelioid Sarcoma; Chordoma","metadata":null},{"id":"3bf5c5bc0a6d4a5a8f01841325cae873","type":"GO_TERM","name":"Tea1 cell-end complex","canonical_id":"go:GO:0031500","description":"\"A high molecular weight complex characterized in S. pombe containing the cell-end anchoring protein Tea1. This complex is transported to the cell ends by microtubules and is involved in bipolar growth and the maintennce of normal cell polarity.\" [PMID:15936270]","metadata":null},{"id":"79560a5a939b41989469820c0cbf85c5","type":"DISEASE","name":"Tear film insufficiency","canonical_id":"mesh:D015352","description":null,"metadata":null},{"id":"cf3ba632c6c44b3384df2685eb8bd800","type":"GO_TERM","name":"Tec1p-Ste12p-Dig1p complex","canonical_id":"go:GO:1990527","description":"\"A multiprotein complex that is involved in the transcriptional regulation of primarily filamentation genes, but also mating genes, in the yeast S. cerevisiae.\" [GOC:rb, PMID:16782869]","metadata":null},{"id":"d677d7b8454a403b83d00abf1041b4f7","type":"DRUG","name":"Tedizolid phosphate","canonical_id":"mesh:C515040","description":null,"metadata":null},{"id":"c3eaac08811b467b86a458fe998096d3","type":"TRIAL","name":"Teduglutide for Enterocutaneous Fistula (ECF)","canonical_id":"clinicaltrials.gov:NCT02889393","description":"Postoperative Fistula","metadata":null},{"id":"5c1b472eabee4144a7be7c7d4502b269","type":"TRIAL","name":"Teduglutide in Short Bowel Syndrome Patients","canonical_id":"clinicaltrials.gov:NCT04857801","description":"Short Bowel Syndrome","metadata":null},{"id":"52ee9bbae5404b34bd4de0dcdb399553","type":"DRUG","name":"Tegafur","canonical_id":"mesh:D005641","description":null,"metadata":null},{"id":"ef11205a78ac45a2bceb03bd43b49abd","type":"TRIAL","name":"Teh Effect of Subgingival Irrigation Wif Ketorolac and Chlorhexidine in Patients Wif Chronic Periodontist","canonical_id":"clinicaltrials.gov:NCT03836781","description":"Chronic Periodontitis","metadata":null},{"id":"0e522b94afce4eda8d4ae39e66893119","type":"DRUG","name":"Teicoplanin","canonical_id":"mesh:D017334","description":null,"metadata":null},{"id":"10a0e0ddf6d940d6993a54afd928daed","type":"DRUG","name":"Telaprevir","canonical_id":"mesh:C486464","description":null,"metadata":null},{"id":"34fe8323faf04e69ab3d9bc3abdba3e6","type":"DRUG","name":"Telavancin","canonical_id":"mesh:C487637","description":null,"metadata":null},{"id":"a45fc3f14a964fa09eac593f1bfeb4ef","type":"DRUG","name":"Telbivudine","canonical_id":"mesh:C487779","description":null,"metadata":null},{"id":"7d95267ed16841a69b6a2a409f98a9c6","type":"TRIAL","name":"Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)","canonical_id":"clinicaltrials.gov:NCT00443209","description":"Migraine","metadata":null},{"id":"0aca2e6a796746dca62dbd821ecb3839","type":"TRIAL","name":"Telemonitoring to Treat Group 2 Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT04882774","description":"Pulmonary Hypertension Due to Left Heart Disease","metadata":null},{"id":"11c852f7743a47e78c358324f4011874","type":"TRIAL","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT07323641","description":"Lung Non-Small Cell Carcinoma","metadata":null},{"id":"6f522fbd300d4231a420225868d66b01","type":"TRIAL","name":"Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension","canonical_id":"clinicaltrials.gov:NCT00281580","description":"Hypertension","metadata":null},{"id":"45383465e1e140e8915fc7c2c508f781","type":"TRIAL","name":"Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension","canonical_id":"clinicaltrials.gov:NCT00926289","description":"Hypertension","metadata":null},{"id":"c6ecb0dd1ec042f1b4c9fcbf00f1af76","type":"TRIAL","name":"Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension","canonical_id":"clinicaltrials.gov:NCT02177461","description":"Hypertension","metadata":null},{"id":"cd93b1a81eb94005b5fbec1d99f0aa05","type":"TRIAL","name":"Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension","canonical_id":"clinicaltrials.gov:NCT02242812","description":"Hypertension","metadata":null},{"id":"e7ea6a78e0bc4f6db4f8cf0c0934b124","type":"TRIAL","name":"Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT00877929","description":"Hypertension","metadata":null},{"id":"5cf29f1530444ef88d57a79ac3de179b","type":"TRIAL","name":"Telmisartan and Amlodipine Versus Monocomponent Tablets","canonical_id":"clinicaltrials.gov:NCT01278797","description":"Hypertension","metadata":null},{"id":"38ef759e180541c6a0c210e822f44b35","type":"TRIAL","name":"Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00981526","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"dfdceecbe36f4b8c8f3794487fae3568","type":"TRIAL","name":"Telmisartan in Mild to Moderate Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT02260089","description":"Hypertension","metadata":null},{"id":"66a1c8012e4d4570bf8b5b80afa294c6","type":"TRIAL","name":"Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose","canonical_id":"clinicaltrials.gov:NCT00034840","description":"Hypertension","metadata":null},{"id":"3f577acb2ddf4d63bad4877b21d8c10f","type":"TRIAL","name":"Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease","canonical_id":"clinicaltrials.gov:NCT04541407","description":"Non Small Cell Lung Cancer; CNS Progression","metadata":null},{"id":"65a74c28b5de4a0f8fee789fd05ad8de","type":"DRUG","name":"Temozolomide","canonical_id":"ncit:C1244","description":null,"metadata":null},{"id":"e932f292ee7740f1973722cc5a7dbddc","type":"TRIAL","name":"Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT01550224","description":"Acute Myeloid Leukemia With 11q23-abnormality in Relapse","metadata":null},{"id":"0390aa1ea66b4b959c49a1ab14a9bec6","type":"DRUG","name":"Temsirolimus","canonical_id":"ncit:C1844","description":null,"metadata":null},{"id":"bb8cc368da414384b0ec117c861fc06c","type":"TRIAL","name":"Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma","canonical_id":"clinicaltrials.gov:NCT00093782","description":"Metastatic Gastrointestinal Carcinoid Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma","metadata":null},{"id":"63640cd8388e46478e057f313511511c","type":"TRIAL","name":"Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01403415","description":"Childhood B Acute Lymphoblastic Leukemia; Childhood T Acute Lymphoblastic Leukemia; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Lymphoblastic Lymphoma","metadata":null},{"id":"e567ada5ea65492f926ed78369838339","type":"TRIAL","name":"Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors","canonical_id":"clinicaltrials.gov:NCT01141244","description":"Unspecified Childhood Solid Tumor, Protocol Specific","metadata":null},{"id":"8feb2f6119534e5f9048be6d50cf2ac7","type":"TRIAL","name":"Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV","canonical_id":"clinicaltrials.gov:NCT01166126","description":"Mucosal Melanoma; Recurrent Melanoma; Stage IV Melanoma","metadata":null},{"id":"b5a1aadcc69640ac8b6c2c8be23f79ce","type":"DISEASE","name":"Tendinitis","canonical_id":"mesh:D052256","description":null,"metadata":null},{"id":"eaa40d64f636468b9e077de2bd6fbfc2","type":"TRIAL","name":"Tenelia Elderly CGMS Study(TEDDY)","canonical_id":"clinicaltrials.gov:NCT03508323","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"b8d862597b9c439b860d811f623daf6e","type":"TRIAL","name":"Tenelia Triple Combination Study","canonical_id":"clinicaltrials.gov:NCT02567994","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"7fd91b65edbb458fa158bbf5a93878a3","type":"DRUG","name":"Teneligliptin","canonical_id":"mesh:C579035","description":null,"metadata":null},{"id":"8182015f3eca4ac8810f9c9ac3d77ce9","type":"TRIAL","name":"Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients","canonical_id":"clinicaltrials.gov:NCT03011177","description":"Type2 Diabetes Mellitus","metadata":null},{"id":"aec3b6cf949d4eadace1c518c28228a7","type":"TRIAL","name":"Teneligliptin and Atorvastatin DDI Study","canonical_id":"clinicaltrials.gov:NCT03769870","description":"Diabete Mellitus","metadata":null},{"id":"921f9cad7e024368bf2f27a6308cd169","type":"TRIAL","name":"Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study","canonical_id":"clinicaltrials.gov:NCT02449330","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"1a56f316c6194b9e8ec83469bcf1c825","type":"TRIAL","name":"Teneligliptin-Glimepiride DDI Study","canonical_id":"clinicaltrials.gov:NCT03009513","description":"Diabetes Mellitus","metadata":null},{"id":"1b4db934d39e4e249b6d50e011eae783","type":"DISEASE","name":"Tennis Elbow","canonical_id":"mesh:D013716","description":null,"metadata":null},{"id":"b7eb15e30eae458c9650420d1281f2dc","type":"DRUG","name":"Tenofovir alafenamide","canonical_id":"mesh:C442442","description":null,"metadata":null},{"id":"1f960a18001c45099b8734a072a87660","type":"DISEASE","name":"Tenosynovitis","canonical_id":"mesh:D013717","description":null,"metadata":null},{"id":"6a01041b53ec48f993ec0cd1d94fb04c","type":"TRIAL","name":"Tenoxicam for Intrapartum Analgesia","canonical_id":"clinicaltrials.gov:NCT02549118","description":"Analgesia; Obstetrical","metadata":null},{"id":"d59345b8cea2409e869fde9620108ee6","type":"DISEASE","name":"Tension-type headache","canonical_id":"mesh:D018781","description":null,"metadata":null},{"id":"abfea847a38d4f199d2fca4d2e733ccb","type":"TRIAL","name":"Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05213481","description":"Healthy","metadata":null},{"id":"e60411a076db494f834b679f7a092d30","type":"TRIAL","name":"Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT05203822","description":"Healthy","metadata":null},{"id":"f2a8e8e829944146ad714ebefcce20e9","type":"TRIAL","name":"Tepotinib Hepatic Impairment Trial","canonical_id":"clinicaltrials.gov:NCT03546608","description":"Hepatic Impairment","metadata":null},{"id":"43abda3ccf554b90ab3ab2ff757e9857","type":"TRIAL","name":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","canonical_id":"clinicaltrials.gov:NCT02864992","description":"Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Lung Adenocarcinoma Stage IIIB/IV","metadata":null},{"id":"30acc2eb84014ca49e23606034fd2fbe","type":"TRIAL","name":"Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma","canonical_id":"clinicaltrials.gov:NCT05439993","description":"Gastric Cancer; Gastroesophageal-junction Cancer","metadata":null},{"id":"ddac7c24f6444dc0a803230c4f5d331a","type":"TRIAL","name":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","canonical_id":"clinicaltrials.gov:NCT01982955","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"cb727061ba2441d89ebd881cfdbee025","type":"TRIAL","name":"Tepotinib in Solid Tumors Harboring MET Alterations","canonical_id":"clinicaltrials.gov:NCT04647838","description":"Solid Tumor; MET Exon 14 Skipping Mutation; MET Amplification","metadata":null},{"id":"ae3b1896fa1c48d8bb46efb27ecc8ab1","type":"TRIAL","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","canonical_id":"clinicaltrials.gov:NCT06908993","description":"Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation","metadata":null},{"id":"082e5e12961b43eab06ef71bee11717d","type":"DRUG","name":"Teprotumumab","canonical_id":"ncit:C95797","description":null,"metadata":null},{"id":"213db5cb77594ec7a6680823cc853cde","type":"TRIAL","name":"Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease","canonical_id":"clinicaltrials.gov:NCT01868997","description":"Thyroid Associated Ophthalmopathies; Thyroid-Associated Ophthalmopathy","metadata":null},{"id":"d3a5ebd419f84e50a60977c5f31c6d47","type":"TRIAL","name":"Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy","canonical_id":"clinicaltrials.gov:NCT07594912","description":"Thyroid Eye Disease, TED; Graves Ophthalmopathy; Optic Neuropathy","metadata":null},{"id":"dd58c580a3ff4d3f8df05150c3104ba9","type":"DRUG","name":"Terazosin","canonical_id":"mesh:C041226","description":null,"metadata":null},{"id":"4d4f94933e4948e59fea565a2ce3a945","type":"TRIAL","name":"Terazosin And Metabolic Energetics in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT07464028","description":"Parkinson's Disease (PD)","metadata":null},{"id":"7847fcb54b9f4f5690acb63c8c67476c","type":"TRIAL","name":"Terazosin And Metabolic Engagement in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT07796308","description":"Alzheimer s Disease","metadata":null},{"id":"d2f907feae8d4703a0dfbdc4828400d4","type":"TRIAL","name":"Terazosin And Metabolic Engagement in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT07288450","description":"Parkinson's Disease","metadata":null},{"id":"cd97e29a19f6403eb54f4a9b8698dfc7","type":"TRIAL","name":"Terazosin Effect on Cardiac Changes in Early Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04386317","description":"REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease; Symptomatic Parkinson Disease","metadata":null},{"id":"be0f5050234e47dc92b56343562a2db8","type":"TRIAL","name":"Terazosin and Parkinson's Disease Extension Study","canonical_id":"clinicaltrials.gov:NCT05109364","description":"Symptomatic Parkinson Disease; REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease","metadata":null},{"id":"594b0ff155f64a3b843f78c8afffc8ed","type":"TRIAL","name":"Terazosin for Dementia With Lewy Bodies","canonical_id":"clinicaltrials.gov:NCT04760860","description":"Dementia With Lewy Bodies","metadata":null},{"id":"cd2f72d28e0e43f2b85d0b5edf46756f","type":"TRIAL","name":"Terbutaline Concentrations in Blood and Urine","canonical_id":"clinicaltrials.gov:NCT00914797","description":"Asthma","metadata":null},{"id":"1094a89c851c4eec917f502dba48ca11","type":"TRIAL","name":"Terbutaline Sulfate in Adults With Asthma","canonical_id":"clinicaltrials.gov:NCT04973345","description":"Asthma","metadata":null},{"id":"6d6067cb25ef4444b66e3516b15e4dcb","type":"TRIAL","name":"Teriflunomide Observational Effectiveness Study","canonical_id":"clinicaltrials.gov:NCT02490982","description":"Relapsing Remitting Multiple Sclerosis","metadata":null},{"id":"fefb73afaa914e5e88243b49c56ec843","type":"TRIAL","name":"Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT06176235","description":"Immune Thrombocytopenia","metadata":null},{"id":"780ab717291f458d81000ddd945c4088","type":"TRIAL","name":"Teriflunomide Tecfidera LMCE","canonical_id":"clinicaltrials.gov:NCT03526224","description":"Tecfidera; Teriflunomide","metadata":null},{"id":"e5c5d21ad19740be9b8b759ad12c804f","type":"TRIAL","name":"Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT06190145","description":"Immune Thrombocytopenia","metadata":null},{"id":"7ffe050fc94d47deb41439bb3b2f6c10","type":"TRIAL","name":"Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease","canonical_id":"clinicaltrials.gov:NCT04806737","description":"Celiac Disease","metadata":null},{"id":"86a00c46089841539f9ddd92b5aba5fe","type":"TRIAL","name":"Teriparatide Treatment in Patients With Inherited Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01360424","description":"Osteoporosis","metadata":null},{"id":"7d660a307ccb47cda3259275d11bcdf7","type":"TRIAL","name":"Teriparatide Use in Hip Replaced Subjects","canonical_id":"clinicaltrials.gov:NCT00191321","description":"Osteoporosis","metadata":null},{"id":"8e4ce853ef0444f49904c39cf1c000f0","type":"TRIAL","name":"Teriparatide for Fracture Repair in Humans","canonical_id":"clinicaltrials.gov:NCT02091492","description":"Osteoporosis, Age-Related; Humeral Fractures","metadata":null},{"id":"12fd1e916c40459fafbcf677edfc2942","type":"TRIAL","name":"Teriparatide on Maxillary Sinus Floor Osseointegration","canonical_id":"clinicaltrials.gov:NCT06061354","description":"Bone Regeneration","metadata":null},{"id":"d8d8798f401241adb6b12c5703c8b0d3","type":"DRUG","name":"Terpin","canonical_id":"mesh:C005804","description":null,"metadata":null},{"id":"70157154a7e64a28ac52c1dff690d3f2","type":"TRIAL","name":"Tesamorelin Effects on Liver Fat and Histology in HIV","canonical_id":"clinicaltrials.gov:NCT02196831","description":"Human Immunodeficiency Virus (HIV); Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)","metadata":null},{"id":"79bf8dd41257418ba0d8c40a18a383f0","type":"TRIAL","name":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","canonical_id":"clinicaltrials.gov:NCT06554717","description":"HIV-1-infection; Frailty; Impaired Physical Function; Abdominal Obesity; Aging","metadata":null},{"id":"4cbe07c0d52d467abf5731799d494520","type":"TRIAL","name":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","canonical_id":"clinicaltrials.gov:NCT07481734","description":"Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis","metadata":null},{"id":"868033ab96e040d58fabf9c8eb6b3bfb","type":"TRIAL","name":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","canonical_id":"clinicaltrials.gov:NCT03150511","description":"Peripheral Nerve Injuries","metadata":null},{"id":"523bb2d40d7f4f1d86f37ee8c126b427","type":"TRIAL","name":"Test-retest Study With [18F]FBB in Cardiac Amyloidosis","canonical_id":"clinicaltrials.gov:NCT06790394","description":"Cardiac Amyloidosis","metadata":null},{"id":"d96ea4ec100d4168a76140191166b792","type":"TRIAL","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT04941287","description":"Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Recurrent Distal Bile Duct Adenocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Liver Carcinoma","metadata":null},{"id":"8062a09cf2854b81882190b21447b88f","type":"TRIAL","name":"Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)","canonical_id":"clinicaltrials.gov:NCT04439123","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma","metadata":null},{"id":"5a852f96544145d1955b17c6716d6997","type":"TRIAL","name":"Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment","canonical_id":"clinicaltrials.gov:NCT07636564","description":"Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; T Acute Lymphoblastic Leukemia","metadata":null},{"id":"2add60a8e0514649ae00046266879b2c","type":"TRIAL","name":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)","canonical_id":"clinicaltrials.gov:NCT06360575","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma","metadata":null},{"id":"a5c06599a417482e8a330921056b620b","type":"TRIAL","name":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)","canonical_id":"clinicaltrials.gov:NCT06357975","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma","metadata":null},{"id":"f8ed758257644969b6566b4bfa5e3a59","type":"TRIAL","name":"Testing Doxazosin to Treat Stress Mechanisms in Alcoholism","canonical_id":"clinicaltrials.gov:NCT02989493","description":"Alcoholism","metadata":null},{"id":"a3f60edcb52646ed8ea198320f093bcb","type":"TRIAL","name":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","canonical_id":"clinicaltrials.gov:NCT04269902","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"9262fbf3083641feac571220b5df3970","type":"TRIAL","name":"Testing Effects of Melatonin on Uterine Contractions in Women","canonical_id":"clinicaltrials.gov:NCT05358834","description":"Pregnant Women","metadata":null},{"id":"7d55f73437b3496c856e1f6a82478f8a","type":"TRIAL","name":"Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)","canonical_id":"clinicaltrials.gov:NCT06357988","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma","metadata":null},{"id":"5ededc53b9174ba9963e8d8679338c2a","type":"TRIAL","name":"Testing Miglustat Administration in Subjects With Spastic Paraplegia 11","canonical_id":"clinicaltrials.gov:NCT04768166","description":"Hereditary Spastic Paraparesis","metadata":null},{"id":"b24e7055180b417ba0bb69f1e0261741","type":"TRIAL","name":"Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)","canonical_id":"clinicaltrials.gov:NCT06400264","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma","metadata":null},{"id":"5637e2a06b924483861b4fe7d6acebc4","type":"TRIAL","name":"Testing Obeticholic Acid for Familial Adenomatous Polyposis","canonical_id":"clinicaltrials.gov:NCT05223036","description":"Attenuated Familial Adenomatous Polyposis; Colorectal Carcinoma; Duodenal Carcinoma; Familial Adenomatous Polyposis","metadata":null},{"id":"dfb2420ac2244e6f860acfb36428ce09","type":"TRIAL","name":"Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)","canonical_id":"clinicaltrials.gov:NCT06390839","description":"Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm","metadata":null},{"id":"7726950a02104493a8d840b98d7f660e","type":"TRIAL","name":"Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement","canonical_id":"clinicaltrials.gov:NCT04221438","description":"Melanoma of Unknown Primary; Metastatic Malignant Neoplasm in Lymph Node; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Recurrent Cutaneous Melanoma","metadata":null},{"id":"b21b659259bc47db92f85d4acdd69ae5","type":"TRIAL","name":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07151586","description":"Triple Negative Breast Neoplasms; Neoplasm Metastasis; HER 2 Low-expressing Breast Cancer","metadata":null},{"id":"b0a0502e99634671b1d3fd6edd1103fe","type":"TRIAL","name":"Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread","canonical_id":"clinicaltrials.gov:NCT02196181","description":"Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma","metadata":null},{"id":"574aa20ec6554b6f8d65d4c77c39c285","type":"TRIAL","name":"Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects","canonical_id":"clinicaltrials.gov:NCT04520217","description":"Photosensitivity; Microvesicle Particle","metadata":null},{"id":"94444f7453e9405d8380df8309575840","type":"TRIAL","name":"Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT06980038","description":"Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Nasal Cavity Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Nasal Cavity Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous\u2026","metadata":null},{"id":"a74fa92f6e634b399f21976d0597ed5b","type":"TRIAL","name":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","canonical_id":"clinicaltrials.gov:NCT07391774","description":"Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma","metadata":null},{"id":"e1b1785df7eb4cf28a5033ce8375512b","type":"TRIAL","name":"Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence","canonical_id":"clinicaltrials.gov:NCT00390923","description":"Nicotine Dependence","metadata":null},{"id":"030e8a04b8454149bb80bdb40307b5c2","type":"TRIAL","name":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","canonical_id":"clinicaltrials.gov:NCT07485010","description":"Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease","metadata":null},{"id":"cddf89cd10044f3fa7ade87f0bf5b000","type":"TRIAL","name":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05353439","description":"Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma","metadata":null},{"id":"a33d366edce741669a8df4a6c511b2c8","type":"TRIAL","name":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","canonical_id":"clinicaltrials.gov:NCT03126916","description":"Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma","metadata":null},{"id":"a80cf3de60d44b85925fe0f8b6670e81","type":"TRIAL","name":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT06102902","description":"Metastatic Colorectal Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8","metadata":null},{"id":"88fd87aac95646cda58ee61d9183607f","type":"TRIAL","name":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","canonical_id":"clinicaltrials.gov:NCT06029270","description":"Metastatic Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8","metadata":null},{"id":"e0becbd2d4e04119968c14c4688a5d5e","type":"TRIAL","name":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04345913","description":"Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma","metadata":null},{"id":"7eb9551638aa4552b65619b60afd50d3","type":"TRIAL","name":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","canonical_id":"clinicaltrials.gov:NCT07072585","description":"Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma","metadata":null},{"id":"5b464185eeb5432c894ee1bbf16d6376","type":"TRIAL","name":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","canonical_id":"clinicaltrials.gov:NCT04484818","description":"Prostate Carcinoma","metadata":null},{"id":"b936398b9f974452bf79da94879fbf75","type":"TRIAL","name":"Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial","canonical_id":"clinicaltrials.gov:NCT06931340","description":"Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"dcc7df1c84ad4c48a184298cd0f0628b","type":"TRIAL","name":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04803201","description":"Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Follicular T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Peripheral T-Cell Lymphoma, Not Otherwise Specified","metadata":null},{"id":"5b4ed544b36942e1904d6cd719541337","type":"TRIAL","name":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","canonical_id":"clinicaltrials.gov:NCT07437963","description":"Recurrent Ganglioneuroblastoma; Recurrent Neuroblastoma; Refractory Ganglioneuroblastoma; Refractory Neuroblastoma","metadata":null},{"id":"ab8e61be1c75450b9fe7cc01fe212696","type":"TRIAL","name":"Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial","canonical_id":"clinicaltrials.gov:NCT03941860","description":"Multiple Myeloma","metadata":null},{"id":"d60ecd9aa39a4f75ad8ac22949504878","type":"TRIAL","name":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","canonical_id":"clinicaltrials.gov:NCT04548752","description":"Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8","metadata":null},{"id":"d6dcccdb3c4446bf92827bc5fa202759","type":"TRIAL","name":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03654768","description":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","metadata":null},{"id":"5a18fa3d45f14af586b485b29a17c19b","type":"TRIAL","name":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","canonical_id":"clinicaltrials.gov:NCT05687123","description":"Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor","metadata":null},{"id":"fa88688b71b0445c9aa619c293cef448","type":"TRIAL","name":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","canonical_id":"clinicaltrials.gov:NCT03854474","description":"Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8","metadata":null},{"id":"2718d23336f34073980e3bf44be7fa2a","type":"TRIAL","name":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT06917911","description":"Core Binding Factor Acute Myeloid Leukemia","metadata":null},{"id":"c4d1310d931345ddb5694d9da3274297","type":"TRIAL","name":"Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer","canonical_id":"clinicaltrials.gov:NCT06900595","description":"Locally Advanced Adrenal Cortical Carcinoma; Metastatic Adrenal Cortical Carcinoma; Recurrent Adrenal Cortical Carcinoma; Stage III Adrenal Cortical Carcinoma AJCC v8; Stage IV Adrenal Cortical Carcinoma AJCC v8; Unresectable Adrenal Cortical Carcinoma","metadata":null},{"id":"aef6bed60efc484a8f1a2abb1adcc792","type":"TRIAL","name":"Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer","canonical_id":"clinicaltrials.gov:NCT07605364","description":"Advanced Glioblastoma","metadata":null},{"id":"24d925391e7b4951bb32f3d8b4ee855f","type":"TRIAL","name":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT05198830","description":"Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8","metadata":null},{"id":"bf20542539ac439381fd7b0dd9593699","type":"TRIAL","name":"Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread","canonical_id":"clinicaltrials.gov:NCT04631029","description":"Extensive Stage Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Brain","metadata":null},{"id":"8b385535ea3c4cee98ef4a10afa48204","type":"TRIAL","name":"Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment","canonical_id":"clinicaltrials.gov:NCT04541017","description":"Mycosis Fungoides; Recurrent Mycosis Fungoides; Recurrent Mycosis Fungoides and Sezary Syndrome; Recurrent Sezary Syndrome; Refractory Mycosis Fungoides; Refractory Mycosis Fungoides and Sezary Syndrome; Refractory Sezary Syndrome; Sezary Syndrome; Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8","metadata":null},{"id":"b8edf8e612f549d38100d52a4426b032","type":"TRIAL","name":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06590558","description":"Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Negative Breast Carcinoma; Locally Advanced Hormone Receptor-Positive Breast Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Hormone Receptor-Positive B\u2026","metadata":null},{"id":"d289d5f52e4b4918b0c83f3ad67773e3","type":"TRIAL","name":"Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer","canonical_id":"clinicaltrials.gov:NCT02317874","description":"Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm","metadata":null},{"id":"a8e0bdab948e45608a079c6651052d3b","type":"TRIAL","name":"Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT06661720","description":"Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma (RCC); Stage II Renal Pelvis Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8","metadata":null},{"id":"d9c5529bd12f4aadb8913cb93e56b433","type":"TRIAL","name":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","canonical_id":"clinicaltrials.gov:NCT06317662","description":"Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia","metadata":null},{"id":"d092193928ce4b0cb9282f816411e274","type":"TRIAL","name":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","canonical_id":"clinicaltrials.gov:NCT05092958","description":"Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Ure\u2026","metadata":null},{"id":"96892de4068746769c124652a335f616","type":"TRIAL","name":"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment","canonical_id":"clinicaltrials.gov:NCT04557956","description":"Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma","metadata":null},{"id":"ec841fc9f598434a85c6b8a9df41ef44","type":"TRIAL","name":"Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial","canonical_id":"clinicaltrials.gov:NCT04134260","description":"Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8","metadata":null},{"id":"986df35de67d4545861a92b474d06a95","type":"TRIAL","name":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT04310007","description":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"60f41ee2f350411d86f389f79a191e20","type":"TRIAL","name":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","canonical_id":"clinicaltrials.gov:NCT05669664","description":"Locally Advanced Salivary Gland Carcinoma; Metastatic Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Unresectable Salivary Gland Carcinoma","metadata":null},{"id":"1c85953b19114b2d9403a2d82205e386","type":"TRIAL","name":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","canonical_id":"clinicaltrials.gov:NCT05691504","description":"Advanced Endometrial Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Platinum-Resistant Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","metadata":null},{"id":"e98964b7b7cc46118db244f8559ea996","type":"TRIAL","name":"Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial","canonical_id":"clinicaltrials.gov:NCT05142241","description":"Malignant Solid Neoplasm","metadata":null},{"id":"082c2695c126482fbd3a8649b1dd7908","type":"TRIAL","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07619521","description":"Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma","metadata":null},{"id":"d9f48bafb46b42a092884dee78de7b7a","type":"TRIAL","name":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06015880","description":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"a5b4ffd918de441caadccad90248da42","type":"TRIAL","name":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","canonical_id":"clinicaltrials.gov:NCT03660826","description":"Endometrial Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","metadata":null},{"id":"ae128866386b493582f16113ab5d2c44","type":"TRIAL","name":"Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma","canonical_id":"clinicaltrials.gov:NCT04751383","description":"High Risk Neuroblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Neuroblastoma; Resectable Osteosarcoma","metadata":null},{"id":"becff7f9638d459b850c575d403f0a89","type":"TRIAL","name":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","canonical_id":"clinicaltrials.gov:NCT05327010","description":"Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm","metadata":null},{"id":"6ccbbf673b804ce2b8ca6d15ceb8539c","type":"TRIAL","name":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06649812","description":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent T-Cell/Histiocyte-Rich Large B-C\u2026","metadata":null},{"id":"8315393a511d48f78dfb4239806d411d","type":"TRIAL","name":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07147231","description":"Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Unresectable Colorectal Adenocarcinoma","metadata":null},{"id":"5650cc1b6fff40dc932059702bddfd72","type":"TRIAL","name":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT07061951","description":"Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma","metadata":null},{"id":"609daa5e081b4c3bac561985694ff7a5","type":"TRIAL","name":"Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland","canonical_id":"clinicaltrials.gov:NCT04530552","description":"Localized Prostate Carcinoma; Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8","metadata":null},{"id":"f5c0b0aeea3049eca3bfcd069a4a22e1","type":"TRIAL","name":"Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04600336","description":"Prostate Carcinoma","metadata":null},{"id":"12db12e73ab84eceb6894fdd1b60f3ed","type":"TRIAL","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","canonical_id":"clinicaltrials.gov:NCT07388524","description":"Lung Non-Small Cell Carcinoma","metadata":null},{"id":"33ceb101f1f84f2faf85b4cb0494d7e8","type":"TRIAL","name":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","canonical_id":"clinicaltrials.gov:NCT07085728","description":"Myeloma Multiple","metadata":null},{"id":"2a7b9a8134b2488699aa9f28cdb230ce","type":"TRIAL","name":"Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT07862517","description":"Acute Myeloid Leukemia","metadata":null},{"id":"19c3346b8d994239ba678168fa064634","type":"TRIAL","name":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","canonical_id":"clinicaltrials.gov:NCT05372614","description":"Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Malignant Solid Neoplasm; Unresectable Pancreatic Adenocarcinoma","metadata":null},{"id":"3278de7bac7940db873480b92c76e0e7","type":"TRIAL","name":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","canonical_id":"clinicaltrials.gov:NCT05627245","description":"Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Recurrent Follicular Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Refractory Follicular Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Pr\u2026","metadata":null},{"id":"9e37f8d8c59643ed996fbe00b12d41f9","type":"TRIAL","name":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","canonical_id":"clinicaltrials.gov:NCT05710406","description":"Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8","metadata":null},{"id":"0f440e5721b3495da1a09c669fcbaee2","type":"TRIAL","name":"Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT07852195","description":"Metastatic Castration-Resistant Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8","metadata":null},{"id":"8928afd95a94497fa6b72cee1bde9189","type":"TRIAL","name":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT06126276","description":"Malignant Female Reproductive System Neoplasm; Malignant Solid Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm","metadata":null},{"id":"4fb1f91781f344a28960640bdf23ee01","type":"TRIAL","name":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","canonical_id":"clinicaltrials.gov:NCT04530565","description":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","metadata":null},{"id":"c56135c342af45ebb056dde2de3bc930","type":"TISSUE","name":"Testis","canonical_id":"uberon:UBERON:0000473","description":null,"metadata":null},{"id":"43d73d5026474d96985f515b6f426819","type":"TRIAL","name":"Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty","canonical_id":"clinicaltrials.gov:NCT00001181","description":"Polyostotic Fibrous Dysplasia; Precocious Puberty","metadata":null},{"id":"e820402b73664aadb8440dd016792692","type":"DRUG","name":"Testosterone","canonical_id":"mesh:D013739","description":null,"metadata":null},{"id":"73db67a219c74a2b8bcb148b27032da5","type":"TRIAL","name":"Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","canonical_id":"clinicaltrials.gov:NCT07742553","description":"Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion; Spinal Cord Trauma; Trauma, Nervous System; Wounds and Injuries; Spinal Cord Compression; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male","metadata":null},{"id":"bd654ef3e4d647c9bbd9335e8ede8113","type":"TRIAL","name":"Testosterone and Alendronate in Hypogonadal Men","canonical_id":"clinicaltrials.gov:NCT01460654","description":"Hypogonadism; Osteopenia; Osteoporosis","metadata":null},{"id":"14ac768eac54433bb56156f48b2c9e99","type":"DRUG","name":"Testosterone enantate","canonical_id":"mesh:C004648","description":null,"metadata":null},{"id":"db54989f8ad9418c8e50bdb9dd5534fd","type":"DRUG","name":"Testosterone propionate","canonical_id":"mesh:D043343","description":null,"metadata":null},{"id":"ee47f8987e284573b9317ab89e0392e7","type":"DISEASE","name":"Tetanus","canonical_id":"mesh:D013742","description":null,"metadata":null},{"id":"3bdaff31ec37439cb463c6fb3a50300f","type":"DISEASE","name":"Tetany","canonical_id":"mesh:D013746","description":null,"metadata":null},{"id":"8e13ee35b7e948f9b60572cf478b418f","type":"DRUG","name":"Tetrabenazine","canonical_id":"mesh:D013747","description":null,"metadata":null},{"id":"5cce286030534a94b3035f511cdf1902","type":"TRIAL","name":"Tetrabenazine for Partial Responders","canonical_id":"clinicaltrials.gov:NCT00362804","description":"Schizophrenia; Schizoaffective Disorder","metadata":null},{"id":"133069eb9a6249af8d3d18b972f2b3a1","type":"DRUG","name":"Tetracosactide","canonical_id":"mesh:D003366","description":null,"metadata":null},{"id":"3902edf8f3314b4cb65b276e320a8a2d","type":"TRIAL","name":"Tetracycline Versus Doxycycline for HP Rescue Therapy","canonical_id":"clinicaltrials.gov:NCT05018923","description":"Helicobacter Pylori Infection","metadata":null},{"id":"35435f636727404c8eeff8ce3130e894","type":"DISEASE","name":"Tetralogy of Fallot","canonical_id":"mesh:D013771","description":null,"metadata":null},{"id":"f0365a337bc54147ac9bd6de157176f0","type":"TRIAL","name":"Texture Analysis for Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT00145977","description":"Osteoporosis; Osteopenia","metadata":null},{"id":"5b1a13f8b22341aaac106c37ee8dc076","type":"TRIAL","name":"Tezepelumab CRSwNP Real World Study (CREW Study)","canonical_id":"clinicaltrials.gov:NCT07790198","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"5b1c924769a54038b8e999afa64c2512","type":"TRIAL","name":"Tezepelumab Home Use Study","canonical_id":"clinicaltrials.gov:NCT03968978","description":"Asthma","metadata":null},{"id":"0c2c06bbb2f040bda4932aa64f6e08fe","type":"TRIAL","name":"Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects","canonical_id":"clinicaltrials.gov:NCT04362410","description":"Healthy Subjects","metadata":null},{"id":"12408eab26b2423c86ac57a6b09ac5c3","type":"TRIAL","name":"Tezepelumab Treatment in Korean Severe Asthma Patients","canonical_id":"clinicaltrials.gov:NCT06438913","description":"Asthma","metadata":null},{"id":"ab76c9e68688414093aafab497bed31d","type":"TRIAL","name":"Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma","canonical_id":"clinicaltrials.gov:NCT05740748","description":"Asthma, Allergic","metadata":null},{"id":"d254abbb7e7042db86cb281e7a3b372e","type":"TRIAL","name":"Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)","canonical_id":"clinicaltrials.gov:NCT06189742","description":"Asthma With Allergic Rhinitis","metadata":null},{"id":"eaced30f8dc946c898b76c0039bb0466","type":"TRIAL","name":"Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)","canonical_id":"clinicaltrials.gov:NCT06705764","description":"Severe Asthma","metadata":null},{"id":"e30b9a5fd5f741f3852f4e976135ffc8","type":"TRIAL","name":"Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma","canonical_id":"clinicaltrials.gov:NCT05280418","description":"Asthma","metadata":null},{"id":"40c89d6d1b544887a1aaad407f72e180","type":"TRIAL","name":"Tezspire Cardiac Events PASS","canonical_id":"clinicaltrials.gov:NCT06951867","description":"Cardiovascular Events; MACE","metadata":null},{"id":"4fc0e9f0c36447c9b6d575a3d945d94a","type":"TRIAL","name":"The \"Power 15 Study\": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting","canonical_id":"clinicaltrials.gov:NCT00467896","description":"Pulmonary Hypertension","metadata":null},{"id":"06e20803e49f4b93b6e96102441b3b1d","type":"TRIAL","name":"The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis","canonical_id":"clinicaltrials.gov:NCT04981327","description":"Deep Vein Thrombosis","metadata":null},{"id":"ac7c058b58b94eb593fbd81e7cc97160","type":"TRIAL","name":"The ARIES HeartMate 3 Pump IDE Study","canonical_id":"clinicaltrials.gov:NCT04069156","description":"Heart Failure","metadata":null},{"id":"424c5f95b200453480928161b2de1ce7","type":"TRIAL","name":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03414658","description":"Breast Cancer","metadata":null},{"id":"0fcea51850ec43d38dee628bc2d9268e","type":"TRIAL","name":"The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy","canonical_id":"clinicaltrials.gov:NCT04272476","description":"Depressive Disorder, Major","metadata":null},{"id":"7ac41e77849f46998a1c8d404f55fd21","type":"TRIAL","name":"The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study","canonical_id":"clinicaltrials.gov:NCT03010995","description":"Cigarette Smoking Toxicity; Nicotine; Acute Cardiovascular Disease","metadata":null},{"id":"c528c75861344452ba62d0dd54cb362c","type":"TRIAL","name":"The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution","canonical_id":"clinicaltrials.gov:NCT00741156","description":"Hypertension; Congestive Cardiomyopathy","metadata":null},{"id":"ef77a02bc1f847ee993f5adcd5f0c184","type":"TRIAL","name":"The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT03117023","description":"Gastric Cancer","metadata":null},{"id":"46703a67822e4ecf99c5bffd24504269","type":"TRIAL","name":"The Addition of Hydromorphone to Local Anesthetics for the Repair of Inguinal Hernias in Elderly Patients","canonical_id":"clinicaltrials.gov:NCT06218160","description":"Inguinal Hernia","metadata":null},{"id":"c5f94b10bdf542939d77732712a9e66e","type":"TRIAL","name":"The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention","canonical_id":"clinicaltrials.gov:NCT06319469","description":"Prostatic Hyperplasia","metadata":null},{"id":"df938a1f6ec24738b47f58dc877cecd4","type":"TRIAL","name":"The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial","canonical_id":"clinicaltrials.gov:NCT03542110","description":"Saphenous Vein Graft Atherosclerosis","metadata":null},{"id":"a12df205e23444d8a205e0374fa23429","type":"TRIAL","name":"The Analgesic Effect of Butorphanol After Cesarean Section","canonical_id":"clinicaltrials.gov:NCT04490980","description":"Analgesia","metadata":null},{"id":"08afb4a340ea4060af8cf29f85e9311a","type":"TRIAL","name":"The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster","canonical_id":"clinicaltrials.gov:NCT07361809","description":"Herpes Zoster; Pain","metadata":null},{"id":"9cbc8d931de3433cb0f2a07ce8276a7d","type":"TRIAL","name":"The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster","canonical_id":"clinicaltrials.gov:NCT07370402","description":"Herpes Zoster; Pain","metadata":null},{"id":"bcd5ee6878b84b4ebb698b05b179c966","type":"TRIAL","name":"The Anifrolumab PRIM Program","canonical_id":"clinicaltrials.gov:NCT06795893","description":"Systemic Lupus Erythematosus","metadata":null},{"id":"43c6caa682364f5891bb1f14a7c1c031","type":"TRIAL","name":"The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals","canonical_id":"clinicaltrials.gov:NCT07687589","description":"Emesis","metadata":null},{"id":"a3797ec536c94ca4a11b46174607adc4","type":"TRIAL","name":"The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations","canonical_id":"clinicaltrials.gov:NCT00502437","description":"Antiggaging Effect; Antiemetic; Granisetron; Gag Reflex; Dental Situations","metadata":null},{"id":"d886872e98864b7ab7477e571c0a2ada","type":"TRIAL","name":"The Antiplatelet and Immune Response Trial","canonical_id":"clinicaltrials.gov:NCT01846559","description":"Healthy","metadata":null},{"id":"4a98711930b940ed99c7fe79e9d3dae0","type":"TRIAL","name":"The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy","canonical_id":"clinicaltrials.gov:NCT01063881","description":"Sexual Dysfunction, Physiological","metadata":null},{"id":"c3b0d63bd08745beaf1a556017570c9b","type":"TRIAL","name":"The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder","canonical_id":"clinicaltrials.gov:NCT00044187","description":"Schizophrenia; Psychotic Disorders; Bipolar Disorder","metadata":null},{"id":"50a3023349224475b1728a5ee345aec9","type":"TRIAL","name":"The Association Between Epidural Labor Analgesia and Pregnancy Outcomes","canonical_id":"clinicaltrials.gov:NCT03381495","description":"Labor Pain; Pregnancy Outcomes; Psychological Disorder","metadata":null},{"id":"082f2389f3c64891807e87552bde2701","type":"TRIAL","name":"The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR","canonical_id":"clinicaltrials.gov:NCT00247702","description":"Deep Venous Thromboembolism","metadata":null},{"id":"ea63dbda00d34542944452375e8048f5","type":"TRIAL","name":"The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children","canonical_id":"clinicaltrials.gov:NCT05697614","description":"Drug Resistant Epilepsy","metadata":null},{"id":"8e0c84c0cd05421ba8ce31f3fdddcd79","type":"TRIAL","name":"The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia","canonical_id":"clinicaltrials.gov:NCT01083784","description":"Cardiac Arrest","metadata":null},{"id":"07dc333b7d6e448daba9259111f51b1a","type":"TRIAL","name":"The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome","canonical_id":"clinicaltrials.gov:NCT03436303","description":"Menopause Syndrome","metadata":null},{"id":"dd58e6b6fef54dbdbb586ff9e7e01c5b","type":"TRIAL","name":"The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT04688294","description":"Heart Failure","metadata":null},{"id":"f9df563e8d5b401a8932c7f67c9312de","type":"TRIAL","name":"The Bioequivalence Of Two Different Lurasidone Formulations In Patients","canonical_id":"clinicaltrials.gov:NCT01082250","description":"Schizophrenia","metadata":null},{"id":"b2cd7d5c9f664e23af9db4e7a2868a92","type":"TRIAL","name":"The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT06228339","description":"Healthy Volunteer","metadata":null},{"id":"45a03122ae054501a3db2aec8d333642","type":"TRIAL","name":"The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT01701622","description":"Blood Pressure; Gout","metadata":null},{"id":"d2a3d77fc8ef4ad5aee89c0cd52586fd","type":"TRIAL","name":"The Bridging Antiplatelet Therapy With Cangrelor 2 Study","canonical_id":"clinicaltrials.gov:NCT07225842","description":"Coronary Arterial Disease (CAD)","metadata":null},{"id":"41c20c20d10249bca3d245e76c686219","type":"TRIAL","name":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","canonical_id":"clinicaltrials.gov:NCT01106677","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"fcba1bdcca4c46669b7a7dda2ed8deb2","type":"TRIAL","name":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","canonical_id":"clinicaltrials.gov:NCT01106690","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"7c3a98d477d24673a8813d304aa9e277","type":"TRIAL","name":"The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)","canonical_id":"clinicaltrials.gov:NCT01106625","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"394f8c6bca8e42548b967b915fe96444","type":"TRIAL","name":"The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine","canonical_id":"clinicaltrials.gov:NCT02657031","description":"Headache","metadata":null},{"id":"112c9ac5aa694b44ab7bfa66c908aa8c","type":"TRIAL","name":"The CHORAL Flow Study","canonical_id":"clinicaltrials.gov:NCT04073134","description":"Coronary Artery Disease; Atherosclerosis; Hyperlipidemias","metadata":null},{"id":"b149c3812e2a4c41b5c47e43d5df75cd","type":"TRIAL","name":"The CLEVER Study - Coreg And Left Ventricular Mass Regression","canonical_id":"clinicaltrials.gov:NCT00108082","description":"Hypertrophy, Left Ventricular","metadata":null},{"id":"1b7df81cb5f347fbbb9057d2fdbf6cc5","type":"TRIAL","name":"The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration","canonical_id":"clinicaltrials.gov:NCT00227357","description":"HIV Infections; AIDS; Opiate Dependence; Post-Traumatic Stress Disorders","metadata":null},{"id":"2f96c5b1ecc240f4a5729344aeac3ee6","type":"TRIAL","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","canonical_id":"clinicaltrials.gov:NCT02000089","description":"Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation; Germline Mutation Carrier; Lynch Syndrome","metadata":null},{"id":"b23e994600ca4a9bbb2c897714be3e5f","type":"TRIAL","name":"The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)","canonical_id":"clinicaltrials.gov:NCT02137733","description":"Chronic Heart Failure","metadata":null},{"id":"e80ccf0c0d774b0bafe08e2303c85297","type":"TRIAL","name":"The Carotid and Middle Cerebral Artery Occlusion Surgery Study","canonical_id":"clinicaltrials.gov:NCT01758614","description":"Carotid Artery Occlusion; Middle Cerebral Artery Occlusion; Stroke","metadata":null},{"id":"c5822ba451d54157aa49a4665f8471c9","type":"TRIAL","name":"The Central Analgesic Effects of Paracetamol on Serotonergic Pathways","canonical_id":"clinicaltrials.gov:NCT00970450","description":"Analgesia","metadata":null},{"id":"b80aea57e38d46e78118d200c3151860","type":"TRIAL","name":"The Changes of Urine Growth Factors Level","canonical_id":"clinicaltrials.gov:NCT06282731","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"185ad5b9c7734c09a4c1be208199b137","type":"TRIAL","name":"The Childhood and Adolescent Migraine Prevention Study","canonical_id":"clinicaltrials.gov:NCT01581281","description":"Migraine; Migraine Disorders; Headache","metadata":null},{"id":"8155638b0c0e490bbdcbd543acd34beb","type":"TRIAL","name":"The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study","canonical_id":"clinicaltrials.gov:NCT04669561","description":"Dry Eye","metadata":null},{"id":"cbd4dbc4fb3e48fd97ce5cd36bc38432","type":"TRIAL","name":"The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis","canonical_id":"clinicaltrials.gov:NCT02480335","description":"Scleroderma, Systemic","metadata":null},{"id":"200c15fe5a01410aabb102c123757e50","type":"TRIAL","name":"The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma","canonical_id":"clinicaltrials.gov:NCT04979611","description":"Insulinoma","metadata":null},{"id":"0746458b506443878a1b2c0162133c90","type":"TRIAL","name":"The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)","canonical_id":"clinicaltrials.gov:NCT00911547","description":"Asthma","metadata":null},{"id":"0b126755b7144cea801229d083d0055f","type":"TRIAL","name":"The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.","canonical_id":"clinicaltrials.gov:NCT06029829","description":"Hepatocellular Carcinoma","metadata":null},{"id":"5efd6df45b9e46adb1d46664876751b2","type":"TRIAL","name":"The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)","canonical_id":"clinicaltrials.gov:NCT07855692","description":"HFpEF - Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"bc2d7d0841974dda8a55a1febca70364","type":"TRIAL","name":"The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty","canonical_id":"clinicaltrials.gov:NCT01634321","description":"Central Precocious Puberty","metadata":null},{"id":"b75026509a874880a7afc9631a06d39e","type":"TRIAL","name":"The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT03551171","description":"Ovarian Cancer","metadata":null},{"id":"2a6ed1f4770d487186dc5dc9d3275e54","type":"TRIAL","name":"The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT01667263","description":"Autoimmune Thrombocytopenia","metadata":null},{"id":"2acd1c1c5e724e3c92fbf4d544d5b223","type":"TRIAL","name":"The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT03460808","description":"Immune Thrombocytopenia","metadata":null},{"id":"2f51d55155e34465b7773ff6cc652a92","type":"TRIAL","name":"The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05281068","description":"ITP; Immune Thrombocytopenia","metadata":null},{"id":"c5e724a03ece46fd8bb2a3f68538f99b","type":"TRIAL","name":"The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05353673","description":"Immune Thrombocytopenia; Blood Coagulation Disorders; Thrombocytopenia; Physiological Effects of Drugs","metadata":null},{"id":"65b35f42eeb74688a34cfe5e1bf44370","type":"TRIAL","name":"The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05471050","description":"Immune Thrombocytopenia","metadata":null},{"id":"8a307fb880604834b69971a4280b9852","type":"TRIAL","name":"The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT05494307","description":"Immune Thrombocytopenia","metadata":null},{"id":"febf5f8cf9c041c793974fe685a3bed3","type":"TRIAL","name":"The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT04481282","description":"Immune Thrombocytopenia","metadata":null},{"id":"4b264424b16e41c282e71ae4453fd7d0","type":"TRIAL","name":"The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT06176911","description":"Immune Thrombocytopenia","metadata":null},{"id":"fef5ac61a2804a988c8124f365578eae","type":"TRIAL","name":"The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT07064889","description":"Immune Thrombocytopenia","metadata":null},{"id":"11ac679473f042b8b47365eefefb58dd","type":"TRIAL","name":"The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT04447768","description":"Chronic Lymphocytic Leukemia (CLL)","metadata":null},{"id":"405e3687513a407394da64d2ac1f2b21","type":"TRIAL","name":"The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT03892447","description":"Children AKI Patients","metadata":null},{"id":"4fb5de5b7ac247409ec3243f3b2f3803","type":"TRIAL","name":"The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever","canonical_id":"clinicaltrials.gov:NCT06744777","description":"Dengue Fever; Dengue Hemorrhagic Fever; Severe Dengue","metadata":null},{"id":"2224b801fdac44f78a49ea491afb9e49","type":"TRIAL","name":"The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne","canonical_id":"clinicaltrials.gov:NCT03650881","description":"Acne","metadata":null},{"id":"41355f968885443e859f193ef1454284","type":"TRIAL","name":"The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT00999869","description":"Alopecia Areata","metadata":null},{"id":"a3063e44381140bfa7f15f1dc54ca732","type":"TRIAL","name":"The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism","canonical_id":"clinicaltrials.gov:NCT02362256","description":"Opiate Addiction","metadata":null},{"id":"cb1e695fd06c4bf48b0c8a24d7fc2283","type":"TRIAL","name":"The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF","canonical_id":"clinicaltrials.gov:NCT02602028","description":"Familial Mediterranean Fever","metadata":null},{"id":"2b78733ae3fe4204bd95f0e3edaf2cb6","type":"TRIAL","name":"The Confirmatory Olmesartan Plaque Regression Study","canonical_id":"clinicaltrials.gov:NCT01132768","description":"Essential Hypertension; Carotid Plaque","metadata":null},{"id":"5e88318326d74ed58943f1ea7e50287d","type":"TRIAL","name":"The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)","canonical_id":"clinicaltrials.gov:NCT01250548","description":"Rheumatoid Arthritis","metadata":null},{"id":"f0a5c7fd334a46029722738238b089ba","type":"TRIAL","name":"The DAWN Antivirals Trial for Ambulatory COVID-19 Patients","canonical_id":"clinicaltrials.gov:NCT04730206","description":"Covid19; SARS-CoV Infection","metadata":null},{"id":"3df7f1a32c7642299eeb889cd9b57dba","type":"TRIAL","name":"The DDI Study of SP2086 and Simvastatin","canonical_id":"clinicaltrials.gov:NCT02817243","description":"Type 2 Diabetes","metadata":null},{"id":"3be56212bb154e8f9a67bf1fe33f849a","type":"TRIAL","name":"The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial","canonical_id":"clinicaltrials.gov:NCT00095654","description":"Impaired Glucose Tolerance; Cardiovascular Disease; Glucose Metabolism Disorders","metadata":null},{"id":"28372177e79a4516af2c6d060155d3dc","type":"TRIAL","name":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT03129490","description":"Atrial Fibrillation; Atrial Flutter","metadata":null},{"id":"424c0c9d60264f87a688c264405d1a97","type":"TRIAL","name":"The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation","canonical_id":"clinicaltrials.gov:NCT02013037","description":"Antibody-mediated Rejection; Hyperacute Rejection of Cardiac Transplant; Left Ventricular Dysfunction; Cardiac Allograft Vasculopathy; Heart Graft Dysfunction","metadata":null},{"id":"a74893c0c79c41379ba9d93a8aec59e8","type":"TRIAL","name":"The Depression in Alzheimer's Disease Study (DIADS)","canonical_id":"clinicaltrials.gov:NCT00009191","description":"Alzheimer Disease; Depression","metadata":null},{"id":"e66dffee228948d998f9c06aa83e0a86","type":"TRIAL","name":"The Discriminative Effects of Tramadol in Humans","canonical_id":"clinicaltrials.gov:NCT00499746","description":"Opioid Abuse; Opioid Addiction; Stimulant Abuse; Stimulant Addiction","metadata":null},{"id":"bfb8295d3fbe4a1ba6f6a71d8caed6fc","type":"TRIAL","name":"The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure","canonical_id":"clinicaltrials.gov:NCT02754570","description":"Glaucoma, Open-angle; Hypertension, Ocular","metadata":null},{"id":"fa2c752e069643d8afc74c4156abaf66","type":"TRIAL","name":"The Drug Rediscovery Protocol (DRUP Trial)","canonical_id":"clinicaltrials.gov:NCT02925234","description":"Cancer; Tumors; Neoplasm; Neoplasia","metadata":null},{"id":"8e34cf3ac0274a47bd8695df19ba4767","type":"TRIAL","name":"The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout","canonical_id":"clinicaltrials.gov:NCT03131583","description":"Gout","metadata":null},{"id":"c615e96eb33a43699e659e697c417ae7","type":"TRIAL","name":"The Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05881811","description":"PHN - Post-Herpetic Neuritis","metadata":null},{"id":"1a9a8e376fdd4d439387cf93daba0452","type":"TRIAL","name":"The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)","canonical_id":"clinicaltrials.gov:NCT00359138","description":"Hypersensitivity","metadata":null},{"id":"4f60a6b292754b1287511b1f65554399","type":"TRIAL","name":"The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.","canonical_id":"clinicaltrials.gov:NCT04328480","description":"COVID-19","metadata":null},{"id":"fdeb59b839a240869418f1ee21f8de62","type":"TRIAL","name":"The ENCHANTMENT HIV Study","canonical_id":"clinicaltrials.gov:NCT04153136","description":"HIV/AIDS; Heart Failure With Preserved Ejection Fraction","metadata":null},{"id":"011a94c423a04329b85b586ba1747df5","type":"TRIAL","name":"The ENERGITO\u00ae 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto\u00ae) Taken Using the Respimat\u00ae Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus","canonical_id":"clinicaltrials.gov:NCT03240575","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"5f21503719834111b2ceb6c418474fc4","type":"TRIAL","name":"The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)","canonical_id":"clinicaltrials.gov:NCT01832558","description":"CKD II-III","metadata":null},{"id":"8d375906ca804e78b6a1595a3c3cbdad","type":"TRIAL","name":"The Efface of Ketamine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy","canonical_id":"clinicaltrials.gov:NCT07248358","description":"Laparoscopic Cholecystectomy Surgery; Postoperative Pain Management","metadata":null},{"id":"43e984229be04ddfb31e84a73d1ba7a1","type":"TRIAL","name":"The Effect Dialysis on the Pharmacokinetics of Fexofenadine","canonical_id":"clinicaltrials.gov:NCT03078777","description":"Hemodialysis","metadata":null},{"id":"bf133aabc174469ea67cbfe509848d7a","type":"TRIAL","name":"The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency","canonical_id":"clinicaltrials.gov:NCT01598337","description":"Coronary Artery Disease","metadata":null},{"id":"d49febdf641a410782dd0f091f5df4ab","type":"TRIAL","name":"The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms","canonical_id":"clinicaltrials.gov:NCT00401245","description":"Vasomotor Symptoms","metadata":null},{"id":"d5ef9c819c3e4374a8dd2c5c83555df3","type":"TRIAL","name":"The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT03866629","description":"Dry Eye","metadata":null},{"id":"beae57eec24143adb605f1735d386d7a","type":"TRIAL","name":"The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.","canonical_id":"clinicaltrials.gov:NCT07419776","description":"Poly Cystic Ovary Syndrome","metadata":null},{"id":"2537970f07274a0e9173a55f35d78f4f","type":"TRIAL","name":"The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma","canonical_id":"clinicaltrials.gov:NCT05702944","description":"Pheochromocytoma; Paraganglioma; Adrenalectomy; Status; Adrenergics Causing Adverse Effects in Therapeutic Use","metadata":null},{"id":"cd57477675c64603a2f5f9a334283299","type":"TRIAL","name":"The Effect and Safety of the Four Points Transversus Abdominis Plane Block","canonical_id":"clinicaltrials.gov:NCT03598192","description":"Liver Diseases; Adult Disease","metadata":null},{"id":"09cd29d1d5dd4d90a52467a8bc53f033","type":"TRIAL","name":"The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.","canonical_id":"clinicaltrials.gov:NCT04393493","description":"Cardiorenal Syndrome","metadata":null},{"id":"ef157f7c57e6406986170c0b906730d9","type":"TRIAL","name":"The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist","canonical_id":"clinicaltrials.gov:NCT03397888","description":"Hepatic Impairment","metadata":null},{"id":"f1247f0d0e5d4c16a8a3fcbe0909a7ca","type":"TRIAL","name":"The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues","canonical_id":"clinicaltrials.gov:NCT02457312","description":"Pregnancy","metadata":null},{"id":"0af14f9b1a5743e7916e14d006c6842d","type":"TRIAL","name":"The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream","canonical_id":"clinicaltrials.gov:NCT01883102","description":"Pain","metadata":null},{"id":"995af13477074bcaad7d1d1bc0c62660","type":"TRIAL","name":"The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation","canonical_id":"clinicaltrials.gov:NCT04361656","description":"Colonoscopy Preparation","metadata":null},{"id":"06a3a20e2c674235b9a34949989f807d","type":"TRIAL","name":"The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section","canonical_id":"clinicaltrials.gov:NCT02716129","description":"Postoperative Pain","metadata":null},{"id":"a94407c00644437694f656250ece0c34","type":"TRIAL","name":"The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder","canonical_id":"clinicaltrials.gov:NCT00451490","description":"Depressive Disorder, Major","metadata":null},{"id":"da9f0a18f66a433e8d2c127c340b0085","type":"TRIAL","name":"The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients","canonical_id":"clinicaltrials.gov:NCT03193086","description":"Multiple Sclerosis","metadata":null},{"id":"2e2b456764ac4145915a88218038bc20","type":"TRIAL","name":"The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT02057263","description":"Hepatitis B","metadata":null},{"id":"06220db411624be493769bbc0f86b59d","type":"TRIAL","name":"The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure","canonical_id":"clinicaltrials.gov:NCT00132106","description":"Heart Failure, Congestive","metadata":null},{"id":"0a5a7c693cf44c2297ad68ec010a7f8b","type":"TRIAL","name":"The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes","canonical_id":"clinicaltrials.gov:NCT01165983","description":"Diabetes Type 2","metadata":null},{"id":"e5a118b71729475f996336ac98ad1482","type":"TRIAL","name":"The Effect of Allopurinol on Insulin Resistance and Blood Pressure","canonical_id":"clinicaltrials.gov:NCT00639756","description":"Metabolic Syndrome","metadata":null},{"id":"cc6bda1cae2947d6be286a2840bdb024","type":"TRIAL","name":"The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk","canonical_id":"clinicaltrials.gov:NCT05943821","description":"Cardiovascular Diseases; Uric Acid","metadata":null},{"id":"0def9005867e4444b73f7e8c9c9480c2","type":"TRIAL","name":"The Effect of Amiloride and Spironolactone in Healthy Persons","canonical_id":"clinicaltrials.gov:NCT00857909","description":"High Blood Pressure","metadata":null},{"id":"34c173bb6ef64bf991c462a21cafee5f","type":"TRIAL","name":"The Effect of Amiloride and Spironolactone in Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT01388088","description":"Hypertension","metadata":null},{"id":"78dccdc5cc2844c6ab33dba912a80536","type":"TRIAL","name":"The Effect of Anakinra on Insulin Secretion","canonical_id":"clinicaltrials.gov:NCT01285232","description":"Glucose Intolerance; Impaired Insulin Secretion; Diabetes Mellitus Type 2","metadata":null},{"id":"c813f61901d54f0497be63c291097e99","type":"TRIAL","name":"The Effect of Analgesic Drugs on Respiratory Center","canonical_id":"clinicaltrials.gov:NCT04372342","description":"The Effect of Analgesic Drugs on Respiratory Center","metadata":null},{"id":"60310342e58040dfa8eb29b053c86bf7","type":"TRIAL","name":"The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients","canonical_id":"clinicaltrials.gov:NCT04452929","description":"Migraine; Migraine Without Aura; Migraine With Aura","metadata":null},{"id":"61df478c380a40ae833887465b8b3804","type":"TRIAL","name":"The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients","canonical_id":"clinicaltrials.gov:NCT00480870","description":"Alzheimer Disease; Sleep Apnea, Obstructive","metadata":null},{"id":"545117c698844375a924e0631d3d50bf","type":"TRIAL","name":"The Effect of Antiemetics on Bowel Preparation Before Colonoscopy","canonical_id":"clinicaltrials.gov:NCT04583111","description":"Bowel Preparation","metadata":null},{"id":"f91ac24abbd540e8b2ead1eca51c7ced","type":"TRIAL","name":"The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT05772676","description":"Obesity; Nausea and Vomiting, Postoperative","metadata":null},{"id":"df46b60eca994a4dbf7dd5f0729b00ac","type":"TRIAL","name":"The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women","canonical_id":"clinicaltrials.gov:NCT01072097","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"8234bed4d2094938a1575b0dc47043e6","type":"TRIAL","name":"The Effect of BEVESPI AEROSPHERE \u00ae Therapy on Exercise Tolerance in COPD","canonical_id":"clinicaltrials.gov:NCT03081156","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"967bbc6655224831b9061c1f41b2f9db","type":"TRIAL","name":"The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients","canonical_id":"clinicaltrials.gov:NCT01878578","description":"Epilepsy","metadata":null},{"id":"bc9cea1fe8fb4caf98493a6aa41f44c1","type":"TRIAL","name":"The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT02170376","description":"Parkinson's Disease (PD)","metadata":null},{"id":"37387e46fc6f4b65819f409f375f0586","type":"TRIAL","name":"The Effect of Bethanechol on Tracheobronchomalacia","canonical_id":"clinicaltrials.gov:NCT05299008","description":"Tracheobronchomalacia","metadata":null},{"id":"0a671bb66ed34c3d95e409559ce2aea9","type":"TRIAL","name":"The Effect of Bezafibrate on Cholestatic Itch","canonical_id":"clinicaltrials.gov:NCT02701166","description":"Primary Biliary Cholangitis; Primary Sclerosing Cholangitis; Secondary Sclerosing Cholangitis","metadata":null},{"id":"e90e50e705984310bed92c51d74e1d8d","type":"TRIAL","name":"The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)","canonical_id":"clinicaltrials.gov:NCT01165060","description":"X-linked Adrenoleukodystrophy; Adrenomyeloneuropathy","metadata":null},{"id":"a2d1dd9aa7c64005ba6734d118dcdfe9","type":"TRIAL","name":"The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients","canonical_id":"clinicaltrials.gov:NCT03139708","description":"Intraocular Pressure","metadata":null},{"id":"c907984ccc3f456fa7ba21f437ed21ff","type":"TRIAL","name":"The Effect of Celecoxib on Neuroinflammation in MDD","canonical_id":"clinicaltrials.gov:NCT04814355","description":"Major Depressive Disorder; Neuroinflammation","metadata":null},{"id":"dd86a133582e499391ff5397c5adc8bc","type":"TRIAL","name":"The Effect of Central Sensitization on Treatment Response in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT05020600","description":"Central Sensitisation; Fibromyalgia","metadata":null},{"id":"6ab571e548cf4ce2bac7092d3881bd09","type":"TRIAL","name":"The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.","canonical_id":"clinicaltrials.gov:NCT03183310","description":"Esophageal Reflux","metadata":null},{"id":"d6fc3be65d3d4334bac62a75e07a4499","type":"TRIAL","name":"The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients","canonical_id":"clinicaltrials.gov:NCT03116269","description":"Ischemic Stroke; Endothelial Dysfunction","metadata":null},{"id":"9282d3b7e987491aab74c89e43888af3","type":"TRIAL","name":"The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00336739","description":"Healthy","metadata":null},{"id":"42830a210f6241e9a1524d1c6e78f8d6","type":"TRIAL","name":"The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass","canonical_id":"clinicaltrials.gov:NCT01619436","description":"Glycemia During Coronary Artery Bypass Graft; Sedation During Pre-anesthetic Medication","metadata":null},{"id":"cdb9036454ed49efaaa578b96147d6ed","type":"TRIAL","name":"The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man","canonical_id":"clinicaltrials.gov:NCT02120092","description":"Acute Coronary Syndrome","metadata":null},{"id":"de94629e45eb4d478b5d31ebe5c05484","type":"TRIAL","name":"The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor","canonical_id":"clinicaltrials.gov:NCT02702674","description":"Poor; Labor","metadata":null},{"id":"377bb14486ef41179290b079a67a2c4c","type":"TRIAL","name":"The Effect of Colchicine on Platelet Function Profiles in Patients With Stable Coronary Artery Disease","canonical_id":"clinicaltrials.gov:NCT06567678","description":"Coronary Artery Disease","metadata":null},{"id":"b0ce9b6931d341c5a0712e4d51ed9a3f","type":"TRIAL","name":"The Effect of Combination Therapy Using Li-ESWT and PDE-5 Inhibitor in Patients With Erectile Dysfunction","canonical_id":"clinicaltrials.gov:NCT05043896","description":"Erectile Dysfunction","metadata":null},{"id":"afe70e9ba7414a8d8d1f4919c2612a98","type":"TRIAL","name":"The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT06778330","description":"Heart Failure NYHA Class II","metadata":null},{"id":"9440df5d73a443b295085db73e48cedd","type":"TRIAL","name":"The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00318201","description":"Healthy","metadata":null},{"id":"65e89ab74b1649e9a3a9b9292a67f532","type":"TRIAL","name":"The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)","canonical_id":"clinicaltrials.gov:NCT00789152","description":"Allergic Rhinitis","metadata":null},{"id":"0e5573210ca9410c8b2a906eb5c569eb","type":"TRIAL","name":"The Effect of Diclofenac Potassium Insitu Gel Vs Calcium Hydroxide as Intra-canal Medications on Post-operative Pain and Anti-bacterial Effect","canonical_id":"clinicaltrials.gov:NCT04622488","description":"Post Operative Pain","metadata":null},{"id":"d88e1ec72ec54bb5acc5f69e7cb4c190","type":"TRIAL","name":"The Effect of Different Types of Progestin on Sleeping of Menopausal Women","canonical_id":"clinicaltrials.gov:NCT02086032","description":"Menopausal and Postmenopausal Disorders","metadata":null},{"id":"2c65608940a147bc8189c2933831f316","type":"TRIAL","name":"The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise","canonical_id":"clinicaltrials.gov:NCT02965963","description":"Health","metadata":null},{"id":"ba13c38792b047d9855aea1f399131f6","type":"TRIAL","name":"The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium","canonical_id":"clinicaltrials.gov:NCT02118753","description":"Ischemia-reperfusion Injury","metadata":null},{"id":"401162ce1c6740bb86c7aa5917408314","type":"TRIAL","name":"The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy","canonical_id":"clinicaltrials.gov:NCT01056419","description":"Graves' Ophthalmopathy","metadata":null},{"id":"f8a37b7ecada42c39f336da47b53c5b7","type":"TRIAL","name":"The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs","canonical_id":"clinicaltrials.gov:NCT00017758","description":"HIV Infections; HIV Seronegativity; Lipodystrophy","metadata":null},{"id":"a3c2df962af04ef8b4cea5d48f6c65d0","type":"TRIAL","name":"The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.","canonical_id":"clinicaltrials.gov:NCT04450953","description":"Kidney Transplantation for More Than One Year; Patients with a Kidney Transplantation on Cyclosporine","metadata":null},{"id":"ff69ba38b96344e1bca2e1065fad92a1","type":"TRIAL","name":"The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.","canonical_id":"clinicaltrials.gov:NCT00409903","description":"Healthy","metadata":null},{"id":"075a02b5d45e4cc8ae916e745c88f80b","type":"TRIAL","name":"The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00438945","description":"Essential Hypertension","metadata":null},{"id":"8b250695ca594f838117bff4c6cc2637","type":"TRIAL","name":"The Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery","canonical_id":"clinicaltrials.gov:NCT07665099","description":"Perioperative Neurocognitive Disorders","metadata":null},{"id":"f7f43b7e959b47e8b2bf1e7e405e355a","type":"TRIAL","name":"The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial","canonical_id":"clinicaltrials.gov:NCT05703048","description":"Patient's Satisfaction; Depth of Anesthesia","metadata":null},{"id":"6bcf61ac02e64c9884af9896f39a61f8","type":"TRIAL","name":"The Effect of Esmolol on Patients With Sepsis","canonical_id":"clinicaltrials.gov:NCT04537767","description":"Sepsis","metadata":null},{"id":"194b21e401d34cbcbf5d68d364a50759","type":"TRIAL","name":"The Effect of Fasudil on Vascular Function in Humans","canonical_id":"clinicaltrials.gov:NCT00120718","description":"Atherosclerosis; Hypercholesterolemia","metadata":null},{"id":"669b144cc24d4f5da38b0d1169f9d42c","type":"TRIAL","name":"The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery","canonical_id":"clinicaltrials.gov:NCT00743106","description":"Partial Nephrectomy","metadata":null},{"id":"675c79081c1a4aabaa7a7683ee7fdda7","type":"TRIAL","name":"The Effect of Fluvastatin XL\u00ae Treatment in Patients With Metabolic Syndrome","canonical_id":"clinicaltrials.gov:NCT00664742","description":"Metabolic Syndrome","metadata":null},{"id":"3012fdd69ab54b728530c65ec4b85c84","type":"TRIAL","name":"The Effect of Fluvoxamine on Polysonogram in Depressed Patients With Insomnia","canonical_id":"clinicaltrials.gov:NCT02442713","description":"Depression","metadata":null},{"id":"a20e4f4f6400444fbc9c9e6da4c096ae","type":"TRIAL","name":"The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib","canonical_id":"clinicaltrials.gov:NCT01002378","description":"Dietary Fats; Pharmacokinetics","metadata":null},{"id":"3a140ab2ab3247359be4dac5055ccf14","type":"TRIAL","name":"The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men","canonical_id":"clinicaltrials.gov:NCT00256256","description":"Type 2 Diabetes; Stroke; Myocardial Infarction","metadata":null},{"id":"c2af526e4e194c63aade29f1cdd3f8d1","type":"TRIAL","name":"The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches","canonical_id":"clinicaltrials.gov:NCT06901518","description":"Post-Traumatic Headache","metadata":null},{"id":"2dc09906aed4445faee1a881ed9cb107","type":"TRIAL","name":"The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream","canonical_id":"clinicaltrials.gov:NCT01836198","description":"Healthy Volunteers","metadata":null},{"id":"ffd00d189d5943c892991b55db31a65f","type":"TRIAL","name":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","canonical_id":"clinicaltrials.gov:NCT05386186","description":"Diabetes Mellitus, Type 2; Severe Insulin Deficient Diabetes","metadata":null},{"id":"06b79710ec644703bd366b7dda638d6e","type":"TRIAL","name":"The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)","canonical_id":"clinicaltrials.gov:NCT00856960","description":"Hypertension","metadata":null},{"id":"00a48be9770a4a59b962fb18fc11dc29","type":"TRIAL","name":"The Effect of IV Cangrelor and Oral Ticagrelor Study","canonical_id":"clinicaltrials.gov:NCT02733341","description":"Acute Coronary Syndrome (ACS); High On-treatment Platelet Reactivity (HTPR); Microvascular Obstruction (MVO); ST-segment Elevation Myocardial Infarction (STEMI); Thrombolysis in Myocardial Infarction (TIMI); Unstable Angina (UA)","metadata":null},{"id":"bb72c1f91737450984c2729887474384","type":"TRIAL","name":"The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery","canonical_id":"clinicaltrials.gov:NCT03936140","description":"Lung Cancer","metadata":null},{"id":"ed5b06e6b8d14efc851e6f288451d547","type":"TRIAL","name":"The Effect of Imipramine on Early Information Processing","canonical_id":"clinicaltrials.gov:NCT00206999","description":"Healthy Volunteers","metadata":null},{"id":"3aad815df07f45a9b9a146642b666c01","type":"TRIAL","name":"The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","canonical_id":"clinicaltrials.gov:NCT03753555","description":"Stroke, Ischemic; Atherosclerosis, Cerebral","metadata":null},{"id":"2809044a70234f57be6ec03862b6257c","type":"TRIAL","name":"The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children","canonical_id":"clinicaltrials.gov:NCT03040596","description":"Vocal Fold Nodules","metadata":null},{"id":"5260f9a9edf64a5b99066ab2d004c810","type":"TRIAL","name":"The Effect of Intracameral Carbachol and Epinephrine on Choroidal Thickness","canonical_id":"clinicaltrials.gov:NCT05225597","description":"Epinephrine Toxicity; Cataract; Carbachol Adverse Reaction; Choroid Disease","metadata":null},{"id":"8c594dd771114b94a11c1029e006a8a4","type":"TRIAL","name":"The Effect of Intraoperative Labetalol on Time to Discharge","canonical_id":"clinicaltrials.gov:NCT02997800","description":"Bloodpressure; Heart Rate","metadata":null},{"id":"2e469846029c482e96263ff02fc0ea44","type":"TRIAL","name":"The Effect of Intraperitoneal Injection of Magnesium Sulphate Versus Dexmedetomidine as an Adjuvant to Bupivacaine on Postoperative Analgesia in Patients Undergoing Abdominal Aortic Surgery","canonical_id":"clinicaltrials.gov:NCT05577260","description":"Abdominal Aortic Surgery","metadata":null},{"id":"182a314314a74d8585abc206f48bc0f0","type":"TRIAL","name":"The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.","canonical_id":"clinicaltrials.gov:NCT03786562","description":"Abdominal Obesity","metadata":null},{"id":"42673cddd56345d993ca880ade78353d","type":"TRIAL","name":"The Effect of Ixazomib on the Latent HIV Reservoir","canonical_id":"clinicaltrials.gov:NCT02946047","description":"Human Immunodeficiency Virus (HIV)","metadata":null},{"id":"ea10abb818084e9a907e35e5222c8066","type":"TRIAL","name":"The Effect of Late Na Current Blocker Mexiletine on Giant T-wave Electrical Alternans(STOP-TWA)","canonical_id":"clinicaltrials.gov:NCT05619120","description":"Giant T-wave Electrical Alternans","metadata":null},{"id":"1b93119da3ce45b3b97385aa37434423","type":"TRIAL","name":"The Effect of Linagliptin on Mitochondrial and Endothelial Function","canonical_id":"clinicaltrials.gov:NCT01969084","description":"Type II Diabetes Mellitus","metadata":null},{"id":"48d19c3b423c4980a847a82439843181","type":"TRIAL","name":"The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure","canonical_id":"clinicaltrials.gov:NCT02284230","description":"Kidney Failure, Chronic; Prediabetic State","metadata":null},{"id":"4baee3a4081e48af91719f29332963fc","type":"TRIAL","name":"The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes","canonical_id":"clinicaltrials.gov:NCT00422058","description":"Metabolism and Nutrition Disorder; Obesity","metadata":null},{"id":"d303e7e607d64d1d9c843843bd7e9f88","type":"TRIAL","name":"The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans","canonical_id":"clinicaltrials.gov:NCT02403284","description":"Insulin Resistance","metadata":null},{"id":"e49dc1c21fe845e7af06f64c47cc15bc","type":"TRIAL","name":"The Effect of Lixisenatide on the Effect of Pituitary Hormones","canonical_id":"clinicaltrials.gov:NCT05804513","description":"Healthy; Type 1 Diabetes","metadata":null},{"id":"32b9b88651384763901cd031b14588f6","type":"TRIAL","name":"The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction","canonical_id":"clinicaltrials.gov:NCT03680404","description":"Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction","metadata":null},{"id":"7b1283d09a7946179c3bb132866469f8","type":"TRIAL","name":"The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery","canonical_id":"clinicaltrials.gov:NCT06983886","description":"Postoperative Blood Loss in Patient Undergoing Orthognathic Surgery","metadata":null},{"id":"501b98fa27374a6c8896a2c31f256a60","type":"TRIAL","name":"The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery","canonical_id":"clinicaltrials.gov:NCT06450392","description":"Orbital Edema; Orbital Ecchymosis","metadata":null},{"id":"0736ac644d4745c7843126f2c0263616","type":"TRIAL","name":"The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury","canonical_id":"clinicaltrials.gov:NCT01275729","description":"Acute Kidney Failure","metadata":null},{"id":"485edcabb23e4e0d9cd5dbca31428f96","type":"TRIAL","name":"The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema","canonical_id":"clinicaltrials.gov:NCT00358423","description":"Cystoid Macular Edema","metadata":null},{"id":"4ea24bc404c54acb8ae6967a4746459e","type":"TRIAL","name":"The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep","canonical_id":"clinicaltrials.gov:NCT00893269","description":"Marijuana Dependence","metadata":null},{"id":"017f3fbc7d0a405b92ad0c28986778dc","type":"TRIAL","name":"The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment","canonical_id":"clinicaltrials.gov:NCT00544791","description":"Mild Cognitive Impairment (MCI)","metadata":null},{"id":"8a2c8ec9721d4eb888c681ab39ac8691","type":"TRIAL","name":"The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension","canonical_id":"clinicaltrials.gov:NCT01342614","description":"Diabetes Mellitus; Essential Hypertension","metadata":null},{"id":"00605f7098dd4678931aee54f0ef07f2","type":"TRIAL","name":"The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT01554046","description":"Attention Deficit/Hyperactivity Disorder Combined Type; ADHD Predominantly Inattentive Type; ADHD Predominantly Hyperactivity Type; ADHD-not Other Specified","metadata":null},{"id":"cb7bd28be86f4f89a183bcc5a30368bb","type":"TRIAL","name":"The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.","canonical_id":"clinicaltrials.gov:NCT03532802","description":"Hypertrophic Cardiomyopathy","metadata":null},{"id":"b719523bb9bc406a8d89b7b6c83f8910","type":"TRIAL","name":"The Effect of Milnacipran in Patients With Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01108731","description":"Fibromyalgia","metadata":null},{"id":"48392f83107740db8e655601afe95b6c","type":"TRIAL","name":"The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients","canonical_id":"clinicaltrials.gov:NCT01359826","description":"Systemic Lupus Erythematosus; Widespread Pain; Fibromyalgia","metadata":null},{"id":"5a4728489df14d29b56ef1361b44cdfe","type":"TRIAL","name":"The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects","canonical_id":"clinicaltrials.gov:NCT01719419","description":"Overweight","metadata":null},{"id":"6afd9b766b9b4271baad3feb1190947a","type":"TRIAL","name":"The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02305901","description":"Healthy","metadata":null},{"id":"c5fd26c4801245d9a450aa68cafd7006","type":"TRIAL","name":"The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy","canonical_id":"clinicaltrials.gov:NCT01761994","description":"Acute Kidney Injury","metadata":null},{"id":"fc97d55be0fa43b488711b8b2ad68444","type":"TRIAL","name":"The Effect of Naldemedine on Opioid-induced Bowel Dysfunction","canonical_id":"clinicaltrials.gov:NCT06334198","description":"Opioid-Induced Bowel Dysfunction; Constipation","metadata":null},{"id":"11287e3ee0c4453a8b1f30e9b5c731d3","type":"TRIAL","name":"The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health","canonical_id":"clinicaltrials.gov:NCT03014843","description":"Endogenous and Esophageal Sensitivity","metadata":null},{"id":"896e514de8d44b87879c251e826e259b","type":"TRIAL","name":"The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT01455220","description":"Multiple Sclerosis","metadata":null},{"id":"414ebe7b72b048babf89319069363507","type":"TRIAL","name":"The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm","canonical_id":"clinicaltrials.gov:NCT03930433","description":"Coronary Vasospasm","metadata":null},{"id":"ab2a6ddc6749454294726b50098faceb","type":"TRIAL","name":"The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT03190304","description":"Heart Failure; Exercise Tolerance; Vasodilation; Body Composition; Muscle Strength","metadata":null},{"id":"2a3e98a436bc46dcaac9491afba2ac58","type":"TRIAL","name":"The Effect of Nimodipine on the Postoperative Cognitive Dysfunction","canonical_id":"clinicaltrials.gov:NCT02537080","description":"Mild Cognitive Impairment","metadata":null},{"id":"8c37b43c5d4a4accb04abd644162cbc5","type":"TRIAL","name":"The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.","canonical_id":"clinicaltrials.gov:NCT04931108","description":"Hypertension","metadata":null},{"id":"fe68bfca3fad499083bfa14f2dbf1e6c","type":"TRIAL","name":"The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection","canonical_id":"clinicaltrials.gov:NCT01612975","description":"Pleural Effusion; Pleural Effusion Malignant","metadata":null},{"id":"35978896fd764c7e80fe2f4c372e7de6","type":"TRIAL","name":"The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex","canonical_id":"clinicaltrials.gov:NCT03860662","description":"Stroke Sequelae; Spastic Hemiplegia","metadata":null},{"id":"3a8f9420445b40ce9ad3b3efce94e240","type":"TRIAL","name":"The Effect of Osteoporotic Medications on Vertebral Bone Quality Score","canonical_id":"clinicaltrials.gov:NCT07587775","description":"Lumbar Degenerative Disease","metadata":null},{"id":"0716bfd362014535bb736123cea97424","type":"TRIAL","name":"The Effect of Oxytocin (OT) and Oxytocin Plus Human Chorionic Gonadotropin (hCG), in Cycles Induced by Letrozole or Clomiphene Citrate","canonical_id":"clinicaltrials.gov:NCT00844350","description":"Ovarian Response","metadata":null},{"id":"2054042293254be6ac5fb44b061d39fc","type":"TRIAL","name":"The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories","canonical_id":"clinicaltrials.gov:NCT03031405","description":"Intrusive Memories","metadata":null},{"id":"6256a938108242ff91ab3e5129e22a47","type":"TRIAL","name":"The Effect of Oxytocin on the Gastric Emptying","canonical_id":"clinicaltrials.gov:NCT00776360","description":"Postprocedural Delayed Gastric Emptying","metadata":null},{"id":"20ec489fe91941768c95c7e811099ecb","type":"TRIAL","name":"The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors","canonical_id":"clinicaltrials.gov:NCT00421733","description":"Diabetic Nephropathy; Chronic Kidney Disease","metadata":null},{"id":"dfefead40c7244ef850a1c16ff9a2799","type":"TRIAL","name":"The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate","canonical_id":"clinicaltrials.gov:NCT01163162","description":"Chronic Kidney Disease","metadata":null},{"id":"9a990f2456cc466eb5ee420b55da2afa","type":"TRIAL","name":"The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance","canonical_id":"clinicaltrials.gov:NCT01187719","description":"HIV-infection; Pregnancy; Mother to Child Transmission","metadata":null},{"id":"2971fa2441d14d7e85f961f6b722b9e0","type":"TRIAL","name":"The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy","canonical_id":"clinicaltrials.gov:NCT01121497","description":"Cognitive Dysfunction","metadata":null},{"id":"686820bc3be348519b178c6543e43f54","type":"TRIAL","name":"The Effect of Piroxicam Addition During Arthrocentesis on Mouth Opening and Postoperative Pain","canonical_id":"clinicaltrials.gov:NCT06508203","description":"Temporomandibular Joint Disorders","metadata":null},{"id":"749f2d9230fa42bca911d95ed1b6650a","type":"TRIAL","name":"The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis","canonical_id":"clinicaltrials.gov:NCT02126683","description":"Hashimoto's Thyroiditis","metadata":null},{"id":"fb985344634a4ac488c5c55ac866c602","type":"TRIAL","name":"The Effect of Pre-emptive Analgesia on the Postoperative Pain in Children Undergoing Pediatric Stomatology Day Surgeries","canonical_id":"clinicaltrials.gov:NCT05878262","description":"Ankyloglossia; Oral Mucoceles; Supernumerary Teeth","metadata":null},{"id":"e80442431c974b3da3f43229f4e14661","type":"TRIAL","name":"The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate","canonical_id":"clinicaltrials.gov:NCT04848181","description":"Prostate Hyperplasia","metadata":null},{"id":"58414e66e4d64ac9964445e1f7a25cbc","type":"TRIAL","name":"The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination","canonical_id":"clinicaltrials.gov:NCT06401499","description":"Back Pain Lower Back Chronic","metadata":null},{"id":"f418a29c33ca4342a73364ede43a6f75","type":"TRIAL","name":"The Effect of Pretreatment With Dydrogesterone Vs Combined Estradiol Valerate and Dydrogestrone on Clinical Pregnancy Outcome of ICSI in PCOS Patients\"","canonical_id":"clinicaltrials.gov:NCT05300841","description":"PCOS; ICSI","metadata":null},{"id":"b5de36854cc643928113f843d0658bb0","type":"TRIAL","name":"The Effect of Pretreatment With Roc on Succinylcholine Myalgias","canonical_id":"clinicaltrials.gov:NCT04581395","description":"Myalgia","metadata":null},{"id":"d980bb256f99434098dc8ca2dc96cfc0","type":"TRIAL","name":"The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders","canonical_id":"clinicaltrials.gov:NCT01305889","description":"Major Depressive Disorder","metadata":null},{"id":"4ec08ced1fb24bbfa941e7fae3518597","type":"TRIAL","name":"The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians","canonical_id":"clinicaltrials.gov:NCT00761904","description":"Hypertension; Hyperlipidemia","metadata":null},{"id":"753c7b8b6f0c488eb69d48b1000ae5ae","type":"TRIAL","name":"The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU","canonical_id":"clinicaltrials.gov:NCT03931070","description":"Delirium","metadata":null},{"id":"cc65123e8b2e4addb6bdba8ff54bc3fb","type":"TRIAL","name":"The Effect of Rasagiline on Cognition in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01382342","description":"Parkinson's Disease","metadata":null},{"id":"a653377792b5425eab07e39571169a21","type":"TRIAL","name":"The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil","canonical_id":"clinicaltrials.gov:NCT01131845","description":"Pulmonary Arterial Hypertension; Renal Dysfunction","metadata":null},{"id":"d84d4591ff374f2c893dc10c6af0668b","type":"TRIAL","name":"The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria","canonical_id":"clinicaltrials.gov:NCT00674596","description":"Diabetes; Proteinuria; Renin Angiotensin System","metadata":null},{"id":"95a729811e604d56b9fc0f6ab8f86dce","type":"TRIAL","name":"The Effect of Renin Inhibition on Nerve Function in Diabetes","canonical_id":"clinicaltrials.gov:NCT00935064","description":"Diabetes","metadata":null},{"id":"bca609dd835d47c6a69767adfe72b786","type":"TRIAL","name":"The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia","canonical_id":"clinicaltrials.gov:NCT07277881","description":"Postoperative Delirium; Sedation; Remimazolam; Hip Arthroplasty, Total","metadata":null},{"id":"51ca7f99c8314c519d6e8b3e604e0eeb","type":"TRIAL","name":"The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)","canonical_id":"clinicaltrials.gov:NCT00444912","description":"Non-Hodgkin Lymphoma; Hodgkin Disease","metadata":null},{"id":"3a55029f07654c9aa93eb11b93ba8a82","type":"TRIAL","name":"The Effect of Rivaroxaban in Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT02072668","description":"Sickle Cell Anemia; Sickle Cell-Beta0-Thalassemia","metadata":null},{"id":"92374da9a1934756aae9dea3d3f6ed38","type":"TRIAL","name":"The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02021201","description":"Schizophrenia","metadata":null},{"id":"cf060a35be76469bb5c5e1fd5a9f0a3b","type":"TRIAL","name":"The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT00612079","description":"Healthy","metadata":null},{"id":"5d8534e003924ca7af3f561d96732589","type":"TRIAL","name":"The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients","canonical_id":"clinicaltrials.gov:NCT00629252","description":"Schizophrenia","metadata":null},{"id":"64e8b480ce4d495cbb63fed17a499a0f","type":"TRIAL","name":"The Effect of Solifenacin on Post Void Dribbling in Women","canonical_id":"clinicaltrials.gov:NCT01470001","description":"Post-micturition Incontinence; Incontinence","metadata":null},{"id":"64cb98453db3438ea3871a6ababa9a6e","type":"TRIAL","name":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","canonical_id":"clinicaltrials.gov:NCT03819790","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"a8a850ee899b4a5b8ca1f17d93d9da6e","type":"TRIAL","name":"The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography","canonical_id":"clinicaltrials.gov:NCT03329443","description":"Acute Kidney Injury; IHD; Contrast-induced Nephropathy","metadata":null},{"id":"cd3c7202de6445eba4230d6f682fee2e","type":"TRIAL","name":"The Effect of Spironolactone on Pain in Older People With Osteoarthritis","canonical_id":"clinicaltrials.gov:NCT02046668","description":"Osteoarthritis, Knee","metadata":null},{"id":"ce50731bd8284d7b9bb734ae79d44f8e","type":"TRIAL","name":"The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache","canonical_id":"clinicaltrials.gov:NCT02486276","description":"Migraine","metadata":null},{"id":"a19883037c6b40f39d1c41994959af55","type":"TRIAL","name":"The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache","canonical_id":"clinicaltrials.gov:NCT02485340","description":"Migraine","metadata":null},{"id":"3b6af7e213cb451e81a1dd3136b3c1c0","type":"TRIAL","name":"The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment","canonical_id":"clinicaltrials.gov:NCT06039137","description":"Solid Tumor","metadata":null},{"id":"f9d5ec0072074a05b820c25b5ef47f8f","type":"TRIAL","name":"The Effect of Tamsulosin on Postoperative Urinary Retention","canonical_id":"clinicaltrials.gov:NCT04682366","description":"Urinary Retention","metadata":null},{"id":"5c435afad45543feaff2fb243056fa2e","type":"TRIAL","name":"The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction","canonical_id":"clinicaltrials.gov:NCT06275373","description":"Thyroid Eye Disease; Graves Ophthalmopathy; Graves Disease","metadata":null},{"id":"0cea27db15854b08b07394bc7b3d7aa5","type":"TRIAL","name":"The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms","canonical_id":"clinicaltrials.gov:NCT01530243","description":"Disorder of Urinary Stent","metadata":null},{"id":"8fefaaf80d65400bb8f7218b221b390b","type":"TRIAL","name":"The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA","canonical_id":"clinicaltrials.gov:NCT03133195","description":"Unstable Intertrochanteric Fracture; Pertrochanteric Fracture of Femur, Closed","metadata":null},{"id":"c70a43ead5174083b4e5afaa8ef889e4","type":"TRIAL","name":"The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation","canonical_id":"clinicaltrials.gov:NCT02626169","description":"Atherosclerosis","metadata":null},{"id":"1c2767379d494a3aafd310d4fbd9d13b","type":"TRIAL","name":"The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","canonical_id":"clinicaltrials.gov:NCT05688904","description":"Imipramine; Photodynamic Therapy; Actinic Keratosis","metadata":null},{"id":"4b86deddb66a448387628061dde11a32","type":"TRIAL","name":"The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans","canonical_id":"clinicaltrials.gov:NCT06778434","description":"Actinic Keratosis; Imipramine; Photodynamic Therapy","metadata":null},{"id":"e9361d420dac4855af11800e7de9aac5","type":"TRIAL","name":"The Effect of Tranexamic Acid for Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT02094066","description":"Hemorrhage","metadata":null},{"id":"d2c70a69ff164087af6f0d111b4b5a12","type":"TRIAL","name":"The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression","canonical_id":"clinicaltrials.gov:NCT04162743","description":"Sleep Apnea Syndromes; Cerebral Infarction","metadata":null},{"id":"23bfeb1a0e9048ae91dc59b7cb4b1a60","type":"TRIAL","name":"The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.","canonical_id":"clinicaltrials.gov:NCT03275116","description":"Chronic Obstructive Airway Disease","metadata":null},{"id":"37562b164d1547d981be511e3d8cd75d","type":"TRIAL","name":"The Effect of Two Different Analgesic Techniques on Postoperative Recovery Quality","canonical_id":"clinicaltrials.gov:NCT06766994","description":"Abdominal Hysterectomy","metadata":null},{"id":"94ed3c1fb85d4488be18716243ed1646","type":"TRIAL","name":"The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve","canonical_id":"clinicaltrials.gov:NCT02361892","description":"Infertility","metadata":null},{"id":"45c9a3c84bc64f9ea87239efc271ab04","type":"TRIAL","name":"The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance","canonical_id":"clinicaltrials.gov:NCT04831047","description":"Ptosis, Eyelid; Conjunctiva Inflamed; Eye Manifestations","metadata":null},{"id":"88a9c5ffcf1b470ca51b5e331d9dc9a6","type":"TRIAL","name":"The Effect of Uric Acid Lowering in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02344602","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"2357b2e9e9584668a7700f70694da9f8","type":"TRIAL","name":"The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria","canonical_id":"clinicaltrials.gov:NCT01541267","description":"Chronic Kidney Disease; Proteinuria","metadata":null},{"id":"bedfefa3ee2446a89998de23dbcf24ac","type":"TRIAL","name":"The Effect of Weight Loss on Anti-M\u00fcllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)","canonical_id":"clinicaltrials.gov:NCT01475019","description":"Obesity; Polycystic Ovaries Syndrome","metadata":null},{"id":"b9f79c98f139496abd5bc900855c345a","type":"TRIAL","name":"The Effect of Xolair (Omalizumab) on Allergy Blood Cells","canonical_id":"clinicaltrials.gov:NCT00657891","description":"Asthma","metadata":null},{"id":"43b6f494c50a4672a6c1544d5c4d2b3d","type":"TRIAL","name":"The Effect of Yohimbine on Cocaine Cue Reactivity","canonical_id":"clinicaltrials.gov:NCT00535002","description":"Cocaine Related Disorders","metadata":null},{"id":"4b5edff7d7c842b8974726e900a6a740","type":"TRIAL","name":"The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion","canonical_id":"clinicaltrials.gov:NCT00709657","description":"Macular Degeneration; Regional Blood Flow; Vascular Endothelial Growth Factor","metadata":null},{"id":"3c786ebf24c140f6904faaabe51c3832","type":"TRIAL","name":"The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin","canonical_id":"clinicaltrials.gov:NCT02597309","description":"Diabetes, Obesity","metadata":null},{"id":"68cbdd3c348347b698f694abf5344196","type":"TRIAL","name":"The Effect of an \u03b12-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery","canonical_id":"clinicaltrials.gov:NCT00814047","description":"Blood Flow Velocity; Autoregulation; Ocular Physiology","metadata":null},{"id":"c0734592cbbd4290bd65e50ab0cf3b78","type":"TRIAL","name":"The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)","canonical_id":"clinicaltrials.gov:NCT01386606","description":"Secondary Hypogonadism","metadata":null},{"id":"6e951e9e25754d5ea0ce76a60fcd6414","type":"TRIAL","name":"The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active \"Drug: Crohn's Disease\"","canonical_id":"clinicaltrials.gov:NCT00245505","description":"Crohn's Disease","metadata":null},{"id":"7a88442fed824ba5b37efc9f09a80b12","type":"TRIAL","name":"The Effectiveness of ABT-450/r - Ombitasvir, \u00b1 Dasabuvir, \u00b1 Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland","canonical_id":"clinicaltrials.gov:NCT02582671","description":"Chronic Hepatitis C","metadata":null},{"id":"e4159070c12549edbf7e052ba40809d8","type":"TRIAL","name":"The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","canonical_id":"clinicaltrials.gov:NCT02788851","description":"Attention Deficit Hyperactivity Disorder (ADHD)","metadata":null},{"id":"98e3ead307d541dcb49f9ca60278ec2f","type":"TRIAL","name":"The Effectiveness of Aspirin on Preventing Pre-eclampsia","canonical_id":"clinicaltrials.gov:NCT04656665","description":"Pre-Eclampsia","metadata":null},{"id":"e2483ad008934adf90d05957bca41810","type":"TRIAL","name":"The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)","canonical_id":"clinicaltrials.gov:NCT06628921","description":"Migraine","metadata":null},{"id":"9a506123cfce4fc8bddb7096ba2e30c9","type":"TRIAL","name":"The Effectiveness of Lubiprostone in Constipated Diabetics","canonical_id":"clinicaltrials.gov:NCT01170039","description":"Constipation; Diabetes","metadata":null},{"id":"24797548ffd149dd8aed21532c46fdf1","type":"TRIAL","name":"The Effectiveness of Peripheral Magnetic Stimulation in Men With Lower Urinary Tract Symptoms","canonical_id":"clinicaltrials.gov:NCT04807569","description":"Bladder Hypersensitivity","metadata":null},{"id":"6959214a23844fa59422644a098062c4","type":"TRIAL","name":"The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia","canonical_id":"clinicaltrials.gov:NCT01987219","description":"Familial Dysautonomia","metadata":null},{"id":"96f1213775f543fabeacea2d50adbf7f","type":"TRIAL","name":"The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT04792580","description":"Graft-versus-host-disease; Ocular Graft-versus-host Disease","metadata":null},{"id":"71aa620b320142049b57cd1050786bca","type":"TRIAL","name":"The Effects of ADHD Medication (TEAM) Study","canonical_id":"clinicaltrials.gov:NCT02293655","description":"ADHD","metadata":null},{"id":"bb53ef222dc34735be5b2bdd30158e16","type":"TRIAL","name":"The Effects of Active VItamin D on Left Atrial Volume Index","canonical_id":"clinicaltrials.gov:NCT01630408","description":"Heart Failure","metadata":null},{"id":"c05a9bac04f44719ba07cd15c7b34106","type":"TRIAL","name":"The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG","canonical_id":"clinicaltrials.gov:NCT00446017","description":"Cardiac Output, Low","metadata":null},{"id":"261c6b7ff8c6408f8ee4494cd4dbee60","type":"TRIAL","name":"The Effects of Aldara as an Adjunct to Laser Treatment","canonical_id":"clinicaltrials.gov:NCT00979550","description":"Port Wine Stains","metadata":null},{"id":"6530e8a6c4a14569928cb1340bd48994","type":"TRIAL","name":"The Effects of Ambrisentan on Exercise Capacity in Fontan Patients","canonical_id":"clinicaltrials.gov:NCT01971580","description":"Single Ventricle Fontan Palliation","metadata":null},{"id":"ee00a8225db44a379d98dccf44b994b0","type":"TRIAL","name":"The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables","canonical_id":"clinicaltrials.gov:NCT01195805","description":"Essential Hypertension","metadata":null},{"id":"92c9b9e2c38f483e95b36f047f430991","type":"TRIAL","name":"The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain","canonical_id":"clinicaltrials.gov:NCT02969629","description":"Chronic Low Back Pain","metadata":null},{"id":"eb2cb88b0bfa46d891a0acd6cefd3758","type":"TRIAL","name":"The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty","canonical_id":"clinicaltrials.gov:NCT00909064","description":"Total Knee Replacement","metadata":null},{"id":"cf1dc3f5764d463097f149f33e547c11","type":"TRIAL","name":"The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype","canonical_id":"clinicaltrials.gov:NCT00548327","description":"Schizophrenia; Memory Disorders; Cognition Disorders","metadata":null},{"id":"6097b9f6907e4f05a8247cb3b5db03b1","type":"TRIAL","name":"The Effects of Bethanechol on Glucose Homeostasis","canonical_id":"clinicaltrials.gov:NCT01434901","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"94840ab15ab64889ab74fc80aed18dc5","type":"TRIAL","name":"The Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood","canonical_id":"clinicaltrials.gov:NCT00981955","description":"Cognitive Function; Mood","metadata":null},{"id":"157ecf369c34437eb61ba21ec8cea888","type":"TRIAL","name":"The Effects of Combined Gum-chewing and Parenteral Metoclopramide on Post-operative Ileus","canonical_id":"clinicaltrials.gov:NCT05669781","description":"Ileus Postoperative","metadata":null},{"id":"f5e9e7cbd7bc42c3935defc198cdde4e","type":"TRIAL","name":"The Effects of Cosopt\u00ae Vs Xalacom\u00ae on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)","canonical_id":"clinicaltrials.gov:NCT00815373","description":"Open-Angle Glaucoma; Ocular Hypertension","metadata":null},{"id":"7d3e74fd5e0549aab187929c95b59197","type":"TRIAL","name":"The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement","canonical_id":"clinicaltrials.gov:NCT01375335","description":"Heart Failure","metadata":null},{"id":"d0d72891393b415c8da2e1b7d613574c","type":"TRIAL","name":"The Effects of Dopamine on Reward Processing","canonical_id":"clinicaltrials.gov:NCT01253421","description":"Major Depressive Disorder (MDD)","metadata":null},{"id":"b33e5acb3b7344f38c6a6fd6c2cb13d4","type":"TRIAL","name":"The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT02563405","description":"Hypertension","metadata":null},{"id":"2c546bf70b7d44f09ebaa640504358ca","type":"TRIAL","name":"The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine","canonical_id":"clinicaltrials.gov:NCT01062945","description":"Cocaine Addiction; Cocaine Abuse; Cocaine Dependence; Substance Abuse","metadata":null},{"id":"bc0cfea7d66a48dbab6ffc4baa0abb6e","type":"TRIAL","name":"The Effects of Enoximone in Acute Exacerbation COPD","canonical_id":"clinicaltrials.gov:NCT04420455","description":"COPD Exacerbation; Enoximone; Phosphodiesterase Inhibitor","metadata":null},{"id":"f78ded904b1f40a2b863603eaceccee0","type":"TRIAL","name":"The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease","canonical_id":"clinicaltrials.gov:NCT01971593","description":"Tetralogy of Fallot; Transposition of the Great Vessels With an Arterial Switch; Single Ventricle With a Fontan Palliation","metadata":null},{"id":"630bd2deadd84e22af98b749e95681ab","type":"TRIAL","name":"The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation","canonical_id":"clinicaltrials.gov:NCT04264286","description":"Beta Blocker; Hemodynamic Instability","metadata":null},{"id":"f0687b5f24034e31b527ef5974c41474","type":"TRIAL","name":"The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density","canonical_id":"clinicaltrials.gov:NCT00446589","description":"Osteoporosis","metadata":null},{"id":"a3deae255c044d58935ac5ae13dd802f","type":"TRIAL","name":"The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers","canonical_id":"clinicaltrials.gov:NCT03104634","description":"Smoking","metadata":null},{"id":"8aa71229f8c446fea55cdc4d5adda62b","type":"TRIAL","name":"The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01600885","description":"NMDA Receptor Function","metadata":null},{"id":"2e604592eb144c409b14db10e2d7e80f","type":"TRIAL","name":"The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy","canonical_id":"clinicaltrials.gov:NCT02252432","description":"Laminectomy","metadata":null},{"id":"fa355ecfc08b4d8cb65e26f688577c7f","type":"TRIAL","name":"The Effects of Lemborexant on the Ability to Sleep During Daytime","canonical_id":"clinicaltrials.gov:NCT06231641","description":"Shift-Work Sleep Disorder","metadata":null},{"id":"70970320a2ba4db1a19750f402a781f0","type":"TRIAL","name":"The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)","canonical_id":"clinicaltrials.gov:NCT01577017","description":"Polycystic Ovarian Syndrome","metadata":null},{"id":"409aa423393e4e1e96f9dc51952524b0","type":"TRIAL","name":"The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03426085","description":"Autonomic Nervous System Diseases; Sweat Gland Diseases; Diabetic Neuropathy With Neurologic Complication","metadata":null},{"id":"dd299420d9b847e5bdc56be3df362b19","type":"TRIAL","name":"The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT01234675","description":"Sleep Disorders; Fibromyalgia; Sleep","metadata":null},{"id":"cd621dec3f4748a29fedb9786cc35bab","type":"TRIAL","name":"The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics","canonical_id":"clinicaltrials.gov:NCT05051436","description":"Pre-diabetes; Obesity","metadata":null},{"id":"2e294f07a15f41fcb08952ad96c2bf23","type":"TRIAL","name":"The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers","canonical_id":"clinicaltrials.gov:NCT00874003","description":"Alcohol Dependence","metadata":null},{"id":"3a2568bff55f49149db8055f3dcf1f43","type":"TRIAL","name":"The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients","canonical_id":"clinicaltrials.gov:NCT01854814","description":"IgA Nephropathy","metadata":null},{"id":"844f9c0a852e4eeabed03f18d4369978","type":"TRIAL","name":"The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT02893553","description":"Spinal Cord Injury; Autonomic Dysreflexia; Baroreceptor Integrity; Sympathetic Integrity; Vagal Integrity; Autonomic Integrity; Hypotensive; Cognitive Function; Cerebral Blood Flow; Blood Pressure","metadata":null},{"id":"043c905cdab74cc2a17c4e23907bed7a","type":"TRIAL","name":"The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS","canonical_id":"clinicaltrials.gov:NCT02866786","description":"Polycystic Ovary Syndrome","metadata":null},{"id":"2ec037aabbcf4c49939452ea33b4aa70","type":"TRIAL","name":"The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge","canonical_id":"clinicaltrials.gov:NCT01003301","description":"Cat Allergy","metadata":null},{"id":"abd56614c6b9426ba4fe1859695c1a7e","type":"TRIAL","name":"The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia","canonical_id":"clinicaltrials.gov:NCT01091571","description":"Endotoxemia","metadata":null},{"id":"ffd729cec3f141a395937507d911a754","type":"TRIAL","name":"The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study","canonical_id":"clinicaltrials.gov:NCT06329037","description":"Healthy","metadata":null},{"id":"de3127f6c13a4863816773eeb76e7324","type":"TRIAL","name":"The Effects of Orexin Antagonism on Fear Extinction in PTSD","canonical_id":"clinicaltrials.gov:NCT06788522","description":"Insomnia; PTSD","metadata":null},{"id":"fcd61b2078004371a560976cccbc6d24","type":"TRIAL","name":"The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","canonical_id":"clinicaltrials.gov:NCT00441584","description":"Hepatitis C, Chronic","metadata":null},{"id":"8579ae4a040544edb6c0e1b1394954d1","type":"TRIAL","name":"The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study","canonical_id":"clinicaltrials.gov:NCT01999530","description":"Healthy","metadata":null},{"id":"93ce4f9d5ab6400ab6574dcfdddd719b","type":"TRIAL","name":"The Effects of Preemptive Multimodal Analgesic on Endodontic Pain Following Root Canal Therapy.","canonical_id":"clinicaltrials.gov:NCT07400471","description":"Post Endodontic Pain; Mechanical Detection Threshold; Mechanical Pain Threshold; Mechanical Pain Sensitivity","metadata":null},{"id":"6b7cdb7360a74c3a8a14aa388174fc9e","type":"TRIAL","name":"The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass","canonical_id":"clinicaltrials.gov:NCT01268917","description":"Coronary Artery Disease; Off-pump Coronary Artery Bypass; Aspirin","metadata":null},{"id":"ca7eb9fbed0b4a67a0041f23041a3460","type":"TRIAL","name":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","canonical_id":"clinicaltrials.gov:NCT01369771","description":"Ocular Hypertension; Open-Angle Glaucoma","metadata":null},{"id":"44971bacf75f49a88fb0a7e88d3fbd7a","type":"TRIAL","name":"The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression","canonical_id":"clinicaltrials.gov:NCT00517387","description":"Unipolar Depression","metadata":null},{"id":"1e48b651fd0446809e70415c5430e844","type":"TRIAL","name":"The Effects of RPL554 in Addition to Tiotropium in COPD Patients","canonical_id":"clinicaltrials.gov:NCT03028142","description":"Chronic Obstructive Pulmonary Disease Moderate","metadata":null},{"id":"baa6323c9c5b4c09abef1a7de8671afc","type":"TRIAL","name":"The Effects of RPL554 on Top of Standard COPD Reliever Medications","canonical_id":"clinicaltrials.gov:NCT02542254","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"43befc14fa44482483d5bdf367801d9c","type":"TRIAL","name":"The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT00696215","description":"Parkinson's Disease","metadata":null},{"id":"215e92440a174b46a633526f80cf23e9","type":"TRIAL","name":"The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function","canonical_id":"clinicaltrials.gov:NCT03115853","description":"High Blood Pressure","metadata":null},{"id":"ee9cb74f293140aeaa2debf391fa4ce2","type":"TRIAL","name":"The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT06048380","description":"Fuchs' Endothelial Dystrophy; Cataract","metadata":null},{"id":"92c99fab52f1412ab811e0c9f63f7b68","type":"TRIAL","name":"The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity","canonical_id":"clinicaltrials.gov:NCT06489457","description":"Type 2 Diabetes Mellitus; Obesity; Functional Hypogonadism","metadata":null},{"id":"65802ecbca5648969855d14442cbbe29","type":"TRIAL","name":"The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder","canonical_id":"clinicaltrials.gov:NCT05711862","description":"Methamphetamine Use Disorder","metadata":null},{"id":"597556e0949b421ab4b62113570cc5f4","type":"TRIAL","name":"The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)","canonical_id":"clinicaltrials.gov:NCT05922995","description":"REM Behavior Disorder","metadata":null},{"id":"a553c1e9146248edab19ec8423b1b5e4","type":"TRIAL","name":"The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL","canonical_id":"clinicaltrials.gov:NCT00347737","description":"Osteoporosis","metadata":null},{"id":"4a3f87fa524a478daa4d06393dec3152","type":"TRIAL","name":"The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid","canonical_id":"clinicaltrials.gov:NCT04465292","description":"Pemphigoid, Bullous","metadata":null},{"id":"52350bd4c8e84915af92ca0d56cca87a","type":"TRIAL","name":"The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients","canonical_id":"clinicaltrials.gov:NCT01560013","description":"Alcohol-dependence","metadata":null},{"id":"92690904518043b3a12f62ea8178e7f4","type":"TRIAL","name":"The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT01942993","description":"Melanoma","metadata":null},{"id":"d805cf305ad04bfb9518c9c6b8dc3778","type":"TRIAL","name":"The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives","canonical_id":"clinicaltrials.gov:NCT02028026","description":"Major Depressive Disorder; Anxiety; Comorbidity","metadata":null},{"id":"8b5fb1c2de1f49ab90f4ed3f925130d4","type":"TRIAL","name":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","canonical_id":"clinicaltrials.gov:NCT00705757","description":"Glaucoma; Application Site Pigmentation Changes","metadata":null},{"id":"cff3236c753249a5b040edebdd87dae0","type":"TRIAL","name":"The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients","canonical_id":"clinicaltrials.gov:NCT01250171","description":"Dry Eye","metadata":null},{"id":"fb40dd5698d64545991ac6772789c99a","type":"TRIAL","name":"The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib","canonical_id":"clinicaltrials.gov:NCT02800330","description":"Colorectal Neoplasms; Gastrointestinal Stromal Tumors","metadata":null},{"id":"90feb3ce21de4dd5a183207fc2c0c4f7","type":"TRIAL","name":"The Effects of \u03b1-adrenergic Receptor Antagonists on Choroid and Pupil","canonical_id":"clinicaltrials.gov:NCT03144596","description":"Benign Prostatic Hyperplasia; Pupil Anomaly; Choroid Disease","metadata":null},{"id":"1e0b62f87a2e4420ab0cf2bf191393db","type":"TRIAL","name":"The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.","canonical_id":"clinicaltrials.gov:NCT02336607","description":"Hypertension","metadata":null},{"id":"e66c4564745241b286d70ce52576a666","type":"TRIAL","name":"The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation","canonical_id":"clinicaltrials.gov:NCT02935998","description":"Schizophrenia","metadata":null},{"id":"6a7eed6b021d41e8aeebcd99bbc8dab5","type":"TRIAL","name":"The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT04238208","description":"Diabetic Nerve Problems; Diabetic Neuropathy; Diabetic Complications Neurological","metadata":null},{"id":"0ff7b20fab5f4c9bb245dd5bd2fb547e","type":"TRIAL","name":"The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT02729545","description":"Polycystic Ovarian Syndrome","metadata":null},{"id":"c9fee70a060d49d880d58890d36d796a","type":"TRIAL","name":"The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis","canonical_id":"clinicaltrials.gov:NCT06470386","description":"Hypertension, Portal","metadata":null},{"id":"07258160e2c0425eb98c1010d3e37f98","type":"TRIAL","name":"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04185649","description":"HER2-positive Advanced Breast Cancer","metadata":null},{"id":"7cee5614a467487794b0117acc1a931b","type":"TRIAL","name":"The Efficacy and Safety of Benmelstobart for GC/EGC","canonical_id":"clinicaltrials.gov:NCT06603974","description":"Gastric Cancer","metadata":null},{"id":"5f4c1ec38a7548c1b8bcce44d9a86ce2","type":"TRIAL","name":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","canonical_id":"clinicaltrials.gov:NCT07340463","description":"Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN)","metadata":null},{"id":"985fb7e32fd445ca85f3a8596be353c2","type":"TRIAL","name":"The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)","canonical_id":"clinicaltrials.gov:NCT07065968","description":"Immune Thrombocytopenia (ITP)","metadata":null},{"id":"92957f2889804c548fe0176f58db9ae8","type":"TRIAL","name":"The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy","canonical_id":"clinicaltrials.gov:NCT02939495","description":"Premature Ejaculation; Erectile Dysfunction","metadata":null},{"id":"874c57b232764830a52a823590c66a6a","type":"TRIAL","name":"The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","canonical_id":"clinicaltrials.gov:NCT07013838","description":"Takayasu Arteritis (TAK)","metadata":null},{"id":"6ff43622dee9482691df24eb4dd93141","type":"TRIAL","name":"The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .","canonical_id":"clinicaltrials.gov:NCT07247656","description":"Diabete Mellitus","metadata":null},{"id":"631244cd41c941a6be11719047aff1b3","type":"TRIAL","name":"The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05555901","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"31ae43755245415881f59a2af2eb21dc","type":"TRIAL","name":"The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP","canonical_id":"clinicaltrials.gov:NCT06479304","description":"Immune Thrombocytopenia With Positive ANA Antibodies","metadata":null},{"id":"61ea9f64c49e4ab6af3095ecd518df2f","type":"TRIAL","name":"The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT02558231","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"5d9c366ed95541d981a98873fe107125","type":"TRIAL","name":"The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT07139587","description":"Gastric Cancer; Gastroesophageal Junction Adenocarcinoma","metadata":null},{"id":"eb1bbbce0fd648edba87d9c75b204713","type":"TRIAL","name":"The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI","canonical_id":"clinicaltrials.gov:NCT05511831","description":"ST-segment Elevation Myocardial Infarction (STEMI)","metadata":null},{"id":"32b54285d6f54b62a109113beb1ace4d","type":"TRIAL","name":"The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus","canonical_id":"clinicaltrials.gov:NCT06403150","description":"Status Epilepticus","metadata":null},{"id":"9d4ab81eb056400fa459fc8b544623cb","type":"TRIAL","name":"The Efficacy and Safety of NALDEBAIN for the Treatment of Post-Laparotomy Surgery","canonical_id":"clinicaltrials.gov:NCT03296488","description":"Pain, Postoperative","metadata":null},{"id":"46c8fd9e90c9411a809a7631179c96fb","type":"TRIAL","name":"The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT02262897","description":"Small Cell Lung Cancer","metadata":null},{"id":"eb5cd32cb44c465d9d66fa664028e42d","type":"TRIAL","name":"The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2","canonical_id":"clinicaltrials.gov:NCT06523400","description":"Myotonic Dystrophy","metadata":null},{"id":"34ca89a0bd324368b1b3a09eb7e59d01","type":"TRIAL","name":"The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis","canonical_id":"clinicaltrials.gov:NCT00425451","description":"Periodontitis","metadata":null},{"id":"6a5ebe0a2afc4c7f846bf9ff7e5210ad","type":"TRIAL","name":"The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL","canonical_id":"clinicaltrials.gov:NCT07514169","description":"Large B-Cell Lymphoma (LBCL)","metadata":null},{"id":"bbbd349585b945c89f3f7e32ee174662","type":"TRIAL","name":"The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06522555","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"50bd403ae8b44fd4b0e8af7f553b273a","type":"TRIAL","name":"The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH","canonical_id":"clinicaltrials.gov:NCT07134907","description":"BPH (Benign Prostatic Hyperplasia)","metadata":null},{"id":"536ab8bef1364cb9971d312a88621b99","type":"TRIAL","name":"The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics","canonical_id":"clinicaltrials.gov:NCT02142556","description":"Schizophrenia","metadata":null},{"id":"7c1fbcac0b954ba1aa8bfd9b2a6c115c","type":"TRIAL","name":"The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT07362355","description":"Primary Gout and Hyperuricemia","metadata":null},{"id":"9e1739322a9549e1b1ba310bbc7e179e","type":"TRIAL","name":"The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH","canonical_id":"clinicaltrials.gov:NCT00159861","description":"Pulmonary Hypertension","metadata":null},{"id":"5e2ca6c1adf145c6b1b702dd5a8c50b0","type":"TRIAL","name":"The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia","canonical_id":"clinicaltrials.gov:NCT05551221","description":"Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","metadata":null},{"id":"31832fb43c0d4c76817efefd8356356c","type":"TRIAL","name":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06528405","description":"Acute Kidney Injury","metadata":null},{"id":"2f1013dc63c043b89b26f0216e2e6ec1","type":"TRIAL","name":"The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent","canonical_id":"clinicaltrials.gov:NCT07818083","description":"Ruptured Intracranial Aneurysms; Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"068ee1c4c6114b55bdb4f3c5ad31a1a3","type":"TRIAL","name":"The Efficacy and Safety of Tropisetron in Preventing Emergence Delirium","canonical_id":"clinicaltrials.gov:NCT04027751","description":"Emergence Delirium; Postoperative Delirium","metadata":null},{"id":"8b091f2ca9444d72a226ca8fa57ba017","type":"TRIAL","name":"The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT00718952","description":"Pulmonary Hypertension","metadata":null},{"id":"2286d93ada594604a31c7e72ef18890b","type":"TRIAL","name":"The Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine Adhesions","canonical_id":"clinicaltrials.gov:NCT02496052","description":"Intrauterine Adhesions","metadata":null},{"id":"0cb4f5cf94f349f8a8fba33408325400","type":"TRIAL","name":"The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.","canonical_id":"clinicaltrials.gov:NCT05990985","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"830b747756de4ca295f196c8d3380e6e","type":"TRIAL","name":"The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder","canonical_id":"clinicaltrials.gov:NCT00438971","description":"Panic Disorder","metadata":null},{"id":"114503ac8e9149dd821d7036dda32ae0","type":"TRIAL","name":"The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine","canonical_id":"clinicaltrials.gov:NCT00724815","description":"Migraine Disorders","metadata":null},{"id":"92b51b4f22024fb18d705d0acd4068ee","type":"TRIAL","name":"The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia","canonical_id":"clinicaltrials.gov:NCT01285544","description":"Dyslipidemia; Cardiovascular Disease; Hypercholesterolemia","metadata":null},{"id":"de1369e1f2574fcca7fe770063942053","type":"TRIAL","name":"The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones","canonical_id":"clinicaltrials.gov:NCT00451061","description":"Renal Colic","metadata":null},{"id":"fef57ee20e364b6485bb5678122fd20f","type":"TRIAL","name":"The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea","canonical_id":"clinicaltrials.gov:NCT01598012","description":"Primary Dysmenorrhea","metadata":null},{"id":"18c09e68c0d0400bbc4a7ff839b8afd0","type":"TRIAL","name":"The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics","canonical_id":"clinicaltrials.gov:NCT06390787","description":"Vomiting","metadata":null},{"id":"34ebaa352734472f9f2b04185acb8c23","type":"TRIAL","name":"The Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure","canonical_id":"clinicaltrials.gov:NCT05797220","description":"Anal Fissure Chronic","metadata":null},{"id":"c8e69478c757413b8dc2369f102cde13","type":"TRIAL","name":"The Efficacy of Dexmedetomidine Versus Labetalol In Providing Controlled Hypotension In Dacryocystorhinostomy SurgeryA Comparative Randomized Prospective Study","canonical_id":"clinicaltrials.gov:NCT06346561","description":"Nasolacrimal Duct Obstruction","metadata":null},{"id":"7688ae6331814fc7867851a8d1aa7898","type":"TRIAL","name":"The Efficacy of Doxazosin for Cocaine Users","canonical_id":"clinicaltrials.gov:NCT00880997","description":"Cocaine Dependence","metadata":null},{"id":"e18c95ffea754440b44a67b94bb7dff0","type":"TRIAL","name":"The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis","canonical_id":"clinicaltrials.gov:NCT03351205","description":"Intrauterine Adhesion","metadata":null},{"id":"8cc987863ccf4f9b998cf01fd34ed480","type":"TRIAL","name":"The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient","canonical_id":"clinicaltrials.gov:NCT04542733","description":"Kidney Transplant Infection; BK Virus Infection","metadata":null},{"id":"26762ad2743a4764bdd36e6f5431e744","type":"TRIAL","name":"The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma","canonical_id":"clinicaltrials.gov:NCT03363191","description":"Asthma","metadata":null},{"id":"c721db0d3fa44ee88ca0ce55993965fb","type":"TRIAL","name":"The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia","canonical_id":"clinicaltrials.gov:NCT00164775","description":"Functional Gastrointestinal Disorder","metadata":null},{"id":"9cb6b458347b42edadd6ddda4568fc61","type":"TRIAL","name":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","canonical_id":"clinicaltrials.gov:NCT01618162","description":"Diabetes; Diabetes Mellitus, Type 2","metadata":null},{"id":"e4f497a04aa24fa798a21256e0e6ba59","type":"TRIAL","name":"The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.","canonical_id":"clinicaltrials.gov:NCT07201766","description":"Keloids Scars","metadata":null},{"id":"a876ddaf666a489ab17ef2174bb2e757","type":"TRIAL","name":"The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity","canonical_id":"clinicaltrials.gov:NCT02958046","description":"Gastroesophageal Reflux Disease","metadata":null},{"id":"a9149c61d615421b880d4f3260badbc4","type":"TRIAL","name":"The Efficacy of Melatonin in the Burning Mouth Syndrome","canonical_id":"clinicaltrials.gov:NCT03788733","description":"Sleep Disorders, Circadian Rhythm","metadata":null},{"id":"48a058f210154fc2984ac680926bddc9","type":"TRIAL","name":"The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study","canonical_id":"clinicaltrials.gov:NCT03491098","description":"Otitis Media With Effusion","metadata":null},{"id":"0137dfb846454b758a84fe8699e21064","type":"TRIAL","name":"The Efficacy of Regional Scalp Block in Craniotomy","canonical_id":"clinicaltrials.gov:NCT06720285","description":"Scalp Nerve Block; Craniotomy Surgery","metadata":null},{"id":"5943672d35ee4982b232f4edaa64196c","type":"TRIAL","name":"The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment","canonical_id":"clinicaltrials.gov:NCT00372372","description":"Osteoporosis","metadata":null},{"id":"d9900a88c37e4d67a59133d39e2e07b1","type":"TRIAL","name":"The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)","canonical_id":"clinicaltrials.gov:NCT01533597","description":"Overactive Bladder","metadata":null},{"id":"1f3c4be8d27d4bcbbbba3be0493d289b","type":"TRIAL","name":"The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT02796183","description":"Diabetic Macular Edema","metadata":null},{"id":"ad782f5c0e7b47ee870fd14dfdf18baf","type":"TRIAL","name":"The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial","canonical_id":"clinicaltrials.gov:NCT03412591","description":"Sleep Disturbance; Craving; Cortisol; Hypersecretion","metadata":null},{"id":"7f978fe98cf6409c925c4d54dc05e531","type":"TRIAL","name":"The Efficacy of Topical Sesame Oil Versus Topical Triamcinolone on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker [MDA]","canonical_id":"clinicaltrials.gov:NCT03738176","description":"Oral Lichen Planus","metadata":null},{"id":"f7ba1b82d0ae4a69bfdd3e32ba21dc33","type":"TRIAL","name":"The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans","canonical_id":"clinicaltrials.gov:NCT04233749","description":"Lichen Planus Pigmentosus; Erythema Dyschromicum Perstans; Ashy Dermatosis of Ramirez","metadata":null},{"id":"ed295eba6f7940bebc99f6bd2c9c636c","type":"TRIAL","name":"The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD","canonical_id":"clinicaltrials.gov:NCT07771530","description":"PTSD; Posttraumatic Stress Disorder","metadata":null},{"id":"2cec9e621c6349c595462e9aa525e94b","type":"TRIAL","name":"The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score","canonical_id":"clinicaltrials.gov:NCT00540891","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"87530e15c0c34c2d8eb7c349a56d15df","type":"TRIAL","name":"The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment","canonical_id":"clinicaltrials.gov:NCT03401957","description":"Colorectal Cancer; Drug Resistance; Mass Spectrometry; RAS-RAF Pathway Deregulation","metadata":null},{"id":"b7920fceb1284aa699c08bbbce298eaf","type":"TRIAL","name":"The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)","canonical_id":"clinicaltrials.gov:NCT03694262","description":"Endometrial Cancer; Uterine Carcinosarcoma","metadata":null},{"id":"5eff08774222451a90e5325b1cf1cd5e","type":"TRIAL","name":"The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.","canonical_id":"clinicaltrials.gov:NCT05913817","description":"Crohn Disease; Ulcerative Colitis; Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa","metadata":null},{"id":"cd9e854bb3eb4589a6f6b2f5ad86425c","type":"TRIAL","name":"The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months","canonical_id":"clinicaltrials.gov:NCT00224133","description":"Benign Prostatic Hyperplasia","metadata":null},{"id":"17c70185e65e42cfa2a183aec8c28609","type":"TRIAL","name":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","canonical_id":"clinicaltrials.gov:NCT04372615","description":"Autoimmune Encephalitis; Encephalitis","metadata":null},{"id":"3f1828c2c0bb4d47ae419a23e9228aca","type":"TRIAL","name":"The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy","canonical_id":"clinicaltrials.gov:NCT02669082","description":"Insomnia; Major Depressive Disorder","metadata":null},{"id":"9f8d2dadc8fa4d8e9177256b7298aef3","type":"TRIAL","name":"The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials","canonical_id":"clinicaltrials.gov:NCT05203172","description":"Solid Tumors","metadata":null},{"id":"30e120e3213a4ca39ea4cd6fa5836a94","type":"TRIAL","name":"The Fabrazyme\u00ae and Arbs and ACE Inhibitor Treatment (FAACET) Study","canonical_id":"clinicaltrials.gov:NCT00446862","description":"Fabry Disease; Proteinuria","metadata":null},{"id":"75a018d7d1804f949af695ee941fe5bb","type":"TRIAL","name":"The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)","canonical_id":"clinicaltrials.gov:NCT01265498","description":"Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)","metadata":null},{"id":"9c8ec2803d9c44ffb893bc49f3d84d32","type":"TRIAL","name":"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs","canonical_id":"clinicaltrials.gov:NCT05159245","description":"Advanced Cancer; Solid Tumor; Haematological Malignancy","metadata":null},{"id":"791451acdaee43d2aff2272df1ef080c","type":"TRIAL","name":"The Forteo Alendronate Comparator Trial","canonical_id":"clinicaltrials.gov:NCT02416271","description":"Osteoporosis","metadata":null},{"id":"7505f4857553428ebefecc8c0f30e01a","type":"TRIAL","name":"The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab","canonical_id":"clinicaltrials.gov:NCT06244823","description":"Migraine Disorders; Migraine With Aura; Migraine Without Aura; Brain Diseases","metadata":null},{"id":"d5e744d52a4845b2a60a7a824db2f151","type":"TRIAL","name":"The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients","canonical_id":"clinicaltrials.gov:NCT02533076","description":"Cystinosis","metadata":null},{"id":"be6fd7e124444c129ec8e99b46f336ee","type":"TRIAL","name":"The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)","canonical_id":"clinicaltrials.gov:NCT00108823","description":"Chronic Obstructive Pulmonary Disease, COPD","metadata":null},{"id":"8f5b5cf64f7c4ecf89dabf94a2205a0d","type":"TRIAL","name":"The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study","canonical_id":"clinicaltrials.gov:NCT05904808","description":"Chronic Heart Failure; Diuretics Drug Reactions; Congestive Heart Failure","metadata":null},{"id":"c30da66b09564afb9948b48981ab85cc","type":"TRIAL","name":"The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04231617","description":"Hemodynamics of Cranial Arteries; Headache; Cerebral Blood Flow","metadata":null},{"id":"d07013ed7ac84299b3584bd4a3e5b86c","type":"TRIAL","name":"The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04960657","description":"Migraine; Headache; Pain","metadata":null},{"id":"0afc6f88bbda4d9e97144aa314850360","type":"TRIAL","name":"The INFUSE - Anterior Myocardial Infarction (AMI) Study","canonical_id":"clinicaltrials.gov:NCT00976521","description":"Acute Anterior Myocardial Infarction","metadata":null},{"id":"bdfdaffc6d884bcdb1e6bd21f281eae5","type":"TRIAL","name":"The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)","canonical_id":"clinicaltrials.gov:NCT01454440","description":"Coronary Artery Disease","metadata":null},{"id":"33406315d10344eea2306f061c83c9c6","type":"TRIAL","name":"The Impact and Benefit of Physical Activity on Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT02844998","description":"Premature Ejaculation","metadata":null},{"id":"04f2b1e0e06b4282b08925cec8b3d55a","type":"TRIAL","name":"The Impact of Anti- Asthmatic Medications on Salivary pH and Dental Caries Pattern in a Group of Egyptian Children With Bronchial Asthma","canonical_id":"clinicaltrials.gov:NCT03877874","description":"pH","metadata":null},{"id":"9b97c4ec94cb4c6981f90bce747d3536","type":"TRIAL","name":"The Impact of Arousal Threshold in Obstructive Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT02264353","description":"Obstructive Sleep Apnea","metadata":null},{"id":"fdf6b868195b437590e70928497a128e","type":"TRIAL","name":"The Impact of Camostat Mesilate on COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04321096","description":"Corona Virus Infection","metadata":null},{"id":"b5b71194fbf4425d84ec408a35a34a80","type":"TRIAL","name":"The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery","canonical_id":"clinicaltrials.gov:NCT01267305","description":"Lung Neoplasms; Esophageal Neoplasms; Venous Thromboembolism","metadata":null},{"id":"3a8ab3bf9f6a45b6baeaeb7d1d75cb86","type":"TRIAL","name":"The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT07013149","description":"Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension (PAH); Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","metadata":null},{"id":"89270e9a94af4257927b37917839ece6","type":"TRIAL","name":"The Impact of Esmolol Administration on Postoperative Recovery","canonical_id":"clinicaltrials.gov:NCT05567822","description":"Pain, Acute; Pain, Postoperative; Pain, Chronic Post-Surgical; Esmolol; Inguinal Hernia Repair; Analgesia; Nociceptive Pain","metadata":null},{"id":"eaac617e3931497b9f6e2e8ea4953d36","type":"TRIAL","name":"The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT07381803","description":"Zhejiang University","metadata":null},{"id":"59e7c588b3a64bf7bccd4dd8a2553ddf","type":"TRIAL","name":"The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder","canonical_id":"clinicaltrials.gov:NCT01822288","description":"Menopausal Syndromes","metadata":null},{"id":"fcb808ed748d4c66baec49abadaf5ae1","type":"TRIAL","name":"The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time","canonical_id":"clinicaltrials.gov:NCT07661030","description":"Gout","metadata":null},{"id":"2ecd409303d349a6b5e602f308e5cf27","type":"TRIAL","name":"The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects","canonical_id":"clinicaltrials.gov:NCT02640118","description":"Diabetes After Total Pancreatectomy","metadata":null},{"id":"84f494ce5ee545ca8577f2d99921234d","type":"TRIAL","name":"The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation","canonical_id":"clinicaltrials.gov:NCT01872494","description":"Pain","metadata":null},{"id":"a317bc6999394372a2c5abd538208ebb","type":"TRIAL","name":"The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration","canonical_id":"clinicaltrials.gov:NCT06994312","description":"Sepsis-induced Coagulopathy (SIC)","metadata":null},{"id":"7e0176604a3e4f7e8da890e6ad16e79e","type":"TRIAL","name":"The Impact of Rosiglitazone on Regression of Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT00166803","description":"Diabetes Mellitus, Atherosclerosis","metadata":null},{"id":"aefc2d437d1a4f089549e22fcf9ee6c4","type":"TRIAL","name":"The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients","canonical_id":"clinicaltrials.gov:NCT06209268","description":"Sepsis","metadata":null},{"id":"a56fd5c26312433ab4d7f6fb53b08381","type":"TRIAL","name":"The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02882737","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"e0efcbea64434e09bc2ff4327bc7bfa1","type":"TRIAL","name":"The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer","canonical_id":"clinicaltrials.gov:NCT07346053","description":"Advanced Bladder Cancer","metadata":null},{"id":"bc80d3076a2d42c3b347e162c207040b","type":"TRIAL","name":"The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)","canonical_id":"clinicaltrials.gov:NCT03336203","description":"Gout; CKD Stage 1-4; SUA Level (>8 mg/dL; 480 \u00b5mol/L)","metadata":null},{"id":"ad402de3214f45e4ac3952c8c3c0dfb7","type":"TRIAL","name":"The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates","canonical_id":"clinicaltrials.gov:NCT00722722","description":"Kidney Transplantation","metadata":null},{"id":"698e6265bd9b47fb87e034893eb4c80b","type":"TRIAL","name":"The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)","canonical_id":"clinicaltrials.gov:NCT01668004","description":"Ankylosing Spondylitis","metadata":null},{"id":"f77b3199d2fc4865881ba80d7e80729c","type":"TRIAL","name":"The Influence of Amitriptyline on Learning in a Visual Discrimination Task","canonical_id":"clinicaltrials.gov:NCT01566825","description":"Healthy Subjects","metadata":null},{"id":"94639dc2971047b99ad5de5f74b636a2","type":"TRIAL","name":"The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation","canonical_id":"clinicaltrials.gov:NCT01065376","description":"In Vitro Fertilization","metadata":null},{"id":"60e5e3de15914d00847d9f267284f78f","type":"TRIAL","name":"The Influence of Intranasal Oxytocin on Communication","canonical_id":"clinicaltrials.gov:NCT02415920","description":"Healthy","metadata":null},{"id":"9c91fef804bc44e1bc0cdfc8c2176c98","type":"TRIAL","name":"The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT01767025","description":"Healthy","metadata":null},{"id":"860958a807494692b0579673ee5ced51","type":"TRIAL","name":"The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01743300","description":"Healthy","metadata":null},{"id":"e49f486235464b4bb68d3af562c687b5","type":"TRIAL","name":"The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride","canonical_id":"clinicaltrials.gov:NCT00285805","description":"Insulin Resistance","metadata":null},{"id":"0d707dfc28294c33a2badd869872a236","type":"TRIAL","name":"The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06807112","description":"Pancreatic Adenocarcinoma; Pancreatic Cancer","metadata":null},{"id":"b524c2d02efc4124b03df56a41622957","type":"TRIAL","name":"The Influence of Timing of Cabergoline Initiation on Prevention of OHSS","canonical_id":"clinicaltrials.gov:NCT02620605","description":"Ovarian Hyperstimulation Syndrome","metadata":null},{"id":"93dd61c1cbc14fdcb88faf5ac254797d","type":"TRIAL","name":"The International Collaborative Exfoliation Syndrome Treatment Study","canonical_id":"clinicaltrials.gov:NCT00804115","description":"Exfoliation Syndrome; Glaucoma; Ocular Hypertension","metadata":null},{"id":"8a82f0a0c12f491bb0bca6f51f2d0092","type":"TRIAL","name":"The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation","canonical_id":"clinicaltrials.gov:NCT01981668","description":"Prostatic Neoplasms","metadata":null},{"id":"ad911f42f7dd4f55958ab9b4cc5fe4ea","type":"TRIAL","name":"The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema","canonical_id":"clinicaltrials.gov:NCT01564108","description":"Uveitis Related Cystoid Macular Edema; Steroid-induced Glaucoma - Borderline","metadata":null},{"id":"989b30121b4b42fd8b21688069888c38","type":"TRIAL","name":"The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients","canonical_id":"clinicaltrials.gov:NCT05632133","description":"Effect of Drug; Migraine Disorders","metadata":null},{"id":"1a7105d72a244afb970eea39bb9f39ed","type":"TRIAL","name":"The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis","canonical_id":"clinicaltrials.gov:NCT04080947","description":"Steatohepatitis, Nonalcoholic","metadata":null},{"id":"e897ad01d21c490b9e088b3a1d615d3f","type":"TRIAL","name":"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)","canonical_id":"clinicaltrials.gov:NCT02269267","description":"Leukemia, Myeloid, Chronic","metadata":null},{"id":"84ef044856e544c1b8c71500d963f059","type":"TRIAL","name":"The Lipid Profile of the Skin Surface in Acne","canonical_id":"clinicaltrials.gov:NCT02180425","description":"Acne","metadata":null},{"id":"d746298229b248b3979c958108c54b2f","type":"TRIAL","name":"The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients","canonical_id":"clinicaltrials.gov:NCT00696761","description":"BPH","metadata":null},{"id":"f28f0574594845daa664193b59f8da5d","type":"TRIAL","name":"The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years","canonical_id":"clinicaltrials.gov:NCT00147615","description":"Hypertension","metadata":null},{"id":"92f4c51656fb4fbeb2687f65998b6bb5","type":"TRIAL","name":"The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot","canonical_id":"clinicaltrials.gov:NCT00605423","description":"Age Related Macular Degeneration","metadata":null},{"id":"00cdbc0c9c744beb919c45c59d5ef192","type":"TRIAL","name":"The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI","canonical_id":"clinicaltrials.gov:NCT04316676","description":"Coronary Artery Disease","metadata":null},{"id":"46a9a80131ed4696b84edb53119e6e7d","type":"TRIAL","name":"The Maintenance Effect of Enstilar Foam in Combination With Otezla","canonical_id":"clinicaltrials.gov:NCT04555707","description":"Psoriasis","metadata":null},{"id":"7f5b062eacec4feba651e739da52c1eb","type":"TRIAL","name":"The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy","canonical_id":"clinicaltrials.gov:NCT03423849","description":"Breast Cancer; Chemotherapy Effect; Disease-free Survival","metadata":null},{"id":"48a74f822f5b4207a9fff0b521d3688d","type":"TRIAL","name":"The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone","canonical_id":"clinicaltrials.gov:NCT02030314","description":"Resistant Hypertension in Kidney Transplant Patients","metadata":null},{"id":"d6d2e5584c724b1e819f0cefa1c133f8","type":"TRIAL","name":"The Mannitol-Asthma-Ciclesonide-Study","canonical_id":"clinicaltrials.gov:NCT03839433","description":"Asthma, Bronchial","metadata":null},{"id":"b448e0f76bae4c79aa8dd20a08063bc7","type":"TRIAL","name":"The Maraviroc Central Nervous System (CNS) Study","canonical_id":"clinicaltrials.gov:NCT00982878","description":"HIV Infections","metadata":null},{"id":"c85513fff6a840b195b2f34c35a9b868","type":"TRIAL","name":"The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT02191124","description":"Major Depressive Disorder","metadata":null},{"id":"21ed6755c76b46bc8a3237f64a26e1a8","type":"TRIAL","name":"The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty","canonical_id":"clinicaltrials.gov:NCT00640094","description":"Acute Myocardial Infarction","metadata":null},{"id":"c3192e0482a44384bc7e4244e81e0144","type":"TRIAL","name":"The Menopause After Cancer Study","canonical_id":"clinicaltrials.gov:NCT04766229","description":"Menopause; Cancer; Insomnia","metadata":null},{"id":"115a488d195c49e39c83af8b482c9586","type":"TRIAL","name":"The MetNET-2 Trial","canonical_id":"clinicaltrials.gov:NCT02823691","description":"Neuroendocrine Tumors","metadata":null},{"id":"6ff3bbf4b828418dbeb39f7f66485706","type":"TRIAL","name":"The Modified \"Pills-in-the-Pocket\" Strategy","canonical_id":"clinicaltrials.gov:NCT06657404","description":"Atrial Fibrillation (AF)","metadata":null},{"id":"b789417e164f4b419093ebb1cca9f57a","type":"TRIAL","name":"The Montefiore Metoclopramide Study","canonical_id":"clinicaltrials.gov:NCT00475306","description":"Nausea; Extrapyramidal Symptoms","metadata":null},{"id":"eb325ff2dc544252af5535b7a2b2368d","type":"TRIAL","name":"The Myocet/Lapatinib Study. ICORG 10-03, V5","canonical_id":"clinicaltrials.gov:NCT01495884","description":"Her2 Positive Metastatic Breast Cancer","metadata":null},{"id":"6dea897cd6df41efb3389eeebafceee3","type":"TRIAL","name":"The Natural History of Procalcitonin in Hemorrhagic Stroke","canonical_id":"clinicaltrials.gov:NCT01498705","description":"Intraventricular Hemorrhage; Intracerebral Hemorrhage","metadata":null},{"id":"a6989121151940829573421735444b36","type":"TRIAL","name":"The New Strategy for Pharmacological Treatment in People With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT00352339","description":"Schizophrenia","metadata":null},{"id":"0f12a531ebd34ab28083df23187f90e4","type":"TRIAL","name":"The Nicotinic Cholinergic System and Cognitive Aging","canonical_id":"clinicaltrials.gov:NCT03408574","description":"Healthy Aging","metadata":null},{"id":"e46b713e256b4e239d8e1e503097f8d7","type":"TRIAL","name":"The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial","canonical_id":"clinicaltrials.gov:NCT04161014","description":"Pneumoconiosis Coal; Asbestosis; Silicosis","metadata":null},{"id":"5ca6d586344546d2b41f2942904d983f","type":"TRIAL","name":"The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss","canonical_id":"clinicaltrials.gov:NCT02990403","description":"Recurrent Pregnancy Loss","metadata":null},{"id":"0ca03516dd554ae588c7b74ad542b7c1","type":"TRIAL","name":"The OPTIMISE Study","canonical_id":"clinicaltrials.gov:NCT05716945","description":"Pseudophakic Bullous Keratopathy; Fuchs' Endothelial Dystrophy; Intraocular Pressure","metadata":null},{"id":"3b01a5606b494f5fa0549aa866758a39","type":"TRIAL","name":"The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold","canonical_id":"clinicaltrials.gov:NCT07683442","description":"OSA - Obstructive Sleep Apnea","metadata":null},{"id":"0fdd22a9dc2543ec834a48a0d7630193","type":"TRIAL","name":"The Optimised Use of Romozosumab Study","canonical_id":"clinicaltrials.gov:NCT06059222","description":"Osteoporosis","metadata":null},{"id":"567492ecded349f8b939ce253a3824dc","type":"TRIAL","name":"The Oral Contraceptive Pill for Premenstrual Worsening of Depression","canonical_id":"clinicaltrials.gov:NCT00633360","description":"Premenstrual Syndrome; Depression","metadata":null},{"id":"dc3c510c00de4964aacdb2669c4bdbd6","type":"TRIAL","name":"The Oral Microbiota is Associated With Autoimmune Thyroiditis","canonical_id":"clinicaltrials.gov:NCT03447093","description":"Microbiota","metadata":null},{"id":"3822f8d88f404b0e871ed8a76a5f3c1e","type":"TRIAL","name":"The Oslo Study of Clonidine in Elderly Patients With Delirium","canonical_id":"clinicaltrials.gov:NCT01956604","description":"Delirium","metadata":null},{"id":"a334d1bfae814a1daf1a030748a3cc64","type":"TRIAL","name":"The Oxford Marfan Trial","canonical_id":"clinicaltrials.gov:NCT01949233","description":"Marfan Syndrome","metadata":null},{"id":"fdee1d56462941ebb874b55b86c13a10","type":"TRIAL","name":"The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","canonical_id":"clinicaltrials.gov:NCT04329923","description":"COVID-19","metadata":null},{"id":"b056f97d48d545e1811c5e6756941090","type":"TRIAL","name":"The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers","canonical_id":"clinicaltrials.gov:NCT03247140","description":"Hypertension With Dyslipidemia","metadata":null},{"id":"420cb6c162fe4fe1b087d1d7229a9a7d","type":"TRIAL","name":"The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM","canonical_id":"clinicaltrials.gov:NCT02582840","description":"Type 1 Diabetes Mellitus","metadata":null},{"id":"5d87c8d594a34e1c81a22c7dc6b31483","type":"TRIAL","name":"The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5","canonical_id":"clinicaltrials.gov:NCT00616902","description":"Chronic Kidney Disease (CKD) Stage 5; Hypertrophy, Left Ventricular","metadata":null},{"id":"d4e2df991b9343fa8c38e87ceb791f50","type":"TRIAL","name":"The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4","canonical_id":"clinicaltrials.gov:NCT00497146","description":"Chronic Kidney Disease; Left Ventricular Hypertrophy","metadata":null},{"id":"f70f75a49cf8464db586c7c487942ac5","type":"TRIAL","name":"The PROMISE Study: Duavee in Women With DCIS","canonical_id":"clinicaltrials.gov:NCT02694809","description":"Ductal Breast Carcinoma In Situ; Postmenopausal","metadata":null},{"id":"910489e1075348eda25dddc3d2f29c36","type":"TRIAL","name":"The Pain Pen for Breakthrough Cancer Pain","canonical_id":"clinicaltrials.gov:NCT00125801","description":"Neoplasms; Pain","metadata":null},{"id":"e3f74ce01cc74e94924a6b7997466d21","type":"TRIAL","name":"The Pathophysiology of Orthostatic Hypotension","canonical_id":"clinicaltrials.gov:NCT00748059","description":"Autonomic Nervous System Diseases; Orthostatic Hypotension; Dopamine Beta-Hydroxylase Deficiency; Orthostatic Intolerance","metadata":null},{"id":"b7fc1392553748f59eeb07260c5246c6","type":"TRIAL","name":"The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery","canonical_id":"clinicaltrials.gov:NCT07089251","description":"Knee Arthroplasty, Total; Knee Arthritis, Osteoarthritis; Total Knee Anthroplasty; Blood Loss; Tranexamic Acid Use; Epinephrine","metadata":null},{"id":"cfde5e05cba74889ac33ce68a6f25440","type":"TRIAL","name":"The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT02251119","description":"Healthy","metadata":null},{"id":"865ce34a88de4f768067ca4d7a809e3e","type":"TRIAL","name":"The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects","canonical_id":"clinicaltrials.gov:NCT00511823","description":"Nausea and Vomiting, Chemotherapy-Induced","metadata":null},{"id":"1775c5228cb34cbd94f6d37aeb278930","type":"TRIAL","name":"The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01527669","description":"Healthy Subjects","metadata":null},{"id":"6e4d8579930a49a5bed4538677bf39ae","type":"TRIAL","name":"The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)","canonical_id":"clinicaltrials.gov:NCT00413634","description":"Essential Thrombocythaemia","metadata":null},{"id":"746e5a31fe6e4776ac2a49b95288e2d9","type":"TRIAL","name":"The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT05066516","description":"Diabetes Mellitus","metadata":null},{"id":"4f8252f29d8f4fc29f95ceab054681fa","type":"TRIAL","name":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT05624138","description":"Neuropathy;Peripheral","metadata":null},{"id":"c6e347866f77437cbc503b7d3c550e80","type":"TRIAL","name":"The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy","canonical_id":"clinicaltrials.gov:NCT04737967","description":"Oncology Pain; Chemotherapy-induced Peripheral Neuropathy","metadata":null},{"id":"df327e32de02439e800afd8df4323a6b","type":"TRIAL","name":"The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine","canonical_id":"clinicaltrials.gov:NCT03698331","description":"Tardive Dyskinesia (TD)","metadata":null},{"id":"69dfe41853954b82a38fb257052d1001","type":"TRIAL","name":"The Potential of Camostat in COVID-19","canonical_id":"clinicaltrials.gov:NCT04625114","description":"Covid19","metadata":null},{"id":"778511f3444740f2809564296c8a9552","type":"TRIAL","name":"The Potential of Candesartan to Retard the Progression of Aortic Stenosis","canonical_id":"clinicaltrials.gov:NCT00699452","description":"Aortic Valve Stenosis","metadata":null},{"id":"6a7970420add4c64807dd3085b9f66f9","type":"TRIAL","name":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","canonical_id":"clinicaltrials.gov:NCT02231021","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"0753064903114f2b86dab3d67b1f9eae","type":"TRIAL","name":"The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT03228368","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"149a27dcf18c45db95bce10e00c47257","type":"TRIAL","name":"The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques","canonical_id":"clinicaltrials.gov:NCT01773512","description":"Coronary Artery Disease","metadata":null},{"id":"88445611651d490eb68c46526eba215c","type":"TRIAL","name":"The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation","canonical_id":"clinicaltrials.gov:NCT02373384","description":"Urolithiasis; Renal Stones","metadata":null},{"id":"6aad55bcb35f44e4b0c3df96f7b69a62","type":"TRIAL","name":"The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study","canonical_id":"clinicaltrials.gov:NCT02200172","description":"Cancer","metadata":null},{"id":"bbd8e3be07164444adaa90d9e1e16be8","type":"TRIAL","name":"The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.","canonical_id":"clinicaltrials.gov:NCT05696392","description":"Atopic Dermatitis","metadata":null},{"id":"458df668b9b348978b0297403cf90abd","type":"TRIAL","name":"The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD","canonical_id":"clinicaltrials.gov:NCT01777334","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"9d15b882a45443a292a057d6661e4225","type":"TRIAL","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","canonical_id":"clinicaltrials.gov:NCT04781192","description":"Advanced Biliary Tract Cancer","metadata":null},{"id":"4650f346a0d247698b11ed9b57856b52","type":"TRIAL","name":"The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04839380","description":"Atopic Dermatitis","metadata":null},{"id":"83f00392ad164feea6c92ea653d30e31","type":"TRIAL","name":"The R-E-V-I-V-A-L Study","canonical_id":"clinicaltrials.gov:NCT06992674","description":"Vestibular Migraine","metadata":null},{"id":"99594cdcb04d4945b785fa9c780572dd","type":"TRIAL","name":"The Re-Prosper HF Study","canonical_id":"clinicaltrials.gov:NCT04551222","description":"Heart Failure","metadata":null},{"id":"d3a1eafcd4b64fb6934befa3bd07a4d8","type":"TRIAL","name":"The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China","canonical_id":"clinicaltrials.gov:NCT06728345","description":"Migraine; Migraine Prophylaxis","metadata":null},{"id":"8963f2bf4edd49799bdae349a2fe42a9","type":"TRIAL","name":"The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia","canonical_id":"clinicaltrials.gov:NCT02892214","description":"Localized Provoked Vulvodynia","metadata":null},{"id":"ebb693d7fb554d16a14f6b11510df738","type":"TRIAL","name":"The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment","canonical_id":"clinicaltrials.gov:NCT02575092","description":"Homocysteine; Coronary Disease; Angioplasty,Balloon,Coronary; Contrast Media; Nephropathy; Hypertension","metadata":null},{"id":"9d2d9caac9bb486e83a1fb156df9bdd7","type":"TRIAL","name":"The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)","canonical_id":"clinicaltrials.gov:NCT02015949","description":"Traumatic Brain Injury","metadata":null},{"id":"4ecae4772ffe4c9a9903ddb5a1ea7669","type":"TRIAL","name":"The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons","canonical_id":"clinicaltrials.gov:NCT00969644","description":"Interaction Between the GH/IGF-I System and the Immune-system","metadata":null},{"id":"fa66482953534799be7f8c92970db74c","type":"TRIAL","name":"The Relationship Between the Residual Renal Function and Osteoporosis Treatment","canonical_id":"clinicaltrials.gov:NCT02304887","description":"Osteoporosis","metadata":null},{"id":"4e4b12d6a20b4c7da0e8ae8ff268146e","type":"TRIAL","name":"The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT00830219","description":"Healthy","metadata":null},{"id":"2dac0bcfa920490e8b7780cb6c2e2988","type":"TRIAL","name":"The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT00185055","description":"Healthy","metadata":null},{"id":"d776af2c15464f628cf76eff9b1f666e","type":"TRIAL","name":"The Renin-Angiotensin System in Essential Hypertension","canonical_id":"clinicaltrials.gov:NCT00141583","description":"Hypertension","metadata":null},{"id":"75244f53c3bd4508805021d03989b409","type":"TRIAL","name":"The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study","canonical_id":"clinicaltrials.gov:NCT01691781","description":"Hyperparathyroidism","metadata":null},{"id":"219a98eb00a544bd99eaeb367cce0706","type":"TRIAL","name":"The Research of Standard Diagnosis and Treatment for HSPN in Children","canonical_id":"clinicaltrials.gov:NCT02532777","description":"Henoch-Schoenlein Purpura Nephritis","metadata":null},{"id":"71db0b1a9818410e92b734fb2320c2c3","type":"TRIAL","name":"The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude","canonical_id":"clinicaltrials.gov:NCT07517068","description":"Hypoxemia; Acute Mountain Sickness (AMS); Inflammation; Immune Response","metadata":null},{"id":"38c697fabc144d7a85fdd03533f0ed14","type":"TRIAL","name":"The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT00773916","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"fa85283ea0d54411bffbb7cc7a1f5e10","type":"TRIAL","name":"The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD","canonical_id":"clinicaltrials.gov:NCT05440422","description":"Systemic Lupus Erythematosus; Cardiovascular Disease; Premature Atherosclerosis","metadata":null},{"id":"414527bbfef94ee287a5661437fd906c","type":"TRIAL","name":"The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC","canonical_id":"clinicaltrials.gov:NCT04664829","description":"Metastatic Triple-Negative Breast Carcinoma","metadata":null},{"id":"0b63aefd6c544d69baa1078ca950c17d","type":"TRIAL","name":"The Role of Brain Dopamine in Chronic Pain","canonical_id":"clinicaltrials.gov:NCT05285683","description":"Chronic Pain","metadata":null},{"id":"568a120b51d6454e965fe1c6e54096c3","type":"TRIAL","name":"The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis","canonical_id":"clinicaltrials.gov:NCT05931744","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"12e1f1fbb46849228d67e5a452051d5a","type":"TRIAL","name":"The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control","canonical_id":"clinicaltrials.gov:NCT00660751","description":"Healthy","metadata":null},{"id":"9f9fefb035c646ea8ac62f245e5cf59a","type":"TRIAL","name":"The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury","canonical_id":"clinicaltrials.gov:NCT05734612","description":"Reperfusion Injury, Myocardial","metadata":null},{"id":"7a862e2ebee94a5991e55c7bcc75fdff","type":"TRIAL","name":"The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression","canonical_id":"clinicaltrials.gov:NCT00254020","description":"Depression","metadata":null},{"id":"ca8a416fcda34a178542dfdf8acc7c8a","type":"TRIAL","name":"The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage","canonical_id":"clinicaltrials.gov:NCT04941846","description":"Subarachnoid Hemorrhage, Aneurysmal","metadata":null},{"id":"f27b99b8c1774e6aa7bcb95210c571cf","type":"TRIAL","name":"The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement","canonical_id":"clinicaltrials.gov:NCT05208294","description":"Placebo Effect on Mood Improvement","metadata":null},{"id":"d8ed3cd9faa94ddf93a39a3b7a1525d4","type":"TRIAL","name":"The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making","canonical_id":"clinicaltrials.gov:NCT04371146","description":"Healthy","metadata":null},{"id":"1cd1d372d9aa4115bef942333fb1fe27","type":"TRIAL","name":"The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis","canonical_id":"clinicaltrials.gov:NCT03040427","description":"Cardiac Amyloidosis","metadata":null},{"id":"3c4c7ba0effd4b29831476004b4ace98","type":"TRIAL","name":"The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT04134130","description":"Prostate Cancer Recurrent","metadata":null},{"id":"d2e88b6fe7ab499faf85a803706712f8","type":"TRIAL","name":"The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors","canonical_id":"clinicaltrials.gov:NCT02792400","description":"Type 2 Diabetes","metadata":null},{"id":"5d194d6c73524dda96dc2cb1bb8aafcd","type":"TRIAL","name":"The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve)","canonical_id":"clinicaltrials.gov:NCT05919992","description":"Glucocorticoid Effect","metadata":null},{"id":"d694b91696354bd1a38040139749dd09","type":"TRIAL","name":"The Role of Histamine in Muscle Protein Synthesis Following Resistance Training","canonical_id":"clinicaltrials.gov:NCT06152497","description":"Histamine","metadata":null},{"id":"9addaa9559ff469fac6310d69d9f6b65","type":"TRIAL","name":"The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation","canonical_id":"clinicaltrials.gov:NCT02820116","description":"Non-small Cell Lung Cancer(NSCLC)","metadata":null},{"id":"6c3d34f4d4834325bd54cd6e9dbacf61","type":"TRIAL","name":"The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT03585894","description":"Headache","metadata":null},{"id":"a9a7edca88fc40b8af77e2b2b52f0986","type":"TRIAL","name":"The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis","canonical_id":"clinicaltrials.gov:NCT05498467","description":"Allergic Contact Dermatitis","metadata":null},{"id":"b0288ed047604c38831d2d44b5ab354b","type":"TRIAL","name":"The Role of Intra-articular Injection of PRP Versus Corticosteriods in Treatment of Lumbar Facet Disease","canonical_id":"clinicaltrials.gov:NCT04860531","description":"Lumbar Facet Joint Syndrome","metadata":null},{"id":"1182c2eaae1c4cc083eb75c5f769859c","type":"TRIAL","name":"The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)","canonical_id":"clinicaltrials.gov:NCT03562169","description":"Multiple Myeloma","metadata":null},{"id":"8d86a68fa1bd482681b7d30b9a63b6c2","type":"TRIAL","name":"The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch","canonical_id":"clinicaltrials.gov:NCT07203274","description":"Itchiness","metadata":null},{"id":"867d633e7d3f46a39411fda31d5d988f","type":"TRIAL","name":"The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition","canonical_id":"clinicaltrials.gov:NCT03068442","description":"Cognitive Impairment; Carotid Artery Plaque; Inflammation","metadata":null},{"id":"a626fc2a22f740a38ee3fd6b1880ca2e","type":"TRIAL","name":"The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT01065545","description":"Acute Myeloid Leukemia","metadata":null},{"id":"84ad8068932640068f984ef8acd47e77","type":"TRIAL","name":"The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production","canonical_id":"clinicaltrials.gov:NCT02871648","description":"Healthy Volunteers","metadata":null},{"id":"a6d4c9a4ca114b0a9abe0031ba8f8231","type":"TRIAL","name":"The Role of Orexin in Human Panic Disorder","canonical_id":"clinicaltrials.gov:NCT02593682","description":"Panic Disorder","metadata":null},{"id":"08090ffa5c7943f5afccb37352ee6b2f","type":"TRIAL","name":"The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology","canonical_id":"clinicaltrials.gov:NCT01112670","description":"Healthy","metadata":null},{"id":"79af1eb0992e48f0b8a06602bf4ebafa","type":"TRIAL","name":"The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression","canonical_id":"clinicaltrials.gov:NCT04156425","description":"Major Depressive Disorder","metadata":null},{"id":"f3c58bf823944b93803b9aa34a59f399","type":"TRIAL","name":"The Role of Secretin on the Energy Homeostasis","canonical_id":"clinicaltrials.gov:NCT04613700","description":"Obesity; Metabolic Disease; Diabetes; Adiposity","metadata":null},{"id":"5abbe3abbc3b45488434a772cfe32e3e","type":"TRIAL","name":"The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat","canonical_id":"clinicaltrials.gov:NCT04359147","description":"Yohimbine; Hydrocortisone; Yohimbine + Hydrocortisone; Placebo","metadata":null},{"id":"b1c6da723dc7411ca5bbb7bb4396dd6e","type":"TRIAL","name":"The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing","canonical_id":"clinicaltrials.gov:NCT01580423","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"9360c46017894dc282efcc02033ec1fe","type":"TRIAL","name":"The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT01621620","description":"Pain","metadata":null},{"id":"3d5a551b4fda49beb61c9842267138ab","type":"TRIAL","name":"The Role of TRP Channels in CIPN","canonical_id":"clinicaltrials.gov:NCT04415892","description":"Chemotherapy-induced Peripheral Neuropathy","metadata":null},{"id":"1b1c22c47f974103bdef6c398fca51ac","type":"TRIAL","name":"The Role of Verapamil in Radial Artery Spasm","canonical_id":"clinicaltrials.gov:NCT06447688","description":"Radial Artery Spasm","metadata":null},{"id":"92a288b7027f4b75b620da29111ed806","type":"TRIAL","name":"The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment","canonical_id":"clinicaltrials.gov:NCT02650102","description":"Schizophrenia","metadata":null},{"id":"295b369c42954f1ea6b736dadeedaafb","type":"TRIAL","name":"The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II","canonical_id":"clinicaltrials.gov:NCT06422494","description":"Diabetes Mellitus, Type 1; Inflammation","metadata":null},{"id":"b881d66acb7b4897a42092299231d334","type":"TRIAL","name":"The Role of the Brain in Mental and Physical Fatigue","canonical_id":"clinicaltrials.gov:NCT05880342","description":"Fatigue","metadata":null},{"id":"132d6c92badd4f07b733be06fc0fd827","type":"TRIAL","name":"The Role of the Circadian System in Binge Eating Disorder","canonical_id":"clinicaltrials.gov:NCT04724668","description":"Binge-Eating Disorder; Circadian Rhythm Disorders","metadata":null},{"id":"c072dc3e7b024b5797bfddab00c5c85b","type":"TRIAL","name":"The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT04346394","description":"Parkinson Disease","metadata":null},{"id":"29a8a5d28ef849daae8a3fa92c5fb9bc","type":"TRIAL","name":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","canonical_id":"clinicaltrials.gov:NCT04591431","description":"Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer","metadata":null},{"id":"3c814a8dd633491d95c08f3b0e15d84d","type":"TRIAL","name":"The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line","canonical_id":"clinicaltrials.gov:NCT02962388","description":"Essential Thrombocythemia","metadata":null},{"id":"6270e881494246849cd7a37233f89497","type":"TRIAL","name":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06439693","description":"Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"10aafe132b6a46408721672968bfa023","type":"TRIAL","name":"The SPECTRA Study","canonical_id":"clinicaltrials.gov:NCT00537667","description":"Rheumatoid Arthritis","metadata":null},{"id":"b818fac330764427a798b963d455db9c","type":"TRIAL","name":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","canonical_id":"clinicaltrials.gov:NCT06075147","description":"Visual Impairment; Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macula Edema (DME)","metadata":null},{"id":"daee96494ab44f8a9bbbcac1f8555af9","type":"TRIAL","name":"The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa","canonical_id":"clinicaltrials.gov:NCT03521635","description":"Parkinson Disease","metadata":null},{"id":"00223294c7f047ceb0b6094aaa3cdb24","type":"TRIAL","name":"The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab","canonical_id":"clinicaltrials.gov:NCT00833729","description":"Plaque Psoriasis","metadata":null},{"id":"d612fe6bb13d46a98d67561e586bf229","type":"TRIAL","name":"The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01530464","description":"High Altitude Pulmonary Hypertension","metadata":null},{"id":"8faf5400e49a4ca38f02bedbb9324389","type":"TRIAL","name":"The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT01566565","description":"High Altitude Pulmonary Hypertension","metadata":null},{"id":"a99e9514646c45fc9af4554275b0a5c3","type":"TRIAL","name":"The Safety and Effectiveness of Latuda\u00ae Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients","canonical_id":"clinicaltrials.gov:NCT04432688","description":"Schizophrenia","metadata":null},{"id":"f489f1a168bb40afa8da6a843c10b9e8","type":"TRIAL","name":"The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin Diseases","canonical_id":"clinicaltrials.gov:NCT04937101","description":"Inflammatory Skin Disease","metadata":null},{"id":"0185a639cb244354b19d9fb32ae0597a","type":"TRIAL","name":"The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01732276","description":"Breast Cancer","metadata":null},{"id":"6f9d444382e141348450dc747ef97b87","type":"TRIAL","name":"The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain","canonical_id":"clinicaltrials.gov:NCT03171987","description":"Acute Back Pain","metadata":null},{"id":"0be8dc8b016c458b9572dd9019ecbea4","type":"TRIAL","name":"The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors","canonical_id":"clinicaltrials.gov:NCT07109167","description":"Biliary Tract Neoplasms","metadata":null},{"id":"d77cdde407a34f7db6d17af435c3d558","type":"TRIAL","name":"The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada","canonical_id":"clinicaltrials.gov:NCT01105507","description":"Cryopyrin Associated Periodic Syndrome","metadata":null},{"id":"6bbc4f7124594d909228c1527edb7a0b","type":"TRIAL","name":"The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","canonical_id":"clinicaltrials.gov:NCT01757431","description":"Atypical Hemolytic Uremic Syndrome (aHUS)","metadata":null},{"id":"0f6706a5c44947c6a583e6559d230eb4","type":"TRIAL","name":"The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT05011669","description":"Schizophrenia","metadata":null},{"id":"e17335b85d4845119e51ee8ced4cd76b","type":"TRIAL","name":"The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances","canonical_id":"clinicaltrials.gov:NCT01703559","description":"Night Vision Complaints; Decrease in Night Vision; Disturbance; Vision, Loss","metadata":null},{"id":"1d028510d37f487f8141f89bb7998968","type":"TRIAL","name":"The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors","canonical_id":"clinicaltrials.gov:NCT05964543","description":"Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"a8840ac628c54128b5b65df1fb6c71ae","type":"TRIAL","name":"The Safety and Efficacy of Roflumilast Foam in HS","canonical_id":"clinicaltrials.gov:NCT07263230","description":"Hidradenitis Suppurativa (HS)","metadata":null},{"id":"83dca515fe10498e9ea5bc8603a445c8","type":"TRIAL","name":"The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement","canonical_id":"clinicaltrials.gov:NCT02644616","description":"Tricuspid Regurgitation; Right Heart Failure","metadata":null},{"id":"0e5a00857132441484b9f78aea0e888f","type":"TRIAL","name":"The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients","canonical_id":"clinicaltrials.gov:NCT05579418","description":"STEMI; Dyslipidemias","metadata":null},{"id":"001d3c1120aa455dbe81bc304da66f68","type":"TRIAL","name":"The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis","canonical_id":"clinicaltrials.gov:NCT01349673","description":"Proctitis; Proctosigmoiditis","metadata":null},{"id":"4767b3e1bfcd4a7b8a9524a0310be8b9","type":"TRIAL","name":"The Safety of Dapoxetine/Tadalafil Combination Therapy","canonical_id":"clinicaltrials.gov:NCT03177746","description":"Premature Ejaculation; Erectile Dysfunction; Safety Issues","metadata":null},{"id":"c1aa2442202847328f9e1870b122c1ea","type":"TRIAL","name":"The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT05874674","description":"Dialysis; Complications; Bleeding","metadata":null},{"id":"1919c39b7e2842f4827f92e93633fb48","type":"TRIAL","name":"The Safety of Vardenafil in Patients Undergoing Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT01260285","description":"Ischemia-reperfusion Injury.","metadata":null},{"id":"807230fc87db4aaaa25e051bd8be918c","type":"TRIAL","name":"The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation","canonical_id":"clinicaltrials.gov:NCT05145296","description":"Sensitisation; Highly Sensitised Dialysis Patients","metadata":null},{"id":"11dd5568d0714100838441596a6251c9","type":"TRIAL","name":"The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia","canonical_id":"clinicaltrials.gov:NCT01654562","description":"Choroideremia","metadata":null},{"id":"f09d0d0fdaa847a3aa9bb4dddc3efc06","type":"TRIAL","name":"The Staged Treatment in Early Psychosis Study","canonical_id":"clinicaltrials.gov:NCT02751632","description":"Psychotic Disorders; Personality Disorders; Clinical High Risk","metadata":null},{"id":"b37282d166384f538295dd3e0d647ef5","type":"TRIAL","name":"The Standardized Management of Hypertension in Rural Shaanxi","canonical_id":"clinicaltrials.gov:NCT04371874","description":"Hypertension","metadata":null},{"id":"4ae73bba36494981aafcde10e697e884","type":"TRIAL","name":"The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.","canonical_id":"clinicaltrials.gov:NCT05329844","description":"Diabetes Mellitus","metadata":null},{"id":"5ad79d0925744d80a7b273cfbcc5c747","type":"TRIAL","name":"The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.","canonical_id":"clinicaltrials.gov:NCT05329857","description":"To Determine Bioequivalence Under Fed Conditions","metadata":null},{"id":"179d215cbeb84dee984c023ffd6fde82","type":"TRIAL","name":"The Study of Abatacept in Combination With Etanercept","canonical_id":"clinicaltrials.gov:NCT00162279","description":"Rheumatoid Arthritis","metadata":null},{"id":"0f6a3f76c68740199cdd1a6aa29e7e5c","type":"TRIAL","name":"The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry","canonical_id":"clinicaltrials.gov:NCT07612878","description":"COPD (Chronic Obstructive Pulmonary Disease)","metadata":null},{"id":"391db60663bb40c98d28807a39a05c61","type":"TRIAL","name":"The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia","canonical_id":"clinicaltrials.gov:NCT03461042","description":"Chronic Insomnia","metadata":null},{"id":"3976bd7000d74bef9764ddfe80a0f012","type":"TRIAL","name":"The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death","canonical_id":"clinicaltrials.gov:NCT00568737","description":"Sepsis","metadata":null},{"id":"3063b5e8c8ca4235a13c550670e21b0c","type":"TRIAL","name":"The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis","canonical_id":"clinicaltrials.gov:NCT00045760","description":"Sepsis","metadata":null},{"id":"4b9113780e6e453d8877100b1b959892","type":"TRIAL","name":"The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC","canonical_id":"clinicaltrials.gov:NCT05904015","description":"Lung Neoplasms","metadata":null},{"id":"f3452780d18d4840b6e5b5228d7fc2d0","type":"TRIAL","name":"The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux","canonical_id":"clinicaltrials.gov:NCT02123498","description":"Eustachian Tube Dysfunction; Laryngopharyngeal Reflux","metadata":null},{"id":"f215f8023586479781c94f4998d12175","type":"TRIAL","name":"The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT03179839","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"fb9b2e488d75417ab23f47ca40c9284d","type":"TRIAL","name":"The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin","canonical_id":"clinicaltrials.gov:NCT00908453","description":"Epilepsy","metadata":null},{"id":"aafaa3b63043418ebf43600d8c0122ff","type":"TRIAL","name":"The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)","canonical_id":"clinicaltrials.gov:NCT01767909","description":"Amnestic Mild Cognitive Impairment; Alzheimer's Disease","metadata":null},{"id":"81d2a9e83c764777b5a11854a12c7350","type":"TRIAL","name":"The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression","canonical_id":"clinicaltrials.gov:NCT05861635","description":"Breast Cancer; Neoadjuvant Therapy","metadata":null},{"id":"dd7ff8dead1e470fad9d56f0a8c6c179","type":"TRIAL","name":"The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.","canonical_id":"clinicaltrials.gov:NCT00346190","description":"Osteoporosis","metadata":null},{"id":"1481afd7bc6f47e7b34c3057c3b40458","type":"TRIAL","name":"The Study of the Pathogenesis and Cognitive Behavioral Group Therapy in Obsessive-Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT02739061","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"e0855416af9d4e62837ae094fc21a831","type":"TRIAL","name":"The Sub-Sero Study","canonical_id":"clinicaltrials.gov:NCT03994965","description":"Schizophrenia; Psychosis","metadata":null},{"id":"407d8b0039cd46e0aad8eb9c5bfe55d7","type":"TRIAL","name":"The Swedish BioFINDER - Preclinical AD Study","canonical_id":"clinicaltrials.gov:NCT06121544","description":"Alzheimer Disease; Mild Cognitive Impairment; Mild Dementia","metadata":null},{"id":"19efb55dedf54115917d37c20f40c35b","type":"TRIAL","name":"The Swedish BioFINDER 2 Study","canonical_id":"clinicaltrials.gov:NCT03174938","description":"Dementia; Alzheimer Disease; Parkinson Disease; Lewy Body Disease; Parkinson-Dementia Syndrome; Frontotemporal Degeneration; Semantic Dementia; Progressive Nonfluent Aphasia; Progressive Supranuclear Palsy; Corticobasal Degeneration; Multiple System Atrophy; Mild Cognitive Impairment; ALS (Amyotrophic Lateral Sclerosis)","metadata":null},{"id":"f12034cfa1834ed8ac8ba819e6b3e232","type":"TRIAL","name":"The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT04638517","description":"Pulmonary Fibrosis; Telomere Shortening; Telomere Disease; Dyskeratosis Congenita","metadata":null},{"id":"b0951a809ed448cd83eff4086e718569","type":"TRIAL","name":"The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism","canonical_id":"clinicaltrials.gov:NCT00451672","description":"Hyperaldosteronism; Hypertension","metadata":null},{"id":"812ac4f22ee54b36b9870b6dacfbcd55","type":"TRIAL","name":"The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT06932848","description":"Oral Lichen Planus","metadata":null},{"id":"ad13680e51194da6b4769357f72bcb4b","type":"TRIAL","name":"The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT02917122","description":"Parkinson Disease; Depression","metadata":null},{"id":"e6796f3078f44a839d9071f5a23208d1","type":"TRIAL","name":"The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CD","canonical_id":"clinicaltrials.gov:NCT03393247","description":"Crohn Disease","metadata":null},{"id":"8fade80665d24ee79773f02ea049d3d8","type":"TRIAL","name":"The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis","canonical_id":"clinicaltrials.gov:NCT02733731","description":"Atrophic Vaginitis","metadata":null},{"id":"cd05f81c2e564720934d34022a2a4696","type":"TRIAL","name":"The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT04076371","description":"Schizophrenia","metadata":null},{"id":"88586e673d3e487583cff622bb1d1279","type":"TRIAL","name":"The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","canonical_id":"clinicaltrials.gov:NCT00911157","description":"Thrombosis, Venous","metadata":null},{"id":"bbfa32cf58e341b98993e635113456a8","type":"TRIAL","name":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","canonical_id":"clinicaltrials.gov:NCT00981409","description":"Embolism, Pulmonary","metadata":null},{"id":"889ea4163a8046f1acc924e525486c39","type":"TRIAL","name":"The Treatment of Insomnia in Patients With HIV Disease","canonical_id":"clinicaltrials.gov:NCT00465972","description":"HIV Infections; Insomnia","metadata":null},{"id":"6ba622b6812342668c3a372cd5ced44a","type":"TRIAL","name":"The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial","canonical_id":"clinicaltrials.gov:NCT03182634","description":"Advanced Breast Cancer","metadata":null},{"id":"e1640ab590fd4bcb8a5016114da048f3","type":"TRIAL","name":"The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy","canonical_id":"clinicaltrials.gov:NCT03737721","description":"Squamous Cell Carcinoma of the Skin","metadata":null},{"id":"498a605055cc423f9b20309fcf6ca55b","type":"TRIAL","name":"The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.","canonical_id":"clinicaltrials.gov:NCT04248179","description":"Breast Cancer; Ductal Carcinoma in Situ","metadata":null},{"id":"7e7fd04fe668433386abbfc436e27d63","type":"TRIAL","name":"The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms","canonical_id":"clinicaltrials.gov:NCT03810287","description":"Gastroparesis","metadata":null},{"id":"b899d03f26a3423db5f46524ed82e944","type":"TRIAL","name":"The Use of Cilostazol in Patients With Diabetic Nephropathy","canonical_id":"clinicaltrials.gov:NCT00272831","description":"Diabetes Mellitus, Type 2; Diabetes Complications","metadata":null},{"id":"d291b2cd3c8340e4b721aa1c89b263e9","type":"TRIAL","name":"The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery","canonical_id":"clinicaltrials.gov:NCT03762109","description":"Lumbar Spine Injury","metadata":null},{"id":"274b2cdcd36e473988baf35ed3821750","type":"TRIAL","name":"The Use of Domperidone for Gastroparesis","canonical_id":"clinicaltrials.gov:NCT01378884","description":"Gastroparesis","metadata":null},{"id":"0873a2da100440e6b40a825bd2c8af2a","type":"TRIAL","name":"The Use of Drospirenone/Estetrol in Random Start Rapid Endometrial Preparation","canonical_id":"clinicaltrials.gov:NCT06316180","description":"Endometrial Polyp; Endometrial Diseases","metadata":null},{"id":"e4728058423a427b9f039b0c4d478982","type":"TRIAL","name":"The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders","canonical_id":"clinicaltrials.gov:NCT04727476","description":"Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder; Hyperkinetic Disorder","metadata":null},{"id":"388b1a430c60420c993352ca936c51ee","type":"TRIAL","name":"The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements","canonical_id":"clinicaltrials.gov:NCT02030990","description":"Corneal Opacity","metadata":null},{"id":"eef892d596be4ab5b6dfc2b840ab99e7","type":"TRIAL","name":"The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT02660242","description":"Diabetes Mellitus, Type 1","metadata":null},{"id":"ba4bd5796c8f45abac211a6499aee9bb","type":"TRIAL","name":"The Use of Oracea and Epiduo Forte in Severe Acne Patients","canonical_id":"clinicaltrials.gov:NCT03457636","description":"Acne","metadata":null},{"id":"8027c23dc21148029971b58b654e81fe","type":"TRIAL","name":"The Use of Rosiglitazone to Treat Asthma","canonical_id":"clinicaltrials.gov:NCT00614874","description":"Asthma","metadata":null},{"id":"f8620f83dc5d41a0a65b8011059581ab","type":"TRIAL","name":"The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.","canonical_id":"clinicaltrials.gov:NCT00464737","description":"Fibromyalgia Syndrome","metadata":null},{"id":"296e48b5c92645029b302f9d3410d26d","type":"TRIAL","name":"The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion","canonical_id":"clinicaltrials.gov:NCT05038072","description":"Macular Edema; Retinal Vein Occlusion","metadata":null},{"id":"d101e45fabc54d22aa065315de8d9451","type":"TRIAL","name":"The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.","canonical_id":"clinicaltrials.gov:NCT02973659","description":"Hyperhidrosis","metadata":null},{"id":"be7c56d3fee64422a4cfe015af4ceba5","type":"TRIAL","name":"The Use of Trifluoperazine in Transfusion Dependent DBA","canonical_id":"clinicaltrials.gov:NCT03966053","description":"Diamond Blackfan Anemia; Pure Red Cell Aplasia","metadata":null},{"id":"af5eb90c342b46babbdce6720fe0ad2f","type":"TRIAL","name":"The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit","canonical_id":"clinicaltrials.gov:NCT01780909","description":"Concentration-Time Profiles in Stomach & Intestine.","metadata":null},{"id":"87b0aecb5c3b443c86f8737f37fdf4c9","type":"TRIAL","name":"The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications","canonical_id":"clinicaltrials.gov:NCT04435015","description":"Coagulopathy; Cardiovascular Complication; COVID-19","metadata":null},{"id":"325dbb2c8cf54cceb23db7481400595f","type":"TRIAL","name":"The Utility of Nexium in Chronic Cough and Reflux Disease","canonical_id":"clinicaltrials.gov:NCT00287339","description":"Cough; GERD","metadata":null},{"id":"5bb11fb498dd48ff9bac6a60d509e9c1","type":"TRIAL","name":"The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol","canonical_id":"clinicaltrials.gov:NCT00283335","description":"Coronary Heart Disease","metadata":null},{"id":"251223034253435a9f7c2f46fc273a44","type":"TRIAL","name":"The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT04212598","description":"Esophageal Squamous Cell Carcinoma","metadata":null},{"id":"ad79606232f94663948cd81c95917b09","type":"TRIAL","name":"The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women","canonical_id":"clinicaltrials.gov:NCT03820206","description":"Intraoperative Bleeding","metadata":null},{"id":"14db0cc07bc7410fb7776daf21161d1e","type":"TRIAL","name":"Theophylline Effects in the Fontan Circulation","canonical_id":"clinicaltrials.gov:NCT05717049","description":"Congenital Heart Disease","metadata":null},{"id":"31eca8f39a96474e877e789494c1ec16","type":"TRIAL","name":"Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage","canonical_id":"clinicaltrials.gov:NCT05853601","description":"Acute Kidney Injury; HIE","metadata":null},{"id":"c77db7ac3ab445c5bb04760672f86168","type":"TRIAL","name":"Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old","canonical_id":"clinicaltrials.gov:NCT04551170","description":"Pseudohypoparathyroidism; Albright Hereditary Osteodystrophy; Pseudohypoparathyroidism Type 1a","metadata":null},{"id":"d607ce2073cc4b26b3a54740447db013","type":"TRIAL","name":"Theophylline for Treatment of Pseudohypoparathyroidism","canonical_id":"clinicaltrials.gov:NCT04240821","description":"Pseudohypoparathyroidism; Pseudohypoparathyroidism Type 1a; Albright Hereditary Osteodystrophy","metadata":null},{"id":"dc7d43c31eb14593bc3aebcc11ac1515","type":"TRIAL","name":"Theophylline in Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT00299858","description":"COPD","metadata":null},{"id":"4d5c4c7faeed409889903dab34cf71e5","type":"TRIAL","name":"Theophylline in Rhinitis","canonical_id":"clinicaltrials.gov:NCT01132781","description":"Rhinosinusitis; Asthma; Allergic Rhinitis","metadata":null},{"id":"80bba6d68f6b45948539be9c76055b6d","type":"TRIAL","name":"Theophylline in Treating Cancer Patients With Shortness of Breath","canonical_id":"clinicaltrials.gov:NCT00003684","description":"Pulmonary Complications; Quality of Life; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"7c9b756751724bd284a0a2a6f1e19409","type":"TRIAL","name":"Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT00003808","description":"Leukemia","metadata":null},{"id":"6b2588d154714722b24233713c39f9a4","type":"TRIAL","name":"Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy","canonical_id":"clinicaltrials.gov:NCT02088502","description":"Contrast-Induced Nephropathy","metadata":null},{"id":"062b8bd4588f473284e00a69f0de9ebf","type":"TRIAL","name":"TherApeutics in Early ProState Cancer (TAPS02)","canonical_id":"clinicaltrials.gov:NCT05191680","description":"Prostate Cancer","metadata":null},{"id":"04728151ed284732bc93e331b2c2f35a","type":"TRIAL","name":"Therapeutic Approaches to Malnutrition Enteropathy","canonical_id":"clinicaltrials.gov:NCT03716115","description":"Severe Acute Malnutrition","metadata":null},{"id":"ac2679c39d3b43178e369c677fe07efd","type":"TRIAL","name":"Therapeutic Dose Monitoring (TDM) of Tamoxifen","canonical_id":"clinicaltrials.gov:NCT05133674","description":"Breast Cancer; Breast Carcinoma; Breast Tumors; Cancer of Breast; Malignant Neoplasm of Breast","metadata":null},{"id":"bd3851d90f714c79b7102831840b47ae","type":"TRIAL","name":"Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01777685","description":"Healthy","metadata":null},{"id":"9d7ca2be80f940768c2e8c6e04d4824e","type":"TRIAL","name":"Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT03781310","description":"Rheumatoid Arthritis; Tocilizumab","metadata":null},{"id":"5d27670e1cb14adbaa5eef2b8397a4aa","type":"TRIAL","name":"Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients","canonical_id":"clinicaltrials.gov:NCT05792644","description":"ALK Phosphorylation","metadata":null},{"id":"cabe411246ff44a7bb2db7690ef60416","type":"TRIAL","name":"Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT04120623","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"a74512ead5e843e99cef3c0ddb1dee7f","type":"TRIAL","name":"Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice","canonical_id":"clinicaltrials.gov:NCT01106118","description":"Erectile Dysfunction","metadata":null},{"id":"b9fb00fe6fe54037b0e2011c35bf54a9","type":"TRIAL","name":"Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan","canonical_id":"clinicaltrials.gov:NCT03044912","description":"Overactive Bladder Syndrome","metadata":null},{"id":"930ef743d4654deebde268c0fcc4727b","type":"TRIAL","name":"Therapeutic Efficacy in Women With Stress Urinary Incontinence","canonical_id":"clinicaltrials.gov:NCT05677295","description":"Women With Stress Urinary Incontinence","metadata":null},{"id":"bbb7a4bb256047fab5b3c5ff634d518c","type":"TRIAL","name":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","canonical_id":"clinicaltrials.gov:NCT01722604","description":"Glaucoma; Open Angle or Ocular Hypertension","metadata":null},{"id":"d5fc5c5652c0497d8662e9cfcb51aeb4","type":"TRIAL","name":"Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration","canonical_id":"clinicaltrials.gov:NCT07088445","description":"Neovascular Age-related Macular Degeneration(nAMD)","metadata":null},{"id":"2986a8fceb8e4aa4ba4276422c022b24","type":"TRIAL","name":"Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.","canonical_id":"clinicaltrials.gov:NCT05379049","description":"Rheumatoid Arthritis; Inflammatory Arthritis; Ankylosing Spondylitis","metadata":null},{"id":"0d4ecd277f204fbf87f54477cec9c93e","type":"DRUG","name":"Therapeutic Tumor Infiltrating Lymphocytes","canonical_id":"ncit:C28699","description":null,"metadata":null},{"id":"1b462a3e40a04887aa230ca29582cd41","type":"TRIAL","name":"Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic","canonical_id":"clinicaltrials.gov:NCT02503839","description":"Tuberculosis","metadata":null},{"id":"bf423f27cea84ed4ad72421aedf1c477","type":"TRIAL","name":"Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)","canonical_id":"clinicaltrials.gov:NCT00988559","description":"HPV16 Positive; Cervical Intraepithelial Neoplasia (CIN 2/3)","metadata":null},{"id":"e50bb9b41dca47eb8c63e53cb3def801","type":"TRIAL","name":"Therapies for Treatment-Resistant Panic Disorder Symptoms","canonical_id":"clinicaltrials.gov:NCT00118417","description":"Panic Disorder","metadata":null},{"id":"48861b116ddb41eba5b5cb57eca24368","type":"TRIAL","name":"Therapy Pathways in the Treatment of Hormone Na\u00efve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.","canonical_id":"clinicaltrials.gov:NCT02234089","description":"Advanced Prostate Cancer","metadata":null},{"id":"0aa67a163db642e2bf99084d059bba8a","type":"TRIAL","name":"Therapy of Chronic Cold Agglutinin Disease With Eculizumab","canonical_id":"clinicaltrials.gov:NCT01303952","description":"Cold Agglutinin Disease","metadata":null},{"id":"d240232a5c7847f1b29e49769431b4b2","type":"TRIAL","name":"Therapy of Essential Hypertension With Kinzal\u00ae/ Kinzalplus\u00ae","canonical_id":"clinicaltrials.gov:NCT00927537","description":"Hypertension","metadata":null},{"id":"3994c21f39794290b28d5a5095b577ff","type":"TRIAL","name":"Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab","canonical_id":"clinicaltrials.gov:NCT03457818","description":"Diabetes Mellitus, Type 2; Osteoporosis","metadata":null},{"id":"e2926bcdbcab45bdaa4b6a2564083edc","type":"TRIAL","name":"Thermosensitive Gel Nasal Spray With Exosomes, Azelastine, and Interferon for Acute Phase of Chronic Sinusitis","canonical_id":"clinicaltrials.gov:NCT07635459","description":"Chronic Rhinosinusitis Without Polyps","metadata":null},{"id":"90935b4ef17e4aff8afe12b90148aa87","type":"DRUG","name":"Thiabendazole","canonical_id":"mesh:D013827","description":null,"metadata":null},{"id":"d59b0c2fc1ac4bdab819f6efc7d0f954","type":"DISEASE","name":"Thiamin deficiency","canonical_id":"mesh:D013832","description":null,"metadata":null},{"id":"be6f270e0a59432486d272335cfb4dec","type":"DRUG","name":"Thiamine","canonical_id":"mesh:D013831","description":null,"metadata":null},{"id":"4924585cdd0d46b09233eac1b6b101e8","type":"DRUG","name":"Thiocolchicoside","canonical_id":"mesh:C004280","description":null,"metadata":null},{"id":"966374dd1da441d98da28f3ebc65ccfe","type":"DRUG","name":"Thioguanine","canonical_id":"mesh:D013866","description":null,"metadata":null},{"id":"87e79c7baff844468dcf3c9c508c62a7","type":"DRUG","name":"Thiopental","canonical_id":"mesh:D013874","description":null,"metadata":null},{"id":"84c2b872fbeb40e9a5af9c2221826d69","type":"TRIAL","name":"Thiopurine EnhAnced Maintenance Therapy","canonical_id":"clinicaltrials.gov:NCT02912676","description":"Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma","metadata":null},{"id":"7889046b8a3249858111ef3b78fa6a04","type":"TRIAL","name":"Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy","canonical_id":"clinicaltrials.gov:NCT05276284","description":"Solid Tumor, Adult; Metastatic Cancer","metadata":null},{"id":"14ea4d5bb507441fa48d1d103287a92e","type":"TRIAL","name":"Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies","canonical_id":"clinicaltrials.gov:NCT00857389","description":"Stem Cell Transplantation; Leukemia; Lymphoma","metadata":null},{"id":"fd81cf11aa614632b5e79df28de70c2e","type":"DRUG","name":"Thiothixene","canonical_id":"mesh:D013888","description":null,"metadata":null},{"id":"147e8aeb64164858b2b783681633d2c9","type":"TRIAL","name":"Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma","canonical_id":"clinicaltrials.gov:NCT04848064","description":"Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Adult T-Cell Leukemia/Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"302d195933e84a60a089f64f17e613b3","type":"TRIAL","name":"This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization","canonical_id":"clinicaltrials.gov:NCT07587658","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"564ce366fd554ec187ee4c0036ae7011","type":"TRIAL","name":"This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated","canonical_id":"clinicaltrials.gov:NCT03165240","description":"Diabetic Nephropathies","metadata":null},{"id":"2e571a34f12048b396a7e7f74538e900","type":"TRIAL","name":"This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding","canonical_id":"clinicaltrials.gov:NCT03343704","description":"Hemorrhage","metadata":null},{"id":"fdb58e2c0cb24f8a8ea491529d074ef3","type":"TRIAL","name":"This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood","canonical_id":"clinicaltrials.gov:NCT03259490","description":"Healthy","metadata":null},{"id":"a9e63189cd674356b4d91ee62e2e2610","type":"TRIAL","name":"This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men","canonical_id":"clinicaltrials.gov:NCT03307252","description":"Healthy","metadata":null},{"id":"302f2b9055a94ebe95aa09568547a412","type":"TRIAL","name":"This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax","canonical_id":"clinicaltrials.gov:NCT03343678","description":"Leukemia, Lymphocytic, Chronic, B-Cell","metadata":null},{"id":"6027ed68db3f4acf872cfdcd5fce100e","type":"TRIAL","name":"This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction","canonical_id":"clinicaltrials.gov:NCT06853223","description":"Primary Graft Dysfunction; Lung Transplantation; Acute Lung Injury(ALI); Natural Killer Cell Mediated Immunity","metadata":null},{"id":"4e6a6ca16d9d469bb843f241175e33c4","type":"TRIAL","name":"This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment","canonical_id":"clinicaltrials.gov:NCT00150800","description":"Epilepsy","metadata":null},{"id":"0641be7ae266464db35d7ccf80b8c549","type":"TRIAL","name":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT01972841","description":"Urinary Bladder Overactive; Urinary Bladder Diseases\\Urologic Diseases; Overactive Bladder; Urgency Incontinence","metadata":null},{"id":"f41de5a423f540b9b826e801bfcde839","type":"TRIAL","name":"This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.","canonical_id":"clinicaltrials.gov:NCT00720603","description":"Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma","metadata":null},{"id":"9d251f8053394ebe868cdd8621ce0afc","type":"TRIAL","name":"This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra\u00ae (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye","canonical_id":"clinicaltrials.gov:NCT07490535","description":"Ocular Surface Disease; Dry Eye Syndrome (DES)","metadata":null},{"id":"e2c45cfdb54e42f3bc27c1f7134e85c3","type":"TRIAL","name":"This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response","canonical_id":"clinicaltrials.gov:NCT06851169","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"9f36a8e713db4e6cae135b5956340c73","type":"TRIAL","name":"This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06978153","description":"Limited Stage Small Cell Lung Cancer","metadata":null},{"id":"14e1553b9b514f05a0bbc7263d3c3436","type":"TRIAL","name":"Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery","canonical_id":"clinicaltrials.gov:NCT03214510","description":"Liver and Intrahepatic Bile Duct Disorder","metadata":null},{"id":"086c430e187c44e29e3b89d8d49cdfbe","type":"TRIAL","name":"Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib","canonical_id":"clinicaltrials.gov:NCT05252988","description":"Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive","metadata":null},{"id":"c1bb79a8261f404da4b5b624b2564274","type":"TRIAL","name":"Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome","canonical_id":"clinicaltrials.gov:NCT00136045","description":"Restless Legs Syndrome","metadata":null},{"id":"59b16536c595460ab627f3a565aa7d65","type":"TRIAL","name":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","canonical_id":"clinicaltrials.gov:NCT00001521","description":"Congenital Adrenal Hyperplasia (CAH)","metadata":null},{"id":"5dfdd4c89f1944229413ad086bce62f7","type":"TRIAL","name":"Three New Ideas to Protect Special Forces From the Stress of High Altitude","canonical_id":"clinicaltrials.gov:NCT02463357","description":"Mountain Sickness","metadata":null},{"id":"0024e9e388b94ff2a8c5b0624025ae01","type":"TRIAL","name":"Thrombectomy Under Reopro Versus Alteplase to Treat Stoke","canonical_id":"clinicaltrials.gov:NCT02016547","description":"Infarction, Middle Cerebral Artery","metadata":null},{"id":"7f7b93ac78f94c92bac26ea4677c729e","type":"DISEASE","name":"Thromboangiitis obliterans","canonical_id":"mesh:D013919","description":null,"metadata":null},{"id":"75f0581445b94a1eb80fd105adeb318c","type":"DISEASE","name":"Thrombocytopenia","canonical_id":"hp:0001873","description":null,"metadata":null},{"id":"3cb2ae1e996c42878505a95a08fb441f","type":"DISEASE","name":"Thrombocytopenic disorder","canonical_id":"mesh:D013921","description":null,"metadata":null},{"id":"f8dbce6bf30348308f0ff9bd937d7b55","type":"DISEASE","name":"Thrombocytosis","canonical_id":"hp:0001894","description":null,"metadata":null},{"id":"564144c698b5431c887377cda34c5b87","type":"DISEASE","name":"Thromboembolic disorder","canonical_id":"mesh:D013923","description":null,"metadata":null},{"id":"28ba1840836b46dbb1199fd5e0eb649c","type":"DISEASE","name":"Thromboembolism","canonical_id":"hp:0001907","description":null,"metadata":null},{"id":"370bb1d0f34142efb12e573419eb97d8","type":"DISEASE","name":"Thrombophlebitis","canonical_id":"hp:0004418","description":null,"metadata":null},{"id":"3d1a9e2a22b8477dbfcfe8fd6e642732","type":"TRIAL","name":"Thromboprophylaxis After Surgery for Gynecologic Malignancy in China","canonical_id":"clinicaltrials.gov:NCT02935530","description":"Gynecologic Neoplasms; Venous Thromboembolism; Low Molecular Weight Heparin; Argatroban","metadata":null},{"id":"f699137b5d174ab68a3d052ff5172e19","type":"TRIAL","name":"Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT01727401","description":"Medical Patient; Thrombocytopenia","metadata":null},{"id":"045e8f51cf9944a4a392b2a898e40303","type":"DISEASE","name":"Thrombosis","canonical_id":"mesh:D013927","description":null,"metadata":null},{"id":"3ca86a059f7d4293a25c690e74f35711","type":"PROTEIN","name":"Thromboxane-A synthase","canonical_id":"uniprot:P24557","description":null,"metadata":null},{"id":"27c966c1a70a4ba8b19fe9c050822488","type":"PROTEIN","name":"Thymidine phosphorylase","canonical_id":"uniprot:P19971","description":null,"metadata":null},{"id":"cef922d436004de998e3391cc68dc89c","type":"TRIAL","name":"Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT01046955","description":"End-Stage Renal Disease; Living Donors","metadata":null},{"id":"eaa8fec6ea7e4937838caa58a0508b3e","type":"TRIAL","name":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation","canonical_id":"clinicaltrials.gov:NCT00685061","description":"Renal Transplantation","metadata":null},{"id":"95d5e31316a94381b43e072f461b5d45","type":"TISSUE","name":"Thyroid","canonical_id":"uberon:UBERON:0002046","description":null,"metadata":null},{"id":"220643870d84498e94d3a56043473aa3","type":"DISEASE","name":"Thyroid Cancer","canonical_id":"doid:1781","description":null,"metadata":null},{"id":"636cbbc25fb841bc8fda5307c8cdf7a1","type":"DISEASE","name":"Thyroid Cancer, Papillary","canonical_id":"mesh:D000077273","description":null,"metadata":null},{"id":"530831484f2b4d59970594689fd3f003","type":"TRIAL","name":"Thyroid Disease in Pregnancy: Case Finding Versus Universal Screening","canonical_id":"clinicaltrials.gov:NCT00846755","description":"Thyroid Disease; Pregnancy","metadata":null},{"id":"443deb9852d94f38874c8cffb5350262","type":"DISEASE","name":"Thyroid cancer (Diagnostic)","canonical_id":"mesh:D013964","description":null,"metadata":null},{"id":"877a2ef10a4d46cc88229a8d69b45ffb","type":"DISEASE","name":"Thyroiditis","canonical_id":"mesh:D013966","description":null,"metadata":null},{"id":"92bb136fc6e84d57a79c3ecc8c819d6d","type":"DISEASE","name":"Thyrotoxic crisis","canonical_id":"mesh:D013958","description":null,"metadata":null},{"id":"f32217d7f5a645659a117dc6a4a3d616","type":"TRIAL","name":"Tiagabine for the Treatment of Cocaine Dependence - 1","canonical_id":"clinicaltrials.gov:NCT00086255","description":"Cocaine-Related Disorders","metadata":null},{"id":"a7bda5ea7ce243529e959245914dd6d4","type":"TRIAL","name":"Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea","canonical_id":"clinicaltrials.gov:NCT02387710","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"d7926ef5119f46b6af14130ac4c57bd6","type":"TRIAL","name":"Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9","canonical_id":"clinicaltrials.gov:NCT00015132","description":"Cocaine-Related Disorders","metadata":null},{"id":"936066a9d9e041a79eda5db0147fe9f7","type":"TRIAL","name":"Tibial Nerve Stimulation in Combination With Biofeedback","canonical_id":"clinicaltrials.gov:NCT02888899","description":"Fecal Incontinence","metadata":null},{"id":"b18783055cf449478db3409b71cd271f","type":"GO_TERM","name":"Tic complex","canonical_id":"go:GO:0031897","description":"\"The translocon of the inner envelope of chloroplasts, which facilitates the import of proteins across the chloroplast inner membrane.\" [PMID:12180471, PMID:12393016]","metadata":null},{"id":"31d9a3cd817c4d70873fccb5bdb03586","type":"DRUG","name":"Ticagrelor","canonical_id":"mesh:C503700","description":null,"metadata":null},{"id":"38a8da8fa64948fd99e69efdc4bd5073","type":"TRIAL","name":"Ticagrelor Administered as Standard Tablet or Orodispersible Formulation","canonical_id":"clinicaltrials.gov:NCT03822377","description":"ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI","metadata":null},{"id":"0ca286ce7cfc4a8d9ba598ab03d7fae7","type":"TRIAL","name":"Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg","canonical_id":"clinicaltrials.gov:NCT06233266","description":"Healthy Subjects","metadata":null},{"id":"5ef9d24f438d4151aa3f80c4de92f07f","type":"TRIAL","name":"Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT06202755","description":"Ischemic Stroke","metadata":null},{"id":"dcbddce974364eb2976d7eabfb240a4c","type":"TRIAL","name":"Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA","canonical_id":"clinicaltrials.gov:NCT06196047","description":"Ischemic Stroke","metadata":null},{"id":"37d597db4e174e2d8e5c65ac6b7de086","type":"TRIAL","name":"Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT02270242","description":"Cardiovascular Disease; Interventional Cardiology","metadata":null},{"id":"2a8ba019403946a682bea4f2b8d717a9","type":"TRIAL","name":"Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT01373411","description":"Coronary Artery Disease","metadata":null},{"id":"b640d13f66cb4d6b9d4b0527db52d141","type":"TRIAL","name":"Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion","canonical_id":"clinicaltrials.gov:NCT01919723","description":"Acute Coronary Syndrome","metadata":null},{"id":"a405ab6296ea490c9fd25a76a4d14bb4","type":"TRIAL","name":"Tick-borne Encephalitis and Positive Borrelial Antibodies","canonical_id":"clinicaltrials.gov:NCT02463942","description":"Tick-borne Encephalitis","metadata":null},{"id":"4517b777bcf3466492fd00cf2d3d686b","type":"GO_TERM","name":"Tie signaling pathway","canonical_id":"go:GO:0048014","description":"\"The series of molecular signals initiated by an angiopoietin binding to the Tie receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb, GOC:signaling, PMID:11283723, PMID:11566266]","metadata":null},{"id":"804802fda0de43349da80023d6727a5a","type":"DRUG","name":"Tigecycline","canonical_id":"mesh:D000078304","description":null,"metadata":null},{"id":"a3dfa830dde9426983f096745a53bb89","type":"TRIAL","name":"Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol","canonical_id":"clinicaltrials.gov:NCT01404767","description":"Vascular Disease; Hypertension; Angina; Cardiac Disease","metadata":null},{"id":"eb3be08750c24fff8c3ca0904596dfa3","type":"TRIAL","name":"Tigulixostat (IBI128) vs Febuxostat in Gout","canonical_id":"clinicaltrials.gov:NCT07414394","description":"Gout","metadata":null},{"id":"c818ee76d4f84d6f8ef3b00f50e7ee6c","type":"TRIAL","name":"Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT04112810","description":"Hematologic Malignancies","metadata":null},{"id":"36009f4762f14529a22c67eab3c83a79","type":"TRIAL","name":"Tilrdakizumab Almirall","canonical_id":"clinicaltrials.gov:NCT07244744","description":"Psoriasis","metadata":null},{"id":"e26bbe570ae848d29fe3e3cb1b0cdda3","type":"DRUG","name":"Tiludronic acid","canonical_id":"mesh:C058651","description":null,"metadata":null},{"id":"4c88c3907c2c46aca280262641ac1f0f","type":"TRIAL","name":"Timing of VTE Prophylaxis in TBI","canonical_id":"clinicaltrials.gov:NCT03081169","description":"TBI (Traumatic Brain Injury); VTE (Venous Thromboembolism)","metadata":null},{"id":"6853d564456c4ab3a512ebff8f66a6b1","type":"DISEASE","name":"Timothy syndrome","canonical_id":"mondo:0010979","description":null,"metadata":null},{"id":"636b7202bd1d45058fd61ab1b46102b0","type":"DISEASE","name":"Tinea capitis","canonical_id":"mesh:D014006","description":null,"metadata":null},{"id":"ea51bc8ef9d047d79ce739528ee0163e","type":"DISEASE","name":"Tinea pedis","canonical_id":"mesh:D014008","description":null,"metadata":null},{"id":"85d35f39993f49c081053dca9aecac89","type":"DRUG","name":"Tinidazole","canonical_id":"mesh:D014011","description":null,"metadata":null},{"id":"a894b3312d3e45c2b5be718ba3b40393","type":"TRIAL","name":"Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00293501","description":"Kidney Cancer","metadata":null},{"id":"0c76a06d36444c148d8b02686777e25f","type":"DRUG","name":"Tioconazole","canonical_id":"mesh:C020527","description":null,"metadata":null},{"id":"894cb620a3b942d4ac17e8bae9634f9a","type":"DRUG","name":"Tiopronin","canonical_id":"mesh:D008625","description":null,"metadata":null},{"id":"0f8b0638183d4529811bbb204cffdd58","type":"TRIAL","name":"Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients","canonical_id":"clinicaltrials.gov:NCT00394485","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"f6ccfd59013c44c68b4abcffd6dd4f83","type":"TRIAL","name":"Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT04780984","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"e4184fddc8294c7f818fda78bb9c4b87","type":"TRIAL","name":"Tiotropium and Salmeterol PK Study in COPD Patients","canonical_id":"clinicaltrials.gov:NCT00673478","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"15753cb39ec14e69b7f7a8690aeb090e","type":"TRIAL","name":"Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects","canonical_id":"clinicaltrials.gov:NCT02172417","description":"Healthy","metadata":null},{"id":"1eee1566ff734cce89ccbc79c09f2982","type":"TRIAL","name":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01431274","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"ec561bcbf0024d70a20fcad2917d32cf","type":"TRIAL","name":"Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT06540963","description":"Neuroblastoma","metadata":null},{"id":"5c426f7fb7414d349bc23ab7b205d901","type":"TRIAL","name":"Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)","canonical_id":"clinicaltrials.gov:NCT06940791","description":"Primary Central Nervous System Lymphoma","metadata":null},{"id":"3f3824621baf4e22a28194f8c6a16b42","type":"TRIAL","name":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","canonical_id":"clinicaltrials.gov:NCT05661188","description":"Squamous Cell Carcinoma of the Anal Canal","metadata":null},{"id":"498d41d4fed94f3db4bb5bfffbfc547c","type":"TRIAL","name":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","canonical_id":"clinicaltrials.gov:NCT05286801","description":"Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid\u2026","metadata":null},{"id":"01758b60ecfe42198bf4d64b708f8ddd","type":"TRIAL","name":"Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","canonical_id":"clinicaltrials.gov:NCT05746481","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"ef0d6045577b45368c0d74f699a01d9f","type":"DRUG","name":"Tirofiban","canonical_id":"mesh:D000077466","description":null,"metadata":null},{"id":"4b3a4ce236404f3d8b278a39189bd8d4","type":"TRIAL","name":"Tirofiban Combined With Aspirin in Moderate Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT07760922","description":"Ischemic Stroke, Acute","metadata":null},{"id":"8f2e35558d21400db6bbb30979322a2c","type":"TRIAL","name":"Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients","canonical_id":"clinicaltrials.gov:NCT01109134","description":"Acute Myocardial Infarction","metadata":null},{"id":"8fa8b24ac7124ede83e0ecb85136af6c","type":"TRIAL","name":"Tirofiban Plus Intravenous Thrombolysis in Acute Anterior Choroidal Infarction or Paramedian Pontine Infarction","canonical_id":"clinicaltrials.gov:NCT05733507","description":"Acute Anterior Choroidal Infarction (ACI); Paramedian Pontine Infarction (IPP)","metadata":null},{"id":"539cbe2032754b10a76c507c338884db","type":"TRIAL","name":"Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke","canonical_id":"clinicaltrials.gov:NCT07095790","description":"Mild Stroke","metadata":null},{"id":"3dc0d90cee444d77bcc6b2acdce9ddc0","type":"TRIAL","name":"Tirofiban and Enoxaparin in High Risk Coronary Intervention","canonical_id":"clinicaltrials.gov:NCT00790387","description":"Acute Coronary Syndrome","metadata":null},{"id":"246af3cb99994037bd6d2b3abb833a34","type":"TRIAL","name":"Tirofiban for Patients Treated With Alteplase","canonical_id":"clinicaltrials.gov:NCT03357133","description":"Ischemic Stroke","metadata":null},{"id":"233712af9fb24921863852d3f822258b","type":"TRIAL","name":"Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4\uff09","canonical_id":"clinicaltrials.gov:NCT06319846","description":"Ischemic Stroke, Acute; TIA; Symptomatic Intracranial Artery Stenosis","metadata":null},{"id":"fedd880cf5e94017b6454c0f6f8bc5f4","type":"TRIAL","name":"Tirofiban for Successful Endovascular Stroke Thrombectomy","canonical_id":"clinicaltrials.gov:NCT06373042","description":"Stroke, Acute Ischemic","metadata":null},{"id":"44afdac968a445fab3321de651c48e8d","type":"TRIAL","name":"Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke","canonical_id":"clinicaltrials.gov:NCT06587347","description":"Acute Stroke; Ischemic Stroke, Acute; Cerebral Infarction","metadata":null},{"id":"bfaa2541cc2e4eacadda14865f5d26f8","type":"TRIAL","name":"Tirofiban in Stenting for Long Coronary Lesion","canonical_id":"clinicaltrials.gov:NCT01498003","description":"Coronary Artery Disease","metadata":null},{"id":"d5bbb40f4f1246d3a3f7393ec2319093","type":"TRIAL","name":"Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC","canonical_id":"clinicaltrials.gov:NCT04405674","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"a102e462e84b46079fd3b88ec860e988","type":"TRIAL","name":"Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT05024266","description":"Lung Squamous Cell Carcinoma; Neoadjuvant Therapy; Immunotherapy","metadata":null},{"id":"d3042e028af24f9fac9dce24af46d88a","type":"TRIAL","name":"Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC","canonical_id":"clinicaltrials.gov:NCT04924179","description":"Patients With Advanced Metastatic Colorectal Cancer","metadata":null},{"id":"d411ed4010854542866ed064034956f6","type":"TRIAL","name":"Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05690035","description":"Metastatic Colorectal Cancer; mCRC","metadata":null},{"id":"e3a2fc26a30a4f1281a627e3102294f1","type":"TRIAL","name":"Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer\uff1aA Prospective, Single-Arm, Phase II Study","canonical_id":"clinicaltrials.gov:NCT07085182","description":"NSCLC; Tislelizumab; Chemotherapy; Hypofractionated Radiotherapy","metadata":null},{"id":"280cca730c8847ea8349123f171b2ecd","type":"TRIAL","name":"Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT06793917","description":"Gastric Cancer","metadata":null},{"id":"d3b3b02651d44324808f6306920f98da","type":"TRIAL","name":"Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT07502768","description":"Extranodal NK/T-cell Lymphoma; NK/T-cell Lymphoma; Relapsed or Refractory NK/T-Cell Lymphoma","metadata":null},{"id":"790ffece08b74a02a6c3ea45171973ba","type":"TRIAL","name":"Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06692270","description":"Esophagus Cancer","metadata":null},{"id":"4b29dbfede304d02baf862247bc24a33","type":"TRIAL","name":"Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT04996459","description":"Hepatocellular Carcinoma","metadata":null},{"id":"1695146ec7ae463983051b5d39a5a189","type":"TRIAL","name":"Tisotumab Vedotin (HuMax\u00ae-TF-ADC) Safety Study in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02552121","description":"Ovary Cancer; Cervix Cancer; Endometrium Cancer; Bladder Cancer; Prostate Cancer (CRPC); Esophagus Cancer; Lung Cancer (NSCLC)","metadata":null},{"id":"2b900ee375e24cfabd3cd09ad5c7b878","type":"TRIAL","name":"Tisotumab Vedotin (HuMax\u00ae-TF-ADC) Safety Study in Patients With Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02001623","description":"Ovary Cancer; Cervix Cancer; Endometrium Cancer; Bladder Cancer; Prostate Cancer (CRPC); Esophagus Cancer; Lung Cancer(NSCLC); Squamous Cell Carcinoma of the Head and Neck (SCCHN)","metadata":null},{"id":"54fd3cf5ed874b1c865da76a92542a47","type":"TRIAL","name":"Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.","canonical_id":"clinicaltrials.gov:NCT03245736","description":"Ovary Cancer; Cervix Cancer; Endometrium Cancer; Bladder Cancer; Prostate Cancer; Esophagus Cancer; Lung Cancer, Nonsmall Cell; Squamous Cell Carcinoma of the Head and Neck","metadata":null},{"id":"cbb5ec88b9e4497e85fe5215ed5db8b8","type":"TRIAL","name":"Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva","canonical_id":"clinicaltrials.gov:NCT07672782","description":"Vulvar Carcinoma; Recurrent or Metastatic Vulvar Cancer; Squamous Cell Carcinoma Vulva","metadata":null},{"id":"91f52b91c7be4873a13417cc15630fda","type":"TRIAL","name":"Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT04697628","description":"Cervical Cancer","metadata":null},{"id":"e14dd3b827e7492489a9c4fdd6b55469","type":"TRIAL","name":"Tissue Biomarker for Pegvisomant Action","canonical_id":"clinicaltrials.gov:NCT01261000","description":"Acromegaly","metadata":null},{"id":"d89929945d4547eebc7271565135b329","type":"TRIAL","name":"Tissue Sodium in Pre-hypertensive Patients","canonical_id":"clinicaltrials.gov:NCT02236520","description":"Hypertension","metadata":null},{"id":"f38cbee8534e47e8b6ced5941d4133c0","type":"TRIAL","name":"Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation","canonical_id":"clinicaltrials.gov:NCT02639273","description":"AUD","metadata":null},{"id":"42f6a26509844537b93087aa411dab0c","type":"TRIAL","name":"Titration of Intravenous Hydromorphone","canonical_id":"clinicaltrials.gov:NCT01892709","description":"Acute Severe Pain","metadata":null},{"id":"4cb80b4c47f349b48826bc8cca01c8bb","type":"TRIAL","name":"Tivozanib + Enzalutamide in Adv Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT01885949","description":"Prostate Cancer","metadata":null},{"id":"8e8cd7c652a64809bec39cdcd46d406e","type":"TRIAL","name":"Tivozanib + Gemcitabine in Metastatic RCC","canonical_id":"clinicaltrials.gov:NCT01834183","description":"Renal Cell Carcinoma","metadata":null},{"id":"0ac101207aa845d8ae41420fd26e67a4","type":"TRIAL","name":"Tivozanib As Maintenance Therapy In GYN","canonical_id":"clinicaltrials.gov:NCT01972516","description":"Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma","metadata":null},{"id":"d698de9cb88a427585b3f66b7f0a3a97","type":"TRIAL","name":"Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT01769885","description":"Stage II Renal Cell Cancer; Stage III Renal Cell Cancer","metadata":null},{"id":"8f0fe7e3d36d48de82eeca55d0290a04","type":"TRIAL","name":"Tivozanib for Recurrent Glioblastoma","canonical_id":"clinicaltrials.gov:NCT01846871","description":"Glioblastoma","metadata":null},{"id":"3efc46adff8b4e2186fdc53c92996e9f","type":"TRIAL","name":"Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01745367","description":"Triple Negative Breast Cancer","metadata":null},{"id":"36f666f8cf8f4cd79af9a7d01051ab97","type":"TRIAL","name":"Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT01853644","description":"Recurrent Epithelial Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer","metadata":null},{"id":"8ae2f1ca4d754f3ca66f94747b0412f7","type":"TRIAL","name":"Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT01835223","description":"Advanced Adult Hepatocellular Carcinoma; Non-Resectable Hepatocellular Carcinoma","metadata":null},{"id":"d216f73ddd8e4dc4be313e47360d8fb1","type":"TRIAL","name":"Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial","canonical_id":"clinicaltrials.gov:NCT06303076","description":"Depressive Disorder, Major","metadata":null},{"id":"e659e57cefe5476bb4088f97a56c35eb","type":"GO_TERM","name":"Tle3-Aes complex","canonical_id":"go:GO:0070722","description":"\"A transcriptional repressor complex that consists of a heterodimer of the proteins Tle3 (also known as Grg3b) and Aes (Grg5), which are homologs of the Drosophila groucho gene product.\" [GOC:mah, PMID:8955148]","metadata":null},{"id":"0935c7a16ea74163afc8caa20cd50420","type":"TRIAL","name":"To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup","canonical_id":"clinicaltrials.gov:NCT02593747","description":"Histamine H1 Antagonists, Non-Sedating","metadata":null},{"id":"603612ef206d49768801dbb81c360f82","type":"TRIAL","name":"To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients","canonical_id":"clinicaltrials.gov:NCT04445714","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"6ce2aa0aff634616a113fbb1d8bb62a1","type":"TRIAL","name":"To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT06823284","description":"Healthy","metadata":null},{"id":"3c7e941644eb4b849e613aaedf225268","type":"TRIAL","name":"To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02823171","description":"Healthy","metadata":null},{"id":"effc48bff27847d1b606ee8421775390","type":"TRIAL","name":"To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT01974349","description":"Solid Tumours","metadata":null},{"id":"dfb4ebeb94724631bdc06328a3300106","type":"TRIAL","name":"To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours","canonical_id":"clinicaltrials.gov:NCT01900028","description":"Solid Tumours","metadata":null},{"id":"bac6a49a5e2545448fe8a41052947550","type":"TRIAL","name":"To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake","canonical_id":"clinicaltrials.gov:NCT00829140","description":"Obesity","metadata":null},{"id":"d08690d43d15470aa266399f5b517e7d","type":"TRIAL","name":"To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers","canonical_id":"clinicaltrials.gov:NCT02046850","description":"Solid Tumours","metadata":null},{"id":"ee0e927ca85f4543b1893ad2c138655b","type":"TRIAL","name":"To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT02476968","description":"BRCA or HRR+ Mutated Ovarian Cancer Patients","metadata":null},{"id":"5b3791bb50af4a609bc2a1ece81df50a","type":"TRIAL","name":"To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants","canonical_id":"clinicaltrials.gov:NCT07279233","description":"Healthy; Volunteer","metadata":null},{"id":"5230ed5149be41f39a000ceb73e6b827","type":"TRIAL","name":"To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02063230","description":"Solid Tumors","metadata":null},{"id":"5db91908bec642a7a75ba1c7ff31be7f","type":"TRIAL","name":"To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)","canonical_id":"clinicaltrials.gov:NCT00659750","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"0eba60c8731a46e99172943161a726c1","type":"TRIAL","name":"To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)","canonical_id":"clinicaltrials.gov:NCT00659841","description":"Rhinitis, Allergic, Seasonal; Hay Fever","metadata":null},{"id":"9872258ece4f43ad91f56e7131b71cd3","type":"TRIAL","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT06344052","description":"Basal Cell Carcinoma","metadata":null},{"id":"46b704da0b6249d29a973afcebec89d2","type":"TRIAL","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","canonical_id":"clinicaltrials.gov:NCT04661007","description":"Non Hodgkins Lymphoma; Diffuse Large B-cell Lymphoma","metadata":null},{"id":"dbe57df89f3d46b4b5d14ff2ffac694e","type":"TRIAL","name":"To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)","canonical_id":"clinicaltrials.gov:NCT00658918","description":"Rhinitis, Allergic, Perennial; Hay Fever","metadata":null},{"id":"e5b5f38ae1484e8986c89962a48e9c18","type":"TRIAL","name":"To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas","canonical_id":"clinicaltrials.gov:NCT03277209","description":"Pancreas Cancer","metadata":null},{"id":"8dbdc01515a04638898e14f383be3946","type":"TRIAL","name":"To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital","canonical_id":"clinicaltrials.gov:NCT07337434","description":"Chronic Plaque Psoriasis","metadata":null},{"id":"ea0f9b0c5c2a4392896754dc45418f4b","type":"TRIAL","name":"To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol","canonical_id":"clinicaltrials.gov:NCT01478490","description":"Pharmacokinetics of Mirabegron; Healthy Subjects","metadata":null},{"id":"2bbc7374b6f944c59d8192dee29309f4","type":"TRIAL","name":"To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","canonical_id":"clinicaltrials.gov:NCT04058067","description":"Diabetic Macular Edema","metadata":null},{"id":"c2ad30e3a9024120b48937f9fa99a21f","type":"TRIAL","name":"To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia","canonical_id":"clinicaltrials.gov:NCT00589693","description":"Ventilator-Associated Pneumonia","metadata":null},{"id":"2ba72cac983a4958bb53d1e681cd6e6f","type":"TRIAL","name":"To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02459795","description":"Actinic Keratosis","metadata":null},{"id":"0fad7cbeea7c4d7a84ca6dc269c68558","type":"TRIAL","name":"To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis","canonical_id":"clinicaltrials.gov:NCT02385318","description":"Actinic Keratosis","metadata":null},{"id":"75eb955359cf4030b08fb54726fe8257","type":"TRIAL","name":"To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01496313","description":"Thyroid Cancer","metadata":null},{"id":"5cfbc0fd97eb4100a728aa2c3ede8e36","type":"TRIAL","name":"To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema","canonical_id":"clinicaltrials.gov:NCT00371111","description":"Resistant Cystoid Macular Edema","metadata":null},{"id":"77b2007eb511418fad5062c69a4d1b6a","type":"TRIAL","name":"To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject","canonical_id":"clinicaltrials.gov:NCT02098460","description":"Severe Hypercholesterolemia","metadata":null},{"id":"e90c5c068b5c4a748963a21c05f2689b","type":"TRIAL","name":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","canonical_id":"clinicaltrials.gov:NCT01068860","description":"Type 2 Diabetes Mellitus; Impaired Glucose Tolerance","metadata":null},{"id":"44ec96a863f446de9aae3dd9a3a269db","type":"TRIAL","name":"To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia","canonical_id":"clinicaltrials.gov:NCT02849184","description":"Hypertension; Insomnia","metadata":null},{"id":"e73a0b3cb81f4438b7cda0dfa51f7d69","type":"TRIAL","name":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","canonical_id":"clinicaltrials.gov:NCT04944290","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"12f6c003758648e387193ec5a95533ff","type":"TRIAL","name":"To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","canonical_id":"clinicaltrials.gov:NCT01785433","description":"COPD","metadata":null},{"id":"d01ccdaac25b4e4290f81aa2b6b1c106","type":"TRIAL","name":"To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis","canonical_id":"clinicaltrials.gov:NCT06147518","description":"Compensated Cirrhosis; Decompensated Cirrhosis","metadata":null},{"id":"23abc241aebd48828a909f0817187f16","type":"TRIAL","name":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","canonical_id":"clinicaltrials.gov:NCT04024072","description":"Glaucoma, Open-Angle; Ocular Hypertension","metadata":null},{"id":"e81487f3dfd0447798e53d36b864516d","type":"TRIAL","name":"To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately","canonical_id":"clinicaltrials.gov:NCT01535677","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"629b54773785416781cb77a239ddbd75","type":"TRIAL","name":"To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product","canonical_id":"clinicaltrials.gov:NCT02308098","description":"Asthma","metadata":null},{"id":"de2efee9d3104e41857193d914664b17","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets","canonical_id":"clinicaltrials.gov:NCT00946608","description":"Allergy","metadata":null},{"id":"cb298983236246b7bd8b03204c916d1a","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Atenolol Tablets","canonical_id":"clinicaltrials.gov:NCT00913965","description":"Hypertension","metadata":null},{"id":"2a14ad17c7dc4053a88acf3900277a47","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg","canonical_id":"clinicaltrials.gov:NCT00946725","description":"Angina; Hypertension","metadata":null},{"id":"e7f7c41d33594c40b02ed7ba57732fcd","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets","canonical_id":"clinicaltrials.gov:NCT00913237","description":"Depression","metadata":null},{"id":"939d4e98004247c5930b0d3e303950b7","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets","canonical_id":"clinicaltrials.gov:NCT00913822","description":"Depression","metadata":null},{"id":"118d3f55e7714f28a692b9f3eb6bae78","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg","canonical_id":"clinicaltrials.gov:NCT00947076","description":"Depression","metadata":null},{"id":"7cffc71d0fb843718ad86c01e3b8f7cf","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT00913783","description":"Depression","metadata":null},{"id":"3ff52c66cc224a3e84f9503fc67bc237","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions","canonical_id":"clinicaltrials.gov:NCT00913952","description":"Depression","metadata":null},{"id":"3e0e02b6fc434b6cb2336c7ca33d6aa7","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00946764","description":"Depression","metadata":null},{"id":"313d30bf93b54140b6518cd88c132ee7","type":"TRIAL","name":"To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00946686","description":"Rheumatoid Arthritis; Psoriatic Arthritis","metadata":null},{"id":"8bcc0fa73b944fecaa126e2c4125bdbd","type":"TRIAL","name":"To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed","canonical_id":"clinicaltrials.gov:NCT00883506","description":"Hypertension","metadata":null},{"id":"d332c1ae2c9e4437981717145e624b88","type":"TRIAL","name":"To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets","canonical_id":"clinicaltrials.gov:NCT00913549","description":"Allergy","metadata":null},{"id":"eafd2d8b430f484c9429b75a05773a98","type":"TRIAL","name":"To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets","canonical_id":"clinicaltrials.gov:NCT00914004","description":"Depression","metadata":null},{"id":"f02034ce32244fda82e18a33552d6fd9","type":"TRIAL","name":"To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets","canonical_id":"clinicaltrials.gov:NCT00913809","description":"Depression","metadata":null},{"id":"cb6f89f8e63e4dfa9b0f2077eb93b265","type":"TRIAL","name":"To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers","canonical_id":"clinicaltrials.gov:NCT00946491","description":"Psychosis","metadata":null},{"id":"94175671ba494c76aec48a53910d8f9b","type":"TRIAL","name":"To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)","canonical_id":"clinicaltrials.gov:NCT00150176","description":"Schizophrenia","metadata":null},{"id":"6847638db5b34637967f3cafcdf169b0","type":"TRIAL","name":"To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours","canonical_id":"clinicaltrials.gov:NCT01921140","description":"Solid Tumours","metadata":null},{"id":"ce96de898a4a4bb8bc4ad241e7554cde","type":"TRIAL","name":"To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers","canonical_id":"clinicaltrials.gov:NCT06821698","description":"Healty Volunteers","metadata":null},{"id":"fc1966e4a93f4f30b1eeccdc3398f74e","type":"TRIAL","name":"To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer","canonical_id":"clinicaltrials.gov:NCT05335460","description":"Colon Cancer","metadata":null},{"id":"d55b5156e6404d1ea3c426162970ff5f","type":"TRIAL","name":"To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection","canonical_id":"clinicaltrials.gov:NCT00238667","description":"Cervical Artery Dissection; Carotid Artery Dissection; Vertebral Artery Dissection; Stroke","metadata":null},{"id":"f87dfb10df3f445aa3d39a090cb94646","type":"TRIAL","name":"To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol","canonical_id":"clinicaltrials.gov:NCT01272362","description":"Chronic Obstructive Pulmonary Disease (COPD)","metadata":null},{"id":"c8327d0c75f04c79bdf446a8bdecc9d6","type":"TRIAL","name":"To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT03181880","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"b0c49df8df284cb993908cdfd6f9dbb6","type":"TRIAL","name":"To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","canonical_id":"clinicaltrials.gov:NCT03915769","description":"Colitis, Ulcerative","metadata":null},{"id":"332a983177104976b44447e33b007081","type":"TRIAL","name":"To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)","canonical_id":"clinicaltrials.gov:NCT04796922","description":"Follicular Lymphoma ( FL); Marginal Zone Lymphoma (MZL)","metadata":null},{"id":"31e40aeda3db4e258017cbb2717f7945","type":"TRIAL","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","canonical_id":"clinicaltrials.gov:NCT05468489","description":"Extensive Stage Small Cell Lung Cancer","metadata":null},{"id":"258633007d1c4e6c87afc3ce78195753","type":"TRIAL","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","canonical_id":"clinicaltrials.gov:NCT06072131","description":"Peripheral T Cell Lymphoma","metadata":null},{"id":"a54b0741277147ff8d19fb6d975feb36","type":"TRIAL","name":"To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies","canonical_id":"clinicaltrials.gov:NCT05866354","description":"Solid Malignancies","metadata":null},{"id":"5216e8cf31c24cf2b065a6000ff01041","type":"TRIAL","name":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02057250","description":"RA","metadata":null},{"id":"1cd3a41c853f410e8cb4a13c7241b50f","type":"TRIAL","name":"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","canonical_id":"clinicaltrials.gov:NCT01709578","description":"Rheumatoid Arthritis","metadata":null},{"id":"1d4e77bfeed74714856ffb8c5bbfa788","type":"TRIAL","name":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","canonical_id":"clinicaltrials.gov:NCT01768572","description":"Rheumatoid Arthritis","metadata":null},{"id":"1e716506dbd14f689737c90a7cb1f64d","type":"TRIAL","name":"To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients","canonical_id":"clinicaltrials.gov:NCT02542605","description":"Migraine","metadata":null},{"id":"91bad57ea4904b038cb79609447fef52","type":"TRIAL","name":"To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02807207","description":"Healthy Subjects","metadata":null},{"id":"e1ef183f9b5e47cd81c4e366b60c81ab","type":"TRIAL","name":"To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects","canonical_id":"clinicaltrials.gov:NCT02807051","description":"Drug Interaction Study","metadata":null},{"id":"8fb438d9f20c44b496c42f3cc2146588","type":"TRIAL","name":"To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656","canonical_id":"clinicaltrials.gov:NCT01083212","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f1e678d5d333463f9bcda91609e23ff0","type":"TRIAL","name":"To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways","canonical_id":"clinicaltrials.gov:NCT02085161","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"4aebdafc0f224175bd47f9870140024c","type":"TRIAL","name":"To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together","canonical_id":"clinicaltrials.gov:NCT01478568","description":"Pharmacokinetics of Mirabegron; Healthy Subjects","metadata":null},{"id":"147308a49f9944faa34c9e9fe9286f22","type":"TRIAL","name":"To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03950505","description":"Non-alcoholic Steatohepatitis; Type2 Diabetes","metadata":null},{"id":"d3c0b7924ce441e4af54df1a360875ec","type":"TRIAL","name":"To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants","canonical_id":"clinicaltrials.gov:NCT02885454","description":"Healthy","metadata":null},{"id":"fcff010adc3b46f4b35d0a24ffa1faa6","type":"TRIAL","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","canonical_id":"clinicaltrials.gov:NCT06389006","description":"Breast Cancer","metadata":null},{"id":"859733c458c14355811503c81238884f","type":"TRIAL","name":"To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)","canonical_id":"clinicaltrials.gov:NCT05968768","description":"Ewing Sarcoma","metadata":null},{"id":"d2fda53c357e454e892d886b8e34d072","type":"TRIAL","name":"To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus","canonical_id":"clinicaltrials.gov:NCT05075408","description":"Chronic Kidney Disease Associated Moderate to Severe Pruritus","metadata":null},{"id":"7087b8cd249f4640a17cfdb9286c9f6c","type":"TRIAL","name":"To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT05607446","description":"Allergic Rhinitis","metadata":null},{"id":"b410a710cd344e75a8a2ce69127d9679","type":"TRIAL","name":"To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women","canonical_id":"clinicaltrials.gov:NCT01904110","description":"Osteoporosis","metadata":null},{"id":"7e672a002d83449ebc99d24dd8e65da9","type":"TRIAL","name":"To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects","canonical_id":"clinicaltrials.gov:NCT01450111","description":"Epilepsy","metadata":null},{"id":"483e034cb3114c468482166e7d89bc6b","type":"TRIAL","name":"To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.","canonical_id":"clinicaltrials.gov:NCT04801043","description":"Bacterial Infections","metadata":null},{"id":"37f7986ab3f7473b8b1149d7c8df55b1","type":"TRIAL","name":"To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03856619","description":"Relapsing Multiple Sclerosis","metadata":null},{"id":"f534a3ffe80b4d478896b01ab1ef622a","type":"TRIAL","name":"To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches","canonical_id":"clinicaltrials.gov:NCT00433732","description":"Migraine Headaches","metadata":null},{"id":"91744fbc466747c4a89e94eb0a10dcf1","type":"TRIAL","name":"To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults","canonical_id":"clinicaltrials.gov:NCT06578676","description":"Type 2 Diabetes; Dyslipidemias","metadata":null},{"id":"fa7cc7c62bdc4e3c9feba48e2fc4c8e7","type":"TRIAL","name":"To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence","canonical_id":"clinicaltrials.gov:NCT00190632","description":"Stress Urinary Incontinence","metadata":null},{"id":"c4a55a5c3b304388be757db030244120","type":"TRIAL","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","canonical_id":"clinicaltrials.gov:NCT06378242","description":"High-risk Non-muscle Invasive Bladder Cancer","metadata":null},{"id":"d808288644684ece89e081b402db9338","type":"TRIAL","name":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03006172","description":"Breast Cancer; Solid Tumor","metadata":null},{"id":"81011ee43db94c3cb44c39c01bb82842","type":"TRIAL","name":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis","canonical_id":"clinicaltrials.gov:NCT03880357","description":"Scalp Psoriasis","metadata":null},{"id":"ad1ac0f987774c66bfeff25e554f567a","type":"TRIAL","name":"To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT04682587","description":"Renal Cell Carcinoma","metadata":null},{"id":"812874c752d04e97b4c46257773835ed","type":"TRIAL","name":"To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil\u00ae Nasal Spray","canonical_id":"clinicaltrials.gov:NCT04817800","description":"Seasonal Allergic Rhinitis","metadata":null},{"id":"01329e4822cd4038ade71a0ececed5cd","type":"TRIAL","name":"To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.","canonical_id":"clinicaltrials.gov:NCT00426608","description":"Depressive Disorder and Anxiety Disorders","metadata":null},{"id":"54d714b6994f48409deb016d7c3d2dc0","type":"TRIAL","name":"To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.","canonical_id":"clinicaltrials.gov:NCT00661115","description":"Erectile Dysfunction","metadata":null},{"id":"2a8a5119965f4a888a4bdd30744a959e","type":"TRIAL","name":"To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)","canonical_id":"clinicaltrials.gov:NCT05060523","description":"Liver Cirrhosis","metadata":null},{"id":"f59594a555c04fddb483b6d241404062","type":"TRIAL","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07368998","description":"Breast Cancer","metadata":null},{"id":"9952eab1078d41f5a4926b9ce5c46f54","type":"TRIAL","name":"To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT00050648","description":"Psoriasis","metadata":null},{"id":"e93a28b4cba84bbe9a6792ee6f243532","type":"TRIAL","name":"To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism","canonical_id":"clinicaltrials.gov:NCT02265484","description":"Cirrhosis Related Parkinsonism","metadata":null},{"id":"7e180e25bf9f46a7b8f1377d7883a59f","type":"TRIAL","name":"To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)","canonical_id":"clinicaltrials.gov:NCT00273468","description":"Chemotherapy-induced Nausea and Vomiting","metadata":null},{"id":"11c096626d87448481e734ba5d95cc13","type":"TRIAL","name":"To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris","canonical_id":"clinicaltrials.gov:NCT00050661","description":"Psoriasis","metadata":null},{"id":"23f67bab5afd4cf6bfd313cdc1ffe76a","type":"TRIAL","name":"Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment","canonical_id":"clinicaltrials.gov:NCT04634071","description":"Smoking Cessation; Cancer, Treatment-Related","metadata":null},{"id":"50cf80e41196400985ee27778fb385e1","type":"GO_TERM","name":"Toc complex","canonical_id":"go:GO:0010006","description":"\"Protein translocon complex at the chloroplast outer membrane.\" [PMID:10646606]","metadata":null},{"id":"c334ad91e51e4993bb61da4da083411c","type":"DRUG","name":"Tocilizumab","canonical_id":"mesh:C502936","description":null,"metadata":null},{"id":"97565377ce754b358b4da45a8315b80f","type":"TRIAL","name":"Tocilizumab REMission in Early RA","canonical_id":"clinicaltrials.gov:NCT04157010","description":"Rheumatoid Arthritis","metadata":null},{"id":"23d03eede84148cd91d55e83d637bf42","type":"TRIAL","name":"Tocilizumab Treatment in Patients With COVID-19","canonical_id":"clinicaltrials.gov:NCT04363853","description":"Sars-CoV2","metadata":null},{"id":"d948276360cb43c09f1cdf361acbc8ff","type":"TRIAL","name":"Tocilizumab Versus Baricitinib in Patients With Severe COVID-19","canonical_id":"clinicaltrials.gov:NCT05082714","description":"COVID-19","metadata":null},{"id":"9d41c8f489084378b24c23d35f6d182d","type":"TRIAL","name":"Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection","canonical_id":"clinicaltrials.gov:NCT04377659","description":"COVID-19","metadata":null},{"id":"24963ccd15174c05bedd57a409ccb06e","type":"TRIAL","name":"Tocilizumab for Renal Graft Inflammation","canonical_id":"clinicaltrials.gov:NCT02108600","description":"Late Complication From Kidney Transplant","metadata":null},{"id":"9844eaf572524eadadb873ed7fa73132","type":"TRIAL","name":"Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT01475162","description":"Acute Graft Versus Host Disease","metadata":null},{"id":"a156cb4283f84ca9900a253108b84e66","type":"TRIAL","name":"Tocilizumab in Coronavirus-19 Positive Patients","canonical_id":"clinicaltrials.gov:NCT04423042","description":"Covid19; COVID-19; Severe Acute Respiratory Syndrome Coronavirus 2; Coronavirus; Inflammation","metadata":null},{"id":"6f6bab0652b34d71ae784b718118f30a","type":"TRIAL","name":"Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis","canonical_id":"clinicaltrials.gov:NCT01603355","description":"Juvenile Idiopathic Arthritis Associated Uveitis","metadata":null},{"id":"88fca5857b424bbab7093e2028c5881b","type":"DRUG","name":"Tofacitinib","canonical_id":"mesh:C479163","description":null,"metadata":null},{"id":"435da19adf4944ef98b4a6d1796f5ed6","type":"TRIAL","name":"Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01932372","description":"Rheumatoid Arthritis","metadata":null},{"id":"e3135fa591b643608abfc7d01e7e4179","type":"TRIAL","name":"Tofacitinib for Immune Skin Conditions in Down Syndrome","canonical_id":"clinicaltrials.gov:NCT04246372","description":"Down Syndrome; Alopecia Areata; Atopic Dermatitis / Eczema; Hidradenitis Suppurativa; Vitiligo; Psoriasis","metadata":null},{"id":"ab7c551bc1dc4a958e24ba3418318b35","type":"TRIAL","name":"Tofacitinib in Depression (TIDE)","canonical_id":"clinicaltrials.gov:NCT04141904","description":"Depression; Inflammation","metadata":null},{"id":"290dbacf622a49d8a9742dc65bef4583","type":"TRIAL","name":"Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia","canonical_id":"clinicaltrials.gov:NCT04469114","description":"Covid19","metadata":null},{"id":"76a5981d64174f4b9f3aeee94982ee20","type":"TRIAL","name":"Tofatib Treatment for IgG4-related Disease","canonical_id":"clinicaltrials.gov:NCT05625581","description":"IgG4-related Disease","metadata":null},{"id":"c07dab9dc9904919a167c1ad52423432","type":"TRIAL","name":"Tofogliflozin GLP-1 Analogue Combination Trial","canonical_id":"clinicaltrials.gov:NCT02537834","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"f7eded3d8f8645de8706a6b405907033","type":"DRUG","name":"Tolbutamide","canonical_id":"mesh:D014044","description":null,"metadata":null},{"id":"95eec4605e08475990a4111ed5d621db","type":"DRUG","name":"Tolcapone","canonical_id":"mesh:C066340","description":null,"metadata":null},{"id":"3dbea268a31e458c8e023b119c463449","type":"TRIAL","name":"Tolcapone Treatment of Pathological Gambling","canonical_id":"clinicaltrials.gov:NCT00927563","description":"Pathological Gambling","metadata":null},{"id":"1e89ccdc5a334eb6800112e4973667de","type":"TRIAL","name":"Tolcapone in Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT03348930","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"6fc8e4d1e7d247b18e16ced91b4a4dc6","type":"TRIAL","name":"Tolerability Comparison Between Differin\u00ae Cream 0.1% Versus Differin\u00ae Lotion 0.1% in Subjects With Healthy Skin","canonical_id":"clinicaltrials.gov:NCT01046565","description":"Skin Manifestations","metadata":null},{"id":"821e167635354c0e929ea55eda79797d","type":"TRIAL","name":"Tolerability Comparison of Differin\u00ae Cream 0.1% Versus Differin\u00ae Lotion 0.1% in Subjects With Healthy Skin","canonical_id":"clinicaltrials.gov:NCT01046396","description":"Skin Manifestations","metadata":null},{"id":"7f29cfa2fe114ec9b61f0f4eafe10593","type":"TRIAL","name":"Tolerability Comparison of Flarex to Lotemax SM","canonical_id":"clinicaltrials.gov:NCT07588074","description":"Ocular Inflammation; Keratoconjunctivitis; Dry Eye Disease (DED); Post-operative Complications; Kerato Conjunctivitis Sicca; Dry Eye Syndromes; Postoperative Complications","metadata":null},{"id":"d9d2f6a2d2c84fbe9354a161254bef75","type":"TRIAL","name":"Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas","canonical_id":"clinicaltrials.gov:NCT05029960","description":"Brain Tumor","metadata":null},{"id":"a3142e58d78742dbaedc84a20fe2589a","type":"TRIAL","name":"Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT02820519","description":"Neuropathic Pain","metadata":null},{"id":"3207e47e4c5c42c58a3e009eac92d14f","type":"TRIAL","name":"Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT05487963","description":"Atopic Dermatitis","metadata":null},{"id":"a31b9032fddb409fb774da26a49ab798","type":"TRIAL","name":"Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients","canonical_id":"clinicaltrials.gov:NCT04097470","description":"AML/MDS","metadata":null},{"id":"771cc811c8c841babd3ee16d96bf98f4","type":"TRIAL","name":"Tolerability and Safety of Duloxetine BID in Healthy Female Subjects","canonical_id":"clinicaltrials.gov:NCT02232542","description":"Healthy","metadata":null},{"id":"f5d376ac908f4a56ab13c9c7cb734c4f","type":"TRIAL","name":"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05019534","description":"BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody","metadata":null},{"id":"2f75c79819104f45ad70001b6af2e751","type":"TRIAL","name":"Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain","canonical_id":"clinicaltrials.gov:NCT00082316","description":"Herpes Zoster; Neuralgia; Pain; HIV Infections; Peripheral Nervous System Diseases; Diabetic Neuropathies; Diabetes Mellitus; Polyneuropathies","metadata":null},{"id":"086b8c1c34784016ab6a3db8c5d292ed","type":"TRIAL","name":"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01273610","description":"Breast Neoplasms; HER2/Neu Positive; Geriatric Health Services","metadata":null},{"id":"8af181c6dfe24bb3abe19fb0b03999e3","type":"TRIAL","name":"Tolerability, Safety and Efficacy of Vortioxetine","canonical_id":"clinicaltrials.gov:NCT04301492","description":"Depression","metadata":null},{"id":"21d8786b4a4846e3aab52d12a36b6f78","type":"TRIAL","name":"Tolerance and Pharmacokinetics Study of MNTX Tablets","canonical_id":"clinicaltrials.gov:NCT01366339","description":"Normal Healthy Volunteers","metadata":null},{"id":"869aefe068784e1b81be1487f7b52493","type":"GO_TERM","name":"Toll binding","canonical_id":"go:GO:0005121","description":"\"Binding to a Toll protein, a transmembrane receptor.\" [GOC:ceb]","metadata":null},{"id":"b66497d4bd994f7ca5bb510a9054433e","type":"GO_TERM","name":"Toll receptor ligand protein activation cascade","canonical_id":"go:GO:0160032","description":"\"A protein activation cascade that generates the active Toll receptor ligand and consists of the cascade of enzymatic reactions initiated by extracellular recognition factors, leading to the cleavage of the inactive form of spatzle family of ligands.\" [PMID:23632253]","metadata":null},{"id":"db729523d7134bbc8661bf82c1db8f55","type":"GO_TERM","name":"Toll signaling pathway","canonical_id":"go:GO:0008063","description":"\"The series of molecular signals initiated by an extracellular ligand binding to the receptor Toll on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:curators, PMID:11135568, PMID:19126860]","metadata":null},{"id":"a323f237c7c940319e17bde923d02e88","type":"TRIAL","name":"Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases","canonical_id":"clinicaltrials.gov:NCT01421017","description":"Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer","metadata":null},{"id":"158e1dd5146e47f794c2f3bbf6b971f4","type":"GO_TERM","name":"Toll-like receptor 1-Toll-like receptor 2 protein complex","canonical_id":"go:GO:0035354","description":"\"A heterodimeric protein complex containing Toll-like receptor 1 (TLR1) and Toll-like receptor 2 (TLR2).\" [GOC:add, GOC:signaling, PMID:17889651, PMID:21481769]","metadata":null},{"id":"7000de53bc84403aa924a678a9480453","type":"PROTEIN","name":"Toll-like receptor 2","canonical_id":"uniprot:O60603","description":null,"metadata":null},{"id":"fd90defcd5e5405fb31e212f23174534","type":"GO_TERM","name":"Toll-like receptor 2 binding","canonical_id":"go:GO:0035663","description":"\"Binding to a Toll-like 2 protein, a pattern recognition receptor that binds microbial pattern motifs to initiate an innate immune response.\" [GOC:BHF]","metadata":null},{"id":"1ca75b816b6d4333a1c1a000d0fd897e","type":"GO_TERM","name":"Toll-like receptor 2-Toll-like receptor 6 protein complex","canonical_id":"go:GO:0035355","description":"\"A heterodimeric protein complex containing Toll-like receptor 2 (TLR2) and Toll-like receptor 6 (TLR6).\" [GOC:add, GOC:signaling, PMID:19931471, PMID:21481769]","metadata":null},{"id":"b452d9b80975467092c44e646077ccbb","type":"PROTEIN","name":"Toll-like receptor 4","canonical_id":"uniprot:O00206","description":null,"metadata":null},{"id":"f899a64c2ecf4cb082d2321599490b78","type":"GO_TERM","name":"Toll-like receptor 4 binding","canonical_id":"go:GO:0035662","description":"\"Binding to a Toll-like 4 protein, a pattern recognition receptor that binds bacterial lipopolysaccharide (LPS) to initiate an innate immune response.\" [GOC:BHF, PMID:18304834]","metadata":null},{"id":"c7082764d027441896ad71ac4e29eb03","type":"PROTEIN","name":"Toll-like receptor 9","canonical_id":"uniprot:Q9NR96","description":null,"metadata":null},{"id":"d2bc33db192a42fa9053f4f031edfdd8","type":"GO_TERM","name":"Toll-like receptor binding","canonical_id":"go:GO:0035325","description":"\"Binding to a Toll-like protein, a pattern recognition receptor that binds pattern motifs from a variety of microbial sources to initiate an innate immune response.\" [PMID:19076341]","metadata":null},{"id":"d46ff488a07441a79a75702fd3ddd80a","type":"DRUG","name":"Tolmetin","canonical_id":"mesh:D014046","description":null,"metadata":null},{"id":"33d42baf1b9c4b189d73b358f53bcd2a","type":"DRUG","name":"Tolnaftate","canonical_id":"mesh:D014047","description":null,"metadata":null},{"id":"7a950e3ee72c4786952cab095b7de290","type":"DRUG","name":"Toloxatone","canonical_id":"mesh:C010798","description":null,"metadata":null},{"id":"50e92daf5d5c46a2bd12ddd05bffdb17","type":"DRUG","name":"Tolrestat","canonical_id":"mesh:C040550","description":null,"metadata":null},{"id":"063458c0f8d5474394e2bf573497ebdb","type":"DRUG","name":"Tolterodine","canonical_id":"mesh:D000068737","description":null,"metadata":null},{"id":"ec4f8f7e11ed4e5b82379e001da83496","type":"TRIAL","name":"Tolvaptan Extension Study in Participants With ADPKD","canonical_id":"clinicaltrials.gov:NCT01214421","description":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","metadata":null},{"id":"abf3d5ac00df4c768b3ba570a9179f19","type":"TRIAL","name":"Tolvaptan in Hyponatremic Cancer Patients","canonical_id":"clinicaltrials.gov:NCT01199198","description":"Advanced Cancers","metadata":null},{"id":"36f70a737c36447fa6b5b93260f187d6","type":"TRIAL","name":"Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia","canonical_id":"clinicaltrials.gov:NCT01890694","description":"Hyponatremia","metadata":null},{"id":"94a9757edac64d7586b26e9f33c78796","type":"TRIAL","name":"Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure","canonical_id":"clinicaltrials.gov:NCT01863511","description":"Acute Decompensated Heart Failure","metadata":null},{"id":"1d5c2235ef504246a14f2e9abf476461","type":"DISEASE","name":"Tonic-clonic epilepsy","canonical_id":"mesh:D004830","description":null,"metadata":null},{"id":"da54abd70173494fb1a8bdef128aeda7","type":"DISEASE","name":"Tonic-clonic seizure","canonical_id":"mesh:D012640","description":null,"metadata":null},{"id":"d5cded97833f4b74a9358aee05b10728","type":"DISEASE","name":"Toothache","canonical_id":"mesh:D014098","description":null,"metadata":null},{"id":"8a7a7b0da7034a7b9021c481b1e18c05","type":"TRIAL","name":"Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema","canonical_id":"clinicaltrials.gov:NCT00900887","description":"Diabetic Retinopathy; Macular Edema","metadata":null},{"id":"49307ab76ae541d493ee07bb6011a377","type":"TRIAL","name":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT03535233","description":"Alopecia Areata","metadata":null},{"id":"fa632aaa0d8f4cbd83459917c6d06e13","type":"TRIAL","name":"Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study","canonical_id":"clinicaltrials.gov:NCT07473895","description":"Acne Vulgaris","metadata":null},{"id":"8184e587aa324cc3ba6daccda5576eab","type":"TRIAL","name":"Topical Anti-Androgens in Pilonidal Sinus Disease","canonical_id":"clinicaltrials.gov:NCT06286397","description":"Pilonidal Disease; Pilonidal Disease of Natal Cleft; Pilonidal Sinus; Pilonidal Cyst","metadata":null},{"id":"58d07232aa42422193d3ea64e1094c79","type":"TRIAL","name":"Topical Aprepitant in Prurigo Patients","canonical_id":"clinicaltrials.gov:NCT01963793","description":"Pruritus","metadata":null},{"id":"4467cd9b66124597829e91904b52a19f","type":"TRIAL","name":"Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus","canonical_id":"clinicaltrials.gov:NCT03026478","description":"Oral Lichen Planus","metadata":null},{"id":"129b418f6d904989835ceb937aa62393","type":"TRIAL","name":"Topical Betaxolol for the Prevention of Retinopathy of Prematurity","canonical_id":"clinicaltrials.gov:NCT01660620","description":"Development of Side Effects From Betaxolol","metadata":null},{"id":"48b076edb3ce4851a6eb4acd51ced4a5","type":"TRIAL","name":"Topical Bethanechol for Improvement of Esophageal Dysmotility","canonical_id":"clinicaltrials.gov:NCT01031043","description":"Esophageal Dysmotility","metadata":null},{"id":"6f38236e83bb45e4aaec078fc0fcd264","type":"TRIAL","name":"Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome","canonical_id":"clinicaltrials.gov:NCT01312402","description":"Infantile Nystagmus Syndrome","metadata":null},{"id":"26ae5f4603644a8eb29313e25bbf46e8","type":"TRIAL","name":"Topical Bromfenac for Intraoperative Miosis and Pain Reduction","canonical_id":"clinicaltrials.gov:NCT03831984","description":"Cataract","metadata":null},{"id":"7e994fc74d504424bba7dc060ef3ccdf","type":"TRIAL","name":"Topical Capsaicin Versus Diclofenac for Chronic Temporomandibular Joint-Related Pain","canonical_id":"clinicaltrials.gov:NCT07598994","description":"Temporomandibular Disorders (TMD); Temporomandibular Pain","metadata":null},{"id":"893a1aa6c6764417b7bd1596710483c3","type":"TRIAL","name":"Topical Capsaicin for Cyclical Vomiting","canonical_id":"clinicaltrials.gov:NCT03223350","description":"Cyclical Vomiting","metadata":null},{"id":"0e55533f7e5f458cb337d5732fbf66d5","type":"TRIAL","name":"Topical Cetirizine in Androgenetic Alopecia in Females","canonical_id":"clinicaltrials.gov:NCT04481412","description":"Androgenetic Alopecia","metadata":null},{"id":"1bf9b62e96f149e28cb84f892763baef","type":"TRIAL","name":"Topical Cetirizine in Treatment of Localized Alopecia Areata","canonical_id":"clinicaltrials.gov:NCT05803070","description":"Alopecia Areata","metadata":null},{"id":"a327cf09482b4cb19413c67eba7d254f","type":"TRIAL","name":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","canonical_id":"clinicaltrials.gov:NCT00824811","description":"Epiphora","metadata":null},{"id":"0a0a331718bd49978ce17b4b3ad9065b","type":"TRIAL","name":"Topical Delgocitinib for Facial Vitiligo","canonical_id":"clinicaltrials.gov:NCT07820098","description":"Vitiligo","metadata":null},{"id":"994cb27685194a2199a5c5210b242628","type":"TRIAL","name":"Topical Doxepin for Radiation-induced Dermatitis","canonical_id":"clinicaltrials.gov:NCT02447211","description":"Breast Cancer","metadata":null},{"id":"0f4246191d3c4f20895b005b1e1952d8","type":"TRIAL","name":"Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT04403282","description":"Pseudofolliculitis Barbae","metadata":null},{"id":"4f573d75cb804041afcc4e95099d0aa0","type":"TRIAL","name":"Topical Finasteride in the Treatment of Idiopathic Hirsutism","canonical_id":"clinicaltrials.gov:NCT00564252","description":"Idiopathic Hirsutism","metadata":null},{"id":"643a06d1a24e471587babb74678d1349","type":"TRIAL","name":"Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1","canonical_id":"clinicaltrials.gov:NCT00865644","description":"Neurofibromatosis Type 1; Cutaneous Neurofibromas","metadata":null},{"id":"84b43924e6174c9d82eadee68f1874ba","type":"TRIAL","name":"Topical Imiquimod Treatment of Oral Dysplasia","canonical_id":"clinicaltrials.gov:NCT07210775","description":"Oral Dysplasia; Leukoplakia Oral; Leukoplakia","metadata":null},{"id":"f55fff3bef714239b6416a34135e8168","type":"TRIAL","name":"Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00821964","description":"Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer","metadata":null},{"id":"016b05d3319546558cf612e4e1432085","type":"TRIAL","name":"Topical Imiquimod for Bowen's Disease of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT00384124","description":"Bowens Disease","metadata":null},{"id":"076972af962642be998b3f34e1dc776a","type":"TRIAL","name":"Topical Intra-Oral Ketoprofen for Migraine Prevention","canonical_id":"clinicaltrials.gov:NCT01211795","description":"Migraine","metadata":null},{"id":"18c6eb120e184d23b826655fa6b78146","type":"TRIAL","name":"Topical JAK-Inhibition of Early-Stage CTCL","canonical_id":"clinicaltrials.gov:NCT07781449","description":"Mycosis Fungoides; Cutaneous T-cell Lymphoma","metadata":null},{"id":"4d2954de90f049a0b67038131cbf32c8","type":"TRIAL","name":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","canonical_id":"clinicaltrials.gov:NCT07257029","description":"Provoked Vestibulodynia; Secondary Provoked Vestibulodynia; Vulvodynia; Vulvary Pain Disorders; Neuroproliferative Vestibulodynia; Mast Cell-mediated Neuroinflammation; Instertional Dyspareunia","metadata":null},{"id":"e6dd394cd97f4a6ebbb74f99cbe9fd9c","type":"TRIAL","name":"Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing","canonical_id":"clinicaltrials.gov:NCT02711891","description":"Pain","metadata":null},{"id":"89a17e7e03d0462c8eea3ac6abf5a018","type":"TRIAL","name":"Topical Morphine for Analgesia in Patients With Skin Grafts","canonical_id":"clinicaltrials.gov:NCT00362219","description":"Skin Transplantation; Pain","metadata":null},{"id":"f88cf9f401bc4e249c162bef866f48b6","type":"TRIAL","name":"Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention","canonical_id":"clinicaltrials.gov:NCT02832115","description":"Radial Artery Spasm; Angina; Coronary Artery Disease","metadata":null},{"id":"621f393ab0cf4f0ea717374ce526be33","type":"TRIAL","name":"Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)","canonical_id":"clinicaltrials.gov:NCT00536692","description":"Diabetic Macular Edema","metadata":null},{"id":"d5eee509419e41558013a6043990921b","type":"TRIAL","name":"Topical Phenytoin for Management of Gingival Recession","canonical_id":"clinicaltrials.gov:NCT07590375","description":"Gingival Recession","metadata":null},{"id":"18ee9f7f8b914ae182b59ec75d4044bf","type":"TRIAL","name":"Topical Phenytoin-Loaded Hydrogel Dressing for Postoperative Wound Management After Oral Squamous Cell Carcinoma Resection","canonical_id":"clinicaltrials.gov:NCT07801157","description":"Postoperative Wound Healing After Oral Cancer Surgery","metadata":null},{"id":"bf67167dc87c40c19b57493534596399","type":"TRIAL","name":"Topical Roflumilast in Adults With Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT01856764","description":"Atopic Dermatitis","metadata":null},{"id":"af95911d23a4447fb9576b85f4029b10","type":"TRIAL","name":"Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)","canonical_id":"clinicaltrials.gov:NCT05028582","description":"Scalp Psoriasis","metadata":null},{"id":"8a76281837e64576b78393cfa397fa67","type":"TRIAL","name":"Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01445340","description":"Mycosis Fungoides; Cutaneous T-Cell Lymphoma; Neoplasms","metadata":null},{"id":"fe18bd0c66ac49e18e971ab5d3ab0fd9","type":"TRIAL","name":"Topical Simvastatin for Treating Infantile Hemangioma","canonical_id":"clinicaltrials.gov:NCT06273111","description":"Hemangioma Skin","metadata":null},{"id":"d06869a315a14505a5bf7c60e07c0851","type":"TRIAL","name":"Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study","canonical_id":"clinicaltrials.gov:NCT07508124","description":"Urinary Tract Infection","metadata":null},{"id":"44cb3d751810462683af4f2e2bd47429","type":"TRIAL","name":"Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT01233570","description":"Crohn Disease","metadata":null},{"id":"c4cdc8886310494b9f7c9e78640862bb","type":"TRIAL","name":"Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions","canonical_id":"clinicaltrials.gov:NCT04071756","description":"Solid Tumor; Hand-Foot Skin Reaction (HFSR)","metadata":null},{"id":"8267a2f9de3847e8979e3a6b553ce333","type":"TRIAL","name":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back","canonical_id":"clinicaltrials.gov:NCT00783965","description":"Skin Carcinoma","metadata":null},{"id":"1f7b399bda074fa8a83f2dcce11c9b9f","type":"TRIAL","name":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face","canonical_id":"clinicaltrials.gov:NCT00489086","description":"Neoplastic Syndrome","metadata":null},{"id":"5a5860a8eeae41d0b2b1cdb697d1ddf3","type":"TRIAL","name":"Topical Timolol Benefit in Venous Ulcers","canonical_id":"clinicaltrials.gov:NCT02422017","description":"Venous Leg Ulcers","metadata":null},{"id":"f7881e2043c740da99f411d88086d704","type":"TRIAL","name":"Topical Timolol Gel for the Treatment of Infantile Hemangiomas","canonical_id":"clinicaltrials.gov:NCT02145884","description":"Hemangioma","metadata":null},{"id":"529e560838694c81a4b43ed51e4bd870","type":"TRIAL","name":"Topical Tranexamic Acid Spray Versus No Spray on Postoperative Outcomes Following Mesh Repair of Umbilical Hernia","canonical_id":"clinicaltrials.gov:NCT07845370","description":"Umbilical Hernia Repair","metadata":null},{"id":"c26ac79f76dc4f3e8a8f5dd5f05340fa","type":"TRIAL","name":"Topical Treatment of Under Eye Dark Circles and Swelling","canonical_id":"clinicaltrials.gov:NCT01172522","description":"Edema","metadata":null},{"id":"cd0fc5233c384faeb840f92b80661508","type":"TRIAL","name":"Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.","canonical_id":"clinicaltrials.gov:NCT07778472","description":"Healthy","metadata":null},{"id":"c0e8efbd5d9b48ec976c6588569e9679","type":"TRIAL","name":"Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01789047","description":"Idiopathic Parkinson's Disease; Drug Induced Dyskinesia","metadata":null},{"id":"0fca5831a67047dbad4db0b359d85481","type":"PROTEIN","name":"Topoisomeraze 4","canonical_id":"uniprot:P0C1U9","description":null,"metadata":null},{"id":"8a582cbd5ced45cda4cd64f536b4f6d0","type":"PROTEIN","name":"Topoisomeraze 4","canonical_id":"uniprot:P72525","description":null,"metadata":null},{"id":"e8ae54ccfddb42f0b9c7d404e45b9e95","type":"GO_TERM","name":"Tor2-Mei2-Ste11 complex","canonical_id":"go:GO:0034064","description":"\"A protein complex that contains the transcription factor Ste11 and the RNA binding protein Mei2; involved in regulation of conjugation in fission yeast.\" [GOC:vw, PMID:17046992]","metadata":null},{"id":"672cc68c874143998cab2bb55300b19f","type":"TRIAL","name":"Toradol (Ketorolac) in Breast Surgery to Reduce Pain & Opioid Use","canonical_id":"clinicaltrials.gov:NCT04439396","description":"Breast Reduction; Breast Reconstruction","metadata":null},{"id":"12d2d428c7884583819d24db1d3acc51","type":"TRIAL","name":"TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.","canonical_id":"clinicaltrials.gov:NCT06117722","description":"Chronic Heart Failure","metadata":null},{"id":"f66d179ecbce479fbab6e3155b675987","type":"DISEASE","name":"Toriello-Lacassie-Droste syndrome","canonical_id":"mondo:0010854","description":null,"metadata":null},{"id":"12e42435f1824aeeb64ce653a6e24466","type":"TRIAL","name":"Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study","canonical_id":"clinicaltrials.gov:NCT04190745","description":"Gastric Adenocarcinoma","metadata":null},{"id":"ead762b1bdcd4d238e0fe76fdd8db4bb","type":"TRIAL","name":"Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT04988191","description":"Colorectal Carcinoma","metadata":null},{"id":"88530cbf5d504391907ef101df9e6675","type":"TRIAL","name":"Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT04926532","description":"Hepatocellular Carcinoma","metadata":null},{"id":"5c5522236ea745d1aa123ce2f34621e6","type":"TRIAL","name":"Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00240565","description":"Lymphoma, Non-Hodgkin","metadata":null},{"id":"a6061d4b9e224ec28b32c721882f2c7b","type":"TRIAL","name":"Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission","canonical_id":"clinicaltrials.gov:NCT00476047","description":"Lymphoid Leukemia in Remission; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma","metadata":null},{"id":"bfb50cd6d1ff4c7d8d63b45398c60976","type":"TRIAL","name":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","canonical_id":"clinicaltrials.gov:NCT04083183","description":"Non-Malignant Neoplasm","metadata":null},{"id":"9db0ab3d417e43a4892bfd5bf4e1e85b","type":"TRIAL","name":"Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia","canonical_id":"clinicaltrials.gov:NCT04262843","description":"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome","metadata":null},{"id":"28421f4c01db4dacb94da783b7f30609","type":"TRIAL","name":"Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT07582172","description":"Acute Myeloid Leukemia With Complex Karyotype; Myelodysplastic Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Secondary Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome; Refractory Secondary Acute Myeloid Leukemia","metadata":null},{"id":"0f0ac2a45153485d8a02063c878cc6eb","type":"TRIAL","name":"Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer","canonical_id":"clinicaltrials.gov:NCT07810114","description":"Rectal Cancer","metadata":null},{"id":"34a57b753ea0475eae86c3bff23c378a","type":"TRIAL","name":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","canonical_id":"clinicaltrials.gov:NCT03117751","description":"Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma","metadata":null},{"id":"0ec78331948b47a8870cf5bfd18b6997","type":"DISEASE","name":"Tourette syndrome","canonical_id":"mondo:0007661","description":null,"metadata":null},{"id":"bbdf164e0ad14a0eb6f406d378aefb93","type":"DISEASE","name":"Tourette\u2019s Disorder","canonical_id":"mesh:D005879","description":null,"metadata":null},{"id":"f98e595bd62e4edc91c157ade787fad8","type":"DRUG","name":"Tovorafenib","canonical_id":"ncit:C106254","description":null,"metadata":null},{"id":"77d5f1012c1b48e9b85280f8237b15dc","type":"TRIAL","name":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","canonical_id":"clinicaltrials.gov:NCT04366518","description":"Hallucinations, Auditory; Psychosis","metadata":null},{"id":"0cac98b3b28d4c8ea5119eb0c621e928","type":"TRIAL","name":"Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders","canonical_id":"clinicaltrials.gov:NCT03294525","description":"Affective Disorder","metadata":null},{"id":"73a1d6ccde7241d2b80e48d72bc6c812","type":"TRIAL","name":"Towards Personalized Dosing of Natalizumab in Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT03516526","description":"Multiple Sclerosis","metadata":null},{"id":"1fc15db6614b48048a3cfe43358a4f4a","type":"DISEASE","name":"Toxic effect of arsenic AND/OR its compounds","canonical_id":"mesh:D020261","description":null,"metadata":null},{"id":"79246c643c624cc6acd81515c46f7781","type":"TRIAL","name":"Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy","canonical_id":"clinicaltrials.gov:NCT00147355","description":"HIV Infections","metadata":null},{"id":"190ca8b5e63a41208f936be47859b0a9","type":"PROTEIN","name":"Toxin B","canonical_id":"uniprot:P18177","description":null,"metadata":null},{"id":"e33afaca7d3448f1a7fc0d6218ee05d4","type":"DISEASE","name":"Toxoplasmosis","canonical_id":"mesh:D014123","description":null,"metadata":null},{"id":"fd76932223e84b2b99c0e922cc57a5b5","type":"GO_TERM","name":"Tpg-containing telomere binding complex","canonical_id":"go:GO:0043769","description":"\"A complex composed of four polypeptides, a telomere-protecting terminal protein (Tpg), a telomere-associated protein (Tap), DNA polymerase (PolA) and topoisomerase I (TopA), that functions in the replication of the telomeric regions of linear chromosomes, plasmids and circular replicons of some bacterial species.\" [PMID:15353591]","metadata":null},{"id":"7e1a39e483b04e5ebcbea86cec8c4ef1","type":"DRUG","name":"Trabectedin","canonical_id":"mesh:C099150","description":null,"metadata":null},{"id":"08da7a218f2b4a85991ef93e2e665071","type":"TRIAL","name":"Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma","canonical_id":"clinicaltrials.gov:NCT03437070","description":"Leiomyosarcoma","metadata":null},{"id":"9a2ad93ebf824740a415430a09402ce0","type":"DISEASE","name":"Trachoma","canonical_id":"mesh:D014141","description":null,"metadata":null},{"id":"61fc12b564bf489d8dda6101d4036feb","type":"TRIAL","name":"Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle","canonical_id":"clinicaltrials.gov:NCT04935073","description":"Infertility, Female","metadata":null},{"id":"ada67543b6664f9d8a16f48c01779698","type":"TRIAL","name":"Traditional Clomiphene Citrate Administration vs. Stair-step Approach","canonical_id":"clinicaltrials.gov:NCT01008319","description":"Ovulatory Dysfunction; Anovulation; Ovulation Induction","metadata":null},{"id":"b8c2745805094d0b98c93935ba360209","type":"TRIAL","name":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","canonical_id":"clinicaltrials.gov:NCT03500328","description":"Multiple Sclerosis, Relapsing-Remitting","metadata":null},{"id":"b8a13a9f46c94b08a855553ca794c030","type":"TRIAL","name":"Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).","canonical_id":"clinicaltrials.gov:NCT03526861","description":"Atopic Dermatitis","metadata":null},{"id":"b6841d969ac64436870ca41db79e2d51","type":"TRIAL","name":"Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)","canonical_id":"clinicaltrials.gov:NCT05388760","description":"Atopic Dermatitis","metadata":null},{"id":"734b3a56c1b140029e578de4d29d6f81","type":"TRIAL","name":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","canonical_id":"clinicaltrials.gov:NCT03131648","description":"Atopic Dermatitis","metadata":null},{"id":"ae6bc83c77054cbcb9c36854f0a4b46a","type":"TRIAL","name":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","canonical_id":"clinicaltrials.gov:NCT03160885","description":"Atopic Dermatitis","metadata":null},{"id":"146f1d28f5f54d378da1824ee7d3edec","type":"TRIAL","name":"Tralokinumab for Dupilumab Failures","canonical_id":"clinicaltrials.gov:NCT06773455","description":"Atopic Dermatitis","metadata":null},{"id":"67cb72144ad8481f9ae75ec0f4df09ea","type":"TRIAL","name":"Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3","canonical_id":"clinicaltrials.gov:NCT03363854","description":"Atopic Dermatitis","metadata":null},{"id":"591a39e1509a4f4dbba926020e803dff","type":"TRIAL","name":"Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04587453","description":"Atopic Dermatitis","metadata":null},{"id":"0fb986bd04074faeb2d5b5a5ce470c17","type":"TRIAL","name":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","canonical_id":"clinicaltrials.gov:NCT03761537","description":"Atopic Dermatitis","metadata":null},{"id":"3a1878bafc634ae39808474cccefd55b","type":"TRIAL","name":"Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction","canonical_id":"clinicaltrials.gov:NCT03714672","description":"Acute Pain","metadata":null},{"id":"c022141b92194767a1a678b79dabd00c","type":"DRUG","name":"Tramazoline","canonical_id":"mesh:C005370","description":null,"metadata":null},{"id":"a170487478094f7380997c432ca79ff0","type":"DRUG","name":"Trametinib","canonical_id":"ncit:C77908","description":null,"metadata":null},{"id":"32730a32483942b18ae55a3f9fa207db","type":"TRIAL","name":"Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01964924","description":"Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma","metadata":null},{"id":"de7dc6d552374578a53b46c743d7478d","type":"TRIAL","name":"Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors","canonical_id":"clinicaltrials.gov:NCT02079740","description":"Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm","metadata":null},{"id":"5f092efab5f7404a9030bf84448a1177","type":"TRIAL","name":"Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT02881242","description":"Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer","metadata":null},{"id":"9a9fcb4813d0478bb473d61ad2127a83","type":"TRIAL","name":"Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery","canonical_id":"clinicaltrials.gov:NCT02042443","description":"Adult Cholangiocarcinoma; Advanced Adult Hepatocellular Carcinoma; BCLC Stage C Adult Hepatocellular Carcinoma; BCLC Stage D Adult Hepatocellular Carcinoma; Hilar Cholangiocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Recurrent Adult Liver Carcinoma; Recurrent Childhood Liver Cancer; Recurrent Extrahepatic Bile Duct Carcinoma; Recurrent Gallbladder Carcinoma; Stage II Gallbladder Cancer; Stage III Childhood Hepatocellular Carcinoma; Stage IIIA Gallbladder Cancer; Stage IIIB Gallbla\u2026","metadata":null},{"id":"46ea45b6b8e44b6cb7ebb72530604bae","type":"TRIAL","name":"Trandolapril 4 mg Tablet Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00840632","description":"Healthy","metadata":null},{"id":"12b9fbcd103842d38b24c46fe157ef4e","type":"TRIAL","name":"Trandolapril 4 mg Tablet Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00840073","description":"Healthy","metadata":null},{"id":"a16e0b4bf5b442ed8366269a815b6ea0","type":"TRIAL","name":"Tranexamic Acid Injection With Different Drainage Clamping Time After Anterior Cruciate Ligament Reconstruction","canonical_id":"clinicaltrials.gov:NCT06280456","description":"Anterior Cruciate Ligament Reconstruction; Tranexamic Acid; Hemarthrosis, Knee","metadata":null},{"id":"54575aaa2a9d4500908e9fb847e7fc66","type":"TRIAL","name":"Tranexamic Acid Use in Acute Hip Fractures","canonical_id":"clinicaltrials.gov:NCT02947529","description":"Acute Hip Fractures","metadata":null},{"id":"d1c973b2dfa349529cf6ec46b78133ac","type":"TRIAL","name":"Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection","canonical_id":"clinicaltrials.gov:NCT01651182","description":"Cancer; Tumour; Surgery","metadata":null},{"id":"ae7d2af934434488b18a9e3bae93e99f","type":"TRIAL","name":"Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases","canonical_id":"clinicaltrials.gov:NCT04117243","description":"Post Partum Hemorrhage","metadata":null},{"id":"a10791c4bb28479084d4eb7947721d69","type":"TRIAL","name":"Tranexamic Acid Versus Vaginal Misoprostol in Abdominal Myomectomy","canonical_id":"clinicaltrials.gov:NCT04358965","description":"Myomectomy","metadata":null},{"id":"07eda24b483143db958f34e62be70741","type":"TRIAL","name":"Tranexamic Acid for Alloplastic Breast Reconstruction","canonical_id":"clinicaltrials.gov:NCT04918589","description":"Hematoma Postoperative; Breast Cancer; Tranexamic Acid","metadata":null},{"id":"222ab66b79c9495a8aca85a17ddade8e","type":"TRIAL","name":"Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery","canonical_id":"clinicaltrials.gov:NCT04863339","description":"Pituitary Tumor; Blood Loss; Surgery","metadata":null},{"id":"39de7fa244dd47b1ae4e18ed951bf409","type":"TRIAL","name":"Tranexamic Acid in Major Orthopedic Surgery: Comparison of 3 Dosage Regimen","canonical_id":"clinicaltrials.gov:NCT03573245","description":"Tranexamic Acid; Knee Osteoarthritis; Ankle Osteoarthritis; Bleeding","metadata":null},{"id":"4ed57557bbff44a781eedf5bfbabe426","type":"TRIAL","name":"Tranexamic Acid in Major Vascular Surgery","canonical_id":"clinicaltrials.gov:NCT02335359","description":"Blood Loss, Surgical","metadata":null},{"id":"2b81a9cf596c41ea882a47f456dd779c","type":"TRIAL","name":"Tranexamic Acid in Trauma Surgery Tranexamic Acid in Trauma Surgery Tranexamic Acid in Trauma Surgery","canonical_id":"clinicaltrials.gov:NCT04986813","description":"Tranexamic Acid; Trauma; Lower Extremity Fracture","metadata":null},{"id":"963afb1da3c641aa8cf4e3e867b11fb7","type":"TRIAL","name":"Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects","canonical_id":"clinicaltrials.gov:NCT06000423","description":"Bleeding; Contraceptive Device; Complications","metadata":null},{"id":"6d0b7b72d6964725ab64c1c3606e967f","type":"DRUG","name":"Tranilast","canonical_id":"mesh:C012293","description":null,"metadata":null},{"id":"4e34a61c2990411ea025fc76f0667f69","type":"TRIAL","name":"Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)","canonical_id":"clinicaltrials.gov:NCT01109121","description":"Moderate to Severe Gout; Hyperuricemia","metadata":null},{"id":"da416e6483df43e790efdb0880111e1d","type":"TRIAL","name":"Transcriptome and Metabolic Analyses of CHAPLE Disease","canonical_id":"clinicaltrials.gov:NCT03950804","description":"CD55 - Cluster of Differentiation Antigen 55 Deficiency; Primary Intestinal Lymphangiectasis; Protein-Losing Enteropathies; Complement Regulatory Factor Defect","metadata":null},{"id":"d68a84d820434cf8a0784e61610e62a3","type":"TRIAL","name":"Transcutaneous Electrical Acupoint Stimulation of P6 to Prevent Postoperation Nausea and Vomiting","canonical_id":"clinicaltrials.gov:NCT02096835","description":"Postoperative Nausea and Vomiting","metadata":null},{"id":"2755486def734c8d92cd44cb183c29db","type":"TRIAL","name":"Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT04207723","description":"Premature Ejaculation","metadata":null},{"id":"f6b18a88998d49949c7017fdb1a033ce","type":"TRIAL","name":"Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00224146","description":"Overactive Bladder; Urinary Incontinence; Quality of Life","metadata":null},{"id":"f848f7c8d77f4afd8677b54e88757fae","type":"TRIAL","name":"Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)","canonical_id":"clinicaltrials.gov:NCT00367822","description":"Restless Legs Syndrome","metadata":null},{"id":"7905e436ab8a47cc8b17a8321bec694b","type":"TRIAL","name":"Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)","canonical_id":"clinicaltrials.gov:NCT05790252","description":"Opioid Use Disorder; Pregnancy Related; Pregnancy, High Risk; Pregnancy Complications; Buprenorphine Withdrawal","metadata":null},{"id":"9fa167443d08439cad4d7831b2ca3cfc","type":"TRIAL","name":"Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder","canonical_id":"clinicaltrials.gov:NCT05886582","description":"Substance-Related Disorders","metadata":null},{"id":"43a9b6b0f10e4f91a8e8402cd568b0ac","type":"TRIAL","name":"Transdermal Versus Oral Oxybutynin in Pediatric OAB","canonical_id":"clinicaltrials.gov:NCT07081906","description":"Overactive Bladder (OAB); Drug Delivery Systems; Anticholinergic Side Effects; Children and Adolescents, Boys and Girls","metadata":null},{"id":"0c17ba2b5c3448e88e3e669c7638d95f","type":"TRIAL","name":"Transformation of Paralysis to Stepping","canonical_id":"clinicaltrials.gov:NCT04105114","description":"Spinal Cord Injuries","metadata":null},{"id":"fd94cea71cfa47c895c45ce54f48881f","type":"TRIAL","name":"Transgender Estradiol Affirming Therapy","canonical_id":"clinicaltrials.gov:NCT05010707","description":"Transgenderism","metadata":null},{"id":"9466b45985ea44ad9f5dab85518a0ea1","type":"PROTEIN","name":"Transient receptor potential cation channel subfamily V member 4","canonical_id":"uniprot:Q9HBA0","description":null,"metadata":null},{"id":"278fe9ac6fb54858a1b5c86e05a6e971","type":"TRIAL","name":"Transition From Alendronate to Romosozumab (AMG 785)","canonical_id":"clinicaltrials.gov:NCT01588509","description":"Osteoporosis","metadata":null},{"id":"6827bb2350704c5d8257e4ad57f86d29","type":"DISEASE","name":"Transitional cell carcinoma","canonical_id":"mesh:D002295","description":null,"metadata":null},{"id":"b9b5d9f41305494d8c0e0dd520896c22","type":"TRIAL","name":"Transitioning From Cyclosporine to Alefacept in Psoriasis","canonical_id":"clinicaltrials.gov:NCT00143806","description":"Psoriasis","metadata":null},{"id":"47ad0bb6fe0f4bd9ab54b1a08bd45030","type":"TRIAL","name":"Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.","canonical_id":"clinicaltrials.gov:NCT03047278","description":"Neuropathic Pain; Type 2 Diabetes Mellitus; Diabetic Neuropathy, Painful","metadata":null},{"id":"40edac678ca444468bc2c5f105b2fc8c","type":"PROTEIN","name":"Transthyretin","canonical_id":"uniprot:P02766","description":null,"metadata":null},{"id":"abe5ddfd03f24992b8befc8d6aa299a9","type":"TRIAL","name":"Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial","canonical_id":"clinicaltrials.gov:NCT01931215","description":"Postoperative Pain","metadata":null},{"id":"0575f3becc4c47709f05e94354777357","type":"DRUG","name":"Tranylcypromine","canonical_id":"mesh:D014191","description":null,"metadata":null},{"id":"5de1bb4605c34975abf65f986a46520c","type":"TRIAL","name":"Tranylcypromine Treatment of Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT01430455","description":"Bipolar Disorder I or II","metadata":null},{"id":"fc115106c99149afb05ed2a089a69782","type":"DRUG","name":"Trastuzumab","canonical_id":"ncit:C1647","description":null,"metadata":null},{"id":"6e6dbd4a42c843aa9a0f6c8082beed9d","type":"TRIAL","name":"Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients","canonical_id":"clinicaltrials.gov:NCT00428922","description":"Breast Cancer","metadata":null},{"id":"b72b45e29dc4445cae029d5cffa4b143","type":"TRIAL","name":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","canonical_id":"clinicaltrials.gov:NCT05063786","description":"Advanced Breast Cancer","metadata":null},{"id":"f8652a0c54a94c41b8f10b3903d017cc","type":"DRUG","name":"Trastuzumab Deruxtecan","canonical_id":"ncit:C128799","description":null,"metadata":null},{"id":"d176d642058345cda49d75a95ff12c28","type":"DRUG","name":"Trastuzumab Deruxtecan","canonical_id":"ncit:C152716","description":null,"metadata":null},{"id":"5e87cacbe8814fcbb5fc1ca871590a9c","type":"TRIAL","name":"Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT06085755","description":"Stomach Neoplasm","metadata":null},{"id":"3877246a81bb4da09aa8e3e37bef8fb0","type":"DRUG","name":"Trastuzumab Emtansine","canonical_id":"ncit:C82492","description":null,"metadata":null},{"id":"b52b45c3d3254abcb59f8651faaabbb0","type":"TRIAL","name":"Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer","canonical_id":"clinicaltrials.gov:NCT02004769","description":"Stomach Neoplasms; Neoplasms Metastasis; ERBB2 Gene Amplification","metadata":null},{"id":"195d5992ae7b40f987c539af10abf5ef","type":"TRIAL","name":"Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00674414","description":"Breast Cancer","metadata":null},{"id":"ebd3eec791794a7f89214b160f1495ae","type":"TRIAL","name":"Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00079326","description":"HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"e77cefb310c74bef8d10f2a2817e76e1","type":"TRIAL","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","canonical_id":"clinicaltrials.gov:NCT07506057","description":"Urothelial Carcinoma; Biliary Tract Cancer; HER2","metadata":null},{"id":"16fc456268ce49959859f50eb0691a46","type":"TRIAL","name":"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00077376","description":"HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"bef921b364d34ff99f8736db9d68c118","type":"TRIAL","name":"Trastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07857226","description":"Breast Cancer","metadata":null},{"id":"168c012275cd45b2a55dc1235492d0ff","type":"TRIAL","name":"Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX\u00ae): Efficacy and Safety Study (MEDITA)","canonical_id":"clinicaltrials.gov:NCT03585374","description":"Acute Traumatic Pain","metadata":null},{"id":"926163338b894773b18a55b0344a0286","type":"DRUG","name":"Travoprost","canonical_id":"mesh:D000069557","description":null,"metadata":null},{"id":"f8c47cd9544e491bb527323a496123de","type":"TRIAL","name":"Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)","canonical_id":"clinicaltrials.gov:NCT00762645","description":"Angle-closure Glaucoma","metadata":null},{"id":"57ca2a96c2bb46e98652b52e6dbe16cc","type":"TRIAL","name":"Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT","canonical_id":"clinicaltrials.gov:NCT00767494","description":"Glaucoma; Ocular Hypertension","metadata":null},{"id":"20f5ad37e0de4ce8b22efdcaac76bf0d","type":"TRIAL","name":"Trazodone Dose Tolerance and APAP Adherence","canonical_id":"clinicaltrials.gov:NCT02945644","description":"Sleep Apnea, Obstructive","metadata":null},{"id":"9ad8193e606344aa905a48c88775a9a0","type":"TRIAL","name":"Trazodone Once a Day in Major Depression Disorder","canonical_id":"clinicaltrials.gov:NCT02086929","description":"Major Depressive Disorder","metadata":null},{"id":"d9eb03ac9a774a7f838bf5e98dab9219","type":"TRIAL","name":"Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia","canonical_id":"clinicaltrials.gov:NCT00791739","description":"Fibromyalgia","metadata":null},{"id":"8ffbc9fd5a8e41a09bb2f4a9122fe240","type":"TRIAL","name":"Trazodone and the Risk of Serious Adverse Events","canonical_id":"clinicaltrials.gov:NCT07381101","description":"Chronic Kidney Disease (CKD); Older Adults (65 Years and Older)","metadata":null},{"id":"0f0204128ee840e09d659eafad9d38fc","type":"TRIAL","name":"Trazodone for SSRI-sexual Dsyfunction","canonical_id":"clinicaltrials.gov:NCT01097980","description":"Sexual Dysfunction","metadata":null},{"id":"275c8237ebd8457987a4131e97fd8b52","type":"TRIAL","name":"Trazodone for Sleep Disorders in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT01142258","description":"Sleep; Sleep Disorders; Insomnia; Alzheimer's Disease","metadata":null},{"id":"7d75c08fa1e646c383a38d2b500073e9","type":"TRIAL","name":"Trazodone for Sleep Disturbance in Early Alcohol Recovery","canonical_id":"clinicaltrials.gov:NCT00027053","description":"Alcoholism","metadata":null},{"id":"f93c571ab89346b5aa1d8e5f9d9d2f86","type":"TRIAL","name":"Trazodone on NREM Sleep Stage \u2162 in Depressed Insomniac Co-morbid Patients","canonical_id":"clinicaltrials.gov:NCT06740188","description":"Depressed Insomniac Co-morbid Patients","metadata":null},{"id":"215a18a0d2d04cb59d2fe75ff59c6a8e","type":"TRIAL","name":"Trazodone on OSA Endotypes","canonical_id":"clinicaltrials.gov:NCT06286189","description":"Obstructive Sleep Apnea","metadata":null},{"id":"ea53630bcc4d4be58563b16a2045e15e","type":"TRIAL","name":"Trazodone vs. Quetiapine for the Treatment of ICU Delirium","canonical_id":"clinicaltrials.gov:NCT05307003","description":"Delirium; Delirium of Mixed Origin; Delirium, Sepsis Associated; Delirium in Old Age; Delirium Confusional State; Psych; Morality; Treatment Side Effects","metadata":null},{"id":"ab61d944119041d88d676fd8cf16e288","type":"TRIAL","name":"Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy","canonical_id":"clinicaltrials.gov:NCT03749642","description":"Painful Diabetic Neuropathy","metadata":null},{"id":"5a3a9132b744449fb13820e1706062bf","type":"TRIAL","name":"Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)","canonical_id":"clinicaltrials.gov:NCT02575833","description":"Stable Angina","metadata":null},{"id":"06887fd0effe49fab059231d8f5464dd","type":"TRIAL","name":"Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial","canonical_id":"clinicaltrials.gov:NCT05610319","description":"Diabetic Macular Edema","metadata":null},{"id":"e503828bffb54c5bb8caf6211f60e09d","type":"TRIAL","name":"Treat COVID-19 Patients With Regadenoson","canonical_id":"clinicaltrials.gov:NCT04606069","description":"COVID-19; Lung Inflammation","metadata":null},{"id":"e0dec3ab37e7475cb13c5e4380d2eccd","type":"TRIAL","name":"Treat and Extend Analysis Trial With Aflibercept in Wet-AMD","canonical_id":"clinicaltrials.gov:NCT04113538","description":"Wet Age-related Macular Degeneration","metadata":null},{"id":"1628fb335a804395915e1a4a4d0d30ba","type":"TRIAL","name":"TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato\u00ae) on Patients Satisfaction","canonical_id":"clinicaltrials.gov:NCT04202445","description":"Actinic Keratosis","metadata":null},{"id":"c50003c459f64034826d181aa1f4be5c","type":"TRIAL","name":"Treating Acute MI Patients With Aggrastat on Their Way to Hospital","canonical_id":"clinicaltrials.gov:NCT00300833","description":"Acute Myocardial Infarction","metadata":null},{"id":"86ed03cd3c13462f8c2f16b419f830f4","type":"TRIAL","name":"Treating Acutely Agitated Patients With Asenapine Sublingual Tablets","canonical_id":"clinicaltrials.gov:NCT01400113","description":"Agitation","metadata":null},{"id":"13a9e6c3daa54be7afbd98cf19f310e7","type":"TRIAL","name":"Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure","canonical_id":"clinicaltrials.gov:NCT03879629","description":"Breast Cancer","metadata":null},{"id":"3745051c04ed4dd9ae78c75b051681c9","type":"TRIAL","name":"Treating Exacerbations of Asthma With Oral Montelukast in Children","canonical_id":"clinicaltrials.gov:NCT05819541","description":"Status Asthmaticus","metadata":null},{"id":"98cd019c0b14408a8a112a5d36a1f168","type":"TRIAL","name":"Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan","canonical_id":"clinicaltrials.gov:NCT05194111","description":"Heart Failure; Heart Dysfunction","metadata":null},{"id":"d56e94d2d92747b993a466d15c88a519","type":"TRIAL","name":"Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia","canonical_id":"clinicaltrials.gov:NCT05593653","description":"Insomnia; Metabolic Health; Menopause","metadata":null},{"id":"c462dcf5d4b74e68bddb50bfbb8e3faf","type":"TRIAL","name":"Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy","canonical_id":"clinicaltrials.gov:NCT05003648","description":"Adrenoleukodystrophy; Restless Legs Syndrome","metadata":null},{"id":"b8ebd79010754ee18914e569c8780af7","type":"TRIAL","name":"Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation","canonical_id":"clinicaltrials.gov:NCT05975307","description":"Muscle-Invasive Bladder Carcinoma; Programmed Cell Death Protein 1 Inhibitor; Radiotherapy","metadata":null},{"id":"b3b97e5e6ed14a9cafb7509bd3fec215","type":"TRIAL","name":"Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin","canonical_id":"clinicaltrials.gov:NCT05360953","description":"Posttraumatic Stress Disorder","metadata":null},{"id":"7bb33ccd70a7489498738da63314d603","type":"TRIAL","name":"Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy","canonical_id":"clinicaltrials.gov:NCT00331344","description":"Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"5ed6b96fea7743dd8a557206673ce29c","type":"TRIAL","name":"Treating Periodontal Infection: Effects on Glycemic","canonical_id":"clinicaltrials.gov:NCT00016835","description":"Periodontal Disease; Diabetes Mellitus, Type 2","metadata":null},{"id":"e6509c3a77c74f3591452a10897c7a15","type":"TRIAL","name":"Treating Respiratory Emergencies in Children Study","canonical_id":"clinicaltrials.gov:NCT06074185","description":"Asthma in Children","metadata":null},{"id":"f650cd56eca645c9beb546bbb59e71e0","type":"TRIAL","name":"Treating Schizophrenia by Correcting Abnormal Brain Development","canonical_id":"clinicaltrials.gov:NCT00179465","description":"Schizophrenia","metadata":null},{"id":"a6004372e8a34ab19bc028d3fe9770a5","type":"TRIAL","name":"Treating Severe Brain-injured Patients With Apomorphine","canonical_id":"clinicaltrials.gov:NCT03623828","description":"Disorder of Consciousness","metadata":null},{"id":"07ae399c4e094b08b54836a5dbf34697","type":"TRIAL","name":"Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon","canonical_id":"clinicaltrials.gov:NCT00907595","description":"Huntington's Disease; Parkinson's Disease; Dementia With Lewy Bodies; Sleep Disorders; Circadian Dysregulation","metadata":null},{"id":"4c2f1e0124af4c87b33610b5a3a8c04b","type":"TRIAL","name":"Treating Smokeless Tobacco Use in Rural Veterans","canonical_id":"clinicaltrials.gov:NCT02994082","description":"Smokeless Tobacco; Nicotine Dependence","metadata":null},{"id":"19a611ea453344c5a4fea400451891ed","type":"TRIAL","name":"Treating Young Children With Attention Deficit Hyperactivity Disorder","canonical_id":"clinicaltrials.gov:NCT07300956","description":"Attention-Deficit/Hyperactivity Disorder (ADHD)","metadata":null},{"id":"5f620293a3c74c8588773469f0634967","type":"TRIAL","name":"Treatment Compliance in Children and Adolescents on ADHD Medication","canonical_id":"clinicaltrials.gov:NCT00540826","description":"ADHD","metadata":null},{"id":"f9c98360f71e4336ab8038bafab3bc3b","type":"TRIAL","name":"Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'hor\u00e1n","canonical_id":"clinicaltrials.gov:NCT03877120","description":"Alcohol Withdrawal Delirium","metadata":null},{"id":"7da68dc0b5a64fb196b3163d35dc4479","type":"TRIAL","name":"Treatment Of Chronic Anal Fissure","canonical_id":"clinicaltrials.gov:NCT02158013","description":"Chronic Anal Fissure","metadata":null},{"id":"27cc09abfec042baacd65fbc8bd44712","type":"TRIAL","name":"Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain","canonical_id":"clinicaltrials.gov:NCT00256932","description":"Bowel Dysfunction; Constipation","metadata":null},{"id":"4ef47a00840a466b8118034cdbfde665","type":"TRIAL","name":"Treatment Of Patients With Social Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT00397722","description":"Social Phobia","metadata":null},{"id":"233c711189be466788d8e696329d174c","type":"TRIAL","name":"Treatment Outcome of Vascular Depression","canonical_id":"clinicaltrials.gov:NCT00045773","description":"Depressive Disorder; Depression","metadata":null},{"id":"b86ce076ae874e3a802596feea9126ae","type":"TRIAL","name":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","canonical_id":"clinicaltrials.gov:NCT05022563","description":"Venous Thromboembolism","metadata":null},{"id":"64530b412c6847b59b53114cdc67e65a","type":"TRIAL","name":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","canonical_id":"clinicaltrials.gov:NCT03602508","description":"Overactive Bladder (OAB)","metadata":null},{"id":"89235bfcb1ae4937aa6e97bddb478abc","type":"TRIAL","name":"Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT03231709","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"310fe898bdea4fab8e0535f8c71c67a4","type":"TRIAL","name":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","canonical_id":"clinicaltrials.gov:NCT06175702","description":"Lymphoblastic Leukemia; Philadelphia-Positive ALL; Adult ALL","metadata":null},{"id":"ba3d9abbc3b642f98ae0a9d8c4a603ad","type":"TRIAL","name":"Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT04220203","description":"HER2-positive Breast Cancer","metadata":null},{"id":"d07a285b0c4c49a598e40e8f47597ab7","type":"TRIAL","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","canonical_id":"clinicaltrials.gov:NCT03206671","description":"Mature B-cell Non-Hodgkin Lymphoma","metadata":null},{"id":"22df2beba0364d748497bfa299671627","type":"TRIAL","name":"Treatment Regimens in Meibomian Gland Dysfunction","canonical_id":"clinicaltrials.gov:NCT05594745","description":"Dry Eye Syndromes","metadata":null},{"id":"3a3855d5b10248a5a7eeb220a5904f7d","type":"TRIAL","name":"Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea","canonical_id":"clinicaltrials.gov:NCT03271554","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"cc25bc5410414926af9390755a76d6ff","type":"TRIAL","name":"Treatment Resistant Depression (Pilot)","canonical_id":"clinicaltrials.gov:NCT01179009","description":"Depressive Disorder, Treatment-Resistant","metadata":null},{"id":"731c36908f1845dcb397c748c549fd4f","type":"TRIAL","name":"Treatment Strategies for Children With Smith-Magenis Syndrome","canonical_id":"clinicaltrials.gov:NCT00506259","description":"Developmental Delay Disorders; Chromosome Deletion; Mental Retardation; Sleep Disorders, Circadian Rhythm; Self Injurious Behavior","metadata":null},{"id":"4c44e54823164f678e501f4d6e69a26c","type":"TRIAL","name":"Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement","canonical_id":"clinicaltrials.gov:NCT05789017","description":"Autoimmune Diseases","metadata":null},{"id":"36044646d05547d5b6cd43c6260d3ab9","type":"TRIAL","name":"Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine","canonical_id":"clinicaltrials.gov:NCT01401491","description":"Schizophrenia","metadata":null},{"id":"47d85aa7784d47c3bd14d48fb254aeb1","type":"TRIAL","name":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","canonical_id":"clinicaltrials.gov:NCT02282085","description":"Schizophrenia","metadata":null},{"id":"966211aa42684921a85291c1f9ef59b2","type":"TRIAL","name":"Treatment Targets for Chronic Hypertension in Pregnancy","canonical_id":"clinicaltrials.gov:NCT00194974","description":"Pregnancy Toxemia; Hypertension; Proteinuria","metadata":null},{"id":"8fb7e6e559da48679e685538ea88d164","type":"TRIAL","name":"Treatment Use of Domperidone for Gastroparesis","canonical_id":"clinicaltrials.gov:NCT02227927","description":"Gastroesophageal Reflux Disease; GERD; Gastroparesis","metadata":null},{"id":"18f842b40e944241a3b687a3da567038","type":"TRIAL","name":"Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation","canonical_id":"clinicaltrials.gov:NCT00396383","description":"Multiple Myeloma","metadata":null},{"id":"ecf21d037e034338a38306a59ea2f80c","type":"TRIAL","name":"Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT01098383","description":"Autism","metadata":null},{"id":"57493a946fe34d79a3cdee210aea83be","type":"TRIAL","name":"Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension","canonical_id":"clinicaltrials.gov:NCT04972656","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"5b11fcd2730447faa7d19de2478042d6","type":"TRIAL","name":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","canonical_id":"clinicaltrials.gov:NCT07042295","description":"Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma","metadata":null},{"id":"9bc3b2fc99254884ae2b0b73ad946347","type":"TRIAL","name":"Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma","canonical_id":"clinicaltrials.gov:NCT05080790","description":"Leiomyosarcoma","metadata":null},{"id":"3238185e5ebc43b9810364811f58e00b","type":"TRIAL","name":"Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)","canonical_id":"clinicaltrials.gov:NCT04385277","description":"Ganglioneuroblastoma, Nodular; Neuroblastoma","metadata":null},{"id":"1b0b5c1cabeb4cbca47fd7bc03a623b0","type":"TRIAL","name":"Treatment With Leflunomide in Patients With Polymyalgia Rheumatica","canonical_id":"clinicaltrials.gov:NCT03576794","description":"Polymyalgia Rheumatica","metadata":null},{"id":"4689784f6d6d4fa1bfa6ce04ce02ae25","type":"TRIAL","name":"Treatment With Lorcaserin for Cocaine Use: The TLC Study","canonical_id":"clinicaltrials.gov:NCT03192995","description":"Cocaine Use Disorder","metadata":null},{"id":"f5bf6e4bd48649e8b17d0922b9b809ef","type":"TRIAL","name":"Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)","canonical_id":"clinicaltrials.gov:NCT00060476","description":"Prostate Cancer","metadata":null},{"id":"3fbbc192ae3b43469b59f5aebc0244c7","type":"TRIAL","name":"Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients","canonical_id":"clinicaltrials.gov:NCT00342563","description":"Alcoholism","metadata":null},{"id":"85f377a3318b4461881dccd9c2ef3d17","type":"TRIAL","name":"Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome","canonical_id":"clinicaltrials.gov:NCT03117517","description":"Polycystic Ovarian Syndrome","metadata":null},{"id":"c2ab189ec2924ee7a170a0d58bbd8e27","type":"TRIAL","name":"Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus","canonical_id":"clinicaltrials.gov:NCT02388997","description":"Asthma","metadata":null},{"id":"933c798096cd4418a5f9deaf8642f07e","type":"TRIAL","name":"Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI","canonical_id":"clinicaltrials.gov:NCT05101018","description":"Osteoporosis; Spinal Cord Injuries","metadata":null},{"id":"d5b6e8888b3f415f89e220994b763c45","type":"TRIAL","name":"Treatment With TNF Blockade, Infliximab, in Patients With Myositis","canonical_id":"clinicaltrials.gov:NCT00443222","description":"Refractory Myositis","metadata":null},{"id":"099c93e4f5804c23824cb1d0a6f43705","type":"TRIAL","name":"Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism","canonical_id":"clinicaltrials.gov:NCT01817894","description":"Hirsutism","metadata":null},{"id":"0940c67a1618488d8d99c8b78444672d","type":"TRIAL","name":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05041842","description":"Metastatic Breast Cancer With a Isolated Brain Progression","metadata":null},{"id":"dacb869d216347b0933260ab5f023fb9","type":"TRIAL","name":"Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)","canonical_id":"clinicaltrials.gov:NCT00224874","description":"Graft vs Host Disease; Immune System Disorders","metadata":null},{"id":"36f78214ce7b464eb9b9f5d7ac6c55c5","type":"TRIAL","name":"Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT07393555","description":"Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"a4edc8cf9cf141359942ee667ac870de","type":"TRIAL","name":"Treatment for Anxiety in Children","canonical_id":"clinicaltrials.gov:NCT00000389","description":"Obsessive-Compulsive Disorder; Anxiety Disorders; Generalized Anxiety Disorder; Social Phobia; Separation Anxiety","metadata":null},{"id":"7ed85459b83f4b5b9cf0f67b49cbe3c0","type":"TRIAL","name":"Treatment for Nicotine Addiction in Women","canonical_id":"clinicaltrials.gov:NCT02448654","description":"Nicotine Dependence","metadata":null},{"id":"7bce50823b1945c2ac69ce5f29353399","type":"TRIAL","name":"Treatment for Opioid Dependent Offenders","canonical_id":"clinicaltrials.gov:NCT01082679","description":"Opioid Dependence","metadata":null},{"id":"36cab71d53b44870949a8147978e3a02","type":"TRIAL","name":"Treatment for Patients With Osteoarthritis (OA) of the Knee","canonical_id":"clinicaltrials.gov:NCT00110916","description":"Osteoarthritis","metadata":null},{"id":"eaf737fcf2b64115ac21c7f4989d07cb","type":"TRIAL","name":"Treatment for Post Acute COVID-19 Syndrome","canonical_id":"clinicaltrials.gov:NCT05507372","description":"Tinnitus, Subjective","metadata":null},{"id":"ea72f69336364c1b8400010ba819b283","type":"TRIAL","name":"Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors","canonical_id":"clinicaltrials.gov:NCT03205228","description":"Globus","metadata":null},{"id":"7918d2aee3a24c76b215b45810797619","type":"TRIAL","name":"Treatment of ACuTe Coronary Syndromes With Low-dose colchICine","canonical_id":"clinicaltrials.gov:NCT06215989","description":"Acute Coronary Syndrome; Unstable Angina; ST Elevation Myocardial Infarction; Non ST Segment Elevation Myocardial Infarction; Colchicine","metadata":null},{"id":"2b00a119ceaa49a881adccf1ee995f10","type":"TRIAL","name":"Treatment of ARDS With Sivelestat Sodium","canonical_id":"clinicaltrials.gov:NCT04909697","description":"Acute Respiratory Distress Syndrome","metadata":null},{"id":"b27a67f7ff4c4e418ef6c28547f22671","type":"TRIAL","name":"Treatment of Actinic Keratoses (AK) on the Face","canonical_id":"clinicaltrials.gov:NCT02411851","description":"Actinic Keratoses","metadata":null},{"id":"cd5bf30fb83148a38f0b9fdb4a500b98","type":"TRIAL","name":"Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%","canonical_id":"clinicaltrials.gov:NCT00595543","description":"Acute Pseudophakic Cystoid Macular Edema","metadata":null},{"id":"dd5116a496e048069a7da0c91832c719","type":"TRIAL","name":"Treatment of Adiposity Related hypErTension (TARGET)","canonical_id":"clinicaltrials.gov:NCT01138423","description":"Hypertension; Abdominal Obesity; Metabolic Syndrome","metadata":null},{"id":"84c1bc8613cd4faa8cd6578f884f7ff5","type":"TRIAL","name":"Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome","canonical_id":"clinicaltrials.gov:NCT03090620","description":"Anticholinergics Toxicity","metadata":null},{"id":"7dc04a5990844fc1b7bbfe805f042654","type":"TRIAL","name":"Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar","canonical_id":"clinicaltrials.gov:NCT00174226","description":"Attention Deficit Disorder With Hyperactivity","metadata":null},{"id":"77be9f61538d411ca3b6d5dbc43c8239","type":"TRIAL","name":"Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)","canonical_id":"clinicaltrials.gov:NCT02640573","description":"Hemoglobin SC Disease","metadata":null},{"id":"dc4116c617994fb58b2a3b66967e4c0b","type":"TRIAL","name":"Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT04522622","description":"Adynamic Bone Disease; Chronic Kidney Diseases; Cardiac Disease; Chronic Kidney Disease-Mineral and Bone Disorder","metadata":null},{"id":"b8b3fe5244854caf839dce8b8dcb0e0a","type":"TRIAL","name":"Treatment of Apomorphine-induced Skin Reactions: a Pilot Study","canonical_id":"clinicaltrials.gov:NCT02230930","description":"Parkinson's Disease; Apomorphine-induced Skin Reactions","metadata":null},{"id":"017291208cad43a6a024a190f215bef4","type":"TRIAL","name":"Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes","canonical_id":"clinicaltrials.gov:NCT00510276","description":"Attention Deficit Hyperactivity Disorder","metadata":null},{"id":"7ccca24f73594c15911e6680b32ff7fd","type":"TRIAL","name":"Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients","canonical_id":"clinicaltrials.gov:NCT00975000","description":"Chronic Allograft Nephropathy; Chronic Kidney Disease; Chronic Renal Failure; Disordered Mineral Metabolism; End Stage Renal Disease; Hyperparathyroidism; Hypophosphatemia; Kidney Disease; Kidney Transplantation; Post Renal Transplantation","metadata":null},{"id":"99c98a03fcc74fb1a4d2983b744ccb33","type":"TRIAL","name":"Treatment of Behavioral Symptoms in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT00009217","description":"Alzheimer's Disease; Psychosis; Agitation","metadata":null},{"id":"6f9ef5f70b604ec1a6de2ac1dc0e03dd","type":"TRIAL","name":"Treatment of Binge Eating in Obese Patients in Primary Care","canonical_id":"clinicaltrials.gov:NCT00537810","description":"Obesity; Binge Eating","metadata":null},{"id":"850a01ec9b014b69ad789efb34a43b3f","type":"TRIAL","name":"Treatment of Boys With Precocious Puberty","canonical_id":"clinicaltrials.gov:NCT00001202","description":"Precocious Puberty","metadata":null},{"id":"f9107863131b428594da4dcf9b25ea13","type":"TRIAL","name":"Treatment of COVID-19 Patients With Anti-interleukin Drugs","canonical_id":"clinicaltrials.gov:NCT04330638","description":"COVID-19","metadata":null},{"id":"22e8c01d010f4c3f84fc4f46d65e5194","type":"TRIAL","name":"Treatment of Chemotherapy-related Hiccups With Baclofen","canonical_id":"clinicaltrials.gov:NCT03778281","description":"Hiccup","metadata":null},{"id":"44c71791d779478093c25c0100c1d85a","type":"TRIAL","name":"Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT00186966","description":"Acute Myeloid Leukemia","metadata":null},{"id":"27a72affe7ad453ab6f03f290d9c58cc","type":"TRIAL","name":"Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab","canonical_id":"clinicaltrials.gov:NCT07006532","description":"Kidney Transplant Rejection","metadata":null},{"id":"e60712db0ffa459591a162de31593364","type":"TRIAL","name":"Treatment of Chronic Laryngitis With Amitriptyline","canonical_id":"clinicaltrials.gov:NCT02552225","description":"Laryngeal Diseases","metadata":null},{"id":"5228d1801f0640eaa31b7d8d1b2d6e79","type":"TRIAL","name":"Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab","canonical_id":"clinicaltrials.gov:NCT01123356","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"e469757003774573ae04952eb4114059","type":"TRIAL","name":"Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy","canonical_id":"clinicaltrials.gov:NCT04152434","description":"Refractory Chronic Migraine","metadata":null},{"id":"42797b7fe8204221bc0587ea75447b49","type":"TRIAL","name":"Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury","canonical_id":"clinicaltrials.gov:NCT00208572","description":"Traumatic Brain Injury","metadata":null},{"id":"0bf91c9105df4a73a80183f1d0819c3d","type":"TRIAL","name":"Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide","canonical_id":"clinicaltrials.gov:NCT00381589","description":"Hypersalivation","metadata":null},{"id":"744109a037df4cacb44a35ae00e542cb","type":"TRIAL","name":"Treatment of Cocaine Dependence With Lisdexamfetamine","canonical_id":"clinicaltrials.gov:NCT00958282","description":"Cocaine Dependence","metadata":null},{"id":"bed5e93d63f24bedbdc1db3b07eb8db7","type":"TRIAL","name":"Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss","canonical_id":"clinicaltrials.gov:NCT03139422","description":"Menorrhagia","metadata":null},{"id":"f01264b2d18a46ff8eae6b7b53c3b061","type":"TRIAL","name":"Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol","canonical_id":"clinicaltrials.gov:NCT00480883","description":"Leishmaniasis, Cutaneous","metadata":null},{"id":"c9bf069f3b38424093bde0855b5323a1","type":"TRIAL","name":"Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial","canonical_id":"clinicaltrials.gov:NCT01633593","description":"Elderly; Delirium of Unknown (Axis III) Etiology; Intensive Care (ICU) Myopathy","metadata":null},{"id":"83de2b182cc8473cb3a7a3d40e290026","type":"TRIAL","name":"Treatment of Depression Following Multiple Brain Tests","canonical_id":"clinicaltrials.gov:NCT00296777","description":"Major Depression; Dysthymia","metadata":null},{"id":"3b39551eaa404828a1a09b9c38890c35","type":"TRIAL","name":"Treatment of Depression in Parkinson's Disease Trial","canonical_id":"clinicaltrials.gov:NCT00062738","description":"Parkinson Disease; Depression","metadata":null},{"id":"a42dda60c5504baea7e625d99b28e221","type":"TRIAL","name":"Treatment of Depression in Youth With Bipolar Disorders","canonical_id":"clinicaltrials.gov:NCT00005015","description":"Bipolar Disorder; Depression","metadata":null},{"id":"2a9d59ee3cdc40c090ebc28df404f51a","type":"TRIAL","name":"Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)","canonical_id":"clinicaltrials.gov:NCT04014387","description":"Progressive Supranuclear Palsy(PSP); Insomnia","metadata":null},{"id":"2abf93e8595b4b059c858e0797b23145","type":"TRIAL","name":"Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)","canonical_id":"clinicaltrials.gov:NCT00259610","description":"Rheumatoid Arthritis","metadata":null},{"id":"365254607b6442bbb373525713949fbc","type":"TRIAL","name":"Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)","canonical_id":"clinicaltrials.gov:NCT00053703","description":"Schizophrenia","metadata":null},{"id":"87e4180d6180461a99829bfee49a8031","type":"TRIAL","name":"Treatment of Early Systemic Sclerosis by Bosentan","canonical_id":"clinicaltrials.gov:NCT00226889","description":"Systemic Sclerosis (Scleroderma)","metadata":null},{"id":"91a8007bb973407795bd48505e6af26c","type":"TRIAL","name":"Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost","canonical_id":"clinicaltrials.gov:NCT00216931","description":"Persistent Pulmonary Hypertension; Respiratory Distress Syndrome","metadata":null},{"id":"56952764e49345fe9b3d66f09b7eee0b","type":"TRIAL","name":"Treatment of Elevated Blood Pressures in Early Pregnancy","canonical_id":"clinicaltrials.gov:NCT05955040","description":"Elevated Blood Pressure; Pregnancy Induced Hypertension","metadata":null},{"id":"afe36723f9c548a5b11ae4e198d850ae","type":"TRIAL","name":"Treatment of Functional Bowel Disorders","canonical_id":"clinicaltrials.gov:NCT00006157","description":"Irritable Bowel Syndrome; Constipation; Abdominal Pain; Functional Colonic Diseases","metadata":null},{"id":"75bf9969f3e94c6da3b42d3c917570a6","type":"TRIAL","name":"Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab","canonical_id":"clinicaltrials.gov:NCT01784900","description":"Patients With Gastric Peritoneal Carcinomatosis","metadata":null},{"id":"639564256e324861aea2bf03ebe019a1","type":"TRIAL","name":"Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00128739","description":"Graft Vs Host Disease","metadata":null},{"id":"5ef3152aff2b4fdf9269dd01a40d4142","type":"TRIAL","name":"Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","canonical_id":"clinicaltrials.gov:NCT00177567","description":"Bipolar Disorder","metadata":null},{"id":"a5573d4d02f2426c9c7b5cb57b4fef07","type":"TRIAL","name":"Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole","canonical_id":"clinicaltrials.gov:NCT02727738","description":"Graves' Disease","metadata":null},{"id":"523a104c8c5a479387862a0f61cc2797","type":"TRIAL","name":"Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study","canonical_id":"clinicaltrials.gov:NCT03298867","description":"Thyroid Eye Disease; Graves' Orbitopathy","metadata":null},{"id":"591b48e7a89c4fe0b7c3f9ab1b3a4a95","type":"TRIAL","name":"Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study","canonical_id":"clinicaltrials.gov:NCT03461211","description":"Thyroid Eye Disease","metadata":null},{"id":"61987f89cc5d42d89a6e19663d33237e","type":"TRIAL","name":"Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause","canonical_id":"clinicaltrials.gov:NCT02943655","description":"Improve Quality of Life; Heavy Menstrual Bleeding","metadata":null},{"id":"b91c7d4530664059bba187f8e6c0eac9","type":"TRIAL","name":"Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS","canonical_id":"clinicaltrials.gov:NCT02048969","description":"Hepatic Encephalopathy; Liver Cirrhosis","metadata":null},{"id":"6fd7d2e953d14eb1b9412ca8d3d11d71","type":"TRIAL","name":"Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker","canonical_id":"clinicaltrials.gov:NCT00185120","description":"Hypertension","metadata":null},{"id":"76ceb16a5fec4256b99a520a901a5c17","type":"TRIAL","name":"Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)","canonical_id":"clinicaltrials.gov:NCT02864147","description":"Cervical Intraepithelial Neoplasia; Cervical Dysplasia","metadata":null},{"id":"50d4c95100014e0da9329d8dd2550b46","type":"TRIAL","name":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","canonical_id":"clinicaltrials.gov:NCT06282588","description":"Prostate Cancer","metadata":null},{"id":"c7c9ee436127410db9132b0f18228584","type":"TRIAL","name":"Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma","canonical_id":"clinicaltrials.gov:NCT01011751","description":"Adenocarcinoma, Prostate","metadata":null},{"id":"f5cbb8e446cf4279b6dd05ff92749da2","type":"TRIAL","name":"Treatment of Huntington's Chorea With Amantadine","canonical_id":"clinicaltrials.gov:NCT00001930","description":"Chorea; Huntington's Disease","metadata":null},{"id":"f1816c9c4e33414d9095462e74ca2b62","type":"TRIAL","name":"Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole","canonical_id":"clinicaltrials.gov:NCT03038308","description":"Hyperprolactinemia; Prolactinoma","metadata":null},{"id":"b825fcf6772a4524898a6bb01c57942c","type":"TRIAL","name":"Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study","canonical_id":"clinicaltrials.gov:NCT02591628","description":"Hypertension","metadata":null},{"id":"b89a648bcde3459c83cea2e8323add81","type":"TRIAL","name":"Treatment of Hypertension in Tibetan Adult Population","canonical_id":"clinicaltrials.gov:NCT02217852","description":"Hypertension","metadata":null},{"id":"a9cb80ba995b47b9831952e7733bf75f","type":"TRIAL","name":"Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery","canonical_id":"clinicaltrials.gov:NCT02487212","description":"Hypertrophic Scars","metadata":null},{"id":"c6ef105e8b6c4f49bd4368f166c2e095","type":"TRIAL","name":"Treatment of Hypoglycemia Following Gastric Bypass Surgery","canonical_id":"clinicaltrials.gov:NCT02527993","description":"Hypoglycemia; Obesity; Surgery","metadata":null},{"id":"9580de91bdd94c7d873ffac109920f7e","type":"TRIAL","name":"Treatment of Hypopigmented Scars With Bimatoprost","canonical_id":"clinicaltrials.gov:NCT06122090","description":"Scars; Hypopigmented Scar; Hypopigmented Skin; Burn Scar; Scarring; Cicatrix, Hypertrophic; Cicatrix; Pigmentation Disorder; Burns Laser","metadata":null},{"id":"9a412e526a764cde92662a1aedbbe261","type":"TRIAL","name":"Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT06807593","description":"Cancer","metadata":null},{"id":"9c794b4f3f7c41dda72503415afcb844","type":"TRIAL","name":"Treatment of Latent Autoimmune Diabetes of the Adult","canonical_id":"clinicaltrials.gov:NCT01140438","description":"Diabetes","metadata":null},{"id":"f6b8a6ac6432407183c985dfc11bd90c","type":"TRIAL","name":"Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","canonical_id":"clinicaltrials.gov:NCT01059552","description":"Locally Advanced Non-small Cell Lung Cancer","metadata":null},{"id":"3499d18d6b684953b0f1532faca34f69","type":"TRIAL","name":"Treatment of Low Bone Density in Cystic Fibrosis.","canonical_id":"clinicaltrials.gov:NCT01812551","description":"Osteoporosis; Cystic Fibrosis","metadata":null},{"id":"8a555cf6be7944ac9122212f66b16c08","type":"TRIAL","name":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT06035133","description":"Rectal Cancer","metadata":null},{"id":"6e184575c2844ed69da278f34f601f07","type":"TRIAL","name":"Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine","canonical_id":"clinicaltrials.gov:NCT00224302","description":"Psychotic Disorders","metadata":null},{"id":"3f56a192f6b84d29b326664dcadda5af","type":"TRIAL","name":"Treatment of Meniere's Disease With Migraine Medications","canonical_id":"clinicaltrials.gov:NCT05582837","description":"M\u00e9ni\u00e8re","metadata":null},{"id":"fd297e45cfa0458089f403ecbf2dae90","type":"TRIAL","name":"Treatment of Mild Hypertension Study (TOMHS)","canonical_id":"clinicaltrials.gov:NCT00000522","description":"Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases","metadata":null},{"id":"c962b26f5aac460d9b5665b6368f9cd6","type":"TRIAL","name":"Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury","canonical_id":"clinicaltrials.gov:NCT00735670","description":"Spinal Cord Injury","metadata":null},{"id":"b369f3de77164b298f5d0c5603865028","type":"TRIAL","name":"Treatment of Moderate Hidradenitis Suppurativa","canonical_id":"clinicaltrials.gov:NCT03910803","description":"Hidradenitis Suppurativa","metadata":null},{"id":"d7c2c341e0e741909d3d5de5f2d21fd1","type":"TRIAL","name":"Treatment of Mood and Marriage Study (TOMMS)","canonical_id":"clinicaltrials.gov:NCT00612807","description":"Major Depressive Disorder; Partner Relational Disorder (V61.10)","metadata":null},{"id":"2402e7c8c5254029801986e0fa5b5869","type":"TRIAL","name":"Treatment of Multiple Attacks of Acute Migraine (0462-025)","canonical_id":"clinicaltrials.gov:NCT00899379","description":"Migraine Headache","metadata":null},{"id":"9fd33ed006e3435187db8f4bfb8df87d","type":"TRIAL","name":"Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy","canonical_id":"clinicaltrials.gov:NCT03092011","description":"Neonatal Abstinence Syndrome","metadata":null},{"id":"fcd5c47a5d8140fbb4c6ff18fff34bd8","type":"TRIAL","name":"Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia","canonical_id":"clinicaltrials.gov:NCT06098833","description":"Neonatal Encephalopathy","metadata":null},{"id":"3dfa8a7521ff44acb58a7bce003cb933","type":"TRIAL","name":"Treatment of Neuroleptic Induced Acute Akathisia With Trazodone","canonical_id":"clinicaltrials.gov:NCT00659919","description":"Schizophrenia","metadata":null},{"id":"c7bbc796eb644c4db50d3bf1ed123f44","type":"TRIAL","name":"Treatment of Non-Cardiac Chest Pain With Imipramine or Cognitive-Behavioral Therapy","canonical_id":"clinicaltrials.gov:NCT00005575","description":"Chest Pain","metadata":null},{"id":"65923737924740708ca592d4c9e9a526","type":"TRIAL","name":"Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic","canonical_id":"clinicaltrials.gov:NCT02699125","description":"Obstructive Sleep Apnea","metadata":null},{"id":"9e79334ea95349708929f1fa34213b59","type":"TRIAL","name":"Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care","canonical_id":"clinicaltrials.gov:NCT00829283","description":"Obesity; Binge Eating","metadata":null},{"id":"8e91bb61d4e34d0db5d29c28f841d1c9","type":"TRIAL","name":"Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications","canonical_id":"clinicaltrials.gov:NCT04354545","description":"Glaucoma; Ocular Surface Disease","metadata":null},{"id":"958a5e2a69704772a99b9038faea5f4d","type":"TRIAL","name":"Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream","canonical_id":"clinicaltrials.gov:NCT00321750","description":"Oral Erosive Lichen Planus","metadata":null},{"id":"4787ebb4894b4ba7b342c54948424dcd","type":"TRIAL","name":"Treatment of Orthostatic Hypotension in Autonomic Failure","canonical_id":"clinicaltrials.gov:NCT00223691","description":"Autonomic Failure; Orthostatic Hypotension","metadata":null},{"id":"de0e22dd9ffe478ba31471716bea9a7d","type":"TRIAL","name":"Treatment of Orthostatic Intolerance","canonical_id":"clinicaltrials.gov:NCT00262470","description":"Tachycardia; Chronic Orthostatic Intolerance","metadata":null},{"id":"72d81409e9684ce0838526ce8a946dc7","type":"TRIAL","name":"Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil","canonical_id":"clinicaltrials.gov:NCT01219023","description":"Hand Foot Syndrome; Palmar Plantar Erythrodysesthesia","metadata":null},{"id":"fbae51f044dd4a69827a9fb607228e98","type":"TRIAL","name":"Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)","canonical_id":"clinicaltrials.gov:NCT00543387","description":"Cancer, Neoplasms, Tumors","metadata":null},{"id":"bd11a98adbd74ee8a994db56a9975ed9","type":"TRIAL","name":"Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro\u00ae As-needed Use","canonical_id":"clinicaltrials.gov:NCT02197598","description":"Alcohol Dependence","metadata":null},{"id":"b0d6dba79b9a4fe18dd72ecacc1bb170","type":"TRIAL","name":"Treatment of Patients With Diabetic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT06187493","description":"Diabetic Kidney Disease","metadata":null},{"id":"53124a19f35841bcb838223ecefaa104","type":"TRIAL","name":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01679119","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"5846214cd8a844dc81fb547f5670e345","type":"TRIAL","name":"Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","canonical_id":"clinicaltrials.gov:NCT01086826","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"d6baf095aad44eecafa1ee10e0def7de","type":"TRIAL","name":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)","canonical_id":"clinicaltrials.gov:NCT00035009","description":"Major Depressive Disorder","metadata":null},{"id":"98f85616d6c541638180f490e91e59cb","type":"TRIAL","name":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)","canonical_id":"clinicaltrials.gov:NCT00034944","description":"Major Depressive Disorder","metadata":null},{"id":"4c500258eeaa4709854760dfe121bebe","type":"TRIAL","name":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)","canonical_id":"clinicaltrials.gov:NCT00042029","description":"Major Depressive Disorder","metadata":null},{"id":"d9b46078d9384601afca250fcbb2bf15","type":"TRIAL","name":"Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients","canonical_id":"clinicaltrials.gov:NCT04290429","description":"Graft Versus Host Disease","metadata":null},{"id":"fe5140ff87634fbba7d7422b4bb89270","type":"TRIAL","name":"Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)","canonical_id":"clinicaltrials.gov:NCT02945527","description":"Neurocysticercosis","metadata":null},{"id":"e3784365bc3f4162b60e8ee5ad9cbdff","type":"TRIAL","name":"Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.","canonical_id":"clinicaltrials.gov:NCT00149136","description":"Acute Lymphocytic Leukemia","metadata":null},{"id":"51bda12f5a9643aea9f50c9b579f48db","type":"TRIAL","name":"Treatment of Polydrug-Using Opiate Dependents During Withdrawal","canonical_id":"clinicaltrials.gov:NCT00367874","description":"Opiate Dependence; Drug Dependence; Substance Withdrawal Syndrome","metadata":null},{"id":"8963e9e137ea4a06b40b43fbc42ce24b","type":"TRIAL","name":"Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)","canonical_id":"clinicaltrials.gov:NCT04300881","description":"Vitreomacular Traction; Subretinal Edema","metadata":null},{"id":"a57b9a8bf1d643738d8ae89e03286e9d","type":"TRIAL","name":"Treatment of Post-Stroke Central Pain","canonical_id":"clinicaltrials.gov:NCT07593313","description":"Central Post-Stroke Pain","metadata":null},{"id":"91ca9b82d62347918c407aba40d916ee","type":"TRIAL","name":"Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate","canonical_id":"clinicaltrials.gov:NCT00120640","description":"Premature Birth; Premature Labor","metadata":null},{"id":"cdb15c4f9e8941f9a1ad02844d278e91","type":"TRIAL","name":"Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.","canonical_id":"clinicaltrials.gov:NCT03027557","description":"Primary Hyperparathyroidism; Parathyroid Adenoma; Parathyroid Hyperplasia","metadata":null},{"id":"82c514265a154ffaad2660d1606ab6f8","type":"TRIAL","name":"Treatment of Psychotic Major Depression With Mifepristone","canonical_id":"clinicaltrials.gov:NCT00867360","description":"Affective Disorders, Psychotic; Depressive Disorder","metadata":null},{"id":"0c96ccd06c74462ab52eb3543b50c095","type":"TRIAL","name":"Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents","canonical_id":"clinicaltrials.gov:NCT04718350","description":"Hypertension, Pulmonary; Cardiac Failure; Pulmonary Vascular Resistance Abnormality","metadata":null},{"id":"af5686d707014f83984f4840f072775c","type":"TRIAL","name":"Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E","canonical_id":"clinicaltrials.gov:NCT05710471","description":"Age-Related Macular Degeneration","metadata":null},{"id":"44edbb99484f4fc982fcb2e78c53d248","type":"TRIAL","name":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","canonical_id":"clinicaltrials.gov:NCT02634008","description":"Hepatitis C, Acute","metadata":null},{"id":"5d019b56f9664bf9b8f0d6d4aef215eb","type":"TRIAL","name":"Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab","canonical_id":"clinicaltrials.gov:NCT05737368","description":"Recurrent Glioblastoma","metadata":null},{"id":"8cd9c1c3bf9a4644ae589168552e9753","type":"TRIAL","name":"Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag","canonical_id":"clinicaltrials.gov:NCT04269889","description":"Anemia, Diamond-Blackfan","metadata":null},{"id":"daf2b46b484f4845bc442604a1f5da8f","type":"TRIAL","name":"Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)","canonical_id":"clinicaltrials.gov:NCT00651482","description":"Kidney Neoplasms; Kidney (Renal Cell) Cancer","metadata":null},{"id":"4b0f6fbc858d4d20ba8a4d183e80399d","type":"TRIAL","name":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03367572","description":"Breast Carcinoma","metadata":null},{"id":"2fe48ed2a11a482381d3b8209805bcd8","type":"TRIAL","name":"Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study","canonical_id":"clinicaltrials.gov:NCT02317679","description":"Port-wine Stains","metadata":null},{"id":"4dd63f15d4264431815de4ef57ca653b","type":"TRIAL","name":"Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD","canonical_id":"clinicaltrials.gov:NCT04759703","description":"Sleep Disorder; Restless Legs Syndrome; Opioid-use Disorder; Opioid Withdrawal","metadata":null},{"id":"fcbe4223eeb343d28d99cf1c8ab4f8da","type":"TRIAL","name":"Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant","canonical_id":"clinicaltrials.gov:NCT03755310","description":"Restless Legs Syndrome","metadata":null},{"id":"f49cc91ab71740fcaa985da02599e47f","type":"TRIAL","name":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","canonical_id":"clinicaltrials.gov:NCT03414502","description":"Rheumatoid Arthritis","metadata":null},{"id":"d4a19aac094c4927a285e8d6359f4b72","type":"TRIAL","name":"Treatment of Schizophrenic Patients With Ziprasidone","canonical_id":"clinicaltrials.gov:NCT00579670","description":"Schizophrenia","metadata":null},{"id":"c09594e657bf4b1ba9540b2714be34c2","type":"TRIAL","name":"Treatment of Seizures in Neonate With HIE","canonical_id":"clinicaltrials.gov:NCT07284498","description":"Neonatal Seizures; HIE - Hypoxic - Ischemic Encephalopathy","metadata":null},{"id":"274c4cdea11a4bcfa3d264a144bd2622","type":"TRIAL","name":"Treatment of Severe Infection With Antihyperlipidemia Drug","canonical_id":"clinicaltrials.gov:NCT03634293","description":"Sepsis; Septic Shock","metadata":null},{"id":"b5364fc141a743029184f4e6c33b9fa9","type":"TRIAL","name":"Treatment of Severe Influenza A Infection","canonical_id":"clinicaltrials.gov:NCT02108366","description":"Influenza, Human","metadata":null},{"id":"db9f679c8b7040579e70dbced81dda14","type":"TRIAL","name":"Treatment of Sleep Disturbances in Trauma-affected Refugees","canonical_id":"clinicaltrials.gov:NCT02761161","description":"Post Traumatic Stress Disorder; Depression","metadata":null},{"id":"55084d8c808749f3935ce7b2c8c485cf","type":"TRIAL","name":"Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT01427192","description":"Pulmonary Hypertension; Breathing-Related Sleep Disorder","metadata":null},{"id":"831fb526eb1f49a4b8b9e8eaf48e4fbc","type":"TRIAL","name":"Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron","canonical_id":"clinicaltrials.gov:NCT03612401","description":"Spinal Cord Injuries; Neurogenic Bladder; Cognitive Change","metadata":null},{"id":"28abf011b6e543aea1129878a254632b","type":"TRIAL","name":"Treatment of Supine Hypertension in Autonomic Failure","canonical_id":"clinicaltrials.gov:NCT00223717","description":"Hypertension","metadata":null},{"id":"8e996eed3f0043f19c76dc41aa60ff88","type":"TRIAL","name":"Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT00963703","description":"Rheumatoid Arthritis","metadata":null},{"id":"5bf1f1af9f2349dc844006ebcec1aad5","type":"TRIAL","name":"Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan","canonical_id":"clinicaltrials.gov:NCT01447550","description":"Thromboangiitis Obliterans","metadata":null},{"id":"041d6b64e52a4e11844f0e27b7b101b7","type":"TRIAL","name":"Treatment of Tinnitus With Migraine Medications","canonical_id":"clinicaltrials.gov:NCT04404439","description":"Tinnitus, Subjective; Tinnitus","metadata":null},{"id":"4076b9b760fc4b56a1f95b8922edfc54","type":"TRIAL","name":"Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser","canonical_id":"clinicaltrials.gov:NCT05335317","description":"Postmenopausal Period; Vaginal Atrophy; Vaginal Prolapse","metadata":null},{"id":"c0a64e351d004b52a98a8dc79bf59c1b","type":"TRIAL","name":"Treatment of Vascular Stiffness in ADPKD","canonical_id":"clinicaltrials.gov:NCT05228574","description":"Autosomal Dominant Polycystic Kidney","metadata":null},{"id":"a53077abfbe7489da879f7c9bc823b06","type":"TRIAL","name":"Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.","canonical_id":"clinicaltrials.gov:NCT07240389","description":"Vulvar Lichen Sclerosus","metadata":null},{"id":"8bb43004eba149ad9888d37eb7684d69","type":"TRIAL","name":"Treatment of Youth With ADHD and Anxiety","canonical_id":"clinicaltrials.gov:NCT00012584","description":"Attention Deficit Hyperactivity Disorder; Anxiety, Separation; Social Phobia; Generalized Anxiety Disorder","metadata":null},{"id":"6ab0e88fea4c4391833300c2dd747d68","type":"TRIAL","name":"Treatment of the Dumping Syndrome With Lanreotide Autogel\u00ae","canonical_id":"clinicaltrials.gov:NCT00543179","description":"Dumping Syndrome","metadata":null},{"id":"6661952b603f402aa2cd251b9681bd3e","type":"TRIAL","name":"Treatment to Quit Smoking","canonical_id":"clinicaltrials.gov:NCT00018161","description":"Smoking","metadata":null},{"id":"13ce3a351dd64c45b2c009efe58f071b","type":"TRIAL","name":"Treatment w/ Tri-Luma\u00ae Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma","canonical_id":"clinicaltrials.gov:NCT00669071","description":"Melasma","metadata":null},{"id":"a5a735346c7942e0a5d59cb2c605c3cf","type":"TRIAL","name":"Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study","canonical_id":"clinicaltrials.gov:NCT02452879","description":"Overactive Bladder","metadata":null},{"id":"97aedd862acb4e0dba80ae3271fe0bcc","type":"TRIAL","name":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","canonical_id":"clinicaltrials.gov:NCT01698905","description":"Chronic Myeloid Leukemia","metadata":null},{"id":"88c7c738257f40f482c944569ae8a4c0","type":"TRIAL","name":"Treatments for Insomnia in Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01489982","description":"Parkinson's Disease; Insomnia","metadata":null},{"id":"8d434008dc4244a29eeefd3fcc5a0635","type":"TRIAL","name":"Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma","canonical_id":"clinicaltrials.gov:NCT02794883","description":"Malignant Glioma; Recurrent Glioblastoma","metadata":null},{"id":"5651003004b54203bfb9e5f49ab935de","type":"DISEASE","name":"Treponemal Infections","canonical_id":"mesh:D014211","description":null,"metadata":null},{"id":"306f87fc9a2b4626b0b9c22999979937","type":"DRUG","name":"Treprostinil","canonical_id":"mesh:C427248","description":null,"metadata":null},{"id":"fd7609b0147c4f9e833b389f09db211a","type":"TRIAL","name":"Treprostinil Combined With Tadalafil for Pulmonary Hypertension","canonical_id":"clinicaltrials.gov:NCT01302444","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"b84f2f3b295a4a85a487b34d2bcba2b7","type":"TRIAL","name":"Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study","canonical_id":"clinicaltrials.gov:NCT03120533","description":"Scleroderma, Systemic","metadata":null},{"id":"b5ba5aded62848218a3db6968f20e2d9","type":"TRIAL","name":"Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome","canonical_id":"clinicaltrials.gov:NCT00002479","description":"Lymphoma","metadata":null},{"id":"c7d4167fda014ed29dbf204ac6b978de","type":"TRIAL","name":"Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine","canonical_id":"clinicaltrials.gov:NCT01300546","description":"Migraine","metadata":null},{"id":"feb5ec3147d64135bdd2b32dc06fe238","type":"TRIAL","name":"Treximet \u2122 Pharmacy Budget Impact Model Database Validation Study","canonical_id":"clinicaltrials.gov:NCT01332500","description":"Migraine Disorders","metadata":null},{"id":"31c559ceb946447ebd16820cc13a98b5","type":"TRIAL","name":"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders","canonical_id":"clinicaltrials.gov:NCT02392559","description":"Heterozygous Familial Hypercholesterolemia","metadata":null},{"id":"cae91fcd295e478abf4804d51bf17085","type":"TRIAL","name":"Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma","canonical_id":"clinicaltrials.gov:NCT07234058","description":"Pleural Mesotheliomas","metadata":null},{"id":"6fac3f9f830d46e68d2a411f4a2d22c8","type":"TRIAL","name":"Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia","canonical_id":"clinicaltrials.gov:NCT01798277","description":"Ventricular Tachycardia; Coronary Artery Disease","metadata":null},{"id":"0d5fe080b7dd46549152213f60cc7ade","type":"TRIAL","name":"Trial Comparing Daily Atropine Versus Weekend Atropine","canonical_id":"clinicaltrials.gov:NCT00094614","description":"Amblyopia","metadata":null},{"id":"c99b8293dc67442c9431264d3e763963","type":"TRIAL","name":"Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium","canonical_id":"clinicaltrials.gov:NCT01811459","description":"Delirium","metadata":null},{"id":"ee6d665b4bae473da26075d2f3875e16","type":"TRIAL","name":"Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty","canonical_id":"clinicaltrials.gov:NCT04591353","description":"Total Hip Arthroplasty","metadata":null},{"id":"efdd8d89a5604fed8bd4c553081b28e8","type":"TRIAL","name":"Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)","canonical_id":"clinicaltrials.gov:NCT00114764","description":"Myeloid Leukemia","metadata":null},{"id":"75b5fc0ce5e64bd1b4d093e5e78e74b2","type":"TRIAL","name":"Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas","canonical_id":"clinicaltrials.gov:NCT01556009","description":"Basal Cell Nevus Syndrome; Gorlin's Syndrome","metadata":null},{"id":"54ceddea8fa9481da64a46b00db19f2d","type":"TRIAL","name":"Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","canonical_id":"clinicaltrials.gov:NCT04172441","description":"Congenital Hyperinsulinism","metadata":null},{"id":"ffe3368706fe4929979020c875096a00","type":"TRIAL","name":"Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia","canonical_id":"clinicaltrials.gov:NCT03422640","description":"Frontal Fibrosing Alopecia","metadata":null},{"id":"ac240f3185f34ce2a289a5dec85177df","type":"TRIAL","name":"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers","canonical_id":"clinicaltrials.gov:NCT02639026","description":"Metastatic; Melanoma; Non Small Cell Lung Cancer (NSCLC); Breast Cancer; Pancreatic Cancer","metadata":null},{"id":"8361ead0494348baa779f6ff5de227b1","type":"TRIAL","name":"Trial for People With Established Type 2 Diabetes During Ramadan","canonical_id":"clinicaltrials.gov:NCT02292290","description":"Type 2 Diabetes","metadata":null},{"id":"aee53834cb9641949c8994b41746d11f","type":"TRIAL","name":"Trial for Treatment Refractory Trigeminal Neuralgia","canonical_id":"clinicaltrials.gov:NCT03941834","description":"Trigeminal Neuralgia","metadata":null},{"id":"cddc0e86f03e419894a89565bc83b48c","type":"TRIAL","name":"Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab","canonical_id":"clinicaltrials.gov:NCT00199004","description":"Adult Acute Lymphocytic Leukemia","metadata":null},{"id":"b94b909e12004beb83615e9de4f94a36","type":"TRIAL","name":"Trial for the Treatment of Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT00120601","description":"Alcoholism","metadata":null},{"id":"e0c54e3e8c664d318ba0ff3fd7484297","type":"TRIAL","name":"Trial in Adult Subjects With Acute Migraines","canonical_id":"clinicaltrials.gov:NCT03461757","description":"Migraine, With or Without Aura","metadata":null},{"id":"be345b00b1af40ba86ad9e3257ad0abc","type":"TRIAL","name":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT07042685","description":"Metastatic Colorectal Cancer (CRC)","metadata":null},{"id":"6a5f4ae7e0d64c958d60a53dd544bf2f","type":"TRIAL","name":"Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children","canonical_id":"clinicaltrials.gov:NCT02458482","description":"Asthma","metadata":null},{"id":"8d18005a7e3f4daba04ee6c4981e96ae","type":"TRIAL","name":"Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT03819101","description":"Prostate Cancer","metadata":null},{"id":"5f951459f2f24d66935bcc14c39cbfad","type":"TRIAL","name":"Trial of Afatinib in Pediatric Tumours","canonical_id":"clinicaltrials.gov:NCT02372006","description":"Neuroectodermal Tumors; Rhabdomyosarcoma","metadata":null},{"id":"87b6f398b43d45a3ade5941a12497115","type":"TRIAL","name":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","canonical_id":"clinicaltrials.gov:NCT05470491","description":"HIV; Hematologic Malignancies","metadata":null},{"id":"ed2fa24c200f48218526d862e78e4737","type":"TRIAL","name":"Trial of Alvimopan in Major Spine Surgery","canonical_id":"clinicaltrials.gov:NCT02789111","description":"Constipation","metadata":null},{"id":"9501afb7e6c14783a3027bf7a2c9517d","type":"TRIAL","name":"Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age","canonical_id":"clinicaltrials.gov:NCT01206478","description":"Chronic Oral Food Refusal","metadata":null},{"id":"8ac0669e999c46b69cdfb1b5867c06de","type":"TRIAL","name":"Trial of Aspirin and Arginine Restriction in Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00578721","description":"Colorectal Cancer","metadata":null},{"id":"9652399ac9b9440dad9722b60f88a0a1","type":"TRIAL","name":"Trial of Asthma Patient Education (TAPE)","canonical_id":"clinicaltrials.gov:NCT00148408","description":"Asthma","metadata":null},{"id":"7824881032ea453fa93eabb1a3d81e23","type":"TRIAL","name":"Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM","canonical_id":"clinicaltrials.gov:NCT03608774","description":"Anal Chlamydia Infection","metadata":null},{"id":"d30b3e03d19d4bf0a2ed805848a83b13","type":"TRIAL","name":"Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05954143","description":"Metastatic Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"1796f2f23c284e0182959b4e6c38302f","type":"TRIAL","name":"Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT05863936","description":"Lupus Nephritis; Remission; Safety Issues","metadata":null},{"id":"1c7a54d4cf0345e3adb48d9410618008","type":"TRIAL","name":"Trial of Belimumab in Early Lupus","canonical_id":"clinicaltrials.gov:NCT03543839","description":"Lupus Erythematosus, Systemic; Lupus Erythematosus","metadata":null},{"id":"a82a72e38c404d48ad41db3a38bb4510","type":"TRIAL","name":"Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors","canonical_id":"clinicaltrials.gov:NCT02706626","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"e195839c4e574899818fc78af5fb6649","type":"TRIAL","name":"Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation","canonical_id":"clinicaltrials.gov:NCT04356495","description":"Corona Virus Infection; Sars-CoV2","metadata":null},{"id":"e24592ac7f9f47a58ecd57f120619f0c","type":"TRIAL","name":"Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases","canonical_id":"clinicaltrials.gov:NCT02132598","description":"Non Small Cell Lung Cancer (NSCLC); Metastases to the Brain","metadata":null},{"id":"b6b50b05a20b4803ad20df551388b1ad","type":"TRIAL","name":"Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca","canonical_id":"clinicaltrials.gov:NCT04988074","description":"HPV-Related Squamous Cell Carcinoma","metadata":null},{"id":"38b1dc78d7364f0c9062a648b189541f","type":"TRIAL","name":"Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas","canonical_id":"clinicaltrials.gov:NCT00148109","description":"Sarcoma","metadata":null},{"id":"e2891d8b627a4969b64bae9f34d7151d","type":"TRIAL","name":"Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.","canonical_id":"clinicaltrials.gov:NCT05068427","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"95e3210c292246a4b25ebd28e84e2bf9","type":"TRIAL","name":"Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II","canonical_id":"clinicaltrials.gov:NCT00130039","description":"Cerebral Infarction; Atherosclerosis","metadata":null},{"id":"3471c35b2bba46ebabe4fe0eb970fba4","type":"TRIAL","name":"Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00924352","description":"Metastatic Breast Cancer","metadata":null},{"id":"b865cf1d0f5749919ea14f2ff43ef607","type":"TRIAL","name":"Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)","canonical_id":"clinicaltrials.gov:NCT07671157","description":"Frontal Fibrosing Alopecia","metadata":null},{"id":"58514b8a33f14eb79b923f31f0722c35","type":"TRIAL","name":"Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT02783625","description":"Lymphoma; Relapsed/Refractory T-cell Lymphomas","metadata":null},{"id":"0703af6a844945b1abec6def89b588b6","type":"TRIAL","name":"Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients","canonical_id":"clinicaltrials.gov:NCT00086281","description":"Obstructive Sleep Apnea Syndrome","metadata":null},{"id":"2950a490db3c498cb99b9e1cb5864ede","type":"TRIAL","name":"Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","canonical_id":"clinicaltrials.gov:NCT01483144","description":"Familial Adenomatous Polyposis","metadata":null},{"id":"567c18bbdf8c4f0d9c2e7e0cc26e57a7","type":"TRIAL","name":"Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy","canonical_id":"clinicaltrials.gov:NCT01401959","description":"Metastatic Breast Cancer","metadata":null},{"id":"438643b4b78e4113b8688b0e19be7dc6","type":"TRIAL","name":"Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache","canonical_id":"clinicaltrials.gov:NCT01148303","description":"Headache; Fasting; Fasting Headache; Ramadan Headache","metadata":null},{"id":"0da92c8d52f84d6cba8f7472bcd3610c","type":"TRIAL","name":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","canonical_id":"clinicaltrials.gov:NCT06816927","description":"Newly Diagnosed Glioblastoma","metadata":null},{"id":"1fdb92fc5ff74661b7db80c44972523e","type":"TRIAL","name":"Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01296763","description":"Pancreatic Cancer","metadata":null},{"id":"87dcf6b092c54195bf643b3c16c9e81b","type":"TRIAL","name":"Trial of Ibudilast for Methamphetamine Dependence","canonical_id":"clinicaltrials.gov:NCT01860807","description":"Methamphetamine Dependence; HIV Infection","metadata":null},{"id":"d9918e551aa9476a8f7b5968a1c27004","type":"TRIAL","name":"Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03576443","description":"Diffuse Large B Cell Lymphoma","metadata":null},{"id":"daab3e37e783494baa5d95f583c76fd3","type":"TRIAL","name":"Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)","canonical_id":"clinicaltrials.gov:NCT00086463","description":"Pulmonary Arterial Hypertension; Ayerza Syndrome; Pulmonary Hypertension","metadata":null},{"id":"f177beb7ee9b4a05b5c40151e503b609","type":"TRIAL","name":"Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT00439543","description":"Pulmonary Fibrosis; Pulmonary Hypertension","metadata":null},{"id":"95485efbc0fc437da1d0ba2c9cf95fff","type":"TRIAL","name":"Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation","canonical_id":"clinicaltrials.gov:NCT00948818","description":"Irritable Bowel Syndrome Characterized by Constipation","metadata":null},{"id":"10912c1dba0c41909d32fea1b476bc90","type":"TRIAL","name":"Trial of Linaclotide in Patients With Chronic Constipation","canonical_id":"clinicaltrials.gov:NCT00730015","description":"Chronic Constipation","metadata":null},{"id":"9c9013cf66234434bb3de8b74d536df1","type":"TRIAL","name":"Trial of Linaclotide in Patients With Chronic Idiopathic Constipation","canonical_id":"clinicaltrials.gov:NCT02291679","description":"Chronic Idiopathic Constipation","metadata":null},{"id":"c4ad547ad75d4954b17522db5f68431e","type":"TRIAL","name":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT02559206","description":"Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"6073009dd371403fbff8014c13d587cf","type":"TRIAL","name":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","canonical_id":"clinicaltrials.gov:NCT00938717","description":"Irritable Bowel Syndrome With Constipation","metadata":null},{"id":"b75b6385f66c4075a585a7f3434d00c0","type":"TRIAL","name":"Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01240941","description":"Metastatic Breast Cancer","metadata":null},{"id":"a45d38cad3cd4442971ff6bf1d79dabc","type":"TRIAL","name":"Trial of Maintenance With Niraparib- Uterine Serous Carcinoma","canonical_id":"clinicaltrials.gov:NCT04080284","description":"Endometrial Cancer; Papillary Serous Endometrial Carcinoma; Uterine Serous Carcinoma; Endometrial Carcinoma; Cancer of the Endometrium","metadata":null},{"id":"da8dcc0faa5046b6bbe27225d271128f","type":"TRIAL","name":"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects","canonical_id":"clinicaltrials.gov:NCT00098722","description":"HIV Infections","metadata":null},{"id":"b8c95624759144c5be406ebeeeb086b9","type":"TRIAL","name":"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine","canonical_id":"clinicaltrials.gov:NCT00098293","description":"HIV-1","metadata":null},{"id":"4cba7083eed7455cb9fe577e6ebfb90f","type":"TRIAL","name":"Trial of Mirtazapine for Depression in IBD","canonical_id":"clinicaltrials.gov:NCT06309472","description":"Major Depressive Disorder; Inflammatory Bowel Diseases","metadata":null},{"id":"d20c48f4414c4703902bd37d6bce83ea","type":"TRIAL","name":"Trial of Montelukast in Eosinophilic Esophagitis","canonical_id":"clinicaltrials.gov:NCT00511316","description":"Eosinophilic Esophagitis","metadata":null},{"id":"80a952f275424c29880390483ecdb845","type":"TRIAL","name":"Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma","canonical_id":"clinicaltrials.gov:NCT03275818","description":"Tumor, Desmoplastic Small Round Cell, Adult; Tumor, Desmoplastic Small Round Cell, Childhood; Sarcoma, Ewing; Sarcoma; Desmoid","metadata":null},{"id":"b0c95a67afa0468e9be95712b2d18f8a","type":"TRIAL","name":"Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL","canonical_id":"clinicaltrials.gov:NCT00981799","description":"Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma","metadata":null},{"id":"39003b99a3be4a6f88b79bc0a75c9059","type":"TRIAL","name":"Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling","canonical_id":"clinicaltrials.gov:NCT04965064","description":"Breast Cancer","metadata":null},{"id":"2d50f2ecbaf2432ea9b8d829967ae4ec","type":"TRIAL","name":"Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine","canonical_id":"clinicaltrials.gov:NCT02169830","description":"Migraine Disorders","metadata":null},{"id":"a811ec951830465fabe1e727055cfd43","type":"TRIAL","name":"Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)","canonical_id":"clinicaltrials.gov:NCT02039219","description":"Alcoholic Hepatitis","metadata":null},{"id":"ae5d9ad7dfe94232b5464189d45574af","type":"TRIAL","name":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","canonical_id":"clinicaltrials.gov:NCT03448718","description":"Metastatic Urothelial Cancer","metadata":null},{"id":"35ac450d8d6d4c7cac77b631ebffe76a","type":"TRIAL","name":"Trial of Ondansetron as a Parkinson's HAllucinations Treatment","canonical_id":"clinicaltrials.gov:NCT04167813","description":"Parkinson's Hallucinations; Dementia With Lewy Bodies","metadata":null},{"id":"fe8b966054924f8f9294034a0d3f69e4","type":"TRIAL","name":"Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients","canonical_id":"clinicaltrials.gov:NCT00136058","description":"Osteoporosis","metadata":null},{"id":"f994b3ede10248fda3035cb1ba200696","type":"TRIAL","name":"Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor","canonical_id":"clinicaltrials.gov:NCT00315913","description":"Dysfunctional Labor","metadata":null},{"id":"13fcf7e1b9ba4d85879acd856e005d32","type":"TRIAL","name":"Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis","canonical_id":"clinicaltrials.gov:NCT05001984","description":"Intracranial Atherosclerosis; Acute Ischemic Stroke; ICAS - Intracranial Atherosclerosis","metadata":null},{"id":"7626b37f59914ff18dbaf1fca1d70e77","type":"TRIAL","name":"Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)","canonical_id":"clinicaltrials.gov:NCT04973228","description":"Seborrheic Dermatitis","metadata":null},{"id":"2a00254a040a45b7ace34f9b8588b1fe","type":"TRIAL","name":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT04773587","description":"Atopic Dermatitis Eczema","metadata":null},{"id":"e655400b2d834307b774fedc80078bf0","type":"TRIAL","name":"Trial of PED-1 in Male Patients With Premature Ejaculation","canonical_id":"clinicaltrials.gov:NCT01439984","description":"Premature Ejaculation","metadata":null},{"id":"cc665b5191a04769908556ec8e46523f","type":"TRIAL","name":"Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.","canonical_id":"clinicaltrials.gov:NCT03242382","description":"Soft-tissue Sarcoma; Osteosarcoma; Chordoma","metadata":null},{"id":"1a7277ff2eff4d1c9c20b0bfa7bc7e01","type":"TRIAL","name":"Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer","canonical_id":"clinicaltrials.gov:NCT01128387","description":"Cancer","metadata":null},{"id":"379635373c7e4025a1005820638c7d04","type":"TRIAL","name":"Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer","canonical_id":"clinicaltrials.gov:NCT01143974","description":"Locally Advanced Malignant Neoplasm","metadata":null},{"id":"ec3ec477433140979ad51b93f1285604","type":"TRIAL","name":"Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT01681563","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"9a3cdaa356fd497a8ba8825d51d7b14b","type":"TRIAL","name":"Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression","canonical_id":"clinicaltrials.gov:NCT00159146","description":"Major Depression","metadata":null},{"id":"44d5d1eaacbe41fba75e7a94663ef825","type":"TRIAL","name":"Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma","canonical_id":"clinicaltrials.gov:NCT02478164","description":"Glioblastoma","metadata":null},{"id":"6a21a8ca9573411a9d5ea2a21a982d8a","type":"TRIAL","name":"Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies","canonical_id":"clinicaltrials.gov:NCT00984217","description":"Adenoma, Pleomorphic; Mixed Salivary Gland Tumor; Salivary Gland Tumor, Mixed; Syringoma, Chondroid","metadata":null},{"id":"5d8e72644fda45dab215c0e4e9bc2b35","type":"TRIAL","name":"Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients","canonical_id":"clinicaltrials.gov:NCT00371904","description":"Kidney Transplantation","metadata":null},{"id":"245e55a9be4546f8adbca215b2363c39","type":"TRIAL","name":"Trial of Romidepsin and Bortezomib for Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00765102","description":"Multiple Myeloma","metadata":null},{"id":"884dc71ad37a46c2a72c2c98b90cb806","type":"TRIAL","name":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","canonical_id":"clinicaltrials.gov:NCT03413995","description":"Prostate Cancer Metastatic","metadata":null},{"id":"da7329736fcc4770bd520a01d146c088","type":"TRIAL","name":"Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)","canonical_id":"clinicaltrials.gov:NCT01232738","description":"Amyotrophic Lateral Sclerosis (ALS)","metadata":null},{"id":"39cf4dafb5cc424b863e4e9902308954","type":"TRIAL","name":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","canonical_id":"clinicaltrials.gov:NCT07064018","description":"Soft-tissue Sarcoma; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Ovarian Cancer; KRAS Mutation-Related Tumors","metadata":null},{"id":"795d47eae4d34c9a9925f4b7a8ce3f6b","type":"TRIAL","name":"Trial of Suvorexant for Sleep in Children With Autism","canonical_id":"clinicaltrials.gov:NCT05546554","description":"Autism; Autism Spectrum Disorder","metadata":null},{"id":"b8df754145354b6e857b195ff972909b","type":"TRIAL","name":"Trial of Terbutaline for the Treatment of Status Asthmaticus in Children","canonical_id":"clinicaltrials.gov:NCT00124995","description":"Status Asthmaticus","metadata":null},{"id":"77fbe8c6556441ecb4431b50a343e7e6","type":"TRIAL","name":"Trial of Tolcapone With Oxaliplatin for Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT02630043","description":"Neuroblastoma","metadata":null},{"id":"9d03535a43e54f329084dba411b84013","type":"TRIAL","name":"Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03704688","description":"Non Small Cell Lung Cancer; KRAS Gene Mutation","metadata":null},{"id":"7c16021c09e8440a9a9197e4e367aee1","type":"TRIAL","name":"Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)","canonical_id":"clinicaltrials.gov:NCT00667615","description":"Hodgkin's Disease; Lymphoma","metadata":null},{"id":"88509c90ad6847e48ec53ec21703dac6","type":"TRIAL","name":"Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01004419","description":"Carcinoma, Non Small Cell Lung","metadata":null},{"id":"62993d1a57dd408bab56b365589ac565","type":"TRIAL","name":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","canonical_id":"clinicaltrials.gov:NCT02892123","description":"HER2-expressing Cancers","metadata":null},{"id":"9d7fe36182d941f0a6b4b94847f45bfb","type":"TRIAL","name":"Trial of Zileuton CR in Children and Adults With Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT01136941","description":"Sickle Cell Disease","metadata":null},{"id":"735f8328776442d88e15f64ed041fb5b","type":"TRIAL","name":"Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil\u00ae) in a Population at Risk for Poor Stem Cell Mobilization","canonical_id":"clinicaltrials.gov:NCT01037517","description":"Multiple Myeloma; Lymphoma","metadata":null},{"id":"57bb437ebc464e7a8f843ce62813e3f5","type":"TRIAL","name":"Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01417806","description":"Small Cell Lung Cancer","metadata":null},{"id":"1ab6b89499bf4a8c97c5a7ebe3280ccc","type":"TRIAL","name":"Trial on Metoclopramide and Ketoprofen in Acute Migraine of Childhood","canonical_id":"clinicaltrials.gov:NCT00557544","description":"Migraine","metadata":null},{"id":"3b8bf260a6154ab39e983ea4038fc4b8","type":"TRIAL","name":"Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy","canonical_id":"clinicaltrials.gov:NCT00349089","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"23ff5267fc054ed28282665ef0223b12","type":"TRIAL","name":"Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee","canonical_id":"clinicaltrials.gov:NCT00485472","description":"Osteoarthritis","metadata":null},{"id":"249a155cf7754e89968c5c4c2d548d20","type":"TRIAL","name":"Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure","canonical_id":"clinicaltrials.gov:NCT01235403","description":"Partial Epilepsies","metadata":null},{"id":"b5ec9a3452f94ca199c4062dc50badfa","type":"TRIAL","name":"Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA\u2022CER) (Study P04736)","canonical_id":"clinicaltrials.gov:NCT00527943","description":"Atherosclerosis; Myocardial Ischemia; Myocardial Infarction","metadata":null},{"id":"c2725db9e4d942a9bafe5e01b14dcb94","type":"TRIAL","name":"Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2\u00b0P - TIMI 50) (P04737)","canonical_id":"clinicaltrials.gov:NCT00526474","description":"Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident; Peripheral Arterial Disease","metadata":null},{"id":"38ac1ec648db4778adbafe653937b23a","type":"TRIAL","name":"Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy","canonical_id":"clinicaltrials.gov:NCT02478242","description":"Acute Kidney Injury","metadata":null},{"id":"37e00cc9acc443d4a491bafbaff76df2","type":"TRIAL","name":"Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML","canonical_id":"clinicaltrials.gov:NCT01830361","description":"Acute Myeloid Leukemia","metadata":null},{"id":"3b857e6b7b1040e9a82df012abd45730","type":"TRIAL","name":"Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)","canonical_id":"clinicaltrials.gov:NCT00617123","description":"Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident","metadata":null},{"id":"72810a9efbc34a439109dce15186543c","type":"TRIAL","name":"Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)","canonical_id":"clinicaltrials.gov:NCT00684203","description":"Atherosclerosis; Myocardial Ischemia; Myocardial Infarction","metadata":null},{"id":"4f9181156567410b9cfb2b827b66d1b3","type":"TRIAL","name":"Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)","canonical_id":"clinicaltrials.gov:NCT00684515","description":"Cerebral Infarction","metadata":null},{"id":"86153b037aad446ba57f33da38276994","type":"TRIAL","name":"Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome","canonical_id":"clinicaltrials.gov:NCT00103402","description":"Prostatitis","metadata":null},{"id":"182b802fbc0c4bb0bc1b03fdb54ced68","type":"TRIAL","name":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","canonical_id":"clinicaltrials.gov:NCT04107727","description":"Acute Myeloid Leukemia","metadata":null},{"id":"3be3b4c05a584d3e9a9dfc17bb69df23","type":"TRIAL","name":"Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy","canonical_id":"clinicaltrials.gov:NCT02768714","description":"Breast Cancer","metadata":null},{"id":"c4f2c92b3e204b239aa0a17fdf984eee","type":"TRIAL","name":"Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","canonical_id":"clinicaltrials.gov:NCT00189488","description":"Graft Versus Host Disease; Hematologic Malignancies","metadata":null},{"id":"d37fc4a61467446083c65894749fd2df","type":"TRIAL","name":"Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH","canonical_id":"clinicaltrials.gov:NCT04062565","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"34edc5f1c18e415ea6a3da105d7ef3f5","type":"TRIAL","name":"Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy","canonical_id":"clinicaltrials.gov:NCT01782222","description":"Idiopathic Parkinson's Disease","metadata":null},{"id":"f380cf0f2fe440ba8de06fdf454408a8","type":"TRIAL","name":"Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury","canonical_id":"clinicaltrials.gov:NCT06622239","description":"Nonsuicidal Self-Injury","metadata":null},{"id":"94aec16942734b24abd7d47cf139faae","type":"TRIAL","name":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","canonical_id":"clinicaltrials.gov:NCT02971683","description":"Polymyositis; Dermatomyositis; Autoimmune Necrotizing Myopathy; Overlap Myositis; Juvenile Myositis Above the Age of 18","metadata":null},{"id":"6696bc7e581a40af954f1bb33d6bc422","type":"TRIAL","name":"Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers","canonical_id":"clinicaltrials.gov:NCT00171262","description":"Dyslipidemia","metadata":null},{"id":"39bc26160491488d80fc336451f02d71","type":"TRIAL","name":"Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder","canonical_id":"clinicaltrials.gov:NCT03661983","description":"Tourette's Disorder (TD)","metadata":null},{"id":"c8c49ab75e4e4f4391c75bbc2dfaddb4","type":"TRIAL","name":"Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)","canonical_id":"clinicaltrials.gov:NCT04710199","description":"Virus Diseases","metadata":null},{"id":"c4d39004d08e41ecb4641bb0ff25228d","type":"TRIAL","name":"Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","canonical_id":"clinicaltrials.gov:NCT07495852","description":"Glaucoma","metadata":null},{"id":"20c40422eec64478882d0fcbacbae34b","type":"TRIAL","name":"Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes","canonical_id":"clinicaltrials.gov:NCT05419908","description":"Hot Flashes","metadata":null},{"id":"3620e1d9af0645e5b913b9ac00599a36","type":"TRIAL","name":"Trial to Optimize Mineral Outcomes in Dialysis Patients","canonical_id":"clinicaltrials.gov:NCT01100723","description":"Secondary Hyperparathyroidism; Chronic Kidney Disease","metadata":null},{"id":"1372bfd87b45460290fdd475086391b8","type":"TRIAL","name":"Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.","canonical_id":"clinicaltrials.gov:NCT05106192","description":"Mycosis Fungoides of Skin (Diagnosis); Cutaneous T-cell Lymphoma; Non Hodgkin Lymphoma; Lymphomatoid Papulosis; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Follicular","metadata":null},{"id":"146bdd93f6054381adfe23c26ccd5b9b","type":"TRIAL","name":"Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption","canonical_id":"clinicaltrials.gov:NCT01017926","description":"Healthy Volunteers","metadata":null},{"id":"e6e1b43921ef4626a1cc42f01395a4fd","type":"DRUG","name":"Trichlormethiazide","canonical_id":"mesh:D014237","description":null,"metadata":null},{"id":"94d1a8f53452462688df4585c85b2cdc","type":"DRUG","name":"Trichloroacetic Acid","canonical_id":"mesh:D014238","description":null,"metadata":null},{"id":"c52ffe65849a413896be8f4ea1f0702c","type":"DISEASE","name":"Trichuriasis","canonical_id":"mesh:D014257","description":null,"metadata":null},{"id":"8ab2d50b18314ef8a78a25804c03a7ab","type":"TRIAL","name":"Tricyclic Antidepressants (TCAs) on Gastric Emptying","canonical_id":"clinicaltrials.gov:NCT00220844","description":"Dyspepsia","metadata":null},{"id":"672a94bc0e094853859e559167677a19","type":"DRUG","name":"Tridihexethyl","canonical_id":"mesh:C005386","description":null,"metadata":null},{"id":"cc6d42c401ac4119ab7e61353e3f435b","type":"DRUG","name":"Trientine","canonical_id":"mesh:D014266","description":null,"metadata":null},{"id":"68b3428c3ab845a790d98d0812ee54c9","type":"DRUG","name":"Trifluoperazine","canonical_id":"mesh:D014268","description":null,"metadata":null},{"id":"f9c7895781e34b978bad33bd22e3ccff","type":"DRUG","name":"Triflupromazine","canonical_id":"mesh:D014273","description":null,"metadata":null},{"id":"6db514a65399474493e256cca7fa55a6","type":"DRUG","name":"Trifluridine","canonical_id":"mesh:D014271","description":null,"metadata":null},{"id":"912b51d5ee1347839e8ec86d46ea03e9","type":"TRIAL","name":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT05007132","description":"Metastatic Colorectal Cancer","metadata":null},{"id":"a0b5d2ef189f41d38b34234c7020b074","type":"TRIAL","name":"Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer","canonical_id":"clinicaltrials.gov:NCT04511039","description":"Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroeso\u2026","metadata":null},{"id":"4c8b8b7998e04f6c81add0fee911877b","type":"DISEASE","name":"Trigeminal neuralgia","canonical_id":"mesh:D014277","description":null,"metadata":null},{"id":"5d3badd17fa140b0bc0e108004a41982","type":"TRIAL","name":"Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05113966","description":"Triple Negative Breast Cancer","metadata":null},{"id":"850f22a03c67464985f00fba84744f1c","type":"TRIAL","name":"Trilostane for Androgen-Independent Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00181597","description":"Prostate Cancer; Prostate Adenocarcinoma","metadata":null},{"id":"c407ef155d984587b67a0e5d0812fdce","type":"DRUG","name":"Trimazosin","canonical_id":"mesh:C005185","description":null,"metadata":null},{"id":"2ae06fbdb5cc456ba453753c2ea578d0","type":"DRUG","name":"Trimethobenzamide","canonical_id":"mesh:C100146","description":null,"metadata":null},{"id":"f92d3ebab107415ebc46b92598add7c3","type":"DRUG","name":"Trimipramine","canonical_id":"mesh:D014299","description":null,"metadata":null},{"id":"6d3cd2e51bcd4c419ca3edafb1ad4493","type":"DRUG","name":"Trioxsalen","canonical_id":"mesh:D014307","description":null,"metadata":null},{"id":"4017ec157d784cbca38ad31b8f5b757b","type":"PROTEIN","name":"Tripeptidyl-peptidase 1","canonical_id":"uniprot:O14773","description":null,"metadata":null},{"id":"b39accdcaad4461493929cb1c5d0158e","type":"TRIAL","name":"Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer","canonical_id":"clinicaltrials.gov:NCT05564286","description":"Cervical Cancer; Nasopharyngeal Cancer; Chemotherapy-induced Nausea and Vomiting; Radiation-Induced Nausea and Vomiting; Antiemetic","metadata":null},{"id":"29ee27e316254dd69343c528d9947194","type":"TRIAL","name":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT07374328","description":"Type 2 Diabetes","metadata":null},{"id":"308bc7a8d17b4004a37b389853231b3b","type":"TRIAL","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","canonical_id":"clinicaltrials.gov:NCT07104266","description":"Triple-Negative Breast Cancer","metadata":null},{"id":"8646435fbf554e6f96d3b2a5faf65a36","type":"TRIAL","name":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","canonical_id":"clinicaltrials.gov:NCT05773950","description":"Postoperative Nausea and Vomiting; Gynecologic Surgical Procedures; Laparoscopy","metadata":null},{"id":"525974f54f544283b45e577e24815063","type":"TRIAL","name":"Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation","canonical_id":"clinicaltrials.gov:NCT00404716","description":"Acute Coronary Syndrome","metadata":null},{"id":"c515d73149e54569ad0d738ba4024a1c","type":"DISEASE","name":"Triple-negative Breast Cancer","canonical_id":"doid:0060081","description":null,"metadata":null},{"id":"21d944f8fff14c20be03113fc89044f7","type":"TRIAL","name":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","canonical_id":"clinicaltrials.gov:NCT06761313","description":"Glaucoma; Quality of Life (QOL)","metadata":null},{"id":"dd48f845d3d843a6bc1c9a4a2aa7a3b3","type":"TRIAL","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00104741","description":"Prostate Cancer","metadata":null},{"id":"714f578bce634ea698e12f11b8e1e3a1","type":"DRUG","name":"Troglitazone","canonical_id":"mesh:D000077288","description":null,"metadata":null},{"id":"60a5a9aff35947819d36bbfeebe3c210","type":"TRIAL","name":"Troglitazone in Treating Patients With Liposarcoma","canonical_id":"clinicaltrials.gov:NCT00003058","description":"Sarcoma","metadata":null},{"id":"aeac693bb80948ff856b7048d58e365b","type":"TRIAL","name":"Trop-2 Targeted PET Probes in Advanced TNBC","canonical_id":"clinicaltrials.gov:NCT07046455","description":"TNBC - Triple-Negative Breast Cancer","metadata":null},{"id":"04da321340a042f3ba5a35c1ab652fdd","type":"DRUG","name":"Tropicamide","canonical_id":"mesh:D014331","description":null,"metadata":null},{"id":"4f1164882c4a4624a59a06247fe54bbf","type":"PROTEIN","name":"Troponin C, slow skeletal and cardiac muscles","canonical_id":"uniprot:P63316","description":null,"metadata":null},{"id":"abb0fd77b49b4e12b04f996b5e6a99d3","type":"DRUG","name":"Trovafloxacin","canonical_id":"mesh:C080163","description":null,"metadata":null},{"id":"c0075d62aacc4d708ad7153c5e8c2a43","type":"TRIAL","name":"Tubal Flushing Using Water Soluble Media for Unexplained Infertility","canonical_id":"clinicaltrials.gov:NCT02433418","description":"Infertility","metadata":null},{"id":"538be8f43c474bfab364c8b83af82e9f","type":"DISEASE","name":"Tuberculosis of meninges","canonical_id":"mesh:D014390","description":null,"metadata":null},{"id":"c404101e375a45b4b8ef9af5648ca91e","type":"DISEASE","name":"Tuberculosis, Miliary","canonical_id":"mesh:D014391","description":null,"metadata":null},{"id":"d13bf85a3d98444299fb90290d0c8e6c","type":"DISEASE","name":"Tuberous Sclerosis","canonical_id":"mesh:D014402","description":null,"metadata":null},{"id":"a3967f7b8cf948e6bd17775c616303ff","type":"TRIAL","name":"Tubular Markers in Response to Saxagliptin Therapy","canonical_id":"clinicaltrials.gov:NCT04521049","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"ef05d46fbc224508a6989eceeabb6a38","type":"PROTEIN","name":"Tubulin alpha-1A chain","canonical_id":"uniprot:Q71U36","description":null,"metadata":null},{"id":"00f906e55bc243b085477708379a874c","type":"PROTEIN","name":"Tubulin beta chain","canonical_id":"uniprot:P07437","description":null,"metadata":null},{"id":"44ca0c2474974a47a27ee7def0d5f70f","type":"PROTEIN","name":"Tubulin beta chain Trichophyton rubrum (Athlete's foot fungus)","canonical_id":"uniprot:Q5UBX3","description":null,"metadata":null},{"id":"3dee653f165a4d4bbecc443bb2ede440","type":"PROTEIN","name":"Tubulin beta-1 chain","canonical_id":"uniprot:Q9H4B7","description":null,"metadata":null},{"id":"4660d14e05b54d2d86b5134c532a1c96","type":"TRIAL","name":"Tucatinib + Abemaciclib + Herceptin for HER2+ MBC","canonical_id":"clinicaltrials.gov:NCT03846583","description":"Breast Cancer","metadata":null},{"id":"eb510f67745d44868957f7c90c82e9b2","type":"TRIAL","name":"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","canonical_id":"clinicaltrials.gov:NCT05356897","description":"Metastatic Colon Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Stage IV Colon Cancer AJCC V8; Stage IV Colorectal Cancer AJCC V8; Stage IV Rectal Cancer AJCC V8","metadata":null},{"id":"080d77a92f2d42f4a2f8ff02f286e991","type":"TRIAL","name":"Tucatinib Continuation Study","canonical_id":"clinicaltrials.gov:NCT07768358","description":"HER2-positive Breast Cancer; Cervical Cancer; Biliary Tract Neoplasms; Urothelial Cancer; Advanced Non-Small Cell Lung Cancer; Gastric or Gastroesophageal Junction Adenocarcinoma (GEC); Colorectal Cancer","metadata":null},{"id":"d5a4f61b5fcc4c7c88260a98d7cec8bc","type":"TRIAL","name":"Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT03043313","description":"Metastatic Colorectal Adenocarcinoma","metadata":null},{"id":"209a8475037e41ae8bfb652b75ed6afb","type":"TRIAL","name":"Tucatinib Together With Pembrolizumab and Trastuzumab","canonical_id":"clinicaltrials.gov:NCT04789096","description":"Breast Cancer; HER2-positive Breast Cancer","metadata":null},{"id":"cb9e8f4f3d5e4bd7bc39a5229b668481","type":"TRIAL","name":"Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT04896320","description":"Breast Cancer Stage IV","metadata":null},{"id":"e1a6a77e395f4875849b64f8bfd9e973","type":"TRIAL","name":"Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07193394","description":"Metastatic Breast Cancer ( HER2 Negative); Unresectable Breast Cancer","metadata":null},{"id":"1f80371822794f59a8d799ad13a7786d","type":"TRIAL","name":"Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05955170","description":"HER2-positive Breast Cancer","metadata":null},{"id":"770e80f2d49a4ef5997c88def8a8fb4b","type":"TRIAL","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","canonical_id":"clinicaltrials.gov:NCT05458674","description":"Breast Cancer; Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer","metadata":null},{"id":"a8103c7c89a44d509cdbd6d7b490cc9e","type":"TRIAL","name":"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT03054363","description":"Breast Cancer","metadata":null},{"id":"191955ff690041d7b32cb51aa38076f8","type":"TRIAL","name":"Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer","canonical_id":"clinicaltrials.gov:NCT04499924","description":"Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma","metadata":null},{"id":"bb9a1d98757a4c31961d79c41845e169","type":"TRIAL","name":"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05553522","description":"Brain Metastases; HER2-positive Breast Cancer","metadata":null},{"id":"9d0a169b05ed428fad25cfc71d163334","type":"DISEASE","name":"Tularemia","canonical_id":"mesh:D014406","description":null,"metadata":null},{"id":"3a8851c2f91e4c52ba49f9639ebd42b9","type":"TRIAL","name":"Tumescent Lidocaine Maximum Safe mg/kg Dosage","canonical_id":"clinicaltrials.gov:NCT00977028","description":"Anesthesia","metadata":null},{"id":"215554589a084a9bb14c774a3eaed0f8","type":"TRIAL","name":"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum","canonical_id":"clinicaltrials.gov:NCT01313429","description":"Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancies","metadata":null},{"id":"08dcc4a1b54d4e518283162b535d6dcd","type":"TRIAL","name":"Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer","canonical_id":"clinicaltrials.gov:NCT07115095","description":"HER2-positive Breast Cancer","metadata":null},{"id":"bbc5fb008bb740c596514ac6d43f7566","type":"TRIAL","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","canonical_id":"clinicaltrials.gov:NCT04589845","description":"Solid Tumors","metadata":null},{"id":"1678eef6ef9f4b36abf21d12d2b191c9","type":"TRIAL","name":"Turkish Acquired Haemophilia Registry","canonical_id":"clinicaltrials.gov:NCT01403740","description":"Acquired Haemophilia","metadata":null},{"id":"8621c03549fd4b07a04df4f42b20c9b3","type":"DISEASE","name":"Turner syndrome","canonical_id":"mondo:0019499","description":null,"metadata":null},{"id":"bf11b25b0d574a2694be7bf40c46635a","type":"DISEASE","name":"Turner syndrome","canonical_id":"mesh:D014424","description":null,"metadata":null},{"id":"c7cdced0aed749c38a5e7eef85aba796","type":"TRIAL","name":"Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed","canonical_id":"clinicaltrials.gov:NCT04942340","description":"Emergence From Anesthesia","metadata":null},{"id":"ab3a8492e51144ee9a633804f2321bc4","type":"DRUG","name":"Turoctocog alfa","canonical_id":"mesh:C577506","description":null,"metadata":null},{"id":"5564c39e5c0243978a03764ee8fa987a","type":"TRIAL","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)","canonical_id":"clinicaltrials.gov:NCT04394624","description":"Non-small Cell Lung Cancer Metastatic","metadata":null},{"id":"5e069d3ca42f463d84f3a384127c529a","type":"TRIAL","name":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","canonical_id":"clinicaltrials.gov:NCT01193166","description":"Schizophrenia","metadata":null},{"id":"f50e7c9bea94414cba451438cfcb4b85","type":"TRIAL","name":"Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT01977235","description":"Small Cell Lung Carcinoma","metadata":null},{"id":"cbe907798ea5454781af94845612af9c","type":"TRIAL","name":"Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00233610","description":"Prostate Cancer","metadata":null},{"id":"1d17a5d8f4294bf48b08e617d30839a9","type":"TRIAL","name":"Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00091806","description":"Tumors; Oncology; Solid Tumors","metadata":null},{"id":"3296d3913dae41ec8b75bae3e47bfe0b","type":"TRIAL","name":"Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.","canonical_id":"clinicaltrials.gov:NCT02455687","description":"Bronchial Asthma","metadata":null},{"id":"4399bfdd867240e8a33f090637ba385f","type":"TRIAL","name":"Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT01382654","description":"Allergic Rhinitis","metadata":null},{"id":"ed2c6b11db52481da52f13833df7a4a2","type":"TRIAL","name":"Two Rizatriptan Prescribing Portions for Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT00397254","description":"Migraine","metadata":null},{"id":"b8d10d5a008647958f7fc3daa62682bb","type":"TRIAL","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","canonical_id":"clinicaltrials.gov:NCT04513717","description":"Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8","metadata":null},{"id":"f883d7849e514615add4a354f1ee552a","type":"TRIAL","name":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","canonical_id":"clinicaltrials.gov:NCT05050084","description":"Prostate Adenocarcinoma","metadata":null},{"id":"871c07130cb9472d8cf11facfb98ad54","type":"TRIAL","name":"Two Way Bioequivalence Study Under Fed Conditions","canonical_id":"clinicaltrials.gov:NCT01217801","description":"Healthy","metadata":null},{"id":"71310daeaeef4ffa8f3540f25e383040","type":"TRIAL","name":"Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets","canonical_id":"clinicaltrials.gov:NCT01712568","description":"Pharmacokinetic Study","metadata":null},{"id":"8357354e15c346f4add4dd1d220debff","type":"TRIAL","name":"Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis","canonical_id":"clinicaltrials.gov:NCT01252420","description":"Venous Thrombosis; Pulmonary Embolism","metadata":null},{"id":"bf73830ecd75452bbf000d96eee83cc5","type":"TRIAL","name":"Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT05784012","description":"Head and Neck Squamous Cell Carcinoma","metadata":null},{"id":"bcd27ff595dd42dd9b19da83c28457ad","type":"TRIAL","name":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","canonical_id":"clinicaltrials.gov:NCT02059434","description":"Chronic Obstructive Pulmonary Disease (COPD); Asthma","metadata":null},{"id":"50dc15d42a62487280a762b8d51f6730","type":"TRIAL","name":"Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto\u00ae.","canonical_id":"clinicaltrials.gov:NCT01947153","description":"Healthy","metadata":null},{"id":"c17a629950254377b5dcce02f94ec3ab","type":"TRIAL","name":"Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","canonical_id":"clinicaltrials.gov:NCT00926367","description":"Acne Vulgaris","metadata":null},{"id":"2f644497cab74e63ace832d76c9e5f3b","type":"DRUG","name":"Tyloxapol","canonical_id":"mesh:C016811","description":null,"metadata":null},{"id":"70621a328198475a980aeee1f7f878c8","type":"TRIAL","name":"Type III Dysbetalipoproteinemia","canonical_id":"clinicaltrials.gov:NCT00214604","description":"Hyperlipoproteinemia Type III","metadata":null},{"id":"e9b34a0dc7aa4c05803217b95af61713","type":"DISEASE","name":"Typhoid fever","canonical_id":"mesh:D014435","description":null,"metadata":null},{"id":"599e718798414dcb938c472aa9fc37ca","type":"DISEASE","name":"Typhus, Endemic Flea-Borne","canonical_id":"mesh:D014437","description":null,"metadata":null},{"id":"3342da16702f4bc98b3fc46ba53c9433","type":"DISEASE","name":"Typhus, Epidemic Louse-Borne","canonical_id":"mesh:D014438","description":null,"metadata":null},{"id":"283ca285237f43a0ac451f34057bd6ae","type":"PROTEIN","name":"Tyrosinase","canonical_id":"uniprot:P14679","description":null,"metadata":null},{"id":"49f9eae7620f47b4b240c57d6dfb3e7f","type":"PROTEIN","name":"Tyrosine 3-monooxygenase","canonical_id":"uniprot:P07101","description":null,"metadata":null},{"id":"5bcb40da12304392ab156243f4644108","type":"TRIAL","name":"Tyrosine Kinase 2 (TYK2) for GA and CS","canonical_id":"clinicaltrials.gov:NCT06725264","description":"Sarcoidosis; Granuloma Annulare","metadata":null},{"id":"0a0481fc59bd40b6860bf16771a54d23","type":"PROTEIN","name":"Tyrosine-protein phosphatase non-receptor type","canonical_id":"uniprot:P35236","description":null,"metadata":null},{"id":"d7bad3ec944f47a380783657bc3154e6","type":"DISEASE","name":"Tyrosinemia type I","canonical_id":"mesh:D020176","description":null,"metadata":null},{"id":"fe82f4ea604240469d11436e82afde1e","type":"GO_TERM","name":"U1 snRNA 3'-end processing","canonical_id":"go:GO:0034473","description":"\"Any process involved in forming the mature 3' end of a U1 snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"3b3549b012f44de287ad2925f1ff8a1e","type":"GO_TERM","name":"U1 snRNA binding","canonical_id":"go:GO:0030619","description":"\"Binding to a U1 small nuclear RNA (U1 snRNA).\" [GOC:mah]","metadata":null},{"id":"4b9fc5f4a2fb4f9eaa520ba407a7c208","type":"GO_TERM","name":"U1 snRNP","canonical_id":"go:GO:0005685","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U1, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U1 snRNP, most of which remain associated with the U1 snRNA both while the U1 snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"99921484a1c049e39c3bf1c653932fef","type":"GO_TERM","name":"U1 snRNP binding","canonical_id":"go:GO:1990446","description":"\"Binding to a U1 small nuclear ribonucleoprotein particle.\" [PMID:14713954]","metadata":null},{"id":"ee1ce58bb5834673865cf7c79a08c5d3","type":"GO_TERM","name":"U11 snRNA binding","canonical_id":"go:GO:0030625","description":"\"Binding to a U11 small nuclear RNA (U11 snRNA).\" [GOC:jl]","metadata":null},{"id":"f307a60ea7f84b6d87c5bd1133aa77cb","type":"GO_TERM","name":"U11 snRNP","canonical_id":"go:GO:0005692","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U11, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U11 snRNP, most of which remain associated with the U11 snRNA both while the U11 snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"9651d89873294d6ba704dbe333e81551","type":"GO_TERM","name":"U11/U12 snRNP","canonical_id":"go:GO:0034693","description":"\"A ribonucleoprotein complex that is formed by the association of the U11 and U12 small nuclear ribonucleoproteins.\" [GOC:mah, PMID:15146077]","metadata":null},{"id":"44e896d75a4d45598d8db2a3f1330039","type":"GO_TERM","name":"U12 snRNA binding","canonical_id":"go:GO:0030626","description":"\"Binding to a U12 small nuclear RNA (U12 snRNA).\" [GOC:jl]","metadata":null},{"id":"47aa475c2c0841668338eb848f22cea3","type":"GO_TERM","name":"U12 snRNP","canonical_id":"go:GO:0005693","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U12, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U12 snRNP, most of which remain associated with the U12 snRNA both while the U12 snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"f1c241a6df484ac597e46585e05e48d4","type":"GO_TERM","name":"U12-type catalytic step 1 spliceosome","canonical_id":"go:GO:0071017","description":"\"A spliceosomal complex that is formed by the displacement of the U11 and U4atac snRNPs from the precatalytic spliceosome; the U12, U5 and U6atac snRNPs remain associated with the mRNA. This complex, sometimes called the activated spliceosome, is the catalytically active form of the spliceosome, and includes many proteins in addition to those found in the U12, and U5 and U6atac snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:16201866]","metadata":null},{"id":"3a259c5bc2454d1bad16e3f4050ac29c","type":"GO_TERM","name":"U12-type catalytic step 2 spliceosome","canonical_id":"go:GO:0071018","description":"\"A spliceosomal complex that contains the U12, U5 and U6atac snRNPs bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the U12, U5 and U6atac snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:16201866]","metadata":null},{"id":"8bbb4a5990f74f2bb8ca42d365012bbf","type":"GO_TERM","name":"U12-type post-mRNA release spliceosomal complex","canonical_id":"go:GO:0071019","description":"\"A spliceosomal complex that is formed following the release of the spliced product from the post-spliceosomal complex and contains the excised intron and the U12, U5 and U6atac snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:16201866]","metadata":null},{"id":"0da0d0ad7f1b40b6936b78af88a94a20","type":"GO_TERM","name":"U12-type post-spliceosomal complex","canonical_id":"go:GO:0071022","description":"\"A spliceosomal complex that is formed following the second splicing event and contains the spliced product, the excised intron, and three snRNPs, U5, U12 and U6atac.\" [GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393]","metadata":null},{"id":"9bdd88288d9f4aa384d4b98bee2c27e3","type":"GO_TERM","name":"U12-type precatalytic spliceosome","canonical_id":"go:GO:0071016","description":"\"A spliceosomal complex that is formed by the recruitment of the preassembled U4atac/U6atac.U5 tri-snRNP to the U12-type prespliceosome. Although all 5 snRNPs are present, the precatalytic spliceosome is catalytically inactive. The precatalytic spliceosome includes many proteins in addition to those found in the U11, U12 and U4atac/U6atac.U5 snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, PMID:16201866]","metadata":null},{"id":"205525ee8644400280eeb36b331142c6","type":"GO_TERM","name":"U12-type prespliceosome","canonical_id":"go:GO:0071015","description":"\"A spliceosomal complex that is formed by the cooperative binding of the heterodimeric U11/U12 snRNP to the 5' splice site and the branch point sequence. The U12-type prespliceosome includes many proteins in addition to those found in the U11/U12 heterodimeric snRNPs. Commitment to a given pair of 5' and 3' splice sites occurs at the time of prespliceosome formation.\" [GOC:ab, GOC:krc, GOC:mah, PMID:10197985, PMID:16201866]","metadata":null},{"id":"fb3e7950dc414eb39f116b8324e8f465","type":"GO_TERM","name":"U12-type spliceosomal complex","canonical_id":"go:GO:0005689","description":"\"Any spliceosomal complex that forms during the splicing of a messenger RNA primary transcript to excise an intron; the series of U12-type spliceosomal complexes is involved in the splicing of the majority of introns that contain atypical AT-AC terminal dinucleotides, as well as other non-canonical introns. The entire splice site signal, not just the terminal dinucleotides, is involved in determining which spliceosome utilizes the site.\" [GOC:krc, GOC:mah, PMID:11574683, PMID:11971955]","metadata":null},{"id":"fd333d5e19934bff8c7e9baaea413b71","type":"GO_TERM","name":"U2 snRNA (2'-O-methyladenosine-N6)-methyltransferase activity","canonical_id":"go:GO:0106347","description":"\"Catalysis of the reaction: a 2'-O-methyladenosine in U2 snRNA + S-adenosyl-L-methionine = an N6-methyl-2'-O-methyladenosine in U2 snRNA + S-adenosyl-L-homocysteine + H+; methylates the 6th position of adenine residues with a pre-deposited 2'-O-methylation.\" [PMID:31913360, RHEA:62672]","metadata":null},{"id":"dd86aa3584204345b63a77b160fb5c97","type":"GO_TERM","name":"U2 snRNA (adenine-N6)-methyltransferase activity","canonical_id":"go:GO:0106348","description":"\"Catalysis of the reaction: a adenosine in U2 snRNA + S-adenosyl-L-methionine = an N6-methyl-adenosine in U2 snRNA + S-adenosyl-L-homocysteine + H+.\" [PMID:32637152]","metadata":null},{"id":"8e8214d444f1406897dc5b488b8f8a8b","type":"GO_TERM","name":"U2 snRNA 3'-end processing","canonical_id":"go:GO:0034474","description":"\"Any process involved in forming the mature 3' end of a U2 snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"6d6f15b73f5947a09a2a678e7448c125","type":"GO_TERM","name":"U2 snRNA binding","canonical_id":"go:GO:0030620","description":"\"Binding to a U2 small nuclear RNA (U2 snRNA).\" [GOC:jl]","metadata":null},{"id":"f7defdbd755947898e6469b80b2dedff","type":"GO_TERM","name":"U2 snRNP","canonical_id":"go:GO:0005686","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U2, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U2 snRNP, most of which remain associated with the U2 snRNA both while the U2 snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"ba40a18c0cee47b9944f4b89a0077039","type":"GO_TERM","name":"U2 snRNP binding","canonical_id":"go:GO:1990447","description":"\"Binding to a U2 small nuclear ribonucleoprotein particle.\" [PMID:14713954]","metadata":null},{"id":"c2320bcb88544c42a0dff6faab960396","type":"GO_TERM","name":"U2-type catalytic step 1 spliceosome","canonical_id":"go:GO:0071006","description":"\"A spliceosomal complex that is formed by the displacement of the U1 and U4 snRNPs from the precatalytic spliceosome; the U2, U5 and U6 snRNPs remain associated with the mRNA. This complex, sometimes called the activated spliceosome, is the catalytically active form of the spliceosome, and includes many proteins in addition to those found in the U2, and U5 and U6 snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:18322460, PMID:19239890]","metadata":null},{"id":"cfe24eec7c534937a96e40a480c7dcc3","type":"GO_TERM","name":"U2-type catalytic step 2 spliceosome","canonical_id":"go:GO:0071007","description":"\"A spliceosomal complex that contains the U2, U5 and U6 snRNPs bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the U2, U5 and U6 snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:18322460, PMID:19239890]","metadata":null},{"id":"da85f1cea6e943baa99cccb93680bec8","type":"GO_TERM","name":"U2-type post-mRNA release spliceosomal complex","canonical_id":"go:GO:0071008","description":"\"A spliceosomal complex that is formed following the release of the spliced product from the post-spliceosomal complex and contains the excised intron and the U2, U5 and U6 snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:19239890]","metadata":null},{"id":"9e6c2e370dd54e2ca7b61161d238e5b8","type":"GO_TERM","name":"U2-type post-spliceosomal complex","canonical_id":"go:GO:0071021","description":"\"A spliceosomal complex that is formed following the second splicing event and contains the spliced product, the excised intron, and three snRNPs, U5, U2 and U6.\" [GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393]","metadata":null},{"id":"0c9096ac6c504f719cbe6bab5c6ae360","type":"GO_TERM","name":"U2-type precatalytic spliceosome","canonical_id":"go:GO:0071005","description":"\"A spliceosomal complex that is formed by the recruitment of the preassembled U4/U6.U5 tri-snRNP to the prespliceosome. Although all 5 snRNPs are present, the precatalytic spliceosome is catalytically inactive. The precatalytic spliceosome includes many proteins in addition to those found in the U1, U2 and U4/U6.U5 snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, PMID:18322460, PMID:19239890]","metadata":null},{"id":"78daf556d9b940bcafd5dbc3c648e8ce","type":"GO_TERM","name":"U2-type prespliceosome","canonical_id":"go:GO:0071004","description":"\"A spliceosomal complex that is formed by association of the 5' splice site with the U1 snRNP, while the branch point sequence is recognized by the U2 snRNP. The prespliceosome includes many proteins in addition to those found in the U1 and U2 snRNPs. Commitment to a given pair of 5' and 3' splice sites occurs at the time of prespliceosome formation.\" [GOC:ab, GOC:krc, GOC:mah, PMID:17332742, PMID:19239890]","metadata":null},{"id":"f0674b833a144314b4fd3c90d529c819","type":"GO_TERM","name":"U2-type prespliceosome assembly","canonical_id":"go:GO:1903241","description":"\"The aggregation, arrangement and bonding together of a set of components to form an U2-type prespliceosome.\" [GO_REF:0000079, GOC:TermGenie, PMID:12374752]","metadata":null},{"id":"040d8cbfde954330aced346c57bbee1e","type":"GO_TERM","name":"U2-type spliceosomal complex","canonical_id":"go:GO:0005684","description":"\"Any spliceosomal complex that forms during the splicing of a messenger RNA primary transcript to excise an intron that has canonical consensus sequences near the 5' and 3' ends.\" [GOC:krc, GOC:mah, PMID:11343900]","metadata":null},{"id":"d20316554326422d971a378e9ca878d6","type":"GO_TERM","name":"U2AF complex","canonical_id":"go:GO:0089701","description":"\"A heterodimeric protein complex consisting of conserved large and small U2AF subunits that contributes to spliceosomal RNA splicing by binding to consensus sequences at the 3' splice site. U2AF is required to stabilize the association of the U2 snRNP with the branch point.\" [GOC:dos, GOC:mah, PMID:15231733, PMID:1538748, PMID:2963698, PMID:8657565]","metadata":null},{"id":"47f255d09db54a218f74c61d757553bc","type":"GENE","name":"U2AF1","canonical_id":"hgnc:HGNC:12453","description":"U2 small nuclear RNA auxiliary factor 1","metadata":{"aliases":["U2AF35","RNU2AF1","RN","U2AFBP"]}},{"id":"cd3b9523c0ca45bab4d004cbae93d8ed","type":"GENE","name":"U2AF1L4","canonical_id":"hgnc:HGNC:23020","description":"U2 small nuclear RNA auxiliary factor 1 like 4","metadata":{"aliases":["MGC33901","U2af26","U2AF1L3"]}},{"id":"2265c9224a644416aeaa2deb419b29a4","type":"GENE","name":"U2AF2","canonical_id":"hgnc:HGNC:23156","description":null,"metadata":null},{"id":"72fb46d31bcb4f7cb8e36ffdd38aec89","type":"GENE","name":"U2SURP","canonical_id":"hgnc:HGNC:30855","description":"U2 snRNP associated SURP domain containing","metadata":{"aliases":["fSAPa","SR140"]}},{"id":"0555e33e977f44798a0b5ea4bf375f6c","type":"GENE","name":"U2SURP-AS1","canonical_id":"hgnc:HGNC:58691","description":"U2SURP antisense RNA 1","metadata":null},{"id":"a5b76a7102fe4b10b1503b86d242e866","type":"GENE","name":"U2SURPP1","canonical_id":"hgnc:HGNC:56431","description":"U2SURP pseudogene 1","metadata":null},{"id":"5c1d5efd62034a03bb64bd20be3d7d0e","type":"GO_TERM","name":"U3 snoRNA binding","canonical_id":"go:GO:0034511","description":"\"Binding to a U3 small nucleolar RNA.\" [GOC:mah]","metadata":null},{"id":"77c13e3e1b844d7a897fd38bd14f81c6","type":"GO_TERM","name":"U4 snRNA 3'-end processing","canonical_id":"go:GO:0034475","description":"\"Any process involved in forming the mature 3' end of a U4 snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"01c1b54eb372456d8b6ab1a2b4abb3ee","type":"GO_TERM","name":"U4 snRNA binding","canonical_id":"go:GO:0030621","description":"\"Binding to a U4 small nuclear RNA (U4 snRNA).\" [GOC:jl]","metadata":null},{"id":"9f64c34e367e45e2a14026b83eb27498","type":"GO_TERM","name":"U4 snRNP","canonical_id":"go:GO:0005687","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U4, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U4 snRNP, most of which remain associated with the U4 snRNA both while the U4 snRNP is free or assembled into the U4/U6 snRNP or into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"61e083a6f76a4f10be3a8ad75d722240","type":"GO_TERM","name":"U4/U6 snRNP","canonical_id":"go:GO:0071001","description":"\"A ribonucleoprotein complex that contains the extensively base paired small nuclear RNAs U4 and U6, a heptameric ring of Sm proteins associated with U4, the Lsm2-8 heptameric ring complex associated with U6, as well as several proteins that are unique to the U4 snRNP or U6 snRNPs, some of which remain associated with the U4/U6 snRNA both while the U4 snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897, PMID:14685174]","metadata":null},{"id":"5d61a1b4a5e94472a483e365e764bedd","type":"GO_TERM","name":"U4/U6 x U5 tri-snRNP complex","canonical_id":"go:GO:0046540","description":"\"A ribonucleoprotein complex that is formed by the association of the U4/U6 and U5 snRNPs.\" [GOC:krc, GOC:pr, ISBN:0879695897, PMID:11867543]","metadata":null},{"id":"4092505243794aa583860c436a28e6b8","type":"GO_TERM","name":"U4atac snRNA binding","canonical_id":"go:GO:0030622","description":"\"Binding to a U4atac small nuclear RNA (U4atac snRNA).\" [GOC:jl]","metadata":null},{"id":"083925eb4c564518b48f6a8965a31e3b","type":"GO_TERM","name":"U4atac snRNP","canonical_id":"go:GO:0005690","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U4atac, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U4atac snRNP, most of which remain associated with the U4atac snRNA both while the U4atac snRNP is free or assembled into the U4atac/U6atac complex or into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"c76dffac879f49278e364a49c89f9774","type":"GO_TERM","name":"U4atac/U6atac snRNP","canonical_id":"go:GO:0071002","description":"\"A ribonucleoprotein complex that contains the extensively base paired small nuclear RNAs U4atac and U6atac, a heptameric ring of Sm proteins associated with U4atac, the Lsm2-8 heptameric ring complex associated with U6atac, as well as several proteins that are unique to the U4atac snRNP or U6atac snRNPs, some of which remain associated with the U4atac/U6atac snRNA both while the U4atac snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897, PMID:14685174]","metadata":null},{"id":"e893d3a29b8c48c8a5439e75b1f0d9a4","type":"GO_TERM","name":"U4atac/U6atac x U5 tri-snRNP complex","canonical_id":"go:GO:0071009","description":"\"A spliceosomal snRNP complex that is formed by the association of the U4atac/U6atac and U5 snRNPs.\" [GOC:krc, GOC:mah, GOC:pr, ISBN:0879695897, PMID:16201866]","metadata":null},{"id":"42caf92a142546a486274f97cecc5313","type":"GO_TERM","name":"U5 snRNA 3'-end processing","canonical_id":"go:GO:0034476","description":"\"Any process involved in forming the mature 3' end of a U5 snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"8d7a22e1874248b6a3a6a3b6f75dc203","type":"GO_TERM","name":"U5 snRNA binding","canonical_id":"go:GO:0030623","description":"\"Binding to a U5 small nuclear RNA (U5 snRNA).\" [GOC:jl]","metadata":null},{"id":"65a3274497b6485d9a36970e16894c03","type":"GO_TERM","name":"U5 snRNP","canonical_id":"go:GO:0005682","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U5, a heptameric ring of Sm proteins, as well as several proteins that are unique to the U5 snRNP, most of which remain associated with the U5 snRNA both while the U5 snRNP is free or assembled into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"bd8f585a8d364ef2b0da324a068aa663","type":"GO_TERM","name":"U6 2'-O-snRNA methylation","canonical_id":"go:GO:1990438","description":"\"The posttranscriptional addition a methyl group to the 2'-oxygen atom of a nucleotide residue in an U6 snRNA molecule.\" [PMID:11842100, PMID:9844635]","metadata":null},{"id":"143855faa45949b1ae2e9d755bad1124","type":"GO_TERM","name":"U6 snRNA (adenine(43)-N6)-methyltransferase activity","canonical_id":"go:GO:0120048","description":"\"Catalysis of the reaction: adenosine in U6 snRNA + S-adenosyl-L-methionine = H+ + N(6)-methyladenosine in U6 snRNA + S-adenosyl-L-homocysteine.\" [PMID:28525753, PMID:32266935, RHEA:52808]","metadata":null},{"id":"3a68b261cb4742fe9ef053a31683c2dd","type":"GO_TERM","name":"U6 snRNA (guanine-N(2))-methyltransferase activity","canonical_id":"go:GO:0160230","description":"\"Catalysis of the reaction: guanosine in U6 snRNA + S-adenosyl-L-methionine = H+ + N(2)-methylguanosine in U6 snRNA + S-adenosyl-L-homocysteine.\" [PMID:37283053]","metadata":null},{"id":"a93a413d2a3c45bd9f7495da909556de","type":"GO_TERM","name":"U6 snRNA 2'-O-ribose methyltransferase activity","canonical_id":"go:GO:0180021","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + U6 snRNA = S-adenosyl-L-homocysteine + U6 containing a 3'-terminal 2'-O-methylnucleotide + H+.\" [PMID:37403782, RHEA:63088]","metadata":null},{"id":"fe5c593689b1482a827f485383525c00","type":"GO_TERM","name":"U6 snRNA 3'-end binding","canonical_id":"go:GO:0030629","description":"\"Binding to a U6 small nuclear RNA (U6 snRNA) at the 3' end.\" [GOC:mah]","metadata":null},{"id":"bf2b53e1c5c443b992a60afe67419a32","type":"GO_TERM","name":"U6 snRNA 3'-end processing","canonical_id":"go:GO:0034477","description":"\"Any process involved in forming the mature 3' end of a U6 snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"b2d069a3612d407d827b6188ce31c663","type":"GO_TERM","name":"U6 snRNA binding","canonical_id":"go:GO:0017070","description":"\"Binding to a U6 small nuclear RNA (U6 snRNA).\" [GOC:mah]","metadata":null},{"id":"d635fb9a5e03497fb76df62c4fc2d9ba","type":"GO_TERM","name":"U6 snRNP","canonical_id":"go:GO:0005688","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U6, the Lsm2-8 heptameric ring complex, as well as several proteins that are unique to the U6 snRNP, most of which remain associated with the U6 snRNA both while the U6 snRNP is free or assembled into the U4/U6 snRNP or into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"b5c1bdbf0957484c96ae568763c0df8b","type":"GO_TERM","name":"U6atac snRNA binding","canonical_id":"go:GO:0030624","description":"\"Binding to a U6atac small nuclear RNA (U6atac snRNA).\" [GOC:jl]","metadata":null},{"id":"d766b864aedf4e63bcd4db66197743a7","type":"GO_TERM","name":"U6atac snRNP","canonical_id":"go:GO:0005691","description":"\"A ribonucleoprotein complex that contains small nuclear RNA U6atac, the Lsm2-8 heptameric ring complex, as well as several proteins that are unique to the U6atac snRNP, most of which remain associated with the U6atac snRNA both while the U6atac snRNP is free or assembled into the U4atac/U6atac snRNP or into a series of spliceosomal complexes.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"abeb4ef9fb9049b4a22c126670017a35","type":"GO_TERM","name":"U7 snRNA binding","canonical_id":"go:GO:0071209","description":"\"Binding to a U7 small nuclear RNA (U7 snRNA).\" [GOC:mah, PMID:12975319]","metadata":null},{"id":"480210c4385e4e679001bb9d98b3fde8","type":"GO_TERM","name":"U7 snRNP","canonical_id":"go:GO:0005683","description":"\"A ribonucleoprotein complex that contains the U7 snRNA and is required for the 3'-end processing of replication-dependent histone pre-mRNAs.\" [PMID:12872004]","metadata":null},{"id":"c8df8c28e793401398482af1128d8fbe","type":"GO_TERM","name":"UAA codon-amino acid adaptor activity","canonical_id":"go:GO:0033411","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UAA codon.\" [GOC:mah]","metadata":null},{"id":"9418214c9498483099438ea26215a3b7","type":"GO_TERM","name":"UAC codon-amino acid adaptor activity","canonical_id":"go:GO:0033410","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UAC codon.\" [GOC:mah]","metadata":null},{"id":"621dcdad6c3446b4a6da3ac5f45e7b7a","type":"GENE","name":"UACA","canonical_id":"hgnc:HGNC:15947","description":"uveal autoantigen with coiled-coil domains and ankyrin repeats","metadata":{"aliases":["FLJ10128","KIAA1561"]}},{"id":"70cbf4f2a6d14b0db055703db7db97ba","type":"GO_TERM","name":"UAG codon-amino acid adaptor activity","canonical_id":"go:GO:0033412","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UAG codon.\" [GOC:mah]","metadata":null},{"id":"e297e94bef294146ada836225b911f80","type":"GENE","name":"UAP1","canonical_id":"hgnc:HGNC:12457","description":"UDP-N-acetylglucosamine pyrophosphorylase 1","metadata":{"aliases":["AGX1","AgX","SPAG2"]}},{"id":"0ed8a8c0f1114d5a851129e3e0f1fbd8","type":"GENE","name":"UAP1-DT","canonical_id":"hgnc:HGNC:55410","description":"UAP1 divergent transcript","metadata":null},{"id":"45f1430dc3c5483fbf66a01c0a523b47","type":"GENE","name":"UAP1L1","canonical_id":"hgnc:HGNC:28082","description":"UDP-N-acetylglucosamine pyrophosphorylase 1 like 1","metadata":null},{"id":"d7cd63fce4044c5d97bd22e78ad8e7e9","type":"TRIAL","name":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","canonical_id":"clinicaltrials.gov:NCT00574080","description":"Multiple Myeloma","metadata":null},{"id":"bfa80c13e0414909bc31cd2c141a8a88","type":"TRIAL","name":"UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination","canonical_id":"clinicaltrials.gov:NCT02578121","description":"Multiple Myeloma","metadata":null},{"id":"5a8c10e8eaf14ffdb8d6183bfbac8b20","type":"GO_TERM","name":"UAU codon-amino acid adaptor activity","canonical_id":"go:GO:0033409","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UAU codon.\" [GOC:mah]","metadata":null},{"id":"7acf91e35fa747a59b4a97556753f4d5","type":"GENE","name":"UBA1","canonical_id":"hgnc:HGNC:12469","description":"ubiquitin like modifier activating enzyme 1","metadata":{"aliases":["UBE1X","POC20","CFAP124","A1S9T","GXP1","UBE1"]}},{"id":"8f70315716ba4aa3be2847d8e11274e2","type":"GENE","name":"UBA2","canonical_id":"hgnc:HGNC:30661","description":"ubiquitin like modifier activating enzyme 2","metadata":{"aliases":["FLJ13058","HRIHFB2115","SAE2"]}},{"id":"ee3a39b97515409b8743338d55d8bb12","type":"GENE","name":"UBA3","canonical_id":"hgnc:HGNC:12470","description":"ubiquitin like modifier activating enzyme 3","metadata":{"aliases":["hUba3","NAE2","UBE1C"]}},{"id":"3de2ba187af848dd93232a1984775d53","type":"GENE","name":"UBA5","canonical_id":"hgnc:HGNC:23230","description":"ubiquitin like modifier activating enzyme 5","metadata":{"aliases":["FLJ23251","UBE1DC1"]}},{"id":"aa9eea6fefd64558939bc7fa9371cdec","type":"GENE","name":"UBA52","canonical_id":"hgnc:HGNC:12458","description":"ubiquitin A-52 residue ribosomal protein fusion product 1","metadata":{"aliases":["RPL40","CEP52","HUBCEP52","MGC57125","MGC126879","MGC126881","L40"]}},{"id":"d692a5c228624b05b129dec25f431e2d","type":"GENE","name":"UBA52P1","canonical_id":"hgnc:HGNC:12459","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 1","metadata":null},{"id":"96917e835e0643c2b2424468377822e6","type":"GENE","name":"UBA52P2","canonical_id":"hgnc:HGNC:12460","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 2","metadata":null},{"id":"fe4559a9cf5e4201833b7dd88f80e838","type":"GENE","name":"UBA52P3","canonical_id":"hgnc:HGNC:20056","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 3","metadata":null},{"id":"4c1748fbe6bc4bf3a5f50e6c037ec587","type":"GENE","name":"UBA52P4","canonical_id":"hgnc:HGNC:35929","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 4","metadata":null},{"id":"0bd4146b7a9447058440660edbcac7e1","type":"GENE","name":"UBA52P5","canonical_id":"hgnc:HGNC:36993","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 5","metadata":null},{"id":"435e37940bf24cf18460fc5a58dc8c13","type":"GENE","name":"UBA52P6","canonical_id":"hgnc:HGNC:36763","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 6","metadata":null},{"id":"5543eb65fd8b4869a9345cc5f482872b","type":"GENE","name":"UBA52P7","canonical_id":"hgnc:HGNC:36615","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 7","metadata":null},{"id":"6be773e2333a4868ae76947d8c6e1089","type":"GENE","name":"UBA52P8","canonical_id":"hgnc:HGNC:35625","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 8","metadata":null},{"id":"4ec62cc4e6eb4bd8907414e595b24882","type":"GENE","name":"UBA52P9","canonical_id":"hgnc:HGNC:36169","description":"ubiquitin A-52 residue ribosomal protein fusion product 1 pseudogene 9","metadata":null},{"id":"25bff17b5bec4ae788b0148b815dfa8b","type":"GENE","name":"UBA5P1","canonical_id":"hgnc:HGNC:56790","description":"UBA5 pseudogene 1","metadata":null},{"id":"2988eae4090447b59003080cd4c816ed","type":"GENE","name":"UBA6","canonical_id":"hgnc:HGNC:25581","description":"ubiquitin like modifier activating enzyme 6","metadata":{"aliases":["FLJ10808","UBE1L2"]}},{"id":"821e710961d04d859a36327b59a449e1","type":"GENE","name":"UBA6-DT","canonical_id":"hgnc:HGNC:49083","description":"UBA6 divergent transcript","metadata":{"aliases":["LOC550112","UBA6-AS1"]}},{"id":"2525972099b349109af16ffa0c2ecc5e","type":"GENE","name":"UBA7","canonical_id":"hgnc:HGNC:12471","description":null,"metadata":null},{"id":"d42f7c8aaa21428da0b6b0e375632c12","type":"GENE","name":"UBAC1","canonical_id":"hgnc:HGNC:30221","description":"UBA domain containing 1","metadata":{"aliases":["GBDR1","KPC2","UBADC1"]}},{"id":"0f3b28964b0e4ee08a6f8287d1a7a2a4","type":"GENE","name":"UBAC2","canonical_id":"hgnc:HGNC:20486","description":"UBA domain containing 2","metadata":{"aliases":["FLJ30548","RP11-178C10.1","PHGDHL1"]}},{"id":"c89a2b16fac6403ab60ef5a56dee3926","type":"GENE","name":"UBAC2-AS1","canonical_id":"hgnc:HGNC:42502","description":"UBAC2 antisense RNA 1","metadata":null},{"id":"32babb9d36884dc999c76d847f1bd518","type":"GENE","name":"UBALD1","canonical_id":"hgnc:HGNC:29576","description":"UBA like domain containing 1","metadata":{"aliases":["FAM100A"]}},{"id":"d773b1ba520043b1aac5107d5c5872bf","type":"GENE","name":"UBALD2","canonical_id":"hgnc:HGNC:28438","description":"UBA like domain containing 2","metadata":{"aliases":["MGC29814","FAM100B"]}},{"id":"a89736f47eb2464b86d4960c5285b198","type":"GENE","name":"UBAP1","canonical_id":"hgnc:HGNC:12461","description":"ubiquitin associated protein 1","metadata":{"aliases":["UBAP"]}},{"id":"0ea93cc2d50d48c59a18ba76817e78b3","type":"GENE","name":"UBAP1L","canonical_id":"hgnc:HGNC:40028","description":"ubiquitin associated protein 1 like","metadata":null},{"id":"dedf11b734f34ac5a4bc079dd73eabd8","type":"GENE","name":"UBAP2","canonical_id":"hgnc:HGNC:14185","description":"ubiquitin associated protein 2","metadata":{"aliases":["KIAA1491","bA176F3.5","FLJ22435"]}},{"id":"5d644486956942bd91b00c27bd6e5eef","type":"GENE","name":"UBAP2L","canonical_id":"hgnc:HGNC:29877","description":"ubiquitin associated protein 2 like","metadata":{"aliases":["NICE-4","KIAA0144"]}},{"id":"c9f53580a2454588af3bb614dc5b9f54","type":"GENE","name":"UBASH3A","canonical_id":"hgnc:HGNC:12462","description":"ubiquitin associated and SH3 domain containing A","metadata":{"aliases":["STS-2","TULA","CLIP4"]}},{"id":"05a2706d2ec64798aab001e5c310340f","type":"GENE","name":"UBASH3B","canonical_id":"hgnc:HGNC:29884","description":"ubiquitin associated and SH3 domain containing B","metadata":{"aliases":["KIAA1959","STS-1","TULA2","TULA-2"]}},{"id":"70652bc48e984c8e9d53c903f631a3de","type":"GENE","name":"UBB","canonical_id":"hgnc:HGNC:12463","description":null,"metadata":null},{"id":"67dbde28a5ae4abfb1e9dd980244c6d7","type":"GENE","name":"UBB-AS1","canonical_id":"hgnc:HGNC:58390","description":"UBB antisense RNA 1","metadata":null},{"id":"1a39a438574e410cbff7b66fae68b1d0","type":"GENE","name":"UBBP1","canonical_id":"hgnc:HGNC:12464","description":"ubiquitin B pseudogene 1","metadata":null},{"id":"bf258726691d4f52af2e0fed72c0f2aa","type":"GENE","name":"UBBP2","canonical_id":"hgnc:HGNC:12465","description":"ubiquitin B pseudogene 2","metadata":null},{"id":"18db5271a36f44f4818ae8f2684767a1","type":"GENE","name":"UBBP3","canonical_id":"hgnc:HGNC:12466","description":"ubiquitin B pseudogene 3","metadata":null},{"id":"25cb874f25ce483aa208d7aa74490044","type":"GENE","name":"UBBP4","canonical_id":"hgnc:HGNC:12467","description":"ubiquitin B pseudogene 4","metadata":null},{"id":"4d4f84a9f9ac4e76bec730f8bccebb8d","type":"GENE","name":"UBBP5","canonical_id":"hgnc:HGNC:42645","description":"ubiquitin B pseudogene 5","metadata":null},{"id":"aeaeb89858064036af3e4d88745d3195","type":"GENE","name":"UBC","canonical_id":"hgnc:HGNC:12468","description":null,"metadata":null},{"id":"5eb7b2ced2324f498abca8a099ee4b72","type":"GO_TERM","name":"UBC13-MMS2 complex","canonical_id":"go:GO:0031372","description":"\"A heterodimeric ubiquitin conjugating enzyme complex that catalyzes assembly of K63-linked polyubiquitin chains. In Saccharomyces cerevisiae, the complex comprises Ubc13p and Mms2p; in human it comprises UBE2N and UBE2V1/UBE2V2; and in plants UBC35/UBC36 and UEV1A/UEV1B/UEV1C/UEV1D-4.\" [GOC:sjm, PMID:15772086, PMID:16129784]","metadata":null},{"id":"cdc7aeae03354c1bba8aa70ff14abbb6","type":"GENE","name":"UBD","canonical_id":"hgnc:HGNC:18795","description":"ubiquitin like modifier D","metadata":{"aliases":["FAT10"]}},{"id":"9f770cd27c474158ba9a7bfa0f264007","type":"GENE","name":"UBDP1","canonical_id":"hgnc:HGNC:18796","description":"ubiquitin D pseudogene 1","metadata":{"aliases":["dJ994E9.3"]}},{"id":"84f801d507de499e9b29d570e229c575","type":"GENE","name":"UBE2A","canonical_id":"hgnc:HGNC:12472","description":"ubiquitin conjugating enzyme E2 A","metadata":{"aliases":["UBC2","HHR6A","RAD6A","HR6A"]}},{"id":"8d6e5da8ff284387a99452e0aa16891d","type":"GENE","name":"UBE2B","canonical_id":"hgnc:HGNC:12473","description":"ubiquitin conjugating enzyme E2 B","metadata":{"aliases":["UBC2","HHR6B","RAD6B"]}},{"id":"19a881462e2846f6a830d420a8f7ed0e","type":"GENE","name":"UBE2C","canonical_id":"hgnc:HGNC:15937","description":null,"metadata":null},{"id":"ab0f1acfcb764847a3bbac300cb85ab1","type":"GENE","name":"UBE2CP1","canonical_id":"hgnc:HGNC:19670","description":"ubiquitin conjugating enzyme E2 C pseudogene 1","metadata":null},{"id":"3cc8ef7fd8ba42e3ab51cddd6108b2e0","type":"GENE","name":"UBE2CP2","canonical_id":"hgnc:HGNC:43551","description":"ubiquitin conjugating enzyme E2 C pseudogene 2","metadata":null},{"id":"c979fde57ecd46e79dc685b636eee0d5","type":"GENE","name":"UBE2CP3","canonical_id":"hgnc:HGNC:43552","description":"ubiquitin conjugating enzyme E2 C pseudogene 3","metadata":null},{"id":"90bc2bd4457b4be08cdc8df44de4be2b","type":"GENE","name":"UBE2CP4","canonical_id":"hgnc:HGNC:43553","description":"ubiquitin conjugating enzyme E2 C pseudogene 4","metadata":null},{"id":"93fca5832203476686c48ad7862334a6","type":"GENE","name":"UBE2CP5","canonical_id":"hgnc:HGNC:43554","description":"ubiquitin conjugating enzyme E2 C pseudogene 5","metadata":null},{"id":"0f9747d5b8b04eeda3ca798b9fd04e3f","type":"GENE","name":"UBE2D1","canonical_id":"hgnc:HGNC:12474","description":"ubiquitin conjugating enzyme E2 D1","metadata":{"aliases":["UbcH5A","UBCH5","UBC4/5","E2(17)KB1","SFT"]}},{"id":"863c7f4c4e8b4e889df4736bcbb2634e","type":"GENE","name":"UBE2D2","canonical_id":"hgnc:HGNC:12475","description":"ubiquitin conjugating enzyme E2 D2","metadata":{"aliases":["UbcH5B","UBC4"]}},{"id":"6fdca11c1cef47358b1d22ecd2b15273","type":"GENE","name":"UBE2D3","canonical_id":"hgnc:HGNC:12476","description":null,"metadata":null},{"id":"7b0f9d8eeb4e47c1a9e1c39deb6ed11e","type":"GENE","name":"UBE2D3-AS1","canonical_id":"hgnc:HGNC:54095","description":"UBE2D3 antisense RNA 1","metadata":null},{"id":"6ec15d8da86940f4b68ff33b3cf08bb9","type":"GENE","name":"UBE2D3P1","canonical_id":"hgnc:HGNC:33349","description":"ubiquitin conjugating enzyme E2 D3 pseudogene 1","metadata":{"aliases":["RP4-680N4","UBE2D5P","UBE2D3P"]}},{"id":"806c6ee530944e59895e68aa462883d3","type":"GENE","name":"UBE2D3P2","canonical_id":"hgnc:HGNC:39010","description":"ubiquitin conjugating enzyme E2 D3 pseudogene 2","metadata":null},{"id":"d400a6030f9846e48c30856063678d6d","type":"GENE","name":"UBE2D3P3","canonical_id":"hgnc:HGNC:39011","description":"ubiquitin conjugating enzyme E2 D3 pseudogene 3","metadata":null},{"id":"9aff9d5585cd45cda496b44c06267720","type":"GENE","name":"UBE2D3P4","canonical_id":"hgnc:HGNC:39391","description":"ubiquitin conjugating enzyme E2 D3 pseudogene 4","metadata":null},{"id":"eecda96be24b4e479779c8a11239db1e","type":"GENE","name":"UBE2D3P5","canonical_id":"hgnc:HGNC:56916","description":"UBE2D3 pseudogene 5","metadata":null},{"id":"572c7daaa8c640b3918270e3b054d72f","type":"GENE","name":"UBE2D4","canonical_id":"hgnc:HGNC:21647","description":"ubiquitin conjugating enzyme E2 D4","metadata":{"aliases":["HBUCE1"]}},{"id":"00b2e57b4e8349a69a6fad48afea54d5","type":"GENE","name":"UBE2D4P1","canonical_id":"hgnc:HGNC:58632","description":"UBE2D4 pseudogene 1","metadata":null},{"id":"14af97cd7c6a406c830759b4880cebcc","type":"GENE","name":"UBE2D4P2","canonical_id":"hgnc:HGNC:58633","description":"UBE2D4 pseudogene 2","metadata":null},{"id":"dc2f0964f3f040bc98da91b7b3e649e1","type":"GENE","name":"UBE2D4P3","canonical_id":"hgnc:HGNC:58634","description":"UBE2D4 pseudogene 3","metadata":null},{"id":"ff32736db03f4abbabb7e2e617058450","type":"GENE","name":"UBE2DNL","canonical_id":"hgnc:HGNC:28656","description":"ubiquitin conjugating enzyme E2 D N-terminal like (pseudogene)","metadata":{"aliases":["MGC42638"]}},{"id":"1b98c501f66a4787ab688e4880b75cee","type":"GENE","name":"UBE2E1","canonical_id":"hgnc:HGNC:12477","description":"ubiquitin conjugating enzyme E2 E1","metadata":{"aliases":["UbcH6"]}},{"id":"4b3cf6a027b24d81ae9c09b02c22782b","type":"GENE","name":"UBE2E1-AS1","canonical_id":"hgnc:HGNC:40598","description":"UBE2E1 antisense RNA 1","metadata":null},{"id":"d05f2f2ff5744b66a09ea0e9c65026b3","type":"GENE","name":"UBE2E2","canonical_id":"hgnc:HGNC:12478","description":"ubiquitin conjugating enzyme E2 E2","metadata":{"aliases":["UbcH8","FLJ25157"]}},{"id":"a4a450b114584826abe92b4de00fe483","type":"GENE","name":"UBE2E2-DT","canonical_id":"hgnc:HGNC:44512","description":"UBE2E2 divergent transcript","metadata":{"aliases":["UBE2E2-AS1"]}},{"id":"d3c64fec10f246f59e23288d5e99027b","type":"GENE","name":"UBE2E3","canonical_id":"hgnc:HGNC:12479","description":"ubiquitin conjugating enzyme E2 E3","metadata":{"aliases":["UbcH9"]}},{"id":"5ae9d4c243b948788e5b40e9d3b20817","type":"GENE","name":"UBE2E3-DT","canonical_id":"hgnc:HGNC:40599","description":"UBE2E3 divergent transcript","metadata":null},{"id":"3d0a5b5903b54081bcc967dd7f0f2f14","type":"GENE","name":"UBE2E4P","canonical_id":"hgnc:HGNC:32199","description":"ubiquitin conjugating enzyme E2 E4 pseudogene","metadata":{"aliases":["UbcM2"]}},{"id":"ecb6a6e010c14588b701f6c351fa0d37","type":"GENE","name":"UBE2F","canonical_id":"hgnc:HGNC:12480","description":"ubiquitin conjugating enzyme E2 F (putative)","metadata":{"aliases":["NCE2"]}},{"id":"abe9188ef8894d34b07b3c5fac9d27bc","type":"GENE","name":"UBE2F-SCLY","canonical_id":"hgnc:HGNC:48339","description":"UBE2F-SCLY readthrough (NMD candidate)","metadata":null},{"id":"136b94e424e048babbf5fd56125dc29a","type":"GENE","name":"UBE2FP1","canonical_id":"hgnc:HGNC:44535","description":"UBE2F pseudogene 1","metadata":null},{"id":"99fe710c39074feab552c77cd2297fad","type":"GENE","name":"UBE2FP2","canonical_id":"hgnc:HGNC:44536","description":"UBE2F pseudogene 2","metadata":null},{"id":"09a9b3f6ff05408180d15b0f350c043d","type":"GENE","name":"UBE2FP3","canonical_id":"hgnc:HGNC:44537","description":"UBE2F pseudogene 3","metadata":null},{"id":"db406665dbe441408d2ba0c96b8a0eea","type":"GENE","name":"UBE2G1","canonical_id":"hgnc:HGNC:12482","description":"ubiquitin conjugating enzyme E2 G1","metadata":{"aliases":["UBC7","UBE2G"]}},{"id":"97f1248e22c145f7873c82aed110cfc2","type":"GENE","name":"UBE2G2","canonical_id":"hgnc:HGNC:12483","description":"ubiquitin conjugating enzyme E2 G2","metadata":{"aliases":["UBC7"]}},{"id":"2b0e23ecb0414e61bf0afe78c138134b","type":"GENE","name":"UBE2H","canonical_id":"hgnc:HGNC:12484","description":"ubiquitin conjugating enzyme E2 H","metadata":{"aliases":["UBCH","UBC8","GID3"]}},{"id":"ef1cdbb550d34ff6a05f55b82b3460ee","type":"GENE","name":"UBE2H-DT","canonical_id":"hgnc:HGNC:55615","description":"UBE2H divergent transcript","metadata":null},{"id":"ef6d8b900d94464e9db8ea9c5dcbb826","type":"GENE","name":"UBE2HP1","canonical_id":"hgnc:HGNC:31079","description":"ubiquitin conjugating enzyme E2 H pseudogene 1","metadata":{"aliases":["UBE2HP"]}},{"id":"423eb4a375e948ddb665f1b2683f4e1d","type":"GENE","name":"UBE2I","canonical_id":"hgnc:HGNC:12485","description":null,"metadata":null},{"id":"c0dc5e0470a1499899d19d4e50def274","type":"GENE","name":"UBE2I-AS1","canonical_id":"hgnc:HGNC:58131","description":"UBE2I antisense RNA 1","metadata":{"aliases":["RP11-616M22.7"]}},{"id":"1939675fd2ee46b9805f4c7bb93ec0d2","type":"GENE","name":"UBE2J1","canonical_id":"hgnc:HGNC:17598","description":"ubiquitin conjugating enzyme E2 J1","metadata":{"aliases":["HSPC153","CGI-76","NCUBE1","UBC6"]}},{"id":"c4b22ed1773044c2b07dac3c13817110","type":"GENE","name":"UBE2J2","canonical_id":"hgnc:HGNC:19268","description":"ubiquitin conjugating enzyme E2 J2","metadata":{"aliases":["Ubc6p","NCUBE2"]}},{"id":"5f0a07deae0443d0b64c414097f2aecb","type":"GENE","name":"UBE2K","canonical_id":"hgnc:HGNC:4914","description":"ubiquitin conjugating enzyme E2 K","metadata":{"aliases":["HYPG","UBC1","HIP2"]}},{"id":"1c8241578571450f95c127b4ec1b8fb9","type":"GENE","name":"UBE2L1","canonical_id":"hgnc:HGNC:12486","description":"ubiquitin conjugating enzyme E2 L1 (pseudogene)","metadata":{"aliases":["UBEL1","L-UBC","UBCH7N3","UBE2L7P","UBE2L7"]}},{"id":"1ddea32f521c49e29303ed0468e46df5","type":"GENE","name":"UBE2L2","canonical_id":"hgnc:HGNC:12487","description":"ubiquitin conjugating enzyme E2 L2 (pseudogene)","metadata":null},{"id":"ac6829f812da4867a890b37e29e4a0e0","type":"GENE","name":"UBE2L3","canonical_id":"hgnc:HGNC:12488","description":"ubiquitin conjugating enzyme E2 L3","metadata":{"aliases":["UBCH7"]}},{"id":"8cc697c95d114747a9913e1b15392bb8","type":"GENE","name":"UBE2L3P1","canonical_id":"hgnc:HGNC:58636","description":"UBE2L3 pseudogene 1","metadata":null},{"id":"3d978ec84af047e394e405e3f6fc29a4","type":"GENE","name":"UBE2L3P2","canonical_id":"hgnc:HGNC:58637","description":"UBE2L3 pseudogene 2","metadata":null},{"id":"3e3fb3e15bfd4078b911475b9c9734d3","type":"GENE","name":"UBE2L3P3","canonical_id":"hgnc:HGNC:58638","description":"UBE2L3 pseudogene 3","metadata":null},{"id":"f92a260be7884f7490b81a769d2b3e8f","type":"GENE","name":"UBE2L4","canonical_id":"hgnc:HGNC:12489","description":"ubiquitin conjugating enzyme E2 L4 (pseudogene)","metadata":null},{"id":"f2bce96e067a4b998653750513dae440","type":"GENE","name":"UBE2L5","canonical_id":"hgnc:HGNC:13477","description":"ubiquitin conjugating enzyme E2 L5","metadata":{"aliases":["UBE2L5P"]}},{"id":"c11e1a7509db4be999e5a744a06b7de0","type":"GENE","name":"UBE2L6","canonical_id":"hgnc:HGNC:12490","description":"ubiquitin conjugating enzyme E2 L6","metadata":{"aliases":["UBCH8"]}},{"id":"96ede70e8d324577a7bc1a5a16550a99","type":"GENE","name":"UBE2M","canonical_id":"hgnc:HGNC:12491","description":"ubiquitin conjugating enzyme E2 M","metadata":{"aliases":["hUbc12","UBC12"]}},{"id":"e22c87db41c042fc9640a0031bbb7fab","type":"GENE","name":"UBE2MP1","canonical_id":"hgnc:HGNC:32195","description":"ubiquitin conjugating enzyme E2 M pseudogene 1","metadata":null},{"id":"3fe52301f1e546b78659ef86d763328a","type":"GENE","name":"UBE2N","canonical_id":"hgnc:HGNC:12492","description":"ubiquitin conjugating enzyme E2 N","metadata":{"aliases":["UbcH-ben","UBC13","MGC8489"]}},{"id":"93e4d1481f934fb8871850bd3948c98e","type":"GENE","name":"UBE2NL","canonical_id":"hgnc:HGNC:31710","description":"ubiquitin conjugating enzyme E2 N like (gene/pseudogene)","metadata":null},{"id":"b843864ca32b469ca1766c9e493b1a49","type":"GENE","name":"UBE2NP1","canonical_id":"hgnc:HGNC:20337","description":"ubiquitin conjugating enzyme E2 N pseudogene 1","metadata":null},{"id":"3fbac1a4b8954c0eb539f68a30163181","type":"GENE","name":"UBE2O","canonical_id":"hgnc:HGNC:29554","description":"ubiquitin conjugating enzyme E2 O","metadata":{"aliases":["E2-230K"]}},{"id":"74cd0ebd23454c4095dd49546e4f2922","type":"GENE","name":"UBE2Q1","canonical_id":"hgnc:HGNC:15698","description":"ubiquitin conjugating enzyme E2 Q1","metadata":{"aliases":["PRO3094","NICE-5","UBE2Q"]}},{"id":"fc68596e1edf4f60a426f637eb0681ac","type":"GENE","name":"UBE2Q1-AS1","canonical_id":"hgnc:HGNC:40722","description":"UBE2Q1 antisense RNA 1","metadata":null},{"id":"a79cfd3639194b4186877d111cac5e42","type":"GENE","name":"UBE2Q2","canonical_id":"hgnc:HGNC:19248","description":"ubiquitin conjugating enzyme E2 Q2","metadata":{"aliases":["DKFZp762C143"]}},{"id":"2078e35183ee412a825987979c4e7db3","type":"GENE","name":"UBE2Q2P1","canonical_id":"hgnc:HGNC:37439","description":"UBE2Q2 pseudogene 1","metadata":{"aliases":["FLJ43276","UBE2QP1"]}},{"id":"8b9f8fab340d4c859e9f84330aa71cfa","type":"GENE","name":"UBE2Q2P10","canonical_id":"hgnc:HGNC:49518","description":"UBE2Q2 pseudogene 10","metadata":null},{"id":"6da5dc63feff4cf9b34a6ae14539520d","type":"GENE","name":"UBE2Q2P11","canonical_id":"hgnc:HGNC:49522","description":"UBE2Q2 pseudogene 11","metadata":null},{"id":"f508b2177d894e46b1693176a16c5550","type":"GENE","name":"UBE2Q2P12","canonical_id":"hgnc:HGNC:49523","description":"UBE2Q2 pseudogene 12","metadata":null},{"id":"d831cd8e05834103bf073c6c269068f4","type":"GENE","name":"UBE2Q2P13","canonical_id":"hgnc:HGNC:56078","description":"UBE2Q2 pseudogene 13","metadata":null},{"id":"b840e16c5902426eb7b70f5a89f15706","type":"GENE","name":"UBE2Q2P16","canonical_id":"hgnc:HGNC:44656","description":"UBE2Q2 pseudogene 16","metadata":{"aliases":["UBE2Q2L"]}},{"id":"ba0e2b2a35b2426ca85e285eb4baf972","type":"GENE","name":"UBE2Q2P2","canonical_id":"hgnc:HGNC:37440","description":"UBE2Q2 pseudogene 2","metadata":{"aliases":["UBE2QP2","UBE2Q2P3"]}},{"id":"d9c1789a4c5d42118dca88b365f8a8ef","type":"GENE","name":"UBE2Q2P4Y","canonical_id":"hgnc:HGNC:38429","description":"UBE2Q2 pseudogene 4, Y-linked","metadata":{"aliases":["UBE2Q2PY1"]}},{"id":"13c91bb19b7b4353921cdd4b60a8f0b4","type":"GENE","name":"UBE2Q2P5Y","canonical_id":"hgnc:HGNC:38466","description":"UBE2Q2 pseudogene 5, Y-linked","metadata":{"aliases":["UBE2Q2PY2"]}},{"id":"f04ab9c7d4274af7a97580fb491392cc","type":"GENE","name":"UBE2Q2P6","canonical_id":"hgnc:HGNC:49412","description":"UBE2Q2 pseudogene 6","metadata":null},{"id":"b2a0ce0fa14e47dc85f092b682405712","type":"GENE","name":"UBE2Q2P7","canonical_id":"hgnc:HGNC:49413","description":"UBE2Q2 pseudogene 7","metadata":null},{"id":"ed81b2fdebef4d23b55dfb5c2dbc7572","type":"GENE","name":"UBE2Q2P8","canonical_id":"hgnc:HGNC:49521","description":"UBE2Q2 pseudogene 8","metadata":null},{"id":"d8b4aadf7a5c45c69a6e184e94b8d5b1","type":"GENE","name":"UBE2Q2P9","canonical_id":"hgnc:HGNC:49517","description":"UBE2Q2 pseudogene 9","metadata":null},{"id":"ac6d41e76f2e490fa43f6e0062ac8c3f","type":"GENE","name":"UBE2QL1","canonical_id":"hgnc:HGNC:37269","description":"ubiquitin conjugating enzyme E2 QL1","metadata":{"aliases":["FLJ25076"]}},{"id":"ef74c1b170ba46c5a95aa6266c61d36b","type":"GENE","name":"UBE2R2","canonical_id":"hgnc:HGNC:19907","description":"ubiquitin conjugating enzyme E2 R2","metadata":{"aliases":["UBC3B","CDC34B","FLJ20419","MGC10481"]}},{"id":"57e558ed2bbf43978469ed32a927ffeb","type":"GENE","name":"UBE2R2-AS1","canonical_id":"hgnc:HGNC:49911","description":"UBE2R2 antisense RNA 1","metadata":{"aliases":["LINC01251"]}},{"id":"f157c034622f4378a6289472c93205af","type":"GENE","name":"UBE2S","canonical_id":"hgnc:HGNC:17895","description":null,"metadata":null},{"id":"c45c5eff0b30443bad6fd2bbdc148d2c","type":"GENE","name":"UBE2SP1","canonical_id":"hgnc:HGNC:30864","description":"ubiquitin conjugating enzyme E2 S pseudogene 1","metadata":null},{"id":"aafb7bae5b604e8eaae119e9c3c78d85","type":"GENE","name":"UBE2SP2","canonical_id":"hgnc:HGNC:32196","description":"ubiquitin conjugating enzyme E2 S pseudogene 2","metadata":null},{"id":"d662bc33bc0a417c91c0f44fcebfd6de","type":"GENE","name":"UBE2T","canonical_id":"hgnc:HGNC:25009","description":"ubiquitin conjugating enzyme E2 T","metadata":{"aliases":["HSPC150","FANCT"]}},{"id":"452f64a6c9fd455da5ff3a3007dcc102","type":"GENE","name":"UBE2U","canonical_id":"hgnc:HGNC:28559","description":"ubiquitin conjugating enzyme E2 U","metadata":{"aliases":["MGC35130"]}},{"id":"522b2ef143794975a0212e4e9a32a823","type":"GENE","name":"UBE2V1","canonical_id":"hgnc:HGNC:12494","description":"ubiquitin conjugating enzyme E2 V1","metadata":{"aliases":["UEV-1","CROC-1","UEV1A","CROC1","UBE2V"]}},{"id":"b655bf73af584d9a8eecce317e5d62fe","type":"GENE","name":"UBE2V1P1","canonical_id":"hgnc:HGNC:16581","description":"UBE2V1 pseudogene 1","metadata":{"aliases":["dJ687F11.3"]}},{"id":"3a6be0426ca1486f88095598dc79f68b","type":"GENE","name":"UBE2V1P10","canonical_id":"hgnc:HGNC:44895","description":"UBE2V1 pseudogene 10","metadata":null},{"id":"362fa03a2b6e47988217bc502870144e","type":"GENE","name":"UBE2V1P11","canonical_id":"hgnc:HGNC:44896","description":"UBE2V1 pseudogene 11","metadata":null},{"id":"bc224509e43f4a8fb3bf6cb61c6caa26","type":"GENE","name":"UBE2V1P12","canonical_id":"hgnc:HGNC:44897","description":"UBE2V1 pseudogene 12","metadata":null},{"id":"70f8fbb5757a498cbf41d1b840e895b9","type":"GENE","name":"UBE2V1P13","canonical_id":"hgnc:HGNC:52411","description":"UBE2V1 pseudogene 13","metadata":null},{"id":"874256007c054f54bfa4b87f969f4096","type":"GENE","name":"UBE2V1P14","canonical_id":"hgnc:HGNC:52412","description":"UBE2V1 pseudogene 14","metadata":null},{"id":"a08db4523d204298bdd8ebe62b65141f","type":"GENE","name":"UBE2V1P15","canonical_id":"hgnc:HGNC:52414","description":"UBE2V1 pseudogene 15","metadata":null},{"id":"2b481a64d8734a76bb8966acbde26d02","type":"GENE","name":"UBE2V1P16","canonical_id":"hgnc:HGNC:55086","description":"UBE2V1 pseudogene 16","metadata":null},{"id":"89b8cb01cc074c0d9267f2436f4a41e4","type":"GENE","name":"UBE2V1P2","canonical_id":"hgnc:HGNC:32648","description":"UBE2V1 pseudogene 2","metadata":null},{"id":"105ce8b609a944578de1f779f22b6e38","type":"GENE","name":"UBE2V1P3","canonical_id":"hgnc:HGNC:23983","description":"UBE2V1 pseudogene 3","metadata":null},{"id":"43ccb78a1b034cee8bfcf2f34f3893ac","type":"GENE","name":"UBE2V1P4","canonical_id":"hgnc:HGNC:44886","description":"UBE2V1 pseudogene 4","metadata":null},{"id":"7f45ed41831a4ac099f49fdbe256399c","type":"GENE","name":"UBE2V1P5","canonical_id":"hgnc:HGNC:44888","description":"UBE2V1 pseudogene 5","metadata":null},{"id":"d7cbb2b368164574aecb45239e78d271","type":"GENE","name":"UBE2V1P6","canonical_id":"hgnc:HGNC:44889","description":"UBE2V1 pseudogene 6","metadata":null},{"id":"6a7bb9db0e3545f58b2db9562031df8d","type":"GENE","name":"UBE2V1P7","canonical_id":"hgnc:HGNC:44890","description":"UBE2V1 pseudogene 7","metadata":null},{"id":"e74fd05a6c5f477ebc0985d596126063","type":"GENE","name":"UBE2V1P8","canonical_id":"hgnc:HGNC:44893","description":"UBE2V1 pseudogene 8","metadata":null},{"id":"bc88608d5ac3451b827908644f83f651","type":"GENE","name":"UBE2V1P9","canonical_id":"hgnc:HGNC:44894","description":"UBE2V1 pseudogene 9","metadata":null},{"id":"d3cbdf9960b446eba85a71472e7bb895","type":"GENE","name":"UBE2V2","canonical_id":"hgnc:HGNC:12495","description":"ubiquitin conjugating enzyme E2 V2","metadata":{"aliases":["UEV-2","DDVit-1","EDPF-1","MMS2","UEV2","EDPF1","DDVIT1","EDAF-1"]}},{"id":"ca0b8b137cfa4f009bf38f472f81d426","type":"GENE","name":"UBE2V2-AS1","canonical_id":"hgnc:HGNC:56732","description":"UBE2V2 antisense RNA 1","metadata":{"aliases":["TCONS_00068220"]}},{"id":"3049c160a05f4208ae9c74d6d77713cc","type":"GENE","name":"UBE2V2P1","canonical_id":"hgnc:HGNC:44885","description":"ubiquitin conjugating enzyme E2 V2 pseudogene 1","metadata":null},{"id":"1e5bf60df3c849cbbcc13f74fa500b75","type":"GENE","name":"UBE2V2P2","canonical_id":"hgnc:HGNC:44887","description":"ubiquitin conjugating enzyme E2 V2 pseudogene 2","metadata":null},{"id":"070ddf55c051459293a7d7579b7bb42c","type":"GENE","name":"UBE2V2P3","canonical_id":"hgnc:HGNC:44891","description":"ubiquitin conjugating enzyme E2 V2 pseudogene 3","metadata":null},{"id":"5a502b4640e74a27b9e86c581f7dcbca","type":"GENE","name":"UBE2V2P4","canonical_id":"hgnc:HGNC:44892","description":"ubiquitin conjugating enzyme E2 V2 pseudogene 4","metadata":null},{"id":"80f00f2a1f1a47d1a58c566b92a6d558","type":"GENE","name":"UBE2W","canonical_id":"hgnc:HGNC:25616","description":"ubiquitin conjugating enzyme E2 W","metadata":{"aliases":["FLJ11011","UBC-16"]}},{"id":"1dc8b213f01e4e629db2cf17e9a8d05d","type":"GENE","name":"UBE2WP1","canonical_id":"hgnc:HGNC:32198","description":"ubiquitin conjugating enzyme E2 W pseudogene 1","metadata":{"aliases":["UBE2WP"]}},{"id":"16d28d7cb36f4d51ae735d3bc6a1bcbc","type":"GENE","name":"UBE2Z","canonical_id":"hgnc:HGNC:25847","description":"ubiquitin conjugating enzyme E2 Z","metadata":{"aliases":["FLJ13855","USE1"]}},{"id":"92c7d99f810644fe9f639d8570a4bae3","type":"GENE","name":"UBE3A","canonical_id":"hgnc:HGNC:12496","description":"ubiquitin protein ligase E3A","metadata":{"aliases":["AS","ANCR","E6-AP","FLJ26981","EPVE6AP","HPVE6A"]}},{"id":"e82148b5c00a4a7895cef9184e349ca1","type":"GENE","name":"UBE3AP1","canonical_id":"hgnc:HGNC:12497","description":"ubiquitin protein ligase E3A pseudogene 1","metadata":null},{"id":"5a2c5870ffd74f879f3fde2e85a99845","type":"GENE","name":"UBE3AP2","canonical_id":"hgnc:HGNC:12498","description":"ubiquitin protein ligase E3A pseudogene 2","metadata":null},{"id":"cdde2d3da2314ef9acd3edaec20b60c8","type":"GENE","name":"UBE3B","canonical_id":"hgnc:HGNC:13478","description":"ubiquitin protein ligase E3B","metadata":null},{"id":"71ecded016c04d669de1a3f37f3bf508","type":"GENE","name":"UBE3C","canonical_id":"hgnc:HGNC:16803","description":"ubiquitin protein ligase E3C","metadata":{"aliases":["KIAA0010","KIAA10"]}},{"id":"d444dd6438794a748129114a845bd817","type":"GENE","name":"UBE3D","canonical_id":"hgnc:HGNC:21381","description":"ubiquitin protein ligase E3D","metadata":{"aliases":["DKFZp434A1520","H10BH","YJR141W","C6orf157","UBE2CBP"]}},{"id":"08444cdefecb4c8e8fc0f478da686a4b","type":"GENE","name":"UBE4A","canonical_id":"hgnc:HGNC:12499","description":"ubiquitination factor E4A","metadata":{"aliases":["UBOX2","UFD2","KIAA0126","E4"]}},{"id":"bda77e6fe2004d599a816c4507bfdeee","type":"GENE","name":"UBE4B","canonical_id":"hgnc:HGNC:12500","description":"ubiquitination factor E4B","metadata":{"aliases":["UBOX3","E4","UFD2","KIAA0684"]}},{"id":"063a23b7210648239235ea195c28ed32","type":"GENE","name":"UBFD1","canonical_id":"hgnc:HGNC:30565","description":"ubiquitin family domain containing 1","metadata":{"aliases":["FLJ42145","FLJ38870","UBPH"]}},{"id":"d61672f7e42544ecbbfbd403d71de2ce","type":"GENE","name":"UBFD1P1","canonical_id":"hgnc:HGNC:42389","description":"ubiquitin family domain containing 1 pseudogene 1","metadata":null},{"id":"f098aeeb65c44769acf2ea14584373f8","type":"GENE","name":"UBIAD1","canonical_id":"hgnc:HGNC:30791","description":"UbiA prenyltransferase domain containing 1","metadata":{"aliases":["TERE1","SCCD"]}},{"id":"241c22e7837d47f494f78fb53fc2aeee","type":"GENE","name":"UBL3","canonical_id":"hgnc:HGNC:12504","description":"ubiquitin like 3","metadata":{"aliases":["HCG-1","DKFZP434K151","FLJ32018","PNSC1"]}},{"id":"05f94a50fede437992fa2631919eec92","type":"GENE","name":"UBL4A","canonical_id":"hgnc:HGNC:12505","description":"ubiquitin like 4A","metadata":{"aliases":["GDX","DXS254E","GET5","MDY2","TMA24","UBL4"]}},{"id":"e15521ba172348c6a46e67fd650ef3a7","type":"GENE","name":"UBL4B","canonical_id":"hgnc:HGNC:32309","description":"ubiquitin like 4B","metadata":{"aliases":["FLJ25690"]}},{"id":"79cbc94236af4b0e87e7c316906467d4","type":"GENE","name":"UBL5","canonical_id":"hgnc:HGNC:13736","description":"ubiquitin like 5","metadata":null},{"id":"ae742577cbc846918a721efd4067529e","type":"GENE","name":"UBL5P1","canonical_id":"hgnc:HGNC:44639","description":"ubiquitin like 5 pseudogene 1","metadata":null},{"id":"7c1f1036a60e46f2b0de8689261f42aa","type":"GENE","name":"UBL5P2","canonical_id":"hgnc:HGNC:44640","description":"ubiquitin like 5 pseudogene 2","metadata":null},{"id":"62591d216b184552addf07188f7a357a","type":"GENE","name":"UBL5P3","canonical_id":"hgnc:HGNC:44641","description":"ubiquitin like 5 pseudogene 3","metadata":null},{"id":"8c13fae0059f49448a75b3740de0e2ff","type":"GENE","name":"UBL5P4","canonical_id":"hgnc:HGNC:44642","description":"ubiquitin like 5 pseudogene 4","metadata":null},{"id":"18769839dc844a6c83b9ed9f38c84961","type":"GENE","name":"UBL7","canonical_id":"hgnc:HGNC:28221","description":"ubiquitin like 7","metadata":{"aliases":["BMSC-UbP","MGC14421"]}},{"id":"7a81600eeb6646379e5af5725fc49a6b","type":"GENE","name":"UBL7-DT","canonical_id":"hgnc:HGNC:48614","description":"UBL7 divergent transcript","metadata":{"aliases":["UBL7-AS1"]}},{"id":"23bcf148616f4e26af9a95d69173dd3e","type":"GENE","name":"UBLCP1","canonical_id":"hgnc:HGNC:28110","description":"ubiquitin like domain containing CTD phosphatase 1","metadata":{"aliases":["MGC10067","CPUB1"]}},{"id":"5209a28aa7cc437aa1beeb8c740c613b","type":"GENE","name":"UBLCP1-AS1","canonical_id":"hgnc:HGNC:59294","description":"UBLCP1 antisense RNA 1","metadata":null},{"id":"ba30eccc6b5a4d949b473842c263b35e","type":"GENE","name":"UBN1","canonical_id":"hgnc:HGNC:12506","description":"ubinuclein 1","metadata":null},{"id":"0627892edcc3498bbbc9842420c05d9a","type":"GENE","name":"UBN2","canonical_id":"hgnc:HGNC:21931","description":"ubinuclein 2","metadata":{"aliases":["FLJ25778","KIAA2030"]}},{"id":"dfc5290429804a8488c99d1f2a276982","type":"GENE","name":"UBOX5","canonical_id":"hgnc:HGNC:17777","description":"U-box domain containing 5","metadata":{"aliases":["UIP5","KIAA0860","Ubce7ip5","RNF37"]}},{"id":"5ec0d953f2d94b4bb1036b3ddd4fff82","type":"GENE","name":"UBOX5-AS1","canonical_id":"hgnc:HGNC:44111","description":"UBOX5 antisense RNA 1","metadata":null},{"id":"374577f03f6b47019328f1e68a4e2488","type":"GENE","name":"UBP1","canonical_id":"hgnc:HGNC:12507","description":null,"metadata":null},{"id":"8c56983b33424c02874ae6c6c0761394","type":"GENE","name":"UBQLN1","canonical_id":"hgnc:HGNC:12508","description":"ubiquilin 1","metadata":{"aliases":["DSK2","PLIC-1","XDRP1","DA41"]}},{"id":"0bb59415dc344d9599e9c345e3bccf7d","type":"GENE","name":"UBQLN1-AS1","canonical_id":"hgnc:HGNC:55518","description":"UBQLN1 antisense RNA 1","metadata":null},{"id":"41eab9c8d86b4643bcb4e3965b4e995d","type":"GENE","name":"UBQLN1P1","canonical_id":"hgnc:HGNC:21633","description":"ubiquilin 1 pseudogene 1","metadata":{"aliases":["UBQLN1P"]}},{"id":"651f08e3d671429eadabfd8df75737c8","type":"GENE","name":"UBQLN2","canonical_id":"hgnc:HGNC:12509","description":"ubiquilin 2","metadata":{"aliases":["Chap1","Dsk2","RIHFB2157","LIC-2","CHAP1/DSK2","PLIC-2","N4BP4","PLIC2"]}},{"id":"4b348796379b437082ad596348776123","type":"GENE","name":"UBQLN3","canonical_id":"hgnc:HGNC:12510","description":"ubiquilin 3","metadata":{"aliases":["TUP-1"]}},{"id":"e569164dd97e41bead1bd417383388a9","type":"GENE","name":"UBQLN4","canonical_id":"hgnc:HGNC:1237","description":"ubiquilin 4","metadata":{"aliases":["A1U","UBIN","CIP75","C1orf6"]}},{"id":"83b9890fbb9b438a81a1ccdfbf180eb2","type":"GENE","name":"UBQLN4P1","canonical_id":"hgnc:HGNC:31133","description":"ubiquilin 4 pseudogene 1","metadata":{"aliases":["C3orf12","UBQLN4P"]}},{"id":"5c002aa279b84070a2ade8d3deff2206","type":"GENE","name":"UBQLN4P2","canonical_id":"hgnc:HGNC:38662","description":"ubiquilin 4 pseudogene 2","metadata":null},{"id":"b539c6365bb24ba98681bbdf3a763b38","type":"GENE","name":"UBQLNL","canonical_id":"hgnc:HGNC:28294","description":"ubiquilin like","metadata":{"aliases":["MGC20470","MGC26958"]}},{"id":"6ba0eb784efb456bbdda5c6946e0262f","type":"GENE","name":"UBR1","canonical_id":"hgnc:HGNC:16808","description":"ubiquitin protein ligase E3 component n-recognin 1","metadata":null},{"id":"7b80075eb7224455b8fc1779d5411acf","type":"GO_TERM","name":"UBR1-RAD6 ubiquitin ligase complex","canonical_id":"go:GO:1990303","description":"\"A ubiquitin ligase complex consisting of UBR1 and RAD6 components. It polyubiquitinates proteins containing non-acetylated N-terminal residues causing their subsequent degradation by the proteasome as part of the Ac/N-End Rule pathway. It recognizes non-acetylated N-terminal methionine if it is followed by a hydrophobic residue. Additionally, it acts in an N-end rule independent manner as a component of a novel quality control pathway for proteins synthesized on cytosolic ribosomes.\" [GOC:bhm, PMID:19531475]","metadata":null},{"id":"39f3735d72e649feab9d643393c1f56c","type":"GENE","name":"UBR2","canonical_id":"hgnc:HGNC:21289","description":"ubiquitin protein ligase E3 component n-recognin 2","metadata":{"aliases":["bA49A4.1","dJ392M17.3","KIAA0349","C6orf133"]}},{"id":"edf96a3470524ae3bf3a63c7c3801cde","type":"GENE","name":"UBR2-AS1","canonical_id":"hgnc:HGNC:59406","description":"UBR2 antisense RNA 1","metadata":null},{"id":"a13874846c5b4fd7b3d360c7f59bbb94","type":"GENE","name":"UBR3","canonical_id":"hgnc:HGNC:30467","description":"ubiquitin protein ligase E3 component n-recognin 3","metadata":{"aliases":["KIAA2024","DKFZp434P117","FLJ37422","ZNF650"]}},{"id":"36a65aa5462e4f1992ec3582d094c5ab","type":"GENE","name":"UBR4","canonical_id":"hgnc:HGNC:30313","description":"ubiquitin protein ligase E3 component n-recognin 4","metadata":{"aliases":["KIAA1307","KIAA0462","RBAF600","p600","ZUBR1"]}},{"id":"e6abc539c4a1461ea5d789798787fd5e","type":"GENE","name":"UBR5","canonical_id":"hgnc:HGNC:16806","description":"ubiquitin protein ligase E3 component n-recognin 5","metadata":{"aliases":["DD5","HYD","EDD","KIAA0896","EDD1"]}},{"id":"a374d8940b83455e96f33a8854fafefc","type":"GENE","name":"UBR5-DT","canonical_id":"hgnc:HGNC:51661","description":"UBR5 divergent transcript","metadata":{"aliases":["UBR5-AS1"]}},{"id":"9b313d02910d46288da0f2c856c998ee","type":"GENE","name":"UBR7","canonical_id":"hgnc:HGNC:20344","description":"ubiquitin protein ligase E3 component n-recognin 7","metadata":{"aliases":["C14orf130"]}},{"id":"27eadf92f82c4e76aa38895ae2ccd771","type":"GENE","name":"UBTD1","canonical_id":"hgnc:HGNC:25683","description":"ubiquitin domain containing 1","metadata":{"aliases":["FLJ11807"]}},{"id":"ec3e389f68594a149d877d8d62c9c46d","type":"GENE","name":"UBTD2","canonical_id":"hgnc:HGNC:24463","description":"ubiquitin domain containing 2","metadata":{"aliases":["DC-UbP","MGC30022"]}},{"id":"4c30155a9dc042b5ae96ee43d6f3e01c","type":"GENE","name":"UBTD2P1","canonical_id":"hgnc:HGNC:56554","description":"UBTD2 pseudogene 1","metadata":null},{"id":"76e1268686f64ce4b80c9037af95d441","type":"GENE","name":"UBTF","canonical_id":"hgnc:HGNC:12511","description":null,"metadata":null},{"id":"966e55809ffb409c94e4e085011df65c","type":"GENE","name":"UBTFL1","canonical_id":"hgnc:HGNC:14533","description":"upstream binding transcription factor like 1","metadata":{"aliases":["C11orf27"]}},{"id":"9bbba5d894824e29ae6e4ca467a893d1","type":"GENE","name":"UBTFL10","canonical_id":"hgnc:HGNC:50287","description":"UBTF like 10 (pseudogene)","metadata":null},{"id":"881c84a9fbb545a28d724553de023fd5","type":"GENE","name":"UBTFL11","canonical_id":"hgnc:HGNC:50288","description":"UBTF like 11 (pseudogene)","metadata":null},{"id":"aca09208e0424901b6af58db7bf74868","type":"GENE","name":"UBTFL2","canonical_id":"hgnc:HGNC:35169","description":"UBTF like 2 (pseudogene)","metadata":null},{"id":"10d7190f5c3048ee9e6834e9f43b4d8c","type":"GENE","name":"UBTFL3","canonical_id":"hgnc:HGNC:35402","description":"UBTF like 3 (pseudogene)","metadata":null},{"id":"6689f53001804d1ba53a22aea81757a5","type":"GENE","name":"UBTFL5","canonical_id":"hgnc:HGNC:35405","description":"UBTF like 5 (pseudogene)","metadata":null},{"id":"ad873d2f25154ff589d28bb875eb9cfe","type":"GENE","name":"UBTFL6","canonical_id":"hgnc:HGNC:35406","description":"UBTF like 6 (pseudogene)","metadata":null},{"id":"665d2ab4a007480a9d5f197827088405","type":"GENE","name":"UBTFL7","canonical_id":"hgnc:HGNC:35404","description":"UBTF like 7 (pseudogene)","metadata":null},{"id":"5597e50658a9414484209c8d807b929a","type":"GENE","name":"UBTFL8","canonical_id":"hgnc:HGNC:44476","description":"UBTF like 8 (pseudogene)","metadata":null},{"id":"47556f3db0224711ad971e0fd7585a7d","type":"GENE","name":"UBTFL9","canonical_id":"hgnc:HGNC:50286","description":"UBTF like 9 (pseudogene)","metadata":null},{"id":"f127e2e6d149483787c5a5cb4378fbcd","type":"GENE","name":"UBXN1","canonical_id":"hgnc:HGNC:18402","description":"UBX domain protein 1","metadata":{"aliases":["LOC51035","2B28","UBXD10","SAKS1"]}},{"id":"ce63275d7a8d43d79a2b4f3ad33c8b1d","type":"GENE","name":"UBXN10","canonical_id":"hgnc:HGNC:26354","description":"UBX domain protein 10","metadata":{"aliases":["FLJ25429","UBXD3"]}},{"id":"3fa7dd63776241cfa45308f6852c4a09","type":"GENE","name":"UBXN11","canonical_id":"hgnc:HGNC:30600","description":"UBX domain protein 11","metadata":{"aliases":["SOC","SOCI","UBXD5"]}},{"id":"41e7a51bb9c24934a689e13c61e635c0","type":"GENE","name":"UBXN2A","canonical_id":"hgnc:HGNC:27265","description":"UBX domain protein 2A","metadata":{"aliases":["UBXD4"]}},{"id":"09ac89c58f524a52b5339d65b82a82c2","type":"GENE","name":"UBXN2AP1","canonical_id":"hgnc:HGNC:57001","description":"UBXN2A pseudogene 1","metadata":null},{"id":"e78d442c504e4a4ca5aebd59a373bb7f","type":"GENE","name":"UBXN2B","canonical_id":"hgnc:HGNC:27035","description":"UBX domain protein 2B","metadata":{"aliases":["p37"]}},{"id":"815e2ea28ccb4e7c83b4b6ad3aab458c","type":"GENE","name":"UBXN4","canonical_id":"hgnc:HGNC:14860","description":"UBX domain protein 4","metadata":{"aliases":["KIAA0242","UBXDC1","UBXD2"]}},{"id":"fbfe56cc47e646e58d58d5cb8908383a","type":"GENE","name":"UBXN6","canonical_id":"hgnc:HGNC:14928","description":"UBX domain protein 6","metadata":{"aliases":["UBXDC2","UBXD1"]}},{"id":"2010e9269f37474da6076a65abf189e7","type":"GENE","name":"UBXN7","canonical_id":"hgnc:HGNC:29119","description":"UBX domain protein 7","metadata":{"aliases":["KIAA0794","UBXD7"]}},{"id":"0b768b15a48d47dbb86add0f75b589c0","type":"GENE","name":"UBXN7-AS1","canonical_id":"hgnc:HGNC:41227","description":"UBXN7 antisense RNA 1","metadata":null},{"id":"914828bc0de04450b895bfc5e213d554","type":"GENE","name":"UBXN8","canonical_id":"hgnc:HGNC:30307","description":"UBX domain protein 8","metadata":{"aliases":["D8S2298E","REP8","UBXD6"]}},{"id":"25c4d66755354c3c81b67e9b19438269","type":"GO_TERM","name":"UCA codon-amino acid adaptor activity","canonical_id":"go:GO:0033407","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UCA codon.\" [GOC:mah]","metadata":null},{"id":"0d031989cb1f4ca09a2d1998fd1a494a","type":"GENE","name":"UCA1","canonical_id":"hgnc:HGNC:37126","description":"urothelial cancer associated 1","metadata":{"aliases":["LINC00178","CUDR","UCAT1","onco-lncRNA-36"]}},{"id":"22c5d99aabd14035a37b80fc39e2b8ea","type":"GENE","name":"UCA1-AS1","canonical_id":"hgnc:HGNC:52553","description":"UCA1 antisense RNA 1","metadata":{"aliases":["LINC01764"]}},{"id":"55770bfc7c394f14828caf7ffa360e2b","type":"GO_TERM","name":"UCC codon-amino acid adaptor activity","canonical_id":"go:GO:0033406","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UCC codon.\" [GOC:mah]","metadata":null},{"id":"0639c2e5112e4dacb954f4732737973b","type":"TRIAL","name":"UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients","canonical_id":"clinicaltrials.gov:NCT03158883","description":"Metastatic Non-small Cell Lung Cancer (NSCLC)","metadata":null},{"id":"8b96153a2dc34060b312816555ab8af8","type":"GO_TERM","name":"UCG codon-amino acid adaptor activity","canonical_id":"go:GO:0033408","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UCG codon.\" [GOC:mah]","metadata":null},{"id":"e9a4aaaa4784409da1a1076d6f4cfaf4","type":"GENE","name":"UCHL1","canonical_id":"hgnc:HGNC:12513","description":"ubiquitin C-terminal hydrolase L1","metadata":{"aliases":["PGP9.5","Uch-L1","UCHL-1","PARK5"]}},{"id":"30b731fb59474ce29ec2a58a192ea2ce","type":"GENE","name":"UCHL1-DT","canonical_id":"hgnc:HGNC:40600","description":"UCHL1 divergent transcript","metadata":{"aliases":["UCHL1-AS1"]}},{"id":"a386e213a30345ca99ce9da8472039af","type":"GENE","name":"UCHL3","canonical_id":"hgnc:HGNC:12515","description":"ubiquitin C-terminal hydrolase L3","metadata":null},{"id":"c96dac1385d54f17b6d42fae0cbe82eb","type":"GENE","name":"UCHL5","canonical_id":"hgnc:HGNC:19678","description":"ubiquitin C-terminal hydrolase L5","metadata":{"aliases":["UCH37","CGI-70","INO80R"]}},{"id":"2dc2ec22e5d64204b3b1d49b4292eb5d","type":"GENE","name":"UCK1","canonical_id":"hgnc:HGNC:14859","description":"uridine-cytidine kinase 1","metadata":{"aliases":["URK1","FLJ12255"]}},{"id":"6796b2e17bdf43948cbd5f7300097756","type":"GENE","name":"UCK2","canonical_id":"hgnc:HGNC:12562","description":"uridine-cytidine kinase 2","metadata":{"aliases":["UMPK"]}},{"id":"77126b3b743649fab81d6a4d7c8e927b","type":"GENE","name":"UCKL1","canonical_id":"hgnc:HGNC:15938","description":"uridine-cytidine kinase 1 like 1","metadata":{"aliases":["FLJ20517","URKL1"]}},{"id":"df3eab907753444bb82e15bc35a94a22","type":"GENE","name":"UCKL1-AS1","canonical_id":"hgnc:HGNC:31967","description":"UCKL1 antisense RNA 1","metadata":{"aliases":["FLJ46647","UCKL1OS","UCKL1AS","UCKL1-AS"]}},{"id":"42ad7a5a164c4b33b02e253a09281502","type":"GENE","name":"UCMA","canonical_id":"hgnc:HGNC:25205","description":"upper zone of growth plate and cartilage matrix associated","metadata":{"aliases":["GRP","C10orf49"]}},{"id":"02b609fe1d344f3f9f0fff35bbf72c05","type":"GENE","name":"UCN","canonical_id":"hgnc:HGNC:12516","description":null,"metadata":null},{"id":"362fdbde08a5498299502060b24738b2","type":"GENE","name":"UCN2","canonical_id":"hgnc:HGNC:18414","description":"urocortin 2","metadata":{"aliases":["UCNI","SRP","URP","UCN-II"]}},{"id":"094b0c7c6c6f4c56b07511dadc06c85c","type":"GENE","name":"UCN3","canonical_id":"hgnc:HGNC:17781","description":"urocortin 3","metadata":{"aliases":["UCNIII","SPC"]}},{"id":"8db3f7d1fdce44ed85bdfc5c6d24d5cb","type":"GENE","name":"UCP1","canonical_id":"hgnc:HGNC:12517","description":null,"metadata":null},{"id":"fa347dc981124034a424315b0681e220","type":"GENE","name":"UCP2","canonical_id":"hgnc:HGNC:12518","description":null,"metadata":null},{"id":"95dd8c8963ab4bc889b548ebfd5427ce","type":"GENE","name":"UCP3","canonical_id":"hgnc:HGNC:12519","description":"uncoupling protein 3","metadata":{"aliases":["SLC25A9"]}},{"id":"3a7f7cc23c6444ef8fecf7bd85ab0bfb","type":"GO_TERM","name":"UCU codon-amino acid adaptor activity","canonical_id":"go:GO:0033405","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UCU codon.\" [GOC:mah]","metadata":null},{"id":"69631bbc958343ba8e53de423039a0ed","type":"GO_TERM","name":"UDP biosynthetic process","canonical_id":"go:GO:0006225","description":"\"The chemical reactions and pathways resulting in the formation of UDP, uridine (5'-)diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"03d92668f5e24f7fbd4426a13884627a","type":"GO_TERM","name":"UDP catabolic process","canonical_id":"go:GO:0006256","description":"\"The chemical reactions and pathways resulting in the breakdown of UDP, uridine (5'-)diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"0d3c9741c9c94ae7962be851b9a2c039","type":"GO_TERM","name":"UDP metabolic process","canonical_id":"go:GO:0046048","description":"\"The chemical reactions and pathways involving UDP, uridine (5'-)diphosphate.\" [GOC:curators]","metadata":null},{"id":"bcdc57c95ee543cea348465ca344894f","type":"GO_TERM","name":"UDP phosphatase activity","canonical_id":"go:GO:0045134","description":"\"Catalysis of the reaction: UDP + H2O = UMP + phosphate.\" [RHEA:64876]","metadata":null},{"id":"81e0110b94ef4629a27fa0e7aaeed148","type":"GO_TERM","name":"UDP reductase activity","canonical_id":"go:GO:0051062","description":"\"Catalysis of the reaction: dUDP + thioredoxin disulfide + H2O = UDP + thioredoxin.\" [MetaCyc:UDPREDUCT-RXN]","metadata":null},{"id":"58e1bef938e64cc3a9ee96a051992192","type":"GO_TERM","name":"UDP-2,3-diacylglucosamine hydrolase activity","canonical_id":"go:GO:0008758","description":"\"Catalysis of the reaction: H2O + UDP-2,3-bis(3-hydroxymyristoyl)glucosamine = 2,3-bis(3-hydroxymyristoyl)-beta-D-glucosaminyl 1-phosphate + UMP.\" [MetaCyc:LIPIDXSYNTHESIS-RXN, PMID:12000770]","metadata":null},{"id":"343b2eba6e7842fa964b714f51206261","type":"GO_TERM","name":"UDP-3-O-[(3R)-3-hydroxyacyl]-glucosamine N-acyltransferase activity","canonical_id":"go:GO:0103118","description":"\"Catalysis of the reaction: a UDP-3-O-[(3R)-3-hydroxyacyl]-alpha-D-glucosamine + a (3R)-hydroxyacyl-[ACP] = a UDP-2-N,3-O-bis[(3R)-3-hydroxyacyl]-alpha-D-glucosamine + holo-[ACP] + H+.\" [RHEA:53836]","metadata":null},{"id":"5193f7dc312c4f139fea26b9754228b6","type":"GO_TERM","name":"UDP-3-O-acyl-N-acetylglucosamine deacetylase activity","canonical_id":"go:GO:0103117","description":"\"Catalysis of the reaction: a UDP-3-O-[(3R)-3-hydroxyacyl]-N-acetyl-alpha-D-glucosamine + H2O = a UDP-3-O-[(3R)-3-hydroxyacyl]-alpha-D-glucosamine + acetate.\" [GOC:pz, RHEA:67816]","metadata":null},{"id":"274b5563ae114ed6bdd14d062421b3d9","type":"GO_TERM","name":"UDP-3-dehydro-alpha-D-glucose dehydrogenase activity","canonical_id":"go:GO:0102982","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + NAD = H+ + UDP-3-keto-alpha-D-glucose + NADH.\" [GOC:pz, PMID:11278540]","metadata":null},{"id":"01f8ee181eca46e6aaaffd6bec2c0e85","type":"GO_TERM","name":"UDP-4-amino-4-deoxy-L-arabinose formyltransferase activity","canonical_id":"go:GO:0099619","description":"\"Catalysis of the reaction: 10-formyltetrahydrofolate + UDP-4-amino-4-deoxy-beta-L-arabinopyranose = 5,6,7,8-tetrahydrofolate + UDP-4-deoxy-4-formamido-beta-L-arabinopyranose.\" [PMID:15695810, PMID:15807526, PMID:15809294, PMID:15939024, PMID:17928292]","metadata":null},{"id":"e4321b6fe03f4f6f91622cf903d4b740","type":"GO_TERM","name":"UDP-4-amino-4-deoxy-L-arabinose:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0099620","description":"\"Catalysis of the reaction: UDP-4-amino-4-deoxy-beta-L-arabinose + 2-oxoglutarate = UDP-beta-L-threo-pentopyranos-4-ulose + L-glutamate.\" [PMID:12429098, PMID:12704196, RHEA:24710]","metadata":null},{"id":"e4a1a8322d7740a789a3f8285a7a85f9","type":"GO_TERM","name":"UDP-4-deoxy-4-formamido-beta-L-arabinopyranose biosynthetic process","canonical_id":"go:GO:2001315","description":"\"The chemical reactions and pathways resulting in the formation of a UDP-4-deoxy-4-formamido-beta-L-arabinopyranose.\" [GOC:yaf, UniPathway:UPA00032]","metadata":null},{"id":"cf4d7c1ce5b547f293e253456738ace2","type":"GO_TERM","name":"UDP-4-keto-6-deoxy-glucose-3,5-epimerase activity","canonical_id":"go:GO:0010489","description":"\"Catalysis of the reaction: UDP-4-keto-6-deoxyglucose = UDP-4-keto-rhamnose.\" [GOC:tair_curators, PMID:17190829]","metadata":null},{"id":"2fcc897fb90445fd8baa5e94acd1ee6e","type":"GO_TERM","name":"UDP-4-keto-rhamnose-4-keto-reductase activity","canonical_id":"go:GO:0010490","description":"\"Catalysis of the reaction: UDP-4-keto-rhamnose + NADPH = UDP-rhamnose + NADP+.\" [GOC:tair_curators, PMID:17190829]","metadata":null},{"id":"8a9ec39409864b26bee8ffa105d3f8a9","type":"GO_TERM","name":"UDP-D-apiose biosynthetic process","canonical_id":"go:GO:0033352","description":"\"The chemical reactions and pathways resulting in the formation of UDP-D-apiose, uridinediphosphoapicose, a substance composed of apiose in glycosidic linkage with uridine diphosphate.\" [GOC:mah, MetaCyc:PWY-5113]","metadata":null},{"id":"cf81a091acaf4e469fcba5294bd65495","type":"GO_TERM","name":"UDP-D-apiose synthase activity","canonical_id":"go:GO:0102765","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate + H+ = UDP-alpha-D-apiose + CO2.\" [RHEA:70523]","metadata":null},{"id":"f8d1a7592fa5492185e8f459b1a9cc42","type":"GO_TERM","name":"UDP-D-galactose metabolic process","canonical_id":"go:GO:0052573","description":"\"The chemical reactions and pathways involving UDP-D-galactose, a substance composed of D-galactose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"275284f4559844768f5b3eda8292aff7","type":"GO_TERM","name":"UDP-D-galacturonate biosynthetic process","canonical_id":"go:GO:0033480","description":"\"The chemical reactions and pathways resulting in the formation of UDP-D-galacturonate, a substance composed of galacturonic acid in glycosidic linkage with uridine diphosphate.\" [GOC:mah]","metadata":null},{"id":"43ac1cfa0ddd4695be5c964be7ad3467","type":"GO_TERM","name":"UDP-D-glucose:delphinidin 3-O-glucosyl-5-O-caffeoylglucoside -O-beta-D-glucosyltransferase activity","canonical_id":"go:GO:0102816","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + delphinidin 3-O-glucosyl-5-O-caffeoylglucoside = H+ + delphinidin 3-O-glucosyl-5-O-(caffeoylglucoside-3'-O-glucoside) + UDP.\" [EC:2.4.1.298, GOC:pz]","metadata":null},{"id":"0c2ad631460f4e24b6f5f68eb831abbe","type":"GO_TERM","name":"UDP-D-xylose biosynthetic process","canonical_id":"go:GO:0033320","description":"\"The chemical reactions and pathways resulting in the formation of UDP-D-xylose, uridinediphosphoxylose, a substance composed of xylose in glycosidic linkage with uridine diphosphate.\" [GOC:mah, MetaCyc:PWY-4821]","metadata":null},{"id":"f3a623fbcf4c4df881228835003bfb9f","type":"GO_TERM","name":"UDP-D-xylose metabolic process","canonical_id":"go:GO:0033319","description":"\"The chemical reactions and pathways involving UDP-D-xylose, uridinediphosphoxylose, a substance composed of xylose in glycosidic linkage with uridine diphosphate.\" [GOC:mah]","metadata":null},{"id":"56b2f2c2d32f4577a787d1a26b88d7e6","type":"GO_TERM","name":"UDP-D-xylose:beta-D-glucoside alpha-1,3-D-xylosyltransferase activity","canonical_id":"go:GO:0140563","description":"\"Catalyzes the reaction: UDP-alpha-D-xylose + [protein with EGF-like domain]-3-O-(beta-D-glucosyl)-L-serine = UDP + [protein with EGF-like domain]-3-O-(alpha-D-xylosyl-(1->3)-beta-D-glucosyl)-L-serine.\" [EC:2.4.2.42, PMID:30127001, RHEA:56064]","metadata":null},{"id":"f80936f13d774a4b8d42369b0130648a","type":"GO_TERM","name":"UDP-L-arabinose biosynthetic process","canonical_id":"go:GO:0033358","description":"\"The chemical reactions and pathways resulting in the formation of UDP-L-arabinose, uridinediphosphoarabinose, a substance composed of arabinose in glycosidic linkage with uridine diphosphate.\" [GOC:mah, MetaCyc:PWY-82]","metadata":null},{"id":"b6076b16f766458eac4a4fe2f067dc09","type":"GO_TERM","name":"UDP-L-arabinose metabolic process","canonical_id":"go:GO:0033356","description":"\"The chemical reactions and pathways involving UDP-L-arabinose, uridinediphosphoarabinose, a substance composed of arabinose in glycosidic linkage with uridine diphosphate.\" [GOC:mah]","metadata":null},{"id":"009d46684d78450dafcf6b01363f0baf","type":"GO_TERM","name":"UDP-L-rhamnose synthase activity","canonical_id":"go:GO:0010280","description":"\"Catalysis of the reaction: UDP-D-glucose + NADPH + H+ = UDP-L-rhamnose + NADP+ + H2O.\" [MetaCyc:RXN-5482, PMID:14701918]","metadata":null},{"id":"a2bbe68bbb11412784fbdbfa3c8d1986","type":"GO_TERM","name":"UDP-N,N'-diacetylbacillosamine 2-epimerase activity","canonical_id":"go:GO:0102388","description":"\"Catalysis of the reaction: UDP-N,N'-diacetylbacillosamine + H2O = 2,4-diacetamido-2,4,6-trideoxy-alpha-D-mannopyranose + UDP + H+.\" [EC:3.2.1.184, GOC:pz]","metadata":null},{"id":"257c1fdd8a994ba8b97369b5a6610417","type":"GO_TERM","name":"UDP-N-acetyl-D-glucosamine:N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine-diphosphoundecaprenol 4-beta-N-acetylglucosaminlytransferase activity","canonical_id":"go:GO:0051991","description":"\"Catalysis of the reaction: di-trans-octa-cis-undecaprenyl diphospho-N-acetyl-alpha-D-muramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine + UDP-N-acetyl-alpha-D-glucosamine = di-trans-octa-cis-undecaprenyl diphospho-[N-acetyl-alpha-D-glucosaminyl-(1->4)]-N-acetyl-alpha-D-muramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine + H+ + UDP.\" [RHEA:31227]","metadata":null},{"id":"44cac73ab96648318f4ddfdf08dc73ab","type":"GO_TERM","name":"UDP-N-acetyl-D-mannosamine dehydrogenase activity","canonical_id":"go:GO:0089714","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-mannosamine + 2 NAD+ + H2O = UDP-N-acetyl-alpha-D-mannosaminuronate + 2 NADH + 2 H+.\" [EC:1.1.1.336]","metadata":null},{"id":"57219f4d50c7412daa344a175b6b7635","type":"GO_TERM","name":"UDP-N-acetyl-alpha-D-fucosamine dehydrogenase activity","canonical_id":"go:GO:0102539","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-fucosamine + NAD(P) = UDP-2-acetamido-4-dehydro-2,6-dideoxy-beta-D-glucose + H+ + NAD(P)H.\" [GOC:pz, PMID:10627048]","metadata":null},{"id":"bd80965695d94acd9a96d697e7c766ca","type":"GO_TERM","name":"UDP-N-acetyl-alpha-D-quinovosamine dehydrogenase activity","canonical_id":"go:GO:0102538","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-quinovosamine + NAD(P) = UDP-2-acetamido-4-dehydro-2,6-dideoxy-beta-D-glucose + H+ + NAD(P)H.\" [EC:1.1.1.426, PMID:10627048, PMID:24817117]","metadata":null},{"id":"7f79acfe4287403bbd7e3fa380422c2b","type":"GO_TERM","name":"UDP-N-acetylbacillosamine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047302","description":"\"Catalysis of the reaction: UDP-N-acetylbacillosamine + 2-oxoglutarate = UDP-2-acetamido-2,6-dideoxy-alpha-D-xylo-hex-4-ulose + L-glutamate.\" [PMID:16286454, RHEA:31663]","metadata":null},{"id":"8f37a4991a5d44a7be3906711f4d7707","type":"GO_TERM","name":"UDP-N-acetylgalactosamine biosynthetic process","canonical_id":"go:GO:0019277","description":"\"The chemical reactions and pathways resulting in the formation of UDP-N-acetylgalactosamine, a substance composed of N-acetylgalactosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"8528a814a6da46d1bda8da760fc07e07","type":"GO_TERM","name":"UDP-N-acetylgalactosamine diphosphorylase activity","canonical_id":"go:GO:0052630","description":"\"Catalysis of the reaction: UTP + N-acetyl-alpha-D-galactosamine 1-phosphate = diphosphate + UDP-N-acetyl-D-galactosamine.\" [EC:2.7.7.83, RHEA:34363]","metadata":null},{"id":"d06e91f7788f45269aa1367bffd3c911","type":"GO_TERM","name":"UDP-N-acetylgalactosamine metabolic process","canonical_id":"go:GO:0019276","description":"\"The chemical reactions and pathways involving UDP-N-acetylgalactosamine, a substance composed of N-acetylgalactosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"6121c12133ef4c70952553833273e43a","type":"GO_TERM","name":"UDP-N-acetylgalactosamine transmembrane transport","canonical_id":"go:GO:0015789","description":"\"The directed movement of UDP-N-acetylgalactosamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. UDP-N-acetylgalactosamine is a substance composed of N-acetylgalactosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"eb4603bb8921415891a3672d058183d5","type":"GO_TERM","name":"UDP-N-acetylgalactosamine transmembrane transporter activity","canonical_id":"go:GO:0005463","description":"\"Enables the transfer of a N-acetylgalactosamine from one side of a membrane to the other. N-acetylgalactosamine is a substance composed of N-acetylgalactosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"f5875f4a7a1f4ca08ba1a1d2f9f2749b","type":"GO_TERM","name":"UDP-N-acetylgalactosamine-4-sulfate sulfotransferase activity","canonical_id":"go:GO:0047368","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + UDP-N-acetyl-D-galactosamine 4-sulfate = adenosine 3',5'-diphosphate + H+ + UDP-N-acetyl-D-galactosamine 4,6-disulfate.\" [EC:2.8.2.7, RHEA:14337]","metadata":null},{"id":"d03636b809bf4794a4f2ceabbd2f95a0","type":"PROTEIN","name":"UDP-N-acetylglucosamine 1-carboxyvinyltransferase","canonical_id":"uniprot:P0A749","description":null,"metadata":null},{"id":"82afdaada0fe463f9b8ba50b82ecee9f","type":"GO_TERM","name":"UDP-N-acetylglucosamine 1-carboxyvinyltransferase activity","canonical_id":"go:GO:0008760","description":"\"Catalysis of the reaction: phosphoenolpyruvate + UDP-N-acetyl-alpha-D-glucosamine = phosphate + UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine.\" [EC:2.5.1.7, RHEA:18681]","metadata":null},{"id":"0255188f9e6d4a7383251b204bdf49a0","type":"GO_TERM","name":"UDP-N-acetylglucosamine 2-epimerase activity","canonical_id":"go:GO:0008761","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine = UDP-N-acetyl-D-mannosamine.\" [EC:5.1.3.14]","metadata":null},{"id":"5e197ea024ad46f9b4f645218e531f1b","type":"GO_TERM","name":"UDP-N-acetylglucosamine 4-epimerase activity","canonical_id":"go:GO:0003974","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine = UDP-N-acetyl-D-galactosamine.\" [EC:5.1.3.7]","metadata":null},{"id":"66081a911a2140cd9be991520b6c2993","type":"GO_TERM","name":"UDP-N-acetylglucosamine 6-dehydrogenase activity","canonical_id":"go:GO:0047004","description":"\"Catalysis of the reaction: H2O + 2 NAD+ + UDP-N-acetyl-alpha-D-glucosamine = 3 H+ + 2 NADH + UDP-N-acetyl-2-amino-2-deoxy-D-glucuronate.\" [EC:1.1.1.136, RHEA:13325]","metadata":null},{"id":"68f5e7b209b84606a850349868fa3b4a","type":"GO_TERM","name":"UDP-N-acetylglucosamine biosynthetic process","canonical_id":"go:GO:0006048","description":"\"The chemical reactions and pathways resulting in the formation of UDP-N-acetylglucosamine, a substance composed of N-acetylglucosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"7c4de60fd15d41068f1c68906d21ffac","type":"GO_TERM","name":"UDP-N-acetylglucosamine diphosphorylase activity","canonical_id":"go:GO:0003977","description":"\"Catalysis of the reaction: N-acetyl-alpha-D-glucosamine 1-phosphate + UTP = diphosphate + UDP-N-acetyl-alpha-D-glucosamine.\" [EC:2.7.7.23, RHEA:13509]","metadata":null},{"id":"a4229f17c17a402799b5f15665204cf2","type":"GO_TERM","name":"UDP-N-acetylglucosamine metabolic process","canonical_id":"go:GO:0006047","description":"\"The chemical reactions and pathways involving UDP-N-acetylglucosamine, a substance composed of N-acetylglucosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"ec05948a0b2c457ea7dbdd71a0b33f29","type":"GO_TERM","name":"UDP-N-acetylglucosamine transferase complex","canonical_id":"go:GO:0043541","description":"\"A multienzyme, heterooligomeric complex involved in dolichyl-linked oligosaccharide synthesis. In yeast the complex is composed of Alg7p, which catalyzes the first step (GlcNAc1-PP-Dol from dolichol-phosphate and UDP-GlcNAc), and Alg13p plus Alg14p, the catalytic and anchoring subunits respectively, which together catalyze the second step (GlcNAc2-PP-dolichol from GlcNAc1-PP-Dol and UDP-GlcNAc) of dolichyl-linked oligosaccharide synthesis.\" [GOC:rn, PMID:19129246]","metadata":null},{"id":"575fd79e4efa4c06ae39580b35763e4e","type":"GO_TERM","name":"UDP-N-acetylglucosamine transmembrane transport","canonical_id":"go:GO:1990569","description":"\"The process in which UDP-N-acetylglucosamine is transported across a membrane.\" [PMID:10788474]","metadata":null},{"id":"20a094a9ab094bb29601d2a40728e655","type":"GO_TERM","name":"UDP-N-acetylglucosamine transmembrane transporter activity","canonical_id":"go:GO:0005462","description":"\"Enables the transfer of a UDP-N-acetylglucosamine from one side of a membrane to the other. N-acetylglucosamine is a substance composed of N-acetylglucosamine, a common structural unit of oligosaccharides, in glycosidic linkage with uridine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"deda7760deb842b7b5ee711ae108eef0","type":"GO_TERM","name":"UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase activity","canonical_id":"go:GO:0003975","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + dolichyl phosphate = UMP + N-acetyl-D-glucosaminyl-diphosphodolichol.\" [EC:2.7.8.15]","metadata":null},{"id":"23e23a413c1b4f28912274839b42ad49","type":"GO_TERM","name":"UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity","canonical_id":"go:GO:0003976","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + lysosomal-enzyme D-mannose = UMP + lysosomal-enzyme N-acetyl-D-glucosaminyl-phospho-D-mannose.\" [EC:2.7.8.17]","metadata":null},{"id":"342e486b5bee4157bfbbeb20d6b7a45a","type":"GO_TERM","name":"UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase complex","canonical_id":"go:GO:0070622","description":"\"A protein complex that possesses UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity; the bovine complex contains disulfide-linked homodimers of 166- and 51-kDa subunits and two identical, noncovalently associated 56-kDa subunits.\" [GOC:mah, PMID:8940155]","metadata":null},{"id":"c91fa70d96a342bf8f70ae5f5635fd4a","type":"GO_TERM","name":"UDP-N-acetylglucosamine-undecaprenyl-phosphate N-acetylglucosaminephosphotransferase activity","canonical_id":"go:GO:0036380","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-glucosamine + ditrans,octacis-undecaprenyl phosphate = UMP + N-acetyl-alpha-D-glucosaminyldiphospho-ditrans,octacis-undecaprenol.\" [EC:2.7.8.33, GOC:rs]","metadata":null},{"id":"0a7b51222d9f46f7a3264e68f65a8485","type":"GO_TERM","name":"UDP-N-acetylmuramate dehydrogenase activity","canonical_id":"go:GO:0008762","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-muramate + NADP+ = UDP-N-acetyl-3-O-(1-carboxyvinyl)-alpha-D-glucosamine + NADPH + H+.\" [RHEA:12248]","metadata":null},{"id":"0cfd1bb8a88548a9a6e98175a6450226","type":"GO_TERM","name":"UDP-N-acetylmuramate-L-alanine ligase activity","canonical_id":"go:GO:0008763","description":"\"Catalysis of the reaction: L-alanine + ATP + UDP-N-acetylmuramate = ADP + 2 H+ + phosphate + UDP-N-acetylmuramoyl-L-alanine.\" [EC:6.3.2.8, RHEA:23372]","metadata":null},{"id":"7f6f77c0ef4f45698e450ba36f0a55db","type":"GO_TERM","name":"UDP-N-acetylmuramate-L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptanedioate ligase activity","canonical_id":"go:GO:0106418","description":"\"Catalysis of the reaction: ATP + UDP-N-acetyl-alpha-D-muramate + L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptanedioate = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptanedioate.\" [PMID:17384195, PMID:8808921, RHEA:29563]","metadata":null},{"id":"b34ddd7bba564b34b601663f053e88ab","type":"GO_TERM","name":"UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--D-lysine ligase activity","canonical_id":"go:GO:0102195","description":"\"Catalysis of the reaction: UDP-N-acetylmuramoyl-L-alanyl-D-glutamate + D-lysinium(1+) + ATP = UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-D-lysine + ADP + hydrogenphosphate + H+.\" [EC:6.3.2.37, GOC:pz]","metadata":null},{"id":"8d6fcb0dcf3246ac8ce50a695107cba8","type":"GO_TERM","name":"UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-L-lysine ligase activity","canonical_id":"go:GO:0047482","description":"\"Catalysis of the reaction: L-lysine + ATP + UDP-N-acetylmuramoyl-L-alanyl-D-glutamate = ADP + 2 H+ + phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysine.\" [EC:6.3.2.7, RHEA:17969]","metadata":null},{"id":"47591cc7ca7845bd9d261099330c4b66","type":"GO_TERM","name":"UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine:undecaprenyl-phosphate transferase activity","canonical_id":"go:GO:0051992","description":"\"Catalysis of the reaction: di-trans,octa-cis-undecaprenyl phosphate + UDP-N-acetyl-alpha-D-muramoyl-L-alanyl-gamma-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine = di-trans-octa-cis-undecaprenyl diphospho-N-acetyl-alpha-D-muramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimeloyl-D-alanyl-D-alanine + UMP.\" [RHEA:28386]","metadata":null},{"id":"2dcc6f7ec9ec47fea9532a048f56d454","type":"GO_TERM","name":"UDP-N-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase activity","canonical_id":"go:GO:0047480","description":"\"Catalysis of the reaction: UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysine + ATP + D-alanyl-D-alanine = phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanine + ADP.\" [EC:6.3.2.10]","metadata":null},{"id":"25cf4c55ca6045f992d9a9028d9e87c9","type":"GO_TERM","name":"UDP-N-acetylmuramoylalanine-D-glutamate ligase activity","canonical_id":"go:GO:0008764","description":"\"Catalysis of the reaction: D-glutamate + ATP + UDP-N-acetylmuramoyl-L-alanine = ADP + 2 H+ + phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-glutamate.\" [RHEA:16429]","metadata":null},{"id":"c1e591f01b3943dbbe55cf13b205be2f","type":"GO_TERM","name":"UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-diaminopimelate ligase activity","canonical_id":"go:GO:0008765","description":"\"Catalysis of the reaction: meso-2,6-diaminopimelate + ATP + UDP-N-acetylmuramoyl-L-alanyl-D-glutamate = ADP + 2 H+ + phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminoheptanedioate.\" [EC:6.3.2.13, RHEA:23676]","metadata":null},{"id":"62dd133db4e948d5ada029d76e5be0a0","type":"GO_TERM","name":"UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-D-alanyl-D-alanine ligase activity","canonical_id":"go:GO:0008766","description":"\"Catalysis of the reaction: ATP + UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminoheptanedioate + D-alanyl-D-alanine = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-6-carboxy-L-lysyl-D-alanyl-D-alanine.\" [RHEA:28374]","metadata":null},{"id":"e6c026650e554934a9e8cae14a6f5f5f","type":"GO_TERM","name":"UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase activity","canonical_id":"go:GO:0047206","description":"\"Catalysis of the reaction: UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-D-alanyl-D-alanine + L-alanyl-tRNA(Ala) = UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-N6-(L-alanyl)-L-lysyl-D-alanyl-D-alanine + tRNA(Ala).\" [EC:2.3.2.10]","metadata":null},{"id":"ab51fd2808f04392a4fb016537c4d24e","type":"GO_TERM","name":"UDP-alpha-D-glucose biosynthetic process","canonical_id":"go:GO:0120530","description":"\"The chemical reactions and pathways resulting in the formation of UDP-alpha-D-glucose, a substance composed of alpha-D-glucose in glycosidic linkage with uridine diphosphate.\" [MetaCyc:PWY-7343]","metadata":null},{"id":"dfff811315d24b378188984ae6356e18","type":"GO_TERM","name":"UDP-alpha-D-glucose metabolic process","canonical_id":"go:GO:0006011","description":"\"The chemical reactions and pathways involving UDP-alpha-D-glucose, a substance composed of alpha-D-glucose in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"1002e23737b242b8a73df71b5e31dc7c","type":"GO_TERM","name":"UDP-arabinopyranose mutase activity","canonical_id":"go:GO:0052691","description":"\"Catalysis of the reaction: UDP-beta-L-arabinofuranose = UDP-beta-L-arabinopyranose.\" [EC:5.4.99.30, RHEA:28350]","metadata":null},{"id":"4f068e68a56a4853ac56747c46fbaa0b","type":"GO_TERM","name":"UDP-arabinose 4-epimerase activity","canonical_id":"go:GO:0050373","description":"\"Catalysis of the reaction: UDP-L-arabinose = UDP-alpha-D-xylose.\" [EC:5.1.3.5, RHEA:11320]","metadata":null},{"id":"c6d5a7b8a02d4082beac5a6acb1e9aef","type":"GO_TERM","name":"UDP-beta-L-arabinofuranose import into Golgi lumen","canonical_id":"go:GO:0140821","description":"\"The directed movement of UDP-beta-L-arabinofuranose from the cytosol to the Golgi apparatus of a cell.\" [PMID:28373556]","metadata":null},{"id":"768c374ad4f84c15890d154ccc75679a","type":"GO_TERM","name":"UDP-beta-L-arabinofuranose transporter activity","canonical_id":"go:GO:0140819","description":"\"Enables the transfer of UDP-beta-L-arabinofuranose from one side of a membrane to the other.\" [PMID:28373556]","metadata":null},{"id":"c209680ff5814d6d875ecaab6f22eec0","type":"GO_TERM","name":"UDP-galactopyranose mutase activity","canonical_id":"go:GO:0008767","description":"\"Catalysis of the reaction: UDP-D-galactopyranose = UDP-D-galacto-1,4-furanose.\" [EC:5.4.99.9]","metadata":null},{"id":"40d9cbc405b943cb943cde743f3e26e6","type":"GO_TERM","name":"UDP-galactose biosynthetic process","canonical_id":"go:GO:0052574","description":"\"The chemical reactions and pathways resulting in the formation of UDP-D-galactose, a substance composed of D-galactose in glycosidic linkage with guanosine diphosphate.\" [GOC:ai]","metadata":null},{"id":"e9a35a4e1eaf4bcd85ce9c30178a6735","type":"GO_TERM","name":"UDP-galactose transmembrane import into Golgi lumen","canonical_id":"go:GO:0097624","description":"\"The directed movement of UDP-galactose into the Golgi lumen across the Golgi membrane.\" [GOC:vw, PMID:11378902]","metadata":null},{"id":"1c2cd329266840d084bd91109e9326c0","type":"GO_TERM","name":"UDP-galactose transmembrane transport","canonical_id":"go:GO:0072334","description":"\"The process in which UDP-galactose is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"5a5008715b6a41e5821e2d7d0390330b","type":"GO_TERM","name":"UDP-galactose transmembrane transporter activity","canonical_id":"go:GO:0005459","description":"\"Enables the transfer of a UDP-galactose from one side of a membrane to the other. UDP-galactose is a substance composed of galactose in glycosidic linkage with uridine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e81d8fb2686c4d9288f217f2a32a4289","type":"GO_TERM","name":"UDP-galactose-UDP-N-acetylglucosamine galactose phosphotransferase activity","canonical_id":"go:GO:0047357","description":"\"Catalysis of the reaction: UDP-N-acetyl-alpha-D-glucosamine + UDP-D-galactose = H+ + UDP-N-acetyl-6-(D-galactose-1-phospho)-D-glucosamine + UMP.\" [EC:2.7.8.18, RHEA:22440]","metadata":null},{"id":"6fc5c82d2d964eb5866e7dcbe4deb63b","type":"GO_TERM","name":"UDP-galactose:N-glycan beta-1,3-galactosyltransferase activity","canonical_id":"go:GO:0010488","description":"\"Catalysis of the reaction: UDP-galactose + N-glycan = galactose-beta-1,3-N-glycan + UDP.\" [PMID:17630273]","metadata":null},{"id":"9a9865dbabeb4603abd7e2a36281ed66","type":"GO_TERM","name":"UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity","canonical_id":"go:GO:0008489","description":"\"Catalysis of the reaction: a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine + UDP-alpha-D-galactose = a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + H+ + UDP.\" [PMID:9593693, RHEA:31495]","metadata":null},{"id":"4664f09c05214190ade0b560a085cb7e","type":"GO_TERM","name":"UDP-galactosyltransferase activity","canonical_id":"go:GO:0035250","description":"\"Catalysis of the transfer of a galactose group from UDP-galactose to an acceptor molecule.\" [PMID:19858195]","metadata":null},{"id":"d5a5212278044fa8bdb594970226b8e8","type":"GO_TERM","name":"UDP-galacturonate decarboxylase activity","canonical_id":"go:GO:0050374","description":"\"Catalysis of the reaction: H+ + UDP-alpha-D-galacturonate = CO2 + UDP-L-arabinose.\" [EC:4.1.1.67, RHEA:19725]","metadata":null},{"id":"c1be91d5ebd44830ae89b8133363a500","type":"GO_TERM","name":"UDP-glucosamine 4-epimerase activity","canonical_id":"go:GO:0050376","description":"\"Catalysis of the reaction: UDP-glucosamine = UDP-galactosamine.\" [EC:5.1.3.16, MetaCyc:UDP-GLUCOSAMINE-EPIMERASE-RXN]","metadata":null},{"id":"e0f8f900122e4a9f939349bf0e5a0f17","type":"GO_TERM","name":"UDP-glucose 4,6-dehydratase activity","canonical_id":"go:GO:0050377","description":"\"Catalysis of the reaction: UDP-D-glucose = H2O + UDP-4-dehydro-6-deoxy-D-glucose.\" [EC:4.2.1.76, RHEA:21500]","metadata":null},{"id":"bf502fb447af4145ba9a26f1bb304e22","type":"GO_TERM","name":"UDP-glucose 4-epimerase activity","canonical_id":"go:GO:0003978","description":"\"Catalysis of the reaction: UDP-glucose = UDP-galactose.\" [EC:5.1.3.2]","metadata":null},{"id":"e2c5d135e23643668ddc6e2f565ce767","type":"GO_TERM","name":"UDP-glucose 6-dehydrogenase activity","canonical_id":"go:GO:0003979","description":"\"Catalysis of the reaction: H2O + 2 NAD+ + UDP-alpha-D-glucose = 3 H+ + 2 NADH + UDP-alpha-D-glucuronate.\" [EC:1.1.1.22, RHEA:23596]","metadata":null},{"id":"b6fd4d46aaa94bb2b0699d3bb8369cc4","type":"GO_TERM","name":"UDP-glucose transmembrane transport","canonical_id":"go:GO:0015786","description":"\"The process in which UDP-glucose is transported across a membrane.\" [GOC:ai]","metadata":null},{"id":"33672e318e57412ea86ff8fc165bda37","type":"GO_TERM","name":"UDP-glucose transmembrane transport into endoplasmic reticulum","canonical_id":"go:GO:0120112","description":"\"The directed movement of UDP-glucose from cytosol to endoplasmic reticulum.\" [PMID:27587357]","metadata":null},{"id":"400608c35fb347919cbd0656ad4d3e38","type":"GO_TERM","name":"UDP-glucose transmembrane transporter activity","canonical_id":"go:GO:0005460","description":"\"Enables the transfer of a UDP-glucose from one side of a membrane to the other. UDP-glucose is a substance composed of glucose in glycosidic linkage with uridine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"def68cee15cd48f3bba7e5e791c4a9f8","type":"GO_TERM","name":"UDP-glucose-glycoprotein glucose phosphotransferase activity","canonical_id":"go:GO:0047358","description":"\"Catalysis of the reaction: glycoprotein D-mannose + UDP-D-glucose = glycoprotein 6-(D-glucose-1-phospho)-D-mannose + UMP.\" [EC:2.7.8.19, MetaCyc:2.7.8.19-RXN]","metadata":null},{"id":"c248f6c9077447b1a98203cbe7c3be28","type":"GO_TERM","name":"UDP-glucose:4-aminobenzoate acylglucosyltransferase activity","canonical_id":"go:GO:0080002","description":"\"Catalysis of the reaction: 4-aminobenzoate + UDP-alpha-D-glucose = 1-O-(4-aminobenzoyl)-beta-D-glucose + UDP.\" [PMID:18385129, RHEA:85851]","metadata":null},{"id":"f9b468b0563748c1b3e9da28436f661b","type":"GO_TERM","name":"UDP-glucose:glycoprotein glucosyltransferase activity","canonical_id":"go:GO:0003980","description":"\"Catalysis of the addition of UDP-glucose on to asparagine-linked (N-linked) oligosaccharides of the form Man7-9GlcNAc2 on incorrectly folded glycoproteins.\" [GOC:al, PMID:10764828]","metadata":null},{"id":"3f7555db80c94b2aa67bc8796806c7f5","type":"GO_TERM","name":"UDP-glucose:hexose-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0008108","description":"\"Catalysis of the reaction: alpha-D-galactose 1-phosphate + UDP-D-glucose = alpha-D-glucose 1-phosphate + UDP-D-galactose.\" [EC:2.7.7.12, RHEA:13989]","metadata":null},{"id":"78e563566e0b49e993b66f9eb1957073","type":"GO_TERM","name":"UDP-glucosylation","canonical_id":"go:GO:0097359","description":"\"The covalent attachment of a UDP-glucose residue to a substrate molecule.\" [GOC:al]","metadata":null},{"id":"645618762ee44057bb9a9b00b0eb43af","type":"GO_TERM","name":"UDP-glucosyltransferase activity","canonical_id":"go:GO:0035251","description":"\"Catalysis of the transfer of a glucosyl group from UDP-glucose to an acceptor molecule.\" [PMID:19858195]","metadata":null},{"id":"33da550172774a6293f48b4ea1b29810","type":"GO_TERM","name":"UDP-glucuronate 4-epimerase activity","canonical_id":"go:GO:0050378","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate = UDP-alpha-D-galacturonate.\" [RHEA:11404]","metadata":null},{"id":"b7321eee9d8a4a08994b65c6d8903e97","type":"GO_TERM","name":"UDP-glucuronate 5'-epimerase activity","canonical_id":"go:GO:0050379","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate = UDP-L-iduronate.\" [GOC:curators]","metadata":null},{"id":"e320f331b7ef44748d2997f232baaa94","type":"GO_TERM","name":"UDP-glucuronate biosynthetic process","canonical_id":"go:GO:0006065","description":"\"The chemical reactions and pathways resulting in the formation of UDP-glucuronate, a substance composed of glucuronic acid in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"86cbd406a2ac4d63913c3dd9de82e49f","type":"GO_TERM","name":"UDP-glucuronate decarboxylase activity","canonical_id":"go:GO:0048040","description":"\"Catalysis of the reaction: H+ + UDP-alpha-D-glucuronate = CO2 + UDP-alpha-D-xylose.\" [EC:4.1.1.35, RHEA:23916]","metadata":null},{"id":"d694603d40b04b9eae335618d7123e1f","type":"GO_TERM","name":"UDP-glucuronate dehydrogenase activity","canonical_id":"go:GO:0099618","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate + NAD+ = UDP-beta-L-threo-pentopyranos-4-ulose + CO2 + NADH.\" [RHEA:24702]","metadata":null},{"id":"4d7124a9000a4f6eaa55dda1adb08e88","type":"GO_TERM","name":"UDP-glucuronate metabolic process","canonical_id":"go:GO:0046398","description":"\"The chemical reactions and pathways involving UDP-glucuronate, a substance composed of glucuronic acid in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"915bb79cf9a949648d71b650a6c48621","type":"GO_TERM","name":"UDP-glucuronate transmembrane transport","canonical_id":"go:GO:0015787","description":"\"The directed movement of UDP-glucuronic acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. UDP-glucuronic acid is a substance composed of glucuronic acid in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"045a0dfe51bf45dfb8d5e6cd5edfe5d2","type":"GO_TERM","name":"UDP-glucuronate transmembrane transporter activity","canonical_id":"go:GO:0005461","description":"\"Enables the transfer of a UDP-glucuronic acid from one side of a membrane to the other. UDP-glucuronic acid is a substance composed of glucuronic acid in glycosidic linkage with uridine diphosphate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"7f51d19d67db4be7b1fa9f7db1389787","type":"GO_TERM","name":"UDP-glycosyltransferase activity","canonical_id":"go:GO:0008194","description":"\"Catalysis of the transfer of a glycosyl group from a UDP-sugar to a small hydrophobic molecule.\" [PMID:11846783]","metadata":null},{"id":"c371769bd6e24d59ae022d36802e945e","type":"GO_TERM","name":"UDP-rhamnose biosynthetic process","canonical_id":"go:GO:0010253","description":"\"The chemical reactions and pathways resulting in the formation of UDP-L-rhamnose, a substance composed of rhamnose in glycosidic linkage with uridine diphosphate.\" [PMID:15134748]","metadata":null},{"id":"e481f6395032461f858f091300c5fc0f","type":"GO_TERM","name":"UDP-sugar diphosphatase activity","canonical_id":"go:GO:0008768","description":"\"Catalysis of the reaction: UDP-sugar + H2O = UMP + sugar 1-phosphate.\" [EC:3.6.1.45]","metadata":null},{"id":"b65ccd434187497a9560a1e13e71a79e","type":"GO_TERM","name":"UDP-sulfoquinovose:DAG sulfoquinovosyltransferase activity","canonical_id":"go:GO:0046510","description":"\"Catalysis of the reaction: UDP-sulfoquinovose + 1,2-diacylglycerol = sulfoquinovosyldiacylglycerol + UDP.\" [MetaCyc:RXN-1224]","metadata":null},{"id":"6f21c0078cd64071951e7ab9cb334eed","type":"GO_TERM","name":"UDP-xylose transmembrane transport","canonical_id":"go:GO:0015790","description":"\"The directed movement of UDP-xylose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. UDP-xylose is a substance composed of xylose in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"c287b71ef6184bdeb31cfb44fa108f8f","type":"GO_TERM","name":"UDP-xylose transmembrane transporter activity","canonical_id":"go:GO:0005464","description":"\"Enables the transfer of UDP-xylose from one side of a membrane to the other. UDP-xylose is a substance composed of xylose in glycosidic linkage with uridine diphosphate.\" [GOC:ai]","metadata":null},{"id":"9da2bc71d60148e9a4e1144806458042","type":"GO_TERM","name":"UDP-xylosyltransferase activity","canonical_id":"go:GO:0035252","description":"\"Catalysis of the transfer of a xylosyl group from UDP-xylose to an acceptor molecule.\" [PMID:30127001]","metadata":null},{"id":"ccc8a36b5d47429d8271bb148125c601","type":"GO_TERM","name":"UDPG:cyclo-DOPA 5-O-glucosyltransferase activity","canonical_id":"go:GO:0102894","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + leucodopachrome = H+ + cyclo-dopa 5-O-glucoside + UDP.\" [GOC:pz, PMID:15196939, PMID:15695438]","metadata":null},{"id":"b3f85bbeb7994b0a939b99797c58176b","type":"GO_TERM","name":"UDPsulfoquinovose synthase activity","canonical_id":"go:GO:0046507","description":"\"Catalysis of the reaction: sulfite + UDP-D-glucose = H2O + UDP-6-sulfoquinovose.\" [EC:3.13.1.1, RHEA:13197]","metadata":null},{"id":"c9ffd0eaafa8415bb7904997b6671d09","type":"GENE","name":"UEVLD","canonical_id":"hgnc:HGNC:30866","description":"UEV and lactate/malate dehyrogenase domains","metadata":{"aliases":["Attp","UEV3"]}},{"id":"01e4a6bfb8e94804abac9581e616afa2","type":"GENE","name":"UFC1","canonical_id":"hgnc:HGNC:26941","description":"ubiquitin-fold modifier conjugating enzyme 1","metadata":{"aliases":["HSPC155"]}},{"id":"8b9f71ccd994442f8372e089895f9644","type":"GENE","name":"UFC1P1","canonical_id":"hgnc:HGNC:56788","description":"UFC1 pseudogene 1","metadata":null},{"id":"c9e85c455f94468bb2720c9506811f3b","type":"GENE","name":"UFD1","canonical_id":"hgnc:HGNC:12520","description":"ubiquitin recognition factor in ER associated degradation 1","metadata":{"aliases":["UFD1L"]}},{"id":"ab55e1a9888d4fc6a6f2c0f6c7125230","type":"GENE","name":"UFD1-AS1","canonical_id":"hgnc:HGNC:55917","description":"UFD1 antisense RNA 1","metadata":null},{"id":"d98981859c0947adb257c1b0bc4e6e18","type":"GO_TERM","name":"UFD1-NPL4 complex","canonical_id":"go:GO:0036501","description":"\"A dimeric protein complex that contains the co-factors for the ATPase VCP/p97 (Cdc48p in budding yeast). In mammals, this complex consists of UFD1L (UFD1) and NPLOC4 (NPL4). In budding yeast, the complex is a dimer of Ufd1p and Npl4p.\" [GOC:bf, GOC:PARL, PMID:10811609, PMID:17289586]","metadata":null},{"id":"6c2a4cb566ce45888e6a1b63a04c2b5a","type":"GENE","name":"UFD1P1","canonical_id":"hgnc:HGNC:58643","description":"UFD1 pseudogene 1","metadata":null},{"id":"cd5afbedc7bf47658f9b15a3d0e07bdc","type":"GENE","name":"UFL1","canonical_id":"hgnc:HGNC:23039","description":"UFM1 specific ligase 1","metadata":{"aliases":["NLBP","Maxer","RCAD","KIAA0776"]}},{"id":"374e7a81441743c890f575eb78e57f8c","type":"GENE","name":"UFL1-AS1","canonical_id":"hgnc:HGNC:41007","description":"UFL1 antisense RNA 1","metadata":null},{"id":"ea45051cecfa48df9ab22066a38b6e8e","type":"GENE","name":"UFM1","canonical_id":"hgnc:HGNC:20597","description":"ubiquitin fold modifier 1","metadata":{"aliases":["bA131P10.1","C13orf20"]}},{"id":"b704f0033bff4d5cab9f53b9c297e2d0","type":"GO_TERM","name":"UFM1 activating enzyme activity","canonical_id":"go:GO:0071566","description":"\"Catalysis of the activation of the small ubiquitin-related modifier UFM1, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:sp, PMID:20018847]","metadata":null},{"id":"cae0af82b528433786414cf52f8117c1","type":"GO_TERM","name":"UFM1 conjugating enzyme activity","canonical_id":"go:GO:0061657","description":"\"Isoenergetic transfer of UFM1 from one protein to another via the reaction X-UFM1 + Y = Y-UFM1 + X, where both the X-UFM1 and Y-UFM1 linkages are thioester bonds between the C-terminal amino acid of UFM1 and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"ed75e33e627b4ef79caf68e642403549","type":"GO_TERM","name":"UFM1 ligase activity","canonical_id":"go:GO:0061666","description":"\"Catalysis of the transfer of UFM1 to a substrate protein via the reaction X-UFM1 + S = X + S-UFM1, where X is either an E2 or E3 enzyme, the X-UFM1 linkage is a thioester bond, and the S-UFM1 linkage is an isopeptide bond between the C-terminal amino acid of UFM1 and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"689bfad6a5ec45c78d7206f7d8d3c63b","type":"GO_TERM","name":"UFM1 transferase activity","canonical_id":"go:GO:0071568","description":"\"Catalysis of the transfer of UFM1 from one protein to another via the reaction X-UFM1 + Y = Y-UFM1 + X, where both X-UFM1 and Y-UFM1 are covalent linkages.\" [GOC:sp, PMID:20018847]","metadata":null},{"id":"c35e4d538064409b9e3e9d98c5b40d0b","type":"GO_TERM","name":"UFM1-modified protein reader activity","canonical_id":"go:GO:0141185","description":"\"A molecular adaptor recognizes and binds a target protein containing a UFM1 modification and brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.\" [PMID:32537488, PMID:36848233, PMID:38383785, PMID:38383789]","metadata":null},{"id":"c609411537ab4ee188e4e3998931bdc5","type":"GENE","name":"UFM1P1","canonical_id":"hgnc:HGNC:55146","description":"UFM1 pseudogene 1","metadata":null},{"id":"1c8c5fc461eb45f0840f62958a6406f4","type":"GENE","name":"UFM1P2","canonical_id":"hgnc:HGNC:55147","description":"UFM1 pseudogene 2","metadata":null},{"id":"473200c126bd4a738daf9e2b43dd5426","type":"GENE","name":"UFM1P3","canonical_id":"hgnc:HGNC:55148","description":"UFM1 pseudogene 3","metadata":{"aliases":["UFM1P1"]}},{"id":"040d908706af4e1dbdd476ad9d4c0744","type":"GENE","name":"UFSP1","canonical_id":"hgnc:HGNC:33821","description":"UFM1 specific peptidase 1","metadata":{"aliases":["UFSP"]}},{"id":"21646ac493cb4e6b896b572111e72f54","type":"GENE","name":"UFSP2","canonical_id":"hgnc:HGNC:25640","description":"UFM1 specific peptidase 2","metadata":{"aliases":["FLJ11200","C4orf20"]}},{"id":"3d8296d40f6e43d19c3b7afb7a560a54","type":"GO_TERM","name":"UGA codon-amino acid adaptor activity","canonical_id":"go:GO:0033415","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UGA codon.\" [GOC:mah]","metadata":null},{"id":"6e736bb288e34294bf14cdf8d391f0de","type":"GO_TERM","name":"UGC codon-amino acid adaptor activity","canonical_id":"go:GO:0033414","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UGC codon.\" [GOC:mah]","metadata":null},{"id":"0a074b60320b44b5ba452a502a7d049b","type":"GENE","name":"UGCG","canonical_id":"hgnc:HGNC:12524","description":null,"metadata":null},{"id":"726481a0d87e451eb9b1ec12c1a209ee","type":"PROTEIN","name":"UGCG","canonical_id":"uniprot:Q16739","description":null,"metadata":null},{"id":"53185f85c70346b18b95a11ea790dcea","type":"GENE","name":"UGDH","canonical_id":"hgnc:HGNC:12525","description":null,"metadata":null},{"id":"459b53c1d0ba4dd5ab7ac575eb03b451","type":"GENE","name":"UGDH-AS1","canonical_id":"hgnc:HGNC:40601","description":"UGDH antisense RNA 1","metadata":null},{"id":"8437c0ae4709483d96230af3595ef199","type":"GO_TERM","name":"UGG codon-amino acid adaptor activity","canonical_id":"go:GO:0033416","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UGG codon.\" [GOC:mah]","metadata":null},{"id":"ce08bc53acdb4444ab0b0d7ef8145db3","type":"GENE","name":"UGGT1","canonical_id":"hgnc:HGNC:15663","description":"UDP-glucose glycoprotein glucosyltransferase 1","metadata":{"aliases":["HUGT1","UGCGL1"]}},{"id":"10040e0b734c4587ab98443c74b8ab80","type":"GENE","name":"UGGT2","canonical_id":"hgnc:HGNC:15664","description":"UDP-glucose glycoprotein glucosyltransferase 2","metadata":{"aliases":["FLJ11485","HUGT2","FLJ10873","MGC150689","MGC87276","MGC117360","UGCGL2"]}},{"id":"dca6f09a604448cba0b0779ca9a97747","type":"GENE","name":"UGP2","canonical_id":"hgnc:HGNC:12527","description":"UDP-glucose pyrophosphorylase 2","metadata":{"aliases":["UGPP1","SVUGP2","UGP1"]}},{"id":"b5e7e7734171460b8b09eac5091b839f","type":"GENE","name":"UGT1A","canonical_id":"hgnc:HGNC:12529","description":"UDP glucuronosyltransferase family 1 member A complex locus","metadata":{"aliases":["UGT","UGT1A@"]}},{"id":"e233a25a86f8408e915d452b87ef0c3e","type":"GENE","name":"UGT1A1","canonical_id":"hgnc:HGNC:12530","description":null,"metadata":null},{"id":"c12c3add58d74414b25a330d1bb3a49c","type":"GENE","name":"UGT1A10","canonical_id":"hgnc:HGNC:12531","description":null,"metadata":null},{"id":"f1deea5ef02141ae915f0d324ac67bdd","type":"GENE","name":"UGT1A11P","canonical_id":"hgnc:HGNC:12532","description":"UDP glucuronosyltransferase family 1 member A11, pseudogene","metadata":{"aliases":["UGT1K"]}},{"id":"5e4ef7920322489f849b1cee97bc2051","type":"GENE","name":"UGT1A12P","canonical_id":"hgnc:HGNC:12533","description":"UDP glucuronosyltransferase family 1 member A12, pseudogene","metadata":{"aliases":["UGT1L"]}},{"id":"97c7bbc8be42455d88f444f9602e87ee","type":"GENE","name":"UGT1A13P","canonical_id":"hgnc:HGNC:32191","description":"UDP glucuronosyltransferase family 1 member A13, pseudogene","metadata":null},{"id":"6b6c7f160e634b7795ee5c5e53338e92","type":"GENE","name":"UGT1A2P","canonical_id":"hgnc:HGNC:12534","description":"UDP glucuronosyltransferase family 1 member A2, pseudogene","metadata":{"aliases":["UGT1BP"]}},{"id":"122bc37b7fbf4c2db19b2509b4991f0b","type":"GENE","name":"UGT1A3","canonical_id":"hgnc:HGNC:12535","description":"UDP glucuronosyltransferase family 1 member A3","metadata":{"aliases":["UGT1C"]}},{"id":"da8ebc259a184618a6564261997ba765","type":"GENE","name":"UGT1A4","canonical_id":"hgnc:HGNC:12536","description":null,"metadata":null},{"id":"18d603c829894daba2f8b9db6e556ac0","type":"GENE","name":"UGT1A5","canonical_id":"hgnc:HGNC:12537","description":"UDP glucuronosyltransferase family 1 member A5","metadata":{"aliases":["UGT1E"]}},{"id":"5ebb8c2cb0304217888236b6cc909c56","type":"GENE","name":"UGT1A6","canonical_id":"hgnc:HGNC:12538","description":null,"metadata":null},{"id":"2cd405ea7d4f451d810394cc4195e5cc","type":"GENE","name":"UGT1A7","canonical_id":"hgnc:HGNC:12539","description":null,"metadata":null},{"id":"77b5cdbb65be432691ca59e6894dd44b","type":"GENE","name":"UGT1A8","canonical_id":"hgnc:HGNC:12540","description":null,"metadata":null},{"id":"4ddfc25e4a024a749a322d1ad4bdce43","type":"GENE","name":"UGT1A9","canonical_id":"hgnc:HGNC:12541","description":null,"metadata":null},{"id":"0021f11457bb4a69a0afa12b6f14895c","type":"GENE","name":"UGT2A1","canonical_id":"hgnc:HGNC:12542","description":"UDP glucuronosyltransferase family 2 member A1 complex locus","metadata":null},{"id":"aa53503607904cdba86f71d4c4ccac68","type":"GENE","name":"UGT2A2","canonical_id":"hgnc:HGNC:28183","description":"UDP glucuronosyltransferase family 2 member A2","metadata":null},{"id":"c06fafbf97c241a48b97167309a15b7d","type":"GENE","name":"UGT2A3","canonical_id":"hgnc:HGNC:28528","description":"UDP glucuronosyltransferase family 2 member A3","metadata":{"aliases":["FLJ21934"]}},{"id":"498a56fce40a477e8605336df049ffc9","type":"GENE","name":"UGT2A3P7","canonical_id":"hgnc:HGNC:39429","description":"UDP glucuronosyltransferase family 2 member A3 pseudogene 7","metadata":null},{"id":"613f13d685484f849874e686b1814051","type":"GENE","name":"UGT2B10","canonical_id":"hgnc:HGNC:12544","description":"UDP glucuronosyltransferase family 2 member B10","metadata":null},{"id":"834ca38f7f9544598d1647145a36c152","type":"GENE","name":"UGT2B11","canonical_id":"hgnc:HGNC:12545","description":"UDP glucuronosyltransferase family 2 member B11","metadata":null},{"id":"f14b83556740424786aee9678107ee5f","type":"GENE","name":"UGT2B11-AS1","canonical_id":"hgnc:HGNC:58803","description":"UGT2B11 antisense RNA 1","metadata":null},{"id":"b02d1c4c79434bb288f2c8c0b153d13f","type":"GENE","name":"UGT2B15","canonical_id":"hgnc:HGNC:12546","description":null,"metadata":null},{"id":"f3db46271b184a3ca4b539ace128c575","type":"GENE","name":"UGT2B17","canonical_id":"hgnc:HGNC:12547","description":null,"metadata":null},{"id":"ec5e3c85e0be44459bf1693f19ae814c","type":"GENE","name":"UGT2B24P","canonical_id":"hgnc:HGNC:12548","description":"UDP glucuronosyltransferase family 2 member B24, pseudogene","metadata":null},{"id":"90d523dc850144e99ac813281b9aae73","type":"GENE","name":"UGT2B25P","canonical_id":"hgnc:HGNC:12549","description":"UDP glucuronosyltransferase family 2 member B25, pseudogene","metadata":null},{"id":"248278f21c9d4a5393f69a6a1b52d0ac","type":"GENE","name":"UGT2B26P","canonical_id":"hgnc:HGNC:12550","description":"UDP glucuronosyltransferase family 2 member B26, pseudogene","metadata":null},{"id":"5e9234c16eb14e35be47654696304c55","type":"GENE","name":"UGT2B27P","canonical_id":"hgnc:HGNC:12551","description":"UDP glucuronosyltransferase family 2 member B27, pseudogene","metadata":null},{"id":"74f5205a026a4cfb84ac3e205ae9b379","type":"GENE","name":"UGT2B28","canonical_id":"hgnc:HGNC:13479","description":"UDP glucuronosyltransferase family 2 member B28","metadata":null},{"id":"ab6057e8831d4d35a698ecc702ad330c","type":"GENE","name":"UGT2B28-AS1","canonical_id":"hgnc:HGNC:58804","description":"UGT2B28 antisense RNA 1","metadata":null},{"id":"838d282fee2e4d1c86025c71d4775a1b","type":"GENE","name":"UGT2B29P","canonical_id":"hgnc:HGNC:12552","description":"UDP glucuronosyltransferase family 2 member B29, pseudogene","metadata":null},{"id":"fd3df3efc7ac4d1cb31d893361fc0604","type":"GENE","name":"UGT2B4","canonical_id":"hgnc:HGNC:12553","description":null,"metadata":null},{"id":"3610e69490e54b2bb4230a33f9f16ec6","type":"GENE","name":"UGT2B7","canonical_id":"hgnc:HGNC:12554","description":null,"metadata":null},{"id":"cd27cfb75af04995ba08983b86b46ed4","type":"GENE","name":"UGT2B7-AS1","canonical_id":"hgnc:HGNC:58801","description":"UGT2B7 antisense RNA 1","metadata":null},{"id":"ad5a882d1f9f421e925ad960fb4aafda","type":"GENE","name":"UGT2B7-AS2","canonical_id":"hgnc:HGNC:58802","description":"UGT2B7 antisense RNA 2","metadata":null},{"id":"146c66ab60aa42b181bd8c791d1177e5","type":"GENE","name":"UGT3A1","canonical_id":"hgnc:HGNC:26625","description":"UDP glycosyltransferase family 3 member A1","metadata":{"aliases":["FLJ34658"]}},{"id":"beec204eb8164066a234a03f9e529706","type":"GENE","name":"UGT3A2","canonical_id":"hgnc:HGNC:27266","description":"UDP glycosyltransferase family 3 member A2","metadata":null},{"id":"9927e8572a2248a6b1e173f24ecbddab","type":"GENE","name":"UGT8","canonical_id":"hgnc:HGNC:12555","description":"UDP glycosyltransferase 8","metadata":{"aliases":["CGT"]}},{"id":"adb3b05ace654e409dfb322ffe541454","type":"GENE","name":"UGT8-AS1","canonical_id":"hgnc:HGNC:58875","description":"UGT8 antisense RNA 1","metadata":null},{"id":"81ba9833c24b4cb0b769c6867d6d4cc9","type":"GO_TERM","name":"UGU codon-amino acid adaptor activity","canonical_id":"go:GO:0033413","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UGU codon.\" [GOC:mah]","metadata":null},{"id":"af81b845459e4c82a072a1aa1fc43777","type":"GENE","name":"UHMK1","canonical_id":"hgnc:HGNC:19683","description":"U2AF homology motif kinase 1","metadata":{"aliases":["KIS","Kist"]}},{"id":"dd4f0c30bdef4bf08ebc6ed1986f9e37","type":"GENE","name":"UHRF1","canonical_id":"hgnc:HGNC:12556","description":null,"metadata":null},{"id":"7b7de070a1c14e16a87b3391cb5a2db3","type":"GENE","name":"UHRF1BP1","canonical_id":"hgnc:HGNC:21216","description":null,"metadata":null},{"id":"3b51aa0f12e8487d8c60d3b4960e7eec","type":"GENE","name":"UHRF2","canonical_id":"hgnc:HGNC:12557","description":"ubiquitin like with PHD and ring finger domains 2","metadata":{"aliases":["RNF107","NIRF","URF2","MGC33463","TDRD23"]}},{"id":"43e0ef38d5304a71839e80ec0f961e48","type":"GENE","name":"UHRF2-AS1","canonical_id":"hgnc:HGNC:58384","description":"UHRF2 antisense RNA 1","metadata":null},{"id":"f73ae96dd1654282a03f3124afe502ae","type":"GENE","name":"UHRF2P1","canonical_id":"hgnc:HGNC:39565","description":"ubiquitin like with PHD and ring finger domains 2 pseudogene 1","metadata":null},{"id":"6099243726484a7eb2b771431955b97e","type":"TRIAL","name":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","canonical_id":"clinicaltrials.gov:NCT07001254","description":"Aplastic Anemia","metadata":null},{"id":"4249e3ed84924f65a52092daa1aed028","type":"GENE","name":"UICLM","canonical_id":"hgnc:HGNC:54869","description":"up-regulated in colorectal cancer liver metastasis","metadata":{"aliases":["CROCC2-AS1"]}},{"id":"28c793366c0f4d4b8349f5c16e284be8","type":"GENE","name":"UIMC1","canonical_id":"hgnc:HGNC:30298","description":"ubiquitin interaction motif containing 1","metadata":{"aliases":["RAP80"]}},{"id":"b662ee7b32c240e0a0dcba15a1e8351b","type":"TRIAL","name":"UK ENcorafenib and BInimetinib Real-world Study in Melanoma","canonical_id":"clinicaltrials.gov:NCT07022457","description":"Metastatic Melanoma, BRAF V600 Mutation Positive","metadata":null},{"id":"a497873da46545c392663ed9d1c84974","type":"GENE","name":"ULBP1","canonical_id":"hgnc:HGNC:14893","description":null,"metadata":null},{"id":"08d0d0c7f6494a4985210a6705c425ba","type":"GENE","name":"ULBP2","canonical_id":"hgnc:HGNC:14894","description":"UL16 binding protein 2","metadata":{"aliases":["RAET1H"]}},{"id":"1f77015d173847538f28176ff0844d82","type":"GENE","name":"ULBP3","canonical_id":"hgnc:HGNC:14895","description":"UL16 binding protein 3","metadata":{"aliases":["RAET1N"]}},{"id":"26351c7ccb494ee6b175b3752d9a8576","type":"GENE","name":"ULK1","canonical_id":"hgnc:HGNC:12558","description":null,"metadata":null},{"id":"23605b82cec7426aa52508851c7c1606","type":"GENE","name":"ULK2","canonical_id":"hgnc:HGNC:13480","description":"unc-51 like autophagy activating kinase 2","metadata":{"aliases":["KIAA0623","Unc51.2","ATG1B"]}},{"id":"194b55daaf334c09994bd84a003460dd","type":"GENE","name":"ULK3","canonical_id":"hgnc:HGNC:19703","description":"unc-51 like kinase 3","metadata":{"aliases":["DKFZP434C131","FLJ90566"]}},{"id":"c90d0a5fcdb74e12bde52726d2a1af70","type":"GENE","name":"ULK4","canonical_id":"hgnc:HGNC:15784","description":"unc-51 like kinase 4","metadata":{"aliases":["FLJ20574","REC01035","FAM7C1"]}},{"id":"6cbf113d1c7e4181b15e5340b5f7a816","type":"GENE","name":"ULK4P1","canonical_id":"hgnc:HGNC:15775","description":"ULK4 pseudogene 1","metadata":{"aliases":["D-X","FAM7A1"]}},{"id":"2f2cef6efc1240a1b41c97b48d727ea7","type":"GENE","name":"ULK4P2","canonical_id":"hgnc:HGNC:15776","description":"ULK4 pseudogene 2","metadata":{"aliases":["D-X","FAM7A2"]}},{"id":"9780f2f2799b4903a2730a0c91c08299","type":"GENE","name":"ULK4P3","canonical_id":"hgnc:HGNC:15777","description":"ULK4 pseudogene 3","metadata":{"aliases":["D-X","FAM7A3"]}},{"id":"97e4960a81a34b65a1c77bfe7cf2995a","type":"GENE","name":"UMAD1","canonical_id":"hgnc:HGNC:48955","description":"UBAP1-MVB12-associated (UMA) domain containing 1","metadata":{"aliases":["RPA3-AS1","RPA3OS"]}},{"id":"ef55bfb2bfa74a14a9abd260f4673017","type":"GENE","name":"UMLILO","canonical_id":"hgnc:HGNC:51824","description":"upstream master lncRNA of the inflammatory chemokine locus","metadata":null},{"id":"257b062cca39451ea29925938a6ea68a","type":"GENE","name":"UMOD","canonical_id":"hgnc:HGNC:12559","description":null,"metadata":null},{"id":"008eff0d3e6b48a8aa503e4b30825968","type":"GENE","name":"UMODL1","canonical_id":"hgnc:HGNC:12560","description":"uromodulin like 1","metadata":null},{"id":"ad2a5225c3554a769721b29a8e243cd0","type":"GENE","name":"UMODL1-AS1","canonical_id":"hgnc:HGNC:23821","description":"UMODL1 antisense RNA 1","metadata":{"aliases":["FLJ33471","C21orf128"]}},{"id":"e97d0935dedf41fd848f6ebf14b50dda","type":"GO_TERM","name":"UMP biosynthetic process","canonical_id":"go:GO:0006222","description":"\"The chemical reactions and pathways resulting in the formation of UMP, uridine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"b91b6ada7fe24a2686b720a83554b356","type":"GO_TERM","name":"UMP catabolic process","canonical_id":"go:GO:0046050","description":"\"The chemical reactions and pathways resulting in the breakdown of UMP, uridine monophosphate.\" [GOC:curators]","metadata":null},{"id":"3dbf52f88efb4096bf7a2d3cf5257708","type":"GO_TERM","name":"UMP kinase activity","canonical_id":"go:GO:0033862","description":"\"Catalysis of the reaction: ATP + UMP = ADP + UDP.\" [EC:2.7.4.22]","metadata":null},{"id":"ecbcd4e913e547598dd7154ecf0fdcce","type":"GO_TERM","name":"UMP metabolic process","canonical_id":"go:GO:0046049","description":"\"The chemical reactions and pathways involving UMP, uridine monophosphate.\" [GOC:curators]","metadata":null},{"id":"1bad1deee180422fa949e0e19f685cc1","type":"GO_TERM","name":"UMP salvage","canonical_id":"go:GO:0044206","description":"\"Any process which produces UMP, uridine monophosphate, from derivatives of it (e.g. cytidine, uridine, cytosine) without de novo synthesis.\" [GOC:ecd, PMID:15096496]","metadata":null},{"id":"ea660592e5e64730b9d0eb2fc05ad922","type":"GENE","name":"UMPS","canonical_id":"hgnc:HGNC:12563","description":"uridine monophosphate synthetase","metadata":{"aliases":["OPRT","ODC"]}},{"id":"a72e21dece0f41b79135e4d03d79c59f","type":"GENE","name":"UNC119","canonical_id":"hgnc:HGNC:12565","description":"unc-119 lipid binding chaperone","metadata":{"aliases":["HRG4","POC7","POC7A"]}},{"id":"99a91a8d30cd45689377a49f930716c3","type":"GENE","name":"UNC119B","canonical_id":"hgnc:HGNC:16488","description":"unc-119 lipid binding chaperone B","metadata":{"aliases":["MGC5139","POC7B"]}},{"id":"0fedc011aa854c61a0325efff31e86ce","type":"GENE","name":"UNC13A","canonical_id":"hgnc:HGNC:23150","description":"unc-13 homolog A","metadata":{"aliases":["KIAA1032","Munc13-1"]}},{"id":"50cea49d2f8c466ba8c239931230b9b1","type":"GENE","name":"UNC13B","canonical_id":"hgnc:HGNC:12566","description":"unc-13 homolog B","metadata":{"aliases":["hmunc13","Unc13h2","Munc13-2","UNC13"]}},{"id":"e6b4ae918fce46a799378c1e72d9251c","type":"GENE","name":"UNC13C","canonical_id":"hgnc:HGNC:23149","description":"unc-13 homolog C","metadata":{"aliases":["Munc13-3","DKFZp547H074"]}},{"id":"501d12c4a73247a0b4a2c1bacd05a24c","type":"GENE","name":"UNC13D","canonical_id":"hgnc:HGNC:23147","description":"unc-13 homolog D","metadata":{"aliases":["Munc13-4"]}},{"id":"c4119d696f934790b024a6c653e7edf7","type":"GENE","name":"UNC45A","canonical_id":"hgnc:HGNC:30594","description":"unc-45 myosin chaperone A","metadata":{"aliases":["SMAP-1","GC-UNC45"]}},{"id":"01d361a9fe9b42e7b6fd363e0b58636c","type":"GENE","name":"UNC45B","canonical_id":"hgnc:HGNC:14304","description":"unc-45 myosin chaperone B","metadata":{"aliases":["UNC45","CMYA4"]}},{"id":"2552d8fa1d724015b3cbffc994ffd1ae","type":"GENE","name":"UNC50","canonical_id":"hgnc:HGNC:16046","description":"unc-50 inner nuclear membrane RNA binding protein","metadata":{"aliases":["URP","UNCL","GMH1"]}},{"id":"450f8e2e23134189a156924660df55fb","type":"GENE","name":"UNC5A","canonical_id":"hgnc:HGNC:12567","description":"unc-5 netrin receptor A","metadata":{"aliases":["KIAA1976","UNC5H1"]}},{"id":"50e38a81ffb74dcca655110799b9d8a4","type":"GENE","name":"UNC5A-AS1","canonical_id":"hgnc:HGNC:59311","description":"UNC5A antisense RNA 1","metadata":null},{"id":"39101136fa1c44c6bd1631ed863af1c9","type":"GENE","name":"UNC5B","canonical_id":"hgnc:HGNC:12568","description":"unc-5 netrin receptor B","metadata":{"aliases":["UNC5H2","p53RDL1"]}},{"id":"1a133095cd1444bd9df43de6269d7fd5","type":"GENE","name":"UNC5B-AS1","canonical_id":"hgnc:HGNC:45096","description":"UNC5B antisense RNA 1","metadata":{"aliases":["UASR1","TP53LC05"]}},{"id":"993cd93835e848c1b837bea1d9db6224","type":"GENE","name":"UNC5C","canonical_id":"hgnc:HGNC:12569","description":"unc-5 netrin receptor C","metadata":null},{"id":"0d9453948b424f8fa2495836671c56a3","type":"GENE","name":"UNC5C-AS1","canonical_id":"hgnc:HGNC:55246","description":"UNC5C antisense RNA 1","metadata":null},{"id":"3cb2f1d4adbf465cba8ccaa465fde11c","type":"GENE","name":"UNC5CL","canonical_id":"hgnc:HGNC:21203","description":"unc-5 family C-terminal like","metadata":{"aliases":["MGC34763","ZUD"]}},{"id":"293bf7ca24a04f698b94be220061174c","type":"GENE","name":"UNC5D","canonical_id":"hgnc:HGNC:18634","description":"unc-5 netrin receptor D","metadata":{"aliases":["KIAA1777","Unc5h4"]}},{"id":"d9f9b49cc6fb4b7fa918ecb1fec6981a","type":"GENE","name":"UNC79","canonical_id":"hgnc:HGNC:19966","description":"unc-79 subunit of NALCN channel complex","metadata":{"aliases":["KIAA1409"]}},{"id":"bbba1fe053384108b30a5787e7aea344","type":"GENE","name":"UNC80","canonical_id":"hgnc:HGNC:26582","description":"unc-80 subunit of NALCN channel complex","metadata":{"aliases":["FLJ33496","KIAA1843","UNC-80","C2orf21"]}},{"id":"af5a493ad1054524aac85e6f9a965bb5","type":"GENE","name":"UNC93A","canonical_id":"hgnc:HGNC:12570","description":"unc-93 homolog A","metadata":{"aliases":["dJ366N23.2","dJ366N23.1"]}},{"id":"742f9c315dd1479783c9875206cda581","type":"GENE","name":"UNC93B1","canonical_id":"hgnc:HGNC:13481","description":"unc-93B1 regulator of TLR signaling","metadata":{"aliases":["UNC93","UNC-93B"]}},{"id":"75f97690a3ba44fca0ce5973d6e46c70","type":"GENE","name":"UNC93B2","canonical_id":"hgnc:HGNC:13482","description":"unc-93 homolog B2 (pseudogene)","metadata":{"aliases":["UNC93B2P"]}},{"id":"146699e141ef4806b0e56289f1b57595","type":"GENE","name":"UNC93B3","canonical_id":"hgnc:HGNC:13483","description":"unc-93 homolog B3 (pseudogene)","metadata":{"aliases":["UNC93B3P"]}},{"id":"3daf6ee56b794380822b672eee790cc3","type":"GENE","name":"UNC93B4","canonical_id":"hgnc:HGNC:13484","description":"unc-93 homolog B4 (pseudogene)","metadata":null},{"id":"b2f6830f126545eb9503a982e76f4523","type":"GENE","name":"UNC93B5","canonical_id":"hgnc:HGNC:34051","description":"unc-93 homolog B5 (pseudogene)","metadata":null},{"id":"797391c369f041c8a647488c48f08112","type":"GENE","name":"UNC93B6","canonical_id":"hgnc:HGNC:34053","description":"unc-93 homolog B6 (pseudogene)","metadata":null},{"id":"4d9d2633bb0c439289e56ea91614f9b8","type":"GENE","name":"UNC93B7","canonical_id":"hgnc:HGNC:44036","description":"unc-93 homolog B7 (pseudogene)","metadata":null},{"id":"6b5b13cabe8a47558a47225cff61ca76","type":"GENE","name":"UNC93B8","canonical_id":"hgnc:HGNC:44037","description":"unc-93 homolog B8 (pseudogene)","metadata":null},{"id":"607306fb417d4f3c913053dc452dea63","type":"GENE","name":"UNCX","canonical_id":"hgnc:HGNC:33194","description":"UNC homeobox","metadata":{"aliases":["Uncx4.1"]}},{"id":"bda3524184854723a5611b10b777a7a5","type":"GENE","name":"UNG","canonical_id":"hgnc:HGNC:12572","description":"uracil DNA glycosylase","metadata":{"aliases":["UDG","UNG1","UNG2","HIGM4","DGU"]}},{"id":"480ce7c4f3724fa1a6edab89c5844910","type":"GENE","name":"UNGP1","canonical_id":"hgnc:HGNC:18579","description":"uracil-DNA glycosylase pseudogene 1","metadata":null},{"id":"6e351c5240af48d680eff7daeff16917","type":"GENE","name":"UNGP2","canonical_id":"hgnc:HGNC:18580","description":"uracil-DNA glycosylase pseudogene 2","metadata":null},{"id":"a61ed62e22ae422fbf7d82fd734a673f","type":"GENE","name":"UNGP3","canonical_id":"hgnc:HGNC:20036","description":"uracil-DNA glycosylase pseudogene 3","metadata":null},{"id":"58fb67bb14e74197a91b72a5c7a579fe","type":"TRIAL","name":"UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC","canonical_id":"clinicaltrials.gov:NCT04940637","description":"Lung Cancer; Mesothelioma","metadata":null},{"id":"350cc5a6662e42e59b0d509926b32ea6","type":"GENE","name":"UNK","canonical_id":"hgnc:HGNC:29369","description":"unk zinc finger","metadata":{"aliases":["KIAA1753","ZC3HDC5","ZC3H5"]}},{"id":"4bc280865897490381e4d0142151f15d","type":"GENE","name":"UNKL","canonical_id":"hgnc:HGNC:14184","description":"unk like zinc finger","metadata":{"aliases":["ZC3HDC5L","ZC3H5L","FLJ23360","C16orf28"]}},{"id":"6a63a023f4d949c48bdad15d1536b5d0","type":"GENE","name":"UNKL-AS1","canonical_id":"hgnc:HGNC:58300","description":"UNKL antisense RNA 1","metadata":null},{"id":"2afce34a59da470dba8f9ac0cf5cfff8","type":"GENE","name":"UOX","canonical_id":"hgnc:HGNC:12575","description":"urate oxidase (pseudogene)","metadata":{"aliases":["UOXP"]}},{"id":"f80d5a26e4cc41aa915ba9cdba4cbc5e","type":"GENE","name":"UPB1","canonical_id":"hgnc:HGNC:16297","description":"beta-ureidopropionase 1","metadata":{"aliases":["BUP1"]}},{"id":"ec338248c0bc4005ae9a3049a291b102","type":"GENE","name":"UPF1","canonical_id":"hgnc:HGNC:9962","description":null,"metadata":null},{"id":"913adf58c7ce4c59a8c42ded552a1891","type":"GENE","name":"UPF2","canonical_id":"hgnc:HGNC:17854","description":null,"metadata":null},{"id":"3f38f07b08a34f32b5ff170b1de77805","type":"GENE","name":"UPF3A","canonical_id":"hgnc:HGNC:20332","description":"UPF3A regulator of nonsense mediated mRNA decay","metadata":{"aliases":["RENT3A","UPF3","HUPF3A"]}},{"id":"fdbd719e578248d38072b0b37360f3e2","type":"GENE","name":"UPF3AP1","canonical_id":"hgnc:HGNC:30568","description":"UPF3A pseudogene 1","metadata":null},{"id":"fde017bf6626412a84580f4ede810c43","type":"GENE","name":"UPF3AP2","canonical_id":"hgnc:HGNC:30567","description":"UPF3A pseudogene 2","metadata":null},{"id":"53509eeccd7e487a9a2dabad5e6712f1","type":"GENE","name":"UPF3AP3","canonical_id":"hgnc:HGNC:38395","description":"UPF3A pseudogene 3","metadata":null},{"id":"0406d82a4ae742b9b50296ede1848d3b","type":"GENE","name":"UPF3B","canonical_id":"hgnc:HGNC:20439","description":null,"metadata":null},{"id":"a50871844f594b299920a304a196492e","type":"GENE","name":"UPK1A","canonical_id":"hgnc:HGNC:12577","description":"uroplakin 1A","metadata":{"aliases":["TSPAN21"]}},{"id":"e3321ff955924f21ae04a8940ff1a7dc","type":"GENE","name":"UPK1A-AS1","canonical_id":"hgnc:HGNC:40603","description":"UPK1A antisense RNA 1","metadata":null},{"id":"f476e338c82a4cb5b6cc037b738c06cd","type":"GENE","name":"UPK1B","canonical_id":"hgnc:HGNC:12578","description":"uroplakin 1B","metadata":{"aliases":["TSPAN20","UPK1"]}},{"id":"078b726d9ef9423ca3da2a83fc905eb8","type":"GENE","name":"UPK2","canonical_id":"hgnc:HGNC:12579","description":"uroplakin 2","metadata":{"aliases":["UP2","UPII","MGC138598"]}},{"id":"0733539583114110bfb8477324fff2e6","type":"GENE","name":"UPK3A","canonical_id":"hgnc:HGNC:12580","description":"uroplakin 3A","metadata":{"aliases":["UPK3"]}},{"id":"c2786e5fc05c4dee887eb7c7731ebf43","type":"GENE","name":"UPK3B","canonical_id":"hgnc:HGNC:21444","description":"uroplakin 3B","metadata":{"aliases":["MGC10902","p35","UPIIIb","FLJ32198"]}},{"id":"547f8961b038493ca90b4bfa9c653733","type":"GENE","name":"UPK3BL1","canonical_id":"hgnc:HGNC:37278","description":"uroplakin 3B like 1","metadata":{"aliases":["UPLP","UPK3BL"]}},{"id":"3d20c7865625496ca37ba8cd2138b386","type":"GENE","name":"UPK3BL2","canonical_id":"hgnc:HGNC:53444","description":"uroplakin 3B like 2","metadata":null},{"id":"f45650c5a73b4b35a095c27107fb55cc","type":"GENE","name":"UPK3BL3P","canonical_id":"hgnc:HGNC:55757","description":"uroplakin 3B like 3, pseudogene","metadata":null},{"id":"951d8687bb614af59c5f6e1a8d4846d9","type":"GENE","name":"UPK3BP1","canonical_id":"hgnc:HGNC:42353","description":"uroplakin 3B pseudogene 1","metadata":null},{"id":"fea8391529694232b62cda1ce45f2756","type":"GENE","name":"UPP1","canonical_id":"hgnc:HGNC:12576","description":null,"metadata":null},{"id":"49ee26dac28144f484655831759db776","type":"GENE","name":"UPP2","canonical_id":"hgnc:HGNC:23061","description":"uridine phosphorylase 2","metadata":{"aliases":["UPASE2","UP2","UDRPASE2"]}},{"id":"553a5ac6d60c4af6a27081b330234106","type":"GENE","name":"UPRT","canonical_id":"hgnc:HGNC:28334","description":"uracil phosphoribosyltransferase homolog","metadata":{"aliases":["DKFZp781E1243","MGC23937","FUR1","RP11-311P8.3"]}},{"id":"01dde395e8e04f90b0288f156797c693","type":"GENE","name":"UQCC1","canonical_id":"hgnc:HGNC:15891","description":"ubiquinol-cytochrome c reductase complex assembly factor 1","metadata":{"aliases":["FLJ10850","CBP3","BFZB","C20orf44","UQCC"]}},{"id":"52c2c5e0cfa94d5c93689a93b95bc59c","type":"GENE","name":"UQCC2","canonical_id":"hgnc:HGNC:21237","description":"ubiquinol-cytochrome c reductase complex assembly factor 2","metadata":{"aliases":["MGC14833","bA6B20.2","M19","Cbp6","C6orf125","MNF1"]}},{"id":"cfb66ad7b91246999aa34cae6d8f59af","type":"GENE","name":"UQCC3","canonical_id":"hgnc:HGNC:34399","description":"ubiquinol-cytochrome c reductase complex assembly factor 3","metadata":{"aliases":["UNQ655","C11orf83"]}},{"id":"9a7c219630374f0a961986228f66c838","type":"GENE","name":"UQCC4","canonical_id":"hgnc:HGNC:27558","description":"ubiquinol-cytochrome c reductase complex assembly factor 4","metadata":{"aliases":["gs103","CCSMST1","URLC5","C16orf91"]}},{"id":"fdad9ffd792749b1a9bee2c775bfb212","type":"GENE","name":"UQCC5","canonical_id":"hgnc:HGNC:37257","description":"ubiquinol-cytochrome c reductase complex assembly factor 5","metadata":{"aliases":["C3orf78","SMIM4"]}},{"id":"3a31310bbf014091a18991c240974023","type":"GENE","name":"UQCC6","canonical_id":"hgnc:HGNC:34450","description":"ubiquinol-cytochrome c reductase complex assembly factor 6","metadata":{"aliases":["FLJ13975","DKFZp547P055","BR","C12orf73"]}},{"id":"d0e1bdc1ed29463ba9bd53114c42b128","type":"GENE","name":"UQCR10","canonical_id":"hgnc:HGNC:30863","description":"ubiquinol-cytochrome c reductase, complex III subunit X","metadata":{"aliases":["HSPC051","UCRC","QCR9","UCCR7.2"]}},{"id":"10d5ed8dcecc4c1284436d5e9ee1b321","type":"GENE","name":"UQCR10P1","canonical_id":"hgnc:HGNC:54960","description":"UQCR10 pseudogene 1","metadata":null},{"id":"517a2fd6fcff4a5cbc220a0292c60dc2","type":"GENE","name":"UQCR11","canonical_id":"hgnc:HGNC:30862","description":"ubiquinol-cytochrome c reductase, complex III subunit XI","metadata":{"aliases":["QCR10","UQCR"]}},{"id":"1b3c235d26b24d0b99c28dfcfa3ce548","type":"GENE","name":"UQCRB","canonical_id":"hgnc:HGNC:12582","description":"ubiquinol-cytochrome c reductase binding protein","metadata":{"aliases":["QP-C","QCR7","UQCR6","UQBP"]}},{"id":"6a5bdb9611764038b213a389b9cc496a","type":"GENE","name":"UQCRB-AS1","canonical_id":"hgnc:HGNC:55521","description":"UQCRB antisense RNA 1","metadata":null},{"id":"5aac7da5678d46bebb0c50124a34f1e2","type":"GENE","name":"UQCRBP1","canonical_id":"hgnc:HGNC:12583","description":"ubiquinol-cytochrome c reductase binding protein pseudogene 1","metadata":null},{"id":"a35ae0718fd441cfa94ca0749809e94b","type":"GENE","name":"UQCRBP2","canonical_id":"hgnc:HGNC:12584","description":"ubiquinol-cytochrome c reductase binding protein pseudogene 2","metadata":null},{"id":"8ef937dfb89d40158285b0763657efce","type":"GENE","name":"UQCRBP3","canonical_id":"hgnc:HGNC:39033","description":"ubiquinol-cytochrome c reductase binding protein pseudogene 3","metadata":null},{"id":"ab03d4f41c9d406c917c7f83f7c9b1b1","type":"GENE","name":"UQCRC1","canonical_id":"hgnc:HGNC:12585","description":"ubiquinol-cytochrome c reductase core protein 1","metadata":{"aliases":["D3S3191","QCR1","UQCR1"]}},{"id":"97cad79143194337b2a39315029ec1a7","type":"GENE","name":"UQCRC2","canonical_id":"hgnc:HGNC:12586","description":"ubiquinol-cytochrome c reductase core protein 2","metadata":{"aliases":["QCR2","UQCR2"]}},{"id":"5e15a63918b64eecaf58856cb079408c","type":"GENE","name":"UQCRC2P1","canonical_id":"hgnc:HGNC:44309","description":"ubiquinol-cytochrome c reductase core protein 2 pseudogene 1","metadata":null},{"id":"c95a98c4e8484e80b59853828e054e0b","type":"GENE","name":"UQCRFS1","canonical_id":"hgnc:HGNC:12587","description":"ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1","metadata":{"aliases":["ISP","RIS1","RIP1","UQCR5","RISP"]}},{"id":"8de161d0dc5742528ba3eae81971c95b","type":"GENE","name":"UQCRFS1-DT","canonical_id":"hgnc:HGNC:55295","description":"UQCRFS1 divergent transcript","metadata":null},{"id":"12f0f54ecde149ea9f9a69b2c14cfccb","type":"GENE","name":"UQCRFS1P1","canonical_id":"hgnc:HGNC:12588","description":"ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 pseudogene 1","metadata":{"aliases":["UQCRFSL1"]}},{"id":"9dff3bb3aff34e2d98d1a15c158200ec","type":"GENE","name":"UQCRFS1P2","canonical_id":"hgnc:HGNC:39172","description":"ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 pseudogene 2","metadata":null},{"id":"12625137ebb64ffbaa3617bdbe40b9e5","type":"GENE","name":"UQCRFS1P3","canonical_id":"hgnc:HGNC:39173","description":"ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 pseudogene 3","metadata":null},{"id":"ea80c0a8d3d84b0f8e8982f4c471ba7e","type":"GENE","name":"UQCRH","canonical_id":"hgnc:HGNC:12590","description":"ubiquinol-cytochrome c reductase hinge protein","metadata":{"aliases":["QCR6","UQCR8"]}},{"id":"e70894f74a3d43518a0ec457823ee22f","type":"GENE","name":"UQCRHL","canonical_id":"hgnc:HGNC:51714","description":"ubiquinol-cytochrome c reductase hinge protein like","metadata":null},{"id":"4d92cfcbf0f34a39af94a2ffcf67209a","type":"GENE","name":"UQCRHP1","canonical_id":"hgnc:HGNC:31341","description":"ubiquinol-cytochrome c reductase hinge protein pseudogene 1","metadata":{"aliases":["Em:AF129756.18","UQCRHP5"]}},{"id":"79ff536d2b724b8fb862a6f8e592ec53","type":"GENE","name":"UQCRHP2","canonical_id":"hgnc:HGNC:38045","description":"ubiquinol-cytochrome c reductase hinge protein pseudogene 2","metadata":null},{"id":"9ede8653ab36442c91d180625d3ad86e","type":"GENE","name":"UQCRHP3","canonical_id":"hgnc:HGNC:38046","description":"ubiquinol-cytochrome c reductase hinge protein pseudogene 3","metadata":null},{"id":"751e42e263404f0e87cc76afa5bc6b0f","type":"GENE","name":"UQCRHP4","canonical_id":"hgnc:HGNC:38047","description":"ubiquinol-cytochrome c reductase hinge protein pseudogene 4","metadata":null},{"id":"8ab2459fc6f04b29bb4dc4b94431b7c6","type":"GENE","name":"UQCRQ","canonical_id":"hgnc:HGNC:29594","description":"ubiquinol-cytochrome c reductase complex III subunit VII","metadata":{"aliases":["QP-C","QCR8","UQCR7"]}},{"id":"fbb2bb53b6cd429bb27b3847c43f03ee","type":"GENE","name":"URAD","canonical_id":"hgnc:HGNC:17785","description":"ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase","metadata":{"aliases":["PRHOXNB"]}},{"id":"53394b301dbe4cbda10e6f4a9fd0a6ae","type":"GENE","name":"URAHP","canonical_id":"hgnc:HGNC:43695","description":"urate (hydroxyiso-) hydrolase, pseudogene","metadata":{"aliases":["URAH"]}},{"id":"6985fe64c0d547a29bbcd3901a967f4d","type":"GENE","name":"URB1","canonical_id":"hgnc:HGNC:17344","description":"URB1 ribosome biogenesis factor","metadata":{"aliases":["KIAA0539","NPA1","C21orf108"]}},{"id":"5200e419e07e419fad4ca624831faca9","type":"GENE","name":"URB1-DT","canonical_id":"hgnc:HGNC:23128","description":"URB1 divergent transcript","metadata":{"aliases":["PRED84","MGC14136","C21orf119","URB1-AS1"]}},{"id":"95ba39a184da4150be0db8c28064979d","type":"GENE","name":"URB2","canonical_id":"hgnc:HGNC:28967","description":"URB2 ribosome biogenesis homolog","metadata":{"aliases":["NPA2","NET10","KIAA0133"]}},{"id":"2ea817b35aa5488a9bca97f8d1b4b61b","type":"GENE","name":"URGCP","canonical_id":"hgnc:HGNC:30890","description":"upregulator of cell proliferation","metadata":{"aliases":["URG4","KIAA1507","FLJ20654","DKFZp666G166","DKFZp686O0457"]}},{"id":"914e11eec5e242e4a159a944e3b6894b","type":"GENE","name":"URGCP-MRPS24","canonical_id":"hgnc:HGNC:49188","description":"URGCP-MRPS24 readthrough","metadata":null},{"id":"0d99bc5add02473bb38e2df58b903406","type":"GENE","name":"URI1","canonical_id":"hgnc:HGNC:13236","description":null,"metadata":null},{"id":"5eea322056d545b8b8fbe7cfbcee3c32","type":"GENE","name":"URM1","canonical_id":"hgnc:HGNC:28378","description":"ubiquitin related modifier 1","metadata":{"aliases":["MGC2668","C9orf74"]}},{"id":"0adc208a261b40e2b069cddb3141c7a1","type":"GO_TERM","name":"URM1 activating enzyme activity","canonical_id":"go:GO:0042292","description":"\"Catalysis of the activation of the small ubiquitin-related modifier URM1, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:mah]","metadata":null},{"id":"da87006cf942450e998ce32fc7ccd9d6","type":"GO_TERM","name":"URM1 conjugating enzyme activity","canonical_id":"go:GO:0061658","description":"\"Isoenergetic transfer of URM1 from one protein to another via the reaction X-URM1 + Y = Y-URM1 + X, where both the X-URM1 and Y-URM1 linkages are thioester bonds between the C-terminal amino acid of URM1 and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"995153f6b1e2457d8ee381b3978239f1","type":"GO_TERM","name":"URM1 ligase activity","canonical_id":"go:GO:0061667","description":"\"Catalysis of the transfer of URM1 to a substrate protein via the reaction X-URM1 + S = X + S-URM1, where X is either an E2 or E3 enzyme, the X-URM1 linkage is a thioester bond, and the S-URM1 linkage is an isopeptide bond between the C-terminal amino acid of URM1 and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"cb83569e78a648a09747fb40a92d872e","type":"GO_TERM","name":"URM1 transferase activity","canonical_id":"go:GO:0042294","description":"\"Catalysis of the transfer of URM1 from one protein to another via the reaction X-URM1 + Y = Y-URM1 + X, where both X-URM1 and Y-URM1 are covalent linkages.\" [GOC:mah, PMID:12826404]","metadata":null},{"id":"4ba8b47f454d4f15a4a00568f2f3305e","type":"GENE","name":"UROC1","canonical_id":"hgnc:HGNC:26444","description":"urocanate hydratase 1","metadata":{"aliases":["FLJ31300","HMFN0320"]}},{"id":"7c66222db88649189fb11a48648d726d","type":"GENE","name":"UROD","canonical_id":"hgnc:HGNC:12591","description":"uroporphyrinogen decarboxylase","metadata":null},{"id":"97739925314a451f84b1142cb2d4a10b","type":"GENE","name":"UROS","canonical_id":"hgnc:HGNC:12592","description":"uroporphyrinogen III synthase","metadata":null},{"id":"766f18e297e6416b80eae5b9031a3d0a","type":"TRIAL","name":"US Phase III Study of APD421 in PONV","canonical_id":"clinicaltrials.gov:NCT01991860","description":"PONV","metadata":null},{"id":"bbb78e20f3fd46f98287b0acdbdf36c3","type":"TRIAL","name":"US-guided SAPB for Rib Fractures in the ED","canonical_id":"clinicaltrials.gov:NCT03619785","description":"Rib Fractures; Rib Fracture Multiple","metadata":null},{"id":"536020fd307b4d5eb7ef50a408017063","type":"GENE","name":"USB1","canonical_id":"hgnc:HGNC:25792","description":"U6 snRNA biogenesis phosphodiesterase 1","metadata":{"aliases":["FLJ13154","HVSL1","Mpn1","C16orf57"]}},{"id":"6bb38521454a490d878a3b05273b6841","type":"GENE","name":"USE1","canonical_id":"hgnc:HGNC:30882","description":"unconventional SNARE in the ER 1","metadata":{"aliases":["p31","SLT1","MDS032","D12"]}},{"id":"d5860bb55267485792cb8e6d07e78d51","type":"GENE","name":"USF1","canonical_id":"hgnc:HGNC:12593","description":null,"metadata":null},{"id":"5d7db0f34c9b47228be11c138b81eff9","type":"GENE","name":"USF1P1","canonical_id":"hgnc:HGNC:23773","description":"upstream transcription factor 1 pseudogene 1","metadata":{"aliases":["USF1P"]}},{"id":"e09e5b994ae8428fbb4ca5b5d829e3c4","type":"GENE","name":"USF2","canonical_id":"hgnc:HGNC:12594","description":null,"metadata":null},{"id":"211bd64c04c44b4e9e00730e2bccdbb1","type":"GENE","name":"USF3","canonical_id":"hgnc:HGNC:30494","description":"upstream transcription factor family member 3","metadata":{"aliases":["KIAA2018"]}},{"id":"39617932ff0847c8abfd68e71901213b","type":"GENE","name":"USH1C","canonical_id":"hgnc:HGNC:12597","description":"USH1 protein network component harmonin","metadata":{"aliases":["PDZ73","harmonin","NY-CO-37","NY-CO-38","PDZ-73","AIE-75","PDZD7C","DFNB18"]}},{"id":"0fb334a1444646c585a816dc77c1b329","type":"GENE","name":"USH1G","canonical_id":"hgnc:HGNC:16356","description":"USH1 protein network component sans","metadata":{"aliases":["Sans","FLJ33924","ANKS4A"]}},{"id":"20e23517368c4f6dbb80abee26b9a36e","type":"GO_TERM","name":"USH2 complex","canonical_id":"go:GO:1990696","description":"\"A protein complex composed of four proteins, loss of which results in Usher Syndrome type 2 (USH2 syndrome), a leading genetic cause of combined hearing and vision loss. This complex is conserved in many species; in mice, it is composed of USH2A, GPR98 (aka ADGRV1), WHRN, and PDZD7.\" [GOC:krc, PMID:25406310]","metadata":null},{"id":"fc7b442e238e4c30bd14b233ebc46997","type":"GENE","name":"USH2A","canonical_id":"hgnc:HGNC:12601","description":"usherin","metadata":{"aliases":["USHRN","RP39","USH2"]}},{"id":"c6c54c6a61e64977b531dfc8e60f69b4","type":"GENE","name":"USH2A-AS1","canonical_id":"hgnc:HGNC:40606","description":"USH2A antisense RNA 1","metadata":null},{"id":"4ba1c7f503b0442c977340be542e3a8e","type":"GENE","name":"USH2A-AS2","canonical_id":"hgnc:HGNC:40605","description":"USH2A antisense RNA 2","metadata":null},{"id":"ac1e54fe3849411f9e2884fc8943697c","type":"GENE","name":"USHBP1","canonical_id":"hgnc:HGNC:24058","description":"USH1 protein network component harmonin binding protein 1","metadata":{"aliases":["MCC2","AIEBP","FLJ38709"]}},{"id":"de5b87fac63d4a07b71ce68cc8fa8e04","type":"GENE","name":"USO1","canonical_id":"hgnc:HGNC:30904","description":"USO1 vesicle transport factor","metadata":{"aliases":["TAP","VDP","p115"]}},{"id":"6378b9196ee449f8a83d678907868586","type":"GENE","name":"USP1","canonical_id":"hgnc:HGNC:12607","description":"ubiquitin specific peptidase 1","metadata":null},{"id":"1dbdaf4fb4e44bc5a41bb6c8c1644cf9","type":"GENE","name":"USP10","canonical_id":"hgnc:HGNC:12608","description":"ubiquitin specific peptidase 10","metadata":{"aliases":["UBPO","KIAA0190"]}},{"id":"fb2c5a11e35542d29bd9777cd81f7810","type":"GENE","name":"USP10P1","canonical_id":"hgnc:HGNC:31752","description":"USP10 pseudogene 1","metadata":null},{"id":"f4aea8ae65e44e99bc0660b168d1fba7","type":"GENE","name":"USP10P2","canonical_id":"hgnc:HGNC:33272","description":"USP10 pseudogene 2","metadata":null},{"id":"1ab053efc1704555bacd0b95ed7cf44b","type":"GENE","name":"USP10P3","canonical_id":"hgnc:HGNC:56965","description":"USP10 pseudogene 3","metadata":null},{"id":"76a751e50ae94971a9901f228a60e489","type":"GENE","name":"USP11","canonical_id":"hgnc:HGNC:12609","description":"ubiquitin specific peptidase 11","metadata":{"aliases":["UHX1"]}},{"id":"5656501a6eeb4b7580163a5496d13e52","type":"GENE","name":"USP12","canonical_id":"hgnc:HGNC:20485","description":"ubiquitin specific peptidase 12","metadata":{"aliases":["USP12L1"]}},{"id":"9d997a34d8d144059a23d58722e50b45","type":"GENE","name":"USP12-AS1","canonical_id":"hgnc:HGNC:39961","description":"USP12 antisense RNA 1","metadata":{"aliases":["USP12-AS2","USP12-DT"]}},{"id":"4d23c5fbfa9046f1b42e42cb389aa460","type":"GENE","name":"USP12P1","canonical_id":"hgnc:HGNC:12610","description":"USP12 pseudogene 1","metadata":{"aliases":["UBH1","USP12"]}},{"id":"062862fa79d04564b91ca914669f324c","type":"GENE","name":"USP12P2","canonical_id":"hgnc:HGNC:54575","description":"USP12 pseudogene 2","metadata":null},{"id":"cff6dd956329489ab0e9c0bdeb2eb72c","type":"GENE","name":"USP12P3","canonical_id":"hgnc:HGNC:54576","description":"USP12 pseudogene 3","metadata":null},{"id":"63eef716a18c4604b898363f630ee883","type":"GENE","name":"USP12PX","canonical_id":"hgnc:HGNC:21410","description":"USP12 pseudogene X-linked","metadata":{"aliases":["USP12P2"]}},{"id":"306d7f19b4404bcfb8f16e0831d52adf","type":"GENE","name":"USP12PY","canonical_id":"hgnc:HGNC:23195","description":"USP12 pseudogene Y-linked","metadata":{"aliases":["USP12P3"]}},{"id":"f8ee8c01f1d64eab8b376140a2a19763","type":"GENE","name":"USP13","canonical_id":"hgnc:HGNC:12611","description":"ubiquitin specific peptidase 13","metadata":{"aliases":["IsoT-3"]}},{"id":"3a2c8ff6a48841ca866c0b5ae9c4b584","type":"GENE","name":"USP14","canonical_id":"hgnc:HGNC:12612","description":"ubiquitin specific peptidase 14","metadata":{"aliases":["TGT","Ubp6"]}},{"id":"997986a0e54d489e935ec6a3f58e2696","type":"GENE","name":"USP15","canonical_id":"hgnc:HGNC:12613","description":"ubiquitin specific peptidase 15","metadata":{"aliases":["KIAA0529","UNPH4"]}},{"id":"e67895a35e11493f98f7862cba4cd443","type":"GENE","name":"USP16","canonical_id":"hgnc:HGNC:12614","description":"ubiquitin specific peptidase 16","metadata":{"aliases":["Ubp-M"]}},{"id":"f8a3d8827d734d16a979d7c78488e05b","type":"GENE","name":"USP17L1","canonical_id":"hgnc:HGNC:37182","description":"ubiquitin specific peptidase 17 like family member 1","metadata":{"aliases":["USP17L1P"]}},{"id":"16d3044bed4f4e4d8a7186755e094684","type":"GENE","name":"USP17L10","canonical_id":"hgnc:HGNC:44438","description":"ubiquitin specific peptidase 17 like family member 10","metadata":null},{"id":"39f5987eee9d4157a28cd37d0c484456","type":"GENE","name":"USP17L11","canonical_id":"hgnc:HGNC:44439","description":"ubiquitin specific peptidase 17 like family member 11","metadata":null},{"id":"b4c417a27e2e46a7aef6ed85a7739201","type":"GENE","name":"USP17L12","canonical_id":"hgnc:HGNC:44440","description":"ubiquitin specific peptidase 17 like family member 12","metadata":null},{"id":"58e942a5d0ae4ec098552d52aff94430","type":"GENE","name":"USP17L13","canonical_id":"hgnc:HGNC:44441","description":"ubiquitin specific peptidase 17 like family member 13","metadata":null},{"id":"6a1263b66cbe4edd81a4273563038176","type":"GENE","name":"USP17L14P","canonical_id":"hgnc:HGNC:44442","description":"ubiquitin specific peptidase 17 like family member 14, pseudogene","metadata":null},{"id":"b71c3165b1bd460fab63556f8467c48a","type":"GENE","name":"USP17L15","canonical_id":"hgnc:HGNC:44443","description":"ubiquitin specific peptidase 17 like family member 15","metadata":null},{"id":"8b66c0f52999487ea375605f6c5623e1","type":"GENE","name":"USP17L16P","canonical_id":"hgnc:HGNC:44444","description":"ubiquitin specific peptidase 17 like family member 16, pseudogene","metadata":null},{"id":"a0c7e767109c4453be7da06b6f93252d","type":"GENE","name":"USP17L17","canonical_id":"hgnc:HGNC:44445","description":"ubiquitin specific peptidase 17 like family member 17","metadata":null},{"id":"9586a766b8904fedb224be2a4d29262d","type":"GENE","name":"USP17L18","canonical_id":"hgnc:HGNC:44446","description":"ubiquitin specific peptidase 17 like family member 18","metadata":null},{"id":"2932dccba34943038f2e559b7b5edd81","type":"GENE","name":"USP17L19","canonical_id":"hgnc:HGNC:44447","description":"ubiquitin specific peptidase 17 like family member 19","metadata":null},{"id":"c9429ac65d4245d39ab5b18148be1d91","type":"GENE","name":"USP17L2","canonical_id":"hgnc:HGNC:34434","description":"ubiquitin specific peptidase 17 like family member 2","metadata":{"aliases":["DUB3"]}},{"id":"7d854a4481c4423e9d3c75455b2876a0","type":"GENE","name":"USP17L20","canonical_id":"hgnc:HGNC:44448","description":"ubiquitin specific peptidase 17 like family member 20","metadata":null},{"id":"40340bec2bbc49189238bf8ff69fd1ac","type":"GENE","name":"USP17L21","canonical_id":"hgnc:HGNC:44449","description":"ubiquitin specific peptidase 17 like family member 21","metadata":null},{"id":"b92859c5d0ac4c1b9cdf99db5c6bcabe","type":"GENE","name":"USP17L22","canonical_id":"hgnc:HGNC:44450","description":"ubiquitin specific peptidase 17 like family member 22","metadata":null},{"id":"56fb2acd327341ab9e3b5e40741fe756","type":"GENE","name":"USP17L23","canonical_id":"hgnc:HGNC:44451","description":"ubiquitin specific peptidase 17 like family member 23","metadata":null},{"id":"b5e9d4ee1e1944afb0b14a77df5e07fd","type":"GENE","name":"USP17L24","canonical_id":"hgnc:HGNC:44453","description":"ubiquitin specific peptidase 17 like family member 24","metadata":null},{"id":"675a4de610c84b558fdadbe1f37d179a","type":"GENE","name":"USP17L25","canonical_id":"hgnc:HGNC:44452","description":"ubiquitin specific peptidase 17 like family member 25","metadata":null},{"id":"f796a61f6da848c9969c301b9da72b64","type":"GENE","name":"USP17L26","canonical_id":"hgnc:HGNC:44454","description":"ubiquitin specific peptidase 17 like family member 26","metadata":null},{"id":"fe07cf2f9254425cb9ff25634d176a22","type":"GENE","name":"USP17L27","canonical_id":"hgnc:HGNC:44455","description":"ubiquitin specific peptidase 17 like family member 27","metadata":null},{"id":"458c364216f64447976f713334a2ded1","type":"GENE","name":"USP17L28","canonical_id":"hgnc:HGNC:44456","description":"ubiquitin specific peptidase 17 like family member 28","metadata":null},{"id":"a2487c3d1d0d49e58cb3cadafa705eba","type":"GENE","name":"USP17L29","canonical_id":"hgnc:HGNC:44457","description":"ubiquitin specific peptidase 17 like family member 29","metadata":null},{"id":"7a5f4fbb38b742679f71cabf707999a9","type":"GENE","name":"USP17L3","canonical_id":"hgnc:HGNC:37175","description":"ubiquitin specific peptidase 17 like family member 3","metadata":{"aliases":["USP17B","USP17F"]}},{"id":"41be5467142e4565a2112c59c70d99c9","type":"GENE","name":"USP17L30","canonical_id":"hgnc:HGNC:44458","description":"ubiquitin specific peptidase 17 like family member 30","metadata":null},{"id":"830f9fd5eb5644228b30c1ac8e29f2bb","type":"GENE","name":"USP17L4","canonical_id":"hgnc:HGNC:37176","description":"ubiquitin specific peptidase 17 like family member 4","metadata":null},{"id":"8ae50af60d8b47f1931f882999df8330","type":"GENE","name":"USP17L5","canonical_id":"hgnc:HGNC:37177","description":"ubiquitin specific peptidase 17 like family member 5","metadata":null},{"id":"4cc3ff3cffb14fb08528c5b9f45a0ea4","type":"GENE","name":"USP17L6P","canonical_id":"hgnc:HGNC:37179","description":"ubiquitin specific peptidase 17 like family member 6, pseudogene","metadata":{"aliases":["DUB4","vDUB4","USP17L6"]}},{"id":"93ead8e414e44d87884d1d407dbb5dc7","type":"GENE","name":"USP17L7","canonical_id":"hgnc:HGNC:37180","description":"ubiquitin specific peptidase 17 like family member 7","metadata":null},{"id":"2554caad0af04dbc924f36cfe374ce8b","type":"GENE","name":"USP17L8","canonical_id":"hgnc:HGNC:37181","description":"ubiquitin specific peptidase 17 like family member 8","metadata":null},{"id":"f6b8c23fcb524626ab5963443689bfaf","type":"GENE","name":"USP17L9P","canonical_id":"hgnc:HGNC:12615","description":"ubiquitin specific peptidase 17 like family member 9, pseudogene","metadata":{"aliases":["RS447","USP17"]}},{"id":"ef0b44ee70b6403aaa9c3d7ce80d983a","type":"GENE","name":"USP18","canonical_id":"hgnc:HGNC:12616","description":"ubiquitin specific peptidase 18","metadata":null},{"id":"a6f3c24b3ae643bda7178fac2a88df3e","type":"GENE","name":"USP19","canonical_id":"hgnc:HGNC:12617","description":"ubiquitin specific peptidase 19","metadata":{"aliases":["KIAA0891","ZMYND9"]}},{"id":"d7c5e0d6438c44b99e89e6f5389930a5","type":"GENE","name":"USP2","canonical_id":"hgnc:HGNC:12618","description":"ubiquitin specific peptidase 2","metadata":{"aliases":["UBP41"]}},{"id":"15cb12b670d642a1afa77f4b69d8c3a4","type":"GENE","name":"USP2-AS1","canonical_id":"hgnc:HGNC:48673","description":"USP2 antisense RNA 1","metadata":{"aliases":["THY1-AS1","gLINC"]}},{"id":"492784dd7053472c9be1a7938894568f","type":"GENE","name":"USP20","canonical_id":"hgnc:HGNC:12619","description":"ubiquitin specific peptidase 20","metadata":{"aliases":["KIAA1003"]}},{"id":"439063565641432e9661b96cb1217a73","type":"GENE","name":"USP21","canonical_id":"hgnc:HGNC:12620","description":null,"metadata":null},{"id":"428ffee17e764518bef5d02ceef9d9d0","type":"GENE","name":"USP21P1","canonical_id":"hgnc:HGNC:54618","description":"USP21 pseudogene 1","metadata":null},{"id":"6426e7e2fb244ffe9f644069deec298d","type":"GENE","name":"USP21P2","canonical_id":"hgnc:HGNC:54650","description":"USP21 pseudogene 2","metadata":null},{"id":"2b7400618b0d4a27a606cb582e18328e","type":"GENE","name":"USP22","canonical_id":"hgnc:HGNC:12621","description":"ubiquitin specific peptidase 22","metadata":{"aliases":["KIAA1063","USP3L"]}},{"id":"1dd37492b8fa42918057a3e850236689","type":"GENE","name":"USP24","canonical_id":"hgnc:HGNC:12623","description":"ubiquitin specific peptidase 24","metadata":{"aliases":["KIAA1057"]}},{"id":"e494467bf42b43bfa093b8c7b20ec736","type":"GENE","name":"USP24P1","canonical_id":"hgnc:HGNC:42014","description":"ubiquitin specific peptidase 24 pseudogene 1","metadata":null},{"id":"7489008a0d1640d79a507ddac9af97a0","type":"GENE","name":"USP25","canonical_id":"hgnc:HGNC:12624","description":"ubiquitin specific peptidase 25","metadata":{"aliases":["USP21"]}},{"id":"b3688e576f2840788a181c9baaf5373c","type":"GENE","name":"USP26","canonical_id":"hgnc:HGNC:13485","description":null,"metadata":null},{"id":"3481232cbe774694b30abd7ba30c817e","type":"GENE","name":"USP27X","canonical_id":"hgnc:HGNC:13486","description":"ubiquitin specific peptidase 27 X-linked","metadata":{"aliases":["USP27"]}},{"id":"8e8109b132e94173815fb2bcea3c9ed5","type":"GENE","name":"USP27X-DT","canonical_id":"hgnc:HGNC:27249","description":"USP27X divergent transcript","metadata":{"aliases":["USP27X-AS1"]}},{"id":"7bd0680714a8479d83e49e1273bd7720","type":"GENE","name":"USP28","canonical_id":"hgnc:HGNC:12625","description":"ubiquitin specific peptidase 28","metadata":{"aliases":["KIAA1515"]}},{"id":"930de1548f9244baa3898a40a4ce5e4c","type":"GENE","name":"USP29","canonical_id":"hgnc:HGNC:18563","description":"ubiquitin specific peptidase 29","metadata":null},{"id":"21acb17157ef42b490c14ee406419e50","type":"GENE","name":"USP3","canonical_id":"hgnc:HGNC:12626","description":"ubiquitin specific peptidase 3","metadata":null},{"id":"eccd15e257c94e0097497f47de28ce62","type":"GENE","name":"USP3-AS1","canonical_id":"hgnc:HGNC:44140","description":"USP3 antisense RNA 1","metadata":null},{"id":"010a0445e6104f3ba63bc85a99b6eec6","type":"GENE","name":"USP30","canonical_id":"hgnc:HGNC:20065","description":"ubiquitin specific peptidase 30","metadata":{"aliases":["MGC10702","FLJ40511"]}},{"id":"22ba79b92c1442a0a649a0fbc250b5eb","type":"GENE","name":"USP30-AS1","canonical_id":"hgnc:HGNC:40909","description":"USP30 antisense RNA 1","metadata":null},{"id":"746f8199eb684e2eb614fd63d8df2500","type":"GENE","name":"USP31","canonical_id":"hgnc:HGNC:20060","description":"ubiquitin specific peptidase 31","metadata":{"aliases":["KIAA1203"]}},{"id":"4b563d9b4a934e89ac6203d261f940b1","type":"GENE","name":"USP32","canonical_id":"hgnc:HGNC:19143","description":"ubiquitin specific peptidase 32","metadata":{"aliases":["NY-REN-60","USP10"]}},{"id":"59e4f623158e47e9905aae5e425bcbdd","type":"GENE","name":"USP32P1","canonical_id":"hgnc:HGNC:43570","description":"ubiquitin specific peptidase 32 pseudogene 1","metadata":null},{"id":"673b0e1b9e3f416b9b44450fdacb7be1","type":"GENE","name":"USP32P2","canonical_id":"hgnc:HGNC:30751","description":"ubiquitin specific peptidase 32 pseudogene 2","metadata":{"aliases":["TL132"]}},{"id":"8d122c6ae95247c482837ec689956ef5","type":"GENE","name":"USP32P3","canonical_id":"hgnc:HGNC:43576","description":"ubiquitin specific peptidase 32 pseudogene 3","metadata":null},{"id":"2f008b35a2634d9695fd5fe83b78a2a3","type":"GENE","name":"USP32P4","canonical_id":"hgnc:HGNC:43577","description":"ubiquitin specific peptidase 32 pseudogene 4","metadata":null},{"id":"7255c5809dbf4451a22f418a41d2e559","type":"GENE","name":"USP33","canonical_id":"hgnc:HGNC:20059","description":"ubiquitin specific peptidase 33","metadata":{"aliases":["KIAA1097","VDU1"]}},{"id":"9daf28a1f8884c2d9d29d089d02f9dee","type":"GENE","name":"USP34","canonical_id":"hgnc:HGNC:20066","description":"ubiquitin specific peptidase 34","metadata":{"aliases":["KIAA0570","KIAA0729"]}},{"id":"4f85de62d9944fe58752f0ae0516c11b","type":"GENE","name":"USP34-DT","canonical_id":"hgnc:HGNC:55262","description":"USP34 divergent transcript","metadata":{"aliases":["AC016727.1"]}},{"id":"96edfcbfc4fb4e798b5074005323ad2c","type":"GENE","name":"USP35","canonical_id":"hgnc:HGNC:20061","description":"ubiquitin specific peptidase 35","metadata":{"aliases":["KIAA1372"]}},{"id":"3e065f0bbfae4b1b82080591d07b84ba","type":"GENE","name":"USP36","canonical_id":"hgnc:HGNC:20062","description":"ubiquitin specific peptidase 36","metadata":{"aliases":["KIAA1453","FLJ12851"]}},{"id":"07fdea2f102a4f09af1d6b5474ebc526","type":"GENE","name":"USP37","canonical_id":"hgnc:HGNC:20063","description":"ubiquitin specific peptidase 37","metadata":{"aliases":["KIAA1594"]}},{"id":"695705af3b3a41f5a4dc7b7dfbdc5891","type":"GENE","name":"USP37P1","canonical_id":"hgnc:HGNC:55020","description":"USP37 pseudogene 1","metadata":null},{"id":"277007da7abd4c80bbc48e88aabcb4e8","type":"GENE","name":"USP38","canonical_id":"hgnc:HGNC:20067","description":"ubiquitin specific peptidase 38","metadata":{"aliases":["KIAA1891","HP43.8KD"]}},{"id":"ec442d7c0b9b45b880f21951e76cfb78","type":"GENE","name":"USP38-DT","canonical_id":"hgnc:HGNC:55554","description":"USP38 divergent transcript","metadata":null},{"id":"75740df63dcb4580aeadb4c39c7a25ba","type":"GENE","name":"USP39","canonical_id":"hgnc:HGNC:20071","description":"ubiquitin specific peptidase 39","metadata":{"aliases":["SAD1","CGI-21","SNRNP65"]}},{"id":"aff31bd3662246f7b370cd5f4a7d487a","type":"GENE","name":"USP4","canonical_id":"hgnc:HGNC:12627","description":"ubiquitin specific peptidase 4","metadata":{"aliases":["Unph","UNP"]}},{"id":"37adef7b07484980a189e4614fef36ff","type":"GENE","name":"USP40","canonical_id":"hgnc:HGNC:20069","description":"ubiquitin specific peptidase 40","metadata":{"aliases":["FLJ10785"]}},{"id":"307f4272d13a4e5e872aa32e5c7f316e","type":"GENE","name":"USP41P","canonical_id":"hgnc:HGNC:20070","description":"ubiquitin specific peptidase 41, pseudogene","metadata":{"aliases":["USP18B","USP41"]}},{"id":"8ac2b4b7bae34b4bb4f78faea9dfc455","type":"GENE","name":"USP42","canonical_id":"hgnc:HGNC:20068","description":"ubiquitin specific peptidase 42","metadata":{"aliases":["FLJ12697"]}},{"id":"edd34e43ba234b09b1295274dc5190c4","type":"GENE","name":"USP43","canonical_id":"hgnc:HGNC:20072","description":"ubiquitin specific peptidase 43","metadata":{"aliases":["FLJ30626"]}},{"id":"2b3f8c481f4e4d5f8f653ddce514456c","type":"GENE","name":"USP44","canonical_id":"hgnc:HGNC:20064","description":"ubiquitin specific peptidase 44","metadata":{"aliases":["FLJ14528"]}},{"id":"594da7b21ddf493e9c56dfd52902ded4","type":"GENE","name":"USP45","canonical_id":"hgnc:HGNC:20080","description":"ubiquitin specific peptidase 45","metadata":{"aliases":["MGC14793"]}},{"id":"d1fb95083dae467cb06a23acb3e696d7","type":"GENE","name":"USP46","canonical_id":"hgnc:HGNC:20075","description":"ubiquitin specific peptidase 46","metadata":{"aliases":["FLJ12552"]}},{"id":"337630eee15a4a5e902e41f70974ce73","type":"GENE","name":"USP46-DT","canonical_id":"hgnc:HGNC:43991","description":"USP46 divergent transcript","metadata":{"aliases":["USP46-AS1"]}},{"id":"070851f3a2e34f51a79f4ac88acf48be","type":"GENE","name":"USP47","canonical_id":"hgnc:HGNC:20076","description":"ubiquitin specific peptidase 47","metadata":null},{"id":"a278b9c713d1400387f6f3c64ae23e24","type":"GENE","name":"USP48","canonical_id":"hgnc:HGNC:18533","description":"ubiquitin specific peptidase 48","metadata":{"aliases":["FLJ23277","FLJ11328","FLJ20103","FLJ23054","MGC14879","USP31"]}},{"id":"577a29adf8444779b20efd00ac4f3ca8","type":"GENE","name":"USP49","canonical_id":"hgnc:HGNC:20078","description":"ubiquitin specific peptidase 49","metadata":{"aliases":["MGC20741"]}},{"id":"76f8b46fdfab4e7a94319403a21837fe","type":"GENE","name":"USP5","canonical_id":"hgnc:HGNC:12628","description":"ubiquitin specific peptidase 5","metadata":{"aliases":["IsoT"]}},{"id":"ea37db9ccb924858b3089211355f8d0c","type":"GENE","name":"USP50","canonical_id":"hgnc:HGNC:20079","description":"ubiquitin specific peptidase 50","metadata":null},{"id":"a0ce28e5ef93498494a3b62377565f4c","type":"GENE","name":"USP51","canonical_id":"hgnc:HGNC:23086","description":"ubiquitin specific peptidase 51","metadata":null},{"id":"55d1abea34be458e963bf506640a2a4e","type":"GENE","name":"USP53","canonical_id":"hgnc:HGNC:29255","description":"ubiquitin specific peptidase 53","metadata":{"aliases":["KIAA1350"]}},{"id":"84acd4f277f44491a5ee0e204f8c7297","type":"GENE","name":"USP53-DT","canonical_id":"hgnc:HGNC:58879","description":"USP53 divergent transcript","metadata":null},{"id":"341bc6daf88a4d9c958605afbcc242d0","type":"GENE","name":"USP54","canonical_id":"hgnc:HGNC:23513","description":"ubiquitin specific peptidase 54","metadata":{"aliases":["FLJ37318","bA137L10.3","bA137L10.4","C10orf29"]}},{"id":"ccaead2a5b514942b0d57d2bc0ed6238","type":"GENE","name":"USP6","canonical_id":"hgnc:HGNC:12629","description":"ubiquitin specific peptidase 6","metadata":{"aliases":["Tre-2","TRE17","Tre2","HRP1","TRESMCR"]}},{"id":"c12a1f740761420585102e287f328736","type":"GENE","name":"USP6NL","canonical_id":"hgnc:HGNC:16858","description":"USP6 N-terminal like","metadata":{"aliases":["RNTRE","KIAA0019","TRE2NL","RN-tre","USP6NL-IT1"]}},{"id":"7e4b8ded88a544f9ae221ec902ad3ba1","type":"GENE","name":"USP6NL-AS1","canonical_id":"hgnc:HGNC:55251","description":"USP6NL antisense RNA 1","metadata":null},{"id":"4ecff9df9858460db6ede32202e56a62","type":"GENE","name":"USP7","canonical_id":"hgnc:HGNC:12630","description":null,"metadata":null},{"id":"9e385bcd7a80447eb3dec89bbd8fb7a7","type":"GENE","name":"USP7-AS1","canonical_id":"hgnc:HGNC:55379","description":"USP7 antisense RNA 1","metadata":null},{"id":"c260908983c247039c0793ff174f7b7e","type":"GENE","name":"USP7P1","canonical_id":"hgnc:HGNC:59238","description":"USP7 pseudogene 1","metadata":null},{"id":"2d1d0f44b0db4477a3bd2618a3322365","type":"GENE","name":"USP8","canonical_id":"hgnc:HGNC:12631","description":"ubiquitin specific peptidase 8","metadata":{"aliases":["HumORF8","KIAA0055","UBPY","SPG59"]}},{"id":"b21e8c24e61b4c4e9e85a4af625d33a3","type":"GENE","name":"USP8P1","canonical_id":"hgnc:HGNC:13987","description":"USP8 pseudogene 1","metadata":{"aliases":["KIAA0055-hom","D84394.7","USP8P"]}},{"id":"494778a0f40c46a7b24e4865b972d719","type":"GENE","name":"USP8P2","canonical_id":"hgnc:HGNC:54601","description":"USP8 pseudogene 2","metadata":null},{"id":"e675dd26036e4f4994633849e9e05516","type":"GENE","name":"USP9X","canonical_id":"hgnc:HGNC:12632","description":"ubiquitin specific peptidase 9 X-linked","metadata":{"aliases":["DFFRX","FAF","FAF-X","MRX99"]}},{"id":"683ed01604de42a985945e18b146946c","type":"GENE","name":"USP9Y","canonical_id":"hgnc:HGNC:12633","description":"ubiquitin specific peptidase 9 Y-linked","metadata":{"aliases":["DFFRY","FAF-Y","AZFA"]}},{"id":"2d404e437f8f4a10a3c452fcd94c346a","type":"GENE","name":"USP9YP1","canonical_id":"hgnc:HGNC:31741","description":"USP9Y pseudogene 1","metadata":null},{"id":"ac8c157828d9493295f300bd5497ab12","type":"GENE","name":"USP9YP10","canonical_id":"hgnc:HGNC:38454","description":"USP9Y pseudogene 10","metadata":null},{"id":"6bd93209031943f6a9c9b83dd86df94e","type":"GENE","name":"USP9YP11","canonical_id":"hgnc:HGNC:38460","description":"USP9Y pseudogene 11","metadata":null},{"id":"81b699259ce342149cb83fd5061bf448","type":"GENE","name":"USP9YP12","canonical_id":"hgnc:HGNC:38720","description":"USP9Y pseudogene 12","metadata":null},{"id":"b6a6954cfc5a49d2a26cb48cab3a6789","type":"GENE","name":"USP9YP13","canonical_id":"hgnc:HGNC:38721","description":"USP9Y pseudogene 13","metadata":null},{"id":"18afbeb158d74ec793532ec7435c94c0","type":"GENE","name":"USP9YP14","canonical_id":"hgnc:HGNC:38748","description":"USP9Y pseudogene 14","metadata":null},{"id":"e079ab0eddc44600847a06d53f7c1401","type":"GENE","name":"USP9YP15","canonical_id":"hgnc:HGNC:38751","description":"USP9Y pseudogene 15","metadata":null},{"id":"0b1c8a517b50486cb9929b4b2664e1a7","type":"GENE","name":"USP9YP16","canonical_id":"hgnc:HGNC:38752","description":"USP9Y pseudogene 16","metadata":null},{"id":"59a529670eab4cf5967b678319e917b0","type":"GENE","name":"USP9YP17","canonical_id":"hgnc:HGNC:38753","description":"USP9Y pseudogene 17","metadata":null},{"id":"a871829bb51c451ca36c0008d801bc81","type":"GENE","name":"USP9YP18","canonical_id":"hgnc:HGNC:38754","description":"USP9Y pseudogene 18","metadata":null},{"id":"cccae4af8d1f45bba6f75e431ee7f486","type":"GENE","name":"USP9YP19","canonical_id":"hgnc:HGNC:38755","description":"USP9Y pseudogene 19","metadata":null},{"id":"74de57ee407d4c73bb8f7d35453272f7","type":"GENE","name":"USP9YP2","canonical_id":"hgnc:HGNC:31742","description":"USP9Y pseudogene 2","metadata":null},{"id":"9bbd4bd4fcc6467baa4f9aed22fc8689","type":"GENE","name":"USP9YP20","canonical_id":"hgnc:HGNC:38767","description":"USP9Y pseudogene 20","metadata":null},{"id":"c344e88fdb9e45eea603ef5ff8f62304","type":"GENE","name":"USP9YP21","canonical_id":"hgnc:HGNC:38757","description":"USP9Y pseudogene 21","metadata":null},{"id":"a97c99eb854d490fa320f2cb8010b447","type":"GENE","name":"USP9YP22","canonical_id":"hgnc:HGNC:38758","description":"USP9Y pseudogene 22","metadata":null},{"id":"31c747c43c134adb89e736baec0f14c4","type":"GENE","name":"USP9YP23","canonical_id":"hgnc:HGNC:38759","description":"USP9Y pseudogene 23","metadata":null},{"id":"68ba1a7436284cdcb67116a21c7afe60","type":"GENE","name":"USP9YP24","canonical_id":"hgnc:HGNC:38760","description":"USP9Y pseudogene 24","metadata":null},{"id":"e7ef9024e7fb46c1b69336ca35368bac","type":"GENE","name":"USP9YP25","canonical_id":"hgnc:HGNC:38761","description":"USP9Y pseudogene 25","metadata":null},{"id":"ff530881096a4beaae6bbe46a787ac17","type":"GENE","name":"USP9YP26","canonical_id":"hgnc:HGNC:38762","description":"USP9Y pseudogene 26","metadata":null},{"id":"9772d1319bd74a9e89b9ef02ce91fd6e","type":"GENE","name":"USP9YP27","canonical_id":"hgnc:HGNC:38763","description":"USP9Y pseudogene 27","metadata":null},{"id":"0604b9a8c4c1463685f453ea69360246","type":"GENE","name":"USP9YP28","canonical_id":"hgnc:HGNC:38764","description":"USP9Y pseudogene 28","metadata":null},{"id":"0e1a4e562e1a4cfc9cc9efbe17e183a3","type":"GENE","name":"USP9YP29","canonical_id":"hgnc:HGNC:38765","description":"USP9Y pseudogene 29","metadata":null},{"id":"9f4521751bb242eebce21093e9ebeeaf","type":"GENE","name":"USP9YP3","canonical_id":"hgnc:HGNC:37739","description":"USP9Y pseudogene 3","metadata":null},{"id":"07d508de11a4433cb82a6d230c370ce0","type":"GENE","name":"USP9YP30","canonical_id":"hgnc:HGNC:38766","description":"USP9Y pseudogene 30","metadata":null},{"id":"e5c8288ef57c49a08dd264ac15c0a110","type":"GENE","name":"USP9YP31","canonical_id":"hgnc:HGNC:38775","description":"USP9Y pseudogene 31","metadata":null},{"id":"30985215f37e4cbea92365a42feb29d8","type":"GENE","name":"USP9YP32","canonical_id":"hgnc:HGNC:38776","description":"USP9Y pseudogene 32","metadata":null},{"id":"9c700b514a754077bdfe753e69210506","type":"GENE","name":"USP9YP33","canonical_id":"hgnc:HGNC:38777","description":"USP9Y pseudogene 33","metadata":null},{"id":"49a084c994314133af989ef0dedf17c5","type":"GENE","name":"USP9YP34","canonical_id":"hgnc:HGNC:38778","description":"USP9Y pseudogene 34","metadata":null},{"id":"4ee787e4059d4e3e89b392a12cd45fcf","type":"GENE","name":"USP9YP35","canonical_id":"hgnc:HGNC:38779","description":"USP9Y pseudogene 35","metadata":null},{"id":"2e308a7b8502477ba186945be9bfb86c","type":"GENE","name":"USP9YP36","canonical_id":"hgnc:HGNC:38780","description":"USP9Y pseudogene 36","metadata":null},{"id":"b4ae4b44cc5e45f1ad1ad13a0004c70d","type":"GENE","name":"USP9YP4","canonical_id":"hgnc:HGNC:37740","description":"USP9Y pseudogene 4","metadata":null},{"id":"4164fb4d593f4ad6877f13666415999e","type":"GENE","name":"USP9YP5","canonical_id":"hgnc:HGNC:38418","description":"USP9Y pseudogene 5","metadata":null},{"id":"670c37a7e3344ee3a2aa22f13b601d13","type":"GENE","name":"USP9YP6","canonical_id":"hgnc:HGNC:38078","description":"USP9Y pseudogene 6","metadata":{"aliases":["CDY24P"]}},{"id":"a1356ffd76c241549cdd3bc56af77606","type":"GENE","name":"USP9YP7","canonical_id":"hgnc:HGNC:38079","description":"USP9Y pseudogene 7","metadata":null},{"id":"8f013dff96b447b6a48c7661e20ac8af","type":"GENE","name":"USP9YP8","canonical_id":"hgnc:HGNC:38424","description":"USP9Y pseudogene 8","metadata":null},{"id":"aa51954189b04a92b729583f82340a83","type":"GENE","name":"USP9YP9","canonical_id":"hgnc:HGNC:38435","description":"USP9Y pseudogene 9","metadata":null},{"id":"78fc9109d68e43b59d83d27b161a2e23","type":"GENE","name":"USPL1","canonical_id":"hgnc:HGNC:20294","description":"ubiquitin specific peptidase like 1","metadata":{"aliases":["bA121O19.1","D13S106E","C13orf22"]}},{"id":"e680a5e5149a419aa45ce7126d149a26","type":"GENE","name":"UST","canonical_id":"hgnc:HGNC:17223","description":"uronyl 2-sulfotransferase","metadata":{"aliases":["2OST"]}},{"id":"87c7afa09e2e49929a024312cfd967be","type":"GENE","name":"UST-AS1","canonical_id":"hgnc:HGNC:40802","description":"UST antisense RNA 1","metadata":null},{"id":"b67076fdd24449d3bc30ad9a4b3e9807","type":"GENE","name":"UST-AS2","canonical_id":"hgnc:HGNC:40803","description":"UST antisense RNA 2","metadata":null},{"id":"1242248931fe4b4f80fce07c96ba8329","type":"TRIAL","name":"USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)","canonical_id":"clinicaltrials.gov:NCT04496063","description":"Crohn's Disease","metadata":null},{"id":"6575d95e291c458dae6fb72132316610","type":"TRIAL","name":"UT-15C SR in the Treatment of Critical Limb Ischemia","canonical_id":"clinicaltrials.gov:NCT00445159","description":"Critical Limb Ischemia","metadata":null},{"id":"8f7cac94e775461bb1f0f0fb5397e4e8","type":"GENE","name":"UTF1","canonical_id":"hgnc:HGNC:12634","description":null,"metadata":null},{"id":"d223fe12516a4925b9f9bd8c2e8d8fd7","type":"GO_TERM","name":"UTP binding","canonical_id":"go:GO:0002134","description":"\"Binding to UTP, uridine 5'-triphosphate.\" [GOC:hjd, ISBN:0198506732]","metadata":null},{"id":"83c6f43fea0c4d2db091d1f8a5998ce1","type":"GO_TERM","name":"UTP biosynthetic process","canonical_id":"go:GO:0006228","description":"\"The chemical reactions and pathways resulting in the formation of UTP, uridine (5'-)triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"9104a75a6f004a13895215a2da356d8d","type":"GO_TERM","name":"UTP catabolic process","canonical_id":"go:GO:0046052","description":"\"The chemical reactions and pathways resulting in the breakdown of UTP, uridine (5'-)triphosphate.\" [GOC:curators]","metadata":null},{"id":"51f75992d626441689ab0a8309222cc6","type":"GO_TERM","name":"UTP diphosphatase activity","canonical_id":"go:GO:0036221","description":"\"Catalysis of the reaction: UTP + H2O = UMP + H+ + diphosphate.\" [GOC:dgf, PMID:17899088, RHEA:29395]","metadata":null},{"id":"76b0bcaebebe4598bc58859385a2affd","type":"GO_TERM","name":"UTP metabolic process","canonical_id":"go:GO:0046051","description":"\"The chemical reactions and pathways involving UTP, uridine (5'-)triphosphate.\" [GOC:curators]","metadata":null},{"id":"56918d34d3ea4750b8ccc8936a28353d","type":"GO_TERM","name":"UTP thiamine diphosphokinase activity","canonical_id":"go:GO:0141200","description":"\"Catalysis of the reaction: UTP + thiamine = UMP + thiamine diphosphate.\" [PMID:38547260, RHEA:79423]","metadata":null},{"id":"ea6cfdef3d4b4188ad88d3315fdd5a99","type":"GO_TERM","name":"UTP-C complex","canonical_id":"go:GO:0034456","description":"\"A protein complex that forms a subcomplex of the 90S preribosome. In S. cerevisiae, it is composed of Rrp7p, Utp22p, Ckb1p, Cka1p, Ckb2p and Cka2p.\" [GOC:mah, PMID:17515605]","metadata":null},{"id":"d2639f69a96c4f9d96c89e9ac989f87b","type":"GO_TERM","name":"UTP-monosaccharide-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0051748","description":"\"Catalysis of the reaction: UTP + a monosaccharide 1-phosphate = diphosphate + UDP-monosaccharide.\" [EC:2.7.7.64, PMID:15326166]","metadata":null},{"id":"92789049dbb24f6a94e2cb3dd4b6204e","type":"GENE","name":"UTP11","canonical_id":"hgnc:HGNC:24329","description":"UTP11 small subunit processome component","metadata":{"aliases":["CGI-94","UTP11L"]}},{"id":"21a76a0c073b43938e10930c69855dd8","type":"GENE","name":"UTP14A","canonical_id":"hgnc:HGNC:10665","description":"UTP14A small subunit processome component","metadata":{"aliases":["NY-CO-16","Utp14","SDCCAG16"]}},{"id":"24248fc449cd49e485e7f608d0a798cb","type":"GENE","name":"UTP14C","canonical_id":"hgnc:HGNC:20321","description":"UTP14C small subunit processome component","metadata":{"aliases":["2700066J21Rik","KIAA0266"]}},{"id":"22d44db18a314b47829fb3cd42565245","type":"GENE","name":"UTP15","canonical_id":"hgnc:HGNC:25758","description":"UTP15 small subunit processome component","metadata":{"aliases":["FLJ12787","NET21","FLJ23637"]}},{"id":"138f42789aa142ffa00294c6d5ae2cbe","type":"GENE","name":"UTP18","canonical_id":"hgnc:HGNC:24274","description":"UTP18 small subunit processome component","metadata":{"aliases":["CGI-48","WDR50"]}},{"id":"24ad7e77740d4ac6bbdc9acfa00b9093","type":"GENE","name":"UTP20","canonical_id":"hgnc:HGNC:17897","description":"UTP20 small subunit processome component","metadata":{"aliases":["DRIM","1A6/DRIM"]}},{"id":"01839aee899146ef984e420ecc036c3c","type":"GENE","name":"UTP23","canonical_id":"hgnc:HGNC:28224","description":"UTP23 small subunit processome component","metadata":{"aliases":["MGC14595","C8orf53"]}},{"id":"ef3fb401b43d4d168a7d37b97e45cf9b","type":"GENE","name":"UTP25","canonical_id":"hgnc:HGNC:28440","description":"UTP25 small subunit processome component","metadata":{"aliases":["MGC29875","DEF","C1orf107","DIEXF"]}},{"id":"07dc0e8ee7b042d1bc5818ab9eb672bd","type":"GENE","name":"UTP3","canonical_id":"hgnc:HGNC:24477","description":"UTP3 small subunit processome component","metadata":{"aliases":["FLJ23256","DKFZp761F222","SAS10","CRLZ1"]}},{"id":"317057745513488d82f960f8ed61dd43","type":"GENE","name":"UTP4","canonical_id":"hgnc:HGNC:1983","description":"UTP4 small subunit processome component","metadata":{"aliases":["NAIC","FLJ14728","KIAA1988","TEX292","CIRHIN","CIRH1A"]}},{"id":"814a3128f3d542fd9034f3dc39ab0e88","type":"GENE","name":"UTP6","canonical_id":"hgnc:HGNC:18279","description":"UTP6 small subunit processome component","metadata":{"aliases":["HCA66","C17orf40"]}},{"id":"6c6a735475a442d197641e2a79f90e80","type":"GO_TERM","name":"UTP:arabinose-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0010491","description":"\"Catalysis of the reaction: alpha-L-arabinose 1-phosphate + UTP = UDP-L-arabinose + diphosphate.\" [PMID:17341835]","metadata":null},{"id":"620c2785fb6e448084f82299893c4b8d","type":"GO_TERM","name":"UTP:galactose-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0017103","description":"\"Catalysis of the reaction: alpha-D-galactose 1-phosphate + UTP = diphosphate + UDP-D-galactose.\" [EC:2.7.7.10, RHEA:14209]","metadata":null},{"id":"094efc15fc3d457198a8d019b1c78578","type":"GO_TERM","name":"UTP:glucose-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0003983","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + UTP = diphosphate + UDP-D-glucose.\" [EC:2.7.7.9, RHEA:19889]","metadata":null},{"id":"e17cecd99435419a9bf0160e071a7206","type":"GO_TERM","name":"UTP:glucose-1-phosphate uridylyltransferase regulator activity","canonical_id":"go:GO:0043763","description":"\"Binds to and modulates the activity of UTP:glucose-1-phosphate uridylyltransferase.\" [GOC:jl]","metadata":null},{"id":"3fc01fc771f0487aa09ae10f23ba8fd2","type":"GO_TERM","name":"UTP:xylose-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0047338","description":"\"Catalysis of the reaction: alpha-D-xylose 1-phosphate + UTP = UDP-D-xylose + diphosphate.\" [EC:2.7.7.11, MetaCyc:2.7.7.11-RXN]","metadata":null},{"id":"4e34acdf21f9405cae1d1256a316a9e2","type":"GENE","name":"UTRN","canonical_id":"hgnc:HGNC:12635","description":null,"metadata":null},{"id":"c6f0eb111ea84d82a24fefc7a55ab11f","type":"GENE","name":"UTS2","canonical_id":"hgnc:HGNC:12636","description":"urotensin 2","metadata":{"aliases":["UII","U-II","UCN2","PRO1068"]}},{"id":"bf595c645e884c5e9a8fb285ce7d34ce","type":"GENE","name":"UTS2B","canonical_id":"hgnc:HGNC:30894","description":"urotensin 2B","metadata":{"aliases":["URP","U2B","UTS2D"]}},{"id":"5f50f21c41bc418f8221e31bc5684fd4","type":"GENE","name":"UTS2R","canonical_id":"hgnc:HGNC:4468","description":"urotensin 2 receptor","metadata":{"aliases":["GPR14"]}},{"id":"ee1c27b2db9f443991cd6f0950d1ab4e","type":"GENE","name":"UTY","canonical_id":"hgnc:HGNC:12638","description":"ubiquitously transcribed tetratricopeptide repeat containing, Y-linked","metadata":{"aliases":["KDM6AL","KDM6C"]}},{"id":"d8213b67009a4fa5afeb01a9b9c407d9","type":"GO_TERM","name":"UUA codon-amino acid adaptor activity","canonical_id":"go:GO:0033403","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UUA codon.\" [GOC:mah]","metadata":null},{"id":"9ee5d085494b488185a98a6599aa6f2d","type":"GO_TERM","name":"UUC codon-amino acid adaptor activity","canonical_id":"go:GO:0033402","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UUC codon.\" [GOC:mah]","metadata":null},{"id":"6b235cba36e341d6aef74e6f55427528","type":"GO_TERM","name":"UUG codon-amino acid adaptor activity","canonical_id":"go:GO:0033404","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UUG codon.\" [GOC:mah]","metadata":null},{"id":"3bd881e6704c452e875ed7a879b19774","type":"GO_TERM","name":"UUU codon-amino acid adaptor activity","canonical_id":"go:GO:0033401","description":"\"A triplet codon-amino acid adaptor activity that recognizes a UUU codon.\" [GOC:mah]","metadata":null},{"id":"f9ba944ffab3495aaa78a172186e87e1","type":"GO_TERM","name":"UV protection","canonical_id":"go:GO:0009650","description":"\"Any process in which an organism or cell protects itself from ultraviolet radiation (UV), which may also result in resistance to repeated exposure to UV.\" [GOC:jl, GOC:ml]","metadata":null},{"id":"24406d3ddc444c67933790a6a9d1b3b9","type":"GO_TERM","name":"UV-A, blue light phototransduction","canonical_id":"go:GO:0009588","description":"\"The sequence of reactions within a cell required to convert absorbed photons from UV-A or blue light into a molecular signal; the UV-A, blue light range is defined as having a wavelength within the range of 315 to 400 nm.\" [GOC:mah]","metadata":null},{"id":"43bc820f7a5c446d8ef65c0954537b22","type":"GO_TERM","name":"UV-damage excision repair","canonical_id":"go:GO:0070914","description":"\"A DNA repair process that is initiated by an endonuclease that introduces a single-strand incision immediately 5' of a UV-induced damage site. UV-damage excision repair acts on both cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone 6-4 photoproducts (6-4PPs).\" [GOC:mah, PMID:9619100]","metadata":null},{"id":"12bac187769b488297d1de62a806429d","type":"GENE","name":"UVRAG","canonical_id":"hgnc:HGNC:12640","description":"UV radiation resistance associated","metadata":{"aliases":["VPS38"]}},{"id":"2aacbbf822e64e4aa381b0684b8149a1","type":"GENE","name":"UVRAG-DT","canonical_id":"hgnc:HGNC:53952","description":"UVRAG divergent transcript","metadata":{"aliases":["LOC100506113"]}},{"id":"b569a60135264919b40b016d6f96c703","type":"GENE","name":"UVSSA","canonical_id":"hgnc:HGNC:29304","description":"UV stimulated scaffold protein A","metadata":{"aliases":["KIAA1530"]}},{"id":"9ab86814c4504c16a96360228b65637b","type":"GENE","name":"UXS1","canonical_id":"hgnc:HGNC:17729","description":"UDP-glucuronate decarboxylase 1","metadata":{"aliases":["FLJ23591","UGD","SDR6E1"]}},{"id":"f78722a597c44fb5ac03de109ce26ba8","type":"GENE","name":"UXT","canonical_id":"hgnc:HGNC:12641","description":null,"metadata":null},{"id":"fa1601ad956c41dbb1b93b4b2ed9522d","type":"GENE","name":"UXT-AS1","canonical_id":"hgnc:HGNC:49239","description":"UXT antisense RNA 1","metadata":null},{"id":"5bb666c758ac444e948b7e01e8eb150c","type":"DRUG","name":"Ubidecarenone","canonical_id":"mesh:C010524","description":null,"metadata":null},{"id":"307c98d1d3714f69af80e16473303387","type":"GO_TERM","name":"Ubisch body","canonical_id":"go:GO:0070645","description":"\"A small, granular structure that is found in the extracellular matrix of cell of the secretory tapetal layer that surrounds developing pollen grains. Ubisch bodies have a sporopollenin coat, are attached to the peritapetal wall, and may play a role in pollen development.\" [GOC:ecd, GOC:mah, PMID:14612572, PMID:16524248]","metadata":null},{"id":"f49887a62e8f4642bb7fd780a6af76c8","type":"TRIAL","name":"Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis","canonical_id":"clinicaltrials.gov:NCT07225361","description":"Multiple Sclerosis; Multiple Sclerosis (MS) - Relapsing-remitting","metadata":null},{"id":"3e0f4b9953a2471faae857738e8d8955","type":"TRIAL","name":"Ublituximab + Ibrutinib in Select B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT02013128","description":"Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma","metadata":null},{"id":"192b674587524630af2f395163278fc2","type":"TRIAL","name":"Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT02612311","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"83d84d3204bd4e3c916442858bab92e2","type":"TRIAL","name":"Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma","canonical_id":"clinicaltrials.gov:NCT04508647","description":"Marginal Zone Lymphoma; Follicular Lymphoma","metadata":null},{"id":"47cb8389d00948c9a686a4fa216f626f","type":"TRIAL","name":"Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses","canonical_id":"clinicaltrials.gov:NCT02276963","description":"Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorder","metadata":null},{"id":"9ede3d5722434f3194f363ca1b08a08d","type":"TRIAL","name":"Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy","canonical_id":"clinicaltrials.gov:NCT07103746","description":"Autoimmune Disorders","metadata":null},{"id":"6e9485793b524de2b35d2c4c2560b3c9","type":"TRIAL","name":"Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","canonical_id":"clinicaltrials.gov:NCT02301156","description":"Chronic Lymphocytic Leukemia","metadata":null},{"id":"0c5a12a9849b469e9af541c3e1416ef3","type":"TRIAL","name":"Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT01744912","description":"Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; B-cell Lymphomas; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia","metadata":null},{"id":"1127887ce8d049de9f41644c53f3f048","type":"TRIAL","name":"Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT02006485","description":"Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma","metadata":null},{"id":"ba217e700f184b51a7de7a0fc38d8a45","type":"GO_TERM","name":"Ubp3-Bre5 deubiquitination complex","canonical_id":"go:GO:1990861","description":"\"A protein complex that cleaves ubiquitin from specific substrates. In the budding yeast Saccharomyces cerevisiae, this complex consists of Ubp3p and Bre5p.\" [GOC:rb, PMID:12778054, PMID:18391941]","metadata":null},{"id":"5c56ca4af70148d5a7418119dd41d1ca","type":"DRUG","name":"Udenafil","canonical_id":"mesh:C419664","description":null,"metadata":null},{"id":"82e534ed6b0740dd8670a1e27d519c04","type":"TRIAL","name":"Ulcer Prevention Study in Post Gastric Bypass Patients","canonical_id":"clinicaltrials.gov:NCT00557349","description":"Marginal Ulcers","metadata":null},{"id":"304606a6b62a4ae4ae5f7167fddcde10","type":"DISEASE","name":"Ulcerative Colitis","canonical_id":"mesh:D003093","description":null,"metadata":null},{"id":"55fc081a83434872abba66d681612370","type":"TRIAL","name":"Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study","canonical_id":"clinicaltrials.gov:NCT06188637","description":"Ulcerative Colitis","metadata":null},{"id":"2c235a0793f141b69d2a9828b7863189","type":"TRIAL","name":"Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation","canonical_id":"clinicaltrials.gov:NCT02357563","description":"Fibroid","metadata":null},{"id":"c061b78241344de6be212de786fc5423","type":"TRIAL","name":"Ulipristal Acetate for Cervical Preparation","canonical_id":"clinicaltrials.gov:NCT03802149","description":"Termination of Pregnancy","metadata":null},{"id":"ab646fa347e74a579b968aa68a2622e2","type":"TRIAL","name":"Ulipristal Acetate for Use in Early Pregnancy Loss","canonical_id":"clinicaltrials.gov:NCT05216952","description":"Missed Abortion; Anembryonic Pregnancy; Non-Viable Pregnancy","metadata":null},{"id":"237a1a6399494008a7a8ab18b074e5da","type":"TRIAL","name":"Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas","canonical_id":"clinicaltrials.gov:NCT02361905","description":"Fibroid","metadata":null},{"id":"92c8eeb7f3194cd88712047f0f422aed","type":"TRIAL","name":"Ulipristal Acetate in Symptomatic Uterine Fibroid","canonical_id":"clinicaltrials.gov:NCT04132349","description":"Uterine Fibroid; Heavy Menstrual Bleeding","metadata":null},{"id":"1764cef9479e4686889bbf88c3205320","type":"TRIAL","name":"Ulipristal Emergency Contraception Used Before or After Ovulation","canonical_id":"clinicaltrials.gov:NCT02517463","description":"Contraception","metadata":null},{"id":"cc679f8cbd0d4c3bb67f8e2ac14e06ca","type":"TRIAL","name":"Ulipristal Use in Chinese Population","canonical_id":"clinicaltrials.gov:NCT02825719","description":"Fibroid","metadata":null},{"id":"d82c142a35b24b3bb2bbae3d75464194","type":"DRUG","name":"Ulobetasol propionate","canonical_id":"mesh:C064466","description":null,"metadata":null},{"id":"b35631fad62d4064b7541c16cb2b5894","type":"TRIAL","name":"Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis","canonical_id":"clinicaltrials.gov:NCT07204093","description":"Endometriosis","metadata":null},{"id":"f505c4a9bd7a4f5391ec5b848cd39399","type":"TRIAL","name":"Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.","canonical_id":"clinicaltrials.gov:NCT02684812","description":"Subarachnoid Hemorrhage","metadata":null},{"id":"d43d605771c94f8c9bcf7d696f764e91","type":"TRIAL","name":"Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics","canonical_id":"clinicaltrials.gov:NCT02682862","description":"Asthma","metadata":null},{"id":"e6d28783cc0a44dd9bb00eb355e68f16","type":"TRIAL","name":"Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol","canonical_id":"clinicaltrials.gov:NCT07012993","description":"Alzheimer Disease; Mild Cognitive Impairment; Dementia; Healthy Volunteers","metadata":null},{"id":"141672a0eae2458e9c4e595c92b262ac","type":"TRIAL","name":"Ultrasonic Enhancement Delivery of Phosphodiesterase Inhibitors Nanoparticles for Diabetic Management of the Foot","canonical_id":"clinicaltrials.gov:NCT07690566","description":"Diabetic Foot; Wound Healing Delayed; Diabete Mellitus; Amputation","metadata":null},{"id":"12151d35ecac407e97b2d90b270f6438","type":"TRIAL","name":"Ultrasound Assessment of Metoclopramide Effect on Gastric Volume in Cesarean Section","canonical_id":"clinicaltrials.gov:NCT04157998","description":"Aspiration Pneumonia","metadata":null},{"id":"50d2893b8cd44ef9be6e0df6024514e4","type":"TRIAL","name":"Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain","canonical_id":"clinicaltrials.gov:NCT02024724","description":"Typical Facial Pain; Atypical Facial Pain","metadata":null},{"id":"363fd987a28a428799182e4c057059a4","type":"TRIAL","name":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT01602302","description":"Rheumatoid Arthritis","metadata":null},{"id":"a7157fa746364896884ea3119e971814","type":"TRIAL","name":"Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance","canonical_id":"clinicaltrials.gov:NCT02931383","description":"Osteoarthritis; Obesity","metadata":null},{"id":"31e278d16ffe4fa0ae7177821658bbd8","type":"TRIAL","name":"Ultrasound-Guided Ilioinguinal-Iliohypogastric Nerve Block Following Spinal Anesthesia Comparing Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Unilateral Inguinal Hernia Repair","canonical_id":"clinicaltrials.gov:NCT07837492","description":"Inguinal Hernia; Postoperative Pain","metadata":null},{"id":"b4caa93c52bb4610b5bec0f1387e18e8","type":"TRIAL","name":"Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides","canonical_id":"clinicaltrials.gov:NCT00056056","description":"Lymphoma","metadata":null},{"id":"c256478227dc4f13ba6f7302cfccb002","type":"TRIAL","name":"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT01729091","description":"Plasma Cell Leukemia; Plasma Cell Myeloma","metadata":null},{"id":"eb692fbd2d434032a7cb233f9cd6156f","type":"TRIAL","name":"Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy","canonical_id":"clinicaltrials.gov:NCT04149821","description":"Chronic Lymphocytic Leukemia; CLL Progression; CLL/SLL","metadata":null},{"id":"01d36e6f2dab4c748d194fde46ab7e53","type":"TRIAL","name":"Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT03776864","description":"Hodgkin's Lymphoma","metadata":null},{"id":"092db7c18d5f416ba8a8aa0f5aed0918","type":"TRIAL","name":"Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma","canonical_id":"clinicaltrials.gov:NCT03919175","description":"Lymphoma; Follicular Lymphoma; Follicular Lymphoma, Grade 1; Follicular Lymphoma Grade 2; Follicular Lymphoma Grade IIIa; Marginal Zone Lymphoma; Marginal Zone B Cell Lymphoma","metadata":null},{"id":"0124e9c241ea4ed9b56fe527c3c3cf46","type":"TRIAL","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","canonical_id":"clinicaltrials.gov:NCT06955325","description":"Non-Small Cell Lung Cancer","metadata":null},{"id":"b6b62be570b44dca828b4758c6abdde8","type":"TRIAL","name":"Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer","canonical_id":"clinicaltrials.gov:NCT05101564","description":"Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer","metadata":null},{"id":"967f8cfdb376487c8acad8c5b40ea844","type":"TRIAL","name":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","canonical_id":"clinicaltrials.gov:NCT00262054","description":"Coronary Disease; Angina Pectoris","metadata":null},{"id":"62740ec969bf4c758f3179fc2ffae633","type":"TRIAL","name":"Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program","canonical_id":"clinicaltrials.gov:NCT02024204","description":"Lung Diseases; Medication Compliance","metadata":null},{"id":"04af247eb8704c09be029ee0cc20be07","type":"TRIAL","name":"Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome","canonical_id":"clinicaltrials.gov:NCT02687165","description":"Post Treatment Lyme Syndrome (PTLS); Chronic Pain","metadata":null},{"id":"4bea730aa1ea4090a7798d16b77e1993","type":"TRIAL","name":"Understanding Experimentally Induced Hot Flushes","canonical_id":"clinicaltrials.gov:NCT00455689","description":"Hot Flashes","metadata":null},{"id":"7eda00d4c9b14e83bfc56d6fecb65ac4","type":"TRIAL","name":"Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics","canonical_id":"clinicaltrials.gov:NCT02430545","description":"Healthy Volunteers","metadata":null},{"id":"7545421e7083414990797ad7535a6eb3","type":"DISEASE","name":"Undescended testicle","canonical_id":"mesh:D003456","description":null,"metadata":null},{"id":"20b957c7d83c450c98b053911fe6d737","type":"TRIAL","name":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","canonical_id":"clinicaltrials.gov:NCT07281014","description":"Heart Failure","metadata":null},{"id":"65f13d973a8649c184cd7f3961c8e45e","type":"DRUG","name":"Unoprostone isopropyl","canonical_id":"mesh:C072630","description":null,"metadata":null},{"id":"3a239bb581b44df39dc7962350eb073a","type":"TRIAL","name":"Updated Diagnostic Cortisol Values for Adrenal Insufficiency","canonical_id":"clinicaltrials.gov:NCT05149638","description":"Adrenal Insufficiency","metadata":null},{"id":"fb32a657318f47869f5c96fbcdf4d81c","type":"TRIAL","name":"Upfront Ruxolitinib for Chronic Graft-vs-host Disease","canonical_id":"clinicaltrials.gov:NCT06695507","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"8fe42ef6fc6d408c87f7131395412714","type":"TRIAL","name":"Upper GI Handling of Branded vs. Generic Alendronate","canonical_id":"clinicaltrials.gov:NCT00400530","description":"Osteoporosis","metadata":null},{"id":"10e2c006b89c46eca24ab3429c2d3696","type":"TRIAL","name":"Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML","canonical_id":"clinicaltrials.gov:NCT05569512","description":"Acute Myeloid Leukemia; Pediatric Cancer","metadata":null},{"id":"2f17fb8cf3ea4c95a776b5edb184e243","type":"TRIAL","name":"Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT04964505","description":"Acute Myeloid Leukemia","metadata":null},{"id":"ad0261e6662740ce9e2812cc5457118c","type":"DRUG","name":"Uprosertib","canonical_id":"ncit:C84870","description":null,"metadata":null},{"id":"b5d266741d284993968db0d169367c9f","type":"TRIAL","name":"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","canonical_id":"clinicaltrials.gov:NCT01902173","description":"Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma","metadata":null},{"id":"f658b540768146fc888ae9794b1db97c","type":"TRIAL","name":"Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder","canonical_id":"clinicaltrials.gov:NCT00360555","description":"Sexual Dysfunctions, Psychological","metadata":null},{"id":"d20ed0811dee473e8d706ea0e52373b5","type":"TRIAL","name":"Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction","canonical_id":"clinicaltrials.gov:NCT03534037","description":"Hyperuricemia; Metabolic Syndrome; Left Ventricular Diastolic Dysfunction","metadata":null},{"id":"7f09c9c7f4f24f1788ff786094a17056","type":"TRIAL","name":"Ureteral Stent Study","canonical_id":"clinicaltrials.gov:NCT03043612","description":"Urolithiasis","metadata":null},{"id":"ccf91474af8a45b59a56353b797fc2cc","type":"TRIAL","name":"Ureteral Stent-related Pain and Mirabegron (SPAM) Trial","canonical_id":"clinicaltrials.gov:NCT02095665","description":"Nephrolithiasis","metadata":null},{"id":"10b2c7c4e652452695a521ab2bc39c01","type":"DISEASE","name":"Urethritis","canonical_id":"mesh:D014526","description":null,"metadata":null},{"id":"b0e31489d04b439eaf62db324acbe81e","type":"DISEASE","name":"Urge Incontinence","canonical_id":"mesh:D053202","description":null,"metadata":null},{"id":"22229daf313943d38ab8d481f7de05da","type":"TRIAL","name":"Uric Acid Effects on Endothelium and Oxydative Stress","canonical_id":"clinicaltrials.gov:NCT03395977","description":"Oxidative Stress; Endothelial Function; Cardiovascular System; Hypertension","metadata":null},{"id":"12e76068aa694205a078362674569d05","type":"TRIAL","name":"Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease","canonical_id":"clinicaltrials.gov:NCT03865407","description":"Hyperuricemia; Chronic Kidney Diseases","metadata":null},{"id":"bb87026e9a484ccb8dc3920624bd0501","type":"DISEASE","name":"Urinary Bladder Cancer","canonical_id":"doid:11054","description":null,"metadata":null},{"id":"090550b3d0f646348c7fe580b1aebb01","type":"DISEASE","name":"Urinary Bladder Neoplasms","canonical_id":"mesh:D001749","description":null,"metadata":null},{"id":"40d126caa21d4d3ba211ff1acccb7115","type":"TRIAL","name":"Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01467258","description":"Healthy Metabolism","metadata":null},{"id":"3f08a6c4a0ea478d97d009ea90e12957","type":"DISEASE","name":"Urinary bladder stone","canonical_id":"mesh:D001744","description":null,"metadata":null},{"id":"738f7588e6884b15a0a651acecaaf21f","type":"DISEASE","name":"Urinary incontinence","canonical_id":"hp:0000020","description":null,"metadata":null},{"id":"f1be5fde24f2434f811109e15bd98417","type":"DISEASE","name":"Urinary incontinence","canonical_id":"mesh:D014549","description":null,"metadata":null},{"id":"98d538090231413b85f3fe66376ae7b8","type":"DISEASE","name":"Urinary retention","canonical_id":"hp:0000016","description":null,"metadata":null},{"id":"688508984ce44f8c8422569a123e6a6c","type":"TRIAL","name":"Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)","canonical_id":"clinicaltrials.gov:NCT00256399","description":"BPH; Erectile Dysfunction","metadata":null},{"id":"247d767e83054a8aa2a8af0b8e07af10","type":"DRUG","name":"Ursodeoxycholic Acid","canonical_id":"mesh:D014580","description":null,"metadata":null},{"id":"97557281264843d2a878074e5ab7a55e","type":"DISEASE","name":"Urticaria","canonical_id":"mesh:D014581","description":null,"metadata":null},{"id":"0cfb531982214ddaa3c30134c96b50de","type":"TRIAL","name":"Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","canonical_id":"clinicaltrials.gov:NCT03415178","description":"Hypercholesterolaemia","metadata":null},{"id":"42cd71a8a0d741df900cb4521c93c180","type":"TRIAL","name":"Usage of Baclofen for Sleep Improvement After Cardiac Surgery","canonical_id":"clinicaltrials.gov:NCT02529514","description":"Sleep","metadata":null},{"id":"44f881a651ff4a23bacd31b6f3cc9c2d","type":"TRIAL","name":"Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers","canonical_id":"clinicaltrials.gov:NCT03431272","description":"Contact Lens Dry Eye","metadata":null},{"id":"65bd2ddb08a04cecb3a5d72bffd39aab","type":"TRIAL","name":"Use of Alfuzosin in Stone Treatment With ESWL","canonical_id":"clinicaltrials.gov:NCT00388271","description":"Urinary Calculi","metadata":null},{"id":"4b56ef175fe84a2796360b21420acd31","type":"TRIAL","name":"Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy","canonical_id":"clinicaltrials.gov:NCT03000309","description":"Plaque Psoriasis","metadata":null},{"id":"4abffb02f5f54b89b0b37bd31f9074e7","type":"TRIAL","name":"Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function","canonical_id":"clinicaltrials.gov:NCT06091995","description":"Use of Belatacept in Kidney Transplant Patients","metadata":null},{"id":"d92c7041d6d34e939396b2d993994e40","type":"TRIAL","name":"Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders","canonical_id":"clinicaltrials.gov:NCT02937012","description":"Primary Biliary Cirrhosis","metadata":null},{"id":"c87f60b604954af49580a7d2c1641ff3","type":"TRIAL","name":"Use of Biperiden for the Prevention of Post-traumatic Epilepsy","canonical_id":"clinicaltrials.gov:NCT01048138","description":"Traumatic Brain Injury","metadata":null},{"id":"b2380849fc5c40129deed19a7207982b","type":"TRIAL","name":"Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","canonical_id":"clinicaltrials.gov:NCT06275555","description":"Extracorporeal Membrane Oxygenation Complication","metadata":null},{"id":"2ca34eee673c4d9a84517f688f3c684f","type":"TRIAL","name":"Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients","canonical_id":"clinicaltrials.gov:NCT00727090","description":"Hyponatremia","metadata":null},{"id":"45a21e3130ee43b0a2672e972167de14","type":"TRIAL","name":"Use of Cyclosporin A for the Treatment of Recurrent Miscarriage","canonical_id":"clinicaltrials.gov:NCT02706470","description":"Miscarriage, Recurrent","metadata":null},{"id":"80f5b9bef6b747f5b0b00dca96610f25","type":"TRIAL","name":"Use of Dalfampridine in Primary Lateral Sclerosis","canonical_id":"clinicaltrials.gov:NCT02868567","description":"Motor Neuron Disease, Upper","metadata":null},{"id":"ac850cff875440a1980e2f04ecffb5f2","type":"TRIAL","name":"Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)","canonical_id":"clinicaltrials.gov:NCT01709942","description":"PCOS; OHSS; INFERTILITY","metadata":null},{"id":"064ae839da714ad2a5bce64e743c694c","type":"TRIAL","name":"Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.","canonical_id":"clinicaltrials.gov:NCT05953142","description":"Sepsis; Hypoperfusion; Hyperlactatemia","metadata":null},{"id":"08c3046700aa4782a75ff2ec4c3bd6bc","type":"TRIAL","name":"Use of Domperidone for Treatment of Upper Gastrointestinal Disorders","canonical_id":"clinicaltrials.gov:NCT03128398","description":"Gastroparesis","metadata":null},{"id":"651d817db88c4b42b175ae3a515d0cd0","type":"TRIAL","name":"Use of Domperidone to Increase Milk Production in Mothers With Newborns in Neonatology","canonical_id":"clinicaltrials.gov:NCT03221855","description":"Breastfeeding","metadata":null},{"id":"2ebe7baa2c9a46a4a4410b60d46e005e","type":"TRIAL","name":"Use of Donepezil for Treatment of Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT00467389","description":"Cocaine Abuse and Dependence","metadata":null},{"id":"e01839c66a7a4393b8fd8740acaf0020","type":"TRIAL","name":"Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women","canonical_id":"clinicaltrials.gov:NCT03116022","description":"Dyspareunia; Menopause; Sexual Dysfunction","metadata":null},{"id":"d0ed702dab19411f9e3144b3029f809d","type":"TRIAL","name":"Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease","canonical_id":"clinicaltrials.gov:NCT00143572","description":"Anemia, Sickle Cell","metadata":null},{"id":"58681209f1fb496b95d6092ce0f5318e","type":"TRIAL","name":"Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation","canonical_id":"clinicaltrials.gov:NCT03750656","description":"Lower Urinary Tract Symptoms","metadata":null},{"id":"96c003a796ef461584fe46bcf59a4fe0","type":"TRIAL","name":"Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients","canonical_id":"clinicaltrials.gov:NCT03105661","description":"Obesity, Morbid; Preeclampsia","metadata":null},{"id":"3f65054466d34cc3add554a4372da5de","type":"TRIAL","name":"Use of Infliximab for the Treatment of Pemphigus Vulgaris","canonical_id":"clinicaltrials.gov:NCT00283712","description":"Pemphigus","metadata":null},{"id":"e9ea7d640f5b44d7a8e7d2b6c45ed216","type":"TRIAL","name":"Use of Intraoperative Clonidine for Prevention of Postoperative Agitation in Pedriatic Anesthesia With Sevoflurane.","canonical_id":"clinicaltrials.gov:NCT02181543","description":"Is an Only Child","metadata":null},{"id":"0254ec9199144acab57ecf1488b15376","type":"TRIAL","name":"Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye","canonical_id":"clinicaltrials.gov:NCT01404364","description":"Blind Painful Eye; Refractory Glaucoma; Control of Pain Through Drug Injection","metadata":null},{"id":"71a8fff4e91d45f99c9083681fc1065e","type":"TRIAL","name":"Use of Low-dose Zolpidem in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03621046","description":"Parkinson Disease","metadata":null},{"id":"36613ea664144c87a8779928ca65974d","type":"TRIAL","name":"Use of Methazolamide to Lower Intraocular Pressure","canonical_id":"clinicaltrials.gov:NCT05498103","description":"Glaucoma, Open-Angle","metadata":null},{"id":"218a6b15808044fa8cfd719903ab720d","type":"TRIAL","name":"Use of Methylphenidate in Children and Adolescents in France","canonical_id":"clinicaltrials.gov:NCT03371069","description":"Use of Methylphenidate in Children and Adolescents","metadata":null},{"id":"51cd8f20af38493baf486526cff41f0b","type":"TRIAL","name":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","canonical_id":"clinicaltrials.gov:NCT02061280","description":"Asthma","metadata":null},{"id":"361a7fb6d9404add85b03ecae5e130d0","type":"TRIAL","name":"Use of Montelukast to Treat Children With Mild to Moderate Acute Asthma","canonical_id":"clinicaltrials.gov:NCT00213252","description":"Asthma, Bronchial","metadata":null},{"id":"9434ff6181d042cfbb2c4802057c1b30","type":"TRIAL","name":"Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO","canonical_id":"clinicaltrials.gov:NCT06276010","description":"Extracorporeal Membrane Oxygenation Complication","metadata":null},{"id":"75be6f4f9ae24effb7fe736fb32295c4","type":"TRIAL","name":"Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study","canonical_id":"clinicaltrials.gov:NCT01310712","description":"Hyperhidrosis","metadata":null},{"id":"352a6232eccd4c8e99ec5bb52f532795","type":"TRIAL","name":"Use of Oxybutynin to Treat Axillary Hyperhidrosis","canonical_id":"clinicaltrials.gov:NCT01118429","description":"Axillary Hyperhidrosis; Osmidrosis","metadata":null},{"id":"a993e92fe1ed45939c5ecd06c2d7d0b1","type":"TRIAL","name":"Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass","canonical_id":"clinicaltrials.gov:NCT00620945","description":"Congenital Heart Surgery; Cardiopulmonary Bypass","metadata":null},{"id":"3172c5a9025043bfb8151f62bbf15d47","type":"TRIAL","name":"Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies","canonical_id":"clinicaltrials.gov:NCT02263365","description":"Dehydration, Diverting Ileostomy, Loperamide","metadata":null},{"id":"17a46122071745cf8d05857dc893bfa9","type":"TRIAL","name":"Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery","canonical_id":"clinicaltrials.gov:NCT01069341","description":"Rubeosis Iridis; Proliferative Diabetic Retinopathy","metadata":null},{"id":"771955c09eb9438babadf07c675e5dd5","type":"TRIAL","name":"Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)","canonical_id":"clinicaltrials.gov:NCT01830959","description":"Sarcoidosis","metadata":null},{"id":"37e845ee9e284615be0ab22f11ae5092","type":"TRIAL","name":"Use of Sanvar\u00ae With Endoscopic Treatment for the Control of Acute Variceal Bleeding","canonical_id":"clinicaltrials.gov:NCT00331188","description":"Esophageal Varices; Portal Hypertension; Gastric Varices; Esophageal Bleeding","metadata":null},{"id":"17da3bfa8d244b6996015543fbfa1e67","type":"TRIAL","name":"Use of Selincro and Impact on Usual Practice","canonical_id":"clinicaltrials.gov:NCT02492581","description":"Alcohol Dependence","metadata":null},{"id":"37ae752c24054bcab43398c3fc5febde","type":"TRIAL","name":"Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.","canonical_id":"clinicaltrials.gov:NCT00740779","description":"Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome","metadata":null},{"id":"b4d942e315914204ab2f800d419b01b8","type":"TRIAL","name":"Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia","canonical_id":"clinicaltrials.gov:NCT00974051","description":"Type 1 Diabetes","metadata":null},{"id":"993c0dab57924609908070399e12b22c","type":"TRIAL","name":"Use of Teriparatide to Accelerate Fracture Healing","canonical_id":"clinicaltrials.gov:NCT00594906","description":"Pelvic Fracture","metadata":null},{"id":"8760db51fb2d4dfd90045afe7389f8c8","type":"TRIAL","name":"Use of Tranexamic Acid in Blepharoplasties","canonical_id":"clinicaltrials.gov:NCT04724772","description":"Pain, Postoperative; Bruising","metadata":null},{"id":"82a8f320a80d48f199d58e1b4c912219","type":"TRIAL","name":"Use of Transdermal Clonidine in Trauma Patients","canonical_id":"clinicaltrials.gov:NCT01139996","description":"Delirium","metadata":null},{"id":"0f3b3a88be9b4dcc9e53db2aa875b326","type":"TRIAL","name":"Use of Zolpidem in Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT01351168","description":"Parkinson's Disease","metadata":null},{"id":"ef569aaafdc64a68bdeac46c4fd8e1cb","type":"TRIAL","name":"Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients","canonical_id":"clinicaltrials.gov:NCT01551368","description":"Infertility","metadata":null},{"id":"905567c3f2c34307b9fecad6f9dc4e02","type":"TRIAL","name":"Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder","canonical_id":"clinicaltrials.gov:NCT02932215","description":"Cannabis Use Disorder","metadata":null},{"id":"b31baaba8c414ef599b4cbc252ee76fe","type":"TRIAL","name":"Use of a New Medicine \"Daratumumab\" to Treat Left-over Cancer in a Blood Cancer Called \"T Acute Lymphoblastic Leukemia\"","canonical_id":"clinicaltrials.gov:NCT07021677","description":"T Acute Lymphoblastic Leukemia","metadata":null},{"id":"97f6d3d8e3214216a4a5032d686f1bc3","type":"TRIAL","name":"Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI","canonical_id":"clinicaltrials.gov:NCT04671030","description":"Spinal Cord Injuries; Constipation; Neurogenic Bowel","metadata":null},{"id":"33364a8b0465428e8e19028ee4164a02","type":"TRIAL","name":"Usefulness of Selegiline as an Aid to Quit Smoking - 1","canonical_id":"clinicaltrials.gov:NCT00129311","description":"Tobacco Use Cessation","metadata":null},{"id":"eb4f50a909bb4d9dbf831dfb1145abe9","type":"TRIAL","name":"Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes","canonical_id":"clinicaltrials.gov:NCT00707421","description":"Glaucoma; Trabeculectomy; Fibrosis; Intraocular Pressure","metadata":null},{"id":"a65b6f6e0b0e40eaad6081e4c19b7379","type":"TRIAL","name":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","canonical_id":"clinicaltrials.gov:NCT01868360","description":"Corneal Neovascularization","metadata":null},{"id":"4a75db501b704290bdaecd5cc13e7546","type":"TRIAL","name":"Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels","canonical_id":"clinicaltrials.gov:NCT00987415","description":"Heart Failure; Elevated Serum Uric Acid","metadata":null},{"id":"fc67ee516bfe43618d70a142dd16c081","type":"TRIAL","name":"Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder","canonical_id":"clinicaltrials.gov:NCT00127270","description":"Urinary Incontinence","metadata":null},{"id":"c4fbfb89ec7e40b9a730c5923a2c1261","type":"TRIAL","name":"Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant","canonical_id":"clinicaltrials.gov:NCT01011114","description":"Hypophosphatemia; Renal Transplant","metadata":null},{"id":"a1aa8241ec0542769209350a655a4354","type":"TRIAL","name":"Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT04942834","description":"Atrial Fibrillation, Persistent; Arrhythmias, Cardiac","metadata":null},{"id":"5143a8e735d8411db71fd87309de70ec","type":"TRIAL","name":"Using Doxepin for Urticaria","canonical_id":"clinicaltrials.gov:NCT05115136","description":"Urticaria","metadata":null},{"id":"a3ab8128b52f461c80cfa93873d054ff","type":"TRIAL","name":"Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment","canonical_id":"clinicaltrials.gov:NCT00466609","description":"Obsessive Compulsive Disorder","metadata":null},{"id":"4b352fab09364c1f9a2f78b022793a5d","type":"TRIAL","name":"Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor","canonical_id":"clinicaltrials.gov:NCT05065021","description":"Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High Grade Serous Cancer; High Grade Endometrioid Cancer","metadata":null},{"id":"2b78aa8521ab4f01881c0ca3bb647180","type":"TRIAL","name":"Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients","canonical_id":"clinicaltrials.gov:NCT01895335","description":"Multiple Sclerosis","metadata":null},{"id":"bbd7a6d790e943c8839bddfcda851ca6","type":"TRIAL","name":"Using Preoperative Anxiety Score to Determine the Precise Dose of Butorphanol for Sedation","canonical_id":"clinicaltrials.gov:NCT03429179","description":"Preoperative Anxiety; Precise Dose of Butorphanol","metadata":null},{"id":"ba490c9b576642e2ac8925fdcbb9f750","type":"TRIAL","name":"Using Preoperative Anxiety Score to Determine the Total Dose of Butorphanol for Sedation","canonical_id":"clinicaltrials.gov:NCT03810391","description":"Preoperative Anxiety Score; Total Dose of Butorphanol","metadata":null},{"id":"ddc00d0a64c347e399ef59777d7a2cd2","type":"TRIAL","name":"Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma","canonical_id":"clinicaltrials.gov:NCT04673266","description":"Lymphoma Patients; Thrombocytopenia","metadata":null},{"id":"9c12fe00d27c4a6d90b43bc768404e79","type":"TRIAL","name":"Using Tumor Models to Determine Treatments","canonical_id":"clinicaltrials.gov:NCT06813079","description":"Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor","metadata":null},{"id":"816c709bbc7243cd9f5c854987021d78","type":"TRIAL","name":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","canonical_id":"clinicaltrials.gov:NCT05535738","description":"Skin Inflammation; Allergic Contact Dermatitis","metadata":null},{"id":"a1db087fe2af4629b354e478e8c8e84c","type":"TRIAL","name":"Using an Internet Study to Improve Adherence for Psoriasis Patients","canonical_id":"clinicaltrials.gov:NCT01802580","description":"Psoriasis","metadata":null},{"id":"95942be436604bac8a0e2061cc952ad8","type":"TRIAL","name":"Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use","canonical_id":"clinicaltrials.gov:NCT04181515","description":"Stress; Opioid-use Disorder","metadata":null},{"id":"36dc678dab4f416cb4ddb77bf6c42fa7","type":"TRIAL","name":"Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology","canonical_id":"clinicaltrials.gov:NCT03366142","description":"LAD1","metadata":null},{"id":"0ac7ec9f11c948fa8f7cd74d77bf27a7","type":"TRIAL","name":"Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)","canonical_id":"clinicaltrials.gov:NCT02911116","description":"Uveitis","metadata":null},{"id":"33a6b3d1fab24620a445978c82277749","type":"DISEASE","name":"Uterine Cancer","canonical_id":"doid:363","description":null,"metadata":null},{"id":"28c82ed89eb843f1a3f6c91e52093fc2","type":"DISEASE","name":"Uterine Corpus Endometrial Carcinoma","canonical_id":"doid:0050939","description":null,"metadata":null},{"id":"0fa4a424ee2d459fb8a238300fdea7b5","type":"DISEASE","name":"Uterine Inertia","canonical_id":"efo:1001863","description":null,"metadata":null},{"id":"5545bae3e11c4a23819a15bb70ff2732","type":"DISEASE","name":"Uterine leiomyoma","canonical_id":"mesh:D007889","description":null,"metadata":null},{"id":"4382d7bd0ac84a4d8ac43f208c8e27d2","type":"TISSUE","name":"Uterus","canonical_id":"uberon:UBERON:0000995","description":null,"metadata":null},{"id":"77d09de259b24ad6b16ce5a2e1766746","type":"TRIAL","name":"Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US","canonical_id":"clinicaltrials.gov:NCT07226531","description":"Alopecia Areata","metadata":null},{"id":"008c84f21f394bc3b65325a639f4adbc","type":"TRIAL","name":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","canonical_id":"clinicaltrials.gov:NCT07352566","description":"Psoriasis; Atopic Dermatitis","metadata":null},{"id":"fdeae98e0f964693b96a097675fdacde","type":"TRIAL","name":"Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib","canonical_id":"clinicaltrials.gov:NCT06083038","description":"Metastatic Breast Cancer","metadata":null},{"id":"99ae59350c6f478887626501f04aef53","type":"TRIAL","name":"Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program","canonical_id":"clinicaltrials.gov:NCT03364829","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"339b1f7478b44ed19772192ae567a2ad","type":"GO_TERM","name":"V(D)J recombination","canonical_id":"go:GO:0033151","description":"\"The process in which immune receptor V, D, and J, or V and J gene segments, depending on the specific receptor, are recombined within a single locus utilizing the conserved heptamer and nonomer recombination signal sequences (RSS).\" [GOC:add, ISBN:0781700221, ISBN:0781735149]","metadata":null},{"id":"92ab37ed884b45e7aa8bf25482a20f17","type":"PROTEIN","name":"V-type proton ATPase catalytic subunit A","canonical_id":"uniprot:P38606","description":null,"metadata":null},{"id":"a155373b973f4c1aab415e8d0999d34f","type":"PROTEIN","name":"V-type proton ATPase subunit a (Candida albicans)","canonical_id":"uniprot:Q59R99","description":null,"metadata":null},{"id":"f1b362af7e3b4359b36a74be18395b2f","type":"GO_TERM","name":"V1A vasopressin receptor binding","canonical_id":"go:GO:0031894","description":"\"Binding to a V1A vasopressin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"69d7fe62679a4f1391f9ea26581aa10c","type":"GO_TERM","name":"V1B vasopressin receptor binding","canonical_id":"go:GO:0031895","description":"\"Binding to a V1B vasopressin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7883afd077e14f77b0ef1e71c27cecce","type":"GO_TERM","name":"V2 vasopressin receptor binding","canonical_id":"go:GO:0031896","description":"\"Binding to a V2 vasopressin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"825f95529dd54560881aa4d2d48781a8","type":"GENE","name":"VAC14","canonical_id":"hgnc:HGNC:25507","description":"VAC14 component of PIKFYVE complex","metadata":{"aliases":["FLJ10305","ArPIKfyve","TAX1BP2"]}},{"id":"ef02c4dd55234dad976d142c0468b196","type":"GENE","name":"VAC14-AS1","canonical_id":"hgnc:HGNC:48605","description":"VAC14 antisense RNA 1","metadata":null},{"id":"7fa426af1b354b27b37daa7bb0345cc6","type":"GENE","name":"VAC14-AS2","canonical_id":"hgnc:HGNC:58481","description":"VAC14 antisense RNA 2","metadata":null},{"id":"c3ed70cdb66949f283049b90b73f88fd","type":"TRIAL","name":"VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women","canonical_id":"clinicaltrials.gov:NCT00171132","description":"Hypertension","metadata":null},{"id":"58830714820249e0a57c23b4e3280ae0","type":"TRIAL","name":"VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis","canonical_id":"clinicaltrials.gov:NCT00171080","description":"Hypertension","metadata":null},{"id":"c32712119bd54569962a2a3839b79fab","type":"GENE","name":"VAMP1","canonical_id":"hgnc:HGNC:12642","description":"vesicle associated membrane protein 1","metadata":{"aliases":["VAMP-1","SYB1"]}},{"id":"781022fa432e43f881e6c5e39d6eb9b4","type":"GENE","name":"VAMP1-AS1","canonical_id":"hgnc:HGNC:56361","description":"VAMP1 antisense RNA 1","metadata":null},{"id":"683e38e957f3408eae952702fdc9712a","type":"GENE","name":"VAMP2","canonical_id":"hgnc:HGNC:12643","description":null,"metadata":null},{"id":"29e12817d2eb4d6dbdc6236015ca81d2","type":"GENE","name":"VAMP3","canonical_id":"hgnc:HGNC:12644","description":"vesicle associated membrane protein 3","metadata":{"aliases":["CEB"]}},{"id":"8abafa1283ba4b288260e433c4e56a84","type":"GENE","name":"VAMP4","canonical_id":"hgnc:HGNC:12645","description":"vesicle associated membrane protein 4","metadata":null},{"id":"6402fa40714448588da5d62095f170e0","type":"GO_TERM","name":"VAMP4-syntaxin-6-syntaxin-16-Vti1a complex","canonical_id":"go:GO:0070068","description":"\"A SNARE complex that contains VAMP4, syntaxin 6, syntaxin 16, and Vti1a (or orthologs thereof).\" [PMID:11839770]","metadata":null},{"id":"42af6369ba4d4c429bb627955957a5a3","type":"GENE","name":"VAMP5","canonical_id":"hgnc:HGNC:12646","description":"vesicle associated membrane protein 5","metadata":null},{"id":"32d08d5406e741e58bfe5d0374fdffa0","type":"GENE","name":"VAMP7","canonical_id":"hgnc:HGNC:11486","description":"vesicle associated membrane protein 7","metadata":{"aliases":["VAMP-7","TI-VAMP","SYBL1"]}},{"id":"d8b8dabafd3d4ec580b565bfc322052d","type":"GENE","name":"VAMP8","canonical_id":"hgnc:HGNC:12647","description":"vesicle associated membrane protein 8","metadata":{"aliases":["EDB","VAMP-8"]}},{"id":"a84a327f5183426992313693e97c3366","type":"GENE","name":"VAMP9P","canonical_id":"hgnc:HGNC:53817","description":"vesicle associated membrane protein 9, pseudogene","metadata":{"aliases":["TCONS_00008138"]}},{"id":"33ad1fa24f274cc8bbb01045ef4b5e17","type":"GENE","name":"VANGL1","canonical_id":"hgnc:HGNC:15512","description":"VANGL planar cell polarity protein 1","metadata":{"aliases":["STB2"]}},{"id":"89baed315938459abdaf10e60b26c125","type":"GENE","name":"VANGL2","canonical_id":"hgnc:HGNC:15511","description":"VANGL planar cell polarity protein 2","metadata":{"aliases":["KIAA1215","LTAP","LPP1","STBM","STB1","STBM1","MGC119403","MGC119404"]}},{"id":"94bf2ac933964ffe9fa0831d7fde9253","type":"TRIAL","name":"VANOS Cream and Skin Barrier Function","canonical_id":"clinicaltrials.gov:NCT00819507","description":"Atopic Dermatitis","metadata":null},{"id":"4d1cb7395a464bea9c23a541fbf5ac5b","type":"GENE","name":"VAPA","canonical_id":"hgnc:HGNC:12648","description":"VAMP associated protein A","metadata":{"aliases":["hVAP-33","VAP-A"]}},{"id":"3e3b52e0776c43a9810c79d63a7db089","type":"GENE","name":"VAPB","canonical_id":"hgnc:HGNC:12649","description":"VAMP associated protein B and C","metadata":{"aliases":["VAP-B","VAP-C","ALS8"]}},{"id":"dffeb15b8be6473e9f3c5ec272f844a9","type":"TRIAL","name":"VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure","canonical_id":"clinicaltrials.gov:NCT07375212","description":"Heart Failure Congestive","metadata":null},{"id":"21c58e842c3d46b0a93a7b1aaff9764d","type":"GENE","name":"VARS1","canonical_id":"hgnc:HGNC:12651","description":"valyl-tRNA synthetase 1","metadata":{"aliases":["VARS2","VARS"]}},{"id":"edefea343f5a4577a055c0677c65c064","type":"GENE","name":"VARS2","canonical_id":"hgnc:HGNC:21642","description":"valyl-tRNA synthetase 2, mitochondrial","metadata":{"aliases":["DKFZP434L1435","KIAA1885","G7a","VARS2L","VARSL"]}},{"id":"3526b794c4094d9db518a5f6775cfee5","type":"GENE","name":"VASH1","canonical_id":"hgnc:HGNC:19964","description":"vasohibin 1","metadata":{"aliases":["KIAA1036"]}},{"id":"faaca9a9c7af4ee48bb13c207d485675","type":"GENE","name":"VASH1-AS1","canonical_id":"hgnc:HGNC:53215","description":"VASH1 antisense RNA 1","metadata":null},{"id":"c7ba802f94594b2ea7d208daa3ec693f","type":"GENE","name":"VASH1-DT","canonical_id":"hgnc:HGNC:55446","description":"VASH1 divergent transcript","metadata":null},{"id":"b580eecf55b84de6a08d0fb90e619ccf","type":"GENE","name":"VASH2","canonical_id":"hgnc:HGNC:25723","description":"vasohibin 2","metadata":{"aliases":["FLJ12505"]}},{"id":"48f50b33f3834280af137a02fd6aede6","type":"GENE","name":"VASN","canonical_id":"hgnc:HGNC:18517","description":"vasorin","metadata":{"aliases":["SLITL2"]}},{"id":"0526ef1900cd45c88fe90c3c37f37fc5","type":"GENE","name":"VASP","canonical_id":"hgnc:HGNC:12652","description":"vasodilator stimulated phosphoprotein","metadata":null},{"id":"cc375851bea14a93acac1ac09b029a82","type":"GENE","name":"VAT1","canonical_id":"hgnc:HGNC:16919","description":"vesicle amine transport 1","metadata":{"aliases":["VATI","FLJ20230"]}},{"id":"5e304b33ca86443cbb0b39faea74a6e2","type":"GENE","name":"VAT1L","canonical_id":"hgnc:HGNC:29315","description":"vesicle amine transport 1 like","metadata":{"aliases":["KIAA1576"]}},{"id":"d5a2c304eb2e4d80a19d23adf146bad5","type":"GENE","name":"VAV1","canonical_id":"hgnc:HGNC:12657","description":"vav guanine nucleotide exchange factor 1","metadata":{"aliases":["VAV"]}},{"id":"6cbc6867f5f04dfd8dfacfcf617d5854","type":"GENE","name":"VAV2","canonical_id":"hgnc:HGNC:12658","description":"vav guanine nucleotide exchange factor 2","metadata":null},{"id":"c53e2e3031504e768d040665a94f8c60","type":"GENE","name":"VAV3","canonical_id":"hgnc:HGNC:12659","description":"vav guanine nucleotide exchange factor 3","metadata":null},{"id":"cc468bab672b4fcc8281154f4aba9c9e","type":"GENE","name":"VAV3-AS1","canonical_id":"hgnc:HGNC:40608","description":"VAV3 antisense RNA 1","metadata":{"aliases":["LINC02785"]}},{"id":"1fdd8a19de8d4c14ba2aa3c059fcb570","type":"GENE","name":"VAX1","canonical_id":"hgnc:HGNC:12660","description":"ventral anterior homeobox 1","metadata":null},{"id":"6165a193189e4a87918ba49425662d36","type":"GENE","name":"VAX2","canonical_id":"hgnc:HGNC:12661","description":"ventral anterior homeobox 2","metadata":{"aliases":["DRES93"]}},{"id":"189b2a88fe904cf88c02a306a6cf5b5b","type":"GENE","name":"VBP1","canonical_id":"hgnc:HGNC:12662","description":"VHL binding protein 1","metadata":{"aliases":["PFD3","PFDN3"]}},{"id":"8f1fffe12ee9406c84ef4c81945f8db4","type":"GENE","name":"VCAM1","canonical_id":"hgnc:HGNC:12663","description":null,"metadata":null},{"id":"a409df72464c4c1995c03d9dce8d2eb8","type":"GENE","name":"VCAN","canonical_id":"hgnc:HGNC:2464","description":null,"metadata":null},{"id":"506c95e27ddb4743ba3a7eb67f30a375","type":"GENE","name":"VCAN-AS1","canonical_id":"hgnc:HGNC:40163","description":"VCAN antisense RNA 1","metadata":null},{"id":"efbf87d1b4244482a124602f88471a3a","type":"GO_TERM","name":"VCB complex","canonical_id":"go:GO:0030891","description":"\"A protein complex that possesses ubiquitin ligase activity; the complex is usually pentameric; for example, in mammals the subunits are pVHL, elongin B, elongin C, cullin-2 (Cul2), and Rbx1.\" [GOC:mah, PMID:11865071]","metadata":null},{"id":"3f5f9ca3dcd649d6825848df1a6ba5ec","type":"GENE","name":"VCF1","canonical_id":"hgnc:HGNC:25918","description":"VCP nuclear cofactor family member 1","metadata":{"aliases":["FLJ14775","FAM104A"]}},{"id":"50ce3517716141db9a299a8d913e3226","type":"GENE","name":"VCF2","canonical_id":"hgnc:HGNC:25085","description":"VCP nuclear cofactor family member 2","metadata":{"aliases":["FLJ20434","CXorf44","FAM104B"]}},{"id":"0bff86047c134c7ba181bd7e80718b61","type":"GENE","name":"VCL","canonical_id":"hgnc:HGNC:12665","description":"vinculin","metadata":{"aliases":["VINC"]}},{"id":"1bdf1ab8e90f4a4184ed87e9cd109fed","type":"GENE","name":"VCP","canonical_id":"hgnc:HGNC:12666","description":null,"metadata":null},{"id":"76cb777533f1449184123b28fb48b91b","type":"GO_TERM","name":"VCP-NPL4-UFD1 AAA ATPase complex","canonical_id":"go:GO:0034098","description":"\"A multiprotein ATPase complex required for the efficient dislocation of ER-lumenal degradation substrates, and their subsequent proteolysis by the proteasome. In budding yeast, this complex includes Cdc48p, Npl4p and Ufd1p proteins. In mammals, this complex includes a hexamer of VCP/p97 (a cytosolic ATPase) and trimers of each of its cofactors UFD1L and NPL4 (NPLOC4) (e.g. a 6:3:3 stoichiometry).\" [PMID:11813000, PMID:16179952]","metadata":null},{"id":"d803fc1e8e1849ddb0b7bd3dbfff4fd0","type":"GO_TERM","name":"VCP-NPL4-UFD1 AAA ATPase complex assembly","canonical_id":"go:GO:1904210","description":"\"The aggregation, arrangement and bonding together of a set of components to form a VCP-NPL4-UFD1 AAA ATPase complex.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:17000876]","metadata":null},{"id":"e5bb5dc27a754a3f84e9f9dc7c5ed304","type":"GO_TERM","name":"VCP-NSFL1C complex","canonical_id":"go:GO:1990730","description":"\"A protein complex between the ATPase VCP (p97) and its cofactor p47 (NSFL1C). In human, the protein complex consists of one homotrimer of NSFL1C/p47 per homohexamer of VCP/p97.\" [GOC:bf, GOC:PARL, PMID:9214505]","metadata":null},{"id":"1624c66b8fe44bda9086378786342470","type":"GENE","name":"VCPIP1","canonical_id":"hgnc:HGNC:30897","description":"valosin containing protein interacting protein 1","metadata":{"aliases":["VCIP135","KIAA1850","FLJ23132","DUBA3"]}},{"id":"ce603cb949c74140b6eea4a862d664dd","type":"GENE","name":"VCPKMT","canonical_id":"hgnc:HGNC:20352","description":"valosin containing protein lysine methyltransferase","metadata":{"aliases":["VCP-KMT","C14orf138","METTL21D"]}},{"id":"2227bf28f97748efb5c888332636cc0f","type":"GENE","name":"VCX","canonical_id":"hgnc:HGNC:12667","description":"variable charge X-linked","metadata":{"aliases":["VCX1","VCX10R","VCX-10r","VCX-B1"]}},{"id":"bc61ca8999ce406ebcd36f275a7c6b4f","type":"GENE","name":"VCX2","canonical_id":"hgnc:HGNC:18158","description":"variable charge X-linked 2","metadata":{"aliases":["VCX-2r","VCX-2R"]}},{"id":"b2a339f33fc84e419d3ba943ddc8c8cc","type":"GENE","name":"VCX3A","canonical_id":"hgnc:HGNC:18159","description":"variable charge X-linked 3A","metadata":{"aliases":["VCX-8r","VCX-8R","VCX-A","VCX3"]}},{"id":"501d46d7664f48f3b520a47d39f5ac66","type":"GENE","name":"VCX3B","canonical_id":"hgnc:HGNC:31838","description":"variable charge X-linked 3B","metadata":{"aliases":["VCX-C"]}},{"id":"7ae49919220b4cb290196e7c389cc2c7","type":"GENE","name":"VCY","canonical_id":"hgnc:HGNC:12668","description":"variable charge Y-linked","metadata":{"aliases":["BPY1","VCY1A","VCY1"]}},{"id":"743b1ed294274ac28392865a19287327","type":"GENE","name":"VCY1B","canonical_id":"hgnc:HGNC:31751","description":"variable charge Y-linked 1B","metadata":{"aliases":["BPY1B"]}},{"id":"9b36838125dd4b9eb3f14da928de1cfa","type":"GENE","name":"VDAC1","canonical_id":"hgnc:HGNC:12669","description":"voltage dependent anion channel 1","metadata":{"aliases":["MGC111064","PORIN"]}},{"id":"bb8c9a2dae0342b8bda4a779103fd21d","type":"GENE","name":"VDAC1-AS1","canonical_id":"hgnc:HGNC:59145","description":"VDAC1 antisense RNA 1","metadata":null},{"id":"a842e0ba4a5643c4ae980811e1113208","type":"GENE","name":"VDAC1P1","canonical_id":"hgnc:HGNC:12671","description":"voltage dependent anion channel 1 pseudogene 1","metadata":{"aliases":["VDAC1P"]}},{"id":"d83a1873a24d486587cb8948b8909d8b","type":"GENE","name":"VDAC1P10","canonical_id":"hgnc:HGNC:37479","description":"voltage dependent anion channel 1 pseudogene 10","metadata":null},{"id":"9106ee9571c442bba7f711a9f459da31","type":"GENE","name":"VDAC1P11","canonical_id":"hgnc:HGNC:37480","description":"voltage dependent anion channel 1 pseudogene 11","metadata":null},{"id":"d2baaab013f44124bf861e3a4e511b38","type":"GENE","name":"VDAC1P12","canonical_id":"hgnc:HGNC:39680","description":"voltage dependent anion channel 1 pseudogene 12","metadata":null},{"id":"0b709b1f0bdb48978424618a1761ca70","type":"GENE","name":"VDAC1P13","canonical_id":"hgnc:HGNC:50515","description":"voltage dependent anion channel 1 pseudogene 13","metadata":null},{"id":"ba1947f5246649d881b97663c2707dc0","type":"GENE","name":"VDAC1P2","canonical_id":"hgnc:HGNC:12670","description":"voltage dependent anion channel 1 pseudogene 2","metadata":{"aliases":["VDAC1LP"]}},{"id":"7873e541d38a4671bd0ee9b38865a419","type":"GENE","name":"VDAC1P3","canonical_id":"hgnc:HGNC:37478","description":"voltage dependent anion channel 1 pseudogene 3","metadata":null},{"id":"dbb70d169ce34842ae6a881e777497f6","type":"GENE","name":"VDAC1P4","canonical_id":"hgnc:HGNC:12675","description":"voltage dependent anion channel 1 pseudogene 4","metadata":{"aliases":["VDAC4","VDAC4P"]}},{"id":"866ea6fe29024cfca7465d8a8ea027e7","type":"GENE","name":"VDAC1P5","canonical_id":"hgnc:HGNC:12676","description":"voltage dependent anion channel 1 pseudogene 5","metadata":{"aliases":["VDAC3","VDAC5P"]}},{"id":"48c3882f8a82402e816f6cf27a869ead","type":"GENE","name":"VDAC1P6","canonical_id":"hgnc:HGNC:37481","description":"voltage dependent anion channel 1 pseudogene 6","metadata":null},{"id":"b4c525bfa4bd492381c52998af2a831d","type":"GENE","name":"VDAC1P7","canonical_id":"hgnc:HGNC:37482","description":"voltage dependent anion channel 1 pseudogene 7","metadata":null},{"id":"0c16011d5ce54df4ad0ffdb59cb80508","type":"GENE","name":"VDAC1P8","canonical_id":"hgnc:HGNC:37483","description":"voltage dependent anion channel 1 pseudogene 8","metadata":null},{"id":"5eedf971f95347c88e808cb2ce46dc95","type":"GENE","name":"VDAC1P9","canonical_id":"hgnc:HGNC:37484","description":"voltage dependent anion channel 1 pseudogene 9","metadata":null},{"id":"bafe8269d90b4d0db00a78b31b8cf9f9","type":"GENE","name":"VDAC2","canonical_id":"hgnc:HGNC:12672","description":"voltage dependent anion channel 2","metadata":null},{"id":"1a38262ee1b54c4d8f148705aaf3f85f","type":"GENE","name":"VDAC2P1","canonical_id":"hgnc:HGNC:12673","description":"VDAC2 pseudogene 1","metadata":{"aliases":["VDAC2P"]}},{"id":"6c8bd84827b34df9a986122b68b3f82a","type":"GENE","name":"VDAC2P2","canonical_id":"hgnc:HGNC:32693","description":"VDAC2 pseudogene 2","metadata":null},{"id":"af6196d8a1da46cead85e67dd2d5436c","type":"GENE","name":"VDAC2P3","canonical_id":"hgnc:HGNC:51931","description":"VDAC2 pseudogene 3","metadata":null},{"id":"834377cb5b37475b84abbc0fa7611a04","type":"GENE","name":"VDAC2P4","canonical_id":"hgnc:HGNC:51932","description":"VDAC2 pseudogene 4","metadata":null},{"id":"90060687bceb410db05237287801a463","type":"GENE","name":"VDAC2P5","canonical_id":"hgnc:HGNC:54753","description":"VDAC2 pseudogene 5","metadata":null},{"id":"cb4fd931de024b5a9b65c3fcda561b6b","type":"GENE","name":"VDAC3","canonical_id":"hgnc:HGNC:12674","description":"voltage dependent anion channel 3","metadata":{"aliases":["HD-VDAC3"]}},{"id":"a45217cc704546baa8172d68c2088eab","type":"GENE","name":"VDAC3P1","canonical_id":"hgnc:HGNC:20722","description":"voltage dependent anion channel 3 pseudogene 1","metadata":{"aliases":["VDAC3P"]}},{"id":"94faa5d8e9d34273b75442a35dab5d48","type":"GENE","name":"VDR","canonical_id":"hgnc:HGNC:12679","description":null,"metadata":null},{"id":"75d1479fc5d946aca19c5f5617a38e9c","type":"PROTEIN","name":"VDR","canonical_id":"uniprot:P11473","description":null,"metadata":null},{"id":"100b2c1d32904a64bed8d9bf1da225b2","type":"TRIAL","name":"VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer","canonical_id":"clinicaltrials.gov:NCT00407654","description":"Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer","metadata":null},{"id":"3d87f8cddc5342ab8b8f5345c7690655","type":"TRIAL","name":"VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide","canonical_id":"clinicaltrials.gov:NCT00369590","description":"Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor","metadata":null},{"id":"a9a189ea2a8b462e8dab4edd30338017","type":"TRIAL","name":"VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer","canonical_id":"clinicaltrials.gov:NCT00462826","description":"Recurrent Endometrial Carcinoma","metadata":null},{"id":"41b6c4f861a24f73ab81f223359a12ab","type":"GO_TERM","name":"VEGF-A complex","canonical_id":"go:GO:1990150","description":"\"A homodimeric, extracellular protein complex containing two VEGF-A monomers. Binds to and activates a receptor tyrosine kinase.\" [GOC:bf, GOC:bhm, PMID:12207021, PMID:19658168]","metadata":null},{"id":"b7d93bd0282749a791e9d833adfb052c","type":"GO_TERM","name":"VEGF-activated neuropilin signaling pathway","canonical_id":"go:GO:0038190","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to a neuropilin protein on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:rl, PMID:12852851]","metadata":null},{"id":"19efee2c77ad4fc082bd4e39c57943ea","type":"GO_TERM","name":"VEGF-activated platelet-derived growth factor receptor signaling pathway","canonical_id":"go:GO:0038086","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to a platelet-derived growth factor receptor (PDGFR) on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:17470632]","metadata":null},{"id":"791bfe7ac457455097b73af45cde7b8e","type":"GO_TERM","name":"VEGF-activated platelet-derived growth factor receptor-alpha signaling pathway","canonical_id":"go:GO:0038087","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to an alpha-type platelet-derived growth factor receptor (PDGFR) on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:17470632]","metadata":null},{"id":"2cd6eb69f768463992587b377a7551cc","type":"GO_TERM","name":"VEGF-activated platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:0038088","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to a beta-type platelet-derived growth factor receptor (PDGFR) on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:17470632]","metadata":null},{"id":"e4d9daed608945a2b7ecec1152580c0b","type":"GENE","name":"VEGFA","canonical_id":"hgnc:HGNC:12680","description":null,"metadata":null},{"id":"a4043cdeb6cc43eaa5bd42473c55537f","type":"PROTEIN","name":"VEGFA","canonical_id":"uniprot:P15692","description":null,"metadata":null},{"id":"e6351b682b5f4aa98e4c2e47f06d6c69","type":"GENE","name":"VEGFA","canonical_id":"ensembl:ENSG00000112715","description":null,"metadata":null},{"id":"d1c39685926b475685176cd0b3d1480a","type":"GENE","name":"VEGFB","canonical_id":"hgnc:HGNC:12681","description":null,"metadata":null},{"id":"7d5b9390d9a449d881c685bcb358802d","type":"GENE","name":"VEGFC","canonical_id":"hgnc:HGNC:12682","description":null,"metadata":null},{"id":"7bb97fa379ce40829605ce037f868607","type":"GENE","name":"VEGFD","canonical_id":"hgnc:HGNC:3708","description":null,"metadata":null},{"id":"d3cf931265c64f3cae75e658ab2f9a58","type":"GENE","name":"VENTX","canonical_id":"hgnc:HGNC:13639","description":"VENT homeobox","metadata":{"aliases":["HPX42B","VENTX2"]}},{"id":"d5ddfb2d8fd54a1094bc527a217b62b6","type":"GENE","name":"VENTXP1","canonical_id":"hgnc:HGNC:30900","description":"VENT homeobox pseudogene 1","metadata":{"aliases":["NA88A","CT18"]}},{"id":"27236270eaee43389ad25bad2f1c2462","type":"GENE","name":"VENTXP2","canonical_id":"hgnc:HGNC:30901","description":"VENT homeobox pseudogene 2","metadata":null},{"id":"5fad7308cbe646e29602a89f3d8e8fde","type":"GENE","name":"VENTXP3","canonical_id":"hgnc:HGNC:30902","description":"VENT homeobox pseudogene 3","metadata":null},{"id":"4bbbe80faff04e119897df060df0ce14","type":"GENE","name":"VENTXP4","canonical_id":"hgnc:HGNC:30903","description":"VENT homeobox pseudogene 4","metadata":null},{"id":"5e266cef9efc45948ac8bb360bc5404e","type":"GENE","name":"VENTXP5","canonical_id":"hgnc:HGNC:32214","description":"VENT homeobox pseudogene 5","metadata":null},{"id":"12710498e3f14e9dba5c769d740a6ee2","type":"GENE","name":"VENTXP6","canonical_id":"hgnc:HGNC:32216","description":"VENT homeobox pseudogene 6","metadata":null},{"id":"b14eb85948ec4375a40b28c74ea62843","type":"GENE","name":"VENTXP7","canonical_id":"hgnc:HGNC:13638","description":"VENT homeobox pseudogene 7","metadata":{"aliases":["HPX42","VENTX1"]}},{"id":"aade4666740b44fab13c349e1bc05872","type":"GENE","name":"VENTXP8","canonical_id":"hgnc:HGNC:54910","description":"VENTX pseudogene 8","metadata":null},{"id":"14235963a1d74bb2930a79122d0f87a7","type":"GENE","name":"VEPH1","canonical_id":"hgnc:HGNC:25735","description":"ventricular zone expressed PH domain containing 1","metadata":{"aliases":["FLJ12604","KIAA1692"]}},{"id":"a199afa57b9948a69aa7b49e16d88a06","type":"GENE","name":"VESTAR","canonical_id":"hgnc:HGNC:28325","description":"VEGFC mRNA stability associated lncRNA","metadata":{"aliases":["MGC23270","LINC00638"]}},{"id":"97cbe80c54734b219cbcb8c84b0afcc1","type":"GENE","name":"VEZF1","canonical_id":"hgnc:HGNC:12949","description":null,"metadata":null},{"id":"26ccde70cf1a47f081cf9b448ef5d6c4","type":"GENE","name":"VEZF1P1","canonical_id":"hgnc:HGNC:32320","description":"vascular endothelial zinc finger 1 pseudogene 1","metadata":{"aliases":["ZNF161L1","VEZF1L1"]}},{"id":"afd17b3f570b488ab7980c088bf2b939","type":"GENE","name":"VEZT","canonical_id":"hgnc:HGNC:18258","description":"vezatin, adherens junctions transmembrane protein","metadata":{"aliases":["DKFZP761C241"]}},{"id":"09fab378a81847238cc61f36d6f3d1d4","type":"GENE","name":"VEZTP1","canonical_id":"hgnc:HGNC:54949","description":"VEZT pseudogene 1","metadata":null},{"id":"259b074f2e9a4c549324288e072313c3","type":"GENE","name":"VGF","canonical_id":"hgnc:HGNC:12684","description":null,"metadata":null},{"id":"e4f75149d36b41628b7f1f17224930ce","type":"GENE","name":"VGLL1","canonical_id":"hgnc:HGNC:20985","description":"vestigial like family member 1","metadata":{"aliases":["TONDU","TDU"]}},{"id":"5a99a5f5157946668ed8521844292875","type":"GENE","name":"VGLL2","canonical_id":"hgnc:HGNC:20232","description":"vestigial like family member 2","metadata":null},{"id":"63a89982e839430fa8bc8ca2e2b3340d","type":"GENE","name":"VGLL3","canonical_id":"hgnc:HGNC:24327","description":"vestigial like family member 3","metadata":{"aliases":["VGL-3"]}},{"id":"5709e5df8e62415fbc7935f2b86bddb2","type":"GENE","name":"VGLL4","canonical_id":"hgnc:HGNC:28966","description":"vestigial like family member 4","metadata":{"aliases":["KIAA0121"]}},{"id":"0657cefacf9349acb6ebea20273f93c8","type":"GENE","name":"VHL","canonical_id":"hgnc:HGNC:12687","description":null,"metadata":null},{"id":"65f81cb885ee449d91d3962bb218efe7","type":"GENE","name":"VHLL","canonical_id":"hgnc:HGNC:30666","description":"VHL like","metadata":{"aliases":["VLP","VHLP"]}},{"id":"e0fea106cf5240dbb04a1d8d03c7b68e","type":"GENE","name":"VHRT","canonical_id":"hgnc:HGNC:50688","description":"ventricular heart development associated lncRNA","metadata":{"aliases":["MASCC1","RP1-46F2.2","LINC01405"]}},{"id":"e9cc8fdf1ed94716b0e4382855add2e1","type":"TRIAL","name":"VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa","canonical_id":"clinicaltrials.gov:NCT04772547","description":"Status Epilepticus, Electrographic; Coma","metadata":null},{"id":"568fbbe10ded47e9894257ea8bc92934","type":"GENE","name":"VIL1","canonical_id":"hgnc:HGNC:12690","description":"villin 1","metadata":{"aliases":["D2S1471","VIL"]}},{"id":"ffd77a13fbdd48d39dc7beffe3a9685c","type":"GENE","name":"VILL","canonical_id":"hgnc:HGNC:30906","description":"villin like","metadata":null},{"id":"20465c6b634b4886bc3553073da62841","type":"GENE","name":"VILMIR","canonical_id":"hgnc:HGNC:56888","description":"virus inducible lncRNA modulator of interferon response","metadata":null},{"id":"4d49318f5be54af2b8180a5e585d9ebd","type":"GENE","name":"VIM","canonical_id":"hgnc:HGNC:12692","description":null,"metadata":null},{"id":"3d9187f1f49f40a0a7e9ca169ab8e7c4","type":"GENE","name":"VIM-AS1","canonical_id":"hgnc:HGNC:44879","description":"VIM antisense RNA 1","metadata":null},{"id":"344a2c0d7ce64869ab40d0ff3c5122b0","type":"GENE","name":"VIM-AS2","canonical_id":"hgnc:HGNC:59259","description":"VIM antisense RNA 2","metadata":{"aliases":["AL133415.1","lncTRDMT1\u20135"]}},{"id":"01982f780c194278b610419be8998220","type":"GENE","name":"VIM2P","canonical_id":"hgnc:HGNC:43891","description":"vimentin 2, pseudogene","metadata":{"aliases":["lncRNA-CIR","RP11-162L10.1","VIM2","CIR","VIMP1"]}},{"id":"a32cb37f63884a2c86873eb58bd6be87","type":"GENE","name":"VINAC1P","canonical_id":"hgnc:HGNC:53736","description":"vinculin/alpha-catenin family member 1, pseudogene","metadata":null},{"id":"4e7b9bdcaf2644f9bb5e6c85d36a0df8","type":"GENE","name":"VIP","canonical_id":"hgnc:HGNC:12693","description":null,"metadata":null},{"id":"51b0e1b950354b168b109745dede43e1","type":"GENE","name":"VIPAS39","canonical_id":"hgnc:HGNC:20347","description":"VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 homolog","metadata":{"aliases":["VIPAR","VPS16B","SPE-39","SPE39","hSPE-39","C14orf133"]}},{"id":"036ffa2a45f048e3a801e96f63050232","type":"GENE","name":"VIPR1","canonical_id":"hgnc:HGNC:12694","description":"vasoactive intestinal peptide receptor 1","metadata":{"aliases":["VPAC1","RDC1","HVR1","VPAC1R"]}},{"id":"d0d377b84bb7458db91eb22f9a4ad668","type":"GENE","name":"VIPR1-AS1","canonical_id":"hgnc:HGNC:40610","description":"VIPR1 antisense RNA 1","metadata":null},{"id":"2f7b45d215e74b019ad505ceee2313ad","type":"GENE","name":"VIPR2","canonical_id":"hgnc:HGNC:12695","description":"vasoactive intestinal peptide receptor 2","metadata":{"aliases":["VPAC2","VPAC2R"]}},{"id":"c25caa7686674e20a7f70db0826a2ba4","type":"GENE","name":"VIRMA","canonical_id":"hgnc:HGNC:24500","description":"vir like m6A methyltransferase associated","metadata":{"aliases":["DKFZP434I116","fSAP121","KIAA1429"]}},{"id":"3d5b1ca667d74665be6a7edde19f4660","type":"GENE","name":"VIRMA-DT","canonical_id":"hgnc:HGNC:55531","description":"VIRMA divergent transcript","metadata":null},{"id":"e4bb60e6df3649a59e71a8a30f64d8fd","type":"GENE","name":"VIS1","canonical_id":"hgnc:HGNC:12696","description":"viral integration site 1","metadata":{"aliases":["HIS1","HIS-1"]}},{"id":"37bba9f9723f415c93db4b8a66c33d24","type":"TRIAL","name":"VISmodegib for ORbital and Periocular Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT02436408","description":"Carcinoma, Basal Cell","metadata":null},{"id":"491095cd152a4f1b97f437e13a09a86d","type":"GENE","name":"VIT","canonical_id":"hgnc:HGNC:12697","description":"vitrin","metadata":null},{"id":"23e880b12fc344dbb275069f09b2e0b6","type":"GENE","name":"VKORC1","canonical_id":"hgnc:HGNC:23663","description":"vitamin K epoxide reductase complex subunit 1","metadata":{"aliases":["VKCFD2"]}},{"id":"bef799efa9a94c1f8d65501d93b9d890","type":"PROTEIN","name":"VKORC1","canonical_id":"uniprot:Q9BQB6","description":null,"metadata":null},{"id":"f7b122dd46584b7fa1b919773e7bda32","type":"GENE","name":"VKORC1L1","canonical_id":"hgnc:HGNC:21492","description":"vitamin K epoxide reductase complex subunit 1L1","metadata":null},{"id":"b081c7dbe1114379b17b4d1fadd3b69d","type":"GENE","name":"VKORC1P1","canonical_id":"hgnc:HGNC:33182","description":"VKORC1 pseudogene 1","metadata":null},{"id":"28754b99133643cda0e7353bfeb3a213","type":"GENE","name":"VKORC1P2","canonical_id":"hgnc:HGNC:33183","description":"VKORC1 pseudogene 2","metadata":null},{"id":"72b7b3b61aa0438c9b6f4da95bc07a42","type":"GENE","name":"VLDLR","canonical_id":"hgnc:HGNC:12698","description":null,"metadata":null},{"id":"ba7c79520e634f0184cf8f013cf5768a","type":"GENE","name":"VLDLR-AS1","canonical_id":"hgnc:HGNC:49621","description":"VLDLR antisense RNA 1","metadata":{"aliases":["lincRNA-VLDLR"]}},{"id":"654f9e76fd2c42beb1c8c1a91720838b","type":"GENE","name":"VMA12","canonical_id":"hgnc:HGNC:18085","description":"vacuolar ATPase assembly factor VMA12","metadata":{"aliases":["VPH2","MGC45714","TMEM199","C17orf32"]}},{"id":"90da6d43e8e3474f9decc9e9da0ee3e8","type":"GENE","name":"VMA21","canonical_id":"hgnc:HGNC:22082","description":"vacuolar ATPase assembly factor VMA21","metadata":{"aliases":["XMEA","MEAX"]}},{"id":"58500ecf847646049582e36517ba1f62","type":"GENE","name":"VMA22","canonical_id":"hgnc:HGNC:28178","description":"vacuolar ATPase assembly factor VMA22","metadata":{"aliases":["MGC12981","FLJ30131","ccp1","CCDC115"]}},{"id":"bb873a0bb5d74c04902d84c00a81a6ec","type":"GENE","name":"VMAC","canonical_id":"hgnc:HGNC:33803","description":"vimentin type intermediate filament associated coiled-coil protein","metadata":null},{"id":"f46cd4ead32f4b5ba03ba36e4c4938e1","type":"GENE","name":"VMO1","canonical_id":"hgnc:HGNC:30387","description":"vitelline membrane outer layer 1 homolog","metadata":null},{"id":"500b85bb8451467488b69ce2ccf849fd","type":"GENE","name":"VMP1","canonical_id":"hgnc:HGNC:29559","description":null,"metadata":null},{"id":"8662c0f3381d4666bc5964508588ed44","type":"GENE","name":"VN1R1","canonical_id":"hgnc:HGNC:13548","description":"vomeronasal 1 receptor 1","metadata":{"aliases":["V1RL1","ZVNR1","ZVNH1","VNR19I1"]}},{"id":"867ba110cdc14bff85ded129c807c7ff","type":"GENE","name":"VN1R100P","canonical_id":"hgnc:HGNC:37420","description":"vomeronasal 1 receptor 100 pseudogene","metadata":null},{"id":"6ae7671a295b4ccbba34c61e547fef2f","type":"GENE","name":"VN1R101P","canonical_id":"hgnc:HGNC:37424","description":"vomeronasal 1 receptor 101 pseudogene","metadata":null},{"id":"1b048296b7744dd9be26d3920d4469aa","type":"GENE","name":"VN1R102P","canonical_id":"hgnc:HGNC:37425","description":"vomeronasal 1 receptor 102 pseudogene","metadata":null},{"id":"eb5c1e8b59ec4776bacc7c40802556d7","type":"GENE","name":"VN1R103P","canonical_id":"hgnc:HGNC:37426","description":"vomeronasal 1 receptor 103 pseudogene","metadata":null},{"id":"67ca4620716e451280af839f413b9e80","type":"GENE","name":"VN1R104P","canonical_id":"hgnc:HGNC:37427","description":"vomeronasal 1 receptor 104 pseudogene","metadata":null},{"id":"7c40090cd33449aa8347706af16fdaf6","type":"GENE","name":"VN1R105P","canonical_id":"hgnc:HGNC:37428","description":"vomeronasal 1 receptor 105 pseudogene","metadata":null},{"id":"7c579c685b0e4e3d88cd6096ff72504b","type":"GENE","name":"VN1R106P","canonical_id":"hgnc:HGNC:37429","description":"vomeronasal 1 receptor 106 pseudogene","metadata":null},{"id":"9b2217ff4b6847f49aec650cf84c5019","type":"GENE","name":"VN1R107P","canonical_id":"hgnc:HGNC:37431","description":"vomeronasal 1 receptor 107 pseudogene","metadata":null},{"id":"ae3c41a3250e45d39a9c982cde7d5b18","type":"GENE","name":"VN1R108P","canonical_id":"hgnc:HGNC:37432","description":"vomeronasal 1 receptor 108 pseudogene","metadata":null},{"id":"751934f06c9e4bdda294a9445caaada9","type":"GENE","name":"VN1R109P","canonical_id":"hgnc:HGNC:37434","description":"vomeronasal 1 receptor 109 pseudogene","metadata":null},{"id":"e0574230a81d411f905126b968cab249","type":"GENE","name":"VN1R10P","canonical_id":"hgnc:HGNC:13550","description":"vomeronasal 1 receptor 10, pseudogene","metadata":{"aliases":["hs6V1-1p","b24o18.2","VNR6I1P"]}},{"id":"7c531d0b8c5b4d74862725a8ffec3c05","type":"GENE","name":"VN1R110P","canonical_id":"hgnc:HGNC:37438","description":"vomeronasal 1 receptor 110 pseudogene","metadata":null},{"id":"974257df6d994e97ad4961346f51858b","type":"GENE","name":"VN1R111P","canonical_id":"hgnc:HGNC:37332","description":"vomeronasal 1 receptor 111 pseudogene","metadata":null},{"id":"035bc188862044638f1e4bde8a9d7d08","type":"GENE","name":"VN1R112P","canonical_id":"hgnc:HGNC:37437","description":"vomeronasal 1 receptor 112 pseudogene","metadata":null},{"id":"11e7c42f17e34401a3a2d70441639a9b","type":"GENE","name":"VN1R11P","canonical_id":"hgnc:HGNC:13551","description":"vomeronasal 1 receptor 11, pseudogene","metadata":{"aliases":["dJ86C11.7","hs6V1-2p","VNR6I2P"]}},{"id":"e8291113aed5443895b253691f13761d","type":"GENE","name":"VN1R12P","canonical_id":"hgnc:HGNC:18722","description":"vomeronasal 1 receptor 12, pseudogene","metadata":{"aliases":["VNR6I3P","bA373D17.2","hs6V1-3p"]}},{"id":"a328730432c74b93ab10ac3af1de3c01","type":"GENE","name":"VN1R13P","canonical_id":"hgnc:HGNC:18723","description":"vomeronasal 1 receptor 13 pseudogene","metadata":{"aliases":["bA373D17.3","hs6V1-4p","VNR6I4P"]}},{"id":"bf7bcd97523e4d1ea973460b4e0ad874","type":"GENE","name":"VN1R14P","canonical_id":"hgnc:HGNC:18721","description":"vomeronasal 1 receptor 14 pseudogene","metadata":{"aliases":["bA457M11.4","hs6M1-5p","VNR6I5P"]}},{"id":"acbeceac0a4346c08435b4ee7494895d","type":"GENE","name":"VN1R15P","canonical_id":"hgnc:HGNC:37327","description":"vomeronasal 1 receptor 15 pseudogene","metadata":null},{"id":"1e61731f8c344f34a770277e6e0ed5a5","type":"GENE","name":"VN1R16P","canonical_id":"hgnc:HGNC:37330","description":"vomeronasal 1 receptor 16 pseudogene","metadata":null},{"id":"e4bee6f044814de6860c10cc6befdedf","type":"GENE","name":"VN1R17P","canonical_id":"hgnc:HGNC:37331","description":"vomeronasal 1 receptor 17 pseudogene","metadata":null},{"id":"3b6f5ccda2ca4c74a50bb56f75a61bcf","type":"GENE","name":"VN1R18P","canonical_id":"hgnc:HGNC:37334","description":"vomeronasal 1 receptor 18 pseudogene","metadata":null},{"id":"bcd835dea03c4def9f4f1ee753c9172b","type":"GENE","name":"VN1R19P","canonical_id":"hgnc:HGNC:37328","description":"vomeronasal 1 receptor 19 pseudogene","metadata":null},{"id":"209db005474c4586acdfe8157f477333","type":"GENE","name":"VN1R2","canonical_id":"hgnc:HGNC:19872","description":"vomeronasal 1 receptor 2","metadata":{"aliases":["V1RL2"]}},{"id":"275b72d03a104716a7c9ac77d1172c38","type":"GENE","name":"VN1R20P","canonical_id":"hgnc:HGNC:37335","description":"vomeronasal 1 receptor 20 pseudogene","metadata":null},{"id":"4c13aa9fc3174bc0a24cb2f007e47ab0","type":"GENE","name":"VN1R21P","canonical_id":"hgnc:HGNC:37336","description":"vomeronasal 1 receptor 21 pseudogene","metadata":null},{"id":"53831b6adb82484b886963a2386c9ce4","type":"GENE","name":"VN1R22P","canonical_id":"hgnc:HGNC:37337","description":"vomeronasal 1 receptor 22 pseudogene","metadata":null},{"id":"7ac0f3e8da4d47f89c91e5301d0abfe5","type":"GENE","name":"VN1R23P","canonical_id":"hgnc:HGNC:37338","description":"vomeronasal 1 receptor 23 pseudogene","metadata":null},{"id":"4aa10b9c59784afc9f3757bd245a0231","type":"GENE","name":"VN1R24P","canonical_id":"hgnc:HGNC:37344","description":"vomeronasal 1 receptor 24 pseudogene","metadata":null},{"id":"57ac0020baf0472ab23dd394fe6f4c1b","type":"GENE","name":"VN1R25P","canonical_id":"hgnc:HGNC:37345","description":"vomeronasal 1 receptor 25 pseudogene","metadata":null},{"id":"17d88c8766f84bea868a2309367d0ada","type":"GENE","name":"VN1R26P","canonical_id":"hgnc:HGNC:37346","description":"vomeronasal 1 receptor 26 pseudogene","metadata":null},{"id":"65e0c1e182744ef0a6ad97e5469b90b8","type":"GENE","name":"VN1R27P","canonical_id":"hgnc:HGNC:37347","description":"vomeronasal 1 receptor 27 pseudogene","metadata":null},{"id":"32d59215b54540b5b0835f4219da8719","type":"GENE","name":"VN1R28P","canonical_id":"hgnc:HGNC:37348","description":"vomeronasal 1 receptor 28 pseudogene","metadata":null},{"id":"6587cf20c4c54fa1b9626bacb7dc120a","type":"GENE","name":"VN1R29P","canonical_id":"hgnc:HGNC:37349","description":"vomeronasal 1 receptor 29 pseudogene","metadata":null},{"id":"b7228e0393d24cfd98ffe089dc6fbef9","type":"GENE","name":"VN1R3","canonical_id":"hgnc:HGNC:19867","description":"vomeronasal 1 receptor 3","metadata":{"aliases":["V1RL3","FKSG46"]}},{"id":"f83d080b766a452498ef15bbd3b470a3","type":"GENE","name":"VN1R30P","canonical_id":"hgnc:HGNC:37350","description":"vomeronasal 1 receptor 30 pseudogene","metadata":null},{"id":"dec0f17dd8dc40aa83a0c50bc4a0fd45","type":"GENE","name":"VN1R31P","canonical_id":"hgnc:HGNC:37351","description":"vomeronasal 1 receptor 31 pseudogene","metadata":null},{"id":"7e186783a8bb40edaad89e570e7d7ee3","type":"GENE","name":"VN1R32P","canonical_id":"hgnc:HGNC:37352","description":"vomeronasal 1 receptor 32 pseudogene","metadata":null},{"id":"e56dba26083041cebaaa935370875b03","type":"GENE","name":"VN1R33P","canonical_id":"hgnc:HGNC:37353","description":"vomeronasal 1 receptor 33 pseudogene","metadata":null},{"id":"aa89dedb18ea41d0a7a36d874f6f02e6","type":"GENE","name":"VN1R34P","canonical_id":"hgnc:HGNC:37354","description":"vomeronasal 1 receptor 34 pseudogene","metadata":null},{"id":"cd52baf88f6d46fc88a6f4fcd47d5598","type":"GENE","name":"VN1R35P","canonical_id":"hgnc:HGNC:37355","description":"vomeronasal 1 receptor 35 pseudogene","metadata":null},{"id":"863127af398a438c8908d61f38498931","type":"GENE","name":"VN1R36P","canonical_id":"hgnc:HGNC:37356","description":"vomeronasal 1 receptor 36 pseudogene","metadata":null},{"id":"89a4c9cb643146cea2920e439d4824f8","type":"GENE","name":"VN1R37P","canonical_id":"hgnc:HGNC:37357","description":"vomeronasal 1 receptor 37 pseudogene","metadata":null},{"id":"5d4c8811568a4d86aec4cc698c9480cf","type":"GENE","name":"VN1R38P","canonical_id":"hgnc:HGNC:37358","description":"vomeronasal 1 receptor 38 pseudogene","metadata":null},{"id":"ba4e3d554e344b8f8b9508eb246e9cec","type":"GENE","name":"VN1R39P","canonical_id":"hgnc:HGNC:37359","description":"vomeronasal 1 receptor 39 pseudogene","metadata":null},{"id":"ce38b2c5b30a40309f5b4d3ce1e71a0d","type":"GENE","name":"VN1R4","canonical_id":"hgnc:HGNC:19871","description":"vomeronasal 1 receptor 4","metadata":{"aliases":["V1RL4"]}},{"id":"6f9d82678c3c43cdb2188e87e412aab2","type":"GENE","name":"VN1R40P","canonical_id":"hgnc:HGNC:37360","description":"vomeronasal 1 receptor 40 pseudogene","metadata":null},{"id":"8a3c7212849143b3a1319dc4be94efc3","type":"GENE","name":"VN1R41P","canonical_id":"hgnc:HGNC:37361","description":"vomeronasal 1 receptor 41 pseudogene","metadata":null},{"id":"2eb9fe9f4f044589adb959962c76ae2d","type":"GENE","name":"VN1R42P","canonical_id":"hgnc:HGNC:37362","description":"vomeronasal 1 receptor 42 pseudogene","metadata":null},{"id":"25517b82de364785bce7cf5b49cf3a72","type":"GENE","name":"VN1R43P","canonical_id":"hgnc:HGNC:37363","description":"vomeronasal 1 receptor 43 pseudogene","metadata":null},{"id":"ba971ae8e5784a14822ba74ca7d3b6c5","type":"GENE","name":"VN1R44P","canonical_id":"hgnc:HGNC:37364","description":"vomeronasal 1 receptor 44 pseudogene","metadata":null},{"id":"6556211001224bae97a010f864c707d9","type":"GENE","name":"VN1R45P","canonical_id":"hgnc:HGNC:37365","description":"vomeronasal 1 receptor 45 pseudogene","metadata":null},{"id":"9d3fa3990520471fbf825c940b9c7c27","type":"GENE","name":"VN1R46P","canonical_id":"hgnc:HGNC:37366","description":"vomeronasal 1 receptor 46 pseudogene","metadata":null},{"id":"18f695ed23ec4f399e3cc6939fb7de30","type":"GENE","name":"VN1R47P","canonical_id":"hgnc:HGNC:37367","description":"vomeronasal 1 receptor 47 pseudogene","metadata":null},{"id":"55294a1413ea4f8c968b2f3b16f22f7d","type":"GENE","name":"VN1R48P","canonical_id":"hgnc:HGNC:37368","description":"vomeronasal 1 receptor 48 pseudogene","metadata":null},{"id":"194f566e7044455daa9d9d47b9666aa9","type":"GENE","name":"VN1R49P","canonical_id":"hgnc:HGNC:37369","description":"vomeronasal 1 receptor 49 pseudogene","metadata":{"aliases":["VN1R50P"]}},{"id":"5ed8847138fb4fb1be56598b92c0d6e1","type":"GENE","name":"VN1R5","canonical_id":"hgnc:HGNC:19870","description":"vomeronasal 1 receptor 5 (gene/pseudogene)","metadata":{"aliases":["V1RL5"]}},{"id":"e199e60e902845638cf02644fe8cafbb","type":"GENE","name":"VN1R51P","canonical_id":"hgnc:HGNC:37371","description":"vomeronasal 1 receptor 51 pseudogene","metadata":null},{"id":"131843601ec644eca81c48c74745be91","type":"GENE","name":"VN1R52P","canonical_id":"hgnc:HGNC:37372","description":"vomeronasal 1 receptor 52 pseudogene","metadata":null},{"id":"3a435f29c9e4486e8090acb24532971a","type":"GENE","name":"VN1R53P","canonical_id":"hgnc:HGNC:37373","description":"vomeronasal 1 receptor 53 pseudogene","metadata":null},{"id":"9d2a0c9b69f64d14a281d7e901a41455","type":"GENE","name":"VN1R54P","canonical_id":"hgnc:HGNC:37374","description":"vomeronasal 1 receptor 54 pseudogene","metadata":null},{"id":"eab00bcc8e824a43800ecc7199ffe9c3","type":"GENE","name":"VN1R55P","canonical_id":"hgnc:HGNC:37375","description":"vomeronasal 1 receptor 55 pseudogene","metadata":null},{"id":"388ca4b9819b4c2eb237172d8fd98d4e","type":"GENE","name":"VN1R56P","canonical_id":"hgnc:HGNC:37376","description":"vomeronasal 1 receptor 56 pseudogene","metadata":null},{"id":"2a9750bc233748cfbf225250c389ea73","type":"GENE","name":"VN1R57P","canonical_id":"hgnc:HGNC:37377","description":"vomeronasal 1 receptor 57 pseudogene","metadata":null},{"id":"129a057aca524451ae723e62e42bb951","type":"GENE","name":"VN1R58P","canonical_id":"hgnc:HGNC:37378","description":"vomeronasal 1 receptor 58 pseudogene","metadata":null},{"id":"38c39c365ac2429c901409998138807c","type":"GENE","name":"VN1R59P","canonical_id":"hgnc:HGNC:37379","description":"vomeronasal 1 receptor 59 pseudogene","metadata":null},{"id":"1195018705bc4a7a9b6db6b52d323726","type":"GENE","name":"VN1R60P","canonical_id":"hgnc:HGNC:37380","description":"vomeronasal 1 receptor 60 pseudogene","metadata":null},{"id":"b9980d523c4a42dd90c777c9b5c3b5dc","type":"GENE","name":"VN1R61P","canonical_id":"hgnc:HGNC:37381","description":"vomeronasal 1 receptor 61 pseudogene","metadata":null},{"id":"4c1a6bdd36064ae4b87353ac3badf023","type":"GENE","name":"VN1R62P","canonical_id":"hgnc:HGNC:37382","description":"vomeronasal 1 receptor 62 pseudogene","metadata":null},{"id":"a85ac756ea3849e7947fbac669e69c46","type":"GENE","name":"VN1R63P","canonical_id":"hgnc:HGNC:37383","description":"vomeronasal 1 receptor 63 pseudogene","metadata":null},{"id":"e4db01e599164b6985d8c99402bffbc3","type":"GENE","name":"VN1R64P","canonical_id":"hgnc:HGNC:37384","description":"vomeronasal 1 receptor 64 pseudogene","metadata":null},{"id":"5f14051605944484ba9deabc1dec8137","type":"GENE","name":"VN1R65P","canonical_id":"hgnc:HGNC:37385","description":"vomeronasal 1 receptor 65 pseudogene","metadata":null},{"id":"6fcb456f15954d0cb221dbd910a03381","type":"GENE","name":"VN1R66P","canonical_id":"hgnc:HGNC:37386","description":"vomeronasal 1 receptor 66 pseudogene","metadata":null},{"id":"e47bb113132b45cbaacacb64fa99f525","type":"GENE","name":"VN1R67P","canonical_id":"hgnc:HGNC:37387","description":"vomeronasal 1 receptor 67 pseudogene","metadata":null},{"id":"fda6f71058fa4984a048521ea7f36c0a","type":"GENE","name":"VN1R68P","canonical_id":"hgnc:HGNC:37389","description":"vomeronasal 1 receptor 68 pseudogene","metadata":null},{"id":"e96a9ee56ba34114807361b1006e0e59","type":"GENE","name":"VN1R69P","canonical_id":"hgnc:HGNC:37390","description":"vomeronasal 1 receptor 69 pseudogene","metadata":null},{"id":"f1b75a1a4dd1401aa3cd1e9384b71260","type":"GENE","name":"VN1R6P","canonical_id":"hgnc:HGNC:13712","description":"vomeronasal 1 receptor 6, pseudogene","metadata":{"aliases":["ZVNR2","ZVNH2","VNR19I2"]}},{"id":"cb7e56a8b9fa4d938e1ceb868863589b","type":"GENE","name":"VN1R70P","canonical_id":"hgnc:HGNC:37391","description":"vomeronasal 1 receptor 70 pseudogene","metadata":null},{"id":"b60304569efb487dbbe5ce7b4727567b","type":"GENE","name":"VN1R71P","canonical_id":"hgnc:HGNC:37392","description":"vomeronasal 1 receptor 71 pseudogene","metadata":null},{"id":"1d586efa00914b5ea76e0d8747cc53cb","type":"GENE","name":"VN1R72P","canonical_id":"hgnc:HGNC:37393","description":"vomeronasal 1 receptor 72 pseudogene","metadata":null},{"id":"04ddf9b036054eeb8c66ce7edabc9ef9","type":"GENE","name":"VN1R73P","canonical_id":"hgnc:HGNC:37394","description":"vomeronasal 1 receptor 73 pseudogene","metadata":null},{"id":"90640d1fac6e42c79d845a381a08f9e8","type":"GENE","name":"VN1R74P","canonical_id":"hgnc:HGNC:37395","description":"vomeronasal 1 receptor 74 pseudogene","metadata":null},{"id":"7a1b824213c84201af72c4a10af8bd02","type":"GENE","name":"VN1R75P","canonical_id":"hgnc:HGNC:37396","description":"vomeronasal 1 receptor 75 pseudogene","metadata":null},{"id":"56365ccfdfea4fa3b2f8c60956f1663e","type":"GENE","name":"VN1R76P","canonical_id":"hgnc:HGNC:37397","description":"vomeronasal 1 receptor 76 pseudogene","metadata":null},{"id":"f7deada4b7f042cd9a477d5fb1eff74f","type":"GENE","name":"VN1R77P","canonical_id":"hgnc:HGNC:37398","description":"vomeronasal 1 receptor 77 pseudogene","metadata":null},{"id":"81ea0ec9f8e84128a4587b8682c2ead9","type":"GENE","name":"VN1R78P","canonical_id":"hgnc:HGNC:37399","description":"vomeronasal 1 receptor 78 pseudogene","metadata":null},{"id":"13d0bded9834408988fdeb42f54cebfe","type":"GENE","name":"VN1R79P","canonical_id":"hgnc:HGNC:37400","description":"vomeronasal 1 receptor 79 pseudogene","metadata":null},{"id":"ec37af93f52f4e8994e0b19bc2dc4194","type":"GENE","name":"VN1R7P","canonical_id":"hgnc:HGNC:8496","description":"vomeronasal 1 receptor 7, pseudogene","metadata":{"aliases":["ORLP1"]}},{"id":"a8a681d93c8a4a20a79dd3503dad8dc8","type":"GENE","name":"VN1R80P","canonical_id":"hgnc:HGNC:37329","description":"vomeronasal 1 receptor 80 pseudogene","metadata":null},{"id":"258803d2be394081af627e0014362c35","type":"GENE","name":"VN1R81P","canonical_id":"hgnc:HGNC:37401","description":"vomeronasal 1 receptor 81 pseudogene","metadata":null},{"id":"ce1be91019894a0c8dccf60df8b7686a","type":"GENE","name":"VN1R82P","canonical_id":"hgnc:HGNC:37402","description":"vomeronasal 1 receptor 82 pseudogene","metadata":null},{"id":"a3a30510d55e4df89ec2ff5ddaf52048","type":"GENE","name":"VN1R83P","canonical_id":"hgnc:HGNC:37403","description":"vomeronasal 1 receptor 83 pseudogene","metadata":null},{"id":"fb2cc64a19c34efeaa02f75b9cb6a5e0","type":"GENE","name":"VN1R84P","canonical_id":"hgnc:HGNC:37404","description":"vomeronasal 1 receptor 84 pseudogene","metadata":null},{"id":"1c6c1e18ff89441dbc9d2c21014d729d","type":"GENE","name":"VN1R85P","canonical_id":"hgnc:HGNC:37405","description":"vomeronasal 1 receptor 85 pseudogene","metadata":null},{"id":"85c5b6a551e14db4b3649179e9264fd9","type":"GENE","name":"VN1R86P","canonical_id":"hgnc:HGNC:37406","description":"vomeronasal 1 receptor 86 pseudogene","metadata":null},{"id":"f1167eadbadc48d292cd478ed7d9217a","type":"GENE","name":"VN1R87P","canonical_id":"hgnc:HGNC:37407","description":"vomeronasal 1 receptor 87 pseudogene","metadata":null},{"id":"6630d3fd155940f3baf29dcfff92f2e3","type":"GENE","name":"VN1R88P","canonical_id":"hgnc:HGNC:37408","description":"vomeronasal 1 receptor 88 pseudogene","metadata":null},{"id":"f88ec70783e24a47a2e006596956ad01","type":"GENE","name":"VN1R89P","canonical_id":"hgnc:HGNC:37409","description":"vomeronasal 1 receptor 89 pseudogene","metadata":null},{"id":"39714145c3574aa2bf2c2ed082f2fcb1","type":"GENE","name":"VN1R8P","canonical_id":"hgnc:HGNC:8497","description":"vomeronasal 1 receptor 8, pseudogene","metadata":{"aliases":["ORLP2"]}},{"id":"e070424b46ab4a739eb3b7f2a30d32dd","type":"GENE","name":"VN1R90P","canonical_id":"hgnc:HGNC:37410","description":"vomeronasal 1 receptor 90 pseudogene","metadata":null},{"id":"7f84bc50a36a4994aa9233a0a4603315","type":"GENE","name":"VN1R91P","canonical_id":"hgnc:HGNC:37411","description":"vomeronasal 1 receptor 91 pseudogene","metadata":null},{"id":"6dab4f641e494ec28e3bca3a16ffbd87","type":"GENE","name":"VN1R92P","canonical_id":"hgnc:HGNC:37412","description":"vomeronasal 1 receptor 92 pseudogene","metadata":null},{"id":"b734dceea84c4025ae3c2c5795bec57b","type":"GENE","name":"VN1R93P","canonical_id":"hgnc:HGNC:37413","description":"vomeronasal 1 receptor 93 pseudogene","metadata":null},{"id":"1bae99293b774f24acdb34ada23f7054","type":"GENE","name":"VN1R94P","canonical_id":"hgnc:HGNC:37414","description":"vomeronasal 1 receptor 94 pseudogene","metadata":null},{"id":"259487516aa6486d97250d343fa95add","type":"GENE","name":"VN1R95P","canonical_id":"hgnc:HGNC:37415","description":"vomeronasal 1 receptor 95 pseudogene","metadata":null},{"id":"bc9d5820ee8049b8a971720df6179156","type":"GENE","name":"VN1R96P","canonical_id":"hgnc:HGNC:37416","description":"vomeronasal 1 receptor 96 pseudogene","metadata":null},{"id":"3630842fb2da4f3d9f98f2cabd369226","type":"GENE","name":"VN1R97P","canonical_id":"hgnc:HGNC:37417","description":"vomeronasal 1 receptor 97 pseudogene","metadata":null},{"id":"9111776060ef43489daeed52e633f872","type":"GENE","name":"VN1R98P","canonical_id":"hgnc:HGNC:37418","description":"vomeronasal 1 receptor 98 pseudogene","metadata":null},{"id":"4de3e541c82d459aa5057091f38b816d","type":"GENE","name":"VN1R99P","canonical_id":"hgnc:HGNC:37419","description":"vomeronasal 1 receptor 99 pseudogene","metadata":null},{"id":"24d52d54ff9d4017b9386441fe5fe2c3","type":"GENE","name":"VN1R9P","canonical_id":"hgnc:HGNC:20257","description":"vomeronasal 1 receptor 9, pseudogene","metadata":{"aliases":["VN1R22-1P"]}},{"id":"e2911d241c084f2e9aaff54a79239676","type":"GENE","name":"VN2R10P","canonical_id":"hgnc:HGNC:33216","description":"vomeronasal 2 receptor 10, pseudogene","metadata":null},{"id":"27caafcc19c04384ad194846b1887e17","type":"GENE","name":"VN2R11P","canonical_id":"hgnc:HGNC:33217","description":"vomeronasal 2 receptor 11, pseudogene","metadata":null},{"id":"9051c6d1641648919d5edc05a1974e71","type":"GENE","name":"VN2R12P","canonical_id":"hgnc:HGNC:33218","description":"vomeronasal 2 receptor 12, pseudogene","metadata":null},{"id":"32af966ab5514fabbc45ebe52d8638ba","type":"GENE","name":"VN2R13P","canonical_id":"hgnc:HGNC:33219","description":"vomeronasal 2 receptor 13, pseudogene","metadata":null},{"id":"450e573871734b0da6a08f3f71d2654f","type":"GENE","name":"VN2R14P","canonical_id":"hgnc:HGNC:33220","description":"vomeronasal 2 receptor 14, pseudogene","metadata":null},{"id":"0bc6939e45184d84b1bc1e5697534a35","type":"GENE","name":"VN2R15P","canonical_id":"hgnc:HGNC:33221","description":"vomeronasal 2 receptor 15, pseudogene","metadata":null},{"id":"ef7efb881b6946628d1e0e7bc9cb46c1","type":"GENE","name":"VN2R16P","canonical_id":"hgnc:HGNC:33222","description":"vomeronasal 2 receptor 16, pseudogene","metadata":null},{"id":"79dc5fa469234136963b5fd15109f113","type":"GENE","name":"VN2R17P","canonical_id":"hgnc:HGNC:33223","description":"vomeronasal 2 receptor 17, pseudogene","metadata":null},{"id":"72cb016e8f3f4a81ba987a499c07caaf","type":"GENE","name":"VN2R18P","canonical_id":"hgnc:HGNC:33224","description":"vomeronasal 2 receptor 18, pseudogene","metadata":null},{"id":"06eac9f0bfa847c78bec4cd641f92a13","type":"GENE","name":"VN2R19P","canonical_id":"hgnc:HGNC:33225","description":"vomeronasal 2 receptor 19, pseudogene","metadata":null},{"id":"fcb5dada8a854b4b88b3796d92c2b794","type":"GENE","name":"VN2R1P","canonical_id":"hgnc:HGNC:30344","description":"vomeronasal 2 receptor 1, pseudogene","metadata":{"aliases":["GPRC2B","CASRL1"]}},{"id":"7dd6116a41c145c89b31b65b9aba5539","type":"GENE","name":"VN2R20P","canonical_id":"hgnc:HGNC:33226","description":"vomeronasal 2 receptor 20, pseudogene","metadata":null},{"id":"4d5bcf33a1ab4af7868d9ff615bdb76b","type":"GENE","name":"VN2R21P","canonical_id":"hgnc:HGNC:33938","description":"vomeronasal 2 receptor 21, pseudogene","metadata":null},{"id":"d0e5aa5da8d24690ae37c5c2f25ae4ff","type":"GENE","name":"VN2R2P","canonical_id":"hgnc:HGNC:33208","description":"vomeronasal 2 receptor 2, pseudogene","metadata":null},{"id":"1904b3099641424296425bd455f8bd79","type":"GENE","name":"VN2R3P","canonical_id":"hgnc:HGNC:33209","description":"vomeronasal 2 receptor 3, pseudogene","metadata":{"aliases":["VN2R4P","VN2R5P","VN2R8P"]}},{"id":"66cf7eccaf484055bb919796b703ac80","type":"GENE","name":"VN2R6P","canonical_id":"hgnc:HGNC:33212","description":"vomeronasal 2 receptor 6, pseudogene","metadata":null},{"id":"a6163ea0cb6b4ff69701e96431ac0326","type":"GENE","name":"VN2R7P","canonical_id":"hgnc:HGNC:33213","description":"vomeronasal 2 receptor 7, pseudogene","metadata":null},{"id":"a1dbee1d611f4cbf9baa1ccd59bf552c","type":"GENE","name":"VN2R9P","canonical_id":"hgnc:HGNC:33215","description":"vomeronasal 2 receptor 9, pseudogene","metadata":null},{"id":"4c2daca2e87b4de88316a31cc25b0637","type":"GENE","name":"VNN1","canonical_id":"hgnc:HGNC:12705","description":"vanin 1","metadata":{"aliases":["Tiff66"]}},{"id":"95cba369bf9b4bb183a6b5fbffffd888","type":"GENE","name":"VNN2","canonical_id":"hgnc:HGNC:12706","description":"vanin 2","metadata":{"aliases":["FOAP-4","GPI-80"]}},{"id":"b4e2daf6314446e6b455b49356eaba59","type":"GENE","name":"VNN3P","canonical_id":"hgnc:HGNC:16431","description":"vanin 3, pseudogene","metadata":{"aliases":["HSA238982","VNN3"]}},{"id":"7f61d8c1f3094c19976e26fda393805a","type":"TRIAL","name":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","canonical_id":"clinicaltrials.gov:NCT06249555","description":"Crohn's Disease","metadata":null},{"id":"cee477fc30a84bfaa63cf7e5df703f01","type":"GENE","name":"VOPP1","canonical_id":"hgnc:HGNC:34518","description":"VOPP1 WW domain binding protein","metadata":{"aliases":["ECop","GASP","FLJ20532","DKFZp564K0822","WBP1L2"]}},{"id":"1991e7037db14af88ef1836583cdf72f","type":"GENE","name":"VOPP1-DT","canonical_id":"hgnc:HGNC:55874","description":"VOPP1 divergent transcript","metadata":null},{"id":"9e6e0956713242fd84706be066721ca7","type":"GENE","name":"VOPP2P","canonical_id":"hgnc:HGNC:58490","description":"VOPP family member 2, pseudogene","metadata":null},{"id":"bb7260a7472b449386d9216e374060fd","type":"GENE","name":"VPREB1","canonical_id":"hgnc:HGNC:12709","description":"V-set pre-B cell surrogate light chain 1","metadata":{"aliases":["VpreB","CD179A"]}},{"id":"99b4a321359848f5903915114e88c709","type":"GENE","name":"VPREB3","canonical_id":"hgnc:HGNC:12710","description":"V-set pre-B cell surrogate light chain 3","metadata":{"aliases":["8HS20"]}},{"id":"ce41b4137fb14b7c848273aa2bfbfeb5","type":"GENE","name":"VPS11","canonical_id":"hgnc:HGNC:14583","description":"VPS11 core subunit of CORVET and HOPS complexes","metadata":{"aliases":["RNF108","PEP5"]}},{"id":"9754acb5f71c4162b43de027a4946cde","type":"GENE","name":"VPS11-DT","canonical_id":"hgnc:HGNC:55227","description":"VPS11 divergent transcript","metadata":{"aliases":["TCONS_00019777"]}},{"id":"c7275b96cca540619f3765fef7361b6e","type":"GENE","name":"VPS13A","canonical_id":"hgnc:HGNC:1908","description":"vacuolar protein sorting 13 homolog A","metadata":{"aliases":["KIAA0986","BLTP5A","CHAC"]}},{"id":"ff76323f68a54f70abe03a8972f0b1d6","type":"GENE","name":"VPS13A-AS1","canonical_id":"hgnc:HGNC:44167","description":"VPS13A antisense RNA 1","metadata":null},{"id":"22753ff7dd6945c691ed0a634ac0dcbc","type":"GENE","name":"VPS13B","canonical_id":"hgnc:HGNC:2183","description":"vacuolar protein sorting 13 homolog B","metadata":{"aliases":["BLTP5B","CHS1","COH1"]}},{"id":"dd8b6d0dc9464087ae111ed3023b8026","type":"GENE","name":"VPS13B-DT","canonical_id":"hgnc:HGNC:54375","description":"VPS13B divergent transcript","metadata":{"aliases":["OLC8"]}},{"id":"270b5a08bcdf4af5ab406740455f7e4a","type":"GENE","name":"VPS13C","canonical_id":"hgnc:HGNC:23594","description":"vacuolar protein sorting 13 homolog C","metadata":{"aliases":["FLJ20136","FLJ10381","KIAA1421","BLTP5C","PARK23"]}},{"id":"ac6db7c613784037a8b3de78e53def96","type":"GENE","name":"VPS13C-DT","canonical_id":"hgnc:HGNC:55425","description":"VPS13C divergent transcript","metadata":null},{"id":"7b0e22476e384721a1433296d4de7494","type":"GENE","name":"VPS13D","canonical_id":"hgnc:HGNC:23595","description":"vacuolar protein sorting 13 homolog D","metadata":{"aliases":["FLJ10619","KIAA0453","BLTP5D"]}},{"id":"7fa1346d12d64b959e1389731ae3877f","type":"GENE","name":"VPS16","canonical_id":"hgnc:HGNC:14584","description":"VPS16 core subunit of CORVET and HOPS complexes","metadata":null},{"id":"f897807259f943d88f0ed19a6a527530","type":"GENE","name":"VPS18","canonical_id":"hgnc:HGNC:15972","description":"VPS18 core subunit of CORVET and HOPS complexes","metadata":{"aliases":["KIAA1475","PEP3"]}},{"id":"5ec6e818379b4badb35844c4ccb49c21","type":"GENE","name":"VPS25","canonical_id":"hgnc:HGNC:28122","description":"vacuolar protein sorting 25 homolog","metadata":{"aliases":["MGC10540","EAP20","DERP9"]}},{"id":"1de8fbb7a4e34e099567910f8e5eac0c","type":"GENE","name":"VPS25P1","canonical_id":"hgnc:HGNC:44250","description":"VPS25 pseudogene 1","metadata":null},{"id":"5304a13736294306a92d9935b5245dd2","type":"GENE","name":"VPS26A","canonical_id":"hgnc:HGNC:12711","description":"VPS26 retromer complex component A","metadata":{"aliases":["Hbeta58","PEP8A","VPS26"]}},{"id":"5e06a3c624e94d9c9f66f0f203c6dab9","type":"GENE","name":"VPS26AP1","canonical_id":"hgnc:HGNC:44611","description":"VPS26A pseudogene 1","metadata":null},{"id":"33585ec17bd248eab41cd5c73d2ff7af","type":"GENE","name":"VPS26B","canonical_id":"hgnc:HGNC:28119","description":"VPS26 retromer complex component B","metadata":{"aliases":["MGC10485","Pep8b"]}},{"id":"6d409c4507fd432db0b61501d5e01231","type":"GENE","name":"VPS26BP1","canonical_id":"hgnc:HGNC:44612","description":"VPS26B pseudogene 1","metadata":null},{"id":"5cae956f10fd4b32869758bf6ec937b7","type":"GENE","name":"VPS26C","canonical_id":"hgnc:HGNC:3044","description":"VPS26 endosomal protein sorting factor C","metadata":{"aliases":["DCRA","DSCR3"]}},{"id":"3b857466c01c4173b052788ec3fc3ed3","type":"GENE","name":"VPS26CP1","canonical_id":"hgnc:HGNC:54684","description":"VPS26C pseudogene 1","metadata":null},{"id":"34c224d1417f45978a052acd0a090a58","type":"GENE","name":"VPS28","canonical_id":"hgnc:HGNC:18178","description":"VPS28 subunit of ESCRT-I","metadata":{"aliases":["CIIA"]}},{"id":"7a2e047bf60b4383a3ce8d10a35f8536","type":"GENE","name":"VPS29","canonical_id":"hgnc:HGNC:14340","description":"VPS29 retromer complex component","metadata":{"aliases":["PEP11","DC7","DC15"]}},{"id":"adb819cd88cf45de9b423bd7c25e9050","type":"GENE","name":"VPS33A","canonical_id":"hgnc:HGNC:18179","description":"VPS33A core subunit of CORVET and HOPS complexes","metadata":null},{"id":"70cf5a92e42e44b2962f492456e4fac9","type":"GENE","name":"VPS33B","canonical_id":"hgnc:HGNC:12712","description":"VPS33B late endosome and lysosome associated","metadata":{"aliases":["FLJ14848"]}},{"id":"1143ab96eb8c494f8d22a0100a312403","type":"GENE","name":"VPS33B-DT","canonical_id":"hgnc:HGNC:51413","description":"VPS33B divergent transcript","metadata":null},{"id":"310b5b7f466e4ab4a531e93f91807b73","type":"GENE","name":"VPS35","canonical_id":"hgnc:HGNC:13487","description":"VPS35 retromer complex component","metadata":{"aliases":["FLJ10752","MEM3","PARK17"]}},{"id":"6f05c50a6a53405894419634c736cb37","type":"GENE","name":"VPS35L","canonical_id":"hgnc:HGNC:24641","description":"VPS35 endosomal protein sorting factor like","metadata":{"aliases":["MGC16824","C16orf62"]}},{"id":"06d89c2bd3704740a3304fb9c0f36f17","type":"GENE","name":"VPS35P1","canonical_id":"hgnc:HGNC:51805","description":"VPS35 pseudogene 1","metadata":null},{"id":"1a19e8d836e6404b83daafec77f56252","type":"GENE","name":"VPS36","canonical_id":"hgnc:HGNC:20312","description":"vacuolar protein sorting 36 homolog","metadata":{"aliases":["CGI-145","Eap45","C13orf9"]}},{"id":"288c3050167249389b8e31c344426ad2","type":"GENE","name":"VPS37A","canonical_id":"hgnc:HGNC:24928","description":"VPS37A subunit of ESCRT-I","metadata":{"aliases":["FLJ32642","HCRP1","SPG53","PQBP2"]}},{"id":"1b43f9a040454b30addbe63b8895dfbb","type":"GENE","name":"VPS37B","canonical_id":"hgnc:HGNC:25754","description":"VPS37B subunit of ESCRT-I","metadata":{"aliases":["FLJ12750"]}},{"id":"4f2128bf6a37442385e5e0070dc5e4ba","type":"GENE","name":"VPS37C","canonical_id":"hgnc:HGNC:26097","description":"VPS37C subunit of ESCRT-I","metadata":{"aliases":["FLJ20847"]}},{"id":"ed91bbc282904466a7fb5b2da641e71a","type":"GENE","name":"VPS37D","canonical_id":"hgnc:HGNC:18287","description":"VPS37D subunit of ESCRT-I","metadata":{"aliases":["MGC35352","WBSCR24"]}},{"id":"2bfb0e95dfaf4e8d8164896fb82c1f36","type":"GENE","name":"VPS39","canonical_id":"hgnc:HGNC:20593","description":"VPS39 subunit of HOPS complex","metadata":{"aliases":["KIAA0770","VAM6"]}},{"id":"ccbc91f6eec0402092504bfd978cd3c6","type":"GENE","name":"VPS39-DT","canonical_id":"hgnc:HGNC:55378","description":"VPS39 divergent transcript","metadata":null},{"id":"b9d9b8cd8a8046eb99c40c8dac35940b","type":"GENE","name":"VPS41","canonical_id":"hgnc:HGNC:12713","description":"VPS41 subunit of HOPS complex","metadata":{"aliases":["HVSP41"]}},{"id":"50a3d7a21a334a52bade9eb7e62d890d","type":"GENE","name":"VPS45","canonical_id":"hgnc:HGNC:14579","description":"vacuolar protein sorting 45 homolog","metadata":{"aliases":["h-vps45","H1","VPS45B","VPS45A"]}},{"id":"4c2ebca8f1f34032833b68becdc8b978","type":"GENE","name":"VPS45-AS1","canonical_id":"hgnc:HGNC:58766","description":"VPS45 antisense RNA 1","metadata":{"aliases":["AC244033.2"]}},{"id":"5d8f49df0992426d84642f231ebed395","type":"GENE","name":"VPS4A","canonical_id":"hgnc:HGNC:13488","description":"vacuolar protein sorting 4 homolog A","metadata":{"aliases":["VPS4","VPS4-1","FLJ22197","SKD2","SKD1","SKD1A"]}},{"id":"3673afd6a34548e2bbdd6795d0888ae3","type":"GENE","name":"VPS4B","canonical_id":"hgnc:HGNC:10895","description":"vacuolar protein sorting 4 homolog B","metadata":{"aliases":["VPS4-2","SKD1B","SKD1"]}},{"id":"e0f9b7fbd6c14b4fa2a9a72bd82ef89b","type":"GENE","name":"VPS50","canonical_id":"hgnc:HGNC:25956","description":"VPS50 subunit of EARP/GARPII complex","metadata":{"aliases":["KIAA1861","FLJ20097","DKFZp313I2429","VPS54L","CCDC132"]}},{"id":"943e9ef0ca404a108a87dc4710435370","type":"GENE","name":"VPS51","canonical_id":"hgnc:HGNC:1172","description":"VPS51 subunit of GARP complex","metadata":{"aliases":["ANG2","ANG3","FFR","C11orf3","C11orf2"]}},{"id":"c9837d6f33ba43dd8f615639dab3ba63","type":"GENE","name":"VPS51P1","canonical_id":"hgnc:HGNC:56433","description":"VPS51 pseudogene 1","metadata":null},{"id":"d2c0dff265284ef3b0e85303225db18f","type":"GENE","name":"VPS51P10","canonical_id":"hgnc:HGNC:56442","description":"VPS51 pseudogene 10","metadata":null},{"id":"71588262a5434f07b04f51a94db93e33","type":"GENE","name":"VPS51P11","canonical_id":"hgnc:HGNC:56443","description":"VPS51 pseudogene 11","metadata":null},{"id":"b9234cb6b7e840c79d1f8d0e0f6a2705","type":"GENE","name":"VPS51P12","canonical_id":"hgnc:HGNC:56444","description":"VPS51 pseudogene 12","metadata":null},{"id":"1a84804fd8644388ac7cd3e6e35d26d0","type":"GENE","name":"VPS51P13","canonical_id":"hgnc:HGNC:56445","description":"VPS51 pseudogene 13","metadata":null},{"id":"4b68b82f29ba460aac64d861be90c7c5","type":"GENE","name":"VPS51P14","canonical_id":"hgnc:HGNC:56446","description":"VPS51 pseudogene 14","metadata":null},{"id":"4724f6f506cc4cb19483a12164db399d","type":"GENE","name":"VPS51P15","canonical_id":"hgnc:HGNC:56447","description":"VPS51 pseudogene 15","metadata":null},{"id":"e535685ec5c14dac8b510461715be80d","type":"GENE","name":"VPS51P16","canonical_id":"hgnc:HGNC:56448","description":"VPS51 pseudogene 16","metadata":null},{"id":"9d10cbff3228407a8545b30d92e2cd59","type":"GENE","name":"VPS51P17","canonical_id":"hgnc:HGNC:56449","description":"VPS51 pseudogene 17","metadata":null},{"id":"94977d8e08194a48babe1d1b16341c4e","type":"GENE","name":"VPS51P18","canonical_id":"hgnc:HGNC:56450","description":"VPS51 pseudogene 18","metadata":null},{"id":"fd27469433da451998c5bfba7aac19ea","type":"GENE","name":"VPS51P19","canonical_id":"hgnc:HGNC:56451","description":"VPS51 pseudogene 19","metadata":null},{"id":"b05aa713c42b4692be1db92c859639d0","type":"GENE","name":"VPS51P2","canonical_id":"hgnc:HGNC:56434","description":"VPS51 pseudogene 2","metadata":null},{"id":"f9969d47bec14baaa80fe69a2a8f80d6","type":"GENE","name":"VPS51P3","canonical_id":"hgnc:HGNC:56435","description":"VPS51 pseudogene 3","metadata":null},{"id":"e19655b34bd245909f4844dd92be0a9c","type":"GENE","name":"VPS51P4","canonical_id":"hgnc:HGNC:56436","description":"VPS51 pseudogene 4","metadata":null},{"id":"98590d94db794388ab4c4b2f7a405ae0","type":"GENE","name":"VPS51P5","canonical_id":"hgnc:HGNC:56437","description":"VPS51 pseudogene 5","metadata":null},{"id":"287c76470ec24661ba9e472d3d9f8ccb","type":"GENE","name":"VPS51P6","canonical_id":"hgnc:HGNC:56438","description":"VPS51 pseudogene 6","metadata":null},{"id":"b0b9714227844d0bb306eba5011302cd","type":"GENE","name":"VPS51P7","canonical_id":"hgnc:HGNC:56439","description":"VPS51 pseudogene 7","metadata":null},{"id":"e1f23c29e4f245b4842ddd262ad31828","type":"GENE","name":"VPS51P8","canonical_id":"hgnc:HGNC:56440","description":"VPS51 pseudogene 8","metadata":null},{"id":"a1384db903c9488b93c2f09fd8b03c66","type":"GENE","name":"VPS51P9","canonical_id":"hgnc:HGNC:56441","description":"VPS51 pseudogene 9","metadata":null},{"id":"207e2aa4a0a14d26a730f651bfddc9d0","type":"GENE","name":"VPS52","canonical_id":"hgnc:HGNC:10518","description":"VPS52 subunit of GARP complex","metadata":{"aliases":["ARE1","SACM2L"]}},{"id":"d16265dfa3984ee6978e1ddd7ba3d062","type":"GENE","name":"VPS53","canonical_id":"hgnc:HGNC:25608","description":"VPS53 subunit of GARP complex","metadata":{"aliases":["FLJ10979","HCCS1"]}},{"id":"c7d7ebc8c05d4cb581a517a967032890","type":"GENE","name":"VPS53-AS1","canonical_id":"hgnc:HGNC:58554","description":"VPS53 antisense RNA 1","metadata":null},{"id":"6272763295db431c8b26d4e1f4500195","type":"GENE","name":"VPS54","canonical_id":"hgnc:HGNC:18652","description":"VPS54 subunit of GARP complex","metadata":{"aliases":["HCC8","PPP1R164"]}},{"id":"8e07f6c8a60b4d56afa9d52bb8d6255e","type":"GENE","name":"VPS72","canonical_id":"hgnc:HGNC:11644","description":"vacuolar protein sorting 72 homolog","metadata":{"aliases":["YL-1","YL1","Swc2","TCFL1"]}},{"id":"522883fae4174deaa71bf02e54364a85","type":"GENE","name":"VPS8","canonical_id":"hgnc:HGNC:29122","description":"VPS8 subunit of CORVET complex","metadata":{"aliases":["FLJ32099","KIAA0804"]}},{"id":"48ff4507964348628cdeeb775b92ecca","type":"GENE","name":"VPS9D1","canonical_id":"hgnc:HGNC:13526","description":"VPS9 domain containing 1","metadata":{"aliases":["ATP-BL","C16orf7"]}},{"id":"50487d4d992e4278bb1aa867195969ee","type":"GENE","name":"VPS9D1-AS1","canonical_id":"hgnc:HGNC:48915","description":"VPS9D1 antisense RNA 1","metadata":{"aliases":["MYU","FAISL"]}},{"id":"30061f33a47e4687b0c0ea96aa2ac4de","type":"GENE","name":"VRK1","canonical_id":"hgnc:HGNC:12718","description":"VRK serine/threonine kinase 1","metadata":null},{"id":"dc122a8f756b49baa37474b9a539a305","type":"GENE","name":"VRK2","canonical_id":"hgnc:HGNC:12719","description":"VRK serine/threonine kinase 2","metadata":null},{"id":"886b9d83d15242708bebfd4a85c1850f","type":"GENE","name":"VRK3","canonical_id":"hgnc:HGNC:18996","description":"VRK serine/threonine kinase 3","metadata":null},{"id":"22a03528430d45acb733b0e1c6c5d050","type":"GO_TERM","name":"VRK3/VHR/ERK complex","canonical_id":"go:GO:0002167","description":"\"A ternary complex consisting of VRK3, VHR (Dusp3), and ERK1 (Mapk3) existing in neuronal cells, and is involved in regulation of the ERK signaling pathway.\" [GOC:hjd, PMID:16845380]","metadata":null},{"id":"7ab65f1438304862b096cfa50e26caef","type":"GENE","name":"VRTN","canonical_id":"hgnc:HGNC:20223","description":"vertebrae development associated","metadata":{"aliases":["FLJ10811","vertnin","C14orf115"]}},{"id":"7d8fb994bee0468ab42682adf8154aa5","type":"GENE","name":"VSIG1","canonical_id":"hgnc:HGNC:28675","description":"V-set and immunoglobulin domain containing 1","metadata":{"aliases":["MGC44287","GPA34"]}},{"id":"93be31aba2454264baab48263d9b1f9d","type":"GENE","name":"VSIG10","canonical_id":"hgnc:HGNC:26078","description":"V-set and immunoglobulin domain containing 10","metadata":null},{"id":"41062be0f5184d2a9449ad3462b1d4f9","type":"GENE","name":"VSIG10L","canonical_id":"hgnc:HGNC:27111","description":"V-set and immunoglobulin domain containing 10 like","metadata":null},{"id":"7f38b9431fbc4b51912099ea4d73a675","type":"GENE","name":"VSIG10L-AS1","canonical_id":"hgnc:HGNC:55282","description":"VSIG10L antisense RNA 1","metadata":null},{"id":"159500db80344e52b28dbf6ac8d66bc3","type":"GENE","name":"VSIG10L2","canonical_id":"hgnc:HGNC:27879","description":"V-set and immunoglobulin domain containing 10 like 2","metadata":null},{"id":"8a520d86acdb403dab8c577a6859bf0d","type":"GENE","name":"VSIG2","canonical_id":"hgnc:HGNC:17149","description":"V-set and immunoglobulin domain containing 2","metadata":{"aliases":["CTXL","CTH"]}},{"id":"61c06a187ae9423f9e689cd3ee79f1c8","type":"GENE","name":"VSIG4","canonical_id":"hgnc:HGNC:17032","description":"V-set and immunoglobulin domain containing 4","metadata":{"aliases":["Z39IG","CRIg"]}},{"id":"b874febe23df41e396289c705aba8e83","type":"GENE","name":"VSIG8","canonical_id":"hgnc:HGNC:32063","description":"V-set and immunoglobulin domain containing 8","metadata":null},{"id":"7b7190296ec84f91936ab585acde319b","type":"GENE","name":"VSIR","canonical_id":"hgnc:HGNC:30085","description":"V-set immunoregulatory receptor","metadata":{"aliases":["SISP1","GI24","B7-H5","B7H5","VISTA","PD-1H","Dies1","C10orf54"]}},{"id":"98004233dfcd4e068e4a4375957f14de","type":"GENE","name":"VSNL1","canonical_id":"hgnc:HGNC:12722","description":"visinin like 1","metadata":{"aliases":["VILIP","HPCAL3","HUVISL1","HLP3","VILIP-1"]}},{"id":"59bdf90d9fe34485a3f6878a3de16a4d","type":"GENE","name":"VSTM1","canonical_id":"hgnc:HGNC:29455","description":"V-set and transmembrane domain containing 1","metadata":{"aliases":["UNQ3033"]}},{"id":"4a44284efff5490ab7052dc566896790","type":"GENE","name":"VSTM2A","canonical_id":"hgnc:HGNC:28499","description":"V-set and transmembrane domain containing 2A","metadata":{"aliases":["MGC33530","VSTM2"]}},{"id":"386b03c7abe14a9c9459c62d2219acd8","type":"GENE","name":"VSTM2A-OT1","canonical_id":"hgnc:HGNC:50770","description":"VSTM2A overlapping transcript 1","metadata":null},{"id":"af3848fe466d49cab4de94d9bf16a831","type":"GENE","name":"VSTM2B","canonical_id":"hgnc:HGNC:33595","description":"V-set and transmembrane domain containing 2B","metadata":null},{"id":"a267179144ab4c0f80ec741e50795749","type":"GENE","name":"VSTM2B-DT","canonical_id":"hgnc:HGNC:27615","description":"VSTM2B divergent transcript","metadata":null},{"id":"baea06b2ccc64dcaa15aa62c01d94ce4","type":"GENE","name":"VSTM2L","canonical_id":"hgnc:HGNC:16096","description":"V-set and transmembrane domain containing 2 like","metadata":{"aliases":["dJ1118M15.2","C20orf102"]}},{"id":"d51e4a718fb14f03ab5f804128cd57b1","type":"GENE","name":"VSTM4","canonical_id":"hgnc:HGNC:26470","description":"V-set and transmembrane domain containing 4","metadata":{"aliases":["FLJ31737","C10orf72"]}},{"id":"dcb7fed13702490bad5dacc8defdaac1","type":"GENE","name":"VSTM5","canonical_id":"hgnc:HGNC:34443","description":"V-set and transmembrane domain containing 5","metadata":{"aliases":["LOC387804","C11orf90"]}},{"id":"5be522c4ca424bb0aa091a502e082ddb","type":"GENE","name":"VSX1","canonical_id":"hgnc:HGNC:12723","description":"visual system homeobox 1","metadata":{"aliases":["PPD","PPCD1","PPCD"]}},{"id":"3a010dbc4d7b4689aeb23fe241d3fdee","type":"GENE","name":"VSX2","canonical_id":"hgnc:HGNC:1975","description":null,"metadata":null},{"id":"71ad3915f82142159474dc00f3064689","type":"GENE","name":"VTA1","canonical_id":"hgnc:HGNC:20954","description":"vesicle trafficking 1","metadata":{"aliases":["HSPC228","My012","C6orf55"]}},{"id":"5a2228d1426044e7a1358a59189b6da7","type":"GENE","name":"VTA1P1","canonical_id":"hgnc:HGNC:50483","description":"vesicle trafficking 1 pseudogene 1","metadata":null},{"id":"84d5717bb14646ddab773c043869fa28","type":"GENE","name":"VTA1P2","canonical_id":"hgnc:HGNC:50484","description":"vesicle trafficking 1 pseudogene 2","metadata":null},{"id":"cae17c85dffa499d840c14c653904cea","type":"GENE","name":"VTCN1","canonical_id":"hgnc:HGNC:28873","description":"V-set domain containing T cell activation inhibitor 1","metadata":{"aliases":["B7-H4","FLJ22418","B7S1","B7x","B7H4"]}},{"id":"c1e3b7e0abd44e30bb9dc854c9140fc6","type":"GENE","name":"VTCN1P1","canonical_id":"hgnc:HGNC:56951","description":"VTCN1 pseudogene 1","metadata":null},{"id":"84f47725149b4e9aade0223b1e2e7f10","type":"GENE","name":"VTI1A","canonical_id":"hgnc:HGNC:17792","description":"vesicle transport through interaction with t-SNAREs 1A","metadata":{"aliases":["MVti1","Vti1-rp2"]}},{"id":"33a933f1ccb74345956b02da18a5ada5","type":"GENE","name":"VTI1B","canonical_id":"hgnc:HGNC:17793","description":"vesicle transport through interaction with t-SNAREs 1B","metadata":{"aliases":["VTI2"]}},{"id":"89966f33caba4515b0a928b31a52dca3","type":"GENE","name":"VTI1BP1","canonical_id":"hgnc:HGNC:43727","description":"vesicle transport through interaction with t-SNAREs 1B pseudogene 1","metadata":null},{"id":"13d6da5e6fb84b079f0624c36c8a7887","type":"GENE","name":"VTI1BP2","canonical_id":"hgnc:HGNC:43728","description":"vesicle transport through interaction with t-SNAREs 1B pseudogene 2","metadata":null},{"id":"dc693cd1c0964f868860e84e1959c219","type":"GENE","name":"VTI1BP3","canonical_id":"hgnc:HGNC:43729","description":"vesicle transport through interaction with t-SNAREs 1B pseudogene 3","metadata":null},{"id":"71341c4e3db44badb8ba6ef0efc9c1e1","type":"GENE","name":"VTI1BP4","canonical_id":"hgnc:HGNC:43730","description":"vesicle transport through interaction with t-SNAREs 1B pseudogene 4","metadata":null},{"id":"ab331f89a7e748a3be700458681b5d7f","type":"GENE","name":"VTN","canonical_id":"hgnc:HGNC:12724","description":"vitronectin","metadata":{"aliases":["VN"]}},{"id":"f8f5cd80e4334348a58bb922cd1b789a","type":"GENE","name":"VTRNA1-1","canonical_id":"hgnc:HGNC:12654","description":"vault RNA 1-1","metadata":{"aliases":["hvg-1","HVG1","vRNA","VR1","VAULTRC1"]}},{"id":"b49e707311a947d093bc654b7354c535","type":"GENE","name":"VTRNA1-2","canonical_id":"hgnc:HGNC:12655","description":"vault RNA 1-2","metadata":{"aliases":["hvg-2","HVG2","VR2","VAULTRC2"]}},{"id":"ff3d887d2cae46b9b8e12555097ac26a","type":"GENE","name":"VTRNA1-3","canonical_id":"hgnc:HGNC:12656","description":"vault RNA 1-3","metadata":{"aliases":["hvg-3","HVG3","VR3","VAULTRC3"]}},{"id":"6895beef616f4e7db4bee5f9647dd7ce","type":"GENE","name":"VTRNA2-1","canonical_id":"hgnc:HGNC:37054","description":"vault RNA 2-1","metadata":{"aliases":["vtRNA2","hvg-5","CBL-3","hsa-mir-886","nc886","pre-miR-886","MIR886","MIRN886","VTRNA2"]}},{"id":"c1d0ab095ed74b7ea8e0364cffa4aa58","type":"GENE","name":"VTRNA2-2P","canonical_id":"hgnc:HGNC:46889","description":"vault RNA 2-2, pseudogene","metadata":null},{"id":"95112a23cfb24df2b831b64bbfbabdee","type":"GENE","name":"VTRNA3-1P","canonical_id":"hgnc:HGNC:23027","description":"vault RNA 3-1, pseudogene","metadata":{"aliases":["vtRNA3P","hvg-4","HVG4","VAULTRC4","VTRNA3P"]}},{"id":"d3843cb975c742de96a093239877370c","type":"GENE","name":"VWA1","canonical_id":"hgnc:HGNC:30910","description":"von Willebrand factor A domain containing 1","metadata":{"aliases":["FLJ22215","VWA-1","WARP"]}},{"id":"d3385f3dd6db459ab7b7948671e2061c","type":"GENE","name":"VWA2","canonical_id":"hgnc:HGNC:24709","description":"von Willebrand factor A domain containing 2","metadata":{"aliases":["FLJ45857","FLJ16213","CCSP-2","AMACO","NET42"]}},{"id":"6de9457a92154c0b9a3c25e0396a70a2","type":"GENE","name":"VWA3A","canonical_id":"hgnc:HGNC:27088","description":"von Willebrand factor A domain containing 3A","metadata":{"aliases":["FLJ46765","FLJ40941"]}},{"id":"6fb9e4c837084260bdb5d1fd2fe79d98","type":"GENE","name":"VWA3B","canonical_id":"hgnc:HGNC:28385","description":"von Willebrand factor A domain containing 3B","metadata":{"aliases":["DKFZp686F2227","MGC26733"]}},{"id":"419722a1455b4e65aeff0753cb7dc1b6","type":"GENE","name":"VWA5A","canonical_id":"hgnc:HGNC:6658","description":"von Willebrand factor A domain containing 5A","metadata":{"aliases":["BCSC-1","LOH11CR2A"]}},{"id":"e9fad1482fdb4cb5adec8b609754407e","type":"GENE","name":"VWA5B1","canonical_id":"hgnc:HGNC:26538","description":"von Willebrand factor A domain containing 5B1","metadata":{"aliases":["FLJ32784"]}},{"id":"140eb2175d7149419a767686aef05222","type":"GENE","name":"VWA5B1-AS1","canonical_id":"hgnc:HGNC:41146","description":"VWA5B1 antisense RNA 1","metadata":null},{"id":"015211c83c354ae0883649b9f7f64f2a","type":"GENE","name":"VWA5B2","canonical_id":"hgnc:HGNC:25144","description":"von Willebrand factor A domain containing 5B2","metadata":{"aliases":["DKFZp761K032","LOC90113"]}},{"id":"e21f5efc78594cd492ee90f51780e8dc","type":"GENE","name":"VWA7","canonical_id":"hgnc:HGNC:13939","description":"von Willebrand factor A domain containing 7","metadata":{"aliases":["G7c","NG37","C6orf27"]}},{"id":"11e69d519c16409f8d220c52c847f2a8","type":"GENE","name":"VWA8","canonical_id":"hgnc:HGNC:29071","description":"von Willebrand factor A domain containing 8","metadata":{"aliases":["P7BP2","KIAA0564"]}},{"id":"a3dc559593a74c52ae5f9cc90b70c572","type":"GENE","name":"VWA8-AS1","canonical_id":"hgnc:HGNC:44270","description":"VWA8 antisense RNA 1","metadata":null},{"id":"b996fe9df9774db69e13d32d9188bba9","type":"GENE","name":"VWA8P1","canonical_id":"hgnc:HGNC:44271","description":"von Willebrand factor A domain containing 8 pseudogene 1","metadata":null},{"id":"6fbf42cd4e7a42dcbf3c1022f8a319b4","type":"GENE","name":"VWC2","canonical_id":"hgnc:HGNC:30200","description":"von Willebrand factor C domain containing 2","metadata":{"aliases":["PSST739","UNQ739"]}},{"id":"daec5d4d0a5944e9a3f4946140989870","type":"GENE","name":"VWC2L","canonical_id":"hgnc:HGNC:37203","description":"von Willebrand factor C domain containing 2 like","metadata":null},{"id":"7faeb2ba704f4e1290d705e0a3cf25ce","type":"GENE","name":"VWC2L-IT1","canonical_id":"hgnc:HGNC:41508","description":"VWC2L intronic transcript 1","metadata":null},{"id":"1edf7084a93f452bb7a5da565ae16ef3","type":"GENE","name":"VWCE","canonical_id":"hgnc:HGNC:26487","description":"von Willebrand factor C and EGF domains","metadata":{"aliases":["URG11","FLJ32009","VWC1"]}},{"id":"2a59580835554f21be9a4f9e28da4cf8","type":"GENE","name":"VWDE","canonical_id":"hgnc:HGNC:21897","description":"von Willebrand factor D and EGF domains","metadata":{"aliases":["FLJ14712"]}},{"id":"431ac19553764ddb9222ddaace706a95","type":"GENE","name":"VWF","canonical_id":"hgnc:HGNC:12726","description":null,"metadata":null},{"id":"d46f84c1b47f4f57b066dd44da884da2","type":"PROTEIN","name":"VWF","canonical_id":"uniprot:P04275","description":null,"metadata":null},{"id":"c04644bdfdff4209b82ec1edf5691768","type":"GENE","name":"VWFP1","canonical_id":"hgnc:HGNC:12727","description":"von Willebrand factor pseudogene 1","metadata":{"aliases":["F8VWFP","F8VWFL","VWFP"]}},{"id":"5a9233c3aaea4e12a4047b9cc1a5c604","type":"TRIAL","name":"VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT03268057","description":"Carcinoma, Non-Small-Cell Lung","metadata":null},{"id":"95a7e12afe604011a5ba2d943dc85016","type":"GENE","name":"VXN","canonical_id":"hgnc:HGNC:28498","description":"vexin","metadata":{"aliases":["MGC33510","C8orf46"]}},{"id":"af4774f4061046ecab678ff59b32d15d","type":"TRIAL","name":"Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study","canonical_id":"clinicaltrials.gov:NCT02229084","description":"Breast Cancer; Breast Neoplasms","metadata":null},{"id":"c8fadb2bb8734b978417eede39da72f2","type":"TRIAL","name":"Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod","canonical_id":"clinicaltrials.gov:NCT00799110","description":"Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer","metadata":null},{"id":"faca386450ae4e17ba71878eb3e34687","type":"TRIAL","name":"Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)","canonical_id":"clinicaltrials.gov:NCT03562377","description":"Atopic Dermatitis","metadata":null},{"id":"4cdcb784bff34c208fd178ca736416f4","type":"TRIAL","name":"Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00020254","description":"Prostate Cancer","metadata":null},{"id":"4d1a839c71ca4048b27eb99590aa9801","type":"TRIAL","name":"Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00450463","description":"Prostate Cancer","metadata":null},{"id":"aa0da85823204b80a8b0dd54f3323b3b","type":"TRIAL","name":"Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia","canonical_id":"clinicaltrials.gov:NCT00788164","description":"Cervical Cancer; Precancerous Condition; HPV Disease; Human Papilomavirus","metadata":null},{"id":"b3b680920efe4cd88851ecb9f24a3829","type":"TRIAL","name":"Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","canonical_id":"clinicaltrials.gov:NCT00373217","description":"Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer","metadata":null},{"id":"adccd81c970d4404b34163cf17c17139","type":"TISSUE","name":"Vagina","canonical_id":"uberon:UBERON:0000996","description":null,"metadata":null},{"id":"b680421706aa4a6a89d344d02b8327fe","type":"TRIAL","name":"Vaginal Bromocriptine for Treatment of Adenomyosis","canonical_id":"clinicaltrials.gov:NCT01821001","description":"Adenomyosis","metadata":null},{"id":"491cdb3b938d44ec9687e9bf397fcd52","type":"TRIAL","name":"Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients","canonical_id":"clinicaltrials.gov:NCT03032848","description":"Vaginitis Atropic; Pelvic Organ Prolapse; Endometrial Hyperplasia","metadata":null},{"id":"113926c48b18481c83d500ac0df0b708","type":"TRIAL","name":"Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia","canonical_id":"clinicaltrials.gov:NCT03992937","description":"Endometrial Hyperplasia Without Atypia","metadata":null},{"id":"631e671d9cb1487286a35ca492c9c296","type":"TRIAL","name":"Vaginal PROgesterone as Maintenance Treatment After an epISode of prEterm Labor (PROMISE Study)","canonical_id":"clinicaltrials.gov:NCT00646802","description":"Threatened Premature Labor","metadata":null},{"id":"624c5fd5e7e84526a39af14f5e90e5f1","type":"TRIAL","name":"Vaginal Prasterone Versus Estriol in Women With Pelvic Floor Disorders","canonical_id":"clinicaltrials.gov:NCT07854873","description":"Pelvic Organ Prolapse (POP); Stress Urinary Incontinence (SUI)","metadata":null},{"id":"854a49c30d5640319d2651982f898a1e","type":"TRIAL","name":"Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.","canonical_id":"clinicaltrials.gov:NCT01122342","description":"Vaginitis; Dyspareunia; Breast Neoplasms","metadata":null},{"id":"6232f7c5761a47c8ae7e225bebebe572","type":"TRIAL","name":"Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease","canonical_id":"clinicaltrials.gov:NCT02864407","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"c94bacd93aaa45068c21db6b40a0f99c","type":"TRIAL","name":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","canonical_id":"clinicaltrials.gov:NCT06107829","description":"Tardive Dyskinesia; Intellectual Disability; Developmental Disabilities","metadata":null},{"id":"1f0800ed5ce64f58bddcd9f0034d4b90","type":"TRIAL","name":"Valbenazine in Obsessive Compulsive Disorder","canonical_id":"clinicaltrials.gov:NCT07111988","description":"Obsessive-Compulsive Disorder","metadata":null},{"id":"43ef0e95f0174ea49c85ef75a5e50d20","type":"TRIAL","name":"Valdecoxib in Treating Chronic Pain in Cancer Patients","canonical_id":"clinicaltrials.gov:NCT00021996","description":"Pain; Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"79b8f2f14e6e4d43819d61fff69ca315","type":"TRIAL","name":"Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum","canonical_id":"clinicaltrials.gov:NCT03785691","description":"Hyperemesis Gravidarum; Nausea Gravidarum; Vomiting of Pregnancy","metadata":null},{"id":"94d90f674f8c429e90e9f66161fcefdf","type":"TRIAL","name":"Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)","canonical_id":"clinicaltrials.gov:NCT00346775","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"3689bee4685e4721a2e673e3021bcddc","type":"TRIAL","name":"Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation","canonical_id":"clinicaltrials.gov:NCT00964106","description":"Drug Interactions","metadata":null},{"id":"bd0fedde47534a5fa82aa41a5e928026","type":"TRIAL","name":"Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)","canonical_id":"clinicaltrials.gov:NCT04490681","description":"Heart Failure With Nonischemic Cardiomyopathy","metadata":null},{"id":"4ab2e3480ad14e3e897f90928dd82937","type":"TRIAL","name":"Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency","canonical_id":"clinicaltrials.gov:NCT02558829","description":"Growth Hormone Deficiency With Pituitary Anomalies","metadata":null},{"id":"e7f2df4c7c154a6c8f0293b258a2d1d2","type":"TRIAL","name":"Validation of Stimulated \u2206FGF19 for Diagnosing Bile Acid Diarrhoea","canonical_id":"clinicaltrials.gov:NCT03059537","description":"Bile Acid Malabsorption","metadata":null},{"id":"92fd35b4f2e24478b293292f648aced9","type":"TRIAL","name":"Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix\u00ae and FOLFIRI or FOLFOX in First Line (VALIDATE)","canonical_id":"clinicaltrials.gov:NCT03043950","description":"Metastatic Colorectal Cancer; RAS Wild-type","metadata":null},{"id":"01cbdc2fec7c4e54882eebda0b402c14","type":"TRIAL","name":"Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia","canonical_id":"clinicaltrials.gov:NCT02335268","description":"Myelodysplastic Syndromes","metadata":null},{"id":"d212078e952c4f3b8e04869a220e3a5b","type":"TRIAL","name":"Validation of the Rhinitis Control Scoring System (RCSS)","canonical_id":"clinicaltrials.gov:NCT00967967","description":"Asthma; Rhinitis","metadata":null},{"id":"9f136c286a7a4ed895e77c4d0199cf52","type":"TRIAL","name":"Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium","canonical_id":"clinicaltrials.gov:NCT04513314","description":"Covid19; Hyperactive Delirium; Pneumonia, Viral","metadata":null},{"id":"e4fb017b32234292aab6db0f557b7eee","type":"DRUG","name":"Valproic Acid","canonical_id":"mesh:D014635","description":null,"metadata":null},{"id":"4be7025d20b14ad181291556c6b9b2f8","type":"TRIAL","name":"Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine","canonical_id":"clinicaltrials.gov:NCT03885154","description":"Migraine in Children","metadata":null},{"id":"cbc28095c923439594de7d683c5759b5","type":"TRIAL","name":"Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU","canonical_id":"clinicaltrials.gov:NCT02343575","description":"Hyperactive Delirium; Mixed Delirium","metadata":null},{"id":"83d2b1a23b5447438ed1b0b7fb0286b7","type":"TRIAL","name":"Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)","canonical_id":"clinicaltrials.gov:NCT00133250","description":"Myocardial Infarction","metadata":null},{"id":"827de0f12bd644cfa4afa104c765b61e","type":"TRIAL","name":"Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol","canonical_id":"clinicaltrials.gov:NCT03263299","description":"Invitro Fertilization","metadata":null},{"id":"c9f68352c27c466188b546dc9e0485ec","type":"TRIAL","name":"Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks","canonical_id":"clinicaltrials.gov:NCT01615731","description":"Abortion, Induced","metadata":null},{"id":"f1f2b41781454d3ebb5dff95db7ecc32","type":"TRIAL","name":"Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT02768532","description":"Crohn Disease","metadata":null},{"id":"9f3ac3aad9394373a4427a70cd4995d2","type":"TRIAL","name":"Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer","canonical_id":"clinicaltrials.gov:NCT00753675","description":"Biliary Tract Cancer; Gallbladder Cancer; Cancer Of The Extrahepatic Bile Duct; Ampullary Carcinoma","metadata":null},{"id":"bb1aa5ee34914f09aed8e31af8519fa9","type":"TRIAL","name":"Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer","canonical_id":"clinicaltrials.gov:NCT01582191","description":"Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm","metadata":null},{"id":"7184b874f3fa41bb8f1bfd0f21442601","type":"TRIAL","name":"Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery","canonical_id":"clinicaltrials.gov:NCT00601614","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"cd7245f0350d40d191405947dcd65936","type":"TRIAL","name":"Vandetanib in Advanced NSCLC With RET Rearrangement","canonical_id":"clinicaltrials.gov:NCT01823068","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"e22139b6a50d4a12a2a9f96a3a658fc6","type":"TRIAL","name":"Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions","canonical_id":"clinicaltrials.gov:NCT01414426","description":"Lip and Oral Cavity Squamous Cell Carcinoma; Oral Cavity Verrucous Carcinoma; Precancerous Condition","metadata":null},{"id":"3aff36c17fbd48bf81987e3250a0897d","type":"TRIAL","name":"Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT00514046","description":"Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B","metadata":null},{"id":"c4af1b344b194454a7e8142cb126ee3e","type":"TRIAL","name":"Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","canonical_id":"clinicaltrials.gov:NCT00445549","description":"Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms","metadata":null},{"id":"f83e31f8b68f4c60ad29ec2922a725d1","type":"DRUG","name":"Vaniprevir","canonical_id":"mesh:C540393","description":null,"metadata":null},{"id":"b3b43ff8d2c748909fded29dbfe3c8ba","type":"TRIAL","name":"Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection","canonical_id":"clinicaltrials.gov:NCT00014651","description":"Pancreatic Cancer; Perioperative/Postoperative Complications","metadata":null},{"id":"17319ebafd864fc4a1f80a30cc4b2eac","type":"DRUG","name":"Vardenafil","canonical_id":"mesh:D000069058","description":null,"metadata":null},{"id":"0aae17fad59d44ffb4931934ed230e5c","type":"TRIAL","name":"Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study","canonical_id":"clinicaltrials.gov:NCT01348880","description":"Erectile Dysfunction","metadata":null},{"id":"7bfd9b5e1ad345949681c6028ec0b080","type":"TRIAL","name":"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.","canonical_id":"clinicaltrials.gov:NCT00655629","description":"Erectile Dysfunction","metadata":null},{"id":"35bee96c2b494f91bb3d89f5cca8f6bc","type":"TRIAL","name":"Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men","canonical_id":"clinicaltrials.gov:NCT00470873","description":"Erectile Dysfunction","metadata":null},{"id":"6b419ba4a4be4b51a68b679ebd661822","type":"TRIAL","name":"Vardenafil Vs Sildenafil for the Treatment of Pulmonary Hypertension of the Newborn","canonical_id":"clinicaltrials.gov:NCT06860399","description":"PPHN","metadata":null},{"id":"13cb5a225e96408f90bec58f682aa006","type":"TRIAL","name":"Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)","canonical_id":"clinicaltrials.gov:NCT02450188","description":"Erectile Dysfunction","metadata":null},{"id":"72717e234f4349d69163c6ee83ad4361","type":"TRIAL","name":"Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy","canonical_id":"clinicaltrials.gov:NCT00461123","description":"Prostatic Hypertrophy, Benign","metadata":null},{"id":"389e866e6de84fe99b530a1e85a1ff4d","type":"TRIAL","name":"Vardenafil in Tinnitus","canonical_id":"clinicaltrials.gov:NCT00666809","description":"Tinnitus","metadata":null},{"id":"2daecbf2448d400e8e51f65959e91130","type":"TRIAL","name":"Varenicline + Prazosin for Heavy Drinking Smokers","canonical_id":"clinicaltrials.gov:NCT02193256","description":"Cigarette Smoking; Alcohol Use Disorders","metadata":null},{"id":"048e6f3367b44468910cede73687f962","type":"TRIAL","name":"Varenicline For Smokers In Recovery From Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT01092702","description":"Tobacco Abstinence","metadata":null},{"id":"504e7904e9cc4fe4a8d8ba85f93c477b","type":"TRIAL","name":"Varenicline In-Patient Study","canonical_id":"clinicaltrials.gov:NCT01413516","description":"Smoking Cessation","metadata":null},{"id":"55a528a426e749839ca0b58184af267b","type":"TRIAL","name":"Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking","canonical_id":"clinicaltrials.gov:NCT00301145","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"7efd480ee2844b658782e3a6a1aee262","type":"TRIAL","name":"Varenicline Treatment for Active Alcoholic Smokers","canonical_id":"clinicaltrials.gov:NCT01347112","description":"Smoking; Tobacco Dependence; Alcohol Dependence","metadata":null},{"id":"ac7f1fe4e2134daa85582e15adc87ae6","type":"TRIAL","name":"Varenicline and Alcohol in Inpatient Addictions Program (IAP)","canonical_id":"clinicaltrials.gov:NCT01169610","description":"Alcoholism; Nicotine Dependence","metadata":null},{"id":"531e677850ad4ad4a42efc18e00d4836","type":"TRIAL","name":"Varenicline for Treatment of E-cigarette Dependence","canonical_id":"clinicaltrials.gov:NCT05541497","description":"Smoking Cessation","metadata":null},{"id":"8df6d84d958147528886328b47d54f53","type":"TRIAL","name":"Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation","canonical_id":"clinicaltrials.gov:NCT01444131","description":"Tobacco Dependence","metadata":null},{"id":"e36833fe9a7844f2914f793da13a4c0a","type":"DISEASE","name":"Varicella","canonical_id":"mesh:D002644","description":null,"metadata":null},{"id":"72ba20df267e4fbe99719c78c011ce5d","type":"DISEASE","name":"Varicose veins","canonical_id":"hp:0002619","description":null,"metadata":null},{"id":"c552b957aac24f01955d8b17529aef35","type":"DISEASE","name":"Vascular Diseases","canonical_id":"mesh:D014652","description":null,"metadata":null},{"id":"56a3ae512ef34c038a8d7843aea4487e","type":"TRIAL","name":"Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1","canonical_id":"clinicaltrials.gov:NCT04770155","description":"Vascular Function; Racial Disparity","metadata":null},{"id":"2a55ecfbaa6b495f8fd9529f7a5c549e","type":"TRIAL","name":"Vascular Dysfunction in Human Obesity Hypertension","canonical_id":"clinicaltrials.gov:NCT01983462","description":"Obesity; Prehypertension; Hypertension","metadata":null},{"id":"715fbb0d50ec4c7bb33de77b4aa9df84","type":"TRIAL","name":"Vascular Effects of High-Salt After Preeclampsia","canonical_id":"clinicaltrials.gov:NCT06749418","description":"Preeclampsia; Preeclampsia Postpartum","metadata":null},{"id":"574072152c1145cca151e397eeebdb2b","type":"TRIAL","name":"Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease","canonical_id":"clinicaltrials.gov:NCT02497300","description":"Chronic Kidney Disease; Albuminuria","metadata":null},{"id":"9b0a01f085634524b67421f8fe8d755b","type":"TRIAL","name":"Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients","canonical_id":"clinicaltrials.gov:NCT00123643","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"d7f8f7f30bfa4843a6401a75204b7d64","type":"TRIAL","name":"Vascular Effects of Sertraline in Heart Failure","canonical_id":"clinicaltrials.gov:NCT00585455","description":"Heart Failure; Depression","metadata":null},{"id":"e5cacf421e4146659aa89ca458316cb5","type":"TRIAL","name":"Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment","canonical_id":"clinicaltrials.gov:NCT04707625","description":"Retinal Vein Occlusion","metadata":null},{"id":"a57ec9a2c7c0473e9ead7b2da35242ed","type":"TRIAL","name":"Vascular Improvement With Olmesartan Medoxomil Study","canonical_id":"clinicaltrials.gov:NCT00772499","description":"Hypertension","metadata":null},{"id":"4b3c036f7d9b4c1f82492e4eb4e5637a","type":"TRIAL","name":"Vascular Inflammation in Psoriasis - Apremilast","canonical_id":"clinicaltrials.gov:NCT03082729","description":"Psoriasis; Cardiovascular Diseases","metadata":null},{"id":"fbad921b673b4edb8aa71a2364c2ee53","type":"TRIAL","name":"Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)","canonical_id":"clinicaltrials.gov:NCT02187172","description":"Psoriasis; Cardiovascular Disease","metadata":null},{"id":"fb9729ac6a5248cfa03768c088ff0be0","type":"DISEASE","name":"Vascular headache","canonical_id":"mesh:D014653","description":null,"metadata":null},{"id":"ee06691c54484bb9a7008cbaf8f9fbae","type":"TRIAL","name":"Vasodilation Effect of Inhalational Anesthetics","canonical_id":"clinicaltrials.gov:NCT00815269","description":"General Anesthesia","metadata":null},{"id":"6c73f87735aa476199f1c129c88fc9ac","type":"TRIAL","name":"Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy","canonical_id":"clinicaltrials.gov:NCT07456852","description":"Malignant Digestive System Neoplasm","metadata":null},{"id":"c7ac7b3d0d6b4195ac73f927af547897","type":"TRIAL","name":"Vasodilator and Exercise Study for DMD (VASO-REx)","canonical_id":"clinicaltrials.gov:NCT06290713","description":"Duchenne Muscular Dystrophy; Duchenne Disease; Muscular Dystrophy; Muscular Dystrophy in Children; Vasodilation; Exercise; DMD","metadata":null},{"id":"d5df1ce7d219449ba0b25bc1e4ad77c3","type":"TRIAL","name":"Vasodilators and Anti-Oxidant Therapy in Early ATN","canonical_id":"clinicaltrials.gov:NCT00286403","description":"Acute Renal Failure","metadata":null},{"id":"6f40bd17694c4642b38bf712faa13136","type":"DISEASE","name":"Vasomotor rhinitis","canonical_id":"mesh:D012223","description":null,"metadata":null},{"id":"825335681ed844ccbd47724849d1c861","type":"TRIAL","name":"Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination","canonical_id":"clinicaltrials.gov:NCT00251082","description":"Postmenopause","metadata":null},{"id":"2171abd36fd1479cbc3ad754db970b86","type":"DRUG","name":"Vasopressin","canonical_id":"mesh:C016671","description":null,"metadata":null},{"id":"1ccf956392874caa80d46ada85db893a","type":"TRIAL","name":"Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial","canonical_id":"clinicaltrials.gov:NCT01393704","description":"Blood Loss, Surgical","metadata":null},{"id":"d8e4581737064affbf3b5647920666de","type":"TRIAL","name":"Vasopressin Effects on Human Social Communication","canonical_id":"clinicaltrials.gov:NCT01327027","description":"Healthy","metadata":null},{"id":"6010dc302a01440eabaeef9067c6681a","type":"TRIAL","name":"Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator","canonical_id":"clinicaltrials.gov:NCT06426407","description":"Shock, Septic","metadata":null},{"id":"ddecb5b6fa3a4563b4939c9e72b15247","type":"TRIAL","name":"Vasopressin to Prevent Hypotension During Beach Chair Surgery","canonical_id":"clinicaltrials.gov:NCT01687894","description":"Rotator Cuff Tear Arthropathy","metadata":null},{"id":"83bcd963f54b443baee8af25a9ec5a7a","type":"TRIAL","name":"Vasopressin, Epinephrine, and Steroids for Cardiac Arrest","canonical_id":"clinicaltrials.gov:NCT00729794","description":"Cardiac Arrest","metadata":null},{"id":"3ded7e545c324108975ed958e2ed34cf","type":"TRIAL","name":"Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia","canonical_id":"clinicaltrials.gov:NCT06083948","description":"Hypotension","metadata":null},{"id":"261bff0bc1964014be738213dff7cb01","type":"DISEASE","name":"Vasospasm, Intracranial","canonical_id":"mesh:D020301","description":null,"metadata":null},{"id":"18e3ea4a6a3e487fb06da1d32f29c654","type":"DRUG","name":"Vedolizumab","canonical_id":"mesh:C543529","description":null,"metadata":null},{"id":"efb5e1959ff942b4990af958828977a0","type":"TRIAL","name":"Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption","canonical_id":"clinicaltrials.gov:NCT02788175","description":"HIV","metadata":null},{"id":"7d0a1bbc67844c268cd939fe207d65e2","type":"TRIAL","name":"Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT02630966","description":"Crohn's Disease","metadata":null},{"id":"073c7e7cc6a44ee4836355815d1fa745","type":"TRIAL","name":"Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)","canonical_id":"clinicaltrials.gov:NCT03138655","description":"Ulcerative Colitis; Crohn's Disease","metadata":null},{"id":"3c3de8fe1cf94263a08904392ab70b4f","type":"TRIAL","name":"Vedolizumab Induction May Prevent Celiac Enteritis","canonical_id":"clinicaltrials.gov:NCT02929316","description":"Celiac Disease","metadata":null},{"id":"902991c2c76e416a83fff1cb68fea97e","type":"TRIAL","name":"Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease","canonical_id":"clinicaltrials.gov:NCT02913508","description":"Ulcerative Colitis; Crohn's Disease","metadata":null},{"id":"b924b0b0413a485cb6d4b79a4936d382","type":"TRIAL","name":"Vedolizumab for Immune Mediated Colitis","canonical_id":"clinicaltrials.gov:NCT04797325","description":"Immune-Mediated Colitis","metadata":null},{"id":"c21c0efa1a0e402dbaaed693392ff238","type":"TRIAL","name":"Vedolizumab for the Treatment of Collagenous Gastritis","canonical_id":"clinicaltrials.gov:NCT06317220","description":"Collagenous Gastritis","metadata":null},{"id":"b95006a5c05c4e669c656eb0821ea9fe","type":"TRIAL","name":"Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial","canonical_id":"clinicaltrials.gov:NCT00169832","description":"Diabetes; Coronary Artery Bypass Grafting","metadata":null},{"id":"971f03aeb5ce4ed093653ba34e314426","type":"TRIAL","name":"Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00441168","description":"Multiple Myeloma","metadata":null},{"id":"eb80744d2bd742f48ef75a6cc570ae57","type":"DRUG","name":"Veliparib","canonical_id":"ncit:C60768","description":null,"metadata":null},{"id":"b55352ae80a84fc08e66fb2f95aa69c6","type":"DRUG","name":"Vemurafenib","canonical_id":"ncit:C64768","description":null,"metadata":null},{"id":"e27f597154f0448fbe8be5ec9a18e5b0","type":"TRIAL","name":"Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib","canonical_id":"clinicaltrials.gov:NCT01983124","description":"Malignant Melanoma Stage IV","metadata":null},{"id":"40aa2a3e04e14cdd96742778b311ede1","type":"TRIAL","name":"Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT01709292","description":"Thyroid Cancer","metadata":null},{"id":"c66c16e667ac44ef807dac873ca18620","type":"TRIAL","name":"Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation","canonical_id":"clinicaltrials.gov:NCT01959633","description":"Melanoma","metadata":null},{"id":"fddbe9af0f8c453aa1cd25b4860ac924","type":"TRIAL","name":"Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients","canonical_id":"clinicaltrials.gov:NCT03224208","description":"Melanoma; Melanoma (Skin); Melanoma Stage","metadata":null},{"id":"e5664efa9a2742fca87eae50243a3464","type":"TRIAL","name":"Vemurafenib Plus Cobimetinib in Metastatic Melanoma","canonical_id":"clinicaltrials.gov:NCT02414750","description":"Metastatic Melanoma","metadata":null},{"id":"e0ac6d2b9f4340cdb5f31c44c3ddf805","type":"TRIAL","name":"Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT02537600","description":"Malignant Melanoma","metadata":null},{"id":"a5f0aa7ed64b487ab30a3ab5d2a0be9b","type":"TRIAL","name":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","canonical_id":"clinicaltrials.gov:NCT06440850","description":"Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma","metadata":null},{"id":"bd75271d4ea848a4b5d617e97be5ac74","type":"TRIAL","name":"Vemurafenib and White Blood Cell Therapy for Advanced Melanoma","canonical_id":"clinicaltrials.gov:NCT01585415","description":"Metastatic Cancer; Melanoma","metadata":null},{"id":"1e8f470326964ff39c15406a437fbefc","type":"TRIAL","name":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","canonical_id":"clinicaltrials.gov:NCT03220035","description":"Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid N\u2026","metadata":null},{"id":"a457caca78ad42d08e153cd8c1fafa31","type":"TRIAL","name":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","canonical_id":"clinicaltrials.gov:NCT03554083","description":"Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8","metadata":null},{"id":"9fac6cd8e39f40c49f86de6744b61758","type":"TRIAL","name":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","canonical_id":"clinicaltrials.gov:NCT05177731","description":"AML, Adult; Chemotherapy Effect","metadata":null},{"id":"b972277de1d54814820a1e9054137523","type":"TRIAL","name":"Venetoclax Plus Inotuzumab for B-ALL","canonical_id":"clinicaltrials.gov:NCT05016947","description":"B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoma; ALL","metadata":null},{"id":"ea96f01b81e64ed2aa190b8173eab794","type":"TRIAL","name":"Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03064867","description":"Diffuse Large B-cell-lymphoma","metadata":null},{"id":"632f66de365541caa39151e70194e837","type":"TRIAL","name":"Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies","canonical_id":"clinicaltrials.gov:NCT05583175","description":"Leukemia, Myeloid, Acute; MDS; Hematopoietic Stem Cell Transplantation; Myeloid Malignancy","metadata":null},{"id":"4095ec6cd5c0450495dcbd08d6013646","type":"TRIAL","name":"Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL","canonical_id":"clinicaltrials.gov:NCT05791409","description":"CLL/SLL","metadata":null},{"id":"1a3c27234ed24479ae66b7608667029b","type":"TRIAL","name":"Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","canonical_id":"clinicaltrials.gov:NCT04550442","description":"Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome","metadata":null},{"id":"692bf4ac882e4bdc851e6dbcbe013c4c","type":"TRIAL","name":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT04990778","description":"Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma","metadata":null},{"id":"825eaaadf63a447896bf07cffb895979","type":"TRIAL","name":"Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT03735875","description":"Acute Myeloid Leukemia With FLT3/ITD Mutation; Recurrent Acute Myeloid Leukemia; Refractory Acute Leukemia","metadata":null},{"id":"fbb2895f9b724efbbfbb8331e10bd419","type":"TRIAL","name":"Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03534180","description":"Anaplastic Large Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","metadata":null},{"id":"977e756169c84a8eb7a7c2207c29e667","type":"TRIAL","name":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","canonical_id":"clinicaltrials.gov:NCT02250937","description":"Acute Myeloid Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"cea92d13c5514029a3ad8151ea81be1a","type":"TRIAL","name":"Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT07726576","description":"Leukemia, Myeloid, Acute","metadata":null},{"id":"8a4e68dfd0384d91be0d78d8d0f31d55","type":"TRIAL","name":"Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML","canonical_id":"clinicaltrials.gov:NCT06611839","description":"AML; IDH1 Mutation; Treatment","metadata":null},{"id":"9477586d45bb4e7ba2f3110b59126cc3","type":"TRIAL","name":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","canonical_id":"clinicaltrials.gov:NCT04708054","description":"Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome","metadata":null},{"id":"72ffa6785fbc4f3c90844c2aab775002","type":"TRIAL","name":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT03223610","description":"Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma","metadata":null},{"id":"79d6e93ac0f54783a7fdb4ae985bd605","type":"TRIAL","name":"Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT03399539","description":"Recurrent Plasma Cell Myeloma; T(11;14)","metadata":null},{"id":"97280842e95d4b608ad1013a97a0a30a","type":"TRIAL","name":"Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT03576547","description":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Lymphoblastic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; t(9;22)","metadata":null},{"id":"88326b6c93a6475da3114cb471fe07fb","type":"TRIAL","name":"Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS","canonical_id":"clinicaltrials.gov:NCT07238686","description":"Myelodysplastic Syndromes","metadata":null},{"id":"b9046c5173df480dbbf9b10e1a293098","type":"TRIAL","name":"Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML","canonical_id":"clinicaltrials.gov:NCT07078591","description":"Acute Myeloid Leukemia","metadata":null},{"id":"3098e99a7179420cbebcd4d33f8dfb64","type":"TRIAL","name":"Venlafaxine 25 mg Tablets Under Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00834964","description":"Healthy","metadata":null},{"id":"91941f27f11b4985a6fc917346484454","type":"TRIAL","name":"Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT01485887","description":"Major Depressive Disorder","metadata":null},{"id":"0751de8a48844839bbc1905d0df2e199","type":"TRIAL","name":"Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00084669","description":"Breast Cancer; Hot Flashes; Sleep Disorders","metadata":null},{"id":"d3a02ed5ca324924b090d593aa4a9e28","type":"TRIAL","name":"Venlafaxine for Hot Flashes After Breast Cancer","canonical_id":"clinicaltrials.gov:NCT00198250","description":"Breast Cancer","metadata":null},{"id":"b9550766ac614c36ab76b6ceccce57aa","type":"TRIAL","name":"Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide","canonical_id":"clinicaltrials.gov:NCT06945848","description":"Idiopathic Intracranial Hypertension (IIH)","metadata":null},{"id":"7ebc18006a944f9886c9bb025d0bd390","type":"DISEASE","name":"Venous Thrombosis","canonical_id":"mesh:D020246","description":null,"metadata":null},{"id":"1b7fa7cfe82448dd91081b373354efc0","type":"DISEASE","name":"Venous malformation","canonical_id":"hp:0012721","description":null,"metadata":null},{"id":"c8f241b4e28c4a8abc58e8477a29547e","type":"DISEASE","name":"Venous thrombosis","canonical_id":"hp:0004936","description":null,"metadata":null},{"id":"6a09c8eee32f4e6d9e62160b1cf717d5","type":"DISEASE","name":"Venous varices","canonical_id":"mesh:D014648","description":null,"metadata":null},{"id":"d819b18d73274e5b9560694895077511","type":"TRIAL","name":"Ventavis\u00ae Registry Protocol","canonical_id":"clinicaltrials.gov:NCT00902603","description":"Pulmonary Arterial Hypertension","metadata":null},{"id":"d3239741758c42489fe8101e6a736aa8","type":"DISEASE","name":"Ventricular Fibrillation","canonical_id":"mesh:D014693","description":null,"metadata":null},{"id":"2842f4d41ad446c8aa70325a6b770a2c","type":"DISEASE","name":"Ventricular Premature Complexes","canonical_id":"mesh:D018879","description":null,"metadata":null},{"id":"dae8126e26fe4492ad0babc654dba3b4","type":"DISEASE","name":"Ventricular arrhythmia","canonical_id":"hp:0004308","description":null,"metadata":null},{"id":"4d0f07be820d4b0da00fc1ab08a5d34e","type":"TRIAL","name":"Verapamil Effect in Cystic Fibrosis-related Dysglycemia","canonical_id":"clinicaltrials.gov:NCT07688070","description":"Cystic Fibrosis Related Diabetes; Cystic Fibrosis (CF); Abnormal Glucose Tolerance","metadata":null},{"id":"2526a0025c284c099196b6e4044656a4","type":"TRIAL","name":"Verapamil and Catamenial Epilepsy","canonical_id":"clinicaltrials.gov:NCT00559169","description":"Catamenial Epilepsy","metadata":null},{"id":"8363ef4fedcd4224b6b237d5606989ab","type":"TRIAL","name":"Verapamil for Neuroprotection in Stroke","canonical_id":"clinicaltrials.gov:NCT03347786","description":"Ischemic Stroke","metadata":null},{"id":"18d4f54c010a401a93195bfd899a78dd","type":"TRIAL","name":"Verapamil in Supraclavicular Brachial Plexus Block","canonical_id":"clinicaltrials.gov:NCT05183997","description":"Regional Anesthesia Morbidity","metadata":null},{"id":"130af92d97cd44e780f26449422b83df","type":"TRIAL","name":"Verapamil vs Heparin in Transradial Procedures","canonical_id":"clinicaltrials.gov:NCT02454491","description":"Heart Disease, Ischemic","metadata":null},{"id":"10a064df8f2042b0bd8b0f5e5edefa1c","type":"TRIAL","name":"Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness","canonical_id":"clinicaltrials.gov:NCT01669304","description":"Vestibular Migraine; Chronic Subjective Dizziness","metadata":null},{"id":"4aff133feb4f4cc2bfa0bb2855cc28d1","type":"DRUG","name":"Vernakalant","canonical_id":"mesh:C524581","description":null,"metadata":null},{"id":"968e33fe37a2426a8b96e7520bccf409","type":"TRIAL","name":"Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation","canonical_id":"clinicaltrials.gov:NCT01447862","description":"Atrial Fibrillation","metadata":null},{"id":"ae08fedd78974d978a80ce8e6a1b3f80","type":"DISEASE","name":"Verruca","canonical_id":"mesh:D014860","description":null,"metadata":null},{"id":"3dab1991e34d4d5bac1efcd0a931088f","type":"DISEASE","name":"Vertigo","canonical_id":"mesh:D014717","description":null,"metadata":null},{"id":"3cee9287169d46b7a75d04596a685269","type":"TRIAL","name":"Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study","canonical_id":"clinicaltrials.gov:NCT03517137","description":"Advanced Hodgkin Lymphoma","metadata":null},{"id":"4cf215fa61fb43bea2819ca6712e39f2","type":"TRIAL","name":"Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications","canonical_id":"clinicaltrials.gov:NCT00528671","description":"Mechanical Heart Valve Recipients","metadata":null},{"id":"9d8471ad21ba401a834a0d74f922441f","type":"TRIAL","name":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","canonical_id":"clinicaltrials.gov:NCT03844412","description":"Vestibulodynia; Temporomandibular Disorder; Fibromyalgia Syndrome; Irritable Bowel Syndrome; Migraines; Tension Headache; Endometriosis; Interstitial Cystitis; Back Pain; Chronic Fatigue Syndrome","metadata":null},{"id":"4cee925f579c481ba053e470d07fb8b2","type":"TRIAL","name":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","canonical_id":"clinicaltrials.gov:NCT04787744","description":"Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer","metadata":null},{"id":"a6249a72e3364e96b668907670754360","type":"TRIAL","name":"Vibegron for ENergy Thinking and Resilience in Aging","canonical_id":"clinicaltrials.gov:NCT06987383","description":"Obesity","metadata":null},{"id":"0fa559315c294f23bad0a40541a96bee","type":"TRIAL","name":"Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel","canonical_id":"clinicaltrials.gov:NCT00350155","description":"Healthy Volunteers","metadata":null},{"id":"4a48033406464a758575a7eaeedf390b","type":"DRUG","name":"Vigabatrin","canonical_id":"mesh:D020888","description":null,"metadata":null},{"id":"76179ee9f49f47128c9af51186f49678","type":"TRIAL","name":"Vigabatrin Ph 1 Cocaine Interaction Study","canonical_id":"clinicaltrials.gov:NCT00626834","description":"Cocaine Addiction","metadata":null},{"id":"7ef525429800401e96090e684772d05e","type":"TRIAL","name":"Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm","canonical_id":"clinicaltrials.gov:NCT04302116","description":"Infantile Spasm; West Syndrome","metadata":null},{"id":"477db853c7064ef8b2fc638703182a92","type":"TRIAL","name":"Vigabatrin and Insulin Sensitivity","canonical_id":"clinicaltrials.gov:NCT04321395","description":"NAFLD; Obesity","metadata":null},{"id":"97cc7bc79600467988b4152a822c4dda","type":"TRIAL","name":"Vigabatrin for Cocaine and Alcohol Dependence","canonical_id":"clinicaltrials.gov:NCT01335867","description":"Alcoholism; Cocaine Dependence","metadata":null},{"id":"d78d8481dc2a4b7187c0282a7bac84d5","type":"TRIAL","name":"Vigabatrin for Treatment of Cocaine Dependence","canonical_id":"clinicaltrials.gov:NCT00611130","description":"Cocaine Dependence","metadata":null},{"id":"0a5ea3e286714bf1a20ddf5c07c94cfa","type":"TRIAL","name":"Vigabatrin for the Treatment of Cocaine Dependency","canonical_id":"clinicaltrials.gov:NCT01281202","description":"Cocaine Addiction; Cocaine Dependence","metadata":null},{"id":"80e9da366ed447b08c30f9d2fac17a75","type":"DRUG","name":"Vilanterol","canonical_id":"mesh:C550468","description":null,"metadata":null},{"id":"844e0be218a64980aef6c4906af6d0c8","type":"TRIAL","name":"Vilazodone Treatment for Marijuana Dependence","canonical_id":"clinicaltrials.gov:NCT01574183","description":"Marijuana Dependence","metadata":null},{"id":"0597a6fe1f6b4e8b9994838e9dc771f2","type":"TRIAL","name":"Vilazodone for Corticosteroid-Induced Memory Impairment","canonical_id":"clinicaltrials.gov:NCT01828515","description":"Memory Impairment","metadata":null},{"id":"af4121be34d84e14bb622c5e649a7253","type":"TRIAL","name":"Vilazodone for Menopausal Hot Flashes","canonical_id":"clinicaltrials.gov:NCT01680900","description":"Hot Flushes","metadata":null},{"id":"a8d7cbd1c6c24bd2a6a20da4bb16c99f","type":"TRIAL","name":"Vilazodone for Separation Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT01999920","description":"Separation Anxiety Disorder","metadata":null},{"id":"7bd6db3ccdde4d0fbfa475d4de76d2f3","type":"TRIAL","name":"Vilazodone for Treatment of Geriatric Depression","canonical_id":"clinicaltrials.gov:NCT01608295","description":"Major Depressive Disorder","metadata":null},{"id":"9dd4e107bed64f819e1965a12318b0a8","type":"TRIAL","name":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT00106340","description":"Diabetes Mellitus, Type 2","metadata":null},{"id":"21f637a91d8c463782db324b8a98adc7","type":"TRIAL","name":"Vildagliptin Versus Dapagliflozin on Glucagon","canonical_id":"clinicaltrials.gov:NCT02475070","description":"Type 2 Diabetes","metadata":null},{"id":"b0a6c86f218248ef9e81e144ded4db15","type":"TRIAL","name":"Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy","canonical_id":"clinicaltrials.gov:NCT01398592","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"3ef025797ed840bfba4fa85173023980","type":"TRIAL","name":"Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets","canonical_id":"clinicaltrials.gov:NCT06248801","description":"Healthy Subjects","metadata":null},{"id":"5f591775f52c40599da76c37e9a553e2","type":"TRIAL","name":"Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes","canonical_id":"clinicaltrials.gov:NCT01147276","description":"Diabetes; Hypoglycemia","metadata":null},{"id":"c5c27d360b02487ea763ba3a6af8e178","type":"TRIAL","name":"Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment","canonical_id":"clinicaltrials.gov:NCT03819127","description":"Mild Cognitive Impairment","metadata":null},{"id":"1647028c72b74a67a8685c0255d30612","type":"TRIAL","name":"Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function","canonical_id":"clinicaltrials.gov:NCT01686932","description":"Diabetes Mellitus Type 2","metadata":null},{"id":"2e94d72a00134903a29345e02c2722a4","type":"TRIAL","name":"Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension","canonical_id":"clinicaltrials.gov:NCT02145611","description":"Type 2 Diabetes Mellitus; Hypertension; Endothelial Dysfunction","metadata":null},{"id":"d95db060380447ea94bf506053f494ac","type":"DRUG","name":"Viloxazine","canonical_id":"mesh:D014745","description":null,"metadata":null},{"id":"7b675b2cda994d448a53fc9842649b5e","type":"TRIAL","name":"Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma","canonical_id":"clinicaltrials.gov:NCT00352495","description":"Brain and Central Nervous System Tumors; Neurofibromatosis Type 1","metadata":null},{"id":"9b478c1a77af49ed8c15a14f3af0c6b2","type":"TRIAL","name":"Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours","canonical_id":"clinicaltrials.gov:NCT02343718","description":"Recurrent Lymphoma; Refractory Lymphoma; Solid Tumours; Central Nervous System","metadata":null},{"id":"46065df271d648d68b03b96bcfe3e9fa","type":"TRIAL","name":"Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)","canonical_id":"clinicaltrials.gov:NCT02670707","description":"Langerhans Cell Histiocytosis","metadata":null},{"id":"614386fa2dd34e9d936a687830d81c12","type":"DRUG","name":"Vincristine","canonical_id":"mesh:D014750","description":null,"metadata":null},{"id":"33dcd750ac8647cab47a4ce722e43e82","type":"DRUG","name":"Vindesine","canonical_id":"mesh:D014751","description":null,"metadata":null},{"id":"76b85737b085485d8772193f3a88ec6c","type":"DRUG","name":"Vinorelbine","canonical_id":"ncit:C1275","description":null,"metadata":null},{"id":"df46b60b38764e6280a11575611c5428","type":"TRIAL","name":"Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination","canonical_id":"clinicaltrials.gov:NCT06307808","description":"HBV; Kidney Transplantation; Liver Transplantation","metadata":null},{"id":"65e1dcfb325f4a159bc864b47fa292cf","type":"TRIAL","name":"Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT04977544","description":"Phobia","metadata":null},{"id":"5c6229f662c84e40b1a50dd5b3917059","type":"DISEASE","name":"Visceral leishmaniasis","canonical_id":"mesh:D007898","description":null,"metadata":null},{"id":"b17c31f035ea4d97ad3570c1555ba979","type":"TRIAL","name":"Vision Response to Dopamine Replacement","canonical_id":"clinicaltrials.gov:NCT01663935","description":"Albinism; Oculocutaneous Albinism","metadata":null},{"id":"706983d2ab664415be6f1346c89de794","type":"TRIAL","name":"Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT06616623","description":"Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8","metadata":null},{"id":"8a6301dd2a0042f68007b9e31b4ef4df","type":"TRIAL","name":"Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma","canonical_id":"clinicaltrials.gov:NCT01154452","description":"Adult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Myxoid Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Mesenchymoma; Adult Malignant Peripheral Nerve Sheath Tumor; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Adult Unclassified Pleomorphic Sarcoma; Chondrosarcoma; Clear Cell Sarco\u2026","metadata":null},{"id":"28c6d6de5cb146b99a0f468cfca0a35a","type":"TRIAL","name":"Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT01195415","description":"Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer","metadata":null},{"id":"51d1e2d7565245899c7716d9ae39ef23","type":"TRIAL","name":"Vismodegib for Treatment of Basal Cell Carcinoma","canonical_id":"clinicaltrials.gov:NCT01543581","description":"Basal Cell Carcinoma","metadata":null},{"id":"f28b55a82ae441e4a8f4f4c1d76b3124","type":"TRIAL","name":"Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention","canonical_id":"clinicaltrials.gov:NCT02067104","description":"Basal Cell Carcinomas","metadata":null},{"id":"14023bc6857e47fcb554becb472e621d","type":"TRIAL","name":"Vismodegib in Treating Patients With Advanced Chondrosarcomas","canonical_id":"clinicaltrials.gov:NCT01267955","description":"Clear Cell Chondrosarcoma; Dedifferentiated Chondrosarcoma; Locally Advanced Chondrosarcoma; Mesenchymal Chondrosarcoma; Metastatic Chondrosarcoma; Primary Central Chondrosarcoma; Unresectable Primary Central Chondrosarcoma","metadata":null},{"id":"8df6824dcd394efebddb6c8a9b0fa9e2","type":"TRIAL","name":"Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)","canonical_id":"clinicaltrials.gov:NCT01631331","description":"Basal Cell Carcinoma of the Skin; Recurrent Skin Cancer","metadata":null},{"id":"c9a206a5f01e43bc9c5726ed5333c2c0","type":"TRIAL","name":"Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma","canonical_id":"clinicaltrials.gov:NCT00939484","description":"Adult Medulloblastoma","metadata":null},{"id":"568358d85aaf42dea4cc0a3b411e7c07","type":"TRIAL","name":"Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease","canonical_id":"clinicaltrials.gov:NCT02337517","description":"Chronic Graft Versus Host Disease","metadata":null},{"id":"e7f147b7fe1e43c79ae66eb386f05300","type":"TRIAL","name":"Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma","canonical_id":"clinicaltrials.gov:NCT01239316","description":"Recurrent Childhood Medulloblastoma","metadata":null},{"id":"63dc0ae9c0eb44149b426eb7d690fc3a","type":"TRIAL","name":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","canonical_id":"clinicaltrials.gov:NCT02523014","description":"Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation","metadata":null},{"id":"d293316db85442698be714afc38e5532","type":"TRIAL","name":"Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab","canonical_id":"clinicaltrials.gov:NCT03973138","description":"Diabetic Macular Edema","metadata":null},{"id":"0b12b9d1bef14d56b2cddcebb544fb5b","type":"TRIAL","name":"Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin","canonical_id":"clinicaltrials.gov:NCT06440473","description":"Healthy Skin","metadata":null},{"id":"4557757ee21b47f49b8b05dc707ce196","type":"TRIAL","name":"Visualizing Beta Cells in Patients With a History of Gestational Diabetes","canonical_id":"clinicaltrials.gov:NCT03182296","description":"Gestational Diabetes","metadata":null},{"id":"20a7a3727c1546c4ab016684b6bd32e2","type":"TRIAL","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure","canonical_id":"clinicaltrials.gov:NCT07219459","description":"Unresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma; Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound","metadata":null},{"id":"08483c0118b24332a4e84b6224b7a628","type":"TRIAL","name":"Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)","canonical_id":"clinicaltrials.gov:NCT00344825","description":"Leukemia, B-Cell, Chronic","metadata":null},{"id":"e26a28c274c648a3849fa88ff8379f9d","type":"DISEASE","name":"Vitamin A deficiency","canonical_id":"mesh:D014802","description":null,"metadata":null},{"id":"c5c2847aeed94c48bc375ae697c21510","type":"DISEASE","name":"Vitamin B6 deficiency","canonical_id":"mesh:D026681","description":null,"metadata":null},{"id":"6e1e7ef9e15248aea507ebc346e33179","type":"TRIAL","name":"Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1","canonical_id":"clinicaltrials.gov:NCT01890772","description":"Hepatitis C","metadata":null},{"id":"a2e3d38c633944ecaed210e51d7261e6","type":"TRIAL","name":"Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients","canonical_id":"clinicaltrials.gov:NCT00958451","description":"Secondary Hyperparathyroidism; Chronic Kidney Disease","metadata":null},{"id":"0b0d27762c8c4201ad30757de7d8c16e","type":"TRIAL","name":"Vitamin D Deficiency in Patients With Hypertension","canonical_id":"clinicaltrials.gov:NCT00974922","description":"Vitamin D Deficiency; Hypertension","metadata":null},{"id":"a5bc967763e049b88ab6c3afe2873b58","type":"TRIAL","name":"Vitamin D Supplementation in Acne","canonical_id":"clinicaltrials.gov:NCT06141330","description":"Acne Vulgaris","metadata":null},{"id":"864a24da863e41328950466fb8c0fe8a","type":"TRIAL","name":"Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet","canonical_id":"clinicaltrials.gov:NCT06201013","description":"Urinary Bladder, Overactive; Overactive Bladder; Urinary Incontinence, Urge","metadata":null},{"id":"8f8f7245d3fb439d99393b41251963e1","type":"DISEASE","name":"Vitamin D deficiency","canonical_id":"mesh:D014808","description":null,"metadata":null},{"id":"b21619e38f024258ba6d4d94842d372c","type":"TRIAL","name":"Vitamin D, Insulin Resistance and Inflammation in ESRD","canonical_id":"clinicaltrials.gov:NCT00656032","description":"End Stage Renal Disease","metadata":null},{"id":"1431222cdf0e4dc69898195b407df58c","type":"DRUG","name":"Vitamin E","canonical_id":"mesh:D014810","description":null,"metadata":null},{"id":"0f3d2d2686ba42e194c2f4c8ac2571de","type":"TRIAL","name":"Vitamin E Plus Mefenamic Acid Versus Mefenamic Acid Alone for Treating Primary Dysmenorrhea in Women","canonical_id":"clinicaltrials.gov:NCT07466342","description":"Dysmenorrhea Primary; Vitamin E; Mefenamic Acid","metadata":null},{"id":"6f6c5685070546b1954d7512899f6ca7","type":"DISEASE","name":"Vitamin E deficiency","canonical_id":"mesh:D014811","description":null,"metadata":null},{"id":"6e61d1e72d334c3dbca49a67cf7e37ad","type":"DISEASE","name":"Vitamin deficiency","canonical_id":"mesh:D001361","description":null,"metadata":null},{"id":"04d5d0eda0174edd95d5c36f06b8f807","type":"GO_TERM","name":"Viteagnusin D synthase activity","canonical_id":"go:GO:0062203","description":"\"Catalysis of the reaction: H2O + peregrinol diphosphate = diphosphate + viteagnusin D.\" [PMID:29315936, RHEA:62180]","metadata":null},{"id":"374e3de67fbd48d0a72ff1ca11b290b7","type":"DISEASE","name":"Vitiligo","canonical_id":"mesh:D014820","description":null,"metadata":null},{"id":"b63844371288449c90243004c80cb63a","type":"TRIAL","name":"Vitiligo Treatment by Targeting TYK2 Mediated Responses","canonical_id":"clinicaltrials.gov:NCT06327321","description":"Vitiligo, Generalized","metadata":null},{"id":"210802f62cdd47e1a048b75f1e31a767","type":"TRIAL","name":"Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)","canonical_id":"clinicaltrials.gov:NCT01082393","description":"Vitiligo","metadata":null},{"id":"62ac296dbe48440989464b536aa15671","type":"DISEASE","name":"Vivax malaria","canonical_id":"mesh:D016780","description":null,"metadata":null},{"id":"7818635741eb4723a66f755ea82ec6e1","type":"TRIAL","name":"Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)","canonical_id":"clinicaltrials.gov:NCT01470326","description":"Osteoporosis","metadata":null},{"id":"85ce423230ac465ea41bb3ceab49ce6c","type":"GO_TERM","name":"Vma12-Vma22 assembly complex","canonical_id":"go:GO:1990871","description":"\"A protein complex that is involved in the assembly of the V-ATPase complex. In the budding yeast Saccharomyces cerevisiae, this complex consists of Vma12p and Vma22p.\" [GOC:rb, PMID:9660861]","metadata":null},{"id":"c39be712bca84aa6ad56cf5b33129f6e","type":"TRIAL","name":"Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis","canonical_id":"clinicaltrials.gov:NCT05288855","description":"Adolescent Lupus Nephritis; Pediatric Lupus Nephritis","metadata":null},{"id":"766cbf476f634ab084cfc7199fcaa299","type":"TRIAL","name":"Voclosporin in Healthy Japanese Volunteers","canonical_id":"clinicaltrials.gov:NCT02949999","description":"Volunteers","metadata":null},{"id":"8fec3995c5af4f30b07c987e8c527b7e","type":"PROTEIN","name":"Voltage-dependent L-type calcium channel subunit beta-1","canonical_id":"uniprot:Q02641","description":null,"metadata":null},{"id":"439b2a4af3d44679b5e4f57fffdf14df","type":"PROTEIN","name":"Voltage-dependent P/Q-type calcium channel subunit alpha-1A","canonical_id":"uniprot:O00555","description":null,"metadata":null},{"id":"359aef1eaf9b4a11a120fca67bbd6998","type":"PROTEIN","name":"Voltage-dependent R-type calcium channel subunit alpha-1E","canonical_id":"uniprot:Q15878","description":null,"metadata":null},{"id":"f2eaa0a900f849c080d30c6e78556eca","type":"PROTEIN","name":"Voltage-dependent T-type calcium channel subunit alpha-1H","canonical_id":"uniprot:O95180","description":null,"metadata":null},{"id":"01100f4512b34888a4acbe7209292718","type":"PROTEIN","name":"Voltage-dependent calcium channel gamma-1 subunit","canonical_id":"uniprot:Q06432","description":null,"metadata":null},{"id":"019ee359ac3540898c16d84682fca561","type":"PROTEIN","name":"Voltage-dependent calcium channel subunit alpha-2/delta-1","canonical_id":"uniprot:P54289","description":null,"metadata":null},{"id":"956ec7dde2e04fbca41e5c5fa6a97ebc","type":"PROTEIN","name":"Voltage-dependent calcium channel subunit alpha-2/delta-2","canonical_id":"uniprot:Q9NY47","description":null,"metadata":null},{"id":"77fecad515ae456b8559beb614138339","type":"DISEASE","name":"Vomiting","canonical_id":"hp:0002013","description":null,"metadata":null},{"id":"eaea59e0a12a440caddf201ac927de74","type":"DISEASE","name":"Vomiting","canonical_id":"mesh:D014839","description":null,"metadata":null},{"id":"aeddda4117d64e18b42da4ec04ab2577","type":"DISEASE","name":"Von Willebrand disease","canonical_id":"orphanet:903","description":null,"metadata":null},{"id":"5feda569effe4c71b2f1f2a264c7e1fb","type":"DISEASE","name":"Von Willebrand disorder","canonical_id":"mesh:D014842","description":null,"metadata":null},{"id":"d901e32fb116486bb7faaa3defcb2d50","type":"DRUG","name":"Vonoprazan","canonical_id":"mesh:C552956","description":null,"metadata":null},{"id":"6a37085c44574bf989f3650a8f7d0f9d","type":"TRIAL","name":"Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access","canonical_id":"clinicaltrials.gov:NCT02475837","description":"AV Fistula","metadata":null},{"id":"a991099556294555aed393867bd4cc05","type":"TRIAL","name":"Vorapaxar and Lower Extremity Bypass Grafts","canonical_id":"clinicaltrials.gov:NCT02975583","description":"Peripheral Artery Disease","metadata":null},{"id":"062254fd865547268585475a45c2b1a9","type":"TRIAL","name":"Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus","canonical_id":"clinicaltrials.gov:NCT02548650","description":"Myocardial Infarction; Diabetes Mellitus; Peripheral Arterial Disease","metadata":null},{"id":"7264cab222b84d57bcf3460a43a92f71","type":"TRIAL","name":"Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor","canonical_id":"clinicaltrials.gov:NCT02545933","description":"Myocardial Infarction","metadata":null},{"id":"d77ee6b3165c4ed195e271e236a4e38d","type":"TRIAL","name":"Vorapaxar in the Human Endotoxemia Model","canonical_id":"clinicaltrials.gov:NCT02875028","description":"Healthy Volunteers","metadata":null},{"id":"db98773925eb493da0ae32559c1121e9","type":"TRIAL","name":"Vorapaxar on Thrombin Generation and Coagulability","canonical_id":"clinicaltrials.gov:NCT03207451","description":"Coronary Artery Disease; Peripheral Vascular Disease; Myocardial Infarction","metadata":null},{"id":"eb435bfc46fd416f9f6cb130b2d0cd4f","type":"DRUG","name":"Vorinostat","canonical_id":"ncit:C1796","description":null,"metadata":null},{"id":"18f52ead374d4b29923f5309a0736014","type":"TRIAL","name":"Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01578343","description":"Mantle Cell Lymphoma","metadata":null},{"id":"a71127f2351046b98714e482d61f4ee7","type":"TRIAL","name":"Vorinostat Plus Radiation Therapy in Pancreatic Cancer","canonical_id":"clinicaltrials.gov:NCT00831493","description":"Pancreatic Cancer","metadata":null},{"id":"9c2d4995a2c54326b5c496ce29a4dae8","type":"TRIAL","name":"Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant","canonical_id":"clinicaltrials.gov:NCT01790568","description":"Graft vs Host Disease; Hematologic Neoplasms; Non-Neoplastic Hematologic and Lymphocytic Disorder","metadata":null},{"id":"1b7be6a3d425416ab82e8c4b4756dc93","type":"TRIAL","name":"Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies","canonical_id":"clinicaltrials.gov:NCT01421173","description":"Lymphoma","metadata":null},{"id":"4dc0c238d47c45e3bab597fb59909284","type":"TRIAL","name":"Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00336063","description":"Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7","metadata":null},{"id":"7994cab1f89a4c108082f17719f3ad38","type":"TRIAL","name":"Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00310024","description":"Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma","metadata":null},{"id":"08543cbea83c4d5db45729b80f68456a","type":"TRIAL","name":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","canonical_id":"clinicaltrials.gov:NCT01193842","description":"AIDS-Related Plasmablastic Lymphoma; AIDS-Related Primary Effusion Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma; Ann Arbor Stage I Grade 3 Follicular Lymphoma; Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Ann \u2026","metadata":null},{"id":"9847eb5037de47f89dcd940119f20181","type":"TRIAL","name":"Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia","canonical_id":"clinicaltrials.gov:NCT00275080","description":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute \u2026","metadata":null},{"id":"8417eab2b853412ba9a6a024883f148e","type":"TRIAL","name":"Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00331955","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"854ca21c95e543f386b3753488bd03eb","type":"TRIAL","name":"Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors","canonical_id":"clinicaltrials.gov:NCT00243100","description":"Unspecified Adult Solid Tumor, Protocol Specific","metadata":null},{"id":"0f2ada9b80724108a645426bb2ff2480","type":"TRIAL","name":"Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma","canonical_id":"clinicaltrials.gov:NCT01208454","description":"Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma","metadata":null},{"id":"9ef1c20b7ba244e9a53e7d6cd8e07832","type":"TRIAL","name":"Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00729118","description":"Multiple Myeloma; Plasma Cell Neoplasm","metadata":null},{"id":"2ce11c8d020a4b479f9ce70b2a054323","type":"TRIAL","name":"Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies","canonical_id":"clinicaltrials.gov:NCT04308330","description":"Ewing Sarcoma; Rhabdomyosarcoma; Wilms Tumor; Neuroblastoma; Hepatoblastoma; Germ Cell Tumor","metadata":null},{"id":"213629ddbb84431eb286f898c2af886e","type":"TRIAL","name":"Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00253630","description":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Nodal Marginal Zone Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma","metadata":null},{"id":"a6a575955b86414fa2ff045d0d28a41a","type":"TRIAL","name":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","canonical_id":"clinicaltrials.gov:NCT01587352","description":"Metastatic Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7","metadata":null},{"id":"66b647de1c7b40d88a123cde1187486d","type":"TRIAL","name":"Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma","canonical_id":"clinicaltrials.gov:NCT00121225","description":"Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Uveal Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IV Melanoma","metadata":null},{"id":"5fddc1ca69e4455c912cb63a109710e6","type":"TRIAL","name":"Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00330161","description":"Recurrent Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"02ddf053b26d44678ce5a0922d67f3ff","type":"TRIAL","name":"Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00132028","description":"Adult Favorable Prognosis Hodgkin Lymphoma; Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Adult Unfavorable Prognosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma","metadata":null},{"id":"8a0a13bd0a2b4436b882c2654b0f0efa","type":"TRIAL","name":"Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT01720602","description":"Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer","metadata":null},{"id":"5dfb612a1d01489fb5ee5a50f16cba39","type":"TRIAL","name":"Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)","canonical_id":"clinicaltrials.gov:NCT01720875","description":"Multiple Myeloma","metadata":null},{"id":"2428192ed5ad40b3bb761ce35e300046","type":"TRIAL","name":"Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT00910000","description":"Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer","metadata":null},{"id":"7f48f442e00e43399a47b2b5bb6d98b6","type":"TRIAL","name":"Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment","canonical_id":"clinicaltrials.gov:NCT00942266","description":"Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer","metadata":null},{"id":"3c970a7c24414b4aa634957984d2f1eb","type":"TRIAL","name":"Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer","canonical_id":"clinicaltrials.gov:NCT00537121","description":"Esophageal Cancer; Gastric Cancer; Liver Cancer","metadata":null},{"id":"e7fc7997dd184cf486f9727b46b10a6a","type":"TRIAL","name":"Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00601718","description":"Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult D\u2026","metadata":null},{"id":"2b88950008384640918a4b299cc50dc5","type":"TRIAL","name":"Vortioxetine Adjunctive Treatment in Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT05481957","description":"Bipolar Depression","metadata":null},{"id":"c871bd32146c42508701c34df8ae2016","type":"TRIAL","name":"Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes","canonical_id":"clinicaltrials.gov:NCT03580967","description":"Type2 Diabetes; Major Depressive Disorder","metadata":null},{"id":"22337f831e494ff7a6531a396f98662a","type":"TRIAL","name":"Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder","canonical_id":"clinicaltrials.gov:NCT02294305","description":"Social Anxiety Disorder; Major Depressive Disorder","metadata":null},{"id":"8255f2b5226942dd9c65bbc63589f6f0","type":"TRIAL","name":"Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression","canonical_id":"clinicaltrials.gov:NCT03598868","description":"Bipolar Disorder Depression","metadata":null},{"id":"644dcea2270f4822b1feb93859b902b1","type":"TRIAL","name":"Vortioxetine for Cancer Patients With Depression: An Observational Study","canonical_id":"clinicaltrials.gov:NCT04253678","description":"Major Depressive Disorder; Cancer","metadata":null},{"id":"2a137258ebac432a9df3c864d68ca782","type":"TRIAL","name":"Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease","canonical_id":"clinicaltrials.gov:NCT06805266","description":"Parkinson Disease, Idiopathic; Freezing of Gait; Depression Not Otherwise Specified","metadata":null},{"id":"8f08fabdef0a4912babdf49c94bc76b1","type":"TRIAL","name":"Vortioxetine for Menopausal Depression","canonical_id":"clinicaltrials.gov:NCT02234362","description":"Depression; Menopause; Vasomotor Disturbance; Hot Flashes; Sleep","metadata":null},{"id":"cc3e2021ddad4c28964a0f8055329fcb","type":"TRIAL","name":"Vortioxetine for Newly Diagnosed Glioblastoma","canonical_id":"clinicaltrials.gov:NCT07284628","description":"Glioblastoma","metadata":null},{"id":"8f146372e62e4263bbf33fd9574bdaeb","type":"TRIAL","name":"Vortioxetine for Post-COVID-19 Condition","canonical_id":"clinicaltrials.gov:NCT05047952","description":"Post-COVID-19 Condition; Post-COVID-19 Syndrome; Cognitive Impairment","metadata":null},{"id":"b5f01527fcb54c8b916e314bbc31e9c1","type":"TRIAL","name":"Vortioxetine for Treatment of Depressive Mood and Alcohol Use","canonical_id":"clinicaltrials.gov:NCT04498897","description":"Depressive Disorder, Major; Alcoholism","metadata":null},{"id":"c232b72e29404f99bc8f1dceb19a16f3","type":"TRIAL","name":"Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)","canonical_id":"clinicaltrials.gov:NCT02845349","description":"TBI; Major Depression","metadata":null},{"id":"13446d90c6d94710bd1cb955aa3d1c06","type":"TRIAL","name":"Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia","canonical_id":"clinicaltrials.gov:NCT06604520","description":"Fronto-temporal Dementia; Fronto-temporal Lobar Dementia; Frontotemporal Degeneration; Frontotemporal Dementia (FTD); Frontotemporal Dementia, Behavioral Variant; Frontotemporal Dementia","metadata":null},{"id":"f3aef875dd36475083a45cd973ed7650","type":"TRIAL","name":"Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)","canonical_id":"clinicaltrials.gov:NCT04220996","description":"MDD; Anxiety Disorders","metadata":null},{"id":"2559c944a8a44ebe83d86d5ea0203250","type":"TRIAL","name":"Vortioxetine in Patients With Depression and Early Dementia","canonical_id":"clinicaltrials.gov:NCT04294654","description":"Major Depressive Disorder; Dementia","metadata":null},{"id":"892786d275de4f4fa95091a41e2b9fe7","type":"TRIAL","name":"Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy","canonical_id":"clinicaltrials.gov:NCT04818099","description":"Radiation Injuries","metadata":null},{"id":"810b4095990b4af291a3abe22d84a502","type":"TRIAL","name":"Vortioxetine vs Sertraline in Mexicans","canonical_id":"clinicaltrials.gov:NCT03978286","description":"Depression; Type 2 Diabetes Mellitus","metadata":null},{"id":"812c50d7902d453d8b2874d40ff67dbe","type":"TRIAL","name":"Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)","canonical_id":"clinicaltrials.gov:NCT02371980","description":"Major Depressive Disorder","metadata":null},{"id":"7e646e0511fd459f8babed35d1e615bd","type":"TRIAL","name":"Voxelotor CYP and Transporter Cocktail Interaction Study","canonical_id":"clinicaltrials.gov:NCT05981365","description":"Sickle Cell Disease","metadata":null},{"id":"bb6d7e63c1744eb980380eb20aa9dd64","type":"GO_TERM","name":"Vps55/Vps68 complex","canonical_id":"go:GO:0034424","description":"\"A membrane-associated protein complex that is required for a late stage of endosomal transport. In budding yeast, this complex consists of Vps55p and Vps68p proteins.\" [PMID:18216282]","metadata":null},{"id":"d4f784fcb8c2470ab676af25c352dbbc","type":"TRIAL","name":"Vtama in Psoriasis Patients Being Treated With Biologics.","canonical_id":"clinicaltrials.gov:NCT06103695","description":"Psoriasis","metadata":null},{"id":"1877fb84eed4419286ddad975772547a","type":"TRIAL","name":"Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser","canonical_id":"clinicaltrials.gov:NCT02416531","description":"Vulvar Lichen Sclerosus","metadata":null},{"id":"78dc01f242104736836896c8d05c8c82","type":"TRIAL","name":"Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine","canonical_id":"clinicaltrials.gov:NCT00276068","description":"Vulvar Disease","metadata":null},{"id":"1ced2f7753754aa1980e64d9e1192781","type":"TRIAL","name":"Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA","canonical_id":"clinicaltrials.gov:NCT02784613","description":"Vulvovaginal Atrophy; Dyspareunia","metadata":null},{"id":"dd91b457f8684736b7348840610fdc62","type":"DISEASE","name":"Vulvovaginitis","canonical_id":"mesh:D014848","description":null,"metadata":null},{"id":"55bf27bed0e54bbe871b03e2d8d0f640","type":"TRIAL","name":"Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia","canonical_id":"clinicaltrials.gov:NCT07373847","description":"Plaque Psoriasis","metadata":null},{"id":"fb6329609e114d5fa2522b7138c813a7","type":"TRIAL","name":"Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus","canonical_id":"clinicaltrials.gov:NCT06881290","description":"Lupus Erythematosus, Systemic","metadata":null},{"id":"432cb1339a3943c4883d1aaf31cd2d98","type":"TRIAL","name":"Vyvanse in Children Aged 6 to 12 Years","canonical_id":"clinicaltrials.gov:NCT05416125","description":"Obesity, Childhood","metadata":null},{"id":"61219c02317c4bfabeebb22d09802a62","type":"GO_TERM","name":"W chromosome","canonical_id":"go:GO:0000804","description":"\"The sex chromosome present in females of species in which the female is the heterogametic sex; generally, the sex chromosome that pairs with the Z chromosome in the heterogametic sex. The W chromosome is absent from the cells of males and present in one copy in the somatic cells of females.\" [GOC:mah, GOC:mr, ISBN:0321000382, PMID:20622855]","metadata":null},{"id":"846bd7fac14d4b8c8d724df419c16ea0","type":"GO_TERM","name":"W-molybdopterin cofactor biosynthetic process","canonical_id":"go:GO:0042047","description":"\"The chemical reactions and pathways resulting in the formation of the W-molybdopterin cofactor, essential for the catalytic activity of some enzymes. The cofactor consists of a mononuclear tungsten ion (W) coordinated by one or two molybdopterin ligands.\" [ISSN:09498257]","metadata":null},{"id":"11db32daaf0d4ed39a3b8200a80b5e10","type":"GO_TERM","name":"W-molybdopterin cofactor catabolic process","canonical_id":"go:GO:0032327","description":"\"The chemical reactions and pathways resulting in the breakdown of the W-molybdopterin cofactor, essential for the catalytic activity of some enzymes. The cofactor consists of a mononuclear tungsten ion (W) coordinated by one or two molybdopterin ligands.\" [GOC:mah]","metadata":null},{"id":"337941befed647f8be0bb58279dea101","type":"GENE","name":"WAC","canonical_id":"hgnc:HGNC:17327","description":"WW domain containing adaptor with coiled-coil","metadata":{"aliases":["Wwp4","FLJ31290","PRO1741","BM-016","MGC10753"]}},{"id":"dd8bd3aa62564551a943a3a90210b057","type":"GENE","name":"WAC-AS1","canonical_id":"hgnc:HGNC:27347","description":"WAC antisense RNA 1","metadata":null},{"id":"6eeb06823320408981fafc794e8a89e9","type":"TRIAL","name":"WAKIX\u00ae (Pitolisant) Pregnancy Registry","canonical_id":"clinicaltrials.gov:NCT05536011","description":"Pregnancy Related; Narcolepsy","metadata":null},{"id":"27ae06abfb434841bf7e8dbaa2541608","type":"GENE","name":"WAKMAR1","canonical_id":"hgnc:HGNC:53753","description":"wound and keratinocyte migration associated lncRNA 1","metadata":null},{"id":"afcfd88c47a149d7ac6844fde5c7077c","type":"GENE","name":"WAKMAR2","canonical_id":"hgnc:HGNC:53754","description":"wound and keratinocyte migration associated lncRNA 2","metadata":{"aliases":["lnc-TNFAIP3"]}},{"id":"614dfeebccce4c0b89082005da02ce70","type":"TRIAL","name":"WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients","canonical_id":"clinicaltrials.gov:NCT02182557","description":"Dermatitis, Atopic","metadata":null},{"id":"fbf338ebf7ca43478d0d8dd7a5ce6021","type":"TRIAL","name":"WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis","canonical_id":"clinicaltrials.gov:NCT02182544","description":"Rhinitis, Allergic, Perennial","metadata":null},{"id":"0f027b17200f4abebf24d8a4c5ceb9f8","type":"GENE","name":"WAPL","canonical_id":"hgnc:HGNC:23293","description":"WAPL cohesin release factor","metadata":{"aliases":["FOE","KIAA0261","WAPAL"]}},{"id":"9551e5f9f5984cdd80c98aed93baa368","type":"GENE","name":"WAPL-DT","canonical_id":"hgnc:HGNC:55805","description":"WAPL divergent transcript","metadata":null},{"id":"962b8faf2fc3439794a84eb22f7fad2c","type":"GENE","name":"WARS1","canonical_id":"hgnc:HGNC:12729","description":"tryptophanyl-tRNA synthetase 1","metadata":{"aliases":["IFP53","IFI53","WARS"]}},{"id":"fffdf8f82548470dbdab6731f1cad1d3","type":"GENE","name":"WARS1-AS1","canonical_id":"hgnc:HGNC:58289","description":"WARS1 antisense RNA 1","metadata":null},{"id":"167f88dc756042be808bedc0372b338f","type":"GENE","name":"WARS1P1","canonical_id":"hgnc:HGNC:50482","description":"tryptophanyl-tRNA synthetase 1 pseudogene 1","metadata":{"aliases":["WARSP1"]}},{"id":"47f36164f6ad4889b698a8b013b97d0b","type":"GENE","name":"WARS2","canonical_id":"hgnc:HGNC:12730","description":"tryptophanyl tRNA synthetase 2, mitochondrial","metadata":{"aliases":["mtTrpRS"]}},{"id":"452826b48ea94ac9b2c6fa80d5e8fea1","type":"GENE","name":"WARS2-AS1","canonical_id":"hgnc:HGNC:40612","description":"WARS2 antisense RNA 1","metadata":null},{"id":"8dedced5ec65451d8cb6dcd028d647b1","type":"GENE","name":"WARS2-IT1","canonical_id":"hgnc:HGNC:41393","description":"WARS2 intronic transcript 1","metadata":null},{"id":"a6228836c1ce4eb4abec90e8aabcb3f6","type":"GENE","name":"WARS2P1","canonical_id":"hgnc:HGNC:45116","description":"tryptophanyl tRNA synthetase 2 pseudogene 1","metadata":null},{"id":"2690cf8b6f9e41729fac8f8701150fb9","type":"GENE","name":"WAS","canonical_id":"hgnc:HGNC:12731","description":null,"metadata":null},{"id":"c8aae1e6053b4f9e940767ac29ffff2a","type":"GENE","name":"WASF1","canonical_id":"hgnc:HGNC:12732","description":"WASP family member 1","metadata":{"aliases":["WAVE1","SCAR1","KIAA0269","WAVE","WAVE-1"]}},{"id":"d1042cea177540b99a9027a6afbabba7","type":"GENE","name":"WASF1P1","canonical_id":"hgnc:HGNC:51533","description":"WASF1 pseudogene 1","metadata":null},{"id":"1c3485aec28f4793910a30d3524c6d7d","type":"GENE","name":"WASF2","canonical_id":"hgnc:HGNC:12733","description":null,"metadata":null},{"id":"839acd34da074b7c9fb1d3a728b738a6","type":"GENE","name":"WASF3","canonical_id":"hgnc:HGNC:12734","description":null,"metadata":null},{"id":"6d2948f8e81c49618d150407ecbddf27","type":"GENE","name":"WASF3-AS1","canonical_id":"hgnc:HGNC:39841","description":"WASF3 antisense RNA 1","metadata":null},{"id":"e53d0ea9d8a54c88a183471e605f22a8","type":"GENE","name":"WASF4P","canonical_id":"hgnc:HGNC:20801","description":"WASP family member 4, pseudogene","metadata":{"aliases":["WASF4"]}},{"id":"6ed65c14167a40b98fd83ea2a75d12f9","type":"GENE","name":"WASF5P","canonical_id":"hgnc:HGNC:21665","description":"WASP family member 5, pseudogene","metadata":{"aliases":["Em:D84394.5"]}},{"id":"b6fe461ce031492899c4f614d33a9d0f","type":"GO_TERM","name":"WASH complex","canonical_id":"go:GO:0071203","description":"\"A protein complex that localizes at the surface of endosomes, where it recruits and activates the Arp2/3 complex to induce actin polymerization. In human, the WASH complex is composed of F-actin-capping protein subunits alpha and beta, WASH1, FAM21, KIAA1033, KIAA0196 and CCDC53.\" [GOC:sp, PMID:19922875]","metadata":null},{"id":"80f491d7981848859fb4e563d493b489","type":"GENE","name":"WASH2P","canonical_id":"hgnc:HGNC:33145","description":"WASP family homolog 2, pseudogene","metadata":{"aliases":["MGC52000","FAM39B"]}},{"id":"766bf04b040a47dca71f632e0680ac17","type":"GENE","name":"WASH3P","canonical_id":"hgnc:HGNC:24362","description":"WASP family homolog 3, pseudogene","metadata":{"aliases":["FLJ25222","FAM39DP"]}},{"id":"12e58464c7134a378649b3c8281afd4c","type":"GENE","name":"WASH4P","canonical_id":"hgnc:HGNC:14126","description":"WASP family homolog 4, pseudogene","metadata":{"aliases":["FLJ31670","FAM39CP"]}},{"id":"bf286523cdb44820ad8e7f020a9bc6ac","type":"GENE","name":"WASH5P","canonical_id":"hgnc:HGNC:33884","description":"WASP family homolog 5, pseudogene","metadata":null},{"id":"f1ba1d922e84474cbfacbd39ff7397a0","type":"GENE","name":"WASH6P","canonical_id":"hgnc:HGNC:31685","description":"WASP family homolog 6, pseudogene","metadata":{"aliases":["FAM39A","CXYorf1"]}},{"id":"720c57d8c9b14ab490cc14bf5bad0abe","type":"GENE","name":"WASH7P","canonical_id":"hgnc:HGNC:38034","description":"WASP family homolog 7, pseudogene","metadata":{"aliases":["FAM39F"]}},{"id":"4c8289eec10d45d095e3f4e8acfdbf87","type":"GENE","name":"WASH8P","canonical_id":"hgnc:HGNC:53913","description":"WAS protein family homolog 8, pseudogene","metadata":null},{"id":"5cc918f14d2c4a11a8d09aafe2df5ed6","type":"GENE","name":"WASH9P","canonical_id":"hgnc:HGNC:53981","description":"WAS protein family homolog 9, pseudogene","metadata":null},{"id":"9ccbb18665a94f6086814b4f7f6b7171","type":"GENE","name":"WASHC1","canonical_id":"hgnc:HGNC:24361","description":"WASH complex subunit 1","metadata":{"aliases":["FLJ00038","FAM39E","WASH1"]}},{"id":"26eb28bdf4154a1bbf41905dfbda937a","type":"GENE","name":"WASHC2A","canonical_id":"hgnc:HGNC:23416","description":"WASH complex subunit 2A","metadata":{"aliases":["bA56A21.1","bA98I6.1","FLJ10824","FAM21B","FAM21A"]}},{"id":"b0355aec89f74bedbc5d505dff723342","type":"GENE","name":"WASHC2C","canonical_id":"hgnc:HGNC:23414","description":"WASH complex subunit 2C","metadata":{"aliases":["VPEF","KIAA0592","FAM21C"]}},{"id":"3e85b6127b26467b8705dd4118f10bc6","type":"GENE","name":"WASHC2EP","canonical_id":"hgnc:HGNC:45010","description":"WASHC2E, pseudogene","metadata":{"aliases":["FLJ31813","FAM21EP"]}},{"id":"24acdeff92df4f28bbb66dda5a4192f0","type":"GENE","name":"WASHC2FP","canonical_id":"hgnc:HGNC:45011","description":"WASHC2F, pseudogene","metadata":{"aliases":["FAM21FP"]}},{"id":"e99807c9598c408f949a86959415c8f4","type":"GENE","name":"WASHC3","canonical_id":"hgnc:HGNC:24256","description":"WASH complex subunit 3","metadata":{"aliases":["CGI-116","CCDC53"]}},{"id":"62cb1ea1635b40d98c816d7e08e5d6fc","type":"GENE","name":"WASHC3P1","canonical_id":"hgnc:HGNC:54983","description":"WASHC3 pseudogene 1","metadata":null},{"id":"f66c33931971488e9d0fff4cfc7cae51","type":"GENE","name":"WASHC4","canonical_id":"hgnc:HGNC:29174","description":"WASH complex subunit 4","metadata":{"aliases":["SWIP","KIAA1033"]}},{"id":"8cf6fa1f473441c1b07ec68d676fee47","type":"GENE","name":"WASHC5","canonical_id":"hgnc:HGNC:28984","description":"WASH complex subunit 5","metadata":{"aliases":["SPG8","KIAA0196"]}},{"id":"1c03ec8721f24470bc9a70d2414ce993","type":"GENE","name":"WASHC5-AS1","canonical_id":"hgnc:HGNC:43440","description":"WASHC5 antisense RNA 1","metadata":{"aliases":["KIAA0196-AS1"]}},{"id":"7a5cc8dbbee54592941e9c59909af2a0","type":"GENE","name":"WASIR1","canonical_id":"hgnc:HGNC:38513","description":"WASH and IL9R antisense RNA 1","metadata":{"aliases":["NCRNA00286B"]}},{"id":"d7095aa02d814b198ca077e92737314d","type":"GENE","name":"WASIR2","canonical_id":"hgnc:HGNC:38609","description":"WASIR family lncRNA 2","metadata":{"aliases":["NCRNA00286A"]}},{"id":"010db12fdb7946869858254c2983908d","type":"GENE","name":"WASL","canonical_id":"hgnc:HGNC:12735","description":"WASP like actin nucleation promoting factor","metadata":{"aliases":["N-WASP","NWASP","WASPB"]}},{"id":"46f075141ef34d9cbd3fae164c9f868f","type":"GENE","name":"WASL-DT","canonical_id":"hgnc:HGNC:54820","description":"WASL divergent transcript","metadata":null},{"id":"15dbb4dc7fef4ed1a4f4084c035255e5","type":"GENE","name":"WBP1","canonical_id":"hgnc:HGNC:12737","description":null,"metadata":null},{"id":"da4d7807747c48baa912ce52f2bf8173","type":"GENE","name":"WBP11","canonical_id":"hgnc:HGNC:16461","description":"WW domain binding protein 11","metadata":{"aliases":["NPWBP","SIPP1","PPP1R165","BUG13"]}},{"id":"442eee26f7754212b6cd54a8623906b5","type":"GENE","name":"WBP11P1","canonical_id":"hgnc:HGNC:26250","description":"WBP11 pseudogene 1","metadata":{"aliases":["HsT3017"]}},{"id":"7a36f26cae194386b278c951612412de","type":"GENE","name":"WBP11P2","canonical_id":"hgnc:HGNC:54786","description":"WBP11 pseudogene 2","metadata":null},{"id":"9368cc72aaf74820a263bf688d625c13","type":"GENE","name":"WBP11P3","canonical_id":"hgnc:HGNC:54789","description":"WBP11 pseudogene 3","metadata":null},{"id":"4329d75469e44c6a96140b01a758432f","type":"GENE","name":"WBP1L","canonical_id":"hgnc:HGNC:23510","description":"WW domain binding protein 1 like","metadata":{"aliases":["FLJ20154","OPAL1","C10orf26"]}},{"id":"ed91560827bb4d18a14b53b075547e41","type":"GENE","name":"WBP1LP1","canonical_id":"hgnc:HGNC:43948","description":"WBP1L pseudogene 1","metadata":null},{"id":"1bac6c1510164419bb25362c5ee0c88c","type":"GENE","name":"WBP1LP10","canonical_id":"hgnc:HGNC:51470","description":"WBP1L pseudogene 10","metadata":null},{"id":"1a5fb6391035440ca9b1079201c0dd67","type":"GENE","name":"WBP1LP11","canonical_id":"hgnc:HGNC:51471","description":"WBP1L pseudogene 11","metadata":null},{"id":"c4847f5be2d641359204b0acfa1fda62","type":"GENE","name":"WBP1LP12","canonical_id":"hgnc:HGNC:51472","description":"WBP1L pseudogene 12","metadata":null},{"id":"f6799174e0c84c46abc65461e18477fa","type":"GENE","name":"WBP1LP2","canonical_id":"hgnc:HGNC:43949","description":"WBP1L pseudogene 2","metadata":null},{"id":"5d86912f6051478faa51677d60d17463","type":"GENE","name":"WBP1LP3","canonical_id":"hgnc:HGNC:43958","description":"WBP1L pseudogene 3","metadata":null},{"id":"99fca36b80bb4d9baa5d8c45e087e345","type":"GENE","name":"WBP1LP4","canonical_id":"hgnc:HGNC:43951","description":"WBP1L pseudogene 4","metadata":null},{"id":"4834823e41934c6890dc776498af8183","type":"GENE","name":"WBP1LP5","canonical_id":"hgnc:HGNC:43957","description":"WBP1L pseudogene 5","metadata":null},{"id":"1cdb8a3e142d44089f160027a66beb3a","type":"GENE","name":"WBP1LP6","canonical_id":"hgnc:HGNC:43956","description":"WBP1L pseudogene 6","metadata":null},{"id":"8972dfca5afa4b19b55ef38c07876a63","type":"GENE","name":"WBP1LP7","canonical_id":"hgnc:HGNC:43955","description":"WBP1L pseudogene 7","metadata":null},{"id":"e3e7f873bf4d4ecd9b14c4d25bd06bd0","type":"GENE","name":"WBP1LP8","canonical_id":"hgnc:HGNC:51468","description":"WBP1L pseudogene 8","metadata":null},{"id":"a07243eacd0745cfbd3aa126c5910e10","type":"GENE","name":"WBP1LP9","canonical_id":"hgnc:HGNC:51469","description":"WBP1L pseudogene 9","metadata":null},{"id":"81088b72db2f4c0fa358007a1d3ffdba","type":"GENE","name":"WBP1P1","canonical_id":"hgnc:HGNC:54567","description":"WBP1 pseudogene 1","metadata":null},{"id":"e4b08c459183425d80f5fe3a8eb047dc","type":"GENE","name":"WBP1P2","canonical_id":"hgnc:HGNC:54568","description":"WBP1 pseudogene 2","metadata":null},{"id":"f67636042e1347bb8698d6a4f88b9efc","type":"GENE","name":"WBP2","canonical_id":"hgnc:HGNC:12738","description":"WW domain binding protein 2","metadata":{"aliases":["WBP-2","GRAMD6"]}},{"id":"d8509c8b06004e44b771daf1e7cc1e2c","type":"GENE","name":"WBP2NL","canonical_id":"hgnc:HGNC:28389","description":"WBP2 N-terminal like","metadata":{"aliases":["FLJ26145","MGC26816","PAWP","GRAMD7"]}},{"id":"294ea3a87b6b4582ad469210223b533f","type":"GENE","name":"WBP2P1","canonical_id":"hgnc:HGNC:31695","description":"WW domain binding protein 2 pseudogene 1","metadata":null},{"id":"7165dd27bed3483c9b480e39fcaed0ff","type":"GENE","name":"WBP4","canonical_id":"hgnc:HGNC:12739","description":"WW domain binding protein 4","metadata":{"aliases":["FBP21","MGC117310"]}},{"id":"e419b6148f0c44abb848c0471587425e","type":"GENE","name":"WBSCR2","canonical_id":"hgnc:HGNC:12746","description":"Williams-Beuren syndrome chromosome region 2","metadata":{"aliases":["WSCR2"]}},{"id":"9fc09cc805b145cabdb5b687aaa81926","type":"GO_TERM","name":"WD40-repeat domain binding","canonical_id":"go:GO:0071987","description":"\"Binding to a WD40 repeat domain of a protein. The WD40 repeat is a short structural motif of approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) dipeptide. Several of these repeats are combined to form a type of protein domain called the WD domain.\" [GOC:yaf, InterPro:IPR017986]","metadata":null},{"id":"2d06a5ad257b46549858884b7f74c95f","type":"GENE","name":"WDCP","canonical_id":"hgnc:HGNC:26157","description":"WD repeat and coiled coil containing","metadata":{"aliases":["FLJ21945","MMAP","C2orf44"]}},{"id":"10378b947ddd424aa4183e53f90424a3","type":"GENE","name":"WDFY1","canonical_id":"hgnc:HGNC:20451","description":"WD repeat and FYVE domain containing 1","metadata":{"aliases":["KIAA1435","FENS-1","WDF1","ZFYVE17"]}},{"id":"bf243231e27e4e9cb8ebd6851f6439f9","type":"GENE","name":"WDFY2","canonical_id":"hgnc:HGNC:20482","description":"WD repeat and FYVE domain containing 2","metadata":{"aliases":["ZFYVE22"]}},{"id":"76661117f1514877a9b9f3b567146ea8","type":"GENE","name":"WDFY3","canonical_id":"hgnc:HGNC:20751","description":"WD repeat and FYVE domain containing 3","metadata":{"aliases":["KIAA0993","ALFY","ZFYVE25"]}},{"id":"f0894c7332534dbfa764d3914ba0372e","type":"GENE","name":"WDFY3-AS1","canonical_id":"hgnc:HGNC:40935","description":"WDFY3 antisense RNA 1","metadata":null},{"id":"0bc0f4a06c64426f8aac96b8bdba1fbb","type":"GENE","name":"WDFY3-AS2","canonical_id":"hgnc:HGNC:21603","description":"WDFY3 antisense RNA 2","metadata":{"aliases":["FBI4","C4orf12","NCRNA00247"]}},{"id":"1545f9b444174ed8b320bc2466887a96","type":"GENE","name":"WDFY4","canonical_id":"hgnc:HGNC:29323","description":null,"metadata":null},{"id":"34869ccd77cc4bfa8441506143efc1fc","type":"GENE","name":"WDHD1","canonical_id":"hgnc:HGNC:23170","description":"WD repeat and HMG-box DNA binding protein 1","metadata":{"aliases":["AND-1","CTF4","CHTF4"]}},{"id":"7b808b54df2e44eca2a5453959af9f47","type":"GENE","name":"WDPCP","canonical_id":"hgnc:HGNC:28027","description":"WD repeat containing planar cell polarity effector","metadata":{"aliases":["hFrtz","fritz","BBS15","CPLANE5","C2orf86"]}},{"id":"61c101c5c9d6453b95a7b639774527f0","type":"GENE","name":"WDR1","canonical_id":"hgnc:HGNC:12754","description":"WD repeat domain 1","metadata":{"aliases":["AIP1"]}},{"id":"1ca7fe47c422417bb0cad8e2fe010086","type":"GENE","name":"WDR1-AS1","canonical_id":"hgnc:HGNC:58731","description":"WDR1 antisense RNA 1","metadata":null},{"id":"2bd6771e9bf64b40b4648af265693233","type":"GENE","name":"WDR11","canonical_id":"hgnc:HGNC:13831","description":"WD repeat domain 11","metadata":{"aliases":["KIAA1351","FLJ10506","WDR15","HH14","DR11","SRI1","BRWD2"]}},{"id":"4ead87145b8d4929b060999efe4f0729","type":"GENE","name":"WDR11-DT","canonical_id":"hgnc:HGNC:27437","description":"WDR11 divergent transcript","metadata":{"aliases":["WDR11-AS1"]}},{"id":"a582e0492d5c4d68b1cab25dda9d5857","type":"GENE","name":"WDR12","canonical_id":"hgnc:HGNC:14098","description":"WD repeat domain 12","metadata":{"aliases":["YTM1","FLJ10881"]}},{"id":"8987e5af947d4088bfe05dacbb45700d","type":"GENE","name":"WDR12P1","canonical_id":"hgnc:HGNC:58639","description":"WDR12 pseudogene 1","metadata":null},{"id":"302ee0f53bf14b13831c0e9fcb489c79","type":"GENE","name":"WDR12P2","canonical_id":"hgnc:HGNC:58640","description":"WDR12 pseudogene 2","metadata":null},{"id":"f8f0b439d8384500b4efa44a30d2cfb1","type":"GENE","name":"WDR12P3","canonical_id":"hgnc:HGNC:58641","description":"WDR12 pseudogene 3","metadata":null},{"id":"b230662af4124e859b7aa7027ac08ce9","type":"GENE","name":"WDR13","canonical_id":"hgnc:HGNC:14352","description":"WD repeat domain 13","metadata":null},{"id":"9d9df5f9ba09453b89594532ea0ca74a","type":"GENE","name":"WDR17","canonical_id":"hgnc:HGNC:16661","description":"WD repeat domain 17","metadata":null},{"id":"16fb734e70d74b5dbef9be270359d4a1","type":"GENE","name":"WDR18","canonical_id":"hgnc:HGNC:17956","description":"WD repeat domain 18","metadata":{"aliases":["Ipi3"]}},{"id":"52fcb735a826483d8bdbfd012d3ebdd7","type":"GENE","name":"WDR19","canonical_id":"hgnc:HGNC:18340","description":"WD repeat domain 19","metadata":{"aliases":["Pwdmp","KIAA1638","FLJ23127","ORF26","DYF-2","Oseg6","IFT144","NPHP13","FAP66","CFAP66"]}},{"id":"002d6d8aa1034dd19372e416d221e778","type":"GENE","name":"WDR19-DT","canonical_id":"hgnc:HGNC:58761","description":"WDR19 divergent transcript","metadata":null},{"id":"be658519b31a496c8e76b4f62f4a992f","type":"GENE","name":"WDR20","canonical_id":"hgnc:HGNC:19667","description":"WD repeat domain 20","metadata":{"aliases":["DMR","MGC33177","FLJ33659","Bun107"]}},{"id":"25ee9efecd63426ebcf0f4ddd1a76ceb","type":"GENE","name":"WDR24","canonical_id":"hgnc:HGNC:20852","description":"WD repeat domain 24","metadata":{"aliases":["DKFZp434F054","JFP7","C16orf21"]}},{"id":"3246b8d240454ae986f4c585ee1efdf9","type":"GENE","name":"WDR25","canonical_id":"hgnc:HGNC:21064","description":"WD repeat domain 25","metadata":{"aliases":["MGC4645","C14orf67"]}},{"id":"212cd1331354416ca709cbc338558499","type":"GENE","name":"WDR26","canonical_id":"hgnc:HGNC:21208","description":"WD repeat domain 26","metadata":{"aliases":["FLJ21016","GID7"]}},{"id":"63b9a3222cbe47f19cb074897f55314f","type":"GENE","name":"WDR27","canonical_id":"hgnc:HGNC:21248","description":"WD repeat domain 27","metadata":{"aliases":["MGC43690"]}},{"id":"ff00a48fad4b4158bbc58c3614504b79","type":"GENE","name":"WDR3","canonical_id":"hgnc:HGNC:12755","description":"WD repeat domain 3","metadata":{"aliases":["FLJ12796","UTP12","DIP2"]}},{"id":"b61b2f5639aa4317ab6559e6e4162dfe","type":"GENE","name":"WDR31","canonical_id":"hgnc:HGNC:21421","description":"WD repeat domain 31","metadata":{"aliases":["FLJ35921"]}},{"id":"621bd3f130264d52be139f17f0b6df57","type":"GENE","name":"WDR33","canonical_id":"hgnc:HGNC:25651","description":"WD repeat domain 33","metadata":{"aliases":["FLJ11294","WDC146","NET14"]}},{"id":"ee62ab1202474a1db8476c03b426b1a0","type":"GENE","name":"WDR35","canonical_id":"hgnc:HGNC:29250","description":"WD repeat domain 35","metadata":{"aliases":["MGC33196","KIAA1336","IFT121","IFTA1","FAP118","CFAP118"]}},{"id":"7e7f4e34e93c4282b2cf163e2ce09303","type":"GENE","name":"WDR35-DT","canonical_id":"hgnc:HGNC:55818","description":"WDR35 divergent transcript","metadata":null},{"id":"3f182cb9312f4999af4f99e25c9c8f7a","type":"GENE","name":"WDR36","canonical_id":"hgnc:HGNC:30696","description":"WD repeat domain 36","metadata":{"aliases":["TA-WDRP","UTP21","GLC1G"]}},{"id":"659aeba19cc849fd8f8201c41b9efdd0","type":"GENE","name":"WDR37","canonical_id":"hgnc:HGNC:31406","description":"WD repeat domain 37","metadata":{"aliases":["KIAA0982"]}},{"id":"6da8896af955422ba79a5323ca7cf706","type":"GENE","name":"WDR38","canonical_id":"hgnc:HGNC:23745","description":"WD repeat domain 38","metadata":null},{"id":"9662b1c1a50042d094e720d163494d1e","type":"GENE","name":"WDR4","canonical_id":"hgnc:HGNC:12756","description":"WDR4 tRNA N7-guanosine methyltransferase non-catalytic subunit","metadata":{"aliases":["TRM82","TRMT82","Wuho"]}},{"id":"038c8148179e41ea926a460dbce8b94d","type":"GENE","name":"WDR41","canonical_id":"hgnc:HGNC:25601","description":"WD repeat domain 41","metadata":{"aliases":["FLJ10904"]}},{"id":"bdc50c2956004cc1ad651f7dd0a9a70a","type":"GENE","name":"WDR43","canonical_id":"hgnc:HGNC:28945","description":"WD repeat domain 43","metadata":{"aliases":["KIAA0007","NET12","UTP5"]}},{"id":"fa8f1a6c494c4b63926b2fc62d58c21e","type":"GENE","name":"WDR44","canonical_id":"hgnc:HGNC:30512","description":"WD repeat domain 44","metadata":{"aliases":["DKFZp686L20145","RPH11","RAB11BP","SYM-4"]}},{"id":"110c4c5e18a447cb96adcb9f6318867b","type":"GENE","name":"WDR45","canonical_id":"hgnc:HGNC:28912","description":"WD repeat domain 45","metadata":{"aliases":["JM5","WIPI4","NBIA5","WDRX1"]}},{"id":"f0279dd5c09d482da119a854f9d6661a","type":"GENE","name":"WDR45B","canonical_id":"hgnc:HGNC:25072","description":"WD repeat domain 45B","metadata":{"aliases":["WIPI3","WDR45L"]}},{"id":"40015faddc124ea79d4e8ab369198bb6","type":"GENE","name":"WDR45BP1","canonical_id":"hgnc:HGNC:26605","description":"WD repeat domain 45B pseudogene 1","metadata":{"aliases":["WDR45LP1"]}},{"id":"ce5ce15af7de413797ea1b27054a64db","type":"GENE","name":"WDR45P1","canonical_id":"hgnc:HGNC:52406","description":"WD repeat domain 45 pseudogene 1","metadata":null},{"id":"019ba74850274b1787973f688f011d1b","type":"GENE","name":"WDR46","canonical_id":"hgnc:HGNC:13923","description":"WD repeat domain 46","metadata":{"aliases":["BING4","UTP7","C6orf11"]}},{"id":"7b3f32cf54084c03ab1d5d441f617c65","type":"GENE","name":"WDR47","canonical_id":"hgnc:HGNC:29141","description":"WD repeat domain 47","metadata":{"aliases":["KIAA0893"]}},{"id":"962ff9dff1b546088b2d1b0aa0902216","type":"GENE","name":"WDR48","canonical_id":"hgnc:HGNC:30914","description":"WD repeat domain 48","metadata":{"aliases":["UAF1","KIAA1449","P80","SPG60","Bun62"]}},{"id":"e03e3a270bb04ad6a33ab6081fa2e701","type":"GENE","name":"WDR49","canonical_id":"hgnc:HGNC:26587","description":"WD repeat domain 49","metadata":{"aliases":["FLJ33620"]}},{"id":"d44e9fc04d5a459eb0205f3843f4434f","type":"GENE","name":"WDR4P1","canonical_id":"hgnc:HGNC:55134","description":"WDR4 pseudogene 1","metadata":null},{"id":"72375eb928ae4c12af181df50baf4514","type":"GENE","name":"WDR4P2","canonical_id":"hgnc:HGNC:55135","description":"WDR4 pseudogene 2","metadata":null},{"id":"f9ffdc7c6b3f4e22815b62f62d0b79a2","type":"GENE","name":"WDR5","canonical_id":"hgnc:HGNC:12757","description":null,"metadata":null},{"id":"84f79b5556d046b8b3fecfd329160e73","type":"GENE","name":"WDR5-DT","canonical_id":"hgnc:HGNC:55141","description":"WDR5 divergent transcript","metadata":null},{"id":"d42019ac009d4c7d9690abc9754da108","type":"GENE","name":"WDR53","canonical_id":"hgnc:HGNC:28786","description":"WD repeat domain 53","metadata":{"aliases":["MGC64882","MGC12928"]}},{"id":"8fd433ed2f334a39b9ae75ad85827bc4","type":"GENE","name":"WDR53P1","canonical_id":"hgnc:HGNC:56422","description":"WDR53 pseudogene 1","metadata":null},{"id":"324cea0cc3ff49f5a8ab328a6347db8c","type":"GENE","name":"WDR54","canonical_id":"hgnc:HGNC:25770","description":"WD repeat domain 54","metadata":{"aliases":["FLJ12953"]}},{"id":"3314e86230df4c1a90e1779788a9558e","type":"GENE","name":"WDR55","canonical_id":"hgnc:HGNC:25971","description":"WD repeat domain 55","metadata":{"aliases":["FLJ20195","FLJ21702"]}},{"id":"dd5ba9299de849d78f6238d6935778aa","type":"GENE","name":"WDR59","canonical_id":"hgnc:HGNC:25706","description":"WD repeat domain 59","metadata":{"aliases":["FLJ12270"]}},{"id":"6f1c8e5d5fc24ab897320c6d6bf4b961","type":"GENE","name":"WDR5B","canonical_id":"hgnc:HGNC:17826","description":"WD repeat domain 5B","metadata":{"aliases":["FLJ11287"]}},{"id":"eddda754728c4913a8f37cf64d7b1c51","type":"GENE","name":"WDR5B-DT","canonical_id":"hgnc:HGNC:55192","description":"WDR5B divergent transcript","metadata":null},{"id":"462e4a6e804e484bb5537b908e8c56dd","type":"GENE","name":"WDR5CP","canonical_id":"hgnc:HGNC:57046","description":"WD repeat domain 5C, pseudogene","metadata":null},{"id":"e3ab760221ac4edf99a4273bda338c16","type":"GENE","name":"WDR6","canonical_id":"hgnc:HGNC:12758","description":"WD repeat domain 6","metadata":{"aliases":["Trm734"]}},{"id":"18e1746cd9124a08a7bb57f3ac4f52c7","type":"GENE","name":"WDR62","canonical_id":"hgnc:HGNC:24502","description":"WD repeat domain 62","metadata":{"aliases":["DKFZP434J046","FLJ33298","C19orf14","MCPH2"]}},{"id":"dcf6622236ad4d63a682855688fda6ed","type":"GENE","name":"WDR64","canonical_id":"hgnc:HGNC:26570","description":"WD repeat domain 64","metadata":{"aliases":["FLJ32978"]}},{"id":"a461e71017614b84adfe68a9fa38e170","type":"GENE","name":"WDR7","canonical_id":"hgnc:HGNC:13490","description":"WD repeat domain 7","metadata":{"aliases":["KIAA0541","TRAG"]}},{"id":"8bd2cbb7562744eebe610d9f94b4213d","type":"GENE","name":"WDR7-AS1","canonical_id":"hgnc:HGNC:58568","description":"WDR7 antisense RNA 1","metadata":null},{"id":"ded4db07b35040599084bb685be3ba13","type":"GENE","name":"WDR7-OT1","canonical_id":"hgnc:HGNC:45131","description":"WDR7 overlapping transcript 1","metadata":{"aliases":["WDR7-UA1","WDR7-UT1"]}},{"id":"fad166f26b3a4208bae1b79ecd91a644","type":"GENE","name":"WDR70","canonical_id":"hgnc:HGNC:25495","description":"WD repeat domain 70","metadata":{"aliases":["FLJ10233"]}},{"id":"79d1cd4dcdbf452dbe7917b5681f67c9","type":"GENE","name":"WDR70P1","canonical_id":"hgnc:HGNC:56557","description":"WDR70 pseudogene 1","metadata":null},{"id":"fc5b44060f274f86a750bde4fdf4bac3","type":"GENE","name":"WDR72","canonical_id":"hgnc:HGNC:26790","description":"WD repeat domain 72","metadata":{"aliases":["FLJ38736"]}},{"id":"6a150e0b9749457aaa67c5b99c2b65ca","type":"GENE","name":"WDR73","canonical_id":"hgnc:HGNC:25928","description":"WD repeat domain 73","metadata":{"aliases":["FLJ14888","HSPC264"]}},{"id":"4ff2e87856ec4da4ba7495c513f1a239","type":"GENE","name":"WDR74","canonical_id":"hgnc:HGNC:25529","description":"WD repeat domain 74","metadata":{"aliases":["FLJ10439","Nsa1"]}},{"id":"d0ba450c2d0a453bb20206d3e8c2b00c","type":"GENE","name":"WDR75","canonical_id":"hgnc:HGNC:25725","description":"WD repeat domain 75","metadata":{"aliases":["FLJ12519","NET16","UTP17"]}},{"id":"f4dcae0cc8aa4cfa97178a798772be51","type":"GENE","name":"WDR76","canonical_id":"hgnc:HGNC:25773","description":"WD repeat domain 76","metadata":{"aliases":["FLJ12973","Cmr1"]}},{"id":"53e4c8e1738a4f5083a179a542ea445a","type":"GENE","name":"WDR77","canonical_id":"hgnc:HGNC:29652","description":"WD repeat domain 77","metadata":{"aliases":["MEP50","p44"]}},{"id":"6b500d7dc83941dcadf89b590d4b7544","type":"GENE","name":"WDR77P1","canonical_id":"hgnc:HGNC:56815","description":"WDR77 pseudogene 1","metadata":null},{"id":"aff38d9296e2402aa1275d92973a4ac5","type":"GENE","name":"WDR81","canonical_id":"hgnc:HGNC:26600","description":"WD repeat domain 81","metadata":{"aliases":["FLJ33817","PPP1R166","CAMRQ2","SORF-2"]}},{"id":"ec42e652d8864ea0a48033fdc2767d4a","type":"GENE","name":"WDR81-AS1","canonical_id":"hgnc:HGNC:58142","description":"WDR81 antisense RNA 1","metadata":{"aliases":["lnc-TLCD2-1"]}},{"id":"33d594ffac7a4d339d72d179aec88cb8","type":"GENE","name":"WDR82","canonical_id":"hgnc:HGNC:28826","description":"WD repeat domain 82","metadata":{"aliases":["PRO2730","MST107","MSTP107","PRO34047","WDR82A","SWD2","TMEM113"]}},{"id":"6e23f21009fc4de180495936e553090f","type":"GENE","name":"WDR82P1","canonical_id":"hgnc:HGNC:32447","description":"WD repeat domain 82 pseudogene 1","metadata":{"aliases":["SW2","hCG26824","WDR82B","WDR82"]}},{"id":"6027b328c1964d46b480104afbd3f5ff","type":"GENE","name":"WDR82P2","canonical_id":"hgnc:HGNC:33513","description":"WD repeat domain 82 pseudogene 2","metadata":{"aliases":["WDR82C"]}},{"id":"fe4d3b7cfe5c454d8fd9e6fde82f6d9e","type":"GENE","name":"WDR83","canonical_id":"hgnc:HGNC:32672","description":"WD repeat domain 83","metadata":{"aliases":["MORG1"]}},{"id":"496df14aefcd40299d862481427cd29d","type":"GENE","name":"WDR83OS","canonical_id":"hgnc:HGNC:30203","description":"WD repeat domain 83 opposite strand","metadata":{"aliases":["PTD008","PAT10","C19orf56"]}},{"id":"e5c690378e7f46d9a60398826e2b859e","type":"GENE","name":"WDR86","canonical_id":"hgnc:HGNC:28020","description":"WD repeat domain 86","metadata":null},{"id":"a0a8751547c1462884fb5784a66ad196","type":"GENE","name":"WDR86-AS1","canonical_id":"hgnc:HGNC:41186","description":"WDR86 antisense RNA 1","metadata":null},{"id":"fbf9d370ea084f7bb845ba20ad3cf9ef","type":"GENE","name":"WDR87","canonical_id":"hgnc:HGNC:29934","description":"WD repeat domain 87","metadata":{"aliases":["NYD-SP11"]}},{"id":"c96d2fe7bddb4c7dab5f1fc0d061aa67","type":"GENE","name":"WDR87BP","canonical_id":"hgnc:HGNC:55125","description":"WD repeat domain 87B, pseudogene","metadata":null},{"id":"3a2adbcfe03f429ab1f9cf3a1d280bff","type":"GENE","name":"WDR88","canonical_id":"hgnc:HGNC:26999","description":"WD repeat domain 88","metadata":{"aliases":["PQWD"]}},{"id":"6caed2bf745d4a5f8ae218cafbfdf81c","type":"GENE","name":"WDR89","canonical_id":"hgnc:HGNC:20489","description":"WD repeat domain 89","metadata":{"aliases":["MGC9907","C14orf150"]}},{"id":"cb7774d667ec4736a09714d35b959015","type":"GENE","name":"WDR90","canonical_id":"hgnc:HGNC:26960","description":"WD repeat domain 90","metadata":{"aliases":["FLJ36483","KIAA1924","POC16","C16orf17","C16orf15","C16orf16","C16orf19","C16orf18"]}},{"id":"87e6a584169e4a629280aef1a3a5625a","type":"GENE","name":"WDR91","canonical_id":"hgnc:HGNC:24997","description":"WD repeat domain 91","metadata":{"aliases":["HSPC049","SORF-1"]}},{"id":"3b00ebfc25da48c3a60fb7ef30722d4c","type":"GENE","name":"WDR93","canonical_id":"hgnc:HGNC:26924","description":"WD repeat domain 93","metadata":{"aliases":["FAP297","C1d-87","CFAP297"]}},{"id":"26f0bc711c4d49e8ad121b967e73a6fa","type":"GENE","name":"WDR95P","canonical_id":"hgnc:HGNC:42637","description":"WD repeat domain 95, pseudogene","metadata":null},{"id":"23a0b66bec5343d98ecbe6068a4fc562","type":"GENE","name":"WDR97","canonical_id":"hgnc:HGNC:26959","description":"WD repeat domain 97","metadata":{"aliases":["KIAA1875"]}},{"id":"55dded4d99064514a52c806cb0b39c99","type":"GENE","name":"WDSUB1","canonical_id":"hgnc:HGNC:26697","description":"WD repeat, sterile alpha motif and U-box domain containing 1","metadata":{"aliases":["UBOX6","FLJ36175","WDSAM1"]}},{"id":"7c32aa86b0954403be3b07620ecda821","type":"GENE","name":"WDTC1","canonical_id":"hgnc:HGNC:29175","description":"WD and tetratricopeptide repeats 1","metadata":{"aliases":["KIAA1037","ADP","DCAF9"]}},{"id":"011b1057414b42dcaabfd320b7d8626c","type":"GENE","name":"WDTC1-DT","canonical_id":"hgnc:HGNC:55858","description":"WDTC1 divergent transcript","metadata":null},{"id":"2191f6e9d73b426e9aed00f2ae488423","type":"GENE","name":"WEE1","canonical_id":"hgnc:HGNC:12761","description":null,"metadata":null},{"id":"f78d04f9a5714f47a0aa5b247cc2592c","type":"GENE","name":"WEE1P1","canonical_id":"hgnc:HGNC:56216","description":"WEE1 pseudogene 1","metadata":null},{"id":"322e1522eb814233a2eef1abc354b220","type":"GENE","name":"WEE1P2","canonical_id":"hgnc:HGNC:56217","description":"WEE1 pseudogene 2","metadata":null},{"id":"0f933bbfcfa947de90a0097a77898219","type":"GENE","name":"WEE2","canonical_id":"hgnc:HGNC:19684","description":"WEE2 oocyte meiosis inhibiting kinase","metadata":{"aliases":["FLJ16107","WEE1B"]}},{"id":"0dbf621f629143808a089de2ad498573","type":"GENE","name":"WEE2-AS1","canonical_id":"hgnc:HGNC:48669","description":"WEE2 antisense RNA 1","metadata":null},{"id":"2fa468786ae745259119fe13eb7c42fe","type":"GENE","name":"WEE2P1","canonical_id":"hgnc:HGNC:51823","description":"WEE2 pseudogene 1","metadata":null},{"id":"fd31565a778a453a9d8a9aa8f572be87","type":"GENE","name":"WFDC1","canonical_id":"hgnc:HGNC:15466","description":"WAP four-disulfide core domain 1","metadata":{"aliases":["PS20"]}},{"id":"b5855ee7cf534a7a8b0f7af419093490","type":"GENE","name":"WFDC10A","canonical_id":"hgnc:HGNC:16139","description":"WAP four-disulfide core domain 10A","metadata":{"aliases":["dJ688G8.3","WAP10","C20orf146"]}},{"id":"8a00e84309f64358ae2b38127a1f6d64","type":"GENE","name":"WFDC10B","canonical_id":"hgnc:HGNC:20479","description":"WAP four-disulfide core domain 10B","metadata":{"aliases":["WAP12"]}},{"id":"09780a7f299a4d81b8694be0350a380f","type":"GENE","name":"WFDC11","canonical_id":"hgnc:HGNC:20478","description":"WAP four-disulfide core domain 11","metadata":{"aliases":["WAP11"]}},{"id":"738f328c1d7a4ab6963e50cba4fcb559","type":"GENE","name":"WFDC12","canonical_id":"hgnc:HGNC:16115","description":"WAP four-disulfide core domain 12","metadata":{"aliases":["dJ211D12.4","WAP2","C20orf122"]}},{"id":"c34eccad2abc4e13b9f21f445973715a","type":"GENE","name":"WFDC13","canonical_id":"hgnc:HGNC:16131","description":"WAP four-disulfide core domain 13","metadata":{"aliases":["dJ601O1.3","WAP13","C20orf138"]}},{"id":"2d9bda02fa8e4f55b575e2b7cc966be0","type":"GENE","name":"WFDC2","canonical_id":"hgnc:HGNC:15939","description":null,"metadata":null},{"id":"a5fd937a651844cbb1ac16ff3e03116d","type":"GENE","name":"WFDC21P","canonical_id":"hgnc:HGNC:50357","description":"WAP four-disulfide core domain 21, pseudogene","metadata":{"aliases":["LOC645638","lnc-DC","LNCDC"]}},{"id":"e2da3ea109a54e5ea76259c5a6c813ab","type":"GENE","name":"WFDC3","canonical_id":"hgnc:HGNC:15957","description":"WAP four-disulfide core domain 3","metadata":{"aliases":["dJ447F3.3","WAP14"]}},{"id":"23b0cd6121724ad1b5e182d268b39c92","type":"GENE","name":"WFDC5","canonical_id":"hgnc:HGNC:20477","description":"WAP four-disulfide core domain 5","metadata":{"aliases":["WAP1","dJ211D12.5"]}},{"id":"290d5dfd5f444631aa8d78c16aa0b390","type":"GENE","name":"WFDC6","canonical_id":"hgnc:HGNC:16164","description":"WAP four-disulfide core domain 6","metadata":{"aliases":["dJ461P17.11","WAP6","C20orf171"]}},{"id":"7d6d218eb8484fb5b80418a08aad2f7e","type":"GENE","name":"WFDC8","canonical_id":"hgnc:HGNC:16163","description":"WAP four-disulfide core domain 8","metadata":{"aliases":["dJ461P17.1","WAP8","C20orf170"]}},{"id":"aef8a6bc5de842d8a16679ea04813cf1","type":"GENE","name":"WFDC9","canonical_id":"hgnc:HGNC:20380","description":"WAP four-disulfide core domain 9","metadata":{"aliases":["WAP9","dJ688G8.2"]}},{"id":"cb1daa857c0b411fb026f1b21986462b","type":"GENE","name":"WFIKKN1","canonical_id":"hgnc:HGNC:30912","description":"WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1","metadata":{"aliases":["RJD2","WFIKKN","WFDC20A","C16orf12"]}},{"id":"f65bf5f6fc814c2cae0fcebf3b1ad7d6","type":"GENE","name":"WFIKKN2","canonical_id":"hgnc:HGNC:30916","description":"WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2","metadata":{"aliases":["WFIKKNRP","WFDC20B"]}},{"id":"9244c6fcdb2d46ca976fa474b0cc9f2b","type":"GENE","name":"WFS1","canonical_id":"hgnc:HGNC:12762","description":null,"metadata":null},{"id":"80abd54902cb455ebd3355294de2af36","type":"GENE","name":"WFS1-AS1","canonical_id":"hgnc:HGNC:58722","description":"WFS1 antisense RNA 1","metadata":null},{"id":"d6157504eabf4a089b80edc12ff8fb35","type":"GENE","name":"WHAMM","canonical_id":"hgnc:HGNC:30493","description":"WASP homolog associated with actin, golgi membranes and microtubules","metadata":{"aliases":["KIAA1971","WHAMM1","WHDC1"]}},{"id":"669f13df5df3433e99cdfe5421a929e2","type":"GENE","name":"WHAMMP1","canonical_id":"hgnc:HGNC:32361","description":"WHAMM pseudogene 1","metadata":{"aliases":["WHDC1P1"]}},{"id":"2a783c3f89e6404484da2d99acaeabe4","type":"GENE","name":"WHAMMP2","canonical_id":"hgnc:HGNC:32360","description":"WHAMM pseudogene 2","metadata":{"aliases":["WHDC1L2","WHAMML2"]}},{"id":"9c98090b25bd4f87902d3a8ab2e4d6ad","type":"GENE","name":"WHAMMP3","canonical_id":"hgnc:HGNC:27892","description":"WHAMM pseudogene 3","metadata":{"aliases":["WHDC1L1","WHAMML1"]}},{"id":"0cfa083b66194885ba5b2c3d8ee75bb5","type":"GENE","name":"WHAMMP4","canonical_id":"hgnc:HGNC:55700","description":"WHAMM pseudogene 4","metadata":null},{"id":"0b9a481f7dc340fea58c9cae6bf6467e","type":"DISEASE","name":"WHIM syndrome","canonical_id":"mondo:0023880","description":null,"metadata":null},{"id":"f5b5643927ef471f80a98684b5776cad","type":"DISEASE","name":"WHIM syndrome 1","canonical_id":"mondo:8000006","description":null,"metadata":null},{"id":"651550d72e34498bb1b45ab426e8c928","type":"GENE","name":"WHR1","canonical_id":"hgnc:HGNC:11398","description":"winged helix repair factor 1","metadata":{"aliases":["G11","RP1","D6S60","TWH19","STK19"]}},{"id":"04dc4ecabf254370bc6365cc390e0fe2","type":"GENE","name":"WHR1B","canonical_id":"hgnc:HGNC:21668","description":"winged helix repair factor 1B (pseudogene)","metadata":{"aliases":["bPG116M5.10","RP2","STK19B","STK19P"]}},{"id":"7303d11cc0ca4397bfb2f06016485aae","type":"GENE","name":"WHRN","canonical_id":"hgnc:HGNC:16361","description":"whirlin","metadata":{"aliases":["CIP98","USH2D","PDZD7B","DFNB31"]}},{"id":"85e034031b814183ac51f4c9c6f4e4ee","type":"GENE","name":"WHSC1","canonical_id":"hgnc:HGNC:12766","description":null,"metadata":null},{"id":"7551e5c294494011a5b087e295fc4be6","type":"GENE","name":"WHSC1L2P","canonical_id":"hgnc:HGNC:14647","description":"Wolf-Hirschhorn syndrome candidate 1-like 2, pseudogene","metadata":{"aliases":["NSD4P","HsT36289","WHSC1L1P"]}},{"id":"329faa5bcfc049f4ad6b67baebd22f9a","type":"TRIAL","name":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","canonical_id":"clinicaltrials.gov:NCT03854903","description":"Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer","metadata":null},{"id":"8c976a1e35fe4beaba9ce90cd00e0c0b","type":"GO_TERM","name":"WICH complex","canonical_id":"go:GO:0090535","description":"\"An ISWI complex that contains an ATPase subunit of the ISWI family (specifically SNF2H in mammals, which contain two ISWI homologs) and WSTF (Williams Syndrome Transcription Factor). WICH plays roles in regulation of RNAP I and III transcription and in DNA replication and repair.\" [GOC:krc, PMID:15284901, PMID:16568949, PMID:21810179]","metadata":null},{"id":"268a334547a34446bf4b94ea17546ca8","type":"GENE","name":"WIF1","canonical_id":"hgnc:HGNC:18081","description":null,"metadata":null},{"id":"a59470f5333548e5ba2be6dd0d770874","type":"GENE","name":"WIPF1","canonical_id":"hgnc:HGNC:12736","description":"WAS/WASL interacting protein family member 1","metadata":{"aliases":["WIP","WASPIP"]}},{"id":"c5e0674d7f5d43eba5f13b8018681052","type":"GENE","name":"WIPF1-AS1","canonical_id":"hgnc:HGNC:40613","description":"WIPF1 and CHRNA1 antisense RNA 1","metadata":null},{"id":"42beb950af0140f08b522e7c234b4935","type":"GENE","name":"WIPF2","canonical_id":"hgnc:HGNC:30923","description":"WAS/WASL interacting protein family member 2","metadata":{"aliases":["WICH","WIRE"]}},{"id":"117fe9ece63a496eb7d03a5c210eb6d0","type":"GENE","name":"WIPF3","canonical_id":"hgnc:HGNC:22004","description":"WAS/WASL interacting protein family member 3","metadata":{"aliases":["CR16","FLJ36931"]}},{"id":"d2bec01d14654474a93705ebb8facb5c","type":"GENE","name":"WIPI1","canonical_id":"hgnc:HGNC:25471","description":"WD repeat domain, phosphoinositide interacting 1","metadata":{"aliases":["FLJ10055","WIPI49","ATG18","ATG18A"]}},{"id":"4a8f0b1730c44b648e97371e2a3458a8","type":"GENE","name":"WIPI2","canonical_id":"hgnc:HGNC:32225","description":"WD repeat domain, phosphoinositide interacting 2","metadata":{"aliases":["ATG21","CGI-50","FLJ12979","FLJ14217","FLJ42984","DKFZP434J154","DKFZp686P02188","ATG18B"]}},{"id":"a14faa8c77504a2686a53ab6b297c070","type":"GENE","name":"WISP2","canonical_id":"hgnc:HGNC:12770","description":null,"metadata":null},{"id":"c177ecca85c0444ab11a42f118d986bb","type":"GENE","name":"WIZ","canonical_id":"hgnc:HGNC:30917","description":"WIZ zinc finger","metadata":{"aliases":["ZNF803"]}},{"id":"ed1ea874e63b41a7b1ab34ab8389580f","type":"GENE","name":"WIZP1","canonical_id":"hgnc:HGNC:51696","description":"WIZ pseudogene 1","metadata":null},{"id":"22338b99ad24424abf95b93b98a34805","type":"GENE","name":"WLS","canonical_id":"hgnc:HGNC:30238","description":"Wnt ligand secretion mediator","metadata":{"aliases":["FLJ23091","MRP","EVI","mig-14","C1orf139","GPR177"]}},{"id":"82326cae66134d76b9d655785613355d","type":"GENE","name":"WNK1","canonical_id":"hgnc:HGNC:14540","description":"WNK lysine deficient protein kinase 1","metadata":{"aliases":["HSAN2","PPP1R167","PRKWNK1","HSN2"]}},{"id":"8f62be5989dd44d7a3b1a58b5f88ad1b","type":"GENE","name":"WNK2","canonical_id":"hgnc:HGNC:14542","description":"WNK lysine deficient protein kinase 2","metadata":{"aliases":["NY-CO-43","KIAA1760","SDCCAG43","PRKWNK2"]}},{"id":"84418fb4f4cc4807b29ac4d336a49a84","type":"GENE","name":"WNK3","canonical_id":"hgnc:HGNC:14543","description":"WNK lysine deficient protein kinase 3","metadata":{"aliases":["PRKWNK3"]}},{"id":"0798d00533234fbca45ee779e7346e35","type":"GENE","name":"WNK4","canonical_id":"hgnc:HGNC:14544","description":"WNK lysine deficient protein kinase 4","metadata":{"aliases":["PRKWNK4"]}},{"id":"f92d93a95dce4acab5ab5749bbedba86","type":"GENE","name":"WNT1","canonical_id":"hgnc:HGNC:12774","description":"Wnt family member 1","metadata":{"aliases":["INT1"]}},{"id":"c3279b3b5ad64b05837030c6560069bb","type":"GENE","name":"WNT10A","canonical_id":"hgnc:HGNC:13829","description":"Wnt family member 10A","metadata":null},{"id":"af237b088172485a931726678e5beba0","type":"GENE","name":"WNT10B","canonical_id":"hgnc:HGNC:12775","description":"Wnt family member 10B","metadata":{"aliases":["WNT-12","SHFM6"]}},{"id":"ad472f89230b438683590ac7c91ef66f","type":"GENE","name":"WNT11","canonical_id":"hgnc:HGNC:12776","description":null,"metadata":null},{"id":"079392e751604469af3d2037500458db","type":"GENE","name":"WNT16","canonical_id":"hgnc:HGNC:16267","description":"Wnt family member 16","metadata":null},{"id":"a458970413a343f697d1777337607b14","type":"GENE","name":"WNT2","canonical_id":"hgnc:HGNC:12780","description":null,"metadata":null},{"id":"bf082fbd42cf47d097fd912145451956","type":"GENE","name":"WNT2B","canonical_id":"hgnc:HGNC:12781","description":null,"metadata":null},{"id":"9a6e2a7c21724a92a65364139a54a31f","type":"GENE","name":"WNT3","canonical_id":"hgnc:HGNC:12782","description":"Wnt family member 3","metadata":{"aliases":["MGC131950","MGC138321","MGC138323","INT4"]}},{"id":"7bdec08d77f443c0af82dfa26059d888","type":"GENE","name":"WNT3A","canonical_id":"hgnc:HGNC:15983","description":null,"metadata":null},{"id":"97318bd5a3f8441f99b175b2a46d52f1","type":"GENE","name":"WNT4","canonical_id":"hgnc:HGNC:12783","description":null,"metadata":null},{"id":"36bdbad08ec34b45abff258841bf4cfc","type":"GENE","name":"WNT5A","canonical_id":"hgnc:HGNC:12784","description":null,"metadata":null},{"id":"89da2fc4d8d74523ba120e11cb1ca19f","type":"GENE","name":"WNT5A-AS1","canonical_id":"hgnc:HGNC:40616","description":"WNT5A antisense RNA 1","metadata":null},{"id":"cdcb624660ae460a9f0d8082289a3834","type":"GENE","name":"WNT5B","canonical_id":"hgnc:HGNC:16265","description":"Wnt family member 5B","metadata":null},{"id":"93b05468ac994ec8b9afaf31468dd3d7","type":"GENE","name":"WNT6","canonical_id":"hgnc:HGNC:12785","description":"Wnt family member 6","metadata":null},{"id":"63aad23e70e0428bb80baec890197341","type":"GENE","name":"WNT7A","canonical_id":"hgnc:HGNC:12786","description":"Wnt family member 7A","metadata":{"aliases":["Wnt-7a"]}},{"id":"2b7eb7009fdc46788a58b1832dc843cb","type":"GENE","name":"WNT7B","canonical_id":"hgnc:HGNC:12787","description":null,"metadata":null},{"id":"a97914557d8d46da97928d683c36969b","type":"GENE","name":"WNT8A","canonical_id":"hgnc:HGNC:12788","description":"Wnt family member 8A","metadata":{"aliases":["WNT8D"]}},{"id":"8e3561424dfd4bb1a2b60030dbce7302","type":"GENE","name":"WNT8B","canonical_id":"hgnc:HGNC:12789","description":"Wnt family member 8B","metadata":null},{"id":"1ef06b3eb0c54a4285c4f23597a10e3f","type":"GENE","name":"WNT9A","canonical_id":"hgnc:HGNC:12778","description":"Wnt family member 9A","metadata":{"aliases":["WNT14"]}},{"id":"a80780db5e18419e90cdddab60727895","type":"GENE","name":"WNT9B","canonical_id":"hgnc:HGNC:12779","description":"Wnt family member 9B","metadata":{"aliases":["WNT14B","WNT15"]}},{"id":"43c554b482b4433f996e5807fe4ec9d3","type":"GENE","name":"WRAP53","canonical_id":"hgnc:HGNC:25522","description":"WD repeat containing antisense to TP53","metadata":{"aliases":["FLJ10385","TCAB1","WDR79"]}},{"id":"cf64cb4e197a44d0bbd62716ac894cbe","type":"GENE","name":"WRAP73","canonical_id":"hgnc:HGNC:12759","description":"WD repeat containing, antisense to TP73","metadata":{"aliases":["WDR8"]}},{"id":"182f3dee5bee4c5bacaa5782b43369f5","type":"GENE","name":"WRN","canonical_id":"hgnc:HGNC:12791","description":null,"metadata":null},{"id":"60b14c470dc24c8faba907028c16f857","type":"GENE","name":"WRN-AS1","canonical_id":"hgnc:HGNC:58431","description":"WRN antisense RNA 1","metadata":null},{"id":"619e8e0fb7ad4129a2cb392164f919dd","type":"GENE","name":"WRNIP1","canonical_id":"hgnc:HGNC:20876","description":"WRN helicase interacting protein 1","metadata":{"aliases":["WHIP","FLJ22526","bA420G6.2","FAP93","CFAP93"]}},{"id":"31be901d2a63483b9c456baf8fce3fae","type":"GENE","name":"WSB1","canonical_id":"hgnc:HGNC:19221","description":"WD repeat and SOCS box containing 1","metadata":{"aliases":["DKFZp564A122","DKFZp564B0482","SWIP1"]}},{"id":"a7779ebbd7ac40d396f19da3249fa84c","type":"GENE","name":"WSB2","canonical_id":"hgnc:HGNC:19222","description":"WD repeat and SOCS box containing 2","metadata":{"aliases":["SBA2","MGC10210"]}},{"id":"bbca27c2a346486eaf02b055053ba12e","type":"GENE","name":"WSCD1","canonical_id":"hgnc:HGNC:29060","description":"WSC domain sialate O sulfotransferase 1","metadata":{"aliases":["KIAA0523"]}},{"id":"6b731449d8a94e269f8baa3bd2c9da77","type":"GENE","name":"WSCD2","canonical_id":"hgnc:HGNC:29117","description":"WSC domain sialate O sulfotransferase 2","metadata":{"aliases":["KIAA0789"]}},{"id":"6a187b4f477744d0bb6dcd5b9dd27ae7","type":"GENE","name":"WSPAR","canonical_id":"hgnc:HGNC:51639","description":"Wnt signaling pathway activating non-coding RNA","metadata":{"aliases":["TCONS_00009511-XLOC_004555","lncTCF7"]}},{"id":"5b6163bc1e8d414e9c245da49491016c","type":"GENE","name":"WT1","canonical_id":"hgnc:HGNC:12796","description":null,"metadata":null},{"id":"107a9905b60942e28b576aaa82e49564","type":"GENE","name":"WT1-AS","canonical_id":"hgnc:HGNC:18135","description":"WT1 antisense RNA","metadata":{"aliases":["WIT-1","WT1AS","WT1-AS1","WIT1"]}},{"id":"155a4b67e1484de7a2145650bc9cba76","type":"GENE","name":"WTAP","canonical_id":"hgnc:HGNC:16846","description":null,"metadata":null},{"id":"e714c0cde8d543d79b1b22319875877b","type":"GENE","name":"WTAPP1","canonical_id":"hgnc:HGNC:44115","description":"WTAP pseudogene 1","metadata":null},{"id":"0bc4f429619d4ee89752bffdcc8af7f8","type":"GENE","name":"WTAPP2","canonical_id":"hgnc:HGNC:56934","description":"WTAP pseudogene 2","metadata":null},{"id":"f42f703b173a4b2aa53765237507683f","type":"GENE","name":"WTIP","canonical_id":"hgnc:HGNC:20964","description":"WT1 interacting protein","metadata":null},{"id":"59a81f30dc8a4dfa8b4b3b89d9cf9cbd","type":"GO_TERM","name":"WW domain binding","canonical_id":"go:GO:0050699","description":"\"Binding to a WW domain of a protein, a small module composed of 40 amino acids and plays a role in mediating protein-protein interactions via proline-rich regions.\" [PMID:14531730]","metadata":null},{"id":"0861c26b0daa489eb41901668f179dce","type":"GENE","name":"WWC1","canonical_id":"hgnc:HGNC:29435","description":null,"metadata":null},{"id":"bdd01478431d46bab2238ae422b9371c","type":"GENE","name":"WWC1-AS1","canonical_id":"hgnc:HGNC:59296","description":"WWC1 antisense RNA 1","metadata":null},{"id":"d2c5a87daeba4233b1d505f5d7bcf8ed","type":"GENE","name":"WWC1-AS2","canonical_id":"hgnc:HGNC:59297","description":"WWC1 antisense RNA 2","metadata":null},{"id":"4794608e8fdd46499d987fc4c8083548","type":"GENE","name":"WWC2","canonical_id":"hgnc:HGNC:24148","description":"WW and C2 domain containing 2","metadata":{"aliases":["BOMB","FLJ22029"]}},{"id":"24cab4903dcb434982d9fa12fb1e705f","type":"GENE","name":"WWC2-AS1","canonical_id":"hgnc:HGNC:41041","description":"WWC2 antisense RNA 1","metadata":{"aliases":["REIR10"]}},{"id":"2892cd7056b04caf899e27c41f913438","type":"GENE","name":"WWC2-AS2","canonical_id":"hgnc:HGNC:26390","description":"WWC2 antisense RNA 2","metadata":{"aliases":["FLJ30277","C4orf38"]}},{"id":"b322b36f903741aeb67aae59a6bccdb8","type":"GENE","name":"WWC3","canonical_id":"hgnc:HGNC:29237","description":"WWC family member 3","metadata":{"aliases":["KIAA1280","BM042"]}},{"id":"85a19933495d4cb6bb6a973461790611","type":"GENE","name":"WWC3-AS1","canonical_id":"hgnc:HGNC:41236","description":"WWC3 antisense RNA 1","metadata":null},{"id":"0b2e7b52b6844de3a4dd3875c24e32af","type":"GENE","name":"WWOX","canonical_id":"hgnc:HGNC:12799","description":null,"metadata":null},{"id":"f8ab38afc92747af99728e99fc4a76d2","type":"GENE","name":"WWOX-AS1","canonical_id":"hgnc:HGNC:53169","description":"WWOX antisense RNA 1","metadata":{"aliases":["RP11-190D6.2"]}},{"id":"fdef057fad6c4886837d4b3452db31e3","type":"GENE","name":"WWOX-AS2","canonical_id":"hgnc:HGNC:58302","description":"WWOX antisense RNA 2","metadata":null},{"id":"f04cd3bac14143849053f8bcab8aad33","type":"GENE","name":"WWP1","canonical_id":"hgnc:HGNC:17004","description":null,"metadata":null},{"id":"81b30d181d7d40838acef9dc826b40a4","type":"GENE","name":"WWP1-AS1","canonical_id":"hgnc:HGNC:55520","description":"WWP1 antisense RNA 1","metadata":{"aliases":["AC103760.1"]}},{"id":"d3ce46aa92144ca5bc5bbc2971b0465f","type":"GENE","name":"WWP1P1","canonical_id":"hgnc:HGNC:48944","description":"WW domain containing E3 ubiquitin protein ligase 1 pseudogene 1","metadata":null},{"id":"24efae23f7064823a173ae9cb14bea82","type":"GENE","name":"WWP2","canonical_id":"hgnc:HGNC:16804","description":"WW domain containing E3 ubiquitin protein ligase 2","metadata":{"aliases":["AIP2"]}},{"id":"145cb6ef0f694fd8a15a259e34424495","type":"GENE","name":"WWTR1","canonical_id":"hgnc:HGNC:24042","description":null,"metadata":null},{"id":"820e6c869b3d4c28922e939899925e6b","type":"GENE","name":"WWTR1-AS1","canonical_id":"hgnc:HGNC:41035","description":"WWTR1 antisense RNA 1","metadata":null},{"id":"85da0c64a6c14b3fbf342ca548965f8c","type":"GENE","name":"WWTR1-IT1","canonical_id":"hgnc:HGNC:41469","description":"WWTR1 intronic transcript 1","metadata":null},{"id":"e5793b5602ce48bba1304679f23f1ebd","type":"DISEASE","name":"Waardenburg syndrome","canonical_id":"mondo:0018094","description":null,"metadata":null},{"id":"9b76192737c04900a14611ca47e5109b","type":"DISEASE","name":"Waardenburg syndrome type 4A","canonical_id":"mondo:0010192","description":null,"metadata":null},{"id":"dc457034188b4650968d1bcc3692adc8","type":"DISEASE","name":"Waardenburg-Shah syndrome","canonical_id":"mondo:0019518","description":null,"metadata":null},{"id":"3d07685a0e2346d8a7c785767bbd936a","type":"DISEASE","name":"Waldenstrom macroglobulinemia","canonical_id":"mondo:0100280","description":null,"metadata":null},{"id":"409eb118716840e7af6bdcadcddd83e4","type":"DISEASE","name":"Waldenstr\u00f6m macroglobulinemia","canonical_id":"mesh:D008258","description":null,"metadata":null},{"id":"f722bfd41d134cacbf6735d750307644","type":"TRIAL","name":"Warfarin After Anterior ST-Elevation Myocardial Infarction","canonical_id":"clinicaltrials.gov:NCT00662467","description":"Myocardial Infarction","metadata":null},{"id":"83b0a72008624509a105c673aacb725b","type":"TRIAL","name":"Warfarin Dosage Adjustment Model Analysis Study","canonical_id":"clinicaltrials.gov:NCT05609500","description":"Warfarin","metadata":null},{"id":"e6991d1a30ea4c61adfd471d15d533e9","type":"TRIAL","name":"Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection","canonical_id":"clinicaltrials.gov:NCT02247414","description":"Cirrhosis; Hypertension; Status;Splenectomy; Venous Thrombosis","metadata":null},{"id":"7b96c73f69d14f90bd6787283d67b383","type":"TRIAL","name":"Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters","canonical_id":"clinicaltrials.gov:NCT00024297","description":"Thromboembolism","metadata":null},{"id":"cde8fe7683a446dabbcd7eaf48bab661","type":"GO_TERM","name":"Watasenia-luciferin 2-monooxygenase activity","canonical_id":"go:GO:0050397","description":"\"Catalysis of the reaction: Watasenia luciferin + O2 = oxidized Watasenia luciferin + CO2 + light.\" [EC:1.13.12.8]","metadata":null},{"id":"9a8c1f8326a6462c94877e3a6c469595","type":"TRIAL","name":"Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems","canonical_id":"clinicaltrials.gov:NCT05300386","description":"Anxiety Disorders; Sleep Apnea","metadata":null},{"id":"85b6597ead784c6689d1374d048ca867","type":"TRIAL","name":"Wearing-Off Period of Pharmacological Dilation and Anisocoria","canonical_id":"clinicaltrials.gov:NCT05238233","description":"Anisocoria","metadata":null},{"id":"a70177efb80d4c9298e28cd01ec2800b","type":"DISEASE","name":"Weaver syndrome","canonical_id":"mondo:0010193","description":null,"metadata":null},{"id":"b2c9f43796674675a41eaf4a18d06116","type":"TRIAL","name":"Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture","canonical_id":"clinicaltrials.gov:NCT04473989","description":"Colles' Fracture","metadata":null},{"id":"08039007d00e4f4686c5ffc721421a4a","type":"TRIAL","name":"Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01760798","description":"Osteoporosis","metadata":null},{"id":"b3ceea1e308a4f2ea9d3b42503513421","type":"GO_TERM","name":"Weibel-Palade body","canonical_id":"go:GO:0033093","description":"\"A large, elongated, rod-shaped secretory granule characteristic of vascular endothelial cells that contain a number of structurally and functionally distinct proteins, of which the best characterized are von Willebrand factor (VWF) and P-selectin. Weibel-Palade bodies are formed from the trans-Golgi network in a process that depends on VWF, which is densely packed in a highly organized manner, and on coat proteins that remain associated with the granules. Upon cell stimulation, regulated exocytosis releases the contained proteins to the cell surface, where they act in the recruitment of platelets and leukocytes and in inflammatory and vasoactive responses.\" [PMID:11935287, PMID:16087708]","metadata":null},{"id":"d611409ec35a4d2abf538d2e395a4353","type":"TRIAL","name":"Weight Loss Aid in an Exposed Population","canonical_id":"clinicaltrials.gov:NCT03582722","description":"Polybrominated Biphenyl Poisoning","metadata":null},{"id":"32f73808658a42c08919bb86a1bc229b","type":"TRIAL","name":"Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes","canonical_id":"clinicaltrials.gov:NCT00433641","description":"Obesity","metadata":null},{"id":"7be34f1d95e540689944ab300807e04f","type":"TRIAL","name":"Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing","canonical_id":"clinicaltrials.gov:NCT01453920","description":"Age Related Macular Degeneration","metadata":null},{"id":"24bc71b3ba65428a8db44e8b20bdfe61","type":"TRIAL","name":"Wheeze and Intermittent Treatment","canonical_id":"clinicaltrials.gov:NCT01142505","description":"Wheezing","metadata":null},{"id":"66094befb0a44c718319427444888f99","type":"DISEASE","name":"Wheezing","canonical_id":"hp:0030828","description":null,"metadata":null},{"id":"1277f4d0e2ae4018a8af97bdc010d62f","type":"TISSUE","name":"Whole Blood","canonical_id":"uberon:UBERON:0013756","description":null,"metadata":null},{"id":"c689085987e0477586db93becb0606a5","type":"TRIAL","name":"Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients","canonical_id":"clinicaltrials.gov:NCT00937079","description":"Hyperinsulinism; Hypoglycemia; Insulinoma","metadata":null},{"id":"3e4c20fdcc464d90b6430ea424be0f9a","type":"DISEASE","name":"Whooping Cough","canonical_id":"mesh:D014917","description":null,"metadata":null},{"id":"2ea6530f8d524ce7a387fa12e1241851","type":"TRIAL","name":"Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity","canonical_id":"clinicaltrials.gov:NCT02919683","description":"Head and Neck Cancer","metadata":null},{"id":"2d5dc5bcd1ee4717a872de173a805cd4","type":"TRIAL","name":"Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)","canonical_id":"clinicaltrials.gov:NCT07210632","description":"Brain Cancer; HGG; Glioma; High Grade Glioma; High Grade Gliomas; High Grade Glioma (III or IV); High Grade Glioma (HGG) of the Brain With BRAF Aberration","metadata":null},{"id":"22a2392ee7e84b709caff7e5e3b1d55f","type":"TRIAL","name":"Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer","canonical_id":"clinicaltrials.gov:NCT06819228","description":"HNSCC; HNSCC,Larynx, Pharynx and Oral Cavity; SCC - Squamous Cell Carcinoma","metadata":null},{"id":"5871c80206f148c58e969e9ccfdf4b7b","type":"TRIAL","name":"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors","canonical_id":"clinicaltrials.gov:NCT03911453","description":"Breast Cancer","metadata":null},{"id":"58292349425e4eea92fad88d1a59c232","type":"TRIAL","name":"Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder","canonical_id":"clinicaltrials.gov:NCT01430754","description":"Non-24-Hour Sleep-Wake Disorder","metadata":null},{"id":"be54c71658844ec0973ab343a2225251","type":"TRIAL","name":"Withdrawal of Dupilumab in Severe Asthma","canonical_id":"clinicaltrials.gov:NCT06818019","description":"Severe Asthma","metadata":null},{"id":"9964de2ed7c54e3986a7e32bcafaa79a","type":"TRIAL","name":"Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care","canonical_id":"clinicaltrials.gov:NCT00440687","description":"Chronic Obstructive Pulmonary Disease","metadata":null},{"id":"b203a5a300a84f5891b4b2160ac712c7","type":"GO_TERM","name":"Wnt protein secretion","canonical_id":"go:GO:0061355","description":"\"The controlled release of a Wnt protein from a cell.\" [GOC:bf, PMID:19223472]","metadata":null},{"id":"0557835cb9194992a5af123a28fd44e9","type":"GO_TERM","name":"Wnt receptor activity","canonical_id":"go:GO:0042813","description":"\"Combining with a Wnt protein and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:curators]","metadata":null},{"id":"3108968bb5c24f8488c2100e87bc0a30","type":"GO_TERM","name":"Wnt receptor catabolic process","canonical_id":"go:GO:0038018","description":"\"The chemical reactions and pathways resulting in the breakdown of a Wnt receptor. Internalized Wnt receptors can be recycled to the plasma membrane or sorted to lysosomes for protein degradation.\" [GOC:BHF, GOC:rl, GOC:signaling, PMID:19643732]","metadata":null},{"id":"57103af91d214158b05df85175ecc1ee","type":"GO_TERM","name":"Wnt receptor internalization","canonical_id":"go:GO:0038017","description":"\"A receptor-mediated endocytosis process that results in the movement of a Wnt receptor from the plasma membrane to the inside of the cell.\" [GOC:bf, PMID:17908284]","metadata":null},{"id":"d65d99facd324f4bbc8cdb3f43b1638f","type":"GO_TERM","name":"Wnt receptor recycling","canonical_id":"go:GO:0038019","description":"\"The process that results in the return of a Wnt receptor to an active state at the plasma membrane. An active state is when the receptor is ready to receive a Wnt signal. Internalized Wnt receptors can be recycled to the plasma membrane or sorted to lysosomes for protein degradation.\" [GOC:bf, GOC:signaling, PMID:19643732]","metadata":null},{"id":"5f66c937339f49378c2eb42cdc233aa7","type":"GO_TERM","name":"Wnt signaling pathway","canonical_id":"go:GO:0016055","description":"\"The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of a target cell and ending with a change in cell state.\" [PMID:11532397]","metadata":null},{"id":"867ec0d4c1374d5e97d228c6cc25c0b5","type":"GO_TERM","name":"Wnt signaling pathway involved in forebrain neuroblast division","canonical_id":"go:GO:0021874","description":"\"The series of molecular signals initiated by binding of Wnt protein to a receptor on the surface of the target cell that contributes to the self renewal of neuroblasts in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"662388c42f1b403d8049a330c98889c5","type":"GO_TERM","name":"Wnt signaling pathway involved in heart development","canonical_id":"go:GO:0003306","description":"\"The series of molecular signals initiated by binding of Wnt protein to a receptor on the surface of the target cell, resulting a change in cell state that contributes to the progression of the heart over time.\" [GOC:mtg_heart]","metadata":null},{"id":"a40c335f988c4c1796a06b00dcc932ac","type":"GO_TERM","name":"Wnt signaling pathway involved in somitogenesis","canonical_id":"go:GO:0090244","description":"\"The series of molecular signals initiated by binding of Wnt protein to a frizzled family receptor on the surface of the target cell and ending with a change in cell state that contributes to somitogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"98059b9b45a84e0488ba8cdce621b381","type":"GO_TERM","name":"Wnt signaling pathway, calcium modulating pathway","canonical_id":"go:GO:0007223","description":"\"A type of non-canonical Wnt signaling in which Wnt binding to its receptor on the surface of a target cell leads to an increase in intracellular calcium and activation of protein kinase C (PKC).\" [PMID:11532397, PMID:37804416]","metadata":null},{"id":"3de738d4f5694748937033fdcc4e80c2","type":"GO_TERM","name":"Wnt signaling pathway, planar cell polarity pathway","canonical_id":"go:GO:0060071","description":"\"A type of non-canonical Wnt signaling pathway in which Wnt binding to its receptor on the surface of a target cell results in the activation small G proteins such as Rho, Rac, and Cdc42 which, in turn activate effectors, including C-Jun N-terminal kinase (JNK) and Rho kinase (Rok). The signaling ends with change in the transcription of target genes and/or reorganisation of the cytoskeleton.\" [PMID:11532397, PMID:25349257, PMID:28293032, PMID:37804416]","metadata":null},{"id":"6a29c262e71e4e9ba278ccf5b2a9729a","type":"GO_TERM","name":"Wnt signaling pathway, regulating spindle positioning","canonical_id":"go:GO:0060069","description":"\"The series of molecular signals initiated by binding of Wnt protein to a frizzled family receptor on the surface of the target cell and ending with the positioning of the mitotic spindle.\" [GOC:bf, GOC:dph, PMID:11532397]","metadata":null},{"id":"afd2e639516348529cbe007b39160257","type":"GO_TERM","name":"Wnt signalosome","canonical_id":"go:GO:1990909","description":"\"A multiprotein protein complex containing membrane-localized Wnt receptors and cytosolic protein complexes, which is capable of transmitting the Wnt signal. Contains at least a Wnt protein, LRP5 or LRP6, a member of the Frizzled (Fz) family, Axin and and a Dishevelled (DVL) protein.\" [GOC:bf, GOC:PARL, PMID:22899650, PMID:25336320]","metadata":null},{"id":"bf627dc45f934d63adc28e607d313d7a","type":"GO_TERM","name":"Wnt signalosome assembly","canonical_id":"go:GO:1904887","description":"\"The aggregation, arrangement and bonding together of a set of components to form a Wnt signalosome.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22899650]","metadata":null},{"id":"2f7f1f67510d4a66b5e22e485bb6cc03","type":"GO_TERM","name":"Wnt-Frizzled-LRP5/6 complex","canonical_id":"go:GO:1990851","description":"\"A protein complex containing a secreted Wnt protein associated with its receptor, Frizzled (Fz), and co-receptor low density lipoprotein receptor-related protein 5 (LRP5) or LRP6.\" [GOC:bf, GOC:PARL, PMID:11448771, PMID:20093360]","metadata":null},{"id":"32f01eaaee70400ba7708101aba8a4e7","type":"GO_TERM","name":"Wnt-Frizzled-LRP5/6 complex assembly","canonical_id":"go:GO:1904701","description":"\"The aggregation, arrangement and bonding together of a set of components to form a Wnt-Frizzled-LRP5/6 complex.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11448771]","metadata":null},{"id":"144cf5dcfcd54d2697be70675d25d2b8","type":"GO_TERM","name":"Wnt-protein binding","canonical_id":"go:GO:0017147","description":"\"Binding to a Wnt-protein, a secreted growth factor involved in signaling.\" [GOC:jl]","metadata":null},{"id":"a104953765854b19b6cd7be35d9bb622","type":"DISEASE","name":"Wolff-Parkinson-White syndrome","canonical_id":"mondo:0008685","description":null,"metadata":null},{"id":"0020ef9e10c04b0191eecd3ee14c8aee","type":"DISEASE","name":"Wolman's disease","canonical_id":"mesh:D015223","description":null,"metadata":null},{"id":"d516beb26c5e445fb802ad173b371492","type":"TRIAL","name":"Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol","canonical_id":"clinicaltrials.gov:NCT07792122","description":"Post-Traumatic Stress Disorder, PTSD","metadata":null},{"id":"dd188c45aa654c6c8250cc798d34153b","type":"TRIAL","name":"Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC","canonical_id":"clinicaltrials.gov:NCT02593175","description":"Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma","metadata":null},{"id":"10ec51eb43ee452e947978f79f27a273","type":"GO_TERM","name":"Woronin body","canonical_id":"go:GO:0140266","description":"\"Peroxisome-derived dense-core vesicle that seals septal pores upon hyphal lysis to prevent excessive cytoplasmic loss. It is specific to several genera of filamentous ascomycetes.\" [PMID:12640443, PMID:15155882, PMID:18227279, PMID:20707002, PMID:23882222]","metadata":null},{"id":"e9c3a0bd9d664eff9d747407be53c8f2","type":"GO_TERM","name":"Wpl/Pds5 cohesin loading/unloading complex","canonical_id":"go:GO:0090695","description":"\"A eukaryotically conserved heterodimeric protein complex (comprising Wings apart-like protein and the Pds5 Armadillo repeat cohesin associated protein) involved in the loading and unloading of a cohesin complex onto DNA.\" [GOC:vw, PMID:26687354]","metadata":null},{"id":"b040d6d7329a489d9b118ec089e4304b","type":"GO_TERM","name":"X chromosome","canonical_id":"go:GO:0000805","description":"\"The sex chromosome present in both sexes of species in which the male is the heterogametic sex. Two copies of the X chromosome are present in each somatic cell of females and one copy is present in males.\" [GOC:mah, GOC:mr, ISBN:0582227089, PMID:20622855, Wikipedia:XY_sex-determination_system]","metadata":null},{"id":"1eb1602ba5964c20a3480bc1ee39e95f","type":"GO_TERM","name":"X chromosome located dosage compensation complex, transcription activating","canonical_id":"go:GO:0016456","description":"\"An RNA-protein complex localized to the X chromosome of males where it is required for the hyper-transcriptional activation of the X chromosome. An example of this is found in Drosophila melanogaster.\" [GOC:ma, GOC:mr, GOC:mtg_sensu, PMID:20622855, Wikipedia:XY_sex-determination_system]","metadata":null},{"id":"9b10c4ef53b54f429d07b0ad1e314a1c","type":"DISEASE","name":"X-linked dominant hypophosphatemic rickets","canonical_id":"mondo:0010619","description":null,"metadata":null},{"id":"1ac54ff06a09425390ba9db6942e773f","type":"DISEASE","name":"X-linked spasticity-intellectual disability-epilepsy syndrome","canonical_id":"mondo:0017856","description":null,"metadata":null},{"id":"2bb99248cea94b9d8435e847da0849da","type":"GO_TERM","name":"X11-like protein binding","canonical_id":"go:GO:0042988","description":"\"Binding to X11-like protein, a neuron-specific adaptor protein.\" [GOC:jl, PMID:12780348]","metadata":null},{"id":"0f3beccddedd493c9ac8ba64e914a419","type":"GENE","name":"XAB2","canonical_id":"hgnc:HGNC:14089","description":"XPA binding protein 2","metadata":{"aliases":["HCNP","HCRN","SYF1","NTC90"]}},{"id":"d619b732f3864f02b6863e85425c3f32","type":"GENE","name":"XACT","canonical_id":"hgnc:HGNC:45056","description":"X active specific transcript","metadata":null},{"id":"a755400c6bcb4d2fb233bb628984ef78","type":"GENE","name":"XAF1","canonical_id":"hgnc:HGNC:30932","description":null,"metadata":null},{"id":"ec7d6ac494054cebad61019e335f9965","type":"GENE","name":"XAGE1A","canonical_id":"hgnc:HGNC:4111","description":"X antigen family member 1A","metadata":{"aliases":["XAGE-1","CT12.1a","GAGED2","XAGE1"]}},{"id":"0959b46c5c6344bb9dca61f191f7df51","type":"GENE","name":"XAGE1B","canonical_id":"hgnc:HGNC:25400","description":"X antigen family member 1B","metadata":{"aliases":["CT12.1b","CT12.1c","CT12.1d","XAGE1C","XAGE1D","XAGE1E"]}},{"id":"769dd4ca9d074a4d97511ea05dad301b","type":"GENE","name":"XAGE2","canonical_id":"hgnc:HGNC:4112","description":"X antigen family member 2","metadata":{"aliases":["XAGE-2","CT12.2","GAGED3","XAGE2B"]}},{"id":"991f28836a6d4822a05a29360945d747","type":"GENE","name":"XAGE3","canonical_id":"hgnc:HGNC:14618","description":"X antigen family member 3","metadata":{"aliases":["XAGE-3","pp9012","CT12.3a","CT12.3b","PLAC6","GAGED4"]}},{"id":"ac1d0f95f3554344b4c6c51c2689bb0c","type":"GENE","name":"XAGE5","canonical_id":"hgnc:HGNC:30930","description":"X antigen family member 5","metadata":{"aliases":["XAGE-5","CT12.5","GAGED5"]}},{"id":"521921586aaa46259ed866fba8f15c5e","type":"GENE","name":"XBP1","canonical_id":"hgnc:HGNC:12801","description":null,"metadata":null},{"id":"315cd27b8842420eb2eff2b4e814bf33","type":"GENE","name":"XBP1P1","canonical_id":"hgnc:HGNC:12802","description":"X-box binding protein 1 pseudogene 1","metadata":{"aliases":["XBP1","XBPP1"]}},{"id":"f6737868269c418faf5855cf365c063d","type":"GENE","name":"XCE","canonical_id":"hgnc:HGNC:12804","description":"X chromosome controlling element","metadata":null},{"id":"69e405a13c3b460faa50561e3e787b54","type":"TRIAL","name":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","canonical_id":"clinicaltrials.gov:NCT06055179","description":"Xiao Chai Hu Tang; Irinotecan-induced Diarrhea","metadata":null},{"id":"d8485c1d8c664991818046aef22f12c4","type":"GENE","name":"XCL1","canonical_id":"hgnc:HGNC:10645","description":"X-C motif chemokine ligand 1","metadata":{"aliases":["LPTN","ATAC","SCM-1a","SCM-1","LTN","SCYC1"]}},{"id":"a90a6c117660481a87ead63edf35689f","type":"GO_TERM","name":"XCL1 production","canonical_id":"go:GO:0140779","description":"\"The appearance of XCL1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [PMID:7973732]","metadata":null},{"id":"5c5159f6ad6a4a2c85140e0b3a4b5951","type":"GENE","name":"XCL2","canonical_id":"hgnc:HGNC:10646","description":"X-C motif chemokine ligand 2","metadata":{"aliases":["SCM-1b","SCYC2"]}},{"id":"2083cb5e40bd44de9819750050ff794c","type":"GENE","name":"XCR1","canonical_id":"hgnc:HGNC:1625","description":"X-C motif chemokine receptor 1","metadata":{"aliases":["GPR5","CCXCR1"]}},{"id":"154514206b5e4632a0d14c6cbc9479d2","type":"GO_TERM","name":"XCR1 chemokine receptor binding","canonical_id":"go:GO:0031738","description":"\"Binding to a XCR1 chemokine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"48cd700ee2d4422887b5172d8b82d77d","type":"GENE","name":"XDH","canonical_id":"hgnc:HGNC:12805","description":"xanthine dehydrogenase","metadata":{"aliases":["XOR","XO","XDH/XO"]}},{"id":"a95aef5a35cb41b0880880cdf5d9017d","type":"PROTEIN","name":"XDH","canonical_id":"uniprot:P47989","description":null,"metadata":null},{"id":"60f78838df9a47c3b245443869185365","type":"GENE","name":"XG","canonical_id":"hgnc:HGNC:12806","description":"Xg glycoprotein (Xg blood group)","metadata":{"aliases":["PBDX"]}},{"id":"0bc9efaa3b1e42c6a027b37fa9ce30b5","type":"GENE","name":"XGY1","canonical_id":"hgnc:HGNC:12807","description":"XG Y-linked 1 (pseudogene)","metadata":{"aliases":["XGPY1","XGPY"]}},{"id":"765f3847f4214bff9c47c177dc4e4148","type":"GENE","name":"XGY2","canonical_id":"hgnc:HGNC:34022","description":"XG Y-linked 2 (pseudogene)","metadata":{"aliases":["XGPY2"]}},{"id":"9010068f7d864c96aeab99585aaf84cb","type":"GENE","name":"XIAP","canonical_id":"hgnc:HGNC:592","description":null,"metadata":null},{"id":"4725d7e48d024774adfec8bd6feddc1a","type":"GENE","name":"XIAP-AS1","canonical_id":"hgnc:HGNC:40078","description":"XIAP antisense RNA 1","metadata":null},{"id":"2a365af30f6e49369cbbb074159c6572","type":"GENE","name":"XIAPP1","canonical_id":"hgnc:HGNC:52375","description":"X-linked inhibitor of apoptosis pseudogene 1","metadata":null},{"id":"20e6eeaee88f4889a23235f4fa9f0ea2","type":"GENE","name":"XIAPP2","canonical_id":"hgnc:HGNC:52376","description":"X-linked inhibitor of apoptosis pseudogene 2","metadata":null},{"id":"c674d5b3aa7a428582558bbf481e016e","type":"GENE","name":"XIAPP3","canonical_id":"hgnc:HGNC:52377","description":"X-linked inhibitor of apoptosis pseudogene 3","metadata":null},{"id":"841ff2bda3d44e49a0cd50bc036dedad","type":"GENE","name":"XIC","canonical_id":"hgnc:HGNC:12809","description":"X chromosome inactivation center","metadata":null},{"id":"4f2ca0dc688c4d02a3a602be197beeaf","type":"TRIAL","name":"XIENCE V\u00ae Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V\u00ae USA-Phase 1)","canonical_id":"clinicaltrials.gov:NCT00676520","description":"Coronary Artery Disease","metadata":null},{"id":"ce7c99a9b0c94907b226c65efd696e8f","type":"GENE","name":"XIRP1","canonical_id":"hgnc:HGNC:14301","description":"xin actin binding repeat containing 1","metadata":{"aliases":["DKFZp451D042","Xin","CMYA1"]}},{"id":"ee73d5358aec4e4e9646b823d04c19bd","type":"GENE","name":"XIRP2","canonical_id":"hgnc:HGNC:14303","description":"xin actin binding repeat containing 2","metadata":{"aliases":["CMYA3"]}},{"id":"b65a46711ff2484f993a59c8f71b7014","type":"GENE","name":"XIRP2-AS1","canonical_id":"hgnc:HGNC:40679","description":"XIRP2 antisense RNA 1","metadata":null},{"id":"70595cbbe1414d9b91fd15ec854b51a9","type":"GENE","name":"XIST","canonical_id":"hgnc:HGNC:12810","description":"X inactive specific transcript","metadata":{"aliases":["NCRNA00001","DXS1089","swd66","LINC00001","DXS399E"]}},{"id":"d9398836140f4afeade8c30e708cbe5b","type":"GENE","name":"XK","canonical_id":"hgnc:HGNC:12811","description":"X-linked Kx blood group antigen, Kell and VPS13A binding protein","metadata":{"aliases":["XKR1","Kx","X1k","NA","NAC"]}},{"id":"e9d5dfce4ac144859200a3cdd6fcfa26","type":"GENE","name":"XKR3","canonical_id":"hgnc:HGNC:28778","description":"XK related 3","metadata":{"aliases":["MGC57211","XTES"]}},{"id":"212886e91a8544f1a5a709b112f79430","type":"GENE","name":"XKR4","canonical_id":"hgnc:HGNC:29394","description":"XK related 4","metadata":{"aliases":["KIAA1889"]}},{"id":"a907c28201424fc4a4d4e10282f744f7","type":"GENE","name":"XKR4-AS1","canonical_id":"hgnc:HGNC:56156","description":"XKR4 antisense RNA 1","metadata":null},{"id":"4d3b130a3dd94622b210e0078d6e5ad8","type":"GENE","name":"XKR5","canonical_id":"hgnc:HGNC:20782","description":"XK related 5","metadata":null},{"id":"6aa8c457c0b045ff8ebfef591306842f","type":"GENE","name":"XKR6","canonical_id":"hgnc:HGNC:27806","description":"XK related 6","metadata":{"aliases":["C8orf7","C8orf21","C8orf5"]}},{"id":"3a0b447858374016a0711a24f094d752","type":"GENE","name":"XKR7","canonical_id":"hgnc:HGNC:23062","description":"XK related 7","metadata":{"aliases":["dJ310O13.4","C20orf159"]}},{"id":"fe9c918f76f4413699cd9bacca675c1b","type":"GENE","name":"XKR8","canonical_id":"hgnc:HGNC:25508","description":"XK related 8","metadata":{"aliases":["FLJ10307"]}},{"id":"c9bba67337b04693bddfe2c6546102fc","type":"GENE","name":"XKR9","canonical_id":"hgnc:HGNC:20937","description":"XK related 9","metadata":null},{"id":"447e07f408704e7a99445866e57f7438","type":"GENE","name":"XKRX","canonical_id":"hgnc:HGNC:29845","description":"XK related X-linked","metadata":{"aliases":["XPLAC","XKR2"]}},{"id":"992b706d047044a6b9667b63ce03a487","type":"GENE","name":"XKRY","canonical_id":"hgnc:HGNC:18571","description":"XK related, Y-linked (pseudogene)","metadata":{"aliases":["XKRY1"]}},{"id":"a6e1ce0e76f84759a6a005dfe54e8509","type":"GENE","name":"XKRYP1","canonical_id":"hgnc:HGNC:23908","description":"XK related, Y-linked pseudogene 1","metadata":null},{"id":"26783ac68cf74d938cd7fc68e67c3944","type":"GENE","name":"XKRYP2","canonical_id":"hgnc:HGNC:23909","description":"XK related, Y-linked pseudogene 2","metadata":null},{"id":"447b96a6d9cb4840b79dc7efc9398e19","type":"GENE","name":"XKRYP3","canonical_id":"hgnc:HGNC:23910","description":"XK related, Y-linked pseudogene 3","metadata":null},{"id":"126d864bd5c5497ca28a49d6efeac8b6","type":"GENE","name":"XKRYP4","canonical_id":"hgnc:HGNC:23911","description":"XK related, Y-linked pseudogene 4","metadata":null},{"id":"8135ddf3ccbb4b45b43cf2e135206391","type":"GENE","name":"XKRYP5","canonical_id":"hgnc:HGNC:23912","description":"XK related, Y-linked pseudogene 5","metadata":null},{"id":"e15ee5525fe547cea9d53c290d18721c","type":"GENE","name":"XKRYP6","canonical_id":"hgnc:HGNC:23913","description":"XK related, Y-linked pseudogene 6","metadata":null},{"id":"3b89adf69552470990aa8f73d3bb5232","type":"GENE","name":"XKRYP7","canonical_id":"hgnc:HGNC:23922","description":"XK related, Y-linked pseudogene 7","metadata":{"aliases":["XKRY2"]}},{"id":"e38ffa8dc85b4997bd6827d5be07d260","type":"TRIAL","name":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","canonical_id":"clinicaltrials.gov:NCT02721459","description":"Melanoma; Skin Cancer","metadata":null},{"id":"c0e8d594a098470b8b28a7d0a9a6203e","type":"GO_TERM","name":"XMP biosynthetic process","canonical_id":"go:GO:0097293","description":"\"The chemical reactions and pathways resulting in the formation of XMP, xanthosine monophosphate.\" [GOC:yaf]","metadata":null},{"id":"1929cd38661a4b429dcfd082c56af458","type":"GO_TERM","name":"XMP metabolic process","canonical_id":"go:GO:0097292","description":"\"The chemical reactions and pathways involving XMP, xanthosine monophosphate.\" [GOC:yaf]","metadata":null},{"id":"3aecd8583cb84341886b05ec1414b4ea","type":"GO_TERM","name":"XMP salvage","canonical_id":"go:GO:0032265","description":"\"Any process which produces xanthosine monophosphate from derivatives of it, without de novo synthesis.\" [GOC:mah]","metadata":null},{"id":"a306bb50c02348e88a77ea77ed5aa476","type":"GENE","name":"XNDC1CP","canonical_id":"hgnc:HGNC:54662","description":"XRCC1 N-terminal domain containing 1, C-terminal like pseudogene","metadata":null},{"id":"8a574f4c3c0f4815bbe7d4c3f0043fa2","type":"GENE","name":"XNDC1N","canonical_id":"hgnc:HGNC:54661","description":"XRCC1 N-terminal domain containing 1, N-terminal like","metadata":null},{"id":"c524a677c57145e38113484541cbdb45","type":"GENE","name":"XNDC1N-ZNF705EP-ALG1L9P","canonical_id":"hgnc:HGNC:55871","description":"XNDC1N-ZNF705EP-ALG1L9P readthrough","metadata":null},{"id":"34a4cb5e1d264fbeb989361e48e8973a","type":"GENE","name":"XPA","canonical_id":"hgnc:HGNC:12814","description":null,"metadata":null},{"id":"afe28e763e0148f5ba140110df22f52b","type":"GENE","name":"XPC","canonical_id":"hgnc:HGNC:12816","description":null,"metadata":null},{"id":"30afb6e532aa4703bc58f9e492433f7c","type":"GO_TERM","name":"XPC complex","canonical_id":"go:GO:0071942","description":"\"A nucleotide-excision repair complex that is involved in damage sensing during global genome nucleotide excision repair (GG-NER). It is part of the pre-incision (or initial recognition) complex bound to sites of DNA damage. In human, it is composed of XPC, RAD23B and CETN2.\" [PMID:11279143, PMID:15964821, PMID:19941824]","metadata":null},{"id":"30426ee8b99d4fadb6391291355a00e1","type":"GENE","name":"XPC-AS1","canonical_id":"hgnc:HGNC:55014","description":"XPC antisense RNA 1","metadata":null},{"id":"32ac87ea364546a1928709332f6dc7f0","type":"GENE","name":"XPNPEP1","canonical_id":"hgnc:HGNC:12822","description":"X-prolyl aminopeptidase 1","metadata":{"aliases":["XPNPEP","XPNPEPL1","XPNPEPL"]}},{"id":"f429a99cdf3646a996036172e11579f3","type":"GENE","name":"XPNPEP2","canonical_id":"hgnc:HGNC:12823","description":"X-prolyl aminopeptidase 2","metadata":null},{"id":"e1500eddefcb46de8aade3e38ab9d794","type":"GENE","name":"XPNPEP3","canonical_id":"hgnc:HGNC:28052","description":"X-prolyl aminopeptidase 3","metadata":{"aliases":["APP3","NPHPL1","ICP55"]}},{"id":"ed77607bdfc64d68a8def5d442d83b60","type":"GENE","name":"XPO1","canonical_id":"hgnc:HGNC:12825","description":null,"metadata":null},{"id":"42ffb7d99f0c430c8bb850c956d308a9","type":"GENE","name":"XPO4","canonical_id":"hgnc:HGNC:17796","description":"exportin 4","metadata":{"aliases":["FLJ13046","KIAA1721"]}},{"id":"b1fb618696234224863fc15ab3137e57","type":"GENE","name":"XPO5","canonical_id":"hgnc:HGNC:17675","description":"exportin 5","metadata":{"aliases":["KIAA1291"]}},{"id":"0717a612da8d47819376a9ed3441a56a","type":"GENE","name":"XPO6","canonical_id":"hgnc:HGNC:19733","description":"exportin 6","metadata":{"aliases":["KIAA0370","FLJ22519","RANBP20"]}},{"id":"87716d0912d64b6699f2777382040af0","type":"GENE","name":"XPO6P1","canonical_id":"hgnc:HGNC:19734","description":"XPO6 pseudogene 1","metadata":{"aliases":["RANBP20P"]}},{"id":"5079d14835ef40f385c630f7019481e6","type":"GENE","name":"XPO7","canonical_id":"hgnc:HGNC:14108","description":"exportin 7","metadata":{"aliases":["KIAA0745","EXP7","RANBP16"]}},{"id":"c00e63d9ef6940d38de4d48466da03c2","type":"GENE","name":"XPOT","canonical_id":"hgnc:HGNC:12826","description":"exportin for tRNA","metadata":{"aliases":["XPO3"]}},{"id":"aaa9e15f35954207a9793502ec221964","type":"GENE","name":"XPOTP1","canonical_id":"hgnc:HGNC:16586","description":"exportin for tRNA pseudogene 1","metadata":{"aliases":["dJ785G19.1","XPO3P1"]}},{"id":"dd7fcf1476a842fe9495f16f5efdb471","type":"GENE","name":"XPOTP2","canonical_id":"hgnc:HGNC:58653","description":"XPOT pseudogene 2","metadata":null},{"id":"832aeedab36c406ca1cac862c3249b85","type":"GENE","name":"XPOTP3","canonical_id":"hgnc:HGNC:58654","description":"XPOT pseudogene 3","metadata":null},{"id":"1e51c8a80b034cf6998ea1972281afc6","type":"GENE","name":"XPR1","canonical_id":"hgnc:HGNC:12827","description":"xenotropic and polytropic retrovirus receptor 1","metadata":{"aliases":["SYG1","X3","SLC53A1"]}},{"id":"96fcb11e028f4ddaaef9964d8a8f4899","type":"GENE","name":"XRCC1","canonical_id":"hgnc:HGNC:12828","description":null,"metadata":null},{"id":"4a89003c58dc4d51982311869eeae3b4","type":"GENE","name":"XRCC2","canonical_id":"hgnc:HGNC:12829","description":"X-ray repair cross complementing 2","metadata":{"aliases":["FANCU"]}},{"id":"657116dc368149c9a7648900db9e7458","type":"GO_TERM","name":"XRCC2-RAD51D complex","canonical_id":"go:GO:0033064","description":"\"A heterodimeric DNA recombinase mediator complex that contains the Rad51 paralogs RAD51D and XRCC2, or orthologs thereof; conserved from fission yeast to human but absent from budding yeast.\" [GOC:mah, GOC:vw, PMID:16093548]","metadata":null},{"id":"a6327f23d9954a0c8c1309391b261262","type":"GENE","name":"XRCC3","canonical_id":"hgnc:HGNC:12830","description":"X-ray repair cross complementing 3","metadata":null},{"id":"581335e47aaf48229248bc051950f2da","type":"GENE","name":"XRCC4","canonical_id":"hgnc:HGNC:12831","description":"X-ray repair cross complementing 4","metadata":{"aliases":["hXRCC4"]}},{"id":"c5066cc9138d42d4b37c60ed4b211945","type":"GENE","name":"XRCC5","canonical_id":"hgnc:HGNC:12833","description":null,"metadata":null},{"id":"419d0f0930f8483f86550e4ccdecb91d","type":"GENE","name":"XRCC6","canonical_id":"hgnc:HGNC:4055","description":null,"metadata":null},{"id":"1533523ce97c4551af2e8c4986d35b3d","type":"GENE","name":"XRCC6P1","canonical_id":"hgnc:HGNC:45183","description":"X-ray repair cross complementing 6 pseudogene 1","metadata":null},{"id":"a5a59c78d22347f6b6c6006c44e3080c","type":"GENE","name":"XRCC6P2","canonical_id":"hgnc:HGNC:45184","description":"X-ray repair cross complementing 6 pseudogene 2","metadata":null},{"id":"6d15cf82d85f428f9f2ddc03dd24b60d","type":"GENE","name":"XRCC6P3","canonical_id":"hgnc:HGNC:45185","description":"X-ray repair cross complementing 6 pseudogene 3","metadata":null},{"id":"1e874b3f1f074af08c82e39a13c08d1f","type":"GENE","name":"XRCC6P4","canonical_id":"hgnc:HGNC:45186","description":"X-ray repair cross complementing 6 pseudogene 4","metadata":null},{"id":"0ae31c85c0534f658a53eda6dc907be2","type":"GENE","name":"XRCC6P5","canonical_id":"hgnc:HGNC:45187","description":"X-ray repair cross complementing 6 pseudogene 5","metadata":null},{"id":"0e5850540372441a84c1307ff393e5d2","type":"GENE","name":"XRN1","canonical_id":"hgnc:HGNC:30654","description":"5'-3' exoribonuclease 1","metadata":{"aliases":["SEP1"]}},{"id":"d64e26a641df4154b2abf3231770c44b","type":"GENE","name":"XRN2","canonical_id":"hgnc:HGNC:12836","description":"5'-3' exoribonuclease 2","metadata":null},{"id":"285256c514fe4f218000e77f1c7febe9","type":"GENE","name":"XRRA1","canonical_id":"hgnc:HGNC:18868","description":"X-ray radiation resistance associated 1","metadata":{"aliases":["FLJ00225"]}},{"id":"ff3dd87092c440deb2d5245896591678","type":"GENE","name":"XTBD1","canonical_id":"hgnc:HGNC:30545","description":"XRN2 binding domain containing 1","metadata":{"aliases":["MGC13017","C2AIL","CDKN2AIPNL"]}},{"id":"933fe21aec9e4dcca5c06efc768b0ed1","type":"GENE","name":"XTBD1-DT","canonical_id":"hgnc:HGNC:59146","description":"XTBD1 divergent transcript","metadata":null},{"id":"6c98470b28254714a043369b143ce320","type":"GENE","name":"XTBD1P1","canonical_id":"hgnc:HGNC:39854","description":"XTBD1 pseudogene 1","metadata":{"aliases":["CDKN2AIPNLP1"]}},{"id":"8099166d747e4b7880a188b3dd5cf680","type":"GENE","name":"XTBD1P2","canonical_id":"hgnc:HGNC:39855","description":"XTBD1 pseudogene 2","metadata":{"aliases":["CDKN2AIPNLP2"]}},{"id":"220d7939fb6a4afd9232192960c38b80","type":"GENE","name":"XTBD1P3","canonical_id":"hgnc:HGNC:39853","description":"XTBD1 pseudogene 3","metadata":{"aliases":["CDKN2AIPNLP3"]}},{"id":"dbdd4802468f41e69c3082a7989e7192","type":"GO_TERM","name":"XTP binding","canonical_id":"go:GO:1901640","description":"\"Binding to XTP.\" [GOC:TermGenie]","metadata":null},{"id":"fd952844836140b3b3f25b24ddf7494c","type":"GO_TERM","name":"XTP diphosphatase activity","canonical_id":"go:GO:0036222","description":"\"Catalysis of the reaction: XTP + H2O = XMP + H+ + diphosphate.\" [GOC:pz, PMID:16216582, PMID:22531138, RHEA:28610]","metadata":null},{"id":"d32eb16a6cb441c8bbfd4ffa5b806ba3","type":"GENE","name":"XXYLT1","canonical_id":"hgnc:HGNC:26639","description":"xyloside xylosyltransferase 1","metadata":{"aliases":["FLJ35155","C3orf21"]}},{"id":"d4c47c5024104c9c88eed7416341cfda","type":"GENE","name":"XXYLT1-AS1","canonical_id":"hgnc:HGNC:41153","description":"XXYLT1 antisense RNA 1","metadata":null},{"id":"22945905e80d48c2952f096035fc1e0f","type":"GENE","name":"XXYLT1-AS2","canonical_id":"hgnc:HGNC:41154","description":"XXYLT1 antisense RNA 2","metadata":null},{"id":"06d924c68a8f453faa569283c576b375","type":"GO_TERM","name":"XY body","canonical_id":"go:GO:0001741","description":"\"A structure found in a male mammalian spermatocyte containing an unpaired X chromosome that has become densely heterochromatic, silenced and localized at the nuclear periphery.\" [GOC:hjd, GOC:mr, PMID:20622855, Wikipedia:XY_sex-determination_system]","metadata":null},{"id":"b721ae517a564d4fb7cb0326de7e6658","type":"GENE","name":"XYLB","canonical_id":"hgnc:HGNC:12839","description":"xylulokinase","metadata":{"aliases":["FLJ10343","FLJ12539"]}},{"id":"1ce1257fdadd4384824d629dd90d80cf","type":"GENE","name":"XYLT1","canonical_id":"hgnc:HGNC:15516","description":"xylosyltransferase 1","metadata":{"aliases":["XT-I","PXYLT1"]}},{"id":"0d00be40d86244e48c6272feacee5d46","type":"GENE","name":"XYLT2","canonical_id":"hgnc:HGNC:15517","description":"xylosyltransferase 2","metadata":{"aliases":["XT-II","PXYLT2"]}},{"id":"699d2d5a00e64a14956397f2f5cac210","type":"TRIAL","name":"Xamiol\u00aeGel in BODY Psoriasis: A One-year Non-interventional Study","canonical_id":"clinicaltrials.gov:NCT02636101","description":"Psoriasis Vulgaris","metadata":null},{"id":"b2dc31d4b33345828865e087f3ab64c2","type":"TRIAL","name":"Xarelto Regulatory Post-Marketing Surveillance","canonical_id":"clinicaltrials.gov:NCT01029743","description":"Venous Thromboembolism","metadata":null},{"id":"b940b5bb0e7d4ff391ba74cc2720d6d3","type":"TRIAL","name":"Xarelto [SPAF] Post-marketing Surveillance in Japan","canonical_id":"clinicaltrials.gov:NCT01582737","description":"Brain Ischemia","metadata":null},{"id":"634625abb18f49efba7492b86e6ffd43","type":"TRIAL","name":"Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region","canonical_id":"clinicaltrials.gov:NCT01800006","description":"Atrial Fibrillation","metadata":null},{"id":"bda50a60b7384a34b2ae748f51431790","type":"TRIAL","name":"Xenazine in Late Dyskinetic Syndrome With Neuroleptics","canonical_id":"clinicaltrials.gov:NCT01543321","description":"Tardive Dyskinesia","metadata":null},{"id":"68ae59cf28174e5da4344de90053eee4","type":"TRIAL","name":"Xerostomia in Patients With a Life-limiting Condition or Frailty","canonical_id":"clinicaltrials.gov:NCT05506137","description":"Xerostomia; Dry Mouth","metadata":null},{"id":"48d5b39a63cb490e9e71c8f0061a3908","type":"TRIAL","name":"Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research","canonical_id":"clinicaltrials.gov:NCT02517957","description":"Eczema","metadata":null},{"id":"08399818d6fd49ee8684b5e344d478be","type":"TRIAL","name":"Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease","canonical_id":"clinicaltrials.gov:NCT04413253","description":"Dry Eye Syndromes","metadata":null},{"id":"3b1f5b26d13546f0afebccd5a7058183","type":"TRIAL","name":"Xirtam H Combination In the Treatment of Hypertension Evaluation Study.","canonical_id":"clinicaltrials.gov:NCT01219556","description":"Hypertension","metadata":null},{"id":"63f79ccb212e46e0b4e155b4048cf745","type":"TRIAL","name":"Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00073957","description":"Lymphoma","metadata":null},{"id":"ec1ca4fc20134912906e8a84fcbf469d","type":"GO_TERM","name":"Y chromosome","canonical_id":"go:GO:0000806","description":"\"The sex chromosome present in males of species in which the male is the heterogametic sex; generally, the sex chromosome that pairs with the X chromosome in the heterogametic sex. The Y chromosome is absent from the cells of females and present in one copy in the somatic cells of males.\" [GOC:mah, GOC:mr, ISBN:0582227089, PMID:20622855, Wikipedia:XY_sex-determination_system]","metadata":null},{"id":"16709b555f1944c4b1428c5f2cf0d8e3","type":"GO_TERM","name":"Y-form DNA binding","canonical_id":"go:GO:0000403","description":"\"Binding to a DNA segment shaped like a Y. This shape occurs when DNA contains a region of paired double-stranded DNA on one end and a region of unpaired DNA strands on the opposite end.\" [GOC:elh, PMID:16781730]","metadata":null},{"id":"45eda5adbfaf4fe486f8dc7cdf9b7671","type":"GO_TERM","name":"Y-shaped link","canonical_id":"go:GO:0097537","description":"\"A Y-shaped protein complex in the ciliary transition zone that connects the cilium axoneme to the ciliary necklace. Both protein sorting and protein gating occur at this point in the cilium allowing some, but not all proteins to enter the cilium.\" [GOC:cilia, PMID:22653444, PMID:4554367]","metadata":null},{"id":"f787df0f3cd440718508ffb574489b0e","type":"GO_TERM","name":"Y-shaped link assembly","canonical_id":"go:GO:1905350","description":"\"The aggregation, arrangement and bonding together of a set of components to form a Y-shaped link. Two distinct protein complexes are known to be involved in proper linker assembly: the MKS complex and the NPHP complex. Improper assembly of Y-shaped links may cause malfunctioning of the transition zone as a molecular gate.\" [GO_REF:0000079, GOC:cilia, GOC:TermGenie, PMID:23728985, PMID:24664739, PMID:26595381, PMID:4554367]","metadata":null},{"id":"569b38cbf8824edaaf4a953ff8e2d5f6","type":"GENE","name":"YAE1","canonical_id":"hgnc:HGNC:24857","description":"YAE1 maturation factor of ABCE1","metadata":{"aliases":["GK003","CIAB2","C7orf36","YAE1D1"]}},{"id":"dc7bb670346d4bd9b14fbe80aca88dda","type":"GENE","name":"YAE1-DT","canonical_id":"hgnc:HGNC:55820","description":"YAE1 divergent transcript","metadata":null},{"id":"2377e9e906d54598a1f0ae33ce76bad7","type":"GENE","name":"YAF2","canonical_id":"hgnc:HGNC:17363","description":"YY1 associated factor 2","metadata":null},{"id":"1cf71320e4db40b4ab7e832b8f622df5","type":"GENE","name":"YAM1","canonical_id":"hgnc:HGNC:49034","description":"YY1-associated myogenesis RNA 1","metadata":{"aliases":["Yam-1"]}},{"id":"366b79da1bcb417f8afc54c808f6dfc6","type":"GENE","name":"YAP1","canonical_id":"hgnc:HGNC:16262","description":"Yes1 associated transcriptional regulator","metadata":{"aliases":["YAP65","YAP-1"]}},{"id":"06478f44d6b14b47961214c350971dbd","type":"GENE","name":"YAP1-DT","canonical_id":"hgnc:HGNC:58148","description":"YAP1 divergent transcript","metadata":{"aliases":["RP11-732A21.3","AC107464.2"]}},{"id":"a72eaa81257743adbf380bb69588aa74","type":"GENE","name":"YAP1P1","canonical_id":"hgnc:HGNC:38016","description":"YAP1 pseudogene 1","metadata":null},{"id":"4b9e84671c68438a89e3f53e7c64e21a","type":"GENE","name":"YAP1P2","canonical_id":"hgnc:HGNC:38017","description":"YAP1 pseudogene 2","metadata":null},{"id":"118f7c6f47474110951e4274de577925","type":"GENE","name":"YAP1P3","canonical_id":"hgnc:HGNC:43890","description":"YAP1 pseudogene 3","metadata":null},{"id":"eb3bc15f16af45db8070e912f4f255db","type":"GENE","name":"YARS1","canonical_id":"hgnc:HGNC:12840","description":"tyrosyl-tRNA synthetase 1","metadata":{"aliases":["YTS","YRS","tyrRS","YARS"]}},{"id":"a7269bbdfb03466aa20651fec8830a52","type":"GENE","name":"YARS2","canonical_id":"hgnc:HGNC:24249","description":"tyrosyl-tRNA synthetase 2","metadata":{"aliases":["FLJ13995","CGI-04","mt-TyrRS"]}},{"id":"4d1a43b7bd3c45858cd32f022e22a25b","type":"GENE","name":"YBEY","canonical_id":"hgnc:HGNC:1299","description":"ybeY metalloendoribonuclease","metadata":{"aliases":["C21orf57"]}},{"id":"b7d04c03b85a4ae49c2748829834934f","type":"GENE","name":"YBX1","canonical_id":"hgnc:HGNC:8014","description":null,"metadata":null},{"id":"13881911edaa4f718698dd22f6a38a94","type":"GENE","name":"YBX1P1","canonical_id":"hgnc:HGNC:8015","description":"Y-box binding protein 1 pseudogene 1","metadata":{"aliases":["PSDBPB1","NSEP1P"]}},{"id":"b4185593fe87415d91889888df2b98c0","type":"GENE","name":"YBX1P10","canonical_id":"hgnc:HGNC:42432","description":"Y-box binding protein 1 pseudogene 10","metadata":null},{"id":"8c95829c509443b0813d33b7652d1f77","type":"GENE","name":"YBX1P2","canonical_id":"hgnc:HGNC:22635","description":"Y-box binding protein 1 pseudogene 2","metadata":{"aliases":["TCAG_1818537"]}},{"id":"5421ed2741754947b497dbf4e082aedf","type":"GENE","name":"YBX1P3","canonical_id":"hgnc:HGNC:42424","description":"Y-box binding protein 1 pseudogene 3","metadata":null},{"id":"76c647638d524be3986deb6f9da6a3b6","type":"GENE","name":"YBX1P4","canonical_id":"hgnc:HGNC:42425","description":"Y-box binding protein 1 pseudogene 4","metadata":null},{"id":"59218f441c1c4d94866876d67fa68cc5","type":"GENE","name":"YBX1P5","canonical_id":"hgnc:HGNC:42426","description":"Y-box binding protein 1 pseudogene 5","metadata":null},{"id":"756f8673fbc040a7b194f4111b8a290c","type":"GENE","name":"YBX1P6","canonical_id":"hgnc:HGNC:42427","description":"Y-box binding protein 1 pseudogene 6","metadata":null},{"id":"bdda149b78de42e5963973ea17007ebb","type":"GENE","name":"YBX1P7","canonical_id":"hgnc:HGNC:42428","description":"Y-box binding protein 1 pseudogene 7","metadata":null},{"id":"3c38dcbc89234946b87c57110a20e9a4","type":"GENE","name":"YBX1P8","canonical_id":"hgnc:HGNC:42429","description":"Y-box binding protein 1 pseudogene 8","metadata":null},{"id":"3e4d37217be448abbcbbbe023ba342e3","type":"GENE","name":"YBX1P9","canonical_id":"hgnc:HGNC:42430","description":"Y-box binding protein 1 pseudogene 9","metadata":null},{"id":"9f97ef7ff80446a2b690b30a2acdf953","type":"GENE","name":"YBX2","canonical_id":"hgnc:HGNC:17948","description":"Y-box binding protein 2","metadata":{"aliases":["MSY2","CSDA3","Contrin"]}},{"id":"f67facc0e8174f3b92fd14ee50bc1f7b","type":"GENE","name":"YBX2P1","canonical_id":"hgnc:HGNC:49498","description":"YBX2 pseudogene 1","metadata":null},{"id":"bb7d20b32b134e8789ba4b3e7590c0ca","type":"GENE","name":"YBX2P2","canonical_id":"hgnc:HGNC:54721","description":"YBX2 pseudogene 2","metadata":null},{"id":"2edc82142bf34567b92452fa72d5c5f4","type":"GENE","name":"YBX3","canonical_id":"hgnc:HGNC:2428","description":"Y-box binding protein 3","metadata":{"aliases":["dbpA","ZONAB","CSDA1","CSDA"]}},{"id":"e10261cec56b42868eae006f66356479","type":"GENE","name":"YBX3P1","canonical_id":"hgnc:HGNC:2429","description":"Y-box binding protein 3 pseudogene 1","metadata":{"aliases":["CSDAP1"]}},{"id":"d5bd34447fe64ed794fcd62de47f3c2f","type":"GENE","name":"YDJC","canonical_id":"hgnc:HGNC:27158","description":"YdjC chitooligosaccharide deacetylase homolog","metadata":null},{"id":"9d1c02152323441d8b34e4a8f0f20e49","type":"GENE","name":"YEATS2","canonical_id":"hgnc:HGNC:25489","description":"YEATS domain containing 2","metadata":{"aliases":["FLJ10201","FLJ12841","FLJ13308","KIAA1197"]}},{"id":"0255a8a3d9eb4e4295f86b39f1bfc027","type":"GENE","name":"YEATS2-AS1","canonical_id":"hgnc:HGNC:41101","description":"YEATS2 antisense RNA 1","metadata":null},{"id":"64956e45a3a74bd9829ecad5c64bc32c","type":"GENE","name":"YEATS4","canonical_id":"hgnc:HGNC:24859","description":null,"metadata":null},{"id":"d8ef89105c3448b49e7febf191382ad9","type":"GENE","name":"YES1","canonical_id":"hgnc:HGNC:12841","description":null,"metadata":null},{"id":"bdd53123e7bc4e48b0e790c43a37a649","type":"GENE","name":"YES1P1","canonical_id":"hgnc:HGNC:12842","description":"YES1 pseudogene 1","metadata":{"aliases":["D22S670","SYR","YES2","YESP"]}},{"id":"02f22e31cf5b4b0bb5bab5e92cfbf1a7","type":"TRIAL","name":"YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma","canonical_id":"clinicaltrials.gov:NCT05448820","description":"Advanced Sarcoma; Metastatic Sarcoma; Soft Tissue Sarcoma","metadata":null},{"id":"9acf7e76bbde49f9b1dbdc773b8963a6","type":"GENE","name":"YIF1A","canonical_id":"hgnc:HGNC:16688","description":"Yip1 interacting factor homolog A, membrane trafficking protein","metadata":{"aliases":["YIF1P","54TM","FinGER7","YIF1"]}},{"id":"22a5121a9a2d4a3a90dc79aeaeb7f26a","type":"GENE","name":"YIF1B","canonical_id":"hgnc:HGNC:30511","description":"Yip1 interacting factor homolog B, membrane trafficking protein","metadata":{"aliases":["FinGER8"]}},{"id":"1ec2cbbff79c475bbe2ecf8e08a23a97","type":"GENE","name":"YIPF1","canonical_id":"hgnc:HGNC:25231","description":"Yip1 domain family member 1","metadata":{"aliases":["DJ167A19.1","FinGER1","Yip5a","YIPFbeta3A"]}},{"id":"b96b4f01d46348a49060336da9b962c1","type":"GENE","name":"YIPF2","canonical_id":"hgnc:HGNC:28476","description":"Yip1 domain family member 2","metadata":{"aliases":["MGC3262","FinGER2","Yip5C","YIPFbeta3B"]}},{"id":"9502a6cfe8ca447db35e60a155fa8d71","type":"GENE","name":"YIPF3","canonical_id":"hgnc:HGNC:21023","description":"Yip1 domain family member 3","metadata":{"aliases":["DKFZp566C243","KLIP1","dJ337H4.3","FinGER3","Yip5b","YIPFbeta2","C6orf109"]}},{"id":"f5d5a647f9c242dd9d773bf12e888d81","type":"GENE","name":"YIPF4","canonical_id":"hgnc:HGNC:28145","description":"Yip1 domain family member 4","metadata":{"aliases":["MGC11061","FinGER4","YIPFalpha2"]}},{"id":"873d9a198a254bb280ed4ef8a663fc5c","type":"GENE","name":"YIPF5","canonical_id":"hgnc:HGNC:24877","description":"Yip1 domain family member 5","metadata":{"aliases":["SMAP-5","FinGER5","Yip1a","YIPFalpha1A"]}},{"id":"9e942d911f7f45bcbc4b7aae12661155","type":"GENE","name":"YIPF6","canonical_id":"hgnc:HGNC:28304","description":"Yip1 domain family member 6","metadata":{"aliases":["MGC21416","FinGER6","Yip4","YIPFalpha3"]}},{"id":"4231d084d0174fdb85dde793e2d8e21c","type":"GENE","name":"YIPF7","canonical_id":"hgnc:HGNC:26825","description":"Yip1 domain family member 7","metadata":{"aliases":["FLJ39576","FinGER9","Yip1b","YIPFalpha1b"]}},{"id":"089430606e714fd0a826e48f8b4b2e98","type":"GENE","name":"YJEFN3","canonical_id":"hgnc:HGNC:24785","description":"YjeF N-terminal domain containing 3","metadata":{"aliases":["hYjeF_N3-19p13.11","FLJ44968"]}},{"id":"5551a6b01cbe45319623b589b3ca70f6","type":"GENE","name":"YJU2","canonical_id":"hgnc:HGNC:25518","description":"YJU2 splicing factor homolog","metadata":{"aliases":["FLJ10374","CCDC94"]}},{"id":"da7e567fc6f3443f97c5c1abaf43f48b","type":"GENE","name":"YJU2B","canonical_id":"hgnc:HGNC:28118","description":"YJU2 splicing factor homolog B","metadata":{"aliases":["MGC10471","CCDC130"]}},{"id":"10965b57ae9143328210671dbb9db45c","type":"GENE","name":"YKT6","canonical_id":"hgnc:HGNC:16959","description":"YKT6 vesicular SNARE protein","metadata":null},{"id":"126d504eb50548bb928837358d12589b","type":"GENE","name":"YKT6P1","canonical_id":"hgnc:HGNC:58635","description":"YKT6 pseudogene 1","metadata":null},{"id":"1078114ffe4d4cb7b53f885afe6b2511","type":"GENE","name":"YLPM1","canonical_id":"hgnc:HGNC:17798","description":"YLP motif containing 1","metadata":{"aliases":["ZAP","PPP1R169","C14orf170"]}},{"id":"ec334a9ef27143418b38873c53f9e7fd","type":"GENE","name":"YME1L1","canonical_id":"hgnc:HGNC:12843","description":"YME1 like 1 ATPase","metadata":{"aliases":["YME1L"]}},{"id":"0adc5e3675134e458c576506ab77663b","type":"GENE","name":"YME1L1P1","canonical_id":"hgnc:HGNC:12844","description":"YME1L1 pseudogene 1","metadata":{"aliases":["YME1L2"]}},{"id":"bc53eae4fd9e43778671c62ebe8c2d13","type":"GENE","name":"YME1L1P2","canonical_id":"hgnc:HGNC:59241","description":"YME1L1 pseudogene 2","metadata":null},{"id":"a0189000370b46afa994af7aeb125489","type":"TRIAL","name":"YN001-004 in Patients With Coronary Atherosclerosis in Australia","canonical_id":"clinicaltrials.gov:NCT06700720","description":"Coronary Artery Disease; Coronary Atherosclerotic Disease","metadata":null},{"id":"e074447b3e494a5fa135c392118f4b56","type":"GENE","name":"YOD1","canonical_id":"hgnc:HGNC:25035","description":"YOD1 deubiquitinase","metadata":{"aliases":["DKFZp451J1719","OTUD2","DUBA8"]}},{"id":"7fcfbf7ccc8c4ae7941fc991be1fc29c","type":"GENE","name":"YPEL1","canonical_id":"hgnc:HGNC:12845","description":"yippee like 1","metadata":null},{"id":"684e7edc8a5540dfa888d3d57b451f8a","type":"GENE","name":"YPEL2","canonical_id":"hgnc:HGNC:18326","description":"yippee like 2","metadata":{"aliases":["FKSG4"]}},{"id":"b3241c852015473e99df2e9bb7b8c61d","type":"GENE","name":"YPEL3","canonical_id":"hgnc:HGNC:18327","description":"yippee like 3","metadata":{"aliases":["MGC10500"]}},{"id":"9f273316e68c4dfba5873f64969124a6","type":"GENE","name":"YPEL3-DT","canonical_id":"hgnc:HGNC:55547","description":"YPEL3 divergent transcript","metadata":null},{"id":"9479be99b50b4d609a460a2f9bd04745","type":"GENE","name":"YPEL4","canonical_id":"hgnc:HGNC:18328","description":"yippee like 4","metadata":{"aliases":["FLJ30213"]}},{"id":"e83ac851efdb48dfbeda8a47c4e0ee48","type":"GENE","name":"YPEL5","canonical_id":"hgnc:HGNC:18329","description":"yippee like 5","metadata":{"aliases":["CGI-127"]}},{"id":"345159f634eb40eaa524adbb7ceed223","type":"GENE","name":"YPEL5P1","canonical_id":"hgnc:HGNC:50555","description":"YPEL5 pseudogene 1","metadata":null},{"id":"ff4d288a08c7460e9cb93d62b0cc059d","type":"GENE","name":"YPEL5P2","canonical_id":"hgnc:HGNC:50556","description":"YPEL5 pseudogene 2","metadata":null},{"id":"dff1705a613546dc9d0da0de546a0148","type":"GENE","name":"YPEL5P3","canonical_id":"hgnc:HGNC:50557","description":"YPEL5 pseudogene 3","metadata":null},{"id":"b1a30f3231bc47e3846da1e80644739d","type":"GENE","name":"YPEL5P4","canonical_id":"hgnc:HGNC:57004","description":"YPEL5 pseudogene 4","metadata":null},{"id":"6f8a84bd19bb41139993a24f8f64acc7","type":"GENE","name":"YRDC","canonical_id":"hgnc:HGNC:28905","description":"yrdC N6-threonylcarbamoyltransferase domain containing","metadata":{"aliases":["FLJ23476","IRIP","SUA5"]}},{"id":"b9474511c0884722bcfdebe9e18907af","type":"GENE","name":"YRDCP1","canonical_id":"hgnc:HGNC:39919","description":"yrdC N(6)-threonylcarbamoyltransferase domain containing pseudogene 1","metadata":null},{"id":"5598d4906d1344adb6b07a93e1f0fa84","type":"GENE","name":"YRDCP2","canonical_id":"hgnc:HGNC:39920","description":"yrdC N(6)-threonylcarbamoyltransferase domain containing pseudogene 2","metadata":null},{"id":"2f09c6b28d5343c5ac476c4c8c37ec86","type":"GENE","name":"YRDCP3","canonical_id":"hgnc:HGNC:39921","description":"yrdC N(6)-threonylcarbamoyltransferase domain containing pseudogene 3","metadata":null},{"id":"c51795c5e9644b769ee551e8e2d601f4","type":"GENE","name":"YTHDC1","canonical_id":"hgnc:HGNC:30626","description":"YTH N6-methyladenosine RNA binding protein C1","metadata":{"aliases":["YT521","KIAA1966","YT521-B"]}},{"id":"9b5c1080c0cb468db16c09849a83ef5f","type":"GENE","name":"YTHDC2","canonical_id":"hgnc:HGNC:24721","description":"YTH N6-methyladenosine RNA binding protein C2","metadata":{"aliases":["FLJ2194","FLJ10053","DKFZp564A186"]}},{"id":"c79e934fa4d34c508db7a43568dda241","type":"GENE","name":"YTHDC2-DT","canonical_id":"hgnc:HGNC:59114","description":"YTHDC2 divergent transcript","metadata":null},{"id":"000810fef71442159566aa499739b0af","type":"GENE","name":"YTHDF1","canonical_id":"hgnc:HGNC:15867","description":"YTH N6-methyladenosine RNA binding protein F1","metadata":{"aliases":["FLJ20391","C20orf21"]}},{"id":"f27397d49ba64248b57b2f2c74c20cef","type":"GENE","name":"YTHDF1P1","canonical_id":"hgnc:HGNC:31681","description":"YTH domain family member 1 pseudogene 1","metadata":{"aliases":["YTHDF1P"]}},{"id":"2c7705922b2840f58d8d3b9e2fddda78","type":"GENE","name":"YTHDF2","canonical_id":"hgnc:HGNC:31675","description":"YTH N6-methyladenosine RNA binding protein F2","metadata":{"aliases":["HGRG8","NY-REN-2","CAHL"]}},{"id":"496ab38e5a0d4f04a9afcf0bf6209102","type":"GENE","name":"YTHDF2P1","canonical_id":"hgnc:HGNC:19865","description":"YTH domain family member 2 pseudogene 1","metadata":{"aliases":["HGRG8","NY-REN-2","YTHDF2P"]}},{"id":"a647e5ce5f504a82b539c32b39145da0","type":"GENE","name":"YTHDF3","canonical_id":"hgnc:HGNC:26465","description":"YTH N6-methyladenosine RNA binding protein F3","metadata":{"aliases":["FLJ31657"]}},{"id":"d82a3a74bb50426a9e4301eb4db66b89","type":"GENE","name":"YTHDF3-DT","canonical_id":"hgnc:HGNC:48728","description":"YTHDF3 divergent transcript","metadata":{"aliases":["YTHDF3-AS1"]}},{"id":"b54e437f4f664d52ae198102acd768e1","type":"GENE","name":"YTHDF3P1","canonical_id":"hgnc:HGNC:56498","description":"YTHDF3 pseudogene 1","metadata":null},{"id":"4a32d1b66d454d1ca42f9a4ba5d54775","type":"GENE","name":"YWHAB","canonical_id":"hgnc:HGNC:12849","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta","metadata":{"aliases":["YWHAA"]}},{"id":"9429d2512f2d42dfb83564d8209fe639","type":"GENE","name":"YWHABP1","canonical_id":"hgnc:HGNC:50294","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta pseudogene 1","metadata":null},{"id":"f385b5affa274f3c8e0310465714b257","type":"GENE","name":"YWHABP2","canonical_id":"hgnc:HGNC:50295","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta pseudogene 2","metadata":null},{"id":"dae7355876dd411fbe2ecba413490294","type":"GENE","name":"YWHAE","canonical_id":"hgnc:HGNC:12851","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon","metadata":{"aliases":["FLJ45465"]}},{"id":"8018566017ec45a1a76a0f18e0122463","type":"GENE","name":"YWHAEP1","canonical_id":"hgnc:HGNC:49442","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 1","metadata":null},{"id":"57d945cf2b884b7ea3c561a7677f1413","type":"GENE","name":"YWHAEP2","canonical_id":"hgnc:HGNC:49429","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 2","metadata":null},{"id":"87c72930ffdb4771aa89199f609c2125","type":"GENE","name":"YWHAEP3","canonical_id":"hgnc:HGNC:49430","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 3","metadata":null},{"id":"1841401057134938a28039e9a1394a63","type":"GENE","name":"YWHAEP4","canonical_id":"hgnc:HGNC:49440","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 4","metadata":null},{"id":"072e73d5f2aa4604b9b525ca8c63d962","type":"GENE","name":"YWHAEP5","canonical_id":"hgnc:HGNC:49439","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 5","metadata":null},{"id":"3164b1c5af0e412c95a2f5df4b6a49cd","type":"GENE","name":"YWHAEP6","canonical_id":"hgnc:HGNC:49435","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 6","metadata":null},{"id":"34c07bdad2f64a8db370d69f75b9c4c4","type":"GENE","name":"YWHAEP7","canonical_id":"hgnc:HGNC:49437","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon pseudogene 7","metadata":{"aliases":["LOC284100"]}},{"id":"d2d48d15427d43e9b5db174416bb29c3","type":"GENE","name":"YWHAG","canonical_id":"hgnc:HGNC:12852","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma","metadata":{"aliases":["PPP1R170","14-3-3GAMMA","14-3-3\u03b3"]}},{"id":"dd17e70c81e94306938b793011d0b206","type":"GENE","name":"YWHAH","canonical_id":"hgnc:HGNC:12853","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta","metadata":{"aliases":["YWHA1"]}},{"id":"d6e8f8a7af2c4f2a97005be4316dfe0a","type":"GENE","name":"YWHAH-AS1","canonical_id":"hgnc:HGNC:23051","description":"YWHAH antisense RNA 1","metadata":{"aliases":["HSN44A4A","C22orf24"]}},{"id":"50c887f7fc6b45ae9ca8ac476e9a5373","type":"GENE","name":"YWHAQ","canonical_id":"hgnc:HGNC:12854","description":null,"metadata":null},{"id":"d890ebf041914ee8b179f9cb92257be4","type":"GENE","name":"YWHAQP1","canonical_id":"hgnc:HGNC:19937","description":"YWHAQ pseudogene 1","metadata":{"aliases":["YWHAQP"]}},{"id":"e3a14b1d09ab42a9b2a08c1f3a35196f","type":"GENE","name":"YWHAQP10","canonical_id":"hgnc:HGNC:56392","description":"YWHAQ pseudogene","metadata":null},{"id":"ed6efe27863f4cab9940af6b45ee6338","type":"GENE","name":"YWHAQP2","canonical_id":"hgnc:HGNC:23211","description":"YWHAQ pseudogene 2","metadata":null},{"id":"c04de7b6f61b4568bcf1d20f4845743e","type":"GENE","name":"YWHAQP3","canonical_id":"hgnc:HGNC:37682","description":"YWHAQ pseudogene 3","metadata":null},{"id":"170a12c872b34f66a63a99282cf97714","type":"GENE","name":"YWHAQP4","canonical_id":"hgnc:HGNC:37683","description":"YWHAQ pseudogene 4","metadata":null},{"id":"d1b8327c76f042b5bf96b92a91f1d4eb","type":"GENE","name":"YWHAQP5","canonical_id":"hgnc:HGNC:37684","description":"YWHAQ pseudogene 5","metadata":null},{"id":"eb5edec730c945638e2bbdd368a8af88","type":"GENE","name":"YWHAQP6","canonical_id":"hgnc:HGNC:37685","description":"YWHAQ pseudogene 6","metadata":null},{"id":"dc3ba95052e549ba84c837fee4607870","type":"GENE","name":"YWHAQP7","canonical_id":"hgnc:HGNC:37686","description":"YWHAQ pseudogene 7","metadata":null},{"id":"17808ef393d84681a1cbb08394969592","type":"GENE","name":"YWHAQP8","canonical_id":"hgnc:HGNC:37687","description":"YWHAQ pseudogene 8","metadata":null},{"id":"840d09154f864c8e924bff884f82205c","type":"GENE","name":"YWHAQP9","canonical_id":"hgnc:HGNC:37688","description":"YWHAQ pseudogene 9","metadata":null},{"id":"7589d91bab4c41cda4afc314613fa2df","type":"GENE","name":"YWHAZ","canonical_id":"hgnc:HGNC:12855","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta","metadata":{"aliases":["KCIP-1","14-3-3-zeta","YWHAD"]}},{"id":"b59829265d8648afaf65e7d8cbe2fc93","type":"GENE","name":"YWHAZP1","canonical_id":"hgnc:HGNC:19938","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 1","metadata":{"aliases":["YWHAZP"]}},{"id":"7c70096115114f6a940a90d376d419c3","type":"GENE","name":"YWHAZP10","canonical_id":"hgnc:HGNC:54939","description":"YWHAZ pseudogene 10","metadata":null},{"id":"fe99425ce95e4d33ae8734fd909bb243","type":"GENE","name":"YWHAZP2","canonical_id":"hgnc:HGNC:31078","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 2","metadata":null},{"id":"01d3cd335be8421bbad577c4f83bb807","type":"GENE","name":"YWHAZP3","canonical_id":"hgnc:HGNC:31101","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 3","metadata":null},{"id":"7d29b41c98984e0b80db5eeeee87ac3a","type":"GENE","name":"YWHAZP4","canonical_id":"hgnc:HGNC:30851","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 4","metadata":null},{"id":"bca89a3f382249748ce32a4f8381e650","type":"GENE","name":"YWHAZP5","canonical_id":"hgnc:HGNC:30564","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 5","metadata":null},{"id":"2828010ce2c344b1a66159ae147b309a","type":"GENE","name":"YWHAZP6","canonical_id":"hgnc:HGNC:30849","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 6","metadata":null},{"id":"18df6265f12242e6882c55e5aa875443","type":"GENE","name":"YWHAZP7","canonical_id":"hgnc:HGNC:39028","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 7","metadata":null},{"id":"acd4fc1be8b14103ab1d2debf6d38841","type":"GENE","name":"YWHAZP8","canonical_id":"hgnc:HGNC:39029","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 8","metadata":null},{"id":"1cf88a2cf1d049428c8effe80ee6694d","type":"GENE","name":"YWHAZP9","canonical_id":"hgnc:HGNC:39030","description":"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 9","metadata":null},{"id":"73e38721572347b38e19fe2e073a6220","type":"GENE","name":"YY1","canonical_id":"hgnc:HGNC:12856","description":null,"metadata":null},{"id":"4da07454d3ab4bcb8074476d1cc08f31","type":"GENE","name":"YY1-DT","canonical_id":"hgnc:HGNC:56936","description":"YY1 divergent transcript","metadata":{"aliases":["RP11-638I2.4"]}},{"id":"9957102fccc54f9f9fe9fdbdb50232d1","type":"GENE","name":"YY1AP1","canonical_id":"hgnc:HGNC:30935","description":"YY1 associated protein 1","metadata":{"aliases":["YY1AP","HCCA2","YAP"]}},{"id":"e90744e6aeea48f5ba4fa856d0c6be1d","type":"GENE","name":"YY1P1","canonical_id":"hgnc:HGNC:45094","description":"YY1 transcription factor pseudogene 1","metadata":null},{"id":"131511566a10496186ec694f2e1eddc7","type":"GENE","name":"YY1P2","canonical_id":"hgnc:HGNC:45095","description":"YY1 transcription factor pseudogene 2","metadata":null},{"id":"3d83753d734f4ff3b7d02700f33a6500","type":"GENE","name":"YY2","canonical_id":"hgnc:HGNC:31684","description":"YY2 transcription factor","metadata":{"aliases":["ZNF631"]}},{"id":"bb68587e6d22480783ce1cb27c799803","type":"GO_TERM","name":"Yae1-Lto1 complex","canonical_id":"go:GO:0062092","description":"\"A cytosolic complex that functions as an substrate-specific adaptor, linking the cytosolic iron-sulfur protein assembly (CIA) targeting complex to apo-Rli1p, an ABC protein involved in ribosome recycling, facilitating Fe-S cluster insertion and the maturation of the Rli1p.\" [PMID:26182403]","metadata":null},{"id":"8d1d53c70713427f8a79b306159ed7e3","type":"DISEASE","name":"Yaws","canonical_id":"mesh:D015001","description":null,"metadata":null},{"id":"cbadc32a74e54ec691ea158a529d7eef","type":"GO_TERM","name":"Yb body","canonical_id":"go:GO:0070725","description":"\"A cytoplasmic part that appears as an electron-dense sphere of around 1.5 micron diameter containing Yb protein found in somatic cells of ovary and testis. There are one to two Yb bodies per cell.\" [GOC:sart, PMID:19433453, PMID:28595904, PMID:31267711]","metadata":null},{"id":"79ace87c12a444ab97b8a3766eba804a","type":"GO_TERM","name":"Ycf2/FtsHi complex","canonical_id":"go:GO:0062091","description":"\"A protein complex located in the chloroplast inner membrane and facing the stroma that is associated with the chloroplast inner membrane translocase complex and provides the ATPase motor activity to drive import of proteins into the chloroplast stroma.\" [PMID:30309901]","metadata":null},{"id":"ac02920c9e4f4399bfbef94caefb2ac0","type":"TRIAL","name":"Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients","canonical_id":"clinicaltrials.gov:NCT03898856","description":"Chronic Diarrhea of Unknown Origin","metadata":null},{"id":"047a27bc8fca4dd0bca1880279bb317a","type":"TRIAL","name":"Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety","canonical_id":"clinicaltrials.gov:NCT00958880","description":"Social Anxiety Disorder","metadata":null},{"id":"7e98dde69ae74585957f0b9fbba3d204","type":"TRIAL","name":"Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)","canonical_id":"clinicaltrials.gov:NCT00549926","description":"Coronary Disease; Hypercholesterolemia","metadata":null},{"id":"03be85536bed434b845f55acb920794a","type":"TRIAL","name":"Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00386321","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"ded2fb6d220e4c5b8812276349579f3b","type":"TRIAL","name":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01973062","description":"Primary Central Nervous System Non-Hodgkin Lymphoma","metadata":null},{"id":"fbb96bba453345a2b25e703a426a7104","type":"TRIAL","name":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder","canonical_id":"clinicaltrials.gov:NCT00064246","description":"Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Waldenstr\u00f6m Macroglobulinemia","metadata":null},{"id":"2c08299f238a4568b2ef1f8798722d80","type":"TRIAL","name":"Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia","canonical_id":"clinicaltrials.gov:NCT00060294","description":"Lymphoma","metadata":null},{"id":"ab3a79461eeb4349adecd69e5d805c29","type":"TRIAL","name":"Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00119392","description":"B-cell Chronic Lymphocytic Leukemia; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follic\u2026","metadata":null},{"id":"3a0e1dacaae04b3abb1d95b17f0ca5a4","type":"TRIAL","name":"Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00695409","description":"Lymphoma","metadata":null},{"id":"c5e4ee3b39df459b9240cf55fc8d72fc","type":"TRIAL","name":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT04871607","description":"Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma","metadata":null},{"id":"4f0c63667dc240d79eeee6a35da4586f","type":"GO_TERM","name":"Z chromosome","canonical_id":"go:GO:0000807","description":"\"The sex chromosome present in both sexes of species in which the female is the heterogametic sex. Two copies of the Z chromosome are present in each somatic cell of males and one copy is present in females.\" [GOC:mah, GOC:mr, ISBN:0321000382, PMID:20622855]","metadata":null},{"id":"291f63112ab14123936ae08355767ec0","type":"GO_TERM","name":"Z disc","canonical_id":"go:GO:0030018","description":"\"Platelike region of a muscle sarcomere to which the plus ends of actin filaments are attached.\" [GOC:mtg_muscle, ISBN:0815316194]","metadata":null},{"id":"f73c451c1292420790a2ab7faf3f3804","type":"GO_TERM","name":"Z granule","canonical_id":"go:GO:0120279","description":"\"A small cytoplasmic, non-membranous RNA/protein complex aggregate in the primordial germ cells that are distinct from, but colocalize with or are adjacent to, P granules and mutator foci and are associated with RNA metabolism. Z granules have been observed in C. elegans.\" [GOC:dr, GOC:krc, PMID:29769721, PMID:31378614, PMID:32650583]","metadata":null},{"id":"241f7f4d1f154af69e425f533539a474","type":"TRIAL","name":"Z-Drugs for Sleep Disorders in Alzheimer's Disease","canonical_id":"clinicaltrials.gov:NCT03075241","description":"Sleep; Sleep Disorders; Insomnia; Alzheimer's Disease","metadata":null},{"id":"faaa28cb50b74f6984effc798e23e1e8","type":"GO_TERM","name":"Z-farnesyl diphosphate synthase activity","canonical_id":"go:GO:0033850","description":"\"Catalysis of the reaction: geranyl diphosphate + isopentenyl diphosphate = 2-cis,6-trans-farnesyl diphosphate + diphosphate.\" [EC:2.5.1.68, RHEA:23300]","metadata":null},{"id":"5c8d9c4255fc4d8d8882b46b00d593d2","type":"GO_TERM","name":"Z-phenylacetaldoxime biosynthetic process","canonical_id":"go:GO:0046307","description":"\"The chemical reactions and pathways resulting in the formation of Z-phenylacetaldoxime, a member of the glucosinolate group of compounds.\" [GOC:ai]","metadata":null},{"id":"a73caa00f8204c8f9600e81e5e6bc296","type":"GO_TERM","name":"Z-phenylacetaldoxime catabolic process","canonical_id":"go:GO:0046308","description":"\"The chemical reactions and pathways resulting in the breakdown of Z-phenylacetaldoxime, a member of the glucosinolate group of compounds.\" [MetaCyc:P345-PWY]","metadata":null},{"id":"f7fc193ac40147c4b40b254c863696b4","type":"GENE","name":"ZACN","canonical_id":"hgnc:HGNC:29504","description":"zinc activated ion channel","metadata":{"aliases":["LGICZ","L2","ZAC","ZAC1","LGICZ1"]}},{"id":"644c1564e4cf4c0ca840cf235a301beb","type":"GENE","name":"ZACNP1","canonical_id":"hgnc:HGNC:51915","description":"zinc activated ion channel pseudogene 1","metadata":null},{"id":"e849feed03f643ce82cf96b2430f5f80","type":"TRIAL","name":"ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer","canonical_id":"clinicaltrials.gov:NCT00312377","description":"Non-small Cell Lung Cancer; Lung Cancer","metadata":null},{"id":"5a92e96b84f24bb292110bedf4485911","type":"GENE","name":"ZAN","canonical_id":"hgnc:HGNC:12857","description":"zonadhesin","metadata":null},{"id":"e33385c182024918909978ce2e2e01cb","type":"TRIAL","name":"ZAP, US. Zomig for Appropriate for Primary Care","canonical_id":"clinicaltrials.gov:NCT00637286","description":"Migraine","metadata":null},{"id":"8c189f3cc6c04aa8a5b1d7009439084b","type":"GENE","name":"ZAP70","canonical_id":"hgnc:HGNC:12858","description":null,"metadata":null},{"id":"67be59fb54124648be18746fa8f80528","type":"GENE","name":"ZAR1","canonical_id":"hgnc:HGNC:20436","description":"zygote arrest 1","metadata":{"aliases":["Z3CXXC6"]}},{"id":"d0c4e338c17b49e5996bc6cd0a280620","type":"GENE","name":"ZAR1L","canonical_id":"hgnc:HGNC:37116","description":"zygote arrest 1 like","metadata":{"aliases":["Z3CXXC7"]}},{"id":"64ca480e2a3045a9880ec60bea74a3f8","type":"TRIAL","name":"ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin\u00ae) Versus Maintenance Treatment With Rituximab (MabThera\u00ae)","canonical_id":"clinicaltrials.gov:NCT00662948","description":"Lymphoma","metadata":null},{"id":"faa1bcdf22a94f93930f423ece3af017","type":"GENE","name":"ZBBX","canonical_id":"hgnc:HGNC:26245","description":"zinc finger B-box domain containing","metadata":{"aliases":["FLJ23049"]}},{"id":"d3204debbf7f40a58f5afd44d0d0ad02","type":"GENE","name":"ZBED1","canonical_id":"hgnc:HGNC:447","description":"zinc finger BED-type containing 1","metadata":{"aliases":["TRAMP","KIAA0785","DREF","hDREF","ALTE"]}},{"id":"f1f9c2f1517f4326bd1a4ee126c719a5","type":"GENE","name":"ZBED10P","canonical_id":"hgnc:HGNC:21720","description":"zinc finger BED-type containing 10, pseudogene","metadata":{"aliases":["C7orf29","ZBED6CL"]}},{"id":"8c18610c46364b1086c43fa291b23953","type":"GENE","name":"ZBED11","canonical_id":"hgnc:HGNC:27740","description":"zinc finger BED-type containing 11","metadata":{"aliases":["C4orf53","FAM200B"]}},{"id":"ccec461d54044b03afc8f3462ce6d432","type":"GENE","name":"ZBED1P1","canonical_id":"hgnc:HGNC:44004","description":"zinc finger BED-type containing 1 pseudogene 1","metadata":null},{"id":"53100ae2d03d41bca6ccd94859c963dc","type":"GENE","name":"ZBED2","canonical_id":"hgnc:HGNC:20710","description":"zinc finger BED-type containing 2","metadata":{"aliases":["MGC10796"]}},{"id":"4365864a6bd34ca89cd48af3d6c72f74","type":"GENE","name":"ZBED3","canonical_id":"hgnc:HGNC:20711","description":"zinc finger BED-type containing 3","metadata":{"aliases":["MGC15435"]}},{"id":"23c5a6650f704ca1b532a7bcd506470e","type":"GENE","name":"ZBED3-AS1","canonical_id":"hgnc:HGNC:44188","description":"ZBED3 antisense RNA 1","metadata":{"aliases":["lnc13728"]}},{"id":"26ce82a7f9fe4fed9a89b945614d67fb","type":"GENE","name":"ZBED4","canonical_id":"hgnc:HGNC:20721","description":"zinc finger BED-type containing 4","metadata":{"aliases":["KIAA0637"]}},{"id":"24f7c77436bc418e9709562ae0b826e9","type":"GENE","name":"ZBED5","canonical_id":"hgnc:HGNC:30803","description":"zinc finger BED-type containing 5","metadata":{"aliases":["Buster1"]}},{"id":"5ac5c70a5c304126965488280f9da92c","type":"GENE","name":"ZBED5-AS1","canonical_id":"hgnc:HGNC:48646","description":"ZBED5 antisense RNA 1","metadata":null},{"id":"b347e571bd504d459ff7d3190f457236","type":"GENE","name":"ZBED6","canonical_id":"hgnc:HGNC:33273","description":"zinc finger BED-type containing 6","metadata":null},{"id":"3218ac6eb3764ec69a344aa1efa80f07","type":"GENE","name":"ZBED8","canonical_id":"hgnc:HGNC:30804","description":"zinc finger BED-type containing 8","metadata":{"aliases":["Buster3","C5orf54","FAM200C"]}},{"id":"64141051fb2b4f90b0d6732131d61f1f","type":"GENE","name":"ZBED8L","canonical_id":"hgnc:HGNC:25401","description":"ZBED8 like","metadata":{"aliases":["FLJ36794","DKFZp727G131","C7orf38","FAM200A"]}},{"id":"84989ae4b5f548d5b680ba951837e499","type":"GENE","name":"ZBP1","canonical_id":"hgnc:HGNC:16176","description":"Z-DNA binding protein 1","metadata":{"aliases":["dJ718J7.3","DLM1","DLM-1","DAI","C20orf183"]}},{"id":"7d384e2868ec4969a3e862c947f28696","type":"GENE","name":"ZBTB1","canonical_id":"hgnc:HGNC:20259","description":"zinc finger and BTB domain containing 1","metadata":{"aliases":["KIAA0997","ZNF909"]}},{"id":"b3ea57d1c1d14a648809d63ca7b03f12","type":"GENE","name":"ZBTB10","canonical_id":"hgnc:HGNC:30953","description":"zinc finger and BTB domain containing 10","metadata":{"aliases":["RINZF","FLJ12752"]}},{"id":"5b3d89cb448e438da14a24a32052af37","type":"GENE","name":"ZBTB11","canonical_id":"hgnc:HGNC:16740","description":"zinc finger and BTB domain containing 11","metadata":{"aliases":["ZNF-U69274","ZNF913"]}},{"id":"6f7843117a2c42dfbb3e1f7ed6c473d1","type":"GENE","name":"ZBTB11-AS1","canonical_id":"hgnc:HGNC:48573","description":"ZBTB11 antisense RNA 1","metadata":null},{"id":"06dcba0ded294bb4868f7cf13ec45796","type":"GENE","name":"ZBTB12","canonical_id":"hgnc:HGNC:19066","description":"zinc finger and BTB domain containing 12","metadata":{"aliases":["G10","NG35","D6S59E","C6orf46"]}},{"id":"85c8dd7abffb4fb2be12f76bfe377729","type":"GENE","name":"ZBTB12BP","canonical_id":"hgnc:HGNC:37702","description":"zinc finger and BTB domain containing 12B, pseudogene","metadata":{"aliases":["ZNF920","ZBTB12B","ZBTB12P1"]}},{"id":"b1f6832b887d457abd998e99658780b0","type":"GENE","name":"ZBTB14","canonical_id":"hgnc:HGNC:12860","description":null,"metadata":null},{"id":"56c7e1ce0ffb413d9aaa92629e2ea4c2","type":"GENE","name":"ZBTB16","canonical_id":"hgnc:HGNC:12930","description":null,"metadata":null},{"id":"747105052b4540f49d1f6f342d242a99","type":"GENE","name":"ZBTB17","canonical_id":"hgnc:HGNC:12936","description":null,"metadata":null},{"id":"e9f8a86468cd4403bf77510e195c1e89","type":"GENE","name":"ZBTB18","canonical_id":"hgnc:HGNC:13030","description":"zinc finger and BTB domain containing 18","metadata":{"aliases":["C2H2-171","TAZ-1","RP58","ZNF238"]}},{"id":"dafe8cd924744aecb1adff39b0b8b2c9","type":"GENE","name":"ZBTB2","canonical_id":"hgnc:HGNC:20868","description":null,"metadata":null},{"id":"766a76844cea46d7b4b65ab02d31bdb0","type":"GENE","name":"ZBTB20","canonical_id":"hgnc:HGNC:13503","description":"zinc finger and BTB domain containing 20","metadata":{"aliases":["ODA-8S","DKFZp566F123","DPZF","ZNF288"]}},{"id":"a227381e24c246f0aa1689f05c56c008","type":"GENE","name":"ZBTB20-AS1","canonical_id":"hgnc:HGNC:40640","description":"ZBTB20 antisense RNA 1","metadata":null},{"id":"bbc5c7e9190b4f0e84f54d05c24b6fbf","type":"GENE","name":"ZBTB20-AS2","canonical_id":"hgnc:HGNC:42421","description":"ZBTB20 antisense RNA 2","metadata":null},{"id":"c37be898e0d045c9bfd25da7ac9443c5","type":"GENE","name":"ZBTB20-AS3","canonical_id":"hgnc:HGNC:42422","description":"ZBTB20 antisense RNA 3","metadata":null},{"id":"6cfb44db4e91445e8bf3e9647db9b753","type":"GENE","name":"ZBTB20-AS4","canonical_id":"hgnc:HGNC:42423","description":"ZBTB20 antisense RNA 4","metadata":null},{"id":"1147d112299f4cb1bd2e31b4cb5a6ebc","type":"GENE","name":"ZBTB20-AS5","canonical_id":"hgnc:HGNC:52841","description":"ZBTB20 antisense RNA 5","metadata":null},{"id":"4790e209446e4c6a90f38eb1fe8134d0","type":"GENE","name":"ZBTB21","canonical_id":"hgnc:HGNC:13083","description":"zinc finger and BTB domain containing 21","metadata":{"aliases":["KIAA1227","ZNF295"]}},{"id":"da71e4d1d4a54846961a208d3c327417","type":"GENE","name":"ZBTB22","canonical_id":"hgnc:HGNC:13085","description":"zinc finger and BTB domain containing 22","metadata":{"aliases":["BING1","ZNF297A","fruitless","fru","ZBTB22A","ZNF297"]}},{"id":"249bbac1f45e4e9fbaa733e24dae9c6d","type":"GENE","name":"ZBTB24","canonical_id":"hgnc:HGNC:21143","description":"zinc finger and BTB domain containing 24","metadata":{"aliases":["KIAA0441","BIF1","PATZ2","ZNF450"]}},{"id":"61efd619515c4f60bc851f44fd1d11d3","type":"GENE","name":"ZBTB24-DT","canonical_id":"hgnc:HGNC:55872","description":"ZBTB24 divergent transcript","metadata":null},{"id":"ea32986c489640969453bd10cda87411","type":"GENE","name":"ZBTB25","canonical_id":"hgnc:HGNC:13112","description":"zinc finger and BTB domain containing 25","metadata":{"aliases":["KUP","ZNF46","C14orf51"]}},{"id":"f2a70dd7dd8441708ae36120914f63fe","type":"GENE","name":"ZBTB26","canonical_id":"hgnc:HGNC:23383","description":"zinc finger and BTB domain containing 26","metadata":{"aliases":["ZNF481"]}},{"id":"9dc0443bc837467d93ad18b9bb7f6f61","type":"GENE","name":"ZBTB2P1","canonical_id":"hgnc:HGNC:54544","description":"ZBTB2 pseudogene 1","metadata":null},{"id":"15d8039105254509b70e348b5e34afed","type":"GENE","name":"ZBTB3","canonical_id":"hgnc:HGNC:22918","description":"zinc finger and BTB domain containing 3","metadata":{"aliases":["FLJ23392"]}},{"id":"7316f19bca9b403c818d2d0294d34a42","type":"GENE","name":"ZBTB32","canonical_id":"hgnc:HGNC:16763","description":"zinc finger and BTB domain containing 32","metadata":{"aliases":["TZFP","FAZF","FAXF","Rog","ZNF538","mynn"]}},{"id":"e37ef2cb48274354a81815811901d065","type":"GENE","name":"ZBTB33","canonical_id":"hgnc:HGNC:16682","description":"zinc finger and BTB domain containing 33","metadata":{"aliases":["ZNF-kaiso","kaiso","WUGSC:H_DJ525N14.1","KAISO","ZNF348"]}},{"id":"1f17b54409e944f3b2b5bbfc096beab6","type":"GENE","name":"ZBTB34","canonical_id":"hgnc:HGNC:31446","description":"zinc finger and BTB domain containing 34","metadata":{"aliases":["KIAA1993","MGC24652","ZNF918"]}},{"id":"6774241971194a1985970e5a141332ca","type":"GENE","name":"ZBTB35","canonical_id":"hgnc:HGNC:12915","description":"zinc finger and BTB domain containing 35","metadata":{"aliases":["ZBTB35","ZNF131"]}},{"id":"d56181d4e7aa4811a0638543a1024e2a","type":"GENE","name":"ZBTB37","canonical_id":"hgnc:HGNC:28365","description":"zinc finger and BTB domain containing 37","metadata":{"aliases":["MGC2629","ZNF908"]}},{"id":"935f8293d08f46b89c6ca6fbfac01c5b","type":"GENE","name":"ZBTB38","canonical_id":"hgnc:HGNC:26636","description":"zinc finger and BTB domain containing 38","metadata":{"aliases":["FLJ35036","CIBZ","ZNF921","PPP1R171"]}},{"id":"5229ca1608f045c791ebffe21f121914","type":"GENE","name":"ZBTB39","canonical_id":"hgnc:HGNC:29014","description":"zinc finger and BTB domain containing 39","metadata":{"aliases":["KIAA0352","ZNF922"]}},{"id":"a55fb5c91785499a90c7c6b7ea7fa6a9","type":"GENE","name":"ZBTB4","canonical_id":"hgnc:HGNC:23847","description":"zinc finger and BTB domain containing 4","metadata":{"aliases":["KIAA1538","KAISO-L1","ZNF903"]}},{"id":"5f03f73393c849beb992fe1a0b757af5","type":"GENE","name":"ZBTB40","canonical_id":"hgnc:HGNC:29045","description":"zinc finger and BTB domain containing 40","metadata":{"aliases":["KIAA0478","ZNF923"]}},{"id":"a363b7f6c78a476f9be4e52120b5ea99","type":"GENE","name":"ZBTB40-IT1","canonical_id":"hgnc:HGNC:41493","description":"ZBTB40 intronic transcript 1","metadata":null},{"id":"9d225733bbb345c3befea8225f8a3d71","type":"GENE","name":"ZBTB41","canonical_id":"hgnc:HGNC:24819","description":"zinc finger and BTB domain containing 41","metadata":{"aliases":["FRBZ1","FLJ36199","DKFZp686C06120","ZNF924"]}},{"id":"ef15ad52cd804ef285c811559ee349ac","type":"GENE","name":"ZBTB42","canonical_id":"hgnc:HGNC:32550","description":"zinc finger and BTB domain containing 42","metadata":{"aliases":["ZNF925"]}},{"id":"61a6b9ca522940439a3f9b1dc6aebc02","type":"GENE","name":"ZBTB43","canonical_id":"hgnc:HGNC:17908","description":"zinc finger and BTB domain containing 43","metadata":{"aliases":["KIAA0414","ZNF-X","FLJ22470","ZBTB22B","ZNF297B"]}},{"id":"b84b9920cfcf4ce6928e971bfe21b718","type":"GENE","name":"ZBTB44","canonical_id":"hgnc:HGNC:25001","description":"zinc finger and BTB domain containing 44","metadata":{"aliases":["HSPC063","ZNF851","BTBD15"]}},{"id":"5838cf6e17fe460582971751aa3dbec0","type":"GENE","name":"ZBTB44-DT","canonical_id":"hgnc:HGNC:54265","description":"ZBTB44 divergent transcript","metadata":null},{"id":"4e07c339ec48402aa77dd0d26a19e42d","type":"GENE","name":"ZBTB45","canonical_id":"hgnc:HGNC:23715","description":"zinc finger and BTB domain containing 45","metadata":{"aliases":["FLJ14486","ZNF499"]}},{"id":"6843fd33392e4f15b71146c67f6083d4","type":"GENE","name":"ZBTB45P1","canonical_id":"hgnc:HGNC:49227","description":"zinc finger and BTB domain containing 45 pseudogene 1","metadata":null},{"id":"421e478829e04735a1322c94bc1f18b1","type":"GENE","name":"ZBTB45P2","canonical_id":"hgnc:HGNC:49228","description":"zinc finger and BTB domain containing 45 pseudogene 2","metadata":null},{"id":"b2736409d50846cfb0d3600124a32d78","type":"GENE","name":"ZBTB46","canonical_id":"hgnc:HGNC:16094","description":"zinc finger and BTB domain containing 46","metadata":{"aliases":["FLJ13502","RINZF","BZEL","ZNF340","BTBD4"]}},{"id":"076830a8ec07403e8efa6fd44dab1344","type":"GENE","name":"ZBTB46-AS1","canonical_id":"hgnc:HGNC:40753","description":"ZBTB46 antisense RNA 1","metadata":null},{"id":"4bc14baab7924b4f84cc9a21ce78d1e8","type":"GENE","name":"ZBTB46-AS2","canonical_id":"hgnc:HGNC:40752","description":"ZBTB46 antisense RNA 2","metadata":null},{"id":"5a7ca5a1df924f25a463df4c5e2d0b55","type":"GENE","name":"ZBTB47","canonical_id":"hgnc:HGNC:26955","description":"zinc finger and BTB domain containing 47","metadata":{"aliases":["KIAA1190","DKFZp434N0615","ZNF651"]}},{"id":"7baff51f1e2d40649f0cf6830ae94331","type":"GENE","name":"ZBTB47-AS1","canonical_id":"hgnc:HGNC:41174","description":"ZBTB47 and NKTR antisense RNA 1","metadata":null},{"id":"8c57d116e9ce4131a5588c713422917f","type":"GENE","name":"ZBTB48","canonical_id":"hgnc:HGNC:4930","description":"zinc finger and BTB domain containing 48","metadata":{"aliases":["ZNF855","TZAP","HKR3"]}},{"id":"73742e2c05c448b4bfdb8d5301518a63","type":"GENE","name":"ZBTB49","canonical_id":"hgnc:HGNC:19883","description":"zinc finger and BTB domain containing 49","metadata":{"aliases":["FLJ38559","ZNF509"]}},{"id":"821a00fdd29a4751811ee625a7a50a7f","type":"GENE","name":"ZBTB5","canonical_id":"hgnc:HGNC:23836","description":null,"metadata":null},{"id":"396708ea2ef242e693463df26328577f","type":"GENE","name":"ZBTB6","canonical_id":"hgnc:HGNC:16764","description":"zinc finger and BTB domain containing 6","metadata":{"aliases":["ZID","ZNF482"]}},{"id":"23ec294ed59e40f3a7a573a40940fd1c","type":"GENE","name":"ZBTB7B","canonical_id":"hgnc:HGNC:18668","description":"zinc finger and BTB domain containing 7B","metadata":{"aliases":["ZBTB15","c-Krox","hcKrox","ZNF857B","vGAF","ThPOK","ZFP67"]}},{"id":"0d0b0ff2739f4f4eb6e6a29d3bbef2e2","type":"GENE","name":"ZBTB7C","canonical_id":"hgnc:HGNC:31700","description":"zinc finger and BTB domain containing 7C","metadata":{"aliases":["ZNF857C","ZBTB36"]}},{"id":"5dc1312d357e45c9aaef4bfacdaad7f6","type":"GENE","name":"ZBTB7C-AS1","canonical_id":"hgnc:HGNC:55846","description":"ZBTB7C antisense RNA 1","metadata":null},{"id":"1be93fc152964a48aadfe1e07c460e09","type":"GENE","name":"ZBTB7C-AS2","canonical_id":"hgnc:HGNC:24918","description":"ZBTB7C antisense RNA 2","metadata":{"aliases":["HEIL1","HsT2508","C18orf12"]}},{"id":"f8dc0bf68e124ef0a111e2a493af145f","type":"GENE","name":"ZBTB8A","canonical_id":"hgnc:HGNC:24172","description":"zinc finger and BTB domain containing 8A","metadata":{"aliases":["BOZF1","FLJ90065","ZNF916A","ZBTB8"]}},{"id":"70c329da81b64a6ba161e6d8d5d913c5","type":"GENE","name":"ZBTB8B","canonical_id":"hgnc:HGNC:37057","description":"zinc finger and BTB domain containing 8B","metadata":{"aliases":["RP1-27O5.1","DKFZp547H154","ZNF916B"]}},{"id":"2cee042ba6364849993f1110e4acce21","type":"GENE","name":"ZBTB8OSP1","canonical_id":"hgnc:HGNC:19043","description":"zinc finger and BTB domain containing 8 opposite strand pseudogene 1","metadata":null},{"id":"93210aca148842f6bf136077fee9f438","type":"GENE","name":"ZBTB8OSP2","canonical_id":"hgnc:HGNC:30326","description":"zinc finger and BTB domain containing 8 opposite strand pseudogene 2","metadata":null},{"id":"e2b025c9dc2e453a9758acd1021d6916","type":"GENE","name":"ZBTB9","canonical_id":"hgnc:HGNC:28323","description":"zinc finger and BTB domain containing 9","metadata":{"aliases":["MGC23166","ZNF919"]}},{"id":"f1bcd18145f748489da435a5a2418a3a","type":"GENE","name":"ZC2HC1A","canonical_id":"hgnc:HGNC:24277","description":"zinc finger C2HC-type containing 1A","metadata":{"aliases":["CGI-62","C8orf70","FAM164A"]}},{"id":"eba4b248730449f5a47cf745561921ab","type":"GENE","name":"ZC2HC1B","canonical_id":"hgnc:HGNC:21174","description":"zinc finger C2HC-type containing 1B","metadata":{"aliases":["dJ468K18.5","FAM164B","C6orf94"]}},{"id":"b053ef981c004ed48e0a6c36dc58240a","type":"GENE","name":"ZC2HC1C","canonical_id":"hgnc:HGNC:20354","description":"zinc finger C2HC-type containing 1C","metadata":{"aliases":["C14orf140","FAM164C"]}},{"id":"f767c87aa99a4f82a84ce54e82cefa2d","type":"GENE","name":"ZC3H10","canonical_id":"hgnc:HGNC:25893","description":"zinc finger CCCH-type containing 10","metadata":{"aliases":["FLJ14451","ZC3HDC10"]}},{"id":"63b3a04e16b74aa3bacf65866afe0ff0","type":"GENE","name":"ZC3H11A","canonical_id":"hgnc:HGNC:29093","description":"zinc finger CCCH-type containing 11A","metadata":{"aliases":["KIAA0663","ZC3HDC11A"]}},{"id":"d71876a2667c46af816d63e3483a8441","type":"GENE","name":"ZC3H11B","canonical_id":"hgnc:HGNC:25659","description":"zinc finger CCCH-type containing 11B","metadata":{"aliases":["ZC3HDC11B"]}},{"id":"69620fc316814d5a96c677e8e2cac9d5","type":"GENE","name":"ZC3H11C","canonical_id":"hgnc:HGNC:56304","description":"zinc finger CCCH-type containing 11C","metadata":null},{"id":"ecdf7b54aac344918d96196c3d4fc2a4","type":"GENE","name":"ZC3H11D","canonical_id":"hgnc:HGNC:26665","description":"zinc finger CCCH-type containing 11D","metadata":{"aliases":["FLJ35821","C12orf50"]}},{"id":"c6dc4b84ac374f429503b56836421b15","type":"GENE","name":"ZC3H12A","canonical_id":"hgnc:HGNC:26259","description":"zinc finger CCCH-type containing 12A","metadata":{"aliases":["FLJ23231","MCPIP1","Regnase-1"]}},{"id":"9c154cc6d3494ea891f084bf9a34d268","type":"GENE","name":"ZC3H12B","canonical_id":"hgnc:HGNC:17407","description":"zinc finger CCCH-type containing 12B","metadata":{"aliases":["MCPIP2","CXorf32"]}},{"id":"dd591b4b13db464c89625d3a863184e2","type":"GENE","name":"ZC3H12C","canonical_id":"hgnc:HGNC:29362","description":"zinc finger CCCH-type containing 12C","metadata":{"aliases":["KIAA1726","MCPIP3"]}},{"id":"f1e9735a26154e4282a3d3c0c659d2cb","type":"GENE","name":"ZC3H12D","canonical_id":"hgnc:HGNC:21175","description":"zinc finger CCCH-type containing 12D","metadata":{"aliases":["dJ281H8.1","MCPIP4","C6orf95"]}},{"id":"6996e8d5a0a944fca872760b37a82079","type":"GENE","name":"ZC3H13","canonical_id":"hgnc:HGNC:20368","description":"zinc finger CCCH-type containing 13","metadata":{"aliases":["DKFZp434D1812","Xio","KIAA0853"]}},{"id":"6d8db72095d14497b2d6f5c4cf7f7c78","type":"GENE","name":"ZC3H14","canonical_id":"hgnc:HGNC:20509","description":"zinc finger CCCH-type containing 14","metadata":{"aliases":["FLJ11806","UKp68","NY-REN-37"]}},{"id":"a77a83c3b39e4a39b03384c97a247b23","type":"GENE","name":"ZC3H15","canonical_id":"hgnc:HGNC:29528","description":"zinc finger CCCH-type containing 15","metadata":{"aliases":["DFRP1","LEREPO4"]}},{"id":"dffd054c464c43fc9ccfadaea0aef039","type":"GENE","name":"ZC3H18","canonical_id":"hgnc:HGNC:25091","description":"zinc finger CCCH-type containing 18","metadata":{"aliases":["NHN1"]}},{"id":"1b3f5a1868a246a08e41c8a93c604be1","type":"GENE","name":"ZC3H18-DT","canonical_id":"hgnc:HGNC:33799","description":"ZC3H18 divergent transcript","metadata":{"aliases":["FLJ45530","C16orf85","LINC00859","ZC3H18-AS1"]}},{"id":"c4e83cce1c754ac782f46ac99e9b3bb1","type":"GENE","name":"ZC3H3","canonical_id":"hgnc:HGNC:28972","description":"zinc finger CCCH-type containing 3","metadata":{"aliases":["KIAA0150","ZC3HDC3"]}},{"id":"e2067b1b7d5740e38789e75baf30cea3","type":"GENE","name":"ZC3H4","canonical_id":"hgnc:HGNC:17808","description":"zinc finger CCCH-type containing 4","metadata":{"aliases":["KIAA1064","C19orf7"]}},{"id":"7613771afad54adea0c3e9311de81f27","type":"GENE","name":"ZC3H6","canonical_id":"hgnc:HGNC:24762","description":"zinc finger CCCH-type containing 6","metadata":{"aliases":["FLJ41410","FLJ45877","KIAA2035","ZC3HDC6"]}},{"id":"2141382c878a4529872e2ab445aaf353","type":"GENE","name":"ZC3H7A","canonical_id":"hgnc:HGNC:30959","description":"zinc finger CCCH-type containing 7A","metadata":{"aliases":["HSPC055","FLJ20318","ZC3HDC7","ZC3H7"]}},{"id":"a80edb026b5b477e815e68d22e766042","type":"GENE","name":"ZC3H7B","canonical_id":"hgnc:HGNC:30869","description":"zinc finger CCCH-type containing 7B","metadata":{"aliases":["RoXaN","FLJ13787","DKFZp434K0920","KIAA1031"]}},{"id":"11c4d8ee296a4106b1c69c07dafac7cf","type":"GENE","name":"ZC3H8","canonical_id":"hgnc:HGNC:30941","description":"zinc finger CCCH-type containing 8","metadata":{"aliases":["Fliz1","ZC3HDC8"]}},{"id":"9a90b959daa64c2081cf6ebb607abd7f","type":"GENE","name":"ZC3HAV1","canonical_id":"hgnc:HGNC:23721","description":"zinc finger CCCH-type containing, antiviral 1","metadata":{"aliases":["ZAP","FLB6421","FLJ13288","MGC48898","ZC3HDC2","ZC3H2","PARP13","ARTD13"]}},{"id":"b29d2af8aa704f1ba2924ef90734de4b","type":"GENE","name":"ZC3HAV1L","canonical_id":"hgnc:HGNC:22423","description":"ZC3HAV1 like","metadata":{"aliases":["MGC14289","C7orf39"]}},{"id":"3d536cbf9d2f46cc9e581fbd122db1d6","type":"GENE","name":"ZC3HC1","canonical_id":"hgnc:HGNC:29913","description":"zinc finger C3HC-type containing 1","metadata":{"aliases":["NIPA"]}},{"id":"fa75398cf9df487d96ecce45a9eb4337","type":"GENE","name":"ZC4H2","canonical_id":"hgnc:HGNC:24931","description":"zinc finger C4H2-type containing","metadata":{"aliases":["HCA127","KIAA1166","WWS","MCS","MRXS4"]}},{"id":"84b40afc7960449e8e70f5e40a962e6d","type":"GENE","name":"ZCCHC10","canonical_id":"hgnc:HGNC:25954","description":"zinc finger CCHC-type containing 10","metadata":{"aliases":["FLJ20094"]}},{"id":"43ca41e2f8e549319c8cdd122d9bb2e3","type":"GENE","name":"ZCCHC10-AS1","canonical_id":"hgnc:HGNC:59144","description":"ZCCHC10 antisense RNA 1","metadata":null},{"id":"15a83b5922694ea19098336d9bec3588","type":"GENE","name":"ZCCHC10P1","canonical_id":"hgnc:HGNC:56594","description":"ZCCHC10 pseudogene 1","metadata":null},{"id":"1bda819a29b44319b3b2b62d2208f681","type":"GENE","name":"ZCCHC10P2","canonical_id":"hgnc:HGNC:56595","description":"ZCCHC10 pseudogene 2","metadata":null},{"id":"20154b5d783f445db9be5c303506bb46","type":"GENE","name":"ZCCHC12","canonical_id":"hgnc:HGNC:27273","description":"zinc finger CCHC-type containing 12","metadata":{"aliases":["FLJ16123","SIZN","SIZN1","PNMA7A"]}},{"id":"1cb519d7ac554a26a2415c2a8a822ac5","type":"GENE","name":"ZCCHC13","canonical_id":"hgnc:HGNC:31749","description":"zinc finger CCHC-type containing 13","metadata":{"aliases":["4930513O09RIK","Cnbp2","ZNF9L"]}},{"id":"d50a75b263544fb8b221606fc9f08609","type":"GENE","name":"ZCCHC14","canonical_id":"hgnc:HGNC:24134","description":"zinc finger CCHC-type containing 14","metadata":{"aliases":["BDG29","MGC14139"]}},{"id":"1c88fb5a6f274d3fab764da2ef8df07b","type":"GENE","name":"ZCCHC14-DT","canonical_id":"hgnc:HGNC:52996","description":"ZCCHC14 divergent transcript","metadata":null},{"id":"1da845b3689b482f9ddaab998598b72c","type":"GENE","name":"ZCCHC17","canonical_id":"hgnc:HGNC:30246","description":"zinc finger CCHC-type containing 17","metadata":{"aliases":["PS1D","HSPC251","pNO40"]}},{"id":"1aadb3bfb5164ce8b55f24db63fc63d0","type":"GENE","name":"ZCCHC18","canonical_id":"hgnc:HGNC:32459","description":"zinc finger CCHC-type containing 18","metadata":{"aliases":["SIZN2","PNMA7B"]}},{"id":"7ad996a036d442c2bbd837c8baf3f59c","type":"GENE","name":"ZCCHC2","canonical_id":"hgnc:HGNC:22916","description":"zinc finger CCHC-type containing 2","metadata":{"aliases":["FLJ20281","KIAA1744","FLJ20222","C18orf49"]}},{"id":"f2bb2ba3724440d6b9d60b4b66fa12c0","type":"GENE","name":"ZCCHC24","canonical_id":"hgnc:HGNC:26911","description":"zinc finger CCHC-type containing 24","metadata":{"aliases":["FLJ90798","Z3CXXC8","C10orf56"]}},{"id":"ff8fe4fe435e4bbe9823bb0db3ac4ba5","type":"GENE","name":"ZCCHC3","canonical_id":"hgnc:HGNC:16230","description":"zinc finger CCHC-type containing 3","metadata":{"aliases":["dJ1103G7.7","C20orf99"]}},{"id":"205a2ebdb60d4eccad531520844d9e28","type":"GENE","name":"ZCCHC4","canonical_id":"hgnc:HGNC:22917","description":"zinc finger CCHC-type containing 4","metadata":{"aliases":["HSPC052","FLJ23024","ZGRF4"]}},{"id":"57ebf49f3a814695bfcab3cfbb431419","type":"GENE","name":"ZCCHC7","canonical_id":"hgnc:HGNC:26209","description":"zinc finger CCHC-type containing 7","metadata":{"aliases":["FLJ22611","AIR1"]}},{"id":"7ad07389d465415aae18b5af9435467a","type":"GENE","name":"ZCCHC8","canonical_id":"hgnc:HGNC:25265","description":"zinc finger CCHC-type containing 8","metadata":{"aliases":["DKFZp434E2220"]}},{"id":"d4745d9b4a084f58a7be3cbb2ad8bbc2","type":"GENE","name":"ZCCHC9","canonical_id":"hgnc:HGNC:25424","description":"zinc finger CCHC-type containing 9","metadata":{"aliases":["DKFZp761J139","PPP1R41"]}},{"id":"ac0723c24b3942ccafe393e1d22609c2","type":"GENE","name":"ZCRB1","canonical_id":"hgnc:HGNC:29620","description":"zinc finger CCHC-type and RNA binding motif containing 1","metadata":{"aliases":["MADP-1","MADP1","RBM36","ZCCHC19","SNRNP31"]}},{"id":"d3749aa70451458baa51c2d47d2228f7","type":"GENE","name":"ZCRB1P1","canonical_id":"hgnc:HGNC:54987","description":"ZCRB1 pseudogene 1","metadata":null},{"id":"f184192e0dd446fb90772c8d343bf678","type":"GENE","name":"ZCWPW1","canonical_id":"hgnc:HGNC:23486","description":"zinc finger CW-type and PWWP domain containing 1","metadata":{"aliases":["FLJ10057","DKFZp434N0510","ZCW1"]}},{"id":"0d7e128bb73e44b2b8be3600aa55867c","type":"GENE","name":"ZCWPW2","canonical_id":"hgnc:HGNC:23574","description":"zinc finger CW-type and PWWP domain containing 2","metadata":{"aliases":["ZCW2"]}},{"id":"e680bf2446f94368abbbbdca312b1a6f","type":"TRIAL","name":"ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer","canonical_id":"clinicaltrials.gov:NCT00014183","description":"Kidney Cancer","metadata":null},{"id":"0b154485009b4d60ae0af44954b6e2bc","type":"TRIAL","name":"ZD6474 Phase IIa Dose Finding Multicentre Study","canonical_id":"clinicaltrials.gov:NCT00252746","description":"Non Small Cell Lung Carcinoma","metadata":null},{"id":"e8fbf048e09349498ecba3138b46d042","type":"GENE","name":"ZDBF2","canonical_id":"hgnc:HGNC:29313","description":"zinc finger DBF-type containing 2","metadata":{"aliases":["FLJ45338","KIAA1571"]}},{"id":"ae79c5cf281d4c6da744b29771593099","type":"GENE","name":"ZDHHC1","canonical_id":"hgnc:HGNC:17916","description":"zDHHC palmitoyltransferase 1","metadata":{"aliases":["HSU90653","ZNF377","C16orf1"]}},{"id":"a8c68f16973c419ba662e171302e7909","type":"GENE","name":"ZDHHC11","canonical_id":"hgnc:HGNC:19158","description":"zDHHC palmitoyltransferase 11","metadata":{"aliases":["ZNF399","FLJ13153"]}},{"id":"9a6b2cb2e5b94158acad2ff65f61227d","type":"GENE","name":"ZDHHC11B","canonical_id":"hgnc:HGNC:32962","description":"zDHHC palmitoyltransferase 11B (putative)","metadata":null},{"id":"ec62904ccb114aaa9315319d4c222e8c","type":"GENE","name":"ZDHHC12","canonical_id":"hgnc:HGNC:19159","description":"zDHHC palmitoyltransferase 12","metadata":{"aliases":["ZNF400","FLJ14524"]}},{"id":"be9df4dcade34dc4a64c61fa7f70873c","type":"GENE","name":"ZDHHC12-DT","canonical_id":"hgnc:HGNC:55873","description":"ZDHHC12 divergent transcript","metadata":null},{"id":"c21ed943e8804063ad54055d0322eba2","type":"GENE","name":"ZDHHC13","canonical_id":"hgnc:HGNC:18413","description":"zDHHC palmitoyltransferase 13","metadata":{"aliases":["FLJ10852","FLJ10941","HIP14L"]}},{"id":"a0330eff316a44a78ad1f95b39fda14b","type":"GENE","name":"ZDHHC14","canonical_id":"hgnc:HGNC:20341","description":"zDHHC palmitoyltransferase 14","metadata":{"aliases":["FLJ20984","NEW1CP"]}},{"id":"ea87560f4a034bdb9fc9ede0e8769113","type":"GENE","name":"ZDHHC15","canonical_id":"hgnc:HGNC:20342","description":"zDHHC palmitoyltransferase 15","metadata":{"aliases":["FLJ31812","MRX91","DHHC15"]}},{"id":"3ef8952cdb3d46e08444c7442387e9f2","type":"GENE","name":"ZDHHC16","canonical_id":"hgnc:HGNC:20714","description":"zDHHC palmitoyltransferase 16","metadata":{"aliases":["APH2"]}},{"id":"bcf83ae90cc742538833501f5614485c","type":"GENE","name":"ZDHHC17","canonical_id":"hgnc:HGNC:18412","description":"zDHHC palmitoyltransferase 17","metadata":{"aliases":["HIP14","HYPH","KIAA0946"]}},{"id":"99340cba88f44c92b3c33e8a30141f63","type":"GENE","name":"ZDHHC18","canonical_id":"hgnc:HGNC:20712","description":"zDHHC palmitoyltransferase 18","metadata":{"aliases":["DKFZp667O2416"]}},{"id":"c7037eda404149eaac94a7e36de4af11","type":"GENE","name":"ZDHHC19","canonical_id":"hgnc:HGNC:20713","description":"zDHHC palmitoyltransferase 19","metadata":{"aliases":["MGC33345"]}},{"id":"511a8a3269c24af897ba7d34cbdd4e8b","type":"GENE","name":"ZDHHC1P1","canonical_id":"hgnc:HGNC:56630","description":"ZDHHC1 pseudogene 1","metadata":null},{"id":"4b8a5df0ca91434f9ce51e1590f9f906","type":"GENE","name":"ZDHHC2","canonical_id":"hgnc:HGNC:18469","description":"zDHHC palmitoyltransferase 2","metadata":{"aliases":["ZNF372","DHHC2"]}},{"id":"764f3c975c394090bded9c4e5622420b","type":"GENE","name":"ZDHHC20","canonical_id":"hgnc:HGNC:20749","description":"zDHHC palmitoyltransferase 20","metadata":{"aliases":["FLJ25952","DHHC20"]}},{"id":"9e5398c3c16d41ea836244fb8a001fce","type":"GENE","name":"ZDHHC20-IT1","canonical_id":"hgnc:HGNC:39900","description":"ZDHHC20 intronic transcript 1","metadata":null},{"id":"7766c81b752142049acbfdbe3c39366c","type":"GENE","name":"ZDHHC20P1","canonical_id":"hgnc:HGNC:33456","description":"ZDHHC20 pseudogene 1","metadata":{"aliases":["OTTHUMG00000086707"]}},{"id":"1dccbcd8fce14e978931d6efd4265b37","type":"GENE","name":"ZDHHC20P2","canonical_id":"hgnc:HGNC:33457","description":"ZDHHC20 pseudogene 2","metadata":{"aliases":["OTTHUMG00000133740"]}},{"id":"5a93620ed6e64be8abe1d13091211f0f","type":"GENE","name":"ZDHHC20P3","canonical_id":"hgnc:HGNC:39775","description":"ZDHHC20 pseudogene 3","metadata":null},{"id":"22a8a5a117504081bbb66be71ba5d668","type":"GENE","name":"ZDHHC20P4","canonical_id":"hgnc:HGNC:39776","description":"ZDHHC20 pseudogene 4","metadata":null},{"id":"dac8ea1d189c441fab39bcd803a96677","type":"GENE","name":"ZDHHC21","canonical_id":"hgnc:HGNC:20750","description":"zDHHC palmitoyltransferase 21","metadata":{"aliases":["HSPC097","DNZ1","DHHC21"]}},{"id":"9957c56a58dc43408a04057991412522","type":"GENE","name":"ZDHHC22","canonical_id":"hgnc:HGNC:20106","description":"zDHHC palmitoyltransferase 22","metadata":{"aliases":["C14orf59"]}},{"id":"4affd3f69d084997a6e3750f58ab5f52","type":"GENE","name":"ZDHHC23","canonical_id":"hgnc:HGNC:28654","description":"zDHHC palmitoyltransferase 23","metadata":{"aliases":["MGC42530"]}},{"id":"959a31b94936457384582094db630941","type":"GENE","name":"ZDHHC24","canonical_id":"hgnc:HGNC:27387","description":"zDHHC palmitoyltransferase 24","metadata":null},{"id":"a4e0d6b6c8fa43f1a4fb039003f3bd59","type":"GENE","name":"ZDHHC3","canonical_id":"hgnc:HGNC:18470","description":"zDHHC palmitoyltransferase 3","metadata":{"aliases":["ZNF373","GODZ","DHHC3"]}},{"id":"c3688dc61b4c45338f6336df0068486d","type":"GENE","name":"ZDHHC4","canonical_id":"hgnc:HGNC:18471","description":"zDHHC palmitoyltransferase 4","metadata":{"aliases":["FLJ10479","ZNF374"]}},{"id":"7e2cde97f992426a82c195b15ee1da2c","type":"GENE","name":"ZDHHC4P1","canonical_id":"hgnc:HGNC:39443","description":"ZDHHC4 pseudogene 1","metadata":null},{"id":"9879e84fa6a143628f9f9b4b253e9fb2","type":"GENE","name":"ZDHHC5","canonical_id":"hgnc:HGNC:18472","description":"zDHHC palmitoyltransferase 5","metadata":{"aliases":["KIAA1748","ZNF375","DHHC5"]}},{"id":"359ad1d7b081412ebeeed93aecf78618","type":"GENE","name":"ZDHHC6","canonical_id":"hgnc:HGNC:19160","description":"zDHHC palmitoyltransferase 6","metadata":{"aliases":["ZNF376","FLJ21952"]}},{"id":"ce6e833305ca4623b205130536d7c907","type":"GENE","name":"ZDHHC7","canonical_id":"hgnc:HGNC:18459","description":"zDHHC palmitoyltransferase 7","metadata":{"aliases":["FLJ10792","ZNF370","FLJ20279","SERZ-B","SERZ1","DHHC7"]}},{"id":"fd6d6979c56f484e985095505af359a6","type":"GENE","name":"ZDHHC8","canonical_id":"hgnc:HGNC:18474","description":"zDHHC palmitoyltransferase 8","metadata":{"aliases":["ZNF378","KIAA1292","DHHC8"]}},{"id":"d09123aa199d49b4a51ba198d2e43172","type":"GENE","name":"ZDHHC8BP","canonical_id":"hgnc:HGNC:26461","description":"ZDHHC8B, pseudogene","metadata":{"aliases":["FLJ31568","ZDHHC8P","ZDHHC8P1"]}},{"id":"ba168744935247499ae5f0f8046d56eb","type":"GENE","name":"ZDHHC9","canonical_id":"hgnc:HGNC:18475","description":"zDHHC palmitoyltransferase 9","metadata":{"aliases":["ZNF379","CGI-89","ZNF380","DHHC9","ZDHHC10","CXorf11"]}},{"id":"23e62463d6044cbb988a4b0a9c11ae70","type":"GENE","name":"ZEB1","canonical_id":"hgnc:HGNC:11642","description":null,"metadata":null},{"id":"5d13a0345a9f4f31a7f8558eeac7adc8","type":"GENE","name":"ZEB1-AS1","canonical_id":"hgnc:HGNC:42354","description":"ZEB1 antisense RNA 1","metadata":null},{"id":"eff4fcaa2e1041c89d580f40f198a0b8","type":"GENE","name":"ZEB2","canonical_id":"hgnc:HGNC:14881","description":null,"metadata":null},{"id":"04c5eba8f62242de9c197e90a46afeac","type":"GENE","name":"ZEB2-AS1","canonical_id":"hgnc:HGNC:37149","description":"ZEB2 antisense RNA 1","metadata":{"aliases":["ZEB2NAT","ZEB2AS","ZEB2-AS"]}},{"id":"41b029325dfe401c93144669dc98bb5f","type":"GENE","name":"ZEB2P1","canonical_id":"hgnc:HGNC:33346","description":"zinc finger E-box binding homeobox 2 pseudogene 1","metadata":{"aliases":["ZEB1P1"]}},{"id":"350ab66ee0fe48238a518d854ff2c00f","type":"GENE","name":"ZEBTR","canonical_id":"hgnc:HGNC:53967","description":"ZEB1 transcriptional regulator RNA","metadata":{"aliases":["LncRNA-BX111"]}},{"id":"d2430d80d07f442b83b10e2b57f897a9","type":"TRIAL","name":"ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors","canonical_id":"clinicaltrials.gov:NCT06161493","description":"Ovarian Cancer; Recurrent Solid Tumors","metadata":null},{"id":"59ad1ff7d91649ca969195abb41995b9","type":"GENE","name":"ZER1","canonical_id":"hgnc:HGNC:30960","description":"zyg-11 related cell cycle regulator","metadata":{"aliases":["ZYG","Hzyg","C9orf60","ZYG11BL"]}},{"id":"31cac6c2e4e64b33a46ccc36ba63af6a","type":"TRIAL","name":"ZETA : Prospective Observational Study","canonical_id":"clinicaltrials.gov:NCT03730558","description":"Metastatic Colon Cancer","metadata":null},{"id":"102d5a9049004d69869cc3164c3ba88f","type":"GENE","name":"ZFAND1","canonical_id":"hgnc:HGNC:25858","description":"zinc finger AN1-type containing 1","metadata":{"aliases":["FLJ14007"]}},{"id":"c13a57fe3bbe454b80db217e7133e8e9","type":"GENE","name":"ZFAND2A","canonical_id":"hgnc:HGNC:28073","description":"zinc finger AN1-type containing 2A","metadata":{"aliases":["AIRAP"]}},{"id":"f8985b6983d04a2ba5b589be56967125","type":"GENE","name":"ZFAND2A-DT","canonical_id":"hgnc:HGNC:41187","description":"ZFAND2A divergent transcript","metadata":null},{"id":"cfb92e297843470ab44d43b217fb4764","type":"GENE","name":"ZFAND2AP1","canonical_id":"hgnc:HGNC:56472","description":"ZFAND2A pseudogene 1","metadata":null},{"id":"2a6c3dea3dc5476f891578e506420e49","type":"GENE","name":"ZFAND2AP2","canonical_id":"hgnc:HGNC:56473","description":"ZFAND2A pseudogene 2","metadata":null},{"id":"ca984c8ef74f47cba846d355b4648f26","type":"GENE","name":"ZFAND2B","canonical_id":"hgnc:HGNC:25206","description":"zinc finger AN1-type containing 2B","metadata":{"aliases":["AIRAPL"]}},{"id":"1272ba0048df4211bb746f374b032fd8","type":"GENE","name":"ZFAND3","canonical_id":"hgnc:HGNC:18019","description":"zinc finger AN1-type containing 3","metadata":{"aliases":["FLJ13222","TEX27"]}},{"id":"544fa68f0f214383b2bf0d2a3854f407","type":"GENE","name":"ZFAND3-DT","canonical_id":"hgnc:HGNC:55841","description":"ZFAND3 divergent transcript","metadata":null},{"id":"7b8e974b9ada458bb2dc4ef5ce045d40","type":"GENE","name":"ZFAND4","canonical_id":"hgnc:HGNC:23504","description":"zinc finger AN1-type containing 4","metadata":{"aliases":["FLJ40185","ANUBL1"]}},{"id":"b78c7e2f253948dc8c680b9f706ba2e4","type":"GENE","name":"ZFAND5","canonical_id":"hgnc:HGNC:13008","description":"zinc finger AN1-type containing 5","metadata":{"aliases":["ZFAND5A","ZNF216","ZA20D2"]}},{"id":"e6df494ca86749dd91425ebb8e8bea61","type":"GENE","name":"ZFAND6","canonical_id":"hgnc:HGNC:30164","description":"zinc finger AN1-type containing 6","metadata":{"aliases":["ZFAND5B","AWP1","ZA20D3"]}},{"id":"2a67587ca6e7484b8477d5d8bfd1e4e0","type":"GENE","name":"ZFAND6P1","canonical_id":"hgnc:HGNC:42978","description":"zinc finger AN1-type containing 6 pseudogene 1","metadata":null},{"id":"14cd63d6bbc44ed6827c9dd3b9aac75b","type":"GENE","name":"ZFAS1","canonical_id":"hgnc:HGNC:33101","description":"ZNFX1 antisense RNA 1","metadata":{"aliases":["HSUP1","HSUP2","C20orf199","NCRNA00275","ZNFX1-AS1"]}},{"id":"0006618bc52647878b8f1b6eb815cb10","type":"GENE","name":"ZFAT","canonical_id":"hgnc:HGNC:19899","description":"zinc finger and AT-hook domain containing","metadata":{"aliases":["KIAA1485","ZNF406","ZFAT1"]}},{"id":"01e2ad5f5b6a416b98eadf6b6a075cab","type":"GENE","name":"ZFAT-AS1","canonical_id":"hgnc:HGNC:33992","description":"ZFAT antisense RNA 1","metadata":{"aliases":["SAS-ZFAT","NCRNA00070","ZFATAS","ZFAT-AS"]}},{"id":"ec2bfe88ba0a4849a2e619de5423531e","type":"GENE","name":"ZFC3H1","canonical_id":"hgnc:HGNC:28328","description":"zinc finger C3H1-type containing","metadata":{"aliases":["MGC23401","KIAA0546","CSRC2","PSRC2","CCDC131"]}},{"id":"c031ecf7df6a4b73b782b2859fb4cd71","type":"GENE","name":"ZFHX2","canonical_id":"hgnc:HGNC:20152","description":"zinc finger homeobox 2","metadata":{"aliases":["KIAA1762","KIAA1056","ZFH-5","ZNF409"]}},{"id":"0568a5ec575c444480b133db96e7eccb","type":"GENE","name":"ZFHX2-AS1","canonical_id":"hgnc:HGNC:52658","description":"ZFHX2 antisense RNA 1","metadata":{"aliases":["LncZFHX2"]}},{"id":"354fd554a51341cf92d7aec4c5bf72c9","type":"GENE","name":"ZFHX3","canonical_id":"hgnc:HGNC:777","description":null,"metadata":null},{"id":"0f5c03ab5d0a4ef2824379e6c55aee33","type":"GENE","name":"ZFHX3-AS1","canonical_id":"hgnc:HGNC:56033","description":"ZFHX3 antisense RNA 1","metadata":{"aliases":["AC004943.2"]}},{"id":"c70666983b2545f89577f8cbaf1ca22a","type":"GENE","name":"ZFHX3-AS2","canonical_id":"hgnc:HGNC:58537","description":"ZFHX3 antisense RNA 2","metadata":null},{"id":"de989be9cbf04461be36f3df2a1cdcd3","type":"GENE","name":"ZFHX3-AS3","canonical_id":"hgnc:HGNC:58538","description":"ZFHX3 antisense RNA 3","metadata":{"aliases":["SHIELD"]}},{"id":"7be3bb3933a149709e3c3735f4b5e19e","type":"GENE","name":"ZFHX4","canonical_id":"hgnc:HGNC:30939","description":"zinc finger homeobox 4","metadata":{"aliases":["ZFH4","FLJ20980"]}},{"id":"3a083f03bf8b43de91158b42733c44d5","type":"GENE","name":"ZFHX4-AS1","canonical_id":"hgnc:HGNC:44165","description":"ZFHX4 antisense RNA 1","metadata":null},{"id":"b0d62609fb624c87aecee8d55df2f82d","type":"GENE","name":"ZFP1","canonical_id":"hgnc:HGNC:23328","description":"ZFP1 zinc finger protein","metadata":{"aliases":["PITA","FLJ34243","ZNF475"]}},{"id":"478a5e935be148d4ae973ac3a4ff8f51","type":"GENE","name":"ZFP14","canonical_id":"hgnc:HGNC:29312","description":"ZFP14 zinc finger protein","metadata":{"aliases":["KIAA1559","ZNF531"]}},{"id":"d5c415cf9cdd417b88eb967e63633082","type":"GENE","name":"ZFP14-AS1","canonical_id":"hgnc:HGNC:58566","description":"ZFP14 antisense RNA 1","metadata":null},{"id":"2a3aae1c54a94dc996c3884280798c71","type":"GENE","name":"ZFP2","canonical_id":"hgnc:HGNC:26138","description":"ZFP2 zinc finger protein","metadata":{"aliases":["FLJ21628","ZNF751"]}},{"id":"8f585dead005415d93039c8fbc7bdcdf","type":"GENE","name":"ZFP28","canonical_id":"hgnc:HGNC:17801","description":"ZFP28 zinc finger protein","metadata":{"aliases":["KIAA1431","mkr5"]}},{"id":"93b4d4ad05dc41979ba57f29b6849e1b","type":"GENE","name":"ZFP28-DT","canonical_id":"hgnc:HGNC:55297","description":"ZFP28 divergent transcript","metadata":null},{"id":"e5d50ca74b7d4a26bd019dc223dcaee2","type":"GENE","name":"ZFP3","canonical_id":"hgnc:HGNC:12861","description":"ZFP3 zinc finger protein","metadata":{"aliases":["FLJ30726","ZNF752"]}},{"id":"ce21dabf9d9141c9ab7c3a7fd00e1e56","type":"GENE","name":"ZFP3-DT","canonical_id":"hgnc:HGNC:55340","description":"ZFP3 divergent transcript","metadata":null},{"id":"22200e02e69647688ca4dbc334a0ca42","type":"GENE","name":"ZFP30","canonical_id":"hgnc:HGNC:29555","description":"ZFP30 zinc finger protein","metadata":{"aliases":["ZNF745","KIAA0961"]}},{"id":"1cc6b8de2d2641bc86c8c5ea29460cc4","type":"GENE","name":"ZFP36","canonical_id":"hgnc:HGNC:12862","description":null,"metadata":null},{"id":"e511554216a24f5780a40985e3b481e3","type":"GENE","name":"ZFP36L1","canonical_id":"hgnc:HGNC:1107","description":null,"metadata":null},{"id":"8b328bdb27e8499c9668216ae69a1500","type":"GENE","name":"ZFP36L2","canonical_id":"hgnc:HGNC:1108","description":"ZFP36 like 2 zinc finger CCCH-type","metadata":{"aliases":["ERF2","TIS11D","BRF2"]}},{"id":"398909e43ebb4b5b8e804f2488c8a2a3","type":"GENE","name":"ZFP37","canonical_id":"hgnc:HGNC:12863","description":"ZFP37 zinc finger protein","metadata":{"aliases":["ZNF906"]}},{"id":"6be3d2ed4b7b45fcadf15befdad8c10c","type":"GENE","name":"ZFP41","canonical_id":"hgnc:HGNC:26786","description":"ZFP41 zinc finger protein","metadata":{"aliases":["FLJ38705","FLJ00028","ZNF753"]}},{"id":"6ead3daf12a84ea8bf6d079497ad19fc","type":"GENE","name":"ZFP42","canonical_id":"hgnc:HGNC:30949","description":null,"metadata":null},{"id":"809b6ab8efdd417381e6dfe6ad53d625","type":"GENE","name":"ZFP57","canonical_id":"hgnc:HGNC:18791","description":"ZFP57 zinc finger protein","metadata":{"aliases":["ZNF698","bA145L22","bA145L22.2","C6orf40"]}},{"id":"3a6051e2138048ce9af9f62047e64a94","type":"GENE","name":"ZFP62","canonical_id":"hgnc:HGNC:23241","description":"ZFP62 zinc finger protein","metadata":{"aliases":["FLJ34231","ZET","ZNF755"]}},{"id":"e75f3cb087e54f1592507bb865a28ca7","type":"GENE","name":"ZFP62-DT","canonical_id":"hgnc:HGNC:59322","description":"ZFP62 divergent transcript","metadata":null},{"id":"b8564a5fb6b943f3942f9d4979580bcf","type":"GENE","name":"ZFP64","canonical_id":"hgnc:HGNC:15940","description":"ZFP64 zinc finger protein","metadata":{"aliases":["FLJ10734","dJ831D17.1","FLJ12628","dJ548G19.1","ZNF338"]}},{"id":"cb6e358c134b46e8a0a2f1b41e73960d","type":"GENE","name":"ZFP64P1","canonical_id":"hgnc:HGNC:19820","description":"ZFP64 zinc finger protein pseudogene 1","metadata":{"aliases":["ZNF405P"]}},{"id":"15d9735b4aea46a0ba94fd080addc03f","type":"GENE","name":"ZFP69","canonical_id":"hgnc:HGNC:24708","description":"ZFP69 zinc finger protein","metadata":{"aliases":["ZKSCAN23A","FLJ16030","ZFP69A","ZSCAN54A","ZNF642"]}},{"id":"7da645444dc24c65829f940c852465be","type":"GENE","name":"ZFP69B","canonical_id":"hgnc:HGNC:28053","description":"ZFP69 zinc finger protein B","metadata":{"aliases":["ZKSCAN23B","FLJ34293","ZSCAN54B","ZNF643"]}},{"id":"ebea8a530c394b34b6e39044f8f85182","type":"GENE","name":"ZFP69B-DT","canonical_id":"hgnc:HGNC:58138","description":"ZFP69B divergent transcript","metadata":null},{"id":"aa19b2453b4b442bbd60b33ad5368429","type":"GENE","name":"ZFP82","canonical_id":"hgnc:HGNC:28682","description":"ZFP82 zinc finger protein","metadata":{"aliases":["MGC45380","KIAA1948","ZNF545"]}},{"id":"6a1ed6dcde51489dbf7d3ae98da6c4cc","type":"GENE","name":"ZFP90","canonical_id":"hgnc:HGNC:23329","description":"ZFP90 zinc finger protein","metadata":{"aliases":["KIAA1954","NK10","ZNF756"]}},{"id":"6e9252d8b8794176beacc34217299ec4","type":"GENE","name":"ZFP91","canonical_id":"hgnc:HGNC:14983","description":"ZFP91 zinc finger protein, atypical E3 ubiquitin ligase","metadata":{"aliases":["PZF","ZNF757"]}},{"id":"990a60bbf3dd4b85b9c070206312eec8","type":"GENE","name":"ZFP91-CNTF","canonical_id":"hgnc:HGNC:33441","description":"ZFP91-CNTF readthrough (NMD candidate)","metadata":null},{"id":"a655c3c7704e4200a0b853519c6d3d86","type":"GENE","name":"ZFP91P1","canonical_id":"hgnc:HGNC:54652","description":"ZFP91 pseudogene 1","metadata":null},{"id":"7eeb625e7e7a47ddaa3c4a4b5672c142","type":"GENE","name":"ZFP92","canonical_id":"hgnc:HGNC:12865","description":"ZFP92 zinc finger protein","metadata":{"aliases":["ZNF897"]}},{"id":"0dc12344857542f1a3537e0379659fa9","type":"GENE","name":"ZFPL1","canonical_id":"hgnc:HGNC:12868","description":"zinc finger protein like 1","metadata":{"aliases":["D11S750","MCG4"]}},{"id":"906f6efc5a9e4cc1b242dc49c2214b1b","type":"GENE","name":"ZFPM1","canonical_id":"hgnc:HGNC:19762","description":"zinc finger protein, FOG family member 1","metadata":{"aliases":["PRDM18","FOG1","FOG","ZNF89A"]}},{"id":"122ef1dbee2f49da986949368f9a641c","type":"GENE","name":"ZFPM1-AS1","canonical_id":"hgnc:HGNC:55351","description":"ZFPM1 antisense RNA 1","metadata":null},{"id":"37486a14ddb846ceb3da4f0ebd0d41c1","type":"GENE","name":"ZFPM2","canonical_id":"hgnc:HGNC:16700","description":"zinc finger protein, FOG family member 2","metadata":{"aliases":["PRDM19","FOG2","hFOG-2","ZNF89B"]}},{"id":"e6dc82a939b44c31b0e935a0e144d01c","type":"GENE","name":"ZFPM2-AS1","canonical_id":"hgnc:HGNC:50698","description":"ZFPM2 antisense RNA 1","metadata":{"aliases":["SCAT3"]}},{"id":"c03a842ae7e9433a894950ac30a50f5f","type":"GENE","name":"ZFR","canonical_id":"hgnc:HGNC:17277","description":"zinc finger RNA binding protein","metadata":{"aliases":["ZFR1","SPG71"]}},{"id":"278c8daedbd94c66b4db881dc699c6e4","type":"GENE","name":"ZFR-AS1","canonical_id":"hgnc:HGNC:59024","description":"ZFR antisense RNA 1","metadata":null},{"id":"e0fdb41edea946d18ed9949bc24441a7","type":"GENE","name":"ZFR2","canonical_id":"hgnc:HGNC:29189","description":"zinc finger RNA binding protein 2","metadata":{"aliases":["KIAA1086"]}},{"id":"0bba931611fa486b9bba6a497900de59","type":"GENE","name":"ZFRP1","canonical_id":"hgnc:HGNC:38030","description":"zinc finger RNA binding protein pseudogene 1","metadata":null},{"id":"9f02786305b6436da2bee09deb76af5b","type":"GENE","name":"ZFTA","canonical_id":"hgnc:HGNC:28449","description":"zinc finger translocation associated","metadata":{"aliases":["MGC3032","C11orf95"]}},{"id":"eb53fe3f52ae41ee999fa0d5e52b09be","type":"GENE","name":"ZFTRAF1","canonical_id":"hgnc:HGNC:17806","description":"zinc finger TRAF-type and ring finger containing 1","metadata":{"aliases":["CHRP","KIAA0496","MGC13010","CYHR1"]}},{"id":"f0b9d67a3a194b6ba97cbe36a1fc063e","type":"GENE","name":"ZFX","canonical_id":"hgnc:HGNC:12869","description":"zinc finger protein X-linked","metadata":{"aliases":["ZNF926"]}},{"id":"32ab2925e1384b9db6b4d37e46506104","type":"GENE","name":"ZFX-AS1","canonical_id":"hgnc:HGNC:40617","description":"ZFX antisense RNA 1","metadata":null},{"id":"739c596dd791420a8de5fbdc4b37f2ca","type":"GENE","name":"ZFY","canonical_id":"hgnc:HGNC:12870","description":"zinc finger protein Y-linked","metadata":{"aliases":["ZNF911"]}},{"id":"880648d26dc34466ad3f0a822aefcd07","type":"GENE","name":"ZFY-AS1","canonical_id":"hgnc:HGNC:38798","description":"ZFY antisense RNA 1","metadata":{"aliases":["ZFYAS","ZFY-AS"]}},{"id":"922f15bc3e194e63b835997413abea3b","type":"GENE","name":"ZFYVE1","canonical_id":"hgnc:HGNC:13180","description":"zinc finger FYVE-type containing 1","metadata":{"aliases":["DFCP1","KIAA1589","TAFF1","PPP1R172","ZNFN2A1"]}},{"id":"212ef2b6c4b44aea99f304faba32d932","type":"GENE","name":"ZFYVE16","canonical_id":"hgnc:HGNC:20756","description":"zinc finger FYVE-type containing 16","metadata":{"aliases":["KIAA0305","PPP1R69"]}},{"id":"13ebbb1929fe42c7ae9d03829462efdb","type":"GENE","name":"ZFYVE19","canonical_id":"hgnc:HGNC:20758","description":"zinc finger FYVE-type containing 19","metadata":{"aliases":["FLJ14840","ANCHR","MPFYVE"]}},{"id":"831d9e46cb02441881947e85751969d1","type":"GENE","name":"ZFYVE21","canonical_id":"hgnc:HGNC:20760","description":"zinc finger FYVE-type containing 21","metadata":{"aliases":["MGC2550","ZF21"]}},{"id":"c1d14b21794842d6bc78d6f3f40ebd93","type":"GENE","name":"ZFYVE26","canonical_id":"hgnc:HGNC:20761","description":"zinc finger FYVE-type containing 26","metadata":{"aliases":["KIAA0321","SPG15"]}},{"id":"f3789747c7d6412597b6d768822f0db8","type":"GENE","name":"ZFYVE27","canonical_id":"hgnc:HGNC:26559","description":"zinc finger FYVE-type containing 27","metadata":{"aliases":["FLJ32919","SPG33"]}},{"id":"a3eeb43c8ac04296bce79bb968f67895","type":"GENE","name":"ZFYVE28","canonical_id":"hgnc:HGNC:29334","description":"zinc finger FYVE-type containing 28","metadata":{"aliases":["KIAA1643","lst-2"]}},{"id":"d743f3c31a444884a1a68ec834a41051","type":"GENE","name":"ZFYVE28-AS1","canonical_id":"hgnc:HGNC:58711","description":"ZFYVE28 antisense RNA 1","metadata":null},{"id":"2904521e00b24b45bb9763e22e139e32","type":"GENE","name":"ZFYVE9","canonical_id":"hgnc:HGNC:6775","description":"zinc finger FYVE-type containing 9","metadata":{"aliases":["SMADIP","SARA","PPP1R173","MADHIP"]}},{"id":"3804874e852c4e99890a62a8ea69e208","type":"GENE","name":"ZFYVE9P1","canonical_id":"hgnc:HGNC:33359","description":"zinc finger FYVE-type containing 9 pseudogene 1","metadata":null},{"id":"0ab50c403f044b859391f6b119522bc2","type":"GENE","name":"ZFYVE9P2","canonical_id":"hgnc:HGNC:39046","description":"zinc finger FYVE-type containing 9 pseudogene 2","metadata":null},{"id":"236f282831dc4de28a8449d3ef0222b8","type":"GENE","name":"ZG16","canonical_id":"hgnc:HGNC:30961","description":"zymogen granule protein 16","metadata":{"aliases":["hZG16","JCLN1","ZG16A","JCLN"]}},{"id":"76c6ced95c3d44c98cac4364f9020563","type":"GENE","name":"ZG16B","canonical_id":"hgnc:HGNC:30456","description":"zymogen granule protein 16B","metadata":{"aliases":["HRPE773","PRO1567","JCLN2"]}},{"id":"c7adf67525a14adf866ec985f27534d9","type":"GENE","name":"ZGLP1","canonical_id":"hgnc:HGNC:37245","description":"zinc finger GATA like protein 1","metadata":{"aliases":["GLP1","GLP-1","GATAD3"]}},{"id":"a2307faf172e46019f5daf317bb94148","type":"GENE","name":"ZGPAT","canonical_id":"hgnc:HGNC:15948","description":"zinc finger CCCH-type and G-patch domain containing","metadata":{"aliases":["dJ583P15.3","MGC44880","FLJ14972","ZC3HDC9","ZC3H9","GPATC6","GPATCH6","ZIP","KIAA1847"]}},{"id":"44a0018338e240e4a22b22fe3d30df16","type":"GENE","name":"ZGRF1","canonical_id":"hgnc:HGNC:25654","description":"zinc finger GRF-type containing 1","metadata":{"aliases":["FLJ11331","C4orf21"]}},{"id":"91109fee6e9f4221becd41d5b15a3319","type":"GENE","name":"ZHX1","canonical_id":"hgnc:HGNC:12871","description":"zinc fingers and homeoboxes 1","metadata":null},{"id":"43a32a8554a44d05bfddfd8554a9258d","type":"GENE","name":"ZHX1-C8orf76","canonical_id":"hgnc:HGNC:42975","description":"ZHX1-C8orf76 readthrough","metadata":null},{"id":"5ddcfcfd31b240a6ade47c73b2186051","type":"GENE","name":"ZHX2","canonical_id":"hgnc:HGNC:18513","description":null,"metadata":null},{"id":"acc7b4a07e7a4345b54969c94da3e926","type":"GENE","name":"ZHX2-AS1","canonical_id":"hgnc:HGNC:58136","description":"ZHX2 antisense RNA 2","metadata":{"aliases":["AC016405.3"]}},{"id":"9d0f2665d98741fb98336627940a8896","type":"GENE","name":"ZHX3","canonical_id":"hgnc:HGNC:15935","description":"zinc fingers and homeoboxes 3","metadata":{"aliases":["KIAA0395","TIX1"]}},{"id":"e11d43ef8dd0402192979268644921e4","type":"GENE","name":"ZIC1","canonical_id":"hgnc:HGNC:12872","description":null,"metadata":null},{"id":"e041268bb8cb485fa195b57081fffede","type":"GENE","name":"ZIC2","canonical_id":"hgnc:HGNC:12873","description":null,"metadata":null},{"id":"76b8c4dfe19646ba92a5cf7c03c6fd17","type":"GENE","name":"ZIC3","canonical_id":"hgnc:HGNC:12874","description":null,"metadata":null},{"id":"eac4114c6c774d44ade8a6c8725115cd","type":"GENE","name":"ZIC4","canonical_id":"hgnc:HGNC:20393","description":"Zic family zinc finger 4","metadata":null},{"id":"16f9bdda2b6b4284bc41d9d2f8b42f6a","type":"GENE","name":"ZIC4-AS1","canonical_id":"hgnc:HGNC:40920","description":"ZIC4 antisense RNA 1","metadata":null},{"id":"234356d12f8c45599c3f91a8ce152305","type":"GENE","name":"ZIC5","canonical_id":"hgnc:HGNC:20322","description":"Zic family zinc finger 5","metadata":null},{"id":"d74f3aec32654a489517f80ce6819e07","type":"GENE","name":"ZIK1","canonical_id":"hgnc:HGNC:33104","description":"zinc finger protein interacting with K protein 1","metadata":{"aliases":["ZNF762"]}},{"id":"561b3eaf5c1242d689fabfeaa02d6978","type":"GENE","name":"ZIK1P1","canonical_id":"hgnc:HGNC:38031","description":"zinc finger protein interacting with K protein 1 pseudogene 1","metadata":null},{"id":"491cb013fbed41ec85eb04f2562622f6","type":"GENE","name":"ZIM2","canonical_id":"hgnc:HGNC:12875","description":"zinc finger imprinted 2","metadata":{"aliases":["ZNF656"]}},{"id":"7130d6aa678744c296d0c2b4ee01a08e","type":"GENE","name":"ZIM2-AS1","canonical_id":"hgnc:HGNC:51304","description":"ZIM2 antisense RNA 1","metadata":{"aliases":["ZIM2as"]}},{"id":"3fbcf4f074024bcbb5388aea1b072ecb","type":"GENE","name":"ZIM3","canonical_id":"hgnc:HGNC:16366","description":"zinc finger imprinted 3","metadata":{"aliases":["ZNF657"]}},{"id":"e7433cf04a134a7c9d0c329b250e3034","type":"TRIAL","name":"ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction","canonical_id":"clinicaltrials.gov:NCT06856590","description":"Hand-Foot Skin Reaction (HFSR)","metadata":null},{"id":"bffbe3bcc47843d090cba5070b43bcfb","type":"TRIAL","name":"ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD","canonical_id":"clinicaltrials.gov:NCT03911505","description":"Pompe Disease (Late-onset)","metadata":null},{"id":"9e2996a2afd04848af0552a0577c38c2","type":"GENE","name":"ZKSCAN1","canonical_id":"hgnc:HGNC:13101","description":"zinc finger with KRAB and SCAN domains 1","metadata":{"aliases":["KOX18","PHZ-37","ZSCAN33","ZNF139","ZNF36"]}},{"id":"fafe6b1de9a04fb298f72559e52da13b","type":"GENE","name":"ZKSCAN2","canonical_id":"hgnc:HGNC:25677","description":"zinc finger with KRAB and SCAN domains 2","metadata":{"aliases":["FLJ23199","ZSCAN34","ZNF694"]}},{"id":"b3384f9288ae4670a237a8447e130aca","type":"GENE","name":"ZKSCAN2-DT","canonical_id":"hgnc:HGNC:53912","description":"ZKSCAN2 divergent transcript","metadata":{"aliases":["CTD-2547G23.4"]}},{"id":"000932ee97bd4759a648bfaab5a734fb","type":"GENE","name":"ZKSCAN3","canonical_id":"hgnc:HGNC:13853","description":"zinc finger with KRAB and SCAN domains 3","metadata":{"aliases":["Zfp47","ZF47","ZSCAN35","ZNF306","ZNF309"]}},{"id":"577bbbbd571b460aa140b8054a94d8c2","type":"GENE","name":"ZKSCAN4","canonical_id":"hgnc:HGNC:13854","description":"zinc finger with KRAB and SCAN domains 4","metadata":{"aliases":["p373c6.1","P1P373C6","FLJ32136","ZSCAN36","ZNF307","ZNF427"]}},{"id":"b4574dc0801b44ba9394a76a822445bb","type":"GENE","name":"ZKSCAN5","canonical_id":"hgnc:HGNC:12867","description":"zinc finger with KRAB and SCAN domains 5","metadata":{"aliases":["ZNF914","ZSCAN37","ZFP95"]}},{"id":"29d77b9b531245e28bbe549644906326","type":"GENE","name":"ZKSCAN7","canonical_id":"hgnc:HGNC:12955","description":"zinc finger with KRAB and SCAN domains 7","metadata":{"aliases":["FLJ12738","ZSCAN39","ZNF64","ZNF448","ZNF167"]}},{"id":"c481178901ca4587bb1a6132fb0721e2","type":"GENE","name":"ZKSCAN7-AS1","canonical_id":"hgnc:HGNC:53964","description":"ZKSCAN7 ZNF cluster antisense RNA 1","metadata":{"aliases":["RP11-944L7.4","ZNF197-AS1"]}},{"id":"a5be7cf1f88f491b912d549f97ed68ea","type":"GENE","name":"ZKSCAN7P1","canonical_id":"hgnc:HGNC:49867","description":"zinc finger with KRAB and SCAN domains 7 pseudogene 1","metadata":null},{"id":"d3a2e148b5ed4534853e632c53ef9e03","type":"GENE","name":"ZKSCAN8","canonical_id":"hgnc:HGNC:12983","description":"zinc finger with KRAB and SCAN domains 8","metadata":{"aliases":["LD5-1","ZSCAN40","ZNF192"]}},{"id":"fb7bc65520eb452ca999971c8aeabe3c","type":"GENE","name":"ZKSCAN8P1","canonical_id":"hgnc:HGNC:18777","description":"ZKSCAN8 pseudogene 1","metadata":{"aliases":["dJ265C24.4","ZNF389P","ZNF389","ZNF192P1"]}},{"id":"bb28132f47ac43cd8eb878da1c5732d3","type":"GENE","name":"ZKSCAN8P2","canonical_id":"hgnc:HGNC:42862","description":"ZKSCAN8 pseudogene 2","metadata":{"aliases":["ZNF192P2"]}},{"id":"116d98e05a7a4de6bf51347f2ade32dd","type":"GENE","name":"ZMAT1","canonical_id":"hgnc:HGNC:29377","description":"zinc finger matrin-type 1","metadata":{"aliases":["KIAA1789"]}},{"id":"663a91089d2e440fa45e0dce438b9ae0","type":"GENE","name":"ZMAT2","canonical_id":"hgnc:HGNC:26433","description":"zinc finger matrin-type 2","metadata":{"aliases":["FLJ31121","hSNU23","Snu23"]}},{"id":"55180a38e93d4f158cbde13b2b912d99","type":"GENE","name":"ZMAT3","canonical_id":"hgnc:HGNC:29983","description":"zinc finger matrin-type 3","metadata":{"aliases":["WIG1","MGC10613","FLJ12296","WIG-1","PAG608"]}},{"id":"2933fcb4bc934341a864f203901db8f4","type":"GENE","name":"ZMAT4","canonical_id":"hgnc:HGNC:25844","description":"zinc finger matrin-type 4","metadata":{"aliases":["FLJ13842"]}},{"id":"a9c5fc063b1f4721aaa2a68195a770fd","type":"GENE","name":"ZMAT5","canonical_id":"hgnc:HGNC:28046","description":"zinc finger matrin-type 5","metadata":{"aliases":["SNRNP20","ZC3H19"]}},{"id":"e28dabe23b1947d5b8826edd3fc64c8a","type":"GENE","name":"ZMIZ1","canonical_id":"hgnc:HGNC:16493","description":"zinc finger MIZ-type containing 1","metadata":{"aliases":["RP11-519K18.1","KIAA1224","FLJ13541","hZIMP10","Zimp10","MIZ","RAI17"]}},{"id":"d4f5549f43ba4a6c8d4ee8ebf1548033","type":"GENE","name":"ZMIZ1-AS1","canonical_id":"hgnc:HGNC:27433","description":"ZMIZ1 antisense RNA 1","metadata":null},{"id":"556a863083d3479bb212de5a98a794c8","type":"GENE","name":"ZMIZ2","canonical_id":"hgnc:HGNC:22229","description":"zinc finger MIZ-type containing 2","metadata":{"aliases":["KIAA1886","hZIMP7","ZIMP7","DKFZp761I2123","NET27"]}},{"id":"a79006c819e74846bfbf8936f6948b36","type":"GENE","name":"ZMPSTE24","canonical_id":"hgnc:HGNC:12877","description":"zinc metallopeptidase STE24","metadata":{"aliases":["FACE-1","Ste24p","STE24","HGPS","PRO1"]}},{"id":"ea6d74385f5a42cdb49d3a9c4d76b78c","type":"GENE","name":"ZMPSTE24-DT","canonical_id":"hgnc:HGNC:55402","description":"ZMPSTE24 divergent transcript","metadata":null},{"id":"dbae6b7395a2426a8bc639acf2d4b4de","type":"GENE","name":"ZMYM1","canonical_id":"hgnc:HGNC:26253","description":"zinc finger MYM-type containing 1","metadata":{"aliases":["FLJ23151","MYM"]}},{"id":"2e99527b8fe947eabb108e951633ed88","type":"GENE","name":"ZMYM2","canonical_id":"hgnc:HGNC:12989","description":"zinc finger MYM-type containing 2","metadata":{"aliases":["RAMP","FIM","MYM","ZNF198"]}},{"id":"a6ca2df9c66e4f4896be228b8d8e6871","type":"GENE","name":"ZMYM3","canonical_id":"hgnc:HGNC:13054","description":"zinc finger MYM-type containing 3","metadata":{"aliases":["ZNF198L2","DXS6673E","KIAA0385","MYM","ZNF261"]}},{"id":"db50b163750c49819d1c37c748073a1f","type":"GENE","name":"ZMYM4","canonical_id":"hgnc:HGNC:13055","description":"zinc finger MYM-type containing 4","metadata":{"aliases":["KIAA0425","ZNF198L3","MYM","ZNF262"]}},{"id":"ac0f03d79ddd4d63a78091dc5f56f658","type":"GENE","name":"ZMYM4-AS1","canonical_id":"hgnc:HGNC:40624","description":"ZMYM4 antisense RNA 1","metadata":null},{"id":"6a8a83d452914707bbbd712676525278","type":"GENE","name":"ZMYM5","canonical_id":"hgnc:HGNC:13029","description":"zinc finger MYM-type containing 5","metadata":{"aliases":["ZNF198L1","MYM","ZNF237"]}},{"id":"76f67b4a36254e92829dd093eb34ae10","type":"GENE","name":"ZMYM6","canonical_id":"hgnc:HGNC:13050","description":"zinc finger MYM-type containing 6","metadata":{"aliases":["ZNF198L4","MYM","Buster2","ZBED7","KIAA1353","ZNF258"]}},{"id":"e7eba29cce0d4a4095a97ddcf66484b8","type":"GENE","name":"ZMYND10","canonical_id":"hgnc:HGNC:19412","description":"zinc finger MYND-type containing 10","metadata":{"aliases":["BLU","CILD22","DNAAF7"]}},{"id":"5bd50fe089a940b7b327959affd63bbd","type":"GENE","name":"ZMYND10-AS1","canonical_id":"hgnc:HGNC:40890","description":"ZMYND10 antisense RNA 1","metadata":null},{"id":"98b44bcb7e294f939f89dcc2b49f2f8d","type":"GENE","name":"ZMYND11","canonical_id":"hgnc:HGNC:16966","description":null,"metadata":null},{"id":"de67738ac4044a95b8b9921e3db4e1b6","type":"GENE","name":"ZMYND12","canonical_id":"hgnc:HGNC:21192","description":"zinc finger MYND-type containing 12","metadata":{"aliases":["DKFZp434N2435"]}},{"id":"e7d038e48f33498d9d755633dad1f5a4","type":"GENE","name":"ZMYND15","canonical_id":"hgnc:HGNC:20997","description":"zinc finger MYND-type containing 15","metadata":{"aliases":["DKFZp434N127"]}},{"id":"66313da4d1b647be9f7a91a6618e0da0","type":"GENE","name":"ZMYND19","canonical_id":"hgnc:HGNC:21146","description":"zinc finger MYND-type containing 19","metadata":{"aliases":["MIZIP"]}},{"id":"bc9d991c4f6143cab20883a79379d243","type":"GENE","name":"ZMYND19P1","canonical_id":"hgnc:HGNC:44540","description":"zinc finger MYND-type containing 19 pseudogene 1","metadata":null},{"id":"7737926b207f42648f7e592bedd7a4e3","type":"GENE","name":"ZMYND8","canonical_id":"hgnc:HGNC:9397","description":"zinc finger MYND-type containing 8","metadata":{"aliases":["RACK7","KIAA1125","PRKCBP1"]}},{"id":"b344511444cf43249ec2cf3583b70f0f","type":"GENE","name":"ZNF10","canonical_id":"hgnc:HGNC:12879","description":"zinc finger protein 10","metadata":{"aliases":["KOX1"]}},{"id":"75dbb39eca084e508e022331f4744d52","type":"GENE","name":"ZNF100","canonical_id":"hgnc:HGNC:12880","description":"zinc finger protein 100","metadata":null},{"id":"f1fcd85b9f9845edbcd1d72ae3359b14","type":"GENE","name":"ZNF101","canonical_id":"hgnc:HGNC:12881","description":"zinc finger protein 101","metadata":{"aliases":["HZF12","DKFZp570I0164"]}},{"id":"0fbc64a9c58d4d2ea39a7c96aed89b51","type":"GENE","name":"ZNF101P1","canonical_id":"hgnc:HGNC:44940","description":"zinc finger protein 101 pseudogene 1","metadata":null},{"id":"385ca56b98a949b790693bf85362e436","type":"GENE","name":"ZNF101P2","canonical_id":"hgnc:HGNC:44942","description":"zinc finger protein 101 pseudogene 2","metadata":null},{"id":"c561f6f4816f460681fc4732ffd468f1","type":"GENE","name":"ZNF106","canonical_id":"hgnc:HGNC:12886","description":"zinc finger protein 106","metadata":{"aliases":["ZNF474","SH3BP3","ZFP106"]}},{"id":"ddc98da5cc2c4dbfaf8eca0e21a95bfd","type":"GENE","name":"ZNF107","canonical_id":"hgnc:HGNC:12887","description":"zinc finger protein 107","metadata":{"aliases":["ZFD25","smap-7","ZNF588"]}},{"id":"57c3d438543c4c36adb7f8a2f63372a4","type":"GENE","name":"ZNF112","canonical_id":"hgnc:HGNC:12892","description":"zinc finger protein 112","metadata":{"aliases":["ZFP112","ZNF228"]}},{"id":"96a17198affe4cdd8c24d10a0c1c4ec5","type":"GENE","name":"ZNF114","canonical_id":"hgnc:HGNC:12894","description":"zinc finger protein 114","metadata":{"aliases":["MGC17986"]}},{"id":"28bc8c9f1b0e4fc69e52ac1d3f6d66e1","type":"GENE","name":"ZNF114-AS1","canonical_id":"hgnc:HGNC:53930","description":"ZNF114 antisense RNA 1","metadata":{"aliases":["AC008392.1"]}},{"id":"aa6360c098d44e5fbef6c78e1c055798","type":"GENE","name":"ZNF114P1","canonical_id":"hgnc:HGNC:23771","description":"zinc finger protein 114 pseudogene 1","metadata":null},{"id":"31c5f269f07e41fbb25f02aa12b8cd63","type":"GENE","name":"ZNF117","canonical_id":"hgnc:HGNC:12897","description":"zinc finger protein 117","metadata":{"aliases":["HPF9","H-plk"]}},{"id":"7db565145ef1463ca4346ff0d9ceefb6","type":"GENE","name":"ZNF12","canonical_id":"hgnc:HGNC:12902","description":"zinc finger protein 12","metadata":{"aliases":["KOX3","GIOT-3","ZNF325"]}},{"id":"1d60855ca7914eb2b068ca74eedca6c8","type":"GENE","name":"ZNF121","canonical_id":"hgnc:HGNC:12904","description":"zinc finger protein 121","metadata":{"aliases":["ZHC32","ZNF20","D19S204"]}},{"id":"af591c759d5e4708ac0e44f5248fc52b","type":"GENE","name":"ZNF123P","canonical_id":"hgnc:HGNC:12906","description":"zinc finger protein 123, pseudogene","metadata":{"aliases":["HZF-1","ZNF123"]}},{"id":"5674dd341ea549e6bf8f1bc1cc52b5be","type":"GENE","name":"ZNF124","canonical_id":"hgnc:HGNC:12907","description":"zinc finger protein 124","metadata":{"aliases":["HZF16","HZF-16"]}},{"id":"560f37c0d26f40b8850facd898a4078a","type":"GENE","name":"ZNF132","canonical_id":"hgnc:HGNC:12916","description":"zinc finger protein 132","metadata":{"aliases":["pHZ-12"]}},{"id":"85f42f166a224d558d179cf1b9d07999","type":"GENE","name":"ZNF132-DT","canonical_id":"hgnc:HGNC:55273","description":"ZNF132 divergent transcript","metadata":null},{"id":"b3f5125508c14cab9c36766032104eb7","type":"GENE","name":"ZNF133","canonical_id":"hgnc:HGNC:12917","description":"zinc finger protein 133","metadata":{"aliases":["pHZ-13","pHZ-66","ZNF150"]}},{"id":"460066beb7064b7881bedb68595ed403","type":"GENE","name":"ZNF133-AS1","canonical_id":"hgnc:HGNC:40618","description":"ZNF133 antisense RNA 1","metadata":null},{"id":"be87081ef77f45a09e43b1614c782a99","type":"GENE","name":"ZNF134","canonical_id":"hgnc:HGNC:12918","description":"zinc finger protein 134","metadata":{"aliases":["pHZ-15"]}},{"id":"45dc5c261977478693df2e7201f622dc","type":"GENE","name":"ZNF135","canonical_id":"hgnc:HGNC:12919","description":"zinc finger protein 135","metadata":{"aliases":["pHZ-17","ZNF61","ZNF78L1"]}},{"id":"6d24895e697f4d5fb295a4f794e3377d","type":"GENE","name":"ZNF136","canonical_id":"hgnc:HGNC:12920","description":"zinc finger protein 136","metadata":{"aliases":["pHZ-20"]}},{"id":"eea48d65cdbb4522b3a643b89f070ad7","type":"GENE","name":"ZNF137P","canonical_id":"hgnc:HGNC:12921","description":"zinc finger protein 137, pseudogene","metadata":{"aliases":["pHZ-30","ZNF137"]}},{"id":"0cca0f851e3a43e4b0a72bd9b7eba6bd","type":"GENE","name":"ZNF138","canonical_id":"hgnc:HGNC:12922","description":"zinc finger protein 138","metadata":{"aliases":["pHZ-32"]}},{"id":"f346255e27c743ecb4ba4b63d0754e44","type":"GENE","name":"ZNF14","canonical_id":"hgnc:HGNC:12924","description":"zinc finger protein 14","metadata":{"aliases":["KOX6","GIOT-4"]}},{"id":"ede2047f97d143b2a63f2d231dcaad33","type":"GENE","name":"ZNF140","canonical_id":"hgnc:HGNC:12925","description":"zinc finger protein 140","metadata":{"aliases":["pHZ-39"]}},{"id":"ffee2c98e5ea4f129bc65ab0632cba7e","type":"GENE","name":"ZNF141","canonical_id":"hgnc:HGNC:12926","description":"zinc finger protein 141","metadata":{"aliases":["pHZ-44","D4S90"]}},{"id":"857fc6d964904a6095c9a7cab53256a8","type":"GENE","name":"ZNF142","canonical_id":"hgnc:HGNC:12927","description":"zinc finger protein 142","metadata":{"aliases":["KIAA0236","pHZ-49"]}},{"id":"8b09be55b2c342e59f481063c45f78cb","type":"GENE","name":"ZNF143","canonical_id":"hgnc:HGNC:12928","description":null,"metadata":null},{"id":"a1c272b00fa44896ba517cfe42ff1e83","type":"GENE","name":"ZNF143-AS1","canonical_id":"hgnc:HGNC:58073","description":"ZNF143 antisense RNA 1","metadata":null},{"id":"20d605999bc9438ba379e6cefc106924","type":"GENE","name":"ZNF146","canonical_id":"hgnc:HGNC:12931","description":"zinc finger protein 146","metadata":{"aliases":["OZF"]}},{"id":"2bfecb9eba1e4bd9a3cdc644c9bca5e2","type":"GENE","name":"ZNF148","canonical_id":"hgnc:HGNC:12933","description":null,"metadata":null},{"id":"775fed5a359646d29763ab6e8892fa2f","type":"GENE","name":"ZNF154","canonical_id":"hgnc:HGNC:12939","description":"zinc finger protein 154","metadata":{"aliases":["pHZ-92"]}},{"id":"3a21db8a42074d489e476075cb858482","type":"GENE","name":"ZNF155","canonical_id":"hgnc:HGNC:12940","description":"zinc finger protein 155","metadata":{"aliases":["pHZ-96"]}},{"id":"a6fed7057eed46539b24f2586e235a3e","type":"GENE","name":"ZNF157","canonical_id":"hgnc:HGNC:12942","description":"zinc finger protein 157","metadata":{"aliases":["HZF22"]}},{"id":"a9bab15b6c864fa798c43096966eca59","type":"GENE","name":"ZNF16","canonical_id":"hgnc:HGNC:12947","description":"zinc finger protein 16","metadata":{"aliases":["KOX9"]}},{"id":"04748d2c7d3f4be9a0292ae7d6a0d8ec","type":"GENE","name":"ZNF160","canonical_id":"hgnc:HGNC:12948","description":null,"metadata":null},{"id":"90dabf1a48ff499fa82e474a86fbba64","type":"GENE","name":"ZNF165","canonical_id":"hgnc:HGNC:12953","description":"zinc finger protein 165","metadata":{"aliases":["ZSCAN7","CT53"]}},{"id":"f08c9ebd32dc4a5fb43d0df94918fcba","type":"GENE","name":"ZNF169","canonical_id":"hgnc:HGNC:12957","description":"zinc finger protein 169","metadata":{"aliases":["MGC51961"]}},{"id":"6af2c118f46e484c8c1f63f0a946201e","type":"GENE","name":"ZNF17","canonical_id":"hgnc:HGNC:12958","description":"zinc finger protein 17","metadata":{"aliases":["HPF3","KOX10","KIAA1947","FLJ40864","FLJ46058","FLJ46615"]}},{"id":"2e6ce9d22143432c8bcb26172c8c722c","type":"GENE","name":"ZNF174","canonical_id":"hgnc:HGNC:12963","description":"zinc finger protein 174","metadata":{"aliases":["ZSCAN8"]}},{"id":"4da1b5ae2f184890a8a0da1c5f50e793","type":"GENE","name":"ZNF175","canonical_id":"hgnc:HGNC:12964","description":null,"metadata":null},{"id":"bcc441e51f3744fcb0a8eb2ea20dd17e","type":"GENE","name":"ZNF177","canonical_id":"hgnc:HGNC:12966","description":"zinc finger protein 177","metadata":null},{"id":"24e27ef811a44dde9afc7cb48b6941cc","type":"GENE","name":"ZNF18","canonical_id":"hgnc:HGNC:12969","description":"zinc finger protein 18","metadata":{"aliases":["ZKSCAN6","KOX11","HDSG1","Zfp535","ZNF535","ZSCAN38"]}},{"id":"d5eb2ba3ea8f4b8291d0e075f2bc3891","type":"GENE","name":"ZNF180","canonical_id":"hgnc:HGNC:12970","description":"zinc finger protein 180","metadata":{"aliases":["HHZ168"]}},{"id":"447ad95ffb4244f09f72ca6b735d14f6","type":"GENE","name":"ZNF181","canonical_id":"hgnc:HGNC:12971","description":"zinc finger protein 181","metadata":{"aliases":["HHZ181","MGC44316"]}},{"id":"5cbd8b0c191c45b6bf29e3a3d73cc891","type":"GENE","name":"ZNF182","canonical_id":"hgnc:HGNC:13001","description":"zinc finger protein 182","metadata":{"aliases":["KOX14","HHZ150","Zfp182","ZNF21"]}},{"id":"4d5158c69e264597b4a55f4c0cc33270","type":"GENE","name":"ZNF184","canonical_id":"hgnc:HGNC:12975","description":"zinc finger protein 184","metadata":null},{"id":"bfb9a3816ebc40dead34d06e897d92eb","type":"GENE","name":"ZNF185","canonical_id":"hgnc:HGNC:12976","description":"zinc finger protein 185 with LIM domain","metadata":{"aliases":["SCELL"]}},{"id":"a1a063e56d0e4803b083a8af97373e0a","type":"GENE","name":"ZNF189","canonical_id":"hgnc:HGNC:12980","description":"zinc finger protein 189","metadata":null},{"id":"864284f9567b43feae8fc754b7b2aa92","type":"GENE","name":"ZNF19","canonical_id":"hgnc:HGNC:12981","description":"zinc finger protein 19","metadata":{"aliases":["KOX12","MGC51021"]}},{"id":"6198c53b7bc2437ca766cb868f9a1ae9","type":"GENE","name":"ZNF195","canonical_id":"hgnc:HGNC:12986","description":"zinc finger protein 195","metadata":null},{"id":"91697fcf90c244538c2721b96107a9b4","type":"GENE","name":"ZNF197","canonical_id":"hgnc:HGNC:12988","description":"zinc finger protein 197","metadata":{"aliases":["P18","D3S1363E","ZKSCAN9","ZSCAN41","ZNF166"]}},{"id":"3ebeaefedb234e9b8d387d18706b4ff5","type":"GENE","name":"ZNF2","canonical_id":"hgnc:HGNC:12991","description":"zinc finger protein 2","metadata":{"aliases":["A1-5","ZNF661","Zfp661"]}},{"id":"d9300e50c76744598a434add48592c8f","type":"GENE","name":"ZNF20","canonical_id":"hgnc:HGNC:12992","description":"zinc finger protein 20","metadata":{"aliases":["KOX13"]}},{"id":"13dd8c28ca9349c1b41282054c09c02a","type":"GENE","name":"ZNF200","canonical_id":"hgnc:HGNC:12993","description":"zinc finger protein 200","metadata":null},{"id":"42236d23af104b54941c71fd55e1218d","type":"GENE","name":"ZNF202","canonical_id":"hgnc:HGNC:12994","description":null,"metadata":null},{"id":"3bd223177381478588b5f1294867b71b","type":"GENE","name":"ZNF204P","canonical_id":"hgnc:HGNC:12995","description":"zinc finger protein 204, pseudogene","metadata":{"aliases":["b24o18.1","ZNF184-Lp","ZNF204","ZNF315P"]}},{"id":"f923031a072749d4a7393037aed0767d","type":"GENE","name":"ZNF205","canonical_id":"hgnc:HGNC:12996","description":null,"metadata":null},{"id":"b69bbe99129a4b64bf0ff56b3c887515","type":"GENE","name":"ZNF205-AS1","canonical_id":"hgnc:HGNC:28586","description":"ZNF205 antisense RNA 1","metadata":{"aliases":["MGC3771"]}},{"id":"ea693f61386d46ceb33feed4727b7997","type":"GENE","name":"ZNF207","canonical_id":"hgnc:HGNC:12998","description":"zinc finger protein 207","metadata":{"aliases":["BuGZ"]}},{"id":"1f23d0d6e8494accb6a0338a850afedc","type":"GENE","name":"ZNF208","canonical_id":"hgnc:HGNC:12999","description":"zinc finger protein 208","metadata":{"aliases":["PMIDP","ZNF95"]}},{"id":"407a6e889c7141268ee3d0e3f6722b97","type":"GENE","name":"ZNF209P","canonical_id":"hgnc:HGNC:13000","description":"zinc finger protein 209, pseudogene","metadata":{"aliases":["ZNF209"]}},{"id":"e2292d3540df4642b66d3c18a1adcb27","type":"GENE","name":"ZNF211","canonical_id":"hgnc:HGNC:13003","description":"zinc finger protein 211","metadata":{"aliases":["ZNF-25","CH2H2-25"]}},{"id":"b2506da6190d41ae83d8328aff6a5423","type":"GENE","name":"ZNF212","canonical_id":"hgnc:HGNC:13004","description":"zinc finger protein 212","metadata":{"aliases":["C2H2-150"]}},{"id":"7e6f969edf754fab908232ace7166a07","type":"GENE","name":"ZNF213","canonical_id":"hgnc:HGNC:13005","description":"zinc finger protein 213","metadata":{"aliases":["CR53","ZKSCAN21","ZSCAN53"]}},{"id":"83d48cba63dd40f9bfd015e6a4eaae91","type":"GENE","name":"ZNF213-AS1","canonical_id":"hgnc:HGNC:50505","description":"ZNF213 antisense RNA 1","metadata":null},{"id":"17e32c3afa514957a822233c495b3feb","type":"GENE","name":"ZNF214","canonical_id":"hgnc:HGNC:13006","description":"zinc finger protein 214","metadata":null},{"id":"0381bde05cff43c1952af21cf4fbcf60","type":"GENE","name":"ZNF215","canonical_id":"hgnc:HGNC:13007","description":"zinc finger protein 215","metadata":{"aliases":["ZKSCAN11","ZSCAN43"]}},{"id":"0f8a7e5c88ad426da701b141cfbbe59b","type":"GENE","name":"ZNF217","canonical_id":"hgnc:HGNC:13009","description":null,"metadata":null},{"id":"8b01aac59d04457ea7d64bfb9d80c58b","type":"GENE","name":"ZNF217-AS1","canonical_id":"hgnc:HGNC:56842","description":"ZNF217 antisense RNA 1","metadata":null},{"id":"3fabf7bd591947a7aa02c03dc6a7ce5f","type":"GENE","name":"ZNF219","canonical_id":"hgnc:HGNC:13011","description":"zinc finger protein 219","metadata":null},{"id":"db62867418634decab063efb848e7222","type":"GENE","name":"ZNF22","canonical_id":"hgnc:HGNC:13012","description":"zinc finger protein 22","metadata":{"aliases":["KOX15","HKR-T1","ZNF422","Zfp422"]}},{"id":"501470ed86f74a429f8cb342b2801abb","type":"GENE","name":"ZNF22-AS1","canonical_id":"hgnc:HGNC:23509","description":"ZNF22 antisense RNA 1","metadata":{"aliases":["FLJ30567","C10orf25"]}},{"id":"41a5faffb0804ca59a2b57fb4e69d914","type":"GENE","name":"ZNF221","canonical_id":"hgnc:HGNC:13014","description":"zinc finger protein 221","metadata":null},{"id":"1f44a5fd577f4462ae2176d283783482","type":"GENE","name":"ZNF222","canonical_id":"hgnc:HGNC:13015","description":"zinc finger protein 222","metadata":null},{"id":"d458922872df452294a409b5044f2b49","type":"GENE","name":"ZNF222-DT","canonical_id":"hgnc:HGNC:55310","description":"ZNF222 divergent transcript","metadata":null},{"id":"fd0f249d19fc4cc28a075a5a5a2007a1","type":"GENE","name":"ZNF223","canonical_id":"hgnc:HGNC:13016","description":"zinc finger protein 223","metadata":null},{"id":"b6709396f8004bcc90ce3a31167694ba","type":"GENE","name":"ZNF224","canonical_id":"hgnc:HGNC:13017","description":null,"metadata":null},{"id":"f8fc604c087f45258e4b056d90edf361","type":"GENE","name":"ZNF225","canonical_id":"hgnc:HGNC:13018","description":"zinc finger protein 225","metadata":null},{"id":"10aa3581568e4180af6d5b46ff518aac","type":"GENE","name":"ZNF225-AS1","canonical_id":"hgnc:HGNC:55916","description":"ZNF225 and ZNF224 antisense RNA 1","metadata":null},{"id":"7134ffb13eca4ee680baf02277fc3600","type":"GENE","name":"ZNF226","canonical_id":"hgnc:HGNC:13019","description":"zinc finger protein 226","metadata":null},{"id":"b63e4c68696f4f07a7d5d8fbbf6df8c9","type":"GENE","name":"ZNF227","canonical_id":"hgnc:HGNC:13020","description":"zinc finger protein 227","metadata":null},{"id":"f85773a6379b40f8bf6dcca5cc760eee","type":"GENE","name":"ZNF229","canonical_id":"hgnc:HGNC:13022","description":"zinc finger protein 229","metadata":null},{"id":"096e6e96fe7e48999898e6a9a36e82f9","type":"GENE","name":"ZNF23","canonical_id":"hgnc:HGNC:13023","description":"zinc finger protein 23","metadata":{"aliases":["KOX16","Zfp612","ZNF612","ZNF359"]}},{"id":"87499d128013445186bc30264e09c3d8","type":"GENE","name":"ZNF230","canonical_id":"hgnc:HGNC:13024","description":"zinc finger protein 230","metadata":{"aliases":["FDZF2"]}},{"id":"2f4841fbe83c41deaa9f28edc5ff8f1a","type":"GENE","name":"ZNF230-DT","canonical_id":"hgnc:HGNC:55316","description":"ZNF230 divergent transcript","metadata":null},{"id":"bbf57a8add5f4fe8bd8eb552889b3742","type":"GENE","name":"ZNF232","canonical_id":"hgnc:HGNC:13026","description":"zinc finger protein 232","metadata":{"aliases":["ZSCAN11"]}},{"id":"60c396fdb50d41ccb3055d3fa5f51816","type":"GENE","name":"ZNF232-AS1","canonical_id":"hgnc:HGNC:40623","description":"ZNF232 antisense RNA 1","metadata":null},{"id":"4b64bbca633446d3b926a184b33598f9","type":"GENE","name":"ZNF233","canonical_id":"hgnc:HGNC:30946","description":"zinc finger protein 233","metadata":{"aliases":["FLJ38032"]}},{"id":"f544c59d29c544468751fd65952218e5","type":"GENE","name":"ZNF234","canonical_id":"hgnc:HGNC:13027","description":"zinc finger protein 234","metadata":{"aliases":["HZF4","ZNF269"]}},{"id":"de056ea31de445d5883ca0bd781fa489","type":"GENE","name":"ZNF235","canonical_id":"hgnc:HGNC:12866","description":"zinc finger protein 235","metadata":{"aliases":["HZF6","ANF270","ZNF270","ZFP93"]}},{"id":"3c4631913ecd48aa9779c4641042349b","type":"GENE","name":"ZNF236","canonical_id":"hgnc:HGNC:13028","description":"zinc finger protein 236","metadata":null},{"id":"2977a7203a1147fe8bbc8cbb142bf16d","type":"GENE","name":"ZNF236-DT","canonical_id":"hgnc:HGNC:53779","description":"ZNF236 divergent transcript","metadata":null},{"id":"6d77e8f6ed224d13869cf9e100768eb3","type":"GENE","name":"ZNF239","canonical_id":"hgnc:HGNC:13031","description":null,"metadata":null},{"id":"6bad5a241140407f8f707d6d86407cac","type":"GENE","name":"ZNF24","canonical_id":"hgnc:HGNC:13032","description":null,"metadata":null},{"id":"e34100ce80344377aa9f602ddf08542a","type":"GENE","name":"ZNF248","canonical_id":"hgnc:HGNC:13041","description":"zinc finger protein 248","metadata":{"aliases":["bA162G10.3"]}},{"id":"3839be09b13c495b83e1701eb2747f5b","type":"GENE","name":"ZNF248-AS1","canonical_id":"hgnc:HGNC:56681","description":"ZNF248 antisense RNA 1","metadata":{"aliases":["RP11-162G10.5"]}},{"id":"b103ee79cb614999a3105f6151a96317","type":"GENE","name":"ZNF24TR","canonical_id":"hgnc:HGNC:55876","description":"ZNF24 transcription regulator","metadata":{"aliases":["ZNFTR","AC007998.3"]}},{"id":"e3289d665f7a4dcebcd22bfdf35fe436","type":"GENE","name":"ZNF25","canonical_id":"hgnc:HGNC:13043","description":"zinc finger protein 25","metadata":{"aliases":["KOX19","FLJ31890","Zfp9"]}},{"id":"bf967db7319843f8ad460628ef5d65c2","type":"GENE","name":"ZNF25-DT","canonical_id":"hgnc:HGNC:54109","description":"ZNF25 divergent transcript","metadata":null},{"id":"0b038669d4664187a7c7eaf4f745beeb","type":"GENE","name":"ZNF250","canonical_id":"hgnc:HGNC:13044","description":"zinc finger protein 250","metadata":{"aliases":["MGC9718","ZFP647","ZNF647"]}},{"id":"435e5a61e4e9429a8db975d5fd2d1b26","type":"GENE","name":"ZNF251","canonical_id":"hgnc:HGNC:13045","description":"zinc finger protein 251","metadata":null},{"id":"eee0eeb162204026b219c37753698e7a","type":"GENE","name":"ZNF252P","canonical_id":"hgnc:HGNC:13046","description":"zinc finger protein 252, pseudogene","metadata":{"aliases":["ZNF252"]}},{"id":"8e5e4551d95542da8906c522f7eaf34c","type":"GENE","name":"ZNF252P-AS1","canonical_id":"hgnc:HGNC:27821","description":"ZNF252P antisense RNA 1","metadata":{"aliases":["C8orf77"]}},{"id":"190a9cd37e9e4759ac776d8b257fd08a","type":"GENE","name":"ZNF253","canonical_id":"hgnc:HGNC:13497","description":"zinc finger protein 253","metadata":{"aliases":["BMZF-1","FLJ90391","ZNF411"]}},{"id":"05db17ccc5884a87b4010223b93d7d30","type":"GENE","name":"ZNF254","canonical_id":"hgnc:HGNC:13047","description":"zinc finger protein 254","metadata":{"aliases":["HD-ZNF1","BMZF-5","ZNF91L","ZNF539"]}},{"id":"d2458fe2bf0a42849aed16e28105910f","type":"GENE","name":"ZNF256","canonical_id":"hgnc:HGNC:13049","description":"zinc finger protein 256","metadata":{"aliases":["BMZF-3"]}},{"id":"c49b71b5d09c4f21aedcf32283325d83","type":"GENE","name":"ZNF257","canonical_id":"hgnc:HGNC:13498","description":"zinc finger protein 257","metadata":{"aliases":["BMZF-4"]}},{"id":"b513f9aa6bf34cebb6881208157460b3","type":"GENE","name":"ZNF26","canonical_id":"hgnc:HGNC:13053","description":"zinc finger protein 26","metadata":{"aliases":["KOX20","FLJ20755"]}},{"id":"b948fa7553e84469bd2b4142392e3ac2","type":"GENE","name":"ZNF260","canonical_id":"hgnc:HGNC:13499","description":"zinc finger protein 260","metadata":{"aliases":["ozrf1","Zfp260"]}},{"id":"86d095ff31894c158dee6044e0e66c87","type":"GENE","name":"ZNF263","canonical_id":"hgnc:HGNC:13056","description":"zinc finger protein 263","metadata":{"aliases":["FPM315","ZKSCAN12","ZSCAN44"]}},{"id":"0e8d290c47534e72af59cd4600eafd3e","type":"GENE","name":"ZNF264","canonical_id":"hgnc:HGNC:13057","description":"zinc finger protein 264","metadata":{"aliases":["KIAA0412"]}},{"id":"0e9abff92c59400da67f49e557809421","type":"GENE","name":"ZNF266","canonical_id":"hgnc:HGNC:13059","description":"zinc finger protein 266","metadata":{"aliases":["HZF1"]}},{"id":"60bd705a1c8943a08dafa88e51fef056","type":"GENE","name":"ZNF267","canonical_id":"hgnc:HGNC:13060","description":null,"metadata":null},{"id":"c9cdab689f9f488d82a28ddf6d8d04ab","type":"GENE","name":"ZNF268","canonical_id":"hgnc:HGNC:13061","description":null,"metadata":null},{"id":"9113a19582ad469da6710c2683afbb49","type":"GENE","name":"ZNF271P","canonical_id":"hgnc:HGNC:13065","description":"zinc finger protein 271, pseudogene","metadata":{"aliases":["HZF7","ZNFEB","ZNF271"]}},{"id":"233c73e5b1354979a05f4067022291c6","type":"GENE","name":"ZNF273","canonical_id":"hgnc:HGNC:13067","description":"zinc finger protein 273","metadata":{"aliases":["HZF9"]}},{"id":"704f478055e74cde8ad94625fa15af00","type":"GENE","name":"ZNF274","canonical_id":"hgnc:HGNC:13068","description":null,"metadata":null},{"id":"15161f2482e14365ac714506f3b5d6e7","type":"GENE","name":"ZNF275","canonical_id":"hgnc:HGNC:13069","description":"zinc finger protein 275","metadata":null},{"id":"3839bd08884f431e9d08ea5af122af3f","type":"GENE","name":"ZNF276","canonical_id":"hgnc:HGNC:23330","description":"zinc finger protein 276","metadata":{"aliases":["MGC45417","ZNF477","CENPZ","CENP-Z","ZADT","ZFP276"]}},{"id":"dbfdbb4c33204d3fb9bb9ccd4b3637be","type":"GENE","name":"ZNF276-AS1","canonical_id":"hgnc:HGNC:58110","description":"ZNF276 antisense RNA 1","metadata":null},{"id":"0335d68b6b1e41618f3914aca550a189","type":"GENE","name":"ZNF277","canonical_id":"hgnc:HGNC:13070","description":"zinc finger protein 277","metadata":{"aliases":["NRIF4","ZNF277P"]}},{"id":"199adc76e1634f2eb2a706604d341296","type":"GENE","name":"ZNF277-AS1","canonical_id":"hgnc:HGNC:55828","description":"ZNF277 antisense RNA 1","metadata":null},{"id":"0b2302f7f8044c6eb5602a171c62872f","type":"GENE","name":"ZNF28","canonical_id":"hgnc:HGNC:13073","description":"zinc finger protein 28","metadata":{"aliases":["KOX24","DKFZp781D0275"]}},{"id":"43d9c0703d0e498c8d10cc7b79461b39","type":"GENE","name":"ZNF280A","canonical_id":"hgnc:HGNC:18597","description":"zinc finger protein 280A","metadata":{"aliases":["3'OY11.1","ZNF636","ZNF280","SUHW1"]}},{"id":"b0d37ba7d8eb47febfa03d732b927019","type":"GENE","name":"ZNF280B","canonical_id":"hgnc:HGNC:23022","description":"zinc finger protein 280B","metadata":{"aliases":["5'OY11.1","ZNF632","ZNF279","SUHW2"]}},{"id":"5d8e160dd2c84d50a24229771ecd9a63","type":"GENE","name":"ZNF280C","canonical_id":"hgnc:HGNC:25955","description":"zinc finger protein 280C","metadata":{"aliases":["FLJ20095","ZNF633","ZPET","SUHW3"]}},{"id":"84ddbc6e9e6247acaf9fb66c4f6e67a8","type":"GENE","name":"ZNF280D","canonical_id":"hgnc:HGNC:25953","description":"zinc finger protein 280D","metadata":{"aliases":["FLJ20086","ZNF634","SUHW4"]}},{"id":"1559764ada56418ea498cd0d2d75e3cf","type":"GENE","name":"ZNF281","canonical_id":"hgnc:HGNC:13075","description":"zinc finger protein 281","metadata":{"aliases":["ZBP-99"]}},{"id":"bc6f7d711b5e4c76805cde0b16532011","type":"GENE","name":"ZNF282","canonical_id":"hgnc:HGNC:13076","description":"zinc finger protein 282","metadata":{"aliases":["HUB1"]}},{"id":"a2d70bdb60e64635bb3402481c268e10","type":"GENE","name":"ZNF283","canonical_id":"hgnc:HGNC:13077","description":"zinc finger protein 283","metadata":null},{"id":"9056ee2c0929413282b3bc42c4cbd367","type":"GENE","name":"ZNF284","canonical_id":"hgnc:HGNC:13078","description":"zinc finger protein 284","metadata":{"aliases":["DKFZp781F1775"]}},{"id":"5aed869ec50349dc98fe167bf72414a6","type":"GENE","name":"ZNF285","canonical_id":"hgnc:HGNC:13079","description":"zinc finger protein 285","metadata":{"aliases":["ZNF285A"]}},{"id":"9196a1567bde4cdba204f3663f3dddef","type":"GENE","name":"ZNF285BP","canonical_id":"hgnc:HGNC:33262","description":"zinc finger protein 285B, pseudogene","metadata":{"aliases":["ZNF285B"]}},{"id":"7e4d0d3b2b5246968bd888f86d04d97e","type":"GENE","name":"ZNF285CP","canonical_id":"hgnc:HGNC:33228","description":"zinc finger protein 285C, pseudogene","metadata":{"aliases":["ZNF806"]}},{"id":"1cb692c2ec27484b8e2758c84ba3d1f3","type":"GENE","name":"ZNF285DP","canonical_id":"hgnc:HGNC:51790","description":"zinc finger protein 285D, pseudogene","metadata":null},{"id":"ab33f3c0fdc5422b9143a7e015553cf3","type":"GENE","name":"ZNF286A","canonical_id":"hgnc:HGNC:13501","description":"zinc finger protein 286A","metadata":{"aliases":["KIAA1874","ZNF286"]}},{"id":"f58539a8f7a240a08c650c3dbff081c2","type":"GENE","name":"ZNF286A-TBC1D26","canonical_id":"hgnc:HGNC:55384","description":"ZNF286A-TBC1D26 readthrough (NMD candidate)","metadata":null},{"id":"4c296a7109674eb3b77bcc29a0b99204","type":"GENE","name":"ZNF286B","canonical_id":"hgnc:HGNC:33241","description":"zinc finger protein 286B (pseudogene)","metadata":{"aliases":["ZNF590","ZNF286L","ZNF286C"]}},{"id":"cf5d8e8b39ea49be9f0dbdd77c5ed5e1","type":"GENE","name":"ZNF287","canonical_id":"hgnc:HGNC:13502","description":"zinc finger protein 287","metadata":{"aliases":["ZKSCAN13","ZSCAN45"]}},{"id":"a8a045d1655e4fd5ab14aaf2cddb984f","type":"GENE","name":"ZNF292","canonical_id":"hgnc:HGNC:18410","description":"zinc finger protein 292","metadata":{"aliases":["KIAA0530","ZFP292","bA393I2.3","Zn-15","Zn-16"]}},{"id":"540500a07d4649f9836b88ecca2f9f59","type":"GENE","name":"ZNF295-AS1","canonical_id":"hgnc:HGNC:23130","description":"ZNF295 antisense RNA 1","metadata":{"aliases":["PRED87","C21orf121","NCRNA00318"]}},{"id":"f0e851383f554de0af7f461e2bd9c454","type":"GENE","name":"ZNF296","canonical_id":"hgnc:HGNC:15981","description":"zinc finger protein 296","metadata":{"aliases":["ZNF342"]}},{"id":"05eedb3eab8f4cddbacd208f08905a4d","type":"GENE","name":"ZNF299P","canonical_id":"hgnc:HGNC:13088","description":"zinc finger protein 299, pseudogene","metadata":{"aliases":["ZNF299","ZNF299P1"]}},{"id":"5081963966fd4d77a5c6287f44763960","type":"GENE","name":"ZNF29P","canonical_id":"hgnc:HGNC:13080","description":"zinc finger protein 29, pseudogene","metadata":{"aliases":["KOX26","ZNF29"]}},{"id":"17f90cf685cf43aaae9e5e7834fd6164","type":"GENE","name":"ZNF3","canonical_id":"hgnc:HGNC:13089","description":"zinc finger protein 3","metadata":{"aliases":["A8-51","KOX25","PP838","FLJ20216","HF.12","Zfp113"]}},{"id":"96394e47d1534f25ae43c79a2ceea01e","type":"GENE","name":"ZNF30","canonical_id":"hgnc:HGNC:13090","description":"zinc finger protein 30","metadata":{"aliases":["KOX28","DKFZp686N19164","FLJ20562"]}},{"id":"4b8900bb4f864db3af9d25c9a0c450ea","type":"GENE","name":"ZNF30-AS1","canonical_id":"hgnc:HGNC:51179","description":"ZNF30 antisense RNA 1","metadata":null},{"id":"e1058d216e2e4a308faec789ce5ec2f7","type":"GENE","name":"ZNF300","canonical_id":"hgnc:HGNC:13091","description":null,"metadata":null},{"id":"11f6d65b78fc43a5a3a8d7b0b1eb6661","type":"GENE","name":"ZNF300-DT","canonical_id":"hgnc:HGNC:59283","description":"ZNF300 divergent transcript","metadata":null},{"id":"8047387f116148dc81707cb240a32d8c","type":"GENE","name":"ZNF300P1","canonical_id":"hgnc:HGNC:27032","description":"zinc finger protein 300 pseudogene 1","metadata":null},{"id":"ecaf7c30ebc749e79ac6cec05e6c27e3","type":"GENE","name":"ZNF302","canonical_id":"hgnc:HGNC:13848","description":"zinc finger protein 302","metadata":{"aliases":["ZNF327","ZNF135L","ZNF140L"]}},{"id":"53ea3720583b44b7907bd99c24d51fbb","type":"GENE","name":"ZNF304","canonical_id":"hgnc:HGNC:13505","description":"zinc finger protein 304","metadata":null},{"id":"df4b4fa30ab24485ba3fff5739acadfe","type":"GENE","name":"ZNF311","canonical_id":"hgnc:HGNC:13847","description":"zinc finger protein 311","metadata":null},{"id":"f6c5767e475b4372bafaeb0979d28559","type":"GENE","name":"ZNF316","canonical_id":"hgnc:HGNC:13843","description":"zinc finger protein 316","metadata":{"aliases":["MZF-3","ENST00000305834"]}},{"id":"cffef9b6e4c248acae4ac66c1fd9b188","type":"GENE","name":"ZNF317","canonical_id":"hgnc:HGNC:13507","description":"zinc finger protein 317","metadata":null},{"id":"39ab9687594b4a25b138297575bb3b59","type":"GENE","name":"ZNF317P1","canonical_id":"hgnc:HGNC:31062","description":"zinc finger protein 317 pseudogene 1","metadata":null},{"id":"c7d793cf66194de8a6dc04b1dcc3260c","type":"GENE","name":"ZNF318","canonical_id":"hgnc:HGNC:13578","description":"zinc finger protein 318","metadata":{"aliases":["HRIHFB2436","ZFP318"]}},{"id":"194ba8cbb5484ebbbbd5fa31e30abe29","type":"GENE","name":"ZNF318-AS1","canonical_id":"hgnc:HGNC:59411","description":"ZNF318 antisense RNA 1","metadata":null},{"id":"ec8648fa2b0648b8990013a670293d2f","type":"GENE","name":"ZNF318-DT","canonical_id":"hgnc:HGNC:59412","description":"ZNF318 divergent transcript","metadata":null},{"id":"679c0c77841241ca990d741c6bfb2e89","type":"GENE","name":"ZNF319","canonical_id":"hgnc:HGNC:13644","description":"zinc finger protein 319","metadata":{"aliases":["KIAA1388","Zfp319"]}},{"id":"c329c8a6e6a340afb1de81f1b9fdbf83","type":"GENE","name":"ZNF32","canonical_id":"hgnc:HGNC:13095","description":"zinc finger protein 32","metadata":{"aliases":["KOX30","ZNF637","Zfp637"]}},{"id":"b510c64d869144c9bf776b03c82e76e0","type":"GENE","name":"ZNF32-AS1","canonical_id":"hgnc:HGNC:23577","description":"ZNF32 antisense RNA 1","metadata":{"aliases":["bA402L1.8","ZNF32OS1"]}},{"id":"8d01c86127354853ab5ae9f4f0312aa7","type":"GENE","name":"ZNF32-AS2","canonical_id":"hgnc:HGNC:23593","description":"ZNF32 antisense RNA 2","metadata":{"aliases":["b402L1.7","C10orf44","ZNF32OS2","ZNF32-AS3"]}},{"id":"5e9e1ab99b0f4a1ba7e1727268e5e488","type":"GENE","name":"ZNF320","canonical_id":"hgnc:HGNC:13842","description":"zinc finger protein 320","metadata":{"aliases":["ZFPL","DKFZp686G16228"]}},{"id":"1cc20386f23c4347a765eff6dcb1b654","type":"GENE","name":"ZNF321P","canonical_id":"hgnc:HGNC:13827","description":"zinc finger protein 321, pseudogene","metadata":{"aliases":["MGC35402","ZNF321"]}},{"id":"69508b34d6d54fce9e92c2492f72ae17","type":"GENE","name":"ZNF322","canonical_id":"hgnc:HGNC:23640","description":"zinc finger protein 322","metadata":{"aliases":["bA457M11.3","bA457M11.2","ZNF489","ZNF388","HCG12","ZNF322A"]}},{"id":"ccce3c78f4b54d50a90ac835dc070b4f","type":"GENE","name":"ZNF322P1","canonical_id":"hgnc:HGNC:14003","description":"zinc finger protein 322 pseudogene 1","metadata":{"aliases":["ZNF322","ZNF322B"]}},{"id":"9e3c13a0b0274c03b9ccb6e2a3942105","type":"GENE","name":"ZNF324","canonical_id":"hgnc:HGNC:14096","description":"zinc finger protein 324","metadata":{"aliases":["ZF5128","ZNF324A"]}},{"id":"3c6136ba0ce84f358cd0e93eb9e7e8b7","type":"GENE","name":"ZNF324B","canonical_id":"hgnc:HGNC:33107","description":"zinc finger protein 324B","metadata":{"aliases":["FLJ45850"]}},{"id":"55de4aae401748a88b2893acdff882fe","type":"GENE","name":"ZNF326","canonical_id":"hgnc:HGNC:14104","description":"zinc finger protein 326","metadata":{"aliases":["Zfp326","ZAN75","FLJ20403","ZIRD"]}},{"id":"76fabee5dbc845b3b0fa70f31a167711","type":"GENE","name":"ZNF329","canonical_id":"hgnc:HGNC:14209","description":"zinc finger protein 329","metadata":{"aliases":["FLJ12586"]}},{"id":"c7d77321ff3e407ba0e2a0443f794e8d","type":"GENE","name":"ZNF331","canonical_id":"hgnc:HGNC:15489","description":"zinc finger protein 331","metadata":{"aliases":["RITA","ZNF463","ZNF361"]}},{"id":"e3f8e12f03d84bdea3df875480ed669d","type":"GENE","name":"ZNF333","canonical_id":"hgnc:HGNC:15624","description":"zinc finger protein 333","metadata":{"aliases":["KIAA1806"]}},{"id":"307e69c95755435180eb172b49157c68","type":"GENE","name":"ZNF334","canonical_id":"hgnc:HGNC:15806","description":"zinc finger protein 334","metadata":{"aliases":["bA179N14.1"]}},{"id":"3c540e9b195342169195296b6dd23b6e","type":"GENE","name":"ZNF335","canonical_id":"hgnc:HGNC:15807","description":null,"metadata":null},{"id":"73fba79889134693a6f4bc3ab97bb88c","type":"GENE","name":"ZNF337","canonical_id":"hgnc:HGNC:15809","description":"zinc finger protein 337","metadata":{"aliases":["dJ694B14.1"]}},{"id":"b59482aa78eb4d6890d42a02ae638bd8","type":"GENE","name":"ZNF337-AS1","canonical_id":"hgnc:HGNC:40759","description":"ZNF337 antisense RNA 1","metadata":null},{"id":"c2a57dcf2ee34767b34b58d82bba6d23","type":"GENE","name":"ZNF33A","canonical_id":"hgnc:HGNC:13096","description":"zinc finger protein 33A","metadata":{"aliases":["KOX5","KOX31","KIAA0065","FLJ23404","ZZAPK","ZNF33","ZNF11A"]}},{"id":"26f567bb55d042989e7d6b7dbccc1889","type":"GENE","name":"ZNF33B","canonical_id":"hgnc:HGNC:13097","description":"zinc finger protein 33B","metadata":{"aliases":["KOX31","KOX2","ZNF11B"]}},{"id":"7a8b192589db403aa5c022b71a84313f","type":"GENE","name":"ZNF33BP1","canonical_id":"hgnc:HGNC:44975","description":"zinc finger protein 33B pseudogene 1","metadata":null},{"id":"67671e98c07446fd8c6bd34efbf436fc","type":"GENE","name":"ZNF33CP","canonical_id":"hgnc:HGNC:30957","description":"zinc finger protein 33C, pseudogene","metadata":{"aliases":["BA393J16.4","ZNF33AP1"]}},{"id":"dc1e4da3952b425a974fab80b6318a6b","type":"GENE","name":"ZNF34","canonical_id":"hgnc:HGNC:13098","description":"zinc finger protein 34","metadata":{"aliases":["KOX32"]}},{"id":"f65df7ad9791420a86c7c90f11054d2f","type":"GENE","name":"ZNF341","canonical_id":"hgnc:HGNC:15992","description":"zinc finger protein 341","metadata":{"aliases":["dJ553F4.3"]}},{"id":"be81e9bc9f924dc089a49ec825db5dcc","type":"GENE","name":"ZNF341-AS1","canonical_id":"hgnc:HGNC:50736","description":"ZNF341 antisense RNA 1","metadata":null},{"id":"1348d1f994ba422eb13a389e86039977","type":"GENE","name":"ZNF343","canonical_id":"hgnc:HGNC:16017","description":"zinc finger protein 343","metadata":{"aliases":["MGC10715"]}},{"id":"86a81d74c61d45ecb28f4c05d7d26ed6","type":"GENE","name":"ZNF345","canonical_id":"hgnc:HGNC:16367","description":"zinc finger protein 345","metadata":{"aliases":["HZF10"]}},{"id":"d1777e4b074b4b74bac5d2e28ac1cb5e","type":"GENE","name":"ZNF346","canonical_id":"hgnc:HGNC:16403","description":"zinc finger protein 346","metadata":{"aliases":["JAZ","Zfp346"]}},{"id":"60ef92c0a5454375bf88cd1862fbc1db","type":"GENE","name":"ZNF346-IT1","canonical_id":"hgnc:HGNC:41423","description":"ZNF346 intronic transcript 1","metadata":null},{"id":"db68fb9906744a4ea3a1113a056f5f21","type":"GENE","name":"ZNF347","canonical_id":"hgnc:HGNC:16447","description":"zinc finger protein 347","metadata":{"aliases":["ZNF1111"]}},{"id":"0bbb32f4b0b443b69866dd2215090a27","type":"GENE","name":"ZNF35","canonical_id":"hgnc:HGNC:13099","description":"zinc finger protein 35","metadata":{"aliases":["HF.10","HF10","Zfp105"]}},{"id":"db11e1d929764e8d893b63c6e9350fd4","type":"GENE","name":"ZNF350","canonical_id":"hgnc:HGNC:16656","description":null,"metadata":null},{"id":"c18ff342e91a4e1698bdc231848052b2","type":"GENE","name":"ZNF350-AS1","canonical_id":"hgnc:HGNC:48598","description":"ZNF350 antisense RNA 1","metadata":{"aliases":["uc002pyc","HCCAT3"]}},{"id":"edc939f663944f998e9f971d2eda05f2","type":"GENE","name":"ZNF354A","canonical_id":"hgnc:HGNC:11628","description":"zinc finger protein 354A","metadata":{"aliases":["KID-1","EZNF","HKL1","KID1","TCF17"]}},{"id":"1a71e6117d6043b48db28c2839f2b56b","type":"GENE","name":"ZNF354B","canonical_id":"hgnc:HGNC:17197","description":"zinc finger protein 354B","metadata":{"aliases":["KID2","FLJ25008"]}},{"id":"bd3bd254387042b6840980223cdaf16e","type":"GENE","name":"ZNF354C","canonical_id":"hgnc:HGNC:16736","description":"zinc finger protein 354C","metadata":{"aliases":["KID3"]}},{"id":"9820ad6a5f5d48fc9b1db2eed2172065","type":"GENE","name":"ZNF355P","canonical_id":"hgnc:HGNC:17218","description":"zinc finger protein 355, pseudogene","metadata":{"aliases":["PRED65","ZNF834"]}},{"id":"c12dcef7f681470f94b2ba1f53204760","type":"GENE","name":"ZNF358","canonical_id":"hgnc:HGNC:16838","description":"zinc finger protein 358","metadata":{"aliases":["FLJ10390","ZFEND"]}},{"id":"29682013c7c24517bcaeb40ed9715751","type":"GENE","name":"ZNF362","canonical_id":"hgnc:HGNC:18079","description":"zinc finger protein 362","metadata":{"aliases":["FLJ25476","lin-29","RN"]}},{"id":"5b110ab973e34db4aad0f5fc1f74b027","type":"GENE","name":"ZNF365","canonical_id":"hgnc:HGNC:18194","description":"zinc finger protein 365","metadata":{"aliases":["KIAA0844","UAN","Su48"]}},{"id":"565df0103c474c17b09784890209c116","type":"GENE","name":"ZNF366","canonical_id":"hgnc:HGNC:18316","description":"zinc finger protein 366","metadata":{"aliases":["FLJ39796"]}},{"id":"de957eadccff47bbb525d62db042fa9d","type":"GENE","name":"ZNF367","canonical_id":"hgnc:HGNC:18320","description":"zinc finger protein 367","metadata":{"aliases":["FLJ33970"]}},{"id":"910f3581ff9b44acb560debfa1792313","type":"GENE","name":"ZNF37A","canonical_id":"hgnc:HGNC:13102","description":"zinc finger protein 37A","metadata":{"aliases":["KOX21","ZNF37"]}},{"id":"4b585a58f0b641cd999272c88b2ca6ad","type":"GENE","name":"ZNF37BP","canonical_id":"hgnc:HGNC:13103","description":"zinc finger protein 37B, pseudogene","metadata":{"aliases":["KOX21","FLJ23327","ZNF37B"]}},{"id":"5353a53bb3ea48ff961ccbd64a774119","type":"GENE","name":"ZNF37CP","canonical_id":"hgnc:HGNC:29445","description":"zinc finger protein 37C, pseudogene","metadata":{"aliases":["ZNF37C"]}},{"id":"fa568e3c37c84c9d9a952cd6dd69a023","type":"GENE","name":"ZNF382","canonical_id":"hgnc:HGNC:17409","description":null,"metadata":null},{"id":"50fee36b36034317a69eb2b5ca46015b","type":"GENE","name":"ZNF383","canonical_id":"hgnc:HGNC:18609","description":null,"metadata":null},{"id":"b6a95e35d7dc4643b57c18ba17c9045f","type":"GENE","name":"ZNF384","canonical_id":"hgnc:HGNC:11955","description":"zinc finger protein 384","metadata":{"aliases":["CAGH1A","CIZ","NMP4","NP","TNRC1"]}},{"id":"c1b1b8319a77447da11f2546a1e064a1","type":"GENE","name":"ZNF385A","canonical_id":"hgnc:HGNC:17521","description":"zinc finger protein 385A","metadata":{"aliases":["DKFZp586G1122","Hzf","ZFP385","ZNF385"]}},{"id":"064f5d51bba04d1b9d3394ef3442044b","type":"GENE","name":"ZNF385B","canonical_id":"hgnc:HGNC:26332","description":"zinc finger protein 385B","metadata":{"aliases":["FLJ25270","ZNF533"]}},{"id":"351e9e3c69b3483f91cb35724ced1974","type":"GENE","name":"ZNF385C","canonical_id":"hgnc:HGNC:33722","description":"zinc finger protein 385C","metadata":null},{"id":"cfdf84a1f88a4e6c9d5331f49f3938a0","type":"GENE","name":"ZNF385D","canonical_id":"hgnc:HGNC:26191","description":"zinc finger protein 385D","metadata":{"aliases":["FLJ22419","ZNF659"]}},{"id":"0b7e0e421d304bceacd13946b423c11e","type":"GENE","name":"ZNF385D-AS1","canonical_id":"hgnc:HGNC:41136","description":"ZNF385D antisense RNA 1","metadata":null},{"id":"b6aa055252b447f283c353f8758253c2","type":"GENE","name":"ZNF385D-AS2","canonical_id":"hgnc:HGNC:42420","description":"ZNF385D antisense RNA 2","metadata":null},{"id":"4fc37e60fe9042149f489df05b460058","type":"GENE","name":"ZNF391","canonical_id":"hgnc:HGNC:18779","description":"zinc finger protein 391","metadata":{"aliases":["dJ153G14.3"]}},{"id":"37d12a39490c4b97b84013787e9051a5","type":"GENE","name":"ZNF394","canonical_id":"hgnc:HGNC:18832","description":"zinc finger protein 394","metadata":{"aliases":["ZKSCAN14","FLJ12298","ZSCAN46"]}},{"id":"d3de2e78834c4a38a6a9c53e7d29a66f","type":"GENE","name":"ZNF395","canonical_id":"hgnc:HGNC:18737","description":"zinc finger protein 395","metadata":{"aliases":["PRF-1","HDBP2","PBF","DKFZp434K1210"]}},{"id":"688316e364f54edc97b8d3636734f2ee","type":"GENE","name":"ZNF396","canonical_id":"hgnc:HGNC:18824","description":"zinc finger protein 396","metadata":{"aliases":["ZSCAN14","FLJ31213"]}},{"id":"2afe86db0d044b90979564052ef4b7c8","type":"GENE","name":"ZNF397","canonical_id":"hgnc:HGNC:18818","description":"zinc finger protein 397","metadata":{"aliases":["ZSCAN15","MGC13250","ZNF47"]}},{"id":"411ba7fe440449e49b8e1d758dfddc90","type":"GENE","name":"ZNF398","canonical_id":"hgnc:HGNC:18373","description":"zinc finger protein 398","metadata":{"aliases":["p71-ZER6","p52-ZER6","ZER6","KIAA1339","P51","P71"]}},{"id":"6eea1bbf1dfa459887c46e4e8885726e","type":"GENE","name":"ZNF402P","canonical_id":"hgnc:HGNC:19292","description":"zinc finger protein 402, pseudogene","metadata":null},{"id":"9d0d0a4057a14263b1f9d98e9953aa75","type":"GENE","name":"ZNF404","canonical_id":"hgnc:HGNC:19417","description":"zinc finger protein 404","metadata":null},{"id":"e581bc0b39e44249b4cc2080e698571d","type":"GENE","name":"ZNF407","canonical_id":"hgnc:HGNC:19904","description":"zinc finger protein 407","metadata":{"aliases":["FLJ20307","FLJ13839","KIAA1703"]}},{"id":"94b176480ae94b2183135fc01ef68f54","type":"GENE","name":"ZNF407-AS1","canonical_id":"hgnc:HGNC:44331","description":"ZNF407 antisense RNA 1","metadata":{"aliases":["LINC00909"]}},{"id":"68161903245244cea9caaf3640595b18","type":"GENE","name":"ZNF408","canonical_id":"hgnc:HGNC:20041","description":"zinc finger protein 408","metadata":{"aliases":["FLJ12827","PRDM17"]}},{"id":"ee54c1c2fac3406fbcd3d002389de7df","type":"GENE","name":"ZNF41","canonical_id":"hgnc:HGNC:13107","description":"zinc finger protein 41","metadata":{"aliases":["MGC8941","MRX89"]}},{"id":"3a1f53eafd7044c994dd139585c0e1d9","type":"GENE","name":"ZNF410","canonical_id":"hgnc:HGNC:20144","description":null,"metadata":null},{"id":"55c2855923c043dcbb92b17cf3e6562d","type":"GENE","name":"ZNF414","canonical_id":"hgnc:HGNC:20630","description":"zinc finger protein 414","metadata":{"aliases":["MGC15716","Zfp414"]}},{"id":"e528d00818fc476ab3864315ae061c07","type":"GENE","name":"ZNF415","canonical_id":"hgnc:HGNC:20636","description":"zinc finger protein 415","metadata":null},{"id":"600dda9d9ae44497b5ddc3e2334d6ea7","type":"GENE","name":"ZNF415P1","canonical_id":"hgnc:HGNC:49869","description":"zinc finger protein 415 pseudogene 1","metadata":null},{"id":"8e62b069f74142b4b63ae666bf294f51","type":"GENE","name":"ZNF416","canonical_id":"hgnc:HGNC:20645","description":"zinc finger protein 416","metadata":{"aliases":["FLJ20557"]}},{"id":"1755ca84c27342b18842c7813808bccf","type":"GENE","name":"ZNF417","canonical_id":"hgnc:HGNC:20646","description":"zinc finger protein 417","metadata":{"aliases":["MGC34079"]}},{"id":"15eb60bdd0ed479abf370e5c2e583c0e","type":"GENE","name":"ZNF418","canonical_id":"hgnc:HGNC:20647","description":"zinc finger protein 418","metadata":{"aliases":["KIAA1956","FLJ31551"]}},{"id":"e8564e1fff2645c594d287bb621e7efc","type":"GENE","name":"ZNF419","canonical_id":"hgnc:HGNC:20648","description":"zinc finger protein 419","metadata":{"aliases":["ZAPHIR","ZNF419A"]}},{"id":"f8c95e0088c34476a3126ef35fdca5ef","type":"GENE","name":"ZNF420","canonical_id":"hgnc:HGNC:20649","description":"zinc finger protein 420","metadata":{"aliases":["FLJ32191"]}},{"id":"c4f485c7f7014f41807c758c533647c4","type":"GENE","name":"ZNF423","canonical_id":"hgnc:HGNC:16762","description":null,"metadata":null},{"id":"401e2c76772c4696ac7c8aa129b1701b","type":"GENE","name":"ZNF425","canonical_id":"hgnc:HGNC:20690","description":"zinc finger protein 425","metadata":null},{"id":"1fa93443ee18438dacee888678107292","type":"GENE","name":"ZNF426","canonical_id":"hgnc:HGNC:20725","description":"zinc finger protein 426","metadata":{"aliases":["MGC2663"]}},{"id":"13e6f45197d546849c0289e84692d914","type":"GENE","name":"ZNF426-DT","canonical_id":"hgnc:HGNC:53777","description":"ZNF426 divergent transcript","metadata":null},{"id":"78c72bbb58714114984a2377a41a7c15","type":"GENE","name":"ZNF428","canonical_id":"hgnc:HGNC:20804","description":"zinc finger protein 428","metadata":{"aliases":["MGC51082","Zfp428","C19orf37"]}},{"id":"5d571f043fca4b24b4c381f0ec3c5247","type":"GENE","name":"ZNF429","canonical_id":"hgnc:HGNC:20817","description":"zinc finger protein 429","metadata":null},{"id":"7c3e8b53b83b4377a5a29fa69769d00a","type":"GENE","name":"ZNF43","canonical_id":"hgnc:HGNC:13109","description":"zinc finger protein 43","metadata":{"aliases":["HTF6","KOX27","ZNF39L1"]}},{"id":"62b94ca1d6cc4b3baa5bc3ede5c4e412","type":"GENE","name":"ZNF430","canonical_id":"hgnc:HGNC:20808","description":"zinc finger protein 430","metadata":{"aliases":["FLJ13659"]}},{"id":"7bdeb5b5c4a745de95005b5b712dbdf1","type":"GENE","name":"ZNF431","canonical_id":"hgnc:HGNC:20809","description":"zinc finger protein 431","metadata":{"aliases":["KIAA1969"]}},{"id":"e605d29b812a4b979976f9fddf0f918c","type":"GENE","name":"ZNF432","canonical_id":"hgnc:HGNC:20810","description":"zinc finger protein 432","metadata":{"aliases":["KIAA0798"]}},{"id":"cface37a870d4f30a267e08320106c14","type":"GENE","name":"ZNF433","canonical_id":"hgnc:HGNC:20811","description":"zinc finger protein 433","metadata":{"aliases":["FLJ40981"]}},{"id":"43b7d2523bf948f1a309ba74eaf87763","type":"GENE","name":"ZNF433-AS1","canonical_id":"hgnc:HGNC:53776","description":"ZNF433 and ZNF878 antisense RNA 1","metadata":null},{"id":"8263208a903549d2983b4d5805bd25dc","type":"GENE","name":"ZNF436","canonical_id":"hgnc:HGNC:20814","description":"zinc finger protein 436","metadata":{"aliases":["KIAA1710","Zfp46"]}},{"id":"b01bb5e1474f49a98329e2deed877656","type":"GENE","name":"ZNF436-AS1","canonical_id":"hgnc:HGNC:25122","description":"ZNF436 antisense RNA 1","metadata":{"aliases":["FLJ90508","C1orf213"]}},{"id":"3578267b6bbb42d38f5f7ef83928498e","type":"GENE","name":"ZNF438","canonical_id":"hgnc:HGNC:21029","description":"zinc finger protein 438","metadata":{"aliases":["bA330O11.1"]}},{"id":"5471ad436a714a408045ea209c09aa56","type":"GENE","name":"ZNF439","canonical_id":"hgnc:HGNC:20873","description":"zinc finger protein 439","metadata":{"aliases":["DKFZp571K0837"]}},{"id":"94f290a6807f4dbb8eb86cf7d6f92b1e","type":"GENE","name":"ZNF44","canonical_id":"hgnc:HGNC:13110","description":"zinc finger protein 44","metadata":{"aliases":["KOX7","ZNF504","ZNF58","ZNF55"]}},{"id":"dd11e03696f144959ebada0b240684d7","type":"GENE","name":"ZNF440","canonical_id":"hgnc:HGNC:20874","description":"zinc finger protein 440","metadata":{"aliases":["FLJ37933"]}},{"id":"2a82a7e6872f4d55b153dbe9a4cd28ac","type":"GENE","name":"ZNF441","canonical_id":"hgnc:HGNC:20875","description":"zinc finger protein 441","metadata":{"aliases":["FLJ38637"]}},{"id":"a2bbbd236f0d4afdbabfdc945dcdf6c2","type":"GENE","name":"ZNF442","canonical_id":"hgnc:HGNC:20877","description":"zinc finger protein 442","metadata":{"aliases":["FLJ14356"]}},{"id":"3d3033cc99534789b239aa03a5c97e52","type":"GENE","name":"ZNF443","canonical_id":"hgnc:HGNC:20878","description":"zinc finger protein 443","metadata":{"aliases":["ZK1"]}},{"id":"9c6d6241057f471ebb4d4c26e3f3f557","type":"GENE","name":"ZNF444","canonical_id":"hgnc:HGNC:16052","description":null,"metadata":null},{"id":"a8cb077869ad437a8e9155f74bc9f81b","type":"GENE","name":"ZNF444P1","canonical_id":"hgnc:HGNC:35157","description":"zinc finger protein 444 pseudogene 1","metadata":{"aliases":["ZNF864P"]}},{"id":"368789f683e84a04aa319366504fcd54","type":"GENE","name":"ZNF445","canonical_id":"hgnc:HGNC:21018","description":"zinc finger protein 445","metadata":{"aliases":["ZKSCAN15","ZSCAN47","ZNF168"]}},{"id":"0c3cc9d7e284449e85d68e5a6db619a0","type":"GENE","name":"ZNF446","canonical_id":"hgnc:HGNC:21036","description":"zinc finger protein 446","metadata":{"aliases":["ZKSCAN20","FLJ20626","ZSCAN52"]}},{"id":"6d5e086b94bb4a46bb0386c14dc2c42e","type":"GENE","name":"ZNF449","canonical_id":"hgnc:HGNC:21039","description":"zinc finger protein 449","metadata":{"aliases":["ZSCAN19","FLJ23614"]}},{"id":"5bd699095b1642c1837325d46f1a70cb","type":"GENE","name":"ZNF45","canonical_id":"hgnc:HGNC:13111","description":"zinc finger protein 45","metadata":{"aliases":["ZNF13"]}},{"id":"2f36897c086a4b0c89135b4712f4f81c","type":"GENE","name":"ZNF45-AS1","canonical_id":"hgnc:HGNC:55308","description":"ZNF45 antisense RNA 1","metadata":null},{"id":"c9daa942a0ab4bcd832db288ad69c13b","type":"GENE","name":"ZNF451","canonical_id":"hgnc:HGNC:21091","description":"zinc finger protein 451","metadata":{"aliases":["KIAA0576","COASTER","dJ417I1.1","KIAA1702","ZATT"]}},{"id":"fadc0dc415714daa8fe69978b2652097","type":"GENE","name":"ZNF451-AS1","canonical_id":"hgnc:HGNC:53824","description":"ZNF451 regulatory antisense RNA 1","metadata":{"aliases":["BC032020"]}},{"id":"ca3e0726779b4ab492e68f439235db4b","type":"GENE","name":"ZNF454","canonical_id":"hgnc:HGNC:21200","description":"zinc finger protein 454","metadata":{"aliases":["FLJ37444"]}},{"id":"72e6553c9d534225a4d4877209718057","type":"GENE","name":"ZNF454-DT","canonical_id":"hgnc:HGNC:55213","description":"ZNF454 divergent transcript","metadata":{"aliases":["TCONS_00009823"]}},{"id":"053928b01cb0430ba430c9577a98d76a","type":"GENE","name":"ZNF460","canonical_id":"hgnc:HGNC:21628","description":"zinc finger protein 460","metadata":{"aliases":["HZF8","ZNF272"]}},{"id":"5fd01ebb6a5e48feb183524f9810c466","type":"GENE","name":"ZNF460-AS1","canonical_id":"hgnc:HGNC:53774","description":"ZNF460 antisense RNA 1","metadata":null},{"id":"5092ae246a304830a6f7ea04117abb04","type":"GENE","name":"ZNF461","canonical_id":"hgnc:HGNC:21629","description":"zinc finger protein 461","metadata":{"aliases":["GIOT-1","MGC33911"]}},{"id":"10dc0a3047ed4bd98112a425b8c5c654","type":"GENE","name":"ZNF462","canonical_id":"hgnc:HGNC:21684","description":"zinc finger protein 462","metadata":{"aliases":["DKFZP762N2316","KIAA1803","Zfp462"]}},{"id":"3da65055ae724ff6a873f9f1e2c5cc7c","type":"GENE","name":"ZNF467","canonical_id":"hgnc:HGNC:23154","description":"zinc finger protein 467","metadata":{"aliases":["EZI","Zfp467"]}},{"id":"2acb69be380c4c88987924e73062d3ba","type":"GENE","name":"ZNF468","canonical_id":"hgnc:HGNC:33105","description":"zinc finger protein 468","metadata":null},{"id":"5962b2cd6a394097a5714b41c04c32c2","type":"GENE","name":"ZNF469","canonical_id":"hgnc:HGNC:23216","description":"zinc finger protein 469","metadata":{"aliases":["KIAA1858","Zfp469"]}},{"id":"0a07be9c3d4743598a0064547dd4027d","type":"GENE","name":"ZNF470","canonical_id":"hgnc:HGNC:22220","description":"zinc finger protein 470","metadata":{"aliases":["CZF-1","FLJ26175"]}},{"id":"9587ac93e47e4ca58c537b455ccc6137","type":"GENE","name":"ZNF470-DT","canonical_id":"hgnc:HGNC:55272","description":"ZNF470 divergent transcript","metadata":null},{"id":"b4ada809180c4239b263b51626a5c9be","type":"GENE","name":"ZNF471","canonical_id":"hgnc:HGNC:23226","description":"zinc finger protein 471","metadata":{"aliases":["KIAA1396","Z1971","Zfp78"]}},{"id":"a756029bf3c5481190ca96232e971a40","type":"GENE","name":"ZNF473","canonical_id":"hgnc:HGNC:23239","description":"zinc finger protein 473","metadata":{"aliases":["KIAA1141","DKFZP434N043","HZFP100"]}},{"id":"45a7d89ee31c47648a29ac9e18200c09","type":"GENE","name":"ZNF473-AS1","canonical_id":"hgnc:HGNC:58330","description":"ZNF473 antisense RNA 1","metadata":null},{"id":"47378fced36c45e8b078161f8897bef2","type":"GENE","name":"ZNF473CR","canonical_id":"hgnc:HGNC:56021","description":"ZNF473 cis regulating lncRNA","metadata":{"aliases":["FLJ26850"]}},{"id":"83b1d9da3c6a4c97a4ba0ef710be283a","type":"GENE","name":"ZNF474","canonical_id":"hgnc:HGNC:23245","description":"zinc finger protein 474","metadata":{"aliases":["4933409D10Rik","FLJ32921"]}},{"id":"7951348fc9f74e4180e0d9045c33d6f8","type":"GENE","name":"ZNF474-AS1","canonical_id":"hgnc:HGNC:41019","description":"ZNF474 antisense RNA 1","metadata":null},{"id":"1c53387051dc449581f27c29630ed34c","type":"GENE","name":"ZNF475","canonical_id":"hgnc:HGNC:53564","description":"zinc finger protein 475","metadata":null},{"id":"93b67e63d7ae4cb09360687070e97dd4","type":"GENE","name":"ZNF479","canonical_id":"hgnc:HGNC:23258","description":"zinc finger protein 479","metadata":{"aliases":["KR19"]}},{"id":"26bcc87d42bb4a388184d4b1df81c260","type":"GENE","name":"ZNF48","canonical_id":"hgnc:HGNC:13114","description":"zinc finger protein 48","metadata":{"aliases":["DKFZp762K013","FLJ31751","MGC43952","ZNF553"]}},{"id":"f2a14ec23c4e4134a407752b1e2fb3fb","type":"GENE","name":"ZNF480","canonical_id":"hgnc:HGNC:23305","description":"zinc finger protein 480","metadata":{"aliases":["MGC32104"]}},{"id":"55060291b05d458ab6139388eecaa2c6","type":"GENE","name":"ZNF483","canonical_id":"hgnc:HGNC:23384","description":"zinc finger protein 483","metadata":{"aliases":["ZKSCAN16","KIAA1962","ZSCAN48"]}},{"id":"4235e326f43d4846b5473877a320bac9","type":"GENE","name":"ZNF484","canonical_id":"hgnc:HGNC:23385","description":"zinc finger protein 484","metadata":{"aliases":["BA526D8.4","FLJ33884"]}},{"id":"1826405415ca421fab7d42c9a6e764c0","type":"GENE","name":"ZNF485","canonical_id":"hgnc:HGNC:23440","description":"zinc finger protein 485","metadata":null},{"id":"74ae9c70b02f4b188ab30a016796cfc7","type":"GENE","name":"ZNF486","canonical_id":"hgnc:HGNC:20807","description":"zinc finger protein 486","metadata":{"aliases":["MGC2396","KRBO2"]}},{"id":"0dec205b9846426191d560d07dbef495","type":"GENE","name":"ZNF487","canonical_id":"hgnc:HGNC:23488","description":"zinc finger protein 487","metadata":{"aliases":["KRBO1","ZNF487P"]}},{"id":"3e2a2c10f8334abdbb3bc303fd784f54","type":"GENE","name":"ZNF488","canonical_id":"hgnc:HGNC:23535","description":"zinc finger protein 488","metadata":{"aliases":["FLJ32104"]}},{"id":"42ba58f649ac4d18a8e268043ee787e9","type":"GENE","name":"ZNF490","canonical_id":"hgnc:HGNC:23705","description":"zinc finger protein 490","metadata":{"aliases":["KIAA1198"]}},{"id":"97e59920f9dc4c46b02447937f18d6ba","type":"GENE","name":"ZNF491","canonical_id":"hgnc:HGNC:23706","description":"zinc finger protein 491","metadata":{"aliases":["FLJ34791"]}},{"id":"6c1a82344d79477fb7fd0bd886359ff3","type":"GENE","name":"ZNF492","canonical_id":"hgnc:HGNC:23707","description":"zinc finger protein 492","metadata":{"aliases":["KIAA1473","ZNF115"]}},{"id":"8bf8c1a1d5714e03a3bf3e5e2ea2b705","type":"GENE","name":"ZNF493","canonical_id":"hgnc:HGNC:23708","description":"zinc finger protein 493","metadata":{"aliases":["FLJ36504"]}},{"id":"5ba5b8d6672a4f2f859efed08cb3770e","type":"GENE","name":"ZNF496","canonical_id":"hgnc:HGNC:23713","description":"zinc finger protein 496","metadata":{"aliases":["ZKSCAN17","MGC15548","ZSCAN49"]}},{"id":"527b66e9e248495f99fc85d3b5f20c86","type":"GENE","name":"ZNF496-DT","canonical_id":"hgnc:HGNC:55991","description":"ZNF496 divergent transcript","metadata":{"aliases":["XLOC_000647"]}},{"id":"4bc50ea2b1ef433cb56024db0d81ab9c","type":"GENE","name":"ZNF497","canonical_id":"hgnc:HGNC:23714","description":"zinc finger protein 497","metadata":{"aliases":["FLJ44773"]}},{"id":"62d6b881042b4ad0b8c0ebab40aa4e19","type":"GENE","name":"ZNF497-AS1","canonical_id":"hgnc:HGNC:55277","description":"ZNF497 antisense RNA 1","metadata":null},{"id":"846aed35251145dcb4daa1e547344983","type":"GENE","name":"ZNF497-AS2","canonical_id":"hgnc:HGNC:58325","description":"ZNF497 antisense RNA 2","metadata":null},{"id":"68ecff4a2be34933a550c6a1baecbb60","type":"GENE","name":"ZNF500","canonical_id":"hgnc:HGNC:23716","description":"zinc finger protein 500","metadata":{"aliases":["ZKSCAN18","KIAA0557","ZSCAN50"]}},{"id":"92fb8ff8b94742cbb79fd23ffa965eee","type":"GENE","name":"ZNF501","canonical_id":"hgnc:HGNC:23717","description":"zinc finger protein 501","metadata":{"aliases":["MGC21738","ZNF52"]}},{"id":"738cf67dea2a4225931dafa4eeba9d40","type":"GENE","name":"ZNF502","canonical_id":"hgnc:HGNC:23718","description":"zinc finger protein 502","metadata":{"aliases":["FLJ14855","FLJ12515"]}},{"id":"213dd98b9bbd4ebd907807e64eec818d","type":"GENE","name":"ZNF503","canonical_id":"hgnc:HGNC:23589","description":"zinc finger protein 503","metadata":{"aliases":["ZPO2","ZEPPO2","FLJ45745","MGC2555","Nlz2"]}},{"id":"5dfcacfcdf7442a0ae4eabf6e4613d89","type":"GENE","name":"ZNF503-AS1","canonical_id":"hgnc:HGNC:27370","description":"ZNF503 antisense RNA 1","metadata":{"aliases":["uc.286"]}},{"id":"9a6963e8f5344d10813149de98ef71a3","type":"GENE","name":"ZNF503-AS2","canonical_id":"hgnc:HGNC:23525","description":"ZNF503 antisense RNA 2","metadata":{"aliases":["C10orf41","NCRNA00245"]}},{"id":"7eb54b77b0a84bc692a59a135d539432","type":"GENE","name":"ZNF506","canonical_id":"hgnc:HGNC:23780","description":"zinc finger protein 506","metadata":{"aliases":["DKFZp761G1812"]}},{"id":"90a4c168c83c42ff8da96b402334cbdb","type":"GENE","name":"ZNF507","canonical_id":"hgnc:HGNC:23783","description":"zinc finger protein 507","metadata":{"aliases":["KIAA1084","Zfp507"]}},{"id":"fc9f667b9ed6470781bb9f5272909d6b","type":"GENE","name":"ZNF510","canonical_id":"hgnc:HGNC:29161","description":"zinc finger protein 510","metadata":{"aliases":["KIAA0972"]}},{"id":"5ec104f4514f4520b5ce66ce89b112c4","type":"GENE","name":"ZNF511","canonical_id":"hgnc:HGNC:28445","description":"zinc finger protein 511","metadata":{"aliases":["MGC30006","Zfp511"]}},{"id":"bf4dea4745264e589aeaadf4866c7e15","type":"GENE","name":"ZNF511-PRAP1","canonical_id":"hgnc:HGNC:38088","description":"ZNF511-PRAP1 readthrough","metadata":null},{"id":"1bc83e613eff411c9506959ac95dca71","type":"GENE","name":"ZNF512","canonical_id":"hgnc:HGNC:29380","description":"zinc finger protein 512","metadata":{"aliases":["KIAA1805"]}},{"id":"b7061ac6a7224ae98139130c4e606881","type":"GENE","name":"ZNF512B","canonical_id":"hgnc:HGNC:29212","description":"zinc finger protein 512B","metadata":{"aliases":["GM632","MGC149845","MGC149846"]}},{"id":"45dffc6fa15548e18870fbd241acf9b5","type":"GENE","name":"ZNF513","canonical_id":"hgnc:HGNC:26498","description":"zinc finger protein 513","metadata":{"aliases":["FLJ32203","RP58","Zfp513"]}},{"id":"b5404ba89dad4af3aa0ec7cb1b351308","type":"GENE","name":"ZNF514","canonical_id":"hgnc:HGNC:25894","description":"zinc finger protein 514","metadata":{"aliases":["FLJ14457"]}},{"id":"3f7d68ee8de043d0a69100717fbc69c4","type":"GENE","name":"ZNF516","canonical_id":"hgnc:HGNC:28990","description":"zinc finger protein 516","metadata":{"aliases":["HsT287","KIAA0222"]}},{"id":"29f699c38bce4eb4be33285723acda35","type":"GENE","name":"ZNF516-AS1","canonical_id":"hgnc:HGNC:55324","description":"ZNF516 antisense RNA 1","metadata":null},{"id":"ff944fe5b88d42518dc12189e291bdcc","type":"GENE","name":"ZNF516-DT","canonical_id":"hgnc:HGNC:51248","description":"ZNF516 divergent transcript","metadata":{"aliases":["C18orf65"]}},{"id":"3ceaf9a61fc14a498099976c653cfe38","type":"GENE","name":"ZNF517","canonical_id":"hgnc:HGNC:27984","description":"zinc finger protein 517","metadata":null},{"id":"e143a654ff68457dbbf4494d3856787f","type":"GENE","name":"ZNF518A","canonical_id":"hgnc:HGNC:29009","description":"zinc finger protein 518A","metadata":{"aliases":["KIAA0335","ZNF518"]}},{"id":"49803cc8671c46a7af68f71ccf9e2f70","type":"GENE","name":"ZNF518B","canonical_id":"hgnc:HGNC:29365","description":"zinc finger protein 518B","metadata":{"aliases":["KIAA1729"]}},{"id":"94b126f0c86e4b0eb6ff80b020fa2951","type":"GENE","name":"ZNF519","canonical_id":"hgnc:HGNC:30574","description":"zinc finger protein 519","metadata":{"aliases":["HsT2362","FLJ36809"]}},{"id":"f849d5a55a9941fc935980d6804a89e8","type":"GENE","name":"ZNF519-AS1","canonical_id":"hgnc:HGNC:58569","description":"ZNF519 antisense RNA 1","metadata":null},{"id":"fb0f9fd6b7034dd6a98857114cc1fe77","type":"GENE","name":"ZNF519P1","canonical_id":"hgnc:HGNC:50785","description":"zinc finger protein 519 pseudogene 1","metadata":null},{"id":"94c92eda7b03484b9a6238de41d10a02","type":"GENE","name":"ZNF519P2","canonical_id":"hgnc:HGNC:50786","description":"zinc finger protein 519 pseudogene 2","metadata":null},{"id":"c12df0a296474df699e873e9c13fb24b","type":"GENE","name":"ZNF519P3","canonical_id":"hgnc:HGNC:50787","description":"zinc finger protein 519 pseudogene 3","metadata":null},{"id":"948683540c854f74a7628ab6e1fa4e38","type":"GENE","name":"ZNF519P4","canonical_id":"hgnc:HGNC:50788","description":"zinc finger protein 519 pseudogene 4","metadata":null},{"id":"6c09f509d7a74609a8a05eb64e014bb1","type":"GENE","name":"ZNF521","canonical_id":"hgnc:HGNC:24605","description":"zinc finger protein 521","metadata":{"aliases":["EHZF","Evi3"]}},{"id":"0ea8b029e6fd4594b50af34d4353c15b","type":"GENE","name":"ZNF524","canonical_id":"hgnc:HGNC:28322","description":"zinc finger protein 524","metadata":{"aliases":["MGC23143"]}},{"id":"10be6b3bc2ba40a4b4ec6d99615b164f","type":"GENE","name":"ZNF525","canonical_id":"hgnc:HGNC:29423","description":"zinc finger protein 525","metadata":{"aliases":["KIAA1979"]}},{"id":"8ca2fea530404218be146e34a7b3259e","type":"GENE","name":"ZNF526","canonical_id":"hgnc:HGNC:29415","description":"zinc finger protein 526","metadata":{"aliases":["KIAA1951","MGC4267"]}},{"id":"20a1ce853a304f43871641f10d56262c","type":"GENE","name":"ZNF527","canonical_id":"hgnc:HGNC:29385","description":"zinc finger protein 527","metadata":{"aliases":["KIAA1829"]}},{"id":"3b2c4cc14d824935a2380301b4a3aa91","type":"GENE","name":"ZNF528","canonical_id":"hgnc:HGNC:29384","description":"zinc finger protein 528","metadata":{"aliases":["KIAA1827"]}},{"id":"bb2a2077786c4d2ea2f40e2a1d7ff441","type":"GENE","name":"ZNF528-AS1","canonical_id":"hgnc:HGNC:51305","description":"ZNF528 antisense RNA 1","metadata":null},{"id":"e1bb972f4f2c4e0daf3a4e166e84b56b","type":"GENE","name":"ZNF529","canonical_id":"hgnc:HGNC:29328","description":"zinc finger protein 529","metadata":{"aliases":["KIAA1615"]}},{"id":"f79c28a12b174a5fa2ac1bd39790b3f8","type":"GENE","name":"ZNF529-AS1","canonical_id":"hgnc:HGNC:51275","description":"ZNF529 antisense RNA 1","metadata":null},{"id":"d390ad47b0c4429b8695c97a8d5297bb","type":"GENE","name":"ZNF530","canonical_id":"hgnc:HGNC:29297","description":"zinc finger protein 530","metadata":{"aliases":["KIAA1508"]}},{"id":"00fe5a877b7c43be9d969312acb75d30","type":"GENE","name":"ZNF532","canonical_id":"hgnc:HGNC:30940","description":"zinc finger protein 532","metadata":{"aliases":["FLJ10697"]}},{"id":"2b7db6bc8468474d8dfe1c8baea010b1","type":"GENE","name":"ZNF534","canonical_id":"hgnc:HGNC:26337","description":"zinc finger protein 534","metadata":{"aliases":["FLJ25344","KRBO3"]}},{"id":"f7ea0af805c44105bba64f25348429d4","type":"GENE","name":"ZNF536","canonical_id":"hgnc:HGNC:29025","description":"zinc finger protein 536","metadata":{"aliases":["KIAA0390"]}},{"id":"c1b949d7f9b7404eb6afac08b7e53fe3","type":"GENE","name":"ZNF536-AS1","canonical_id":"hgnc:HGNC:58590","description":"ZNF536 antisense RNA 1","metadata":null},{"id":"ca9b5104db67473f9a6396db26cedd20","type":"GENE","name":"ZNF540","canonical_id":"hgnc:HGNC:25331","description":"zinc finger protein 540","metadata":{"aliases":["DKFZp547B0714"]}},{"id":"e6e0d01d12c845159305dea521e70f47","type":"GENE","name":"ZNF541","canonical_id":"hgnc:HGNC:25294","description":"zinc finger protein 541","metadata":{"aliases":["DKFZp434I1930"]}},{"id":"163049ecda1e41c59fd69f4ee9f3c312","type":"GENE","name":"ZNF542P","canonical_id":"hgnc:HGNC:25393","description":"zinc finger protein 542, pseudogene","metadata":{"aliases":["DKFZp686B2197","ZNF542"]}},{"id":"cd9490ab0196472eaa238abdb4038287","type":"GENE","name":"ZNF543","canonical_id":"hgnc:HGNC:25281","description":"zinc finger protein 543","metadata":{"aliases":["DKFZp434H055"]}},{"id":"42fd76ace5c046499da45c567c2c2711","type":"GENE","name":"ZNF544","canonical_id":"hgnc:HGNC:16759","description":"zinc finger protein 544","metadata":{"aliases":["AF020591"]}},{"id":"0f5beaaf610943b0a5737e7c07da5d0b","type":"GENE","name":"ZNF546","canonical_id":"hgnc:HGNC:28671","description":"zinc finger protein 546","metadata":{"aliases":["MGC43537","ZNF49"]}},{"id":"7a2e47d31e7346b69e7b4062be792d99","type":"GENE","name":"ZNF547","canonical_id":"hgnc:HGNC:26432","description":"zinc finger protein 547","metadata":{"aliases":["FLJ31100"]}},{"id":"8758f389724c4b73af52c4c69e19d0dd","type":"GENE","name":"ZNF548","canonical_id":"hgnc:HGNC:26561","description":"zinc finger protein 548","metadata":{"aliases":["FLJ32932"]}},{"id":"dda91047fad745168575a9fe2b5a38df","type":"GENE","name":"ZNF549","canonical_id":"hgnc:HGNC:26632","description":"zinc finger protein 549","metadata":{"aliases":["FLJ34917"]}},{"id":"1c114a4de1b949c18d072bd0f239103e","type":"GENE","name":"ZNF550","canonical_id":"hgnc:HGNC:28643","description":"zinc finger protein 550","metadata":{"aliases":["MGC41917"]}},{"id":"49f628c109c8431490447df000d04448","type":"GENE","name":"ZNF551","canonical_id":"hgnc:HGNC:25108","description":"zinc finger protein 551","metadata":{"aliases":["DKFZp686H1038"]}},{"id":"af83c358e5974993a3fe5270c21b5d5c","type":"GENE","name":"ZNF552","canonical_id":"hgnc:HGNC:26135","description":"zinc finger protein 552","metadata":{"aliases":["FLJ21603"]}},{"id":"ba42482c8a074ec695edd259eef38417","type":"GENE","name":"ZNF554","canonical_id":"hgnc:HGNC:26629","description":"zinc finger protein 554","metadata":{"aliases":["FLJ34817"]}},{"id":"2e90f095faae412d9cd67e4c2daa8838","type":"GENE","name":"ZNF555","canonical_id":"hgnc:HGNC:28382","description":"zinc finger protein 555","metadata":{"aliases":["MGC26707"]}},{"id":"3969449eedab41dc8bcfca34e2ce2c2d","type":"GENE","name":"ZNF555-AS1","canonical_id":"hgnc:HGNC:58567","description":"ZNF555 antisense RNA 1","metadata":null},{"id":"a896d497197c4b59b90c6b2387532a00","type":"GENE","name":"ZNF556","canonical_id":"hgnc:HGNC:25669","description":"zinc finger protein 556","metadata":{"aliases":["FLJ11637"]}},{"id":"618ec39b9e0647a4b8baeb9f01361435","type":"GENE","name":"ZNF557","canonical_id":"hgnc:HGNC:28632","description":"zinc finger protein 557","metadata":{"aliases":["MGC4054"]}},{"id":"c081d2b44e8147c7b31dba3d25bf3a0a","type":"GENE","name":"ZNF558","canonical_id":"hgnc:HGNC:26422","description":"zinc finger protein 558","metadata":{"aliases":["FLJ30932"]}},{"id":"665c50b358b048039c30d6ec98785f2f","type":"GENE","name":"ZNF559","canonical_id":"hgnc:HGNC:28197","description":"zinc finger protein 559","metadata":{"aliases":["MGC13105"]}},{"id":"08b8b5d611ce464da10ca4a4b51e7fb1","type":"GENE","name":"ZNF559-ZNF177","canonical_id":"hgnc:HGNC:42964","description":"ZNF559-ZNF177 readthrough","metadata":null},{"id":"880344b0fdfd4d51a86046acdfc59ac5","type":"GENE","name":"ZNF560","canonical_id":"hgnc:HGNC:26484","description":"zinc finger protein 560","metadata":{"aliases":["FLJ31986"]}},{"id":"e42cf20d431b4913b03d05a04f5906fd","type":"GENE","name":"ZNF561","canonical_id":"hgnc:HGNC:28684","description":"zinc finger protein 561","metadata":{"aliases":["MGC45408"]}},{"id":"7cf46fcebf224b38af45185292386c5d","type":"GENE","name":"ZNF561-AS1","canonical_id":"hgnc:HGNC:27613","description":"ZNF561 antisense RNA 1","metadata":{"aliases":["C19orf82"]}},{"id":"a5cf8b14dc3c4a869b527a3657666fc0","type":"GENE","name":"ZNF562","canonical_id":"hgnc:HGNC:25950","description":"zinc finger protein 562","metadata":{"aliases":["FLJ20079"]}},{"id":"dd297b73d3ad4259a82d61c616564aa8","type":"GENE","name":"ZNF563","canonical_id":"hgnc:HGNC:30498","description":"zinc finger protein 563","metadata":{"aliases":["FLJ34797"]}},{"id":"c6e8f7fc20e54caa8a9befdbc06e0291","type":"GENE","name":"ZNF564","canonical_id":"hgnc:HGNC:31106","description":"zinc finger protein 564","metadata":{"aliases":["MGC26914"]}},{"id":"e4cb1fc20c56425cb70a062cf3e77148","type":"GENE","name":"ZNF565","canonical_id":"hgnc:HGNC:26726","description":"zinc finger protein 565","metadata":{"aliases":["FLJ36991"]}},{"id":"465cb2b607a442abb43b7a7c666cb92d","type":"GENE","name":"ZNF566","canonical_id":"hgnc:HGNC:25919","description":"zinc finger protein 566","metadata":{"aliases":["FLJ14779","MGC12515"]}},{"id":"6a07d5af612d4b55bc0dece29a111859","type":"GENE","name":"ZNF566-AS1","canonical_id":"hgnc:HGNC:55301","description":"ZNF566 antisense RNA 1","metadata":null},{"id":"39198fd61e6e48d9bfce84a85833cdce","type":"GENE","name":"ZNF567","canonical_id":"hgnc:HGNC:28696","description":"zinc finger protein 567","metadata":{"aliases":["MGC45586"]}},{"id":"14b15d44dd9a4f8f9278821efb961016","type":"GENE","name":"ZNF567-DT","canonical_id":"hgnc:HGNC:51281","description":"ZNF567 divergent transcript","metadata":{"aliases":["LINC01534"]}},{"id":"910f5fc3fc96477b8a10f63e156e342e","type":"GENE","name":"ZNF568","canonical_id":"hgnc:HGNC:25392","description":"zinc finger protein 568","metadata":{"aliases":["PISA","DKFZp686B0797"]}},{"id":"2f4ed5c5be404851956a10b62bb5ed4b","type":"GENE","name":"ZNF569","canonical_id":"hgnc:HGNC:24737","description":"zinc finger protein 569","metadata":{"aliases":["FLJ32053","ZAP1","Zfp74"]}},{"id":"0e17cbf85cad425daa77b6fef907ded9","type":"GENE","name":"ZNF56P","canonical_id":"hgnc:HGNC:13124","description":"zinc finger protein 56, pseudogene","metadata":{"aliases":["ZNF742","ZNF56"]}},{"id":"d82904e3459b451d8d291ff86237189f","type":"GENE","name":"ZNF57","canonical_id":"hgnc:HGNC:13125","description":"zinc finger protein 57","metadata":{"aliases":["ZNF424"]}},{"id":"6cb60f2414c247f2a25c78fa326937ec","type":"GENE","name":"ZNF570","canonical_id":"hgnc:HGNC:26416","description":"zinc finger protein 570","metadata":{"aliases":["FLJ30791"]}},{"id":"ac15f2a1f01b4f3f985462be8c02934f","type":"GENE","name":"ZNF571","canonical_id":"hgnc:HGNC:25000","description":"zinc finger protein 571","metadata":{"aliases":["HSPC059"]}},{"id":"6e6a28eff30a470ebc9f285b02b3e172","type":"GENE","name":"ZNF571-AS1","canonical_id":"hgnc:HGNC:44324","description":"ZNF571 antisense RNA 1","metadata":null},{"id":"7b62c29ea4fa452f94940f4732314e79","type":"GENE","name":"ZNF572","canonical_id":"hgnc:HGNC:26758","description":"zinc finger protein 572","metadata":{"aliases":["FLJ38002"]}},{"id":"3fd357fcfde8457da517680543bef277","type":"GENE","name":"ZNF573","canonical_id":"hgnc:HGNC:26420","description":"zinc finger protein 573","metadata":{"aliases":["FLJ30921"]}},{"id":"c0fb9df3476543bfbc8ea02150c4db6a","type":"GENE","name":"ZNF574","canonical_id":"hgnc:HGNC:26166","description":"zinc finger protein 574","metadata":{"aliases":["FLJ22059"]}},{"id":"9cfdc75810c34c818f38ae1b12f0a50c","type":"GENE","name":"ZNF575","canonical_id":"hgnc:HGNC:27606","description":"zinc finger protein 575","metadata":{"aliases":["FLJ32567"]}},{"id":"dce22525efed46b5a2ddab686fad266c","type":"GENE","name":"ZNF576","canonical_id":"hgnc:HGNC:28357","description":"zinc finger protein 576","metadata":{"aliases":["MGC2508"]}},{"id":"b72fd9b0a7b4474fa647a9525b460811","type":"GENE","name":"ZNF577","canonical_id":"hgnc:HGNC:28673","description":"zinc finger protein 577","metadata":{"aliases":["MGC4400"]}},{"id":"91ca4211c7884261b669c9065f30b5f6","type":"GENE","name":"ZNF578","canonical_id":"hgnc:HGNC:26449","description":"zinc finger protein 578","metadata":{"aliases":["FLJ31384"]}},{"id":"d0246692eeed4382987db76421eef788","type":"GENE","name":"ZNF579","canonical_id":"hgnc:HGNC:26646","description":"zinc finger protein 579","metadata":{"aliases":["FLJ35453"]}},{"id":"c54c893524224207b33a49ec0e75b3df","type":"GENE","name":"ZNF580","canonical_id":"hgnc:HGNC:29473","description":"zinc finger protein 580","metadata":null},{"id":"f4deebb693fc42b29b1bffb61225cf55","type":"GENE","name":"ZNF581","canonical_id":"hgnc:HGNC:25017","description":"zinc finger protein 581","metadata":{"aliases":["HSPC189","FLJ22550"]}},{"id":"4024911dc5ce40b6bc7af59d80924b8a","type":"GENE","name":"ZNF582","canonical_id":"hgnc:HGNC:26421","description":"zinc finger protein 582","metadata":{"aliases":["FLJ30927"]}},{"id":"fe937e12962a4e3a87c748a504defe4b","type":"GENE","name":"ZNF582-DT","canonical_id":"hgnc:HGNC:25213","description":"ZNF582 divergent transcript","metadata":{"aliases":["ZNF582-AS1"]}},{"id":"12ee501f6e2f4bacb962cf14e1892fa9","type":"GENE","name":"ZNF583","canonical_id":"hgnc:HGNC:26427","description":"zinc finger protein 583","metadata":{"aliases":["FLJ31030"]}},{"id":"4dfa2c6bf63a40e5ae956da62551de06","type":"GENE","name":"ZNF584","canonical_id":"hgnc:HGNC:27318","description":"zinc finger protein 584","metadata":{"aliases":["FLJ39899"]}},{"id":"c5f7164015384d3d907384b1f2985a52","type":"GENE","name":"ZNF584-DT","canonical_id":"hgnc:HGNC:56027","description":"ZNF584 divergent transcript","metadata":{"aliases":["CTD-2619J13.14"]}},{"id":"b2266412004445b1919dbd836c6b2891","type":"GENE","name":"ZNF585A","canonical_id":"hgnc:HGNC:26305","description":"zinc finger protein 585A","metadata":{"aliases":["FLJ23765","Zfp27"]}},{"id":"6d917512ed8a481580935e7b82f5d3fd","type":"GENE","name":"ZNF585B","canonical_id":"hgnc:HGNC:30948","description":"zinc finger protein 585B","metadata":{"aliases":["FLJ14928","SZFP41","Zfp27"]}},{"id":"ac3a66414cc44f46a5fe3a008bd3e848","type":"GENE","name":"ZNF586","canonical_id":"hgnc:HGNC:25949","description":"zinc finger protein 586","metadata":{"aliases":["FLJ20070"]}},{"id":"798a936aa53d41968bbe0d54481dfdba","type":"GENE","name":"ZNF587","canonical_id":"hgnc:HGNC:30955","description":"zinc finger protein 587","metadata":{"aliases":["ZF6","FLJ14710","UBF-fl","FLJ20813"]}},{"id":"7f45dec77c33480ea14b2ef5b3101205","type":"GENE","name":"ZNF587B","canonical_id":"hgnc:HGNC:37142","description":"zinc finger protein 587B","metadata":null},{"id":"8c1cef886825442c883931926ccbf73a","type":"GENE","name":"ZNF587P1","canonical_id":"hgnc:HGNC:42438","description":"zinc finger protein 587 pseudogene 1","metadata":null},{"id":"03a85218c40c49929c3775d59133f05d","type":"GENE","name":"ZNF589","canonical_id":"hgnc:HGNC:16747","description":"zinc finger protein 589","metadata":{"aliases":["SZF1"]}},{"id":"1e40f24f6d0a4a3db5ee182537fb5437","type":"GENE","name":"ZNF592","canonical_id":"hgnc:HGNC:28986","description":"zinc finger protein 592","metadata":{"aliases":["KIAA0211","CAMOS","SCAR5"]}},{"id":"a01c12986b134cddb96f6dc3c7f965dc","type":"GENE","name":"ZNF593","canonical_id":"hgnc:HGNC:30943","description":"zinc finger protein 593","metadata":{"aliases":["ZT86"]}},{"id":"7ec36be1828f454eb352822ebf8175de","type":"GENE","name":"ZNF593OS","canonical_id":"hgnc:HGNC:41278","description":"ZNF593 opposite strand","metadata":{"aliases":["ZNF593-AS"]}},{"id":"131ed30ed35e4ae5a9b466301a6479d4","type":"GENE","name":"ZNF594","canonical_id":"hgnc:HGNC:29392","description":"zinc finger protein 594","metadata":{"aliases":["KIAA1871"]}},{"id":"432c5c43d1c04009a609cf21e0b3af75","type":"GENE","name":"ZNF594-DT","canonical_id":"hgnc:HGNC:55347","description":"ZNF594 divergent transcript","metadata":null},{"id":"f57e6befd45c456d9d60fd95bde88fe2","type":"GENE","name":"ZNF595","canonical_id":"hgnc:HGNC:27196","description":"zinc finger protein 595","metadata":{"aliases":["FLJ31740"]}},{"id":"a907326cdfe54496b796184bf0012f78","type":"GENE","name":"ZNF596","canonical_id":"hgnc:HGNC:27268","description":"zinc finger protein 596","metadata":null},{"id":"9adc225eae844cacb66d7fc8dece9ae9","type":"GENE","name":"ZNF597","canonical_id":"hgnc:HGNC:26573","description":"zinc finger protein 597","metadata":{"aliases":["FLJ33071","HIT-4"]}},{"id":"207dec417d48402fa349b689e7ae2292","type":"GENE","name":"ZNF598","canonical_id":"hgnc:HGNC:28079","description":"zinc finger protein 598, E3 ubiquitin ligase","metadata":{"aliases":["FLJ00086","HEL2"]}},{"id":"fb2c0921feb6421fbf6c12e7da3ab5cb","type":"GENE","name":"ZNF599","canonical_id":"hgnc:HGNC:26408","description":"zinc finger protein 599","metadata":{"aliases":["FLJ30663"]}},{"id":"100a997d907044f18d196a6ad0bf737d","type":"GENE","name":"ZNF600","canonical_id":"hgnc:HGNC:30951","description":"zinc finger protein 600","metadata":{"aliases":["KR-ZNF1","DKFZp686F06123"]}},{"id":"f789dbbc314742298024d0fe990ec05e","type":"GENE","name":"ZNF601P","canonical_id":"hgnc:HGNC:29407","description":"zinc finger protein 601, pseudogene","metadata":{"aliases":["dJ313I6.8","D6S2711","PRD51p"]}},{"id":"469ff5f3a981413f996179b7190703e8","type":"GENE","name":"ZNF602P","canonical_id":"hgnc:HGNC:23313","description":"zinc finger protein 602, pseudogene","metadata":{"aliases":["dJ265C24.5"]}},{"id":"a2009a78643240c3ab0b1f2d4fd6227f","type":"GENE","name":"ZNF603P","canonical_id":"hgnc:HGNC:23322","description":"zinc finger protein 603, pseudogene","metadata":{"aliases":["p373c6.7"]}},{"id":"0418ea5d8b434d52a0fca38170f71dcd","type":"GENE","name":"ZNF605","canonical_id":"hgnc:HGNC:28068","description":"zinc finger protein 605","metadata":null},{"id":"26066eab718840fbb2ea1d2a69166f72","type":"GENE","name":"ZNF606","canonical_id":"hgnc:HGNC:25879","description":"zinc finger protein 606","metadata":{"aliases":["FLJ14260","KIAA1852","ZNF328"]}},{"id":"0f75b76c67ba46ef8375610b9b8611da","type":"GENE","name":"ZNF606-AS1","canonical_id":"hgnc:HGNC:44322","description":"ZNF606 antisense RNA 1","metadata":null},{"id":"eb55b3dcc09a4614a5450426c98340f7","type":"GENE","name":"ZNF607","canonical_id":"hgnc:HGNC:28192","description":"zinc finger protein 607","metadata":{"aliases":["MGC13071","FLJ14802"]}},{"id":"f9951742b53d46ab99222ba6e15b4fb7","type":"GENE","name":"ZNF608","canonical_id":"hgnc:HGNC:29238","description":"zinc finger protein 608","metadata":{"aliases":["KIAA1281","DKFZp434M098","NY-REN-36"]}},{"id":"96a3d88b48524b2082a7a4b91752645c","type":"GENE","name":"ZNF608-AS1","canonical_id":"hgnc:HGNC:59124","description":"ZNF608 antisense RNA 1","metadata":null},{"id":"5c7c4630ee8f4316a06ec0b3aa9dccfb","type":"GENE","name":"ZNF609","canonical_id":"hgnc:HGNC:29003","description":"zinc finger protein 609","metadata":{"aliases":["KIAA0295"]}},{"id":"120b58ac4894471bb3103b4bb1ecebce","type":"GENE","name":"ZNF610","canonical_id":"hgnc:HGNC:26687","description":"zinc finger protein 610","metadata":{"aliases":["FLJ36040"]}},{"id":"99608d9571f74b8485b0248db4b6d5cb","type":"GENE","name":"ZNF611","canonical_id":"hgnc:HGNC:28766","description":"zinc finger protein 611","metadata":{"aliases":["MGC5384"]}},{"id":"6aacb592873c4ce09c520e15500a283a","type":"GENE","name":"ZNF613","canonical_id":"hgnc:HGNC:25827","description":"zinc finger protein 613","metadata":{"aliases":["FLJ13590"]}},{"id":"3a970200a3774000ab4e8407c00aee9f","type":"GENE","name":"ZNF614","canonical_id":"hgnc:HGNC:24722","description":"zinc finger protein 614","metadata":{"aliases":["FLJ21941"]}},{"id":"d309253c898d4c7fb1c9850835d6ef5c","type":"GENE","name":"ZNF615","canonical_id":"hgnc:HGNC:24740","description":"zinc finger protein 615","metadata":{"aliases":["FLJ33710"]}},{"id":"1faf84215506471bb069683d4ecc0522","type":"GENE","name":"ZNF616","canonical_id":"hgnc:HGNC:28062","description":"zinc finger protein 616","metadata":{"aliases":["MGC45556"]}},{"id":"e8d8150223e646c8a13ab950e08d8f86","type":"GENE","name":"ZNF618","canonical_id":"hgnc:HGNC:29416","description":"zinc finger protein 618","metadata":{"aliases":["KIAA1952","NEDD10"]}},{"id":"653041626e4045ab8c38a45cb4f28f6e","type":"GENE","name":"ZNF619","canonical_id":"hgnc:HGNC:26910","description":"zinc finger protein 619","metadata":{"aliases":["FLJ90764"]}},{"id":"096db95bbc0943aca3d76c510da64687","type":"GENE","name":"ZNF619P1","canonical_id":"hgnc:HGNC:50784","description":"zinc finger protein 619 pseudogene 1","metadata":null},{"id":"c921e41e94194b898f94b6921b27355a","type":"GENE","name":"ZNF620","canonical_id":"hgnc:HGNC:28742","description":"zinc finger protein 620","metadata":{"aliases":["MGC50836"]}},{"id":"635db11328de4d83b3e2fc14a44be350","type":"GENE","name":"ZNF621","canonical_id":"hgnc:HGNC:24787","description":"zinc finger protein 621","metadata":{"aliases":["FLJ45246"]}},{"id":"a03e15ae872942aba7aa30dacee808ba","type":"GENE","name":"ZNF622","canonical_id":"hgnc:HGNC:30958","description":"zinc finger protein 622","metadata":{"aliases":["MGC2485","MGC17552","ZPR9"]}},{"id":"06faa6cd7a92488893a0ce25c110978b","type":"GENE","name":"ZNF622P1","canonical_id":"hgnc:HGNC:55158","description":"ZNF622 pseudogene 1","metadata":null},{"id":"2461489085964f1991187d7fdbaa4afd","type":"GENE","name":"ZNF623","canonical_id":"hgnc:HGNC:29084","description":"zinc finger protein 623","metadata":{"aliases":["KIAA0628"]}},{"id":"8c957ab3b40b47a5a540938bbc26b036","type":"GENE","name":"ZNF624","canonical_id":"hgnc:HGNC:29254","description":"zinc finger protein 624","metadata":{"aliases":["KIAA1349"]}},{"id":"10e4b3e846644825a154653eadf4a638","type":"GENE","name":"ZNF625","canonical_id":"hgnc:HGNC:30571","description":"zinc finger protein 625","metadata":null},{"id":"15496baa740f4cb780b6ac64622a5cd5","type":"GENE","name":"ZNF625-ZNF20","canonical_id":"hgnc:HGNC:48368","description":"ZNF625-ZNF20 readthrough (NMD candidate)","metadata":null},{"id":"572b3a3c600e46fca1d8184c14b40ac4","type":"GENE","name":"ZNF626","canonical_id":"hgnc:HGNC:30461","description":"zinc finger protein 626","metadata":null},{"id":"35007a421d014739b5febc5912d472f7","type":"GENE","name":"ZNF627","canonical_id":"hgnc:HGNC:30570","description":"zinc finger protein 627","metadata":{"aliases":["FLJ90365"]}},{"id":"77922bdc546e4f7793ffaa1d7ff76265","type":"GENE","name":"ZNF628","canonical_id":"hgnc:HGNC:28054","description":"zinc finger protein 628","metadata":{"aliases":["ZEC","Zfp628"]}},{"id":"e0681d6dc82d4c4c9ed312614140f654","type":"GENE","name":"ZNF628-DT","canonical_id":"hgnc:HGNC:55271","description":"ZNF628 divergent transcript","metadata":null},{"id":"14149796eb2541cca4387ed1fdfb61b5","type":"GENE","name":"ZNF629","canonical_id":"hgnc:HGNC:29008","description":"zinc finger protein 629","metadata":{"aliases":["KIAA0326","ZNF65"]}},{"id":"cbf24ee93cc84aa5b8acb28959ab2e30","type":"GENE","name":"ZNF630","canonical_id":"hgnc:HGNC:28855","description":"zinc finger protein 630","metadata":{"aliases":["BC037316","dJ54B20.2","FLJ20573","MGC138344"]}},{"id":"a285f805286d49e99855793c5817aa65","type":"GENE","name":"ZNF630-AS1","canonical_id":"hgnc:HGNC:41215","description":"ZNF630 antisense RNA 1","metadata":null},{"id":"1aa6e063444d413f84cf9520df217518","type":"GENE","name":"ZNF638","canonical_id":"hgnc:HGNC:17894","description":"zinc finger protein 638","metadata":{"aliases":["NP220","MGC26130","Zfp638","ZFML"]}},{"id":"0d504299afe345dd9b1144842bccdda2","type":"GENE","name":"ZNF639","canonical_id":"hgnc:HGNC:30950","description":"zinc finger protein 639","metadata":{"aliases":["ANC-2H01","ZASC1"]}},{"id":"e609eb3e1438433c9c73218b66815834","type":"GENE","name":"ZNF641","canonical_id":"hgnc:HGNC:31834","description":"zinc finger protein 641","metadata":{"aliases":["FLJ31295"]}},{"id":"9521d68ad7824380b0b364401bf4fbee","type":"GENE","name":"ZNF644","canonical_id":"hgnc:HGNC:29222","description":"zinc finger protein 644","metadata":{"aliases":["KIAA1221","BM-005","MGC60165","MGC70410"]}},{"id":"2f01b78a29f24fd08b74b2e8a5a081e6","type":"GENE","name":"ZNF646","canonical_id":"hgnc:HGNC:29004","description":"zinc finger protein 646","metadata":{"aliases":["KIAA0296"]}},{"id":"2d78ebc6006f459f993f9ef72b658fe2","type":"GENE","name":"ZNF646P1","canonical_id":"hgnc:HGNC:39749","description":"zinc finger protein 646 pseudogene 1","metadata":null},{"id":"b9e6a27d7cb540839e34234306b0a3b2","type":"GENE","name":"ZNF648","canonical_id":"hgnc:HGNC:18190","description":"zinc finger protein 648","metadata":{"aliases":["FLJ46813"]}},{"id":"dbf174e22b654be5af36f69ba2c3aafd","type":"GENE","name":"ZNF649","canonical_id":"hgnc:HGNC:25741","description":"zinc finger protein 649","metadata":{"aliases":["FLJ12644"]}},{"id":"c7b8c7cfcf404d8da21699d5d57e8ee9","type":"GENE","name":"ZNF649-AS1","canonical_id":"hgnc:HGNC:51285","description":"ZNF649 antisense RNA 1","metadata":null},{"id":"4d32597ae1fa4078bb79278f3bf28c98","type":"GENE","name":"ZNF652","canonical_id":"hgnc:HGNC:29147","description":null,"metadata":null},{"id":"9a7af9e86070414faf59168c0d434b42","type":"GENE","name":"ZNF652-AS1","canonical_id":"hgnc:HGNC:55582","description":"ZNF652 antisense RNA 1","metadata":null},{"id":"29dea21f3a4a4a3cb88c629353407280","type":"GENE","name":"ZNF652P1","canonical_id":"hgnc:HGNC:35166","description":"zinc finger protein 652 pseudogene 1","metadata":{"aliases":["ZNF652P"]}},{"id":"0e018e74de3c447ea31a97ae6b612611","type":"GENE","name":"ZNF653","canonical_id":"hgnc:HGNC:25196","description":"zinc finger protein 653","metadata":{"aliases":["Zip67"]}},{"id":"82c663cfaad94785823d7e0f403460a4","type":"GENE","name":"ZNF654","canonical_id":"hgnc:HGNC:25612","description":"zinc finger protein 654","metadata":{"aliases":["FLJ10997","FLJ21142"]}},{"id":"984b7729dac94e8eb027842ba26e4300","type":"GENE","name":"ZNF655","canonical_id":"hgnc:HGNC:30899","description":"zinc finger protein 655","metadata":{"aliases":["VIK-1","VIK"]}},{"id":"64df078e3d9c498a96e84d7d9300090d","type":"GENE","name":"ZNF658","canonical_id":"hgnc:HGNC:25226","description":"zinc finger protein 658","metadata":{"aliases":["MGC35232","DKFZp572C163","FLJ32813"]}},{"id":"84beb454dfb44069b8af960f606e2e56","type":"GENE","name":"ZNF658B","canonical_id":"hgnc:HGNC:32033","description":"zinc finger protein 658B (pseudogene)","metadata":null},{"id":"6eb1a90f1e8c44d4a5ee4976083cd510","type":"GENE","name":"ZNF66","canonical_id":"hgnc:HGNC:13135","description":"zinc finger protein 66","metadata":{"aliases":["FLJ16537","ZNF66P"]}},{"id":"32f5ac730192415fb1049c8e7814cd4a","type":"GENE","name":"ZNF660","canonical_id":"hgnc:HGNC:26720","description":"zinc finger protein 660","metadata":{"aliases":["FLJ36870"]}},{"id":"fe19db28bbac4f408b7c75eacb7b95cc","type":"GENE","name":"ZNF662","canonical_id":"hgnc:HGNC:31930","description":"zinc finger protein 662","metadata":{"aliases":["FLJ45880"]}},{"id":"d42b481c096744aab3942bf5827d2429","type":"GENE","name":"ZNF663P","canonical_id":"hgnc:HGNC:25342","description":"zinc finger protein 663, pseudogene","metadata":{"aliases":["DKFZp547G0215","ZNF663"]}},{"id":"c2c89068153144f995ed29152caf0d62","type":"GENE","name":"ZNF664","canonical_id":"hgnc:HGNC:25406","description":"zinc finger protein 664","metadata":{"aliases":["ZFOC1","DKFZp761B128","ZNF176"]}},{"id":"125d332d9730430996b47beae4eb5f52","type":"GENE","name":"ZNF665","canonical_id":"hgnc:HGNC:25885","description":"zinc finger protein 665","metadata":{"aliases":["FLJ14345","ZFP160L"]}},{"id":"4c62d1e80bd543ef84e21c2bb621d3a1","type":"GENE","name":"ZNF667","canonical_id":"hgnc:HGNC:28854","description":"zinc finger protein 667","metadata":{"aliases":["FLJ14011"]}},{"id":"d9d0750144d049b8a3da99d262b31266","type":"GENE","name":"ZNF667-AS1","canonical_id":"hgnc:HGNC:44321","description":"ZNF667 antisense RNA 1","metadata":{"aliases":["MORT"]}},{"id":"97853707b74645c2824bf959bb8b607f","type":"GENE","name":"ZNF668","canonical_id":"hgnc:HGNC:25821","description":"zinc finger protein 668","metadata":{"aliases":["FLJ13479"]}},{"id":"93988afa2b724a0db57fc09b090c8139","type":"GENE","name":"ZNF669","canonical_id":"hgnc:HGNC:25736","description":"zinc finger protein 669","metadata":{"aliases":["FLJ12606"]}},{"id":"1ffa39f37ef94818b4b547a326d57f37","type":"GENE","name":"ZNF670","canonical_id":"hgnc:HGNC:28167","description":"zinc finger protein 670","metadata":{"aliases":["MGC12466"]}},{"id":"548bf87d52854585824705167cefbde9","type":"GENE","name":"ZNF670-ZNF695","canonical_id":"hgnc:HGNC:49200","description":"ZNF670-ZNF695 readthrough (NMD candidate)","metadata":null},{"id":"f112f8cc55324748a72f81487a3ba7fa","type":"GENE","name":"ZNF671","canonical_id":"hgnc:HGNC:26279","description":"zinc finger protein 671","metadata":{"aliases":["FLJ23506"]}},{"id":"d0a36faae4d94279a352637be1f48e95","type":"GENE","name":"ZNF672","canonical_id":"hgnc:HGNC:26179","description":"zinc finger protein 672","metadata":{"aliases":["FLJ22301"]}},{"id":"1428e18018c24897991aa57d4c0d2c9b","type":"GENE","name":"ZNF674","canonical_id":"hgnc:HGNC:17625","description":"zinc finger protein 674","metadata":{"aliases":["ZNF673B","MRX92"]}},{"id":"e88508e691b84d9294a2bda243dc4672","type":"GENE","name":"ZNF674-AS1","canonical_id":"hgnc:HGNC:44266","description":"ZNF674 antisense RNA 1","metadata":null},{"id":"c2f7445191a54d0fa2ab1003d4986aef","type":"GENE","name":"ZNF675","canonical_id":"hgnc:HGNC:30768","description":"zinc finger protein 675","metadata":{"aliases":["TIZ","TBZF"]}},{"id":"7a974cc6a1e44df1a24521497115836f","type":"GENE","name":"ZNF676","canonical_id":"hgnc:HGNC:20429","description":"zinc finger protein 676","metadata":null},{"id":"1a6ee5d7a2e1434a8d45f993faee93a2","type":"GENE","name":"ZNF677","canonical_id":"hgnc:HGNC:28730","description":"zinc finger protein 677","metadata":{"aliases":["MGC48625"]}},{"id":"f20ee386865b458ba5af55013723a5c6","type":"GENE","name":"ZNF678","canonical_id":"hgnc:HGNC:28652","description":"zinc finger protein 678","metadata":{"aliases":["MGC42493"]}},{"id":"ebffdfdeb3d04f80bfd264c3c50c2ecb","type":"GENE","name":"ZNF679","canonical_id":"hgnc:HGNC:28650","description":"zinc finger protein 679","metadata":{"aliases":["MGC42415"]}},{"id":"26b3d717b2ed486a94ffde5722c7a9bf","type":"GENE","name":"ZNF680","canonical_id":"hgnc:HGNC:26897","description":"zinc finger protein 680","metadata":{"aliases":["FLJ90430"]}},{"id":"d01357ad482046d28d056890d6a4c7c4","type":"GENE","name":"ZNF680P1","canonical_id":"hgnc:HGNC:50379","description":"ZNF680 pseudogene 1","metadata":null},{"id":"e03ea73ea62640ee8979bb5ad68b553d","type":"GENE","name":"ZNF681","canonical_id":"hgnc:HGNC:26457","description":"zinc finger protein 681","metadata":{"aliases":["FLJ31526"]}},{"id":"4efc829772ee41c99ae4c30574a56a78","type":"GENE","name":"ZNF682","canonical_id":"hgnc:HGNC:28857","description":"zinc finger protein 682","metadata":{"aliases":["BC39498_3"]}},{"id":"a764f710cb814b90ad1f7903c8f203cb","type":"GENE","name":"ZNF683","canonical_id":"hgnc:HGNC:28495","description":"zinc finger protein 683","metadata":{"aliases":["MGC33414","Hobit"]}},{"id":"dc3e63fc94ab4f31aa96a4614a4ce268","type":"GENE","name":"ZNF684","canonical_id":"hgnc:HGNC:28418","description":"zinc finger protein 684","metadata":{"aliases":["MGC27466"]}},{"id":"b6f31bbf90f64a52ac357cc7b24cc2a3","type":"GENE","name":"ZNF687","canonical_id":"hgnc:HGNC:29277","description":"zinc finger protein 687","metadata":{"aliases":["KIAA1441"]}},{"id":"f1d16b745688424b9ecde3d5788f52af","type":"GENE","name":"ZNF687-AS1","canonical_id":"hgnc:HGNC:54048","description":"ZNF687 antisense RNA 1","metadata":null},{"id":"5627bcdbb35e4b308ed3624539840262","type":"GENE","name":"ZNF688","canonical_id":"hgnc:HGNC:30489","description":"zinc finger protein 688","metadata":null},{"id":"8c4d7642149947af93651a6423a3728b","type":"GENE","name":"ZNF689","canonical_id":"hgnc:HGNC:25173","description":"zinc finger protein 689","metadata":{"aliases":["FLJ90415","TIPUH1"]}},{"id":"24a4e6da05c948558a70cadd8286cb96","type":"GENE","name":"ZNF69","canonical_id":"hgnc:HGNC:13138","description":"zinc finger protein 69","metadata":{"aliases":["Cos5"]}},{"id":"fb8fed43b673488aac9dd6b0bf78970e","type":"GENE","name":"ZNF691","canonical_id":"hgnc:HGNC:28028","description":"zinc finger protein 691","metadata":{"aliases":["Zfp691"]}},{"id":"8fa94da94281452c89326a4e1539ca58","type":"GENE","name":"ZNF691-DT","canonical_id":"hgnc:HGNC:55800","description":"ZNF691 divergent transcript","metadata":null},{"id":"165598d8fec94c6dae7207a220ffee05","type":"GENE","name":"ZNF692","canonical_id":"hgnc:HGNC:26049","description":"zinc finger protein 692","metadata":{"aliases":["FLJ20531","Zfp692","AREBP"]}},{"id":"eb0fae5f3b5442d8bf6d3abbe4034328","type":"GENE","name":"ZNF692-DT","canonical_id":"hgnc:HGNC:55817","description":"ZNF692 divergent transcript","metadata":null},{"id":"de6df781584c464ca9f2748340200aa5","type":"GENE","name":"ZNF695","canonical_id":"hgnc:HGNC:30954","description":"zinc finger protein 695","metadata":{"aliases":["SBZF3"]}},{"id":"0c3e7395d0d149b98f56dd8f8a002450","type":"GENE","name":"ZNF696","canonical_id":"hgnc:HGNC:25872","description":"zinc finger protein 696","metadata":{"aliases":["FLJ14129"]}},{"id":"a82047262bf44f8c8533bed252f26368","type":"GENE","name":"ZNF697","canonical_id":"hgnc:HGNC:32034","description":"zinc finger protein 697","metadata":{"aliases":["MGC45731"]}},{"id":"b40f9b9bf848413289994096245bd03d","type":"GENE","name":"ZNF699","canonical_id":"hgnc:HGNC:24750","description":"zinc finger protein 699","metadata":{"aliases":["FLJ38144"]}},{"id":"1247334e59814c00975e70f2eff11b88","type":"GENE","name":"ZNF7","canonical_id":"hgnc:HGNC:13139","description":"zinc finger protein 7","metadata":{"aliases":["KOX4","HF.16"]}},{"id":"bd8718eb98fb47b2b17123498fe8a38e","type":"GENE","name":"ZNF70","canonical_id":"hgnc:HGNC:13140","description":"zinc finger protein 70","metadata":{"aliases":["Cos17","MGC48959"]}},{"id":"1dfcf5483f324c87b7c4823fc9ff0168","type":"GENE","name":"ZNF700","canonical_id":"hgnc:HGNC:25292","description":"zinc finger protein 700","metadata":{"aliases":["DKFZp434I1610"]}},{"id":"a75b57d244ca4bf68bc3688be75f1b39","type":"GENE","name":"ZNF701","canonical_id":"hgnc:HGNC:25597","description":"zinc finger protein 701","metadata":{"aliases":["FLJ10891"]}},{"id":"2f0e378490ed4ca49184ebae47d3124a","type":"GENE","name":"ZNF702P","canonical_id":"hgnc:HGNC:25775","description":"zinc finger protein 702, pseudogene","metadata":{"aliases":["FLJ12985","ZNF702"]}},{"id":"ec233fc8891544a682b87fe006bb378d","type":"GENE","name":"ZNF703","canonical_id":"hgnc:HGNC:25883","description":"zinc finger protein 703","metadata":{"aliases":["FLJ14299","ZNF503L","NLZ1","Zpo1","ZEPPO1"]}},{"id":"fac571c3b2e1488d873de561f1fde1c6","type":"GENE","name":"ZNF704","canonical_id":"hgnc:HGNC:32291","description":"zinc finger protein 704","metadata":{"aliases":["FLJ16218","Gig1"]}},{"id":"9a442b990d32426db2990f33fcee642c","type":"GENE","name":"ZNF705A","canonical_id":"hgnc:HGNC:32281","description":"zinc finger protein 705A","metadata":{"aliases":["FLJ16353"]}},{"id":"7d11113ebbdd46f6979eb1dcaafa895e","type":"GENE","name":"ZNF705B","canonical_id":"hgnc:HGNC:32284","description":"zinc finger protein 705B","metadata":null},{"id":"ea9311c597cf415f99b9c923d15bd455","type":"GENE","name":"ZNF705CP","canonical_id":"hgnc:HGNC:32283","description":"zinc finger protein 705C, pseudogene","metadata":{"aliases":["ZNF705C"]}},{"id":"5b46a0ad09124aeaa12f63cce135fac0","type":"GENE","name":"ZNF705D","canonical_id":"hgnc:HGNC:33202","description":"zinc finger protein 705D","metadata":null},{"id":"c39089186d194f86a64daa41379fa646","type":"GENE","name":"ZNF705EP","canonical_id":"hgnc:HGNC:33203","description":"zinc finger protein 705E, pseudogene","metadata":{"aliases":["ZNF705E"]}},{"id":"f7f5af0f9bfb413c915dbcaacc8a6c05","type":"GENE","name":"ZNF705G","canonical_id":"hgnc:HGNC:37134","description":"zinc finger protein 705G","metadata":null},{"id":"1c8efa934a2d4252b0132511dbf9f1bd","type":"GENE","name":"ZNF706","canonical_id":"hgnc:HGNC:24992","description":"zinc finger protein 706","metadata":{"aliases":["HSPC038"]}},{"id":"923044031fd34c55addab7722fe42323","type":"GENE","name":"ZNF707","canonical_id":"hgnc:HGNC:27815","description":"zinc finger protein 707","metadata":null},{"id":"458148d4fd92453c824810bf412aa7fa","type":"GENE","name":"ZNF708","canonical_id":"hgnc:HGNC:12945","description":"zinc finger protein 708","metadata":{"aliases":["KOX8","ZNF15","ZNF15L1"]}},{"id":"66ac4dbb9b83446ba9acf2ac4a98169a","type":"GENE","name":"ZNF709","canonical_id":"hgnc:HGNC:20629","description":"zinc finger protein 709","metadata":{"aliases":["FLJ38281"]}},{"id":"0b0c9b8ebd454956910ae120eeb62733","type":"GENE","name":"ZNF70P1","canonical_id":"hgnc:HGNC:13846","description":"zinc finger protein 70 pseudogene 1","metadata":{"aliases":["dJ1033B10.7","bCX269C15.3","ZNF314P"]}},{"id":"24d1621e0cfb433fae7fc6c7ce6232d9","type":"GENE","name":"ZNF71","canonical_id":"hgnc:HGNC:13141","description":"zinc finger protein 71","metadata":{"aliases":["Cos26","EZFIT"]}},{"id":"2dde8dadeb0f4226b736ecbbb9ca9d8c","type":"GENE","name":"ZNF710","canonical_id":"hgnc:HGNC:25352","description":"zinc finger protein 710","metadata":{"aliases":["DKFZp547K1113","FLJ37393","FLJ00306"]}},{"id":"818e50ef8bfe49f59cde5f799f525dac","type":"GENE","name":"ZNF710-AS1","canonical_id":"hgnc:HGNC:53141","description":"ZNF710 antisense RNA 1","metadata":{"aliases":["ENST00000558334"]}},{"id":"37f17a5810da49f1b66cb3a42cbbddd8","type":"GENE","name":"ZNF711","canonical_id":"hgnc:HGNC:13128","description":"ZFX family zinc finger ZNF711","metadata":{"aliases":["CMPX1","ZNF4","ZNF5","dJ75N13.1","Zfp711","MRX97","ZNF6","MRX65"]}},{"id":"ad4d04de5e4a47608e69284d19ae33b5","type":"GENE","name":"ZNF713","canonical_id":"hgnc:HGNC:22043","description":"zinc finger protein 713","metadata":{"aliases":["FLJ39963"]}},{"id":"57f4f688c40448d3921512494b5cc4a3","type":"GENE","name":"ZNF714","canonical_id":"hgnc:HGNC:27124","description":"zinc finger protein 714","metadata":null},{"id":"4f78af5ceaf840a68b6768d5a0e4c3bb","type":"GENE","name":"ZNF716","canonical_id":"hgnc:HGNC:32458","description":"zinc finger protein 716","metadata":{"aliases":["FLJ46189"]}},{"id":"a30fdda92a50404ab7671c36db6815e4","type":"GENE","name":"ZNF717","canonical_id":"hgnc:HGNC:29448","description":"zinc finger protein 717","metadata":{"aliases":["X17","ZNF838"]}},{"id":"d740e16a0b04476188dc6b25fffa36de","type":"GENE","name":"ZNF718","canonical_id":"hgnc:HGNC:26889","description":"zinc finger protein 718","metadata":{"aliases":["FLJ90036"]}},{"id":"472825403f0044ef8f352e175dc7d6f7","type":"GENE","name":"ZNF721","canonical_id":"hgnc:HGNC:29425","description":"zinc finger protein 721","metadata":{"aliases":["KIAA1982"]}},{"id":"180a6bfedb594659a3b14cfccf3dd78d","type":"GENE","name":"ZNF722","canonical_id":"hgnc:HGNC:22571","description":"zinc finger protein 722","metadata":{"aliases":["ZNF722P"]}},{"id":"099dab0ac23040acb87b157ee0d90a6d","type":"GENE","name":"ZNF723","canonical_id":"hgnc:HGNC:32286","description":"zinc finger protein 723","metadata":{"aliases":["ZNF723P"]}},{"id":"8a6460e1d06f4f9a9434fe2e2f0ea283","type":"GENE","name":"ZNF724","canonical_id":"hgnc:HGNC:32460","description":"zinc finger protein 724","metadata":{"aliases":["ZNF724P"]}},{"id":"892457da70c74bd28745d02fbd3aeec6","type":"GENE","name":"ZNF725P","canonical_id":"hgnc:HGNC:32461","description":"zinc finger protein 725, pseudogene","metadata":{"aliases":["ZNF725"]}},{"id":"5d61eca8afdc4162a63b93ff026c40fb","type":"GENE","name":"ZNF726","canonical_id":"hgnc:HGNC:32462","description":"zinc finger protein 726","metadata":{"aliases":["ZNF92P3"]}},{"id":"3b56ad35f1f64e69a288839562fceb96","type":"GENE","name":"ZNF726P1","canonical_id":"hgnc:HGNC:13136","description":"zinc finger protein 726 pseudogene 1","metadata":{"aliases":["ZNF67","ZNF67P"]}},{"id":"9dc2f5624efd4a60bb41713b3f81c297","type":"GENE","name":"ZNF727","canonical_id":"hgnc:HGNC:22785","description":"zinc finger protein 727","metadata":{"aliases":["ZNF727P"]}},{"id":"9eeacb5346dd47258b6473aa29107c0a","type":"GENE","name":"ZNF728","canonical_id":"hgnc:HGNC:32463","description":"zinc finger protein 728","metadata":null},{"id":"0ae3e37d415a4ea2a540558257f8bbbf","type":"GENE","name":"ZNF729","canonical_id":"hgnc:HGNC:32464","description":"zinc finger protein 729","metadata":null},{"id":"4c7f477203de4ae18f6c3d82f42c6e5e","type":"GENE","name":"ZNF72AP","canonical_id":"hgnc:HGNC:54974","description":"zinc finger protein 72A, pseudogene","metadata":{"aliases":["ZNF72","Cos8","hZNF1"]}},{"id":"4cd50339d2784cd188e0b03260a6a69c","type":"GENE","name":"ZNF72BP","canonical_id":"hgnc:HGNC:13142","description":"zinc finger protein 72B, pseudogene","metadata":{"aliases":["ZNF72","ZNF72P"]}},{"id":"bfa35765fbb84aa0a16eb68ec415e355","type":"GENE","name":"ZNF730","canonical_id":"hgnc:HGNC:32470","description":"zinc finger protein 730","metadata":null},{"id":"3260975f6d144e22acf74e2c78ed43b1","type":"GENE","name":"ZNF731P","canonical_id":"hgnc:HGNC:32471","description":"zinc finger protein 731, pseudogene","metadata":{"aliases":["ZNF731"]}},{"id":"904ae862818b480fb73049bd5b52e6e9","type":"GENE","name":"ZNF732","canonical_id":"hgnc:HGNC:37138","description":"zinc finger protein 732","metadata":{"aliases":["FLJ59067"]}},{"id":"c3e4700ba5a1466db63dae4075445b4d","type":"GENE","name":"ZNF733P","canonical_id":"hgnc:HGNC:32473","description":"zinc finger protein 733, pseudogene","metadata":{"aliases":["ZNF733"]}},{"id":"77fb9a638c66449ea285670f34e3b4db","type":"GENE","name":"ZNF734P","canonical_id":"hgnc:HGNC:32465","description":"zinc finger protein 734, pseudogene","metadata":{"aliases":["ZNF734"]}},{"id":"fd103cc7bbe04b1b8c88888b79f5cd0c","type":"GENE","name":"ZNF735","canonical_id":"hgnc:HGNC:32466","description":"zinc finger protein 735","metadata":{"aliases":["ZNF735P"]}},{"id":"f4f5a8de8ad548ff872931ffe50b872e","type":"GENE","name":"ZNF736","canonical_id":"hgnc:HGNC:32467","description":"zinc finger protein 736","metadata":null},{"id":"935bfa8f49dc410692f30be56a821516","type":"GENE","name":"ZNF736P10Y","canonical_id":"hgnc:HGNC:38410","description":"zinc finger protein 736 pseudogene 10, Y-linked","metadata":null},{"id":"df8997ab15e94af199ac9eedf54e4938","type":"GENE","name":"ZNF736P11Y","canonical_id":"hgnc:HGNC:38426","description":"zinc finger protein 736 pseudogene 11, Y-linked","metadata":null},{"id":"b47110d5dabf49e995befebf8340a267","type":"GENE","name":"ZNF736P12Y","canonical_id":"hgnc:HGNC:38431","description":"zinc finger protein 736 pseudogene 12, Y-linked","metadata":null},{"id":"22905341daa7407389661a16e5e3a940","type":"GENE","name":"ZNF736P1Y","canonical_id":"hgnc:HGNC:37726","description":"zinc finger protein 736 pseudogene 1, Y-linked","metadata":{"aliases":["ZNF736P1"]}},{"id":"244bac323cc84b4196af711ac509b4b6","type":"GENE","name":"ZNF736P2Y","canonical_id":"hgnc:HGNC:37727","description":"zinc finger protein 736 pseudogene 2, Y-linked","metadata":{"aliases":["ZNF736P2"]}},{"id":"2209c81625264e2a96ea3a3e13181bd8","type":"GENE","name":"ZNF736P3Y","canonical_id":"hgnc:HGNC:37728","description":"zinc finger protein 736 pseudogene 3, Y-linked","metadata":{"aliases":["ZNF381P","ZNF736P3"]}},{"id":"919e50958ee54312984aff4bd8d4c0ab","type":"GENE","name":"ZNF736P4Y","canonical_id":"hgnc:HGNC:38464","description":"zinc finger protein 736 pseudogene 4, Y-linked","metadata":null},{"id":"e4ba4c964c854a77babb77728eb1b3ea","type":"GENE","name":"ZNF736P5Y","canonical_id":"hgnc:HGNC:38597","description":"zinc finger protein 736 pseudogene 5, Y-linked","metadata":null},{"id":"1e4ce04c889842cb8cd14b21603895c0","type":"GENE","name":"ZNF736P6Y","canonical_id":"hgnc:HGNC:38440","description":"zinc finger protein 736 pseudogene 6, Y-linked","metadata":null},{"id":"efe091343df94a4c8b20b3bd442f6467","type":"GENE","name":"ZNF736P7Y","canonical_id":"hgnc:HGNC:38404","description":"zinc finger protein 736 pseudogene 7, Y-linked","metadata":null},{"id":"4cc5e6eab82b4dba926ddfe58385df63","type":"GENE","name":"ZNF736P8Y","canonical_id":"hgnc:HGNC:38406","description":"zinc finger protein 736 pseudogene 8, Y-linked","metadata":null},{"id":"d9ebd4a7f8d14bd2bb1f401c891e22ec","type":"GENE","name":"ZNF736P9Y","canonical_id":"hgnc:HGNC:38408","description":"zinc finger protein 736 pseudogene 9, Y-linked","metadata":null},{"id":"fd927e039e4949e3b321ae94ce10cdaa","type":"GENE","name":"ZNF737","canonical_id":"hgnc:HGNC:32468","description":"zinc finger protein 737","metadata":{"aliases":["ZNF102"]}},{"id":"56e9e79c768646feaaa973ddbbe14a14","type":"GENE","name":"ZNF738","canonical_id":"hgnc:HGNC:32469","description":"zinc finger protein 738","metadata":null},{"id":"e56b7829bcc84a5fb52d474a9058b1c6","type":"GENE","name":"ZNF73P","canonical_id":"hgnc:HGNC:13143","description":"zinc finger protein 73, pseudogene","metadata":{"aliases":["hZNF2","Cos12","ZNF186","ZNF73"]}},{"id":"2e8dfb148c6e4af7a0cb4a52a952c283","type":"GENE","name":"ZNF74","canonical_id":"hgnc:HGNC:13144","description":"zinc finger protein 74","metadata":{"aliases":["Cos52","Zfp520","ZNF520"]}},{"id":"0dc58bbbe9404a8598080c8572bb4a14","type":"GENE","name":"ZNF740","canonical_id":"hgnc:HGNC:27465","description":"zinc finger protein 740","metadata":{"aliases":["Zfp740"]}},{"id":"2767e4e6652a41bb8c47e1827f89dea5","type":"GENE","name":"ZNF746","canonical_id":"hgnc:HGNC:21948","description":"zinc finger protein 746","metadata":{"aliases":["FLJ31413","PARIS"]}},{"id":"50a11c853ab441f09c1029caf710a72a","type":"GENE","name":"ZNF747","canonical_id":"hgnc:HGNC:28350","description":"zinc finger protein 747","metadata":{"aliases":["MGC2474"]}},{"id":"138f4a695e6e4ed3925454d8cd867643","type":"GENE","name":"ZNF747-DT","canonical_id":"hgnc:HGNC:55668","description":"ZNF747 divergent transcript","metadata":{"aliases":["AC002310.12"]}},{"id":"088bd4bab9044327a3dd1618bc7a53f7","type":"GENE","name":"ZNF749","canonical_id":"hgnc:HGNC:32783","description":"zinc finger protein 749","metadata":{"aliases":["FLJ16360"]}},{"id":"2a942411bb5c439b9326f8cb2fb18ec7","type":"GENE","name":"ZNF750","canonical_id":"hgnc:HGNC:25843","description":null,"metadata":null},{"id":"7d564d74212a409e8a20e41bcf1acd71","type":"GENE","name":"ZNF75A","canonical_id":"hgnc:HGNC:13146","description":"zinc finger protein 75A","metadata":{"aliases":["FLJ31529"]}},{"id":"6c740fb41a6c47f6a1c52778ac6fcb5d","type":"GENE","name":"ZNF75BP","canonical_id":"hgnc:HGNC:13147","description":"zinc finger protein 75B, pseudogene","metadata":{"aliases":["ZNF75B"]}},{"id":"f65eaee862c94dc08abc6efa5f5d2782","type":"GENE","name":"ZNF75CP","canonical_id":"hgnc:HGNC:13148","description":"zinc finger protein 75C, pseudogene","metadata":{"aliases":["ZNF75C"]}},{"id":"1827f0c903e746cb9184545fff59d0ed","type":"GENE","name":"ZNF75D","canonical_id":"hgnc:HGNC:13145","description":"zinc finger protein 75D","metadata":{"aliases":["ZKSCAN24","D8C6","ZSCAN28","ZNF82","ZNF75"]}},{"id":"57506b917d05455995f05ca0672fa64d","type":"GENE","name":"ZNF76","canonical_id":"hgnc:HGNC:13149","description":null,"metadata":null},{"id":"8387963d3e12476a917580e451b9b177","type":"GENE","name":"ZNF761","canonical_id":"hgnc:HGNC:23179","description":"zinc finger protein 761","metadata":{"aliases":["KIAA2033","FLJ16231","FLJ35333"]}},{"id":"54a6f930e5dc454f8de32b44997b85fc","type":"GENE","name":"ZNF763","canonical_id":"hgnc:HGNC:27614","description":"zinc finger protein 763","metadata":{"aliases":["ZNF440L"]}},{"id":"23b2246dd5f24b6180b8a6668950c137","type":"GENE","name":"ZNF764","canonical_id":"hgnc:HGNC:28200","description":"zinc finger protein 764","metadata":{"aliases":["MGC13138"]}},{"id":"4f67a48e8340466c8c85ceafda778502","type":"GENE","name":"ZNF765","canonical_id":"hgnc:HGNC:25092","description":"zinc finger protein 765","metadata":null},{"id":"0ad50542218448fa8acdc1f72f16ac6b","type":"GENE","name":"ZNF766","canonical_id":"hgnc:HGNC:28063","description":"zinc finger protein 766","metadata":null},{"id":"596ea7d69e3a4b46a5144842b7bea987","type":"GENE","name":"ZNF767P","canonical_id":"hgnc:HGNC:21884","description":"zinc finger family member 767, pseudogene","metadata":{"aliases":["FLJ12700","ZNF767"]}},{"id":"3db9e132564141009542a1581b7940a8","type":"GENE","name":"ZNF768","canonical_id":"hgnc:HGNC:26273","description":"zinc finger protein 768","metadata":{"aliases":["FLJ23436"]}},{"id":"bcea513f37ec4183a5b9a1c1b3973fb5","type":"GENE","name":"ZNF77","canonical_id":"hgnc:HGNC:13150","description":"zinc finger protein 77","metadata":{"aliases":["pT1"]}},{"id":"eb9f0af155a54fb1ac49ee576d560ee5","type":"GENE","name":"ZNF770","canonical_id":"hgnc:HGNC:26061","description":"zinc finger protein 770","metadata":{"aliases":["FLJ20582","PRO1914"]}},{"id":"2a888a7c9a8746369fba60842047db88","type":"GENE","name":"ZNF771","canonical_id":"hgnc:HGNC:29653","description":"zinc finger protein 771","metadata":{"aliases":["DSC43"]}},{"id":"5b9924b32b0943aab3fe98831c285271","type":"GENE","name":"ZNF772","canonical_id":"hgnc:HGNC:33106","description":"zinc finger protein 772","metadata":{"aliases":["DKFZp686I1569"]}},{"id":"b0971381fcf54af98ffe18832d181396","type":"GENE","name":"ZNF773","canonical_id":"hgnc:HGNC:30487","description":"zinc finger protein 773","metadata":{"aliases":["MGC4728","ZNF419B"]}},{"id":"6decb3a022484c79847d7717ea18a3c4","type":"GENE","name":"ZNF774","canonical_id":"hgnc:HGNC:33108","description":"zinc finger protein 774","metadata":{"aliases":["MGC75360"]}},{"id":"051fa80d3ab748149273239936b7e9d7","type":"GENE","name":"ZNF775","canonical_id":"hgnc:HGNC:28501","description":"zinc finger protein 775","metadata":{"aliases":["MGC33584"]}},{"id":"a0694e1c85d542ed9f79e7e8274397e1","type":"GENE","name":"ZNF775-AS1","canonical_id":"hgnc:HGNC:41202","description":"ZNF775 antisense RNA 1","metadata":null},{"id":"73bfca46d49a4592ac83492c4ff1c9ab","type":"GENE","name":"ZNF776","canonical_id":"hgnc:HGNC:26765","description":"zinc finger protein 776","metadata":{"aliases":["FLJ38288"]}},{"id":"f5ffbabcea6a4c68bfb16e88f05a6acc","type":"GENE","name":"ZNF777","canonical_id":"hgnc:HGNC:22213","description":"zinc finger protein 777","metadata":{"aliases":["KIAA1285"]}},{"id":"bbcedad9fe4f4596818ddabb5b0882f3","type":"GENE","name":"ZNF778","canonical_id":"hgnc:HGNC:26479","description":"zinc finger protein 778","metadata":{"aliases":["FLJ31875"]}},{"id":"fd353c6b1a744dbfaabb9591c1d37867","type":"GENE","name":"ZNF778-DT","canonical_id":"hgnc:HGNC:56034","description":"ZNF778 divergent transcript","metadata":{"aliases":["RP5-821D11.7"]}},{"id":"d5bf34fbdcac4181ac992fb88fdeabeb","type":"GENE","name":"ZNF780A","canonical_id":"hgnc:HGNC:27603","description":"zinc finger protein 780A","metadata":{"aliases":["ZNF780"]}},{"id":"ac5cce3a53ac45e0a46b3d1e4d1daa7b","type":"GENE","name":"ZNF780B","canonical_id":"hgnc:HGNC:33109","description":"zinc finger protein 780B","metadata":{"aliases":["ZNF779"]}},{"id":"11ad8d08b5574999b3490f4351da5a21","type":"GENE","name":"ZNF781","canonical_id":"hgnc:HGNC:26745","description":"zinc finger protein 781 (pseudogene)","metadata":{"aliases":["FLJ37549"]}},{"id":"289ff37857404ebb82e6ff25aa191764","type":"GENE","name":"ZNF782","canonical_id":"hgnc:HGNC:33110","description":"zinc finger protein 782","metadata":{"aliases":["FLJ16636"]}},{"id":"f6424a8c10c84b6e8de2dcf84339c0b9","type":"GENE","name":"ZNF783","canonical_id":"hgnc:HGNC:27222","description":"zinc finger protein 783","metadata":{"aliases":["DKFZp667J212"]}},{"id":"9b1f8e87e5364737a4b83968392a9ef0","type":"GENE","name":"ZNF784","canonical_id":"hgnc:HGNC:33111","description":"zinc finger protein 784","metadata":{"aliases":["MGC75238"]}},{"id":"945b22c9c633443eb8bb6ed221d63007","type":"GENE","name":"ZNF785","canonical_id":"hgnc:HGNC:26496","description":"zinc finger protein 785","metadata":{"aliases":["FLJ32130"]}},{"id":"0880bb69608c49c3ae0ba077461173bb","type":"GENE","name":"ZNF786","canonical_id":"hgnc:HGNC:21806","description":"zinc finger protein 786","metadata":{"aliases":["DKFZp762I137"]}},{"id":"76a3b473e9cd477b9fc83cc79f902edf","type":"GENE","name":"ZNF787","canonical_id":"hgnc:HGNC:26998","description":"zinc finger protein 787","metadata":null},{"id":"a58ef8f0eb124dbca11adb6f50cab633","type":"GENE","name":"ZNF788P","canonical_id":"hgnc:HGNC:33112","description":"zinc finger family member 788, pseudogene","metadata":{"aliases":["FLJ46419","ZNF788"]}},{"id":"80dfdd5a2df5432fad1980271bc07b82","type":"GENE","name":"ZNF789","canonical_id":"hgnc:HGNC:27801","description":"zinc finger protein 789","metadata":null},{"id":"e21d1374444645c5b7ae66706d09d6a7","type":"GENE","name":"ZNF79","canonical_id":"hgnc:HGNC:13153","description":"zinc finger protein 79","metadata":{"aliases":["pT7"]}},{"id":"452ea916dcdf4e1ab241494e929db592","type":"GENE","name":"ZNF790","canonical_id":"hgnc:HGNC:33114","description":"zinc finger protein 790","metadata":{"aliases":["MGC62100","FLJ20350"]}},{"id":"24d891fef4604e9baf99605d7262151e","type":"GENE","name":"ZNF790-AS1","canonical_id":"hgnc:HGNC:27617","description":"ZNF790 antisense RNA 1","metadata":null},{"id":"cf5ec2d1387d431eb15184a8cc7916e6","type":"GENE","name":"ZNF791","canonical_id":"hgnc:HGNC:26895","description":"zinc finger protein 791","metadata":{"aliases":["FLJ90396"]}},{"id":"2417fafc24364303844a103f4fe5b394","type":"GENE","name":"ZNF792","canonical_id":"hgnc:HGNC:24751","description":"zinc finger protein 792","metadata":{"aliases":["FLJ38451"]}},{"id":"93bd844a09f741e5a93f5a30ab3c4cef","type":"GENE","name":"ZNF793","canonical_id":"hgnc:HGNC:33115","description":"zinc finger protein 793","metadata":null},{"id":"4b32d6dc5ff441debc2e0cbb466998c3","type":"GENE","name":"ZNF793-AS1","canonical_id":"hgnc:HGNC:51303","description":"ZNF793 antisense RNA 1","metadata":null},{"id":"b0cbd71b39ee4b5c986798ece9bb631a","type":"GENE","name":"ZNF799","canonical_id":"hgnc:HGNC:28071","description":"zinc finger protein 799","metadata":{"aliases":["HIT-40","MGC71805","ZNF842"]}},{"id":"a95a18b6bf6047aca32de5617396c11c","type":"GENE","name":"ZNF8","canonical_id":"hgnc:HGNC:13154","description":"zinc finger protein 8","metadata":{"aliases":["HF.18","Zfp128"]}},{"id":"ac77a59e6a21416b9b71856f5e720b4b","type":"GENE","name":"ZNF8-DT","canonical_id":"hgnc:HGNC:55280","description":"ZNF8 divergent transcript","metadata":null},{"id":"608d2dca901e4733a08489aeaba07601","type":"GENE","name":"ZNF8-ERVK3-1","canonical_id":"hgnc:HGNC:56757","description":"ZNF8-ERVK3-1 readthrough (NMD candidate)","metadata":{"aliases":["AC010642.1"]}},{"id":"4756f7854c874ee19dd6b1fb1ff016ea","type":"GENE","name":"ZNF80","canonical_id":"hgnc:HGNC:13155","description":"zinc finger protein 80","metadata":{"aliases":["pT17"]}},{"id":"c45b5de6b95b45d5b372f6b2abd5a2e1","type":"GENE","name":"ZNF800","canonical_id":"hgnc:HGNC:27267","description":"zinc finger protein 800","metadata":null},{"id":"91ad02e8ec7b45bea3d62e1dd5a14545","type":"GENE","name":"ZNF804A","canonical_id":"hgnc:HGNC:21711","description":"zinc finger protein 804A","metadata":{"aliases":["C2orf10"]}},{"id":"fe754112ec5f4dc298d57feedcf35b28","type":"GENE","name":"ZNF804B","canonical_id":"hgnc:HGNC:21958","description":"zinc finger protein 804B","metadata":{"aliases":["FLJ32110"]}},{"id":"6bcee15ec9d64a5e84d900d7b40dc41b","type":"GENE","name":"ZNF805","canonical_id":"hgnc:HGNC:23272","description":"zinc finger protein 805","metadata":null},{"id":"b6024a7abd854e909b20f1565878429c","type":"GENE","name":"ZNF807P","canonical_id":"hgnc:HGNC:33229","description":"zinc finger protein 807, pseudogene","metadata":{"aliases":["ZNF181P1","ZNF807"]}},{"id":"1eb0d244eb2c4475b636afe620bd1106","type":"GENE","name":"ZNF808","canonical_id":"hgnc:HGNC:33230","description":"zinc finger protein 808","metadata":null},{"id":"9d24c287385c4360b542fdcb491e867d","type":"GENE","name":"ZNF81","canonical_id":"hgnc:HGNC:13156","description":"zinc finger protein 81","metadata":{"aliases":["HFZ20","MRX45"]}},{"id":"6f7785e58dbd42118112dea0b336a6f7","type":"GENE","name":"ZNF812P","canonical_id":"hgnc:HGNC:33242","description":"zinc finger protein 812, pseudogene","metadata":{"aliases":["ZNF812"]}},{"id":"841d33f1733e473e8e2d9738b503ade2","type":"GENE","name":"ZNF813","canonical_id":"hgnc:HGNC:33257","description":"zinc finger protein 813","metadata":{"aliases":["FLJ16542"]}},{"id":"03225a2ee5ab4ce287572c50fbc451aa","type":"GENE","name":"ZNF814","canonical_id":"hgnc:HGNC:33258","description":"zinc finger protein 814","metadata":null},{"id":"37540878b100405698bffb2772985279","type":"GENE","name":"ZNF815P","canonical_id":"hgnc:HGNC:22029","description":"zinc finger protein 815, pseudogene","metadata":{"aliases":["FLJ38969","ZNF815"]}},{"id":"f6240b1c0ddd460b8aa76ace1d37eed5","type":"GENE","name":"ZNF816","canonical_id":"hgnc:HGNC:26995","description":"zinc finger protein 816","metadata":{"aliases":["ZNF816A"]}},{"id":"2ca417277d8044e4b4acb2c6518431e0","type":"GENE","name":"ZNF816-ZNF321P","canonical_id":"hgnc:HGNC:38879","description":"ZNF816-ZNF321P readthrough","metadata":{"aliases":["ZNF816-ZNF321"]}},{"id":"a2fbc0d972c94469874b1b6db887660b","type":"GENE","name":"ZNF818P","canonical_id":"hgnc:HGNC:33265","description":"zinc finger protein 818, pseudogene","metadata":{"aliases":["FLJ46385","ZNF818"]}},{"id":"c91b0b747fe246549dbca360a4e2dd5e","type":"GENE","name":"ZNF821","canonical_id":"hgnc:HGNC:28043","description":"zinc finger protein 821","metadata":null},{"id":"fa357f67c46d4c79acecdfaf1eed80dc","type":"GENE","name":"ZNF823","canonical_id":"hgnc:HGNC:30936","description":"zinc finger protein 823","metadata":{"aliases":["HSZFP36"]}},{"id":"3814bfd7764248dfbbb2ae81d30b3535","type":"GENE","name":"ZNF826P","canonical_id":"hgnc:HGNC:33875","description":"zinc finger protein 826, pseudogene","metadata":{"aliases":["FLJ44894","ZNF826"]}},{"id":"1b9ff188e75d45728c840b402242eacc","type":"GENE","name":"ZNF827","canonical_id":"hgnc:HGNC:27193","description":"zinc finger protein 827","metadata":null},{"id":"b81eb05d3f9f420aa6516f12096bb3c8","type":"GENE","name":"ZNF829","canonical_id":"hgnc:HGNC:34032","description":"zinc finger protein 829","metadata":{"aliases":["DKFZp779O175"]}},{"id":"a9284c3087cd412ba3f536d14a5c4700","type":"GENE","name":"ZNF83","canonical_id":"hgnc:HGNC:13158","description":"zinc finger protein 83","metadata":{"aliases":["FLJ11015","HPF1","ZNF816B"]}},{"id":"081dc22f68d9478a8b5918ba60aaeedc","type":"GENE","name":"ZNF830","canonical_id":"hgnc:HGNC:28291","description":"zinc finger protein 830","metadata":{"aliases":["MGC20398","OMCG1","CCDC16"]}},{"id":"54a26752a1624785ae06bb7d923ab713","type":"GENE","name":"ZNF831","canonical_id":"hgnc:HGNC:16167","description":"zinc finger protein 831","metadata":{"aliases":["dJ492J12.1","C20orf174"]}},{"id":"769cb120e4ef484c85fe061bcbe806e8","type":"GENE","name":"ZNF833P","canonical_id":"hgnc:HGNC:33819","description":"zinc finger protein 833, pseudogene","metadata":{"aliases":["ZNF833"]}},{"id":"9e52b96382f8487abf39cfcbff514376","type":"GENE","name":"ZNF835","canonical_id":"hgnc:HGNC:34332","description":"zinc finger protein 835","metadata":{"aliases":["BC37295_3"]}},{"id":"c2cbf8de7a9a4caa9cf73b780f5aa173","type":"GENE","name":"ZNF836","canonical_id":"hgnc:HGNC:34333","description":"zinc finger protein 836","metadata":{"aliases":["FLJ16287"]}},{"id":"912a102749db4cf986f76859c3373906","type":"GENE","name":"ZNF837","canonical_id":"hgnc:HGNC:25164","description":"zinc finger protein 837","metadata":null},{"id":"7c668c6f23e54420a63f7f451d7b2603","type":"GENE","name":"ZNF839","canonical_id":"hgnc:HGNC:20345","description":"zinc finger protein 839","metadata":{"aliases":["C14orf131"]}},{"id":"59e4b4fd64124082818b1b9507c0206f","type":"GENE","name":"ZNF839P1","canonical_id":"hgnc:HGNC:38455","description":"zinc finger protein 839 pseudogene 1","metadata":null},{"id":"eaa1d3b76ae94e2bbdda84bfd1d9219d","type":"GENE","name":"ZNF839P2","canonical_id":"hgnc:HGNC:53414","description":"zinc finger protein 839 pseudogene 2","metadata":{"aliases":["FAM239A"]}},{"id":"ff9b20c69c3a458c9bc47a2a2050d05c","type":"GENE","name":"ZNF839P3","canonical_id":"hgnc:HGNC:53415","description":"zinc finger protein 839 pseudogene 3","metadata":{"aliases":["FAM239B"]}},{"id":"b609b89462874b2c8ebd7c441df2507c","type":"GENE","name":"ZNF839P4","canonical_id":"hgnc:HGNC:59230","description":"zinc finger protein 839 pseudogene 4","metadata":null},{"id":"2ba00c9906164a9a994e0f27c0c88c85","type":"GENE","name":"ZNF84","canonical_id":"hgnc:HGNC:13159","description":"zinc finger protein 84","metadata":{"aliases":["HPF2"]}},{"id":"3ce9313ffce34d22a9d7be14110c38be","type":"GENE","name":"ZNF84-DT","canonical_id":"hgnc:HGNC:53355","description":"ZNF84 divergent transcript","metadata":null},{"id":"e927d317105a4194a455246156e91cb9","type":"GENE","name":"ZNF840P","canonical_id":"hgnc:HGNC:34344","description":"zinc finger protein 840, pseudogene","metadata":{"aliases":["dJ981L23.3","C20orf157","ZNF840"]}},{"id":"0b82b212ea9d469b839cc8053b05eb17","type":"GENE","name":"ZNF841","canonical_id":"hgnc:HGNC:27611","description":"zinc finger protein 841","metadata":{"aliases":["LOC284371"]}},{"id":"30f7726ba5514a6a9f301402aaa6a7cb","type":"GENE","name":"ZNF843","canonical_id":"hgnc:HGNC:28710","description":"zinc finger protein 843","metadata":{"aliases":["MGC46336"]}},{"id":"806b9bced64e485d892b0e24b7720b7e","type":"GENE","name":"ZNF844","canonical_id":"hgnc:HGNC:25932","description":"zinc finger protein 844","metadata":{"aliases":["FLJ14959"]}},{"id":"0c4cee781a064558a9caabc82fad3bb5","type":"GENE","name":"ZNF845","canonical_id":"hgnc:HGNC:25112","description":"zinc finger protein 845","metadata":null},{"id":"2133297db8ea4cd3bf4a60e193f587cd","type":"GENE","name":"ZNF846","canonical_id":"hgnc:HGNC:27260","description":"zinc finger protein 846","metadata":null},{"id":"28563743752f44d9bf814acef7309926","type":"GENE","name":"ZNF846-DT","canonical_id":"hgnc:HGNC:59023","description":"ZNF846 divergent transcript","metadata":null},{"id":"7b4896ebbb0d43f0af3fe766fcf11590","type":"GENE","name":"ZNF847P","canonical_id":"hgnc:HGNC:34384","description":"zinc finger protein 847, pseudogene","metadata":{"aliases":["gm127"]}},{"id":"7b345086fe0744f9966f8b1694e5430b","type":"GENE","name":"ZNF848P","canonical_id":"hgnc:HGNC:34387","description":"zinc finger protein 848, pseudogene","metadata":null},{"id":"60bb6d9ed484424b93d86e93227c2470","type":"GENE","name":"ZNF849P","canonical_id":"hgnc:HGNC:34389","description":"zinc finger protein 849, pseudogene","metadata":null},{"id":"aa349cddc71f4c5db3d4e6e8af1ed05e","type":"GENE","name":"ZNF85","canonical_id":"hgnc:HGNC:13160","description":"zinc finger protein 85","metadata":{"aliases":["HPF4","HTF1"]}},{"id":"ec71ac40ed1648b8a829ed7278b7f749","type":"GENE","name":"ZNF850","canonical_id":"hgnc:HGNC:27994","description":"zinc finger protein 850","metadata":{"aliases":["ZNF850P"]}},{"id":"936ee1ae737d4b8fa9f0e589318cdbfb","type":"GENE","name":"ZNF850-DT","canonical_id":"hgnc:HGNC:52671","description":"ZNF850 divergent transcript","metadata":null},{"id":"2f6e2bf6752b4b47a44c5aebbcd78726","type":"GENE","name":"ZNF852","canonical_id":"hgnc:HGNC:27713","description":"zinc finger protein 852","metadata":null},{"id":"41c3144a9774485795af94c2deff9a14","type":"GENE","name":"ZNF853","canonical_id":"hgnc:HGNC:21767","description":"zinc finger protein 853","metadata":{"aliases":["DKFZp434J1015"]}},{"id":"7bbb5aa08e5e472c9e96a3262c6f1a59","type":"GENE","name":"ZNF859P","canonical_id":"hgnc:HGNC:34507","description":"zinc finger protein 859, pseudogene","metadata":null},{"id":"41474ccb143d4161b1f0b3788dbbce04","type":"GENE","name":"ZNF860","canonical_id":"hgnc:HGNC:34513","description":"zinc finger protein 860","metadata":null},{"id":"8d4381e55dd14d639844c81f345977a1","type":"GENE","name":"ZNF861P","canonical_id":"hgnc:HGNC:34514","description":"zinc finger protein 861, pseudogene","metadata":null},{"id":"820736036aeb4defb6504f5c5396fd3e","type":"GENE","name":"ZNF862","canonical_id":"hgnc:HGNC:34519","description":"zinc finger protein 862","metadata":null},{"id":"629beb2972754a048a186d45d38ba1e5","type":"GENE","name":"ZNF863P","canonical_id":"hgnc:HGNC:35156","description":"zinc finger protein 863, pseudogene","metadata":null},{"id":"b6e4509fca6243b39fac1da1b6807f15","type":"GENE","name":"ZNF865","canonical_id":"hgnc:HGNC:38705","description":"zinc finger protein 865","metadata":null},{"id":"8b22581f2093468ebae3b2dd72343f61","type":"GENE","name":"ZNF875","canonical_id":"hgnc:HGNC:4928","description":"zinc finger protein 875","metadata":{"aliases":["HKR1"]}},{"id":"bcedb4d35cb34bbbb9819d957f53c9f5","type":"GENE","name":"ZNF876P","canonical_id":"hgnc:HGNC:32472","description":"zinc finger protein 876, pseudogene","metadata":null},{"id":"5f112eff099d4283a16436de9d440f08","type":"GENE","name":"ZNF877P","canonical_id":"hgnc:HGNC:38697","description":"zinc finger protein 877, pseudogene","metadata":null},{"id":"6075fd9ec0fa4970bef26e9623601f19","type":"GENE","name":"ZNF878","canonical_id":"hgnc:HGNC:37246","description":"zinc finger protein 878","metadata":null},{"id":"f21d9d8b4fbf41ebb6d90560bf1328e2","type":"GENE","name":"ZNF879","canonical_id":"hgnc:HGNC:37273","description":"zinc finger protein 879","metadata":{"aliases":["DKFZp686E2433"]}},{"id":"ad1a93c3295c4db2b753ab622f4f3552","type":"GENE","name":"ZNF880","canonical_id":"hgnc:HGNC:37249","description":"zinc finger protein 880","metadata":null},{"id":"cd188103144c4b09b50c3f18ee44e5d6","type":"GENE","name":"ZNF883","canonical_id":"hgnc:HGNC:27271","description":"zinc finger protein 883","metadata":null},{"id":"c6a8c30558d2429aa08b6a5d55fed10d","type":"GENE","name":"ZNF884P","canonical_id":"hgnc:HGNC:38421","description":"zinc finger protein 884, pseudogene","metadata":null},{"id":"418c500ef53f4a9aaa457fb34bca146c","type":"GENE","name":"ZNF885P","canonical_id":"hgnc:HGNC:38456","description":"zinc finger protein 885, pseudogene","metadata":null},{"id":"516f7df6a6ef44219547388dc9076c83","type":"GENE","name":"ZNF886P","canonical_id":"hgnc:HGNC:38420","description":"zinc finger protein 886, pseudogene","metadata":null},{"id":"dd03254c5f8c492a8d1075f337025719","type":"GENE","name":"ZNF887P","canonical_id":"hgnc:HGNC:38700","description":"zinc finger protein 887, pseudogene","metadata":{"aliases":["ZNF887"]}},{"id":"6e89c15258a443e6a21c4986e40b648e","type":"GENE","name":"ZNF888","canonical_id":"hgnc:HGNC:38695","description":"zinc finger protein 888","metadata":null},{"id":"25ca6e19ff1b471eaebaf76d335e4190","type":"GENE","name":"ZNF888-AS1","canonical_id":"hgnc:HGNC:56044","description":"ZNF888 antisense RNA 1","metadata":null},{"id":"c4834ffe0cc5451aad821f7f58dc132e","type":"GENE","name":"ZNF890P","canonical_id":"hgnc:HGNC:38691","description":"zinc finger protein 890, pseudogene","metadata":null},{"id":"3b7f680148094b049ce88f43ced6425f","type":"GENE","name":"ZNF891","canonical_id":"hgnc:HGNC:38709","description":"zinc finger protein 891","metadata":null},{"id":"22001b96f9ca4886bff88d0f4d69f345","type":"GENE","name":"ZNF892","canonical_id":"hgnc:HGNC:38707","description":"zinc finger protein 892","metadata":null},{"id":"7b2a787f7f43407a8aea6f6f27cfeb99","type":"GENE","name":"ZNF90","canonical_id":"hgnc:HGNC:13165","description":"zinc finger protein 90","metadata":{"aliases":["HTF9"]}},{"id":"7952554f673e4cc7bccdd26910648e30","type":"GENE","name":"ZNF90P1","canonical_id":"hgnc:HGNC:12888","description":"zinc finger protein 90 pseudogene 1","metadata":{"aliases":["ZNF108","ZNF108P"]}},{"id":"c21e1e223eb84f959a1dddf002416722","type":"GENE","name":"ZNF90P2","canonical_id":"hgnc:HGNC:21687","description":"zinc finger protein 90 pseudogene 2","metadata":{"aliases":["dJ111M5.3","ZNF463P"]}},{"id":"0176be2e272b4cd4bb2d6b6be0ab1266","type":"GENE","name":"ZNF90P3","canonical_id":"hgnc:HGNC:39882","description":"zinc finger protein 90 pseudogene 3","metadata":null},{"id":"f66949e073984cb395e8b8555e1e7607","type":"GENE","name":"ZNF91","canonical_id":"hgnc:HGNC:13166","description":"zinc finger protein 91","metadata":{"aliases":["HPF7","HTF10"]}},{"id":"9c61bb0064974aabb77860916f53f67f","type":"GENE","name":"ZNF92","canonical_id":"hgnc:HGNC:13168","description":"zinc finger protein 92","metadata":{"aliases":["HPF12","TF12"]}},{"id":"ae47f31252b14b44a2e68017404bdd3b","type":"GENE","name":"ZNF92P1Y","canonical_id":"hgnc:HGNC:39553","description":"zinc finger protein 92 pseudogene 1, Y-linked","metadata":null},{"id":"5ade329fc2b540c1a69e7fdbf978efcd","type":"GENE","name":"ZNF92P2","canonical_id":"hgnc:HGNC:39554","description":"zinc finger protein 92 pseudogene 2","metadata":null},{"id":"9f770fa572014b75875177d9d1de8716","type":"GENE","name":"ZNF93","canonical_id":"hgnc:HGNC:13169","description":"zinc finger protein 93","metadata":{"aliases":["HPF34","TF34","FLJ12488","ZNF505"]}},{"id":"5426aab11781476b84fcf08e54b77556","type":"GENE","name":"ZNF962P","canonical_id":"hgnc:HGNC:39250","description":"zinc finger protein 962, pseudogene","metadata":null},{"id":"cf5381356dfa4cbeac1f1c7c8ec9eb36","type":"GENE","name":"ZNF965P","canonical_id":"hgnc:HGNC:42025","description":"zinc finger protein 965, pseudogene","metadata":null},{"id":"96c3f77e09f1418ca8b19849eb9243f7","type":"GENE","name":"ZNF968P","canonical_id":"hgnc:HGNC:44091","description":"zinc finger protein 968, pseudogene","metadata":null},{"id":"ceaa68b87fb1474f9c765079696ecedf","type":"GENE","name":"ZNF969P","canonical_id":"hgnc:HGNC:44211","description":"zinc finger protein 969, pseudogene","metadata":null},{"id":"6e13ac3fc340435682685e070559a125","type":"GENE","name":"ZNF970P","canonical_id":"hgnc:HGNC:44511","description":"zinc finger protein 970, pseudogene","metadata":null},{"id":"9a5e3ac19cdf49f78bf0a100b2d38ff3","type":"GENE","name":"ZNF971P","canonical_id":"hgnc:HGNC:51848","description":"zinc finger protein 971, pseudogene","metadata":null},{"id":"c1571234f3ed4a398bbdb950f6a071ca","type":"GENE","name":"ZNF98","canonical_id":"hgnc:HGNC:13174","description":"zinc finger protein 98","metadata":{"aliases":["ZNF739","F7175"]}},{"id":"2a1f2f3e06a84504a0028712ab469b4b","type":"GENE","name":"ZNF99","canonical_id":"hgnc:HGNC:13175","description":"zinc finger protein 99","metadata":{"aliases":["MGC24986","C19orf9"]}},{"id":"8766a47f4cc54e589445ee8b29eae1ac","type":"GENE","name":"ZNFX1","canonical_id":"hgnc:HGNC:29271","description":"zinc finger NFX1-type containing 1","metadata":{"aliases":["KIAA1404","FLJ11277"]}},{"id":"63a24a67fadf417688f748b11293081a","type":"GENE","name":"ZNG1A","canonical_id":"hgnc:HGNC:17134","description":"Zn regulated GTPase metalloprotein activator 1A","metadata":{"aliases":["CBWD1"]}},{"id":"a007c5d724e343f784764072349a5b78","type":"GENE","name":"ZNG1B","canonical_id":"hgnc:HGNC:17907","description":"Zn regulated GTPase metalloprotein activator 1B","metadata":{"aliases":["CBWD2"]}},{"id":"2130a87d05d64cdba4e0c53dcfe204a1","type":"GENE","name":"ZNG1C","canonical_id":"hgnc:HGNC:18519","description":"Zn regulated GTPase metalloprotein activator 1C","metadata":{"aliases":["bA561O23.1","CBWD3"]}},{"id":"6d4553f909f342b6b4aa024b7c3845ee","type":"GENE","name":"ZNG1DP","canonical_id":"hgnc:HGNC:18520","description":"Zn regulated GTPase metalloprotein activator 1D, pseudogene","metadata":{"aliases":["CBWD4P"]}},{"id":"527234226d53454c87812cee99d43205","type":"GENE","name":"ZNG1E","canonical_id":"hgnc:HGNC:24584","description":"Zn regulated GTPase metalloprotein activator 1E","metadata":{"aliases":["CBWD5"]}},{"id":"cb757a39db9e438b899072535d8f821a","type":"GENE","name":"ZNG1F","canonical_id":"hgnc:HGNC:31978","description":"Zn regulated GTPase metalloprotein activator 1F","metadata":{"aliases":["OTTHUMG00000066820","OTTHUMG00000067194","CBWD7","CBWD6"]}},{"id":"edba35aadb0548c596fe2d1b00d2bf47","type":"GENE","name":"ZNHIT1","canonical_id":"hgnc:HGNC:21688","description":"zinc finger HIT-type containing 1","metadata":{"aliases":["CG1I","H_DJ0747G18.14","p18(Hamlet)","ZNFN4A1"]}},{"id":"e358c44d16ab442d9b3fb86cbbcb2971","type":"GENE","name":"ZNHIT1P1","canonical_id":"hgnc:HGNC:44474","description":"zinc finger HIT-type containing 1 pseudogene 1","metadata":null},{"id":"3b2e354510ad4199be300a567f81b6cc","type":"GENE","name":"ZNHIT2","canonical_id":"hgnc:HGNC:1177","description":"zinc finger HIT-type containing 2","metadata":{"aliases":["FON","C11orf5"]}},{"id":"b2592572b56c45bcbd579529525eafab","type":"GENE","name":"ZNHIT3","canonical_id":"hgnc:HGNC:12309","description":"zinc finger HIT-type containing 3","metadata":{"aliases":["Hit1","TRIP3"]}},{"id":"b02d5664b29e4ab0868be388ff56c288","type":"GENE","name":"ZNHIT6","canonical_id":"hgnc:HGNC:26089","description":"zinc finger HIT-type containing 6","metadata":{"aliases":["FLJ20729","NY-BR-75","BCD1","C1orf181"]}},{"id":"0d961ddcfb26468481ece081aa5888b8","type":"GENE","name":"ZNNT1","canonical_id":"hgnc:HGNC:54438","description":"ZNF706 neighboring transcript 1","metadata":{"aliases":["AP003469.4"]}},{"id":"a2478a5d9def4dbeaf976a34d20fe548","type":"GENE","name":"ZNRD1","canonical_id":"hgnc:HGNC:13182","description":null,"metadata":null},{"id":"2fa95c0afffa452e9d3f6330defbb64c","type":"GENE","name":"ZNRD2","canonical_id":"hgnc:HGNC:11328","description":"zinc ribbon domain containing 2","metadata":{"aliases":["p27","SSSCA1"]}},{"id":"50dab22f6b7247a4a970ecca89f24215","type":"GENE","name":"ZNRD2-DT","canonical_id":"hgnc:HGNC:27384","description":"ZNRD2 divergent transcript","metadata":{"aliases":["SSSCA1-AS1","ZNRD2-AS1"]}},{"id":"87231a8578b241ad81dc729777c60305","type":"GENE","name":"ZNRF1","canonical_id":"hgnc:HGNC:18452","description":"zinc and ring finger 1","metadata":{"aliases":["nin283","FLJ14846","DKFZp434E229"]}},{"id":"dbfffe5056fa49a6b5fe2f02bf938309","type":"GENE","name":"ZNRF2","canonical_id":"hgnc:HGNC:22316","description":"zinc and ring finger 2","metadata":{"aliases":["RNF202"]}},{"id":"591da7a57d4a470cbcbbeade79a2fae5","type":"GENE","name":"ZNRF2P1","canonical_id":"hgnc:HGNC:42792","description":"zinc and ring finger 2 pseudogene 1","metadata":null},{"id":"e25d7e0cac53440797cf910f4ba0bf29","type":"GENE","name":"ZNRF2P2","canonical_id":"hgnc:HGNC:42793","description":"zinc and ring finger 2 pseudogene 2","metadata":null},{"id":"3a17da16148b49f38314b0dff8da7d3c","type":"GENE","name":"ZNRF2P3","canonical_id":"hgnc:HGNC:45113","description":"zinc and ring finger 2 pseudogene 3","metadata":null},{"id":"565f55e7910d45eb8e683c94ec940d71","type":"GENE","name":"ZNRF3","canonical_id":"hgnc:HGNC:18126","description":"zinc and ring finger 3","metadata":{"aliases":["KIAA1133","BK747E2.3","FLJ22057","RNF203"]}},{"id":"330b6b2acda04558aa4eb6bfe0f2a44e","type":"GENE","name":"ZNRF3-AS1","canonical_id":"hgnc:HGNC:41927","description":"ZNRF3 antisense RNA 1","metadata":null},{"id":"a9da460e0fc64e1ea9e7e0cffe650e07","type":"GENE","name":"ZNRF3-IT1","canonical_id":"hgnc:HGNC:41440","description":"ZNRF3 intronic transcript 1","metadata":null},{"id":"adb1b607de2e458d997db22f9908167a","type":"GENE","name":"ZNRF4","canonical_id":"hgnc:HGNC:17726","description":"zinc and ring finger 4","metadata":{"aliases":["spzn","Ssrzf1","RNF204"]}},{"id":"0cc9c972f07f44a89f9799fb55830102","type":"GENE","name":"ZP1","canonical_id":"hgnc:HGNC:13187","description":"zona pellucida glycoprotein 1","metadata":{"aliases":["ZPB1"]}},{"id":"6dd0bfb64f1f49faaf8d2b6f02299533","type":"GENE","name":"ZP2","canonical_id":"hgnc:HGNC:13188","description":"zona pellucida glycoprotein 2","metadata":{"aliases":["ZPA"]}},{"id":"f24af7a6f3644cdfa802c4dd0dceb5a4","type":"GENE","name":"ZP3","canonical_id":"hgnc:HGNC:13189","description":"zona pellucida glycoprotein 3","metadata":{"aliases":["ZP3-424","ZP3-372","ZPC","ZP3A","ZP3B"]}},{"id":"e45d9bcaf8ab442a8954f86f632c8c64","type":"GENE","name":"ZP3P1","canonical_id":"hgnc:HGNC:50856","description":"ZP3 pseudogene 1","metadata":null},{"id":"6af6b8ed9eb24817a1a3ab47ffa54e7b","type":"GENE","name":"ZP3P2","canonical_id":"hgnc:HGNC:50857","description":"ZP3 pseudogene 2","metadata":null},{"id":"1fd055a0f7ef453784fb0ca6549491c8","type":"GENE","name":"ZP3RP","canonical_id":"hgnc:HGNC:1326","description":"zona pellucida 3 receptor, pseudogene","metadata":{"aliases":["C4BPAL1","C4BPAP1"]}},{"id":"96e8f90600894f7b93de271dd6d9a5b7","type":"GENE","name":"ZP4","canonical_id":"hgnc:HGNC:15770","description":"zona pellucida glycoprotein 4","metadata":{"aliases":["ZPB","ZPB2","ZP1B"]}},{"id":"58911b7bb808497b975dcefa3d628aa0","type":"GENE","name":"ZPAXP","canonical_id":"hgnc:HGNC:51635","description":"zona pellucida glycoprotein AX, pseudogene","metadata":{"aliases":["ZPX1P"]}},{"id":"18b7bc8b38fe48aeb09a9e50f6c92710","type":"GENE","name":"ZPBP","canonical_id":"hgnc:HGNC:15662","description":"zona pellucida binding protein","metadata":{"aliases":["SP38","ZPBP1"]}},{"id":"c03a78f2a4db492a92101b86100de7aa","type":"GENE","name":"ZPBP2","canonical_id":"hgnc:HGNC:20678","description":"zona pellucida binding protein 2","metadata":{"aliases":["ZPBPL","MGC41930"]}},{"id":"dded2c003c95436198c5a387849f6b18","type":"GENE","name":"ZPLD1","canonical_id":"hgnc:HGNC:27022","description":"zona pellucida like domain containing 1","metadata":null},{"id":"b6ee3fdfce1a4b34b362e083dc4f7c22","type":"GENE","name":"ZPLD2P","canonical_id":"hgnc:HGNC:54510","description":"zona pellucida like domain containing 2, pseudogene","metadata":null},{"id":"0c4a09523cc647a99f2fcf4d75ab6004","type":"GENE","name":"ZPR1","canonical_id":"hgnc:HGNC:13051","description":"ZPR1 zinc finger","metadata":{"aliases":["ZNF259"]}},{"id":"9d0f8752baba41a68f02adc2ecdda046","type":"GENE","name":"ZPR1P1","canonical_id":"hgnc:HGNC:13052","description":"ZPR1 pseudogene 1","metadata":{"aliases":["354J5","ZNF259P","ZNF259P1"]}},{"id":"d109b414a9b649f0a3dbaf85e58acb6c","type":"GENE","name":"ZRANB1","canonical_id":"hgnc:HGNC:18224","description":"zinc finger RANBP2-type containing 1","metadata":{"aliases":["TRABID"]}},{"id":"22aa73138bbe4508be8562125988771d","type":"GENE","name":"ZRANB2","canonical_id":"hgnc:HGNC:13058","description":"zinc finger RANBP2-type containing 2","metadata":{"aliases":["ZIS","ZIS1","ZIS2","ZNF265"]}},{"id":"14f3e3dedcc448e4b590170b4e2ffb2a","type":"GENE","name":"ZRANB2-AS1","canonical_id":"hgnc:HGNC:43594","description":"ZRANB2 antisense RNA 1","metadata":null},{"id":"a15a9afa01ea48fc8d26cbce85e51fb0","type":"GENE","name":"ZRANB2-DT","canonical_id":"hgnc:HGNC:43595","description":"ZRANB2 divergent transcript","metadata":{"aliases":["ZRANB2-AS2"]}},{"id":"04463fc5e6ff44c6a964403bd2b1802a","type":"GENE","name":"ZRANB3","canonical_id":"hgnc:HGNC:25249","description":"zinc finger RANBP2-type containing 3","metadata":{"aliases":["DKFZP434B1727","AH2"]}},{"id":"0fef38c8bb70499d9e3d93fc7e9e70e9","type":"GENE","name":"ZRSR2","canonical_id":"hgnc:HGNC:23019","description":"zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2","metadata":{"aliases":["U2AF1-RS2","URP","ZC3H22","U2AF1L2"]}},{"id":"d2132e2f55bd4b53816c06398b1a78a4","type":"GENE","name":"ZRSR2P1","canonical_id":"hgnc:HGNC:12456","description":"ZRSR2 pseudogene 1","metadata":{"aliases":["U2AF1-RS1","U2AF1RS1","ZC3H21","U2AFBPL","U2AF1P","U2AF1L1","ZRSR1"]}},{"id":"37a0ac4d27e443b9a3254aac68b592fe","type":"GENE","name":"ZSCAN1","canonical_id":"hgnc:HGNC:23712","description":"zinc finger and SCAN domain containing 1","metadata":{"aliases":["FLJ33779","ZNF915"]}},{"id":"2f5717f301b446b9b05cbd142963bde3","type":"GENE","name":"ZSCAN10","canonical_id":"hgnc:HGNC:12997","description":"zinc finger and SCAN domain containing 10","metadata":{"aliases":["ZNF206"]}},{"id":"fa9f2855c74744629be8c2c46cd3a78b","type":"GENE","name":"ZSCAN12","canonical_id":"hgnc:HGNC:13172","description":"zinc finger and SCAN domain containing 12","metadata":{"aliases":["KIAA0426","ZNF29K1","ZFP96","dJ29K1.2","ZNF305","ZNF96"]}},{"id":"d93470b32b2b488e8cadca791d943a95","type":"GENE","name":"ZSCAN12-DT","canonical_id":"hgnc:HGNC:59377","description":"ZSCAN12 divergent transcript","metadata":null},{"id":"fe2e6b32ac134caba4bfcf0524474003","type":"GENE","name":"ZSCAN12P1","canonical_id":"hgnc:HGNC:13850","description":"zinc finger and SCAN domain containing 12 pseudogene 1","metadata":{"aliases":["ZNF187p1","dJ313I6.7","ZNF305P1","ZNF96P1","ZNF96L1","ZSCAN12L1"]}},{"id":"6b44249b7246404a8fe3f8baedd3739f","type":"GENE","name":"ZSCAN16","canonical_id":"hgnc:HGNC:20813","description":"zinc finger and SCAN domain containing 16","metadata":{"aliases":["FLJ22191","dJ265C24.3","ZNF392","ZNF435"]}},{"id":"103f08c18d27434297534f4ec93d2402","type":"GENE","name":"ZSCAN16-AS1","canonical_id":"hgnc:HGNC:48982","description":"ZSCAN16 antisense RNA 1","metadata":null},{"id":"1b0e84182d8f49cbb0eb339f0fc77dba","type":"GENE","name":"ZSCAN18","canonical_id":"hgnc:HGNC:21037","description":"zinc finger and SCAN domain containing 18","metadata":{"aliases":["FLJ12895","ZNF447"]}},{"id":"992c06e56f2e49758c3c67350c3a2ff6","type":"GENE","name":"ZSCAN2","canonical_id":"hgnc:HGNC:20994","description":"zinc finger and SCAN domain containing 2","metadata":{"aliases":["FLJ20595","ZNF854","ZFP29"]}},{"id":"0d674de04e034f4ba4dbf15f2329b92a","type":"GENE","name":"ZSCAN2-AS1","canonical_id":"hgnc:HGNC:56673","description":"ZSCAN2 antisense RNA 1","metadata":{"aliases":["AC048382.5"]}},{"id":"cd4a1373d4424e409a0d15290edd32e2","type":"GENE","name":"ZSCAN20","canonical_id":"hgnc:HGNC:13093","description":"zinc finger and SCAN domain containing 20","metadata":{"aliases":["KOX29","ZNF360","ZNF31"]}},{"id":"ddd3a20f0f75416ba8ab8dc8db434efb","type":"GENE","name":"ZSCAN21","canonical_id":"hgnc:HGNC:13104","description":"zinc finger and SCAN domain containing 21","metadata":{"aliases":["DKFZp434L134","NY-REN-21","Zipro1","ZNF38"]}},{"id":"e673ca95551b4146a6b5daee7368aaee","type":"GENE","name":"ZSCAN22","canonical_id":"hgnc:HGNC:4929","description":"zinc finger and SCAN domain containing 22","metadata":{"aliases":["ZNF50","HKR2"]}},{"id":"97ed1d1f39a1442382e5c68ba7dd7cef","type":"GENE","name":"ZSCAN23","canonical_id":"hgnc:HGNC:21193","description":"zinc finger and SCAN domain containing 23","metadata":{"aliases":["dJ29K1.3.1","ZNF453","ZNF390"]}},{"id":"7bfad939c2a74f1eb2e80b8ce3c63c9c","type":"GENE","name":"ZSCAN25","canonical_id":"hgnc:HGNC:21961","description":"zinc finger and SCAN domain containing 25","metadata":{"aliases":["FLJ32468","ZNF498"]}},{"id":"37be305b61a94f448a7d41c253fc9e74","type":"GENE","name":"ZSCAN26","canonical_id":"hgnc:HGNC:12978","description":"zinc finger and SCAN domain containing 26","metadata":{"aliases":["SRE-ZBP","ZNF187"]}},{"id":"6ff265cd9c574161a3d16a9aab145368","type":"GENE","name":"ZSCAN29","canonical_id":"hgnc:HGNC:26673","description":"zinc finger and SCAN domain containing 29","metadata":{"aliases":["FLJ35867","Zfp690","ZNF690"]}},{"id":"e90344d9cf7243a591d774401758ea48","type":"GENE","name":"ZSCAN30","canonical_id":"hgnc:HGNC:33517","description":"zinc finger and SCAN domain containing 30","metadata":{"aliases":["ZNF917","ZNF397OS"]}},{"id":"8207da7443e74d69a619a07c6c721f0e","type":"GENE","name":"ZSCAN31","canonical_id":"hgnc:HGNC:14097","description":"zinc finger and SCAN domain containing 31","metadata":{"aliases":["ZNF310P","ZNF323"]}},{"id":"c9c4aa1b7a7e4270a6eebc94d606ebdb","type":"GENE","name":"ZSCAN32","canonical_id":"hgnc:HGNC:20812","description":"zinc finger and SCAN domain containing 32","metadata":{"aliases":["FLJ20417","ZNF434"]}},{"id":"e9192263886c493e9630dca9f22f1938","type":"GENE","name":"ZSCAN4","canonical_id":"hgnc:HGNC:23709","description":"zinc finger and SCAN domain containing 4","metadata":{"aliases":["FLJ35105","ZNF494"]}},{"id":"a0d9d80709754241a49f013c0db02111","type":"GENE","name":"ZSCAN5A","canonical_id":"hgnc:HGNC:23710","description":"zinc finger and SCAN domain containing 5A","metadata":{"aliases":["MGC4161","ZNF495","ZSCAN5"]}},{"id":"07ef4008bb7247c5a86888ff6d94bf06","type":"GENE","name":"ZSCAN5A-AS1","canonical_id":"hgnc:HGNC:55294","description":"ZSCAN5A antisense RNA 1","metadata":null},{"id":"041b151db40b48279690dfe8a8f0502e","type":"GENE","name":"ZSCAN5B","canonical_id":"hgnc:HGNC:34246","description":"zinc finger and SCAN domain containing 5B","metadata":{"aliases":["ZNF495B","ZNF371"]}},{"id":"946294fbb7b44813825e05ae15ca66b6","type":"GENE","name":"ZSCAN5C","canonical_id":"hgnc:HGNC:34294","description":"zinc finger and SCAN domain containing 5C","metadata":{"aliases":["ZNF495C","ZSCAN5CP"]}},{"id":"86dc58f71fb1449d95523f52924be914","type":"GENE","name":"ZSCAN5DP","canonical_id":"hgnc:HGNC:37706","description":"zinc finger and SCAN domain containing 5D pseudogene","metadata":{"aliases":["ZNF495D","ZSCAN5D"]}},{"id":"f15e15e25e484ef4ab8236f0ab6c852a","type":"GENE","name":"ZSCAN9","canonical_id":"hgnc:HGNC:12984","description":"zinc finger and SCAN domain containing 9","metadata":{"aliases":["PRD51","ZNF193"]}},{"id":"0644de679d294d4cbe7452485cd501a5","type":"GENE","name":"ZSWIM1","canonical_id":"hgnc:HGNC:16155","description":"zinc finger SWIM-type containing 1","metadata":{"aliases":["dJ337O18.5","C20orf162"]}},{"id":"1904bd1cb3b74ca8918223fb26a03e5c","type":"GENE","name":"ZSWIM2","canonical_id":"hgnc:HGNC:30990","description":"zinc finger SWIM-type containing 2","metadata":{"aliases":["MGC33890","ZZZ2","MEX"]}},{"id":"fa6346d49e6c4918bb7d04bd7d713a55","type":"GENE","name":"ZSWIM3","canonical_id":"hgnc:HGNC:16157","description":"zinc finger SWIM-type containing 3","metadata":{"aliases":["dJ337O18.7","PPP1R174","C20orf164"]}},{"id":"86238810130446f8a14ddc152060e188","type":"GENE","name":"ZSWIM4","canonical_id":"hgnc:HGNC:25704","description":"zinc finger SWIM-type containing 4","metadata":{"aliases":["FLJ12221"]}},{"id":"8a309c36d7e541a9b12c4520d8d1c252","type":"GENE","name":"ZSWIM4-AS1","canonical_id":"hgnc:HGNC:58773","description":"ZSWIM4 antisense RNA 1","metadata":{"aliases":["AC020916.1"]}},{"id":"f5e9f29d39c24c7bb3908cdd0670676b","type":"GENE","name":"ZSWIM5","canonical_id":"hgnc:HGNC:29299","description":"zinc finger SWIM-type containing 5","metadata":{"aliases":["KIAA1511"]}},{"id":"a1711e4dd89e4bef95cab138b183cf2f","type":"GENE","name":"ZSWIM5P1","canonical_id":"hgnc:HGNC:43768","description":"zinc finger SWIM-type containing 5 pseudogene 1","metadata":null},{"id":"7b6d4586404740d3acc19f955c55e5f3","type":"GENE","name":"ZSWIM5P2","canonical_id":"hgnc:HGNC:43769","description":"zinc finger SWIM-type containing 5 pseudogene 2","metadata":null},{"id":"5254282c1c4541a6b317b33aca7771ff","type":"GENE","name":"ZSWIM5P3","canonical_id":"hgnc:HGNC:43770","description":"zinc finger SWIM-type containing 5 pseudogene 3","metadata":null},{"id":"f8cec8a7f23f4fc7882e57d33fb85028","type":"GENE","name":"ZSWIM6","canonical_id":"hgnc:HGNC:29316","description":"zinc finger SWIM-type containing 6","metadata":{"aliases":["KIAA1577"]}},{"id":"5e730db63e664fbd8b8b131e808d34a0","type":"GENE","name":"ZSWIM6-DT","canonical_id":"hgnc:HGNC:59059","description":"ZSWIM6 divergent transcript","metadata":null},{"id":"2fa9bce84d6b447f97168e9cd1474e7d","type":"GENE","name":"ZSWIM7","canonical_id":"hgnc:HGNC:26993","description":"zinc finger SWIM-type containing 7","metadata":{"aliases":["SWS1"]}},{"id":"862739d8ca5b4b8b82499fe2bd5a8536","type":"GENE","name":"ZSWIM8","canonical_id":"hgnc:HGNC:23528","description":"zinc finger SWIM-type containing 8","metadata":{"aliases":["4832404P21Rik","KIAA0913"]}},{"id":"2fef6449904447b1a0223c8a8bd86f88","type":"GENE","name":"ZSWIM8-AS1","canonical_id":"hgnc:HGNC:45103","description":"ZSWIM8 antisense RNA 1","metadata":null},{"id":"027bd2aec6e54d47828475951a127ad9","type":"GENE","name":"ZSWIM9","canonical_id":"hgnc:HGNC:34495","description":"zinc finger SWIM-type containing 9","metadata":{"aliases":["LOC374920","C19orf68"]}},{"id":"a327fbbab37742f2bd15328bc7aaff93","type":"GENE","name":"ZUP1","canonical_id":"hgnc:HGNC:21224","description":"zinc finger containing ubiquitin peptidase 1","metadata":{"aliases":["dJ412I7.3","C6orf113","ZUFSP"]}},{"id":"c1ea7efc685b4673851c0c274deaa441","type":"GENE","name":"ZW10","canonical_id":"hgnc:HGNC:13194","description":"zw10 kinetochore protein","metadata":{"aliases":["KNTC1AP"]}},{"id":"81179400eaf64c5cbdfea3d45331c6fc","type":"GENE","name":"ZWILCH","canonical_id":"hgnc:HGNC:25468","description":"zwilch kinetochore protein","metadata":{"aliases":["FLJ10036","KNTC1AP"]}},{"id":"d140e9e0fde543608aa70552dc2bb630","type":"GENE","name":"ZWINT","canonical_id":"hgnc:HGNC:13195","description":"ZW10 interacting kinetochore protein","metadata":{"aliases":["KNTC2AP","SIP30","Zwint1"]}},{"id":"a2522019965646b1ba0ceaca3bebab2a","type":"GENE","name":"ZXDA","canonical_id":"hgnc:HGNC:13198","description":"zinc finger X-linked duplicated A","metadata":{"aliases":["ZNF896"]}},{"id":"292ec3c230b348da8932b2ce73f70d34","type":"GENE","name":"ZXDB","canonical_id":"hgnc:HGNC:13199","description":"zinc finger X-linked duplicated B","metadata":{"aliases":["ZNF905"]}},{"id":"475c2dae592b458ab535025977b2f2e4","type":"GENE","name":"ZXDC","canonical_id":"hgnc:HGNC:28160","description":"ZXD family zinc finger C","metadata":{"aliases":["MGC11349","FLJ13861"]}},{"id":"6382861fd7844acaaf16d554fee19ec3","type":"GENE","name":"ZYG11A","canonical_id":"hgnc:HGNC:32058","description":"zyg-11 family member A, cell cycle regulator","metadata":{"aliases":["ZYG11"]}},{"id":"fcab872128644fb5a26118795ddbb6da","type":"GENE","name":"ZYG11AP1","canonical_id":"hgnc:HGNC:38032","description":"zyg-11 family member A, cell cycle regulator pseudogene 1","metadata":null},{"id":"f73a7d9b33eb4cf58c2f139d96c1a556","type":"GENE","name":"ZYG11B","canonical_id":"hgnc:HGNC:25820","description":"zyg-11 family member B, cell cycle regulator","metadata":{"aliases":["FLJ13456","ZYG11"]}},{"id":"377c36ab44ed4b968d0e642a530a5bb4","type":"GENE","name":"ZYX","canonical_id":"hgnc:HGNC:13200","description":"zyxin","metadata":null},{"id":"b5fee7b6de794a5b9eee4bf45e07d733","type":"GENE","name":"ZYXP1","canonical_id":"hgnc:HGNC:51695","description":"zyxin pseudogene 1","metadata":null},{"id":"b32f0085878f44709dc260daef8bfaee","type":"GENE","name":"ZZEF1","canonical_id":"hgnc:HGNC:29027","description":"zinc finger ZZ-type and EF-hand domain containing 1","metadata":{"aliases":["KIAA0399","ZZZ4","FLJ10821"]}},{"id":"a2080c69e0c14e5792f8776513f7e089","type":"GENE","name":"ZZZ3","canonical_id":"hgnc:HGNC:24523","description":"zinc finger ZZ-type containing 3","metadata":{"aliases":["DKFZP564I052","ATAC1"]}},{"id":"8c6318eccfb048bea2f46ad33905d35c","type":"TRIAL","name":"Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine","canonical_id":"clinicaltrials.gov:NCT00753714","description":"Non Small Cell Lung Cancer","metadata":null},{"id":"b32e38e6dafb47f3958c4fc5166e30fb","type":"DRUG","name":"Zafirlukast","canonical_id":"mesh:C062735","description":null,"metadata":null},{"id":"f5d348c410664cb88b357188692baf18","type":"TRIAL","name":"Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer","canonical_id":"clinicaltrials.gov:NCT04339140","description":"Ovarian Cancer","metadata":null},{"id":"08abc1b94ae849b9bbffb626dc45ddf7","type":"DRUG","name":"Zalcitabine","canonical_id":"mesh:D016047","description":null,"metadata":null},{"id":"26c149ac4dcd4528a79d047e92a183c5","type":"TRIAL","name":"Zandelisib + Tazemetostat in R/R Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT05604417","description":"Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma","metadata":null},{"id":"73b8d2506ab7482eb9bd03c60a262f32","type":"TRIAL","name":"Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","canonical_id":"clinicaltrials.gov:NCT06544785","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma","metadata":null},{"id":"7583555841224abd976f9b76e3240f67","type":"TRIAL","name":"Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies","canonical_id":"clinicaltrials.gov:NCT07283965","description":"Chronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases","metadata":null},{"id":"58b5d99e19ee4c5ba36389a5ba2e3620","type":"TRIAL","name":"Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT06474481","description":"FL","metadata":null},{"id":"bfdfe7a3a40b4416a0bfbf6774a6a2b3","type":"TRIAL","name":"Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT06029309","description":"Mantle Cell Lymphoma","metadata":null},{"id":"5d840b573633435381427799783bdd0d","type":"TRIAL","name":"Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma","canonical_id":"clinicaltrials.gov:NCT06553352","description":"Follicular Lymphoma; Newly Diagnosed","metadata":null},{"id":"daf99f1cd0174d80b84176027d2e50ac","type":"TRIAL","name":"Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL","canonical_id":"clinicaltrials.gov:NCT06849713","description":"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL)","metadata":null},{"id":"ecba8a3666024f31a5f518b465df9d0a","type":"TRIAL","name":"Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer","canonical_id":"clinicaltrials.gov:NCT07470489","description":"Anaplastic Thyroid Cancer","metadata":null},{"id":"09f433812be042e18e355feab45b8d93","type":"TRIAL","name":"Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas","canonical_id":"clinicaltrials.gov:NCT00493467","description":"Lymphoma","metadata":null},{"id":"0b04d47e493448799d5eea31dcc54ba7","type":"TRIAL","name":"Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT01811368","description":"Refractory Non Hodgkin Lymphoma; Relapsed Non Hodgkin Lymphoma","metadata":null},{"id":"48d99b24fd994d4ca5eecd1bf1ada536","type":"TRIAL","name":"Zevalin Post-marketing Surveillance in Japan","canonical_id":"clinicaltrials.gov:NCT01448928","description":"Non-Hodgkin's Lymphoma (NHL)","metadata":null},{"id":"af3d37b89fbb4d4a827866d97f47ed4b","type":"TRIAL","name":"Zevalin Twice in Aggressive Non-Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00902525","description":"Diffuse Large B-Cell Lymphoma","metadata":null},{"id":"879ff7b162e942069a8f3d0176110667","type":"TRIAL","name":"Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma","canonical_id":"clinicaltrials.gov:NCT00807196","description":"Non-Hodgkins Lymphoma","metadata":null},{"id":"dc3ce43cdff44fff92faa274aef30bc8","type":"TRIAL","name":"Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00463463","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"f740b3c204b840e8b29f7fc38b1fe8c5","type":"TRIAL","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT01497275","description":"Mantle-Cell Lymphoma","metadata":null},{"id":"8ac531eff9224c77ad1dcabba0206feb","type":"TRIAL","name":"Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma","canonical_id":"clinicaltrials.gov:NCT00514475","description":"Mantle Cell Lymphoma","metadata":null},{"id":"b7f2dd5542be4a0498da8b6c3afe0738","type":"TRIAL","name":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","canonical_id":"clinicaltrials.gov:NCT01490723","description":"Leukemia; Lymphoma","metadata":null},{"id":"f68108ebf00d42a581b1b9977c9e7332","type":"TRIAL","name":"Zevalin-beam for Aggressive Lymphoma","canonical_id":"clinicaltrials.gov:NCT00491491","description":"Non-Hodgkin's Lymphoma","metadata":null},{"id":"7721bcc2b6cc44a0a95ba303d847b63f","type":"TRIAL","name":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","canonical_id":"clinicaltrials.gov:NCT00591630","description":"Diffuse Large Cell Lymphoma; Lymphoma","metadata":null},{"id":"9f4a0b89d0e241d9a6b7ef93be7a34ed","type":"TRIAL","name":"Zevalin\u00ae Followed by Rituxan\u00ae Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma","canonical_id":"clinicaltrials.gov:NCT00168727","description":"Lymphoma, Non-Hodgkin; Lymphoma, Low-Grade","metadata":null},{"id":"caf6a0dd06df464d91f95b661c4636a2","type":"TRIAL","name":"Zhuochuming\u00ae-3T&E-DME Study (Treatment-na\u00efve Patients)","canonical_id":"clinicaltrials.gov:NCT07612904","description":"Diabetic Macular Edema (DME)","metadata":null},{"id":"47c54227eb2549bfb8b331caed4ec3c5","type":"DRUG","name":"Ziconotide","canonical_id":"mesh:C078452","description":null,"metadata":null},{"id":"30b2661ebe244efdb027a290f45940d4","type":"DRUG","name":"Zidovudine","canonical_id":"mesh:D015215","description":null,"metadata":null},{"id":"c56c8f49c7a043b8b6a3339b79794e85","type":"TRIAL","name":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","canonical_id":"clinicaltrials.gov:NCT05103332","description":"Hypertension","metadata":null},{"id":"9f030ceab576425d912c94c0ff5233b7","type":"TRIAL","name":"Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS","canonical_id":"clinicaltrials.gov:NCT00486343","description":"Asthma","metadata":null},{"id":"78089e3b09604c25877fc6f0ca1d2e4e","type":"TRIAL","name":"Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers","canonical_id":"clinicaltrials.gov:NCT01021215","description":"Tobacco Use Disorder","metadata":null},{"id":"6a16d023de864f2885d30b7b375b9e00","type":"TRIAL","name":"Zileuton and Exhaled Nitric Oxide in Asthmatics","canonical_id":"clinicaltrials.gov:NCT00575861","description":"Asthma","metadata":null},{"id":"5bef368469b44064a1329fda02d5beee","type":"TRIAL","name":"Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis","canonical_id":"clinicaltrials.gov:NCT00262405","description":"Idiopathic Pulmonary Fibrosis","metadata":null},{"id":"ab909e46ace849a5b70b0f03228f1d7f","type":"TRIAL","name":"Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia","canonical_id":"clinicaltrials.gov:NCT00056004","description":"Head and Neck Cancer; Lung Cancer","metadata":null},{"id":"9e1d88774fd84f4dbe13724780d5df97","type":"TRIAL","name":"Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)","canonical_id":"clinicaltrials.gov:NCT00493974","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"96bf8b052b9d48b5b7e3b5a2a83af0cd","type":"DRUG","name":"Zinc oxide","canonical_id":"mesh:D015034","description":null,"metadata":null},{"id":"5e679bed6381477ea072e5340a864fd8","type":"TRIAL","name":"Ziprasidone And Olanzapine's Outcomes In Mania","canonical_id":"clinicaltrials.gov:NCT00329108","description":"Acute Mania; Bipolar Disorder, Manic","metadata":null},{"id":"adb575d2745543b697ef05af83597074","type":"TRIAL","name":"Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs","canonical_id":"clinicaltrials.gov:NCT00633399","description":"Major Depressive Disorder","metadata":null},{"id":"5043df5505c246c6bbb7cae5b7f497de","type":"TRIAL","name":"Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00374543","description":"Generalized Anxiety Disorder; Bipolar Disorder","metadata":null},{"id":"c8182305503f4020b1af4f3bb6008227","type":"TRIAL","name":"Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder","canonical_id":"clinicaltrials.gov:NCT00181922","description":"Bipolar Disorder; Mania","metadata":null},{"id":"5516ab448248442790e838c2d89ebe77","type":"TRIAL","name":"Ziprasidone in Early Onset Schizophrenia Spectrum Disorders","canonical_id":"clinicaltrials.gov:NCT01006551","description":"Schizophrenia","metadata":null},{"id":"48ae3ac2ad8b4a86b28c52216a233c8a","type":"TRIAL","name":"Ziprasidone in the Psychosis Prodrome","canonical_id":"clinicaltrials.gov:NCT00635700","description":"Psychosis Prodrome","metadata":null},{"id":"41127d0878cc4aef99aa1c7c3044e364","type":"TRIAL","name":"Ziprasidone in the Treatment of Borderline Personality Disorder","canonical_id":"clinicaltrials.gov:NCT00635921","description":"Borderline Personality Disorder","metadata":null},{"id":"99c49dca500c49a8b00f5513defc3b23","type":"TRIAL","name":"Ziprasidone vs Standard Therapy for Agitated Patients in the ED","canonical_id":"clinicaltrials.gov:NCT00786318","description":"Psychosis; Agitation; Delirium","metadata":null},{"id":"7a553741d8bf459d8d422d73b613e740","type":"TRIAL","name":"Ziv-aflibercept Efficacy in Better Regulating AMD","canonical_id":"clinicaltrials.gov:NCT03423823","description":"Wet Macular Degeneration; Wet Age-related Macular Degeneration","metadata":null},{"id":"4ca0cc32be6247cd80091445eecc1ff7","type":"TRIAL","name":"Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I","canonical_id":"clinicaltrials.gov:NCT02173873","description":"Age Related Macular Degeneration; Central Retinal Vein Occlusion","metadata":null},{"id":"2a448bd72bfc4c3d89b5d692b34c1af9","type":"TRIAL","name":"Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers","canonical_id":"clinicaltrials.gov:NCT07723534","description":"Advanced Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma","metadata":null},{"id":"0cecc8cbed6e4e7d8601fb27652a2c2d","type":"TRIAL","name":"Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)","canonical_id":"clinicaltrials.gov:NCT07858500","description":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma","metadata":null},{"id":"7f008898a3c74109bd55a3d4aaefaa05","type":"TRIAL","name":"Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma","canonical_id":"clinicaltrials.gov:NCT00432458","description":"Multiple Myeloma and Plasma Cell Neoplasm","metadata":null},{"id":"6c160fcb22ee4e98bea5bd96155ecc15","type":"TRIAL","name":"Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer","canonical_id":"clinicaltrials.gov:NCT00039104","description":"Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer","metadata":null},{"id":"bfea6d528383450b99288b33bb73cd4b","type":"TRIAL","name":"Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy","canonical_id":"clinicaltrials.gov:NCT00329797","description":"Osteoporosis; Prostate Cancer","metadata":null},{"id":"ed69bb32ec8746e49663782a9d54ab06","type":"DRUG","name":"Zoledronic Acid","canonical_id":"ncit:C1699","description":null,"metadata":null},{"id":"dc8eead0ab4349c9824933dad6bc6fad","type":"TRIAL","name":"Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation","canonical_id":"clinicaltrials.gov:NCT00297830","description":"Heart Transplantation; Liver Transplantation; Bone Resorption","metadata":null},{"id":"262be694294347cb864ebd0f8322cbc1","type":"TRIAL","name":"Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)","canonical_id":"clinicaltrials.gov:NCT02589600","description":"Osteoporotic Fractures; Osteoporosis, Postmenopausal","metadata":null},{"id":"69a2d4e8e1944aa79ac7a3d1b9e5b9fb","type":"TRIAL","name":"Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms","canonical_id":"clinicaltrials.gov:NCT01194440","description":"Ductal Carcinoma in Situ; Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer","metadata":null},{"id":"95403d4ef1fd454b95f1649250ed3244","type":"TRIAL","name":"Zoledronic Acid in Rheumatoid Arthritis","canonical_id":"clinicaltrials.gov:NCT02123264","description":"Arthritis, Rheumatoid","metadata":null},{"id":"ebc97ef4210d4412bcbc8e63cd8bfb7c","type":"TRIAL","name":"Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation","canonical_id":"clinicaltrials.gov:NCT02499237","description":"Postmenopausal Osteoporosis","metadata":null},{"id":"5c62810fea3748909268a8bfadfc0923","type":"DISEASE","name":"Zollinger-Ellison Syndrome","canonical_id":"mesh:D015043","description":null,"metadata":null},{"id":"4ea1893489114b96b0cad13e0eb0d85e","type":"DISEASE","name":"Zollinger-Ellison syndrome","canonical_id":"mondo:0019610","description":null,"metadata":null},{"id":"5e989f5b0c38417db1761d20f01c0d4b","type":"TRIAL","name":"Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine","canonical_id":"clinicaltrials.gov:NCT01276977","description":"Acute Migraine; Migraine Headache; Headache Disorders","metadata":null},{"id":"c0ac3cd51bda45b4a4abf49b6959a6c0","type":"TRIAL","name":"Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography","canonical_id":"clinicaltrials.gov:NCT00653562","description":"Insomnia; Sleep Initiation and Maintenance Disorders","metadata":null},{"id":"207410c38cc64a349ab2e0347c5919ad","type":"TRIAL","name":"Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions","canonical_id":"clinicaltrials.gov:NCT00833937","description":"Healthy","metadata":null},{"id":"5e7b3063411e4d989ad36e03d864d48e","type":"TRIAL","name":"Zolpidem or Exercise for Insomnia?","canonical_id":"clinicaltrials.gov:NCT03160404","description":"Chronic Insomnia","metadata":null},{"id":"65c1dea71dd34b95ad3315cf7c8f497f","type":"TRIAL","name":"Zomig - Treatment of Acute Migraine Headache in Adolescents","canonical_id":"clinicaltrials.gov:NCT01211145","description":"Migraine Headache","metadata":null},{"id":"54a22420b0f04607a52d30a4e4f7598b","type":"DRUG","name":"Zongertinib","canonical_id":"ncit:C199022","description":null,"metadata":null},{"id":"407f50d6ae1447c3a25238fda001615b","type":"TRIAL","name":"Zonisamide Versus Propranolol in Migraine","canonical_id":"clinicaltrials.gov:NCT06361446","description":"Migraine","metadata":null},{"id":"57fc1e1cfdcd4c15b9414b6a94d01c8d","type":"TRIAL","name":"Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","canonical_id":"clinicaltrials.gov:NCT07551414","description":"NSCLC (Non-small Cell Lung Carcinoma); Leptomeningeal Metastasis; EGFR-TKI Sensitizing Mutation; Zorifertinib","metadata":null},{"id":"3e4b3f949fd349049c211f08c0a6906a","type":"TRIAL","name":"Zorifertinib With Osimertinib for NSCLC With Meningeal Progression","canonical_id":"clinicaltrials.gov:NCT07361705","description":"Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment","metadata":null},{"id":"d5d6ae5f0bb1454da74666eb0251ee2a","type":"TRIAL","name":"Zurig (Febuxostat) 40mg Efficacy and Safety Trial","canonical_id":"clinicaltrials.gov:NCT02600780","description":"Hyperuricemia","metadata":null},{"id":"453c7035ce094c5cbccb8d4870035202","type":"TRIAL","name":"Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial","canonical_id":"clinicaltrials.gov:NCT00689611","description":"Acute Coronary Syndrome; Myocardial Infarction; Smoking","metadata":null},{"id":"dbd2e08405704ad2b83c0973e742247a","type":"TRIAL","name":"[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease","canonical_id":"clinicaltrials.gov:NCT02012595","description":"Parkinson's Disease","metadata":null},{"id":"e7deb4d814e147ca883c5eceeb3e71c9","type":"TRIAL","name":"[11C]Yohimbine PET Study of alpha2-AR","canonical_id":"clinicaltrials.gov:NCT03520543","description":"Healthy Controls","metadata":null},{"id":"afdfe27fb9e843dd881e444de4662c98","type":"TRIAL","name":"[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis","canonical_id":"clinicaltrials.gov:NCT02700763","description":"Melanoma","metadata":null},{"id":"7fc75c718a7f48e8ae3afd99e59c4036","type":"TRIAL","name":"[18F]F-DOPA Imaging in Patients With Autonomic Failure","canonical_id":"clinicaltrials.gov:NCT04246437","description":"Autonomic Failure; Pure Autonomic Failure; Parkinson Disease; Multiple System Atrophy; Dementia With Lewy Bodies","metadata":null},{"id":"705289ae181447309923826091fb5a1e","type":"GO_TERM","name":"[2Fe-2S] cluster assembly","canonical_id":"go:GO:0044571","description":"\"The incorporation of two iron atoms and two sulfur atoms into an iron-sulfur cluster.\" [GOC:jl, GOC:mengo_curators, GOC:pde, GOC:tt, GOC:vw, PMID:15952888]","metadata":null},{"id":"f4d9647b8481460980b9b61b2abf1833","type":"GO_TERM","name":"[3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)] kinase activity","canonical_id":"go:GO:0047323","description":"\"Catalysis of the reaction: ATP + L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] = ADP + H+ + O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase].\" [RHEA:17301]","metadata":null},{"id":"86bd8e6fedd04ba9a18578d16ec0afa5","type":"GO_TERM","name":"[3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity","canonical_id":"go:GO:0047385","description":"\"Catalysis of the reaction: H2O + O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] = L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] + phosphate.\" [EC:3.1.3.52]","metadata":null},{"id":"f6e82b2e147542a8b924c9ec97bb8fb9","type":"GO_TERM","name":"[4Fe-4S] cluster assembly","canonical_id":"go:GO:0044572","description":"\"The incorporation of four iron atoms and four sulfur atoms into an iron-sulfur cluster.\" [GOC:jl, GOC:mengo_curators, GOC:pde, GOC:tt, GOC:vw, PMID:15952888]","metadata":null},{"id":"04459d090ddc48ec8c5a5cf89062b33f","type":"GO_TERM","name":"[Ni-Fe] hydrogenase complex","canonical_id":"go:GO:0044569","description":"\"A microbial enzyme complex which contains nickel and iron in its active site. In Acetomicrobium flavidum it is an alpha 2 beta 2 tetramer.\" [GOC:mengo_curators, GOC:tt, PMID:8936309]","metadata":null},{"id":"5eaf56f398654ef5ab0a0820043c8d24","type":"TRIAL","name":"[S,S]-Reboxetine Add-On Trial","canonical_id":"clinicaltrials.gov:NCT00334685","description":"Pain","metadata":null},{"id":"8df530bee2db4014bb5838c72a58a9f3","type":"TRIAL","name":"[S,S]-Reboxetine Dose-Range Finding Trial","canonical_id":"clinicaltrials.gov:NCT00288652","description":"Pain","metadata":null},{"id":"62a0b8bb1afd45d381f94796ca8d5b00","type":"TRIAL","name":"[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.","canonical_id":"clinicaltrials.gov:NCT00348894","description":"Pain","metadata":null},{"id":"7f16d346f5344a91a61e8ee3a88f8b21","type":"TRIAL","name":"[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.","canonical_id":"clinicaltrials.gov:NCT00354094","description":"Pain","metadata":null},{"id":"58dd6c7cf61042a599e1718b77f0bcdf","type":"GO_TERM","name":"[acetyl-CoA carboxylase]-phosphatase activity","canonical_id":"go:GO:0050406","description":"\"Catalysis of the reaction: [acetyl-CoA carboxylase]-phosphate + H2O = [acetyl-CoA carboxylase] + phosphate.\" [EC:3.1.3.44, MetaCyc:ACETYL-COA-CARBOXYLASE-PHOSPHATASE-RXN]","metadata":null},{"id":"18c848509ff04c1c955fc2568a5e98dd","type":"GO_TERM","name":"[acyl-carrier-protein] S-acetyltransferase activity","canonical_id":"go:GO:0004313","description":"\"Catalysis of the reaction: acetyl-CoA + [acyl-carrier protein] = CoA + acetyl-[acyl-carrier protein].\" [RHEA:41788]","metadata":null},{"id":"189eb83204f247f8b5cdde163ec26939","type":"GO_TERM","name":"[acyl-carrier-protein] S-malonyltransferase activity","canonical_id":"go:GO:0004314","description":"\"Catalysis of the reaction: malonyl-CoA + [acyl-carrier protein] = CoA + malonyl-[acyl-carrier protein].\" [EC:2.3.1.39]","metadata":null},{"id":"8181fbb421e4424aa3236a078c7df247","type":"GO_TERM","name":"[acyl-carrier-protein] phosphodiesterase activity","canonical_id":"go:GO:0008770","description":"\"Catalysis of the reaction: [acyl-carrier protein] + H2O = 4'-phosphopantetheine + apoprotein.\" [EC:3.1.4.14]","metadata":null},{"id":"01d9a105c70f4bd58e44f42ab639aebc","type":"GO_TERM","name":"[choline trimethylamine-lyase]-activating enzyme activity","canonical_id":"go:GO:0140111","description":"\"Catalyzes the activation of choline trimethylamine-lyase by generation of an organic free radical on a glycine residue via a homolytic cleavage of S-adenosyl-L-methionine (SAM).\" [PMID:24854437]","metadata":null},{"id":"f4ae8491af924c3c8f4e2a392e46ec93","type":"GO_TERM","name":"[citrate (pro-3S)-lyase] ligase activity","canonical_id":"go:GO:0008771","description":"\"Catalysis of the reaction: ATP + acetate + (citrate (pro-3S)-lyase) (thiol form) = AMP + diphosphate + (citrate (pro-3S)-lyase) (acetyl form).\" [EC:6.2.1.22]","metadata":null},{"id":"6044774d381c4f368fe000331037fc5d","type":"GO_TERM","name":"[citrate-(pro-3S)-lyase] thiolesterase activity","canonical_id":"go:GO:0047778","description":"\"Catalysis of the reaction: [citrate (pro-3S)-lyase](acetyl form) + H2O = [citrate (pro-3S)-lyase](thiol form) + acetate.\" [EC:3.1.2.16, MetaCyc:CITRATE-PRO-3S-LYASE-THIOLESTERASE-RXN]","metadata":null},{"id":"7dd3f2f74f51428b872f673c59784bb7","type":"GO_TERM","name":"[cytochrome c]-lysine N-methyltransferase activity","canonical_id":"go:GO:0000277","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + cytochrome c L-lysine = S-adenosyl-L-homocysteine + cytochrome c N6-methyl-L-lysine. This is the addition of a methyl group to the N6 atom of a lysine residue in cytochrome c.\" [EC:2.1.1.59]","metadata":null},{"id":"91e3b45fd9ef4f5ab65db0061b3f2aa2","type":"GO_TERM","name":"[cytochrome c]-methionine S-methyltransferase activity","canonical_id":"go:GO:0030783","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + [cytochrome c]-methionine = S-adenosyl-L-homocysteine + [cytochrome c]-S-methyl-methionine.\" [EC:2.1.1.123]","metadata":null},{"id":"c2f29c7c536b4ec68bfc3ac73141600d","type":"GO_TERM","name":"[formate-C-acetyltransferase]-activating enzyme activity","canonical_id":"go:GO:0043365","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + dihydroflavodoxin + [formate C-acetyltransferase]-glycine = 5'-deoxyadenosine + L-methionine + flavodoxin semiquinone + [formate C-acetyltransferase]-glycin-2-yl radical.\" [EC:1.97.1.4, GOC:jl, PMID:18307109]","metadata":null},{"id":"2140d0a01ed84b9593f8a00909d40998","type":"GO_TERM","name":"[glutamate-ammonia-ligase] adenylyltransferase activity","canonical_id":"go:GO:0008882","description":"\"Catalysis of the reaction: ATP + [L-glutamate:ammonia ligase (ADP-forming)] = diphosphate + adenylyl-[L-glutamate:ammonia ligase (ADP-forming)].\" [EC:2.7.7.42]","metadata":null},{"id":"424dfe8bfffb49f1aa63c5e50435e90f","type":"GO_TERM","name":"[glutamine synthetase]-adenylyl-L-tyrosine phosphorylase activity","canonical_id":"go:GO:0047388","description":"\"Catalysis of the reaction: [glutamine synthetase]-O(4)-(5'-adenylyl)-L-tyrosine + phosphate = [glutamine synthetase]-L-tyrosine + ADP.\" [RHEA:43716]","metadata":null},{"id":"48e6c3931fc8456887ea36124b86776f","type":"GO_TERM","name":"[glycogen-synthase-D] phosphatase activity","canonical_id":"go:GO:0050407","description":"\"Catalysis of the reaction: [glycogen-synthase D] + H2O = [glycogen-synthase I] + phosphate.\" [EC:3.1.3.42, MetaCyc:GLYCOGEN-SYNTHASE-D-PHOSPHATASE-RXN]","metadata":null},{"id":"d505238755554a63a62c5a328e17889a","type":"GO_TERM","name":"[heparan sulfate]-glucosamine 3-sulfotransferase activity","canonical_id":"go:GO:0008467","description":"\"Catalysis of the reaction: alpha-D-glucosaminyl-[heparan sulfate](n) + 3'-phosphoadenylyl sulfate = 3-sulfo-alpha-D-glucosaminyl-[heparan sulfate](n) + adenosine 3',5'-bisphosphate + H+.\" [RHEA:15461]","metadata":null},{"id":"5c272c99687e47e3a0eee2c23971112d","type":"GO_TERM","name":"[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity","canonical_id":"go:GO:0047322","description":"\"Catalysis of the reaction: [3-hydroxy-3-methylglutaryl-CoA reductase (NADPH)] + ATP = [3-hydroxy-3-methylglutaryl-CoA reductase (NADPH)] phosphate + ADP.\" [EC:2.7.11.31]","metadata":null},{"id":"1c2c0272c95a4e43927bc577d9f4bb9d","type":"GO_TERM","name":"[hydroxymethylglutaryl-CoA reductase (NADPH)]-phosphatase activity","canonical_id":"go:GO:0047384","description":"\"Catalysis of the reaction: H2O + [hydroxymethylglutaryl-CoA reductase (NADPH)] phosphate = phosphate + [hydroxymethylglutaryl-CoA reductase (NADPH)].\" [EC:3.1.3.47, MetaCyc:3.1.3.47-RXN]","metadata":null},{"id":"12b455d8931543879d72f267a942478b","type":"GO_TERM","name":"[isocitrate dehydrogenase (NADP+)] kinase activity","canonical_id":"go:GO:0008772","description":"\"Catalysis of the reaction: ATP + L-seryl-[isocitrate dehydrogenase] = ADP + H+ + O-phospho-L-seryl-[isocitrate dehydrogenase].\" [RHEA:43540]","metadata":null},{"id":"449158a846a24ab8b681eacbad5fe617","type":"GO_TERM","name":"[isocitrate dehydrogenase (NADP+)] phosphatase activity","canonical_id":"go:GO:0101014","description":"\"Catalysis of the reaction: [isocitrate dehydrogenase] phosphate + H2O = [isocitrate dehydrogenase] + phosphate.\" [MetaCyc:DEPHOSICITDEHASE-RXN, PMID:6292732]","metadata":null},{"id":"d68714022b074f718c7959205fd391c7","type":"GO_TERM","name":"[methionine synthase] reductase (NADPH) activity","canonical_id":"go:GO:0030586","description":"\"Catalysis of the reaction: [methionine synthase]-cob(II)alamin + NADPH + H+ + S-adenosyl methionine = [methionine synthase]-methylcob(I)alamin + S-adenosylhomocysteine + NADP+.\" [RHEA:23908]","metadata":null},{"id":"141fa52fe9124e75bcaecc27484afe72","type":"GO_TERM","name":"[methyl-Co(III) methanol-specific corrinoid protein]:coenzyme M methyltransferase activity","canonical_id":"go:GO:1990088","description":"\"Catalysis of the reaction: a [methyl-Co(III) methanol-specific corrinoid protein] + coenzyme M = methyl-coenzyme M + a [Co(I) methanol-specific corrinoid protein] + H+.\" [PMID:10077852, RHEA:45208]","metadata":null},{"id":"6af2c74688cd414d8e9621275bc6f1c4","type":"GO_TERM","name":"[methyl-Co(III) methylamine-specific corrinoid protein]:coenzyme M methyltransferase activity","canonical_id":"go:GO:0043833","description":"\"Catalysis of the reaction: [methyl-Co(III) methylamine-specific corrinoid protein] + coenzyme M = [Co(I) methylamine-specific corrinoid protein] + H+ + methyl-coenzyme M. This reaction is the transfer of the methyl group from the methylated corrinoid cofactor of a methylamine corrinoid protein to coenzyme M.\" [RHEA:18773]","metadata":null},{"id":"c26ed71bf9f4491aac09094d0ef31fc3","type":"GO_TERM","name":"[phosphorylase] phosphatase activity","canonical_id":"go:GO:0050196","description":"\"Catalysis of the reaction: [phosphorylase a] + 4 H2O = 2 [phosphorylase b] + 4 phosphate.\" [EC:3.1.3.17, MetaCyc:PHOSPHORYLASE-PHOSPHATASE-RXN]","metadata":null},{"id":"c8c8db4e58f142a0a93a04dda4a86715","type":"GO_TERM","name":"[protein-PII] uridylyltransferase activity","canonical_id":"go:GO:0008773","description":"\"Catalysis of the reaction: UTP + (protein-PII) = diphosphate + uridylyl-(protein-PII).\" [EC:2.7.7.59]","metadata":null},{"id":"92fda344c2f446018b28faf95cba9cb6","type":"GO_TERM","name":"[protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine/L-threonine O-N-acetyl-alpha-D-glucosaminase activity","canonical_id":"go:GO:0102571","description":"\"Catalysis of the reaction: 3-O-(N-acetyl-beta-D-glucosaminyl)-L-seryl/L-threonyl-[protein] + H2O = L-seryl//L-threonyl-[protein] + N-acetyl-D-glucosamine.\" [EC:3.2.1.169]","metadata":null},{"id":"249b857af0424b279bbb3c7eb2309046","type":"GO_TERM","name":"[protein]-asparagine 3-dioxygenase activity","canonical_id":"go:GO:0036140","description":"\"Catalysis of the reaction: peptidyl L-asparagine + 2-oxoglutarate + O2 = peptidyl 3-hydroxy-L-asparagine + succinate + CO2.\" [GOC:reh, PMID:12215170, RHEA:54260]","metadata":null},{"id":"0edc947bfff64f298db6027dfdfaca40","type":"GO_TERM","name":"[pyruvate dehydrogenase (acetyl-transferring)]-phosphatase activity","canonical_id":"go:GO:0004741","description":"\"Catalysis of the reaction: O-phospho-L-seryl-[pyruvate dehydrogenase E1 alpha subunit] + H2O = L-seryl-[pyruvate dehydrogenase E1 alpha subunit] + phosphate.\" [EC:3.1.3.43]","metadata":null},{"id":"2172e309e9544c99ab456df560b3a4ed","type":"GO_TERM","name":"[pyruvate kinase]-phosphatase activity","canonical_id":"go:GO:0050408","description":"\"Catalysis of the reaction: [pyruvate kinase] phosphate + H2O = [pyruvate kinase] + phosphate.\" [EC:3.1.3.49, MetaCyc:PYRUVATE-KINASE-PHOSPHATASE-RXN]","metadata":null},{"id":"1b92206a608045018bd92e1cbb55a7cc","type":"GO_TERM","name":"[ribulose-bisphosphate carboxylase]-lysine N-methyltransferase activity","canonical_id":"go:GO:0030785","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + [ribulose-1,5-bisphosphate carboxylase]-lysine = S-adenosyl-L-homocysteine + [ribulose-1,5-bisphosphate carboxylase]-N6-methyl-L-lysine.\" [EC:2.1.1.127]","metadata":null},{"id":"84cfc9e6f82f4aefa4d6643dd7980914","type":"GO_TERM","name":"[tyrosine 3-monooxygenase] kinase activity","canonical_id":"go:GO:0050369","description":"\"Catalysis of the reaction: ATP + L-seryl-[tyrosine-3-monooxygenase] = ADP + H+ + O-phospho-L-seryl-[tyrosine-3-monooxygenase].\" [EC:2.7.11.6]","metadata":null},{"id":"e54ad4f56ee64090af0d39ccffcbfa76","type":"TRIAL","name":"a Comparive Study of Ketamine-Propofol Versus Dexmedetomidine-Propofol Sedation in Pediatric Patients Undergoing Cardiac Catheterization for Device Closure of Simple Left-to-right Shunts","canonical_id":"clinicaltrials.gov:NCT07669012","description":"Sedation and Analgesia","metadata":null},{"id":"b2ed12dc08164e0eb59e92e669faac5f","type":"TRIAL","name":"a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","canonical_id":"clinicaltrials.gov:NCT07007949","description":"Acute Myeloid Leukemia; IDH1 Gene Mutation; Ivosidenib","metadata":null},{"id":"8b84b7a0473d47a38e9155a70dd8d646","type":"TRIAL","name":"a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics","canonical_id":"clinicaltrials.gov:NCT03430596","description":"Extrapyramidal Syndrome","metadata":null},{"id":"26993125b76b4658a98e76ebcfb0ecd6","type":"DRUG","name":"abacavir","canonical_id":"mesh:C106538","description":null,"metadata":null},{"id":"57918d021f714177b528d6fbb6c086a2","type":"DRUG","name":"abaloparatide","canonical_id":"gtopdb:8299","description":null,"metadata":null},{"id":"0d45d71cb89a45b6a912b804c39558a1","type":"DRUG","name":"abaloparatide","canonical_id":"chembl:CHEMBL3301581","description":null,"metadata":null},{"id":"31718a7ca7f049baaea2af014a060dd7","type":"COMBINATION_TREATMENT","name":"abaloparatide + romosozumab","canonical_id":"ctgov_combo:ctgov-combo-14d07cc78e05b1c8","description":null,"metadata":null},{"id":"c1989978a0b84a2dbb91654aba0c4f24","type":"DRUG","name":"abarelix","canonical_id":"gtopdb:1188","description":null,"metadata":null},{"id":"200b2395643f46acad8896096e1bdfcb","type":"DRUG","name":"abarelix","canonical_id":"chembl:CHEMBL1252","description":null,"metadata":null},{"id":"409531b0a6884d53b065f703efc2ffc1","type":"DRUG","name":"abatacept","canonical_id":"gtopdb:6891","description":null,"metadata":null},{"id":"efb52b96d3624388898352d545b11592","type":"DRUG","name":"abatacept","canonical_id":"chembl:CHEMBL1201823","description":null,"metadata":null},{"id":"f340740ae4234d9caccdfd96de99db0e","type":"COMBINATION_TREATMENT","name":"abatacept + adalimumab + tacrolimus + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-5c6a1af64c9a3822","description":null,"metadata":null},{"id":"3b64eefc7a744cf29b394eab25fc783f","type":"COMBINATION_TREATMENT","name":"abatacept + alemtuzumab + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-33356b0aa638c0d6","description":null,"metadata":null},{"id":"315830b86d3a453f818686308dc2e844","type":"COMBINATION_TREATMENT","name":"abatacept + golimumab","canonical_id":"ctgov_combo:ctgov-combo-76305e6b9db12656","description":null,"metadata":null},{"id":"8454077283cb46f38c4c98087c224bd9","type":"COMBINATION_TREATMENT","name":"abatacept + ixazomib","canonical_id":"ctgov_combo:ctgov-combo-03409110ea546402","description":null,"metadata":null},{"id":"db9caf78bb884476860bc081d0be594e","type":"COMBINATION_TREATMENT","name":"abatacept + sarilumab + tocilizumab + tofacitinib","canonical_id":"ctgov_combo:ctgov-combo-d8788da128aa526e","description":null,"metadata":null},{"id":"93d7c577642f4025a16c08350d38e9b6","type":"COMBINATION_TREATMENT","name":"abatacept + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-14dcc3f19c3cd2a9","description":null,"metadata":null},{"id":"aca40dee2e774ef887f18103c38909c1","type":"GO_TERM","name":"abaxial cell fate specification","canonical_id":"go:GO:0010158","description":"\"The process in which a cell becomes capable of differentiating autonomously into an abaxial cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:mg]","metadata":null},{"id":"fc9516b9243d4bb9b03865ce2e16239a","type":"DRUG","name":"abciximab","canonical_id":"gtopdb:6584","description":null,"metadata":null},{"id":"b141280f4a07498ab5d3933229747bd3","type":"DRUG","name":"abciximab","canonical_id":"chembl:CHEMBL1201584","description":null,"metadata":null},{"id":"104abd6499ec4f18b7dcdea81d421e98","type":"COMBINATION_TREATMENT","name":"abciximab + bivalirudin","canonical_id":"ctgov_combo:ctgov-combo-01d0c764e5f97226","description":null,"metadata":null},{"id":"ed691de52340488c837f9cd4f7a6a723","type":"COMBINATION_TREATMENT","name":"abciximab + enoxaparin","canonical_id":"ctgov_combo:ctgov-combo-0cd70634c958a769","description":null,"metadata":null},{"id":"21072f8560894ca794853f607efc014e","type":"COMBINATION_TREATMENT","name":"abciximab + tirofiban","canonical_id":"ctgov_combo:ctgov-combo-6a0f62850d440dc4","description":null,"metadata":null},{"id":"489dfc1e146348ba8c48ca3237d4aa1b","type":"DISEASE","name":"abdominal aortic aneurysm","canonical_id":"mondo:0005350","description":null,"metadata":null},{"id":"a3886e946d7742e9b1fe99fa0bd1a160","type":"GO_TERM","name":"abducens nerve development","canonical_id":"go:GO:0021560","description":"\"The process whose specific outcome is the progression of the abducens nerve over time, from its formation to the mature structure. The motor function of the abducens nerve is to contract the lateral rectus which results in abduction of the eye.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"90a02ae083194063b9b02838c877c3e6","type":"GO_TERM","name":"abducens nerve formation","canonical_id":"go:GO:0021599","description":"\"The process that gives rise to the abducens nerve. This process pertains to the initial formation of a structure from unspecified parts. The motor function of the abducens nerve is to contract the lateral rectus which results in abduction of the eye.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d97e57a11c6147f2a5d775dd70225c90","type":"GO_TERM","name":"abducens nerve maturation","canonical_id":"go:GO:0021601","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the abducens nerve to attain its fully functional state. The motor function of the abducens nerve is to contract the lateral rectus which results in abduction of the eye.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"9182638f64864cc8be535abf5e640f0d","type":"GO_TERM","name":"abducens nerve morphogenesis","canonical_id":"go:GO:0021598","description":"\"The process in which the anatomical structure of the abducens nerve is generated and organized. The motor function of the abducens nerve is to contract the lateral rectus which results in abduction of the eye.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"63e8af644c804ad6a000ba3dd801e93a","type":"GO_TERM","name":"abducens nerve structural organization","canonical_id":"go:GO:0021600","description":"\"The process that contributes to the act of creating the structural organization of the abducens nerve. This process pertains to the physical shaping of a rudimentary structure. The motor function of the abducens nerve is to contract the lateral rectus which results in abduction of the eye.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"6917db286e2d4eb2a8db1195236833ae","type":"GO_TERM","name":"abducens nucleus development","canonical_id":"go:GO:0021742","description":"\"The process whose specific outcome is the progression of the abducens nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e5f2a4a3778643ba91d2029fa37b9176","type":"GO_TERM","name":"abequosyltransferase activity","canonical_id":"go:GO:0047600","description":"\"Catalysis of the reaction: CDP-abequose + D-mannosyl-L-rhamnosyl-D-galactose-1-diphospholipid = CDP + D-abequosyl-D-mannosyl-rhamnosyl-D-galactose-1-diphospholipid.\" [EC:2.4.1.60, MetaCyc:ABEQUOSYLTRANSFERASE-RXN]","metadata":null},{"id":"b82bb18051b843a3a4c3afaec4011061","type":"GO_TERM","name":"abieta-7,13-dien-18-al (NAD+) dehydrogenase activity","canonical_id":"go:GO:0036188","description":"\"Catalysis of the reaction: abieta-7,13-diene-18-al + H2O + NAD+ = abieta-7,13-diene-18-oate + NADH + H+.\" [EC:1.2.1.74]","metadata":null},{"id":"374b5c2eec5b4ebf9383350ec4047dc1","type":"GO_TERM","name":"abieta-7,13-dien-18-ol hydroxylase activity","canonical_id":"go:GO:0036204","description":"\"Catalysis of the reaction: abieta-7,13-dien-18-ol + NADPH + H+ + O2 = abieta-7,13-dien-18-al + NADP+ + 2 H2O. This is a two step reaction. The first step is: abieta-7,13-dien-18-ol + NADPH + H+ + O2 = abieta-7,13-dien-18,18-diol + + NADP+ + H2O. The second step is a spontaneous reaction: abieta-7,13-dien-18,18-diol = abieta-7,13-dien-18-al + H2O.\" [EC:1.14.14.145]","metadata":null},{"id":"e1b5d614aa954acbbebd7b5b22f776f9","type":"GO_TERM","name":"abieta-7,13-diene hydroxylase activity","canonical_id":"go:GO:0036189","description":"\"Catalysis of the reaction: abieta-7,13-diene + NADPH + H+ + O2 = abieta-7,13-dien-18-ol + NADP+ + H2O.\" [EC:1.14.14.144]","metadata":null},{"id":"6a9c495c746240f383c748709b27282e","type":"GO_TERM","name":"abietadiene synthase activity","canonical_id":"go:GO:0050554","description":"\"Catalysis of the reaction: (+)-copalyl diphosphate = (-)-abietadiene + diphosphate.\" [EC:4.2.3.18, RHEA:13873]","metadata":null},{"id":"1e91c3fbc74c4c75a96778322caba6e7","type":"DRUG","name":"abiraterone acetate","canonical_id":"mesh:D000069501","description":null,"metadata":null},{"id":"a37adee48e8d435aa0539dfe1e3db0a4","type":"DISEASE","name":"abortion","canonical_id":"efo:1001491","description":null,"metadata":null},{"id":"3149d450e6f24bfebd8142d2506ca902","type":"GO_TERM","name":"abscisic acid binding","canonical_id":"go:GO:0010427","description":"\"Binding to abscisic acid, a plant hormone that regulates aspects of plant growth.\" [PMID:17347412]","metadata":null},{"id":"a3206075dd374503a58ae07a96bd6af2","type":"GO_TERM","name":"abscisic acid biosynthetic process","canonical_id":"go:GO:0009688","description":"\"The chemical reactions and pathways resulting in the formation of abscisic acid, 5-(1-hydroxy-2,6,6,trimethyl-4-oxocyclohex-2-en-1-y1)-3-methylpenta-2,4-dienoic acid.\" [ISBN:0387969845]","metadata":null},{"id":"89733077747f47d7837155b4b6e3f900","type":"GO_TERM","name":"abscisic acid catabolic process","canonical_id":"go:GO:0046345","description":"\"The chemical reactions and pathways resulting in the breakdown of abscisic acid, 5-(1-hydroxy-2,6,6,trimethyl-4-oxocyclohex-2-en-1-y1)-3-methylpenta-2,4-dienoic acid.\" [GOC:ai]","metadata":null},{"id":"63fc928b0b774720be7ec380f7e3ceb1","type":"GO_TERM","name":"abscisic acid glucose ester beta-glucosidase activity","canonical_id":"go:GO:0051993","description":"\"Catalysis of the reaction: abscisic acid glucose ester + H2O = abscisic acid + beta-D-glucose.\" [PMID:16990135]","metadata":null},{"id":"9b6ad79977a442ac8c977efb3122f3a1","type":"GO_TERM","name":"abscisic acid glucosyltransferase activity","canonical_id":"go:GO:0010294","description":"\"Catalysis of the reaction: (+)-abscisate + UDP-D-glucose = abscisic acid glucose ester + UDP.\" [DOI:10.1016/j.tetasy.2004.11.062]","metadata":null},{"id":"9cc98daf42f94e49b91717842b54a311","type":"GO_TERM","name":"abscisic acid homeostasis","canonical_id":"go:GO:1902265","description":"\"Any process involved in the maintenance of an internal steady state of abscisic acid within an organism or cell.\" [GOC:TermGenie, PMID:23252460]","metadata":null},{"id":"8a89d6b8abc04d84b6baae994cf44459","type":"GO_TERM","name":"abscisic acid metabolic process","canonical_id":"go:GO:0009687","description":"\"The chemical reactions and pathways involving abscisic acid, 5-(1-hydroxy-2,6,6,trimethyl-4-oxocyclohex-2-en-1-y1)-3-methylpenta-2,4-dienoic acid.\" [ISBN:0387969845]","metadata":null},{"id":"e4a595f1bcc04fb8b0d4b99f5f626838","type":"GO_TERM","name":"abscisic acid transmembrane transporter activity","canonical_id":"go:GO:0090440","description":"\"Enables the transfer of abscisic acid from one side of a membrane to the other.\" [GOC:tb]","metadata":null},{"id":"2a476ec5937a4e06823148e78a855b7f","type":"GO_TERM","name":"abscisic acid transport","canonical_id":"go:GO:0080168","description":"\"The directed movement of abscisic acid into, out of, within or between cells by means of some external agent such as a transporter or pore.\" [PMID:20133881]","metadata":null},{"id":"d1ce644f4220470ab3a11b06d027e205","type":"GO_TERM","name":"abscisic acid-activated signaling pathway","canonical_id":"go:GO:0009738","description":"\"The series of molecular signals generated by the binding of the plant hormone abscisic acid (ABA) to a receptor, and ending with modulation of a cellular process, e.g. transcription.\" [GOC:signaling, GOC:sm, PMID:24269821]","metadata":null},{"id":"dc7066b5d46a4fb984e4777a151052d1","type":"GO_TERM","name":"abscisic acid-activated signaling pathway involved in stomatal movement","canonical_id":"go:GO:1901527","description":"\"Any abscisic acid mediated signaling pathway that is involved in stomatal movement.\" [GOC:TermGenie, PMID:22730405]","metadata":null},{"id":"b37ca0eb98b6466e987619270449fcb6","type":"GO_TERM","name":"abscisic aldehyde oxidase activity","canonical_id":"go:GO:0010293","description":"\"Catalysis of the reaction: a 2-cis-(+)-abscisic aldehyde + H2O + O2 = 2-cis-(+)-abscisate + H+ + H2O2.\" [RHEA:20529]","metadata":null},{"id":"b8228c2aae0041eab10b1eea05fb6d07","type":"GO_TERM","name":"abscission","canonical_id":"go:GO:0009838","description":"\"The controlled shedding of a body part.\" [ISBN:0140514031]","metadata":null},{"id":"40c43d37200b4cc887cc6fd08f2b1cc0","type":"GO_TERM","name":"absorption of UV light","canonical_id":"go:GO:0016039","description":"\"The reception of a (UV light) photon by a cell, UV light being defined as having a wavelength within the range 13.6-400 nm.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b0cccd629dd54cfbbfa5b672ea8f0c9c","type":"GO_TERM","name":"absorption of visible light","canonical_id":"go:GO:0016038","description":"\"The reception of a (visible light) photon by a cell, visible light being defined as having a wavelength within the range 380-780 nm.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0312061c780443079c0567624ed393e6","type":"DRUG","name":"acalabrutinib","canonical_id":"gtopdb:8912","description":null,"metadata":null},{"id":"f0fd26444f5a4785aa2ff17ed9354f4f","type":"DRUG","name":"acalabrutinib","canonical_id":"chembl:CHEMBL3707348","description":null,"metadata":null},{"id":"3630df5060284667a85615647cd4bd9c","type":"COMBINATION_TREATMENT","name":"acalabrutinib + duvelisib","canonical_id":"ctgov_combo:ctgov-combo-b0674e90e9a7a8b1","description":null,"metadata":null},{"id":"d9cbabff19724f9e805f57cba71f4e55","type":"COMBINATION_TREATMENT","name":"acalabrutinib + ibrutinib","canonical_id":"ctgov_combo:ctgov-combo-a633bd4bca8596f2","description":null,"metadata":null},{"id":"7c926738ca96461db71ecd70421286d8","type":"COMBINATION_TREATMENT","name":"acalabrutinib + ibrutinib","canonical_id":"ctgov_combo:ctgov-combo-34703ba0b2868270","description":null,"metadata":null},{"id":"cbbfe51211f64da3bcab2ba849d618ad","type":"COMBINATION_TREATMENT","name":"acalabrutinib + ibrutinib","canonical_id":"ctgov_combo:ctgov-combo-236a7324225f4879","description":null,"metadata":null},{"id":"293dd9338a784c60818430ed950e886d","type":"COMBINATION_TREATMENT","name":"acalabrutinib + ibrutinib + rituximab","canonical_id":"ctgov_combo:ctgov-combo-396d89e482b54c68","description":null,"metadata":null},{"id":"be289bb5eb10428aaf6b52a4a6ce26f6","type":"COMBINATION_TREATMENT","name":"acalabrutinib + idelalisib","canonical_id":"ctgov_combo:ctgov-combo-085fa9cfc3d8ab70","description":null,"metadata":null},{"id":"7153e946390247728b01b38f69cbb523","type":"COMBINATION_TREATMENT","name":"acalabrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-0ae1eee3c27a21d2","description":null,"metadata":null},{"id":"4b5c56caaa4e4e31801377af21bbf1e5","type":"COMBINATION_TREATMENT","name":"acalabrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-3961a9f874fc4776","description":null,"metadata":null},{"id":"3f019efe8bff4db0a4631ed67494749a","type":"COMBINATION_TREATMENT","name":"acalabrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-639339f3676ce7e6","description":null,"metadata":null},{"id":"351ff4f38979435a90dc851c57544641","type":"COMBINATION_TREATMENT","name":"acalabrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-5db6664cd8b806c3","description":null,"metadata":null},{"id":"c33236e381824d0ebe72e8253a8632b4","type":"COMBINATION_TREATMENT","name":"acalabrutinib + tafasitamab","canonical_id":"ctgov_combo:ctgov-combo-e735879e3302fe37","description":null,"metadata":null},{"id":"844f811d257e40b5b2468b9ca779c0ed","type":"COMBINATION_TREATMENT","name":"acalabrutinib + tafasitamab + tazemetostat","canonical_id":"ctgov_combo:ctgov-combo-2662c3059ad4c547","description":null,"metadata":null},{"id":"bfb46bca55a440328d4cb34c485e9bad","type":"COMBINATION_TREATMENT","name":"acalabrutinib + ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-8ff66ac18959d80c","description":null,"metadata":null},{"id":"a94799958fb843ed9e55d3ed9fb40931","type":"COMBINATION_TREATMENT","name":"acalabrutinib + ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-0feb34d00379a689","description":null,"metadata":null},{"id":"b4d6eccd25df4f18878167aa7de26eae","type":"COMBINATION_TREATMENT","name":"acalabrutinib + vincristine","canonical_id":"ctgov_combo:ctgov-combo-bafa2e8109ad0533","description":null,"metadata":null},{"id":"d283010386494b41a15e60a36ff4b00f","type":"DRUG","name":"acamprosate","canonical_id":"mesh:C043877","description":null,"metadata":null},{"id":"4e6a3e254fd940e1a457307aa70d1404","type":"DRUG","name":"acarbose","canonical_id":"mesh:D020909","description":null,"metadata":null},{"id":"974e701e7c744753a0ea71e43116ee50","type":"GO_TERM","name":"acceptance of pollen","canonical_id":"go:GO:0060321","description":"\"The recognition and acceptance of pollen by cells in the stigma, mediated by the sharing and interaction of the single locus incompatibility haplotypes.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bec40d34f7d94fcbb22c21df059e3231","type":"GO_TERM","name":"accessory nerve development","canonical_id":"go:GO:0021565","description":"\"The process whose specific outcome is the progression of the accessory nerve over time, from its formation to the mature structure. In mice, the spinal branch of this motor nerve innervates the trapezius and the sternocleidomastoid muscles. The cranial branch joins the vagus nerve and innervates the same targets as the vagus nerve.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"891c6787a8e44077a918e67ca77d3f2c","type":"GO_TERM","name":"accessory nerve formation","canonical_id":"go:GO:0021608","description":"\"The process that gives rise to the accessory nerve. This process pertains to the initial formation of a structure from unspecified parts. The spinal branch of this motor nerve innervates the trapezius and the sternocleidomastoid muscles. The cranial branch joins the vagus nerve and innervates the same targets as the vagus nerve.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"c132bb8c4d7a4696a7486a33b7416c19","type":"GO_TERM","name":"accessory nerve maturation","canonical_id":"go:GO:0021606","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the accessory nerve to attain its fully functional state. The spinal branch of this motor nerve innervates the trapezius and the sternocleidomastoid muscles. The cranial branch joins the vagus nerve and innervates the same targets as the vagus nerve.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"b179d177351b4341ae629806a03ef9a2","type":"GO_TERM","name":"accessory nerve morphogenesis","canonical_id":"go:GO:0021607","description":"\"The process in which the anatomical structure of the accessory nerve is generated and organized. The spinal branch of this motor nerve innervates the trapezius and the sternocleidomastoid muscles. The cranial branch joins the vagus nerve and innervates the same targets as the vagus nerve.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"87fe2e6b1dfa44f5ab60aefcfc3d33df","type":"GO_TERM","name":"accessory nerve structural organization","canonical_id":"go:GO:0021609","description":"\"The process that contributes to the act of creating the structural organization of the accessory nerve This process pertains to the physical shaping of a rudimentary structure. The spinal branch of this motor nerve innervates the trapezius and the sternocleidomastoid muscles. The cranial branch joins the vagus nerve and innervates the same targets as the vagus nerve.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"52181959091b429bbd9d6faf8c498309","type":"GO_TERM","name":"accessory outer segment","canonical_id":"go:GO:1990906","description":"\"A cilium-like cell projection emanating from the inner segment and running alongside the outer segment of photoreceptors.\" [GOC:dph, PMID:25125189]","metadata":null},{"id":"a7d95d8715254ef99b66512eeb54f276","type":"DRUG","name":"acebutolol","canonical_id":"gtopdb:7107","description":null,"metadata":null},{"id":"4e21f1ac766649eca48a392a6df2156e","type":"DRUG","name":"aceclofenac","canonical_id":"mesh:C056498","description":null,"metadata":null},{"id":"556c26215a1443fb9a9759312b6ca79e","type":"DRUG","name":"acemetacin","canonical_id":"mesh:C026784","description":null,"metadata":null},{"id":"d1ccf4eb53c842bca6ca3a5cd0c4b9c8","type":"DRUG","name":"acenocoumarol","canonical_id":"mesh:D000074","description":null,"metadata":null},{"id":"479c6ec0aa134462aa589d49cc36b3a0","type":"GO_TERM","name":"acetaldehyde biosynthetic process","canonical_id":"go:GO:0046186","description":"\"The chemical reactions and pathways resulting in the formation of acetaldehyde, a colorless, flammable liquid intermediate in the metabolism of alcohol.\" [GOC:ai]","metadata":null},{"id":"fc03807db8e94703ae33f84acdfb4a20","type":"GO_TERM","name":"acetaldehyde catabolic process","canonical_id":"go:GO:0046187","description":"\"The chemical reactions and pathways resulting in the breakdown of acetaldehyde, a colorless, flammable liquid intermediate in the metabolism of alcohol.\" [GOC:ai]","metadata":null},{"id":"2f942e79ee7349568ae80f55fad6b32b","type":"GO_TERM","name":"acetaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0140087","description":"\"Catalysis of the reaction: acetaldehyde + NAD+ + H2O = acetate + NADH + 2 H+.\" [PMID:9473035, RHEA:25294]","metadata":null},{"id":"d4d2198f933f4e9ca1e4aacf9c87da39","type":"GO_TERM","name":"acetaldehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0140088","description":"\"Catalysis of the reaction: acetaldehyde + NADP+ + H2O = acetate + NADPH + 2 H+.\" [PMID:15659684, PMID:9473035, RHEA:25298]","metadata":null},{"id":"e9097be79fc742a68fc7ffa8f8df4b6b","type":"GO_TERM","name":"acetaldehyde dehydrogenase (acetylating, NAD+) activity","canonical_id":"go:GO:0008774","description":"\"Catalysis of the reaction: acetaldehyde + CoA + NAD+ = acetyl-CoA + NADH + H+.\" [RHEA:23288]","metadata":null},{"id":"347dddc006874c1f975bc0a478c3c276","type":"GO_TERM","name":"acetaldehyde metabolic process","canonical_id":"go:GO:0006117","description":"\"The chemical reactions and pathways involving acetaldehyde, a colorless, flammable liquid intermediate in the metabolism of alcohol.\" [GOC:curators]","metadata":null},{"id":"6b412a07ae444f17b755503b6133d0b9","type":"GO_TERM","name":"acetate CoA-transferase activity","canonical_id":"go:GO:0008775","description":"\"Catalysis of the reaction: an acyl-CoA + acetate = a carboxylate + acetyl-CoA.\" [RHEA:13381]","metadata":null},{"id":"1aaaf185d6ae4f05818337b4f38de495","type":"GO_TERM","name":"acetate CoA-transferase complex","canonical_id":"go:GO:0009329","description":"\"A heterotetrameric enzyme complex made up of two alpha subunits and two beta subunits. Part of the acetyl-CoA carboxylase complex. Catalyzes the transfer of a carboxyl group to form malonyl-CoA.\" [GOC:jl, PMID:2719476, PMID:8423010]","metadata":null},{"id":"401adc2e4b8d41489fce066eaa534fe9","type":"GO_TERM","name":"acetate biosynthetic process","canonical_id":"go:GO:0019413","description":"\"The chemical reactions and pathways resulting in the formation of acetate, the anion of acetic acid.\" [GOC:curators]","metadata":null},{"id":"0d23ae48811d4641ad29bd86900dba84","type":"GO_TERM","name":"acetate catabolic process","canonical_id":"go:GO:0045733","description":"\"The chemical reactions and pathways resulting in the breakdown of acetate, the anion of acetic acid.\" [GOC:curators]","metadata":null},{"id":"3a71fd3e915e4ba7b150fbb7c32d6ad0","type":"GO_TERM","name":"acetate ester transmembrane transporter activity","canonical_id":"go:GO:1901375","description":"\"Enables the transfer of an acetate ester from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"28bebdf4a0bc4be9bab546be5afa88ce","type":"GO_TERM","name":"acetate ester transport","canonical_id":"go:GO:1901374","description":"\"The directed movement of an acetate ester into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie]","metadata":null},{"id":"7f0a5132b15047b89d3de9eaa2d5c080","type":"GO_TERM","name":"acetate kinase (diphosphate) activity","canonical_id":"go:GO:0047601","description":"\"Catalysis of the reaction: acetate + diphosphate = acetyl phosphate + phosphate.\" [EC:2.7.2.12, RHEA:24276]","metadata":null},{"id":"a4e854071ce5478c9e6a3933112e9ef0","type":"GO_TERM","name":"acetate kinase activity","canonical_id":"go:GO:0008776","description":"\"Catalysis of the reaction: ATP + acetate = ADP + acetyl phosphate.\" [EC:2.7.2.1]","metadata":null},{"id":"c778ea13cf084ae6ad5fb79e3a130141","type":"GO_TERM","name":"acetate metabolic process","canonical_id":"go:GO:0006083","description":"\"The chemical reactions and pathways involving acetate, the anion of acetic acid.\" [GOC:curators]","metadata":null},{"id":"237329ee771b4e07a5fdc10ace1066b6","type":"GO_TERM","name":"acetate transmembrane transport","canonical_id":"go:GO:0035433","description":"\"The process in which acetate is transported across a membrane. Acetate is the 2-carbon carboxylic acid ethanoic acid.\" [GOC:vw]","metadata":null},{"id":"2eedb8a1fe7c47f1bbe5d24f08ea6054","type":"GO_TERM","name":"acetate transmembrane transporter activity","canonical_id":"go:GO:0015123","description":"\"Enables the transfer of acetate from one side of a membrane to the other. Acetate is the 2-carbon carboxylic acid ethanoic acid.\" [GOC:ai]","metadata":null},{"id":"1ebaa452677147e8a6041e2285c73817","type":"GO_TERM","name":"acetate transport","canonical_id":"go:GO:0006846","description":"\"The directed movement of acetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"4b8076ae83dd48748313a8670e1d4ddc","type":"GO_TERM","name":"acetate-CoA ligase (ADP-forming) activity","canonical_id":"go:GO:0043758","description":"\"Catalysis of the reaction: ATP + acetate + CoA = ADP + phosphate + acetyl-CoA.\" [RHEA:15081]","metadata":null},{"id":"3ca4f54fd8ba4d5881d03d5e7fd64d84","type":"GO_TERM","name":"acetate:monoatomic cation symporter activity","canonical_id":"go:GO:0043893","description":"\"Enables the transfer of acetate from one side of a membrane to the other according to the reaction: acetate(out) + cation(out) = acetate(in) + cation(in).\" [GOC:jl, PMID:14563880]","metadata":null},{"id":"f395ad1f91da48ba83d673ad50083f63","type":"GO_TERM","name":"acetate:proton symporter activity","canonical_id":"go:GO:0015360","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: acetate(out) + H+(out) = acetate(in) + H+(in).\" [TC:2.A.44.4.1]","metadata":null},{"id":"8ee194ddce0447809bd71ac43e8402cb","type":"DRUG","name":"acetazolamide","canonical_id":"gtopdb:6792","description":null,"metadata":null},{"id":"75901c8a68a340b989f9d5af274911ff","type":"DRUG","name":"acetazolamide","canonical_id":"chembl:CHEMBL20","description":null,"metadata":null},{"id":"206104ca62a049edac7cd5cca481e3d6","type":"COMBINATION_TREATMENT","name":"acetazolamide + atomoxetine + trazodone","canonical_id":"ctgov_combo:ctgov-combo-a5a0a1a88315dcfa","description":null,"metadata":null},{"id":"ab8ae21e95ff40e8bf3e94fe8afacbae","type":"COMBINATION_TREATMENT","name":"acetazolamide + bimatoprost + brinzolamide + methazolamide + timolol","canonical_id":"ctgov_combo:ctgov-combo-f9c4effcfd3415ab","description":null,"metadata":null},{"id":"bef380c596ad4a0aa8797c7c9605ba46","type":"COMBINATION_TREATMENT","name":"acetazolamide + bumetanide + chlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-30aee089c58af1f2","description":null,"metadata":null},{"id":"397f49b8c8884a788a1dbce378bc7c50","type":"COMBINATION_TREATMENT","name":"acetazolamide + methazolamide","canonical_id":"ctgov_combo:ctgov-combo-56597f6c8bf28569","description":null,"metadata":null},{"id":"f87dee9385604b538cfd8bd1bc55c7fb","type":"COMBINATION_TREATMENT","name":"acetazolamide + metolazone","canonical_id":"ctgov_combo:ctgov-combo-80a3f1aee64c4dea","description":null,"metadata":null},{"id":"4134638c43114f32b31873814bdc14e3","type":"COMBINATION_TREATMENT","name":"acetazolamide + metolazone","canonical_id":"ctgov_combo:ctgov-combo-cad087bfcb2f354c","description":null,"metadata":null},{"id":"1ea28ef3f1214f1a9144c32575f54c38","type":"COMBINATION_TREATMENT","name":"acetazolamide + nimodipine","canonical_id":"ctgov_combo:ctgov-combo-c81ec01e8a1a99d9","description":null,"metadata":null},{"id":"3ff8d1b17479461ab7b1e30bb42dcdbb","type":"COMBINATION_TREATMENT","name":"acetazolamide + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-4dfc4897625da7bc","description":null,"metadata":null},{"id":"801d2d09d4ce451799c8f70c0475e552","type":"COMBINATION_TREATMENT","name":"acetazolamide + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-0a2cfd7bea8354ed","description":null,"metadata":null},{"id":"493c1f83297e47f29ae64ed5d9be99a4","type":"COMBINATION_TREATMENT","name":"acetazolamide + timolol","canonical_id":"ctgov_combo:ctgov-combo-11104fa51a7b4d7d","description":null,"metadata":null},{"id":"6b0e3913bfb34cc989179e187a30b01d","type":"GO_TERM","name":"acetoacetate decarboxylase activity","canonical_id":"go:GO:0047602","description":"\"Catalysis of the reaction: acetoacetate + H+ = acetone + CO2.\" [EC:4.1.1.4, RHEA:19729]","metadata":null},{"id":"432f12c5d2fd497995e9b6b23ebdd7d2","type":"GO_TERM","name":"acetoacetate-CoA ligase activity","canonical_id":"go:GO:0030729","description":"\"Catalysis of the reaction: acetoacetate + ATP + CoA = acetoacetyl-CoA + AMP + diphosphate + H+.\" [EC:6.2.1.16, RHEA:16117]","metadata":null},{"id":"c262958aa1b1464fb95447af47452981","type":"GO_TERM","name":"acetoacetyl-CoA hydrolase activity","canonical_id":"go:GO:0047603","description":"\"Catalysis of the reaction: acetoacetyl-CoA + H2O = acetoacetate + CoA + H+.\" [EC:3.1.2.11, RHEA:15673]","metadata":null},{"id":"c59385d876ee41b28239ae99b3daffe7","type":"GO_TERM","name":"acetoacetyl-CoA reductase activity","canonical_id":"go:GO:0018454","description":"\"Catalysis of the reaction: (R)-3-hydroxyacyl-CoA + NADP+ = 3-oxoacyl-CoA + NADPH + H+.\" [EC:1.1.1.36]","metadata":null},{"id":"e592ab0e4ee3469a9b560991da12d351","type":"DRUG","name":"acetohydroxamic acid","canonical_id":"mesh:C006358","description":null,"metadata":null},{"id":"49a3632acc1a42a59ebd1ade5bb0db4c","type":"GO_TERM","name":"acetoin biosynthetic process","canonical_id":"go:GO:0045151","description":"\"The chemical reactions and pathways resulting in the formation of acetoin, 3-hydroxy-2-butanone.\" [GOC:mlg]","metadata":null},{"id":"1ccad93df7914200a656bae32772d0c6","type":"GO_TERM","name":"acetoin catabolic process","canonical_id":"go:GO:0045150","description":"\"The chemical reactions and pathways resulting in the breakdown of acetoin, 3-hydroxy-2-butanone.\" [GOC:mlg]","metadata":null},{"id":"37b776cb026d4eb1a00bc5b73fd764f9","type":"GO_TERM","name":"acetoin dehydrogenase (NAD+) activity","canonical_id":"go:GO:0019152","description":"\"Catalysis of the reaction: acetoin + NAD+ = diacetyl + NADH + H+. This reaction is catalyzed in the reverse direction.\" [MetaCyc:ACETOINDEHYDROG-RXN]","metadata":null},{"id":"65fc31327e464597b5c14dface5c6e8b","type":"GO_TERM","name":"acetoin metabolic process","canonical_id":"go:GO:0045149","description":"\"The chemical reactions and pathways involving acetoin, 3-hydroxy-2-butanone, often as part of a fermentation pathway or for use as a carbon source.\" [GOC:mlg]","metadata":null},{"id":"b82709dc274f4a5f9c8120d51e997639","type":"GO_TERM","name":"acetoin racemase activity","canonical_id":"go:GO:0047604","description":"\"Catalysis of the reaction: (S)-acetoin = (R)-acetoin.\" [EC:5.1.2.4, RHEA:12092]","metadata":null},{"id":"ba7df44a17f542c484eb6fa003b2dbf6","type":"GO_TERM","name":"acetoin-ribose-5-phosphate transaldolase activity","canonical_id":"go:GO:0047156","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + acetoin = 1-deoxy-D-altro-heptulose 7-phosphate + acetaldehyde.\" [RHEA:21504]","metadata":null},{"id":"9c8327508226490d8e7b19771d5c517a","type":"GO_TERM","name":"acetolactate decarboxylase activity","canonical_id":"go:GO:0047605","description":"\"Catalysis of the reaction: (S)-2-hydroxy-2-methyl-3-oxobutanoate = (R)-2-acetoin + CO2.\" [EC:4.1.1.5, MetaCyc:ACETOLACTATE-DECARBOXYLASE-RXN]","metadata":null},{"id":"f10829a016ad4f119f50f73418cb8d7e","type":"GO_TERM","name":"acetolactate synthase activity","canonical_id":"go:GO:0003984","description":"\"Catalysis of the reaction: H+ + 2 pyruvate = (2S)-2-acetolactate + CO2. Can also convert 2-oxobutanoate and pyruvate to (S)-2-ethyl-2-hydroxy-3-oxobutanoate.\" [EC:2.2.1.6]","metadata":null},{"id":"a0acd7fdf31444fdbc8c241611b14a37","type":"GO_TERM","name":"acetolactate synthase complex","canonical_id":"go:GO:0005948","description":"\"A dimeric (a large and a small chain) or tetrameric (two large and two small chains) enzyme complex. Catalyzes the formation of acetolactate from pyruvate.\" [GOC:jl, PMID:16458324, PMID:8756689]","metadata":null},{"id":"0ff8666cdb484efb8abced586dd438bb","type":"GO_TERM","name":"acetolactate synthase regulator activity","canonical_id":"go:GO:1990610","description":"\"Binds to and modulates the activity of acetolactate synthase.\" [PMID:8972574]","metadata":null},{"id":"db425e475e9d473384bece77c5871721","type":"GO_TERM","name":"acetone carboxylase activity","canonical_id":"go:GO:0018710","description":"\"Catalysis of the reaction: acetone + ATP + CO2 + 2 H2O = acetoacetate + AMP + 4 H+ + 2 phosphate.\" [EC:6.4.1.6, RHEA:18385]","metadata":null},{"id":"9d63394650b84890abd79361fef6750e","type":"GO_TERM","name":"acetoxybutynylbithiophene deacetylase activity","canonical_id":"go:GO:0047373","description":"\"Catalysis of the reaction: 5-(4-acetoxybut-1-ynyl)-2,2'-bithiophene + H2O = 5-(4-hydroxy-but-1-ynyl)-2,2'-bithiophene + acetate + H+.\" [EC:3.1.1.54, RHEA:11548]","metadata":null},{"id":"b52103953b7644738a04b69b5e1a02e7","type":"GO_TERM","name":"acetyl CoA:(Z)-3-hexen-1-ol acetyltransferase activity","canonical_id":"go:GO:0010327","description":"\"Catalysis of the reaction: acetyl-CoA + (Z)-3-hexen-1-ol = CoA + (Z)-3-hexen-1-yl acetate.\" [PMID:17163883]","metadata":null},{"id":"e5a5e31282a4438f97750b5b9f98b0a3","type":"GO_TERM","name":"acetyl-CoA C-acetyltransferase activity","canonical_id":"go:GO:0003985","description":"\"Catalysis of the reaction: 2 acetyl-CoA = CoA + acetoacetyl-CoA.\" [RHEA:21036]","metadata":null},{"id":"f2de292904244d8394c2978b8928a8b2","type":"GO_TERM","name":"acetyl-CoA C-acyltransferase activity","canonical_id":"go:GO:0003988","description":"\"Catalysis of the reaction: acyl-CoA + acetyl-CoA = CoA + 3-oxoacyl-CoA.\" [RHEA:21564]","metadata":null},{"id":"a00413bed4fc4cbcbf635411a3fc2c07","type":"GO_TERM","name":"acetyl-CoA C-myristoyltransferase activity","canonical_id":"go:GO:0050633","description":"\"Catalysis of the reaction: myristoyl-CoA + acetyl-CoA = 3-oxopalmitoyl-CoA + CoA.\" [EC:2.3.1.155, MetaCyc:2.3.1.155-RXN]","metadata":null},{"id":"03ac380a062e473fb6f3879dabca136b","type":"GO_TERM","name":"acetyl-CoA assimilation pathway","canonical_id":"go:GO:0019681","description":"\"The pathways by which acetyl-CoA is processed and converted into alpha-ketoglutarate (2-oxoglutarate); methanogenic archaea use these pathways to assimilate acetyl-CoA into the cell.\" [MetaCyc:P22-PWY]","metadata":null},{"id":"d46d8f4813d84745a700c70cb21bcb91","type":"GO_TERM","name":"acetyl-CoA binding","canonical_id":"go:GO:1905502","description":"\"Binding to acetyl-CoA, an acyl-CoA having acetyl as its S-acetyl component.\" [GO_REF:0000067, GOC:bc, GOC:krc, GOC:PARL, GOC:TermGenie, PMID:24927529]","metadata":null},{"id":"3fe724b1ec894c018b4d927225df0b4e","type":"GO_TERM","name":"acetyl-CoA biosynthetic process","canonical_id":"go:GO:0006085","description":"\"The chemical reactions and pathways resulting in the formation of acetyl-CoA, a derivative of coenzyme A in which the sulfhydryl group is acetylated.\" [GOC:curators]","metadata":null},{"id":"32096e93a3af495e82062484b562a6c7","type":"GO_TERM","name":"acetyl-CoA carboxylase activity","canonical_id":"go:GO:0003989","description":"\"Catalysis of the reaction: ATP + acetyl-CoA + HCO3- = ADP + phosphate + malonyl-CoA.\" [EC:6.4.1.2]","metadata":null},{"id":"1a09ae0a53c74795b236d8db9dd890c3","type":"GO_TERM","name":"acetyl-CoA carboxylase complex","canonical_id":"go:GO:0009317","description":"\"A protein complex that catalyzes the first step in long-chain fatty acid biosynthesis. For example, in E. coli the complex is heterohexameric and composed of biotin carbonyl carrier protein, biotin carboxylase and the acetate CoA-transferase complex.\" [GOC:jl, GOC:mah, PMID:12121720]","metadata":null},{"id":"00a16d9fb2864d1f966d0fe9a5e5ab5b","type":"GO_TERM","name":"acetyl-CoA catabolic process","canonical_id":"go:GO:0046356","description":"\"The chemical reactions and pathways resulting in the breakdown of acetyl-CoA, a derivative of coenzyme A in which the sulfhydryl group is acetylated.\" [GOC:ai]","metadata":null},{"id":"87c9894b14564b6c99cc6866a4036476","type":"GO_TERM","name":"acetyl-CoA decarbonylase/synthase-carbon monoxide dehydrogenase complex","canonical_id":"go:GO:0044672","description":"\"A multifunctional enzyme complex composed of five different polypeptides that catalyzes the decarbonylation of acetyl-CoA, cleaves the C-C and C-S bonds in the acetyl moiety of acetyl-CoA, oxidizes the carbonyl group to CO2 and transfers the methyl group to tetrahydrosarcinapterin. These reactions are important for methanogenesis.\" [GOC:mengo_curators, PMID:11607176, PMID:7693685, PMID:8955306]","metadata":null},{"id":"5c1b223e71204f5eaf61a963a58e30c8","type":"GO_TERM","name":"acetyl-CoA fermentation to butanoate","canonical_id":"go:GO:0030645","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of acetyl-CoA to butyrate, yielding energy in the form of ATP. Butanoate is secreted by the cell.\" [MetaCyc:PWY-5676]","metadata":null},{"id":"0c648343a96a4ab8b2302e2de149143b","type":"GO_TERM","name":"acetyl-CoA hydrolase activity","canonical_id":"go:GO:0003986","description":"\"Catalysis of the reaction: acetyl-CoA + H2O = acetate + CoA + H+.\" [EC:3.1.2.1, RHEA:20289]","metadata":null},{"id":"0c6967a3dbd5456e8f51e63994eb5932","type":"GO_TERM","name":"acetyl-CoA metabolic process","canonical_id":"go:GO:0006084","description":"\"The chemical reactions and pathways involving acetyl-CoA, a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is a metabolite derived from several pathways (e.g. glycolysis, fatty acid oxidation, amino-acid catabolism) and is further metabolized by the tricarboxylic acid cycle. It is a key intermediate in lipid and terpenoid biosynthesis.\" [ISBN:0198547684]","metadata":null},{"id":"2d11fa4c04ae4a70b7978efdaebf08a5","type":"GO_TERM","name":"acetyl-CoA synthetase acetyltransferase activity","canonical_id":"go:GO:0043894","description":"\"Catalysis of the acetylation of a lysine of the enzyme acetyl-CoA ligase, using acetyl-CoA as substrate. In Bacillus subtilis, this is Lys609, but it may correspond to another position in orthologs. This acetylation results in inhibition of acetyl-CoA synthetase.\" [PMID:15236963, PMID:39019872, PMID:40089509]","metadata":null},{"id":"bd304addc5d14931a4ae544c5bedd14d","type":"GO_TERM","name":"acetyl-CoA synthetase activity","canonical_id":"go:GO:0003987","description":"\"Catalysis of the reaction: acetate + ATP + CoA = acetyl-CoA + AMP + diphosphate.\" [RHEA:23176]","metadata":null},{"id":"f8fd1743dea14a8dbe0c39afa8f3cd5c","type":"GO_TERM","name":"acetyl-CoA transmembrane transport","canonical_id":"go:GO:0035348","description":"\"The process in which acetyl-CoA is transported across a membrane. Acetyl-CoA is a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is a metabolite derived from several pathways (e.g. glycolysis, fatty acid oxidation, amino-acid catabolism) and is further metabolized by the tricarboxylic acid cycle. It is a key intermediate in lipid and terpenoid biosynthesis.\" [GO:bf]","metadata":null},{"id":"e6e98348fa374a28b978869105b1b9d4","type":"GO_TERM","name":"acetyl-CoA transmembrane transporter activity","canonical_id":"go:GO:0008521","description":"\"Enables the transfer of acetyl-CoA from one side of a membrane to the other. Acetyl-CoA is a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is a metabolite derived from several pathways (e.g. glycolysis, fatty acid oxidation, amino-acid catabolism) and is further metabolized by the tricarboxylic acid cycle. It is a key intermediate in lipid and terpenoid biosynthesis.\" [GOC:ai]","metadata":null},{"id":"56eda40ab85f4db7aa73e2dd22729d8e","type":"GO_TERM","name":"acetyl-CoA transport","canonical_id":"go:GO:0015876","description":"\"The directed movement of acetyl-CoA into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Acetyl-CoA is a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is a metabolite derived from several pathways (e.g. glycolysis, fatty acid oxidation, amino-acid catabolism) and is further metabolized by the tricarboxylic acid cycle. It is a key intermediate in lipid and terpenoid biosynthesis.\" [GOC:ai]","metadata":null},{"id":"74879bc4c3534bf29b0c799a8d180d56","type":"GO_TERM","name":"acetyl-CoA:CoA antiporter activity","canonical_id":"go:GO:0015325","description":"\"Catalysis of the reaction: acetyl-CoA(out) + CoA(in) = acetyl-CoA(in) + CoA(out).\" [TC:2.A.1.25.1]","metadata":null},{"id":"004d5abe713a46dab3f550802704040f","type":"GO_TERM","name":"acetyl-CoA:oxalate CoA-transferase activity","canonical_id":"go:GO:0036412","description":"\"Catalysis of the reaction: acetyl-CoA + oxalate = acetate + oxalyl-CoA.\" [PMID:23935849, RHEA:37883]","metadata":null},{"id":"1b2e2eb7557048ca82626bc873820b81","type":"GO_TERM","name":"acetyl-coenzyme A:acetyl alcohol acetyltransferase activity","canonical_id":"go:GO:0102720","description":"\"Catalysis of the reaction: acetyl-CoA + benzyl alcohol = benzyl acetate + CoA. Also converts (E)-cinnamyl alcohol into (E)-cinnamyl acetate.\" [EC:2.3.1.224]","metadata":null},{"id":"0cb19aa1b35d4ac8a167d00c9988d550","type":"GO_TERM","name":"acetylacetone-cleaving enzyme activity","canonical_id":"go:GO:0033752","description":"\"Catalysis of the reaction: pentane-2,4-dione + O2 = acetate + 2-oxopropanal.\" [EC:1.13.11.50]","metadata":null},{"id":"454ee87d35754f8a9e8504fd7bbdf021","type":"GO_TERM","name":"acetylajmaline esterase activity","canonical_id":"go:GO:0033879","description":"\"Catalysis of the reactions: 17-O-acetylajmaline + H2O = ajmaline + acetate, and 17-O-acetylnorajmaline + H2O = norajmaline + acetate.\" [EC:3.1.1.80]","metadata":null},{"id":"de6d442b52df40b9a52ef62ca429693e","type":"GO_TERM","name":"acetylalkylglycerol acetylhydrolase activity","canonical_id":"go:GO:0047378","description":"\"Catalysis of the reaction: 2-acetyl-1-alkyl-sn-glycerol + H2O = 1-alkyl-sn-glycerol + acetate + H+.\" [EC:3.1.1.71, RHEA:11552]","metadata":null},{"id":"ef59676cb13545b6a4b89e92aa637597","type":"GO_TERM","name":"acetylation-dependent protein binding","canonical_id":"go:GO:0140033","description":"\"Binding to a protein upon acetylation of the target protein.\" [PMID:26060076]","metadata":null},{"id":"8101542899f345729601a12e367e174b","type":"GO_TERM","name":"acetylcholine binding","canonical_id":"go:GO:0042166","description":"\"Binding to acetylcholine, an acetic acid ester of the organic base choline that functions as a neurotransmitter, released at the synapses of parasympathetic nerves and at neuromuscular junctions.\" [GOC:ai]","metadata":null},{"id":"a4cd4cdeaf504d77857c3a65c6c6ae7b","type":"GO_TERM","name":"acetylcholine biosynthetic process","canonical_id":"go:GO:0008292","description":"\"The chemical reactions and pathways resulting in the formation of acetylcholine, the acetic acid ester of the organic base choline.\" [GOC:jl, ISBN:0192800752]","metadata":null},{"id":"826803d3c3eb49d68aeae536bdb6a953","type":"GO_TERM","name":"acetylcholine catabolic process","canonical_id":"go:GO:0006581","description":"\"The chemical reactions and pathways resulting in the breakdown of acetylcholine, the acetic acid ester of the organic base choline.\" [GOC:jl, ISBN:0192800752]","metadata":null},{"id":"1c0b444aecd34cef8ed7a4f2a69fb9a9","type":"GO_TERM","name":"acetylcholine catabolic process in synaptic cleft","canonical_id":"go:GO:0001507","description":"\"The chemical reactions and pathways resulting in the breakdown of acetylcholine that occurs in the synaptic cleft during synaptic transmission.\" [GOC:ai]","metadata":null},{"id":"89f32b5f59694393ac4d49609ce839b9","type":"GO_TERM","name":"acetylcholine metabolic process","canonical_id":"go:GO:0008291","description":"\"The chemical reactions and pathways involving acetylcholine, the acetic acid ester of the organic base choline. Acetylcholine is a major neurotransmitter and neuromodulator both in the central and peripheral nervous systems. It also acts as a paracrine signal in various non-neural tissues.\" [GOC:jl, GOC:nln, ISBN:0192800752]","metadata":null},{"id":"afe262468bfc4cd3aee12b88500ad748","type":"GO_TERM","name":"acetylcholine receptor activator activity","canonical_id":"go:GO:0030549","description":"\"Interacting (directly or indirectly) with acetylcholine receptors such that the proportion of receptors in the active form is increased.\" [GOC:mah]","metadata":null},{"id":"c26adb4e1e2f4346aeaffebc17fdabc4","type":"GO_TERM","name":"acetylcholine receptor activity","canonical_id":"go:GO:0015464","description":"\"Combining with an acetylcholine receptor ligand and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"2e3b3131e7594e448fcbd9ca3605788e","type":"GO_TERM","name":"acetylcholine receptor binding","canonical_id":"go:GO:0033130","description":"\"Binding to an acetylcholine receptor.\" [GOC:mah]","metadata":null},{"id":"91a6dfa3db494ce4aa71dc95c92f388d","type":"GO_TERM","name":"acetylcholine receptor inhibitor activity","canonical_id":"go:GO:0030550","description":"\"Binds to and stops, prevents or reduces the activity of an acetylcholine receptor.\" [GOC:mah]","metadata":null},{"id":"5124425da6b54420aa8b896b6a3ee43b","type":"GO_TERM","name":"acetylcholine receptor regulator activity","canonical_id":"go:GO:0030548","description":"\"Interacting (directly or indirectly) with acetylcholine receptors such that the proportion of receptors in the active form is changed.\" [GOC:mah]","metadata":null},{"id":"28eb4b6272d64222b4c1ad0df328a133","type":"GO_TERM","name":"acetylcholine receptor signaling pathway","canonical_id":"go:GO:0095500","description":"\"The series of molecular signals generated as a consequence of an acetylcholine receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"9c7dae1d79b9475d94d5b082820ea0ca","type":"GO_TERM","name":"acetylcholine secretion","canonical_id":"go:GO:0061526","description":"\"The regulated release of acetylcholine by a cell.\" [GOC:dph]","metadata":null},{"id":"5dbd0a4273ef4c8a93524b4cb523fb34","type":"GO_TERM","name":"acetylcholine secretion, neurotransmission","canonical_id":"go:GO:0014055","description":"\"The regulated release of acetylcholine by a cell. The acetylcholine acts as a neurotransmitter that acts in both the peripheral nervous system (PNS) and central nervous system (CNS).\" [GOC:ef]","metadata":null},{"id":"cc5efca6dcde40aa9ebcf1e5d5666647","type":"GO_TERM","name":"acetylcholine transmembrane transporter activity","canonical_id":"go:GO:0005277","description":"\"Enables the transfer of acetylcholine from one side of a membrane to the other. Acetylcholine is an acetic acid ester of the organic base choline and functions as a neurotransmitter, released at the synapses of parasympathetic nerves and at neuromuscular junctions.\" [GOC:ai]","metadata":null},{"id":"d1b6f3f354b04b8e9046d3e5489feab2","type":"GO_TERM","name":"acetylcholine transport","canonical_id":"go:GO:0015870","description":"\"The directed movement of acetylcholine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Acetylcholine is an acetic acid ester of the organic base choline and functions as a neurotransmitter, released at the synapses of parasympathetic nerves and at neuromuscular junctions.\" [GOC:ai]","metadata":null},{"id":"67166400ce294316b87d2151219b4c0c","type":"GO_TERM","name":"acetylcholine uptake","canonical_id":"go:GO:0051630","description":"\"The directed movement of acetylcholine into a cell, typically presynaptic neurons or glial cells. Acetylcholine is a major neurotransmitter and neuromodulator both in the central and peripheral nervous systems. It also acts as a paracrine signal in various non-neural tissues.\" [GOC:ai]","metadata":null},{"id":"6aeb6c3ff7564ff1a31308903abf3028","type":"GO_TERM","name":"acetylcholine-gated channel complex","canonical_id":"go:GO:0005892","description":"\"A homo- or hetero-pentameric protein complex that forms a transmembrane channel through which ions may pass in response to acetylcholine binding.\" [GOC:bf, GOC:mah, PMID:12381728, PMID:15579462]","metadata":null},{"id":"daefc9a894c144ac8a9992189f11d626","type":"GO_TERM","name":"acetylcholine-gated monoatomic cation-selective channel activity","canonical_id":"go:GO:0022848","description":"\"Selectively enables the transmembrane transfer of a cation by a channel that opens upon binding acetylcholine.\" [GOC:mah, PMID:2466967]","metadata":null},{"id":"02d072fea3154052b74254ebeb77f3e2","type":"GO_TERM","name":"acetylcholine-induced gastric acid secretion","canonical_id":"go:GO:0001699","description":"\"The regulated release of gastric acid by parietal cells in response to acetylcholine.\" [GOC:hjd]","metadata":null},{"id":"dbca27eb17a1424d93cdf1b9f700195d","type":"GO_TERM","name":"acetylcholine-mediated vasodilation involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0003069","description":"\"The process in which acetylcholine signaling causes vasodilation, resulting in a change in blood pressure.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"1ff7c78aa91d4b2cb53e5a29219c650d","type":"GO_TERM","name":"acetylcholine:proton antiporter activity","canonical_id":"go:GO:0005278","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + acetylcholine(in) = H+(in) + acetylcholine(out).\" [TC:2.A.1.2.13]","metadata":null},{"id":"da5f09c69e78475791538785757aa703","type":"GO_TERM","name":"acetylcholinesterase activity","canonical_id":"go:GO:0003990","description":"\"Catalysis of the reaction: acetylcholine + H2O = choline + acetate.\" [EC:3.1.1.7]","metadata":null},{"id":"53eb7347c2f2433293e5be4ceccfcf5d","type":"DRUG","name":"acetyldigitoxin","canonical_id":"gtopdb:6794","description":null,"metadata":null},{"id":"e44a6ed3a34346a9b3cca17dbe2bba41","type":"DRUG","name":"acetyldigitoxin","canonical_id":"mesh:D000112","description":null,"metadata":null},{"id":"a2beacf9a3a045f3a28420b830663a59","type":"DRUG","name":"acetyldigitoxin","canonical_id":"chembl:CHEMBL3545057","description":null,"metadata":null},{"id":"4b8ebd4dc6dc4d858b10cd776f1c45d2","type":"GO_TERM","name":"acetylene hydratase activity","canonical_id":"go:GO:0018818","description":"\"Catalysis of the reaction: acetaldehyde = acetylene + H2O.\" [EC:4.2.1.112, RHEA:17885]","metadata":null},{"id":"81d6d58133bd453f801ca27bb0ca7b6f","type":"GO_TERM","name":"acetylenecarboxylate hydratase activity","canonical_id":"go:GO:0050079","description":"\"Catalysis of the reaction: 3-oxopropanoate = propynoate + H2O.\" [RHEA:17957]","metadata":null},{"id":"e5cdd7a4166246ce918f9ac61e8be95e","type":"GO_TERM","name":"acetylenedicarboxylate decarboxylase activity","canonical_id":"go:GO:0050476","description":"\"Catalysis of the reaction: H2O + acetylenedicarboxylate = CO2 + pyruvate.\" [EC:4.1.1.78]","metadata":null},{"id":"a34f24e564e8426cbcfd19216ac14ad3","type":"GO_TERM","name":"acetylesterase activity","canonical_id":"go:GO:0008126","description":"\"Catalysis of the reaction: an acetic ester + H2O = an alcohol + acetate.\" [EC:3.1.1.6]","metadata":null},{"id":"90fa1c552dbc489d9309499f1c46db6c","type":"GO_TERM","name":"acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047224","description":"\"Catalysis of the reaction: 3-O-N-acetyl-D-galactosalaminyl-[protein] + UDP-N-acetyl-D-glucosamine = 3-O-N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosaminyl-[protein] + UDP. Linkage of the glycan to the protein occurs via the oxygen atom in the side chain of an L-serine or L-threonine residue.\" [EC:2.4.1.147]","metadata":null},{"id":"efa6d3d96a614ac68c117384efdc1095","type":"GO_TERM","name":"acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047225","description":"\"Catalysis of the reaction: N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-D-galactosaminyl-R + UDP-N-acetyl-D-glucosamine = N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-D-galactosaminyl-R + UDP.\" [EC:2.4.1.148]","metadata":null},{"id":"6edc9db5a7e44859950ab268521bd9c4","type":"GO_TERM","name":"acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0008376","description":"\"Catalysis of the transfer of an N-acetylgalactosaminyl residue from UDP-N-acetyl-galactosamine to an oligosaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"89b637e7108243248c0cc18af9fa22cb","type":"GO_TERM","name":"acetylglucosaminyltransferase activity","canonical_id":"go:GO:0008375","description":"\"Catalysis of the transfer of an N-acetylglucosaminyl residue from UDP-N-acetyl-glucosamine to a sugar.\" [ISBN:0198506732]","metadata":null},{"id":"57de35202a2c425899a78db1a4242588","type":"GO_TERM","name":"acetylglutamate kinase activity","canonical_id":"go:GO:0003991","description":"\"Catalysis of the reaction: ATP + N-acetyl-L-glutamate = ADP + N-acetyl-L-glutamate-5-phosphate.\" [EC:2.7.2.8]","metadata":null},{"id":"cbcdb480984241579b1405373d20746d","type":"GO_TERM","name":"acetylglutamate kinase regulator activity","canonical_id":"go:GO:0010307","description":"\"Binds to and modulates the activity of acetylglutamate kinase.\" [PMID:16377628]","metadata":null},{"id":"5796f4ab23ca4e349395577b85527a5f","type":"GO_TERM","name":"acetylindoxyl oxidase activity","canonical_id":"go:GO:0047608","description":"\"Catalysis of the reaction: N-acetylindoxyl + O2 = N-acetylisatin + unknown.\" [EC:1.7.3.2]","metadata":null},{"id":"20d2192574c743dfa3bc40c897de9559","type":"GO_TERM","name":"acetylornithine deacetylase activity","canonical_id":"go:GO:0008777","description":"\"Catalysis of the reaction: N2-acetyl-L-ornithine + H2O = acetate + L-ornithine.\" [EC:3.5.1.16]","metadata":null},{"id":"80d52ad7ad40400d80cbe20b1e0964f6","type":"GO_TERM","name":"acetylputrescine deacetylase activity","canonical_id":"go:GO:0047609","description":"\"Catalysis of the reaction: N-acetylputrescine + H2O = acetate + putrescine.\" [EC:3.5.1.62, RHEA:23412]","metadata":null},{"id":"1a0c677d50d54c629ba9db562c4bbd00","type":"GO_TERM","name":"acetylpyruvate hydrolase activity","canonical_id":"go:GO:0018773","description":"\"Catalysis of the reaction: acetylpyruvate + H2O = acetate + H+ + pyruvate.\" [RHEA:16097]","metadata":null},{"id":"ffa7c2ac87dc448cad7384c167349970","type":"GO_TERM","name":"acetylsalicylate deacetylase activity","canonical_id":"go:GO:0047610","description":"\"Catalysis of the reaction: acetylsalicylate + H2O = acetate + H+ + salicylate.\" [EC:3.1.1.55, RHEA:11752]","metadata":null},{"id":"2395f9c6983f41008b8b4643fa27dca8","type":"GO_TERM","name":"acetylserotonin O-methyltransferase activity","canonical_id":"go:GO:0017096","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + N-acetylserotonin = S-adenosyl-L-homocysteine + melatonin. Melatonin is also known as N-acetyl-5-methoxytryptamine.\" [EC:2.1.1.4]","metadata":null},{"id":"fe5d0549b71a4407be4c12ce9383acc6","type":"GO_TERM","name":"acetylspermidine deacetylase activity","canonical_id":"go:GO:0047611","description":"\"Catalysis of the reaction: N(8)-acetylspermidine + H2O = acetate + spermidine.\" [EC:3.5.1.48, RHEA:23928]","metadata":null},{"id":"7269be9e19c94a56aa92f6817b3dba0d","type":"GO_TERM","name":"acetyltransferase activator activity","canonical_id":"go:GO:0010698","description":"\"Binds to and increases the activity of an acetyltransferase, an enzyme which catalyzes the transfer of an acetyl group to an acceptor molecule.\" [GOC:dph, GOC:jp, GOC:tb, PMID:23912279]","metadata":null},{"id":"2dc961c52d584e08bfd8a68136c39a42","type":"GO_TERM","name":"acetyltransferase activity","canonical_id":"go:GO:0016407","description":"\"Catalysis of the transfer of an acetyl group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"a32757df8ca84029bc97e11bc50e7065","type":"GO_TERM","name":"acetyltransferase complex","canonical_id":"go:GO:1902493","description":"\"A protein complex which is capable of acetyltransferase activity.\" [GOC:bhm, GOC:TermGenie, PMID:8077207]","metadata":null},{"id":"a629d1709d5b45d9b65fbef86df0bb47","type":"GO_TERM","name":"acetylxylan esterase activity","canonical_id":"go:GO:0046555","description":"\"Catalysis of the deacetylation of xylans and xylo-oligosaccharides.\" [EC:3.1.1.72]","metadata":null},{"id":"af57633e43b345a888133f5995bf06d4","type":"GO_TERM","name":"acharan sulfate lyase activity","canonical_id":"go:GO:0052809","description":"\"Catalysis of the cleavage of a carbon-oxygen bond in acharan sulfate, a glycosaminoglycan with a uniformly repeating disaccharide structure of alpha-D-N-acetylglucosaminyl-2-O-sulfo-alpha-L-iduronic acid.\" [GOC:mengo_curators, PMID:19566715]","metadata":null},{"id":"3d9d4d013533406fb54c589e30ab0520","type":"GO_TERM","name":"achiasmate meiosis I","canonical_id":"go:GO:0000705","description":"\"The first division of meiosis in which homologous chromosomes are paired and segregated from each other, occurring in the constitutive absence of chiasmata.\" [GOC:elh, GOC:sart, PMID:10690419]","metadata":null},{"id":"e4521278ca474e17b1ddffb3d8d5e789","type":"DISEASE","name":"achondroplasia","canonical_id":"mondo:0007037","description":null,"metadata":null},{"id":"ee65f14b70124c289c55fffe8eb1c9f6","type":"GO_TERM","name":"achromobactin biosynthetic process","canonical_id":"go:GO:0042861","description":"\"The chemical reactions and pathways resulting in the formation of achromobactin, a citrate siderophore.\" [GOC:jl, PMID:10928541]","metadata":null},{"id":"e2a9162c890948ddb64bd9c79b08a926","type":"GO_TERM","name":"achromobactin catabolic process","canonical_id":"go:GO:0042862","description":"\"The chemical reactions and pathways resulting in the breakdown of achromobactin, a citrate siderophore.\" [GOC:jl, PMID:10928541]","metadata":null},{"id":"1ce2520d39d241e586ca0e8dd64a9fac","type":"GO_TERM","name":"achromobactin transmembrane transporter activity","canonical_id":"go:GO:0042934","description":"\"Enables the transfer of achromobactin, a citrate siderophore, from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"3435695b85e24095b692c11973a00a37","type":"GO_TERM","name":"achromobactin transport","canonical_id":"go:GO:0042935","description":"\"The directed movement of achromobactin, a citrate siderophore, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:10928541]","metadata":null},{"id":"d4ecb88879f74381a6a738c5846aadfa","type":"DRUG","name":"aciclovir","canonical_id":"mesh:D000212","description":null,"metadata":null},{"id":"096d8efee50c4ad78ef02809c996a8e9","type":"GO_TERM","name":"acid phosphatase activity","canonical_id":"go:GO:0003993","description":"\"Catalysis of the reaction: an orthophosphoric monoester + H2O = an alcohol + phosphate, with an acid pH optimum.\" [EC:3.1.3.2]","metadata":null},{"id":"8924133c6cd542f79b7d0000dbef3412","type":"GO_TERM","name":"acid phosphatase complex","canonical_id":"go:GO:1904097","description":"\"A protein complex which is capable of acid phosphatase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:8132635]","metadata":null},{"id":"049cfe0c33ab4dc5ba99f8cae973b6ea","type":"GO_TERM","name":"acid secretion","canonical_id":"go:GO:0046717","description":"\"The controlled release of acid by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"d57800f6f5f2447d85d7bce2d2a850eb","type":"GO_TERM","name":"acid sphingomyelin phosphodiesterase activity","canonical_id":"go:GO:0061750","description":"\"Catalysis of the reaction: H2O + sphingomyelin = ceramide + choline phosphate + H+ in an acidic environment.\" [GOC:dph, PMID:26493087]","metadata":null},{"id":"7270e89d85c34d63b9ec8766525b25b9","type":"GO_TERM","name":"acid-CoA ligase (GDP-forming) activity","canonical_id":"go:GO:0047612","description":"\"Catalysis of the reaction: a carboxylate + CoA + GTP = acyl-CoA + GDP + H+ + phosphate.\" [RHEA:10968]","metadata":null},{"id":"f7ee94279d3e4a85967ec08092b9ce8e","type":"GO_TERM","name":"acid-amino acid ligase activity","canonical_id":"go:GO:0016881","description":"\"Catalysis of the ligation of an acid to an amino acid via a carbon-nitrogen bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"72f6cd76272e415bb895ad4a5201dcf1","type":"GO_TERM","name":"acid-ammonia (or amide) ligase activity","canonical_id":"go:GO:0016880","description":"\"Catalysis of the ligation of an acid to ammonia (NH4+) or an amide via a carbon-nitrogen bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"ed929d8b56f74f248b182964872ae9e5","type":"GO_TERM","name":"acid-thiol ligase activity","canonical_id":"go:GO:0016878","description":"\"Catalysis of the joining of an acid and a thiol via a carbon-sulfur bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.2.1.-, GOC:mah]","metadata":null},{"id":"308daef56ec14aef9178c57509a08007","type":"GO_TERM","name":"acidic amino acid transmembrane transporter activity","canonical_id":"go:GO:0015172","description":"\"Enables the transfer of acidic amino acids from one side of a membrane to the other. Acidic amino acids have side chains with a negative charge at pH 7.3.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"daab86df0c584403a5e98e531b6e06d3","type":"GO_TERM","name":"acidic amino acid transport","canonical_id":"go:GO:0015800","description":"\"The directed movement of acidic amino acids, amino acids with a pH below 7, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"d0fafdb36f7b4328ad43616a5bb6b195","type":"GO_TERM","name":"acidocalcisome","canonical_id":"go:GO:0020022","description":"\"An electron-dense acidic membrane-bounded organelle which contains a matrix of pyrophosphate and polyphosphates with bound calcium and other cations.\" [GOC:mb]","metadata":null},{"id":"3c7ca8dc82b34a149839d8ea91261b93","type":"GO_TERM","name":"acidocalcisome lumen","canonical_id":"go:GO:0033985","description":"\"The volume enclosed by the membranes of an acidocalcisome.\" [GOC:mah]","metadata":null},{"id":"adb83680093140d09ef8fc38e3e02bd5","type":"GO_TERM","name":"acidocalcisome membrane","canonical_id":"go:GO:0033102","description":"\"The lipid bilayer surrounding an acidocalcisome.\" [GOC:ecd, PMID:11378195]","metadata":null},{"id":"9c3d00e4537043bdb6a51acae683ac35","type":"GO_TERM","name":"acidocalcisome organization","canonical_id":"go:GO:0106117","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an acidocalcisome. An acidocalcisome is an electron-dense acidic membrane-bounded organelle which contains a matrix of pyrophosphate and polyphosphates with bound calcium and other cations.\" [GO:0020022, PMID:25964650, PMID:26523947]","metadata":null},{"id":"a7fd76a41ef348cf8d2921eb1fd1a075","type":"GO_TERM","name":"acinar cell differentiation","canonical_id":"go:GO:0090425","description":"\"The epithelial cell differentiation process in which a relatively unspecialized cell acquires specialized features of an acinar cell, a secretory cell that is grouped together with other cells of the same type to form grape-shaped clusters known as acini.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1a0b8ebe8d3f4c18a33c54cfad3c1ccd","type":"GO_TERM","name":"acinar cell of sebaceous gland differentiation","canonical_id":"go:GO:1903680","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an acinar cell of sebaceous gland.\" [GO_REF:0000086, GOC:TermGenie, PMID:17018284, PMID:18334552, PMID:19944183]","metadata":null},{"id":"6bb6070e6f3943e999b6217fd3131048","type":"GO_TERM","name":"acinar cell proliferation","canonical_id":"go:GO:1990863","description":"\"The multiplication or reproduction of acinar cells, resulting in the expansion of a cell population. An acinar cell is a secretory cell that is grouped together with other cells of the same type to form grape-shaped clusters known as acini (singular acinus).\" [PMID:9788538]","metadata":null},{"id":"9277cae2269e41a6a5b2f679f47193ea","type":"GO_TERM","name":"acireductone dioxygenase (Ni2+-requiring) activity","canonical_id":"go:GO:0010308","description":"\"Catalysis of the reaction: 1,2-dihydroxy-5-(methylthio)pent-1-en-3-one + O2 = 3-(methylthio)propanoate + CO + formate.\" [EC:1.13.11.53, RHEA:14161]","metadata":null},{"id":"df755e72e3784fb3b6fc2d764fbe3317","type":"GO_TERM","name":"acireductone dioxygenase [iron(II)-requiring] activity","canonical_id":"go:GO:0010309","description":"\"Catalysis of the reaction: 1,2-dihydroxy-5-(methylthio)pent-1-en-3-one + O2 = 4-methylthio-2-oxobutanoate + formate + H+.\" [EC:1.13.11.54, RHEA:24504]","metadata":null},{"id":"20144c39ec1948aeaf1a2a8daab3e32d","type":"GO_TERM","name":"acireductone synthase activity","canonical_id":"go:GO:0043874","description":"\"Catalysis of the reactions:5-methylsulfanyl-2,3-dioxopentyl phosphate + H2O = 1,2-dihydroxy-5-(methylsulfanyl)pent-1-en-3-one + phosphate.\" [RHEA:21700]","metadata":null},{"id":"78bd0ac2bc884eb1bd1103e8adfb0344","type":"GO_TERM","name":"aclacinomycin T methylesterase activity","canonical_id":"go:GO:0102530","description":"\"Catalysis of the reaction: aclacinomycin T(1+) + H2O = 15-demethylaclacinomycin T + methanol + H+.\" [EC:3.1.1.95, GOC:pz]","metadata":null},{"id":"1cbec08f421343de8075b7c303ed44e7","type":"DRUG","name":"aclidinium","canonical_id":"gtopdb:7449","description":null,"metadata":null},{"id":"1f439bbc8c3d4cb5b4e58fbb46e0de14","type":"COMBINATION_TREATMENT","name":"aclidinium + formoterol","canonical_id":"ctgov_combo:ctgov-combo-5f9a047ce4dcee88","description":null,"metadata":null},{"id":"a74ce3a84c17466eb85e04c7c92117a2","type":"COMBINATION_TREATMENT","name":"aclidinium + formoterol","canonical_id":"ctgov_combo:ctgov-combo-890c6bc2981d0db1","description":null,"metadata":null},{"id":"68f6364fa0b34f579dab52e765cbb70b","type":"COMBINATION_TREATMENT","name":"aclidinium + formoterol","canonical_id":"ctgov_combo:ctgov-combo-0cde17fd4e419174","description":null,"metadata":null},{"id":"569dce7150604665a93af99aef0371a4","type":"DISEASE","name":"acne","canonical_id":"mondo:0011438","description":null,"metadata":null},{"id":"2ec1605e5cec4f7fb76b13ebe0faf14b","type":"DISEASE","name":"acne vulgaris","canonical_id":"mesh:D000152","description":null,"metadata":null},{"id":"7b794592041148b8bbe8a66697e765e2","type":"GO_TERM","name":"aconitate decarboxylase activity","canonical_id":"go:GO:0047613","description":"\"Catalysis of the reaction: cis-aconitate + H+ = CO2 + itaconate.\" [EC:4.1.1.6, RHEA:15253]","metadata":null},{"id":"ba30a31510bc4499872a9522be51f2b9","type":"GO_TERM","name":"aconitate delta-isomerase activity","canonical_id":"go:GO:0047614","description":"\"Catalysis of the reaction: trans-aconitate = cis-aconitate.\" [RHEA:17265]","metadata":null},{"id":"e9f2bbaf91734645985279199501d97d","type":"GO_TERM","name":"aconitate hydratase activity","canonical_id":"go:GO:0003994","description":"\"Catalysis of the reaction: citrate = isocitrate. The reaction occurs in two steps: (1) citrate = cis-aconitate + H2O, (2) cis-aconitate + H2O = isocitrate. This reaction is the interconversion of citrate and isocitrate via the labile, enzyme-bound intermediate cis-aconitate. Water is removed from one part of the citrate molecule and added back to a different atom to form isocitrate.\" [EC:4.2.1.3, GOC:pde, GOC:vw]","metadata":null},{"id":"1bddbe16a16e40379024c8d62956eb4d","type":"DISEASE","name":"acquired long QT syndrome","canonical_id":"efo:0005138","description":null,"metadata":null},{"id":"52548bb495f24e05acc6b3b6545d5fb0","type":"DISEASE","name":"acquired polycythemia vera","canonical_id":"mondo:0009891","description":null,"metadata":null},{"id":"7d7d03c56b564b689ab7ca4fa01876fc","type":"GO_TERM","name":"acquisition of desiccation tolerance","canonical_id":"go:GO:0097439","description":"\"The process in which tolerance to severe drying is acquired, before entering into a dry, either dormant or quiescent state.\" [GOC:PO_curators]","metadata":null},{"id":"d3afca0d6e714bdd9f7feb6f85b90961","type":"GO_TERM","name":"acquisition of desiccation tolerance in seed","canonical_id":"go:GO:0048700","description":"\"The process in which a seed acquires tolerance to severe drying, before entering into a dry, either dormant or quiescent state.\" [GOC:jid, GOC:ki, GOC:PO_curators, ISBN:9781405139830]","metadata":null},{"id":"5d65fe7b42e94830a7990fb7dbca727c","type":"GO_TERM","name":"acquisition of mycelium reproductive competence","canonical_id":"go:GO:0097737","description":"\"A maturation process by which an organism acquires the ability to reproduce. In fungi, reproductive competence only occurs in a population of filamentous cells that form a mycelium.\" [GOC:di, PMID:23864594]","metadata":null},{"id":"4c4d00741b254ed6ab0e1c701b9791a1","type":"GO_TERM","name":"acquisition of nutrients from host","canonical_id":"go:GO:0044002","description":"\"The process that begins with the production and formation of structures and molecules in an organism that are required for the acquisition and utilization of nutrients from its host organism, and the ends with the acquirement of the nutrients. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:cc, GOC:jl]","metadata":null},{"id":"817448398a4041cd927fe3269cd3ed85","type":"GO_TERM","name":"acquisition of nutrients from symbiont","canonical_id":"go:GO:0051850","description":"\"The production of structures and/or molecules in an organism that are required for the acquisition and/or utilization of nutrients obtained from its symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"132a16d8d4cc4578ab37cc16302116b2","type":"GO_TERM","name":"acquisition of plant reproductive competence","canonical_id":"go:GO:0010049","description":"\"The process in which a plant acquires the ability to respond to a floral inductive signal.\" [GOC:tair_curators]","metadata":null},{"id":"6dfe9c04cd2f44479cadeef53c6dc534","type":"GO_TERM","name":"acquisition of seed longevity","canonical_id":"go:GO:0140547","description":"\"The acquisition of seed longevity is the ordered series of events during seed development, that prevent embryo deterioration and ROS damage and thus contribute to seed viability over time or in response to adverse environmental conditions. These events include protective (e.g. production of glassy cytoplasm ) and repair (e.g. oxidative stress responses) processes.\" [PMID:26637538]","metadata":null},{"id":"3ef1b3e7e84a42dd8091a1dbc2270e9d","type":"GO_TERM","name":"acridine:proton antiporter activity","canonical_id":"go:GO:0042962","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + acridine(in) = H+(in) + acridine(out).\" [PMID:10735876]","metadata":null},{"id":"f6821ba47623468eb0c453e5e5a3df52","type":"GO_TERM","name":"acridone synthase activity","canonical_id":"go:GO:0050635","description":"\"Catalysis of the reaction: N-methylanthranilyl-CoA + 3 H+ + 3 malonyl-CoA = 1,3-dihydroxy-N-methylacridone + 3 CO2 + 4 CoA + H2O.\" [EC:2.3.1.159, RHEA:22224]","metadata":null},{"id":"652a5ff896024e28ae6a9d8c8671e556","type":"DRUG","name":"acrivastine","canonical_id":"mesh:C043648","description":null,"metadata":null},{"id":"1567f55ef318468b83137688507f6920","type":"GO_TERM","name":"acroblast","canonical_id":"go:GO:0036063","description":"\"A cone-shaped structure in the head of a spermatozoon, which is formed by the coalescence of Golgi fragments following the completion of meiosis. The acroblast is situated adjacent to the acrosomal vesicle.\" [GOC:sart, PMID:19934220]","metadata":null},{"id":"16002e9f751147239957b34950dc10cb","type":"DISEASE","name":"acrocephalosyndactyly","canonical_id":"mondo:0019796","description":null,"metadata":null},{"id":"db87be0e0cdf46cea0922e14d4bc0227","type":"DISEASE","name":"acrodysostosis","canonical_id":"mondo:0019797","description":null,"metadata":null},{"id":"e4dbb4eae0da45c4a3fc4eccab5c1280","type":"DISEASE","name":"acrodysostosis 2 with or without hormone resistance","canonical_id":"mondo:0013822","description":null,"metadata":null},{"id":"d1e3c78482a94669a6132f9ba3100d7f","type":"GO_TERM","name":"acrolein reductase activity","canonical_id":"go:GO:0102232","description":"\"Catalysis of the reaction: propanal + NADP+ = acrolein + NADPH + H+.\" [PMID:21169366, RHEA:64716]","metadata":null},{"id":"05a0bfac52db4ea79775989222459605","type":"DISEASE","name":"acromegaly","canonical_id":"mondo:0019933","description":null,"metadata":null},{"id":"5c4c769d0775452d8421dfc5e5c1dd04","type":"DISEASE","name":"acromesomelic dysplasia 1, Maroteaux type","canonical_id":"mondo:0011275","description":null,"metadata":null},{"id":"740f299c2e934e7bb012d4c7752d33d8","type":"DISEASE","name":"acroosteolysis-keloid-like lesions-premature aging syndrome","canonical_id":"mondo:0011150","description":null,"metadata":null},{"id":"db8183512fb24dde852e3d3b73fd089b","type":"GO_TERM","name":"acropetal auxin transport","canonical_id":"go:GO:0010541","description":"\"The unidirectional movement of auxin from the base towards the apex of an organ, including the shoot, leaf, primary root, or lateral root.\" [PMID:10677441]","metadata":null},{"id":"b559cd2ff7c44049a271d174d9d3446e","type":"GO_TERM","name":"acrosin binding","canonical_id":"go:GO:0032190","description":"\"Binding to acrosin, a protein that is found in the acrosomes of sperm and possesses protease and carbohydrate binding activities.\" [GOC:mah, PMID:12398221]","metadata":null},{"id":"260854561cd2463692646b9be4bb55e9","type":"GO_TERM","name":"acrosomal lumen","canonical_id":"go:GO:0043160","description":"\"The volume enclosed within the acrosome membrane.\" [GOC:curators]","metadata":null},{"id":"6e526d1498cc48c8912c5179e19d9a5f","type":"GO_TERM","name":"acrosomal matrix","canonical_id":"go:GO:0043159","description":"\"A structural framework, or 'dense core' at the interior of an acrosome. May regulate the distribution of hydrolases within the acrosome and their release during the acrosome reaction.\" [GOC:jl, PMID:8949900, PMID:9139729]","metadata":null},{"id":"b4b609fa61f34711b8fa8f7317c258aa","type":"GO_TERM","name":"acrosomal membrane","canonical_id":"go:GO:0002080","description":"\"The membrane that surrounds the acrosomal lumen. The acrosome is a special type of lysosome in the head of a spermatozoon that contains acid hydrolases and is concerned with the breakdown of the outer membrane of the ovum during fertilization.\" [GOC:dph]","metadata":null},{"id":"d9323c5f5fc64b6992f3cd6770436e6a","type":"GO_TERM","name":"acrosomal vesicle","canonical_id":"go:GO:0001669","description":"\"A structure in the head of a spermatozoon that contains acid hydrolases, and is concerned with the breakdown of the outer membrane of the ovum during fertilization. It lies just beneath the plasma membrane and is derived from the lysosome.\" [ISBN:0124325653, ISBN:0198506732]","metadata":null},{"id":"f76f957b114e4392b562c06972cbb56a","type":"GO_TERM","name":"acrosomal vesicle exocytosis","canonical_id":"go:GO:0060478","description":"\"The calcium ion regulated exocytosis which results in fusion of the acrosomal vesicle with the plasma membrane of the sperm as part of the acrosome reaction.\" [GOC:dph]","metadata":null},{"id":"75413caa2d8849ad952468f67613880f","type":"GO_TERM","name":"acrosome assembly","canonical_id":"go:GO:0001675","description":"\"The formation of the acrosome from the spermatid Golgi.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"dfc1f0f0cdb54962940535d702f49efe","type":"GO_TERM","name":"acrosome matrix dispersal","canonical_id":"go:GO:0002077","description":"\"The proteolytic digestion of components in the acrosomal matrix that occurs as part of the acrosome reaction. The process can occur either in the cumulus oophorous facilitating the penetration of it by the sperm, or at the zona pellucida allowing the sperm to reach the plasma membrane of the egg where the inner acrosomal membrane of the sperm can interact with the egg plasma membrane.\" [GOC:dph, PMID:3886029]","metadata":null},{"id":"66a2e06cfd48423bb220c91ead99ce80","type":"GO_TERM","name":"acrosome reaction","canonical_id":"go:GO:0007340","description":"\"The discharge, by sperm, of a single, anterior secretory granule following the sperm's attachment to the zona pellucida of the oocyte. The process begins with the fusion of the outer acrosomal membrane with the sperm plasma membrane and ends with the exocytosis of the acrosomal contents into the zona pellucida.\" [GOC:dph, PMID:11175768, PMID:21042299, PMID:3886029]","metadata":null},{"id":"4e752112023e425381034ed2cecfa238","type":"GO_TERM","name":"acrylonitrile catabolic process","canonical_id":"go:GO:0019256","description":"\"The chemical reactions and pathways resulting in the breakdown of acrylonitrile, a colorless, volatile liquid with a pungent odor. Acrylonitrile is used in the production of acrylic fibers, plastics, and synthetic rubbers.\" [GOC:ai, PMID:1390687, PMID:3830164]","metadata":null},{"id":"b8f7f04a39c34ddd897f417f2ab1e556","type":"GO_TERM","name":"acryloyl-CoA reductase (NADH) activity","canonical_id":"go:GO:0043958","description":"\"Catalysis of the reaction: propanoyl-CoA + NAD+ = acryloyl-CoA + H+ + NADH.\" [GOC:jl, PMID:12603323]","metadata":null},{"id":"4c661a7bae2b425f8abb6a49c8ecf4b7","type":"GO_TERM","name":"acryloyl-CoA reductase (NADPH) activity","canonical_id":"go:GO:0043957","description":"\"Catalysis of the reaction: acryloyl-CoA + NADPH + H+ = propionyl-CoA + NADP+.\" [GOC:jl, PMID:11821399, RHEA:26454]","metadata":null},{"id":"5f15e149e2a841a99f88ca727d029e07","type":"GO_TERM","name":"actin binding","canonical_id":"go:GO:0003779","description":"\"Binding to monomeric or multimeric forms of actin, including actin filaments.\" [GOC:clt]","metadata":null},{"id":"e229e6e177894a9ca1d54e6bc7198d24","type":"GO_TERM","name":"actin body","canonical_id":"go:GO:0099079","description":"\"An amorphous cytoskeletal structure consisting of aggregated actin filaments and associated proteins (including fibrin and capping protein) in which there is little or no actin filament turnover. In yeast (S. pombe and S. cerevisiae) these are found only in quiescent cells and are thought to serve as a reserve store of actin.\" [PMID:16914523]","metadata":null},{"id":"b5f13a80a1fb4b8698687a0da45eb62f","type":"GO_TERM","name":"actin cap","canonical_id":"go:GO:0030478","description":"\"Polarized accumulation of cytoskeletal proteins (including F-actin) and regulatory proteins in a cell. An example of this is the actin cap found in Saccharomyces cerevisiae.\" [GOC:mah, PMID:21494665]","metadata":null},{"id":"9ac0f75e2b944b088665e95b7737b6c0","type":"GO_TERM","name":"actin cortical patch","canonical_id":"go:GO:0030479","description":"\"An endocytic patch that consists of an actin-containing structure found at the plasma membrane in cells; formed of networks of branched actin filaments that lie just beneath the plasma membrane and assemble, move, and disassemble rapidly. An example of this is the actin cortical patch found in Saccharomyces cerevisiae.\" [GOC:mah, GOC:vw, ISBN:0879693568, ISBN:0879693649, PMID:16959963]","metadata":null},{"id":"b524e392b1a54da2a30ccc9da2d33c30","type":"GO_TERM","name":"actin cortical patch assembly","canonical_id":"go:GO:0000147","description":"\"Assembly of an actin cortical patch, a discrete actin-containing structure found at the plasma membrane of fungal cells.\" [GOC:mah]","metadata":null},{"id":"becc75e77aad40aa8221557ab2924e62","type":"GO_TERM","name":"actin cortical patch localization","canonical_id":"go:GO:0051666","description":"\"Any process in which actin cortical patches are transported to, or maintained in, a specific location. An actin cortical patch is a discrete actin-containing structure found just beneath the plasma membrane in fungal cells.\" [GOC:mah]","metadata":null},{"id":"dc2f8b8f192e4c34b5ecb67c305eb814","type":"GO_TERM","name":"actin cortical patch organization","canonical_id":"go:GO:0044396","description":"\"A process that is carried out at the cellular level and results in the assembly, arrangement of constituent parts, or disassembly of an actin cortical patch, a discrete actin-containing structure found at the plasma membrane in cells, at sites of endocytosis.\" [GOC:jl]","metadata":null},{"id":"367c992fc380477fba9f288ab2078f7f","type":"GO_TERM","name":"actin crosslink formation","canonical_id":"go:GO:0051764","description":"\"The process in which two or more actin filaments are connected together by proteins that act as crosslinks between the filaments. The crosslinked filaments may be on the same or differing axes.\" [GOC:ai]","metadata":null},{"id":"90bd57cae1f54912a6aa35b8eccddc6c","type":"GO_TERM","name":"actin cytoskeleton","canonical_id":"go:GO:0015629","description":"\"The part of the cytoskeleton (the internal framework of a cell) composed of actin and associated proteins. Includes actin cytoskeleton-associated complexes.\" [GOC:jl, ISBN:0395825172, ISBN:0815316194]","metadata":null},{"id":"4374a4e95d49411aa538fba45416c392","type":"GO_TERM","name":"actin cytoskeleton of dendritic spine","canonical_id":"go:GO:0098938","description":"\"The actin cytoskeleton that is part of a dendritic spine.\" [GOC:dos]","metadata":null},{"id":"dea52e9146654764b5f4694608b663e7","type":"GO_TERM","name":"actin cytoskeleton organization","canonical_id":"go:GO:0030036","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"c49562c5533d420987bbe2a2414e663c","type":"GO_TERM","name":"actin cytoskeleton-regulatory complex","canonical_id":"go:GO:1990964","description":"\"A protein complex probably required for the internalization of endosomes during actin-coupled endocytosis. Links the site of endocytosis to the cell membrane-associated actin cytoskeleton, coordinating ARP2/3 stimulation at the later stages of endocytosis. Present in the late endocytic coat.\" [GOC:bhm, PMID:10594004, PMID:11739778]","metadata":null},{"id":"67255e2d8f2f419ba9e2aa0a0d555e33","type":"GO_TERM","name":"actin filament","canonical_id":"go:GO:0005884","description":"\"A filamentous structure formed of a two-stranded helical polymer of the protein actin and associated proteins. Actin filaments are a major component of the contractile apparatus of skeletal muscle and the microfilaments of the cytoskeleton of eukaryotic cells. The filaments, comprising polymerized globular actin molecules, appear as flexible structures with a diameter of 5-9 nm. They are organized into a variety of linear bundles, two-dimensional networks, and three dimensional gels. In the cytoskeleton they are most highly concentrated in the cortex of the cell just beneath the plasma membrane.\" [GOC:mah, ISBN:0198506732, PMID:10666339]","metadata":null},{"id":"ce7feee67a8f47868d6fa2e1ab9987e9","type":"GO_TERM","name":"actin filament binding","canonical_id":"go:GO:0051015","description":"\"Binding to an actin filament, also known as F-actin, a helical filamentous polymer of globular G-actin subunits.\" [ISBN:0198506732]","metadata":null},{"id":"37cb8487582548b49f29a5331a452d85","type":"GO_TERM","name":"actin filament branch point","canonical_id":"go:GO:0061834","description":"\"The part of an actin filament where the structure forks.\" [PMID:18256280]","metadata":null},{"id":"19305831a1df449d917b55fb28ebcd46","type":"GO_TERM","name":"actin filament branching","canonical_id":"go:GO:0090135","description":"\"The formation of daughter actin filament branches at an angle on the sides of preexisting mother filaments.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"3428ee2919a944ed9586c20725f9e221","type":"GO_TERM","name":"actin filament bundle","canonical_id":"go:GO:0032432","description":"\"An assembly of actin filaments that are on the same axis but may be oriented with the same or opposite polarities and may be packed with different levels of tightness.\" [GOC:mah]","metadata":null},{"id":"8f51602622f24701a12f9439cfea392f","type":"GO_TERM","name":"actin filament bundle assembly","canonical_id":"go:GO:0051017","description":"\"The assembly of actin filament bundles; actin filaments are on the same axis but may be oriented with the same or opposite polarities and may be packed with different levels of tightness.\" [GOC:ai]","metadata":null},{"id":"f5876014ad46480780c609a9e79f1fde","type":"GO_TERM","name":"actin filament bundle convergence","canonical_id":"go:GO:0090426","description":"\"A process of actin filament bundle distribution that results in the compaction of actin filaments.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2d20d2050d8a4439bd92ae0ae5250282","type":"GO_TERM","name":"actin filament bundle distribution","canonical_id":"go:GO:0070650","description":"\"Any cellular process that establishes the spatial arrangement of actin filament bundles within the cell.\" [GOC:mah]","metadata":null},{"id":"188bb039b8bd43ae8396fb4515ad80f4","type":"GO_TERM","name":"actin filament bundle of actin-based cell projection","canonical_id":"go:GO:0098859","description":"\"A bundle of cross-linked actin filaments that is part of an actin-based cell protrusion, in which filaments are oriented such that the plus (barbed) ends are at the tip of the protrusion, capped by a tip complex which stabilizes the filaments.\" [PMID:12566431, PMID:15661519]","metadata":null},{"id":"6fc1f9f178c544ab945e7ff87afe5170","type":"GO_TERM","name":"actin filament bundle of filopodium","canonical_id":"go:GO:0098861","description":"\"A parallel bundle of actin filaments that is part of filopodium. Filaments are oriented such that the plus (barbed) ends are at the tip of the protrusion, capped by a tip complex.\" [PMID:12566431]","metadata":null},{"id":"736933bf86ff4e3e9cb1fc3240f721f6","type":"GO_TERM","name":"actin filament bundle of stereocilium","canonical_id":"go:GO:0098860","description":"\"A bundle of hundreds of cross-linked actin filaments (an actin cable), that is the supporting structure of a stereocilium. Filaments are oriented such that the the plus (barbed) ends are at the tip of the protrusion and are capped by a tip complex which bridges to the plasma membrane.\" [PMID:15661519]","metadata":null},{"id":"ddb367d538f542d38d14e3d98ce13c1f","type":"GO_TERM","name":"actin filament bundle organization","canonical_id":"go:GO:0061572","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of an actin filament bundle.\" [GOC:dph]","metadata":null},{"id":"1ac4a534870c4d7498c1d350387c5970","type":"GO_TERM","name":"actin filament bundle retrograde transport","canonical_id":"go:GO:0061573","description":"\"A process of actin filament bundle distribution that results in the arrangement of actin filament bundles from the periphery toward the interior of the cell.\" [GOC:dph]","metadata":null},{"id":"d8c80124d45e4cfc905aeced09396e63","type":"GO_TERM","name":"actin filament capping","canonical_id":"go:GO:0051693","description":"\"The binding of a protein or protein complex to the end of an actin filament, thus preventing the addition, exchange or removal of further actin subunits.\" [ISBN:071673706X]","metadata":null},{"id":"5b889c2cc340440ba2e08a12b34dc1c5","type":"GO_TERM","name":"actin filament debranching","canonical_id":"go:GO:0071846","description":"\"An actin filament severing process that results in the removal of actin filament branches specifically at the branch points.\" [GOC:jh, GOC:mah, PMID:20362448]","metadata":null},{"id":"73b715b961f04bf8859d05a55f35d5c7","type":"GO_TERM","name":"actin filament debranching activity","canonical_id":"go:GO:0140775","description":"\"Binding to an actin filament and promoting the dissociation of an actin filament branch.\" [PMID:20362448]","metadata":null},{"id":"f661b52a43bf445d9fa81d6e91ad4251","type":"GO_TERM","name":"actin filament depolymerization","canonical_id":"go:GO:0030042","description":"\"Disassembly of actin filaments by the removal of actin monomers from a filament.\" [GOC:mah]","metadata":null},{"id":"ad1223056c1c45b793ceea8413649138","type":"GO_TERM","name":"actin filament fragmentation","canonical_id":"go:GO:0030043","description":"\"The severing of actin filaments into numerous short fragments, usually mediated by actin severing proteins.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"d534a079e8e84828bfc3b1e329d2facc","type":"GO_TERM","name":"actin filament network formation","canonical_id":"go:GO:0051639","description":"\"The assembly of a network of actin filaments; actin filaments on different axes and with differing orientations are crosslinked together to form a mesh of filaments.\" [GOC:ai]","metadata":null},{"id":"5abf48971ae34dd4a801b066aa683282","type":"GO_TERM","name":"actin filament of cell cortex of cell tip","canonical_id":"go:GO:1903145","description":"\"Any actin filament that is part of a cell cortex of cell tip.\" [GO_REF:0000064, GOC:TermGenie, PMID:20807799, PMID:24954052]","metadata":null},{"id":"7da263bc6b66450d98f6be2d8e04ff8d","type":"GO_TERM","name":"actin filament organization","canonical_id":"go:GO:0007015","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments. Includes processes that control the spatial distribution of actin filaments, such as organizing filaments into meshworks, bundles, or other structures, as by cross-linking.\" [GOC:mah]","metadata":null},{"id":"daf705414f1d4e82b5c0f76e1b0d5239","type":"GO_TERM","name":"actin filament polymerization","canonical_id":"go:GO:0030041","description":"\"Assembly of actin filaments by the addition of actin monomers to a filament.\" [GOC:mah]","metadata":null},{"id":"13155caa9393443ea3c08663e3144302","type":"GO_TERM","name":"actin filament severing","canonical_id":"go:GO:0051014","description":"\"The process in which an actin filament is broken down into smaller filaments.\" [GOC:ai, PMID:14657234]","metadata":null},{"id":"78879bd438d44621b6944414fe2af79e","type":"GO_TERM","name":"actin filament severing activity","canonical_id":"go:GO:0003789","description":"\"Binding to an actin subunit and promoting its dissociation from an actin filament by a local change in actin subunit conformation and orientation, and severing of filaments.\" [PMID:11812157, PMID:23395798, PMID:23727096]","metadata":null},{"id":"a7f979ae09c64ca7845b71f295123a1d","type":"GO_TERM","name":"actin filament uncapping","canonical_id":"go:GO:0051695","description":"\"The removal of capping protein from the end of actin filaments to free the ends for addition, exchange or removal of further actin subunits.\" [GOC:pf]","metadata":null},{"id":"a5d50ff97ce541b2b6c3230b80a1c672","type":"GO_TERM","name":"actin filament-based movement","canonical_id":"go:GO:0030048","description":"\"Movement of organelles or other particles along actin filaments, or sliding of actin filaments past each other, mediated by motor proteins.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"459ff08e97244535942a5e071de2082c","type":"GO_TERM","name":"actin filament-based process","canonical_id":"go:GO:0030029","description":"\"Any cellular process that depends upon or alters the actin cytoskeleton, that part of the cytoskeleton comprising actin filaments and their associated proteins.\" [GOC:mah]","metadata":null},{"id":"c62edf9824934d3b8cc7f02898fe309f","type":"GO_TERM","name":"actin filament-based transport","canonical_id":"go:GO:0099515","description":"\"The transport of organelles or other particles from one location in the cell to another along actin filaments.\" [GOC:dos, GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"ed5a2be7e6fe403f9608956a2525e604","type":"GO_TERM","name":"actin lateral binding","canonical_id":"go:GO:0003786","description":"\"Binding to an actin filament along its length.\" [GOC:mah]","metadata":null},{"id":"da31f5b306d8428494d2219c67705daf","type":"GO_TERM","name":"actin modification","canonical_id":"go:GO:0030047","description":"\"Covalent modification of an actin molecule.\" [GOC:mah]","metadata":null},{"id":"9d60a4f2338f42f39496984a215e6f0e","type":"GO_TERM","name":"actin monomer binding","canonical_id":"go:GO:0003785","description":"\"Binding to monomeric actin, also known as G-actin.\" [GOC:ai]","metadata":null},{"id":"e847845b335046d7ab34083bb51cdac7","type":"GO_TERM","name":"actin monomer sequestering activity","canonical_id":"go:GO:0003788","description":"\"Binding to an actin monomer to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:11274401, PMID:1447300]","metadata":null},{"id":"c40d2b83eee1480fb0bced397655cfd8","type":"GO_TERM","name":"actin nucleation","canonical_id":"go:GO:0045010","description":"\"The initial step in the formation of an actin filament, in which actin monomers combine to form a new filament. Nucleation is slow relative to the subsequent addition of more monomers to extend the filament.\" [ISBN:0815316194]","metadata":null},{"id":"112211de7e5a482d9141293563b9be42","type":"GO_TERM","name":"actin polymerization or depolymerization","canonical_id":"go:GO:0008154","description":"\"Assembly or disassembly of actin filaments by the addition or removal of actin monomers from a filament.\" [GOC:mah]","metadata":null},{"id":"e0ab706ed88146ff986502207d480ebd","type":"GO_TERM","name":"actin polymerization-dependent cell motility","canonical_id":"go:GO:0070358","description":"\"A process involved in the controlled movement of a bacterial cell powered by the continuous polymerization of actin at one pole of the cell.\" [GOC:mah, PMID:15773977]","metadata":null},{"id":"82cd4c800cc348168c6f0c28efcb4fcc","type":"GO_TERM","name":"actin rod","canonical_id":"go:GO:0031002","description":"\"A cellular structure consisting of parallel, hexagonally arranged actin tubules, comprising filamentous actin and associated proteins. Actin rod structures are found in diverse organisms, having been observed in spores of Dictyostelium discoideum, Drosophila melanogaster oocytes, as well as in numerous animal cells under stress conditions.\" [GOC:kp, GOC:krc, PMID:11858703, PMID:19459188, PMID:22623727, PMID:24813767, PMID:27535426, PMID:7820870]","metadata":null},{"id":"d5c2f58620954d9b902d9461d440e2c0","type":"GO_TERM","name":"actin rod assembly","canonical_id":"go:GO:0031247","description":"\"The assembly of actin rods, a cellular structure consisting of parallel, hexagonally arranged actin tubules.\" [GOC:pg, PMID:14706699]","metadata":null},{"id":"a921f6fa859c4586a69420ce65f559f2","type":"GO_TERM","name":"actin severing activator activity","canonical_id":"go:GO:0000513","description":"\"Binds to and increases the activity of a actin severing protein.\" [PMID:25451933]","metadata":null},{"id":"b09b414a1d0d4028af2853748d135bc1","type":"GO_TERM","name":"actin tubule","canonical_id":"go:GO:0031003","description":"\"A cellular structure, approximately 13 nm in diameter, consisting of three actin filaments bundled together.\" [GOC:kp]","metadata":null},{"id":"5d979ada4d384e83847c9b045a6be073","type":"GO_TERM","name":"actin ubiquitination","canonical_id":"go:GO:0007014","description":"\"The modification of actin by addition of ubiquitin groups.\" [GOC:mah]","metadata":null},{"id":"6319c95cba664402a92f56450180bb57","type":"GO_TERM","name":"actin wave","canonical_id":"go:GO:0062201","description":"\"A cellular anatomical entity that is part of the actin cytoskeleton and results in a wave-like propagation of actin networks. It consists of dynamic structures traveling on the ventral (substrate-attached) side of the cell during cell migration, cytokinesis, adhesion and neurogenesis.\" [PMID:26190109, PMID:31230946, PMID:31390543, PMID:31678045, PMID:31774725]","metadata":null},{"id":"e92eca6420ab466480511349eb9d00c5","type":"GO_TERM","name":"actin-based cell projection","canonical_id":"go:GO:0098858","description":"\"A cell projection supported by an assembly of actin filaments, and which lacks microtubules.\" [PMID:15661519]","metadata":null},{"id":"7e9a9f3af94c4bc982226180047474af","type":"GO_TERM","name":"actin-dependent intracellular transport of virus","canonical_id":"go:GO:0075520","description":"\"The directed movement of a virus, or part of a virus, within the host cell cytoplasm via the host's actin filaments. Actin-dependent transport is induced by viral proteins that interact with actin and/or host cell motor proteins like myosins or that promotes actin polymerization/depolymerization reactions.\" [UniProtKB-KW:KW-1178, VZ:991]","metadata":null},{"id":"e3b5ff1837d94ac8b9f8559d89bbebc4","type":"GO_TERM","name":"actin-dependent intracellular transport of virus towards nucleus","canonical_id":"go:GO:0039680","description":"\"The directed movement of a virus, or part of a virus, towards the host cell nucleus using actin filaments.\" [UniProtKB-KW:KW-1178, VZ:991]","metadata":null},{"id":"28f86556a8dc426284898fd94ecb2df5","type":"GO_TERM","name":"actin-dependent nuclear migration","canonical_id":"go:GO:1990974","description":"\"The process whereby the centrosome is held at the cell center while the nucleus moves to the cell rear by actin retrograde flow resulting in the position of the centrosome between the nucleus and the leading edge of the cell.\" [GOC:hjd, PMID:21173262]","metadata":null},{"id":"3de47b8c1a73495ba69cb79cebdf52d3","type":"GO_TERM","name":"actin-filament cross-linking activity","canonical_id":"go:GO:7770064","description":"\"An adaptor activity that brings together two actin filaments, enabling the bundling or networking of actin filaments (F-actin).\" [GOC:vw, PMID:37025173]","metadata":null},{"id":"58abc0e649334ceb80385029edc54163","type":"GO_TERM","name":"actin-mediated cell contraction","canonical_id":"go:GO:0070252","description":"\"The actin filament-based process in which cytoplasmic actin filaments slide past one another resulting in contraction of all or part of the cell body.\" [GOC:mah]","metadata":null},{"id":"a24d2cf3c4f745e9b83678c1dc5610d4","type":"GO_TERM","name":"actin-myosin filament sliding","canonical_id":"go:GO:0033275","description":"\"The sliding movement of actin thin filaments and myosin thick filaments past each other.\" [GOC:pf]","metadata":null},{"id":"11760466231c4e7aa0a079a519c46a83","type":"DISEASE","name":"actinic keratosis","canonical_id":"mondo:0005173","description":null,"metadata":null},{"id":"6e05bb7b0e5045a2aa18ff10d0d50427","type":"GO_TERM","name":"actinin binding","canonical_id":"go:GO:0042805","description":"\"Binding to actinin, any member of a family of proteins that crosslink F-actin.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"d8107275a0034439a2960bf022a9f68b","type":"GO_TERM","name":"actinomycete-type spore formation","canonical_id":"go:GO:0034304","description":"\"The process in which differentiated, resting cells are formed from a substrate mycelium; characteristic of many members of the order Actinomycetales.\" [GOC:ds, ISBN:0122268008]","metadata":null},{"id":"c9f64facdaeb402892aee39a34e9558e","type":"GO_TERM","name":"actinomycin lactonase activity","canonical_id":"go:GO:0047615","description":"\"Catalysis of the reaction: actinomycin + H2O = actinomycinic monolactone.\" [EC:3.1.1.39, MetaCyc:ACTINOMYCIN-LACTONASE-RXN]","metadata":null},{"id":"9fff604f2a3c4d6fb435acfaf3f9d287","type":"GO_TERM","name":"actinorhodin biosynthetic process","canonical_id":"go:GO:1901112","description":"\"The chemical reactions and pathways resulting in the formation of actinorhodin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00173]","metadata":null},{"id":"af487428b80847349c7dc5822c25212b","type":"GO_TERM","name":"actinorhodin catabolic process","canonical_id":"go:GO:1901111","description":"\"The chemical reactions and pathways resulting in the breakdown of actinorhodin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00173]","metadata":null},{"id":"1ef37aee1b4148a28ece6ba9eec3ff3f","type":"GO_TERM","name":"action potential","canonical_id":"go:GO:0001508","description":"\"A process in which membrane potential cycles through a depolarizing spike, triggered in response to depolarization above some threshold, followed by repolarization. This cycle is driven by the flow of ions through various voltage gated channels with different thresholds and ion specificities.\" [GOC:curators, GOC:dph, GOC:tb, ISBN:978-0-07-139011-8]","metadata":null},{"id":"d1522dae371b4cd3bd12d400fed02792","type":"GO_TERM","name":"action potential initiation","canonical_id":"go:GO:0099610","description":"\"The initiating cycle of an action potential. In vertebrate neurons this typically occurs at an axon hillock. Not all initiated axon potentials propagate.\" [ISBN:978-0071390118, PMID:19439602]","metadata":null},{"id":"d85fc4ec8f9845c98c41fad7c2f75672","type":"GO_TERM","name":"action potential propagation","canonical_id":"go:GO:0098870","description":"\"The propagation of an action potential along the plane of an excitable membrane. Action potentials typically propagate once triggered because the depolarization of adjacent membrane regions due to an action potential crosses the firing threshold.\" [GOC:dos]","metadata":null},{"id":"2cb5049c84a947d3ad09815cec85b943","type":"GO_TERM","name":"activated CD4-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905398","description":"\"Any apoptotic process in an activated CD4-positive, alpha-beta T cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"52a6542b1193466e8c81a6fb6af43cf7","type":"GO_TERM","name":"activated CD4-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:0035741","description":"\"The expansion of an activated CD4-positive, alpha-beta T cell population by cell division.\" [CL:0000896, GOC:BHF]","metadata":null},{"id":"392d4af82f844611bfd68902b9091336","type":"GO_TERM","name":"activated CD8-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905397","description":"\"Any apoptotic process in an activated CD8-positive, alpha-beta T cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"4cd8586a7dbc4527bfdcf0a591962016","type":"GO_TERM","name":"activated CD8-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:0035742","description":"\"The expansion of an activated CD8-positive, alpha-beta T cell population by cell division.\" [CL:0000906, GOC:BHF]","metadata":null},{"id":"addc90223f3240eba779844687d8b0e9","type":"DISEASE","name":"activated PI3K-delta syndrome","canonical_id":"mondo:0018338","description":null,"metadata":null},{"id":"4401cf7fe6444322a4d1243ca7a8a771","type":"GO_TERM","name":"activated SUMO-E1 ligase complex","canonical_id":"go:GO:1990354","description":"\"A protein complex consisting of a SUMO protein bound to a SUMO activating enzyme complex. Activation by the E1 complex and linkage to the E2 enzyme UBE2I is required for the formation of covalent bonds between SUMO and its ultimate target proteins.\" [GOC:bhm, PMID:15660128]","metadata":null},{"id":"8723801db84842508daeaec39cc13c9a","type":"GO_TERM","name":"activated T cell autonomous cell death","canonical_id":"go:GO:0070238","description":"\"A T cell apoptotic process that occurs towards the end of the expansion phase following the initial activation of mature T cells by antigen via the accumulation of pro-apoptotic gene products and decrease in anti-apoptotic gene products.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"435eaba46c604145b590f7f8dfff39bb","type":"GO_TERM","name":"activated T cell proliferation","canonical_id":"go:GO:0050798","description":"\"The expansion of a T cell population following activation by an antigenic stimulus.\" [GOC:add, GOC:dph]","metadata":null},{"id":"00dece52970544249c65295ae202c7c4","type":"GO_TERM","name":"activating MHC class I receptor activity","canonical_id":"go:GO:0032397","description":"\"Combining with a MHC class I protein complex to mediate signaling that activates a lymphocyte.\" [GOC:add, PMID:11858820, PMID:9597134]","metadata":null},{"id":"cb046642824e4e5fab39ea93df3441a8","type":"GO_TERM","name":"activating MHC class Ib receptor activity","canonical_id":"go:GO:0062081","description":"\"Combining with a MHC class Ib protein complex to mediate signaling that activates a lymphocyte.\" [DOI:10.1002/9780470015902.a0024246]","metadata":null},{"id":"6f9eea4fdd3949eca95f6b49a1d465d1","type":"GO_TERM","name":"activation of GTPase activity","canonical_id":"go:GO:0090630","description":"\"Any process that initiates the activity of an inactive GTPase through the replacement of GDP by GTP.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"04706e26893b47318c6260fc67c49c74","type":"GO_TERM","name":"activation of Janus kinase activity","canonical_id":"go:GO:0042976","description":"\"The process of introducing a phosphate group to a tyrosine residue of a JAK (Janus Activated Kinase) protein, thereby activating it.\" [GOC:jl, PMID:12479803]","metadata":null},{"id":"b2b11dc11fe0442682591f0584096aaf","type":"GO_TERM","name":"activation of NF-kappaB-inducing kinase activity","canonical_id":"go:GO:0007250","description":"\"The stimulation of the activity of NF-kappaB-inducing kinase through phosphorylation at specific residues.\" [GOC:jl, PMID:12773372]","metadata":null},{"id":"322056fa6b554f62b444df181fb9d65a","type":"GO_TERM","name":"activation of adenylate cyclase activity","canonical_id":"go:GO:0007190","description":"\"Any process that initiates the activity of the inactive enzyme adenylate cyclase.\" [GOC:ai]","metadata":null},{"id":"019a0a857739421984b93cc47feac356","type":"GO_TERM","name":"activation of blood coagulation via clotting cascade","canonical_id":"go:GO:0002543","description":"\"Any process that initiates the clotting cascade of blood coagulation, a cascade of plasma enzymes that is triggered following damage to blood vessels, leading to formation of a clot.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"645b70af9f92479d80f27c04b9329b87","type":"GO_TERM","name":"activation of immune response","canonical_id":"go:GO:0002253","description":"\"Any process that initiates an immune response.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"dee8668a0e6b4456b79f53370fd0179e","type":"GO_TERM","name":"activation of innate immune response","canonical_id":"go:GO:0002218","description":"\"Any process that initiates an innate immune response. Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. Examples of this process include activation of the hypersensitive response of Arabidopsis thaliana and activation of any NOD or TLR signaling pathway in vertebrate species.\" [GO_REF:0000022, GOC:add, GOC:mtg_sensu, ISBN:0781735149, PMID:15199967, PMID:16177805]","metadata":null},{"id":"205b9c54373e458880bf2ef2020027f2","type":"GO_TERM","name":"activation of meiosis","canonical_id":"go:GO:0090427","description":"\"Any process that starts the inactive process of meiosis.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3de0e4afb86045a1983d75228edae76f","type":"GO_TERM","name":"activation of meiosis I spindle assembly checkpoint","canonical_id":"go:GO:0090687","description":"\"Any process that starts the inactive process of a meiosis I cell cycle spindle assembly checkpoint.\" [GOC:mah]","metadata":null},{"id":"ec3d28caf60343eaa8db06a6f01c56eb","type":"GO_TERM","name":"activation of meiosis involved in egg activation","canonical_id":"go:GO:0060466","description":"\"Any process that starts the inactive process of meiosis in an egg after the egg has been fertilized or physiologically activated. Eggs generally arrest in meiosis and complete the process after activation.\" [GOC:dph]","metadata":null},{"id":"f0a0a947383b4004b10a6b6dbfd875bf","type":"GO_TERM","name":"activation of membrane attack complex","canonical_id":"go:GO:0001905","description":"\"The activation of the membrane attack complex components of the complement cascade which can result in death of a target cell through cytolysis.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"32d0b7ab102743dc822cdd4181adfc43","type":"GO_TERM","name":"activation of microtubule nucleation","canonical_id":"go:GO:0090064","description":"\"Any process that starts the inactive process of microtubule nucleation. Microtubule nucleation is the 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates, some of which go on to support formation of a complete microtubule. Microtubule nucleation usually occurs from a specific site within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9eca8c5cd3cf4108b73bd5b021c31ef4","type":"GO_TERM","name":"activation of mitotic cell cycle spindle assembly checkpoint","canonical_id":"go:GO:0090268","description":"\"Any process that starts the inactive process of a mitotic cell cycle spindle assembly checkpoint.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"4212e1a41a314bdab19e3cae9544d636","type":"GO_TERM","name":"activation of monopolar cell growth","canonical_id":"go:GO:0051522","description":"\"Any process that initiates the inactive process of monopolar cell growth, polarized growth from one end of a cell.\" [GOC:ai]","metadata":null},{"id":"cee9b1bdd8d84769ae2ded68085175a6","type":"GO_TERM","name":"activation of plasma proteins involved in acute inflammatory response","canonical_id":"go:GO:0002541","description":"\"Any process activating plasma proteins by proteolysis as part of an acute inflammatory response.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"d89039b03773485e8da52a6514de744d","type":"GO_TERM","name":"activation of protein kinase A activity","canonical_id":"go:GO:0034199","description":"\"Any process that initiates the activity of the inactive enzyme protein kinase A.\" [GOC:pde]","metadata":null},{"id":"1a9717ebb94d4126be3d25857be269b6","type":"GO_TERM","name":"activation of protein kinase B activity","canonical_id":"go:GO:0032148","description":"\"Any process that initiates the activity of the inactive enzyme protein kinase B.\" [GOC:pg]","metadata":null},{"id":"e733eaf04e34453eadffbd38619d793b","type":"GO_TERM","name":"activation of protein kinase C activity","canonical_id":"go:GO:1990051","description":"\"Any process that initiates the activity of the inactive enzyme protein kinase C.\" [PMID:3156004]","metadata":null},{"id":"3fae6e41ab9c446b872eef654e19ee24","type":"GO_TERM","name":"activation of protein kinase activity","canonical_id":"go:GO:0032147","description":"\"Any process that initiates the activity of an inactive protein kinase.\" [GOC:mah]","metadata":null},{"id":"26a24d2888cc418c909358fb955c5a5a","type":"GO_TERM","name":"activation of reciprocal meiotic recombination","canonical_id":"go:GO:0010846","description":"\"Any process that starts the inactive process of reciprocal meiotic recombination. Reciprocal meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"40bf89e8632940b2bbff425809204b6f","type":"GO_TERM","name":"activation of recombination (HML)","canonical_id":"go:GO:0007536","description":"\"The activation of recombination at a mating type locus, such that it is used in preference to the other donor locus for mating type switching; exemplified by the HML locus and surrounding sequences on Chromosome III in Saccharomyces cerevisiae.\" [GOC:mah, PMID:9928492]","metadata":null},{"id":"814cb2fbea034cc4bf811e2fe4840852","type":"GO_TERM","name":"activation of store-operated calcium channel activity","canonical_id":"go:GO:0032237","description":"\"A process that initiates the activity of an inactive store-operated calcium channel.\" [GOC:mah]","metadata":null},{"id":"8385f9fb0d774a5b81960c7318548910","type":"GO_TERM","name":"activation of transmembrane receptor protein tyrosine kinase activity","canonical_id":"go:GO:0007171","description":"\"Any process that initiates the activity of the inactive transmembrane receptor protein tyrosine kinase activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7bd48822a2f64c768d743b6e2b93bc26","type":"GO_TERM","name":"activation-induced B cell apoptotic process","canonical_id":"go:GO:0071948","description":"\"B cell apoptotic process that occurs upon engagement of either the B cell receptor or CD40. Engagement of either receptor, but not both, leads to expression of fas or related receptors that make the B cell susceptible to fas-ligand mediated death.\" [GOC:mtg_apoptosis, GOC:tfm, PMID:11032170, PMID:19300454]","metadata":null},{"id":"69c2004e054f404ab097f7bd5f8f8daf","type":"GO_TERM","name":"activation-induced cell death of T cells","canonical_id":"go:GO:0006924","description":"\"A T cell apoptotic process that occurs towards the end of the expansion phase following the initial activation of mature T cells by antigen and is triggered by T cell receptor stimulation and signals transmitted via various surface-expressed members of the TNF receptor family such as Fas ligand, Fas, and TNF and the p55 and p75 TNF receptors.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196, PMID:12414721, PMID:12752672]","metadata":null},{"id":"a5658fe4ec92464c83bd605009af2817","type":"GO_TERM","name":"activator ecdysone receptor complex","canonical_id":"go:GO:0008232","description":"\"A protein complex consisting of a heterodimer of Ecdysone receptor (EcR) and ultraspiracle (usp) bound to the ligand ecdysone, which activates transcription of target genes.\" [PMID:10488333]","metadata":null},{"id":"783bcd250a55416b87f592c937d5fcdc","type":"GO_TERM","name":"active monoatomic ion transmembrane transporter activity","canonical_id":"go:GO:0022853","description":"\"Enables the transfer of an ion from one side of a membrane to the other up the solute's concentration gradient. This is carried out by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"7b4c5d2e7b714b47969c452fa6186e1c","type":"GO_TERM","name":"active sex chromosome","canonical_id":"go:GO:0098579","description":"\"A sex chromosome that has not been inactivated.\" [GOC:dos]","metadata":null},{"id":"05489f01adc843f6a630e0f34589322b","type":"GO_TERM","name":"active transmembrane transporter activity","canonical_id":"go:GO:0022804","description":"\"Enables the transfer of a specific substance or related group of substances from one side of a membrane to the other, up the solute's concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"80889ab0b49d4a92a1200c4dac2932bd","type":"GO_TERM","name":"activin A complex","canonical_id":"go:GO:0043509","description":"\"A nonsteroidal regulator, composed of two covalently linked inhibin beta-A subunits (sometimes known as activin beta-A or activin/inhibin beta-A).\" [GOC:curators]","metadata":null},{"id":"8adb362ac423465baf3ee60d6caef4be","type":"GO_TERM","name":"activin AB complex","canonical_id":"go:GO:0048183","description":"\"A nonsteroidal regulator, composed of two covalently linked inhibin beta subunits (sometimes known as activin beta or activin/inhibin beta), inhibin beta-A and inhibin beta-B.\" [GOC:curators]","metadata":null},{"id":"0bbd48da98874cd5a7c4281b171bcc07","type":"GO_TERM","name":"activin B complex","canonical_id":"go:GO:0043510","description":"\"A nonsteroidal regulator, composed of two covalently linked inhibin beta-B subunits (sometimes known as activin beta-B or activin/inhibin beta-B).\" [GOC:curators]","metadata":null},{"id":"8426efd3c7af4967939619dee2b070e4","type":"GO_TERM","name":"activin binding","canonical_id":"go:GO:0048185","description":"\"Binding to activin, a dimer of inhibin-beta subunits.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"9a14436ab9a9406b9bbbd729fe26d147","type":"GO_TERM","name":"activin complex","canonical_id":"go:GO:0048180","description":"\"A nonsteroidal regulator, composed of two covalently linked inhibin beta subunits, inhibin beta-A and inhibin beta-B (sometimes known as activin beta or activin/inhibin beta). There are three forms of activin complex, activin A, which is composed of 2 inhibin beta-A subunits, activin B, which is composed of 2 inhibin beta-B subunits, and activin AB, which is composed of an inhibin beta-A and an inhibin beta-B subunit.\" [GOC:curators]","metadata":null},{"id":"a6c27bcacbef4e8ea66e2c3c60804a8b","type":"GO_TERM","name":"activin receptor activity","canonical_id":"go:GO:0017002","description":"\"Combining with activin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Activin is one of two gonadal glycoproteins related to transforming growth factor beta.\" [GOC:mah, GOC:signaling, ISBN:0198506732]","metadata":null},{"id":"d42cfdca6ba94bb1a59d02d4d071bbb6","type":"GO_TERM","name":"activin receptor activity, type I","canonical_id":"go:GO:0016361","description":"\"Combining with activin-bound type II activin receptor to initiate a change in cell activity; upon binding, acts as a downstream transducer of activin signals.\" [GOC:mah, PMID:8622651]","metadata":null},{"id":"c1233c49347b49169edf55f04d652d06","type":"GO_TERM","name":"activin receptor activity, type II","canonical_id":"go:GO:0016362","description":"\"Combining with activin to initiate a change in cell activity; upon ligand binding, binds to and catalyses the phosphorylation of a type I activin receptor.\" [GOC:mah, PMID:8622651]","metadata":null},{"id":"23b2eb2587574be98e3f9a0fc780487b","type":"GO_TERM","name":"activin receptor antagonist activity","canonical_id":"go:GO:0038102","description":"\"Interacting with an activin receptor complex to reduce the action of another ligand, the agonist. A receptor antagonist does not initiate signaling upon binding to a receptor, but instead blocks an agonist from binding to the receptor.\" [GOC:signaling, PMID:15062104]","metadata":null},{"id":"ad0e10d9efef4a388acff014b73605fb","type":"GO_TERM","name":"activin receptor binding","canonical_id":"go:GO:0070697","description":"\"Binding to an activin receptor.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"4b25e4fbdba94c569f32618a40ef7a0d","type":"GO_TERM","name":"activin receptor complex","canonical_id":"go:GO:0048179","description":"\"A protein complex that acts as an activin receptor. Heterodimeric activin receptors, comprising one Type I activin receptor and one Type II receptor polypeptide, and heterotrimeric receptors have been observed.\" [PMID:8307945, PMID:8622651]","metadata":null},{"id":"f4620c41b908473e9817b719f05d9137","type":"GO_TERM","name":"activin receptor signaling pathway","canonical_id":"go:GO:0032924","description":"\"The series of molecular signals initiated by an extracellular ligand binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:rl, GOC:signaling]","metadata":null},{"id":"340de42dd9364bf6a7ba85332e6fd280","type":"GO_TERM","name":"activin responsive factor complex","canonical_id":"go:GO:0032444","description":"\"A transcriptionally active complex that binds to an activin response element (ARE) in the promoter of target genes, and is composed of two SMAD2 proteins, one SMAD4 protein and a Forkhead activin signal transducer (FAST) transcription factor.\" [PMID:12374795, PMID:9288972]","metadata":null},{"id":"ebd11d103787432aa5d5d22e0f33f98f","type":"GO_TERM","name":"activin secretion","canonical_id":"go:GO:0032333","description":"\"The regulated release of activin, a nonsteroidal regulator composed of two covalently linked beta subunits, which is synthesized in the pituitary gland and gonads and stimulates the secretion of follicle-stimulating hormone.\" [GOC:mah]","metadata":null},{"id":"d6ade97a95724986a29dfab00eaf819f","type":"GO_TERM","name":"actomyosin","canonical_id":"go:GO:0042641","description":"\"Any complex of actin, myosin, and accessory proteins.\" [GOC:curators]","metadata":null},{"id":"5ae3337fb4a24006a6a2ee05f6c06df3","type":"GO_TERM","name":"actomyosin contractile ring","canonical_id":"go:GO:0005826","description":"\"A cytoskeletal structure composed of actin filaments and myosin that forms beneath the plasma membrane of many cells, including animal cells and yeast cells, in a plane perpendicular to the axis of the spindle, i.e. the cell division plane. In animal cells, the contractile ring is located at the cleavage furrow. In budding fungal cells, e.g. mitotic S. cerevisiae cells, the contractile ring forms at the mother-bud neck before mitosis.\" [GOC:expert_jrp, GOC:sgd_curators, GOC:vw, ISBN:0805319409, ISBN:0815316194, PMID:28914606]","metadata":null},{"id":"d0839c4b4cbd47808c29b0b2610d47ca","type":"GO_TERM","name":"actomyosin contractile ring actin filament","canonical_id":"go:GO:1903144","description":"\"Any actin filament that is part of a actomyosin contractile ring.\" [GO_REF:0000064, GOC:TermGenie, PMID:20807799, PMID:24954052]","metadata":null},{"id":"f473116da09e48348f744c2d939cd11e","type":"GO_TERM","name":"actomyosin contractile ring actin filament bundle assembly","canonical_id":"go:GO:0071519","description":"\"A process of actin filament bundle formation that occurs in the context of assembling an actomyosin contractile ring during cytokinesis.\" [GOC:mah, PMID:19713940]","metadata":null},{"id":"d5e445cff86e495fa33edddbac56fb7e","type":"GO_TERM","name":"actomyosin contractile ring assembly","canonical_id":"go:GO:0000915","description":"\"The process of assembly of a ring composed of actin, myosin, and associated proteins that will function in cytokinesis.\" [GOC:clt, GOC:dph, GOC:tb]","metadata":null},{"id":"526de026ad2a4badad706ba186e01ed7","type":"GO_TERM","name":"actomyosin contractile ring assembly actin filament bundle convergence","canonical_id":"go:GO:0071520","description":"\"A process of actin filament bundle distribution that occurs in the context of assembling an actomyosin contractile ring during cytokinesis, and that results in the compaction of actin filaments into a tight ring.\" [GOC:mah, PMID:19713940]","metadata":null},{"id":"59ed94100e4d499594e4de659541dc59","type":"GO_TERM","name":"actomyosin contractile ring assembly actin filament organization","canonical_id":"go:GO:2000689","description":"\"An actin filament organization process that contributes to actomyosin contractile ring assembly during cytokinesis.\" [GOC:mah]","metadata":null},{"id":"5c05402bb7394cb18f9dc100e6b755a4","type":"GO_TERM","name":"actomyosin contractile ring contraction","canonical_id":"go:GO:0000916","description":"\"The process of an actomyosin ring getting smaller in diameter, in the context of cytokinesis that takes place as part of a cell cycle.\" [GOC:clt, GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"728886db79914544bc764821f1443104","type":"GO_TERM","name":"actomyosin contractile ring maturation","canonical_id":"go:GO:0031566","description":"\"The cellular process in which the contractile ring cytokinetic ring attains its fully functional state.\" [GOC:vw, PMID:25451933]","metadata":null},{"id":"d3ed413d6e3a494391ef0c3e3d918241","type":"GO_TERM","name":"actomyosin contractile ring organization","canonical_id":"go:GO:0044837","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of an actomyosin contractile ring.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"414dd5a28b854e4299a682d0dbd741b8","type":"GO_TERM","name":"actomyosin structure organization","canonical_id":"go:GO:0031032","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures containing both actin and myosin or paramyosin. The myosin may be organized into filaments.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"2f8a1e2d127a4d60aa09d0cdfbb8ecf8","type":"GO_TERM","name":"actomyosin, myosin complex part","canonical_id":"go:GO:0042642","description":"\"The myosin part of any complex of actin, myosin, and accessory proteins.\" [GOC:curators]","metadata":null},{"id":"b799551ca4b1410c946fe57b568bbc75","type":"GO_TERM","name":"aculeacin-A deacylase activity","canonical_id":"go:GO:0033965","description":"\"Catalysis of the hydrolysis of the amide bond in aculeacin A and related neutral lipopeptide antibiotics, releasing the long-chain fatty acid side-chain.\" [EC:3.5.1.70]","metadata":null},{"id":"252f56a5f2de4446936098e916f6a0ba","type":"DISEASE","name":"acute coronary syndrome","canonical_id":"mondo:0005542","description":null,"metadata":null},{"id":"c65190a0819d4c7b91ecf37f29f7cf8d","type":"GO_TERM","name":"acute inflammatory response","canonical_id":"go:GO:0002526","description":"\"Inflammation which comprises a rapid, short-lived, relatively uniform response to acute injury or antigenic challenge and is characterized by accumulations of fluid, plasma proteins, and granulocytic leukocytes. An acute inflammatory response occurs within a matter of minutes or hours, and either resolves within a few days or becomes a chronic inflammatory response.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"6fcdd6614f204bb98b3dc1b624e70283","type":"GO_TERM","name":"acute inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002438","description":"\"An acute inflammatory response to an antigenic stimulus. An acute inflammatory response occurs within a matter of minutes or hours, and either resolves within a few days or becomes a chronic inflammatory response.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"3374fbf6b6b44abf90028f2c60c1246e","type":"GO_TERM","name":"acute inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002525","description":"\"An acute inflammatory response to non-antigenic stimuli such as heat or physical trauma.\" [GOC:jal, PMID:16459497, PMID:9073326]","metadata":null},{"id":"29229c223cc6422aa939ff605068ddbe","type":"DISEASE","name":"acute kidney injury","canonical_id":"mondo:0002492","description":null,"metadata":null},{"id":"65bffbe75c794e56891aad10ec94b751","type":"DISEASE","name":"acute lung injury","canonical_id":"mondo:0015796","description":null,"metadata":null},{"id":"f3054c10874442eebae0ea6358f38310","type":"DISEASE","name":"acute lymphoblastic leukemia","canonical_id":"mondo:0004967","description":null,"metadata":null},{"id":"8c7f5bbaf3404d16a718f0dac2271149","type":"DISEASE","name":"acute myeloid leukemia","canonical_id":"mondo:0018874","description":null,"metadata":null},{"id":"15e81721034441a58cd15095261b6eed","type":"DISEASE","name":"acute myeloid leukemia by FAB classification","canonical_id":"mondo:0015667","description":null,"metadata":null},{"id":"5d8fc71111d24d08aa644071ba5fad8a","type":"DISEASE","name":"acute myeloid leukemia with minimal differentiation","canonical_id":"mondo:0005223","description":null,"metadata":null},{"id":"5d0a3153140d438b944fcf84555b5758","type":"DISEASE","name":"acute myelomonocytic leukemia M4","canonical_id":"mondo:0018871","description":null,"metadata":null},{"id":"2414c16571374c7383254d266d230932","type":"DISEASE","name":"acute promyelocytic leukemia","canonical_id":"mondo:0012883","description":null,"metadata":null},{"id":"2a91c6c5955e483d8fdbb0d0a9a95de8","type":"GO_TERM","name":"acute-phase response","canonical_id":"go:GO:0006953","description":"\"An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals.\" [ISBN:0198506732]","metadata":null},{"id":"dd0d953e06c04a7281f97c6ffedb1319","type":"GO_TERM","name":"acyl binding","canonical_id":"go:GO:0000035","description":"\"Binding to an acyl group, any group formally derived by removal of the hydroxyl group from the acid function of a carboxylic acid.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b086186a28a84c89921733f76b440de3","type":"GO_TERM","name":"acyl carrier activity","canonical_id":"go:GO:0000036","description":"\"Binding an acyl group and presenting it for processing or offloading to a cognate enzyme. Covalently binds the acyl group via a phosphopantetheine prosthetic group and mediates protein-protein interactions with the enzyme conferring specificity. The acyl carrier protein (ACP) presents substrates to enzymes involved in fatty acid biosynthesis or in polyketide secondary metabolite biosynthesis.\" [GOC:jl, GOC:vw]","metadata":null},{"id":"35df351fcf13483398c50be8966f73a8","type":"GO_TERM","name":"acyl-CoA (8-3)-desaturase activity","canonical_id":"go:GO:0062076","description":"\"Catalysis of the reaction: (8Z,11Z,14Z)-eicosatrienoyl-CoA + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O. Can also use a substrate with 3 double bonds (a (8Z,11Z,14Z,17Z)-eicosatetraenoyl-CoA) and add a fourth double bond (a (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA).\" [PMID:10601301, PMID:10769175, RHEA:46424]","metadata":null},{"id":"d4e8eb5df7944c8faa97eafb5fb05832","type":"GO_TERM","name":"acyl-CoA (9+3)-desaturase activity","canonical_id":"go:GO:0102985","description":"\"Catalysis of the introduction of a cis double bond at position 12 of fatty-acyl-CoAs that contain a cis double bond at position 9. Specific reactions include: (9Z)-hexadecenoyl-CoA + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = (9Z,12Z)-hexadecadienoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O; and (9Z)-hexadecenoyl-CoA + 2 Fe(II)-[cytochrome b5] + O2 + 2 H(+) = (9Z,12Z)-hexadecadienoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [EC:1.14.19.6]","metadata":null},{"id":"d6b10bce26704b61b59dbe98b5c10092","type":"GO_TERM","name":"acyl-CoA 11-(E)-desaturase activity","canonical_id":"go:GO:0050600","description":"\"Catalysis of the reaction: an 11,12-saturated fatty acyl-CoA + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = an (11E)-delta11-fatty acyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:46396]","metadata":null},{"id":"17b22754156d478c8ede1de41f9556c3","type":"GO_TERM","name":"acyl-CoA 11-(Z)-desaturase activity","canonical_id":"go:GO:0017105","description":"\"Catalysis of the reaction: an 11,12-saturated fatty acyl-CoA + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = an (11Z)-delta-11-fatty acyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [PMID:15063718, PMID:15544945, RHEA:25852]","metadata":null},{"id":"0bae4ebe6678489183163c6a2b530ad4","type":"GO_TERM","name":"acyl-CoA 15-desaturase activity","canonical_id":"go:GO:0102988","description":"\"Catalysis of the reaction: (9Z,12Z)-hexadecadienoyl-CoA + O2 + a reduced electron acceptor = 9,12,15-cis-hexadecatrienoyl-CoA + 2 H2O + an oxidized electron acceptor.\" [EC:1.14.19.13]","metadata":null},{"id":"8b285875d6584a1b89905e8fbf3e6104","type":"GO_TERM","name":"acyl-CoA 6-desaturase activity","canonical_id":"go:GO:0016213","description":"\"Catalysis of the introduction of a cis double bond at carbon 6 of acyl-CoAs, introducing a new double bond between a pre-existing double bond and the carboxyl-end of the fatty acid. Specific reactions include: (9Z,12Z)-octadecadienoyl-CoA + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = (6Z,9Z,12Z)-octadecatrienoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O; and (9Z,12Z,15Z)-octadecatrienoyl-CoA + 2 Fe(II)-[cytochrome b5] + O2 + 2 H+ = (6Z,9Z,12Z,15Z)-octadecatetraenoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [EC:1.14.19.3, PMID:12713571, PMID:7212717]","metadata":null},{"id":"77c8f26d016a485b84fff9110a572d96","type":"GO_TERM","name":"acyl-CoA binding","canonical_id":"go:GO:0120227","description":"\"Binding to an acyl-CoA, a thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any carboxylic acid.\" [GOC:krc]","metadata":null},{"id":"b8c9b2fc3aaf436494168b222771d787","type":"GO_TERM","name":"acyl-CoA biosynthetic process","canonical_id":"go:GO:0071616","description":"\"The chemical reactions and pathways resulting in the formation of acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with an acyl group.\" [GOC:cjk]","metadata":null},{"id":"aedaeee9b3fd464dba20f0fd1090380f","type":"GO_TERM","name":"acyl-CoA ceramide synthase complex","canonical_id":"go:GO:0061576","description":"\"A protein complex that catalyzes the reaction acyl-CoA + sphingosine = CoA + N-acylsphingosine. In S. cerevisiae it contains three subunits: lag1, lac1 and lip1.\" [GOC:dph, PMID:15692566]","metadata":null},{"id":"220999f5935545a8adb391033dfceba3","type":"GO_TERM","name":"acyl-CoA dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047616","description":"\"Catalysis of the reaction: acyl-CoA + NADP+ = 2,3-dehydroacyl-CoA + NADPH + H+.\" [EC:1.3.1.8]","metadata":null},{"id":"64181f9bd4554bf884ae789342995e8e","type":"GO_TERM","name":"acyl-CoA dehydrogenase activity","canonical_id":"go:GO:0003995","description":"\"Catalysis of the reaction: a 2,3-saturated acyl-CoA + H+ oxidized [electron-transfer flavoprotein] = a (2E)-enoyl-CoA + reduced [electron-transfer flavoprotein].\" [RHEA:44704]","metadata":null},{"id":"471bf08b016d4f5c86553ac99dd83713","type":"GO_TERM","name":"acyl-CoA desaturase activity","canonical_id":"go:GO:0016215","description":"\"Catalysis of the reaction: acyl-CoA + reduced acceptor + O2 = desaturated-acyl-CoA + acceptor + 2 H2O.\" [PMID:36017969]","metadata":null},{"id":"6e5ea1894e3b431d95740e72e3005229","type":"GO_TERM","name":"acyl-CoA hydrolase activity","canonical_id":"go:GO:0016289","description":"\"Catalysis of the reaction: an acyl-CoA + H2O = a carboxylate + CoA + H+.\" [RHEA:70423]","metadata":null},{"id":"706f199ff4364613902e7f71d440a783","type":"GO_TERM","name":"acyl-CoA metabolic process","canonical_id":"go:GO:0006637","description":"\"The chemical reactions and pathways involving acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with an acyl group.\" [ISBN:0198506732]","metadata":null},{"id":"4af8077ccbe546f490b2c211a1f43ddc","type":"GO_TERM","name":"acyl-CoA oxidase activity","canonical_id":"go:GO:0003997","description":"\"Catalysis of the reaction: a 2,3-saturated acyl-CoA + O2 = a (2E)-enoyl-CoA + H2O2.\" [RHEA:38959]","metadata":null},{"id":"d92b5ab2555349a4a356c06466519441","type":"GO_TERM","name":"acyl-L-homoserine-lactone lactonohydrolase activity","canonical_id":"go:GO:0102007","description":"\"Catalysis of the reaction: H2O + an N-acyl-L-homoserine lactone = H+ + an N-acyl-L-homoserine.\" [EC:3.1.1.81]","metadata":null},{"id":"0cb8234ee8fd40f08675a8e117981174","type":"GO_TERM","name":"acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase activity","canonical_id":"go:GO:0008780","description":"\"Catalysis of the reaction: a (3R)-hydroxyacyl-[ACP] + UDP-N-acetyl-alpha-D-glucosamine = a UDP-3-O-[(3R)-3-hydroxyacyl]-N-acetyl-alpha-D-glucosamine + holo-[ACP].\" [RHEA:67812]","metadata":null},{"id":"abcb62c0d4184d28b375c6de6b2ad997","type":"GO_TERM","name":"acyl-[acyl-carrier-protein]-phospholipid O-acyltransferase activity","canonical_id":"go:GO:0008779","description":"\"Catalysis of the reaction: acyl-[acyl-carrier protein] + O-(2-acyl-sn-glycero-3-phospho)ethanolamine = [acyl-carrier protein] + O-(1-beta-acyl-2-acyl-sn-glycero-3-phospho)ethanolamine.\" [EC:2.3.1.40]","metadata":null},{"id":"5905882dedac47f7940bef4f88fc2f26","type":"GO_TERM","name":"acyl-glucuronidase activity","canonical_id":"go:GO:0036237","description":"\"Catalysis of the reaction: an acyl-glucuronoside + H2O = an alcohol + D-glucuronate.\" [GOC:BHF, GOC:vk, PMID:22294686]","metadata":null},{"id":"53e30f402cb240c5990b12475ed98b44","type":"GO_TERM","name":"acyl-lipid (11-3)-desaturase activity","canonical_id":"go:GO:0102003","description":"\"Catalysis of the reaction: an (11Z,14Z)-icosadienoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = an (8Z,11Z,14Z)-icosatrienoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O or an (11Z,14Z,17Z)-icosatrienoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = an (8Z,11Z,14Z,17Z)-eicosatetraenoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [EC:1.14.19.4]","metadata":null},{"id":"0d15303749354f3b952cbff4f7a14bbc","type":"GO_TERM","name":"acyl-lipid (8-3)-desaturase activity","canonical_id":"go:GO:0102866","description":"\"Catalysis of the reaction: an (8Z,11Z,14Z)-icosatrienoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = (5Z,8Z,11Z,14Z)-eicosatetraenoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O. Also converts an (8Z,11Z,14Z,17Z)-eicosatetraenoyl-containing glycerolipid into a (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-containing glycerolipid.\" [EC:1.14.19.30]","metadata":null},{"id":"084f66505415403ebe2908900cdd2f4c","type":"GO_TERM","name":"acyl-lipid (n+3)-(Z)-desaturase (ferredoxin) activity","canonical_id":"go:GO:0102850","description":"\"Catalysis of the reaction: a (9Z)-octadecenoyl-containing glycerolipid + 2 H+ + O2 + 2 reduced [2Fe-2S]-[ferredoxin] = a (9Z,12Z)-octadecadienoyl-containing glycerolipid + 2 H2O + 2 oxidized [2Fe-2S]-[ferredoxin].\" [RHEA:46376]","metadata":null},{"id":"a8ca3a623afe4283b171a3d185efa3f5","type":"GO_TERM","name":"acyl-lipid Delta(12)-acetylenase activity","canonical_id":"go:GO:0016720","description":"\"Catalysis of the reaction: (9Z,12Z)-octadecadienoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = a (9Z)-octadec-9-en-12-ynoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:46552]","metadata":null},{"id":"6425f8203da44f6ebfbc86a57ab233a1","type":"GO_TERM","name":"acyl-lipid omega-(9-4) desaturase activity","canonical_id":"go:GO:0102431","description":"\"Catalysis of the reaction: a (9Z,12Z)-octadecadienoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = a (5Z,9Z,12Z)-octadecatrienoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O. Can also use a substrate with 3 double bonds (a (9Z,12Z,15Z)-octadecatrienoyl-containing glycerolipid) and add a fourth double bond (a (5Z,9Z,12Z,15Z)-octadecatetraenoyl-containing glycerolipid).\" [EC:1.14.19.12]","metadata":null},{"id":"8acad48a012f4db1847e232b1e5f3d2d","type":"GO_TERM","name":"acyl-lipid omega-3 desaturase (cytochrome b5) activity","canonical_id":"go:GO:0102859","description":"\"Catalysis of the reaction: a (9Z,12Z)-octadecadienoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = (9Z,12Z,15Z)-octadecatrienoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:46404]","metadata":null},{"id":"5f5db11cea0a48aeac44e352de1be56c","type":"GO_TERM","name":"acyl-lipid omega-6 desaturase (cytochrome b5) activity","canonical_id":"go:GO:0050184","description":"\"Catalysis of the reaction: a (9Z)-octadecenoyl-containing glycerolipid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = a (9Z,12Z)-octadecadienoyl-containing glycerolipid + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:46332]","metadata":null},{"id":"9e3c85be4b0e44ac970d2fe9dc35d565","type":"GO_TERM","name":"acyl-lysine deacylase activity","canonical_id":"go:GO:0050477","description":"\"Catalysis of the reaction: H2O + N6-acyl-L-lysine = L-lysine + a carboxylate.\" [EC:3.5.1.17]","metadata":null},{"id":"c8ad31623e7d4afea410105fe30dcc63","type":"GO_TERM","name":"acyl-phosphate glycerol-3-phosphate acyltransferase activity","canonical_id":"go:GO:0043772","description":"\"Catalysis of the reaction: acyl phosphate + sn-glycerol 3-phosphate = 1-acyl-sn-glycerol 3-phosphate + orthophosphate.\" [PMID:17308305]","metadata":null},{"id":"ad16f4f185d34fd2809b2962a307e79a","type":"GO_TERM","name":"acyl-phosphate-hexose phosphotransferase activity","canonical_id":"go:GO:0047328","description":"\"Catalysis of the reaction: D-hexose + acyl phosphate = D-hexose phosphate + an acid.\" [EC:2.7.1.61, MetaCyc:2.7.1.61-RXN]","metadata":null},{"id":"e7f244d98b25449b9595952c8298030d","type":"GO_TERM","name":"acylagmatine amidase activity","canonical_id":"go:GO:0047618","description":"\"Catalysis of the reaction: N(4)-benzoylagmatine + H2O = agmatine + benzoate.\" [EC:3.5.1.40, RHEA:15065]","metadata":null},{"id":"34ee6f6c7dda409aad9d831a2ab6dc41","type":"GO_TERM","name":"acylcarnitine hydrolase activity","canonical_id":"go:GO:0047619","description":"\"Catalysis of the reaction: O-acylcarnitine + H2O = a fatty acid + L-carnitine.\" [EC:3.1.1.28, MetaCyc:ACYLCARNITINE-HYDROLASE-RXN]","metadata":null},{"id":"d958e92b452140debd66139e186ee751","type":"GO_TERM","name":"acylglycerol O-acyltransferase activity","canonical_id":"go:GO:0016411","description":"\"Catalysis of the transfer of an acyl group to an oxygen atom on the acylglycerol molecule.\" [GOC:ai]","metadata":null},{"id":"c6fa951fd2204ef4b6175211febae927","type":"GO_TERM","name":"acylglycerol acyl-chain remodeling","canonical_id":"go:GO:0036155","description":"\"Remodeling the acyl chains of an acylglycerol, through sequential deacylation and re-acylation reactions, to generate an acylglycerol containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:15364929]","metadata":null},{"id":"274b959ee2994c67b9cd95c1ac3c9ed1","type":"GO_TERM","name":"acylglycerol biosynthetic process","canonical_id":"go:GO:0046463","description":"\"The chemical reactions and pathways resulting in the formation of acylglycerol, any mono-, di- or triester of glycerol with (one or more) fatty acids.\" [GOC:ai]","metadata":null},{"id":"ac62c21d3ad8407a9dcffd5b64849498","type":"GO_TERM","name":"acylglycerol catabolic process","canonical_id":"go:GO:0046464","description":"\"The chemical reactions and pathways resulting in the breakdown of acylglycerol, any mono-, di- or triester of glycerol with (one or more) fatty acids.\" [GOC:ai]","metadata":null},{"id":"27e1335cd3184c6e81e44f5c8084ce9f","type":"GO_TERM","name":"acylglycerol homeostasis","canonical_id":"go:GO:0055090","description":"\"Any process involved in the maintenance of an internal steady state of acylglycerol within an organism or cell.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"8a5069ca003141eda6b2f7cc275eea43","type":"GO_TERM","name":"acylglycerol kinase activity","canonical_id":"go:GO:0047620","description":"\"Catalysis of the reaction: ATP + acylglycerol = ADP + acyl-sn-glycerol 3-phosphate.\" [EC:2.7.1.94, MetaCyc:ACYLGLYCEROL-KINASE-RXN]","metadata":null},{"id":"04dbe9607c45434cba91dc4cf14c78f6","type":"GO_TERM","name":"acylglycerol metabolic process","canonical_id":"go:GO:0006639","description":"\"The chemical reactions and pathways involving acylglycerol, any mono-, di- or triester of glycerol with (one or more) fatty acids.\" [ISBN:0198506732]","metadata":null},{"id":"c27b19e7360a4802a6b57c5d5b6027dd","type":"GO_TERM","name":"acylglycerol transport","canonical_id":"go:GO:0034196","description":"\"The directed movement of an acylglycerol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. An acylglycerol is any mono-, di- or triester of glycerol with (one or more) fatty acids.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"cee394c436ac4235b7e4b8ee4678fcdf","type":"GO_TERM","name":"acylglycerone-phosphate reductase (NADP+) activity","canonical_id":"go:GO:0000140","description":"\"Catalysis of the reaction: 1-hexadecanoyl-sn-glycero-3-phosphate + NADP+ = 1-hexadecanoylglycerone 3-phosphate + H+ + NADPH.\" [RHEA:17341]","metadata":null},{"id":"bbf15b536076487e875bfdaf5200184c","type":"GO_TERM","name":"acyloxyacyl hydrolase activity","canonical_id":"go:GO:0050528","description":"\"Catalysis of the reaction: 3-(acyloxy)acyl group of bacterial toxin = 3-hydroxyacyl group of bacterial toxin + a fatty acid.\" [EC:3.1.1.77, MetaCyc:3.1.1.77-RXN]","metadata":null},{"id":"4602b615a94e4eebb4e777a566de037a","type":"GO_TERM","name":"acylphosphatase activity","canonical_id":"go:GO:0003998","description":"\"Catalysis of the reaction: an acyl phosphate + H2O = a carboxylate + phosphate.\" [EC:3.6.1.7]","metadata":null},{"id":"f4906e89b09441a49a99ef65227c9949","type":"GO_TERM","name":"acylpyruvate hydrolase activity","canonical_id":"go:GO:0047621","description":"\"Catalysis of the reaction: a 3-acylpyruvate + H2O = a carboxylate + pyruvate.\" [RHEA:19009]","metadata":null},{"id":"5c9db3cbd059460cb5863ed767c84f9d","type":"GO_TERM","name":"acyltransferase activity","canonical_id":"go:GO:0016746","description":"\"Catalysis of the transfer of an acyl group from one compound (donor) to another (acceptor).\" [EC:2.3.-.-]","metadata":null},{"id":"a3572a4eba4142eea8c37504f677cd21","type":"GO_TERM","name":"acyltransferase activity, acyl groups converted into alkyl on transfer","canonical_id":"go:GO:0046912","description":"\"Catalysis of the transfer of an acyl group from one compound (donor) to another (acceptor), with the acyl group being converted into alkyl on transfer.\" [EC:2.3.3.-, GOC:jl]","metadata":null},{"id":"4a6e3a75ce0648a2a370fac3f91c136a","type":"GO_TERM","name":"acyltransferase activity, transferring groups other than amino-acyl groups","canonical_id":"go:GO:0016747","description":"\"Catalysis of the transfer of an acyl group, other than amino-acyl, from one compound (donor) to another (acceptor).\" [EC:2.3.1.-]","metadata":null},{"id":"d26bafe7ef864205a7ac9a0914fd3620","type":"DRUG","name":"adalimumab","canonical_id":"gtopdb:4860","description":null,"metadata":null},{"id":"ca4ccf3fc0f942b093d4b2266865e0a1","type":"DRUG","name":"adalimumab","canonical_id":"mesh:D000068879","description":null,"metadata":null},{"id":"27a571912fcc44b08f5a2adbc5e3ba8d","type":"DRUG","name":"adalimumab","canonical_id":"chembl:CHEMBL1201580","description":null,"metadata":null},{"id":"0dabc907f19e4039848e7d05d3fadfd8","type":"COMBINATION_TREATMENT","name":"adalimumab + certolizumab pegol","canonical_id":"ctgov_combo:ctgov-combo-3b0a8a52bddf0ffb","description":null,"metadata":null},{"id":"0a262f8bbc2c47e891a4e4b94002f25b","type":"COMBINATION_TREATMENT","name":"adalimumab + etanercept","canonical_id":"ctgov_combo:ctgov-combo-54b4e497398a94d9","description":null,"metadata":null},{"id":"6225eb2eddb44e79ae50362d4059e1b4","type":"COMBINATION_TREATMENT","name":"adalimumab + etanercept + infliximab","canonical_id":"ctgov_combo:ctgov-combo-7042f6e71aed54cb","description":null,"metadata":null},{"id":"830da2b3ce8d4997aa99b8220d609656","type":"COMBINATION_TREATMENT","name":"adalimumab + etanercept + infliximab","canonical_id":"ctgov_combo:ctgov-combo-8ddb4e58d4a23721","description":null,"metadata":null},{"id":"b1ff6b7c02204bea9defb39ba62e0bee","type":"COMBINATION_TREATMENT","name":"adalimumab + golimumab + infliximab + ustekinumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-6b59536f730ab56d","description":null,"metadata":null},{"id":"614a628e180548c39dd2ff575d8af46f","type":"COMBINATION_TREATMENT","name":"adalimumab + infliximab","canonical_id":"ctgov_combo:ctgov-combo-75255fcf528360c8","description":null,"metadata":null},{"id":"421e4a952f884f0db8b0d9b8535b7246","type":"COMBINATION_TREATMENT","name":"adalimumab + infliximab + ustekinumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-c0ea16393af04a74","description":null,"metadata":null},{"id":"ed92685566c84589bc0eb814b3cad82e","type":"COMBINATION_TREATMENT","name":"adalimumab + methotrexate + tofacitinib","canonical_id":"ctgov_combo:ctgov-combo-0548d2faf207bac5","description":null,"metadata":null},{"id":"8eb50d902c3d4166b7d52ea37bdee24d","type":"COMBINATION_TREATMENT","name":"adalimumab + prednisone","canonical_id":"ctgov_combo:ctgov-combo-cbf6e0c7d36c7229","description":null,"metadata":null},{"id":"3c4edd19c2624776ab6f78428888f05e","type":"COMBINATION_TREATMENT","name":"adalimumab + prednisone","canonical_id":"ctgov_combo:ctgov-combo-82e75c059fb2c2ed","description":null,"metadata":null},{"id":"c150909f856e4e06b727db75386be537","type":"COMBINATION_TREATMENT","name":"adalimumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-ecbe61ec30b42416","description":null,"metadata":null},{"id":"ee9387e365db4b82b04d6417144cf4bd","type":"COMBINATION_TREATMENT","name":"adalimumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-5e9ed7f9104dbe29","description":null,"metadata":null},{"id":"1ad174f661584fa0b4d5ac69a41a0aa8","type":"GO_TERM","name":"adamantanone catabolic process","canonical_id":"go:GO:0019263","description":"\"The chemical reactions and pathways resulting in the breakdown of adamantanone, tricyclo(3.3.1.13,7)decanone, a white crystalline solid used as an intermediate for microelectronics in the production of photoresists.\" [GOC:ai]","metadata":null},{"id":"07602a7d29c34ae2a35d4009c69f8967","type":"DRUG","name":"adapalene","canonical_id":"gtopdb:5429","description":null,"metadata":null},{"id":"ca99a89e2bab4f8d913ac1de488278fd","type":"DRUG","name":"adapalene","canonical_id":"chembl:CHEMBL1265","description":null,"metadata":null},{"id":"e511661fd9fc44c1a152a21e78bcbce2","type":"COMBINATION_TREATMENT","name":"adapalene + clascoterone","canonical_id":"ctgov_combo:ctgov-combo-afcacf79e63a1025","description":null,"metadata":null},{"id":"4fa89ca15a3f405ea88fb2b8218d1ca0","type":"COMBINATION_TREATMENT","name":"adapalene + tazarotene","canonical_id":"ctgov_combo:ctgov-combo-a081d5c46238251c","description":null,"metadata":null},{"id":"ef63dbbdbce14379b08a6ef39f41d043","type":"COMBINATION_TREATMENT","name":"adapalene + tazarotene","canonical_id":"ctgov_combo:ctgov-combo-9decde4d7af382e4","description":null,"metadata":null},{"id":"19256a3865894a00897cdd7218fa6672","type":"GO_TERM","name":"adaptation of signaling pathway","canonical_id":"go:GO:0023058","description":"\"The regulation of a signal transduction pathway in response to a stimulus upon prolonged exposure to that stimulus.\" [GOC:mtg_signal]","metadata":null},{"id":"97c38f06c6a54b81874406c2b4aea244","type":"GO_TERM","name":"adaptation to pheromone regulating conjugation with mutual genetic exchange","canonical_id":"go:GO:0000760","description":"\"In organisms that undergo conjugation without cellular fusion, the process resulting in desensitization following exposure to pheromone stimulus that act to down-regulate further stimulation or block initial conjugation responses.\" [GOC:clt]","metadata":null},{"id":"d38158c6c96f446f9bb2f9bff544f8ba","type":"GO_TERM","name":"adaptive immune effector response","canonical_id":"go:GO:0090718","description":"\"An adaptive immune response that involves one or more immune effector processes and takes place during the effector phase of the adaptive immune response.\" [GOC:add, ISBN:1405196831]","metadata":null},{"id":"53634406eff94381a076d2215ace1798","type":"GO_TERM","name":"adaptive immune effector response involving T cells and B lineage cells","canonical_id":"go:GO:0090719","description":"\"An adaptive immune effector response involving T cells and B lineage cells. In the case of B lineage cells, the effector cells are the antibody secreting plasma cells whereas for T cells the effector cells may be helper T cells or cytotoxic T cells.\" [GOC:add, ISBN:1405196831]","metadata":null},{"id":"378a121b90554f07993494dc043fe5e9","type":"GO_TERM","name":"adaptive immune memory response","canonical_id":"go:GO:0090716","description":"\"An immune response directed against a previously encountered antigen, being quicker and quantitatively better compared with the primary response.\" [GOC:add, PMID:26831526]","metadata":null},{"id":"b2257c1c467c459396fc83af87c383cc","type":"GO_TERM","name":"adaptive immune memory response involving T cells and B cells","canonical_id":"go:GO:0090717","description":"\"An immune response mediated by reactivated memory T cells and B cells and directed against a previously encountered antigen, being quicker and quantitatively better compared with the primary response.\" [GOC:add, PMID:26831526]","metadata":null},{"id":"85d3aa57d5184a029529f341f631d023","type":"GO_TERM","name":"adaptive immune response","canonical_id":"go:GO:0002250","description":"\"An immune response mediated by cells expressing specific receptors for antigens produced through a somatic diversification process, and allowing for an enhanced secondary response to subsequent exposures to the same antigen (immunological memory).\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"334d94d3eeb44639ac797c966ff8852a","type":"GO_TERM","name":"adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains","canonical_id":"go:GO:0002460","description":"\"An immune response mediated by lymphocytes expressing specific receptors for antigen produced through a somatic diversification process that includes somatic recombination of germline gene segments encoding immunoglobulin superfamily domains. Recombined receptors for antigen encoded by immunoglobulin superfamily domains include T cell receptors and immunoglobulins (antibodies) produced by B cells. The first encounter with antigen elicits a primary immune response that is slow and not of great magnitude. T and B cells selected by antigen become activated and undergo clonal expansion. A fraction of antigen-reactive T and B cells become memory cells, whereas others differentiate into effector cells. The memory cells generated during the primary response enable a much faster and stronger secondary immune response upon subsequent exposures to the same antigen (immunological memory). An example of this is the adaptive immune response found in Mus musculus.\" [GOC:add, GOC:mtg_sensu, ISBN:0781735149, ISBN:1405196831]","metadata":null},{"id":"7991855c82aa4b66b4aa596eeac57bed","type":"GO_TERM","name":"adaptive immune response based on somatic recombination of immune receptors built from leucine-rich repeat domains","canonical_id":"go:GO:0002459","description":"\"An immune response mediated by lymphocytes expressing specific receptors for antigen produced through a somatic diversification process that includes somatic recombination of variable lymphocyte receptors (VLR) incorporating leucine-rich repeat (LRR) domains, and allowing for enhanced responses upon subsequent exposures to the same antigen (immunological memory). Examples of this process are found in jawless fish, including the lampreys (Petromyzontidae) and hagfishes (Myxinidae).\" [GOC:add, GOC:mtg_sensu, PMID:16373579]","metadata":null},{"id":"a3aeb7de0f8e482a99e757dded5fafaa","type":"GO_TERM","name":"adaptive thermogenesis","canonical_id":"go:GO:1990845","description":"\"The regulated production of heat in response to short term environmental changes, such as stress, diet or reduced temperature.\" [PMID:17260010, PMID:20363363]","metadata":null},{"id":"b1bfe4b0ede3451d9f9994a5bbd6b6dd","type":"GO_TERM","name":"adaxial/abaxial axis specification","canonical_id":"go:GO:0009943","description":"\"The establishment, maintenance and elaboration of the adaxial / abaxial axis. Adaxial refers to being situated toward an axis of an anatomical structure. Abaxial refers to being situated away from an axis of an anatomical structure.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"14aff4441cba4c4b9718d3105d08b479","type":"GO_TERM","name":"adaxial/abaxial pattern specification","canonical_id":"go:GO:0009955","description":"\"The regionalization process in which differences in cell differentiation along the adaxial/abaxial are generated. Adaxial refers to being situated toward an axis of an anatomical structure. Abaxial refers to being situated away from an axis of an anatomical structure.\" [GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"679527f204de4c4499dbbd06639206ac","type":"DRUG","name":"adefovir dipivoxil","canonical_id":"mesh:C106812","description":null,"metadata":null},{"id":"d81ae78f654f4b0b955c68318e4239ec","type":"GO_TERM","name":"adenine binding","canonical_id":"go:GO:0002055","description":"\"Binding to adenine, a purine base.\" [GOC:hjd]","metadata":null},{"id":"ce5f1785d3da4c41a4d73a803f5024df","type":"GO_TERM","name":"adenine biosynthetic process","canonical_id":"go:GO:0046084","description":"\"The chemical reactions and pathways resulting in the formation of adenine, 6-aminopurine, one of the five main bases found in nucleic acids and a component of numerous important derivatives of its corresponding ribonucleoside, adenosine.\" [GOC:curators]","metadata":null},{"id":"12192a35c0384c5dbf3921fef0f3b2cf","type":"GO_TERM","name":"adenine catabolic process","canonical_id":"go:GO:0006146","description":"\"The chemical reactions and pathways resulting in the breakdown of adenine, 6-aminopurine, one of the 5 main bases found in nucleic acids and a component of numerous important derivatives of its corresponding ribonucleoside, adenosine.\" [ISBN:0198506732]","metadata":null},{"id":"a458c72d1e8a4628986b53fd4d6c8566","type":"GO_TERM","name":"adenine deaminase activity","canonical_id":"go:GO:0000034","description":"\"Catalysis of the reaction: adenine + H+ + H2O = hypoxanthine + NH4+.\" [RHEA:23688]","metadata":null},{"id":"bd9c605a148340eaa4bc5bfbc2855fbf","type":"GO_TERM","name":"adenine import across plasma membrane","canonical_id":"go:GO:0098702","description":"\"The directed movement of adenine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"dddf433eb77d4cecb95c3ac431fd3016","type":"GO_TERM","name":"adenine metabolic process","canonical_id":"go:GO:0046083","description":"\"The chemical reactions and pathways involving adenine, 6-aminopurine, one of the five main bases found in nucleic acids and a component of numerous important derivatives of its corresponding ribonucleoside, adenosine.\" [GOC:curators]","metadata":null},{"id":"da78c56e2e50403e9d6e3f0f8b6fce31","type":"GO_TERM","name":"adenine nucleotide transmembrane transporter activity","canonical_id":"go:GO:0000295","description":"\"Enables the transfer of adenine nucleotides (AMP, ADP, and ATP) from one side of a membrane to the other.\" [PMID:11566870]","metadata":null},{"id":"5f353c012d4b439b91b978150cef69d9","type":"GO_TERM","name":"adenine nucleotide transport","canonical_id":"go:GO:0051503","description":"\"The directed movement of adenine nucleotides, ATP, ADP, and/or AMP, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"90a09e760b554883ac31aacbf7dbb9b7","type":"GO_TERM","name":"adenine phosphoribosyltransferase activity","canonical_id":"go:GO:0003999","description":"\"Catalysis of the reaction: AMP + diphosphate = adenine + 5-phospho-alpha-D-ribose 1-diphosphate.\" [RHEA:16609]","metadata":null},{"id":"e16b9a17701a43109444c0437f909d8f","type":"GO_TERM","name":"adenine salvage","canonical_id":"go:GO:0006168","description":"\"Any process that generates adenine, 6-aminopurine, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"62eb2df7b8f74c959a11a35316e9b9d3","type":"GO_TERM","name":"adenine transmembrane transporter activity","canonical_id":"go:GO:0015207","description":"\"Enables the transfer of adenine, 6-aminopurine, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"4c92b432f8d24ef592feee8036034eb0","type":"GO_TERM","name":"adenine transport","canonical_id":"go:GO:0015853","description":"\"The directed movement of adenine, 6-aminopurine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0ab6a978f8c042bd9a623381a6a24fbb","type":"GO_TERM","name":"adenine/adenine mispair binding","canonical_id":"go:GO:0035484","description":"\"Binding to a double-stranded DNA region containing an A/A mispair.\" [GOC:bf, GOC:jh]","metadata":null},{"id":"3bd69c3a4fb346b49e0415d743894f5a","type":"GO_TERM","name":"adenine/cytosine mispair binding","canonical_id":"go:GO:0032136","description":"\"Binding to a double-stranded DNA region containing an A/C mispair.\" [GOC:vk]","metadata":null},{"id":"96087613320e492991241170192ea055","type":"GO_TERM","name":"adenine/guanine mispair binding","canonical_id":"go:GO:0035485","description":"\"Binding to a double-stranded DNA region containing an A/G mispair.\" [GOC:bf, GOC:jh]","metadata":null},{"id":"c4d400a54e1f489aa6afda058cf82afc","type":"DISEASE","name":"adenocarcinoma","canonical_id":"mondo:0004970","description":null,"metadata":null},{"id":"ea50d914c7e746e5b97b3be6c0f5f459","type":"GO_TERM","name":"adenohypophysis development","canonical_id":"go:GO:0021984","description":"\"The progression of the adenohypophysis over time from its initial formation until its mature state. The adenohypophysis is the anterior part of the pituitary. It secretes a variety of hormones and its function is regulated by the hypothalamus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"79d12f7f4e764c6f96ec38299a9b90f8","type":"GO_TERM","name":"adenohypophysis formation","canonical_id":"go:GO:0048847","description":"\"The process that gives rise to adenohypophysis. This process pertains to the initial formation of a structure from unspecified parts. The adenohypophysis is the anterior part of the pituitary. It secretes a variety of hormones and its function is regulated by the hypothalamus.\" [GOC:cvs, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a8688c4b10834daa8bf64d679576dd37","type":"GO_TERM","name":"adenohypophysis morphogenesis","canonical_id":"go:GO:0048855","description":"\"The process in which the anatomical structures of the adenohypophysis are generated and organized. The adenohypophysis is the anterior part of the pituitary. It secretes a variety of hormones and its function is regulated by the hypothalamus.\" [GOC:cvs, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"cc72c142958b4dccafb7cfbe746dc52d","type":"DISEASE","name":"adenoma","canonical_id":"mondo:0004972","description":null,"metadata":null},{"id":"c950c6106cde47daa3880a7b0f5a07df","type":"DRUG","name":"adenosine","canonical_id":"gtopdb:2844","description":null,"metadata":null},{"id":"813d09e3aede4d4698cd8d2bed9d3711","type":"COMBINATION_TREATMENT","name":"adenosine + diltiazem","canonical_id":"ctgov_combo:ctgov-combo-8815e0fbef1349fe","description":null,"metadata":null},{"id":"d064a93e091240bca12b06dc3410622c","type":"COMBINATION_TREATMENT","name":"adenosine + regadenoson","canonical_id":"ctgov_combo:ctgov-combo-01d44f326407ac39","description":null,"metadata":null},{"id":"dbb93dc1f5f842eab6529cebd54c6640","type":"COMBINATION_TREATMENT","name":"adenosine + regadenoson","canonical_id":"ctgov_combo:ctgov-combo-49544f64b10492b2","description":null,"metadata":null},{"id":"980b993fcad64484b0e8323652dfc343","type":"COMBINATION_TREATMENT","name":"adenosine + regadenoson","canonical_id":"ctgov_combo:ctgov-combo-a179887e44db61d7","description":null,"metadata":null},{"id":"a6b71049d1014e1e9f6d457f27b5ceb7","type":"GO_TERM","name":"adenosine 3',5'-bisphosphate transmembrane transport","canonical_id":"go:GO:0071106","description":"\"The process in which adenosine 3',5'-bisphosphate is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"a43e3c9af44948c880bdb97cbca9abd4","type":"GO_TERM","name":"adenosine 3',5'-bisphosphate transmembrane transporter activity","canonical_id":"go:GO:0071077","description":"\"Enables the transfer of adenosine 3',5'-bisphosphate from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"5058f85949f54520ba87ccfc3ad42971","type":"GO_TERM","name":"adenosine 5'-(hexahydrogen pentaphosphate) catabolic process","canonical_id":"go:GO:1901911","description":"\"The chemical reactions and pathways resulting in the breakdown of adenosine 5'-(hexahydrogen pentaphosphate).\" [GOC:TermGenie, PMID:10090752]","metadata":null},{"id":"f02e0d4af26b48a7a0520fcabcebab95","type":"GO_TERM","name":"adenosine 5'-monophosphoramidase activity","canonical_id":"go:GO:0043530","description":"\"Catalysis of the reaction: adenosine 5'-monophosphoramidate + H2O = AMP + NH4+. Other substrates include AMP-morpholidate, AMP-N-alanine methyl ester and AMP-alpha-acetyl lysine methyl ester.\" [PMID:11805111, RHEA:67916]","metadata":null},{"id":"14ba6fbfd5a54bbea6e17dc5e695b869","type":"GO_TERM","name":"adenosine biosynthetic process","canonical_id":"go:GO:0046086","description":"\"The chemical reactions and pathways resulting in the formation of adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes.\" [GOC:curators]","metadata":null},{"id":"643da6256f2642548acc9c72b6a93372","type":"GO_TERM","name":"adenosine catabolic process","canonical_id":"go:GO:0006154","description":"\"The chemical reactions and pathways resulting in the breakdown of adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes.\" [GOC:curators]","metadata":null},{"id":"2dee4eb327bf4cdc9662c251cc583d13","type":"GO_TERM","name":"adenosine deaminase activity","canonical_id":"go:GO:0004000","description":"\"Catalysis of the reaction: adenosine + H2O = inosine + NH4+.\" [RHEA:24408]","metadata":null},{"id":"40fcacafdbce4b24b9b2eeaa3ddbdcc8","type":"GO_TERM","name":"adenosine kinase activity","canonical_id":"go:GO:0004001","description":"\"Catalysis of the reaction: ATP + adenosine = ADP + AMP.\" [EC:2.7.1.20, PMID:11223943]","metadata":null},{"id":"e141c8effb4d4334ab65e6cc1bc4472c","type":"GO_TERM","name":"adenosine metabolic process","canonical_id":"go:GO:0046085","description":"\"The chemical reactions and pathways involving adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes.\" [GOC:curators]","metadata":null},{"id":"94ac3a0106644f2690c368b62c2c42f3","type":"GO_TERM","name":"adenosine nucleosidase activity","canonical_id":"go:GO:0047622","description":"\"Catalysis of the reaction: adenosine + H2O = D-ribose + adenine.\" [EC:3.2.2.7, MetaCyc:ADENOSINE-NUCLEOSIDASE-RXN]","metadata":null},{"id":"0797ab2d55e743ffa132ba2e429002e5","type":"DRUG","name":"adenosine phosphate","canonical_id":"mesh:D000249","description":null,"metadata":null},{"id":"57ff25d767c54523bb7206c8ad198aa9","type":"GO_TERM","name":"adenosine receptor binding","canonical_id":"go:GO:0031685","description":"\"Binding to an adenosine receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"f8675c2ec86f43d3baaf4e8f9b52a169","type":"GO_TERM","name":"adenosine salvage","canonical_id":"go:GO:0006169","description":"\"Any process that generates adenosine, adenine riboside, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"22eba2f72bb842ec9aea8f9b5b4ac6bc","type":"GO_TERM","name":"adenosine to inosine editing","canonical_id":"go:GO:0006382","description":"\"The conversion of an adenosine residue to inosine in an RNA molecule by deamination.\" [PMID:11092837]","metadata":null},{"id":"b698e1ada6ba4b328bf32ff326988313","type":"GO_TERM","name":"adenosine transport","canonical_id":"go:GO:0032238","description":"\"The directed movement of adenosine, adenine riboside, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"f1219a186f994f3fa5525ff71076b278","type":"GO_TERM","name":"adenosine-phosphate deaminase activity","canonical_id":"go:GO:0047623","description":"\"Catalysis of the reaction: an adenosine-phosphate + H20 = an inosine phosphate + NH4+. Catalyzes the deamination of AMP, ADP or ATP.\" [EC:3.5.4.17]","metadata":null},{"id":"aee3ce656f23423f8d5a9bff2759eb72","type":"GO_TERM","name":"adenosine-tetraphosphatase activity","canonical_id":"go:GO:0047624","description":"\"Catalysis of the reaction: adenosine 5'-tetraphosphate + H2O = phosphate + ATP + H+.\" [RHEA:24500]","metadata":null},{"id":"01e22db1a98e492fbcc00dd65b426aa8","type":"GO_TERM","name":"adenosyl-fluoride synthase activity","canonical_id":"go:GO:0033846","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + fluoride = 5'-deoxy-5'-fluoroadenosine + L-methionine.\" [EC:2.5.1.63]","metadata":null},{"id":"55f7ed5ae9e74126b474b195d521cfb7","type":"GO_TERM","name":"adenosylcobinamide hydrolase activity","canonical_id":"go:GO:0043756","description":"\"Catalysis of the reaction: adenosylcobinamide + H2O = (R)-1-aminopropan-2-ol + adenosylcobyrate.\" [EC:3.5.1.90, RHEA:23504]","metadata":null},{"id":"fdea6ac55a5d48e4883b3080710ac673","type":"GO_TERM","name":"adenosylcobinamide kinase activity","canonical_id":"go:GO:0043752","description":"\"Catalysis of the reaction: RTP + adenosylcobinamide = adenosylcobinamide phosphate + RDP (where RTP is either ATP or GTP).\" [EC:2.7.1.156]","metadata":null},{"id":"fbff95da245d4b72bbd4cbf5bf730449","type":"GO_TERM","name":"adenosylcobinamide-GDP ribazoletransferase activity","canonical_id":"go:GO:0051073","description":"\"Catalysis of the reaction: adenosylcobinamide-GDP + alpha-ribazole = GMP + adenosylcobalamin.\" [EC:2.7.8.26, MetaCyc:COBALAMINSYN-RXN]","metadata":null},{"id":"6060b49393e94083b7c1c8f274e1a907","type":"GO_TERM","name":"adenosylcobinamide-phosphate synthase activity","canonical_id":"go:GO:0043757","description":"\"Catalysis of the reactions: ATP + adenosylcobyric acid + (R)-1-aminopropan-2-yl phosphate = ADP + phosphate + adenosylcobinamide phosphate, and ATP + adenosylcobyric acid + (R)-1-aminopropan-2-ol = ADP + phosphate + adenosylcobinamide.\" [EC:6.3.1.10]","metadata":null},{"id":"6ec9af4f61ef4325960dc7f6dac017aa","type":"GO_TERM","name":"adenosylcobyric acid synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0051921","description":"\"Catalysis of the reaction: 4 L-glutamine + adenosylcob(III)yrinate a,c-diamide + 4 ATP + 4 H2O = 4 L-glutamate + adenosylcobyrate + 4 ADP + 8 H+ + 4 phosphate.\" [EC:6.3.5.10, RHEA:23256]","metadata":null},{"id":"fc5adf72bf2245e0b98995b74cee44ce","type":"GO_TERM","name":"adenosylhomocysteinase activity","canonical_id":"go:GO:0004013","description":"\"Catalysis of the reaction: S-adenosyl-L-homocysteine + H2O = adenosine + L-homocysteine.\" [RHEA:21708]","metadata":null},{"id":"9626257b565b41e1adaef51b4a8c7adb","type":"GO_TERM","name":"adenosylhomocysteine nucleosidase activity","canonical_id":"go:GO:0008782","description":"\"Catalysis of the reaction: S-adenosyl-L-homocysteine + H2O = adenine + S-D-ribosyl-L-homocysteine.\" [EC:3.2.2.9]","metadata":null},{"id":"2d39d67bc26642b38543b646bbb67da1","type":"GO_TERM","name":"adenosylmethionine decarboxylase activity","canonical_id":"go:GO:0004014","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + H+ = S-adenosylmethioninamine + CO2.\" [EC:4.1.1.50, RHEA:15981]","metadata":null},{"id":"16a266cb399147bfa098a7cc15028c7b","type":"GO_TERM","name":"adenosylselenohomocysteinase activity","canonical_id":"go:GO:0098604","description":"\"Catalysis of the reaction: Se-Adenosyl-L-selenohomocysteine + H2O = Adenosine + Selenohomocysteine.\" [GOC:dos, PMID:1711890, PMID:7305945]","metadata":null},{"id":"8c892a707aae482392289a0d582f5f62","type":"GO_TERM","name":"adenyl deoxyribonucleotide binding","canonical_id":"go:GO:0032558","description":"\"Binding to an adenyl deoxyribonucleotide, any compound consisting of adenosine esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety.\" [GOC:mah]","metadata":null},{"id":"bd8c223e2bce4489ac6d9d7a7f1a9103","type":"GO_TERM","name":"adenyl nucleotide binding","canonical_id":"go:GO:0030554","description":"\"Binding to an adenyl nucleotide, an adenosine esterified with (ortho)phosphate.\" [ISBN:0198506732]","metadata":null},{"id":"cea485cdc0b445e18eaa222e453ed502","type":"GO_TERM","name":"adenyl ribonucleotide binding","canonical_id":"go:GO:0032559","description":"\"Binding to an adenyl ribonucleotide, any compound consisting of adenosine esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety.\" [GOC:mah]","metadata":null},{"id":"e382cf96be9f4985bfb2d7173c563314","type":"GO_TERM","name":"adenyl-nucleotide exchange factor activity","canonical_id":"go:GO:0000774","description":"\"Binds to and stimulates the hydrolysis and exchange of adenyl nucleotides by other proteins.\" [GOC:kd]","metadata":null},{"id":"318b71757d0f4084bc03d78a123434b5","type":"GO_TERM","name":"adenylate cyclase activator activity","canonical_id":"go:GO:0010856","description":"\"Binds to and increases the activity of adenylate cyclase.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"36259c046fcc4e558bf9508835e43787","type":"GO_TERM","name":"adenylate cyclase activity","canonical_id":"go:GO:0004016","description":"\"Catalysis of the reaction: ATP = 3',5'-cyclic AMP + diphosphate.\" [EC:4.6.1.1]","metadata":null},{"id":"6c9b505a7a1948cf8d4332b781006895","type":"GO_TERM","name":"adenylate cyclase binding","canonical_id":"go:GO:0008179","description":"\"Binding to an adenylate cyclase.\" [GOC:jl]","metadata":null},{"id":"91f0ee9298c848cebc0e302aff822c73","type":"GO_TERM","name":"adenylate cyclase inhibiting G protein-coupled glutamate receptor activity","canonical_id":"go:GO:0001640","description":"\"Combining with glutamate and transmitting the signal across the membrane by activating the alpha-subunit of an associated heterotrimeric G-protein complex to inhibit downstream adenylate cyclase activity.\" [GOC:bf, GOC:dph]","metadata":null},{"id":"05deaa4e01d34217b86d87f8fda77611","type":"GO_TERM","name":"adenylate cyclase inhibitor activity","canonical_id":"go:GO:0010855","description":"\"Binds to and decreases the activity of adenylate cyclase.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1d581a8c533342f1a11b566b4e923ad8","type":"GO_TERM","name":"adenylate cyclase regulator activity","canonical_id":"go:GO:0010854","description":"\"Binds to and modulates the activity of adenylate cyclase.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bf04a89c67ad4075b12d44fc268d7e96","type":"GO_TERM","name":"adenylate cyclase-activating G protein-coupled bile acid receptor signaling pathway","canonical_id":"go:GO:0038184","description":"\"An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to a bile acid receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process.\" [PMID:12419312, PMID:19442546, PMID:36409000]","metadata":null},{"id":"20deecd43a2d4ed2893e97e2915da585","type":"GO_TERM","name":"adenylate cyclase-activating G protein-coupled cAMP receptor signaling pathway","canonical_id":"go:GO:0140582","description":"\"An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by extracellular cAMP binding to its receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process.\" [PMID:9578623]","metadata":null},{"id":"78dfd9f35bc340d0a75e3b0b262efa5e","type":"GO_TERM","name":"adenylate cyclase-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0007189","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of adenylyl cyclase activity which results in an increase in the intracellular concentration of cyclic AMP (cAMP). This pathway is negatively regulated by phosphodiesterase, which cleaves cAMP and terminates the signaling.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194]","metadata":null},{"id":"d03e598883d54caea4851f65b242c4ef","type":"GO_TERM","name":"adenylate cyclase-activating adrenergic receptor signaling pathway","canonical_id":"go:GO:0071880","description":"\"An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process.\" [GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"9b10c8322c5d4efd9222444b4558bcef","type":"GO_TERM","name":"adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process","canonical_id":"go:GO:0086023","description":"\"The series of molecular signals beginning with a G protein-coupled adrenergic cell surface receptor combining with epinephrine or norepinephrine, to activate adenylate cyclase, which contributes to a circulatory system process carried out by the heart.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"310afb0558b14f1ca4bcce3a53bed79a","type":"GO_TERM","name":"adenylate cyclase-activating dopamine receptor signaling pathway","canonical_id":"go:GO:0007191","description":"\"An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"b04014df0ef247ad948585872ebb58ef","type":"GO_TERM","name":"adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0010619","description":"\"An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by glucose binding to its receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:signaling, GOC:tb]","metadata":null},{"id":"5e4aa45fc0b341bb9b5af853dbdb18b3","type":"GO_TERM","name":"adenylate cyclase-activating serotonin receptor signaling pathway","canonical_id":"go:GO:0007192","description":"\"An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by serotonin binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"d3d1db1202e7484ba8a843d64c7b8055","type":"GO_TERM","name":"adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway","canonical_id":"go:GO:0007197","description":"\"An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by acetylcholine binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"83a0088596204d9ebe3cf6ca8715d9a9","type":"GO_TERM","name":"adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway","canonical_id":"go:GO:0007196","description":"\"An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by glutamate binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"f7c9c6df60ce47ef843ccf6c1c156ebe","type":"GO_TERM","name":"adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0007193","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the inhibition of adenylyl cyclase activity and a subsequent decrease in the intracellular concentration of cyclic AMP (cAMP).\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194]","metadata":null},{"id":"8a23ab59cb0c4323beda5d5b06b9c5af","type":"GO_TERM","name":"adenylate cyclase-inhibiting adrenergic receptor signaling pathway","canonical_id":"go:GO:0071881","description":"\"An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor, and ending with the regulation of a downstream cellular process.\" [GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"b1ad1f053921436ab10fcd498a5db216","type":"GO_TERM","name":"adenylate cyclase-inhibiting dopamine receptor signaling pathway","canonical_id":"go:GO:0007195","description":"\"An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"918f6cf1a2f44ff38dc257573e293fe4","type":"GO_TERM","name":"adenylate cyclase-inhibiting opioid receptor signaling pathway","canonical_id":"go:GO:0031635","description":"\"An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by an opioid binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"13dd4d4ddc6c4bbba4e78a426b46fafe","type":"GO_TERM","name":"adenylate cyclase-inhibiting serotonin receptor signaling pathway","canonical_id":"go:GO:0007198","description":"\"An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by serotonin binding to its receptor, and ending with the regulation of a downstream cellular process.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"b2a3c30c27294b2b9f131024e3f789c7","type":"GO_TERM","name":"adenylate cyclase-modulating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0007188","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation or inhibition of adenylyl cyclase activity and a subsequent change in the intracellular concentration of cyclic AMP (cAMP).\" [GOC:mah, GOC:signaling, ISBN:0815316194]","metadata":null},{"id":"20f8718c509d40d3a91f0a928f0e93cf","type":"GO_TERM","name":"adenylosuccinate synthase activity","canonical_id":"go:GO:0004019","description":"\"Catalysis of the reaction: L-aspartate + GTP + IMP = N(6)-(1,2-dicarboxyethyl)-AMP + GDP + 3 H+ + phosphate.\" [EC:6.3.4.4, RHEA:15753]","metadata":null},{"id":"23d95bc595fb40769935d87a821e7d19","type":"GO_TERM","name":"adenylyl-sulfate reductase (glutathione) activity","canonical_id":"go:GO:0033741","description":"\"Catalysis of the reaction: AMP + glutathione disulfide + H+ + sulfite = 5'-adenylyl sulfate + 2 glutathione.\" [EC:1.8.4.9, RHEA:14141]","metadata":null},{"id":"a5ea724e9e9e451bb540c003eea0b7d2","type":"GO_TERM","name":"adenylyl-sulfate reductase (thioredoxin) activity","canonical_id":"go:GO:0043866","description":"\"Catalysis of the reaction: AMP + sulfite + thioredoxin disulfide = 5'-adenylyl sulfate + thioredoxin.\" [EC:1.8.4.10]","metadata":null},{"id":"206323eb256542beaae70db1bfb7365c","type":"GO_TERM","name":"adenylyl-sulfate reductase activity","canonical_id":"go:GO:0009973","description":"\"Catalysis of the reaction: A + AMP + 2 H+ + sulfite = adenosine 5'-phosphosulfate + AH2.\" [PMID:5421934, RHEA:24240]","metadata":null},{"id":"606b284f3edd4aa4b80bec9d773da7fe","type":"GO_TERM","name":"adenylylselenate kinase activity","canonical_id":"go:GO:0098617","description":"\"Catalysis of the reaction: ATP + adenylylselenate = ADP + 3'-phosphoadenylylselenate.\" [PMID:2537056]","metadata":null},{"id":"e3a69e9aa6f4410cb577aa88406a3dec","type":"GO_TERM","name":"adenylylsulfatase activity","canonical_id":"go:GO:0047627","description":"\"Catalysis of the reaction: 5'-adenylyl sulfate + H2O = AMP + 2 H+ + sulfate.\" [EC:3.6.2.1, RHEA:17041]","metadata":null},{"id":"f0ed48c677eb47bf9dfa0bba4b05ef11","type":"GO_TERM","name":"adenylylsulfate kinase activity","canonical_id":"go:GO:0004020","description":"\"Catalysis of the reaction: adenosine 5'-phosphosulfate + ATP = 3'-phosphoadenylyl sulfate + ADP + H+.\" [EC:2.7.1.25]","metadata":null},{"id":"c17c9e1e17ec432991428036d86d3e81","type":"GO_TERM","name":"adenylylsulfate-ammonia adenylyltransferase activity","canonical_id":"go:GO:0047352","description":"\"Catalysis of the reaction: 5'-adenylyl sulfate + NH4 = adenosine 5'-phosphoramidate + 2 H+ + sulfate.\" [EC:2.7.7.51, RHEA:19197]","metadata":null},{"id":"d99e86cdec32476b86595b0b5b6e0efe","type":"GO_TERM","name":"adenylyltransferase activity","canonical_id":"go:GO:0070566","description":"\"Catalysis of the transfer of an adenylyl group to an acceptor.\" [GOC:mah]","metadata":null},{"id":"1d2dcc2c98b14995a0ed620e06d88f17","type":"GO_TERM","name":"adenylyltransferase complex","canonical_id":"go:GO:1902503","description":"\"A protein complex which is capable of adenylyltransferase activity.\" [GOC:bhm, GOC:TermGenie, PMID:11713534]","metadata":null},{"id":"6337eda0534147cda2ea2e681700e36a","type":"GO_TERM","name":"adherens junction","canonical_id":"go:GO:0005912","description":"\"A cell-cell junction composed of the epithelial cadherin-catenin complex. The epithelial cadherins, or E-cadherins, of each interacting cell extend through the plasma membrane into the extracellular space and bind to each other. The E-cadherins bind to catenins on the cytoplasmic side of the membrane, where the E-cadherin-catenin complex binds to cytoskeletal components and regulatory and signaling molecules.\" [GOC:aruk, GOC:bc, GOC:mah, ISBN:0198506732, PMID:17854762, PMID:20571587, PMID:21422226, PMID:28096264]","metadata":null},{"id":"0e1ccf21b8a147318505acc98ea940ea","type":"GO_TERM","name":"adherens junction assembly","canonical_id":"go:GO:0034333","description":"\"The aggregation, arrangement and bonding together of a set of components to form an adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GOC:aruk, GOC:bc, GOC:mah]","metadata":null},{"id":"7888542156a7455bae127e40a4235608","type":"GO_TERM","name":"adherens junction disassembly","canonical_id":"go:GO:0120179","description":"\"The disaggregation of an adherens junction into its constituent components. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GOC:aruk, GOC:bc, PMID:25490267]","metadata":null},{"id":"505fc931384449a7b59d530e5255cefb","type":"GO_TERM","name":"adherens junction maintenance","canonical_id":"go:GO:0034334","description":"\"The maintenance of an adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GOC:aruk, GOC:bc, GOC:mah]","metadata":null},{"id":"c7a82b0f7b744e50848fba6ebf7ab52b","type":"GO_TERM","name":"adherens junction organization","canonical_id":"go:GO:0034332","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GOC:aruk, GOC:bc, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"3a491687afd74c72849740ff6c81b8e5","type":"GO_TERM","name":"adhesion between unicellular organisms","canonical_id":"go:GO:0098610","description":"\"The attachment of two unicellular organisms to each other.\" [GOC:dos]","metadata":null},{"id":"ad3245001c3b44c798725b7c3be44caf","type":"GO_TERM","name":"adhesion of symbiont appressorium to host","canonical_id":"go:GO:0075003","description":"\"The attachment of an appressorium of the symbiont to its host via adhesion molecules. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"bc033a2982da4beb9bb40283efa0d2db","type":"GO_TERM","name":"adhesion of symbiont germination tube to host","canonical_id":"go:GO:0075002","description":"\"The attachment of a germination tube of the symbiont to its host via adhesion molecules. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"9c0600daa35e4ba8a946cf45d29e2deb","type":"GO_TERM","name":"adhesion of symbiont haustorium mother cell to host","canonical_id":"go:GO:0075196","description":"\"The attachment of a haustorium mother cell of the symbiont to its host via adhesion molecules. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"e489a1047b4c41c3aae97ae7c9079b1d","type":"GO_TERM","name":"adhesion of symbiont hyphopodium to host","canonical_id":"go:GO:0075070","description":"\"The attachment of a hyphopodium of the symbiont to its host via adhesion molecules. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"658b2ca0b112476391c27876843024d9","type":"GO_TERM","name":"adhesion of symbiont infection cushion to host","canonical_id":"go:GO:0075069","description":"\"The attachment of an infection cushion of the symbiont to its host via adhesion molecules. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"2890dae40be745ff91ea45891d918b71","type":"GO_TERM","name":"adhesion of symbiont infection structure to host","canonical_id":"go:GO:0075001","description":"\"The attachment of an infection structure of the symbiont to its host via adhesion molecules, general stickiness etc., either directly or indirectly. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"0d62556a361947b3bb5aaffe35aa5e4b","type":"GO_TERM","name":"adhesion of symbiont spore to host","canonical_id":"go:GO:0075004","description":"\"The attachment of a spore of the symbiont to its host via adhesion molecules, general stickiness etc. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"7a257cd3456d4a2e928c05896417fcdb","type":"GO_TERM","name":"adhesion of symbiont to host","canonical_id":"go:GO:0044406","description":"\"The attachment of a symbiont to its host via either adhesion molecules, general stickiness, or other mechanisms. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:cc, GOC:dos, GOC:jl]","metadata":null},{"id":"443642cb4890482e9317997798af238f","type":"GO_TERM","name":"adhesion of symbiont to host cell","canonical_id":"go:GO:0044650","description":"\"The attachment of a symbiont to a host cell via adhesion molecules, general stickiness etc., either directly or indirectly.\" [GOC:jl]","metadata":null},{"id":"cd58e29508e146b78014a3c678a9a01a","type":"GO_TERM","name":"adhesion of symbiont to host cell surface via host glycoprotein","canonical_id":"go:GO:0141025","description":"\"The attachment of a symbiont to its host by binding to a glycoprotein on the host cell surface. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:12010488, PMID:15487949, PMID:17630833, PMID:29184850]","metadata":null},{"id":"a3d6bc70aed940298a7bdcba88f53846","type":"GO_TERM","name":"adhesion of symbiont to host cell surface via host membrane carbohydrate","canonical_id":"go:GO:0141024","description":"\"The attachment of a symbiont to its host by binding to a carbohydrate on the host cell surface. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15210807, PMID:19527885, PMID:30736336]","metadata":null},{"id":"4e8cf5f566e447f4827dfac43e75373d","type":"GO_TERM","name":"adhesion of symbiont to host cell surface via host membrane cholesterol","canonical_id":"go:GO:0141026","description":"\"The attachment of a symbiont to its host by binding to cholesterol on the host cell surface. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:17557817, PMID:23239883]","metadata":null},{"id":"8b84ec1e949143efa7cc947b5fe55d4c","type":"GO_TERM","name":"adhesion of symbiont to host endothelial cell","canonical_id":"go:GO:0044652","description":"\"The attachment of a symbiont to a host endothelial cell via adhesion molecules, general stickiness etc., either directly or indirectly.\" [GOC:jl, PMID:10066176]","metadata":null},{"id":"114908ce137440349a6dc9b274b9f2b7","type":"GO_TERM","name":"adhesion of symbiont to host epithelial cell","canonical_id":"go:GO:0044651","description":"\"The attachment of a symbiont to a host epithelial cell via adhesion molecules, general stickiness etc., either directly or indirectly.\" [GOC:jl, PMID:10066176]","metadata":null},{"id":"55ad284c12144919b6881a6926ee15b1","type":"GO_TERM","name":"adhesion of symbiont to host via host extracellular matrix","canonical_id":"go:GO:0141018","description":"\"The attachment of a symbiont to its host by binding to a component of the host extracellular matrix. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15228540, PMID:21270401, PMID:23586629]","metadata":null},{"id":"8a1e7ba3623e45dea4d48a37d9a72fec","type":"GO_TERM","name":"adhesion of symbiont to microvasculature","canonical_id":"go:GO:0020035","description":"\"The adherence of symbiont-infected erythrocytes to microvascular endothelium via symbiont proteins embedded in the membrane of the erythrocyte.\" [GOC:mb, PMID:10362584]","metadata":null},{"id":"201687ec8d494c2995d806c8cd35956c","type":"GO_TERM","name":"adhesion receptor-mediated virion attachment to host cell","canonical_id":"go:GO:0098671","description":"\"The process by which a virion attaches to a host cell by binding to a receptor on the host cell surface that does not mediate or trigger entry into the host cell. This binding is typically reversible and enhances significantly infectivity by concentrating the virus in the vicinity of its entry receptors, or bringing it to an organ in which its target cells are located.\" [PMID:18351291, VZ:3943]","metadata":null},{"id":"dad2edab929147fe9828be80fc4d6ae9","type":"GO_TERM","name":"adhesion to host cell via type IV pili","canonical_id":"go:GO:0052001","description":"\"Attachment of bacterial clusters to the surface of the host in a type IV pili dependent manner. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:ml]","metadata":null},{"id":"9b95db56c6764cfd84632053ea2f0efd","type":"GO_TERM","name":"adipokinetic hormone binding","canonical_id":"go:GO:0097004","description":"\"Binding to an adipokinetic hormone. Adipokinetic hormones (AKHs) are peptide hormones that are involved in the mobilization of sugar and lipids from the insect fat body during energy-requiring activities such as flight and locomotion. They also contribute to hemolymph sugar homeostasis.\" [GOC:sart, PMID:11904407]","metadata":null},{"id":"ad0db0cc3db54e61afbbec503ac83310","type":"GO_TERM","name":"adipokinetic hormone receptor activity","canonical_id":"go:GO:0097003","description":"\"Combining with an adipokinetic hormone to initiate a change in cell activity. Adipokinetic hormones (AKHs) are protein or peptide hormones that are important for sugar and fat homeostasis in metazoa. In insects, they mobilize sugar and lipids from the insect fat body during energy-requiring activities such as flight and locomotion. They also contribute to hemolymph sugar homeostasis.\" [GOC:sart, PMID:11904407]","metadata":null},{"id":"354ec1e531d240c2b58824e7294120d9","type":"GO_TERM","name":"adipokinetic hormone receptor binding","canonical_id":"go:GO:0097005","description":"\"Binding to an adipokinetic hormone receptor. Adipokinetic hormones (AKHs) are peptide hormones that are involved in the mobilization of sugar and lipids from the insect fat body during energy-requiring activities such as flight and locomotion. They also contribute to hemolymph sugar homeostasis.\" [GOC:sart, PMID:11904407]","metadata":null},{"id":"5110d8c2caae499dbeedd077888aafeb","type":"GO_TERM","name":"adiponectin binding","canonical_id":"go:GO:0055100","description":"\"Binding to adiponectin, a protein hormone produced by adipose tissue that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism.\" [GOC:BHF, GOC:rl, PMID:15210937]","metadata":null},{"id":"d914575a35fe4e7585d8e94a7c3a05e5","type":"GO_TERM","name":"adiponectin secretion","canonical_id":"go:GO:0070162","description":"\"The regulated release of adiponectin, a protein hormone, by adipose tissue.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"8914cd43d0ea492889b60aa43c2e72c3","type":"GO_TERM","name":"adiponectin-activated signaling pathway","canonical_id":"go:GO:0033211","description":"\"The series of molecular signals initiated by adiponectin binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling, PMID:20536390]","metadata":null},{"id":"d031af6bdba842d2a90374f1b2008f83","type":"GO_TERM","name":"adipose tissue development","canonical_id":"go:GO:0060612","description":"\"The process whose specific outcome is the progression of adipose tissue over time, from its formation to the mature structure. Adipose tissue is specialized tissue that is used to store fat.\" [GOC:dph]","metadata":null},{"id":"7bff575600d34868a0127a01115c338a","type":"GO_TERM","name":"adrenal chromaffin cell differentiation","canonical_id":"go:GO:0061104","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of an adrenal chromaffin cell. An adrenal chromaffin cell is a neuroendocrine cell that stores epinephrine secretory vesicles.\" [GOC:dph]","metadata":null},{"id":"e34cd35290954c5d86dc2a8f6660b968","type":"DISEASE","name":"adrenal cortex carcinoma","canonical_id":"mondo:0006639","description":null,"metadata":null},{"id":"63f159ea8ff944948ab67bd350153b18","type":"GO_TERM","name":"adrenal cortex development","canonical_id":"go:GO:0035801","description":"\"The process whose specific outcome is the progression of the adrenal cortex over time, from its formation to the mature structure. The adrenal cortex is located at the periphery of the adrenal gland and controls glucose and electrolyte metabolism, response to stress and sexual development through the production of different classes of steroid hormones (glucocorticoids, mineralocorticoids and androgens).\" [PMID:12185666, PMID:21115154, Wikipedia:Adrenal_cortex]","metadata":null},{"id":"8f1a124dcb5348e18c77c10f4dcf5b92","type":"GO_TERM","name":"adrenal cortex formation","canonical_id":"go:GO:0035802","description":"\"The process that gives rise to the adrenal cortex. This process pertains to the initial formation of a structure from unspecified parts. The adrenogonadal primordium from which the adrenal cortex is formed derives from a condensation of coelomic epithelial cells (the urogenital ridge; the same structure from which gonads and kidney also originate).\" [PMID:12185666, PMID:21115154]","metadata":null},{"id":"e846c95ebe6c4c63b6cc0301a822b36d","type":"GO_TERM","name":"adrenal gland development","canonical_id":"go:GO:0030325","description":"\"The process whose specific outcome is the progression of the adrenal gland over time, from its formation to the mature structure. This gland can either be a discrete structure located bilaterally above each kidney, or a cluster of cells in the head kidney that perform the functions of the adrenal gland. In either case, this organ consists of two cells types, aminergic chromaffin cells and steroidogenic cortical cells.\" [GOC:dgh]","metadata":null},{"id":"8fadaa7e97084df0991926cbd673a093","type":"DISEASE","name":"adrenal gland disorder","canonical_id":"mondo:0005495","description":null,"metadata":null},{"id":"3ab7b3e7d78348ad95d8cef8a7b974b6","type":"DISEASE","name":"adrenal gland hyperfunction","canonical_id":"mondo:0006640","description":null,"metadata":null},{"id":"5f378444287944f5a987195ac17f250e","type":"DISEASE","name":"adrenal gland pheochromocytoma","canonical_id":"mondo:0004974","description":null,"metadata":null},{"id":"50347d7ebea245edb57f21a6f7f678df","type":"GO_TERM","name":"adrenergic receptor activity","canonical_id":"go:GO:0004935","description":"\"Combining with epinephrine or norepinephrine and transmitting the signal across the membrane by activating the alpha-subunit of an associated heterotrimeric G-protein complex.\" [GOC:bf, GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"3863c264e1214821a5e5e74a48182462","type":"GO_TERM","name":"adrenergic receptor binding","canonical_id":"go:GO:0031690","description":"\"Binding to an adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"728fb8588af84af1a3681733050cdd93","type":"GO_TERM","name":"adrenergic receptor signaling pathway","canonical_id":"go:GO:0071875","description":"\"A G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:BHF]","metadata":null},{"id":"5eb5a24e39a14daeafdcceb994a92be4","type":"DISEASE","name":"adrenocortical insufficiency","canonical_id":"mondo:0000004","description":null,"metadata":null},{"id":"1093ddcf074343829dabefb8c0dd93ab","type":"DISEASE","name":"adrenogenital syndrome","canonical_id":"mondo:0015898","description":null,"metadata":null},{"id":"baae116f8dc1481c8ba4a17ed79d9f1a","type":"GO_TERM","name":"adrenomedullin binding","canonical_id":"go:GO:1990409","description":"\"Binding to adrenomedullin (AM).\" [GOC:bhm, PMID:10882736]","metadata":null},{"id":"42f4b95a38394ec8b5866262d7adf91b","type":"GO_TERM","name":"adrenomedullin receptor activity","canonical_id":"go:GO:0001605","description":"\"Combining with adrenomedullin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"87bd4b468ab3402183efa896ad8176ae","type":"GO_TERM","name":"adrenomedullin receptor binding","canonical_id":"go:GO:0031700","description":"\"Binding to an adrenomedullin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a0b4139a159e4761a22542e5f5960cb6","type":"GO_TERM","name":"adrenomedullin receptor complex","canonical_id":"go:GO:1903143","description":"\"A transmembrane, G protein-coupled signaling receptor complex which is capable of adrenomedullin receptor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:22102369]","metadata":null},{"id":"fb906eaea12c404ba58d94f9a383ed52","type":"GO_TERM","name":"adrenomedullin receptor signaling pathway","canonical_id":"go:GO:1990410","description":"\"The series of molecular signals initiated by an extracellular adrenomedullin combining with a dimeric adrenomedullin receptor on the surface of the target cell.\" [GOC:bhm, PMID:10882736]","metadata":null},{"id":"185f67365d094e7180d9578e9ef8322f","type":"DRUG","name":"aducanumab","canonical_id":"gtopdb:8325","description":null,"metadata":null},{"id":"5e5063d0ae5c470abd88ca50c9d9dabb","type":"DRUG","name":"aducanumab","canonical_id":"chembl:CHEMBL3039540","description":null,"metadata":null},{"id":"5bf7a2c6ddeb4a11af7c91e816ad3613","type":"DISEASE","name":"adult T-cell leukemia/lymphoma","canonical_id":"mondo:0019471","description":null,"metadata":null},{"id":"9d9d8a79bd1a4eed943b4ceb9353468a","type":"GO_TERM","name":"adult behavior","canonical_id":"go:GO:0030534","description":"\"Behavior in a fully developed and mature organism.\" [GOC:mah, ISBN:0877797099]","metadata":null},{"id":"39272a1e45bd4c18a62662cd8763ea1e","type":"GO_TERM","name":"adult chitin-based cuticle development","canonical_id":"go:GO:0008365","description":"\"Synthesis and deposition of the chitin-based cuticle of adults following the apolysis of the pupal cuticle. The adult insect cuticle contains cuticullin, a protein epicuticle and a lamellate procuticle. An example of this process is adult chitin-based cuticle development in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"9f6473508f36407cadac7c2275c3c5ab","type":"GO_TERM","name":"adult chitin-based cuticle pattern formation","canonical_id":"go:GO:0035018","description":"\"The process that gives rise to the patterns of cell differentiation that will arise in the chitin-based adult cuticle. An example of this process is adult chitin-based cuticle pattern formation in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"04e8ff310ac341fbbc2f99f154dd2cf0","type":"GO_TERM","name":"adult chitin-containing cuticle pigmentation","canonical_id":"go:GO:0048085","description":"\"Establishment of the adult pattern of pigmentation in the chitin-containing cuticle of an organism. An example of this is the adult cuticle pigmentation process in Drosophila melanogaster.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"9ec82280fa2c40a5825fa6b070292a50","type":"GO_TERM","name":"adult fat body development","canonical_id":"go:GO:0007505","description":"\"The process whose specific outcome is the progression of the adult fat body over time, from its formation to the mature structure. Larval fat body cells that remain at eclosion degenerate in the first 2 to 4 days of adult life, leaving behind the smaller cells of the adult fat body.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"8785e36524a14a38b3f1c6a07af41ac2","type":"GO_TERM","name":"adult feeding behavior","canonical_id":"go:GO:0008343","description":"\"Feeding behavior in a fully developed and mature organism.\" [GOC:mah]","metadata":null},{"id":"67f48dad8da24532a5bc0cea715fdfe4","type":"GO_TERM","name":"adult foraging behavior","canonical_id":"go:GO:0060757","description":"\"Behavior by which an adult locates food.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"eacda27890d1431ab5c2cccaa8d33469","type":"GO_TERM","name":"adult heart development","canonical_id":"go:GO:0007512","description":"\"The process whose specific outcome is the progression of the adult heart over time, from its formation to the mature structure.\" [GOC:bf]","metadata":null},{"id":"6ab13a3b7e3343ecac9da899dde9710f","type":"GO_TERM","name":"adult locomotory behavior","canonical_id":"go:GO:0008344","description":"\"Locomotory behavior in a fully developed and mature organism.\" [GOC:ai]","metadata":null},{"id":"c590f7300bf84c0f9e41668846cc2a8c","type":"DISEASE","name":"adult onset asthma","canonical_id":"efo:1002011","description":null,"metadata":null},{"id":"08bd830f2d6a4dc88d0c9fd98f83d70b","type":"GO_TERM","name":"adult salivary gland boundary specification","canonical_id":"go:GO:0007434","description":"\"Determination in an adult organism of where the salivary gland forms, the total number of salivary gland cells and how many cells are allocated to each of the specialised cell types within the salivary gland.\" [GOC:tb, PMID:11598957]","metadata":null},{"id":"24303803d0484bdc90b8260970745ccc","type":"GO_TERM","name":"adult salivary gland morphogenesis","canonical_id":"go:GO:0007437","description":"\"The process in which the anatomical structures of the adult salivary gland are generated and organized.\" [GOC:curators]","metadata":null},{"id":"42eb1a1fc15c486e8a2d01bcb82c901a","type":"GO_TERM","name":"adult somatic muscle development","canonical_id":"go:GO:0007527","description":"\"The process whose specific outcome is the progression of the adult somatic muscle over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"6a0cc9f98b7f46f094bee700ac7317e7","type":"GO_TERM","name":"adult visceral muscle development","canonical_id":"go:GO:0007524","description":"\"The process whose specific outcome is the progression of the adult visceral muscle over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"36f57d2bd2364f84b96bed11b21d913a","type":"GO_TERM","name":"adult walking behavior","canonical_id":"go:GO:0007628","description":"\"The behavior of an adult relating to the progression of that organism along the ground by the process of lifting and setting down each leg.\" [GOC:jid, GOC:pr, ISBN:0198606907]","metadata":null},{"id":"c25af8a5980447e6a6e96cf2f7d09aa1","type":"GO_TERM","name":"advanced glycation end-product binding","canonical_id":"go:GO:1904599","description":"\"Binding to advanced glycation end-product.\" [GO_REF:0000067, GOC:krc, GOC:TermGenie, PMID:1650387]","metadata":null},{"id":"584dbe7385d842bd9c6401bd9855e5d8","type":"GO_TERM","name":"advanced glycation end-product receptor activity","canonical_id":"go:GO:0050785","description":"\"Combining with advanced glycation end-products and transmitting the signal to initiate a change in cell activity. Advanced glycation end-products (AGEs) form from a series of chemical reactions after an initial glycation event (a non-enzymatic reaction between reducing sugars and free amino groups of proteins).\" [GOC:signaling, PMID:12453678, PMID:12707408, PMID:7592757, PMID:9224812, Wikipedia:RAGE_(receptor)]","metadata":null},{"id":"3686ca757af3456e86af1f939b7067e2","type":"GO_TERM","name":"adventitious root development","canonical_id":"go:GO:0048830","description":"\"The process whose specific outcome is the progression of adventitious root over time, from its formation to the mature structure. Adventitious roots are post-embryonic roots that develop from the plant shoot.\" [GOC:tb]","metadata":null},{"id":"a4cdfa9fc5504f7e8751b180f6875147","type":"GO_TERM","name":"adventitious septum","canonical_id":"go:GO:0000933","description":"\"A cell septum whose formation is independent of nuclear division.\" [GOC:clt, ISBN:0471940526]","metadata":null},{"id":"0832c526cdfb46ec973b8c9dca541605","type":"GO_TERM","name":"adventurous gliding motility","canonical_id":"go:GO:0030982","description":"\"A process involved in the controlled movement of a bacterial cell powered by the rearward secretion of carbohydrate slime.\" [GOC:mlg, PMID:11967173]","metadata":null},{"id":"3f650d97838d481c94e5769cdd8a7d27","type":"GO_TERM","name":"aeciospore formation","canonical_id":"go:GO:0075247","description":"\"The process in which a dikaryotic spore of typically a rust fungus is produced in an aecium; in heteroecious rusts, the aeciospore is a spore stage that infects the alternate host.\" [GOC:pamgo_curators]","metadata":null},{"id":"1b74d70ddcb24efb8a4104b6d1276608","type":"GO_TERM","name":"aecium development","canonical_id":"go:GO:0075267","description":"\"The process in which a cup-like structure containing chains of aeciospores is formed. This is characteristic of the rust fungus and typically, the first dikaryotic spores (aeciospores) are produced in the aecium.\" [GOC:pamgo_curators]","metadata":null},{"id":"bed6d14b5ec7437a8280b2158e60bd97","type":"GO_TERM","name":"aerenchyma formation","canonical_id":"go:GO:0010618","description":"\"The process that gives rise to aerenchyma, parenchyma tissue containing particularly large intercellular spaces of schizogenous or lysigenous origin. This process pertains to the initial formation of a structure from unspecified parts.\" [PMID:18055613, PO:0005702]","metadata":null},{"id":"131972b836d54e918170b5923e824907","type":"GO_TERM","name":"aerial mycelium formation","canonical_id":"go:GO:0097736","description":"\"The process by which hyphae grow in an upward or outward direction from the surface of the substrate; from there, propagative spores develop in or on characteristic structures that are distinctive of some fungal and bacterial species. The species that form an aerial mycelium develop conidiophores at the ends of the aerial hyphae.\" [GOC:di, PMID:12832397]","metadata":null},{"id":"198c6480fdc94cc5ace8f97415f9fbe5","type":"GO_TERM","name":"aerobactin biosynthetic process","canonical_id":"go:GO:0019270","description":"\"The chemical reactions and pathways resulting in the formation of aerobactin (C22H36N4O13), a hydroxamate iron transport compound. It is a conjugate of 6-(N-acetyl-N-hydroxylamine)-2-aminohexanoic acid and citric acid.\" [GOC:ai]","metadata":null},{"id":"664b081a260e4e8a82bf0095cebd7d25","type":"GO_TERM","name":"aerobactin synthase activity","canonical_id":"go:GO:0050565","description":"\"Catalysis of the reaction: ATP + N2-citryl-N6-acetyl-N6-hydroxy-L-lysine + N6-acetyl-N6-hydroxy-L-lysine = aerobactin + AMP + diphosphate + H+.\" [RHEA:32167]","metadata":null},{"id":"15fbe2d420e447fdb6771afcc48914e5","type":"GO_TERM","name":"aerobactin transport","canonical_id":"go:GO:0019271","description":"\"The directed movement of the hydroxamate iron transport compound aerobactin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Aerobactin (C22H36N4O13) is a conjugate of 6-(N-acetyl-N-hydroxylamine)-2-aminohexanoic acid and citric acid.\" [GOC:ai, PMID:23192658]","metadata":null},{"id":"6dc60c7f55b74114bdd64c0f4ae62f61","type":"GO_TERM","name":"aerobic carbon monoxide dehydrogenase activity","canonical_id":"go:GO:0008805","description":"\"Catalysis of the reaction: CO + a quinone + H2O = a quinol + CO2.\" [RHEA:48880]","metadata":null},{"id":"b6c42d98011141f8bff37b64d3dbc573","type":"GO_TERM","name":"aerobic electron transport chain","canonical_id":"go:GO:0019646","description":"\"A process in which a series of electron carriers operate together to transfer electrons from donors such as NADH and FADH2 to oxygen to generate a transmembrane electrochemical gradient.\" [GOC:ai, GOC:mtg_electron_transport]","metadata":null},{"id":"96232fdbd1d342cb8397dfb2408852eb","type":"GO_TERM","name":"aerobic lactate catabolic process","canonical_id":"go:GO:1990484","description":"\"The chemical reactions and pathways resulting in the breakdown of lactate (2-hydroxypropanoic acid) in the presence of oxygen.\" [GOC:mengo_curators, PMID:8941775]","metadata":null},{"id":"568438cbaf4c43299c65e7aedb694f5b","type":"GO_TERM","name":"aerobic phenol-containing compound biosynthetic process","canonical_id":"go:GO:0046190","description":"\"The chemical reactions and pathways resulting in the formation of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring, in the presence of oxygen.\" [GOC:ai]","metadata":null},{"id":"2744b435e20a410abafe49cf3adc30b3","type":"GO_TERM","name":"aerobic phenol-containing compound catabolic process","canonical_id":"go:GO:0046191","description":"\"The chemical reactions and pathways resulting in the breakdown of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring, in the presence of oxygen.\" [GOC:ai]","metadata":null},{"id":"113b8db43f2243379cd02a1b6ff3998b","type":"GO_TERM","name":"aerobic raffinose catabolic process","canonical_id":"go:GO:0036259","description":"\"The chemical reactions and pathways resulting in the breakdown of raffinose that occur in the presence of oxygen.\" [GOC:al, PMID:10082789]","metadata":null},{"id":"dc6f7fa296914c11aba42ea9aef74ffe","type":"GO_TERM","name":"aerobic respiration","canonical_id":"go:GO:0009060","description":"\"The enzymatic release of energy from inorganic and organic compounds (especially carbohydrates and fats) which requires oxygen as the terminal electron acceptor.\" [GOC:das, GOC:jl, ISBN:0140513590]","metadata":null},{"id":"cbf8796583ea420da09bd9a2f918e43c","type":"GO_TERM","name":"aerobic respiration, using ammonia as electron donor","canonical_id":"go:GO:0019409","description":"\"The metabolic process in which ammonia (NH4+) is oxidized to nitrite (NO2) in the presence of oxygen; enzymatic reactions convert ammonia to hydrazine, and hydrazine to nitrite.\" [MetaCyc:AMMOXID-PWY]","metadata":null},{"id":"5244b538d94d4fae8f5be52f258e4d4d","type":"GO_TERM","name":"aerobic respiration, using arsenite as electron donor","canonical_id":"go:GO:0043554","description":"\"The oxidation of arsenite to arsenate, using oxygen (O2) as the electron acceptor. Arsenite oxidase provides electrons to an electron carrier which transfers them to oxygen utilizing respiratory systems.\" [GOC:mlg]","metadata":null},{"id":"6a99596f1e2c485297edcb380e69bdd9","type":"GO_TERM","name":"aerobic respiration, using carbon monoxide as electron donor","canonical_id":"go:GO:0019410","description":"\"The metabolic process in which carbon monoxide (CO) is oxidized to carbon dioxide (CO2) to generate energy. Conservation of energy in this process likely uses sodium ion gradients for ATP synthesis and is coupled to quantitative sulfide methylation.\" [PMID:18024677]","metadata":null},{"id":"cc5b5077d4ab44e3be67b028661394d9","type":"GO_TERM","name":"aerobic respiration, using ferrous ions as electron donor","canonical_id":"go:GO:0019411","description":"\"The metabolic process in which ferrous ions (Fe2+) are oxidized to ferric ions (Fe3+) to generate energy, coupled to the reduction of carbon dioxide.\" [ISBN:3131084111]","metadata":null},{"id":"c5eddaac19574437a4914010a35f3c8e","type":"GO_TERM","name":"aerobic respiration, using hydrogen as electron donor","canonical_id":"go:GO:0019412","description":"\"The oxidation of hydrogen (H2) to water (H2O), using oxygen (O2) as the electron acceptor. A hydrogenase enzyme binds H2 and the hydrogen atoms are passed through an electron transfer chain to O2 to form water.\" [MetaCyc:P283-PWY]","metadata":null},{"id":"58fecced94bc4005a1bd2e8abbfe8410","type":"GO_TERM","name":"aerobic respiration, using nitrite as electron donor","canonical_id":"go:GO:0019332","description":"\"The oxidation of nitrite (NO2) to nitrate (NO3), using oxygen (O2) as the electron acceptor. Nitrite oxidation is the final step in nitrification, the oxidation of ammonia to nitrate, and nitrite oxidoreductase (NOR) is the key enzyme complex that catalyzes the conversion of nitrite to nitrate in nitrite oxidizing species.\" [MetaCyc:P282-PWY]","metadata":null},{"id":"7eef1f23bd71491d8e686873a4616e9d","type":"GO_TERM","name":"aerobic respiration, using sulfur or sulfate as electron donor","canonical_id":"go:GO:0019414","description":"\"An aerobic respiration process in which a sulfur-containing molecule (hydrogen sulfide, sulfur, sulfite, thiosulfate, and various polythionates) is oxidized.\" [PMID:11425697]","metadata":null},{"id":"ee8a113ca699484b92d762c1b99177f8","type":"GO_TERM","name":"aerotaxis","canonical_id":"go:GO:0009454","description":"\"The directed movement of a motile cell or organism in response to environmental oxygen.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"f185f217787f4835b3b7691184a24c80","type":"DRUG","name":"afatinib","canonical_id":"gtopdb:5667","description":null,"metadata":null},{"id":"0386996d3d3241d98fa2fd342b5b3f3e","type":"COMBINATION_TREATMENT","name":"afatinib + gefitinib","canonical_id":"ctgov_combo:ctgov-combo-ddc26dfa86f6fbf9","description":null,"metadata":null},{"id":"eff489fb5053440292f27ec758ff1321","type":"GO_TERM","name":"afferent axon development in anterior lateral line nerve","canonical_id":"go:GO:0048910","description":"\"The process whose specific outcome is the progression of an afferent axon in the anterior lateral line nerve over time from its formation to the mature structure. This process includes axonogenesis and pathfinding of the afferent axons in the anterior lateral line nerve.\" [PMID:15018940]","metadata":null},{"id":"294f215132e347f2a92137cfbaf22652","type":"GO_TERM","name":"afferent axon development in lateral line nerve","canonical_id":"go:GO:0048893","description":"\"The process whose specific outcome is the progression of an afferent axon in a lateral line nerve over time from its formation to the mature structure. This process includes axonogenesis and pathfinding of the afferent axons in any lateral line nerve.\" [PMID:15832385]","metadata":null},{"id":"e6a9c404a3524fd49169a23fb73eef9e","type":"GO_TERM","name":"afferent axon development in posterior lateral line nerve","canonical_id":"go:GO:0048933","description":"\"The process whose specific outcome is the progression of an afferent axon in the posterior lateral line nerve over time from its formation to the mature structure. This process includes axonogenesis and pathfinding of the afferent axons in the posterior lateral line nerve.\" [PMID:15018940]","metadata":null},{"id":"384485c216a24f28b7f7b31f07d28321","type":"GO_TERM","name":"aflatoxin B synthase activity","canonical_id":"go:GO:0140399","description":"\"Catalyzes the reaction: 8-O-methylsterigmatocystin + 2 [reduced NADPH--hemoprotein reductase] + 2 O2 = aflatoxin B + 2 [oxidized NADPH--hemoprotein reductase] + H2O + methanol + CO2. Produces both aflatoxin B(1) and aflatoxin B(2).\" [EC:1.14.14.117]","metadata":null},{"id":"83bc3b0548514b56a0f8bb11508a877c","type":"GO_TERM","name":"aflatoxin biosynthetic process","canonical_id":"go:GO:0045122","description":"\"The chemical reactions and pathways resulting in the formation of aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.\" [ISBN:0716731363, ISBN:0815316194, PMID:15006741]","metadata":null},{"id":"1742c3def6a045d6be742e6eb2ca294e","type":"GO_TERM","name":"aflatoxin catabolic process","canonical_id":"go:GO:0046223","description":"\"The chemical reactions and pathways resulting in the breakdown of aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.\" [GOC:ai, PMID:20807200]","metadata":null},{"id":"42c6f062581b40c8a2707b9de96d43e2","type":"GO_TERM","name":"aflatoxin metabolic process","canonical_id":"go:GO:0046222","description":"\"The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.\" [GOC:ai]","metadata":null},{"id":"43aa1de1c9204ccea366f6be66bc8358","type":"GO_TERM","name":"aflatoxin reductase (coenzyme F420) activity","canonical_id":"go:GO:0052807","description":"\"Catalysis of the reaction: aflatoxin + 1,5-dihydrocoenzyme F420 = aflatoxin with reduced furanocoumarin moiety + coenzyme F420. 1,5-dihydrocoenzyme F420 is also known as reduced coenzyme F420.\" [GOC:mengo_curators, PMID:20807200]","metadata":null},{"id":"b4e153eb29dd4f05a5c7cb2db11e720e","type":"DRUG","name":"aflibercept","canonical_id":"gtopdb:6786","description":null,"metadata":null},{"id":"7af45f42593440b9b051582a2ba1f7bf","type":"DRUG","name":"aflibercept","canonical_id":"chembl:CHEMBL1742982","description":null,"metadata":null},{"id":"d147ecee902f4cde916a51e720679ffd","type":"COMBINATION_TREATMENT","name":"aflibercept + brolucizumab","canonical_id":"ctgov_combo:ctgov-combo-856cdad1482823fd","description":null,"metadata":null},{"id":"59d9c6df80684313999a44631c6903df","type":"COMBINATION_TREATMENT","name":"aflibercept + brolucizumab","canonical_id":"ctgov_combo:ctgov-combo-660cd5dd3db3a75c","description":null,"metadata":null},{"id":"ff6c58b3b0b04eb1aa8ad0cc46f99566","type":"COMBINATION_TREATMENT","name":"aflibercept + ranibizumab","canonical_id":"ctgov_combo:ctgov-combo-88b0fa06a16cb229","description":null,"metadata":null},{"id":"ee4d0acbeef541e9a80f2f2c831316eb","type":"COMBINATION_TREATMENT","name":"aflibercept + ranibizumab","canonical_id":"ctgov_combo:ctgov-combo-983697b9b38b3dfa","description":null,"metadata":null},{"id":"69cd60ea5895429b813d28c8166119db","type":"DISEASE","name":"agammaglobulinemia","canonical_id":"mondo:0015977","description":null,"metadata":null},{"id":"8e3c904b0e4a412d8b9a7b9ab8e0d10b","type":"DISEASE","name":"age-related macular degeneration","canonical_id":"mondo:0005150","description":null,"metadata":null},{"id":"9237023aa49a45eca006ce3f7ff7b3df","type":"GO_TERM","name":"age-related resistance","canonical_id":"go:GO:0090644","description":"\"An innate immune response that is positively correlated with host plant development. As a plant develops, its innate resistance to pathogenic infections increases. The mechanisms involved in age-related resistance differ in nature or in aspects of regulation from the hypersensitive response (HR), systemic acquired resistance (SAR), or induced systemic resistance (ISR).\" [PMID:17635216, PMID:19694953]","metadata":null},{"id":"d3f0cf0535a240d999b5ab8c1bbdf470","type":"GO_TERM","name":"agglutination involved in conjugation with cellular fusion","canonical_id":"go:GO:0000752","description":"\"The aggregation or adhesion of compatible mating types via complementary cell-cell interactions during conjugation with cellular fusion of a unicellular organism. An example of this process is agglutination in Saccharomyces cerevisiae.\" [GOC:elh]","metadata":null},{"id":"7759a6723eb14595813c1b77737077c1","type":"GO_TERM","name":"aggregation involved in sorocarp development","canonical_id":"go:GO:0031152","description":"\"The process whose specific outcome is the progression of the aggregate over time, from its formation to the point when a slug is formed. Aggregate development begins in response to starvation and continues by the chemoattractant-mediated movement of cells toward each other. The aggregate is a multicellular structure that gives rise to the slug.\" [GOC:mah, GOC:mtg_sensu, ISBN:0521583640]","metadata":null},{"id":"9b3e7e8e99b24385b94867d3594496e9","type":"GO_TERM","name":"aggregation of unicellular organisms","canonical_id":"go:GO:0098630","description":"\"The clustering together of unicellular organisms in suspension form aggregates.\" [GOC:dos]","metadata":null},{"id":"22140e43430b4e2fb0733cc70af77f49","type":"GO_TERM","name":"aggrephagy","canonical_id":"go:GO:0035973","description":"\"The selective degradation of protein aggregates by macroautophagy.\" [GOC:autophagy, GOC:kmv, PMID:18508269, PMID:25062811]","metadata":null},{"id":"900dc675c088472198c90447c4271578","type":"GO_TERM","name":"aggresome","canonical_id":"go:GO:0016235","description":"\"An inclusion body formed by dynein-dependent retrograde transport of an aggregated protein on microtubules.\" [PMID:11121744]","metadata":null},{"id":"655e771c92e14e5f8da4a8675af3de4e","type":"GO_TERM","name":"aggresome assembly","canonical_id":"go:GO:0070842","description":"\"The aggregation, arrangement and bonding together of a set of components to form an aggresome; requires the microtubule cytoskeleton and dynein.\" [GOC:BHF, GOC:rl, PMID:14675537]","metadata":null},{"id":"e8a115c99a254eea810afa21171f9d62","type":"GO_TERM","name":"aggressive behavior","canonical_id":"go:GO:0002118","description":"\"A behavioral interaction between organisms in which one organism has the intention of inflicting physical damage on another individual.\" [GOC:hjd]","metadata":null},{"id":"035a8ab5b8274cfba3f845cb22ba7761","type":"DISEASE","name":"aggressive behavior","canonical_id":"efo:0003015","description":null,"metadata":null},{"id":"5b0ed1041ceb475f846165358dc53b4a","type":"GO_TERM","name":"agmatinase activity","canonical_id":"go:GO:0008783","description":"\"Catalysis of the reaction: agmatine + H2O = putrescine + urea.\" [EC:3.5.3.11, RHEA:13929]","metadata":null},{"id":"1cb24ce9b625430a9274cd3a0fecf9b8","type":"GO_TERM","name":"agmatine N4-coumaroyltransferase activity","canonical_id":"go:GO:0047634","description":"\"Catalysis of the reaction: 4-coumaroyl-CoA + agmatine = N-(4-guanidiniumylbutyl)-4-hydroxycinnamamide + CoA + H+.\" [EC:2.3.1.64, RHEA:13405]","metadata":null},{"id":"952c0fd6cf874cd5be3f3855076deff6","type":"GO_TERM","name":"agmatine aminopropyltransferase activity","canonical_id":"go:GO:0043919","description":"\"Catalysis of the reaction: agmatine + S-adenosyl 3-(methylsulfanyl)propylamine = H+ + N1-(3-aminopropyl)agmatine + S-methyl-5'-thioadenosine.\" [PMID:15983049, RHEA:36487]","metadata":null},{"id":"1f364bf71f5e4892ab65bd08d4b4bcb9","type":"GO_TERM","name":"agmatine biosynthetic process","canonical_id":"go:GO:0097055","description":"\"The chemical reactions and pathways resulting in the formation of agmatine ((4-aminobutyl)guanidine, NH2-CH2-CH2-CH2-CH2-NH-C(-NH2)(=NH)). Agmatine is the decarboxylation product of the amino acid arginine and is an intermediate in polyamine biosynthesis. It is synthesized in the brain, stored in synaptic vesicles, accumulated by uptake, released by membrane depolarization, and inactivated by agmatinase.\" [GOC:pr, GOC:yaf]","metadata":null},{"id":"cbc11cebf94d4413998c10500364119a","type":"GO_TERM","name":"agmatine deiminase activity","canonical_id":"go:GO:0047632","description":"\"Catalysis of the reaction: agmatine + H2O = N-carbamoylputrescine + NH4+.\" [RHEA:18037]","metadata":null},{"id":"af31370a4f7749a5b7f64eef2b8b6408","type":"GO_TERM","name":"agmatine kinase activity","canonical_id":"go:GO:0047633","description":"\"Catalysis of the reaction: agmatine + ATP = N(4)-phosphoagmatine + ADP + 3 H+.\" [EC:2.7.3.10, RHEA:15953]","metadata":null},{"id":"08e21d6d857a450aac1f7f450148f1f0","type":"GO_TERM","name":"agmatine:putrescine antiporter activity","canonical_id":"go:GO:0043861","description":"\"Catalysis of the reaction: agmatine(out) + putrescine(in) = agmatine(in) + putrescine(out).\" [GOC:jl, PMID:17028272]","metadata":null},{"id":"0ae3a878802f472d927e8e24c844a189","type":"DRUG","name":"agomelatine","canonical_id":"gtopdb:198","description":null,"metadata":null},{"id":"0f485231981d4332a9d87bf585d59f5c","type":"DRUG","name":"agomelatine","canonical_id":"mesh:C084711","description":null,"metadata":null},{"id":"41d5dcf1992f4f81a15fd64153c38f88","type":"DRUG","name":"agomelatine","canonical_id":"chembl:CHEMBL10878","description":null,"metadata":null},{"id":"3f9fda42529b4e8684f6a8049c53dfba","type":"COMBINATION_TREATMENT","name":"agomelatine + amisulpride + biperiden + buspirone + clomipramine + clonazepam + doxepin + flupentixol + fluphenazine + imipramine + maprotiline + mianserin + moclobemide + nortriptyline + perphenazine + pimozide + reboxetine + sertindole + sulpiride + thioridazine + tranylcypromine + trazodone + triazolam + trimipramine","canonical_id":"ctgov_combo:ctgov-combo-85221757e3403486","description":null,"metadata":null},{"id":"669fe35f427b47e2ab9ce888d4176b32","type":"COMBINATION_TREATMENT","name":"agomelatine + trazodone","canonical_id":"ctgov_combo:ctgov-combo-d2012a78b0113279","description":null,"metadata":null},{"id":"2e9d4d92198646f397dc476b5a0972b4","type":"COMBINATION_TREATMENT","name":"agomelatine + vortioxetine","canonical_id":"ctgov_combo:ctgov-combo-d13372f659e19bfe","description":null,"metadata":null},{"id":"ee075a0bfcfb437c8d6052e721965114","type":"GO_TERM","name":"ajmaline biosynthetic process","canonical_id":"go:GO:1900988","description":"\"The chemical reactions and pathways resulting in the formation of ajmaline.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"aafd85e79e244e73950f1aa1d04d9d14","type":"GO_TERM","name":"ajugose biosynthetic process","canonical_id":"go:GO:0033536","description":"\"The chemical reactions and pathways resulting in the formation of ajugose, the hexasaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"095ad0289ec3475e9a4bd9bfecb86033","type":"GO_TERM","name":"akinete formation","canonical_id":"go:GO:0034302","description":"\"The process in which an akinete, a thick-walled (encysted) dormant cell derived from the enlargement of a vegetative cell, is formed. Akinetes typically have granular cytoplasm, are more resistant to environmental extremes than vegetative cells, and are characteristic of several groups of Cyanobacteria.\" [GOC:ds, GOC:mah, https://doi.org/10.1016/S1369-703X(02)00136-5, PMID:11948167]","metadata":null},{"id":"2e7b1f17c5e74ddead800a18702e6d22","type":"GO_TERM","name":"alae of collagen and cuticulin-based cuticle extracellular matrix","canonical_id":"go:GO:0060111","description":"\"Raised, thickened cuticular ridges that run longitudinally, and in parallel, along the left and right sides of the animal. The alae lie above the hypodermal cells known as the lateral seam cells. In C. elegans, alae are produced in L1 larvae, dauer larvae and adult stage animals, where they consist of three, five, and three ridges of distinct morphology, respectively.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"7332897c9f154ccf9832e4f5d32b71d1","type":"GO_TERM","name":"alanine biosynthetic process","canonical_id":"go:GO:0006523","description":"\"The chemical reactions and pathways resulting in the formation of alanine, 2-aminopropanoic acid.\" [GOC:curators]","metadata":null},{"id":"c059fa10192141a880892a6f53508895","type":"GO_TERM","name":"alanine racemase activity","canonical_id":"go:GO:0008784","description":"\"Catalysis of the reaction: L-alanine = D-alanine.\" [EC:5.1.1.1, RHEA:20249]","metadata":null},{"id":"f07e86ad074a4abea108a3f344e031a9","type":"GO_TERM","name":"alanine transmembrane transporter activity","canonical_id":"go:GO:0022858","description":"\"Enables the transfer of alanine from one side of a membrane to the other. Alanine is 2-aminopropanoic acid.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"24c676fd501b4ace84476698b112ce41","type":"GO_TERM","name":"alanine transport","canonical_id":"go:GO:0032328","description":"\"The directed movement of alanine, 2-aminopropanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"1e62be2af2b24c89a2b40f250e87ff24","type":"GO_TERM","name":"alanine-tRNA ligase activity","canonical_id":"go:GO:0004813","description":"\"Catalysis of the reaction: ATP + L-alanine + tRNA(Ala) = AMP + diphosphate + L-alanyl-tRNA(Ala).\" [EC:6.1.1.7]","metadata":null},{"id":"c3219c90d0b147f487712e3e016c368f","type":"GO_TERM","name":"alanine:sodium symporter activity","canonical_id":"go:GO:0015655","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: alanine(out) + Na+(out) = alanine(in) + Na+(in).\" [GOC:ai]","metadata":null},{"id":"a3b12529303244529c7b385d3450d2dc","type":"GO_TERM","name":"alanopine dehydrogenase activity","canonical_id":"go:GO:0047636","description":"\"Catalysis of the reaction: 2,2'-iminodipropanoate + H2O + NAD+ = L-alanine + H+ + NADH + pyruvate.\" [EC:1.5.1.17, RHEA:17589]","metadata":null},{"id":"12c3ac741d3843f4882de101dc25e87e","type":"GO_TERM","name":"alanyl aminopeptidase activity","canonical_id":"go:GO:0016285","description":"\"Catalysis of the release of an N-terminal amino acid, preferentially alanine, from a wide range of peptides, amides and arylamides.\" [EC:3.4.11.14]","metadata":null},{"id":"59960d7fb6fe40b0841273d2c56e160a","type":"GO_TERM","name":"alanyl-tRNA aminoacylation","canonical_id":"go:GO:0006419","description":"\"The process of coupling alanine to alanyl-tRNA, catalyzed by alanyl-tRNA synthetase. The alanyl-tRNA synthetase is a class-II synthetases. The activated amino acid is transferred to the 3'-OH group of an alanine accetping tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"0c3284daae71406586c315e027e604e0","type":"DRUG","name":"alatrofloxacin","canonical_id":"mesh:C106856","description":null,"metadata":null},{"id":"db271d2c97624a6b9729fb3f849eb74d","type":"DRUG","name":"albendazole","canonical_id":"mesh:D015766","description":null,"metadata":null},{"id":"67dfd651eb5444538d6d78c4d54996b3","type":"GO_TERM","name":"albendazole monooxygenase activity","canonical_id":"go:GO:0047638","description":"\"Catalysis of the reaction: albendazole + H+ + NADPH + O2 = albendazole S-oxide + H2O + NADP+.\" [EC:1.14.13.32, RHEA:10796]","metadata":null},{"id":"15499fce8bb94401949218f8c825973f","type":"DRUG","name":"alcaftadine","canonical_id":"mesh:C557708","description":null,"metadata":null},{"id":"3d3de151585c4cc4a968bd7e9316a66b","type":"DRUG","name":"alclometasone dipropionate","canonical_id":"mesh:C021137","description":null,"metadata":null},{"id":"0c0214d2cb124e189cd8ce0d5b8aaff8","type":"GO_TERM","name":"alcohol O-acetyltransferase activity","canonical_id":"go:GO:0004026","description":"\"Catalysis of the reaction: acetyl-CoA + an alcohol = CoA + an acetyl ester.\" [EC:2.3.1.84]","metadata":null},{"id":"eb5533ccb0f04674a560680dbf13912c","type":"GO_TERM","name":"alcohol O-acyltransferase activity","canonical_id":"go:GO:0034318","description":"\"Catalysis of the transfer of an acyl group to an oxygen atom on an alcohol acceptor molecule.\" [GOC:mah]","metadata":null},{"id":"af4353cfd29d4fdf8d5669c410b50d25","type":"GO_TERM","name":"alcohol O-cinnamoyltransferase activity","canonical_id":"go:GO:0047182","description":"\"Catalysis of the reaction: an alcohol + 1-O-trans-cinnamoyl-beta-D-glucopyranose = beta-D-glucose + alkyl cinnamate.\" [EC:2.3.1.152, MetaCyc:2.3.1.152-RXN]","metadata":null},{"id":"69516f871f9a401eac44abb560bdddfe","type":"GO_TERM","name":"alcohol binding","canonical_id":"go:GO:0043178","description":"\"Binding to an alcohol, any of a class of alkyl compounds containing a hydroxyl group.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"8fb8d66ffc8a46f4b9d6133ce3e0c7e2","type":"GO_TERM","name":"alcohol biosynthetic process","canonical_id":"go:GO:0046165","description":"\"The chemical reactions and pathways resulting in the formation of alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.\" [GOC:ai]","metadata":null},{"id":"1363f969b5f247bcba815b8bbd05591f","type":"GO_TERM","name":"alcohol catabolic process","canonical_id":"go:GO:0046164","description":"\"The chemical reactions and pathways resulting in the breakdown of alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.\" [GOC:ai]","metadata":null},{"id":"b03b4cb462c245519b0cd19a9126c0f3","type":"GO_TERM","name":"alcohol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004022","description":"\"Catalysis of the reaction: an alcohol + NAD+ = an aldehyde or ketone + NADH + H+.\" [EC:1.1.1.1]","metadata":null},{"id":"9f10de5987764e7d9ce7cfca83cfbd45","type":"GO_TERM","name":"alcohol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0008106","description":"\"Catalysis of the reaction: an alcohol + NADP+ = an aldehyde or ketone + NADPH + H+.\" [EC:1.1.1.2]","metadata":null},{"id":"65753c0659c04391b10fa098328bc73e","type":"GO_TERM","name":"alcohol dehydrogenase (cytochrome c(L)) activity","canonical_id":"go:GO:0052933","description":"\"Catalysis of the reaction: 2 [Fe(III)cytochrome cL] + a primary alcohol = 2 [Fe(II)cytochrome cL] + an aldehyde + 2 H+.\" [RHEA:51004]","metadata":null},{"id":"ad11ef66c0f94331bb84d067eda3649e","type":"GO_TERM","name":"alcohol dehydrogenase (cytochrome c) activity","canonical_id":"go:GO:0052934","description":"\"Catalysis of the reaction: 2 [Fe(III)cytochrome c] + a primary alcohol = 2 [Fe(II)cytochrome c] + an aldehyde + 2 H+.\" [RHEA:51020]","metadata":null},{"id":"37b631adabc24d1b8decfa1574213e4d","type":"GO_TERM","name":"alcohol dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0018455","description":"\"Catalysis of the reaction: an alcohol + NAD(P)+ = an aldehyde or ketone + NAD(P)H + H+.\" [GOC:curators]","metadata":null},{"id":"c7f7a6992d944706b2cf33319415e068","type":"DISEASE","name":"alcohol dependence","canonical_id":"mondo:0007079","description":null,"metadata":null},{"id":"029bcb81e93e40fa97c6727f1970f4ea","type":"DISEASE","name":"alcohol drinking","canonical_id":"efo:0004329","description":null,"metadata":null},{"id":"f29db5dd15864744b35ece5f8a609035","type":"GO_TERM","name":"alcohol metabolic process","canonical_id":"go:GO:0006066","description":"\"The chemical reactions and pathways involving alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.\" [ISBN:0198506732]","metadata":null},{"id":"16c81ea9ad824f55992b1464c4f380e8","type":"GO_TERM","name":"alcohol oxidase activity","canonical_id":"go:GO:0047639","description":"\"Catalysis of the reaction: a primary alcohol + O2 = an aldehyde + H2O2.\" [EC:1.1.3.13, MetaCyc:ALCOHOL-OXIDASE-RXN]","metadata":null},{"id":"08462792d1764ba2b478cc20826d5d35","type":"GO_TERM","name":"alcohol sulfotransferase activity","canonical_id":"go:GO:0004027","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + an alcohol = adenosine 3',5'-bisphosphate + an alkyl sulfate.\" [EC:2.8.2.2]","metadata":null},{"id":"35ad6a71768d487ebba641f4a09f846b","type":"GO_TERM","name":"alcohol transmembrane transporter activity","canonical_id":"go:GO:0015665","description":"\"Enables the transfer of an alcohol from one side of a membrane to the other. An alcohol is any carbon compound that contains a hydroxyl group.\" [ISBN:0198506732]","metadata":null},{"id":"698ae98de2774d04ad433743aa1f2903","type":"GO_TERM","name":"alcohol-forming long-chain fatty acyl-CoA reductase (NADP+) activity","canonical_id":"go:GO:0102965","description":"\"Catalysis of the reaction: a long-chain fatty acyl-CoA + 2 H+ + 2 NADPH = a long-chain primary fatty alcohol + CoA + 2 NADP+. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:pz, RHEA:52716]","metadata":null},{"id":"1fbffdd3506f4bcd8a86da7aae8299f7","type":"GO_TERM","name":"alcohol-forming very long-chain fatty acyl-CoA reductase (NADP+) activity","canonical_id":"go:GO:0080019","description":"\"Catalysis of the reaction: a very long-chain fatty acyl-CoA + 2 NADPH + 2 H+ = a very long-chain primary fatty alcohol + 2 NADP+ + CoA.\" [PMID:16980563, RHEA:81751]","metadata":null},{"id":"25a941430dbd4b82acbc1437d511d412","type":"DISEASE","name":"alcohol-related disorders","canonical_id":"mondo:0021698","description":null,"metadata":null},{"id":"c824c8d2841c4200b85aacbe36027dc4","type":"GO_TERM","name":"aldarate transmembrane transport","canonical_id":"go:GO:0042869","description":"\"The process in which aldarate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"9306546ebafa4cfaba3c9f51735d7a9a","type":"GO_TERM","name":"aldarate transmembrane transporter activity","canonical_id":"go:GO:0042876","description":"\"Enables the transfer of aldarate from one side of a membrane to the other.\" [GOC:curators, PMID:15034926]","metadata":null},{"id":"99f2371b851f4dfbb8147ebf05a39588","type":"GO_TERM","name":"aldaric acid biosynthetic process","canonical_id":"go:GO:0019578","description":"\"The chemical reactions and pathways resulting in the formation of aldaric acid, any dicarboxylic acid formed by oxidation of by the terminal groups of an aldose to carboxyl group.\" [ISBN:0198506732]","metadata":null},{"id":"ab4c0aa02b5749d2b07c047886546e58","type":"GO_TERM","name":"aldaric acid catabolic process","canonical_id":"go:GO:0019579","description":"\"The chemical reactions and pathways resulting in the breakdown of aldaric acid, any dicarboxylic acid formed by oxidation of by the terminal groups of an aldose to carboxyl group.\" [ISBN:0198506732]","metadata":null},{"id":"3985ead1c9d046d588c5d3817be41098","type":"GO_TERM","name":"aldehyde biosynthetic process","canonical_id":"go:GO:0046184","description":"\"The chemical reactions and pathways resulting in the formation of aldehydes, any organic compound with the formula R-CH=O.\" [GOC:ai]","metadata":null},{"id":"ad2b491c4e1b408c909749154a965e99","type":"GO_TERM","name":"aldehyde catabolic process","canonical_id":"go:GO:0046185","description":"\"The chemical reactions and pathways resulting in the breakdown of aldehydes, any organic compound with the formula R-CH=O.\" [GOC:ai]","metadata":null},{"id":"c6fd6f82227340f59dd27dad20ae554b","type":"GO_TERM","name":"aldehyde dehydrogenase (FAD-independent) activity","canonical_id":"go:GO:0033727","description":"\"Catalysis of the reaction: an aldehyde + H2O + acceptor = a carboxylate + reduced acceptor.\" [EC:1.2.99.7]","metadata":null},{"id":"bf7caaeae0544348a57fd7e3dfb15ef9","type":"GO_TERM","name":"aldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004029","description":"\"Catalysis of the reaction: an aldehyde + H2O + NAD+ = a carboxylate + 2 H+ + NADH.\" [RHEA:16185]","metadata":null},{"id":"2fb7194568114ccdb7e71c16e1790a39","type":"GO_TERM","name":"aldehyde dehydrogenase (NAD+) inhibitor activity","canonical_id":"go:GO:0140631","description":"\"Binds to and stops, prevents or reduces the activity of aldehyde dehydrogenase (NAD+).\" [PMID:33495566]","metadata":null},{"id":"72e746c25b124e13ae65832559b6f85f","type":"GO_TERM","name":"aldehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0033721","description":"\"Catalysis of the reaction: an aldehyde + NADP+ + H2O = an acid + NADPH + H+.\" [RHEA:11888]","metadata":null},{"id":"d6b66f34977f420fa0c4bdadfd579047","type":"GO_TERM","name":"aldehyde dehydrogenase (quinone) activity","canonical_id":"go:GO:0047113","description":"\"Catalysis of the reaction: a quinone + an aldehyde + H2O = a carboxylate + a quinol + H+.\" [RHEA:13881]","metadata":null},{"id":"09a3fbbd170b4700af737034b2ac6f67","type":"GO_TERM","name":"aldehyde dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0004030","description":"\"Catalysis of the reaction: an aldehyde + NAD(P)+ + H2O = an acid + NAD(P)H + H+.\" [EC:1.2.1.5]","metadata":null},{"id":"7bc40ef324624f53b4dabbefdb81969f","type":"GO_TERM","name":"aldehyde ferredoxin oxidoreductase activity","canonical_id":"go:GO:0033726","description":"\"Catalysis of the reaction: an aldehyde + H2O + 2 oxidized ferredoxin = an acid + 2 H+ + 2 reduced ferredoxin.\" [EC:1.2.7.5]","metadata":null},{"id":"3f2b18bb48174bd5aa9bc84262522b48","type":"GO_TERM","name":"aldehyde metabolic process","canonical_id":"go:GO:0006081","description":"\"The chemical reactions and pathways involving aldehydes, any organic compound with the formula R-CH=O, as carried out by individual cells.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"dd8f5af95ad04b08a3dc090ba08ba539","type":"GO_TERM","name":"aldehyde oxidase activity","canonical_id":"go:GO:0004031","description":"\"Catalysis of the reaction: an aldehyde + O2 + H2O = a carboxylate + H2O2 + H+.\" [RHEA:16829]","metadata":null},{"id":"28f646b8e10f4715944d5f7a69490a4e","type":"GO_TERM","name":"aldehyde oxygenase (deformylating) activity","canonical_id":"go:GO:0071771","description":"\"Catalysis of the reaction: a long-chain fatty aldehyde + H+ + 2 NADPH + O2 = a long-chain alkane + formate + H2O + 2 NADP+.\" [PMID:6593720, PMID:8718622, RHEA:21440]","metadata":null},{"id":"2fdd7d0e764144488ece0494538fbdd1","type":"GO_TERM","name":"aldehyde-lyase activity","canonical_id":"go:GO:0016832","description":"\"Catalysis of the cleavage of a C-C bond in a molecule containing a hydroxyl group and a carbonyl group to form two smaller molecules, each being an aldehyde or a ketone.\" [GOC:curators]","metadata":null},{"id":"2d9d33bd2eea4c93b7a9095df7c89e3e","type":"GO_TERM","name":"alditol biosynthetic process","canonical_id":"go:GO:0019401","description":"\"The chemical reactions and pathways resulting in the formation of alditols, any polyhydric alcohol derived from the acyclic form of a monosaccharide by reduction of its aldehyde or keto group to an alcoholic group.\" [ISBN:0198506732]","metadata":null},{"id":"60d4a674a816411282f5ee798a55b892","type":"GO_TERM","name":"alditol catabolic process","canonical_id":"go:GO:0019405","description":"\"The chemical reactions and pathways resulting in the breakdown of alditols, any polyhydric alcohol derived from the acyclic form of a monosaccharide by reduction of its aldehyde or keto group to an alcoholic group.\" [ISBN:0198506732]","metadata":null},{"id":"3f2ec70a62ab4edca73113a8f15681b2","type":"GO_TERM","name":"alditol phosphate metabolic process","canonical_id":"go:GO:0052646","description":"\"The chemical reactions and pathways involving alditol phosphates, any phosphorylated polyhydric alcohol derived from the acyclic form of a monosaccharide by reduction of its aldehyde or keto group to an alcoholic group.\" [PMID:30240188]","metadata":null},{"id":"e10acdf9ac5e4100a6992cac3ac82457","type":"GO_TERM","name":"aldonate transmembrane transport","canonical_id":"go:GO:0042873","description":"\"The process in which aldonate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"cd5deae33cf5460496b72fd5eb80015a","type":"GO_TERM","name":"aldonate transmembrane transporter activity","canonical_id":"go:GO:0042879","description":"\"Enables the transfer of aldonate from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"bbf12980531e477bbd0fd3e935879f6f","type":"GO_TERM","name":"aldonic acid biosynthetic process","canonical_id":"go:GO:0046175","description":"\"The chemical reactions and pathways resulting in the formation of aldonic acid, a monocarboxylic acid with a chain of three or more carbon atoms, derived from an aldose by oxidation of the aldehydic group.\" [ISBN:0198506732]","metadata":null},{"id":"8c79b1f2665847f3936cc0e504b078ed","type":"GO_TERM","name":"aldonic acid catabolic process","canonical_id":"go:GO:0046176","description":"\"The chemical reactions and pathways resulting in the breakdown of aldonic acid, a monocarboxylic acid with a chain of three or more carbon atoms, derived from an aldose by oxidation of the aldehydic group.\" [ISBN:0198506732]","metadata":null},{"id":"03fe33d85ba94edabd372367578d70b3","type":"GO_TERM","name":"aldos-2-ulose dehydratase activity","canonical_id":"go:GO:0033991","description":"\"Catalysis of the reactions: 1,5-anhydro-D-fructose = 2-hydroxy-2-(hydroxymethyl)-2H-pyran-3(6H)-one + H2O; (1a) 1,5-anhydro-D-fructose = 1,5-anhydro-4-deoxy-D-glycero-hex-3-en-2-ulose + H2O and (1b) 1,5-anhydro-4-deoxy-D-glycero-hex-3-en-2-ulose = 2-hydroxy-2-(hydroxymethyl)-2H-pyran-3(6H)-one.\" [EC:4.2.1.110]","metadata":null},{"id":"9a6d23b8520d44bcbc0e858217b0c431","type":"GO_TERM","name":"aldose 1-dehydrogenase activity","canonical_id":"go:GO:0047640","description":"\"Catalysis of the reaction: D-aldose + NAD+ = D-aldonolactone + NADH.\" [EC:1.1.1.121, MetaCyc:ALDOSE-1-DEHYDROGENASE-RXN]","metadata":null},{"id":"ba464d30e780456b8564b8f5bc1fe228","type":"GO_TERM","name":"aldose 1-epimerase activity","canonical_id":"go:GO:0004034","description":"\"Catalysis of the reaction: alpha-D-glucose = beta-D-glucose. Also acts on L-arabinose, D-xylose, D-galactose, maltose and lactose.\" [EC:5.1.3.3]","metadata":null},{"id":"d8a20aa0e7b14f3bafa149c60bb5b11d","type":"GO_TERM","name":"aldose beta-D-fructosyltransferase activity","canonical_id":"go:GO:0047642","description":"\"Catalysis of the reaction: alpha-D-aldosyl1 beta-D-fructoside + D-aldose2 = D-aldose1 + alpha-D-aldosyl2 beta-D-fructoside.\" [EC:2.4.1.162, MetaCyc:ALDOSE-BETA-FRUCTOSYLTRANSFERASE-RXN]","metadata":null},{"id":"e2fd074dc2af45f7a179329c322b95dd","type":"GO_TERM","name":"aldose reductase (NADPH) activity","canonical_id":"go:GO:0004032","description":"\"Catalysis of the reaction: an alditol + NADP+ = an aldose + NADPH + H+.\" [EC:1.1.1.21]","metadata":null},{"id":"136641cc4e494a3b8194ae09dca45241","type":"GO_TERM","name":"aldose sugar dehydrogenase activity","canonical_id":"go:GO:0103040","description":"\"Catalysis of the reaction: H2O + an aldose + an oxidized electron acceptor = H+ + an aldonate + a reduced electron acceptor.\" [GOC:pz, MetaCyc:RXN0-6371, PMID:16864586]","metadata":null},{"id":"5dbd0599ca0b49f896378aee707f45fb","type":"GO_TERM","name":"aldose-1-phosphate adenylyltransferase activity","canonical_id":"go:GO:0047346","description":"\"Catalysis of the reaction: aldose 1-phosphate + ADP = phosphate + ADP-aldose.\" [EC:2.7.7.36, MetaCyc:2.7.7.36-RXN]","metadata":null},{"id":"ab27839a65cc450ba4dc8c7f5ae7a7e7","type":"GO_TERM","name":"aldose-1-phosphate nucleotidyltransferase activity","canonical_id":"go:GO:0047347","description":"\"Catalysis of the reaction: aldose 1-phosphate + NDP = phosphate + NDP-aldose.\" [EC:2.7.7.37, MetaCyc:2.7.7.37-RXN]","metadata":null},{"id":"f5cc3e5a229247e58df686d823232e13","type":"GO_TERM","name":"aldose-6-phosphate reductase (NADPH) activity","canonical_id":"go:GO:0047641","description":"\"Catalysis of the reaction: D-glucitol 6-phosphate + NADP+ = D-glucose 6-phosphate + H+ + NADPH.\" [EC:1.1.1.200, RHEA:20037]","metadata":null},{"id":"ed41f70476b04fd88972c4bdd3eb95d2","type":"GO_TERM","name":"aldosterone biosynthetic process","canonical_id":"go:GO:0032342","description":"\"The chemical reactions and pathways resulting in the formation of aldosterone, a corticosteroid hormone that is produced by the zona glomerulosa of the adrenal cortex and regulates salt (sodium and potassium) and water balance.\" [PMID:16527843]","metadata":null},{"id":"333c3740bf7a4c52b5300e4046d2fdc7","type":"GO_TERM","name":"aldosterone catabolic process","canonical_id":"go:GO:0032343","description":"\"The chemical reactions and pathways resulting in the breakdown of aldosterone, a corticosteroid hormone that is produced by the zona glomerulosa of the adrenal cortex and regulates salt (sodium and potassium) and water balance.\" [PMID:16527843]","metadata":null},{"id":"6134cef10dad46dfbeed5a94ed9d05d1","type":"GO_TERM","name":"aldosterone metabolic process","canonical_id":"go:GO:0032341","description":"\"The chemical reactions and pathways involving aldosterone, a corticosteroid hormone that is produced by the zona glomerulosa of the adrenal cortex and regulates salt (sodium and potassium) and water balance.\" [PMID:16527843]","metadata":null},{"id":"10b63c96770443bc86f5c294bada56d3","type":"GO_TERM","name":"aldosterone secretion","canonical_id":"go:GO:0035932","description":"\"The regulated release of aldosterone into the circulatory system. Aldosterone is a pregnane-based steroid hormone produced by the outer-section (zona glomerulosa) of the adrenal cortex in the adrenal gland, and acts on the distal tubules and collecting ducts of the kidney to cause the conservation of sodium, secretion of potassium, increased water retention, and increased blood pressure. The overall effect of aldosterone is to increase reabsorption of ions and water in the kidney.\" [GOC:sl]","metadata":null},{"id":"2e54a25d2a5f48a3aa695a343ea20607","type":"DISEASE","name":"aldosterone-producing adenoma with seizures and neurological abnormalities","canonical_id":"mondo:0014200","description":null,"metadata":null},{"id":"69ea2bb0e7e04e928854b6685737ebad","type":"DISEASE","name":"aldosterone-producing adrenal cortex adenoma","canonical_id":"mondo:0016505","description":null,"metadata":null},{"id":"61308791ca3c442fb0e31af7212f0bc0","type":"DRUG","name":"alectinib","canonical_id":"gtopdb:7739","description":null,"metadata":null},{"id":"f0a58ab19544460b87bf1538ff01ff72","type":"COMBINATION_TREATMENT","name":"alectinib + atezolizumab + cobimetinib + erlotinib + pertuzumab + vemurafenib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-80a4095bd3e94e72","description":null,"metadata":null},{"id":"73a40c04376e45a494bd3701dbcbf7da","type":"COMBINATION_TREATMENT","name":"alectinib + atezolizumab + cobimetinib + inavolisib + pertuzumab + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-30b86b92f0c920cb","description":null,"metadata":null},{"id":"8601c9b3856c4790b4ab3c92f4996b39","type":"COMBINATION_TREATMENT","name":"alectinib + brigatinib","canonical_id":"ctgov_combo:ctgov-combo-5f34ecc37541110b","description":null,"metadata":null},{"id":"552f15423faf49ae9844c029cdb37bc6","type":"COMBINATION_TREATMENT","name":"alectinib + brigatinib + cemiplimab + dabrafenib + lorlatinib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-e6a43fa3e14206ae","description":null,"metadata":null},{"id":"c18f4fd8d59e41f69f98d3c8f88eef99","type":"COMBINATION_TREATMENT","name":"alectinib + capmatinib + cobimetinib","canonical_id":"ctgov_combo:ctgov-combo-714adc598bdb1563","description":null,"metadata":null},{"id":"05e6a67d427e4b32b76fcf570f74b87e","type":"COMBINATION_TREATMENT","name":"alectinib + cobimetinib","canonical_id":"ctgov_combo:ctgov-combo-130c747a9acd8ef6","description":null,"metadata":null},{"id":"8e26730f7c9a40d1851cc3cf6628aa8f","type":"COMBINATION_TREATMENT","name":"alectinib + cobimetinib + lorlatinib + rucaparib + talazoparib + tepotinib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-efd74737eafccf9a","description":null,"metadata":null},{"id":"3d4258deec494e6eb9ccd8f83a3731f4","type":"COMBINATION_TREATMENT","name":"alectinib + crizotinib","canonical_id":"ctgov_combo:ctgov-combo-b6762174486eab18","description":null,"metadata":null},{"id":"053be070d4e0404786b0f8a8a87d2888","type":"COMBINATION_TREATMENT","name":"alectinib + crizotinib + idelalisib + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-2c32cbe6d00d4c66","description":null,"metadata":null},{"id":"bdd6bf2954e04f03869c3bc8d5287ba6","type":"COMBINATION_TREATMENT","name":"alectinib + crizotinib + niraparib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-a3aab49975d04c75","description":null,"metadata":null},{"id":"a465abff26344d1c95052cfb719c84e2","type":"COMBINATION_TREATMENT","name":"alectinib + envafolimab + serplulimab","canonical_id":"ctgov_combo:ctgov-combo-d0cb8c1936c7a677","description":null,"metadata":null},{"id":"3ec581b54ee344e5b88337acba2f13a1","type":"COMBINATION_TREATMENT","name":"alectinib + inavolisib + pralsetinib","canonical_id":"ctgov_combo:ctgov-combo-aece1067a39613df","description":null,"metadata":null},{"id":"1bcdc22a8099486680eb68cb198d1335","type":"COMBINATION_TREATMENT","name":"alectinib + necitumumab + selumetinib","canonical_id":"ctgov_combo:ctgov-combo-f7191b49f56fab1a","description":null,"metadata":null},{"id":"a434e5f2f42a45258f18fcfbc9093dfa","type":"COMBINATION_TREATMENT","name":"alectinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-4662cf3f7e857980","description":null,"metadata":null},{"id":"cfe5d1612d5f4b26ae6d00cd6da6c3f8","type":"COMBINATION_TREATMENT","name":"alectinib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-826bbb6f2edc31ca","description":null,"metadata":null},{"id":"8f4210dfbb3d4e71bb239e97b6c45b69","type":"COMBINATION_TREATMENT","name":"alectinib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-32aff5f91d785be8","description":null,"metadata":null},{"id":"3009b49d0cfd4d0c9451e2c9143a6017","type":"DRUG","name":"alefacept","canonical_id":"gtopdb:6787","description":null,"metadata":null},{"id":"0428655feecb4254b20650484083e9f4","type":"DRUG","name":"alefacept","canonical_id":"chembl:CHEMBL1201571","description":null,"metadata":null},{"id":"bb664734ad5a444d9a940af5115dfcbf","type":"DRUG","name":"alemtuzumab","canonical_id":"gtopdb:6770","description":null,"metadata":null},{"id":"64931b3560c3429cbd1e31b5a0709f95","type":"DRUG","name":"alemtuzumab","canonical_id":"mesh:C096529","description":null,"metadata":null},{"id":"fbd2e9ba0eed47bca89aa037d7cef037","type":"DRUG","name":"alemtuzumab","canonical_id":"chembl:CHEMBL1201587","description":null,"metadata":null},{"id":"c1bd6ae467c141deb2be55dc83ed7863","type":"COMBINATION_TREATMENT","name":"alemtuzumab + allopurinol + imatinib","canonical_id":"ctgov_combo:ctgov-combo-b5e82f971d876db5","description":null,"metadata":null},{"id":"f454753650054526b0b42bc4096abe95","type":"COMBINATION_TREATMENT","name":"alemtuzumab + clofarabine + hydroxyurea","canonical_id":"ctgov_combo:ctgov-combo-7d884b0332a6be1b","description":null,"metadata":null},{"id":"aecc438bec154ee5a86ebc53bf1a6b70","type":"COMBINATION_TREATMENT","name":"alemtuzumab + fingolimod + natalizumab + ocrelizumab + ofatumumab + ozanimod + ponesimod + siponimod + teriflunomide + ublituximab","canonical_id":"ctgov_combo:ctgov-combo-0028b7c0eaf725c4","description":null,"metadata":null},{"id":"92376cdcd2f748e0a5e26a479493873d","type":"COMBINATION_TREATMENT","name":"alemtuzumab + fingolimod + natalizumab + teriflunomide","canonical_id":"ctgov_combo:ctgov-combo-62b1db229bc1fb54","description":null,"metadata":null},{"id":"92eb047774824ace8147d2c62025d291","type":"COMBINATION_TREATMENT","name":"alemtuzumab + fludarabine","canonical_id":"ctgov_combo:ctgov-combo-1197abfcad473117","description":null,"metadata":null},{"id":"7909c3f034b54cccb1119aed96eb86fc","type":"COMBINATION_TREATMENT","name":"alemtuzumab + hydroxyurea","canonical_id":"ctgov_combo:ctgov-combo-d6dc4a0b9b5e955e","description":null,"metadata":null},{"id":"15a513aa1a5e4e0d86829ee8d7e8c750","type":"COMBINATION_TREATMENT","name":"alemtuzumab + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-c159ace8c9813cec","description":null,"metadata":null},{"id":"37f6dec529bc4bbca5979bec8d04129d","type":"COMBINATION_TREATMENT","name":"alemtuzumab + pentostatin","canonical_id":"ctgov_combo:ctgov-combo-2e457e7b6bf901df","description":null,"metadata":null},{"id":"8b9bb8770e2c4e6eb7424c0a722b74ad","type":"COMBINATION_TREATMENT","name":"alemtuzumab + pentostatin","canonical_id":"ctgov_combo:ctgov-combo-8c70a854c38c2588","description":null,"metadata":null},{"id":"ef15e2a0ddd74b9e85882b2f2bc45181","type":"COMBINATION_TREATMENT","name":"alemtuzumab + pentostatin","canonical_id":"ctgov_combo:ctgov-combo-82ea345a5b36e215","description":null,"metadata":null},{"id":"cf69db10947c481488fa5d8065d9a5dc","type":"COMBINATION_TREATMENT","name":"alemtuzumab + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-8874674a9f11b009","description":null,"metadata":null},{"id":"c2a229cc5bea453ba7c7e420c93c08af","type":"DRUG","name":"alendronate","canonical_id":"gtopdb:3141","description":null,"metadata":null},{"id":"1c959416ce384c749eb848375b4043db","type":"DRUG","name":"alendronate","canonical_id":"chembl:CHEMBL675","description":null,"metadata":null},{"id":"fec82012f9a84c93bf4664460e0d58e2","type":"COMBINATION_TREATMENT","name":"alendronate + denosumab","canonical_id":"ctgov_combo:ctgov-combo-7bf51bf1e1709bb5","description":null,"metadata":null},{"id":"d8de80b685bd480c81dc154f0f38d943","type":"COMBINATION_TREATMENT","name":"alendronate + denosumab","canonical_id":"ctgov_combo:ctgov-combo-93c1b4eecc860584","description":null,"metadata":null},{"id":"fcd3097770ad4cdb8d7c01f0180581bd","type":"COMBINATION_TREATMENT","name":"alendronate + denosumab","canonical_id":"ctgov_combo:ctgov-combo-1ac829114c0c4ceb","description":null,"metadata":null},{"id":"e8dfdbf6024a43a0afcc8f09a5f28198","type":"COMBINATION_TREATMENT","name":"alendronate + denosumab","canonical_id":"ctgov_combo:ctgov-combo-fcb3af385cf355e4","description":null,"metadata":null},{"id":"218b9a92eeeb42d1b8ecd56597e24ea3","type":"COMBINATION_TREATMENT","name":"alendronate + risedronate","canonical_id":"ctgov_combo:ctgov-combo-c9ff00ecccbc398f","description":null,"metadata":null},{"id":"75906904734d4905a4a49602afbee8a6","type":"COMBINATION_TREATMENT","name":"alendronate + risedronate","canonical_id":"ctgov_combo:ctgov-combo-bb47c16cc77ab021","description":null,"metadata":null},{"id":"38af94c43b524eb69eeeaa55b4423f82","type":"COMBINATION_TREATMENT","name":"alendronate + romosozumab + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-ba1c40d0fc3b4ef4","description":null,"metadata":null},{"id":"bbfba4ee8f3a427587b8532744feccfa","type":"COMBINATION_TREATMENT","name":"alendronate + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-b70d1f97eb1f6fae","description":null,"metadata":null},{"id":"1e6d3739354948cdb1e9ba0ac8549549","type":"COMBINATION_TREATMENT","name":"alendronate + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-72be353aa28adbcc","description":null,"metadata":null},{"id":"833c5f14a9f14a7e9dd824fa659f84ee","type":"DRUG","name":"alendronic acid","canonical_id":"mesh:D019386","description":null,"metadata":null},{"id":"a8bdcaedd18d421392a5495a0e12158f","type":"GO_TERM","name":"aleurone grain","canonical_id":"go:GO:0033095","description":"\"A membrane-bounded storage granule found in cells of the aleurone layer in plants; contains either a protein matrix, protein-carbohydrate bodies and/or globoids. Aleurone grains are formed by the vacuole, rough endoplasmic reticulum and dictyosomes.\" [PMID:22452734, Wikipedia:Aleurone]","metadata":null},{"id":"89dc83a17fab4784827c645956091b5d","type":"GO_TERM","name":"aleurone grain lumen","canonical_id":"go:GO:0034422","description":"\"The volume enclosed by the membrane of an aleurone grain.\" [GOC:rph]","metadata":null},{"id":"aa3cb02f4b4e4f348714f774199b43f0","type":"GO_TERM","name":"aleurone grain membrane","canonical_id":"go:GO:0032578","description":"\"The lipid bilayer surrounding an aleurone grain.\" [GOC:ecd]","metadata":null},{"id":"db9c4ff0d4bc45aa98eb301ccbdb8ce9","type":"DRUG","name":"alfacalcidol","canonical_id":"mesh:C008088","description":null,"metadata":null},{"id":"139ff82cf53b472da2791cfcf84a4e7e","type":"DRUG","name":"alfuzosin","canonical_id":"gtopdb:7109","description":null,"metadata":null},{"id":"c4ca8d5a0e434024b3a42c339031b72c","type":"COMBINATION_TREATMENT","name":"alfuzosin + doxazosin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-9058f8c16a09f19a","description":null,"metadata":null},{"id":"1c25924952ef471896e8571596af142e","type":"COMBINATION_TREATMENT","name":"alfuzosin + finasteride","canonical_id":"ctgov_combo:ctgov-combo-084f36451245e63a","description":null,"metadata":null},{"id":"34e037ac4ba34defb90c2d3492575dd4","type":"GO_TERM","name":"alginate synthase activity","canonical_id":"go:GO:0047643","description":"\"Catalysis of the reaction: GDP-D-mannuronate + alginate(n) = GDP + alginate(n+1).\" [EC:2.4.1.33, MetaCyc:ALGINATE-SYNTHASE-RXN]","metadata":null},{"id":"cd429d6812aa4d15af2d33d6aec12838","type":"GO_TERM","name":"alginic acid acetylation","canonical_id":"go:GO:0051979","description":"\"The addition of O-acetyl ester groups to alginic acid, a linear polymer of D-mannuronate and L-guluronate.\" [GOC:mlg]","metadata":null},{"id":"0c0ce6e0b8b741539ca97a94a15c4c88","type":"GO_TERM","name":"alginic acid biosynthetic process","canonical_id":"go:GO:0042121","description":"\"The chemical reactions and pathways resulting in the formation of alginic acid, a hydrophilic polysaccharide occurring in, for example, the cell walls of brown algae (brown seaweeds).\" [ISBN:0198506732]","metadata":null},{"id":"3922a0cf892e4ebea29b84db25d7f6f9","type":"GO_TERM","name":"alginic acid catabolic process","canonical_id":"go:GO:0042122","description":"\"The chemical reactions and pathways resulting in the breakdown of alginic acid, a hydrophilic polysaccharide occurring in, for example, the cell walls of brown algae (brown seaweeds).\" [ISBN:0198506732]","metadata":null},{"id":"2cff44eeca1c4ef5a7e7ff86a920daa9","type":"DRUG","name":"alglucosidase alfa","canonical_id":"mesh:C509951","description":null,"metadata":null},{"id":"53178028d16d41d7be95dca384dd6aa2","type":"GO_TERM","name":"alignment of 3' and 5' splice sites of mRNA","canonical_id":"go:GO:0034403","description":"\"Recognition of both the 5' and 3'-splice sites and positioning them in the correct alignment with respect to each other so that the second catalytic step of nuclear mRNA splicing can occur.\" [GOC:krc, PMID:9430647]","metadata":null},{"id":"c1e047b2b7b946eca4f51307635e3272","type":"GO_TERM","name":"aliphatic (R)-hydroxynitrile lyase activity","canonical_id":"go:GO:0052919","description":"\"Catalysis of the reaction: an aliphatic (R)-hydroxynitrile = an aliphatic aldehyde or ketone + hydrogen cyanide.\" [EC:4.1.2.46]","metadata":null},{"id":"2feb7c3fc42a4576bf50fab60d293532","type":"GO_TERM","name":"aliphatic (S)-hydroxynitrile lyase activity","canonical_id":"go:GO:0052891","description":"\"Catalysis of the reaction: an aliphatic (S)-hydroxynitrile = an aliphatic aldehyde or ketone + cyanide.\" [PMID:15299689]","metadata":null},{"id":"f74d9d4e8c5d483295ab34b68475cda6","type":"GO_TERM","name":"aliphatic aldoxime dehydratase activity","canonical_id":"go:GO:0034013","description":"\"Catalysis of the reaction: an aliphatic aldoxime = an aliphatic nitrile + H2O.\" [RHEA:11316]","metadata":null},{"id":"f45605394640417dbe1c0cc45ffda211","type":"GO_TERM","name":"aliphatic amine dehydrogenase activity","canonical_id":"go:GO:0030058","description":"\"Catalysis of the reaction: an aliphatic amine + an acceptor (A) + H2O = an aldehyde + a reduced acceptor (AH2) + NH4+.\" [RHEA:51128]","metadata":null},{"id":"8b89b28de61a4c11ba8e797460255ee6","type":"GO_TERM","name":"aliphatic desulfoglucosinolate sulfotransferase activity","canonical_id":"go:GO:0120527","description":"\"Catalysis of the reaction: 3'-phosphoadenylyl sulfate + an aliphatic (Z)-desulfo-glucosinolate = a (Z)-omega-(methylsulfanyl)-N-sulfo-alkylhydroximate S-glucoside + adenosine 3',5'-bisphosphate + H+.\" [RHEA:52724]","metadata":null},{"id":"764f75f75887481ab609e8fafd8c41c7","type":"GO_TERM","name":"aliphatic nitrilase activity","canonical_id":"go:GO:0018762","description":"\"Catalysis of the reaction: an aliphatic nitrile + 2 H2O = a carboxylate + NH4+.\" [RHEA:46188]","metadata":null},{"id":"1f2c9c189d424f5483ec359f4226eedb","type":"DRUG","name":"alirocumab","canonical_id":"gtopdb:6744","description":null,"metadata":null},{"id":"72369b4259c841328a1f9deed798f978","type":"DRUG","name":"alirocumab","canonical_id":"mesh:C571059","description":null,"metadata":null},{"id":"2510a60d48564b60bc4b1319d22d3732","type":"DRUG","name":"alirocumab","canonical_id":"chembl:CHEMBL2109540","description":null,"metadata":null},{"id":"ff3ac3bbd1bb4bba94a95c5f820e0e8a","type":"COMBINATION_TREATMENT","name":"alirocumab + bezafibrate + ciprofibrate","canonical_id":"ctgov_combo:ctgov-combo-31a517b1a6a4f5c1","description":null,"metadata":null},{"id":"27275cde536a4ef8a5a3b4ed96cfaa85","type":"COMBINATION_TREATMENT","name":"alirocumab + cemiplimab","canonical_id":"ctgov_combo:ctgov-combo-73781334037fb35b","description":null,"metadata":null},{"id":"4b577456aacd4eb79d86aa1ec727b2b3","type":"COMBINATION_TREATMENT","name":"alirocumab + evolocumab","canonical_id":"ctgov_combo:ctgov-combo-020c4f93044fdb4d","description":null,"metadata":null},{"id":"47cf84137cf4489088b86d9fd9a0852e","type":"COMBINATION_TREATMENT","name":"alirocumab + evolocumab + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-e6682b46203492ea","description":null,"metadata":null},{"id":"fd02d072014e42aab273228dd3e40d46","type":"COMBINATION_TREATMENT","name":"alirocumab + ezetimibe","canonical_id":"ctgov_combo:ctgov-combo-e2eb8d0a5cb3f6df","description":null,"metadata":null},{"id":"b5722d968f654e87aee65eea75e9a522","type":"COMBINATION_TREATMENT","name":"alirocumab + ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-c66c46b42c96e62f","description":null,"metadata":null},{"id":"ce76088f112f46aaa360500265a40284","type":"COMBINATION_TREATMENT","name":"alirocumab + ezetimibe + rosuvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-add7eab3c7c5f5fe","description":null,"metadata":null},{"id":"6a1022dd573945fb9d1fce6043af709c","type":"COMBINATION_TREATMENT","name":"alirocumab + fenofibrate","canonical_id":"ctgov_combo:ctgov-combo-5396e5af201a48f2","description":null,"metadata":null},{"id":"a0331e30615647468aec9fe8cc7163ae","type":"COMBINATION_TREATMENT","name":"alirocumab + fluvastatin","canonical_id":"ctgov_combo:ctgov-combo-1231d5a13bb00151","description":null,"metadata":null},{"id":"047b75b89d664bcd9f2abc99cc78c6be","type":"DRUG","name":"aliskiren","canonical_id":"gtopdb:4812","description":null,"metadata":null},{"id":"2910d2201bfd47bc827ebbcc52dfd256","type":"COMBINATION_TREATMENT","name":"aliskiren + candesartan","canonical_id":"ctgov_combo:ctgov-combo-47fd4959ca82e126","description":null,"metadata":null},{"id":"90e81a1d3c5944208069e51f3b279b72","type":"COMBINATION_TREATMENT","name":"aliskiren + chlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-85f361e834e012e4","description":null,"metadata":null},{"id":"895af3181aa3453aa9c954690c87f737","type":"COMBINATION_TREATMENT","name":"aliskiren + chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-f4a6cbcc6f651c1c","description":null,"metadata":null},{"id":"c3aea320ad884f6e8958dea6c91a4013","type":"COMBINATION_TREATMENT","name":"aliskiren + chlorothiazide + hydrochlorothiazide + ramipril","canonical_id":"ctgov_combo:ctgov-combo-c46d77c1d5782c7e","description":null,"metadata":null},{"id":"2d2d234748d4409fa1bbf0e7968710cd","type":"COMBINATION_TREATMENT","name":"aliskiren + furosemide","canonical_id":"ctgov_combo:ctgov-combo-c163ad2e1c179c05","description":null,"metadata":null},{"id":"12ce167317ec43c4a53b1f2b1e991e72","type":"COMBINATION_TREATMENT","name":"aliskiren + losartan","canonical_id":"ctgov_combo:ctgov-combo-fc1c41dd7ba6a524","description":null,"metadata":null},{"id":"d1a0c4c02df24fc2a76a2dc923220fd9","type":"COMBINATION_TREATMENT","name":"aliskiren + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-3f89f4453c3e856d","description":null,"metadata":null},{"id":"7f1275bc115a44048b4e1985e7ad3e76","type":"COMBINATION_TREATMENT","name":"aliskiren + ramipril","canonical_id":"ctgov_combo:ctgov-combo-f8933b7a76f16cad","description":null,"metadata":null},{"id":"fd02c816d2d54b1bb9bdd5a01655c900","type":"COMBINATION_TREATMENT","name":"aliskiren + ramipril","canonical_id":"ctgov_combo:ctgov-combo-0b6080740b0d7ab9","description":null,"metadata":null},{"id":"06326179e1e6426793d1547328c0c5cb","type":"COMBINATION_TREATMENT","name":"aliskiren + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-78468bead631b51a","description":null,"metadata":null},{"id":"05d869ee9f6a43d8b3ec4329e69a8bb9","type":"COMBINATION_TREATMENT","name":"aliskiren + valsartan","canonical_id":"ctgov_combo:ctgov-combo-ecdb0402fc29f299","description":null,"metadata":null},{"id":"7ee0173c29e446f185bc9dec46d06025","type":"DRUG","name":"alitretinoin","canonical_id":"gtopdb:2645","description":null,"metadata":null},{"id":"b39c8593e8d14ebc8537a432aa150d59","type":"DRUG","name":"alitretinoin","canonical_id":"chembl:CHEMBL705","description":null,"metadata":null},{"id":"7930775ebd98421b9ca0b5ffe777721d","type":"COMBINATION_TREATMENT","name":"alitretinoin + tretinoin","canonical_id":"ctgov_combo:ctgov-combo-e54f52bcba58d9ec","description":null,"metadata":null},{"id":"07e12f6d8b344416b1bf7dca3ad73569","type":"GO_TERM","name":"alizarin 2-beta-glucosyltransferase activity","canonical_id":"go:GO:0047644","description":"\"Catalysis of the reaction: alizarin + UDP-D-glucose = 1-hydroxy-2-(beta-D-glucosyloxy)-9,10-anthraquinone + H+ + UDP.\" [EC:2.4.1.103, RHEA:20677]","metadata":null},{"id":"8a690aba32ee488993520a32300f31c5","type":"GO_TERM","name":"alkali metal ion binding","canonical_id":"go:GO:0031420","description":"\"Binding to an alkali metal ion; alkali metals are those elements in group Ia of the periodic table, with the exception of hydrogen.\" [GOC:mah]","metadata":null},{"id":"29915921ad0d464fb8243c97a3e8be50","type":"GO_TERM","name":"alkaline phosphatase activity","canonical_id":"go:GO:0004035","description":"\"Catalysis of the reaction: a phosphate monoester + H2O = an alcohol + phosphate, with an alkaline pH optimum.\" [EC:3.1.3.1]","metadata":null},{"id":"5059914080414936bfcc83612d22b781","type":"GO_TERM","name":"alkaloid biosynthetic process","canonical_id":"go:GO:0009821","description":"\"The chemical reactions and pathways resulting in the formation of alkaloids, nitrogen-containing natural products which are not otherwise classified as nonprotein amino acids, amines, peptides, amines, cyanogenic glycosides, glucosinolates, cofactors, phytohormones, or primary metabolite (such as purine or pyrimidine bases).\" [GOC:lr, ISBN:0122146743]","metadata":null},{"id":"8fa1f45f73aa4d258ce2c3b9670c1fd9","type":"GO_TERM","name":"alkaloid catabolic process","canonical_id":"go:GO:0009822","description":"\"The chemical reactions and pathways resulting in the breakdown of alkaloids, nitrogen containing natural products not otherwise classified as peptides, nonprotein amino acids, amines, cyanogenic glycosides, glucosinolates, cofactors, phytohormones or primary metabolites (such as purine or pyrimidine bases).\" [GOC:lr, ISBN:0122146743]","metadata":null},{"id":"594c2ca582ad46948d5bc25e1e711960","type":"GO_TERM","name":"alkaloid metabolic process","canonical_id":"go:GO:0009820","description":"\"The chemical reactions and pathways involving alkaloids, nitrogen containing natural products which are not otherwise classified as peptides, nonprotein amino acids, amines, cyanogenic glycosides, glucosinolates, cofactors, phytohormones or primary metabolites (such as purine or pyrimidine bases).\" [GOC:lr, ISBN:0122146743]","metadata":null},{"id":"a6cdfabe26af4a5d9fed6391815f5a2f","type":"GO_TERM","name":"alkan-1-ol dehydrogenase (acceptor) activity","canonical_id":"go:GO:0047645","description":"\"Catalysis of the reaction: primary alcohol + acceptor = aldehyde + reduced acceptor.\" [EC:1.1.99.20, MetaCyc:ALKAN-1-OL-DEHYDROGENASE-ACCEPTOR-RXN]","metadata":null},{"id":"eba7915325834230b9ea936f363ac65f","type":"GO_TERM","name":"alkanal monooxygenase (FMN-linked) activity","canonical_id":"go:GO:0047646","description":"\"Catalysis of the reaction: R-CHO + reduced FMN + O2 = R-COOH + FMN + H2O + light.\" [EC:1.14.14.3, MetaCyc:ALKANAL-MONOOXYGENASE-FMN-LINKED-RXN]","metadata":null},{"id":"29f9c5ecaa824bd7b478b4386131fc0e","type":"GO_TERM","name":"alkane 1-monooxygenase activity","canonical_id":"go:GO:0018685","description":"\"Catalysis of the reaction: octane + reduced rubredoxin + O2 = 1-octanol + oxidized rubredoxin + H2O.\" [RHEA:19341]","metadata":null},{"id":"3623128a61684bdfaa303477e698225c","type":"GO_TERM","name":"alkane biosynthetic process","canonical_id":"go:GO:0043447","description":"\"The chemical reactions and pathways resulting in the formation of an alkane, any acyclic branched or unbranched hydrocarbon having the general formula CnH2n+2.\" [GOC:jl, Wikipedia:Alkane]","metadata":null},{"id":"838b5a4b468844a1b7d7e20b7a165748","type":"GO_TERM","name":"alkane catabolic process","canonical_id":"go:GO:0043448","description":"\"The chemical reactions and pathways resulting in the breakdown of an alkane, any acyclic branched or unbranched hydrocarbon having the general formula CnH2n+2.\" [GOC:jl, Wikipedia:Alkane]","metadata":null},{"id":"d29e9cb97e174d5a9e239c8c51f94464","type":"GO_TERM","name":"alkane transmembrane transporter activity","canonical_id":"go:GO:0015567","description":"\"Enables the transfer of alkanes from one side of a membrane to the other. Alkanes are saturated aliphatic hydrocarbon compounds.\" [GOC:ai]","metadata":null},{"id":"0647925e83404c00b654cde6596c5930","type":"GO_TERM","name":"alkane transport","canonical_id":"go:GO:0015895","description":"\"The directed movement of alkanes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Alkanes are saturated aliphatic hydrocarbon compounds.\" [GOC:ai]","metadata":null},{"id":"b7f64164787a48d5a2f9183017613b13","type":"GO_TERM","name":"alkanesulfonate binding","canonical_id":"go:GO:0043210","description":"\"Binding to alkanesulfonates, the anion of alkanesulfonic acids, sulfonic acid derivatives containing an aliphatic hydrocarbon group.\" [GOC:mlg]","metadata":null},{"id":"0fc7ce1da4fc4d44af5262e9ae5f2ef6","type":"GO_TERM","name":"alkanesulfonate biosynthetic process","canonical_id":"go:GO:0046305","description":"\"The chemical reactions and pathways resulting in the formation of alkanesulfonates, the anion of alkanesulfonic acids, sulfonic acid derivatives containing an aliphatic hydrocarbon group.\" [GOC:ai]","metadata":null},{"id":"2564b54339094bddb9bfa34f86fc0d52","type":"GO_TERM","name":"alkanesulfonate catabolic process","canonical_id":"go:GO:0046306","description":"\"The chemical reactions and pathways resulting in the breakdown of alkanesulfonates, the anion of alkanesulfonic acids, sulfonic acid derivatives containing an aliphatic hydrocarbon group.\" [GOC:ai]","metadata":null},{"id":"16503418276c441a8d6f343e548dee38","type":"GO_TERM","name":"alkanesulfonate metabolic process","canonical_id":"go:GO:0019694","description":"\"The chemical reactions and pathways involving alkanesulfonates, the anion of alkanesulfonic acids, sulfonic acid derivatives containing an aliphatic hydrocarbon group.\" [GOC:ai]","metadata":null},{"id":"8e666023757243b6b9c1a50997135942","type":"GO_TERM","name":"alkanesulfonate monooxygenase activity","canonical_id":"go:GO:0008726","description":"\"Catalysis of the reaction: an alkanesulfonate + O2 + FMNH2 = an aldehyde + sulfite + H2O + FMN.\" [MetaCyc:RXN0-280]","metadata":null},{"id":"b77d724e04684490a88823e27da13202","type":"GO_TERM","name":"alkanesulfonate monooxygenase complex","canonical_id":"go:GO:1990201","description":"\"A protein complex capable of alkanesulfonate monooxygenase activity. Involved in the utilization of alkanesulfonates as sulfur sources under conditions of sulfate or cysteine starvation, catalyzing the conversion of alkanesulfonates into aldehydes and sulfite. In E.coli the complex consists of a SsuD tetramer.\" [GOC:bhm, PMID:10480865, PMID:16997955]","metadata":null},{"id":"b550e87273ad4bab82ec669ed82a5dab","type":"GO_TERM","name":"alkanesulfonate transmembrane transport","canonical_id":"go:GO:0042918","description":"\"The directed movement of an alkanesulfonate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Alkanesulfonates are organic esters or salts of sulfonic acid containing an aliphatic hydrocarbon radical.\" [PMID:31802112]","metadata":null},{"id":"51b8027cc372468f858401bada82f2f0","type":"GO_TERM","name":"alkene binding","canonical_id":"go:GO:0072328","description":"\"Binding to an alkene, any acyclic branched or unbranched hydrocarbon having one carbon-carbon double bond and the general formula CnH2n.\" [GOC:mah]","metadata":null},{"id":"0f2d4b37221440ffb530100eb3b718d7","type":"GO_TERM","name":"alkene biosynthetic process","canonical_id":"go:GO:0043450","description":"\"The chemical reactions and pathways resulting in the formation of an alkene, any acyclic branched or unbranched hydrocarbon having one carbon-carbon double bond and the general formula CnH2n.\" [GOC:jl, Wikipedia:Alkene]","metadata":null},{"id":"95c016121b304d0480c0eb357af410d1","type":"GO_TERM","name":"alkene catabolic process","canonical_id":"go:GO:0043451","description":"\"The chemical reactions and pathways resulting in the breakdown of an alkene, any acyclic branched or unbranched hydrocarbon having one carbon-carbon double bond and the general formula CnH2n.\" [GOC:jl, Wikipedia:Alkene]","metadata":null},{"id":"18ce8c1d23b344ae9ce9cc3608571055","type":"GO_TERM","name":"alkene monooxygenase activity","canonical_id":"go:GO:0018645","description":"\"Catalysis of the reaction: propene + NADH + H+ + O2 = 1,2-epoxypropane + NAD+ + H2O.\" [EC:1.14.13.69]","metadata":null},{"id":"118c0c531ea0441aa6c8908134eeb5b5","type":"GO_TERM","name":"alkenylglycerophosphocholine hydrolase activity","canonical_id":"go:GO:0047408","description":"\"Catalysis of the reaction: H2O + 1-(1-alkenyl)-sn-glycero-3-phosphocholine = L-1-glycero-3-phosphocholine + an aldehyde.\" [EC:3.3.2.2, MetaCyc:3.3.2.2-RXN]","metadata":null},{"id":"37690f0582d8437695e6cc04b5593d83","type":"GO_TERM","name":"alkyl caffeate ester biosynthetic process","canonical_id":"go:GO:0090431","description":"\"The chemical reactions and pathways resulting in the formation of ester derivatives of alkyl caffeate.\" [GOC:pz]","metadata":null},{"id":"6161aebd5dbb4a7480b0b1f283bdcced","type":"GO_TERM","name":"alkyl hydroperoxide reductase complex","canonical_id":"go:GO:0009321","description":"\"An enzyme complex, usually a homodimer, which directly reduces cellular levels of organic hydroperoxides.\" [GOC:jl, PMID:2649484]","metadata":null},{"id":"44c429aae25645a89a114d3a8f795ad0","type":"GO_TERM","name":"alkylacetylglycerophosphatase activity","canonical_id":"go:GO:0047647","description":"\"Catalysis of the reaction: 1-alkyl-2-acetyl-sn-glycerol 3-phosphate + H2O = 2-acetyl-1-alkyl-sn-glycerol + phosphate.\" [RHEA:18221]","metadata":null},{"id":"fcbdd834d52947c68d3ef621577680d1","type":"GO_TERM","name":"alkylamidase activity","canonical_id":"go:GO:0047648","description":"\"Catalysis of the reaction: N-methylhexanamide + H2O = hexanoate + methylammonium.\" [EC:3.5.1.39, RHEA:20081]","metadata":null},{"id":"81a9a80017cf4d63a6a21e9aa53473af","type":"GO_TERM","name":"alkylated DNA binding","canonical_id":"go:GO:0032131","description":"\"Binding to an alkylated residue in DNA.\" [GOC:mah]","metadata":null},{"id":"1395403dae5f4c36a03ffe37ce99b9f1","type":"GO_TERM","name":"alkylbase DNA N-glycosylase activity","canonical_id":"go:GO:0003905","description":"\"Catalysis of the reaction: DNA with alkylated base + H2O = DNA with abasic site + alkylated base. This reaction is the hydrolysis of DNA by cleavage of the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar to remove an alkylated base, leaving an apyrimidinic or apurinic site.\" [EC:3.2.2.21, GOC:elh, PMID:10872450, PMID:9224623]","metadata":null},{"id":"55db916caf82451fb63e534178095dee","type":"GO_TERM","name":"alkylglycerol kinase activity","canonical_id":"go:GO:0047649","description":"\"Catalysis of the reaction: 1-alkyl-sn-glycerol + ATP = 1-alkyl-sn-glycerol 3-phosphate + ADP + 2 H+.\" [EC:2.7.1.93, RHEA:16937]","metadata":null},{"id":"08f843101dbb4708b288f457e2d2e49e","type":"GO_TERM","name":"alkylglycerone kinase activity","canonical_id":"go:GO:0047650","description":"\"Catalysis of the reaction: O-alkylglycerone + ATP = O-alkylglycerone phosphate + ADP + 2 H+.\" [EC:2.7.1.84, RHEA:23088]","metadata":null},{"id":"e2120a2974214fa880783726dd1d0a3e","type":"GO_TERM","name":"alkylglycerone-phosphate synthase activity","canonical_id":"go:GO:0008609","description":"\"Catalysis of the reaction: 1-acyl-glycerone 3-phosphate + a long-chain alcohol = 1-alkyl-glycerone 3-phosphate + a long-chain acid anion.\" [EC:2.5.1.26]","metadata":null},{"id":"c5250a1ea39a47319fcbad757ce711ff","type":"GO_TERM","name":"alkylglycerophosphate 2-O-acetyltransferase activity","canonical_id":"go:GO:0047160","description":"\"Catalysis of the reaction: 1-alkyl-sn-glycerol 3-phosphate + acetyl-CoA = 1-alkyl-2-acetyl-sn-glycerol 3-phosphate + CoA.\" [EC:2.3.1.105, RHEA:18557]","metadata":null},{"id":"67feb198816f4f49b55dba843ad315c5","type":"GO_TERM","name":"alkylglycerophosphoethanolamine phosphodiesterase activity","canonical_id":"go:GO:0047391","description":"\"Catalysis of the reaction: H2O + 1-alkyl-sn-glycero-3-phosphoethanolamine = ethanolamine + 1-alkyl-sn-glycerol 3-phosphate.\" [EC:3.1.4.39, MetaCyc:3.1.4.39-RXN]","metadata":null},{"id":"add6050a4fc94bd1a7d7f8eccb706eea","type":"GO_TERM","name":"alkylhalidase activity","canonical_id":"go:GO:0047651","description":"\"Catalysis of the reaction: bromochloromethane + H2O = bromide + chloride + formaldehyde + 2 H+.\" [RHEA:13765]","metadata":null},{"id":"b40952041e024b0e93aa6672e4d057f6","type":"GO_TERM","name":"alkylmercury lyase activity","canonical_id":"go:GO:0018836","description":"\"Catalysis of the reaction: an alkylmercury + H+ = an alkane + Hg2+.\" [RHEA:18777]","metadata":null},{"id":"d6301d2797bf4e31821086c334ad0523","type":"GO_TERM","name":"alkylthioltransferase activity","canonical_id":"go:GO:0050497","description":"\"Catalysis of the transfer of an alkylthio group from one compound (donor) to another (acceptor).\" [EC:2.8.4.-, GOC:ai]","metadata":null},{"id":"89859f3065ae4546bf71af54202643e1","type":"GO_TERM","name":"alkyne biosynthetic process","canonical_id":"go:GO:0043453","description":"\"The chemical reactions and pathways resulting in the formation of an alkyne, any acyclic branched or unbranched hydrocarbon (compound composed only of carbon and hydrogen) having a carbon-carbon triple bond and the general formula CnH2n-2.\" [GOC:jl, GOC:krc, Wikipedia:Alkyne]","metadata":null},{"id":"e3fa43922ca04bcf94517e5c90eb5300","type":"GO_TERM","name":"alkyne catabolic process","canonical_id":"go:GO:0043454","description":"\"The chemical reactions and pathways resulting in the breakdown of an alkyne, any acyclic branched or unbranched hydrocarbon (compound composed only of carbon and hydrogen) having a carbon-carbon triple bond and the general formula CnH2n-2.\" [GOC:jl, GOC:krc, Wikipedia:Alkyne]","metadata":null},{"id":"d07acc0c4d7b4043944e8421266bafc8","type":"GO_TERM","name":"all-trans retinal 3,4-desaturase activity","canonical_id":"go:GO:0061897","description":"\"Catalysis of the reaction: all-trans-retinal + 2 H+ + O2 + 2 reduced [adrenodoxin] = all-trans-3,4-didehydro retinal + 2 H2O + 2 oxidized [adrenodoxin].\" [PMID:27059013]","metadata":null},{"id":"ff4beab0059741938ec50919a2816dea","type":"GO_TERM","name":"all-trans retinal binding","canonical_id":"go:GO:0005503","description":"\"Binding to all-trans retinal, a compound that plays an important role in the visual process in most vertebrates. All-trans retinal (trans r., visual yellow) results from the bleaching of rhodopsin by light, in which the 11-cis form is converted to the all-trans form. Retinal is one of the forms of vitamin A.\" [GOC:curators]","metadata":null},{"id":"41febffbbb1f4c5fa47b4f4f254df9d4","type":"GO_TERM","name":"all-trans retinoic acid 18-hydroxylase activity","canonical_id":"go:GO:0062183","description":"\"Catalysis of the reaction: all-trans-retinoate + O2 + reduced [NADPH--hemoprotein reductase] = all-trans-18-hydroxyretinoate + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [PMID:22020119, RHEA:55856]","metadata":null},{"id":"c9679ba75177460e89544b0799ad56ce","type":"GO_TERM","name":"all-trans retinoic acid 3,4-desaturase activity","canonical_id":"go:GO:0061898","description":"\"Catalysis of the reaction: all-trans-retinoic acid + 2 H+ + O2 + 2 reduced [adrenodoxin] = all-trans-3,4-didehydro retinoic acid + 2 H2O + 2 oxidized [adrenodoxin].\" [PMID:27059013]","metadata":null},{"id":"69c57a13213c46b0ad2ab04cd7037ebb","type":"GO_TERM","name":"all-trans retinoic acid 4-hydrolase activity","canonical_id":"go:GO:0062182","description":"\"Catalysis of the reaction: all-trans-retinoate + O2 + reduced [NADPH--hemoprotein reductase] = all-trans-(4S)-hydroxyretinoate + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [PMID:9250660, PMID:9716180, RHEA:51492]","metadata":null},{"id":"8e82fcfd99e44dd6b662b7748ed13338","type":"GO_TERM","name":"all-trans retinol 3,4-desaturase activity","canonical_id":"go:GO:0061896","description":"\"Catalysis of the reaction: all-trans-retinol + 2 H+ + O2 + 2 reduced [adrenodoxin] = all-trans-3,4-didehydro retinol + 2 H2O + 2 oxidized [adrenodoxin].\" [PMID:27059013]","metadata":null},{"id":"cbfb5d5ec30a42629c5d6d7d1847ebd5","type":"GO_TERM","name":"all-trans undecaprenol kinase activity","canonical_id":"go:GO:0036432","description":"\"Catalysis of the reaction: ATP + undecaprenol + all-trans-undecaprenyl phosphate + ADP + H+.\" [RHEA:23752]","metadata":null},{"id":"8b2ec045879e4b469aadf9a056c80e7a","type":"GO_TERM","name":"all-trans-8'-apo-beta-carotenal 15,15'-oxygenase activity","canonical_id":"go:GO:0102162","description":"\"Catalysis of the reaction: 8'-apo-beta,psi-caroten-8'-al + O2 = all-trans-retinal + 2,6-dimethylocta-2,4,6-trienedial.\" [EC:1.13.11.75, GOC:pz]","metadata":null},{"id":"0dd909d3b35a4f75a75f20b12c94e3bd","type":"GO_TERM","name":"all-trans-beta-apo-10'-carotenal cleavage oxygenase activity","canonical_id":"go:GO:0102251","description":"\"Catalysis of the reaction: 10'-apo-beta-carotenal + O2 = 13-apo-beta-carotenone + 4-methylocta-2,4,6-trienedial.\" [EC:1.13.11.70, GOC:pz]","metadata":null},{"id":"c556d7b4b0fc49f688e415d50be8b77a","type":"GO_TERM","name":"all-trans-decaprenyl-diphosphate synthase activity","canonical_id":"go:GO:0097269","description":"\"Catalysis of the reaction: 7 isopentenyl diphosphate + (2E,6E)-farnesyl diphosphate = all-trans-decaprenyl diphosphate + 7 diphosphate.\" [PMID:16262699, RHEA:27802]","metadata":null},{"id":"d2b0dbfeb1c34107870cafa33b89b39d","type":"GO_TERM","name":"all-trans-nonaprenyl-diphosphate synthase (geranyl-diphosphate specific) activity","canonical_id":"go:GO:0052923","description":"\"Catalysis of the reaction: 7 isopentenyl diphosphate + (2E)-geranyl diphosphate = all-trans-nonaprenyl diphosphate + 7 diphosphate.\" [RHEA:27563]","metadata":null},{"id":"75606ac9825b4f1e9e23496986998664","type":"GO_TERM","name":"all-trans-nonaprenyl-diphosphate synthase (geranylgeranyl-diphosphate specific) activity","canonical_id":"go:GO:0052924","description":"\"Catalysis of the reaction: 5 isopentenyl diphosphate + (2E,6E,10E)-geranylgeranyl diphosphate = all-trans-nonaprenyl diphosphate + 5 diphosphate.\" [RHEA:27594]","metadata":null},{"id":"9402c19060804f5792596a5fd8b44713","type":"GO_TERM","name":"all-trans-octaprenyl-diphosphate synthase activity","canonical_id":"go:GO:0106350","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + 5 isopentenyl diphosphate = 5 diphosphate + all-trans-octaprenyl diphosphate.\" [PMID:3519603, PMID:8037730, RHEA:27798]","metadata":null},{"id":"00ce15a02b8b483d904c7b635f8ca691","type":"GO_TERM","name":"all-trans-phytoene synthase activity","canonical_id":"go:GO:0140630","description":"\"Catalysis of the reaction: 2 geranylgeranyl diphosphate = all-trans-phytoene + 2 diphosphate.\" [PMID:12641468, PMID:7896759]","metadata":null},{"id":"54c6ac62318b4f2ba80e98402252f196","type":"GO_TERM","name":"all-trans-retinol 13,14-reductase activity","canonical_id":"go:GO:0051786","description":"\"Catalysis of the reaction: all-trans-13,14-dihydroretinol + A = all-trans-retinol + AH(2). Note that this reaction has only been observed to occur in the opposite direction.\" [EC:1.3.99.23, RHEA:19193]","metadata":null},{"id":"8ad67ca5f1014be995e8433246e5244b","type":"GO_TERM","name":"all-trans-retinol binding","canonical_id":"go:GO:1904768","description":"\"Binding to all-trans-retinol.\" [GO_REF:0000067, GOC:kmv, GOC:TermGenie, PMID:19828452]","metadata":null},{"id":"f5de25a4f03e4585a1cc7133efa28121","type":"GO_TERM","name":"all-trans-retinol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004745","description":"\"Catalysis of the reaction: all-trans-retinol--[retinol-binding protein] + NAD+ = all-trans-retinal--[retinol-binding protein] + H+ + NADH. Recognizes the substrate both in free form and when bound to cellular-retinol-binding-protein (CRBP1), but has higher affinity for the bound form.\" [RHEA:48488]","metadata":null},{"id":"a9feee656af043419484d5a98c7c5e6a","type":"GO_TERM","name":"all-trans-retinol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0052650","description":"\"Catalysis of the reaction: all-trans-retinol + NADP+ = all-trans-retinal + NADPH + H+.\" [RHEA:25033]","metadata":null},{"id":"cf7c51b368754fe3850b86ce6dfa92ec","type":"GO_TERM","name":"all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity","canonical_id":"go:GO:0052885","description":"\"Catalysis of the reaction: H2O + all-trans-retinyl ester = 11-cis-retinol + fatty acid.\" [RHEA:31771]","metadata":null},{"id":"d9b56c21640a42718a431445f1020b2e","type":"GO_TERM","name":"all-trans-retinyl-palmitate hydrolase, 11-cis retinol forming activity","canonical_id":"go:GO:0052884","description":"\"Catalysis of the reaction: H2O + all-trans-retinyl palmitate = 11-cis-retinol + H+ + palmitate.\" [RHEA:31775]","metadata":null},{"id":"31d0bac287e049ffa1ae302312233fdd","type":"GO_TERM","name":"all-trans-retinyl-palmitate hydrolase, all-trans-retinol forming activity","canonical_id":"go:GO:0047376","description":"\"Catalysis of the reaction: all-trans-retinyl palmitate + H2O = all-trans-retinol + H+ + palmitate.\" [RHEA:13933]","metadata":null},{"id":"7ec27ee5c2214d7eb29e45ed2c2e4734","type":"GO_TERM","name":"all-trans-undecaprenyl-phosphate mannosyltransferase activity","canonical_id":"go:GO:0036427","description":"\"Catalysis of the reaction: all-trans-undecaprenyl phosphate + GDP-alpha-D-mannose = D-mannosyl undecaprenyl phosphate + GDP.\" [RHEA:28118]","metadata":null},{"id":"2d1ecc78b62b47a9a2135cda92b9a2eb","type":"GO_TERM","name":"allantoate deiminase activity","canonical_id":"go:GO:0047652","description":"\"Catalysis of the reaction: allantoate + H2O + 2 H+ = (S)-2-ureidoglycine + NH4+ + CO2.\" [RHEA:27485]","metadata":null},{"id":"ffc6c3e64e5941dfb89d46715ffe4e1b","type":"GO_TERM","name":"allantoate transmembrane transporter activity","canonical_id":"go:GO:0015124","description":"\"Enables the transfer of allantoate from one side of a membrane to the other. Allantoate is the end product of purine metabolism in mammals and some fish, formed form allantoin. It is widely distributed in plants as an important source of stored nitrogen.\" [GOC:ai, ISBN:0198547684]","metadata":null},{"id":"c8ab844f29444a6ca7bbd9428de16655","type":"GO_TERM","name":"allantoate transport","canonical_id":"go:GO:0015719","description":"\"The directed movement of allantoate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"cc0c7150fff74b048fcf489082951344","type":"GO_TERM","name":"allantoicase activity","canonical_id":"go:GO:0004037","description":"\"Catalysis of the reaction: allantoate + H2O = (S)-ureidoglycolate + urea.\" [EC:3.5.3.4, RHEA:11016]","metadata":null},{"id":"2192f66d15964527b02b25925362c427","type":"DRUG","name":"allantoin","canonical_id":"mesh:D000481","description":null,"metadata":null},{"id":"c15adceaa56e4dd5801d6ac5017b9ba5","type":"GO_TERM","name":"allantoin biosynthetic process","canonical_id":"go:GO:0019428","description":"\"The chemical reactions and pathways resulting in the formation of allantoin, (2,5-dioxo-4-imidazolidinyl)urea.\" [GOC:curators]","metadata":null},{"id":"5abb7f6cab0b439eb1bbe2f15c2b6512","type":"GO_TERM","name":"allantoin catabolic process","canonical_id":"go:GO:0000256","description":"\"The chemical reactions and pathways resulting in the breakdown of allantoin, (2,5-dioxo-4-imidazolidinyl)urea.\" [PMID:41016821]","metadata":null},{"id":"c7318b02dde54eeaa30dab6486d174b3","type":"GO_TERM","name":"allantoin metabolic process","canonical_id":"go:GO:0000255","description":"\"The chemical reactions and pathways involving allantoin, (2,5-dioxo-4-imidazolidinyl)urea, an intermediate or end product of purine catabolism.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"284bd169c3fd437dab6b54749ff12a97","type":"GO_TERM","name":"allantoin racemase activity","canonical_id":"go:GO:0047653","description":"\"Catalysis of the reaction: (S)-(+)-allantoin = (R)-(-)-allantoin.\" [EC:5.1.99.3, RHEA:10804]","metadata":null},{"id":"b2340f26c2764e9594bd1a2184763b62","type":"GO_TERM","name":"allantoin transport","canonical_id":"go:GO:0015720","description":"\"The directed movement of allantoin, (2,5-dioxo-4-imidazolidinyl)urea, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f544f5137dfa4f47b077a47dd7abde51","type":"GO_TERM","name":"allantoin:proton symporter activity","canonical_id":"go:GO:0005274","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: allantoin(out) + H+(out) = allantoin(in) + H+(in) by secondary active transport.\" [GOC:mtg_transport, ISBN:0815340729, TC:2.A.39.3.1]","metadata":null},{"id":"8999a862ed7347a0bcfd2dc2d2265753","type":"GO_TERM","name":"allantoinase activity","canonical_id":"go:GO:0004038","description":"\"Catalysis of the reaction: allantoin + H2O = allantoate.\" [EC:3.5.2.5]","metadata":null},{"id":"8df3150b7c3b4303aca0a61e35e86096","type":"GO_TERM","name":"allantois development","canonical_id":"go:GO:1905069","description":"\"The process whose specific outcome is the progression of an allantois over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, PMID:17440924, PMID:21470579]","metadata":null},{"id":"ab6da66ee31048ae976f184ec66b022c","type":"GO_TERM","name":"allatostatin receptor activity","canonical_id":"go:GO:0008261","description":"\"Combining with allatostatin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"df27bebfee0145e9a74d5b1d3a1d5118","type":"GO_TERM","name":"allene oxide synthase activity","canonical_id":"go:GO:0009978","description":"\"Catalysis of the reaction: 13(S)-hydroperoxylinolenate = 12,13(S)-epoxylinolenate + H2O.\" [EC:4.2.1.92, PMID:9778849]","metadata":null},{"id":"f94567108de34f48a291f432b1f65e60","type":"GO_TERM","name":"allene-oxide cyclase activity","canonical_id":"go:GO:0046423","description":"\"Catalysis of the reaction: (9Z,13S,15Z)-12,13-epoxyoctadeca-9,11,15-trienoate = (15Z)-12-oxophyto-10,15-dienoate.\" [EC:5.3.99.6, RHEA:22592]","metadata":null},{"id":"354afc2617014d45b067dc35fc351d07","type":"DISEASE","name":"allergic asthma","canonical_id":"mondo:0004784","description":null,"metadata":null},{"id":"0c26f93513444780a0cece69763911c5","type":"DISEASE","name":"allergic disease","canonical_id":"mondo:0005271","description":null,"metadata":null},{"id":"e4bd2588c28543a1add52947bcbd460f","type":"DISEASE","name":"allergic rhinitis","canonical_id":"mondo:0011786","description":null,"metadata":null},{"id":"d866ba8ec1934c12b5159cc5b3153c35","type":"DISEASE","name":"allergic skin disorders","canonical_id":"mesh:D017449","description":null,"metadata":null},{"id":"4ace0dc84d86425eb4a92008225f9d1f","type":"GO_TERM","name":"alliin lyase activity","canonical_id":"go:GO:0047654","description":"\"Catalysis of the reaction: an S-alkyl-L-cysteine S-oxide = an alkyl sulfenate + 2-aminoacrylate.\" [EC:4.4.1.4, MetaCyc:ALLIIN-LYASE-RXN]","metadata":null},{"id":"2317c3b4ff1a4a3da78e1efe9d79005d","type":"GO_TERM","name":"allophanate hydrolase activity","canonical_id":"go:GO:0004039","description":"\"Catalysis of the reaction: H2O + 3 H+ + urea-1-carboxylate = 2 CO2 + 2 NH4.\" [EC:3.5.1.54, RHEA:19029]","metadata":null},{"id":"c54dbebfe3ad403caec6bbbc75e2ac8b","type":"DRUG","name":"allopurinol","canonical_id":"gtopdb:6795","description":null,"metadata":null},{"id":"3b236a2099bc43ed9cb0eecfb7d08b6e","type":"DRUG","name":"allopurinol","canonical_id":"mesh:D000493","description":null,"metadata":null},{"id":"e9d6bef8aac940ada8399813a45fea4c","type":"DRUG","name":"allopurinol","canonical_id":"chembl:CHEMBL1467","description":null,"metadata":null},{"id":"dc9aaa478fc64f9b9f5970d16fac91c4","type":"COMBINATION_TREATMENT","name":"allopurinol + canakinumab","canonical_id":"ctgov_combo:ctgov-combo-faaf66cb2d7083c3","description":null,"metadata":null},{"id":"4a2b42ee54b246f2a5f0726f11ac620a","type":"COMBINATION_TREATMENT","name":"allopurinol + candesartan + ramipril","canonical_id":"ctgov_combo:ctgov-combo-34d8de3368fbedc7","description":null,"metadata":null},{"id":"4400b408b71c4a99b040acbc2331de11","type":"COMBINATION_TREATMENT","name":"allopurinol + colchicine","canonical_id":"ctgov_combo:ctgov-combo-77c8f4f9b6959983","description":null,"metadata":null},{"id":"262db37c5c6742c7906f3405ea42ec22","type":"COMBINATION_TREATMENT","name":"allopurinol + colchicine","canonical_id":"ctgov_combo:ctgov-combo-ca77fe3a04209b19","description":null,"metadata":null},{"id":"8a9797b17f544ffab6a19f60803a2579","type":"COMBINATION_TREATMENT","name":"allopurinol + dotinurad","canonical_id":"ctgov_combo:ctgov-combo-b32985e10d2e1fba","description":null,"metadata":null},{"id":"026ebbc2d54743e7b1630d178c34725f","type":"COMBINATION_TREATMENT","name":"allopurinol + dotinurad","canonical_id":"ctgov_combo:ctgov-combo-24544e04f68bd5dd","description":null,"metadata":null},{"id":"170b157d9e9147d481af431e105952cf","type":"COMBINATION_TREATMENT","name":"allopurinol + febuxostat","canonical_id":"ctgov_combo:ctgov-combo-61a6a89570eb839c","description":null,"metadata":null},{"id":"7ab72b97bb154d34b675e011097e538f","type":"COMBINATION_TREATMENT","name":"allopurinol + febuxostat","canonical_id":"ctgov_combo:ctgov-combo-c26c8e7b7060adab","description":null,"metadata":null},{"id":"8d34b88630f142d3a0fb69610cc4f1a5","type":"COMBINATION_TREATMENT","name":"allopurinol + febuxostat","canonical_id":"ctgov_combo:ctgov-combo-2049eaa457c15c54","description":null,"metadata":null},{"id":"e7b404b5a9d04a55b041a56710835eed","type":"COMBINATION_TREATMENT","name":"allopurinol + febuxostat","canonical_id":"ctgov_combo:ctgov-combo-f6d496205ddff003","description":null,"metadata":null},{"id":"b641b844a0a94d26b04b1aaedf49b47a","type":"COMBINATION_TREATMENT","name":"allopurinol + probenecid","canonical_id":"ctgov_combo:ctgov-combo-ceca8b90e68ae86f","description":null,"metadata":null},{"id":"437cf1952f984801a9aefea55b932ba6","type":"GO_TERM","name":"allulose 6-phosphate 3-epimerase activity","canonical_id":"go:GO:0034700","description":"\"Catalysis of the reaction: D-allulose 6-phosphate = keto-D-fructose 6-phosphate.\" [RHEA:28426]","metadata":null},{"id":"2c65a27609ab4b88b85925a6063e8430","type":"GO_TERM","name":"allyl-alcohol dehydrogenase activity","canonical_id":"go:GO:0047655","description":"\"Catalysis of the reaction: allyl alcohol + NADP+ = acrolein + H+ + NADPH.\" [EC:1.1.1.54, RHEA:12168]","metadata":null},{"id":"f46398b00a3b48ca89bcab1126721e20","type":"DRUG","name":"alogliptin","canonical_id":"gtopdb:6319","description":null,"metadata":null},{"id":"9c3b4b431d1a4fddba894100fc0ee3fc","type":"DRUG","name":"alogliptin","canonical_id":"mesh:C520853","description":null,"metadata":null},{"id":"5ab010a726fa494d8f7aa853944ae4c7","type":"COMBINATION_TREATMENT","name":"alogliptin + linagliptin + liraglutide + saxagliptin","canonical_id":"ctgov_combo:ctgov-combo-6e143af1df814814","description":null,"metadata":null},{"id":"5c314f7ab4ef4f0a91525e4b55124e97","type":"COMBINATION_TREATMENT","name":"alogliptin + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-fd4ffa59fef219a3","description":null,"metadata":null},{"id":"bb056e1116dc450bb0b2d0148b7eb4b7","type":"COMBINATION_TREATMENT","name":"alogliptin + roflumilast","canonical_id":"ctgov_combo:ctgov-combo-23019d5af4c4c491","description":null,"metadata":null},{"id":"fccca464660c48129b5a877e69ce5f19","type":"DISEASE","name":"alopecia","canonical_id":"mondo:0004907","description":null,"metadata":null},{"id":"b570dda4649d41b9bf2b5650ad1b2971","type":"DISEASE","name":"alopecia areata","canonical_id":"mondo:0005340","description":null,"metadata":null},{"id":"629123f89be94202b6058df04565cd60","type":"DRUG","name":"alosetron","canonical_id":"gtopdb:2296","description":null,"metadata":null},{"id":"5f696fc841c243b0af14f9b98d51f06d","type":"DRUG","name":"alpelisib","canonical_id":"gtopdb:7955","description":null,"metadata":null},{"id":"69f0752ae4ed43b39e7d05ef7d0ebbc2","type":"DRUG","name":"alpelisib","canonical_id":"chembl:CHEMBL2396661","description":null,"metadata":null},{"id":"5a7ed6094cdb446b8b6d22007d682119","type":"COMBINATION_TREATMENT","name":"alpelisib + atezolizumab + binimetinib + cobimetinib + dabrafenib + nivolumab + olaparib + palbociclib + pembrolizumab + ribociclib + talazoparib + trametinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-ddd3b1b3d16cbe07","description":null,"metadata":null},{"id":"327b69b1aa8c46f9a84089831d322256","type":"COMBINATION_TREATMENT","name":"alpelisib + binimetinib + neratinib + nilotinib + selumetinib","canonical_id":"ctgov_combo:ctgov-combo-54d2991f348ee6be","description":null,"metadata":null},{"id":"6c9776ad33954458b0ca6229c104eae8","type":"COMBINATION_TREATMENT","name":"alpelisib + dabrafenib + lenvatinib + olaparib + palbociclib + pazopanib + sacituzumab govitecan + trametinib","canonical_id":"ctgov_combo:ctgov-combo-08d914534ef10d4f","description":null,"metadata":null},{"id":"1b25e5e1bbaa46e4ab8a345978f6211f","type":"COMBINATION_TREATMENT","name":"alpelisib + enzalutamide","canonical_id":"ctgov_combo:ctgov-combo-c6c588c64fd1ef95","description":null,"metadata":null},{"id":"8062965c5b784769a2b5968a3f81d7db","type":"COMBINATION_TREATMENT","name":"alpelisib + eribulin","canonical_id":"ctgov_combo:ctgov-combo-a6de6da46f4e67c4","description":null,"metadata":null},{"id":"9346fae3800f4c16bec9a86ce46a79e1","type":"COMBINATION_TREATMENT","name":"alpelisib + fulvestrant + gedatolisib + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-aa51326216d435d5","description":null,"metadata":null},{"id":"3379608b05514157aec3f71cdd80b73f","type":"COMBINATION_TREATMENT","name":"alpelisib + fulvestrant + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-87b55d7c341f39ea","description":null,"metadata":null},{"id":"f1f9169cf4e24df6992f9ac954d9f67d","type":"COMBINATION_TREATMENT","name":"alpelisib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-422bd850d09c8fe5","description":null,"metadata":null},{"id":"b78df0bf97054bb0af0e429dc07868d3","type":"COMBINATION_TREATMENT","name":"alpelisib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-a5bd7c147b1b1ca0","description":null,"metadata":null},{"id":"f712fd420c54441d80bfc17775352f5c","type":"COMBINATION_TREATMENT","name":"alpelisib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-d164215f2da3a968","description":null,"metadata":null},{"id":"88bdde5e3c2f4fea825f7e01936fb05f","type":"COMBINATION_TREATMENT","name":"alpelisib + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-b79ec74a51f5ee9e","description":null,"metadata":null},{"id":"c29eac2bb1da4841a3686bce054d51a8","type":"DISEASE","name":"alpha 1-antitrypsin deficiency","canonical_id":"mondo:0013282","description":null,"metadata":null},{"id":"d086a187542c48219e0c08a745c99c85","type":"GO_TERM","name":"alpha DNA polymerase:primase complex","canonical_id":"go:GO:0005658","description":"\"A complex of four polypeptides, comprising large and small DNA polymerase alpha subunits and two primase subunits, which are capable of catalyzing the synthesis of an RNA primer on the lagging strand of replicating DNA and the subsequent synthesis of a small stretch of DNA. The smaller of the two primase subunits alone can catalyze oligoribonucleotide synthesis.\" [GOC:mah, PMID:11395402, PMID:26975377]","metadata":null},{"id":"ce2b69f591264119afb92d912aa57e3f","type":"GO_TERM","name":"alpha helical protein insertion into mitochondrial outer membrane","canonical_id":"go:GO:7770059","description":"\"The import of alpha helical and tail-anchored proteins from the cytosol and their insertion into the mitochondrial outer membrane.\" [PMID:40782022]","metadata":null},{"id":"e08a5ee4b6e14823ac2fefab137b089b","type":"GO_TERM","name":"alpha,alpha-phosphotrehalase activity","canonical_id":"go:GO:0008788","description":"\"Catalysis of the reaction: alpha,alpha-trehalose 6-phosphate + H2O = D-glucose + D-glucose 6-phosphate.\" [EC:3.2.1.93]","metadata":null},{"id":"5e6169c4225a4622a89063858c881ba7","type":"GO_TERM","name":"alpha,alpha-trehalase activity","canonical_id":"go:GO:0004555","description":"\"Catalysis of the reaction: alpha,alpha-trehalose + H2O = 2 D-glucose.\" [PMID:19897915, RHEA:32675]","metadata":null},{"id":"f3972a5268ce4e1b80005d15f9c610f2","type":"GO_TERM","name":"alpha,alpha-trehalose phosphorylase (configuration-retaining) activity","canonical_id":"go:GO:0033832","description":"\"Catalysis of the reaction: alpha,alpha-trehalose + phosphate = alpha-D-glucose + alpha-D-glucose 1-phosphate.\" [RHEA:16257]","metadata":null},{"id":"92f8142be0264ed2907ce311cb9b537f","type":"GO_TERM","name":"alpha,alpha-trehalose phosphorylase activity","canonical_id":"go:GO:0047656","description":"\"Catalysis of the reaction: alpha,alpha-trehalose + phosphate = D-glucose + beta-D-glucose 1-phosphate.\" [EC:2.4.1.64, MetaCyc:ALPHAALPHA-TREHALOSE-PHOSPHORYLASE-RXN]","metadata":null},{"id":"46c15f9358484d65a14656f8f52f267b","type":"GO_TERM","name":"alpha,alpha-trehalose-phosphate synthase (GDP-forming) activity","canonical_id":"go:GO:0047260","description":"\"Catalysis of the reaction: GDP-D-glucose + glucose-6-phosphate = alpha,alpha-trehalose 6-phosphate + GDP.\" [EC:2.4.1.36, MetaCyc:2.4.1.36-RXN]","metadata":null},{"id":"5de1da8798e34d5fb0ee470cdd88c1d0","type":"GO_TERM","name":"alpha,alpha-trehalose-phosphate synthase (UDP-forming) activity","canonical_id":"go:GO:0003825","description":"\"Catalysis of the reaction: UDP-glucose + D-glucose-6-phosphate = UDP + alpha,alpha-trehalose-6-phosphate.\" [EC:2.4.1.15]","metadata":null},{"id":"c4b0283c9adc461bb572ef7ababbd674","type":"GO_TERM","name":"alpha,alpha-trehalose-phosphate synthase complex (UDP-forming)","canonical_id":"go:GO:0005946","description":"\"A protein complex that possesses alpha,alpha-trehalose-phosphate synthase (UDP-forming) and trehalose-phosphatase activities, and thus catalyzes two reactions in trehalose biosynthesis. In the complex identified in Saccharomyces, Tps1p has alpha,alpha-trehalose-phosphate synthase (UDP-forming) activity, Tps2p has trehalose 6-phosphate phosphatase activity; Tps3p is a regulatory subunit, and an additional subunit, Tsl1p, may be present.\" [PMID:9837904]","metadata":null},{"id":"f8faa326d71c4897a8297bac03a7840c","type":"GO_TERM","name":"alpha-(1,2)-fucosyltransferase activity","canonical_id":"go:GO:0031127","description":"\"Catalysis of the transfer of an L-fucosyl group from GDP-beta-L-fucose to an acceptor molecule to form an alpha-(1->2) linkage.\" [GOC:mah]","metadata":null},{"id":"0ae17c93941f4ff689abc7442b8b8ee6","type":"GO_TERM","name":"alpha-(1->3)-fucosyltransferase activity","canonical_id":"go:GO:0046920","description":"\"Catalysis of the transfer of an L-fucosyl group from GDP-beta-L-fucose to an acceptor molecule to form an alpha-(1->3) linkage.\" [GOC:ai]","metadata":null},{"id":"233fca1f22804c188b3d77b3cc9f22e1","type":"GO_TERM","name":"alpha-(1->6)-fucosyltransferase activity","canonical_id":"go:GO:0046921","description":"\"Catalysis of the transfer of an L-fucosyl group from GDP-beta-L-fucose to an acceptor molecule to form an alpha-(1->6) linkage.\" [GOC:ai]","metadata":null},{"id":"538394c7ff5c406a87305a26e009bc84","type":"GO_TERM","name":"alpha-1,2-galactosyltransferase activity","canonical_id":"go:GO:0031278","description":"\"Catalysis of the transfer of a galactose residue from a donor molecule, such as GDP-galactose or UDP-galactose, to an oligosaccharide, forming an alpha-1,2-linkage.\" [PMID:7522655]","metadata":null},{"id":"4a8b1e3e67e045b5aef3ba2911ae8ee5","type":"GO_TERM","name":"alpha-1,2-mannosyltransferase activity","canonical_id":"go:GO:0000026","description":"\"Catalysis of the transfer of a mannose residue to an oligosaccharide, forming an alpha-(1->2) linkage.\" [GOC:mcc, PMID:10521541]","metadata":null},{"id":"3b4071310f3b480dab301e268d66277d","type":"GO_TERM","name":"alpha-1,3-galactosyltransferase activity","canonical_id":"go:GO:0001962","description":"\"Catalysis of the transfer of a galactose residue from a donor molecule, such as GDP-galactose or UDP-galactose, to an oligosaccharide, forming an alpha-(1->3) linkage.\" [GOC:hjd, PMID:10854427]","metadata":null},{"id":"8f308fa8e7bf4765a0e6c37732887d00","type":"GO_TERM","name":"alpha-1,3-glucan synthase activity","canonical_id":"go:GO:0047657","description":"\"Catalysis of the reaction: UDP-glucose + [alpha-D-glucosyl-(1,3)]n = UDP + [alpha-D-glucosyl-(1,3)]n+1.\" [EC:2.4.1.183, MetaCyc:ALPHA-13-GLUCAN-SYNTHASE-RXN]","metadata":null},{"id":"5fbdde3fafb348409e87102d5e0c38fe","type":"GO_TERM","name":"alpha-1,3-mannosylglycoprotein 2-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0003827","description":"\"Catalysis of the reaction: 3-(alpha-D-mannosyl)-beta-D-mannosyl-R + UDP-N-acetyl-alpha-D-glucosamine = 3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R + H+ + UDP.\" [EC:2.4.1.101, RHEA:11456]","metadata":null},{"id":"b85e4132284d45dba893731d2546f7e2","type":"GO_TERM","name":"alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0008454","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + (N-acetyl-beta-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,3-(beta-N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6)-beta-D-mannosyl-R = UDP + N-acetyl-beta-D-glucosaminyl-1,4-(N-acetyl-D-glucosaminyl-1,2)-alpha-D-mannosyl-1,3-(beta-N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6)-beta-D-mannosyl-R.\" [EC:2.4.1.145]","metadata":null},{"id":"490ed6294c9c477cb6e90d0053c1961f","type":"GO_TERM","name":"alpha-1,3-mannosyltransferase activity","canonical_id":"go:GO:0000033","description":"\"Catalysis of the transfer of a mannose residue to an oligosaccharide, forming an alpha-(1->3) linkage.\" [GOC:mcc, PMID:10521541]","metadata":null},{"id":"079816b1115248b09928767b72335068","type":"GO_TERM","name":"alpha-1,4-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0035248","description":"\"Catalysis of the reaction: an N-acetyl-beta-D-galactosaminyl derivative + UDP-N-acetyl-alpha-D-galactosamine = an N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-beta-D-galactosaminyl derivative + UDP + H+.\" [PMID:15130086, RHEA:86251]","metadata":null},{"id":"9c2e7175af7a47f3af71fbf6372b388c","type":"GO_TERM","name":"alpha-1,4-glucan glucosyltransferase (ADP-glucose donor) activity","canonical_id":"go:GO:0009011","description":"\"Catalysis of the reaction: [(1->4)-alpha-D-glucosyl](n) + ADP-alpha-D-glucose = [(1->4)-alpha-D-glucosyl](n+1) + ADP + H+.\" [RHEA:18189]","metadata":null},{"id":"7c4111b0694e4851a89a9cac667624a9","type":"GO_TERM","name":"alpha-1,4-glucan glucosyltransferase (NDP-glucose donor) activity","canonical_id":"go:GO:0033840","description":"\"Catalysis of the reaction: [(1->4)-alpha-D-glucosyl](n) + an NDP-alpha-D-glucose = [(1->4)-alpha-D-glucosyl](n+1) + a ribonucleoside 5'-diphosphate + H+, where NDP is ADP or UDP.\" [EC:2.4.1.242, PMID:17472966, RHEA:15873]","metadata":null},{"id":"170fdd68d7cc4b82be9ed659bbeb2350","type":"GO_TERM","name":"alpha-1,4-glucan glucosyltransferase (UDP-glucose donor) activity","canonical_id":"go:GO:0004373","description":"\"Catalysis of the reaction: [(1->4)-alpha-D-glucosyl](n) + UDP-alpha-D-glucose = [(1->4)-alpha-D-glucosyl](n+1) + H+ + UDP.\" [RHEA:18549]","metadata":null},{"id":"3e5420a69f2c4329ae65b2ab878e8baf","type":"GO_TERM","name":"alpha-1,4-glucan-protein synthase (ADP-forming) activity","canonical_id":"go:GO:0047211","description":"\"Catalysis of the reaction: ADP-D-glucose + protein = alpha-D-glucosyl-protein + ADP.\" [EC:2.4.1.113, MetaCyc:2.4.1.113-RXN]","metadata":null},{"id":"6e27300fef714e61bc0287be12f7e710","type":"GO_TERM","name":"alpha-1,4-glucosidase activity","canonical_id":"go:GO:0004558","description":"\"Catalysis of the hydrolysis of terminal, non-reducing alpha-(1->4)-linked alpha-D-glucose residues with release of alpha-D-glucose.\" [EC:3.2.1.20]","metadata":null},{"id":"dac60ee0384e4ca5bd7e98012e6419ee","type":"GO_TERM","name":"alpha-1,4-mannosyltransferase activity","canonical_id":"go:GO:0051751","description":"\"Catalysis of the transfer of a mannose residue to an oligosaccharide, forming an alpha-(1->4) linkage.\" [PMID:15772281]","metadata":null},{"id":"0334fc6b8bb64b3e8b4dbd131e1664ac","type":"GO_TERM","name":"alpha-1,6-mannosylglycoprotein 2-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0008455","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-R = UDP + N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-R.\" [EC:2.4.1.143]","metadata":null},{"id":"8cae82ef42d04904a4558382c5ceff8c","type":"GO_TERM","name":"alpha-1,6-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047253","description":"\"Catalysis of the reaction: N-acetyl-beta-D-glucosaminyl-1,6-beta-D-(N-acetyl-B-glucosaminyl-1,2)-beta-D-mannosyl-R + UDP-N-acetyl-D-glucosamine = N-acetyl-beta-D-glucosaminyl-1,6-beta-D-(N-acetyl-D-glucosaminyl-1,2-beta)-(N-acetyl-D-glucosaminyl-1,4-beta)-D-mannosyl-R + UDP.\" [EC:2.4.1.201, MetaCyc:2.4.1.201-RXN]","metadata":null},{"id":"49e9d33f761442429616c3def583b871","type":"GO_TERM","name":"alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0030144","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3(6)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl,1,6(3))-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP + N-acetyl-beta-D-glucosaminyl-1,2-(N-acetyl-beta-D-glucosaminyl-1,6)-1,2-alpha-D-mannosyl-1,3(6)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R. Only branched mannose glycopeptides with non-reducing N-acetylglucosamine terminal residues act as acceptors.\" [EC:2.4.1.155]","metadata":null},{"id":"17b0358f4f73466aa0c731d7c8b267de","type":"GO_TERM","name":"alpha-1,6-mannosyltransferase activity","canonical_id":"go:GO:0000009","description":"\"Catalysis of the transfer of a mannose residue to an oligosaccharide, forming an alpha-(1->6) linkage.\" [GOC:mcc, PMID:2644248]","metadata":null},{"id":"75f5fe75c00c4aa6a969f3ceca18d36b","type":"GO_TERM","name":"alpha-1A adrenergic receptor binding","canonical_id":"go:GO:0031691","description":"\"Binding to an alpha-1A adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a89bdad8c2e4491bb80425921fcd5c91","type":"GO_TERM","name":"alpha-1B adrenergic receptor binding","canonical_id":"go:GO:0031692","description":"\"Binding to an alpha-1B adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e4aa95b73df74477ab195ebcf913843e","type":"GO_TERM","name":"alpha-1D adrenergic receptor binding","canonical_id":"go:GO:0031693","description":"\"Binding to an alpha-1D adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e80ca438c26c4caa8a3bb8388a9bd6d4","type":"GO_TERM","name":"alpha-2 macroglobulin receptor activity","canonical_id":"go:GO:0016964","description":"\"Combining with alpha-2 macroglobulin and delivering alpha-2 macroglobulin into the cell via receptor-mediated endocytosis.\" [GOC:bf, GOC:ma, PMID:6188403]","metadata":null},{"id":"e708fecc970045d9818e05deaf5de337","type":"GO_TERM","name":"alpha-2A adrenergic receptor binding","canonical_id":"go:GO:0031694","description":"\"Binding to an alpha-2A adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"df1e9f9b0e364b8fa0eea49d6426c514","type":"GO_TERM","name":"alpha-2B adrenergic receptor binding","canonical_id":"go:GO:0031695","description":"\"Binding to an alpha-2B adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"394db605d39643fda5f1aab806ee3225","type":"GO_TERM","name":"alpha-2C adrenergic receptor binding","canonical_id":"go:GO:0031696","description":"\"Binding to an alpha-2C adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d093381dad3149cf9acb5b2f56700bdb","type":"GO_TERM","name":"alpha-D-glucan binding","canonical_id":"go:GO:2001083","description":"\"Binding to alpha-D-glucan.\" [GOC:mengo_curators]","metadata":null},{"id":"06a74d69e7f84c51ac5f5df5cd2b976d","type":"GO_TERM","name":"alpha-D-ribose 1-methylphosphonate 5-phosphate C-P-lyase activity","canonical_id":"go:GO:0098848","description":"\"Catalysis of the reaction: alpha-D-ribose 1-methylphosphonate 5-phosphate = alpha-D-ribose 1,2-cyclic phosphate 5-phosphate + methane.\" [EC:4.7.1.1, GOC:dos, GOC:ik]","metadata":null},{"id":"d2e0e16559ea49b2a699783b93d58dcd","type":"GO_TERM","name":"alpha-D-ribose 1-methylphosphonate 5-triphosphate synthase activity","canonical_id":"go:GO:0061693","description":"\"Catalysis of the reaction: ATP + methylphosphonate = alpha-D-ribose 1-methylphosphonate 5-triphosphate + adenine.\" [EC:2.7.8.37, GOC:dph, PMID:22089136]","metadata":null},{"id":"954222de1c3b4ca4ac945acfbedead99","type":"GO_TERM","name":"alpha-D-ribose 1-methylphosphonate 5-triphosphate synthase complex","canonical_id":"go:GO:0061694","description":"\"A catalytic protein complex that is capable of alpha-D-ribose 1-methylphosphonate 5-triphosphate synthase activity.\" [GOC:dph, PMID:22089136]","metadata":null},{"id":"073ed47a245f443a91a5bb55c43a4935","type":"GO_TERM","name":"alpha-D-xyloside xylohydrolase activity","canonical_id":"go:GO:0061634","description":"\"Catalysis of the hydrolysis of terminal, non-reducing alpha-D-xylose residues with release of alpha-D-xylose.\" [EC:3.2.1.177]","metadata":null},{"id":"4ad1537fe51f475786e0f148cec405bc","type":"GO_TERM","name":"alpha-L-arabinofuranosidase activity","canonical_id":"go:GO:0046556","description":"\"Catalysis of the hydrolysis of terminal non-reducing alpha-L-arabinofuranoside residues in alpha-L-arabinosides.\" [EC:3.2.1.55, GOC:mf]","metadata":null},{"id":"09f79fd4156245cdb4b878ac0685c856","type":"GO_TERM","name":"alpha-L-fucosidase activity","canonical_id":"go:GO:0004560","description":"\"Catalysis of the reaction: an alpha-L-fucoside + H2O = an alcohol + L-fucose.\" [EC:3.2.1.51]","metadata":null},{"id":"1855caf4346e449286631c95db2b3714","type":"GO_TERM","name":"alpha-L-rhamnosidase activity","canonical_id":"go:GO:0030596","description":"\"Catalysis of the hydrolysis of terminal non-reducing alpha-L-rhamnose residues in alpha-L-rhamnosides.\" [EC:3.2.1.40]","metadata":null},{"id":"2c36449863b74b7a9daac9e7cc2dc7e0","type":"GO_TERM","name":"alpha-N-acetylgalactosaminidase activity","canonical_id":"go:GO:0008456","description":"\"Catalysis of the hydrolysis of terminal non-reducing N-acetyl-D-galactosamine residues in N-acetyl-alpha-D-galactosaminides.\" [EC:3.2.1.49]","metadata":null},{"id":"ab2f5a1e590342109b606b74cd2490f6","type":"GO_TERM","name":"alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase activity","canonical_id":"go:GO:0001665","description":"\"Catalysis of the reaction: CMP-N-acetylneuraminate + glycano-(1->3)-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP + glycano-[(2->6)-alpha-N-acetylneuraminyl]-(N-acetyl-D-galactosaminyl)-glycoprotein.\" [EC:2.4.3.3]","metadata":null},{"id":"8b4f6e9e71114ff6ba477fe8d2d40999","type":"GO_TERM","name":"alpha-N-acetylglucosaminidase activity","canonical_id":"go:GO:0004561","description":"\"Catalysis of the hydrolysis of terminal non-reducing N-acetyl-D-glucosamine residues in N-acetyl-alpha-D-glucosaminides.\" [EC:3.2.1.50]","metadata":null},{"id":"c81062df9ae14f898344d52a3f855a5f","type":"GO_TERM","name":"alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity","canonical_id":"go:GO:0003828","description":"\"Catalysis of the reaction: CMP-N-acetylneuraminate + alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-R = CMP + alpha-N-acetylneuraminyl-(2->8)-alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-R.\" [EC:2.4.3.8]","metadata":null},{"id":"a36d0eaf8d4142138735725c4de11a1f","type":"GO_TERM","name":"alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide 6-alpha-sialyltransferase activity","canonical_id":"go:GO:0047290","description":"\"Catalysis of the reaction: alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-D-galactosaminyl-R + CMP-N-acetyl-beta-neuraminate = alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-[N-acetyl-alpha-neuraminyl-(2->6)]-N-acetyl-D-galactosaminyl-R + CMP.\" [RHEA:53896]","metadata":null},{"id":"1e13589b5fa74b828fe2667955c1fafc","type":"GO_TERM","name":"alpha-actinin binding","canonical_id":"go:GO:0051393","description":"\"Binding to alpha-actinin, one of a family of proteins that cross-link F-actin as antiparallel homodimers. Alpha-actinin has a molecular mass of 93-103 KDa; at the N-terminus there are two calponin homology domains, at the C-terminus there are two EF-hands. These two domains are connected by the rod domain. This domain is formed by triple-helical spectrin repeats.\" [PMID:10984498, PMID:11699871, PMID:15014165]","metadata":null},{"id":"f9b1891bf84a4972be665874d61b78a6","type":"GO_TERM","name":"alpha-adrenergic receptor activity","canonical_id":"go:GO:0004936","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha-adrenergic receptors.\" [GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"041d057cfe884995beaa5c3518f139d7","type":"GO_TERM","name":"alpha-agarase activity","canonical_id":"go:GO:0033953","description":"\"Catalysis of the endohydrolysis of 1,3-alpha-L-galactosidic linkages in agarose, yielding agarotetraose as the major product.\" [EC:3.2.1.158]","metadata":null},{"id":"0561aa3f1bf242ee8741ec4f71c257b1","type":"GO_TERM","name":"alpha-amino-acid esterase activity","canonical_id":"go:GO:0047658","description":"\"Catalysis of the reaction: an alpha-amino acid ester + H2O = an alpha-amino acid + an alcohol.\" [EC:3.1.1.43, MetaCyc:ALPHA-AMINO-ACID-ESTERASE-RXN]","metadata":null},{"id":"9d5c7a54a0964afb860fbbe605ce54fb","type":"GO_TERM","name":"alpha-aminoacyl-tRNA binding","canonical_id":"go:GO:1904678","description":"\"Binding to an alpha-aminoacyl-tRNA.\" [GO_REF:0000067, GOC:TermGenie, ISBN:155581073X]","metadata":null},{"id":"6dd86e3256984d168bfad3ae5163ce8a","type":"GO_TERM","name":"alpha-aminoadipate acetyltransferase activity","canonical_id":"go:GO:0043741","description":"\"Catalysis of the reaction: alpha-aminoadipate + acetyl-CoA = N2-acetyl-alpha-aminoadipate + coenzyme A.\" [PMID:10613839, PMID:12925802, PMID:29053735]","metadata":null},{"id":"7e92179c048c4fdb90c14f7ebc648261","type":"GO_TERM","name":"alpha-amylase activity","canonical_id":"go:GO:0004556","description":"\"Catalysis of the endohydrolysis of (1->4)-alpha-D-glucosidic linkages in polysaccharides containing three or more alpha-(1->4)-linked D-glucose units.\" [PMID:12527308]","metadata":null},{"id":"33e90c7922a1448398642d801aa7fc9e","type":"GO_TERM","name":"alpha-amylase inhibitor activity","canonical_id":"go:GO:0015066","description":"\"Binds to and stops, prevents or reduces the activity of alpha-amylase.\" [GOC:mah]","metadata":null},{"id":"6edcb74860d344ee9759ed84df1606f5","type":"GO_TERM","name":"alpha-amyrin synthase activity","canonical_id":"go:GO:0042561","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = alpha-amyrin.\" [PMID:10848960, RHEA:31387]","metadata":null},{"id":"7a10c43a83314e3f9c202c424321203c","type":"GO_TERM","name":"alpha-beta T cell activation","canonical_id":"go:GO:0046631","description":"\"The change in morphology and behavior of an alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [GOC:add]","metadata":null},{"id":"684f68fb9b6f4a17a8c16f116362bec2","type":"GO_TERM","name":"alpha-beta T cell activation by superantigen","canonical_id":"go:GO:0042722","description":"\"The change in morphology and behavior of alpha-beta T cells resulting from exposure to a superantigen, a microbial antigen with an extremely potent activating effect on T cells that bear a specific variable region.\" [GOC:jl]","metadata":null},{"id":"3d292cf01fc54f1485823f428ee3a19d","type":"GO_TERM","name":"alpha-beta T cell activation involved in immune response","canonical_id":"go:GO:0002287","description":"\"The change in morphology and behavior of an alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"bc8fa033fb4249bcae031e15d83d34dc","type":"GO_TERM","name":"alpha-beta T cell differentiation","canonical_id":"go:GO:0046632","description":"\"The process in which a precursor cell type acquires the specialized features of an alpha-beta T cell. An alpha-beta T cell is a T cell that expresses an alpha-beta T cell receptor complex.\" [CL:0000789, GOC:ai]","metadata":null},{"id":"5c52854950434dc584971457a549f615","type":"GO_TERM","name":"alpha-beta T cell lineage commitment","canonical_id":"go:GO:0002363","description":"\"The process in which a pro-T cell becomes committed to becoming an alpha-beta T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"062a8efd43fb4e618bd8da7ca9964a94","type":"GO_TERM","name":"alpha-beta T cell proliferation","canonical_id":"go:GO:0046633","description":"\"The expansion of an alpha-beta T cell population by cell division.\" [GOC:ai]","metadata":null},{"id":"151755b3e1c74677aaafc8b9beebb5c8","type":"GO_TERM","name":"alpha-beta T cell receptor complex","canonical_id":"go:GO:0042105","description":"\"A T cell receptor complex in which the TCR heterodimer comprises alpha and beta chains, associated with the CD3 complex; recognizes a complex consisting of an antigen-derived peptide bound to a class I or class II MHC protein.\" [GOC:mah, ISBN:0781735149]","metadata":null},{"id":"6d5994d5de4744988adb269069b22a09","type":"GO_TERM","name":"alpha-beta intraepithelial T cell differentiation","canonical_id":"go:GO:0002299","description":"\"The process in which a precursor cell type acquires the specialized features of an alpha-beta intraepithelial T cell. Intraepithelial T cells are found among epithelial cells in mucosal areas and have distinct phenotypes and developmental pathways.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"55bdc8c0c5d5466a91699dac6c7faacc","type":"GO_TERM","name":"alpha-bisabolene synthase activity","canonical_id":"go:GO:0052681","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (E,R)-alpha-bisabolene + diphosphate.\" [RHEA:25436]","metadata":null},{"id":"8405a24734bb4a37bc2388a998743219","type":"GO_TERM","name":"alpha-carotene biosynthetic process","canonical_id":"go:GO:1901824","description":"\"The chemical reactions and pathways resulting in the formation of alpha-carotene.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5946, PMID:8837512, UniPathway:UPA00801]","metadata":null},{"id":"4fe54686a38c4b51a5f3799e8c22de90","type":"GO_TERM","name":"alpha-catenin binding","canonical_id":"go:GO:0045294","description":"\"Binding to catenin complex alpha subunit.\" [GOC:bf]","metadata":null},{"id":"73fdbf1f57d340c2879a7018ef3e7024","type":"GO_TERM","name":"alpha-copaene biosynthetic process","canonical_id":"go:GO:1901931","description":"\"The chemical reactions and pathways resulting in the formation of alpha-copaene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"4512e29b23a24ece9847c0d119b20ec7","type":"GO_TERM","name":"alpha-copaene catabolic process","canonical_id":"go:GO:1901930","description":"\"The chemical reactions and pathways resulting in the breakdown of alpha-copaene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"28321b193caf4d1a8cc8b116bdb1f741","type":"GO_TERM","name":"alpha-copaene synthase activity","canonical_id":"go:GO:0102877","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = alpha-copaene + diphosphoric acid.\" [EC:4.2.3.133, GOC:pz]","metadata":null},{"id":"734d2c17dde34f3da27b952430cdb856","type":"GO_TERM","name":"alpha-cuprenene synthase activity","canonical_id":"go:GO:0102885","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (-)-alpha-cuprenene + diphosphoric acid.\" [EC:4.2.3.95, GOC:pz]","metadata":null},{"id":"4d35581922b5484cbd8cc13c6a90a65e","type":"GO_TERM","name":"alpha-farnesene synthase activity","canonical_id":"go:GO:0052578","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (3E,6E)-alpha-farnesene + diphosphate.\" [RHEA:27421]","metadata":null},{"id":"0764d47287624e6faa44386729cb994c","type":"GO_TERM","name":"alpha-galactosidase activity","canonical_id":"go:GO:0004557","description":"\"Catalysis of the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids.\" [EC:3.2.1.22]","metadata":null},{"id":"c81b3e9ca39f4287808f981db3b017c3","type":"GO_TERM","name":"alpha-glucan biosynthetic process","canonical_id":"go:GO:0030979","description":"\"The chemical reactions and pathways resulting in the formation of alpha-glucans, compounds composed of glucose residues linked by alpha-D-glucosidic bonds.\" [GOC:mah]","metadata":null},{"id":"b6cb833c823940919ada8ad7023a175e","type":"GO_TERM","name":"alpha-glucan catabolic process","canonical_id":"go:GO:0030980","description":"\"The chemical reactions and pathways resulting in the breakdown of alpha-glucans.\" [GOC:mah]","metadata":null},{"id":"dc3cfffbe5414e508aa6db4a6dadb550","type":"GO_TERM","name":"alpha-glucan metabolic process","canonical_id":"go:GO:0030978","description":"\"The chemical reactions and pathways involving alpha-glucans, compounds composed of glucose residues linked by alpha-D-glucosidic bonds.\" [GOC:mah]","metadata":null},{"id":"d16e35acb28c410fb3be2008acbf2cf8","type":"GO_TERM","name":"alpha-glucan, water dikinase activity","canonical_id":"go:GO:0050521","description":"\"Catalysis of the reaction: [(1->4)-alpha-D-glucosyl](n) + n ATP + n H2O = [(1->4)-6-phospho-alpha-D-glucosyl](n) + n AMP + 2n H+ + n phosphate.\" [RHEA:11668]","metadata":null},{"id":"a8d3264536c94b84bc044b520d062a93","type":"GO_TERM","name":"alpha-glucosidase activity","canonical_id":"go:GO:0090599","description":"\"Catalysis of the hydrolysis of terminal, non-reducing alpha-linked alpha-D-glucose residue with release of alpha-D-glucose.\" [GOC:tb]","metadata":null},{"id":"fd716ad7f2b242f4ae7645e66043357f","type":"GO_TERM","name":"alpha-glucoside transmembrane transporter activity","canonical_id":"go:GO:0015151","description":"\"Enables the transfer of alpha-glucosides from one side of a membrane to the other. Alpha-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in an alpha configuration.\" [GOC:jl, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729, PMID:28510148]","metadata":null},{"id":"76bfee1570634f1ea6d0d5d27d8e2dcf","type":"GO_TERM","name":"alpha-glucoside transport","canonical_id":"go:GO:0000017","description":"\"The directed movement of alpha-glucosides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Alpha-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in an alpha configuration.\" [GOC:jl, ISBN:0198506732, PMID:9919658]","metadata":null},{"id":"4dbf9d6d9b394419bbf63e3c07b789d3","type":"GO_TERM","name":"alpha-glucoside:proton symporter activity","canonical_id":"go:GO:0005352","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: alpha-glucoside(out) + H+(out) = alpha-glucoside(in) + H+(in). Alpha-glucosides include trehalose, maltose, turanose, isomaltose, alpha-methylglucoside, maltotriose, palatinose, trehalose and melezitose.\" [TC:2.A.1.1.11]","metadata":null},{"id":"719da3d2533d4e6c8db0756d008ea2d8","type":"GO_TERM","name":"alpha-glucuronidase activity","canonical_id":"go:GO:0046559","description":"\"Catalysis of the reaction: an alpha-D-glucuronoside + H2O = an alcohol + D-glucuronate.\" [EC:3.2.1.139]","metadata":null},{"id":"6e31c3748ed84040aa6c5639c5dbff81","type":"GO_TERM","name":"alpha-heterochromatin","canonical_id":"go:GO:0005723","description":"\"A small, compact region of heterochromatin located in the middle of the polytene chromosome chromocenter, which undergoes little or no replication during polytenization.\" [PMID:8878678]","metadata":null},{"id":"680eca8ddef94a02b86cebfa7a0e7547","type":"GO_TERM","name":"alpha-humulene 10-hydroxylase activity","canonical_id":"go:GO:0102068","description":"\"Catalysis of the reaction: (1E,4E,8E)-alpha-humulene + NADPH + O2 + H+ = 10-hydroxy-alpha-humulene + NADP + H2O.\" [EC:1.14.14.113, GOC:pz]","metadata":null},{"id":"fa833b06ac0e49678394eba508d018db","type":"GO_TERM","name":"alpha-humulene synthase activity","canonical_id":"go:GO:0080017","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = alpha-humulene + diphosphate.\" [PMID:12566586, PMID:9442047, RHEA:31895]","metadata":null},{"id":"cd93750493664e4db23c14565d688bcd","type":"GO_TERM","name":"alpha-keto amide reductase activity","canonical_id":"go:GO:0051268","description":"\"Catalysis of the reaction: alpha-keto amide + 2 H+ (from donor) = (R)-hydroxy amide. Alpha-keto amides are of the form R-CO-CONH2, where R may be aromatic or aliphatic.\" [GOC:ai, PMID:15564669]","metadata":null},{"id":"08d938b7e9bf46e7ba23a7842e633b94","type":"GO_TERM","name":"alpha-ketoacid dehydrogenase complex","canonical_id":"go:GO:0045240","description":"\"A multi-enzyme complex that catalyzes the oxidative decarboxylation of an alpha-ketoacid - pyruvate, a branched-chain alpha-ketoacid or alpha-ketoglutarate (also known as 2-oxoglutarate). The complex comprises multiple copies of three enzymes referred to as E1, E2 and E3: a dihydrolipoyl transacylase (E2) forms the core of the complex, with an alpha-ketoacid dehydrogenase (E1) and a dihydrolipoamide dehydrogenase (E3) attached through non-covalent bonds. The E1 and E2 components are specific to different alpha-ketoacid dehydrogenase complexes, whereas the E3 component is the same. Additional proteins may also be present.\" [GOC:mah, PMID:10745006]","metadata":null},{"id":"d36e60b2f795439294831c10de82e94b","type":"GO_TERM","name":"alpha-ketoester reductase (NADP+) activity","canonical_id":"go:GO:0051269","description":"\"Catalysis of the reaction: alpha-ketoester + H+ + NADPH = (R)-hydroxy ester + NADP+.\" [PMID:15564669, RHEA:80767]","metadata":null},{"id":"f69b30487185438282e93f9bbc23a2ed","type":"GO_TERM","name":"alpha-ketoglutarate transmembrane transporter activity","canonical_id":"go:GO:0015139","description":"\"Enables the transfer of alpha-ketoglutarate from one side of a membrane to the other. Alpha-ketoglutarate (or oxoglutarate) is a compound with important roles in carbohydrate and amino acid metabolism, especially in transamination reactions and as a component of the TCA cycle.\" [GOC:ai, ISBN:0198547684]","metadata":null},{"id":"7dddad1145bb420ab28025e0fd0a0de6","type":"GO_TERM","name":"alpha-ketoglutarate transport","canonical_id":"go:GO:0015742","description":"\"The directed movement of alpha-ketoglutarate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"0bb9f900d84544a996e5337c71b34ef1","type":"GO_TERM","name":"alpha-ketoglutarate-dependent xanthine dioxygenase activity","canonical_id":"go:GO:0097641","description":"\"Catalysis of the reaction: xanthine + 2-oxoglutarate + O2 = urate + succinate + CO2.\" [PMID:15948966, PMID:17429948, RHEA:43120]","metadata":null},{"id":"52a55ade7fb04bf0824749ab4bc664d1","type":"GO_TERM","name":"alpha-ketoglutarate:proton symporter activity","canonical_id":"go:GO:0015532","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: alpha-ketoglutarate(out) + H+(out) = alpha-ketoglutarate(in) + H+(in).\" [TC:2.A.1.6.2]","metadata":null},{"id":"a90788bc9c6c4347906be1b947d642aa","type":"GO_TERM","name":"alpha-latrotoxin receptor binding","canonical_id":"go:GO:0061761","description":"\"Binding to an alpha-latrotoxin receptor.\" [GOC:dph, PMID:21724987]","metadata":null},{"id":"95936e32494b4191a8c63554abaf51b9","type":"GO_TERM","name":"alpha-linolenic acid metabolic process","canonical_id":"go:GO:0036109","description":"\"The chemical reactions and pathways involving alpha-linolenic acid, an unsaturated omega-6 fatty acid that has the molecular formula C18H32O2.\" [PMID:15538555]","metadata":null},{"id":"09090ed8dcd24a3cac6b31b7e1bb39b0","type":"GO_TERM","name":"alpha-mannosidase activity","canonical_id":"go:GO:0004559","description":"\"Catalysis of the hydrolysis of terminal, non-reducing alpha-D-mannose residues in alpha-D-mannosides.\" [EC:3.2.1.24]","metadata":null},{"id":"d38837cf4c88475084d1118a716cacc5","type":"GO_TERM","name":"alpha-methylacyl-CoA racemase activity","canonical_id":"go:GO:0008111","description":"\"Catalysis of the reaction: (2S)-2-methylacyl-CoA = (2R)-2-methylacyl-CoA.\" [EC:5.1.99.4]","metadata":null},{"id":"5e7d2b5ccb924109904882af9d7c397f","type":"DRUG","name":"alpha-methyltyrosine","canonical_id":"gtopdb:6956","description":null,"metadata":null},{"id":"417550e741654f34b0dd70e64290dc71","type":"GO_TERM","name":"alpha-neoagaro-oligosaccharide hydrolase activity","canonical_id":"go:GO:0033954","description":"\"Catalysis of the hydrolysis of the 1,3-alpha-L-galactosidic linkages of neoagaro-oligosaccharides that are smaller than a hexamer, yielding 3,6-anhydro-L-galactose and D-galactose.\" [EC:3.2.1.159]","metadata":null},{"id":"692d472b4e7243b7aa27c366096fe966","type":"GO_TERM","name":"alpha-pinene biosynthetic process","canonical_id":"go:GO:0046248","description":"\"The chemical reactions and pathways resulting in the formation of alpha-pinene, a monoterpene that may be a significant factor affecting bacterial activities in nature.\" [GOC:ai]","metadata":null},{"id":"193b106ec2a6461fa6f047fa0fa5f390","type":"GO_TERM","name":"alpha-pinene catabolic process","canonical_id":"go:GO:0046249","description":"\"The chemical reactions and pathways resulting in the breakdown of alpha-pinene, a monoterpene that may be a significant factor affecting bacterial activities in nature.\" [PMID:10192895, PMID:14736461, PMID:29414896]","metadata":null},{"id":"487002350cc54a39ab099ab42434245e","type":"GO_TERM","name":"alpha-pinene metabolic process","canonical_id":"go:GO:0018867","description":"\"The chemical reactions and pathways involving alpha-pinene, a monoterpene that may be a significant factor affecting bacterial activities in nature. It is a major component in tea-tree oils, and gives off a piney smelling odor.\" [UM-BBD_pathwayID:apn]","metadata":null},{"id":"e5462acfb3af41daa9549a666e629217","type":"GO_TERM","name":"alpha-pinene monooxygenase (NADH) activity","canonical_id":"go:GO:0018634","description":"\"Catalysis of the reaction: alpha-pinene + NADH + H+ + O2 = NAD+ + H2O + alpha-pinene oxide.\" [RHEA:32891]","metadata":null},{"id":"b9567e39aaeb4579ba0c29b36fc603ea","type":"GO_TERM","name":"alpha-pinene-oxide decyclase activity","canonical_id":"go:GO:0018851","description":"\"Catalysis of the reaction: alpha-pinene oxide = (Z)-2-methyl-5-isopropylhexa-2,5-dienal.\" [EC:5.5.1.10, RHEA:16693]","metadata":null},{"id":"876449c110164b628131d4b869d073c6","type":"GO_TERM","name":"alpha-ribazole phosphatase activity","canonical_id":"go:GO:0043755","description":"\"Catalysis of the reaction: alpha-ribazole 5'-phosphate + H2O = alpha-ribazole + phosphate.\" [RHEA:24456]","metadata":null},{"id":"582c79b090c346c182dc168ccbf0e6ba","type":"GO_TERM","name":"alpha-santalene synthase activity","canonical_id":"go:GO:0102062","description":"\"Catalysis of the reaction: 2-cis,6-cis-farnesyl diphosphate = (+)-alpha-santalene + diphosphoric acid.\" [EC:4.2.3.50, GOC:pz]","metadata":null},{"id":"8a1a8b9ee634434ea8467f12c4670a5a","type":"GO_TERM","name":"alpha-santonin 1,2-reductase activity","canonical_id":"go:GO:0047659","description":"\"Catalysis of the reaction: 1,2-dihydrosantonin + NAD(P)+ = alpha-santonin + NAD(P)H + H+.\" [EC:1.3.1.47, MetaCyc:ALPHA-SANTONIN-12-REDUCTASE-RXN]","metadata":null},{"id":"61497b9baa684c9ea1b404db8f242755","type":"GO_TERM","name":"alpha-sialidase activity","canonical_id":"go:GO:0016997","description":"\"Catalysis of the hydrolysis of alpha-glycosidic linkages in oligo- or poly(sialic) acids.\" [GOC:mah]","metadata":null},{"id":"9e9fe8f8128146fe948adb6b870b3e98","type":"GO_TERM","name":"alpha-thujene synthase activity","canonical_id":"go:GO:0102700","description":"\"Catalysis of the reaction: geranyl diphosphate(3-) = alpha-thujene + diphosphoric acid.\" [MetaCyc:RXN-5105]","metadata":null},{"id":"d595d80295434a85a650bdc25a9106b5","type":"GO_TERM","name":"alpha-tocopherol omega-hydroxylase activity","canonical_id":"go:GO:0052871","description":"\"Catalysis of the reaction: (+)-alpha-tocopherol + O2 + reduced [NADPH--hemoprotein reductase] = 13-hydroxy-alpha-tocopherol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:45108]","metadata":null},{"id":"25c390fde1bf4ea3a32b923d0fa72242","type":"GO_TERM","name":"alpha-tubulin acetylation","canonical_id":"go:GO:0071929","description":"\"The addition of an acetyl group to the lysine 40 residue of alpha-tubulin.\" [GOC:kmv, PMID:17786050]","metadata":null},{"id":"174a0ee64da14502a2fe98f46dfea765","type":"GO_TERM","name":"alpha-tubulin binding","canonical_id":"go:GO:0043014","description":"\"Binding to the microtubule constituent protein alpha-tubulin.\" [GOC:jl]","metadata":null},{"id":"72d93801b6b14ce5a69643dfd39d0b15","type":"GO_TERM","name":"alpha-zeacarotene biosynthetic process","canonical_id":"go:GO:1901821","description":"\"The chemical reactions and pathways resulting in the formation of alpha-zeacarotene.\" [GOC:TermGenie, GOC:yaf, PMID:6060456, UniPathway:UPA00804]","metadata":null},{"id":"5fde12b4ed254b08a9cc3dd368a50a6f","type":"GO_TERM","name":"alpha-zeacarotene catabolic process","canonical_id":"go:GO:1901820","description":"\"The chemical reactions and pathways resulting in the breakdown of alpha-zeacarotene.\" [GOC:TermGenie, GOC:yaf, PMID:6060456, UniPathway:UPA00804]","metadata":null},{"id":"72c4d73d55ac4a218d08671e9faa7a9d","type":"GO_TERM","name":"alpha-zingiberene synthase activity","canonical_id":"go:GO:0102884","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = zingiberene + diphosphoric acid.\" [EC:4.2.3.65, GOC:pz]","metadata":null},{"id":"3b3efaa51e6a404e941149fefd00e883","type":"GO_TERM","name":"alpha1-adrenergic receptor activity","canonical_id":"go:GO:0004937","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha1-adrenergic receptors; the activity involves transmitting the signal to the Gq alpha subunit of a heterotrimeric G protein.\" [GOC:cb, GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"71a0480aea9647069d438e8052db5504","type":"GO_TERM","name":"alpha1-beta1 integrin-alpha3(VI) complex","canonical_id":"go:GO:0070465","description":"\"A protein complex that consists of an alpha1-beta1 integrin complex bound to a type VI collagen triple helix containing an alpha3(VI) chain.\" [PMID:8387021]","metadata":null},{"id":"b96983446c394acbbdbd6274da3259d6","type":"GO_TERM","name":"alpha1-beta1 integrin-tissue transglutaminase complex","canonical_id":"go:GO:0071091","description":"\"A protein complex that consists of an alpha1-beta1 integrin complex bound to tissue transglutaminase.\" [PMID:10684262]","metadata":null},{"id":"d87f2724a46e46f18acdd58b389b522a","type":"GO_TERM","name":"alpha1-beta1 integrin-tyrosine-protein phosphatase non-receptor type 2 complex","canonical_id":"go:GO:0071124","description":"\"A protein complex that consists of an alpha1-beta1 integrin complex bound to tyrosine-protein phosphatase non-receptor type 2.\" [PMID:15592458]","metadata":null},{"id":"be813f0b81014ef6b891cc7ad358d223","type":"DRUG","name":"alpha1-proteinase inhibitor","canonical_id":"gtopdb:7487","description":null,"metadata":null},{"id":"667193733415426ea7e772766ef79f6d","type":"DRUG","name":"alpha1-proteinase inhibitor","canonical_id":"chembl:CHEMBL4297879","description":null,"metadata":null},{"id":"d75e22fb804046a693fdda0143d8853c","type":"GO_TERM","name":"alpha11-beta1 integrin-collagen type I complex","canonical_id":"go:GO:0071087","description":"\"A protein complex that consists of an alpha11-beta1 integrin complex bound to a type I collagen.\" [PMID:10464311]","metadata":null},{"id":"91b18f4401db4ab5a8fb88c11a41c60d","type":"GO_TERM","name":"alpha2-adrenergic receptor activity","canonical_id":"go:GO:0004938","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha2-adrenergic receptors; the activity involves transmitting the signal to the Gi alpha subunit of a heterotrimeric G protein.\" [GOC:cb, GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"09ecaab627d340af806a190117ab6a63","type":"GO_TERM","name":"alpha2-beta1 integrin-CD47 complex","canonical_id":"go:GO:0071084","description":"\"A protein complex that consists of an alpha2-beta1 integrin complex bound to the cell surface protein CD47.\" [PMID:10397731]","metadata":null},{"id":"c0da59de54ed4b5aa4b3043191193a4d","type":"GO_TERM","name":"alpha2-beta1 integrin-alpha3(VI) complex","canonical_id":"go:GO:0070466","description":"\"A protein complex that consists of an alpha2-beta1 integrin complex bound to a type VI collagen triple helix containing an alpha3(VI) chain.\" [PMID:8387021]","metadata":null},{"id":"4531bdc7ae9f44c6902bc38df4ccae4d","type":"GO_TERM","name":"alpha2-beta1 integrin-chondroadherin complex","canonical_id":"go:GO:0071079","description":"\"A protein complex that consists of an alpha2-beta1 integrin complex bound to the cartilage matrix protein chondroadherin.\" [PMID:9281592]","metadata":null},{"id":"c3080ece62e7482d9f8affbf89d0e21d","type":"GO_TERM","name":"alpha3-beta1 integrin-CD151 complex","canonical_id":"go:GO:0071058","description":"\"A protein complex that consists of an alpha3-beta1 integrin complex bound to the tetraspanin CD151.\" [PMID:10811835, PMID:11884516]","metadata":null},{"id":"995f6de5ea704822a1e1c8448ec745b3","type":"GO_TERM","name":"alpha3-beta1 integrin-CD63 complex","canonical_id":"go:GO:0071081","description":"\"A protein complex that consists of an alpha3-beta1 integrin complex bound to the tetraspanin CD63.\" [PMID:7629079]","metadata":null},{"id":"d944f0ae7c9f48a2b49337af8d5ac6f5","type":"GO_TERM","name":"alpha3-beta1 integrin-basigin complex","canonical_id":"go:GO:0071080","description":"\"A protein complex that consists of an alpha3-beta1 integrin complex bound to the cell surface protein basigin.\" [PMID:9360995]","metadata":null},{"id":"3f097013ee1a49039bb68309f3f1af6d","type":"GO_TERM","name":"alpha3-beta1 integrin-thrombospondin complex","canonical_id":"go:GO:0071095","description":"\"A protein complex that consists of an alpha3-beta1 integrin complex bound to thrombospondin.\" [PMID:11358957]","metadata":null},{"id":"eb6753377831486eac427585ea05c092","type":"GO_TERM","name":"alpha3-beta1 integrin-tissue transglutaminase complex","canonical_id":"go:GO:0071092","description":"\"A protein complex that consists of an alpha3-beta1 integrin complex bound to tissue transglutaminase.\" [PMID:10684262]","metadata":null},{"id":"092629d9f51a4110badc1741a24b2e3f","type":"GO_TERM","name":"alpha4-beta1 integrin-CD47 complex","canonical_id":"go:GO:0071120","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to the cell surface antigen CD47.\" [PMID:15292185]","metadata":null},{"id":"8da6fe8ed2a24563a273d6c237c11ce1","type":"GO_TERM","name":"alpha4-beta1 integrin-CD53 complex","canonical_id":"go:GO:0070518","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to membrane protein CD53, a member of the tetraspan family.\" [PMID:8757325]","metadata":null},{"id":"f8e317dffd7f4ad4b152e4b1eedb3911","type":"GO_TERM","name":"alpha4-beta1 integrin-CD63 complex","canonical_id":"go:GO:0070519","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to membrane protein CD63, a member of the tetraspan family.\" [PMID:8757325]","metadata":null},{"id":"b90e16ae04cf4068ae5dbcd0606d8930","type":"GO_TERM","name":"alpha4-beta1 integrin-CD81 complex","canonical_id":"go:GO:0070520","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to membrane protein CD81, a member of the tetraspan family.\" [PMID:10229664, PMID:8757325]","metadata":null},{"id":"f68f0e11fb4e43889776411c22613f14","type":"GO_TERM","name":"alpha4-beta1 integrin-CD82 complex","canonical_id":"go:GO:0070521","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to membrane protein CD82, a member of the tetraspan family.\" [PMID:8757325]","metadata":null},{"id":"26fcad29415645cfa86e07005f6a22d7","type":"GO_TERM","name":"alpha4-beta1 integrin-JAM2 complex","canonical_id":"go:GO:0071101","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to the cell adhesion molecule JAM2.\" [PMID:12070135]","metadata":null},{"id":"0ba71e7b66744e859e898f08c3c09c5a","type":"GO_TERM","name":"alpha4-beta1 integrin-paxillin complex","canonical_id":"go:GO:0071102","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to paxillin.\" [PMID:12221126]","metadata":null},{"id":"3dfc98ad42c94db7a4019bd526e4192c","type":"GO_TERM","name":"alpha4-beta1 integrin-thrombospondin-1 complex","canonical_id":"go:GO:0071069","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to thrombospondin-1.\" [PMID:11980922]","metadata":null},{"id":"12b0e55c61584a8ca245ce06848c254f","type":"GO_TERM","name":"alpha4-beta1 integrin-thrombospondin-2 complex","canonical_id":"go:GO:0071070","description":"\"A protein complex that consists of an alpha4-beta1 integrin complex bound to thrombospondin-2.\" [PMID:11980922]","metadata":null},{"id":"7433d70377f545528bb3d3ce372e3e4f","type":"GO_TERM","name":"alpha4-beta4 integrin-EMILIN-1 complex","canonical_id":"go:GO:0071112","description":"\"A protein complex that consists of an alpha4-beta4 integrin complex bound to EMILIN-1 (ElastinMicrofibril Interface Located ProteIN).\" [PMID:12456677]","metadata":null},{"id":"96275396c7744328ae12004de77dafb9","type":"GO_TERM","name":"alpha5-beta1 integrin-LPP3 complex","canonical_id":"go:GO:0071130","description":"\"A protein complex that consists of an alpha5-beta1 integrin complex bound to lipid phosphate phosphohydrolase-3.\" [PMID:16099422]","metadata":null},{"id":"b6d59db215164078a3f0eecc394e8a28","type":"GO_TERM","name":"alpha5-beta1 integrin-endostatin complex","canonical_id":"go:GO:0071115","description":"\"A protein complex that consists of an alpha5-beta1 integrin complex bound to endostatin, the NC1 domain of the alpha1 chain of type XVIII collagen.\" [PMID:12682293]","metadata":null},{"id":"b8a80cc8adf24d198b5dca9939466be7","type":"GO_TERM","name":"alpha5-beta1 integrin-fibronectin-NOV complex","canonical_id":"go:GO:0071117","description":"\"A protein complex that consists of an alpha5-beta1 integrin complex bound to fibronectin and the extracellular matrix protein NOV.\" [PMID:12902636]","metadata":null},{"id":"796b41306c2a458fa2bf61d3e6bd8c63","type":"GO_TERM","name":"alpha5-beta1 integrin-fibronectin-tissue transglutaminase complex","canonical_id":"go:GO:0071093","description":"\"A protein complex that consists of an alpha5-beta1 integrin complex bound to fibronectin and tissue transglutaminase.\" [PMID:10684262]","metadata":null},{"id":"16cc4f8366684b05aaf0ecb257714f8a","type":"GO_TERM","name":"alpha5-beta1 integrin-osteopontin complex","canonical_id":"go:GO:0071128","description":"\"A protein complex that consists of an alpha5-beta1 integrin complex bound to osteopontin.\" [PMID:16005200]","metadata":null},{"id":"8c6573035e3a4ee0a3e08e778cedec78","type":"GO_TERM","name":"alpha5-beta1 integrin-tissue transglutaminase complex","canonical_id":"go:GO:0071088","description":"\"A protein complex that consists of an alpha5-beta1 integrin complex bound to tissue transglutaminase.\" [PMID:10684262]","metadata":null},{"id":"de2ff9c255a54068801992cdabb3ad22","type":"GO_TERM","name":"alpha5-beta5-fibronectin-SFRP2 complex","canonical_id":"go:GO:0071138","description":"\"A protein complex that consists of an alpha5-beta5 integrin complex bound to fibronectin and secreted frizzled-related protein 2.\" [PMID:14709558]","metadata":null},{"id":"b382f3bb7ed047b68c16806617225079","type":"GO_TERM","name":"alpha6-beta1 integrin-CD151 complex","canonical_id":"go:GO:0071059","description":"\"A protein complex that consists of an alpha6-beta1 integrin complex bound to the tetraspanin CD151.\" [PMID:11884516]","metadata":null},{"id":"a8bce23cec64486f9fec87964e31c227","type":"GO_TERM","name":"alpha6-beta1 integrin-CYR61 complex","canonical_id":"go:GO:0071116","description":"\"A protein complex that consists of an alpha6-beta1 integrin complex bound to CYR61, a cysteine-rich protein involved in angiogenesis.\" [PMID:12826661]","metadata":null},{"id":"259d28832b704a9396dabcba50cfb48f","type":"GO_TERM","name":"alpha6-beta4 integrin-CD151 complex","canonical_id":"go:GO:0071061","description":"\"A protein complex that consists of an alpha6-beta4 integrin complex bound to the tetraspanin CD151.\" [PMID:10811835]","metadata":null},{"id":"e139323acfad428d856883e43eef09f7","type":"GO_TERM","name":"alpha6-beta4 integrin-CD9 complex","canonical_id":"go:GO:0071094","description":"\"A protein complex that consists of an alpha6-beta4 integrin complex bound to the cell surface protein CD9.\" [PMID:10711425]","metadata":null},{"id":"2559be7fac0b43ebb71cdfe0aef41eaf","type":"GO_TERM","name":"alpha6-beta4 integrin-Fyn complex","canonical_id":"go:GO:0071098","description":"\"A protein complex that consists of an alpha6-beta4 integrin complex bound to the Src family tyrosine kinase Fyn.\" [PMID:11684709]","metadata":null},{"id":"f5261bfb1cee4d609ef9248a5aced7b2","type":"GO_TERM","name":"alpha6-beta4 integrin-Shc-Grb2 complex","canonical_id":"go:GO:0070333","description":"\"A protein complex that consists of an alpha6-beta4 integrin complex bound to the adaptor proteins Shc and Grb2.\" [PMID:7556090]","metadata":null},{"id":"c78d1ca4621449a0abbfa724f79bfcce","type":"GO_TERM","name":"alpha6-beta4 integrin-laminin 5 complex","canonical_id":"go:GO:0070334","description":"\"A protein complex that consists of an alpha6-beta4 integrin complex bound to laminin 5.\" [GOC:mah, PMID:7556090]","metadata":null},{"id":"48061ba38bec40dda9e5691fb1c798bc","type":"GO_TERM","name":"alpha7-beta1 integrin-CD151 complex","canonical_id":"go:GO:0071060","description":"\"A protein complex that consists of an alpha7-beta1 integrin complex bound to the tetraspanin CD151.\" [PMID:11884516]","metadata":null},{"id":"6c69b7e5f4c64bb5a9b9c9d809a0f1af","type":"GO_TERM","name":"alpha7-beta1 integrin-focal adhesion kinase complex","canonical_id":"go:GO:0071135","description":"\"A protein complex that consists of an alpha7-beta1 integrin complex bound to focal adhesion kinase.\" [PMID:17598176]","metadata":null},{"id":"6df3cfbe7f5d4737854634a1b63cd332","type":"GO_TERM","name":"alpha7-beta1 integrin-laminin alpha-2 complex","canonical_id":"go:GO:0071136","description":"\"A protein complex that consists of an alpha7-beta1 integrin complex bound to laminin alpha-2.\" [PMID:17598176]","metadata":null},{"id":"2a1de4d27d3d46038df2844b5ebb4404","type":"GO_TERM","name":"alpha7-beta1 integrin-nicotinamide riboside kinase complex","canonical_id":"go:GO:0071119","description":"\"A protein complex that consists of an alpha7-beta1 integrin complex bound to nicotinamide riboside kinase 2 (also known as muscle integrin binding protein, MIBP).\" [PMID:12941630]","metadata":null},{"id":"99dd24077af34f1fb6627017936778c7","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM1 complex","canonical_id":"go:GO:0071052","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM1.\" [PMID:11882657]","metadata":null},{"id":"3649e89a98d6445ba143d857299b1b25","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM12 complex","canonical_id":"go:GO:0071068","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM12.\" [PMID:10944520]","metadata":null},{"id":"280014001e4043a8b674fe7cf3f60058","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM15 complex","canonical_id":"go:GO:0071056","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM15.\" [PMID:11882657]","metadata":null},{"id":"a3fe1c0389f6495da9e024017256797b","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM2 complex","canonical_id":"go:GO:0071053","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM2.\" [PMID:11882657]","metadata":null},{"id":"3192667279f3426081ffc82ab6cd0e1e","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM3 complex","canonical_id":"go:GO:0071054","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM3.\" [PMID:11882657]","metadata":null},{"id":"d3d1631437f54a98b94436df56f9d016","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM8 complex","canonical_id":"go:GO:0071133","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM8.\" [PMID:16995821]","metadata":null},{"id":"2e9bd596640a40a8bd6310110018a04a","type":"GO_TERM","name":"alpha9-beta1 integrin-ADAM9 complex","canonical_id":"go:GO:0071055","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM9.\" [PMID:11882657]","metadata":null},{"id":"6d61b3699bd14e259a980c86304b57d5","type":"GO_TERM","name":"alpha9-beta1 integrin-VEGF-A complex","canonical_id":"go:GO:0071122","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to vascular endothelial growth factor A.\" [PMID:17363377]","metadata":null},{"id":"77d9352da46147dbb2ca79175616c097","type":"GO_TERM","name":"alpha9-beta1 integrin-VEGF-C complex","canonical_id":"go:GO:0071123","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to vascular endothelial growth factor C.\" [PMID:15590642]","metadata":null},{"id":"52489d25d1d640e58fbe18f8fa7a80d9","type":"GO_TERM","name":"alpha9-beta1 integrin-VEGF-D complex","canonical_id":"go:GO:0071121","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to vascular endothelial growth factor D.\" [PMID:15590642]","metadata":null},{"id":"d9a94fce7e984bcba492e976e2b0f98a","type":"GO_TERM","name":"alpha9-beta1 integrin-osteopontin complex","canonical_id":"go:GO:0071127","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to osteopontin.\" [PMID:16005200]","metadata":null},{"id":"b771f61e266f48d491c5dd921940bcb8","type":"GO_TERM","name":"alpha9-beta1 integrin-tenascin complex","canonical_id":"go:GO:0071082","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to the extracellular matrix protein tenascin.\" [PMID:9565552]","metadata":null},{"id":"2dd07e945b154c2d8c7b0215f9be7a61","type":"GO_TERM","name":"alpha9-beta1 integrin-thrombospondin-1 complex","canonical_id":"go:GO:0071134","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to thrombospondin-1.\" [PMID:17413041]","metadata":null},{"id":"810d5095f78a4ccb9591625ad61353fc","type":"GO_TERM","name":"alpha9-beta1 integrin-vascular cell adhesion molecule-1 complex","canonical_id":"go:GO:0071065","description":"\"A protein complex that consists of an alpha9-beta1 integrin complex bound to vascular cell adhesion molecule-1.\" [PMID:10209034]","metadata":null},{"id":"f8952af249654ed7a5134cd81c2f71f0","type":"GO_TERM","name":"alphaE-beta7 integrin-E-cadherin complex","canonical_id":"go:GO:0071064","description":"\"A protein complex that consists of an alphaE-beta7 integrin complex bound to E-cadherin.\" [PMID:10837471]","metadata":null},{"id":"06679f67c6624ce09209661ba6881981","type":"GO_TERM","name":"alphaIIb-beta3 integrin-CD47-FAK complex","canonical_id":"go:GO:0070770","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to the cell surface antigen CD47 and the kinase FAK.\" [PMID:9169439]","metadata":null},{"id":"dc0cfd1ddd3b4aac84823a13c095838c","type":"GO_TERM","name":"alphaIIb-beta3 integrin-CD47-Src complex","canonical_id":"go:GO:0070771","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to the cell surface antigen CD47 and the kinase c-Src.\" [PMID:9169439]","metadata":null},{"id":"f9cf1b1755984cb98bc5a76810980c3c","type":"GO_TERM","name":"alphaIIb-beta3 integrin-CD9 complex","canonical_id":"go:GO:0071085","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to the cell surface protein CD9.\" [PMID:10429193]","metadata":null},{"id":"9e21643a18cd40d8a287bba21df3908d","type":"GO_TERM","name":"alphaIIb-beta3 integrin-CD9-CD47-platelet glycoprotein Ib complex","canonical_id":"go:GO:0071086","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to the cell surface proteins CD9 and CD47, and the heterodimeric platelet glycoprotein Ib.\" [PMID:10429193]","metadata":null},{"id":"85ff1ae680ce4ff0be45f780de587b9e","type":"GO_TERM","name":"alphaIIb-beta3 integrin-CIB complex","canonical_id":"go:GO:0070769","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to CIB, a protein that binds calcium as well as the alphaIIb-beta3 integrin.\" [PMID:9030514]","metadata":null},{"id":"a0468df8f86e46389e2823cace75f21e","type":"GO_TERM","name":"alphaIIb-beta3 integrin-ICAM-4 complex","canonical_id":"go:GO:0071113","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to the cell adhesion molecule ICAM-4.\" [PMID:12477717]","metadata":null},{"id":"2b281204dfdd4829962c10ba282e88a2","type":"GO_TERM","name":"alphaIIb-beta3 integrin-fibronectin-tissue transglutaminase complex","canonical_id":"go:GO:0071090","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to fibronectin and tissue transglutaminase.\" [PMID:10684262]","metadata":null},{"id":"16104311ad674270a6f9836ae90b32e2","type":"GO_TERM","name":"alphaIIb-beta3 integrin-talin complex","canonical_id":"go:GO:0070515","description":"\"A protein complex that consists of an alphaIIb-beta3 integrin complex bound to talin.\" [PMID:8663236]","metadata":null},{"id":"6480f90079f94725b528cbddea887ef1","type":"GO_TERM","name":"alphaM-beta2 integrin-CD63 complex","canonical_id":"go:GO:0070558","description":"\"A protein complex that consists of an alphaM-beta2 integrin complex bound to membrane protein CD63, a member of the tetraspan family.\" [PMID:8871662]","metadata":null},{"id":"cd5485502e8c4ade90e314aa132ab8f0","type":"GO_TERM","name":"alphaPDGFR-PLC-gamma-1-PI3K-SHP-2 complex","canonical_id":"go:GO:0070719","description":"\"A protein complex that contains the platelet-derived growth factor alpha receptor (alphaPDGFR; PDGFRA), phospholipase C-gamma-1 (PLC-gamma-1), phosphatidylinositol 3-kinase (PI3K) and the adaptor protein SHP-2, and is involved signaling via the PDGFR signaling pathway.\" [GOC:mah, PMID:8943348]","metadata":null},{"id":"adee8f7f41c548d5899c815482f52629","type":"GO_TERM","name":"alphaPDGFR-SHP-2 complex","canonical_id":"go:GO:0070718","description":"\"A protein complex that contains the platelet-derived growth factor alpha receptor (alphaPDGFR; PDGFRA) and the adaptor protein SHP-2, and is involved signaling via the PDGFR signaling pathway.\" [GOC:mah, PMID:8943348]","metadata":null},{"id":"ca0a5e88b025427bad508e85324a4f8f","type":"GO_TERM","name":"alphaV-beta3 integrin-CD47-FCER2 complex","canonical_id":"go:GO:0071083","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to the cell surface protein CD47 and the low-affinity immunoglobulin epsilon Fc receptor (FCER2).\" [PMID:10037797]","metadata":null},{"id":"a549a1e0bc5f483fa35a659d89653f2a","type":"GO_TERM","name":"alphaV-beta3 integrin-CD98 complex","canonical_id":"go:GO:0071137","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to the cell surface antigen CD98.\" [PMID:18032696]","metadata":null},{"id":"1325fd79bd3a4373b7eae6b7e6ccdfae","type":"GO_TERM","name":"alphaV-beta3 integrin-EGFR complex","canonical_id":"go:GO:0071125","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to epidermal growth factor receptor.\" [PMID:15834425]","metadata":null},{"id":"bd4346e0d0994129ad14e6f2b8ce305a","type":"GO_TERM","name":"alphaV-beta3 integrin-LPP3 complex","canonical_id":"go:GO:0071129","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to lipid phosphate phosphohydrolase-3.\" [PMID:16099422]","metadata":null},{"id":"ebc509f1636447cdaef043ee6c9ea7de","type":"GO_TERM","name":"alphaV-beta3 integrin-NOV complex","canonical_id":"go:GO:0071118","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to the extracellular matrix protein NOV.\" [PMID:12902636]","metadata":null},{"id":"aabc933fe7c3451da7a5b945c162a0f6","type":"GO_TERM","name":"alphaV-beta3 integrin-gelsolin complex","canonical_id":"go:GO:0071096","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to gelsolin.\" [PMID:11577104]","metadata":null},{"id":"ed5b3d67e1124402a5c174ded9f7641a","type":"GO_TERM","name":"alphaV-beta3 integrin-laminin alpha-4 complex","canonical_id":"go:GO:0071131","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to laminin alpha-4.\" [PMID:16824487]","metadata":null},{"id":"8b5e866ae0364ee28349e19b5027ac7d","type":"GO_TERM","name":"alphaV-beta3 integrin-paxillin-Pyk2 complex","canonical_id":"go:GO:0071097","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to paxillin and the FAK-related kinase Pyk2.\" [PMID:11683411]","metadata":null},{"id":"93b9bbbdb19d464eba5dd55545347d52","type":"GO_TERM","name":"alphaV-beta3 integrin-tissue transglutaminase complex","canonical_id":"go:GO:0071089","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to tissue transglutaminase.\" [PMID:10684262]","metadata":null},{"id":"fc75042a256c44839eeb833bb46f01ff","type":"GO_TERM","name":"alphaV-beta3 integrin-tumstatin complex","canonical_id":"go:GO:0071114","description":"\"A protein complex that consists of an alphaV-beta3 integrin complex bound to tumstatin, the NC1 domain of the alpha3 chain of type IV collagen.\" [PMID:12682293]","metadata":null},{"id":"ffb780189bca4639b2ea339db2be568d","type":"GO_TERM","name":"alphaV-beta6 integrin-TGFbeta-3 complex","canonical_id":"go:GO:0071099","description":"\"A protein complex that consists of an alphaV-beta6 integrin complex bound to transforming growth factor beta-3 (TGFbeta-3).\" [PMID:11821050]","metadata":null},{"id":"90d81d7f47314d8cbb8df8972c772165","type":"GO_TERM","name":"alphaV-beta6 integrin-osteopontin complex","canonical_id":"go:GO:0071126","description":"\"A protein complex that consists of an alphaV-beta6 integrin complex bound to osteopontin.\" [PMID:16005200]","metadata":null},{"id":"cfebafc336c14534a7c13390a740b463","type":"GO_TERM","name":"alphaV-beta8 integrin-MMP14-TGFbeta-1 complex","canonical_id":"go:GO:0071100","description":"\"A protein complex that consists of an alphaV-beta8 integrin complex bound to matrix metalloproteinase 14 and transforming growth factor beta-1 (TGFbeta-1).\" [PMID:11970960]","metadata":null},{"id":"38a76c18ef1b4dad939489811d69ca07","type":"GO_TERM","name":"alphaX-beta2 integrin-ICAM-4 complex","canonical_id":"go:GO:0071132","description":"\"A protein complex that consists of an alphaX-beta2 integrin complex bound to intercellular adhesion molecule 4.\" [PMID:16985175]","metadata":null},{"id":"d4fdef7e584240c19406a1ee7791e7bb","type":"GO_TERM","name":"alphav-beta1 integrin-osteopontin complex","canonical_id":"go:GO:0070030","description":"\"A protein complex that consists of an alphav-beta1 integrin complex bound to osteopontin.\" [PMID:7592829]","metadata":null},{"id":"c16232be3268463d8686f590220e150a","type":"GO_TERM","name":"alphav-beta3 integrin-ADAM15 complex","canonical_id":"go:GO:0071057","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to the transmembrane metallopeptidase ADAM15.\" [PMID:10944520, PMID:11882657]","metadata":null},{"id":"9ed4fd1284a54a5ab25d9128ded5d4a7","type":"GO_TERM","name":"alphav-beta3 integrin-ADAM23 complex","canonical_id":"go:GO:0071067","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to the transmembrane metallopeptidase ADAM23.\" [PMID:10749942]","metadata":null},{"id":"74be01ff208846e0a830fed7a7a6f2fd","type":"GO_TERM","name":"alphav-beta3 integrin-CD47 complex","canonical_id":"go:GO:0070357","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to CD47 (also known as IAP).\" [PMID:2277087, PMID:7691831]","metadata":null},{"id":"6f268902f4274d6abe41321ea6c8715f","type":"GO_TERM","name":"alphav-beta3 integrin-HMGB1 complex","canonical_id":"go:GO:0035868","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to high mobility group box 1 protein.\" [GOC:BHF, GOC:ebc, PMID:20826760]","metadata":null},{"id":"402edc2afe8c4bc08fac5ea003dec0e4","type":"GO_TERM","name":"alphav-beta3 integrin-IGF-1-IGF1R complex","canonical_id":"go:GO:0035867","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to insulin-like growth factor-1 (IGF-1) and type I insulin-like growth factor receptor (IGF1R). IGF1R is a heterotetramer that consists of two alpha-subunits and two beta-subunits.\" [GOC:BHF, GOC:ebc, PMID:19578119]","metadata":null},{"id":"4139cf3946f84a90a3b92746364b8244","type":"GO_TERM","name":"alphav-beta3 integrin-PKCalpha complex","canonical_id":"go:GO:0035866","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to protein kinase C alpha.\" [GOC:BHF, GOC:ebc, PMID:16014375]","metadata":null},{"id":"6bb7bdbb71ee4ff39a2e219c23c2e06b","type":"GO_TERM","name":"alphav-beta3 integrin-collagen alpha3(VI) complex","canonical_id":"go:GO:0070464","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to the alpha3 chain of type VI collagen; the integrin binds most strongly to unfolded collagen.\" [PMID:8387021]","metadata":null},{"id":"ac5190841971454185582c25497c8d46","type":"GO_TERM","name":"alphav-beta3 integrin-osteopontin complex","canonical_id":"go:GO:0070029","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to osteopontin.\" [PMID:7532190]","metadata":null},{"id":"aa90c3613c144fa398d0e494cc433db0","type":"GO_TERM","name":"alphav-beta3 integrin-thrombospondin complex","canonical_id":"go:GO:0070017","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to thrombospondin.\" [PMID:2478219]","metadata":null},{"id":"6d7d14058dc04d5da5cdb163dd3c67f9","type":"GO_TERM","name":"alphav-beta3 integrin-vitronectin complex","canonical_id":"go:GO:0071062","description":"\"A protein complex that consists of an alphav-beta3 integrin complex bound to vitronectin.\" [PMID:10835423]","metadata":null},{"id":"94ba069468884f7d83b4d4e773c255f1","type":"GO_TERM","name":"alphav-beta5 integrin-osteopontin complex","canonical_id":"go:GO:0070031","description":"\"A protein complex that consists of an alphav-beta5 integrin complex bound to osteopontin.\" [PMID:7592829]","metadata":null},{"id":"610314e9afe94e03bb39a15480c61f5d","type":"GO_TERM","name":"alphav-beta5 integrin-vitronectin complex","canonical_id":"go:GO:0034997","description":"\"A protein complex that comprises one integrin alphav subunit, one integrin beta5 subunit, and vitronectin.\" [PMID:1694173]","metadata":null},{"id":"49a00a4279ac4254b08aca76b06619a1","type":"DRUG","name":"alprenolol","canonical_id":"gtopdb:563","description":null,"metadata":null},{"id":"325252cb5dcb4d6a87286080941b9c27","type":"GO_TERM","name":"alternate splicing of immunoglobulin genes","canonical_id":"go:GO:0002564","description":"\"The generation of alternate transcripts of immunoglobulin genes through alternate splicing of exons.\" [ISBN:0781735149, PMID:9185563]","metadata":null},{"id":"268f8969e6e544dba5ba9c76584c5aad","type":"GO_TERM","name":"alternative mRNA splicing, via spliceosome","canonical_id":"go:GO:0000380","description":"\"The process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition.\" [GOC:krc, PMID:12110900]","metadata":null},{"id":"503a6d6ee7e14af08ecda3c4b8449e48","type":"GO_TERM","name":"alternative oxidase activity","canonical_id":"go:GO:0009916","description":"\"Catalysis of the oxidation of ubiquinol by diverting electrons from the standard electron transfer chain, transferring them from ubiquinol to oxygen and generating water as the product.\" [ISBN:0943088399]","metadata":null},{"id":"b5ca3e38e3894589a8f4e18493e09d83","type":"GO_TERM","name":"alternative respiration","canonical_id":"go:GO:0010230","description":"\"Alternative respiration pathway consumes oxygen, oxidizes NADH to NAD+ and generates water. During electron flow, proton motive force is diminished resulting in fewer molecules of ATP compared to cytochrome pathway. The pathway is found in plants, algae and some protozoa.\" [ISBN:0943088399]","metadata":null},{"id":"228d225ad83c430cbeb80ef59509ee98","type":"DISEASE","name":"altitude sickness","canonical_id":"mondo:0006625","description":null,"metadata":null},{"id":"beaef839638f4b29ad40917b284e60ab","type":"GO_TERM","name":"altronate dehydratase activity","canonical_id":"go:GO:0008789","description":"\"Catalysis of the reaction: D-altronate = 2-dehydro-3-deoxy-D-gluconate + H2O.\" [EC:4.2.1.7, RHEA:15957]","metadata":null},{"id":"9650c727c5b7404695d4f519e6b86499","type":"GO_TERM","name":"altruistic, chimeric sorocarp development","canonical_id":"go:GO:0099138","description":"\"Development of a chimeric sorocarp in which cells of all genotypes have an equal chance of becoming a spore cell.\" [PMID:18272966]","metadata":null},{"id":"8945316e0b8445f3860b21a043c124de","type":"GO_TERM","name":"altruistic, chimeric, non-reproductive fruiting body development","canonical_id":"go:GO:0099137","description":"\"Development of a chimeric, non-reproductive fruiting body in which cells of all genotypes have an equal chance of becoming a spore cell.\" [PMID:18272966]","metadata":null},{"id":"b8b3d295821141f3a06545295598f630","type":"DRUG","name":"alum","canonical_id":"mesh:D000534","description":null,"metadata":null},{"id":"091273b446014857985d27d8752fca93","type":"GO_TERM","name":"aluminum cation transport","canonical_id":"go:GO:0015690","description":"\"The directed movement of aluminum (Al) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"656cd3593bd94ea0b9e780918808a311","type":"GO_TERM","name":"aluminum ion transmembrane transport","canonical_id":"go:GO:1902602","description":"\"The directed movement of aluminium ions across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"5c94e96d8fa54973909b781391d66428","type":"GO_TERM","name":"aluminum ion transmembrane transporter activity","canonical_id":"go:GO:0015083","description":"\"Enables the transfer of aluminum (Al) ions from one side of a membrane to the other.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"c2c8fadb02054b0bb5e46871a7607bb1","type":"GO_TERM","name":"alveolar lamellar body","canonical_id":"go:GO:0097208","description":"\"A specialized secretory organelle found in type II pneumocytes and involved in the synthesis, secretion, and reutilization of pulmonary surfactant.\" [GOC:cjm, Wikipedia:Lamellar_granule]","metadata":null},{"id":"465f492d70204fb2bfdc860664746c4c","type":"GO_TERM","name":"alveolar lamellar body membrane","canonical_id":"go:GO:0097233","description":"\"The lipid bilayer surrounding an alveolar lamellar body, a specialized secretory organelle found in type II pneumocytes and involved in the synthesis, secretion, and reutilization of pulmonary surfactant.\" [GOC:sl, PMID:11940594]","metadata":null},{"id":"5a17f347fd984eca978cc43c63099ee8","type":"GO_TERM","name":"alveolar primary septum development","canonical_id":"go:GO:0061143","description":"\"The progression of a primary alveolar septum over time, from its formation to the mature structure. A primary alveolar septum is a specialized epithelium that surrounds the saccule as it forms.\" [GOC:dph]","metadata":null},{"id":"fc4a77394aa94ab68c5c11a31e376a04","type":"GO_TERM","name":"alveolar secondary septum development","canonical_id":"go:GO:0061144","description":"\"The progression of a secondary alveolar septum over time, from its formation to the mature structure. A secondary alveolar septum is a specialized epithelium that subdivides the initial saccule.\" [GOC:dph]","metadata":null},{"id":"3aa1775ecbaf4874b46ae2385a882033","type":"DRUG","name":"alvimopan","canonical_id":"gtopdb:7471","description":null,"metadata":null},{"id":"3b84f35b24034afc9431e57f89d08b81","type":"DRUG","name":"alvimopan","canonical_id":"chembl:CHEMBL270190","description":null,"metadata":null},{"id":"db21b26dae364011bc63e2d83545f920","type":"GO_TERM","name":"amacrine cell differentiation","canonical_id":"go:GO:0035881","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an amacrine cell, an interneuron generated in the inner nuclear layer (INL) of the vertebrate retina. Amacrine cells integrate, modulate, and interpose a temporal domain in the visual message presented to the retinal ganglion cells, with which they synapse in the inner plexiform layer. Amacrine cells lack large axons.\" [CL:0000561, GOC:bf]","metadata":null},{"id":"af3ced88bb6b4f5e8d11c693b4c85a35","type":"DRUG","name":"amantadine","canonical_id":"gtopdb:4128","description":null,"metadata":null},{"id":"33897f77f68f43eeaf6cf6cb1d7698cc","type":"GO_TERM","name":"amastigogenesis","canonical_id":"go:GO:0120310","description":"\"The morphological, biochemical and genetic changes that induce the differentiation of metacyclic parasites into amastigotes in some of the Trypanosomatidae species such as Leishmania parasites and Trypanosoma cruzi. This process occurs inside the cells of the mammalian hosts, particularly in macrophages and other phagocytic cells for Leishmania parasites.\" [DOI:10.5772/intechopen.84639, GOC:ach, GOC:krc, PMID:12377273, PMID:13129524, PMID:26752404]","metadata":null},{"id":"9a8c4d8b8e9d43e5b4a8c8922dc0a4e5","type":"DRUG","name":"ambenonium","canonical_id":"mesh:D000549","description":null,"metadata":null},{"id":"33c5cd2fe43f448b8a04017f8ad11d8d","type":"DRUG","name":"ambrisentan","canonical_id":"gtopdb:3951","description":null,"metadata":null},{"id":"2adc9ced44274b1b97cc67a57e9eacfa","type":"DRUG","name":"ambrisentan","canonical_id":"mesh:C467894","description":null,"metadata":null},{"id":"b97a8c08fc47444da80590289f6f6bdf","type":"DRUG","name":"ambrisentan","canonical_id":"chembl:CHEMBL1111","description":null,"metadata":null},{"id":"fa4a74afeaad4c03bbf0514f687e8f5b","type":"COMBINATION_TREATMENT","name":"ambrisentan + bosentan","canonical_id":"ctgov_combo:ctgov-combo-0fae01fc09e50d73","description":null,"metadata":null},{"id":"c1212c29b7e145c887332a4d9a4f5350","type":"COMBINATION_TREATMENT","name":"ambrisentan + bosentan","canonical_id":"ctgov_combo:ctgov-combo-fece1db247d726f8","description":null,"metadata":null},{"id":"f7588b5a63ca4550bc5317893cef8e6a","type":"COMBINATION_TREATMENT","name":"ambrisentan + bosentan + sitaxsentan","canonical_id":"ctgov_combo:ctgov-combo-88920d8cb12b3f0c","description":null,"metadata":null},{"id":"b14473a145bf4b57bf9042e6edd25818","type":"COMBINATION_TREATMENT","name":"ambrisentan + macitentan + treprostinil","canonical_id":"ctgov_combo:ctgov-combo-cc7c4a46b689ce7e","description":null,"metadata":null},{"id":"d7b7c486422348d0ae00a995f4f107c2","type":"COMBINATION_TREATMENT","name":"ambrisentan + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-2d3e5d269000cd77","description":null,"metadata":null},{"id":"dd616be4646c4df1b21610770dc03de0","type":"DRUG","name":"ambroxol","canonical_id":"mesh:D000551","description":null,"metadata":null},{"id":"0f6dfda35c0e4f84ad001427bb8c31a9","type":"GO_TERM","name":"ameboidal-type cell migration","canonical_id":"go:GO:0001667","description":"\"Cell migration that is accomplished by extension and retraction of a pseudopodium.\" [GOC:dph]","metadata":null},{"id":"47596501dfc643ff844f6972b0fd0602","type":"GO_TERM","name":"ameloblast differentiation","canonical_id":"go:GO:0036305","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an ameloblast, a cylindrical epithelial cell in the innermost layer of the enamel organ.\" [CL:0000059]","metadata":null},{"id":"eafbd521a94442b29f815aba194cd3b7","type":"GO_TERM","name":"amelogenesis","canonical_id":"go:GO:0097186","description":"\"The process whose specific outcome is the formation of tooth enamel, occurring in two stages: secretory stage and maturation stage.\" [GOC:cjm, GOC:sl, PMID:10206335, PMID:21196346]","metadata":null},{"id":"1ea8bc8249be4720ac18b139d30ff3a8","type":"DISEASE","name":"amenorrhea","canonical_id":"mondo:0001836","description":null,"metadata":null},{"id":"b453fd36cd8140d9a3538aee8accce71","type":"GO_TERM","name":"amidase activity","canonical_id":"go:GO:0004040","description":"\"Catalysis of the reaction: a monocarboxylic acid amide + H2O = a monocarboxylate + NH4+.\" [RHEA:12020]","metadata":null},{"id":"68bedf77f15a4044bff9a287e6c625ea","type":"GO_TERM","name":"amidine-lyase activity","canonical_id":"go:GO:0016842","description":"\"Catalysis of the release of amides or amidines by the cleavage of a carbon-nitrogen bond or the reverse reaction with an amide or amidine as a substrate.\" [GOC:krc]","metadata":null},{"id":"8b34a69b7b154339933d2fbf736a27d6","type":"GO_TERM","name":"amidinoaspartase activity","canonical_id":"go:GO:0047660","description":"\"Catalysis of the reaction: N-amidino-L-aspartate + H2O = L-aspartate + urea.\" [EC:3.5.3.14, RHEA:14849]","metadata":null},{"id":"44dc23280bf74f4b95f50b831e493f9f","type":"GO_TERM","name":"amidinotransferase activity","canonical_id":"go:GO:0015067","description":"\"Catalysis of the reversible transfer of an amidino group to an acceptor.\" [GOC:ai]","metadata":null},{"id":"3831c15ec84b4d0f93b785673c022395","type":"GO_TERM","name":"amidophosphoribosyltransferase activity","canonical_id":"go:GO:0004044","description":"\"Catalysis of the reaction: 5-phospho-beta-D-ribosylamine + L-glutamate + diphosphate = 5-phospho-alpha-D-ribose 1-diphosphate + L-glutamine + H2O.\" [EC:2.4.2.14, RHEA:14905]","metadata":null},{"id":"b6d15bb5e4f24db8ac6a8d7986fdd593","type":"DRUG","name":"amikacin","canonical_id":"mesh:D000583","description":null,"metadata":null},{"id":"2464065101eb43a8948057aa8c485d17","type":"DRUG","name":"amiloride","canonical_id":"gtopdb:2421","description":null,"metadata":null},{"id":"f16166aec74c4dc1b3e49049ae60e76c","type":"DRUG","name":"amiloride","canonical_id":"mesh:D000584","description":null,"metadata":null},{"id":"2d4c175cef4849968e656e9575e507c0","type":"COMBINATION_TREATMENT","name":"amiloride + chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-1d42ff7df210c30b","description":null,"metadata":null},{"id":"99b822091adf487ea4e7e516e59a73e8","type":"COMBINATION_TREATMENT","name":"amiloride + chlorthalidone","canonical_id":"ctgov_combo:ctgov-combo-67199c599599b10e","description":null,"metadata":null},{"id":"2219772206b44de69b862b76db880f47","type":"COMBINATION_TREATMENT","name":"amiloride + chlorthalidone","canonical_id":"ctgov_combo:ctgov-combo-f4d7f1e97a7969ea","description":null,"metadata":null},{"id":"0d7d1d91d6604793816aafa0ac5607d0","type":"COMBINATION_TREATMENT","name":"amiloride + doxazosin + pindolol","canonical_id":"ctgov_combo:ctgov-combo-1ac6e2bd329b8f10","description":null,"metadata":null},{"id":"f14ab5a5b14743cc9feca16cfc4499b7","type":"COMBINATION_TREATMENT","name":"amiloride + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-8d9d8200b30dc07b","description":null,"metadata":null},{"id":"8cb370ff9f314533920726c7acea8844","type":"COMBINATION_TREATMENT","name":"amiloride + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-2cb9438224164af9","description":null,"metadata":null},{"id":"cb7b39a4205e47dfa90526a607a722b2","type":"COMBINATION_TREATMENT","name":"amiloride + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-028a517a89e2b773","description":null,"metadata":null},{"id":"766e68596bc54d688ce821bfd8da20bd","type":"COMBINATION_TREATMENT","name":"amiloride + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-d7d9b9c69efc7ba7","description":null,"metadata":null},{"id":"074caf5e68c4418aa00da846b8f69cf3","type":"COMBINATION_TREATMENT","name":"amiloride + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-4bea92758acf5b40","description":null,"metadata":null},{"id":"733f7f1f4d7144638ee3d3aefb7d8335","type":"COMBINATION_TREATMENT","name":"amiloride + triamterene","canonical_id":"ctgov_combo:ctgov-combo-08e1ceabe8b450b7","description":null,"metadata":null},{"id":"61604d88285d4401b346dd6d472bb03b","type":"COMBINATION_TREATMENT","name":"amiloride + triamterene","canonical_id":"ctgov_combo:ctgov-combo-c1a16770535531a8","description":null,"metadata":null},{"id":"53fea2f8d2ee4fe5a34696aa6611204c","type":"COMBINATION_TREATMENT","name":"amiloride + troglitazone","canonical_id":"ctgov_combo:ctgov-combo-b21296e6cffb5701","description":null,"metadata":null},{"id":"728c19c0d40a4721bacf624aa807f5c1","type":"GO_TERM","name":"amine N-methyltransferase activity","canonical_id":"go:GO:0030748","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + an amine = S-adenosyl-L-homocysteine + a methylated amine. Acts on primary, secondary and tertiary amines.\" [EC:2.1.1.49]","metadata":null},{"id":"3100281700c6451da8c7578bc2e2097e","type":"GO_TERM","name":"amine binding","canonical_id":"go:GO:0043176","description":"\"Binding to an amine, a weakly basic organic compound that contains an amino or a substituted amino group.\" [GOC:jl]","metadata":null},{"id":"93a503ff300843548f0dfcd09fe4d99d","type":"GO_TERM","name":"amine biosynthetic process","canonical_id":"go:GO:0009309","description":"\"The chemical reactions and pathways resulting in the formation of any organic compound that is weakly basic in character and contains an amino or a substituted amino group. Amines are called primary, secondary, or tertiary according to whether one, two, or three carbon atoms are attached to the nitrogen atom.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"bb5b2edff946414b830542934791207d","type":"GO_TERM","name":"amine catabolic process","canonical_id":"go:GO:0009310","description":"\"The chemical reactions and pathways resulting in the breakdown of any organic compound that is weakly basic in character and contains an amino or a substituted amino group. Amines are called primary, secondary, or tertiary according to whether one, two, or three carbon atoms are attached to the nitrogen atom.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f676e90ac11742ac8ea815bcf59029e8","type":"GO_TERM","name":"amine metabolic process","canonical_id":"go:GO:0009308","description":"\"The chemical reactions and pathways involving any organic compound that is weakly basic in character and contains an amino or a substituted amino group. Amines are called primary, secondary, or tertiary according to whether one, two, or three carbon atoms are attached to the nitrogen atom.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"6dc35e733f664ef79b888a4939235905","type":"GO_TERM","name":"amine sulfotransferase activity","canonical_id":"go:GO:0047685","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + an amine = adenosine 3',5'-bisphosphate + a sulfamate.\" [EC:2.8.2.3, MetaCyc:ARYLAMINE-SULFOTRANSFERASE-RXN]","metadata":null},{"id":"7383da4d2ad543bcb0ed025a255e5cca","type":"GO_TERM","name":"amine transmembrane transporter activity","canonical_id":"go:GO:0005275","description":"\"Enables the transfer of amines, including polyamines, from one side of a membrane to the other. Amines are organic compounds that are weakly basic in character and contain an amino (-NH2) or substituted amino group.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"41cc21e364b24eceb6e949dbcd2a5d13","type":"GO_TERM","name":"amine transport","canonical_id":"go:GO:0015837","description":"\"The directed movement of amines, including polyamines, organic compounds containing one or more amino groups, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"018eba281c44496fa7a9a1c52535994c","type":"GO_TERM","name":"amine-lyase activity","canonical_id":"go:GO:0016843","description":"\"Catalysis of the release of amines by the cleavage of a carbon-nitrogen bond or the reverse reaction with an amine as a substrate.\" [GOC:krc]","metadata":null},{"id":"c838c9b23290406482bacbf58883e851","type":"GO_TERM","name":"aminergic neurotransmitter loading into synaptic vesicle","canonical_id":"go:GO:0015842","description":"\"The active transport of aminergic neurotransmitters into a synaptic vesicle. This import is fuelled by an electrochemical gradient across the vesicle membrane, established by the action proton pumps.\" [GOC:ai]","metadata":null},{"id":"fbc830a5dbc34b21b75320ed998a8cb8","type":"GO_TERM","name":"amino acid activation","canonical_id":"go:GO:0043038","description":"\"The modification of an amino acid to an active form, for incorporation into a peptide, protein or other macromolecule.\" [GOC:jl]","metadata":null},{"id":"b97d7985f1224ff296c3423aa0dfada8","type":"GO_TERM","name":"amino acid activation for nonribosomal peptide biosynthetic process","canonical_id":"go:GO:0043041","description":"\"Activation of an amino acid for incorporation into a peptide by a nonribosomal process.\" [GOC:jl]","metadata":null},{"id":"1a0b43b3f7854e5d83ecc71710ad58e4","type":"GO_TERM","name":"amino acid acyltransferase activity","canonical_id":"go:GO:0140379","description":"\"Catalysis of the transfer of an acyl group to an acceptor group on a free amino acid, usually using acetyl-CoA as donor.\" [GOC:curators]","metadata":null},{"id":"77537d55051c44cc85d91fd29845a859","type":"GO_TERM","name":"amino acid adenylylation by nonribosomal peptide synthase","canonical_id":"go:GO:0043042","description":"\"Activation of an amino acid for incorporation into a peptide by a nonribosomal process, catalyzed by subunits of nonribosomal peptide synthase. The amino acid is adenylated at its carboxylate group (ATP-dependent) then transferred to the thiol group of an enzyme-bound phosphopantetheine cofactor.\" [GOC:jl, PMID:9250661, PMID:9712910]","metadata":null},{"id":"a68979a7593243abb613272db6de66b9","type":"GO_TERM","name":"amino acid binding","canonical_id":"go:GO:0016597","description":"\"Binding to an amino acid, organic acids containing one or more amino substituents.\" [GOC:ai]","metadata":null},{"id":"44e31d9b2e794c668ff5e6ee02b8f443","type":"GO_TERM","name":"amino acid biosynthetic process","canonical_id":"go:GO:0008652","description":"\"The chemical reactions and pathways resulting in the formation of amino acids, organic acids containing one or more amino substituents.\" [ISBN:0198506732]","metadata":null},{"id":"f3ddb758308a4bbf97541a14c5c331af","type":"GO_TERM","name":"amino acid catabolic process","canonical_id":"go:GO:0009063","description":"\"The chemical reactions and pathways resulting in the breakdown of amino acids, organic acids containing one or more amino substituents.\" [GOC:ai]","metadata":null},{"id":"738ba5f7fe964d2fb29859f02be3dd8b","type":"GO_TERM","name":"amino acid conjugated cholate hydrolase activity","canonical_id":"go:GO:7770003","description":"\"Catalysis of the reaction: an L-alpha-amino acid + cholate = an N-choloyl-L-alpha-amino acid + H2O.\" [PMID:38326608, PMID:38326609, PMID:40446798, RHEA:79087]","metadata":null},{"id":"6265bf4d20cb426bbc5eb9627bf790c4","type":"GO_TERM","name":"amino acid export across plasma membrane","canonical_id":"go:GO:0032973","description":"\"The directed movement of amino acids from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:jl]","metadata":null},{"id":"a15463ad523b433990564c99b3bd2f42","type":"GO_TERM","name":"amino acid fermentation","canonical_id":"go:GO:0019665","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of amino acids to ammonia, CO2, H2, acetate and short chain fatty acids, under anoxic conditions.\" [PMID:38821505]","metadata":null},{"id":"5a1448f1bd1e465b8f66801a80554ae3","type":"GO_TERM","name":"amino acid import","canonical_id":"go:GO:0043090","description":"\"The directed movement of amino acids into a cell or organelle.\" [GOC:jl]","metadata":null},{"id":"1bef9ce8d2e34923b8ae14fa0c23614b","type":"GO_TERM","name":"amino acid import across plasma membrane","canonical_id":"go:GO:0089718","description":"\"The directed movement of an amino acid from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:krc, PMID:8195186]","metadata":null},{"id":"ca038bc86c2d4b4d9c098b622761db99","type":"GO_TERM","name":"amino acid kinase activity","canonical_id":"go:GO:0019202","description":"\"Catalysis of the transfer of a phosphate group, usually from ATP, to an amino acid substrate.\" [GOC:jl]","metadata":null},{"id":"f7ab648e42254553b68e4ebe0ebe46ee","type":"GO_TERM","name":"amino acid ligation activity by nonribosomal peptide synthase","canonical_id":"go:GO:0097429","description":"\"Catalysis of the ligation of an amino acid to another amino acid via a carbon-nitrogen bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate, carried out by a nonribosomal peptide synthase.\" [GOC:vw]","metadata":null},{"id":"19e99ca70c1d493aa8460212b32d12bd","type":"GO_TERM","name":"amino acid metabolic process","canonical_id":"go:GO:0006520","description":"\"The chemical reactions and pathways involving amino acids, carboxylic acids containing one or more amino groups.\" [ISBN:0198506732]","metadata":null},{"id":"9aeab6c1c981498ebbf55e75467eec71","type":"GO_TERM","name":"amino acid neurotransmitter reuptake","canonical_id":"go:GO:0051933","description":"\"The uptake of amino acid neurotransmitters by neurons or glial cells. This process leads to inactivation and recycling of neurotransmitters.\" [ISBN:0123668387]","metadata":null},{"id":"4515a63d7e7144dfa9008edb29d417bf","type":"GO_TERM","name":"amino acid salvage","canonical_id":"go:GO:0043102","description":"\"Any process which produces an amino acid from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"f7fc0d0126694869807c1343c63876ae","type":"GO_TERM","name":"amino acid sensor activity","canonical_id":"go:GO:0140785","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of an amino acid.\" [GOC:pg]","metadata":null},{"id":"686886a943e84ca688de98a3d211e4ab","type":"GO_TERM","name":"amino acid transaminase activity","canonical_id":"go:GO:0140385","description":"\"Transfer of an amino group from an amino acid to an acceptor, usually a 2-oxo acid.\" [GOC:curators]","metadata":null},{"id":"7bbbcede45bd49bba06acac7d6181557","type":"GO_TERM","name":"amino acid transmembrane export from vacuole","canonical_id":"go:GO:0032974","description":"\"The directed movement of amino acids out of the vacuole, across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"a0894cf30caf4a1db12104d8610a9a6a","type":"GO_TERM","name":"amino acid transmembrane import into vacuole","canonical_id":"go:GO:0032975","description":"\"The directed movement of amino acids into the vacuole across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"b7b6cb07aecc4076951f83fc4bb6180a","type":"GO_TERM","name":"amino acid transmembrane transport","canonical_id":"go:GO:0003333","description":"\"The process in which an amino acid is transported across a membrane.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f61cf992f7014693ae81cac8e3864739","type":"GO_TERM","name":"amino acid transmembrane transporter activity","canonical_id":"go:GO:0015171","description":"\"Enables the transfer of amino acids from one side of a membrane to the other. Amino acids are organic molecules that contain an amino group and a carboxyl group.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b6ba9ea3b92f452895ab05130e4652a1","type":"GO_TERM","name":"amino acid transport","canonical_id":"go:GO:0006865","description":"\"The directed movement of amino acids, organic acids containing one or more amino substituents, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"53ff0cd6e1cc448a911d8f9ad7706c26","type":"GO_TERM","name":"amino acid transport complex","canonical_id":"go:GO:1990184","description":"\"A heteromeric protein complex consisting of a multi-transmembrane spanning subunit (the light chain) and a type II glycoprotein subunit (the heavy chain) that functions to transport amino acids across a plasma membrane.\" [GOC:kmv, PMID:14668347]","metadata":null},{"id":"2b581c1df8b94b7fb7c0f1c9c8abc5b5","type":"GO_TERM","name":"amino acid:monoatomic cation antiporter activity","canonical_id":"go:GO:0140848","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: solute(out) + monoatomic cation(in) = solute(in) + monoatomic cation(out). Monoatomic cations include H+, Mg2+, Ca2+, etc.\" [GOC:curators]","metadata":null},{"id":"950efc78693b4980ae435c006d7845b4","type":"GO_TERM","name":"amino acid:monoatomic cation symporter activity","canonical_id":"go:GO:0005416","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: amino acid(out) + cation(out) = amino acid(in) + cation(in).\" [GOC:ai]","metadata":null},{"id":"4480a686df694410ba906873cae056b5","type":"GO_TERM","name":"amino acid:potassium symporter activity","canonical_id":"go:GO:0017032","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: amino acid(out) + K+(out) = amino acid(in) + K+(in).\" [GOC:ai]","metadata":null},{"id":"2d5166697e3e41d3aea541f090566f83","type":"GO_TERM","name":"amino acid:proton symporter activity","canonical_id":"go:GO:0005280","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: amino acid(out) + H+(out) = amino acid(in) + H+(in).\" [GOC:ai]","metadata":null},{"id":"10feb16349e049f18993fb25ae8328e2","type":"GO_TERM","name":"amino acid:sodium symporter activity","canonical_id":"go:GO:0005283","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: amino acid(out) + Na+(out) = amino acid(in) + Na+(in).\" [GOC:ai]","metadata":null},{"id":"37f54ea918fd4a678c8547ac554d37d7","type":"GO_TERM","name":"amino sugar biosynthetic process","canonical_id":"go:GO:0046349","description":"\"The chemical reactions and pathways resulting in the formation of any amino sugar, sugars containing an amino group in place of a hydroxyl group.\" [GOC:curators]","metadata":null},{"id":"57eca8bd19914465a281455644cecf6c","type":"GO_TERM","name":"amino sugar catabolic process","canonical_id":"go:GO:0046348","description":"\"The chemical reactions and pathways resulting in the breakdown of any amino sugar, sugars containing an amino group in place of a hydroxyl group.\" [GOC:curators]","metadata":null},{"id":"a54f92ddec74464b9147320edb65f240","type":"GO_TERM","name":"amino sugar metabolic process","canonical_id":"go:GO:0006040","description":"\"The chemical reactions and pathways involving any amino sugar, sugars containing an amino group in place of a hydroxyl group.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"b220cd3a438f44f399c756c067a18971","type":"GO_TERM","name":"amino-acid betaine biosynthetic process","canonical_id":"go:GO:0006578","description":"\"The chemical reactions and pathways resulting in the formation of any betaine, the N-trimethyl derivative of an amino acid.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"272ed8595ced4a71a963503fb7161d59","type":"GO_TERM","name":"amino-acid betaine catabolic process","canonical_id":"go:GO:0006579","description":"\"The chemical reactions and pathways resulting in the breakdown of any betaine, the N-trimethyl derivative of an amino acid.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"6c4d69cca6264d63b9fd67204eb2b2e1","type":"GO_TERM","name":"amino-acid betaine metabolic process","canonical_id":"go:GO:0006577","description":"\"The chemical reactions and pathways involving any betaine, the N-trimethyl derivative of an amino acid.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"2774b0c8b29b43b280c9297828bca8ea","type":"GO_TERM","name":"amino-acid betaine transmembrane transporter activity","canonical_id":"go:GO:0015199","description":"\"Enables the transfer of betaine from one side of a membrane to the other. Betaine is the N-trimethyl derivative of an amino acid.\" [GOC:ai]","metadata":null},{"id":"45c355649ce5433db9f9c49cc2271575","type":"GO_TERM","name":"amino-acid betaine transport","canonical_id":"go:GO:0015838","description":"\"The directed movement of betaine, the N-trimethyl derivative of an amino acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"448db24064084034b1d30f76a2255792","type":"GO_TERM","name":"amino-acid dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0050018","description":"\"Catalysis of the reaction: an L-alpha-amino acid +NAD(P)+ + H2O = a 2-oxocarboxylate + NH4+ + NAD(P)H + H+.\" [GOC:curators]","metadata":null},{"id":"67205d81dd484b959b2a99e442242182","type":"GO_TERM","name":"amino-acid racemase activity","canonical_id":"go:GO:0047661","description":"\"Catalysis of the reaction: an L-amino acid = a D-amino acid.\" [EC:5.1.1.10, MetaCyc:AMINO-ACID-RACEMASE-RXN]","metadata":null},{"id":"cc6450c7cd8a4af19869977b56c19529","type":"GO_TERM","name":"aminoacyl-tRNA deacylase activity","canonical_id":"go:GO:0002161","description":"\"The hydrolysis of an incorrectly aminoacylated tRNA.\" [GOC:hjd, PMID:14663147, PMID:16087889]","metadata":null},{"id":"98d813731f8344c6b9f4a9b9a17c30f9","type":"GO_TERM","name":"aminoacyl-tRNA ligase activity","canonical_id":"go:GO:0004812","description":"\"Catalysis of the formation of aminoacyl-tRNA from ATP, amino acid, and tRNA with the release of diphosphate and AMP.\" [ISBN:0198506732]","metadata":null},{"id":"7976c80d8ed64a08a499b0198c141807","type":"GO_TERM","name":"aminoacyl-tRNA metabolism involved in translational fidelity","canonical_id":"go:GO:0106074","description":"\"Any process which detects an amino-acid acetylated tRNA is charged with the correct amino acid, or removes incorrect amino acids from a charged tRNA. This process can be performed by tRNA synthases, or by subsequent reactions after tRNA aminoacylation.\" [GOC:hjd]","metadata":null},{"id":"fda6b44706eb44d69db43b1b2c054350","type":"GO_TERM","name":"aminoacyl-tRNA synthetase multienzyme complex","canonical_id":"go:GO:0017101","description":"\"A multienzyme complex found in all multicellular eukaryotes composed of eight proteins with aminoacyl-tRNA synthetase activities (abbreviated as: ArgRS, AspRS, GluProRS, GlnRS, IleRS, LeuRS, LysRS, MetRS where RS is the enzyme, preceded by the amino acid it uses as a substrate) as well as three non-synthetase proteins (p43, p38, and p18) with diverse functions. Several of these subunits are known dimers, so the total polypeptide count in the multisynthetase complex is at least fifteen. All of the enzymes in this assembly catalyze the same reaction, the covalent attachment of an amino acid to either the 2'- or 3'-hydroxyl of the 3'-terminal adenosine of tRNA, but using different substrates.\" [GOC:jl, PMID:16169847]","metadata":null},{"id":"5613dd90f7da48419c484bf80d427af7","type":"GO_TERM","name":"aminoacylase activity","canonical_id":"go:GO:0004046","description":"\"Catalysis of the reaction: an N-acyl-L-amino acid + H2O = a carboxylate + an L-amino acid.\" [EC:3.5.1.14]","metadata":null},{"id":"8eb55d86ef6f4b2a887bcb35de88da42","type":"GO_TERM","name":"aminoacyltransferase activity","canonical_id":"go:GO:0016755","description":"\"Catalysis of the transfer of an amino-acyl group from one compound (donor) to another (acceptor).\" [GOC:jl]","metadata":null},{"id":"a732408ec1964ebc83d096c98b5008a9","type":"GO_TERM","name":"aminobenzoate decarboxylase activity","canonical_id":"go:GO:0047662","description":"\"Catalysis of the reaction: 4(or 2)-aminobenzoate = aniline + CO2.\" [EC:4.1.1.24, MetaCyc:AMINOBENZOATE-DECARBOXYLASE-RXN]","metadata":null},{"id":"82e19cb652e5426a8d6bb9df2bb58cf6","type":"DRUG","name":"aminobenzoic acid","canonical_id":"mesh:D010129","description":null,"metadata":null},{"id":"254c8f673610455ca90373fe6f35af9d","type":"GO_TERM","name":"aminobutyraldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0019145","description":"\"Catalysis of the reaction: 4-aminobutanal + NAD+ + H2O = 4-aminobutanoate + NADH + 2 H+.\" [EC:1.2.1.19]","metadata":null},{"id":"c0804f40ebe44a31aa1df54074992ad3","type":"GO_TERM","name":"aminocarboxymuconate-semialdehyde decarboxylase activity","canonical_id":"go:GO:0001760","description":"\"Catalysis of the reaction: 2-amino-3-carboxymuconate 6-semialdehyde + H+ = 2-aminomuconate 6-semialdehyde + CO2.\" [EC:4.1.1.45, RHEA:16557]","metadata":null},{"id":"d2c1dcf50da141b782072e96ed36baed","type":"GO_TERM","name":"aminodeoxychorismate synthase activity","canonical_id":"go:GO:0046820","description":"\"Catalysis of the reaction: L-glutamine + chorismate = 4-amino-4-deoxychorismate + L-glutamate. It is composed of two enzymatic activities (which may be present on one or two polypeptides); the first is a glutaminase which yields ammonia from glutamine, releasing glutamate. The ammonia is used by the second activity which catalyzes the amination of chorismate to form 4-amino-4-deoxychorismate.\" [EC:2.6.1.85, RHEA:11672]","metadata":null},{"id":"a34fcd3b2d284417b24e37408da19a3b","type":"GO_TERM","name":"aminodeoxychorismate synthase complex","canonical_id":"go:GO:0009356","description":"\"A heterodimeric protein complex that possesses 4-amino-4-deoxychorismate synthase activity.\" [PMID:2251281, PMID:7592344]","metadata":null},{"id":"8e220f43362341c4b2079f99a531a0cb","type":"GO_TERM","name":"aminodeoxyfutalosine synthase activity","canonical_id":"go:GO:0102573","description":"\"Catalysis of the reaction: 3-[(1-carboxylatovinyl)oxy]benzoate(2-) + S-adenosyl-L-methionine + H2O = aminodeoxyfutalosinate + L-methionine + hydrogencarbonate + H+.\" [EC:2.5.1.120, GOC:pz]","metadata":null},{"id":"b2b88e065fcc45f789008eae48a46af8","type":"DRUG","name":"aminoglutethimide","canonical_id":"gtopdb:7054","description":null,"metadata":null},{"id":"2663bac764054c6a99fa880d1cae6d5e","type":"DRUG","name":"aminoglutethimide","canonical_id":"mesh:D000616","description":null,"metadata":null},{"id":"6c81cedf368c4c8fab04b16607150872","type":"DRUG","name":"aminoglutethimide","canonical_id":"chembl:CHEMBL488","description":null,"metadata":null},{"id":"6705ede18bb144fba1242f5219234dca","type":"GO_TERM","name":"aminoglycan biosynthetic process","canonical_id":"go:GO:0006023","description":"\"The chemical reactions and pathways resulting in the formation of aminoglycans, any polymer containing amino groups that consists of more than about 10 monosaccharide residues joined to each other by glycosidic linkages.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"3c2ef46659354fd79474426f027fc85d","type":"GO_TERM","name":"aminoglycan catabolic process","canonical_id":"go:GO:0006026","description":"\"The chemical reactions and pathways resulting in the breakdown of aminoglycans, any polymer containing amino groups that consists of more than about 10 monosaccharide residues joined to each other by glycosidic linkages.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"7ab182cdad9b4af6b6e9a6128c24d2c4","type":"GO_TERM","name":"aminoglycan metabolic process","canonical_id":"go:GO:0006022","description":"\"The chemical reactions and pathways involving aminoglycans, any polymer containing amino groups that consists of more than about 10 monosaccharide residues joined to each other by glycosidic linkages.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"26e20774c8684f0da0d587af8e1a6c93","type":"GO_TERM","name":"aminoglycoside 2''-nucleotidyltransferase activity","canonical_id":"go:GO:0008871","description":"\"Catalysis of the reaction: nucleoside triphosphate + aminoglycoside = diphosphate + 2''-nucleotidylaminoglycoside.\" [EC:2.7.7.46, GOC:cb]","metadata":null},{"id":"37132289269a4a0b97be3b7174ab6f51","type":"GO_TERM","name":"aminoglycoside 2'-N-acetyltransferase activity","canonical_id":"go:GO:0047921","description":"\"Catalysis of the reaction: acetyl-CoA + gentamicin C(1a) = N(2')-acetylgentamicin C(1a) + CoA + H+. This is acetylation of the 2'-amino group of the 6-deoxy-6-aminoglucose ring.\" [EC:2.3.1.59, RHEA:24516]","metadata":null},{"id":"d29cbec1ff854662a6ca51d9d610ba27","type":"GO_TERM","name":"aminoglycoside 3''-adenylyltransferase activity","canonical_id":"go:GO:0009012","description":"\"Catalysis of the reaction: ATP + streptomycin = 3''-adenylylstreptomycin + diphosphate + H+.\" [EC:2.7.7.47, RHEA:20245]","metadata":null},{"id":"a5f2b4c43bdb4765ac286608cabac51b","type":"GO_TERM","name":"aminoglycoside 3-N-acetyltransferase activity","canonical_id":"go:GO:0046353","description":"\"Catalysis of the reaction: a 2-deoxystreptamine antibiotic + acetyl-CoA = an N(3)-acetyl-2-deoxystreptamine antibiotic + CoA + H+.\" [RHEA:12665]","metadata":null},{"id":"ec92b47076c74a10ac5c73d2b636c1a7","type":"GO_TERM","name":"aminoglycoside 6'-N-acetyltransferase activity","canonical_id":"go:GO:0047663","description":"\"Catalysis of the reaction: acetyl-CoA + kanamycin B = N(6')-acetylkanamycin B + CoA + H+. This is acetylation of the 6'-amino group of the 6-deoxy-6-aminoglucose ring.\" [EC:2.3.1.82, RHEA:16449]","metadata":null},{"id":"3900ae24d42f44c9bcdc01f089b9a4d6","type":"GO_TERM","name":"aminoglycoside 6-kinase activity","canonical_id":"go:GO:0050300","description":"\"Catalysis of the reaction: ATP + streptomycin = ADP + 2 H+ + streptomycin 6-phosphate.\" [EC:2.7.1.72, RHEA:22268]","metadata":null},{"id":"d9005191d6c0425b9018812d63cff9b7","type":"GO_TERM","name":"aminoglycoside N-acetyltransferase activity","canonical_id":"go:GO:0034069","description":"\"Catalysis of the reaction: acetyl-CoA + aminoglycoside = CoA + N-acetylaminoglycoside.\" [GOC:cb]","metadata":null},{"id":"687f69587c80440fb6c10b3e6e187ed1","type":"GO_TERM","name":"aminoglycoside antibiotic biosynthetic process","canonical_id":"go:GO:0030648","description":"\"The chemical reactions and pathways resulting in the formation of an aminoglycoside antibiotic, any member of a group of broad spectrum antibiotics, of similar toxicity and pharmacology, that contain an aminodeoxysugar, an amino- or guanidino-substituted inositol ring, and one or more residues of other sugars. The group includes streptomycin, neomycin, framycetin, kanamycin, paromomycin, and gentamicin.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"36b3ec89b7304803bc65022b624c3b2f","type":"GO_TERM","name":"aminoglycoside antibiotic catabolic process","canonical_id":"go:GO:0030649","description":"\"The chemical reactions and pathways resulting in the breakdown of an aminoglycoside antibiotic, any member of a group of broad spectrum antibiotics, of similar toxicity and pharmacology, that contain an aminodeoxysugar, an amino- or guanidino-substituted inositol ring, and one or more residues of other sugars. The group includes streptomycin, neomycin, framycetin, kanamycin, paromomycin, and gentamicin.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"e89440c5f34f450da3abd7bc739aa5a7","type":"GO_TERM","name":"aminoglycoside nucleotidyltransferase activity","canonical_id":"go:GO:0034068","description":"\"Catalysis of the reaction: nucleoside triphosphate + aminoglycoside = diphosphate + nucleotidylaminoglycoside.\" [GOC:cb]","metadata":null},{"id":"dfa903ce86ae488ab47128f12d877c91","type":"GO_TERM","name":"aminoglycoside phosphotransferase activity","canonical_id":"go:GO:0034071","description":"\"Catalysis of the reaction: ATP + aminoglycoside = ADP + phosphoaminoglycoside.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"97ccc98abbe24230a08425fa786bf093","type":"GO_TERM","name":"aminoimidazolase activity","canonical_id":"go:GO:0047664","description":"\"Catalysis of the reaction: 4-aminoimidazole + H2O + H+ = imidazol-4-one + NH4+.\" [RHEA:22348]","metadata":null},{"id":"d8e0772435664e539301796223cd8f55","type":"GO_TERM","name":"aminolevulinate:pyruvate transaminase activity","canonical_id":"go:GO:0047665","description":"\"Catalysis of the reaction: 5-aminolevulinate + pyruvate = 4,5-dioxopentanoate + L-alanine.\" [RHEA:12480]","metadata":null},{"id":"3ee3d361aacf4dc38756e492cc30d543","type":"GO_TERM","name":"aminomethyltransferase activity","canonical_id":"go:GO:0004047","description":"\"Catalysis of the reaction: N(6)-[(R)-S(8)-aminomethyldihydrolipoyl]-L-lysyl-[protein] + (6S)-5,6,7,8-tetrahydrofolate = N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NH4+.\" [RHEA:16945]","metadata":null},{"id":"0999ecd69a034e398742016feed598d2","type":"GO_TERM","name":"aminomuconate-semialdehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047102","description":"\"Catalysis of the reaction: H2O + NAD+ + 2-aminomuconate semialdehyde = NADH + 2-amino-muconate.\" [EC:1.2.1.32, MetaCyc:1.2.1.32-RXN]","metadata":null},{"id":"5a5d438b095941f699f2ec6a4ad5d3f6","type":"GO_TERM","name":"aminopeptidase activity","canonical_id":"go:GO:0004177","description":"\"Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain.\" [EC:3.4.11.-, https://www.ebi.ac.uk/merops/about/glossary.shtml#AMINOPEPTIDASE, PMID:24157837]","metadata":null},{"id":"e1c550cbb0e24959a75d706f831e6be2","type":"GO_TERM","name":"aminophospholipid flippase activity","canonical_id":"go:GO:0015247","description":"\"Enables the transfer of aminophospholipids from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP. Aminophospholipids contain phosphoric acid as a mono- or diester and an amino (NH2) group.\" [GOC:pg]","metadata":null},{"id":"b02d31ca15b94fc4a48e005745c0e0cb","type":"GO_TERM","name":"aminophospholipid translocation","canonical_id":"go:GO:0140331","description":"\"The movement of an aminophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet.\" [GOC:pg]","metadata":null},{"id":"8be7628c94a3445b9afaa69d05d3db63","type":"GO_TERM","name":"aminophospholipid transport","canonical_id":"go:GO:0015917","description":"\"The directed movement of aminophospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Aminophospholipids contain phosphoric acid as a mono- or diester and an amino (NH2) group.\" [GOC:ai]","metadata":null},{"id":"fa8738848f5644db9e4a9b4886d47ae6","type":"GO_TERM","name":"aminophosphonate metabolic process","canonical_id":"go:GO:0033051","description":"\"The chemical reactions and pathways involving aminophosphonates, phosphonic acid derivatives that contain an amino group.\" [GOC:mah]","metadata":null},{"id":"91f88f9e0eec4e0faa5735dbbbc08f0d","type":"GO_TERM","name":"aminopropylagmatine ureohydrolase activity","canonical_id":"go:GO:0043920","description":"\"Catalysis of the reaction: N1-aminopropylagmatine + H2O = spermidine + urea.\" [GOC:jl, PMID:15983049, RHEA:35827]","metadata":null},{"id":"075ec2978a43445982bca5d91660e094","type":"GO_TERM","name":"aminotriazole transmembrane transporter activity","canonical_id":"go:GO:1901478","description":"\"Enables the transfer of amitrole from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"ce66a45ac8684068bb0b47681dbf02e1","type":"GO_TERM","name":"aminotriazole transport","canonical_id":"go:GO:0015899","description":"\"The directed movement of aminotriazole into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Aminotriazole is an effective weed killer that also possesses some antithyroid activity.\" [GOC:curators]","metadata":null},{"id":"e894f8cb133b4258864e70e4c39d56ba","type":"GO_TERM","name":"aminotriazole:proton antiporter activity","canonical_id":"go:GO:0015314","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + aminotriazole(in) = H+(in) + aminotriazole(out).\" [TC:2.A.1.3.1]","metadata":null},{"id":"baa7fbd790ed4a5199add6660d24a4f1","type":"DRUG","name":"amiodarone","canonical_id":"mesh:D000638","description":null,"metadata":null},{"id":"afd43c4dbfec4414bc280f2d5175f1b6","type":"DRUG","name":"amisulpride","canonical_id":"gtopdb:963","description":null,"metadata":null},{"id":"e196cd6d686d427cbaac19477e49d1e7","type":"DRUG","name":"amisulpride","canonical_id":"chembl:CHEMBL243712","description":null,"metadata":null},{"id":"1c77609329294d8dac2c30c11bfede6e","type":"COMBINATION_TREATMENT","name":"amisulpride + fluphenazine + perphenazine + pimozide + sertindole + sulpiride + thioridazine","canonical_id":"ctgov_combo:ctgov-combo-750c26f835800333","description":null,"metadata":null},{"id":"34c9bfd3075a40c68c1dc918e1ecb167","type":"COMBINATION_TREATMENT","name":"amisulpride + moclobemide","canonical_id":"ctgov_combo:ctgov-combo-ca74d3edcd8983c8","description":null,"metadata":null},{"id":"dbbcf33ada95445692eebe7aaad32d6c","type":"COMBINATION_TREATMENT","name":"amisulpride + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-21b5a6845627163c","description":null,"metadata":null},{"id":"2531e9b73dc04fc6a16e85d2d0d406ce","type":"COMBINATION_TREATMENT","name":"amisulpride + perphenazine","canonical_id":"ctgov_combo:ctgov-combo-2cc463771b30b956","description":null,"metadata":null},{"id":"2d3ceee142e6478486bf4d2ea9928b0d","type":"COMBINATION_TREATMENT","name":"amisulpride + pimozide","canonical_id":"ctgov_combo:ctgov-combo-fe6436a33b7a0390","description":null,"metadata":null},{"id":"d4540507c7754c7ca016d824c3f5f1c8","type":"GO_TERM","name":"amitosis","canonical_id":"go:GO:0051337","description":"\"Nuclear division that occurs by simple constriction of the nucleus without chromosome condensation or spindle formation.\" [GOC:curators, ISBN:0721662544]","metadata":null},{"id":"3be90d7ef28847e7b2acba5a86e8e4f7","type":"DRUG","name":"amitriptyline","canonical_id":"gtopdb:200","description":null,"metadata":null},{"id":"20483e40431349b3b0892499cff96436","type":"COMBINATION_TREATMENT","name":"amitriptyline + baclofen + ketoprofen + loperamide","canonical_id":"ctgov_combo:ctgov-combo-58bccd13d1dc9d51","description":null,"metadata":null},{"id":"6076383516964dfa9b463c12b26024b8","type":"COMBINATION_TREATMENT","name":"amitriptyline + chlorpromazine + mirtazapine","canonical_id":"ctgov_combo:ctgov-combo-fe4ed08851bc9b34","description":null,"metadata":null},{"id":"da3e312797a34eaba823bd39b2dc2edf","type":"COMBINATION_TREATMENT","name":"amitriptyline + citalopram","canonical_id":"ctgov_combo:ctgov-combo-2c1723ef20bb82c9","description":null,"metadata":null},{"id":"24f51565f5434a7cb72377335414e102","type":"COMBINATION_TREATMENT","name":"amitriptyline + desvenlafaxine + fenoterol + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-a1b18780244d42c7","description":null,"metadata":null},{"id":"e0ec508e530247c7ae968de809854349","type":"COMBINATION_TREATMENT","name":"amitriptyline + duloxetine","canonical_id":"ctgov_combo:ctgov-combo-3538bd5c1f75489a","description":null,"metadata":null},{"id":"7c5c65ea6697444c85c6bffa914113c7","type":"COMBINATION_TREATMENT","name":"amitriptyline + duloxetine","canonical_id":"ctgov_combo:ctgov-combo-3173ac57e7f933d1","description":null,"metadata":null},{"id":"7166d1b8a6084fe18d269ebcbb96f5a6","type":"COMBINATION_TREATMENT","name":"amitriptyline + imipramine","canonical_id":"ctgov_combo:ctgov-combo-dd5e5305dfcfcb06","description":null,"metadata":null},{"id":"4374195f0b6c439b9f58d47ec8ac7ab5","type":"COMBINATION_TREATMENT","name":"amitriptyline + mexiletine","canonical_id":"ctgov_combo:ctgov-combo-d054d8eb4f4eb8f5","description":null,"metadata":null},{"id":"e600f9a9190b40fc84f3df14dc7916b9","type":"COMBINATION_TREATMENT","name":"amitriptyline + nortriptyline + trimipramine","canonical_id":"ctgov_combo:ctgov-combo-34d34e7b096de260","description":null,"metadata":null},{"id":"2aa3d51e1a394a9ea8424197130e3d59","type":"COMBINATION_TREATMENT","name":"amitriptyline + propranolol","canonical_id":"ctgov_combo:ctgov-combo-e8acf731a6c42ea4","description":null,"metadata":null},{"id":"c334d2831305417ba78d29a90e34620a","type":"DRUG","name":"amivantamab","canonical_id":"gtopdb:10505","description":null,"metadata":null},{"id":"ec2f2db195244e7994917e224fec6973","type":"DRUG","name":"amivantamab","canonical_id":"chembl:CHEMBL4297774","description":null,"metadata":null},{"id":"6e23e012eed54066a245f78b2c42b1fa","type":"COMBINATION_TREATMENT","name":"amivantamab + avelumab","canonical_id":"ctgov_combo:ctgov-combo-64138953b9612873","description":null,"metadata":null},{"id":"41fe25cc03554bb8b41189259f0d3383","type":"COMBINATION_TREATMENT","name":"amivantamab + capmatinib","canonical_id":"ctgov_combo:ctgov-combo-a3b8dcb05e3931d5","description":null,"metadata":null},{"id":"31ecea1947eb44859c5485b6618445a1","type":"COMBINATION_TREATMENT","name":"amivantamab + doxycycline + propranolol + ruxolitinib + timolol","canonical_id":"ctgov_combo:ctgov-combo-7a9abda00b210023","description":null,"metadata":null},{"id":"6ee96247837d40db9b90e226bf023d94","type":"COMBINATION_TREATMENT","name":"amivantamab + irinotecan","canonical_id":"ctgov_combo:ctgov-combo-28a3d53a67b496b0","description":null,"metadata":null},{"id":"65f7d3b1c59c4943af7ef1775bc61de0","type":"COMBINATION_TREATMENT","name":"amivantamab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-6acc048f3713cf04","description":null,"metadata":null},{"id":"544c2ee84c8848438df70bccfbd47ba0","type":"COMBINATION_TREATMENT","name":"amivantamab + tepotinib","canonical_id":"ctgov_combo:ctgov-combo-127cc09c91e62f0f","description":null,"metadata":null},{"id":"e639f9e6f48f43dfa3a684d531f3f729","type":"DRUG","name":"amlexanox","canonical_id":"mesh:C045742","description":null,"metadata":null},{"id":"1ff2dee091aa42c7b9916656e66ace48","type":"GO_TERM","name":"ammeline aminohydrolase activity","canonical_id":"go:GO:0018756","description":"\"Catalysis of the reaction: ammeline + H2O = ammelide + NH4+. Also converts melamine to ammeline.\" [EC:3.5.4.45, PMID:1991731]","metadata":null},{"id":"d92af666adba4024bd642d0d3aec677f","type":"GO_TERM","name":"ammon gyrus development","canonical_id":"go:GO:0021541","description":"\"The process whose specific outcome is the progression of the ammon gyrus over time, from its formation to the mature structure. The ammon gyrus, often subdivided into the CA1 and CA3 regions, is one of the two interlocking gyri of the hippocampus that is rich in large pyramidal neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"aba0c37f78d948d7a14f20e04249a575","type":"GO_TERM","name":"ammonia assimilation cycle","canonical_id":"go:GO:0019676","description":"\"The pathway by which ammonia is processed and incorporated into a cell. In an energy-rich (glucose-containing), nitrogen-poor environment, glutamine synthetase and glutamate synthase form an ammonia assimilatory cycle, in which ammonia is incorporated into L-glutamate to form L-glutamine, which then combines with alpha-ketoglutarate to regenerate L-glutamate. This ATP-dependent cycle is essential for nitrogen-limited growth and for steady-state growth with some sources of nitrogen.\" [MetaCyc:AMMASSIM-PWY]","metadata":null},{"id":"ed47eda40f3444098ef9beae1339c57f","type":"GO_TERM","name":"ammonia kinase activity","canonical_id":"go:GO:0047666","description":"\"Catalysis of the reaction: ATP + NH4 = ADP + 3 H+ + phosphoramidate.\" [EC:2.7.3.8, RHEA:11024]","metadata":null},{"id":"0c18f54842ac4558a7d04a4a05f14fac","type":"GO_TERM","name":"ammonia ligase activity","canonical_id":"go:GO:0016211","description":"\"Catalysis of the ligation of ammonia (NH4+) to another substance via a carbon-nitrogen bond with concomitant breakage of a diphosphate linkage, usually in a nucleoside triphosphate.\" [GOC:jl]","metadata":null},{"id":"5968012fc26a48f2bc9060783b9c6de7","type":"GO_TERM","name":"ammonia monooxygenase activity","canonical_id":"go:GO:0018597","description":"\"Catalysis of the reaction: AH2 + NH4+ + O2 = A + H+ + H2O + hydroxylamine.\" [PMID:16347810, RHEA:27341]","metadata":null},{"id":"538db334819f449896e61fc370991820","type":"GO_TERM","name":"ammonia oxidation","canonical_id":"go:GO:0019329","description":"\"The chemical reactions and pathways by which ammonia or ammonium is converted to molecular nitrogen or another nitrogen compound, with accompanying loss of electrons.\" [GOC:mah]","metadata":null},{"id":"d07b9387c69a4815841856829fab18df","type":"GO_TERM","name":"ammonia-lyase activity","canonical_id":"go:GO:0016841","description":"\"Catalysis of the release of ammonia by the cleavage of a carbon-nitrogen bond or the reverse reaction with ammonia as a substrate.\" [GOC:krc]","metadata":null},{"id":"c279336c9923459f9a4564466b5a8a87","type":"GO_TERM","name":"ammonium channel activity","canonical_id":"go:GO:0008519","description":"\"Enables the energy-independent facilitated diffusion of ammonium through a transmembrane aqueous pore or channel.\" [PMID:17710640]","metadata":null},{"id":"95c777fd34dd40abab25d7ad6b6b0bcc","type":"DRUG","name":"ammonium chloride","canonical_id":"mesh:D000643","description":null,"metadata":null},{"id":"11e24d1fd7fd4cef85f4310ffb2d531f","type":"GO_TERM","name":"ammonium excretion","canonical_id":"go:GO:0140734","description":"\"The elimination of ammonium ions from an excretory cell.\" [PMID:25740900]","metadata":null},{"id":"de7ffdaee6e64a0ea713e2b4ba19a432","type":"GO_TERM","name":"ammonium homeostasis","canonical_id":"go:GO:0097272","description":"\"Any biological process involved in the maintenance of an internal steady state of ammonium.\" [GOC:yaf, PMID:12695560]","metadata":null},{"id":"ddc2b49e119341a0b20ad8d989ec525f","type":"GO_TERM","name":"ammonium import across plasma membrane","canonical_id":"go:GO:0140157","description":"\"The directed movement of an ammonium ion from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:vw, PMID:16999738]","metadata":null},{"id":"5bbe4630a76e4c19939427b0c65b6438","type":"GO_TERM","name":"ammonium ion binding","canonical_id":"go:GO:0070405","description":"\"Binding to ammonium ions (NH4+).\" [CHEBI:28938, GOC:ecd]","metadata":null},{"id":"989db3f19f2c46d5bc8900d4411fc34d","type":"GO_TERM","name":"ammonium transmembrane transport","canonical_id":"go:GO:0072488","description":"\"The process in which ammonium is transported across a membrane. Ammonium is the cation NH4+.\" [GOC:mah]","metadata":null},{"id":"763196d5e40a41c18a1649c16a058056","type":"GO_TERM","name":"ammonium transmembrane transporter complex","canonical_id":"go:GO:0110067","description":"\"High affinity ammonium transporter complex that enables the transfer of ammonium from one side of a membrane to the other.\" [GOC:bhm, PMID:17026539, PMID:23463773]","metadata":null},{"id":"308277b0252444c88c2abb125cb809f5","type":"GO_TERM","name":"amnioserosa formation","canonical_id":"go:GO:0007378","description":"\"Formation of the amnioserosa, an epithelium that occupies a hole in the embryonic dorsal epidermis. This occurs by the transformation of a narrow strip of cells at the dorsal midline of the blastoderm from columnar to squamous cells, accompanied by a lateral shift.\" [ISBN:0879694238]","metadata":null},{"id":"8770f6c8308c41819aa2015b3a509f9d","type":"GO_TERM","name":"amnioserosa maintenance","canonical_id":"go:GO:0046665","description":"\"Maintenance of the amnioserosa, an epithelium that occupies a hole in the embryonic dorsal epidermis.\" [GOC:bf]","metadata":null},{"id":"1ce1e51b2c0641e8973ccd2e6d1e8f1e","type":"GO_TERM","name":"amniotic stem cell differentiation","canonical_id":"go:GO:0097086","description":"\"The process whereby a relatively unspecialized cell acquires specialized features of an amniotic stem cell. An amniotic stem cell is a mesenchymal stem cell extracted from amniotic fluid. Amniotic stem cells are able to differentiate into various tissue types such as skin, cartilage, cardiac tissue, nerves, muscle, and bone.\" [CL:0002639, GOC:yaf, PMID:20942606, Wikipedia:Amniotic_stem_cells]","metadata":null},{"id":"ab6cdcde1e35417aa32c218511fce42e","type":"DRUG","name":"amobarbital","canonical_id":"mesh:D000654","description":null,"metadata":null},{"id":"b250c299730147279085ca1bad06ef94","type":"GO_TERM","name":"amoeboid sperm motility","canonical_id":"go:GO:0097723","description":"\"Any process involved in the controlled movement of an amoeboid sperm cell.\" [GOC:cilia, GOC:krc]","metadata":null},{"id":"8d977642cc894483b1ee640f207a0184","type":"GO_TERM","name":"amorpha-4,11-diene 12-monooxygenase activity","canonical_id":"go:GO:0062150","description":"\"Catalysis of the reaction:(+)-amorpha-4,11-diene + 3 O2 + 3 reduced [NADPH--hemoprotein reductase] = (+)-artemisinate + 4 H+ + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase].\" [PMID:16458889, PMID:16612385, PMID:23246612, RHEA:32999]","metadata":null},{"id":"c4f175045d70461cb8cad2813a6b9867","type":"GO_TERM","name":"amorpha-4,11-diene synthase activity","canonical_id":"go:GO:0034006","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = amorpha-4,11-diene + diphosphate.\" [EC:4.2.3.24, RHEA:18325]","metadata":null},{"id":"116f9d54b867456484ceac6c4d97cdbc","type":"GO_TERM","name":"amorphous vesicle","canonical_id":"go:GO:1990006","description":"\"A cytoplasmic membrane-bounded vesicle first described in dendrites, categorized by smooth membranes, electron-lucent interiors and irregular shapes. Sometimes occurs in clumps. Amorphous vesicles have been found to contain material taken up from the extracellular space, therefore suggesting that they may be part of the endosomal pathway.\" [NIF_Subcellular:sao1531915298, PMID:11896161]","metadata":null},{"id":"4e8b526a36cd4d16897d4588fcae492b","type":"DRUG","name":"amoxapine","canonical_id":"gtopdb:201","description":null,"metadata":null},{"id":"0e212a89c38d426da1ea4b144aadf942","type":"DRUG","name":"amoxapine","canonical_id":"mesh:D000657","description":null,"metadata":null},{"id":"5119e46c4a974c0d9479d560a3dbc5be","type":"DRUG","name":"amoxapine","canonical_id":"chembl:CHEMBL1113","description":null,"metadata":null},{"id":"3a22d4f8936443f09040194c3efbc7bc","type":"DRUG","name":"amoxicillin","canonical_id":"mesh:D000658","description":null,"metadata":null},{"id":"6c3baffeedec4a24bef98c8166d9d87e","type":"GO_TERM","name":"amphibian larval development","canonical_id":"go:GO:0002117","description":"\"The process whose specific outcome is the progression of the amphibian larva over time, from its formation to the mature structure. Amphibian larvae, sometimes called pollywogs or tadpoles, hatch from eggs and begin to grow limbs and other adult physical features at various times, depending on the species, before they metamorphose into the adult form.\" [GOC:bf, PMID:27143402]","metadata":null},{"id":"8623b8fd53f84ef8a3795c6a3e8fb10d","type":"GO_TERM","name":"amphid sensory organ dendrite retrograde extension","canonical_id":"go:GO:0003391","description":"\"The progression of an amphid sensory organ's neuronal dendrite over time by the attachment of a part of the cell to an anchor and the subsequent migration of the cell body away from the anchor point.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0936393ea5bd47d28a65d51356d5a38d","type":"GO_TERM","name":"amphid sensory organ development","canonical_id":"go:GO:0003386","description":"\"The progression of the amphid sensory organ over time, from its formation to the mature structure. Amphid sensory organs are the sensory organs of nematodes.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"be2efe75b5b4483592654e9ef73084a1","type":"GO_TERM","name":"amphiregulin production","canonical_id":"go:GO:0140730","description":"\"The appearance of amphiregulin due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Amphiregulin (AREG) is a ligand of the epidermal growth factor receptor (EGFR), a widely expressed transmembrane tyrosine kinase. AREG is synthesized as a membrane-anchored precursor protein that can engage in juxtacrine signaling on adjacent cells. Alternatively, after proteolytic processing by cell membrane proteases, mainly TACE/ADAM17, AREG is secreted and behaves as an autocrine or paracrine factor.\" [PMID:24463227]","metadata":null},{"id":"d2609a0104d946eca36c6d7856fabb39","type":"GO_TERM","name":"amphisome","canonical_id":"go:GO:0044753","description":"\"Intermediate organelles formed during macroautophagy through the fusion between autophagosomes and endosomes.\" [GOC:autophagy, GOC:sart, PMID:19008921, PMID:9705327]","metadata":null},{"id":"eea6314b05fa4ec59d9049ffab4ce787","type":"GO_TERM","name":"amphisome membrane","canonical_id":"go:GO:1904930","description":"\"Any membrane that is part of an amphisome.\" [GO_REF:0000064, GOC:bhm, GOC:TermGenie, PMID:17984323]","metadata":null},{"id":"5083a353ee1843a7ac2bc97b890c5117","type":"GO_TERM","name":"amphisome-lysosome fusion","canonical_id":"go:GO:0061911","description":"\"The process in which amphisomes fuse with a vacuole (yeast) or lysosome (e.g. mammals and insects). In the case of yeast, inner membrane-bounded structures (autophagic bodies) appear in the vacuole. Fusion provides an acidic environment and digestive function to the interior of the amphisome.\" [PMID:24219988]","metadata":null},{"id":"494e8b156351404b8616ea696d13bc99","type":"DRUG","name":"amphotericin B","canonical_id":"mesh:D000666","description":null,"metadata":null},{"id":"e605e882ef674303ace078980604f129","type":"DRUG","name":"ampicillin","canonical_id":"mesh:D000667","description":null,"metadata":null},{"id":"d30460a386ca45a088d567581cc8b7ed","type":"GO_TERM","name":"amygdala development","canonical_id":"go:GO:0021764","description":"\"The progression of the amygdala over time from its initial formation until its mature state. The amygdala is an almond-shaped set of neurons in the medial temporal lobe of the brain that play a key role in processing emotions such as fear and pleasure.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"803c7205695340d49e2df223a915cebb","type":"GO_TERM","name":"amygdalin beta-glucosidase activity","canonical_id":"go:GO:0047668","description":"\"Catalysis of the reaction: (R)-amygdalin + H2O = (R)-prunasin + D-glucose.\" [EC:3.2.1.117, RHEA:14177]","metadata":null},{"id":"c0292e7c09f64ed8840c1eb50d884974","type":"GO_TERM","name":"amylase activity","canonical_id":"go:GO:0016160","description":"\"Catalysis of the hydrolysis of amylose or an amylose derivative.\" [GOC:ai]","metadata":null},{"id":"f10ac9f934aa456ebecc226be0232553","type":"GO_TERM","name":"amylase secretion","canonical_id":"go:GO:0036394","description":"\"The controlled release of amylase from a cell.\" [GOC:jc, PMID:19028687]","metadata":null},{"id":"71a1dd63155540ffb67c8b11610f7cca","type":"GO_TERM","name":"amylin binding","canonical_id":"go:GO:0097645","description":"\"Binding to amylin.\" [GOC:bhm, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"062d7c7d3f6345e9a067b54f3930e756","type":"GO_TERM","name":"amylin receptor 1 signaling pathway","canonical_id":"go:GO:0150059","description":"\"The series of molecular signals initiated by an extracellular amylin, or another ligand, combining with an amylin receptor 1 (AMY1), a G protein-coupled receptor complex, on the surface of the target cell. Other ligands that have been shown to initiate the AMY1 signaling pathway include the calcitonin related peptide (CGRP) and adrenomedullin (AM/ADM).\" [GOC:aruk, GOC:bc, PMID:22500019]","metadata":null},{"id":"1d2098f5eece4e26a26206c036edccf4","type":"GO_TERM","name":"amylin receptor 2 signaling pathway","canonical_id":"go:GO:0150060","description":"\"The series of molecular signals initiated by an extracellular amylin, or another ligand, combining with an amylin receptor 2 (AMY2), a G protein-coupled receptor complex, on the surface of the target cell. The AMY2 signaling pathway can also be initiated by adrenomedullin (AM/ADM).\" [GOC:aruk, GOC:bc, PMID:22500019]","metadata":null},{"id":"0c992d4f1c3541138865c3c63f1bd2cd","type":"GO_TERM","name":"amylin receptor 3 signaling pathway","canonical_id":"go:GO:0150061","description":"\"The series of molecular signals initiated by an extracellular amylin, or another ligand, combining with an amylin receptor 3 (AMY3), a G protein-coupled receptor complex, on the surface of the target cell. The AMY3 signaling pathway can also be initiated by the amyloid-beta complex. AMY3 signaling results in increased import of calcium ions into the cytosol across plasma membrane, increased phosphorylation of ERK1/2, Act, and a PKA regulatory subunit II, as well as increased expression of cFos.\" [GOC:aruk, GOC:bc, PMID:22500019]","metadata":null},{"id":"7c7b8efa076544dda4f64e14ac655bb8","type":"GO_TERM","name":"amylin receptor activity","canonical_id":"go:GO:0097643","description":"\"Combining with amylin to initiate a change in cell activity.\" [GOC:bhm, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"2c05bf958eb2437386ce4334e83e3ee6","type":"GO_TERM","name":"amylin receptor complex","canonical_id":"go:GO:1903440","description":"\"A protein complex which is capable of amylin receptor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"6b4044edb6064e2fa972c9e0911909e0","type":"GO_TERM","name":"amylin receptor complex 1","canonical_id":"go:GO:0150056","description":"\"A G protein-coupled receptor complex that serves as a receptor for amylin polypeptide (AMY) and consists of a calcitonin receptor (CTR/CALCR) and a receptor activity-modifying protein (RAMP) 1. Amylin receptor complex 1 (AMY1) also serves as a receptor for the calcitonin related peptide (CGRP) and adrenomedullin (AM/ADM).\" [GOC:aruk, GOC:bc, PMID:22500019]","metadata":null},{"id":"44756765249b43aa84a6b71c7868264f","type":"GO_TERM","name":"amylin receptor complex 2","canonical_id":"go:GO:0150057","description":"\"A G protein-coupled receptor complex that serves as a receptor for amylin polypeptide (AMY) and consists of a calcitonin receptor (CTR/CALCR) and a receptor activity-modifying protein (RAMP) 2. Amylin receptor complex 2 (AMY2) also serves as a receptor for adrenomedullin (AM/ADM).\" [GOC:aruk, GOC:bc, PMID:22500019]","metadata":null},{"id":"db88566b815d4e248c02aebf32ba85d7","type":"GO_TERM","name":"amylin receptor complex 3","canonical_id":"go:GO:0150058","description":"\"A G protein-coupled receptor complex that serves as a receptor for amylin polypeptide (AMY) and consists of a calcitonin receptor (CTR/CALCR) and a receptor activity-modifying protein (RAMP) 3. Amylin receptor complex 3 (AMY3) also serves as a receptor for the amyloid-beta complex. Ligand binding to AMY3 results in increased cytosolic calcium ion levels and in activation on multiple intracellular signaling pathways.\" [GOC:aruk, GOC:bc, PMID:22500019]","metadata":null},{"id":"1c6cbed2b0d94850a2c806350f8d329d","type":"GO_TERM","name":"amylin receptor signaling pathway","canonical_id":"go:GO:0097647","description":"\"A G protein-coupled receptor signaling pathway initiated by amylin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:bhm, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"c718fc4a49fb448cbb1c0b858b414c43","type":"GO_TERM","name":"amylo-alpha-1,6-glucosidase activity","canonical_id":"go:GO:0004135","description":"\"Catalysis of the hydrolysis of (1->6)-alpha-D-glucosidic branch linkages in glycogen phosphorylase limit dextrin. Limit dextrin is the highly branched core that remains after exhaustive treatment of glycogen with glycogen phosphorylase. It is formed because these enzymes cannot hydrolyze the (1->6) glycosidic linkages present.\" [EC:3.2.1.33]","metadata":null},{"id":"bbc69d6eae7a422c9a87f393104168d0","type":"GO_TERM","name":"amyloid fibril formation","canonical_id":"go:GO:1990000","description":"\"The generation of amyloid fibrils, insoluble fibrous protein aggregates exhibiting beta sheet structure, from proteins.\" [GOC:cvs, GOC:jj, GOC:ppm, GOC:sj, PMID:21148556, PMID:22817896, PMID:28937655, PMID:29654159]","metadata":null},{"id":"4ef2e0cdcd8f47a9a9ddd74b451dce36","type":"GO_TERM","name":"amyloid precursor protein biosynthetic process","canonical_id":"go:GO:0042983","description":"\"The chemical reactions and pathways resulting in the formation of amyloid precursor protein (APP), the precursor of amyloid-beta, a glycoprotein associated with Alzheimer's disease.\" [GOC:curators]","metadata":null},{"id":"1ac4ff40f688401489188389784e9d2c","type":"GO_TERM","name":"amyloid precursor protein catabolic process","canonical_id":"go:GO:0042987","description":"\"The chemical reactions and pathways resulting in the breakdown of amyloid precursor protein (APP), the precursor of amyloid-beta, a glycoprotein associated with Alzheimer's disease.\" [GOC:curators]","metadata":null},{"id":"1477a1086a744e95ab199c296add52cb","type":"GO_TERM","name":"amyloid precursor protein metabolic process","canonical_id":"go:GO:0042982","description":"\"The chemical reactions and pathways involving amyloid precursor protein (APP), the precursor of amyloid-beta, a glycoprotein associated with Alzheimer's disease.\" [GOC:curators]","metadata":null},{"id":"0aa8a755464642568cbdda9c0c1d72ca","type":"GO_TERM","name":"amyloid-beta binding","canonical_id":"go:GO:0001540","description":"\"Binding to an amyloid-beta peptide/protein.\" [GOC:hjd]","metadata":null},{"id":"b3b21b65488d44c8bb1a79dfb18eb17e","type":"GO_TERM","name":"amyloid-beta clearance","canonical_id":"go:GO:0097242","description":"\"The process in which amyloid-beta is removed from extracellular brain regions by mechanisms involving cell surface receptors.\" [GOC:aruk, GOC:bc, GOC:BHF, PMID:18289866, PMID:19098903, PMID:26005850]","metadata":null},{"id":"f401fd9bd0534f5690bcbaa9d880afc6","type":"GO_TERM","name":"amyloid-beta clearance by cellular catabolic process","canonical_id":"go:GO:0150094","description":"\"The process in which amyloid-beta is removed from extracellular brain regions by cell surface receptor-mediated endocytosis, followed by intracellular degradation.\" [GOC:aruk, GOC:bc, PMID:18289866]","metadata":null},{"id":"78ddbd7533d54f3eb16d352e78b0261e","type":"GO_TERM","name":"amyloid-beta clearance by transcytosis","canonical_id":"go:GO:0150093","description":"\"The process in which amyloid-beta is removed from extracellular brain regions by cell surface receptor-mediated endocytosis, followed by transcytosis across the blood-brain barrier.\" [GOC:aruk, GOC:bc, PMID:26005850]","metadata":null},{"id":"509b4afe5e0247e3bfa37ae41815077f","type":"GO_TERM","name":"amyloid-beta complex","canonical_id":"go:GO:0106003","description":"\"Protein complex involved in modulation of signaling and synaptic function in the brain, predominantly in the cerebral cortex and hippocampus. Forms dimers and multimers of amyloid beta peptide 40 and peptide 42 (proteolytic cleavage products of amyloid beta A4 protein, also known as amyloid beta precursor protein). Mostly found in the extracellular space with a proportion occurring as membrane-bound species. Influences synaptic plasticity through various receptors, mediates dendritic spine loss leading to decreased synapse density, inhibits long-term potentiation (LTP) and enhances long-term depression (LTD). Soluble multimeric form is the main pathogenic species linked to Alzheimer's disease.\" [GOC:bhm, PMID:18568035]","metadata":null},{"id":"f4235d64e3ea44d28a6818ac44625420","type":"GO_TERM","name":"amyloid-beta formation","canonical_id":"go:GO:0034205","description":"\"The generation of amyloid-beta by cleavage of the amyloid precursor protein (APP).\" [GOC:mah]","metadata":null},{"id":"6ad77d7003824cdfae72281fb4a05db6","type":"GO_TERM","name":"amyloid-beta metabolic process","canonical_id":"go:GO:0050435","description":"\"The chemical reactions and pathways involving amyloid-beta, a glycoprotein associated with Alzheimer's disease, and its precursor, amyloid precursor protein (APP).\" [GOC:ai]","metadata":null},{"id":"c32eb65f12b740eba1e4e5c81ae38bf5","type":"DISEASE","name":"amyloidosis","canonical_id":"mondo:0019065","description":null,"metadata":null},{"id":"31fa8409c73f48c18028880e42acd38a","type":"GO_TERM","name":"amylopectin binding","canonical_id":"go:GO:2001066","description":"\"Binding to amylopectin.\" [GOC:mengo_curators]","metadata":null},{"id":"746dd8560cef437b95ac37330f47c253","type":"GO_TERM","name":"amylopectin biosynthetic process","canonical_id":"go:GO:0010021","description":"\"The chemical reactions and pathways resulting in the formation of amylopectin, the (1->4) linked alpha glucose units with alpha-(1->6) linkages.\" [ISBN:0943088399]","metadata":null},{"id":"5689f29480f44144847cc9b9f204c963","type":"GO_TERM","name":"amylopectin catabolic process","canonical_id":"go:GO:2000897","description":"\"The chemical reactions and pathways resulting in the breakdown of an amylopectin.\" [GOC:mengo_curators]","metadata":null},{"id":"5ae61463104f41749f3eae2969e5f78c","type":"GO_TERM","name":"amylopectin metabolic process","canonical_id":"go:GO:2000896","description":"\"The chemical reactions and pathways involving an amylopectin.\" [GOC:mengo_curators]","metadata":null},{"id":"aa91b2c25ea34b7fa11ea6ca4749f191","type":"GO_TERM","name":"amyloplast","canonical_id":"go:GO:0009501","description":"\"A plastid whose main function is to synthesize and store starch.\" [ISBN:0140514031]","metadata":null},{"id":"9555e5edf478452a80818a331ecb89b4","type":"GO_TERM","name":"amyloplast ADPG pyrophosphorylase complex","canonical_id":"go:GO:0030932","description":"\"An ADPG pyrophosphorylase complex found in the amyloplast.\" [GOC:mah]","metadata":null},{"id":"89b8d867352841c394c2b8a2c58e2a34","type":"GO_TERM","name":"amyloplast envelope","canonical_id":"go:GO:0033096","description":"\"The double lipid bilayer enclosing the amyloplast and separating its contents from the rest of the cytoplasm; includes the intermembrane space.\" [GOC:mah]","metadata":null},{"id":"ca9c31ef56924014b92726eb485cc46b","type":"GO_TERM","name":"amyloplast inner membrane","canonical_id":"go:GO:0033098","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the amyloplast envelope; also faces the amyloplast stroma.\" [GOC:ecd]","metadata":null},{"id":"bbb7c9e2ae5b441b8fe491f5e462fdce","type":"GO_TERM","name":"amyloplast membrane","canonical_id":"go:GO:0033097","description":"\"Either of the lipid bilayers that surround an amyloplast and form the amyloplast envelope.\" [GOC:ecd]","metadata":null},{"id":"516d7492c2ca461ca319f54df1e89561","type":"GO_TERM","name":"amyloplast organization","canonical_id":"go:GO:0009660","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an amyloplast. An amyloplast is a plastid whose main function is to synthesize and store starch.\" [GOC:jid]","metadata":null},{"id":"c02f676a01a74554a2aa66a64d5fe1d9","type":"GO_TERM","name":"amyloplast starch grain","canonical_id":"go:GO:0009568","description":"\"Plant storage body for amylose and amylopectin, 1-100um in diameter, and located in amyloplasts. Also contains small amounts of enzymes, amino acids, lipids and nucleic acids. The shape of the grain varies widely amongst species, but is often spherical or disk-shaped.\" [GOC:jl, PMID:11217978]","metadata":null},{"id":"1df2b1182bf749e5a7f56d579a815586","type":"GO_TERM","name":"amylosucrase activity","canonical_id":"go:GO:0047669","description":"\"Catalysis of the reaction: sucrose + 1,4-alpha-D-glucosyl(n) = D-fructose + 1,4-alpha-D-glucosyl(n+1).\" [EC:2.4.1.4, MetaCyc:AMYLOSUCRASE-RXN]","metadata":null},{"id":"ded3c07d8af14e4aa5fb548e7add7346","type":"DISEASE","name":"amyotrophic lateral sclerosis","canonical_id":"mondo:0004976","description":null,"metadata":null},{"id":"c02035f7014140f99607858e17914215","type":"GO_TERM","name":"anaerobic 2,4,6-trinitrotoluene catabolic process","canonical_id":"go:GO:0046258","description":"\"The chemical reactions and pathways resulting in the breakdown of 2,4,6-trinitrotoluene, 1-methyl-2,4,6-trinitrobenzene, a highly explosive pale yellow crystalline solid, in the absence of oxygen.\" [GOC:ai]","metadata":null},{"id":"26b45b0efd184fbb9e47d33736b70249","type":"GO_TERM","name":"anaerobic acetylene catabolic process","canonical_id":"go:GO:0019487","description":"\"The chemical reactions and pathways involving acetylene, a colorless, volatile, explosive gas, that occur in the absence of oxygen.\" [ISBN:0721662544]","metadata":null},{"id":"c66e300616c14439907566f1e708f7e5","type":"GO_TERM","name":"anaerobic carbon-monoxide dehydrogenase activity","canonical_id":"go:GO:0043885","description":"\"Catalysis of the reaction: CO + 2 oxidized [2Fe-2S]-[ferredoxin] + H2O = 2 reduced [2Fe-2S]-[ferredoxin] + CO2 + 2 H+.\" [RHEA:21040]","metadata":null},{"id":"d3f77fca86994b78b279fd537bd8389d","type":"GO_TERM","name":"anaerobic catabolism of pairs of amino acids","canonical_id":"go:GO:0019668","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of amino acids; in these reactions, one amino acid is oxidised (acts as an electron donor) and a different amino acid is reduced (acts as an electron acceptor); oxidation of the electron-donating amino acid yields energy in the form of ATP.\" [GOC:mah, PMID:13140081]","metadata":null},{"id":"474bbe65222649dbbfc9e82a58ab650b","type":"GO_TERM","name":"anaerobic cellulose catabolic process","canonical_id":"go:GO:1990488","description":"\"The chemical reactions and pathways resulting in the breakdown of cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation, in absence of oxygen.\" [GOC:mengo_curators, PMID:8561466]","metadata":null},{"id":"bd46691ea1b74653ba572538726b6661","type":"GO_TERM","name":"anaerobic electron transport chain","canonical_id":"go:GO:0019645","description":"\"A process in which a series of electron carriers operate together to transfer electrons from donors such as NADH and FADH2 to any of several different terminal electron acceptors other than oxygen to generate a transmembrane electrochemical gradient.\" [GOC:ai, GOC:mtg_electron_transport]","metadata":null},{"id":"5eee775b62454ce2905edcb8e6b3ca2e","type":"GO_TERM","name":"anaerobic ethylbenzene catabolic process","canonical_id":"go:GO:0010130","description":"\"The chemical reactions and pathways resulting in the breakdown of ethylbenzene, a benzene derivative with an ethyl group attached to the ring, which occurs in the absence of oxygen.\" [GOC:pz]","metadata":null},{"id":"8852d89687ea4dfaba5793afa4ee3637","type":"GO_TERM","name":"anaerobic glycerol catabolic process","canonical_id":"go:GO:0019588","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of glycerol, yielding energy in the form of ATP.\" [GOC:mah]","metadata":null},{"id":"5a686d8cff8041beb3f4dbd1d536d6a8","type":"GO_TERM","name":"anaerobic lactate catabolic process","canonical_id":"go:GO:1990485","description":"\"The chemical reactions and pathways resulting in the breakdown of lactate (2-hydroxypropanoic acid) in the absence of oxygen.\" [GOC:mengo_curators, PMID:11133436]","metadata":null},{"id":"d85769c4b1c345a3ac5dfe0e558d21fc","type":"GO_TERM","name":"anaerobic lignin catabolic process","canonical_id":"go:GO:1990487","description":"\"The chemical reactions and pathways resulting in the breakdown of lignin in the absence of oxygen. Lignin is a class of polymers of phenylpropanoid units.\" [DOI:10.1039/C3EE40932E, GOC:mengo_curators]","metadata":null},{"id":"a2ad6cdaa39349d5b215868ac08a34d5","type":"GO_TERM","name":"anaerobic phenol-containing compound biosynthetic process","canonical_id":"go:GO:0046192","description":"\"The chemical reactions and pathways resulting in the formation of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring, in the absence of oxygen.\" [GOC:ai]","metadata":null},{"id":"0de99c5e2af34a70bf0f26dca18695d5","type":"GO_TERM","name":"anaerobic phenol-containing compound catabolic process","canonical_id":"go:GO:0046193","description":"\"The chemical reactions and pathways resulting in the breakdown of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring, in the absence of oxygen.\" [GOC:ai]","metadata":null},{"id":"f9dd7d5663f4408a84888070b0588fc3","type":"GO_TERM","name":"anaerobic phenol-containing compound metabolic process","canonical_id":"go:GO:0042215","description":"\"The chemical reactions and pathways involving a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring, in the absence of oxygen.\" [PMID:12697029]","metadata":null},{"id":"8dbd3560d1774698b3a9aa9300101fce","type":"GO_TERM","name":"anaerobic respiration","canonical_id":"go:GO:0009061","description":"\"The enzymatic release of energy from inorganic and organic compounds (especially carbohydrates and fats) which uses compounds other than oxygen (e.g. nitrate, sulfate) as the terminal electron acceptor.\" [GOC:das, GOC:jl, ISBN:0140513590]","metadata":null},{"id":"a4f20e0d4c774874ab36e0b434d49476","type":"GO_TERM","name":"anaerobic respiration, using ammonium as electron donor","canonical_id":"go:GO:0019331","description":"\"The oxidation of ammonium (NH4) to nitrogen (N2) in the absence of oxygen, using nitrite (NO2) as the electron acceptor. Hydroxylamine and ammonium are combined to yield hydrazine, which is subsequently oxidized to N2.\" [MetaCyc:P303-PWY]","metadata":null},{"id":"8edb939cb305409d9264fde37d10de3b","type":"GO_TERM","name":"anaerobic ribonucleoside-triphosphate reductase complex","canonical_id":"go:GO:0031250","description":"\"An enzyme complex composed of 4 subunits, 2 copies of the large protein (nrdD in E. coli) and 2 copies of the small protein (nrdG in E. coli). It catalyzes the generation of 2'deoxyribonucleotides under anaerobic growth conditions. The larger subunit is the catalytic unit that is activated by the smaller iron-binding subunit.\" [GOC:mlg]","metadata":null},{"id":"0f1cde5e55d94a9789cadf35cd2fbca2","type":"GO_TERM","name":"anaerobic toluene biosynthetic process","canonical_id":"go:GO:0046253","description":"\"The chemical reactions and pathways resulting in the formation of toluene, a volatile monoaromatic hydrocarbon found in crude petroleum and petroleum products, in the absence of oxygen.\" [GOC:ai, PMID:8573493]","metadata":null},{"id":"a303b8f62da340e2ba34cde6f75ca5f9","type":"GO_TERM","name":"anaerobic toluene catabolic process","canonical_id":"go:GO:0046254","description":"\"The chemical reactions and pathways resulting in the breakdown of toluene, a volatile monoaromatic hydrocarbon found in crude petroleum and petroleum products, in the absence of oxygen.\" [GOC:ai]","metadata":null},{"id":"e9acfe11eb9c4726999dd8d6e5c19a48","type":"GO_TERM","name":"anagen","canonical_id":"go:GO:0042640","description":"\"The growth phase of the hair cycle. Lasts, for example, about 3 to 6 years for human scalp hair.\" [PMID:12230507]","metadata":null},{"id":"6867d9ee39de44daabfe1c6092f1beab","type":"DRUG","name":"anagliptin","canonical_id":"mesh:C583175","description":null,"metadata":null},{"id":"089b26e9a360412cacfd7368d1d202e9","type":"DRUG","name":"anagrelide","canonical_id":"gtopdb:7114","description":null,"metadata":null},{"id":"418d75fc62584c90b0cbed511c248bac","type":"DRUG","name":"anakinra","canonical_id":"gtopdb:6972","description":null,"metadata":null},{"id":"19424c1c1eeb4a739e1e4b872afcd975","type":"DRUG","name":"anakinra","canonical_id":"chembl:CHEMBL1201570","description":null,"metadata":null},{"id":"9f6602ad764c4fd281aca32f6a0fdffd","type":"COMBINATION_TREATMENT","name":"anakinra + denosumab + everolimus","canonical_id":"ctgov_combo:ctgov-combo-39c4cf0f6aa7a547","description":null,"metadata":null},{"id":"bee24cd8623143709c6a3eca4deb1e5b","type":"GO_TERM","name":"anal fin development","canonical_id":"go:GO:0033335","description":"\"The process whose specific outcome is the progression of the anal fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"0aa2d52b90be4350979c4d45a9efa710","type":"GO_TERM","name":"anal fin morphogenesis","canonical_id":"go:GO:0035144","description":"\"The process in which the anatomical structures of the anal fin are generated and organized. An anal fin is an unpaired medial fin on the ventral aspect near the caudal end of a fish, which provides lateral stability while swimming.\" [GOC:dgh]","metadata":null},{"id":"e0620c4f54104fe7bcc21234253e5103","type":"GO_TERM","name":"analia development","canonical_id":"go:GO:0007487","description":"\"The process whose specific outcome is the progression of the analia over time, from its formation to the mature structure. The analia is the posterior-most vertral appendage that develops from the genital disc. An example of this process is analia development in Drosophila melanogaster.\" [GOC:ai, GOC:mtg_sensu]","metadata":null},{"id":"510fe9bed7e14d5b8ae7ca59f2d6d37d","type":"GO_TERM","name":"analia morphogenesis","canonical_id":"go:GO:0048809","description":"\"The process in which the anatomical structures of analia are generated and organized. The analia is the posterior-most vertral appendage that develops from the genital disc. An example of this process is analia morphogenesis in Drosophila melanogaster.\" [GOC:ai, GOC:mtg_sensu]","metadata":null},{"id":"a94930f18e7b4682bd64d6320c221618","type":"GO_TERM","name":"anammoxosome","canonical_id":"go:GO:0044222","description":"\"An intracytoplasmic membrane-bounded compartment in anaerobic ammonium oxidation (anammox) bacteria, is the site of anammox catabolism.\" [GOC:dh, PMID:17993524, PMID:19682260]","metadata":null},{"id":"74c60fa322654970bc372e4cd2f28944","type":"GO_TERM","name":"anandamide 11,12 epoxidase activity","canonical_id":"go:GO:0062188","description":"\"Catalysis of the reaction: N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + N-(11,12-epoxy-5Z,8Z,14Z-eicosatrienoyl)-ethanolamine + oxidized [NADPH--hemoprotein reductase].\" [PMID:21289075, RHEA:53144]","metadata":null},{"id":"e7064d907e244b5c98c2d93d2b918ed3","type":"GO_TERM","name":"anandamide 14,15 epoxidase activity","canonical_id":"go:GO:0062189","description":"\"Catalysis of the reaction: N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + N-(14,15-epoxy-5Z,8Z,11Z-eicosatrienoyl)-ethanolamine + oxidized [NADPH--hemoprotein reductase].\" [PMID:21289075, RHEA:53148]","metadata":null},{"id":"9458bbd1b2394eeca63517c244872f96","type":"GO_TERM","name":"anandamide 8,9 epoxidase activity","canonical_id":"go:GO:0062187","description":"\"Catalysis of the reaction: N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + N-(8,9-epoxy-5Z,11Z,14Z-eicosatrienoyl)-ethanolamine + oxidized [NADPH--hemoprotein reductase].\" [PMID:21289075, RHEA:53140]","metadata":null},{"id":"0e34d629e9b54616be8808d07691e214","type":"GO_TERM","name":"anandamide epoxidase activity","canonical_id":"go:GO:0062186","description":"\"Catalysis of the epoxidation of double bonds of the arachidonoyl moiety of anandamide.\" [PMID:21289075]","metadata":null},{"id":"8308afbb3b69426ea3a8b328e094190e","type":"GO_TERM","name":"anaphase","canonical_id":"go:GO:0051322","description":"\"The cell cycle phase, following metaphase, during which the chromosomes separate and migrate towards the poles of the spindle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"c0904e8f69c34b0c978381b26583c30f","type":"GO_TERM","name":"anaphase-promoting complex","canonical_id":"go:GO:0005680","description":"\"A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis. Substrate recognition by APC occurs through degradation signals, the most common of which is termed the Dbox degradation motif, originally discovered in cyclin B.\" [GOC:jh, GOC:vw, PMID:10465783, PMID:10611969]","metadata":null},{"id":"72bc9e48bdca4d55ab4007908c8686a9","type":"GO_TERM","name":"anaphase-promoting complex assembly","canonical_id":"go:GO:1904824","description":"\"The aggregation, arrangement and bonding together of a set of components to form an anaphase-promoting complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:16950791]","metadata":null},{"id":"d1f2b25b379d4e6591648eee30852933","type":"GO_TERM","name":"anaphase-promoting complex binding","canonical_id":"go:GO:0010997","description":"\"Binding to an anaphase-promoting complex. A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"382a9558390a4254837e49a56ac9666f","type":"GO_TERM","name":"anaphase-promoting complex-dependent catabolic process","canonical_id":"go:GO:0031145","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by the anaphase-promoting complex, and mediated by the proteasome.\" [GOC:mah, PMID:15380083, PMID:15840442]","metadata":null},{"id":"4bd3dbffe3164cecb7288d90bdb49e22","type":"DISEASE","name":"anaplastic large cell lymphoma","canonical_id":"mondo:0020325","description":null,"metadata":null},{"id":"bffd59b57d3047c2a8234d16d183e039","type":"GO_TERM","name":"anastral spindle assembly","canonical_id":"go:GO:0055048","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle, the array of microtubules and associated molecules that serves to move duplicated chromosomes apart, in the absence of centrosomes. Formation is initiated by the nucleation of microtubules (MTs) in the vicinity of condensed chromatin. MTs then attach to and congress around the chromatin due to activity of microtubule motors. A bipolar spindle is formed by focusing of the terminal ends of the MT array into spindle poles by molecular motors and cross-linking proteins.\" [GOC:expert_rg, GOC:mtg_sensu, GOC:tb, PMID:15034926]","metadata":null},{"id":"72c192e8179c4b309635501b6e5539f3","type":"GO_TERM","name":"anastral spindle assembly involved in male meiosis","canonical_id":"go:GO:0009971","description":"\"The aggregation, arrangement and bonding together of a set of components to form the anastral spindle in male meiotic cells.\" [GOC:tb, PMID:11973272]","metadata":null},{"id":"7175cf6beb024c6c94ff9f486f9e80bb","type":"DRUG","name":"anastrozole","canonical_id":"gtopdb:5137","description":null,"metadata":null},{"id":"6f1b514f7e75431e91d8728533cf7814","type":"DRUG","name":"anastrozole","canonical_id":"mesh:D000077384","description":null,"metadata":null},{"id":"7aeb60f9499e4040bc21a4503b0d9323","type":"DRUG","name":"anastrozole","canonical_id":"chembl:CHEMBL1399","description":null,"metadata":null},{"id":"576f4469086f44828154cf08aea65895","type":"COMBINATION_TREATMENT","name":"anastrozole + bupropion + chlorthalidone + danazol","canonical_id":"ctgov_combo:ctgov-combo-a691670777a51354","description":null,"metadata":null},{"id":"d6f96487fd374eedbcc13a9bad7682e4","type":"COMBINATION_TREATMENT","name":"anastrozole + capivasertib + durvalumab + fulvestrant + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-63d065939ab7fd6d","description":null,"metadata":null},{"id":"8e03538164554b68b4ea8157fa142e31","type":"COMBINATION_TREATMENT","name":"anastrozole + clomiphene","canonical_id":"ctgov_combo:ctgov-combo-2ea63acacb6b0ad5","description":null,"metadata":null},{"id":"13d770fc7a684b5aa7e52fc68e4bc3bb","type":"COMBINATION_TREATMENT","name":"anastrozole + enzalutamide + exemestane + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-dc39b8e16695122b","description":null,"metadata":null},{"id":"10043505e5db4cfd9e18f422de7c4d96","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane","canonical_id":"ctgov_combo:ctgov-combo-9d85f169b4fb1e5e","description":null,"metadata":null},{"id":"f18683a76cb34fcaaa3840867868cfb5","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + fulvestrant + goserelin + letrozole","canonical_id":"ctgov_combo:ctgov-combo-9fda675f6d0efa20","description":null,"metadata":null},{"id":"5541781baa4c472cae7471787f68c62e","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + fulvestrant + letrozole + palbociclib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-d2728f98f851b062","description":null,"metadata":null},{"id":"09497798e57d44e1934107a28753bc11","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + fulvestrant + letrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-9b064993362369c5","description":null,"metadata":null},{"id":"0230140594724cd3a9db24ec0ea0ed3a","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + fulvestrant + letrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-eff7f76818c84fd0","description":null,"metadata":null},{"id":"6f1967a844ea42ae81dcb9374021f07f","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + goserelin + letrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-5a06cf5bf08ecc9d","description":null,"metadata":null},{"id":"edd5804364df4e7ca6a8b4db50f709fa","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + goserelin + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-f177d05eba831d51","description":null,"metadata":null},{"id":"34df83af59d94a2d81b537e3eecde771","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + letrozole","canonical_id":"ctgov_combo:ctgov-combo-e4f1d8e6c88b7386","description":null,"metadata":null},{"id":"5a0af977642c49d39c9229bc6dda0ac7","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + letrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-02da52e0d002f6f3","description":null,"metadata":null},{"id":"b93b45de655f44839002aa2c1b3e74a8","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + letrozole + vorinostat","canonical_id":"ctgov_combo:ctgov-combo-0eccf405953f9dc8","description":null,"metadata":null},{"id":"625428bbba37426a857c89a3135bc8fe","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + leuprolide + pertuzumab","canonical_id":"ctgov_combo:ctgov-combo-3856d878e5e9651e","description":null,"metadata":null},{"id":"6f9d553cc7ec40409da7365a89235699","type":"COMBINATION_TREATMENT","name":"anastrozole + exemestane + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-a8c585eec9e5066d","description":null,"metadata":null},{"id":"4cbeaba45b5f4f718431742cfede16b3","type":"COMBINATION_TREATMENT","name":"anastrozole + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-efe3a486c2004159","description":null,"metadata":null},{"id":"eee8e0ee279a4b66ae1d5de7e5c2e656","type":"COMBINATION_TREATMENT","name":"anastrozole + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-78cbce93ee6a6a39","description":null,"metadata":null},{"id":"aec55881c996468c8f768819f6ed5ddc","type":"COMBINATION_TREATMENT","name":"anastrozole + fulvestrant + letrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-36caf872357fc3d7","description":null,"metadata":null},{"id":"da746e09fe634e98bb16d59db5bd4387","type":"COMBINATION_TREATMENT","name":"anastrozole + letrozole","canonical_id":"ctgov_combo:ctgov-combo-fef4dab29d64674d","description":null,"metadata":null},{"id":"5531a3d9a44148b394ed96b112791f22","type":"COMBINATION_TREATMENT","name":"anastrozole + letrozole","canonical_id":"ctgov_combo:ctgov-combo-12aca04b7e28dde0","description":null,"metadata":null},{"id":"fd760bab96b24d84a72945dd29294a1b","type":"COMBINATION_TREATMENT","name":"anastrozole + letrozole + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-7f9e641bb223d616","description":null,"metadata":null},{"id":"1df80a3262fc401b808fe4ffb7490318","type":"COMBINATION_TREATMENT","name":"anastrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-13d985e90529022c","description":null,"metadata":null},{"id":"494effb2475841dab751d82f0af074a5","type":"COMBINATION_TREATMENT","name":"anastrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-4fc3f5d46df0fd6b","description":null,"metadata":null},{"id":"da28f394f9ce4747a53a8d394db2b632","type":"GO_TERM","name":"anatomical structure arrangement","canonical_id":"go:GO:0048532","description":"\"The process that gives rise to the configuration of the constituent parts of an anatomical structure. This process pertains to the physical shaping of a rudimentary structure. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.\" [GOC:curators]","metadata":null},{"id":"9f1562a18160437fa892aaa0b83fc3f5","type":"GO_TERM","name":"anatomical structure development","canonical_id":"go:GO:0048856","description":"\"The biological process whose specific outcome is the progression of an anatomical structure from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure, whatever form that may be including its natural destruction. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.\" [GO_REF:0000021]","metadata":null},{"id":"5c90866e5b44450e80f26d20feb40fd8","type":"GO_TERM","name":"anatomical structure formation involved in morphogenesis","canonical_id":"go:GO:0048646","description":"\"The developmental process pertaining to the initial formation of an anatomical structure from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"61cf09de6ea84ba5bfd7604ce3e2110e","type":"GO_TERM","name":"anatomical structure homeostasis","canonical_id":"go:GO:0060249","description":"\"A homeostatic process involved in the maintenance of an internal steady state within a defined anatomical structure of an organism, including control of cellular proliferation and death and control of metabolic function. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.\" [GOC:dph]","metadata":null},{"id":"3eb6578ef39b4051b2cad36b2c8343a2","type":"GO_TERM","name":"anatomical structure maturation","canonical_id":"go:GO:0071695","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an anatomical structure to attain its fully functional state.\" [GOC:mah]","metadata":null},{"id":"46c72c7ba0464020a612b3d972ca3e42","type":"GO_TERM","name":"anatomical structure morphogenesis","canonical_id":"go:GO:0009653","description":"\"The process in which anatomical structures are generated and organized. Morphogenesis pertains to the creation of form.\" [GOC:curators, ISBN:0521436125]","metadata":null},{"id":"82dcdd6ba54f42b6bab843e078e2fdc6","type":"GO_TERM","name":"anatomical structure regression","canonical_id":"go:GO:0060033","description":"\"The developmental process in which an anatomical structure is destroyed as a part of its normal progression.\" [GOC:dph]","metadata":null},{"id":"b1cc41eba1dc4cecb7742e1ded9619ee","type":"GO_TERM","name":"anchoring junction","canonical_id":"go:GO:0070161","description":"\"A cell junction that mechanically attaches a cell (and its cytoskeleton) to neighboring cells or to the extracellular matrix.\" [ISBN:0815332181]","metadata":null},{"id":"99412a324d2346978710fb5011fe7674","type":"GO_TERM","name":"andrastin A biosynthetic process","canonical_id":"go:GO:0140876","description":"\"The chemical reactions and pathways resulting in the formation of andrastin A, a meroterpenoid that exhibits inhibitory activity against ras farnesyltransferase, suggesting that it could have promising antitumor activity.\" [DOI:10.1016/j.tet.2013.07.029]","metadata":null},{"id":"acf583c3e5bf450d9a7d675880f035a0","type":"GO_TERM","name":"androecium development","canonical_id":"go:GO:0048466","description":"\"The process whose specific outcome is the progression of the androecium over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"65329c5f70fe4f67b7c906feab8c529e","type":"GO_TERM","name":"androgen binding","canonical_id":"go:GO:0005497","description":"\"Binding to an androgen, a male sex hormone.\" [GOC:jl]","metadata":null},{"id":"f4df23712f3d49bc88d73bad0592f96b","type":"GO_TERM","name":"androgen biosynthetic process","canonical_id":"go:GO:0006702","description":"\"The chemical reactions and pathways resulting in the formation of androgens, C19 steroid hormones that can stimulate the development of male sexual characteristics.\" [ISBN:0198506732]","metadata":null},{"id":"f4d7f6e8f82d4cef843a8d7571e0a862","type":"GO_TERM","name":"androgen catabolic process","canonical_id":"go:GO:0006710","description":"\"The chemical reactions and pathways resulting in the breakdown of androgens, C19 steroid hormones that can stimulate the development of male sexual characteristics.\" [ISBN:0198506732]","metadata":null},{"id":"3a84d9d8f51843b2b5c5a6741e10ff21","type":"DISEASE","name":"androgen insensitivity syndrome","canonical_id":"mondo:0019154","description":null,"metadata":null},{"id":"5eff73575f64425caad82bedaa526648","type":"GO_TERM","name":"androgen metabolic process","canonical_id":"go:GO:0008209","description":"\"The chemical reactions and pathways involving androgens, C19 steroid hormones that can stimulate the development of male sexual characteristics.\" [ISBN:0198506732]","metadata":null},{"id":"14ca1d8f1c24437bb6dc52b071e7e48a","type":"GO_TERM","name":"androgen receptor signaling pathway","canonical_id":"go:GO:0030521","description":"\"A nuclear receptor-mediated signaling pathway initiated by an androgen binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah]","metadata":null},{"id":"5433246e98054a3f8c88555ef2467abc","type":"GO_TERM","name":"androgen secretion","canonical_id":"go:GO:0035935","description":"\"The regulated release of an androgen into the circulatory system. Androgens are steroid hormones that stimulate or control the development and maintenance of masculine characteristics in vertebrates.\" [GOC:sl]","metadata":null},{"id":"676e931695914d35bb7adbb407c5bd4e","type":"DISEASE","name":"androgenetic alopecia","canonical_id":"mondo:0005339","description":null,"metadata":null},{"id":"0f279fd1299d492191ff6f257319bf34","type":"DISEASE","name":"androgenic alopecia","canonical_id":"mesh:D000505","description":null,"metadata":null},{"id":"ef26596f6ef14b7e806d9d533f8f2602","type":"GO_TERM","name":"androst-4-ene-3,17-dione biosynthetic process","canonical_id":"go:GO:1903449","description":"\"The chemical reactions and pathways resulting in the formation of androst-4-ene-3,17-dione.\" [GO_REF:0000068, GOC:mr, GOC:TermGenie, PMID:2028480, PMID:4149619]","metadata":null},{"id":"89bcc3d1540f4cbb85894929b8ca0650","type":"GO_TERM","name":"androst-4-ene-3,17-dione monooxygenase activity","canonical_id":"go:GO:0047096","description":"\"Catalysis of the reaction: AH(2) + androst-4-ene-3,17-dione + O2 = A + H2O + testololactone.\" [EC:1.14.99.12, RHEA:22696]","metadata":null},{"id":"d1d07ad20f1940fe959aa3cb6fffbf9a","type":"GO_TERM","name":"androstan-3-alpha,17-beta-diol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047044","description":"\"Catalysis of the reaction: NAD+ + androstan-3-alpha,17-beta-diol = 17-beta-hydroxyandrostan-3-one + NADH + H+.\" [RHEA:22400]","metadata":null},{"id":"8d9275c24a26424495b2b1a5e2fbca30","type":"GO_TERM","name":"androstenedione secretion","canonical_id":"go:GO:0035941","description":"\"The regulated release of androstenedione (androst-4-ene-3,17-dione) into the circulatory system.\" [GOC:sl]","metadata":null},{"id":"35c0790eb0ee4191bdedb360bc7b1134","type":"GO_TERM","name":"androsterone dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0047023","description":"\"Catalysis of the reaction: NAD(P)+ + androsterone = NAD(P)H + H+ + 5-alpha-androstane-3,17-dione.\" [EC:1.1.1.209]","metadata":null},{"id":"957406fe07a44bed82dde6739e4a90e4","type":"DISEASE","name":"anemia","canonical_id":"mondo:0002280","description":null,"metadata":null},{"id":"2d5694715a7f4a349f4cc5b9c6987f33","type":"DISEASE","name":"anemia (phenotype)","canonical_id":"efo:0004272","description":null,"metadata":null},{"id":"33f03aff2b0c4b47aa2a72c739fb20bc","type":"GO_TERM","name":"anesthesia-resistant memory","canonical_id":"go:GO:0007615","description":"\"The memory process that results in the formation of consolidated memory resistant to disruption of the patterned activity of the brain, without requiring protein synthesis.\" [PMID:15143285, PMID:17088531]","metadata":null},{"id":"4950948b70054217b6b010a385c0b31e","type":"GO_TERM","name":"anestrus phase","canonical_id":"go:GO:0160266","description":"\"A biological phase of reproductive dormancy characterized by the temporary cessation of reproductive cyclicity, marked by the absence of ovarian follicular development, estrous behavior, and ovulation. This phase represents a period of sexual quiescence between estrous cycles or breeding seasons.\" [PMID:34635709, WIKIPEDIA:Estrous_cycle]","metadata":null},{"id":"581198a1412c4c7a863e5b090a110212","type":"DISEASE","name":"aneurysm","canonical_id":"efo:0009659","description":null,"metadata":null},{"id":"ed5c7ca6ab9d4950ae846f2e3f3eff37","type":"GO_TERM","name":"angelicin synthase activity","canonical_id":"go:GO:0102995","description":"\"Catalysis of the reaction: columbianetin + NADPH + O2 + H+ = angelicin + acetone + NADP + 2 H2O.\" [EC:1.14.14.148, GOC:pz]","metadata":null},{"id":"dac76e0f5a984c6bb453065356408325","type":"DISEASE","name":"angina pectoris","canonical_id":"efo:0003913","description":null,"metadata":null},{"id":"b75b48c8672d4493a03182f8501d23d9","type":"DISEASE","name":"angina unstable","canonical_id":"efo:0020925","description":null,"metadata":null},{"id":"1c8cf3b914ac42deb3ef1ac27f9c0cc0","type":"GO_TERM","name":"angioblast cell differentiation","canonical_id":"go:GO:0035779","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of an angioblast cell. Angioblasts are one of the two products formed from hemangioblast cells (the other being pluripotent hemopoietic stem cells).\" [CL:0000566, GOC:yaf]","metadata":null},{"id":"5f5fd63f8c27452e913a324dfeddd46b","type":"GO_TERM","name":"angioblast cell migration","canonical_id":"go:GO:0035476","description":"\"The orderly movement of angioblasts, cells involved in blood vessel morphogenesis.\" [GOC:dgh, PMID:19815777]","metadata":null},{"id":"e4e3205d497341bb82579b44996395ef","type":"GO_TERM","name":"angioblast cell migration from lateral mesoderm to midline","canonical_id":"go:GO:0035479","description":"\"The directed movement of angioblasts from the lateral mesoderm to the midline which occurs as part of the formation of the early midline vasculature.\" [GOC:dgh, PMID:11861480]","metadata":null},{"id":"80ae4588b26041f9a300e34f00568b7c","type":"GO_TERM","name":"angioblast cell migration involved in selective angioblast sprouting","canonical_id":"go:GO:0035475","description":"\"The directional migration of angioblast cells as part of selective angioblast sprouting, which results in angioblast segregation into arterial and venous populations.\" [GOC:dgh, PMID:19815777]","metadata":null},{"id":"4fe97b3ea91c4a34a7b93408b1d5bf7c","type":"DISEASE","name":"angioedema","canonical_id":"mondo:0010481","description":null,"metadata":null},{"id":"76dddd39b38c42b4a5390d0e014a8ff0","type":"GO_TERM","name":"angiogenesis","canonical_id":"go:GO:0001525","description":"\"Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.\" [ISBN:0878932453]","metadata":null},{"id":"2d9490c1d51d4f57b622ea470365b966","type":"GO_TERM","name":"angiogenesis involved in coronary vascular morphogenesis","canonical_id":"go:GO:0060978","description":"\"Blood vessel formation in the heart when new vessels emerge from the proliferation of pre-existing blood vessels.\" [GOC:mtg_heart]","metadata":null},{"id":"ca03ee92501c4152b310f353b3d92086","type":"GO_TERM","name":"angiogenesis involved in wound healing","canonical_id":"go:GO:0060055","description":"\"Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to a damaged tissue, following an injury.\" [GOC:dph, PMID:15039218]","metadata":null},{"id":"4b42639c9cb644a7b9505fa5b1e1a99f","type":"GO_TERM","name":"angiogenic sprout fusion","canonical_id":"go:GO:0120077","description":"\"The connection of an angiogenic sprout to another vessel or sprout during the formation of vascular networks by sprouting angiogenesis.\" [GOC:cvs, PMID:28264837]","metadata":null},{"id":"7437d2bf454248a6bd8954a3586e67c7","type":"GO_TERM","name":"angiogenin-PRI complex","canonical_id":"go:GO:0032311","description":"\"A stable heterodimer of angiogenin and placental ribonuclease inhibitor; interaction between angiogenin and PRI prevents angiogenin binding to its receptor to stimulate angiogenesis.\" [PMID:2706246, PMID:3470787]","metadata":null},{"id":"19bc8b2505704046939dfac9f8c4530b","type":"DISEASE","name":"angiomyolipoma","canonical_id":"mondo:0002603","description":null,"metadata":null},{"id":"02474d69f55a49fdb7b3ccf1aff951da","type":"DISEASE","name":"angioosteohypertrophic syndrome","canonical_id":"mondo:0007864","description":null,"metadata":null},{"id":"04d891dafe8d476180eb27d2b5ea6d1d","type":"GO_TERM","name":"angiostatin binding","canonical_id":"go:GO:0043532","description":"\"Binding to angiostatin, a proteolytic product of plasminogen or plasmin containing at least one intact kringle domain, and which is an inhibitor of angiogenesis.\" [PMID:16043488]","metadata":null},{"id":"a9158259a1c34ba481362561361855a0","type":"GO_TERM","name":"angiotensin maturation","canonical_id":"go:GO:0002003","description":"\"The process leading to the attainment of the full functional capacity of angiotensin by conversion of angiotensinogen into mature angiotensin in the blood.\" [ISBN:0721643949]","metadata":null},{"id":"0f4276cafebe4c33b210291a16968c2b","type":"GO_TERM","name":"angiotensin receptor activity","canonical_id":"go:GO:0001595","description":"\"Combining with angiotensin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"5f0ba36ebfbd40248569e3413843f8d0","type":"GO_TERM","name":"angiotensin receptor binding","canonical_id":"go:GO:0031701","description":"\"Binding to an angiotensin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c6ec4e4eef9e434c892e6a60020d899b","type":"GO_TERM","name":"angiotensin type I receptor activity","canonical_id":"go:GO:0001596","description":"\"An angiotensin receptor activity that acts via Gq-mediated activation of phospholipase C followed by phosphoinositide hydrolysis and Ca2+ signaling, and may act via additional signaling mechanisms.\" [GOC:mah, PMID:10977869]","metadata":null},{"id":"a6e4736a236f4da79ae1996c6f6efd48","type":"GO_TERM","name":"angiotensin type II receptor activity","canonical_id":"go:GO:0004945","description":"\"An angiotensin receptor activity that acts via Gi protein coupling and cGMP (NO) generation, and may also act via additional signaling mechanisms.\" [GOC:mah, PMID:10977869]","metadata":null},{"id":"701020947818411d9c772ec9a5851d96","type":"GO_TERM","name":"angiotensin-activated signaling pathway","canonical_id":"go:GO:0038166","description":"\"A G protein-coupled receptor signaling pathway initiated by angiotensin II binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nhn, GOC:signaling, PMID:10977869]","metadata":null},{"id":"367d50059fdf40bbb8221302ab86e4aa","type":"GO_TERM","name":"angiotensin-activated signaling pathway involved in heart process","canonical_id":"go:GO:0086098","description":"\"An angiotensin receptor signaling pathway which contributes to a circulatory system process carried out by the heart.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, PMID:17376402]","metadata":null},{"id":"18b7c38351ae45e988c7908150abd8f8","type":"GO_TERM","name":"angiotensin-mediated drinking behavior","canonical_id":"go:GO:0003051","description":"\"The drinking behavior that is mediated by the action of angiotensin in the brain. Angiotensin stimulates the brain centers that control thirst.\" [GOC:mtg_cardio]","metadata":null},{"id":"b833d5a6750d4398a873795dda30372b","type":"GO_TERM","name":"angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0001998","description":"\"The decrease in blood vessel diameter as a result of the release of angiotensin into the blood stream.\" [GOC:mtg_cardio, GOC:pr, ISBN:0721643949]","metadata":null},{"id":"2adf87bd3c1b44ceae264dfc7eb2fa66","type":"GO_TERM","name":"angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0002033","description":"\"The process that increases the diameter of a blood vessel via the renin-angiotensin system.\" [GOC:pr, ISBN:0323031951, PMID:10425188]","metadata":null},{"id":"d0480461a4b24492bb30d8ba8f43af1c","type":"DISEASE","name":"angle-closure glaucoma","canonical_id":"mondo:0001744","description":null,"metadata":null},{"id":"75d3a66c2ef540219f023500e91d033b","type":"GO_TERM","name":"angular vestibuloocular reflex","canonical_id":"go:GO:0060006","description":"\"A vestibular reflex by which a response to an angular acceleration stimulus begins with an afferent nerve impulse from a receptor in the semi-circular canal and ends with the compensatory action of eye muscles. Signaling never reaches a level of consciousness.\" [GOC:dph, PMID:11784757]","metadata":null},{"id":"d1b710318cdc48e696c3a908783a52e1","type":"GO_TERM","name":"anhydrosialidase activity","canonical_id":"go:GO:0033995","description":"\"Catalysis of the reaction: an N-acetylneuraminate glycoside = 2,7-anhydro-alpha-N-acetylneuraminate + an alpha-sialyl group. This reaction is the elimination of alpha-sialyl groups in N-acetylneuraminic acid glycosides, releasing 2,7-anhydro-alpha-N-acetylneuraminate.\" [EC:4.2.2.15]","metadata":null},{"id":"d34895461d564895bc04120276270b73","type":"GO_TERM","name":"anhydrotetracycline monooxygenase activity","canonical_id":"go:GO:0047670","description":"\"Catalysis of the reaction: anhydrotetracycline + H+ + NADPH + O2 = 12-dehydrotetracycline + H2O + NADP+.\" [EC:1.14.13.38, RHEA:11976]","metadata":null},{"id":"8548cb0861254cf88fe5b6417db4ab96","type":"DRUG","name":"anidulafungin","canonical_id":"mesh:C102786","description":null,"metadata":null},{"id":"168f242d10e94d4eb1e24c466e5cfcbd","type":"DRUG","name":"anifrolumab","canonical_id":"gtopdb:8258","description":null,"metadata":null},{"id":"93d732ffb27044aa935597bf25921214","type":"DRUG","name":"anifrolumab","canonical_id":"chembl:CHEMBL2364653","description":null,"metadata":null},{"id":"4548449768c5425f822f0fab697ab59e","type":"COMBINATION_TREATMENT","name":"anifrolumab + belimumab","canonical_id":"ctgov_combo:ctgov-combo-1299cd453e6d089b","description":null,"metadata":null},{"id":"eae80c5d43bb4f33ba2e831af344812e","type":"GO_TERM","name":"animal gross anatomical part developmental process","canonical_id":"go:GO:0160108","description":"\"A developmental process whose specific outcome is the progression of a gross anatomical part of an animal over time from an initial condition to a later condition.\" [GOC:pg]","metadata":null},{"id":"1a0c82000278492197690b66def38ed8","type":"GO_TERM","name":"animal organ development","canonical_id":"go:GO:0048513","description":"\"Development of a tissue or tissues that work together to perform a specific function or functions. Development pertains to the process whose specific outcome is the progression of a structure over time, from its formation to the mature structure. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"1469009b404c41ab8d2c40d551b662bd","type":"GO_TERM","name":"animal organ formation","canonical_id":"go:GO:0048645","description":"\"The process pertaining to the initial formation of an animal organ from unspecified parts. The process begins with the specific processes that contribute to the appearance of the discrete structure, such as inductive events, and ends when the structural rudiment of the organ is recognizable, such as a condensation of mesenchymal cells into the organ rudiment. Organs are a natural part or structure in an animal or a plant, capable of performing some special action (termed its function), which is essential to the life or well-being of the whole. The heart and lungs are organs of animals, and the petal and leaf are organs of plants. In animals the organs are generally made up of several tissues, one of which usually predominates, and determines the principal function of the organ.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"b156077152f24a4da7d3e7430ddf555a","type":"GO_TERM","name":"animal organ maturation","canonical_id":"go:GO:0048799","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an animal organ to attain its fully functional state. An organ is a tissue or set of tissues that work together to perform a specific function or functions.\" [GOC:curators]","metadata":null},{"id":"bced727fc8804af09a2d5cac03858b89","type":"GO_TERM","name":"animal organ morphogenesis","canonical_id":"go:GO:0009887","description":"\"Morphogenesis of an animal organ. An organ is defined as a tissue or set of tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:curators, GOC:dgh, ISBN:0471245208, ISBN:0721662544]","metadata":null},{"id":"83b807fa541c4395a72ffc4b63061a6b","type":"GO_TERM","name":"animal organ regeneration","canonical_id":"go:GO:0031100","description":"\"The regrowth of a lost or destroyed animal organ.\" [GOC:mah]","metadata":null},{"id":"63974a3f25a44c3897fa68c513bc0fce","type":"GO_TERM","name":"anion binding","canonical_id":"go:GO:0043168","description":"\"Binding to an anion, a charged atom or group of atoms with a net negative charge.\" [GOC:jl]","metadata":null},{"id":"b5613eed8a2d4af5945ff25374bb3a8c","type":"DRUG","name":"anisindione","canonical_id":"gtopdb:6960","description":null,"metadata":null},{"id":"9fdea73a378f48b2b7867065a6cae30f","type":"DRUG","name":"anisindione","canonical_id":"chembl:CHEMBL712","description":null,"metadata":null},{"id":"19a91886a19b4759812689439f3c2f17","type":"GO_TERM","name":"anisotropic cell growth","canonical_id":"go:GO:0051211","description":"\"The process in which a cell irreversibly increases in size in one or more axes, where the growth rate varies according to the direction of growth. Growth may be limited to a particular axis, axes, or to particular locations on the surface of the cell.\" [GOC:ai]","metadata":null},{"id":"1a856d2962614c06a75d2ff3d4dfbeb9","type":"DISEASE","name":"ankylosing spondylitis","canonical_id":"mondo:0005306","description":null,"metadata":null},{"id":"75fbb257865b465b81ccd31b2f88f178","type":"GO_TERM","name":"ankyrin binding","canonical_id":"go:GO:0030506","description":"\"Binding to ankyrin, a 200 kDa cytoskeletal protein that attaches other cytoskeletal proteins to integral membrane proteins.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"ce08607a3ed34f74852862bbf0c67ea3","type":"GO_TERM","name":"ankyrin repeat binding","canonical_id":"go:GO:0071532","description":"\"Binding to an ankyrin repeat of a protein. Ankyrin repeats are tandemly repeated modules of about 33 amino acids; each repeat folds into a helix-loop-helix structure with a beta-hairpin/loop region projecting out from the helices at a 90-degree angle, and repeats stack to form an L-shaped structure.\" [GOC:mah, InterPro:IPR002110]","metadata":null},{"id":"39fd5023ef0246cd88b92bcf487a9e88","type":"GO_TERM","name":"ankyrin-1 complex","canonical_id":"go:GO:0170014","description":"\"A complex composed of ANK1, RHCE, RHAG, SLC4A1, EPB42, GYPA, GYPB and AQP1, that functions in the stability and shape of the erythrocyte membrane in human.\" [PMID:35835865]","metadata":null},{"id":"633ef70cb33247388e8745a018e2b6c7","type":"GO_TERM","name":"annealing activity","canonical_id":"go:GO:0140666","description":"\"An activity that facilitates the formation of a complementary double-stranded polynucleotide molecule.\" [PMID:22888405]","metadata":null},{"id":"17a7a3b887804882aff4784a5221477d","type":"GO_TERM","name":"annular furrow extracellular matrix","canonical_id":"go:GO:0060108","description":"\"The extracellular matrix part that is a regularly spaced indentation in the outer cortical layer of the cuticle. The pattern of annular furrows corresponds to sites of invaginations in hypodermal cell membranes that, in turn, correspond to submembranous regions where actin microfilament bundles assemble early in lethargus, the first phase of the molting cycle in which activity and feeding decline.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"d8aa2f5ea16045f68e02e608725271bd","type":"GO_TERM","name":"annulate lamellae","canonical_id":"go:GO:0005642","description":"\"Stacks of endoplasmic reticulum (ER) membranes containing a high density of nuclear pores, thought to form from excess nuclear membrane components, that have been described in a number of different cells. Annulate lamellar membranes are continuous with and embedded within the ER.\" [PMID:12631728]","metadata":null},{"id":"a830d97df2e3471090506ca4f39a80e3","type":"GO_TERM","name":"annuli extracellular matrix","canonical_id":"go:GO:0060107","description":"\"The extracellular matrix that is a regularly spaced circumferential ridge present in the cortical region of the cuticle. Annuli are delineated by annular furrows and are present throughout the cuticle with the exception of lateral regions where longitudinal alae are present.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"fc75523b3c954706a9b057325a5e0f64","type":"DISEASE","name":"anogenital human papillomavirus infection","canonical_id":"mondo:0005647","description":null,"metadata":null},{"id":"1638293dd5b44c52b8b2a337f46cf2b4","type":"GO_TERM","name":"anoikis","canonical_id":"go:GO:0043276","description":"\"Apoptosis triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.\" [GOC:jl, PMID:37667281]","metadata":null},{"id":"0b837fba725b406ba7814c3684024e54","type":"DISEASE","name":"anovulation","canonical_id":"mondo:0002775","description":null,"metadata":null},{"id":"18062050bd73440b8c25008f85c7e656","type":"GO_TERM","name":"anoxia protection","canonical_id":"go:GO:0090519","description":"\"Any process in which an organism or cell protects itself from anoxia, which may also result in resistance to repeated exposure to anoxia.\" [GOC:tb, PMID:19372430]","metadata":null},{"id":"51214941f58b4b6aa4a144cb123492ed","type":"DRUG","name":"anrikefon","canonical_id":"gtopdb:14403","description":null,"metadata":null},{"id":"6202c65a94ba45e1aeabe56966aaf165","type":"GO_TERM","name":"ansamycin biosynthetic process","canonical_id":"go:GO:0033070","description":"\"The chemical reactions and pathways leading to the formation of ansamycins, any of a group of complex macrolactam compounds characterized by a cyclic structure in which an aliphatic ansa chain forms a bridge between two non-adjacent positions of a cyclic p-system; many exhibit antibacterial, antifungal or antitumor activity.\" [GOC:mah, https://doi.org/10.1016/j.crci.2008.07.003]","metadata":null},{"id":"1cde50cb0e2b4f838d560f50f0b4a04e","type":"DRUG","name":"antazoline","canonical_id":"mesh:D000865","description":null,"metadata":null},{"id":"6483ad025fad47faac9017abc1d7abd7","type":"GO_TERM","name":"antennal development","canonical_id":"go:GO:0007469","description":"\"The process whose specific outcome is the progression of the antenna over time, from its formation to the mature structure. The antenna are the sensory structures on the head that are capable of detecting various environmental stimuli.\" [http://fly.ebi.ac.uk/.bin/cvreport2?id=FBcv0004526]","metadata":null},{"id":"72de2a55ff3642a78cc684924a9d974b","type":"GO_TERM","name":"antennal joint development","canonical_id":"go:GO:0048098","description":"\"The process whose specific outcome is the progression of the antennal joint over time, from its formation to the mature structure. The antennal joint is the joint between antennal segments.\" [GOC:jid]","metadata":null},{"id":"bcd8cc4d94484aab9f441ed2371778ca","type":"GO_TERM","name":"antennal joint morphogenesis","canonical_id":"go:GO:0048801","description":"\"The process in which the anatomical structures of the antennal joint are generated and organized.\" [GOC:jid]","metadata":null},{"id":"fe97d88701a9461f990d11fd1689a030","type":"GO_TERM","name":"antennal morphogenesis","canonical_id":"go:GO:0048800","description":"\"The process in which the anatomical structures of the antenna are generated and organized.\" [GOC:jid]","metadata":null},{"id":"c20711b0b0344cd5a0126cd484c35aee","type":"GO_TERM","name":"anterior Malpighian tubule development","canonical_id":"go:GO:0061327","description":"\"The process whose specific outcome is the progression of the anterior Malpighian tubule over time, from its formation to the mature structure. The pair of anterior tubules arise from a dorsal region of the embryonic hindgut and projects forwards through the body cavity. A Malpighian tubule is a fine, thin-walled excretory tubule in insects which connects with the posterior part of the gut.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"9f7c9817f76c494ea6ceaf71d3de35b9","type":"GO_TERM","name":"anterior cell cortex","canonical_id":"go:GO:0061802","description":"\"The region that lies just beneath the plasma membrane in the part of a cell that is closest to the anterior as defined by the developing, or existing, anterior/posterior axis.\" [GOC:15666355, GOC:17981131, GOC:dph, GOC:kmv]","metadata":null},{"id":"05bff70236c14783ba05ef62b3d94011","type":"GO_TERM","name":"anterior cibarial plate development","canonical_id":"go:GO:0048722","description":"\"The process whose specific outcome is the progression of the anterior cibarial plate over time, from their formation to the mature structure.\" [GOC:rc]","metadata":null},{"id":"c074582004e34f78bc6fef3fe6d12056","type":"GO_TERM","name":"anterior cibarial plate morphogenesis","canonical_id":"go:GO:0048717","description":"\"The process in which the anatomical structures of the anterior cibarial plate are generated and organized.\" [GOC:rc]","metadata":null},{"id":"8e0ccf21a15c4b59ac6786459500b132","type":"GO_TERM","name":"anterior commissure morphogenesis","canonical_id":"go:GO:0021960","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in one half of the cerebral cortex towards target cells in the contralateral half. This axonal process is a member of those that make up the anterior commissure, a small midline fiber tract that lies at the anterior end of the corpus callosum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"54634a77e4a74ef2b3f145a21eb78bac","type":"GO_TERM","name":"anterior compartment pattern formation","canonical_id":"go:GO:0007387","description":"\"The process giving rise to specification of cell identity in the anterior compartments of the segmented embryo.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"e96db2408eb349778c212236094e6025","type":"GO_TERM","name":"anterior head development","canonical_id":"go:GO:0097065","description":"\"The process whose specific outcome is the progression of the anterior part of the head over time, from its formation to the mature structure.\" [GOC:yaf, PMID:14695376, PMID:15857913]","metadata":null},{"id":"7209ceb700f64b6b9f44fe801674a514","type":"GO_TERM","name":"anterior head segmentation","canonical_id":"go:GO:0035288","description":"\"Partitioning the insect head anlage into procephalic (labral, (ocular), antennal and intercalary) segments. The procephalic segments lie anterior to the gnathal (posterior head) segments, and are pattered by different segmentation gene cascades to the abdominal, thoracic and posterior head (gnathal) segments.\" [PMID:15382136]","metadata":null},{"id":"5cca5cb93f5f4e6b9cde69f68bf5929a","type":"GO_TERM","name":"anterior lateral line development","canonical_id":"go:GO:0048899","description":"\"The process whose specific outcome is the progression of the anterior lateral line over time, from its formation to the mature structure. The anterior lateral line consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians. The anterior lateral line develops from cranial ectodermal placodes situated between the eye and ear.\" [ISBN:0125296509]","metadata":null},{"id":"a17338256597412a8d1d83c9d4bdb4d7","type":"GO_TERM","name":"anterior lateral line ganglion development","canonical_id":"go:GO:0048907","description":"\"The process whose specific outcome is the progression of the anterior lateral line ganglion over time, from its formation to the mature structure. The anterior lateral line ganglion develops from cranial ectodermal placodes situated between the eye and ear.\" [ISBN:0125296509]","metadata":null},{"id":"da3aad7a6e3f4abdad4a096b18417cbb","type":"GO_TERM","name":"anterior lateral line ganglion neuron differentiation","canonical_id":"go:GO:0048908","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron of the anterior lateral line ganglion.\" [PMID:15018940]","metadata":null},{"id":"0ec309ca17b8418eb7a840e5cbe6402a","type":"GO_TERM","name":"anterior lateral line nerve development","canonical_id":"go:GO:0048909","description":"\"The process whose specific outcome is the progression of the anterior lateral line nerve over time, form its formation to the mature structure. The anterior lateral line nerve contains efferent axons that innervate hair cells of the ALL and afferent axons that project to an octavolateralis column in the hindbrain. The octavolateralis column consists of the medial octavolateralis nucleus (MON), the caudal octavolateralis nucleus, and the magnocellular nucleus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0125296509]","metadata":null},{"id":"2633c3bd62544253b953b132cf2aec8e","type":"GO_TERM","name":"anterior lateral line nerve glial cell development","canonical_id":"go:GO:0048939","description":"\"The process aimed at the progression of a glial cell in the anterior lateral line nerve over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dgh]","metadata":null},{"id":"1e1ac74c77b745ceb61e191e8055346c","type":"GO_TERM","name":"anterior lateral line nerve glial cell differentiation","canonical_id":"go:GO:0048913","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glial cell in the anterior lateral line nerve.\" [PMID:15832385]","metadata":null},{"id":"61fc5d2cb8a34e27b5d0e613856ce2eb","type":"GO_TERM","name":"anterior lateral line nerve glial cell morphogenesis involved in differentiation","canonical_id":"go:GO:0048940","description":"\"The process in which the structures of a glial cell in the anterior lateral line nerve are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of a glial cell in the anterior lateral line nerve.\" [GOC:dgh]","metadata":null},{"id":"cce9e33f5db64f70b02352af475a4738","type":"GO_TERM","name":"anterior lateral line neuromast cupula development","canonical_id":"go:GO:0048904","description":"\"The process whose specific outcome is the progression of the anterior lateral line neuromast cupula over time, from its formation to the mature structure. The cupula is secreted by mantle cells and the ciliary bundles of all of the hair cells of the neuromast are embedded in it. The cupula provides a mechanical linkage between the hair cells and the external hydrodynamic environment. The cupula of superficial neuromasts grows continuously, while the height of the cupula of canal neuromasts is limited by canal diameter.\" [ISBN:0125296509]","metadata":null},{"id":"c4d07c02d30347e1accbbb20b1115611","type":"GO_TERM","name":"anterior lateral line neuromast deposition","canonical_id":"go:GO:0048902","description":"\"The process in which a migrating neuromast primordium deposits clusters of undifferentiated cells (proneuromasts) along its migratory path in the developing anterior lateral line.\" [PMID:15832385]","metadata":null},{"id":"e7ad65f374ac495c8e9c9aa48b72aab3","type":"GO_TERM","name":"anterior lateral line neuromast development","canonical_id":"go:GO:0048901","description":"\"The process whose specific outcome is the progression of the anterior lateral line neuromast over time, from its formation to the mature structure. The neuromast is the sensory receptor of the anterior lateral line system and is composed of a population of sensory hair cells, and nonsensory supporting cells and mantle cells. Neuromast are located superficially on the epithelium or in lateral line canals.\" [ISBN:0125296509]","metadata":null},{"id":"c196cf46024d4c7fb952cf2a3d4a6648","type":"GO_TERM","name":"anterior lateral line neuromast hair cell development","canonical_id":"go:GO:0035676","description":"\"The process whose specific outcome is the progression of an anterior lateral line neuromast hair cell over time, from its formation to the mature structure. A neuromast hair cell is a hair cell that acts as a sensory receptor of the neuromast; it is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface. Cell development does not include the steps involved in committing a cell to a specific fate.\" [ISBN:0125296509, ISBN:0387968377]","metadata":null},{"id":"7b692ebd9928426db2117cc350dbdff0","type":"GO_TERM","name":"anterior lateral line neuromast hair cell differentiation","canonical_id":"go:GO:0048903","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an anterior lateral line neuromast hair cell. Neuromast hair cells are the sensory receptors of the neuromast and are located in a portion of the neuromast called the sensory strip. Each hair cell of the neuromast is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface. There are approximately seven hair cells within each neuromast, with each hair cell innervated by afferent and efferent neurons.\" [ISBN:0125296509, ISBN:0387968377]","metadata":null},{"id":"5afabac9701745ceb1c1121fe41445ec","type":"GO_TERM","name":"anterior lateral line neuromast hair cell morphogenesis","canonical_id":"go:GO:0035679","description":"\"The change in form (cell shape and size) that occurs when an anterior lateral line neuromast hair cell progresses from its initial formation to its mature state. A neuromast hair cell is a hair cell that acts as a sensory receptor of the neuromast; it is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface.\" [ISBN:0125296509, ISBN:0387968377]","metadata":null},{"id":"f55a7f6a53b84b539a1878d26cbac249","type":"GO_TERM","name":"anterior lateral line neuromast mantle cell differentiation","canonical_id":"go:GO:0048905","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an anterior lateral line neuromast mantle cell. Mantle cells are non-sensory cells that surround the sensory strip, separating the neuromast from the epidermis. Mantle cells secrete the cupula in which the ciliary bundles of all of the hair cells are embedded.\" [ISBN:0125296509]","metadata":null},{"id":"3965396f9e544c90a92c53ad8122c1cf","type":"GO_TERM","name":"anterior lateral line neuromast primordium migration","canonical_id":"go:GO:0048900","description":"\"The migration of a cluster of a relatively undifferentiated cell along the developing anterior lateral line, originating from cranial ectodermal placodes situated between the eye and the ear. The neuromast primordium deposits proneuromasts along the lateral line, from which the neuromasts will develop.\" [GOC:dgh, PMID:15832385]","metadata":null},{"id":"39a361817eb74050b4be71baed637f2c","type":"GO_TERM","name":"anterior lateral line neuromast support cell differentiation","canonical_id":"go:GO:0048906","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an anterior lateral line neuromast support cell. Support cells are non-sensory cells of the neuromast that extend between the sensory hair cells from the basement membrane to the apical surface; they are surrounded by mantle cells.\" [ISBN:0387968377]","metadata":null},{"id":"2bd3662e099445a49d73b734851a494f","type":"GO_TERM","name":"anterior lateral line system development","canonical_id":"go:GO:0048898","description":"\"The process whose specific outcome is the progression of the anterior lateral line system over time, from its formation to the mature structure. The anterior lateral line system develops from cranial ectodermal placodes, situated between the eye and the ear, that give rise to both the neuromasts and the anterior lateral line sensory nerves that innervate the neuromasts. The anterior lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians and are innervated by several lateral line nerves, which project to the hindbrain. The anterior lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance.\" [ISBN:0125296509, PMID:15018940]","metadata":null},{"id":"beacd6ef807043e7aeaa616d55c459c4","type":"GO_TERM","name":"anterior mRNA localization involved in anterior/posterior axis specification","canonical_id":"go:GO:0060813","description":"\"Any process in which a mRNA is transported to, and maintained in the anterior portion of the oocyte and/or syncytial embryo contributing to the specification of the anterior/posterior axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"d5df8e57e9ba4adea31a238324e455b3","type":"GO_TERM","name":"anterior mesonephric tubule development","canonical_id":"go:GO:0072165","description":"\"The progression of the anterior mesonephric tubule over time, from its initial formation to the mature structure. The anterior mesonephric tubule is an epithelial tube that is part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"74af9148c31b41d1b73fd1b2f04b776d","type":"GO_TERM","name":"anterior midgut (ectodermal) morphogenesis","canonical_id":"go:GO:0007441","description":"\"The process in which the anatomical structures of the anterior midgut (ectodermal) are generated and organized.\" [GOC:curators]","metadata":null},{"id":"7494c0d8622043f1b30caa53260c9937","type":"GO_TERM","name":"anterior midgut development","canonical_id":"go:GO:0007496","description":"\"The process whose specific outcome is the progression of the anterior midgut over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"f44d2d22b43544d8b5f52232c9955e34","type":"GO_TERM","name":"anterior midgut invagination","canonical_id":"go:GO:0007375","description":"\"Internalization of the anterior midgut into the interior of the embryo.\" [ISBN:0879694238]","metadata":null},{"id":"a727cb89b51043edb0ba9ac40f8bcf84","type":"GO_TERM","name":"anterior neural plate formation","canonical_id":"go:GO:0090017","description":"\"The formation of anterior end of the flat, thickened layer of ectodermal cells known as the neural plate.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"c08d196fdd0e4577b8545167d8cf5b7d","type":"GO_TERM","name":"anterior neural tube closure","canonical_id":"go:GO:0061713","description":"\"The step in the formation of the neural tube, where the paired anterior neural folds are brought together and fuse at the dorsal midline.\" [GOC:BHF, GOC:dph, GOC:hal, PMID:17286298]","metadata":null},{"id":"04ba7b07781547619e214362502c65af","type":"GO_TERM","name":"anterior neuropore closure","canonical_id":"go:GO:0021506","description":"\"The joining together of the neural folds of the rostral opening of the neural tube. The anterior neuropore appears before the process of neural tube closure is complete.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"65c9b74e00dd4f6e9160a3faccee7cf9","type":"GO_TERM","name":"anterior region determination","canonical_id":"go:GO:0007355","description":"\"Specification of the anterior (head and thoracic segments) of the embryo by the gap genes; exemplified in insects by the actions of hunchback gene product.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"7ba897b854154596ba9213e00a757fc1","type":"GO_TERM","name":"anterior rotation of the optic cup","canonical_id":"go:GO:0003410","description":"\"A 90 degree-rotation of the optic cup resulting in its alignment with the anterior-posterior body axis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"888af5dbdb4449f88d6ee4062bb2a335","type":"GO_TERM","name":"anterior semicircular canal development","canonical_id":"go:GO:0060873","description":"\"The progession of the anterior semicircular canal from its initial formation to the mature structure.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"6652fbf738094e019c28d779635a50ce","type":"DISEASE","name":"anterior uveitis","canonical_id":"mondo:0006651","description":null,"metadata":null},{"id":"33cbe2a9e29d454494ba5cad799a789a","type":"GO_TERM","name":"anterior visceral endoderm cell migration","canonical_id":"go:GO:1905070","description":"\"The orderly movement of an anterior visceral endoderm cell from one site to another.\" [GO_REF:0000091, GOC:TermGenie, PMID:17078044]","metadata":null},{"id":"9113df7a244d4bea8e8d224cdec4e5d3","type":"GO_TERM","name":"anterior/posterior axis specification","canonical_id":"go:GO:0009948","description":"\"The establishment, maintenance and elaboration of the anterior/posterior axis. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"ee4d43cea3d84273b01d27c418c00469","type":"GO_TERM","name":"anterior/posterior axis specification, embryo","canonical_id":"go:GO:0008595","description":"\"The specification of the anterior/posterior axis of the embryo by the products of genes expressed maternally and genes expressed in the zygote.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"0f96b79590be458f97ed132555779402","type":"GO_TERM","name":"anterior/posterior axis specification, follicular epithelium","canonical_id":"go:GO:0030714","description":"\"Polarization of the follicle cells of an insect ovary along the anterior/posterior axis.\" [GOC:bf]","metadata":null},{"id":"3749397d911a4126845e86d5ff64c8b7","type":"GO_TERM","name":"anterior/posterior axon guidance","canonical_id":"go:GO:0033564","description":"\"The process in which the migration of an axon growth cone is directed to a specific target site along the anterior-posterior body axis in response to a combination of attractive and repulsive cues. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"c708a745d27744688825785dd571807f","type":"GO_TERM","name":"anterior/posterior lineage restriction, imaginal disc","canonical_id":"go:GO:0048099","description":"\"Formation and/or maintenance of a lineage boundary between anterior and posterior compartments that cells cannot cross, thus separating the populations of cells in each compartment.\" [GOC:jid, PMID:10625531, PMID:9374402]","metadata":null},{"id":"9a4a3a81f9084a35a78139d48d5db2fa","type":"GO_TERM","name":"anterior/posterior pattern specification","canonical_id":"go:GO:0009952","description":"\"The regionalization process in which specific areas of cell differentiation are determined along the anterior-posterior axis. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism.\" [GOC:curators, GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"9c52b2b37dd945d99e54b1fa2b6b8c6f","type":"GO_TERM","name":"anterior/posterior pattern specification involved in pronephros development","canonical_id":"go:GO:0034672","description":"\"The developmental process that results in the creation of defined areas or spaces within the pronephros along the anterior/posterior axis to which cells respond and eventually are instructed to differentiate.\" [GOC:mah]","metadata":null},{"id":"71ddec95eb434095afcf5ea6cfdaad80","type":"GO_TERM","name":"anterior/posterior pattern specification involved in ureteric bud development","canonical_id":"go:GO:0072099","description":"\"The developmental process that results in the creation of defined areas or spaces within the ureteric bud along the anterior/posterior axis to which cells respond and eventually are instructed to differentiate.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1d7a766e994845d6bcab095307c99559","type":"GO_TERM","name":"anterior/posterior pattern specification, imaginal disc","canonical_id":"go:GO:0007448","description":"\"The establishment, maintenance and elaboration of the anterior/posterior axis of the imaginal disc. Imaginal discs are epithelial infoldings in the larvae of holometabolous insects that rapidly develop into adult appendages during metamorphosis from larval to adult form.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"c8ee410eaf514716b565510388db0870","type":"GO_TERM","name":"anterograde axonal protein transport","canonical_id":"go:GO:0099641","description":"\"The directed movement of proteins along microtubules from the cell body toward the cell periphery in nerve cell axons.\" [GOC:dos]","metadata":null},{"id":"9eae166b8a5a4c52b237974b28e4a9cf","type":"GO_TERM","name":"anterograde axonal transport","canonical_id":"go:GO:0008089","description":"\"The directed movement of organelles or molecules along microtubules from the cell body toward the cell periphery in nerve cell axons.\" [ISBN:0815316194]","metadata":null},{"id":"43ef80933d424a3094a13dded37e734c","type":"GO_TERM","name":"anterograde axonal transport of messenger ribonucleoprotein complex","canonical_id":"go:GO:0099087","description":"\"The directed movement of a messenger ribonucleoprotein complex along microtubules in axons, towards the presynapse.\" [GOC:dos, PMID:26586091]","metadata":null},{"id":"89b4b46f8ce14fe1905aa6964e209a1c","type":"GO_TERM","name":"anterograde axonal transport of mitochondrion","canonical_id":"go:GO:0098957","description":"\"The directed movement of mitochondria along microtubules in axons away from the cell body and towards the presynapse.\" [GOC:dos]","metadata":null},{"id":"0b28de39fa9f46058056759d58d522e1","type":"GO_TERM","name":"anterograde axonal transport of neurotransmitter receptor complex","canonical_id":"go:GO:0140231","description":"\"The directed movement of a neurotransmitter receptor complex along microtubules from the cell body toward the cell periphery in nerve cell axons.\" [PMID:28680963]","metadata":null},{"id":"01aaf53fd05c43e9a8d2f49fa43bf9b8","type":"GO_TERM","name":"anterograde dendritic transport","canonical_id":"go:GO:0098937","description":"\"The directed movement of organelles or molecules along microtubules from the cell body toward the postsynapse in dendrites.\" [ISBN:0815316194]","metadata":null},{"id":"37a8ef9bbf8344f3bf50c75a0ee2d4d9","type":"GO_TERM","name":"anterograde dendritic transport of messenger ribonucleoprotein complex","canonical_id":"go:GO:0098964","description":"\"The directed movement of a messenger ribonucleoprotein complex along microtubules in nerve cell dendrites towards the postsynapse.\" [GOC:dos]","metadata":null},{"id":"692daba5d8e643deac91e384cf4aea56","type":"GO_TERM","name":"anterograde dendritic transport of mitochondrion","canonical_id":"go:GO:0098972","description":"\"The directed movement of mitochondria along microtubules in dendrites towards the postsynapse and away from the cell body.\" [GOC:dos]","metadata":null},{"id":"a5eaa90d02fb4129b135204b563dc361","type":"GO_TERM","name":"anterograde dendritic transport of neurotransmitter receptor complex","canonical_id":"go:GO:0098971","description":"\"The directed movement of a neurotransmitter receptor complex along microtubules in nerve cell dendrites towards the postsynapse.\" [GOC:dos]","metadata":null},{"id":"64aa4a96fb124498a01f0c1a09f0186f","type":"GO_TERM","name":"anterograde neuronal dense core vesicle transport","canonical_id":"go:GO:1990048","description":"\"The directed movement of substances in neuronal dense core vesicles along axonal microtubules towards the presynapse.\" [GOC:kmv, PMID:23358451]","metadata":null},{"id":"ffd976bf98aa498089347cebf06bd87a","type":"GO_TERM","name":"anterograde synaptic vesicle transport","canonical_id":"go:GO:0048490","description":"\"The directed movement of synaptic vesicle along axonal microtubules from the cell body to the presynapse.\" [GOC:jid, GOC:lmg]","metadata":null},{"id":"89c2a64d2b9d443eabc9f713c62abf87","type":"GO_TERM","name":"anterograde trans-synaptic signaling","canonical_id":"go:GO:0098916","description":"\"Cell-cell signaling from pre to post-synapse, across the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"15d65652443648a1b29b93998a2dc521","type":"GO_TERM","name":"anterograde trans-synaptic signaling by nitric oxide","canonical_id":"go:GO:0098940","description":"\"Cell-cell signaling from presynapse to postynapse, across the synaptic cleft, mediated by nitric oxide.\" [GOC:dos]","metadata":null},{"id":"b2a8662c15ad491e829c124e95d989bb","type":"GO_TERM","name":"anterograde trans-synaptic signaling by trans-synaptic protein complex","canonical_id":"go:GO:0098941","description":"\"Cell-cell signaling from presynapse to postynapse, across the synaptic cleft, mediated by a trans-synaptic protein complex.\" [GOC:dos]","metadata":null},{"id":"2658e03e4cb14c9b961c58a8cc098651","type":"GO_TERM","name":"anther dehiscence","canonical_id":"go:GO:0009901","description":"\"The dehiscence of an anther to release the pollen grains contained within it.\" [GOC:tb]","metadata":null},{"id":"4d63d54c2abc4bed9ca67ab1bbf3ef37","type":"GO_TERM","name":"anther development","canonical_id":"go:GO:0048653","description":"\"The process whose specific outcome is the progression of the anther over time, from its formation to the mature structure.\" [GOC:jid, GOC:sm]","metadata":null},{"id":"5c1d3d1cfba9425894e2e1092fd34ff0","type":"GO_TERM","name":"anther morphogenesis","canonical_id":"go:GO:0048654","description":"\"The process in which the anatomical structures of the anther are generated and organized.\" [GOC:jid, GOC:sm]","metadata":null},{"id":"ad036b33e82b418492ca246325b30adb","type":"GO_TERM","name":"anther septum development","canonical_id":"go:GO:0080128","description":"\"The process whose specific outcome is the progression of the anther septum over time, from its formation to the mature structure. The anther septum is a thin partition or stretch of cells that are present in the anther dehiscence zone.\" [GOC:dhl, PO:0005010]","metadata":null},{"id":"bc0e92ecc0fb43ea825e18698c6388fe","type":"GO_TERM","name":"anther wall tapetum cell differentiation","canonical_id":"go:GO:0048657","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an anther cell wall tapetum cell. The tapetum is a layer of cells that provides a source of nutrition for the pollen grains as they mature.\" [GOC:jid, GOC:sm]","metadata":null},{"id":"761d03a613f741a3ba96a4275ee08af0","type":"GO_TERM","name":"anther wall tapetum cell fate specification","canonical_id":"go:GO:0010234","description":"\"The process in which a cell becomes capable of differentiating autonomously into a tapetal cell of anthers in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:mg]","metadata":null},{"id":"783090b182a846fda6d8463bb1871ea3","type":"GO_TERM","name":"anther wall tapetum development","canonical_id":"go:GO:0048658","description":"\"The process whose specific outcome is the progression of the anther wall tapetum over time, from its formation to the mature structure.\" [GOC:jid, GOC:sm, GOC:tb]","metadata":null},{"id":"5ff16e2ac24947578233725a121370e2","type":"GO_TERM","name":"anther wall tapetum formation","canonical_id":"go:GO:0048656","description":"\"The process that gives rise to the anther wall tapetum. This process pertains to the initial formation of a structure from unspecified parts. The anther wall tapetum is a layer of cells that provides a source of nutrition for the pollen grains as they mature.\" [GOC:jid, GOC:sm, GOC:tb]","metadata":null},{"id":"e6faaeaa7cb649e5bcc2f86f4687befe","type":"GO_TERM","name":"anther wall tapetum morphogenesis","canonical_id":"go:GO:0048655","description":"\"The process in which the anatomical structures of the anther wall tapetum are generated and organized. The anther wall tapetum is a layer of cells that provides a source of nutrition for the pollen grains as they mature.\" [GOC:jid, GOC:sm, GOC:tb]","metadata":null},{"id":"79136a5c5d6b48b09930e9302ac572a5","type":"GO_TERM","name":"anthocyanidin 3-O-glucoside 2''-O-glucosyltransferase activity","canonical_id":"go:GO:0102455","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + an anthocyanidin-3-O-beta-D-glucoside = UDP + H+ + an anthocyanidin 3-O-sophoroside.\" [GOC:pz, RHEA:35419]","metadata":null},{"id":"145f80d988704b5ea2eac981799fc2c7","type":"GO_TERM","name":"anthocyanidin 3-O-glucoside 6''-O-acyltransferase activity","canonical_id":"go:GO:0102453","description":"\"Catalysis of the reaction: 4-coumaryl-CoA + H+ + an anthocyanidin-3-O-beta-D-glucoside = coenzyme A + H+ + an anthocyanidin-3-O-[6-O-(hydroxycinnamoyl)-beta-D-glucoside].\" [GOC:pz, RHEA:35411]","metadata":null},{"id":"45b01e080f5a4e8fa694311abdef6be2","type":"GO_TERM","name":"anthocyanidin 3-O-glucosyltransferase activity","canonical_id":"go:GO:0047213","description":"\"Catalysis of the reaction: anthocyanidin + UDP-D-glucose = anthocyanidin-3-O-D-glucoside + UDP.\" [EC:2.4.1.115, MetaCyc:2.4.1.115-RXN]","metadata":null},{"id":"34e29c95bad04579baa0073e316f812c","type":"GO_TERM","name":"anthocyanidin 3-glucoside rhamnosyltransferase activity","canonical_id":"go:GO:0051566","description":"\"Catalysis of the reaction: anthocyanidin 3-glucoside + UDP-rhamnose = anthocyanidin 3-rutinoside + UDP.\" [PMID:8130800]","metadata":null},{"id":"a9f25b946d354ccf805037a3f99a6594","type":"GO_TERM","name":"anthocyanidin reductase activity","canonical_id":"go:GO:0033729","description":"\"Catalysis of the reaction: a flavan-3-ol + 2 NAD(P)+ = an anthocyanidin + 2 NAD(P)H + H+.\" [EC:1.3.1.77]","metadata":null},{"id":"bd024e7a12b24d63b4376f22d507593a","type":"GO_TERM","name":"anthocyanin 3'-O-beta-glucosyltransferase activity","canonical_id":"go:GO:0033837","description":"\"Catalysis of the reaction: UDP-glucose + an anthocyanin = UDP + an anthocyanin 3'-O-beta-D-glucoside.\" [EC:2.4.1.238]","metadata":null},{"id":"87abafdac1f64df9b89cc598900c6fe5","type":"GO_TERM","name":"anthocyanin 5-(6'''-hydroxycinnamoyltransferase) activity","canonical_id":"go:GO:0047183","description":"\"Catalysis of the reaction: (E)-4-coumaroyl-CoA + an anthocyanidin 3,5-di-O-beta-D-glucoside = an anthocyanidin 3-O-beta-D-glucoside 5-O-beta-D-[(6-O-(E)-4-coumaroyl)glucoside] + CoA. Caffeoyl-CoA can also act as an acyl donor.\" [EC:2.3.1.153, RHEA:15661]","metadata":null},{"id":"df7241020aa74d439e5d7d1ce570abdf","type":"GO_TERM","name":"anthocyanin 5-O-glucoside 6'''-O-malonyltransferase activity","canonical_id":"go:GO:0033810","description":"\"Catalysis of the reaction: malonyl-CoA + pelargonidin 3-O-(6-caffeoyl-beta-D-glucoside) 5-O-beta-D-glucoside = CoA + 4'''-demalonylsalvianin.\" [EC:2.3.1.172]","metadata":null},{"id":"6868023e32b74974b612ee552d819f65","type":"GO_TERM","name":"anthocyanin 5-O-glucoside-4'''-O-malonyltransferase activity","canonical_id":"go:GO:0102801","description":"\"Catalysis of the reaction: 4'''-demalonylsalvianin + malonyl-CoA = salvianin + coenzyme A.\" [GOC:pz, RHEA:35515]","metadata":null},{"id":"0c46e4c51b624ba08ae054314005a1f2","type":"GO_TERM","name":"anthocyanin 5-O-glucosyltransferase activity","canonical_id":"go:GO:0080018","description":"\"Catalysis of the reaction: an anthocyanin + UDP-D-glucose = an anthocyanin-5-O-glucoside + UDP.\" [PMID:15807784]","metadata":null},{"id":"a3c9297ffeb742a6b6e2199e92779513","type":"GO_TERM","name":"anthocyanin 6''-O-malonyltransferase activity","canonical_id":"go:GO:0033809","description":"\"Catalysis of the reaction: malonyl-CoA + an anthocyanidin 3-O-beta-D-glucoside = CoA + an anthocyanidin 3-O-(6-O-malonyl-beta-D-glucoside).\" [RHEA:16025]","metadata":null},{"id":"4120e967cd524875b95341686b8c56c7","type":"GO_TERM","name":"anthocyanin accumulation in tissues in response to UV light","canonical_id":"go:GO:0043481","description":"\"The aggregation of the pigment anthocyanin in a particular location in a tissue, occurring in response to a UV light stimulus.\" [GOC:jl]","metadata":null},{"id":"92734e4522694057b7233b16329b8a9c","type":"GO_TERM","name":"anthocyanin-containing compound biosynthetic process","canonical_id":"go:GO:0009718","description":"\"The chemical reactions and pathways resulting in the formation of anthocyanins, any member of a group of intensely colored soluble glycosides of anthocyanidins.\" [GOC:ai]","metadata":null},{"id":"297d6023cba84c5f8ec0d537f95542e8","type":"GO_TERM","name":"anthocyanin-containing compound catabolic process","canonical_id":"go:GO:0046284","description":"\"The chemical reactions and pathways resulting in the breakdown of anthocyanins, any member of a group of intensely colored soluble glycosides of anthocyanidins.\" [GOC:ai]","metadata":null},{"id":"8f73dd68fd11469cb90528346cecc490","type":"GO_TERM","name":"anthocyanin-containing compound metabolic process","canonical_id":"go:GO:0046283","description":"\"The chemical reactions and pathways involving anthocyanins, any member of a group of intensely colored soluble glycosides of anthocyanidins that occur in plants. They are responsible from most of the scarlet, purple, mauve and blue coloring in higher plants, especially of flowers.\" [ISBN:0198506732]","metadata":null},{"id":"86926376fd114b6b94e085452ec5f430","type":"GO_TERM","name":"anthranilate 1,2-dioxygenase (deaminating, decarboxylating) activity","canonical_id":"go:GO:0018618","description":"\"Catalysis of the reaction: anthranilate + NAD(P)H + O2 + 3 H+ = catechol + NH4+ + CO2 + NAD(P)+.\" [EC:1.14.12.1]","metadata":null},{"id":"d40876248d584821a9c35b432a9301eb","type":"GO_TERM","name":"anthranilate 3-monooxygenase (deaminating) activity","canonical_id":"go:GO:0018672","description":"\"Catalysis of the reaction: anthranilate + 2 H+ + NADPH + O2 = 2,3-dihydroxybenzoate + NADP+ + NH4.\" [EC:1.14.13.35, RHEA:21236]","metadata":null},{"id":"6176d28d705046cb99be72ff0fa55e01","type":"GO_TERM","name":"anthranilate N-benzoyltransferase activity","canonical_id":"go:GO:0047672","description":"\"Catalysis of the reaction: anthranilate + benzoyl-CoA = N-benzoylanthranilate + CoA.\" [EC:2.3.1.144, RHEA:21600]","metadata":null},{"id":"ef2db569b8034cd88adb3e653f162509","type":"GO_TERM","name":"anthranilate N-malonyltransferase activity","canonical_id":"go:GO:0047673","description":"\"Catalysis of the reaction: anthranilate + malonyl-CoA = N-malonylanthranilate + CoA.\" [EC:2.3.1.113, RHEA:17557]","metadata":null},{"id":"ae9bb0835fee4d32a19b11276770a5bb","type":"GO_TERM","name":"anthranilate N-methyltransferase activity","canonical_id":"go:GO:0030774","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + anthranilate = N-methylanthranilate + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.111, RHEA:12180]","metadata":null},{"id":"15534a485d6f492baa29ffae12d5adae","type":"GO_TERM","name":"anthranilate catabolic process","canonical_id":"go:GO:0043421","description":"\"The chemical reactions and pathways resulting in the breakdown of anthranilate (2-aminobenzoate).\" [GOC:jl]","metadata":null},{"id":"3a382b15c65e4eb780a4ff73bcef38e2","type":"GO_TERM","name":"anthranilate phosphoribosyltransferase activity","canonical_id":"go:GO:0004048","description":"\"Catalysis of the reaction: N-(5-phospho-beta-D-ribosyl)anthranilate + diphosphate = 5-phospho-alpha-D-ribose 1-diphosphate + anthranilate.\" [EC:2.4.2.18, RHEA:11768]","metadata":null},{"id":"b0c435e384614845915c0b991bea19c5","type":"GO_TERM","name":"anthranilate synthase activity","canonical_id":"go:GO:0004049","description":"\"Catalysis of the reaction: chorismate + L-glutamine = anthranilate + pyruvate + L-glutamate.\" [EC:4.1.3.27]","metadata":null},{"id":"bea6a7336ffb466f97fabe8987436f6d","type":"GO_TERM","name":"anthranilate synthase complex","canonical_id":"go:GO:0005950","description":"\"A heterotetrameric enzyme complex made up of two components I and two components II. Catalyzes the formation of anthranilate, pyruvate and L-glutamate from chorismate and L-glutamine.\" [PMID:4886290]","metadata":null},{"id":"7ef0f027b86140d5b0b6736e1acd6e8a","type":"GO_TERM","name":"anthranilate-CoA ligase activity","canonical_id":"go:GO:0018860","description":"\"Catalysis of the reaction: ATP + anthranilate + CoA = AMP + diphosphate + anthranilyl-CoA.\" [EC:6.2.1.32]","metadata":null},{"id":"840531871a8743f3b6c8edcb4f30be58","type":"GO_TERM","name":"anthraniloyl-CoA monooxygenase activity","canonical_id":"go:GO:0018673","description":"\"Catalysis of the reaction: 2-aminobenzoyl-CoA + 2 NADPH + 2 H+ + O2 = 2-amino-5-oxocyclohex-1-enecarboxyl-CoA + H2O + 2 NADP+.\" [EC:1.14.13.40]","metadata":null},{"id":"84c558fdeb6849aeba36ef6ba01de59c","type":"DISEASE","name":"anthrax infection","canonical_id":"mondo:0005119","description":null,"metadata":null},{"id":"0a3858f7649c43e38028c783c99f05c1","type":"GO_TERM","name":"anti-Mullerian hormone receptor activity","canonical_id":"go:GO:1990272","description":"\"Combining with anti-Mullerian hormone to initiate a change in cell activity.\" [GOC:hjd, PMID:23624077]","metadata":null},{"id":"ff4d8504c39b43929b2033b0b08536a7","type":"GO_TERM","name":"anti-Mullerian hormone receptor signaling pathway","canonical_id":"go:GO:1990262","description":"\"The series of molecular signals initiated by the binding of anti-Mullerian hormone to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Upon ligand binding, the receptor  forms a complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators.\" [GOC:hjd, PMID:23624077]","metadata":null},{"id":"e08d0279f6664f18a2092c31d245d74d","type":"GO_TERM","name":"anti-sigma factor antagonist activity","canonical_id":"go:GO:0043856","description":"\"The function of binding to an anti-sigma factor and stopping, preventing or reducing the rate of its activity.\" [GOC:jl, GOC:txnOH, PMID:15576799]","metadata":null},{"id":"e4b3307cef2f4330a62ecc8333890a65","type":"GO_TERM","name":"antibacterial humoral response","canonical_id":"go:GO:0019731","description":"\"An immune response against bacteria mediated through a body fluid. Examples of this process are the antibacterial humoral responses in Mus musculus and Drosophila melanogaster.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"3284a31cfeee4ba9ade1160de20ab99a","type":"GO_TERM","name":"antibacterial innate immune response","canonical_id":"go:GO:0140367","description":"\"An defense response against a bacteria mediated through an innate immune response. An innate immune response is mediated by germline encoded components that directly recognize components of potential pathogens.\" [PMID:16177355, PMID:23006328]","metadata":null},{"id":"b83f337cb14843a19aaa8634fb5b988f","type":"GO_TERM","name":"antibacterial peptide biosynthetic process","canonical_id":"go:GO:0002780","description":"\"The chemical reactions and pathways resulting in the formation of an antibacterial peptide.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"3296914b8d8a459e8db51bfd758d811d","type":"GO_TERM","name":"antibacterial peptide production","canonical_id":"go:GO:0002778","description":"\"The synthesis or release of an antibacterial peptide during an immune response, resulting in an increase in intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"876cdbe096734dff8279dc4d94cf5daa","type":"GO_TERM","name":"antibacterial peptide secretion","canonical_id":"go:GO:0002779","description":"\"The regulated release of an antibacterial peptide from a cell or a tissue.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"0287157d1b494f248c21e091d8b158f9","type":"GO_TERM","name":"antibiotic biosynthetic process","canonical_id":"go:GO:0017000","description":"\"The chemical reactions and pathways resulting in the formation of an antibiotic, a substance produced by or derived from certain fungi, bacteria, and other organisms, that can destroy or inhibit the growth of other microorganisms.\" [GOC:curators]","metadata":null},{"id":"a4672297c06f44f6860a82e0a2ea484b","type":"GO_TERM","name":"antibiotic catabolic process","canonical_id":"go:GO:0017001","description":"\"The chemical reactions and pathways resulting in the breakdown of antibiotic, a substance produced by or derived from certain fungi, bacteria, and other organisms, that can destroy or inhibit the growth of other microorganisms.\" [GOC:curators]","metadata":null},{"id":"4e32cd38f54a4e03931e5bb46b7cb794","type":"GO_TERM","name":"antibiotic metabolic process","canonical_id":"go:GO:0016999","description":"\"The chemical reactions and pathways involving an antibiotic, a substance produced by or derived from certain fungi, bacteria, and other organisms, that can destroy or inhibit the growth of other microorganisms.\" [GOC:cab2]","metadata":null},{"id":"fa2c3ee255e64673bf23767a906e2ad9","type":"GO_TERM","name":"antibody-dependent cellular cytotoxicity","canonical_id":"go:GO:0001788","description":"\"Cytolysis of target cells by natural killer cells, eosinophils, neutrophils, monocytes, or macrophages following engagement of antibodies bound to the target cells by Fc receptors on the effector cells.\" [GOC:pr, ISBN:0781735149, PMID:11677095, PMID:9581795]","metadata":null},{"id":"158f010327a4421cb8f80651ddf674cf","type":"GO_TERM","name":"anticlinal cell division","canonical_id":"go:GO:0090510","description":"\"A cell division process where the division plane is perpendicular to the surface of the organ. It adds cells to the existing cell layer or cell file.\" [GOC:tair_curators, PMID:21391814]","metadata":null},{"id":"b20fa3ce72434f439e43901c0f5eca97","type":"GO_TERM","name":"antifreeze activity","canonical_id":"go:GO:0016172","description":"\"Inhibits the growth and recrystallization of ice crystals, thereby lowering the freezing point of water and preventing cellular damage at subzero temperatures. This activity is observed in various cold-adapted organisms, including certain fish, insects, and plants, and contributes to survival in extreme cold environments by stabilizing supercooled liquid states.\" [GOC:cjm, PMID:33317024]","metadata":null},{"id":"a23766bfed764d65832615df2e2d6121","type":"GO_TERM","name":"antifungal humoral response","canonical_id":"go:GO:0019732","description":"\"An immune response against a fungus mediated through a body fluid. An example of this process is the antifungal humoral response in Drosophila melanogaster.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"5e6bce6945ef4083b3d44edf25afbad5","type":"GO_TERM","name":"antifungal innate immune response","canonical_id":"go:GO:0061760","description":"\"An defense response against a fungus mediated through an innate immune response. An innate immune response is mediated by germline encoded components that directly recognize components of potential pathogens.\" [GOC:dph, PMID:22470487]","metadata":null},{"id":"e88398ac7c3b4a80a21298dbabeda369","type":"GO_TERM","name":"antifungal peptide biosynthetic process","canonical_id":"go:GO:0002783","description":"\"The chemical reactions and pathways resulting in the formation of an antifungal peptide.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"75400c32eace4fc98e2bf3fdc85ab0fd","type":"GO_TERM","name":"antifungal peptide production","canonical_id":"go:GO:0002781","description":"\"The synthesis or release of an antifungal peptide during an immune response, resulting in an increase in intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"96627de272aa40c69953e7ece3c73217","type":"GO_TERM","name":"antifungal peptide secretion","canonical_id":"go:GO:0002782","description":"\"The regulated release of an antifungal peptide from a cell or a tissue.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"6f6cab3dce6e47099ba15a5d03d30c1a","type":"GO_TERM","name":"antigen binding","canonical_id":"go:GO:0003823","description":"\"Binding to an antigen, any substance which is capable of inducing a specific immune response and of reacting with the products of that response, the specific antibody or specifically sensitized T-lymphocytes, or both. Binding may counteract the biological activity of the antigen. Antigen binding by an MHC protein complex allows the antigen to be displayed to a T cell or NK cell.\" [GOC:jl, ISBN:0198506732, ISBN:0721662544]","metadata":null},{"id":"ed9a85f801c840e68c1fd9190227e4cf","type":"GO_TERM","name":"antigen processing and presentation","canonical_id":"go:GO:0019882","description":"\"The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GO_REF:0000022, GOC:add, ISBN:0781735149, PMID:15771591, PMID:15928678]","metadata":null},{"id":"c4fb2faea7c54e1aa4acde654f28ee36","type":"GO_TERM","name":"antigen processing and presentation following macropinocytosis","canonical_id":"go:GO:0002750","description":"\"Antigen processing and presentation which is initiated by uptake of antigen via macropinocytosis.\" [GOC:add, PMID:16556257]","metadata":null},{"id":"85e5b5541b1144e7ad2419286d98e420","type":"GO_TERM","name":"antigen processing and presentation following phagocytosis","canonical_id":"go:GO:0002747","description":"\"Antigen processing and presentation which is initiated by uptake of antigen via phagocytosis.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"2ff10ff6861d464db9b303af5ba14f42","type":"GO_TERM","name":"antigen processing and presentation following pinocytosis","canonical_id":"go:GO:0002746","description":"\"Antigen processing and presentation which is initiated by uptake of antigen via pinocytosis.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5456487696a9453b99663a127aa6fd2c","type":"GO_TERM","name":"antigen processing and presentation following receptor mediated endocytosis","canonical_id":"go:GO:0002751","description":"\"Antigen processing and presentation which is initiated by uptake of antigen receptor-mediated endocytosis.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c83c9278e5eb4dea91bd64e833eaee36","type":"GO_TERM","name":"antigen processing and presentation initiated by pattern recognition receptor mediated uptake of antigen","canonical_id":"go:GO:0002748","description":"\"Antigen processing and presentation which is initiated by uptake of antigen bound to a cell surface pattern recognition receptor (PRR).\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"73c1d239a5de447db5869d7a793c1930","type":"GO_TERM","name":"antigen processing and presentation initiated by receptor mediated uptake of antigen","canonical_id":"go:GO:0002745","description":"\"Antigen processing and presentation which is initiated by uptake of antigen bound to a cell surface receptor.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1a0dbabf3584456c93269808bd6e0d64","type":"GO_TERM","name":"antigen processing and presentation of endogenous antigen","canonical_id":"go:GO:0019883","description":"\"The process in which an antigen-presenting cell expresses antigen (peptide or lipid) of endogenous origin on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591, PMID:15928678]","metadata":null},{"id":"01792ce44fd7402787a0462fb808588e","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen","canonical_id":"go:GO:0002483","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC protein complex. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"9a0a3618ded24d0b862c59225527a7cd","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class I","canonical_id":"go:GO:0019885","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex. The peptide antigen is typically, but not always, processed from a whole protein. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"2c35d63c16714b7d9d8776a56fd2a10c","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway","canonical_id":"go:GO:0002484","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via an ER pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class I molecule in the ER. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:14647477, PMID:15771591]","metadata":null},{"id":"234227173cb047ed92c07f1b8762a092","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent","canonical_id":"go:GO:0002485","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP-dependent ER pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class I molecule in the ER following TAP-dependent transport from the cytosol. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:14647477, PMID:15771591]","metadata":null},{"id":"7cf03f0d8b1a40fea0c711ea82ab2c80","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent","canonical_id":"go:GO:0002486","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP-independent ER pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class I molecule in the ER following transport from the cytosol via a TAP-independent pathway. Class I here refers to classical class I molecules.\" [GOC:add, PMID:14647477, PMID:15771591]","metadata":null},{"id":"6e36907a928d4894b8a6d9c484304732","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class I via endolysosomal pathway","canonical_id":"go:GO:0002487","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class I molecule in an endolysosome. Class I here refers to classical class I molecules.\" [GOC:add, PMID:10631943]","metadata":null},{"id":"17590987643f431285a8250b8e8e3975","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class II","canonical_id":"go:GO:0002491","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class II protein complex. The peptide antigen is typically, but not always, processed from a whole protein.\" [GOC:add, PMID:15531770, PMID:16181338]","metadata":null},{"id":"d4e8cced32c6463e96a8206c6ed72335","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class Ib","canonical_id":"go:GO:0002476","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class Ib protein complex. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"8256c9b0593c4c3eae256e193d95a58b","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway","canonical_id":"go:GO:0002488","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via an ER pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class Ib molecule in the ER. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"ccc9636bca9d4f54969063231a17dcd1","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-dependent","canonical_id":"go:GO:0002489","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class Ib molecule. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"69953a62e88f4849a2b4bf38857b3190","type":"GO_TERM","name":"antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-independent","canonical_id":"go:GO:0002490","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"4a448cce66934c3289f12652b3014ea0","type":"GO_TERM","name":"antigen processing and presentation of exogenous antigen","canonical_id":"go:GO:0019884","description":"\"The process in which an antigen-presenting cell expresses antigen (peptide or lipid) of exogenous origin on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591, PMID:15928678]","metadata":null},{"id":"4c9cf849cf5f48b3a54f1337f070af78","type":"GO_TERM","name":"antigen processing and presentation of exogenous peptide antigen","canonical_id":"go:GO:0002478","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC protein complex. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"327316f91f824bdeafe7ee5b5e6f565f","type":"GO_TERM","name":"antigen processing and presentation of exogenous peptide antigen via MHC class I","canonical_id":"go:GO:0042590","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex. The peptide antigen is typically, but not always, processed from a whole protein. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"fdcbbd2d593f437b97139a3ea144d9aa","type":"GO_TERM","name":"antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent","canonical_id":"go:GO:0002479","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class I molecule. Class I here refers to classical class I molecules.\" [GOC:add, PMID:15224093, PMID:15771591, PMID:16181335]","metadata":null},{"id":"04f08d84626f4e7eb23b6efe05c45236","type":"GO_TERM","name":"antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent","canonical_id":"go:GO:0002480","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class I here refers to classical class I molecules.\" [GOC:add, PMID:15224093, PMID:15771591, PMID:16181335]","metadata":null},{"id":"abe6f165f78a435ca0474e03ef8631e4","type":"GO_TERM","name":"antigen processing and presentation of exogenous peptide antigen via MHC class II","canonical_id":"go:GO:0019886","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class II protein complex. The peptide antigen is typically, but not always, processed from a whole protein.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"e6fae1d375f14b9f86cc0b764eded8f0","type":"GO_TERM","name":"antigen processing and presentation of exogenous peptide antigen via MHC class Ib","canonical_id":"go:GO:0002477","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class Ib protein complex. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"d1264d8a3f494a199f4383f8c9d738e5","type":"GO_TERM","name":"antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent","canonical_id":"go:GO:0002481","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class Ib molecule. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"6de8994185324038b7a59e8f7877365f","type":"GO_TERM","name":"antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-independent","canonical_id":"go:GO:0002482","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"67b7547628264d6487dd9a5cb5d48e40","type":"GO_TERM","name":"antigen processing and presentation of lipid antigen via MHC class Ib","canonical_id":"go:GO:0048003","description":"\"The process in which an antigen-presenting cell expresses lipid antigen in association with an MHC class Ib protein complex on its cell surface, including lipid extraction, degradation, and transport steps for the lipid antigen both prior to and following assembly with the MHC protein complex. The lipid antigen may originate from an endogenous or exogenous source of lipid. Class Ib here refers to non-classical class I molecules, such as those of the CD1 family.\" [GOC:add, PMID:10375559, PMID:15928678, PMID:15928680]","metadata":null},{"id":"9fe7a8f5920f4a8898c55ac6f782b4ad","type":"GO_TERM","name":"antigen processing and presentation of peptide antigen","canonical_id":"go:GO:0048002","description":"\"The process in which an antigen-presenting cell expresses peptide antigen in association with an MHC protein complex on its cell surface, including proteolysis and transport steps for the peptide antigen both prior to and following assembly with the MHC protein complex. The peptide antigen is typically, but not always, processed from an endogenous or exogenous protein.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"ad5dbccba20d4d718268f86ed5084859","type":"GO_TERM","name":"antigen processing and presentation of peptide antigen via MHC class I","canonical_id":"go:GO:0002474","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:15224092, PMID:15771591]","metadata":null},{"id":"852a6a9b4e28461da91524346f7ce9fc","type":"GO_TERM","name":"antigen processing and presentation of peptide antigen via MHC class II","canonical_id":"go:GO:0002495","description":"\"The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class II protein complex. The peptide antigen is typically, but not always, processed from a whole protein.\" [GOC:add, ISBN:0781735149, PMID:15531770, PMID:15771591]","metadata":null},{"id":"99d2ca29c6c64e98904fd0201091e96b","type":"GO_TERM","name":"antigen processing and presentation of peptide antigen via MHC class Ib","canonical_id":"go:GO:0002428","description":"\"The process in which an antigen-presenting cell expresses peptide antigen in association with an MHC class Ib protein complex on its cell surface. The peptide antigen may originate from an endogenous or exogenous protein. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"caad83c81d814cc79ba731337e881663","type":"GO_TERM","name":"antigen processing and presentation of peptide or polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002504","description":"\"The process in which an antigen-presenting cell expresses antigen (peptide or polysaccharide) on its cell surface in association with an MHC class II protein complex.\" [GOC:add, ISBN:0781735149, PMID:15531770, PMID:15771591, PMID:16153240]","metadata":null},{"id":"7f725c348aa04050ad65f65f0c1d27f5","type":"GO_TERM","name":"antigen processing and presentation of polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002505","description":"\"The process in which an antigen-presenting cell expresses a polysaccharide antigen on its cell surface in association with an MHC class II protein complex.\" [GOC:add, PMID:16153240]","metadata":null},{"id":"acf8e82e9e604e95ae77e8392b42b106","type":"GO_TERM","name":"antigen processing and presentation via MHC class Ib","canonical_id":"go:GO:0002475","description":"\"The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC class Ib protein complex. Class Ib here refers to non-classical class I molecules, such as those of the CD1 or HLA-E gene families.\" [GOC:add, PMID:15928678, PMID:15928680]","metadata":null},{"id":"207263ad0028451db4f17feb5de14a9a","type":"GO_TERM","name":"antigen processing and presentation, endogenous lipid antigen via MHC class Ib","canonical_id":"go:GO:0048006","description":"\"The process in which an antigen-presenting cell expresses lipid antigen of endogenous origin in association with an MHC class Ib protein complex on its cell surface. Class Ib here refers to non-classical class I molecules, such as those of the CD1 family.\" [GOC:add, PMID:10375559, PMID:15928678, PMID:15928680]","metadata":null},{"id":"6bdfda8b1ffc453eaeb0a69a007a1eeb","type":"GO_TERM","name":"antigen processing and presentation, exogenous lipid antigen via MHC class Ib","canonical_id":"go:GO:0048007","description":"\"The process in which an antigen-presenting cell expresses lipid antigen of exogenous origin in association with an MHC class Ib protein complex on its cell surface. Class Ib here refers to non-classical class I molecules, such as those of the CD1 family.\" [GOC:add, PMID:10375559, PMID:15928678, PMID:15928680]","metadata":null},{"id":"4374ca84e3614853b94d407cb65d4ed7","type":"GO_TERM","name":"antigen receptor-mediated signaling pathway","canonical_id":"go:GO:0050851","description":"\"The series of molecular signals initiated by the cross-linking of an antigen receptor on a B or T cell.\" [GOC:add]","metadata":null},{"id":"6977ce702b6049d8a5f8e1589378533d","type":"GO_TERM","name":"antigen sampling by M cells in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002406","description":"\"The process of antigen samples carried out by M cells in the mucosal-associated lymphoid tissue.\" [GOC:jal, PMID:11896763]","metadata":null},{"id":"11b93fe3ac7c4fcba47a427261605a5f","type":"GO_TERM","name":"antigen sampling by dendritic cells in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002405","description":"\"The process of antigen sampling carried out by dendritic cells in the mucosal-associated lymphoid tissue.\" [GOC:jal, PMID:11896763, PMID:15681746]","metadata":null},{"id":"ce63661703fb45f8af8aad39d609631e","type":"GO_TERM","name":"antigen sampling in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002404","description":"\"The process of apical-to-basolateral delivery of soluble and particulate antigens to underlying mucosal-associated lymphoid tissue.\" [GOC:jal, PMID:11896763, PMID:12843411, PMID:15681746]","metadata":null},{"id":"d37d2a2b545d4d1b96751b05ac32236b","type":"GO_TERM","name":"antigen transcytosis by M cells in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002412","description":"\"The process of antigen transcytosis carried out by M cells in the mucosal-associated lymphoid tissue (MALT). Transcytosis is the process of the directed movement of endocytosed material through the cell and its exocytosis from the plasma membrane at the opposite side. M cells are specialized epithelia cells with a microfold structure that are adept at moving antigens from the gut lumen to antigen presenting cells in the MALT.\" [GOC:jal, ISBN:0781735149, PMID:12843411]","metadata":null},{"id":"adc15c7e398049278b64f27ac72129a0","type":"GO_TERM","name":"antigenic variation","canonical_id":"go:GO:0020033","description":"\"A process by which a symbiont evades the host adaptive immune response by changing antigenic determinants on the symbiont surface that are exposed to host antibodies.\" [PMID:29116635, PMID:37524976]","metadata":null},{"id":"1aba1bd46cf34a25b9e104ab6637b9fb","type":"GO_TERM","name":"antimicrobial humoral immune response mediated by antimicrobial peptide","canonical_id":"go:GO:0061844","description":"\"An immune response against microbes mediated by anti-microbial peptides in body fluid.\" [PMID:15761415, PMID:24287494]","metadata":null},{"id":"6d41d35a9db142ec94e759313c04efb0","type":"GO_TERM","name":"antimicrobial humoral response","canonical_id":"go:GO:0019730","description":"\"An immune response against microbes mediated through a body fluid. Examples of this process are seen in the antimicrobial humoral response of Drosophila melanogaster and Mus musculus.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"382b3ada58024feea10e2a88aaacb1cd","type":"GO_TERM","name":"antimicrobial peptide biosynthetic process","canonical_id":"go:GO:0002777","description":"\"The chemical reactions and pathways resulting in the formation of an antimicrobial peptide. Such peptides may have protective properties against bacteria, fungi, viruses, or protozoa.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"3c30c4792dd046c7a32adffe1c3754e5","type":"GO_TERM","name":"antimicrobial peptide production","canonical_id":"go:GO:0002775","description":"\"The synthesis or release of an antimicrobial peptide during an immune response, resulting in an increase in intracellular or extracellular levels. Such peptides may have protective properties against bacteria, fungi, viruses, or protozoa.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"4139fc97501847ceab378f806876d144","type":"GO_TERM","name":"antimicrobial peptide secretion","canonical_id":"go:GO:0002776","description":"\"The regulated release of an antimicrobial peptide from a cell or a tissue. Such peptides may have protective properties against bacteria, fungi, viruses, or protozoa.\" [GOC:add, ISBN:0781735149, PMID:11807545, PMID:15638771]","metadata":null},{"id":"f14542e796dc4a91ab33a904fc53e1c4","type":"GO_TERM","name":"antimonite secondary active transmembrane transporter activity","canonical_id":"go:GO:0042960","description":"\"Enables the transfer of antimonite from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:jl]","metadata":null},{"id":"088bc3ebdb424f9eb593439ce0538e6a","type":"GO_TERM","name":"antimonite transmembrane transport","canonical_id":"go:GO:0015699","description":"\"The directed movement of antimonite into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"8faa0da02b6a4af59cd174950d96ee0b","type":"GO_TERM","name":"antimonite transmembrane transporter activity","canonical_id":"go:GO:0015104","description":"\"Enables the transfer of antimonite from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"59aec6ed651241a1ab25c19a2fc3f222","type":"GO_TERM","name":"antioxidant activity","canonical_id":"go:GO:0016209","description":"\"Inhibition of the reactions brought about by dioxygen (O2) or peroxides. Usually the antioxidant is effective because it can itself be more easily oxidized than the substance protected. The term is often applied to components that can trap free radicals, thereby breaking the chain reaction that normally leads to extensive biological damage.\" [ISBN:0198506732]","metadata":null},{"id":"81a9628a90394bcab3c86586ebfaf77a","type":"GO_TERM","name":"antipodal cell degeneration","canonical_id":"go:GO:0055045","description":"\"The process in which the antipodal cells undergo programmed cell death.\" [GOC:mtg_plant]","metadata":null},{"id":"162dbee2842e41798c462aa7268c1220","type":"GO_TERM","name":"antipodal cell differentiation","canonical_id":"go:GO:0009557","description":"\"The process in which an uncellularized nucleus cellularizes and acquires the specialized features of an antipodal cell.\" [GOC:jid, GOC:mtg_plant]","metadata":null},{"id":"2cad90d1b81148a59bd15afa6a7cd474","type":"GO_TERM","name":"antipodal cell nucleus","canonical_id":"go:GO:0043079","description":"\"The nucleus of an antipodal cell, one of three cells of the embryo sac in angiosperms, found at the chalazal end of the embryo away from the point of entry of the pollen tube, and its descendents.\" [CL:0000537, GOC:jl]","metadata":null},{"id":"5abd2ada21d448628bfe33db7f730b3c","type":"GO_TERM","name":"antipodal site","canonical_id":"go:GO:0140525","description":"\"The pole of the kinetoplast associated with kinetoplast DNA replication. The antipodal sites flank the kinetoplast DNA disk and are positioned approximately 180 degrees apart. In Trypanosoma brucei and Crithidia fasciculata, minicircles are attached at antipodal sites and they contain enzymes that catalyse some of the later reactions in minicircle replication.\" [PMID:12455998, PMID:17462016, PMID:8045928]","metadata":null},{"id":"deecdea1619c4791b0c4280021f5b4e7","type":"GO_TERM","name":"antiporter activity","canonical_id":"go:GO:0015297","description":"\"Enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported in opposite directions in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy. The reaction is: solute A(out) + solute B(in) = solute A(in) + solute B(out).\" [GOC:mtg_transport, ISBN:0815340729, PMID:10839820]","metadata":null},{"id":"a275710c04294b33977a82b069ce6559","type":"GO_TERM","name":"antisense RNA metabolic process","canonical_id":"go:GO:0042868","description":"\"The chemical reactions and pathways involving antisense RNA, an RNA molecule complementary in sequence to another RNA or DNA molecule, which, by binding the latter, acts to inhibit its function and/or completion of synthesis.\" [GOC:jl]","metadata":null},{"id":"366b23f395004f128ec00bbfcac228e9","type":"GO_TERM","name":"antisense RNA transcript catabolic process","canonical_id":"go:GO:0071041","description":"\"The chemical reactions and pathways resulting in the breakdown of antisense transcripts, i.e. transcripts that were produced from the antisense strand of a gene that produces a gene product and which often have a regulatory effect on the transcription of that gene product.\" [GOC:dgf, GOC:krc]","metadata":null},{"id":"85041a7ed4ed40feb8cb454cf974fc1c","type":"GO_TERM","name":"antisense RNA transcription","canonical_id":"go:GO:0009300","description":"\"The synthesis of antisense RNA, an RNA molecule complementary in sequence to another RNA or DNA molecule, which, by binding the latter, acts to inhibit its function and/or completion of synthesis, on a template of DNA.\" [GOC:jl]","metadata":null},{"id":"18ad719712d445799c747217d3023a47","type":"GO_TERM","name":"antisigma factor binding","canonical_id":"go:GO:0045152","description":"\"Binding to an antisigma factor, a factor which inhibits the ability of the sigma factor to function as a transcriptional initiator.\" [GOC:mlg]","metadata":null},{"id":"949223eedc224a27888696ccfa0994b3","type":"GO_TERM","name":"antiviral innate immune response","canonical_id":"go:GO:0140374","description":"\"A defense response against viruses mediated through an innate immune response. An innate immune response is mediated by germline encoded components that directly recognize components of potential pathogens.\" [PMID:31006531]","metadata":null},{"id":"61a19251af574f648ec07c686048c0ce","type":"GO_TERM","name":"antral ovarian follicle growth","canonical_id":"go:GO:0001547","description":"\"Increase in size of antral follicles due to cell proliferation and/or growth of the antral cavity.\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"3a8d0f31cdb24877803e84a0df5ba73d","type":"DISEASE","name":"anxiety","canonical_id":"mondo:0011918","description":null,"metadata":null},{"id":"ee3132ce7afa4b8ca0c7746d4052be3a","type":"DISEASE","name":"anxiety disorder","canonical_id":"mondo:0005618","description":null,"metadata":null},{"id":"ee66b46e1c494273846a06d54fc80193","type":"GO_TERM","name":"aorta development","canonical_id":"go:GO:0035904","description":"\"The progression of the aorta over time, from its initial formation to the mature structure. An aorta is an artery that carries blood from the heart to other parts of the body.\" [GOC:bf, GOC:dgh, MA:0000062, UBERON:0000947, Wikipedia:Aorta]","metadata":null},{"id":"3caaef99dc4649b682135276451d50c7","type":"GO_TERM","name":"aorta morphogenesis","canonical_id":"go:GO:0035909","description":"\"The process in which the anatomical structures of an aorta are generated and organized. An aorta is an artery that carries blood from the heart to other parts of the body.\" [GOC:bf, GOC:dgh, MA:0000062, UBERON:0000947, Wikipedia:Aorta]","metadata":null},{"id":"c0855ac199cb48f3b6f93f75e679da0f","type":"GO_TERM","name":"aorta smooth muscle tissue morphogenesis","canonical_id":"go:GO:0060414","description":"\"The process in which the structure of the smooth muscle tissue surrounding the aorta is generated and organized. An aorta is an artery that carries blood from the heart to other parts of the body.\" [GOC:bf, GOC:dgh, GOC:dph, Wikipedia:Aorta]","metadata":null},{"id":"00729d5b966d436581511dade10dbd63","type":"GO_TERM","name":"aortic smooth muscle cell differentiation","canonical_id":"go:GO:0035887","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell surrounding the aorta.\" [GOC:sl]","metadata":null},{"id":"8862f16091ff479aaa11216f6f6d5b84","type":"DISEASE","name":"aortic stenosis","canonical_id":"efo:0000266","description":null,"metadata":null},{"id":"586cae937a8341e0b9ee05fa3391918b","type":"GO_TERM","name":"aortic valve development","canonical_id":"go:GO:0003176","description":"\"The progression of the aortic valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"f571587992fb4809a6b60e56c7c8aafe","type":"GO_TERM","name":"aortic valve formation","canonical_id":"go:GO:0003189","description":"\"The developmental process pertaining to the initial formation of the aortic valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"965b0439c8e34d2b98570111c4b139a6","type":"GO_TERM","name":"aortic valve morphogenesis","canonical_id":"go:GO:0003180","description":"\"The process in which the structure of the aortic valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"b5bddd7181b34e6792439fe4f60b7a3e","type":"DRUG","name":"apalutamide","canonical_id":"gtopdb:9043","description":null,"metadata":null},{"id":"59c799f7dbc7438caa42682aa154d975","type":"DRUG","name":"apalutamide","canonical_id":"mesh:C572045","description":null,"metadata":null},{"id":"29d8bfbbb71c41aa9e9fc3e3acf57cca","type":"DRUG","name":"apalutamide","canonical_id":"chembl:CHEMBL3183409","description":null,"metadata":null},{"id":"5416a7fa5feb4e06a1e2cd25347c6be9","type":"COMBINATION_TREATMENT","name":"apalutamide + bicalutamide + degarelix + flutamide","canonical_id":"ctgov_combo:ctgov-combo-2309990ba01d7b2e","description":null,"metadata":null},{"id":"8b7390173a154609bc0d5cdd81d659a0","type":"COMBINATION_TREATMENT","name":"apalutamide + bicalutamide + enzalutamide","canonical_id":"ctgov_combo:ctgov-combo-aa246dc9f1770770","description":null,"metadata":null},{"id":"932350f9e4f94f90aa69d6a316b724ca","type":"COMBINATION_TREATMENT","name":"apalutamide + cabazitaxel + degarelix + enzalutamide + goserelin","canonical_id":"ctgov_combo:ctgov-combo-bbc29e68144a02ff","description":null,"metadata":null},{"id":"9f8aff00aa7742bd867f64f2a0691f00","type":"COMBINATION_TREATMENT","name":"apalutamide + darolutamide","canonical_id":"ctgov_combo:ctgov-combo-dd12abe64d719042","description":null,"metadata":null},{"id":"c7708a7180f147389675d06e602f8032","type":"COMBINATION_TREATMENT","name":"apalutamide + darolutamide","canonical_id":"ctgov_combo:ctgov-combo-1ce603972a68bd87","description":null,"metadata":null},{"id":"05b83dd1e3de464e91f03018c70825ea","type":"COMBINATION_TREATMENT","name":"apalutamide + darolutamide","canonical_id":"ctgov_combo:ctgov-combo-2731cfac28856d23","description":null,"metadata":null},{"id":"deae6eeeff0c4842b700c268fd04a399","type":"COMBINATION_TREATMENT","name":"apalutamide + darolutamide","canonical_id":"ctgov_combo:ctgov-combo-261a3b99bc585a2d","description":null,"metadata":null},{"id":"85ce662953f74009956b51899e7fecef","type":"COMBINATION_TREATMENT","name":"apalutamide + darolutamide","canonical_id":"ctgov_combo:ctgov-combo-ae25704fbb999082","description":null,"metadata":null},{"id":"a45cc46d6e85412ea624120e22b54adf","type":"COMBINATION_TREATMENT","name":"apalutamide + darolutamide + degarelix","canonical_id":"ctgov_combo:ctgov-combo-688e473676726ff6","description":null,"metadata":null},{"id":"3cee8bb9afa54d78a7524eda537c4129","type":"COMBINATION_TREATMENT","name":"apalutamide + degarelix + enzalutamide + goserelin + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-c911d0c8a06ed3c1","description":null,"metadata":null},{"id":"b6247c43efb8429c8043a4c070a01c27","type":"COMBINATION_TREATMENT","name":"apalutamide + degarelix + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-b3ab37199220077b","description":null,"metadata":null},{"id":"ef4ae39f3b374ef39282f0616cc547f7","type":"COMBINATION_TREATMENT","name":"apalutamide + prednisone","canonical_id":"ctgov_combo:ctgov-combo-4dec08f33092305e","description":null,"metadata":null},{"id":"6a029f79f1dd4e248d816c10bcda1e23","type":"GO_TERM","name":"apelin receptor activity","canonical_id":"go:GO:0060182","description":"\"Combining with the peptide apelin to initiate a change in cell activity.\" [GOC:dph]","metadata":null},{"id":"13c17e0582c041358975aa99b015e29a","type":"GO_TERM","name":"apelin receptor binding","canonical_id":"go:GO:0031704","description":"\"Binding to an apelin receptor.\" [GOC:mah, GOC:nln, GOC:vp, PMID:12787050]","metadata":null},{"id":"9fddb5d9fc564e1e8235587617b569ff","type":"GO_TERM","name":"apelin receptor signaling pathway","canonical_id":"go:GO:0060183","description":"\"A G protein-coupled receptor signaling pathway initiated by apelin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:dph]","metadata":null},{"id":"c7223c94afe74428a6fea215fea5d6d3","type":"GO_TERM","name":"aphidicolan-16 beta-ol synthase activity","canonical_id":"go:GO:0046567","description":"\"Catalysis of the reaction: 9-alpha-copalyl diphosphate + H2O = aphidicolan-16-beta-ol + diphosphate.\" [EC:4.2.3.42, PMID:12149019]","metadata":null},{"id":"7185efed751f46da9fae05b40b8793c8","type":"GO_TERM","name":"apical cell fate commitment","canonical_id":"go:GO:0010654","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an apical cell. The apical cell is the upper cell formed after the first division of the zygote.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4a5bfbbf07ee409084d8d9cfebfa65bf","type":"GO_TERM","name":"apical complex","canonical_id":"go:GO:0020007","description":"\"A group of cytoskeletal structures and associated membrane-bounded organelles found at the anterior end of adult obligate intracellular protozoan parasites in the phylum Apicomplexa. The apical complex is involved in attachment to and penetration of the host cell, and in parasite proliferation.\" [GOC:giardia, GOC:mb, PMID:16518471]","metadata":null},{"id":"0d5a673de864447f9ff22e5f1231f063","type":"GO_TERM","name":"apical constriction","canonical_id":"go:GO:0003383","description":"\"The actin-mediated process that results in the contraction of the apical end of a polarized columnar epithelial cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"5948c2a33d494829bd50741279bef9fe","type":"GO_TERM","name":"apical constriction involved in gastrulation","canonical_id":"go:GO:0003384","description":"\"The actin-mediated process that results in the contraction of the apical end of a polarized columnar epithelial cell, contributing to the process of gastrulation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"59c453ed08b1487bb6fbe1dcbb9d0c27","type":"GO_TERM","name":"apical constriction involved in ventral furrow formation","canonical_id":"go:GO:0110072","description":"\"The actin-mediated process that results in contraction of the apical end of a polarized columnar epithelial cell, contributing to formation of a ventral indentation (furrow) from the blastoderm epithelium, which is internalized to form a tube in the interior of the embryo, marking the start of gastrulation.\" [GOC:ha, PMID:28495958]","metadata":null},{"id":"73fd9050f7d5459abce3056375cf403c","type":"GO_TERM","name":"apical cortex","canonical_id":"go:GO:0045179","description":"\"The region that lies just beneath the plasma membrane on the apical edge of a cell.\" [GOC:bf]","metadata":null},{"id":"bd424f90d71147d28b1f1acee4204cf9","type":"GO_TERM","name":"apical cytoplasm","canonical_id":"go:GO:0090651","description":"\"The region of the cytoplasm located at the apical side of the cell. Used in reference to animal polarized epithelial cells.\" [PMID:17494872]","metadata":null},{"id":"55f83057090f438bb9875e45d4580583","type":"GO_TERM","name":"apical dendrite","canonical_id":"go:GO:0097440","description":"\"A dendrite that emerges near the apical pole of a neuron. In bipolar neurons, apical dendrites are located on the opposite side of the soma from the axon.\" [NIF_Subcellular:sao273773228]","metadata":null},{"id":"75bf793774fb4887954c7d6da5e9ec47","type":"GO_TERM","name":"apical dendrite arborization","canonical_id":"go:GO:0150023","description":"\"The process in which the anatomical structures of a dendritic tree are generated on the apical neuron side and organized into dendritic branches.\" [GOC:aruk, GOC:bc, PMID:22683681]","metadata":null},{"id":"61295f1b61834997b9b3776e0172d232","type":"GO_TERM","name":"apical dendrite development","canonical_id":"go:GO:0150022","description":"\"The process whose specific outcome is the progression of an apical dendrite over time, from its formation to the mature structure.\" [GOC:aruk, GOC:bc, PMID:22683681]","metadata":null},{"id":"e50d1c6922514c728183ef09fd19f971","type":"GO_TERM","name":"apical dendrite morphogenesis","canonical_id":"go:GO:0150021","description":"\"The process in which the anatomical structures of an apical dendrite are generated and organized.\" [GOC:aruk, GOC:bc, PMID:22683681]","metadata":null},{"id":"aa2963cafeee4fc898cdbd48ab657c63","type":"GO_TERM","name":"apical distal dendrite","canonical_id":"go:GO:0150014","description":"\"Any dendrite in a dendritic tree that emerges near the apical pole of a neuron, and which is farthest away from the neuronal cell body (the soma).\" [GO:bc, GOC:aruk, PMID:1720142, PMID:20629984, PMID:9214543]","metadata":null},{"id":"3a9376317c7c456fab68c3108ea8dcf9","type":"GO_TERM","name":"apical ectodermal ridge formation","canonical_id":"go:GO:1905139","description":"\"The process that gives rise to the apical ectodermal ridge. This process pertains to the initial formation of a structure from unspecified parts.\" [GO_REF:0000081, GOC:TermGenie, PMID:18359901, PMID:9323126, PMID:9596583]","metadata":null},{"id":"cf453d744434472ba1a7fc8e7b4c9262","type":"GO_TERM","name":"apical ectoplasmic specialization","canonical_id":"go:GO:0061831","description":"\"Testis-specific junction between mature spermatids and Sertoli cells at the luminal end of the Sertoli cell.\" [GOC:aruk, GOC:bc, GOC:dph, PMID:22332112, PMID:23546604]","metadata":null},{"id":"c542416f27344658965361ff04d1c2c5","type":"GO_TERM","name":"apical junction assembly","canonical_id":"go:GO:0043297","description":"\"The formation of an apical junction, a functional unit located near the cell apex at the points of contact between epithelial cells composed of the tight junction, the zonula adherens junction and the desmosomes, by the aggregation, arrangement and bonding together of its constituents.\" [GOC:curators, PMID:10854689, PMID:14729475, PMID:15196556]","metadata":null},{"id":"3b6d86ebcabe4ac6ab752e192d2a054a","type":"GO_TERM","name":"apical junction complex","canonical_id":"go:GO:0043296","description":"\"A functional unit located near the cell apex at the points of contact between epithelial cells, which in vertebrates is composed of the tight junction, the zonula adherens, and desmosomes and in some invertebrates, such as Drosophila, is composed of the subapical complex (SAC), the zonula adherens and the septate junction. Functions in the regulation of cell polarity, tissue integrity and intercellular adhesion and permeability.\" [GOC:curators, GOC:kmv, PMID:12525486, PMID:15196556]","metadata":null},{"id":"2156cac64c524c19a1dd40f5ed544d37","type":"GO_TERM","name":"apical lamina of hyaline layer","canonical_id":"go:GO:0032579","description":"\"A fibrous network that is part of the hyalin layer extracellular matrix. The apical lamina is thought to be principally composed of the glycoproteins fibropellins. This matrix has been found in echinoderms.\" [GOC:ecd, PMID:2060714, PMID:7608987, PMID:9638331]","metadata":null},{"id":"69e803a4ecb042d99ef12debfc3bfa07","type":"GO_TERM","name":"apical part of cell","canonical_id":"go:GO:0045177","description":"\"The region of a polarized cell that forms a tip or is distal to a base. For example, in a polarized epithelial cell, the apical region has an exposed surface and lies opposite to the basal lamina that separates the epithelium from other tissue.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"0919d4444b6440f5b305beefd300a22a","type":"GO_TERM","name":"apical plasma membrane","canonical_id":"go:GO:0016324","description":"\"The region of the plasma membrane located at the apical end of the cell.\" [GOC:curators]","metadata":null},{"id":"48f7b7e0e5cf44339b5644f1adf5ce83","type":"GO_TERM","name":"apical plasma membrane urothelial plaque","canonical_id":"go:GO:0120001","description":"\"A scallop-shaped plaque, also referred to as an asymmetric unit membrane (AUM), found in the apical plasma membrane of urothelial superficial (umbrella) cells which form a a barrier to the passage of water and soluble toxic compounds found in urine. The plaques are thickened regions of membrane composed of uroplakin transmembrane proteins which form a crystalline array.\" [GOC:krc, PMID:21468280, PMID:21887288]","metadata":null},{"id":"5918b78e4b2c4333b65d2d24775d8bcd","type":"GO_TERM","name":"apical pole of neuron","canonical_id":"go:GO:0044225","description":"\"Portion of a neuron cell soma closest to the point where the apical dendrite emerges.\" [NIF_Subcellular:sao1186862860]","metadata":null},{"id":"1f55932940e3499881bd8d43264a9470","type":"GO_TERM","name":"apical protein localization","canonical_id":"go:GO:0045176","description":"\"Any process in which a protein is transported to, or maintained in, apical regions of the cell.\" [GOC:bf]","metadata":null},{"id":"99e18fc757134727908fed87ff891476","type":"GO_TERM","name":"apical proximal dendrite","canonical_id":"go:GO:0150015","description":"\"The dendrite of the dendritic tree, which emerges near the apical pole of a neuron, and which is the closest to the cell body of the neuron (the soma).\" [GOC:aruk, GOC:bc, PMID:16899232, PMID:1720142, PMID:9214543]","metadata":null},{"id":"4493e255b17d451c9951a91dfe4bdfec","type":"GO_TERM","name":"apical recycling endosome","canonical_id":"go:GO:0090653","description":"\"Tubulo-vesicular structure located in the apical cytoplasm that participates in apical cargo recycling in polarized epithelial cells.\" [PMID:12669082, PMID:16394106, PMID:17494872, PMID:21170358, PMID:9405315]","metadata":null},{"id":"7cb67576be534f59be883f9a9eb8c36a","type":"GO_TERM","name":"apical tubulobulbar complex","canonical_id":"go:GO:0061828","description":"\"Actin-based structures involved in establishing close contact between mature spermatids and Sertoli cells at the luminal end of the Sertoli cell.\" [PMID:20403871, PMID:22510523]","metadata":null},{"id":"e9c4f932472b45899107d93bb1328ca8","type":"GO_TERM","name":"apicolateral plasma membrane","canonical_id":"go:GO:0016327","description":"\"The apical end of the lateral plasma membrane of epithelial cells.\" [GOC:hb]","metadata":null},{"id":"6c43346f5ee14251ae190665c8da0e3d","type":"GO_TERM","name":"apicomedial cortex","canonical_id":"go:GO:0106037","description":"\"The region that lies just beneath the plasma membrane in the middle of the apical edge of a cell.\" [PMID:23831726, PMID:28263180]","metadata":null},{"id":"aae85940a74642509c903ade1356cca3","type":"GO_TERM","name":"apicomplexan dense granule","canonical_id":"go:GO:0020026","description":"\"Electron-dense organelle with a granular internal matrix found in a apicomplexan parasite; contains proteins destined to be secreted into the parasitophorous vacuole following parasite invasion of a host cell.\" [GOC:mb, GOC:mtg_sensu, PMID:15978597, PMID:35302693]","metadata":null},{"id":"9430dcd0943b46faaced609750388fc4","type":"GO_TERM","name":"apicomplexan dense granule membrane","canonical_id":"go:GO:0030668","description":"\"The lipid bilayer surrounding a dense granule of the type found in apicomplexan parasites.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"89b8c4fcd35b42a3a752b78b8bfb070a","type":"GO_TERM","name":"apicoplast","canonical_id":"go:GO:0020011","description":"\"The plastid organelle found in apicomplexans.\" [ISBN:0521664470]","metadata":null},{"id":"1fc1b143cbb146c7a744711aacee2a3e","type":"GO_TERM","name":"apicoplast membrane","canonical_id":"go:GO:0160211","description":"\"Any of the lipid bilayers that surround an apicoplast and form the apicoplast envelope.\" [PMID:20124342, PMID:38865262]","metadata":null},{"id":"6fe52fa2c55d49cc867bc80191d6ffe2","type":"GO_TERM","name":"apigenin 4'-O-methyltransferase activity","canonical_id":"go:GO:0030754","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 5,7,4'-trihydroxyflavone = S-adenosyl-L-homocysteine + 4'-methoxy-5,7-dihydroxyflavone.\" [EC:2.1.1.75]","metadata":null},{"id":"10390de0f5e24b06a07a455e7e2c9134","type":"GO_TERM","name":"apigenin 7-O-methyltransferase activity","canonical_id":"go:GO:0102529","description":"\"Catalysis of the reaction: apigenin + S-adenosyl-L-methionine = genkwanin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:73071]","metadata":null},{"id":"08de7773329b47d091b1ccca09ed444e","type":"GO_TERM","name":"apigenin-7,4'-dimethyl ether 6-hydroxylase activity","canonical_id":"go:GO:0102534","description":"\"Catalysis of the reaction: apigenin 4',7-dimethyl ether + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + ladanein + oxidized [NADPH--hemoprotein reductase].\" [RHEA:73435]","metadata":null},{"id":"a92e3a65f5944aa29e62bbd25c55d52d","type":"GO_TERM","name":"apiose 1-reductase activity","canonical_id":"go:GO:0047674","description":"\"Catalysis of the reaction: D-apiitol + NAD+ = D-apiose + H+ + NADH.\" [EC:1.1.1.114, RHEA:15301]","metadata":null},{"id":"a3cb2724fc2042f7afa0b471cbd53985","type":"GO_TERM","name":"apiose biosynthetic process","canonical_id":"go:GO:0033350","description":"\"The chemical reactions and pathways resulting in the formation of apiose, the branched tetrose 3-C-(hydroxymethyl)-D-glycero-tetrose.\" [GOC:mah]","metadata":null},{"id":"7cfc02a08ab74b8e8ee16b3ca17c618d","type":"DRUG","name":"apixaban","canonical_id":"gtopdb:6390","description":null,"metadata":null},{"id":"f59a7bc9730b473cb65a72d7f1517fc8","type":"DRUG","name":"apixaban","canonical_id":"chembl:CHEMBL231779","description":null,"metadata":null},{"id":"3d4369a97b4940e89faaf5c46044cfbf","type":"COMBINATION_TREATMENT","name":"apixaban + dalteparin + enoxaparin + rivaroxaban + tinzaparin","canonical_id":"ctgov_combo:ctgov-combo-b7026d7b88d04755","description":null,"metadata":null},{"id":"66f8ae315b1c4a768b7143063771ae57","type":"COMBINATION_TREATMENT","name":"apixaban + edoxaban","canonical_id":"ctgov_combo:ctgov-combo-6915b109c70529d7","description":null,"metadata":null},{"id":"0b55330d803c4e65a16c846b89cedfae","type":"COMBINATION_TREATMENT","name":"apixaban + edoxaban","canonical_id":"ctgov_combo:ctgov-combo-84e1020ffc72c98f","description":null,"metadata":null},{"id":"712661260dcc4b308d1bfefb7cfec800","type":"COMBINATION_TREATMENT","name":"apixaban + edoxaban","canonical_id":"ctgov_combo:ctgov-combo-3d16cc5b28c78f4f","description":null,"metadata":null},{"id":"e953b9a60e64424aa11addaa64086dc6","type":"COMBINATION_TREATMENT","name":"apixaban + edoxaban","canonical_id":"ctgov_combo:ctgov-combo-0dfec96a75fd792a","description":null,"metadata":null},{"id":"a7bdf65a99ec4c36ad4d646758bd5846","type":"COMBINATION_TREATMENT","name":"apixaban + edoxaban + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-f80aedb3c77642ed","description":null,"metadata":null},{"id":"c5eaa4b08e72434d8fa35e1d85739c72","type":"COMBINATION_TREATMENT","name":"apixaban + edoxaban + rivaroxaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-3dbafba67540accc","description":null,"metadata":null},{"id":"aede1e2d5ade40fda0fe8da817d02eb3","type":"COMBINATION_TREATMENT","name":"apixaban + enoxaparin","canonical_id":"ctgov_combo:ctgov-combo-7a9261f8af6d3412","description":null,"metadata":null},{"id":"1d7639ba00b44ebb92bcf4954e36082a","type":"COMBINATION_TREATMENT","name":"apixaban + enoxaparin","canonical_id":"ctgov_combo:ctgov-combo-92fcc89a12252add","description":null,"metadata":null},{"id":"c84d212605b24e61adb0f7afc421df18","type":"COMBINATION_TREATMENT","name":"apixaban + enoxaparin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-a6d2e8d1a3e4b65b","description":null,"metadata":null},{"id":"8a6756be12a149a0b276ecb8d64d4137","type":"COMBINATION_TREATMENT","name":"apixaban + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-647debbb2848f714","description":null,"metadata":null},{"id":"12b575694e6441f69215531d6572e015","type":"COMBINATION_TREATMENT","name":"apixaban + rivaroxaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-0196004de2ea907e","description":null,"metadata":null},{"id":"cee3c5eca91545f291611d1f27f8cd0f","type":"COMBINATION_TREATMENT","name":"apixaban + rivaroxaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-6953789b141c92db","description":null,"metadata":null},{"id":"cc54aefdf98b45d1a08a5f0ece119afd","type":"COMBINATION_TREATMENT","name":"apixaban + rivaroxaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-4cae9a828358d5ac","description":null,"metadata":null},{"id":"0d1bf70ab6f441bebebb630f15da6f79","type":"COMBINATION_TREATMENT","name":"apixaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-f195f76ca66e6a73","description":null,"metadata":null},{"id":"3a897c93353f477d9643b4841e025376","type":"COMBINATION_TREATMENT","name":"apixaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-9110c4807d08c48c","description":null,"metadata":null},{"id":"16d9cb3ce52e47179956521cab8f03ea","type":"COMBINATION_TREATMENT","name":"apixaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-14941237e1e049aa","description":null,"metadata":null},{"id":"f0f01321150f4ec8a396a031c4927672","type":"COMBINATION_TREATMENT","name":"apixaban + warfarin","canonical_id":"ctgov_combo:ctgov-combo-2128d8f516e3cbff","description":null,"metadata":null},{"id":"b4ae06c4fb054506aaf68de1a58210cb","type":"GO_TERM","name":"aplanospore formation","canonical_id":"go:GO:0075289","description":"\"The process in which a nonmotile, asexual spore is formed within a cell in certain algae and fungi (commonly in the Phycomycetes), the wall of aplanospore is distinct from that of the parent cell.\" [GOC:pamgo_curators]","metadata":null},{"id":"15470b26ff4b4b6986977907c9804bb2","type":"DISEASE","name":"aplastic anemia","canonical_id":"mondo:0015909","description":null,"metadata":null},{"id":"a926e71643ed4bf58fad7f155017fc49","type":"GO_TERM","name":"apo-beta-carotenoid-14',13'-dioxygenase activity","canonical_id":"go:GO:0050588","description":"\"Catalysis of the reaction: 8'-apo-beta-carotenol + O2 = (E,E)-7-hydroxy-6-methylhepta-3,5-dienal + 14'-apo-beta-carotenal.\" [EC:1.13.11.67, RHEA:26023]","metadata":null},{"id":"22024e3f602e45848c73339174ec1d12","type":"GO_TERM","name":"apocarotenoid biosynthetic process","canonical_id":"go:GO:0043289","description":"\"The chemical reactions and pathways resulting in the formation of apocarotenoids by the oxidative cleavage of carotenoids. Many apocarotenoids are biologically important e.g. retinal and abscisic acid.\" [GOC:jl, PMID:27485225]","metadata":null},{"id":"719f2eca07e04fbf8b916ff1eadfca55","type":"GO_TERM","name":"apocarotenoid catabolic process","canonical_id":"go:GO:0043290","description":"\"The chemical reactions and pathways resulting in the breakdown of apocarotenoids, a class of compounds derived from the oxidative cleavage of carotenoids, many of which are biologically important e.g. retinal and abscisic acid.\" [GOC:jl, PMID:33721905, PMID:34956282]","metadata":null},{"id":"eab5a3d0d67a48b5b621679392fc64f1","type":"GO_TERM","name":"apocrine secretion","canonical_id":"go:GO:0160022","description":"\"The controlled release of a substance by a cell or a tissue by discharging a portion of the secreting cell when intracellular components are freed into a lumen through the shedding of whole pieces of the cytoplasm.\" [PMID:25960390]","metadata":null},{"id":"a3c0a9e492004bd3998b045e4ed4adf6","type":"GO_TERM","name":"apolipoprotein A-I binding","canonical_id":"go:GO:0034186","description":"\"Binding to apolipoprotein A-I.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"75508dc8a0e9479f855a81ac53636d46","type":"GO_TERM","name":"apolipoprotein A-I receptor activity","canonical_id":"go:GO:0034188","description":"\"Combining with an apolipoprotein A-I receptor ligand and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:BHF, GOC:rl, GOC:signaling, PMID:16443932]","metadata":null},{"id":"c2ed5fb077f84ae9986cab786209664a","type":"GO_TERM","name":"apolipoprotein A-I receptor binding","canonical_id":"go:GO:0034191","description":"\"Binding to an apolipoprotein A-I receptor.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"e3584b7fdad745e4905c9ca90f356656","type":"GO_TERM","name":"apolipoprotein A-I-mediated signaling pathway","canonical_id":"go:GO:0038027","description":"\"The series of molecular signals initiated by apolipoprotein A-I binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:signaling, PMID:16443932]","metadata":null},{"id":"ca11a74e7e3e402691db31ef56adecd0","type":"GO_TERM","name":"apolipoprotein B mRNA editing enzyme complex","canonical_id":"go:GO:0030895","description":"\"Protein complex that mediates editing of the mRNA encoding apolipoprotein B; catalyzes the deamination of C to U (residue 6666 in the human mRNA). Contains a catalytic subunit, APOBEC-1, and other proteins (e.g. human ASP; rat ASP and KSRP).\" [PMID:10781591, PMID:12683974]","metadata":null},{"id":"23b1447515b7440abb0971755ed8ddd0","type":"GO_TERM","name":"apolipoprotein E recycling","canonical_id":"go:GO:0071828","description":"\"The process in which chylomicron remnant-associated apolipoprotein E is internalized by endocytosis, localized to recycling endosomes and then secreted in association with a high-density lipoprotein particle.\" [GOC:BHF, PMID:16373604]","metadata":null},{"id":"3530d185f6e0470bb2e5e98a624677d5","type":"GO_TERM","name":"apolipoprotein binding","canonical_id":"go:GO:0034185","description":"\"Binding to an apolipoprotein, the protein component of a lipoprotein complex.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"78668d5b4fbb4fa79529a8c336192040","type":"GO_TERM","name":"apolipoprotein receptor activity","canonical_id":"go:GO:0030226","description":"\"Combining with an apolipoprotein to initiate a change in cell activity.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"cb6964aff26141d3968e705b576d2321","type":"GO_TERM","name":"apolipoprotein receptor binding","canonical_id":"go:GO:0034190","description":"\"Binding to an apolipoprotein receptor.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"864870c9811940989e5eb825aae370f5","type":"GO_TERM","name":"apolysis","canonical_id":"go:GO:0018989","description":"\"The first process of molting, characterized by the detachment of the old cuticle from the underlying epidermal cells.\" [GOC:jl]","metadata":null},{"id":"11f69617e3dd472a8e69e85c7841b746","type":"DRUG","name":"apomorphine","canonical_id":"gtopdb:33","description":null,"metadata":null},{"id":"b36f0b1cc07e46d0af7117ecf46c6afd","type":"DRUG","name":"apomorphine","canonical_id":"chembl:CHEMBL3187985","description":null,"metadata":null},{"id":"fb1c69ba3219451b8ac69c9271d699d0","type":"GO_TERM","name":"apoplast","canonical_id":"go:GO:0048046","description":"\"The cell membranes and intracellular regions in a plant are connected through plasmodesmata, and plants may be described as having two major compartments: the living symplast and the non-living apoplast. The apoplast is external to the plasma membrane and includes cell walls, intercellular spaces and the lumen of dead structures such as xylem vessels. Water and solutes pass freely through it.\" [GOC:jid]","metadata":null},{"id":"d9af88598a0141d0b003b306418a69e1","type":"GO_TERM","name":"apoptosome","canonical_id":"go:GO:0043293","description":"\"A multisubunit protein complex involved in the signaling phase of the apoptotic process. In mammals it is typically composed of seven Apaf-1 subunits bound to cytochrome c and caspase-9. A similar complex to promote apoptosis is formed from homologous gene products in other eukaryotic organisms.\" [GOC:mtg_apoptosis, PMID:10428850, PMID:11406413, PMID:12176339, PMID:15189137]","metadata":null},{"id":"ace118c6916f4646a0ccc8df9152e040","type":"GO_TERM","name":"apoptosome assembly","canonical_id":"go:GO:0097314","description":"\"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"c61bb85cf88643f380e335a6bcc7d9f7","type":"GO_TERM","name":"apoptotic DNA fragmentation","canonical_id":"go:GO:0006309","description":"\"The cleavage of DNA during apoptosis, which usually occurs in two stages: cleavage into fragments of about 50 kbp followed by cleavage between nucleosomes to yield 200 bp fragments.\" [GOC:dph, GOC:mah, GOC:mtg_apoptosis, GOC:tb, ISBN:0721639976, PMID:15723341, PMID:23379520]","metadata":null},{"id":"f451d5b4c5f745c4b3bc153fbc3dba89","type":"GO_TERM","name":"apoptotic body","canonical_id":"go:GO:0097189","description":"\"A vesicle containing parts of a dying cell. Apoptotic bodies can be formed during the execution phase of the apoptotic process, when the cell's cytoskeleton breaks up and causes the membrane to bulge outward. These bulges may separate from the cell, taking a portion of cytoplasm with them, to become apoptotic bodies. These are then engulfed by phagocytic cells, and their components recycled. Apoptotic bodies may range in size from 0.8 to 5um.\" [GOC:mtg_apoptosis, GOC:vesicles, PMID:15242875, PMID:24223256, Wikipedia:Apoptosis, Wikipedia:Bleb_(cell_biology)]","metadata":null},{"id":"1074229048184db09bbf963ce7053802","type":"GO_TERM","name":"apoptotic cell clearance","canonical_id":"go:GO:0043277","description":"\"The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte.\" [GOC:rk, PMID:14685684]","metadata":null},{"id":"4de31229ac8d4aa291bbd905022ca74b","type":"GO_TERM","name":"apoptotic chromosome condensation","canonical_id":"go:GO:0030263","description":"\"The compaction of chromatin during apoptosis.\" [GOC:mah]","metadata":null},{"id":"0d775ad7738d41139ee59aeead9c4312","type":"GO_TERM","name":"apoptotic mitochondrial changes","canonical_id":"go:GO:0008637","description":"\"The morphological and physiological alterations undergone by mitochondria during apoptosis.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"0147085a14c249f18ad2f6c7c3bcca42","type":"GO_TERM","name":"apoptotic nuclear changes","canonical_id":"go:GO:0030262","description":"\"Alterations undergone by nuclei at the molecular and morphological level as part of the execution phase of apoptosis.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"be33356a22a346d4b5b47d69824259b8","type":"GO_TERM","name":"apoptotic process","canonical_id":"go:GO:0006915","description":"\"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.\" [GOC:cjm, GOC:curators, GOC:dhl, GOC:ecd, GOC:mtg_apoptosis, GOC:tb, ISBN:0198506732, PMID:18846107, PMID:21494263]","metadata":null},{"id":"daf072cc9b8349ada8df319649dc9ab3","type":"GO_TERM","name":"apoptotic process in bone marrow cell","canonical_id":"go:GO:0071839","description":"\"The apoptotic process in cells in the bone marrow.\" [GOC:mah, GOC:mtg_apoptosis, PMID:17063141]","metadata":null},{"id":"af9084464a6e4d01a24359ccf77b8115","type":"GO_TERM","name":"apoptotic process in response to mitochondrial fragmentation","canonical_id":"go:GO:0140208","description":"\"Any apoptotic process that occurs as a result of mitochondrial fragmentation.\" [PMID:18940801]","metadata":null},{"id":"ee4c10cce8c74ad1bfe7879aed457cd4","type":"GO_TERM","name":"apoptotic process involved in blood vessel morphogenesis","canonical_id":"go:GO:1902262","description":"\"Any apoptotic process that is involved in blood vessel morphogenesis.\" [GOC:dph, GOC:mtg_apoptosis, GOC:TermGenie, PMID:16163358]","metadata":null},{"id":"43927004eb9448b88b9a3dc8b92c790c","type":"GO_TERM","name":"apoptotic process involved in development","canonical_id":"go:GO:1902742","description":"\"Any apoptotic process that is involved in anatomical structure development.\" [GO_REF:0000060, GOC:mtg_apoptosis, GOC:pg, GOC:TermGenie]","metadata":null},{"id":"7092a8269e5c4c2faeb7ee7ed7a6b4b4","type":"GO_TERM","name":"apoptotic process involved in embryonic digit morphogenesis","canonical_id":"go:GO:1902263","description":"\"Any apoptotic process that is involved in embryonic digit morphogenesis.\" [GOC:dph, GOC:mtg_apoptosis, GOC:TermGenie, PMID:15967824]","metadata":null},{"id":"5276aea0c01740efaaf1ab7c755c21b8","type":"GO_TERM","name":"apoptotic process involved in endocardial cushion morphogenesis","canonical_id":"go:GO:0003277","description":"\"Any apoptotic process that contributes to the shaping of an endocardial cushion. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.\" [GOC:mtg_apoptosis, GOC:mtg_heart]","metadata":null},{"id":"9414838a4a0d49aa840684afa7e5daae","type":"GO_TERM","name":"apoptotic process involved in heart morphogenesis","canonical_id":"go:GO:0003278","description":"\"Any apoptotic process that contributes to the shaping of the heart.\" [GOC:mtg_apoptosis, GOC:mtg_heart]","metadata":null},{"id":"6d246e7ae20b47b6bb26e0dc0706cb51","type":"GO_TERM","name":"apoptotic process involved in luteolysis","canonical_id":"go:GO:0061364","description":"\"The apoptotic process that contributes to luteolysis.\" [GOC:mtg_apoptosis, PMID:18566128]","metadata":null},{"id":"fd643bddbbb24e7db5257c3b41cbf00e","type":"GO_TERM","name":"apoptotic process involved in mammary gland involution","canonical_id":"go:GO:0060057","description":"\"Any apoptotic process that triggers the activity of proteolytic caspases whose actions dismantle the mammary epithelial cells resulting in their programmed cell death.\" [GOC:dph, GOC:mtg_apoptosis]","metadata":null},{"id":"75bd253d8cbd4fdaa9176e6fd82cc7b5","type":"GO_TERM","name":"apoptotic process involved in morphogenesis","canonical_id":"go:GO:0060561","description":"\"Any apoptotic process that contributes to the shaping of an anatomical structure.\" [GOC:dph, GOC:mtg_apoptosis]","metadata":null},{"id":"3e70ba3e5440456eb4fdb9f04c56b699","type":"GO_TERM","name":"apoptotic process involved in outflow tract morphogenesis","canonical_id":"go:GO:0003275","description":"\"Any apoptotic process that contributes to the shaping of the outflow tract. The outflow tract is the portion of the heart through which blood flows into the arteries.\" [GOC:mtg_apoptosis, GOC:mtg_heart]","metadata":null},{"id":"af825728bdce4f1e83e1b346f9050cfe","type":"GO_TERM","name":"apoptotic signaling pathway","canonical_id":"go:GO:0097190","description":"\"The series of molecular signals which triggers the apoptotic death of a cell. The pathway starts with reception of a signal, and ends when the execution phase of apoptosis is triggered.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"02499c02846d4b09b95a8a04713e3e15","type":"GO_TERM","name":"appendage development","canonical_id":"go:GO:0048736","description":"\"The process whose specific outcome is the progression of an appendage over time, from its formation to the mature structure. An appendage is an organ or part that is attached to the trunk of an organism, such as a limb or a branch.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"d08581eb5347428ba0fcb9a1f26bd3fd","type":"GO_TERM","name":"appendage morphogenesis","canonical_id":"go:GO:0035107","description":"\"The process in which the anatomical structures of appendages are generated and organized. An appendage is an organ or part that is attached to the trunk of an organism, such as a limb or a branch.\" [ISBN:0582227089]","metadata":null},{"id":"72645c39f56b4815a400c07724034d09","type":"GO_TERM","name":"appendage segmentation","canonical_id":"go:GO:0035285","description":"\"Division of an appendage, an organ or part that is attached to the main body of an organism, into a series of semi-repetitive parts or segments. Most arthropod appendages, such as the legs and antennae, are visibly segmented.\" [PMID:10357895]","metadata":null},{"id":"74a371ec67924a729d9d06f2e892a97a","type":"GO_TERM","name":"apposition of dorsal and ventral imaginal disc-derived wing surfaces","canonical_id":"go:GO:0007475","description":"\"The coming together of the dorsal and ventral surfaces of the imaginal disc-derived wing during the conversion of a folded single layered wing disc to a flat bilayered wing.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"496540c016814b178b21a1c69ea93584","type":"GO_TERM","name":"appressorium formation","canonical_id":"go:GO:0075016","description":"\"The process in which a swollen, flattened portion of a symbiont filament is formed on or near its host organism, to adhere to and for the purpose of penetrating the host surface.\" [GOC:pamgo_curators]","metadata":null},{"id":"a0480c39f876420f9fce74d13366316b","type":"GO_TERM","name":"appressorium maturation","canonical_id":"go:GO:0075035","description":"\"The process in which specialized features of the symbiont appressorium are acquired post initiation, to aid in infection of the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"65cf579e0eb449c1b58ec13be3ba4c62","type":"GO_TERM","name":"appressorium-mediated entry into host","canonical_id":"go:GO:0120326","description":"\"Penetration by a symbiont into a host organism via an appressorium. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:ach, GOC:krc, PMID:14731267, PMID:22589729]","metadata":null},{"id":"c181d0addce04755bc6ff52d66253311","type":"DRUG","name":"apraclonidine","canonical_id":"gtopdb:7117","description":null,"metadata":null},{"id":"9d7b70cbd5aa4dc388fb59eb7c447d1f","type":"DRUG","name":"apraclonidine","canonical_id":"mesh:C016986","description":null,"metadata":null},{"id":"edaae17734074a4184afde3ede206634","type":"DRUG","name":"apremilast","canonical_id":"gtopdb:7372","description":null,"metadata":null},{"id":"cb67d838158e4b18b0b077fb2c394085","type":"DRUG","name":"apremilast","canonical_id":"chembl:CHEMBL514800","description":null,"metadata":null},{"id":"041a8aa5cf0a4b89958afb8e3b89771a","type":"COMBINATION_TREATMENT","name":"apremilast + bimekizumab + deucravacitinib + dupilumab + ixekizumab + nemolizumab + risankizumab + roflumilast + secukinumab + tapinarof + tildrakizumab + tralokinumab + upadacitinib + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-10d60268d4beb377","description":null,"metadata":null},{"id":"bff412b9a63b4be4aa0a0922d2da461f","type":"COMBINATION_TREATMENT","name":"apremilast + certolizumab pegol + golimumab + ixekizumab + leflunomide","canonical_id":"ctgov_combo:ctgov-combo-70b0d1eecd48629a","description":null,"metadata":null},{"id":"e7f202052de249058cc3573fcd9297b5","type":"COMBINATION_TREATMENT","name":"apremilast + deucravacitinib","canonical_id":"ctgov_combo:ctgov-combo-b287e6d52f413f43","description":null,"metadata":null},{"id":"323c57e9d1fa4e60abef4ef393412519","type":"COMBINATION_TREATMENT","name":"apremilast + risankizumab","canonical_id":"ctgov_combo:ctgov-combo-918f2902dc60815d","description":null,"metadata":null},{"id":"9d25ce30a3554aabb2e3d59b7579a736","type":"DRUG","name":"aprepitant","canonical_id":"gtopdb:3490","description":null,"metadata":null},{"id":"9e129b4181ee40a78c1ca935c66effb3","type":"DRUG","name":"aprepitant","canonical_id":"chembl:CHEMBL1471","description":null,"metadata":null},{"id":"4f19dcbcf8a448a49d342919ce9f31ed","type":"COMBINATION_TREATMENT","name":"aprepitant + dexamethasone + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-ea6667e4b0115514","description":null,"metadata":null},{"id":"8332065a12f9410fa55f3d7cf78c8cfa","type":"COMBINATION_TREATMENT","name":"aprepitant + granisetron","canonical_id":"ctgov_combo:ctgov-combo-078dda5c835e4f9d","description":null,"metadata":null},{"id":"abf1a9d66e82481aa3dd59edcbb55918","type":"COMBINATION_TREATMENT","name":"aprepitant + granisetron","canonical_id":"ctgov_combo:ctgov-combo-6384cc64ff4619a0","description":null,"metadata":null},{"id":"3d23fc44abed471cabc0aecc34050bdc","type":"COMBINATION_TREATMENT","name":"aprepitant + granisetron","canonical_id":"ctgov_combo:ctgov-combo-f5c792eedfe72848","description":null,"metadata":null},{"id":"4ed3704b36e941b2b7265bae9b069bbd","type":"COMBINATION_TREATMENT","name":"aprepitant + granisetron + haloperidol + hydrocodone + metoclopramide + palonosetron + tropisetron","canonical_id":"ctgov_combo:ctgov-combo-fd176e8c2fb2f5e9","description":null,"metadata":null},{"id":"d193eeef88174d88b6eff7fce455deff","type":"COMBINATION_TREATMENT","name":"aprepitant + hydroxyzine","canonical_id":"ctgov_combo:ctgov-combo-f247879732b25a7c","description":null,"metadata":null},{"id":"fa5924edd3e64f4a889a1c1596914dd0","type":"COMBINATION_TREATMENT","name":"aprepitant + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-5705554de71fe6dc","description":null,"metadata":null},{"id":"2c8081a848194d7fa719094a4b66124f","type":"COMBINATION_TREATMENT","name":"aprepitant + metoclopramide + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-44de9bacf22f1070","description":null,"metadata":null},{"id":"ea8129f7365f4174be605be6dcf1ce55","type":"COMBINATION_TREATMENT","name":"aprepitant + mirtazapine","canonical_id":"ctgov_combo:ctgov-combo-cff06b60158e250f","description":null,"metadata":null},{"id":"27b5971f00224c1bab3fd2632689e191","type":"COMBINATION_TREATMENT","name":"aprepitant + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-f8d247b91f39ba97","description":null,"metadata":null},{"id":"551f2fe59c4240d192750f0176516662","type":"COMBINATION_TREATMENT","name":"aprepitant + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-9eec00ecf3b32428","description":null,"metadata":null},{"id":"0a89ada740714ff48f4bb3cb730a55a3","type":"COMBINATION_TREATMENT","name":"aprepitant + palonosetron","canonical_id":"ctgov_combo:ctgov-combo-9a551fc50c4832fd","description":null,"metadata":null},{"id":"426311f480254d4a9869659f4c9460e7","type":"COMBINATION_TREATMENT","name":"aprepitant + palonosetron","canonical_id":"ctgov_combo:ctgov-combo-0b2cd7d58ed22dae","description":null,"metadata":null},{"id":"83c60d2188eb4aeeb66c6551666c46b5","type":"COMBINATION_TREATMENT","name":"aprepitant + palonosetron","canonical_id":"ctgov_combo:ctgov-combo-4e2c7c59517c0c6b","description":null,"metadata":null},{"id":"3761dd74d37b423ab7a37c32afbdaaf2","type":"COMBINATION_TREATMENT","name":"aprepitant + paroxetine","canonical_id":"ctgov_combo:ctgov-combo-cac1b5a86090122b","description":null,"metadata":null},{"id":"d83424d78ecd4782a633b5894b8f4b9d","type":"COMBINATION_TREATMENT","name":"aprepitant + scopolamine","canonical_id":"ctgov_combo:ctgov-combo-80d71061d8c3a2f4","description":null,"metadata":null},{"id":"fd2bb52c0cfe416baedfe6552bec2f3c","type":"COMBINATION_TREATMENT","name":"aprepitant + tropisetron","canonical_id":"ctgov_combo:ctgov-combo-2663e69f5e4b5437","description":null,"metadata":null},{"id":"519ac01cac924793b6fa90959047c17b","type":"DRUG","name":"aprotinin","canonical_id":"gtopdb:6570","description":null,"metadata":null},{"id":"661b5bdff95f4cd18f3f6e8e87791f8c","type":"DRUG","name":"aprotinin","canonical_id":"chembl:CHEMBL1201619","description":null,"metadata":null},{"id":"6ede9628df164f0380eded75a7204665","type":"GO_TERM","name":"apyrase activity","canonical_id":"go:GO:0004050","description":"\"Catalysis of the reaction: a ribonucleoside 5'-triphosphate + 2 H2O = a ribonucleoside 5'-phosphate + 2 phosphate. This reaction consists of two distinct successive phosphate-releasing steps, with NDPs as intermediates. Apyrases are active against both di- and triphosphate nucleotides (NDPs and NTPs) and hydrolyze NTPs to nucleotide monophosphates (NMPs).\" [EC:3.6.1.5]","metadata":null},{"id":"153ffedc89a844758c8087e579bc9281","type":"GO_TERM","name":"arabidiol synthase activity","canonical_id":"go:GO:0034075","description":"\"Catalysis of the reaction: oxidosqualene + H2O = arabidiol ((13R,14R,17E)-malabarica-17,21-diene-3beta,14-diol).\" [GOC:cb, PMID:16774269, PMID:17474751]","metadata":null},{"id":"161acb1598134f349d0e3be4fe97b11d","type":"GO_TERM","name":"arabinan biosynthetic process","canonical_id":"go:GO:0035884","description":"\"The chemical reactions and pathways resulting in the formation of arabinan, a polysaccharide composed of arabinose residues.\" [GOC:rs, ISBN:0198506732]","metadata":null},{"id":"1d7289f4b6cc406c90437c839354d5b1","type":"GO_TERM","name":"arabinan catabolic process","canonical_id":"go:GO:0031222","description":"\"The chemical reactions and pathways resulting in the breakdown of arabinan, a polysaccharide composed of arabinose residues.\" [GOC:mlg, ISBN:0198506732]","metadata":null},{"id":"e1ee9593eadf4582bca79d2c22f8e022","type":"GO_TERM","name":"arabinan endo-1,5-alpha-L-arabinosidase activity","canonical_id":"go:GO:0046558","description":"\"Catalysis of the endohydrolysis of (1->5)-alpha-arabinofuranosidic linkages in (1->5) arabinans.\" [EC:3.2.1.99]","metadata":null},{"id":"b41e8172ce3645eda976c587bd464d67","type":"GO_TERM","name":"arabinan metabolic process","canonical_id":"go:GO:0031221","description":"\"The chemical reactions and pathways involving arabinan, a polysaccharide composed of arabinose residues.\" [GOC:mlg, ISBN:0198506732]","metadata":null},{"id":"7b1ad7bc0f084bafb7d903ca93ea6118","type":"GO_TERM","name":"arabinan transmembrane transport","canonical_id":"go:GO:0042899","description":"\"The process in which arabinan is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"aea7786d0d9c467aba7ff3c83e962ba5","type":"GO_TERM","name":"arabinan transmembrane transporter activity","canonical_id":"go:GO:0042901","description":"\"Enables the transfer of an arabinan, a polysaccharide composed of arabinose residues, from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"2b8cfd279054460a9d941be826e2bec9","type":"GO_TERM","name":"arabinitol transmembrane transport","canonical_id":"go:GO:0015792","description":"\"The process in which arabitol is transported across a lipid bilayer, from one side of a membrane to the other. Arabitol is the pentitol derived from arabinose or lyxose by reduction of the aldehyde group. The D enantiomer is present in lichens and mushrooms.\" [ISBN:0198506732]","metadata":null},{"id":"f3769759369f48ffaf6478f5bdadb1e6","type":"GO_TERM","name":"arabinogalactan binding","canonical_id":"go:GO:2001085","description":"\"Binding to arabinogalactan.\" [GOC:mengo_curators]","metadata":null},{"id":"f21661cdd71c45389fccd7a235dd990e","type":"GO_TERM","name":"arabinogalactan endo-1,4-beta-galactosidase activity","canonical_id":"go:GO:0031218","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-galactosidic linkages in arabinogalactans.\" [EC:3.2.1.89, GOC:mlg]","metadata":null},{"id":"baaa4d8701e94dd6bc4902cdb768f3ec","type":"GO_TERM","name":"arabinogalactan protein metabolic process","canonical_id":"go:GO:0010405","description":"\"The chemical reactions and pathways involving a cell wall arabinogalactan II glycoprotein, which is composed of a group of core protein of highly varying length and domain complexity. These are O-glycosylated at one or more hydroxyproline residues by arabinogalactan (AG) type II groups, which consist of (1->3)-beta-galactan and (1->6)-beta-linked galactan chains connected to each other by (1->3,1->6)-linked branch points, O-3 and O-6 positions substituted with terminal arabinosyl residues. Also, rhamnose, fucose, glucuronic and galacturonic acid can be present in the glycan structures.\" [GOC:tair_curators]","metadata":null},{"id":"14ba2e333322454a9c0eed9e08c81afa","type":"GO_TERM","name":"arabinonate dehydratase activity","canonical_id":"go:GO:0047675","description":"\"Catalysis of the reaction: D-arabinonate = 2-dehydro-3-deoxy-D-arabinonate + H2O.\" [EC:4.2.1.5, RHEA:21836]","metadata":null},{"id":"b89b10090ecb41099e535ba187a0ba5c","type":"GO_TERM","name":"arabinose biosynthetic process","canonical_id":"go:GO:0019567","description":"\"The chemical reactions and pathways resulting in the formation of arabinose, arabino-pentose.\" [GOC:ai]","metadata":null},{"id":"2c95d5c1905f438b8ee051d9ab0b62e5","type":"GO_TERM","name":"arabinose catabolic process","canonical_id":"go:GO:0019568","description":"\"The chemical reactions and pathways resulting in the breakdown of arabinose, arabino-pentose.\" [GOC:ai]","metadata":null},{"id":"8c6528d09384426eb554b9314b6321ab","type":"GO_TERM","name":"arabinose isomerase activity","canonical_id":"go:GO:0008790","description":"\"Catalysis of the reaction: D-arabinose = D-ribulose.\" [EC:5.3.1.3]","metadata":null},{"id":"ca0ef1c8c28545bdbc05ad30be1d0581","type":"GO_TERM","name":"arabinose metabolic process","canonical_id":"go:GO:0019566","description":"\"The chemical reactions and pathways involving arabinose, arabino-pentose. L-Arabinose occurs both free, for example in the heartwood of many conifers, and in the combined state, as a constituent of plant hemicelluloses, bacterial polysaccharides etc. D-arabinose is a constituent of arabinonucleosides.\" [ISBN:0198506732]","metadata":null},{"id":"c99a58a8a14e46d8a90a42e65cbb69f9","type":"GO_TERM","name":"arabinose transmembrane transport","canonical_id":"go:GO:0015751","description":"\"The process in which arabinose, a pentose monosaccharide that occurs in both D and L configurations, is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"c8b5195c12e14cbe9b55cd74ba32037f","type":"GO_TERM","name":"arabinose transmembrane transporter activity","canonical_id":"go:GO:0042900","description":"\"Enables the transfer of arabinose, a pentose monosaccharide that occurs in both D and L configurations, and as a polymer, from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e3007e76ff5546dda9e23ee09b195368","type":"GO_TERM","name":"arabinose-5-phosphate isomerase activity","canonical_id":"go:GO:0019146","description":"\"Catalysis of the reaction: D-arabinose 5-phosphate = D-ribulose 5-phosphate + 2 H+.\" [EC:5.3.1.13, RHEA:23104]","metadata":null},{"id":"d99e94ced3f44bb08238109e1475285a","type":"GO_TERM","name":"arabinose:proton symporter activity","canonical_id":"go:GO:0015518","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: arabinose(out) + H+(out) = arabinose(in) + H+(in).\" [TC:2.A.1.1.2]","metadata":null},{"id":"55647a2b542840269dce79dc3d4e2a5d","type":"GO_TERM","name":"arabinosyltransferase activity","canonical_id":"go:GO:0052636","description":"\"Catalysis of the transfer of an arabinosyl group from one compound (donor) to another (acceptor).\" [GOC:ai]","metadata":null},{"id":"02fc1c923efb41e79a23f2ac5aa1015a","type":"GO_TERM","name":"arabinotriose transport","canonical_id":"go:GO:2001092","description":"\"The directed movement of an arabinotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"2089d6ccea724934bd2d06fd1c8dc160","type":"GO_TERM","name":"arabinoxylan binding","canonical_id":"go:GO:2001068","description":"\"Binding to arabinoxylan.\" [GOC:mengo_curators]","metadata":null},{"id":"a0f721dd59b644ce97e9222bd9a2748a","type":"GO_TERM","name":"arabinoxylan-containing compound catabolic process","canonical_id":"go:GO:2000888","description":"\"The chemical reactions and pathways resulting in the breakdown of an arabinoxylan.\" [GOC:mengo_curators]","metadata":null},{"id":"93bf91f660054114955b10ea675cfe90","type":"GO_TERM","name":"arabitol catabolic process","canonical_id":"go:GO:0051157","description":"\"The chemical reactions and pathways resulting in the breakdown of arabitol, the pentitol derived from arabinose or lyxose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"f94b952cc66642d49ee2487b64c03865","type":"GO_TERM","name":"arabitol transmembrane transporter activity","canonical_id":"go:GO:0015167","description":"\"Enables the transfer of an arabitol from one side of a membrane to the other. Arabitol is the pentitol derived from arabinose or lyxose by reduction of the aldehyde group. The D enantiomer is present in lichens and mushrooms.\" [ISBN:0198506732]","metadata":null},{"id":"aed3b03744e4468a8c1e1985f24dc649","type":"GO_TERM","name":"arachidonate 11,12-epoxygenase activity","canonical_id":"go:GO:0008405","description":"\"Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to cis-11,12-epoxyeicosatrienoic acid.\" [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, RHEA:51480]","metadata":null},{"id":"9d1c47f84d5c45508d1e067a8b767261","type":"GO_TERM","name":"arachidonate 12(R)-lipoxygenase activity","canonical_id":"go:GO:0106237","description":"\"Catalysis of the reaction: arachidonate + O2 = (5Z,8Z,10E,12R,14Z)-12-hydroperoxyicosa-5,8,10,14-tetraenoate.\" [GOC:gap, PMID:10100631, PMID:11256953, RHEA:41336]","metadata":null},{"id":"9bb20435ba3f41eba2970adb5d237ec2","type":"GO_TERM","name":"arachidonate 12(S)-lipoxygenase activity","canonical_id":"go:GO:0004052","description":"\"Catalysis of the reaction: arachidonate + O2 = (5Z,8Z,10E,12S,14Z)-12-hydroperoxyicosa-5,8,10,14-tetraenoate.\" [EC:1.13.11.31, RHEA:10428]","metadata":null},{"id":"8cb21cba82cb469bb71ac12796d6474b","type":"GO_TERM","name":"arachidonate 14,15-epoxygenase activity","canonical_id":"go:GO:0008404","description":"\"Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to cis-14,15-epoxyeicosatrienoic acid.\" [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, RHEA:51472]","metadata":null},{"id":"faf7ae139862412fbd211d8e49b9b94e","type":"GO_TERM","name":"arachidonate 15-lipoxygenase activity","canonical_id":"go:GO:0050473","description":"\"Catalysis of the reaction: arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate.\" [EC:1.13.11.33]","metadata":null},{"id":"0240be49dc1c4104935d05775fb6a44e","type":"GO_TERM","name":"arachidonate 5,6-epoxygenase activity","canonical_id":"go:GO:0106301","description":"\"Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to cis-5,6-epoxyeicosatrienoic acid.\" [PMID:10491410, PMID:8631948, RHEA:49936]","metadata":null},{"id":"0bca862b7c9044e29b451198cf407c88","type":"GO_TERM","name":"arachidonate 5-lipoxygenase activity","canonical_id":"go:GO:0004051","description":"\"Catalysis of the reaction: (5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = H2O + leukotriene A4.\" [RHEA:32307]","metadata":null},{"id":"8e3fc3a9c03948d79ba7ac4d1267208f","type":"GO_TERM","name":"arachidonate 8(R)-lipoxygenase activity","canonical_id":"go:GO:0047677","description":"\"Catalysis of the reaction: arachidonate + O2 = (5Z,8R,9E,11Z,14Z)-8-hydroperoxyicosa-5,9,11,14-tetraenoate.\" [EC:1.13.11.40, RHEA:14985]","metadata":null},{"id":"fde678059d574256bb6b5c63fc1968d0","type":"GO_TERM","name":"arachidonate 8(S)-lipoxygenase activity","canonical_id":"go:GO:0036403","description":"\"Catalysis of the reaction: arachidonate + O2 = (5Z,8S,9E,11Z,14Z)-8-hydroperoxyicosa-5,9,11,14-tetraenoate.\" [GOC:lb, PMID:10625675, RHEA:38675]","metadata":null},{"id":"a159defb902e4912bc6d2b7d44190dfd","type":"GO_TERM","name":"arachidonate 8,9-epoxygenase activity","canonical_id":"go:GO:0106302","description":"\"Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to cis-8,9-epoxyeicosatrienoic acid.\" [PMID:10491410, PMID:8246128, RHEA:64984]","metadata":null},{"id":"808cc1b0b47d4992a798c3e9a29491ba","type":"GO_TERM","name":"arachidonate binding","canonical_id":"go:GO:0050544","description":"\"Binding to arachidonic acid, a straight chain fatty acid with 20 carbon atoms and four double bonds per molecule. Arachidonic acid is the all-Z-(5,8,11,14)-isomer.\" [GOC:ai]","metadata":null},{"id":"4787e862aa0d449bb23bc5410c2e6990","type":"GO_TERM","name":"arachidonate epoxygenase activity","canonical_id":"go:GO:0008392","description":"\"Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to a cis-epoxyeicosatrienoic acid.\" [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, PMID:18952572]","metadata":null},{"id":"ba3de238a22c4012af91bcbef0b28ca9","type":"GO_TERM","name":"arachidonate metabolic process","canonical_id":"go:GO:0019369","description":"\"The chemical reactions and pathways involving arachidonic acid, a straight chain fatty acid with 20 carbon atoms and four double bonds per molecule. Arachidonic acid is the all-Z-(5,8,11,14)-isomer.\" [ISBN:0198506732]","metadata":null},{"id":"e8b71818d6584442bd151cdc21391b6d","type":"GO_TERM","name":"arachidonate metabolite production involved in inflammatory response","canonical_id":"go:GO:0002538","description":"\"The synthesis or release of products of arachidonic acid metabolism following a stimulus as part of an inflammatory response, resulting in an increase in their intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"cfb68e81368e433eb4b0dbc1ec9a8452","type":"GO_TERM","name":"arachidonate monooxygenase activity","canonical_id":"go:GO:0008391","description":"\"Catalysis of the incorporation of one atom from molecular oxygen into arachidonic acid and the reduction of the other atom of oxygen to water.\" [GOC:mah]","metadata":null},{"id":"67d20982085640aca3b7359f7b634359","type":"GO_TERM","name":"arachidonate omega-hydroxylase activity","canonical_id":"go:GO:0052869","description":"\"Catalysis of the reaction: (5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. (5Z,8Z,11Z,14Z)-icosatetraenoic acid is also known as arachidonic acid is also and 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate as 20-HETE.\" [RHEA:39755]","metadata":null},{"id":"7bedaeccff2449f48d60596faeb73d52","type":"GO_TERM","name":"arachidonate secretion","canonical_id":"go:GO:0050482","description":"\"The controlled release of arachidonic acid from a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"c1c55d6d59db441a8a378b6f14c5b0b0","type":"GO_TERM","name":"arachidonate transmembrane transporter activity","canonical_id":"go:GO:1903962","description":"\"Enables the transfer of arachidonate from one side of a membrane to the other.\" [GO_REF:0000066, GOC:bhm, GOC:TermGenie, PMID:15642721]","metadata":null},{"id":"9ba8cd70108a4f328b17ddf3c5a63986","type":"GO_TERM","name":"arachidonate transport","canonical_id":"go:GO:1903963","description":"\"The directed movement of an arachidonate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GO_REF:0000065, GOC:bhm, GOC:TermGenie, PMID:15642721]","metadata":null},{"id":"5c6e4880f3fa405c9f63cc2f3fd57d3b","type":"GO_TERM","name":"arachidonate-CoA ligase activity","canonical_id":"go:GO:0047676","description":"\"Catalysis of the reaction: arachidonate + ATP + CoA = AMP + arachidonoyl-CoA + diphosphate + H+.\" [RHEA:19713]","metadata":null},{"id":"1bf21763ae3e4297975072851d97f525","type":"GO_TERM","name":"aralkylamine N-acetyltransferase activity","canonical_id":"go:GO:0004059","description":"\"Catalysis of the reaction: a 2-arylethylamine + acetyl-CoA = an N-acetyl-2-arylethylamine + CoA + H+.\" [RHEA:20497]","metadata":null},{"id":"26f7a2f1a4d241ebace92624831d0f45","type":"GO_TERM","name":"aralkylamine dehydrogenase (azurin) activity","canonical_id":"go:GO:0030059","description":"\"Catalysis of the reaction: an aralkylamine + H2O + 2 oxidized [azurin] = an aromatic aldehyde + 2 H+ + NH4+ + 2 reduced [azurin].\" [PMID:10506161, RHEA:47796]","metadata":null},{"id":"696ffdd3a89f476a86aae07a0714c131","type":"DRUG","name":"aranidipine","canonical_id":"mesh:C059427","description":null,"metadata":null},{"id":"e4b8c93421c34db4b821c5d6d52450f6","type":"GO_TERM","name":"arbuscular mycorrhizal association","canonical_id":"go:GO:0036377","description":"\"A form of mutualism between a fungus and the roots of a vascular plant, where hyphae of the fungus penetrate the plant cell wall and invaginate its cell membrane. Once inside, the fungus forms highly branched structures for nutrient exchange with the plant called arbuscules. Aids in the acquisition by the plant of nutrients such as phosphorus from the soil.\" [GOC:sk, Wikipedia:Arbuscular_mycorrhiza]","metadata":null},{"id":"cc682b6b8f8e4eaaa0302c111a391c43","type":"GO_TERM","name":"arbuscule","canonical_id":"go:GO:0085041","description":"\"Highly branched symbiont haustoria within host root cortex cells, responsible for nutrient exchange.\" [GOC:pamgo_curators]","metadata":null},{"id":"713e85ad9cd54b1fae1b4c73beacf2ed","type":"GO_TERM","name":"arbutin transmembrane transporter activity","canonical_id":"go:GO:0042951","description":"\"Enables the transfer of arbutin, a glycoside found in the bearberry and related plants which has been used to treat urinary-tract diseases, from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, PMID:19965875]","metadata":null},{"id":"9b1ea65e19344373adfaea642bc52f2e","type":"GO_TERM","name":"arbutin transport","canonical_id":"go:GO:0042949","description":"\"The directed movement of arbutin, a glycoside found in the bearberry and related plants which has been used to treat urinary-tract diseases, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:19965875]","metadata":null},{"id":"4073f4347d064b119721ff082005a9dd","type":"GO_TERM","name":"archaeal or bacterial-type flagellum-dependent cell motility","canonical_id":"go:GO:0097588","description":"\"Cell motility due to movement of bacterial- or archaeal-type flagella.\" [GOC:cilia, GOC:krc]","metadata":null},{"id":"f91194e4b3c74ba5abdd9b0fe1b26fb3","type":"GO_TERM","name":"archaeal proton-transporting A-type ATPase complex","canonical_id":"go:GO:1990490","description":"\"A large proton-transporting two-sector ATPase protein complex that catalyzes the synthesis or hydrolysis of ATP by a rotational mechanism, coupled to the transport of protons across a membrane and is found in Archaea.\" [GOC:mengo_curators, PMID:15473999, PMID:24650628]","metadata":null},{"id":"584959b74ff9417d80364f70f84731ab","type":"GO_TERM","name":"archaeal-type flagellum","canonical_id":"go:GO:0097589","description":"\"A non-membrane-bounded organelle superficially similar to a bacterial-type flagellum; they both consist of filaments extending outside the cell, and rotate to propel the cell, but the archaeal flagella (also called archaella) have a unique structure which lacks a central channel. Similar to bacterial type IV pilins, the archaeal flagellins (archaellins) are made with class 3 signal peptides and they are processed by a type IV prepilin peptidase-like enzyme. The archaellins are typically modified by the addition of N-linked glycans which are necessary for proper assembly and/or function.\" [GOC:cilia, GOC:krc, PMID:21265748, PMID:23146836, PMID:23204365, PMID:24330313, Wikipedia:Flagellum#Archaeal]","metadata":null},{"id":"ee8daddc34af4f7e82968fe91a6b89b5","type":"GO_TERM","name":"archaeal-type flagellum-dependent cell motility","canonical_id":"go:GO:0097590","description":"\"Cell motility due to the motion of one or more archaeal-type flagella. An archaeal-type flagellum (also called archaellum) is a non-membrane-bounded organelle superficially similar to a bacterial-type flagellum, but having a different molecular structure and lacking a central channel.\" [GOC:cilia, GOC:krc, Wikipedia:Flagellum#Archaeal]","metadata":null},{"id":"0f8a2e8542bf4797a9bc00304d929469","type":"GO_TERM","name":"archaeosine synthase activity","canonical_id":"go:GO:0002948","description":"\"Catalysis of the reaction: L-glutamine + 7-cyano-7-carbaguanine15 in tRNA + H2O = L-glutamate + archaeine15 in tRNA.\" [PMID:20129918, RHEA:54084]","metadata":null},{"id":"1b23f867a2d94e7ba663032f09bf9260","type":"GO_TERM","name":"archaeosine-tRNA biosynthetic process","canonical_id":"go:GO:0002927","description":"\"The chemical reactions and pathways involved in the biosynthesis of archaeosine, an archaea-specific modified base found at position 15 in the D-loop of certain archaeal tRNAs.\" [PMID:20129918]","metadata":null},{"id":"56d727d4ec63446a8fc6c8fbed3aad42","type":"GO_TERM","name":"archaetidylserine synthase activity","canonical_id":"go:GO:0043761","description":"\"Catalysis of the reaction: CDP-digeranylgeranylglycerol + L-serine = archaetidylserine + CMP.\" [PMID:12562787]","metadata":null},{"id":"4eccbe3fdaf448eeb04f9847917cc371","type":"GO_TERM","name":"arciform density","canonical_id":"go:GO:0098682","description":"\"An electron dense structure that anchors a synaptic ribbon to the presynaptic membrane.\" [PMID:15626493]","metadata":null},{"id":"9bb969729b044c8fad4d59e5e7b6f9c4","type":"GO_TERM","name":"arg-arg specific dibasic protein processing","canonical_id":"go:GO:0090474","description":"\"Any protein processing achieved by the cleavage of a peptide bond after two consecutive arginine amino acid residues within a protein.\" [GOC:al]","metadata":null},{"id":"65fda4b7e8ef41c6b90bc41ade61a3b3","type":"DRUG","name":"argatroban","canonical_id":"gtopdb:6385","description":null,"metadata":null},{"id":"14df2e1b5aa04820a6be2c7c9ee9bef0","type":"DRUG","name":"argatroban","canonical_id":"chembl:CHEMBL1166","description":null,"metadata":null},{"id":"e33e6896f1914c0b950ffdcb2a7b7591","type":"COMBINATION_TREATMENT","name":"argatroban + danaparoid","canonical_id":"ctgov_combo:ctgov-combo-5044ac3e93be448d","description":null,"metadata":null},{"id":"bd30f83bab314f74b9a5a7564b904a47","type":"COMBINATION_TREATMENT","name":"argatroban + danaparoid + fondaparinux + lepirudin","canonical_id":"ctgov_combo:ctgov-combo-d60ad60b3fdc0763","description":null,"metadata":null},{"id":"7df5d984bf3a4865882dcbe594a381f1","type":"COMBINATION_TREATMENT","name":"argatroban + desirudin","canonical_id":"ctgov_combo:ctgov-combo-74556e2b16a482c7","description":null,"metadata":null},{"id":"792c25b1d8764cb1ae73a1b9fbe5dfc7","type":"COMBINATION_TREATMENT","name":"argatroban + eptifibatide","canonical_id":"ctgov_combo:ctgov-combo-abc66f2c253e9039","description":null,"metadata":null},{"id":"f27b90b3d187403db2875efd10a8b9f8","type":"COMBINATION_TREATMENT","name":"argatroban + lepirudin","canonical_id":"ctgov_combo:ctgov-combo-289267d765d35916","description":null,"metadata":null},{"id":"2ad32e15afc1439ab4f85bf23f9a60d9","type":"COMBINATION_TREATMENT","name":"argatroban + lepirudin","canonical_id":"ctgov_combo:ctgov-combo-88c0b552540d76ad","description":null,"metadata":null},{"id":"645502cb48734380871aadb74bdf8a72","type":"GO_TERM","name":"arginase activity","canonical_id":"go:GO:0004053","description":"\"Catalysis of the reaction: L-arginine + H2O = L-ornithine + urea.\" [EC:3.5.3.1]","metadata":null},{"id":"5947d4f58eaa4650bd1838c69b54fcfd","type":"GO_TERM","name":"arginine 2-monooxygenase activity","canonical_id":"go:GO:0047678","description":"\"Catalysis of the reaction: L-arginine + O2 = 4-guanidinobutanamide + CO2 + H2O.\" [EC:1.13.12.1, RHEA:10548]","metadata":null},{"id":"08d0fa2e05d3492eb2418afbdf122c83","type":"GO_TERM","name":"arginine N-methyltransferase activity","canonical_id":"go:GO:0016273","description":"\"Enables the transfer of a methyl group from S-adenosyl-L-methionine to an amino group of an arginine residue.\" [GOC:mah]","metadata":null},{"id":"62ab8c4797d5402c972754da1d90ba0b","type":"GO_TERM","name":"arginine binding","canonical_id":"go:GO:0034618","description":"\"Binding to 2-amino-5-(carbamimidamido)pentanoic acid.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"57519762f7f94768a6adc9305547943f","type":"GO_TERM","name":"arginine decarboxylase activity","canonical_id":"go:GO:0008792","description":"\"Catalysis of the reaction: L-arginine + H+ = agmatine + CO2.\" [EC:4.1.1.19, RHEA:17641]","metadata":null},{"id":"1020af3cdbd741bd93224a5f29dcc640","type":"GO_TERM","name":"arginine deiminase activity","canonical_id":"go:GO:0016990","description":"\"Catalysis of the reaction: L-arginine + H2O = L-citrulline + NH4+.\" [RHEA:19597]","metadata":null},{"id":"2b60f148b345409fa01641ca102db172","type":"GO_TERM","name":"arginine kinase activity","canonical_id":"go:GO:0004054","description":"\"Catalysis of the reaction: L-arginine + ATP = N(omega)-phospho-L-arginine + ADP + 2 H+.\" [EC:2.7.3.3, RHEA:22940]","metadata":null},{"id":"ce557ef205a14ffe9caa2309aa8431cc","type":"GO_TERM","name":"arginine metabolic process","canonical_id":"go:GO:0006525","description":"\"The chemical reactions and pathways involving arginine, 2-amino-5-(carbamimidamido)pentanoic acid.\" [GOC:curators]","metadata":null},{"id":"9d776dfb688740d2859126f98421159a","type":"GO_TERM","name":"arginine racemase activity","canonical_id":"go:GO:0047679","description":"\"Catalysis of the reaction: L-arginine = D-arginine.\" [EC:5.1.1.9, MetaCyc:ARGININE-RACEMASE-RXN]","metadata":null},{"id":"2dc4f302b7484831a1b90d3f57a986c4","type":"GO_TERM","name":"arginine-tRNA ligase activity","canonical_id":"go:GO:0004814","description":"\"Catalysis of the reaction: ATP + L-arginine + tRNA(Arg) = AMP + diphosphate + L-arginyl-tRNA(Arg).\" [EC:6.1.1.19]","metadata":null},{"id":"ad02e4ec85e94bc5afbbc439ac8a73ef","type":"GO_TERM","name":"arginine:agmatine antiporter activity","canonical_id":"go:GO:0043862","description":"\"Catalysis of the reaction: arginine(out) + agmatine(in) = arginine(in) + agmatine(out).\" [GOC:jl, PMID:17099215]","metadata":null},{"id":"9946413ec98a4bbaa666caf1738829a5","type":"GO_TERM","name":"arginine:ornithine antiporter activity","canonical_id":"go:GO:0043858","description":"\"Catalysis of the reaction: arginine(out) + ornithine(in) = arginine(in) + ornithine(out).\" [GOC:jl, PMID:17110979, RHEA:34991]","metadata":null},{"id":"967e9fa550af42e3a67b6ef3e8870425","type":"GO_TERM","name":"argininosuccinate lyase activity","canonical_id":"go:GO:0004056","description":"\"Catalysis of the reaction: N-(L-arginino)succinate = fumarate + L-arginine.\" [EC:4.3.2.1]","metadata":null},{"id":"6b2344abffba4cdca17fc258751651da","type":"GO_TERM","name":"argininosuccinate synthase activity","canonical_id":"go:GO:0004055","description":"\"Catalysis of the reaction: ATP + L-citrulline + L-aspartate = AMP + diphosphate + (N(omega)-L-arginino)succinate.\" [EC:6.3.4.5]","metadata":null},{"id":"63298a6a3fea460b8af62668d8b47003","type":"GO_TERM","name":"arginyl-tRNA aminoacylation","canonical_id":"go:GO:0006420","description":"\"The process of coupling arginine to arginyl-tRNA, catalyzed by arginyl-tRNA synthetase. The arginyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of an alanine accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"029c56b091b0458a93cfae67f42247d5","type":"GO_TERM","name":"arginyl-tRNA--protein transferase activity","canonical_id":"go:GO:0004057","description":"\"Catalysis of the reaction: an N-terminal L-alpha-aminoacyl-[protein] + L-arginyl-tRNA(Arg) = H+ + N-terminal L-arginyl-L-amino acid-[protein] + tRNA(Arg).\" [PMID:16492767, PMID:9858543, RHEA:10208]","metadata":null},{"id":"42b51145c43f44ec8c6b0a4995b375df","type":"DRUG","name":"aripiprazole","canonical_id":"gtopdb:34","description":null,"metadata":null},{"id":"37da348ce6cb4a7da73af01982903536","type":"DRUG","name":"aripiprazole","canonical_id":"chembl:CHEMBL1112","description":null,"metadata":null},{"id":"ec062f1da5e242e8971f2f2d21019f0a","type":"COMBINATION_TREATMENT","name":"aripiprazole + asenapine + chlorpromazine + clozapine + fluphenazine + haloperidol + loxapine + olanzapine + perphenazine + pimozide + prochlorperazine + quetiapine + risperidone + thioridazine + thiothixene + trifluoperazine + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-b6e6b54b8c6429c5","description":null,"metadata":null},{"id":"0867312f404f497a94473ff543199b6a","type":"COMBINATION_TREATMENT","name":"aripiprazole + bupropion + nortriptyline","canonical_id":"ctgov_combo:ctgov-combo-223b98661c0302c2","description":null,"metadata":null},{"id":"fd81ea6f7d80476d88d0c6beac924e7b","type":"COMBINATION_TREATMENT","name":"aripiprazole + haloperidol","canonical_id":"ctgov_combo:ctgov-combo-e129d594a8066f1d","description":null,"metadata":null},{"id":"57d7ef9546fc47b69b5aa320145f5039","type":"COMBINATION_TREATMENT","name":"aripiprazole + haloperidol","canonical_id":"ctgov_combo:ctgov-combo-c5a2d3b2907c4cb2","description":null,"metadata":null},{"id":"642f6711fdd24e0e938ce96cb4e8055b","type":"COMBINATION_TREATMENT","name":"aripiprazole + haloperidol + olanzapine + perphenazine + quetiapine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-37801685e6614562","description":null,"metadata":null},{"id":"480de6dc9ce44192b9d56533f4012fe3","type":"COMBINATION_TREATMENT","name":"aripiprazole + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-1fc30efede2d64c8","description":null,"metadata":null},{"id":"50d69c0ae22f49568f86e6234bad6802","type":"COMBINATION_TREATMENT","name":"aripiprazole + olanzapine + quetiapine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-25e0a748f1280925","description":null,"metadata":null},{"id":"9c33a6e76532414fb7aea1d0f766dd6d","type":"COMBINATION_TREATMENT","name":"aripiprazole + olanzapine + quetiapine + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-d85ea6921abd17c1","description":null,"metadata":null},{"id":"ecc498ddcfe247ddb21c1b4a8c0168bd","type":"COMBINATION_TREATMENT","name":"aripiprazole + risperidone","canonical_id":"ctgov_combo:ctgov-combo-259f38b48d6be1ee","description":null,"metadata":null},{"id":"52cfc57badac40629d2c5c19c3e269e8","type":"COMBINATION_TREATMENT","name":"aripiprazole + risperidone","canonical_id":"ctgov_combo:ctgov-combo-3b1f5e4cc74bf897","description":null,"metadata":null},{"id":"cde2fa4cb7274d24baa149f60c48eb3a","type":"COMBINATION_TREATMENT","name":"aripiprazole + risperidone","canonical_id":"ctgov_combo:ctgov-combo-52bf2bf66fdd7ead","description":null,"metadata":null},{"id":"91c5f471d6e1429cbc618e53e9aeeada","type":"COMBINATION_TREATMENT","name":"aripiprazole + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-2084a74e7709e792","description":null,"metadata":null},{"id":"057817fe18f94b8ebca04b8eb44348e6","type":"GO_TERM","name":"aristolochene synthase activity","canonical_id":"go:GO:0045483","description":"\"Catalysis of the reaction: trans,trans-farnesyl diphosphate = aristolochene + diphosphate.\" [EC:4.2.3.9]","metadata":null},{"id":"13b9d7e1a362466fa40f327f5a188d77","type":"GO_TERM","name":"armadillo repeat domain binding","canonical_id":"go:GO:0070016","description":"\"Binding to an armadillo repeat domain, an approximately 40 amino acid long tandemly repeated sequence motif first identified in the Drosophila segment polarity protein armadillo. Arm-repeat proteins are involved in various processes, including intracellular signaling and cytoskeletal regulation.\" [GOC:BHF, GOC:mah, GOC:vk, InterPro:IPR000225]","metadata":null},{"id":"35488fcb788f4bdaafe6ac7132c7e250","type":"GO_TERM","name":"arogenate dehydratase activity","canonical_id":"go:GO:0047769","description":"\"Catalysis of the reaction: L-arogenate = L-phenylalanine + H2O + CO2.\" [EC:4.2.1.91]","metadata":null},{"id":"4ff0d0ec8a1b4d8f8c1ff85037c0bac3","type":"GO_TERM","name":"arogenate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0033730","description":"\"Catalysis of the reaction: L-arogenate + NADP+ = L-tyrosine + NADPH + CO2.\" [EC:1.3.1.78]","metadata":null},{"id":"457950cb4baf4568873d91a610137b64","type":"GO_TERM","name":"arogenate dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0033731","description":"\"Catalysis of the reaction: L-arogenate + NAD(P)+ = L-tyrosine + NAD(P)H + CO2.\" [EC:1.3.1.79]","metadata":null},{"id":"6577cab5a14f4e788f1edda545e2a654","type":"GO_TERM","name":"aromatase activity","canonical_id":"go:GO:0070330","description":"\"Catalysis of the reaction: 3 O2 + 3 reduced [NADPH--hemoprotein reductase] + testosterone = 17beta-estradiol + formate + 4 H+ + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase]. Also converts androst-4-ene-3,17-dione into estrone.\" [EC:1.14.14.14]","metadata":null},{"id":"e2c832fc9bbb46c999fd0ce314f20fc9","type":"DISEASE","name":"aromatase deficiency","canonical_id":"mondo:0013301","description":null,"metadata":null},{"id":"d353d0878e36498da99a54176df2bc51","type":"DISEASE","name":"aromatase excess syndrome","canonical_id":"mondo:0007690","description":null,"metadata":null},{"id":"10dbe51747584924832f470540c73189","type":"GO_TERM","name":"aromatic (S)-hydroxynitrile lyase activity","canonical_id":"go:GO:0052892","description":"\"Catalysis of the reaction: an aromatic (S)-hydroxynitrile = an aromatic aldehyde + cyanide.\" [RHEA:54660]","metadata":null},{"id":"1fdfd88a3d814c62af41ee9985a5b32e","type":"DISEASE","name":"aromatic L-amino acid decarboxylase deficiency","canonical_id":"mondo:0012084","description":null,"metadata":null},{"id":"fe140b2e60ec4123821386b5034dcc51","type":"GO_TERM","name":"aromatic amino acid biosynthetic process","canonical_id":"go:GO:0009073","description":"\"The chemical reactions and pathways resulting in the formation of an amino acid whose structure includes an aromatic ring.\" [GOC:curators]","metadata":null},{"id":"de14870087bb4bbf9bc2b82b301f29e5","type":"GO_TERM","name":"aromatic amino acid catabolic process","canonical_id":"go:GO:0009074","description":"\"The chemical reactions and pathways resulting in the breakdown of an amino acid whose structure includes an aromatic ring.\" [GOC:curators]","metadata":null},{"id":"0137623e4bc244c9acf73e2d3cbe45a5","type":"GO_TERM","name":"aromatic amino acid metabolic process","canonical_id":"go:GO:0009072","description":"\"The chemical reactions and pathways involving aromatic amino acid family, amino acids with aromatic ring (phenylalanine, tyrosine, tryptophan).\" [GOC:curators]","metadata":null},{"id":"cd25992620ae4878a8342f59172c8cfd","type":"GO_TERM","name":"aromatic amino acid transmembrane transporter activity","canonical_id":"go:GO:0015173","description":"\"Enables the transfer of aromatic amino acids from one side of a membrane to the other. Aromatic amino acids have an aromatic ring.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"3cd0e1565b7843e09973e3342c732643","type":"GO_TERM","name":"aromatic amino acid transport","canonical_id":"go:GO:0015801","description":"\"The directed movement of aromatic amino acids, amino acids with aromatic ring, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"75600bdee74e4f8fbbcccd1b8e796766","type":"GO_TERM","name":"aromatic amino acid:proton symporter activity","canonical_id":"go:GO:0015494","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: aromatic amino acid(out) + H+(out) = aromatic amino acid(in) + H+(in).\" [TC:2.A.3.1.3]","metadata":null},{"id":"0a8ce824fd0f49208eedea4f6dbd8321","type":"GO_TERM","name":"aromatic desulfoglucosinolate sulfotransferase activity","canonical_id":"go:GO:0047364","description":"\"Catalysis of the reaction: (Z)-desulfoglucotropeolin + 3'-phosphoadenylyl sulfate = (Z)-glucotropeolin + adenosine 3',5'-bisphosphate + H+. Also converts (Z)-indolylmethyl desulfoglucosinolate to (Z)-glucobrassicin. This is the final step in the biosynthesis of the glucosinolate core structure.\" [EC:2.8.2.24]","metadata":null},{"id":"258cde0e4e044c4bab7a6462689f3b0b","type":"GO_TERM","name":"aromatic primary alcohol biosynthetic process","canonical_id":"go:GO:1902655","description":"\"The chemical reactions and pathways resulting in the formation of aromatic primary alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:19219878]","metadata":null},{"id":"f190e8fc9752425fa114a59883c2b6d7","type":"GO_TERM","name":"aromatic primary alcohol metabolic process","canonical_id":"go:GO:1902654","description":"\"The chemical reactions and pathways involving aromatic primary alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:19219878]","metadata":null},{"id":"64bcb0c4f8954c979f5175737171756c","type":"GO_TERM","name":"aromatic-L-amino-acid decarboxylase activity","canonical_id":"go:GO:0004058","description":"\"Catalysis of the reaction: L-amino acid + H+ = R-H + CO2.\" [EC:4.1.1.28]","metadata":null},{"id":"7f539e77343e460caf8ceb4f180e1c18","type":"GO_TERM","name":"aromatic-amino-acid:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0008793","description":"\"Catalysis of the reaction: an L-alpha aromatic amino acid + 2-oxoglutarate = an aromatic oxo acid + L-glutamate.\" [RHEA:17533]","metadata":null},{"id":"4102960df867443398645883f7d2fd5f","type":"GO_TERM","name":"aromatic-amino-acid:glyoxylate transaminase activity","canonical_id":"go:GO:0047313","description":"\"Catalysis of the reaction: an aromatic L-alpha-amino acid + glyoxylate = an aromatic oxo-acid + glycine.\" [RHEA:10900]","metadata":null},{"id":"a1624226975a4cc49c7a83e98f452368","type":"GO_TERM","name":"aromatic-hydroxylamine O-acetyltransferase activity","canonical_id":"go:GO:0047188","description":"\"Catalysis of the reaction: N-hydroxy-4-aminobiphenyl + N-hydroxy-4-acetylaminonbiphenyl = N-acetoxy-4-aminobiphenyl + N-hydroxy-4-aminobiphenyl.\" [EC:2.3.1.56, MetaCyc:2.3.1.56-RXN]","metadata":null},{"id":"270d92851f9a4e6da80869f10d2edfb8","type":"GO_TERM","name":"arrestin family protein binding","canonical_id":"go:GO:1990763","description":"\"Binding to a member of the arrestin family, proteins involved in agonist-mediated desensitization of G protein-coupled receptors.\" [PMID:23911909]","metadata":null},{"id":"edf6abf672534c2085f8bd23e0b1bf22","type":"GO_TERM","name":"arsenate ion transmembrane transport","canonical_id":"go:GO:1901684","description":"\"The process in which arsenate is transported across a membrane.\" [GOC:TermGenie]","metadata":null},{"id":"377ed94d0a644573af68a1c0379736e1","type":"GO_TERM","name":"arsenate ion transmembrane transporter activity","canonical_id":"go:GO:1901683","description":"\"Enables the transfer of an arsenate ion from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"82252c8c59704ae4893ee872f18ddadc","type":"GO_TERM","name":"arsenate reductase (azurin) activity","canonical_id":"go:GO:0050611","description":"\"Catalysis of the reaction: H2O + arsenite + 2 oxidized azurin = 2 H+ + 2 reduced azurin + arsenate.\" [EC:1.20.9.1, MetaCyc:1.20.98.1-RXN]","metadata":null},{"id":"0452b0e5c719403c82129675f81765e0","type":"GO_TERM","name":"arsenate reductase (glutaredoxin) activity","canonical_id":"go:GO:0008794","description":"\"Catalysis of the reaction: arsenate + reduced glutaredoxin = arsenite + oxidized glutaredoxin. Glutaredoxin functions as the electron donor for arsenate reduction. The electron flow therefore is ( NADPH -> glutathione reductase (EC:1.6.4.2) -> ) glutathione -> glutaredoxin -> arsenate reductase, i.e. glutathione is reduced by glutathione reductase and glutaredoxin is reduced by glutathione.\" [EC:1.20.4.1, GOC:kd, PMID:10593884]","metadata":null},{"id":"1096052b1d284274913ee8c796c166b7","type":"GO_TERM","name":"arsenate reductase (thioredoxin) activity","canonical_id":"go:GO:0030612","description":"\"Catalysis of the reaction: arsenate + [thioredoxin]-dithiol + H+ = arsenite + [thioredoxin]-disulfide + H2O.\" [RHEA:43848]","metadata":null},{"id":"5e15aeffd7a44135a851e950910ffd49","type":"GO_TERM","name":"arsenate reductase activity","canonical_id":"go:GO:0030611","description":"\"Catalysis of the reaction: arsenite + A + H2O = arsenate + AH2 + H+.\" [RHEA:18449]","metadata":null},{"id":"e5475cdc0b0941dc8496b80cc52de119","type":"DRUG","name":"arsenic trioxide","canonical_id":"mesh:C006632","description":null,"metadata":null},{"id":"d5b24e448f5d4288a4621e8d6c6bd8d5","type":"GO_TERM","name":"arsenite methyltransferase activity","canonical_id":"go:GO:0030791","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + arsenite = S-adenosyl-L-homocysteine + methylarsonate.\" [EC:2.1.1.137]","metadata":null},{"id":"d4872666b04742a09c647732cedf7f77","type":"GO_TERM","name":"arsenite secondary active transmembrane transporter activity","canonical_id":"go:GO:0008490","description":"\"Enables the transfer of arsenite from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:jl]","metadata":null},{"id":"47d6791692824736b37fdac7441f1134","type":"GO_TERM","name":"arsenite transmembrane transporter activity","canonical_id":"go:GO:0015105","description":"\"Enables the transfer of arsenite from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"167256e8015c41c084c0af49d33d80f5","type":"GO_TERM","name":"arsenite transport","canonical_id":"go:GO:0015700","description":"\"The directed movement of arsenite into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"ff812fed47e34e3e94f52c5782d776fa","type":"GO_TERM","name":"arsonoacetate catabolic process","canonical_id":"go:GO:0019501","description":"\"The chemical reactions and pathways resulting in the breakdown of arsonoacetate, a synthetic, organic compound containing a single arsenic atom.\" [GOC:jl]","metadata":null},{"id":"470d344ee2fa4935a9adc438a4a3b9da","type":"GO_TERM","name":"arsonoacetate metabolic process","canonical_id":"go:GO:0018872","description":"\"The chemical reactions and pathways involving arsonoacetate, a synthetic, organic compound containing a single arsenic atom. Arsonoacetate and other arsenic containing compounds are used in agricultural applications as animal feed additives, cotton defoliants and post-emergence grass herbicides.\" [UM-BBD_pathwayID:ara]","metadata":null},{"id":"d0ec92578a024749815d854c5988cf66","type":"DRUG","name":"artemisinin","canonical_id":"mesh:C031327","description":null,"metadata":null},{"id":"b85d2bef3ebb4b5b9c0cd3cbf56985d5","type":"GO_TERM","name":"arterial endothelial cell differentiation","canonical_id":"go:GO:0060842","description":"\"The process in which a relatively unspecialized endothelial cell acquires specialized features of an arterial endothelial cell, a thin flattened cell that lines the inside surfaces of arteries.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"88f1f5878540415091a093b35f04f378","type":"GO_TERM","name":"arterial endothelial cell fate commitment","canonical_id":"go:GO:0060844","description":"\"The commitment of a cell to an arterial endothelial cell fate and its capacity to differentiate into an arterial endothelial cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3a360ae86fb3495a9b3d86346e8e2151","type":"GO_TERM","name":"arteriole smooth muscle contraction","canonical_id":"go:GO:0014830","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the arteriole. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The arteriole is the smallest division of the artery located between the muscular arteries and the capillaries.\" [GOC:mtg_muscle, MA:0000706, MSH:D001160]","metadata":null},{"id":"54ee5db63f95447bbabc1e9eb902294f","type":"DISEASE","name":"arteriosclerosis","canonical_id":"efo:0009086","description":null,"metadata":null},{"id":"0bf3890ebd424e29949eeefca2148061","type":"GO_TERM","name":"artery development","canonical_id":"go:GO:0060840","description":"\"The progression of the artery over time, from its initial formation to the mature structure. An artery is a blood vessel that carries blood away from the heart to a capillary bed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"268997c511c84eb3bad0d1c4b2bfc047","type":"GO_TERM","name":"artery morphogenesis","canonical_id":"go:GO:0048844","description":"\"The process in which the anatomical structures of arterial blood vessels are generated and organized. Arteries are blood vessels that transport blood from the heart to the body and its organs.\" [GOC:dsf, PMID:16740480]","metadata":null},{"id":"1f822c6c53f54353aa218168c2332345","type":"GO_TERM","name":"artery smooth muscle contraction","canonical_id":"go:GO:0014824","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the artery. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The artery is a vessel carrying blood away from the heart.\" [GOC:mtg_muscle, MA:0000708, MSH:D001158]","metadata":null},{"id":"f882a629c14043168c1217af3369e098","type":"GO_TERM","name":"artery vasodilation involved in baroreceptor response to increased systemic arterial blood pressure","canonical_id":"go:GO:0001984","description":"\"An increase in the internal diameter of an artery, triggered by vasomotor suppression, during the chemoreceptor response to decreased blood pressure.\" [ISBN:0721643949]","metadata":null},{"id":"527c9988c7814cbdaadf93ab914d0a27","type":"DISEASE","name":"arthritic joint disease","canonical_id":"mondo:0005578","description":null,"metadata":null},{"id":"8745e61a064c477eb1b14534be488de0","type":"GO_TERM","name":"arthro-series glucosylceramide biosynthetic process","canonical_id":"go:GO:0140269","description":"\"The chemical reactions and pathways resulting in the formation of arthro-series glucosylceramides that begins with the synthesis of a tetrasaccharide core GalNAc-beta-1,4-GlcNAc-beta-1,3-Man-beta-1,4Glc-ceramide. This core can be further elongated with the sequential addition of various carbohydrate units.\" [PMID:35536927]","metadata":null},{"id":"d99598e581d34b69b8952c7e934d973b","type":"DISEASE","name":"arthrogryposis multiplex congenita","canonical_id":"mondo:0015168","description":null,"metadata":null},{"id":"54b573ddc4bf4378872462c663511e87","type":"GO_TERM","name":"arthrospore formation","canonical_id":"go:GO:0034298","description":"\"The formation of conidia by the conversion of a pre-existing hypha. An arthrospore is produced by the last cell on a hypha breaking off and dispersing. Usually the walls thicken and the cell(s) separates before swelling of each spore. Sometimes further septa form in each cell prior to disarticulation.\" [GOC:mah]","metadata":null},{"id":"52cd123084b844579f4f2d24654afbb3","type":"GO_TERM","name":"articular cartilage development","canonical_id":"go:GO:0061975","description":"\"The process whose specific outcome is the progression of articular cartilage over time, from its formation to the mature structure.\" [PMID:20097540, PMID:20679519]","metadata":null},{"id":"d3d940b070c14711abd6d33eef329a88","type":"GO_TERM","name":"arugosin biosynthetic process","canonical_id":"go:GO:1900587","description":"\"The chemical reactions and pathways resulting in the formation of arugosin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"cda5d74cc8c0483f92bf29f029c46fa9","type":"GO_TERM","name":"arugosin catabolic process","canonical_id":"go:GO:1900586","description":"\"The chemical reactions and pathways resulting in the breakdown of arugosin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"9b17807f5f8f42d297097c4f5735b89f","type":"GO_TERM","name":"aryl hydrocarbon receptor binding","canonical_id":"go:GO:0017162","description":"\"Binding to an aryl hydrocarbon receptor.\" [GOC:ai]","metadata":null},{"id":"b98986935a7449c4a5f4cd35a90422d8","type":"GO_TERM","name":"aryl hydrocarbon receptor complex","canonical_id":"go:GO:0034751","description":"\"A protein complex that acts as an aryl hydrocarbon (Ah) receptor. Cytosolic and nuclear Ah receptor complexes have different subunit composition, but both contain the ligand-binding subunit AhR.\" [GOC:mah, PMID:7598497]","metadata":null},{"id":"7487dc1567364c31bbefc418892b8d44","type":"GO_TERM","name":"aryl sulfotransferase activity","canonical_id":"go:GO:0004062","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + a phenol = adenosine 3',5'-bisphosphate + an aryl sulfate.\" [EC:2.8.2.1]","metadata":null},{"id":"943f93692ce9415aa6ef0dd132695dad","type":"GO_TERM","name":"aryl-acylamidase activity","canonical_id":"go:GO:0047680","description":"\"Catalysis of the reaction: anilide + H2O = a carboxylate + aniline + H+.\" [EC:3.5.1.13, RHEA:20297]","metadata":null},{"id":"a6bb63f1ea294d4687c2be61f7a17de1","type":"GO_TERM","name":"aryl-alcohol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018456","description":"\"Catalysis of the reaction: an aromatic alcohol + NAD+ = an aromatic aldehyde + NADH + H+.\" [EC:1.1.1.90]","metadata":null},{"id":"bcfdee753f9a450ca6c1f8136f8adfc5","type":"GO_TERM","name":"aryl-alcohol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047681","description":"\"Catalysis of the reaction: an aromatic alcohol + NADP+ = an aromatic aldehyde + NADPH.\" [EC:1.1.1.91, MetaCyc:ARYL-ALCOHOL-DEHYDROGENASE-NADP+-RXN]","metadata":null},{"id":"c9e444041382497c8ed72997faafe7a5","type":"GO_TERM","name":"aryl-alcohol oxidase activity","canonical_id":"go:GO:0047682","description":"\"Catalysis of the reaction: an aromatic primary alcohol + O2 = an aromatic aldehyde + H2O2.\" [EC:1.1.3.7, MetaCyc:ARYL-ALCOHOL-OXIDASE-RXN]","metadata":null},{"id":"eeff40526e614ad38f27efb6184bbd5e","type":"GO_TERM","name":"aryl-aldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0019108","description":"\"Catalysis of the reaction: an aromatic aldehyde + NAD+ + H2O = an aromatic acid + NADH + H+.\" [EC:1.2.1.29]","metadata":null},{"id":"792702b6481947cd930dffa1bdd25011","type":"GO_TERM","name":"aryl-aldehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047683","description":"\"Catalysis of the reaction: an aromatic aldehyde + NADP+ + AMP + diphosphate + H2O = an aromatic acid + NADPH + ATP.\" [RHEA:19229]","metadata":null},{"id":"050b92ef61fb4ebc911d1084e8e606bc","type":"GO_TERM","name":"aryl-aldehyde oxidase activity","canonical_id":"go:GO:0018488","description":"\"Catalysis of the reaction: an aromatic aldehyde + O2 + H2O = an aromatic carboxylate + H2O2 + H+.\" [RHEA:18569]","metadata":null},{"id":"90dfe6741a194f52b6140626c2b4af80","type":"GO_TERM","name":"arylacetonitrilase activity","canonical_id":"go:GO:0047428","description":"\"Catalysis of the reaction: 4-chlorophenylacetonitrile + 2 H2O = 4-chlorophenylacetate + NH4+.\" [RHEA:20657]","metadata":null},{"id":"59942d95c94f41168faed14e2fdd33d1","type":"GO_TERM","name":"arylalkyl acylamidase activity","canonical_id":"go:GO:0047416","description":"\"Catalysis of the reaction: H2O + N-acetylarylalkylamine = acetate + arylalkylamine.\" [EC:3.5.1.76, MetaCyc:3.5.1.76-RXN]","metadata":null},{"id":"53854151208c408c81de7e67060bc235","type":"GO_TERM","name":"arylamine N-acetyltransferase activity","canonical_id":"go:GO:0004060","description":"\"Catalysis of the reaction: acetyl-CoA + an arylamine = CoA + an N-acetylarylamine.\" [EC:2.3.1.5]","metadata":null},{"id":"a36021755de24694a92b193a1f5a1a06","type":"GO_TERM","name":"arylamine glucosyltransferase activity","canonical_id":"go:GO:0047684","description":"\"Catalysis of the reaction: UDP-glucose + an arylamine = UDP + an N-D-glucosylarylamine.\" [EC:2.4.1.71, MetaCyc:ARYLAMINE-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"e7d2bd9898344a02abff791e926e3d32","type":"GO_TERM","name":"aryldialkylphosphatase activity","canonical_id":"go:GO:0004063","description":"\"Catalysis of the reaction: aryl dialkyl phosphate + H2O = dialkyl phosphate + an aryl alcohol.\" [EC:3.1.8.1]","metadata":null},{"id":"ef3d37118f834cec807a79f6d69d6fb4","type":"GO_TERM","name":"arylesterase activity","canonical_id":"go:GO:0004064","description":"\"Catalysis of the reaction: a phenyl acetate + H2O = a phenol + acetate.\" [EC:3.1.1.2]","metadata":null},{"id":"9e736df1a3ed45c09db83001c9466827","type":"GO_TERM","name":"arylformamidase activity","canonical_id":"go:GO:0004061","description":"\"Catalysis of the reaction: N-formyl-L-kynurenine + H2O = formate + L-kynurenine.\" [EC:3.5.1.9]","metadata":null},{"id":"997bb85740c34ac3af9a001181a0c105","type":"GO_TERM","name":"arylmalonate decarboxylase activity","canonical_id":"go:GO:0047436","description":"\"Catalysis of the reaction: 2-aryl-2-methylmalonate + H+ = 2-arylpropionate + CO2.\" [EC:4.1.1.76, RHEA:20513]","metadata":null},{"id":"923370e4a39946b28beac552713f8732","type":"GO_TERM","name":"arylsulfatase activity","canonical_id":"go:GO:0004065","description":"\"Catalysis of the reaction: a phenol sulfate + H2O = a phenol + sulfate.\" [EC:3.1.6.1]","metadata":null},{"id":"3697106cd3be46caa93c07590d4054b2","type":"GO_TERM","name":"arylsulfate sulfotransferase activity","canonical_id":"go:GO:0047686","description":"\"Catalysis of the reaction: an aryl sulfate + a phenol = a phenol + an aryl sulfate.\" [EC:2.8.2.22, MetaCyc:ARYLSULFATE-SULFOTRANSFERASE-RXN]","metadata":null},{"id":"2048e06f108d4e16ba1657315a53f628","type":"GO_TERM","name":"ascaroside biosynthetic process","canonical_id":"go:GO:1904070","description":"\"The chemical reactions and pathways resulting in the formation of ascaroside.\" [GO_REF:0000068, GOC:kmv, GOC:TermGenie, PMID:25775534]","metadata":null},{"id":"d5ea6efe4c6e4b439f79a66cc8b53609","type":"GO_TERM","name":"ascending aorta development","canonical_id":"go:GO:0035905","description":"\"The progression of the ascending aorta over time, from its initial formation to the mature structure. The ascending aorta is the portion of the aorta in a two-pass circulatory system that lies between the heart and the arch of aorta. In a two-pass circulatory system blood passes twice through the heart to supply the body once.\" [GOC:bf, GOC:dgh, MA:0002570, UBERON:0001496, Wikipedia:Ascending_aorta]","metadata":null},{"id":"a7bae6bc079c4243aa479df36532eb8c","type":"GO_TERM","name":"ascending aorta morphogenesis","canonical_id":"go:GO:0035910","description":"\"The process in which the anatomical structures of the ascending aorta are generated and organized. The ascending aorta is the portion of the aorta in a two-pass circulatory system that lies between the heart and the arch of aorta. In a two-pass circulatory system blood passes twice through the heart to supply the body once.\" [GOC:bf, GOC:dgh, MA:0002570, UBERON:0001496, Wikipedia:Ascending_aorta]","metadata":null},{"id":"e3d1f17452ac4c85948760f35c459708","type":"GO_TERM","name":"ascending thin limb development","canonical_id":"go:GO:0072021","description":"\"The process whose specific outcome is the progression of an ascending thin limb over time, from its formation to the mature structure. The ascending thin limb is a segment of a nephron tubule lying in the inner medulla that is permeable to ions but not to water and has a simple epithelium; active transepithelial solute transport is absent.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0cca2f4ee055472988d253102d6481cd","type":"GO_TERM","name":"ascopyrone tautomerase activity","canonical_id":"go:GO:0034018","description":"\"Catalysis of the reaction: 1,5-anhydro-4-deoxy-D-glycero-hex-3-en-2-ulose = 1,5-anhydro-4-deoxy-D-glycero-hex-1-en-3-ulose.\" [EC:5.3.2.7]","metadata":null},{"id":"581b4f9c23924cfd813020eeb0a34aaf","type":"GO_TERM","name":"ascorbate glutathione cycle","canonical_id":"go:GO:0033355","description":"\"A cyclic series of interconversions involving L-ascorbate and glutathione that scavenges H2O2 and reduces it to water, with concomitant oxidation of NADPH.\" [GOC:mah, MetaCyc:PWY-2261]","metadata":null},{"id":"7f2a86abbff2487184362864fd8753c5","type":"GO_TERM","name":"ascorbate homeostasis","canonical_id":"go:GO:0140576","description":"\"Any process involved in the maintenance of an internal steady state of ascorbate at the level of a cell.\" [PMID:1623014, PMID:17068337, PMID:32547589]","metadata":null},{"id":"3f4e5d55370c4bfb876669cfe065b8cd","type":"DRUG","name":"ascorbic acid","canonical_id":"mesh:D001205","description":null,"metadata":null},{"id":"cac2aa16dd2a4cab9ede319364786fa1","type":"GO_TERM","name":"ascospore formation","canonical_id":"go:GO:0030437","description":"\"The process in which cells that are products of meiosis acquire the specialized features of ascospores. Ascospores are generally found in clusters of four or eight spores within a single mother cell, the ascus, and are characteristic of the ascomycete fungi (phylum Ascomycota).\" [GOC:di, GOC:mah, GOC:mcc, PMID:16339736]","metadata":null},{"id":"38d924f8773a4bf19f1114d3d06e8258","type":"GO_TERM","name":"ascospore release from ascus","canonical_id":"go:GO:0071998","description":"\"A developmental process that results in the discharge of ascospores from the ascus. Ascospore release may be active or passive.\" [DOI:10.1016/S0953-7562(96)80057-8, GOC:mah]","metadata":null},{"id":"bc295137ee4846a5816569f21454cd48","type":"GO_TERM","name":"ascospore wall","canonical_id":"go:GO:0005619","description":"\"The specialized cell wall of the ascospore (spore), which is the product of meiotic division. Examples of this component are found in Fungi.\" [GOC:vw, PMID:36266346]","metadata":null},{"id":"7d7231c2440d4673992a4614f5c9c9eb","type":"GO_TERM","name":"ascospore wall (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0034413","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in the walls of ascospores.\" [GOC:mah]","metadata":null},{"id":"52b4ced288104fec85536c02eccb30ea","type":"GO_TERM","name":"ascospore wall (1->3)-beta-D-glucan metabolic process","canonical_id":"go:GO:0034409","description":"\"The chemical reactions and pathways involving (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in the walls of ascospores.\" [GOC:mah]","metadata":null},{"id":"59267990be0b452abf5bb562a25e04d1","type":"GO_TERM","name":"ascospore wall assembly","canonical_id":"go:GO:0030476","description":"\"The aggregation, arrangement and bonding together of a set of components to form an ascospore wall. During sporulation in Ascomycota, each ascospore nucleus becomes surrounded by a specialized spore wall, formed by deposition of spore wall components in the lumenal space between the outer and inner leaflets of the prospore membrane. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:mcc, PMID:14702385]","metadata":null},{"id":"4f7e27cde57747cb86a3effe7ad02d5a","type":"GO_TERM","name":"ascospore wall beta-glucan biosynthetic process","canonical_id":"go:GO:0034412","description":"\"The chemical reactions and pathways resulting in the formation of beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of ascospores.\" [GOC:mah]","metadata":null},{"id":"c0b35f89132c4ac1a6de80e15f8200d2","type":"GO_TERM","name":"ascospore wall beta-glucan metabolic process","canonical_id":"go:GO:0034408","description":"\"The chemical reactions and pathways involving beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of ascospores.\" [GOC:mah]","metadata":null},{"id":"e683417013624d0a9cee7a09b64f279d","type":"GO_TERM","name":"ascospore wall biogenesis","canonical_id":"go:GO:0070591","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of an ascospore wall.\" [GOC:mah]","metadata":null},{"id":"16dfacfaac494bde8ef353c4708f968f","type":"GO_TERM","name":"ascospore-type prospore","canonical_id":"go:GO:0042764","description":"\"An immature spore undergoing development. The spore usually consists of nucleic acid, prospore membrane(s) that encase the nucleic acid, and ultimately a cell wall that covers the membrane(s). This type of spore is observed in ascospore-forming fungi.\" [GOC:curators]","metadata":null},{"id":"34921d34472744649c2f38d64fc32c2d","type":"GO_TERM","name":"ascospore-type prospore assembly","canonical_id":"go:GO:0031321","description":"\"During ascospore formation, the process in which each haploid nucleus becomes encapsulated by a double membrane.\" [GOC:mah, PMID:14702385]","metadata":null},{"id":"853d9bc1bc4944339a9c93f03d21b9f0","type":"GO_TERM","name":"ascospore-type prospore membrane formation","canonical_id":"go:GO:0032120","description":"\"The process in which the nascent membrane forms at the meiotic outer plaque and grows until closure occurs and forespores, or prospores, are formed.\" [GOC:clt, PMID:27630265]","metadata":null},{"id":"28c313e9d177463d9751d8b1c197e350","type":"GO_TERM","name":"ascospore-type prospore nucleus","canonical_id":"go:GO:1905754","description":"\"Any nucleus that is part of a ascospore-type prospore.\" [GO_REF:0000064, GOC:TermGenie, PMID:26942678]","metadata":null},{"id":"f3ee6fb307db4a2686c50d6a1adf6be2","type":"GO_TERM","name":"ascospore-type prospore-specific spindle pole body remodeling","canonical_id":"go:GO:0031322","description":"\"A spindle pole body (SPB) organization process that takes place during the second meiotic division during ascospore formation and results in the structural reorganization of the SPB; includes the recruitment of sporulation-specific proteins to the outer plaque to form the meiotic outer plaque (MOP).\" [GOC:mah, PMID:14702385]","metadata":null},{"id":"b324f128b55e4789af6d74d26b0e3048","type":"GO_TERM","name":"ascr#2 binding","canonical_id":"go:GO:1904067","description":"\"Binding to ascr#2.\" [GO_REF:0000067, GOC:kmv, GOC:TermGenie, PMID:22665789]","metadata":null},{"id":"443290852dfe47ddb2fa9bd37c4a68bb","type":"GO_TERM","name":"ascus development","canonical_id":"go:GO:0075317","description":"\"The process that leads to the development of ascus, a sac-like structure produced by fungi of the phylum Ascomycota (sac fungi) in which sexually produced spores (ascospores), usually four or eight in number, are formed.\" [GOC:di, GOC:mah, GOC:mcc, GOC:pamgo_curators]","metadata":null},{"id":"eef12cd363804cf0b7d7c8441e25394f","type":"GO_TERM","name":"ascus epiplasm","canonical_id":"go:GO:0072324","description":"\"Ascus cytoplasm that is not packaged into ascospores.\" [DOI:10.1016/S0953-7562(96)80057-8, GOC:mcc]","metadata":null},{"id":"e855ba4b9ebe416b9a3e5f7eaead53d5","type":"GO_TERM","name":"ascus lipid droplet","canonical_id":"go:GO:0005633","description":"\"Any particle of coalesced lipids in an ascus or ascospore. May include associated proteins.\" [GOC:mah, PMID:12702293]","metadata":null},{"id":"6237ac038152415799481c3791e8cbb8","type":"GO_TERM","name":"ascus membrane","canonical_id":"go:GO:0036362","description":"\"A double layer of lipid molecules that surrounds an ascus, a capsule containing the sexual spores in some fungi.\" [GOC:mcc, GOC:vw, PMID:21900489]","metadata":null},{"id":"f81617004d114a6ab71690efa499f935","type":"DRUG","name":"asenapine","canonical_id":"gtopdb:22","description":null,"metadata":null},{"id":"13e71c3bc9f845198a4f377786c9a2a2","type":"COMBINATION_TREATMENT","name":"asenapine + clonazepam + clozapine","canonical_id":"ctgov_combo:ctgov-combo-194b99bad0c0fdb6","description":null,"metadata":null},{"id":"f77e4a60457a440b8de5aa5e3e6d4d58","type":"COMBINATION_TREATMENT","name":"asenapine + desvenlafaxine + doxepin + fluvoxamine + lurasidone + perphenazine + vilazodone","canonical_id":"ctgov_combo:ctgov-combo-269eaae69846be0c","description":null,"metadata":null},{"id":"c3e8635899e34e09af9f45332bc73080","type":"COMBINATION_TREATMENT","name":"asenapine + haloperidol","canonical_id":"ctgov_combo:ctgov-combo-ad3f85d67c09131d","description":null,"metadata":null},{"id":"0fe11b843b914250a5ba4a7c6ade6432","type":"COMBINATION_TREATMENT","name":"asenapine + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-9ca9b402c61baa50","description":null,"metadata":null},{"id":"08079fa71f994e3689d21592c3166232","type":"COMBINATION_TREATMENT","name":"asenapine + perphenazine","canonical_id":"ctgov_combo:ctgov-combo-8f3b88cfc2e3576f","description":null,"metadata":null},{"id":"ec0499bb7bef436babf17dd5a0df7e7a","type":"COMBINATION_TREATMENT","name":"asenapine + sertindole","canonical_id":"ctgov_combo:ctgov-combo-24139f857a57de09","description":null,"metadata":null},{"id":"6ba8f044ebe84d618b930f4bea519955","type":"GO_TERM","name":"asexual reproduction","canonical_id":"go:GO:0019954","description":"\"A type of reproduction in which new individuals are produced from a single organism, either from an unfertilized egg or from a single cell or group of cells.\" [ISBN:0387520546, PMID:22977071, PMID:28779329, PMID:29559496]","metadata":null},{"id":"d7f69ecbddbf4c07b0fb5a0f2a18559d","type":"GO_TERM","name":"asexual spore wall","canonical_id":"go:GO:0097515","description":"\"A specialized envelope lying outside the cell membrane of a spore derived from an asexual process. Examples of this process are found in bacterial and fungal species.\" [GOC:cjm, GOC:mah]","metadata":null},{"id":"3778cbafe9bb4c27badaf59c2c2bab39","type":"GO_TERM","name":"asexual spore wall assembly","canonical_id":"go:GO:0042243","description":"\"The aggregation, arrangement and bonding together of a set of components to form an asexual spore wall, the specialized envelope lying outside the cell membrane of a spore derived from an asexual process. Examples of this process are found in Bacterial and Fungal species.\" [GOC:mah]","metadata":null},{"id":"e6a016070ae44d71854be3f2641e6677","type":"GO_TERM","name":"asexual sporulation","canonical_id":"go:GO:0030436","description":"\"The formation of spores derived from the products of an asexual cell division. Examples of this process are found in bacteria and fungi.\" [GOC:mah, PMID:9529886]","metadata":null},{"id":"98e9044e04cf4ff583cca46ae777c63e","type":"GO_TERM","name":"asexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043936","description":"\"The formation of a cellular spore derived from the products of mitosis. A cellular spore is a cell form that can be used for dissemination, for survival of adverse conditions because of its heat and desiccation resistance, and/or for reproduction.\" [GOC:pamgo_curators]","metadata":null},{"id":"ec2c25d2751c447289248b73de43ec03","type":"GO_TERM","name":"asexual sporulation resulting in formation of a multicellular or syncytial spore","canonical_id":"go:GO:0075284","description":"\"The formation of a multicellular or syncytial spore via septations derived from mitosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"01d17ec761094437bff449f13334c4cb","type":"DRUG","name":"asfotase alfa","canonical_id":"mesh:C570710","description":null,"metadata":null},{"id":"9fe3c630e8b14049be0d2ed1a3a97850","type":"GO_TERM","name":"asialoglycoprotein receptor activity","canonical_id":"go:GO:0004873","description":"\"Receiving an asialoglycoprotein, and delivering the asialoglycoprotein into the cell via endocytosis. An asialoglycoprotein is a plasma glycoproteins from which the terminal sialic acid residue on their complex carbohydrate groups has been removed. The asialoglycoprotein receptor recognizes the terminal galactose and N-acetylgalactosamine units of the asialoglycoprotein, the receptor-ligand complex is internalized and transported to a sorting organelle where disassociation occurs before the receptor is recycled to the cell membrane.\" [GOC:bf, PMID:11278827, PMID:7624395, Wikipedia:Asialoglycoprotein]","metadata":null},{"id":"2e093c2a0e124762adf454bb900975ee","type":"GO_TERM","name":"asioloorosomucoid beta-1,3-glucuronosyltransferase activity","canonical_id":"go:GO:0046988","description":"\"Catalysis of the transfer, in a beta 1,3 linkage, of D-glucuronic acid (GlcUA) from UDP-GlcUA to asioloorosomucoid.\" [GOC:bf, PMID:12511570]","metadata":null},{"id":"ab182eff558b461f89fd6677c63b4f2e","type":"GO_TERM","name":"asparaginase activity","canonical_id":"go:GO:0004067","description":"\"Catalysis of the reaction: L-asparagine + H2O = L-aspartate + NH4+.\" [EC:3.5.1.1]","metadata":null},{"id":"77699d08e21240b5b7804d246c2f030c","type":"GO_TERM","name":"asparagine synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0004066","description":"\"Catalysis of the reaction: ATP + L-aspartate + L-glutamine = AMP + diphosphate + L-asparagine + L-glutamate.\" [EC:6.3.5.4, RHEA:12228]","metadata":null},{"id":"5d11b8705133406c93028ffcf30ae608","type":"GO_TERM","name":"asparagine transmembrane import into vacuole","canonical_id":"go:GO:1990591","description":"\"The directed movement of asparagine into the vacuole across the vacuolar membrane.\" [PMID:20388511]","metadata":null},{"id":"77964854607244adbe5e82b1d002e230","type":"GO_TERM","name":"asparagine transmembrane transport","canonical_id":"go:GO:1903713","description":"\"The directed movement of asparagine across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:18503766]","metadata":null},{"id":"2046b9c23ed34fffb279ad00537a85a4","type":"GO_TERM","name":"asparagine transport","canonical_id":"go:GO:0006867","description":"\"The directed movement of asparagine, alpha-aminosuccinamic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"15a0c8d2c61e4b1882c3bacb2be08cb0","type":"GO_TERM","name":"asparagine-tRNA ligase activity","canonical_id":"go:GO:0004816","description":"\"Catalysis of the reaction: L-asparagine + ATP + tRNA(Asn) = AMP + Asn-tRNA(Asn) + diphosphate + 2 H+.\" [EC:6.1.1.22, RHEA:11180]","metadata":null},{"id":"fb1b8dfed8ff41769a23f7471d5f0185","type":"GO_TERM","name":"asparaginyl-tRNA aminoacylation","canonical_id":"go:GO:0006421","description":"\"The process of coupling asparagine to asparaginyl-tRNA, catalyzed by asparaginyl-tRNA synthetase. The asparaginyl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of an asparagine-accetping tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"9ab8c20c40ee4a71aa877eb4b5350b64","type":"GO_TERM","name":"asparaginyl-tRNA synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0050566","description":"\"Catalysis of the reaction: L-glutamine + aspartyl-tRNA(Asn) + ATP = L-glutamate + asparaginyl-tRNA(Asn) + phosphate + ADP.\" [EC:6.3.5.6, MetaCyc:6.3.5.6-RXN]","metadata":null},{"id":"b41a8e59124a45c397fb0bab06c4c637","type":"GO_TERM","name":"asparagusate reductase (NADH) activity","canonical_id":"go:GO:0050445","description":"\"Catalysis of the reaction: 3-sulfanyl-2-(sulfanylmethyl)propanoate + NAD+ = asparagusate + NADH + H+.\" [RHEA:14881]","metadata":null},{"id":"f2ca3b4f67234343977e43f7378a7029","type":"GO_TERM","name":"aspartate 1-decarboxylase activity","canonical_id":"go:GO:0004068","description":"\"Catalysis of the reaction: L-aspartate = beta-alanine + CO2.\" [EC:4.1.1.11]","metadata":null},{"id":"dafd6db4cf6f42d49dc8ba48704fecc5","type":"GO_TERM","name":"aspartate 4-decarboxylase activity","canonical_id":"go:GO:0047688","description":"\"Catalysis of the reaction: L-aspartate = L-alanine + CO2.\" [EC:4.1.1.12, MetaCyc:ASPARTATE-4-DECARBOXYLASE-RXN]","metadata":null},{"id":"fd70c843df0e44e585799d9ac20fa082","type":"GO_TERM","name":"aspartate ammonia-lyase activity","canonical_id":"go:GO:0008797","description":"\"Catalysis of the reaction: L-aspartate = fumarate + NH4+.\" [RHEA:16601]","metadata":null},{"id":"39babc6e645044d2be66433caf59c80b","type":"GO_TERM","name":"aspartate binding","canonical_id":"go:GO:0070335","description":"\"Binding to aspartate, the alpha-amino-acid anion of 2-aminobutanedioic acid that has formula C4H5NO4.\" [CHEBI:29995, GOC:mah]","metadata":null},{"id":"f455f677aa6040b190d9afc5b5688f29","type":"GO_TERM","name":"aspartate carbamoyltransferase activity","canonical_id":"go:GO:0004070","description":"\"Catalysis of the reaction: L-aspartate + carbamoyl phosphate = N-carbamoyl-L-aspartate + H+ + phosphate.\" [EC:2.1.3.2, RHEA:20013]","metadata":null},{"id":"7198c308bb1c4c9a81d41f3579205b78","type":"GO_TERM","name":"aspartate carbamoyltransferase complex","canonical_id":"go:GO:0009347","description":"\"A multienzyme complex that catalyzes the formation N-carbamoyl-L-aspartate from carbamoyl phosphate and L-aspartate. It exhibits a variety of architectural organizations, but in all microorganisms the core catalytic component is a homotrimer of approximately 34 kDa polypeptides.\" [PMID:10447693]","metadata":null},{"id":"d7fc07a4651f47c79cab2bb73b467dc0","type":"GO_TERM","name":"aspartate family amino acid biosynthetic process","canonical_id":"go:GO:0009067","description":"\"The chemical reactions and pathways resulting in the formation of L-aspartate or any of the amino acids synthesised from it (L-asparagine, L-lysine, L-methionine, L-threonine and L-isoleucine).\" [GOC:curators]","metadata":null},{"id":"b47844ba237846009fc589b2d2d0becb","type":"GO_TERM","name":"aspartate kinase activity","canonical_id":"go:GO:0004072","description":"\"Catalysis of the reaction: L-aspartate + ATP = 4-phospho-L-aspartate + ADP + H+.\" [EC:2.7.2.4, RHEA:23776]","metadata":null},{"id":"5a6c2e2916bd4745ab9bfec03d1d90e2","type":"GO_TERM","name":"aspartate metabolic process","canonical_id":"go:GO:0006531","description":"\"The chemical reactions and pathways involving aspartate, the anion derived from aspartic acid, 2-aminobutanedioic acid.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a8fb90f085ed4547be4103ee118cd9ea","type":"GO_TERM","name":"aspartate racemase activity","canonical_id":"go:GO:0047689","description":"\"Catalysis of the reaction: L-aspartate = D-aspartate.\" [EC:5.1.1.13, RHEA:14973]","metadata":null},{"id":"13f1c05240e94f7e949a02fadfc700fc","type":"GO_TERM","name":"aspartate secretion","canonical_id":"go:GO:0061528","description":"\"The regulated release of aspartate by a cell.\" [GOC:dph]","metadata":null},{"id":"684b3649c1cb4a41897df4aeee509717","type":"GO_TERM","name":"aspartate secretion, neurotransmission","canonical_id":"go:GO:0061530","description":"\"The regulated release of aspartate by a cell in which the aspartate acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"52de3481ed064dfba039b9cb625543be","type":"GO_TERM","name":"aspartate transmembrane import into vacuole","canonical_id":"go:GO:0090453","description":"\"The directed movement of aspartate into the vacuole across the vacuolar membrane.\" [GOC:tb]","metadata":null},{"id":"bcedeccfe51c48a2a0f65a0008055ec5","type":"GO_TERM","name":"aspartate transmembrane transport","canonical_id":"go:GO:0015810","description":"\"The process in which aspartate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c1e02f1643f1474dbe4c1941b85c576e","type":"GO_TERM","name":"aspartate-ammonia ligase (ADP-forming) activity","canonical_id":"go:GO:0047478","description":"\"Catalysis of the reaction: L-aspartate + ATP + NH4 = L-asparagine + ADP + 2 H+ + phosphate.\" [EC:6.3.1.4, RHEA:14197]","metadata":null},{"id":"9795815d04484c3fa9306a1c09e7b008","type":"GO_TERM","name":"aspartate-ammonia ligase activity","canonical_id":"go:GO:0004071","description":"\"Catalysis of the reaction: ATP + L-aspartate + NH4+ = AMP + diphosphate + L-asparagine.\" [RHEA:11372]","metadata":null},{"id":"f43c9ad0dc3d416ca26a3bb4a982bca1","type":"GO_TERM","name":"aspartate-semialdehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004073","description":"\"Catalysis of the reaction: L-aspartate 4-semialdehyde + NADP+ + phosphate = 4-phospho-L-aspartate + H+ + NADPH.\" [RHEA:24284]","metadata":null},{"id":"d124fbf0137f42adb7941afa8cc8bedd","type":"GO_TERM","name":"aspartate-tRNA ligase activity","canonical_id":"go:GO:0004815","description":"\"Catalysis of the reaction: ATP + L-aspartate + tRNA(Asp) = AMP + diphosphate + L-aspartyl-tRNA(Asp).\" [EC:6.1.1.12]","metadata":null},{"id":"ffc77751b55d4979a1df548342148da9","type":"GO_TERM","name":"aspartate-tRNA(Asn) ligase activity","canonical_id":"go:GO:0050560","description":"\"Catalysis of the reaction: tRNA(Asx) + L-aspartate + ATP = aspartyl-tRNA(Asx) + diphosphate + AMP.\" [EC:6.1.1.23, MetaCyc:6.1.1.23-RXN]","metadata":null},{"id":"b9b0423cb96b4eeda30ef6fde2243a05","type":"GO_TERM","name":"aspartate:alanine antiporter activity","canonical_id":"go:GO:0070906","description":"\"Catalysis of the reaction: aspartate(out) + alanine(in) = aspartate(in) + alanine(out).\" [GOC:dh]","metadata":null},{"id":"7ca5afffc6964e9ea515aa04f1601f2a","type":"GO_TERM","name":"aspartate:glutamate, proton antiporter activity","canonical_id":"go:GO:0000515","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + L-aspartate(in) + L-glutamate(out) = H+(in) + L-aspartate(out) + L-glutamate(in).\" [PMID:11566871, RHEA:70783]","metadata":null},{"id":"6c259fc77b3b484786b2bd2995253e87","type":"GO_TERM","name":"aspartic acid methylthiotransferase activity","canonical_id":"go:GO:0035599","description":"\"Catalysis of the methylthiolation (-SCH3 addition) of the beta-carbon of peptidyl-aspartic acid to form peptidyl-L-beta-methylthioaspartic acid.\" [PMID:18252828, PMID:8844851, RESID:AA0232]","metadata":null},{"id":"f020d59512ca48e58663de4ff2ba0cdb","type":"GO_TERM","name":"aspartic endopeptidase activity, intramembrane cleaving","canonical_id":"go:GO:0042500","description":"\"Catalysis of the hydrolysis of nonterminal peptide bonds in a polypeptide chain, occurring within a membrane.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"15191f52725e4566b50f80bb38ffa7c6","type":"GO_TERM","name":"aspartic-type endopeptidase activity","canonical_id":"go:GO:0004190","description":"\"Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which a water molecule bound by the side chains of aspartic residues at the active center acts as a nucleophile.\" [ISBN:0198506732]","metadata":null},{"id":"65692b9451f94c3db04892ec683fde10","type":"GO_TERM","name":"aspartic-type endopeptidase inhibitor activity","canonical_id":"go:GO:0019828","description":"\"Binds to and stops, prevents or reduces the activity of aspartic-type endopeptidases.\" [GOC:ai]","metadata":null},{"id":"5580adc882d24022a9a44eb5532c7dd0","type":"GO_TERM","name":"aspartic-type peptidase activity","canonical_id":"go:GO:0070001","description":"\"Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a mechanism in which a water molecule bound by the side chains of aspartic residues at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"b8326f70e7494ab6ab4c8b98e2c6f56d","type":"GO_TERM","name":"aspartoacylase activity","canonical_id":"go:GO:0019807","description":"\"Catalysis of the reaction: N-acyl-L-aspartate + H2O = a fatty acid anion + L-aspartate.\" [EC:3.5.1.15]","metadata":null},{"id":"41fd22de3598463c8870273fada39e1e","type":"GO_TERM","name":"aspartyl-tRNA aminoacylation","canonical_id":"go:GO:0006422","description":"\"The process of coupling aspartate to aspartyl-tRNA, catalyzed by aspartyl-tRNA synthetase. The aspartyl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of an aspartic acid accetping tRNA.\" [GOC:mah, ISBN:0716730510]","metadata":null},{"id":"9c1d492ca9e944c4a83e2f43b091074e","type":"GO_TERM","name":"asperfuranone biosynthetic process","canonical_id":"go:GO:1900554","description":"\"The chemical reactions and pathways resulting in the formation of asperfuranone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"444aff1096f84bea9a5d12050adb5fe6","type":"GO_TERM","name":"asperfuranone catabolic process","canonical_id":"go:GO:1900553","description":"\"The chemical reactions and pathways resulting in the breakdown of asperfuranone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7bffcb3f642e41fb809be0263280e3ef","type":"GO_TERM","name":"asperthecin biosynthetic process","canonical_id":"go:GO:0036184","description":"\"The chemical reactions and pathways resulting in the formation of asperthecin, an anthraquinone pigment obtained from the mould Aspergillus nidulans.\" [GOC:di]","metadata":null},{"id":"ebb97ba32275401688593f29e9219a2e","type":"GO_TERM","name":"asperthecin catabolic process","canonical_id":"go:GO:0036183","description":"\"The chemical reactions and pathways resulting in the breakdown of asperthecin, an anthraquinone pigment obtained from the mould Aspergillus nidulans.\" [GOC:di]","metadata":null},{"id":"3537810046f948478e865938986b113c","type":"GO_TERM","name":"asperthecin metabolic process","canonical_id":"go:GO:0036182","description":"\"The chemical reactions and pathways involving asperthecin, an anthraquinone pigment obtained from the mould Aspergillus nidulans.\" [GOC:di]","metadata":null},{"id":"29f9d86e50964669b822e18011b8dfb5","type":"DRUG","name":"aspirin","canonical_id":"gtopdb:4139","description":null,"metadata":null},{"id":"6749a9cb52bf484282f06b80e4affed5","type":"DRUG","name":"aspirin","canonical_id":"chembl:CHEMBL25","description":null,"metadata":null},{"id":"ac2e17e9f2e341cebe56fbbe69cb9022","type":"COMBINATION_TREATMENT","name":"aspirin + atorvastatin","canonical_id":"ctgov_combo:ctgov-combo-63527149f0f495e5","description":null,"metadata":null},{"id":"4e1d6e01a4f14255a71c907e82a31f24","type":"COMBINATION_TREATMENT","name":"aspirin + atorvastatin + colchicine + valsartan","canonical_id":"ctgov_combo:ctgov-combo-0921364b8f18cf93","description":null,"metadata":null},{"id":"010a65a294d9436ea5cf9df99d0cfa3c","type":"COMBINATION_TREATMENT","name":"aspirin + enoxaparin","canonical_id":"ctgov_combo:ctgov-combo-541912e6021d19e7","description":null,"metadata":null},{"id":"a7acce0d73d34dd6ba3a9c70c350f983","type":"COMBINATION_TREATMENT","name":"aspirin + everolimus","canonical_id":"ctgov_combo:ctgov-combo-d55886154feb456d","description":null,"metadata":null},{"id":"4080acbbb42e4e35bc57e52d28e4ef09","type":"COMBINATION_TREATMENT","name":"aspirin + heparin","canonical_id":"ctgov_combo:ctgov-combo-af7b5d2bbd6080c1","description":null,"metadata":null},{"id":"a8d20f319ed34b6b98c0f43f31847c50","type":"COMBINATION_TREATMENT","name":"aspirin + hydroxychloroquine","canonical_id":"ctgov_combo:ctgov-combo-129041955c48d809","description":null,"metadata":null},{"id":"2e5926c6d2534e92af09049c11cbb781","type":"COMBINATION_TREATMENT","name":"aspirin + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-fa4efcd22364da52","description":null,"metadata":null},{"id":"dd8341dd6fe246a792b8bc3c420dfab7","type":"COMBINATION_TREATMENT","name":"aspirin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-6655cabfd99e09f4","description":null,"metadata":null},{"id":"dd7198af90f140b5bf97bbea5728e6e7","type":"COMBINATION_TREATMENT","name":"aspirin + ticagrelor","canonical_id":"ctgov_combo:ctgov-combo-ed3d13b4b164c872","description":null,"metadata":null},{"id":"a894da961546469a8f7c501b9480ad12","type":"COMBINATION_TREATMENT","name":"aspirin + ticagrelor","canonical_id":"ctgov_combo:ctgov-combo-ac6282c1a85df62c","description":null,"metadata":null},{"id":"ef5ffffa8fc1488baa8775babf71c60c","type":"COMBINATION_TREATMENT","name":"aspirin + ticagrelor","canonical_id":"ctgov_combo:ctgov-combo-645c05139f626dbb","description":null,"metadata":null},{"id":"c041707aa83d4326ae9f468a7f5aef44","type":"COMBINATION_TREATMENT","name":"aspirin + warfarin","canonical_id":"ctgov_combo:ctgov-combo-ab692c81907dc720","description":null,"metadata":null},{"id":"93169cc64f0d4e90a7d0615ad79eebb2","type":"GO_TERM","name":"aspulvinone dimethylallyltransferase activity","canonical_id":"go:GO:0047691","description":"\"Catalysis of the reaction: aspulvinone E + 2 dimethylallyl diphosphate = aspulvinone H + 2 diphosphate.\" [EC:2.5.1.35, RHEA:13809]","metadata":null},{"id":"d99751c2589946d8ab7a6435d52fd508","type":"GO_TERM","name":"aspyridone A biosynthetic process","canonical_id":"go:GO:1901518","description":"\"The chemical reactions and pathways resulting in the formation of aspyridone A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"71f77184232e46f889e52cd360ad2ae9","type":"GO_TERM","name":"aspyridone A catabolic process","canonical_id":"go:GO:1901517","description":"\"The chemical reactions and pathways resulting in the breakdown of aspyridone A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a88f04b65fab4352becdc6fffff1ea25","type":"GO_TERM","name":"aspyridone B biosynthetic process","canonical_id":"go:GO:1901521","description":"\"The chemical reactions and pathways resulting in the formation of aspyridone B.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"98c4c159b0f94e49b096ef9e0c43cb67","type":"GO_TERM","name":"aspyridone B catabolic process","canonical_id":"go:GO:1901520","description":"\"The chemical reactions and pathways resulting in the breakdown of aspyridone B.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"15bca937599f42698098cbd40f1ba9c4","type":"GO_TERM","name":"assembly of actomyosin apparatus involved in cytokinesis","canonical_id":"go:GO:0000912","description":"\"The assembly and arrangement of an apparatus composed of actin, myosin, and associated proteins that will function in cytokinesis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"3a645711477747e6937642174f0f7833","type":"GO_TERM","name":"assembly of actomyosin apparatus involved in mitotic cytokinesis","canonical_id":"go:GO:1902407","description":"\"Any assembly of mitotic cytokinetic actomyosin apparatus.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"4c9525cd7e1d49b2b2994e262557f126","type":"GO_TERM","name":"assembly of apicomedial cortex actomyosin","canonical_id":"go:GO:0106036","description":"\"A process which results in the assembly or arrangement of constituent parts apicomedial cortex actomyosin.\" [PMID:28263180]","metadata":null},{"id":"627c947225b845a395e5310dfd0570af","type":"GO_TERM","name":"assembly of large subunit precursor of preribosome","canonical_id":"go:GO:1902626","description":"\"The aggregation, arrangement and bonding together of a set of components to form the large subunit precursor of the preribosome.\" [GO_REF:0000079, GOC:di, GOC:TermGenie, PMID:22735702]","metadata":null},{"id":"f3ddc61b289f49b79c584b9de532eca8","type":"GO_TERM","name":"associative learning","canonical_id":"go:GO:0008306","description":"\"Learning by associating a stimulus (the cause) with a particular outcome (the effect).\" [ISBN:0582227089]","metadata":null},{"id":"4f7c13c623ce41828adecf15ada85369","type":"GO_TERM","name":"astaxanthin biosynthetic process","canonical_id":"go:GO:1901815","description":"\"The chemical reactions and pathways resulting in the formation of astaxanthin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5288, PMID:16434154, UniPathway:UPA00387]","metadata":null},{"id":"a17e78c699f04a34a93929d4a7709e6b","type":"DRUG","name":"astemizole","canonical_id":"gtopdb:2603","description":null,"metadata":null},{"id":"1a012e2ec0154f85846c24aa4958cda4","type":"DRUG","name":"astemizole","canonical_id":"chembl:CHEMBL296419","description":null,"metadata":null},{"id":"f37cb9a25f4c461f9e940ebf47d2e52f","type":"GO_TERM","name":"aster","canonical_id":"go:GO:0005818","description":"\"An array of microtubules emanating from a spindle pole MTOC that do not connect to kinetochores.\" [GOC:clt]","metadata":null},{"id":"bf8519573f6849a2998558d753316b84","type":"DISEASE","name":"asthma","canonical_id":"mondo:0004979","description":null,"metadata":null},{"id":"66d8aa14ba014059a26728ebbf87dd20","type":"GO_TERM","name":"astral microtubule","canonical_id":"go:GO:0000235","description":"\"Any of the spindle microtubules that radiate in all directions from the spindle poles and are thought to contribute to the forces that separate the poles and position them in relation to the rest of the cell.\" [ISBN:0815316194]","metadata":null},{"id":"71c561ce01de46f3b84d1d44ccd4a345","type":"GO_TERM","name":"astral microtubule anchoring at mitotic spindle pole body","canonical_id":"go:GO:1990734","description":"\"Any process in which an astral microtubule is maintained in a specific location in a cell by attachment to a mitotic spindle pole body. Microtubules attach to spindle pole bodies at the minus end.\" [PMID:15004232]","metadata":null},{"id":"3675e0714c0240f48758e6d813b34786","type":"GO_TERM","name":"astral microtubule depolymerization","canonical_id":"go:GO:0060172","description":"\"The removal of tubulin heterodimers from one or both ends of an astral microtubule. An astral microtubule is any of the spindle microtubules that radiate in all directions from the spindle poles and are thought to contribute to the forces that separate the poles and position them in relation to the rest of the cell.\" [GOC:dph]","metadata":null},{"id":"6c485c774b9a4410b712c4d939ef73c0","type":"GO_TERM","name":"astral microtubule nucleation","canonical_id":"go:GO:0030954","description":"\"The 'de novo' formation of an astral microtubule, in which tubulin heterodimers form metastable oligomeric aggregates, some of which go on to support formation of a complete microtubule.\" [GOC:mah]","metadata":null},{"id":"f880023be97146f3a7e841b0d23ed584","type":"GO_TERM","name":"astral microtubule organization","canonical_id":"go:GO:0030953","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of astral microtubules, any of the spindle microtubules that radiate in all directions from the spindle poles.\" [GOC:mah]","metadata":null},{"id":"11fffc59aff94135bcd296ebcd1330ab","type":"GO_TERM","name":"astrocyte activation","canonical_id":"go:GO:0048143","description":"\"A change in morphology and behavior of an astrocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, PMID:10526094, PMID:10695728, PMID:12529254, PMID:12580336, PMID:9585813]","metadata":null},{"id":"e995d44661c84678b3e438bb03cfc14b","type":"GO_TERM","name":"astrocyte activation involved in immune response","canonical_id":"go:GO:0002265","description":"\"A change in the morphology or behavior of an astrocyte resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response.\" [GOC:add, PMID:11138785]","metadata":null},{"id":"b81da294f5a84328a69e50dbfd5e2393","type":"GO_TERM","name":"astrocyte cell migration","canonical_id":"go:GO:0043615","description":"\"The orderly movement of an astrocyte, a class of large neuroglial (macroglial) cells in the central nervous system, the largest and most numerous neuroglial cells in the brain and spinal cord.\" [CL:0000127, GOC:curators]","metadata":null},{"id":"a116c00e29d44331b991fbd7b5a28770","type":"GO_TERM","name":"astrocyte chemotaxis","canonical_id":"go:GO:0035700","description":"\"The directed movement of an astrocyte guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [CL:0000127, GOC:BHF, PMID:12271471]","metadata":null},{"id":"393ad9d84428493a9a36609b2de4cf3d","type":"GO_TERM","name":"astrocyte development","canonical_id":"go:GO:0014002","description":"\"The process aimed at the progression of an astrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function.\" [GOC:dgh, GOC:ef]","metadata":null},{"id":"0534747bc7c04912aaa2ea8a0d00784a","type":"GO_TERM","name":"astrocyte differentiation","canonical_id":"go:GO:0048708","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an astrocyte. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"79b12556f6e343a486f38178864f38ff","type":"GO_TERM","name":"astrocyte end-foot","canonical_id":"go:GO:0097450","description":"\"Terminal process of astrocyte abutting non-neuronal surfaces in the brain.\" [NIF_Subcellular:sao388182739]","metadata":null},{"id":"3e79756b6580484381ebd68cadb8bdc8","type":"GO_TERM","name":"astrocyte fate commitment","canonical_id":"go:GO:0060018","description":"\"The commitment of a cells to a specific astrocyte fate and its restriction to develop only into an astrocyte.\" [GOC:dph]","metadata":null},{"id":"6996e1ccc1c04268b491cceaa4ce3fd8","type":"GO_TERM","name":"astrocyte projection","canonical_id":"go:GO:0097449","description":"\"A prolongation or process extending from the soma of an astrocyte and wrapping around neurons.\" [NIF_Subcellular:sao1630537580]","metadata":null},{"id":"2f6482decc7e4b01bdea59d97eb87306","type":"GO_TERM","name":"astrocyte-dopaminergic neuron signaling","canonical_id":"go:GO:0036520","description":"\"Cell-cell signaling that mediates the transfer of information from an astrocyte to a dopaminergic neuron.\" [GOC:bf, GOC:PARL, PMID:12794311, PMID:21752258]","metadata":null},{"id":"1d932d70432e44c9b7c77053ffa49c6a","type":"DISEASE","name":"astrocytoma (excluding glioblastoma)","canonical_id":"mondo:0019781","description":null,"metadata":null},{"id":"fa021f840bb74f3e854197e5139058bb","type":"GO_TERM","name":"asymmetric Golgi ribbon formation","canonical_id":"go:GO:0090164","description":"\"The asymmetric formation of a continuous ribbon of interconnected Golgi stacks of flat cisternae that contributes to the establishment of epithelial cell polarity.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1e58982df2fe467a810028bfd7d3f032","type":"GO_TERM","name":"asymmetric cell division","canonical_id":"go:GO:0008356","description":"\"The asymmetric division of cells to produce two daughter cells with different developmental potentials. It is of fundamental significance for the generation of cell diversity.\" [PMID:11672519]","metadata":null},{"id":"c1fb594939c5462f85dc2631792450bf","type":"GO_TERM","name":"asymmetric neuroblast division","canonical_id":"go:GO:0055059","description":"\"The process resulting in the physical partitioning and separation of a neuroblast into two daughter cells with different developmental potentials.\" [GOC:dph]","metadata":null},{"id":"1c2f8aaec3564f378e1fef089d83e27a","type":"GO_TERM","name":"asymmetric neuroblast division resulting in ganglion mother cell formation","canonical_id":"go:GO:0055060","description":"\"Any process resulting in the physical partitioning and separation of a neuroblast into a neuroblast and a ganglion mother cell.\" [GOC:dph]","metadata":null},{"id":"10eca8fc622a4d5b837deadb2cf2209c","type":"GO_TERM","name":"asymmetric protein localization involved in cell fate determination","canonical_id":"go:GO:0045167","description":"\"Any process in which a protein is transported to, or maintained in, a specific asymmetric distribution, resulting in the formation of daughter cells of different types.\" [GOC:ai]","metadata":null},{"id":"b5216c8c45ea401d9b6e86b6ee613de0","type":"GO_TERM","name":"asymmetric stem cell division","canonical_id":"go:GO:0098722","description":"\"Division of a stem cell during which it retains its identity and buds off a daughter cell with a new identity.\" [GOC:dos, PMID:18513950]","metadata":null},{"id":"75a5a1c48c2546429a98fef683d4dd4b","type":"GO_TERM","name":"asymmetric synapse","canonical_id":"go:GO:0032279","description":"\"A type of synapse occurring between an axon and a dendritic spine or dendritic shaft. Asymmetric synapses, the most abundant synapse type in the central nervous system, involve axons that contain predominantly spherical vesicles and contain a thickened postsynaptic density. Most or all synapses of this type are excitatory.\" [GOC:dgh, GOC:ef]","metadata":null},{"id":"a7464fe54d4b4cca8ea935dc9658b88e","type":"GO_TERM","name":"asymmetric, glutamatergic, excitatory synapse","canonical_id":"go:GO:0098985","description":"\"A neuron to neuron synapse with a postsynaptic density, that uses glutamate as a neurotransmitter and whose activity results in excitatory postsynaptic potentials.\" [GOC:dos]","metadata":null},{"id":"9ffbdb8589ba4d9084cf386ef83ad3a9","type":"GO_TERM","name":"asynchronous neurotransmitter secretion","canonical_id":"go:GO:0071912","description":"\"Release of neurotransmitter at the synapse that persists for tens to hundreds of milliseconds after action potential invasion.\" [GOC:dsf, PMID:19477156, PMID:20643933]","metadata":null},{"id":"43885e5f01e343caa35203f095cb1d5b","type":"DRUG","name":"ataluren","canonical_id":"mesh:C515878","description":null,"metadata":null},{"id":"8d5ef1bd879a4e62805103eae8bd5d0e","type":"DRUG","name":"atazanavir","canonical_id":"mesh:D000069446","description":null,"metadata":null},{"id":"aac809dd24364f549debc6d34ea14176","type":"DRUG","name":"atenolol","canonical_id":"gtopdb:548","description":null,"metadata":null},{"id":"dbf33445f737457a90e08cd83d2b5ca3","type":"DRUG","name":"atenolol","canonical_id":"chembl:CHEMBL24","description":null,"metadata":null},{"id":"226accd92f3244689fc7442be211b3a2","type":"COMBINATION_TREATMENT","name":"atenolol + brivaracetam + lacosamide","canonical_id":"ctgov_combo:ctgov-combo-94d3079f2e986113","description":null,"metadata":null},{"id":"b2ad806fb91a42b0816ae4c6a0e09b37","type":"COMBINATION_TREATMENT","name":"atenolol + carvedilol + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-3d76ac0df505f5b3","description":null,"metadata":null},{"id":"1c097580881648f088d40a04434c97ea","type":"COMBINATION_TREATMENT","name":"atenolol + chlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-bd8be4654536f5d4","description":null,"metadata":null},{"id":"861553eeab6d438c954b41bbdc39f7a3","type":"COMBINATION_TREATMENT","name":"atenolol + chlorothiazide + hydrochlorothiazide + trandolapril + verapamil","canonical_id":"ctgov_combo:ctgov-combo-bea13e4f1c9e93cf","description":null,"metadata":null},{"id":"8d94791110ac43e29c826b6b6140d620","type":"COMBINATION_TREATMENT","name":"atenolol + diltiazem","canonical_id":"ctgov_combo:ctgov-combo-d50718eec417718b","description":null,"metadata":null},{"id":"14b4edcc2ae84b2cb69d345c4b3b0ddc","type":"COMBINATION_TREATMENT","name":"atenolol + doxazosin + irbesartan + ramipril","canonical_id":"ctgov_combo:ctgov-combo-79f8acba42087a8f","description":null,"metadata":null},{"id":"f325afb69c9f45a9abf956133c75060a","type":"COMBINATION_TREATMENT","name":"atenolol + enalapril","canonical_id":"ctgov_combo:ctgov-combo-5462378c7be3c00b","description":null,"metadata":null},{"id":"8c543e9bf7d94dbc92c9e084a2d3eb03","type":"COMBINATION_TREATMENT","name":"atenolol + irbesartan","canonical_id":"ctgov_combo:ctgov-combo-f222902715620a22","description":null,"metadata":null},{"id":"897881dd34d44d0cad40d3797a2d60db","type":"COMBINATION_TREATMENT","name":"atenolol + irbesartan","canonical_id":"ctgov_combo:ctgov-combo-59b57272db43bff1","description":null,"metadata":null},{"id":"de18295f6b724efaa4853741e6d8fec1","type":"COMBINATION_TREATMENT","name":"atenolol + labetalol","canonical_id":"ctgov_combo:ctgov-combo-8ff36c86e9e90a0a","description":null,"metadata":null},{"id":"f34ce2c1eec545e8980ee538eca15d3e","type":"COMBINATION_TREATMENT","name":"atenolol + labetalol","canonical_id":"ctgov_combo:ctgov-combo-8879332a4fc7b0bd","description":null,"metadata":null},{"id":"0ff3805e692141aaaede71c41def1aae","type":"COMBINATION_TREATMENT","name":"atenolol + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-1aaed127668fb303","description":null,"metadata":null},{"id":"012bd6a7f0914241a88aad1ed741f712","type":"COMBINATION_TREATMENT","name":"atenolol + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-24d5370f6d737f3f","description":null,"metadata":null},{"id":"d394453defec4831bba92f3f67e6b9f0","type":"COMBINATION_TREATMENT","name":"atenolol + losartan + propranolol","canonical_id":"ctgov_combo:ctgov-combo-f811b1006b7bd51f","description":null,"metadata":null},{"id":"71e22830d8d54ff7a1f2609d72e4a00f","type":"COMBINATION_TREATMENT","name":"atenolol + nitrendipine","canonical_id":"ctgov_combo:ctgov-combo-38c4c3a4633de04d","description":null,"metadata":null},{"id":"444dc44e36a844f384d7ee2b2ee245d8","type":"COMBINATION_TREATMENT","name":"atenolol + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-98d72a09d023ddb9","description":null,"metadata":null},{"id":"727e8e76a144415ea8da11fa0a1b4a66","type":"COMBINATION_TREATMENT","name":"atenolol + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-04f700a75c24bbbc","description":null,"metadata":null},{"id":"57fe111f9d6f4b88bd128e594b39493a","type":"COMBINATION_TREATMENT","name":"atenolol + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-7302b42d4784ee73","description":null,"metadata":null},{"id":"258a7381a69149a69f5a9a0dd8d4d6ae","type":"COMBINATION_TREATMENT","name":"atenolol + perindopril + verapamil","canonical_id":"ctgov_combo:ctgov-combo-6d20dde07e23c030","description":null,"metadata":null},{"id":"ae411aa0fbdd4ea0b1dcd6ff0415ec08","type":"DRUG","name":"atezolizumab","canonical_id":"gtopdb:7990","description":null,"metadata":null},{"id":"a13e7cf82fbb417498badbea6cf5bb4d","type":"DRUG","name":"atezolizumab","canonical_id":"chembl:CHEMBL3707227","description":null,"metadata":null},{"id":"235f4d43785c42e3a807b3bd5b5dd2bc","type":"COMBINATION_TREATMENT","name":"atezolizumab + bevacizumab","canonical_id":"ctgov_combo:ctgov-combo-fe87583a90acb382","description":null,"metadata":null},{"id":"a55a674e6e394066b3c360fe5f09c348","type":"COMBINATION_TREATMENT","name":"atezolizumab + bevacizumab","canonical_id":"ctgov_combo:ctgov-combo-e449c72cb430dada","description":null,"metadata":null},{"id":"2b32d693cd1443b1ad91d82009941885","type":"COMBINATION_TREATMENT","name":"atezolizumab + bevacizumab + etoposide","canonical_id":"ctgov_combo:ctgov-combo-b3c4d79ffcb5059f","description":null,"metadata":null},{"id":"751e3e0d035941a2b61dd8696f685a32","type":"COMBINATION_TREATMENT","name":"atezolizumab + cobimetinib + hydroxychloroquine","canonical_id":"ctgov_combo:ctgov-combo-af4eaf6f9e638bf4","description":null,"metadata":null},{"id":"d68e5743030b42c5b03bbc051e146bd6","type":"COMBINATION_TREATMENT","name":"atezolizumab + durvalumab","canonical_id":"ctgov_combo:ctgov-combo-be4e7e6d33717940","description":null,"metadata":null},{"id":"992a3f6768f74c3d862473aa74b9e342","type":"COMBINATION_TREATMENT","name":"atezolizumab + eribulin","canonical_id":"ctgov_combo:ctgov-combo-06336528096e4fbb","description":null,"metadata":null},{"id":"2945f2b06e824ff0b42dc24f09d7e1bb","type":"COMBINATION_TREATMENT","name":"atezolizumab + etoposide","canonical_id":"ctgov_combo:ctgov-combo-88b7e22f63d373ce","description":null,"metadata":null},{"id":"444be39c0afc47c4ae042929ad670c7d","type":"COMBINATION_TREATMENT","name":"atezolizumab + etoposide","canonical_id":"ctgov_combo:ctgov-combo-5c8635f6662e6299","description":null,"metadata":null},{"id":"c7286d3c9a7e4eafacfca03daaeb82f8","type":"COMBINATION_TREATMENT","name":"atezolizumab + imatinib","canonical_id":"ctgov_combo:ctgov-combo-7d3122bb4e67afed","description":null,"metadata":null},{"id":"fb8c033042224c8a8fa23f79cf579574","type":"COMBINATION_TREATMENT","name":"atezolizumab + inavolisib","canonical_id":"ctgov_combo:ctgov-combo-eeeb8220f0574a0a","description":null,"metadata":null},{"id":"dac20e6640904133b30da399720082d3","type":"COMBINATION_TREATMENT","name":"atezolizumab + lenvatinib + regorafenib + sintilimab + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-bfc99db318e86b4e","description":null,"metadata":null},{"id":"b0792198fe794c01aa404f135830e342","type":"COMBINATION_TREATMENT","name":"atezolizumab + obinutuzumab + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-7aa61ecd8d467317","description":null,"metadata":null},{"id":"a1ea11f2844e4288abdccd04ca04f47a","type":"COMBINATION_TREATMENT","name":"atezolizumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-d679aae507dadc9c","description":null,"metadata":null},{"id":"6816b3f98a85416fbbd7cb6e92e0cecd","type":"COMBINATION_TREATMENT","name":"atezolizumab + ramucirumab","canonical_id":"ctgov_combo:ctgov-combo-343be653bb6ca51e","description":null,"metadata":null},{"id":"f4299849b9f94bd2b1b93368226012cc","type":"COMBINATION_TREATMENT","name":"atezolizumab + rucaparib","canonical_id":"ctgov_combo:ctgov-combo-f94665847f9491c7","description":null,"metadata":null},{"id":"a04cd804eaf94851b2514f762d66b3d8","type":"GO_TERM","name":"atf1-pcr1 complex","canonical_id":"go:GO:1990243","description":"\"A heterodimeric transcription factor complex composed of the bZIP proteins atf1 and pcr1. The heterodimer binds m26 sites (homologous to CRE).\" [PMID:24224056]","metadata":null},{"id":"1d296f97d6aa468d83917c51b24593ce","type":"DISEASE","name":"atherosclerosis","canonical_id":"mondo:0005311","description":null,"metadata":null},{"id":"8456514611074d1ca72d3b4059c8943c","type":"DRUG","name":"atomoxetine","canonical_id":"gtopdb:7118","description":null,"metadata":null},{"id":"fcb00d1343894ad9837013fc8c0a1b31","type":"COMBINATION_TREATMENT","name":"atomoxetine + buspirone","canonical_id":"ctgov_combo:ctgov-combo-b508076919d10126","description":null,"metadata":null},{"id":"71618691886f4354b9a363c1ec77a2a5","type":"COMBINATION_TREATMENT","name":"atomoxetine + clozapine","canonical_id":"ctgov_combo:ctgov-combo-078a09911e07bb13","description":null,"metadata":null},{"id":"6e8df44845c74997bfd033c79d1e4cb4","type":"COMBINATION_TREATMENT","name":"atomoxetine + dexamfetamine","canonical_id":"ctgov_combo:ctgov-combo-43c924f2b0956805","description":null,"metadata":null},{"id":"24c8181b0557413d93e644e99d4d729e","type":"COMBINATION_TREATMENT","name":"atomoxetine + guanfacine","canonical_id":"ctgov_combo:ctgov-combo-e1279a315c028b18","description":null,"metadata":null},{"id":"fc9d734d30e145acb8124df4c0b0283c","type":"COMBINATION_TREATMENT","name":"atomoxetine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-0033907ad765cd9d","description":null,"metadata":null},{"id":"75f87d5252da4296a76548ae4a402b26","type":"COMBINATION_TREATMENT","name":"atomoxetine + methylphenidate","canonical_id":"ctgov_combo:ctgov-combo-574722977054fd05","description":null,"metadata":null},{"id":"25d890882dd147c3b05e3c6955d27a98","type":"COMBINATION_TREATMENT","name":"atomoxetine + methylphenidate","canonical_id":"ctgov_combo:ctgov-combo-f5c00cd7a88b04c9","description":null,"metadata":null},{"id":"719064bf0b8b42df9d9dc65a54283121","type":"COMBINATION_TREATMENT","name":"atomoxetine + oxybutynin","canonical_id":"ctgov_combo:ctgov-combo-dff0f895aa165a44","description":null,"metadata":null},{"id":"f4de30920a6f432e8d7d1b200b3bebf6","type":"COMBINATION_TREATMENT","name":"atomoxetine + oxybutynin","canonical_id":"ctgov_combo:ctgov-combo-cbf48d69475bde3e","description":null,"metadata":null},{"id":"ebb49e867a6549bb910ae7ab498b10ac","type":"COMBINATION_TREATMENT","name":"atomoxetine + oxybutynin","canonical_id":"ctgov_combo:ctgov-combo-724a6477f66c9efa","description":null,"metadata":null},{"id":"2885c252826e4c88a3681f86832904d5","type":"COMBINATION_TREATMENT","name":"atomoxetine + oxybutynin + trazodone","canonical_id":"ctgov_combo:ctgov-combo-6ddca29a85c73ba1","description":null,"metadata":null},{"id":"cb6eb93bc8cf409e9d3e77c71747e505","type":"DISEASE","name":"atopic conjunctivitis","canonical_id":"mondo:0005642","description":null,"metadata":null},{"id":"c38a59b4192341b8affd38afa06bd145","type":"DISEASE","name":"atopic eczema","canonical_id":"mondo:0004980","description":null,"metadata":null},{"id":"bbc50e8d3a94444ca28e7e1abb6139c9","type":"DRUG","name":"atorvastatin","canonical_id":"gtopdb:2949","description":null,"metadata":null},{"id":"bbebcbf8a872429cad7aa800490bca2e","type":"DRUG","name":"atorvastatin","canonical_id":"mesh:D000069059","description":null,"metadata":null},{"id":"b95fdd85327041ef9b942bbb790042c2","type":"COMBINATION_TREATMENT","name":"atorvastatin + digoxin + liraglutide + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-cee8f855abe9e0f7","description":null,"metadata":null},{"id":"326d2d8100f84c46893e440c5b07c403","type":"COMBINATION_TREATMENT","name":"atorvastatin + enoxaparin","canonical_id":"ctgov_combo:ctgov-combo-db9f8f0071ff12bc","description":null,"metadata":null},{"id":"9f3b4c87f11f4172943a51f781eb48a1","type":"COMBINATION_TREATMENT","name":"atorvastatin + evolocumab","canonical_id":"ctgov_combo:ctgov-combo-5839e866e5164de8","description":null,"metadata":null},{"id":"bcc3884338df4a7aa21ce92489a04ad2","type":"COMBINATION_TREATMENT","name":"atorvastatin + ezetimibe","canonical_id":"ctgov_combo:ctgov-combo-b0b27d0dccaed8a8","description":null,"metadata":null},{"id":"723ab7290c8643bdaede51ef25d81bb3","type":"COMBINATION_TREATMENT","name":"atorvastatin + ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-7623946f2d96a10f","description":null,"metadata":null},{"id":"73c86e8f817a4063a74cf8df63a88905","type":"COMBINATION_TREATMENT","name":"atorvastatin + ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-4d36bfd415506727","description":null,"metadata":null},{"id":"33b34168a3fc4a02b4d2e1464a026e5e","type":"COMBINATION_TREATMENT","name":"atorvastatin + fenofibrate","canonical_id":"ctgov_combo:ctgov-combo-26635da6b4aea2a0","description":null,"metadata":null},{"id":"4ade078545804bb285bac0d563fec6b8","type":"COMBINATION_TREATMENT","name":"atorvastatin + fenofibrate","canonical_id":"ctgov_combo:ctgov-combo-71daa30355b3bc77","description":null,"metadata":null},{"id":"b8d8a28efaed47de834832ae5da536d6","type":"COMBINATION_TREATMENT","name":"atorvastatin + gemfibrozil","canonical_id":"ctgov_combo:ctgov-combo-3923d93ff7db1062","description":null,"metadata":null},{"id":"474badbf685d49a6a0d262423b429cd7","type":"COMBINATION_TREATMENT","name":"atorvastatin + hydroxychloroquine","canonical_id":"ctgov_combo:ctgov-combo-d3982667ab22cf09","description":null,"metadata":null},{"id":"6c98f095c6ae4017b5a9d7a4bf1b6c3f","type":"COMBINATION_TREATMENT","name":"atorvastatin + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-1d492bb4e231c8e8","description":null,"metadata":null},{"id":"a96027e99a544eb5a20881e90ecd0614","type":"COMBINATION_TREATMENT","name":"atorvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-956622a7ae2ebe9d","description":null,"metadata":null},{"id":"9559b643e63c41aa959d9055815a3bbb","type":"COMBINATION_TREATMENT","name":"atorvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-0c171013a1883ec9","description":null,"metadata":null},{"id":"c04b60e9f6a244bca8c12af31fff6884","type":"COMBINATION_TREATMENT","name":"atorvastatin + teneligliptin","canonical_id":"ctgov_combo:ctgov-combo-fc664a3dd34e0462","description":null,"metadata":null},{"id":"56649ee969d84506a817d3edc28f5b2e","type":"DRUG","name":"atrasentan","canonical_id":"gtopdb:3487","description":null,"metadata":null},{"id":"70f78d0c18ed4fae970e8d84f8bcec6c","type":"GO_TERM","name":"atrazine catabolic process","canonical_id":"go:GO:0019381","description":"\"The chemical reactions and pathways resulting in the breakdown of atrazine, a triazine ring-containing herbicide.\" [GOC:jl, MetaCyc:PWY-5724]","metadata":null},{"id":"413c12c9c66440f39d7b5d7e238b7b0e","type":"GO_TERM","name":"atrazine chlorohydrolase activity","canonical_id":"go:GO:0018788","description":"\"Catalysis of the reaction: atrazine + H2O = chloride + H+ + hydroxyatrazine.\" [RHEA:11312]","metadata":null},{"id":"b3a3aef5fe1740de8bfa0cb721962c20","type":"GO_TERM","name":"atrial cardiac muscle cell action potential","canonical_id":"go:GO:0086014","description":"\"An action potential that occurs in an atrial cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"47b844f0b1da4f8d945a2fabb44f43a7","type":"GO_TERM","name":"atrial cardiac muscle cell development","canonical_id":"go:GO:0055014","description":"\"The process whose specific outcome is the progression of an atrial cardiac muscle cell over time, from its formation to the mature state. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. The atrium is the part of the heart that receives blood into the organ.\" [GOC:devbiol]","metadata":null},{"id":"855d6461025a47e5be54446ee7923ce1","type":"GO_TERM","name":"atrial cardiac muscle cell differentiation","canonical_id":"go:GO:0055011","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a cardiac muscle cell in the atrium. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. The atrium is the part of the heart that receives blood into the organ.\" [GOC:devbiol, GOC:mtg_heart]","metadata":null},{"id":"6de0096d9d704ec698fd61c0c236895d","type":"GO_TERM","name":"atrial cardiac muscle cell fate commitment","canonical_id":"go:GO:0060924","description":"\"The commitment of cells to atrial cardiac muscle cell fates and their capacity to differentiate into cardiac muscle cells of the atrium. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.\" [GOC:mtg_heart]","metadata":null},{"id":"16a67842e33b4515aed4916c29120984","type":"GO_TERM","name":"atrial cardiac muscle cell membrane repolarization","canonical_id":"go:GO:0099624","description":"\"The process in which ions are transported across the plasma membrane of an atrial cardiac muscle cell such that the membrane potential changes in the repolarizing direction, toward the steady state potential. For example, the repolarization during an action potential is from a positive membrane potential towards a negative resting potential.\" [GOC:BHF]","metadata":null},{"id":"8a289accbf574100a322c5bf056402b4","type":"GO_TERM","name":"atrial cardiac muscle cell to AV node cell communication","canonical_id":"go:GO:0086066","description":"\"The process that mediates interactions between an atrial cardiomyocyte and its surroundings that contributes to the process of the atrial cardiomyocyte communicating with an AV node cell in cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"96f8d9cec39d4211b7346265ee382270","type":"GO_TERM","name":"atrial cardiac muscle cell to AV node cell communication by electrical coupling","canonical_id":"go:GO:0086044","description":"\"The process that mediates signaling interactions between an atrial cardiomyocyte and an AV node cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"48031f27eae8441b96552063406c4d95","type":"GO_TERM","name":"atrial cardiac muscle cell to AV node cell signaling","canonical_id":"go:GO:0086026","description":"\"Any process that mediates the transfer of information from an atrial cardiomyocyte to an AV node cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"ecb288a120654b56ae6566eb244f50bd","type":"GO_TERM","name":"atrial cardiac muscle tissue development","canonical_id":"go:GO:0003228","description":"\"The process whose specific outcome is the progression of cardiac muscle of the atrium over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"85fe8d6fa35f44eca699d84c871d573f","type":"GO_TERM","name":"atrial cardiac muscle tissue morphogenesis","canonical_id":"go:GO:0055009","description":"\"The process in which the anatomical structure of cardiac atrium muscle is generated and organized.\" [GOC:devbiol]","metadata":null},{"id":"297ad84fd989419ba43735a0519ebcc6","type":"GO_TERM","name":"atrial cardiac myofibril assembly","canonical_id":"go:GO:0055004","description":"\"The process whose specific outcome is the progression of the atrial cardiac myofibril over time, from its formation to the mature structure. A cardiac myofibril is a myofibril specific to cardiac muscle cells.\" [GOC:devbiol]","metadata":null},{"id":"336570f693c0493e8b558282ef88ce0b","type":"DISEASE","name":"atrial fibrillation","canonical_id":"mondo:0004981","description":null,"metadata":null},{"id":"b4a498dc5ea34ed487463690e4a96186","type":"DISEASE","name":"atrial fibrillation, familial, 10","canonical_id":"mondo:0013530","description":null,"metadata":null},{"id":"72f73947eb4047678b424336b54bc082","type":"DISEASE","name":"atrial flutter","canonical_id":"mondo:0005310","description":null,"metadata":null},{"id":"5136da26441c4c72a5f913d801736068","type":"GO_TERM","name":"atrial septum development","canonical_id":"go:GO:0003283","description":"\"The progression of the atrial septum over time, from its initial formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"301761c1728e4a25846916df8d692acf","type":"GO_TERM","name":"atrial septum intermedium development","canonical_id":"go:GO:0003286","description":"\"The progression of the atrial septum intermedium over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"bafc990b5dc04f619df92bf2f23b555b","type":"GO_TERM","name":"atrial septum intermedium morphogenesis","canonical_id":"go:GO:0003291","description":"\"The process in which anatomical structure of an atrial septum intermedium is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"bbf88336f2bd41c3baca9dd211dac152","type":"GO_TERM","name":"atrial septum morphogenesis","canonical_id":"go:GO:0060413","description":"\"The developmental process in which atrial septum is generated and organized. The atrial septum separates the upper chambers (the atria) of the heart from one another.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"c032df45351340ef92e160f15ecd34e3","type":"GO_TERM","name":"atrial septum primum morphogenesis","canonical_id":"go:GO:0003289","description":"\"The process in which anatomical structure of an atrial septum primum is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"b8df096799b74fb88a38ed91dca127b4","type":"GO_TERM","name":"atrial septum secundum morphogenesis","canonical_id":"go:GO:0003290","description":"\"The process in which anatomical structure of an atrial septum secundum is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"b64374241d2c44be99a21745bd1ae443","type":"GO_TERM","name":"atrial ventricular junction remodeling","canonical_id":"go:GO:0003294","description":"\"The reorganization or renovation of heart tissue that contributes to the maturation of the connection between an atrium and a ventricle.\" [GOC:mtg_heart]","metadata":null},{"id":"c85c03cf1b49450da5940cfbab3d48e3","type":"GO_TERM","name":"atrichoblast differentiation","canonical_id":"go:GO:0010055","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an atrichoblast, a root epidermal cell that will not give rise to a root hair.\" [GOC:tb]","metadata":null},{"id":"a4cb727878c348838471cfd73bd4e98c","type":"GO_TERM","name":"atrichoblast fate specification","canonical_id":"go:GO:0010056","description":"\"The process involved in the specification of an atrichoblast.\" [GOC:tb]","metadata":null},{"id":"01ae75dff2524568b43e86d2ee2d9d6a","type":"GO_TERM","name":"atrioventricular bundle cell differentiation","canonical_id":"go:GO:0003167","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a cell of the atrioventricular bundle. These cells are specialized cardiomyocytes that transmit signals from the AV node to the cardiac Purkinje fibers.\" [GOC:mtg_heart]","metadata":null},{"id":"8b697324468a4067a0c21a1715fa2b96","type":"GO_TERM","name":"atrioventricular canal development","canonical_id":"go:GO:0036302","description":"\"The progression of the atrioventricular canal over time, from its formation to the mature structure. The atrioventricular canal is the part of the heart connecting the atrium to the cardiac ventricle.\" [GOC:BHF, GOC:gr, PMID:14701881, UBERON:0002087, ZFA:0001315]","metadata":null},{"id":"c0930d66a9b448238d36ea188d491ec4","type":"GO_TERM","name":"atrioventricular canal morphogenesis","canonical_id":"go:GO:1905222","description":"\"The developmental process by which an atrioventricular canal is generated and organized.\" [GO_REF:0000083, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19703439]","metadata":null},{"id":"0e853823973c4323b097c1e2b8337512","type":"GO_TERM","name":"atrioventricular node cell development","canonical_id":"go:GO:0060928","description":"\"The process whose specific outcome is the progression of an atrioventricular (AV) node cell over time, from its formation to the mature state.\" [GOC:mtg_heart]","metadata":null},{"id":"a7cb8172fa78492f9d2caebf57d80ff3","type":"GO_TERM","name":"atrioventricular node cell differentiation","canonical_id":"go:GO:0060922","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an atrioventricular (AV) node cell. AV node cells are pacemaker cells that are found in the atrioventricular node.\" [GOC:mtg_heart]","metadata":null},{"id":"d09e8c9e67b04dd19b12090f8df0d8fd","type":"GO_TERM","name":"atrioventricular node cell fate commitment","canonical_id":"go:GO:0060929","description":"\"The commitment of cells to atrioventricular (AV) node cell fates and their capacity to differentiate into AV node cells.\" [GOC:mtg_heart]","metadata":null},{"id":"12d2a7a19a3742e7a83cc49412d92d4e","type":"GO_TERM","name":"atrioventricular node development","canonical_id":"go:GO:0003162","description":"\"The process whose specific outcome is the progression of the atrioventricular (AV) node over time, from its formation to the mature structure. The AV node is part of the cardiac conduction system that controls the timing of ventricle contraction by receiving electrical signals from the sinoatrial (SA) node and relaying them to the His-Purkinje system.\" [GOC:mtg_heart]","metadata":null},{"id":"0f3af4a39bfd4648a6fe9905468d9e2a","type":"GO_TERM","name":"atrioventricular valve development","canonical_id":"go:GO:0003171","description":"\"The progression of the atrioventricular valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"f19ff2a770ee459f8871a86bc4958af7","type":"GO_TERM","name":"atrioventricular valve formation","canonical_id":"go:GO:0003190","description":"\"The developmental process pertaining to the initial formation of the atrioventricular valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"a81d1d70218a4204be65a365d1788953","type":"GO_TERM","name":"atrioventricular valve morphogenesis","canonical_id":"go:GO:0003181","description":"\"The process in which the structure of the atrioventricular valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"2b4f53a6b06a43fa98f38c3c50f664a4","type":"DRUG","name":"atropine","canonical_id":"gtopdb:320","description":null,"metadata":null},{"id":"c13edad752c34790916113c6091de1d6","type":"COMBINATION_TREATMENT","name":"atropine + clonidine + metoclopramide + phenylephrine + propranolol + yohimbine","canonical_id":"ctgov_combo:ctgov-combo-2685baa8a22eb07e","description":null,"metadata":null},{"id":"9fb45f805d184090926aea61336a78ab","type":"COMBINATION_TREATMENT","name":"atropine + esmolol + glycopyrrolate + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-2ec341fc82a7cd5c","description":null,"metadata":null},{"id":"d2d8056fe93c4f04aebb7b93c46356bb","type":"COMBINATION_TREATMENT","name":"atropine + glycopyrrolate","canonical_id":"ctgov_combo:ctgov-combo-b4fb2955e9709c54","description":null,"metadata":null},{"id":"efcd593b9f93458187ba258811ef2fac","type":"COMBINATION_TREATMENT","name":"atropine + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-ea894c304cf33295","description":null,"metadata":null},{"id":"4763faa4a0cd44edb76171b914f97646","type":"COMBINATION_TREATMENT","name":"atropine + regadenoson","canonical_id":"ctgov_combo:ctgov-combo-7242768aec3e863f","description":null,"metadata":null},{"id":"aa44f5cb4a15487289252f21fc15d49e","type":"GO_TERM","name":"atropine biosynthetic process","canonical_id":"go:GO:1901051","description":"\"The chemical reactions and pathways resulting in the formation of atropine. Atropine is the racemic mixture of hyoscyamine.\" [GOC:TermGenie, GOC:yaf, PMID:2879005, PMID:33572199]","metadata":null},{"id":"2e12cfbd08554203aa708c2fd872bd05","type":"GO_TERM","name":"attachment of GPI anchor to protein","canonical_id":"go:GO:0016255","description":"\"A transamidation reaction that results in the cleavage of the polypeptide chain and the concomitant transfer of the GPI anchor to the newly formed carboxy-terminal amino acid of the anchored protein. The cleaved C-terminal contains the C-terminal GPI signal sequence of the newly synthesized polypeptide chain.\" [ISBN:0879695595]","metadata":null},{"id":"3865a5a723fb4c48b2c64eefa28365f3","type":"GO_TERM","name":"attachment of meiotic spindle microtubules to kinetochore","canonical_id":"go:GO:0051316","description":"\"The cellular process in which spindle microtubules become physically associated with the proteins making up the kinetochore complex in meiosis.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"d72b542d9a584b75a1b6e9271322d703","type":"GO_TERM","name":"attachment of meiotic spindle microtubules to meiosis II kinetochore","canonical_id":"go:GO:0051456","description":"\"The cellular process in which spindle microtubules become physically associated with the proteins making up the kinetochore complex in meiosis II. During meiosis II sister kinetochores are situated facing opposite spindle poles and bipolar attachment of the sister chromosomes to the spindle occurs.\" [GOC:ai, GOC:clt, GOC:dph, GOC:tb]","metadata":null},{"id":"56f30f752e37419187ff5dd5432468f8","type":"GO_TERM","name":"attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:0051315","description":"\"The cellular process in which spindle microtubules become physically associated with the proteins making up the kinetochore complex in mitosis.\" [GOC:ai, GOC:clt, GOC:dph, GOC:tb, PMID:26258632, PMID:26705896]","metadata":null},{"id":"a3a4727173854676acb20b4ae516fdd0","type":"GO_TERM","name":"attachment of spindle microtubules to kinetochore","canonical_id":"go:GO:0008608","description":"\"The process in which spindle microtubules become physically associated with the proteins making up the kinetochore complex.\" [GOC:vw, PMID:10322137]","metadata":null},{"id":"4528a7dbae2245e0b9db5bd362e9844a","type":"GO_TERM","name":"attachment of telomeric heterochromatin to nuclear envelope","canonical_id":"go:GO:0140698","description":"\"The process in which physical connections are formed between sub-telomeric heterochromatin and the nuclear envelope facilitating bouquet formation.\" [PMID:31635174]","metadata":null},{"id":"0d602bf54b1746dc83e44e2b9ccfc8ee","type":"GO_TERM","name":"attachment organelle","canonical_id":"go:GO:0033099","description":"\"A membrane-bounded extension of the cell, originally characterized in Mycoplasma species, that contains an electron-dense core that is part of the cytoskeleton and is oriented lengthwise and ends distally in a bulbous knob (terminal button). Required for adherence to host cells and involved in gliding motility and cell division.\" [PMID:11325545, PMID:12003948]","metadata":null},{"id":"53fda0465fa849aab35140e73aa0fa15","type":"GO_TERM","name":"attachment organelle membrane","canonical_id":"go:GO:0033111","description":"\"The lipid bilayer surrounding an attachment organelle. This is a region of the cell membrane facing the environment - in mycoplasma, part of the mycolate outer membrane.\" [GOC:ecd]","metadata":null},{"id":"cde3022c8f324c54ae663f599b7832d6","type":"DISEASE","name":"attention deficit-hyperactivity disorder","canonical_id":"mondo:0007743","description":null,"metadata":null},{"id":"8afc30247a574e019aae752e186292e0","type":"DISEASE","name":"atypical endometrial hyperplasia","canonical_id":"mondo:0006096","description":null,"metadata":null},{"id":"dd274e396ac546f6a78f345f487ef81a","type":"DISEASE","name":"atypical hemolytic-uremic syndrome","canonical_id":"mondo:0016244","description":null,"metadata":null},{"id":"4f8b08d7ffc142a9b856be02096a626c","type":"GO_TERM","name":"auditory behavior","canonical_id":"go:GO:0031223","description":"\"The behavior of an organism in response to a sound.\" [GOC:pr, GOC:rc]","metadata":null},{"id":"fdee9f42ae9c405d81a6cb9228ca13c9","type":"GO_TERM","name":"auditory receptor cell development","canonical_id":"go:GO:0060117","description":"\"The process whose specific outcome is the progression of an auditory receptor cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:dph]","metadata":null},{"id":"76450c1a87fe441e925f8f63fec24924","type":"GO_TERM","name":"auditory receptor cell fate commitment","canonical_id":"go:GO:0009912","description":"\"The process in which the cellular identity of auditory hair cells is acquired and determined.\" [GOC:lr]","metadata":null},{"id":"89c9fc8644cc4b4584bf6a0714673263","type":"GO_TERM","name":"auditory receptor cell fate determination","canonical_id":"go:GO:0042668","description":"\"The process in which a cell becomes capable of differentiating autonomously into an auditory hair cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators]","metadata":null},{"id":"cae21d67955047e2a00e69e3a3759af9","type":"GO_TERM","name":"auditory receptor cell fate specification","canonical_id":"go:GO:0042667","description":"\"The process in which a cell becomes capable of differentiating autonomously into an auditory hair cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:curators]","metadata":null},{"id":"4fb9dccb56e84161a4778def84465ec5","type":"GO_TERM","name":"auditory receptor cell morphogenesis","canonical_id":"go:GO:0002093","description":"\"Any process that alters the size or shape of an auditory receptor cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"41e3379380d74607a065c121909006eb","type":"GO_TERM","name":"auditory receptor cell stereocilium organization","canonical_id":"go:GO:0060088","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a stereocilium. A stereocilium is an actin-based protrusion from the apical surface of auditory hair cells.\" [GOC:dph, PMID:10978835]","metadata":null},{"id":"b008838d52994b8dbe428c4c466c470e","type":"GO_TERM","name":"aureusidin synthase activity","canonical_id":"go:GO:0033793","description":"\"Catalysis of the reactions: 2',4,4',6'-tetrahydroxychalcone 4'-O-beta-D-glucoside + H+ + O2 = aureusidin 6-O-beta-glucoside + H2O, 2 2',3,4,4',6'-pentahydroxychalcone 4'-O-beta-D-glucoside + 2 H+ + O2 = 2 aureusidin 6-O-beta-glucoside + 2 H2O, and 2',3,4,4',6'-pentahydroxychalcone 4'-O-beta-D-glucoside + H+ + O2 = bracteatin 6-O-beta-glucoside + H2O. This activity consists of two separate chemical transformations: 3-hydroxylation and oxidative cyclization (2',-dehydrogenation).\" [EC:1.21.3.6]","metadata":null},{"id":"ea2635b9e54747f899065d14e6c67130","type":"GO_TERM","name":"aurone biosynthetic process","canonical_id":"go:GO:0051551","description":"\"The chemical reactions and pathways resulting in the formation of aurones, a series of yellow plant pigments.\" [GOC:ai, PMID:20035037]","metadata":null},{"id":"3c5169340a7243238c7b2afbe285c7f6","type":"GO_TERM","name":"austinol biosynthetic process","canonical_id":"go:GO:1900560","description":"\"The chemical reactions and pathways resulting in the formation of austinol.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6831b5fb81d34f91a310a40161bffdc3","type":"GO_TERM","name":"austinol catabolic process","canonical_id":"go:GO:1900559","description":"\"The chemical reactions and pathways resulting in the breakdown of austinol.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"d8df3fd571a24e029c5ca942716dce18","type":"DISEASE","name":"autism","canonical_id":"mondo:0005260","description":null,"metadata":null},{"id":"7321a8363c8c4f0482f86ddbc5e61356","type":"DISEASE","name":"autism spectrum disorder","canonical_id":"mondo:0005258","description":null,"metadata":null},{"id":"1750b42b19244bccabdbda92fd4d62e8","type":"GO_TERM","name":"autocrine signaling","canonical_id":"go:GO:0035425","description":"\"Signaling between cells of the same type. The signal produced by the signaling cell binds to a receptor on, and affects a cell of the same type.\" [GOC:bf, ISBN:3527303782]","metadata":null},{"id":"c9efd449bc4745c6919f18c5e61ecc50","type":"DISEASE","name":"autoimmune disease","canonical_id":"mondo:0007179","description":null,"metadata":null},{"id":"02241a0b25a844e6bcb9d0fdc9338818","type":"DISEASE","name":"autoimmune hemolytic anemia","canonical_id":"mondo:0020108","description":null,"metadata":null},{"id":"6003f109a37f424ebc2d7394417fa12b","type":"DISEASE","name":"autoimmune lymphoproliferative syndrome","canonical_id":"mondo:0017979","description":null,"metadata":null},{"id":"7386d1ef90f844239466c9a7e5a0dec0","type":"DISEASE","name":"autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency","canonical_id":"mondo:0014493","description":null,"metadata":null},{"id":"bf9ead3d6496431a894440e94f41033b","type":"DISEASE","name":"autoimmune lymphoproliferative syndrome type 4","canonical_id":"mondo:0013767","description":null,"metadata":null},{"id":"fedca9c745e946178c6636afa1f1ae3c","type":"DISEASE","name":"autoimmune thrombocytopenic purpura","canonical_id":"mondo:0008558","description":null,"metadata":null},{"id":"adbfb4f0d4104c098620c3b19479b54c","type":"DISEASE","name":"autoimmune thyroid disease","canonical_id":"mondo:0005623","description":null,"metadata":null},{"id":"f7ed4d777f8c41568a4ae188d6782f06","type":"GO_TERM","name":"autoinducer AI-2 transmembrane transport","canonical_id":"go:GO:1905887","description":"\"The process in which (2R,4S)-2-methyltetrahydrofuran-2,3,3,4-tetrol (autoinducer AI-2) is transported across a membrane. AI-2 is produced by prokaryotes and is believed to play a role in quorum sensing.\" [GO_REF:0000069, GOC:TermGenie, PMID:15601708]","metadata":null},{"id":"00f5ecbb24194c959c1ba80b491bfa86","type":"GO_TERM","name":"autoinducer-2 kinase activity","canonical_id":"go:GO:0071518","description":"\"Catalysis of the reaction: (S)-4,5-dihydroxypentane-2,3-dione + ATP = (2S)-2-hydroxy-3,4-dioxopentyl phosphate + ADP + H+.\" [PMID:17274596, PMID:20025244, RHEA:15377]","metadata":null},{"id":"698502d10d9e411f8d4a095d98fcd11a","type":"DISEASE","name":"autoinflammation, immune dysregulation, and eosinophilia","canonical_id":"mondo:0033558","description":null,"metadata":null},{"id":"2d1944c7faa74d39880b918f65c3c8ac","type":"DISEASE","name":"autoinflammatory syndrome","canonical_id":"mondo:0019751","description":null,"metadata":null},{"id":"998117f209404227a864bbddfd814d91","type":"GO_TERM","name":"autolysis","canonical_id":"go:GO:0001896","description":"\"A programmed cell death process observed in bacteria and filamentous fungi and leading to spontaneous death by lysis. Examples are lysis of the mother cell during sporulation of Bacillus subtilis and self-degradation of fungal cells in Aspergillus nidulans. Autolysis is also involved in bacterial biofilm formation.\" [GOC:add, GOC:jh2, GOC:mtg_apoptosis, PMID:10974124, PMID:19286987, PMID:26811896]","metadata":null},{"id":"f329ddd932f54d4196a67e5425df7a16","type":"GO_TERM","name":"autolysosome","canonical_id":"go:GO:0044754","description":"\"A type of secondary lysosome in which a primary lysosome has fused with the outer membrane of an autophagosome or amphisome. It is involved in the second step of autophagy in which it degrades contents with acidic lysosomal hydrolases.\" [GOC:sart, NIF_Subcellular:sao8444068431, PMID:19008921, PMID:24657946]","metadata":null},{"id":"d82b786173b540a8a5a3faa2a68fd6d9","type":"GO_TERM","name":"autolysosome lumen","canonical_id":"go:GO:0120282","description":"\"The volume that is enclosed within the autolysosome single-membrane.\" [GOC:krc, GOC:nhn, PMID:17182262, PMID:24657946, PMID:26382870, PMID:32047650]","metadata":null},{"id":"b4431b7e4e334911b68c85792efc50ce","type":"GO_TERM","name":"autolysosome membrane","canonical_id":"go:GO:0120281","description":"\"A lipid bilayer that surrounds an autolysosome, a single-membrane-bounded vesicle in which endogenous cellular material is degraded.\" [GOC:krc, GOC:nhn, PMID:17182262, PMID:24657946, PMID:26382870, PMID:32047650]","metadata":null},{"id":"465b56d8e5ba4462bb6b0e2fca8a2ecc","type":"GO_TERM","name":"autonomic nervous system development","canonical_id":"go:GO:0048483","description":"\"The process whose specific outcome is the progression of the autonomic nervous system over time, from its formation to the mature structure. The autonomic nervous system is composed of neurons that are not under conscious control, and is comprised of two antagonistic components, the sympathetic and parasympathetic nervous systems. The autonomic nervous system regulates key functions including the activity of the cardiac (heart) muscle, smooth muscles (e.g. of the gut), and glands.\" [FMA:9905, GOC:jid, GOC:sr]","metadata":null},{"id":"681c00bf69a54ef7a77bd53d3607b364","type":"GO_TERM","name":"autophagic cell death","canonical_id":"go:GO:0048102","description":"\"A form of programmed cell death that is accompanied by the formation of autophagosomes. Autophagic cell death is characterized by lack of chromatin condensation and massive vacuolization of the cytoplasm, with little or no uptake by phagocytic cells.\" [GOC:autophagy, GOC:mah, GOC:mtg_apoptosis, PMID:18846107, PMID:23347517]","metadata":null},{"id":"8c4284cb32974ef49a7acc99dc016bbf","type":"GO_TERM","name":"autophagosome","canonical_id":"go:GO:0005776","description":"\"A double-membrane-bounded compartment that engulfs endogenous cellular material as well as invading microorganisms to target them to the lytic vacuole/lysosome for degradation as part of macroautophagy.\" [GOC:autophagy, ISBN:0198547684, PMID:11099404]","metadata":null},{"id":"7de7bab010ea4fc8a45f1633237c7881","type":"GO_TERM","name":"autophagosome assembly","canonical_id":"go:GO:0000045","description":"\"The formation of a double membrane-bounded structure, the autophagosome, that occurs when a specialized membrane sac, called the isolation membrane, starts to enclose a portion of the cytoplasm.\" [GOC:autophagy, PMID:9412464]","metadata":null},{"id":"4d1332938b084b37b37a1097b087ebd6","type":"GO_TERM","name":"autophagosome localization","canonical_id":"go:GO:0061906","description":"\"Any process in which an autophagosome is transported to, and/or maintained in, a specific location within the cell.\" [PMID:26763909]","metadata":null},{"id":"012845cc63044a3d999b35d28808b584","type":"GO_TERM","name":"autophagosome lumen","canonical_id":"go:GO:0034423","description":"\"The volume enclosed within the autophagosome double-membrane.\" [GOC:autophagy, GOC:rph]","metadata":null},{"id":"c56c19a6c7974716b2ecb938b612ac04","type":"GO_TERM","name":"autophagosome maturation","canonical_id":"go:GO:0097352","description":"\"Removal of PI3P and Atg8/LC3 after the closure of the phagophore and before the fusion with the endosome/lysosome (e.g. mammals and insects) or vacuole (yeast), and that very likely destabilizes other Atg proteins and thus enables their efficient dissociation and recycling.\" [GOC:autophagy, GOC:lf, PMID:28077293]","metadata":null},{"id":"322a23ffe22e4b12a8c03c18a46e9040","type":"GO_TERM","name":"autophagosome membrane","canonical_id":"go:GO:0000421","description":"\"The lipid bilayer surrounding an autophagosome, a double-membrane-bounded vesicle in which endogenous cellular material is sequestered.\" [GOC:autophagy, GOC:isa_complete]","metadata":null},{"id":"7baef1b50699469cb2ebaab9c761dab2","type":"GO_TERM","name":"autophagosome membrane disassembly","canonical_id":"go:GO:0030399","description":"\"The controlled breakdown of the membranes of autophagosomes.\" [GOC:autophagy, GOC:mah]","metadata":null},{"id":"dff42d954f6745a79dd9c9a5b718d7d7","type":"GO_TERM","name":"autophagosome membrane docking","canonical_id":"go:GO:0016240","description":"\"The initial attachment of an autophagosome membrane to a target membrane, mediated by proteins protruding from the membrane of the vesicle and the target membrane. Docking requires only that the two membranes come close enough for these proteins to interact and adhere.\" [GOC:autophagy, GOC:mah]","metadata":null},{"id":"19797b48ce824be78fb3f90ff8625ed6","type":"GO_TERM","name":"autophagosome organization","canonical_id":"go:GO:1905037","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an autophagosome.\" [GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22186024]","metadata":null},{"id":"6b30bfae7aa142ecbdc4230550910dc5","type":"GO_TERM","name":"autophagosome-dependent secretion","canonical_id":"go:GO:0160192","description":"\"A process of exocytosis that uses the autophagy machinery to facilitate secretion of the cytosolic cargo such as leaderless cytosolic proteins which cannot enter the conventional secretory pathway operating via the endoplasmic reticulum and the Golgi apparatus.\" [PMID:25988755, PMID:38534758]","metadata":null},{"id":"a542c6286d5f4b7ebb9be7d6ab1a448d","type":"GO_TERM","name":"autophagosome-endosome fusion","canonical_id":"go:GO:0061910","description":"\"The process in which an autophagosome fuses with an endosome to create an intermediate autophagic organelle called amphisome.\" [PMID:24219988]","metadata":null},{"id":"b69068271b68482ab3699914db32cd4b","type":"GO_TERM","name":"autophagosome-lysosome fusion","canonical_id":"go:GO:0061909","description":"\"The process in which autophagosomes, double-membraned vesicles containing cytoplasmic material, fuse with a vacuole (yeast) or lysosome (e.g. mammals and insects). In the case of yeast, inner membrane-bounded structures (autophagic bodies) appear in the vacuole. Fusion provides an acidic environment and digestive function to the interior of the autophagosome.\" [PMID:28077293]","metadata":null},{"id":"03652ed9b61c4e84babbb34d5b5cb82c","type":"GO_TERM","name":"autophagosome-membrane adaptor activity","canonical_id":"go:GO:0160183","description":"\"The binding activity of a molecule that brings together a target membrane and an autophagosome membrane during autophagy.\" [PMID:30544615, PMID:36635405]","metadata":null},{"id":"cdebbe8cdd0c40ffa9a4f02ee8a8f1db","type":"GO_TERM","name":"autophagy","canonical_id":"go:GO:0006914","description":"\"The cellular catabolic process in which cells digest cellular materials, such as organelles and other macromolecular constituents, or non-self materials such as intracellular pathogens. Autophagy serves to provide essential nutrients under conditions of cellular stress; or can remodel intracellular structures during cell differentiation.\" [GOC:autophagy, ISBN:0198547684, PMID:11099404, PMID:29455577, PMID:9412464]","metadata":null},{"id":"cb83cfdad31449f0a2d55f31910b4f00","type":"GO_TERM","name":"autophagy cargo adaptor activity","canonical_id":"go:GO:0160247","description":"\"The binding activity of a molecule that brings together a cargo, targeted for degradation via autophagy, to a phagophore.\" [PMID:23545414, PMID:31585693, PMID:36538890]","metadata":null},{"id":"fe21742bc8c845c7bc3a2b2a98a874ee","type":"GO_TERM","name":"autophagy of mitochondrion","canonical_id":"go:GO:0000422","description":"\"The autophagic process in which mitochondria are delivered to a type of vacuole and degraded in response to changing cellular conditions.\" [GOC:autophagy, PMID:15798367, PMID:19289147, PMID:23065344]","metadata":null},{"id":"03127ad1eb8846edb1f5efdcde7b6e0e","type":"GO_TERM","name":"autophagy of peroxisome","canonical_id":"go:GO:0030242","description":"\"The process in which peroxisomes are delivered to a type of vacuole and degraded in response to changing nutrient conditions.\" [GOC:autophagy, PMID:10547367, PMID:20083110]","metadata":null},{"id":"e7bcf968e9f4479baebb51e409550ccc","type":"DISEASE","name":"autosomal agammaglobulinemia","canonical_id":"mondo:0011096","description":null,"metadata":null},{"id":"68b50db27380404eaae90dc2a826fb2a","type":"DISEASE","name":"autosomal dominant hyperinsulinism due to Kir6.2 deficiency","canonical_id":"mondo:0017185","description":null,"metadata":null},{"id":"14284d8aa44a423f8c0a003b2d18f0fb","type":"DISEASE","name":"autosomal dominant hyperinsulinism due to SUR1 deficiency","canonical_id":"mondo:0017184","description":null,"metadata":null},{"id":"1f5fabc3dcb24d7496d553006635c305","type":"DISEASE","name":"autosomal dominant hypocalcemia","canonical_id":"mondo:0018543","description":null,"metadata":null},{"id":"b452a5f99914469d833d8d12fd93f4e8","type":"DISEASE","name":"autosomal dominant hypocalcemia 1","canonical_id":"mondo:0011013","description":null,"metadata":null},{"id":"6b163ab6a4c0447285e25343b5bcadb7","type":"DISEASE","name":"autosomal dominant nonsyndromic hearing loss","canonical_id":"mondo:0019587","description":null,"metadata":null},{"id":"ea5f9d568705432eac7b9913f0a2fbce","type":"DISEASE","name":"autosomal dominant nonsyndromic hearing loss 2A","canonical_id":"mondo:0010817","description":null,"metadata":null},{"id":"e6af4eca0d584bc4a385eb2d73a53ded","type":"DISEASE","name":"autosomal dominant polycystic kidney disease","canonical_id":"mondo:0004691","description":null,"metadata":null},{"id":"669ac1dac4ec43eeb9f9166023403abc","type":"DISEASE","name":"autosomal dominant pseudohypoaldosteronism type 1","canonical_id":"mondo:0008329","description":null,"metadata":null},{"id":"574d6ddee0604d61a3f510d75d355114","type":"DISEASE","name":"autosomal dominant severe congenital neutropenia","canonical_id":"mondo:0008742","description":null,"metadata":null},{"id":"78cb9c2bd8724e83b916075b45520218","type":"DISEASE","name":"autosomal recessive distal spinal muscular atrophy 2","canonical_id":"mondo:0011585","description":null,"metadata":null},{"id":"4b24b81c13514f9080973ffbaf59ea46","type":"DISEASE","name":"autosomal recessive primary microcephaly","canonical_id":"mondo:0016660","description":null,"metadata":null},{"id":"1046d8e2d1a9408596323c1a85e52bcc","type":"DISEASE","name":"autosomal recessive severe congenital neutropenia due to CSF3R deficiency","canonical_id":"mondo:0014865","description":null,"metadata":null},{"id":"62a2176923f5468d800443b9b3e4df1f","type":"GO_TERM","name":"autosome","canonical_id":"go:GO:0030849","description":"\"Any chromosome other than a sex chromosome.\" [GOC:mah]","metadata":null},{"id":"bbe6fb07fdbe4d7c81800a476db4e85c","type":"GO_TERM","name":"autosome genomic imprinting","canonical_id":"go:GO:0141068","description":"\"The establishment of epigenetic modifications (imprints) in autosomal (non-sexual) chromosomes during gametogenesis, and propagation of these imprints during the organism's life. Genomic imprinting leads to an asymmetry between the maternal and paternal alleles and differential expression of the corresponding alleles. This can happen through heterochromatin formation or differential chromatin loop formation.\" [PMID:31782494]","metadata":null},{"id":"69862fce7c5841bd864a75b30631f7c7","type":"GO_TERM","name":"autotransporter activity","canonical_id":"go:GO:0015474","description":"\"Transports a passenger protein from the periplasm to the external milieu; the passenger protein and the porin are the N- and C-terminal regions of the same protein, respectively.\" [GOC:mtg_transport, ISBN:0815340729, TC:1.B.12.-.-]","metadata":null},{"id":"eb4bc010fb5e4e19ac888f3ef7de4d32","type":"GO_TERM","name":"auxin binding","canonical_id":"go:GO:0010011","description":"\"Binding to auxin, a plant hormone that regulates aspects of plant growth.\" [GOC:sm]","metadata":null},{"id":"864d4d1aa0874ac2b9d3d63bdc3fc617","type":"GO_TERM","name":"auxin biosynthetic process","canonical_id":"go:GO:0009851","description":"\"The chemical reactions and pathways resulting in the formation of auxins, plant hormones that regulate aspects of plant growth.\" [GOC:lm, GOC:lr, ISBN:0122146743]","metadata":null},{"id":"3f3bd16713044ab7ad3cab6b2499245b","type":"GO_TERM","name":"auxin catabolic process","canonical_id":"go:GO:0009852","description":"\"The chemical reactions and pathways resulting in the breakdown of auxins, a group of plant hormones that regulate aspects of plant growth.\" [GOC:lm, GOC:lr, ISBN:0198547684]","metadata":null},{"id":"0c433e1151714ba38145227e106a658e","type":"GO_TERM","name":"auxin conjugate metabolic process","canonical_id":"go:GO:0010249","description":"\"The chemical reactions and pathways involving auxin conjugates, a bound form of auxin.\" [GOC:sm]","metadata":null},{"id":"7b2f3e8719ef42eca624a13c64a83d4f","type":"GO_TERM","name":"auxin efflux carrier complex","canonical_id":"go:GO:0009921","description":"\"The protein complex associated with the plasma membrane of certain plant cells (e.g. root cortex, epidermal cells) that functions to transport auxin out of the cell.\" [PMID:9843496]","metadata":null},{"id":"19438a2960374c90b2ab7522c0d01629","type":"GO_TERM","name":"auxin efflux transmembrane transporter activity","canonical_id":"go:GO:0010329","description":"\"Enables the transfer of auxin, from one side of a membrane to the other, out of a cell.\" [PMID:16839804]","metadata":null},{"id":"70323269b9704d4db0096b0361b10edd","type":"GO_TERM","name":"auxin export across the plasma membrane","canonical_id":"go:GO:0010315","description":"\"The directed movement of auxins from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:tair_curators, PMID:16990790]","metadata":null},{"id":"75fb113bdaa64c6d8d561bf3ecc69013","type":"GO_TERM","name":"auxin import into cell","canonical_id":"go:GO:0060919","description":"\"The directed movement of auxins from outside of a cell into a cell.\" [PMID:22773749]","metadata":null},{"id":"4ddb44a0e2a94953ba07f6d7706a9808","type":"GO_TERM","name":"auxin influx transmembrane transporter activity","canonical_id":"go:GO:0010328","description":"\"Enables the transfer of auxin, from one side of a membrane to the other, into a cell.\" [PMID:16839804]","metadata":null},{"id":"d5047feb917042b4a5cd1e8a09c435e9","type":"GO_TERM","name":"auxin metabolic process","canonical_id":"go:GO:0009850","description":"\"The chemical reactions and pathways involving auxins, a group of plant hormones that regulate aspects of plant growth.\" [GOC:lr]","metadata":null},{"id":"7d64fd815ef34f859216945d719de6e3","type":"GO_TERM","name":"auxin polar transport","canonical_id":"go:GO:0009926","description":"\"The unidirectional movement of auxin in the stem from tip to base along the vector of gravity or basipetally.\" [GOC:sm]","metadata":null},{"id":"6a9410f02b5e45c8af443e99b7f1e7f6","type":"GO_TERM","name":"auxin receptor activity","canonical_id":"go:GO:0038198","description":"\"Combining with auxin and transmitting the signal in the cell to initiate a change in cell activity. Auxin is a plant hormone (phytohormone).\" [GOC:signaling, PMID:15917797]","metadata":null},{"id":"6dc416ea4615489eb37ce2285261265e","type":"GO_TERM","name":"auxin transmembrane transporter activity","canonical_id":"go:GO:0080161","description":"\"Enables the transfer of auxins from one side of a membrane to the other. Auxins are plant hormones that regulate aspects of plant growth.\" [PMID:19506555]","metadata":null},{"id":"82ebf3eefcdf4f4a9a1df2a50d6c2347","type":"GO_TERM","name":"auxin transport","canonical_id":"go:GO:0060918","description":"\"The directed movement of auxin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Auxins are a group of plant hormones that regulates aspects of plant growth.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bdd3a6800630418aa49c51175f980d75","type":"GO_TERM","name":"auxin-activated signaling pathway","canonical_id":"go:GO:0009734","description":"\"The series of molecular signals generated by the binding of the plant hormone auxin to a receptor, and ending with modulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:sm, PMID:16990790, PMID:18647826]","metadata":null},{"id":"167dfe5d15c545bebef029ae5b148b13","type":"GO_TERM","name":"auxin:proton symporter activity","canonical_id":"go:GO:0009672","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: auxin(out) + H+(out) = auxin(in) + H+(in).\" [PMID:8688077]","metadata":null},{"id":"1bea179fbaf546d2ad23c02955e8830e","type":"DRUG","name":"avanafil","canonical_id":"mesh:C553414","description":null,"metadata":null},{"id":"e0b706a7d0bc40988ba95115d15d6eb6","type":"GO_TERM","name":"avascular cornea development in camera-type eye","canonical_id":"go:GO:0036331","description":"\"The progression of an avascular cornea over time, from its formation to the mature structure. Corneal avascularity (the absence of blood vessels in the cornea) is required for optical clarity and optimal vision. Avascular corneas are present in most animals, except Manatees.\" [GOC:uh, PMID:16849433, PMID:17051153]","metadata":null},{"id":"83a928b0999d40bf859368de4bf4c3e9","type":"DRUG","name":"avelumab","canonical_id":"gtopdb:8735","description":null,"metadata":null},{"id":"286eaf81f2ea4f1da8c947da8d647724","type":"DRUG","name":"avelumab","canonical_id":"mesh:C000609138","description":null,"metadata":null},{"id":"b67b7e150c074abfa5431cd2f5cdb84c","type":"DRUG","name":"avelumab","canonical_id":"chembl:CHEMBL3833373","description":null,"metadata":null},{"id":"91cc0ce83a3f4151beecaa9692ccef30","type":"COMBINATION_TREATMENT","name":"avelumab + axitinib","canonical_id":"ctgov_combo:ctgov-combo-91fe20fc0e308d8c","description":null,"metadata":null},{"id":"33916722c80b4328a95a4cb7ee0b1171","type":"COMBINATION_TREATMENT","name":"avelumab + axitinib","canonical_id":"ctgov_combo:ctgov-combo-2d07e3ea2937a30d","description":null,"metadata":null},{"id":"86f2d06d6fa549328783c9b507ba9208","type":"COMBINATION_TREATMENT","name":"avelumab + axitinib + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-0471085eee5218cf","description":null,"metadata":null},{"id":"f9299ff114f7497b9ffbb8adaa6a02b7","type":"COMBINATION_TREATMENT","name":"avelumab + cabozantinib","canonical_id":"ctgov_combo:ctgov-combo-e7c49547629ad12e","description":null,"metadata":null},{"id":"a5a5e50610b54cfa8c1141b56fe584e6","type":"COMBINATION_TREATMENT","name":"avelumab + cetuximab","canonical_id":"ctgov_combo:ctgov-combo-ba33bc3b8c7eeb4e","description":null,"metadata":null},{"id":"c1b563b5b0fe4359979ebdb83ab5b842","type":"COMBINATION_TREATMENT","name":"avelumab + enzalutamide + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-0f827d1fe782c7c1","description":null,"metadata":null},{"id":"9648c5379cc34d0bae7a516059821e03","type":"COMBINATION_TREATMENT","name":"avelumab + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-143fcbfbf1461856","description":null,"metadata":null},{"id":"6b9f6a82570c47568e6c206f30551bbe","type":"COMBINATION_TREATMENT","name":"avelumab + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-d295d4468a667e7e","description":null,"metadata":null},{"id":"332445e70f654ddaa9402b26cf74b169","type":"COMBINATION_TREATMENT","name":"avelumab + ramucirumab","canonical_id":"ctgov_combo:ctgov-combo-81e63797fb13dcfd","description":null,"metadata":null},{"id":"3eafb652ed2a4b1a9f48899d4a30d8f7","type":"COMBINATION_TREATMENT","name":"avelumab + sunitinib","canonical_id":"ctgov_combo:ctgov-combo-20edcd9cb9b72925","description":null,"metadata":null},{"id":"b5d403c2a2e94e4a8dd0747c4160badc","type":"COMBINATION_TREATMENT","name":"avelumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-28b20ae6e9ab9c2b","description":null,"metadata":null},{"id":"e97ebe0cb9bf4931a83fd5a38da5d079","type":"GO_TERM","name":"averantin biosynthetic process","canonical_id":"go:GO:1900763","description":"\"The chemical reactions and pathways resulting in the formation of averantin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"84c2acea10a4495ab82630b8c3127f04","type":"GO_TERM","name":"averantin catabolic process","canonical_id":"go:GO:1900762","description":"\"The chemical reactions and pathways resulting in the breakdown of averantin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"049382df0e7c49888bdfce021a10fbb7","type":"GO_TERM","name":"averantin hydroxylase activity","canonical_id":"go:GO:0140395","description":"\"Catalyzes the reaction: (1'S)-averantin + [reduced NADPH--hemoprotein reductase] + O2 = (1'S,5'S)-5'-hydroxyaverantin + [oxidized NADPH--hemoprotein reductase] + H2O. Involved in aflatoxin biosynthesis.\" [EC:1.14.14.116, PMID:8368836]","metadata":null},{"id":"4e9b4ac5ae7b44d1b88a60b0063dcd31","type":"DRUG","name":"avibactam","canonical_id":"mesh:C543519","description":null,"metadata":null},{"id":"519263c512ec4ca1802ecf5687630827","type":"GO_TERM","name":"axial cellular bud site selection","canonical_id":"go:GO:0007120","description":"\"The process of defining the next site of bud emergence adjacent to the last site of bud emergence on a budding cell.\" [GOC:clt]","metadata":null},{"id":"6e24861ab7df4b7e89825e803d5c8780","type":"GO_TERM","name":"axial mesoderm development","canonical_id":"go:GO:0048318","description":"\"The process whose specific outcome is the progression of the axial mesoderm over time, from its formation to the mature structure. The axial mesoderm includes the prechordal mesoderm and the chordamesoderm. It gives rise to the prechordal plate and to the notochord.\" [GOC:dgh]","metadata":null},{"id":"850eb84dd3bb480fb7839c37e8d015f8","type":"GO_TERM","name":"axial mesoderm formation","canonical_id":"go:GO:0048320","description":"\"The process that gives rise to the axial mesoderm. This process pertains to the initial formation of the structure from unspecified parts.\" [GOC:dgh]","metadata":null},{"id":"5e1965e1619f4754ac21502808017f6b","type":"GO_TERM","name":"axial mesoderm morphogenesis","canonical_id":"go:GO:0048319","description":"\"The process in which the anatomical structures of the axial mesoderm are generated and organized.\" [GOC:curators]","metadata":null},{"id":"d4e1539063f84b7db91734115d1190ad","type":"GO_TERM","name":"axial mesoderm structural organization","canonical_id":"go:GO:0048331","description":"\"The process that contributes to the act of creating the structural organization of the axial mesoderm. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dgh]","metadata":null},{"id":"7184bc44b6ad40f3bc22f10336a4a1a7","type":"GO_TERM","name":"axial mesodermal cell differentiation","canonical_id":"go:GO:0048321","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an axial mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"72af17ee13ae45d187e7753b5f27e273","type":"GO_TERM","name":"axial mesodermal cell fate commitment","canonical_id":"go:GO:0048322","description":"\"The process in which a cell becomes committed to become an axial mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"8eb88359ee67423bbe480c52745e7a51","type":"GO_TERM","name":"axial mesodermal cell fate determination","canonical_id":"go:GO:0048323","description":"\"The process in which a cell becomes capable of differentiating autonomously into an axial mesoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:dgh]","metadata":null},{"id":"fccdd02647b94fa5a43d1dbf03525033","type":"GO_TERM","name":"axial mesodermal cell fate specification","canonical_id":"go:GO:0048327","description":"\"The process in which a cell becomes capable of differentiating autonomously into an axial mesoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dgh]","metadata":null},{"id":"ae43faaaa99a4629a345eef69748e789","type":"GO_TERM","name":"axillary shoot meristem initiation","canonical_id":"go:GO:0090506","description":"\"A developmental process that results in the initiation of an axillary shoot meristem. An axillary shoot meristem is a shoot meristem formed in the axil of a leaf.\" [GOC:tb]","metadata":null},{"id":"ceef79c958bd4edc98d837077a047a4a","type":"GO_TERM","name":"axis elongation","canonical_id":"go:GO:0003401","description":"\"The developmental growth that results in the elongation of a line that defines polarity or symmetry in an anatomical structure.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"e1f20cbbcb604adeb9b0727854544247","type":"GO_TERM","name":"axis elongation involved in somitogenesis","canonical_id":"go:GO:0090245","description":"\"The developmental growth that results in the elongation of the rostral-caudal axis that contributes to somitogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b7e3d753f28c4f2c8de070aed9157174","type":"GO_TERM","name":"axis specification","canonical_id":"go:GO:0009798","description":"\"The establishment, maintenance and elaboration of a pattern along a line or around a point.\" [GOC:curators, GOC:dph, GOC:isa_complete]","metadata":null},{"id":"adad6d7156fc4e5a8f2804b516684fa5","type":"DRUG","name":"axitinib","canonical_id":"gtopdb:5659","description":null,"metadata":null},{"id":"e36d75801e264bfc80bdf45f494f069f","type":"DRUG","name":"axitinib","canonical_id":"chembl:CHEMBL1289926","description":null,"metadata":null},{"id":"89319609684e482488ebf09e382152e6","type":"COMBINATION_TREATMENT","name":"axitinib + binimetinib","canonical_id":"ctgov_combo:ctgov-combo-20bfc72843c0b0a9","description":null,"metadata":null},{"id":"d6f75d209b2c4f058cd4c46f371da9e3","type":"COMBINATION_TREATMENT","name":"axitinib + binimetinib + enfortumab vedotin + lorlatinib + sacituzumab govitecan + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-8bb10db7f0095b24","description":null,"metadata":null},{"id":"d3b35d85899349f786a80ac940d4a127","type":"COMBINATION_TREATMENT","name":"axitinib + bosutinib + cobimetinib + crizotinib + dasatinib + erlotinib + ipilimumab + olaparib + palbociclib + pertuzumab + sunitinib + temsirolimus + tucatinib + vemurafenib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-918f063c6e6210b6","description":null,"metadata":null},{"id":"1bbb8ee1206148a3b7f7bae1ff092398","type":"COMBINATION_TREATMENT","name":"axitinib + cabozantinib + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-14a9eaca2052db1d","description":null,"metadata":null},{"id":"ae53fd37ba3a435eaa35c7848928197b","type":"COMBINATION_TREATMENT","name":"axitinib + crizotinib + palbociclib + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-b52cb8ca39df4f49","description":null,"metadata":null},{"id":"f02a824c44c043928ef93f27e0a09a20","type":"COMBINATION_TREATMENT","name":"axitinib + envafolimab","canonical_id":"ctgov_combo:ctgov-combo-3814395db247226e","description":null,"metadata":null},{"id":"0be39725a3024c0bae035acb8729291d","type":"COMBINATION_TREATMENT","name":"axitinib + everolimus + fruquintinib + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-ba566efc74cbf01c","description":null,"metadata":null},{"id":"7595f190f41f4dfdb089f2f9b90f89eb","type":"COMBINATION_TREATMENT","name":"axitinib + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-4168feab060676f8","description":null,"metadata":null},{"id":"02d2c336c5c64be99bf57790eb98a8e0","type":"COMBINATION_TREATMENT","name":"axitinib + sunitinib","canonical_id":"ctgov_combo:ctgov-combo-f77756b6dad92f5e","description":null,"metadata":null},{"id":"5fc5e6da495c4cf7a458d41437ad0253","type":"GO_TERM","name":"axo-dendritic protein transport","canonical_id":"go:GO:0099640","description":"\"The directed movement of proteins along microtubules in neuron projections.\" [ISBN:0815316194]","metadata":null},{"id":"373a0126e1314cc6a1bbfc0afd0003c8","type":"GO_TERM","name":"axo-dendritic transport","canonical_id":"go:GO:0008088","description":"\"The directed movement of organelles or molecules along microtubules in neuron projections.\" [ISBN:0815316194]","metadata":null},{"id":"7fcdb609aa8c4777968012a0ae9351a0","type":"GO_TERM","name":"axolemma","canonical_id":"go:GO:0030673","description":"\"The portion of the plasma membrane surrounding an axon; it is a specialized trilaminar random mosaic of protein molecules floating within a fluid matrix of highly mobile phospholipid molecules, 7-8 nm in thickness.\" [PMID:9527135]","metadata":null},{"id":"39bac571ef894885905b07bf8e4e7eb4","type":"GO_TERM","name":"axon","canonical_id":"go:GO:0030424","description":"\"The long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminals and varicosities, which are sites of storage and release of neurotransmitter.\" [GOC:nln, ISBN:0198506732]","metadata":null},{"id":"85838bff47554d95bf48bd4a7c324a59","type":"GO_TERM","name":"axon arborization","canonical_id":"go:GO:0140060","description":"\"The process in which the terminal anatomical structures of an axon are generated and organized into branches of specialised projections, or boutons. An axon is the long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminal branches.\" [GOC:aruk, GOC:bc, PMID:23764288]","metadata":null},{"id":"ad1f94d2eb524342941dec2e6d669f3d","type":"GO_TERM","name":"axon choice point recognition","canonical_id":"go:GO:0016198","description":"\"The recognition of molecules at a choice point by an axon growth cone; at a choice point the growth cone determines the direction of its future growth.\" [PMID:10218152]","metadata":null},{"id":"88a3fe42a04d43c684afebe76611549c","type":"GO_TERM","name":"axon collateral","canonical_id":"go:GO:0044303","description":"\"Any of the smaller branches of an axon that emanate from the main axon cylinder.\" [NIF_Subcellular:sao1470140754]","metadata":null},{"id":"6a95e035921e4c62ab50e00c536d2168","type":"GO_TERM","name":"axon cytoplasm","canonical_id":"go:GO:1904115","description":"\"Any cytoplasm that is part of a axon.\" [GO_REF:0000064, GOC:TermGenie, PMID:18667152]","metadata":null},{"id":"bd4bfe5ee5f84fbf9c1dc85f42a94033","type":"GO_TERM","name":"axon development","canonical_id":"go:GO:0061564","description":"\"The progression of an axon over time. Covers axonogenesis (de novo generation of an axon) and axon regeneration (regrowth), as well as processes pertaining to the progression of the axon over time (fasciculation and defasciculation).\" [GOC:dph, GOC:pg, GOC:pr]","metadata":null},{"id":"12359a2b5aa14307b916e8709852fe17","type":"GO_TERM","name":"axon ensheathment","canonical_id":"go:GO:0008366","description":"\"Any process in which the axon of a neuron is insulated, and that insulation maintained, thereby preventing dispersion of the electrical signal.\" [GOC:jl, ISBN:0878932437]","metadata":null},{"id":"0253a7bd3e224b0b860457c49fae8bfa","type":"GO_TERM","name":"axon ensheathment in central nervous system","canonical_id":"go:GO:0032291","description":"\"The process in which a glial cell membrane closes around an axon in the central nervous system. This can be a myelinating or a non-myelinating neuron-glial interaction.\" [GOC:dgh]","metadata":null},{"id":"f6b460f0c2094333a87773df5304069f","type":"GO_TERM","name":"axon extension","canonical_id":"go:GO:0048675","description":"\"Long distance growth of a single axon process involved in cellular development.\" [GOC:BHF, GOC:dgh, GOC:dph, GOC:jid, GOC:lm, GOC:rl]","metadata":null},{"id":"e3488bdbac624057a30a6b0684892f1e","type":"GO_TERM","name":"axon extension involved in axon guidance","canonical_id":"go:GO:0048846","description":"\"The long distance growth of a single cell process, that is involved in the migration of an axon growth cone, where the migration is directed to a specific target site by a combination of attractive and repulsive cues.\" [GOC:ef, GOC:jid]","metadata":null},{"id":"79c0c1bceb28495887cd78c4694c0731","type":"GO_TERM","name":"axon extension involved in regeneration","canonical_id":"go:GO:0048677","description":"\"Long distance growth of a single axon process involved in regeneration of the neuron.\" [GOC:jid]","metadata":null},{"id":"5831d24440f74e61aef7d4f8b2c73e0d","type":"GO_TERM","name":"axon guidance","canonical_id":"go:GO:0007411","description":"\"The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.\" [ISBN:0878932437]","metadata":null},{"id":"89f4d2211ab94360af0254b079cb106c","type":"GO_TERM","name":"axon guidance receptor activity","canonical_id":"go:GO:0008046","description":"\"Combining with an extracellular messenger and transmitting the signal from one side of the membrane to the other to results in a change in cellular activity involved in axon guidance.\" [GOC:dph, GOC:signaling, GOC:tb, PMID:15107857, PMID:15339666]","metadata":null},{"id":"d196a3af7ba84a41ae600f827747bbfc","type":"GO_TERM","name":"axon hillock","canonical_id":"go:GO:0043203","description":"\"Portion of the neuronal cell soma from which the axon originates.\" [GOC:nln]","metadata":null},{"id":"fd0a667a93fc48fa952ca117a028eccb","type":"GO_TERM","name":"axon initial segment","canonical_id":"go:GO:0043194","description":"\"Portion of the axon proximal to the neuronal cell body, at the level of the axon hillock. The action potentials that propagate along the axon are generated at the level of this initial segment.\" [GOC:nln, GOC:sl, PMID:1754851, PMID:21551097]","metadata":null},{"id":"9f7a47b1bdbe4ea3904a1e2885587185","type":"GO_TERM","name":"axon microtubule bundle","canonical_id":"go:GO:1901589","description":"\"An arrangement of closely apposed microtubules running parallel to each other in the axon hillock and initial segment.\" [GOC:TermGenie, NIF_Subcellular:sao707332678]","metadata":null},{"id":"040c5f9710f94210b744f8cdacc4a487","type":"GO_TERM","name":"axon midline choice point recognition","canonical_id":"go:GO:0016199","description":"\"The recognition of molecules at the central nervous system midline choice point by an axon growth cone; this choice point determines whether the growth cone will cross the midline.\" [PMID:11376484]","metadata":null},{"id":"a24ec3700f5a4c7890c3e2aa30844922","type":"GO_TERM","name":"axon regeneration","canonical_id":"go:GO:0031103","description":"\"The regrowth of axons following their loss or damage.\" [GOC:dgh, GOC:dph, GOC:tb]","metadata":null},{"id":"8d4b54cf02ac4ea284d9d2daf0daa99e","type":"GO_TERM","name":"axon regeneration at neuromuscular junction","canonical_id":"go:GO:0014814","description":"\"The regrowth of axons following their loss or damage at the neuromuscular junction. Motor axons regenerate after injury and they form neuro-muscular junctions with skeletal myofibers similar to normal ones.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"053b2c969acf418c84839293c11d2660","type":"GO_TERM","name":"axon target recognition","canonical_id":"go:GO:0007412","description":"\"The process in which an axon recognizes and binds to a set of cells with which it may form stable connections.\" [ISBN:0878932437]","metadata":null},{"id":"f037cb5968d54e3092792f8ac934bc09","type":"GO_TERM","name":"axon terminus","canonical_id":"go:GO:0043679","description":"\"Terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters. The axon terminus is considered to be the whole region of thickening and the terminal button is a specialized region of it.\" [GOC:dph, GOC:jl]","metadata":null},{"id":"20b29a7911e94da1b7379c1a32262e71","type":"GO_TERM","name":"axonal defasciculation","canonical_id":"go:GO:0007414","description":"\"Separation of axons away from a bundle of axons known as a fascicle.\" [GOC:dgh, ISBN:039751820X]","metadata":null},{"id":"da8ec84907bd4b86a191517fba1c9c03","type":"GO_TERM","name":"axonal dopamine secretion","canonical_id":"go:GO:0099124","description":"\"The regulated release of dopamine from an axon.\" [GOC:bf, GOC:PARL, PMID:21576241]","metadata":null},{"id":"865b5c7eb9b5400a875d058f0f22d0ac","type":"GO_TERM","name":"axonal fasciculation","canonical_id":"go:GO:0007413","description":"\"The collection of axons into a bundle of rods, known as a fascicle.\" [GOC:dgh]","metadata":null},{"id":"7de3b40ecdfa4738ac061f8e2f2188c2","type":"GO_TERM","name":"axonal growth cone","canonical_id":"go:GO:0044295","description":"\"The migrating motile tip of a growing nerve cell axon.\" [GOC:jl, NIF_Subcellular:sao203987954]","metadata":null},{"id":"9837fc4712b14d9d832e184fc20476ed","type":"GO_TERM","name":"axonal spine","canonical_id":"go:GO:0044308","description":"\"A spine that originates from the axon, usually from the initial segment.\" [NIF_Subcellular:sao18239917]","metadata":null},{"id":"974878db3f764478a87fe11f38e99164","type":"GO_TERM","name":"axonal transport","canonical_id":"go:GO:0098930","description":"\"The directed movement of organelles or molecules along microtubules in axons.\" [ISBN:0815316194]","metadata":null},{"id":"c6d943b8aa564ee780a1fcdf9e6fc394","type":"GO_TERM","name":"axonal transport of messenger ribonucleoprotein complex","canonical_id":"go:GO:0099088","description":"\"The directed movement of a messenger ribonucleoprotein complex along microtubules in axons.\" [GOC:dos, PMID:26586091]","metadata":null},{"id":"91d2c374efa44c5e82099f474b6e37bf","type":"GO_TERM","name":"axonal transport of mitochondrion","canonical_id":"go:GO:0019896","description":"\"The directed movement of mitochondria along microtubules in nerve cell axons.\" [GOC:ai]","metadata":null},{"id":"9932f65a778d4db9bc6e527388abf657","type":"GO_TERM","name":"axonemal A tubule inner sheath","canonical_id":"go:GO:0160111","description":"\"A structural network of microtubule inner proteins (MIPs) located inside the lumen of the A tubule of the axonemal microtubule doublet that helps stabilize the A tubule.\" [GOC:krc, PMID:29430673, PMID:37295417]","metadata":null},{"id":"d87e10013fed441794117912725e1fa1","type":"GO_TERM","name":"axonemal B tubule inner sheath","canonical_id":"go:GO:0160112","description":"\"A structural network of microtubule inner proteins (MIPs) located inside the lumen of the B tubule of the axonemal microtubule doublet that helps stabilize the B tubule.\" [GOC:krc, PMID:29430673, PMID:37295417]","metadata":null},{"id":"80dfbcbfbda1434c8e5e2326a9639b85","type":"GO_TERM","name":"axonemal basal plate","canonical_id":"go:GO:0097541","description":"\"Part of the axoneme consisting of a highly electron-dense region at the distal end of the ciliary transition zone within the axonemal lumen at which the axonemal central pair of microtubules is connected to the rest of the axonemal structure.\" [GOC:cilia, PMID:23352055, PMID:4554367]","metadata":null},{"id":"49960e739afc4f4386350b8a3110c1d9","type":"GO_TERM","name":"axonemal basal plate assembly","canonical_id":"go:GO:0062235","description":"\"The aggregation, arrangement and bonding together of a set of components to form an axonemal basal plate.\" [PMID:23352055, PMID:30810527]","metadata":null},{"id":"0052bb2bc5b34c959abeb2f017b91bcb","type":"GO_TERM","name":"axonemal central apparatus","canonical_id":"go:GO:1990716","description":"\"Part of the 9+2 axoneme, that occurs in most motile cilia, consisting of the pair of two single central microtubules and their associated structures which include the central pair projections, the central pair bridges linking the two tubules, and the central pair caps which are attached to the distal or plus ends of the microtubules.\" [GOC:cilia, PMID:21586547, PMID:9295136]","metadata":null},{"id":"be8ac54873f74bf5825fcff8fe0ac86a","type":"GO_TERM","name":"axonemal central apparatus assembly","canonical_id":"go:GO:1904158","description":"\"The aggregation, arrangement and bonding together of a set of components to form an axonemal central apparatus.\" [GO_REF:0000079, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:9295136]","metadata":null},{"id":"0c904414a91d4380acb6b588fc1ea5b2","type":"GO_TERM","name":"axonemal central bridge","canonical_id":"go:GO:1990717","description":"\"Part of the 9+2 axoneme, that occurs in most motile cilia, consisting of the two bridges which connect the central pair of single microtubules.\" [GOC:cilia, PMID:21586547, PMID:9295136]","metadata":null},{"id":"35f91c6008934de4b77f37b8a32648db","type":"GO_TERM","name":"axonemal central pair","canonical_id":"go:GO:0097540","description":"\"Part of the axoneme consisting of the inner two microtubule doublets of the 9+2 axoneme occurring in most motile cilia.\" [GOC:cilia, GOC:krc, PMID:24283352]","metadata":null},{"id":"76df449a08724bb5a7001215481d4e77","type":"GO_TERM","name":"axonemal central pair projection","canonical_id":"go:GO:1990718","description":"\"Part of the 9+2 axoneme, that occurs in most motile cilia, consisting of the projections off of the central pair of single microtubules.\" [GOC:cilia, PMID:21586547, PMID:9295136]","metadata":null},{"id":"5963950c3ae4451e8ef4d4c11dc84739","type":"GO_TERM","name":"axonemal doublet microtubule","canonical_id":"go:GO:0097545","description":"\"A cellular anatomical entity that is part of an axoneme consisting of a doublet microtubule.\" [GOC:cilia, GOC:krc, GOC:pr, https://github.com/geneontology/go-ontology/issues/26128, PMID:5044758, PMID:5664206, Wikipedia:Axoneme]","metadata":null},{"id":"157dd65cf21a4547b40a1d958485bc21","type":"GO_TERM","name":"axonemal dynein complex","canonical_id":"go:GO:0005858","description":"\"A dynein complex found in eukaryotic cilia and flagella; the motor domain heads interact with adjacent microtubules to generate a sliding force which is converted to a bending motion.\" [GOC:cilia, GOC:hla, GOC:krc, ISBN:0815316194]","metadata":null},{"id":"f172b36f167c4233ae7a4775732b4d21","type":"GO_TERM","name":"axonemal dynein complex assembly","canonical_id":"go:GO:0070286","description":"\"The aggregation, arrangement and bonding together of a set of components to form an axonemal dynein complex, a dynein complex found in eukaryotic cilia and flagella, in which the motor domain heads interact with adjacent microtubules to generate a sliding force which is converted to a bending motion.\" [GOC:cilia, GOC:mah, PMID:19052621]","metadata":null},{"id":"fc8f8a9dacf445fb86d657b0c49794d5","type":"GO_TERM","name":"axonemal heterotrimeric kinesin-II complex","canonical_id":"go:GO:0030993","description":"\"A kinesin complex found in eukaryotic axonemes that contains two distinct plus end-directed kinesin motor proteins and at least one accessory subunit, and that functions in the anterograde transport of molecules (cargo) from the basal body to the distal tip of the axoneme.\" [GOC:kmv, PMID:14570576]","metadata":null},{"id":"ab87641b44df4c7bb7802099f0749814","type":"GO_TERM","name":"axonemal microtubule","canonical_id":"go:GO:0005879","description":"\"A microtubule in the axoneme of a eukaryotic cilium or flagellum; an axoneme contains nine modified doublet microtubules, which may or may not surround a pair of single microtubules.\" [GOC:cilia, ISBN:0815316194]","metadata":null},{"id":"78e83e8412a343db9bd2e08c14327b9a","type":"GO_TERM","name":"axonemal microtubule depolymerization","canonical_id":"go:GO:0060404","description":"\"The removal of tubulin heterodimers from one or both ends of an axonemal microtubule. An axonemal microtubule is a microtubule in the axoneme of a cilium or flagellum; an axoneme contains nine modified doublet microtubules surrounding a pair of single microtubules.\" [GOC:cilia, GOC:dph, GOC:krc, GOC:tb]","metadata":null},{"id":"5b7cd19bd924462eb37d9cd8cd806474","type":"GO_TERM","name":"axonemal microtubule doublet inner junction","canonical_id":"go:GO:0160113","description":"\"The structure which joins the B10 protofilament of the B tubule to the A1 protofilament of the A tubule within an axonemal microtubule doublet.\" [GOC:krc, PMID:29430673, PMID:37295417]","metadata":null},{"id":"238d73313c36446c86cc6aba106f473f","type":"GO_TERM","name":"axonemal microtubule doublet inner sheath","canonical_id":"go:GO:0160110","description":"\"A structural network of microtubule inner proteins (MIPs) located inside the lumens of the A and B tubules of the axonemal microtuble doublet that helps stabilize the doublet microtubule.\" [GOC:krc, PMID:29430673, PMID:37295417]","metadata":null},{"id":"c4803be73d8e4fed83f090d067994b65","type":"GO_TERM","name":"axonemal microtubule doublet outer junction","canonical_id":"go:GO:0160114","description":"\"The structure which joins the B1 protofilament of the B tubule to the A10 and A11 protofilaments of the A tubule within an axonemal microtubule doublet.\" [GOC:krc, PMID:29430673, PMID:37295417]","metadata":null},{"id":"094a9f050ed9411ca36a7ac73d9f3608","type":"GO_TERM","name":"axonemal microtubule doublet ribbon","canonical_id":"go:GO:0160115","description":"\"The 3 protofilaments A11, A12, and A13 of the A tubule along with associated inner sheath microtuble inner proteins (MIPs), either in the lumen of the A tubule or of the B tubule, which stabilize these three filiments within the axonemal doublet microtubule. The ribbon protofilaments separate the lumens of the A and B tubules.\" [GOC:krc, PMID:1262413, PMID:29430673]","metadata":null},{"id":"fcba349ada8e41c0bcd945027ea7ef61","type":"GO_TERM","name":"axonemal nexin link","canonical_id":"go:GO:0005931","description":"\"A protein complex found in the axoneme of eukaryotic cilia and flagella. It forms interconnections between the microtubule outer doublets that surround the inner central pair of microtubules.\" [GOC:cilia, GOC:krc, ISBN:0198506732, PMID:21586547, PMID:21728999, PMID:22683354, PMID:9295136]","metadata":null},{"id":"296d37dff0c3483082633e8b6ccbe178","type":"GO_TERM","name":"axonemal outer doublet assembly","canonical_id":"go:GO:0120308","description":"\"The aggregation, arrangement and bonding together of a set of components to form an axonemal outer doublet, a part of an axoneme consisting of a doublet microtubule.\" [GOC:ach, GOC:krc, PMID:16278296]","metadata":null},{"id":"e2889e4b43ec4cd0a24ccc951f508d69","type":"GO_TERM","name":"axoneme","canonical_id":"go:GO:0005930","description":"\"The bundle of microtubules and associated proteins that forms the core of cilia (also called flagella) in eukaryotic cells and is responsible for their movements.\" [GOC:bf, GOC:cilia, ISBN:0198547684]","metadata":null},{"id":"a9994151b169484d8c83fedc8ead0e98","type":"GO_TERM","name":"axoneme assembly","canonical_id":"go:GO:0035082","description":"\"The assembly and organization of an axoneme, the bundle of microtubules and associated proteins that forms the core of cilia (also called flagella) in eukaryotic cells and is responsible for their movements.\" [GOC:bf, GOC:cilia, GOC:jl, ISBN:0815316194]","metadata":null},{"id":"042f6762d8c84e0787c4457c8653a969","type":"GO_TERM","name":"axonogenesis","canonical_id":"go:GO:0007409","description":"\"De novo generation of a long process of a neuron, including the terminal branched region. Refers to the morphogenesis or creation of shape or form of the developing axon, which carries efferent (outgoing) action potentials from the cell body towards target cells.\" [GOC:dph, GOC:jid, GOC:pg, GOC:pr, ISBN:0198506732]","metadata":null},{"id":"de46b7c733bc41748088fa9034e1c8be","type":"GO_TERM","name":"axonogenesis involved in innervation","canonical_id":"go:GO:0060385","description":"\"The neurite development process that generates a long process of a neuron, as it invades a target tissue.\" [GOC:dph, GOC:sart]","metadata":null},{"id":"473094ad78164887a125defcc9fca03e","type":"DRUG","name":"azatadine","canonical_id":"mesh:C006656","description":null,"metadata":null},{"id":"6bd18a371925424b9fafa623eb6b10d5","type":"DRUG","name":"azelaic acid","canonical_id":"mesh:C010038","description":null,"metadata":null},{"id":"d099852201bd4a4199ab2bdb2cd3461f","type":"DRUG","name":"azelastine","canonical_id":"gtopdb:7121","description":null,"metadata":null},{"id":"562a526dc03849ce9fe16c477f0f1721","type":"DRUG","name":"azelastine","canonical_id":"mesh:C020976","description":null,"metadata":null},{"id":"16f73d412b444509b185ea8f6c5e8348","type":"COMBINATION_TREATMENT","name":"azelastine + budesonide + montelukast","canonical_id":"ctgov_combo:ctgov-combo-72d3df22e18726f9","description":null,"metadata":null},{"id":"9dc42a5de09f437cb0f568f7339aecca","type":"COMBINATION_TREATMENT","name":"azelastine + ciclesonide","canonical_id":"ctgov_combo:ctgov-combo-6c1e1bc4baa8da4a","description":null,"metadata":null},{"id":"fdbdbfcafc25496abfd945736dd81bae","type":"COMBINATION_TREATMENT","name":"azelastine + epinastine","canonical_id":"ctgov_combo:ctgov-combo-1be8c9d4eef02339","description":null,"metadata":null},{"id":"8e036349188c47b1a289246e104c2c50","type":"COMBINATION_TREATMENT","name":"azelastine + epinastine","canonical_id":"ctgov_combo:ctgov-combo-0171f499e65bc61f","description":null,"metadata":null},{"id":"9822506e76664d1e80bb3b311c6fa953","type":"COMBINATION_TREATMENT","name":"azelastine + fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-9dbc7bfacb566cc4","description":null,"metadata":null},{"id":"7fbacc56e74c462a924544cacf682345","type":"COMBINATION_TREATMENT","name":"azelastine + fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-3234720eb8605ad5","description":null,"metadata":null},{"id":"2e6f932a370b401d8902904865250ef7","type":"COMBINATION_TREATMENT","name":"azelastine + fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-7854d5f4eea440c0","description":null,"metadata":null},{"id":"b19317b63ef645feb579d80104b580db","type":"COMBINATION_TREATMENT","name":"azelastine + mometasone","canonical_id":"ctgov_combo:ctgov-combo-d4ab95f0178e2e92","description":null,"metadata":null},{"id":"b905c4c787b843dc81cfc9854876804b","type":"COMBINATION_TREATMENT","name":"azelastine + mometasone","canonical_id":"ctgov_combo:ctgov-combo-825f371751fde0aa","description":null,"metadata":null},{"id":"2e624faf0a8e433d95ba220804f0e68d","type":"COMBINATION_TREATMENT","name":"azelastine + rupatadine","canonical_id":"ctgov_combo:ctgov-combo-60bb3521ecbd4aa6","description":null,"metadata":null},{"id":"968db25dba7248c89ba011188c78dcbe","type":"DRUG","name":"azelnidipine","canonical_id":"mesh:C061679","description":null,"metadata":null},{"id":"bbd7c99a3f114ac692989af38e2417da","type":"GO_TERM","name":"azetidine-2-carboxylic acid acetyltransferase activity","canonical_id":"go:GO:0046941","description":"\"Catalysis of the reaction: L-azetidine-2-carboxylic acid + acetyl-CoA = CoA-SH + N-acetyl azetidine-2-carboxylic acid.\" [PMID:12761200]","metadata":null},{"id":"e5d66143a137489384db785ad10420e9","type":"DRUG","name":"azidocillin","canonical_id":"mesh:C100243","description":null,"metadata":null},{"id":"06ad58ad4aae4f018c466eff29dc762a","type":"DRUG","name":"azithromycin","canonical_id":"mesh:D017963","description":null,"metadata":null},{"id":"31a7501d163a43cba8b3d34e3c616827","type":"GO_TERM","name":"azobenzene reductase (NADP+) activity","canonical_id":"go:GO:0050446","description":"\"Catalysis of the reaction: aniline + N,N-dimethyl-1,4-phenylenediamine + 2 NADP+ = 4-(dimethylamino)azobenzene + 2 H+ + 2 NADPH.\" [RHEA:16269]","metadata":null},{"id":"4008a5508e704737aef278f5955b43c8","type":"GO_TERM","name":"azole transmembrane transport","canonical_id":"go:GO:0045117","description":"\"The directed movement of azoles, heterocyclic compounds found in many biologically important substances, across a lipid bilayer, across a membrane.\" [GOC:curators, ISBN:3527307206, Wikipedia:Azole]","metadata":null},{"id":"0de9e48d3f1f4c87b4d872741fcff064","type":"GO_TERM","name":"azole transmembrane transporter activity","canonical_id":"go:GO:1901474","description":"\"Enables the directed movement of azoles, heterocyclic compound found in many biologically important substances, from one side of a membrane to the other.\" [GOC:curators, ISBN:3527307206, Wikipedia:Azole]","metadata":null},{"id":"aaff927996e34b26a6af15ace1ceafc2","type":"GO_TERM","name":"azole:proton antiporter activity","canonical_id":"go:GO:0045119","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + azole(in) = H+(in) + azole(out). Azoles are heterocyclic compounds found in many biologically important substances.\" [GOC:ai, ISBN:3527307206, Wikipedia:Azole]","metadata":null},{"id":"14f8e2c20a8f42bd856cf440861b0c8d","type":"DRUG","name":"azosemide","canonical_id":"mesh:C018222","description":null,"metadata":null},{"id":"83770057459a41858239925f9d467196","type":"GO_TERM","name":"azurophil granule","canonical_id":"go:GO:0042582","description":"\"Primary lysosomal granule readily stainable with a Romanowsky stain.\" [GOC:jl, PMID:17152095, PMID:28717070, PMID:5914694, WIKIPEDIA:Azurophilic_granule]","metadata":null},{"id":"8a89ac418bc34c37b27a5f98b9a8a110","type":"GO_TERM","name":"azurophil granule lumen","canonical_id":"go:GO:0035578","description":"\"The volume enclosed by the membrane of an azurophil granule, a primary lysosomal granule found in neutrophil granulocytes that contains a wide range of hydrolytic enzymes and is released into the extracellular fluid.\" [GOC:bf, PMID:17152095]","metadata":null},{"id":"4f7c584300754b379b26120cea23cd75","type":"GO_TERM","name":"azurophil granule membrane","canonical_id":"go:GO:0035577","description":"\"The lipid bilayer surrounding an azurophil granule, a primary lysosomal granule found in neutrophil granulocytes that contains a wide range of hydrolytic enzymes and is released into the extracellular fluid.\" [GOC:bf, PMID:17152095]","metadata":null},{"id":"c18d33f8751e409da5b815673fe928ac","type":"GO_TERM","name":"bBAF complex","canonical_id":"go:GO:0140092","description":"\"A brain-specific SWI/SNF-type complex that contains eight or nine proteins, including both conserved (core) and nonconserved components; contains the ATPase product of either the SMARCA4/BAF190A/BRG1 gene, the mammalian ortholog of the yeast SNF2 gene, or the SMARCA2/BAF190B/BRM gene, the mammalian ortholog of the Drosophila brm (brahma) gene, or an ortholog of either of these genes. Compared to the neuron-specific nBAF complex (GO:0071565) it does not contain DPF1, DPF3 or SMARCC1 or their orthologs. May contain PB1/BAF180.\" [GOC:bhm, PMID:12368262, PMID:12620226, PMID:15525990, PMID:17640523, PMID:17920018, PMID:8804307, PMID:8895581]","metadata":null},{"id":"3233622e83334d538700d71c553129ea","type":"GO_TERM","name":"bHLH transcription factor binding","canonical_id":"go:GO:0043425","description":"\"Binding to a basic Helix-Loop-Helix (bHLH) superfamily of transcription factors, important regulatory components in transcriptional networks of many developmental pathways.\" [PMID:9144210]","metadata":null},{"id":"22f38f3c06cd4a2798bb8dd6495e9d95","type":"GO_TERM","name":"bI3 intron splicing complex","canonical_id":"go:GO:0106392","description":"\"Aprotein complex required for the splicing of intron 3 of the cytochrome b (COB) gene. In S. cerevisiae, the complex contains the maturase bI3 (which derives from one of the products of the splicing), the MRS1 cofactor and the intron 4 of the cytochrome b pre-mRNA. The two proteins stimulate the ribozyme activity of the pre-mRNA which autoctalyse a group I intron splicing.\" [GOC:lnp, PMID:11773622]","metadata":null},{"id":"8d7974642578428982b1b48ff3253ec5","type":"GO_TERM","name":"bI4 intron splicing complex","canonical_id":"go:GO:0106391","description":"\"A protein complex required for the splicing of intron 4 of the cytochrome b (COB) gene. In S. cerevisiae, the complex contains the maturase bI4 (which derives from one of the products of the splicing), Leucyl-tRNA synthetase NAM2 and the intron 4 of the cytochrome b pre-mRNA. The two proteins stimulate the ribozyme activity of the pre-mRNA which autoctalyse a group I intron splicing.\" [GOC:lnp, PMID:19622748]","metadata":null},{"id":"9a7a54516e974feb8c6241b1dd86fadd","type":"GO_TERM","name":"bacillithiol biosynthetic process","canonical_id":"go:GO:0071793","description":"\"The chemical reactions and pathways resulting in the formation of bacillithiol, the alpha-anomeric glycoside of L-cysteinyl-D-glucosamine with L-malic acid. Bacillithiol, produced widely in the Firmicutes and sporadically in other bacterial lineages, is a low-molecular-weight thiol analogous to mycothiol in the Actinomycetes and glutathione in many species.\" [GOC:dh, PMID:20308541]","metadata":null},{"id":"393e272e8d194a35b50ab7265e79f43b","type":"DRUG","name":"bacitracin","canonical_id":"mesh:D001414","description":null,"metadata":null},{"id":"b9f43653c5dd4df99cc4101ca2b68f66","type":"GO_TERM","name":"bacitracin A biosynthetic process","canonical_id":"go:GO:1901124","description":"\"The chemical reactions and pathways resulting in the formation of bacitracin A.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00179]","metadata":null},{"id":"634b10ada1b64cdfa0f7b4a97a4b8f38","type":"GO_TERM","name":"bacitracin A catabolic process","canonical_id":"go:GO:1901123","description":"\"The chemical reactions and pathways resulting in the breakdown of bacitracin A.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00179]","metadata":null},{"id":"d734c847f7074a4483b1fd8b26402ad1","type":"GO_TERM","name":"background adaptation","canonical_id":"go:GO:0120302","description":"\"Any process in which an organism changes its pigmentation (lightening in response to a brighter environment or darkening in response to a dimmer environment) in response to a change in light intensity.\" [GOC:cvs, GOC:krc, PMID:10493760, PMID:29239123, PMID:32898924]","metadata":null},{"id":"378d6b13d0c34f6bb6a707412687e930","type":"GO_TERM","name":"backward locomotion","canonical_id":"go:GO:0043057","description":"\"Posterior movement of an organism, e.g. following the direction of the tail of an animal.\" [GOC:curators]","metadata":null},{"id":"e381a40502224b72827baa07a4dbe2d4","type":"DRUG","name":"baclofen","canonical_id":"gtopdb:1084","description":null,"metadata":null},{"id":"fbc49d54fbc84717a75894102e2dc716","type":"DRUG","name":"baclofen","canonical_id":"chembl:CHEMBL701","description":null,"metadata":null},{"id":"76d9d0b2247b4c86bd8f7bdba57c74d1","type":"COMBINATION_TREATMENT","name":"baclofen + cyproheptadine","canonical_id":"ctgov_combo:ctgov-combo-637a532b294d2fc9","description":null,"metadata":null},{"id":"f04d1eaee22a4815904b044dd930a30c","type":"COMBINATION_TREATMENT","name":"baclofen + diazepam","canonical_id":"ctgov_combo:ctgov-combo-6ee0c59fd3745f67","description":null,"metadata":null},{"id":"b4243ce64b40468cb933f769a6da76ae","type":"COMBINATION_TREATMENT","name":"baclofen + diltiazem","canonical_id":"ctgov_combo:ctgov-combo-8bb3d6aa7d3c1ac4","description":null,"metadata":null},{"id":"454fb5c98b8d4c70b43a661d4aeb6803","type":"GO_TERM","name":"bacterial biofilm matrix","canonical_id":"go:GO:0097311","description":"\"A structure lying external to bacterial cells. A biofilm is an aggregate of surface-associated bacteria, and the biofilm matrix is the envelope of polymeric substances that surrounds the bacteria.\" [GOC:imk, PMID:22571672, Wikipedia:Biofilm]","metadata":null},{"id":"caf74cdeb88d458aa6d0d030759da6ca","type":"GO_TERM","name":"bacterial biofilm matrix surface","canonical_id":"go:GO:0097313","description":"\"The external part of the biofilm matrix, a structure lying external to bacterial cells. A biofilm is an aggregate of surface-associated bacteria, and the biofilm matrix is the envelope of polymeric substances that surrounds the bacteria.\" [GOC:imk, PMID:22571672, Wikipedia:Biofilm]","metadata":null},{"id":"902ece6f4c5747f5a1ce9262b5e62585","type":"GO_TERM","name":"bacterial cellulose biosynthetic process","canonical_id":"go:GO:0090540","description":"\"The chemical reactions and pathways resulting in the formation of cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation, as it occurs in certain types of bacteria, mainly Acetobacter, Sarcina ventriculi and Agrobacteria.\" [GOC:yaf, PMID:24097954]","metadata":null},{"id":"d02f1495074d47598340c80a4ae89d05","type":"GO_TERM","name":"bacterial degradosome","canonical_id":"go:GO:1990061","description":"\"The degradosome is a protein complex playing a key role in mRNA degradation and RNA processing. It includes a RNA helicase, a 3'-5' phosphate-dependent PNPase and a RNase E bound-enolase.\" [GOC:bhm, PMID:21805185]","metadata":null},{"id":"5e229b0ac37543b397af3e5c152092d1","type":"GO_TERM","name":"bacterial extracellular vesicle","canonical_id":"go:GO:0097691","description":"\"Small membrane vesicle (< 1 um) that buds off a prokaryotic cell plasma membrane, able to carry proteins, phospholipids, lipopolysaccharides, nucleic acids, viruses, and more. Important in intercellular communication and pathogenesis; can exist within host cells.\" [GOC:aa, PMID:25704309]","metadata":null},{"id":"dbbefcc4a25e4e2280073344e3df5b88","type":"DISEASE","name":"bacterial infectious disease","canonical_id":"mondo:0005113","description":null,"metadata":null},{"id":"8b993ff57ff64f91aa0c4efbaaf47645","type":"GO_TERM","name":"bacterial microcompartment","canonical_id":"go:GO:0031469","description":"\"An organelle found in bacteria consisting of a proteinaceous coat containing metabolic enzymes whose purpose is the sequestration or concentration of metabolites and which has the appearance of a polygonal granule by electron microscopy.\" [GOC:js, PMID:10498708, PMID:11844753, PMID:12923081, PMID:34058518, PMID:34340100]","metadata":null},{"id":"2ebee80e0097476f9e567465ec937a32","type":"GO_TERM","name":"bacterial nucleoid","canonical_id":"go:GO:0043590","description":"\"The region of a bacterial cell to which the DNA is confined.\" [GOC:jl]","metadata":null},{"id":"0144afbb744e48c7b7b550272f557b43","type":"GO_TERM","name":"bacterial nucleoid DNA packaging","canonical_id":"go:GO:0036386","description":"\"A process in which chromosomal DNA and associated proteins organize into a compact, orderly bacterial nucleoid. Often resulting in DNA supercoiling.\" [GOC:bf, GOC:bhm, PMID:17097674, PMID:17360520]","metadata":null},{"id":"fedb5d3699464b4381c3f333aef952c6","type":"GO_TERM","name":"bacterial outer membrane vesicle","canonical_id":"go:GO:0061701","description":"\"A spherical, bilayered proteolipid vesicle released from gram-negative bacterial outer membranes.\" [GOC:dph, GOC:pr, PMID:20596524]","metadata":null},{"id":"8f177647831b4b29b9e99e7a127ced0d","type":"DISEASE","name":"bacterial pneumonia","canonical_id":"mondo:0004652","description":null,"metadata":null},{"id":"e38ebf77c6fb421d98d7470e80c6087a","type":"GO_TERM","name":"bacterial pre-replicative complex","canonical_id":"go:GO:0036389","description":"\"A protein-DNA complex that forms at the bacterial oriC during the initial step of DNA replication and allows the origin to become competent, or 'licensed', for replication.\" [GOC:bf, GOC:bhm, GOC:jh2, PMID:19833870, PMID:21035377, Wikipedia:Pre-replication_complex]","metadata":null},{"id":"9c0cc0f31b7c45aaae33d26ae22c683e","type":"GO_TERM","name":"bacterial thylakoid","canonical_id":"go:GO:0030075","description":"\"A thylakoid that is derived from and attached to, but not necessarily continuous with, the plasma membrane, and is not enclosed in a plastid. It bears the photosynthetic pigments in photosynthetic cyanobacteria.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"f283fee0be174ee4bc4e7d1049725423","type":"GO_TERM","name":"bacterial-type DNA replication","canonical_id":"go:GO:0044787","description":"\"The DNA-dependent DNA replication, exemplified by prokaryotes, that occurs as part of the cell cycle. Prokaryotic DNA replication is bi-directional and originates at a single origin of replication on the circular genome.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"2d056c8a420748c2935179ff62c5a213","type":"GO_TERM","name":"bacterial-type DNA replication initiation","canonical_id":"go:GO:1902328","description":"\"Any DNA replication initiation that is involved in bacterial-type DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"5ab710a54d9745ae8b86ef4e6018d2b0","type":"GO_TERM","name":"bacterial-type DNA replication termination","canonical_id":"go:GO:1902329","description":"\"Any DNA replication termination that is involved in bacterial-type DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"fb8a6736e82142b5a658f10a142746c8","type":"GO_TERM","name":"bacterial-type RNA polymerase core enzyme binding","canonical_id":"go:GO:0001000","description":"\"Binding to a bacterial-type RNA polymerase core enzyme, typically consisting of two alpha, one beta, one beta prime, and one omega subunit.\" [GOC:txnOH]","metadata":null},{"id":"62db65517c3b40eda0b76a169f88f9c9","type":"GO_TERM","name":"bacterial-type RNA polymerase holo enzyme binding","canonical_id":"go:GO:0001108","description":"\"Binding to a component of the basal transcription machinery which is composed of a bacterial-type RNA polymerase core enzyme and a sigma factor, the minimal set of factors required for formation of the preinitiation complex (PIC) by a bacterial-type RNA polymerase.\" [GOC:txnOH]","metadata":null},{"id":"4ff2606e231e4ccbba484af065332b1e","type":"GO_TERM","name":"bacterial-type flagellum","canonical_id":"go:GO:0009288","description":"\"A motor complex composed of an extracellular helical protein filament coupled to a rotary motor embedded in the cell envelope.\" [GOC:cilia, GOC:jh2, GOC:krc, GOC:mtg_sensu, PMID:7787060, Wikipedia:Flagellum#Bacterial]","metadata":null},{"id":"5f1826dd9cdf43d0936143af1835521f","type":"GO_TERM","name":"bacterial-type flagellum assembly","canonical_id":"go:GO:0044780","description":"\"The assembly of a bacterial-type flagellum, a motor complex composed of an extracellular helical protein filament coupled to a rotary motor embedded in the cell envelope which functions in cell motility.\" [GOC:jl]","metadata":null},{"id":"48d9f3182a074bb9b26556a041078c1c","type":"GO_TERM","name":"bacterial-type flagellum basal body","canonical_id":"go:GO:0009425","description":"\"One of the three major substructures of the bacterial-type flagellum, the basal body is embedded in the cell envelope (the plasma membrane, peptidoglycan cell wall, and, if one is present, the outer membrane); it houses the secretion apparatus that exports the more distal components and the flagellar motor.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192, PMID:24697492]","metadata":null},{"id":"d65dd4bb037743bebb0621501f67d052","type":"GO_TERM","name":"bacterial-type flagellum basal body, C ring","canonical_id":"go:GO:0009433","description":"\"Cytoplasmic ring located at the base of the bacterial-type flagellar basal body; acts as a rotor; includes three switch proteins, which generate torque and can change their conformational state in a bimodal fashion, so that the motor direction can switch between clockwise and counterclockwise.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"01f1f9dce35649f4a0c975b80d3c7907","type":"GO_TERM","name":"bacterial-type flagellum basal body, MS ring","canonical_id":"go:GO:0009431","description":"\"One of the rings of the bacterial-type flagellar basal body; a double-flanged ring that anchors the basal body to the cytoplasmic membrane.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"f985992cf7f94c7cbbb5695bffe92f4e","type":"GO_TERM","name":"bacterial-type flagellum basal body, distal rod","canonical_id":"go:GO:0009426","description":"\"The portion of the central rod of the bacterial-type flagellar basal body that is distal to the cell membrane; spans most of the distance between the inner and outer membranes.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:11133968, PMID:12624192]","metadata":null},{"id":"0284e95d0e464eaaabc2badb1de064a5","type":"GO_TERM","name":"bacterial-type flagellum basal body, distal rod, L ring","canonical_id":"go:GO:0009427","description":"\"One of the rings of the bacterial-type flagellar basal body; anchors the basal body to the outer membrane.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"6725cee00c1a4368b3dc734380783476","type":"GO_TERM","name":"bacterial-type flagellum basal body, distal rod, P ring","canonical_id":"go:GO:0009428","description":"\"One of the rings of the bacterial-type flagellar basal body; anchors the basal body to the peptidoglycan layer.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"8ec624149aaf49e88cb1c9567b68c169","type":"GO_TERM","name":"bacterial-type flagellum basal body, proximal rod","canonical_id":"go:GO:0009429","description":"\"The portion of the central rod of the bacterial-type flagellar basal body that is proximal to the cell membrane; the proximal rod connects the distal rod to the flagellar motor.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:11133968, PMID:12624192]","metadata":null},{"id":"7bb70e7724464e339e6ede197a9febc3","type":"GO_TERM","name":"bacterial-type flagellum basal body, rod","canonical_id":"go:GO:0030694","description":"\"The central portion of the bacterial-type flagellar basal body, which spans the periplasm and threads through the rings.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:11133968, PMID:12624192]","metadata":null},{"id":"30847f96d2a24ef8be7e86426aabdd3b","type":"GO_TERM","name":"bacterial-type flagellum filament","canonical_id":"go:GO:0009420","description":"\"The long (approximately 20 nm), thin external structure of the bacterial-type flagellum, which acts as a propeller.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"3b1dcd5fb57f40d98957db534cea7262","type":"GO_TERM","name":"bacterial-type flagellum filament cap","canonical_id":"go:GO:0009421","description":"\"The proteinaceous structure at the distal tip of the bacterial-type flagellar filament.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"b38d6d0674ab40dc88db36d539651753","type":"GO_TERM","name":"bacterial-type flagellum hook","canonical_id":"go:GO:0009424","description":"\"The portion of the bacterial-type flagellum that connects the filament to the basal body.\" [GOC:cilia, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"01963a95dd524ddab53b2939ff1bda7c","type":"GO_TERM","name":"bacterial-type flagellum hook-filament junction","canonical_id":"go:GO:0009422","description":"\"The region of the bacterial-type flagellum where the hook and filament meet.\" [GOC:cilia, GOC:mah, GOC:mtg_sensu, PMID:10572114, PMID:12624192]","metadata":null},{"id":"4912501f6f474c4584020e00be9cd06b","type":"GO_TERM","name":"bacterial-type flagellum motor","canonical_id":"go:GO:0120100","description":"\"A transmembrane complex embedded in the cytoplasmic membrane which is the motor force, or torque, generator of the bacterial-type flagellum. The motor consists of a membrane-anchored rotor complex surrounded by one or more stator complexes in the cytoplasmic membrane. The stator consists of a hetero-hexameric complex of 2 membrane proteins, A and B, with stoichiometry A4B2. Examples are the H+ driven MotA-MotB stator complex of Escherichia coli and Salmonella enterica, and the Na+ driven PomA-PomB stator complex of Vibrio and Shewanella species. The rotor complex consists of a membrane-anchored ring and the motor switch complex, which controls the direction of flagellar rotation.\" [DOI:10.1002/9780470015902.a0000744.pub4, GOC:cilia, PMID:10572114, PMID:12624192, PMID:24697492, PMID:25251856]","metadata":null},{"id":"ac1d4f39b9ef485faa4243dd70a7015a","type":"GO_TERM","name":"bacterial-type flagellum organization","canonical_id":"go:GO:0044781","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a bacterial-type flagellum, a motor complex composed of an extracellular helical protein filament coupled to a rotary motor embedded in the cell envelope which functions in cell motility.\" [GOC:jl]","metadata":null},{"id":"d3aa51d038934320acb6517452d08718","type":"GO_TERM","name":"bacterial-type flagellum rotor complex","canonical_id":"go:GO:0120107","description":"\"The rotor complex of the bacterial-type flagellum consists of a membrane-anchored ring and the motor switch complex, which participates in the conversion of proton/Na+ energy into the mechanical work of rotation and controls the direction of flagellar rotation.\" [GOC:cilia, PMID:10572114, PMID:12624192, PMID:25251856]","metadata":null},{"id":"79f192e29356485695d1f95ebc13d280","type":"GO_TERM","name":"bacterial-type flagellum secretion apparatus","canonical_id":"go:GO:0120102","description":"\"A part of the bacterial-type flagellum that is located at the cytoplasmic side of the MS ring and composed of six membrane proteins (FlhA, FlhB, FliP, FliQ, FliR, and FliO, or orthologs thereof) and three soluble proteins (FliI, FliH, and FliJ, or orthologs thereof) in the cytoplasm. It is responsible for secretion of flagellar type III protein substrates, including the proteins of the flagellar rod, hook, and filament.\" [DOI:10.1002/9780470015902.a0000744.pub4, GOC:cilia, PMID:10572114, PMID:12624192, PMID:24697492, PMID:25251856]","metadata":null},{"id":"478c56db18cf4d4eac0ddc1c0a6ef1d8","type":"GO_TERM","name":"bacterial-type flagellum stator complex","canonical_id":"go:GO:0120101","description":"\"A hetero-hexameric complex of 2 membrane proteins, A and B, with stoichiometry A4B2. The A and B proteins form a channel through which flow the ions that power the bacterial-type flagellum. They form the stator, or nonrotating portion, of the flagellum motor with the B protein apparently attached to the peptidoglycan cell wall. Examples include the H+ driven MotA-MotB stator complex of Escherichia coli and Salmonella enterica, and the Na+ driven PomA-PomB stator complex of Vibrio and Shewanella species.\" [GOC:cilia, PMID:10572114, PMID:12624192, PMID:24697492, PMID:25251856]","metadata":null},{"id":"e622b618ca474bcda4f70a2bd62b5f34","type":"GO_TERM","name":"bacterial-type flagellum-dependent cell motility","canonical_id":"go:GO:0071973","description":"\"Cell motility due to the motion of one or more bacterial-type flagella. A bacterial-type flagellum is a motor complex composed of an extracellular helical protein filament coupled to a rotary motor embedded in the cell envelope.\" [GOC:cilia, GOC:krc, GOC:mah]","metadata":null},{"id":"8bc0f0aa549e4747b8a13de384980135","type":"GO_TERM","name":"bacterial-type flagellum-dependent swarming motility","canonical_id":"go:GO:0071978","description":"\"Bacterial-type flagellum-dependent cell motility in which the action of numerous flagella results in the smooth movement of a group of cells along a solid surface. Swarming motility is observed in groups of bacteria.\" [GOC:cilia, PMID:14527279, PMID:18461074]","metadata":null},{"id":"66c62c90cea74973bbbf2d7212560304","type":"GO_TERM","name":"bacterial-type flagellum-dependent swimming motility","canonical_id":"go:GO:0071977","description":"\"Bacterial-type flagellum-dependent cell motility that results in the smooth movement of a cell through a liquid medium.\" [GOC:cilia, PMID:18461074]","metadata":null},{"id":"a494dd76cb49496297bef4efc8a7e998","type":"GO_TERM","name":"bacteriochlorophyll binding","canonical_id":"go:GO:0042314","description":"\"Binding to bacteriochlorophyll, a form of chlorophyll found in photosynthetic bacteria, such as the purple and green bacteria. There are several types, designated a to g. Bacteriochlorophyll a and bacteriochlorophyll b are structurally similar to the chlorophyll a and chlorophyll b found in plants.\" [ISBN:0192800981]","metadata":null},{"id":"31fff84ac8904921bf973c3f78bbb17d","type":"GO_TERM","name":"bacteriochlorophyll biosynthetic process","canonical_id":"go:GO:0030494","description":"\"The chemical reactions and pathways resulting in the formation of a bacteriochlorophyll, any of the chlorophylls of photosynthetic bacteria. They differ structurally from the chlorophylls of higher plants.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"958b028614474b9baca956236014c38c","type":"GO_TERM","name":"bacteriochlorophyll c binding","canonical_id":"go:GO:0016169","description":"\"Binding to bacteriochlorophyll c, a chlorophyll of photosynthetic bacteria, for example green sulfur bacteria.\" [ISBN:0192800981]","metadata":null},{"id":"129d780c6cfa45d988ab7b2d676798d5","type":"GO_TERM","name":"bacteriochlorophyll catabolic process","canonical_id":"go:GO:0030495","description":"\"The chemical reactions and pathways resulting in the breakdown of bacteriochlorophyll, any of the chlorophylls of photosynthetic bacteria. They differ structurally from the chlorophylls of higher plants.\" [GOC:curators]","metadata":null},{"id":"7743c183298e417ab41416b633177285","type":"GO_TERM","name":"bacteriochlorophyllide-a dehydrogenase activity","canonical_id":"go:GO:0036354","description":"\"Catalysis of the reaction: 3-deacetyl-3-(1-hydroxyethyl)bacteriochlorophyllide a + NAD+ = bacteriochlorophyllide a + NADH + H+.\" [PMID:8437569, RHEA:19733]","metadata":null},{"id":"c13088b7275349ed8b5d9461575d2fcb","type":"GO_TERM","name":"bacteriocin biosynthetic process","canonical_id":"go:GO:0030152","description":"\"The chemical reactions and pathways resulting in the formation of a bacteriocin, any of a heterogeneous group of polypeptide antibiotics that are secreted by certain bacterial strains and are able to kill cells of other susceptible (frequently related) strains after adsorption at specific receptors on the cell surface. They include the colicins, and their mechanisms of action vary.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"67d81e9bc34049159ee831229a56e875","type":"GO_TERM","name":"bacteriocin catabolic process","canonical_id":"go:GO:0046225","description":"\"The chemical reactions and pathways resulting in the breakdown of a bacteriocin, any of a heterogeneous group of polypeptide antibiotics that are secreted by certain bacterial strains and are able to kill cells of other susceptible (frequently related) strains after adsorption at specific receptors on the cell surface. They include the colicins, and their mechanisms of action vary.\" [GOC:ai]","metadata":null},{"id":"dc975430a6974112be83d437ca04b800","type":"GO_TERM","name":"bacteriocin immunity","canonical_id":"go:GO:0030153","description":"\"A process that mediates resistance to a bacteriocin: any of a heterogeneous group of polypeptide antibiotics that are secreted by certain bacterial strains and are able to kill cells of other susceptible (frequently related) strains after adsorption at specific receptors on the cell surface. They include the colicins, and their mechanisms of action vary.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"bf5c794c185e45a7bba1108d0b3ab42f","type":"GO_TERM","name":"bacteriocin metabolic process","canonical_id":"go:GO:0046224","description":"\"The chemical reactions and pathways involving bacteriocins, any of a heterogeneous group of polypeptide antibiotics that are secreted by certain bacterial strains and are able to kill cells of other susceptible (frequently related) strains after adsorption at specific receptors on the cell surface. They include the colicins, and their mechanisms of action vary.\" [GOC:ai]","metadata":null},{"id":"08bf6273b31e4ac7af001261f833dbb0","type":"GO_TERM","name":"bacteriocin transmembrane transporter activity","canonical_id":"go:GO:0022885","description":"\"Enables the transfer of a bacteriocin from one side of a membrane to the other.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"aca5cbaeb9c1483da1897eb5612318d0","type":"GO_TERM","name":"bacteriocin transport","canonical_id":"go:GO:0043213","description":"\"The directed movement of a bacteriocin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Bacteriocins are a group of antibiotics produced by bacteria and are encoded by a group of naturally occurring plasmids, e.g. Col E1. Bacteriocins are toxic to bacteria closely related to the bacteriocin producing strain.\" [GOC:mlg]","metadata":null},{"id":"5e45e9a3d6104a2387e4393402485c82","type":"GO_TERM","name":"bacteroid-containing symbiosome","canonical_id":"go:GO:0043660","description":"\"A symbiosome containing any of various structurally modified bacteria, such as those occurring on the root nodules of leguminous plants.\" [GOC:cc]","metadata":null},{"id":"542172ace8c04d879a2d4c209f1ffa23","type":"GO_TERM","name":"baculum development","canonical_id":"go:GO:1990375","description":"\"The reproductive developmental process whose specific outcome is the progression of the baculum over time, from its formation to the mature structure.\" [GOC:sl, PMID:21471296]","metadata":null},{"id":"b536b88112e0439284aca91df508c81c","type":"GO_TERM","name":"baicalein 7-O-glucuronosyltransferase activity","canonical_id":"go:GO:0102159","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate + baicalein = H+ + UDP + baicalin.\" [RHEA:28314]","metadata":null},{"id":"0d51724a461c442986c5a56599582a6c","type":"GO_TERM","name":"baicalin beta-D-glucuronidase activity","canonical_id":"go:GO:0052748","description":"\"Catalysis of the reaction: baicalin + H2O = baicalein + D-glucuronate.\" [GOC:mengo_curators, RHEA:28130]","metadata":null},{"id":"8c6ce9af4b96467eabe1758eb04f2581","type":"DRUG","name":"balsalazide","canonical_id":"mesh:C038637","description":null,"metadata":null},{"id":"6e5c9297420b4dbc8009b5e6aff1cdf9","type":"GO_TERM","name":"barbed-end actin filament capping","canonical_id":"go:GO:0051016","description":"\"The binding of a protein or protein complex to the barbed (or plus) end of an actin filament, thus preventing the addition, exchange or removal of further actin subunits.\" [ISBN:071673706X]","metadata":null},{"id":"39c934be8b924213b9658be24dca706c","type":"GO_TERM","name":"barbed-end actin filament uncapping","canonical_id":"go:GO:0051638","description":"\"The removal of capping protein from the barbed (or plus) end of actin filaments to free the ends for addition, exchange or removal of further actin subunits.\" [GOC:pf]","metadata":null},{"id":"42f647ff1c7747c3b9475f2e25040c6e","type":"GO_TERM","name":"barbiturase activity","canonical_id":"go:GO:0047694","description":"\"Catalysis of the reaction: barbiturate + H2O = malonate + urea.\" [EC:3.5.2.1, MetaCyc:BARBITURASE-RXN]","metadata":null},{"id":"0aba494f4b13442998fad3251b4a9ae0","type":"DRUG","name":"baricitinib","canonical_id":"gtopdb:7792","description":null,"metadata":null},{"id":"c1d4ad87e1f148d49e2e030d2b493754","type":"DRUG","name":"baricitinib","canonical_id":"mesh:C000596027","description":null,"metadata":null},{"id":"d7e3edcf464347dda613821e871a9c05","type":"DRUG","name":"baricitinib","canonical_id":"chembl:CHEMBL2105759","description":null,"metadata":null},{"id":"c08d3a83e1fc4cc3b479dc515f0c1e8d","type":"COMBINATION_TREATMENT","name":"baricitinib + danazol","canonical_id":"ctgov_combo:ctgov-combo-4cba06255a3e9787","description":null,"metadata":null},{"id":"1adafc481de44c3c9a13f33b44438bfc","type":"COMBINATION_TREATMENT","name":"baricitinib + dupilumab + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-b1f63cd8e28f3dcc","description":null,"metadata":null},{"id":"c8ccc1dde8ca4d108411f36e09823395","type":"COMBINATION_TREATMENT","name":"baricitinib + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-26a190aab0bfdbfc","description":null,"metadata":null},{"id":"bf84c3f7fcdc46988f3230fb387f1ffd","type":"COMBINATION_TREATMENT","name":"baricitinib + tofacitinib","canonical_id":"ctgov_combo:ctgov-combo-cc0c307387a4e9f0","description":null,"metadata":null},{"id":"4bbf9f12dcc841a985f72623849e26d5","type":"COMBINATION_TREATMENT","name":"baricitinib + tofacitinib + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-4306c8aecf980dd9","description":null,"metadata":null},{"id":"1745cdcae6054d0c9fec01b4c82bfbfb","type":"GO_TERM","name":"baroreceptor detection of arterial stretch","canonical_id":"go:GO:0001981","description":"\"The series of events by which the change in diameter of an artery is detected and converted to a molecular signal.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"5d50dd27d5a94e5ab57461c5bdb203db","type":"GO_TERM","name":"baroreceptor detection of decreased arterial stretch","canonical_id":"go:GO:0003024","description":"\"The series of events by which a decrease in diameter of an artery is detected and converted to a molecular signal.\" [GOC:mtg_cardio]","metadata":null},{"id":"6cb69a221d9b4760a030fc0c940ada4f","type":"GO_TERM","name":"baroreceptor detection of increased arterial stretch","canonical_id":"go:GO:0003023","description":"\"The series of events by which an increase in diameter of an artery is detected and converted to a molecular signal.\" [GOC:mtg_cardio]","metadata":null},{"id":"06138d099a714ad396847cacface134a","type":"GO_TERM","name":"baroreceptor response to decreased systemic arterial blood pressure","canonical_id":"go:GO:0001982","description":"\"The lowering of the number of nerve impulses from baroreceptors as a result of decreased stretch of an artery that results in an increased in sympathetic nerve impulses to peripheral blood vessels.\" [GOC:dph, GOC:mtg_cardio, ISBN:0323031951, ISBN:0721643949]","metadata":null},{"id":"38fb414e966b4a6dba6941a92db8964c","type":"GO_TERM","name":"baroreceptor response to increased systemic arterial blood pressure","canonical_id":"go:GO:0001983","description":"\"The increase in nerve impulses from baroreceptors as a result of increased pressure on an artery that results in an inhibition of sympathetic nerve impulses to peripheral blood vessels.\" [GOC:mtg_cardio, ISBN:0323031951, ISBN:0721643949]","metadata":null},{"id":"a811ba4dde794a23b1482fdae79ecbe1","type":"GO_TERM","name":"baruol synthase activity","canonical_id":"go:GO:0080011","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = baruol. Baruol is also known as D:B-Friedo-Baccharan-5,21-dien-3-ol.\" [PMID:17705488, RHEA:31987]","metadata":null},{"id":"8b983002795b4f269e4a3375a52742c8","type":"GO_TERM","name":"basal body patch","canonical_id":"go:GO:0120220","description":"\"The region in the apical portion of multiciliated epithelial cells where the ciliary basal bodies cluster.\" [GOC:krc, PMID:20164345, PMID:20685736, PMID:29891944]","metadata":null},{"id":"f303ccdd2a4a4c15ae46b9f6040716a5","type":"DISEASE","name":"basal cell carcinoma","canonical_id":"mondo:0020804","description":null,"metadata":null},{"id":"4b3c1ed4a2a0491f852ac30ea30e6d76","type":"GO_TERM","name":"basal cortex","canonical_id":"go:GO:0045180","description":"\"The region that lies just beneath the plasma membrane on the basal edge of a cell.\" [GOC:bf]","metadata":null},{"id":"fd2ee6cbcdb94cb39468a862c052c362","type":"GO_TERM","name":"basal dendrite","canonical_id":"go:GO:0097441","description":"\"A dendrite that emerges near the basal pole of a neuron. In bipolar neurons, basal dendrites are either on the same side of the soma as the axon, or project toward the axon.\" [GOC:aruk, GOC:bc, NIF_Subcellular:sao1079900774, PMID:17046728, PMID:22683681]","metadata":null},{"id":"7f77b2bf91b44c4ebed73086ecdac351","type":"GO_TERM","name":"basal dendrite arborization","canonical_id":"go:GO:0150020","description":"\"The process in which the anatomical structures of a dendritic tree are generated on the basal neuron side and organized into dendritic branches.\" [GOC:aruk, GOC:bc, PMID:22683681]","metadata":null},{"id":"53888a3881574bbeb86f6a3c545b9fd6","type":"GO_TERM","name":"basal dendrite development","canonical_id":"go:GO:0150018","description":"\"The process whose specific outcome is the progression of a basal dendrite over time, from its formation to the mature structure.\" [GOC:aruk, GOC:bc, PMID:22683681]","metadata":null},{"id":"f70bde300ec24aa9aa817ddf3ccadfe2","type":"GO_TERM","name":"basal dendrite morphogenesis","canonical_id":"go:GO:0150019","description":"\"The process in which the anatomical structures of a basal dendrite are generated and organized.\" [GOC:aruk, GOC:bc, PMID:22683681]","metadata":null},{"id":"74a52dfc87ea466fb1b7d2e9298ff582","type":"GO_TERM","name":"basal distal dendrite","canonical_id":"go:GO:0150016","description":"\"Any dendrite in a dendritic tree that emerges near the basal pole of a neuron (e.g. in bipolar neurons, basal dendrites are either on the same side of the soma as the axon, or project toward the axon), and which is farthest away from the neuronal cell body (the soma).\" [GOC:aruk, GOC:bc, PMID:17046728, PMID:1720142, PMID:20629984, PMID:22683681, PMID:9214543]","metadata":null},{"id":"ca5e3c2c4749492f8941441762f87869","type":"GO_TERM","name":"basal ectoplasmic specialization","canonical_id":"go:GO:0061832","description":"\"Testis-specific junction between mature Sertoli cells involved in establishing the blood-testis barrier of the Sertoli cell.\" [GOC:aruk, GOC:bc, GOC:dph, PMID:22332112, PMID:23546604]","metadata":null},{"id":"f648ea59f0504e3ab8cd8927f62f2008","type":"GO_TERM","name":"basal labyrinth","canonical_id":"go:GO:0033774","description":"\"A region in the lower half of some cells formed from extensive infoldings of the basal plasma membrane; includes cytoplasm adjacent to the infolded membrane.\" [GOC:mah, GOC:sart, PMID:11640882]","metadata":null},{"id":"cee691cf67344c8ea53a2c70e6c4e62c","type":"GO_TERM","name":"basal layer of collagen and cuticulin-based cuticle extracellular matrix","canonical_id":"go:GO:0060110","description":"\"The layer of cuticle most closely apposed to the hypodermal cells. The morphology of the basal layer varies with life stage. In adult C. elegans animals, the basal layers is comprised of three sublayers: two fibrous layers whose fibers run in clockwise and counter-clockwise directions meeting one another at a 60 degree angle, and an amorphous basal layer that lies underneath the fibrous layers and directly contacts the hypodermis. In C. elegans dauer and L1 larval stage animals, the basal layer is characterized by a striated pattern that appears to derive from interwoven laminae. An example of this component is found in Caenorhabditis elegans.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"8545bd50f3ad436f831ace4382b0c523","type":"GO_TERM","name":"basal part of cell","canonical_id":"go:GO:0045178","description":"\"The region of a cell situated near the base. For example, in a polarized epithelial cell, the basal surface rests on the basal lamina that separates the epithelium from other tissue.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"1e5d8064fd334a6c95675da0bc31e8fd","type":"GO_TERM","name":"basal plasma membrane","canonical_id":"go:GO:0009925","description":"\"The region of the plasma membrane located at the basal end of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis.\" [GOC:curators]","metadata":null},{"id":"9aef650d3aa3486084ce73ed49ea68f2","type":"GO_TERM","name":"basal pole of neuron","canonical_id":"go:GO:0044226","description":"\"Portion of a neuron cell soma closest to the point where the basilar dendrite emerges.\" [NIF_Subcellular:sao1186862860]","metadata":null},{"id":"ac97d7cc010f49bba6bb07894d8605fc","type":"GO_TERM","name":"basal pole of outer hair cell","canonical_id":"go:GO:0090712","description":"\"The end of the outer hair cell which receives and transmits neural signals.\" [GOC:sl, PMID:12845523]","metadata":null},{"id":"c2b0f3069376482a9d7a84764e26e724","type":"GO_TERM","name":"basal protein localization","canonical_id":"go:GO:0045175","description":"\"Any process in which a protein is transported to, or maintained in, basal regions of the cell.\" [GOC:bf]","metadata":null},{"id":"7c3a1b9e46de478cbe9c135e2e60a6d3","type":"GO_TERM","name":"basal proximal dendrite","canonical_id":"go:GO:0150017","description":"\"Any dendrite in a dendritic tree that emerges near the basal pole of a neuron (e.g. in bipolar neurons, basal dendrites are either on the same side of the soma as the axon, or project toward the axon), and which is the closest to the cell body of the neuron (the soma).\" [GOC:aruk, GOC:bc, PMID:16899232, PMID:17046728, PMID:1720142, PMID:22683681, PMID:9214543]","metadata":null},{"id":"073e6abae03543ffbe48eef109217ea6","type":"GO_TERM","name":"basal ring of apical complex","canonical_id":"go:GO:0020032","description":"\"An electron dense ring at the most posterior position of the apical complex, from which the subpellicular microtubules originate; formed during an invasive life cycle stage of an apicomplexan parasite.\" [GOC:mah, PMID:16518471]","metadata":null},{"id":"a84b0629398346c89843a6b960b60794","type":"GO_TERM","name":"basal tubulobulbar complex","canonical_id":"go:GO:0061829","description":"\"Actin-based structures involved in establishing the blood-testis barrier of the Sertoli cell.\" [PMID:20403871, PMID:22510523]","metadata":null},{"id":"f207d8e0aa44400688fb4dcda853d2c2","type":"GO_TERM","name":"base J metabolic process","canonical_id":"go:GO:0070580","description":"\"The chemical reactions and pathways involving base J (beta-D-glucosyl-hydroxymethyluracil), a hypermodified thymidine residue found in the genome of kinetoplastid parasites. This modified base is localized primarily to repetitive DNA, namely the telomeres, and is implicated in the regulation of antigenic variation. The base is synthesized in a two-step pathway. Initially, a thymidine residue in DNA is hydroxylated by a thymidine hydroxylase (TH) to form the intermediate hydroxymethyluracil, which is then glucosylated to form base J.\" [PMID:19114062]","metadata":null},{"id":"99ed5e4f87104e60bb375ace010d015f","type":"GO_TERM","name":"base conversion or substitution editing","canonical_id":"go:GO:0016553","description":"\"Any base modification or substitution events that result in alterations in the coding potential or structural properties of RNAs as a result of changes in the base-pairing properties of the modified ribonucleoside(s).\" [PMID:11092837]","metadata":null},{"id":"142d11fcb35f49069a2662fce09baabc","type":"GO_TERM","name":"base-excision repair","canonical_id":"go:GO:0006284","description":"\"In base excision repair, an altered base is removed by a DNA glycosylase enzyme, followed by excision of the resulting sugar phosphate. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase.\" [ISBN:0815316194]","metadata":null},{"id":"94a3bdb265774d7291f9828f6ed750b6","type":"GO_TERM","name":"base-excision repair, AP site formation","canonical_id":"go:GO:0006285","description":"\"The formation of an AP site, a deoxyribose sugar with a missing base, by DNA glycosylase which recognizes an altered base in DNA and catalyzes its hydrolytic removal. This sugar phosphate is the substrate recognized by the AP endonuclease, which cuts the DNA phosphodiester backbone at the 5' side of the altered site to leave a gap which is subsequently repaired.\" [ISBN:0815316194]","metadata":null},{"id":"dbc1dd8995c64ac885d76b26d0ddaf24","type":"GO_TERM","name":"base-excision repair, AP site formation via deaminated base removal","canonical_id":"go:GO:0097510","description":"\"A base-excision repair, AP site formation process occurring via excision of a deaminated base.\" [GOC:al, PMID:18789404]","metadata":null},{"id":"228e41d4240542c893801314eb48d896","type":"GO_TERM","name":"base-excision repair, gap-filling","canonical_id":"go:GO:0006287","description":"\"Repair of the damaged strand by the combined action of an apurinic endouclease that degrades a few bases on the damaged strand and a polymerase that synthesizes a 'patch' in the 5' to 3' direction, using the undamaged strand as a template.\" [ISBN:1550091131]","metadata":null},{"id":"d086969244c74858b4f80c3bccc5cc73","type":"GO_TERM","name":"basement membrane","canonical_id":"go:GO:0005604","description":"\"A collagen-containing extracellular matrix consisting of a thin layer of dense material found in various animal tissues interposed between the cells and the adjacent connective tissue. It consists of the basal lamina plus an associated layer of reticulin fibers.\" [PMID:22505934, PMID:33605520, PMID:39223427]","metadata":null},{"id":"9c8f00bdab094fb1a950b9abf6e47723","type":"GO_TERM","name":"basement membrane assembly","canonical_id":"go:GO:0070831","description":"\"The aggregation, arrangement and bonding together of a set of components to form a basement membrane, a part of the extracellular region that consists of a thin layer of dense material found in various animal tissues interposed between the cells and the adjacent connective tissue.\" [GOC:mah]","metadata":null},{"id":"0c5a951203864368812d2a14d0864cb6","type":"GO_TERM","name":"basement membrane assembly involved in embryonic body morphogenesis","canonical_id":"go:GO:2001197","description":"\"Any basement membrane assembly that is involved in embryonic body morphogenesis.\" [GOC:obol]","metadata":null},{"id":"eec3f0d2f5c84f83a12e0405e6f36bba","type":"GO_TERM","name":"basement membrane constituent secretion","canonical_id":"go:GO:0061864","description":"\"The controlled release of molecules that form the basement membrane, including carbohydrates and glycoproteins by a cell.\" [PMID:26610918, PMID:28228250]","metadata":null},{"id":"5f2cf9085e2c40a79ef29f2cb497835a","type":"GO_TERM","name":"basement membrane disassembly","canonical_id":"go:GO:0034769","description":"\"The controlled breakdown of the basement membrane in the context of a normal process such as imaginal disc eversion.\" [GOC:sart, PMID:17301221]","metadata":null},{"id":"787d77bc1e514edd81372149184ed8a2","type":"GO_TERM","name":"basement membrane organization","canonical_id":"go:GO:0071711","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the basement membrane.\" [GOC:mah]","metadata":null},{"id":"4bfa680c281344e69c686da128770bba","type":"GO_TERM","name":"basement membrane/interstitial matrix interface","canonical_id":"go:GO:0140086","description":"\"The structure located at the interface of the basement membrane and interstitial extracellular matrix and anchoring the two types of ECM to one another.\" [PMID:19945621, PMID:26377767, PMID:7767545, PMID:9334230]","metadata":null},{"id":"5df9d6d45b0747ff853251f84163de4d","type":"GO_TERM","name":"basic amino acid transmembrane export from vacuole","canonical_id":"go:GO:0034488","description":"\"The directed movement of basic amino acids out of the vacuole, across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"f4737c34030445d79c8a2336d2e26f01","type":"GO_TERM","name":"basic amino acid transmembrane import into vacuole","canonical_id":"go:GO:0034490","description":"\"The directed movement of basic amino acids into the vacuole across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"bd0d275a9d23410a904419ea0c2b7902","type":"GO_TERM","name":"basic amino acid transmembrane transport","canonical_id":"go:GO:1990822","description":"\"The directed movement of basic amino acids from one side of a membrane to the other.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"1c608e36ae43468caa666be84d726bd3","type":"GO_TERM","name":"basic amino acid transmembrane transporter activity","canonical_id":"go:GO:0015174","description":"\"Enables the transfer of basic amino acids from one side of a membrane to the other. Basic amino acids have side chains with a positive charge at pH 7.3.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ac007abc62f64daf97cdddba40c30446","type":"GO_TERM","name":"basic amino acid transport","canonical_id":"go:GO:0015802","description":"\"The directed movement of basic amino acids, amino acids with a pH above 7, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"c57c7ab875c949489ed76a3395d5cb01","type":"GO_TERM","name":"basidiospore formation","canonical_id":"go:GO:0034295","description":"\"The process in which spores form outside a specialized end cell known as a basidium. Basidia are characteristic of the basidiomycete fungi (phylum Basidiomycota), and give rise to spores that each contain a haploid nucleus that is the product of meiosis. The spores are usually attached to the basidium by short spikes called sterigmata (singular: sterigma). In most basidiomycetes there are four sterigmata (and four spores) to a basidium.\" [GOC:di, GOC:ds, GOC:mah, GOC:mcc, https://en.wikipedia.org/wiki/Basidiospore]","metadata":null},{"id":"4e6ff8549e524f8e92fbd1be3a495e5b","type":"GO_TERM","name":"basidium development","canonical_id":"go:GO:0075313","description":"\"The process that leads to the development of basidium, a small, specialized club-shaped structure typically bearing four basidiospores at the tips of minute projections. The basidium is unique to Basidiomycetes and distinguishes them from other kinds of fungi.\" [GOC:di, GOC:mah, GOC:mcc, GOC:pamgo_curators]","metadata":null},{"id":"bf4bae7e54594021b1ec4bea1f4d65e3","type":"GO_TERM","name":"basipetal auxin transport","canonical_id":"go:GO:0010540","description":"\"The unidirectional movement of auxin from the apex to base of an organ, including the shoot, leaf, primary root, or lateral root.\" [PMID:10677441]","metadata":null},{"id":"787d515829ce4f6a82c54b352acdb1c0","type":"GO_TERM","name":"basket cell precursor proliferation","canonical_id":"go:GO:0021928","description":"\"The multiplication or reproduction of neuroblasts that will give rise to basket cells. A cerebellar basket cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"2801e59701ca4294a9838e7719493cf7","type":"GO_TERM","name":"basolateral cytoplasm","canonical_id":"go:GO:0090652","description":"\"The region of the cytoplasm located at the basolateral side of the cell. Used in reference to animal polarized epithelial cells.\" [PMID:17494872]","metadata":null},{"id":"9c3264ff21064fd4a1ba9a179e7826c6","type":"GO_TERM","name":"basolateral part of cell","canonical_id":"go:GO:1990794","description":"\"The region of a cell situated by the cell sides which interface adjacent cells and near the base. Often used in reference to animal polarized epithelial cells.\" [PMID:18495799]","metadata":null},{"id":"d3ed23b55f344d18a84b2a2af80f7e89","type":"GO_TERM","name":"basolateral plasma membrane","canonical_id":"go:GO:0016323","description":"\"The region of the plasma membrane that includes the basal end and sides of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis.\" [GOC:curators]","metadata":null},{"id":"2a965c3d568b438f9dc3dae78187f56c","type":"GO_TERM","name":"basolateral protein secretion","canonical_id":"go:GO:0110010","description":"\"The controlled release of proteins from a cell at the sides which interface adjacent cells and near the base.\" [GOC:ha, PMID:27404358]","metadata":null},{"id":"dc9a8cce2ca744e4a6edeb24122e70f6","type":"GO_TERM","name":"basolateral recycling endosome","canonical_id":"go:GO:0090654","description":"\"Tubulo-vesicular structure located in the basolateral cytoplasm that participates in basolateral cargo recycling in polarized epithelial cells.\" [PMID:11389442, PMID:16394106, PMID:17494872, PMID:21170358, PMID:9405315]","metadata":null},{"id":"4d3164b1cf9f4479b1b09bc1678a8b96","type":"GO_TERM","name":"basophil activation","canonical_id":"go:GO:0045575","description":"\"The change in morphology and behavior of a basophil resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the basophil has specifically bound via IgE bound to Fc-epsilonRI receptors.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"0514cae896d24ca1908097a69a953e4c","type":"GO_TERM","name":"basophil activation involved in immune response","canonical_id":"go:GO:0002276","description":"\"A change in morphology and behavior of a basophil resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the basophil has specifically bound via IgE bound to Fc-epsilonRI receptors, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"65903348dc344239bb5b81ea00fde377","type":"GO_TERM","name":"basophil chemotaxis","canonical_id":"go:GO:0002575","description":"\"The movement of a basophil in response to an external stimulus.\" [GOC:add, PMID:11292027]","metadata":null},{"id":"6dcf36ec7a984325a78fdaa7594fafff","type":"GO_TERM","name":"basophil degranulation","canonical_id":"go:GO:0002561","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as histamine, serotonin, and neutral proteases by a basophil.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"921c939f18eb4379800ad8d044b899bb","type":"GO_TERM","name":"basophil differentiation","canonical_id":"go:GO:0030221","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires specialized features of a basophil cell.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"5338582159474446be952439914a4dde","type":"GO_TERM","name":"basophil homeostasis","canonical_id":"go:GO:1990960","description":"\"The process of regulating the proliferation and elimination of basophils such that the total number of basophils within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [PMID:10606160]","metadata":null},{"id":"42a647451fa6447a938ef2e02cf1896e","type":"GO_TERM","name":"basophil mediated immunity","canonical_id":"go:GO:0002560","description":"\"Any process involved in the carrying out of an immune response by a basophil.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5e0ed4f19dab433893f817d3f32c747a","type":"DRUG","name":"bazedoxifene","canonical_id":"gtopdb:7355","description":null,"metadata":null},{"id":"21ee4b23f31d4cfdb644d710c3a75f28","type":"DRUG","name":"bazedoxifene","canonical_id":"mesh:C447119","description":null,"metadata":null},{"id":"b74a4ac34d83400180b22e712ddd0bed","type":"COMBINATION_TREATMENT","name":"bazedoxifene + raloxifene","canonical_id":"ctgov_combo:ctgov-combo-6d1ee82314b5c5e3","description":null,"metadata":null},{"id":"8cfc59f1761740e1a01e392a0f595da0","type":"COMBINATION_TREATMENT","name":"bazedoxifene + raloxifene","canonical_id":"ctgov_combo:ctgov-combo-30b884048b6ed1db","description":null,"metadata":null},{"id":"5af981648ee34b1687a99375b6847c32","type":"GO_TERM","name":"beak development","canonical_id":"go:GO:0071728","description":"\"The progression of the beak over time from its initial formation until its mature state. The avian beak is an external anatomical structure, in the head region, that is adapted for feeding self and young, catching prey, probing, etc. It encompasses, but is not restricted to, the maxilla, mandible, maxillary rhamphotheca, mandibular rhamphotheca, nostril, nasal fossa, nasal bones, egg tooth and rictus.\" [GOC:lp, ISBN:0702008729]","metadata":null},{"id":"d30c40f109cf4c49a6665340bfb0f753","type":"GO_TERM","name":"beak formation","canonical_id":"go:GO:0071730","description":"\"The process that gives rise to the beak. This process pertains to the initial formation of a structure from unspecified parts. The avian beak is an external anatomical structure, in the head region, that is adapted for feeding self and young, catching prey, probing, etc. It encompasses, but is not restricted to, the maxilla, mandible, maxillary rhamphotheca, mandibular rhamphotheca, nostril, nasal fossa, nasal bones, egg tooth and rictus.\" [GOC:lp, ISBN:0702008729]","metadata":null},{"id":"8377d0e2baa342c39872e20af538e1b6","type":"GO_TERM","name":"beak morphogenesis","canonical_id":"go:GO:0071729","description":"\"The process in which the anatomical structures of the beak are generated and organized. The avian beak is an external anatomical structure, in the head region, that is adapted for feeding self and young, catching prey, probing, etc. It encompasses, but is not restricted to, the maxilla, mandible, maxillary rhamphotheca, mandibular rhamphotheca, nostril, nasal fossa, nasal bones, egg tooth and rictus.\" [GOC:lp, ISBN:0702008729]","metadata":null},{"id":"73ca0f06fac344d0aa95c562afe38c9b","type":"DRUG","name":"beclabuvir","canonical_id":"mesh:C587012","description":null,"metadata":null},{"id":"5a3d579951fa47fea7f9245679ad3a62","type":"DRUG","name":"beclometasone","canonical_id":"gtopdb:7059","description":null,"metadata":null},{"id":"78042f95a06f4a36bd9cbbe395ff5e2a","type":"COMBINATION_TREATMENT","name":"beclometasone + fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-d27c35e4d8b1cb9c","description":null,"metadata":null},{"id":"15ade974c5c641f5aee40767a0c0c6cb","type":"COMBINATION_TREATMENT","name":"beclometasone + fluticasone + formoterol + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-9dcc60b54904794f","description":null,"metadata":null},{"id":"87707fc18f8f4b2db39dafaef6ecd2d8","type":"COMBINATION_TREATMENT","name":"beclometasone + glycopyrrolate","canonical_id":"ctgov_combo:ctgov-combo-d5855eb6bbb6ecb2","description":null,"metadata":null},{"id":"5ccdf5bab9ac41c7aae34d6a473780dd","type":"COMBINATION_TREATMENT","name":"beclometasone + glycopyrrolate","canonical_id":"ctgov_combo:ctgov-combo-71a00645b7f9f94e","description":null,"metadata":null},{"id":"a93f82b54a964952b509d9733aa43b5a","type":"GO_TERM","name":"behavior","canonical_id":"go:GO:0007610","description":"\"The internally coordinated responses (actions or inactions) of animals (individuals or groups) to internal or external stimuli, via a mechanism that involves nervous system activity.\" [GOC:ems, GOC:jl, ISBN:0395448956, PMID:20160973]","metadata":null},{"id":"9e087f653a03453b8cc3a2e47fb4a3d3","type":"GO_TERM","name":"behavioral defense response","canonical_id":"go:GO:0002209","description":"\"A behavioral response seeking to protect an organism from an perceived external threat to that organism.\" [GO_REF:0000022, GOC:add]","metadata":null},{"id":"191c91c76a04458eb52598bc94b47610","type":"GO_TERM","name":"behavioral defense response to insect","canonical_id":"go:GO:0002211","description":"\"A behavioral response seeking to protect an organism from an a perceived external threat from an insect or insects to that organism.\" [GOC:add]","metadata":null},{"id":"a7b12fa0c1ca4046b7285c65282be247","type":"GO_TERM","name":"behavioral defense response to nematode","canonical_id":"go:GO:0002212","description":"\"A behavioral response seeking to protect an organism from an a perceived external threat from a nematode or nematodes to that organism.\" [GOC:add, PMID:14506883]","metadata":null},{"id":"4d8a23b5532043ab94111dc811fb47cb","type":"GO_TERM","name":"behavioral fear response","canonical_id":"go:GO:0001662","description":"\"An acute behavioral change resulting from a perceived external threat.\" [GOC:dph, PMID:9920659]","metadata":null},{"id":"fb2a2b2fa1f14e57a2fdc37219feae15","type":"GO_TERM","name":"behavioral response to acetic acid induced pain","canonical_id":"go:GO:0061367","description":"\"Any process that results in a change in the behaviour of an organism as a result of an acetic acid pain stimulus.\" [GOC:dph]","metadata":null},{"id":"9326b47ba9ba41aeb5b41c4374490557","type":"GO_TERM","name":"behavioral response to chemical pain","canonical_id":"go:GO:0061366","description":"\"Any process that results in a change in the behaviour of an organism as a result of a chemical pain stimulus.\" [GOC:dph]","metadata":null},{"id":"f685becf78eb4f788a226079f710a680","type":"GO_TERM","name":"behavioral response to cocaine","canonical_id":"go:GO:0048148","description":"\"Any process that results in a change in the behavior of an organism as a result of a cocaine stimulus.\" [GOC:jid]","metadata":null},{"id":"065ee64753214638b801ef9ec9fc1b7e","type":"GO_TERM","name":"behavioral response to ethanol","canonical_id":"go:GO:0048149","description":"\"Any process that results in a change in the behavior of an organism as a result of an ethanol stimulus.\" [GOC:jid]","metadata":null},{"id":"d2705f9b5c534627a954701c9ea8a93b","type":"GO_TERM","name":"behavioral response to ether","canonical_id":"go:GO:0048150","description":"\"Any process that results in a change in the behavior of an organism as a result of an ether stimulus.\" [GOC:jid]","metadata":null},{"id":"4d6f7f7885b543a7a2baa8cbfb8b33da","type":"GO_TERM","name":"behavioral response to formalin induced pain","canonical_id":"go:GO:0061368","description":"\"Any process that results in a change in the behaviour of an organism as a result of a formalin pain stimulus.\" [GOC:dph]","metadata":null},{"id":"7e981e7378d44c3ca04a6e4fc7e6619f","type":"GO_TERM","name":"behavioral response to nicotine","canonical_id":"go:GO:0035095","description":"\"Any process that results in a change in the behavior of an organism as a result of a nicotine stimulus.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"149833837b07434483493b903f55ffe6","type":"GO_TERM","name":"behavioral response to nutrient","canonical_id":"go:GO:0051780","description":"\"Any process that results in a change in the behavior of an organism as a result of a nutrient stimulus.\" [GOC:ai]","metadata":null},{"id":"3f39db20eb674e42949e78963044a2a0","type":"GO_TERM","name":"behavioral response to pain","canonical_id":"go:GO:0048266","description":"\"Any process that results in a change in the behavior of an organism as a result of a pain stimulus. Pain stimuli cause activation of nociceptors, peripheral receptors for pain, include receptors which are sensitive to painful mechanical stimuli, extreme heat or cold, and chemical stimuli.\" [GOC:jid]","metadata":null},{"id":"1001c7d300964e949e9d52324f2ec606","type":"GO_TERM","name":"behavioral response to starvation","canonical_id":"go:GO:0042595","description":"\"Any process that results in a change in the behavior of an organism as a result of deprivation of nourishment.\" [GOC:curators]","metadata":null},{"id":"ffdc1e255dcf49acb02903b65d2f3950","type":"GO_TERM","name":"behavioral response to water deprivation","canonical_id":"go:GO:0042630","description":"\"Any process that results in a change in the behavior of an organism as a result of deprivation of water.\" [GOC:jl]","metadata":null},{"id":"81d5b8dcce124edb905ad1892d777718","type":"GO_TERM","name":"behavioral response to wounding","canonical_id":"go:GO:0002210","description":"\"A behavioral response resulting from wounding.\" [GO_REF:0000022, GOC:add]","metadata":null},{"id":"d865a51eef4c4b3b94e52a10601cbd3e","type":"GO_TERM","name":"beige fat cell differentiation","canonical_id":"go:GO:0160274","description":"\"The process in which a white fat cell acquires specialized features of a beige adipocyte. Beige adipocytes reside within white adipose tissue and can be induced to produce heat in response to cold exposure or certain stimuli, resembling brown adipocytes.\" [PMID:24439384]","metadata":null},{"id":"f9d2a4d3a92b4b84871c26511e3ab2e8","type":"DRUG","name":"belatacept","canonical_id":"gtopdb:6892","description":null,"metadata":null},{"id":"2fb80ecc05b64dc48a9e6ec592e49d67","type":"DRUG","name":"belatacept","canonical_id":"chembl:CHEMBL1742990","description":null,"metadata":null},{"id":"241a537cb46749cc9be247d59219c208","type":"COMBINATION_TREATMENT","name":"belatacept + daratumumab","canonical_id":"ctgov_combo:ctgov-combo-2a409df3ac4d3212","description":null,"metadata":null},{"id":"95d1ea098eed4d66845fd510a2004da6","type":"COMBINATION_TREATMENT","name":"belatacept + efalizumab","canonical_id":"ctgov_combo:ctgov-combo-2fd2368c9e9aa0f7","description":null,"metadata":null},{"id":"fa8ae938e3ea4b75b1dbbf951f35ec38","type":"COMBINATION_TREATMENT","name":"belatacept + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-70416f1624cab192","description":null,"metadata":null},{"id":"70c339c4a7c24208a8f50511bbd63b6c","type":"COMBINATION_TREATMENT","name":"belatacept + mycophenolate mofetil + prednisone","canonical_id":"ctgov_combo:ctgov-combo-3345596edb0fd00a","description":null,"metadata":null},{"id":"5a17313d3f2b45268bd048d103dd8e5a","type":"DRUG","name":"belimumab","canonical_id":"gtopdb:6887","description":null,"metadata":null},{"id":"6a4f7b80f14d4d69bcc86ea048c591f4","type":"DRUG","name":"belimumab","canonical_id":"mesh:C511911","description":null,"metadata":null},{"id":"c5802cb608a1417787ca93ce144a14e8","type":"DRUG","name":"belimumab","canonical_id":"chembl:CHEMBL1789843","description":null,"metadata":null},{"id":"1bcab9d597a047a5b50c18269d1b6c24","type":"COMBINATION_TREATMENT","name":"belimumab + diphenhydramine + methylprednisolone + prednisolone + prednisone + rituximab","canonical_id":"ctgov_combo:ctgov-combo-54114ad679f5aca2","description":null,"metadata":null},{"id":"ef65ed78c1ba4050bf24576550dbafb0","type":"COMBINATION_TREATMENT","name":"belimumab + ocrelizumab","canonical_id":"ctgov_combo:ctgov-combo-b711168ac2071823","description":null,"metadata":null},{"id":"cb9f9ecd3d45441c813dc6873afd2512","type":"DRUG","name":"belinostat","canonical_id":"mesh:C487081","description":null,"metadata":null},{"id":"64718e6e833143abb8dd34cc030a5d34","type":"DRUG","name":"belotecan","canonical_id":"mesh:C116963","description":null,"metadata":null},{"id":"5a99f4aa3edb4bdbb9636da7127a8153","type":"DRUG","name":"belumosudil","canonical_id":"gtopdb:9558","description":null,"metadata":null},{"id":"3eba091b5f5a4533b015b818a7187e8c","type":"DRUG","name":"belumosudil","canonical_id":"chembl:CHEMBL2005186","description":null,"metadata":null},{"id":"d43e0556a7d740ae9b3a4e057b916e9c","type":"COMBINATION_TREATMENT","name":"belumosudil + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-a6214f47346538e9","description":null,"metadata":null},{"id":"bb8c3bcfc34e46338d15f6e9fcdf0f34","type":"COMBINATION_TREATMENT","name":"belumosudil + prednisolone + prednisone","canonical_id":"ctgov_combo:ctgov-combo-19b2707df1982f06","description":null,"metadata":null},{"id":"9cc0a94cc17f4bd29c0d0eca27d1a326","type":"COMBINATION_TREATMENT","name":"belumosudil + ruxolitinib","canonical_id":"ctgov_combo:ctgov-combo-91b71d0528fa81ad","description":null,"metadata":null},{"id":"84d1b88de5804b5c9ce8a31308185b2f","type":"COMBINATION_TREATMENT","name":"belumosudil + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-8b92ecb5c859b68e","description":null,"metadata":null},{"id":"b206a6b528504739875bc02576b04c92","type":"DRUG","name":"benazepril","canonical_id":"gtopdb:6374","description":null,"metadata":null},{"id":"d8af00253d2f483bb273edfff66a60e1","type":"COMBINATION_TREATMENT","name":"benazepril + dipyridamole","canonical_id":"ctgov_combo:ctgov-combo-72150dbfa1375e91","description":null,"metadata":null},{"id":"4a2311b57da740afb0097791c55eb164","type":"COMBINATION_TREATMENT","name":"benazepril + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-83999ac9e6273396","description":null,"metadata":null},{"id":"79650e373d7a44d295b6f49f91317c3a","type":"COMBINATION_TREATMENT","name":"benazepril + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-ce3c276a9d970be2","description":null,"metadata":null},{"id":"a1099bd84e6a4077ae7be9d948bd8104","type":"COMBINATION_TREATMENT","name":"benazepril + trandolapril","canonical_id":"ctgov_combo:ctgov-combo-1a42340679798105","description":null,"metadata":null},{"id":"dd19c9c0eea54aae938f09cfa3918087","type":"DRUG","name":"benazeprilat","canonical_id":"gtopdb:6375","description":null,"metadata":null},{"id":"4834c91fac3f41d48505946986830ea2","type":"DRUG","name":"bendamustine","canonical_id":"mesh:D000069461","description":null,"metadata":null},{"id":"7d7aec6549e24219b9b580dd35c2195e","type":"DISEASE","name":"benign familial infantile epilepsy","canonical_id":"mondo:0017615","description":null,"metadata":null},{"id":"60ef1c15101441bbac4c81b3a44166e6","type":"DISEASE","name":"benign neonatal seizures","canonical_id":"mondo:0016027","description":null,"metadata":null},{"id":"f0b9efe95be84056b094c77d4145a29a","type":"DISEASE","name":"benign prostatic hyperplasia","canonical_id":"mondo:0010811","description":null,"metadata":null},{"id":"8d1d7d95d3cb42d59e1a702c60ff18c5","type":"DRUG","name":"benmelstobart","canonical_id":"gtopdb:13790","description":null,"metadata":null},{"id":"e437ff96ec8f4c9eb89ee0c9afef63de","type":"COMBINATION_TREATMENT","name":"benmelstobart + famitinib","canonical_id":"ctgov_combo:ctgov-combo-45e94deffa1d30a4","description":null,"metadata":null},{"id":"dd774319cd214ffda4dcb711516923ff","type":"COMBINATION_TREATMENT","name":"benmelstobart + garsorasib","canonical_id":"ctgov_combo:ctgov-combo-c4253191913880a3","description":null,"metadata":null},{"id":"7e56a0bac38e440484e0bae952f00150","type":"COMBINATION_TREATMENT","name":"benmelstobart + icotinib","canonical_id":"ctgov_combo:ctgov-combo-649e0665e795fca3","description":null,"metadata":null},{"id":"5a5bf8880868457b82ba13d761f6e073","type":"COMBINATION_TREATMENT","name":"benmelstobart + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-ebb310e039bdf724","description":null,"metadata":null},{"id":"651dfc2044f24f5dacd5880635559097","type":"GO_TERM","name":"benomyl:proton antiporter activity","canonical_id":"go:GO:0015310","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + benomyl(in) = H+(in) + benomyl(out).\" [TC:2.A.1.2.6]","metadata":null},{"id":"b6865d4185584e1cb6cd4aaa1414b97b","type":"DRUG","name":"benoxaprofen","canonical_id":"mesh:C011677","description":null,"metadata":null},{"id":"4fcb0e293a614654b5dd0f7f6baad65f","type":"GO_TERM","name":"bent DNA binding","canonical_id":"go:GO:0003681","description":"\"Binding to DNA in a bent conformation.\" [GOC:jl, PMID:12627977]","metadata":null},{"id":"a151f4a163b4471c99fefe47bc3c2f48","type":"DISEASE","name":"bent bone dysplasia syndrome 1","canonical_id":"mondo:0013815","description":null,"metadata":null},{"id":"0c28c2d3a81343c384b18ec49c8ee524","type":"GO_TERM","name":"benzaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018479","description":"\"Catalysis of the reaction: benzaldehyde + NAD+ + H2O = benzoate + NADH + H+.\" [EC:1.2.1.28]","metadata":null},{"id":"0d061b509b3e4e7399ada151dc479bd6","type":"GO_TERM","name":"benzaldehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0018477","description":"\"Catalysis of the reaction: benzaldehyde + NADP+ + H2O = benzoate + NADPH + H+.\" [RHEA:21660]","metadata":null},{"id":"645ab327fbe94e0e9718d55475ee8480","type":"DRUG","name":"benzathine benzylpenicillin","canonical_id":"mesh:D010401","description":null,"metadata":null},{"id":"d1f4c0536bc14ac9ae36ec906d34c76a","type":"DRUG","name":"benzbromarone","canonical_id":"mesh:D001553","description":null,"metadata":null},{"id":"1b20a31cbf8c44aabcc639ed959f59aa","type":"GO_TERM","name":"benzene 1,2-dioxygenase activity","canonical_id":"go:GO:0018619","description":"\"Catalysis of the reaction: benzene + NADH + O2 + H+ = cis-1,2-dihydrobenzene-1,2-diol + NAD+.\" [RHEA:13813]","metadata":null},{"id":"e0970f5956154f3fb413327168f83753","type":"GO_TERM","name":"benzene biosynthetic process","canonical_id":"go:GO:1900997","description":"\"The chemical reactions and pathways resulting in the formation of benzene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00272]","metadata":null},{"id":"584b6793ed15418abd9412efe4a9fc28","type":"GO_TERM","name":"benzene catabolic process","canonical_id":"go:GO:1900996","description":"\"The chemical reactions and pathways resulting in the breakdown of benzene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00272]","metadata":null},{"id":"aaffed89c4e240a6b90df61527f34a4a","type":"GO_TERM","name":"benzene metabolic process","canonical_id":"go:GO:0018910","description":"\"The chemical reactions and pathways involving benzene, C6H6, a volatile, very inflammable liquid, contained in the naphtha produced by the destructive distillation of coal, from which it is separated by fractional distillation.\" [GOC:ai]","metadata":null},{"id":"ceb51ce265c34acabe6add66ce0053c2","type":"GO_TERM","name":"benzene-containing compound metabolic process","canonical_id":"go:GO:0042537","description":"\"The chemical reactions and pathways involving benzene, C6H6, a volatile, very inflammable liquid, contained in the naphtha produced by the destructive distillation of coal, from which it is separated by fractional distillation, or any of its derivatives.\" [GOC:jl]","metadata":null},{"id":"7bc4cd4e8427427f92e42d5dc06ddac7","type":"GO_TERM","name":"benzoate 1,2-dioxygenase activity","canonical_id":"go:GO:0018623","description":"\"Catalysis of the reaction: benzoate + NADH + O2 + H+ = (1R,6S)-1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate + NAD+.\" [RHEA:12633]","metadata":null},{"id":"b82fe8560e5c4e96a043403de36284b1","type":"GO_TERM","name":"benzoate 4-monooxygenase activity","canonical_id":"go:GO:0018664","description":"\"Catalysis of the reaction: benzoate + H+ + NADPH + O2 = 4-hydroxybenzoate + H2O + NADP+.\" [EC:1.14.14.92, RHEA:18033]","metadata":null},{"id":"e2c40131160d45c78322f84e433392f4","type":"GO_TERM","name":"benzoate catabolic process","canonical_id":"go:GO:0043639","description":"\"The chemical reactions and pathways resulting in the breakdown of benzoate, the anion of benzoic acid (benzenecarboxylic acid), a fungistatic compound widely used as a food preservative; it is conjugated to glycine in the liver and excreted as hippuric acid.\" [GOC:jl, MetaCyc:PWY-7402]","metadata":null},{"id":"aba6a83ca944456696bd4a9f5736e92b","type":"GO_TERM","name":"benzoate metabolic process","canonical_id":"go:GO:0018874","description":"\"The chemical reactions and pathways involving benzoate, the anion of benzoic acid (benzenecarboxylic acid), a fungistatic compound widely used as a food preservative; it is conjugated to glycine in the liver and excreted as hippuric acid.\" [ISBN:0721662544]","metadata":null},{"id":"f53db7f9d7554cc3a74aef685b56d178","type":"GO_TERM","name":"benzoate transmembrane transporter activity","canonical_id":"go:GO:0042925","description":"\"Enables the directed movement of benzoate, the anion of benzoic acid (benzenecarboxylic acid) from one side of a membrane to the other.\" [GOC:jl, ISBN:0721662544]","metadata":null},{"id":"b95341fab3e54f30a5087832637e7174","type":"GO_TERM","name":"benzoate transport","canonical_id":"go:GO:0042919","description":"\"The directed movement of benzoate, the anion of benzoic acid (benzenecarboxylic acid) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, ISBN:0721662544]","metadata":null},{"id":"54d4cfa5542648d1a31673741af723aa","type":"GO_TERM","name":"benzoate-CoA ligase activity","canonical_id":"go:GO:0018858","description":"\"Catalysis of the reaction: ATP + benzoate + CoA = AMP + benzoyl-CoA + diphosphate.\" [EC:6.2.1.25, RHEA:10132]","metadata":null},{"id":"4aae013a14604881821b687392a012d6","type":"DRUG","name":"benzocaine","canonical_id":"mesh:D001566","description":null,"metadata":null},{"id":"242207bcbcef41f8b1f8e476a026db3e","type":"GO_TERM","name":"benzodiazepine receptor activity","canonical_id":"go:GO:0008503","description":"\"Combining with benzodiazepines, a class of drugs with hypnotic, anxiolytic, anticonvulsive, amnestic and myorelaxant properties, to initiate a change in cell activity.\" [GOC:jl]","metadata":null},{"id":"1f0cb0c7da854396b0900430fe327739","type":"GO_TERM","name":"benzodiazepine receptor binding","canonical_id":"go:GO:0030156","description":"\"Binding to a peripheral benzodiazepine receptor (PBR).\" [GOC:ceb, GOC:mah, PMID:9915832]","metadata":null},{"id":"996a9cecc7954f09a6358b5bd85f0f0d","type":"GO_TERM","name":"benzoic acid glucosyltransferase activity","canonical_id":"go:GO:0052641","description":"\"Catalysis of the reaction: benzoic acid + UDP-glucose = benzoic acid glucose ester + UDP.\" [MetaCyc:RXN-11660]","metadata":null},{"id":"eca42153bca7494da6a7cdf10ae1929d","type":"GO_TERM","name":"benzoin aldolase activity","canonical_id":"go:GO:0047695","description":"\"Catalysis of the reaction: benzoin = 2 benzaldehyde.\" [EC:4.1.2.38, RHEA:21460]","metadata":null},{"id":"96dd865e43464a00b2ce7b724a4990df","type":"GO_TERM","name":"benzoyl-CoA 3-monooxygenase activity","canonical_id":"go:GO:0047090","description":"\"Catalysis of the reaction: benzoyl-CoA + H+ + NADPH + O2 = 3-hydroxybenzoyl-CoA + H2O + NADP+.\" [EC:1.14.13.58, RHEA:23216]","metadata":null},{"id":"99e259eb6fd64748b59af266b9c8d7d4","type":"GO_TERM","name":"benzoyl-CoA biosynthetic process","canonical_id":"go:GO:1901789","description":"\"The chemical reactions and pathways resulting in the formation of benzoyl-CoA.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"ac7fb550d1a84bec9ccf6e0f5d67a2da","type":"GO_TERM","name":"benzoyl-CoA catabolic process","canonical_id":"go:GO:1901788","description":"\"The chemical reactions and pathways resulting in the breakdown of benzoyl-CoA.\" [GOC:TermGenie, GOC:yaf, MetaCyc:CENTBENZCOA-PWY, MetaCyc:P321-PWY, MetaCyc:PWY-1361]","metadata":null},{"id":"612c227200964aa9af50b3da2577bcaf","type":"GO_TERM","name":"benzoyl-CoA metabolic process","canonical_id":"go:GO:1901787","description":"\"The chemical reactions and pathways involving benzoyl-CoA.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"4a922680f68f4f6d9672e0340e6c9523","type":"GO_TERM","name":"benzoyl-CoA reductase activity","canonical_id":"go:GO:0018522","description":"\"Catalysis of the reaction: 2 ADP + cyclohexa-1,5-diene-1-carbonyl-CoA + oxidized ferredoxin + 2 phosphate = 2 ATP + 2 H2O + benzoyl-CoA + reduced ferredoxin.\" [EC:1.3.7.8]","metadata":null},{"id":"a8962ff999f04c59a9286a7160f1df73","type":"GO_TERM","name":"benzoylformate decarboxylase activity","canonical_id":"go:GO:0050695","description":"\"Catalysis of the reaction: benzoylformate = benzaldehyde + CO2.\" [EC:4.1.1.7, MetaCyc:BENZOYLFORMATE-DECARBOXYLASE-RXN]","metadata":null},{"id":"de176fb450a543fcbfe19f5ce318d0b4","type":"DRUG","name":"benzquinamide","canonical_id":"gtopdb:7124","description":null,"metadata":null},{"id":"35ead3d2bf1741afb90b42f0796cfd9b","type":"DRUG","name":"benzquinamide","canonical_id":"mesh:C100234","description":null,"metadata":null},{"id":"c13226e7d03f456a9b0e50127d05eaee","type":"DRUG","name":"benzydamine","canonical_id":"mesh:D001591","description":null,"metadata":null},{"id":"1ed5bfff7bfe48a0861c13b6d4eccd8c","type":"GO_TERM","name":"benzyl isoquinoline alkaloid biosynthetic process","canonical_id":"go:GO:0009708","description":"\"The chemical reactions and pathways resulting in the formation of benzyl isoquinoline alkaloids, compounds with bicyclic N-containing aromatic rings.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"7214f194adcc47c69c055b710acde6ab","type":"GO_TERM","name":"benzyl-2-methyl-hydroxybutyrate dehydrogenase activity","canonical_id":"go:GO:0047027","description":"\"Catalysis of the reaction: benzyl (2R,3S)-2-methyl-3-hydroxybutanoate + NADP+ = benzyl 2-methyl-3-oxobutanoate + H+ + NADPH.\" [EC:1.1.1.217, RHEA:16405]","metadata":null},{"id":"5705a3a545c24ae98a8ae28960868e18","type":"DRUG","name":"benzylpenicillin","canonical_id":"mesh:D010400","description":null,"metadata":null},{"id":"27d79cc3c6c24882ab7276a4af82e3bd","type":"GO_TERM","name":"benzylpenicillin biosynthetic process","canonical_id":"go:GO:1901088","description":"\"The chemical reactions and pathways resulting in the formation of benzylpenicillin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00149]","metadata":null},{"id":"7538a64cb44146388b9490c1e489e913","type":"GO_TERM","name":"benzylpenicillin catabolic process","canonical_id":"go:GO:1901087","description":"\"The chemical reactions and pathways resulting in the breakdown of benzylpenicillin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00149]","metadata":null},{"id":"29e843cc0e1f47009808424ee0c7bca7","type":"GO_TERM","name":"benzylpenicillin metabolic process","canonical_id":"go:GO:1901086","description":"\"The chemical reactions and pathways involving benzylpenicillin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00149]","metadata":null},{"id":"4b9943c0a54541faa4cba9532fe5b704","type":"GO_TERM","name":"benzylsuccinate synthase activity","canonical_id":"go:GO:0018805","description":"\"Catalysis of the reaction: fumarate + toluene = 2-benzylsuccinate.\" [EC:4.1.99.11, RHEA:10416]","metadata":null},{"id":"75c7dce51e6c496bbf11113887a52546","type":"DRUG","name":"bepridil","canonical_id":"mesh:D015764","description":null,"metadata":null},{"id":"c9cadc6a35754b518175735682ac11ae","type":"DRUG","name":"beractant","canonical_id":"mesh:C072197","description":null,"metadata":null},{"id":"9c77f8b4fa594d62bb6898cabf1100b4","type":"DRUG","name":"beraprost","canonical_id":"mesh:C048081","description":null,"metadata":null},{"id":"3307f69fe4db4e49b7f5b8e0b21adeea","type":"GO_TERM","name":"berbamunine biosynthetic process","canonical_id":"go:GO:0035833","description":"\"The chemical reactions and pathways resulting in the formation of berbamunine, an isoquinoline alkaloid.\" [GOC:yaf]","metadata":null},{"id":"cd47bb50459b4e4c81a550c8a7363f17","type":"GO_TERM","name":"berbamunine synthase activity","canonical_id":"go:GO:0047054","description":"\"Catalysis of the reaction: (S)-N-methylcoclaurine + (R)-N-methylcoclaurine + [reduced NADPH--hemoprotein reductase] + O2 = berbamunine + [oxidized NADPH--hemoprotein reductase] + 2 H2O.\" [RHEA:23576]","metadata":null},{"id":"6aa775dc2acb4608a4f70e2b41687037","type":"GO_TERM","name":"berberine reductase activity","canonical_id":"go:GO:0050623","description":"\"Catalysis of the reaction: (R)-canadine + 2 NADP+ = berberine + H+ + 2 NADPH.\" [EC:1.5.1.31, RHEA:21268]","metadata":null},{"id":"c4674d0afb9845f7b0b01fc192d199be","type":"DRUG","name":"besifloxacin","canonical_id":"mesh:C522124","description":null,"metadata":null},{"id":"43b86bb2b5c14f31bbbd55faeb434475","type":"GO_TERM","name":"beta 2 integrin biosynthetic process","canonical_id":"go:GO:0045114","description":"\"The chemical reactions and pathways resulting in the formation of beta 2 integrins, a subfamily of integrins which contain the beta 2 subunit.\" [GOC:curators]","metadata":null},{"id":"c49f36ce24d745bf8caee901cb95b144","type":"DISEASE","name":"beta Thalassemia","canonical_id":"mesh:D017086","description":null,"metadata":null},{"id":"a31bbd1f46d34b148c51bf54d8dd4be1","type":"GO_TERM","name":"beta barrel protein insertion into mitochondrial outer membrane","canonical_id":"go:GO:7770063","description":"\"The import of beta barrel proteins from the cytosol and their insertion into the mitochondrial outer membrane.\" [PMID:36931257]","metadata":null},{"id":"dd4a15e53f6b4403b48d0d7539a18072","type":"GO_TERM","name":"beta selection","canonical_id":"go:GO:0043366","description":"\"The process in which successful recombination of a T cell receptor beta chain into a translatable protein coding sequence leads to rescue from apoptosis and subsequent proliferation of an immature T cell.\" [ISBN:0781735149, PMID:12220932]","metadata":null},{"id":"ea6f6299cfd84a5fa87a7ebe1889898a","type":"GO_TERM","name":"beta,beta-carotene-9',10'-cleaving oxygenase activity","canonical_id":"go:GO:0102076","description":"\"Catalysis of the reaction: beta-carotene + O2 = 10'-apo-beta-carotenal + beta-ionone.\" [EC:1.13.11.71, GOC:pz]","metadata":null},{"id":"70d53cfc24764f90826b74e7164aeb6a","type":"GO_TERM","name":"beta,beta-carotene-9',10'-dioxygenase activity","canonical_id":"go:GO:0050541","description":"\"Catalysis of the reaction: beta-carotene + O2 = beta-apo-10'-carotenal + beta-ionone.\" [PMID:11278918]","metadata":null},{"id":"fd5b3be3fbda4b00a60eff9ca479a5ed","type":"GO_TERM","name":"beta-1 adrenergic receptor binding","canonical_id":"go:GO:0031697","description":"\"Binding to a beta-1 adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"11e6ffeea2f847029b3303708ac6808a","type":"GO_TERM","name":"beta-1,2-oligomannoside biosynthetic process","canonical_id":"go:GO:0070136","description":"\"The chemical reactions and pathways resulting in the formation of beta-1,2-linked oligomannosides, which are found in fungal cell wall phosphopeptidomannan and phospholipomannan.\" [GOC:mah, PMID:18234669]","metadata":null},{"id":"f753e2bfd625467195025452394f9c46","type":"GO_TERM","name":"beta-1,2-oligomannoside metabolic process","canonical_id":"go:GO:0070135","description":"\"The chemical reactions and pathways involving beta-1,2-linked oligomannosides, which are found in fungal cell wall phosphopeptidomannan and phospholipomannan.\" [GOC:mah, PMID:18234669]","metadata":null},{"id":"13da50af03654dc185bfd76b382f2207","type":"GO_TERM","name":"beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047223","description":"\"Catalysis of the reaction: beta-D-galactosyl-1,3-(N-acetyl-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R + UDP-N-acetyl-D-glucosamine = N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R + UDP.\" [EC:2.4.1.146, MetaCyc:2.4.1.146-RXN]","metadata":null},{"id":"ca90d3921b204d88982068cbb6df9649","type":"GO_TERM","name":"beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0003829","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-D-galactosaminyl-R = UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-D-galactosaminyl-R. This reaction is the addition of N-acetyl-alpha-D-glucosamine to the core 1 structure of O-glycans forming core 2.\" [EC:2.4.1.102]","metadata":null},{"id":"f4dbf79bc19c43339ff3a921ca0768a5","type":"GO_TERM","name":"beta-1,3-galactosyltransferase activity","canonical_id":"go:GO:0048531","description":"\"Catalysis of the transfer of a galactose residue from a donor molecule to an oligosaccharide, forming a beta-1,3-linkage.\" [PMID:11551958]","metadata":null},{"id":"8b1f38386c80437788aaa15d78d5aa65","type":"GO_TERM","name":"beta-1,4-mannosylglycolipid beta-1,3-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0046981","description":"\"Catalysis of the transfer of N-acetylglucosamine (GlcNAc) in a beta-1,3 linkage to the mannose(beta-1,4)Glc disaccharide core of glycolipids.\" [GOC:bf, PMID:12130631, PMID:12130651]","metadata":null},{"id":"632ffeef1d624722a27ca49ddad98c2c","type":"GO_TERM","name":"beta-1,4-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0003830","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + beta-D-mannosyl-R = UDP + 4-(N-acetyl-beta-D-glucosaminyl)-beta-D-mannosyl-R.\" [EC:2.4.1.144]","metadata":null},{"id":"0bc4e469a15744159acb30cd74e1837a","type":"GO_TERM","name":"beta-1,4-mannosyltransferase activity","canonical_id":"go:GO:0019187","description":"\"Catalysis of the transfer of a mannose residue to an oligosaccharide, forming a beta-(1->4) linkage.\" [GOC:mcc, PMID:8166646]","metadata":null},{"id":"f35420a53ca14683994335e5e09522a8","type":"GO_TERM","name":"beta-2 adrenergic receptor binding","canonical_id":"go:GO:0031698","description":"\"Binding to a beta-2 adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e46e79e5fb514fb0ba6a2f7a47f6cdd5","type":"GO_TERM","name":"beta-2-microglobulin binding","canonical_id":"go:GO:0030881","description":"\"Binding to beta-2-microglobulin.\" [GOC:mah]","metadata":null},{"id":"28757a988ff440748bbfd533e40a8803","type":"GO_TERM","name":"beta-3 adrenergic receptor binding","canonical_id":"go:GO:0031699","description":"\"Binding to a beta-3 adrenergic receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7e2ea2f1c48645329238f95c4ea8a832","type":"GO_TERM","name":"beta-6-sulfate-N-acetylglucosaminidase activity","canonical_id":"go:GO:0052769","description":"\"Catalysis of the glycosidic cleavage of the terminal 2-acetamido-2-deoxy-beta-D-glucopyranoside 6-sulfate (6-SO3-GlcNAc) residue from sulfomucin, a sulfated mucin derivative.\" [GOC:mengo_curators, PMID:15716424]","metadata":null},{"id":"28db39b3b1fc437cac6d4586ef0a20c5","type":"GO_TERM","name":"beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc binding","canonical_id":"go:GO:2001079","description":"\"Binding to beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc.\" [GOC:mengo_curators]","metadata":null},{"id":"644edfe6553c42daa007bffa2e01e209","type":"GO_TERM","name":"beta-D-fucosidase activity","canonical_id":"go:GO:0033907","description":"\"Catalysis of the hydrolysis of terminal non-reducing beta-D-fucose residues in beta-D-fucosides.\" [EC:3.2.1.38]","metadata":null},{"id":"e0977600ad68498985a432cf8d9256a5","type":"GO_TERM","name":"beta-D-galactofuranose biosynthetic process","canonical_id":"go:GO:1901358","description":"\"The chemical reactions and pathways resulting in the formation of beta-D-galactofuranose.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a07f27632a114cc79c1a4e15c6a85c0f","type":"GO_TERM","name":"beta-D-galactofuranose catabolic process","canonical_id":"go:GO:1901357","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-D-galactofuranose.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"72a3711fe48146069659e7a487c580e9","type":"GO_TERM","name":"beta-D-galactose catabolic process via UDP-galactose, Leloir pathway","canonical_id":"go:GO:0033499","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-D-galactose, via the intermediate UDP-galactose.\" [MetaCyc:PWY-6317]","metadata":null},{"id":"a47d31b991ec4c07b8ba16f5fc42dc87","type":"GO_TERM","name":"beta-D-galactose-importing ATPase activity","canonical_id":"go:GO:0102014","description":"\"Catalysis of the reaction: ATP(4-) + beta-D-galactoside + H2O = ADP(3-) + hydrogenphosphate + beta-D-galactoside + H+.\" [RHEA:30011]","metadata":null},{"id":"4006d908cdd84e7ead9508943fe0d04a","type":"GO_TERM","name":"beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminide alpha-2,3- sialyltransferase activity","canonical_id":"go:GO:0047288","description":"\"Catalysis of the reaction: beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl derivative + CMP-N-acetyl-beta-neuraminate = N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl derivative + CMP + H+.\" [RHEA:52380]","metadata":null},{"id":"531030db390e422ba1fe07bc258f3ad3","type":"GO_TERM","name":"beta-D-glucose oxidase activity","canonical_id":"go:GO:0046562","description":"\"Catalysis of the reaction: beta-D-glucose + O2 = D-glucono-1,5-lactone + H2O2.\" [RHEA:11428]","metadata":null},{"id":"e35233def126456a884ff73c708744c8","type":"GO_TERM","name":"beta-L-Ara4N-lipid A biosynthetic process","canonical_id":"go:GO:1901760","description":"\"The chemical reactions and pathways resulting in the formation of beta-L-Ara4N-lipid A which occurs as a result of modification of the lipid A moiety of lipopolysaccharide by the addition of the sugar 4-amino-4-deoxy-L-arabinose (L-Ara4N). This strategy is adopted by pathogenic Gram-negative bacteria to evade cationic antimicrobial peptides produced by the innate immune system.\" [GOC:TermGenie, GOC:yaf, PMID:17928292, PMID:19166326, UniPathway:UPA00037]","metadata":null},{"id":"7865f4078a56467faa2021f34efcd0d8","type":"GO_TERM","name":"beta-L-arabinofuranosidase activity","canonical_id":"go:GO:0102478","description":"\"Catalysis of the reaction: beta-L-arabinofuranosyl-(1->2)-beta-L-arabinofuranose + H2O = 2 beta-L-arabinofuranose.\" [GOC:pz, RHEA:36051]","metadata":null},{"id":"115307868aa74b28a6e381c0c32446d2","type":"GO_TERM","name":"beta-L-arabinosidase activity","canonical_id":"go:GO:0047701","description":"\"Catalysis of the reaction: H2O + a beta-L-arabinoside = L-arabinose + an alcohol.\" [EC:3.2.1.88]","metadata":null},{"id":"bcecd22aa41f4c08b6dd276e488e2fb4","type":"GO_TERM","name":"beta-L-rhamnosidase activity","canonical_id":"go:GO:0033908","description":"\"Catalysis of the hydrolysis of terminal, non-reducing beta-L-rhamnose residues in beta-L-rhamnosides.\" [EC:3.2.1.43]","metadata":null},{"id":"d6cfe5f4cf4545ea8a65b76165b736b7","type":"GO_TERM","name":"beta-N-acetylgalactosaminidase activity","canonical_id":"go:GO:0032428","description":"\"Catalysis of the hydrolysis of terminal non-reducing N-acetyl-D-galactosamine residues in N-acetyl-beta-D-galactosaminides.\" [EC:3.2.1.53]","metadata":null},{"id":"80bbc21018cf46798a3be364e5abeb00","type":"GO_TERM","name":"beta-N-acetylglucosaminidase activity","canonical_id":"go:GO:0016231","description":"\"Catalysis of the hydrolysis of terminal non-reducing N-acetyl-D-glucosamine residues in N-acetyl-beta-D-glucosaminides.\" [PMID:29143882, PMID:37590576]","metadata":null},{"id":"afc937140e844568b180ffbc228c5d60","type":"GO_TERM","name":"beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity","canonical_id":"go:GO:0003831","description":"\"Catalysis of the reaction: UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide = UDP + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide.\" [EC:2.4.1.38]","metadata":null},{"id":"18b6d93bf77f402b938371cdd52e40b2","type":"GO_TERM","name":"beta-N-acetylhexosaminidase activity","canonical_id":"go:GO:0004563","description":"\"Catalysis of the hydrolysis of terminal non-reducing N-acetyl-D-hexosamine residues in N-acetyl-beta-D-hexosaminides.\" [EC:3.2.1.52]","metadata":null},{"id":"a248841da01247cab66a9c8da7df5927","type":"GO_TERM","name":"beta-N-acetylhexosaminidase complex","canonical_id":"go:GO:1905379","description":"\"A protein complex which is capable of beta-N-acetylhexosaminidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:6458607]","metadata":null},{"id":"ea83d7c2adb041f58deb0fdab4b5b06f","type":"GO_TERM","name":"beta-acoradiene synthase activity","canonical_id":"go:GO:0102882","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = beta-acoradiene + diphosphate.\" [RHEA:68520]","metadata":null},{"id":"cd2a9f4f0fcd49ba87c4f47dd72f72cc","type":"GO_TERM","name":"beta-adrenergic receptor activity","canonical_id":"go:GO:0004939","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta-adrenergic receptors; the activity involves transmitting the signal to the Gs alpha subunit of a heterotrimeric G protein.\" [GOC:cb, GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"d814c27f9785404a9c0fd9d2362f36bd","type":"GO_TERM","name":"beta-adrenergic receptor kinase activity","canonical_id":"go:GO:0047696","description":"\"Catalysis of the reaction: [beta-adrenergic receptor] + ATP = [beta-adrenergic receptor]-phosphate + ADP + H+.\" [RHEA:19429]","metadata":null},{"id":"598657dd1e43492a97c7226320e79c14","type":"GO_TERM","name":"beta-agarase activity","canonical_id":"go:GO:0033916","description":"\"Catalysis of the hydrolysis of (1->4)-beta-D-galactosidic linkages in agarose, giving the tetramer as the predominant product.\" [EC:3.2.1.81]","metadata":null},{"id":"99f5ddc1424b4bdfa7e4f532853803b9","type":"GO_TERM","name":"beta-alanine biosynthetic process","canonical_id":"go:GO:0019483","description":"\"The chemical reactions and pathways resulting in the formation of beta-alanine (3-aminopropanoic acid), an achiral amino acid and an isomer of alanine. It occurs free (e.g. in brain) and in combination (e.g. in pantothenate) but it is not a constituent of proteins.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"2037effc2b394d2cb51434d8bbbe4bd9","type":"GO_TERM","name":"beta-alanine catabolic process","canonical_id":"go:GO:0019484","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-alanine.\" [GOC:curators]","metadata":null},{"id":"19b02cc7c0da4bb2a85f3aaf66546bff","type":"GO_TERM","name":"beta-alanine transmembrane transporter activity","canonical_id":"go:GO:0001761","description":"\"Enables the transfer of beta-alanine from one side of a membrane to the other. Beta-alanine is 3-aminopropanoic acid.\" [GOC:hjd]","metadata":null},{"id":"e7cc9cad6fa240699f30702fc849558f","type":"GO_TERM","name":"beta-alanine transport","canonical_id":"go:GO:0001762","description":"\"The directed movement of beta-alanine, 3-aminopropanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:hjd]","metadata":null},{"id":"57e36dc6e4604e4388a42b6025b654c5","type":"GO_TERM","name":"beta-alanine:pyruvate transaminase activity","canonical_id":"go:GO:0016223","description":"\"Catalysis of the reaction: L-alanine + 3-oxopropanoate = beta-alanine + pyruvate.\" [RHEA:14077]","metadata":null},{"id":"c3a1a0b8957b4c83ad524dccd9fdb2b3","type":"GO_TERM","name":"beta-alanopine dehydrogenase activity","canonical_id":"go:GO:0047697","description":"\"Catalysis of the reaction: (R)-beta-alanopine + H2O + NAD+ = beta-alanine + H+ + NADH + pyruvate.\" [EC:1.5.1.26, RHEA:21684]","metadata":null},{"id":"7ebeed5422d44639beb3a8014c4ecf0e","type":"GO_TERM","name":"beta-alanyl amine synthase activity","canonical_id":"go:GO:0003833","description":"\"Catalysis of the synthesis of beta-alanyl amine conjugate from a precursor biogenic amine, such as dopamine or histamine.\" [GOC:bf, PMID:12900414, PMID:12957543, PMID:25229196]","metadata":null},{"id":"03b98d7b99b14164b869c09d2d735135","type":"GO_TERM","name":"beta-alanyl-CoA ammonia-lyase activity","canonical_id":"go:GO:0047698","description":"\"Catalysis of the reaction: beta-alanyl-CoA = acryloyl-CoA + NH4+.\" [RHEA:12416]","metadata":null},{"id":"c60a1f40041642b7a840085bd55e5d42","type":"GO_TERM","name":"beta-alanyl-dopamine hydrolase activity","canonical_id":"go:GO:0003832","description":"\"Catalysis of the reaction: beta-alanyl-dopamine + H2O = dopamine + beta-alanine.\" [PMID:16299587, RHEA:73467]","metadata":null},{"id":"e8ce0a64b5fc43e5a08f6a625abb0844","type":"GO_TERM","name":"beta-alanyl-histamine hydrolase activity","canonical_id":"go:GO:0031964","description":"\"Catalysis of the reaction: carcinine + H2O = histamine + beta-alanine. Carcinine is also known as N-beta-alanyl histamine.\" [PMID:16299587, RHEA:73463]","metadata":null},{"id":"6ec46002346648b7941fb4e5363ed821","type":"GO_TERM","name":"beta-amylase activity","canonical_id":"go:GO:0016161","description":"\"Catalysis of the reaction: (1,4-alpha-D-glucosyl)(n+1) + H2O = (1,4-alpha-D-glucosyl)(n-1) + alpha-maltose. This reaction is the hydrolysis of 1,4-alpha-glucosidic linkages in polysaccharides so as to remove successive maltose units from the non-reducing ends of the chains.\" [PMID:18390594]","metadata":null},{"id":"0dd0eab2eb0f4ed48313dec6904c126f","type":"GO_TERM","name":"beta-amyrin 11-oxidase activity","canonical_id":"go:GO:0102289","description":"\"Catalysis of the reaction: beta-amyrin + 2 O2 + 2 NADPH + 2 H+ = 11-oxo-beta-amyrin + 3 H2O + 2 NADP.\" [RHEA:31711]","metadata":null},{"id":"c83347b5b8264c43a79afa1b149a57fa","type":"GO_TERM","name":"beta-amyrin 16beta-monooxygenase activity","canonical_id":"go:GO:0102601","description":"\"Catalysis of the reaction: beta-amyrin + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + maniladiol + oxidized [NADPH--hemoprotein reductase].\" [EC:1.14.14.63]","metadata":null},{"id":"7f06ea0c1f5a4a02a85548053a33a0d2","type":"GO_TERM","name":"beta-amyrin 28-monooxygenase activity","canonical_id":"go:GO:0102373","description":"\"Catalysis of the reaction: beta-amyrin + 3 O2 + 3 reduced [NADPH--hemoprotein reductase] = 4 H+ + 4 H2O + oleanolate + 3 oxidized [NADPH--hemoprotein reductase].\" [PMID:22039103, RHEA:43068]","metadata":null},{"id":"e5c29f625a674c72a865a962d460fd2b","type":"GO_TERM","name":"beta-amyrin synthase activity","canonical_id":"go:GO:0042300","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = beta-amyrin.\" [PMID:9746369, RHEA:31007]","metadata":null},{"id":"4096fbc0f47c4e24b5bb317b3d375eb2","type":"GO_TERM","name":"beta-apiosyl-beta-glucosidase activity","canonical_id":"go:GO:0033956","description":"\"Catalysis of the reaction: 7-[beta-D-apiofuranosyl-(1->6)-beta-D-glucopyranosyloxy]isoflavonoid + H2O = a 7-hydroxyisoflavonoid + beta-D-apiofuranosyl-(1->6)-D-glucose.\" [EC:3.2.1.161]","metadata":null},{"id":"58cf5a8339a44f7b9e8ec5f4f23c2736","type":"GO_TERM","name":"beta-arrestin-dependent dopamine receptor signaling pathway","canonical_id":"go:GO:0160213","description":"\"A beta-arrestin-dependent signaling pathway initiated by a dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [PMID:21711983, PMID:25671228]","metadata":null},{"id":"d9a28fd868244da997df3d79c7c33388","type":"GO_TERM","name":"beta-aspartyl-N-acetylglucosaminidase activity","canonical_id":"go:GO:0047406","description":"\"Catalysis of the reaction: N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine + H2O = N-acetyl-D-glucosamine + L-asparagine.\" [EC:3.2.2.11, RHEA:12324]","metadata":null},{"id":"6cff714164414400a9fb37663b771ba1","type":"GO_TERM","name":"beta-aspartyl-peptidase activity","canonical_id":"go:GO:0008798","description":"\"Catalysis of the cleavage of a beta-linked aspartic residue from the N-terminus of a polypeptide.\" [EC:3.4.19.5]","metadata":null},{"id":"10269fa0658843c6b2641774cd01095f","type":"GO_TERM","name":"beta-carotene 15,15'-dioxygenase activity","canonical_id":"go:GO:0003834","description":"\"Catalysis of the reaction: all-trans-beta-carotene + O2 = 2 all-trans-retinal.\" [RHEA:32887]","metadata":null},{"id":"84ba99aa00574293a5c68f90d5d2b0c0","type":"GO_TERM","name":"beta-carotene 3-hydroxylase activity","canonical_id":"go:GO:0010291","description":"\"Catalysis of the reaction: all-trans-beta-carotene + 4 H+ + 2 O2 + 4 reduced [2Fe-2S]-[ferredoxin] = all-trans-zeaxanthin + 2 H2O + 4 oxidized [2Fe-2S]-[ferredoxin].\" [PMID:16492736, RHEA:30331]","metadata":null},{"id":"6722da1ea9784bfc9648a572bf4275a8","type":"GO_TERM","name":"beta-carotene biosynthetic process","canonical_id":"go:GO:1901812","description":"\"The chemical reactions and pathways resulting in the formation of beta-carotene.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5943, PMID:11387982, UniPathway:UPA00802]","metadata":null},{"id":"44bda3c677b74eda9348499063160b95","type":"GO_TERM","name":"beta-carotene catabolic process","canonical_id":"go:GO:1901811","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-carotene.\" [GOC:TermGenie, GOC:yaf, PMID:11387982, UniPathway:UPA00802]","metadata":null},{"id":"a4985ba14f624f87926fb60ae9368a10","type":"GO_TERM","name":"beta-carotene isomerase activity","canonical_id":"go:GO:0106365","description":"\"Catalyzes the reaction: all-trans-beta-carotene = 9-cis-beta-carotene.\" [PMID:19470589, PMID:22422982, RHEA:34455]","metadata":null},{"id":"06ac38e685ce41dab75e476f7853e29f","type":"GO_TERM","name":"beta-carotene metabolic process","canonical_id":"go:GO:1901810","description":"\"The chemical reactions and pathways involving beta-carotene.\" [GOC:TermGenie, GOC:yaf, PMID:11387982, UniPathway:UPA00802]","metadata":null},{"id":"963ce244d3184533aee248a8f031782b","type":"GO_TERM","name":"beta-caryophyllene biosynthetic process","canonical_id":"go:GO:1901937","description":"\"The chemical reactions and pathways resulting in the formation of beta-caryophyllene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"cff4bfcc15194b6cbd144289bd92c209","type":"GO_TERM","name":"beta-caryophyllene catabolic process","canonical_id":"go:GO:1901936","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-caryophyllene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"866afe27dc334f6f8777b05952d89da2","type":"GO_TERM","name":"beta-catenin binding","canonical_id":"go:GO:0008013","description":"\"Binding to a catenin beta subunit.\" [GOC:bf]","metadata":null},{"id":"57cc5b6784b042c291fcfefdeac3d520","type":"GO_TERM","name":"beta-catenin destruction complex","canonical_id":"go:GO:0030877","description":"\"A cytoplasmic protein complex containing glycogen synthase kinase-3-beta (GSK-3-beta), the adenomatous polyposis coli protein (APC), and the scaffolding protein axin, among others; phosphorylates beta-catenin, targets it for degradation by the proteasome.\" [PMID:14600025]","metadata":null},{"id":"b7055b015f764802819b6ecfc73ec537","type":"GO_TERM","name":"beta-catenin destruction complex assembly","canonical_id":"go:GO:1904885","description":"\"The aggregation, arrangement and bonding together of a set of components to form a beta-catenin destruction complex.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:17143292, PMID:23169527]","metadata":null},{"id":"413e7ae2241c477cb9b00fe28293253d","type":"GO_TERM","name":"beta-catenin destruction complex binding","canonical_id":"go:GO:1904713","description":"\"Binding to a beta-catenin destruction complex.\" [GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22899650]","metadata":null},{"id":"7b210e9f06b94c9192bf2950ac96a5c5","type":"GO_TERM","name":"beta-catenin destruction complex disassembly","canonical_id":"go:GO:1904886","description":"\"The disaggregation of a beta-catenin destruction complex into its constituent components.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23169527]","metadata":null},{"id":"e07c1ef90a3542f88a3f6654ebdb3681","type":"GO_TERM","name":"beta-catenin-ICAT complex","canonical_id":"go:GO:1990711","description":"\"Transcription factor complex that inhibits binding of Tcf to beta-catenin while preserving interaction of catenin with cadherin thus inhibiting transcription mediated by beta-catenin-Tcf complex.\" [GOC:bhm, PMID:12408824]","metadata":null},{"id":"611e0815667d41939d59f712223f2eae","type":"GO_TERM","name":"beta-catenin-TCF complex","canonical_id":"go:GO:1990907","description":"\"A protein complex that contains beta-catenin and a member of the T-cell factor (TCF)/lymphoid enhancer binding factor (LEF) family of transcription factors.\" [GOC:bf, GOC:PARL, PMID:11751639, PMID:16936075, PMID:20123964, PMID:21075118, PMID:9419974]","metadata":null},{"id":"9bb6df77def74944872d76cfb20220de","type":"GO_TERM","name":"beta-catenin-TCF complex assembly","canonical_id":"go:GO:1904837","description":"\"The aggregation, arrangement and bonding together of a set of components to form a beta-catenin-TCF complex.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18936100]","metadata":null},{"id":"5f02815740ec4c3eb4e06d7b2dbd397e","type":"GO_TERM","name":"beta-catenin-TCF7L2 complex","canonical_id":"go:GO:0070369","description":"\"A protein complex that contains beta-catenin and TCF7L2 (TCF4), binds to the TCF DNA motif within a promoter element, and is involved in the regulation of WNT target gene transcription.\" [GOC:BHF, GOC:rl, PMID:9065401, PMID:9065402]","metadata":null},{"id":"208482a14b8747d69ea7bffb41fae359","type":"GO_TERM","name":"beta-cyclopiazonate dehydrogenase activity","canonical_id":"go:GO:0050448","description":"\"Catalysis of the reaction: beta-cyclopiazonate + A = alpha-cyclopiazonate + AH(2).\" [RHEA:14525]","metadata":null},{"id":"974a2c6de30e40eca0edb44b19bbc095","type":"GO_TERM","name":"beta-diketone hydrolase activity","canonical_id":"go:GO:0047699","description":"\"Catalysis of the reaction: H2O + nonane-4,6-dione = butanoate + H+ + pentan-2-one.\" [RHEA:11908]","metadata":null},{"id":"6d4a7c0cdf64414fa7a59e66a33742d8","type":"GO_TERM","name":"beta-elemene synthase activity","canonical_id":"go:GO:0102889","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = beta-elemene + diphosphoric acid.\" [MetaCyc:RXN-8432]","metadata":null},{"id":"5bee3d80824c4d7c9708ec1e97ca11d7","type":"GO_TERM","name":"beta-endorphin binding","canonical_id":"go:GO:0031626","description":"\"Binding to beta-endorphin, a peptide generated by the cleavage of pro-opiomelanocortin.\" [GOC:nln, PMID:6267560]","metadata":null},{"id":"c37f085a7d6c4fadb77d31bfea5ad338","type":"GO_TERM","name":"beta-endorphin receptor activity","canonical_id":"go:GO:0004979","description":"\"Combining with beta-endorphin, and transmitting the signal across the membrane by activating an associated G-protein. Beta-endorphin is a peptide, 31 amino acids long, resulting from processing of the precursor proopiomelanocortin (POMC).\" [GOC:ai, GOC:bf, Wikipedia:Beta-endorphin]","metadata":null},{"id":"4f88d9ec4cc44184b13118d1b5e4cbb2","type":"GO_TERM","name":"beta-endorphin receptor binding","canonical_id":"go:GO:0071857","description":"\"Binding to a beta-endorphin receptor.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"e91813506c3d4cb7be3c0e22da4b5ab7","type":"GO_TERM","name":"beta-fructofuranosidase activity","canonical_id":"go:GO:0004564","description":"\"Catalysis of the reaction: a fructofuranosylated fructofuranosyl acceptor + H2O = a non fructofuranosylated fructofuranosyl acceptor + a beta-D-fructofuranoside.\" [EC:3.2.1.26, MetaCyc:RXN-9985]","metadata":null},{"id":"d2a7891b6e394dffaf0508c219c45e3b","type":"GO_TERM","name":"beta-galactofuranosidase activity","canonical_id":"go:GO:0033944","description":"\"Catalysis of the hydrolysis of terminal non-reducing beta-D-galactofuranosides, releasing galactose.\" [EC:3.2.1.146]","metadata":null},{"id":"43dbaaf5ce2443bca09763de548857c1","type":"GO_TERM","name":"beta-galactosidase activity","canonical_id":"go:GO:0004565","description":"\"Catalysis of the hydrolysis of terminal, non-reducing beta-D-galactose residues in beta-D-galactosides.\" [EC:3.2.1.23]","metadata":null},{"id":"1f99d569b2d244cf8eeee578162170e1","type":"GO_TERM","name":"beta-galactosidase complex","canonical_id":"go:GO:0009341","description":"\"A protein complex that possesses beta-galactosidase activity, i.e. catalyzes the hydrolysis of terminal non-reducing beta-D-galactose residues in beta-D-galactosides. In E. coli, the complex is a homotetramer; dimeric and hexameric beta-galactosidase complexes have been observed in other species.\" [PMID:15950161]","metadata":null},{"id":"432b186303ce43a1b40369fad92a005a","type":"GO_TERM","name":"beta-galactoside (CMP) alpha-2,3-sialyltransferase activity","canonical_id":"go:GO:0003836","description":"\"Catalysis of the reaction: CMP-N-acetylneuraminate + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R = CMP + alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R.\" [EC:2.4.3.4]","metadata":null},{"id":"dd93d293621541e68ef28686a85ab39c","type":"GO_TERM","name":"beta-galactoside alpha-2,3-sialyltransferase activity","canonical_id":"go:GO:0052798","description":"\"Catalysis of the transfer of sialyl residues alpha-2,3-linked to a beta galactosyl residue on the donor to form an alpha-2,3 linkage to a terminal beta galactosyl residue on the acceptor.\" [GOC:mengo_curators, PMID:7826016, PMID:8405811]","metadata":null},{"id":"3dda9bd0a48f4f0a82c573b678e8f445","type":"GO_TERM","name":"beta-galactoside alpha-2,6-sialyltransferase activity","canonical_id":"go:GO:0003835","description":"\"Catalysis of the reaction: CMP-N-acetylneuraminate + beta-D-galactoside = N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl derivative + CMP + H+.\" [EC:2.4.3.1]","metadata":null},{"id":"933d18c413b74abda4192dee05f31d1f","type":"GO_TERM","name":"beta-gentiobiose beta-glucosidase activity","canonical_id":"go:GO:0080083","description":"\"Catalysis of the hydrolysis of glucosidic link in beta-gentiobiose.\" [PMID:15604686]","metadata":null},{"id":"03c54368e74c4c709576f12aa1f301f5","type":"GO_TERM","name":"beta-glucan biosynthetic process","canonical_id":"go:GO:0051274","description":"\"The chemical reactions and pathways resulting in the formation of beta-glucans.\" [GOC:ai]","metadata":null},{"id":"9d56722baf424072bc5decc5d1ce6596","type":"GO_TERM","name":"beta-glucan catabolic process","canonical_id":"go:GO:0051275","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-glucans.\" [GOC:ai]","metadata":null},{"id":"427c8e431c394fd0ac1de7238cde1c6a","type":"GO_TERM","name":"beta-glucan metabolic process","canonical_id":"go:GO:0051273","description":"\"The chemical reactions and pathways involving beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds.\" [GOC:ai]","metadata":null},{"id":"f5b331b23ca04a8599a2bc9e010d2227","type":"GO_TERM","name":"beta-glucan transmembrane transporter activity","canonical_id":"go:GO:0015160","description":"\"Enables the transfer of beta-glucans from one side of a membrane to the other. Beta-glucans are compounds composed of glucose residues linked by beta-glucosidic bonds.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b61e32dceeec4cd794c54538436a295a","type":"GO_TERM","name":"beta-glucan transport","canonical_id":"go:GO:0015775","description":"\"The directed movement of beta-glucans into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Beta-glucans are compounds composed of glucose residues linked by beta-glucosidic bonds.\" [GOC:ai]","metadata":null},{"id":"2673f891e7124083b14dce2d0e13ab26","type":"GO_TERM","name":"beta-glucanase activity","canonical_id":"go:GO:0052736","description":"\"Catalysis of the hydrolysis of linkages in beta-D-glucans; beta-glucans are polysaccharides of D-glucose monomers linked by beta-glycosidic bonds.\" [Wikipedia:Beta-glucan]","metadata":null},{"id":"1b9604136e60432a8efbf3b4f400aa59","type":"GO_TERM","name":"beta-glucogallin O-galloyltransferase activity","canonical_id":"go:GO:0047201","description":"\"Catalysis of the reaction: 2 1-O-galloyl-beta-D-glucose = 1,6-bis-O-galloyl-beta-D-glucose + D-glucose.\" [EC:2.3.1.90, RHEA:11416]","metadata":null},{"id":"c24ef08805d043deb90b44b53ae7da61","type":"GO_TERM","name":"beta-glucogallin-tetrakisgalloylglucose O-galloyltransferase activity","canonical_id":"go:GO:0047176","description":"\"Catalysis of the reaction: 1,2,3,6-tetrakis-O-galloyl-beta-D-glucose + 1-O-galloyl-beta-D-glucose = 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose + D-glucose.\" [EC:2.3.1.143, RHEA:19109]","metadata":null},{"id":"0065e80497704c3d9e9502c7fbd3da79","type":"GO_TERM","name":"beta-glucosidase activity","canonical_id":"go:GO:0008422","description":"\"Catalysis of the hydrolysis of terminal, non-reducing beta-D-glucose residues with release of beta-D-glucose.\" [EC:3.2.1.21, PMID:12594539]","metadata":null},{"id":"1fb21db03c48459e98745c35d7c34d03","type":"GO_TERM","name":"beta-glucoside biosynthetic process","canonical_id":"go:GO:1901806","description":"\"The chemical reactions and pathways resulting in the formation of beta-glucoside.\" [GOC:TermGenie, GOC:yaf, PMID:15205427, PMID:16390337, PMID:8990303, Unipathway:UPA00237]","metadata":null},{"id":"15f0191a184f478da5b64d1faab2f6ab","type":"GO_TERM","name":"beta-glucoside catabolic process","canonical_id":"go:GO:1901805","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-glucoside.\" [GOC:TermGenie, GOC:yaf, PMID:15205427, PMID:16390337, PMID:8990303, Unipathway:UPA00237]","metadata":null},{"id":"3b2f94ab3bec4b0085d2d8b5061fa077","type":"GO_TERM","name":"beta-glucoside kinase activity","canonical_id":"go:GO:0047700","description":"\"Catalysis of the reaction: ATP + cellobiose = ADP + 6-phospho-beta-D-glucosyl-(1,4)-D-glucose.\" [EC:2.7.1.85, MetaCyc:BETA-GLUCOSIDE-KINASE-RXN]","metadata":null},{"id":"0b349c9a3e54403d85022649a1f16146","type":"GO_TERM","name":"beta-glucoside transmembrane transporter activity","canonical_id":"go:GO:0015573","description":"\"Enables the transfer of beta-glucosides from one side of a membrane to the other. Beta-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in a beta configuration.\" [GOC:jl, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729, PMID:7883710]","metadata":null},{"id":"d351b65cd6224f8faa0b66c186c390e0","type":"GO_TERM","name":"beta-glucoside transport","canonical_id":"go:GO:0015759","description":"\"The directed movement of beta-glucosides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Beta-glucosides are glycosides in which the sugar group is a glucose residue, and the anomeric carbon of the bond is in a beta configuration.\" [GOC:jl, ISBN:0198506732, PMID:3034860, PMID:6756954]","metadata":null},{"id":"2976639cbe934f19abe52aafa669d0ea","type":"GO_TERM","name":"beta-glucuronidase activity","canonical_id":"go:GO:0004566","description":"\"Catalysis of the reaction: a beta-D-glucuronoside + H2O = an alcohol + D-glucuronate.\" [EC:3.2.1.31]","metadata":null},{"id":"2f47b4a77e344bc18ec6ead1f38966e8","type":"GO_TERM","name":"beta-heterochromatin","canonical_id":"go:GO:0005722","description":"\"A diffusely banded region of heterochromatin located between euchromatin and alpha-heterochromatin in the polytene chromosome chromocenter; normally replicated during polytenization.\" [PMID:11404334, PMID:8878678]","metadata":null},{"id":"0db077a56e8940bd9ec5afe51599120b","type":"GO_TERM","name":"beta-hexosaminidase A complex","canonical_id":"go:GO:7770082","description":"\"A beta-N-acetylhexosaminidase complex composed of an alpha subunit and a beta subunit. In humans the subunits are encoded by HEXA and HEXB. In association with the GM2 activator protein, the complex degrades GM2 ganglioside within the lysosome.\" [PMID:15485660, PMID:16698036]","metadata":null},{"id":"e21f0a821b3c4daeb36525be98d7dee2","type":"GO_TERM","name":"beta-hydroxybutyrate transmembrane transporter activity","canonical_id":"go:GO:0097253","description":"\"Enables the transfer of beta-hydroxybutyrate from one side of a membrane to the other. Beta-hydroxybutyrate is the conjugate base of (R)-3-hydroxybutyric acid.\" [GOC:dsf, PMID:22302940]","metadata":null},{"id":"583728d1a24f40cf96a47404b587582e","type":"GO_TERM","name":"beta-ketoacyl-acyl-carrier-protein synthase III activity","canonical_id":"go:GO:0033818","description":"\"Catalysis of the reaction: acetyl-CoA + malonyl-[acyl-carrier protein] = acetoacyl-[acyl-carrier protein] + CoA + CO2.\" [EC:2.3.1.180]","metadata":null},{"id":"af988576d7174da4a3fc06f261e98382","type":"GO_TERM","name":"beta-ketoadipate pathway","canonical_id":"go:GO:0042952","description":"\"A pathway of aromatic compound degradation by ortho-cleavage; one branch converts protocatechuate, derived from phenolic compounds, to beta-ketoadipate, and the other branch converts catechol, generated from various aromatic hydrocarbons, amino aromatics, and lignin monomers, also to beta-ketoadipate. Two additional steps accomplish the conversion of beta-ketoadipate to tricarboxylic acid cycle intermediates.\" [GOC:jl, PMID:8905091]","metadata":null},{"id":"27f78f4e90b84a608cfbe68313bec7d6","type":"GO_TERM","name":"beta-ketodecanoyl-[acyl-carrier-protein] synthase activity","canonical_id":"go:GO:0061990","description":"\"Catalysis of the reaction: octanoyl-CoA + H+ + malonyl-[ACP] = 3-oxodecanoyl-[ACP] + CO2 + CoA.\" [PMID:22753057, RHEA:42264]","metadata":null},{"id":"6146746110d24a449df9a972c62b9b7e","type":"GO_TERM","name":"beta-lactam antibiotic biosynthetic process","canonical_id":"go:GO:0030654","description":"\"The chemical reactions and pathways resulting in the formation of a beta-lactam antibiotic, any member of a class of natural or semisynthetic antibiotics whose characteristic feature is a strained, four-membered beta-lactam ring. They include the penicillins and many of the cephalosporins.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"573bd3bc9c0740dd98f7602218c66aa5","type":"GO_TERM","name":"beta-lactam antibiotic catabolic process","canonical_id":"go:GO:0030655","description":"\"The chemical reactions and pathways resulting in the breakdown of a beta-lactam antibiotic, any member of a class of natural or semisynthetic antibiotics whose characteristic feature is a strained, four-membered beta-lactam ring. They include the penicillins and many of the cephalosporins.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"10f2d23a59e24f308e691654955d89e3","type":"GO_TERM","name":"beta-lactamase activity","canonical_id":"go:GO:0008800","description":"\"Catalysis of the reaction: a beta-lactam + H2O = a substituted beta-amino acid.\" [EC:3.5.2.6]","metadata":null},{"id":"7a5cdfb650624b218a5a795ff1bdd815","type":"GO_TERM","name":"beta-mannosidase activity","canonical_id":"go:GO:0004567","description":"\"Catalysis of the hydrolysis of terminal, non-reducing beta-D-mannose residues in beta-D-mannosides.\" [EC:3.2.1.25]","metadata":null},{"id":"00a89b2454a34e758e9eae7ff41829cd","type":"GO_TERM","name":"beta-mannosylphosphodecaprenol-mannooligosaccharide 6-mannosyltransferase activity","canonical_id":"go:GO:0047252","description":"\"Catalysis of the reaction: (1->6)-alpha-D-mannosyloligosaccharide + beta-D-mannosylphosphodecaprenol = (1->6)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-oligosaccharide + decaprenol phosphate.\" [EC:2.4.1.199, MetaCyc:2.4.1.199-RXN]","metadata":null},{"id":"db6108766d334e919031ad4759facb38","type":"GO_TERM","name":"beta-nitroacrylate reductase activity","canonical_id":"go:GO:0047703","description":"\"Catalysis of the reaction: 3-nitropropanoate + NADP+ = 3-nitroacrylate + H+ + NADPH.\" [EC:1.3.1.16, RHEA:23892]","metadata":null},{"id":"5869c1f224d74af580db40612eb9558f","type":"GO_TERM","name":"beta-phosphoglucomutase activity","canonical_id":"go:GO:0008801","description":"\"Catalysis of the reaction: beta-D-glucose 1-phosphate = beta-D-glucose 6-phosphate.\" [EC:5.4.2.6, RHEA:20113]","metadata":null},{"id":"f1061c1e84f94e1c89bfcf4ee0d2d9b3","type":"GO_TERM","name":"beta-pinacene synthase activity","canonical_id":"go:GO:0106100","description":"\"Catalysis of the reaction: (2E,6E,10E)-geranylgeranyl diphosphate = beta-pinacene + diphosphate.\" [PMID:28696553, RHEA:58172]","metadata":null},{"id":"51254a634f594b15a21f1f68026b29f6","type":"GO_TERM","name":"beta-primeverosidase activity","canonical_id":"go:GO:0050535","description":"\"Catalysis of the reaction: a 6-O-(beta-D-xylopyranosyl)-beta-D-glucopyranoside + H2O = 6-O-(beta-D-xylopyranosyl)-beta-D-glucopyranose + an alcohol.\" [RHEA:24480]","metadata":null},{"id":"4b5d234fc84549c89bc845fca394f198","type":"GO_TERM","name":"beta-pyrazolylalanine synthase activity","canonical_id":"go:GO:0047458","description":"\"Catalysis of the reaction: O-acetyl-L-serine + pyrazole = 3-(pyrazol-1-yl)-L-alanine + acetate + H+.\" [RHEA:13117]","metadata":null},{"id":"b68228b4d152427ab44d34d9846fa19d","type":"GO_TERM","name":"beta-ribofuranosylaminobenzene 5'-phosphate synthase activity","canonical_id":"go:GO:0043793","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + 5-phospho-alpha-D-ribose 1-diphosphate + H+ = 4-(beta-D-ribofuranosyl)phenol 5'-phosphate + CO2 + diphosphate. Both 4-hydroxybenzoate and 4-aminobenzoate may be used as substrates, but only the former is known to be produced by methanogenic archaea.\" [EC:2.4.2.54, PMID:12142414]","metadata":null},{"id":"1659e37568704000a60ed16ec935d4cf","type":"GO_TERM","name":"beta-sesquiphellandrene synthase activity","canonical_id":"go:GO:0102887","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = beta-sesquiphellandrene + diphosphoric acid.\" [EC:4.2.3.123, GOC:pz]","metadata":null},{"id":"ce62988105244315a291e890ad64d141","type":"GO_TERM","name":"beta-tubulin binding","canonical_id":"go:GO:0048487","description":"\"Binding to the microtubule constituent protein beta-tubulin.\" [GOC:krc]","metadata":null},{"id":"add5899de5f64d23a0da0f80e8dc3510","type":"GO_TERM","name":"beta-ureidopropionase activity","canonical_id":"go:GO:0003837","description":"\"Catalysis of the reaction: N-carbamoyl-beta-alanine + H2O = beta-alanine + CO2 + NH4+.\" [EC:3.5.1.6]","metadata":null},{"id":"49f874706cde4c448bdf43b8eed2e9f4","type":"GO_TERM","name":"beta-zeacarotene biosynthetic process","canonical_id":"go:GO:1901818","description":"\"The chemical reactions and pathways resulting in the formation of beta-zeacarotene.\" [GOC:TermGenie, GOC:yaf, PMID:3710717, UniPathway:UPA00805]","metadata":null},{"id":"586e26099d6e4d25986d3634b495d0d6","type":"GO_TERM","name":"beta-zeacarotene catabolic process","canonical_id":"go:GO:1901817","description":"\"The chemical reactions and pathways resulting in the breakdown of beta-zeacarotene.\" [GOC:TermGenie, GOC:yaf, PMID:3710717, UniPathway:UPA00805]","metadata":null},{"id":"185add950a5f4ccaa9d977e0a96089ec","type":"GO_TERM","name":"beta1-adrenergic receptor activity","canonical_id":"go:GO:0004940","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta1-adrenergic receptors.\" [GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"6d31c4aafa8442d3b90c9273db178f29","type":"GO_TERM","name":"beta2-adrenergic receptor activity","canonical_id":"go:GO:0004941","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta2-adrenergic receptors.\" [GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"863a00c182c045858b0cc2c0d33f093c","type":"GO_TERM","name":"beta3-adrenergic receptor activity","canonical_id":"go:GO:0015052","description":"\"Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta3-adrenergic receptors.\" [GOC:mah, IUPHAR_GPCR:1274]","metadata":null},{"id":"ce924fa1a5624cfca5380eefacefd16c","type":"GO_TERM","name":"betaine aldehyde biosynthetic process","canonical_id":"go:GO:1902063","description":"\"The chemical reactions and pathways resulting in the formation of betaine aldehyde.\" [GOC:di, GOC:TermGenie, PMID:23563483]","metadata":null},{"id":"af9a17749db44909be96c96e843a0ca6","type":"GO_TERM","name":"betaine aldehyde catabolic process","canonical_id":"go:GO:1902062","description":"\"The chemical reactions and pathways resulting in the breakdown of betaine aldehyde.\" [GOC:di, GOC:TermGenie, PMID:23563483]","metadata":null},{"id":"e2ec7b4b33e14bf390aecf5d49495fdb","type":"GO_TERM","name":"betaine reductase activity","canonical_id":"go:GO:0033795","description":"\"Catalysis of the reaction: [thioredoxin]-disulfide + acetyl phosphate + H2O + trimethylamine = [thioredoxin]-dithiol + glycine betaine + H+ + phosphate.\" [RHEA:11848]","metadata":null},{"id":"44dbf0e5d84e4ac8a278c65de3b635b6","type":"GO_TERM","name":"betaine-aldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008802","description":"\"Catalysis of the reaction: betaine aldehyde + NAD+ + H2O = betaine + NADH + H+.\" [EC:1.2.1.8]","metadata":null},{"id":"310fef093a464b8ab1d485b8bf93249f","type":"GO_TERM","name":"betaine-homocysteine S-methyltransferase activity","canonical_id":"go:GO:0047150","description":"\"Catalysis of the reaction: L-homocysteine + glycine betaine = N,N-dimethylglycine + L-methionine.\" [EC:2.1.1.5, RHEA:22336]","metadata":null},{"id":"0449381f11e34808bff48cd8a75c07c3","type":"DRUG","name":"betamethasone","canonical_id":"gtopdb:7061","description":null,"metadata":null},{"id":"d1c7b8ee43f7426baf545dd83b9d7106","type":"DRUG","name":"betamethasone","canonical_id":"mesh:D001623","description":null,"metadata":null},{"id":"a777f27073554649b7e0fa2db55daba9","type":"DRUG","name":"betamethasone","canonical_id":"chembl:CHEMBL632","description":null,"metadata":null},{"id":"a24ba87974164f7dbda27abcf2eeab29","type":"COMBINATION_TREATMENT","name":"betamethasone + calcipotriol","canonical_id":"ctgov_combo:ctgov-combo-e194d6cff83f44f2","description":null,"metadata":null},{"id":"cf387001e45f42f38d691d9501a7f854","type":"COMBINATION_TREATMENT","name":"betamethasone + cetirizine","canonical_id":"ctgov_combo:ctgov-combo-b1f8f322ef7e2629","description":null,"metadata":null},{"id":"954f6ef569bd439fa50efc5852152696","type":"COMBINATION_TREATMENT","name":"betamethasone + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-d7b06d0ac3c22c54","description":null,"metadata":null},{"id":"14502cff025342b49b05eece6431349e","type":"COMBINATION_TREATMENT","name":"betamethasone + pimecrolimus","canonical_id":"ctgov_combo:ctgov-combo-5142ae6ea7e0689e","description":null,"metadata":null},{"id":"1bb8073d3bcb41c9b28a45ff5339ff8f","type":"COMBINATION_TREATMENT","name":"betamethasone + triamcinolone","canonical_id":"ctgov_combo:ctgov-combo-01d19b22ad66c698","description":null,"metadata":null},{"id":"cdb7f7017fd34d9a8d7c3a43103f570f","type":"DRUG","name":"betamethasone acetate","canonical_id":"mesh:C580789","description":null,"metadata":null},{"id":"b8c0c5adf84a4a0a956cd0a846d28920","type":"DRUG","name":"betamethasone dipropionate","canonical_id":"mesh:C011175","description":null,"metadata":null},{"id":"f710a037f2b04cdaab139400d9e4466b","type":"DRUG","name":"betaxolol","canonical_id":"gtopdb:549","description":null,"metadata":null},{"id":"4aac9b143af44e6c8c3f9fba7c583705","type":"DRUG","name":"betaxolol","canonical_id":"mesh:D015784","description":null,"metadata":null},{"id":"4f534132f9514497bdb32089850c0aa2","type":"COMBINATION_TREATMENT","name":"betaxolol + timolol","canonical_id":"ctgov_combo:ctgov-combo-45d64baa90981974","description":null,"metadata":null},{"id":"6b1638ec34b648c3b78d1dc446cd17c4","type":"DRUG","name":"bethanechol","canonical_id":"gtopdb:297","description":null,"metadata":null},{"id":"8ef9e58a4aaf4e50885398acd12c6467","type":"DRUG","name":"betrixaban","canonical_id":"gtopdb:9602","description":null,"metadata":null},{"id":"8d8b78d0c6f544c0a0a41c663a00b3eb","type":"DRUG","name":"betrixaban","canonical_id":"chembl:CHEMBL512351","description":null,"metadata":null},{"id":"73264dc56d2044928c0ac1343867f49c","type":"COMBINATION_TREATMENT","name":"betrixaban + edoxaban","canonical_id":"ctgov_combo:ctgov-combo-dcc09a7d6b9c7b10","description":null,"metadata":null},{"id":"ac33903497764470b3ab5cdc5aec1ed7","type":"COMBINATION_TREATMENT","name":"betrixaban + enoxaparin","canonical_id":"ctgov_combo:ctgov-combo-e226f5778c9ec986","description":null,"metadata":null},{"id":"ba6099e1e21a4955b322ab8ed9db3a7f","type":"DRUG","name":"bevacizumab","canonical_id":"gtopdb:6771","description":null,"metadata":null},{"id":"0f374a5260fb4ccbba467ba7d130dab7","type":"DRUG","name":"bevacizumab","canonical_id":"chembl:CHEMBL1201583","description":null,"metadata":null},{"id":"102122be404c4224b272e15accd9f98d","type":"COMBINATION_TREATMENT","name":"bevacizumab + capecitabine","canonical_id":"ctgov_combo:ctgov-combo-2ad962989c759362","description":null,"metadata":null},{"id":"0bca6409c6fa47c7b6c60daf7924c322","type":"COMBINATION_TREATMENT","name":"bevacizumab + capecitabine + erlotinib + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-70c9b5cc2e263f65","description":null,"metadata":null},{"id":"ec9bd8be0afd481597badbb435c82b9a","type":"COMBINATION_TREATMENT","name":"bevacizumab + capecitabine + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-323b2f1f10482541","description":null,"metadata":null},{"id":"08bc679b8b664d6c8b4f2d7ae3d17387","type":"COMBINATION_TREATMENT","name":"bevacizumab + capecitabine + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-69fd0ceb77c8f9d1","description":null,"metadata":null},{"id":"a573fc47cb3c4236b9361c7d379c80ff","type":"COMBINATION_TREATMENT","name":"bevacizumab + docetaxel + erlotinib","canonical_id":"ctgov_combo:ctgov-combo-3d823b26fbd6f80b","description":null,"metadata":null},{"id":"189f837396cf49e4ba890c54799ea766","type":"COMBINATION_TREATMENT","name":"bevacizumab + docetaxel + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-f023e3f567feb754","description":null,"metadata":null},{"id":"58ccee56c0e84b0a9a879fc7cc003779","type":"COMBINATION_TREATMENT","name":"bevacizumab + everolimus","canonical_id":"ctgov_combo:ctgov-combo-76552f980ea31945","description":null,"metadata":null},{"id":"ddf492a046ae4ba4919a5ae5e045a52b","type":"COMBINATION_TREATMENT","name":"bevacizumab + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-864706e499063ab4","description":null,"metadata":null},{"id":"1be864156fa04fc7ae15d02fffba8d69","type":"COMBINATION_TREATMENT","name":"bevacizumab + iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-4d97075a5e345d94","description":null,"metadata":null},{"id":"d2f7a6431a7e4df1b687955d784df656","type":"COMBINATION_TREATMENT","name":"bevacizumab + ipilimumab + nivolumab + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-ec2993d0a6e6ae32","description":null,"metadata":null},{"id":"d5ac55072d6043f1be76bc4ba1ff0e9d","type":"COMBINATION_TREATMENT","name":"bevacizumab + irinotecan","canonical_id":"ctgov_combo:ctgov-combo-0a8bdefa85164a71","description":null,"metadata":null},{"id":"ebf57023e9b54a5c93a637cb3f635a40","type":"COMBINATION_TREATMENT","name":"bevacizumab + irinotecan","canonical_id":"ctgov_combo:ctgov-combo-71e1d819839b22f4","description":null,"metadata":null},{"id":"6f6a4677a4864904bfbae66d1b10cb46","type":"COMBINATION_TREATMENT","name":"bevacizumab + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-0580bcf646026071","description":null,"metadata":null},{"id":"248de9ee8bb44981a3b02ae12fe2ed25","type":"COMBINATION_TREATMENT","name":"bevacizumab + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-9d2c6ee973bd5386","description":null,"metadata":null},{"id":"ae6567b45a6f4df987f51576a635b65a","type":"COMBINATION_TREATMENT","name":"bevacizumab + panitumumab","canonical_id":"ctgov_combo:ctgov-combo-17eba1f8096d2925","description":null,"metadata":null},{"id":"87878e050f51497d8ebda3641be9eb8d","type":"COMBINATION_TREATMENT","name":"bevacizumab + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-93479b15f19dce30","description":null,"metadata":null},{"id":"5879ecc34e01448ba4b3197586d26ffb","type":"COMBINATION_TREATMENT","name":"bevacizumab + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-7abefe807d5b42d1","description":null,"metadata":null},{"id":"4de0d5913e764a37b34210fdc73945c9","type":"COMBINATION_TREATMENT","name":"bevacizumab + ranibizumab","canonical_id":"ctgov_combo:ctgov-combo-842f141bdc67c32e","description":null,"metadata":null},{"id":"1b403b9b642443799c07597b83e132fd","type":"COMBINATION_TREATMENT","name":"bevacizumab + serplulimab","canonical_id":"ctgov_combo:ctgov-combo-38b3839b38be31ca","description":null,"metadata":null},{"id":"35662acd9e1148e59a28f7303a7ed3e1","type":"COMBINATION_TREATMENT","name":"bevacizumab + sirolimus + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-cc3c5f1097130426","description":null,"metadata":null},{"id":"a47dceee1f0b4baa9ed59bbb12675ca4","type":"COMBINATION_TREATMENT","name":"bevacizumab + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-365c6d482b4e9045","description":null,"metadata":null},{"id":"1161a43163c74bd7afa5aa161cd6ba01","type":"COMBINATION_TREATMENT","name":"bevacizumab + triamcinolone","canonical_id":"ctgov_combo:ctgov-combo-dd4b020ca8b33b33","description":null,"metadata":null},{"id":"df5723de53a94997b2b2da94a12af5fa","type":"COMBINATION_TREATMENT","name":"bevacizumab + triamcinolone","canonical_id":"ctgov_combo:ctgov-combo-a76428ec172d29e8","description":null,"metadata":null},{"id":"92957bd5fd4b43ffa548671637da821f","type":"DRUG","name":"bexagliflozin","canonical_id":"gtopdb:12335","description":null,"metadata":null},{"id":"41eb6367b5024f4f98845e8b3af66936","type":"DRUG","name":"bexagliflozin","canonical_id":"chembl:CHEMBL1808388","description":null,"metadata":null},{"id":"498ce3ae65944188a471def2a4374fb8","type":"COMBINATION_TREATMENT","name":"bexagliflozin + digoxin","canonical_id":"ctgov_combo:ctgov-combo-187518bb5d4ca5d9","description":null,"metadata":null},{"id":"b65c84729a0348d69140e9420d5fa001","type":"COMBINATION_TREATMENT","name":"bexagliflozin + probenecid","canonical_id":"ctgov_combo:ctgov-combo-57fb8ce0b7381486","description":null,"metadata":null},{"id":"9532e4b036fa470ab8bd18e7c5da6722","type":"DRUG","name":"bexarotene","canonical_id":"gtopdb:2807","description":null,"metadata":null},{"id":"71bd64194c71432391fd17d6ab9c229b","type":"DRUG","name":"bexarotene","canonical_id":"chembl:CHEMBL1023","description":null,"metadata":null},{"id":"39fc1b8fa976419db82e991476c65d67","type":"COMBINATION_TREATMENT","name":"bexarotene + erlotinib","canonical_id":"ctgov_combo:ctgov-combo-11fd2e0169954b72","description":null,"metadata":null},{"id":"3f134e08fd8246d78fb420fa37ee13c1","type":"COMBINATION_TREATMENT","name":"bexarotene + pralatrexate","canonical_id":"ctgov_combo:ctgov-combo-3d87b9a25fba570c","description":null,"metadata":null},{"id":"ed73a274f8864ceeb91f3bd1a5bdcd8a","type":"DRUG","name":"bezafibrate","canonical_id":"gtopdb:2668","description":null,"metadata":null},{"id":"0d3d21ff38d04032a75acd23fcc5cffa","type":"DRUG","name":"bezafibrate","canonical_id":"mesh:D001629","description":null,"metadata":null},{"id":"889ae3effcdb4881920dbba0bf6c2a72","type":"DRUG","name":"bezafibrate","canonical_id":"chembl:CHEMBL264374","description":null,"metadata":null},{"id":"c2a88be7bc8d4afebd9b259263b4e443","type":"COMBINATION_TREATMENT","name":"bezafibrate + danazol","canonical_id":"ctgov_combo:ctgov-combo-af4445c649ed47df","description":null,"metadata":null},{"id":"aed66b0d70714fa6bcddcf3aa8336632","type":"COMBINATION_TREATMENT","name":"bezafibrate + obeticholic acid","canonical_id":"ctgov_combo:ctgov-combo-156e3e3b5f54db7e","description":null,"metadata":null},{"id":"3c0dbe38c88740aeaa7d155820130039","type":"COMBINATION_TREATMENT","name":"bezafibrate + obeticholic acid","canonical_id":"ctgov_combo:ctgov-combo-8accb442b79d617e","description":null,"metadata":null},{"id":"f718cdbad4d3496f9405e22615463f4f","type":"DRUG","name":"bicalutamide","canonical_id":"gtopdb:2863","description":null,"metadata":null},{"id":"6cafa52429e44b2d87162a106b9e300c","type":"DRUG","name":"bicalutamide","canonical_id":"chembl:CHEMBL409","description":null,"metadata":null},{"id":"f26414865fb94720a1196a27b75558a7","type":"COMBINATION_TREATMENT","name":"bicalutamide + cyproterone acetate + flutamide + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-3e6e8171f43ffc23","description":null,"metadata":null},{"id":"9dfcdaee96a343bdb412cbbec9230ef4","type":"COMBINATION_TREATMENT","name":"bicalutamide + degarelix","canonical_id":"ctgov_combo:ctgov-combo-7d2169c8d5e8e3bf","description":null,"metadata":null},{"id":"91a7f7b1d78f4be5ba71250e187d3db1","type":"COMBINATION_TREATMENT","name":"bicalutamide + degarelix + flutamide","canonical_id":"ctgov_combo:ctgov-combo-0bc02c3085c8d84d","description":null,"metadata":null},{"id":"8f4a8b60ef884dde874e76e030eb926a","type":"COMBINATION_TREATMENT","name":"bicalutamide + degarelix + flutamide + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-18962270947d2e54","description":null,"metadata":null},{"id":"c80aac7865254b8d8f77bb6634fc0615","type":"COMBINATION_TREATMENT","name":"bicalutamide + degarelix + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-b3eb6923e58ada8e","description":null,"metadata":null},{"id":"4c1bd6f29765462b8619386b22a23380","type":"COMBINATION_TREATMENT","name":"bicalutamide + disitamab vedotin","canonical_id":"ctgov_combo:ctgov-combo-19f23512e00352e1","description":null,"metadata":null},{"id":"3f2c7caf25964ce1a27ec8d24e4fb7ee","type":"COMBINATION_TREATMENT","name":"bicalutamide + docetaxel + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-9ad3b39fdbf71186","description":null,"metadata":null},{"id":"6da6f7555136456abb228f0566f9725d","type":"COMBINATION_TREATMENT","name":"bicalutamide + everolimus","canonical_id":"ctgov_combo:ctgov-combo-bdfa1017e9ed6c6a","description":null,"metadata":null},{"id":"b3f7c602b23d4c60ae6a32dd08b1e389","type":"COMBINATION_TREATMENT","name":"bicalutamide + everolimus + letrozole","canonical_id":"ctgov_combo:ctgov-combo-6d26b2b933ab130d","description":null,"metadata":null},{"id":"739fdc681ddb4782a5af1bb82e98a56d","type":"COMBINATION_TREATMENT","name":"bicalutamide + exemestane","canonical_id":"ctgov_combo:ctgov-combo-2e8f2b3f6220c46a","description":null,"metadata":null},{"id":"4ed1e8bcec30444bac1ee6f4880c4d40","type":"COMBINATION_TREATMENT","name":"bicalutamide + finasteride","canonical_id":"ctgov_combo:ctgov-combo-00393afa62f0b72a","description":null,"metadata":null},{"id":"8b7260be667d42bfad1979d69e6ebed4","type":"COMBINATION_TREATMENT","name":"bicalutamide + flutamide","canonical_id":"ctgov_combo:ctgov-combo-5c76f9f81b9ce656","description":null,"metadata":null},{"id":"f67df2efb2de499280f916dd72eea6a6","type":"COMBINATION_TREATMENT","name":"bicalutamide + flutamide","canonical_id":"ctgov_combo:ctgov-combo-6919f7faf4668047","description":null,"metadata":null},{"id":"a1f73bb98edc4b3a970b8d818a5d5099","type":"COMBINATION_TREATMENT","name":"bicalutamide + flutamide + goserelin + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-6aa0c9f104cf5e94","description":null,"metadata":null},{"id":"aa2c369f0da84a279a2d70dd8774afdf","type":"COMBINATION_TREATMENT","name":"bicalutamide + flutamide + nilutamide + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-cc4b7e57b756e254","description":null,"metadata":null},{"id":"1d7e80cbb57741a39eb346c9979ae146","type":"COMBINATION_TREATMENT","name":"bicalutamide + goserelin","canonical_id":"ctgov_combo:ctgov-combo-5910d199b2cd1c48","description":null,"metadata":null},{"id":"e30dfc1fca15465fa600ca0eba90086f","type":"COMBINATION_TREATMENT","name":"bicalutamide + goserelin","canonical_id":"ctgov_combo:ctgov-combo-25b8c96da709a878","description":null,"metadata":null},{"id":"a355ee38aef64c35a7acccfa2905f803","type":"COMBINATION_TREATMENT","name":"bicalutamide + goserelin","canonical_id":"ctgov_combo:ctgov-combo-6ae2ea11b1e173f5","description":null,"metadata":null},{"id":"0f4d8baf750a40e9a48163531e4ea2c5","type":"COMBINATION_TREATMENT","name":"bicalutamide + goserelin","canonical_id":"ctgov_combo:ctgov-combo-5c2910fb09a0d25a","description":null,"metadata":null},{"id":"6b90c3a539c44cf8b25061f466bf5c0e","type":"COMBINATION_TREATMENT","name":"bicalutamide + goserelin + leuprolide + vorinostat","canonical_id":"ctgov_combo:ctgov-combo-8275d3d15290351c","description":null,"metadata":null},{"id":"a234e07a058449bebad8a2fce6bbbda2","type":"COMBINATION_TREATMENT","name":"bicalutamide + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-c9e1c517189e9f54","description":null,"metadata":null},{"id":"1253138caa1a4d928cd8673fd511540a","type":"COMBINATION_TREATMENT","name":"bicalutamide + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-7521a8627f9df21e","description":null,"metadata":null},{"id":"b09e895a15b84287ad76c9709fec47be","type":"COMBINATION_TREATMENT","name":"bicalutamide + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-0dfc7233a41072c7","description":null,"metadata":null},{"id":"e35644a0c80e4e3fbd4edd181fe670b1","type":"COMBINATION_TREATMENT","name":"bicalutamide + vandetanib","canonical_id":"ctgov_combo:ctgov-combo-263ffca169fc5057","description":null,"metadata":null},{"id":"5873f92847f747e1b1132ca9f4ba377d","type":"GO_TERM","name":"bicarbonate binding","canonical_id":"go:GO:0071890","description":"\"Binding to bicarbonate ions (CHO3-).\" [GOC:curators]","metadata":null},{"id":"b8303a254e5b4b5c84855179be4b3a86","type":"GO_TERM","name":"bicarbonate channel activity","canonical_id":"go:GO:0160133","description":"\"Enables the energy-independent facilitated diffusion of bicarbonate through a transmembrane aqueous pore or channel.\" [PMID:18400985]","metadata":null},{"id":"0ce38a47250b48eb89b658e74aa2699a","type":"GO_TERM","name":"bicarbonate transmembrane transporter activity","canonical_id":"go:GO:0015106","description":"\"Enables the transfer of bicarbonate from one side of a membrane to the other. Bicarbonate is the hydrogencarbonate ion, HCO3-.\" [GOC:ai]","metadata":null},{"id":"9350c52f434c40cf94a561c4f2d5cd76","type":"GO_TERM","name":"bicarbonate transport","canonical_id":"go:GO:0015701","description":"\"The directed movement of bicarbonate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"47a79eb08dcd46e6a87bac0f5835ef5e","type":"GO_TERM","name":"bicarbonate:monoatomic anion antiporter activity","canonical_id":"go:GO:0140829","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: solute(in) + HCO3-(out) = solute(out) + HCO3-(in).\" [PMID:12440690]","metadata":null},{"id":"e1917045c3e04059adb93f5b40db3eba","type":"GO_TERM","name":"bicellular tight junction","canonical_id":"go:GO:0005923","description":"\"An occluding cell-cell junction that is composed of a branching network of sealing strands that completely encircles the apical end of each cell in an epithelial sheet; the outer leaflets of the two interacting plasma membranes are seen to be tightly apposed where sealing strands are present. Each sealing strand is composed of a long row of transmembrane adhesion proteins embedded in each of the two interacting plasma membranes.\" [GOC:mah, ISBN:0815332181]","metadata":null},{"id":"85998d1544e54af1b8013beea5e8e9b2","type":"GO_TERM","name":"bicellular tight junction assembly","canonical_id":"go:GO:0070830","description":"\"The aggregation, arrangement and bonding together of a set of components to form a tight junction, an occluding cell-cell junction that is composed of a branching network of sealing strands that completely encircles the apical end of each cell in an epithelial sheet.\" [GOC:mah]","metadata":null},{"id":"d2309f9e3fd34367959bef09a1cff553","type":"GO_TERM","name":"bicoid mRNA localization","canonical_id":"go:GO:0045450","description":"\"Any process in which bicoid mRNA is transported to and maintained within the oocyte as part of the specification of the anterior/posterior axis.\" [GOC:curators]","metadata":null},{"id":"15e6468541eb4e52b2beeeeb8488d36a","type":"GO_TERM","name":"bicyclic nitroimidazole catabolic process","canonical_id":"go:GO:0052800","description":"\"The chemical reactions and pathways resulting in the breakdown of a bicyclic nitroimidazole.\" [PMID:16387854, PMID:19039139]","metadata":null},{"id":"646ef1e4f64f4a1997320388be0a3cdd","type":"GO_TERM","name":"bicyclogermacrene biosynthetic process","canonical_id":"go:GO:1901934","description":"\"The chemical reactions and pathways resulting in the formation of bicyclogermacrene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"9862c59f8d9949f4b2868d2f3f6e7aba","type":"GO_TERM","name":"bicyclogermacrene catabolic process","canonical_id":"go:GO:1901933","description":"\"The chemical reactions and pathways resulting in the breakdown of bicyclogermacrene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"a0c709b7ba31406fbfa66b87b4d58dfe","type":"GO_TERM","name":"bicyclomycin transmembrane transport","canonical_id":"go:GO:0015905","description":"\"The directed movement of bicyclomycin across a lipid bilayer, from one side of a membrane to the other. Bicyclomycin (or bicozamycin) is an antibacterial drug often used as a livestock feed additive.\" [PMID:20067529]","metadata":null},{"id":"1966b141f70a4adb811c7f2e341fb589","type":"GO_TERM","name":"bicyclomycin transmembrane transporter activity","canonical_id":"go:GO:0015545","description":"\"Enables the transfer of bicyclomycin from one side of a membrane to the other. Bicyclomycin (or bicozamycin) is an antibacterial drug often used as a livestock feed additive.\" [ISBN:091191028X]","metadata":null},{"id":"adcd9bf5337642f0b7f5b718cb6fc87e","type":"GO_TERM","name":"bidirectional double-stranded viral DNA replication","canonical_id":"go:GO:0039686","description":"\"A viral DNA replication process where replication occurs in both directions from the starting point. This creates two replication forks, moving in opposite directions.\" [GOC:bf, GOC:jl, VZ:1939]","metadata":null},{"id":"390d40ba5eab4c6e919d4558a2c0361b","type":"GO_TERM","name":"bifid shunt","canonical_id":"go:GO:0019658","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of glucose to lactate and acetate, yielding energy in the form of ATP.\" [MetaCyc:P124-PWY]","metadata":null},{"id":"8e15cadfe9284dda88dc26d8bbf2aea5","type":"DRUG","name":"bilastine","canonical_id":"mesh:C445659","description":null,"metadata":null},{"id":"7135843743e44edb906c30c6e735a851","type":"DISEASE","name":"bilateral striopallidodentate calcinosis","canonical_id":"mondo:0008947","description":null,"metadata":null},{"id":"fa1be6f38c7f4cb39aacb65ac93c6e36","type":"GO_TERM","name":"bile acid and bile salt transport","canonical_id":"go:GO:0015721","description":"\"The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:krc, PMID:12663868, PMID:14699511]","metadata":null},{"id":"0a56a4896d6c48908df488c8822c81d5","type":"GO_TERM","name":"bile acid binding","canonical_id":"go:GO:0032052","description":"\"Binding to a bile acid, a steroid carboxylic acids occurring in bile.\" [GOC:rph]","metadata":null},{"id":"ac438daddb054462adbaa85a42d7714f","type":"GO_TERM","name":"bile acid biosynthetic process","canonical_id":"go:GO:0006699","description":"\"The chemical reactions and pathways resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile.\" [GOC:curators]","metadata":null},{"id":"dada3f71248d4694bd9d373dc178a7c1","type":"GO_TERM","name":"bile acid catabolic process","canonical_id":"go:GO:0030573","description":"\"The chemical reactions and pathways resulting in the breakdown of bile acids, any of a group of steroid carboxylic acids occurring in bile.\" [GOC:curators]","metadata":null},{"id":"ac8adb48f5fd4e5faf6a2d879f20802f","type":"GO_TERM","name":"bile acid conjugation","canonical_id":"go:GO:0002152","description":"\"The process in which bile acids are covalently linked to taurine or glycine.\" [PMID:1094911, PMID:708413]","metadata":null},{"id":"2af47bde8e9c4f7081746019f71c6295","type":"DISEASE","name":"bile acid malabsorption, primary, 1","canonical_id":"mondo:0013214","description":null,"metadata":null},{"id":"a669f4b39cce41c5a76e48db6d734d9c","type":"GO_TERM","name":"bile acid metabolic process","canonical_id":"go:GO:0008206","description":"\"The chemical reactions and pathways involving bile acids, a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.\" [GOC:curators]","metadata":null},{"id":"5b53edf19d5f41b3a68ab058049bcfe7","type":"GO_TERM","name":"bile acid nuclear receptor activity","canonical_id":"go:GO:0038186","description":"\"A nuclear receptor activity regulated by a bile acid binding and modulating the transcription of specific gene sets transcribed by RNA polymerase II.\" [PMID:32480317, PMID:35415765, PMID:36409000]","metadata":null},{"id":"167fa78ea4db432e90c5697afb746747","type":"GO_TERM","name":"bile acid secretion","canonical_id":"go:GO:0032782","description":"\"The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue.\" [GOC:ecd]","metadata":null},{"id":"deab2008f37c49a39d18a3dbffc31efe","type":"GO_TERM","name":"bile acid signaling pathway","canonical_id":"go:GO:0038183","description":"\"The series of molecular signals initiated by bile acid binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:12016314, PMID:36409000]","metadata":null},{"id":"9a32d8337a524da1856bbd3b16ad3171","type":"GO_TERM","name":"bile acid transmembrane transporter activity","canonical_id":"go:GO:0015125","description":"\"Enables the transfer of bile acid from one side of a membrane to the other. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.\" [GOC:ai]","metadata":null},{"id":"ccdb13ecae8b4535ab6f2190e990daf6","type":"GO_TERM","name":"bile acid-gated sodium channel activity","canonical_id":"go:GO:0160228","description":"\"Enables the transmembrane transfer of a sodium ion by a channel that opens when bile acid has been bound by the channel complex or one of its constituent parts.\" [PMID:22735174]","metadata":null},{"id":"a9d4791d2c27406981f8b692a7c414ed","type":"GO_TERM","name":"bile acid:sodium symporter activity","canonical_id":"go:GO:0008508","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: bile acid(out) + Na+(out) = bile acid(in) + Na+(in).\" [TC:2.A.28.-.-]","metadata":null},{"id":"78edb6e0f4634754837cb12692611e73","type":"GO_TERM","name":"bile-acid 7alpha-dehydratase activity","canonical_id":"go:GO:0033988","description":"\"Catalysis of the reaction: 7alpha,12alpha-dihydroxy-3-oxochol-4-en-24-oate = 12alpha-hydroxy-3-oxochola-4,6-dien-24-oate + H2O.\" [PMID:26650892, RHEA:10436]","metadata":null},{"id":"ebb7ce6d5890409b83d633b6234fc688","type":"GO_TERM","name":"bile-acid-CoA transferase activity","canonical_id":"go:GO:0033881","description":"\"Catalysis of the reaction: deoxycholoyl-CoA + cholate = deoxycholate + choloyl-CoA.\" [PMID:22021638, RHEA:49436]","metadata":null},{"id":"47a10c7bb5334bdb8fe4f11a9e1515fb","type":"GO_TERM","name":"bile-salt sulfotransferase activity","canonical_id":"go:GO:0047704","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + taurolithocholate = adenosine 3',5'-bisphosphate + taurolithocholate sulfate.\" [EC:2.8.2.14, MetaCyc:BILE-SALT-SULFOTRANSFERASE-RXN]","metadata":null},{"id":"7f1f6c3893154fa0be076009ab99baf8","type":"DISEASE","name":"biliary liver cirrhosis","canonical_id":"efo:0004267","description":null,"metadata":null},{"id":"b4aa22e6f9c44db3995651b2a4ab4521","type":"DISEASE","name":"biliary tract cancer","canonical_id":"mondo:0003060","description":null,"metadata":null},{"id":"30d18f5b58de47a7b2c1db7b133eb9a7","type":"GO_TERM","name":"biliberdin reductase (NADH) activity","canonical_id":"go:GO:0106276","description":"\"Catalysis of the reaction: bilirubin IXalpha + NAD+ = biliverdin IXalpha + NADH+ H+.\" [RHEA:15797]","metadata":null},{"id":"e948e43755aa488d89ebb7f64a28ca24","type":"GO_TERM","name":"bilirubin conjugation","canonical_id":"go:GO:0006789","description":"\"The chemical reactions and pathways resulting in the formation of bilirubin monoglucuronide or bilirubin diglucuronide, water-soluble derivatives of bilirubin.\" [DOI:10.1016/0305-0491(80)90243-6]","metadata":null},{"id":"eb94ae080d744c64b7cbe69ae3a74f0e","type":"GO_TERM","name":"bilirubin oxidase activity","canonical_id":"go:GO:0047705","description":"\"Catalysis of the reaction: 2 bilirubin + O2 = 2 biliverdin + 2 H2O.\" [EC:1.3.3.5, RHEA:20980]","metadata":null},{"id":"94f1caa44a1c4581a0404f336f33bdbf","type":"GO_TERM","name":"bilirubin transmembrane transporter activity","canonical_id":"go:GO:0015127","description":"\"Enables the transfer of bilirubin from one side of a membrane to the other. Bilirubin is a linear tetrapyrrole produced in the reticuloendothelial system from biliverdin and transported to the liver as a complex with serum albumin. In the liver, bilirubin is converted to bilirubin bisglucuronide, which is excreted in the bile.\" [GOC:ai, ISBN:0198547684]","metadata":null},{"id":"b7106b6627874bb7b4a2047351b3fc79","type":"GO_TERM","name":"bilirubin transport","canonical_id":"go:GO:0015723","description":"\"The directed movement of bilirubin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"d0b70d42481f49f09ec118613fa55152","type":"GO_TERM","name":"bilirubin-glucuronoside glucuronosyltransferase activity","canonical_id":"go:GO:0047278","description":"\"Catalysis of the reaction: 2 bilirubin-glucuronoside = bilirubin + bilirubin-bisglucuronoside.\" [RHEA:16885]","metadata":null},{"id":"4867b6a84a4a4e91a6637d1200c1e245","type":"GO_TERM","name":"biliverdin reductase (NADPH) activity","canonical_id":"go:GO:0106277","description":"\"Catalysis of the reaction: bilirubin IXalpha + NADP+ = biliverdin IXalpha + NADPH + H+.\" [RHEA:15793]","metadata":null},{"id":"ea8b99ee7b3c4952ba5d0e8442be4b81","type":"GO_TERM","name":"biliverdin reductase [NAD(P)H] activity","canonical_id":"go:GO:0004074","description":"\"Catalysis of the reaction: bilirubin IXalpha + NAD(P)+ = biliverdin IXalpha + NAD(P)H + H+.\" [EC:1.3.1.24]","metadata":null},{"id":"f59494a07fe547e7ad0a811ac6f2968f","type":"GO_TERM","name":"bilobe structure","canonical_id":"go:GO:0120120","description":"\"A cytoskeletal structure in some kinetoplastid species linking the structures of the ciliary pocket collar and the flagellum attachment zone (aka cilium attachment zone).\" [PMID:22327007, PMID:22445359, PMID:26540076]","metadata":null},{"id":"1dafca0f065a483cb6ec1fc1185788e6","type":"GO_TERM","name":"bilobe structure assembly","canonical_id":"go:GO:0140528","description":"\"The assembly and organization of a bilobe structure, a cytoskeletal structure in some kinetoplastid species linking the structures of the ciliary pocket collar and the flagellum attachment zone (aka cilium attachment zone).\" [PMID:18443217, PMID:32675283]","metadata":null},{"id":"ee7757f56d224466a2ee71b9b22a4843","type":"DRUG","name":"bimatoprost","canonical_id":"gtopdb:1958","description":null,"metadata":null},{"id":"396f3cf3f61c46418a1d19b015dcbb4e","type":"DRUG","name":"bimatoprost","canonical_id":"chembl:CHEMBL1200963","description":null,"metadata":null},{"id":"8034dd14ac09413888162d76fddd2be2","type":"COMBINATION_TREATMENT","name":"bimatoprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-263ccc2de5b8e3d3","description":null,"metadata":null},{"id":"aab400f9ec374e2eabde040246ffad61","type":"COMBINATION_TREATMENT","name":"bimatoprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-1ed6b5f4cd921f0d","description":null,"metadata":null},{"id":"fd180341211e4e1a899a363181927021","type":"COMBINATION_TREATMENT","name":"bimatoprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-c7634d5cf8ca3e17","description":null,"metadata":null},{"id":"bf0efa4ac5bb4377a5f65694ee3a1f2b","type":"COMBINATION_TREATMENT","name":"bimatoprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-4cd7098e72e8aeed","description":null,"metadata":null},{"id":"615526614d1b42f89b3ec217ddffcfb2","type":"DRUG","name":"bimekizumab","canonical_id":"gtopdb:9411","description":null,"metadata":null},{"id":"96f5359e599d4fe08fe1223c34ea34a9","type":"DRUG","name":"bimekizumab","canonical_id":"chembl:CHEMBL4297700","description":null,"metadata":null},{"id":"9783014d3d644289b47dd426d505df33","type":"COMBINATION_TREATMENT","name":"bimekizumab + brodalumab + ixekizumab + risankizumab + tildrakizumab","canonical_id":"ctgov_combo:ctgov-combo-affdd0dcbd7326f7","description":null,"metadata":null},{"id":"cd224833cfa64d02844d13704904415a","type":"COMBINATION_TREATMENT","name":"bimekizumab + risankizumab","canonical_id":"ctgov_combo:ctgov-combo-3facfaa384231cf1","description":null,"metadata":null},{"id":"334a9d55634942f58b932e059e786fe5","type":"GO_TERM","name":"binding","canonical_id":"go:GO:0005488","description":"\"The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule.\" [GOC:ceb, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"4e25e1872d0d45f9981b6d892cedc235","type":"GO_TERM","name":"binding of sperm to zona pellucida","canonical_id":"go:GO:0007339","description":"\"The process in which the sperm binds to the zona pellucida glycoprotein layer of the egg. The process begins with the attachment of the sperm plasma membrane to the zona pellucida and includes attachment of the acrosome inner membrane to the zona pellucida after the acrosomal reaction takes place.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"21c524023062476e8b3ffef191d7f4f3","type":"GO_TERM","name":"bindosome complex","canonical_id":"go:GO:7770042","description":"\"A membrane-associated protein complex found in archaea that consists of sugar binding proteins assembled via a type IV pilin-like assembly system. The complex is located at the cell surface and functions in sugar uptake by facilitating the interaction between solute binding proteins and ABC transporters. The complex forms high molecular mass structures (400-600 kDa) that are integrated within or closely associated with the S-layer.\" [PMID:21234771, PMID:38877064]","metadata":null},{"id":"8236760f973246329cb27985f553eeb2","type":"DISEASE","name":"binge eating disorder","canonical_id":"mondo:0005582","description":null,"metadata":null},{"id":"2cb7dce64b144016b598e337810874b8","type":"DRUG","name":"binimetinib","canonical_id":"gtopdb:7921","description":null,"metadata":null},{"id":"3d508d0b8b944fa29ded948dcd1b2b50","type":"DRUG","name":"binimetinib","canonical_id":"chembl:CHEMBL3187723","description":null,"metadata":null},{"id":"352b9d3d05604e40bc1b028d7404d8a7","type":"COMBINATION_TREATMENT","name":"binimetinib + cetuximab","canonical_id":"ctgov_combo:ctgov-combo-accf0e8c8d2c7c2c","description":null,"metadata":null},{"id":"f1e99d4592f9484791ca53b9ef98b4d1","type":"COMBINATION_TREATMENT","name":"binimetinib + cobimetinib + dabrafenib + trametinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-36763cf460e3b366","description":null,"metadata":null},{"id":"4149375d20804347af0ccce861a6760c","type":"COMBINATION_TREATMENT","name":"binimetinib + crizotinib","canonical_id":"ctgov_combo:ctgov-combo-6e1592571b80f64e","description":null,"metadata":null},{"id":"a4855e2950a8420792fd8d11b9a6ec23","type":"COMBINATION_TREATMENT","name":"binimetinib + lorlatinib","canonical_id":"ctgov_combo:ctgov-combo-f8977845b0440393","description":null,"metadata":null},{"id":"4d043f9f42d048fdb8de990b91d0b29c","type":"COMBINATION_TREATMENT","name":"binimetinib + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-29b7f4842577c4bc","description":null,"metadata":null},{"id":"8cc6ef759c3e4748985e1cebea710c15","type":"COMBINATION_TREATMENT","name":"binimetinib + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-76d542c1184d1e1c","description":null,"metadata":null},{"id":"398cdbdd748944d58849e4a9eb136118","type":"COMBINATION_TREATMENT","name":"binimetinib + pertuzumab","canonical_id":"ctgov_combo:ctgov-combo-258c80f4f3aed516","description":null,"metadata":null},{"id":"ed8a603bb9844a48bd9e639576c303f0","type":"COMBINATION_TREATMENT","name":"binimetinib + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-cb086e46171ab13c","description":null,"metadata":null},{"id":"abb3161f093c478c9a50ba7d99f099f3","type":"COMBINATION_TREATMENT","name":"binimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-1079b19eabdeed19","description":null,"metadata":null},{"id":"26b1fd5924f14336b44754220b1c16bd","type":"GO_TERM","name":"bioactive lipid receptor activity","canonical_id":"go:GO:0045125","description":"\"Combining with a bioactive lipid and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. A bioactive lipid is a lipid for which changes in lipid levels result in functional consequences in a variety of cellular processes.\" [GOC:bf, GOC:mah, PMID:12215548, PMID:18216770]","metadata":null},{"id":"b97a18d66ca14024abde8b04b88ec91a","type":"GO_TERM","name":"bioadhesive activity","canonical_id":"go:GO:0140073","description":"\"A structural molecule ativity that mediates an organism's attachment to an environmental substrate via stable, non-selective binding by a protein to an external surface. Examples includes proteins used by insects to anchor pupae to surfaces.\" [PMID:39370426]","metadata":null},{"id":"d4389192b19c45d9aefebcc8125340e6","type":"GO_TERM","name":"biochanin-A reductase activity","canonical_id":"go:GO:0047706","description":"\"Catalysis of the reaction: dihydrobiochanin A + NADP+ = biochanin A + H+ + NADPH.\" [EC:1.3.1.46, RHEA:12817]","metadata":null},{"id":"4bdf3cdc7f7f4adebbd36da07ae55483","type":"GO_TERM","name":"biofilm formation","canonical_id":"go:GO:0042710","description":"\"A process in which planktonically growing microorganisms grow at a liquid-air interface or on a solid substrate under the flow of a liquid and produce extracellular polymers that facilitate matrix formation, resulting in a change in the organisms' growth rate and gene transcription.\" [GOC:di, PMID:11932229]","metadata":null},{"id":"e8105d4572a042f7b5505d61bb98910b","type":"GO_TERM","name":"biofilm matrix","canonical_id":"go:GO:0062039","description":"\"A type of extracellular matrix that surrounds the cells within a microbial biofilm. The matrix is composed of extracellular polymeric substances including exopolysaccharides, proteins, nucleic acids, lipids, and other biomolecules.\" [PMID:22571672, PMID:27129222, PMID:28516088, PMID:32663461]","metadata":null},{"id":"006870a1fb1149d2bb101f3c5a1df9d6","type":"GO_TERM","name":"biofilm matrix assembly","canonical_id":"go:GO:0098785","description":"\"A process that results in the assembly of a biofilm matrix.\" [GOC:mah]","metadata":null},{"id":"d93130bca06f4e3e99d4505c5ad3a8d7","type":"GO_TERM","name":"biofilm matrix disassembly","canonical_id":"go:GO:0098786","description":"\"A process that results in the disassembly of a biofilm matrix.\" [GOC:mah]","metadata":null},{"id":"1fe16e6c17c645fba5cd0930e6601bb6","type":"GO_TERM","name":"biofilm matrix organization","canonical_id":"go:GO:0098784","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of a biofilm matrix.\" [GOC:mah]","metadata":null},{"id":"f104fa17605f4e14a5f2048b11f598c5","type":"GO_TERM","name":"biogenic amine biosynthetic process","canonical_id":"go:GO:0042401","description":"\"The chemical reactions and pathways occurring at the level of individual cells resulting in the formation of any of a group of naturally occurring, biologically active amines, such as norepinephrine, histamine, and serotonin, many of which act as neurotransmitters.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"46f6907e8f7b4142a0bdeb48c1bf47e0","type":"GO_TERM","name":"biogenic amine catabolic process","canonical_id":"go:GO:0042402","description":"\"The chemical reactions and pathways occurring at the level of individual cells resulting in the breakdown of biogenic amines, any of a group of naturally occurring, biologically active amines, such as norepinephrine, histamine, and serotonin, many of which act as neurotransmitters.\" [GOC:curators, GOC:jl, ISBN:0198506732]","metadata":null},{"id":"befa042009674d1b8532e6a7d5f1dcf9","type":"GO_TERM","name":"biogenic amine metabolic process","canonical_id":"go:GO:0006576","description":"\"The chemical reactions and pathways occurring at the level of individual cells involving any of a group of naturally occurring, biologically active amines, such as norepinephrine, histamine, and serotonin, many of which act as neurotransmitters.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"9ef8e59fbef24e709f2764d99a4c5279","type":"GO_TERM","name":"biological phase","canonical_id":"go:GO:0044848","description":"\"A distinct period or stage in a biological process or cycle.\" [GOC:jl]","metadata":null},{"id":"146700a8bc8c4e088da26b7a36bf5f1d","type":"GO_TERM","name":"biological process involved in interaction with host","canonical_id":"go:GO:0051701","description":"\"An interaction between two organisms living together in more or less intimate association. The term host is used for the larger (macro) of the two members of a symbiosis; the various forms of symbiosis include parasitism, commensalism and mutualism.\" [GOC:cc]","metadata":null},{"id":"9117e2ad6c2047b78d51cd8332b87847","type":"GO_TERM","name":"biological process involved in interaction with symbiont","canonical_id":"go:GO:0051702","description":"\"An interaction between two organisms living together in more or less intimate association. The term symbiont is used for the smaller (macro) of the two members of a symbiosis; the various forms of symbiosis include parasitism, commensalism and mutualism.\" [GOC:cc]","metadata":null},{"id":"2c2867f4efe748518e9deb1fc14f2537","type":"GO_TERM","name":"biological process involved in interspecies interaction between organisms","canonical_id":"go:GO:0044419","description":"\"Any process evolved to enable an interaction with an organism of a different species.\" [GOC:cc]","metadata":null},{"id":"73cc938d05924bf4939bc239ecc22e5c","type":"GO_TERM","name":"biological process involved in intraspecies interaction between organisms","canonical_id":"go:GO:0051703","description":"\"Any process in which an organism has an effect on an organism of the same species.\" [GOC:ai]","metadata":null},{"id":"ff6cb59668804f36acd932ece09309b6","type":"GO_TERM","name":"biological process involved in symbiotic interaction","canonical_id":"go:GO:0044403","description":"\"A process carried out by gene products in an organism that enable the organism to engage in a symbiotic relationship, a more or less intimate association, with another organism. The various forms of symbiosis include parasitism, in which the association is disadvantageous or destructive to one of the organisms; mutualism, in which the association is advantageous, or often necessary to one or both and not harmful to either; and commensalism, in which one member of the association benefits while the other is not affected. However, mutualism, parasitism, and commensalism are often not discrete categories of interactions and should rather be perceived as a continuum of interaction ranging from parasitism to mutualism. In fact, the direction of a symbiotic interaction can change during the lifetime of the symbionts due to developmental changes as well as changes in the biotic/abiotic environment in which the interaction occurs. Microscopic symbionts are often referred to as endosymbionts.\" [GOC:cc, PMID:31257129]","metadata":null},{"id":"f80484a6e754429893b2237bac844aec","type":"GO_TERM","name":"biological regulation","canonical_id":"go:GO:0065007","description":"\"Any process that modulates a measurable attribute of any biological process, quality or function.\" [GOC:dph, GOC:isa_complete, GOC:mah, GOC:pr, GOC:vw]","metadata":null},{"id":"51358fd7796e427bbb066fff5528c3e6","type":"GO_TERM","name":"biological_process","canonical_id":"go:GO:0008150","description":"\"A biological process is the execution of a genetically-encoded biological module or program. It consists of all the steps required to achieve the specific biological objective of the module. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence.\" [GOC:pdt]","metadata":null},{"id":"ca937a4c00d145b39f567ebbf7f30832","type":"GO_TERM","name":"bioluminescence","canonical_id":"go:GO:0008218","description":"\"The production of light by certain enzyme-catalyzed reactions in cells.\" [ISBN:0198506732]","metadata":null},{"id":"520b1fa20f18497ba27861bd43b2329a","type":"GO_TERM","name":"biomineral tissue development","canonical_id":"go:GO:0031214","description":"\"Formation of hard tissues that consist mainly of inorganic compounds, and also contain a small amounts of organic matrices that are believed to play important roles in their formation.\" [PMID:15132736]","metadata":null},{"id":"7be37c7f68ab4fb49153c95068969284","type":"GO_TERM","name":"biopterin transmembrane transporter activity","canonical_id":"go:GO:0015224","description":"\"Enables the transfer of biopterin from one side of a membrane to the other. Biopterin is a growth factor for certain protozoans and some insects; it is widely distributed in tissues and functions in a reduced form, tetrahydrobiopterin, as a hydroxylation coenzyme.\" [ISBN:0198506732]","metadata":null},{"id":"52d84bff96c94098b1c1283fc8844e1a","type":"GO_TERM","name":"biopterin transport","canonical_id":"go:GO:0015877","description":"\"The directed movement of biopterin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Biopterin is a growth factor for certain protozoans and some insects; it is widely distributed in tissues and functions in a reduced form, tetrahydrobiopterin, as a hydroxylation coenzyme.\" [GOC:ai]","metadata":null},{"id":"ac44c82b52a14229a59447631848a616","type":"GO_TERM","name":"biosynthetic process","canonical_id":"go:GO:0009058","description":"\"A cellular process consisting of the biochemical pathways by which a living organism synthesizes chemical substances. This typically represents the energy-requiring part of metabolism in which simpler substances are transformed into more complex ones.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"9638ac05fd2640b7a643a949a35666ed","type":"GO_TERM","name":"biosynthetic process of antibacterial peptides active against Gram-negative bacteria","canonical_id":"go:GO:0002812","description":"\"The chemical reactions and pathways resulting in the formation of an antibacterial peptide with activity against Gram-negative bacteria.\" [GOC:add, PMID:11807545]","metadata":null},{"id":"d526283bc24c404db271b8fec9529c01","type":"GO_TERM","name":"biosynthetic process of antibacterial peptides active against Gram-positive bacteria","canonical_id":"go:GO:0002815","description":"\"The chemical reactions and pathways resulting in the formation of an antibacterial peptide with activity against Gram-positive bacteria.\" [GOC:add]","metadata":null},{"id":"e4f5978835c34c808129e6fbed567f34","type":"GO_TERM","name":"biotin binding","canonical_id":"go:GO:0009374","description":"\"Binding to biotin (cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid), the (+) enantiomer of which is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"123333625aaf40dba1c382a1dc6ff00f","type":"GO_TERM","name":"biotin biosynthetic process","canonical_id":"go:GO:0009102","description":"\"The chemical reactions and pathways resulting in the formation of biotin, cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid.\" [ISBN:0198506732]","metadata":null},{"id":"ab10a65876174212806015678d96dbcf","type":"GO_TERM","name":"biotin carboxyl carrier protein biosynthetic process","canonical_id":"go:GO:0042966","description":"\"The chemical reactions and pathways resulting in the formation of the biotin carboxyl carrier protein, a subunit of acetyl-coenzyme A carboxylase.\" [GOC:curators, PMID:8102363]","metadata":null},{"id":"b31f3db8276d42c9b463597c9c9752c7","type":"GO_TERM","name":"biotin carboxylase activity","canonical_id":"go:GO:0004075","description":"\"Catalysis of the reaction: ATP + biotin-carboxyl-carrier protein + CO2 = ADP + phosphate + carboxybiotin-carboxyl-carrier protein.\" [EC:6.3.4.14]","metadata":null},{"id":"1005106209344f178ea563be830b1613","type":"GO_TERM","name":"biotin catabolic process","canonical_id":"go:GO:0042367","description":"\"The chemical reactions and pathways resulting in the breakdown of biotin, cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid.\" [ISBN:0198506732]","metadata":null},{"id":"a87b7520f2124bd4be814e186022411b","type":"GO_TERM","name":"biotin import across plasma membrane","canonical_id":"go:GO:1905135","description":"\"The directed movement of biotin from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:12557275]","metadata":null},{"id":"d19739f9d8004224833af78e60551042","type":"GO_TERM","name":"biotin metabolic process","canonical_id":"go:GO:0006768","description":"\"The chemical reactions and pathways involving biotin, cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; the (+) enantiomer is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions.\" [ISBN:0198506732]","metadata":null},{"id":"de45983cb4734d59837b051782370f4e","type":"GO_TERM","name":"biotin synthase activity","canonical_id":"go:GO:0004076","description":"\"Catalysis of the reaction: (4R,5S)-dethiobiotin + [sulfur carrier]-SH + 2 reduced [2Fe-2S]-[ferredoxin] + 2 S-adenosyl-L-methionine = [sulfur carrier]-H + biotin + 2 5'-deoxyadenosine + 2 L-methionine + 2 oxidized [2Fe-2S]-[ferredoxin].\" [EC:2.8.1.6, RHEA:22060]","metadata":null},{"id":"0d6383c38eb94201a4922200acb69e2f","type":"GO_TERM","name":"biotin transmembrane transporter activity","canonical_id":"go:GO:0015225","description":"\"Enables the transfer of biotin from one side of a membrane to the other. Biotin is cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; the (+) enantiomer is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions.\" [GOC:ai]","metadata":null},{"id":"5d1fd8f3a844429f80f743c15a4b9de6","type":"GO_TERM","name":"biotin transport","canonical_id":"go:GO:0015878","description":"\"The directed movement of biotin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Biotin is cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; the (+) enantiomer is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions.\" [GOC:ai]","metadata":null},{"id":"b0f9c6e0b87d4fe2b1c092eb0d83afb1","type":"GO_TERM","name":"biotin--[biotin carboxyl-carrier protein] ligase activity","canonical_id":"go:GO:0004077","description":"\"Catalysis of the reaction: ATP + biotin + L-lysyl-[protein] = AMP + diphosphate + H+ + N(6)-biotinyl-L-lysyl-[protein].\" [RHEA:11756]","metadata":null},{"id":"9c2231145ca8400b95166bdd25d6de1d","type":"GO_TERM","name":"biotin-CoA ligase activity","canonical_id":"go:GO:0047707","description":"\"Catalysis of the reaction: ATP + biotin + CoA = AMP + diphosphate + biotinyl-CoA.\" [EC:6.2.1.11, MetaCyc:BIOTIN--COA-LIGASE-RXN]","metadata":null},{"id":"d3c1c896f4c641619bf879e9842e2d96","type":"GO_TERM","name":"biotinidase activity","canonical_id":"go:GO:0047708","description":"\"Catalysis of the reaction: biotin amide + H2O = biotin + NH3.\" [EC:3.5.1.12, MetaCyc:BIOTINIDASE-RXN]","metadata":null},{"id":"60a5b6421e52490596ef79cd55311a82","type":"DRUG","name":"biperiden","canonical_id":"gtopdb:7128","description":null,"metadata":null},{"id":"c26e7b44f4fc4316bb4d2026ce35d0ba","type":"DRUG","name":"biperiden","canonical_id":"mesh:D001712","description":null,"metadata":null},{"id":"c1f7a8bcc41f41a58f391c2c59225821","type":"COMBINATION_TREATMENT","name":"biperiden + caffeine","canonical_id":"ctgov_combo:ctgov-combo-10d15e47115fad8c","description":null,"metadata":null},{"id":"b0e8b41e082a4c3e8333216f5c38defc","type":"GO_TERM","name":"biphenyl 2,3-dioxygenase activity","canonical_id":"go:GO:0018687","description":"\"Catalysis of the reaction: biphenyl + NADH + H+ + O2 = (2R,3S)-3-phenylcyclohexa-3,5-diene-1,2-diol + NAD+. This reaction requires Fe2+.\" [RHEA:18165]","metadata":null},{"id":"768b7487eb0f4d8288246d80d8f9b12f","type":"GO_TERM","name":"biphenyl catabolic process","canonical_id":"go:GO:0070980","description":"\"The chemical reactions and pathways resulting in the breakdown of biphenyl, a toxic aromatic hydrocarbon used as a heat transfer agent, as a fungistat in packaging citrus fruits and in plant disease control. Biphenyl can be chlorinated with 1-10 chlorine molecules to form polychlorinated biphenyls (PCBs).\" [PMID:16310831, PMID:16339959]","metadata":null},{"id":"6d4dc65afe7c423a869858df8e9b3f41","type":"GO_TERM","name":"biphenyl metabolic process","canonical_id":"go:GO:0018879","description":"\"The chemical reactions and pathways involving biphenyl, a toxic aromatic hydrocarbon used as a heat transfer agent, as a fungistat in packaging citrus fruits and in plant disease control. Biphenyl can be chlorinated with 1-10 chlorine molecules to form polychlorinated biphenyls (PCBs).\" [GOC:jl]","metadata":null},{"id":"abe417a323aa4858aa188615b0581c7e","type":"GO_TERM","name":"biphenyl synthase activity","canonical_id":"go:GO:0033815","description":"\"Catalysis of the reaction: 3 malonyl-CoA + benzoyl-CoA = 4 CoA + 3,5-dihydroxybiphenyl + 4 CO2.\" [EC:2.3.1.177]","metadata":null},{"id":"c279a7875cd741308a974f9532f0b633","type":"GO_TERM","name":"biphenyl-2,3-diol 1,2-dioxygenase activity","canonical_id":"go:GO:0018583","description":"\"Catalysis of the reaction: biphenyl-2,3-diol + O2 = 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate + H2O.\" [EC:1.13.11.39]","metadata":null},{"id":"9838b7906f7940cfa33cff8961bac42e","type":"DISEASE","name":"bipolar I disorder","canonical_id":"efo:0009963","description":null,"metadata":null},{"id":"d38c3a04bf074bea8afdf66d51a54226","type":"DISEASE","name":"bipolar II disorder","canonical_id":"efo:0009964","description":null,"metadata":null},{"id":"9da62845f53c4608b56d241c9cecc27a","type":"GO_TERM","name":"bipolar cell growth","canonical_id":"go:GO:0042815","description":"\"The process in which a cell irreversibly increases in size along one axis through simultaneous polarized growth from opposite ends of a cell, resulting in morphogenesis of the cell.\" [GOC:vw]","metadata":null},{"id":"25880424b82a45d89f75f7c65178fad9","type":"GO_TERM","name":"bipolar cellular bud site selection","canonical_id":"go:GO:0007121","description":"\"The process of defining subsequent sites of bud emergence such that budding takes place at alternating poles of a budding cell.\" [GOC:clt]","metadata":null},{"id":"b67ae57b9b364d2fadfd3f5d53a5f93d","type":"DISEASE","name":"bipolar disorder","canonical_id":"mondo:0004985","description":null,"metadata":null},{"id":"dc82698cffb84bc59f17b233e10ec5ec","type":"DRUG","name":"bireociclib","canonical_id":"gtopdb:14404","description":null,"metadata":null},{"id":"685a06cde3ac4ae5a7436f0004584cda","type":"GO_TERM","name":"bis(2-ethylhexyl)phthalate esterase activity","canonical_id":"go:GO:0047709","description":"\"Catalysis of the reaction: bis(2-ethylhexyl)phthalate + H2O = 2-ethylhexan-1-ol + 2-ethylhexyl phthalate + H+.\" [EC:3.1.1.60, RHEA:15529]","metadata":null},{"id":"8c44f1dbb5c84edb8cb561f542e46070","type":"GO_TERM","name":"bis(5'-adenosyl)-hexaphosphatase activity","canonical_id":"go:GO:0034431","description":"\"Catalysis of the reaction: P1-P6-bis(5'-adenosyl) hexaphosphate + H2O = AMP + adenosine 5'-pentaphosphate.\" [PMID:10085096, PMID:9450008, RHEA:32047]","metadata":null},{"id":"066cc0c9fec64c63b87762485dab411a","type":"GO_TERM","name":"bis(5'-adenosyl)-pentaphosphatase activity","canonical_id":"go:GO:0034432","description":"\"Catalysis of the reaction: P1-P6-bis(5'-adenosyl) pentaphosphate + H2O = AMP + adenosine 5'-tetraphosphate.\" [PMID:10085096, PMID:9450008]","metadata":null},{"id":"b158d7937a5448cc8b9516fd2616ba36","type":"GO_TERM","name":"bis(5'-adenosyl)-triphosphatase activity","canonical_id":"go:GO:0047710","description":"\"Catalysis of the reaction: P(1),P(3)-bis(5'-adenosyl) triphosphate + H2O = ADP + AMP + 2 H+.\" [EC:3.6.1.29, RHEA:13893]","metadata":null},{"id":"c9cf3c9e9a084add98e1476b8d6f42ef","type":"GO_TERM","name":"bis(5'-nucleosidyl) oligophosphate biosynthetic process","canonical_id":"go:GO:0015957","description":"\"The chemical reactions and pathways resulting in the formation of a bis(5'-nucleosidyl) oligophosphate, a compound formed of two nucleosides joined together through their 5' carbons by a chain of phosphate molecules.\" [GOC:mah, PMID:10970777]","metadata":null},{"id":"31370d6e54b54b8d846fdedd5ee7d702","type":"GO_TERM","name":"bis(5'-nucleosidyl) oligophosphate catabolic process","canonical_id":"go:GO:0015958","description":"\"The chemical reactions and pathways resulting in the breakdown of a bis(5'-nucleosidyl) oligophosphate, a compound formed of two nucleosides joined together through their 5' carbons by a chain of phosphate molecules.\" [GOC:mah, PMID:10970777]","metadata":null},{"id":"c4cdd56415c04c73a355646a51f0ec25","type":"GO_TERM","name":"bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activity","canonical_id":"go:GO:0004081","description":"\"Catalysis of the reaction: P(1),P(4)-bis(5'-nucleosyl)tetraphosphate + H2O = NTP + NMP. Acts on bis(5'-guanosyl)-, bis(5'-xanthosyl)-, bis(5'-adenosyl)- and bis(5'-uridyl)-tetraphosphate.\" [EC:3.6.1.17, PMID:4955726]","metadata":null},{"id":"0d00f2be092041c68f1a94cab6fec607","type":"GO_TERM","name":"bis(5'-nucleosyl)-tetraphosphatase (symmetrical) activity","canonical_id":"go:GO:0008803","description":"\"Catalysis of the reaction: P(1),P(4)-bis(5'-adenosyl) tetraphosphate + H2O = 2 ADP + 2 H+.\" [EC:3.6.1.41, RHEA:24252]","metadata":null},{"id":"8100d53fc738452c9bcca20b2300e453","type":"GO_TERM","name":"bis(5'-nucleosyl)-tetraphosphatase activity","canonical_id":"go:GO:0008796","description":"\"Catalysis of the hydrolysis of P(1),P(4)-bis(5'-nucleosyl)tetraphosphate into two nucleotides.\" [GOC:ai]","metadata":null},{"id":"ee42d702bcb14adba65051fee1874698","type":"GO_TERM","name":"bis(molybdopterin guanine dinucleotide)molybdenum biosynthetic process","canonical_id":"go:GO:1902758","description":"\"The chemical reactions and pathways resulting in the formation of bis(molybdopterin guanine dinucleotide)molybdenum.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:23201473]","metadata":null},{"id":"0d155a70f70644178e6bf501a3db501e","type":"GO_TERM","name":"bis(monoacylglycero)phosphate synthase activity","canonical_id":"go:GO:0160121","description":"\"Catalysis of the reaction: 2 3-acyl-sn-glycero-1-phospho-(1'-sn-glycerol) = 3-acyl-sn-glycero-1-phospho-(3'-acyl-1'-sn-glycerol) + sn-glycero-1-phospho-(1'-sn-glycerol).\" [PMID:37708259, RHEA:77619]","metadata":null},{"id":"2b22048050234b98b0d212e89960def6","type":"GO_TERM","name":"bis-gamma-L-glutamylcystine reductase (NADPH) activity","canonical_id":"go:GO:0047135","description":"\"Catalysis of the reaction: 2 L-gamma-glutamyl-L-cysteine + NADP+ = bis-gamma-glutamylcystine + H+ + NADPH.\" [EC:1.8.1.13, RHEA:11980]","metadata":null},{"id":"a83a17eaee294a77adcc9e0d7f94bd03","type":"GO_TERM","name":"bisdemethoxycurcumin synthase activity","canonical_id":"go:GO:0102452","description":"\"Catalysis of the reaction: 2 4-coumaryl-CoA + malonyl-CoA + H2O + H+ = 3 coenzyme A + bisdemethoxycurcumin + 2 carbon dioxide.\" [EC:2.3.1.211, GOC:pz]","metadata":null},{"id":"8509b113ad1442d09937586b9efcd099","type":"DRUG","name":"bismuth subsalicylate","canonical_id":"mesh:C015715","description":null,"metadata":null},{"id":"86232e56625f4786a6e09d5661bc7f1f","type":"DRUG","name":"bisoprolol","canonical_id":"mesh:D017298","description":null,"metadata":null},{"id":"40be39a11d644ea3a4eb1486fe2ea058","type":"GO_TERM","name":"bisphenol A catabolic process","canonical_id":"go:GO:0043636","description":"\"The chemical reactions and pathways resulting in the breakdown of bisphenol A, 4,4'-(propane-2,2-diyl)diphenol, a synthetic, aromatic organic compound used as a monomer in the manufacture of polycarbonate plastic and in the manufacture of epoxy resins.\" [GOC:jl, Wikipedia:Bisphenol_A]","metadata":null},{"id":"a76b12bd88874c44b48901ca4e68c99f","type":"GO_TERM","name":"bisphosphoglycerate 3-phosphatase activity","canonical_id":"go:GO:0034417","description":"\"Catalysis of the reaction: (2R)-2,3-bisphosphoglycerate + H2O = (2R)-2-phosphoglycerate + phosphate.\" [GOC:mah, PMID:18413611, RHEA:27381]","metadata":null},{"id":"b6a00cff9421499cb825645089247ff3","type":"GO_TERM","name":"bisphosphoglycerate mutase activity","canonical_id":"go:GO:0004082","description":"\"Catalysis of the reaction: 3-phospho-D-glyceroyl phosphate = 2,3-bisphospho-D-glycerate.\" [EC:5.4.2.4]","metadata":null},{"id":"6f585dffc72d443690092b99ddc94b53","type":"DRUG","name":"bitolterol","canonical_id":"mesh:C011685","description":null,"metadata":null},{"id":"dbfaeea649fa49f0bd24477a235500f2","type":"GO_TERM","name":"bitter taste receptor activity","canonical_id":"go:GO:0033038","description":"\"Combining with soluble bitter compounds to initiate a change in cell activity. These receptors are responsible for the sense of bitter taste.\" [GOC:mah]","metadata":null},{"id":"df3f813e94d7479c8ebe64a5892a2e24","type":"GO_TERM","name":"biuret amidohydrolase activity","canonical_id":"go:GO:0018750","description":"\"Catalysis of the reaction: biuret + H2O = urea-1-carboxylate + NH4+.\" [RHEA:17525]","metadata":null},{"id":"23fa0e39b1eb4c9e9392addbff4d1826","type":"DRUG","name":"bivalirudin","canonical_id":"gtopdb:6470","description":null,"metadata":null},{"id":"ae40e11648e64640984a4170641ccead","type":"DRUG","name":"bivalirudin","canonical_id":"chembl:CHEMBL5314348","description":null,"metadata":null},{"id":"f43650d2583547b2987e9348bd0a571e","type":"COMBINATION_TREATMENT","name":"bivalirudin + eptifibatide","canonical_id":"ctgov_combo:ctgov-combo-dc924b27c22f2f24","description":null,"metadata":null},{"id":"5de119557765421296d57e792f7e7c85","type":"COMBINATION_TREATMENT","name":"bivalirudin + heparin","canonical_id":"ctgov_combo:ctgov-combo-47948de572b8b6d3","description":null,"metadata":null},{"id":"032c6306b30f4a148fe2f2aa139ef11d","type":"COMBINATION_TREATMENT","name":"bivalirudin + heparin","canonical_id":"ctgov_combo:ctgov-combo-d31512e7bd03c0c2","description":null,"metadata":null},{"id":"7cf0423aa31541f3b247cd7f4aff2a54","type":"COMBINATION_TREATMENT","name":"bivalirudin + heparin","canonical_id":"ctgov_combo:ctgov-combo-fb10f7d311996609","description":null,"metadata":null},{"id":"28656aa092d040ef992c1c8e8f9893bf","type":"COMBINATION_TREATMENT","name":"bivalirudin + heparin","canonical_id":"ctgov_combo:ctgov-combo-39a7f2b5bfc5d672","description":null,"metadata":null},{"id":"f91dc7b3440f4335a6e6b75f21eac1da","type":"DISEASE","name":"bladder calculus","canonical_id":"mondo:0006678","description":null,"metadata":null},{"id":"07d8431a10ac4aa2aa7cef078650b476","type":"GO_TERM","name":"blasticidin S biosynthetic process","canonical_id":"go:GO:1905266","description":"\"The chemical reactions and pathways resulting in the formation of blasticidin S.\" [GO_REF:0000068, GOC:pr, GOC:TermGenie, PMID:23874663, Wikipedia:Blasticidin_S]","metadata":null},{"id":"0a3b3e7dc35e48b9a9bfa75404cde9b5","type":"GO_TERM","name":"blasticidin S catabolic process","canonical_id":"go:GO:1905265","description":"\"The chemical reactions and pathways resulting in the breakdown of blasticidin S.\" [GO_REF:0000068, GOC:pr, GOC:TermGenie, PMID:23874663, Wikipedia:Blasticidin_S]","metadata":null},{"id":"d28c6f5f3c71484f84d8120f91e6ed09","type":"GO_TERM","name":"blasticidin-S deaminase activity","canonical_id":"go:GO:0047711","description":"\"Catalysis of the reaction: blasticidin S + H2O + H+ = deaminohydroxyblasticidin S + NH4+.\" [RHEA:10148]","metadata":null},{"id":"06255fe332ee47039e9861021defccfe","type":"GO_TERM","name":"blastocyst development","canonical_id":"go:GO:0001824","description":"\"The process whose specific outcome is the progression of the blastocyst over time, from its formation to the mature structure. The mammalian blastocyst is a hollow ball of cells containing two cell types, the inner cell mass and the trophectoderm. The blastula follows the morula and precedes the gastrula in the developmental sequence.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"db50128aa4e74af287d034eba02180ce","type":"GO_TERM","name":"blastocyst formation","canonical_id":"go:GO:0001825","description":"\"The initial formation of a blastocyst from a solid ball of cells known as a morula.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"ee2364fd1b4842aca52258da1af1449e","type":"GO_TERM","name":"blastocyst growth","canonical_id":"go:GO:0001832","description":"\"An increase in size of a blastocyst due to expansion of the blastocoelic cavity cell shape changes and cell proliferation.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"a21cbff996e34ae7a4140026e710d747","type":"GO_TERM","name":"blastocyst hatching","canonical_id":"go:GO:0001835","description":"\"The hatching of the cellular blastocyst from the zona pellucida.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"ec9af0c5d9e94ea8a3fd67fd141d41f8","type":"GO_TERM","name":"blastoderm segmentation","canonical_id":"go:GO:0007350","description":"\"The hierarchical steps resulting in the progressive subdivision of the anterior/posterior axis of the embryo.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"3e16be78edf348efa99deef9ae4009d0","type":"GO_TERM","name":"bleb","canonical_id":"go:GO:0032059","description":"\"A cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. Blebs are formed during apoptosis and other cellular processes, including cell locomotion, cell division, and as a result of physical or chemical stresses.\" [GOC:mtg_apoptosis, PMID:12083798, PMID:16624291, Wikipedia:Bleb_(cell_biology)]","metadata":null},{"id":"f168979904a44853be04c16595190d1a","type":"GO_TERM","name":"bleb assembly","canonical_id":"go:GO:0032060","description":"\"The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. Plasma membrane blebbing occurs during apoptosis and other cellular processes, including cell locomotion, cell division, and as a result of physical or chemical stresses.\" [GOC:mah, GOC:mtg_apoptosis, PMID:12083798, PMID:16624291, Wikipedia:Bleb_(cell_biology)]","metadata":null},{"id":"1028499736964139a2a51d10aa0785d0","type":"DRUG","name":"bleomycin","canonical_id":"mesh:D001761","description":null,"metadata":null},{"id":"8734c1db1ee8456f8d35acb006db0778","type":"GO_TERM","name":"blepharoplast","canonical_id":"go:GO:0097727","description":"\"An intracellular non-membrane-bounded organelle found in multi-ciliated sperm cells of some primitive land plants, and consisting of many radially arranged ninefold symmetric cylinders. The blepharoplast is involved in de novo formation of multiple centrioles; it enlarges and then disintegrates into many procentrioles, which elongate and ultimately nucleate cilia on the surface of the sperm cell.\" [GOC:cilia, GOC:tb, PMID:22691130, PMID:25047614]","metadata":null},{"id":"00b41138fa244724a1bc74275f906d41","type":"DRUG","name":"blonanserin","canonical_id":"gtopdb:7670","description":null,"metadata":null},{"id":"ce050169d8e240be928a40b2fdde7d06","type":"DRUG","name":"blonanserin","canonical_id":"mesh:C079310","description":null,"metadata":null},{"id":"ec8484f9b95c4e699ac69259684aec99","type":"DRUG","name":"blonanserin","canonical_id":"chembl:CHEMBL178803","description":null,"metadata":null},{"id":"f762521fb7b3459da581ed1ac890b0d3","type":"GO_TERM","name":"blood circulation","canonical_id":"go:GO:0008015","description":"\"The flow of blood through the body of an animal, enabling the transport of nutrients to the tissues and the removal of waste products.\" [GOC:mtg_heart, ISBN:0192800825]","metadata":null},{"id":"e87b1082cea34297a319ae99f224338c","type":"GO_TERM","name":"blood coagulation","canonical_id":"go:GO:0007596","description":"\"The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.\" [PMID:30700128]","metadata":null},{"id":"7d6f69cffadd4dd1ac68213d3e28a59f","type":"DISEASE","name":"blood coagulation disease","canonical_id":"mondo:0001531","description":null,"metadata":null},{"id":"8a114e3b329f4964ab81728ddc206250","type":"GO_TERM","name":"blood coagulation, common pathway","canonical_id":"go:GO:0072377","description":"\"A protein activation cascade that contributes to blood coagulation and consists of events leading from the formation of activated Factor Xa by either the intrinsic or extrinsic pathway, to the formation of active thrombin, the cleavage of fibrinogen by thrombin, and the formation of cleaved fibrin into a stable multimeric, cross-linked complex.\" [GOC:add, GOC:mah, GOC:pde, PMID:1931959]","metadata":null},{"id":"37166c84d709474194b2064040c2ee1b","type":"GO_TERM","name":"blood coagulation, extrinsic pathway","canonical_id":"go:GO:0007598","description":"\"A protein activation cascade that initiates blood coagulation, starting with a signal from tissue factor (TF), a cell-surface, integral-membrane protein, which converts Factor IX to IXa, and Factor IXa converts Factor X to Xa. Factor Xa then initiates the common pathway.\" [GOC:add, GOC:mah, GOC:pde, PMID:26018600]","metadata":null},{"id":"b4e4e0a5cf2845a7a1ea3e4aa1e03280","type":"GO_TERM","name":"blood coagulation, fibrin clot formation","canonical_id":"go:GO:0072378","description":"\"A protein activation cascade that contributes to blood coagulation and consists of the cascade of enzymatic reactions initiated by physical damage to the wall of a blood vessel, leading to the formation of a formation of a fibrin clot at the site of the injury. The process also includes numerous positive and negative regulatory events.\" [GOC:add, GOC:mah, GOC:pde, PMID:26018600]","metadata":null},{"id":"a272fbd96aa94f9eaa594d5f517f5ceb","type":"GO_TERM","name":"blood coagulation, intrinsic pathway","canonical_id":"go:GO:0007597","description":"\"A protein activation cascade that initiates blood coagulation, triggered when Factor XII, prekallikrein (PK) and high-molecular-weight kininogen  (HK) assemble on a suitable surface or polymer. This results in the reciprocal activation of factor XII to Factor XIIa by kallikrein, and PK to kallikrein by Factor XIIa. The resulting generation of Factor XIIa activates Factor XI to Factor XIa, which then converts Factor IX to Factor IXa. Factor IXa converts Factor X to Xa. Factor Xa then initiates the common pathway.\" [GOC:add, GOC:mah, GOC:pde, PMID:26018600]","metadata":null},{"id":"1d106a3b88874b9089cc4f6b32f8363e","type":"GO_TERM","name":"blood microparticle","canonical_id":"go:GO:0072562","description":"\"A phospholipid microvesicle that is derived from any of several cell types, such as platelets, blood cells, endothelial cells, or others, and contains membrane receptors as well as other proteins characteristic of the parental cell. Microparticles are heterogeneous in size, and are characterized as microvesicles free of nucleic acids.\" [GOC:BHF, GOC:mah, PMID:16373184]","metadata":null},{"id":"9b3e58cd7bfe4685986147bfa731f14b","type":"GO_TERM","name":"blood microparticle formation","canonical_id":"go:GO:0072564","description":"\"The cellular component organization process in which microparticles bud off from a parent cell. A microparticle is a phospholipid microvesicle that is derived from any of several cell types, such as platelets, blood cells, endothelial cells, or others, and contains membrane receptors as well as other proteins characteristic of the parental cell.\" [GOC:BHF, GOC:mah, PMID:16373184]","metadata":null},{"id":"6a9a179f13dd46fc851e6ea6c886838a","type":"GO_TERM","name":"blood vessel development","canonical_id":"go:GO:0001568","description":"\"The process whose specific outcome is the progression of a blood vessel over time, from its formation to the mature structure. The blood vessel is the vasculature carrying blood.\" [GOC:hjd, UBERON:0001981]","metadata":null},{"id":"89f64e1ad88946ccbb4943cd1c7d85d4","type":"GO_TERM","name":"blood vessel diameter maintenance","canonical_id":"go:GO:0097746","description":"\"Any process that modulates the diameter of blood vessels.\" [GOC:pr]","metadata":null},{"id":"98c6cd37e1aa4eab8a0bbdcf81cac051","type":"GO_TERM","name":"blood vessel endothelial cell delamination","canonical_id":"go:GO:0097497","description":"\"The process of negative regulation of cell adhesion that results in blood vessel endothelial cells splitting off from an existing endothelial sheet.\" [GOC:dgh, PMID:23698350]","metadata":null},{"id":"b23a88ebc2564a4db65b9ca49864a918","type":"GO_TERM","name":"blood vessel endothelial cell delamination involved in blood vessel lumen ensheathment","canonical_id":"go:GO:1902354","description":"\"Any blood vessel endothelial cell delamination that is involved in blood vessel lumen ensheathment.\" [GOC:dgh, GOC:TermGenie, PMID:23698350]","metadata":null},{"id":"36c7fc827c4a438cb93146570a3898c9","type":"GO_TERM","name":"blood vessel endothelial cell differentiation","canonical_id":"go:GO:0060837","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a blood vessel endothelial cell, a thin flattened cell that lines the inside surfaces of blood vessels.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"2fdfbe8626534e9b89b823d237e239f6","type":"GO_TERM","name":"blood vessel endothelial cell fate commitment","canonical_id":"go:GO:0060846","description":"\"The commitment of a cell to a blood vessel endothelial cell fate and its capacity to differentiate into a blood vessel endothelial cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"8ed6958326134267bb708a8bfea9338c","type":"GO_TERM","name":"blood vessel endothelial cell fate specification","canonical_id":"go:GO:0097101","description":"\"The process involved in the specification of identity of a blood vessel endothelial cell. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment. A blood vessel endothelial cell is an endothelial cell of the vascular tree, which includes blood vessels and lymphatic vessels.\" [CL:0002139, GOC:dgh, PMID:21521739]","metadata":null},{"id":"ff29f04a786b4248a650b1e66d6ea794","type":"GO_TERM","name":"blood vessel endothelial cell migration","canonical_id":"go:GO:0043534","description":"\"The orderly movement of an endothelial cell into the extracellular matrix in order to form new blood vessels during angiogenesis.\" [PMID:11166264]","metadata":null},{"id":"a18d1384edac42f08b9383e37500b29b","type":"GO_TERM","name":"blood vessel endothelial cell migration involved in intussusceptive angiogenesis","canonical_id":"go:GO:0002044","description":"\"The orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels during intussusceptive angiogenesis.\" [PMID:16391003]","metadata":null},{"id":"6d8e664dc889407aba88915b5a7a4268","type":"GO_TERM","name":"blood vessel endothelial cell proliferation involved in sprouting angiogenesis","canonical_id":"go:GO:0002043","description":"\"The multiplication or reproduction of blood vessel endothelial cells, resulting in the expansion of a cell population contributing to sprouting angiogenesis.\" [GOC:dph, GOC:tb, PMID:16391003]","metadata":null},{"id":"e573f06c6b944efd90d217eb7e9730a7","type":"GO_TERM","name":"blood vessel lumen ensheathment","canonical_id":"go:GO:0097496","description":"\"A blood vessel lumenization process that occurs by blood vessel endothelial cells delaminating and aligning along the inner surface of an existing luminal space, extending the open ended lumen, and joining to other blood vessels to form a complete blood vessel.\" [GOC:dgh, PMID:23698350]","metadata":null},{"id":"049e4cc87842497088062e92c466d41f","type":"GO_TERM","name":"blood vessel lumenization","canonical_id":"go:GO:0072554","description":"\"The process in which a developing blood vessel forms an endothelial lumen through which blood will flow.\" [GOC:dsf, PMID:16799567, PMID:20926893]","metadata":null},{"id":"94f7c1d0192d442fbe24754ac4951f37","type":"GO_TERM","name":"blood vessel maturation","canonical_id":"go:GO:0001955","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a blood vessel to attain its fully functional state.\" [GOC:dph]","metadata":null},{"id":"92eadbd4eda34a46b13c45199ee8527e","type":"GO_TERM","name":"blood vessel morphogenesis","canonical_id":"go:GO:0048514","description":"\"The process in which the anatomical structures of blood vessels are generated and organized. The blood vessel is the vasculature carrying blood.\" [GOC:jid]","metadata":null},{"id":"5b806262af4f41449247d4e8f68acc2e","type":"GO_TERM","name":"blood vessel remodeling","canonical_id":"go:GO:0001974","description":"\"The reorganization or renovation of existing blood vessels.\" [GOC:hjd]","metadata":null},{"id":"517ee4d37f594e8d97049a2c8ce06fa0","type":"GO_TERM","name":"blood-group-substance endo-1,4-beta-galactosidase activity","canonical_id":"go:GO:0033929","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-galactosidic linkages in blood group A and B substances.\" [EC:3.2.1.102]","metadata":null},{"id":"771b718881d54f33a1742dca85401dc7","type":"GO_TERM","name":"blue light photoreceptor activity","canonical_id":"go:GO:0009882","description":"\"The function of absorbing and responding to electromagnetic radiation with a wavelength of approximately 400-470nm. The response may involve a change in conformation.\" [GOC:tb]","metadata":null},{"id":"30a78ccfa30a48aba84fde7e1d1b8233","type":"GO_TERM","name":"blue light signaling pathway","canonical_id":"go:GO:0009785","description":"\"The series of molecular signals initiated upon sensing of blue light by photoreceptor molecule, at a wavelength between 400nm and 470nm.\" [GOC:lr, GOC:sm]","metadata":null},{"id":"ecc833a942c34ee4988ad21bfcea825d","type":"DISEASE","name":"blue rubber bleb nevus","canonical_id":"mondo:0007203","description":null,"metadata":null},{"id":"d995b9743aad4f4b9b2df72ed0db26fe","type":"GO_TERM","name":"body fluid secretion","canonical_id":"go:GO:0007589","description":"\"The controlled release of a fluid by a cell or tissue in an animal.\" [GOC:ai, GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"8758d7215e7a4827abc3a25992335274","type":"GO_TERM","name":"body morphogenesis","canonical_id":"go:GO:0010171","description":"\"The process in which the anatomical structures of the soma are generated and organized.\" [GOC:ems, ISBN:0140512888]","metadata":null},{"id":"66a1dcadf1f04a299577ead53b575ddc","type":"DISEASE","name":"body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency","canonical_id":"mondo:0012570","description":null,"metadata":null},{"id":"ec0c90587c6a41618d5514c7524ce92d","type":"GO_TERM","name":"bombesin receptor activity","canonical_id":"go:GO:0004946","description":"\"Combining with bombesin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"e255415fa6e0463ebbf7ca510f59fd3c","type":"GO_TERM","name":"bombesin receptor binding","canonical_id":"go:GO:0031705","description":"\"Binding to a bombesin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"3fb839b63d8a40d8bf808ef9d252b6ce","type":"GO_TERM","name":"bombesin receptor signaling pathway","canonical_id":"go:GO:0031989","description":"\"A G protein-coupled receptor signaling pathway initiated by a bombesin binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah]","metadata":null},{"id":"fcc0919cb7414c748bf824510e4a9de1","type":"DISEASE","name":"bone Paget disease","canonical_id":"mondo:0005382","description":null,"metadata":null},{"id":"36658f0a0926412d8e2a643e77b68a1a","type":"GO_TERM","name":"bone cell development","canonical_id":"go:GO:0098751","description":"\"The process whose specific outcome is the progression of a bone cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dos]","metadata":null},{"id":"b62ab833ef9f47cc96d4c4baf0947a67","type":"GO_TERM","name":"bone development","canonical_id":"go:GO:0060348","description":"\"The process whose specific outcome is the progression of bone over time, from its formation to the mature structure. Bone is the hard skeletal connective tissue consisting of both mineral and cellular components.\" [GOC:dph]","metadata":null},{"id":"402eec811cad4cc1891ded955e9eed1a","type":"DISEASE","name":"bone disorder","canonical_id":"mondo:0005381","description":null,"metadata":null},{"id":"8af456d85f884a6abf31d99f1f47f4a9","type":"DISEASE","name":"bone fracture","canonical_id":"mondo:0005315","description":null,"metadata":null},{"id":"7b3fc51ce261489b8e915bef05febc03","type":"DISEASE","name":"bone giant cell tumor","canonical_id":"mondo:0005674","description":null,"metadata":null},{"id":"f8d6498298e84eb48e1b4be559ee4adb","type":"GO_TERM","name":"bone growth","canonical_id":"go:GO:0098868","description":"\"The increase in size or mass of a bone that contributes to the shaping of that bone.\" [GOC:dos]","metadata":null},{"id":"c63df18155e34a639efc46750bde888a","type":"GO_TERM","name":"bone marrow development","canonical_id":"go:GO:0048539","description":"\"The process whose specific outcome is the progression of the bone marrow over time, from its formation to the mature structure.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0e7a24dbd63b45ae9506ea9ca193a893","type":"GO_TERM","name":"bone maturation","canonical_id":"go:GO:0070977","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for bone to attain its fully functional state.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"09d2442ecc6c45539dfdb00d69894792","type":"DISEASE","name":"bone metastasis","canonical_id":"efo:0009870","description":null,"metadata":null},{"id":"cf2fcf586c804501b62be290561ad1b4","type":"GO_TERM","name":"bone mineralization","canonical_id":"go:GO:0030282","description":"\"The deposition of hydroxyapatite, a form of calcium phosphate with the formula Ca10(PO4)6(OH)2, in bone tissue.\" [GOC:mah, PMID:22936354]","metadata":null},{"id":"cd5d7d699ebe4105808185d9a4cb0540","type":"GO_TERM","name":"bone mineralization involved in bone maturation","canonical_id":"go:GO:0035630","description":"\"The deposition of hydroxyapatite, involved in the progression of the skeleton from its formation to its mature state.\" [GOC:bf, GOC:BHF]","metadata":null},{"id":"768a7ca53752418c91e2365f7e3629ba","type":"GO_TERM","name":"bone morphogenesis","canonical_id":"go:GO:0060349","description":"\"The process in which bones are generated and organized.\" [GOC:dph]","metadata":null},{"id":"847768d4604d4b7e8ebc21f579caf3df","type":"DISEASE","name":"bone neoplasm","canonical_id":"mondo:0019060","description":null,"metadata":null},{"id":"25890535b1824c7e90e776003534c159","type":"GO_TERM","name":"bone regeneration","canonical_id":"go:GO:1990523","description":"\"The regrowth of bone following its loss or destruction.\" [PMID:25257467]","metadata":null},{"id":"727b7b41cc504ba0a6e5f0f2d6b97b97","type":"GO_TERM","name":"bone remodeling","canonical_id":"go:GO:0046849","description":"\"The continuous turnover of bone matrix and mineral that involves first, an increase in resorption (osteoclastic activity) and later, reactive bone formation (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium homeostasis. An imbalance in the regulation of bone resorption and bone formation results in many of the metabolic bone diseases, such as osteoporosis.\" [GOC:curators]","metadata":null},{"id":"bc645190f32249a2b838ff0aaca36f0b","type":"GO_TERM","name":"bone resorption","canonical_id":"go:GO:0045453","description":"\"The process in which specialized cells known as osteoclasts degrade the organic and inorganic portions of bone, and endocytose and transport the degradation products.\" [GOC:mah, PMID:10968780]","metadata":null},{"id":"1e51297d14bc4513a287064f642927e9","type":"DISEASE","name":"bone resorption","canonical_id":"go:0045453","description":null,"metadata":null},{"id":"1716ecd0b6fa49f1813f7d72328f81d8","type":"GO_TERM","name":"bone sialoprotein binding","canonical_id":"go:GO:0044730","description":"\"Binding to a bone sialoprotein, an extracellular matrix glycoprotein found on the surface of bones and dentin.\" [PMID:10642520]","metadata":null},{"id":"50978e85973f4468a2d0780e491c447c","type":"GO_TERM","name":"bone trabecula formation","canonical_id":"go:GO:0060346","description":"\"The process of creating a trabecula in the bone. A trabecula is a tissue element in the form of a small beam, strut or rod.\" [GOC:dph]","metadata":null},{"id":"d7d22381d1c94e4baeb6116eda442da1","type":"GO_TERM","name":"bone trabecula morphogenesis","canonical_id":"go:GO:0061430","description":"\"The process of shaping a trabecula in bone. A trabecula is a tissue element in the form of a small beam, strut or rod.\" [GOC:BHF, GOC:dph, GOC:vk]","metadata":null},{"id":"e4ec3f01eba24c3994ead31128003f53","type":"GO_TERM","name":"borate binding","canonical_id":"go:GO:0046714","description":"\"Binding to borate, the anion (BO3)3-.\" [GOC:curators]","metadata":null},{"id":"e996a6d8057b460483e0f0a5a0e6ccfb","type":"GO_TERM","name":"borate channel activity","canonical_id":"go:GO:0180044","description":"\"Enables the facilitated diffusion of borate (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.\" [PMID:21710975]","metadata":null},{"id":"659d48f093d84025a5d17ea1ccaabc8b","type":"GO_TERM","name":"borate efflux transmembrane transporter activity","canonical_id":"go:GO:0080139","description":"\"Enables the transfer of borate from the inside of the cell to the outside of the cell across a membrane.\" [PMID:18603465]","metadata":null},{"id":"dea3e3aba2394a029cb57f313fad1dd3","type":"GO_TERM","name":"borate export across plasma membrane","canonical_id":"go:GO:0140159","description":"\"The directed movement of borate from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:vw, PMID:17459946]","metadata":null},{"id":"26089487a6754b74929b1c06596f8f29","type":"GO_TERM","name":"borate transmembrane transport","canonical_id":"go:GO:0035445","description":"\"The process in which borate is transported across a membrane. Borate is the anion (BO3)3-; boron is a group 13 element, with properties which are borderline between metals and non-metals.\" [GOC:curators]","metadata":null},{"id":"eeb0fa4510424280ad9a1e0a45371042","type":"GO_TERM","name":"borate transport","canonical_id":"go:GO:0046713","description":"\"The directed movement of borate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Borate is the anion (BO3)3-; boron is a group 13 element, with properties which are borderline between metals and non-metals.\" [PMID:21710975]","metadata":null},{"id":"72b04337002f45009616880dd9cc072f","type":"GO_TERM","name":"border follicle cell delamination","canonical_id":"go:GO:0030709","description":"\"The delamination process that results in the splitting off of border cells from the anterior epithelium, prior to border cell migration.\" [PMID:10822261]","metadata":null},{"id":"381a98182d484440ba513e7fb1f49f95","type":"GO_TERM","name":"border follicle cell migration","canonical_id":"go:GO:0007298","description":"\"The directed movement of a border cell through the nurse cells to reach the oocyte. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:10822261]","metadata":null},{"id":"9f28b12171554afe95f7e079fa64e5b4","type":"DRUG","name":"bortezomib","canonical_id":"gtopdb:6391","description":null,"metadata":null},{"id":"92d531e804ab44d1b2f16059a43e0ebb","type":"DRUG","name":"bortezomib","canonical_id":"chembl:CHEMBL325041","description":null,"metadata":null},{"id":"0cef1f7d6d2041b58f88c3b164b3233c","type":"COMBINATION_TREATMENT","name":"bortezomib + cetuximab","canonical_id":"ctgov_combo:ctgov-combo-b38c4d7cf15abc95","description":null,"metadata":null},{"id":"bf5a608265394565b797948a4e0d34cc","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab","canonical_id":"ctgov_combo:ctgov-combo-bef05fd5cb53675a","description":null,"metadata":null},{"id":"a41bf36eab724e808b41973693fc68d6","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab","canonical_id":"ctgov_combo:ctgov-combo-709c6543fad8ff7d","description":null,"metadata":null},{"id":"27c2693f7d43485e9559e2dd141e6e74","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab","canonical_id":"ctgov_combo:ctgov-combo-daeb9ba088f2642f","description":null,"metadata":null},{"id":"4c69218b63644d7e8e2861fcd9318ae3","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab + dexamethasone","canonical_id":"ctgov_combo:ctgov-combo-c65a3cae62a22d2e","description":null,"metadata":null},{"id":"267b8e82503d4a6fa8d76f328ab74224","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab + dexamethasone","canonical_id":"ctgov_combo:ctgov-combo-a425244231946a17","description":null,"metadata":null},{"id":"16f40ba4df5b44dbb38813dbbfbe3eef","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab + elotuzumab + ixazomib","canonical_id":"ctgov_combo:ctgov-combo-f73baa23aa9e6820","description":null,"metadata":null},{"id":"686811aa384e4ac8a00971e4b1ccedcd","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-11671ecbb2a85fe7","description":null,"metadata":null},{"id":"3428c79e9bb54f4d8f53d9dd954a6a7d","type":"COMBINATION_TREATMENT","name":"bortezomib + daratumumab + prednisone","canonical_id":"ctgov_combo:ctgov-combo-c6d7c7bf17bc2790","description":null,"metadata":null},{"id":"94d9ac5ba2ef4c56ae58e8fff55216dc","type":"COMBINATION_TREATMENT","name":"bortezomib + dexamethasone","canonical_id":"ctgov_combo:ctgov-combo-bdc751cc7f0ed772","description":null,"metadata":null},{"id":"e2acdc3c16cc4294af28b7b981d3bcf3","type":"COMBINATION_TREATMENT","name":"bortezomib + dexamethasone","canonical_id":"ctgov_combo:ctgov-combo-4e1a4739497da8d5","description":null,"metadata":null},{"id":"422f41bca68c48f0aae280b10f8b4360","type":"COMBINATION_TREATMENT","name":"bortezomib + dexamethasone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-a36c8e2b5528ae95","description":null,"metadata":null},{"id":"baed05b58e3245609b2d4d0633f64c2c","type":"COMBINATION_TREATMENT","name":"bortezomib + etoposide + rituximab","canonical_id":"ctgov_combo:ctgov-combo-2308d2cabbeb8341","description":null,"metadata":null},{"id":"87e3238942004898bff5639d4b17e3d4","type":"COMBINATION_TREATMENT","name":"bortezomib + fenofibrate","canonical_id":"ctgov_combo:ctgov-combo-fc187c98b5bf6f7a","description":null,"metadata":null},{"id":"89e976811bfd41b199e319f76e03b7ea","type":"COMBINATION_TREATMENT","name":"bortezomib + ibrutinib","canonical_id":"ctgov_combo:ctgov-combo-371a54cf27b5a535","description":null,"metadata":null},{"id":"a3158f12010f49979669e4dcb1a0395d","type":"COMBINATION_TREATMENT","name":"bortezomib + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-ec64fd23ec067d7e","description":null,"metadata":null},{"id":"e5f370d645dd4ee59b7a53f8fed61086","type":"COMBINATION_TREATMENT","name":"bortezomib + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-4630f5faf4ec5653","description":null,"metadata":null},{"id":"c78203b8cc284004a130c3e5abb991e4","type":"COMBINATION_TREATMENT","name":"bortezomib + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-24ba8dc3453d9079","description":null,"metadata":null},{"id":"2fcb7f1e3c664d1d88d3ee5cd82fcbb5","type":"COMBINATION_TREATMENT","name":"bortezomib + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-6de7e60d47c5bf95","description":null,"metadata":null},{"id":"dfa5bd1463094ea2805d7c5b794ee14a","type":"COMBINATION_TREATMENT","name":"bortezomib + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-11ede3c9ba25c2f1","description":null,"metadata":null},{"id":"ee15b464af704ca3a1ada90804588084","type":"COMBINATION_TREATMENT","name":"bortezomib + panitumumab","canonical_id":"ctgov_combo:ctgov-combo-bfc3f9f3746d5e3e","description":null,"metadata":null},{"id":"7b0f9ad2876949f8a1c8b8bf37f2c67b","type":"COMBINATION_TREATMENT","name":"bortezomib + prednisone","canonical_id":"ctgov_combo:ctgov-combo-fa5df2ef3dcc8ccd","description":null,"metadata":null},{"id":"8a3f9c07cea740e5bf1c5a2ffc93aa30","type":"COMBINATION_TREATMENT","name":"bortezomib + vorinostat","canonical_id":"ctgov_combo:ctgov-combo-499472f4002cc3e2","description":null,"metadata":null},{"id":"87efe007ad8f44f48540625ef6032301","type":"DRUG","name":"bosentan","canonical_id":"gtopdb:3494","description":null,"metadata":null},{"id":"073b3457b1d84f1ca21c8b0e7606ad6c","type":"DRUG","name":"bosentan","canonical_id":"chembl:CHEMBL957","description":null,"metadata":null},{"id":"a3989b82abb04da1a817699016b2137e","type":"COMBINATION_TREATMENT","name":"bosentan + iloprost","canonical_id":"ctgov_combo:ctgov-combo-6788c5195a2524c9","description":null,"metadata":null},{"id":"7d554adc376a4da295577ed5534c8f52","type":"COMBINATION_TREATMENT","name":"bosentan + pacritinib","canonical_id":"ctgov_combo:ctgov-combo-008f47a93559e97f","description":null,"metadata":null},{"id":"4613dbb5a8994d6b88e83eb1080b09e7","type":"GO_TERM","name":"boss receptor activity","canonical_id":"go:GO:0008288","description":"\"Combining with a protein bride of sevenless (boss) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"1ff2406e283644d49d206eb973e05030","type":"DRUG","name":"bosutinib","canonical_id":"gtopdb:5710","description":null,"metadata":null},{"id":"d82703f8689442ecbd4f0267608ea8c6","type":"DRUG","name":"bosutinib","canonical_id":"chembl:CHEMBL288441","description":null,"metadata":null},{"id":"7cc1e4cae26f482cba6b00cc3a55ce0d","type":"COMBINATION_TREATMENT","name":"bosutinib + dasatinib + imatinib + nilotinib","canonical_id":"ctgov_combo:ctgov-combo-c6f4636c4bdeee19","description":null,"metadata":null},{"id":"cc6113bcb8f544ae91af3c4b50dc93f2","type":"COMBINATION_TREATMENT","name":"bosutinib + dasatinib + nilotinib","canonical_id":"ctgov_combo:ctgov-combo-7419d53bf94b6d00","description":null,"metadata":null},{"id":"60c8739c91614f739ebdc80dea9202f6","type":"COMBINATION_TREATMENT","name":"bosutinib + imatinib","canonical_id":"ctgov_combo:ctgov-combo-daff8ee5e7f5fdfd","description":null,"metadata":null},{"id":"a526445b080b40c38eddb795fdeffd9a","type":"COMBINATION_TREATMENT","name":"bosutinib + inotuzumab ozogamicin","canonical_id":"ctgov_combo:ctgov-combo-5a1d41db78a60911","description":null,"metadata":null},{"id":"243c8c63686b44c298e962dca68ca7f2","type":"DISEASE","name":"botulism","canonical_id":"mondo:0005498","description":null,"metadata":null},{"id":"9661898c80dc441a804d5a2f985dd0e3","type":"GO_TERM","name":"bounding membrane of organelle","canonical_id":"go:GO:0098588","description":"\"The lipid bilayer that forms the outer-most layer of an organelle.\" [GOC:dos]","metadata":null},{"id":"da90a2febc134e5ca8904d909910248c","type":"GO_TERM","name":"box C/D RNP complex","canonical_id":"go:GO:0170049","description":"\"A ribonucleoprotein complex consisting of a box C/D type snRNA and three (Archaea) or four (Eukaryotes) core proteins that have diverse functions, including site-specific methylation of rRNA and processing rRNA.\" [PMID:28505386, PMID:30254138]","metadata":null},{"id":"b2d0199960f24654a656436c1be9de35","type":"GO_TERM","name":"box C/D methylation guide RNP complex","canonical_id":"go:GO:0170050","description":"\"A ribonucleoprotein complex containing a box C/D type snoRNA and three (Archaea) or four (Eukaryotes) core proteins that is capable of methylation of target RNAs.\" [PMID:28505386, PMID:30254138]","metadata":null},{"id":"483365d7244a48199eadd85c1bf71bd4","type":"GO_TERM","name":"box C/D methylation guide scaRNP complex","canonical_id":"go:GO:0170051","description":"\"A ribonucleoprotein complex containing a small CB-specific RNA (scaRNA), with a short sequence motif (GU/UG wobble stem) for CB localization that is capable of methylation of target RNAs.\" [PMID:27775477]","metadata":null},{"id":"96b33240e675490c8e2238d98ccc6d94","type":"GO_TERM","name":"box C/D methylation guide snoRNP complex","canonical_id":"go:GO:0031428","description":"\"A ribonucleoprotein complex containing a box C/D type RNA that is capable of ribose-2'-O-methylation of target RNAs. Box C/D type RNAs are widespread in eukaryotes and in Archaea, suggesting that an RNA-based guide mechanism for directing specific RNA 2'-O-ribose methylations was present in the common ancestor of Archaea and Eukarya.\" [ISBN:0879695897, PMID:11842104, PMID:17284456]","metadata":null},{"id":"4798371ddcce4a078989696f6e6650b0","type":"GO_TERM","name":"box C/D methylation guide snoRNP complex binding","canonical_id":"go:GO:0062064","description":"\"Binding to a box C/D methylation guide snoRNP complex.\" [PMID:10679015]","metadata":null},{"id":"1b53900c75134881aa51405cd969a0f1","type":"GO_TERM","name":"box C/D pre-rRNA cleavage RNP complex","canonical_id":"go:GO:0170052","description":"\"A ribonucleoprotein complex containing a box C/D type RNA that is involved in pre-rRNA cleavage.\" [PMID:15367679, PMID:28505386, PMID:30254138]","metadata":null},{"id":"4760665c227c4c5383cdb7cccf42c8ff","type":"GO_TERM","name":"box C/D sno(s)RNA 3'-end processing","canonical_id":"go:GO:0000494","description":"\"Any process involved in forming the mature 3' end of a box C/D RNA molecule.\" [GOC:krc]","metadata":null},{"id":"05c02a6d968c435c95d473dde1512896","type":"GO_TERM","name":"box C/D sno(s)RNA 5'-end processing","canonical_id":"go:GO:0106410","description":"\"Any process involved in forming the mature 5' end of a box C/D RNA molecule.\" [PMID:34352089]","metadata":null},{"id":"845209936f614c90a6cafe1495c2e027","type":"GO_TERM","name":"box C/D sno(s)RNA binding","canonical_id":"go:GO:0034512","description":"\"Binding to a box C/D small nucleolar RNA.\" [GOC:mah]","metadata":null},{"id":"8cfce308f4fd45ae8ab169f553ca37bc","type":"GO_TERM","name":"box C/D sno(s)RNA metabolic process","canonical_id":"go:GO:0033967","description":"\"The chemical reactions and pathways involving box C/D type small nucleolar RNA.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"3892f1d2039f4214bf31a1edfe7f2915","type":"GO_TERM","name":"box C/D sno(s)RNA processing","canonical_id":"go:GO:0034963","description":"\"Any process involved in the conversion of a primary box C/D type small RNA transcript into a mature box C/D RNA.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"8ba1f74695d84a28a692e0bfc035cb22","type":"GO_TERM","name":"box C/D snoRNP assembly","canonical_id":"go:GO:0000492","description":"\"The aggregation, arrangement and bonding together of proteins and a box C/D snoRNA to form a box C/D small nucleolar ribonucleoprotein (snoRNP) complex.\" [GOC:krc]","metadata":null},{"id":"d957a1be64634754a36fa16ef5e14364","type":"GO_TERM","name":"box H/ACA RNP complex","canonical_id":"go:GO:0072588","description":"\"A ribonucleoprotein complex that contains an RNA of the box H/ACA type and the four core proteins dyskerin, NOP10, NHP2, and GAR1 (human protein nomenclature). RNA pseudouridylation (isomerization of uridine to pseudouridine) is the major, and most likely the ancestral, function of H/ACA RNPs. Pseudouridylation targets include both large and small ribosomal RNAs (rRNAs), and small nuclear RNA (U2 snRNA). In addition to these catalytic H/ACA RNPs, a less abundant but more diverse class of structural H/ACA RNPs exists, which does not have pseudouridylation activity. These include the vertebrate telomerase RNP complex.\" [GOC:BHF, GOC:BHF_telomerase, GOC:jbu, GOC:krc, GOC:mah, GOC:vw, PMID:17284456, PMID:20227365, PMID:25590339]","metadata":null},{"id":"ccefba41268746bfaa79df4ed2a9a8d6","type":"GO_TERM","name":"box H/ACA scaRNP complex","canonical_id":"go:GO:0072589","description":"\"A box H/ACA RNP complex that is located in the Cajal body of the nucleoplasm. In higher eukaryotes, box H/ACA RNP located in Cajal bodies mediate pseudouridylation of spliceosomal snRNAs.\" [GOC:mah, PMID:17284456, PMID:20227365]","metadata":null},{"id":"890f5ab1fa974614af36667f7430a321","type":"GO_TERM","name":"box H/ACA sno(s)RNA 3'-end processing","canonical_id":"go:GO:0000495","description":"\"Any process involved in forming the mature 3' end of a box H/ACA RNA molecule.\" [GOC:krc]","metadata":null},{"id":"2fdfa930b5db497f84ee08cd65aef232","type":"GO_TERM","name":"box H/ACA sno(s)RNA metabolic process","canonical_id":"go:GO:0033979","description":"\"The chemical reactions and pathways involving box H/ACA type small nucleolar RNA.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"2037859be0ac429a83bcafa6f29bc1fe","type":"GO_TERM","name":"box H/ACA sno(s)RNA processing","canonical_id":"go:GO:0034964","description":"\"Any process involved in the conversion of a primary box H/ACA type small RNA transcript into a mature box H/ACA RNA.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"c6f9f35c97c3496eb67e4005164fa5db","type":"GO_TERM","name":"box H/ACA snoRNA binding","canonical_id":"go:GO:0034513","description":"\"Binding to a box H/ACA small nucleolar RNA.\" [GOC:mah]","metadata":null},{"id":"0cc7805740e4402a9ad86a01247cc0ad","type":"GO_TERM","name":"box H/ACA snoRNP assembly","canonical_id":"go:GO:0000493","description":"\"The aggregation, arrangement and bonding together of proteins and a box H/ACA snoRNA to form a box H/ACA small nucleolar ribonucleoprotein (snoRNP) complex.\" [GOC:krc, PMID:12515383]","metadata":null},{"id":"6c7df08650cc4a278d555d2a6859a4c6","type":"GO_TERM","name":"box H/ACA snoRNP complex","canonical_id":"go:GO:0031429","description":"\"A box H/ACA small nucleolar ribonucleoprotein complex located in the nucleolus that catalyzes pseudouridylation of ribosomal RNA residues. The complex is composed of four different core proteins that assemble onto a H/ACA guide RNA scaffold that identifies specific uridines in rRNA for modification during ribosome synthesis.\" [GOC:vw, PMID:17284456, PMID:20227365, PMID:22065625]","metadata":null},{"id":"43cffed177c84ab9a9e02ce5e04d1133","type":"GO_TERM","name":"box H/ACA snoRNP complex binding","canonical_id":"go:GO:0062065","description":"\"Binding to a box H/ACA snoRNP complex.\" [PMID:10679015]","metadata":null},{"id":"cae8d3d286f7424c818231864f885f46","type":"GO_TERM","name":"box H/ACA telomerase RNP complex","canonical_id":"go:GO:0090661","description":"\"A box H/ACA ribonucleoprotein complex that contains the RNA component of vertebrate telomerase, the enzyme essential for the replication of chromosome termini in most eukaryotes. This ribonucleoprotein complex is a structural box H/ACA RNP, which does not have the catalytic pseudouridylation function shared by the majority of H/ACA RNPs present in the cell.\" [GOC:BHF, GOC:BHF_telomere, GOC:jbu, PMID:22527283]","metadata":null},{"id":"96f1c49d19394437b83a1867c974a5f8","type":"GO_TERM","name":"bract development","canonical_id":"go:GO:0010432","description":"\"The process whose specific outcome is the progression of the bract over time, from its formation to the mature structure. A bract is a leaf, usually different in form from the foliage leaves, subtending a flower or inflorescence.\" [GOC:tb, PMID:16554366, PO:0009055]","metadata":null},{"id":"9dbef43696f44e33af0b7fcc98e4e6fe","type":"GO_TERM","name":"bract formation","canonical_id":"go:GO:0010434","description":"\"The process that gives rise to a bract. This process pertains to the initial formation of a structure from unspecified parts. A bract is a leaf, usually different in form from the foliage leaves, subtending a flower or inflorescence.\" [GOC:tb, PMID:16554366, PO:0009055]","metadata":null},{"id":"8f4fe18d3d2e4aa2a648e7ea4ccea559","type":"GO_TERM","name":"bract morphogenesis","canonical_id":"go:GO:0010433","description":"\"The process in which the anatomical structure of a bract are generated and organized. A bract is a leaf, usually different in form from the foliage leaves, subtending a flower or inflorescence.\" [GOC:tb, PMID:16554366, PO:0009055]","metadata":null},{"id":"009f5dd71dcd4caaa5a9e25f1bd5fb9c","type":"GO_TERM","name":"bradykinin biosynthetic process","canonical_id":"go:GO:0002936","description":"\"The chemical reactions and pathways resulting in the formation of the peptide hormone bradykinin.\" [PMID:11226291]","metadata":null},{"id":"ef59af77474e47ffa8a32f7e13b67f4e","type":"GO_TERM","name":"bradykinin catabolic process","canonical_id":"go:GO:0010815","description":"\"The chemical reactions and pathways resulting in the breakdown of the peptide bradykinin.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"b0ac4273d703449e8834f7712a4ee535","type":"GO_TERM","name":"bradykinin receptor activity","canonical_id":"go:GO:0004947","description":"\"Combining with bradykinin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"81f4034a56334dd58a39761ae1d76fc5","type":"GO_TERM","name":"bradykinin receptor binding","canonical_id":"go:GO:0031711","description":"\"Binding to a bradykinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"130817ee72b4458d974695b74592957c","type":"GO_TERM","name":"brahma complex","canonical_id":"go:GO:0035060","description":"\"A SWI/SNF-type complex that contains 8 to 14 proteins, including both conserved (core) and nonconserved components; contains the ATPase product of the Drosophila brm (brahma) or mammalian SMARCA2/BAF190B/BRM gene, or an ortholog thereof.\" [GOC:bhm, PMID:10809665, PMID:12482982]","metadata":null},{"id":"0bf94e8722534a87aa4ec0c833994bd0","type":"DISEASE","name":"brain abnormalities, neurodegeneration, and dysosteosclerosis","canonical_id":"efo:0010268","description":null,"metadata":null},{"id":"2b7eb337540e468d8265cbbfd67bb750","type":"DISEASE","name":"brain aneurysm","canonical_id":"mondo:0005291","description":null,"metadata":null},{"id":"670745b3ddf842faa5558a8632040395","type":"DISEASE","name":"brain cancer","canonical_id":"mondo:0001657","description":null,"metadata":null},{"id":"f6b9dba26f184d9a81bdd68eeba30428","type":"GO_TERM","name":"brain development","canonical_id":"go:GO:0007420","description":"\"The process whose specific outcome is the progression of the brain over time, from its formation to the mature structure. Brain development begins with patterning events in the neural tube and ends with the mature structure that is the center of thought and emotion. The brain is responsible for the coordination and control of bodily activities and the interpretation of information from the senses (sight, hearing, smell, etc.).\" [GOC:dph, GOC:jid, GOC:tb, UBERON:0000955]","metadata":null},{"id":"583cd85b8a76472ab0862d534fe6b059","type":"DISEASE","name":"brain dopamine-serotonin vesicular transport disease","canonical_id":"mondo:0018130","description":null,"metadata":null},{"id":"b4b0a376321045839413d2f5b6320f91","type":"DISEASE","name":"brain injury","canonical_id":"mondo:0043510","description":null,"metadata":null},{"id":"fc3302a759e2467b9a55bbfca0b1f483","type":"GO_TERM","name":"brain morphogenesis","canonical_id":"go:GO:0048854","description":"\"The process in which the anatomical structures of the brain are generated and organized. The brain is one of the two components of the central nervous system and is the center of thought and emotion. It is responsible for the coordination and control of bodily activities and the interpretation of information from the senses (sight, hearing, smell, etc.).\" [GOC:dgh, GOC:jid]","metadata":null},{"id":"ca50526b23674fe0808378148bb8c969","type":"DISEASE","name":"brain neoplasm","canonical_id":"mondo:0021211","description":null,"metadata":null},{"id":"b4f9a1bac1f7436ba280b066f063ab89","type":"GO_TERM","name":"brain renin-angiotensin system","canonical_id":"go:GO:0002035","description":"\"The process in which an angiotensin-mediated signaling system present in the brain regulates the force with which blood passes through the circulatory system.\" [PMID:2909574]","metadata":null},{"id":"f75a58cdac194190bd28419442e58d42","type":"GO_TERM","name":"brain segmentation","canonical_id":"go:GO:0035284","description":"\"Division of the brain into a series of semi-repetitive parts or segments.\" [GOC:bf]","metadata":null},{"id":"ab70d325b1be4e019b5ccec09654aa3d","type":"GO_TERM","name":"brain-derived neurotrophic factor binding","canonical_id":"go:GO:0048403","description":"\"Binding to brain-derived neurotrophic factor.\" [GOC:dgh]","metadata":null},{"id":"3d9ebe3dedba482c91084b7c577be275","type":"GO_TERM","name":"brain-derived neurotrophic factor receptor activity","canonical_id":"go:GO:0060175","description":"\"Combining with a brain-derived neurotrophic factor and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:bf, GOC:dph]","metadata":null},{"id":"5863af547f654767ac385a150923fdf1","type":"GO_TERM","name":"brain-derived neurotrophic factor receptor binding","canonical_id":"go:GO:0031546","description":"\"Binding to a brain-derived neurotrophic factor receptor.\" [GOC:mah]","metadata":null},{"id":"c457cc48027546219cfefa7d65649e9d","type":"GO_TERM","name":"brain-derived neurotrophic factor receptor signaling pathway","canonical_id":"go:GO:0031547","description":"\"The series of molecular signals generated as a consequence of a brain-derived neurotrophic factor receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"7ea2cef9362f4b54b7db05a1d863467c","type":"GO_TERM","name":"brainstem development","canonical_id":"go:GO:0003360","description":"\"The progression of the brainstem from its formation to the mature structure. The brainstem is the part of the brain that connects the brain with the spinal cord.\" [GOC:dph]","metadata":null},{"id":"4a3a433c3de64cf59427e6a785a23dc4","type":"GO_TERM","name":"brainstem precerebellar neuron precursor migration","canonical_id":"go:GO:0021949","description":"\"The early migration of a precerebellar neuronal precursor in which a cell move from the rhombic lip, orthogonal to the direction of radial migration and ultimately reside in the brainstem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"05c2f47c4ee247cbbb66b709a32102e0","type":"GO_TERM","name":"branch elongation involved in mammary gland duct branching","canonical_id":"go:GO:0060751","description":"\"The developmental growth process in which a branch of a mammary gland duct elongates.\" [GOC:dph]","metadata":null},{"id":"5645c0018326476c93c20421a60482df","type":"GO_TERM","name":"branch elongation involved in salivary gland morphogenesis","canonical_id":"go:GO:0060667","description":"\"The differential growth of the salivary branches along their axis, resulting in the growth of a branch.\" [GOC:dph]","metadata":null},{"id":"d45ca15917334bf5a8232410407c9769","type":"GO_TERM","name":"branch elongation involved in ureteric bud branching","canonical_id":"go:GO:0060681","description":"\"The growth of a branch of the ureteric bud along its axis.\" [GOC:dph, PMID:16916378]","metadata":null},{"id":"7f067561cfd6401b8a5f221656f7d5c1","type":"GO_TERM","name":"branch elongation of an epithelium","canonical_id":"go:GO:0060602","description":"\"The growth process in which a branch increases in length from its base to its tip.\" [GOC:dph]","metadata":null},{"id":"65d21a8ce87f44bcb6ef0aa592d873db","type":"GO_TERM","name":"branch fusion, open tracheal system","canonical_id":"go:GO:0035147","description":"\"Fusing of specific tracheal branches in an open tracheal system to branches from neighboring hemisegments to form a continuous tracheal network. Branch fusion is mediated by individual cells at the tip of each branch, which contact a similar cell and undergo a coordinated series of morphogenetic events that create a bicellular fusion joint.\" [GOC:mtg_sensu, PMID:14570584]","metadata":null},{"id":"ea4b804a77064b148b365823feff9ced","type":"GO_TERM","name":"branched 1,3-beta-D-glucan synthase activity","canonical_id":"go:GO:0140752","description":"\"Catalysis of the reaction: UDP-glucose + [(1->3)-beta-D-glucosyl](n) = UDP + a branched [(1->3)-beta-D-glucosyl](n+1).\" [PMID:34959732]","metadata":null},{"id":"e086a3dfa8544a9fb19a8547c9369abf","type":"GO_TERM","name":"branched duct epithelial cell fate determination, open tracheal system","canonical_id":"go:GO:0046845","description":"\"Allocation of a set number of cells to each primary branch in an open tracheal system, prior to the onset of cell migration. This establishes different domains of cells within the tracheal placode.\" [GOC:mtg_sensu, PMID:10684581]","metadata":null},{"id":"f2458b87d9b34a58864e91425acfc0ac","type":"GO_TERM","name":"branched-chain 2-oxo acid dehydrogenase activity","canonical_id":"go:GO:0003863","description":"\"Catalysis of the reaction: N(6)-[(R)-lipoyl]-L-lysyl-[dihydrolipoyllysine-residue (2-methylpropanoyl)transferase] + 3-methyl-2-oxobutanoate + H+ = N(6)-[(R)-S(8)-2-methylpropanoyldihydrolipoyl]-L-lysyl-[dihydrolipoyllysine-residue (2-methylpropanoyl)transferase] + CO2. Also acts on 4-methyl-2-oxopentanoate and (S)-3-methyl-2-oxopentanoate, so that it acts on the 2-oxo acids that derive from the action of transaminases on valine, leucine and isoleucine.\" [EC:1.2.4.4]","metadata":null},{"id":"939e58a12f974b0f8190adc4130093fe","type":"GO_TERM","name":"branched-chain alpha-keto acid decarboxylation to branched-chain acyl-CoA","canonical_id":"go:GO:0120552","description":"\"The chemical reactions and pathways resulting in the formation of a branched-chain acyl-CoA by the oxidative decarboxylation of a branched-chain alpha-keto acid derived from L-leucine, L-isoleucine or L-valine. This pathway comprises a series of three reactions carried out by a multisubunit complex called the 'branched-chain alpha-keto acid dehydrogenase complex', even though branched-chain alpha-keto acid dehydrogenase activity describes only one of those reactions. The combination of the three reactions can be summarized as: 3-methyl-2-oxobutanoate + coenzyme A + NAD+ -> branched-chain acyl-CoA + CO2 + NADH. Specific substrates include 3-methyl-2-oxobutanoate (a transamination product of L-valine), (S)-3-methyl-2-oxopentanoate (a transamination product of L-isoleucine) and 4-methyl-2-oxopentanoate (a transamination product of L-leucine), which generate the products 2-methylpropanoyl-CoA, 2-methylbutanoyl-CoA and 3-methylbutanoyl-CoA, respectively.\" [MetaCyc:PWY-5046]","metadata":null},{"id":"d0e74d20b01d43f3aee43392a5db79e9","type":"GO_TERM","name":"branched-chain alpha-ketoacid dehydrogenase complex","canonical_id":"go:GO:0160157","description":"\"A multi-enzyme complex that catalyzes the oxidative decarboxylation of branched-chain alpha-ketoacids derived from L-leucine, L-isoleucine, and L-valine to branched-chain acyl-CoAs. The complex comprises multiple copies of three enzymes referred to as E1, E2 and E3: branched-chain alpha-ketoacid dehydrogenase (E1, a heterotetramer of two alpha and two beta subunits), dihydrolipoyl transacylase (E2), and dihydrolipoamide dehydrogenase (E3). Additional proteins may also be present.\" [PMID:10464218, PMID:10745006, PMID:3593587]","metadata":null},{"id":"cb085419323e436191af7aff861a9e6b","type":"GO_TERM","name":"branched-chain amino acid biosynthetic process","canonical_id":"go:GO:0009082","description":"\"The chemical reactions and pathways resulting in the formation of amino acids containing a branched carbon skeleton, comprising isoleucine, leucine and valine.\" [GOC:ai]","metadata":null},{"id":"ad2ff672e6064feab4872390b8c3c19c","type":"GO_TERM","name":"branched-chain amino acid catabolic process","canonical_id":"go:GO:0009083","description":"\"The chemical reactions and pathways resulting in the breakdown of amino acids containing a branched carbon skeleton, comprising isoleucine, leucine and valine.\" [GOC:ai]","metadata":null},{"id":"f4aaffea8bec4c7fb36963d6d73681b5","type":"GO_TERM","name":"branched-chain amino acid metabolic process","canonical_id":"go:GO:0009081","description":"\"The chemical reactions and pathways involving amino acids containing a branched carbon skeleton, comprising isoleucine, leucine and valine.\" [GOC:ai]","metadata":null},{"id":"95392969b08f4056a44a63c3cebe4800","type":"GO_TERM","name":"branched-chain amino acid transmembrane transporter activity","canonical_id":"go:GO:0015658","description":"\"Enables the transfer of branched-chain amino acids from one side of a membrane to the other. Branched-chain amino acids are amino acids with a branched carbon skeleton without rings.\" [GOC:ai, GOC:bf, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"05b310d5cff0412386b34c0135fa7c22","type":"GO_TERM","name":"branched-chain amino acid transport","canonical_id":"go:GO:0015803","description":"\"The directed movement of branched-chain amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Branched-chain amino acids are amino acids with a branched carbon skeleton without rings.\" [GOC:ai, GOC:bf]","metadata":null},{"id":"7eee578b9241414d98b921243480d9f3","type":"GO_TERM","name":"branched-chain amino acid:sodium symporter activity","canonical_id":"go:GO:0015657","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: branched-chain amino acid(out) + cation(out) = branched-chain amino acid(in) + cation(in).\" [TC:2.A.26.1.1]","metadata":null},{"id":"f33707276594427e9e2a34e977403521","type":"GO_TERM","name":"branched-chain-2-oxoacid decarboxylase activity","canonical_id":"go:GO:0047433","description":"\"Catalysis of the reaction: (S)-3-methyl-2-oxopentanoate + H+ = 2-methylbutanal + CO2.\" [EC:4.1.1.72, RHEA:21108]","metadata":null},{"id":"7bc437d7353e47f3a2b7ff4c35dc10b9","type":"GO_TERM","name":"branched-chain-amino-acid:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0004084","description":"\"Catalysis of the reaction: a branched-chain amino acid (L-leucine, L-isoleucine and L-valine) + 2-oxoglutarate = L-glutamate + a 2-oxocarboxylate derived from the branched-chain amino acid.\" [EC:2.6.1.42]","metadata":null},{"id":"f45a72084c59452dab8778976282c370","type":"GO_TERM","name":"branched-dextran exo-1,2-alpha-glucosidase activity","canonical_id":"go:GO:0033933","description":"\"Catalysis of the hydrolysis of (1->2)-alpha-D-glucosidic linkages at the branch points of dextrans and related polysaccharides, producing free D-glucose.\" [EC:3.2.1.115]","metadata":null},{"id":"ba961a97a8474e87a7492d058599664e","type":"GO_TERM","name":"branching involved in blood vessel morphogenesis","canonical_id":"go:GO:0001569","description":"\"The process of coordinated growth and sprouting of blood vessels giving rise to the organized vascular system.\" [GOC:dph]","metadata":null},{"id":"20310d68c4b54c1f8218effc84ffa553","type":"GO_TERM","name":"branching involved in labyrinthine layer morphogenesis","canonical_id":"go:GO:0060670","description":"\"The process in which the branches of the fetal placental villi are generated and organized. The villous part of the placenta is called the labyrinth layer.\" [GOC:dph, PMID:16916377]","metadata":null},{"id":"615683bcb0c34460b8bae42011a7b2bd","type":"GO_TERM","name":"branching involved in lymph vessel morphogenesis","canonical_id":"go:GO:0060854","description":"\"The process of the coordinated growth and sprouting of lymph vessels giving rise to the organized lymphatic system.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"d197fe77eaa34c978f3068c3abee101e","type":"GO_TERM","name":"branching involved in mammary gland duct morphogenesis","canonical_id":"go:GO:0060444","description":"\"The process in which the branching structure of the mammary gland duct is generated and organized. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.\" [GOC:dph]","metadata":null},{"id":"74eed04c8f444523a121bdb0df834042","type":"GO_TERM","name":"branching involved in open tracheal system development","canonical_id":"go:GO:0060446","description":"\"The process in which the anatomical structures of branches in the open tracheal system are generated and organized.\" [GOC:dph]","metadata":null},{"id":"b932e23135d64948b7118a9225342cb1","type":"GO_TERM","name":"branching involved in pancreas morphogenesis","canonical_id":"go:GO:0061114","description":"\"The process in which the branches of the pancreas are generated and organized.\" [GOC:dph]","metadata":null},{"id":"e993c0c7a92f471fbc83e5ead80f9a30","type":"GO_TERM","name":"branching involved in prostate gland morphogenesis","canonical_id":"go:GO:0060442","description":"\"The process in which the branching structure of the prostate gland is generated and organized. A branch is a division or offshoot from a main stem.\" [GOC:dph]","metadata":null},{"id":"25afffdb6aba4eadbd2a8f2ee275b334","type":"GO_TERM","name":"branching involved in salivary gland morphogenesis","canonical_id":"go:GO:0060445","description":"\"The process in which the branching structure of the salivary gland is generated and organized.\" [GOC:dph]","metadata":null},{"id":"9bd436f9115342bdb8817cf1d2798f86","type":"GO_TERM","name":"branching involved in ureteric bud morphogenesis","canonical_id":"go:GO:0001658","description":"\"The process in which the branching structure of the ureteric bud is generated and organized. The ureteric bud is an epithelial tube that grows out from the metanephric duct. The bud elongates and branches to give rise to the ureter and kidney collecting tubules.\" [GOC:dph, PMID:16916378]","metadata":null},{"id":"3d6918cb84054fd8a707d1c3d2bbb4f9","type":"GO_TERM","name":"branching morphogenesis of a nerve","canonical_id":"go:GO:0048755","description":"\"The process in which the anatomical structures of branches in a nerve are generated and organized. This term refers to an anatomical structure (nerve) not a cell (neuron).\" [GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"0a716763c24f49dc8f49d69c59d213a4","type":"GO_TERM","name":"branching morphogenesis of an epithelial tube","canonical_id":"go:GO:0048754","description":"\"The process in which the anatomical structures of branches in an epithelial tube are generated and organized. A tube is a long hollow cylinder.\" [GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"44907acf21d34bdea2be114a2d58e6c1","type":"GO_TERM","name":"branchiomeric skeletal muscle development","canonical_id":"go:GO:0014707","description":"\"The process whose specific outcome is the progression of the branchiomeric skeletal muscle over time, from its formation to the mature structure. The branchiomeric muscle is derived from cranial mesoderm and controls facial expression, pharyngeal and laryngeal function, operating the jaw. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle. Branchiomeric muscles of mammals correspond to the gill musculature of fish.\" [GOC:mtg_muscle]","metadata":null},{"id":"97077b7666574199b7202450f9b6b318","type":"GO_TERM","name":"branchiomotor neuron axon guidance","canonical_id":"go:GO:0021785","description":"\"The process in which a branchiomotor neuron growth cone is directed to a specific target site. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"94c02198b04d459abcdd88811c9f5b4d","type":"GO_TERM","name":"branchiomotor neuron axon guidance in branchial arch mesenchyme","canonical_id":"go:GO:0021789","description":"\"The process in which a branchiomotor neuron growth cone in the branchial arch mesenchyme is directed to a specific target site in the branchial arch mesenchyme. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"c4ac2740d0f9493ba5c962168b6b26ce","type":"GO_TERM","name":"branchiomotor neuron axon guidance in neural tube","canonical_id":"go:GO:0021786","description":"\"The process in which a branchiomotor neuron growth cone in the neural tube is directed to a specific target site in the neural tube. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"43243cf7ee144e79b55767cb8a20e114","type":"GO_TERM","name":"brassinolide synthase activity","canonical_id":"go:GO:0102734","description":"\"Catalysis of the reaction: castasterone + O2 + reduced [NADPH--hemoprotein reductase] = brassinolide + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. Broad specificity for several brassinosteroids, including castasterone, teasterone, and typhasterol.\" [EC:1.14.14.180]","metadata":null},{"id":"e249a2a1ce6b4864b02351751f5a847b","type":"GO_TERM","name":"brassinosteroid binding","canonical_id":"go:GO:0090411","description":"\"Binding to a brassinosteroid.\" [GOC:tb]","metadata":null},{"id":"1389da3924684abeabed9a7926b7a47e","type":"GO_TERM","name":"brassinosteroid biosynthetic process","canonical_id":"go:GO:0016132","description":"\"The chemical reactions and pathways resulting in the formation of brassinosteroids, any of a group of steroid derivatives that occur at very low concentrations in plant tissues and may have hormone-like effects.\" [ISBN:0192801023]","metadata":null},{"id":"9392e38e81034393b7cff8fb546fd431","type":"GO_TERM","name":"brassinosteroid catabolic process","canonical_id":"go:GO:0016133","description":"\"The chemical reactions and pathways resulting in the breakdown of brassinosteroids, any of a group of steroid derivatives that occur at very low concentrations in plant tissues and may have hormone-like effects.\" [ISBN:0192801023]","metadata":null},{"id":"8254ff269bbc49d99517b64040dc919e","type":"GO_TERM","name":"brassinosteroid homeostasis","canonical_id":"go:GO:0010268","description":"\"Any process involved in the maintenance of an internal steady state of brassinosteroids within an organism or cell.\" [PMID:15908602]","metadata":null},{"id":"d3cbb67957aa4cff92a4e16ab1361661","type":"GO_TERM","name":"brassinosteroid mediated signaling pathway","canonical_id":"go:GO:0009742","description":"\"The series of molecular signals mediated by the detection of brassinosteroid.\" [GOC:sm, PMID:16699538]","metadata":null},{"id":"feb25961b80b4809b096c022932e432d","type":"GO_TERM","name":"brassinosteroid metabolic process","canonical_id":"go:GO:0016131","description":"\"The chemical reactions and pathways involving brassinosteroids, any of a group of steroid derivatives that occur at very low concentrations in plant tissues and may have hormone-like effects.\" [ISBN:0192801023]","metadata":null},{"id":"40dcbe70f7c64d82b5306f779c51203d","type":"GO_TERM","name":"brassinosteroid sulfotransferase activity","canonical_id":"go:GO:0080118","description":"\"Catalysis of the reaction: a brassinosteroid + 3'-phosphoadenosine-5'-phosphosulfate = sulfated brassinosteroid + adenosine-3',5'-diphosphate. This reaction is the transfer of a sulfate group to the hydroxyl group of a brassinosteroid acceptor, producing the sulfated brassinosteroid derivative.\" [PMID:10409637, PMID:17039368]","metadata":null},{"id":"185a2732308646fcbab32f532fda3a6f","type":"DISEASE","name":"breast adenocarcinoma","canonical_id":"mondo:0004988","description":null,"metadata":null},{"id":"9eff69d152ba4d579315fb5438e9d7e9","type":"DISEASE","name":"breast cancer","canonical_id":"mondo:0007254","description":null,"metadata":null},{"id":"65072e94768c496daaa77192088be84f","type":"DISEASE","name":"breast carcinoma","canonical_id":"mondo:0004989","description":null,"metadata":null},{"id":"83e0bf7c5f6249fdb4f333c57d19a237","type":"DISEASE","name":"breast disorder","canonical_id":"mondo:0002657","description":null,"metadata":null},{"id":"7709f0f356c3435c90e951850315f7b2","type":"DISEASE","name":"breast fibrocystic disease","canonical_id":"mondo:0005219","description":null,"metadata":null},{"id":"51ee607513f34e61828d21d47b013dfc","type":"DISEASE","name":"breast neoplasm","canonical_id":"mondo:0021100","description":null,"metadata":null},{"id":"1d7440c7341e446ab6c2efafdd774115","type":"GO_TERM","name":"brefeldin A esterase activity","canonical_id":"go:GO:0052772","description":"\"Catalysis of the hydrolysis of brefeldin A to produce brefeldin A acid. Brefeldin A is also known as gamma,4-dihydroxy-2-(6-hydroxy-1-heptenyl)-4-cyclopentanecrotonic acid lambda-lactone.\" [GOC:mengo_curators, PMID:10201402, PMID:8106385]","metadata":null},{"id":"e832c133b5f449e4aa72b5bd2ad1bc7b","type":"DRUG","name":"brensocatib","canonical_id":"gtopdb:9412","description":null,"metadata":null},{"id":"0bc900ab86164b3abf82a2368929b010","type":"DRUG","name":"brensocatib","canonical_id":"chembl:CHEMBL3900409","description":null,"metadata":null},{"id":"2e0d3bdcde2d4148a9f9f4926ae2a187","type":"DRUG","name":"brentuximab vedotin","canonical_id":"gtopdb:6772","description":null,"metadata":null},{"id":"a15e29ac83394a609ef17468c80527ab","type":"DRUG","name":"brentuximab vedotin","canonical_id":"mesh:C547738","description":null,"metadata":null},{"id":"c967c8f3dcb945d384b70a671b99fc71","type":"DRUG","name":"brentuximab vedotin","canonical_id":"chembl:CHEMBL1742994","description":null,"metadata":null},{"id":"7792a72c9a5944b993481863e7df0c29","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + ceritinib","canonical_id":"ctgov_combo:ctgov-combo-d984f012b62b1b5a","description":null,"metadata":null},{"id":"347d00c4d552483989c47a386512491a","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + crizotinib","canonical_id":"ctgov_combo:ctgov-combo-403308f0e75be1c2","description":null,"metadata":null},{"id":"787aadbce7774e58bf8498b4e3f3be3e","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-4684dba2a2c9efba","description":null,"metadata":null},{"id":"2ac5b95dbc904674a1a6423a5975ce1f","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + pegfilgrastim + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-ee5f0d21ada28ef0","description":null,"metadata":null},{"id":"d50c194390ac46ae8cde7d9a9f092862","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + rituximab","canonical_id":"ctgov_combo:ctgov-combo-80d62101fe117be6","description":null,"metadata":null},{"id":"7ab0726a24154a4280a467e49fabc1db","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + romidepsin","canonical_id":"ctgov_combo:ctgov-combo-9e26ef8102b989c2","description":null,"metadata":null},{"id":"acee588314b34e5b8dba95f7e177990e","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-28cee897a9d0f165","description":null,"metadata":null},{"id":"e3cc3fe0bb964f52af488ae4708b6f9f","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-f41a32db4ccbe755","description":null,"metadata":null},{"id":"d75418f28df949ce8a447bee2cdfb443","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-c8089aca99a074b9","description":null,"metadata":null},{"id":"c78a716ee4454b509d64ec2617c59c17","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-e9de0f3ded9bff6c","description":null,"metadata":null},{"id":"5c007818b2484194a6e43d2e6a2f1cdf","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-3e44ad697847e8aa","description":null,"metadata":null},{"id":"919ddb06ef3745acbfe73d6028c7934d","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-2dba74a58b3bd759","description":null,"metadata":null},{"id":"fc4d75104e4c4deeaefc73feb2a527fb","type":"COMBINATION_TREATMENT","name":"brentuximab vedotin + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-7c9a760ba21ae4ee","description":null,"metadata":null},{"id":"80dd3208dc654da393ecd7b3269d133c","type":"DRUG","name":"bretylium","canonical_id":"mesh:C045166","description":null,"metadata":null},{"id":"9c6592f2d9c94a39964cacd3b43790b0","type":"GO_TERM","name":"brevianamide F biosynthetic process","canonical_id":"go:GO:1900805","description":"\"The chemical reactions and pathways resulting in the formation of brevianamide F. Brevianamide F is the biosynthetic precursor of a large family of biologically active prenylated tryptophan-proline 2,5-diketopiperazines that are produced by some fungi.\" [GOC:di, GOC:TermGenie, PMID:16755625, PMID:17464044]","metadata":null},{"id":"f4680e1f518849369b52020f2c838808","type":"GO_TERM","name":"brexanolone biosynthetic process","canonical_id":"go:GO:0062174","description":"\"The chemical reactions and pathways resulting in the formation of brexanolone.\" [PMID:24390875]","metadata":null},{"id":"9df8699de68e470c829ec176020df965","type":"GO_TERM","name":"brexanolone catabolic process","canonical_id":"go:GO:0062175","description":"\"The chemical reactions and pathways resulting in the breakdown of brexanolone.\" [PMID:24390875]","metadata":null},{"id":"c63e3ad84ccd4178a3aaf2cad57bdcc0","type":"GO_TERM","name":"brexanolone metabolic process","canonical_id":"go:GO:0062173","description":"\"The chemical reactions and pathways by which living organisms transform brexanolone.\" [PMID:24390875]","metadata":null},{"id":"be02f729c07746deb940fbc3e366c815","type":"DRUG","name":"brigatinib","canonical_id":"gtopdb:7741","description":null,"metadata":null},{"id":"c3bacb2bdd9d4db6b1c18aa571452265","type":"DRUG","name":"brigatinib","canonical_id":"mesh:C000598580","description":null,"metadata":null},{"id":"cef9866929874ca491d233d9708027a5","type":"DRUG","name":"brigatinib","canonical_id":"chembl:CHEMBL3545311","description":null,"metadata":null},{"id":"6cf679d179dd44339bb9fa250082000a","type":"COMBINATION_TREATMENT","name":"brigatinib + ceritinib","canonical_id":"ctgov_combo:ctgov-combo-e3393684377d8ba6","description":null,"metadata":null},{"id":"91cef8225d6341ecb15af2f9927e1b80","type":"COMBINATION_TREATMENT","name":"brigatinib + ceritinib","canonical_id":"ctgov_combo:ctgov-combo-03595f42368899ea","description":null,"metadata":null},{"id":"b805a17399eb4d8ea1cebaab8d10a97d","type":"COMBINATION_TREATMENT","name":"brigatinib + ceritinib","canonical_id":"ctgov_combo:ctgov-combo-2bd0617ab4ce1118","description":null,"metadata":null},{"id":"25c0a3cb680643298b18944f92746ac7","type":"COMBINATION_TREATMENT","name":"brigatinib + ceritinib + lorlatinib","canonical_id":"ctgov_combo:ctgov-combo-67696b2cc9af8ad0","description":null,"metadata":null},{"id":"ada61014b3054631a77609be98b6b4d9","type":"COMBINATION_TREATMENT","name":"brigatinib + ceritinib + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-053a39a6a0d523fd","description":null,"metadata":null},{"id":"24856f36db94486f89e9eceef7b97b2f","type":"COMBINATION_TREATMENT","name":"brigatinib + crizotinib","canonical_id":"ctgov_combo:ctgov-combo-05c689665e727920","description":null,"metadata":null},{"id":"6f8caacfdbbb4db4b9d286007a556071","type":"COMBINATION_TREATMENT","name":"brigatinib + neratinib","canonical_id":"ctgov_combo:ctgov-combo-eb7b995362a8abd0","description":null,"metadata":null},{"id":"783865f36de949278bc1d25645066210","type":"COMBINATION_TREATMENT","name":"brigatinib + pralsetinib + tepotinib","canonical_id":"ctgov_combo:ctgov-combo-3926d3686c3a6b6f","description":null,"metadata":null},{"id":"f674a02867af4bfdb8ec8d2fa668d43d","type":"DRUG","name":"brimonidine","canonical_id":"mesh:D000068438","description":null,"metadata":null},{"id":"8d91923461c945729d50b6bccc4a9b85","type":"DRUG","name":"brimonidine (UK14304)","canonical_id":"gtopdb:520","description":null,"metadata":null},{"id":"620aa316373b481d899f490b1654415e","type":"DRUG","name":"brinzolamide","canonical_id":"gtopdb:6797","description":null,"metadata":null},{"id":"72f1e1e2ba1b4659b7ec62286493a267","type":"DRUG","name":"brinzolamide","canonical_id":"mesh:C111827","description":null,"metadata":null},{"id":"025c7f3977fb423aa0e1423509ac68ce","type":"DRUG","name":"brinzolamide","canonical_id":"chembl:CHEMBL220491","description":null,"metadata":null},{"id":"52af66678b914e1a864f120553eb5e69","type":"COMBINATION_TREATMENT","name":"brinzolamide + timolol","canonical_id":"ctgov_combo:ctgov-combo-d87a50a34f2c2019","description":null,"metadata":null},{"id":"5220a4e4210c4f8cb8b38680b3f3fb8e","type":"COMBINATION_TREATMENT","name":"brinzolamide + timolol","canonical_id":"ctgov_combo:ctgov-combo-18c3e01743a74ef8","description":null,"metadata":null},{"id":"5dda4189512e4ae5bf642c4cee35be92","type":"COMBINATION_TREATMENT","name":"brinzolamide + timolol","canonical_id":"ctgov_combo:ctgov-combo-77d8cf56273ba20f","description":null,"metadata":null},{"id":"0688bb146e5d4e80bc08b1aa6077dcd1","type":"COMBINATION_TREATMENT","name":"brinzolamide + timolol","canonical_id":"ctgov_combo:ctgov-combo-ee6df3724c91ffc3","description":null,"metadata":null},{"id":"e5592f1fbffc4c1abbec83240680311a","type":"DRUG","name":"brivaracetam","canonical_id":"gtopdb:9041","description":null,"metadata":null},{"id":"5a21ef5bf55841cb8dc361314ffdbde6","type":"DRUG","name":"brivaracetam","canonical_id":"chembl:CHEMBL607400","description":null,"metadata":null},{"id":"61521809387f4dafaebf5ea6d66445dd","type":"COMBINATION_TREATMENT","name":"brivaracetam + levetiracetam","canonical_id":"ctgov_combo:ctgov-combo-0b993eba5710501f","description":null,"metadata":null},{"id":"68c7f739b89a4609b1df2b1b6fde3912","type":"COMBINATION_TREATMENT","name":"brivaracetam + levetiracetam","canonical_id":"ctgov_combo:ctgov-combo-c2641760428dfa82","description":null,"metadata":null},{"id":"f1342189e4d84ac38d72cad146de2ee0","type":"GO_TERM","name":"broad specificity neutral L-amino acid:basic L-amino acid antiporter activity","canonical_id":"go:GO:0180009","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: basic L-amino acid(in) + neutral L-amino acid(out) = basic L-amino acid(in) + neutral L-amino acid(out).\" [PMID:23506863, PMID:8663357]","metadata":null},{"id":"bd1cd53d0c764ecca28cc359c5358b84","type":"GO_TERM","name":"broad specificity oxidative DNA demethylase activity","canonical_id":"go:GO:0035516","description":"\"Catalysis of the reaction: a methylated nucleobase within DNA + 2-oxoglutarate + O2 = a nucleobase within DNA + formaldehyde + succinate + CO2. Catalyzes oxidative demethylation of the DNA base lesions N1- methyladenine, N3-methylcytosine, N1-methylguanine, and N3- methylthymine. Can also act of RNA.\" [PMID:12594517, PMID:16482161, PMID:18775698, PMID:19786499, RHEA:30299]","metadata":null},{"id":"cc4f9bd61d7a4728a7a98037b873ae5f","type":"DRUG","name":"brodalumab","canonical_id":"gtopdb:7540","description":null,"metadata":null},{"id":"e3afde92e2d2467ca1abcc0efa7834c9","type":"DRUG","name":"brodalumab","canonical_id":"chembl:CHEMBL1742996","description":null,"metadata":null},{"id":"d14b3a878b5b4274955ffac6c8dd384f","type":"COMBINATION_TREATMENT","name":"brodalumab + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-438ebabe76fc1a1f","description":null,"metadata":null},{"id":"3b8a884fac314ef48b425dff4d2927b5","type":"GO_TERM","name":"broken chromosome clustering","canonical_id":"go:GO:0141112","description":"\"The process of bringing together chromosomes fragments resulting from DNA damage. Broken chromosome tethering during mitosis ensures clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss and enhancing genome integrity.\" [PMID:37165191, PMID:37316668]","metadata":null},{"id":"eda948f0803d4b5a918ee96b823d4ed7","type":"DRUG","name":"brolucizumab","canonical_id":"gtopdb:8713","description":null,"metadata":null},{"id":"c7a346e06ea34cfe9ca9c8451e5f6519","type":"DRUG","name":"brolucizumab","canonical_id":"chembl:CHEMBL3707357","description":null,"metadata":null},{"id":"f5018adfa6424266b7ed3969908080c8","type":"DRUG","name":"bromazine","canonical_id":"mesh:C011410","description":null,"metadata":null},{"id":"db5c6a4cf0474047bc52d5a75df8f0e4","type":"DRUG","name":"bromfenac","canonical_id":"gtopdb:7131","description":null,"metadata":null},{"id":"ecc5c961bcef4c27a7142f5554dc42df","type":"DRUG","name":"bromfenac","canonical_id":"mesh:C053083","description":null,"metadata":null},{"id":"8d8d050e28844ef2a40cb4f58ff6db49","type":"COMBINATION_TREATMENT","name":"bromfenac + diclofenac + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-3e02bc3786617e92","description":null,"metadata":null},{"id":"2f8f94168e4b4eb6a4e078a41091964c","type":"COMBINATION_TREATMENT","name":"bromfenac + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-eed5bf6a69b5135a","description":null,"metadata":null},{"id":"e5dc6368a0364261883b7109e1b7e9cd","type":"COMBINATION_TREATMENT","name":"bromfenac + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-d3faa46e5599eab7","description":null,"metadata":null},{"id":"d440b8d1bb9c46608be23925640a9edb","type":"COMBINATION_TREATMENT","name":"bromfenac + pilocarpine","canonical_id":"ctgov_combo:ctgov-combo-bf699a797e3a23b7","description":null,"metadata":null},{"id":"ca7cd6a4a14a4cef93b6e9f6412c2978","type":"GO_TERM","name":"bromide peroxidase activity","canonical_id":"go:GO:0019806","description":"\"Catalysis of the reaction: 2 R-H + 2 bromide + H2O2 = 2 R-Br + 2 H2O. Enzymes with this activity often accept other halide ions as substrates, including chloride and iodide.\" [EC:1.11.1.18]","metadata":null},{"id":"c25a34e6884d44b7b21e345c9e61ede6","type":"DRUG","name":"bromocriptine","canonical_id":"gtopdb:35","description":null,"metadata":null},{"id":"b5167224fe4b41feb374d67dfbfac08e","type":"DRUG","name":"bromocriptine","canonical_id":"mesh:D001971","description":null,"metadata":null},{"id":"e8013ea366b347c688271256bd5b2fd6","type":"DRUG","name":"bromocriptine","canonical_id":"chembl:CHEMBL1200503","description":null,"metadata":null},{"id":"16b89b4c8f254578b5378124c8c22ccd","type":"COMBINATION_TREATMENT","name":"bromocriptine + cabergoline","canonical_id":"ctgov_combo:ctgov-combo-d23a668eaccd1e27","description":null,"metadata":null},{"id":"00149c4734b14e5bac678c1c0e2ecf26","type":"COMBINATION_TREATMENT","name":"bromocriptine + cabergoline","canonical_id":"ctgov_combo:ctgov-combo-3979975c21951d2f","description":null,"metadata":null},{"id":"894511a3bacd433bb0654492c850e8d8","type":"COMBINATION_TREATMENT","name":"bromocriptine + fludrocortisone","canonical_id":"ctgov_combo:ctgov-combo-ac7809de0f562fcc","description":null,"metadata":null},{"id":"154107be3b634154bf81e5547d9bd34b","type":"COMBINATION_TREATMENT","name":"bromocriptine + methimazole","canonical_id":"ctgov_combo:ctgov-combo-b671b9398fd3fad9","description":null,"metadata":null},{"id":"e1c4703970764967a3e1ab01a2a66455","type":"COMBINATION_TREATMENT","name":"bromocriptine + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-c3780926b6160f04","description":null,"metadata":null},{"id":"3bafb4ec11744afbbe5d0414ff227a95","type":"COMBINATION_TREATMENT","name":"bromocriptine + pramipexole","canonical_id":"ctgov_combo:ctgov-combo-c63ac0c04ad25f33","description":null,"metadata":null},{"id":"d3fb7c4f88dc420b85ee141810ecea45","type":"COMBINATION_TREATMENT","name":"bromocriptine + tolcapone","canonical_id":"ctgov_combo:ctgov-combo-8de206cc46a5d2d0","description":null,"metadata":null},{"id":"52b62b56bf58427e90734ed5e274eeff","type":"GO_TERM","name":"bromoxynil nitrilase activity","canonical_id":"go:GO:0018761","description":"\"Catalysis of the reaction: 3,5-dibromo-4-hydroxybenzonitrile + 2 H2O = 3,5-dibromo-4-hydroxybenzoate + NH4. Involved in the bacterial degradation of the herbicide bromoxynil.\" [RHEA:22100]","metadata":null},{"id":"db934141197a41589409fde5808fe107","type":"DISEASE","name":"bronchiectasis","canonical_id":"mondo:0004822","description":null,"metadata":null},{"id":"4d04b944ff1f47e7b1599a60882cb88c","type":"DISEASE","name":"bronchiectasis with or without elevated sweat chloride 1","canonical_id":"mondo:0008887","description":null,"metadata":null},{"id":"0713c4cea7374e36a16a73c70cfedcca","type":"GO_TERM","name":"bronchiole development","canonical_id":"go:GO:0060435","description":"\"The biological process whose specific outcome is the progression of a bronchiole from an initial condition to its mature state. This process begins with the formation of the bronchiole and ends with the mature structure. A bronchiole is the first airway branch that no longer contains cartilage; it is a branch of the bronchi.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"5623c9266d184846839f694c58798fd7","type":"GO_TERM","name":"bronchiole morphogenesis","canonical_id":"go:GO:0060436","description":"\"The process in which a bronchiole is generated and organized. A bronchiole is the first airway branch that no longer contains cartilage; it is a branch of the bronchi.\" [GOC:dph]","metadata":null},{"id":"b4b5ca6f59c4418bb1c68a220aeea2d1","type":"DISEASE","name":"bronchitis","canonical_id":"mondo:0003781","description":null,"metadata":null},{"id":"55319052cd7947e5a5d6cae0051c3f08","type":"DISEASE","name":"bronchus cancer","canonical_id":"mondo:0001672","description":null,"metadata":null},{"id":"0e635573891e4744abc0e0f35b8f32c2","type":"GO_TERM","name":"bronchus cartilage development","canonical_id":"go:GO:0060532","description":"\"The process whose specific outcome is the progression of lung cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"c7e82ca4d1eb47d5b1efe7059f1d5c03","type":"GO_TERM","name":"bronchus cartilage morphogenesis","canonical_id":"go:GO:0060533","description":"\"The process in which the bronchus cartilage is generated and organized. The bronchus cartilage is the connective tissue of the portion of the airway that connects to the lungs.\" [GOC:dph]","metadata":null},{"id":"b7a902facec742e8843b0546a99154ce","type":"GO_TERM","name":"bronchus development","canonical_id":"go:GO:0060433","description":"\"The biological process whose specific outcome is the progression of a bronchus from an initial condition to its mature state. This process begins with the formation of the bronchus and ends with the mature structure. The bronchus is the portion of the airway that connects to the lungs.\" [GOC:dph]","metadata":null},{"id":"1e8be08cdeca407d903b0de53f6e3ff2","type":"GO_TERM","name":"bronchus morphogenesis","canonical_id":"go:GO:0060434","description":"\"The process in which the bronchus is generated and organized. The bronchus is the portion of the airway that connects to the lungs.\" [GOC:dph]","metadata":null},{"id":"d0cdfb1b403c4dd984446b5f45bc74f0","type":"GO_TERM","name":"brown fat cell differentiation","canonical_id":"go:GO:0050873","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a brown adipocyte, an animal connective tissue cell involved in adaptive thermogenesis. Brown adipocytes contain multiple small droplets of triglycerides and a high number of mitochondria.\" [PMID:12588810]","metadata":null},{"id":"f3bce5e107df437ca7e3e3f949341f3f","type":"GO_TERM","name":"brown fat cell proliferation","canonical_id":"go:GO:0070342","description":"\"The multiplication or reproduction of brown fat cells by cell division, resulting in the expansion of their population. A brown fat cell is a fat cell found the thermogenic form of adipose tissue found in newborns of many species.\" [CL:0000449, GOC:mah, GOC:sl]","metadata":null},{"id":"12cf16d8f38145f68a5bc709260dd0dd","type":"DISEASE","name":"brucellosis","canonical_id":"mondo:0005683","description":null,"metadata":null},{"id":"5091a592de6c46afb82d788c1aa5db49","type":"GO_TERM","name":"brush border","canonical_id":"go:GO:0005903","description":"\"The dense covering of microvilli on the apical surface of an epithelial cell in tissues such as the intestine, kidney, and choroid plexus; the microvilli aid absorption by increasing the surface area of the cell.\" [GOC:sl, ISBN:0815316194]","metadata":null},{"id":"f173d335b4e64b64b6e904a5c3040886","type":"GO_TERM","name":"brush border assembly","canonical_id":"go:GO:1904970","description":"\"The aggregation, arrangement and bonding together of adjacent microvilli through the formation of Ca(2+)-dependent adhesion links between them, forming a brush border.\" [GO_REF:0000079, GOC:lb, GOC:TermGenie, PMID:24725409]","metadata":null},{"id":"c3773abf0fef47038459924f999c0f19","type":"GO_TERM","name":"brush border membrane","canonical_id":"go:GO:0031526","description":"\"The portion of the plasma membrane surrounding the brush border.\" [GOC:mah]","metadata":null},{"id":"5306890922c740088f7759d12dc64c5c","type":"GO_TERM","name":"bub1-bub3 complex","canonical_id":"go:GO:1990298","description":"\"Protein complex that associates with the kinetochores.\" [PMID:22521786]","metadata":null},{"id":"e68f689cd09c4eb3b2e389338f3719c0","type":"GO_TERM","name":"bubble DNA binding","canonical_id":"go:GO:0000405","description":"\"Binding to DNA segment that contains a bubble. A bubble occurs when DNA contains a region of unpaired, single-stranded DNA flanked on both sides by regions of paired, double-stranded DNA.\" [GOC:elh, GOC:vw, PMID:16781730]","metadata":null},{"id":"5ef00a5086184c85b57a0939e1194dcc","type":"GO_TERM","name":"bud dilation","canonical_id":"go:GO:0061137","description":"\"The process in which a branch bud increases radially. A branch bud is the initial area of outgrowth in the formation of a new branch.\" [GOC:dph]","metadata":null},{"id":"f5ba57f229ba469586508f2ea5343c5e","type":"GO_TERM","name":"bud dilation involved in lung branching","canonical_id":"go:GO:0060503","description":"\"The process in which a bud in the lung increases radially.\" [GOC:dph]","metadata":null},{"id":"97c240595e324659a71555261c9f5336","type":"GO_TERM","name":"bud dormancy process","canonical_id":"go:GO:0097207","description":"\"A dormancy process in which dormancy (sometimes called a dormant state) is induced, maintained or broken in a bud. Bud dormancy is a suspension of most physiological activity and growth that can be reactivated. It may be a response to environmental conditions such as seasonality or extreme heat, drought, or cold. The exit from bud dormancy is marked by the resumed growth of the bud.\" [GOC:PO_curators, PO_REF:00009]","metadata":null},{"id":"a0c9fe502d554d0abac1888b82e9397c","type":"GO_TERM","name":"bud elongation involved in lung branching","canonical_id":"go:GO:0060449","description":"\"The process in which a bud in the lung grows out from the point where it is formed.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"20416c061a8c4c51846b2dc2d3ac815a","type":"GO_TERM","name":"bud field specification","canonical_id":"go:GO:0061139","description":"\"The regionalization process in which the identity of a bud primordium is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:dph]","metadata":null},{"id":"8169ab4ecd8a4a21a2c927030d4fb499","type":"GO_TERM","name":"bud outgrowth involved in lung branching","canonical_id":"go:GO:0060447","description":"\"The process in which a region of the lung epithelium initiates an outgrowth.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"88d727b5407d41b4a69bc6d30285abac","type":"GO_TERM","name":"budding cell apical bud growth","canonical_id":"go:GO:0007118","description":"\"Growth at the tip of a bud, in a cell that reproduces by budding.\" [GOC:curators]","metadata":null},{"id":"10610485a4e6465d90dd9747532ff44d","type":"GO_TERM","name":"budding cell bud growth","canonical_id":"go:GO:0007117","description":"\"The process in which the bud portion of a cell that reproduces by budding irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.\" [GOC:curators]","metadata":null},{"id":"44d4613f20484ad7b32e24fa386540d5","type":"GO_TERM","name":"budding cell isotropic bud growth","canonical_id":"go:GO:0007119","description":"\"Unlocalized bud growth such that the entire surface of the bud expands evenly, in a cell that reproduces by budding.\" [GOC:curators]","metadata":null},{"id":"522147ddd86f47a380249247eedb28f6","type":"DRUG","name":"budesonide","canonical_id":"gtopdb:7434","description":null,"metadata":null},{"id":"eea30f2211434252bb3bb79b7602e3ff","type":"DRUG","name":"budesonide","canonical_id":"chembl:CHEMBL1370","description":null,"metadata":null},{"id":"e0c3e00d64ae4ce7b49afb7d82e39dde","type":"COMBINATION_TREATMENT","name":"budesonide + fluticasone","canonical_id":"ctgov_combo:ctgov-combo-0bb7785bbb3b114b","description":null,"metadata":null},{"id":"c5a84e6432524b6985abf84d53062aa9","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-0f23ee066f639acc","description":null,"metadata":null},{"id":"6a6e0750694447abab7a2e6c59414bd8","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-67c56f6a65cd0766","description":null,"metadata":null},{"id":"7dcd271dec9d47adac10d1274cd6c62d","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-32af0b6c4c01f98b","description":null,"metadata":null},{"id":"a106df43453a4a88ab8d4a7eb2829ae0","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-c916a39e4aea1a53","description":null,"metadata":null},{"id":"74d235c2eee74e7cbb9eac5b1525bb92","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-7608ded43657be08","description":null,"metadata":null},{"id":"027658425afd48d1bbfa67112430b1bc","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-756693f1d327512e","description":null,"metadata":null},{"id":"d1a9e012f2c0425aa43378ec250b27e9","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-df5168fe5e1ccbc6","description":null,"metadata":null},{"id":"e0209b28575a49c5885fe6f36ae736e5","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-531d8b52dca3b4c5","description":null,"metadata":null},{"id":"e3a430db31f9488991d8e149b825af2b","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol","canonical_id":"ctgov_combo:ctgov-combo-3db80f4c3c3774aa","description":null,"metadata":null},{"id":"a03be7a6d0d244eca03cef58ff18206f","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol + ipratropium","canonical_id":"ctgov_combo:ctgov-combo-81dcca82732c3e12","description":null,"metadata":null},{"id":"d85b5bc70c1548b9955b310950b33def","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-12bf71048977a45b","description":null,"metadata":null},{"id":"915cd1546d99471f9b6c51e14b0c21fb","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol + salbutamol","canonical_id":"ctgov_combo:ctgov-combo-2b8ee48ac50e05b7","description":null,"metadata":null},{"id":"bd59f4435a5b4c4f9575024b76be603e","type":"COMBINATION_TREATMENT","name":"budesonide + formoterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-3e24a4d81035f146","description":null,"metadata":null},{"id":"b64fe4355010469daae1d77636545949","type":"COMBINATION_TREATMENT","name":"budesonide + mesalazine","canonical_id":"ctgov_combo:ctgov-combo-7560f39fb51b305e","description":null,"metadata":null},{"id":"b45cda1e451941c2a8792ec3ad35dcb7","type":"COMBINATION_TREATMENT","name":"budesonide + mesalazine","canonical_id":"ctgov_combo:ctgov-combo-01958be70552c618","description":null,"metadata":null},{"id":"d75988fe4f0547a983ba5ccefe8ffd0c","type":"COMBINATION_TREATMENT","name":"budesonide + montelukast","canonical_id":"ctgov_combo:ctgov-combo-575d33e772db0faa","description":null,"metadata":null},{"id":"e0bf2a1b46ac43808ef64f58502c23a8","type":"COMBINATION_TREATMENT","name":"budesonide + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-db5879e219438179","description":null,"metadata":null},{"id":"e7faa1af7ef448e3aeec90539aac7528","type":"COMBINATION_TREATMENT","name":"budesonide + prednisone","canonical_id":"ctgov_combo:ctgov-combo-02ec7b9c18bb60c1","description":null,"metadata":null},{"id":"21a33fb98aad4fbeb24cfa0f83dc6183","type":"COMBINATION_TREATMENT","name":"budesonide + procaterol","canonical_id":"ctgov_combo:ctgov-combo-b6e8609d21176a7d","description":null,"metadata":null},{"id":"7c6bdd35c7af477eb4c0ab5d989eb6cc","type":"DRUG","name":"buformin","canonical_id":"mesh:D002026","description":null,"metadata":null},{"id":"05f4b437ae3f45f78457a0111a4ad03a","type":"GO_TERM","name":"bulbus arteriosus development","canonical_id":"go:GO:0003232","description":"\"The process whose specific outcome is the progression of the bulbus arteriosus over time, from its formation to the mature structure. The bulbus arteriosus is an elastic heart chamber.\" [GOC:mtg_heart]","metadata":null},{"id":"9829e2a5de854ba797c84d1852c3a427","type":"GO_TERM","name":"bulbus arteriosus formation","canonical_id":"go:GO:0003234","description":"\"The developmental process pertaining to the initial formation of the bulbus arteriosus from unspecified parts. The bulbus arteriosus is an elastic chamber of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"2123c2548cd64ed1a9684588dbf863fa","type":"GO_TERM","name":"bulbus arteriosus morphogenesis","canonical_id":"go:GO:0003233","description":"\"The process in which the bulbus arteriosus is generated and organized. The bulbus arteriosus is an elastic cardiac chamber.\" [GOC:mtg_heart]","metadata":null},{"id":"632ab074b5cc4e0183fd4cd0f4e37a22","type":"GO_TERM","name":"bulk synaptic vesicle endocytosis","canonical_id":"go:GO:0150008","description":"\"Endocytosis of large regions of presynaptic membrane after intense stimulation-mediated fusion of multiple synaptic vesicles. Bulk endocytosis is triggered by high loads of membrane addition through exocytosis of synaptic vesicles and elevated concentration of calcium in the presynapse.\" [GOC:aruk, GOC:bc, GOC:ha, PMID:18250322, PMID:18579735, PMID:19266323, PMID:26430111, PMID:28391090]","metadata":null},{"id":"422f2a37fb2f4e6f83925ca9f1a744ed","type":"DISEASE","name":"bullous pemphigoid","canonical_id":"mondo:0019082","description":null,"metadata":null},{"id":"b32f5a5d3d5a49669bb74cdef76117d5","type":"DRUG","name":"bumetanide","canonical_id":"gtopdb:4837","description":null,"metadata":null},{"id":"8bf584962d3541149472fdfb3cbf9c35","type":"DRUG","name":"bumetanide","canonical_id":"mesh:D002034","description":null,"metadata":null},{"id":"cc32a34ed18444fbbf497e8d0763fbd3","type":"DRUG","name":"bumetanide","canonical_id":"chembl:CHEMBL1072","description":null,"metadata":null},{"id":"e26e984d37214ec9bc678bcafb4e4772","type":"COMBINATION_TREATMENT","name":"bumetanide + chlorthalidone","canonical_id":"ctgov_combo:ctgov-combo-5ca50c766b874a23","description":null,"metadata":null},{"id":"0b29bca62dd54b6db53501da2a18ce27","type":"COMBINATION_TREATMENT","name":"bumetanide + furosemide","canonical_id":"ctgov_combo:ctgov-combo-58c994f509012282","description":null,"metadata":null},{"id":"9d68a2c8b8824fa8a8225200b93b7327","type":"COMBINATION_TREATMENT","name":"bumetanide + furosemide","canonical_id":"ctgov_combo:ctgov-combo-632ab0aead0e3f03","description":null,"metadata":null},{"id":"35c647e234834366acdd2cb1717f1b18","type":"DISEASE","name":"bundle branch block","canonical_id":"efo:0004138","description":null,"metadata":null},{"id":"6ba91d75d24a48ca8f256084746061c4","type":"GO_TERM","name":"bundle of His cell action potential","canonical_id":"go:GO:0086043","description":"\"An action potential that occurs in a bundle of His cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"59c4f1f03de0409a965c2fb814ba890f","type":"GO_TERM","name":"bundle of His cell to Purkinje myocyte communication","canonical_id":"go:GO:0086069","description":"\"The process that mediates interactions between a bundle of His cell and its surroundings that contributes to the process of the bundle of His cell communicating with a Purkinje myocyte in cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f39be7fc080c4dad9ee135aee33c6ca7","type":"GO_TERM","name":"bundle of His cell to Purkinje myocyte communication by electrical coupling","canonical_id":"go:GO:0086054","description":"\"The process that mediates signaling interactions between a bundle of His cardiac muscle cell and a Purkinje myocyte by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"258fa7032a3c4b348da68750e71d2e4d","type":"GO_TERM","name":"bundle of His cell to Purkinje myocyte signaling","canonical_id":"go:GO:0086028","description":"\"Any process that mediates the transfer of information from a bundle of His cardiomyocyte to a Purkinje myocyte.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"4109dd8aab3a4b65ad69fc74f3039e0d","type":"GO_TERM","name":"bundle of His cell-Purkinje myocyte adhesion involved in cell communication","canonical_id":"go:GO:0086073","description":"\"The attachment of a bundle of His cell to a Purkinje myocyte via adhesion molecules that results in the cells being juxtaposed so that they can communicate.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"3175b673e1a84eab8b238405ecd9df38","type":"GO_TERM","name":"bundle of His development","canonical_id":"go:GO:0003166","description":"\"The process whose specific outcome is the progression of the bundle of His over time, from its formation to the mature structure. The bundle of His is part of the His-Purkinje system that transmits signals from the AV node to the cardiac Purkinje fibers.\" [GOC:mtg_heart]","metadata":null},{"id":"11384b290d2247339bf3800df8ae8908","type":"GO_TERM","name":"bundle sheath cell differentiation","canonical_id":"go:GO:1903498","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a bundle sheath cell.\" [GO_REF:0000086, GOC:tb, GOC:TermGenie, PMID:24517883]","metadata":null},{"id":"f5f0068c3bc14503b8faec1e78266abe","type":"GO_TERM","name":"bundle sheath cell fate specification","canonical_id":"go:GO:0090610","description":"\"The process in which a cell becomes capable of differentiating autonomously into a bundle sheath cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:tb, PMID:24517883]","metadata":null},{"id":"06fb8aa0a9734de0aec11a837e55efa5","type":"DRUG","name":"bunolol","canonical_id":"gtopdb:570","description":null,"metadata":null},{"id":"bc44afbea447491f966acda733eb4afd","type":"DRUG","name":"bupranolol","canonical_id":"gtopdb:550","description":null,"metadata":null},{"id":"3e592803781c4ca1ad67a6095936a97c","type":"DRUG","name":"bupranolol","canonical_id":"mesh:D002046","description":null,"metadata":null},{"id":"87d21a168bb1461f9b4460bdc739a4de","type":"DRUG","name":"buprenorphine","canonical_id":"gtopdb:1670","description":null,"metadata":null},{"id":"55d365c2e19946909731b77825180bbb","type":"DRUG","name":"buprenorphine","canonical_id":"chembl:CHEMBL511142","description":null,"metadata":null},{"id":"4cdee35a3b144d62a71f5d675ecdccb4","type":"COMBINATION_TREATMENT","name":"buprenorphine + hydromorphone + naloxone","canonical_id":"ctgov_combo:ctgov-combo-2a2ccfbb78a5a548","description":null,"metadata":null},{"id":"0b9f0633ca304ea8bf59b4c60977cc01","type":"COMBINATION_TREATMENT","name":"buprenorphine + methadone","canonical_id":"ctgov_combo:ctgov-combo-78bab82868939878","description":null,"metadata":null},{"id":"dc7fc63abe7b4882a0d7952d719607e6","type":"COMBINATION_TREATMENT","name":"buprenorphine + methadone","canonical_id":"ctgov_combo:ctgov-combo-0e6cb6ad0c611cd6","description":null,"metadata":null},{"id":"0822d06d31c24c078fa757f490282d53","type":"COMBINATION_TREATMENT","name":"buprenorphine + methadone","canonical_id":"ctgov_combo:ctgov-combo-3bd762b5ff21e8ef","description":null,"metadata":null},{"id":"512da21482c444a8a4dd8cc4bb34cf4c","type":"COMBINATION_TREATMENT","name":"buprenorphine + methadone","canonical_id":"ctgov_combo:ctgov-combo-4be520cad8ef8c0e","description":null,"metadata":null},{"id":"1b448da1ba48493eb912ac52c1168999","type":"COMBINATION_TREATMENT","name":"buprenorphine + methadone + naloxone","canonical_id":"ctgov_combo:ctgov-combo-40f24607db16b961","description":null,"metadata":null},{"id":"91b3946d4b3741d9a530409277d97455","type":"COMBINATION_TREATMENT","name":"buprenorphine + morphine","canonical_id":"ctgov_combo:ctgov-combo-dfc66c652b08480e","description":null,"metadata":null},{"id":"cdedd1f8d2d24f998900a71c0ba9fa6e","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-bf9715e7e83a2b21","description":null,"metadata":null},{"id":"7a5db39e034b44d0a39807cc353f7868","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-18f12aa74f402c05","description":null,"metadata":null},{"id":"c73cfea0adae485f83223b4180f71098","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-45a28613afaafc8b","description":null,"metadata":null},{"id":"45caadae60734017a6a9a23b21dbfa5c","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-fa129afe1d5fb96c","description":null,"metadata":null},{"id":"dc312dbe3b0047dcbe002f57aad50395","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-3505fb25c9511884","description":null,"metadata":null},{"id":"53a7ce201d914fadaf648faa9d294fcb","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-16e4729528546862","description":null,"metadata":null},{"id":"4acf39ef5dda46bba0eefd6ed24119e5","type":"COMBINATION_TREATMENT","name":"buprenorphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-7e19caec7e24a499","description":null,"metadata":null},{"id":"fb6da67206d24783a33635b941d6824c","type":"COMBINATION_TREATMENT","name":"buprenorphine + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-81523d6fbad3d758","description":null,"metadata":null},{"id":"15e70064e7384fa7b7f734a82044e2a8","type":"DRUG","name":"bupropion","canonical_id":"gtopdb:7135","description":null,"metadata":null},{"id":"004766a7788a403ea9b001ece35b0eb5","type":"DRUG","name":"bupropion","canonical_id":"mesh:D016642","description":null,"metadata":null},{"id":"bf494428849d4a1197344346edd65279","type":"COMBINATION_TREATMENT","name":"bupropion + citalopram + duloxetine + escitalopram + fluoxetine + fluvoxamine + mirtazapine + paroxetine + sertraline + trazodone + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-31ed728b9f043c46","description":null,"metadata":null},{"id":"e3ea4c26872a4526a07a2b69c956f330","type":"COMBINATION_TREATMENT","name":"bupropion + duloxetine","canonical_id":"ctgov_combo:ctgov-combo-932616c3abc27380","description":null,"metadata":null},{"id":"62cf958800804b1dae922301fbb79015","type":"COMBINATION_TREATMENT","name":"bupropion + fexofenadine + flurbiprofen","canonical_id":"ctgov_combo:ctgov-combo-72f4270e7fab1afa","description":null,"metadata":null},{"id":"81e2766cc3d8427aba4bdd9565dc9cef","type":"COMBINATION_TREATMENT","name":"bupropion + flurbiprofen + furosemide + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-8e05eca696d72b0e","description":null,"metadata":null},{"id":"0751829f538144dfbdb3a0bf7ccce9bd","type":"COMBINATION_TREATMENT","name":"bupropion + ketamine","canonical_id":"ctgov_combo:ctgov-combo-51d94cd4976975a2","description":null,"metadata":null},{"id":"2424f3a27f704c2f8d5d2c83fd476ccf","type":"COMBINATION_TREATMENT","name":"bupropion + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-8120f07dd4654a17","description":null,"metadata":null},{"id":"157aa441f79c4fdd8805045b56e5145a","type":"COMBINATION_TREATMENT","name":"bupropion + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-3fd319d5d09efcff","description":null,"metadata":null},{"id":"e9ae40ff1fdd458c807c2107717a4966","type":"COMBINATION_TREATMENT","name":"bupropion + naltrexone + semaglutide","canonical_id":"ctgov_combo:ctgov-combo-54d2f669d2ecf6a8","description":null,"metadata":null},{"id":"9c6e03e921444e9fb1984fd7fba021ed","type":"COMBINATION_TREATMENT","name":"bupropion + nefazodone","canonical_id":"ctgov_combo:ctgov-combo-c9357ad58116fdb8","description":null,"metadata":null},{"id":"c3823dee3d0d4ba78adf8165a262e6bc","type":"COMBINATION_TREATMENT","name":"bupropion + nortriptyline + sertraline + tranylcypromine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-77276e7ee7d540a7","description":null,"metadata":null},{"id":"a1eadaf0c5134efaa5bfe3eb43f5162c","type":"COMBINATION_TREATMENT","name":"bupropion + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-25f3a156b10662f7","description":null,"metadata":null},{"id":"1f5ac6284f464890afa25af6a4a54759","type":"COMBINATION_TREATMENT","name":"bupropion + varenicline","canonical_id":"ctgov_combo:ctgov-combo-fd774c7abc46784a","description":null,"metadata":null},{"id":"579d0fa549a746bcaff30dc8374e02cb","type":"COMBINATION_TREATMENT","name":"bupropion + varenicline","canonical_id":"ctgov_combo:ctgov-combo-d3cf3de231de7fdf","description":null,"metadata":null},{"id":"39adf33c9bf04cd1871c99f87f2ad4f3","type":"COMBINATION_TREATMENT","name":"bupropion + varenicline","canonical_id":"ctgov_combo:ctgov-combo-43726588bb6b31d3","description":null,"metadata":null},{"id":"e59d5c53700d4c029e21c02d9050d24c","type":"COMBINATION_TREATMENT","name":"bupropion + varenicline","canonical_id":"ctgov_combo:ctgov-combo-a2a6930fe89c43bb","description":null,"metadata":null},{"id":"18dc6e49c5714d54a7aef1775fbba432","type":"COMBINATION_TREATMENT","name":"bupropion + varenicline","canonical_id":"ctgov_combo:ctgov-combo-7c445c465d300275","description":null,"metadata":null},{"id":"4291de81dd104305addb443c8cb78562","type":"COMBINATION_TREATMENT","name":"bupropion + varenicline","canonical_id":"ctgov_combo:ctgov-combo-fbb8fcf1a2768f21","description":null,"metadata":null},{"id":"050422b1c93c4be6ac4ca71c6c23dcb7","type":"DISEASE","name":"burn","canonical_id":"efo:0009516","description":null,"metadata":null},{"id":"b3c15275cacb4215a87ecd5f11a4cece","type":"DRUG","name":"burosumab","canonical_id":"gtopdb:9292","description":null,"metadata":null},{"id":"8424ff2ddcb746eab227dad0decd1cc1","type":"DRUG","name":"burosumab","canonical_id":"chembl:CHEMBL3707326","description":null,"metadata":null},{"id":"48deb0624d0f49f1969d9e5d23fc8c9c","type":"GO_TERM","name":"bursa of Fabricius development","canonical_id":"go:GO:0048540","description":"\"The process whose specific outcome is the progression of the bursa of Fabricius over time, from its formation to the mature structure. The bursa of Fabricius is an organ found in birds involved in B cell differentiation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5f7dc8dec8c9488a82417ec8e968fb25","type":"GO_TERM","name":"bursicon neuropeptide hormone complex","canonical_id":"go:GO:0031395","description":"\"A neuropeptide hormone secreted by the central nervous system of insects that stimulates the tanning and sclerotization of the adult cuticle following eclosion. The active hormone consists of an obligate heterodimer of the alpha and beta subunits.\" [GOC:rc]","metadata":null},{"id":"8ffcea912ee1446da635f9e8aa6e2ec7","type":"DISEASE","name":"bursitis","canonical_id":"mondo:0002471","description":null,"metadata":null},{"id":"8886fc1c875e40e29dc48f8e83f30973","type":"DRUG","name":"buspirone","canonical_id":"gtopdb:36","description":null,"metadata":null},{"id":"ad97bf1ff8664b5b98620259acbf0e6f","type":"DRUG","name":"buspirone","canonical_id":"chembl:CHEMBL1200399","description":null,"metadata":null},{"id":"2d06b4996d1b4bd2adfa36633f4ad488","type":"COMBINATION_TREATMENT","name":"buspirone + dexmedetomidine","canonical_id":"ctgov_combo:ctgov-combo-cde520c6dbdb938b","description":null,"metadata":null},{"id":"3aecdcb6b1cf4c11beeab3bb67195dc2","type":"COMBINATION_TREATMENT","name":"buspirone + trazodone","canonical_id":"ctgov_combo:ctgov-combo-c0b093a37795422a","description":null,"metadata":null},{"id":"7da92fffdc5f4241aefe3427932f523c","type":"COMBINATION_TREATMENT","name":"buspirone + triazolam","canonical_id":"ctgov_combo:ctgov-combo-9737fd86e36cc369","description":null,"metadata":null},{"id":"c8c98e1bed15461eb60e0522907d7de0","type":"GO_TERM","name":"butanal dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0047759","description":"\"Catalysis of the reaction: butanal + CoA + NAD(P)+ = butanoyl-CoA + NAD(P)H + H+.\" [EC:1.2.1.57]","metadata":null},{"id":"2ec0724e5b2a474badbac8cf980d1ea1","type":"GO_TERM","name":"butane monooxygenase activity","canonical_id":"go:GO:0036174","description":"\"Catalysis of the reaction: butane + O2 + NAD(P)H + H+ = butanol + NAD(P)+ + H2O.\" [GOC:dh, PMID:17526838, PMID:19383682]","metadata":null},{"id":"fda41b8017b14af9a6250715668c4dc7","type":"GO_TERM","name":"butanediol biosynthetic process","canonical_id":"go:GO:0034079","description":"\"The chemical reactions and pathways resulting in the formation of butanediol; the biologically relevant isomer is 2,3-butanediol.\" [GOC:mah, MetaCyc:P125-PWY]","metadata":null},{"id":"ac8efcf43f984777ba69bee818ef2f73","type":"GO_TERM","name":"butanediol catabolic process","canonical_id":"go:GO:0034078","description":"\"The chemical reactions and pathways resulting in the breakdown of butanediol; the biologically relevant isomer is 2,3-butanediol, CH3CH(OH)CH(OH)CH3.\" [GOC:mah, ISBN:0911910123]","metadata":null},{"id":"a58fc352531d4cc3acb4ad6d2b5bbba0","type":"GO_TERM","name":"butanediol metabolic process","canonical_id":"go:GO:0034077","description":"\"The chemical reactions and pathways involving butanediol; the biologically relevant isomer is 2,3-butanediol, CH3CH(OH)CH(OH)CH3.\" [ISBN:0911910123]","metadata":null},{"id":"84d989daec904d4d9d51791bc41fc05c","type":"GO_TERM","name":"butanol dehydrogenase (NAD+) activity","canonical_id":"go:GO:1990362","description":"\"Catalysis of the reaction: butan-1-ol + NAD+ = butanal + H+ + NADH.\" [GOC:mengo_curators, PMID:1999395, RHEA:33199]","metadata":null},{"id":"09165f061fc14fc6a8bd396d45605567","type":"DRUG","name":"butenafine","canonical_id":"mesh:C067594","description":null,"metadata":null},{"id":"8fa1de61c2bd4319b5d8fe9f14a3829f","type":"GO_TERM","name":"butirosin biosynthetic process","canonical_id":"go:GO:1901758","description":"\"The chemical reactions and pathways resulting in the formation of butirosin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00964]","metadata":null},{"id":"118cd8378f884ef1ad86f90661f3eff5","type":"GO_TERM","name":"butirosin catabolic process","canonical_id":"go:GO:1901757","description":"\"The chemical reactions and pathways resulting in the breakdown of butirosin.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"916248e472dc426ba9d51e14a63af915","type":"DRUG","name":"butorphanol","canonical_id":"gtopdb:7591","description":null,"metadata":null},{"id":"dcd4a0959ec4408daa600cedb9f2e455","type":"DRUG","name":"butorphanol","canonical_id":"mesh:D002077","description":null,"metadata":null},{"id":"4cd1c46f2be24754b13ee1a477774a41","type":"DRUG","name":"butriptyline","canonical_id":"mesh:C100242","description":null,"metadata":null},{"id":"bc8655fa3d5f47e28fee770d2bef2443","type":"GO_TERM","name":"butyrate biosynthetic process","canonical_id":"go:GO:0046358","description":"\"The chemical reactions and pathways resulting in the formation of butyrate, the anion of butyric acid.\" [ISBN:0198506732]","metadata":null},{"id":"c3eb85b50ec4454d8d3cd24cfe9a25f0","type":"GO_TERM","name":"butyrate catabolic process","canonical_id":"go:GO:0046359","description":"\"The chemical reactions and pathways resulting in the breakdown of butyrate, the anion of butyric acid.\" [ISBN:0198506732]","metadata":null},{"id":"aac06640162545bb8f978d88d437e5f0","type":"GO_TERM","name":"butyrate kinase activity","canonical_id":"go:GO:0047761","description":"\"Catalysis of the reaction: ATP + butanoate = ADP + butanoyl phosphate + H+.\" [EC:2.7.2.7, RHEA:13585]","metadata":null},{"id":"898f19d193ed433e9abe67443164ce72","type":"GO_TERM","name":"butyrate metabolic process","canonical_id":"go:GO:0019605","description":"\"The chemical reactions and pathways involving any butyrate, the anions of butyric acid (butanoic acid), a saturated, unbranched aliphatic acid.\" [ISBN:0198506732]","metadata":null},{"id":"b2ff17e3365746c0be4e34db49df3b45","type":"GO_TERM","name":"butyrate-acetoacetate CoA-transferase activity","canonical_id":"go:GO:0047371","description":"\"Catalysis of the reaction: acetoacetate + butanoyl-CoA = acetoacetyl-CoA + butanoate.\" [RHEA:12961]","metadata":null},{"id":"f90af46ec275426d860b8fd1383da95b","type":"GO_TERM","name":"butyryl-CoA biosynthetic process","canonical_id":"go:GO:0044578","description":"\"The chemical reactions and pathway resulting in the formation of butyryl-CoA.\" [GOC:jl]","metadata":null},{"id":"fe1035744f154d25a949b88cc4d14cb8","type":"GO_TERM","name":"butyryl-CoA catabolic process","canonical_id":"go:GO:0044580","description":"\"The chemical reactions a resulting in the resulting in the breakdown of butyryl-CoA.\" [GOC:jl]","metadata":null},{"id":"b7826c5e00fd44c8a212bd719c947e55","type":"DISEASE","name":"butyrylcholinesterase deficiency","canonical_id":"mondo:0015270","description":null,"metadata":null},{"id":"3d7ee703d56147ed878cc840672b7505","type":"TRIAL","name":"c-Met Second-Line Hepatocellular Carcinoma","canonical_id":"clinicaltrials.gov:NCT02115373","description":"Carcinoma, Hepatocellular","metadata":null},{"id":"9488187b4f8e4257859549dbe269410c","type":"GO_TERM","name":"c-di-GMP signaling","canonical_id":"go:GO:0061939","description":"\"Any process that mediates the transfer of information from one cell to another using c-di-GMP as the signal.\" [PMID:22864416, PMID:28057864]","metadata":null},{"id":"84f1e9dbcae14dd8a24de557009ef61c","type":"GO_TERM","name":"cADPR-sensitive calcium-release channel activity","canonical_id":"go:GO:0072346","description":"\"Enables the transmembrane transfer of a calcium ion by a channel that opens when cyclic adenosine diphosphate ribose (cADPR) has been bound by the channel complex or one of its constituent parts.\" [PMID:11752598]","metadata":null},{"id":"4b6a9d25cb074627a20a4d71752b6d06","type":"TRIAL","name":"cAMP Signaling and Muscle Adaptations","canonical_id":"clinicaltrials.gov:NCT02557581","description":"Muscle Hypertrophy in Healthy Young Men","metadata":null},{"id":"554eed56cda7480b8aa7cb7e157e0227","type":"GO_TERM","name":"cAMP binding","canonical_id":"go:GO:0030552","description":"\"Binding to cAMP, the nucleotide cyclic AMP (adenosine 3',5'-cyclophosphate).\" [GOC:ai]","metadata":null},{"id":"945714bf6dfa431681f60f0bcbaef323","type":"GO_TERM","name":"cAMP biosynthetic process","canonical_id":"go:GO:0006171","description":"\"The chemical reactions and pathways resulting in the formation of the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate).\" [ISBN:0198506732]","metadata":null},{"id":"13f7b84d7e7449c3ab2d22483fbef45e","type":"GO_TERM","name":"cAMP catabolic process","canonical_id":"go:GO:0006198","description":"\"The chemical reactions and pathways resulting in the breakdown of the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate).\" [ISBN:0198506732]","metadata":null},{"id":"9414d9fa219847b9b7f523cca4ea5f93","type":"GO_TERM","name":"cAMP deaminase activity","canonical_id":"go:GO:0090612","description":"\"Catalysis of the reaction: 3',5'-cyclic AMP + H2O + H+ = 3',5'-cyclic IMP + NH4+.\" [PMID:24074367, RHEA:22908]","metadata":null},{"id":"367f8061eab5417ea7bd480806d8f246","type":"GO_TERM","name":"cAMP metabolic process","canonical_id":"go:GO:0046058","description":"\"The chemical reactions and pathways involving the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate).\" [GOC:curators]","metadata":null},{"id":"ebf2899b8ca74ad09d574c0e3595cd80","type":"GO_TERM","name":"cAMP receptor activity","canonical_id":"go:GO:0001646","description":"\"Combining with cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:pg]","metadata":null},{"id":"b79d406292a14042acd7bde564d8e01d","type":"GO_TERM","name":"cAMP response element binding","canonical_id":"go:GO:0035497","description":"\"Binding to a cyclic AMP response element (CRE), a short palindrome-containing sequence found in the promoters of genes whose expression is regulated in response to cyclic AMP.\" [PMID:2875459, PMID:2900470]","metadata":null},{"id":"bd5d77d98bc54beb98da3c4bd0be9537","type":"GO_TERM","name":"cAMP response element binding protein binding","canonical_id":"go:GO:0008140","description":"\"Binding to a cAMP response element binding protein (a CREB protein).\" [GOC:mah]","metadata":null},{"id":"239212eed5d94161b800ff1b23426716","type":"GO_TERM","name":"cAMP transport","canonical_id":"go:GO:0070730","description":"\"The directed movement of cyclic AMP (cAMP), into, out of or within a cell.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"f043f4ea8c4f4820819c6b8aa768b2c7","type":"GO_TERM","name":"cAMP-dependent protein kinase activity","canonical_id":"go:GO:0004691","description":"\"cAMP-dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein.\" [PMID:32935175, PMID:35053423, PMID:35805104]","metadata":null},{"id":"d093eb0449c148798078b0163a8c192f","type":"GO_TERM","name":"cAMP-dependent protein kinase complex","canonical_id":"go:GO:0005952","description":"\"An enzyme complex, composed of regulatory and catalytic subunits, that catalyzes protein phosphorylation. Inactive forms of the enzyme have two regulatory chains and two catalytic chains; activation by cAMP produces two active catalytic monomers and a regulatory dimer.\" [PMID:18178622]","metadata":null},{"id":"e349e461ff2a4ca28ebadbb39c3650fe","type":"GO_TERM","name":"cAMP-dependent protein kinase inhibitor activity","canonical_id":"go:GO:0004862","description":"\"Binds to and stops, prevents or reduces the activity of a cAMP-dependent protein kinase.\" [GOC:mah]","metadata":null},{"id":"f07cb41edc9f4d52b09ea448d92e4463","type":"GO_TERM","name":"cAMP-dependent protein kinase regulator activity","canonical_id":"go:GO:0008603","description":"\"Modulation of the activity of the enzyme cAMP-dependent protein kinase.\" [GOC:ai]","metadata":null},{"id":"21e250cabc944a63bb46b5399ef8bcc0","type":"PROTEIN","name":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","canonical_id":"uniprot:Q07343","description":null,"metadata":null},{"id":"52c43c00e3e44ad8b33f57016870b3be","type":"GO_TERM","name":"cAMP/PKA signal transduction","canonical_id":"go:GO:0141156","description":"\"An intracellular signaling cassette that starts with production of cyclic AMP (cAMP) by adenylate cyclase (either transmembrane or soluble), which activates protein kinase A, and ends with activation of downstream effectors such as the transcription factor CREB that further transmit the signal within the cell.\" [PMID:23209152]","metadata":null},{"id":"b2233e246d774060b4ca5a4cb22ddcdf","type":"GO_TERM","name":"cGAS/STING signaling pathway","canonical_id":"go:GO:0140896","description":"\"The series of molecular signals initiated by the binding of a double-stranded DNA or RNA from another organism to cytosolic cyclic GMP-AMP (cGAMP) synthase (cGAS) that activates innate immune responses through production of the second messenger cGAMP, which activates the adaptor STING.\" [PMID:27648547, PMID:34261127, PMID:34261128]","metadata":null},{"id":"2e4e2ed0b2994ec8a1ea8141d4a17af2","type":"GO_TERM","name":"cGMP binding","canonical_id":"go:GO:0030553","description":"\"Binding to cGMP, the nucleotide cyclic GMP (guanosine 3',5'-cyclophosphate).\" [GOC:ai]","metadata":null},{"id":"a33dedcb48864e7db30b1f1d6fd390ec","type":"GO_TERM","name":"cGMP biosynthetic process","canonical_id":"go:GO:0006182","description":"\"The chemical reactions and pathways resulting in the formation of cyclic GMP, guanosine 3',5'-phosphate.\" [ISBN:0198506732]","metadata":null},{"id":"3354dd7d3f024d6281f7b0b76115d571","type":"GO_TERM","name":"cGMP catabolic process","canonical_id":"go:GO:0046069","description":"\"The chemical reactions and pathways resulting in the breakdown of cyclic GMP, guanosine 3',5'-phosphate.\" [GOC:curators]","metadata":null},{"id":"84dd34e9f85d4a24a4d23c65f59cb950","type":"GO_TERM","name":"cGMP metabolic process","canonical_id":"go:GO:0046068","description":"\"The chemical reactions and pathways involving cyclic GMP, guanosine 3',5'-phosphate.\" [GOC:curators]","metadata":null},{"id":"933a2ac40da1400484d86c93165e30a3","type":"GO_TERM","name":"cGMP transport","canonical_id":"go:GO:0070731","description":"\"The directed movement of cyclic GMP (cGMP), into, out of or within a cell.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"074c1d17bc184240aaab16f473c9dd9b","type":"GO_TERM","name":"cGMP-dependent protein kinase activity","canonical_id":"go:GO:0004692","description":"\"cGMP dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein.\" [GOC:mah]","metadata":null},{"id":"2cd02eb3182144f7b191c46add3c2656","type":"DRUG","name":"cabazitaxel","canonical_id":"gtopdb:6798","description":null,"metadata":null},{"id":"010117fb6f7b4c63a1ba205ee33eeeaf","type":"DRUG","name":"cabazitaxel","canonical_id":"chembl:CHEMBL1201748","description":null,"metadata":null},{"id":"f1418ebc28224d5d9a9ca5e71f78153a","type":"COMBINATION_TREATMENT","name":"cabazitaxel + cobimetinib + idelalisib + lorlatinib + neratinib + ponatinib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-dbf896839fa15d2c","description":null,"metadata":null},{"id":"cce51615c23e4eeaad92eec0a5f03d34","type":"COMBINATION_TREATMENT","name":"cabazitaxel + darolutamide","canonical_id":"ctgov_combo:ctgov-combo-d0716bb4154880d4","description":null,"metadata":null},{"id":"74c4123c7fd24bb19d8acff76dbaee61","type":"COMBINATION_TREATMENT","name":"cabazitaxel + enzalutamide","canonical_id":"ctgov_combo:ctgov-combo-989435932899793c","description":null,"metadata":null},{"id":"6f9c70a3a09e43ff8692b0065c2c0f11","type":"COMBINATION_TREATMENT","name":"cabazitaxel + enzalutamide","canonical_id":"ctgov_combo:ctgov-combo-34a04ec2a4d24e71","description":null,"metadata":null},{"id":"97e80c85a1a742308a2a818ab257aee3","type":"COMBINATION_TREATMENT","name":"cabazitaxel + ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-a31714bacb5e724d","description":null,"metadata":null},{"id":"80bdd49eb141491c877e59d602ec2dc8","type":"COMBINATION_TREATMENT","name":"cabazitaxel + prednisolone + prednisone","canonical_id":"ctgov_combo:ctgov-combo-a0a6e3865e0778b7","description":null,"metadata":null},{"id":"5551a6443acc4afc9fe6ccfb2a818d5a","type":"DRUG","name":"cabergoline","canonical_id":"gtopdb:37","description":null,"metadata":null},{"id":"e1eee615a27841e0b6cd02e571fa05ce","type":"DRUG","name":"cabergoline","canonical_id":"chembl:CHEMBL1201087","description":null,"metadata":null},{"id":"f61a911d60f44580b88a6479fd2a31e2","type":"COMBINATION_TREATMENT","name":"cabergoline + carbidopa","canonical_id":"ctgov_combo:ctgov-combo-c6ede6a099ecc999","description":null,"metadata":null},{"id":"44b82153882f4a54ab5141ca6455080b","type":"COMBINATION_TREATMENT","name":"cabergoline + dydrogesterone","canonical_id":"ctgov_combo:ctgov-combo-b255d7706462a3e5","description":null,"metadata":null},{"id":"6b2a55ac78514ace9b036992cb6ab967","type":"COMBINATION_TREATMENT","name":"cabergoline + nandrolone + testosterone propionate","canonical_id":"ctgov_combo:ctgov-combo-8764d404daa45f74","description":null,"metadata":null},{"id":"93ebed604c1946f7b951d1e05063752b","type":"COMBINATION_TREATMENT","name":"cabergoline + pasireotide","canonical_id":"ctgov_combo:ctgov-combo-a31c9202e08c859a","description":null,"metadata":null},{"id":"4aa393a320fd45ebae651f3f60f2e4cc","type":"COMBINATION_TREATMENT","name":"cabergoline + pegvisomant","canonical_id":"ctgov_combo:ctgov-combo-c07d8dc07c9925ae","description":null,"metadata":null},{"id":"a3ee419b60884cbfa093b2579779c3aa","type":"COMBINATION_TREATMENT","name":"cabergoline + pegvisomant","canonical_id":"ctgov_combo:ctgov-combo-8e36f76d9e13f107","description":null,"metadata":null},{"id":"73f4b35bcfe448e6af42bf0418cd5a27","type":"DRUG","name":"cabozantinib","canonical_id":"gtopdb:5887","description":null,"metadata":null},{"id":"54dee98043344b74aece78d008860c82","type":"COMBINATION_TREATMENT","name":"cabozantinib + cemiplimab","canonical_id":"ctgov_combo:ctgov-combo-c268c14be4fa0692","description":null,"metadata":null},{"id":"11a0396163564bcba1718087956dcb04","type":"COMBINATION_TREATMENT","name":"cabozantinib + dabrafenib + lenvatinib + pralsetinib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-9dccef0e5f6f4063","description":null,"metadata":null},{"id":"b019ba6a3a024027b462f5329dbfbd0f","type":"COMBINATION_TREATMENT","name":"cabozantinib + dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-8b307b59bb9f193d","description":null,"metadata":null},{"id":"7e880f6287054d5cbd67a05887e68a0c","type":"COMBINATION_TREATMENT","name":"cabozantinib + docetaxel + gemcitabine + nivolumab + paclitaxel + ramucirumab","canonical_id":"ctgov_combo:ctgov-combo-b752d2d94c897cc7","description":null,"metadata":null},{"id":"8b92edf108384c8481ad1ae3f0dec38f","type":"COMBINATION_TREATMENT","name":"cabozantinib + durvalumab","canonical_id":"ctgov_combo:ctgov-combo-369cebe8f0986726","description":null,"metadata":null},{"id":"e593ca69133c482386ba06c461ea8573","type":"COMBINATION_TREATMENT","name":"cabozantinib + enfortumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-52e763afe4cf44dd","description":null,"metadata":null},{"id":"e229fccb3fa14d0f804c57f7f8e7e0bf","type":"COMBINATION_TREATMENT","name":"cabozantinib + ipilimumab","canonical_id":"ctgov_combo:ctgov-combo-0c75742df6f8d069","description":null,"metadata":null},{"id":"d7defc99189d43dea8bfed5c253a09b1","type":"COMBINATION_TREATMENT","name":"cabozantinib + ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-1113ecb26ce2bcb6","description":null,"metadata":null},{"id":"8abd4912f5e44d7d96bc7b74cb81c19e","type":"COMBINATION_TREATMENT","name":"cabozantinib + ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-0dab2085ae6b9b15","description":null,"metadata":null},{"id":"156564d1f2f44940b105d044ffa902c6","type":"COMBINATION_TREATMENT","name":"cabozantinib + ipilimumab + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-0e5cc86f629cd7c2","description":null,"metadata":null},{"id":"19ebf30862854a60b12087323ed91427","type":"COMBINATION_TREATMENT","name":"cabozantinib + panitumumab","canonical_id":"ctgov_combo:ctgov-combo-98874f5f8728c6f9","description":null,"metadata":null},{"id":"c62d2e0d6a164664a2179e4afc5e83aa","type":"COMBINATION_TREATMENT","name":"cabozantinib + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-20596999f6fca2af","description":null,"metadata":null},{"id":"4a960b00081e4045965976eb133bbf20","type":"COMBINATION_TREATMENT","name":"cabozantinib + ramucirumab","canonical_id":"ctgov_combo:ctgov-combo-d13bdf89a05eac42","description":null,"metadata":null},{"id":"07af989c87b0438392404c6e6f77da8d","type":"GO_TERM","name":"cadaverine aminopropyltransferase activity","canonical_id":"go:GO:0043918","description":"\"Catalysis of the reaction: cadaverine + S-adenosyl 3-(methylsulfanyl)propylamine = aminopropylcadaverine + H+ + S-methyl-5'-thioadenosine.\" [PMID:17545282, RHEA:33387]","metadata":null},{"id":"0d001abea4b44f1abe30b5bd23f837f1","type":"GO_TERM","name":"cadaverine transport","canonical_id":"go:GO:0015839","description":"\"The directed movement of cadaverine, 1,5-pentanediamine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"e08bb37d7b21452bbc5f7bce41ccd07b","type":"GO_TERM","name":"cadherin binding","canonical_id":"go:GO:0045296","description":"\"Binding to cadherin, a type I membrane protein involved in cell adhesion.\" [GOC:bf]","metadata":null},{"id":"6fb85a88e2544e27bb9982cb5e0f9796","type":"GO_TERM","name":"cadherin binding involved in cell-cell adhesion","canonical_id":"go:GO:0098641","description":"\"Any cadherin binding that occurs as part of the process of cell-cell adhesion.\" [GOC:dos]","metadata":null},{"id":"bbde5273db9e4d54ad7013d23cdc3c63","type":"GO_TERM","name":"cadinene biosynthetic process","canonical_id":"go:GO:1901928","description":"\"The chemical reactions and pathways resulting in the formation of cadinene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"89e916086caf453eb3d62727c041cdfb","type":"GO_TERM","name":"cadinene catabolic process","canonical_id":"go:GO:1901927","description":"\"The chemical reactions and pathways resulting in the breakdown of cadinene.\" [GOC:TermGenie, PMID:22867794]","metadata":null},{"id":"00982f99b86141ecb6197fd344738d78","type":"GO_TERM","name":"cadmium ion binding","canonical_id":"go:GO:0046870","description":"\"Binding to a cadmium ion (Cd).\" [GOC:ai]","metadata":null},{"id":"fe90d07ea1df42a685aedacd73762d2a","type":"GO_TERM","name":"cadmium ion import into vacuole","canonical_id":"go:GO:0036249","description":"\"The directed movement of cadmium ions into the vacuole.\" [GOC:al]","metadata":null},{"id":"316a1e6df0ae49f781d28bad6ccbb093","type":"GO_TERM","name":"cadmium ion sensor activity","canonical_id":"go:GO:0097063","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of cadmium (Cd++).\" [GOC:rs, PMID:19456862]","metadata":null},{"id":"bcaa11bc5a874aaea9e2e258ab1d2bb9","type":"GO_TERM","name":"cadmium ion transmembrane transport","canonical_id":"go:GO:0070574","description":"\"A process in which a cadmium ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"928578002d754f1ab9e73771af45ff96","type":"GO_TERM","name":"cadmium ion transmembrane transporter activity","canonical_id":"go:GO:0015086","description":"\"Enables the transfer of cadmium (Cd) ions from one side of a membrane to the other.\" [GOC:dgf]","metadata":null},{"id":"56aa53697949439cb2795aa3d0f30a11","type":"GO_TERM","name":"cadmium ion transport","canonical_id":"go:GO:0015691","description":"\"The directed movement of cadmium (Cd) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"06262647c2a3492eaf664e6d4aa0c307","type":"DRUG","name":"cadonilimab","canonical_id":"gtopdb:12966","description":null,"metadata":null},{"id":"4f1e6bceca594e239b1383b6bfb6896c","type":"DRUG","name":"cadonilimab","canonical_id":"chembl:CHEMBL4594456","description":null,"metadata":null},{"id":"23f739275abf4621a12525063626ecec","type":"COMBINATION_TREATMENT","name":"cadonilimab + disitamab vedotin","canonical_id":"ctgov_combo:ctgov-combo-7162355bd9033d42","description":null,"metadata":null},{"id":"ac3556d209c24110ba355322ab8d5180","type":"COMBINATION_TREATMENT","name":"cadonilimab + fruquintinib","canonical_id":"ctgov_combo:ctgov-combo-00e00c3762a810a9","description":null,"metadata":null},{"id":"f9b576f56b8a4d96ab50cff5b498704c","type":"COMBINATION_TREATMENT","name":"cadonilimab + fruquintinib","canonical_id":"ctgov_combo:ctgov-combo-7acda18bf6a9bcef","description":null,"metadata":null},{"id":"7bf58a0d613e4a5aa9d244a4e931011a","type":"COMBINATION_TREATMENT","name":"cadonilimab + fruquintinib","canonical_id":"ctgov_combo:ctgov-combo-5aa189a4b74fafa9","description":null,"metadata":null},{"id":"8022d32ba6124dc98c8150a7011f2a54","type":"COMBINATION_TREATMENT","name":"cadonilimab + fruquintinib","canonical_id":"ctgov_combo:ctgov-combo-c70627471f7d352a","description":null,"metadata":null},{"id":"767f77a4171f45fab06bb03722bddfe4","type":"GO_TERM","name":"caecum development","canonical_id":"go:GO:1903700","description":"\"The process whose specific outcome is the progression of a caecum over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, ISBN:0-683-40008-8]","metadata":null},{"id":"31a65f0af5cc4069b9162bbb8dbf1674","type":"GO_TERM","name":"caffeate 3,4-dioxygenase activity","canonical_id":"go:GO:0047762","description":"\"Catalysis of the reaction: trans-caffeate + O2 = 3-(2-carboxyethenyl)-cis,cis-muconate + 2 H+.\" [EC:1.13.11.22, RHEA:22216]","metadata":null},{"id":"4e780f2bec1845108e9b6ec311c10449","type":"GO_TERM","name":"caffeate O-methyltransferase activity","canonical_id":"go:GO:0047763","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 3,4-dihydroxy-trans-cinnamate = S-adenosyl-L-homocysteine + 3-methoxy-4-hydroxy-trans-cinnamate.\" [EC:2.1.1.68]","metadata":null},{"id":"0a560ec37d5149788bbf50c0fadebf8a","type":"DRUG","name":"caffeine","canonical_id":"gtopdb:407","description":null,"metadata":null},{"id":"e91cf83784ef49238c3a18ef60ad62ac","type":"DRUG","name":"caffeine","canonical_id":"mesh:D002110","description":null,"metadata":null},{"id":"4453488199fe4d459324695d1e562931","type":"DRUG","name":"caffeine","canonical_id":"chembl:CHEMBL113","description":null,"metadata":null},{"id":"750c21dce07e47f693f33b50e4e4b34b","type":"COMBINATION_TREATMENT","name":"caffeine + chlorpheniramine","canonical_id":"ctgov_combo:ctgov-combo-027399a4ba617a6b","description":null,"metadata":null},{"id":"61443e8609dd4aefb1a634ee1f367b2d","type":"COMBINATION_TREATMENT","name":"caffeine + dexmedetomidine","canonical_id":"ctgov_combo:ctgov-combo-92a2a5b48faffbe0","description":null,"metadata":null},{"id":"0a26fc27fd2d4a0db9c1844915cabb76","type":"COMBINATION_TREATMENT","name":"caffeine + digoxin + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-5739977cee3a6801","description":null,"metadata":null},{"id":"8a833b3132b44300bf197bf4449cfc2b","type":"COMBINATION_TREATMENT","name":"caffeine + warfarin","canonical_id":"ctgov_combo:ctgov-combo-922e4bea7e5d33d6","description":null,"metadata":null},{"id":"7d9352ab843246dba6695a8440bcc843","type":"GO_TERM","name":"caffeine oxidase activity","canonical_id":"go:GO:0034875","description":"\"Catalysis of the reaction: caffeine + O2 + 2 H+ + 2 e- = 1,3,7-trimethyluric acid + H2O.\" [RHEA:47148]","metadata":null},{"id":"f9cb46ce93ea4518a7a84dadbd4c607c","type":"GO_TERM","name":"caffeine synthase activity","canonical_id":"go:GO:0102741","description":"\"Catalysis of the reaction: 1,7-dimethylxanthine + S-adenosyl-L-methionine = H+ + caffeine + S-adenosyl-L-homocysteine. Also converts theobromine to caffeine and 7-methylxanthine to theobromine.\" [EC:2.1.1.160]","metadata":null},{"id":"d87f3714bec04411bd89d886226a4584","type":"GO_TERM","name":"caffeoyl-CoA O-methyltransferase activity","canonical_id":"go:GO:0042409","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + caffeoyl-CoA = S-adenosyl-L-homocysteine + feruloyl-CoA.\" [EC:2.1.1.104]","metadata":null},{"id":"b94480bf40d1469d84f3bcc91d87afce","type":"GO_TERM","name":"caffeoyl-CoA: alcohol caffeoyl transferase activity","canonical_id":"go:GO:0090430","description":"\"Catalysis of the reaction: caffeoyl-CoA + a saturated primary alcohol = an alkyl caffeate + CoA.\" [GOC:pz]","metadata":null},{"id":"725dd47229f4432390aa157857feaf95","type":"GO_TERM","name":"calcidiol 1-monooxygenase activity","canonical_id":"go:GO:0004498","description":"\"Catalysis of the reaction: calcidiol + H+ + NADPH + O2 = calcitriol + H2O + NADP+.\" [EC:1.14.15.18, RHEA:20573]","metadata":null},{"id":"92d99575bd2040e4aa40697b7687213a","type":"GO_TERM","name":"calcidiol binding","canonical_id":"go:GO:1902118","description":"\"Binding to calcidiol.\" [GOC:bf, GOC:TermGenie, PMID:11799400]","metadata":null},{"id":"db777989efa64cb7b4aac0df57627ce0","type":"DRUG","name":"calcifediol","canonical_id":"mesh:D002112","description":null,"metadata":null},{"id":"86aac47890c54b1db3f2a65a1860f537","type":"GO_TERM","name":"calcineurin complex","canonical_id":"go:GO:0005955","description":"\"A heterodimeric calcium ion and calmodulin dependent protein phosphatase composed of catalytic and regulatory subunits; the regulatory subunit is very similar in sequence to calmodulin.\" [PMID:26794871]","metadata":null},{"id":"12443c59c0be4dd8a15969bc7ad359df","type":"GO_TERM","name":"calcineurin-NFAT signaling cascade","canonical_id":"go:GO:0033173","description":"\"Any intracellular signal transduction in which the signal is passed on within the cell by activation of a member of the NFAT protein family as a consequence of NFAT dephosphorylation by Ca(2+)-activated calcineurin. The cascade begins with calcium-dependent activation of the phosphatase calcineurin. Calcineurin dephosphorylates multiple phosphoserine residues on NFAT, resulting in the translocation of NFAT to the nucleus. The cascade ends with regulation of transcription by NFAT. The calcineurin-NFAT cascade lies downstream of many cell surface receptors, including G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) that signal to mobilize calcium ions (Ca2+).\" [GOC:lm, GOC:mah, PMID:12975316, PMID:15928679]","metadata":null},{"id":"50f3f1bedc974838b0b7eb3df823c618","type":"GO_TERM","name":"calcineurin-mediated signaling","canonical_id":"go:GO:0097720","description":"\"Any intracellular signal transduction in which the signal is passed on within the cell by activation of a transcription factor as a consequence of dephosphorylation by Ca(2+)-activated calcineurin. The process begins with calcium-dependent activation of the phosphatase calcineurin. Calcineurin is a calcium- and calmodulin-dependent serine/threonine protein phosphatase with a conserved function in eukaryotic species from yeast to humans. In yeast and fungi, calcineurin regulates stress signaling and cell cycle, and sporulation and virulence in pathogenic fungi. In metazoans, calcineurin is involved in cell commitment, organogenesis and organ development and immune function of T-lymphocytes. By a conserved mechanism, calcineurin phosphatase activates fungal Crz1 and mammalian NFATc by dephosphorylation and translocation of these transcription factors to the nucleus to regulate gene expression.\" [GOC:di, PMID:25655284, PMID:25878052, PMID:26851544]","metadata":null},{"id":"74356184612147499860078862de6aac","type":"DRUG","name":"calcipotriol","canonical_id":"gtopdb:2778","description":null,"metadata":null},{"id":"6c517996dd0246d3969bf64b181a832f","type":"COMBINATION_TREATMENT","name":"calcipotriol + clobetasol propionate","canonical_id":"ctgov_combo:ctgov-combo-7b41f6c3af22410b","description":null,"metadata":null},{"id":"ace9e781172349f8ab62d4a41012933d","type":"COMBINATION_TREATMENT","name":"calcipotriol + nortriptyline","canonical_id":"ctgov_combo:ctgov-combo-662fe579c064963f","description":null,"metadata":null},{"id":"1c57c93e96314423a330e028aa0a1316","type":"DRUG","name":"calcitonin","canonical_id":"gtopdb:685","description":null,"metadata":null},{"id":"39a5ebc22d6a4e129c18551ecf74cb1f","type":"DRUG","name":"calcitonin","canonical_id":"chembl:CHEMBL4594242","description":null,"metadata":null},{"id":"adc9eedef886445181f8ae788101ef78","type":"DRUG","name":"calcitonin (salmon)","canonical_id":"gtopdb:6973","description":null,"metadata":null},{"id":"f586d3452c5d4aebaa06e334e9ca643c","type":"COMBINATION_TREATMENT","name":"calcitonin + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-e87361da3244b53a","description":null,"metadata":null},{"id":"f61906d461614db682f0acb5f7e5bb8e","type":"COMBINATION_TREATMENT","name":"calcitonin + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-b76f1fdfdb20047e","description":null,"metadata":null},{"id":"4387e088f46d4e30b6f992d74148b765","type":"GO_TERM","name":"calcitonin binding","canonical_id":"go:GO:0032841","description":"\"Binding to calcitonin, a peptide hormone responsible for reducing serum calcium levels by inhibiting osteoclastic bone reabsorption and promoting renal calcium excretion. It is synthesized and released by the C cells of the thyroid.\" [GOC:ecd]","metadata":null},{"id":"cfcf0e5fd4a648acabcf34bf215a977f","type":"GO_TERM","name":"calcitonin catabolic process","canonical_id":"go:GO:0010816","description":"\"The chemical reactions and pathways resulting in the breakdown of the peptide calcitonin.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"27e8d4a4f6cd4087a79b30310a62b92b","type":"GO_TERM","name":"calcitonin family binding","canonical_id":"go:GO:0097644","description":"\"Binding to a member of the calcitonin family (e.g. adrenomedullin, adrenomedullin 2 (intermedin), amylin, calcitonin and calcitonin gene-related peptides (CGRPs)).\" [GOC:bhm, InterPro:IPR021116, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"c5a43049dc2f4302817cda6c6f9f975c","type":"GO_TERM","name":"calcitonin family receptor activity","canonical_id":"go:GO:0097642","description":"\"Combining with any member of the calcitonin family (e.g. adrenomedullin, adrenomedullin 2 (intermedin), amylin, calcitonin and calcitonin gene-related peptides (CGRPs)) to initiate a change in cell activity.\" [GOC:bhm, InterPro:IPR003287, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"6ee3766fcfb54a32b5e26227ee2852c1","type":"GO_TERM","name":"calcitonin family receptor complex","canonical_id":"go:GO:1903439","description":"\"A protein complex which is capable of calcitonin family receptor activity. Calcitonin family receptors may form dimers, trimers or tetramers; adrenomedullin and amylin receptors have only been observed as dimers so far.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"e722240285ff4c758bf56fd8e6150e81","type":"GO_TERM","name":"calcitonin family receptor signaling pathway","canonical_id":"go:GO:0097646","description":"\"A G protein-coupled receptor signaling pathway initiated by an extracellular member of the calcitonin family (e.g. adrenomedullin, adrenomedullin 2 (intermedin), amylin, calcitonin and calcitonin gene-related peptides (CGRPs)) binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:bhm, PMID:10871296, PMID:12037140, PMID:18687416]","metadata":null},{"id":"d09c6a3a77184d68a6004b80706b628e","type":"GO_TERM","name":"calcitonin gene-related peptide binding","canonical_id":"go:GO:1990407","description":"\"Binding to calcitonin gene-related peptide (CGRP).\" [GOC:bhm, PMID:10882736]","metadata":null},{"id":"87382733a50c497cbb41a351fdbd3018","type":"GO_TERM","name":"calcitonin gene-related peptide receptor activity","canonical_id":"go:GO:0001635","description":"\"Combining with a calcitonin gene-related polypeptide (CGRP) to initiate a change in cell activity.\" [GOC:mah, PMID:12037140]","metadata":null},{"id":"002881f092f045b2a22951c7181ce79c","type":"GO_TERM","name":"calcitonin gene-related peptide receptor signaling pathway","canonical_id":"go:GO:1990408","description":"\"The series of molecular signals initiated by an extracellular calcitonin gene-related peptide (CGRP) combining with a calcitonin gene-related peptide receptor on the surface of the target cell. Calcitonin gene-related peptide receptors may form dimers, trimers or tetramers.\" [GOC:bhm, PMID:10882736]","metadata":null},{"id":"6e4ea8fa4106487c97913eb415fab12c","type":"GO_TERM","name":"calcitonin receptor activity","canonical_id":"go:GO:0004948","description":"\"Combining with calcitonin and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:mah, GOC:signaling, PMID:21649645]","metadata":null},{"id":"11574e41cd18490c9e5525930e6e5151","type":"GO_TERM","name":"calcitonin receptor binding","canonical_id":"go:GO:0031716","description":"\"Binding to a calcitonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"48a6cb30b2ca43c3a0d49b86615fe58c","type":"GO_TERM","name":"calcitonin secretion","canonical_id":"go:GO:0036161","description":"\"The regulated release of calcitonin, a peptide hormone that participates in calcium and phosphorus metabolism, from a cell.\" [GOC:cjm]","metadata":null},{"id":"1ee7bc0dd18149ad8adfb42358830733","type":"DRUG","name":"calcitriol","canonical_id":"mesh:D002117","description":null,"metadata":null},{"id":"25c66fe5c3ab4acbbdbe486b88603442","type":"GO_TERM","name":"calcitriol binding","canonical_id":"go:GO:1902098","description":"\"Binding to calcitriol. Calcitriol (1,25-dihydroxycholecalciferol) is the hormonally active form of vitamin D3.\" [GOC:TermGenie, PMID:21872797, Wikipedia:Calcitriol_receptor]","metadata":null},{"id":"905b56df9dcb47b090c25a211623577a","type":"GO_TERM","name":"calcium activated galactosylceramide scrambling","canonical_id":"go:GO:0061591","description":"\"The movement of a population of galactosylceramide molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet as a result of a calcium stimulus.\" [GOC:krc, PMID:23532839]","metadata":null},{"id":"8d381d9777e54d7dbd7bd7e33ffe85c5","type":"GO_TERM","name":"calcium activated phosphatidylcholine scrambling","canonical_id":"go:GO:0061590","description":"\"The movement of a population of phosphatidylcholine molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet as a result of a calcium stimulus.\" [GOC:krc, PMID:23532839]","metadata":null},{"id":"4d4159572c3e4bfc99b221b6b12d1698","type":"GO_TERM","name":"calcium activated phosphatidylserine scrambling","canonical_id":"go:GO:0061589","description":"\"The movement of a population of phosphatidylserine molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet as a result of a calcium stimulus.\" [GOC:krc, PMID:23532839]","metadata":null},{"id":"ec71c66f471848f89fa50978a691d639","type":"GO_TERM","name":"calcium activated phospholipid scrambling","canonical_id":"go:GO:0061588","description":"\"The movement of a population of phospholipid molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet as a result of a calcium stimulus.\" [GOC:krc, PMID:23532839]","metadata":null},{"id":"c3fc1246e6414cdf9217081a7bfca5b1","type":"GO_TERM","name":"calcium channel activity","canonical_id":"go:GO:0005262","description":"\"Enables the energy-independent facilitated diffusion of a calcium ion through a transmembrane aqueous pore or channel.\" [GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"c9ce7cf1fc644f39a1684b47b5600069","type":"GO_TERM","name":"calcium channel complex","canonical_id":"go:GO:0034704","description":"\"An ion channel complex through which calcium ions pass.\" [GOC:mah]","metadata":null},{"id":"26b60f1e13c54867a586f9b93dc7997d","type":"GO_TERM","name":"calcium channel inhibitor activity","canonical_id":"go:GO:0019855","description":"\"Binds to and stops, prevents, or reduces the activity of a calcium channel.\" [GOC:mah]","metadata":null},{"id":"08fa331e376f40f3a89c09f89da6ebca","type":"GO_TERM","name":"calcium channel regulator activity","canonical_id":"go:GO:0005246","description":"\"Modulates the activity of a calcium channel.\" [GOC:mah]","metadata":null},{"id":"3b91b6bed6c547cd92545307df45535e","type":"DRUG","name":"calcium citrate","canonical_id":"mesh:D019355","description":null,"metadata":null},{"id":"6bc300f03d73416ab3df7b6e3265106a","type":"GO_TERM","name":"calcium export from the mitochondrion","canonical_id":"go:GO:0099093","description":"\"A process in which a calcium ion (Ca2+) is transported out of the mitochondrial matrix, and into the cytosol.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"05f9b11c739b4c56ba0f52cce2149f71","type":"DRUG","name":"calcium glubionate","canonical_id":"mesh:C042131","description":null,"metadata":null},{"id":"1c3c550a05ff499b9ad89dc0c2128e54","type":"DRUG","name":"calcium glucoheptonate","canonical_id":"mesh:C007852","description":null,"metadata":null},{"id":"5da9947abeee40b085974fc2c07c4152","type":"GO_TERM","name":"calcium import into the mitochondrion","canonical_id":"go:GO:0036444","description":"\"A process in which a calcium ion (Ca2+) is transported from the cytosol into the mitochondrial matrix.\" [GOC:vw]","metadata":null},{"id":"8e9ae5b17380420d902d8331c1f53b15","type":"GO_TERM","name":"calcium ion binding","canonical_id":"go:GO:0005509","description":"\"Binding to a calcium ion (Ca2+).\" [GOC:ai]","metadata":null},{"id":"6b9bc2df04544e03bf444e72e5e61966","type":"GO_TERM","name":"calcium ion binding involved in regulation of postsynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:0099567","description":"\"The directed change of free calcium ion concentration in the postsynaptic cytosol via the reversible binding of calcium ions to calcium-binding proteins in the cytosol thereby modulating the spatial and temporal dynamics of changes in postsynaptic cytosolic calcium concentrations.\" [PMID:24442513, PMID:26190970]","metadata":null},{"id":"1b0dcccdf6484c658de29ce2b7991e79","type":"GO_TERM","name":"calcium ion binding involved in regulation of presynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:0099534","description":"\"The directed change of presynaptic cytosolic free calcium ion concentration in the cytosol via the reversible binding of calcium ions to calcium-binding proteins in the cytosol thereby modulating the spatial and temporal dynamics of changes in presynaptic cytosolic calcium concentrations.\" [PMID:24442513, PMID:26190970]","metadata":null},{"id":"4b7c9c1075484457bcdec2a255e46bdf","type":"GO_TERM","name":"calcium ion export","canonical_id":"go:GO:1901660","description":"\"The directed movement of calcium ion out of a cell or organelle.\" [GOC:TermGenie]","metadata":null},{"id":"fc8a6154996a41ba88b5bcef2c2cf864","type":"GO_TERM","name":"calcium ion export across plasma membrane","canonical_id":"go:GO:1990034","description":"\"The directed movement of calcium ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:mah, PMID:2145281]","metadata":null},{"id":"60574143627f44f493722e9aa5407f95","type":"GO_TERM","name":"calcium ion homeostasis","canonical_id":"go:GO:0055074","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions within an organism or cell.\" [GOC:ceb, GOC:jid, GOC:mah]","metadata":null},{"id":"db131c3b852b48798a815808c704e957","type":"GO_TERM","name":"calcium ion import","canonical_id":"go:GO:0070509","description":"\"The directed movement of calcium ions into a cell or organelle.\" [GOC:mah]","metadata":null},{"id":"e91afad857e54fee8f43a7df9f9e61c5","type":"GO_TERM","name":"calcium ion import across plasma membrane","canonical_id":"go:GO:0098703","description":"\"The directed movement of calcium ions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"bb30205a2e7b45aa8140e66916eb345f","type":"GO_TERM","name":"calcium ion import into cytosol","canonical_id":"go:GO:1902656","description":"\"The directed movement of calcium ion into a cytosol.\" [GO_REF:0000075, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"8b5a40477ef24744a73887e6983ca614","type":"GO_TERM","name":"calcium ion import into sarcoplasmic reticulum","canonical_id":"go:GO:1990036","description":"\"The directed movement of calcium ions into a sarcoplasmic reticulum.\" [GOC:BHF, PMID:17286271]","metadata":null},{"id":"5721939bf4624c77b984b345a866a832","type":"GO_TERM","name":"calcium ion import into vacuole","canonical_id":"go:GO:0140146","description":"\"The directed movement of calcium cations into the vacuole across the vacuolar membrane.\" [GOC:vw, PMID:8628289]","metadata":null},{"id":"80166cd457f34108b0692b869887a8fa","type":"GO_TERM","name":"calcium ion regulated lysosome exocytosis","canonical_id":"go:GO:1990927","description":"\"The process of secretion by a cell that results in the release of intracellular molecules contained within a lysosome by fusion of the vesicle with the plasma membrane of a cell, induced by a rise in cytosolic calcium-ion levels.\" [PMID:10725327, PMID:11511344]","metadata":null},{"id":"38ab32808ada4f6689f7776c646184eb","type":"GO_TERM","name":"calcium ion sensor activity","canonical_id":"go:GO:0061891","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of calcium ions (Ca2+).\" [PMID:16005298, PMID:17020874, PMID:28151650]","metadata":null},{"id":"82ecd6d2788747d4a103a1724f1be3c0","type":"GO_TERM","name":"calcium ion sequestering activity","canonical_id":"go:GO:0140314","description":"\"Binding to a calcium ion to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:13130076]","metadata":null},{"id":"3ffec14701a94d85a6da4458fe06e4c4","type":"GO_TERM","name":"calcium ion transmembrane import into cytosol","canonical_id":"go:GO:0097553","description":"\"A process in which a calcium ion is transported from one side of a membrane to the other into the cytosol by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"e43cc45b18a14e12aa53058a9b7e1d95","type":"GO_TERM","name":"calcium ion transmembrane transport","canonical_id":"go:GO:0070588","description":"\"A process in which a calcium ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"d9160f5716d848ca90ab18a469095542","type":"GO_TERM","name":"calcium ion transmembrane transport via high voltage-gated calcium channel","canonical_id":"go:GO:0061577","description":"\"A process in which a calcium ion is transported from one side of a membrane to the other by means of a high voltage-gated calcium channel.\" [GOC:dph]","metadata":null},{"id":"f3c997e1a4fc42259998954c074b3ab3","type":"GO_TERM","name":"calcium ion transmembrane transport via low voltage-gated calcium channel","canonical_id":"go:GO:0090676","description":"\"A process in which a calcium ion is transported from one side of a membrane to the other by means of a low voltage-gated calcium channel.\" [GOC:bf, GOC:PARL, PMID:20371816]","metadata":null},{"id":"2c705dd396a1487b9ffe55c1df924afe","type":"GO_TERM","name":"calcium ion transmembrane transporter activity","canonical_id":"go:GO:0015085","description":"\"Enables the transfer of calcium (Ca) ions from one side of a membrane to the other.\" [GOC:dgf]","metadata":null},{"id":"f521aa059dcd411495600117b218bae2","type":"GO_TERM","name":"calcium ion transport","canonical_id":"go:GO:0006816","description":"\"The directed movement of calcium (Ca) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"d7971e45425d434e9267c34acfa78e2a","type":"GO_TERM","name":"calcium ion transport from cytosol to endoplasmic reticulum","canonical_id":"go:GO:1903515","description":"\"The directed movement of calcium ion from cytosol to endoplasmic reticulum.\" [GO_REF:0000078, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:16402920]","metadata":null},{"id":"d7f30a0b60004e60a458195f7b326bc6","type":"GO_TERM","name":"calcium ion transport into cytosol","canonical_id":"go:GO:0060402","description":"\"The directed movement of calcium ions (Ca2+) into the cytosol.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8c0f5c155d294798a0fff3424442225d","type":"GO_TERM","name":"calcium ion-regulated exocytosis of neurotransmitter","canonical_id":"go:GO:0048791","description":"\"The release of a neurotransmitter into the synaptic cleft by exocytosis of synaptic vesicles, where the release step is dependent on a rise in cytosolic calcium ion levels.\" [GOC:curators]","metadata":null},{"id":"050a9456b7a947e1a7d5aac1ef0f260b","type":"GO_TERM","name":"calcium ion-transporting ATPase complex","canonical_id":"go:GO:0090534","description":"\"Protein complex that carries out the reaction: ATP + H2O + Ca2+(out) = ADP + phosphate + Ca2+(in).\" [GOC:BHF]","metadata":null},{"id":"f992f11edc1e413b9194bcb068cd4792","type":"DISEASE","name":"calcium metabolic disease","canonical_id":"mondo:0005557","description":null,"metadata":null},{"id":"857e4c64ce6647cc89617af4ab4d6f3e","type":"GO_TERM","name":"calcium oxalate binding","canonical_id":"go:GO:0046904","description":"\"Binding to calcium oxalate, CaC2O4, a salt of oxalic acid. In animals, it may be excreted in urine or retained in the form of urinary calculi.\" [ISBN:0721662544]","metadata":null},{"id":"a7c5fa4209ee4ddfb42c7865b88a2c80","type":"DRUG","name":"calcium phosphate","canonical_id":"mesh:C020243","description":null,"metadata":null},{"id":"4fbbde349374499eb1b5b7188d5160ba","type":"DRUG","name":"calcium polystyrene sulfonate","canonical_id":"mesh:C003321","description":null,"metadata":null},{"id":"26e056426a9642d28e446e27000c23c1","type":"GO_TERM","name":"calcium sensitive guanylate cyclase activator activity","canonical_id":"go:GO:0008048","description":"\"Binds to and increases the activity of guanylate cyclase in response to a change in calcium ion concentration.\" [GOC:mah]","metadata":null},{"id":"67169796953c452a9d3011cdd62d45be","type":"GO_TERM","name":"calcium, potassium:sodium antiporter activity","canonical_id":"go:GO:0008273","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Ca2+(in) + K+(in) + Na+(out) = Ca2+(out) + K+(out) + Na+(in).\" [TC:2.A.19.4.1]","metadata":null},{"id":"1245c3438e7d404c9bb9d4d75133c59f","type":"GO_TERM","name":"calcium,diacylglycerol-dependent serine/threonine kinase activity","canonical_id":"go:GO:0004698","description":"\"Calcium-dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein. This reaction is activated in the presence of diacylglycerol and calcium.\" [PMID:34834162]","metadata":null},{"id":"ee56760ca7034a2c803cfc025600e843","type":"GO_TERM","name":"calcium- and calmodulin-dependent protein kinase complex","canonical_id":"go:GO:0005954","description":"\"An enzyme complex which in eukaryotes is composed of four different chains: alpha, beta, gamma, and delta. The different isoforms assemble into homo- or heteromultimeric holoenzymes composed of 8 to 12 subunits. Catalyzes the phosphorylation of proteins to O-phosphoproteins.\" [PMID:20668654]","metadata":null},{"id":"46b50a7c46894bdf99b2f1deccb888d4","type":"GO_TERM","name":"calcium- and calmodulin-responsive adenylate cyclase activity","canonical_id":"go:GO:0008294","description":"\"Catalysis of the reaction: ATP = 3',5'-cyclic AMP + diphosphate, stimulated by calcium-bound calmodulin.\" [GOC:mah, PMID:1739965]","metadata":null},{"id":"fa6b0dd58db84952a8c1ceff58c277f3","type":"GO_TERM","name":"calcium-activated cation channel activity","canonical_id":"go:GO:0005227","description":"\"Enables the transmembrane transfer of an inorganic cation by a channel that opens when a calcium cation has been bound by the channel complex or one of its constituent parts.\" [GOC:dph, GOC:mtg_transport]","metadata":null},{"id":"47ee8e0f7c564cdfbcc91b90f483022d","type":"GO_TERM","name":"calcium-activated potassium channel activity","canonical_id":"go:GO:0015269","description":"\"Enables the transmembrane transfer of a potassium cation by a channel that opens when a calcium cation has been bound by the channel complex or one of its constituent parts.\" [GOC:dph, GOC:mtg_transport]","metadata":null},{"id":"2d03619da46b4887a8b63c36415cd551","type":"GO_TERM","name":"calcium-dependent ATPase activity","canonical_id":"go:GO:0030899","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate. This reaction requires the presence of calcium ion (Ca2+).\" [GOC:mah]","metadata":null},{"id":"6970c79c7d044b1e8a236f073743a640","type":"GO_TERM","name":"calcium-dependent activation of synaptic vesicle fusion","canonical_id":"go:GO:0099502","description":"\"The regulatory process by which increased cytosolic calcium levels lead to the the fusion of synaptic vesicles with the presynaptic active zone membrane by bringing primed synaptic vesicle membrane into contact with membrane presynaptic active zone membrane.\" [PMID:23060190]","metadata":null},{"id":"edda549ecd074dd9b53e95fb57f98c41","type":"GO_TERM","name":"calcium-dependent carbohydrate binding","canonical_id":"go:GO:0120153","description":"\"Binding to a carbohydrate in the presence of calcium.\" [PMID:25912189]","metadata":null},{"id":"8a0e85cd1ffa444faf6eb6f8e40fd6ab","type":"GO_TERM","name":"calcium-dependent cell-cell adhesion","canonical_id":"go:GO:0016339","description":"\"The attachment of one cell to another cell via adhesion molecules that require the presence of calcium for the interaction.\" [GOC:hb]","metadata":null},{"id":"3912e6b7d85f4715b7c19b7dcc4939c7","type":"GO_TERM","name":"calcium-dependent cell-matrix adhesion","canonical_id":"go:GO:0016340","description":"\"The binding of a cell to the extracellular matrix via adhesion molecules that require the presence of calcium for the interaction.\" [GOC:hb]","metadata":null},{"id":"a91fb329f08b4458bea19ffadc2120c4","type":"GO_TERM","name":"calcium-dependent cysteine-type endopeptidase activity","canonical_id":"go:GO:0004198","description":"\"Catalysis of the hydrolysis of nonterminal peptide bonds in a polypeptide chain by a mechanism using a cysteine residue at the enzyme active center, and requiring the presence of calcium.\" [GOC:mah]","metadata":null},{"id":"e70558ac91a74af982951d01df7ad2e4","type":"GO_TERM","name":"calcium-dependent cysteine-type endopeptidase inhibitor activity","canonical_id":"go:GO:0010859","description":"\"Binds to and stops, prevents or reduces the activity of a calcium-dependent cysteine-type endopeptidase, any enzyme that hydrolyzes peptide bonds in polypeptides by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile in a calcium-dependent manner.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9541fb1d1a8240fa824872efc4beabab","type":"GO_TERM","name":"calcium-dependent outer dynein arm binding","canonical_id":"go:GO:0120152","description":"\"Binding to an outer dynein arm in the presence of calcium.\" [GOC:krc, PMID:18620543]","metadata":null},{"id":"0f61ad3b9d64417fbf981ec35bc4f760","type":"GO_TERM","name":"calcium-dependent phospholipid binding","canonical_id":"go:GO:0005544","description":"\"Binding to a phospholipid, a class of lipids containing phosphoric acid as a mono- or diester, in the presence of calcium.\" [GOC:jl]","metadata":null},{"id":"90328222234e421cb230719544616698","type":"GO_TERM","name":"calcium-dependent protein binding","canonical_id":"go:GO:0048306","description":"\"Binding to a protein or protein complex in the presence of calcium.\" [GOC:jid, PMID:10485905]","metadata":null},{"id":"80f2900fd67d4639b2f09bc8cc00c29e","type":"GO_TERM","name":"calcium-dependent protein kinase inhibitor activity","canonical_id":"go:GO:0008427","description":"\"Binds to and stops, prevents or reduces the activity of a calcium-dependent protein kinase.\" [GOC:mah]","metadata":null},{"id":"bad2bd175efb47738e56914f74693bb5","type":"GO_TERM","name":"calcium-dependent protein kinase regulator activity","canonical_id":"go:GO:0010858","description":"\"Modulates the activity of a calcium-dependent protein kinase, an enzyme which phosphorylates a protein in a calcium-dependent manner.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"dd67acff893845ddaf47bf6d518a2479","type":"GO_TERM","name":"calcium-dependent protein serine/threonine kinase activity","canonical_id":"go:GO:0009931","description":"\"Calcium-dependent catalysis of the reactions: ATP + a protein serine = ADP + protein serine phosphate; and ATP + a protein threonine = ADP + protein threonine phosphate.\" [GOC:mah]","metadata":null},{"id":"5034942d840f45c58aaf000958a05a12","type":"GO_TERM","name":"calcium-dependent protein serine/threonine phosphatase activity","canonical_id":"go:GO:0004723","description":"\"Catalysis of the reactions: protein serine phosphate + H2O = protein serine + phosphate; and protein threonine phosphate + H2O = protein threonine + phosphate. These reactions require the presence of calcium ions.\" [GOC:mah]","metadata":null},{"id":"d3fd5f74f4a743beb71c2da2e7e8cfca","type":"GO_TERM","name":"calcium-dependent protein serine/threonine phosphatase regulator activity","canonical_id":"go:GO:0008597","description":"\"Binds to and modulates of the activity of the enzyme calcium-dependent protein serine/threonine phosphatase.\" [GOC:ai]","metadata":null},{"id":"859ca90b344f4de48a0813895480522c","type":"GO_TERM","name":"calcium-dependent self proteolysis","canonical_id":"go:GO:1990092","description":"\"The calcium-dependent hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their own peptide bonds.\" [PMID:20460380]","metadata":null},{"id":"49831205fc45441093d9609109266307","type":"GO_TERM","name":"calcium-independent cell-cell adhesion","canonical_id":"go:GO:0016338","description":"\"The attachment of one cell to another cell via adhesion molecules that do not require the presence of calcium for the interaction.\" [GOC:hb]","metadata":null},{"id":"4f5759a14c044021943f995ba5202536","type":"GO_TERM","name":"calcium-independent cell-matrix adhesion","canonical_id":"go:GO:0007161","description":"\"The binding of a cell to the extracellular matrix via adhesion molecules that do not require the presence of calcium for the interaction.\" [GOC:hb]","metadata":null},{"id":"c0da1ec894c84580b349a6004ea142f1","type":"GO_TERM","name":"calcium-induced calcium release activity","canonical_id":"go:GO:0048763","description":"\"Enables transmembrane transfer of calcium ions from an intracellular store to the cytosol on induction by increased calcium concentration.\" [GOC:jid, GOC:nln, PMID:2990997, PMID:8381210, PMID:8653752]","metadata":null},{"id":"abaeb7fdcc6a451bb1fefcb1613fda26","type":"GO_TERM","name":"calcium-ion regulated exocytosis","canonical_id":"go:GO:0017156","description":"\"The release of intracellular molecules (e.g. hormones, matrix proteins) contained within a membrane-bounded vesicle by fusion of the vesicle with the plasma membrane of a cell, induced by a rise in cytosolic calcium-ion levels.\" [GOC:curators]","metadata":null},{"id":"03edc73277c745ea97c1fd0ce6f6a7de","type":"GO_TERM","name":"calcium-mediated signaling","canonical_id":"go:GO:0019722","description":"\"Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions.\" [GOC:signaling]","metadata":null},{"id":"bfd9c76973e644ecb80f6ab1ae58523f","type":"GO_TERM","name":"calcium/calmodulin-dependent protein kinase activity","canonical_id":"go:GO:0004683","description":"\"Calmodulin-dependent catalysis of the reactions: ATP + a protein serine = ADP + protein serine phosphate; and ATP + a protein threonine = ADP + protein threonine phosphate. This activity require the presence of calcium-bound calmodulin.\" [GOC:mah, PMID:11264466]","metadata":null},{"id":"5dde8bbc649c422393299fa53ad7f1bc","type":"GO_TERM","name":"calcium:manganese antiporter activity","canonical_id":"go:GO:0140983","description":"\"Catalysis of the reaction: Ca2+(in) + Mn2+(out) = Ca2+(out) + Mn2+(in).\" [PMID:30755481]","metadata":null},{"id":"86be5a60cae84606b716748f14d80bc3","type":"GO_TERM","name":"calcium:monoatomic cation antiporter activity","canonical_id":"go:GO:0015368","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Ca2+(in) + cation(out) = Ca2+(out) + cation(in).\" [TC:2.A.19.-.-]","metadata":null},{"id":"535459ca189843a0a56838710e59a437","type":"GO_TERM","name":"calcium:monoatomic cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:1905060","description":"\"Any calcium:cation antiporter activity that is involved in regulation of postsynaptic cytosolic calcium ion concentration.\" [GO_REF:0000061, GOC:TermGenie, PMID:18024055]","metadata":null},{"id":"068c4c1a95a545c080ddc11b5a892c88","type":"GO_TERM","name":"calcium:proton antiporter activity","canonical_id":"go:GO:0015369","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Ca2+(in) + H+(out) = Ca2+(out) + H+(in).\" [RHEA:71799, TC:2.A.19.2.-]","metadata":null},{"id":"1ce1daa70d7743e7a0c20bbcced2d06d","type":"GO_TERM","name":"calcium:proton antiporter complex","canonical_id":"go:GO:0061993","description":"\"A protein complex that enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Ca2+(in) + H+(out) = Ca2+(out) + H+(in).\" [GOC:bhm, PMID:19098009, PMID:28645169]","metadata":null},{"id":"2c110b42d95e4e1ca611b4548a21b0af","type":"GO_TERM","name":"calcium:sodium antiporter activity","canonical_id":"go:GO:0005432","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Ca2+(in) + Na+(out) = Ca2+(out) + Na+(in).\" [GOC:curators, PMID:16371597]","metadata":null},{"id":"0bf94f87c05e4631a64dbe2665944159","type":"GO_TERM","name":"calcium:sodium antiporter activity involved in regulation of cardiac muscle cell membrane potential","canonical_id":"go:GO:0086038","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Ca2+(in) + Na+(out) = Ca2+(out) + Na+(in), which contributes to regulating the membrane potential of a cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"cf86318a00174926960b1de026200881","type":"GO_TERM","name":"callose deposition in cell wall","canonical_id":"go:GO:0052543","description":"\"Any process in which callose is transported to, and/or maintained in, the cell wall. Callose is a linear 1,3-beta-d-glucan formed from UDP-glucose and is found in certain plant cell walls.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"92a2efedefeb4523a5faaa00fff1f18f","type":"GO_TERM","name":"callose deposition in phloem sieve plate","canonical_id":"go:GO:0080165","description":"\"Any process in which callose is transported to, and/or maintained in, phloem sieve plate. Callose is a linear 1,3-beta-d-glucan formed from UDP-glucose and is found in certain plant cell walls.\" [PMID:19470642]","metadata":null},{"id":"187a0f5b5fc94789b50a2058022460b6","type":"GO_TERM","name":"callose localization","canonical_id":"go:GO:0052545","description":"\"Any process in which callose is transported to, and/or maintained in, a specific location. Callose is a linear 1,3-beta-d-glucan formed from UDP-glucose and is found in certain plant cell walls.\" [GOC:mtg_pamgo_17jul06, PMID:18397379]","metadata":null},{"id":"85fe7585d8fd42eb93292d321b5a9497","type":"GO_TERM","name":"callus formation","canonical_id":"go:GO:1990110","description":"\"The process by which a callus is formed at a wound site. A plant callus is a portion of plant tissue that consists of mass of undifferentiated plant cells. It consists primarily of parenchyma cells but possibly contains other cell types as the callus begins to differentiate.\" [ISBN:0070187517]","metadata":null},{"id":"397ea9d671684ef9a2f0003c58ee33cc","type":"GO_TERM","name":"calmodulin binding","canonical_id":"go:GO:0005516","description":"\"Binding to calmodulin, a calcium-binding protein with many roles, both in the calcium-bound and calcium-free states.\" [GOC:krc]","metadata":null},{"id":"4779208de5d748dab911b7a84d13cbab","type":"GO_TERM","name":"calmodulin-activated 3',5'-cyclic-AMP phosphodiesterase activity","canonical_id":"go:GO:0140761","description":"\"Catalysis of the reactions: nucleoside 3',5'-cyclic AMP + H2O = AMP + H+; this activity is activated by binding to calcium-bound calmodulin.\" [PMID:15901640]","metadata":null},{"id":"52bdb21668be41d6b422422f2e740c1d","type":"GO_TERM","name":"calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity","canonical_id":"go:GO:0048101","description":"\"Catalysis of the reactions: nucleoside 3',5'-cyclic GMP + H2O = GMP + H+; this activity is activated by binding to calcium-bound calmodulin.\" [GOC:jid, PMID:35216259]","metadata":null},{"id":"62d562b41cd34d9ab1d7bdd9391713e5","type":"GO_TERM","name":"calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity","canonical_id":"go:GO:0004117","description":"\"Catalysis of the reactions: 3',5'-cyclic AMP + H2O = AMP + H+ and 3',5'-cyclic GMP + H2O = GMP + H+; this activity is activated by binding to calcium-bound calmodulin.\" [PMID:8557689, PMID:9419816]","metadata":null},{"id":"7d1531bbd6f94677a157a8039a2834db","type":"GO_TERM","name":"calmodulin-dependent protein phosphatase activity","canonical_id":"go:GO:0033192","description":"\"Catalysis of the reaction: protein serine/threonine phosphate + H2O = protein serine/threonine + phosphate, dependent on the presence of calcium-bound calmodulin.\" [GOC:mah, PMID:15359118]","metadata":null},{"id":"c8f6d11595ab492b802ea9a6dcde970c","type":"GO_TERM","name":"calmodulin-lysine N-methyltransferase activity","canonical_id":"go:GO:0018025","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + calmodulin L-lysine = S-adenosyl-L-homocysteine + calmodulin N6-methyl-L-lysine.\" [EC:2.1.1.60]","metadata":null},{"id":"4f24ad3ac5414b3b86e2f213e33900bb","type":"GO_TERM","name":"calpain complex","canonical_id":"go:GO:0110158","description":"\"A calcium-dependent protease complex that processes its substrate by limited proteolysis rather than degrading it. In some cases limited proteolysis is required for the activation of its substrate.\" [GOC:bhm, PMID:10639123]","metadata":null},{"id":"16195182eda44d689dfb205c269b0623","type":"GO_TERM","name":"calprotectin complex","canonical_id":"go:GO:1990660","description":"\"A protein complex composed of S100A8 and S100A9 and capable of limiting Mn(2+) and Zn(2+) availability at sites of infection. Also binds Ca(2+). Expressed and released by neutrophils and epithelial cells, it exhibits broad-spectrum antimicrobial activity attributed to its metal-binding properties. Endogenous ligand of toll-like receptor 4 (TLR4) and of the receptor for advanced glycation end products (RAGE) initiating signal transduction through NF-kappa-B pathways.\" [GOC:bhm, PMID:25417112]","metadata":null},{"id":"3a2fa0e6921243859ee252ce6ff83f24","type":"GO_TERM","name":"calyx of Held","canonical_id":"go:GO:0044305","description":"\"The terminal specialization of a calyciferous axon which forms large synapses in the mammalian auditory central nervous system.\" [NIF_Subcellular:sao1684283879, PMID:11823805]","metadata":null},{"id":"c69e6cc712324925af4887dfbedfa174","type":"GO_TERM","name":"camalexin binding","canonical_id":"go:GO:2001147","description":"\"Binding to camalexin.\" [GOC:obol]","metadata":null},{"id":"f5810902d217495ea13a2b61aba32101","type":"GO_TERM","name":"camalexin biosynthetic process","canonical_id":"go:GO:0010120","description":"\"The chemical reactions and pathways resulting in the formation of camalexin, an indole phytoalexin.\" [GOC:pz]","metadata":null},{"id":"2f4b0a09f9b04c40a1fa882c6957463d","type":"GO_TERM","name":"camelliol C synthase activity","canonical_id":"go:GO:0090438","description":"\"Catalyzes the reaction: (S)-2,3-epoxysqualene = camelliol C.\" [PMID:17985917, RHEA:31011]","metadata":null},{"id":"8498af74b98048bd9b0b7f6c11bc0d14","type":"GO_TERM","name":"camera-type eye development","canonical_id":"go:GO:0043010","description":"\"The process whose specific outcome is the progression of the camera-type eye over time, from its formation to the mature structure. The camera-type eye is an organ of sight that receives light through an aperture and focuses it through a lens, projecting it on a photoreceptor field.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"f19e81ba51cb457b9dc498686763f92f","type":"GO_TERM","name":"camera-type eye morphogenesis","canonical_id":"go:GO:0048593","description":"\"The process in which the anatomical structures of the eye are generated and organized. The camera-type eye is an organ of sight that receives light through an aperture and focuses it through a lens, projecting it on a photoreceptor field.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"5f46b424e8324d75a19cd677c5984375","type":"GO_TERM","name":"camera-type eye photoreceptor cell development","canonical_id":"go:GO:0062139","description":"\"The process whose specific outcome is the progression of a light-responsive receptor in a camera-type eye over time, from its formation to the mature structure.\" [PMID:20648062, PMID:30237290]","metadata":null},{"id":"d51b8439a1c74c0bb46f491cf9959270","type":"GO_TERM","name":"camera-type eye photoreceptor cell differentiation","canonical_id":"go:GO:0060219","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a photoreceptor cell in a camera-type eye.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b4d0dc11627c4b55a90863a7e6a9298f","type":"GO_TERM","name":"camera-type eye photoreceptor cell fate commitment","canonical_id":"go:GO:0060220","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a photoreceptor cell in a camera-type eye.\" [GOC:dph]","metadata":null},{"id":"b409a143f52f4ad88c8269ea24e4e6a3","type":"DRUG","name":"camostat","canonical_id":"gtopdb:6432","description":null,"metadata":null},{"id":"f038ef0ed16047b4abe2feb8ad15ded8","type":"GO_TERM","name":"camphene synthase activity","canonical_id":"go:GO:0102703","description":"\"Catalysis of the reaction: geranyl diphosphate = (-)-camphene + diphosphoric acid.\" [EC:4.2.3.117, GOC:pz]","metadata":null},{"id":"b7d0b55f2eae4fdb81a7291cf05e74e5","type":"DRUG","name":"camphor","canonical_id":"mesh:D002164","description":null,"metadata":null},{"id":"449bb74136254d5c95fe4df657ed5d51","type":"GO_TERM","name":"camphor 5-monooxygenase activity","canonical_id":"go:GO:0018683","description":"\"Catalysis of the reaction: (+)-camphor + putidaredoxin + O2 = (+)-exo-5-hydroxycamphor + oxidized putidaredoxin + H2O.\" [EC:1.14.15.1]","metadata":null},{"id":"22d0b692324e457192fdbb88315fc5aa","type":"DISEASE","name":"camptodactyly-tall stature-scoliosis-hearing loss syndrome","canonical_id":"mondo:0012504","description":null,"metadata":null},{"id":"d142ec41e8b4406281e0335dcb91080e","type":"DRUG","name":"canagliflozin","canonical_id":"gtopdb:4582","description":null,"metadata":null},{"id":"a873f15ed5a449f5be6088c8d31620f5","type":"DRUG","name":"canagliflozin","canonical_id":"chembl:CHEMBL4594217","description":null,"metadata":null},{"id":"e5b398698b2a4d9093aca82d05583dfb","type":"COMBINATION_TREATMENT","name":"canagliflozin + dapagliflozin + empagliflozin","canonical_id":"ctgov_combo:ctgov-combo-7b8658b0f2bb028c","description":null,"metadata":null},{"id":"57333be1103f4e47ba32239a1fbbb57f","type":"COMBINATION_TREATMENT","name":"canagliflozin + linagliptin + vildagliptin","canonical_id":"ctgov_combo:ctgov-combo-3c62396422911043","description":null,"metadata":null},{"id":"0c4d92b73b4d468abb9965aae302ddb4","type":"COMBINATION_TREATMENT","name":"canagliflozin + pioglitazone + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-e8c3bd05308a62ed","description":null,"metadata":null},{"id":"44620992140540be891d1cb1b8bb0740","type":"COMBINATION_TREATMENT","name":"canagliflozin + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-d83f40e63faff074","description":null,"metadata":null},{"id":"86e7c56bdbf64f45843a2e2671beedbd","type":"COMBINATION_TREATMENT","name":"canagliflozin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-dea6f80135dfea0e","description":null,"metadata":null},{"id":"0e33138c95c549188fdd05161f65d222","type":"COMBINATION_TREATMENT","name":"canagliflozin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-2cef77f063ae5289","description":null,"metadata":null},{"id":"e152d8d7ef9d479883349848e745fe36","type":"COMBINATION_TREATMENT","name":"canagliflozin + teneligliptin","canonical_id":"ctgov_combo:ctgov-combo-7a5d84fa8742d47e","description":null,"metadata":null},{"id":"164804ab24bd4553855b84f54f2641e9","type":"COMBINATION_TREATMENT","name":"canagliflozin + teneligliptin","canonical_id":"ctgov_combo:ctgov-combo-3d1ff5dd9d3d20fc","description":null,"metadata":null},{"id":"b1e1c12bc5514a2397aabdec7bea2ca9","type":"DRUG","name":"canakinumab","canonical_id":"gtopdb:6773","description":null,"metadata":null},{"id":"eacba4a3592a413993ae870f54712222","type":"DRUG","name":"canakinumab","canonical_id":"chembl:CHEMBL1201834","description":null,"metadata":null},{"id":"e7b29031fe724ebd9839c7162089185d","type":"COMBINATION_TREATMENT","name":"canakinumab + capmatinib","canonical_id":"ctgov_combo:ctgov-combo-679639b41f1fb4ab","description":null,"metadata":null},{"id":"124d70ef332642249470cdfb33f96a65","type":"GO_TERM","name":"canalicular bile acid transmembrane transporter activity","canonical_id":"go:GO:0015126","description":"\"The directed movement of bile acid and bile salts out of a hepatocyte and into the bile canaliculus by means of an agent such as a transporter or pore. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.\" [GOC:dph]","metadata":null},{"id":"a85a68e68f514ab6a94a0803127046e4","type":"GO_TERM","name":"canalicular bile acid transport","canonical_id":"go:GO:0015722","description":"\"Enables the transfer of bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.\" [GOC:dph]","metadata":null},{"id":"4c371a2ab8f748cb90a2bbc873925fa2","type":"DISEASE","name":"cancer","canonical_id":"mondo:0004992","description":null,"metadata":null},{"id":"c8b2b8eb7e8e4f249c5f0a106b8a7ff7","type":"GO_TERM","name":"candelabrum cell differentiation","canonical_id":"go:GO:0021712","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature candelabrum cell. Differentiation includes the processes involved in commitment of a neuroblast to a candelabrum cell fate. A candelabrum cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"8bcae3edbe8f4b95bdf3f463772e57ba","type":"DRUG","name":"candesartan","canonical_id":"gtopdb:587","description":null,"metadata":null},{"id":"9df6f12318034574ae12f711b958d5e5","type":"DRUG","name":"candesartan","canonical_id":"chembl:CHEMBL1016","description":null,"metadata":null},{"id":"d3212194424341ca8ae56a1a5a26bf04","type":"COMBINATION_TREATMENT","name":"candesartan + captopril + enalapril + eplerenone + lisinopril + ramipril + trandolapril","canonical_id":"ctgov_combo:ctgov-combo-feecd4fe926ed555","description":null,"metadata":null},{"id":"6508d7ed16b34087ae8812a8087e2da4","type":"COMBINATION_TREATMENT","name":"candesartan + chlorothiazide + chlorthalidone + hydrochlorothiazide + valsartan","canonical_id":"ctgov_combo:ctgov-combo-42773567f6f2fd68","description":null,"metadata":null},{"id":"6ca762ea8e124cbf9a7e82e3203e5c68","type":"COMBINATION_TREATMENT","name":"candesartan + chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-a965cb1e2396b1eb","description":null,"metadata":null},{"id":"e3915d8f5df84c03b1e13479e5273060","type":"COMBINATION_TREATMENT","name":"candesartan + enalapril","canonical_id":"ctgov_combo:ctgov-combo-738d20c35927422d","description":null,"metadata":null},{"id":"d940b81f099c4839bc2c7f0e7266286d","type":"COMBINATION_TREATMENT","name":"candesartan + enalapril + losartan + ramipril + valsartan","canonical_id":"ctgov_combo:ctgov-combo-3a2208d58601d5ec","description":null,"metadata":null},{"id":"f7a1e3eadce34c119509ae7eada5e2e5","type":"COMBINATION_TREATMENT","name":"candesartan + ezetimibe","canonical_id":"ctgov_combo:ctgov-combo-659e730644fa7243","description":null,"metadata":null},{"id":"ec6854913e41413193a058f51ac4776c","type":"COMBINATION_TREATMENT","name":"candesartan + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-17c941aa81c3e9ff","description":null,"metadata":null},{"id":"303561fe0fbb4ef19a30e38faf740b9b","type":"COMBINATION_TREATMENT","name":"candesartan + perindopril","canonical_id":"ctgov_combo:ctgov-combo-889a5f0da168563c","description":null,"metadata":null},{"id":"74343e1374d944a197a64d39a1eb2936","type":"COMBINATION_TREATMENT","name":"candesartan + ramipril","canonical_id":"ctgov_combo:ctgov-combo-3cb8bfadbab41649","description":null,"metadata":null},{"id":"62a978ecfa1f419997966d45fc439ebb","type":"COMBINATION_TREATMENT","name":"candesartan + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-0da29dbecc1662b1","description":null,"metadata":null},{"id":"df3d12adfa174dd18bd9b8497b605cfd","type":"GO_TERM","name":"candicidin biosynthetic process","canonical_id":"go:GO:1901127","description":"\"The chemical reactions and pathways resulting in the formation of candicidin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00101]","metadata":null},{"id":"0a47cb886a9840fb904a13d44d77393c","type":"GO_TERM","name":"candicidin catabolic process","canonical_id":"go:GO:1901126","description":"\"The chemical reactions and pathways resulting in the breakdown of candicidin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00101]","metadata":null},{"id":"de545eedc8f94bb0984834618f5d4151","type":"DRUG","name":"cangrelor","canonical_id":"gtopdb:1776","description":null,"metadata":null},{"id":"4c1cfb5c7e504841b1276334539a077d","type":"DRUG","name":"cangrelor","canonical_id":"chembl:CHEMBL334966","description":null,"metadata":null},{"id":"2f5664fa43e2413580bcf923bc2dfc6c","type":"COMBINATION_TREATMENT","name":"cangrelor + ticagrelor","canonical_id":"ctgov_combo:ctgov-combo-c9fd66706fce34a5","description":null,"metadata":null},{"id":"76da4e25837b45308132d2bb4c2cb495","type":"COMBINATION_TREATMENT","name":"cangrelor + tirofiban","canonical_id":"ctgov_combo:ctgov-combo-535805a0d2529edd","description":null,"metadata":null},{"id":"b9a10d7e8f1a426ba7e06b1290eae718","type":"GO_TERM","name":"cannabidiolate synthase activity","canonical_id":"go:GO:0102779","description":"\"Catalysis of the reaction: cannabigerolate + O2 = cannabidiolate + H2O2.\" [RHEA:34411]","metadata":null},{"id":"5f58d65ff6f746949f2de1076cf90c71","type":"GO_TERM","name":"cannabinoid biosynthetic process","canonical_id":"go:GO:1901696","description":"\"The chemical reactions and pathways resulting in the formation of cannabinoid.\" [GOC:TermGenie]","metadata":null},{"id":"6d5bcbbf7c42491da9fb0fb417d9cfb5","type":"GO_TERM","name":"cannabinoid receptor activity","canonical_id":"go:GO:0004949","description":"\"Combining with a cannabinoid to initiate a change in cell activity. Cannabinoids are a class of diverse chemical compounds that include the endocannabinoids and the phytocannabinoids.\" [GOC:dph, IUPHAR_GPCR:1279, Wikipedia:Cannabinoid]","metadata":null},{"id":"7f716071943e439e87280b1c0af8793d","type":"GO_TERM","name":"cannabinoid receptor binding","canonical_id":"go:GO:0031717","description":"\"Binding to a cannabinoid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"fe4d6982e28140fb9bb08302753a888c","type":"GO_TERM","name":"cannabinoid signaling pathway","canonical_id":"go:GO:0038171","description":"\"A G protein-coupled receptor signaling pathway initiated by a cannabinoid binding to its receptor on the cell surface, and ending with the regulation of a downstream cellular process, e.g. transcription. Cannabinoids are a class of diverse chemical compounds that include the endocannabinoids and the phytocannabinoids.\" [GOC:bf, GOC:jc, GOC:signaling, Wikipedia:Cannabinoid]","metadata":null},{"id":"9db602d565ca4aa3ba2dda0f571460b2","type":"GO_TERM","name":"canonical NF-kappaB signal transduction","canonical_id":"go:GO:0007249","description":"\"An intracellular signaling cassette characterized by the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB, also known as the canonical NF-kappaB signaling cascade. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. The canonical NF-kappaB pathway is mainly stimulated by proinflammatory cytokines such as IL-1beta, tumor necrosis factor (TNF)-alpha, antigen ligands, and toll-like receptors (TLRs).\" [GOC:bf, PMID:12773372, PMID:34659217]","metadata":null},{"id":"d6956064678c40d483f431a35d61351c","type":"GO_TERM","name":"canonical Wnt signaling pathway","canonical_id":"go:GO:0060070","description":"\"A type of Wnt signaling pathway in which Wnt binding to its receptor on the surface of a target cell results in the by propagation of the molecular signals via beta-catenin, and end with a change in transcription of target genes. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes.\" [PMID:11532397, PMID:19619488]","metadata":null},{"id":"268ccd27ce214fa4bc26f57389e3ac9c","type":"GO_TERM","name":"canonical Wnt signaling pathway involved in heart development","canonical_id":"go:GO:0061316","description":"\"The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes that contributes to the progression of the heart over time. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes.\" [GOC:mtg_heart]","metadata":null},{"id":"ecfcc8a688e5461aac59cad5bfa83d38","type":"GO_TERM","name":"canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation","canonical_id":"go:GO:0044338","description":"\"The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes involved in mesenchymal stem cell differentiation.\" [GOC:BHF, GOC:jl]","metadata":null},{"id":"5392a83318ba4593ad9542e2f5903771","type":"GO_TERM","name":"canonical Wnt signaling pathway involved in negative regulation of apoptotic process","canonical_id":"go:GO:0044336","description":"\"The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes involved in the negative regulation of apoptotic process.\" [GOC:BHF, GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"b8b390cda1f34e4aa5111eb0de75aab5","type":"GO_TERM","name":"canonical Wnt signaling pathway involved in positive regulation of apoptotic process","canonical_id":"go:GO:0044337","description":"\"The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes involved in the positive regulation of apoptotic process.\" [GOC:BHF, GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"8ca521c6720c4b27862a288af20ff2e9","type":"GO_TERM","name":"canonical glycolysis","canonical_id":"go:GO:0061621","description":"\"The glycolytic process that begins with the conversion of glucose to glucose-6-phosphate by glucokinase activity. Glycolytic processes are the chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP.\" [GOC:dph, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"a845a7987510401f9e323fab8187a1cf","type":"GO_TERM","name":"canonical inflammasome complex","canonical_id":"go:GO:0061702","description":"\"A cytosolic protein complex that is capable of activating caspase-1.\" [GOC:dph, PMID:17599095]","metadata":null},{"id":"84f5ef45a60247abb5ce71816f305c2e","type":"GO_TERM","name":"canonical inflammasome complex assembly","canonical_id":"go:GO:0140632","description":"\"The aggregation, arrangement and bonding together of a set of components to form an inflammasome complex.\" [PMID:33420028, PMID:33420033, PMID:33542150]","metadata":null},{"id":"91d63ab0161f4035901557a8f15f5b0f","type":"GO_TERM","name":"cap snatching","canonical_id":"go:GO:0075526","description":"\"A transcription initiation process during which a nucleotide sequence between 10 and 20 nucleotides in size is cleaved from the 5' end of host mRNAs by a viral RNA-dependent polymerase. The capped leader sequence obtained is subsequently used to prime transcription on the viral genome, which ultimately leads to the synthesis of capped, translatable viral mRNAs.\" [GOC:bf, GOC:jl, VZ:839]","metadata":null},{"id":"2d3ff23778914294a27199991c2a54a6","type":"GO_TERM","name":"cap-dependent translation initiation factor activity","canonical_id":"go:GO:0160296","description":"\"A translation initiation factor activity that enables the recognition and binding to the 7-methylguanosine cap structure at the 5' end of eukaryotic mRNAs, promoting ribosome recruitment and assembly and translation initiation in a cap-dependent manner.\" [PMID:31913484, PMID:32496897]","metadata":null},{"id":"cf31cb13dedd405a8cc32be779f8c316","type":"GO_TERM","name":"cap-dependent translational initiation","canonical_id":"go:GO:0002191","description":"\"The process where the cap structure, composed of a 7- methylguanosine (m7G) group and associated cap-binding proteins, located at the 5' end of an mRNA molecule, which serves as a molecular tag that marks the spot where the 40S ribosomal subunit, is recruited and will then scan in a 5' to 3' direction until an AUG codon is encountered in an appropriate sequence context to initiate mRNA translation.\" [PMID:17284590, PMID:19604130]","metadata":null},{"id":"fcee6ea3e94f43c2bb3c86c6cdd1bdca","type":"GO_TERM","name":"cap-independent translational initiation","canonical_id":"go:GO:0002190","description":"\"The process where translation initiation recruits the 40S ribosomal subunits in a Cap and 5' end independent fashion before an AUG codon is encountered in an appropriate sequence context to initiate mRNA or circRNA translation.\" [PMID:17284590]","metadata":null},{"id":"291cb4ce75c143b48d5732b2e730b95c","type":"GO_TERM","name":"cap-independent translational initiation of circular RNA","canonical_id":"go:GO:0110018","description":"\"The process where translation initiation recruits the 40S ribosomal subunits in a cap and 5' end independent fashion before an AUG codon is encountered in an appropriate sequence context to initiate circRNA translation.\" [GOC:sp, PMID:28281539, PMID:28344080, PMID:28344082]","metadata":null},{"id":"2324f32258f54c31b4b22692b940c16a","type":"GO_TERM","name":"cap-independent translational initiation of linear mRNA","canonical_id":"go:GO:0110017","description":"\"The process where translation initiation recruits the 40S ribosomal subunits in a cap and 5' end independent fashion before an AUG codon is encountered in an appropriate sequence context to initiate linear mRNA translation.\" [GOC:kmv]","metadata":null},{"id":"41912295cfd6448d9886ca9cb7c294a4","type":"DRUG","name":"capecitabine","canonical_id":"gtopdb:6799","description":null,"metadata":null},{"id":"fd510ec9c23448fab81f35ef77f87c14","type":"DRUG","name":"capecitabine","canonical_id":"chembl:CHEMBL1773","description":null,"metadata":null},{"id":"ba9513c238b7431a922f45f7ab9f0c40","type":"COMBINATION_TREATMENT","name":"capecitabine + cetuximab + irinotecan","canonical_id":"ctgov_combo:ctgov-combo-ba9cff75ac98f332","description":null,"metadata":null},{"id":"41c924dfaa0f451c86e268ef8828d6bf","type":"COMBINATION_TREATMENT","name":"capecitabine + disitamab vedotin + pembrolizumab + tislelizumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-1a8f6741bc6f8a18","description":null,"metadata":null},{"id":"688fda49580b476b908e92a5d76e92e8","type":"COMBINATION_TREATMENT","name":"capecitabine + docetaxel","canonical_id":"ctgov_combo:ctgov-combo-f7eff2ae039dae4a","description":null,"metadata":null},{"id":"224ad39590404a5d8863ae899a72aee3","type":"COMBINATION_TREATMENT","name":"capecitabine + docetaxel","canonical_id":"ctgov_combo:ctgov-combo-a34bf554c4b73dbe","description":null,"metadata":null},{"id":"eb244e8fb8444d22bb4fc317eb139f1b","type":"COMBINATION_TREATMENT","name":"capecitabine + docetaxel + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-ec2a367190868689","description":null,"metadata":null},{"id":"962fa46a47af4c4a88bebc52499796cf","type":"COMBINATION_TREATMENT","name":"capecitabine + eribulin + gemcitabine + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-fbbd09f223902a42","description":null,"metadata":null},{"id":"5e7b97445f2c4bb68faddeb507df0170","type":"COMBINATION_TREATMENT","name":"capecitabine + etoposide","canonical_id":"ctgov_combo:ctgov-combo-4b5eb55a08d4c8d1","description":null,"metadata":null},{"id":"c7b1084409f54af8b6b096778e78d0ce","type":"COMBINATION_TREATMENT","name":"capecitabine + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-77f9484ecb76962c","description":null,"metadata":null},{"id":"3d129189c744415f991766701e8ddc4b","type":"COMBINATION_TREATMENT","name":"capecitabine + gemcitabine + irinotecan + losartan + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-1ee020c275b37520","description":null,"metadata":null},{"id":"c76e80e84d354c58b6e3db879008f05b","type":"COMBINATION_TREATMENT","name":"capecitabine + gemcitabine + panitumumab","canonical_id":"ctgov_combo:ctgov-combo-61cff23410c55e0c","description":null,"metadata":null},{"id":"2efd393e02f643688e24e042758b6be3","type":"COMBINATION_TREATMENT","name":"capecitabine + irinotecan","canonical_id":"ctgov_combo:ctgov-combo-43fb4cb9a3a9938f","description":null,"metadata":null},{"id":"a16b4d9ec0df4e8d9025dbebb48406a2","type":"COMBINATION_TREATMENT","name":"capecitabine + lapatinib","canonical_id":"ctgov_combo:ctgov-combo-99a7b928d3a59ec4","description":null,"metadata":null},{"id":"c96270ff5c4c42a2b0ae660c898c2e49","type":"COMBINATION_TREATMENT","name":"capecitabine + lapatinib","canonical_id":"ctgov_combo:ctgov-combo-4115fd4ec072bc75","description":null,"metadata":null},{"id":"b5813aa343f84381939347d768685768","type":"COMBINATION_TREATMENT","name":"capecitabine + lapatinib","canonical_id":"ctgov_combo:ctgov-combo-db4b854a7002dac5","description":null,"metadata":null},{"id":"7e2a8d8b376048cda26f9ea1a976d838","type":"COMBINATION_TREATMENT","name":"capecitabine + olaparib + paclitaxel + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-725826672e839774","description":null,"metadata":null},{"id":"b7d63d394332442d92cf1c0db3c139ab","type":"COMBINATION_TREATMENT","name":"capecitabine + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-894f86fc1f3da45b","description":null,"metadata":null},{"id":"db55e095280b49dba4d6ab509ec301fb","type":"COMBINATION_TREATMENT","name":"capecitabine + panitumumab","canonical_id":"ctgov_combo:ctgov-combo-0f6831e1a1e8050b","description":null,"metadata":null},{"id":"f23491a7731f467ea1c75a37908c77a5","type":"COMBINATION_TREATMENT","name":"capecitabine + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-00daab85113a94be","description":null,"metadata":null},{"id":"b3744ac6f06b4fe78e21368794a2af4e","type":"COMBINATION_TREATMENT","name":"capecitabine + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-530cba4ec88248d8","description":null,"metadata":null},{"id":"a10ac828b8344e01a544e9a067a95bc6","type":"COMBINATION_TREATMENT","name":"capecitabine + zolbetuximab","canonical_id":"ctgov_combo:ctgov-combo-316339014644615a","description":null,"metadata":null},{"id":"4c5adb53b8db479f80d1299b0d4293dd","type":"DISEASE","name":"capillary infantile hemangioma","canonical_id":"mondo:0011191","description":null,"metadata":null},{"id":"390399bf90ab4686b0235047cba5a382","type":"GO_TERM","name":"capitate projection","canonical_id":"go:GO:0097387","description":"\"Simple or compound process of epithelial glial cells with a spherical head that inserts into photoreceptor axons. Capitate projections have only been observed in Brachycera (flies).\" [GOC:mc, PMID:3098431]","metadata":null},{"id":"a152efae29e24cc597398f20ffc6afd8","type":"DRUG","name":"capivasertib","canonical_id":"gtopdb:7709","description":null,"metadata":null},{"id":"7e254ea7d6c84b46a1791f1fee214e66","type":"DRUG","name":"capivasertib","canonical_id":"chembl:CHEMBL2325741","description":null,"metadata":null},{"id":"da3172e0101648899545521d1bd66505","type":"COMBINATION_TREATMENT","name":"capivasertib + capmatinib","canonical_id":"ctgov_combo:ctgov-combo-74aee7095fcd237a","description":null,"metadata":null},{"id":"1d927c61de634ea797e2def10294e974","type":"COMBINATION_TREATMENT","name":"capivasertib + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-c51da4c7106dbeb1","description":null,"metadata":null},{"id":"81e26533c18846b0b5c7a697a454e23a","type":"COMBINATION_TREATMENT","name":"capivasertib + selumetinib","canonical_id":"ctgov_combo:ctgov-combo-a7d8211b3d25749b","description":null,"metadata":null},{"id":"ac603af2e8af43b8813ff7f166cac1db","type":"COMBINATION_TREATMENT","name":"capivasertib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-47abc203a3351aaa","description":null,"metadata":null},{"id":"ba96c867e0a048029eca9728e143b080","type":"DRUG","name":"caplacizumab","canonical_id":"gtopdb:9123","description":null,"metadata":null},{"id":"3501db0d73944eacb1be28864f4562c4","type":"DRUG","name":"caplacizumab","canonical_id":"chembl:CHEMBL2109624","description":null,"metadata":null},{"id":"00366706f30046ba969161d861ab1bf9","type":"DRUG","name":"capmatinib","canonical_id":"gtopdb:7904","description":null,"metadata":null},{"id":"7aa5ee893f334ac6b00760681b23a572","type":"DRUG","name":"capmatinib","canonical_id":"chembl:CHEMBL3188267","description":null,"metadata":null},{"id":"545f2dcda1b14057914b43cb3b82f7f0","type":"COMBINATION_TREATMENT","name":"capmatinib + ceritinib","canonical_id":"ctgov_combo:ctgov-combo-771623ce5852da1e","description":null,"metadata":null},{"id":"a62e2797383e437e9d9752926f75950a","type":"COMBINATION_TREATMENT","name":"capmatinib + ceritinib + glasdegib","canonical_id":"ctgov_combo:ctgov-combo-5b3270d7e0686850","description":null,"metadata":null},{"id":"27058af5c4a74534861bf16697d73301","type":"COMBINATION_TREATMENT","name":"capmatinib + neratinib","canonical_id":"ctgov_combo:ctgov-combo-db3224011879d2a8","description":null,"metadata":null},{"id":"42a469e0463544678925de4abb04a223","type":"GO_TERM","name":"caprolactam catabolic process","canonical_id":"go:GO:0019384","description":"\"The chemical reactions and pathways resulting in the breakdown of caprolactam, hexahydro-2h-azepin-2-one, a cyclic amide of caproic acid.\" [GOC:curators]","metadata":null},{"id":"a32687b69c4e49a89b122e2d0518478a","type":"DRUG","name":"capsaicin","canonical_id":"gtopdb:2486","description":null,"metadata":null},{"id":"cb859ea6253c44209d21152f65b22278","type":"DRUG","name":"capsaicin","canonical_id":"chembl:CHEMBL294199","description":null,"metadata":null},{"id":"cf69cbf21a2447a0a99ded48ed010ed0","type":"COMBINATION_TREATMENT","name":"capsaicin + clonazepam","canonical_id":"ctgov_combo:ctgov-combo-46f21911974e9ee0","description":null,"metadata":null},{"id":"440405dad3af4dc3a09c9f2b997e4f1a","type":"COMBINATION_TREATMENT","name":"capsaicin + diclofenac","canonical_id":"ctgov_combo:ctgov-combo-eff019eae3838d68","description":null,"metadata":null},{"id":"de11a92091c1476aa9cd11f76d21afa8","type":"COMBINATION_TREATMENT","name":"capsaicin + diphenhydramine + morphine","canonical_id":"ctgov_combo:ctgov-combo-de399bf0cf00f3c4","description":null,"metadata":null},{"id":"6ebbd90ac77949d8a6ffaea75798f682","type":"COMBINATION_TREATMENT","name":"capsaicin + duloxetine","canonical_id":"ctgov_combo:ctgov-combo-331588b3342442d6","description":null,"metadata":null},{"id":"8f4c68a038eb4b18873738900f7480b6","type":"GO_TERM","name":"capsanthin biosynthetic process","canonical_id":"go:GO:1901809","description":"\"The chemical reactions and pathways resulting in the formation of capsanthin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5174, PMID:10995282, UniPathway:UPA00806]","metadata":null},{"id":"f6b53914552442beac84e43a0e2cbf25","type":"GO_TERM","name":"capsanthin catabolic process","canonical_id":"go:GO:1901808","description":"\"The chemical reactions and pathways resulting in the breakdown of capsanthin.\" [GOC:TermGenie, GOC:yaf, PMID:10995282, UniPathway:UPA00806]","metadata":null},{"id":"ad54f89175d642b0b90ceb23b550dacb","type":"GO_TERM","name":"capsanthin synthase activity","canonical_id":"go:GO:0052727","description":"\"Catalysis of the reaction: all-trans-antheraxanthin = all-trans-capsanthin.\" [RHEA:17373]","metadata":null},{"id":"0f67586587f84f659501ad755af2ebf9","type":"GO_TERM","name":"capsomere","canonical_id":"go:GO:0046727","description":"\"Any of the protein subunits that comprise the closed shell or coat (capsid) of certain viruses.\" [ISBN:0198506732]","metadata":null},{"id":"355a49dfaa8f404d876cb09596bbcc63","type":"GO_TERM","name":"capsorubin biosynthetic process","canonical_id":"go:GO:1901866","description":"\"The chemical reactions and pathways resulting in the formation of capsorubin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5174, UniPathway:UPA00807]","metadata":null},{"id":"bb86203fb6eb41c18694fb0d1b72f3c0","type":"GO_TERM","name":"capsorubin catabolic process","canonical_id":"go:GO:1901865","description":"\"The chemical reactions and pathways resulting in the breakdown of capsorubin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00807]","metadata":null},{"id":"c3250f3fe28e47469cb54f4bfe9a3647","type":"GO_TERM","name":"capsorubin synthase activity","canonical_id":"go:GO:0052728","description":"\"Catalysis of the reaction: all-trans-violaxanthin = all-trans-capsorubin.\" [RHEA:21752]","metadata":null},{"id":"e17f3e00abe4484286f4c884d06457f4","type":"GO_TERM","name":"capsular polysaccharide transport","canonical_id":"go:GO:0015776","description":"\"The directed movement of capsular polysaccharides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Capsular polysaccharides make up the capsule, a protective structure surrounding some species of bacteria and fungi.\" [GOC:ai]","metadata":null},{"id":"9a7a46e52a9b4aaa9a220d63c4d0e843","type":"GO_TERM","name":"capsular-polysaccharide endo-1,3-alpha-galactosidase activity","canonical_id":"go:GO:0033921","description":"\"Catalysis of the random hydrolysis of (1->3)-alpha-D-galactosidic linkages in Aerobacter aerogenes capsular polysaccharide.\" [EC:3.2.1.87]","metadata":null},{"id":"bc7322b1093e4fd09353de0c990cb719","type":"GO_TERM","name":"capsule","canonical_id":"go:GO:0042603","description":"\"A protective structure surrounding some fungi and bacteria, attached externally to the cell wall and composed primarily of polysaccharides. Capsules are highly organized structures that adhere strongly to cells and cannot be easily removed. Capsules play important roles in pathogenicity, preventing phagocytosis by other cells, adherence, and resistance to desiccation.\" [GOC:mlg]","metadata":null},{"id":"11c045afe632401f8c6efeeded23cfca","type":"GO_TERM","name":"capsule organization","canonical_id":"go:GO:0045230","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the capsule, a protective structure surrounding some species of bacteria and fungi.\" [GOC:ai]","metadata":null},{"id":"45a902f8bbd84a89a8823ff5f1f8fad1","type":"GO_TERM","name":"capsule poly-gamma-glutamate biosynthetic process","canonical_id":"go:GO:0070502","description":"\"The chemical reactions and pathways resulting in the formation of poly-gamma-glutamate, a polymer of D- and/or L-glutamic acid residues linked by gamma-peptidyl bonds, that forms all or part of a bacterial capsule.\" [GOC:mah, PMID:16689787]","metadata":null},{"id":"b0e27f192171459486b381fdad9b62c0","type":"GO_TERM","name":"capsule polysaccharide biosynthetic process","canonical_id":"go:GO:0045227","description":"\"The chemical reactions and pathways resulting in the formation of polysaccharides that make up the capsule, a protective structure surrounding some species of bacteria and fungi.\" [GOC:curators]","metadata":null},{"id":"26cab1cabfca46aa8d36d0fafa84f596","type":"DRUG","name":"captodiame","canonical_id":"mesh:C495502","description":null,"metadata":null},{"id":"bd9d1e1d543143c3af93dd48d019cd08","type":"DRUG","name":"captopril","canonical_id":"gtopdb:5158","description":null,"metadata":null},{"id":"1ba39c1a43e34bd9b1d5c32c978cbd19","type":"DRUG","name":"captopril","canonical_id":"chembl:CHEMBL1560","description":null,"metadata":null},{"id":"d7b69e1c9db94c4aa52609fca7c2a3e9","type":"COMBINATION_TREATMENT","name":"captopril + chlorothiazide + hydrochlorothiazide + nitrendipine","canonical_id":"ctgov_combo:ctgov-combo-226a6aaa47aba8ab","description":null,"metadata":null},{"id":"54c7aaeead2a4363b6f21dddb6285771","type":"COMBINATION_TREATMENT","name":"captopril + cosyntropin","canonical_id":"ctgov_combo:ctgov-combo-7bffd8a807408785","description":null,"metadata":null},{"id":"74d8488f26114b4fbbf4e952545c5dbf","type":"COMBINATION_TREATMENT","name":"captopril + dipyridamole + guanfacine + prazosin","canonical_id":"ctgov_combo:ctgov-combo-704114c4eb4e449d","description":null,"metadata":null},{"id":"e929207ce48c4e739bb57a8059ab16c6","type":"COMBINATION_TREATMENT","name":"captopril + enalapril + lisinopril + perindopril + ramipril","canonical_id":"ctgov_combo:ctgov-combo-903f2f6e33e453c1","description":null,"metadata":null},{"id":"c82d0d5f3a65476c859caa1ac1e2f261","type":"COMBINATION_TREATMENT","name":"captopril + nitrendipine","canonical_id":"ctgov_combo:ctgov-combo-3b6ac27267887740","description":null,"metadata":null},{"id":"b251d75cc9564e67b5414317670b5538","type":"COMBINATION_TREATMENT","name":"captopril + trandolapril","canonical_id":"ctgov_combo:ctgov-combo-06186e57934e8862","description":null,"metadata":null},{"id":"feaa0e9d332846b2837d492a545dd057","type":"COMBINATION_TREATMENT","name":"captopril + trandolapril","canonical_id":"ctgov_combo:ctgov-combo-b5c0427922a7e4c3","description":null,"metadata":null},{"id":"a9bd4628c42e4f48a6c7d8a9382f583c","type":"DRUG","name":"carbachol","canonical_id":"gtopdb:298","description":null,"metadata":null},{"id":"d1a238d762ff4ca697656edd54bd1515","type":"DRUG","name":"carbachol","canonical_id":"mesh:D002217","description":null,"metadata":null},{"id":"1272e75f17554dd5923ffd597f169d6c","type":"DRUG","name":"carbachol","canonical_id":"chembl:CHEMBL14","description":null,"metadata":null},{"id":"5a760ee33c8449dd88d4e9cb6e074d46","type":"GO_TERM","name":"carbamate kinase activity","canonical_id":"go:GO:0008804","description":"\"Catalysis of the reaction: hydrogencarbonate + NH4+ + ATP = carbamoyl phosphate + ADP + H2O + H+.\" [RHEA:10152]","metadata":null},{"id":"526cc79f568b49669c1da7791a255a65","type":"DRUG","name":"carbamazepine","canonical_id":"mesh:D002220","description":null,"metadata":null},{"id":"f52f5150dcdb4c2495f3dd9eb5e54068","type":"GO_TERM","name":"carbamoyl phosphate biosynthetic process","canonical_id":"go:GO:0070409","description":"\"The chemical reactions and pathways resulting in the formation of carbamoyl phosphate, an intermediate in the urea cycle and other nitrogen compound metabolic pathways.\" [CHEBI:17672, GOC:mah, GOC:rph]","metadata":null},{"id":"f4a29b00096b4bd8a4c49c58501da575","type":"GO_TERM","name":"carbamoyl phosphate metabolic process","canonical_id":"go:GO:0070408","description":"\"The chemical reactions and pathways involving carbamoyl phosphate, an intermediate in the urea cycle and other nitrogen compound metabolic pathways.\" [CHEBI:17672, GOC:mah, GOC:rph]","metadata":null},{"id":"d5335f13eabf4351b2bb9e0939d66071","type":"GO_TERM","name":"carbamoyl-phosphate synthase (ammonia) activity","canonical_id":"go:GO:0004087","description":"\"Catalysis of the reaction: 2 ATP + hydrogencarbonate + NH4+ = 2 ADP + carbamoyl phosphate + 2 H+ + phosphate.\" [EC:6.3.4.16, RHEA:18029]","metadata":null},{"id":"362f8db7aa384dc485372dd374a458d4","type":"GO_TERM","name":"carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0004088","description":"\"Catalysis of the reaction: hydrogencarbonate + L-glutamine + 2 ATP + H2O = carbamoyl phosphate + L-glutamate + 2 ADP + phosphate + 2 H+.\" [RHEA:18633]","metadata":null},{"id":"d7ea7771b5a4481f8b2bf2d638c8ff77","type":"GO_TERM","name":"carbamoyl-phosphate synthase complex","canonical_id":"go:GO:0005951","description":"\"A protein complex that catalyzes the formation of carbamoyl phosphate; comprises a small subunit that binds and cleaves glutamine, and a large subunit that accepts the ammonia group cleaved from glutamine, binds all of the remaining substrates and effectors, and carries out all of the other catalytic events.\" [PMID:8626695]","metadata":null},{"id":"c051a9555f6546bea5940df78d0b7550","type":"GO_TERM","name":"carbamoyl-serine ammonia-lyase activity","canonical_id":"go:GO:0047766","description":"\"Catalysis of the reaction: O-carbamoyl-L-serine + H2O + H+ = CO2 + 2 NH4 + pyruvate.\" [EC:4.3.1.13, RHEA:15445]","metadata":null},{"id":"ad7f0fcb788c4b98bb775cfa4682b8d9","type":"GO_TERM","name":"carbapenem biosynthetic process","canonical_id":"go:GO:1901769","description":"\"The chemical reactions and pathways resulting in the formation of carbapenem.\" [GOC:TermGenie, GOC:yaf, PMID:9402024, UniPathway:UPA00182]","metadata":null},{"id":"f32b2f2df9334994a2b2ab0d7e7598d0","type":"GO_TERM","name":"carbapenem catabolic process","canonical_id":"go:GO:1901768","description":"\"The chemical reactions and pathways resulting in the breakdown of carbapenem.\" [GOC:TermGenie, GOC:yaf, PMID:9402024]","metadata":null},{"id":"532ccf17ecce4e0d855461ba9e1aeb05","type":"GO_TERM","name":"carbazole 1,9a-dioxygenase [NAD(P)H] activity","canonical_id":"go:GO:0018564","description":"\"Catalysis of the reaction: 9H-carbazole + H+ + NAD(P)H + O2 = 2'-aminobiphenyl-2,3-diol + NAD(P)+.\" [EC:1.14.12.22]","metadata":null},{"id":"1a2a5ec7532b41a1817b0c36041fded9","type":"GO_TERM","name":"carbazole catabolic process","canonical_id":"go:GO:0046232","description":"\"The chemical reactions and pathways resulting in the breakdown of carbazole, a heterocyclic aromatic compound containing a dibenzopyrrole system that is produced during coal gasification and is present in cigarette smoke. Coal tar produced at high temperature contains an average of 1.5% carbazole. It is used widely in synthesis of dyes, pharmaceuticals, and plastics and is a suspected carcinogen.\" [GOC:ai]","metadata":null},{"id":"bbbf79e4dfb444f79a2b7ae28ed7472f","type":"DRUG","name":"carbenoxolone","canonical_id":"mesh:D002229","description":null,"metadata":null},{"id":"462819ba9e664a0e865e9c48fdea4d45","type":"DRUG","name":"carbidopa","canonical_id":"gtopdb:5159","description":null,"metadata":null},{"id":"f845e17b17374df5be0744647f79f83a","type":"DRUG","name":"carbidopa","canonical_id":"mesh:D002230","description":null,"metadata":null},{"id":"124804b269f947b295334b2d54e0dd7e","type":"DRUG","name":"carbidopa","canonical_id":"chembl:CHEMBL1200748","description":null,"metadata":null},{"id":"42e5c7f1ca2d48bfbf0ddcb7bcc567f9","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-ab1b199b3c43ca74","description":null,"metadata":null},{"id":"a38602876cb44001aef5694833dc7db8","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-9767852d6629ffcf","description":null,"metadata":null},{"id":"01826dc4a7b84887906fee594b7abdb1","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-0b50f41b8f33d0e9","description":null,"metadata":null},{"id":"6babab8cb6e54af596f59b25084c454f","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-224af55a95aed6dd","description":null,"metadata":null},{"id":"1f613e3913004414b43bec2360025304","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-9b0e6b1a69f5aa4c","description":null,"metadata":null},{"id":"00bf5a43dfeb4e40a3536c68196de5e1","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-94e540689810520a","description":null,"metadata":null},{"id":"b845b64fc23f4cdba6a4b5f16bbc9512","type":"COMBINATION_TREATMENT","name":"carbidopa + entacapone","canonical_id":"ctgov_combo:ctgov-combo-272d0e6ae5cb4b86","description":null,"metadata":null},{"id":"8bb06eb160f142eab41a1c26c042e587","type":"COMBINATION_TREATMENT","name":"carbidopa + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-4ad531a55828c79f","description":null,"metadata":null},{"id":"32563331b621444390736b9fa91c21c1","type":"DRUG","name":"carbimazole","canonical_id":"mesh:D002231","description":null,"metadata":null},{"id":"bfa312d24f684a9b9f0adb09e960a04c","type":"DRUG","name":"carbinoxamine","canonical_id":"mesh:C004649","description":null,"metadata":null},{"id":"2aa7edb06260417a818f3aa2088b2fce","type":"GO_TERM","name":"carbohydrate binding","canonical_id":"go:GO:0030246","description":"\"Binding to a carbohydrate, which includes monosaccharides, oligosaccharides and polysaccharides as well as substances derived from monosaccharides by reduction of the carbonyl group (alditols), by oxidation of one or more hydroxy groups to afford the corresponding aldehydes, ketones, or carboxylic acids, or by replacement of one or more hydroxy group(s) by a hydrogen atom. Cyclitols are generally not regarded as carbohydrates.\" [GOC:mah]","metadata":null},{"id":"8888b36ddcc8437f9c271701f6252250","type":"GO_TERM","name":"carbohydrate biosynthetic process","canonical_id":"go:GO:0016051","description":"\"The chemical reactions and pathways resulting in the formation of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.\" [ISBN:0198506732]","metadata":null},{"id":"caed9af82e9f4573ade3b2b972de26d6","type":"GO_TERM","name":"carbohydrate catabolic process","canonical_id":"go:GO:0016052","description":"\"The chemical reactions and pathways resulting in the breakdown of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.\" [ISBN:0198506732]","metadata":null},{"id":"73d0123f9dc24203aa3d892c07f155e9","type":"GO_TERM","name":"carbohydrate derivative binding","canonical_id":"go:GO:0097367","description":"\"Binding to a carbohydrate derivative.\" [GOC:pr]","metadata":null},{"id":"0c305535046d40169e53389d7d4c1196","type":"GO_TERM","name":"carbohydrate derivative biosynthetic process","canonical_id":"go:GO:1901137","description":"\"The chemical reactions and pathways resulting in the formation of carbohydrate derivative.\" [GOC:TermGenie]","metadata":null},{"id":"fb4d7e5995144020b56a4d2de7966e97","type":"GO_TERM","name":"carbohydrate derivative catabolic process","canonical_id":"go:GO:1901136","description":"\"The chemical reactions and pathways resulting in the breakdown of carbohydrate derivative.\" [GOC:TermGenie]","metadata":null},{"id":"7d96adcb166b4480a57ac6d4ce1eff83","type":"GO_TERM","name":"carbohydrate derivative metabolic process","canonical_id":"go:GO:1901135","description":"\"The chemical reactions and pathways involving carbohydrate derivative.\" [GOC:TermGenie]","metadata":null},{"id":"b9a6ca9edf644779b4de5eea7569cb61","type":"GO_TERM","name":"carbohydrate derivative transmembrane transporter activity","canonical_id":"go:GO:1901505","description":"\"Enables the transfer of carbohydrate derivative from one side of a membrane to the other.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"cf59e6aaddc149918abae9b582d7838f","type":"GO_TERM","name":"carbohydrate derivative transport","canonical_id":"go:GO:1901264","description":"\"The directed movement of a carbohydrate derivative into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"b69576fa987640ae98c644d519d47903","type":"GO_TERM","name":"carbohydrate export","canonical_id":"go:GO:0033231","description":"\"The directed movement of carbohydrates out of a cell or organelle.\" [GOC:mlg]","metadata":null},{"id":"e35b6b5649184c8caa51b8482aa4e6c7","type":"GO_TERM","name":"carbohydrate homeostasis","canonical_id":"go:GO:0033500","description":"\"A homeostatic process involved in the maintenance of an internal steady state of a carbohydrate within an organism or cell.\" [GOC:mah]","metadata":null},{"id":"1db21bc5833f4fc896860a9882d9bd91","type":"GO_TERM","name":"carbohydrate import across plasma membrane","canonical_id":"go:GO:0098704","description":"\"The directed movement of a carbohydrate from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"5c70ea3bcecf43cda85e7d7e4889a34e","type":"GO_TERM","name":"carbohydrate kinase activity","canonical_id":"go:GO:0019200","description":"\"Catalysis of the transfer of a phosphate group, usually from ATP, to a carbohydrate substrate molecule.\" [GOC:jl]","metadata":null},{"id":"4a4d1accc4324a7ea4298a467ec40575","type":"GO_TERM","name":"carbohydrate localization","canonical_id":"go:GO:0052575","description":"\"Any process in which a carbohydrate is transported to, or maintained in, a specific location. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y.\" [GOC:mah]","metadata":null},{"id":"fee73e8705494670999fcdbcebfeeff0","type":"GO_TERM","name":"carbohydrate mediated signaling","canonical_id":"go:GO:0009756","description":"\"The series of molecular signals mediated by the detection of carbohydrate.\" [GOC:sm]","metadata":null},{"id":"321160468e8e408fabf0060a592fad5e","type":"GO_TERM","name":"carbohydrate metabolic process","canonical_id":"go:GO:0005975","description":"\"The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"27904a79172e42b19dd50e356540c0b0","type":"DISEASE","name":"carbohydrate metabolism disease","canonical_id":"mondo:0037792","description":null,"metadata":null},{"id":"fba346ca00a446b986d8acbd58d24e73","type":"GO_TERM","name":"carbohydrate phosphatase activity","canonical_id":"go:GO:0019203","description":"\"Catalysis of the reaction: carbohydrate phosphate + H2O = carbohydrate + phosphate.\" [GOC:mah]","metadata":null},{"id":"7ceef2afccc9499cbd1030ee6d89df7e","type":"GO_TERM","name":"carbohydrate phosphorylation","canonical_id":"go:GO:0046835","description":"\"The process of introducing a phosphate group into a carbohydrate, any organic compound based on the general formula Cx(H2O)y.\" [ISBN:0198506732]","metadata":null},{"id":"32e11fd11f0744eea3d7220c80c7afa8","type":"GO_TERM","name":"carbohydrate response element binding","canonical_id":"go:GO:0035538","description":"\"Binding to a carbohydrate response element (ChoRE) found in the promoters of genes whose expression is regulated in response to carbohydrates, such as the triglyceride synthesis genes.\" [GOC:BHF, PMID:20001964]","metadata":null},{"id":"9ac19ebac20a4ded8fc2c97831719553","type":"GO_TERM","name":"carbohydrate storage","canonical_id":"go:GO:0052576","description":"\"The accumulation and maintenance in cells or tissues of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.\" [PMID:10758476]","metadata":null},{"id":"b01856f51b4e4cb18625ecd760f48bb6","type":"GO_TERM","name":"carbohydrate transmembrane transport","canonical_id":"go:GO:0034219","description":"\"The process in which a carbohydrate is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"175dc4ae433c499c9b0922bdcbd25e8d","type":"GO_TERM","name":"carbohydrate transmembrane transporter activity","canonical_id":"go:GO:0015144","description":"\"Enables the transfer of carbohydrate from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"d257dfc2f54f4f658701c426b92a9fe0","type":"GO_TERM","name":"carbohydrate transport","canonical_id":"go:GO:0008643","description":"\"The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are a group of organic compounds based of the general formula Cx(H2O)y.\" [GOC:ai]","metadata":null},{"id":"2c4cd641bcb1439e9b5f1cbf0df6dcf4","type":"GO_TERM","name":"carbohydrate utilization","canonical_id":"go:GO:0009758","description":"\"A series of processes that forms an integrated mechanism by which a cell or an organism detects the depletion of primary carbohydrate sources,usually glucose, and then activates genes to scavenge the last traces of the primary carbohydrate source and to transport and metabolize alternate carbohydrate sources. The utilization process begins when the cell or organism detects carbohydrate levels, includes the activation of genes whose products detect, transport or metabolize carbohydrates, and ends when the carbohydrate is incorporated into the cell or organism's metabolism.\" [GOC:mah, GOC:mcc2, GOC:mlg]","metadata":null},{"id":"ab9d7820b2dc45b0ab3d2fbab6d3811f","type":"GO_TERM","name":"carbohydrate:monoatomic cation symporter activity","canonical_id":"go:GO:0005402","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sugar(out) + cation(out) = sugar(in) + cation(in).\" [GOC:ai]","metadata":null},{"id":"b05adb12280b4d9798877cb94d736305","type":"GO_TERM","name":"carbohydrate:proton symporter activity","canonical_id":"go:GO:0005351","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: carbohydrate(out) + H+(out) = carbohydrate(in) + H+(in).\" [TC:2.A.1.1]","metadata":null},{"id":"b4dc85c14b27404b9334b158ff23970c","type":"GO_TERM","name":"carbon catabolite activation of transcription","canonical_id":"go:GO:0045991","description":"\"A transcription regulation process in which the presence of one carbon source leads to an increase in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources.\" [GOC:mah, PMID:10559153]","metadata":null},{"id":"ca5744681c444c2b9bb5bb08c7a922d0","type":"GO_TERM","name":"carbon catabolite activation of transcription from RNA polymerase II promoter","canonical_id":"go:GO:0000436","description":"\"Any process involving carbon catabolites that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.\" [GOC:krc]","metadata":null},{"id":"f22ae2d950854c57bb53e48e41591101","type":"GO_TERM","name":"carbon catabolite regulation of transcription","canonical_id":"go:GO:0045990","description":"\"A transcription regulation process in which the presence of one carbon source leads to the modulation of the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources.\" [GOC:curators, GOC:mah, PMID:18359269, PMID:9618445]","metadata":null},{"id":"659236ddd447485d82636584ca56bdf6","type":"GO_TERM","name":"carbon catabolite regulation of transcription from RNA polymerase II promoter","canonical_id":"go:GO:0000429","description":"\"A transcription regulation process in which the presence of one carbon source leads to the modulation of the frequency, rate, or extent of transcription, from an RNA polymerase II promoter, of specific genes involved in the metabolism of other carbon sources.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"dd749d18a9934b1ba3c879c654b287b4","type":"GO_TERM","name":"carbon catabolite repression","canonical_id":"go:GO:0061985","description":"\"A process in which the presence of one carbon source leads to the modulation of the frequency, rate, or extent of the metabolism of other carbon sources.\" [PMID:29295552]","metadata":null},{"id":"8c6e3f9fd9d24c8cbc15660d8a96f3ea","type":"GO_TERM","name":"carbon catabolite repression of transcription","canonical_id":"go:GO:0045013","description":"\"A transcription regulation process in which the presence of one carbon source leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances.\" [GOC:mah, ISBN:0198506732, PMID:11018147, PMID:18359269, PMID:9618445]","metadata":null},{"id":"2907fa71d66f4ae483282ee014f540f1","type":"GO_TERM","name":"carbon catabolite repression of transcription by galactose","canonical_id":"go:GO:0000410","description":"\"A transcription regulation process in which the presence of galactose that leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances.\" [GOC:mah]","metadata":null},{"id":"f07114e8297d41d68443ff2eb1320144","type":"GO_TERM","name":"carbon catabolite repression of transcription by glucose","canonical_id":"go:GO:0045014","description":"\"A transcription regulation process in which the presence of glucose leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other carbon sources. Carbon catabolite repression is a mechanism of genetic regulation which the accumulation of catabolites of one substance in the cell represses the formation of enzymes that contribute to the catabolism of other substances.\" [ISBN:0198506732, PMID:11018147]","metadata":null},{"id":"9444bf05e4c044e794ac97de9c8b2ca0","type":"GO_TERM","name":"carbon dioxide binding","canonical_id":"go:GO:1902670","description":"\"Binding to carbon dioxide.\" [GO_REF:0000067, GOC:bhm, GOC:TermGenie, PMID:15491402]","metadata":null},{"id":"3477708ab5854baf8a6566bb50e43c02","type":"GO_TERM","name":"carbon dioxide receptor activity","canonical_id":"go:GO:0170015","description":"\"Combining with carbon dioxide to initiate a change in cell activity.\" [PMID:24240097]","metadata":null},{"id":"eabe98712557413b9973a15e8e217b5a","type":"GO_TERM","name":"carbon dioxide transmembrane transport","canonical_id":"go:GO:0035378","description":"\"The process in which carbon dioxide (CO2) is transported across a membrane.\" [GOC:yaf]","metadata":null},{"id":"1c58ae8fd5bc4d269576808e78ed60e3","type":"GO_TERM","name":"carbon dioxide transmembrane transporter activity","canonical_id":"go:GO:0035379","description":"\"Enables the transfer of carbon dioxide (CO2) from one side of a membrane to the other.\" [GOC:yaf]","metadata":null},{"id":"9ab4ccc327564a8b9644b1cce02603a8","type":"GO_TERM","name":"carbon dioxide transport","canonical_id":"go:GO:0015670","description":"\"The directed movement of carbon dioxide (CO2) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"de40471b3b8c403bac70612b0d67c565","type":"GO_TERM","name":"carbon fixation","canonical_id":"go:GO:0015977","description":"\"A metabolic process in which carbon (usually derived from carbon dioxide) is incorporated into organic compounds (usually carbohydrates).\" [GOC:jl, GOC:mah]","metadata":null},{"id":"771d18f49c254dd2910d50a0c6ec7913","type":"GO_TERM","name":"carbon fixation by 3-hydroxypropionate cycle","canonical_id":"go:GO:0043427","description":"\"An autotrophic carbon dioxide fixation pathway by which two molecules of carbon dioxide are fixed to form glyoxylate. Acetyl coenzyme A (acetyl-CoA) is assumed to be converted to malate, and two CO2 molecules are thereby fixed. Malyl-CoA is thought to be cleaved to acetyl-CoA, the starting molecule, and glyoxylate, the carbon fixation product.\" [GOC:jl, PMID:11418572, PMID:15838028]","metadata":null},{"id":"280f2b15ef5742ce804d65a2420ff556","type":"GO_TERM","name":"carbon fixation by acetyl-CoA pathway","canonical_id":"go:GO:0030634","description":"\"A pathway of carbon dioxide fixation in which one molecule of acetyl-CoA is completely synthesized from two molecules of carbon dioxide (CO2).\" [PMID:11607093]","metadata":null},{"id":"282ea8a4b30e45f8bc17a97b81632ce7","type":"GO_TERM","name":"carbon monoxide binding","canonical_id":"go:GO:0070025","description":"\"Binding to carbon monoxide (CO).\" [GOC:ecd]","metadata":null},{"id":"58dab63a282f442cabc3783e352df5eb","type":"GO_TERM","name":"carbon monoxide sensor activity","canonical_id":"go:GO:0070027","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of carbon monoxide (CO).\" [GOC:ecd]","metadata":null},{"id":"c73b421fb6ac46edb14238133af3c5f1","type":"GO_TERM","name":"carbon phosphorus lyase activity","canonical_id":"go:GO:0018835","description":"\"Catalysis of the reaction: alkylphosphonic acid = R-CH3 + phosphate. Substrates include aminomethylphosphonic acid (AMPA) (forms methylamine), dimethylphosphinic acid (forms methylphosphonic acid), glyphosate (forms sarcosine) and methylphosphonic acid (forms phosphate).\" [PMID:3804975]","metadata":null},{"id":"ea1e5eb6444949599b96c4a3758ab1e0","type":"GO_TERM","name":"carbon phosphorus lyase complex","canonical_id":"go:GO:1904176","description":"\"A protein complex which is capable of carbon phosphorus lyase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:17993513, PMID:21705661, PMID:22089136, PMID:23830682]","metadata":null},{"id":"672f5b41f4d741c6b656cf23b94ba722","type":"GO_TERM","name":"carbon tetrachloride catabolic process","canonical_id":"go:GO:0019382","description":"\"The chemical reactions and pathways resulting in the breakdown of carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants.\" [GOC:curators]","metadata":null},{"id":"12e27c68afbe467dabaf97bbb55d435d","type":"GO_TERM","name":"carbon tetrachloride metabolic process","canonical_id":"go:GO:0018885","description":"\"The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants.\" [UM-BBD_pathwayID:ctc]","metadata":null},{"id":"fe5f539a14ff4997a06e8fc060887ef0","type":"GO_TERM","name":"carbon utilization","canonical_id":"go:GO:0015976","description":"\"A series of processes that forms an integrated mechanism by which a cell or an organism detects the depletion of primary carbon sources and then activates genes to scavenge the last traces of the primary carbon source and to transport and metabolize alternative carbon sources such as carbon dioxide or carbonic acid. The utilization process begins when the cell or organism detects carbon levels, includes the activation of genes whose products detect, transport or metabolize carbon-containing substances, and ends when carbon is incorporated into the cell or organism's metabolism.\" [GOC:mah, GOC:mlg]","metadata":null},{"id":"595c0dd049154f069bd55e33e32ab787","type":"GO_TERM","name":"carbon-carbon lyase activity","canonical_id":"go:GO:0016830","description":"\"Catalysis of the cleavage of C-C bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond.\" [GOC:jl]","metadata":null},{"id":"ef560e15d2d54079880e62b2a907e992","type":"GO_TERM","name":"carbon-halide lyase activity","canonical_id":"go:GO:0016848","description":"\"Catalysis of the breakage of a bond between carbon and any halogen atom.\" [GOC:mah]","metadata":null},{"id":"9d1765989a28422bb3df8a33fafb1476","type":"GO_TERM","name":"carbon-nitrogen ligase activity on lipid II","canonical_id":"go:GO:0140282","description":"\"Catalysis of the reaction: L-glutamine + lipid II + ATP + H2O = L-glutamate + beta-D-GlcNAc(1->4)-Mur2Ac(oyl-L-Ala-D-isoGln-L-Lys-D-Ala-D-Ala)-diphospho-di-trans,octa-cis-undecaprenol + ADP + phosphate.\" [PMID:22291598, PMID:30093673, PMID:30154570, RHEA:57928]","metadata":null},{"id":"1cdd1724c891446381c3085954f83ff9","type":"GO_TERM","name":"carbon-nitrogen ligase activity, with glutamine as amido-N-donor","canonical_id":"go:GO:0016884","description":"\"Catalysis of the transfer of the amide nitrogen of glutamine to a substrate. Usually composed of two subunits or domains, one that first hydrolyzes glutamine, and then transfers the resulting ammonia to the second subunit (or domain), where it acts as a source of nitrogen.\" [PMID:12360532]","metadata":null},{"id":"e788c12fca8f4753afd49d09ea2f6587","type":"GO_TERM","name":"carbon-nitrogen lyase activity","canonical_id":"go:GO:0016840","description":"\"Catalysis of the release of ammonia or one of its derivatives, with the formation of a double bond or ring. Enzymes with this activity may catalyze the actual elimination of the ammonia, amine or amide, e.g. CH-CH(-NH-R) = C=CH- + NH2-R. Others, however, catalyze elimination of another component, e.g. water, which is followed by spontaneous reactions that lead to breakage of the C-N bond, e.g. L-serine ammonia-lyase (EC:4.3.1.17), so that the overall reaction is C(-OH)-CH(-NH2) = CH2-CO- + NH4+, i.e. an elimination with rearrangement. The sub-subclasses of EC:4.3 are the ammonia-lyases (EC:4.3.1), lyases acting on amides, amidines, etc. (EC:4.3.2), the amine-lyases (EC:4.3.3), and other carbon-nitrogen lyases (EC:4.3.99).\" [EC:4.3.-.-]","metadata":null},{"id":"1dee1af489d9464e83eea259f1e97996","type":"GO_TERM","name":"carbon-oxygen lyase activity","canonical_id":"go:GO:0016835","description":"\"Catalysis of the breakage of a carbon-oxygen bond.\" [EC:4.2.-.-]","metadata":null},{"id":"1f9045ea891e489fa992d917c7689700","type":"GO_TERM","name":"carbon-oxygen lyase activity, acting on phosphates","canonical_id":"go:GO:0016838","description":"\"Catalysis of the cleavage of a carbon-oxygen bond by elimination of a phosphate.\" [EC:4.2.3.-]","metadata":null},{"id":"215ab68e7097449389a0fda71f3cc7bb","type":"GO_TERM","name":"carbon-oxygen lyase activity, acting on polysaccharides","canonical_id":"go:GO:0016837","description":"\"Catalysis of the cleavage of a carbon-oxygen bond by the elimination of an alcohol from a polysaccharide.\" [EC:4.2.2.-]","metadata":null},{"id":"bd12e4ec680044bf9f9ad248f2931bc9","type":"GO_TERM","name":"carbon-sulfur lyase activity","canonical_id":"go:GO:0016846","description":"\"Catalysis of the elimination of hydrogen sulfide or substituted H2S.\" [EC:4.4.-.-]","metadata":null},{"id":"0e7188bfd44d4d2f946e6e6b29e88aa8","type":"GO_TERM","name":"carbonate dehydratase activity","canonical_id":"go:GO:0004089","description":"\"Catalysis of the reaction: hydrogencarbonate + H+ = CO2 + H2O.\" [EC:4.2.1.1]","metadata":null},{"id":"a0d15faf2754435bb149ccf0ffbab1a3","type":"GO_TERM","name":"carbonyl reductase (NADPH) activity","canonical_id":"go:GO:0004090","description":"\"Catalysis of the reaction: a secondary alcohol + NADP+ = a ketone + H+ + NADPH.\" [RHEA:19257]","metadata":null},{"id":"f0b97804739b44658bebb3690473c6d1","type":"DRUG","name":"carboprost tromethamine","canonical_id":"mesh:C062843","description":null,"metadata":null},{"id":"8cc9a087875f44d783ee0de06b4e3d20","type":"GO_TERM","name":"carboxy-cis,cis-muconate cyclase activity","canonical_id":"go:GO:0047768","description":"\"Catalysis of the reaction: 3-carboxy-2,5-dihydro-5-oxofuran-2-acetate = 3-carboxy-cis,cis-muconate.\" [EC:5.5.1.5, RHEA:14977]","metadata":null},{"id":"74bb223abe3842398d8e3be032840684","type":"GO_TERM","name":"carboxy-lyase activity","canonical_id":"go:GO:0016831","description":"\"Catalysis of the nonhydrolytic addition or removal of a carboxyl group to or from a compound.\" [GOC:curators]","metadata":null},{"id":"2f3ac5897eef4460871d726eb33f3e16","type":"GO_TERM","name":"carboxy-terminal domain protein kinase complex","canonical_id":"go:GO:0032806","description":"\"A protein complex that phosphorylates amino acid residues of RNA polymerase II C-terminal domain repeats; phosphorylation occurs mainly on Ser2 and Ser5.\" [PMID:15047695, PMID:16721054, PMID:17079683]","metadata":null},{"id":"68ca27d5866e46a9a908a4acebbfd922","type":"GO_TERM","name":"carboxyl- or carbamoyltransferase activity","canonical_id":"go:GO:0016743","description":"\"Catalysis of the transfer of a carboxyl- or carbamoyl group from one compound (donor) to another (acceptor).\" [GOC:jl]","metadata":null},{"id":"09d21c12590f4d9a80a232fcd57d520a","type":"GO_TERM","name":"carboxyl-O-methyltransferase activity","canonical_id":"go:GO:0010340","description":"\"Catalysis of the transfer of a methyl group to the carboxyl group of an acceptor molecule to form a methyl ester.\" [PMID:17220201]","metadata":null},{"id":"d6fc231a0de04d019898c490d9094788","type":"GO_TERM","name":"carboxylate reductase activity","canonical_id":"go:GO:0047770","description":"\"Catalysis of the reaction: an aldehyde + acceptor + H2O = a carboxylate + reduced acceptor.\" [EC:1.2.99.6, MetaCyc:CARBOXYLATE-REDUCTASE-RXN]","metadata":null},{"id":"04b26a542e31440390d0d2fdec3d7677","type":"GO_TERM","name":"carboxylesterase activity","canonical_id":"go:GO:0106435","description":"\"Catalysis of the reaction: a carboxylic ester + H2O = a carboxylate + an alcohol + H+.\" [RHEA:21164]","metadata":null},{"id":"7901a4d10cd5439ca4846fcfe8f7ae19","type":"GO_TERM","name":"carboxylic acid binding","canonical_id":"go:GO:0031406","description":"\"Binding to a carboxylic acid, an organic acid containing one or more carboxyl (COOH) groups or anions (COO-).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"90c52c9edccc4c02a240166824844c70","type":"GO_TERM","name":"carboxylic acid biosynthetic process","canonical_id":"go:GO:0046394","description":"\"The chemical reactions and pathways resulting in the formation of carboxylic acids, any organic acid containing one or more carboxyl (-COOH) groups.\" [ISBN:0198506732]","metadata":null},{"id":"898e65f7bdf944a683c4a98b858714cb","type":"GO_TERM","name":"carboxylic acid catabolic process","canonical_id":"go:GO:0046395","description":"\"The chemical reactions and pathways resulting in the breakdown of carboxylic acids, any organic acid containing one or more carboxyl (-COOH) groups.\" [ISBN:0198506732]","metadata":null},{"id":"e0738c77db2041c3a6d86e01fae6f174","type":"GO_TERM","name":"carboxylic acid metabolic process","canonical_id":"go:GO:0019752","description":"\"The chemical reactions and pathways involving carboxylic acids, any organic acid containing one or more carboxyl (COOH) groups or anions (COO-).\" [ISBN:0198506732]","metadata":null},{"id":"6b51ea06270c440fb3614a6d727156f3","type":"GO_TERM","name":"carboxylic acid transmembrane transport","canonical_id":"go:GO:1905039","description":"\"The process in which carboxylic acid is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:10869563]","metadata":null},{"id":"d43a2216e2fb467ba87323cc7af484f5","type":"GO_TERM","name":"carboxylic acid transmembrane transporter activity","canonical_id":"go:GO:0046943","description":"\"Enables the transfer of carboxylic acids from one side of a membrane to the other. Carboxylic acids are organic acids containing one or more carboxyl (COOH) groups or anions (COO-).\" [GOC:ai]","metadata":null},{"id":"4e6473a6198e4934bbdc8f8de613be24","type":"GO_TERM","name":"carboxylic acid transport","canonical_id":"go:GO:0046942","description":"\"The directed movement of carboxylic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carboxylic acids are organic acids containing one or more carboxyl (COOH) groups or anions (COO-).\" [GOC:ai]","metadata":null},{"id":"5a3265b74f73477bac4f064f7ed67bd8","type":"GO_TERM","name":"carboxylic ester hydrolase activity","canonical_id":"go:GO:0052689","description":"\"Catalysis of the hydrolysis of a carboxylic ester bond.\" [EC:3.1.1.-, GOC:curators]","metadata":null},{"id":"fa5cbc0dfa76493582ba4f811f606a7c","type":"GO_TERM","name":"carboxymethylenebutenolidase activity","canonical_id":"go:GO:0008806","description":"\"Catalysis of the reaction: 4-carboxymethylenebut-2-en-4-olide + H2O = 4 oxohex-2-enedioate.\" [EC:3.1.1.45]","metadata":null},{"id":"b6fc399c2dd6487b91da98b9b6bda6bc","type":"GO_TERM","name":"carboxymethylhydantoinase activity","canonical_id":"go:GO:0047771","description":"\"Catalysis of the reaction: L-5-carboxymethylhydantoin + H2O = N-carbamoyl-L-aspartate + H+.\" [EC:3.5.2.4, RHEA:12028]","metadata":null},{"id":"bccc616ede0f47a495989eeeaab7f3eb","type":"GO_TERM","name":"carboxymethyloxysuccinate lyase activity","canonical_id":"go:GO:0047772","description":"\"Catalysis of the reaction: carboxymethoxysuccinate = fumarate + glycolate.\" [EC:4.2.99.12, RHEA:12336]","metadata":null},{"id":"354f68e1aeb64a37a470b8a1fc236e86","type":"GO_TERM","name":"carboxynorspermidine dehydrogenase activity","canonical_id":"go:GO:0102143","description":"\"Catalysis of the reaction: carboxynorspermidine + H2O + NADP+ = H+ + L-aspartate 4-semialdehyde + NADPH + propane-1,3-diamine. Also converts carboxyspermidine to putrescine.\" [EC:1.5.1.43]","metadata":null},{"id":"3e799c42ca514b50a06df3a1322288a8","type":"GO_TERM","name":"carboxypeptidase activity","canonical_id":"go:GO:0004180","description":"\"Catalysis of the hydrolysis of a single C-terminal amino acid residue from a polypeptide chain.\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#CARBOXYPEPTIDASE]","metadata":null},{"id":"aa03a21dbf874f879dbf494dd4051ce0","type":"GO_TERM","name":"carboxysome","canonical_id":"go:GO:0031470","description":"\"An organelle consisting of a proteinaceous coat and enzymes for the fixation of CO2. It augments the concentration of CO2 in the vicinity of RuBisCO to increase the efficiency of CO2 fixation under atmospheric conditions.\" [GOC:js, PMID:28934381, PMID:8157606, PMID:8491708]","metadata":null},{"id":"97fd7a02cc884c05827f654366dbae5b","type":"GO_TERM","name":"carboxyvinyl-carboxyphosphonate phosphorylmutase activity","canonical_id":"go:GO:0008807","description":"\"Catalysis of the reaction: 1-carboxyvinyl carboxyphosphonate = 3-(hydrohydroxyphosphoryl)pyruvate + CO2.\" [EC:2.7.8.23]","metadata":null},{"id":"5fab4bbbb25448a8a6a7975fb96f90b2","type":"GO_TERM","name":"carcinine import across plasma membrane","canonical_id":"go:GO:1905130","description":"\"The directed movement of carcinine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:dph, GOC:TermGenie, PMID:26653853, PMID:26713872]","metadata":null},{"id":"b9850ff7e8a64de08c7a0f432ff07f32","type":"GO_TERM","name":"carcinine transmembrane transporter activity","canonical_id":"go:GO:1905131","description":"\"Enables the transfer of carcinine from one side of a membrane to the other.\" [GO_REF:0000070, GOC:dph, GOC:TermGenie, PMID:26653853, PMID:26713872]","metadata":null},{"id":"f62df3d39c914912ac4144f32ff562ea","type":"DISEASE","name":"carcinoid syndrome","canonical_id":"mondo:0100347","description":null,"metadata":null},{"id":"27e8bd0d215a4ff389b33ca0be69ee0d","type":"DISEASE","name":"carcinoid tumor","canonical_id":"mondo:0005369","description":null,"metadata":null},{"id":"77eab64c5baf41e6a737ff6527201488","type":"DISEASE","name":"carcinoma","canonical_id":"mondo:0004993","description":null,"metadata":null},{"id":"c0faeb6308f5450891607e86007ce219","type":"GO_TERM","name":"cardiac Troponin complex","canonical_id":"go:GO:1990584","description":"\"A complex of accessory proteins (cardiac troponin T, cardiac troponin I and cardiac troponin C) found associated with actin in cardiac muscle thin filaments; involved in calcium regulation important for muscle contraction.\" [GOC:ame, PMID:12840750]","metadata":null},{"id":"2c65296e376c4f158318081ad2225511","type":"DISEASE","name":"cardiac arrhythmia","canonical_id":"efo:0004269","description":null,"metadata":null},{"id":"789bf983f4124075ac978121c641ef02","type":"GO_TERM","name":"cardiac atrium development","canonical_id":"go:GO:0003230","description":"\"The process whose specific outcome is the progression of a cardiac atrium over time, from its formation to the mature structure. A cardiac atrium receives blood from a vein and pumps it to a cardiac ventricle.\" [GOC:mtg_heart]","metadata":null},{"id":"8147dd9e27cb4ab6928419520e8004c3","type":"GO_TERM","name":"cardiac atrium formation","canonical_id":"go:GO:0003210","description":"\"The developmental process pertaining to the initial formation of a cardiac atrium from unspecified parts. A cardiac atrium receives blood from a vein and pumps it to a cardiac ventricle.\" [GOC:mtg_heart]","metadata":null},{"id":"02e860b316504dec9ecb914bb9ad5266","type":"GO_TERM","name":"cardiac atrium morphogenesis","canonical_id":"go:GO:0003209","description":"\"The process in which the cardiac atrium is generated and organized. A cardiac atrium receives blood from a vein and pumps it to a cardiac ventricle.\" [GOC:mtg_heart]","metadata":null},{"id":"848da4e4746643a8a81ff3fa3f0d7adc","type":"GO_TERM","name":"cardiac blood vessel endothelial cell differentiation","canonical_id":"go:GO:0060946","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a blood vessel endothelial cell of the heart. Blood vessel endothelial cells are thin flattened cells that line the inside surfaces of blood vessels.\" [GOC:mtg_heart]","metadata":null},{"id":"ce0f60d7c3be48f5b288707e8f010530","type":"GO_TERM","name":"cardiac cell development","canonical_id":"go:GO:0055006","description":"\"The process whose specific outcome is the progression of a cardiac cell over time, from its formation to the mature state. A cardiac cell is a cell that will form part of the cardiac organ of an individual.\" [GOC:devbiol]","metadata":null},{"id":"1076b84064954c4c92ccbc9abd455ee0","type":"GO_TERM","name":"cardiac cell fate commitment","canonical_id":"go:GO:0060911","description":"\"The commitment of cells to specific cardiac cell fates and their capacity to differentiate into cardiac cells. Cardiac cells are cells that comprise the organ which pumps blood through the circulatory system.\" [GOC:mtg_heart]","metadata":null},{"id":"cf72cd69d5c54054bebfb730428c691c","type":"GO_TERM","name":"cardiac cell fate determination","canonical_id":"go:GO:0060913","description":"\"The process involved in cardiac cell fate commitment. Once determination has taken place, a cell becomes committed to differentiate down a particular pathway regardless of its environment.\" [GOC:mtg_heart]","metadata":null},{"id":"7459ed0f976040a4bd15e6443e6ec10b","type":"GO_TERM","name":"cardiac cell fate specification","canonical_id":"go:GO:0060912","description":"\"The process involved in the specification of cardiac cell identity. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment.\" [GOC:mtg_heart]","metadata":null},{"id":"414f55d2fd6045bcbe9fd3b86a009ff2","type":"GO_TERM","name":"cardiac chamber ballooning","canonical_id":"go:GO:0003242","description":"\"The morphogenic growth in which the chambers of the heart expand in size, contributing to their shaping.\" [GOC:mtg_heart]","metadata":null},{"id":"2e1dbfd6e9da40158c886ae645d4d406","type":"GO_TERM","name":"cardiac chamber development","canonical_id":"go:GO:0003205","description":"\"The progression of a cardiac chamber over time, from its formation to the mature structure. A cardiac chamber is an enclosed cavity within the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"17c3216233424a4b8731d286e9c1267c","type":"GO_TERM","name":"cardiac chamber formation","canonical_id":"go:GO:0003207","description":"\"The developmental process pertaining to the initial formation of a cardiac chamber from unspecified parts. A cardiac chamber is an enclosed cavity within the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"1ec5c5bad39c46799deab66d8c0ebddd","type":"GO_TERM","name":"cardiac chamber morphogenesis","canonical_id":"go:GO:0003206","description":"\"The process in which a cardiac chamber is generated and organized. A cardiac chamber is an enclosed cavity within the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"a0096574b21f4ca1a004b28d2f7d9900","type":"GO_TERM","name":"cardiac conduction","canonical_id":"go:GO:0061337","description":"\"Transfer of an organized electrical impulse across the heart to coordinate the contraction of cardiac muscles. The process begins with generation of an action potential (in the sinoatrial node (SA) in humans) and ends with a change in the rate, frequency, or extent of the contraction of the heart muscles.\" [GOC:dph]","metadata":null},{"id":"83083fe0680143a8b633bec19ede6e15","type":"GO_TERM","name":"cardiac conduction system development","canonical_id":"go:GO:0003161","description":"\"The process whose specific outcome is the progression of the cardiac conduction system over time, from its formation to the mature structure. The cardiac conduction system consists of specialized cardiomyocytes that regulate the frequency of heart beat.\" [GOC:mtg_heart]","metadata":null},{"id":"68dad3f66880494494ec59eb39d31d3e","type":"GO_TERM","name":"cardiac endothelial cell differentiation","canonical_id":"go:GO:0003348","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a cardiac endothelial cell.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"3142151ac96a40b8983e165937613167","type":"GO_TERM","name":"cardiac endothelial to mesenchymal transition","canonical_id":"go:GO:0140074","description":"\"A transition where a cardiac endothelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. Endocardial cells (specialized endothelial cells that line the heart) undergo EndMT, and give rise to mesenchymal cells necessary for proper heart development. EndMT, specifically generates valve progenitor cells that give rise to the mitral and tricuspid valves. EndMT also contributes to endocardial cushion formation, as well as to generation of cardiac fibroblasts and smooth muscle cells, but not cardiac myocytes.\" [GOC:BHF, GOC:nc, PMID:16162442, PMID:26053665]","metadata":null},{"id":"1396bb16cd094d419a841c7bbad4dcc7","type":"GO_TERM","name":"cardiac epithelial to mesenchymal transition","canonical_id":"go:GO:0060317","description":"\"A transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BHF, GOC:dph, PMID:16314491, PMID:1996351]","metadata":null},{"id":"a3bdad495c374169a5b509a12198a77e","type":"GO_TERM","name":"cardiac fibroblast cell development","canonical_id":"go:GO:0060936","description":"\"The process whose specific outcome is the progression of a cardiac fibroblast over time, from its formation to the mature state. A cardiac fibroblast is a connective tissue cell of the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"fb3691b5eacc4f36916686ca45ded5e6","type":"GO_TERM","name":"cardiac fibroblast cell differentiation","canonical_id":"go:GO:0060935","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a cardiac fibroblast. A cardiac fibroblast is a connective tissue cell in the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"bdcca7c20ce549ca907b2450bc82345c","type":"GO_TERM","name":"cardiac fibroblast cell fate commitment","canonical_id":"go:GO:0060937","description":"\"The commitment of cells to a cardiac fibroblast fate and their capacity to differentiate into cardiac fibroblast cells. A cardiac fibroblast is a connective tissue cell in the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"22b7b6781ce04d40aead502115996cb0","type":"GO_TERM","name":"cardiac glial cell development","canonical_id":"go:GO:0060952","description":"\"The process aimed at the progression of a cardiac glial cell over time, from its formation to the fully functional mature cell.\" [GOC:mtg_heart]","metadata":null},{"id":"1966b83a32f748f088689d1fbb8f93a6","type":"GO_TERM","name":"cardiac glial cell differentiation","canonical_id":"go:GO:0060950","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a glial cell of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"63d1b05975c8475ca4ed31b6b015fc4b","type":"GO_TERM","name":"cardiac glial cell fate commitment","canonical_id":"go:GO:0060953","description":"\"The commitment of cells to cardiac glial cell fates and their capacity to differentiate into cardiac glial cells.\" [GOC:mtg_heart]","metadata":null},{"id":"a13056a144cc445b8d20f81aa7054d32","type":"GO_TERM","name":"cardiac jelly development","canonical_id":"go:GO:1905072","description":"\"The process whose specific outcome is the progression of cardiac jelly over time, from its formation to the mature structure. The cardiac jelly is an acellular gelatinous matrix secreted by the myocardium and plays a central role in the septation of the heart.\" [GO_REF:0000094, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:10645959, PMID:16314491, PMID:19703439]","metadata":null},{"id":"1b223ffa5e5148cf88c69c5514042289","type":"GO_TERM","name":"cardiac left atrium formation","canonical_id":"go:GO:0003216","description":"\"The developmental process pertaining to the initial formation of a left cardiac atrium from unspecified parts.\" [GOC:mtg_heart]","metadata":null},{"id":"4c5d5a086355451ab56e91ae0eca4f31","type":"GO_TERM","name":"cardiac left atrium morphogenesis","canonical_id":"go:GO:0003212","description":"\"The process in which the left cardiac atrium is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"90f4203c04a6435c9ae4b4f1cac821a6","type":"GO_TERM","name":"cardiac left ventricle formation","canonical_id":"go:GO:0003218","description":"\"The developmental process pertaining to the initial formation of a left cardiac ventricle from unspecified parts.\" [GOC:mtg_heart]","metadata":null},{"id":"bed661eb5dec4d289ab90adf023d340d","type":"GO_TERM","name":"cardiac left ventricle morphogenesis","canonical_id":"go:GO:0003214","description":"\"The process in which the left cardiac ventricle is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"c78a700512254e479fd4a90ca81a4c92","type":"GO_TERM","name":"cardiac muscle adaptation","canonical_id":"go:GO:0014887","description":"\"The process in which cardiac muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors.\" [GOC:mtg_muscle]","metadata":null},{"id":"76dd81d56bd648f9ba71431e5d54cb52","type":"GO_TERM","name":"cardiac muscle atrophy","canonical_id":"go:GO:0014899","description":"\"A process, occurring in the heart, in which a decrease in cell mass and then in heart size occurs due to shrinking of the individual cells. The shrinkage is caused by protein degradation.\" [GOC:mtg_muscle]","metadata":null},{"id":"c1cda043b6be42729e91b200d2aa10ae","type":"GO_TERM","name":"cardiac muscle cell action potential","canonical_id":"go:GO:0086001","description":"\"An action potential that occurs in a cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"03d493285b324f8cbceb149d1598bdc8","type":"GO_TERM","name":"cardiac muscle cell action potential involved in contraction","canonical_id":"go:GO:0086002","description":"\"An action potential that occurs in a cardiac muscle cell and is involved in its contraction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f66c5fa015a348febb91e1dc51fef474","type":"GO_TERM","name":"cardiac muscle cell apoptotic process","canonical_id":"go:GO:0010659","description":"\"A form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases, whose actions dismantle a cardiac muscle cell and result in its death. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.\" [CL:0000746, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"e9ca3c630a1446c8a46ba49bf7024bf0","type":"GO_TERM","name":"cardiac muscle cell contraction","canonical_id":"go:GO:0086003","description":"\"The actin filament-based process in which cytoplasmic actin filaments slide past one another resulting in contraction of a cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f4b8bef6b4aa4344a280a4d11ad11e06","type":"GO_TERM","name":"cardiac muscle cell development","canonical_id":"go:GO:0055013","description":"\"The process whose specific outcome is the progression of a cardiac muscle cell over time, from its formation to the mature state.\" [GOC:devbiol, GOC:mtg_heart]","metadata":null},{"id":"245f67f9985a44b68fe9da25ceafb5f0","type":"GO_TERM","name":"cardiac muscle cell differentiation","canonical_id":"go:GO:0055007","description":"\"The process in which a cardiac muscle precursor cell acquires specialized features of a cardiac muscle cell. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.\" [GOC:devbiol, GOC:mtg_heart]","metadata":null},{"id":"750637788b4746a582c22467d8f1d12b","type":"GO_TERM","name":"cardiac muscle cell fate commitment","canonical_id":"go:GO:0060923","description":"\"The commitment of cells to specific cardiac muscle cell fates and their capacity to differentiate into cardiac muscle cells. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.\" [GOC:mtg_heart]","metadata":null},{"id":"995d13bb960641a394f7c13c031e94f0","type":"GO_TERM","name":"cardiac muscle cell fate determination","canonical_id":"go:GO:0061442","description":"\"The process involved in cardiac muscle cell fate commitment. Once determination has taken place, a cell becomes committed to differentiate down a particular pathway regardless of its environment.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"2b228a7eec724ae0a34113996bd25845","type":"GO_TERM","name":"cardiac muscle cell membrane repolarization","canonical_id":"go:GO:0099622","description":"\"The process in which ions are transported across the plasma membrane of a cardiac muscle cell such that the membrane potential changes in the repolarizing direction, toward the steady state potential. For example, the repolarization during an action potential is from a positive membrane potential towards a negative resting potential.\" [GOC:BHF]","metadata":null},{"id":"269d35d92bbd4c048724d8b09c795bb3","type":"GO_TERM","name":"cardiac muscle cell myoblast differentiation","canonical_id":"go:GO:0060379","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a cardiac myoblast. A cardiac myoblast is a precursor cell that has been committed to a cardiac muscle cell fate but retains the ability to divide and proliferate throughout life.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f252bc6987a24afcaa307a1d429b61b6","type":"GO_TERM","name":"cardiac muscle cell proliferation","canonical_id":"go:GO:0060038","description":"\"The expansion of a cardiac muscle cell population by cell division.\" [GOC:dph, GOC:rph, PMID:11161571]","metadata":null},{"id":"9068aded39784ce7b4c22a9c4fbf2a68","type":"GO_TERM","name":"cardiac muscle cell-cardiac muscle cell adhesion","canonical_id":"go:GO:0086042","description":"\"The attachment of one cardiomyocyte to another cardiomyocyte via adhesion molecules.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"0d7d00a485994699b45a1b85ddb75032","type":"GO_TERM","name":"cardiac muscle contraction","canonical_id":"go:GO:0060048","description":"\"Muscle contraction of cardiac muscle tissue.\" [GOC:dph]","metadata":null},{"id":"98fd39af2ad44f0483d1cf1894d1bd6e","type":"GO_TERM","name":"cardiac muscle hypertrophy","canonical_id":"go:GO:0003300","description":"\"The enlargement or overgrowth of all or part of the heart muscle due to an increase in size of cardiac muscle cells without cell division.\" [GOC:mtg_heart]","metadata":null},{"id":"a6cc76f55259471c82f5013d3e98160f","type":"GO_TERM","name":"cardiac muscle hypertrophy in response to stress","canonical_id":"go:GO:0014898","description":"\"The physiological enlargement or overgrowth of all or part of the heart muscle due to an increase in size (not length) of individual cardiac muscle fibers, without cell division, as a result of a disturbance in organismal or cellular homeostasis.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:mtg_muscle]","metadata":null},{"id":"01d15b6ef3214142bca2f3e77a79e7e0","type":"GO_TERM","name":"cardiac muscle myoblast proliferation","canonical_id":"go:GO:0110021","description":"\"The multiplication or reproduction of cardiac muscle myoblasts, resulting in the expansion of a cardiac muscle myoblast cell population. A cardiac myoblast is a precursor cell that has been committed to a cardiac muscle cell fate but retains the ability to divide and proliferate throughout life.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26512644]","metadata":null},{"id":"23a325307f044f2fbb5cfd81c0dd5f5b","type":"GO_TERM","name":"cardiac muscle myosin thick filament assembly","canonical_id":"go:GO:0071690","description":"\"The aggregation, arrangement and bonding together of proteins to form the myosin-based thick filaments of myofibrils in cardiac muscle.\" [GOC:mah]","metadata":null},{"id":"fc633eb45e594f289040665a2329ad54","type":"GO_TERM","name":"cardiac muscle progenitor cell migration to the midline involved in heart field formation","canonical_id":"go:GO:0003261","description":"\"The orderly movement of a myocardial progenitor cell toward the midline to form the heart field. Cardiac muscle progenitor cells are non-terminally differentiated, mesoderm-derived cells that are committed to differentiate into myocardial cells of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"6ddf4c736b324603a82e42a56f5e82d4","type":"GO_TERM","name":"cardiac muscle thin filament assembly","canonical_id":"go:GO:0071691","description":"\"The aggregation, arrangement and bonding together of proteins to form the actin-based thin filaments of myofibrils in cardiac muscle.\" [GOC:mah]","metadata":null},{"id":"1965b777889344a78b831d1f4ab24b35","type":"GO_TERM","name":"cardiac muscle tissue development","canonical_id":"go:GO:0048738","description":"\"The process whose specific outcome is the progression of cardiac muscle over time, from its formation to the mature structure.\" [GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"d0ede5b31b774a06b8b39932b5b0522a","type":"GO_TERM","name":"cardiac muscle tissue growth","canonical_id":"go:GO:0055017","description":"\"The increase in size or mass of a cardiac muscle, where the increase in size or mass has the specific outcome of the progression of the organism over time from one condition to another.\" [GOC:devbiol]","metadata":null},{"id":"d0c42ff1ab8e401e9d2a81c4772cc757","type":"GO_TERM","name":"cardiac muscle tissue growth involved in heart morphogenesis","canonical_id":"go:GO:0003245","description":"\"The developmental growth of cardiac muscle tissue that contributes to the shaping of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"b0df3e93bd754d06813af501fc1f36d9","type":"GO_TERM","name":"cardiac muscle tissue morphogenesis","canonical_id":"go:GO:0055008","description":"\"The process in which the anatomical structures of cardiac muscle tissue are generated and organized.\" [GOC:devbiol]","metadata":null},{"id":"c49513d8828c4b9ba7c1ea08e5d7f65d","type":"GO_TERM","name":"cardiac muscle tissue regeneration","canonical_id":"go:GO:0061026","description":"\"The regrowth of cardiac muscle tissue to repair injured or damaged muscle fibers in the postnatal stage.\" [GOC:dph]","metadata":null},{"id":"52cff60a3c8b46748952b41c601d9020","type":"GO_TERM","name":"cardiac myofibril","canonical_id":"go:GO:0097512","description":"\"A cardiac myofibril is a myofibril specific to cardiac muscle cells.\" [GOC:cjm, GOC:devbiol]","metadata":null},{"id":"9ea2f4ebd0ba4c3eb7f4a635a8f63f44","type":"GO_TERM","name":"cardiac myofibril assembly","canonical_id":"go:GO:0055003","description":"\"The process whose specific outcome is the progression of the cardiac myofibril over time, from its formation to the mature structure. A cardiac myofibril is a myofibril specific to cardiac muscle cells.\" [GOC:devbiol]","metadata":null},{"id":"60b70c2b29a24de8aa6a9acc6ce16ad9","type":"GO_TERM","name":"cardiac neural crest cell delamination","canonical_id":"go:GO:0036036","description":"\"The negative regulation of cell adhesion process in which a cardiac neural crest cell physically separates from the rest of the neural tube.\" [GOC:hjd, PMID:17076275, PMID:18539270, PMID:20490374]","metadata":null},{"id":"4e76ad74f11341a99071fe9adf979a90","type":"GO_TERM","name":"cardiac neural crest cell development involved in heart development","canonical_id":"go:GO:0061308","description":"\"The process aimed at the progression of a cardiac neural crest cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell that contributes to the development of the heart.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"c893980970c84224ab0332a1eaab6552","type":"GO_TERM","name":"cardiac neural crest cell development involved in outflow tract morphogenesis","canonical_id":"go:GO:0061309","description":"\"The process aimed at the progression of a cardiac neural crest cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell that contributes to the shaping of the outflow tract.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"f3b27b06e86b48218382a7fa4cfa6c2c","type":"GO_TERM","name":"cardiac neural crest cell differentiation involved in heart development","canonical_id":"go:GO:0061307","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a cardiac neural crest cell that will migrate to the heart and contribute to its development. Cardiac neural crest cells are specialized cells that migrate toward the heart from the third, fourth and sixth pharyngeal arches.\" [GOC:dph, GOC:mtg_heart, PMID:19705442]","metadata":null},{"id":"2391c543610a44f5bcca46fe08724b9c","type":"GO_TERM","name":"cardiac neural crest cell migration involved in outflow tract morphogenesis","canonical_id":"go:GO:0003253","description":"\"The orderly movement of a neural crest cell from one site to another that will contribute to the morphogenesis of the outflow tract.\" [GOC:mtg_heart]","metadata":null},{"id":"efe6940537fe4ba6b36e296b1bdc14c9","type":"GO_TERM","name":"cardiac neuron development","canonical_id":"go:GO:0060959","description":"\"The process whose specific outcome is the progression of a cardiac neuron over time, from its formation to the mature state.\" [GOC:mtg_heart]","metadata":null},{"id":"95b609e966644fcc964f862da1530784","type":"GO_TERM","name":"cardiac neuron differentiation","canonical_id":"go:GO:0060945","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"d2cc7cb392644f1c9fc23944fa6f4e81","type":"GO_TERM","name":"cardiac neuron fate commitment","canonical_id":"go:GO:0060960","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a neuron of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"3612130ea13c497982ab7ec5794acb71","type":"GO_TERM","name":"cardiac pacemaker cell development","canonical_id":"go:GO:0060926","description":"\"The process whose specific outcome is the progression of a pacemaker cell over time, from its formation to the mature state. Pacemaker cells are specialized cardiomyocytes that are responsible for regulating the timing of heart contractions.\" [GOC:mtg_cardiac_conduct_nov11, GOC:mtg_heart]","metadata":null},{"id":"fb8a89a2a18a465a92d24466ce9f65ef","type":"GO_TERM","name":"cardiac pacemaker cell differentiation","canonical_id":"go:GO:0060920","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a pacemaker cell. Pacemaker cells are specialized cardiomyocytes that are responsible for regulating the timing of heart contractions.\" [GOC:mtg_cardiac_conduct_nov11, GOC:mtg_heart]","metadata":null},{"id":"ac842030151c49519983c4861381ce4a","type":"GO_TERM","name":"cardiac pacemaker cell fate commitment","canonical_id":"go:GO:0060927","description":"\"The commitment of cells to pacemaker cell fates and their capacity to differentiate into pacemaker cells. Pacemaker cells are specialized cardiomyocytes that are responsible for regulating the timing of heart contractions.\" [GOC:mtg_cardiac_conduct_nov11, GOC:mtg_heart]","metadata":null},{"id":"aa076b5b072947e498589178ee8566ce","type":"GO_TERM","name":"cardiac right atrium formation","canonical_id":"go:GO:0003217","description":"\"The developmental process pertaining to the initial formation of a cardiac right atrium from unspecified parts.\" [GOC:mtg_heart]","metadata":null},{"id":"e52496dfa7684d6884d3143b8ae06a90","type":"GO_TERM","name":"cardiac right atrium morphogenesis","canonical_id":"go:GO:0003213","description":"\"The process in which the right cardiac atrium is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"bca94f909b7f4bf19d03a3a45d59fedd","type":"GO_TERM","name":"cardiac right ventricle formation","canonical_id":"go:GO:0003219","description":"\"The developmental process pertaining to the initial formation of a right cardiac ventricle from unspecified parts.\" [GOC:mtg_heart]","metadata":null},{"id":"c0ffd1f2e2c4448688fad1608bd02579","type":"GO_TERM","name":"cardiac right ventricle morphogenesis","canonical_id":"go:GO:0003215","description":"\"The process in which the right cardiac ventricle is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"ff6a8ad255704d7db3a1b1e74d0d30cb","type":"GO_TERM","name":"cardiac septum cell differentiation","canonical_id":"go:GO:0003292","description":"\"The process in which an endocardial cushion cell becomes a cell of a cardiac septum.\" [GOC:mtg_heart]","metadata":null},{"id":"f27a4af26ec84aa4a61535859da13401","type":"GO_TERM","name":"cardiac septum development","canonical_id":"go:GO:0003279","description":"\"The progression of a cardiac septum over time, from its initial formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"a32e70364f99490fbfddef2a5a991b69","type":"GO_TERM","name":"cardiac septum morphogenesis","canonical_id":"go:GO:0060411","description":"\"The process in which the anatomical structure of a cardiac septum is generated and organized. A cardiac septum is a partition that separates parts of the heart.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"b04e3eeb897d46f29622d7e36ae46654","type":"GO_TERM","name":"cardiac skeleton development","canonical_id":"go:GO:0003204","description":"\"The progression of the cardiac skeleton over time, from its formation to the mature structure. The cardiac skeleton is a specialized extracellular matrix that separates the atria from the ventricles and provides physical support for the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"960a6699382b47548dc223722b6e58b2","type":"GO_TERM","name":"cardiac vascular smooth muscle cell development","canonical_id":"go:GO:0060948","description":"\"The process whose specific outcome is the progression of a cardiac vascular smooth muscle cell over time, from its formation to the mature state.\" [GOC:mtg_heart]","metadata":null},{"id":"3ba24c7f8a46431ba3318d8810b39a2b","type":"GO_TERM","name":"cardiac vascular smooth muscle cell differentiation","canonical_id":"go:GO:0060947","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a cardiac vascular smooth muscle cell. A cardiac vascular smooth muscle cell covers the heart vasculature and lacks transverse striations in its constituent fibers.\" [GOC:mtg_heart]","metadata":null},{"id":"da53eb7a5e374d6e9c3739826a75f75e","type":"GO_TERM","name":"cardiac vascular smooth muscle cell fate commitment","canonical_id":"go:GO:0060949","description":"\"The commitment of cells to a cardiac vascular smooth muscle cell fate and its capacity to differentiate into a cardiac vascular smooth muscle cell.\" [GOC:mtg_heart]","metadata":null},{"id":"7b9e185d269f49e59d9790ce7017384d","type":"GO_TERM","name":"cardiac ventricle development","canonical_id":"go:GO:0003231","description":"\"The process whose specific outcome is the progression of a cardiac ventricle over time, from its formation to the mature structure. A cardiac ventricle receives blood from a cardiac atrium and pumps it out of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"a5039a606acd427e8c6e31ff542e16b9","type":"GO_TERM","name":"cardiac ventricle formation","canonical_id":"go:GO:0003211","description":"\"The developmental process pertaining to the initial formation of a cardiac ventricle from unspecified parts. A cardiac ventricle receives blood from a cardiac atrium and pumps it out of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"bee32ebd0c3c45f584e2e227aaf10f5b","type":"GO_TERM","name":"cardiac ventricle morphogenesis","canonical_id":"go:GO:0003208","description":"\"The process in which the cardiac ventricle is generated and organized. A cardiac ventricle receives blood from a cardiac atrium and pumps it out of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"49e7c02884bc404ba812548de76f12ed","type":"GO_TERM","name":"cardioblast anterior-lateral migration","canonical_id":"go:GO:0003259","description":"\"The orderly movement of a cardioblast toward the head and laterally to form the heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"38ef0eaa8dea4d08b20d06beb9f2cedf","type":"GO_TERM","name":"cardioblast cell fate commitment","canonical_id":"go:GO:0042684","description":"\"The process in which a cell becomes committed to becoming a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:curators]","metadata":null},{"id":"6db7fd0ec81849279ecec1e173ec0303","type":"GO_TERM","name":"cardioblast cell fate determination","canonical_id":"go:GO:0007510","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a cardioblast cell regardless of its environment; upon determination, the cell fate cannot be reversed. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:curators]","metadata":null},{"id":"ccee5f6d2081428c8dc0d8710794bd71","type":"GO_TERM","name":"cardioblast cell fate specification","canonical_id":"go:GO:0042685","description":"\"The process in which a cell becomes capable of differentiating autonomously into a cardioblast cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:curators]","metadata":null},{"id":"d58d810928b7449fbe44db6a43598b2f","type":"GO_TERM","name":"cardioblast cell midline fusion","canonical_id":"go:GO:0003317","description":"\"The attachment of cardiac progenitor cells to one another that contributes to the formation of the heart rudiment.\" [GOC:mtg_heart]","metadata":null},{"id":"5c8917d8bf46421fa11edd4c8e65414f","type":"GO_TERM","name":"cardioblast differentiation","canonical_id":"go:GO:0010002","description":"\"The process in which a relatively unspecialized mesodermal cell acquires the specialized structural and/or functional features of a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:curators]","metadata":null},{"id":"643eaee788774cf49c91027adf7114eb","type":"GO_TERM","name":"cardioblast migration","canonical_id":"go:GO:0003260","description":"\"The orderly movement of a cardiac progenitor cell to form the heart field. Cardiac progenitor cells are non-terminally differentiated, mesoderm-derived cells that are committed to differentiate into cells of the heart. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"e2e9f552981a430cafa4ab972e60471f","type":"GO_TERM","name":"cardioblast migration to the midline involved in heart field formation","canonical_id":"go:GO:0060975","description":"\"The orderly movement of a cardioblast toward the midline to form the heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"ab1a7738d83c48dea07b58095f02bfcd","type":"GO_TERM","name":"cardioblast migration to the midline involved in heart rudiment formation","canonical_id":"go:GO:0003319","description":"\"The orderly movement of a cardioblast toward the midline that contributes to the initial appearance of the heart rudiment.\" [GOC:mtg_heart]","metadata":null},{"id":"f87a83fb85b94523917c19dd3a884c25","type":"GO_TERM","name":"cardioblast proliferation","canonical_id":"go:GO:0003263","description":"\"The multiplication or reproduction of cardioblasts, resulting in the expansion of the population in the heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"5aa0efbfb61540ebb988f81c715f8994","type":"GO_TERM","name":"cardiocyte differentiation","canonical_id":"go:GO:0035051","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a cell that will form part of the cardiac organ of an individual.\" [GOC:bf]","metadata":null},{"id":"44d823d96d9447b0aea7528e27ab0c52","type":"DISEASE","name":"cardiofaciocutaneous syndrome","canonical_id":"mondo:0015280","description":null,"metadata":null},{"id":"57467a2491714662ac141811c1e094c5","type":"DISEASE","name":"cardiofaciocutaneous syndrome 1","canonical_id":"mondo:0007265","description":null,"metadata":null},{"id":"15dc0f57ea51482a87e87fc327d58410","type":"DISEASE","name":"cardiofaciocutaneous syndrome 2","canonical_id":"mondo:0014112","description":null,"metadata":null},{"id":"8f7177bf53514fe7bb5a911f1b00a8c6","type":"DISEASE","name":"cardiofaciocutaneous syndrome 3","canonical_id":"mondo:0014113","description":null,"metadata":null},{"id":"bee8de17e201483eac37b0c440e2a5c8","type":"GO_TERM","name":"cardiogenic plate morphogenesis","canonical_id":"go:GO:0003142","description":"\"The process in which the anatomical structures of the cardiogenic plate are generated and organized. The cardiogenic plate is the first recognizable structure derived from the heart field.\" [GOC:mtg_heart]","metadata":null},{"id":"f2a69529f7d54928b509af065a1961a2","type":"GO_TERM","name":"cardiolipin acyl-chain remodeling","canonical_id":"go:GO:0035965","description":"\"Remodeling the acyl chains of premature (de novo synthesized) cardiolipin (1,3-bis(3-phosphatidyl)glycerol), through sequential deacylation and re-acylation reactions, to generate mature cardiolipin containing high-levels of unsaturated fatty acids.\" [GOC:bf, GOC:rb, PMID:19244244]","metadata":null},{"id":"b47b3a8d408546628ea0471c7c5cf64f","type":"GO_TERM","name":"cardiolipin binding","canonical_id":"go:GO:1901612","description":"\"Binding to cardiolipin.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"c8cd966936dd41249bfcc7e14f80b679","type":"GO_TERM","name":"cardiolipin biosynthetic process","canonical_id":"go:GO:0032049","description":"\"The chemical reactions and pathways resulting in the formation of cardiolipin, 1,3-bis(3-phosphatidyl)glycerol.\" [GOC:mah]","metadata":null},{"id":"472cc625f79740c1aec7fe007bcce1e0","type":"GO_TERM","name":"cardiolipin dehydrogenase (NAD+) activity","canonical_id":"go:GO:0160241","description":"\"Catalysis of the reaction: a cardiolipin + NAD+ = a diphosphatidylglycerone + NADH + H+.\" [PMID:26338420, RHEA:81091]","metadata":null},{"id":"91d842d827324331b3df1cffe552eef0","type":"GO_TERM","name":"cardiolipin metabolic process","canonical_id":"go:GO:0032048","description":"\"The chemical reactions and pathways involving cardiolipin, 1,3-bis(3-phosphatidyl)glycerol.\" [GOC:mah]","metadata":null},{"id":"2818a85352064fd1af18fcadf4df309d","type":"GO_TERM","name":"cardiolipin phospholipase D activity","canonical_id":"go:GO:0035755","description":"\"Catalysis of the reaction: a cardiolipin + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + a 1,2-diacyl-sn-glycero-3-phosphate + H(+).\" [PMID:17028579, PMID:21397848, RHEA:44884]","metadata":null},{"id":"b7dc9c41069b402db5db8ae8fc253ab2","type":"GO_TERM","name":"cardiolipin synthase (CMP-forming) activity","canonical_id":"go:GO:0043337","description":"\"Catalysis of the reaction: a CDP-1,2-diacyl-sn-glycerol + a 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) = a cardiolipin + CMP + H+.\" [RHEA:32931]","metadata":null},{"id":"8c1b43e2426747bbb95eb465242a67e2","type":"GO_TERM","name":"cardiolipin synthase activity","canonical_id":"go:GO:0008808","description":"\"Catalysis of the reaction: phosphatidylglycerol + phosphatidylglycerol = diphosphatidylglycerol (cardiolipin) + glycerol.\" [GOC:jl, RHEA:31451]","metadata":null},{"id":"8d6ab576accf4e0f82d64a0097c21a16","type":"DISEASE","name":"cardiovascular disorder","canonical_id":"mondo:0004995","description":null,"metadata":null},{"id":"8e9e702cb41440faa1e73ad5b39cf3c0","type":"GO_TERM","name":"cargo adaptor activity","canonical_id":"go:GO:0140312","description":"\"Binding directly to the structural scaffolding elements of a vesicle coat (such as clathrin or COPII), and bridging the membrane, cargo receptor, and membrane deformation machinery.\" [PMID:25795254]","metadata":null},{"id":"e011e1ba566a4754bbae2eb8f7dff443","type":"GO_TERM","name":"cargo receptor activity","canonical_id":"go:GO:0038024","description":"\"Binding specifically to a substance (cargo) to deliver it to a transport vesicle. Cargo receptors span membranes (for instance the plasma membrane or the endoplasmic reticulum membrane), binding simultaneously to cargo molecules and coat adaptors, to efficiently recruit the cargo molecules to nascent vesicles.\" [PMID:15239958, PMID:27903609]","metadata":null},{"id":"d26c4ef2e46045799826dc2721e5c1bc","type":"GO_TERM","name":"cargo receptor complex","canonical_id":"go:GO:0062137","description":"\"Any protein complex that is part of a membrane and which functions as a cargo receptor.\" [PMID:27903609]","metadata":null},{"id":"056ceed191424bcba1f0044c72cdb8e9","type":"GO_TERM","name":"cargo receptor ligand activity","canonical_id":"go:GO:0140355","description":"\"The activity of a gene product that interacts with a cargo receptor and initiates endocytosis.\" [PMID:15797858]","metadata":null},{"id":"fa557b96ab8a4941bc1bc0cb54112fbe","type":"DRUG","name":"cariprazine","canonical_id":"mesh:C533287","description":null,"metadata":null},{"id":"448e2d38aa36462591c5ad7909cf945d","type":"DRUG","name":"carisoprodol","canonical_id":"mesh:D002328","description":null,"metadata":null},{"id":"28dc895f163e401d9d3f6d7888efb25f","type":"DRUG","name":"carmofur","canonical_id":"mesh:C017367","description":null,"metadata":null},{"id":"e42ddab709844a2292961a5c727b2a7a","type":"DRUG","name":"carmustine","canonical_id":"gtopdb:6800","description":null,"metadata":null},{"id":"989c26316fc14677b4461bb0756505a0","type":"DRUG","name":"carmustine","canonical_id":"chembl:CHEMBL513","description":null,"metadata":null},{"id":"5753d6f681d24e7b9cb4f47a7aab70a1","type":"COMBINATION_TREATMENT","name":"carmustine + etoposide","canonical_id":"ctgov_combo:ctgov-combo-de18285f5aab3c11","description":null,"metadata":null},{"id":"b450f63386a249729deeefdf6578604e","type":"COMBINATION_TREATMENT","name":"carmustine + etoposide","canonical_id":"ctgov_combo:ctgov-combo-9cbcb71b01314e7e","description":null,"metadata":null},{"id":"6cb150fab35f4cdcb700f8790515d52e","type":"COMBINATION_TREATMENT","name":"carmustine + ibrutinib","canonical_id":"ctgov_combo:ctgov-combo-17e4f65784170c77","description":null,"metadata":null},{"id":"abcc688cb0b04fbd97ad877d9e4495da","type":"COMBINATION_TREATMENT","name":"carmustine + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-772f453e88677277","description":null,"metadata":null},{"id":"438d37e5da334ff1ae31b2154a68bc8c","type":"COMBINATION_TREATMENT","name":"carmustine + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-1205d4c7f7460ac8","description":null,"metadata":null},{"id":"2978944deb96424b8626d212387cee0c","type":"COMBINATION_TREATMENT","name":"carmustine + pegfilgrastim","canonical_id":"ctgov_combo:ctgov-combo-ae5c77ae158e5214","description":null,"metadata":null},{"id":"1a859fc4e7ec450d8059be9ac458a9d1","type":"COMBINATION_TREATMENT","name":"carmustine + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-0fde62a267dd627f","description":null,"metadata":null},{"id":"a599ac384397409e8efcc76d1e57d82d","type":"GO_TERM","name":"carnitinamidase activity","canonical_id":"go:GO:0047773","description":"\"Catalysis of the reaction: (R)-carnitinamide + H2O = (R)-carnitine + NH4.\" [EC:3.5.1.73, RHEA:17537]","metadata":null},{"id":"fa15d6ac0c2b4c8c815561cbfc5bf6d3","type":"GO_TERM","name":"carnitine 3-dehydrogenase activity","canonical_id":"go:GO:0047728","description":"\"Catalysis of the reaction: carnitine + NAD+ = 3-dehydrocarnitine + H+ + NADH.\" [EC:1.1.1.108, RHEA:19265]","metadata":null},{"id":"5e63b97dc68f4b1087b4ba16b030ae91","type":"GO_TERM","name":"carnitine O-acetyltransferase activity","canonical_id":"go:GO:0004092","description":"\"Catalysis of the reaction: acetyl-CoA + carnitine = (R)-O-acetylcarnitine + CoA.\" [EC:2.3.1.7, RHEA:21136]","metadata":null},{"id":"0ca29eac3397439bb676387d0ba68bfb","type":"GO_TERM","name":"carnitine O-acyltransferase activity","canonical_id":"go:GO:0016406","description":"\"Catalysis of the transfer of an acyl group to an oxygen atom on the carnitine molecule.\" [GOC:ai]","metadata":null},{"id":"eed076e452f84e0da56b2edf34190599","type":"GO_TERM","name":"carnitine O-octanoyltransferase activity","canonical_id":"go:GO:0008458","description":"\"Catalysis of the reaction: (R)-carnitine + octanoyl-CoA = CoA + O-octanoyl-(R)-carnitine.\" [RHEA:17177]","metadata":null},{"id":"aba555e26d544f9884441eae2e4e4195","type":"GO_TERM","name":"carnitine O-palmitoyltransferase activity","canonical_id":"go:GO:0004095","description":"\"Catalysis of the reaction: palmitoyl-CoA + L-carnitine = CoA + L-palmitoylcarnitine.\" [EC:2.3.1.21]","metadata":null},{"id":"ce881027fbc94a37852348ea35d447bd","type":"GO_TERM","name":"carnitine biosynthetic process","canonical_id":"go:GO:0045329","description":"\"The chemical reactions and pathways resulting in the formation of carnitine (hydroxy-trimethyl aminobutyric acid), a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"adf786b9bc5f4cd9a7e45f96295c2012","type":"GO_TERM","name":"carnitine catabolic process","canonical_id":"go:GO:0042413","description":"\"The chemical reactions and pathways resulting in the breakdown of carnitine (hydroxy-trimethyl aminobutyric acid), a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"488e096476874a4a886c87363f455d43","type":"GO_TERM","name":"carnitine decarboxylase activity","canonical_id":"go:GO:0047729","description":"\"Catalysis of the reaction: carnitine + H+ = 2-methylcholine + CO2.\" [EC:4.1.1.42, RHEA:21576]","metadata":null},{"id":"b3a34fc2559847bbace3195c3801325a","type":"GO_TERM","name":"carnitine metabolic process","canonical_id":"go:GO:0009437","description":"\"The chemical reactions and pathways involving carnitine (hydroxy-trimethyl aminobutyric acid), a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"88a9210cdaa14611aa1bab616aa1e37b","type":"GO_TERM","name":"carnitine metabolic process, CoA-linked","canonical_id":"go:GO:0019254","description":"\"The chemical reactions and pathways involving carnitine, where metabolism is linked to CoA.\" [GOC:go_curators]","metadata":null},{"id":"5c79797dbdb04bf1b4a46354dfecc443","type":"GO_TERM","name":"carnitine racemase activity","canonical_id":"go:GO:0008809","description":"\"Catalysis of the reaction: D-carnitine = L-carnitine.\" [MetaCyc:CARNRACE-RXN]","metadata":null},{"id":"bb21889f365c48da9a5c371f74210e72","type":"GO_TERM","name":"carnitine shuttle","canonical_id":"go:GO:0006853","description":"\"The transfer of acyl groups to and from acyl-CoA molecules to form O-acylcarnitine, which can exchange across the mitochondrial inner membrane with unacylated carnitine.\" [ISBN:0198547684]","metadata":null},{"id":"881cf949d62b42a4bfa0e8ccd1352380","type":"GO_TERM","name":"carnitine transmembrane transport","canonical_id":"go:GO:1902603","description":"\"The directed movement of carnitine across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"a788b121a36943ff822be889b94f750e","type":"GO_TERM","name":"carnitine transmembrane transporter activity","canonical_id":"go:GO:0015226","description":"\"Enables the transfer of carnitine across a membrane. Carnitine is a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.\" [GOC:ai]","metadata":null},{"id":"f082eefcf9d84b118c3fb1d0d055b79c","type":"GO_TERM","name":"carnitine transport","canonical_id":"go:GO:0015879","description":"\"The directed movement of carnitine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carnitine is a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.\" [GOC:ai]","metadata":null},{"id":"00423ff3fe9e412b8cf2a8a2249a58f9","type":"GO_TERM","name":"carnitine-CoA ligase activity","canonical_id":"go:GO:0051108","description":"\"Catalysis of the reaction: D-carnitine + CoA + ATP = AMP + diphosphate + D-carnitinyl-CoA.\" [MetaCyc:DCARNCOALIG-RXN]","metadata":null},{"id":"0a6ec091b7f847a2a21e47d9f3b8e142","type":"GO_TERM","name":"carnitine:O-acyl-L-carnitine antiporter activity","canonical_id":"go:GO:0005476","description":"\"Catalysis of the reaction: carnitine (mitochondrial) + O-acyl-L-carnitine (cytoplasm) = carnitine (cytoplasm) + O-acyl-L-carnitine (mitochondrial).\" [PMID:9032458]","metadata":null},{"id":"20b25084fbb246bfb6812bcae2321ebd","type":"GO_TERM","name":"carnosine N-methyltransferase activity","canonical_id":"go:GO:0030735","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + carnosine = S-adenosyl-L-homocysteine + anserine + H+.\" [EC:2.1.1.22, RHEA:14205]","metadata":null},{"id":"509249c4e7f343739ce41e7a2384b455","type":"GO_TERM","name":"carnosine biosynthetic process","canonical_id":"go:GO:0035499","description":"\"The chemical reactions and pathways resulting in the formation of the dipeptide beta-alanyl-L-histidine (carnosine).\" [PMID:20097752]","metadata":null},{"id":"8a794db2e87045ec827c77abe5cf622d","type":"GO_TERM","name":"carnosine metabolic process","canonical_id":"go:GO:0035498","description":"\"The chemical reactions and pathways involving the dipeptide beta-alanyl-L-histidine (carnosine).\" [PMID:20097752]","metadata":null},{"id":"89a7c02a575f40dc8c268fef80eadd78","type":"GO_TERM","name":"carnosine synthase activity","canonical_id":"go:GO:0047730","description":"\"Catalysis of the reaction: beta-alanine + L-histidine + ATP = carnosine + ADP + phosphate + H+.\" [RHEA:19297]","metadata":null},{"id":"9bfae4dfd1624b09b55ee8264ed85d49","type":"GO_TERM","name":"carotene biosynthetic process","canonical_id":"go:GO:0016120","description":"\"The chemical reactions and pathways resulting in the formation of carotenes, hydrocarbon carotenoids.\" [GOC:curators]","metadata":null},{"id":"ecacb0e935d64658a2481861e4b1e0bc","type":"GO_TERM","name":"carotene catabolic process","canonical_id":"go:GO:0016121","description":"\"The chemical reactions and pathways resulting in the breakdown of carotenes, hydrocarbon carotenoids.\" [GOC:curators]","metadata":null},{"id":"a419d8b563654710b3bd16e57f3c92fb","type":"GO_TERM","name":"carotene epsilon hydroxylase activity","canonical_id":"go:GO:0072374","description":"\"Catalysis of the reaction: alpha-carotene + O2 + reduced [NADPH--hemoprotein reductase] = alpha-cryptoxanthin + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]. Zeinoxanthin may also be used as the substrate, in which case lutein is produced.\" [EC:1.14.14.158, PMID:8837513]","metadata":null},{"id":"e2195376ad6747aab2b02884a6258b36","type":"GO_TERM","name":"carotene metabolic process","canonical_id":"go:GO:0016119","description":"\"The chemical reactions and pathways involving carotenes, hydrocarbon carotenoids.\" [ISBN:0198547684]","metadata":null},{"id":"ded5463123d948aab885fba8023accca","type":"GO_TERM","name":"carotenoid biosynthetic process","canonical_id":"go:GO:0016117","description":"\"The chemical reactions and pathways resulting in the formation of carotenoids, tetraterpenoid compounds in which two units of 4 isoprenoid residues joined head-to-tail are themselves joined tail-to-tail.\" [GOC:curators]","metadata":null},{"id":"aac5cbcde5814f53a83cbddedd28277f","type":"GO_TERM","name":"carotenoid catabolic process","canonical_id":"go:GO:0016118","description":"\"The chemical reactions and pathways resulting in the breakdown of carotenoids, tetraterpenoid compounds in which two units of 4 isoprenoid residues joined head-to-tail are themselves joined tail-to-tail.\" [GOC:curators]","metadata":null},{"id":"1ca1360d523d4587806ede0acc412bf7","type":"GO_TERM","name":"carotenoid dioxygenase activity","canonical_id":"go:GO:0010436","description":"\"Catalysis of the oxidative cleavage of carotenoids.\" [PMID:16459333]","metadata":null},{"id":"28fec856682f4786803063bcb630016d","type":"GO_TERM","name":"carotenoid isomerase activity","canonical_id":"go:GO:0046608","description":"\"Catalysis of the isomerization of poly-cis-carotenoids to all-trans-carotenoids.\" [PMID:11884677]","metadata":null},{"id":"8cb9f7cfdafe483cbf87cb23c474846b","type":"GO_TERM","name":"carotenoid isomerooxygenase activity","canonical_id":"go:GO:0106422","description":"\"Catalysis of the reaction: Zeaxanthin + O2 = (3R)-11-cis-3-hydroxyretinal + (3R)-all-trans-3-hydroxyretinal.\" [PMID:19020100, PMID:19889630, RHEA:33931]","metadata":null},{"id":"7da819afae424f12b4bb103d53c4a8b4","type":"GO_TERM","name":"carotenoid metabolic process","canonical_id":"go:GO:0016116","description":"\"The chemical reactions and pathways involving carotenoids, tetraterpenoid compounds in which two units of 4 isoprenoid residues joined head-to-tail are themselves joined tail-to-tail.\" [ISBN:0198547684]","metadata":null},{"id":"6b00d831425346008c010ed28611ab3e","type":"GO_TERM","name":"carotenoid transport","canonical_id":"go:GO:0046867","description":"\"The directed movement of carotenoids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carotenoids are tetraterpenoid compounds in which two units of 4 isoprenoid residues joined head-to-tail are themselves joined tail-to-tail.\" [GOC:ai]","metadata":null},{"id":"d2a35e80adc340ab8c4ede24b51098a9","type":"GO_TERM","name":"carotenoid vesicle","canonical_id":"go:GO:0043702","description":"\"A tissue-specific cytoplasmic vesicle surrounded by a membrane half-leaflet within which carotenoid pigments are stored. Carotenoid vesicles are synthesized in xanthophores and erythrophore cells and are yellow, orange or red in appearance.\" [GOC:mh]","metadata":null},{"id":"686949da79bb4e7f8e30f618df63faa6","type":"GO_TERM","name":"carotid body glomus cell differentiation","canonical_id":"go:GO:0061103","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a glomus cell of the carotid body. The carotid body is a specialized chemosensory organ that helps respond to hypoxia.\" [GOC:dph, PMID:6243386]","metadata":null},{"id":"d377d8fca5a74a388de7a3f505e09598","type":"DRUG","name":"caroxazone","canonical_id":"mesh:C006919","description":null,"metadata":null},{"id":"d1b2cefe1dce46d2b02086cf61d319cc","type":"GO_TERM","name":"carpel development","canonical_id":"go:GO:0048440","description":"\"The process whose specific outcome is the progression of the carpel over time, from its formation to the mature structure. A carpel is an organ (generally believed to be a modified foliar unit) at the centre of a flower, bearing one or more ovules and having its margins fused together or with other carpels to enclose the ovule in an ovary, and consisting also of a stigma and usually a style.\" [GOC:curators]","metadata":null},{"id":"f13cd9ffeac1430d961e0b5b1955a3f8","type":"GO_TERM","name":"carpel formation","canonical_id":"go:GO:0048462","description":"\"The process that gives rise to the carpel. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid]","metadata":null},{"id":"a6bc8c223d9b451e84b5ca176c17b5e1","type":"GO_TERM","name":"carpel morphogenesis","canonical_id":"go:GO:0048445","description":"\"The process in which the anatomical structures of the carpel are generated and organized.\" [GOC:curators]","metadata":null},{"id":"b96b609963754c998ab31f8b78c71b3a","type":"GO_TERM","name":"carpel structural organization","canonical_id":"go:GO:0048463","description":"\"The process that contributes to the act of creating the structural organization of the carpel. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid]","metadata":null},{"id":"94778a335f6c499dbaf6a9b9906a4036","type":"DRUG","name":"carprofen","canonical_id":"gtopdb:7141","description":null,"metadata":null},{"id":"f3b10f618c7f4017a207357ee67d5671","type":"DRUG","name":"carprofen","canonical_id":"chembl:CHEMBL1316","description":null,"metadata":null},{"id":"e6b6577b37e14fc6b4be2ef6798233d4","type":"DRUG","name":"carteolol","canonical_id":"mesh:D002354","description":null,"metadata":null},{"id":"67ae65ca9c024160af0cd218ad2d4689","type":"GO_TERM","name":"cartilage condensation","canonical_id":"go:GO:0001502","description":"\"The condensation of mesenchymal cells that have been committed to differentiate into chondrocytes.\" [ISBN:0878932437]","metadata":null},{"id":"d069570fac1942cda3945f17aec21149","type":"GO_TERM","name":"cartilage development","canonical_id":"go:GO:0051216","description":"\"The process whose specific outcome is the progression of a cartilage element over time, from its formation to the mature structure. Cartilage elements are skeletal elements that consist of connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.\" [GOC:cjm, PMID:23251424]","metadata":null},{"id":"94da190333b24121a8f3a5b46951ab5f","type":"GO_TERM","name":"cartilage development involved in endochondral bone morphogenesis","canonical_id":"go:GO:0060351","description":"\"The process whose specific outcome is the progression of the cartilage that will provide a scaffold for mineralization of endochondral bones.\" [GOC:dph]","metadata":null},{"id":"6e02affd7ee44e93878078773956e9d0","type":"GO_TERM","name":"cartilage homeostasis","canonical_id":"go:GO:1990079","description":"\"A tissue homeostatic process involved in the maintenance of an internal equilibrium within cartilage, including control of cellular proliferation and death and control of metabolic function.\" [GOC:hjd, PMID:21652695]","metadata":null},{"id":"e89d4cc7c5c6443fada9bc2de3158031","type":"GO_TERM","name":"cartilage morphogenesis","canonical_id":"go:GO:0060536","description":"\"The process in which the anatomical structures of cartilage are generated and organized.\" [GOC:dph]","metadata":null},{"id":"c82417e1169a44e58125215436a52c87","type":"DRUG","name":"carvedilol","canonical_id":"gtopdb:551","description":null,"metadata":null},{"id":"26a2fe01f0eb48b98fc3b101efc4cb1f","type":"DRUG","name":"carvedilol","canonical_id":"chembl:CHEMBL723","description":null,"metadata":null},{"id":"2efe945bc6db4fba9492e615e76f5708","type":"COMBINATION_TREATMENT","name":"carvedilol + doxazosin","canonical_id":"ctgov_combo:ctgov-combo-70fc16f76ad7e0d6","description":null,"metadata":null},{"id":"6d53a59713394e5db837c2090900f1c0","type":"COMBINATION_TREATMENT","name":"carvedilol + imatinib","canonical_id":"ctgov_combo:ctgov-combo-4cc255853e1560c6","description":null,"metadata":null},{"id":"c887bea964c3471595dee8db10419569","type":"COMBINATION_TREATMENT","name":"carvedilol + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-20b191e8a78354b5","description":null,"metadata":null},{"id":"95498e14b4ed4f56869afdf763810f7f","type":"COMBINATION_TREATMENT","name":"carvedilol + lisinopril + pravastatin + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-584669833594c940","description":null,"metadata":null},{"id":"8514834af58d4716a39531fb10da1bb3","type":"COMBINATION_TREATMENT","name":"carvedilol + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-f07f590d180517c0","description":null,"metadata":null},{"id":"44cfecae117e4aff9daf521b2a5fcd36","type":"COMBINATION_TREATMENT","name":"carvedilol + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-e5fb4ce3aa5549c4","description":null,"metadata":null},{"id":"0b4b500f334c4e2386d753cad13a66e9","type":"COMBINATION_TREATMENT","name":"carvedilol + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-322fe67713226557","description":null,"metadata":null},{"id":"c25eef39c8644ce6a33f83f24a4290c5","type":"COMBINATION_TREATMENT","name":"carvedilol + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-04d01382269e8dec","description":null,"metadata":null},{"id":"14a46f58578c479fb67ffde9c8a7c31e","type":"COMBINATION_TREATMENT","name":"carvedilol + perindopril + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-6120c88724e9bd61","description":null,"metadata":null},{"id":"d093708c6f074a468d56c9d13e554517","type":"COMBINATION_TREATMENT","name":"carvedilol + prazosin","canonical_id":"ctgov_combo:ctgov-combo-7011ad17daf031cc","description":null,"metadata":null},{"id":"1d1c2eed673b47c6862b4a5fff32ffaf","type":"COMBINATION_TREATMENT","name":"carvedilol + ramipril","canonical_id":"ctgov_combo:ctgov-combo-a918bf49eaf64a58","description":null,"metadata":null},{"id":"6e2d0053e7c64c5eb4e836a038ed2642","type":"COMBINATION_TREATMENT","name":"carvedilol + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-6c8575b3b2ffaa56","description":null,"metadata":null},{"id":"885d54223b6f41a29539522b7ea67523","type":"GO_TERM","name":"carveol dehydrogenase activity","canonical_id":"go:GO:0018459","description":"\"Catalysis of the reaction: (1S,5R)-carveol + NADP+ = (R)-carvone + H+ + NADPH.\" [EC:1.1.1.243, RHEA:13629]","metadata":null},{"id":"e08e8760e88e408caf248fbd3a9b4a44","type":"GO_TERM","name":"carvone reductase activity","canonical_id":"go:GO:0018494","description":"\"Catalysis of the reactions: (1R,4R)-dihydrocarvone + A = (R)-carvone + AH2, and (1R,4S)-isodihydrocarvone + A = (S)-carvone + AH2.\" [EC:1.3.99.25]","metadata":null},{"id":"fd13457486154b2d99358f892ef7acb3","type":"GO_TERM","name":"casbene synthase activity","canonical_id":"go:GO:0050449","description":"\"Catalysis of the reaction: all-trans-geranylgeranyl diphosphate = casbene + diphosphate.\" [EC:4.2.3.8, RHEA:14901]","metadata":null},{"id":"6266a4fdfeb348118b9cbb3b09c13cda","type":"GO_TERM","name":"caspase binding","canonical_id":"go:GO:0089720","description":"\"Binding to a caspase family protein.\" [GOC:dos, GOC:ha]","metadata":null},{"id":"b2658a9059c741dcadba978cad15e1ee","type":"GO_TERM","name":"caspase complex","canonical_id":"go:GO:0008303","description":"\"A protein complex that contains one or more cysteine-type endopeptidases (also called caspases), which give the complex a peptidase activity with specificity for the hydrolysis of aspartyl bonds. These complexes may be involved e.g. in apoptotic or inflammation processes.\" [GOC:cna, GOC:mtg_apoptosis, PMID:15569692]","metadata":null},{"id":"889a85d1766a4454a7ae184ee0a1b97c","type":"GO_TERM","name":"caste determination","canonical_id":"go:GO:0048648","description":"\"The process in which individuals, having the potential to develop any of several distinct developmental paths, have their individual developmental fate determined in response to environmental and/or genetic cues. Individuals with distinct developmental fates perform different functions in a colony of social insects.\" [GOC:jid]","metadata":null},{"id":"9657043a7e3b400a905a7917b29a6455","type":"GO_TERM","name":"caste determination, influence by environmental factors","canonical_id":"go:GO:0048650","description":"\"The process in which individuals, having the potential to develop any of several distinct developmental paths, have their individual developmental fate determined in response to environmental cues. Individuals with distinct developmental fates perform different functions in a colony of social insects.\" [GOC:jid]","metadata":null},{"id":"b481701ad66b4260a953c9e1f6c2384c","type":"GO_TERM","name":"caste determination, influence by genetic factors","canonical_id":"go:GO:0048649","description":"\"The process in which individuals, having the potential to develop any of several distinct developmental paths, have their individual developmental fate determined in response to genetic cues. Individuals with distinct developmental fates perform different functions in a colony of social insects.\" [GOC:jid]","metadata":null},{"id":"624bf79e2d104dd39e0b3a009dda9006","type":"GO_TERM","name":"catabolic process","canonical_id":"go:GO:0009056","description":"\"A cellular process consisting of the biochemical pathways by which a living organism breaks down substances. This includes the breakdown of carbon compounds with the liberation of energy for use by the cell or organism.\" [ISBN:0198547684]","metadata":null},{"id":"fc2e654d14654524933a45982ef1b0d3","type":"GO_TERM","name":"catabolite repression","canonical_id":"go:GO:0061984","description":"\"A process in which the presence of one nutrient source leads to a decrease in the frequency, rate, or extent of processes involved in the metabolism of other nutrient sources.\" [GOC:dph, PMID:29197127, PMID:29295552]","metadata":null},{"id":"fa73f37d3bb74a1fb74dc31260424d17","type":"GO_TERM","name":"catagen","canonical_id":"go:GO:0042637","description":"\"The regression phase of the hair cycle during which cell proliferation ceases, the hair follicle shortens, and an anchored club hair is produced.\" [PMID:12535193]","metadata":null},{"id":"7d3e48abc42d4a8c8ba196dfc104a8c0","type":"GO_TERM","name":"catalase activity","canonical_id":"go:GO:0004096","description":"\"Catalysis of the reaction: 2 H2O2 = O2 + 2 H2O.\" [EC:1.11.1.6]","metadata":null},{"id":"cbf4b330d8c94565ab5cd73b349c677e","type":"GO_TERM","name":"catalase complex","canonical_id":"go:GO:0062151","description":"\"A protein-containing complex that is capable of catalase activity.\" [GOC:bhm, PMID:10656833]","metadata":null},{"id":"f85fc24f2f3f4b5e8e60455e834a962f","type":"GO_TERM","name":"catalytic activity","canonical_id":"go:GO:0003824","description":"\"Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic.\" [GOC:vw, ISBN:0198506732]","metadata":null},{"id":"6d9d8433f28c48049ce137b1fd84b35d","type":"GO_TERM","name":"catalytic activity, acting on DNA","canonical_id":"go:GO:0140097","description":"\"Catalytic activity that acts to modify DNA.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"bc08e51756114b69b7694e41c6e3a8ec","type":"GO_TERM","name":"catalytic activity, acting on RNA","canonical_id":"go:GO:0140098","description":"\"Catalytic activity that acts to modify RNA.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"9a8425095e4f4f61a04877949ebf9dfb","type":"GO_TERM","name":"catalytic activity, acting on a glycoprotein","canonical_id":"go:GO:0140103","description":"\"Catalysis of a biochemical reaction in which one of the substrates is a glycoprotein.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"1541efb4831e467396a3aa4d74085e5e","type":"GO_TERM","name":"catalytic activity, acting on a nucleic acid","canonical_id":"go:GO:0140640","description":"\"Catalytic activity that acts to modify a nucleic acid.\" [GOC:pg]","metadata":null},{"id":"4992cb578bc943e794ab8c7089fe4d3b","type":"GO_TERM","name":"catalytic activity, acting on a protein","canonical_id":"go:GO:0140096","description":"\"Catalytic activity that acts to modify a protein.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"77d441aec8ce47bf81cba4a7f79efd95","type":"GO_TERM","name":"catalytic activity, acting on a rRNA","canonical_id":"go:GO:0140102","description":"\"Catalytic activity that acts to modify a ribosomal RNA.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"7c846fd2f3ba43e7b7aeda9bdd0ef60d","type":"GO_TERM","name":"catalytic activity, acting on a tRNA","canonical_id":"go:GO:0140101","description":"\"Catalytic activity that acts to modify a tRNA.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"4a254a3f758b4bacafbbb42f3cda936f","type":"GO_TERM","name":"catalytic complex","canonical_id":"go:GO:1902494","description":"\"A protein complex which is capable of catalytic activity.\" [GOC:bhm, GOC:TermGenie, PMID:8077207]","metadata":null},{"id":"28b87e457d754d548ad32481914c3dba","type":"GO_TERM","name":"catalytic step 1 spliceosome","canonical_id":"go:GO:0071012","description":"\"A spliceosomal complex that is formed by the displacement of the two snRNPs from the precatalytic spliceosome; three snRNPs including U5 remain associated with the mRNA. This complex, sometimes called the activated spliceosome, is the catalytically active form of the spliceosome, and includes many proteins in addition to those found in the associated snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, PMID:18322460, PMID:19239890]","metadata":null},{"id":"b3d27d08fce14ea1bbe326a858cfd574","type":"GO_TERM","name":"catalytic step 2 spliceosome","canonical_id":"go:GO:0071013","description":"\"A spliceosomal complex that contains three snRNPs, including U5, bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the associated snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393, PMID:18322460, PMID:19239890]","metadata":null},{"id":"153546c469a8430eaff5e927c14a470c","type":"DISEASE","name":"cataract","canonical_id":"mondo:0005129","description":null,"metadata":null},{"id":"e20bb0d90871409788c8cebde3cf9820","type":"GO_TERM","name":"catechin binding","canonical_id":"go:GO:0097246","description":"\"Binding to a catechin, a polyphenolic antioxidant plant metabolite with a flavonoid or flavan-3-ol structure.\" [GOC:sl]","metadata":null},{"id":"8a967fd16d844bd481017e24a39170d6","type":"GO_TERM","name":"catechol 1,2-dioxygenase activity","canonical_id":"go:GO:0018576","description":"\"Catalysis of the reaction: catechol + O2 = cis,cis-muconate.\" [RHEA:23852]","metadata":null},{"id":"645c5c8c688f46ad9ab55df5a79be044","type":"GO_TERM","name":"catechol 2,3-dioxygenase activity","canonical_id":"go:GO:0018577","description":"\"Catalysis of the reaction: catechol + O2 = 2-hydroxymuconate semialdehyde.\" [RHEA:17337]","metadata":null},{"id":"4c0c1f77e387490593ea5100366a04a2","type":"GO_TERM","name":"catechol O-methyltransferase activity","canonical_id":"go:GO:0016206","description":"\"Catalysis of the reaction: a catechol + S-adenosyl-L-methionine = a guaiacol + H+ + S-adenosyl-L-homocysteine. Acts on catechols and on catecholamines such as adrenaline or noradrenaline.\" [EC:2.1.1.6, RHEA:17877]","metadata":null},{"id":"8b94911882f14afbbeca480a54088874","type":"GO_TERM","name":"catechol catabolic process, meta-cleavage","canonical_id":"go:GO:0019616","description":"\"The chemical reactions and pathways resulting in the breakdown of catechol via the meta-cleavage pathway, in which the catechol aromatic ring is broken between a hydroxylated carbon atom and an adjacent unsubstituted carbon atom.\" [GOC:jl, PMID:7765833]","metadata":null},{"id":"d3266d70b5ca4972b72d45bacbc7a8ad","type":"GO_TERM","name":"catechol catabolic process, ortho-cleavage","canonical_id":"go:GO:0019615","description":"\"The chemical reactions and pathways resulting in the breakdown of catechol via the ortho-cleavage pathway, in which the catechol aromatic ring is broken between the two carbon atoms bearing hydroxyl groups.\" [GOC:jl, PMID:7765833]","metadata":null},{"id":"4933d34f4af94b228b39e8629cecbce1","type":"GO_TERM","name":"catechol oxidase (dimerizing) activity","canonical_id":"go:GO:0047731","description":"\"Catalysis of the reaction: 4 catechol + 3 O2 = 2 dibenzo[1,4]dioxin-2,3-dione + 6 H2O.\" [EC:1.1.3.14, MetaCyc:CATECHOL-OXIDASE-DIMERIZING-RXN]","metadata":null},{"id":"5fe02e9d87024b7db7c4f8ea0f8c6670","type":"GO_TERM","name":"catechol oxidase activity","canonical_id":"go:GO:0004097","description":"\"Catalysis of the reaction: 2 catechol + O2 = 2 1,2-benzoquinone + 2 H2O. This reaction catalyzes exclusively the oxidation of catechols (i.e., o-diphenols) to the corresponding o-quinones.\" [EC:1.10.3.1, PMID:22120533]","metadata":null},{"id":"8e2f2d6033c14def81ffde6dbc1be42b","type":"GO_TERM","name":"catechol-containing compound biosynthetic process","canonical_id":"go:GO:0009713","description":"\"The chemical reactions and pathways resulting in the formation of catechol-containing compounds. Catechol is a compound containing a pyrocatechol nucleus or substituent.\" [GOC:curators]","metadata":null},{"id":"1711b75a8a244fc19cae24800b61d9bf","type":"GO_TERM","name":"catechol-containing compound catabolic process","canonical_id":"go:GO:0019614","description":"\"The chemical reactions and pathways resulting in the breakdown of catechol-containing compounds. Catechol is a compound containing a pyrocatechol nucleus or substituent.\" [GOC:curators]","metadata":null},{"id":"7ca33baae62e4da5ae9d8f056abc4fdc","type":"GO_TERM","name":"catechol-containing compound metabolic process","canonical_id":"go:GO:0009712","description":"\"The chemical reactions and pathways involving a compound containing a pyrocatechol (1,2-benzenediol) nucleus or substituent.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"5cce2a91effc4231a7b347bf1fb526b4","type":"GO_TERM","name":"catechol-containing siderophore biosynthetic process","canonical_id":"go:GO:0019540","description":"\"The chemical reactions and pathways resulting in the formation of a siderophore from other compounds, including catechol. Catechol is one of the three major chemical groups incorporated into siderophore structures with hydroxamate and a-hydroxycarboxylate, each having a high selectivity for iron(3+).\" [PMID:20376388]","metadata":null},{"id":"7053403f5add4c4abe6e9ec6b1863b21","type":"GO_TERM","name":"catecholamine binding","canonical_id":"go:GO:1901338","description":"\"Binding to catecholamine.\" [GOC:TermGenie]","metadata":null},{"id":"638e3965ddf7496a86514ed8423056b1","type":"GO_TERM","name":"catecholamine biosynthetic process","canonical_id":"go:GO:0042423","description":"\"The chemical reactions and pathways resulting in the formation of any of a group of physiologically important biogenic amines that possess a catechol (3,4-dihydroxyphenyl) nucleus and are derivatives of 3,4-dihydroxyphenylethylamine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"565597deda2f436c9aa531c49c5db953","type":"GO_TERM","name":"catecholamine catabolic process","canonical_id":"go:GO:0042424","description":"\"The chemical reactions and pathways resulting in the breakdown of any of a group of physiologically important biogenic amines that possess a catechol (3,4-dihydroxyphenyl) nucleus and are derivatives of 3,4-dihydroxyphenylethylamine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"0ac64fa11f2944a7b44de45e88ad75e3","type":"GO_TERM","name":"catecholamine metabolic process","canonical_id":"go:GO:0006584","description":"\"The chemical reactions and pathways involving any of a group of physiologically important biogenic amines that possess a catechol (3,4-dihydroxyphenyl) nucleus and are derivatives of 3,4-dihydroxyphenylethylamine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"d5729b4da0ba49b1b06ed11024156828","type":"GO_TERM","name":"catecholamine secretion","canonical_id":"go:GO:0050432","description":"\"The regulated release of catecholamines by a cell. The catecholamines are a group of physiologically important biogenic amines that possess a catechol (3,4-dihydroxyphenyl) nucleus and are derivatives of 3,4-dihydroxyphenylethylamine.\" [GOC:ai, GOC:ef]","metadata":null},{"id":"ff7ee2286c364543b45e0f8c115adf72","type":"GO_TERM","name":"catecholamine secretion, neurotransmission","canonical_id":"go:GO:0160043","description":"\"The regulated release of catecholamine by a cell in which the catecholamine acts as a neurotransmitter.\" [PMID:10191060]","metadata":null},{"id":"0ae864d851ae4a7dbec2a9bf3efeeec9","type":"GO_TERM","name":"catecholamine uptake","canonical_id":"go:GO:0090493","description":"\"The directed movement of catecholamine into a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9f89b73955934092bce3fa02f8882d10","type":"GO_TERM","name":"catenin complex","canonical_id":"go:GO:0016342","description":"\"Complex of peripheral cytoplasmic proteins (alpha-, beta- and gamma-catenin) that interact with the cytoplasmic region of uvomorulin/E-cadherin to connect it to the actin cytoskeleton.\" [ISBN:0198599323]","metadata":null},{"id":"5d958394aa844b8e808609ac5cb1d70a","type":"GO_TERM","name":"catenin-TCF7L2 complex","canonical_id":"go:GO:0071664","description":"\"A protein complex that contains a catenin and TCF7L2 (TCF4), binds to the TCF DNA motif within a promoter element, and is involved in the regulation of WNT target gene transcription.\" [GOC:BHF, GOC:rl, GOC:vk, PMID:14661054]","metadata":null},{"id":"320ce4a4db41408dbf9e38ff159e513b","type":"GO_TERM","name":"cation binding","canonical_id":"go:GO:0043169","description":"\"Binding to a cation, a charged atom or group of atoms with a net positive charge.\" [GOC:jl]","metadata":null},{"id":"3fe0786056c24c68b64c6b84a7f3813d","type":"GO_TERM","name":"cation channel complex","canonical_id":"go:GO:0034703","description":"\"An ion channel complex through which cations pass.\" [GOC:mah]","metadata":null},{"id":"9deabab78f804ed595f6104ba49213be","type":"GO_TERM","name":"cation-transporting ATPase complex","canonical_id":"go:GO:0090533","description":"\"Protein complex that carries out the reaction: ATP + H2O + cation(out) = ADP + phosphate + cation(in).\" [GOC:BHF]","metadata":null},{"id":"716da3d8030148229d6bd35a36d477bb","type":"DRUG","name":"catumaxomab","canonical_id":"gtopdb:7385","description":null,"metadata":null},{"id":"43ec95a62a8d4c78be97930fd2c6e640","type":"DRUG","name":"catumaxomab","canonical_id":"chembl:CHEMBL2108581","description":null,"metadata":null},{"id":"007eb0f6a82a4c0a8d30f6fe0177fffa","type":"GO_TERM","name":"caudal fin development","canonical_id":"go:GO:0033336","description":"\"The process whose specific outcome is the progression of the caudal fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"12c3df6045c44a2fb048c421078b65e8","type":"GO_TERM","name":"caudal fin morphogenesis","canonical_id":"go:GO:0035143","description":"\"The process in which the anatomical structures of the caudal fin are generated and organized. A caudal fin is an unpaired medial fin mounted at the caudal end of the fish, and is the main fin used for propulsion.\" [GOC:dgh]","metadata":null},{"id":"bcf99e54089348cab8606e30065f6996","type":"GO_TERM","name":"caudal ganglionic eminence cell proliferation","canonical_id":"go:GO:0022021","description":"\"The multiplication or reproduction of caudal ganglionic eminence cells, resulting in the expansion of a cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d8d3aa8b2e9442819549ed0bf08c132b","type":"GO_TERM","name":"caudate nucleus development","canonical_id":"go:GO:0021757","description":"\"The progression of the caudate nucleus over time from its initial formation until its mature state. The caudate nucleus is the C-shaped structures of the striatum containing input neurons involved with control of voluntary movement in the brain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"a0954a2737804d22ac9c1c99b55218f0","type":"GO_TERM","name":"caveola","canonical_id":"go:GO:0005901","description":"\"A membrane raft that forms small pit, depression, or invagination that communicates with the outside of a cell and extends inward, indenting the cytoplasm and the cell membrane. Examples include flask-shaped invaginations of the plasma membrane in adipocytes associated with caveolin proteins, and minute pits or incuppings of the cell membrane formed during pinocytosis. Caveolae may be pinched off to form free vesicles within the cytoplasm.\" [GOC:mah, ISBN:0721662544, PMID:16645198]","metadata":null},{"id":"2edb4028fb2c4780a145474d7587c200","type":"GO_TERM","name":"caveola assembly","canonical_id":"go:GO:0070836","description":"\"The aggregation, arrangement and bonding together of a set of components to form a caveola. A caveola is a plasma membrane raft that forms a small pit, depression, or invagination that communicates with the outside of a cell and extends inward, indenting the cytoplasm and the cell membrane.\" [GOC:BHF, GOC:mah, GOC:vk, PMID:12633858]","metadata":null},{"id":"b78f0b2c56dd40c6a2ecce87c426a07e","type":"GO_TERM","name":"caveola bulb","canonical_id":"go:GO:0099401","description":"\"The region of a caveola that extends into the cytoplasm, excluding the neck (rim). This region is associated with intracellular caveola proteins.\" [GOC:PARL, GOC:POD, PMID:17227843]","metadata":null},{"id":"1a4d67d48a7748fab88207e438261b3e","type":"GO_TERM","name":"caveola neck","canonical_id":"go:GO:0099400","description":"\"A membrane microdomain that forms a necklace around the bulb (crater) of a caveola. Intramembrane particles are concentrated in this region and cytoskeletal components, including actin, are highly enriched in the area underlying it.\" [GOC:pad, GOC:PARL, PMID:17227843]","metadata":null},{"id":"63ae7ac742b642ac88c47a6affec49d7","type":"GO_TERM","name":"caveolar macromolecular signaling complex","canonical_id":"go:GO:0002095","description":"\"A complex composed of proteins required for beta adrenergic receptor activation of protein kinase A. It includes the Cav 12. subunit of L-type calcium channel, protein kinase A regulatory subunit 2(PKAR2), adenyl cyclase, beta-adrenergic receptor, G-alpha-S, protein phosphatase 2A (PP2A) and caveolin 3 (CAV3).\" [PMID:16648270]","metadata":null},{"id":"8a2c6493ff8148b89ac3c13680063cb2","type":"GO_TERM","name":"caveolin-mediated endocytosis","canonical_id":"go:GO:0072584","description":"\"An endocytosis process that begins when material is taken up into plasma membrane caveolae, which then pinch off to form endocytic caveolar carriers.\" [GOC:BHF, GOC:mah, PMID:17318224, PMID:18498251, PMID:8970738, PMID:9234965]","metadata":null},{"id":"4941720f1d9245a1b45414af2999c2e4","type":"GO_TERM","name":"caveolin-mediated endocytosis of virus by host cell","canonical_id":"go:GO:0075513","description":"\"Any caveolin-mediated endocytosis that is involved in the uptake of a virus into a host cell. Begins when material is taken up into plasma membrane caveolae - specialized lipid rafts that form 50-70 nm flask-shaped invaginations of the plasma membrane - which then pinch off to form endocytic caveolar carriers containing the virus.\" [GOC:bf, GOC:jl, VZ:976]","metadata":null},{"id":"ba6146187ba64e8092cc78af860531fd","type":"DRUG","name":"cefalexin","canonical_id":"mesh:D002506","description":null,"metadata":null},{"id":"ef33da41abab490b8895b49ee13c0cb4","type":"DRUG","name":"cefalotin","canonical_id":"mesh:D002512","description":null,"metadata":null},{"id":"41a66d82ad3a409892a9ca7eb63d8c75","type":"DRUG","name":"cefotaxime","canonical_id":"mesh:D002439","description":null,"metadata":null},{"id":"b351da7dcd2a4fb995848e68696a37a0","type":"DRUG","name":"cefotetan","canonical_id":"mesh:D015313","description":null,"metadata":null},{"id":"340b534b77ad445e9200d5b189795729","type":"DRUG","name":"cefoxitin","canonical_id":"mesh:D002440","description":null,"metadata":null},{"id":"7297a44e2d054d33a4bc1f94d5fd3cfc","type":"DRUG","name":"cefpodoxime proxetil","canonical_id":"mesh:C053267","description":null,"metadata":null},{"id":"ffc43129891b418e99ce3dfe176707cf","type":"DRUG","name":"cefprozil","canonical_id":"mesh:C052018","description":null,"metadata":null},{"id":"cac596a21935489b8036ad39eab85e8e","type":"DRUG","name":"ceftazidime","canonical_id":"mesh:D002442","description":null,"metadata":null},{"id":"ccc428cd535e4a5b9c15805a41bb94f6","type":"DRUG","name":"ceftizoxime","canonical_id":"mesh:D015296","description":null,"metadata":null},{"id":"fd25b6ed768b4510ad43f7855a06bd3d","type":"DRUG","name":"ceftolozane","canonical_id":"mesh:C519491","description":null,"metadata":null},{"id":"e8289e4fdcea4b95b3ff86c3082564be","type":"DRUG","name":"cefuroxime","canonical_id":"mesh:D002444","description":null,"metadata":null},{"id":"8b8641f31d7c425c993c756f9230bdcc","type":"DRUG","name":"celecoxib","canonical_id":"gtopdb:2892","description":null,"metadata":null},{"id":"ff105896eefd4506b2e2b27c78ab87e0","type":"DRUG","name":"celecoxib","canonical_id":"mesh:D000068579","description":null,"metadata":null},{"id":"634c681c192145e49772c7b320b51bd2","type":"DRUG","name":"celecoxib","canonical_id":"chembl:CHEMBL118","description":null,"metadata":null},{"id":"f7c4e501660140c8b33b63178c36aee9","type":"COMBINATION_TREATMENT","name":"celecoxib + diazepam + hydrocodone + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-c2118c4d8d28b0ce","description":null,"metadata":null},{"id":"cd034e8aa8db4347ae539cc7b22dc3fe","type":"COMBINATION_TREATMENT","name":"celecoxib + diazepam + hydrocodone + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-2c03cea8d5573c2c","description":null,"metadata":null},{"id":"3ae4d6a8ab6a42dd9adf9497f6db5779","type":"COMBINATION_TREATMENT","name":"celecoxib + diclofenac","canonical_id":"ctgov_combo:ctgov-combo-1ba7079ce4a03c2a","description":null,"metadata":null},{"id":"57da897a01854cd29424fdf7de4e203d","type":"COMBINATION_TREATMENT","name":"celecoxib + diclofenac + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-eceafa21098bcc72","description":null,"metadata":null},{"id":"690df72488eb4da28c3799c47afba9fa","type":"COMBINATION_TREATMENT","name":"celecoxib + durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-7fe20986e7a18044","description":null,"metadata":null},{"id":"cd5742a6b562464787a28b8c3abfbef0","type":"COMBINATION_TREATMENT","name":"celecoxib + etoposide","canonical_id":"ctgov_combo:ctgov-combo-3e18de48c8bdca5a","description":null,"metadata":null},{"id":"4eb788c38a354ef78b4580eba1d97353","type":"COMBINATION_TREATMENT","name":"celecoxib + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-2b7495c58017273a","description":null,"metadata":null},{"id":"8f5c3db1ef364d89a6259ca6d778453c","type":"COMBINATION_TREATMENT","name":"celecoxib + golimumab","canonical_id":"ctgov_combo:ctgov-combo-42fbc7f08713105a","description":null,"metadata":null},{"id":"0d57cfc6fb1c49d7a1bfcacb32410284","type":"COMBINATION_TREATMENT","name":"celecoxib + ibuprofen","canonical_id":"ctgov_combo:ctgov-combo-94db629bab35bf1b","description":null,"metadata":null},{"id":"050777eec61d43fc9e33a428451c6903","type":"COMBINATION_TREATMENT","name":"celecoxib + ketoprofen","canonical_id":"ctgov_combo:ctgov-combo-0120333ee0eb2f2d","description":null,"metadata":null},{"id":"0f929680ae5a4f38995d0412ad33d8e6","type":"COMBINATION_TREATMENT","name":"celecoxib + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-177d8504baf13b93","description":null,"metadata":null},{"id":"e09bed14c04745e3a4802fe5696d61e3","type":"COMBINATION_TREATMENT","name":"celecoxib + naproxen","canonical_id":"ctgov_combo:ctgov-combo-07f85a486f684b3a","description":null,"metadata":null},{"id":"0c412adf268143c38b9047d2832d5b77","type":"COMBINATION_TREATMENT","name":"celecoxib + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-b7e7f7823c640844","description":null,"metadata":null},{"id":"a44c6b2d3c6d48548a9a09fca1c8dffd","type":"COMBINATION_TREATMENT","name":"celecoxib + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-57186ff56bdd48a7","description":null,"metadata":null},{"id":"11f37159f3a040298e9e60df169657af","type":"COMBINATION_TREATMENT","name":"celecoxib + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-3d578fd016e94b85","description":null,"metadata":null},{"id":"0d6fac82238a4ffaafe1c3563403f084","type":"GO_TERM","name":"cell activation","canonical_id":"go:GO:0001775","description":"\"A multicellular organismal process by which exposure to an activating factor such as a cellular or soluble ligand results in a change in the morphology or behavior of a cell.\" [GOC:mgi_curators]","metadata":null},{"id":"87f5ac6250b74cd28e4b9949bde88cca","type":"GO_TERM","name":"cell activation involved in immune response","canonical_id":"go:GO:0002263","description":"\"A change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"ee005acf0690479597ccd674775ed085","type":"GO_TERM","name":"cell adhesion","canonical_id":"go:GO:0007155","description":"\"The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.\" [GOC:hb, GOC:pf]","metadata":null},{"id":"57bf2f2edef6447da05601139968a1e4","type":"GO_TERM","name":"cell adhesion involved in biofilm formation","canonical_id":"go:GO:0043708","description":"\"The attachment of a cell to a solid substrate, via cell adhesion molecules, contributing to the formation of a biofilm.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"0fb26cd3b15641d5be1acdf855ce4e69","type":"GO_TERM","name":"cell adhesion involved in heart morphogenesis","canonical_id":"go:GO:0061343","description":"\"The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules that contributes to the shaping of the heart.\" [GOC:dph, GOC:mtg_heart, PMID:16860783]","metadata":null},{"id":"020dd0e2415c4d878c450538aab3b281","type":"GO_TERM","name":"cell adhesion involved in multi-species biofilm formation","canonical_id":"go:GO:0043710","description":"\"The attachment of a cell to a solid substrate, via cell adhesion molecules, contributing to the formation of a biofilm composed of microorganisms of different species.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"d045ef52faad470eb169f1e617fa53bf","type":"GO_TERM","name":"cell adhesion involved in single-species biofilm formation","canonical_id":"go:GO:0043709","description":"\"The attachment of a cell to a solid substrate, via cell adhesion molecules, during the formation of a biofilm composed of microorganisms of the same species.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"06c51424f8c84451abe1c202d34a5c3e","type":"GO_TERM","name":"cell adhesion involved in single-species biofilm formation in or on host organism","canonical_id":"go:GO:0043707","description":"\"The attachment of a cell to either a host cell or a microbial cell of the same species, or to an underlying host substrate, such as the extracellular matrix, via cell adhesion molecules, occurring during the formation of a biofilm in or on a host species.\" [GOC:jl]","metadata":null},{"id":"237c5cf35262446b9f192c5e66057369","type":"GO_TERM","name":"cell adhesion involved in sprouting angiogenesis","canonical_id":"go:GO:0120078","description":"\"The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules that contributes to the formation of a blood vessel network.\" [GOC:cvs, PMID:28264837]","metadata":null},{"id":"bba8bdd7de0f4d3b9270142cd613137a","type":"GO_TERM","name":"cell adhesion mediated by integrin","canonical_id":"go:GO:0033627","description":"\"The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via an integrin, a heterodimeric adhesion receptor formed by the non-covalent association of particular alpha and beta subunits.\" [GOC:add, PMID:12213832, PMID:14754902]","metadata":null},{"id":"ac6a046b9478465f9390a5a90deea6bc","type":"GO_TERM","name":"cell adhesion mediator activity","canonical_id":"go:GO:0098631","description":"\"The binding by a cell-adhesion protein on a cell surface to an adhesion molecule on another cell surface or an external substrate, to mediate adhesion of the cell to the external substrate or to another cell.\" [GOC:vw, Wikipedia:Cell_adhesion]","metadata":null},{"id":"f3c5305f07724b198212c1cca5eec06f","type":"GO_TERM","name":"cell adhesion molecule binding","canonical_id":"go:GO:0050839","description":"\"Binding to a cell adhesion molecule.\" [GOC:ai]","metadata":null},{"id":"b6b6eec1b23d45e3ab9fc3b33b0c52f3","type":"GO_TERM","name":"cell adhesion molecule production","canonical_id":"go:GO:0060352","description":"\"The appearance of a cell adhesion molecule due to biosynthesis or secretion.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"a32db90113b3432589e6d2d8458db929","type":"GO_TERM","name":"cell adhesion receptor activity","canonical_id":"go:GO:0004895","description":"\"The binding by a cell-adhesion protein on the cell surface to an extracellular matrix component, to mediate adhesion of the cell to the external substrate or to another cell and to initiate intracellular signaling. Cell adhesion receptors include integrins and cadherins.\" [GOC:BHF-UCL, Wikipedia:Cell_adhesion]","metadata":null},{"id":"9f4c5c45e9654f50afbda424f2b6a8e0","type":"GO_TERM","name":"cell adhesive protein binding involved in AV node cell-bundle of His cell communication","canonical_id":"go:GO:0086082","description":"\"Binding to a protein or protein complex that results in the connection of an AV node cell with a bundle of His cell and contributes to the communication between the two cells.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"8e75addb118d45d3a2f0dfa328997e5c","type":"GO_TERM","name":"cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication","canonical_id":"go:GO:0086083","description":"\"Binding to a protein or protein complex that results in the connection of a bundle of His cell with a Purkinje myocyte and contributes to the communication between the two cells.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f45fc1c0c0e3469f9ee65e5b435f5ffe","type":"GO_TERM","name":"cell aggregation","canonical_id":"go:GO:0098743","description":"\"The clustering together and adhesion of initially separate cells to form an aggregate. Examples include the clustering of unicellular organisms or blood cells in suspension and the condensation of mesenchymal cells during cartilage formation.\" [GOC:dos]","metadata":null},{"id":"4399c9731f3d4e83a78ef382954b9758","type":"GO_TERM","name":"cell body","canonical_id":"go:GO:0044297","description":"\"The portion of a cell bearing surface projections such as axons, dendrites, cilia, or flagella that includes the nucleus, but excludes all cell projections.\" [GOC:curators]","metadata":null},{"id":"33ba05b78d1b440f9ce9266c03430234","type":"GO_TERM","name":"cell body fiber","canonical_id":"go:GO:0070852","description":"\"A neuron projection that is found in unipolar neurons and corresponds to the region between the cell body and the point at which the single projection branches.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"127a1701031344f0b1fa6aebe3f0d4f5","type":"GO_TERM","name":"cell body membrane","canonical_id":"go:GO:0044298","description":"\"The plasma membrane of a cell that bears surface projections such as axons, dendrites, cilia, or flagella, excluding the plasma membrane on cell projections.\" [GOC:ecd]","metadata":null},{"id":"ab0c0dfbeff845ae998ae2f9f861a8db","type":"GO_TERM","name":"cell budding","canonical_id":"go:GO:0007114","description":"\"A form of asexual reproduction, occurring in certain bacteria and fungi (e.g. yeasts) and some primitive animals in which an individual arises from a daughter cell formed by pinching off a part of the parent cell. The budlike outgrowths so formed may sometimes remain attached to the parent cell.\" [ISBN:0198506732]","metadata":null},{"id":"1a8704fccb0544a8babe90b4401d98cc","type":"GO_TERM","name":"cell chemotaxis","canonical_id":"go:GO:0060326","description":"\"The directed movement of a motile cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [GOC:dph]","metadata":null},{"id":"4db7173d1b4542caa6de7f7fb4dd9578","type":"GO_TERM","name":"cell chemotaxis involved in Malpighian tubule morphogenesis","canonical_id":"go:GO:0061352","description":"\"The directed movement of the outgrowing Malpighian tubule guided by specific chemical cues/signals. Movement may be towards a guidance cue (positive chemotaxis) or away from it (negative chemotaxis). Guidance contributes to the final positioning of the tubule.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"8edebb2e62e34694ba0ee1cfdbeb86e3","type":"GO_TERM","name":"cell chemotaxis to angiotensin","canonical_id":"go:GO:0071434","description":"\"The directed movement of a motile cell in response to the presence of angiotensin.\" [GOC:mah]","metadata":null},{"id":"87e0a13a9fc44cd188af5220e3d1d229","type":"GO_TERM","name":"cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:0035766","description":"\"The directed movement of a motile cell in response to the presence of fibroblast growth factor (FGF).\" [GOC:BHF]","metadata":null},{"id":"b74b5bb8b96d499dbe858cd60054d9e0","type":"GO_TERM","name":"cell chemotaxis to vascular endothelial growth factor","canonical_id":"go:GO:0090667","description":"\"The directed movement of a motile cell in response to the presence of vascular endothelial growth factor (VEGF).\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:21885851]","metadata":null},{"id":"3ffa1e3848a14de181d44c1b48058afe","type":"GO_TERM","name":"cell communication","canonical_id":"go:GO:0007154","description":"\"Any process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:mah]","metadata":null},{"id":"71ba6abd45534fb3afa9169e989950e1","type":"GO_TERM","name":"cell communication by chemical coupling","canonical_id":"go:GO:0010643","description":"\"The process that mediates signaling interactions between one cell and another cell by the transfer of small, water-soluble molecules or metabolites between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"01af6ee09fb44993bdf420c388d3eb42","type":"GO_TERM","name":"cell communication by electrical coupling","canonical_id":"go:GO:0010644","description":"\"The process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"04c8500b96c848f889329aefa3efda67","type":"GO_TERM","name":"cell communication by electrical coupling involved in cardiac conduction","canonical_id":"go:GO:0086064","description":"\"The process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels and contributes to the process of cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"7cc2cb62d84541a6b1d7ec37ad64b3e3","type":"GO_TERM","name":"cell communication involved in cardiac conduction","canonical_id":"go:GO:0086065","description":"\"Any process that mediates interactions between a cell and its surroundings that contributes to the process of cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"a35acd39857d4cb38dea2735f393d80c","type":"GO_TERM","name":"cell competition in a multicellular organism","canonical_id":"go:GO:0035212","description":"\"Competitive interactions within multicellular organisms between cell populations that differ in growth rates, leading to the elimination of the slowest-growing cells.\" [GOC:bf, PMID:1116643, PMID:15066286]","metadata":null},{"id":"59b6c0ffd6a2454aa357986d0c5cf922","type":"GO_TERM","name":"cell cortex","canonical_id":"go:GO:0005938","description":"\"The region of a cell that lies just beneath the plasma membrane and often, but not always, contains a network of actin filaments and associated proteins.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"d6d9cc90dc314aa2a16264b9839c4af2","type":"GO_TERM","name":"cell cortex of cell tip","canonical_id":"go:GO:0051285","description":"\"The region directly beneath the plasma membrane at the cell tip. The cell tip is the region at either end of the longest axis of a cylindrical or elongated cell.\" [GOC:ai]","metadata":null},{"id":"a4b17ad88d9848af93b2f2987a52f595","type":"GO_TERM","name":"cell cortex of growing cell tip","canonical_id":"go:GO:1902716","description":"\"Any cell cortex that is part of a growing cell tip.\" [GO_REF:0000064, GOC:TermGenie, PMID:24146635]","metadata":null},{"id":"20c694644f6045baa125b25b49e6c338","type":"GO_TERM","name":"cell cortex of non-growing cell tip","canonical_id":"go:GO:0140472","description":"\"The region directly beneath the plasma membrane at the cell tip at which no growth takes place.\" [PMID:17895368]","metadata":null},{"id":"4c71faa8fde048ba8eaedd118ef023bd","type":"GO_TERM","name":"cell cortex region","canonical_id":"go:GO:0099738","description":"\"The complete extent of cell cortex that underlies some some region of the plasma membrane.\" [GOC:dos]","metadata":null},{"id":"38474d512fa04f2e9f06f1e65bfd8940","type":"GO_TERM","name":"cell cycle","canonical_id":"go:GO:0007049","description":"\"The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.\" [GOC:curators, GOC:mtg_cell_cycle]","metadata":null},{"id":"7cb0ece386be444d9f7562f339ab99c2","type":"GO_TERM","name":"cell cycle DNA replication","canonical_id":"go:GO:0044786","description":"\"The DNA-dependent DNA replication that takes place as part of the cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"7de203f782424920afa9e18902e2e30f","type":"GO_TERM","name":"cell cycle DNA replication initiation","canonical_id":"go:GO:1902292","description":"\"Any DNA replication initiation that is involved in cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"e16e7e38e7984137bdfa4111bfe0c61a","type":"GO_TERM","name":"cell cycle DNA replication maintenance of fidelity","canonical_id":"go:GO:1902298","description":"\"Any maintenance of fidelity that is involved in cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"ca3f6877680d4d81aeef43a28b11f867","type":"GO_TERM","name":"cell cycle DNA replication termination","canonical_id":"go:GO:1902294","description":"\"Any DNA replication termination that is involved in cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"218ce6d72f7f4fad9d494b2d246211ae","type":"GO_TERM","name":"cell cycle G1/S phase transition","canonical_id":"go:GO:0044843","description":"\"The cell cycle process by which a cell in G1 phase commits to S phase.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"6e944a9a9e724849b338f81af92e73a4","type":"GO_TERM","name":"cell cycle G2/M phase transition","canonical_id":"go:GO:0044839","description":"\"The cell cycle process by which a cell in G2 phase commits to M phase.\" [GOC:jl, GOC:mtg_cell_cycle]","metadata":null},{"id":"d2c7e434f8e348958d21b33b44a7c238","type":"GO_TERM","name":"cell cycle checkpoint signaling","canonical_id":"go:GO:0000075","description":"\"A signaling process that controls cell cycle progression by monitoring the integrity of specific cell cycle events. A cell cycle checkpoint begins with detection of deficiencies or defects and ends with signal transduction.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d594a60750104729b57f9237ec96f10d","type":"GO_TERM","name":"cell cycle comprising mitosis without cytokinesis","canonical_id":"go:GO:0033301","description":"\"A mitotic cell cycle in which mitosis is completed but cytokinesis does not occur, resulting in a cell containing multiple nuclei each with a chromosomal complement of the original ploidy (usually 2N).\" [GOC:expert_vm, GOC:mah]","metadata":null},{"id":"8b4047ce0ee54e1fa4f3714e7b2f4a88","type":"GO_TERM","name":"cell cycle phase","canonical_id":"go:GO:0022403","description":"\"One of the distinct periods or stages into which the cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"a7170473ec2144f8976c5b466a7d62e4","type":"GO_TERM","name":"cell cycle phase transition","canonical_id":"go:GO:0044770","description":"\"The cell cycle process by which a cell commits to entering the next cell cycle phase.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"46e7e9aaabb54d0da9a12e3952724484","type":"GO_TERM","name":"cell cycle process","canonical_id":"go:GO:0022402","description":"\"The cellular process that ensures successive accurate and complete genome replication and chromosome segregation.\" [GOC:isa_complete, GOC:mtg_cell_cycle]","metadata":null},{"id":"b4e4824d3daf4f8bacc2309ae322ab8b","type":"GO_TERM","name":"cell cycle switching","canonical_id":"go:GO:0060184","description":"\"The process in which a cell switches cell cycle mode.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"ff1178597533464aa81d5911c7f504dc","type":"GO_TERM","name":"cell cycle switching, mitotic to meiotic cell cycle","canonical_id":"go:GO:0051728","description":"\"The process in which a cell switches cell cycle mode from mitotic to meiotic division.\" [GOC:ai, GOC:mtg_cell_cycle]","metadata":null},{"id":"953c01d73ec44e70b48ffc6bc84cd225","type":"GO_TERM","name":"cell death","canonical_id":"go:GO:0008219","description":"\"Any biological process that results in permanent cessation of all vital functions of a cell. A cell should be considered dead when any one of the following molecular or morphological criteria is met: (1) the cell has lost the integrity of its plasma membrane; (2) the cell, including its nucleus, has undergone complete fragmentation into discrete bodies (frequently referred to as apoptotic bodies). The cell corpse (or its fragments) may be engulfed by an adjacent cell in vivo, but engulfment of whole cells should not be considered a strict criteria to define cell death as, under some circumstances, live engulfed cells can be released from phagosomes (see PMID:18045538).\" [GOC:mah, GOC:mtg_apoptosis, PMID:25236395]","metadata":null},{"id":"2a166e1fbe5a4dc9b090949eb4c5e7f6","type":"GO_TERM","name":"cell dedifferentiation","canonical_id":"go:GO:0043697","description":"\"The process in which a specialized cell loses the structural or functional features that characterize it in the mature organism, or some other relatively stable phase of the organism's life history. Under certain conditions, these cells can revert back to the features of the stem cells that were their ancestors.\" [GOC:dph, GOC:pg]","metadata":null},{"id":"d2eb94d842584fa793986f9bdf9114b2","type":"GO_TERM","name":"cell dedifferentiation involved in phenotypic switching","canonical_id":"go:GO:0090678","description":"\"A cell dedifferentiation process that is a part of a reversible switch of a cell from one cell type or form to another, at a frequency above the expected frequency for somatic mutations.\" [GOC:curators]","metadata":null},{"id":"1d2a5dc9834b45bb823dd6bf702ddce8","type":"GO_TERM","name":"cell development","canonical_id":"go:GO:0048468","description":"\"The cellular developmental process in which a specific cell progresses from an immature to a mature state. Cell development start once cell commitment has taken place.\" [GOC:curators]","metadata":null},{"id":"fdc611111fa3491989b8e61ffcb2313a","type":"GO_TERM","name":"cell differentiation","canonical_id":"go:GO:0030154","description":"\"The cellular developmental process in which a relatively unspecialized cell, e.g. embryonic or regenerative cell, acquires specialized structural and/or functional features that characterize a specific cell. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.\" [ISBN:0198506732]","metadata":null},{"id":"7005a129da624e37bbabf3577c24a534","type":"GO_TERM","name":"cell differentiation in hindbrain","canonical_id":"go:GO:0021533","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mature cells of the hindbrain. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e5259c5f36f648c9a546325ee66551b2","type":"GO_TERM","name":"cell differentiation in spinal cord","canonical_id":"go:GO:0021515","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the spinal cord. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"0109bdf86927422fb4c93f4d0791661c","type":"GO_TERM","name":"cell differentiation involved in embryonic placenta development","canonical_id":"go:GO:0060706","description":"\"The process in which a relatively unspecialized cell acquires specialized features of the embryonic placenta.\" [GOC:dph]","metadata":null},{"id":"ea63606848ec49e2995aceb3a916a1bc","type":"GO_TERM","name":"cell differentiation involved in kidney development","canonical_id":"go:GO:0061005","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d1ac2426da15459eb5a3c82e2928d4ef","type":"GO_TERM","name":"cell differentiation involved in phenotypic switching","canonical_id":"go:GO:0090679","description":"\"A cell differentiation process that is a part of a reversible switch of a cell from one cell type or form to another, at a frequency above the expected frequency for somatic mutations.\" [GOC:curators]","metadata":null},{"id":"4a5c70671fba4e0ca7fb695db460bf84","type":"GO_TERM","name":"cell differentiation involved in salivary gland development","canonical_id":"go:GO:0060689","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features that characterize the cells of the salivary gland.\" [GOC:dph]","metadata":null},{"id":"a80bbe62053848f8b552be60abcbde3c","type":"GO_TERM","name":"cell division","canonical_id":"go:GO:0051301","description":"\"The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.\" [GOC:curators, GOC:di, GOC:pr]","metadata":null},{"id":"d0330c2870584234a12ea72794585b2e","type":"GO_TERM","name":"cell division site","canonical_id":"go:GO:0032153","description":"\"The eventual plane of cell division (also known as cell cleavage or cytokinesis) in a dividing cell. In Eukaryotes, the cleavage apparatus, composed of septin structures and the actomyosin contractile ring, forms along this plane, and the mitotic, or meiotic, spindle is aligned perpendicular to the division plane. In bacteria, the cell division site is generally located at mid-cell and is the site at which the cytoskeletal structure, the Z-ring, assembles.\" [GOC:bf, GOC:imk, GOC:krc, GOC:ns, PMID:12101122, PMID:15380095, PMID:16983191, PMID:18165305]","metadata":null},{"id":"f6c68b5b694f403196d82a7d7bca61ce","type":"GO_TERM","name":"cell elongation involved in imaginal disc-derived wing morphogenesis","canonical_id":"go:GO:0090254","description":"\"The process in which a cell elongates and contributes to imaginal disc-derived wing morphogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"9b6c611aec934be6b74d80f1f7820a97","type":"GO_TERM","name":"cell envelope","canonical_id":"go:GO:0030313","description":"\"An envelope that surrounds a bacterial cell and includes the cytoplasmic membrane and everything external, encompassing the periplasmic space, cell wall, and outer membrane if present.\" [GOC:ds, GOC:mlg, http://pathmicro.med.sc.edu/fox/cell_envelope.htm]","metadata":null},{"id":"97fc26943527423f8b50f152a3dd677e","type":"GO_TERM","name":"cell envelope Sec protein transport complex","canonical_id":"go:GO:0031522","description":"\"A transmembrane protein complex involved in the translocation of proteins across the cytoplasmic membrane. In Gram-negative bacteria, Sec-translocated proteins are subsequently secreted via the type II, IV, or V secretion systems. Sec complex components include SecA, D, E, F, G, Y and YajC.\" [GOC:mtg_sensu, PMID:15223057]","metadata":null},{"id":"0b0672a1fc934476925fad52acad81a3","type":"GO_TERM","name":"cell envelope organization","canonical_id":"go:GO:0043163","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the cell envelope, everything external to, but not including, the cytoplasmic membrane of bacteria, encompassing the periplasmic space, cell wall, and outer membrane if present.\" [GOC:jl]","metadata":null},{"id":"6b3448d315124272bccdd3dfb3ffe5f8","type":"GO_TERM","name":"cell fate commitment","canonical_id":"go:GO:0045165","description":"\"The cellular developmental process by which a cell establishes the intrinsic character of a cell or tissue region irreversibly committing it to a particular fate.\" [ISBN:0716731185]","metadata":null},{"id":"9d12ae51c867478f89d246457fd540d7","type":"GO_TERM","name":"cell fate commitment involved in formation of primary germ layer","canonical_id":"go:GO:0060795","description":"\"The commitment of cells to specific cell fates of the endoderm, ectoderm, or mesoderm as a part of gastrulation.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"6ff8f12d2b664437b4461cdc7985a751","type":"GO_TERM","name":"cell fate commitment involved in pattern specification","canonical_id":"go:GO:0060581","description":"\"The commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells within a field of cells that will exhibit a certain pattern of differentiation. Positional information is established through protein signals that emanate from a localized source within a developmental field resulting in specification of a cell type. Those signals are then interpreted in a cell-autonomous manner resulting in the determination of the cell type.\" [GOC:dph]","metadata":null},{"id":"81727ba5e2434111b0ff4e20231606ee","type":"GO_TERM","name":"cell fate determination","canonical_id":"go:GO:0001709","description":"\"The cellular developmental process involved in cell fate commitment that occurs after cell fate specification, in which a cell is irreversibly committed to a cellular developmental fate which is heritable on cell division.\" [ISBN:0878932437]","metadata":null},{"id":"ef44653c6aa1409099595b287bdd8414","type":"GO_TERM","name":"cell fate determination involved in pattern specification","canonical_id":"go:GO:0060582","description":"\"A process involved in commitment of a cell to a fate in a developmental field. Once determination has taken place, a cell becomes committed to differentiate down a particular pathway regardless of its environment.\" [GOC:dph]","metadata":null},{"id":"a4d1896a48d94b909a46d941d570fade","type":"GO_TERM","name":"cell fate specification","canonical_id":"go:GO:0001708","description":"\"The cellular developmental process involved in cell fate commitment in which the cell is designated to follow a developmental path, unless they receive extrinsic cues that direct an alternative fate.\" [GOC:curators]","metadata":null},{"id":"3149468153fa483ead562c8c170f7151","type":"GO_TERM","name":"cell fate specification involved in pattern specification","canonical_id":"go:GO:0060573","description":"\"The process involved in the specification of the identity of a cell in a field of cells that is being instructed as to how to differentiate. Once specification has taken place, that cell will be committed to differentiate down a specific pathway if left in its normal environment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7b8ffb3ff8e445289b32dab785d8edd7","type":"GO_TERM","name":"cell gliding","canonical_id":"go:GO:0071976","description":"\"Cell motility that results in the smooth movement of a cell along a solid surface.\" [PMID:18461074]","metadata":null},{"id":"2c70fc49fa594f74b420958babc0c612","type":"GO_TERM","name":"cell growth","canonical_id":"go:GO:0016049","description":"\"The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.\" [GOC:ai]","metadata":null},{"id":"c66511dadce641509499c5e4a4447b57","type":"GO_TERM","name":"cell growth involved in cardiac muscle cell development","canonical_id":"go:GO:0061049","description":"\"The growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"1d854c7de18c4581ab7663c6cca15b5b","type":"GO_TERM","name":"cell growth mode switching, bipolar to monopolar","canonical_id":"go:GO:0051524","description":"\"The process in which a cell switches from bipolar cell growth to monopolar cell growth.\" [GOC:ai]","metadata":null},{"id":"a7470cb7cd8d4a8cb45fed81627a191d","type":"GO_TERM","name":"cell growth mode switching, budding to filamentous","canonical_id":"go:GO:0036187","description":"\"The process in which a cell switches from growing as a round budding cell to growing as a filament (elongated cells attached end-to-end). An example of this is the yeast-hyphal transition of Candida albicans.\" [GOC:di]","metadata":null},{"id":"6d1d112e89e341c3b689e3968a4ea0b2","type":"GO_TERM","name":"cell growth mode switching, filamentous to budding","canonical_id":"go:GO:0097321","description":"\"The process in which a cell switches from growing as a filament (elongated cells attached end-to-end) to growing as a round budding cell. An example of this is observed in Candida albicans.\" [GOC:di, PMID:14617167]","metadata":null},{"id":"a5a4e2c80c73416da77e75c452d36442","type":"GO_TERM","name":"cell growth mode switching, monopolar to bipolar","canonical_id":"go:GO:0051523","description":"\"The process in which a cell switches from monopolar cell growth to bipolar cell growth.\" [GOC:ai]","metadata":null},{"id":"c76599e3e0144c9da17241727480b747","type":"GO_TERM","name":"cell hair","canonical_id":"go:GO:0070451","description":"\"A long, thin cell projection that contains F-actin and tubulin, with microtubules centrally located and F-actin peripherally located.\" [PMID:11526084]","metadata":null},{"id":"1628a281343d4669aef9e0973dfea343","type":"GO_TERM","name":"cell integrity MAPK cascade","canonical_id":"go:GO:0000196","description":"\"A MAPK cascade that specifically ensures the maintenance and regulation of cellular structure in response to external signals, including plasma membrane stretching or cell wall alteration, to coordinate cellular responses such as growth, differentiation, and stress adaptation, thereby preserving cell integrity. Contains the  SLT2 (S.cerevisiae)/Pmk1 (S.pombe) MAP kinase or orthologs.\" [GOC:vw]","metadata":null},{"id":"a12990e1afa447a8a5d3c50efa2d7410","type":"GO_TERM","name":"cell junction","canonical_id":"go:GO:0030054","description":"\"A cellular component that forms a specialized region of connection between two or more cells, or between a cell and the extracellular matrix, or between two membrane-bound components of a cell, such as flagella.\" [GOC:aruk, GOC:bc, GOC:mah, ISBN:0198506732, PMID:26820516, PMID:28096264]","metadata":null},{"id":"a185adc0f3bf425ea67b25e36c79da3e","type":"GO_TERM","name":"cell junction assembly","canonical_id":"go:GO:0034329","description":"\"A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a cell junction.\" [GOC:mah]","metadata":null},{"id":"a5d3f0f824b9452084d8b63f181e727a","type":"GO_TERM","name":"cell junction disassembly","canonical_id":"go:GO:0150146","description":"\"The disaggregation of a cell junction into its constituent components.\" [GOC:aruk, PMID:25490267]","metadata":null},{"id":"8e3e2fdeef9b44f4bfe9b211bf89214b","type":"GO_TERM","name":"cell junction maintenance","canonical_id":"go:GO:0034331","description":"\"The organization process that preserves a cell junction in a stable functional or structural state. A cell junction is a specialized region of connection between two cells or between a cell and the extracellular matrix.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"78155ad8dde84a10800bfc57b33ac191","type":"GO_TERM","name":"cell junction organization","canonical_id":"go:GO:0034330","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cell junction. A cell junction is a specialized region of connection between two cells or between a cell and the extracellular matrix.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"2c78f79a154d46f5a626a5e350d54806","type":"GO_TERM","name":"cell killing","canonical_id":"go:GO:0001906","description":"\"Any process in an organism that results in the killing of its own cells or those of another organism, including in some cases the death of the other organism. Killing here refers to the induction of death in one cell by another cell, not cell-autonomous death due to internal or other environmental conditions.\" [GOC:add]","metadata":null},{"id":"79ad91f73f8d4541b47e5597b3159c65","type":"GO_TERM","name":"cell leading edge","canonical_id":"go:GO:0031252","description":"\"The area of a motile cell closest to the direction of movement.\" [GOC:pg]","metadata":null},{"id":"f57310eea82a4dc2a6a4ac01cb15f5ad","type":"GO_TERM","name":"cell leading edge cell cortex","canonical_id":"go:GO:1904269","description":"\"The cell cortex of the leading edge of a cell.\" [GO_REF:0000064, GOC:kmv, GOC:TermGenie, PMID:25843030]","metadata":null},{"id":"a1882f55e85d44e49b056eb075fd1e32","type":"GO_TERM","name":"cell maturation","canonical_id":"go:GO:0048469","description":"\"The cellular developmental process, independent of morphogenetic (shape) change, that is required for a specific cell to attain its fully functional state.\" [GOC:curators]","metadata":null},{"id":"d67393b7a4544a1f8ace1c8a44b8759f","type":"GO_TERM","name":"cell migration","canonical_id":"go:GO:0016477","description":"\"The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues.\" [GOC:cjm, GOC:dph, GOC:ems, GOC:pf, Wikipedia:Cell_migration]","metadata":null},{"id":"64d559a8ba724aa1bafb34b49ca00b2c","type":"GO_TERM","name":"cell migration in diencephalon","canonical_id":"go:GO:0061381","description":"\"The orderly movement of a cell that will reside in the diencephalon.\" [GOC:dph]","metadata":null},{"id":"2568c14c5cd74f149a0757b2346ac68a","type":"GO_TERM","name":"cell migration in hindbrain","canonical_id":"go:GO:0021535","description":"\"The orderly movement of a cell that will reside in the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"602a6740e4fe4578a335cd84d8c2c51c","type":"GO_TERM","name":"cell migration involved in coronary angiogenesis","canonical_id":"go:GO:0060981","description":"\"The orderly movement of a cell from one site to another that will contribute to the formation of new blood vessels in the heart from pre-existing blood vessels.\" [GOC:mtg_heart]","metadata":null},{"id":"02d063c877d94b0b8b7bc0928edda544","type":"GO_TERM","name":"cell migration involved in coronary vasculogenesis","canonical_id":"go:GO:0060980","description":"\"The orderly movement of a cell from one site to another that will contribute to the differentiation of an endothelial cell that will form the blood vessels of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"3f48b50ceece42a2951345703e6ae3be","type":"GO_TERM","name":"cell migration involved in endocardial cushion formation","canonical_id":"go:GO:0003273","description":"\"The orderly movement of a cell from one site to another that will contribute to the formation of an endocardial cushion. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.\" [GOC:mtg_heart]","metadata":null},{"id":"26065b60777c47798c9fd340a8757148","type":"GO_TERM","name":"cell migration involved in gastrulation","canonical_id":"go:GO:0042074","description":"\"The migration of individual cells within the blastocyst to help establish the multi-layered body plan of the organism (gastrulation). For example, the migration of cells from the surface to the interior of the embryo (ingression).\" [GOC:jl, PMID:16099638]","metadata":null},{"id":"9c6ff04df30848789d78d0c0ecf73db4","type":"GO_TERM","name":"cell migration involved in heart development","canonical_id":"go:GO:0060973","description":"\"The orderly movement of a cell from one site to another that will contribute to the progression of the heart over time, from its initial formation, to the mature organ.\" [GOC:mtg_heart]","metadata":null},{"id":"b6e9251624204d3eafe32630ea6ddc4f","type":"GO_TERM","name":"cell migration involved in heart formation","canonical_id":"go:GO:0060974","description":"\"The orderly movement of a cell from one site to another that contribute to the formation of the heart. The initial heart structure is made up of mesoderm-derived heart progenitor cells and neural crest-derived cells.\" [GOC:mtg_heart]","metadata":null},{"id":"181046a194694efd88a9eb2a48209d07","type":"GO_TERM","name":"cell migration involved in heart jogging","canonical_id":"go:GO:0003305","description":"\"The orderly movement of a cell of the myocardium from one site to another that will contribute to heart jogging.\" [GOC:mtg_heart]","metadata":null},{"id":"60f7f9da24704d99a7468fe92f945459","type":"GO_TERM","name":"cell migration involved in kidney development","canonical_id":"go:GO:0035787","description":"\"The orderly movement of a cell from one site to another that will contribute to the progression of the kidney over time, from its formation to the mature organ.\" [GOC:bf, GOC:mtg_kidney_jan10, GOC:yaf]","metadata":null},{"id":"aa81404d996c4e1799150a8cf11da5c5","type":"GO_TERM","name":"cell migration involved in mesendoderm migration","canonical_id":"go:GO:0090134","description":"\"The orderly movement of epithelial cells from one site to another that contributes to the migration of mesendodermal tissue.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"977c99288ef34ccaaa7912a550b89f3c","type":"GO_TERM","name":"cell migration involved in metanephros development","canonical_id":"go:GO:0035788","description":"\"The orderly movement of a cell from one site to another that will contribute to the progression of the metanephric kidney over time, from its formation to the mature organ.\" [GOC:bf, GOC:mtg_kidney_jan10, GOC:yaf]","metadata":null},{"id":"5e4c4c1dd42948bca07db02660d63dcd","type":"GO_TERM","name":"cell migration involved in somitogenic axis elongation","canonical_id":"go:GO:0090248","description":"\"Any process involved in the controlled self-propelled movement of a cell that contributes to somitogenic axis elongation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"7817d4969cb84e50b95f7509882e10e0","type":"GO_TERM","name":"cell migration involved in sprouting angiogenesis","canonical_id":"go:GO:0002042","description":"\"The orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels involved in sprouting angiogenesis.\" [PMID:16391003]","metadata":null},{"id":"a6e6e86ea7244b4e8bc804d1ade503d8","type":"GO_TERM","name":"cell migration involved in vasculogenesis","canonical_id":"go:GO:0035441","description":"\"The orderly movement of a cell from one site to another that will contribute to the differentiation of an endothelial cell that will form de novo blood vessels and tubes.\" [GOC:dgh]","metadata":null},{"id":"a12da88ba11348b390e119f454c6ef1f","type":"GO_TERM","name":"cell migration to the midline involved in heart development","canonical_id":"go:GO:0003318","description":"\"The orderly movement of a cell toward the midline that contributes to the progression of the heart over time.\" [GOC:mtg_heart]","metadata":null},{"id":"856b5edf6a52472fb4036aa660f64769","type":"GO_TERM","name":"cell morphogenesis","canonical_id":"go:GO:0000902","description":"\"The developmental process in which the size or shape of a cell is generated and organized.\" [GOC:clt, GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"1edac251ebf34291a8256747357b9972","type":"GO_TERM","name":"cell morphogenesis involved in Malpighian tubule morphogenesis","canonical_id":"go:GO:0061336","description":"\"The shape change of an epithelial cell from a columnar to squamous cell morphology that contributes to the shaping of the Malpighian tubule.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"5075c07c1a4944e6b088b31f6b46217a","type":"GO_TERM","name":"cell morphogenesis involved in conjugation with cellular fusion","canonical_id":"go:GO:0000753","description":"\"The change in form (cell shape and size) that occurs during sexual reproduction in order to facilitate direct contact between the compatible mating types in organisms that undergo conjugation cellular fusion.\" [GOC:clt]","metadata":null},{"id":"d96461e60b434bf49eb7fcf54d8c9680","type":"GO_TERM","name":"cell morphogenesis involved in neuron differentiation","canonical_id":"go:GO:0048667","description":"\"The process in which the structures of a neuron are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of a neuron.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"970d3aad5b464e029e141594fa463b5c","type":"GO_TERM","name":"cell motility","canonical_id":"go:GO:0048870","description":"\"Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another.\" [GOC:dgh, GOC:dph, GOC:isa_complete, GOC:mlg]","metadata":null},{"id":"7713e80ab160450d8473efe2600bc261","type":"GO_TERM","name":"cell motility in response to calcium ion","canonical_id":"go:GO:0097231","description":"\"Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another as a result of a calcium ion stimulus.\" [GOC:pf, PMID:19363786, PMID:21239624, PMID:8937985]","metadata":null},{"id":"8dfb86d390a245d78f8fac7ddaf489ae","type":"GO_TERM","name":"cell motility in response to potassium ion","canonical_id":"go:GO:0097230","description":"\"Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another as a result of a potassium ion stimulus.\" [GOC:pf, PMID:19363786, PMID:21239624]","metadata":null},{"id":"33f463d136ad41938d2a7899739d6094","type":"GO_TERM","name":"cell motility involved in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021814","description":"\"The movement of a cell along the process of a radial glial cell involved in cerebral cortex glial-mediated radial migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"f8d32aa26a924498b8bfad803168d172","type":"GO_TERM","name":"cell outer membrane","canonical_id":"go:GO:0009279","description":"\"A lipid bilayer that forms the outermost membrane of the cell envelope; enriched in polysaccharide and protein; the outer leaflet of the membrane contains specific lipopolysaccharide structures.\" [GOC:md, GOC:mtg_sensu, ISBN:0135712254]","metadata":null},{"id":"d9900bdcb2ca4f10b994e2c7575a93cc","type":"GO_TERM","name":"cell periphery","canonical_id":"go:GO:0071944","description":"\"The broad region around and including the plasma membrane of a cell, encompassing the cell cortex (inside the cell), the plasma membrane, and any external encapsulating structures.\" [GOC:pdt]","metadata":null},{"id":"5bae1498540444b4b8e6af8499b6b421","type":"GO_TERM","name":"cell plate","canonical_id":"go:GO:0009504","description":"\"The nascent cell membrane and cell wall structure that forms between two daughter nuclei near the center of a dividing plant cell. It develops at the equatorial region of the phragmoplast. It grows outwards to join with the lateral walls and form two daughter cells.\" [ISBN:0198547684]","metadata":null},{"id":"f6e826d09b8c4091922a7f7394c1ae58","type":"GO_TERM","name":"cell plate assembly","canonical_id":"go:GO:0000919","description":"\"The process of assembly, maturation, and growth of the cell plate to the cell periphery in cells that divide by cell plate formation; often involves deposition of cell wall material in and around the phragmoplast.\" [GOC:clt]","metadata":null},{"id":"25da1b8871224df7b99e4fa9f175ffac","type":"GO_TERM","name":"cell plate formation involved in plant-type cell wall biogenesis","canonical_id":"go:GO:0009920","description":"\"The cell cycle process in which the cell plate is formed at the equator of the spindle in the dividing cells during early telophase. An example of this is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tb, ISBN:0879015322]","metadata":null},{"id":"cf80677d969e48edbda56f8fb893ada8","type":"GO_TERM","name":"cell pole","canonical_id":"go:GO:0060187","description":"\"Either of two different areas at opposite ends of an axis of a cell.\" [GOC:dph]","metadata":null},{"id":"54673c007b7e4902bab59fc7a3319a3a","type":"GO_TERM","name":"cell population proliferation","canonical_id":"go:GO:0008283","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population.\" [GOC:mah, GOC:mb]","metadata":null},{"id":"ace7e5321fad450db52f33d86b3c6bd5","type":"GO_TERM","name":"cell projection","canonical_id":"go:GO:0042995","description":"\"A prolongation or process extending from a cell, e.g. a flagellum or axon.\" [GOC:jl, PMID:16318917]","metadata":null},{"id":"1ae262a2786a457485aae9ae52e6d824","type":"GO_TERM","name":"cell projection assembly","canonical_id":"go:GO:0030031","description":"\"Formation of a prolongation or process extending from a cell, e.g. a flagellum or axon.\" [GOC:jl, GOC:mah, PMID:18391171]","metadata":null},{"id":"5b0ee4988dcf4954a8a1d57a089110de","type":"GO_TERM","name":"cell projection membrane","canonical_id":"go:GO:0031253","description":"\"The portion of the plasma membrane surrounding a plasma membrane bounded cell surface projection.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"c145e166ecd34ec6ad420533f67f61c3","type":"GO_TERM","name":"cell projection morphogenesis","canonical_id":"go:GO:0048858","description":"\"The process in which the anatomical structures of a cell projection are generated and organized.\" [GO_REF:0000021]","metadata":null},{"id":"2258ec7017a9442cbd93632587fdb99e","type":"GO_TERM","name":"cell projection organization","canonical_id":"go:GO:0030030","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a prolongation or process extending from a cell, e.g. a flagellum or axon.\" [GOC:jl, GOC:mah, PMID:16318917]","metadata":null},{"id":"ba4a428bb1d044388defc7b0598be4ac","type":"GO_TERM","name":"cell proliferation in bone marrow","canonical_id":"go:GO:0071838","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population in the bone marrow.\" [GOC:mah, GOC:yaf, PMID:17063141]","metadata":null},{"id":"c7b1a9f9e8b7408cb213b21afd400316","type":"GO_TERM","name":"cell proliferation in dorsal spinal cord","canonical_id":"go:GO:0010456","description":"\"The multiplication or reproduction of cells, resulting in the expansion of the dorsal spinal cord cell population.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"85d7eda4ae1d46099462abb0aa99484e","type":"GO_TERM","name":"cell proliferation in external granule layer","canonical_id":"go:GO:0021924","description":"\"The multiplication or reproduction of neuroblasts resulting in the expansion of a cell population in the external granule layer of the hindbrain. The external granule layer is the layer that originates from the rostral half of the rhombic lip in the first rhombomere.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"4c6064609b8f4269bac4a598c04b14ac","type":"GO_TERM","name":"cell proliferation in forebrain","canonical_id":"go:GO:0021846","description":"\"The creation of greater cell numbers in the forebrain due to cell division of progenitor cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a82d75d913824fd681e5246f69b9f599","type":"GO_TERM","name":"cell proliferation in hindbrain","canonical_id":"go:GO:0021534","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population in the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9b36d241a5c1486ba58b96e790b32b81","type":"GO_TERM","name":"cell proliferation in hindbrain ventricular zone","canonical_id":"go:GO:0021923","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population in the hindbrain region that is adjacent to the ventricular cavity.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12593981, PMID:15157725]","metadata":null},{"id":"917f3e30fbaa42ff8cc54255adb689a3","type":"GO_TERM","name":"cell proliferation in midbrain","canonical_id":"go:GO:0033278","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population in the midbrain.\" [GO_REF:0000021, GOC:dgf]","metadata":null},{"id":"13a89852cb6142fa8518065e516d72ef","type":"GO_TERM","name":"cell proliferation involved in compound eye morphogenesis","canonical_id":"go:GO:0035736","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population that contributes to compound eye morphogenesis.\" [GOC:bf, GOC:sart]","metadata":null},{"id":"90842b579fe24944a6b93ec198f0ae4c","type":"GO_TERM","name":"cell proliferation involved in embryonic placenta development","canonical_id":"go:GO:0060722","description":"\"The multiplication or reproduction of cells, resulting in the expansion of the population in the embryonic placenta.\" [GOC:dph]","metadata":null},{"id":"e4ef12fac39148cf88a72581ebef8ff9","type":"GO_TERM","name":"cell proliferation involved in endocardial cushion morphogenesis","canonical_id":"go:GO:1905315","description":"\"Any cell proliferation that is involved in endocardial cushion morphogenesis.\" [GO_REF:0000060, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:20652948]","metadata":null},{"id":"d4886adbee8a473fac0de084cf158ec0","type":"GO_TERM","name":"cell proliferation involved in heart morphogenesis","canonical_id":"go:GO:0061323","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population that contributes to the shaping of the heart.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"073972822a44495eae69c63a718fc231","type":"GO_TERM","name":"cell proliferation involved in heart valve development","canonical_id":"go:GO:2000793","description":"\"Any cell proliferation that is involved in heart valve development.\" [GOC:BHF]","metadata":null},{"id":"a6a5e091a8ea4d358044c4033a53b6b6","type":"GO_TERM","name":"cell proliferation involved in imaginal disc-derived wing morphogenesis","canonical_id":"go:GO:0090255","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population that contributes to imaginal disc-derived wing morphogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"3c821fe9696d4382beebdd966d8a68ac","type":"GO_TERM","name":"cell proliferation involved in kidney development","canonical_id":"go:GO:0072111","description":"\"The multiplication or reproduction of cells, resulting in the expansion of the population in the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"84641b2bc5ef41cd97125585a076e8c1","type":"GO_TERM","name":"cell proliferation involved in metanephros development","canonical_id":"go:GO:0072203","description":"\"The multiplication or reproduction of cells, resulting in the expansion of the population in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ad3d3d4b3dfb4b69b19da3b0bc8ccecc","type":"GO_TERM","name":"cell proliferation involved in outflow tract morphogenesis","canonical_id":"go:GO:0061325","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a cell population that contributes to the shaping of the outflow tract.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"a61d72f8062b4a799970e1b81a9993b9","type":"GO_TERM","name":"cell proliferation involved in pronephros development","canonical_id":"go:GO:0039015","description":"\"The multiplication or reproduction of cells, resulting in the expansion of the population in the pronephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0a679a221c8445ebb4bfc821a73b3794","type":"GO_TERM","name":"cell quiescence","canonical_id":"go:GO:0044838","description":"\"A specialized resting state that cells enter in response to cues from the cell's environment. Quiescence is characterized by the absence of cell growth and division, by a reprogramming of global gene expression, and by changes characteristic of the organism and specific cell type. Depending on external conditions, quiescence may persist until cell death or cells may resume cell growth and division. In some cell types or under certain conditions, cellular metabolism may proceed.\" [GOC:jb, GOC:mah]","metadata":null},{"id":"6b6cf43095da4c969685aa9e2e10bd49","type":"GO_TERM","name":"cell rearrangement involved in Malpighian tubule morphogenesis","canonical_id":"go:GO:0061334","description":"\"The movement of an epithelial cell with respect to other epithelial cells that contributes to the shaping of the Malpighian tubule.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"1aaa05a4030745a18b5fb594fb0e88c0","type":"GO_TERM","name":"cell recognition","canonical_id":"go:GO:0008037","description":"\"The process in which a cell in an organism interprets its surroundings.\" [GOC:curators]","metadata":null},{"id":"24ab826c9d7a4f13abc962223e0778ab","type":"GO_TERM","name":"cell redox homeostasis","canonical_id":"go:GO:0045454","description":"\"Any process that maintains the redox environment of a cell or compartment within a cell.\" [GOC:ai, GOC:dph, GOC:tb, PMID:38689066]","metadata":null},{"id":"95b97b60ca8a46b88281fede2693f555","type":"GO_TERM","name":"cell septum","canonical_id":"go:GO:0030428","description":"\"A structure composed of peptidoglycan and often chitin in addition to other materials. It usually forms perpendicular to the long axis of a cell or hypha and grows centripetally from the cell wall to the center of the cell and often functions in the compartmentalization of a cell into two daughter cells.\" [GOC:clt, ISBN:0471940526]","metadata":null},{"id":"2579781de23c41129d19b77c6f2131ae","type":"GO_TERM","name":"cell septum assembly","canonical_id":"go:GO:0090529","description":"\"The assembly and arrangement of a cellular component that is composed of peptidoglycan and often chitin in addition to other materials and usually forms perpendicular to the long axis of a cell or hypha. It grows centripetally from the cell wall to the center of the cell and often functions in the compartmentalization of a cell into two daughter cells.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"239c810ad5af41479d3660b370079ae1","type":"GO_TERM","name":"cell septum edging","canonical_id":"go:GO:0043188","description":"\"The cell wall material that surrounds the septum in fungal cells.\" [GOC:vw]","metadata":null},{"id":"061b195680ba456f8eb1b5f47b4a81a2","type":"GO_TERM","name":"cell septum edging catabolic process","canonical_id":"go:GO:0030995","description":"\"The chemical reactions and pathways resulting in the dissolution of the septum edging during cell separation.\" [GOC:mah, PMID:15194814]","metadata":null},{"id":"0eaaf09ea7d14e1085b438fbe8c8cdfc","type":"GO_TERM","name":"cell surface","canonical_id":"go:GO:0009986","description":"\"The external part of the cell wall and/or plasma membrane.\" [GOC:jl, GOC:mtg_sensu, GOC:sm]","metadata":null},{"id":"c48f0c2b023b4811897b550fe2d35c5f","type":"GO_TERM","name":"cell surface adhesin-mediated gliding motility","canonical_id":"go:GO:0071980","description":"\"Cell gliding that results from the actions of cell surface adhesin proteins that are propelled by membrane motor proteins.\" [PMID:18461074]","metadata":null},{"id":"964173684e20461e8703534f8533bdf7","type":"GO_TERM","name":"cell surface furrow","canonical_id":"go:GO:0097610","description":"\"A furrow that may be found on the cell surface. Examples include the cingulum and sulcus found in some dinoflagellates.\" [GOC:pr]","metadata":null},{"id":"c0adaa28017d413287b6a2ac596dadf7","type":"GO_TERM","name":"cell surface pattern recognition receptor signaling pathway","canonical_id":"go:GO:0002752","description":"\"The series of molecular signals initiated by a ligand binding to a cell surface pattern recognition receptor (PRR). PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species.\" [GOC:add, GOC:ar, ISBN:0781735149, PMID:15199967]","metadata":null},{"id":"f71d16f5e1aa4b88a509beeb60b07f3f","type":"GO_TERM","name":"cell surface receptor protein serine/threonine kinase signaling pathway","canonical_id":"go:GO:0007178","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses serine/threonine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"55aba0fa9b2d4031b482371ef41cd620","type":"GO_TERM","name":"cell surface receptor protein tyrosine kinase signaling pathway","canonical_id":"go:GO:0007169","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb, GOC:signaling]","metadata":null},{"id":"db01cc27446d4a519cc78b7eabba3874","type":"GO_TERM","name":"cell surface receptor protein tyrosine phosphatase signaling pathway","canonical_id":"go:GO:0007185","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses protein tyrosine phosphatase activity, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"b3edadc0b21d404b8e478f2cb4d81c4c","type":"GO_TERM","name":"cell surface receptor signaling pathway","canonical_id":"go:GO:0007166","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor located on the cell surface. The pathway ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling]","metadata":null},{"id":"9b2d84abe44c45309e9ce1751ea3e435","type":"GO_TERM","name":"cell surface receptor signaling pathway involved in heart development","canonical_id":"go:GO:0061311","description":"\"The series of molecular signals initiated by a ligand the binding to its receptor on the surface of a cell, which contributes to the progression of the heart over time.\" [GOC:dph, GOC:mtg_heart, GOC:signaling]","metadata":null},{"id":"5ce001b5874e4927a157b3fd411ce8f0","type":"GO_TERM","name":"cell surface receptor signaling pathway via JAK-STAT","canonical_id":"go:GO:0007259","description":"\"A cell surface receptor signaling pathway in which ligand binding causes the receptor to dimerize, bringing the receptor-associated JAKs into close proximity. The JAKs then phosphorylate and activate each other on tyrosine residues.This leads to the activation of associated STAT protein, causing the STATs to dissociate from the receptor, translocate to the nucleus. The pathway ends with regulation of target gene expression by STAT proteins.\" [PMID:12039028]","metadata":null},{"id":"bc508827f25e4699a84239d4d69ebe86","type":"GO_TERM","name":"cell surface receptor signaling pathway via STAT","canonical_id":"go:GO:0097696","description":"\"An intracellular signal transduction process in which STAT proteins (Signal Transducers and Activators of Transcription) convey a signal to trigger a change in the activity or state of a cell. The STAT cascade begins with receptor activation followed by activation of STAT proteins by kinases. It proceeds through STA dimerization and subsequent nuclear translocation of STAT proteins, and ends with regulation of target gene expression by STAT proteins.\" [GOC:rjd, PMID:21534947, PMID:24587195]","metadata":null},{"id":"4b04e9b0ddaf43d3b954428d8ebedfd3","type":"GO_TERM","name":"cell surface toll-like receptor signaling pathway","canonical_id":"go:GO:0140895","description":"\"The series of molecular signals initiated by a ligand binding to a cell surface pattern recognition receptor (PRR) of the toll-like family.\" [GOC:add, GOC:ar, ISBN:0781735149, PMID:15199967]","metadata":null},{"id":"2752a28ff2884a109cc713e847c5e046","type":"GO_TERM","name":"cell swimming","canonical_id":"go:GO:0071975","description":"\"Cell motility that results in the smooth movement of a cell through a liquid medium.\" [PMID:18461074]","metadata":null},{"id":"3fad741ebd29412fa78cbfd592e8d41b","type":"GO_TERM","name":"cell tip","canonical_id":"go:GO:0051286","description":"\"The region at the end of the longest axis of a cylindrical or elongated cell.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"ca69f12c00e54f64bfb85be943c04a52","type":"GO_TERM","name":"cell tip growth","canonical_id":"go:GO:0009932","description":"\"Growth that occurs specifically at the tip of a cell.\" [GOC:jid]","metadata":null},{"id":"028e03ae32fc4a3fa5313b08c093cfc0","type":"GO_TERM","name":"cell trailing edge","canonical_id":"go:GO:0031254","description":"\"The area of a motile cell opposite to the direction of movement.\" [GOC:pg]","metadata":null},{"id":"67529f3cfc4d44f48f3dacb77a27c917","type":"GO_TERM","name":"cell trailing edge membrane","canonical_id":"go:GO:0031257","description":"\"The portion of the plasma membrane surrounding the trailing edge of a motile cell.\" [GOC:mah]","metadata":null},{"id":"ba58010d5ec84bb584e312ffb9036e36","type":"GO_TERM","name":"cell volume homeostasis","canonical_id":"go:GO:0006884","description":"\"Any process involved in maintaining the steady state of a cell's volume. The cell's volume refers to the three-dimensional space occupied by a cell.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"998b9965c2be46fdb6ab68ee18f93273","type":"GO_TERM","name":"cell wall","canonical_id":"go:GO:0005618","description":"\"The rigid or semi-rigid envelope lying outside the cell membrane of plant, fungal, most prokaryotic cells and some protozoan parasites, maintaining their shape and protecting them from osmotic lysis. In plants it is made of cellulose and, often, lignin; in fungi it is composed largely of polysaccharides; in bacteria it is composed of peptidoglycan; in protozoan parasites such as Giardia species, it's made of carbohydrates and proteins.\" [GOC:giardia, ISBN:0198547684, PMID:15134259, Wikipedia:Microbial_cyst]","metadata":null},{"id":"d6811fe975754a3b8385dec0b320bd20","type":"GO_TERM","name":"cell wall (1->3)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070598","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-alpha-D-glucans, compounds composed of glucose residues linked by (1->3)-alpha-glucosidic bonds, found in the walls of cells.\" [GOC:mah]","metadata":null},{"id":"81d02dd8d95143c3a77843aa9737341d","type":"GO_TERM","name":"cell wall (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0034411","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in the walls of cells.\" [GOC:mah]","metadata":null},{"id":"bdc80dc284074624af53ca7766ccf9ef","type":"GO_TERM","name":"cell wall (1->3)-beta-D-glucan metabolic process","canonical_id":"go:GO:0034407","description":"\"The chemical reactions and pathways involving (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in the walls of cells.\" [GOC:mah]","metadata":null},{"id":"5b751d84a8214598ac3af40ed383c1b9","type":"GO_TERM","name":"cell wall assembly","canonical_id":"go:GO:0070726","description":"\"The aggregation, arrangement and bonding together of a cell wall. A cell wall is a rigid or semi-rigid envelope lying outside the cell membrane of plant, fungal, and most prokaryotic cells.\" [GOC:mah]","metadata":null},{"id":"a70e1668b0eb4ca9addded31cc8f7b6b","type":"GO_TERM","name":"cell wall beta-glucan biosynthetic process","canonical_id":"go:GO:0034410","description":"\"The chemical reactions and pathways resulting in the formation of beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of cells.\" [GOC:mah]","metadata":null},{"id":"77b5bc88e58e471cb09a6a454471c64f","type":"GO_TERM","name":"cell wall beta-glucan metabolic process","canonical_id":"go:GO:0034406","description":"\"The chemical reactions and pathways involving beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of cells.\" [GOC:mah]","metadata":null},{"id":"e0f6dd542dc74a489aae62724ce25c10","type":"GO_TERM","name":"cell wall biogenesis","canonical_id":"go:GO:0042546","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cell wall. Includes biosynthesis of constituent macromolecules, such as proteins and polysaccharides, and those macromolecular modifications that are involved in synthesis or assembly of the cellular component. A cell wall is the rigid or semi-rigid envelope lying outside the cell membrane of plant, fungal and most prokaryotic cells, maintaining their shape and protecting them from osmotic lysis.\" [GOC:jl, GOC:mah, GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"b29ed38f32ec44c696c57a89d28057a5","type":"GO_TERM","name":"cell wall disassembly","canonical_id":"go:GO:0044277","description":"\"A process that results in the breakdown of the cell wall.\" [GOC:jl]","metadata":null},{"id":"05d12bc1d7ba4c40b7d65aaecbfd9b13","type":"GO_TERM","name":"cell wall glycoprotein biosynthetic process","canonical_id":"go:GO:0031506","description":"\"The chemical reactions and pathways resulting in the formation of cell wall glycoproteins, any cell wall protein that contains covalently bound sugar residues.\" [GOC:mah]","metadata":null},{"id":"9a8dcaf47c764b7c9b14dc55264e4aa9","type":"GO_TERM","name":"cell wall macromolecule biosynthetic process","canonical_id":"go:GO:0044038","description":"\"The chemical reactions and pathways resulting in the formation of a macromolecule destined to form part of a cell wall.\" [GOC:curators]","metadata":null},{"id":"aef839f036574199b2825b5a7c7c7857","type":"GO_TERM","name":"cell wall macromolecule catabolic process","canonical_id":"go:GO:0016998","description":"\"The chemical reactions and pathways resulting in the breakdown of macromolecules that form part of a cell wall.\" [GOC:curators]","metadata":null},{"id":"5d00f46a64c8452b827816d815962cff","type":"GO_TERM","name":"cell wall macromolecule metabolic process","canonical_id":"go:GO:0044036","description":"\"The chemical reactions and pathways involving macromolecules forming, or destined to form, part of the cell wall. A cell wall is a rigid or semi-rigid envelope lying outside the cell membrane of plant, fungal and most prokaryotic cells, maintaining their shape and protecting them from osmotic lysis.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"3399fd5387b24189a7edf6d0b0f5fc3b","type":"GO_TERM","name":"cell wall mannoprotein biosynthetic process","canonical_id":"go:GO:0000032","description":"\"The chemical reactions and pathways resulting in the formation of cell wall mannoproteins, any cell wall protein that contains covalently bound mannose residues.\" [GOC:ai]","metadata":null},{"id":"a8488c4652a94ac0ab0da4e163b67137","type":"GO_TERM","name":"cell wall modification","canonical_id":"go:GO:0042545","description":"\"The series of events leading to chemical and structural alterations of an existing cell wall that can result in loosening, increased extensibility or disassembly.\" [GOC:jl]","metadata":null},{"id":"69df891be83b4746abd6e13296940567","type":"GO_TERM","name":"cell wall modification involved in abscission","canonical_id":"go:GO:0009830","description":"\"A cellular process that results in the breakdown of the cell wall that contributes to the process of abscission.\" [GOC:dph, GOC:lr, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"50917ce1149942f5ac355ceb2a98c562","type":"GO_TERM","name":"cell wall modification involved in fruit ripening","canonical_id":"go:GO:0009829","description":"\"The series of events resulting in chemical or structural alterations of existing cell walls that contribute to fruit ripening.\" [GOC:lr]","metadata":null},{"id":"98918338303c4ff4b0fff65a589ecef0","type":"GO_TERM","name":"cell wall modification involved in multidimensional cell growth","canonical_id":"go:GO:0042547","description":"\"The series of events resulting in chemical or structural changes to existing cell walls and contribute to multidimensional cell growth.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"43085252284a4e64a554cd8cbd7350f3","type":"GO_TERM","name":"cell wall organization","canonical_id":"go:GO:0071555","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of the cell wall, the rigid or semi-rigid envelope lying outside the cell membrane of plant, fungal and most prokaryotic cells, maintaining their shape and protecting them from osmotic lysis.\" [GOC:mah]","metadata":null},{"id":"d807ca7016bb4b03b44a3c14d7b8dc9b","type":"GO_TERM","name":"cell wall organization or biogenesis","canonical_id":"go:GO:0071554","description":"\"A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cell wall.\" [GOC:mah]","metadata":null},{"id":"02738082d76c4a7e946f3d419fad8368","type":"GO_TERM","name":"cell wall pectin biosynthetic process","canonical_id":"go:GO:0052325","description":"\"The chemical reactions and pathways resulting in the formation of pectin, a polymer containing a backbone of alpha-1,4-linked D-galacturonic acid residues, as part of the organization and biogenesis of the cell wall.\" [GOC:ai]","metadata":null},{"id":"2fb0318ddbc449459101383902e5b496","type":"GO_TERM","name":"cell wall pectin metabolic process","canonical_id":"go:GO:0052546","description":"\"The chemical reactions and pathways involving pectin, a polymer containing a backbone of alpha-1,4-linked D-galacturonic acid residues, as part of the organization and biogenesis of the cell wall.\" [GOC:ai]","metadata":null},{"id":"74d4cee6033c4a0ca1036b04a444f841","type":"GO_TERM","name":"cell wall polysaccharide biosynthetic process","canonical_id":"go:GO:0070592","description":"\"The chemical reactions and pathways resulting in the formation of a polysaccharide destined to form part of a cell wall.\" [GOC:mah]","metadata":null},{"id":"617611490fcf4029939d089259814a85","type":"GO_TERM","name":"cell wall polysaccharide catabolic process","canonical_id":"go:GO:0044347","description":"\"The chemical reactions and pathways resulting in the breakdown of cell wall polysaccharides.\" [GOC:mengo_curators]","metadata":null},{"id":"0c0f64f926e94a8a9672e0fa97394b8c","type":"GO_TERM","name":"cell wall polysaccharide metabolic process","canonical_id":"go:GO:0010383","description":"\"The chemical reactions and pathways involving cell wall polysaccharides.\" [GOC:tair_curators]","metadata":null},{"id":"7a1c835435cc45c5bc57eacffb8acd16","type":"GO_TERM","name":"cell wall proteoglycan metabolic process","canonical_id":"go:GO:0010384","description":"\"The chemical reactions and pathways involving cell wall peptidoglycan, a group of glycoproteins that consist of a core-protein backbone O-glycosylated by one or more complex carbohydrates.\" [GOC:tair_curators]","metadata":null},{"id":"2e0de472e98047afb2464e09054dbc39","type":"GO_TERM","name":"cell wall repair","canonical_id":"go:GO:0071433","description":"\"A process of cell wall organization that results in the restoration of the cell wall following damage.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"d572b8407d0f44edaa6e46cd9dac9ae1","type":"GO_TERM","name":"cell wall thickening","canonical_id":"go:GO:0052386","description":"\"A type of cell wall modification in which the cell wall is reinforced and made thicker.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"d9969fb8f5224129986177c598bff3fa","type":"GO_TERM","name":"cell wall-bounded periplasmic space","canonical_id":"go:GO:0030287","description":"\"The region between the plasma membrane and the cell wall in organisms lacking an outer cell membrane such as yeast and Gram positive bacteria. The region is thinner than the equivalent in Gram negative bacteria.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"b4815fb54253421388c86acb9f7e23a8","type":"GO_TERM","name":"cell-abiotic substrate adhesion","canonical_id":"go:GO:0036164","description":"\"The attachment of a cell to an underlying abiotic (non-living) substrate via adhesion molecules.\" [GOC:di]","metadata":null},{"id":"43ee52b384894c42a3da6ca3124ea22d","type":"GO_TERM","name":"cell-cell adhesion","canonical_id":"go:GO:0098609","description":"\"The attachment of one cell to another cell via adhesion molecules.\" [GOC:dos]","metadata":null},{"id":"eb2afd53d0e6498db086ea404e17cf0d","type":"GO_TERM","name":"cell-cell adhesion in response to extracellular stimulus","canonical_id":"go:GO:0140039","description":"\"The attachment of one cell to another cell via adhesion molecules as a result of an extracellular stimulus.\" [PMID:14996911]","metadata":null},{"id":"06a1a66250cf4933a0885e0bc1810308","type":"GO_TERM","name":"cell-cell adhesion involved in ameboidal cell migration","canonical_id":"go:GO:0003367","description":"\"The attachment of one ameboid cell to another that contributes to the establishment of cell polarity that is part of the directed movement of one of the cells.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"f08c1ae145f141d082ad3a86765fb668","type":"GO_TERM","name":"cell-cell adhesion involved in gastrulation","canonical_id":"go:GO:0070586","description":"\"The attachment of one cell to another cell affecting gastrulation.\" [GOC:dsf, PMID:19091770]","metadata":null},{"id":"cb438d5b71b645259fb8a0dcaf911cff","type":"GO_TERM","name":"cell-cell adhesion involved in mesendodermal cell migration","canonical_id":"go:GO:0003370","description":"\"The attachment of mesendodermal cells to each other that contributes to the establishment of cell polarity that is part of the directed movement of the cells of the mesendoderm.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"8e074e7da74c4d03a59a0ca1ff6e8252","type":"GO_TERM","name":"cell-cell adhesion involved in neuronal-glial interactions involved in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021813","description":"\"The interaction between two cells that modulates the association of a neuronal cell and a glial cell involved in glial-mediated radial cell migration in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"5ac84d20953843abbbfe115cc25e7a5a","type":"GO_TERM","name":"cell-cell adhesion involved in synapse maturation","canonical_id":"go:GO:0090125","description":"\"The attachment of the pre-synaptic cell to the post-synaptic cell via adhesion molecules that contributes to synapse maturation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"500153206234491bb5bde14730a07758","type":"GO_TERM","name":"cell-cell adhesion mediated by cadherin","canonical_id":"go:GO:0044331","description":"\"The attachment of one cell to another cell via a cadherin, transmembrane proteins having repeating extracellular calcium ion binding domains.\" [GOC:ha, GOC:hjd, GOC:jl, PMID:10923970]","metadata":null},{"id":"68ee4a1bf3d14032be61376454e9ddbe","type":"GO_TERM","name":"cell-cell adhesion mediated by integrin","canonical_id":"go:GO:0033631","description":"\"The attachment of one cell to another cell via an integrin, a heterodimeric adhesion receptor formed by the non-covalent association of particular alpha and beta subunits.\" [GOC:add, PMID:12213832, PMID:14754902]","metadata":null},{"id":"e36b3e2f0b164fb8ba3970a715973fb9","type":"GO_TERM","name":"cell-cell adhesion mediator activity","canonical_id":"go:GO:0098632","description":"\"The binding by a cell-adhesion protein on the cell surface to an extracellular component of a different cell, to mediate adhesion of the cell to another cell.\" [GOC:dos, Wikipedia:Cell_adhesion]","metadata":null},{"id":"d642de6a52374958939816ea0ca99175","type":"GO_TERM","name":"cell-cell contact zone","canonical_id":"go:GO:0044291","description":"\"Extended zone of intimate apposition between two cells containing one or more types of intercellular junctions, e.g., the intercalated disk of muscle.\" [NIF_Subcellular:sao1299635018]","metadata":null},{"id":"09dd45df482b4219b18f28eeb42ccdbd","type":"GO_TERM","name":"cell-cell fusion","canonical_id":"go:GO:0140253","description":"\"A cellular process in which two or more cells combine together, their plasma membrane fusing, producing a single cell. In some cases, nuclei fuse, producing a polyploid cell, while in other cases, nuclei remain separate, producing a syncytium.\" [Wikipedia:Cell_fusion]","metadata":null},{"id":"0e44bf1d4fd64f2fa366ba823c1b0004","type":"GO_TERM","name":"cell-cell junction","canonical_id":"go:GO:0005911","description":"\"A cell junction that forms a connection between two or more cells of an organism; excludes direct cytoplasmic intercellular bridges, such as ring canals in insects.\" [GOC:aruk, GOC:bc, GOC:dgh, GOC:hb, GOC:mah, PMID:21422226, PMID:28096264]","metadata":null},{"id":"b15d1c88ce0042268bcbb22231493677","type":"GO_TERM","name":"cell-cell junction assembly","canonical_id":"go:GO:0007043","description":"\"The aggregation, arrangement and bonding together of a set of components to form a junction between cells.\" [GOC:ai]","metadata":null},{"id":"b6d3ad9f028b410ba8402f97369c760c","type":"GO_TERM","name":"cell-cell junction disassembly","canonical_id":"go:GO:0150147","description":"\"The disaggregation of a cell-cell junction into its constituent components.\" [GOC:aruk, PMID:25490267]","metadata":null},{"id":"c3293de452784fcb886e9de4e83f64ce","type":"GO_TERM","name":"cell-cell junction maintenance","canonical_id":"go:GO:0045217","description":"\"The maintenance of junctions between cells.\" [GOC:ai]","metadata":null},{"id":"31282c02ea0b4abfaff7b7058e1d52b1","type":"GO_TERM","name":"cell-cell junction organization","canonical_id":"go:GO:0045216","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cell-cell junction. A cell-cell junction is a specialized region of connection between two cells.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"5fc6a6bb3ae94b5ea7b3f72526b64557","type":"GO_TERM","name":"cell-cell recognition","canonical_id":"go:GO:0009988","description":"\"Cell recognition between cells. May involve the formation of specialized cell junctions.\" [ISBN:0824072820]","metadata":null},{"id":"69a616cd49b74b5bab38f036f6d5dbf6","type":"GO_TERM","name":"cell-cell self recognition","canonical_id":"go:GO:0097656","description":"\"A cell-cell recognition process by which a cell distinguishes between self and non self during cooperative behavior, such as early development.\" [GOC:pf, PMID:21700835, PMID:23910661]","metadata":null},{"id":"3a7052188f40496d92eaa3e5cbc8835a","type":"GO_TERM","name":"cell-cell signaling","canonical_id":"go:GO:0007267","description":"\"Any process that mediates the transfer of information from one cell to another. This process includes signal transduction in the receiving cell and, where applicable, release of a ligand and any processes that actively facilitate its transport and presentation to the receiving cell. Examples include signaling via soluble ligands, via cell adhesion molecules and via gap junctions.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"fdbc84b6ee074a5e9c6dd3acd50895f7","type":"GO_TERM","name":"cell-cell signaling involved in cell fate commitment","canonical_id":"go:GO:0045168","description":"\"Signaling at long or short range between cells that results in the commitment of a cell to a certain fate.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"d85c950218454b6dbcbf02c2c9181ab0","type":"GO_TERM","name":"cell-cell signaling involved in mammary gland development","canonical_id":"go:GO:0060764","description":"\"Any process that mediates the transfer of information from one cell to another and contributes to the progression of the mammary gland, from its initial state to the mature structure.\" [GOC:dph]","metadata":null},{"id":"b8b52c23060d41dabf33d959cbab77e4","type":"GO_TERM","name":"cell-cell signaling via exosome","canonical_id":"go:GO:0099156","description":"\"Cell-cell signaling in which the ligand is carried between cells by an exosome.\" [GOC:dos, PMID:19837038]","metadata":null},{"id":"ff12a14a70444a29b4fe53ac7126d8f4","type":"GO_TERM","name":"cell-matrix adhesion","canonical_id":"go:GO:0007160","description":"\"The binding of a cell to the extracellular matrix via adhesion molecules.\" [GOC:hb]","metadata":null},{"id":"5d8afabb31b94d9694c4fe5d5823bd9e","type":"GO_TERM","name":"cell-matrix adhesion involved in ameboidal cell migration","canonical_id":"go:GO:0003366","description":"\"The binding of a cell to the extracellular matrix that contributes to the directed movement of an ameboid cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"6b0bfc1fd50b49dc98804249d1e22672","type":"GO_TERM","name":"cell-matrix adhesion mediator activity","canonical_id":"go:GO:0098634","description":"\"The binding by a cell-adhesion protein on the cell surface to an extracellular matrix component, to mediate adhesion of the cell to the extracellular matrix.\" [Wikipedia:Cell_adhesion]","metadata":null},{"id":"f7efa0b998d8476f999a1c49765b1d51","type":"GO_TERM","name":"cell-matrix recognition","canonical_id":"go:GO:0009989","description":"\"Cell recognition that involves the interaction of the cell with the extracellular matrix.\" [ISBN:0824072820]","metadata":null},{"id":"ed9d9b7ca2e645d3a899bff21c7ade33","type":"GO_TERM","name":"cell-substrate adhesion","canonical_id":"go:GO:0031589","description":"\"The attachment of a cell to the underlying substrate via adhesion molecules.\" [GOC:mah, GOC:pf]","metadata":null},{"id":"87e3f4ba53b640368036f9cc17e72ad3","type":"GO_TERM","name":"cell-substrate junction","canonical_id":"go:GO:0030055","description":"\"A cell junction that forms a connection between a cell and the extracellular matrix.\" [GOC:aruk, GOC:bc, GOC:hb, GOC:mah, PMID:10419689, PMID:1643657, PMID:16805308, PMID:26923917, PMID:8314002]","metadata":null},{"id":"66a19ba35bcb4a17b09f17463c81d246","type":"GO_TERM","name":"cell-substrate junction assembly","canonical_id":"go:GO:0007044","description":"\"The aggregation, arrangement and bonding together of a set of components to form a junction between a cell and its substrate.\" [GOC:mah]","metadata":null},{"id":"fb528924271249f0b505aa0f7e5538cf","type":"GO_TERM","name":"cell-substrate junction disassembly","canonical_id":"go:GO:0120180","description":"\"The disaggregation of a cell-substrate junction into its constituent components.\" [GOC:aruk, GOC:bc, PMID:25490267]","metadata":null},{"id":"79c496ac82a64910ba0723fb96f83650","type":"GO_TERM","name":"cell-substrate junction organization","canonical_id":"go:GO:0150115","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cell-substrate junction. A cell-substrate junction is a specialized region of connection between a cell and the extracellular matrix.\" [GOC:aruk, GOC:bc, PMID:10419689, PMID:1643657, PMID:16805308, PMID:26923917, PMID:8314002]","metadata":null},{"id":"78d431257bbe4c769d219bf9ed7fd425","type":"GO_TERM","name":"cellobiose binding","canonical_id":"go:GO:0044585","description":"\"Binding to cellobiose, a disaccharide that represents the basic repeating unit of cellulose.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"0cf309c8083948a0a522ae5133035533","type":"GO_TERM","name":"cellobiose catabolic process","canonical_id":"go:GO:2000892","description":"\"The chemical reactions and pathways resulting in the breakdown of a cellobiose.\" [GOC:mengo_curators]","metadata":null},{"id":"4735d9cef3bc475bb8109a89322bf829","type":"GO_TERM","name":"cellobiose dehydrogenase (acceptor) activity","canonical_id":"go:GO:0047735","description":"\"Catalysis of the reaction: cellobiose + acceptor = cellobiono-1,5-lactone + reduced acceptor.\" [EC:1.1.99.18, MetaCyc:CELLOBIOSE-DEHYDROGENASE-ACCEPTOR-RXN]","metadata":null},{"id":"ed17dd6c7a0b47ffb87d2536251af483","type":"GO_TERM","name":"cellobiose epimerase activity","canonical_id":"go:GO:0047736","description":"\"Catalysis of the reaction: cellobiose = D-glucosyl-D-mannose.\" [EC:5.1.3.11, MetaCyc:CELLOBIOSE-EPIMERASE-RXN]","metadata":null},{"id":"e67b4a19c9c641e890e29d93920cbe8b","type":"GO_TERM","name":"cellobiose glucosidase activity","canonical_id":"go:GO:0080079","description":"\"Catalysis of the reaction: D-cellobiose + H2O = 2 D-glucose.\" [PMID:15604686, RHEA:30679]","metadata":null},{"id":"e939463aef374a2a99ad9df762982224","type":"GO_TERM","name":"cellobiose metabolic process","canonical_id":"go:GO:2000891","description":"\"The chemical reactions and pathways involving a cellobiose.\" [GOC:mengo_curators]","metadata":null},{"id":"af0c677ec5674f9581e1b76092f96ea4","type":"GO_TERM","name":"cellobiose phosphorylase activity","canonical_id":"go:GO:0047738","description":"\"Catalysis of the reaction: cellobiose + phosphate = alpha-D-glucose 1-phosphate + D-glucose.\" [RHEA:19493]","metadata":null},{"id":"ecd720beb1ab49c4b82ced5fa7ec76f2","type":"GO_TERM","name":"cellobiose transmembrane transporter activity","canonical_id":"go:GO:0019191","description":"\"Enables the transfer of cellobiose from one side of a membrane to the other. Cellobiose, or 4-O-beta-D-glucopyranosyl-D-glucose, is a disaccharide that represents the basic repeating unit of cellulose.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"eae93b9dc5ff423d9d2e9d76179db564","type":"GO_TERM","name":"cellobiose transport","canonical_id":"go:GO:0019533","description":"\"The directed movement of cellobiose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Cellobiose, or 4-O-beta-D-glucopyranosyl-D-glucose, is a disaccharide that represents the basic repeating unit of cellulose.\" [GOC:ai]","metadata":null},{"id":"e20028ec1a044af1bf8d7bdc6b632d2d","type":"GO_TERM","name":"cellodextrin binding","canonical_id":"go:GO:0044584","description":"\"Binding to a cellodextrin, a glucose polymer of 2 or more glucose monomers.\" [GOC:mengo_curators, GOC:tt, PMID:18952792]","metadata":null},{"id":"24b1b0deab3b4d2299c73195ad9a9d33","type":"GO_TERM","name":"cellodextrin catabolic process","canonical_id":"go:GO:2000890","description":"\"The chemical reactions and pathways resulting in the breakdown of a cellodextrin.\" [GOC:mengo_curators]","metadata":null},{"id":"8424fa7be0244b97b002959984fa17bc","type":"GO_TERM","name":"cellodextrin phosphorylase activity","canonical_id":"go:GO:0050102","description":"\"Catalysis of the reaction: 1,4-beta-D-glucosyl(n) + phosphate = 1,4-beta-D-glucosyl(n-1) + alpha-D-glucose 1-phosphate.\" [EC:2.4.1.49, MetaCyc:CELLODEXTRIN-PHOSPHORYLASE-RXN]","metadata":null},{"id":"54db7afe681144d18c11d13993e2ff7e","type":"GO_TERM","name":"cellooligosaccharide binding","canonical_id":"go:GO:2001064","description":"\"Binding to cellooligosaccharide.\" [GOC:mengo_curators]","metadata":null},{"id":"3fd279cef019456ba5aa0e569a1b116e","type":"GO_TERM","name":"cellooligosaccharide catabolic process","canonical_id":"go:GO:2000903","description":"\"The chemical reactions and pathways resulting in the breakdown of a cellooligosaccharide.\" [GOC:mengo_curators]","metadata":null},{"id":"e345016cb7534412bf004173d6b7755a","type":"GO_TERM","name":"cellooligosaccharide metabolic process","canonical_id":"go:GO:2000902","description":"\"The chemical reactions and pathways involving a cellooligosaccharide.\" [GOC:mengo_curators]","metadata":null},{"id":"c39d4f7f21524f9b8ae1549c9a8b9ec6","type":"GO_TERM","name":"cellopentaose binding","canonical_id":"go:GO:0044587","description":"\"Binding to a cellopentaose, an oligosaccharide consisting of four glucose residues resulting from hydrolysis of cellulose.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"3e6f48870cb14cc59c14218376ca8f46","type":"GO_TERM","name":"cellotetraose binding","canonical_id":"go:GO:0044586","description":"\"Binding to a cellotetraose, an oligosaccharide consisting of four glucose residues resulting from hydrolysis of cellulose.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"51c83ec6fb59476eb3cec75dd3139c12","type":"GO_TERM","name":"cellotriose binding","canonical_id":"go:GO:0044583","description":"\"Binding to cellotriose.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"55526e3ceb0e450a957047be7fe23d1b","type":"GO_TERM","name":"cellotriose catabolic process","canonical_id":"go:GO:2000894","description":"\"The chemical reactions and pathways resulting in the breakdown of a cellotriose.\" [GOC:mengo_curators]","metadata":null},{"id":"7ecb362257bc4d50a081ef45a0921814","type":"GO_TERM","name":"cellotriose transport","canonical_id":"go:GO:2001096","description":"\"The directed movement of a cellotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"625e5d0a4ab84b5cb8b2d80002fa2cda","type":"GO_TERM","name":"cellubrevin-VAMP4-endobrevin-syntaxin-6 complex","canonical_id":"go:GO:0070066","description":"\"A SNARE complex that contains cellubrevin (VAMP3), VAMP4, endobrevin (VAMP8), and syntaxin 6 (or orthologs thereof).\" [PMID:11839770]","metadata":null},{"id":"57e38f94fe164f2687f3793e3bcdc949","type":"GO_TERM","name":"cellubrevin-VAMP4-syntaxin-16 complex","canonical_id":"go:GO:0070065","description":"\"A SNARE complex that contains cellubrevin (VAMP3), VAMP4, and syntaxin 16 (or orthologs thereof).\" [PMID:11839770]","metadata":null},{"id":"2f74b404737447eda85b59e72d10f986","type":"GO_TERM","name":"cellular anatomical entity morphogenesis","canonical_id":"go:GO:0032989","description":"\"The process in which a cellular entity is generated and organized. A cellular entity has granularity above the level of a protein complex but below that of an anatomical system.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"157194df54a34d84923711ecc1078bf9","type":"GO_TERM","name":"cellular anatomical structure","canonical_id":"go:GO:0110165","description":"\"A part of a cellular organism consisting of a material entity with granularity above the level of a protein complex but below that of an anatomical system. Note that cellular organisms exclude viruses.\" [GOC:kmv]","metadata":null},{"id":"99b1132da4d74fdbb3e08211884cb280","type":"GO_TERM","name":"cellular birth scar","canonical_id":"go:GO:0071597","description":"\"Crater-like ring of chitinous scar tissue located on the surface of the daughter cell, in budding fungi, at the site of separation from the mother cell. It is formed after the newly emerged daughter cell separates, thereby marking the site of cytokinesis and septation.\" [GOC:mcc, PMID:16672383, PMID:7730409]","metadata":null},{"id":"3cacebed2d3e4b68b8fdb7152a5d308c","type":"GO_TERM","name":"cellular bud","canonical_id":"go:GO:0005933","description":"\"A protuberance from a cell of an organism that reproduces by budding, which will grow larger and become a separate daughter cell after nuclear division, cytokinesis, and cell wall formation (when appropriate). The daughter cell may completely separate from the mother cell, or the mother and daughter cells may remain associated.\" [GOC:sgd_curators]","metadata":null},{"id":"32c818aefafa47729d5b50c58b5eb903","type":"GO_TERM","name":"cellular bud membrane","canonical_id":"go:GO:0033101","description":"\"The portion of the plasma membrane surrounding a cellular bud.\" [GOC:mah]","metadata":null},{"id":"3177aecf5b65422285bc405058b2da16","type":"GO_TERM","name":"cellular bud neck","canonical_id":"go:GO:0005935","description":"\"The constriction between the mother cell and daughter cell (bud) in an organism that reproduces by budding.\" [GOC:mah]","metadata":null},{"id":"350f60cdee4c41db9b5366c43f28769b","type":"GO_TERM","name":"cellular bud neck contractile ring","canonical_id":"go:GO:0000142","description":"\"A contractile ring, i.e. a cytoskeletal structure composed of actin filaments and myosin, that forms beneath the plasma membrane at the mother-bud neck in mitotic cells that divide by budding in preparation for completing cytokinesis. An example of this structure is found in Saccharomyces cerevisiae.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"509af540d0534da087ce2d7b57d6557e","type":"GO_TERM","name":"cellular bud neck polarisome","canonical_id":"go:GO:0031560","description":"\"Protein complex that has a role in determining cell polarity, found at the neck of a fungal bud before and during cytokinesis.\" [PMID:9632790]","metadata":null},{"id":"ad0ecfa4ff55475187c6c248d1098a93","type":"GO_TERM","name":"cellular bud neck septin collar","canonical_id":"go:GO:0032174","description":"\"A tubular structure with flared ends, shaped like an hourglass and composed of highly ordered arrays of septin filaments, that forms at the bud neck of a dividing cell. In S. cerevisiae, this structure is located at the bud neck throughout most of the cell cycle and the septins are fixed within the structure, not exchanging with soluble septins. This septin structure acts as a scaffold for other proteins that function at the bud neck.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"aae92578a03541fd8652bcbb08de2932","type":"GO_TERM","name":"cellular bud neck septin ring","canonical_id":"go:GO:0000144","description":"\"A ring-shaped structure that forms at the site of cytokinesis in the bud neck of a budding cell; composed of members of the conserved family of filament forming proteins called septins as well as septin-associated proteins. In S. cerevisiae, this structure forms at the time of bud emergence and the septins show a high rate of exchange.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"2ec68b59d4064b16a106a9ee184fa452","type":"GO_TERM","name":"cellular bud neck septin ring organization","canonical_id":"go:GO:0032186","description":"\"Control of the formation, spatial distribution, and breakdown of a septin ring located at the bud neck.\" [GOC:mah]","metadata":null},{"id":"f61457287d59494599be65cd79091418","type":"GO_TERM","name":"cellular bud neck septin structure","canonical_id":"go:GO:0000399","description":"\"Any of a series of septin structures that are localized in the bud neck of a budding fungal cell during the cell cycle.\" [GOC:krc]","metadata":null},{"id":"e9ccee7fc21c45c09c7ac8fc29eeb958","type":"GO_TERM","name":"cellular bud neck split septin rings","canonical_id":"go:GO:0032177","description":"\"Two separate septin rings that are formed from the septin collar at the time of cytokinesis in cells that divide by budding. These two rings are thought to delineate a special compartment in which factors involved in cytokinesis are concentrated.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"e4c97f6ed13f4dd096c8f3a9791861bc","type":"GO_TERM","name":"cellular bud scar","canonical_id":"go:GO:0005621","description":"\"Crater-like ring of chitinous scar tissue located on the surface of the mother cell. It is formed after the newly emerged daughter cell separates thereby marking the site of cytokinesis and septation. The number of bud scars that accumulate on the surface of a cell is a useful determinant of replicative age.\" [GOC:rn, PMID:14600225, PMID:2005820]","metadata":null},{"id":"06d31bd0d2a3481892db76b6ee1d5f7f","type":"GO_TERM","name":"cellular bud site selection","canonical_id":"go:GO:0000282","description":"\"The specification of the site where a daughter cell will form, in organisms that reproduce by budding. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:mah]","metadata":null},{"id":"3255ac1e8a96415ea17f9932cf797ec3","type":"GO_TERM","name":"cellular bud tip","canonical_id":"go:GO:0005934","description":"\"The end of a cellular bud distal to the site of attachment to the mother cell.\" [GOC:mah]","metadata":null},{"id":"1666f05447334c52af9b933afb910e1c","type":"GO_TERM","name":"cellular bud tip polarisome","canonical_id":"go:GO:0031561","description":"\"Protein complex that has a role in determining cell polarity, found at the tip of a growing fungal bud.\" [PMID:9632790]","metadata":null},{"id":"e0ccff247ef94ba782e32416ffac2d75","type":"GO_TERM","name":"cellular component assembly","canonical_id":"go:GO:0022607","description":"\"The aggregation, arrangement and bonding together of a cellular component.\" [GOC:isa_complete]","metadata":null},{"id":"a2fbbde3d4cd42b1a7d78c2e1840d3d9","type":"GO_TERM","name":"cellular component assembly involved in morphogenesis","canonical_id":"go:GO:0010927","description":"\"The cellular component assembly that is part of the initial shaping of the component during its developmental progression.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e403c0f36eaa4408bfc5565068a7cdf9","type":"GO_TERM","name":"cellular component biogenesis","canonical_id":"go:GO:0044085","description":"\"A process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cellular component. Includes biosynthesis of constituent macromolecules, and those macromolecular modifications that are involved in synthesis or assembly of the cellular component.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"8d1acb02b5f34f7991fb94a7ef53c411","type":"GO_TERM","name":"cellular component disassembly","canonical_id":"go:GO:0022411","description":"\"A cellular process that results in the breakdown of a cellular component.\" [GOC:isa_complete]","metadata":null},{"id":"dab8c5659fdd4bfdbc65854d8ec12933","type":"GO_TERM","name":"cellular component disassembly involved in execution phase of apoptosis","canonical_id":"go:GO:0006921","description":"\"The breakdown of structures such as organelles, proteins, or other macromolecular structures during apoptosis.\" [GOC:dph, GOC:mah, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"d3c77ab0e111474b94c0460e5fce1f8d","type":"GO_TERM","name":"cellular component maintenance","canonical_id":"go:GO:0043954","description":"\"The organization process that preserves a cellular component in a stable functional or structural state.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"7dd2b0e1aaca4dfca6b2217955f37ee6","type":"GO_TERM","name":"cellular component organization","canonical_id":"go:GO:0016043","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of a cellular component.\" [GOC:ai, GOC:jl, GOC:mah]","metadata":null},{"id":"90e47d178c81476590434ed8b7087ef5","type":"GO_TERM","name":"cellular component organization or biogenesis","canonical_id":"go:GO:0071840","description":"\"A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cellular component.\" [GOC:mah]","metadata":null},{"id":"1d9b394885a44d2ca5737ba187097b1a","type":"GO_TERM","name":"cellular defense response","canonical_id":"go:GO:0006968","description":"\"A defense response that is mediated by cells.\" [GOC:ebc]","metadata":null},{"id":"2987831e218b4bbf8deb6e52b5feee14","type":"GO_TERM","name":"cellular detoxification","canonical_id":"go:GO:1990748","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.\" [GOC:vw]","metadata":null},{"id":"ed748ec7d88142a6ba524f8f51ea1a4a","type":"GO_TERM","name":"cellular detoxification of acetone","canonical_id":"go:GO:0140977","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of acetone. These may include chemical modification, for example to methylglyoxal.\" [PMID:22314896, PMID:26958851]","metadata":null},{"id":"ab2c3c5c211a4ef2b32de72ffea47ce0","type":"GO_TERM","name":"cellular detoxification of aldehyde","canonical_id":"go:GO:0110095","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of an aldehyde. These may include transport of aldehydes away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.\" [GOC:vw, PMID:25656103]","metadata":null},{"id":"cee2496490834d458cbd6a17fe263429","type":"GO_TERM","name":"cellular detoxification of cadmium ion","canonical_id":"go:GO:0098849","description":"\"Any process that reduces or removes the toxicity of cadmium cations in a cell. These include transport of cadmium cations away from sensitive areas and to compartments or complexes whose purpose is sequestration.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"9041b2e984f745578d8faaeea552e609","type":"GO_TERM","name":"cellular detoxification of copper ion","canonical_id":"go:GO:1990880","description":"\"Any process that reduces or removes the toxicity of copper ions in a cell. These include transport of copper cations away from sensitive areas and to compartments or complexes whose purpose is sequestration.\" [PMID:10369673]","metadata":null},{"id":"4d46bb4efe4a45d995949fb9f6dc71f9","type":"GO_TERM","name":"cellular detoxification of fluoride","canonical_id":"go:GO:0140114","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of a fluoride. These may include chemical modification or transport of fluoride away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.\" [GOC:vw]","metadata":null},{"id":"efcede4e3ef2474aa1b7acfb9adf69c9","type":"GO_TERM","name":"cellular detoxification of hydrogen peroxide","canonical_id":"go:GO:0061692","description":"\"Any process that reduces or removes the toxicity of hydrogen peroxide in a cell. These include transport of hydrogen peroxide away from sensitive areas and to compartments or complexes whose purpose is sequestration.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"88e77c0ac3c6412fbe3e34cadc24b4a5","type":"GO_TERM","name":"cellular detoxification of metal ion","canonical_id":"go:GO:0140961","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of a metal ion.\" [PMID:26729300, PMID:33046888, PMID:34442707]","metadata":null},{"id":"c79c6fa291024168a3520b2f7f03d8bd","type":"GO_TERM","name":"cellular detoxification of methylglyoxal","canonical_id":"go:GO:0140041","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of methylglyoxal. These may include chemical modification or transport of methylglyoxal away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.\" [PMID:15042280]","metadata":null},{"id":"7813449b22314aedaf3a5fd56ac1d5ba","type":"GO_TERM","name":"cellular detoxification of nitrogen compound","canonical_id":"go:GO:0070458","description":"\"Any cellular process that reduces or removes the toxicity of nitrogenous compounds which are dangerous or toxic. This includes the aerobic conversion of toxic compounds to harmless substances.\" [GOC:mah]","metadata":null},{"id":"1af001306d0d4b0896906493d4d92648","type":"GO_TERM","name":"cellular detoxification of sulfide","canonical_id":"go:GO:0140974","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity of a sulfide. These may include chemical modification or transport of sulfide away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.\" [PMID:20077566, PMID:25747485]","metadata":null},{"id":"714768e6cac44ac7a25c0e04ca3f3b83","type":"GO_TERM","name":"cellular developmental process","canonical_id":"go:GO:0048869","description":"\"A biological process whose specific outcome is the progression of a cell over time from an initial condition to a later condition.\" [GOC:isa_complete]","metadata":null},{"id":"8b39546abf7b49f883b3fcfc70911f4a","type":"GO_TERM","name":"cellular extravasation","canonical_id":"go:GO:0045123","description":"\"The migration of a leukocyte from the blood vessels into the surrounding tissue.\" [GOC:jl]","metadata":null},{"id":"e6512e6ca46f42069c1449618abc507c","type":"GO_TERM","name":"cellular heat acclimation","canonical_id":"go:GO:0070370","description":"\"Any process that increases heat tolerance of a cell in response to high temperatures.\" [GOC:jp]","metadata":null},{"id":"fb02cfc4b87c4e4dac2397207219fa71","type":"GO_TERM","name":"cellular homeostasis","canonical_id":"go:GO:0019725","description":"\"Any process involved in the maintenance of an internal steady state at the level of the cell.\" [GOC:isa_complete, GOC:jl, ISBN:0395825172]","metadata":null},{"id":"d192c22dd69c4986ae7fda87925a394d","type":"GO_TERM","name":"cellular hyperosmotic response","canonical_id":"go:GO:0071474","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hyperosmotic environment, i.e. an environment with a higher concentration of solutes than the organism or cell.\" [GOC:mah]","metadata":null},{"id":"5ca42add5b8649dd886138b8e8653f6c","type":"GO_TERM","name":"cellular hyperosmotic salinity response","canonical_id":"go:GO:0071475","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, an increase in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.\" [GOC:mah]","metadata":null},{"id":"a852058c2c0746f5bb45811f45df96d0","type":"GO_TERM","name":"cellular hypotonic response","canonical_id":"go:GO:0071476","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hypotonic environment, i.e. an environment with a lower concentration of solutes than the organism or cell.\" [GOC:mah]","metadata":null},{"id":"cbed7704691747bf8c816dce9d757a98","type":"GO_TERM","name":"cellular hypotonic salinity response","canonical_id":"go:GO:0071477","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a decrease in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.\" [GOC:mah]","metadata":null},{"id":"3376bea1aba34b88b398de8005de4f57","type":"GO_TERM","name":"cellular localization","canonical_id":"go:GO:0051641","description":"\"A cellular localization process whereby a substance or cellular entity, such as a protein complex or organelle, is transported to, and/or maintained in, a specific location within a cell including the localization of substances or cellular entities to the cell membrane.\" [GOC:tb, GOC:vw]","metadata":null},{"id":"b2986d0cf82d451aa4812eb42b09a985","type":"GO_TERM","name":"cellular oxidant detoxification","canonical_id":"go:GO:0098869","description":"\"Any process carried out at the cellular level that reduces or removes the toxicity superoxide radicals or hydrogen peroxide.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"5219669aa30d4726b1d8cb9551d20b28","type":"GO_TERM","name":"cellular pigment accumulation","canonical_id":"go:GO:0043482","description":"\"The aggregation of coloring matter in a particular location in a cell, occurring in response to some external stimulus.\" [GOC:jl]","metadata":null},{"id":"865b4bd9fee94f8e99d51af8988f2097","type":"GO_TERM","name":"cellular pigmentation","canonical_id":"go:GO:0033059","description":"\"The deposition or aggregation of coloring matter in a cell.\" [GOC:mtg_MIT_16mar07]","metadata":null},{"id":"071dcb6ff0154b0da8a0bb3b90692340","type":"GO_TERM","name":"cellular process","canonical_id":"go:GO:0009987","description":"\"Any process that is carried out at the cellular level, but not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.\" [GOC:curators, GOC:isa_complete]","metadata":null},{"id":"07c28bc68d234eb3a75dc13320d24a67","type":"GO_TERM","name":"cellular process involved in reproduction in multicellular organism","canonical_id":"go:GO:0022412","description":"\"A process, occurring at the cellular level, that is involved in the reproductive function of a multicellular organism.\" [GOC:isa_complete]","metadata":null},{"id":"44c2b2762b6a409d9773cf7261e87542","type":"GO_TERM","name":"cellular respiration","canonical_id":"go:GO:0045333","description":"\"The enzymatic release of energy from inorganic and organic compounds (especially carbohydrates and fats) which either requires oxygen (aerobic respiration) or does not (anaerobic respiration).\" [GOC:das, ISBN:0140513590, ISBN:0198506732]","metadata":null},{"id":"86f07446f97948d091d64093151f3d09","type":"GO_TERM","name":"cellular response to 1-aminocyclopropane-1-carboxylic acid","canonical_id":"go:GO:0071213","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-aminocyclopropane-1-carboxylic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"260b69564ebe4363b819e0dfab9ba484","type":"GO_TERM","name":"cellular response to 1-oleoyl-sn-glycerol 3-phosphate","canonical_id":"go:GO:1904566","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-oleoyl-sn-glycerol 3-phosphate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12139919]","metadata":null},{"id":"65131d5454944909b6962b838e263d7e","type":"GO_TERM","name":"cellular response to 11-deoxycorticosterone","canonical_id":"go:GO:1903497","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 11-deoxycorticosterone stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:3585228]","metadata":null},{"id":"d06154a68ac54ddba3941b19efd1a7cc","type":"GO_TERM","name":"cellular response to 2,3,7,8-tetrachlorodibenzodioxine","canonical_id":"go:GO:1904613","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 2,3,7,8-tetrachlorodibenzodioxine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23196670]","metadata":null},{"id":"ffd04553707a4e5e836c429be3882a40","type":"GO_TERM","name":"cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine","canonical_id":"go:GO:1904317","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:9321918]","metadata":null},{"id":"64cbfd9552eb48e48acfcfd4cecef44c","type":"GO_TERM","name":"cellular response to 3,3',4,4',5-pentachlorobiphenyl","canonical_id":"go:GO:1904611","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 3,3',4,4',5-pentachlorobiphenyl stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23196670]","metadata":null},{"id":"298f96a7aa0146ed8bc2a7af9b4b408a","type":"GO_TERM","name":"cellular response to 3,3',5-triiodo-L-thyronine","canonical_id":"go:GO:1905243","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 3,3',5-triiodo-L-thyronine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21382270]","metadata":null},{"id":"aff94717c6a446b8a4f70661d4a86275","type":"GO_TERM","name":"cellular response to 3-methylcholanthrene","canonical_id":"go:GO:1904682","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 3-methylcholanthrene stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:9224771]","metadata":null},{"id":"cf8ab290fa1b49afacb3ba2f3c993539","type":"GO_TERM","name":"cellular response to 4-nitroquinoline N-oxide","canonical_id":"go:GO:0072725","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 4-nitroquinoline N-oxide stimulus.\" [GOC:mah]","metadata":null},{"id":"1c6aa78138074592b3d4db3e3f53360a","type":"GO_TERM","name":"cellular response to ATP","canonical_id":"go:GO:0071318","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ATP (adenosine 5'-triphosphate) stimulus.\" [GOC:mah]","metadata":null},{"id":"c2a60032d29c48caa99cbf146f49e385","type":"GO_TERM","name":"cellular response to Aroclor 1254","canonical_id":"go:GO:1904011","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an Aroclor 1254 stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18602130]","metadata":null},{"id":"351d0999b7b14cada2dca7922f095138","type":"GO_TERM","name":"cellular response to BMP stimulus","canonical_id":"go:GO:0071773","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bone morphogenetic protein (BMP) stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"65aa12a2d9204f68ba1c976683fb7f05","type":"GO_TERM","name":"cellular response to D-galactosamine","canonical_id":"go:GO:1904422","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a D-galactosamine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12057922]","metadata":null},{"id":"86d9ce7446a64179a727828a6c915f64","type":"GO_TERM","name":"cellular response to D-galactose","canonical_id":"go:GO:1905378","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a D-galactose stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26261574]","metadata":null},{"id":"652b85c2f31d4893a080fa7e321b56db","type":"GO_TERM","name":"cellular response to GW 7647","canonical_id":"go:GO:0072760","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a GW 7647 stimulus.\" [GOC:mah]","metadata":null},{"id":"e2fcbfaf97e640ebb557e6ab377a236b","type":"GO_TERM","name":"cellular response to Gentian violet","canonical_id":"go:GO:0072729","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Gentian violet stimulus.\" [GOC:mah]","metadata":null},{"id":"09fb1a14730e4bb4b35d78e77944ff0c","type":"GO_TERM","name":"cellular response to L-arginine","canonical_id":"go:GO:1903577","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-arginine stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:6394628]","metadata":null},{"id":"ce07391481bf4e92bda823f95fb66b33","type":"GO_TERM","name":"cellular response to L-ascorbic acid","canonical_id":"go:GO:0071298","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an L-ascorbic acid (vitamin C) stimulus.\" [GOC:mah]","metadata":null},{"id":"df7ed1eceafd42f7bfc76cfc8e4c0664","type":"GO_TERM","name":"cellular response to L-canavanine","canonical_id":"go:GO:0036280","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-canavanine stimulus. L-canavanine is L-homoserine substituted at oxygen with a guanidino (carbamimidamido) group.\" [GOC:al]","metadata":null},{"id":"f110e85679dd4ddaac4c17d2bd0f4ace","type":"GO_TERM","name":"cellular response to L-cysteine","canonical_id":"go:GO:0036346","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-cysteine stimulus. L-cysteine is an optically active form of cysteine having L-configuration.\" [GOC:al]","metadata":null},{"id":"aa75bd9056644aa29b3870ffbf48f6f3","type":"GO_TERM","name":"cellular response to L-dopa","canonical_id":"go:GO:1904474","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-dopa stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25044243]","metadata":null},{"id":"7b852039612c4023abdc4ab360fa6d53","type":"GO_TERM","name":"cellular response to L-glutamate","canonical_id":"go:GO:1905232","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-glutamate(1-) stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25962137]","metadata":null},{"id":"01c7ced54acb4076b462d0aa301e57c8","type":"GO_TERM","name":"cellular response to L-glutamine","canonical_id":"go:GO:1904845","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-glutamine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23185570]","metadata":null},{"id":"efbe3574081a495e9feb1b11518aa022","type":"GO_TERM","name":"cellular response to L-leucine","canonical_id":"go:GO:0071233","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-leucine stimulus.\" [GOC:mah]","metadata":null},{"id":"5f8279cf394044b8aec6a5748d901d56","type":"GO_TERM","name":"cellular response to L-phenylalanine derivative","canonical_id":"go:GO:1904387","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-phenylalanine derivative stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12112407]","metadata":null},{"id":"8dea5c64103448499a43a0fdebf89d68","type":"GO_TERM","name":"cellular response to L-thialysine","canonical_id":"go:GO:0072751","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-thialysine stimulus.\" [GOC:mah]","metadata":null},{"id":"4cf31559c89443699890728abaca42d9","type":"GO_TERM","name":"cellular response to N-acetyl-D-glucosamine","canonical_id":"go:GO:0097316","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an N-acetyl-D-glucosamine stimulus.\" [GOC:di, PMID:21700702]","metadata":null},{"id":"55324442bf1343ccbd9f3fb346cf1da1","type":"GO_TERM","name":"cellular response to N-phenylthiourea","canonical_id":"go:GO:1902611","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a N-phenylthiourea stimulus.\" [GO_REF:0000071, GOC:rjd, GOC:TermGenie, PMID:24006265]","metadata":null},{"id":"4f260e1a939e49f4ab1186bc4d7a4235","type":"GO_TERM","name":"cellular response to Thyroglobulin triiodothyronine","canonical_id":"go:GO:1904017","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Thyroglobulin triiodothyronine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:7531505]","metadata":null},{"id":"83c55e3e76084024b8698c8fa62a98f9","type":"GO_TERM","name":"cellular response to Thyroid stimulating hormone","canonical_id":"go:GO:1904401","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Thyroid stimulating hormone stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:11238928]","metadata":null},{"id":"0d216a8ed9b94383b823eaf6ed497235","type":"GO_TERM","name":"cellular response to UV","canonical_id":"go:GO:0034644","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ultraviolet radiation (UV light) stimulus. Ultraviolet radiation is electromagnetic radiation with a wavelength in the range of 10 to 380 nanometers.\" [GOC:mah]","metadata":null},{"id":"0389383df868436aae7ecbff64c47bd8","type":"GO_TERM","name":"cellular response to UV-A","canonical_id":"go:GO:0071492","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-A radiation stimulus. UV-A radiation (UV-A light) spans the wavelengths 315 to 400 nm.\" [GOC:mah]","metadata":null},{"id":"c639df151e964fc18ac6a865a3190371","type":"GO_TERM","name":"cellular response to UV-B","canonical_id":"go:GO:0071493","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-B radiation stimulus. UV-B radiation (UV-B light) spans the wavelengths 280 to 315 nm.\" [GOC:mah]","metadata":null},{"id":"36dd0f0e938642d483ad2f6418db60c9","type":"GO_TERM","name":"cellular response to UV-C","canonical_id":"go:GO:0071494","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-C radiation stimulus. UV-C radiation (UV-C light) spans the wavelengths 100 to 280 nm.\" [GOC:mah]","metadata":null},{"id":"b909502324044f5cbf230d5d3f10e88d","type":"GO_TERM","name":"cellular response to X-ray","canonical_id":"go:GO:0071481","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of X-ray radiation. An X-ray is a form of electromagnetic radiation with a wavelength in the range of 10 nanometers to 100 picometers (corresponding to frequencies in the range 30 PHz to 3 EHz).\" [GOC:mah]","metadata":null},{"id":"75fd14597e92484888d6f5a60cf62095","type":"GO_TERM","name":"cellular response to abiotic stimulus","canonical_id":"go:GO:0071214","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an abiotic (non-living) stimulus.\" [GOC:mah]","metadata":null},{"id":"6a38690f2f40451d8bf8274cc450d1e2","type":"GO_TERM","name":"cellular response to abscisic acid stimulus","canonical_id":"go:GO:0071215","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an abscisic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"b65db8e8db5f48909a397d1c3c4578b5","type":"GO_TERM","name":"cellular response to absence of light","canonical_id":"go:GO:0071485","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an absence of light stimuli.\" [GOC:mah]","metadata":null},{"id":"c2d363c184834478b66c6afa58e39cc4","type":"GO_TERM","name":"cellular response to acadesine","canonical_id":"go:GO:1904102","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acadesine stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:20802119]","metadata":null},{"id":"3d74a08701b44aa3a82468701a082972","type":"GO_TERM","name":"cellular response to acetaldehyde","canonical_id":"go:GO:1905641","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acetaldehyde stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:27687866]","metadata":null},{"id":"bc15991b6e0242eca892955a715cdcf2","type":"GO_TERM","name":"cellular response to acetate","canonical_id":"go:GO:0071311","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acetate stimulus.\" [GOC:mah]","metadata":null},{"id":"7f7118cb83b148f6ad1e212b63cd5f30","type":"GO_TERM","name":"cellular response to acetylcholine","canonical_id":"go:GO:1905145","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acetylcholine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21238497]","metadata":null},{"id":"be0ad77d261f45f588d2887c4ee0f3d7","type":"GO_TERM","name":"cellular response to acid chemical","canonical_id":"go:GO:0071229","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by the chemical structure of the anion portion of the dissociated acid (rather than the acid acting as a proton donor). The acid chemical may be in gaseous, liquid or solid form.\" [GOC:curators, GOC:mah, Wikipedia:Acid]","metadata":null},{"id":"45ddc7ab2b6e4b9893008f3cc940e25d","type":"GO_TERM","name":"cellular response to acidic pH","canonical_id":"go:GO:0071468","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus with pH < 7. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:curators, GOC:mah, Wikipedia:PH]","metadata":null},{"id":"9099106bbc684220a53d6900247a7945","type":"GO_TERM","name":"cellular response to acrylamide","canonical_id":"go:GO:1903938","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acrylamide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16292499]","metadata":null},{"id":"955d64353d4e46b09aeb01c3a10578c8","type":"GO_TERM","name":"cellular response to actin cytoskeletal stress","canonical_id":"go:GO:0120306","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of perturbations or damage to the actin cytoskeleton.\" [GOC:krc, GOC:vw, PMID:32915139]","metadata":null},{"id":"5d3993344c044feeb018840435f64dff","type":"GO_TERM","name":"cellular response to actinomycin D","canonical_id":"go:GO:0072717","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an actinomycin D stimulus.\" [GOC:mah]","metadata":null},{"id":"8fca00c7476a4247b3616c927cbda020","type":"GO_TERM","name":"cellular response to adenine starvation","canonical_id":"go:GO:0036223","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of adenine.\" [GOC:ai]","metadata":null},{"id":"cd8b9102969644af91c546231028d464","type":"GO_TERM","name":"cellular response to alcohol","canonical_id":"go:GO:0097306","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alcohol stimulus.\" [GOC:pr]","metadata":null},{"id":"ef00ce6f06c441d099b9085479edf6c6","type":"GO_TERM","name":"cellular response to aldehyde","canonical_id":"go:GO:0110096","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aldehyde stimulus.\" [GOC:vw, PMID:25656103]","metadata":null},{"id":"be4777ebfe5c43edbcb27443e9125aad","type":"GO_TERM","name":"cellular response to aldosterone","canonical_id":"go:GO:1904045","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aldosterone stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17644563]","metadata":null},{"id":"f7fbe1fc08bc4d91a707bc227965abc6","type":"GO_TERM","name":"cellular response to alkaline pH","canonical_id":"go:GO:0071469","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus with pH > 7. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:curators, GOC:mah, Wikipedia:PH]","metadata":null},{"id":"5b0da46a65e448b89306d7e51ec8746a","type":"GO_TERM","name":"cellular response to alkaloid","canonical_id":"go:GO:0071312","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkaloid stimulus. Alkaloids are a large group of nitrogenous substances found in naturally in plants, many of which have extracts that are pharmacologically active.\" [GOC:mah]","metadata":null},{"id":"1100236dd63c4535a478bd9ea6f879d5","type":"GO_TERM","name":"cellular response to alkane","canonical_id":"go:GO:1902779","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:22958739, PMID:23826995]","metadata":null},{"id":"032117f7a5714f399466d388fe76738b","type":"GO_TERM","name":"cellular response to alkyl hydroperoxide","canonical_id":"go:GO:0071448","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkyl hydroperoxide stimulus. Alkyl hydroperoxides are monosubstitution products of hydrogen peroxide, HOOH, where the substituent is an alkyl group.\" [GOC:mah]","metadata":null},{"id":"585a478727df474995480463b3dc1889","type":"GO_TERM","name":"cellular response to aluminum ion","canonical_id":"go:GO:0071275","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aluminum ion stimulus.\" [GOC:mah]","metadata":null},{"id":"0763d86b0f7345558e35052534f363a1","type":"GO_TERM","name":"cellular response to amine stimulus","canonical_id":"go:GO:0071418","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amine stimulus. An amine is a compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.\" [GOC:mah]","metadata":null},{"id":"e36d0a9bd8c54adc85b47bc83071afc7","type":"GO_TERM","name":"cellular response to amino acid starvation","canonical_id":"go:GO:0034198","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of amino acids.\" [GOC:ecd]","metadata":null},{"id":"43bef797f881455397f661071569ef80","type":"GO_TERM","name":"cellular response to amino acid stimulus","canonical_id":"go:GO:0071230","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amino acid stimulus. An amino acid is a carboxylic acids containing one or more amino groups.\" [GOC:mah]","metadata":null},{"id":"1166697bc7e642d8a5eb560789930931","type":"GO_TERM","name":"cellular response to amitrole","canonical_id":"go:GO:0072723","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amitrole stimulus.\" [GOC:mah]","metadata":null},{"id":"8e90d1c46ec14f75aa84641676c1c878","type":"GO_TERM","name":"cellular response to ammonium ion","canonical_id":"go:GO:0071242","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ammonium stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23509267]","metadata":null},{"id":"e3dd1788087f4980a9f168845243ea1f","type":"GO_TERM","name":"cellular response to amphetamine","canonical_id":"go:GO:0071419","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine.\" [GOC:mah]","metadata":null},{"id":"539a1847b5c4420893e1dd2813d1eae4","type":"GO_TERM","name":"cellular response to amyloid-beta","canonical_id":"go:GO:1904646","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23555824]","metadata":null},{"id":"e14c881a6145440a86983126a023071b","type":"GO_TERM","name":"cellular response to angiotensin","canonical_id":"go:GO:1904385","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an angiotensin stimulus. Angiotensin is any of three physiologically active peptides (angiotensin II, III, or IV) processed from angiotensinogen.\" [GO_REF:0000071, GOC:TermGenie, PMID:22982863]","metadata":null},{"id":"68617748c9c84d5688598f74d12d59da","type":"GO_TERM","name":"cellular response to anisomycin","canonical_id":"go:GO:0072740","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anisomycin stimulus.\" [GOC:mah]","metadata":null},{"id":"229f94817d244fdd920a0a7a4bd58ac2","type":"GO_TERM","name":"cellular response to anoxia","canonical_id":"go:GO:0071454","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating a decline in oxygen levels to trace amounts, <0.1%.\" [GOC:mah]","metadata":null},{"id":"de704c93e5754c3cade98ba1836e945f","type":"GO_TERM","name":"cellular response to antibiotic","canonical_id":"go:GO:0071236","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antibiotic stimulus. An antibiotic is a chemical substance produced by a microorganism which has the capacity to inhibit the growth of or to kill other microorganisms.\" [GOC:mah]","metadata":null},{"id":"91b8d6b292cb4300b8f29838f4fcd6ec","type":"GO_TERM","name":"cellular response to antimycin A","canonical_id":"go:GO:0072745","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antimycin A stimulus.\" [GOC:mah]","metadata":null},{"id":"3c4b05c7af0b499bb604531784352525","type":"GO_TERM","name":"cellular response to arachidonate","canonical_id":"go:GO:1904551","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arachidonic acid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16382163]","metadata":null},{"id":"c7e1c80b3d6145c2a798ae1e776d2312","type":"GO_TERM","name":"cellular response to arsenic-containing substance","canonical_id":"go:GO:0071243","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenic stimulus from compounds containing arsenic, including arsenates, arsenites, and arsenides.\" [GOC:mah]","metadata":null},{"id":"dc967612c79047e1949aef26c3d5c7c2","type":"GO_TERM","name":"cellular response to arsenite ion","canonical_id":"go:GO:1903843","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenite ion stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:12106899]","metadata":null},{"id":"e31c802b94e34f2484cdaa43f2e315aa","type":"GO_TERM","name":"cellular response to arsenite(3-)","canonical_id":"go:GO:1903841","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenite(3-) stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:12106899]","metadata":null},{"id":"fd5c92d5f1c443559aa52701b1d9e14c","type":"GO_TERM","name":"cellular response to astaxanthin","canonical_id":"go:GO:1905218","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an astaxanthin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22309505]","metadata":null},{"id":"7839c754650843618db4c2104590a442","type":"GO_TERM","name":"cellular response to auxin stimulus","canonical_id":"go:GO:0071365","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an auxin stimulus.\" [GOC:mah]","metadata":null},{"id":"76a8b5cefc154342ab4ef06687be82a7","type":"GO_TERM","name":"cellular response to azide","canonical_id":"go:GO:0097185","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an azide stimulus.\" [GOC:yaf, PMID:16846222]","metadata":null},{"id":"ee852574cf594a4480f756a44fb77674","type":"GO_TERM","name":"cellular response to bacterial lipopeptide","canonical_id":"go:GO:0071221","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bacterial lipopeptide stimulus.\" [GOC:mah]","metadata":null},{"id":"ba14f74d0d9b401293692f0f3a015a5a","type":"GO_TERM","name":"cellular response to bacterial lipoprotein","canonical_id":"go:GO:0071220","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bacterial lipoprotein stimulus.\" [GOC:mah]","metadata":null},{"id":"4a29db7139f546a9b98a26ed7d124019","type":"GO_TERM","name":"cellular response to bacteriocin","canonical_id":"go:GO:0071237","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bacteriocin stimulus. A bacteriocin is a protein substance released by certain bacteria that kills but does not lyse closely related strains of bacteria. Specific bacteriocins attach to specific receptors on cell walls and induce specific metabolic block, e.g. cessation of nucleic acid or protein synthesis of oxidative phosphorylation.\" [GOC:mah]","metadata":null},{"id":"6c2269e0371a4adb8d366c352c2eada2","type":"GO_TERM","name":"cellular response to benzoic acid","canonical_id":"go:GO:0071319","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a benzoic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"dbdbaa6cdd7b47ba8e6e694a58c4466f","type":"GO_TERM","name":"cellular response to beta-carotene","canonical_id":"go:GO:1905388","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a beta-carotene stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16771696]","metadata":null},{"id":"13b94e0771b2420db3dfc106be1c86d0","type":"GO_TERM","name":"cellular response to bile acid","canonical_id":"go:GO:1903413","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bile acid stimulus.\" [GO_REF:0000071, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21757002]","metadata":null},{"id":"d212fc7e9a164fe8a9fed1fc7c80f7b3","type":"GO_TERM","name":"cellular response to biotic stimulus","canonical_id":"go:GO:0071216","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biotic stimulus, a stimulus caused or produced by a living organism.\" [GOC:mah]","metadata":null},{"id":"8758995a975745fa842c294590cc2a3a","type":"GO_TERM","name":"cellular response to biotin","canonical_id":"go:GO:0071296","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biotin stimulus.\" [GOC:mah]","metadata":null},{"id":"1d81bbad73f64aff9b95b56e117f1670","type":"GO_TERM","name":"cellular response to biotin starvation","canonical_id":"go:GO:1990383","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of biotin.\" [PMID:12557275]","metadata":null},{"id":"0d91428284be4e41afe61e24ecbaf2bd","type":"GO_TERM","name":"cellular response to biphenyl","canonical_id":"go:GO:1904615","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biphenyl stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23196670]","metadata":null},{"id":"2a2b22240ae94a1994843cd2f0fd3ab9","type":"GO_TERM","name":"cellular response to bismuth","canonical_id":"go:GO:0072701","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bismuth (Bi) stimulus.\" [GOC:mah]","metadata":null},{"id":"2729cc0a288f4478897b2c06ee496c68","type":"GO_TERM","name":"cellular response to bisphenol A","canonical_id":"go:GO:1903926","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bisphenol A stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22957036]","metadata":null},{"id":"11537aaeb50b40b0bc6e0a583c50abab","type":"GO_TERM","name":"cellular response to bleomycin","canonical_id":"go:GO:1904976","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bleomycin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:11553781]","metadata":null},{"id":"172b58c10ab44022acff80bd8490fab4","type":"GO_TERM","name":"cellular response to blue light","canonical_id":"go:GO:0071483","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. Blue light is electromagnetic radiation with a wavelength of between 440 and 500nm.\" [GOC:mah]","metadata":null},{"id":"3ab779ecd5dc47faa441ebdbf27015ac","type":"GO_TERM","name":"cellular response to borneol","canonical_id":"go:GO:1905231","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a borneol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26593909]","metadata":null},{"id":"bb2dbfac2a974d21960561f3375046ad","type":"GO_TERM","name":"cellular response to boron-containing substance deprivation","canonical_id":"go:GO:0080169","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of boron obtained from boron-containing substances.\" [PMID:20059736]","metadata":null},{"id":"fdbbdf93f50c40e08033668630a8aac7","type":"GO_TERM","name":"cellular response to boron-containing substance levels","canonical_id":"go:GO:0080029","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of boron-containing substances.\" [PMID:18952773]","metadata":null},{"id":"ab83b5528fc848909d5b3bba55e22dc7","type":"GO_TERM","name":"cellular response to brain-derived neurotrophic factor stimulus","canonical_id":"go:GO:1990416","description":"\"A process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a brain-derived neurotrophic factor stimulus.\" [PMID:21958434]","metadata":null},{"id":"5b9b3cb98db9418ab4d01eced60ca04a","type":"GO_TERM","name":"cellular response to brassinosteroid stimulus","canonical_id":"go:GO:0071367","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a brassinosteroid stimulus.\" [GOC:mah]","metadata":null},{"id":"381046dd27774a00ae7b64db247ae1ed","type":"GO_TERM","name":"cellular response to brefeldin A","canonical_id":"go:GO:0071238","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a brefeldin A stimulus.\" [GOC:mah]","metadata":null},{"id":"c2789e5dbf344e47acf03028d2022711","type":"GO_TERM","name":"cellular response to butyrate","canonical_id":"go:GO:1903545","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a butyrate stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:9734870]","metadata":null},{"id":"fb6e00aa24aa45b8a1a1e5d9259bc126","type":"GO_TERM","name":"cellular response to cAMP","canonical_id":"go:GO:0071320","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus.\" [GOC:mah]","metadata":null},{"id":"de418a3d6d224ac39f88ecb9a4c3eaca","type":"GO_TERM","name":"cellular response to cGMP","canonical_id":"go:GO:0071321","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cGMP (cyclic GMP, guanosine 3',5'-cyclophosphate) stimulus.\" [GOC:mah]","metadata":null},{"id":"ca9aae33497e423892511b99ae820aee","type":"GO_TERM","name":"cellular response to cadmium ion","canonical_id":"go:GO:0071276","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus.\" [GOC:mah]","metadata":null},{"id":"2663f45b7591405999ef358f5c2fc238","type":"GO_TERM","name":"cellular response to caffeine","canonical_id":"go:GO:0071313","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a caffeine stimulus. Caffeine is an alkaloid found in numerous plant species, where it acts as a natural pesticide that paralyzes and kills certain insects feeding upon them.\" [GOC:mah]","metadata":null},{"id":"70f6581849f64468b97a27f9e92aff1f","type":"GO_TERM","name":"cellular response to calcium ion","canonical_id":"go:GO:0071277","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a calcium ion stimulus.\" [GOC:mah]","metadata":null},{"id":"8f5cdeafbefc482fb40d9eb9d390bc8c","type":"GO_TERM","name":"cellular response to calcium ion starvation","canonical_id":"go:GO:0072732","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of calcium ions.\" [GOC:mah]","metadata":null},{"id":"c98d65588bfa44ad8beb933593f5d809","type":"GO_TERM","name":"cellular response to caloric restriction","canonical_id":"go:GO:0061433","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a of caloric restriction, insufficient food energy intake.\" [GOC:dph, PMID:17914901]","metadata":null},{"id":"67e0b2ac07484f998f0f33aec181ef14","type":"GO_TERM","name":"cellular response to camptothecin","canonical_id":"go:GO:0072757","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a camptothecin stimulus.\" [GOC:mah]","metadata":null},{"id":"c4ed3d76d67746488a5c3b98b43f6b22","type":"GO_TERM","name":"cellular response to capsazepine","canonical_id":"go:GO:0072761","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a capsazepine stimulus.\" [GOC:mah]","metadata":null},{"id":"2dbc5579a95b4333bb96a2a9983276fa","type":"GO_TERM","name":"cellular response to carbendazim","canonical_id":"go:GO:0072762","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbendazim stimulus.\" [GOC:mah]","metadata":null},{"id":"925a17b3ad0e440a93fdfa34485244c1","type":"GO_TERM","name":"cellular response to carbohydrate stimulus","canonical_id":"go:GO:0071322","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbohydrate stimulus.\" [GOC:mah]","metadata":null},{"id":"5178fd511fba46019207d5c705ad43af","type":"GO_TERM","name":"cellular response to carbon dioxide","canonical_id":"go:GO:0071244","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbon dioxide (CO2) stimulus.\" [GOC:mah]","metadata":null},{"id":"f0a8e0eeb32e463cb4bb4b027e7ade1e","type":"GO_TERM","name":"cellular response to carbon monoxide","canonical_id":"go:GO:0071245","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbon monoxide (CO) stimulus.\" [GOC:mah]","metadata":null},{"id":"70017b5a9ebb498d89af09939c36b16d","type":"GO_TERM","name":"cellular response to carcinoembryonic antigen","canonical_id":"go:GO:1990831","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carcinoembryonic antigen stimulus. The carcinoembryonic antigens represent a family of glycoproteins.\" [PMID:10202129, PMID:14597422]","metadata":null},{"id":"c2f1eadc86824d67884bdea7cd2f0a9b","type":"GO_TERM","name":"cellular response to catechin","canonical_id":"go:GO:1902169","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a catechin stimulus.\" [GOC:rjd, GOC:TermGenie, PMID:23516620]","metadata":null},{"id":"770701cf1cab45e489e47bd6792acef5","type":"GO_TERM","name":"cellular response to catecholamine stimulus","canonical_id":"go:GO:0071870","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a catecholamine stimulus. A catecholamine is any of a group of biogenic amines that includes 4-(2-aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"7c44c94e53af4d9da785e386fb439c48","type":"GO_TERM","name":"cellular response to cation stress","canonical_id":"go:GO:0071473","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of cation stress, an increase or decrease in the concentration of positively charged ions in the environment.\" [GOC:mah]","metadata":null},{"id":"27306d33f09d4ab7a9cc5722db31f9d1","type":"GO_TERM","name":"cellular response to cell envelope stress","canonical_id":"go:GO:0036460","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stress acting at the cell envelope.\" [GOC:imk, PMID:15101969, PMID:15882407]","metadata":null},{"id":"ea537ac330604b9b9dc917077787b50f","type":"GO_TERM","name":"cellular response to cell wall damage","canonical_id":"go:GO:1990394","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of cell wall damage. The process begins with detection of the damage and ends with a change in state or activity of the cell.\" [PMID:17287531]","metadata":null},{"id":"ed772d24ebd143e484473db12ad09759","type":"GO_TERM","name":"cellular response to cell-matrix adhesion","canonical_id":"go:GO:0071460","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of cell-matrix adhesion.\" [GOC:sl, PMID:11425869]","metadata":null},{"id":"a6a03c1b3c674441808966e940a550e2","type":"GO_TERM","name":"cellular response to ceramide","canonical_id":"go:GO:0106097","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ceramide stimulus.\" [PMID:18006463]","metadata":null},{"id":"aa3a8b1099d04b31aa67927b8a184a3e","type":"GO_TERM","name":"cellular response to cesium ion","canonical_id":"go:GO:0071278","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cesium stimulus.\" [GOC:mah]","metadata":null},{"id":"bb2e372011884d8f91daa4d2c80ac38e","type":"GO_TERM","name":"cellular response to chemical stimulus","canonical_id":"go:GO:0070887","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chemical stimulus.\" [GOC:mah]","metadata":null},{"id":"62639d291c354058b3d800655a733b8e","type":"GO_TERM","name":"cellular response to chemical stress","canonical_id":"go:GO:0062197","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chemical stimulus indicating the organism is under stress.\" [PMID:26653712]","metadata":null},{"id":"34445a7c62244a78b2ca727d8df93c9c","type":"GO_TERM","name":"cellular response to chemokine","canonical_id":"go:GO:1990869","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chemokine stimulus.\" [PMID:11113082]","metadata":null},{"id":"8f25fa0f020f45f78d23a90304f2c201","type":"GO_TERM","name":"cellular response to chitin","canonical_id":"go:GO:0071323","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chitin stimulus.\" [GOC:mah]","metadata":null},{"id":"bc62072fa1bd4e9fbcbf8108e847a30c","type":"GO_TERM","name":"cellular response to chloramphenicol","canonical_id":"go:GO:0072747","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chloramphenicol stimulus.\" [GOC:mah]","metadata":null},{"id":"84305ffe1fa44c579cfbff1fdeefda46","type":"GO_TERM","name":"cellular response to chlorate","canonical_id":"go:GO:0071246","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chlorate stimulus.\" [GOC:mah]","metadata":null},{"id":"e865fc2a033b481783f90c1bae93d067","type":"GO_TERM","name":"cellular response to chloroquine","canonical_id":"go:GO:1902350","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chloroquine stimulus.\" [GOC:kmv, GOC:TermGenie, PMID:23922869]","metadata":null},{"id":"9c09564c295440108a742899de456f27","type":"GO_TERM","name":"cellular response to cholecystokinin","canonical_id":"go:GO:0061848","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholecystokinin stimulus.\" [PMID:14622258]","metadata":null},{"id":"628477ea616d4b0bad5844a969a0936e","type":"GO_TERM","name":"cellular response to cholesterol","canonical_id":"go:GO:0071397","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholesterol stimulus.\" [GOC:mah]","metadata":null},{"id":"c745a943aa864ea38c6a26c5289f81bb","type":"GO_TERM","name":"cellular response to chondroitin 4'-sulfate","canonical_id":"go:GO:1905442","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chondroitin 4'-sulfate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22365850]","metadata":null},{"id":"1475591efa0e4c87bc93995c89ad7487","type":"GO_TERM","name":"cellular response to chondroitin 6'-sulfate","canonical_id":"go:GO:1905440","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chondroitin 6'-sulfate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22365850]","metadata":null},{"id":"20ad347b79504215aafcbc5e72a721ed","type":"GO_TERM","name":"cellular response to chromate","canonical_id":"go:GO:0071247","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chromate stimulus.\" [GOC:mah]","metadata":null},{"id":"aed481cc1f064eefb5497c6e9bcc92a6","type":"GO_TERM","name":"cellular response to ciliary neurotrophic factor","canonical_id":"go:GO:1904392","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ciliary neurotrophic factor stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16914133]","metadata":null},{"id":"d00b710047e34f72802b0efe93bb0c07","type":"GO_TERM","name":"cellular response to cisplatin","canonical_id":"go:GO:0072719","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cisplatin stimulus.\" [GOC:mah]","metadata":null},{"id":"03125894c62d46068df971952aabcbb8","type":"GO_TERM","name":"cellular response to cobalamin","canonical_id":"go:GO:0071297","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cobalamin (vitamin B12) stimulus.\" [GOC:mah]","metadata":null},{"id":"6d955a74f490477997fb8a0a38c1640a","type":"GO_TERM","name":"cellular response to cobalt ion","canonical_id":"go:GO:0071279","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cobalt ion stimulus.\" [GOC:mah]","metadata":null},{"id":"de6cac17373a4ec4a43fd59806fec4a4","type":"GO_TERM","name":"cellular response to cocaine","canonical_id":"go:GO:0071314","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cocaine stimulus. Cocaine is a crystalline alkaloid obtained from the leaves of the coca plant.\" [GOC:mah]","metadata":null},{"id":"95ca893ccb644062ad4813ce80b54ce4","type":"GO_TERM","name":"cellular response to codeine","canonical_id":"go:GO:1905234","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a codeine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24914722]","metadata":null},{"id":"18ea9f0210e5437297450a2a3df51a4f","type":"GO_TERM","name":"cellular response to cold","canonical_id":"go:GO:0070417","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cold stimulus, a temperature stimulus below the optimal temperature for that organism.\" [GOC:jp]","metadata":null},{"id":"10cc70d3ee5d4898adfcf56c068c4023","type":"GO_TERM","name":"cellular response to copper ion","canonical_id":"go:GO:0071280","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a copper ion stimulus.\" [GOC:mah]","metadata":null},{"id":"a8d3f8725e5f4960b6ee8966c32789c9","type":"GO_TERM","name":"cellular response to copper ion starvation","canonical_id":"go:GO:0035874","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of copper ions.\" [GOC:vw, PMID:16467469]","metadata":null},{"id":"2b2ee6e19773454f84262597f8b78ad7","type":"GO_TERM","name":"cellular response to cordycepin","canonical_id":"go:GO:1904310","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cordycepin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21597460]","metadata":null},{"id":"107966edb78544b9993fe295a8785864","type":"GO_TERM","name":"cellular response to corticosteroid stimulus","canonical_id":"go:GO:0071384","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosteroid hormone stimulus. A corticosteroid is a steroid hormone that is produced in the adrenal cortex. Corticosteroids are involved in a wide range of physiologic systems such as stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. They include glucocorticoids and mineralocorticoids.\" [GOC:mah]","metadata":null},{"id":"e57635c5d1ec4c948a25c15c0764a2f4","type":"GO_TERM","name":"cellular response to corticosterone stimulus","canonical_id":"go:GO:0071386","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosterone stimulus. Corticosterone is a 21 carbon steroid hormone of the corticosteroid type, produced in the cortex of the adrenal glands. In many species, corticosterone is the principal glucocorticoid, involved in regulation of fuel metabolism, immune reactions, and stress responses.\" [GOC:mah]","metadata":null},{"id":"e525d1423e5b400ba1372095911cd726","type":"GO_TERM","name":"cellular response to corticotropin-releasing hormone stimulus","canonical_id":"go:GO:0071376","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticotropin-releasing hormone stimulus. Corticotropin-releasing hormone is a peptide hormone involved in the stress response.\" [GOC:mah]","metadata":null},{"id":"717716e5add24bd5aeebc918c6e3becf","type":"GO_TERM","name":"cellular response to cortisol stimulus","canonical_id":"go:GO:0071387","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cortisol stimulus. Cortisol is the major natural glucocorticoid synthesized in the zona fasciculata of the adrenal cortex; it affects the metabolism of glucose, protein, and fats and has appreciable mineralocorticoid activity. It also regulates the immune system and affects many other functions.\" [GOC:mah]","metadata":null},{"id":"8644925cfeb24dfaa883e296646b6ecb","type":"GO_TERM","name":"cellular response to cortisone stimulus","canonical_id":"go:GO:0071388","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cortisone stimulus. Cortisone is a natural glucocorticoid steroid hormone that is metabolically convertible to cortisol. Cortisone is synthesized from cholesterol in the cortex of the adrenal gland under the stimulation of adrenocorticotropin hormone (ACTH). The main physiological effect of cortisone is on carbohydrate metabolism; it can stimulate increased glucose release from the liver, increased liver glycogen synthesis, and decreased utilization of glucose by the tissues.\" [GOC:mah]","metadata":null},{"id":"41b7cd8740bd42d48da635a677fb585b","type":"GO_TERM","name":"cellular response to curcumin","canonical_id":"go:GO:1904644","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a curcumin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24755072]","metadata":null},{"id":"8e26440563b54aea8118ccc625972d3e","type":"GO_TERM","name":"cellular response to cyanide","canonical_id":"go:GO:1903928","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyanide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21854848]","metadata":null},{"id":"de3f81092a20466282037a1e5ea4b3d1","type":"GO_TERM","name":"cellular response to cycloalkane","canonical_id":"go:GO:0071408","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cycloalkane stimulus. A cycloalkane is a cyclic saturated hydrocarbon having the general formula CnH2n.\" [GOC:mah]","metadata":null},{"id":"88681d409be7458384ac3ebc036d0f0c","type":"GO_TERM","name":"cellular response to cycloheximide","canonical_id":"go:GO:0071409","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cycloheximide stimulus. Cycloheximide (actidione) is an antibiotic produced by some Streptomyces species which interferes with protein synthesis in eukaryotes.\" [GOC:mah]","metadata":null},{"id":"15eb30da09cb425babb176e4df029dd5","type":"GO_TERM","name":"cellular response to cyclopentenone","canonical_id":"go:GO:0071410","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyclopentenone stimulus. Cyclopentenones are oxylipins derived from polyunsaturated fatty acids. They are structurally similar to jasmonic acid, but contain a reactive unsaturated carbonyl structure in the cyclo-ring. Cyclopentenones include phytoprostanes and 12-oxo-phytodienoic acid.\" [GOC:mah]","metadata":null},{"id":"81802bbb5fda44a598e7fa71e86598e2","type":"GO_TERM","name":"cellular response to cyclosporin A","canonical_id":"go:GO:1905238","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyclosporin A stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24914722]","metadata":null},{"id":"1d1b38699538460a9cf930b8c03deb7b","type":"GO_TERM","name":"cellular response to cytochalasin B","canonical_id":"go:GO:0072749","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytochalasin B stimulus.\" [GOC:mah]","metadata":null},{"id":"032399548b7745598a1639d8c4148a02","type":"GO_TERM","name":"cellular response to cytokine stimulus","canonical_id":"go:GO:0071345","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokine stimulus.\" [GOC:mah]","metadata":null},{"id":"2792d7b6324347b29c5479ffc3800c98","type":"GO_TERM","name":"cellular response to cytokinin stimulus","canonical_id":"go:GO:0071368","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokinin stimulus.\" [GOC:mah]","metadata":null},{"id":"1d6452a961c64cf48b4a1bc2aa265940","type":"GO_TERM","name":"cellular response to decane","canonical_id":"go:GO:1902783","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a decane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:23826995]","metadata":null},{"id":"caac74d54fd84831ac22b430d1165108","type":"GO_TERM","name":"cellular response to decreased oxygen levels","canonical_id":"go:GO:0036294","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting a decline in the level of oxygen.\" [GOC:al]","metadata":null},{"id":"3db0061fa71a4099a983cf839764dd48","type":"GO_TERM","name":"cellular response to dehydroepiandrosterone","canonical_id":"go:GO:1903495","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dehydroepiandrosterone stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:3585228]","metadata":null},{"id":"9da7b17e316f410dbe2d7dfef301ccb2","type":"GO_TERM","name":"cellular response to desiccation","canonical_id":"go:GO:0071465","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a desiccation stimulus, extreme dryness resulting from the prolonged deprivation of water.\" [GOC:mah]","metadata":null},{"id":"bd40e714addb435c9ce1744522b31941","type":"GO_TERM","name":"cellular response to desipramine","canonical_id":"go:GO:1904308","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a desipramine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20549303]","metadata":null},{"id":"eeacbb358e484cc49a4f1fda6ad4f39f","type":"GO_TERM","name":"cellular response to dexamethasone stimulus","canonical_id":"go:GO:0071549","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dexamethasone stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"037b51f103204aa3894d3409912bf6d2","type":"GO_TERM","name":"cellular response to dextromethorphan","canonical_id":"go:GO:1904559","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dextromethorphan stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:25796330]","metadata":null},{"id":"9fcd1626d9db4848a47394720e12613d","type":"GO_TERM","name":"cellular response to diacyl bacterial lipopeptide","canonical_id":"go:GO:0071726","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diacylated bacterial lipopeptide stimulus.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"30f75961240b4212b2a36872edac7b9d","type":"GO_TERM","name":"cellular response to diamide","canonical_id":"go:GO:0072738","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diamide (N,N,N',N'-tetramethyldiazene-1,2-dicarboxamide) stimulus.\" [GOC:mah]","metadata":null},{"id":"d92687a7883e4cc89b9cc940edae2da5","type":"GO_TERM","name":"cellular response to diethyl maleate","canonical_id":"go:GO:1902112","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diethyl maleate stimulus.\" [GOC:TermGenie, PMID:12100563]","metadata":null},{"id":"f463ac51464144c7982dff336165b07e","type":"GO_TERM","name":"cellular response to differentiation-inducing factor 1","canonical_id":"go:GO:1903014","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22365144]","metadata":null},{"id":"06a3f67a4842458c8d4966ffa4a9b733","type":"GO_TERM","name":"cellular response to differentiation-inducing factor 2","canonical_id":"go:GO:0061862","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)pentan-1-one stimulus.\" [PMID:19684855]","metadata":null},{"id":"4604f48b904143728463c6c622212885","type":"GO_TERM","name":"cellular response to dimethyl sulfoxide","canonical_id":"go:GO:1904620","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dimethyl sulfoxide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12873812]","metadata":null},{"id":"fd5a083cc19b4612870278c7b209fd65","type":"GO_TERM","name":"cellular response to dinitrophenol","canonical_id":"go:GO:1904642","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dinitrophenol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24336883]","metadata":null},{"id":"b051e10d0ad549ca8d5b44e84dffeb3b","type":"GO_TERM","name":"cellular response to diosgenin","canonical_id":"go:GO:1905093","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diosgenin stimulus.\" [GO_REF:0000071, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25765596]","metadata":null},{"id":"4170371b184e46f986342f2c0cd2ece9","type":"GO_TERM","name":"cellular response to diphenidol","canonical_id":"go:GO:1904561","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diphenidol stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:25796330]","metadata":null},{"id":"1ce4a2e5f8054eca8a439719e4372ae7","type":"GO_TERM","name":"cellular response to disaccharide stimulus","canonical_id":"go:GO:0071324","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disaccharide stimulus.\" [GOC:mah]","metadata":null},{"id":"f04824a2e5f54f958907fe9ab28a35de","type":"GO_TERM","name":"cellular response to diterpene","canonical_id":"go:GO:1904630","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diterpene stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:19765580]","metadata":null},{"id":"b6c3c25be0cf409296bc783d25528583","type":"GO_TERM","name":"cellular response to dithiothreitol","canonical_id":"go:GO:0072721","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dithiothreitol stimulus.\" [GOC:mah]","metadata":null},{"id":"547c61b8a2a64968b981772aeca46aa6","type":"GO_TERM","name":"cellular response to dodecane","canonical_id":"go:GO:1902787","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dodecane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:23826995]","metadata":null},{"id":"d4257c75e834446aae0ddbe8480d3332","type":"GO_TERM","name":"cellular response to dopamine","canonical_id":"go:GO:1903351","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dopamine stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:11118945]","metadata":null},{"id":"e8ca37aab4dd4f4cacfdcf79d1f1e262","type":"GO_TERM","name":"cellular response to dsDNA","canonical_id":"go:GO:1990786","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a double-stranded DNA stimulus.\" [PMID:10051633]","metadata":null},{"id":"ada1925ff42643d79d386fbcfc7c9647","type":"GO_TERM","name":"cellular response to dsRNA","canonical_id":"go:GO:0071359","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a double-stranded RNA stimulus.\" [GOC:mah]","metadata":null},{"id":"d72ce5de3c51420ea25d6de1f74d6d37","type":"GO_TERM","name":"cellular response to ecdysone","canonical_id":"go:GO:0071390","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ecdysone stimulus.\" [GOC:mah]","metadata":null},{"id":"038ec11a3c5649da9508fd431e9fd2da","type":"GO_TERM","name":"cellular response to electrical stimulus","canonical_id":"go:GO:0071257","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus.\" [GOC:mah]","metadata":null},{"id":"299659d8b7a448059b2530bc7803fcc2","type":"GO_TERM","name":"cellular response to endogenous stimulus","canonical_id":"go:GO:0071495","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus arising within the organism.\" [GOC:mah]","metadata":null},{"id":"0f98e7572bdd4d53b9301b8d39f7cc62","type":"GO_TERM","name":"cellular response to endothelin","canonical_id":"go:GO:1990859","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an endothelin stimulus. Endothelin is any of three secretory vasoconstrictive peptides (endothelin-1, -2, -3).\" [PMID:16365184]","metadata":null},{"id":"2225fd9a3f6e468d86d7965baf76b9e7","type":"GO_TERM","name":"cellular response to environmental stimulus","canonical_id":"go:GO:0104004","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an environmental stimulus.\" [GOC:dos]","metadata":null},{"id":"141b93d17c63404d8da8468a4f90616b","type":"GO_TERM","name":"cellular response to epidermal growth factor stimulus","canonical_id":"go:GO:0071364","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth factor stimulus.\" [GOC:mah]","metadata":null},{"id":"8ce8537fdefd4428911bddb26fce1364","type":"GO_TERM","name":"cellular response to epinephrine stimulus","canonical_id":"go:GO:0071872","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epinephrine stimulus. Epinephrine is a catecholamine that has the formula C9H13NO3; it is secreted by the adrenal medulla to act as a hormone, and released by certain neurons to act as a neurotransmitter active in the central nervous system.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"26072bcc288546a5b00d42b0bef27f29","type":"GO_TERM","name":"cellular response to ergosterol","canonical_id":"go:GO:1901625","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ergosterol stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"f9faadd9d5e1481abe9b3f5d1d7cda8d","type":"GO_TERM","name":"cellular response to erythromycin","canonical_id":"go:GO:0072743","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an erythromycin stimulus.\" [GOC:mah]","metadata":null},{"id":"5bb851e9575c4e498f32bc6a8c2f3bce","type":"GO_TERM","name":"cellular response to erythropoietin","canonical_id":"go:GO:0036018","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an erythropoietin stimulus.\" [GOC:yaf]","metadata":null},{"id":"c1d4d33ec0bb432e8ce29cceeddde4a6","type":"GO_TERM","name":"cellular response to estradiol stimulus","canonical_id":"go:GO:0071392","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.\" [GOC:mah]","metadata":null},{"id":"cdda1f83a3bd48258278edb0fc192970","type":"GO_TERM","name":"cellular response to estrogen stimulus","canonical_id":"go:GO:0071391","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics.\" [GOC:mah]","metadata":null},{"id":"01f1e7baa2dd44f8a0ac176457da40a0","type":"GO_TERM","name":"cellular response to ethanol","canonical_id":"go:GO:0071361","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus.\" [GOC:mah]","metadata":null},{"id":"4b78aec2210a40d695bbbf71abf2e741","type":"GO_TERM","name":"cellular response to ether","canonical_id":"go:GO:0071362","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ether stimulus.\" [GOC:mah]","metadata":null},{"id":"d3a4dd8ab03849f39ec83916b32ed918","type":"GO_TERM","name":"cellular response to ethylene stimulus","canonical_id":"go:GO:0071369","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethylene (ethene) stimulus.\" [GOC:mah]","metadata":null},{"id":"3689f221ec034d7f92865f5ba6612d3b","type":"GO_TERM","name":"cellular response to exogenous dsRNA","canonical_id":"go:GO:0071360","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an exogenous double-stranded RNA stimulus.\" [GOC:mah]","metadata":null},{"id":"100875312e324d6cb3ea567046c9d0b9","type":"GO_TERM","name":"cellular response to external biotic stimulus","canonical_id":"go:GO:0071217","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external biotic stimulus, an external stimulus caused by, or produced by living things.\" [GOC:mah]","metadata":null},{"id":"0bc18445d3ad450e881a33b011b581f3","type":"GO_TERM","name":"cellular response to external stimulus","canonical_id":"go:GO:0071496","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus.\" [GOC:mah]","metadata":null},{"id":"06c9751808c84d9fbd630bcc62032f5d","type":"GO_TERM","name":"cellular response to far red light","canonical_id":"go:GO:0071490","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of far red light stimulus. Far red light is electromagnetic radiation of wavelength 700-800nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:mah]","metadata":null},{"id":"16c2a29a40e64d029d125adb720f3ab8","type":"GO_TERM","name":"cellular response to farnesol","canonical_id":"go:GO:0097308","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a farnesol stimulus.\" [GOC:di, PMID:11425711]","metadata":null},{"id":"625a6777411b426abbec16c32af52d07","type":"GO_TERM","name":"cellular response to fatty acid","canonical_id":"go:GO:0071398","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fatty acid stimulus.\" [GOC:mah]","metadata":null},{"id":"a958b39891ce4c8182e725b7df8edabd","type":"GO_TERM","name":"cellular response to fibroblast growth factor stimulus","canonical_id":"go:GO:0044344","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an fibroblast growth factor stimulus.\" [GOC:jl, GOC:yaf]","metadata":null},{"id":"166f96acf03e420881a6d8f57eb9369c","type":"GO_TERM","name":"cellular response to flavonoid","canonical_id":"go:GO:1905396","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a flavonoid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22700048]","metadata":null},{"id":"c30292722c7748bea6c56e489425a52e","type":"GO_TERM","name":"cellular response to fluid shear stress","canonical_id":"go:GO:0071498","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluid shear stress stimulus. Fluid shear stress is the force acting on an object in a system where the fluid is moving across a solid surface.\" [GOC:mah]","metadata":null},{"id":"0596b61f51294e0a9df15e88e8c22fa6","type":"GO_TERM","name":"cellular response to fluoride","canonical_id":"go:GO:1902618","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluoride stimulus.\" [GO_REF:0000071, GOC:kmv, GOC:TermGenie, PMID:8138152]","metadata":null},{"id":"54a1012aa28747d694e28aff9e203c56","type":"GO_TERM","name":"cellular response to fluoxetine","canonical_id":"go:GO:0071411","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluoxetine stimulus. Fluoxetine increases the extracellular level of the neurotransmitter serotonin by inhibiting its reuptake into the presynaptic cell, increasing the level of serotonin available to bind to the postsynaptic receptor.\" [GOC:mah, GOC:pr]","metadata":null},{"id":"bc6e72596c49421f9e935f998077c980","type":"GO_TERM","name":"cellular response to folic acid","canonical_id":"go:GO:0071231","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a folic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"00b56c9f532b47bba5fec2a5666ca475","type":"GO_TERM","name":"cellular response to follicle-stimulating hormone stimulus","canonical_id":"go:GO:0071372","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a follicle-stimulating hormone stimulus.\" [GOC:mah]","metadata":null},{"id":"5a0f4a411ad349509ab5d3ea689177e6","type":"GO_TERM","name":"cellular response to food","canonical_id":"go:GO:0071240","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a food stimulus; food is anything which, when taken into the body, serves to nourish or build up the tissues or to supply body heat.\" [GOC:mah]","metadata":null},{"id":"391d3c74597b4d658c20ec249470fd88","type":"GO_TERM","name":"cellular response to formaldehyde","canonical_id":"go:GO:1904405","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a formaldehyde stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:9149109]","metadata":null},{"id":"fbbd70d3b19a45a7943148b329088dab","type":"GO_TERM","name":"cellular response to forskolin","canonical_id":"go:GO:1904322","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a forskolin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:15937517]","metadata":null},{"id":"f871e6c59cdc4d1d94f0a99b9d3b5acb","type":"GO_TERM","name":"cellular response to freezing","canonical_id":"go:GO:0071497","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a freezing stimulus, temperatures below 0 degrees Celsius.\" [GOC:mah]","metadata":null},{"id":"906aadcca5e0412b9a3e76958a275263","type":"GO_TERM","name":"cellular response to fructose stimulus","canonical_id":"go:GO:0071332","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fructose stimulus.\" [GOC:mah]","metadata":null},{"id":"378f173803e14dc590917f50dd79d7b4","type":"GO_TERM","name":"cellular response to gamma radiation","canonical_id":"go:GO:0071480","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gamma radiation stimulus. Gamma radiation is a form of electromagnetic radiation (EMR) or light emission of a specific frequency produced from sub-atomic particle interaction, such as electron-positron annihilation and radioactive decay. Gamma rays are generally characterized as EMR having the highest frequency and energy, and also the shortest wavelength, within the electromagnetic radiation spectrum.\" [GOC:mah]","metadata":null},{"id":"6cb3ebe3e38e447ea591f59d247e2d99","type":"GO_TERM","name":"cellular response to gastrin","canonical_id":"go:GO:1990878","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gastrin stimulus.\" [PMID:10348814]","metadata":null},{"id":"a294d9f8223f49e9adc3801356c86b0d","type":"GO_TERM","name":"cellular response to genistein","canonical_id":"go:GO:0071412","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a genistein stimulus.\" [GOC:mah]","metadata":null},{"id":"8df826c9cb384098aa3379cff22171a2","type":"GO_TERM","name":"cellular response to gibberellin stimulus","canonical_id":"go:GO:0071370","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gibberellin stimulus.\" [GOC:mah]","metadata":null},{"id":"a1ac6fc2952d4f688b2d8891aec7aa11","type":"GO_TERM","name":"cellular response to glial cell derived neurotrophic factor","canonical_id":"go:GO:1990792","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glial cell derived neurotrophic factor stimulus.\" [PMID:20877310]","metadata":null},{"id":"cf3b017ca8b34058adce0940b1e6bbdf","type":"GO_TERM","name":"cellular response to glucagon stimulus","canonical_id":"go:GO:0071377","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucagon stimulus.\" [GOC:mah]","metadata":null},{"id":"ba8cf9fff10841d2aeeb69ec808ee73c","type":"GO_TERM","name":"cellular response to glucocorticoid stimulus","canonical_id":"go:GO:0071385","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucocorticoid stimulus. Glucocorticoids are hormonal C21 corticosteroids synthesized from cholesterol with the ability to bind with the cortisol receptor and trigger similar effects. Glucocorticoids act primarily on carbohydrate and protein metabolism, and have anti-inflammatory effects.\" [GOC:mah]","metadata":null},{"id":"6f1e7c6ec8834eb28f7016f71bdecb9e","type":"GO_TERM","name":"cellular response to glucose starvation","canonical_id":"go:GO:0042149","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of glucose.\" [GOC:jl]","metadata":null},{"id":"be11ab5b4f3d4ca7b69d24c742dc666e","type":"GO_TERM","name":"cellular response to glucose stimulus","canonical_id":"go:GO:0071333","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucose stimulus.\" [GOC:mah]","metadata":null},{"id":"477ba4df779d4e108c03948c69eca542","type":"GO_TERM","name":"cellular response to glucose-phosphate stress","canonical_id":"go:GO:0036448","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the accumulation of glucose-phosphate.\" [GOC:am, PMID:17383224]","metadata":null},{"id":"7822fd90c67648309dd4f3f694c90699","type":"GO_TERM","name":"cellular response to glucoside","canonical_id":"go:GO:1904632","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucoside stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16842873]","metadata":null},{"id":"7e966cbef89149f69aa6a839a4871e5f","type":"GO_TERM","name":"cellular response to glutathione","canonical_id":"go:GO:0072753","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glutathione stimulus.\" [GOC:mah]","metadata":null},{"id":"43ad623f2d834db8b06bd109432b3ff1","type":"GO_TERM","name":"cellular response to glyceraldehyde","canonical_id":"go:GO:1905631","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glyceraldehyde stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:11377826]","metadata":null},{"id":"86cc81afcb0b4ea1ae0726c74bfead49","type":"GO_TERM","name":"cellular response to glycine","canonical_id":"go:GO:1905430","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glycine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18984164]","metadata":null},{"id":"395c1aa08b2c4c81901735f8cbd4fc11","type":"GO_TERM","name":"cellular response to glycoprotein","canonical_id":"go:GO:1904588","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glycoprotein stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:14597422]","metadata":null},{"id":"61b920e4cdeb49dd9164d2981edf600a","type":"GO_TERM","name":"cellular response to glyoxal","canonical_id":"go:GO:0036471","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glyoxal stimulus.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"ca74718c0cd34ed981ec48d8135b9a69","type":"GO_TERM","name":"cellular response to gold(3+)","canonical_id":"go:GO:1904312","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gold(3+) stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16206274]","metadata":null},{"id":"d84f8b8b2aa845d5b99c2efe597a7fe8","type":"GO_TERM","name":"cellular response to gonadotropin stimulus","canonical_id":"go:GO:0071371","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gonadotropin stimulus.\" [GOC:mah]","metadata":null},{"id":"bee5bde6227e43f9aebb69f523bf7a60","type":"GO_TERM","name":"cellular response to gonadotropin-releasing hormone","canonical_id":"go:GO:0097211","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gonadotropin-releasing hormone stimulus. Gonadotropin-releasing hormone (GnRH) is a peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released by the hypothalamus.\" [GOC:yaf, PMID:15976007]","metadata":null},{"id":"4d1167216a084957ac58a5f6453bc484","type":"GO_TERM","name":"cellular response to granulocyte colony-stimulating factor","canonical_id":"go:GO:1990643","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a granulocyte colony-stimulating factor stimulus.\" [PMID:9488469]","metadata":null},{"id":"1f9206303d734f9ebbec290119e7566f","type":"GO_TERM","name":"cellular response to granulocyte macrophage colony-stimulating factor stimulus","canonical_id":"go:GO:0097011","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a granulocyte macrophage colony-stimulating factor stimulus.\" [GOC:BHF, GOC:ebc, PMID:7901744]","metadata":null},{"id":"8713b2b214544e66888b0e908d6adafd","type":"GO_TERM","name":"cellular response to gravity","canonical_id":"go:GO:0071258","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gravitational stimulus.\" [GOC:mah]","metadata":null},{"id":"43d96bbad8b24bd38f36f51e0397dfad","type":"GO_TERM","name":"cellular response to growth factor stimulus","canonical_id":"go:GO:0071363","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.\" [GOC:mah]","metadata":null},{"id":"86b1da875ca24555bfd72fc28aed6b16","type":"GO_TERM","name":"cellular response to growth hormone stimulus","canonical_id":"go:GO:0071378","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth hormone stimulus. Growth hormone is a peptide hormone that binds to the growth hormone receptor and stimulates growth.\" [GOC:mah]","metadata":null},{"id":"0db78d31a88047c99ffef94a067c8d42","type":"GO_TERM","name":"cellular response to haloperidol","canonical_id":"go:GO:1905120","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a haloperidol stimulus.\" [GO_REF:0000071, GOC:dw, GOC:TermGenie, PMID:24751813]","metadata":null},{"id":"b0a8dcd1bf20487ab65d07ada6b0c104","type":"GO_TERM","name":"cellular response to heat","canonical_id":"go:GO:0034605","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heat stimulus, a temperature stimulus above the optimal temperature for that organism.\" [GOC:mah]","metadata":null},{"id":"5862698377dd41389ea5eb665d2bb33a","type":"GO_TERM","name":"cellular response to heparin","canonical_id":"go:GO:0071504","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heparin stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"0a9d9a6c54bb4725854e46ae4cdc1db9","type":"GO_TERM","name":"cellular response to hepatocyte growth factor stimulus","canonical_id":"go:GO:0035729","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hepatocyte growth factor stimulus.\" [GOC:bf]","metadata":null},{"id":"142cfef95bb24e148037c1c1596a122f","type":"GO_TERM","name":"cellular response to hesperadin","canonical_id":"go:GO:0072763","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hesperadin stimulus.\" [GOC:mah]","metadata":null},{"id":"1aa65af6a8d9472eb34d385833b53b54","type":"GO_TERM","name":"cellular response to hexose stimulus","canonical_id":"go:GO:0071331","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hexose stimulus.\" [GOC:mah]","metadata":null},{"id":"512f21d3468a4a29a4ab6ab74770c6d5","type":"GO_TERM","name":"cellular response to high density lipoprotein particle stimulus","canonical_id":"go:GO:0071403","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a high density lipoprotein particle stimulus.\" [GOC:mah]","metadata":null},{"id":"0bc5df6e41624dd1bf5a15bbc175ddcb","type":"GO_TERM","name":"cellular response to high light intensity","canonical_id":"go:GO:0071486","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a high light intensity stimulus.\" [GOC:mah]","metadata":null},{"id":"fff9d85377d44396b9281b17bcc41d6d","type":"GO_TERM","name":"cellular response to histamine","canonical_id":"go:GO:0071420","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a histamine stimulus. Histamine, the biogenic amine 2-(1H-imidazol-4-yl)ethanamine, is involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.\" [GOC:mah]","metadata":null},{"id":"146bc3962ebd447ead6893886f48dd3a","type":"GO_TERM","name":"cellular response to histidine","canonical_id":"go:GO:0071232","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a histidine stimulus.\" [GOC:mah]","metadata":null},{"id":"32e6bc6435584d319f0e4ff1fab8e42b","type":"GO_TERM","name":"cellular response to homocysteine","canonical_id":"go:GO:1905375","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a homocysteine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26722473]","metadata":null},{"id":"9a427712b06a47c38f18c0516314b410","type":"GO_TERM","name":"cellular response to hormone stimulus","canonical_id":"go:GO:0032870","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus.\" [GOC:mah]","metadata":null},{"id":"6595d025a8cd46c080d679caa37830f9","type":"GO_TERM","name":"cellular response to human chorionic gonadotropin stimulus","canonical_id":"go:GO:0044751","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a human chorionic gonadotropin stimulus.\" [PMID:21325635]","metadata":null},{"id":"cff1fd9a2f504af3a28ba00277a027f6","type":"GO_TERM","name":"cellular response to humidity","canonical_id":"go:GO:0071463","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a humidity stimulus, moisture in the atmosphere.\" [GOC:mah]","metadata":null},{"id":"db09937448844aa181e1cfbf97d02153","type":"GO_TERM","name":"cellular response to hydrogen peroxide","canonical_id":"go:GO:0070301","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus.\" [CHEBI:16240, GOC:mah]","metadata":null},{"id":"4999d812552248349c41b5402bb57da1","type":"GO_TERM","name":"cellular response to hydrogen sulfide","canonical_id":"go:GO:1904881","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen sulfide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24012591]","metadata":null},{"id":"d05e3c358d7f495b9bbd8c7d2a8682c5","type":"GO_TERM","name":"cellular response to hydroperoxide","canonical_id":"go:GO:0071447","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroperoxide stimulus. Hydroperoxides are monosubstitution products of hydrogen peroxide, HOOH.\" [GOC:mah]","metadata":null},{"id":"b8252d5a9d6b4ba792056a66c4389616","type":"GO_TERM","name":"cellular response to hydrostatic pressure","canonical_id":"go:GO:0071464","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrostatic pressure stimulus. Hydrostatic pressure is the force acting on an object in a system where the fluid is at rest (as opposed to moving). The weight of the fluid above the object creates pressure on it.\" [GOC:mah]","metadata":null},{"id":"03490212be2e463cb73de74392c5bb71","type":"GO_TERM","name":"cellular response to hydroxyisoflavone","canonical_id":"go:GO:0071413","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroxyisoflavone stimulus.\" [GOC:mah]","metadata":null},{"id":"2b82896fd8ee41a0a02d119810b205b2","type":"GO_TERM","name":"cellular response to hydroxyurea","canonical_id":"go:GO:0072711","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroxyurea stimulus.\" [GOC:mah]","metadata":null},{"id":"a318eba07a0e499d92785d1ac3d76a42","type":"GO_TERM","name":"cellular response to hyperoxia","canonical_id":"go:GO:0071455","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating increased oxygen tension.\" [GOC:mah]","metadata":null},{"id":"bedfc8b928ff492287bd052051f135e4","type":"GO_TERM","name":"cellular response to hypoxia","canonical_id":"go:GO:0071456","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.\" [GOC:mah]","metadata":null},{"id":"e1425d038757435da19ebbaacbbdce6f","type":"GO_TERM","name":"cellular response to immobilization stress","canonical_id":"go:GO:0035903","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of being rendered immobile.\" [GOC:bf, PMID:17683801, PMID:19893991]","metadata":null},{"id":"563bd4285a8f49d0bead8918d2a45545","type":"GO_TERM","name":"cellular response to increased oxygen levels","canonical_id":"go:GO:0036295","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting an increase in the level of oxygen.\" [GOC:al]","metadata":null},{"id":"d152934975e94f8997a4e4e2571f1e4c","type":"GO_TERM","name":"cellular response to indole-3-methanol","canonical_id":"go:GO:0071681","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an indole-3-methanol stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"e3f5203ea96a4bc689022d2f2a2cd14d","type":"GO_TERM","name":"cellular response to indolebutyric acid stimulus","canonical_id":"go:GO:0071366","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an indolebutyric acid stimulus.\" [GOC:mah]","metadata":null},{"id":"82a21c4023184f3dbb14fd51160618cc","type":"GO_TERM","name":"cellular response to inositol","canonical_id":"go:GO:1902141","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inositol stimulus.\" [GOC:TermGenie, PMID:16496115]","metadata":null},{"id":"3bc6d91777564a3f83543c69abfa3a80","type":"GO_TERM","name":"cellular response to inositol starvation","canonical_id":"go:GO:0036110","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of inositol.\" [GOC:al, PMID:19606215]","metadata":null},{"id":"ae36808e044641eaa0d379b52878ee20","type":"GO_TERM","name":"cellular response to insulin stimulus","canonical_id":"go:GO:0032869","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"be3a2c6bb7204a5d815f3cae99108a34","type":"GO_TERM","name":"cellular response to insulin-like growth factor stimulus","canonical_id":"go:GO:1990314","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin-like growth factor stimulus.\" [PMID:20042609]","metadata":null},{"id":"525b38d0c3354d27862f401b837f1d6e","type":"GO_TERM","name":"cellular response to interferon-alpha","canonical_id":"go:GO:0035457","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-alpha stimulus. Interferon-alpha is a type I interferon.\" [GOC:sl]","metadata":null},{"id":"6fff494f7bdb431088518e74c86c7f61","type":"GO_TERM","name":"cellular response to interferon-beta","canonical_id":"go:GO:0035458","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-beta stimulus. Interferon-beta is a type I interferon.\" [GOC:sl]","metadata":null},{"id":"fdb5b64e53e74a57811d9c31d67da660","type":"GO_TERM","name":"cellular response to interleukin-1","canonical_id":"go:GO:0071347","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus.\" [GOC:mah]","metadata":null},{"id":"1e7753678eff4fe38f356372218b3833","type":"GO_TERM","name":"cellular response to interleukin-11","canonical_id":"go:GO:0071348","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-11 stimulus.\" [GOC:mah]","metadata":null},{"id":"d2353c8f0685430785145c76db10da3b","type":"GO_TERM","name":"cellular response to interleukin-12","canonical_id":"go:GO:0071349","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-12 stimulus.\" [GOC:mah]","metadata":null},{"id":"16d0f1b1e25f42dea0ce877e2d9931f4","type":"GO_TERM","name":"cellular response to interleukin-13","canonical_id":"go:GO:0035963","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-13 stimulus.\" [GOC:sjw, PMID:20100461]","metadata":null},{"id":"158f7689c895497391fb6f68507e4cc3","type":"GO_TERM","name":"cellular response to interleukin-15","canonical_id":"go:GO:0071350","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-15 stimulus.\" [GOC:mah]","metadata":null},{"id":"67f0bca2dd8446659546bfc72aa2a570","type":"GO_TERM","name":"cellular response to interleukin-17","canonical_id":"go:GO:0097398","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-17 stimulus.\" [GOC:pr]","metadata":null},{"id":"c65cff704ff64a2a9ded5f00f76865f9","type":"GO_TERM","name":"cellular response to interleukin-18","canonical_id":"go:GO:0071351","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-18 stimulus.\" [GOC:mah]","metadata":null},{"id":"b238e5b5873741c4a92106f8d61ace24","type":"GO_TERM","name":"cellular response to interleukin-2","canonical_id":"go:GO:0071352","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-2 stimulus.\" [GOC:mah]","metadata":null},{"id":"cefc3d5944dd4472915ed3778b9c49ee","type":"GO_TERM","name":"cellular response to interleukin-21","canonical_id":"go:GO:0098757","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-21 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"309d89c93ce84a61a2ea9e7fa4a1c872","type":"GO_TERM","name":"cellular response to interleukin-3","canonical_id":"go:GO:0036016","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-3 stimulus.\" [GOC:yaf]","metadata":null},{"id":"f698d2314a99449aa802e009457e948f","type":"GO_TERM","name":"cellular response to interleukin-32","canonical_id":"go:GO:0097397","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-32 stimulus.\" [GOC:pr]","metadata":null},{"id":"731878faa45e44ff9b15caaf04221ea8","type":"GO_TERM","name":"cellular response to interleukin-4","canonical_id":"go:GO:0071353","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus.\" [GOC:mah]","metadata":null},{"id":"ebbb49a5597a4dc9a00952e1043f9caf","type":"GO_TERM","name":"cellular response to interleukin-6","canonical_id":"go:GO:0071354","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-6 stimulus.\" [GOC:mah]","metadata":null},{"id":"3beb1f708bcc4303978c97e3f78d3c5a","type":"GO_TERM","name":"cellular response to interleukin-7","canonical_id":"go:GO:0098761","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-7 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1274b2b533ea4c3f82b4bef05be4ff52","type":"GO_TERM","name":"cellular response to interleukin-8","canonical_id":"go:GO:0098759","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-8 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"327820fa820f46cf936374015fe721f8","type":"GO_TERM","name":"cellular response to interleukin-9","canonical_id":"go:GO:0071355","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-9 stimulus.\" [GOC:mah]","metadata":null},{"id":"b3a70c3b818f4e3fac61362387289250","type":"GO_TERM","name":"cellular response to ionizing radiation","canonical_id":"go:GO:0071479","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays.\" [GOC:mah]","metadata":null},{"id":"8317414b8e9c48f58b7ea886d9c79257","type":"GO_TERM","name":"cellular response to ionomycin","canonical_id":"go:GO:1904637","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ionomycin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17516843]","metadata":null},{"id":"34a883f48e8d43e0be53db575c7e57d9","type":"GO_TERM","name":"cellular response to iron ion","canonical_id":"go:GO:0071281","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron ion stimulus.\" [GOC:mah]","metadata":null},{"id":"cf8381e00e1f40cb9e3072e436cf9260","type":"GO_TERM","name":"cellular response to iron ion starvation","canonical_id":"go:GO:0010106","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of iron ions.\" [GOC:mg]","metadata":null},{"id":"be9d2ab96d7843d496bd7d5d29c15c1a","type":"GO_TERM","name":"cellular response to iron(II) ion","canonical_id":"go:GO:0071282","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(II) ion stimulus.\" [GOC:mah]","metadata":null},{"id":"d07eb5c6cc2c4e2c87273c16efe6151d","type":"GO_TERM","name":"cellular response to iron(III) ion","canonical_id":"go:GO:0071283","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(III) ion stimulus.\" [GOC:mah]","metadata":null},{"id":"be562bad4f1e4fdb91657d237e025875","type":"GO_TERM","name":"cellular response to isooctane","canonical_id":"go:GO:1902789","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an isooctane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:22328008]","metadata":null},{"id":"2f9a1c4f0a37460581e3185a6c82454f","type":"GO_TERM","name":"cellular response to isoquinoline alkaloid","canonical_id":"go:GO:0071317","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an isoquinoline alkaloid stimulus. An isoquinoline alkaloid is any member of a group of compounds with the heterocyclic ring structure of benzo(c)pyridine which is a structure characteristic of the group of opium alkaloids.\" [GOC:mah]","metadata":null},{"id":"f512c7d71727427aad2d8cd1702b07a9","type":"GO_TERM","name":"cellular response to jasmonic acid stimulus","canonical_id":"go:GO:0071395","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a jasmonic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"af21fa4a057e4276a980d74e677f9619","type":"GO_TERM","name":"cellular response to kainic acid","canonical_id":"go:GO:1904374","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a kainic acid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17443789]","metadata":null},{"id":"08e3a7d034e84870ae1ad4dab6148b20","type":"GO_TERM","name":"cellular response to ketone","canonical_id":"go:GO:1901655","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ketone stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"af58f0219a0740cd844e4dcdc73cb384","type":"GO_TERM","name":"cellular response to laminar fluid shear stress","canonical_id":"go:GO:0071499","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a laminar fluid shear stress stimulus. Laminar fluid flow is the force acting on an object in a system where the fluid is moving across a solid surface in parallel layers.\" [GOC:mah]","metadata":null},{"id":"a72de36da7714bcf94115e5ff47cae96","type":"GO_TERM","name":"cellular response to lead ion","canonical_id":"go:GO:0071284","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lead ion stimulus.\" [GOC:mah]","metadata":null},{"id":"225763b7c9f04692a1af1a9bac4957b6","type":"GO_TERM","name":"cellular response to lectin","canonical_id":"go:GO:1990858","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lectin stimulus. A lectin is a carbohydrate-binding protein, highly specific for binding sugar moieties.\" [PMID:25996210, PMID:26306444]","metadata":null},{"id":"994ecfdda9344eac97b525b3c10932a8","type":"GO_TERM","name":"cellular response to leptin stimulus","canonical_id":"go:GO:0044320","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leptin stimulus. Leptin is a hormone manufactured primarily in the adipocytes of white adipose tissue, and the level of circulating leptin is directly proportional to the total amount of fat in the body. It plays a key role in regulating energy intake and energy expenditure, including appetite and metabolism.\" [GOC:yaf]","metadata":null},{"id":"8af70977793041d1bce3f9f5164c025d","type":"GO_TERM","name":"cellular response to leptomycin B","canonical_id":"go:GO:0072750","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leptomycin B stimulus.\" [GOC:mah]","metadata":null},{"id":"c1e2556039334057b147fc734b5a8bb9","type":"GO_TERM","name":"cellular response to leucine starvation","canonical_id":"go:GO:1990253","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of leucine.\" [PMID:19033384]","metadata":null},{"id":"8577199901d24a4a864dda4d918756f0","type":"GO_TERM","name":"cellular response to leukemia inhibitory factor","canonical_id":"go:GO:1990830","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukemia inhibitory factor stimulus.\" [PMID:12801913]","metadata":null},{"id":"034861ac8b3c433493c9906653c2908b","type":"GO_TERM","name":"cellular response to leukotriene B4","canonical_id":"go:GO:1905390","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukotriene B4 stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:14656734]","metadata":null},{"id":"a886c05a42dc4f4aaa90963b4100d718","type":"GO_TERM","name":"cellular response to light intensity","canonical_id":"go:GO:0071484","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a light intensity stimulus.\" [GOC:mah]","metadata":null},{"id":"beed601e9ac043e0b9a268b7b8874c40","type":"GO_TERM","name":"cellular response to light stimulus","canonical_id":"go:GO:0071482","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a light stimulus, electromagnetic radiation of wavelengths classified as infrared, visible or ultraviolet light.\" [GOC:mah]","metadata":null},{"id":"7d22f5651ce64ccf9a2f314a1e19b044","type":"GO_TERM","name":"cellular response to linoleic acid","canonical_id":"go:GO:0071399","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a linoleic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"f4b2935530f44f12803c5251bb3755b8","type":"GO_TERM","name":"cellular response to lipid","canonical_id":"go:GO:0071396","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid stimulus.\" [GOC:mah]","metadata":null},{"id":"3150232833564a138c6a4a38ecd0a68b","type":"GO_TERM","name":"cellular response to lipid hydroperoxide","canonical_id":"go:GO:0071449","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid hydroperoxide stimulus. Lipid hydroperoxide is the highly reactive primary oxygenated products of polyunsaturated fatty acids.\" [GOC:mah]","metadata":null},{"id":"02fc6bd8dcb0406d8f7c4e4469d1477e","type":"GO_TERM","name":"cellular response to lipoic acid","canonical_id":"go:GO:1903443","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoic acid stimulus.\" [GO_REF:0000071, GOC:sl, GOC:TermGenie, PMID:23232760]","metadata":null},{"id":"d473acb1fb794d22a7bd9979a36731e3","type":"GO_TERM","name":"cellular response to lipopolysaccharide","canonical_id":"go:GO:0071222","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.\" [GOC:mah]","metadata":null},{"id":"5a561e892b52473ba9c43272a2b29d47","type":"GO_TERM","name":"cellular response to lipoprotein particle stimulus","canonical_id":"go:GO:0071402","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoprotein particle stimulus.\" [GOC:mah]","metadata":null},{"id":"1b04221d55c34a66afd426beeec03409","type":"GO_TERM","name":"cellular response to lipoteichoic acid","canonical_id":"go:GO:0071223","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoteichoic acid stimulus; lipoteichoic acid is a major component of the cell wall of gram-positive bacteria and typically consists of a chain of glycerol-phosphate repeating units linked to a glycolipid anchor.\" [GOC:mah]","metadata":null},{"id":"18f078141fb14ed5bff36b9efaff531c","type":"GO_TERM","name":"cellular response to lithium ion","canonical_id":"go:GO:0071285","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lithium (Li+) ion stimulus.\" [GOC:mah]","metadata":null},{"id":"3cfe388201c7453e83ba118fca5c6427","type":"GO_TERM","name":"cellular response to low light intensity stimulus","canonical_id":"go:GO:0071487","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a low light intensity stimulus. Low light intensity is defined as a level of electromagnetic radiation at or below 0.1 micromols/m2.\" [GOC:mah]","metadata":null},{"id":"a90acf3777b146e7b819915812189e20","type":"GO_TERM","name":"cellular response to low-density lipoprotein particle stimulus","canonical_id":"go:GO:0071404","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a low-density lipoprotein particle stimulus.\" [GOC:mah]","metadata":null},{"id":"1b235baa921f4301aa02d283ad3031ce","type":"GO_TERM","name":"cellular response to luteinizing hormone stimulus","canonical_id":"go:GO:0071373","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a luteinizing hormone stimulus.\" [GOC:mah]","metadata":null},{"id":"d0cd1c2e34fc46759c8dda47952e5dac","type":"GO_TERM","name":"cellular response to macrophage colony-stimulating factor stimulus","canonical_id":"go:GO:0036006","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a macrophage colony-stimulating factor stimulus.\" [GOC:yaf, PMID:14687666]","metadata":null},{"id":"c62e54b8af7a4a269f0374d26ca3880f","type":"GO_TERM","name":"cellular response to magnesium ion","canonical_id":"go:GO:0071286","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnesium ion stimulus.\" [GOC:mah]","metadata":null},{"id":"00848536da1e423ebc7b0b51d67b0cb1","type":"GO_TERM","name":"cellular response to magnesium starvation","canonical_id":"go:GO:0010350","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of magnesium.\" [PMID:17270009]","metadata":null},{"id":"136a4e542a57475e8195029b523ec51a","type":"GO_TERM","name":"cellular response to magnetism","canonical_id":"go:GO:0071259","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnetic stimulus.\" [GOC:mah]","metadata":null},{"id":"d1731e0de3c4467ba35563bd462252d1","type":"GO_TERM","name":"cellular response to maltose stimulus","canonical_id":"go:GO:0071328","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a maltose stimulus.\" [GOC:mah]","metadata":null},{"id":"70d61e274f8e42079b808a2d576ba758","type":"GO_TERM","name":"cellular response to manganese ion","canonical_id":"go:GO:0071287","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a manganese ion stimulus.\" [GOC:mah]","metadata":null},{"id":"2bb33a3e08884e29b205173e975330ee","type":"GO_TERM","name":"cellular response to mannitol stimulus","canonical_id":"go:GO:0071325","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mannitol stimulus.\" [GOC:mah]","metadata":null},{"id":"d7b161f44636442bb2fca6d3b77e58bf","type":"GO_TERM","name":"cellular response to mannose","canonical_id":"go:GO:1905583","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mannose stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16699509]","metadata":null},{"id":"bc321e692f084472ae145b9718386821","type":"GO_TERM","name":"cellular response to mechanical stimulus","canonical_id":"go:GO:0071260","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus.\" [GOC:mah]","metadata":null},{"id":"802a71aa58064af689bb361fe39a8a15","type":"GO_TERM","name":"cellular response to menadione","canonical_id":"go:GO:0036245","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a menadione stimulus. Menadione (also called vitamin K3) is a naphthoquinone having a methyl substituent at the 2-position.\" [GOC:al, Wikipedia:Menadione]","metadata":null},{"id":"13b2662d4c6c48df9ffe5e9361d5a38c","type":"GO_TERM","name":"cellular response to menaquinone","canonical_id":"go:GO:0071308","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a menaquinone (vitamin K2) stimulus.\" [GOC:mah]","metadata":null},{"id":"e363de5a27f9477d86fe43a96df0cae2","type":"GO_TERM","name":"cellular response to mercaptoethanol","canonical_id":"go:GO:0072705","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mercaptoethanol stimulus.\" [GOC:mah]","metadata":null},{"id":"6a107f41675b44b58f4f12be969df7c4","type":"GO_TERM","name":"cellular response to mercury ion","canonical_id":"go:GO:0071288","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mercury ion stimulus.\" [GOC:mah]","metadata":null},{"id":"63dfbd17042e4082bb6d4b7272db6cce","type":"GO_TERM","name":"cellular response to metal ion","canonical_id":"go:GO:0071248","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a metal ion stimulus.\" [GOC:mah]","metadata":null},{"id":"f39b1109d60f4364b30a97c4ae892547","type":"GO_TERM","name":"cellular response to methamphetamine hydrochloride","canonical_id":"go:GO:1904314","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methamphetamine hydrochloride stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22174933]","metadata":null},{"id":"0c3f58104d664ce4a53498a9d69acb48","type":"GO_TERM","name":"cellular response to methanol","canonical_id":"go:GO:0071405","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methanol stimulus.\" [GOC:mah]","metadata":null},{"id":"063b18f4c5274900a1ab6fa91e8bbc66","type":"GO_TERM","name":"cellular response to methionine","canonical_id":"go:GO:0061431","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methionine stimulus.\" [GOC:dph, PMID:7891681]","metadata":null},{"id":"fa31c1d0b9634b508c45dbe269ae95eb","type":"GO_TERM","name":"cellular response to methotrexate","canonical_id":"go:GO:0071414","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methotrexate stimulus. Methotrexate is 4-amino-10-methylformic acid, a folic acid analogue that is a potent competitive inhibitor of dihydrofolate reductase.\" [GOC:mah]","metadata":null},{"id":"0071c93d20554c82a5c33128f4723159","type":"GO_TERM","name":"cellular response to methyl methanesulfonate","canonical_id":"go:GO:0072703","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methyl methanesulfonate (MMS) stimulus.\" [GOC:mah]","metadata":null},{"id":"8612ac5b47db4a5998716ca8adc7c8b0","type":"GO_TERM","name":"cellular response to methylamine","canonical_id":"go:GO:0036256","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylamine stimulus.\" [GOC:mah]","metadata":null},{"id":"73fb5d85aaa54c729c14b73790254122","type":"GO_TERM","name":"cellular response to methylglyoxal","canonical_id":"go:GO:0097238","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylglyoxal stimulus. Methylglyoxal is a 2-oxoaldehyde derived from propanal.\" [GOC:pr]","metadata":null},{"id":"d313ffc3349a467da427d7a86d948f01","type":"GO_TERM","name":"cellular response to methylmercury","canonical_id":"go:GO:0071406","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylmercury stimulus.\" [GOC:mah]","metadata":null},{"id":"b11a1909f96641b8a7f4931616a20276","type":"GO_TERM","name":"cellular response to micafungin","canonical_id":"go:GO:1903968","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a micafungin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16928959]","metadata":null},{"id":"8f6afee0138e48b392b34fea322ff149","type":"GO_TERM","name":"cellular response to miconazole","canonical_id":"go:GO:1905308","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a miconazole stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26108447]","metadata":null},{"id":"54f4068ae3e44bfcaa1ad9423e5d4060","type":"GO_TERM","name":"cellular response to mineralocorticoid stimulus","canonical_id":"go:GO:0071389","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mineralocorticoid stimulus. Mineralocorticoids are hormonal C21 corticosteroids synthesized from cholesterol and characterized by their similarity to aldosterone. Mineralocorticoids act primarily on water and electrolyte balance.\" [GOC:mah]","metadata":null},{"id":"ddaca06af5364014be98199fdb148f2f","type":"GO_TERM","name":"cellular response to misfolded protein","canonical_id":"go:GO:0071218","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a misfolded protein stimulus.\" [GOC:mah]","metadata":null},{"id":"add1872e83a34cdd93659f95e8271b0f","type":"GO_TERM","name":"cellular response to molecule of bacterial origin","canonical_id":"go:GO:0071219","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of bacterial origin such as peptides derived from bacterial flagellin.\" [GOC:mah]","metadata":null},{"id":"2d78bdacf4ce404bbec014e66a2eccf2","type":"GO_TERM","name":"cellular response to molecule of fungal origin","canonical_id":"go:GO:0071226","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of fungal origin such as chito-octamer oligosaccharide.\" [GOC:mah]","metadata":null},{"id":"33490055d78b48ed8634bdb61e38b076","type":"GO_TERM","name":"cellular response to molecule of oomycetes origin","canonical_id":"go:GO:0071227","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of oomycetes origin.\" [GOC:mah]","metadata":null},{"id":"8c22a30c5f4b457fa6cc6b5b58f4ca02","type":"GO_TERM","name":"cellular response to monoamine stimulus","canonical_id":"go:GO:0071868","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a monoamine stimulus. A monoamine is any of a group of molecular messengers that contain one amino group that is connected to an aromatic ring by ethylene group (-CH2-CH2-). Monoamines are derived from the aromatic amino acids phenylalanine, tyrosine, histidine and tryptophan.\" [GOC:mah]","metadata":null},{"id":"2691cea5f39145089d3e138aeef7324a","type":"GO_TERM","name":"cellular response to monosaccharide stimulus","canonical_id":"go:GO:0071326","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a monosaccharide stimulus.\" [GOC:mah]","metadata":null},{"id":"b38ebdfc166f42229099889c2105d9a7","type":"GO_TERM","name":"cellular response to morphine","canonical_id":"go:GO:0071315","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a morphine stimulus. Morphine is an opioid alkaloid, isolated from opium, with a complex ring structure.\" [GOC:mah]","metadata":null},{"id":"f01fb6801d614d7ba06717022d5d259f","type":"GO_TERM","name":"cellular response to muramyl dipeptide","canonical_id":"go:GO:0071225","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muramyl dipeptide stimulus. Muramyl dipeptide is derived from peptidoglycan.\" [GOC:mah]","metadata":null},{"id":"5f36842f662b4a3cafa059643ea466f2","type":"GO_TERM","name":"cellular response to mycophenolic acid","canonical_id":"go:GO:0071506","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mycophenolic acid stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"4e4aa79d65d44f0189ac090c6ea02792","type":"GO_TERM","name":"cellular response to mycotoxin","canonical_id":"go:GO:0036146","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mycotoxin stimulus. A mycotoxin is a toxic chemical substance produced by fungi.\" [GOC:di, PMID:20548963]","metadata":null},{"id":"e039a8c87ab744b1b2d1e8b685bf79ae","type":"GO_TERM","name":"cellular response to nerve growth factor stimulus","canonical_id":"go:GO:1990090","description":"\"A process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nerve growth factor stimulus.\" [PMID:22399805, Wikipedia:Nerve_growth_factor]","metadata":null},{"id":"31a070ae79fe4161ad7f5aea1af5dc81","type":"GO_TERM","name":"cellular response to neutral pH","canonical_id":"go:GO:0036244","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a neutral pH (pH close to 7) stimulus. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:di, Wikipedia:PH]","metadata":null},{"id":"9532a4bad1a7435ba1b88193ea930126","type":"GO_TERM","name":"cellular response to nickel ion","canonical_id":"go:GO:0071289","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nickel ion stimulus.\" [GOC:mah]","metadata":null},{"id":"f506096d764342e1ad6527466682d5fb","type":"GO_TERM","name":"cellular response to nicotine","canonical_id":"go:GO:0071316","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nicotine stimulus.\" [GOC:mah]","metadata":null},{"id":"b50b4ac916bb4dd7ab029c379a9e0854","type":"GO_TERM","name":"cellular response to nitrate","canonical_id":"go:GO:0071249","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrate stimulus.\" [GOC:mah]","metadata":null},{"id":"17603bc364c848509172c26c85b5a5e1","type":"GO_TERM","name":"cellular response to nitric oxide","canonical_id":"go:GO:0071732","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitric oxide stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"e1878a8d8b214972b154185a969d9791","type":"GO_TERM","name":"cellular response to nitrite","canonical_id":"go:GO:0071250","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrite stimulus.\" [GOC:mah]","metadata":null},{"id":"5ecca054c7ed49528da733087c5baf82","type":"GO_TERM","name":"cellular response to nitrogen compound","canonical_id":"go:GO:1901699","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrogen compound stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"397b8dd55ace436b9e1a034fa14f3f3f","type":"GO_TERM","name":"cellular response to nitrogen dioxide","canonical_id":"go:GO:0035714","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrogen dioxide (NO2) stimulus.\" [GOC:BHF]","metadata":null},{"id":"2ad5645fc75a4949b44ca5bda931138d","type":"GO_TERM","name":"cellular response to nitrogen levels","canonical_id":"go:GO:0043562","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of inorganic nitrogen.\" [GOC:jl]","metadata":null},{"id":"a1eb81d2ce584041ad0f7b6ea0ec0a1c","type":"GO_TERM","name":"cellular response to nitrogen starvation","canonical_id":"go:GO:0006995","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of nitrogen.\" [GOC:jl]","metadata":null},{"id":"686120b8b9934bbeb032f19aa0d19915","type":"GO_TERM","name":"cellular response to nitroglycerin","canonical_id":"go:GO:1904843","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitroglycerin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25626975]","metadata":null},{"id":"07d2230fba064760a99cf24b2880a784","type":"GO_TERM","name":"cellular response to nitrosative stress","canonical_id":"go:GO:0071500","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrosative stress stimulus. Nitrosative stress is a state often resulting from exposure to high levels of nitric oxide (NO) or the highly reactive oxidant peroxynitrite, which is produced following interaction of NO with superoxide anions.\" [GOC:mah]","metadata":null},{"id":"40fdd664bfdd40089a9769df040471fd","type":"GO_TERM","name":"cellular response to nocodazole","canonical_id":"go:GO:1904403","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nocodazole stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17822405]","metadata":null},{"id":"e66221d2ebc9458098bd4dc14505a4c9","type":"GO_TERM","name":"cellular response to non-ionic osmotic stress","canonical_id":"go:GO:0071471","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of non-ionic solutes (e.g. mannitol, sorbitol) in the environment.\" [GOC:mah]","metadata":null},{"id":"2e54e2dafbd34ecea4c672894d83de83","type":"GO_TERM","name":"cellular response to nonane","canonical_id":"go:GO:1902781","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nonane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:22958739]","metadata":null},{"id":"6aa6508129ce4e84b018c0510a597534","type":"GO_TERM","name":"cellular response to nonylphenol","canonical_id":"go:GO:1904148","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nonylphenol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:19260726]","metadata":null},{"id":"530e20fc762645beb4e3afe12ac1c964","type":"GO_TERM","name":"cellular response to norepinephrine stimulus","canonical_id":"go:GO:0071874","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a norepinephrine stimulus. Norepinephrine is a catecholamine that has the formula C8H11NO3; it acts as a hormone, and as a neurotransmitter in most of the sympathetic nervous system.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"9cf06e00937a48a5bbd6a78b6455db9c","type":"GO_TERM","name":"cellular response to nutrient","canonical_id":"go:GO:0031670","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nutrient stimulus.\" [GOC:mah]","metadata":null},{"id":"92fa399dedbe47268faafcadb6859f1e","type":"GO_TERM","name":"cellular response to nutrient levels","canonical_id":"go:GO:0031669","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of nutrients.\" [GOC:mah]","metadata":null},{"id":"50f647c3ec9c4e589a005a10b41b65ab","type":"GO_TERM","name":"cellular response to oleic acid","canonical_id":"go:GO:0071400","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oleic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"e8c52d113e5b43a2a835d4246dd9898f","type":"GO_TERM","name":"cellular response to oscillatory fluid shear stress","canonical_id":"go:GO:0097704","description":"\"Any response to oscillatory fluid shear stress that occurs at the level of a cell.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"670dc8a8c116435eaefe8a7589b3d769","type":"GO_TERM","name":"cellular response to osmotic stress","canonical_id":"go:GO:0071470","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:mah]","metadata":null},{"id":"9e680672bb1840ff8ac2959c1982400e","type":"GO_TERM","name":"cellular response to oxidative stress","canonical_id":"go:GO:0034599","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.\" [GOC:mah]","metadata":null},{"id":"17095de6d8ea4634b0f961eed1ddd461","type":"GO_TERM","name":"cellular response to oxidised low-density lipoprotein particle stimulus","canonical_id":"go:GO:0140052","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxidized lipoprotein particle stimulus.\" [GOC:aruk, GOC:BHF, PMID:20037584, PMID:27607416]","metadata":null},{"id":"638aee4d87084ec7a54e838b3a5daf50","type":"GO_TERM","name":"cellular response to oxidopamine","canonical_id":"go:GO:1905842","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxidopamine stimulus.\" [GO_REF:0000071, GOC:rz, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"4d192178b030473f922a869f54e284ad","type":"GO_TERM","name":"cellular response to oxygen levels","canonical_id":"go:GO:0071453","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of oxygen.\" [GOC:mah]","metadata":null},{"id":"8b05c6c8c27246eba95bc4386ed96a53","type":"GO_TERM","name":"cellular response to oxygen radical","canonical_id":"go:GO:0071450","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxygen radical stimulus. An oxygen radical is any oxygen species that carries a free electron; examples include hydroxyl radicals and the superoxide anion.\" [GOC:mah]","metadata":null},{"id":"13e118534080405a8b5d965a227c49ce","type":"GO_TERM","name":"cellular response to oxygen-containing compound","canonical_id":"go:GO:1901701","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxygen-containing compound stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"30b2a93f2b604b74870191ebfb0a404e","type":"GO_TERM","name":"cellular response to oxygen-glucose deprivation","canonical_id":"go:GO:0090650","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the deprivation of oxygen and glucose.\" [GOC:sl, PMID:21525936]","metadata":null},{"id":"33581ca40c0e46d692c14d3de34ef3e7","type":"GO_TERM","name":"cellular response to ozone","canonical_id":"go:GO:0071457","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ozone stimulus.\" [GOC:mah]","metadata":null},{"id":"b7d8b0736d9748a1985fab99949a8a1d","type":"GO_TERM","name":"cellular response to pH","canonical_id":"go:GO:0071467","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:mah, Wikipedia:PH]","metadata":null},{"id":"f8c7fc9a97d04e898a44714731ca5f79","type":"GO_TERM","name":"cellular response to palmitoleic acid","canonical_id":"go:GO:1904927","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a palmitoleic acid stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:25429233]","metadata":null},{"id":"874533b56a674bf6b7f60feb72d3eb56","type":"GO_TERM","name":"cellular response to papulacandin B","canonical_id":"go:GO:0072731","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a papulacandin B stimulus.\" [GOC:mah]","metadata":null},{"id":"ff6c245044c64676bfa4677338f7a912","type":"GO_TERM","name":"cellular response to paraquat","canonical_id":"go:GO:0072756","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a paraquat stimulus.\" [GOC:mah]","metadata":null},{"id":"4ee7ed16e7d14e9eb706c6558cf63fcd","type":"GO_TERM","name":"cellular response to parathyroid hormone stimulus","canonical_id":"go:GO:0071374","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a parathyroid hormone stimulus.\" [GOC:mah]","metadata":null},{"id":"cc1f899b8b3d447faede02d255ce54bd","type":"GO_TERM","name":"cellular response to peptide","canonical_id":"go:GO:1901653","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptide stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"666baa83e1784284b1390765f5533782","type":"GO_TERM","name":"cellular response to peptide hormone stimulus","canonical_id":"go:GO:0071375","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptide hormone stimulus. A peptide hormone is any of a class of peptides that are secreted into the blood stream and have endocrine functions in living animals.\" [GOC:mah]","metadata":null},{"id":"7c754467c06a4493a9332937c0564de4","type":"GO_TERM","name":"cellular response to peptidoglycan","canonical_id":"go:GO:0071224","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptidoglycan stimulus. Peptidoglycan is a bacterial cell wall macromolecule.\" [GOC:mah]","metadata":null},{"id":"9ad123ac950440b7afbdd1da4b65f096","type":"GO_TERM","name":"cellular response to phenylalanine","canonical_id":"go:GO:0071234","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phenylalanine stimulus.\" [GOC:mah]","metadata":null},{"id":"b8499455beff4020953d9fd76fd2354f","type":"GO_TERM","name":"cellular response to phenylpropanoid","canonical_id":"go:GO:1905546","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phenylpropanoid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22700048]","metadata":null},{"id":"b6adb706fa384936ae07546ff0852126","type":"GO_TERM","name":"cellular response to pheromone","canonical_id":"go:GO:0071444","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pheromone stimulus.\" [GOC:mah]","metadata":null},{"id":"850b5e2100164968b47c8d5f8c51ba88","type":"GO_TERM","name":"cellular response to phorbol 13-acetate 12-myristate","canonical_id":"go:GO:1904628","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phorbol 13-acetate 12-myristate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:2200903]","metadata":null},{"id":"4137309f8f704887a245f968e6a1c104","type":"GO_TERM","name":"cellular response to phosphate starvation","canonical_id":"go:GO:0016036","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of phosphate.\" [GOC:jl]","metadata":null},{"id":"ffc5d305b79e4eb0b725ba66a93b3485","type":"GO_TERM","name":"cellular response to phosphatidylethanolamine","canonical_id":"go:GO:1905712","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phosphatidylethanolamine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:1657995]","metadata":null},{"id":"e8dcf545d41b45e988986810431725bc","type":"GO_TERM","name":"cellular response to phylloquinone","canonical_id":"go:GO:0071309","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phylloquinone (vitamin K1) stimulus.\" [GOC:mah]","metadata":null},{"id":"89be514922284bfead16a9663393f45c","type":"GO_TERM","name":"cellular response to platelet-derived growth factor stimulus","canonical_id":"go:GO:0036120","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platelet-derived growth factor stimulus.\" [GOC:yaf]","metadata":null},{"id":"776d280372274a718697863729a316c0","type":"GO_TERM","name":"cellular response to platinum ion","canonical_id":"go:GO:0071290","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platinum stimulus.\" [GOC:mah]","metadata":null},{"id":"80157aadcee949ea865033127d6b7463","type":"GO_TERM","name":"cellular response to plumbagin","canonical_id":"go:GO:1902709","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a plumbagin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23028742]","metadata":null},{"id":"97bbd8182c7f4ec781ebc02619e2cef2","type":"GO_TERM","name":"cellular response to polyamine macromolecule","canonical_id":"go:GO:1904584","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a polyamine macromolecule stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20805360]","metadata":null},{"id":"1e551b41f6eb4a14b590704942aca2b6","type":"GO_TERM","name":"cellular response to polycyclic arene","canonical_id":"go:GO:1903166","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a polycyclic arene stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:10998501]","metadata":null},{"id":"febe749714d84e06925afed8909110c1","type":"GO_TERM","name":"cellular response to potassium ion","canonical_id":"go:GO:0035865","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a potassium ion stimulus.\" [GOC:yaf]","metadata":null},{"id":"d001486ea74b4810961080d1018e1a90","type":"GO_TERM","name":"cellular response to potassium ion starvation","canonical_id":"go:GO:0051365","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of potassium ions.\" [GOC:sm]","metadata":null},{"id":"00e889c88c3c4a29b0941983f40c4dbf","type":"GO_TERM","name":"cellular response to progesterone stimulus","canonical_id":"go:GO:0071393","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a progesterone stimulus.\" [GOC:mah]","metadata":null},{"id":"476e187237944fd8a51069c512e0ffd3","type":"GO_TERM","name":"cellular response to prolactin","canonical_id":"go:GO:1990646","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prolactin stimulus.\" [PMID:7760850]","metadata":null},{"id":"ee4b9139108c4a06a776ca144749b235","type":"GO_TERM","name":"cellular response to proline","canonical_id":"go:GO:0071235","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a proline stimulus.\" [GOC:mah]","metadata":null},{"id":"74ae5ffb044c4effb9a6b138734a90ae","type":"GO_TERM","name":"cellular response to prostaglandin D stimulus","canonical_id":"go:GO:0071799","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin D stimulus.\" [GOC:sl]","metadata":null},{"id":"636ecfc3971f46eea05846ad29924e3b","type":"GO_TERM","name":"cellular response to prostaglandin E stimulus","canonical_id":"go:GO:0071380","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin E stimulus.\" [GOC:mah]","metadata":null},{"id":"7ad44ad9714645d3b425387b7ec8f5a0","type":"GO_TERM","name":"cellular response to prostaglandin F stimulus","canonical_id":"go:GO:0071381","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin F stimulus.\" [GOC:mah]","metadata":null},{"id":"364b5cdcb1fd4d6abb6bf964fa7725c6","type":"GO_TERM","name":"cellular response to prostaglandin I stimulus","canonical_id":"go:GO:0071382","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin I stimulus.\" [GOC:mah]","metadata":null},{"id":"325390b20cfc41aaa27e57ecf0bd61f0","type":"GO_TERM","name":"cellular response to prostaglandin stimulus","canonical_id":"go:GO:0071379","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin stimulus.\" [GOC:mah]","metadata":null},{"id":"3df99676e5404f6d9b56255682a135ca","type":"GO_TERM","name":"cellular response to protozoan","canonical_id":"go:GO:0099141","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a protozoan.\" [GOC:dos]","metadata":null},{"id":"982ca3322ac7400d8bfc925400f21883","type":"GO_TERM","name":"cellular response to pulsatile fluid shear stress","canonical_id":"go:GO:0097703","description":"\"Any response to pulsatile fluid shear stress that occurs at the level of a cell.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"2ea233ec43c14e91b2325e56adaa67b4","type":"GO_TERM","name":"cellular response to purine-containing compound","canonical_id":"go:GO:0071415","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purine-containing compound stimulus.\" [GOC:mah]","metadata":null},{"id":"982018165c1b4046a783e94f419f021c","type":"GO_TERM","name":"cellular response to puromycin","canonical_id":"go:GO:1905795","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a puromycin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25736288]","metadata":null},{"id":"313d0984f8a4427097dfec5a22d21903","type":"GO_TERM","name":"cellular response to purvalanol A","canonical_id":"go:GO:0072754","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purvalanol A stimulus.\" [GOC:mah]","metadata":null},{"id":"66b8cb06fb2f4f9883841c205c3ac358","type":"GO_TERM","name":"cellular response to putrescine","canonical_id":"go:GO:1904586","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a putrescine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20805360]","metadata":null},{"id":"ac2aae6b432545a98ec3ea0628e03f29","type":"GO_TERM","name":"cellular response to pyrimidine ribonucleotide","canonical_id":"go:GO:1905835","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pyrimidine ribonucleotide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22065602]","metadata":null},{"id":"4c7861d65578430cbdd6ca4c7fbc573e","type":"GO_TERM","name":"cellular response to quercetin","canonical_id":"go:GO:1905236","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a quercetin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24914722]","metadata":null},{"id":"f99784f22fb740df9beb7be0f813a5d2","type":"GO_TERM","name":"cellular response to radiation","canonical_id":"go:GO:0071478","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation.\" [GOC:mah]","metadata":null},{"id":"e1c089dbb789494ebb3f99d1984040c3","type":"GO_TERM","name":"cellular response to raffinose","canonical_id":"go:GO:0097403","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a raffinose stimulus.\" [GOC:al]","metadata":null},{"id":"ff425df1172b4a1b97bd8ee5e12b93db","type":"GO_TERM","name":"cellular response to rapamycin","canonical_id":"go:GO:0072752","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rapamycin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"b8e47e842795454d8acfeefb3e20f5c3","type":"GO_TERM","name":"cellular response to reactive nitrogen species","canonical_id":"go:GO:1902170","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive nitrogen species stimulus.\" [GOC:sl, GOC:TermGenie, PMID:22504638]","metadata":null},{"id":"2a7d8528a32448198e57cb6b420f0127","type":"GO_TERM","name":"cellular response to reactive oxygen species","canonical_id":"go:GO:0034614","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals.\" [GOC:mah]","metadata":null},{"id":"2761702f2d1d49fc80e62fbe603c6d30","type":"GO_TERM","name":"cellular response to red light","canonical_id":"go:GO:0071491","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a red light stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:mah]","metadata":null},{"id":"490a06c0a72f4022864bd23f83dce71a","type":"GO_TERM","name":"cellular response to red or far red light","canonical_id":"go:GO:0071489","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a red or far red light stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm. Far red light is electromagnetic radiation of wavelength 700-800nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:mah]","metadata":null},{"id":"ba6c1f13edfe40b9af167ae5f2fbaa1d","type":"GO_TERM","name":"cellular response to redox state","canonical_id":"go:GO:0071461","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating redox state. Redox state refers to the balance of oxidized versus reduced forms of electron donors and acceptors in an organelle, cell or organ; plastoquinone, glutathione (GSH/GSSG), and nicotinamide nucleotides (NAD+/NADH and NADP+/NADPH) are among the most important.\" [GOC:mah]","metadata":null},{"id":"de47ed2869604e8782fc5879381bd11c","type":"GO_TERM","name":"cellular response to resveratrol","canonical_id":"go:GO:1904639","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a resveratrol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23555824]","metadata":null},{"id":"b1b33110eca64c5e8ed05fbe4c6c9efc","type":"GO_TERM","name":"cellular response to retinoic acid","canonical_id":"go:GO:0071300","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"0f1fb23c92ee426abd658222fb4edafa","type":"GO_TERM","name":"cellular response to reversine","canonical_id":"go:GO:0072764","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reversine stimulus.\" [GOC:mah]","metadata":null},{"id":"dc0dcfa89cc54474b5741ed41dca0076","type":"GO_TERM","name":"cellular response to rhamnose stimulus","canonical_id":"go:GO:0071334","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rhamnose stimulus.\" [GOC:mah]","metadata":null},{"id":"d4142f8ff7b24f0884352928290fca53","type":"GO_TERM","name":"cellular response to rotenone","canonical_id":"go:GO:1904648","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rotenone stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18538940]","metadata":null},{"id":"f3ee0892b3594cb0863ef84ddd970ee1","type":"GO_TERM","name":"cellular response to salicylic acid stimulus","canonical_id":"go:GO:0071446","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a salicylic acid stimulus.\" [GOC:mah]","metadata":null},{"id":"98db0723aff44c9d97717fcc0ceef5db","type":"GO_TERM","name":"cellular response to salt","canonical_id":"go:GO:1902075","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a salt stimulus.\" [GOC:mls, GOC:TermGenie, PMID:16666921]","metadata":null},{"id":"e55a556214dd436e8f7b24d585e54eac","type":"GO_TERM","name":"cellular response to salt stress","canonical_id":"go:GO:0071472","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.\" [GOC:mah]","metadata":null},{"id":"7fe835e268bb4636a64d7fdc09081ab8","type":"GO_TERM","name":"cellular response to selenite ion","canonical_id":"go:GO:0072715","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a selenite ion stimulus.\" [GOC:mah]","metadata":null},{"id":"a05a1fe589fe4af39e358f16f5151505","type":"GO_TERM","name":"cellular response to selenium ion","canonical_id":"go:GO:0071291","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from selenium ion.\" [GOC:mah]","metadata":null},{"id":"1b79c589bdf44eb690667f79d58cf365","type":"GO_TERM","name":"cellular response to serotonin","canonical_id":"go:GO:1904015","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a serotonin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:1505525]","metadata":null},{"id":"7db0d5805d384091974a2acb403ab916","type":"GO_TERM","name":"cellular response to silicon dioxide","canonical_id":"go:GO:0071251","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a silicon dioxide stimulus.\" [GOC:mah]","metadata":null},{"id":"39a377bed61144ab9fabd45f894b4355","type":"GO_TERM","name":"cellular response to silver ion","canonical_id":"go:GO:0071292","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a silver (Ag+) ion stimulus.\" [GOC:mah]","metadata":null},{"id":"1a1e2e80cb3044df9d5e26f289693017","type":"GO_TERM","name":"cellular response to singlet oxygen","canonical_id":"go:GO:0071452","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a singlet oxygen stimulus. Singlet oxygen is a dioxygen (O2) molecule in which two 2p electrons have similar spin. Singlet oxygen is more highly reactive than the form in which these electrons are of opposite spin, and it is produced in mutant chloroplasts lacking carotenoids and by leukocytes during metabolic burst.\" [GOC:mah]","metadata":null},{"id":"32b9f35b3726437d97bcca6b82f5445f","type":"GO_TERM","name":"cellular response to sodium arsenite","canonical_id":"go:GO:1903936","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium arsenite stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18674524]","metadata":null},{"id":"4b48eda297354316aac061adb72a0099","type":"GO_TERM","name":"cellular response to sodium dodecyl sulfate","canonical_id":"go:GO:0072707","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium dodecyl sulfate (SDS) stimulus.\" [GOC:mah]","metadata":null},{"id":"af4c8afb558b44fa8d47b11a7040ae63","type":"GO_TERM","name":"cellular response to sodium phosphate","canonical_id":"go:GO:1904384","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium phosphate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24625659]","metadata":null},{"id":"ac0e0a12a7414b92ae9bda6eab78d7e6","type":"GO_TERM","name":"cellular response to sorbitol","canonical_id":"go:GO:0072709","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sorbitol stimulus.\" [GOC:mah]","metadata":null},{"id":"78c10aeb47034b8cb87cf94cf26d1684","type":"GO_TERM","name":"cellular response to starvation","canonical_id":"go:GO:0009267","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of nourishment.\" [GOC:jl]","metadata":null},{"id":"de94b087aff948aa8edc12d410db7c98","type":"GO_TERM","name":"cellular response to staurosporine","canonical_id":"go:GO:0072734","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a staurosporine stimulus.\" [GOC:mah]","metadata":null},{"id":"41d87fd1319d4c02b8506f475a1c31dc","type":"GO_TERM","name":"cellular response to stem cell factor stimulus","canonical_id":"go:GO:0036216","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stem cell factor (SCF) stimulus.\" [GOC:uh, PMID:18787413, PMID:7520444]","metadata":null},{"id":"5ffd969b3b1143d3847ebc1f1d3081f2","type":"GO_TERM","name":"cellular response to steroid hormone stimulus","canonical_id":"go:GO:0071383","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a steroid hormone stimulus.\" [GOC:mah]","metadata":null},{"id":"02d47c18cadd466bb00a750130ca84f7","type":"GO_TERM","name":"cellular response to sterol","canonical_id":"go:GO:0036315","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sterol stimulus.\" [GOC:bf]","metadata":null},{"id":"4a976011831d41b59ade8e4ab9b71fbb","type":"GO_TERM","name":"cellular response to sterol depletion","canonical_id":"go:GO:0071501","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating deprivation of sterols. Sterols are a group of steroids characterized by the presence of one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:mah]","metadata":null},{"id":"dbe3e188a89a4dba906ec05ccee5cae7","type":"GO_TERM","name":"cellular response to stimulus","canonical_id":"go:GO:0051716","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus by a cell and ends with a change in state or activity or the cell.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"5a551c6a8025483b90d607d7ea8675ec","type":"GO_TERM","name":"cellular response to streptomycin","canonical_id":"go:GO:0071239","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a streptomycin stimulus. Streptomycin is a commonly used antibiotic in cell culture media which acts only on prokaryotes and blocks transition from initiation complex to chain elongating ribosome.\" [GOC:mah]","metadata":null},{"id":"08a20e93590b48fb98c854cfa334fac2","type":"GO_TERM","name":"cellular response to stress","canonical_id":"go:GO:0033554","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:mah]","metadata":null},{"id":"2c87699e2c9e4b0bb22089a366d7f2a2","type":"GO_TERM","name":"cellular response to strigolactone","canonical_id":"go:GO:1902348","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a strigolactone stimulus.\" [GOC:TermGenie, PMID:23893171]","metadata":null},{"id":"ed2ab85e681d4d2daa35ef91fc44f7fc","type":"GO_TERM","name":"cellular response to sucrose starvation","canonical_id":"go:GO:0043617","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of sucrose.\" [GOC:jl]","metadata":null},{"id":"3d2976358c8e49958f8e2c29c513be0f","type":"GO_TERM","name":"cellular response to sucrose stimulus","canonical_id":"go:GO:0071329","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sucrose stimulus.\" [GOC:mah]","metadata":null},{"id":"58b8de33c1944a9c969e6a32af07b5d6","type":"GO_TERM","name":"cellular response to sugar-phosphate stress","canonical_id":"go:GO:0036447","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the accumulation of sugar-phosphate.\" [GOC:am, PMID:17383224]","metadata":null},{"id":"c3eded8daad04b1aa75d8df07fa2a294","type":"GO_TERM","name":"cellular response to sulfate starvation","canonical_id":"go:GO:0009970","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of sulfate.\" [GOC:sm]","metadata":null},{"id":"690a48f4f15142a98a2d1cf590e70930","type":"GO_TERM","name":"cellular response to sulfur dioxide","canonical_id":"go:GO:0071252","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sulfur dioxide (SO2) stimulus.\" [GOC:mah]","metadata":null},{"id":"490ed23049a64fccb4559965ec52c19f","type":"GO_TERM","name":"cellular response to sulfur starvation","canonical_id":"go:GO:0010438","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of sulfur.\" [PMID:17420480]","metadata":null},{"id":"b0d83f2c39ec4bbaad1eb0e2a12f188d","type":"GO_TERM","name":"cellular response to superoxide","canonical_id":"go:GO:0071451","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a superoxide stimulus. Superoxide is the anion, oxygen-, formed by addition of one electron to dioxygen (O2) or any compound containing the superoxide anion.\" [GOC:mah]","metadata":null},{"id":"ce9ccda6e98b4457a7214e9ddc3d6a40","type":"GO_TERM","name":"cellular response to tacrolimus","canonical_id":"go:GO:0072748","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tacrolimus (FK506) stimulus.\" [GOC:mah]","metadata":null},{"id":"07f87b187c8b4b639b8fcb42ca824e3d","type":"GO_TERM","name":"cellular response to tellurium ion","canonical_id":"go:GO:0071293","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tellurium ion stimulus.\" [GOC:mah]","metadata":null},{"id":"e606ff3ce8914fb681da38381d683848","type":"GO_TERM","name":"cellular response to temperature stimulus","canonical_id":"go:GO:0071502","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a temperature stimulus.\" [GOC:mah]","metadata":null},{"id":"ecbce5e6c1be41f286829e6e7dc8e037","type":"GO_TERM","name":"cellular response to tert-butyl hydroperoxide","canonical_id":"go:GO:0072736","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tert-butyl hydroperoxide (t-BOOH) stimulus.\" [GOC:mah]","metadata":null},{"id":"e5594c60882c4c11bbd87ce602b5f7f1","type":"GO_TERM","name":"cellular response to testosterone stimulus","canonical_id":"go:GO:0071394","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a testosterone stimulus.\" [GOC:mah]","metadata":null},{"id":"27c791335ab14f299d9a03228c0a42d3","type":"GO_TERM","name":"cellular response to tetracycline","canonical_id":"go:GO:0072746","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetracycline stimulus.\" [GOC:mah]","metadata":null},{"id":"82239e92604d4ac9bd433bda99a2a9c1","type":"GO_TERM","name":"cellular response to tetrahydrofolate","canonical_id":"go:GO:1904482","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetrahydrofolate stimulus.\" [GO_REF:0000071, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:24698160]","metadata":null},{"id":"35c7d39dec4342a69661f36f3b407a1b","type":"GO_TERM","name":"cellular response to thiabendazole","canonical_id":"go:GO:0072713","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thiabendazole stimulus.\" [GOC:mah]","metadata":null},{"id":"6fb8310b1bdd4939a649873ab5eed32c","type":"GO_TERM","name":"cellular response to thyroid hormone stimulus","canonical_id":"go:GO:0097067","description":"\"A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyroid hormone stimulus.\" [GOC:sjw, PMID:9916872]","metadata":null},{"id":"cf30054d77da4eb3beb367ec115fe4ca","type":"GO_TERM","name":"cellular response to thyrotropin-releasing hormone","canonical_id":"go:GO:1905229","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyrotropin-releasing hormone (TRH) stimulus. TRH increases the secretion of thyroid-stimulating hormone by the anterior pituitary.\" [GO_REF:0000071, GOC:TermGenie, PMID:21382270]","metadata":null},{"id":"a90c4c40b7984d71a8548d4c562ceed5","type":"GO_TERM","name":"cellular response to thyroxine stimulus","canonical_id":"go:GO:0097069","description":"\"A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyroxine stimulus.\" [GOC:sjw, PMID:9916872]","metadata":null},{"id":"628dbfc1641a4909baac542648836f05","type":"GO_TERM","name":"cellular response to topoisomerase inhibitor","canonical_id":"go:GO:0072759","description":"\"Any process that results in a change in state or activity of a (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a topoisomerase inhibitor stimulus.\" [GOC:mah]","metadata":null},{"id":"1bd522b7bae145b9b0d28bc81204e953","type":"GO_TERM","name":"cellular response to topologically incorrect protein","canonical_id":"go:GO:0035967","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a protein that is not folded in its correct three-dimensional structure.\" [GOC:bf]","metadata":null},{"id":"f57835c04c44404891868e32cd1f5a71","type":"GO_TERM","name":"cellular response to toxic substance","canonical_id":"go:GO:0097237","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus.\" [GOC:pr]","metadata":null},{"id":"5fe9bc918a544a6fb0ca6173b4a7091e","type":"GO_TERM","name":"cellular response to transforming growth factor beta stimulus","canonical_id":"go:GO:0071560","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus.\" [GOC:ecd, PMID:15451575]","metadata":null},{"id":"c8d4e7e364214dd3b71bfb85e038bda8","type":"GO_TERM","name":"cellular response to trehalose stimulus","canonical_id":"go:GO:0071327","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trehalose stimulus.\" [GOC:mah]","metadata":null},{"id":"9bfa00db51014b7bb497a905220141f2","type":"GO_TERM","name":"cellular response to trehalose-6-phosphate stimulus","canonical_id":"go:GO:0071330","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trehalose-6-phosphate stimulus.\" [GOC:mah]","metadata":null},{"id":"bf1c8001d91a4a37a457e6460ede7016","type":"GO_TERM","name":"cellular response to triacyl bacterial lipopeptide","canonical_id":"go:GO:0071727","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a triacylated bacterial lipopeptide stimulus.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"624cf6e4d2f142cc80e1a70a3f0532a0","type":"GO_TERM","name":"cellular response to trichodermin","canonical_id":"go:GO:0072744","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trichodermin stimulus.\" [GOC:mah]","metadata":null},{"id":"71a09719050346d6a60441ec858dbeee","type":"GO_TERM","name":"cellular response to trichostatin A","canonical_id":"go:GO:0035984","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trichostatin A stimulus.\" [GOC:yaf, PMID:20181743]","metadata":null},{"id":"32095f30078047bd991bfb0426aec6b7","type":"GO_TERM","name":"cellular response to triglyceride","canonical_id":"go:GO:0071401","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a triglyceride stimulus.\" [GOC:mah]","metadata":null},{"id":"d165fb78b0444f2d842aca03d3247e25","type":"GO_TERM","name":"cellular response to triterpenoid","canonical_id":"go:GO:1905837","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a triterpenoid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:28078994]","metadata":null},{"id":"6f8417bd075849a185ac1dbf08a1f16d","type":"GO_TERM","name":"cellular response to tropane","canonical_id":"go:GO:0071416","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tropane stimulus. Tropane is a nitrogenous bicyclic organic compound mainly known for a group of alkaloids derived from it (called tropane alkaloids), which include, among others, atropine and cocaine.\" [GOC:mah]","metadata":null},{"id":"4268169bef914beea7e83e2ae28c1527","type":"GO_TERM","name":"cellular response to tumor cell","canonical_id":"go:GO:0071228","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a tumor cell.\" [GOC:mah]","metadata":null},{"id":"75fea4a6a12a425e9c7d1fbbd67cfeea","type":"GO_TERM","name":"cellular response to tumor necrosis factor","canonical_id":"go:GO:0071356","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus.\" [GOC:mah]","metadata":null},{"id":"0514290cb42b4f77b3d30676cc6bd297","type":"GO_TERM","name":"cellular response to type I interferon","canonical_id":"go:GO:0071357","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type I interferon stimulus. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:mah]","metadata":null},{"id":"54a034f2090a47fea1e685e33a604202","type":"GO_TERM","name":"cellular response to type II interferon","canonical_id":"go:GO:0071346","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon gamma is the only member of the type II interferon found so far.\" [GOC:mah]","metadata":null},{"id":"71b38023d64d44e28183c60c55245100","type":"GO_TERM","name":"cellular response to type III interferon","canonical_id":"go:GO:0071358","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type III interferon stimulus. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:mah]","metadata":null},{"id":"09092f2477c441b6b08f57ed3aed31c5","type":"GO_TERM","name":"cellular response to undecane","canonical_id":"go:GO:1902785","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an undecane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:23826995]","metadata":null},{"id":"d3f7a4418708426c84c203060f1a71d6","type":"GO_TERM","name":"cellular response to unfolded protein","canonical_id":"go:GO:0034620","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an unfolded protein stimulus.\" [GOC:mah]","metadata":null},{"id":"5eea47e8e43b44a8a42f8303b7b8591b","type":"GO_TERM","name":"cellular response to vanadate(3-)","canonical_id":"go:GO:1902439","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vanadate(3-) stimulus.\" [GOC:di, GOC:TermGenie, PMID:7489911]","metadata":null},{"id":"c42ebf6c642f40cb8a3886a7cc6ca6e8","type":"GO_TERM","name":"cellular response to vascular endothelial growth factor stimulus","canonical_id":"go:GO:0035924","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vascular endothelial growth factor stimulus.\" [GOC:BHF, GOC:rl, PMID:18440775]","metadata":null},{"id":"cb22d27072c44a88ba8043f6ce12715d","type":"GO_TERM","name":"cellular response to vasopressin","canonical_id":"go:GO:1904117","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vasopressin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22811487]","metadata":null},{"id":"9ce9751fe32b4f86bd4112d9a2f479f5","type":"GO_TERM","name":"cellular response to very low light intensity stimulus","canonical_id":"go:GO:0071488","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a very low light intensity stimulus. A very low light intensity stimulus is defined as a level of electromagnetic radiation below 0.001 mmol/m2/sec.\" [GOC:mah]","metadata":null},{"id":"4115aafd92db450f9c40772985ecc362","type":"GO_TERM","name":"cellular response to very-low-density lipoprotein particle stimulus","canonical_id":"go:GO:0090731","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a very-low-density lipoprotein particle stimulus.\" [GOC:aruk, GOC:bc]","metadata":null},{"id":"81b051dfdce14ab1af1ab8a6fdc5c7d3","type":"GO_TERM","name":"cellular response to virus","canonical_id":"go:GO:0098586","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus.\" [GOC:dos]","metadata":null},{"id":"64adf50fef684cc1afd77902264e93f6","type":"GO_TERM","name":"cellular response to viscosity","canonical_id":"go:GO:0097715","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a viscosity stimulus.\" [GOC:sl, PMID:7061416]","metadata":null},{"id":"ca1c6ced7f5a40008cd35d415785c535","type":"GO_TERM","name":"cellular response to vitamin","canonical_id":"go:GO:0071295","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin stimulus.\" [GOC:mah]","metadata":null},{"id":"74a8f874f7e34f57a99c3a641d56191b","type":"GO_TERM","name":"cellular response to vitamin A","canonical_id":"go:GO:0071299","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin A stimulus.\" [GOC:mah]","metadata":null},{"id":"cb0273e86a0347b8afc482186c772827","type":"GO_TERM","name":"cellular response to vitamin B1","canonical_id":"go:GO:0071301","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B1 stimulus.\" [GOC:mah]","metadata":null},{"id":"2a13d90b70fd4a73930ff06ef3f3478e","type":"GO_TERM","name":"cellular response to vitamin B1 starvation","canonical_id":"go:GO:0036225","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of vitamin B1 (also called thiamin and thiamine).\" [GOC:al, Wikipedia:Thiamine]","metadata":null},{"id":"0f7b37abe62549a9a6f93fc6df03c57b","type":"GO_TERM","name":"cellular response to vitamin B2","canonical_id":"go:GO:0071302","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B2 stimulus.\" [GOC:mah]","metadata":null},{"id":"c3fc98e27b5e440da7c7698a878f95a1","type":"GO_TERM","name":"cellular response to vitamin B3","canonical_id":"go:GO:0071303","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B3 stimulus.\" [GOC:mah]","metadata":null},{"id":"865cd02ca3e247b2beda28d512b51b78","type":"GO_TERM","name":"cellular response to vitamin B6","canonical_id":"go:GO:0071304","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B6 stimulus. Vitamin B6 encompasses pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"8cd695ecc0f849fa90c2905638072204","type":"GO_TERM","name":"cellular response to vitamin D","canonical_id":"go:GO:0071305","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin D stimulus.\" [GOC:mah]","metadata":null},{"id":"314be87e190e436cbb8aa1b84b3c703c","type":"GO_TERM","name":"cellular response to vitamin E","canonical_id":"go:GO:0071306","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin E stimulus.\" [GOC:mah]","metadata":null},{"id":"bd7f2df987104fd1b57b215bf50871bd","type":"GO_TERM","name":"cellular response to vitamin K","canonical_id":"go:GO:0071307","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin K stimulus.\" [GOC:mah]","metadata":null},{"id":"56b89349d9af4d50be29a3917e514eac","type":"GO_TERM","name":"cellular response to water deprivation","canonical_id":"go:GO:0042631","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of water.\" [GOC:curators]","metadata":null},{"id":"15b3186bac7d4decbcefb4b5fda0fbd9","type":"GO_TERM","name":"cellular response to water stimulus","canonical_id":"go:GO:0071462","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of water.\" [GOC:mah]","metadata":null},{"id":"5386b2acb6464ae790dd5fb23b1e0b2f","type":"GO_TERM","name":"cellular response to wortmannin","canonical_id":"go:GO:1904568","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a wortmannin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20629186]","metadata":null},{"id":"28bddd8d3d824c158632134848898c5e","type":"GO_TERM","name":"cellular response to xenobiotic stimulus","canonical_id":"go:GO:0071466","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"d379f768f4c142d187714560b1594e56","type":"GO_TERM","name":"cellular response to zinc ion","canonical_id":"go:GO:0071294","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a zinc ion stimulus.\" [GOC:mah]","metadata":null},{"id":"7815825a1e1a43b4bf2c2b1d04b28915","type":"GO_TERM","name":"cellular response to zinc ion starvation","canonical_id":"go:GO:0034224","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of zinc ions.\" [GOC:mah]","metadata":null},{"id":"30add2bfb1cb4519b6092e5a92bd7b96","type":"GO_TERM","name":"cellular senescence","canonical_id":"go:GO:0090398","description":"\"A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest.\" [GOC:BHF, PMID:28682291]","metadata":null},{"id":"00b562889928416e87e7213cfadccda8","type":"GO_TERM","name":"cellular stress response to acid chemical","canonical_id":"go:GO:0097533","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in cellular homeostasis caused by the chemical structure of the anion portion of a dissociated acid (rather than the acid acting as a proton donor). The acid chemical may be in gaseous, liquid or solid form.\" [GOC:aa, GOC:BHF, GOC:curators, GOC:rl, PMID:10615049, PMID:19170886, Wikipedia:Acid]","metadata":null},{"id":"9d3b2ecb88344e44934a6f4c39c93700","type":"GO_TERM","name":"cellular stress response to acidic pH","canonical_id":"go:GO:1990451","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in the homeostasis of organismal or cellular pH (with pH < 7). pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:BHF, GOC:curators, GOC:rl, PMID:10615049]","metadata":null},{"id":"d89999db4894485da42ad3fb6e89498d","type":"GO_TERM","name":"cellular_component","canonical_id":"go:GO:0005575","description":"\"A location, relative to cellular compartments and structures, occupied by a macromolecular machine. There are three types of cellular components described in the gene ontology: (1) the cellular anatomical entity where a gene product carries out a molecular function (e.g., plasma membrane, cytoskeleton) or membrane-enclosed compartments (e.g., mitochondrion); (2) virion components, where viral proteins act, and (3) the stable macromolecular complexes of which gene product are parts (e.g., the clathrin complex).\" [GOC:pdt]","metadata":null},{"id":"f86a782446074071b6bd6274d08fdab0","type":"GO_TERM","name":"cellularization","canonical_id":"go:GO:0007349","description":"\"The separation of a multi-nucleate cell or syncytium into individual cells. An example of this is found in Drosophila melanogaster embryo development.\" [GOC:curators, GOC:mtg_sensu, ISBN:0716731363]","metadata":null},{"id":"2499be005e0844128aad2e7df93dc227","type":"GO_TERM","name":"cellularization cleavage furrow","canonical_id":"go:GO:0110070","description":"\"A plasma membrane invagination at the site of separation of a multi-nucleate cell or syncytium into individual cells.\" [GOC:ha, PMID:27226317]","metadata":null},{"id":"9f55a96e74b948f4a4e7749f9ed505e6","type":"GO_TERM","name":"cellularization cleavage furrow invagination front","canonical_id":"go:GO:0110071","description":"\"The base of the cellularization invagination or cleavage furrow most distal to the original multi-nucleate cell or syncytium plasma membrane.\" [GOC:ha, PMID:27226317]","metadata":null},{"id":"ce6ec7e36bad4647b56b0fe2e4674386","type":"GO_TERM","name":"cellulase activity","canonical_id":"go:GO:0008810","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-glucosidic linkages in cellulose, lichenin and cereal beta-D-glucans.\" [EC:3.2.1.4]","metadata":null},{"id":"8911dffa90a2492d8704b1d31dc4e5c7","type":"GO_TERM","name":"cellulose 1,4-beta-cellobiosidase activity","canonical_id":"go:GO:0016162","description":"\"Catalysis of the hydrolysis of (1->4)-beta-D-glucosidic linkages in cellulose and cellotetraose, releasing cellobiose from the non-reducing ends of the chains.\" [EC:3.2.1.91]","metadata":null},{"id":"92e77a2f086f4a5695116b2dc8c7c4c5","type":"GO_TERM","name":"cellulose 1,4-beta-cellobiosidase activity (reducing end)","canonical_id":"go:GO:0102252","description":"\"Catalysis of the reaction: n H2O + a cellodextrin = n beta-cellobiose, releasing cellobiose from the reducing ends of the chains.\" [EC:3.2.1.176, GOC:pz]","metadata":null},{"id":"da7fd6fa990d40888d759fe446bef36f","type":"GO_TERM","name":"cellulose binding","canonical_id":"go:GO:0030248","description":"\"Binding to cellulose.\" [GOC:mah]","metadata":null},{"id":"4f6ecebafc7c4b7e9786d08eb4d3bac2","type":"GO_TERM","name":"cellulose biosynthetic process","canonical_id":"go:GO:0030244","description":"\"The chemical reactions and pathways resulting in the formation of cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"413ebc886d314241b397d2ada051b0bc","type":"GO_TERM","name":"cellulose catabolic process","canonical_id":"go:GO:0030245","description":"\"The chemical reactions and pathways resulting in the breakdown of cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"fede8e3f0fb44e36a31529f2c50e852e","type":"GO_TERM","name":"cellulose catabolism by endo-processive cellulases","canonical_id":"go:GO:0052785","description":"\"The breakdown into simpler components of cellulose. Catabolism is initiated by endohydrolytic attacks on the cellulose chain, and the resulting pieces are further degraded by cellulase enzymes to produce smaller and smaller fragments.\" [GOC:mengo_curators, PMID:18035374]","metadata":null},{"id":"16271cdeb92d4bcc8d98176f201fa8a4","type":"GO_TERM","name":"cellulose metabolic process","canonical_id":"go:GO:0030243","description":"\"The chemical reactions and pathways involving cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"674a42b31e4943758bd436784da4ff73","type":"GO_TERM","name":"cellulose microfibril","canonical_id":"go:GO:0009549","description":"\"A microfibril composed of cellulose arranged in orthogonal layers. Cellulose is a straight chain polysaccharide composed of B(14) linked glucose subunits. It is a major component of plant cell walls. Higher plant microfibrils are about 10nm in diameter and extremely long in relation to their width. The cellulose molecules are oriented parallel to the long axis of the microfibril in a paracrystalline array, which provides great tensile strength. The microfibrils are held in place by the wall matrix and their orientation is closely controlled by the cell.\" [GOC:jid, ISBN:0943088399]","metadata":null},{"id":"5b824ff4650046e5b51330b0f53862bf","type":"GO_TERM","name":"cellulose microfibril organization","canonical_id":"go:GO:0010215","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cellulose microfibril, any of the cellulose structures laid down in orthogonal layers in a plant cell wall.\" [GOC:mah, PMID:12468730]","metadata":null},{"id":"a68b1b761d9f412b8e90f0880a1bf69e","type":"GO_TERM","name":"cellulose synthase (GDP-forming) activity","canonical_id":"go:GO:0016761","description":"\"Catalysis of the reaction: GDP-glucose + ((1,4)-beta-D-glucosyl)(n) = GDP + ((1,4)-beta-D-glucosyl)(n+1).\" [EC:2.4.1.29]","metadata":null},{"id":"5d5259067c474603bcdb02d1b94c793b","type":"GO_TERM","name":"cellulose synthase (UDP-forming) activity","canonical_id":"go:GO:0016760","description":"\"Catalysis of the reaction: UDP-glucose + ((1,4)-beta-D-glucosyl)(n) = UDP + ((1,4)-beta-D-glucosyl)(n+1).\" [EC:2.4.1.12]","metadata":null},{"id":"14ba8295e7f94ffd863bd3602d206f31","type":"GO_TERM","name":"cellulose synthase activity","canonical_id":"go:GO:0016759","description":"\"Catalysis of the reaction: nucleoside-disphosphate-glucose + ((1,4)-beta-D-glucosyl)(n) = nucleoside-disphosphate + ((1,4)-beta-D-glucosyl)(n+1).\" [GOC:curators]","metadata":null},{"id":"0c0c530354a04a98a002d40cf4bf5ca3","type":"GO_TERM","name":"cellulose synthase complex","canonical_id":"go:GO:0010330","description":"\"A large, multimeric protein complex, organized in a rosette, which catalyzes the biosynthesis of cellulose for the plant cell wall.\" [PMID:12514238, PMID:18485800, PMID:21307367]","metadata":null},{"id":"a6aad8ea05df4f08a249dada7910cdbe","type":"GO_TERM","name":"cellulose-polysulfatase activity","canonical_id":"go:GO:0033886","description":"\"Catalysis of the hydrolysis of the 2- and 3-sulfate groups of the polysulfates of cellulose and charonin.\" [EC:3.1.6.7]","metadata":null},{"id":"219a972f6b464cd88711e7f0bf0c6c53","type":"GO_TERM","name":"cellulosome","canonical_id":"go:GO:0043263","description":"\"An extracellular multi-enzyme complex containing up to 11 different enzymes aligned on a non-catalytic scaffolding glycoprotein. Functions to hydrolyze cellulose.\" [GOC:jl, PMID:11601609, PMID:15197390, PMID:20373916]","metadata":null},{"id":"9f71b0ce95c8405dbcb6ae9bbb1e4f68","type":"GO_TERM","name":"cellulosome assembly","canonical_id":"go:GO:0044575","description":"\"The assembly of a cellulosome, a macromolecular multi-enzyme complex in bacteria that facilitates the breakdown of cellulase, hemicellulase and pectin in the plant cell wall.\" [GOC:mengo_curators, GOC:tt, PMID:20373916]","metadata":null},{"id":"18eac5c0e56041c4b9ed8d6ca937997f","type":"GO_TERM","name":"cellulosome binding","canonical_id":"go:GO:1990300","description":"\"Binding to a cellulosome, an extracellular multi-enzyme complex containing several enzymes aligned on a non-catalytic scaffolding that functions to hydrolyze plant cell wall polysaccharides.\" [GOC:mengo_curators, PMID:11893054, PMID:15197390]","metadata":null},{"id":"586d5f2fe27941d386deda9fb2f929a2","type":"GO_TERM","name":"cement gland development","canonical_id":"go:GO:0071570","description":"\"The process whose specific outcome is the progression of the cement gland over time, from its formation to the mature structure. The cement gland is a simple mucus-secreting organ positioned at the anterior of amphibious embryos. The cement gland attaches the newly hatched embryo to a support before the hatchling can swim well or feed.\" [GOC:bf]","metadata":null},{"id":"c4d54a0acf9947d7929fe73aa9f81c47","type":"GO_TERM","name":"cementum mineralization","canonical_id":"go:GO:0071529","description":"\"The process in which calcium salts, mainly carbonated hydroxyapatite, are deposited into the initial acellular cementum.\" [GOC:sl, PMID:17043865]","metadata":null},{"id":"47eb28409efa481abb608092f3952fa2","type":"DRUG","name":"cemiplimab","canonical_id":"gtopdb:10090","description":null,"metadata":null},{"id":"9def31a723e74ae4b57df93ef2617a58","type":"DRUG","name":"cemiplimab","canonical_id":"chembl:CHEMBL4297723","description":null,"metadata":null},{"id":"bc263bb9f2b5484ea51866105668edba","type":"COMBINATION_TREATMENT","name":"cemiplimab + dupilumab","canonical_id":"ctgov_combo:ctgov-combo-0fe1b6aae5ae35f9","description":null,"metadata":null},{"id":"84029549d499450bb292df7880c148ec","type":"COMBINATION_TREATMENT","name":"cemiplimab + ipilimumab","canonical_id":"ctgov_combo:ctgov-combo-6b373bfe328e699c","description":null,"metadata":null},{"id":"51af3ac42e614632b6285c7770725ecb","type":"COMBINATION_TREATMENT","name":"cemiplimab + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-fbb7644cfa51a1fe","description":null,"metadata":null},{"id":"39075966ddf14350aeb1a777c4bb3095","type":"COMBINATION_TREATMENT","name":"cemiplimab + isatuximab","canonical_id":"ctgov_combo:ctgov-combo-7f34d38ad5924ccd","description":null,"metadata":null},{"id":"c72a619d6f35405b9c529ad4476d1235","type":"COMBINATION_TREATMENT","name":"cemiplimab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-7ce4240c9dea1de6","description":null,"metadata":null},{"id":"be8e06827e7c4ad6af3d46a9aac6771f","type":"COMBINATION_TREATMENT","name":"cemiplimab + plerixafor","canonical_id":"ctgov_combo:ctgov-combo-504ca63045a340ea","description":null,"metadata":null},{"id":"9724e825a0714d44b2ec62207d90c779","type":"COMBINATION_TREATMENT","name":"cemiplimab + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-477cb7c9e11cfb00","description":null,"metadata":null},{"id":"afe90ccecf6d4d55a5eb6484b5ad0cd2","type":"COMBINATION_TREATMENT","name":"cemiplimab + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-7fb8a0888bb58b4e","description":null,"metadata":null},{"id":"4b4a4a7fc093442bb23163036bca3aac","type":"COMBINATION_TREATMENT","name":"cemiplimab + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-27c304eb775ed45f","description":null,"metadata":null},{"id":"23da75a56ebd48e4925c6d612024cb53","type":"GO_TERM","name":"central B cell anergy","canonical_id":"go:GO:0002341","description":"\"Any process contributing to anergy, a state of functional inactivation that occurs as part of tolerance induction, in B cells in the bone marrow.\" [GOC:jal]","metadata":null},{"id":"f9b198876af842998e8c81d1e485b0a5","type":"GO_TERM","name":"central B cell deletion","canonical_id":"go:GO:0002342","description":"\"The deletion of B cells by apoptotic process occurring as part of central tolerance induction and B cell selection.\" [GOC:add, GOC:jal, GOC:mtg_apoptosis]","metadata":null},{"id":"25a129e66ea64dee8efa3da4edccd2b8","type":"GO_TERM","name":"central B cell negative selection","canonical_id":"go:GO:0002354","description":"\"Any process leading to negative selection of B cells in the bone marrow.\" [GOC:jal]","metadata":null},{"id":"e29a5935172c4d95bb35d362e9e7d3b5","type":"GO_TERM","name":"central B cell positive selection","canonical_id":"go:GO:0002348","description":"\"Any process leading to positive selection of B cells in the bone marrow. Positive selection is the process in which B or T cells are selected to survive based on signaling through their antigen receptors.\" [GOC:jal]","metadata":null},{"id":"08de861faf5441c48affe9a3377d5a32","type":"GO_TERM","name":"central B cell receptor editing","canonical_id":"go:GO:0002511","description":"\"Receptor editing occurring in B cells in the bone marrow.\" [GOC:jal, PMID:16460922]","metadata":null},{"id":"73c9f6ceb3984ec08bc4fd15524ebdcb","type":"GO_TERM","name":"central B cell selection","canonical_id":"go:GO:0002340","description":"\"Any B cell selection process that occurs in the bone marrow.\" [GOC:jal]","metadata":null},{"id":"427184f9974f4ed4b61ff81569d61a07","type":"GO_TERM","name":"central B cell tolerance induction","canonical_id":"go:GO:0002510","description":"\"Tolerance induction of B cells in the bone marrow.\" [GOC:jal, PMID:16460922]","metadata":null},{"id":"2fb40686f32d4a42917eff0ee46ba12b","type":"GO_TERM","name":"central T cell tolerance induction","canonical_id":"go:GO:0002512","description":"\"Tolerance induction of T cells in the thymus.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"7c8fa10cc38d4f95be7a2a0fce6fe1da","type":"GO_TERM","name":"central canal development","canonical_id":"go:GO:0061524","description":"\"The process whose specific outcome is the formation of the central canal of the spinal cord from its formation to the mature structure. The central canal is a spinal cord structure that is part of the ventricular system and is filled with cerebral-spinal fluid and runs the length of the spinal cord.\" [GOC:cvs, GOC:dph, PMID:23409159]","metadata":null},{"id":"66274ca1d07a4da79c5e5c0775f25bce","type":"GO_TERM","name":"central complex development","canonical_id":"go:GO:0048036","description":"\"The process whose specific outcome is the progression of the central complex over time, from its formation to the mature structure. The central complex region of the insect brain is thought to be crucial for control of locomotive behavior. Located in the middle of the two protocerebral hemispheres, it comprises four neuropilar regions, the fan-shaped body, the ellipsoid body, the protocerebral bridge and the paired noduli.\" [PMID:12490252]","metadata":null},{"id":"fd34d77d0d974afbadc9058c06f08568","type":"DISEASE","name":"central core myopathy","canonical_id":"mondo:0007294","description":null,"metadata":null},{"id":"5e0203e715a84157a7c6494573707d84","type":"GO_TERM","name":"central cylinder","canonical_id":"go:GO:1990805","description":"\"A scaffolding structure present within the inner region of the ciliary transition zone. The central cylinder lies between the outer doublet and inner singlet microtubules.\" [GOC:kmv, PMID:2428682, PMID:26124290]","metadata":null},{"id":"88db7d6c188a403bbaf8d19d992bfd0d","type":"GO_TERM","name":"central element","canonical_id":"go:GO:0000801","description":"\"A structural unit of the synaptonemal complex found between the lateral elements.\" [GOC:elh]","metadata":null},{"id":"3d8284a5b4124fd38594ff84be498c02","type":"DISEASE","name":"central hypoventilation syndrome, congenital, 1, with or without Hirschsprung disease","canonical_id":"mondo:0800026","description":null,"metadata":null},{"id":"3405952afb0d4bb1bb7670097799ecd7","type":"GO_TERM","name":"central nervous system control of baroreceptor feedback","canonical_id":"go:GO:0003019","description":"\"The neurological process in which nerve impulses arising in the aorta or the carotid sinuses travel to the medulla and reach the nucleus of tractus solaris.\" [GOC:mtg_cardio, ISBN:0323031951]","metadata":null},{"id":"28732c5bc22b46ce911f86fa889a6de9","type":"GO_TERM","name":"central nervous system development","canonical_id":"go:GO:0007417","description":"\"The process whose specific outcome is the progression of the central nervous system over time, from its formation to the mature structure. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord.\" [GOC:bf, GOC:jid, ISBN:0582227089]","metadata":null},{"id":"6b9045cd94e141f49d7ec0d0f6b30ffa","type":"DISEASE","name":"central nervous system disorder","canonical_id":"mondo:0002602","description":null,"metadata":null},{"id":"7ca7d3e3c8fb4fd9b814535771fb03e2","type":"GO_TERM","name":"central nervous system formation","canonical_id":"go:GO:0021556","description":"\"The process that gives rise to the central nervous system. This process pertains to the initial formation of a structure from unspecified parts. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain, spinal cord and spinal nerves. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0582227089]","metadata":null},{"id":"fb0a89b42f7041349dbb2c7fd285f63b","type":"GO_TERM","name":"central nervous system interneuron axonogenesis","canonical_id":"go:GO:0021956","description":"\"Generation of a long process that carries efferent (outgoing) action potentials from the cell body towards target cells from a neuron located in the central nervous system whose axons remain within a single brain region.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e9fe9d4379ab4846b3593c3fc07383b6","type":"GO_TERM","name":"central nervous system maturation","canonical_id":"go:GO:0021626","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the central nervous system to attain its fully functional state. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0582227089]","metadata":null},{"id":"dab11ebd126d4f9d97e4b44f141137a0","type":"GO_TERM","name":"central nervous system morphogenesis","canonical_id":"go:GO:0021551","description":"\"The process in which the anatomical structure of the central nervous system is generated and organized. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0582227089]","metadata":null},{"id":"15bcbd98715d4c84a3c042a7653881a4","type":"GO_TERM","name":"central nervous system myelin formation","canonical_id":"go:GO:0032289","description":"\"The process in which the wraps of cell membrane that constitute myelin are laid down around an axon by an oligodendrocyte in the central nervous system.\" [GOC:dgh]","metadata":null},{"id":"858b67c305d2404fb1b9cbf5c11d6000","type":"GO_TERM","name":"central nervous system myelin maintenance","canonical_id":"go:GO:0032286","description":"\"The process in which the structure and material content of mature central nervous system myelin is kept in a functional state.\" [GOC:dgh]","metadata":null},{"id":"12c174df5216438dbe21dd777efe9e27","type":"GO_TERM","name":"central nervous system myelination","canonical_id":"go:GO:0022010","description":"\"The process in which neuronal axons and dendrites become coated with a segmented lipid-rich sheath (myelin) to enable faster and more energetically efficient conduction of electrical impulses. The sheath is formed by the cell membranes of oligodendrocytes in the central nervous system. Adjacent myelin segments are separated by a non-myelinated stretch of axon called a node of Ranvier.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5aeda5f067e04d9c916563f83aa42c1b","type":"GO_TERM","name":"central nervous system neuron axonogenesis","canonical_id":"go:GO:0021955","description":"\"Generation of a long process from a neuron whose cell body resides in the central nervous system. The process carries efferent (outgoing) action potentials from the cell body towards target cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"78630a2d029f463c8ce4a8c72cdb1830","type":"GO_TERM","name":"central nervous system neuron development","canonical_id":"go:GO:0021954","description":"\"The process whose specific outcome is the progression of a neuron whose cell body is located in the central nervous system, from initial commitment of the cell to a neuronal fate, to the fully functional differentiated neuron.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"f9a461c41a3347f59a333698ae18b8b9","type":"GO_TERM","name":"central nervous system neuron differentiation","canonical_id":"go:GO:0021953","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron whose cell body resides in the central nervous system.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9c63fa81408c4f8fbd1e0f4e247a07ac","type":"GO_TERM","name":"central nervous system projection neuron axonogenesis","canonical_id":"go:GO:0021952","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body towards target cells in a different central nervous system region.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3a3e133a1302433fbbf6472089809419","type":"GO_TERM","name":"central nervous system segmentation","canonical_id":"go:GO:0035283","description":"\"Division of the central nervous system into a series of semi-repetitive parts or segments.\" [GOC:bf]","metadata":null},{"id":"32f09d098feb49d88f4a62c00b5769f1","type":"GO_TERM","name":"central nervous system structural organization","canonical_id":"go:GO:0021597","description":"\"The process that contributes to the act of creating the structural organization of the central nervous system structure. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain, spinal cord and spinal nerves. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0582227089]","metadata":null},{"id":"a23c61b013f94a61adea0ccb095e6039","type":"GO_TERM","name":"central nervous system vasculogenesis","canonical_id":"go:GO:0022009","description":"\"The differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes in the central nervous system. The capillary endothelial cells in the brain are specialized to form the blood-brain barrier.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a570421f17444ec2a1244065f2e4dbba","type":"GO_TERM","name":"central plaque of mitotic spindle pole body","canonical_id":"go:GO:0061493","description":"\"One of three laminate structures that form the mitotic spindle pole body; the inner plaque is on the nuclear face of the spindle pole body.\" [GOC:dph]","metadata":null},{"id":"6c7c32d44dba4ce3b0294a1858fcdb00","type":"GO_TERM","name":"central plaque of spindle pole body","canonical_id":"go:GO:0005823","description":"\"One of three laminate structures that form the spindle pole body; the central plaque is embedded in the nuclear envelope.\" [ISBN:0879693568]","metadata":null},{"id":"27516f61ad13454c9ccb626d10c73bf8","type":"DISEASE","name":"central precocious puberty","canonical_id":"mondo:0019165","description":null,"metadata":null},{"id":"f4737872c8e4497cbc0b66642838baa5","type":"GO_TERM","name":"central region of growth cone","canonical_id":"go:GO:0090724","description":"\"The center of the migrating motile tip of a growing nerve cell axon or dendrite.\" [GOC:sl, PMID:16260607]","metadata":null},{"id":"e891d5feb6764855bb934b1e50dffebf","type":"GO_TERM","name":"central tolerance induction","canonical_id":"go:GO:0002508","description":"\"Tolerance induction in the central lymphoid organs: the thymus and bone marrow.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"a1262df349ba4178987ddd97f480ae38","type":"GO_TERM","name":"central tolerance induction to nonself antigen","canonical_id":"go:GO:0002463","description":"\"Tolerance induction to nonself antigens in the central lymphoid organs.\" [GOC:jal, PMID:12547504]","metadata":null},{"id":"a4ac7968921841d583e9d9858490b9d6","type":"GO_TERM","name":"central tolerance induction to self antigen","canonical_id":"go:GO:0002509","description":"\"Tolerance induction in the central lymphoid organs directed at self antigens.\" [GOC:jal, ISBN:0781735149, PMID:16460922]","metadata":null},{"id":"540314b42f9542569efbb7deea2a8424","type":"GO_TERM","name":"central vacuole","canonical_id":"go:GO:0042807","description":"\"A membrane-enclosed sac that takes up most of the volume of a mature plant cell. Functions include storage, separation of toxic byproducts, and cell growth determination.\" [ISBN:9780815341116, Wikipedia:Vacuole]","metadata":null},{"id":"f705a20eb4ad47228e99fdd8f1db9182","type":"GO_TERM","name":"centralspindlin complex","canonical_id":"go:GO:0097149","description":"\"A heterotetrameric protein complex playing a key role in the formation of the central spindle in mitosis. Made up of two molecules each of a mitotic kinesin (ZEN-4 in Caenorhabditis elegans or MKLP1 in mammals) and of two molecules each of a GTPase activating protein (GAP) factor (CYK-4 in Caenorhabditis elegans or MgcRacGAP in mammals).\" [GOC:ans, PMID:11782313, PMID:16236794]","metadata":null},{"id":"d660d0ab2d7a4523bbb42c0c2979657f","type":"GO_TERM","name":"centriolar satellite","canonical_id":"go:GO:0034451","description":"\"A small (70-100 nm) cytoplasmic granule that contains a number of centrosomal proteins; centriolar satellites traffic toward microtubule minus ends and are enriched near the centrosome.\" [GOC:BHF, PMID:10579718, PMID:12403812]","metadata":null},{"id":"9647d6cf6df94aa69f3285572cb356c4","type":"GO_TERM","name":"centriolar subdistal appendage","canonical_id":"go:GO:0120103","description":"\"A protein complex which assembles on the mother centriole during cilium formation, adjacent and proximal to a centriolar distal appendage. In human, it contains ODF2, CNTRL, NIN, CCDC120c and CCDC68.\" [GOC:cilia, PMID:23213374, PMID:27818179, PMID:28422092]","metadata":null},{"id":"e38a6a55d581415f86a367ec0e7f9c20","type":"GO_TERM","name":"centriole","canonical_id":"go:GO:0005814","description":"\"A cellular organelle, found close to the nucleus in many eukaryotic cells, consisting of a small cylinder with microtubular walls, 300-500 nm long and 150-250 nm in diameter. It contains nine short, parallel, peripheral microtubular fibrils, each fibril consisting of one complete microtubule fused to two incomplete microtubules. Cells usually have two centrioles, lying at right angles to each other. At division, each pair of centrioles generates another pair and the twin pairs form the pole of the mitotic spindle.\" [ISBN:0198547684]","metadata":null},{"id":"448c9e104bbb42a6a77dfd48e21a26d5","type":"GO_TERM","name":"centriole assembly","canonical_id":"go:GO:0098534","description":"\"A cellular process that results in the assembly of one or more centrioles.\" [GOC:dos, PMID:24075808]","metadata":null},{"id":"a624bbea99be4bd997acf2b409ce87da","type":"GO_TERM","name":"centriole elongation","canonical_id":"go:GO:0061511","description":"\"The centrosome organization process by which a centriole increases in length as part of the process of replication.\" [GOC:dph, PMID:21576394]","metadata":null},{"id":"b72210aa55ae47218f60f76692ef52a5","type":"GO_TERM","name":"centriole replication","canonical_id":"go:GO:0007099","description":"\"The cell cycle process in which a daughter centriole is formed perpendicular to an existing centriole. An immature centriole contains a ninefold radially symmetric array of single microtubules; mature centrioles consist of a radial array of nine microtubule triplets, doublets, or singlets depending upon the species and cell type. Duplicated centrioles also become the ciliary basal body in cells that form cilia during G0.\" [GOC:cilia, GOC:kmv, ISBN:0815316194, PMID:9889124]","metadata":null},{"id":"8e6ccaaa076f40819b4b1012ae495835","type":"GO_TERM","name":"centriole scaffold activity","canonical_id":"go:GO:0140180","description":"\"The binding activity of a protein that contributes to the stable formation of a centriole by forming persistent structures, or templates, upon which other centriolar proteins assemble.\" [PMID:29784964, PMID:32956907, PMID:34702818]","metadata":null},{"id":"b1b85413274f43029b13da0ec35508bc","type":"GO_TERM","name":"centriole-centriole cohesion","canonical_id":"go:GO:0010457","description":"\"The cell cycle process in which the two centrioles within a centrosome remain tightly paired.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d9ce893b621b4266b36d12b2022400f1","type":"GO_TERM","name":"centripetally migrating follicle cell migration","canonical_id":"go:GO:0060269","description":"\"The cell migration process in which a follicle cell migrates as part of an epithelial sheet between the nurse cells and the oocyte. At the end of migration, they cover the anterior of the oocyte.\" [GOC:dph]","metadata":null},{"id":"fd226ec2936b4ebb8de05ab28d3cc5d2","type":"GO_TERM","name":"centrolateral axis specification","canonical_id":"go:GO:0009947","description":"\"The establishment, maintenance and elaboration of the centrolateral axis. In plants, this axis is duplicated and runs from the midrib to the margin of the leaf.\" [GOC:dsz, GOC:tb, ISBN:0865427429]","metadata":null},{"id":"09ed50cfc0ed450397f02650da93e662","type":"GO_TERM","name":"centrolateral pattern formation","canonical_id":"go:GO:0097353","description":"\"The regionalization process in which the areas along the centrolateral axis are established that will lead to differences in cell differentiation, or in which cells interpret a specific environment.\" [GOC:dsz]","metadata":null},{"id":"952cd758354b4c4f8ee057e028c2fc9c","type":"GO_TERM","name":"centromere clustering","canonical_id":"go:GO:0098653","description":"\"The process by which centromeres/kinetochores become localized to clusters.\" [GOC:di, GOC:dos, PMID:10761928, PMID:23283988, PMID:8486732]","metadata":null},{"id":"5f33f6238c584b55a9bb1aba24c0adab","type":"GO_TERM","name":"centromere clustering at the mitotic interphase nuclear envelope","canonical_id":"go:GO:0072766","description":"\"The process in which chromatin, or kinetochores are anchored to the nuclear envelope. This process involves the microtubule cytoskeleton, and nuclear tethering factors and is responsible for the Rabl-like configuration of chromosomes in the interphase nuclei.\" [GOC:mah, GOC:vw, PMID:21965289, PMID:23166349]","metadata":null},{"id":"c3e74d878a8f4e4fa083e8c2bae8a25e","type":"GO_TERM","name":"centromere localization","canonical_id":"go:GO:0072765","description":"\"A cellular localization process in which a centromere/kinetochore is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"b9a1290be0be42979f9ae5d6563a778f","type":"GO_TERM","name":"centromere separation","canonical_id":"go:GO:0034510","description":"\"The cell cycle process in which centromeres are physically detached from each other during chromosome separation.\" [GOC:mah]","metadata":null},{"id":"5f1ce883bbbe4f8f9e42a98ecb176e70","type":"GO_TERM","name":"centromere-nuclear envelope anchor activity","canonical_id":"go:GO:0140449","description":"\"The binding activity of a molecule that brings together the centromeric region of a chromosome and the inner nuclear membrane by interacting with both the centromere/kinetochore complex and the nuclear membrane, in order to establish and maintain the centromere/kinetochore location.\" [PMID:31635174]","metadata":null},{"id":"1aa29667871849458a2be10c0d518dc8","type":"GO_TERM","name":"centromeric DNA binding","canonical_id":"go:GO:0019237","description":"\"Binding to a centromere, a region of chromosome where the spindle fibers attach during mitosis and meiosis.\" [GOC:jl, SO:0000577]","metadata":null},{"id":"9c97cc3a634841a5bb321013e24b78b2","type":"GO_TERM","name":"centromeric sister chromatid cohesion","canonical_id":"go:GO:0070601","description":"\"The cell cycle process in which the sister chromatids of a replicated chromosome are joined along the length of the centromeric region of the chromosome.\" [GOC:mah]","metadata":null},{"id":"5e6d9bea94bd480d9852db7cd38b5d18","type":"DISEASE","name":"centronuclear myopathy","canonical_id":"mondo:0018947","description":null,"metadata":null},{"id":"ecbcb9ec537940cfbd1608d9a8dde786","type":"GO_TERM","name":"centrosomal and pronuclear rotation","canonical_id":"go:GO:0035047","description":"\"The rotation of centrosomes and associated pronuclei in one-cell embryos such as those of Caenorhabditis elegans, occurring as a transition between pronuclear migration and pronuclear fusion.\" [GOC:bf, ISBN:087969307X, PMID:10085292]","metadata":null},{"id":"18d747a21b984164a8d421b28becfbef","type":"GO_TERM","name":"centrosomal core","canonical_id":"go:GO:0140918","description":"\"The core region of the centrosome, a layered structure containing proteins, surrounded by the centrosomal corona. The core duplicates once per cell cycle at the G2/M transition when two outer layers form the mitotic spindle poles.\" [PMID:28104305, PMID:30413081]","metadata":null},{"id":"0a26ab61fed74bc8901417bbf84f2cf4","type":"GO_TERM","name":"centrosomal corona","canonical_id":"go:GO:0031592","description":"\"An amorphous structure surrounding the core of the centrosome, from which microtubules are nucleated; contains gamma-tubulin.\" [GOC:kp, GOC:mah]","metadata":null},{"id":"031bea67b60248e898ebd223744cb427","type":"GO_TERM","name":"centrosome","canonical_id":"go:GO:0005813","description":"\"A structure comprised of a core structure (in most organisms, a pair of centrioles) and peripheral material from which a microtubule-based structure, such as a spindle apparatus, is organized. Centrosomes occur close to the nucleus during interphase in many eukaryotic cells, though in animal cells it changes continually during the cell-division cycle.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"69d53dda7f9a4012ac26567a7878744e","type":"GO_TERM","name":"centrosome cycle","canonical_id":"go:GO:0007098","description":"\"The cell cycle process in which centrosome duplication and separation takes place. The centrosome cycle can operate with a considerable degree of independence from other processes of the cell cycle.\" [ISBN:0815316194]","metadata":null},{"id":"8ccdbab1a91f4078815d6997689e9b59","type":"GO_TERM","name":"centrosome duplication","canonical_id":"go:GO:0051298","description":"\"The replication of a centrosome, a structure comprised of a pair of centrioles and peri-centriolar material from which a microtubule spindle apparatus is organized.\" [GOC:ai]","metadata":null},{"id":"5a53767b1d5441158dd4c1136dc6eec3","type":"GO_TERM","name":"centrosome localization","canonical_id":"go:GO:0051642","description":"\"Any process in which a centrosome is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"2ab3395868d4495eab9d72b9fdc4c26b","type":"GO_TERM","name":"centrosome separation","canonical_id":"go:GO:0051299","description":"\"The process in which duplicated centrosome components move away from each other. The centriole pair within each centrosome becomes part of a separate microtubule organizing center that nucleates a radial array of microtubules called an aster. The two asters move to opposite sides of the nucleus to form the two poles of the mitotic spindle.\" [GOC:ai]","metadata":null},{"id":"8c6e2f136a37455e989d7390d6d58210","type":"GO_TERM","name":"centrosome-templated microtubule nucleation","canonical_id":"go:GO:0090222","description":"\"The 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates from the centrosome.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"f6387b3b2102450c83ee39353fcbeb53","type":"GO_TERM","name":"cephalic furrow formation","canonical_id":"go:GO:0007376","description":"\"Formation of a partial necklace of inturning tissue on the lateral sides of the embryo, along the dorsal-ventral axis. This furrow demarcates head from thorax in the developing protostome.\" [ISBN:0879694238]","metadata":null},{"id":"632f03cc6ea746c389f51501d72c7108","type":"GO_TERM","name":"cephalosporin C biosynthetic process","canonical_id":"go:GO:1901268","description":"\"The chemical reactions and pathways resulting in the formation of cephalosporin C.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00172]","metadata":null},{"id":"1c8711d194b84c00bd85bbb4e049c7d8","type":"GO_TERM","name":"cephalosporin C catabolic process","canonical_id":"go:GO:1901267","description":"\"The chemical reactions and pathways resulting in the breakdown of cephalosporin C.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00172]","metadata":null},{"id":"f78bbc7f542547a8b9191d380c6c2315","type":"GO_TERM","name":"cephalosporin biosynthetic process","canonical_id":"go:GO:0043646","description":"\"The chemical reactions and pathways resulting in the formation of a cephalosporin, any of large class of tetracyclic triterpene broad-spectrum antibiotics similar both chemically and in their mode of action to penicillin, first isolated from the culture filtrates of mediterranean fungus acremonium (cephalosporium acremonium), and effective against gram-positive bacteria.\" [GOC:jl, Wikipedia:Cephalosporin]","metadata":null},{"id":"23ffaee1c1a4493e9a6fa7071e9089ee","type":"GO_TERM","name":"cephalosporin-C deacetylase activity","canonical_id":"go:GO:0047739","description":"\"Catalysis of the reaction: cephalosporin C + H2O = acetate + deacetylcephalosporin C + H+.\" [EC:3.1.1.41, RHEA:22596]","metadata":null},{"id":"88c36870ac894cbdbcb8f714abf478b2","type":"GO_TERM","name":"cephalosporin-C:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047740","description":"\"Catalysis of the reaction: (7R)-7-(5-carboxylato-5-oxopentanamido)deacetylcephalosporanate + D-glutamate = 2-oxoglutarate + cephalosporin C.\" [RHEA:14553]","metadata":null},{"id":"1714155b75514882ba40b66a619e9b7e","type":"GO_TERM","name":"cephamycin C biosynthetic process","canonical_id":"go:GO:1901118","description":"\"The chemical reactions and pathways resulting in the formation of cephamycin C.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00183]","metadata":null},{"id":"d7e5f9cb979c4d7ba5239939d37fa393","type":"GO_TERM","name":"cephamycin C catabolic process","canonical_id":"go:GO:1901117","description":"\"The chemical reactions and pathways resulting in the breakdown of cephamycin C.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00183]","metadata":null},{"id":"319a31bcac4941c8b22e7a05394a4166","type":"GO_TERM","name":"ceramide 1-phosphate binding","canonical_id":"go:GO:1902387","description":"\"Binding to ceramide 1-phosphate.\" [GOC:TermGenie, PMID:23863933]","metadata":null},{"id":"284a2ea9bef04646bc1a53d5b8a1c1a4","type":"GO_TERM","name":"ceramide 1-phosphate transfer activity","canonical_id":"go:GO:1902388","description":"\"Removes a ceramide 1-phosphate from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:TermGenie, PMID:23863933]","metadata":null},{"id":"f2c1dd970b3147c482cfa0f581f499df","type":"GO_TERM","name":"ceramide 1-phosphate transport","canonical_id":"go:GO:1902389","description":"\"The directed movement of a ceramide 1-phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie, PMID:23863933]","metadata":null},{"id":"6c625052c55041c2b7749ea655221ec9","type":"GO_TERM","name":"ceramide binding","canonical_id":"go:GO:0097001","description":"\"Binding to a ceramide, a class of lipids composed of sphingosine linked to a fatty acid. Ceramides are a major component of cell membranes.\" [GOC:sart]","metadata":null},{"id":"8555b1dd79ff4e0b971c9a1dc5df1584","type":"GO_TERM","name":"ceramide biosynthetic process","canonical_id":"go:GO:0046513","description":"\"The chemical reactions and pathways resulting in the formation of ceramides, any N-acylated sphingoid.\" [GOC:ai]","metadata":null},{"id":"f76dac144b434c40b5e807576a86c65e","type":"GO_TERM","name":"ceramide catabolic process","canonical_id":"go:GO:0046514","description":"\"The chemical reactions and pathways resulting in the breakdown of ceramides, any N-acetylated sphingoid.\" [GOC:ai]","metadata":null},{"id":"1a4ad693e43b4de69504ee3d9e73bd7e","type":"GO_TERM","name":"ceramide cholinephosphotransferase activity","canonical_id":"go:GO:0047493","description":"\"Catalysis of the reaction: CDP-choline + ceramide = CMP + H+ + sphingomyelin.\" [EC:2.7.8.3, RHEA:16273]","metadata":null},{"id":"e6abec0c3c8e4c7e8b9d42c4093ee6d0","type":"GO_TERM","name":"ceramide floppase activity","canonical_id":"go:GO:0099038","description":"\"Catalysis of the movement of ceramide from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [GOC:BHF, GOC:dos, GOC:rl]","metadata":null},{"id":"d73ac62643654a519dc9bccbd81f6fe0","type":"GO_TERM","name":"ceramide glucosyltransferase activity","canonical_id":"go:GO:0008120","description":"\"Catalysis of the reaction: an N-acylsphing-4-enine + UDP-alpha-D-glucose = a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine + H+ + UDP.\" [RHEA:12088]","metadata":null},{"id":"b411c2b2657f4fa891f41998198fa526","type":"GO_TERM","name":"ceramide kinase activity","canonical_id":"go:GO:0001729","description":"\"Catalysis of the reaction: an N-acylsphing-4-enine + ATP = ADP + an N-acylsphing-4-enine 1-phosphate + H+.\" [EC:2.7.1.138]","metadata":null},{"id":"55b4887e81c8449b8b1f6ad444b2b1f8","type":"GO_TERM","name":"ceramide metabolic process","canonical_id":"go:GO:0006672","description":"\"The chemical reactions and pathways involving ceramides, any N-acylated sphingoid.\" [ISBN:0198547684]","metadata":null},{"id":"0f22cbc1a0214f4bba97c2ecf8ed4631","type":"GO_TERM","name":"ceramide phosphoethanolamine biosynthetic process","canonical_id":"go:GO:1905373","description":"\"The chemical reactions and pathways resulting in the formation of ceramide phosphoethanolamine.\" [GO_REF:0000068, GOC:hjd, GOC:TermGenie, PMID:25667419]","metadata":null},{"id":"96748a325f6b4d5f8860e596bcd39827","type":"GO_TERM","name":"ceramide phosphoethanolamine catabolic process","canonical_id":"go:GO:1905372","description":"\"The chemical reactions and pathways resulting in the breakdown of ceramide phosphoethanolamine.\" [GO_REF:0000068, GOC:hjd, GOC:TermGenie, PMID:25667419]","metadata":null},{"id":"ad2fcad670824ac5aa4f2dde5cad0bb8","type":"GO_TERM","name":"ceramide phosphoethanolamine synthase activity","canonical_id":"go:GO:0002950","description":"\"Catalysis of the reaction: an N-acyl-sphingoid base + CDP-ethanolamine = an N-acyl-sphingoid 1-phosphoethanolamine + CMP + H+.\" [EC:2.7.8.48, PMID:25667419]","metadata":null},{"id":"8cb09d7aa00642daa087795a222338da","type":"GO_TERM","name":"ceramide transfer activity","canonical_id":"go:GO:0120017","description":"\"Removes a ceramide from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"df174110cc284646889c5664699df31d","type":"GO_TERM","name":"ceramide translocation","canonical_id":"go:GO:0099040","description":"\"The movement of a ceramide molecule from one leaflet of a membrane bilayer to the opposite leaflet.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"ab9c76eef5ab4444b82613a408d3d065","type":"GO_TERM","name":"ceramide transport","canonical_id":"go:GO:0035627","description":"\"The directed movement of ceramides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Ceramides are a class of lipid composed of sphingosine linked to a fatty acid.\" [GOC:bf, GOC:sart]","metadata":null},{"id":"ac8a9b8209f749919af69fd2fdd3b24f","type":"GO_TERM","name":"ceramide-1-phosphate phosphatase activity","canonical_id":"go:GO:0106235","description":"\"Catalysis of the reaction: ceramide-1-phosphate + H2O = ceramide+ phosphate.\" [GOC:lb, PMID:10359651]","metadata":null},{"id":"d56045b0e82b42ba806ea460a484d554","type":"GO_TERM","name":"cerebellar Golgi cell differentiation","canonical_id":"go:GO:0021701","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature cerebellar Golgi cell. Differentiation includes the processes involved in commitment of a neuroblast to a Golgi cell fate. A cerebellar Golgi cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"0e35672611d04bd993a3833b5a3130bf","type":"GO_TERM","name":"cerebellar Golgi cell to granule cell synapse","canonical_id":"go:GO:0099192","description":"\"A synapse formed by a cerebellar Golgi cell synapsing on to a cerebellar granule cell.\" [PMID:26134650]","metadata":null},{"id":"b8014f04f7f44e64ad6277bab2546ab1","type":"GO_TERM","name":"cerebellar Purkinje cell differentiation","canonical_id":"go:GO:0021702","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature cerebellar Purkinje cell. Differentiation includes the processes involved in commitment of a neuroblast to a Purkinje cell fate. A Purkinje cell is an inhibitory GABAergic neuron found in the cerebellar cortex that projects to the deep cerebellar nuclei and brain stem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"7e55e63504134b25b025265074d6e3a4","type":"GO_TERM","name":"cerebellar Purkinje cell layer development","canonical_id":"go:GO:0021680","description":"\"The process whose specific outcome is the progression of the cerebellar Purkinje cell layer over time, from its formation to the mature structure. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d65e07c615dc4c2aa11d27a3fca4a5c1","type":"GO_TERM","name":"cerebellar Purkinje cell layer formation","canonical_id":"go:GO:0021694","description":"\"The process that gives rise to the cerebellar Purkinje cell layer. This process pertains to the initial formation of a structure from unspecified parts. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"10d695eef88f4d18b2688b517dd6b208","type":"GO_TERM","name":"cerebellar Purkinje cell layer maturation","canonical_id":"go:GO:0021691","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the cerebellar Purkinje cell layer to attain its fully functional state. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8bc1864b14024df586138c0e8991c0ff","type":"GO_TERM","name":"cerebellar Purkinje cell layer morphogenesis","canonical_id":"go:GO:0021692","description":"\"The process in which the anatomical structure of the cerebellar Purkinje cell layer is generated and organized. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"190a6dacee45433b880f37c50a1010c1","type":"GO_TERM","name":"cerebellar Purkinje cell layer structural organization","canonical_id":"go:GO:0021693","description":"\"The process that contributes to the act of creating the structural organization of the cerebellar Purkinje cell layer. This process pertains to the physical shaping of a rudimentary structure. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"582a3f648aea45d2bfabe1919e6fc7c1","type":"GO_TERM","name":"cerebellar Purkinje cell precursor proliferation","canonical_id":"go:GO:0021925","description":"\"The multiplication or reproduction of neuroblasts that will give rise to Purkinje cells. A Purkinje cell is an inhibitory GABAergic neuron found in the cerebellar cortex that projects to the deep cerebellar nuclei and brain stem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"05cf9ce8c130417bbcd207bdb7f432e5","type":"GO_TERM","name":"cerebellar Purkinje cell-granule cell precursor cell signaling","canonical_id":"go:GO:0021937","description":"\"Any process that mediates the transfer of information from Purkinje cells to granule cell precursors.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725, PMID:32554107]","metadata":null},{"id":"30fd0ba56959444da9e69ceca469f62b","type":"GO_TERM","name":"cerebellar basket cell differentiation","canonical_id":"go:GO:0021709","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature cerebellar basket cell. Differentiation includes the processes involved in commitment of a neuroblast to a cerebellar basket cell fate. A cerebellar basket cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"047172d7b08245639ac53c870ef554a5","type":"GO_TERM","name":"cerebellar climbing fiber to Purkinje cell synapse","canonical_id":"go:GO:0150053","description":"\"A synapse of a climbing fiber onto the dendrites of a Purkinje cell in cerebellum. The climbing fiber originates from the inferior olivary nucleus of the medulla oblongata.\" [GOC:aruk, GOC:bc, PMID:19597563, PMID:23811844, PMID:5044254]","metadata":null},{"id":"771f38233800496aa54976ee40c54d0c","type":"GO_TERM","name":"cerebellar cortex development","canonical_id":"go:GO:0021695","description":"\"The process whose specific outcome is the progression of the cerebellar cortex over time, from its formation to the mature structure. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"19ad47f1a2144154ad570e1b2260b5d2","type":"GO_TERM","name":"cerebellar cortex formation","canonical_id":"go:GO:0021697","description":"\"The process that gives rise to the cerebellar cortex. This process pertains to the initial formation of a structure from unspecified parts. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8f5fa39b04c14627bbcad64fcddf97e2","type":"GO_TERM","name":"cerebellar cortex maturation","canonical_id":"go:GO:0021699","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the cerebellar cortex to attain its fully functional state. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"5ea56e27695c4e8985eec2c2fb6e1367","type":"GO_TERM","name":"cerebellar cortex morphogenesis","canonical_id":"go:GO:0021696","description":"\"The process in which the anatomical structure of the cranial nerves are generated and organized. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8cad146f07104c80a386997ce3d1f398","type":"GO_TERM","name":"cerebellar cortex structural organization","canonical_id":"go:GO:0021698","description":"\"The process that contributes to the act of creating the structural organization of the cerebellar cortex. This process pertains to the physical shaping of a rudimentary structure. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"6c651378e7bd42a6bb827a1b2a384466","type":"GO_TERM","name":"cerebellar granular layer development","canonical_id":"go:GO:0021681","description":"\"The process whose specific outcome is the progression of the cerebellar granule layer over time, from its formation to the mature structure. The granular layer is the innermost layer of the cerebellar cortex. This layer contains densely packed small neurons, mostly granule cells. Some Golgi cells are found at the outer border. Granule neurons send parallel fibers to the upper molecular layer, where they synapse with Purkinje cell dendrites. Mossy fibers from the pontine nuclei in the white matter synapse with granule cell axons, Golgi cell axons and unipolar brush interneuron axons at cerebellar glomeruli in the granule cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"7a3f7e0ca36547238d423f5b0af1c18b","type":"GO_TERM","name":"cerebellar granular layer formation","canonical_id":"go:GO:0021684","description":"\"The process that gives rise to the cerebellar granule layer. This process pertains to the initial formation of a structure from unspecified parts. The granular layer is the innermost layer of the cerebellar cortex. This layer contains densely packed small neurons, mostly granule cells. Some Golgi cells are found at the outer border. Granule neurons send parallel fibers to the upper molecular layer, where they synapse with Purkinje cell dendrites. Mossy fibers from the pontine nuclei in the white matter synapse with granule cell axons, Golgi cell axons and unipolar brush interneuron axons at cerebellar glomeruli in the granule cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"62a4db2a4731460e83fc1e5183f2e3e0","type":"GO_TERM","name":"cerebellar granular layer maturation","canonical_id":"go:GO:0021686","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the cerebellar granular layer to attain its fully functional state. The granular layer is the innermost layer of the cerebellar cortex. This layer contains densely packed small neurons, mostly granule cells. Some Golgi cells are found at the outer border. Granule neurons send parallel fibers to the upper molecular layer, where they synapse with Purkinje cell dendrites. Mossy fibers from the pontine nuclei in the white matter synapse with granule cell axons, Golgi cell axons and unipolar brush interneuron axons at cerebellar glomeruli in the granule cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"978c2c212e8e44a9ac124dee533093db","type":"GO_TERM","name":"cerebellar granular layer morphogenesis","canonical_id":"go:GO:0021683","description":"\"The process in which the anatomical structure of the cerebellar granular layer is generated and organized. The granular layer is the innermost layer of the cerebellar cortex. This layer contains densely packed small neurons, mostly granule cells. Some Golgi cells are found at the outer border. Granule neurons send parallel fibers to the upper molecular layer, where they synapse with Purkinje cell dendrites. Mossy fibers from the pontine nuclei in the white matter synapse with granule cell axons, Golgi cell axons and unipolar brush interneuron axons at cerebellar glomeruli in the granule cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"31bcb07ff7f94b24952f9a540c7669a9","type":"GO_TERM","name":"cerebellar granular layer structural organization","canonical_id":"go:GO:0021685","description":"\"The process that contributes to the act of creating the structural organization of the cerebellar granule layer. This process pertains to the physical shaping of a rudimentary structure. The granular layer is the innermost layer of the cerebellar cortex. This layer contains densely packed small neurons, mostly granule cells. Some Golgi cells are found at the outer border. Granule neurons send parallel fibers to the upper molecular layer, where they synapse with Purkinje cell dendrites. Mossy fibers from the pontine nuclei in the white matter synapse with granule cell axons, Golgi cell axons and unipolar brush interneuron axons at cerebellar glomeruli in the granule cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"b2cf64ce27ae40d1ae9a297acc771cf8","type":"GO_TERM","name":"cerebellar granule cell differentiation","canonical_id":"go:GO:0021707","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature cerebellar granule cell. Differentiation includes the processes involved in commitment of a neuroblast to a granule cell fate. A granule cell is a glutamatergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"e8f44b60f5b8486fbd70e1fbac557ff9","type":"GO_TERM","name":"cerebellar granule cell precursor proliferation","canonical_id":"go:GO:0021930","description":"\"The multiplication or reproduction of neuroblasts that will give rise to granule cells. A granule cell is a glutamatergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"5445d2f743bc4b9b99aa82d2dce83aa5","type":"GO_TERM","name":"cerebellar granule cell precursor tangential migration","canonical_id":"go:GO:0021935","description":"\"The early migration of granule cell precursors in which cells move orthogonal to the direction of radial migration and ultimately cover the superficial zone of the cerebellar primordium.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"c6ef7ecec4104dc98eb6eb0998a95b9e","type":"GO_TERM","name":"cerebellar granule cell to Purkinje cell synapse","canonical_id":"go:GO:0150048","description":"\"A synapse of a granule cell fiber onto the dendrites of a Purkinje cell in cerebellum.\" [GOC:aruk, GOC:bc, PMID:12427822]","metadata":null},{"id":"4a779eb07c874a7995b502fd5d55c434","type":"GO_TERM","name":"cerebellar molecular layer development","canonical_id":"go:GO:0021679","description":"\"The process whose specific outcome is the progression of the cerebellar molecular layer nerve over time, from its formation to the mature structure. The molecular layer is the outermost layer of the cerebellar cortex. It contains the parallel fibers of the granule cells, interneurons such as stellate and basket cells, and the dendrites of the underlying Purkinje cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"b1f470c905f146ae9a9c5eb88e310543","type":"GO_TERM","name":"cerebellar molecular layer formation","canonical_id":"go:GO:0021688","description":"\"The process that gives rise to the cerebellar molecular layer. This process pertains to the initial formation of a structure from unspecified parts. The molecular layer is the outermost layer of the cerebellar cortex. It contains the parallel fibers of the granule cells, interneurons such as stellate and basket cells, and the dendrites of the underlying Purkinje cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"f3ba6d465f9848ee95fb975ef1e27880","type":"GO_TERM","name":"cerebellar molecular layer maturation","canonical_id":"go:GO:0021690","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the cerebellar molecular layer to attain its fully functional state. The molecular layer is the outermost layer of the cerebellar cortex. It contains the parallel fibers of the granule cells, interneurons such as stellate and basket cells, and the dendrites of the underlying Purkinje cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"584ae9d9be1044f8bff3ecd653d6e45f","type":"GO_TERM","name":"cerebellar molecular layer morphogenesis","canonical_id":"go:GO:0021687","description":"\"The process in which the anatomical structure of the cerebellar molecular layer is generated and organized. The molecular layer is the outermost layer of the cerebellar cortex. It contains the parallel fibers of the granule cells, interneurons such as stellate and basket cells, and the dendrites of the underlying Purkinje cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"b83d8a7be6564791871b3256855883b1","type":"GO_TERM","name":"cerebellar molecular layer structural organization","canonical_id":"go:GO:0021689","description":"\"The process that contributes to the act of creating the structural organization of the cerebellar molecular layer. This process pertains to the physical shaping of a rudimentary structure. The molecular layer is the outermost layer of the cerebellar cortex. It contains the parallel fibers of the granule cells, interneurons such as stellate and basket cells, and the dendrites of the underlying Purkinje cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"c49b174434ae4d1bb64e585fbdb3bda3","type":"GO_TERM","name":"cerebellar mossy fiber","canonical_id":"go:GO:0044300","description":"\"An axon arising from cerebellar projecting cells in the cochlea, vestibular nuclei, spinal cord, reticular formation, cerebellar nuclei and basilar pontine nuclei. Mossy fibers enter through all three cerebellar peduncles and send collaterals to the deep cerebellar nuclei, then branch in the white matter and terminate in the granule cell layer. Through this branching, a given mossy fiber can innervate several folia. Mossy fibers synapse on granule cells. The synaptic contacts are made at enlargements along the length of the mossy fiber called mossy fiber rosettes. The enlargements of the rosettes give the axons a mossy-looking appearance in Golgi stained preparations.\" [NIF_Subcellular:nlx_subcell_20090209]","metadata":null},{"id":"ed2bb845e24b46ae99085b26eedbcdf0","type":"GO_TERM","name":"cerebellar neuron development","canonical_id":"go:GO:0098749","description":"\"The process whose specific outcome is the progression of a cerebellar neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dos]","metadata":null},{"id":"5a1ab8cf244742f8bb6f65356e3931d6","type":"GO_TERM","name":"cerebellar stellate cell differentiation","canonical_id":"go:GO:0021710","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature cerebellar stellate cell. Differentiation includes the processes involved in commitment of a neuroblast to a cerebellar stellate cell fate. A cerebellar stellate cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"2c2eb441c58c461ca54f2fe30397cfaa","type":"GO_TERM","name":"cerebellar unipolar brush cell differentiation","canonical_id":"go:GO:0021711","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature unipolar brush cell in the cerebellum. Differentiation includes the processes involved in commitment of a neuroblast to a unipolar brush cell fate. A unipolar brush cell is a glutamatergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"ce64fec7047d4378a0d096f739e6731a","type":"GO_TERM","name":"cerebellum development","canonical_id":"go:GO:0021549","description":"\"The process whose specific outcome is the progression of the cerebellum over time, from its formation to the mature structure. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. In mice, the cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"11c304138d3c473c973197faa680a55c","type":"GO_TERM","name":"cerebellum formation","canonical_id":"go:GO:0021588","description":"\"The process that gives rise to the cerebellum. This process pertains to the initial formation of a structure from unspecified parts. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. The cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"25f9b7f02c7a4962851c61eeac8aed93","type":"GO_TERM","name":"cerebellum maturation","canonical_id":"go:GO:0021590","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the cerebellum to attain its fully functional state. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. The cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"1823f9a405334405ac98fe5b8ff6d033","type":"GO_TERM","name":"cerebellum morphogenesis","canonical_id":"go:GO:0021587","description":"\"The process in which the anatomical structure of the cerebellum is generated and organized. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. The cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"be48ae9d6d5f427db7713eef67d5a474","type":"GO_TERM","name":"cerebellum structural organization","canonical_id":"go:GO:0021589","description":"\"The process that contributes to the act of creating the structural organization of the cerebellum. This process pertains to the physical shaping of a rudimentary structure. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. The cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"b87c49d6a6ad487daea08e060e2fcf87","type":"GO_TERM","name":"cerebellum vasculature development","canonical_id":"go:GO:0061300","description":"\"The process whose specific outcome is the progression of the vasculature of the cerebellum over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"81b651eb103a468fa285b956bd7483f7","type":"GO_TERM","name":"cerebellum vasculature morphogenesis","canonical_id":"go:GO:0061301","description":"\"The process in which the vasculature of the cerebellum is generated and organized.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"d57848be08454447afebcdb16f26e9d4","type":"DISEASE","name":"cerebral atherosclerosis","canonical_id":"mondo:0006694","description":null,"metadata":null},{"id":"4d43282b70a2443d8afe698b875a7034","type":"GO_TERM","name":"cerebral blood circulation","canonical_id":"go:GO:0120275","description":"\"The flow of blood through the network of arteries and veins supplying the cerebrum, enabling the transport of nutrients to the tissues and the removal of waste products.\" [GOC:krc, PMID:25397684]","metadata":null},{"id":"a597becf683148b994c4fea7cd2c71ce","type":"GO_TERM","name":"cerebral cortex GABAergic interneuron development","canonical_id":"go:GO:0021894","description":"\"The process whose specific outcome is the progression of a cerebral cortex GABAergic interneuron over time, from initial commitment to its fate, to the fully functional differentiated cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"53ef2083986f4d41b5ea92f80c890d49","type":"GO_TERM","name":"cerebral cortex GABAergic interneuron differentiation","canonical_id":"go:GO:0021892","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a GABAergic interneuron residing in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"be39f7f806d548a3ab389fd701510622","type":"GO_TERM","name":"cerebral cortex GABAergic interneuron fate commitment","canonical_id":"go:GO:0021893","description":"\"The process in which the developmental fate of a neuroblast becomes restricted such that it will develop into a GABAergic interneuron residing in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"e2260dc6fd7c44e0b804f57baeb783f6","type":"GO_TERM","name":"cerebral cortex GABAergic interneuron migration","canonical_id":"go:GO:0021853","description":"\"The migration of GABAergic interneuron precursors from the subpallium to the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"f30b832ec9c842bbb2fb2ca47bf2f417","type":"GO_TERM","name":"cerebral cortex cell migration","canonical_id":"go:GO:0021795","description":"\"The orderly movement of cells from one site to another in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6ce6998b1f8347b89bc2ac8e98dc835e","type":"GO_TERM","name":"cerebral cortex development","canonical_id":"go:GO:0021987","description":"\"The progression of the cerebral cortex over time from its initial formation until its mature state. The cerebral cortex is the outer layered region of the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"bf121adefb6540e3817a771366f8cee9","type":"GO_TERM","name":"cerebral cortex neuron differentiation","canonical_id":"go:GO:0021895","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron residing in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"daa7fcfdfdc441c68c06143d226e008c","type":"GO_TERM","name":"cerebral cortex radial glia-guided migration","canonical_id":"go:GO:0021801","description":"\"The radial migration of neuronal or glial precursor cells along radial glial cells during the development of the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"acd6a3943d274f3494afe619b73d5688","type":"GO_TERM","name":"cerebral cortex radially oriented cell migration","canonical_id":"go:GO:0021799","description":"\"The migration of cells in the developing cerebral cortex in which cells move from the ventricular and/or subventricular zone toward the surface of the brain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"4c2c1c220de948f5a490e9b07bde30fb","type":"GO_TERM","name":"cerebral cortex regionalization","canonical_id":"go:GO:0021796","description":"\"The regionalization process that results in the creation of areas within the cerebral cortex that will direct the behavior of cell migration and differentiation as the cortex develops.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2b7c34d1c4114df183788dccdbf8268a","type":"GO_TERM","name":"cerebral cortex tangential migration","canonical_id":"go:GO:0021800","description":"\"The migration of cells in the cerebral cortex in which cells move orthogonally to the direction of radial migration and do not use radial glial cell processes as substrates for migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"113a56e515154ea9b05b8cf6955912e7","type":"GO_TERM","name":"cerebral cortex tangential migration using cell-axon interactions","canonical_id":"go:GO:0021824","description":"\"The movement of cerebral cortex neuronal precursors tangentially through the cortex using interaction of the migrating cells with axons of other neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"87a918df185a4742a242bcc9b381af81","type":"GO_TERM","name":"cerebral cortex tangential migration using cell-cell interactions","canonical_id":"go:GO:0021823","description":"\"The process in which neurons interact with each other to promote migration along a tangential plane.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"ade6631296804ef2911e790dac649c7c","type":"DISEASE","name":"cerebral infarction","canonical_id":"mondo:0002679","description":null,"metadata":null},{"id":"909dff1c2c3f43edbad969ca9e1a40b5","type":"DISEASE","name":"cerebral palsy","canonical_id":"mondo:0006497","description":null,"metadata":null},{"id":"4e001c0ece3442e6b13fd8a7a4dc0f8a","type":"GO_TERM","name":"cerebroside transfer activity","canonical_id":"go:GO:0140340","description":"\"Directly binding to a cerebroside and delivering it either to an acceptor molecule or to a specific location.\" [PMID:9132017]","metadata":null},{"id":"8987d98a7374437db450b9d63fcace40","type":"GO_TERM","name":"cerebroside-sulfatase activity","canonical_id":"go:GO:0004098","description":"\"Catalysis of the reaction: a cerebroside 3-sulfate + H2O = a cerebroside + sulfate.\" [EC:3.1.6.8]","metadata":null},{"id":"b4c78703648940669be8ea9f85e58069","type":"GO_TERM","name":"cerebrospinal fluid circulation","canonical_id":"go:GO:0090660","description":"\"The neurological system process driven by motile cilia on ependymal cells of the brain by which cerebrospinal fluid circulates from the sites of secretion to the sites of absorption. In ventricular cavities, the flow is unidirectional and rostrocaudal, in subarachnoid spaces, the flow is multi-directional.\" [GOC:mgi_curators, PMID:22100360, PMID:24229449]","metadata":null},{"id":"0a9b65a4bbc54ff3a0aefb41f34240ca","type":"GO_TERM","name":"cerebrospinal fluid secretion","canonical_id":"go:GO:0033326","description":"\"The regulated release of cerebrospinal fluid (CSF) from the choroid plexus of the lateral, third and fourth ventricles. The cerebrospinal fluid is a clear liquid that located within the ventricles, spinal canal, and subarachnoid spaces.\" [GOC:ln, PMID:10716451]","metadata":null},{"id":"0de0d2b784974d95979a7f5085608833","type":"DISEASE","name":"cerebrotendinous xanthomatosis","canonical_id":"mondo:0008948","description":null,"metadata":null},{"id":"382b727e42f040e3a256d9739692ff97","type":"DRUG","name":"ceritinib","canonical_id":"gtopdb:7397","description":null,"metadata":null},{"id":"d2c0e2d1164648d784af98b7568a3f64","type":"DRUG","name":"ceritinib","canonical_id":"mesh:C586847","description":null,"metadata":null},{"id":"ae530f3a9f84440aa6e4d79d6903fe86","type":"DRUG","name":"ceritinib","canonical_id":"chembl:CHEMBL2403108","description":null,"metadata":null},{"id":"3902c6b40f53472381f64608248b2e71","type":"COMBINATION_TREATMENT","name":"ceritinib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-c7520f45083e2b39","description":null,"metadata":null},{"id":"4020e9f9411645c2af97bba558a8fa70","type":"DRUG","name":"cerivastatin","canonical_id":"gtopdb:2950","description":null,"metadata":null},{"id":"c5139e6c9fba4b48b4b77fb8d9317f6a","type":"DRUG","name":"cerliponase alfa","canonical_id":"mesh:C000621431","description":null,"metadata":null},{"id":"1139c00e714c412686895aa7651f8e48","type":"DRUG","name":"certolizumab pegol","canonical_id":"gtopdb:6774","description":null,"metadata":null},{"id":"ddb2acf5a9cb4ebaa8007438ce7fd443","type":"DRUG","name":"certolizumab pegol","canonical_id":"chembl:CHEMBL1201831","description":null,"metadata":null},{"id":"2b69cc30025b44e3b90f8afb8922bdf2","type":"COMBINATION_TREATMENT","name":"certolizumab pegol + leflunomide","canonical_id":"ctgov_combo:ctgov-combo-ba9bd9cdc139b41f","description":null,"metadata":null},{"id":"8c5ff53b96aa45828dfe900cbbc6e358","type":"DISEASE","name":"cervical cancer","canonical_id":"mondo:0002974","description":null,"metadata":null},{"id":"708bd05252ec42f0b0c526962dd869d4","type":"GO_TERM","name":"cervix development","canonical_id":"go:GO:0060067","description":"\"The reproductive developmental process whose specific outcome is the progression of the cervix over time, from its formation to the mature structure.\" [GOC:dph, GOC:ebc]","metadata":null},{"id":"2c5283311c07432ba8d9386d45b33401","type":"DRUG","name":"cetirizine","canonical_id":"gtopdb:1222","description":null,"metadata":null},{"id":"2ea15da4596644f3812729f69bbd0a86","type":"DRUG","name":"cetirizine","canonical_id":"mesh:D017332","description":null,"metadata":null},{"id":"b5d5d32ac4c249d68baf89966dbc3a5d","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-60ce2dbd932bdcaa","description":null,"metadata":null},{"id":"7e21f0156db44278bde181262401fa0f","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-c715a89dc2fa1308","description":null,"metadata":null},{"id":"97b5a5dde2c044868a8a14333720002b","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-0070dbc8be6b5cab","description":null,"metadata":null},{"id":"7bd438a1d4714571a935a683633ce6ea","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-05d39ee4e060ee3e","description":null,"metadata":null},{"id":"06b20c82e55b4580b70405ae5c286a82","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-cf465c58c003a299","description":null,"metadata":null},{"id":"217a307cae8b4974a53a25150ddf96ff","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-9ccbf07e8ca9faf7","description":null,"metadata":null},{"id":"fe3688bdebca41beb6a1d0cb53299395","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine","canonical_id":"ctgov_combo:ctgov-combo-1e4dc4ac77500de1","description":null,"metadata":null},{"id":"d0a749a35c7e48c5ae7ac42f600f7e60","type":"COMBINATION_TREATMENT","name":"cetirizine + desloratadine + fexofenadine","canonical_id":"ctgov_combo:ctgov-combo-dcd297c061261445","description":null,"metadata":null},{"id":"fed41c85410040b89e952d3bc5f690f4","type":"COMBINATION_TREATMENT","name":"cetirizine + diphenhydramine","canonical_id":"ctgov_combo:ctgov-combo-255f529d33b71998","description":null,"metadata":null},{"id":"633cc0a72cfd4719b45c98672650917c","type":"COMBINATION_TREATMENT","name":"cetirizine + disitamab vedotin","canonical_id":"ctgov_combo:ctgov-combo-77a67462c446259e","description":null,"metadata":null},{"id":"550b57e87e164d50912f80f610dba67a","type":"COMBINATION_TREATMENT","name":"cetirizine + famotidine","canonical_id":"ctgov_combo:ctgov-combo-53617d9ee6cfc2dc","description":null,"metadata":null},{"id":"843e97d8c78847d598acc6305e9dd038","type":"COMBINATION_TREATMENT","name":"cetirizine + fexofenadine","canonical_id":"ctgov_combo:ctgov-combo-a817db54913ab6b3","description":null,"metadata":null},{"id":"b0f0129ffc884aaca408eb18adc52332","type":"COMBINATION_TREATMENT","name":"cetirizine + montelukast","canonical_id":"ctgov_combo:ctgov-combo-ccea4ab01ae0bf95","description":null,"metadata":null},{"id":"ab47eed663944126a97189b8314184c3","type":"COMBINATION_TREATMENT","name":"cetirizine + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-d6e3b38b08a0673f","description":null,"metadata":null},{"id":"999f830b59694f90ae0fcf39be52477e","type":"GO_TERM","name":"cetraxate benzylesterase activity","canonical_id":"go:GO:0047741","description":"\"Catalysis of the reaction: benzyl cetraxate + H2O = benzyl alcohol + cetraxate + H+.\" [EC:3.1.1.70, RHEA:23460]","metadata":null},{"id":"1c50e18a79704de6bca4a7d68ecd25bc","type":"DRUG","name":"cetrorelix","canonical_id":"gtopdb:1190","description":null,"metadata":null},{"id":"2d58d910f9a04a0fb1e93e90a834d281","type":"COMBINATION_TREATMENT","name":"cetrorelix + degarelix","canonical_id":"ctgov_combo:ctgov-combo-04bcc2a3f26cccb2","description":null,"metadata":null},{"id":"f68f05f317fc46e7a36356960c743161","type":"COMBINATION_TREATMENT","name":"cetrorelix + degarelix","canonical_id":"ctgov_combo:ctgov-combo-4210c62b85ba3401","description":null,"metadata":null},{"id":"d3749e9bf35a4097b8c72f193cc511ce","type":"COMBINATION_TREATMENT","name":"cetrorelix + dydrogesterone","canonical_id":"ctgov_combo:ctgov-combo-ab281ec93abf1e15","description":null,"metadata":null},{"id":"4a79588aa05348a09fc15dc0435a5559","type":"COMBINATION_TREATMENT","name":"cetrorelix + dydrogesterone","canonical_id":"ctgov_combo:ctgov-combo-f57a7651439eeee0","description":null,"metadata":null},{"id":"e51c727b764845458a60324c3282435e","type":"COMBINATION_TREATMENT","name":"cetrorelix + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-8f52e64039187991","description":null,"metadata":null},{"id":"20fa30bc18dd4ba4a7f12f160a21a22e","type":"DRUG","name":"cetuximab","canonical_id":"gtopdb:6882","description":null,"metadata":null},{"id":"7ec2aa0d9aad4967b03364ee26c2d85c","type":"DRUG","name":"cetuximab","canonical_id":"mesh:D000068818","description":null,"metadata":null},{"id":"c3f23406e5fe437095f5e8e4a2c0083c","type":"DRUG","name":"cetuximab","canonical_id":"chembl:CHEMBL1201577","description":null,"metadata":null},{"id":"5d4e945ba15c4551872c5591e0f78033","type":"COMBINATION_TREATMENT","name":"cetuximab + envafolimab","canonical_id":"ctgov_combo:ctgov-combo-52830c3237770d38","description":null,"metadata":null},{"id":"d16878755d924b62abbe1aa8c3c4e858","type":"COMBINATION_TREATMENT","name":"cetuximab + neratinib","canonical_id":"ctgov_combo:ctgov-combo-9fccacf47de7522d","description":null,"metadata":null},{"id":"64860164adea42a98b51174a5a10d634","type":"COMBINATION_TREATMENT","name":"cetuximab + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-e1e19c29ccccfe92","description":null,"metadata":null},{"id":"393ab4c4803046198cd3d6a9687cb056","type":"COMBINATION_TREATMENT","name":"cetuximab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-7b49eade959585c8","description":null,"metadata":null},{"id":"e75391b5cf82487db11487bb03b48b13","type":"COMBINATION_TREATMENT","name":"cetuximab + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-829cef03df02a2fd","description":null,"metadata":null},{"id":"d708c9c608d64dde94f2f9d84b2539b2","type":"COMBINATION_TREATMENT","name":"cetuximab + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-59804e1237efa706","description":null,"metadata":null},{"id":"d1f643ab9cb5406980c4944b41915c99","type":"COMBINATION_TREATMENT","name":"cetuximab + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-f80c2bb39e46c9b0","description":null,"metadata":null},{"id":"87b1a8413d5e44d493ec6185d08306ce","type":"GO_TERM","name":"chaeta development","canonical_id":"go:GO:0022416","description":"\"The process whose specific outcome is the progression of a chaeta over time, from its formation to the mature structure. A chaeta is a sensory multicellular cuticular outgrowth of a specifically differentiated cell.\" [FBbt:00005177, GOC:bf, GOC:cjm, GOC:dos, GOC:isa_complete]","metadata":null},{"id":"6fb85f3367534dd38e949a4cd6c07a36","type":"GO_TERM","name":"chaeta morphogenesis","canonical_id":"go:GO:0008407","description":"\"The process in which the anatomical structures of the chaeta are generated and organized. A chaeta is a sensory multicellular cuticular outgrowth of a specifically differentiated cell.\" [FBbt:00005177, GOC:bf, GOC:cjm, GOC:curators, GOC:dos]","metadata":null},{"id":"e5693a96652e4df6904278ed439e42b2","type":"GO_TERM","name":"chalcone 4'-O-glucosyltransferase activity","canonical_id":"go:GO:0102890","description":"\"Catalysis of the reaction: UDP-alpha-D-glucose + 2',4,4',6'-tetrahydroxychalcone = UDP + 2',4,4',6'-tetrahydroxychalcone 4'-O-beta-D-glucoside + H+. Also converts 2',3,4,4',6'-pentahydroxychalcone + UDP-alpha-D-glucose into 2',3,4,4',6'-pentahydroxychalcone 4'-O-beta-D-glucoside.\" [EC:2.4.1.286]","metadata":null},{"id":"7eb8f093b5f74343aedcffc743ff91e4","type":"GO_TERM","name":"chalcone biosynthetic process","canonical_id":"go:GO:0009715","description":"\"The chemical reactions and pathways resulting in the formation of chalcone, phenyl steryl ketone or its hydroxylated derivatives.\" [GOC:curators]","metadata":null},{"id":"7f73309d8513455280fb6af01b1b8d86","type":"GO_TERM","name":"chalcone catabolic process","canonical_id":"go:GO:0046280","description":"\"The chemical reactions and pathways resulting in the breakdown of chalcone, phenyl steryl ketone or its hydroxylated derivatives.\" [GOC:ai]","metadata":null},{"id":"e3cfc3c192b249ac8edde2b8e447fb98","type":"GO_TERM","name":"chalcone isomerase activity","canonical_id":"go:GO:0045430","description":"\"Catalysis of the reaction: a chalcone = a flavanone.\" [EC:5.5.1.6]","metadata":null},{"id":"c45612704a9140afb9c5614d3c0fbb44","type":"GO_TERM","name":"channel activator activity","canonical_id":"go:GO:0099103","description":"\"Direct interaction with a channel (binding or modification), resulting in its opening. A channel catalyzes energy-independent facilitated diffusion, mediated by passage of a solute through a transmembrane aqueous pore or channel.\" [GOC:dos]","metadata":null},{"id":"b03f7157070e485aa93d038eb774c045","type":"GO_TERM","name":"channel activity","canonical_id":"go:GO:0015267","description":"\"Enables the energy-independent facilitated diffusion of a solute through a transmembrane aqueous pore or channel. Stereospecificity is not exhibited but this transport may be specific for a particular molecular species or class of molecules.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"4e5082bbfb894059871146b6e937562e","type":"GO_TERM","name":"channel complex","canonical_id":"go:GO:0170013","description":"\"A protein complex that spans a membrane and forms a water-filled channel across the phospholipid bilayer allowing selective ion transport down its electrochemical gradient.\" [PMID:10839820]","metadata":null},{"id":"bc240cc49ed24a91b1f491011117fd38","type":"GO_TERM","name":"channel inhibitor activity","canonical_id":"go:GO:0016248","description":"\"Binds to and stops, prevents, or reduces the activity of a channel.\" [GOC:mah]","metadata":null},{"id":"500ccae95f134855a3fbd9f892ff88a5","type":"GO_TERM","name":"channel regulator activity","canonical_id":"go:GO:0016247","description":"\"Binds to and modulates the activity of a channel. A channel catalyzes energy-independent facilitated diffusion, mediated by passage of a solute through a transmembrane aqueous pore or channel.\" [GOC:mah]","metadata":null},{"id":"b65e2eb50a5345b581dafd3bf9d64b2e","type":"GO_TERM","name":"channel-forming ionophore activity","canonical_id":"go:GO:0022886","description":"\"Enables transport of a solute across a membrane. This kind of transporter interacts much more weakly with the solute than the carrier does. It is an aqueous pore that extends across the membrane. It may change from closed to open and back. It transports faster than a carrier. It is always passive.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"1fd33bba79104797b9a5e309d8616e86","type":"DISEASE","name":"channelopathy-associated congenital insensitivity to pain, autosomal recessive","canonical_id":"mondo:0009459","description":null,"metadata":null},{"id":"c12668c05ead4de2b174c2b9cdb7b934","type":"GO_TERM","name":"chanoclavine-I aldehyde biosynthetic process","canonical_id":"go:GO:1900569","description":"\"The chemical reactions and pathways resulting in the formation of chanoclavine-I aldehyde. Chanoclavine-I aldehyde is at a branching point in the biosynthetic pathways of fumigaclavine C and ergotamine.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c4582c4623964a1c9073f3ffbd394ebd","type":"GO_TERM","name":"chaperone-mediated autophagy","canonical_id":"go:GO:0061684","description":"\"The autophagy process which begins when chaperones and co-chaperones recognize a target motif and unfold the substrate protein. The proteins are then transported to the lysosome where they are degraded.\" [GOC:pad, GOC:PARL, PMID:22743996, PMID:23434281]","metadata":null},{"id":"06187ad36bad491e8ad0e819ba3edf0a","type":"GO_TERM","name":"chaperone-mediated autophagy translocation complex","canonical_id":"go:GO:0061742","description":"\"A lysosomal membrane protein complex that enables the translocation of a target protein across the lysosomal membrane as part of chaperone-mediated autophagy.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:20797626]","metadata":null},{"id":"6b474ca13a3749db9f567c44670a09bc","type":"GO_TERM","name":"chaperone-mediated autophagy translocation complex assembly","canonical_id":"go:GO:1904763","description":"\"The aggregation, arrangement and bonding together of a set of components to form a chaperone-mediated autophagy translocation complex.\" [GO_REF:0000079, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:18644871]","metadata":null},{"id":"0f62de528cd94263973e3f1e99f7e8c1","type":"GO_TERM","name":"chaperone-mediated autophagy translocation complex disassembly","canonical_id":"go:GO:1904764","description":"\"The disaggregation of a chaperone-mediated autophagy translocation complex into its constituent components.\" [GO_REF:0000079, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:18644871]","metadata":null},{"id":"7c9691fa5fec4798bc1f62c1847fe6dc","type":"GO_TERM","name":"chaperone-mediated protein complex assembly","canonical_id":"go:GO:0051131","description":"\"The aggregation, arrangement and bonding together of a set of components to form a protein complex, mediated by chaperone molecules that do not form part of the finished complex.\" [GOC:ai]","metadata":null},{"id":"26486f2d8a4347a985f3811db3ea1180","type":"GO_TERM","name":"chaperonin ATPase complex","canonical_id":"go:GO:0016465","description":"\"Multisubunit protein complex with 2x7 (Type I, in most cells) or 2x8 (Type II, in Archaea) ATP-binding sites involved in maintaining an unfolded polypeptide structure before folding or to entry into mitochondria and chloroplasts.\" [PMID:24816391]","metadata":null},{"id":"ab2bbc25715d47c9a677da563403ab4e","type":"GO_TERM","name":"chaperonin-containing T-complex","canonical_id":"go:GO:0005832","description":"\"A multisubunit ring-shaped complex that mediates protein folding in the cytosol without a cofactor.\" [GOC:sgd_curators, PMID:11580267]","metadata":null},{"id":"186073627b124d96850601a9776cde09","type":"GO_TERM","name":"charged-tRNA amino acid modification","canonical_id":"go:GO:0019988","description":"\"The covalent alteration of an amino acid charged on a tRNA before it is incorporated into a protein, as in N-formylmethionine, selenocysteine or pyrrolysine.\" [GOC:jsg]","metadata":null},{"id":"22c43829aa1a4d6897f62e8956cdbe75","type":"GO_TERM","name":"cheating during chimeric sorocarp development","canonical_id":"go:GO:0099139","description":"\"Any process during chimeric sorocarp development that increases by which a cell increases the number of spore cells sharing its genotype at the expense of cells of other genotypes.\" [PMID:18272966]","metadata":null},{"id":"b330303ed5fa472f8d8c607fb20ee118","type":"GO_TERM","name":"checkpoint clamp complex","canonical_id":"go:GO:0030896","description":"\"Conserved heterotrimeric complex of PCNA-like proteins that is loaded onto DNA at sites of DNA damage.\" [PMID:12531008]","metadata":null},{"id":"4c2b5475502545d0903d7893ab2895c1","type":"GO_TERM","name":"chemical homeostasis","canonical_id":"go:GO:0048878","description":"\"Any biological process involved in the maintenance of an internal steady state of a chemical.\" [GOC:isa_complete]","metadata":null},{"id":"c7a575a5a16b4a3299071de9bb939c5b","type":"GO_TERM","name":"chemical synaptic transmission","canonical_id":"go:GO:0007268","description":"\"The vesicular release of classical neurotransmitter molecules from a presynapse, across a chemical synapse, the subsequent activation of neurotransmitter receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:jl, MeSH:D009435]","metadata":null},{"id":"9faea790f229443da3bd5d20467609fe","type":"GO_TERM","name":"chemical synaptic transmission, postsynaptic","canonical_id":"go:GO:0099565","description":"\"The part of synaptic transmission occurring in the post-synapse: a signal transduction pathway consisting of neurotransmitter receptor activation and its effects on postsynaptic membrane potential and the ionic composition of the postsynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"608d08cc1fe4463290536b04274e3932","type":"GO_TERM","name":"chemoattractant activity","canonical_id":"go:GO:0042056","description":"\"Providing the environmental signal that initiates the directed movement of a motile cell or organism towards a higher concentration of that signal.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"7bca9ecd24774d94adc3e126c41cc68a","type":"GO_TERM","name":"chemoattractant activity involved in axon guidance","canonical_id":"go:GO:1902379","description":"\"Any chemoattractant activity that is involved in axon guidance.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21658587]","metadata":null},{"id":"7b2c066166944234b6d4ce96636c3221","type":"GO_TERM","name":"chemoattraction of axon","canonical_id":"go:GO:0061642","description":"\"The process in which a neuron growth cone is directed to a specific target site in response to an attractive chemical signal.\" [GOC:dph, GOC:krc]","metadata":null},{"id":"62a9d6abaf934967a4ea380a05f1b04c","type":"GO_TERM","name":"chemoattraction of branchiomotor axon","canonical_id":"go:GO:0021792","description":"\"The process in which a branchiomotor neuron growth cone is directed to a specific target site in response to an attractive chemical signal. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"5951ebe4e4074ab6a47682d9c67c9a01","type":"GO_TERM","name":"chemoattraction of branchiomotor neuron axon in branchial arch mesenchyme","canonical_id":"go:GO:0021791","description":"\"The process in which a branchiomotor neuron growth cone in the branchial arch mesenchyme is directed to a specific target site in the branchial arch mesenchyme in response to an attractive chemical cue. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"4709787032614065aaa7903693290bd6","type":"GO_TERM","name":"chemoattraction of branchiomotor neuron axon in neural tube","canonical_id":"go:GO:0021788","description":"\"The process in which a branchiomotor neuron growth cone in the neural tube is directed to a specific target site in the neural tube in response to an attractive chemical cue. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"679ea891c330437e9304f3ce591629f4","type":"GO_TERM","name":"chemoattraction of dopaminergic neuron axon","canonical_id":"go:GO:0036516","description":"\"The process in which a dopaminergic neuron growth cone is directed to a specific target site in response to an attractive chemical signal.\" [GOC:bf, GOC:PARL, PMID:21106844]","metadata":null},{"id":"860b37993a8949a582aa55fdd0257eba","type":"GO_TERM","name":"chemoattraction of serotonergic neuron axon","canonical_id":"go:GO:0036517","description":"\"The process in which a serotonergic neuron growth cone is directed to a specific target site in response to an attractive chemical signal.\" [CL:0000850, GOC:bf, GOC:PARL, PMID:21106844]","metadata":null},{"id":"55818bd88fb6407385bf975eadd440e8","type":"GO_TERM","name":"chemokine (C-C motif) ligand 1 production","canonical_id":"go:GO:0071610","description":"\"The appearance of chemokine (C-C motif) ligand 1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"ad64a5d99ea848d5850ffc9631ddba04","type":"GO_TERM","name":"chemokine (C-C motif) ligand 11 production","canonical_id":"go:GO:0071954","description":"\"The appearance of chemokine (C-C motif) ligand 11 (CCL11, also known as eotaxin-1) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:9600955]","metadata":null},{"id":"2267fe18215b484da7f942ccfe0f1119","type":"GO_TERM","name":"chemokine (C-C motif) ligand 12 binding","canonical_id":"go:GO:0035716","description":"\"Binding to chemokine (C-C motif) ligand 12.\" [GOC:BHF]","metadata":null},{"id":"e5296b6dec6442e5bf7660151bf7eb47","type":"GO_TERM","name":"chemokine (C-C motif) ligand 17 production","canonical_id":"go:GO:0044809","description":"\"The appearance of chemokine (C-C motif) ligand 17 (CCL17) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"19b7cbda684d4bf4abeb6c052fbdeed3","type":"GO_TERM","name":"chemokine (C-C motif) ligand 19 binding","canonical_id":"go:GO:0035757","description":"\"Binding to chemokine (C-C motif) ligand 19.\" [GOC:BHF]","metadata":null},{"id":"c5baa5888b2a482bb44b1f31a1bc2866","type":"GO_TERM","name":"chemokine (C-C motif) ligand 19 production","canonical_id":"go:GO:0097388","description":"\"The appearance of chemokine (C-C motif) ligand 19 (CCL19) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"f5fc4bac05934a3d8d8d81ae2d9b21f7","type":"GO_TERM","name":"chemokine (C-C motif) ligand 19 signaling pathway","canonical_id":"go:GO:0038115","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL19 to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:15059845]","metadata":null},{"id":"c0647bf9e970453c81c41a2e506142dd","type":"GO_TERM","name":"chemokine (C-C motif) ligand 2 binding","canonical_id":"go:GO:0035715","description":"\"Binding to chemokine (C-C motif) ligand 2.\" [GOC:BHF]","metadata":null},{"id":"106eee2e6926434db4ab071337b061a5","type":"GO_TERM","name":"chemokine (C-C motif) ligand 2 signaling pathway","canonical_id":"go:GO:0038148","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL2 to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, Wikipedia:CCL2]","metadata":null},{"id":"fbf4bc688761480f8ac47cc2ca9704b8","type":"GO_TERM","name":"chemokine (C-C motif) ligand 20 production","canonical_id":"go:GO:0036392","description":"\"The appearance of chemokine (C-C motif) ligand 20 (CCL20) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:jc]","metadata":null},{"id":"f7010d04a9194fad8fe4d2cbf5e6f1b9","type":"GO_TERM","name":"chemokine (C-C motif) ligand 21 binding","canonical_id":"go:GO:0035758","description":"\"Binding to chemokine (C-C motif) ligand 21.\" [GOC:BHF]","metadata":null},{"id":"ebf16955983f45009b4b0ba887971f14","type":"GO_TERM","name":"chemokine (C-C motif) ligand 21 production","canonical_id":"go:GO:0097389","description":"\"The appearance of chemokine (C-C motif) ligand 21 (CCL21) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"96f9aa8e85c44d9b961b29d6eb8f91d5","type":"GO_TERM","name":"chemokine (C-C motif) ligand 21 signaling pathway","canonical_id":"go:GO:0038116","description":"\"The series of molecular signals initiated by the binding of the C-C chemokine CCL21 to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:15059845]","metadata":null},{"id":"b729889d06944e69b80846fe92c52181","type":"GO_TERM","name":"chemokine (C-C motif) ligand 22 production","canonical_id":"go:GO:0071924","description":"\"The appearance of chemokine (C-C motif) ligand 22 (CCL22) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:18832724]","metadata":null},{"id":"e82834c2a28d4d06affe185a03836997","type":"GO_TERM","name":"chemokine (C-C motif) ligand 4 production","canonical_id":"go:GO:0071606","description":"\"The appearance of chemokine (C-C motif) ligand 4 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"4bf461be360542758ff6d202ccb547bb","type":"GO_TERM","name":"chemokine (C-C motif) ligand 5 binding","canonical_id":"go:GO:0071791","description":"\"Binding to chemokine (C-C motif) ligand 5.\" [GOC:add, GOC:amm]","metadata":null},{"id":"9dc65a4cb66e459a87d7382f25f647ad","type":"GO_TERM","name":"chemokine (C-C motif) ligand 5 production","canonical_id":"go:GO:0071609","description":"\"The appearance of chemokine (C-C motif) ligand 5 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"453437fae3a142f888c657ab63bd185b","type":"GO_TERM","name":"chemokine (C-C motif) ligand 5 signaling pathway","canonical_id":"go:GO:0035689","description":"\"The series of molecular signals initiated by chemokine CCL5 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, PMID:18337562]","metadata":null},{"id":"33dc566c430f4a3d9b6d5c087815abee","type":"GO_TERM","name":"chemokine (C-C motif) ligand 6 production","canonical_id":"go:GO:0035530","description":"\"The appearance of chemokine (C-C motif) ligand 6 (CCL6) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, PMID:19812544]","metadata":null},{"id":"5fc7a05b79a54956b6b08516c44fea1d","type":"GO_TERM","name":"chemokine (C-C motif) ligand 7 binding","canonical_id":"go:GO:0035717","description":"\"Binding to chemokine (C-C motif) ligand 7.\" [GOC:BHF]","metadata":null},{"id":"a9825aa456ea453684a1a69fba190102","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 1 production","canonical_id":"go:GO:0072566","description":"\"The appearance of chemokine (C-X-C motif) ligand 1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"fc7b0f04fd2148aa8c4aece0bbcb0573","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 12 production","canonical_id":"go:GO:0097390","description":"\"The appearance of chemokine (C-X-C motif) ligand 12 (CXCL12) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"50f442194341497ebb5196872cdf3b49","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 12 signaling pathway","canonical_id":"go:GO:0038146","description":"\"The series of molecular signals initiated by the binding of the chemokine CXCL12 to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, Wikipedia:Stromal_cell-derived_factor-1]","metadata":null},{"id":"797acecf8cb74af9abb75b5d41fc9141","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 13 production","canonical_id":"go:GO:0097391","description":"\"The appearance of chemokine (C-X-C motif) ligand 13 (CXCL13) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"6da44ecdc6a442f39c16b8cd78a8e621","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 16 production","canonical_id":"go:GO:0097392","description":"\"The appearance of chemokine (C-X-C motif) ligand 16 (CXCL16) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"6393773fcf4f48339b22b7f930249113","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 2 production","canonical_id":"go:GO:0072567","description":"\"The appearance of chemokine (C-X-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"59a8fcf13c10462784c86c63035488fe","type":"GO_TERM","name":"chemokine (C-X-C motif) ligand 9 production","canonical_id":"go:GO:0035393","description":"\"The appearance of chemokine (C-X-C motif) ligand 9 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add]","metadata":null},{"id":"aaa2dec920c341d7838e2b6e2d2d3455","type":"GO_TERM","name":"chemokine activity","canonical_id":"go:GO:0008009","description":"\"The function of a family of small chemotactic cytokines; their name is derived from their ability to induce directed chemotaxis in nearby responsive cells. All chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of cells during normal processes of tissue maintenance or development. Chemokines are found in all vertebrates, some viruses and some bacteria.\" [GOC:BHF, GOC:rl, PMID:12183377, Wikipedia:Chemokine]","metadata":null},{"id":"9dbe844984ef461ea9802ef2305d6233","type":"GO_TERM","name":"chemokine binding","canonical_id":"go:GO:0019956","description":"\"Binding to a chemokine. Chemokines are a family of small chemotactic cytokines; their name is derived from their ability to induce directed chemotaxis in nearby responsive cells. All chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of cells during normal processes of tissue maintenance or development. Chemokines are found in all vertebrates, some viruses and some bacteria.\" [GOC:ai, GOC:BHF, GOC:rl, PMID:12183377, Wikipedia:Chemokine]","metadata":null},{"id":"c50eb4476f1e4efeba83b3b2fb921d4c","type":"GO_TERM","name":"chemokine production","canonical_id":"go:GO:0032602","description":"\"The appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. All chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of cells during normal processes of tissue maintenance or development. Chemokines are found in all vertebrates, some viruses and some bacteria.\" [GOC:BHF, GOC:rl, ISBN:0198506732, PMID:12183377, Wikipedia:Chemokine]","metadata":null},{"id":"32cbef992ca54674bc665bf236a9e75a","type":"GO_TERM","name":"chemokine receptor activity","canonical_id":"go:GO:0004950","description":"\"Combining with a chemokine, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Chemokines are a family of small chemotactic cytokines; their name is derived from their ability to induce directed chemotaxis in nearby responsive cells. All chemokines possess a number of conserved cysteine residues involved in intramolecular disulfide bond formation. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of cells during normal processes of tissue maintenance or development. Chemokines are found in all vertebrates, some viruses and some bacteria.\" [GOC:BHF, GOC:rl, GOC:signaling, IUPHAR_GPCR:1280, PMID:12183377, PMID:8662823, Wikipedia:Chemokine]","metadata":null},{"id":"f69e4aa6838d4813a93184045ce13e08","type":"GO_TERM","name":"chemokine receptor antagonist activity","canonical_id":"go:GO:0046817","description":"\"Interacts with chemokine receptors to reduce the action of a chemokine.\" [GOC:ai, ISBN:0781718325]","metadata":null},{"id":"83b3c46a045542e49b9c094bacec350f","type":"GO_TERM","name":"chemokine receptor binding","canonical_id":"go:GO:0042379","description":"\"Binding to a chemokine receptor.\" [GOC:ai]","metadata":null},{"id":"fa225012b6c64748b61e599fc600d999","type":"GO_TERM","name":"chemokine receptor transport out of membrane raft","canonical_id":"go:GO:0032600","description":"\"The directed movement of a chemokine receptor out of a membrane raft.\" [GOC:mah]","metadata":null},{"id":"9657d05bcedc4f8f809769ba65b9143b","type":"GO_TERM","name":"chemokine receptor transport within lipid bilayer","canonical_id":"go:GO:0033606","description":"\"The directed movement of a chemokine receptor within a lipid bilayer.\" [GOC:mah]","metadata":null},{"id":"47c20b36e4cb4733b671094a6ec99a29","type":"GO_TERM","name":"chemokine-mediated signaling pathway","canonical_id":"go:GO:0070098","description":"\"The series of molecular signals initiated by a chemokine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"947c2be388eb49a0ba841c19c90bd0a8","type":"GO_TERM","name":"chemokinesis","canonical_id":"go:GO:0042466","description":"\"A response by a motile cell to a soluble chemical that involves an increase or decrease in speed (positive or negative orthokinesis) or of frequency of movement or a change in the frequency or magnitude of turning behavior (klinokinesis).\" [GOC:jl, PMID:2073411]","metadata":null},{"id":"42ad848c40974db69fa11d9addcb3353","type":"GO_TERM","name":"chemorepellent activity","canonical_id":"go:GO:0045499","description":"\"Providing the environmental signal that initiates the directed movement of a motile cell or organism towards a lower concentration of that signal.\" [GOC:ai]","metadata":null},{"id":"1fc465f93e804d56aa55284d2707e2b2","type":"GO_TERM","name":"chemorepulsion involved in embryonic olfactory bulb interneuron precursor migration","canonical_id":"go:GO:0021834","description":"\"The creation and reception of signals that guide olfactory bulb interneuron precursors down concentration gradients towards the olfactory bulb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"471a085402af4d828784a3a5352a4ff4","type":"GO_TERM","name":"chemorepulsion involved in interneuron migration from the subpallium to the cortex","canonical_id":"go:GO:0021842","description":"\"The creation and reception of signals that result in the movement of interneurons away from the signal during migration from the subpallium to the cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"b4c95a5b6e6e411889ea6ca3656dc206","type":"GO_TERM","name":"chemorepulsion involved in postnatal olfactory bulb interneuron migration","canonical_id":"go:GO:0021836","description":"\"The creation and reception of signals that repel olfactory bulb interneurons from the subventricular zone as a component process in tangential migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"d6f45ccab8564f63a9ba8fac8efe24ba","type":"GO_TERM","name":"chemorepulsion of axon","canonical_id":"go:GO:0061643","description":"\"The process in which a neuron growth cone is directed to a specific target site in response to a repulsive chemical cue.\" [GOC:dph, GOC:krc]","metadata":null},{"id":"658d364dc6c34285970af3c5651e3c9d","type":"GO_TERM","name":"chemorepulsion of branchiomotor axon","canonical_id":"go:GO:0021793","description":"\"The process in which a branchiomotor neuron growth cone is directed to a specific target site in response to a repulsive chemical cue. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"f3d49506b09d49cb8c433b763ee03d8a","type":"GO_TERM","name":"chemorepulsion of branchiomotor neuron axon in branchial arch mesenchyme","canonical_id":"go:GO:0021790","description":"\"The process in which a branchiomotor neuron growth cone in the branchial arch mesenchyme is directed to a specific target site in the branchial arch mesenchyme in response to a repulsive chemical cue. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"688e97b5ff434bd9a654936ebf4e8a05","type":"GO_TERM","name":"chemorepulsion of branchiomotor neuron axon in neural tube","canonical_id":"go:GO:0021787","description":"\"The process in which a branchiomotor neuron growth cone in the neural tube is directed to a specific target site in the neural tube in response to a repulsive chemical cue. Branchiomotor neurons are located in the hindbrain and innervate branchial arch-derived muscles that control jaw movements, facial expression, the larynx, and the pharynx.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:14699587]","metadata":null},{"id":"b11fc207ae5e438aa9f1fcb58157157b","type":"GO_TERM","name":"chemorepulsion of dopaminergic neuron axon","canonical_id":"go:GO:0036518","description":"\"The process in which a dopaminergic neuron growth cone is directed to a specific target site in response to a repulsive chemical cue.\" [GOC:bf, GOC:PARL, PMID:21106844, PMID:23517308]","metadata":null},{"id":"66a919a76097496ab56d5452937bb0ba","type":"GO_TERM","name":"chemorepulsion of serotonergic neuron axon","canonical_id":"go:GO:0036519","description":"\"The process in which a serotonergic neuron growth cone is directed to a specific target site in response to a repulsive chemical cue.\" [CL:0000850, GOC:bf, GOC:PARL, PMID:21106844]","metadata":null},{"id":"e69d35295091499181637e26345c877c","type":"GO_TERM","name":"chemosensory behavior","canonical_id":"go:GO:0007635","description":"\"Behavior that is dependent upon the sensation of chemicals.\" [GOC:curators]","metadata":null},{"id":"e385f8e66eec45f1901296fcaca86506","type":"GO_TERM","name":"chemosensory jump behavior","canonical_id":"go:GO:0007636","description":"\"The sudden, usually upward, movement off the ground or other surface through sudden muscular effort in the legs, following exposure to a chemical substance.\" [GOC:jid]","metadata":null},{"id":"70b6cd9719694eae946771b700556831","type":"GO_TERM","name":"chemosynthesis","canonical_id":"go:GO:0062097","description":"\"The cellular metabolic process in which organic chemical compounds are synthesized from carbon-containing molecules and nutrients using energy obtained from the oxidation of inorganic compounds or methane.\" [PMID:25050523]","metadata":null},{"id":"3aec4a0f70114baa85a9f37b677cd5ed","type":"GO_TERM","name":"chemotaxis","canonical_id":"go:GO:0006935","description":"\"The directed movement of a motile cell or organism, or the directed growth of a cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [ISBN:0198506732]","metadata":null},{"id":"483b0f4a66d24eb5a32ce1efcd65b25e","type":"GO_TERM","name":"chemotaxis to arachidonate","canonical_id":"go:GO:0034670","description":"\"The directed movement of a motile cell or organism in response to the presence of arachidonic acid.\" [GOC:curators, PMID:18202452]","metadata":null},{"id":"50fadf676d414ad1bfe5f6128ed62585","type":"GO_TERM","name":"chemotaxis to cAMP","canonical_id":"go:GO:0043327","description":"\"The directed movement of a motile cell or organism in response to the presence of 3',5'-cAMP.\" [GOC:curators]","metadata":null},{"id":"0dc2c4a2a6394aebb6f20d86c63b06f2","type":"GO_TERM","name":"chemotaxis to folate","canonical_id":"go:GO:0043326","description":"\"The directed movement of a motile cell or organism in response to the presence of folate.\" [GOC:curators]","metadata":null},{"id":"42e1305a31794d1a9be97e61b1bb3360","type":"GO_TERM","name":"chemotaxis to oxidizable substrate","canonical_id":"go:GO:0042333","description":"\"The directed movement of a motile cell or organism in response to the presence of an oxidizable substrate, for example, fructose.\" [GOC:jl, PMID:11029423]","metadata":null},{"id":"5a4a6f0077d94dbca932ce9fba16a079","type":"GO_TERM","name":"chemotropism","canonical_id":"go:GO:0043577","description":"\"The movement of an organism, or part of an organism, in response to an external chemical gradient, usually toward or away from it.\" [GOC:jl, PMID:10087613]","metadata":null},{"id":"e4fbfda8e53f48049ab6b1fdebfb97a4","type":"GO_TERM","name":"chenodeoxycholate 7-alpha-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106281","description":"\"Catalysis of the reaction: chenodeoxycholate + NAD+ = 7-oxolithocholate + H+ + NADH.\" [PMID:12917011, RHEA:42036]","metadata":null},{"id":"33f97f357b0d4c06aa1290ade8a23aee","type":"DRUG","name":"chenodeoxycholic acid","canonical_id":"gtopdb:608","description":null,"metadata":null},{"id":"6ba62a48ee164f95a97b9901c58ee2ed","type":"DRUG","name":"chenodeoxycholic acid","canonical_id":"chembl:CHEMBL240597","description":null,"metadata":null},{"id":"c08bb4826c8b4dd3a1e56de77ec18701","type":"GO_TERM","name":"chenodeoxycholic acid binding","canonical_id":"go:GO:1902122","description":"\"Binding to chenodeoxycholic acid.\" [GOC:bf, GOC:TermGenie, PMID:10334992]","metadata":null},{"id":"8c8c7ea419a04fb4843ddbe59c6a500d","type":"GO_TERM","name":"chenodeoxycholoyltaurine hydrolase activity","canonical_id":"go:GO:0047742","description":"\"Catalysis of the reaction: chenodeoxycholoyltaurine + H2O = chenodeoxycholate + taurine.\" [EC:3.5.1.74, MetaCyc:CHENODEOXYCHOLOYLTAURINE-HYDROLASE-RXN]","metadata":null},{"id":"1547a00d687d47498e30bfcb17f433ae","type":"GO_TERM","name":"chiasma","canonical_id":"go:GO:0005712","description":"\"A connection formed between chromatids, visible during meiosis, thought to be the point of the interchange involved in crossing-over.\" [ISBN:0198506732]","metadata":null},{"id":"f79afab94f464e20b3520a837c4b008e","type":"GO_TERM","name":"chiasma assembly","canonical_id":"go:GO:0051026","description":"\"The cell cycle process in which a connection between chromatids assembles, indicating where an exchange of homologous segments has taken place by the crossing-over of non-sister chromatids.\" [PMID:23396135]","metadata":null},{"id":"3844e8e6684b4d8da79fc770371ef93e","type":"GO_TERM","name":"chicken-wire-like collagen network","canonical_id":"go:GO:0140154","description":"\"Network-forming collagens can either form a chicken-wire-like network or a hexagonal network. Collagen type IV forms a chicken-wire-like structure and is found in the basement membrane.\" [PMID:21421911, PMID:21421915, PMID:31387942]","metadata":null},{"id":"9a4825293e894fd3834039495d0d41aa","type":"DISEASE","name":"childhood absence epilepsy","canonical_id":"mondo:0010826","description":null,"metadata":null},{"id":"66cf0f0e17274b77a283dee026702beb","type":"DISEASE","name":"childhood leukemia","canonical_id":"mondo:0004355","description":null,"metadata":null},{"id":"9d7227315d6343dc985d8b4355017f71","type":"DISEASE","name":"childhood onset asthma","canonical_id":"mondo:0005405","description":null,"metadata":null},{"id":"cd5bd17dc7914bf2b983c1a529ee8eb5","type":"GO_TERM","name":"chimeric colonial development","canonical_id":"go:GO:0099135","description":"\"Development a structure consisting of multiple co-operating unicellular organisms of the same species, involving cells of more that one genotype.\" [PMID:18272966]","metadata":null},{"id":"4dc75616819c46dab64fbff076fda552","type":"GO_TERM","name":"chimeric non-reproductive fruiting body development","canonical_id":"go:GO:0099136","description":"\"Development of a non-reproductive fruiting body formed by aggregation of cells with different genotypes.\" [PMID:18272966]","metadata":null},{"id":"c8582182dce647c7accf62dab7bcc2c7","type":"GO_TERM","name":"chimeric sorocarp development","canonical_id":"go:GO:0099134","description":"\"Development of a sorocarp formed by aggregation of cells with different genotypes.\" [PMID:18272966]","metadata":null},{"id":"9334a23094164026beaf115b585c4881","type":"GO_TERM","name":"chitin binding","canonical_id":"go:GO:0008061","description":"\"Binding to chitin, a linear polysaccharide consisting of beta-(1->4)-linked N-acetyl-D-glucosamine residues.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"37ba1809055549cd833e604c79f4b4ec","type":"GO_TERM","name":"chitin biosynthetic process","canonical_id":"go:GO:0006031","description":"\"The chemical reactions and pathways resulting in the formation of chitin, a linear polysaccharide consisting of beta-(1->4)-linked N-acetyl-D-glucosamine residues.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"b7eb408674384a7da238b214ab71431f","type":"GO_TERM","name":"chitin catabolic process","canonical_id":"go:GO:0006032","description":"\"The chemical reactions and pathways resulting in the breakdown of chitin, a linear polysaccharide consisting of beta-(1->4)-linked N-acetyl-D-glucosamine residues.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"b908ca5b50274685a3627c4fb8afe8d9","type":"GO_TERM","name":"chitin deacetylase activity","canonical_id":"go:GO:0004099","description":"\"Catalysis of the reaction: chitin + H2O = chitosan + acetate.\" [EC:3.5.1.41]","metadata":null},{"id":"3690f99b1c704d3581f9bdf41b6b745f","type":"GO_TERM","name":"chitin disaccharide deacetylase activity","canonical_id":"go:GO:0036311","description":"\"Catalysis of the reaction: H2O + N,N'-diacetylchitobiose = acetate + N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosamine.\" [RHEA:27469]","metadata":null},{"id":"2c3d2cc7501e47cf89c0348848ecfd77","type":"GO_TERM","name":"chitin localization","canonical_id":"go:GO:0006033","description":"\"A process in which chitin is transported to, or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"cc1ff237983e4bcea0f5a5c9805b5a04","type":"GO_TERM","name":"chitin metabolic process","canonical_id":"go:GO:0006030","description":"\"The chemical reactions and pathways involving chitin, a linear polysaccharide consisting of beta-(1->4)-linked N-acetyl-D-glucosamine residues.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"daf43e65b28b4f60a2bfe3d6401ecb88","type":"GO_TERM","name":"chitin synthase activity","canonical_id":"go:GO:0004100","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + [->4)-N-acetyl-beta-D-glucosaminyl-(1-](n) = UDP + [->4)-N-acetyl-beta-D-glucosaminyl-(1-](n+1).\" [EC:2.4.1.16]","metadata":null},{"id":"118d7db1347f4e70b9e6fa200666715f","type":"GO_TERM","name":"chitin-based cuticle attachment to epithelium","canonical_id":"go:GO:0040005","description":"\"Attaching of a chitin-containing cuticle to the epithelium underlying it. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"7628e022818547cab64cc45a5998b50c","type":"GO_TERM","name":"chitin-based cuticle development","canonical_id":"go:GO:0040003","description":"\"Synthesis and deposition of a chitin-based noncellular, hardened, or membranous secretion from an epithelial sheet. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu]","metadata":null},{"id":"4d9efa03daf749ec8fced793f50041ee","type":"GO_TERM","name":"chitin-based cuticle sclerotization","canonical_id":"go:GO:0007593","description":"\"The process of hardening of a chitin-based cuticle.\" [GOC:dos, GOC:mtg_sensu]","metadata":null},{"id":"e6020e72cb564b228b42347c9d64dbfb","type":"GO_TERM","name":"chitin-based cuticle sclerotization by biomineralization","canonical_id":"go:GO:0036340","description":"\"The process of hardening a chitin-based cuticle by mineral incorporation. For example, the cuticle of crustaceans is hardened by the incorporation of calcium carbonate.\" [GOC:sart]","metadata":null},{"id":"c1b7a86f1f8a42779a397862c3588ded","type":"GO_TERM","name":"chitin-based cuticle sclerotization by protein cross-linking","canonical_id":"go:GO:0036341","description":"\"The process of hardening of a chitin-based cuticle by protein cross-linking, and the incorporation of phenolic precursors. This mechanism of cuticle hardening occurs in insects and is usually accompanied by darkening of the cuticle.\" [GOC:bf, GOC:sart]","metadata":null},{"id":"845acdbbcaef43578405634194fd48c9","type":"GO_TERM","name":"chitin-based embryonic cuticle biosynthetic process","canonical_id":"go:GO:0008362","description":"\"Synthesis, including the chemical reactions and pathways resulting in the formation of chitin and other components, and deposition of a chitin-based embryonic cuticle by the underlying epidermal epithelium. This tough, waterproof cuticle layer is essential to provide structural integrity of the larval body. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, PMID:12019232]","metadata":null},{"id":"0b74a60bfc1846b18c8fb5b8853f8c45","type":"GO_TERM","name":"chitin-based extracellular matrix","canonical_id":"go:GO:0062129","description":"\"Any constituent part of a chitin-based noncellular, hardened, or membranous extracellular matrix secreted from the apical surface of an epithelial sheet.\" [PMID:23955854]","metadata":null},{"id":"6de0b38a7c70475aa0c03d1644b67ede","type":"GO_TERM","name":"chitin-based larval cuticle pattern formation","canonical_id":"go:GO:0035293","description":"\"The process that gives rise to the patterns of cell differentiation in the chitin-based larval cuticle. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"85467cdc34944018a49f02b0119e18e6","type":"GO_TERM","name":"chitinase activity","canonical_id":"go:GO:0004568","description":"\"Catalysis of the hydrolysis of (1->4)-beta linkages of N-acetyl-D-glucosamine (GlcNAc) polymers of chitin and chitodextrins.\" [GOC:bf, GOC:kah, GOC:pde, PMID:11468293]","metadata":null},{"id":"346efd74467c40eeba9312a608c21781","type":"GO_TERM","name":"chitobiose catabolic process","canonical_id":"go:GO:0052781","description":"\"The chemical reactions and pathways resulting in the breakdown of any chitobiose, a family of compounds derived from chitin and based on the structure of D-glucosaminyl-(1->4)-D-glucosamine.\" [GOC:curators]","metadata":null},{"id":"5eaac10f39be4f59ad66e6d186ee7c17","type":"GO_TERM","name":"chitobiosyldiphosphodolichol beta-mannosyltransferase activity","canonical_id":"go:GO:0004578","description":"\"Catalysis of the reaction: an N,N'-diacetylchitobiosyl-diphospho-di-trans,poly-cis-dolichol + GDP-alpha-D-mannose = a beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + GDP + H+.\" [RHEA:13865]","metadata":null},{"id":"7a3eb35da1804a658f2d923744c0488f","type":"GO_TERM","name":"chitosan binding","canonical_id":"go:GO:2001080","description":"\"Binding to chitosan.\" [GOC:mengo_curators]","metadata":null},{"id":"d8346f95f6d84522aeb45198dfa7f19c","type":"GO_TERM","name":"chitosan layer of spore wall","canonical_id":"go:GO:0005631","description":"\"The second outermost layer of the spore wall, as described in Saccharomyces.\" [ISBN:0879693568]","metadata":null},{"id":"e753c43361a24a28aade9948c70aa406","type":"GO_TERM","name":"chitosanase activity","canonical_id":"go:GO:0016977","description":"\"Catalysis of the endohydrolysis of beta-1,4-linkages between N-acetyl-D-glucosamine and D-glucosamine residues in a partly acetylated chitosan.\" [EC:3.2.1.132]","metadata":null},{"id":"a75b2caeb07a4e3da5b764cf39d76852","type":"GO_TERM","name":"chitosome","canonical_id":"go:GO:0045009","description":"\"An intracellular membrane-bounded particle found in fungi and containing chitin synthase; it synthesizes chitin microfibrils. Chitin synthase activity exists in chitosomes and they are proposed to act as a reservoir for regulated transport of chitin synthase enzymes to the division septum.\" [ISBN:0198506732, PMID:8970154]","metadata":null},{"id":"2265f4f407e643e6bef2a6eaf3a638e7","type":"GO_TERM","name":"chitosome membrane","canonical_id":"go:GO:0030661","description":"\"The lipid bilayer surrounding a chitosome.\" [GOC:mah]","metadata":null},{"id":"ea45970aa55547ec9b51f4b7e4b15ae8","type":"GO_TERM","name":"chlamydospore formation","canonical_id":"go:GO:0001410","description":"\"The process whose specific outcome is the progression of the chlamydospore over time, from its formation to the mature structure. A chlamydospores is a mitotic (asexual) one-celled spore, produced primarily for survival, not dispersal, originating endogenously and singly within part of a pre-existing cell and possessing an inner secondary and often thickened cell wall. An example of this is found in Candida albicans.\" [GOC:mcc, GOC:mtg_sensu, ISBN:085199377X, PMID:14663094]","metadata":null},{"id":"b0d63d0fff164f378b606b668df757e3","type":"GO_TERM","name":"chlamydospore septin filament array","canonical_id":"go:GO:0032166","description":"\"Arrays of septin filaments, or bars, found in a series of filamentous structures. Observed in the chlamydospore membrane during chlamydospore formation.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"5d5fccbce42745ca9ba7fd6f6dde7b93","type":"DRUG","name":"chloramphenicol","canonical_id":"mesh:D002701","description":null,"metadata":null},{"id":"5c765960133d4ea1bf0f25b05cf8ebf9","type":"GO_TERM","name":"chloramphenicol O-acetyltransferase activity","canonical_id":"go:GO:0008811","description":"\"Catalysis of the reaction: chloramphenicol + acetyl-CoA = chloramphenicol 3-acetate + CoA.\" [EC:2.3.1.28, RHEA:18421]","metadata":null},{"id":"eadeac00ee8c4d048f9d496c7b15a406","type":"DRUG","name":"chloramphenicol succinate","canonical_id":"mesh:C026016","description":null,"metadata":null},{"id":"292d5658d5ab4f7f976afa79bcaf78d1","type":"GO_TERM","name":"chloramphenicol transmembrane transport","canonical_id":"go:GO:0042892","description":"\"The directed movement of chloramphenicol, a broad-spectrum antibiotic that inhibits bacterial protein synthesis, across a lipid bilayer, from one side of a membrane to the other.\" [PMID:29150447]","metadata":null},{"id":"48bd55c166e94f36a209b5e5df934893","type":"GO_TERM","name":"chloramphenicol transmembrane transporter activity","canonical_id":"go:GO:0042896","description":"\"Enables the transfer of chloramphenicol, a broad-spectrum antibiotic that inhibits bacterial protein synthesis, from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"99ab4d30f1284701b6e0faff638abf72","type":"GO_TERM","name":"chlorate reductase activity","canonical_id":"go:GO:0047143","description":"\"Catalysis of the reaction: AH(2) + chlorate = A + chlorite + H2O + H+.\" [EC:1.97.1.1, RHEA:16349]","metadata":null},{"id":"fbc4ac0f536449aa86365be84b762bf7","type":"GO_TERM","name":"chlorate transmembrane transporter activity","canonical_id":"go:GO:0015107","description":"\"Enables the transfer of chlorate, ClO3-, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"d335e7acc70643188fdb66112e49a4fb","type":"GO_TERM","name":"chlorate transport","canonical_id":"go:GO:0015702","description":"\"The directed movement of chlorate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"fe3f261e221046e68c6ce8d5246bbccb","type":"DRUG","name":"chlorcyclizine","canonical_id":"mesh:C084597","description":null,"metadata":null},{"id":"4cd89a7905404dc4bc3a5a955193b200","type":"GO_TERM","name":"chlordecone reductase activity","canonical_id":"go:GO:0047743","description":"\"Catalysis of the reaction: chlordecone alcohol + NADP+ = chlordecone + H+ + NADPH.\" [EC:1.1.1.225, RHEA:14401]","metadata":null},{"id":"19386c3fc67c4b94936d1927bdf76e12","type":"DRUG","name":"chlordiazepoxide","canonical_id":"mesh:D002707","description":null,"metadata":null},{"id":"9a2548b9529540bfa36dedfc7b279328","type":"DRUG","name":"chlorhexidine","canonical_id":"mesh:D002710","description":null,"metadata":null},{"id":"c464d467cb4441948e587d91b13d68a5","type":"GO_TERM","name":"chloridazon-catechol dioxygenase activity","canonical_id":"go:GO:0047744","description":"\"Catalysis of the reaction: 5-amino-4-chloro-2-(2,3-dihydroxyphenyl)pyridazin-3(2H)-one + O2 = 5-amino-4-chloro-2-(2-hydroxymuconoyl)pyridazin-3(2H)-one + 2 H+.\" [EC:1.13.11.36, RHEA:20449]","metadata":null},{"id":"74d8eeb27e4d4875ad2fc01cfae33855","type":"GO_TERM","name":"chloride channel activity","canonical_id":"go:GO:0005254","description":"\"Enables the energy-independent facilitated diffusion of a chloride ion through a transmembrane aqueous pore or channel.\" [GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"bada4cb37a744601968e61f1dd6e7deb","type":"GO_TERM","name":"chloride channel complex","canonical_id":"go:GO:0034707","description":"\"An ion channel complex through which chloride ions pass.\" [GOC:mah]","metadata":null},{"id":"0451cd211a6f47f2b918634a35a59022","type":"GO_TERM","name":"chloride channel inhibitor activity","canonical_id":"go:GO:0019869","description":"\"Binds to and stops, prevents, or reduces the activity of a chloride channel.\" [GOC:mah]","metadata":null},{"id":"1d82e3df8e9543069df71fbca9c51103","type":"GO_TERM","name":"chloride channel regulator activity","canonical_id":"go:GO:0017081","description":"\"Binds to and modulates the activity of a chloride channel.\" [GOC:mah]","metadata":null},{"id":"9b892190aa264846819a2fe9398fe3cf","type":"GO_TERM","name":"chloride ion binding","canonical_id":"go:GO:0031404","description":"\"Binding to a chloride ion (Cl-).\" [GOC:mah]","metadata":null},{"id":"6d7f1cd43e674bf5b78a9f170a57c388","type":"GO_TERM","name":"chloride ion homeostasis","canonical_id":"go:GO:0055064","description":"\"Any process involved in the maintenance of an internal steady state of chloride ions within an organism or cell.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"b7e09df2d5514dcda2fc9f910bf8ad14","type":"GO_TERM","name":"chloride peroxidase activity","canonical_id":"go:GO:0016691","description":"\"Catalysis of the reaction: 2 R-H + 2 chloride + H2O2 = 2 R-Cl + 2 H2O.\" [EC:1.11.1.10]","metadata":null},{"id":"58a8f6319c7446969409d902460e9737","type":"GO_TERM","name":"chloride transmembrane transport","canonical_id":"go:GO:1902476","description":"\"The process in which chloride is transported across a membrane.\" [GOC:TermGenie, GOC:vw]","metadata":null},{"id":"16c88ec03b5345c29d0bbbcb5243f412","type":"GO_TERM","name":"chloride transmembrane transporter activity","canonical_id":"go:GO:0015108","description":"\"Enables the transfer of chloride ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"1f6c12d42f404e34b9a7209de197fcad","type":"GO_TERM","name":"chloride transport","canonical_id":"go:GO:0006821","description":"\"The directed movement of chloride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"e25747278b774bfea334f4dfe1fe7237","type":"GO_TERM","name":"chloride-activated potassium channel activity","canonical_id":"go:GO:0070089","description":"\"Enables the transmembrane transfer of a potassium cation by a channel that opens when a chloride ion has been bound by the channel complex or one of its constituent parts.\" [GOC:kmv, GOC:mtg_transport]","metadata":null},{"id":"e812980031f741b0913e72201775d5a9","type":"GO_TERM","name":"chloride:bicarbonate antiporter activity","canonical_id":"go:GO:0140900","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: chloride(in) + HCO3-(out) = chloride(out) + HCO3-(in).\" [PMID:10428871, PMID:16606687, RHEA:72203]","metadata":null},{"id":"6db660d097244817924265857455b3f4","type":"GO_TERM","name":"chloride:monoatomic cation symporter activity","canonical_id":"go:GO:0015377","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: cation(out) + Cl-(out) = cation(in) + Cl-(in).\" [PMID:31747317]","metadata":null},{"id":"ec9d93b40966411d9bf003dde3e3ffa0","type":"GO_TERM","name":"chloride:proton antiporter activity","canonical_id":"go:GO:0062158","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: chloride(out) + proton(in) = chloride(in) + proton(out).\" [PMID:14985752]","metadata":null},{"id":"51a4336683eb4661a44fc9776d39f25f","type":"GO_TERM","name":"chlorinated hydrocarbon catabolic process","canonical_id":"go:GO:0042205","description":"\"The chemical reactions and pathways resulting in the breakdown of chlorinated hydrocarbons, compounds derived from hydrocarbons by replacing one or more hydrogen atoms with chlorine atoms.\" [GOC:ai, GOC:krc]","metadata":null},{"id":"2bbbc3b115e44ec58aca7c804a37f616","type":"GO_TERM","name":"chlorite O2-lyase activity","canonical_id":"go:GO:0050587","description":"\"Catalysis of the reaction: chloride + O2 = chlorite.\" [EC:1.13.11.49, RHEA:21404]","metadata":null},{"id":"d76bb04d9199406eb1356b9ab05fedda","type":"GO_TERM","name":"chlorobenzene catabolic process","canonical_id":"go:GO:0018914","description":"\"The chemical reactions and pathways resulting in the breakdown of chlorobenzene, a derivative of benzene with a chlorine atoms attached to the ring. It is a colorless liquid that is manufactured for use as a solvent. It quickly evaporates in the air and is degraded by hydroxyl radicals that are produced photochemically. The gas acts as a source of ClOx, which helps in the breakdown of stratospheric ozone.\" [PMID:10808489, PMID:8626733]","metadata":null},{"id":"3c4f429f8a904d9eafb8438aa8ce426c","type":"GO_TERM","name":"chloroethene reductive dehalogenase activity","canonical_id":"go:GO:0018698","description":"\"Catalysis of the reaction: AH2 + chloroethene = A + chloride + ethene + H+.\" [PMID:15294827, PMID:9171062, RHEA:68004]","metadata":null},{"id":"642146ccf66848ecbc7ec36f5509ff4e","type":"GO_TERM","name":"chlorogenate hydrolase activity","canonical_id":"go:GO:0047745","description":"\"Catalysis of the reaction: chlorogenate + H2O = (-)-quinate + cis-caffeate + H+.\" [EC:3.1.1.42, RHEA:20689]","metadata":null},{"id":"e5f59caae5b94cb2ba4dfd9694256616","type":"GO_TERM","name":"chlorogenate-glucarate O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047204","description":"\"Catalysis of the reaction: D-glucarate + chlorogenate = (-)-quinate + 2-O-caffeoylglucarate.\" [EC:2.3.1.98, RHEA:23204]","metadata":null},{"id":"24823b1d060e49b3981872db3bc37951","type":"GO_TERM","name":"chloromuconate cycloisomerase activity","canonical_id":"go:GO:0018850","description":"\"Catalysis of the reaction: 2-chloro-2,5-dihydro-5-oxofuran-2-acetate = 3-chloro-cis,cis-muconate.\" [EC:5.5.1.7]","metadata":null},{"id":"0301e0e640944e219d7d0da7181eb82f","type":"GO_TERM","name":"chlorophenol O-methyltransferase activity","canonical_id":"go:GO:0030790","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + trichlorophenol = S-adenosyl-L-homocysteine + trichloroanisole.\" [EC:2.1.1.136]","metadata":null},{"id":"c8e1220481d74a57ac158187595f677b","type":"GO_TERM","name":"chlorophyll a biosynthetic process","canonical_id":"go:GO:0033305","description":"\"The chemical reactions and pathways leading to the formation of chlorophyll a.\" [GOC:mah]","metadata":null},{"id":"9981fbf1ff3e425b91b314f24fa57a3c","type":"GO_TERM","name":"chlorophyll a catabolic process","canonical_id":"go:GO:0033310","description":"\"The chemical reactions and pathways leading to the breakdown of chlorophyll a.\" [GOC:mah]","metadata":null},{"id":"99b1e66503f14b72bb2310d25920c7c3","type":"GO_TERM","name":"chlorophyll binding","canonical_id":"go:GO:0016168","description":"\"Binding to a chlorophyll; a compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment.\" [GOC:jl]","metadata":null},{"id":"aba7e732484d4fbcaa9ac339c1684cc3","type":"GO_TERM","name":"chlorophyll biosynthetic process","canonical_id":"go:GO:0015995","description":"\"The chemical reactions and pathways resulting in the formation of chlorophyll, any compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment, from less complex precursors.\" [GOC:jl]","metadata":null},{"id":"235f22cd02304c4189f6712d8bcc095a","type":"GO_TERM","name":"chlorophyll catabolic process","canonical_id":"go:GO:0015996","description":"\"The chemical reactions and pathways resulting in the breakdown of chlorophyll, any compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment, into less complex products.\" [GOC:jl]","metadata":null},{"id":"4136f21e36ab453882b8241dc19f741a","type":"GO_TERM","name":"chlorophyll catabolite transmembrane transporter activity","canonical_id":"go:GO:0010290","description":"\"Enables the directed movement of chlorophyll catabolites such as non-fluorescent chlorophyll catabolites (NCCs), from one side of a membrane to the other.\" [PMID:9681016]","metadata":null},{"id":"cfc406e91adf47698121136a6473b1de","type":"GO_TERM","name":"chlorophyll cycle","canonical_id":"go:GO:0033354","description":"\"A cyclic series of interconversions involving chlorophyll a, chlorophyll b and several chlorophyllide intermediates.\" [GOC:mah, MetaCyc:PWY-5068]","metadata":null},{"id":"6eb6b7e5ddb44e7281c227c1cc1d0723","type":"GO_TERM","name":"chlorophyll fluorescence","canonical_id":"go:GO:0090546","description":"\"The process by which excess light energy absorbed by chlorophyll and not used to drive photosynthesis is re-emitted as light.\" [PMID:10938857]","metadata":null},{"id":"4761f3779e704836a898bd49fda79573","type":"GO_TERM","name":"chlorophyll metabolic process","canonical_id":"go:GO:0015994","description":"\"The chemical reactions and pathways involving chlorophyll, any compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment.\" [GOC:jl]","metadata":null},{"id":"f712b7643f334d2a967e80b0d659df46","type":"GO_TERM","name":"chlorophyll synthetase activity","canonical_id":"go:GO:0046408","description":"\"Catalysis of the reaction: chlorophyllide a + phytyl diphosphate + 2 H+ = chlorophyll a + diphosphate.\" [RHEA:17317]","metadata":null},{"id":"1f4c49a2e1a845d58e0b1b67f2cde5db","type":"GO_TERM","name":"chlorophyll(ide) b reductase activity","canonical_id":"go:GO:0034256","description":"\"Catalysis of the reaction: 71-hydroxychlorophyll(ide) a + NAD(P)+ = chlorophyll(ide) b + NAD(P)H + H+.\" [EC:1.1.1.294, MetaCyc:RXN-7678]","metadata":null},{"id":"d0b5fa89942f46a3a74647aa3b0524a8","type":"GO_TERM","name":"chlorophyllase activity","canonical_id":"go:GO:0047746","description":"\"Catalysis of the reaction: chlorophyll + H2O = phytol + chlorophyllide.\" [RHEA:19605]","metadata":null},{"id":"d0f55f9678a94d10a6c7b9d04b17de88","type":"GO_TERM","name":"chlorophyllide a oxygenase activity","canonical_id":"go:GO:0010277","description":"\"Catalysis of the reactions: chlorophyllide a + 2 H+ + 2 NADPH + 2 O2 = chlorophyllide b + 3 H2O + 2 NADP+.\" [RHEA:30359]","metadata":null},{"id":"41838ae90ccc4fc88dd776772afd3e76","type":"GO_TERM","name":"chloroplast","canonical_id":"go:GO:0009507","description":"\"A chlorophyll-containing plastid with thylakoids organized into grana and frets, or stroma thylakoids, and embedded in a stroma.\" [ISBN:0471245208]","metadata":null},{"id":"16e35dc3bb3a4006ad369a1c21fbe449","type":"GO_TERM","name":"chloroplast ADPG pyrophosphorylase complex","canonical_id":"go:GO:0030933","description":"\"An ADPG pyrophosphorylase complex found in the chloroplast.\" [GOC:mah]","metadata":null},{"id":"1b7221a9cdea439c9a61509b08418dd2","type":"GO_TERM","name":"chloroplast RNA modification","canonical_id":"go:GO:1900865","description":"\"Any RNA modification that takes place in chloroplast.\" [GOC:TermGenie]","metadata":null},{"id":"9c08ba943f4b4e3d9c4a389d394260ab","type":"GO_TERM","name":"chloroplast RNA processing","canonical_id":"go:GO:0031425","description":"\"The conversion of a primary RNA molecule transcribed from a chloroplast genome into one or more mature RNA molecules.\" [GOC:mah]","metadata":null},{"id":"5fa5d93844904ed9a862f0b0d2c776a2","type":"GO_TERM","name":"chloroplast accumulation movement","canonical_id":"go:GO:0009904","description":"\"The relocation process in which chloroplasts in photosynthetic cells move toward a brighter area in a cell to optimize photosynthesis.\" [GOC:tb, PMID:11978863]","metadata":null},{"id":"dbb6c85786b24a54b23e345b4db9477c","type":"GO_TERM","name":"chloroplast avoidance movement","canonical_id":"go:GO:0009903","description":"\"The relocation process in which chloroplasts in photosynthetic cells avoid strong light and move away from it in order to preserve the photosynthetic machinery.\" [GOC:tb, PMID:11978863]","metadata":null},{"id":"1311a37f948447fba8829f9423b10896","type":"GO_TERM","name":"chloroplast chromosome","canonical_id":"go:GO:0042648","description":"\"A circular DNA molecule containing chloroplast encoded genes.\" [GOC:jl]","metadata":null},{"id":"31639ece5a2b4eb48f3020bb616a1b6d","type":"GO_TERM","name":"chloroplast disassembly","canonical_id":"go:GO:1904821","description":"\"The disaggregation of a chloroplast into its constituent components.\" [GO_REF:0000079, GOC:TermGenie, PMID:26494759]","metadata":null},{"id":"7e0dce58d7494de497285cb09c8ab64c","type":"GO_TERM","name":"chloroplast elongation","canonical_id":"go:GO:0010151","description":"\"Expansion of the chloroplast that usually precedes division.\" [GOC:lr]","metadata":null},{"id":"f50ee04c07104687b121dcf2ebb99820","type":"GO_TERM","name":"chloroplast envelope","canonical_id":"go:GO:0009941","description":"\"The double lipid bilayer enclosing the chloroplast and separating its contents from the rest of the cytoplasm; includes the intermembrane space.\" [GOC:tb]","metadata":null},{"id":"f38141ce10e64d2886cd224cd296024a","type":"GO_TERM","name":"chloroplast fission","canonical_id":"go:GO:0010020","description":"\"The division of a chloroplast within a cell to form two or more separate chloroplast compartments. This division occurs independently of mitosis.\" [GOC:lr]","metadata":null},{"id":"93719b999c144f589a3abddaa1f8c47d","type":"GO_TERM","name":"chloroplast inner membrane","canonical_id":"go:GO:0009706","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the chloroplast envelope; also faces the chloroplast stroma.\" [GOC:tb]","metadata":null},{"id":"213d116f195a43db8debcfe7868cbc0d","type":"GO_TERM","name":"chloroplast intermembrane space","canonical_id":"go:GO:0031972","description":"\"The region between the inner and outer lipid bilayers of a chloroplast envelope.\" [GOC:mah]","metadata":null},{"id":"02273ec2b50d4e1fb04c2c96cf01aa42","type":"GO_TERM","name":"chloroplast isoamylase complex","canonical_id":"go:GO:0010368","description":"\"A protein complex whose composition varies amongst species; in rice it probably exists in a homo-tetramer to homo-hexamer form and in Gram negative bacteria as a dimer. Functions in the hydrolysis of alpha-(1,6)-D-glucosidic branch linkages. Isoamylases in plants are intracellular and probably chloroplast localized.\" [GOC:tair_curators]","metadata":null},{"id":"d4f8fb617e9d420297b9ea482202e1e5","type":"GO_TERM","name":"chloroplast large ribosomal subunit","canonical_id":"go:GO:0022628","description":"\"The large subunit of a ribosome contained within a chloroplast.\" [GOC:mtg_sensu]","metadata":null},{"id":"cdeab71ed75840f496b7476fb548e126","type":"GO_TERM","name":"chloroplast localization","canonical_id":"go:GO:0019750","description":"\"Any process in which a chloroplast is transported to, and/or maintained in, a specific location within the cell. A chloroplast is a chlorophyll-containing plastid found in cells of algae and higher plants.\" [GOC:bf, GOC:jl, ISBN:0198506732]","metadata":null},{"id":"73fed30333b64a54ac1888e499c086ce","type":"GO_TERM","name":"chloroplast mRNA modification","canonical_id":"go:GO:1900871","description":"\"The covalent alteration within the chloroplast of one or more nucleotides within an mRNA to produce an mRNA molecule with a sequence that differs from that coded genetically.\" [GOC:TermGenie, PMID:1653905]","metadata":null},{"id":"591f3773530c4fa3ad50493b8501ee4e","type":"GO_TERM","name":"chloroplast mRNA processing","canonical_id":"go:GO:0010239","description":"\"Steps involved in processing precursor RNAs arising from transcription of operons in the chloroplast genome into mature mRNAs.\" [GOC:tb, PMID:9648738]","metadata":null},{"id":"825f94e6e61a4e57bb5fb19364da7ee3","type":"GO_TERM","name":"chloroplast membrane","canonical_id":"go:GO:0031969","description":"\"Either of the lipid bilayers that surround a chloroplast and form the chloroplast envelope.\" [GOC:mah, GOC:pz]","metadata":null},{"id":"c836d1457d6e414fb4410ee0c90eb34e","type":"GO_TERM","name":"chloroplast nucleoid","canonical_id":"go:GO:0042644","description":"\"The region of a chloroplast to which the DNA is confined.\" [GOC:jl]","metadata":null},{"id":"68f0ef5706d84c39a83a3a0565e49e13","type":"GO_TERM","name":"chloroplast organization","canonical_id":"go:GO:0009658","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the chloroplast.\" [GOC:jid]","metadata":null},{"id":"d327d6ec46c24dc2a79f5b6c448f28aa","type":"GO_TERM","name":"chloroplast outer membrane","canonical_id":"go:GO:0009707","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the chloroplast envelope.\" [GOC:tb]","metadata":null},{"id":"e00c0ff2189d4da8904f40942c784bb2","type":"GO_TERM","name":"chloroplast outer membrane translocon","canonical_id":"go:GO:0010278","description":"\"The protein transport machinery of the chloroplast outer membrane that contains at least three components Toc159, Toc75 and Toc34, interacts with precursor proteins which are imported into the chloroplast in a GTP dependant manner.\" [PMID:11299338]","metadata":null},{"id":"54cd112aaab44c7eb4e4e51fa2932ab6","type":"GO_TERM","name":"chloroplast photosystem I","canonical_id":"go:GO:0030093","description":"\"Photosystem located in the chloroplast that functions as a light-dependent plastocyanin-ferredoxin oxidoreductase, transferring electrons from plastocyanin to ferredoxin. An example of this is found in Arabidopsis thaliana.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"a01b46af1653417b8800b53ba8f594f1","type":"GO_TERM","name":"chloroplast photosystem I binding","canonical_id":"go:GO:0062067","description":"\"Binding to a chloroplast photosystem I.\" [PMID:17400553]","metadata":null},{"id":"76f5341df2814a8783e5c5da6793d480","type":"GO_TERM","name":"chloroplast photosystem II","canonical_id":"go:GO:0030095","description":"\"An integral chloroplast membrane complex containing the P680 reaction center. In the light, PSII functions as a water-plastoquinone oxidoreductase, transferring electrons from water to plastoquinone.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"43cc5db834ea49eba06058b11a5bc7e3","type":"GO_TERM","name":"chloroplast photosystem II binding","canonical_id":"go:GO:0062068","description":"\"Binding to a chloroplast photosystem II.\" [PMID:17400553]","metadata":null},{"id":"255528521ceb4a2c93a9dbe42d4def4e","type":"GO_TERM","name":"chloroplast protein-transporting ATPase activity","canonical_id":"go:GO:0016464","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O = ADP + phosphate; drives the transport of proteins into the chloroplast stroma.\" [EC:7.4.2.4]","metadata":null},{"id":"488b0fe49b8a42488b44aef110a1c8bb","type":"GO_TERM","name":"chloroplast proton-transporting ATP synthase complex assembly","canonical_id":"go:GO:0033614","description":"\"The aggregation, arrangement and bonding together of a proton-transporting ATP synthase in the chloroplast thylakoid membrane.\" [GOC:mah]","metadata":null},{"id":"80d99594f8924694a00a390fd30d5ffb","type":"GO_TERM","name":"chloroplast rRNA processing","canonical_id":"go:GO:1901259","description":"\"Any rRNA processing that takes place in chloroplast.\" [GOC:TermGenie]","metadata":null},{"id":"74bbb85e56954af1af37767719962c24","type":"GO_TERM","name":"chloroplast relocation","canonical_id":"go:GO:0009902","description":"\"The process in which chloroplasts in photosynthetic cells migrate toward illuminated sites to optimize photosynthesis and move away from excessively illuminated areas to protect the photosynthetic machinery.\" [PMID:11309623]","metadata":null},{"id":"4639410ab6454f37a89343bda6c41345","type":"GO_TERM","name":"chloroplast ribosome","canonical_id":"go:GO:0043253","description":"\"A ribosome contained within a chloroplast.\" [GOC:ecd]","metadata":null},{"id":"b87c3c1914d14a58a80c7378b6069301","type":"GO_TERM","name":"chloroplast ribulose bisphosphate carboxylase complex","canonical_id":"go:GO:0009573","description":"\"A complex, located in the chloroplast, containing either both large and small subunits or just small subunits which carries out the activity of producing 3-phosphoglycerate from carbon dioxide and ribulose-1,5-bisphosphate. An example of this component is found in Arabidopsis thaliana.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"6d62cd7253d44ad3a6c039477b459483","type":"GO_TERM","name":"chloroplast small ribosomal subunit","canonical_id":"go:GO:0022629","description":"\"The small subunit of a ribosome contained within a chloroplast.\" [GOC:mtg_sensu]","metadata":null},{"id":"7c18464d58e343358d5524f0f61f5b72","type":"GO_TERM","name":"chloroplast starch grain","canonical_id":"go:GO:0009569","description":"\"Plant storage body for amylose and amylopectin, 1-100um in diameter, and located in chloroplasts. Also contains small amounts of enzymes, amino acids, lipids and nucleic acids. The shape of the grain varies widely amongst species, but is often spherical or disk-shaped.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"db7f329c7b444aa4bbf2a8842f328cb5","type":"GO_TERM","name":"chloroplast stroma","canonical_id":"go:GO:0009570","description":"\"The space enclosed by the double membrane of a chloroplast but excluding the thylakoid space. It contains DNA, ribosomes and some temporary products of photosynthesis.\" [ISBN:0198547684]","metadata":null},{"id":"5729282097cc42979e01e5955664bed1","type":"GO_TERM","name":"chloroplast stromal thylakoid","canonical_id":"go:GO:0009533","description":"\"Unstacked thylakoids that connect the grana stacks through the stroma.\" [ISBN:0943088399]","metadata":null},{"id":"3cbb4bc31d9e4536a9007354dd8969d0","type":"GO_TERM","name":"chloroplast targeting sequence receptor activity","canonical_id":"go:GO:0030941","description":"\"Binding to a chloroplast targeting sequence, a short stretch of amino acids found in a protein that acts as a signal to localize the protein to the chloroplast.\" [PMID:35929083]","metadata":null},{"id":"9290eda9196146218d6cbced756b7f4b","type":"GO_TERM","name":"chloroplast thylakoid","canonical_id":"go:GO:0009534","description":"\"Sac-like membranous structures (cisternae) in a chloroplast combined into stacks (grana) and present singly in the stroma (stroma thylakoids or frets) as interconnections between grana. An example of this component is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, ISBN:0943088399]","metadata":null},{"id":"43f3f1ce7640474fab9c9d5602bdee92","type":"GO_TERM","name":"chloroplast thylakoid lumen","canonical_id":"go:GO:0009543","description":"\"The cavity enclosed within the chloroplast thylakoid membrane. An example of this component is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, ISBN:0943088399]","metadata":null},{"id":"da50e6d6c4cc45c6a4fb7968acbafbe4","type":"GO_TERM","name":"chloroplast thylakoid membrane","canonical_id":"go:GO:0009535","description":"\"The pigmented membrane of a chloroplast thylakoid. An example of this component is found in Arabidopsis thaliana.\" [GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"2f0b221c7e0b4e4faad83f36af51ca6b","type":"GO_TERM","name":"chloroplast thylakoid membrane protein complex","canonical_id":"go:GO:0098807","description":"\"A protein complex that is part of a chloroplast thylakoid membrane.\" [GOC:dos]","metadata":null},{"id":"55491d6a24484f6eb881dd333666067f","type":"GO_TERM","name":"chloroplast vesicle","canonical_id":"go:GO:0062247","description":"\"A intracellular vesicle that is part of a chloroplast.\" [PMID:32245810]","metadata":null},{"id":"c8ff5fa710344789871a3630e679ffbd","type":"GO_TERM","name":"chloroplast-nucleus signaling pathway","canonical_id":"go:GO:0010019","description":"\"The process in which a molecular signal is transduced between the chloroplast and nucleus, such that expression of nuclear encoding photosynthetic proteins is coupled with chloroplast biogenesis.\" [PMID:8972595]","metadata":null},{"id":"71ed6b20ffb441988cf246879fd33505","type":"GO_TERM","name":"chloroplastic endopeptidase Clp complex","canonical_id":"go:GO:0009840","description":"\"A Clp endopeptidase complex located in the chloroplast.\" [GOC:mah]","metadata":null},{"id":"b69c3e09d124425786b6d706e1bcb0e5","type":"DRUG","name":"chloroquine","canonical_id":"mesh:D002738","description":null,"metadata":null},{"id":"584dcdb84cdf4936b2b3ff603df4fe8d","type":"GO_TERM","name":"chlororespiration","canonical_id":"go:GO:0010478","description":"\"A respiratory electron flow (from NAD(P)H to plastoquinone (PQ) and O2) involving both a nonphotochemical reduction and re-oxidation of PQ pool.\" [GOC:mtg_electron_transport, GOC:tb, PMID:17573537]","metadata":null},{"id":"14a262250a1b4cac9285f567eeaeda2d","type":"GO_TERM","name":"chlorosome","canonical_id":"go:GO:0046858","description":"\"A large enclosure of aggregated pigment, typically bacteriochlorophyll c (BChl c), that acts as a light-harvesting antenna structure and is characteristic of green photosynthetic bacteria (e.g. Chlorobiaceae). The BChl aggregates are organized into lamellar elements by pigment-pigment rather than pigment-protein interactions. Chlorosomes also contain BChl a, carotenoids, quinones, lipids, and proteins, and are attached to the cytoplasmic membrane via a BChl a-containing protein baseplate.\" [ISBN:0198506732, PMID:14729689, PMID:15298919]","metadata":null},{"id":"3739b5165e9941ffbcffc6ba21e6531b","type":"GO_TERM","name":"chlorosome envelope","canonical_id":"go:GO:0033105","description":"\"The structure, composed of a monolayer of glycolipids with embedded proteins, that encloses the pigments and other contents of the chlorosome.\" [PMID:14507718, PMID:14729689, PMID:17303128]","metadata":null},{"id":"6dd984c085c24441990502ae9b9e67f1","type":"DRUG","name":"chlorothiazide","canonical_id":"gtopdb:4835","description":null,"metadata":null},{"id":"f8d2254e61cb47cab9de459085721c7b","type":"DRUG","name":"chlorothiazide","canonical_id":"mesh:D002740","description":null,"metadata":null},{"id":"38daa2c0be544f608229a76704557a13","type":"DRUG","name":"chlorothiazide","canonical_id":"chembl:CHEMBL842","description":null,"metadata":null},{"id":"863ec0c7f05144bcb77d1fdd01243d80","type":"COMBINATION_TREATMENT","name":"chlorothiazide + chlorthalidone","canonical_id":"ctgov_combo:ctgov-combo-857cc5c73c9887b4","description":null,"metadata":null},{"id":"efa1b658f01a422388cc859a92b552eb","type":"COMBINATION_TREATMENT","name":"chlorothiazide + chlorthalidone","canonical_id":"ctgov_combo:ctgov-combo-6a0fe1db610119a2","description":null,"metadata":null},{"id":"0061be810b044872ab11d3e3ae04f91f","type":"COMBINATION_TREATMENT","name":"chlorothiazide + chlorthalidone + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-6dc5a6649850a158","description":null,"metadata":null},{"id":"c0b98699e9cb4caab5cae4e84eb012cb","type":"COMBINATION_TREATMENT","name":"chlorothiazide + chlorthalidone + hydrochlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-e503fb5a8855b0b8","description":null,"metadata":null},{"id":"27c346c655f4490da4cd95cd7f44513a","type":"COMBINATION_TREATMENT","name":"chlorothiazide + chlorthalidone + hydrochlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-03a3ace9b3cf3f1b","description":null,"metadata":null},{"id":"9a813c5a538243f8b16c83d85b08757b","type":"COMBINATION_TREATMENT","name":"chlorothiazide + clonidine + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-c1482ca2eb0a4b21","description":null,"metadata":null},{"id":"05036d379ae44986af3eede542d12a60","type":"COMBINATION_TREATMENT","name":"chlorothiazide + furosemide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-e02c36bd5fa7ae8e","description":null,"metadata":null},{"id":"e06cd06024d843ae9683e4d9f0f0b0f5","type":"COMBINATION_TREATMENT","name":"chlorothiazide + guanfacine","canonical_id":"ctgov_combo:ctgov-combo-1e40ce338ff1c0dd","description":null,"metadata":null},{"id":"2d78101b9bee4aa6a43ab34fa9d52878","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-8ed4b782fd126a20","description":null,"metadata":null},{"id":"7a4785948bd54d299a55c679b7f704cf","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-2646f0af935d6ac5","description":null,"metadata":null},{"id":"21da5057790c4ff09f8cb49bc11779e4","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-f333bc2d767eba85","description":null,"metadata":null},{"id":"ad9e79e559c24ca9b55ccbd05e6ddda2","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide","canonical_id":"ctgov_combo:ctgov-combo-710a9842d9b1f791","description":null,"metadata":null},{"id":"231b00e747db4254afcf05e430673aaf","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + lisinopril + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-80cd6a0f5e664ae9","description":null,"metadata":null},{"id":"617cd7f5b23f42e7a3d2dd89161a61c0","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + losartan","canonical_id":"ctgov_combo:ctgov-combo-ad1f8d01f5fb56b9","description":null,"metadata":null},{"id":"f7a6e7e536d846e394d069be4dafb393","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + losartan","canonical_id":"ctgov_combo:ctgov-combo-3c1abffe92b8c6c3","description":null,"metadata":null},{"id":"03771a6ff1b14c5aa402fd906414136f","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + losartan + ramipril","canonical_id":"ctgov_combo:ctgov-combo-95f8f12cd1d4fdd4","description":null,"metadata":null},{"id":"0a98577853ae404586ba2febe41848e6","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + losartan + trandolapril + verapamil","canonical_id":"ctgov_combo:ctgov-combo-4828702ca6c8197b","description":null,"metadata":null},{"id":"7f506b65a2104226a33255e455aec502","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + nitrendipine + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-05d52abf1d0bf40d","description":null,"metadata":null},{"id":"e5bb577acb644f3e95371259939b9176","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-9059a4153b7da46b","description":null,"metadata":null},{"id":"0441585d40584569ad5f7e3c05270e94","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-d9404ec86ddf13e8","description":null,"metadata":null},{"id":"ef9f036ece5545c5995909d90fd110a8","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-2b0a894366422160","description":null,"metadata":null},{"id":"3344ad8bb31c425f9a14e4831ba6453c","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-1057b49abaf0f49c","description":null,"metadata":null},{"id":"33025fccd68d4a1d9d8b2f7de2036ea6","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + perindopril","canonical_id":"ctgov_combo:ctgov-combo-5e7cd895b1b19a17","description":null,"metadata":null},{"id":"b738961df83047f3ba22bab2acb68592","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-695a05c555cb1174","description":null,"metadata":null},{"id":"5615a291c0744fc38cfd8afbce0279ef","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-26a435dd8d0b10bf","description":null,"metadata":null},{"id":"89e60db9aff449d19130cfc19250859f","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-dfe1211bfdb33450","description":null,"metadata":null},{"id":"c69dd729bcee4a62a011b803ecccd5c4","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-de92b91eba1b706c","description":null,"metadata":null},{"id":"cd206c8f1d1d4499a636f04966718be2","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-77d61ca1f9452cbf","description":null,"metadata":null},{"id":"c2e084b07981464c807e57ef29bd8e5c","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + valsartan","canonical_id":"ctgov_combo:ctgov-combo-ad298612fd09fda5","description":null,"metadata":null},{"id":"501eb098170243a09c7421599ea49557","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + valsartan","canonical_id":"ctgov_combo:ctgov-combo-e16fd1bf816098a0","description":null,"metadata":null},{"id":"7748a613ba6544c4b3bfba589dbf91ad","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + valsartan","canonical_id":"ctgov_combo:ctgov-combo-779d464d39dbb6bd","description":null,"metadata":null},{"id":"91d0ad7c592446a597f482fbf5b0d0f7","type":"COMBINATION_TREATMENT","name":"chlorothiazide + hydrochlorothiazide + valsartan","canonical_id":"ctgov_combo:ctgov-combo-cafe8edf89df6acb","description":null,"metadata":null},{"id":"14f1ebdb004243a18d41aacebcc793d9","type":"COMBINATION_TREATMENT","name":"chlorothiazide + irbesartan","canonical_id":"ctgov_combo:ctgov-combo-ca2ec123b7f65098","description":null,"metadata":null},{"id":"2945182846744764bf4c0f80e34a9844","type":"COMBINATION_TREATMENT","name":"chlorothiazide + metolazone","canonical_id":"ctgov_combo:ctgov-combo-7d80775ef683dde2","description":null,"metadata":null},{"id":"cc627fc6a53349edbda8c7a07fdcb69f","type":"COMBINATION_TREATMENT","name":"chlorothiazide + metolazone + tolvaptan","canonical_id":"ctgov_combo:ctgov-combo-a7295e6485507111","description":null,"metadata":null},{"id":"b95f89618f534c47b973af05d2094ca9","type":"COMBINATION_TREATMENT","name":"chlorothiazide + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-6a0152fa1c57f5ee","description":null,"metadata":null},{"id":"50bf6105d4384562b845e95d973c6cc2","type":"COMBINATION_TREATMENT","name":"chlorothiazide + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-1dec87cde17bf98c","description":null,"metadata":null},{"id":"c57da0b08eb646abb636b212ebac788f","type":"DRUG","name":"chloroxine","canonical_id":"mesh:C004357","description":null,"metadata":null},{"id":"372dff51a75b4d72941a3300f930bbec","type":"DRUG","name":"chlorpheniramine","canonical_id":"gtopdb:6976","description":null,"metadata":null},{"id":"351c0f619c94471b929f687f80c571b8","type":"COMBINATION_TREATMENT","name":"chlorpheniramine + mometasone","canonical_id":"ctgov_combo:ctgov-combo-d7e39c8386f35376","description":null,"metadata":null},{"id":"71ea9a54c6b34d40b25d40a2b31d4209","type":"DRUG","name":"chlorphentermine","canonical_id":"mesh:D002745","description":null,"metadata":null},{"id":"8d4b41824bda4a9cac0d030207cd375f","type":"DRUG","name":"chlorpromazine","canonical_id":"gtopdb:83","description":null,"metadata":null},{"id":"b13fbe1bd4164119a6824bfb6e3b9192","type":"DRUG","name":"chlorpromazine","canonical_id":"mesh:D002746","description":null,"metadata":null},{"id":"8b169c5fdfd147ca82cb9dbc9b670ef2","type":"DRUG","name":"chlorpromazine","canonical_id":"chembl:CHEMBL71","description":null,"metadata":null},{"id":"62da040cd73c4f6cb68dd5eff65dbd1c","type":"COMBINATION_TREATMENT","name":"chlorpromazine + clozapine + olanzapine + quetiapine + risperidone + sulpiride","canonical_id":"ctgov_combo:ctgov-combo-3343562ad81cd145","description":null,"metadata":null},{"id":"e342067dd16247ae99a4609bc221f5ed","type":"DRUG","name":"chlorprothixene","canonical_id":"mesh:D002749","description":null,"metadata":null},{"id":"a1bffb8999df4307bbed3d6a2f84b586","type":"DRUG","name":"chlorthalidone","canonical_id":"gtopdb:7147","description":null,"metadata":null},{"id":"4f7761496ee64186a7cc4306dd0c417b","type":"DRUG","name":"chlorthalidone","canonical_id":"chembl:CHEMBL1055","description":null,"metadata":null},{"id":"f6dfbebd3c02405185d1e89256b97841","type":"COMBINATION_TREATMENT","name":"chlorthalidone + doxazosin + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-687a2e45855c560a","description":null,"metadata":null},{"id":"fb47aa171a19481b9280949df91da1ea","type":"COMBINATION_TREATMENT","name":"chlorthalidone + furosemide","canonical_id":"ctgov_combo:ctgov-combo-7b48176b10acc7f7","description":null,"metadata":null},{"id":"5820f7c875db4fcd934b551e83a1bd2e","type":"COMBINATION_TREATMENT","name":"chlorthalidone + losartan","canonical_id":"ctgov_combo:ctgov-combo-626dbd88d9f24d9c","description":null,"metadata":null},{"id":"f09d08d50fcf4ff6893e8b60a3f7b0e5","type":"COMBINATION_TREATMENT","name":"chlorthalidone + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-1c6c0c1cb4d32545","description":null,"metadata":null},{"id":"c1b604cc24134758a8fe540c101be6a5","type":"COMBINATION_TREATMENT","name":"chlorthalidone + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-6cac85ef558130bc","description":null,"metadata":null},{"id":"de49fb0f82224ac6aecd570a2c3acafe","type":"COMBINATION_TREATMENT","name":"chlorthalidone + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-ce9a35bcf5905b62","description":null,"metadata":null},{"id":"a8e1a1107ac44306aba6f144b623d184","type":"COMBINATION_TREATMENT","name":"chlorthalidone + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-34930b48007d4cf8","description":null,"metadata":null},{"id":"bc094647d77f4a12a3014887b5420704","type":"COMBINATION_TREATMENT","name":"chlorthalidone + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-a27ecf3c1fe9fd8a","description":null,"metadata":null},{"id":"738903d9f23d41f699e9fbb0695cfd72","type":"DRUG","name":"chlorzoxazone","canonical_id":"mesh:D002753","description":null,"metadata":null},{"id":"e7e0cb191e824d39bad0ac0d980f48dc","type":"DISEASE","name":"cholangiocarcinoma","canonical_id":"mondo:0019087","description":null,"metadata":null},{"id":"d482056833994332b9f7e75323eece27","type":"GO_TERM","name":"cholangiocyte apoptotic process","canonical_id":"go:GO:1902488","description":"\"Any apoptotic process in a cholangiocyte.\" [GOC:TermGenie, PMID:22961800]","metadata":null},{"id":"86ea23bbec8b4c1f858129774a5ca151","type":"GO_TERM","name":"cholangiocyte proliferation","canonical_id":"go:GO:1990705","description":"\"The multiplication or reproduction of cholangiocytes, resulting in the expansion of the cholangiocyte population. A cholangiocyte is an epithelial cell that is part of the bile duct. Cholangiocytes contribute to bile secretion via net release of bicarbonate and water.\" [PMID:24434010]","metadata":null},{"id":"94a3a62728264b1db9eeb93361c3d4d2","type":"DISEASE","name":"cholangitis","canonical_id":"mondo:0004789","description":null,"metadata":null},{"id":"0a7aed25c948412a8e835461dda4f9b7","type":"GO_TERM","name":"cholate 12-alpha dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047013","description":"\"Catalysis of the reaction: cholate + NADP+ = 3-alpha,7-alpha-dihydroxy-12-oxo-5-beta-cholanate + H+ + NADPH.\" [RHEA:14129]","metadata":null},{"id":"e9538f0895d54f4889a3d924953558cc","type":"GO_TERM","name":"cholate 7-alpha-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008709","description":"\"Catalysis of the reaction: cholate + NAD+ = -3alpha,12-alpha-dihydroxy-7-oxo--5beta-cholanate + H+ + NADH.\" [RHEA:19409]","metadata":null},{"id":"cba0a718ebe44745b8abdaf8fe535886","type":"GO_TERM","name":"cholate-CoA ligase activity","canonical_id":"go:GO:0047747","description":"\"Catalysis of the reactions: (1) ATP + cholate + CoA = AMP + diphosphate + choloyl-CoA and (2) ATP + (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate + CoA = AMP + diphosphate + (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA. This reaction is the first step in the conjugation of bile acids with amino acids, converting bile acids into their acyl-CoA thioesters. Chenodeoxycholate, deoxycholate, lithocholate and trihydroxycoprostanoate can also act as substrates.\" [EC:6.2.1.7]","metadata":null},{"id":"0cb2e8b488c945038c30d186830d459e","type":"GO_TERM","name":"cholecystokinin receptor activity","canonical_id":"go:GO:0004951","description":"\"Combining with cholecystokinin and transmitting the signal across the membrane by activating an associated G-protein to initiate a change in cell activity. Cholecystokinin can act as a neuropeptide or as a gastrointestinal hormone.\" [GOC:signaling, PMID:9835394]","metadata":null},{"id":"993491c6e65940c5a49fc9b9ece3038c","type":"GO_TERM","name":"cholecystokinin receptor binding","canonical_id":"go:GO:0031739","description":"\"Binding to a cholecystokinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"83390ec21b6f44d9b33cf0c6a5b2fccd","type":"GO_TERM","name":"cholecystokinin signaling pathway","canonical_id":"go:GO:0038188","description":"\"A G protein-coupled receptor signaling pathway initiated by cholecystokinin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:jc, PMID:11181948]","metadata":null},{"id":"13bfc82d44ff4e37b1aae858d0bfcf84","type":"DISEASE","name":"cholelithiasis","canonical_id":"mondo:0012672","description":null,"metadata":null},{"id":"5f6b4e22dd0046d292da96fbef878517","type":"GO_TERM","name":"cholest-4-en-3-one 26-monooxygenase activity","canonical_id":"go:GO:0036199","description":"\"Catalysis of the reaction: cholest-4-en-3-one + NADH + H+ + O2 = 26-hydroxycholest-4-en-3-one + NAD+ + H2O. This reaction involves the hydroxylation of the C26 carbon, followed by oxidation of the alcohol to the carboxylic acid via the aldehyde intermediate.\" [EC:1.14.15.29]","metadata":null},{"id":"c2d7e8442d594de5bcf7bbb8dd93634f","type":"GO_TERM","name":"cholest-5-ene-3-beta,7-alpha-diol 3-beta-dehydrogenase activity","canonical_id":"go:GO:0047016","description":"\"Catalysis of the reaction: NAD+ + 7-alpha-hydroxycholesterol = NADH + H+ + 7-alpha-hydroxycholest-4-en-3-one.\" [EC:1.1.1.181, MetaCyc:1.1.1.181-RXN]","metadata":null},{"id":"4f4fbec84c7c4b5688866e3b249c94e8","type":"GO_TERM","name":"cholestanetetraol 26-dehydrogenase activity","canonical_id":"go:GO:0047748","description":"\"Catalysis of the reaction: 5beta-cholestane-3alpha,7alpha,12alpha-triol + 5 H+ + 3 O2 + 6 reduced [adrenodoxin] = (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate + 4 H2O + 6 oxidized [adrenodoxin].\" [RHEA:34631]","metadata":null},{"id":"429e372e68234076ba8b45b79c2cb234","type":"DISEASE","name":"cholestasis","canonical_id":"mondo:0001751","description":null,"metadata":null},{"id":"8caa6d53782b4842aa93c93d096897dc","type":"GO_TERM","name":"cholestenol delta-isomerase activity","canonical_id":"go:GO:0047750","description":"\"Catalysis of the reaction: 5-alpha-cholest-7-en-3-beta-ol = 5-alpha-cholest-8-en-3-beta-ol.\" [RHEA:15281]","metadata":null},{"id":"eb6883a45ee24682aa72e5c3baa74c2b","type":"GO_TERM","name":"cholesterol 24-hydroxylase activity","canonical_id":"go:GO:0033781","description":"\"Catalysis of the reaction: cholesterol + H+ + NADPH + O2 = (24S)-24-hydroxycholesterol + H2O + NADP+.\" [EC:1.14.14.25, RHEA:22716]","metadata":null},{"id":"824a071b834b4b20b00bc1023075b496","type":"GO_TERM","name":"cholesterol 25-hydroxylase activity","canonical_id":"go:GO:0001567","description":"\"Catalysis of the reaction: AH2 + cholesterol + O2 = 25-hydroxycholesterol + A + H2O.\" [RHEA:21104]","metadata":null},{"id":"7fbcb2288b904468bf8b11c91cc83c6e","type":"GO_TERM","name":"cholesterol 26-hydroxylase activity","canonical_id":"go:GO:0031073","description":"\"Catalysis of the reaction: cholesterol + H+ NADPH + O2 = 26-hydroxycholesterol + H2O + NADP+.\" [PMID:950499, RHEA:43836]","metadata":null},{"id":"51da6900fc784231930b7af6914c75cf","type":"GO_TERM","name":"cholesterol 7-alpha-monooxygenase activity","canonical_id":"go:GO:0008123","description":"\"Catalysis of the reaction: cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 7alpha-hydroxycholesterol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:21812]","metadata":null},{"id":"d1011654b8c44692b56a0f3c9357e072","type":"GO_TERM","name":"cholesterol 7-desaturase [NAD(P)H] activity","canonical_id":"go:GO:0170056","description":"\"Catalysis of the reaction: cholesterol + H+ + NAD(P)H + O2 = 7-dehydrocholesterol + 2 H2O + NAD(P)+.\" [EC:1.14.19.21, PMID:21632547, PMID:31521708]","metadata":null},{"id":"836fbd92f21f4b798eda06d5a52f5ffa","type":"GO_TERM","name":"cholesterol O-acyltransferase activity","canonical_id":"go:GO:0034736","description":"\"Catalysis of the reaction: acyl-CoA + cholesterol = a cholesterol ester + CoA.\" [RHEA:17729]","metadata":null},{"id":"793a62896a5240d69a55e648889de31c","type":"GO_TERM","name":"cholesterol binding","canonical_id":"go:GO:0015485","description":"\"Binding to cholesterol (cholest-5-en-3-beta-ol); the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"54b406b3c65c4f76a7bc59d6d14f995e","type":"GO_TERM","name":"cholesterol biosynthetic process","canonical_id":"go:GO:0006695","description":"\"The chemical reactions and pathways resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:ai]","metadata":null},{"id":"539d0c476916457f9db05c612815c127","type":"GO_TERM","name":"cholesterol catabolic process","canonical_id":"go:GO:0006707","description":"\"The chemical reactions and pathways resulting in the breakdown of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:ai]","metadata":null},{"id":"6b753148eeff4571ae8a2137cce679cb","type":"GO_TERM","name":"cholesterol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0102294","description":"\"Catalysis of the reaction: cholesterol + NAD+ = cholest-5-en-3-one + NADH + H+.\" [RHEA:35459]","metadata":null},{"id":"f9237af7267b479c865a081c7bd79405","type":"GO_TERM","name":"cholesterol efflux","canonical_id":"go:GO:0033344","description":"\"The directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.\" [GOC:sart]","metadata":null},{"id":"fc7fadbd81214850a0bbc5cdeaf52315","type":"GO_TERM","name":"cholesterol ester hydrolysis involved in cholesterol transport","canonical_id":"go:GO:0090122","description":"\"The cholesterol metabolic process in which cholesterol esters are hydrolyzed into free fatty acids and cholesterol in the lysosome that contributes to intracellular cholesterol transport.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d02934abf1374da781e951157213f9da","type":"GO_TERM","name":"cholesterol homeostasis","canonical_id":"go:GO:0042632","description":"\"Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell.\" [GOC:curators]","metadata":null},{"id":"99c65e8081a946cc904b7ea3ef1573ba","type":"GO_TERM","name":"cholesterol import","canonical_id":"go:GO:0070508","description":"\"The directed movement of cholesterol into a cell or organelle.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"45679f6eb9f841a18c78cce36bc3f673","type":"GO_TERM","name":"cholesterol metabolic process","canonical_id":"go:GO:0008203","description":"\"The chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. It is a component of the plasma membrane lipid bilayer and of plasma lipoproteins and can be found in all animal tissues.\" [ISBN:0198506732]","metadata":null},{"id":"7fa62eb07b624df49fa5a3597535a55a","type":"GO_TERM","name":"cholesterol monooxygenase (side-chain-cleaving) activity","canonical_id":"go:GO:0008386","description":"\"Catalysis of the reaction: cholesterol + reduced adrenal ferredoxin + O2 = pregnenolone + 4-methylpentanal + oxidized adrenal ferredoxin + H2O.\" [EC:1.14.15.6]","metadata":null},{"id":"2281fa53a31e4bb997b33236b3e06651","type":"GO_TERM","name":"cholesterol oxidase activity","canonical_id":"go:GO:0016995","description":"\"Catalysis of the reaction: cholesterol + O2 = cholest-5-en-3-one + H2O2.\" [RHEA:32183]","metadata":null},{"id":"6ea8a8cfdc7543d48a44ae2063fc92ec","type":"GO_TERM","name":"cholesterol storage","canonical_id":"go:GO:0010878","description":"\"The accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"dbc3d14ba21446a2b8c229e1fd7e9507","type":"GO_TERM","name":"cholesterol sulfotransferase activity","canonical_id":"go:GO:0051922","description":"\"Catalysis of the reaction: 3'-phosphoadenylyl sulfate + cholesterol = adenosine 3',5'-bisphosphate + cholesterol sulfate + H+.\" [PMID:11416019, PMID:12145317, PMID:12730293, RHEA:52368]","metadata":null},{"id":"c5c195b1ad0842e2b0a9992b75b8416d","type":"GO_TERM","name":"cholesterol transfer activity","canonical_id":"go:GO:0120020","description":"\"Removes cholesterol from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"6aff460debdc431eb5fc4bc13c322bd7","type":"GO_TERM","name":"cholesterol transport","canonical_id":"go:GO:0030301","description":"\"The directed movement of cholesterol, cholest-5-en-3-beta-ol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"24870f60af4643fba71f47159c714592","type":"GO_TERM","name":"cholesterol transport involved in cholesterol storage","canonical_id":"go:GO:0010879","description":"\"The directed movement of cholesterol into cells that is part of their accumulation and maintenance.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"100b033d523d479cb3b959ecd60bbcdc","type":"GO_TERM","name":"cholesterol-5,6-oxide hydrolase activity","canonical_id":"go:GO:0033963","description":"\"Catalysis of the reactions: 5,6alpha-epoxy-5alpha-cholestan-3beta-ol + H2O = cholestane-3beta-5alpha,6beta-triol, and 5,6beta-epoxy-5beta-cholestan-3beta-ol + H2O = cholestane-3beta-5alpha,6beta-triol.\" [EC:3.3.2.11]","metadata":null},{"id":"ab409448bcc7443c9e0ae78b85aa0545","type":"GO_TERM","name":"cholesterol-protein transferase activity","canonical_id":"go:GO:0140853","description":"\"Catalysis of the reaction: cholesterol + glycyl-L-cysteinyl-[protein] + H+ = [protein]-C-terminal glycyl cholesterol ester + N-terminal L-cysteinyl-[protein].\" [PMID:8824192, RHEA:59504]","metadata":null},{"id":"5cb4d01972324d03bc31e7fec4e5753f","type":"DRUG","name":"cholic acid","canonical_id":"mesh:D019826","description":null,"metadata":null},{"id":"7451f61f534b416c801685731ed7e7c5","type":"GO_TERM","name":"choline O-acetyltransferase activity","canonical_id":"go:GO:0004102","description":"\"Catalysis of the reaction: acetyl-CoA + choline = acetylcholine + CoA.\" [EC:2.3.1.6, RHEA:18821]","metadata":null},{"id":"32d1f508d23f43bd9a2be0aa16ac6136","type":"GO_TERM","name":"choline binding","canonical_id":"go:GO:0033265","description":"\"Binding to choline, the amine 2-hydroxy-N,N,N-trimethylethanaminium.\" [GOC:mlg]","metadata":null},{"id":"97853e18291e4db8b2628a3a5e67c54e","type":"GO_TERM","name":"choline biosynthetic process","canonical_id":"go:GO:0042425","description":"\"The chemical reactions and pathways resulting in the formation of choline (2-hydroxyethyltrimethylammonium), an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"be7297e302cc4bb187e19dfb29caf342","type":"GO_TERM","name":"choline catabolic process","canonical_id":"go:GO:0042426","description":"\"The chemical reactions and pathways resulting in the breakdown of choline (2-hydroxyethyltrimethylammonium), an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"b9c956f69abd4ac2a333cbc8c53316d3","type":"GO_TERM","name":"choline dehydrogenase activity","canonical_id":"go:GO:0008812","description":"\"Catalysis of the reaction: A + choline = AH(2) + betaine aldehyde.\" [EC:1.1.99.1, RHEA:17433]","metadata":null},{"id":"12b6e7c1fdf5403cb421b5eb882c4af5","type":"GO_TERM","name":"choline kinase activity","canonical_id":"go:GO:0004103","description":"\"Catalysis of the reaction: ATP + choline = ADP + choline phosphate + 2 H+.\" [EC:2.7.1.32, RHEA:12837]","metadata":null},{"id":"f8428fdcba0a454c94a3530a2021a1a9","type":"GO_TERM","name":"choline metabolic process","canonical_id":"go:GO:0019695","description":"\"The chemical reactions and pathways involving choline (2-hydroxyethyltrimethylammonium), an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"9862ce35e44148f2972c9348fa89327a","type":"GO_TERM","name":"choline monooxygenase (NADP+) activity","canonical_id":"go:GO:0102280","description":"\"Catalysis of the reaction: choline + NADP+ = betaine aldehyde + NADPH + H+.\" [GOC:pz, PMID:21769646]","metadata":null},{"id":"f558d7763f1b45f7b6caceb25ff3830b","type":"GO_TERM","name":"choline monooxygenase activity","canonical_id":"go:GO:0019133","description":"\"Catalysis of the reaction: choline + 2 reduced ferredoxin + O2 + 2 H+ = betaine aldehyde hydrate + 2 oxidized ferredoxin + H2O.\" [EC:1.14.15.7]","metadata":null},{"id":"b6e5520108c442cbaf16c7a7e2a97858","type":"GO_TERM","name":"choline sulfotransferase activity","canonical_id":"go:GO:0047754","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + choline = adenosine 3',5'-diphosphate + choline sulfate + H+.\" [EC:2.8.2.6, RHEA:21984]","metadata":null},{"id":"2a0088d6dbbd4538be05f9e3b6b68390","type":"GO_TERM","name":"choline transmembrane transporter activity","canonical_id":"go:GO:0015220","description":"\"Enables the transfer of choline from one side of a membrane to the other. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.\" [GOC:ai]","metadata":null},{"id":"7c50fd87c4474852be1d7d44fa2d60fd","type":"GO_TERM","name":"choline transport","canonical_id":"go:GO:0015871","description":"\"The directed movement of choline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.\" [GOC:ai]","metadata":null},{"id":"da1113c76510444b8508223891b00092","type":"GO_TERM","name":"choline trimethylamine lyase activity","canonical_id":"go:GO:0120525","description":"\"Catalysis of the reaction: choline = acetaldehyde + trimethylamine.\" [RHEA:35095]","metadata":null},{"id":"eee1515cb72140e79845a8945131d9c5","type":"GO_TERM","name":"choline-phosphate cytidylyltransferase activity","canonical_id":"go:GO:0004105","description":"\"Catalysis of the reaction: CTP + choline phosphate = diphosphate + CDP-choline.\" [EC:2.7.7.15]","metadata":null},{"id":"b88dad89ef014beaac420f4a69fc21e2","type":"GO_TERM","name":"choline-sulfatase activity","canonical_id":"go:GO:0047753","description":"\"Catalysis of the reaction: choline sulfate + H2O = choline + H+ + sulfate.\" [EC:3.1.6.6, RHEA:20820]","metadata":null},{"id":"45fb8cc9e04940e19c47d7455b23ec60","type":"GO_TERM","name":"choline:oxygen 1-oxidoreductase activity","canonical_id":"go:GO:0033713","description":"\"Catalysis of the reaction: choline + O2 = betaine aldehyde + H2O2.\" [EC:1.1.3.17, RHEA:13505]","metadata":null},{"id":"01760c2e9ad54920a2b8877fa9d659d4","type":"GO_TERM","name":"choline:sodium symporter activity","canonical_id":"go:GO:0005307","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: choline(out) + Na+(out) = choline(in) + Na+(in).\" [TC:2.A.22.3.5]","metadata":null},{"id":"b01ccd6aff5b4a00b406072689091b10","type":"GO_TERM","name":"cholinergic synapse","canonical_id":"go:GO:0098981","description":"\"A synapse that uses acetylcholine as a neurotransmitter.\" [GOC:dos]","metadata":null},{"id":"e833957e8f694d71bd0b42cb37845e21","type":"GO_TERM","name":"cholinesterase activity","canonical_id":"go:GO:0004104","description":"\"Catalysis of the reaction: an acylcholine + H2O = choline + a carboxylic acid anion.\" [EC:3.1.1.8]","metadata":null},{"id":"cfb0c4b5274a4f549ba9d95299019b73","type":"GO_TERM","name":"choloyl-CoA hydrolase activity","canonical_id":"go:GO:0033882","description":"\"Catalysis of the reaction: choloyl-CoA + H2O = cholate + CoA.\" [EC:3.1.2.27]","metadata":null},{"id":"9cbafdafff704aa184646101bffa2f80","type":"GO_TERM","name":"choloylglycine hydrolase activity","canonical_id":"go:GO:0045302","description":"\"Catalysis of the reaction: 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholan-24-oylglycine + H2O = 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholanate + glycine.\" [EC:3.5.1.24]","metadata":null},{"id":"8d88e1832875412191cb4fbdcaf2d3ea","type":"GO_TERM","name":"chondro-4-sulfatase activity","canonical_id":"go:GO:0033887","description":"\"Catalysis of the reaction: 4-deoxy-beta-D-gluc-4-enuronosyl-(1->3)-N-acetyl-D-galactosamine 4-sulfate + H2O = 4-deoxy-beta-D-gluc-4-enuronosyl-(1->3)-N-acetyl-D-galactosamine + H+ + sulfate.\" [EC:3.1.6.9, RHEA:11444]","metadata":null},{"id":"64bbd1536b874fdd97ea42997b0bf929","type":"GO_TERM","name":"chondro-6-sulfatase activity","canonical_id":"go:GO:0033888","description":"\"Catalysis of the reaction: 4-deoxy-beta-D-gluc-4-enuronosyl-(1->3)-N-acetyl-D-galactosamine 6-sulfate + H2O = 4-deoxy-beta-D-gluc-4-enuronosyl-(1->3)-N-acetyl-D-galactosamine + H+ + sulfate.\" [EC:3.1.6.10, RHEA:10536]","metadata":null},{"id":"2242675611bf4ddb82807423b3a01021","type":"GO_TERM","name":"chondroblast differentiation","canonical_id":"go:GO:0060591","description":"\"The process in which a mesenchymal cell, acquires specialized structural and/or functional features of a chondroblast. Differentiation includes the processes involved in commitment of a cell to a chondroblast fate. A chondroblast is a precursor cell to chondrocytes.\" [GOC:dph]","metadata":null},{"id":"93879586d1234b4980c7f90a223244e6","type":"GO_TERM","name":"chondrocyte activation","canonical_id":"go:GO:0044566","description":"\"A change in the morphology or behavior of a chondrocyte resulting from exposure to an activating factor such as a cellular or soluble ligand. A chondrocyte is a polymorphic cell that forms cartilage.\" [CL:0000138, GOC:jl]","metadata":null},{"id":"caf5ba46d7aa457bad7a1b5d775a5d0e","type":"GO_TERM","name":"chondrocyte development","canonical_id":"go:GO:0002063","description":"\"The process whose specific outcome is the progression of a chondrocyte over time, from its commitment to its mature state. Chondrocyte development does not include the steps involved in committing a chondroblast to a chondrocyte fate.\" [GOC:dph]","metadata":null},{"id":"f266306c00d041f38d55bcf34c65769c","type":"GO_TERM","name":"chondrocyte development involved in endochondral bone morphogenesis","canonical_id":"go:GO:0003433","description":"\"The progression of a chondrocyte over time from after its commitment to its mature state where the chondrocyte will contribute to the shaping of an endochondral bone.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"16b9c28775a94ae091062f8ce0697de3","type":"GO_TERM","name":"chondrocyte differentiation","canonical_id":"go:GO:0002062","description":"\"The process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte. A chondrocyte is a polymorphic cell that forms cartilage.\" [GOC:dph]","metadata":null},{"id":"fece456cdcb54fb8ba6772d778baf708","type":"GO_TERM","name":"chondrocyte differentiation involved in endochondral bone morphogenesis","canonical_id":"go:GO:0003413","description":"\"The process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte that will contribute to the development of a bone. A chondrocyte is a polymorphic cell that forms cartilage.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"453059de2d174cc3aee8ab2b2fbd2354","type":"GO_TERM","name":"chondrocyte hypertrophy","canonical_id":"go:GO:0003415","description":"\"The growth of a chondrocyte, where growth contributes to the progression of the chondrocyte over time.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"519ac1f133c945dfb809973b097fc270","type":"GO_TERM","name":"chondrocyte intercalation involved in growth plate cartilage morphogenesis","canonical_id":"go:GO:0003428","description":"\"The orderly movement of a chondrocyte from one site to another that contributes to the shaping of growth plate cartilage in an endochondral bone.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"6e064c031a334ef1b6f8853db4b3f518","type":"GO_TERM","name":"chondrocyte morphogenesis","canonical_id":"go:GO:0090171","description":"\"The process in which the structures of a chondrocyte are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of a chondrocyte.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"506e2f33ee5c42d19b2991e2ed7f2313","type":"GO_TERM","name":"chondrocyte proliferation","canonical_id":"go:GO:0035988","description":"\"The multiplication or reproduction of chondrocytes by cell division, resulting in the expansion of their population. A chondrocyte is a polymorphic cell that forms cartilage.\" [CL:0000138, GOC:yaf, PMID:21484705]","metadata":null},{"id":"3f93a05e875e41cdbff54b6bcb5b1319","type":"DISEASE","name":"chondrodysplasia Blomstrand type","canonical_id":"mondo:0008970","description":null,"metadata":null},{"id":"c1f6757dde264aee9e96866d344dd53e","type":"GO_TERM","name":"chondroitin 2-sulfotransferase activity","canonical_id":"go:GO:0034482","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + chondroitin = adenosine 3',5'-bisphosphate + chondroitin 2'-O-sulfate. Results in sulfation of glucuronic acid and iduronic acid residues.\" [PMID:17227754]","metadata":null},{"id":"39fac7313bfd4129a927c651186c0de0","type":"GO_TERM","name":"chondroitin 4-sulfotransferase activity","canonical_id":"go:GO:0047756","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + chondroitin = adenosine 3',5'-bisphosphate + chondroitin 4'-sulfate.\" [EC:2.8.2.5, MetaCyc:CHONDROITIN-4-SULFOTRANSFERASE-RXN]","metadata":null},{"id":"af2c99d92d254647835e24690a6f12b5","type":"GO_TERM","name":"chondroitin 6-sulfotransferase activity","canonical_id":"go:GO:0008459","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + chondroitin = adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate.\" [EC:2.8.2.17]","metadata":null},{"id":"2963ea58e354404499b76cae8968d439","type":"GO_TERM","name":"chondroitin AC lyase activity","canonical_id":"go:GO:0030341","description":"\"Catalysis of the eliminative degradation of polysaccharides containing 1,4-beta-D-hexosaminyl and 1,3-beta-D-glucuronosyl linkages to disaccharides containing 4-deoxy-beta-D-gluc-4-enuronosyl groups.\" [EC:4.2.2.5]","metadata":null},{"id":"f16218640b494e248481482bb7b9b71c","type":"GO_TERM","name":"chondroitin B lyase activity","canonical_id":"go:GO:0033999","description":"\"Catalysis of the reaction: dermatan sulfate = n 4-deoxy-beta-D-gluc-4-enuronosyl-(1,3)-N-acetyl-D-galactosamine 4-sulfate. This reaction is the eliminative cleavage of dermatan sulfate containing 1,4-beta-D-hexosaminyl and 1,3-beta-D-glucurosonyl or 1,3-alpha-L-iduronosyl linkages to disaccharides containing 4-deoxy-beta-D-gluc-4-enuronosyl groups to yield a 4,5-unsaturated dermatan-sulfate disaccharide (DeltaUA-GalNAC-4S). Chondroitin sulfate B is also known as dermatan sulfate.\" [EC:4.2.2.19]","metadata":null},{"id":"716b11c346f446d7ac041338a8b2ac44","type":"GO_TERM","name":"chondroitin hydrolase activity","canonical_id":"go:GO:0052757","description":"\"Catalysis of the hydrolysis of hexosaminic linkages in chondroitin, a linear polymer structure composed of the repeating disaccharide unit [->4)-D-glucuronic acid-(1->3)-N-acetyl-D-galactosamine-(1-], also written as [->4GlcUA1->3GalNAc1-].\" [GOC:mengo_curators, PMID:18390555]","metadata":null},{"id":"70fdac32a6ca424ea2cd4d185e8490e1","type":"GO_TERM","name":"chondroitin sulfate binding","canonical_id":"go:GO:0035374","description":"\"Binding to chondroitin sulfate, a glycosaminoglycan made up of two alternating monosaccharides: D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc).\" [GOC:kmv, ISBN:0198506732]","metadata":null},{"id":"233b99eed8464caf891a7454de66841b","type":"GO_TERM","name":"chondroitin sulfate proteoglycan binding","canonical_id":"go:GO:0035373","description":"\"Binding to a chondroitin sulfate proteoglycan, any proteoglycan containing chondroitin sulfate as the glycosaminoglycan carbohydrate unit.\" [GOC:kmv, ISBN:0198506732]","metadata":null},{"id":"7885e021f4d745ccab2a053655633572","type":"GO_TERM","name":"chondroitin sulfate proteoglycan biosynthetic process","canonical_id":"go:GO:0050650","description":"\"The chemical reactions and pathways resulting in the formation of chondroitin sulfate proteoglycans, which consist of a core protein linked to a chondroitin sulfate glycosaminoglycan. The chondroitin sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, the latter of which can be O-sulfated. Chondroitin sulfate chains are covalently linked to serine/threonine residues (O-linked) of the core protein via a tetrasaccharide linker sequence (xylose-galactose-galactose-glucuronate).\" [PMID:17239763]","metadata":null},{"id":"2f0d90b07efa4f1d8267c63efff61c9c","type":"GO_TERM","name":"chondroitin sulfate proteoglycan catabolic process","canonical_id":"go:GO:0030207","description":"\"The chemical reactions and pathways resulting in the breakdown of chondroitin sulfate proteoglycans, which consist of a core protein linked to a chondroitin sulfate glycosaminoglycan. The chondroitin sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, the latter of which can be O-sulfated.\" [PMID:17239763]","metadata":null},{"id":"239899745d214083a1ea6261c7a8e0a6","type":"GO_TERM","name":"chondroitin sulfate proteoglycan metabolic process","canonical_id":"go:GO:0050654","description":"\"The chemical reactions and pathways involving chondroitin sulfate proteoglycans, which consist of a core protein linked to a chondroitin sulfate glycosaminoglycan. The chondroitin sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, the latter of which can be O-sulfated.\" [PMID:17239763]","metadata":null},{"id":"67c95a9bec07498e80e3f1d20923d711","type":"GO_TERM","name":"chondroitin sulfotransferase activity","canonical_id":"go:GO:0034481","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + chondroitin = adenosine 3',5'-bisphosphate + chondroitin sulfate.\" [GOC:curators]","metadata":null},{"id":"56fb6dbaf7484b05bc2e0ea0342ad97f","type":"GO_TERM","name":"chondroitin-glucuronate 5-epimerase activity","canonical_id":"go:GO:0047757","description":"\"Catalysis of the reaction: chondroitin D-glucuronate = dermatan L-iduronate.\" [EC:5.1.3.19, MetaCyc:CHONDROITIN-GLUCURONATE-5-EPIMERASE-RXN]","metadata":null},{"id":"f763ce132404478b907903cc06291445","type":"GO_TERM","name":"chondroitin-sulfate-ABC endolyase activity","canonical_id":"go:GO:0034000","description":"\"Catalysis of the endolytic cleavage of beta-1,4-galactosaminic bonds between N-acetylgalactosamine and either D-glucuronic acid or L-iduronic acid to produce a mixture of Delta4-unsaturated oligosaccharides of different sizes that are ultimately degraded to Delta4-unsaturated tetra- and disaccharides.\" [EC:4.2.2.20]","metadata":null},{"id":"bd58a9f33ede4ce38a995abc04995dff","type":"GO_TERM","name":"chondroitin-sulfate-ABC exolyase activity","canonical_id":"go:GO:0034001","description":"\"Catalysis of the exolytic cleavage of disaccharide residues from the non-reducing ends of both polymeric chondroitin sulfates and their oligosaccharide fragments.\" [EC:4.2.2.21]","metadata":null},{"id":"b3259aed979c45988ffb57eb37d7b07b","type":"DISEASE","name":"chondrosarcoma","canonical_id":"mondo:0008977","description":null,"metadata":null},{"id":"3f0624bb60ed4d4eb92cb807b5e07fcf","type":"GO_TERM","name":"chordate embryonic development","canonical_id":"go:GO:0043009","description":"\"The process whose specific outcome is the progression of the embryo over time, from zygote formation through a stage including a notochord and neural tube until birth or egg hatching.\" [GOC:mtg_sensu]","metadata":null},{"id":"c490386a50a0406c82b6e23aa4bf3c21","type":"GO_TERM","name":"chordate pharyngeal muscle development","canonical_id":"go:GO:0043282","description":"\"The process whose specific outcome is the progression of the pharyngeal muscle over time, from its formation to the mature structure. A pharyngeal muscle is any muscle that forms part of the pharynx.\" [GOC:curators]","metadata":null},{"id":"0ac075a08bbc4b4fb89e62dfbf0d6ef3","type":"GO_TERM","name":"chordate pharynx development","canonical_id":"go:GO:0160093","description":"\"The process whose specific outcome is the progression of cordate pharynx over time, from its formation to the mature structure.\" [PMID:23020903]","metadata":null},{"id":"a864900102164f64a6d458ace03dfdea","type":"DISEASE","name":"choreatic disease","canonical_id":"mondo:0001595","description":null,"metadata":null},{"id":"df53838f34524f15bb42394815c8e979","type":"GO_TERM","name":"chorio-allantoic fusion","canonical_id":"go:GO:0060710","description":"\"The cell-cell adhesion process in which the cells of the chorion fuse to the cells of the allantois.\" [GOC:dph]","metadata":null},{"id":"b1429ef3b62a4d5eada013fc19686ada","type":"DISEASE","name":"choriocarcinoma","canonical_id":"mondo:0005207","description":null,"metadata":null},{"id":"c0215c3773f24761a91145b500bfed43","type":"GO_TERM","name":"choriogonadotropin hormone binding","canonical_id":"go:GO:0038106","description":"\"Binding to choriogonadotropin hormone, a heterodimer, with an alpha subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH), and a unique beta subunit.\" [GOC:BHF, GOC:rl, Wikipedia:Human_chorionic_gonadotropin]","metadata":null},{"id":"b5628026925d422c9d5d45bb61d923b9","type":"GO_TERM","name":"choriogonadotropin hormone receptor activity","canonical_id":"go:GO:0035472","description":"\"Combining with the choriogonadotropin hormone to initiate a change in cell activity.\" [GOC:bf, ISBN:0198506732, PMID:1922095]","metadata":null},{"id":"29f0b048969d4954a2a192fb94b29dca","type":"GO_TERM","name":"chorion development","canonical_id":"go:GO:0060717","description":"\"The biological process whose specific outcome is the progression of a chorion from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The chorion is an extraembryonic membrane.\" [GOC:dph]","metadata":null},{"id":"456f98f12ea14ec19b7a4eb5ca39784f","type":"GO_TERM","name":"chorion micropyle formation","canonical_id":"go:GO:0046844","description":"\"Establishment of the micropyle, a single cone-shaped specialization of the chorion that allows sperm entry into the egg prior to fertilization.\" [ISBN:0879694238]","metadata":null},{"id":"3dd64c73aa374d96825c1ed75c935c89","type":"GO_TERM","name":"chorion-containing eggshell formation","canonical_id":"go:GO:0007304","description":"\"The construction of a chorion-containing eggshell. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"765e44caef724ac2b1dfe37d670c0eaa","type":"GO_TERM","name":"chorion-containing eggshell pattern formation","canonical_id":"go:GO:0030381","description":"\"The regionalization process that gives rise to the structural pattern of a chorion-containing eggshell such as those found in insects.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"aece0eafa75745bdaf38f07a88288101","type":"GO_TERM","name":"chorionic trophoblast cell development","canonical_id":"go:GO:0060719","description":"\"The process whose specific outcome is the progression of the chorionic trophoblast over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [CL:0011101, GOC:16983341, GOC:dph]","metadata":null},{"id":"b10839ba98114177a15b27604825f66d","type":"GO_TERM","name":"chorionic trophoblast cell differentiation","canonical_id":"go:GO:0060718","description":"\"The process in which relatively unspecialized cells of the ectoplacental cone acquire specialized structural and/or functional features that characterize chorionic trophoblasts. These cells will migrate towards the spongiotrophoblast layer and give rise to syncytiotrophoblasts of the labyrinthine layer.\" [CL:0011101, GOC:dph, PMID:16983341]","metadata":null},{"id":"6d19a13c34d84173a476eb7411902488","type":"GO_TERM","name":"chorionic trophoblast cell proliferation","canonical_id":"go:GO:0097360","description":"\"The multiplication or reproduction of chorionic trophoblast cells, resulting in the expansion of their population.\" [CL:0011101, GOC:BHF, PMID:15150278]","metadata":null},{"id":"5ba2fe8eb9684f73b0cd2364de1ca0da","type":"DISEASE","name":"chorioretinitis","canonical_id":"mondo:0004674","description":null,"metadata":null},{"id":"40a34d27e70042d59e03047bffe9b152","type":"GO_TERM","name":"chorismate biosynthetic process","canonical_id":"go:GO:0009423","description":"\"The chemical reactions and pathways resulting in the formation of the unsymmetrical ether derived from phosphoenolpyruvate and 5-phosphoshikimic acid formed as an intermediate in the biosynthesis of aromatic amino acids and many other compounds.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"cd672dc9ee394991927ecca91514a9fc","type":"GO_TERM","name":"chorismate lyase activity","canonical_id":"go:GO:0008813","description":"\"Catalysis of the reaction: chorismate = 4-hydroxybenzoate + pyruvate.\" [EC:4.1.3.40, RHEA:16505]","metadata":null},{"id":"4606e626b0474980a471cecfda60298c","type":"GO_TERM","name":"chorismate metabolic process","canonical_id":"go:GO:0046417","description":"\"The chemical reactions and pathways involving chorismate, the anion of (3R-trans)-3-((1-carboxyethenyl)oxy)-4-hydroxy-1,5-cyclohexadiene-1-carboxylic acid.\" [ISBN:0198506732]","metadata":null},{"id":"7efe66d68bc14b4caf9f724f580e65a6","type":"GO_TERM","name":"chorismate mutase activity","canonical_id":"go:GO:0004106","description":"\"Catalysis of the reaction: chorismate = prephenate.\" [EC:5.4.99.5, RHEA:13897]","metadata":null},{"id":"6711266fc91c47e380ec6be1e31003d8","type":"GO_TERM","name":"chorismate synthase activity","canonical_id":"go:GO:0004107","description":"\"Catalysis of the reaction: 5-O-(1-carboxyvinyl)-3-phosphoshikimate = chorismate + phosphate.\" [EC:4.2.3.5, RHEA:21020]","metadata":null},{"id":"28d21a7fda1b4c34a5a9838ea1ac5be8","type":"DISEASE","name":"choroidal neovascularization","canonical_id":"mondo:0810000","description":null,"metadata":null},{"id":"17a02980c6dc45b0b4188e490aea19f6","type":"DISEASE","name":"choroiditis","canonical_id":"mondo:0001280","description":null,"metadata":null},{"id":"d45841061c854a5e950b5bd860ee2835","type":"GO_TERM","name":"chromaffin granule","canonical_id":"go:GO:0042583","description":"\"Specialized secretory vesicle found in the cells of adrenal glands and various other organs, which is concerned with the synthesis, storage, metabolism, and secretion of epinephrine and norepinephrine.\" [GOC:jl, PMID:19158310, PMID:1961743]","metadata":null},{"id":"1e0c25a54f2b46409b09613058675781","type":"GO_TERM","name":"chromaffin granule amine transport","canonical_id":"go:GO:0015841","description":"\"The directed movement of amines into, out of or within chromaffin granules.\" [GOC:mah]","metadata":null},{"id":"082e854f90774fdb887b9aad0ad3b50e","type":"GO_TERM","name":"chromaffin granule lumen","canonical_id":"go:GO:0034466","description":"\"The volume enclosed by the membrane of a chromaffin granule.\" [GOC:rph]","metadata":null},{"id":"a55cf8129a0548ee9c061a00c91f62b7","type":"GO_TERM","name":"chromaffin granule membrane","canonical_id":"go:GO:0042584","description":"\"The lipid bilayer surrounding a chromaffin granule, a specialized secretory vesicle found in the cells of adrenal glands and various other organs, which is concerned with the synthesis, storage, metabolism, and secretion of epinephrine and norepinephrine.\" [GOC:jl]","metadata":null},{"id":"705ba39d9e654310b8b34043a460c7e0","type":"GO_TERM","name":"chromate transmembrane transporter activity","canonical_id":"go:GO:0015109","description":"\"Enables the transfer of chromate from one side of a membrane to the other. Chromate is the anion of chromic acid, H2CrO4 (aq) or CrO3.\" [GOC:ai]","metadata":null},{"id":"38d061d560244a6bb97fbecf410f65ea","type":"GO_TERM","name":"chromate transport","canonical_id":"go:GO:0015703","description":"\"The directed movement of chromate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"682f753307de48c8b71b7348ef0e6744","type":"GO_TERM","name":"chromatin","canonical_id":"go:GO:0000785","description":"\"The ordered and organized complex of DNA, protein, and sometimes RNA, that forms the chromosome.\" [GOC:elh, PMID:20404130]","metadata":null},{"id":"aba6fb1b1f8d43929c4d3dc8de6b4919","type":"GO_TERM","name":"chromatin DNA binding","canonical_id":"go:GO:0031490","description":"\"Binding to DNA that is assembled into chromatin.\" [GOC:mah]","metadata":null},{"id":"b68341f41a934d26b9c1abefe4eeccd6","type":"GO_TERM","name":"chromatin binding","canonical_id":"go:GO:0003682","description":"\"Binding to chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase.\" [GOC:jl, ISBN:0198506732, PMID:20404130]","metadata":null},{"id":"dfb12831e3d348b4b9a38ee6ca7221d9","type":"GO_TERM","name":"chromatin extrusion motor activity","canonical_id":"go:GO:0140584","description":"\"A DNA translocase activity that folds chromosomal DNA and catalytically extends the newly formed loop, driven by ATP hydrolysis.\" [PMID:23074191, PMID:26499245, PMID:27210764]","metadata":null},{"id":"953d3315ee064005a1c94e0d790c1dd1","type":"GO_TERM","name":"chromatin insulator sequence binding","canonical_id":"go:GO:0043035","description":"\"Binding to a chromatin insulator sequence, a DNA sequence that prevents enhancer-mediated activation or repression of transcription.\" [GOC:jl, PMID:12783795]","metadata":null},{"id":"52024177582a4800a0cad10a002486fc","type":"GO_TERM","name":"chromatin lock complex","canonical_id":"go:GO:0061793","description":"\"A chromatin silencing complex that binds and bridges separate nucleosomal histones resulting in heterochromatin assembly and chromatin looping.\" [GOC:bhm, GOC:dph, PMID:17540172]","metadata":null},{"id":"a373a3366d3145e5b2926d1c5a461897","type":"GO_TERM","name":"chromatin loop anchoring activity","canonical_id":"go:GO:0140587","description":"\"Bridging together two DNA loop anchors together, maintaining a chromatin loop.\" [PMID:32213323]","metadata":null},{"id":"c8265d5d28ab4f4fb386da966cee3d9f","type":"GO_TERM","name":"chromatin looping","canonical_id":"go:GO:0140588","description":"\"A chromatin organization process that starts with the loading of an extrusion motor (by an SMC family complex) onto the chromatin, followed by chromatin extrusion that stops at loop anchoring sites on the chromosome.\" [PMID:32213323]","metadata":null},{"id":"867c74114a764a3aa7802a0fcb102b48","type":"GO_TERM","name":"chromatin organization","canonical_id":"go:GO:0006325","description":"\"The assembly or remodeling of chromatin composed of DNA complexed with histones, other associated proteins, and sometimes RNA.\" [PMID:20404130]","metadata":null},{"id":"7c674408a3244ed4bcf32421eba9e2fc","type":"GO_TERM","name":"chromatin remodeling","canonical_id":"go:GO:0006338","description":"\"A dynamic process of chromatin reorganization resulting in changes to chromatin structure. These changes allow DNA metabolic processes such as transcriptional regulation, DNA recombination, DNA repair, and DNA replication.\" [GOC:jid, GOC:vw, PMID:12042764, PMID:12697820]","metadata":null},{"id":"9256d532620945b5bab8ae3f68df49a8","type":"GO_TERM","name":"chromatin silencing complex","canonical_id":"go:GO:0005677","description":"\"Any protein complex that mediates changes in chromatin structure that result in transcriptional silencing.\" [GOC:mah]","metadata":null},{"id":"82be60aa86be481cbd322cd674c160fc","type":"GO_TERM","name":"chromatin-nuclear membrane anchor activity","canonical_id":"go:GO:0140707","description":"\"Binding to chromatin and the nuclear inner membrane, in order to establish and maintain the heterochromatin location and organization, or to enable equal segregation of the nuclear membrane during mitosis.\" [PMID:24184107, PMID:31048766]","metadata":null},{"id":"386fb26a2081494db1a6d3e8a9ff8283","type":"GO_TERM","name":"chromatin-protein adaptor activity","canonical_id":"go:GO:0140463","description":"\"An adaptor activity that brings together a protein and a region of the chromatin, such as a nucleosome, to establish or maintain the chromatin localization of the protein, or the complex to which it belongs.\" [PMID:32277274]","metadata":null},{"id":"0c5a65416cbf40eaa1e682476b135973","type":"GO_TERM","name":"chromatin-templated microtubule nucleation","canonical_id":"go:GO:0090223","description":"\"The 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates from chromatin.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"2f360af0f0d844349233a5be18a61285","type":"GO_TERM","name":"chromatoid body","canonical_id":"go:GO:0033391","description":"\"A ribonucleoprotein complex found in the cytoplasm of male germ cells, composed of exceedingly thin filaments that are consolidated into a compact mass or into dense strands of varying thickness that branch to form an irregular network. Contains mRNAs, miRNAs, and protein components involved in miRNA processing (such as Argonaute proteins and the endonuclease Dicer) and in RNA decay (such as the decapping enzyme DCP1a and GW182).\" [PMID:17183363]","metadata":null},{"id":"d441a44c90a04f93be247d9d187de259","type":"GO_TERM","name":"chromatophore ribulose bisphosphate carboxylase complex","canonical_id":"go:GO:0048494","description":"\"A complex, located in the chromatophore, containing either both large and small subunits or just small subunits which carries out the activity of producing 3-phosphoglycerate from carbon dioxide and ribulose-1,5-bisphosphate.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"3bde509d226542d795e214f6be88bd3b","type":"GO_TERM","name":"chromium ion transmembrane transporter activity","canonical_id":"go:GO:0070835","description":"\"Enables the transfer of chromium (Cr) ions from one side of a membrane to the other.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"b3794cacb03447d3bca1ea1f45c4f95e","type":"GO_TERM","name":"chromo shadow domain binding","canonical_id":"go:GO:0070087","description":"\"Binding to a chromo shadow domain, a protein domain that is distantly related, and found in association with, the chromo domain.\" [GOC:BHF, GOC:vk, InterPro:IPR008251, PMID:7667093]","metadata":null},{"id":"aae7ff1356504a2ebc9d8b25d7b64ebd","type":"GO_TERM","name":"chromocenter","canonical_id":"go:GO:0010369","description":"\"A region in which centric, heterochromatic portions from more than one chromosomes form a compact structure.\" [PMID:12384572, PMID:15053486, PMID:16831888]","metadata":null},{"id":"5a7428d28b8c47f184eb19c56826124d","type":"GO_TERM","name":"chromoplast","canonical_id":"go:GO:0009509","description":"\"A plastid containing pigments other than chlorophyll, usually yellow and orange carotenoid pigments.\" [ISBN:0471245208]","metadata":null},{"id":"5918602d1f244992be5bbe5c3b6ecbbc","type":"GO_TERM","name":"chromoplast envelope","canonical_id":"go:GO:0031898","description":"\"The double lipid bilayer enclosing the chromoplast and separating its contents from the rest of the cytoplasm; includes the intermembrane space.\" [GOC:pz]","metadata":null},{"id":"a89870471411449f981cdf8ff6de468b","type":"GO_TERM","name":"chromoplast inner membrane","canonical_id":"go:GO:0031899","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the chromoplast envelope; also faces the chromoplast stroma.\" [GOC:pz]","metadata":null},{"id":"f647d31f556e45ac815c45f9a19d702b","type":"GO_TERM","name":"chromoplast intermembrane space","canonical_id":"go:GO:0031973","description":"\"The region between the inner and outer lipid bilayers of a chromoplast envelope.\" [GOC:mah]","metadata":null},{"id":"b410660dcbdb44fdb81072f793bb7c8d","type":"GO_TERM","name":"chromoplast membrane","canonical_id":"go:GO:0046862","description":"\"Either of the lipid bilayers that surround a chromoplast and form the chromoplast envelope.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"a33e5dc02f9c4bd8a4865e88930a5155","type":"GO_TERM","name":"chromoplast organization","canonical_id":"go:GO:0009661","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the chromoplast. A chromoplast is a plastid containing pigments other than chlorophyll, usually yellow and orange carotenoid pigments.\" [GOC:jid]","metadata":null},{"id":"b0897b38df3e467cabc2c054bf8f8cf4","type":"GO_TERM","name":"chromoplast outer membrane","canonical_id":"go:GO:0031900","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the chromoplast envelope.\" [GOC:pz]","metadata":null},{"id":"9c470288881745229f77f418c5788466","type":"GO_TERM","name":"chromoplast stroma","canonical_id":"go:GO:0009575","description":"\"The space enclosed by the double membrane of a chromoplast but excluding the photosynthetic material.\" [GOC:jl]","metadata":null},{"id":"40d3aa2390204a1a9ede8645af85fd6d","type":"GO_TERM","name":"chromosomal 5-methylcytosine DNA demethylation pathway","canonical_id":"go:GO:0141166","description":"\"A process that chemically modifies 5-methylcytosine (5meC) to make it a substrate for the base excision repair pathway, which then restores the unmodified cytosine.\" [PMID:21862972, PMID:31546611, PMID:36478523]","metadata":null},{"id":"8be6b22b5dea4d2fa20d0d3f855d639a","type":"GO_TERM","name":"chromosomal 5-methylcytosine DNA demethylation, direct 5-methylcytosine excision pathway","canonical_id":"go:GO:0141169","description":"\"An epigenetic cytosine DNA demethylation pathway that involves a DNA glycosylase that directly excises 5-methylcytosine (5-meC) to initiate its replacement with unmethylated cytosine through base excision repair. This pathway is known to occur in plants. In addition to CG sites, plants also methylate cytosines within CHH and CNG sequences.\" [PMID:21862972, PMID:31546611, PMID:36478523]","metadata":null},{"id":"f5109bac11a04628bb1dbe6d9f41155f","type":"GO_TERM","name":"chromosomal 5-methylcytosine DNA demethylation, oxidation pathway","canonical_id":"go:GO:0141167","description":"\"An epigenetic cytosine DNA demethylation pathway that starts with the enzymatic oxidation of the 5-methylcytosine (5meC) to generate 5-hydroxymethylcytosine (5hmC), which successively converted to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC).  A DNA glycosylase (e. g. TDG) recognizes the  intermediate bases 5fC and 5caC and excises the modified base to initiate its replacement with unmethylated cytosine through base excision repair.\" [PMID:21862972, PMID:29875631, PMID:36478523]","metadata":null},{"id":"3c8103714670406ab9d7d407474db588","type":"GO_TERM","name":"chromosomal 5-methylcytosine DNA demethylation, oxidative deamination pathway","canonical_id":"go:GO:0141168","description":"\"An epigenetic cytosine DNA demethylation pathway that includes a deamination step to produce either a thymine (T), or a 5-hydroxymethyluracil (5hmU), if the 5meC had first been converted to 5hmC. A DNA glycosylase (e. g. TDG) recognizes the T mispaired with a G or the 5hmC and excises the modified base to initiate its replacement with unmethylated cytosine through base excision repair.\" [PMID:21862972, PMID:29875631, PMID:36478523]","metadata":null},{"id":"9098bec79e6a46f0a3e7134c06fbccc1","type":"GO_TERM","name":"chromosomal DNA methylation maintenance following DNA replication","canonical_id":"go:GO:0141119","description":"\"The process that maintains methylated cytosine in newly synthesized DNA following DNA replication. After the establishment of novel DNA methylation marks, the newly created patterns must be faithfully transmitted by maintenance DNA methyltransferases during cell division.\" [PMID:11005794, PMID:20142834, PMID:26077819, PMID:34968368]","metadata":null},{"id":"ecf2512c3cf74b4c9b163a71f93c2fe7","type":"DISEASE","name":"chromosomal disorder","canonical_id":"mondo:0019040","description":null,"metadata":null},{"id":"7233acb74a3e49048a472bad5af4ea82","type":"GO_TERM","name":"chromosomal region","canonical_id":"go:GO:0098687","description":"\"Any subdivision of a chromosome along its length.\" [GOC:dos]","metadata":null},{"id":"c6a4b5180955464a9178fa4cb12caef3","type":"GO_TERM","name":"chromosome","canonical_id":"go:GO:0005694","description":"\"A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information.\" [ISBN:0198547684]","metadata":null},{"id":"a44427345fb2419fbf873ed832c61f74","type":"GO_TERM","name":"chromosome attachment to the nuclear envelope","canonical_id":"go:GO:0097240","description":"\"The process in which chromatin is anchored to the nuclear envelope.\" [GOC:vw, PMID:31635174]","metadata":null},{"id":"2fe126df647247fd917db55972e63ead","type":"GO_TERM","name":"chromosome condensation","canonical_id":"go:GO:0030261","description":"\"The progressive compaction of dispersed interphase chromatin into threadlike chromosomes prior to mitotic or meiotic nuclear division, or during apoptosis, in eukaryotic cells.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"46db212173674a129c2b2322afa2f8ea","type":"GO_TERM","name":"chromosome localization","canonical_id":"go:GO:0050000","description":"\"Any process in which a chromosome is transported to, or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"173e56b873544e5b9896c748e79fb446","type":"GO_TERM","name":"chromosome localization to nuclear envelope involved in homologous chromosome segregation","canonical_id":"go:GO:0090220","description":"\"The directed movement of a chromosome to the nuclear envelope that contributes to homologous chromosome segregation and precedes synapsis.\" [GOC:ascb_2009, GOC:dph, GOC:tb, PMID:19913287]","metadata":null},{"id":"6624b4161a334b73ba7502dfe126284a","type":"GO_TERM","name":"chromosome movement towards spindle pole","canonical_id":"go:GO:0051305","description":"\"The directed movement of chromosomes in the center of the spindle towards the spindle poles, mediated by the shortening of microtubules attached to the chromosomes.\" [GOC:ai]","metadata":null},{"id":"a03ea35063b148a19375737c7cc89fe8","type":"GO_TERM","name":"chromosome organization","canonical_id":"go:GO:0051276","description":"\"A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of chromosomes, structures composed of a very long molecule of DNA and associated proteins that carries hereditary information. This term covers covalent modifications at the molecular level as well as spatial relationships among the major components of a chromosome.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"e760f31db879420eb9698521c7e6ea8b","type":"GO_TERM","name":"chromosome organization involved in meiotic cell cycle","canonical_id":"go:GO:0070192","description":"\"A process of chromosome organization that is involved in a meiotic cell cycle.\" [GOC:mah]","metadata":null},{"id":"c9efdc7585d948dab87a261e8b298394","type":"GO_TERM","name":"chromosome passenger complex","canonical_id":"go:GO:0032133","description":"\"A eukaryotically conserved protein complex that localizes to kinetochores in early mitosis, the spindle mid-zone in anaphase B and to the telophase midbody. It has been proposed that the passenger complex coordinates various events based on its location to different structures during the course of mitosis. Complex members include the BIR-domain-containing protein Survivin, Aurora kinase, INCENP and Borealin.\" [GOC:vw, PMID:16824200, PMID:19570910]","metadata":null},{"id":"4cf71e83f98b4a9da27eb4d1057e41a7","type":"GO_TERM","name":"chromosome passenger complex localization to kinetochore","canonical_id":"go:GO:0072356","description":"\"A cellular protein complex localization that acts on a chromosome passenger complex; as a result, the complex is transported to, or maintained in, a specific location at the kinetochore. A chromosome passenger complex is a protein complex that contains the BIR-domain-containing protein Survivin, Aurora B kinase, INCENP and Borealin, and coordinates various events based on its location to different structures during the course of mitosis.\" [GOC:mah]","metadata":null},{"id":"6283c3a2cb114769a119170b0ee76652","type":"GO_TERM","name":"chromosome passenger complex localization to spindle midzone","canonical_id":"go:GO:0035853","description":"\"A cellular protein complex localization that acts on a chromosome passenger complex; as a result, the complex is transported to, or maintained in, a specific location at the spindle midzone. A chromosome passenger complex is a protein complex that contains the BIR-domain-containing protein Survivin, Aurora B kinase, INCENP and Borealin, and coordinates various events based on its location to different structures during the course of mitosis. The spindle midzone is the area in the center of the spindle where the spindle microtubules from opposite poles overlap.\" [GOC:mah, GOC:vw, PMID:15296749]","metadata":null},{"id":"aaaeb39a4e834c9098c254a3f9bfb895","type":"GO_TERM","name":"chromosome segregation","canonical_id":"go:GO:0007059","description":"\"The process in which genetic material, in the form of chromosomes, is organized into specific structures and then physically separated and apportioned to two or more sets. In eukaryotes, chromosome segregation begins with the condensation of chromosomes, includes chromosome separation, and ends when chromosomes have completed movement to the spindle poles.\" [GOC:jl, GOC:mah, GOC:mtg_cell_cycle, GOC:vw]","metadata":null},{"id":"f5d0d182b31540bb8755a681a2507d09","type":"GO_TERM","name":"chromosome separation","canonical_id":"go:GO:0051304","description":"\"The cell cycle process in which paired chromosomes are detached from each other. Chromosome separation begins with the release of cohesin complexes from chromosomes; in budding yeast, this includes the cleavage of cohesin complexes along the chromosome arms, followed by the separation of the centromeric regions. Chromosome separation also includes formation of chromatid axes mediated by condensins, and ends with the disentangling of inter-sister catenation catalyzed by topoisomerase II (topo II).\" [GOC:ai, GOC:lb, GOC:mah, GOC:mtg_cell_cycle, PMID:20352243]","metadata":null},{"id":"a971377221744af4a0dcec0135a76851","type":"GO_TERM","name":"chromosome, centromeric core domain","canonical_id":"go:GO:0034506","description":"\"The innermost portion of the centromeric region of a chromosome, encompassing the core region of a chromosome centromere and the proteins that bind to it.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"2572dd039a95495aa7c5b36884b023fc","type":"GO_TERM","name":"chromosome, centromeric region","canonical_id":"go:GO:0000775","description":"\"The region of a chromosome that includes the centromeric DNA and associated proteins. In monocentric chromosomes, this region corresponds to a single area of the chromosome, whereas in holocentric chromosomes, it is evenly distributed along the chromosome.\" [GOC:cjm, GOC:elh, GOC:kmv, GOC:pr]","metadata":null},{"id":"30d29d0622f74f639b7c440144d447ed","type":"GO_TERM","name":"chromosome, subtelomeric region","canonical_id":"go:GO:0099115","description":"\"A region of the chromosome, adjacent to the telomere (on the centromeric side) that contains repetitive DNA and sometimes genes. This region is usually heterochromatin.\" [GOC:mah, PMID:18761674, PMID:22771823, PMID:26205977, PMID:7660126]","metadata":null},{"id":"9a815c97243a4e82b36e5e1fc1737f47","type":"GO_TERM","name":"chromosome, telomeric region","canonical_id":"go:GO:0000781","description":"\"The end of a linear chromosome, required for the integrity and maintenance of the end. A chromosome telomere usually includes a region of telomerase-encoded repeats the length of which rarely exceeds 20 bp each and that permits the formation of a telomeric loop (T-loop). The telomeric repeat region is usually preceded by a sub-telomeric region that is gene-poor but rich in repetitive elements. Some telomeres only consist of the latter part (for eg. D. melanogaster telomeres).\" [GOC:elh]","metadata":null},{"id":"7af04ec97dc545d9a17e5f69c31b040d","type":"GO_TERM","name":"chromosome, telomeric repeat region","canonical_id":"go:GO:0140445","description":"\"A complex of DNA and protein that seals the end of a chromosome. The telomeric repeat DNA consists of simple tandemly repeated sequences specific for each species. Typically one strand is G-rich and the other C-rich. The G-rich strand forms a 3'-terminal overhang, the length of which varies with species. The single strand overhang is bound by a variety of proteins, including telomere capping proteins that bind to the single-stranded DNA and seal the telomeric loop.\" [PMID:11352055, PMID:30208292]","metadata":null},{"id":"85b50d94a60f4a1889461306fe254a39","type":"DISEASE","name":"chronic beryllium disease","canonical_id":"mondo:0015274","description":null,"metadata":null},{"id":"b36959f07faa42f2952927b5075c1567","type":"DISEASE","name":"chronic bronchitis","canonical_id":"mondo:0005607","description":null,"metadata":null},{"id":"7de502e7bd2c483e8d0702def5d242a3","type":"DISEASE","name":"chronic graft versus host disease","canonical_id":"mondo:0020547","description":null,"metadata":null},{"id":"4d034a6bce854778a239c8da066b859d","type":"DISEASE","name":"chronic hepatitis B virus infection","canonical_id":"mondo:0005366","description":null,"metadata":null},{"id":"5ff11ad6a58d4cdc90ddf6b70d013ad4","type":"DISEASE","name":"chronic hepatitis C virus infection","canonical_id":"mondo:0005354","description":null,"metadata":null},{"id":"019ccccacc7a45898ae706e2f5bb8717","type":"DISEASE","name":"chronic idiopathic urticaria","canonical_id":"mondo:0044212","description":null,"metadata":null},{"id":"4e916f1a8cec4969bb0e421277aea2e7","type":"DISEASE","name":"chronic inflammatory demyelinating polyradiculoneuropathy","canonical_id":"mondo:0006702","description":null,"metadata":null},{"id":"a752d392880d4ed9b36e6ae779e98e1b","type":"GO_TERM","name":"chronic inflammatory response","canonical_id":"go:GO:0002544","description":"\"Inflammation of prolonged duration (weeks or months) in which active inflammation, tissue destruction, and attempts at repair are proceeding simultaneously. Although it may follow acute inflammation, chronic inflammation frequently begins insidiously, as a low-grade, smoldering, often asymptomatic response.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"241b9bd0ce294b24a6f8a26e8660c3d6","type":"GO_TERM","name":"chronic inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002439","description":"\"A chronic inflammatory response to an antigenic stimulus. A chronic inflammatory response persists indefinitely during days, weeks, or months in the life of an individual.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"e19ce32453a14a4f8b165e5d532b34d9","type":"GO_TERM","name":"chronic inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002545","description":"\"A chronic inflammatory response to a non-antigenic stimulus such as heat or physical trauma.\" [GOC:jal]","metadata":null},{"id":"628ce0fe9e594883a0177eb5e71a5dba","type":"DISEASE","name":"chronic kidney disease","canonical_id":"mondo:0005300","description":null,"metadata":null},{"id":"0b24a76fa4a14c048469e740a17ad054","type":"DISEASE","name":"chronic lung disease","canonical_id":"efo:0009910","description":null,"metadata":null},{"id":"3c5dbd489a2e4ce0b88ce0dcec8e9771","type":"DISEASE","name":"chronic mucocutaneous candidiasis","canonical_id":"mondo:0015279","description":null,"metadata":null},{"id":"4d6d488fc32e4fcfaa77e194c83fa831","type":"DISEASE","name":"chronic myeloid leukemia","canonical_id":"mondo:0011996","description":null,"metadata":null},{"id":"0a5cff28dd9943e2b4171e2eca2b28d3","type":"DISEASE","name":"chronic obstructive pulmonary disease","canonical_id":"mondo:0005002","description":null,"metadata":null},{"id":"da438da620cc4e03a1a32945e5a63a57","type":"DISEASE","name":"chronic pancreatitis","canonical_id":"mondo:0005003","description":null,"metadata":null},{"id":"a12430d90e514778abafe0981e794f61","type":"DISEASE","name":"chronic periodontitis","canonical_id":"mondo:0005593","description":null,"metadata":null},{"id":"b0dd8dff3a454f2dae22bfe1487f26f0","type":"DISEASE","name":"chronic primary adrenal insufficiency","canonical_id":"mondo:0015129","description":null,"metadata":null},{"id":"6b51983aeae44a71b451eb4ed2c0c221","type":"DISEASE","name":"chronic progressive multiple sclerosis","canonical_id":"mondo:0005284","description":null,"metadata":null},{"id":"1047ea46373643b1b60063f934270ead","type":"DISEASE","name":"chronic renal failure syndrome","canonical_id":"mondo:0024327","description":null,"metadata":null},{"id":"55f9bc42348d4eb2a31dd6754b17321c","type":"DISEASE","name":"chronic rhinosinusitis","canonical_id":"mondo:0006031","description":null,"metadata":null},{"id":"c17712e61512411fb27b9a4446d365db","type":"GO_TERM","name":"chrorion micropyle","canonical_id":"go:GO:0070825","description":"\"A single cone-shaped specialization that forms an opening in the egg chorion that allows sperm entry into the egg prior to fertilization.\" [GOC:cvs, GOC:mah, PMID:18649270]","metadata":null},{"id":"a6e6779320184cf897b528a75cfa5d51","type":"GO_TERM","name":"chrysanthemyl diphosphate synthase activity","canonical_id":"go:GO:0033849","description":"\"Catalysis of the reaction: 2 dimethylallyl diphosphate = (R,R)-chrysanthemyl diphosphate + diphosphate.\" [EC:2.5.1.67, RHEA:14009]","metadata":null},{"id":"948a77e5f3ec4e1c8dbc7b08dd0007dd","type":"GO_TERM","name":"chrysobactin biosynthetic process","canonical_id":"go:GO:0042858","description":"\"The chemical reactions and pathways resulting in the formation of the siderophore chrysobactin (alpha-N-(2,3-dihydroxybenzoyl)-D-lysyl-L-serine).\" [GOC:jl, PMID:8837459]","metadata":null},{"id":"627fc0a4e0d347499e63bda699d239bb","type":"GO_TERM","name":"chrysobactin catabolic process","canonical_id":"go:GO:0042859","description":"\"The chemical reactions and pathways resulting in the breakdown of the siderophore chrysobactin (alpha-N-(2,3-dihydroxybenzoyl)-D-lysyl-L-serine).\" [GOC:jl, PMID:8837459]","metadata":null},{"id":"a486dc4aa95844d9a43480009bdf19f3","type":"GO_TERM","name":"chrysobactin transmembrane transporter activity","canonical_id":"go:GO:0042933","description":"\"Enables the directed movement of the siderophore chrysobactin (alpha-N-(2,3-dihydroxybenzoyl)-D-lysyl-L-serine) from one side of a membrane to the other.\" [GOC:jl, PMID:8837459]","metadata":null},{"id":"1504d34bfe5d4faf8e59b0fd419936ba","type":"GO_TERM","name":"chrysobactin transport","canonical_id":"go:GO:0042932","description":"\"The directed movement of the siderophore chrysobactin (alpha-N-(2,3-dihydroxybenzoyl)-D-lysyl-L-serine) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:8837459]","metadata":null},{"id":"dd6fdf4508f943c2b5a00c0fb30cf49b","type":"GO_TERM","name":"chylomicron","canonical_id":"go:GO:0042627","description":"\"A large lipoprotein particle (diameter 75-1200 nm) composed of a central core of triglycerides and cholesterol surrounded by a protein-phospholipid coating. The proteins include one molecule of apolipoprotein B-48 and may include a variety of apolipoproteins, including APOAs, APOCs and APOE. Chylomicrons are found in blood or lymph and carry lipids from the intestines into other body tissues.\" [GOC:jl, GOC:rl, PMID:10580165]","metadata":null},{"id":"beda38c3703e439882bb1c4dfebc5caa","type":"GO_TERM","name":"chylomicron assembly","canonical_id":"go:GO:0034378","description":"\"The non-covalent aggregation and arrangement of proteins and lipids in the intestine to form a chylomicron.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a3214ec1b369456e85b3b7e92ee49690","type":"GO_TERM","name":"chylomicron binding","canonical_id":"go:GO:0035478","description":"\"Binding to a chylomicron, a large lipoprotein particle (diameter 75-1200 nm) composed of a central core of triglycerides and cholesterol surrounded by a protein-phospholipid coating. The proteins include one molecule of apolipoprotein B-48 and may include a variety of apolipoproteins, including APOAs, APOCs and APOE.\" [GOC:BHF, PMID:17403372]","metadata":null},{"id":"d2db42270db54cca922f5c84b04e6c10","type":"GO_TERM","name":"chylomicron remnant","canonical_id":"go:GO:0034360","description":"\"A lipoprotein particle that is derived from a mature chylomicron particle by the removal of triglycerides from the chylomicron core by lipoprotein lipase and the subsequent loss of surface components. It characteristically contains apolipoprotein E (APOE) and is cleared from the blood by the liver.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"ac4a3b636db449c68fef212ad8e9d4e1","type":"GO_TERM","name":"chylomicron remnant clearance","canonical_id":"go:GO:0034382","description":"\"The process in which a chylomicron remnant is removed from the blood via receptor-mediated endocytosis into liver cells and its constituent parts degraded.\" [GOC:BHF, GOC:mah, GOC:pde]","metadata":null},{"id":"331df27b72084df1a5d9f22de93e1b16","type":"GO_TERM","name":"chylomicron remodeling","canonical_id":"go:GO:0034371","description":"\"The acquisition, loss or modification of a protein or lipid within a chylomicron, including the hydrolysis of triglyceride by lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"455777fba9ab4d55ab4e9b188635dcc1","type":"GO_TERM","name":"cibarial fish-trap bristle development","canonical_id":"go:GO:0048725","description":"\"The process whose specific outcome is the progression of the cibarial fish-trap bristle over time, from its formation to the mature structure. A cibarial fish-trap bristle is a sensory bristle on the anterior plate of the cibarium.\" [FBbt:00004136, GOC:rc]","metadata":null},{"id":"08768334cffa484595f7318c0f68c096","type":"GO_TERM","name":"cibarial fish-trap bristle morphogenesis","canonical_id":"go:GO:0048718","description":"\"The process in which the anatomical structures of a cibarial fish-trap bristle are generated and organized. A cibarial fish-trap bristle is a sensory bristle on the anterior plate of the cibarium.\" [FBbt:00004136, GOC:rc]","metadata":null},{"id":"ea51aa233af740a0a1215d1ce97fb257","type":"GO_TERM","name":"cichorine biosynthetic process","canonical_id":"go:GO:0062032","description":"\"The chemical reactions and pathways resulting in the formation of cichorine, a secondary metabolite found in some species of fungi.\" [PMID:24244835]","metadata":null},{"id":"7a07feb89fd441c88fb76815b3906bc0","type":"DRUG","name":"ciclesonide","canonical_id":"gtopdb:7469","description":null,"metadata":null},{"id":"3dc3d560495042729bda1388e84bc965","type":"DRUG","name":"ciclesonide","canonical_id":"mesh:C120481","description":null,"metadata":null},{"id":"c3a2f3f53885467d9ef68075ba5a1300","type":"DRUG","name":"ciclesonide","canonical_id":"chembl:CHEMBL2040682","description":null,"metadata":null},{"id":"987fdbb37eae4aa5a8720199324f2cfe","type":"COMBINATION_TREATMENT","name":"ciclesonide + fluticasone + salmeterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-ca48eff8f47c8919","description":null,"metadata":null},{"id":"c34dbc65f802417db5eb8ae785717406","type":"DRUG","name":"ciclopirox","canonical_id":"mesh:C011585","description":null,"metadata":null},{"id":"e0f4bbc1b9d04664abcfc51fb682c009","type":"DRUG","name":"ciclosporin","canonical_id":"mesh:D016572","description":null,"metadata":null},{"id":"53c2d67ec9734c70861e197cbad76048","type":"DRUG","name":"cilastatin","canonical_id":"gtopdb:5166","description":null,"metadata":null},{"id":"5b90f1fdc6a049279e6c6d17b1a3a736","type":"DRUG","name":"cilastatin","canonical_id":"chembl:CHEMBL766","description":null,"metadata":null},{"id":"ecb5f537dac645b4b220e83b1958ae6d","type":"DRUG","name":"cilazapril","canonical_id":"gtopdb:6459","description":null,"metadata":null},{"id":"ed3611bb339a4c98a544dfcc7b3d4caa","type":"DRUG","name":"cilazapril","canonical_id":"chembl:CHEMBL515606","description":null,"metadata":null},{"id":"6d910219402b4982b6c0d870449fa85e","type":"DRUG","name":"cilazaprilat","canonical_id":"gtopdb:6461","description":null,"metadata":null},{"id":"72a11cd004154f7b8f2d2b91ad14747a","type":"GO_TERM","name":"ciliary basal body","canonical_id":"go:GO:0036064","description":"\"A membrane-tethered, short cylindrical array of microtubules and associated proteins found at the base of a eukaryotic cilium (also called flagellum) that is similar in structure to a centriole and derives from it. The cilium basal body is the site of assembly and remodeling of the cilium and serves as a nucleation site for axoneme growth. As well as anchoring the cilium, it is thought to provide a selective gateway regulating the entry of ciliary proteins and vesicles by intraflagellar transport.\" [GOC:cilia, GOC:clt, PMID:21750193]","metadata":null},{"id":"7722863808804e50bd9a6146f44e400a","type":"GO_TERM","name":"ciliary basal body organization","canonical_id":"go:GO:0032053","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a ciliary basal body, a short cylindrical array of microtubules and associated proteins found at the base of a eukaryotic cilium (also called flagellum).\" [GOC:cilia, GOC:dph, GOC:jl, GOC:krc, GOC:mah, PMID:9889124]","metadata":null},{"id":"de1af8817acd495fa8f87e08c7d690b3","type":"GO_TERM","name":"ciliary basal body segregation","canonical_id":"go:GO:0120312","description":"\"The process in which the duplicated basal bodies migrate in pairs to the mitotic poles of the nucleus and results in equal distribution in the daughter cells. Ciliary basal body segregation ensures inheritance of the duplicated mitochondrial DNA to the two daughter cells in the Trypanosoma parasites.\" [GOC:ach, GOC:krc, PMID:1876188, PMID:26272611, PMID:26862392, PMID:27252853, PMID:4055898]","metadata":null},{"id":"1d96a7c6c5cf4a498234e746d872e5b4","type":"GO_TERM","name":"ciliary base","canonical_id":"go:GO:0097546","description":"\"Area of the cilium (also called flagellum) where the basal body and the axoneme are anchored to the plasma membrane. The ciliary base encompasses the distal part of the basal body, transition fibers and transition zone and is structurally and functionally very distinct from the rest of the cilium. In this area proteins are sorted and filtered before entering the cilium, and many ciliary proteins localize specifically to this area.\" [GOC:cilia, GOC:krc, PMID:22653444]","metadata":null},{"id":"51cd107b05ee4cc880be071e5138a988","type":"GO_TERM","name":"ciliary body morphogenesis","canonical_id":"go:GO:0061073","description":"\"The process in which the ciliary body generated and organized. The ciliary body is the circumferential tissue inside the eye composed of the ciliary muscle and ciliary processes.\" [GOC:dph]","metadata":null},{"id":"6d8e29e31d9b4a3c89490c89bafba0fd","type":"GO_TERM","name":"ciliary cap","canonical_id":"go:GO:0061822","description":"\"An intracellular compartmentalized cilium structure found in insect spermatids which is bounded by a membrane derived from the invagination of the cell membrane that remains associated with the primary cilium as it is internalized. The ciliary cap is maintained at the end of the axoneme distal to the centriole and is separated from the cytosolic axoneme/cytoplasm by a putative transition zone, which may extend into the ciliary cap, and include a structure at the base of the ciliary cap termed the ring centriole.\" [PMID:25447994, PMID:27646273]","metadata":null},{"id":"f2099a88045b4fd0ae08c5736bf714b2","type":"GO_TERM","name":"ciliary centrin arm","canonical_id":"go:GO:0120269","description":"\"A rod-shaped protein complex containing Centrin4 protein that flanks the flagellum attachment zone (FAZ) filament and the quartet microtubules.\" [GOC:ach, GOC:krc, PMID:26540076, PMID:31217284]","metadata":null},{"id":"2b521fe16b804db0a50ee0393e24274a","type":"GO_TERM","name":"ciliary centrin arm assembly","canonical_id":"go:GO:0120273","description":"\"The aggregation, arrangement and bonding together of a set of macromolecules to form a ciliary centrin arm, a rod-shaped protein complex containing Centrin4 protein that flanks the flagellum attachment zone (FAZ) filament and the quartet microtubules.\" [GOC:ach, GOC:krc, PMID:32675283]","metadata":null},{"id":"f6f561f2d64345a1a4119dbe89ce4156","type":"GO_TERM","name":"ciliary inversin compartment","canonical_id":"go:GO:0097543","description":"\"Proximal part of the ciliary shaft to which the inversin protein (also called Inv) specifically localizes. The inversin compartment appears to have a different protein composition than the rest of the cilium, although there is no structure that separates it form the distal part of the cilium.\" [GOC:cilia, PMID:19050042]","metadata":null},{"id":"085c9a477fad4f8c9e780728240cfa79","type":"GO_TERM","name":"ciliary membrane","canonical_id":"go:GO:0060170","description":"\"The portion of the plasma membrane surrounding a cilium.\" [GOC:cilia, GOC:dph, GOC:rph]","metadata":null},{"id":"14559354a3e44391b137e2ab5c24e69d","type":"GO_TERM","name":"ciliary microtubule quartet","canonical_id":"go:GO:0120260","description":"\"A set of four specialized microtubules that originates from the basal bodies and wraps around the ciliary pocket membrane, likely supporting its distinct flask shape.\" [DOI:10.5772/66859, GOC:ach, GOC:krc, PMID:19299460, PMID:32518185]","metadata":null},{"id":"a99bcf81659a4255a7b376c3a67cc874","type":"GO_TERM","name":"ciliary necklace","canonical_id":"go:GO:0097538","description":"\"A protein complex located on the cilium membrane in the ciliary transition zone; it is connected to the cilium axoneme via Y-shaped links.\" [GOC:cilia, PMID:22653444, PMID:4554367]","metadata":null},{"id":"2ad0dfadd4a24d83891eb37fb49f977f","type":"GO_TERM","name":"ciliary necklace assembly","canonical_id":"go:GO:1905352","description":"\"The aggregation, arrangement and bonding together of a set of components to form a ciliary necklace.\" [GO_REF:0000079, GOC:cilia, GOC:TermGenie, PMID:20399632, PMID:6409906]","metadata":null},{"id":"4a0038e1a3a34e42a659422729a8989e","type":"GO_TERM","name":"ciliary neurotrophic factor binding","canonical_id":"go:GO:0070119","description":"\"Binding to the cytokine ciliary neurotrophic factor.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"621a65576fa147008cba943d4cdec42f","type":"GO_TERM","name":"ciliary neurotrophic factor receptor activity","canonical_id":"go:GO:0004897","description":"\"Combining with ciliary neurotrophic factor (CNTF) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"5ae3faf6ec8045a6b603c521f480c80b","type":"GO_TERM","name":"ciliary neurotrophic factor receptor binding","canonical_id":"go:GO:0005127","description":"\"Binding to a ciliary neurotrophic factor receptor.\" [GOC:ai]","metadata":null},{"id":"901c4bcf233440c38458c28e4cfdb0bf","type":"GO_TERM","name":"ciliary neurotrophic factor receptor complex","canonical_id":"go:GO:0070110","description":"\"A protein complex that acts as a receptor for the cytokine ciliary neurotrophic factor (CNTF). In humans the receptor complex is a hexamer composed of two molecules each of CNTF and CNTFR and one molecule each of gp130 and LIFR.\" [GOC:BHF, GOC:mah, GOC:rl, PMID:12707266]","metadata":null},{"id":"bf0c9294726c4aac82830b7b2e60ffe1","type":"GO_TERM","name":"ciliary neurotrophic factor-mediated signaling pathway","canonical_id":"go:GO:0070120","description":"\"The series of molecular signals initiated by the binding of a ciliary neurotrophic factor (CNTF) to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"de8b7c66ce5547bab1c2bb46c77a1e51","type":"GO_TERM","name":"ciliary plasm","canonical_id":"go:GO:0097014","description":"\"All of the contents of a cilium, excluding the plasma membrane surrounding the cilium.\" [GOC:BHF, GOC:cilia, GOC:dos, PMID:17895364]","metadata":null},{"id":"bfb491ad648844a58363e516ec02e603","type":"GO_TERM","name":"ciliary pocket","canonical_id":"go:GO:0020016","description":"\"Invagination of the plasma membrane from which a cilium (also called flagellum) protrudes.\" [GOC:cilia, GOC:mb]","metadata":null},{"id":"6aa9743f1e7941b5b1a122fb22d9dccc","type":"GO_TERM","name":"ciliary pocket collar","canonical_id":"go:GO:1990900","description":"\"A constriction site at the junction of the plasma, flagellar and flagellar pocket membranes where the flagellum emerges from the cell body. Observed in some unicellular eukaryotic species such as Chlamydomonas, Giardia and Trypanosoma.\" [GOC:giardia, PMID:18462016, PMID:19806154]","metadata":null},{"id":"a445e0ad2847418eae783177f1757f58","type":"GO_TERM","name":"ciliary pocket membrane","canonical_id":"go:GO:0020018","description":"\"That part of the plasma membrane found in the ciliary pocket (also called flagellar pocket).\" [GOC:cilia, GOC:mb]","metadata":null},{"id":"c6d3102508894910acf53d010fa72e04","type":"GO_TERM","name":"ciliary pro-basal body","canonical_id":"go:GO:0120280","description":"\"The cilary pro-basal body is an immature, partially assembled form of a ciliary basal body found next to the basal body of a cilium. Pro-basal bodies are not capable of nucleating a cilium. As the cell progresses through the cell cycle, continuing assembly will convert the pro-basal body into a mature basal body that is capable of nucleating a cilium.\" [ISBN:0198547684]","metadata":null},{"id":"3bfbf239602c499aac89d465c40a6bb3","type":"GO_TERM","name":"ciliary pro-basal body maturation","canonical_id":"go:GO:0120311","description":"\"A process that is carried out at the cellular level which results in the conversion of an immature and partially assembled ciliary pro-basal body into a mature basal body that is capable of nucleating a cilium.\" [GOC:ach, GOC:krc, PMID:26862392]","metadata":null},{"id":"202d4cbdcb2c48e9ab66f47e6716768a","type":"GO_TERM","name":"ciliary rootlet","canonical_id":"go:GO:0035253","description":"\"A cytoskeleton-like structure, originating from the basal body at the proximal end of a cilium, and extending proximally toward the cell nucleus. Rootlets are typically 80-100 nm in diameter and contain cross striae distributed at regular intervals of approximately 55-70 nm.\" [GOC:cilia, PMID:12427867]","metadata":null},{"id":"309c6a9b4f1243c1bfc39f47f6e2e64b","type":"GO_TERM","name":"ciliary shaft","canonical_id":"go:GO:0097544","description":"\"The mid part of a cilium between the ciliary base and ciliary tip that extends into the extracellular space.\" [GOC:cilia, GOC:krc, PMID:19866682]","metadata":null},{"id":"d0ece0eac56d4e20ae3740fdb7b60060","type":"GO_TERM","name":"ciliary tip","canonical_id":"go:GO:0097542","description":"\"Part of the cilium where the axoneme ends. The ciliary tip has been implicated in ciliary assembly and disassembly, as well as signal transduction.\" [GOC:cilia, PMID:23970417]","metadata":null},{"id":"d3253d44e9684d28b0d14571ad104965","type":"GO_TERM","name":"ciliary transition fiber","canonical_id":"go:GO:0097539","description":"\"A nine-bladed, propeller-like protein complex that links the distal end of the basal body and the cilium to the plasma membrane. Functions in protein sorting and gating (i.e. active and passive transport of proteins in and out of the cilium).\" [GOC:cilia, GOC:kmv, GOC:krc, PMID:22653444, PMID:24231678, PMID:5064817, PMID:5335827]","metadata":null},{"id":"80fd38f076994db28318b6bea5cde011","type":"GO_TERM","name":"ciliary transition zone","canonical_id":"go:GO:0035869","description":"\"A region of the cilium between the basal body and proximal segment that is characterized by Y-shaped assemblages that connect axonemal microtubules to the ciliary membrane. The ciliary transition zone appears to function as a gate that controls ciliary membrane composition and separates the cytosol from the ciliary plasm.\" [GOC:cilia, GOC:kmv, PMID:21422230]","metadata":null},{"id":"c0fb3dc84a77414bb35506f12b8f3fa6","type":"GO_TERM","name":"ciliary transition zone assembly","canonical_id":"go:GO:1905349","description":"\"The aggregation, arrangement and bonding together of a set of components to form a ciliary transition zone.\" [GO_REF:0000079, GOC:cilia, GOC:TermGenie, PMID:21725307, PMID:23644468, PMID:24448408, PMID:26595381, PMID:26982032]","metadata":null},{"id":"72bc6b4fbe984600b825609160149a2f","type":"GO_TERM","name":"ciliary vesicle","canonical_id":"go:GO:0097721","description":"\"A Golgi-derived vesicle to which the ciliary basal body docks via its transitional fibers. Its membrane is compositionally distinct from Golgi membranes, and will become the ciliary membrane once the ciliary vesicle is fused to the plasma membrane. The ciliary vesicle is thought to be formed by multiple smaller vesicles that attach to the transitional fibers and then fuse to form a larger vesicle.\" [GOC:cilia, PMID:13978319, PMID:25686250]","metadata":null},{"id":"ada03dc439f24b1abd4a8aa6fd5c71fc","type":"GO_TERM","name":"ciliary vesicle assembly","canonical_id":"go:GO:1905556","description":"\"The aggregation, arrangement and bonding together of a set of components to form a ciliary vesicle. Multiple smaller vesicles dock to the transitional fibers on a mature basal body and then fuse together to form a larger single vesicle. This then fuses with the plasma membrane and forms the ciliary membrane.\" [GO_REF:0000079, GOC:cilia, GOC:TermGenie, PMID:13978319, PMID:25313408, PMID:25805133, PMID:25812525]","metadata":null},{"id":"cd48b3ecfd924fb0a8aa8106876c98ee","type":"DISEASE","name":"ciliopathy","canonical_id":"mondo:0005308","description":null,"metadata":null},{"id":"87583eef1a8a46c9829edb671059c315","type":"GO_TERM","name":"cilium","canonical_id":"go:GO:0005929","description":"\"A specialized eukaryotic organelle that consists of a filiform extrusion of the cell surface and of some cytoplasmic parts. Each cilium is largely bounded by an extrusion of the cytoplasmic (plasma) membrane, and contains a regular longitudinal array of microtubules, anchored to a basal body.\" [GOC:cilia, GOC:curators, GOC:kmv, GOC:vw, ISBN:0198547684, PMID:16824949, PMID:17009929, PMID:20144998]","metadata":null},{"id":"6628a63b7dfa4368bffb7471189d89c1","type":"GO_TERM","name":"cilium assembly","canonical_id":"go:GO:0060271","description":"\"The assembly of a cilium, a specialized eukaryotic organelle that consists of a filiform extrusion of the cell surface. Each cilium is bounded by an extrusion of the cytoplasmic membrane, and contains a regular longitudinal array of microtubules, anchored basally in a centriole.\" [GOC:BHF, GOC:cilia, GOC:dph, GOC:kmv, GOC:pr, GOC:vw, ISBN:0198506732, PMID:13978319, PMID:27350441]","metadata":null},{"id":"0299c03814d640149f693ae3aecb1955","type":"GO_TERM","name":"cilium attachment to cell body","canonical_id":"go:GO:0120309","description":"\"A process that is carried out at the cellular level which results in the lateral attachment of the cilium to the cell body via the flagellar attachment zone in some trypanosomatid species.\" [GOC:ach, GOC:krc, PMID:11877446, PMID:18820079, PMID:22623724, PMID:26272611]","metadata":null},{"id":"bbe2f0d21eae4a9b9791b31bd85e1f26","type":"GO_TERM","name":"cilium disassembly","canonical_id":"go:GO:0061523","description":"\"A cellular process that results in the breakdown of a cilium.\" [GOC:cilia, GOC:dph, PMID:17604723, PMID:27350441]","metadata":null},{"id":"9221ff54daa842ad8e0a558b3afa49d3","type":"GO_TERM","name":"cilium movement","canonical_id":"go:GO:0003341","description":"\"The directed, self-propelled movement of a cilium.\" [GOC:dph, GOC:jl]","metadata":null},{"id":"965904f06e414e568b65b88c5f1e59eb","type":"GO_TERM","name":"cilium movement involved in cell motility","canonical_id":"go:GO:0060294","description":"\"Movement of cilia mediated by motor proteins that contributes to the movement of a cell.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d32c7bbd6a1c4e6d90f2709eaae9cbbf","type":"GO_TERM","name":"cilium movement involved in otolith formation","canonical_id":"go:GO:0003355","description":"\"The directed, self-propelled movement of cilia of inner ear epithelial cells, resulting the aggregation of otolith seed particles.\" [GOC:dph, GOC:krc, PMID:19043402]","metadata":null},{"id":"e5590db162134edf9ce05bbbefc01e2a","type":"GO_TERM","name":"cilium or flagellum-dependent cell motility","canonical_id":"go:GO:0001539","description":"\"Cell motility due to movement of eukaryotic cilia or bacterial-type flagella or archaeal-type flagella.\" [GOC:cilia, GOC:hjd, GOC:krc]","metadata":null},{"id":"73175f8207cf46869e3e284fc2cb1ced","type":"GO_TERM","name":"cilium organization","canonical_id":"go:GO:0044782","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cilium, a specialized eukaryotic organelle that consists of a filiform extrusion of the cell surface. Each cilium is bounded by an extrusion of the cytoplasmic membrane, and contains a regular longitudinal array of microtubules, anchored basally in a centriole.\" [GOC:cilia, GOC:jl]","metadata":null},{"id":"1656b047a95840e48ca169391d8aeee5","type":"GO_TERM","name":"cilium-dependent cell motility","canonical_id":"go:GO:0060285","description":"\"Cell motility due to the motion of one or more eukaryotic cilia. A eukaryotic cilium is a specialized organelle that consists of a filiform extrusion of the cell surface. Each cilium is bounded by an extrusion of the cytoplasmic (plasma) membrane, and contains a regular longitudinal array of microtubules, anchored basally in a centriole.\" [GOC:cilia, GOC:dgh, GOC:dph, GOC:krc, GOC:mlg, GOC:mtg_cambridge_2013]","metadata":null},{"id":"618e8ea1150d44f9a7cef41ae7e2b4b4","type":"DRUG","name":"cilostazol","canonical_id":"gtopdb:7148","description":null,"metadata":null},{"id":"1f414ff1ef6c4433a23c7176d33c0dd4","type":"DRUG","name":"cilostazol","canonical_id":"mesh:C045645","description":null,"metadata":null},{"id":"af6a366d3e9842a79f712b555bf02650","type":"DRUG","name":"cilostazol","canonical_id":"chembl:CHEMBL799","description":null,"metadata":null},{"id":"13f545135b6243ddbdaa374999b0f8e4","type":"COMBINATION_TREATMENT","name":"cilostazol + probucol","canonical_id":"ctgov_combo:ctgov-combo-6b0a8b55892ab145","description":null,"metadata":null},{"id":"dc5c92b39db44a439e87bb7b939e8e8d","type":"COMBINATION_TREATMENT","name":"cilostazol + probucol","canonical_id":"ctgov_combo:ctgov-combo-234b6847511c551a","description":null,"metadata":null},{"id":"92c1e3c7fc6144d1bd74525b9fa38bbe","type":"COMBINATION_TREATMENT","name":"cilostazol + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-3108457cec0f7e35","description":null,"metadata":null},{"id":"9dad0651c52c47079b3366eeae0bb685","type":"DRUG","name":"cimetidine","canonical_id":"gtopdb:1231","description":null,"metadata":null},{"id":"a9c481514f76486fbe06bc873b5cbea4","type":"DRUG","name":"cimetidine","canonical_id":"chembl:CHEMBL30","description":null,"metadata":null},{"id":"6438feabceb1415bacc292fd53695a03","type":"COMBINATION_TREATMENT","name":"cimetidine + digoxin + furosemide + probenecid + rosuvastatin + verapamil","canonical_id":"ctgov_combo:ctgov-combo-b16061f024300581","description":null,"metadata":null},{"id":"ef7c4866649c46ab9fe307b6e64a7644","type":"COMBINATION_TREATMENT","name":"cimetidine + esomeprazole","canonical_id":"ctgov_combo:ctgov-combo-52aea6e3083745a9","description":null,"metadata":null},{"id":"62a44957bb244c0a94f7ac0baa9e761b","type":"COMBINATION_TREATMENT","name":"cimetidine + famotidine + ranitidine","canonical_id":"ctgov_combo:ctgov-combo-1c56a40d1e846624","description":null,"metadata":null},{"id":"eaa8be15a92441009d4c7df4cce839b8","type":"COMBINATION_TREATMENT","name":"cimetidine + ranitidine + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-257b8aface67ee33","description":null,"metadata":null},{"id":"fc8703422d6e4cab82f93ffc2924795c","type":"DRUG","name":"cinacalcet","canonical_id":"gtopdb:3308","description":null,"metadata":null},{"id":"336c1febdb994833a5396b7a636a0855","type":"COMBINATION_TREATMENT","name":"cinacalcet + paricalcitol","canonical_id":"ctgov_combo:ctgov-combo-1dd577b424e63067","description":null,"metadata":null},{"id":"f9cff1ad67a04ae7a9b9b8140973ea4f","type":"GO_TERM","name":"cingulate gyrus development","canonical_id":"go:GO:0021765","description":"\"The progression of the cingulate gyrus over time from its initial formation until its mature state. The cingulate gyrus is a ridge in the cerebral cortex located dorsal to the corpus callosum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"df0f3c7e27974dc682d75b1fcb3ec230","type":"GO_TERM","name":"cinnamate beta-D-glucosyltransferase activity","canonical_id":"go:GO:0050412","description":"\"Catalysis of the reaction: trans-cinnamate + UDP-D-glucose = 1-O-trans-cinnamoyl-beta-D-glucopyranose + UDP.\" [EC:2.4.1.177, RHEA:13437]","metadata":null},{"id":"6f2875e2f773487c9169b6ca5392851b","type":"GO_TERM","name":"cinnamate reductase activity","canonical_id":"go:GO:0043786","description":"\"Catalysis of the reaction: 3-phenylpropanoate + NAD+ = (E)-cinnamate + NADH + H+.\" [PMID:10849007, RHEA:50944]","metadata":null},{"id":"680dcef6ba614dff9d1d6e93d74698de","type":"GO_TERM","name":"cinnamic acid biosynthetic process","canonical_id":"go:GO:0009800","description":"\"The chemical reactions and pathways resulting in the formation of cinnamic acid, 3-phenyl-2-propenoic acid.\" [GOC:jl]","metadata":null},{"id":"4876010e3bc84d7caea2dae28161f7ec","type":"GO_TERM","name":"cinnamic acid catabolic process","canonical_id":"go:GO:0046281","description":"\"The chemical reactions and pathways resulting in the breakdown of cinnamic acid, 3-phenyl-2-propenoic acid.\" [GOC:ai]","metadata":null},{"id":"0a725b290acd4ef9b99d716bf1d1f5c6","type":"GO_TERM","name":"cinnamic acid ester biosynthetic process","canonical_id":"go:GO:0009802","description":"\"The chemical reactions and pathways resulting in the formation of ester derivatives of cinnamic acid, phenylpropenoic acid.\" [GOC:jl]","metadata":null},{"id":"fb92d4d3557c4b5684bad655b46e68e4","type":"GO_TERM","name":"cinnamic acid ester catabolic process","canonical_id":"go:GO:0046282","description":"\"The chemical reactions and pathways resulting in the breakdown of ester derivatives of cinnamic acid, phenylpropenoic acid.\" [GOC:ai]","metadata":null},{"id":"2757bf51df174d6cb68ebbfd790b8f0c","type":"GO_TERM","name":"cinnamic acid ester metabolic process","canonical_id":"go:GO:0009801","description":"\"The chemical reactions and pathways involving ester derivatives of cinnamic acid, phenylpropenoic acid.\" [GOC:lr, GOC:yl]","metadata":null},{"id":"c6256bca9c594d69babc42583b4786c1","type":"GO_TERM","name":"cinnamic acid metabolic process","canonical_id":"go:GO:0009803","description":"\"The chemical reactions and pathways involving cinnamic acid, 3-phenyl-2-propenoic acid.\" [GOC:jl]","metadata":null},{"id":"5689f309e09649408aed1966d5abe175","type":"GO_TERM","name":"cinnamoyl-CoA reductase (NADP+) activity","canonical_id":"go:GO:0016621","description":"\"Catalysis of the reaction: (E)-cinnamaldehyde + NADP+ + CoA = (E)-cinnamoyl-CoA + NADPH + H+.\" [RHEA:10620]","metadata":null},{"id":"c2b4b088b715472da6b72317c14f32d3","type":"GO_TERM","name":"cinnamoyl-CoA:phenyllactate CoA-transferase activity","canonical_id":"go:GO:0043785","description":"\"Catalysis of the reaction: (E)-cinnamoyl-CoA + (R)-3-phenyllactate = (R)-3-phenyllactoyl-CoA + (E)-cinnamate.\" [RHEA:15601]","metadata":null},{"id":"9f0c524c1c4541e69aa2ef2eec5b4aee","type":"GO_TERM","name":"cinnamyl-alcohol dehydrogenase activity","canonical_id":"go:GO:0045551","description":"\"Catalysis of the reaction: cinnamyl alcohol + NADP+ = cinnamaldehyde + NADPH + H+. Also acts on coniferyl alcohol, sinapyl alcohol and 4-coumaryl alcohol.\" [EC:1.1.1.195]","metadata":null},{"id":"5adc118c85fb4dcf9fadbbfe78bfc420","type":"DRUG","name":"cinoxacin","canonical_id":"mesh:D002937","description":null,"metadata":null},{"id":"c53246811c0c4aa7bf04dbf1bbddbcad","type":"DRUG","name":"ciprofibrate","canonical_id":"gtopdb:3438","description":null,"metadata":null},{"id":"1c339729f9be4934a599be6964c420ee","type":"DRUG","name":"ciprofibrate","canonical_id":"chembl:CHEMBL557555","description":null,"metadata":null},{"id":"86f21dc299004df2869298664fc0b528","type":"DRUG","name":"ciprofloxacin","canonical_id":"mesh:D002939","description":null,"metadata":null},{"id":"e1a08bc372604c56a9ab56299e7a5d60","type":"GO_TERM","name":"circadian behavior","canonical_id":"go:GO:0048512","description":"\"The specific behavior of an organism that recurs with a regularity of approximately 24 hours.\" [GOC:bf, GOC:curators, GOC:pr]","metadata":null},{"id":"1ae9acd790df481aab8fa191034d69ac","type":"GO_TERM","name":"circadian mating behavior","canonical_id":"go:GO:0035648","description":"\"The fluctuation in mating behavior that occurs over an approximately 24 hour cycle.\" [GOC:bf, GOC:dos, PMID:11470898, PMID:17276917]","metadata":null},{"id":"9b1cad31922d4b79a76e4bc2ae6649ae","type":"GO_TERM","name":"circadian regulation of calcium ion oscillation","canonical_id":"go:GO:0010617","description":"\"Any process that modulates the concentration of cytosolic free calcium ion [Ca2+]cyt with a regularity of approximately 24 hours.\" [PMID:17982000]","metadata":null},{"id":"5edd6e8d8a7042429c8661a322a31bc6","type":"GO_TERM","name":"circadian regulation of gene expression","canonical_id":"go:GO:0032922","description":"\"Any process that modulates the frequency, rate or extent of gene expression such that an expression pattern recurs with a regularity of approximately 24 hours.\" [GOC:mah]","metadata":null},{"id":"2c27444d548f4cc0a18f6f4c957e26af","type":"GO_TERM","name":"circadian regulation of heart rate","canonical_id":"go:GO:0003053","description":"\"Any process in which an organism modulates its heart rate at different values with a regularity of approximately 24 hours.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"377c057bda5240f4b215d1d54f783fc3","type":"GO_TERM","name":"circadian regulation of heart rate by the suprachiasmatic nucleus","canonical_id":"go:GO:0003055","description":"\"The process in which the suprachiasmatic nucleus modulates heart rate at different values with a regularity of approximately 24 hours.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"97c9845821354e85b23ed5f567962cdc","type":"GO_TERM","name":"circadian regulation of systemic arterial blood pressure","canonical_id":"go:GO:0003052","description":"\"Any process in which an organism modulates its blood pressure at different values with a regularity of approximately 24 hours.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"9b1ace9bc3354e29a4444256cf5b82af","type":"GO_TERM","name":"circadian regulation of systemic arterial blood pressure by hormone","canonical_id":"go:GO:0003067","description":"\"The process in which hormones modulate the force with which blood passes through the circulatory system contributing to different values of blood pressure oscillating with a regularity of approximately 24 hours. A hormone is one of a group of substances formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells, in the same organism, upon which they have a specific regulatory action.\" [GOC:mtg_cardio]","metadata":null},{"id":"f01dd70493ec46249ca022a1d26fc622","type":"GO_TERM","name":"circadian regulation of systemic arterial blood pressure by the suprachiasmatic nucleus","canonical_id":"go:GO:0003054","description":"\"The process in which the suprachiasmatic nucleus modulates blood pressure at different values with a regularity of approximately 24 hours.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"e3d49800b1b340acb9441b8043167375","type":"GO_TERM","name":"circadian regulation of translation","canonical_id":"go:GO:0097167","description":"\"Any process that modulates the frequency, rate or extent of mRNA translation with a regularity of approximately 24 hours.\" [GOC:ans, PMID:17264215]","metadata":null},{"id":"39a02ceecf1749d3bdc3775dffb1f554","type":"GO_TERM","name":"circadian rhythm","canonical_id":"go:GO:0007623","description":"\"Any biological process in an organism that recurs with a regularity of approximately 24 hours.\" [GOC:bf, GOC:curators]","metadata":null},{"id":"afb3dcda39dd4eea880f753acfb5c900","type":"DISEASE","name":"circadian rhythm sleep disorder","canonical_id":"mondo:0024361","description":null,"metadata":null},{"id":"229925abd81c49de904aa10093e7bf40","type":"GO_TERM","name":"circadian sleep/wake cycle","canonical_id":"go:GO:0042745","description":"\"The cycle from wakefulness through an orderly succession of sleep states and stages that occurs on an approximately 24 hour rhythm.\" [GOC:jl, PMID:26947521, PMID:33537937]","metadata":null},{"id":"597ab7acd4d148398cc8c8e984dd3e30","type":"GO_TERM","name":"circadian sleep/wake cycle process","canonical_id":"go:GO:0022410","description":"\"A behavioral process involved in the cycle from wakefulness through an orderly succession of sleep states and stages that occurs on an approximately 24 hour rhythm.\" [GOC:isa_complete]","metadata":null},{"id":"ab3a74f22c1643c89ab78c97177e4146","type":"GO_TERM","name":"circadian sleep/wake cycle, REM sleep","canonical_id":"go:GO:0042747","description":"\"A stage in the circadian sleep cycle during which dreams occur and the body undergoes marked changes including rapid eye movement, loss of reflexes, and increased pulse rate and brain activity.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"43080f5730d84a50bceccec5f000ef0b","type":"GO_TERM","name":"circadian sleep/wake cycle, non-REM sleep","canonical_id":"go:GO:0042748","description":"\"All sleep stages in the circadian sleep/wake cycle other than REM sleep. These stages are characterized by a slowing of brain waves and other physiological functions.\" [GOC:jl, PMID:33537937]","metadata":null},{"id":"5a64ae575aca4b718a9ada603550446e","type":"GO_TERM","name":"circadian sleep/wake cycle, sleep","canonical_id":"go:GO:0050802","description":"\"The part of the circadian sleep/wake cycle where the organism is asleep.\" [GOC:ai]","metadata":null},{"id":"7d51bbfe88504050ae1a4645f834f2df","type":"GO_TERM","name":"circadian sleep/wake cycle, wakefulness","canonical_id":"go:GO:0042746","description":"\"The part of the circadian sleep/wake cycle where the organism is not asleep.\" [GOC:jl, PMID:12575468]","metadata":null},{"id":"1c5136c589ab4d4cb51dd228519746ea","type":"GO_TERM","name":"circadian temperature homeostasis","canonical_id":"go:GO:0060086","description":"\"Any homeostatic process in which an organism modulates its internal body temperature at different values with a regularity of approximately 24 hours.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7180f7b8cf704a68a903400e73b4175e","type":"GO_TERM","name":"circulatory system development","canonical_id":"go:GO:0072359","description":"\"The process whose specific outcome is the progression of the circulatory system over time, from its formation to the mature structure. The circulatory system is the organ system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis.\" [GOC:mah, UBERON:0001009]","metadata":null},{"id":"ef3cea3ef48f4558849a832db87cc2b5","type":"GO_TERM","name":"circulatory system process","canonical_id":"go:GO:0003013","description":"\"An organ system process carried out by any of the organs or tissues of the circulatory system. The circulatory system is an organ system that moves extracellular fluids to and from tissue within a multicellular organism.\" [GOC:mtg_cardio]","metadata":null},{"id":"bd53b8719f1d4771b90e4f2fcd4a021a","type":"GO_TERM","name":"circumferential growth involved in left ventricle morphogenesis","canonical_id":"go:GO:0003243","description":"\"The morphogenetic growth in which the left ventricle grows expanding its external boundary.\" [GOC:mtg_heart, PMID:14709543]","metadata":null},{"id":"75e60652f28046d684128e19dc4e041b","type":"GO_TERM","name":"circumnutation","canonical_id":"go:GO:0010031","description":"\"The organismal movement by which the tip of a plant organ follows a spiral pattern as a consequence of growth.\" [GOC:mtg_MIT_16mar07, ISBN:0192801023]","metadata":null},{"id":"c7782a32bb1c40c4ac549a1c96538499","type":"DISEASE","name":"cirrhosis of liver","canonical_id":"mondo:0005155","description":null,"metadata":null},{"id":"a016196e7a2640409008b4046316a7a9","type":"GO_TERM","name":"cirsimaritin 4'-O-methyltransferase activity","canonical_id":"go:GO:0102625","description":"\"Catalysis of the reaction: cirsimaritin + S-adenosyl-L-methionine = H+ + S-adenosyl-L-homocysteine + salvigenin.\" [RHEA:73251]","metadata":null},{"id":"02a5adc44857486bba89ff852a54d7eb","type":"GO_TERM","name":"cis assembly of pre-catalytic spliceosome","canonical_id":"go:GO:0000354","description":"\"Assembly of a spliceosomal complex containing the intact pre-mRNA and all of the spliceosomal snRNPs. This occurs when the tri-snRNP associates with the pre-mRNA and associated snRNPs in an ATP-dependent manner.\" [GOC:krc, GOC:mtg_mpo, ISBN:0879695897]","metadata":null},{"id":"4087099f9d94416d99b08eca3235a279","type":"GO_TERM","name":"cis-1,2-dihydro-1,2-dihydroxynaphthalene dehydrogenase activity","canonical_id":"go:GO:0018505","description":"\"Catalysis of the reaction: cis-1,2-dihydronaphthalene-1,2-diol + NAD+ = naphthalene-1,2-diol + NADH + H+.\" [EC:1.3.1.29]","metadata":null},{"id":"6d45cc6c0820400e985fe77ab289b807","type":"GO_TERM","name":"cis-1,2-dihydrobenzene-1,2-diol dehydrogenase activity","canonical_id":"go:GO:0018504","description":"\"Catalysis of the reaction: cis-1,2-dihydrobenzene-1,2-diol + NAD+ = catechol + NADH + H+.\" [EC:1.3.1.19]","metadata":null},{"id":"0fb5a687bffc46819a823e266a285b5e","type":"GO_TERM","name":"cis-1,2-dihydroxy-4-methylcyclohexa-3,5-diene-1-carboxylate dehydrogenase activity","canonical_id":"go:GO:0018520","description":"\"Catalysis of the reaction: cis-1,2-dihydroxy-4-methylcyclohexa-3,5-diene-1-carboxylate + NADP+ = 4-methylcatechol + NADPH + H+ + CO2.\" [EC:1.3.1.67]","metadata":null},{"id":"b1f1ab992b3841e08f150351724a9fe1","type":"GO_TERM","name":"cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase activity","canonical_id":"go:GO:0018509","description":"\"Catalysis of the reaction: cis-3-phenylcyclohexa-3,5-diene-1,2-diol + NAD+ = biphenyl-2,3-diol + NADH + H+.\" [EC:1.3.1.56]","metadata":null},{"id":"5ffead9a7c1c479a8615a0cd44d2f84b","type":"GO_TERM","name":"cis-2-enoyl-CoA reductase (NADPH) activity","canonical_id":"go:GO:0047774","description":"\"Catalysis of the reaction: acyl-CoA + NADP+ = cis-2,3-dehydroacyl-CoA + NADPH.\" [EC:1.3.1.37]","metadata":null},{"id":"de7f2d9dfcad4be3bc93ba1bd420c501","type":"GO_TERM","name":"cis-3,4-dihydrophenanthrene-3,4-diol dehydrogenase activity","canonical_id":"go:GO:0018507","description":"\"Catalysis of the reaction: (3S,4R)-3,4-dihydrophenanthrene-3,4-diol + NAD+ = H+ + NADH + phenanthrene-3,4-diol.\" [EC:1.3.1.49, RHEA:16253]","metadata":null},{"id":"aa3046f8ec574e1c996e100d1a053976","type":"GO_TERM","name":"cis-Golgi network","canonical_id":"go:GO:0005801","description":"\"The network of interconnected tubular and cisternal structures located at the convex side of the Golgi apparatus, which abuts the endoplasmic reticulum.\" [ISBN:0198506732, ISBN:0815316194, PMID:23543640, PMID:9695800]","metadata":null},{"id":"428b113df02446e2a9b9b487524de1fc","type":"GO_TERM","name":"cis-Golgi network membrane","canonical_id":"go:GO:0033106","description":"\"The lipid bilayer surrounding any of the compartments that make up the cis-Golgi network.\" [GOC:mah]","metadata":null},{"id":"4ccfdc6db2f849fb8a9016c48b878344","type":"GO_TERM","name":"cis-Golgi-derived vesicle fusion with Golgi medial cisterna membrane","canonical_id":"go:GO:1990691","description":"\"The joining of the lipid bilayer membrane around a cis-Golgi-derived vesicle to the lipid bilayer membrane around the medial-Golgi cisterna. Vesicles are involved in anterograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"af6dec7e349b406583dd69fb7b07edd6","type":"GO_TERM","name":"cis-abienol biosynthetic process","canonical_id":"go:GO:1902246","description":"\"The chemical reactions and pathways resulting in the formation of cis-abienol.\" [GOC:TermGenie, PMID:22672125]","metadata":null},{"id":"91d2d7a85e3641f6bb52db50c546cb85","type":"GO_TERM","name":"cis-abienol catabolic process","canonical_id":"go:GO:1902245","description":"\"The chemical reactions and pathways resulting in the breakdown of cis-abienol.\" [GOC:TermGenie, PMID:22672125]","metadata":null},{"id":"5f57de12b7c34dbd80f9e7cb8bf8829f","type":"GO_TERM","name":"cis-acting DNA replication termination","canonical_id":"go:GO:0071946","description":"\"A DNA replication termination process that is initiated by protein binding to a binding site on the same chromosome, but remote from the termination site, via DNA looping or chromosome kissing.\" [GOC:vw, PMID:20850009]","metadata":null},{"id":"3af88823363149a5bcd987b9ddccf459","type":"GO_TERM","name":"cis-dihydroethylcatechol dehydrogenase activity","canonical_id":"go:GO:0018519","description":"\"Catalysis of the reaction: cis-1,2-dihydro-3-ethylcatechol + NAD+ = 3-ethylcatechol + H+ + NADH.\" [EC:1.3.1.66, RHEA:18101]","metadata":null},{"id":"1d8affe80c5f4525b1a1f1c05a0502c2","type":"GO_TERM","name":"cis-p-coumarate glucosyltransferase activity","canonical_id":"go:GO:0050644","description":"\"Catalysis of the reaction: cis-4-coumarate + UDP-D-glucose = 4'-O-beta-D-glucosyl-cis-4-coumarate + H+ + UDP.\" [EC:2.4.1.209, RHEA:13129]","metadata":null},{"id":"0b430577eddb4bba9f85292bec3726c6","type":"GO_TERM","name":"cis-regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0000987","description":"\"Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site, located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by some RNA polymerase. Cis-regulatory sites are often referred to as a sequence motifs, enhancers, or silencers.\" [GOC:txnOH-2018]","metadata":null},{"id":"9bc518f73c614610ab2491e27dd62bc6","type":"GO_TERM","name":"cis-stilbene-oxide hydrolase activity","canonical_id":"go:GO:0033961","description":"\"Catalysis of the reaction: cis-stilbene oxide + H2O = (+)-(1R,2R)-1,2-diphenylethane-1,2-diol.\" [EC:3.3.2.9]","metadata":null},{"id":"0e3ee343204d4f38a0ed0bd07e976792","type":"GO_TERM","name":"cis-trans isomerase activity","canonical_id":"go:GO:0016859","description":"\"Catalysis of a reaction that interconverts cis and trans isomers. Atoms or groups are termed cis or trans to one another when they lie respectively on the same or on opposite sides of a reference plane identifiable as common among stereoisomers.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"e851c1e3bc6641d0886c95412940ca7f","type":"GO_TERM","name":"cis-zeatin O-beta-D-glucosyltransferase activity","canonical_id":"go:GO:0050502","description":"\"Catalysis of the reaction: cis-zeatin + UDP-D-glucose = O-beta-D-glucosyl-cis-zeatin + H+ + UDP.\" [EC:2.4.1.215, RHEA:20681]","metadata":null},{"id":"3e694b4212654e7b8a6495236d453574","type":"GO_TERM","name":"cis-zeatin biosynthetic process","canonical_id":"go:GO:0033465","description":"\"The chemical reactions and pathways resulting in the formation of cis-zeatin, (2Z)-2-methyl-4-(9H-purin-6-ylamino)but-2-en-1-ol.\" [GOC:mah]","metadata":null},{"id":"9465be5b4fa04d97b75cd21d0e2b7cf9","type":"DRUG","name":"cisapride","canonical_id":"gtopdb:240","description":null,"metadata":null},{"id":"9a610a1fdba645a8a1e43f80383180f2","type":"DRUG","name":"cisapride","canonical_id":"mesh:D020117","description":null,"metadata":null},{"id":"0e0278a790204575ab4306183e538a29","type":"GO_TERM","name":"cisternal progression","canonical_id":"go:GO:0045057","description":"\"The process that results in the physical movement of a new cis-Golgi stack from the cis-position, nearest the endoplasmic reticulum (ER), to the trans position, farthest from the ER, successively becoming first a medial-Golgi cisterna and then a trans-Golgi cisterna.\" [ISBN:0716731363]","metadata":null},{"id":"35299a6741d94b4f9dd24c39bd920951","type":"DRUG","name":"citalopram","canonical_id":"gtopdb:7547","description":null,"metadata":null},{"id":"507fc1bd0a24415f80e09527a339d799","type":"COMBINATION_TREATMENT","name":"citalopram + duloxetine + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-0892f85b9a07dadf","description":null,"metadata":null},{"id":"6ac8a0af7f5c4acea5cc4ae5deab30aa","type":"COMBINATION_TREATMENT","name":"citalopram + duloxetine + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-1c0b1316daaf9f6b","description":null,"metadata":null},{"id":"b0ab9859c7874a7cb4bc25b1625f814d","type":"COMBINATION_TREATMENT","name":"citalopram + duloxetine + escitalopram + sertraline + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-1179e3ebbb48a45d","description":null,"metadata":null},{"id":"5e0f1144571c49f4b7025c7607845cfe","type":"COMBINATION_TREATMENT","name":"citalopram + duloxetine + escitalopram + sertraline + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-e5545a90c7310417","description":null,"metadata":null},{"id":"4eaabad07cd94822b417954152e75828","type":"COMBINATION_TREATMENT","name":"citalopram + duloxetine + escitalopram + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-111ae5ae9ef0715c","description":null,"metadata":null},{"id":"cf358e1ff71d49828518def72ae13d3f","type":"COMBINATION_TREATMENT","name":"citalopram + duloxetine + fluoxetine + paroxetine + sertraline","canonical_id":"ctgov_combo:ctgov-combo-7c831a98d5711952","description":null,"metadata":null},{"id":"a635bf7847284a04ad8fd96c67e6ca5b","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-5cad747f07eb0e19","description":null,"metadata":null},{"id":"b8b82975719b410aa714408773dbe3b1","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-5d868bb4687c83e9","description":null,"metadata":null},{"id":"146d5ce7c5f14fb0b6ab6334e6e119df","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-9395d36010ce77e5","description":null,"metadata":null},{"id":"a194e6c9264346ccbe7b2b6d4a273cbf","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-ec68a4746ca42ebd","description":null,"metadata":null},{"id":"e7ef4066d20142e7bfbd92cbc621b776","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-5f2a55c00fa6d2e9","description":null,"metadata":null},{"id":"b8c73681a3f54a20a8dc826205636d64","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-d688cc5ac4bcee05","description":null,"metadata":null},{"id":"84fa66e2e9804a43bd381aca75149543","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-f96215762cd12266","description":null,"metadata":null},{"id":"316c3c3ecdac412ca277c287aef9e9ac","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-9db84274ac6cf546","description":null,"metadata":null},{"id":"fb56094f4e3a4764a12027e3630176cb","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-e2cc3c70415d403a","description":null,"metadata":null},{"id":"e3f8dd837f6a4d66b647a0b737a03489","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-3be3f4a5f60f53b6","description":null,"metadata":null},{"id":"b159b9d13f3e4c3ebf16c23efe5ef646","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-a43e5f218164a300","description":null,"metadata":null},{"id":"e92ca4e9f68e4779851fdcddc67fc288","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-6005316dd8cd0865","description":null,"metadata":null},{"id":"af9b470c37db44e2ad39fd1ca09319f5","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-bb600e7590cc2dfd","description":null,"metadata":null},{"id":"b000aa566eb84a1983a221220ac4a7b0","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-0383cc0bd500b2b6","description":null,"metadata":null},{"id":"4167f0538e8a42edba21f6f241d02123","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-287541fd950ceb8a","description":null,"metadata":null},{"id":"bcc424acce2f4b56babd30e45c39dfeb","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-5c48513cb69315ea","description":null,"metadata":null},{"id":"42aaec303b0f45d29136d8cc702a4d92","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-cbe666eff3990bb3","description":null,"metadata":null},{"id":"153f33a049ef40e4a44361b87d3523ed","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-9e6fb973503fcd36","description":null,"metadata":null},{"id":"d2ef1967627c41778de53ae00737c67f","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-4cd1d2746ec2befc","description":null,"metadata":null},{"id":"f58c908762394c4691f6f7cc99c07059","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-6f274a745b6a553a","description":null,"metadata":null},{"id":"b754ad9f45a64a798a858e81b5ffbe6f","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-0bb2a543c66474f3","description":null,"metadata":null},{"id":"d2870cb9304f46978f8cf94acdf76fbe","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram","canonical_id":"ctgov_combo:ctgov-combo-9b5ac5675e1225b4","description":null,"metadata":null},{"id":"f3fa426e1bd542c49296607c6bb2c90d","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram + levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-0760b72b4859b999","description":null,"metadata":null},{"id":"837207457e13482d8b92217e4743e151","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram + mirtazapine + sertraline + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-bba6f8017318e255","description":null,"metadata":null},{"id":"68ecda23f54a4bb8b0ae7f9c79c000ea","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram + quetiapine","canonical_id":"ctgov_combo:ctgov-combo-a831f1086f2a6e13","description":null,"metadata":null},{"id":"9d200a9cd8dd4cc38854df8d56f775b4","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram + quetiapine","canonical_id":"ctgov_combo:ctgov-combo-ecbd784592fa5aad","description":null,"metadata":null},{"id":"ca6af84cda524636b9cf447e08dd14a9","type":"COMBINATION_TREATMENT","name":"citalopram + escitalopram + sertraline","canonical_id":"ctgov_combo:ctgov-combo-937947f48e5755be","description":null,"metadata":null},{"id":"cc942b81b6d5487c9955b64978ccd7c3","type":"COMBINATION_TREATMENT","name":"citalopram + pindolol","canonical_id":"ctgov_combo:ctgov-combo-41ff87b5e32c9ed4","description":null,"metadata":null},{"id":"1af3ba33b5bf46fb84fd70cff10e8cf7","type":"GO_TERM","name":"citramalate CoA-transferase activity","canonical_id":"go:GO:0047775","description":"\"Catalysis of the reaction: citramalate + acetyl-CoA = (3S)-citramalyl-CoA + acetate.\" [RHEA:17621]","metadata":null},{"id":"a57417f37ad64eb7bf2521eeb77e73a7","type":"GO_TERM","name":"citramalate lyase activity","canonical_id":"go:GO:0047776","description":"\"Catalysis of the reaction: S-citramalate = acetate + pyruvate.\" [EC:4.1.3.22, RHEA:15545]","metadata":null},{"id":"94903e3833b3471ba6ee35ddcca27deb","type":"GO_TERM","name":"citrate (pro-3S)-lyase activity","canonical_id":"go:GO:0008815","description":"\"Catalysis of the reaction: citrate = acetate + oxaloacetate.\" [RHEA:10760]","metadata":null},{"id":"a767d55a44f547b6aac12e7ea4203967","type":"GO_TERM","name":"citrate CoA-transferase activity","canonical_id":"go:GO:0008814","description":"\"Catalysis of the reaction: acetyl-CoA + citrate = acetate + (3S)-citryl-CoA.\" [RHEA:19405]","metadata":null},{"id":"0bfd62b72a5249fea53de0806af05578","type":"GO_TERM","name":"citrate metabolic process","canonical_id":"go:GO:0006101","description":"\"The chemical reactions and pathways involving citrate, 2-hydroxy-1,2,3-propanetricarboxylate. Citrate is widely distributed in nature and is an important intermediate in the TCA cycle and the glyoxylate cycle.\" [ISBN:0198506732]","metadata":null},{"id":"c9991df5f78845128f142f9227f148bc","type":"GO_TERM","name":"citrate secondary active transmembrane transporter activity","canonical_id":"go:GO:0071913","description":"\"Enables the transfer of citrate from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mah, GOC:mtg_transport, GOC:vw]","metadata":null},{"id":"41247f73bc0d4a5c84746176da5ec348","type":"GO_TERM","name":"citrate synthase activity","canonical_id":"go:GO:0036440","description":"\"Catalysis of the reaction: acetyl-CoA + H2O + oxaloacetate = citrate + CoA.\" [RHEA:16845]","metadata":null},{"id":"150afa41bfe2448089a32fcb92fc00bb","type":"GO_TERM","name":"citrate transmembrane transporter activity","canonical_id":"go:GO:0015137","description":"\"Enables the transfer of citrate, 2-hydroxy-1,2,3-propanetricarboxylate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"be3710ba51254f76a9e665e3655796bc","type":"GO_TERM","name":"citrate transport","canonical_id":"go:GO:0015746","description":"\"The directed movement of citrate, 2-hydroxy-1,2,3-propanetricarboxylate, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"4580d2444ea14942b88a7313a7d50e4b","type":"GO_TERM","name":"citrate-CoA ligase activity","canonical_id":"go:GO:0047779","description":"\"Catalysis of the reaction: ATP + citrate + CoA = (3S)-citryl-CoA + ADP + H+ + phosphate.\" [EC:6.2.1.18, RHEA:21472]","metadata":null},{"id":"bdb0fb86bf264a818bb5bdef2ad6d5be","type":"GO_TERM","name":"citrate-L-glutamate ligase activity","canonical_id":"go:GO:0072591","description":"\"Catalysis of the reaction: ATP + citrate + L-glutamate = ADP + phosphate + beta-citryl-L-glutamate.\" [PMID:20657015]","metadata":null},{"id":"2f3f56b975f94684ad966f843b537609","type":"GO_TERM","name":"citrate:2-oxoglutarate antiporter activity","canonical_id":"go:GO:0180056","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: citrate(out) + 2-oxogluarate(in) = citrate(in) + 2-oxogluarat(out).\" [PMID:20371607]","metadata":null},{"id":"69300364ec334fa28e8f54c78741f25b","type":"GO_TERM","name":"citrate:proton symporter activity","canonical_id":"go:GO:0015531","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: citrate(out) + H+(out) = citrate(in) + H+(in).\" [TC:2.A.1.6.1]","metadata":null},{"id":"bd7d784cda254393b923c1a1d84d8c1b","type":"GO_TERM","name":"citrate:succinate antiporter activity","canonical_id":"go:GO:0015515","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: citrate(out) + succinate(in) = citrate(in) + succinate(out).\" [TC:2.A.47.3.2]","metadata":null},{"id":"7565fdea53d44019a67229f91c35f29a","type":"GO_TERM","name":"citric acid secretion","canonical_id":"go:GO:0046720","description":"\"The controlled release of citric acid, 2-hydroxy-1,2,3-propanetricarboxylic acid, by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"18e659c7ef824475856d53d1b3ec62e5","type":"GO_TERM","name":"citronellyl-CoA dehydrogenase activity","canonical_id":"go:GO:0034824","description":"\"Catalysis of the reaction: citronellyl-CoA + NAD+ = cis-geranyl-CoA + NADH + H+.\" [PMID:31964529]","metadata":null},{"id":"cafa4eeb752042f5999a9d8cea7c4a8a","type":"GO_TERM","name":"citrullinase activity","canonical_id":"go:GO:0047781","description":"\"Catalysis of the reaction: L-citrulline + H2O + 2 H+ = L-ornithine + NH4+ + CO2.\" [RHEA:11940]","metadata":null},{"id":"a30b04aa61ae4fe89d66af966fb3e99c","type":"GO_TERM","name":"citryl-CoA lyase activity","canonical_id":"go:GO:0008816","description":"\"Catalysis of the reaction: (3S)-citryl-CoA = acetyl-CoA + oxaloacetate.\" [EC:4.1.3.34]","metadata":null},{"id":"e11bd6f8e29b4cfc91f9b23a8caba32d","type":"DRUG","name":"clarithromycin","canonical_id":"mesh:D017291","description":null,"metadata":null},{"id":"706eeac763e145e1beeef80b8c334785","type":"DRUG","name":"clascoterone","canonical_id":"gtopdb:11215","description":null,"metadata":null},{"id":"08fee6523bca4c38978e7f41587ffdf9","type":"DRUG","name":"clascoterone","canonical_id":"chembl:CHEMBL3590187","description":null,"metadata":null},{"id":"0734ba03ba054d238facf1add6a8e707","type":"GO_TERM","name":"class I DNA-(apurinic or apyrimidinic site) endonuclease activity","canonical_id":"go:GO:0140078","description":"\"Catalysis of the cleavage of an AP site 3' of the baseless site by a beta-lyase mechanism, leaving an unsaturated aldehyde, termed a 3'-(4-hydroxy-5-phospho-2-pentenal) residue, and a 5'-phosphate.\" [PMID:1698278, RHEA:66592]","metadata":null},{"id":"fd5fd0bc111547e0904cb4f0237f054f","type":"GO_TERM","name":"class II DNA-(apurinic or apyrimidinic site) endonuclease activity","canonical_id":"go:GO:0052720","description":"\"Catalysis of the hydrolysis of ester linkages immediately 5' to an apurinic/apyrimidinic (AP; also called abasic) site within a deoxyribonucleic acid molecule by creating internal breaks, generating a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl ends.\" [PMID:1698278]","metadata":null},{"id":"abd366cdff404036a0e2458607fae84f","type":"DISEASE","name":"classic Hodgkin lymphoma","canonical_id":"mondo:0009348","description":null,"metadata":null},{"id":"94bc3e0527f24fb08d2d5d3da1f92416","type":"DISEASE","name":"classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","canonical_id":"mondo:0008728","description":null,"metadata":null},{"id":"e31c6cd2d2634d34acf4930870283622","type":"DISEASE","name":"classic dopamine transporter deficiency syndrome","canonical_id":"mondo:0054835","description":null,"metadata":null},{"id":"f509f6b8d2454144a0c5b22fd9f576d3","type":"DISEASE","name":"classic familial adenomatous polyposis","canonical_id":"mondo:0021055","description":null,"metadata":null},{"id":"fd752e980def478cba4745bddd8d1178","type":"DISEASE","name":"classic multiminicore myopathy","canonical_id":"mondo:0017939","description":null,"metadata":null},{"id":"3c2b1cb050764b97a64be32257a7a859","type":"GO_TERM","name":"classical Lewy body","canonical_id":"go:GO:0097414","description":"\"Cytoplasmic inclusion, 5 to 15 micrometers in diameter, with a dense core surrounded by a halo of 10 to 20 nm wide radially oriented alpha-synuclein fibrils.\" [NIF_Subcellular:sao4749542545]","metadata":null},{"id":"a13086ad53c747d58d11976a18306d46","type":"GO_TERM","name":"classical arabinogalactan protein metabolic process","canonical_id":"go:GO:0010406","description":"\"The chemical reactions and pathways involving a cell wall arabinogalactan II glycoprotein, which is composed of a group of core protein containing Hyp, Ala, Ser, Thr and Gly as the major amino acid constituents, and the C-terminus is GPI anchored.\" [GOC:tair_curators]","metadata":null},{"id":"fff987052b374bc48841c82ab0fcbe88","type":"GO_TERM","name":"classical-complement-pathway C3/C5 convertase complex","canonical_id":"go:GO:0005601","description":"\"A heterodimeric protein complex that catalyzes the cleavage of complement components C3 and C5, and acts in the classical pathway of complement activation; consists of one monomer of C2a and one monomer of C4b; C2a is the catalytic subunit, but cannot catalyze cleavage alone.\" [GOC:mah]","metadata":null},{"id":"87076a5fe79c46128ccedf379d272032","type":"GO_TERM","name":"clathrin adaptor complex","canonical_id":"go:GO:0030131","description":"\"A membrane coat adaptor complex that links clathrin to a membrane.\" [GOC:mah]","metadata":null},{"id":"cf3988a2b2014819a1bfb01d852c5c18","type":"GO_TERM","name":"clathrin binding","canonical_id":"go:GO:0030276","description":"\"Binding to a clathrin heavy or light chain, the main components of the coat of coated vesicles and coated pits, and which also occurs in synaptic vesicles.\" [GOC:jl, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"3c972399df7f4ce0bc6622098375a2c2","type":"GO_TERM","name":"clathrin coat","canonical_id":"go:GO:0030118","description":"\"A membrane coat found on coated pits and some coated vesicles; consists of polymerized clathrin triskelions, each comprising three clathrin heavy chains and three clathrin light chains, linked to the membrane via one of the AP adaptor complexes.\" [GOC:mah, PMID:11252894, PMID:9531549]","metadata":null},{"id":"d416577af1424adabef3611cf1c3f8b5","type":"GO_TERM","name":"clathrin coat assembly","canonical_id":"go:GO:0048268","description":"\"The process that results in the assembly of clathrin triskelia into the ordered structure known as a clathrin cage.\" [GOC:jid, PMID:11460887, PMID:11977118, PMID:9531549]","metadata":null},{"id":"c20aeeb630a24928af69e0473e206b2a","type":"GO_TERM","name":"clathrin coat assembly involved in endocytosis","canonical_id":"go:GO:0099049","description":"\"The process that results in the assembly of clathrin triskelia into a clathrin cage during endocytosis. Clathrin is recruited to the plasma membrane via interaction with scaffolding proteins that bridge between clathtin and cell surface receptors. Clathrin coat formation is concomittant with coated pit formation leading to endocytic vesicle formation.\" [PMID:21779028]","metadata":null},{"id":"b778bf4c038345fdb466be0ba3ba5a15","type":"GO_TERM","name":"clathrin coat disassembly","canonical_id":"go:GO:0072318","description":"\"The disaggregation of a clathrin coat into its constituent components; results in stripping or removing the clathrin coat from clathrin-coated vesicles (CCV) before fusing with their targets. CVVs transport cargo from plasma membrane and trans-Golgi to the endosomal system.\" [PMID:11084334, PMID:11146663, PMID:8524399]","metadata":null},{"id":"156fd0674be9491eaeb2ba3884e0e662","type":"GO_TERM","name":"clathrin coat of coated pit","canonical_id":"go:GO:0030132","description":"\"The coat found on coated pits and the coated vesicles derived from coated pits; comprises clathrin and the AP-2 adaptor complex.\" [GOC:mah]","metadata":null},{"id":"0c7389a4915848caa525da6163a4f92c","type":"GO_TERM","name":"clathrin coat of endocytic vesicle","canonical_id":"go:GO:0030128","description":"\"A clathrin coat found on an endocytic vesicle.\" [GOC:mah]","metadata":null},{"id":"a65e62d4e0dc4b559bb307fec11e11ea","type":"GO_TERM","name":"clathrin coat of synaptic vesicle","canonical_id":"go:GO:0030129","description":"\"A clathrin coat found on a synaptic vesicle.\" [GOC:mah]","metadata":null},{"id":"ab5784fcfa864b35beb361347c5d6b90","type":"GO_TERM","name":"clathrin coat of trans-Golgi network vesicle","canonical_id":"go:GO:0030130","description":"\"A clathrin coat found on a vesicle of the trans-Golgi network.\" [GOC:mah]","metadata":null},{"id":"c07c944cdf614f74982a1464851b5fa0","type":"GO_TERM","name":"clathrin coating of Golgi vesicle","canonical_id":"go:GO:0048202","description":"\"The addition of clathrin and adaptor proteins to Golgi membranes during the formation of transport vesicles, forming a vesicle coat.\" [GOC:jid, GOC:mah, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"4e16d7bd79b04e5b8ce18228962ff237","type":"GO_TERM","name":"clathrin coating of Golgi vesicle, trans-Golgi to endosome targeting","canonical_id":"go:GO:0010786","description":"\"The addition of clathrin and adaptor proteins to Golgi membranes during the formation of transport vesicles that will move from the trans-Golgi to the endosome, forming a vesicle coat.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"71635c065b0e41ec86e7e4bd450267bc","type":"GO_TERM","name":"clathrin complex","canonical_id":"go:GO:0071439","description":"\"A protein complex that consists of three clathrin heavy chains and three clathrin light chains, organized into a symmetrical three-legged structure called a triskelion. In clathrin-coated vesicles clathrin is the main component of the coat and forms a polymeric mechanical scaffold on the vesicle surface.\" [GOC:mah, PMID:16493411]","metadata":null},{"id":"9fa35e40f7ec4511bc1b2ba1c55ca281","type":"GO_TERM","name":"clathrin heavy chain binding","canonical_id":"go:GO:0032050","description":"\"Binding to a clathrin heavy chain.\" [GOC:mah]","metadata":null},{"id":"ed304f8f45e0484884b9b47ba927bab6","type":"GO_TERM","name":"clathrin light chain binding","canonical_id":"go:GO:0032051","description":"\"Binding to a clathrin light chain.\" [GOC:mah]","metadata":null},{"id":"d50a8ecf20714214ad3f2ee7aa61c8a8","type":"GO_TERM","name":"clathrin vesicle coat","canonical_id":"go:GO:0030125","description":"\"A clathrin coat found on a vesicle.\" [GOC:mah]","metadata":null},{"id":"3adff05bb5de4c4b9586baf66221353a","type":"GO_TERM","name":"clathrin-cargo adaptor activity","canonical_id":"go:GO:0035615","description":"\"Bringing together a cargo protein with clathrin, responsible for the formation of endocytic vesicles.\" [GOC:BHF, PMID:15728179, PMID:29661000]","metadata":null},{"id":"0958b5f1a27b425f9d2d99e300c3c4b8","type":"GO_TERM","name":"clathrin-coated endocytic vesicle","canonical_id":"go:GO:0045334","description":"\"A clathrin-coated, membrane-bounded intracellular vesicle formed by invagination of the plasma membrane around an extracellular substance.\" [GOC:curators]","metadata":null},{"id":"e3835af58c9b4d0db8a13623b71a88b6","type":"GO_TERM","name":"clathrin-coated endocytic vesicle lumen","canonical_id":"go:GO:0106176","description":"\"The volume enclosed by the membrane of a clathrin-coated endocytic vesicle.\" [GOC:pde, PMID:2516741]","metadata":null},{"id":"fd5b3ae5082f4975b9bf1e6c3341d045","type":"GO_TERM","name":"clathrin-coated endocytic vesicle membrane","canonical_id":"go:GO:0030669","description":"\"The lipid bilayer surrounding a clathrin-coated endocytic vesicle.\" [GOC:mah]","metadata":null},{"id":"4cdbbeb0997e495aa7db86e27fb55c7c","type":"GO_TERM","name":"clathrin-coated phagocytic vesicle","canonical_id":"go:GO:0045336","description":"\"A clathrin-coated, membrane-bounded intracellular vesicle that arises from the ingestion of particulate material by phagocytosis.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"82d44669382f4df3b5f640060cac1482","type":"GO_TERM","name":"clathrin-coated phagocytic vesicle membrane","canonical_id":"go:GO:0030671","description":"\"The lipid bilayer surrounding a clathrin-coated phagocytic vesicle.\" [GOC:mah]","metadata":null},{"id":"4794c94305ed4be1b716a78dae6b7342","type":"GO_TERM","name":"clathrin-coated pit","canonical_id":"go:GO:0005905","description":"\"A part of the endomembrane system in the form of an invagination of a membrane upon which a clathrin coat forms, and that can be converted by vesicle budding into a clathrin-coated vesicle. Coated pits form on the plasma membrane, where they are involved in receptor-mediated selective transport of many proteins and other macromolecules across the cell membrane, in the trans-Golgi network, and on some endosomes.\" [GOC:mah, ISBN:0198506732, NIF_Subcellular:sao1969557946, PMID:10559856, PMID:17284835]","metadata":null},{"id":"0236aa35efd8493aa0677dffe59239f5","type":"GO_TERM","name":"clathrin-coated vesicle","canonical_id":"go:GO:0030136","description":"\"A vesicle with a coat formed of clathrin connected to the membrane via one of the clathrin adaptor complexes.\" [GOC:mah, PMID:11252894]","metadata":null},{"id":"7fdd3afc485e4aa4b527976b1d7a3d3f","type":"GO_TERM","name":"clathrin-coated vesicle cargo loading","canonical_id":"go:GO:0035652","description":"\"Formation of a macromolecular complex between the cytoplasmic coat proteins on clathrin-coated vesicles and proteins and/or lipoproteins that are going to be transported by a vesicle.\" [GOC:lb, PMID:16162817]","metadata":null},{"id":"aa15014ff86544c597b51e45490fa4d3","type":"GO_TERM","name":"clathrin-coated vesicle cargo loading, AP-1-mediated","canonical_id":"go:GO:0035653","description":"\"Formation of a macromolecular complex between proteins of the AP-1 adaptor complex and proteins and/or lipoproteins that are going to be transported by a clathrin-coated vesicle. The AP-1 adaptor protein complex is a component of the cytoplasmic coat found on clathrin-coated vesicles, and binds to sorting signals of cargo to facilitate their trafficking.\" [GOC:lb, PMID:12802059, PMID:16162817]","metadata":null},{"id":"67d2bd2932224b1b87abc40329da8eed","type":"GO_TERM","name":"clathrin-coated vesicle cargo loading, AP-3-mediated","canonical_id":"go:GO:0035654","description":"\"Formation of a macromolecular complex between proteins of the AP-3 adaptor complex and proteins and/or lipoproteins that are going to be transported by a clathrin-coated vesicle. In some cases, the AP-3 complex is a heterotetrameric AP-type membrane coat adaptor complex that, in some organisms, links clathrin to the membrane surface of a vesicle.\" [GOC:lb, PMID:12802059, PMID:16162817]","metadata":null},{"id":"d898d57e6e6f410197b8c8cefc438ae7","type":"GO_TERM","name":"clathrin-coated vesicle membrane","canonical_id":"go:GO:0030665","description":"\"The lipid bilayer surrounding a clathrin-coated vesicle.\" [GOC:mah]","metadata":null},{"id":"b84aa0db1ca449a58a92a64327b1db11","type":"GO_TERM","name":"clathrin-dependent endocytosis","canonical_id":"go:GO:0072583","description":"\"An endocytosis process that begins when material is taken up into clathrin-coated pits, which then pinch off to form clathrin-coated endocytic vesicles.\" [GOC:BHF, GOC:mah, PMID:18498251, PMID:8970738, PMID:9234965]","metadata":null},{"id":"2d4039d1381340b3bc12a7dfa2fada28","type":"GO_TERM","name":"clathrin-dependent endocytosis involved in vitellogenesis","canonical_id":"go:GO:0061883","description":"\"A clathrin-mediated endocytosis process whereby yolk proteins are internalized and trafficked through the endocytic pathway for yolk deposition.\" [PMID:26265702]","metadata":null},{"id":"453ea44622ac4ed6856f67c5d4462b9a","type":"GO_TERM","name":"clathrin-dependent endocytosis of virus by host cell","canonical_id":"go:GO:0075512","description":"\"Any clathrin-mediated endocytosis that is involved in the uptake of a virus into a host cell. Begins by invagination of a specific region of the host cell plasma membrane around the bound virus to form a clathrin-coated pit, which then pinches off to form a clathrin-coated endocytic vesicle containing the virus.\" [GOC:bf, GOC:jl, VZ:957]","metadata":null},{"id":"bd55c3c560fd4c76ac9fddefef5c378c","type":"GO_TERM","name":"clathrin-dependent extracellular exosome endocytosis","canonical_id":"go:GO:1990771","description":"\"The clathrin-mediated endocytosis of an extracellular exosome.\" [PMID:24951588]","metadata":null},{"id":"4d8d6bfc55894417b2f0f5710f9d71b8","type":"GO_TERM","name":"clathrin-dependent synaptic vesicle endocytosis","canonical_id":"go:GO:0150007","description":"\"Clathrin-dependent endocytosis of presynaptic membrane regions comprising synaptic vesicles' membrane constituents. This is a relatively slow process occurring in the range of tens of seconds.\" [GOC:aruk, GOC:bc, GOC:ha, PMID:16982422, PMID:18579735, PMID:18579748, PMID:26430111, PMID:27252645, PMID:28391090, PMID:4348786]","metadata":null},{"id":"8d0010c3d68e402ea59815b8ceaecc6e","type":"GO_TERM","name":"clathrin-mediated membrane bending","canonical_id":"go:GO:0097754","description":"\"A membrane bending process mediated by clathrin.\" [GOC:pr, Wikipedia:Membrane_curvature]","metadata":null},{"id":"856205ba981342b5b92d38e712fc1ab9","type":"GO_TERM","name":"clathrin-sculpted acetylcholine transport vesicle","canonical_id":"go:GO:0060200","description":"\"A clathrin-sculpted lipid bilayer membrane-enclosed vesicle after clathrin release and containing acetylcholine.\" [GOC:dph]","metadata":null},{"id":"c94a256b904a4980a56373bbe2e654d2","type":"GO_TERM","name":"clathrin-sculpted acetylcholine transport vesicle lumen","canonical_id":"go:GO:0060202","description":"\"The volume enclosed by the membrane of the clathrin-sculpted acetylcholine transport vesicle.\" [GOC:dph]","metadata":null},{"id":"40b5dbdb525c48e688679bb61c2337df","type":"GO_TERM","name":"clathrin-sculpted acetylcholine transport vesicle membrane","canonical_id":"go:GO:0060201","description":"\"The lipid bilayer surrounding a clathrin-sculpted acetylcholine transport vesicle.\" [GOC:dph]","metadata":null},{"id":"94fa9124785f4055897fc9beaaab9f95","type":"GO_TERM","name":"clathrin-sculpted gamma-aminobutyric acid transport vesicle","canonical_id":"go:GO:0061200","description":"\"A clathrin-sculpted lipid bilayer membrane-enclosed vesicle after clathrin release and containing gamma-aminobutyric acid transport vesicle.\" [GOC:dph]","metadata":null},{"id":"28c3924035a54d98bab188d919f9f7db","type":"GO_TERM","name":"clathrin-sculpted gamma-aminobutyric acid transport vesicle lumen","canonical_id":"go:GO:0061201","description":"\"The volume enclosed by the membrane of the clathrin-sculpted gamma-aminobutyric acid transport vesicle.\" [GOC:dph]","metadata":null},{"id":"0ce6baf712094ba294d320f527dc47f6","type":"GO_TERM","name":"clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane","canonical_id":"go:GO:0061202","description":"\"The lipid bilayer surrounding a clathrin-sculpted gamma-aminobutyric acid transport vesicle.\" [GOC:dph]","metadata":null},{"id":"cf88d24206dc42b686163ece54de2992","type":"GO_TERM","name":"clathrin-sculpted glutamate transport vesicle","canonical_id":"go:GO:0060199","description":"\"A clathrin-sculpted lipid bilayer membrane-enclosed vesicle after clathrin release and containing glutamate.\" [GOC:dph]","metadata":null},{"id":"8e9f59977fe949b3aa44237dab8d1145","type":"GO_TERM","name":"clathrin-sculpted glutamate transport vesicle lumen","canonical_id":"go:GO:0060204","description":"\"The volume enclosed by the membrane of the clathrin-sculpted glutamate transport vesicle.\" [GOC:dph]","metadata":null},{"id":"49ff92a4cc08478385b5c3178e99e7de","type":"GO_TERM","name":"clathrin-sculpted glutamate transport vesicle membrane","canonical_id":"go:GO:0060203","description":"\"The lipid bilayer surrounding a clathrin-sculpted glutamate transport vesicle.\" [GOC:dph]","metadata":null},{"id":"96f7cccd52804252a38d71691928839f","type":"GO_TERM","name":"clathrin-sculpted monoamine transport vesicle","canonical_id":"go:GO:0070081","description":"\"A clathrin-sculpted lipid bilayer membrane-enclosed vesicle after clathrin release and containing monoamines.\" [GOC:mg2]","metadata":null},{"id":"8f2e11cc56ee471b964e4b1cf819378c","type":"GO_TERM","name":"clathrin-sculpted monoamine transport vesicle lumen","canonical_id":"go:GO:0070082","description":"\"The volume enclosed by the membrane of the clathrin-sculpted monoamine transport vesicle.\" [GOC:mg2]","metadata":null},{"id":"2bed3da8869149818e14ccc483c0465b","type":"GO_TERM","name":"clathrin-sculpted monoamine transport vesicle membrane","canonical_id":"go:GO:0070083","description":"\"The lipid bilayer surrounding a clathrin-sculpted monoamine transport vesicle.\" [GOC:mg2]","metadata":null},{"id":"3a5fb74562c94ca795d2a74fbde20f28","type":"GO_TERM","name":"clathrin-sculpted vesicle","canonical_id":"go:GO:0060198","description":"\"A clathrin-sculpted lipid bilayer membrane-enclosed vesicle after clathrin release.\" [GOC:dph]","metadata":null},{"id":"4a192806e55b4c8db862c3dc44c933b1","type":"GO_TERM","name":"clathrin-uncoating ATPase activity","canonical_id":"go:GO:1990833","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate. Catalysis of the removal of clathrin from vesicle membranes, coupled to the hydrolysis of ATP.\" [PMID:6146630, PMID:8363588]","metadata":null},{"id":"e72fc80f592749e99178c66e8bd04bc2","type":"GO_TERM","name":"clavaminate synthase activity","canonical_id":"go:GO:0033758","description":"\"Catalysis of the reactions: deoxyamidinoproclavaminate + 2-oxoglutarate + O2 = amidinoproclavaminate + succinate + CO2 + H2O; proclavaminate + 2-oxoglutarate + O2 = dihydroclavaminate + succinate + CO2 + 2 H2O; and dihydroclavaminate + 2-oxoglutarate + O2 = clavaminate + succinate + CO2 + 2 H2O.\" [EC:1.14.11.21]","metadata":null},{"id":"d01da75205f54d2d9712bbe3ba3ed46f","type":"DRUG","name":"clavulanic acid","canonical_id":"mesh:D019818","description":null,"metadata":null},{"id":"c4d4e77fecbf41109ad32a55e74c101c","type":"GO_TERM","name":"clavulanic acid biosynthetic process","canonical_id":"go:GO:0033050","description":"\"The chemical reactions and pathways resulting in the formation of clavulanic acid, (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.\" [GOC:mah]","metadata":null},{"id":"190a7e96eac84ab080022adb0c618fad","type":"DISEASE","name":"clear cell renal carcinoma","canonical_id":"mondo:0005005","description":null,"metadata":null},{"id":"0953e7fb509e424c96613198f803586c","type":"GO_TERM","name":"clearance of cells from fusion plate","canonical_id":"go:GO:0060884","description":"\"The morphogenetic process in which cells are removed from the inner loop of a semicircular canal.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"88dff5fb578044e6ab22b8a80680eb63","type":"GO_TERM","name":"clearance of cells from fusion plate by apoptotic process","canonical_id":"go:GO:0060885","description":"\"Any apoptotic process that contributes to the shaping of the semicircular canal by removing cells in the fusion plate, forming the loops of the canals.\" [GOC:dph, GOC:mtg_apoptosis, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"84e9bf325b674f159592c0091bac3c98","type":"GO_TERM","name":"clearance of cells from fusion plate by epithelial to mesenchymal transition","canonical_id":"go:GO:0060886","description":"\"The process of epithelial to mesenchymal transition that contributes to the shaping of the semicircular canal by effectively removing epithelial cells from the fusion plate, forming the loops of the canals.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"49fc67e0b86d453fac7e9c8bf08c1ac1","type":"GO_TERM","name":"clearance of foreign intracellular DNA","canonical_id":"go:GO:0044355","description":"\"A defense process that protects an organism from invading foreign DNA.\" [GO:jl, PMID:20062055]","metadata":null},{"id":"d8804c45292645d9ae64fae82585e12e","type":"GO_TERM","name":"clearance of foreign intracellular RNA","canonical_id":"go:GO:0099047","description":"\"A defense process that protects an organism from invading foreign RNA.\" [GO:dos]","metadata":null},{"id":"58f99aec25064e9dbad771a35831cf53","type":"GO_TERM","name":"clearance of foreign intracellular nucleic acids","canonical_id":"go:GO:0099046","description":"\"A defense process that protects an organism from DNA or RNA from an invading organism.\" [GO:dos]","metadata":null},{"id":"1eb8c7839616444b837b7c21074879bf","type":"GO_TERM","name":"cleavage apparatus septin structure","canonical_id":"go:GO:0032161","description":"\"Any of a series of structures composed of septins and septin-associated proteins localized to the cleavage plane which are involved in cytokinesis.\" [GOC:krc, PMID:12101122, PMID:15774761, PMID:16009555]","metadata":null},{"id":"7e6a0cb75c1d45758eedbb1d88c2624f","type":"GO_TERM","name":"cleavage between 2S rRNA and LSU-rRNA of tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000485","description":"\"Endonucleolytic cleavage between the LSU-rRNA and the 2S rRNA of an rRNA molecule originally produced as a tetracistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, 2S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators, PMID:768488]","metadata":null},{"id":"6c629a157bec465f946c054a17df3ab0","type":"GO_TERM","name":"cleavage between 5.8S rRNA and 2S rRNA of tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000486","description":"\"Endonucleolytic cleavage between the 5.8S rRNA and the 2S rRNA of an rRNA molecule originally produced as a tetracistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, 2S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators, PMID:768488]","metadata":null},{"id":"dbd862fee65c4a2f95a2a4f11b39aaa1","type":"GO_TERM","name":"cleavage between SSU-rRNA and 5.8S rRNA of tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000484","description":"\"Endonucleolytic cleavage between the SSU-rRNA and the 5.8S rRNA of an rRNA molecule originally produced as a tetracistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, 2S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"b5470255deec4ed0ab65c7fd57a3d463","type":"GO_TERM","name":"cleavage body","canonical_id":"go:GO:0071920","description":"\"A nuclear body that contains proteins involved in pre-mRNA 3'-end cleavage and polyadenylation, such as DDX1, CSTF2 and CPSFs, as well as the transcription factors TFIIE and TFIIF. Cleavage bodies are localized adjacent to Cajal bodies and are involved in mRNA3'-end processing.\" [PMID:10564273, PMID:11598190, PMID:8654386]","metadata":null},{"id":"2e494e552f9d469193806fb1f8975c42","type":"GO_TERM","name":"cleavage furrow","canonical_id":"go:GO:0032154","description":"\"The cleavage furrow is a plasma membrane invagination at the cell division site. The cleavage furrow begins as a shallow groove and eventually deepens to divide the cytoplasm.\" [GOC:vw, ISBN:0805319409]","metadata":null},{"id":"5b38865d12f14d4c8902ea71ebe8dac9","type":"GO_TERM","name":"cleavage furrow formation","canonical_id":"go:GO:0036089","description":"\"Generation of the cleavage furrow, a shallow groove in the cell surface near the old metaphase plate that marks the site of cytokinesis. This process includes the recruitment and localized activation of signals such as RhoA at the site of the future furrow to ensure that furrowing initiates at the correct site in the cell.\" [GOC:ans, PMID:15811947, PMID:20687468, PMID:2192590]","metadata":null},{"id":"94c15b70e04d40e1b4b397ad6d30f84d","type":"GO_TERM","name":"cleavage furrow ingression","canonical_id":"go:GO:0036090","description":"\"Advancement of the cleavage furrow from the outside of the cell inward towards the center of the cell. The cleavage furrow acts as a 'purse string' which draws tight to separate daughter cells during cytokinesis and partition the cytoplasm between the two daughter cells. The furrow ingresses until a cytoplasmic bridge is formed.\" [PMID:15811947, PMID:20687468]","metadata":null},{"id":"a676a586dbc547eaa33cb499a316a100","type":"GO_TERM","name":"cleavage furrow leading edge","canonical_id":"go:GO:0090689","description":"\"The 'trough' of the cleavage furrow. This is the part of the cleavage furrow closest to the contractile ring.\" [GOC:vw, PMID:27082518]","metadata":null},{"id":"936d566db8ab4d658e54a9b60bc95196","type":"GO_TERM","name":"cleavage furrow rim","canonical_id":"go:GO:0090688","description":"\"The part of the cleavage furrow closest to the cell surface.\" [GOC:vw, PMID:27082518]","metadata":null},{"id":"8482384223cd49008cfaf4e36903abff","type":"GO_TERM","name":"cleavage in ITS2 between 5.8S rRNA and LSU-rRNA of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000448","description":"\"Endonucleolytic cleavage within ITS2 between the 5.8S rRNA and the LSU-rRNA of an rRNA molecule originally produced as a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators, PMID:10690410]","metadata":null},{"id":"18935a24f56749b1a822988953fedc76","type":"GO_TERM","name":"cleavage of bicistronic rRNA transcript (SSU-rRNA, LSU-rRNA)","canonical_id":"go:GO:0000450","description":"\"Endonucleolytic cleavage of pre-rRNAs originally produced as a bicistronic rRNA transcript that contains the SSU-rRNA and the LSU-rRNA in that order from 5' to 3' along the primary transcript. Primary ribosomal RNA transcripts with two genes in this order are produced in Archaeal species.\" [GOC:curators]","metadata":null},{"id":"fc30877e108f4c3882db0f59d24e5415","type":"GO_TERM","name":"cleistothecium development","canonical_id":"go:GO:0070791","description":"\"The process whose specific outcome is the progression of the cleistothecium over time, from its formation to the mature structure. The cleistothecium is a closed sexual fruiting body that contains ascospores in linear asci, characteristic of some filamentous Ascomycete fungi such as members of the genera Aspergillus and Emericella.\" [ISBN:0471522295, PMID:17446882]","metadata":null},{"id":"dc5270b8a1ce4d70b9216022d5f7b6a6","type":"GO_TERM","name":"cleistothecium formation","canonical_id":"go:GO:0062248","description":"\"The process of producing a cleistothecium, a closed sexual fruiting body that contains ascospores in linear asci. Cleistothecia are present in some filamentous Ascomycete fungi such as members of the genera Aspergillus and Emericella.\" [PMID:20348388, PMID:28889020, PMID:30410052]","metadata":null},{"id":"181d06296aaa455e917ac5229a2a23e4","type":"DRUG","name":"clemastine","canonical_id":"gtopdb:6063","description":null,"metadata":null},{"id":"6b71b44e1d5c488fa03ec9baaf682a7d","type":"COMBINATION_TREATMENT","name":"clemastine + loratadine + omalizumab","canonical_id":"ctgov_combo:ctgov-combo-d793a5b81c3e9f40","description":null,"metadata":null},{"id":"a4fd60df8e5545dda22d9e72de561b1d","type":"DRUG","name":"clementine","canonical_id":"mesh:D002974","description":null,"metadata":null},{"id":"b2c124fe847940d2b3b32bf807c8ca31","type":"DRUG","name":"clevidipine","canonical_id":"mesh:C118563","description":null,"metadata":null},{"id":"fc14f5e9a6444701b241e35789a17007","type":"DRUG","name":"clidinium","canonical_id":"gtopdb:366","description":null,"metadata":null},{"id":"5617e9ce690042f6994dd47b5fbd9df2","type":"DRUG","name":"clidinium","canonical_id":"mesh:C054940","description":null,"metadata":null},{"id":"29bd90ff43924e1ba3e54dd65409c620","type":"GO_TERM","name":"climbing fiber","canonical_id":"go:GO:0044301","description":"\"The axon of inferior olive neuron that projects to the cerebellar cortex, largely via the inferior cerebellar peduncle. They range in diameter from 1-3 um and are myelinated until they enter the granule cell layer. They give off collaterals to the deep cerebellar nuclei. They synapse extensively with the dendrites of Purkinje cells in the molecular layer, where each fiber branches repeatedly to climb along the Purkinje cell dendritic tree. Each Purkinje cell is innervated by only a single climbing fiber.\" [NIF_Subcellular:nlx_subcell_20090203]","metadata":null},{"id":"e182e90089c146e4aa2f6a4f40ec952c","type":"DRUG","name":"clindamycin","canonical_id":"mesh:D002981","description":null,"metadata":null},{"id":"b445ff36b58840199ee1d2f007ea7544","type":"DRUG","name":"clindamycin phosphate","canonical_id":"mesh:C007084","description":null,"metadata":null},{"id":"14595e9e99074c3586078ee3fe533110","type":"DRUG","name":"clioquinol","canonical_id":"mesh:D007464","description":null,"metadata":null},{"id":"3270dec110f945119cab3ff9360a0895","type":"GO_TERM","name":"cloaca development","canonical_id":"go:GO:0035844","description":"\"The process whose specific outcome is the progression of the cloaca over time, from it's formation to the mature structure. The cloaca is the common chamber into which intestinal, genital and urinary canals open in vertebrates.\" [GOC:dgh, ISBN:0582227089]","metadata":null},{"id":"06278a4b9f0d4223baad415a30374300","type":"GO_TERM","name":"cloacal gland development","canonical_id":"go:GO:1904484","description":"\"The process whose specific outcome is the progression of a cloacal gland over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:mr, GOC:TermGenie, PMID:18805421]","metadata":null},{"id":"d112a6a486da469eace674048a8daaeb","type":"GO_TERM","name":"cloacal septation","canonical_id":"go:GO:0060197","description":"\"The separation of the single opening of the digestive, urinary, and reproductive tracts, the cloaca, into multiple isolated openings during development.\" [GOC:dph, GOC:st]","metadata":null},{"id":"05996a9d729d4e5ba204b7fc731175f1","type":"DRUG","name":"clobazam","canonical_id":"mesh:C012255","description":null,"metadata":null},{"id":"5697ac7c862f44ea9863545073a459eb","type":"DRUG","name":"clobetasol propionate","canonical_id":"gtopdb:7062","description":null,"metadata":null},{"id":"40ee0b6c638245edb8204b72f0dfd9f0","type":"DRUG","name":"clobetasol propionate","canonical_id":"chembl:CHEMBL1159650","description":null,"metadata":null},{"id":"abf1c550e84c44d3bc8bf8c39f3d868d","type":"COMBINATION_TREATMENT","name":"clobetasol propionate + pimecrolimus","canonical_id":"ctgov_combo:ctgov-combo-b768d7661d2dc700","description":null,"metadata":null},{"id":"c2cb1fd92976457fa4535d047ce386fd","type":"COMBINATION_TREATMENT","name":"clobetasol propionate + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-17c79dea18a14d3e","description":null,"metadata":null},{"id":"49f45df93b2d461abdd943bcf51e1937","type":"COMBINATION_TREATMENT","name":"clobetasol propionate + progesterone","canonical_id":"ctgov_combo:ctgov-combo-dbbbde6a9e0c6562","description":null,"metadata":null},{"id":"8747174940a445f3974a647436e70bdb","type":"COMBINATION_TREATMENT","name":"clobetasol propionate + tazarotene","canonical_id":"ctgov_combo:ctgov-combo-8cdb2f727846481b","description":null,"metadata":null},{"id":"0385ebbb2fd2473d9a2a238ca5afc623","type":"DRUG","name":"clobetasone butyrate","canonical_id":"mesh:C010893","description":null,"metadata":null},{"id":"751123e8be5c48d690d1ff6c51bd74db","type":"DRUG","name":"clofarabine","canonical_id":"gtopdb:6802","description":null,"metadata":null},{"id":"0cc73ea75135431d8c4dbc16d48b4abd","type":"DRUG","name":"clofarabine","canonical_id":"chembl:CHEMBL1750","description":null,"metadata":null},{"id":"5c37509b2d2448e0af6160d54412904d","type":"COMBINATION_TREATMENT","name":"clofarabine + etoposide","canonical_id":"ctgov_combo:ctgov-combo-7adcff360195b763","description":null,"metadata":null},{"id":"b60bc1b06ee94e9b9c7d27ea39c57d27","type":"COMBINATION_TREATMENT","name":"clofarabine + gemtuzumab ozogamicin","canonical_id":"ctgov_combo:ctgov-combo-075a30024ce9febc","description":null,"metadata":null},{"id":"5b3a234465b2402a8c5ef6c8252b51a8","type":"COMBINATION_TREATMENT","name":"clofarabine + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-335f8092f9a7079d","description":null,"metadata":null},{"id":"b81ca674639b485e86763851d25fde3d","type":"COMBINATION_TREATMENT","name":"clofarabine + mycophenolate mofetil + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-f67ae90a7bc72f01","description":null,"metadata":null},{"id":"9a8442b72d254c79b1debaead6fa2d4e","type":"COMBINATION_TREATMENT","name":"clofarabine + plerixafor","canonical_id":"ctgov_combo:ctgov-combo-4ecdf8388be8b1e7","description":null,"metadata":null},{"id":"2967a38ea6944db1ad9446650d880bfd","type":"COMBINATION_TREATMENT","name":"clofarabine + thioguanine","canonical_id":"ctgov_combo:ctgov-combo-c52a0a7931ff3261","description":null,"metadata":null},{"id":"be146bb6a4844da5bf92a50ce9dd15f3","type":"DRUG","name":"clofazimine","canonical_id":"mesh:D002991","description":null,"metadata":null},{"id":"6c18e8194bab460ca3317fec0cd3bb23","type":"DRUG","name":"clofibrate","canonical_id":"gtopdb:2667","description":null,"metadata":null},{"id":"068cc30afc5e421590c98ae1889d0d82","type":"DRUG","name":"clofibrate","canonical_id":"mesh:D002994","description":null,"metadata":null},{"id":"b93023b2e152459f8ecabcb8f910e34e","type":"DRUG","name":"clofibrate","canonical_id":"chembl:CHEMBL565","description":null,"metadata":null},{"id":"59a84b5196ec4f8dac533871013cdc1e","type":"COMBINATION_TREATMENT","name":"clofibrate + dextrothyroxine","canonical_id":"ctgov_combo:ctgov-combo-39c62eace3725b6b","description":null,"metadata":null},{"id":"29cecde7e2ea4358bf912a368581af54","type":"COMBINATION_TREATMENT","name":"clofibrate + dextrothyroxine","canonical_id":"ctgov_combo:ctgov-combo-e14972c7c859101a","description":null,"metadata":null},{"id":"3bb93274f47848bd83f3659edb9d4adb","type":"DRUG","name":"clomiphene","canonical_id":"gtopdb:4159","description":null,"metadata":null},{"id":"c2b297b3e2854c619c62b0d95776bf79","type":"COMBINATION_TREATMENT","name":"clomiphene + paroxetine","canonical_id":"ctgov_combo:ctgov-combo-1e5b3e8c969274b0","description":null,"metadata":null},{"id":"1ae88d0ebd964a64a8a8fd0bcadd3367","type":"COMBINATION_TREATMENT","name":"clomiphene + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-37ce42373f887445","description":null,"metadata":null},{"id":"046b73896aa4449c8ac5f2c07c70b285","type":"COMBINATION_TREATMENT","name":"clomiphene + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-85eaa415cde9ea48","description":null,"metadata":null},{"id":"88bbdc29e7ae47d7aad3421d87f29b53","type":"COMBINATION_TREATMENT","name":"clomiphene + raloxifene","canonical_id":"ctgov_combo:ctgov-combo-203a933956847379","description":null,"metadata":null},{"id":"e45ac59dd12e408c8e509814f191d0dd","type":"COMBINATION_TREATMENT","name":"clomiphene + raloxifene","canonical_id":"ctgov_combo:ctgov-combo-71d47dee3a02e10e","description":null,"metadata":null},{"id":"5af79593a84946229bb316770160633c","type":"COMBINATION_TREATMENT","name":"clomiphene + sildenafil","canonical_id":"ctgov_combo:ctgov-combo-c369794381985f3f","description":null,"metadata":null},{"id":"9208665f9ba247f1bbe656cd7a49a5e6","type":"COMBINATION_TREATMENT","name":"clomiphene + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-a9c3bab66542f32b","description":null,"metadata":null},{"id":"f103bb6091ea42ec9c4dae2e8f0d052b","type":"DRUG","name":"clomipramine","canonical_id":"gtopdb:2398","description":null,"metadata":null},{"id":"f51063d9d70141e3b0e5beb0ce5d35d0","type":"DRUG","name":"clomipramine","canonical_id":"mesh:D002997","description":null,"metadata":null},{"id":"2c11c35bf71a4e1bae8035eaa1be59ff","type":"COMBINATION_TREATMENT","name":"clomipramine + fluoxetine + quetiapine","canonical_id":"ctgov_combo:ctgov-combo-d1370955b9035258","description":null,"metadata":null},{"id":"ff5a892dca964a7f9f1e9d42689b3aa7","type":"COMBINATION_TREATMENT","name":"clomipramine + fluvoxamine + imipramine + nortriptyline + sulpiride + tranylcypromine + trazodone","canonical_id":"ctgov_combo:ctgov-combo-1b0ad982b17eac95","description":null,"metadata":null},{"id":"d4970adfba0f40879609b79db27ed7ae","type":"DISEASE","name":"clonal hematopoiesis","canonical_id":"efo:0010819","description":null,"metadata":null},{"id":"ec6babe261ba4f968e887df1f4146521","type":"DRUG","name":"clonazepam","canonical_id":"gtopdb:6963","description":null,"metadata":null},{"id":"fa01f4fe6836457c9a0ab781e86313cf","type":"DRUG","name":"clonazepam","canonical_id":"mesh:D002998","description":null,"metadata":null},{"id":"e83f12cde08244b2ab93cfe9e7a2dea2","type":"DRUG","name":"clonazepam","canonical_id":"chembl:CHEMBL452","description":null,"metadata":null},{"id":"513e4245305a49c3accb98cd4463e6bd","type":"COMBINATION_TREATMENT","name":"clonazepam + sertraline + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-595d9477ca941033","description":null,"metadata":null},{"id":"1c31f87a685d487d9b5a169c0964bb62","type":"COMBINATION_TREATMENT","name":"clonazepam + tetrabenazine + trihexyphenidyl","canonical_id":"ctgov_combo:ctgov-combo-15776e8bd7518055","description":null,"metadata":null},{"id":"f9d24d421590434da54c5e798590d429","type":"DRUG","name":"clonidine","canonical_id":"gtopdb:516","description":null,"metadata":null},{"id":"e4c2581aed4544c892704e141c3993d5","type":"DRUG","name":"clonidine","canonical_id":"chembl:CHEMBL134","description":null,"metadata":null},{"id":"f2832a382ebe47df9d4bbbd301fd3415","type":"COMBINATION_TREATMENT","name":"clonidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-47ca109a166a47cc","description":null,"metadata":null},{"id":"62c0b15665b842f69221ae1e2d6b8a2f","type":"COMBINATION_TREATMENT","name":"clonidine + labetalol","canonical_id":"ctgov_combo:ctgov-combo-635226dd2f437617","description":null,"metadata":null},{"id":"ac46001ff9d54e24a2c7f27bdad145a5","type":"COMBINATION_TREATMENT","name":"clonidine + loperamide + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-72afb3e508932777","description":null,"metadata":null},{"id":"c3ea6d5ed81049c7b874256221f623b3","type":"COMBINATION_TREATMENT","name":"clonidine + morphine","canonical_id":"ctgov_combo:ctgov-combo-06749ba2a2fdf2d5","description":null,"metadata":null},{"id":"8ecaf7f19af2412eb11b2b7fddfd0f67","type":"COMBINATION_TREATMENT","name":"clonidine + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-b87dec3cde8b0ae0","description":null,"metadata":null},{"id":"eabd6769ab5141fabf4fb2a3dbe97f28","type":"COMBINATION_TREATMENT","name":"clonidine + propranolol","canonical_id":"ctgov_combo:ctgov-combo-7b52ba5ab4c8d706","description":null,"metadata":null},{"id":"23a9855b7b8440a6a9b214d0dd93a4f1","type":"COMBINATION_TREATMENT","name":"clonidine + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-933e6608f2edb007","description":null,"metadata":null},{"id":"6538e0bc91fd487481b54a7d9e6c1ebd","type":"COMBINATION_TREATMENT","name":"clonidine + yohimbine","canonical_id":"ctgov_combo:ctgov-combo-75f3a2480ba08daf","description":null,"metadata":null},{"id":"747ad1e781644780a31a2f87d4626a46","type":"GO_TERM","name":"closure of embryonic heart tube","canonical_id":"go:GO:0003153","description":"\"Creation of the central hole of the embryonic heart tube by sealing the edges of an epithelial fold.\" [GOC:mtg_heart]","metadata":null},{"id":"a93c8765e613438f9fa4595db0922415","type":"GO_TERM","name":"closure of optic fissure","canonical_id":"go:GO:0061386","description":"\"The closure of the temporary ventral gap in the optic cup that contributes to its shaping.\" [GOC:dph]","metadata":null},{"id":"6e03af036e8841eeb0a0c3f9e29be221","type":"DRUG","name":"clotrimazole","canonical_id":"mesh:D003022","description":null,"metadata":null},{"id":"c696a1fb52f849d8b2ca05ec3842dbb7","type":"DRUG","name":"clozapine","canonical_id":"gtopdb:38","description":null,"metadata":null},{"id":"ff8896c0513e42ab95d7e97e9ab61c68","type":"DRUG","name":"clozapine","canonical_id":"chembl:CHEMBL42","description":null,"metadata":null},{"id":"e99327eaa7894c1d99a189037636618a","type":"COMBINATION_TREATMENT","name":"clozapine + fluphenazine + perphenazine + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-e1a94c6c09a45a1d","description":null,"metadata":null},{"id":"df8dfc0cde20481cb2dece57a8f55a99","type":"COMBINATION_TREATMENT","name":"clozapine + haloperidol","canonical_id":"ctgov_combo:ctgov-combo-6f8b072343e674ed","description":null,"metadata":null},{"id":"705cf82169fd4d888da01910c1536af5","type":"COMBINATION_TREATMENT","name":"clozapine + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-81176a7cc1c99eb9","description":null,"metadata":null},{"id":"4453fcd317474752a0c603fa09d2b63d","type":"COMBINATION_TREATMENT","name":"clozapine + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-753301940d0bde72","description":null,"metadata":null},{"id":"b7ee1307cb62441e84d61bf82fa7763d","type":"COMBINATION_TREATMENT","name":"clozapine + olanzapine + perphenazine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-36a217eaa5ba3f95","description":null,"metadata":null},{"id":"ede668ef4ece4ce4b6fce87113758d71","type":"GO_TERM","name":"club cell differentiation","canonical_id":"go:GO:0060486","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a club cell. A club cell is an unciliated epithelial cell found in the respiratory and terminal bronchioles.\" [GOC:dph, GOC:mtg_lung, PMID:28144783]","metadata":null},{"id":"0b3323e175cd4172bcb729c99dccab6a","type":"GO_TERM","name":"cluster of actin-based cell projections","canonical_id":"go:GO:0098862","description":"\"A cell part consisting of multiple, closely packed actin-based cell projections.\" [GOC:dos]","metadata":null},{"id":"3f289c06e7714eba81742692d92ccace","type":"GO_TERM","name":"clustering of voltage-gated calcium channels","canonical_id":"go:GO:0070073","description":"\"The process in which voltage-gated calcium channels become localized together in high densities.\" [GOC:BHF, GOC:sart, PMID:18385325]","metadata":null},{"id":"5552058693fa4fc4ab58e366c8c38a21","type":"GO_TERM","name":"clustering of voltage-gated potassium channels","canonical_id":"go:GO:0045163","description":"\"The process in which voltage-gated potassium channels become localized together in high densities. In animals, voltage-gated potassium (Kv) channels are clustered beneath the myelin sheath in regions immediately adjacent to paranodes, called juxtaparanodes, and along the inner mesaxon within the internode.\" [PMID:11456440]","metadata":null},{"id":"441faa8da0e6430bbfe94e57f092bd5d","type":"GO_TERM","name":"clustering of voltage-gated sodium channels","canonical_id":"go:GO:0045162","description":"\"The process in which voltage-gated sodium channels become localized together in high densities. In animals, nodes of Ranvier differ dramatically from internodal axonal regions in very high densities of voltage-dependent sodium (Nav) channels responsible for the rapid, inward ionic currents that produce membrane depolarization.\" [PMID:11456440]","metadata":null},{"id":"44a46440241a4835a5a9674f7bf2ee9e","type":"GO_TERM","name":"clypeo-labral disc development","canonical_id":"go:GO:0035213","description":"\"The process whose specific outcome is the progression of the clypeo-labral disc over time, from its formation to the metamorphosis to form adult structures. The clypeo-labral disc develops into the labrum, anterior cibarial plate, fish trap bristles, epistomal sclerite.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"401786cc2cd84d51845593a42e5c786b","type":"GO_TERM","name":"clypeo-labral disc morphogenesis","canonical_id":"go:GO:0007453","description":"\"The process in which the anatomical structures derived from the clypeo-labral disc are generated and organized. This includes the transformation of a clypeo-labal imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into recognizable adult structures including the labrum, anterior and posterior cibarial plates, fish trap bristles, epistomal sclerite and clypeus.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"65a0134834a3475c895724dda8896587","type":"GO_TERM","name":"clypeus development","canonical_id":"go:GO:0048723","description":"\"The process whose specific outcome is the progression of the clypeus over time, from its formation to the mature structure. The clypeus is the shield-shaped plate on an insect's head.\" [GOC:rc]","metadata":null},{"id":"bb3447aed6f84851978288d6accc0564","type":"GO_TERM","name":"clypeus morphogenesis","canonical_id":"go:GO:0048721","description":"\"The process in which the anatomical structures of the clypeus are generated and organized.\" [GOC:rc]","metadata":null},{"id":"796ce159f0ae4f89b39d7bc2dcce6084","type":"GO_TERM","name":"cnida","canonical_id":"go:GO:0140022","description":"\"A giant secretory organelle that comprises a bulb-shape capsule containing a coiled hollow tubule structure attached to it. A cnida defines the phylum Cnidaria.\" [Wikipedia:Cnida#Structure_and_function]","metadata":null},{"id":"6b5ddd8af291412da8a52803bdcf9bc2","type":"GO_TERM","name":"co-SMAD binding","canonical_id":"go:GO:0070410","description":"\"Binding to a common mediator SMAD signaling protein.\" [GOC:BHF, GOC:vk, PMID:19114992]","metadata":null},{"id":"7082fa91f65e427cb6d916687444b760","type":"GO_TERM","name":"co-receptor binding","canonical_id":"go:GO:0039706","description":"\"Binding to a coreceptor. A coreceptor acts in cooperation with a primary receptor to transmit a signal within the cell.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"68523c42c5154b459b2c07f63a4f79b6","type":"GO_TERM","name":"co-transcriptional RNA 3'-end processing, cleavage and polyadenylation pathway","canonical_id":"go:GO:0180012","description":"\"Any process involved in transcription termination-coupled 3' processing of RNA polymerase II RNA transcripts by 3' end cleavage and addition of a poly(A) tail.\" [PMID:31499460]","metadata":null},{"id":"02e17a277e774a42b75553eb8fc1ed91","type":"GO_TERM","name":"co-transcriptional gene silencing by RNA interference machinery","canonical_id":"go:GO:0033562","description":"\"A process in which the RNAi machinery mediates the degradation of nascent transcripts in association with chromatin.\" [GOC:mah, GOC:vw, PMID:17512405, PMID:21151114, PMID:22431512]","metadata":null},{"id":"8c0284cc0c67444abe6c9369e5b6abc3","type":"GO_TERM","name":"co-transcriptional lncRNA 3' end processing, cleavage and polyadenylation pathway","canonical_id":"go:GO:0180034","description":"\"Any process involved in transcription termination-coupled 3' processing of RNA polymerase II lncRNA transcripts by the 3' end cleavage and addition of a poly(A) tail.\" [PMID:31276588]","metadata":null},{"id":"01f7d66503ca4ed0bfd9cb4596f6649f","type":"GO_TERM","name":"co-transcriptional mRNA 3'-end processing, cleavage and polyadenylation pathway","canonical_id":"go:GO:0180010","description":"\"Any process involved in transcription termination-coupled 3' processing of RNA polymerase II mRNA transcripts by the 3' end cleavage and addition of a poly(A) tail.\" [PMID:31499460]","metadata":null},{"id":"83c3d483c0e44aa1909d82f4c2565356","type":"GO_TERM","name":"coagulation","canonical_id":"go:GO:0050817","description":"\"The process in which a fluid solution, or part of it, changes into a solid or semisolid mass.\" [ISBN:0198506732]","metadata":null},{"id":"f96578cb5a804e8f8c07dac67d959d3a","type":"GO_TERM","name":"coated membrane","canonical_id":"go:GO:0048475","description":"\"A single or double lipid bilayer with any of several different proteinaceous coats that can associate with membranes. Membrane coats include those formed by clathrin plus an adaptor complex, the COPI and COPII complexes.\" [GOC:jid]","metadata":null},{"id":"e2532b6fd8264d7d804025594e4c3333","type":"GO_TERM","name":"coated vesicle","canonical_id":"go:GO:0030135","description":"\"Small membrane-bounded organelle formed by pinching off of a coated region of membrane. Some coats are made of clathrin, whereas others are made from other proteins.\" [ISBN:0815316194]","metadata":null},{"id":"727344f774b34897b9e9b1fd2c7b476b","type":"GO_TERM","name":"coated vesicle membrane","canonical_id":"go:GO:0030662","description":"\"The lipid bilayer surrounding a coated vesicle.\" [GOC:mah]","metadata":null},{"id":"21bf4fd61ce04db695c93fc151d8d2ac","type":"GO_TERM","name":"cobalamin 5'-phosphate synthase activity","canonical_id":"go:GO:0008818","description":"\"Catalysis of the reaction: adenosylcobinamide-GDP + alpha-ribazole-5'-phosphate = adenosylcobalamin-5'-phosphate + GMP.\" [MetaCyc:COBALAMIN5PSYN-RXN]","metadata":null},{"id":"36008f0dbe7843848cd1200f97dd66eb","type":"GO_TERM","name":"cobalamin binding","canonical_id":"go:GO:0031419","description":"\"Binding to cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.\" [GOC:mah]","metadata":null},{"id":"63a8737b5ce4402aa71e52ad5ec2434a","type":"GO_TERM","name":"cobalamin biosynthetic process","canonical_id":"go:GO:0009236","description":"\"The chemical reactions and pathways resulting in the formation of cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"35b365bea5ad4728844052dc5d8cd4bc","type":"GO_TERM","name":"cobalamin catabolic process","canonical_id":"go:GO:0042366","description":"\"The chemical reactions and pathways resulting in the breakdown of cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.\" [GOC:curators]","metadata":null},{"id":"f2b22d52a24d4e9d96dcc0ae50e05b72","type":"GO_TERM","name":"cobalamin metabolic process","canonical_id":"go:GO:0009235","description":"\"The chemical reactions and pathways involving cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.\" [GOC:curators]","metadata":null},{"id":"9b8c2f3de10e4c64a0bcbaf61874bad6","type":"GO_TERM","name":"cobalamin transport","canonical_id":"go:GO:0015889","description":"\"The directed movement of cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"6072beeff2c347188b1d2f9f4bf0ac99","type":"GO_TERM","name":"cobalamin transport complex","canonical_id":"go:GO:1990191","description":"\"Protein complex facilitating ATP-dependent cobalamin (vitamin B12) transport through inner cell membrane (periplasm to cytoplasm) in Gram-negative bacteria. In E. coli the system is composed of a periplasmic cobalamin-binding protein (BtuF), an integral membrane homodimer, BtuC, and a cytoplasmic ATP-binding homodimer BtuD.\" [GOC:bhm, PMID:22569249]","metadata":null},{"id":"c8fa2068cf264a73b781930b23f693be","type":"GO_TERM","name":"cobalt ion binding","canonical_id":"go:GO:0050897","description":"\"Binding to a cobalt ion (Co2+).\" [GOC:ai]","metadata":null},{"id":"10b8a8142d904e6bae3f17400bf69a05","type":"GO_TERM","name":"cobalt ion transmembrane transporter activity","canonical_id":"go:GO:0015087","description":"\"Enables the transfer of cobalt (Co2+) ions from one side of a membrane to the other.\" [GOC:dgf]","metadata":null},{"id":"8c95c50df29b4a858b976b6a72823f95","type":"GO_TERM","name":"cobalt ion transport","canonical_id":"go:GO:0006824","description":"\"The directed movement of cobalt (Co2+) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"86211cd048b940408e12dbfb612f9208","type":"GO_TERM","name":"cobalt-factor II C20-methyltransferase activity","canonical_id":"go:GO:0043781","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + cobalt-factor II = S-adenosyl-L-homocysteine + cobalt-factor III.\" [EC:2.1.1.151]","metadata":null},{"id":"194388c902cd4ee68f1425d4b97cccc0","type":"GO_TERM","name":"cobalt-precorrin-3 C17-methyltransferase activity","canonical_id":"go:GO:0043782","description":"\"Catalysis of the reaction: cobalt-precorrin 3 + S-adenosyl-L-methionine = cobalt-precorrin 4 + S-adenosyl-L-homocysteine.\" [MetaCyc:RXN-8761]","metadata":null},{"id":"0e96ca448adf46d984d5fe093a241bb1","type":"GO_TERM","name":"cobalt-precorrin-5A acetaldehyde-lyase activity","canonical_id":"go:GO:0043779","description":"\"Catalysis of the reaction: cobalt-precorrin 5A + H2O = cobalt-precorrin 5B + acetaldehyde + H+.\" [RHEA:26281]","metadata":null},{"id":"0e66826db64a40b6ab098ebae2b7425c","type":"GO_TERM","name":"cobalt-precorrin-5B C1-methyltransferase activity","canonical_id":"go:GO:0043780","description":"\"Catalysis of the reaction: cobalt-precorrin 5B + S-adenosylmethionine = S-adenosylhomocysteine + cobalt-precorrin 6A.\" [MetaCyc:RXN-8764]","metadata":null},{"id":"54c8d45950b94e71802f1773ad5fbf86","type":"GO_TERM","name":"cobalt-precorrin-6B C5-methyltransferase activity","canonical_id":"go:GO:0043776","description":"\"Catalysis of the reaction: S-adenosylmethionine + cobalt-precorrin 6B = S-adenosylhomocysteine + cobalt-precorrin 7.\" [MetaCyc:RXN-8766]","metadata":null},{"id":"c0d809b6cba9456aa68e4c0499be169e","type":"GO_TERM","name":"cobalt-precorrin-7 C15-methyltransferase activity","canonical_id":"go:GO:0043777","description":"\"Catalysis of the reaction: cobalt-precorrin 7 + S-adenosyl-L-methionine = cobalt-precorrin 8 + S-adenosyl-L-homocysteine + CO2.\" [MetaCyc:RXN-8767]","metadata":null},{"id":"f5f0f9af726d4d4fbf85c24ac2fbb00f","type":"GO_TERM","name":"cobalt-precorrin-8 methylmutase activity","canonical_id":"go:GO:0043778","description":"\"Catalysis of the reaction: cobalt-precorrin 8 = cobyrinate.\" [MetaCyc:RXN-8768]","metadata":null},{"id":"995c92b4ecd54e27adc00d3c0eb02fc7","type":"GO_TERM","name":"cobaltochelatase activity","canonical_id":"go:GO:0051116","description":"\"Catalysis of the reaction: ATP + Co(2+) + H2O + hydrogenobyrinate a,c-diamide = ADP + cob(II)yrinate a,c diamide + 4 H+ + phosphate.\" [EC:6.6.1.2, RHEA:15341]","metadata":null},{"id":"2ec15287f9854866bbed0b1999e41004","type":"DRUG","name":"cobicistat","canonical_id":"mesh:D000069547","description":null,"metadata":null},{"id":"a07995d1acdd42029a7245eb56a1f739","type":"DRUG","name":"cobimetinib","canonical_id":"gtopdb:7626","description":null,"metadata":null},{"id":"063e45275deb4fc8b444b01a878c91be","type":"DRUG","name":"cobimetinib","canonical_id":"chembl:CHEMBL2146883","description":null,"metadata":null},{"id":"906263dd2dbb416296c05e718ff18cb8","type":"COMBINATION_TREATMENT","name":"cobimetinib + evolocumab + linagliptin + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-f36ee094d5ed7c9a","description":null,"metadata":null},{"id":"e73e8dec9ffa4ca59b3ccede7dfa8daa","type":"COMBINATION_TREATMENT","name":"cobimetinib + niraparib","canonical_id":"ctgov_combo:ctgov-combo-1d693ded9e606d20","description":null,"metadata":null},{"id":"4ad677898bf344fc9a82f76ad2d4030d","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-753e502859fd7c19","description":null,"metadata":null},{"id":"f3afa15ac2dd4fef85cfced06540e28c","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-014d9d37f6621119","description":null,"metadata":null},{"id":"131e35305c154fe8a81ff781c8c1ba7a","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-cf3f766063d7416b","description":null,"metadata":null},{"id":"87b3570790f6476bba15484dced5f23b","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-f4abb2e96bafb32c","description":null,"metadata":null},{"id":"46ad0633e5154d17b43913707eb56899","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-cf4fb57f7d24ff1e","description":null,"metadata":null},{"id":"6fd4692ed2ca4d648d2c6920f092e4e6","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-a16508c55e4da4f8","description":null,"metadata":null},{"id":"933e48ddf9de4431ba3c7b0524cecf13","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-8dc4293558326462","description":null,"metadata":null},{"id":"3dbcc2bca0a249f99a07cc2b21368709","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-6d2ff6a5ec1e0eaf","description":null,"metadata":null},{"id":"d042724366c146058a3b79cd65b40895","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-f193f05921bdad0a","description":null,"metadata":null},{"id":"517202010225403f95ade011cbac6e07","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-d08581522e99cbf6","description":null,"metadata":null},{"id":"f6cb8510728f4da1bc8047948dcf2996","type":"COMBINATION_TREATMENT","name":"cobimetinib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-bd4fa5e42f0b9695","description":null,"metadata":null},{"id":"552a27c1a3e14fb598a8f9690223c5e7","type":"COMBINATION_TREATMENT","name":"cobimetinib + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-22f2e194b53eff5b","description":null,"metadata":null},{"id":"4a8bb5bfb6e64b07bcf42386889aca58","type":"GO_TERM","name":"cobinamide phosphate guanylyltransferase activity","canonical_id":"go:GO:0008820","description":"\"Catalysis of the reaction: adenosylcobinamide phosphate + GTP + 2 H+ = adenosylcobinamide-GDP + diphosphate.\" [RHEA:22712]","metadata":null},{"id":"c752554db9c34d4f82877ff589ce6764","type":"GO_TERM","name":"cobyrinic acid a,c-diamide synthase activity","canonical_id":"go:GO:0042242","description":"\"Catalysis of the conversion of cobyrinic acid to cobyrinic acid a,c-diamide via the intermediate formation of cobyrinic acid c-monoamide.\" [PMID:2172209, RHEA:26289]","metadata":null},{"id":"8a007f485c304fbd84a218e51a8b1571","type":"DRUG","name":"cocaine","canonical_id":"gtopdb:2286","description":null,"metadata":null},{"id":"a449352d75f74fb9b0ea59c5d3dfc450","type":"COMBINATION_TREATMENT","name":"cocaine + lidocaine","canonical_id":"ctgov_combo:ctgov-combo-01e285a1167c93b9","description":null,"metadata":null},{"id":"bd994fbdb45d4ce4a816d5311c3318e6","type":"GO_TERM","name":"cocaine binding","canonical_id":"go:GO:0019811","description":"\"Binding to cocaine (2-beta-carbomethoxy-3-beta-benzoxytropane), an alkaloid obtained from dried leaves of the South American shrub Erythroxylon coca or by chemical synthesis.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"e81469570c924c6e97ba4101fa311552","type":"GO_TERM","name":"cocaine biosynthetic process","canonical_id":"go:GO:0050799","description":"\"The chemical reactions and pathways resulting in the formation of cocaine, an alkaloid obtained from the dried leaves of the shrub Erythroxylon coca. It is a cerebral stimulant and narcotic.\" [GOC:ai]","metadata":null},{"id":"9516833d20274cd0826b8538aebb09d0","type":"GO_TERM","name":"cocaine catabolic process","canonical_id":"go:GO:0050784","description":"\"The chemical reactions and pathways resulting in the breakdown of cocaine, an alkaloid obtained from the dried leaves of the shrub Erythroxylon coca. It is a cerebral stimulant and narcotic.\" [PMID:17132243]","metadata":null},{"id":"02cbb4acd5bf4712a57c7a60539e531f","type":"GO_TERM","name":"cochlea development","canonical_id":"go:GO:0090102","description":"\"The progression of the cochlea over time from its formation to the mature structure. The cochlea is the snail-shaped portion of the inner ear that is responsible for the detection of sound.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"cce5052358cc49838e8eaa6f27c1852e","type":"GO_TERM","name":"cochlea morphogenesis","canonical_id":"go:GO:0090103","description":"\"The process in which the cochlea is generated and organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9cbbce424b1e4af7a18565c249b0c18f","type":"GO_TERM","name":"cochlear hair cell ribbon synapse","canonical_id":"go:GO:0098683","description":"\"A ribbon synpase of an auditory hair cell of the cochlear. These ribbon synapses contain spherical synaptic ribbons and lack and arciform density.\" [PMID:15626493]","metadata":null},{"id":"c2d494a25e3b4c278a6c0602b6f7aae4","type":"GO_TERM","name":"cochlear nucleus development","canonical_id":"go:GO:0021747","description":"\"The process whose specific outcome is the progression of the cochlear nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"50006e77cf864b4d88f7928e1b700f71","type":"GO_TERM","name":"cochlear outer hair cell electromotile response","canonical_id":"go:GO:0099129","description":"\"A rapid, force generating length change of an outer hair cell in response to electrical stimulation. This occurs naturally as during hearing where it serves a source of mechanical amplification.\" [PMID:12239568, PMID:16887876, PMID:2187727]","metadata":null},{"id":"bfd07d35d8954bd5af6d9a59897ae58e","type":"DRUG","name":"codeine","canonical_id":"gtopdb:1673","description":null,"metadata":null},{"id":"f98cec5d75cc4c0c96f7da054dbfc6e3","type":"DRUG","name":"codeine","canonical_id":"mesh:D003061","description":null,"metadata":null},{"id":"3dbbffeb2f60416b802664394971c779","type":"DRUG","name":"codeine","canonical_id":"chembl:CHEMBL1201463","description":null,"metadata":null},{"id":"db9e8d8ce7c6449c88161f95467def96","type":"COMBINATION_TREATMENT","name":"codeine + diclofenac + lacosamide","canonical_id":"ctgov_combo:ctgov-combo-84fe77b17e51f090","description":null,"metadata":null},{"id":"1a21c6c948924825a8c410583c4071eb","type":"COMBINATION_TREATMENT","name":"codeine + hydrocodone + ibuprofen","canonical_id":"ctgov_combo:ctgov-combo-10eb2babd3bba1b6","description":null,"metadata":null},{"id":"429d591e8a2548949cdded2c0346d7f4","type":"COMBINATION_TREATMENT","name":"codeine + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-b8b0b1e424c3b9c5","description":null,"metadata":null},{"id":"02bdb19de1f14e4db27756046842c3af","type":"COMBINATION_TREATMENT","name":"codeine + naproxen","canonical_id":"ctgov_combo:ctgov-combo-3949ab5246fb89f4","description":null,"metadata":null},{"id":"705136b2e3c94e83810c22a6beccf3e9","type":"COMBINATION_TREATMENT","name":"codeine + naproxen","canonical_id":"ctgov_combo:ctgov-combo-fc0f613c66749603","description":null,"metadata":null},{"id":"81c12fbe0329434191126c313de618ae","type":"GO_TERM","name":"codeine O-demethylase activity","canonical_id":"go:GO:0102805","description":"\"Catalysis of the reaction: codeine + 2-oxoglutarate + O2 = morphine + formaldehyde + succinate + CO2.\" [RHEA:27413]","metadata":null},{"id":"c260e470034b416c9a2ec247d0d9d0bd","type":"GO_TERM","name":"codeine catabolic process","canonical_id":"go:GO:2001292","description":"\"The chemical reactions and pathways resulting in the breakdown of codeine, an alkaloid found in the opium poppy, Papaver somniferum var. album. Codeine has analgesic, anti-tussive and anti-diarrhoeal properties.\" [GOC:yaf, PMID:8845855]","metadata":null},{"id":"6e7f9793963649e99acbed85c1be6349","type":"GO_TERM","name":"codeine metabolic process","canonical_id":"go:GO:2001291","description":"\"The chemical reactions and pathways involving codeine, an alkaloid found in the opium poppy, Papaver somniferum var. album. Codeine has analgesic, anti-tussive and anti-diarrhoeal properties.\" [GOC:yaf]","metadata":null},{"id":"42b718f1cc19448b9b8bd1e8fce912b0","type":"GO_TERM","name":"codeinone reductase (NADPH) activity","canonical_id":"go:GO:0047036","description":"\"Catalysis of the reaction: codeine + NADP+ = codeinone + H+ + NADPH.\" [EC:1.1.1.247, RHEA:19209]","metadata":null},{"id":"4bc14b2da0484186b3db2f4439dd6ac3","type":"GO_TERM","name":"coenzyme A binding","canonical_id":"go:GO:0120225","description":"\"Binding to coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [GOC:krc, ISBN:0198547684]","metadata":null},{"id":"b4bf74b7af9a42129d008ced83412349","type":"GO_TERM","name":"coenzyme A biosynthetic process","canonical_id":"go:GO:0015937","description":"\"The chemical reactions and pathways resulting in the formation of coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [ISBN:0198547684]","metadata":null},{"id":"34c5db5c101545f6977332234133407b","type":"GO_TERM","name":"coenzyme A catabolic process","canonical_id":"go:GO:0015938","description":"\"The chemical reactions and pathways resulting in the breakdown of coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [ISBN:0198547684]","metadata":null},{"id":"38c48cfcfadf47d1bb52ab3ecec34caa","type":"GO_TERM","name":"coenzyme A diphosphatase activity","canonical_id":"go:GO:0010945","description":"\"Catalysis of the reaction: an acyl-coenzyme A or its derivatives + H2O = adenosine 3',5'-bisphosphate + an acyl-4'-phosphopantetheine + 2 H+. This reaction can also use coenzyme A as a substrate.\" [PMID:10922370, PMID:16185196]","metadata":null},{"id":"9841da7c530d4e4b8afcfa3074262c3a","type":"GO_TERM","name":"coenzyme A metabolic process","canonical_id":"go:GO:0015936","description":"\"The chemical reactions and pathways involving coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [ISBN:0198547684]","metadata":null},{"id":"9d42bd6c99c34e90a3880f8a48ab0bc8","type":"GO_TERM","name":"coenzyme A transmembrane transport","canonical_id":"go:GO:0035349","description":"\"The process in which coenzyme A is transported across a membrane. Coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, is an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [GOC:bf]","metadata":null},{"id":"25a5228a3c6e4919842a637149cc5491","type":"GO_TERM","name":"coenzyme A transmembrane transporter activity","canonical_id":"go:GO:0015228","description":"\"Enables the transfer of coenzyme A from one side of a membrane to the other. Coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, is an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [GOC:ai]","metadata":null},{"id":"a1580406d88c4cc8b5531547dbe10285","type":"GO_TERM","name":"coenzyme A transport","canonical_id":"go:GO:0015880","description":"\"The directed movement of coenzyme A into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, is an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.\" [GOC:ai]","metadata":null},{"id":"33e6b22ee3f24470917e74509db36270","type":"GO_TERM","name":"coenzyme B biosynthetic process","canonical_id":"go:GO:0019298","description":"\"The chemical reactions and pathways resulting in the formation of coenzyme B (7-mercaptoheptanoylthreonine phosphate), a coenzyme involved in the utilization of methane by methanogenic prokaryotes.\" [PMID:10940051]","metadata":null},{"id":"4471733eb27b419798312b338c8d4a6d","type":"GO_TERM","name":"coenzyme F420 binding","canonical_id":"go:GO:0070967","description":"\"Binding to F420, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:dh]","metadata":null},{"id":"73e4a63542e741a6869f403d18a92121","type":"GO_TERM","name":"coenzyme F420 hydrogenase activity","canonical_id":"go:GO:0050454","description":"\"Catalysis of the reaction: coenzyme F420 + H(2) + H+ = reduced coenzyme F420.\" [EC:1.12.98.1, RHEA:23760]","metadata":null},{"id":"69f69375301c43f3ac57458285535f59","type":"GO_TERM","name":"coenzyme F420-0 gamma-glutamyl ligase activity","canonical_id":"go:GO:0043773","description":"\"Catalysis of the reactions: (1) GTP + F420-0 + L-glutamate = GDP + phosphate + F420-1, and (2) GTP + F420-1 + L-glutamate = GDP + phosphate + gamma-F420-2. This is the GTP-dependent successive addition of two L-glutamates to the L-lactyl phosphodiester of 7,8-didemethyl-8-hydroxy-5-deazariboflavin (F420-0) to form F420-0-glutamyl-glutamate (F420-2), with a gamma-linkage between the two glutamates.\" [PMID:17669425]","metadata":null},{"id":"5068593820ef4af5afb1436ba9b3414f","type":"GO_TERM","name":"coenzyme F420-0:L-glutamate ligase activity","canonical_id":"go:GO:0052618","description":"\"Catalysis of the reaction: GTP + L-glutamate + factor F420-0 = GDP + H+ + factor gamma-F420-1 + phosphate.\" [MetaCyc:RXN-8080]","metadata":null},{"id":"6f033a08e99841e6a69d7c68e0f5e18e","type":"GO_TERM","name":"coenzyme F420-1:gamma-L-glutamate ligase activity","canonical_id":"go:GO:0052619","description":"\"Catalysis of the reaction: GTP + L-glutamate + factor gamma-F420-1 = GDP + H+ + factor gamma-F420-2 + phosphate.\" [MetaCyc:RXN-8081]","metadata":null},{"id":"b9454a3901ad474ba58e74dcae41b385","type":"GO_TERM","name":"coenzyme F420-2 alpha-glutamyl ligase activity","canonical_id":"go:GO:0043774","description":"\"Catalysis of the reaction: coenzyme F420-2 + L-glutamate + GTP = coenzyme F420-3 + GDP + orthophosphate.\" [PMID:12909715]","metadata":null},{"id":"142b214cecaa4062aade4cf00d915dce","type":"GO_TERM","name":"coenzyme F420-dependent N5,N10-methenyltetrahydromethanopterin reductase activity","canonical_id":"go:GO:0018537","description":"\"Catalysis of the reaction: 5-methyltetrahydromethanopterin + coenzyme F420 + H+ = 5,10-methylenetetrahydromethanopterin + reduced coenzyme F420.\" [EC:1.5.98.2, RHEA:21144]","metadata":null},{"id":"0e143aade918484bbfad8fa0bb67063e","type":"GO_TERM","name":"coenzyme F420-dependent bicyclic nitroimidazole catabolic process","canonical_id":"go:GO:0052799","description":"\"The breakdown of a bicyclic nitroimidazole into simpler components in a process that requires coenzyme F420 and produces reactive nitrogen species. Hydride, from reduced coenzyme F420, is added to the bicyclic nitroimidazole, resulting in unstable substances that break down to form three stable products. The elimination of nitrous acid produces the corresponding des-nitroimidazole; hydrolysis produces a related compound; and further reduction creates an aromatic hydroxylamine metabolite that degrades further. These reactions release hyponitrous acid and nitrous acid, which is unstable and disproportionates into nitric oxide (NO) and other reactive nitrogen intermediates.\" [GOC:mengo_curators, PMID:16387854, PMID:19039139]","metadata":null},{"id":"b0a8395709d840e7a9be4d28be20a3eb","type":"GO_TERM","name":"coenzyme F420H2 oxidase activity","canonical_id":"go:GO:0052765","description":"\"Catalysis of the reaction: 2 reduced coenzyme F420-(gamma-L-Glu)(n) + O2 = 2 oxidized coenzyme F420-(gamma-L-Glu)(n) + 2 H2O + 2 H+.\" [PMID:15340796, RHEA:39711]","metadata":null},{"id":"882ff3be18b34bdc8aa3b3a723cb0df2","type":"GO_TERM","name":"coenzyme F420H2:quinone oxidoreductase activity","canonical_id":"go:GO:0052755","description":"\"Catalysis of the reaction: oxidized coenzyme F420-(gamma-L-Glu)(n) + a quinol + H+ = reduced coenzyme F420-(gamma-L-Glu)(n) + a quinone.\" [PMID:10971593, PMID:8055920, RHEA:39663]","metadata":null},{"id":"f96a8413e6b94fcbb0071e194f45edee","type":"GO_TERM","name":"coenzyme M biosynthetic process","canonical_id":"go:GO:0019295","description":"\"The chemical reactions and pathways resulting in the formation of coenzyme M (2-thioethansulfonate), a coenzyme involved in the utilization of methane by methanogenic prokaryotes.\" [ISBN:0198547684]","metadata":null},{"id":"c998b0e040b545bcbc00ef75c02e392c","type":"GO_TERM","name":"coenzyme gamma-F420-2 biosynthetic process","canonical_id":"go:GO:2001121","description":"\"The chemical reactions and pathways resulting in the formation of a coenzyme gamma-F420-2.\" [GOC:mengo_curators]","metadata":null},{"id":"5586293b2e82427eaa0578804e766090","type":"GO_TERM","name":"coenzyme-B sulfoethylthiotransferase activity","canonical_id":"go:GO:0050524","description":"\"Catalysis of the reaction: coenzyme B + methyl-coenzyme M = coenzyme M-coenzyme B heterodisulfide + methane. Methyl-CoM is also known as 2-(methylthio)ethanesulfonate, coenzyme B as N-(7-mercaptoheptanoyl)threonine 3-O-phosphate, and coenzyme M-coenzyme B heterodisulfide as CoM-S-S-CoB.\" [EC:2.8.4.1, RHEA:12532]","metadata":null},{"id":"3b28cadcadd548a2af5354f21cb4e392","type":"DISEASE","name":"coffee consumption","canonical_id":"efo:0004330","description":null,"metadata":null},{"id":"03d8a0a91f554670a2df081a153b6675","type":"GO_TERM","name":"cofilin-actin rod","canonical_id":"go:GO:0090732","description":"\"A cellular structure consisting of parallel, hexagonally arranged actin tubules, comprising filamentous actin and disulfide cross-linked cofilin multimers.\" [GOC:sl, PMID:22573689, PMID:24760020]","metadata":null},{"id":"f72a31bc4d8840aaa66a23df73b6ab22","type":"GO_TERM","name":"cognition","canonical_id":"go:GO:0050890","description":"\"The operation of the mind by which an organism becomes aware of objects of thought or perception; it includes the mental activities associated with thinking, learning, and memory.\" [ISBN:0721619908]","metadata":null},{"id":"996a877d3a264b10a4adbf0e72af3a62","type":"GO_TERM","name":"cohesin complex","canonical_id":"go:GO:0008278","description":"\"A protein complex that is required for sister chromatid cohesion in eukaryotes. The cohesin complex forms a molecular ring complex, and is composed of structural maintenance of chromosomes (SMC) and kleisin proteins. For example, in yeast, the complex is composed of the SMC proteins Smc1p and Smc3p, and the kleisin protein Scc1p. In vertebrates, the complex is composed of the SMC1 (SMC1A or SMC1B) and SMC3 heterodimer attached via their hinge domains to a kleisin (RAD21, REC8 or RAD21L) which links them, and one STAG protein (STAG1, STAG2 or STAG3).\" [GOC:jl, GOC:sp, GOC:vw, PMID:9887095]","metadata":null},{"id":"41b3c3ab75364e76800d256df0b574b6","type":"GO_TERM","name":"cohesin loader activity","canonical_id":"go:GO:0061775","description":"\"Facilitating a conformational change to load a cohesin complex around sister chromatids.\" [GOC:vw, PMID:26687354]","metadata":null},{"id":"e4558f4a1d5d4d458ddddef5a8320351","type":"GO_TERM","name":"cohesin unloader activity","canonical_id":"go:GO:0140670","description":"\"Facilitating a conformational change to unload a cohesin complex from sister chromatids.\" [PMID:26687354]","metadata":null},{"id":"c4e266c0fb07419d84d4c023646d93ee","type":"GO_TERM","name":"colanic acid biosynthetic process","canonical_id":"go:GO:0009242","description":"\"The chemical reactions and pathways resulting in the formation of colanic acid, a capsular bacterial polysaccharide.\" [GOC:ai]","metadata":null},{"id":"be8c1746ab00468591ec1a17f9d1dd53","type":"GO_TERM","name":"colanic acid metabolic process","canonical_id":"go:GO:0046377","description":"\"The chemical reactions and pathways involving colanic acid, a capsular bacterial polysaccharide composed of glucose, galactose, fucose and glucuronic acid residues.\" [GOC:ai, PMID:35630322]","metadata":null},{"id":"31426a0d2e9a4658b3e55a10e7a2683b","type":"DRUG","name":"colchicine","canonical_id":"gtopdb:2367","description":null,"metadata":null},{"id":"559e02f69e914f95abf77de80e981e85","type":"DRUG","name":"colchicine","canonical_id":"mesh:D003078","description":null,"metadata":null},{"id":"cf7325a1b967442babe6b763cd76b682","type":"DRUG","name":"colchicine","canonical_id":"chembl:CHEMBL107","description":null,"metadata":null},{"id":"82f8639b77804990a8fd6da236e9b2c6","type":"COMBINATION_TREATMENT","name":"colchicine + febuxostat","canonical_id":"ctgov_combo:ctgov-combo-a23fcf1a3f60ca9f","description":null,"metadata":null},{"id":"7b7b905eddc74fbca94f58c495cb4a53","type":"COMBINATION_TREATMENT","name":"colchicine + febuxostat + naproxen","canonical_id":"ctgov_combo:ctgov-combo-f8a79c1565d16db1","description":null,"metadata":null},{"id":"2b4282a7672745919d1d3a32527a55ba","type":"COMBINATION_TREATMENT","name":"colchicine + theophylline","canonical_id":"ctgov_combo:ctgov-combo-e9c18ac6445485b9","description":null,"metadata":null},{"id":"0b0c4eaf2d044415aed07d25f08ac338","type":"GO_TERM","name":"cold acclimation","canonical_id":"go:GO:0009631","description":"\"Any process that increases freezing tolerance of an organism in response to low, nonfreezing temperatures.\" [GOC:syr]","metadata":null},{"id":"e73cb0df81e04ec4b86e1c4d0a34570d","type":"DISEASE","name":"cold agglutinin disease","canonical_id":"mondo:0018922","description":null,"metadata":null},{"id":"5b6a2a4bf51d42249de32eb6f31f4ce6","type":"GO_TERM","name":"cold-induced thermogenesis","canonical_id":"go:GO:0106106","description":"\"The process by which heat is generated by increasing metabolism in response to cold ambient temperatures in order to maintain a stable core body temperature.\" [PMID:27876809]","metadata":null},{"id":"405a75415cdc4fba8dcf57df68f56c83","type":"DRUG","name":"colesevelam","canonical_id":"mesh:D000069472","description":null,"metadata":null},{"id":"94fa46f65c5b48a5bca21e2c0a0d93a8","type":"GO_TERM","name":"colicin transmembrane transporter activity","canonical_id":"go:GO:0042912","description":"\"Enables the transfer of a colicin from one side of a membrane to the other. Colicins are a group of antibiotics produced by E. coli and related species that are encoded by a group of naturally occurring plasmids, e.g. Col E1.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729, PMID:17347522]","metadata":null},{"id":"6173ce90cead44d397c6eab2e946eebd","type":"GO_TERM","name":"colicin transport","canonical_id":"go:GO:0042914","description":"\"The directed movement of a colicin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Colicins are a group of antibiotics produced by E. coli and related species that are encoded by a group of naturally occurring plasmids, e.g. Col E1.\" [GOC:jl, PMID:17347522]","metadata":null},{"id":"5a0fb2f298c64c84bc0cd36d4aad371b","type":"DRUG","name":"colistimethate sodium","canonical_id":"mesh:C004691","description":null,"metadata":null},{"id":"202f9057591d42f49eebf3932dd5ea12","type":"GO_TERM","name":"collagen V binding","canonical_id":"go:GO:0070052","description":"\"Binding to a type V collagen trimer.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1d1d2059a92242ff8bc6c45f5ba2ec20","type":"GO_TERM","name":"collagen anchoring fibril","canonical_id":"go:GO:0098648","description":"\"A specialised collagen fibril that functions as an anchor, binding to other collagen structures.\" [GOC:dos, PMID:19945621]","metadata":null},{"id":"2a81c1b809e748029060548fa01a2d71","type":"GO_TERM","name":"collagen and cuticulin-based cuticle attachment to epithelium","canonical_id":"go:GO:0040004","description":"\"Attaching of a collagen and cuticulin-based cuticle to the epithelium underlying it. An example of this process is found in Caenorhabditis elegans.\" [GOC:ems, GOC:mtg_sensu]","metadata":null},{"id":"1cb29bd101244bdf922bb791a02ce800","type":"GO_TERM","name":"collagen and cuticulin-based cuticle development","canonical_id":"go:GO:0040002","description":"\"Synthesis and deposition of a collagen and cuticulin-based noncellular, hardened, or membranous secretion from an epithelial sheet. An example of this process is found in Caenorhabditis elegans.\" [GOC:mtg_sensu]","metadata":null},{"id":"28aa2ed99129474c9d8a4b64c6ee30b7","type":"GO_TERM","name":"collagen beaded filament","canonical_id":"go:GO:0098647","description":"\"A supramolecular assembly of collagen trimers with a 'beads on a string'-like structure.\" [GOC:dos, PMID:19693541]","metadata":null},{"id":"b2f6329590e94f84aa49b1c26a9c9123","type":"GO_TERM","name":"collagen binding","canonical_id":"go:GO:0005518","description":"\"Binding to collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%).\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"095d9fa55cae4ceaad1c74ece32e5d85","type":"GO_TERM","name":"collagen binding involved in cell-matrix adhesion","canonical_id":"go:GO:0098639","description":"\"Any collagen binding that occurs as part of cell-matrix adhesion.\" [GOC:dos]","metadata":null},{"id":"a372bbd8f8514bf683c51a88e215c3a1","type":"GO_TERM","name":"collagen biosynthetic process","canonical_id":"go:GO:0032964","description":"\"The chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"1d38569cad484058a40549dae7698381","type":"GO_TERM","name":"collagen catabolic process","canonical_id":"go:GO:0030574","description":"\"The proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix, usually carried out by proteases secreted by nearby cells.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"4119f8a4c1324afa8ff2b0437698f317","type":"GO_TERM","name":"collagen fibril binding","canonical_id":"go:GO:0098633","description":"\"Binding to a collagen fibril.\" [GOC:dos, PMID:21421911]","metadata":null},{"id":"3c68944606304742a712455778c4c803","type":"GO_TERM","name":"collagen fibril organization","canonical_id":"go:GO:0030199","description":"\"Any process that determines the size and arrangement of collagen fibrils within an extracellular matrix.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"c3f2f5904fe142218a73654c13633a2f","type":"GO_TERM","name":"collagen metabolic process","canonical_id":"go:GO:0032963","description":"\"The chemical reactions and pathways involving collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"31e5fe8e6e37492c876e4d264197c78b","type":"GO_TERM","name":"collagen receptor activity","canonical_id":"go:GO:0038064","description":"\"Combining with a collagen and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:uh, PMID:21568710]","metadata":null},{"id":"538fd10222b64fa8b9d55f6b839f6a35","type":"GO_TERM","name":"collagen trimer","canonical_id":"go:GO:0005581","description":"\"A protein complex consisting of three collagen chains assembled into a left-handed triple helix. These trimers typically assemble into higher order structures.\" [GOC:dos, GOC:mah, PMID:19693541, PMID:21421911]","metadata":null},{"id":"37a20b6f5ba542889579eb06a2b53b1c","type":"GO_TERM","name":"collagen type I trimer","canonical_id":"go:GO:0005584","description":"\"A collagen trimer containing alpha(I) chains. The most common form of type I collagen is a heterotrimer containing two alpha1(I) chains and one alpha2(I) chain; homotrimers containing three alpha1(I) chains are also found. Type I collagen triple helices associate to form banded fibrils.\" [PMID:21421911]","metadata":null},{"id":"ad618cdeb4d045ce8cc555faba67bd2f","type":"GO_TERM","name":"collagen type II trimer","canonical_id":"go:GO:0005585","description":"\"A collagen homotrimer of alpha1(II) chains; type II collagen triple helices associate to form fibrils.\" [PMID:21421911]","metadata":null},{"id":"8f3041db81d44864911b9e04febc6551","type":"GO_TERM","name":"collagen type III trimer","canonical_id":"go:GO:0005586","description":"\"A collagen homotrimer of alpha1(III) chains; type III collagen triple helices associate to form fibrils.\" [PMID:21421911]","metadata":null},{"id":"e1654acdd3b94359808598394541ca1f","type":"GO_TERM","name":"collagen type IV trimer","canonical_id":"go:GO:0005587","description":"\"A collagen heterotrimer containing type IV alpha chains; [alpha1(IV)]2alpha2(IV) trimers are commonly observed, although more type IV alpha chains exist and may be present in type IV trimers; type IV collagen triple helices associate to form 3 dimensional nets within basement membranes.\" [PMID:19693541, PMID:21421911]","metadata":null},{"id":"7c701b73e6d7400d9dae3642e08e869c","type":"GO_TERM","name":"collagen type IX trimer","canonical_id":"go:GO:0005594","description":"\"A collagen heterotrimer containing type IX alpha chains in alpha1(IX)alpha2(IX)alpha3(IX) trimers; type IX collagen triple helices associate to form a structure that links glycosaminoglycans to type II collagen fibrils.\" [PMID:21421911]","metadata":null},{"id":"9ee301d60d3e423f9b8bb05c396c7650","type":"GO_TERM","name":"collagen type V trimer","canonical_id":"go:GO:0005588","description":"\"A collagen heterotrimer containing type V alpha chains; [alpha1(V)]2alpha2(V) and alpha1(V)alpha2(V)alpha3(V) trimers have been observed; type V collagen triple helices associate to form fibrils.\" [PMID:21421911]","metadata":null},{"id":"67b68bced2434c03b566e61c4a231bac","type":"GO_TERM","name":"collagen type VI trimer","canonical_id":"go:GO:0005589","description":"\"A collagen heterotrimer containing type VI alpha chains in alpha1(VI)alpha2(VI)alpha3(VI) trimers; type VI collagen triple helices associate to form beaded fibrils.\" [PMID:19693541, PMID:21421911]","metadata":null},{"id":"4fb4f40cc5c94045964e96ba8c0e94ac","type":"GO_TERM","name":"collagen type VII trimer","canonical_id":"go:GO:0005590","description":"\"A collagen homotrimer of alpha1(VII) chains; type VII collagen triple helices form antiparallel dimer, which in turn associate laterally to form anchoring fibrils that connect type IV collagen in the basal lamina to plaques in the underlying connective tissue. It binds laminin.\" [PMID:19693541]","metadata":null},{"id":"7fc5ce3ecd18426289f79a29bd901b9b","type":"GO_TERM","name":"collagen type VIII trimer","canonical_id":"go:GO:0005591","description":"\"A collagen heterotrimer containing type VIII alpha chains; [alpha1(VIII)2]alpha2(VIII) and alpha1(VIII)[alpha2(VIII)]2 trimers have been observed; type VIII collagen triple helices associate to form regular hexagonal nets.\" [PMID:21421911]","metadata":null},{"id":"4c99f283fdd54f1a9b577117bcfc5a06","type":"GO_TERM","name":"collagen type X trimer","canonical_id":"go:GO:0005599","description":"\"A collagen homotrimer of alpha1(X) chains; type X collagen triple helices form hexagonal networks (sheets).\" [PMID:21421911]","metadata":null},{"id":"db53e9faca3b40a896d7205af092a6c0","type":"GO_TERM","name":"collagen type XI trimer","canonical_id":"go:GO:0005592","description":"\"A collagen heterotrimer containing type XI and type II alpha chains in alpha1(XI) alpha2(XI) alpha1(II) trimers; type XI collagen triple helices associate to form fibrils.\" [PMID:7642541]","metadata":null},{"id":"c85925d2f5d64c7fbb368ba134f67850","type":"GO_TERM","name":"collagen type XII trimer","canonical_id":"go:GO:0005595","description":"\"A collagen homotrimer of alpha1(XII) chains; type XII collagen triple helices may link sheet-forming or fibrillar collagens to other structures.\" [PMID:21421911]","metadata":null},{"id":"0ab7b170c3ea47079977857cdf8cc044","type":"GO_TERM","name":"collagen type XIII trimer","canonical_id":"go:GO:0005600","description":"\"A collagen homotrimer of alpha1(XIII) chains; type XIII collagen triple helices span the plasma membrane.\" [PMID:21421911]","metadata":null},{"id":"6a4d8006eb854b8f8efe6fb0f2a78fe8","type":"GO_TERM","name":"collagen type XIV trimer","canonical_id":"go:GO:0005596","description":"\"A collagen homotrimer of alpha1(XIV) chains; type XIV collagen triple helices may link sheet-forming or fibrillar collagens to other structures.\" [PMID:21421911]","metadata":null},{"id":"104c5606e73644c1adc740d75502eab1","type":"GO_TERM","name":"collagen type XIX trimer","canonical_id":"go:GO:1990318","description":"\"A collagen homotrimer made of three alpha1(XIX) collagen chains, each presenting interrupted triple helical collagen domains. Localizes to basement membrane ECMs, not known to associate with any fibrillar collagens that are predominantly found in the interstitial extracellular matrix.\" [PMID:10585282, PMID:12579531, PMID:12788917, PMID:17876790, PMID:31823868, PMID:35346795, PMID:9403723]","metadata":null},{"id":"6eaecbd01ad94bdfbb50e1225544a190","type":"GO_TERM","name":"collagen type XV trimer","canonical_id":"go:GO:0005582","description":"\"A collagen homotrimer of alpha1(XV) chains; a chondroitin sulfate proteoglycan often found in specialized basement membranes where it bridges between fibrils.\" [PMID:11158616, PMID:11937714, PMID:21421911]","metadata":null},{"id":"720c4be5fee14df091ab4c3f0c754fb2","type":"GO_TERM","name":"collagen type XVI trimer","canonical_id":"go:GO:0005597","description":"\"A collagen trimer containing alpha(XVI) chains; type XVI trimers can associate with microfibrils.\" [PMID:12782140]","metadata":null},{"id":"d60fb3188c144c809c7643a111cde823","type":"GO_TERM","name":"collagen type XVII trimer","canonical_id":"go:GO:0030937","description":"\"A collagen homotrimer of alpha1(XVII) chains; type XVII collagen triple helices span the plasma membrane and associate with hemidesmosomes and the basal lamina where they bind laminin.\" [PMID:19693541, PMID:21421911]","metadata":null},{"id":"d8cdf3a30b91401cbb21d93aa49a4307","type":"GO_TERM","name":"collagen type XVIII trimer","canonical_id":"go:GO:0030938","description":"\"A collagen homotrimer of alpha1(XVIII) chains.\" [PMID:21421911]","metadata":null},{"id":"a4da0640bcb34f5593a789f286dd1690","type":"GO_TERM","name":"collagen type XX trimer","canonical_id":"go:GO:1990319","description":"\"A collagen homotrimer of alpha1(XX) chains.\" [PMID:17876790]","metadata":null},{"id":"85fc03a9f8fd41b195acb5a7bd38a3f3","type":"GO_TERM","name":"collagen type XXI trimer","canonical_id":"go:GO:1990320","description":"\"A collagen homotrimer of alpha1(XXI) chains; type XXI collagen triple helices found in the extracellular matrix component of blood vessel walls and in the cytoplasm of cultured human aortic smooth muscle.\" [PMID:17876790]","metadata":null},{"id":"d02f739e9fc9427299b7e2d2a233ede7","type":"GO_TERM","name":"collagen type XXII trimer","canonical_id":"go:GO:1990321","description":"\"A collagen homotrimer of alpha1(XXII) chains; type XXII collagen triple helices acts as a cell adhesion ligand for skin epithelial cells and fibroblasts.\" [PMID:17876790]","metadata":null},{"id":"8d7be2b1907846da89207a823635b999","type":"GO_TERM","name":"collagen type XXIII trimer","canonical_id":"go:GO:1990322","description":"\"A collagen homotrimer of alpha1(XXIII) chains; type XXIII collagen triple helices span the plasma membrane.\" [PMID:17876790]","metadata":null},{"id":"1c223e7681554308a00f024a215f424c","type":"GO_TERM","name":"collagen type XXIV trimer","canonical_id":"go:GO:1990323","description":"\"A collagen homotrimer of alpha1(XXIV) chains; type XXIV collagen triple helices may participate in regulating type I collagen fibrillogenesis at specific anatomical locations during fetal development.\" [GOC:bhm, PMID:17876790]","metadata":null},{"id":"9220631c88504b529e57f05b1c54a1ab","type":"GO_TERM","name":"collagen type XXV trimer","canonical_id":"go:GO:1990327","description":"\"A collagen homotrimer of alpha1(XXV) chains; type XXV collagen triple helices span the plasma membrane.\" [PMID:17876790]","metadata":null},{"id":"e50d83905c2b4599b3d9b3cf45906308","type":"GO_TERM","name":"collagen type XXVI trimer","canonical_id":"go:GO:1990324","description":"\"A collagen homotrimer of alpha1(XXVI) chains.\" [GOC:bhm, PMID:17876790]","metadata":null},{"id":"4d1bf10b7ae7417ba261b6ccf0676fb6","type":"GO_TERM","name":"collagen type XXVII trimer","canonical_id":"go:GO:1990325","description":"\"A collagen homotrimer of alpha1(XXVII) chains. These trimers form thin, non-striated fibrils. Type XXVII collagen triple helices play a role during the calcification of cartilage and the transition of cartilage to bone.\" [PMID:17876790, PMID:21421911]","metadata":null},{"id":"94e56545b2324efdab75204861746df2","type":"GO_TERM","name":"collagen type XXVIII trimer","canonical_id":"go:GO:1990326","description":"\"A collagen homotrimer of alpha1(XXVIII) chains.\" [PMID:17876790]","metadata":null},{"id":"59a19000b43d41e78ce2704593f989e3","type":"GO_TERM","name":"collagen-activated signaling pathway","canonical_id":"go:GO:0038065","description":"\"The series of molecular signals initiated by collagen binding to a cell surface receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:uh, PMID:21568710]","metadata":null},{"id":"2a7f5854bf2040e793ae93089120b48e","type":"GO_TERM","name":"collagen-activated tyrosine kinase receptor signaling pathway","canonical_id":"go:GO:0038063","description":"\"The series of molecular signals initiated by collagen binding to its receptor on the surface of a target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:uh, PMID:15888913, PMID:16626936]","metadata":null},{"id":"3ecfa802fda1409aaddad14f963e1725","type":"GO_TERM","name":"collagenous component of basement membrane","canonical_id":"go:GO:0140143","description":"\"Collagenous component of basement membrane ECMs, including collagen IV and other types of collagen specifically expressed in basement membrane.\" [PMID:21123617, PMID:21421915, PMID:28040522, PMID:28324731, PMID:31387942, PMID:39223427]","metadata":null},{"id":"c7ed991b577e4becb3e271654be60d46","type":"GO_TERM","name":"collagenous component of interstitial matrix","canonical_id":"go:GO:0140152","description":"\"Main components of the interstitial matrix solid phase, including fibrillar and fibril-associated collagens.\" [PMID:12064927, PMID:17550969, PMID:21421911, PMID:28101870, PMID:39223427]","metadata":null},{"id":"23a0bb8ac9f840148338d95fd92f33eb","type":"GO_TERM","name":"collateral sprouting","canonical_id":"go:GO:0048668","description":"\"The process in which outgrowths develop from the shafts of existing axons.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"012b98d9a5b840a4b8295b65b3fa8275","type":"GO_TERM","name":"collateral sprouting in absence of injury","canonical_id":"go:GO:0048669","description":"\"The process in which outgrowths develop from the axons of intact undamaged neurons.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"18d03e12238b4866a3c3c81d97a03fba","type":"GO_TERM","name":"collateral sprouting of injured axon","canonical_id":"go:GO:0048674","description":"\"The process resulting in reformation of a growth cone by the tip of an injured axon, or in collateral sprouting of the axon. Collateral sprouting is the process in which outgrowths develop from the shafts of existing axons.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"1c89269cd5a0413ca8d38b49560fb0e0","type":"GO_TERM","name":"collateral sprouting of intact axon in response to injury","canonical_id":"go:GO:0048673","description":"\"The process in which outgrowths develop from the axons of intact undamaged neurons as a result of injury to an axon. The collateral sprouts typically appear from undamaged axons in a tissue which has had part of its nerve supply removed, and they can often innervate successfully any cells that have lost some or all of their original synaptic input.\" [GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"cb195fdc50c14d889218f004d2541299","type":"GO_TERM","name":"collectin binding","canonical_id":"go:GO:0001862","description":"\"Binding to a collectin, a member of a group of structurally related pattern recognition molecules characterized by having a carbohydrate recognition domain of the C-type lectin family at the C-terminus and a collagenous domain at the N-terminus.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a615690db8b34ef9950d411c28a478fe","type":"GO_TERM","name":"collectin receptor activity","canonical_id":"go:GO:0001863","description":"\"Combining with a collectin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"96603e8b6f6542d6810bbb6305e36d06","type":"GO_TERM","name":"collecting duct development","canonical_id":"go:GO:0072044","description":"\"The process whose specific outcome is the progression of a collecting duct over time, from its formation to the mature structure. The collecting duct responds to vasopressin and aldosterone to regulate water, electrolyte and acid-base balance. It is the final common path through which urine flows before entering the ureter and then emptying into the bladder.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b43889fb1c124d6b8e7fc05d09f5e491","type":"GO_TERM","name":"collecting lymphatic vessel constriction","canonical_id":"go:GO:1990192","description":"\"A decrease in the diameter of collecting lymphatic vessels.\" [PMID:23322290]","metadata":null},{"id":"3cf8c8dc520a439ab6abfcf96cf7e86b","type":"GO_TERM","name":"collenchyma cell differentiation","canonical_id":"go:GO:0048761","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a collenchyma cell. This is a plant cell in which the primary cell walls are unevenly thickened, with most thickening occurring at the cell corners. Cells are living and able to grow, they are elongated, and lignin and secondary walls absent. Collenchyma cells make up collenchyma tissue which acts as a supporting tissue in growing shoots, leaves and petioles. This tissue is often arranged in cortical ribs, as seen prominently in celery and rhubarb petioles.\" [CL:0000330, GOC:jid, PO:0000075]","metadata":null},{"id":"29c948cf793b4148ae48424caf97a9d8","type":"GO_TERM","name":"colneleate synthase activity","canonical_id":"go:GO:0102895","description":"\"Catalysis of the reaction: 9(S)-HPODE = colneleate + H2O.\" [EC:4.2.1.121, GOC:pz]","metadata":null},{"id":"cbff33117d7e44518527fbc61e192138","type":"DISEASE","name":"colon carcinoma","canonical_id":"mondo:0002032","description":null,"metadata":null},{"id":"517770a15d2b46ee848b907625b21828","type":"GO_TERM","name":"colon epithelial cell chemotaxis","canonical_id":"go:GO:0061583","description":"\"The directed movement of a colon epithelial cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [GOC:dph]","metadata":null},{"id":"0feaf4d78112447cbfdf3770bb5a93c8","type":"GO_TERM","name":"colon epithelial cell migration","canonical_id":"go:GO:0061580","description":"\"The orderly movement of a colonic epithelial cell from one site to another, often during the development of a multicellular organism.\" [GOC:dph]","metadata":null},{"id":"479a675c1fa547d0b2e225c8cd5cc80c","type":"GO_TERM","name":"colon smooth muscle contraction","canonical_id":"go:GO:1990765","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry of the large intestine, exclusive of the rectum. The colon is that part of the large intestine that connects the small intestine to the rectum.\" [PMID:24170253]","metadata":null},{"id":"1f9861bb9694499cb5ddf8a67f76ce71","type":"DISEASE","name":"colonic neoplasm","canonical_id":"mondo:0005401","description":null,"metadata":null},{"id":"a23f80919c9246708d0e7000eb9114ee","type":"DISEASE","name":"colorectal adenocarcinoma","canonical_id":"mondo:0005008","description":null,"metadata":null},{"id":"d0f01ffbc227456d9f1448f8b3c1fee9","type":"DISEASE","name":"colorectal cancer","canonical_id":"mondo:0005575","description":null,"metadata":null},{"id":"29604aef7baa48aab601a03affeb89a8","type":"DISEASE","name":"colorectal carcinoma","canonical_id":"mondo:0024331","description":null,"metadata":null},{"id":"59d8d1edd8084d66a75d95762bfced87","type":"DISEASE","name":"colorectal neoplasm","canonical_id":"mondo:0005335","description":null,"metadata":null},{"id":"10a17fe5db0b42b088db857378dff66e","type":"GO_TERM","name":"columbamine O-methyltransferase activity","canonical_id":"go:GO:0030778","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + columbamine = S-adenosyl-L-homocysteine + H+ + palmatine.\" [EC:2.1.1.118, RHEA:15373]","metadata":null},{"id":"cd1c50da7626410cb9297952a59996a2","type":"GO_TERM","name":"columbamine oxidase activity","canonical_id":"go:GO:0050455","description":"\"Catalysis of the reaction: 2 columbamine + O2 = 2 berberine + 2 H2O.\" [RHEA:23564]","metadata":null},{"id":"c5e09c7c792d4499896b01d10bd2230c","type":"GO_TERM","name":"columella","canonical_id":"go:GO:0043674","description":"\"A rod-like element of the sexine and ectexine, supporting either the tectum (the layer of sexine which forms a roof over the columella), or supporting a caput (an architectural element on top of a columella).\" [https://en.wikipedia.org/wiki/Columella_(botany)]","metadata":null},{"id":"b3f05496fef040318c35617e861f9053","type":"GO_TERM","name":"columnar/cuboidal epithelial cell development","canonical_id":"go:GO:0002066","description":"\"The process whose specific outcome is the progression of a columnar/cuboidal epithelial cell over time, from its formation to the mature structure. A columnar/cuboidal epithelial cell is a cell usually found in a two dimensional sheet with a free surface. Columnar/cuboidal epithelial cells take on the shape of a column or cube.\" [GOC:dph]","metadata":null},{"id":"9ee9c3b2919e4f2f88bee105c4b86108","type":"GO_TERM","name":"columnar/cuboidal epithelial cell differentiation","canonical_id":"go:GO:0002065","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a columnar/cuboidal epithelial cell. A columnar/cuboidal epithelial cell is a cell usually found in a two dimensional sheet with a free surface. Columnar/cuboidal epithelial cells take on the shape of a column or cube.\" [GOC:dph]","metadata":null},{"id":"c8f07603e5414a5d8d550f088c28dbba","type":"GO_TERM","name":"columnar/cuboidal epithelial cell maturation","canonical_id":"go:GO:0002069","description":"\"The developmental process, independent of morphogenetic (shape) change, that is required for a columna/cuboidal epithelial cell to attain its fully functional state. A columnar/cuboidal epithelial cell is a cell usually found in a two dimensional sheet with a free surface. Columnar/cuboidal epithelial cells take on the shape of a column or cube.\" [GOC:dph]","metadata":null},{"id":"c0578b41db914ad69707324263fc52f4","type":"DISEASE","name":"combined immunodeficiency","canonical_id":"mondo:0015131","description":null,"metadata":null},{"id":"e0575a9c7dd9420890574554e55ec645","type":"DISEASE","name":"combined immunodeficiency with faciooculoskeletal anomalies","canonical_id":"mondo:0013226","description":null,"metadata":null},{"id":"cce22c2845e346579c704338b9a6057d","type":"GO_TERM","name":"comma-shaped body morphogenesis","canonical_id":"go:GO:0072049","description":"\"The process in which the comma-shaped body is generated and organized. The comma-shaped body is the precursor structure to the S-shaped body that contributes to the morphogenesis of the nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6a171560a2e04a93a8f38fe7fa9d583b","type":"GO_TERM","name":"commander complex","canonical_id":"go:GO:0160309","description":"\"A protein complex that promotes the recycling of internalized transmembrane proteins from endosomes back to the plasma membrane. The commander complex consists of the CCC (COMMD/CCDC22/CCDC93) subcomplex and the retriever subcomplex. In human, the CCC subcomplex consists of COMMD1, COMMD2, COMMD3, COMMD4, COMMD5, COMMD6, COMMD7, COMMD8, COMMD9, COMMD10, CCDC22 and CCDC93 and the retriever complex consists of VPS26C, VPS29 and VPS35L.\" [PMID:28892079, PMID:37172566]","metadata":null},{"id":"2b081b26b8a641dea001a8627916820f","type":"GO_TERM","name":"commissural neuron axon guidance","canonical_id":"go:GO:0071679","description":"\"The process in which the migration of an axon growth cone of a commissural neuron is directed to its target in the brain in response to a combination of attractive and repulsive cues.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"8968cb1d7f9a4f2cbc7a51f12b2e8cb9","type":"GO_TERM","name":"commissural neuron differentiation in spinal cord","canonical_id":"go:GO:0021528","description":"\"The process in which neuroepithelial cells in the ventral neural tube acquire specialized structural and/or functional features of commissural neurons. Commissural neurons in both vertebrates and invertebrates transfer information from one side of their bodies to the other through the midline. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"64da34634e8e4328a9dbf049b1f65235","type":"GO_TERM","name":"commitment complex","canonical_id":"go:GO:0000243","description":"\"A spliceosomal complex that is formed by association of the U1 snRNP with the 5' splice site of an unspliced intron in an RNA transcript.\" [GOC:krc, ISBN:0879695897, PMID:9150140]","metadata":null},{"id":"f69f1753e47c4db386cedec21f691a9a","type":"GO_TERM","name":"commitment of multipotent stem cells to neuronal lineage in forebrain","canonical_id":"go:GO:0021898","description":"\"The initial commitment of cells whereby the developmental fate of a cell becomes restricted such that it will develop into some type of neuron in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"f70ba43fed124b4dbc59af4ee95e7b40","type":"GO_TERM","name":"commitment of neuronal cell to specific neuron type in forebrain","canonical_id":"go:GO:0021902","description":"\"The commitment of neuronal precursor cells to become specialized types of neurons in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"602020c09a1c44128d124688d5d6d4a6","type":"GO_TERM","name":"common bile duct development","canonical_id":"go:GO:0061009","description":"\"The progression of the common bile duct over time, from its formation to the mature structure. The common bile duct is formed from the joining of the common hepatic duct running from the liver, and the cystic duct running from the gallbladder. The common bile duct transports bile from the liver and gallbladder to the intestine.\" [PMID:20614624]","metadata":null},{"id":"e000f3e57cb5429895c803f395c038ab","type":"DISEASE","name":"common cold","canonical_id":"mondo:0005709","description":null,"metadata":null},{"id":"adec40dfffa148bb9ca3e4b5a5984d2a","type":"GO_TERM","name":"common myeloid progenitor cell proliferation","canonical_id":"go:GO:0035726","description":"\"The multiplication or reproduction of common myeloid progenitor cells, resulting in the expansion of a cell population. A common myeloid progenitor cell is a progenitor cell committed to the myeloid lineage.\" [CL:0000049, GOC:BHF]","metadata":null},{"id":"80b98c01a8304ad4a808d1b76c26513a","type":"DISEASE","name":"common variable immunodeficiency","canonical_id":"mondo:0015517","description":null,"metadata":null},{"id":"6b8d06249c514ab883b132f7e0c34d86","type":"GO_TERM","name":"compact myelin","canonical_id":"go:GO:0043218","description":"\"The portion of the myelin sheath in which layers of cell membrane are tightly juxtaposed, completely excluding cytoplasm. The juxtaposed cytoplasmic surfaces form the major dense line, while the juxtaposed extracellular surfaces form the interperiod line visible in electron micrographs.\" [GOC:dgh, NIF_Subcellular:sao1123256993]","metadata":null},{"id":"0ec15fc479eb4229b39a5e39486444a8","type":"GO_TERM","name":"companion cell differentiation","canonical_id":"go:GO:0048758","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a companion cell. The companion cell is the specialized parenchyma cell associated with a sieve-tube member in angiosperm phloem and arising from the same mother cell as the sieve-tube member.\" [CL:0000284, GOC:jid]","metadata":null},{"id":"b4e653f2040e4a00b9c879c2243889a3","type":"GO_TERM","name":"compartment boundary maintenance","canonical_id":"go:GO:0060289","description":"\"A homeostatic process involved in the maintenance of a compartment boundary. A compartment boundary is a lineage restriction boundary within a developing tissue which does not correspond to some morphological barrier.\" [GOC:dph]","metadata":null},{"id":"999d83ad5e364eae9cb4b0346afc5484","type":"GO_TERM","name":"compartment pattern specification","canonical_id":"go:GO:0007386","description":"\"The regionalization process in which embryonic segments are divided into compartments that will result in differences in cell differentiation.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"3193cc43abd747f3944057cf730eaa41","type":"GO_TERM","name":"competence pheromone activity","canonical_id":"go:GO:0030413","description":"\"A small peptide excreted by a naturally transformable bacterium (e.g. Bacillus subtilis) that transmits a signal required for the establishment of competence.\" [GOC:mah, PMID:7698645]","metadata":null},{"id":"ddc27df92bea432fab1047e94ba23780","type":"GO_TERM","name":"complement activation","canonical_id":"go:GO:0006956","description":"\"Any process involved in the activation of any of the steps of the complement cascade, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes; the initial steps of complement activation involve one of three pathways, the classical pathway, the alternative pathway, and the lectin pathway, all of which lead to the terminal complement pathway.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"e915d85408b845c49eae304c473a6ea9","type":"GO_TERM","name":"complement activation, GZMK pathway","canonical_id":"go:GO:0160257","description":"\"Any process involved in the activation of any of the steps of the granzyme K pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes.\" [PMID:39814882, PMID:39914456]","metadata":null},{"id":"d1fcbef9634947378ec195e08dd12924","type":"GO_TERM","name":"complement activation, alternative pathway","canonical_id":"go:GO:0006957","description":"\"Any process involved in the activation of any of the steps of the alternative pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"3f316da171fb413093e30393774e8f7e","type":"GO_TERM","name":"complement activation, classical pathway","canonical_id":"go:GO:0006958","description":"\"Any process involved in the activation of any of the steps of the classical pathway of the complement cascade which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b3dbd2c434a14c36aabe0dd307c15796","type":"GO_TERM","name":"complement activation, lectin pathway","canonical_id":"go:GO:0001867","description":"\"Any process involved in the activation of any of the steps of the lectin pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5924e5c06ad64b048ff43cb8a13c026d","type":"GO_TERM","name":"complement binding","canonical_id":"go:GO:0001848","description":"\"Binding to a component or product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"22eeeb7edded4cf7bfe578e8c3dd2833","type":"GO_TERM","name":"complement component C1 complex","canonical_id":"go:GO:0005602","description":"\"A protein complex composed of six subunits of C1q, each formed of the three homologous polypeptide chains C1QA, C1QB, and C1QB, and tetramer of two C1QR and two C1QS polypeptide chains.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0da69070b7104af6be946f3829969b43","type":"GO_TERM","name":"complement component C1q complex","canonical_id":"go:GO:0062167","description":"\"A protein-containing complex composed of six subunits of each of the three homologous polypeptide chains C1QA, C1QB, and C1QB. It is a subunit of the complement C1 complex. In addition to complement activation, C1q appears to have roles in homeostasis and cellular development, superoxide (O2-) production by neutrophils, blood coagulation and neurological synapse pruning.\" [PMID:29449492]","metadata":null},{"id":"7b6e9a1105774590b9934a173ea5fdd8","type":"GO_TERM","name":"complement component C1q complex binding","canonical_id":"go:GO:0001849","description":"\"Binding to a C1q complex, a component of the classical complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0462908795d348938929dc6a0b58958e","type":"GO_TERM","name":"complement component C1q receptor activity","canonical_id":"go:GO:0001857","description":"\"Combining with the C1q complex, a component of the classical complement cascade, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"c7fc971b6c154f60b2935e7af4bd5d7e","type":"DISEASE","name":"complement component C1s deficiency","canonical_id":"mondo:0013419","description":null,"metadata":null},{"id":"fa778bc118294ea5b09b318460811c7a","type":"GO_TERM","name":"complement component C3a binding","canonical_id":"go:GO:0001850","description":"\"Binding to a C3a product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f11f4fc7630741a5a093118858935fa2","type":"GO_TERM","name":"complement component C3a receptor activity","canonical_id":"go:GO:0004876","description":"\"Combining with the C3a product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:mah, GOC:pg, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"8dbfaad116184a2ba03ce4cfe2630869","type":"GO_TERM","name":"complement component C3b binding","canonical_id":"go:GO:0001851","description":"\"Binding to a C3b product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"e0dd5e13d48248b288f62a75682ee9f3","type":"GO_TERM","name":"complement component C3b receptor activity","canonical_id":"go:GO:0004877","description":"\"Combining with the C3b product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"4a54dcd9c76f4f6e96e8557f4af92ee6","type":"GO_TERM","name":"complement component C3d binding","canonical_id":"go:GO:0001854","description":"\"Binding to a C3d product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"3d9b9d7519744f24b9b39f609a3415c1","type":"GO_TERM","name":"complement component C3d receptor activity","canonical_id":"go:GO:0001860","description":"\"Combining with the C3d product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"811ab16c3a594880a4de05d74f4aecf2","type":"GO_TERM","name":"complement component C3dg binding","canonical_id":"go:GO:0001853","description":"\"Binding to a C3dg product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d11a6d4f2d494b8d84269a52c491dab0","type":"GO_TERM","name":"complement component C3dg receptor activity","canonical_id":"go:GO:0001859","description":"\"Combining with the C3dg product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"6990d845ceeb4615828bb746de583767","type":"GO_TERM","name":"complement component C4b binding","canonical_id":"go:GO:0001855","description":"\"Binding to a C4b product of the classical complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ac95b9be111145b2887f2e6762d2f77d","type":"GO_TERM","name":"complement component C4b receptor activity","canonical_id":"go:GO:0001861","description":"\"Combining with the C4b product of the classical complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"b599105875b84a1baf380f1c0a7b86ce","type":"GO_TERM","name":"complement component C5a binding","canonical_id":"go:GO:0001856","description":"\"Binding to a C5a product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b7a04c54ed164c03b445659a1e43e720","type":"GO_TERM","name":"complement component C5a receptor activity","canonical_id":"go:GO:0004878","description":"\"Combining with the C5a product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:mah, GOC:pg, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"b6099a4f9f1f426c8c200270fb120574","type":"GO_TERM","name":"complement component C5a signaling pathway","canonical_id":"go:GO:0038178","description":"\"A G protein-coupled receptor signaling pathway initiated by a C5a component of the complement pathway binding to a complement receptor, and ending with regulation of a downstream cellular process. C5a is a peptide derived from the C5 complement factor.\" [GOC:jc, PMID:15313431, Wikipedia:Complement_component_5a]","metadata":null},{"id":"3911f978e8e3452dbcd28d75ed878515","type":"GO_TERM","name":"complement component iC3b binding","canonical_id":"go:GO:0001852","description":"\"Binding to a iC3b product of the complement cascade.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c0a5ab0a0b1844ab8673875663661ebc","type":"GO_TERM","name":"complement component iC3b receptor activity","canonical_id":"go:GO:0001858","description":"\"Combining with the iC3b product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"e7da3eec5c564e31b7c24a91a5ed1514","type":"DISEASE","name":"complement deficiency","canonical_id":"mondo:0003832","description":null,"metadata":null},{"id":"27157ed0973a4697bfea22db118e8c35","type":"GO_TERM","name":"complement receptor activity","canonical_id":"go:GO:0004875","description":"\"Combining with any component or product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:ai, GOC:pg, GOC:signaling, ISBN:0781735149, PMID:11884446]","metadata":null},{"id":"ad1c21a3802f4b488eff53fdfba5afde","type":"GO_TERM","name":"complement receptor mediated signaling pathway","canonical_id":"go:GO:0002430","description":"\"The series of molecular signals generated as a consequence of a component of the complement pathway binding to a complement receptor. Such components include both whole complement proteins and fragments of complement proteins generated through the activity of the complement pathway.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"bed1ca60dc434cf9baf0cb02903559f4","type":"GO_TERM","name":"complement-dependent cytotoxicity","canonical_id":"go:GO:0097278","description":"\"Cell killing caused by the membrane attack complex formed following complement activation.\" [GOC:add, GOC:rv]","metadata":null},{"id":"ee9b05efbddc4d089ac286ce57f7d15b","type":"GO_TERM","name":"complement-mediated synapse pruning","canonical_id":"go:GO:0150062","description":"\"Synaptic pruning mediated by complement system signaling.\" [GOC:aruk, GOC:bc, PMID:18083105, PMID:22632727, PMID:29844190]","metadata":null},{"id":"83903d9cb80d4454859d5f5f2db8c8d1","type":"DISEASE","name":"complex cortical dysplasia with other brain malformations 6","canonical_id":"mondo:0014341","description":null,"metadata":null},{"id":"669714f66e8d46948c120273d70b7e87","type":"GO_TERM","name":"complex laminated body","canonical_id":"go:GO:1990012","description":"\"A cytoplasmic inclusion body found in some lateral geniculate neurons and composed of sheets of tubules (25 nm in diameter) separated by dense material (about 75 nm wide), which together with the tubules whorl give a structure resembling a fingerprint.\" [NIF_Subcellular:nlx_151681]","metadata":null},{"id":"4f33a4f6f23e45cab5810ff4af36247e","type":"DISEASE","name":"complex neurodevelopmental disorder","canonical_id":"mondo:0100038","description":null,"metadata":null},{"id":"7a7f6611bb9844b198f5b5083bdce652","type":"GO_TERM","name":"complex of collagen trimers","canonical_id":"go:GO:0098644","description":"\"A complex of collagen trimers such as a fibril or collagen network.\" [GOC:dos]","metadata":null},{"id":"59a72dcd69f64659b9450727cc5c0932","type":"GO_TERM","name":"complex of network-forming collagens","canonical_id":"go:GO:0098645","description":"\"A supramolecular complex that consists of collagen triple helices associated to form a network.\" [GOC:dos, PMID:21421911]","metadata":null},{"id":"84b9302630324dd099a689b87a827404","type":"DISEASE","name":"complex partial epilepsy","canonical_id":"mondo:0006710","description":null,"metadata":null},{"id":"c9a0e4999be84fb0a8c4928fd5a50aa5","type":"GO_TERM","name":"compound eye cone cell differentiation","canonical_id":"go:GO:0042675","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a compound eye cone cell, a cone-shaped cell, that focuses light in a compound eye.\" [GOC:mtg_sensu]","metadata":null},{"id":"3301a87517994472a1b5e7b267c523fe","type":"GO_TERM","name":"compound eye cone cell fate commitment","canonical_id":"go:GO:0042676","description":"\"The process in which the cone cells of the compound eye, the lens-secreting cells in the ommatidia, adopt pathways of differentiation that lead to the establishment of their distinct cell type.\" [GOC:mtg_sensu]","metadata":null},{"id":"9c0950ef8d2b4aa7a6c749229b3a46c4","type":"GO_TERM","name":"compound eye cone cell fate determination","canonical_id":"go:GO:0042680","description":"\"The process in which a cell becomes capable of differentiating autonomously into a compound eye cone cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:mtg_sensu]","metadata":null},{"id":"49b9e32cc4094781a965870ed5db55ac","type":"GO_TERM","name":"compound eye cone cell fate specification","canonical_id":"go:GO:0042679","description":"\"The process in which a cell becomes capable of differentiating autonomously into a compound eye cone cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:mtg_sensu]","metadata":null},{"id":"850829e1633043d083799fe0ea6fc689","type":"GO_TERM","name":"compound eye corneal lens development","canonical_id":"go:GO:0048058","description":"\"The process whose specific outcome is the progression of the corneal lens in the compound eye over time, from its formation to the mature structure. The corneal lens is a chitinous extracellular secretion of the four underlying cone cells and the pigment cells.\" [GOC:jid]","metadata":null},{"id":"68310d164bfa454586f58eab20582be5","type":"GO_TERM","name":"compound eye corneal lens morphogenesis","canonical_id":"go:GO:0048750","description":"\"The process in which the anatomical structures of the compound eye corneal lens are generated and organized.\" [GOC:jid]","metadata":null},{"id":"fc1d953309b544c4b5cb8a77053b12c3","type":"GO_TERM","name":"compound eye development","canonical_id":"go:GO:0048749","description":"\"The process whose specific outcome is the progression of the compound eye over time, from its formation to the mature structure. The compound eye is an organ of sight that contains multiple repeating units, often arranged hexagonally. Each unit has its own lens and photoreceptor cell(s) and can generate either a single pixelated image or multiple images, per eye.\" [GOC:jid, GOC:mtg_sensu, Wikipedia:Eye]","metadata":null},{"id":"96d32a35da00482fb63d5d46f1c9b98f","type":"GO_TERM","name":"compound eye morphogenesis","canonical_id":"go:GO:0001745","description":"\"The morphogenetic process in which the anatomical structures of the compound eye are generated and organized. The adult compound eye is a precise assembly of 700-800 ommatidia. Each ommatidium is composed of 20 cells, identified by cell type and position. An example of compound eye morphogenesis is found in Drosophila melanogaster.\" [GOC:dph, GOC:mtg_sensu]","metadata":null},{"id":"8c87ed7e980041809df3dea530e8ca17","type":"GO_TERM","name":"compound eye photoreceptor cell differentiation","canonical_id":"go:GO:0001751","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an eye photoreceptor cell.\" [GOC:curators]","metadata":null},{"id":"d8db04ba93434b888bc21d1455b4dd43","type":"GO_TERM","name":"compound eye photoreceptor development","canonical_id":"go:GO:0042051","description":"\"The process whose specific outcome is the progression of a light-responsive receptor in the compound eye over time, from its formation to the mature structure.\" [GOC:bf]","metadata":null},{"id":"eda8b995a30b4f34948f87ad62839414","type":"GO_TERM","name":"compound eye photoreceptor fate commitment","canonical_id":"go:GO:0001752","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a compound eye photoreceptor cell. A photoreceptor cell is a cell that responds to incident electromagnetic radiation. Different classes of photoreceptor have different spectral sensitivities and express different photosensitive pigments.\" [GOC:mtg_sensu]","metadata":null},{"id":"40b62e1e34784df88c142c016362e671","type":"GO_TERM","name":"compound eye pigment cell differentiation","canonical_id":"go:GO:0062056","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a compound eye pigment cell, a cell of the retina containing screening pigments that functions to screen photoreceptors from light leaking from adjacent ommatidia.\" [GOC:ha, PMID:8929534]","metadata":null},{"id":"903bedb780b6436fa5d5e53e7cfd2f6d","type":"GO_TERM","name":"compound eye pigmentation","canonical_id":"go:GO:0048072","description":"\"Establishment of a pattern of pigment in the compound eye.\" [GOC:jid]","metadata":null},{"id":"56ffc4e9a7014f8e8b2523d3f6ffbf5d","type":"GO_TERM","name":"compound eye retinal cell apoptotic process","canonical_id":"go:GO:1990010","description":"\"Any apoptotic process in a compound eye retinal cell.\" [GOC:mtg_apoptosis, PMID:12021768]","metadata":null},{"id":"d1928a16400a4597aa4e221186c90b01","type":"GO_TERM","name":"compound eye retinal cell programmed cell death","canonical_id":"go:GO:0046667","description":"\"Programmed cell death that occurs in the retina to remove excess cells between ommatidia, thus resulting in a hexagonal lattice, precise with respect to cell number and position surrounding each ommatidium.\" [PMID:12006672]","metadata":null},{"id":"b1474449a342428484a848b7cf336c6f","type":"GO_TERM","name":"compound leaf morphogenesis","canonical_id":"go:GO:0060777","description":"\"The leaf morphogenesis process that results in the shaping of a compound leaf. A compound leaf is a leaf having two or more distinct leaflets that are evident as such from early in development.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"4c40caf5ab0d49059985d6962d61aff6","type":"GO_TERM","name":"compound sieve plate","canonical_id":"go:GO:0097219","description":"\"A sieve plate that contains several specialized sieve areas in either a scalariform or reticulate arrangement.\" [ISBN:0471738433, POC:curators]","metadata":null},{"id":"d0a39783c08a44238d1c2e2eb25b9b01","type":"GO_TERM","name":"concave side of sperm head","canonical_id":"go:GO:0061830","description":"\"The concave part of the late spermatid head or spermatozoon head that forms the ventral portion of the head, particularly in some rodent species.\" [PMID:22332112, PMID:23403943, PMID:26990065]","metadata":null},{"id":"e4afd431d2354c888ec56a33691f739a","type":"GO_TERM","name":"condensed chromatin of inactivated sex chromosome","canonical_id":"go:GO:0098578","description":"\"A condensed form of chromatin that is associated with an inactivated sex chromosome and which is responsible for its inactivation.\" [GOC:dos]","metadata":null},{"id":"6ee09f2b4e90420bb04849335cf4ec16","type":"GO_TERM","name":"condensed chromosome","canonical_id":"go:GO:0000793","description":"\"A highly compacted molecule of DNA and associated proteins resulting in a cytologically distinct structure.\" [GOC:elh]","metadata":null},{"id":"6bf1c37352d54c63a3867a1667fd749c","type":"GO_TERM","name":"condensed chromosome, centromeric region","canonical_id":"go:GO:0000779","description":"\"The region of a condensed chromosome that includes the centromere and associated proteins, including the kinetochore. In monocentric chromosomes, this region corresponds to a single area of the chromosome, whereas in holocentric chromosomes, it is evenly distributed along the chromosome.\" [GOC:elh, GOC:kmv]","metadata":null},{"id":"9037dd5f8ae040c79499d28a6087986f","type":"GO_TERM","name":"condensed mesenchymal cell proliferation","canonical_id":"go:GO:0072137","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a condensed mesenchymal cell population. A condensed mesenchymal cell population is a population of adherent mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5d364c5445cd450ea59f79e0407d0546","type":"GO_TERM","name":"condensed nuclear chromosome","canonical_id":"go:GO:0000794","description":"\"A highly compacted molecule of DNA and associated proteins resulting in a cytologically distinct nuclear chromosome.\" [GOC:elh]","metadata":null},{"id":"137ef44b2d3448408fe94c4b2c3f1fac","type":"GO_TERM","name":"condensin complex","canonical_id":"go:GO:0000796","description":"\"A multisubunit protein complex that plays a central role in chromosome condensation in meiosis and mitosis.\" [GOC:elh, PMID:17268547, PMID:21795393]","metadata":null},{"id":"c060bba5e5bc49b7bd1103eb3d9dfc2e","type":"GO_TERM","name":"conditioned place preference","canonical_id":"go:GO:1990708","description":"\"The associative learning process by which an animal learns and remembers an association between a neutral, unchanging environment and a putatively rewarding, internal state produced by a xenobiotic or drug.\" [PMID:21549821]","metadata":null},{"id":"c83722e1599747c7838f9961ea27a0c7","type":"GO_TERM","name":"conditioned taste aversion","canonical_id":"go:GO:0001661","description":"\"A conditioned aversion to a specific chemical compound as a result of that compound being coupled with a noxious stimulus.\" [GOC:dph, PMID:9920659]","metadata":null},{"id":"f89808266246448d9fa023ca3ee294ef","type":"DISEASE","name":"conduct disorder","canonical_id":"mondo:0005352","description":null,"metadata":null},{"id":"d3ef57578c07428fa2c852319b074533","type":"GO_TERM","name":"cone cell pedicle","canonical_id":"go:GO:0044316","description":"\"A specialized axon terminus which is produced by retinal cone cells. Pedicles are large, conical, flat end-feet (8-10 micrometers diameter) of the retinal cone axon that lie more or less side by side on the same plane at the outer edge of the outer plexiform layer (OPL).\" [PMID:10939333]","metadata":null},{"id":"ada82b87e2bd47369eb43aa25e59313c","type":"GO_TERM","name":"cone matrix sheath","canonical_id":"go:GO:0090658","description":"\"A biochemically and structurally distinct domain of the retinal interphotoreceptor matrix that is specifically associated with cone photoreceptor cell inner and outer segments.\" [GOC:mr, PMID:2055688]","metadata":null},{"id":"07f7cd73a9724db0b415ce2a5cdd5910","type":"GO_TERM","name":"cone photoreceptor disc membrane","canonical_id":"go:GO:0120201","description":"\"Stack of disc membranes located inside a cone photoreceptor outer segment, and containing densely packed molecules of opsin photoreceptor proteins that traverse the lipid bilayer. Cone disc membranes arise as evaginations of the ciliary membrane during the development of the cone outer segment and remain contiguous with the ciliary membrane.\" [GOC:krc, GOC:pde, PMID:19501669, PMID:26574505, PMID:6771304]","metadata":null},{"id":"f6fea25f69544c31af011086c919706b","type":"GO_TERM","name":"cone photoreceptor outer segment","canonical_id":"go:GO:0120199","description":"\"The outer segment of a vertebrate cone photoreceptor that contains membrane discs that are contiguous with the ciliary membrane and containing opsin photoreceptor proteins.\" [GOC:krc, GOC:pde, PMID:19501669, PMID:26574505, PMID:6771304]","metadata":null},{"id":"b13bf92549fe45b9add199ba6bdf0fbc","type":"GO_TERM","name":"cone retinal bipolar cell differentiation","canonical_id":"go:GO:1904390","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a cone retinal bipolar cell.\" [GO_REF:0000086, GOC:TermGenie, PMID:24123365]","metadata":null},{"id":"c7d8875de0db42aa9c7a27c61cc431af","type":"GO_TERM","name":"cone telodendria","canonical_id":"go:GO:0120209","description":"\"Cone telodendria are projections that originate from the cone pedicle and form gap junctions with other photoreceptors within the outer plexiform layer of the retina.\" [GOC:cvs, GOC:krc, PMID:29127712]","metadata":null},{"id":"5f5dbdc59fa44dc29c3ceae1e1311831","type":"DISEASE","name":"congenital adrenal hyperplasia","canonical_id":"mondo:0018479","description":null,"metadata":null},{"id":"db8821ed38f743b8952a5dccf733d35d","type":"DISEASE","name":"congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency","canonical_id":"mondo:0008729","description":null,"metadata":null},{"id":"515506120b264b2bb472438ae936306a","type":"DISEASE","name":"congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency","canonical_id":"mondo:0008727","description":null,"metadata":null},{"id":"b7725b2afdfe4a268fe01bfd8911b140","type":"DISEASE","name":"congenital amegakaryocytic thrombocytopenia","canonical_id":"mondo:0800451","description":null,"metadata":null},{"id":"63dbf13723ca465bae5aad7c045cf19d","type":"DISEASE","name":"congenital amegakaryocytic thrombocytopenia 1","canonical_id":"mondo:0800452","description":null,"metadata":null},{"id":"f2fbd46510194ef3a632ac6204a853cc","type":"DISEASE","name":"congenital anomaly of kidney and urinary tract","canonical_id":"mondo:0019719","description":null,"metadata":null},{"id":"6c7c026628af4371819f6ba55d5bf2f0","type":"DISEASE","name":"congenital bilateral absence of vas deferens","canonical_id":"mondo:0018801","description":null,"metadata":null},{"id":"8d639dd7663949fbb1c4cfa713b7cf61","type":"DISEASE","name":"congenital bilateral aplasia of vas deferens from CFTR mutation","canonical_id":"mondo:0010178","description":null,"metadata":null},{"id":"47e3afc128494f839112ee043ac4ba17","type":"DISEASE","name":"congenital diarrhea 6","canonical_id":"mondo:0013825","description":null,"metadata":null},{"id":"b05a0b1edd6c4d20b7cc151e401926f2","type":"DISEASE","name":"congenital factor V deficiency","canonical_id":"mondo:0009210","description":null,"metadata":null},{"id":"3a4dd713b1e04165a9445498539efd12","type":"DISEASE","name":"congenital factor X deficiency","canonical_id":"mondo:0009212","description":null,"metadata":null},{"id":"94fbb1413cca4fc5b09ed27a3693ef9f","type":"DISEASE","name":"congenital fiber-type disproportion myopathy","canonical_id":"mondo:0009711","description":null,"metadata":null},{"id":"3a483813dd984e35b7f3c2b321c5017b","type":"DISEASE","name":"congenital heart defects and skeletal malformations syndrome","canonical_id":"mondo:0060532","description":null,"metadata":null},{"id":"1dc81cee27e84ae79ba70bdb5b7e4fdc","type":"DISEASE","name":"congenital heart defects, multiple types, 7","canonical_id":"mondo:0032913","description":null,"metadata":null},{"id":"4f0430dd57b1421e9289a8577e118f50","type":"DISEASE","name":"congenital heart disease","canonical_id":"mondo:0005453","description":null,"metadata":null},{"id":"abbfcd4e00324979aa1cb3574c96d442","type":"DISEASE","name":"congenital high-molecular-weight kininogen deficiency","canonical_id":"mondo:0009234","description":null,"metadata":null},{"id":"0a376572ff864617bdac4a2056f61c90","type":"DISEASE","name":"congenital hypothalamic hamartoma syndrome","canonical_id":"mondo:0009436","description":null,"metadata":null},{"id":"79f1dab23ae149f29f9ca33103cb9d74","type":"DISEASE","name":"congenital hypothyroidism","canonical_id":"mondo:0018612","description":null,"metadata":null},{"id":"a55858affef349ecb0dc4d1293b915ef","type":"DISEASE","name":"congenital multicore myopathy with external ophthalmoplegia","canonical_id":"mondo:0009712","description":null,"metadata":null},{"id":"ff88c45577214cb3bd09248121f9d597","type":"DISEASE","name":"congenital muscular dystrophy","canonical_id":"mondo:0019950","description":null,"metadata":null},{"id":"663272fa92a0478d9d5a8555d63d83e9","type":"DISEASE","name":"congenital myasthenic syndrome","canonical_id":"mondo:0018940","description":null,"metadata":null},{"id":"ae28fcd3b6ea4b79a9c90d6bd68c95ff","type":"DISEASE","name":"congenital myasthenic syndrome 16","canonical_id":"mondo:0013620","description":null,"metadata":null},{"id":"a8a3c37f37a6462bb8c5d424ac430889","type":"DISEASE","name":"congenital myopathy","canonical_id":"mondo:0019952","description":null,"metadata":null},{"id":"64bc6de8257a4472a1df6b6f5babe90c","type":"DISEASE","name":"congenital myopathy 18","canonical_id":"mondo:0859514","description":null,"metadata":null},{"id":"3778e4f3287c4410aa62cb10e8d21a04","type":"DISEASE","name":"congenital myopathy 22A, classic","canonical_id":"mondo:0957247","description":null,"metadata":null},{"id":"a1457acc559f4451882f1b8fd77e748e","type":"DISEASE","name":"congenital myopathy 22B, severe fetal","canonical_id":"mondo:0957265","description":null,"metadata":null},{"id":"1de3aff45c0244c481603ce72e371f9c","type":"DISEASE","name":"congenital prothrombin deficiency","canonical_id":"mondo:0013361","description":null,"metadata":null},{"id":"4175c73d65c14eb1b507baa4b77c939b","type":"DISEASE","name":"congestive heart failure","canonical_id":"mondo:0005009","description":null,"metadata":null},{"id":"3569096aded542f09456a3b2674445f1","type":"GO_TERM","name":"conidiogenone biosynthetic process","canonical_id":"go:GO:0140879","description":"\"The chemical reactions and pathways resulting in the formation of conidiogenone , a diterpene known to induce the conidiation.\" [PMID:30343633]","metadata":null},{"id":"8262bd77036a4aac87cf3db89d0c0755","type":"GO_TERM","name":"conidiophore development","canonical_id":"go:GO:0070787","description":"\"The process whose specific outcome is the progression of the conidiophore over time, from its formation to the mature structure. The conidiophore is a specialized hypha that extends aerially from the growth substrate and bears conidia, or asexual spores.\" [PMID:9529886]","metadata":null},{"id":"3b8fa59b12174cf1bd08c2d4f3670b5b","type":"GO_TERM","name":"conidiophore stalk development","canonical_id":"go:GO:0070788","description":"\"The process whose specific outcome is the progression of the conidiophore stalk over time, from its formation to the mature structure. The conidiophore stalk is part of a specialized hypha that extends aerially from the growth substrate and supports structures from which conidia, or asexual spores, develop.\" [PMID:9529886]","metadata":null},{"id":"66b67b3c7a224351a9a288444cebf84f","type":"GO_TERM","name":"conidium formation","canonical_id":"go:GO:0048315","description":"\"The process of producing non-motile spores, called conidia, via mitotic asexual reproduction in higher fungi. Conidia are haploid cells genetically identical to their haploid parent. They are produced by conversion of hyphal elements, or are borne on sporogenous cells on or within specialized structures termed conidiophores, and participate in dispersal of the fungus.\" [GOC:di, ISBN:0963117211, PMID:2524423, PMID:9529886]","metadata":null},{"id":"95c8725071c844209d463360c98f7da7","type":"GO_TERM","name":"conidium germination","canonical_id":"go:GO:0120164","description":"\"The physiological and developmental changes that occur in a conidium or asexual spore following release from dormancy up to the earliest signs of development such as swelling of conidia, adhesion and nuclear decondensation followed by hyphal growth several hours later. In many genera of plant pathogenic fungi (e.g. Magnaporthe, Colletotrichum, Ustilago), swelling of the hyphal tips to form appressorium, metabolic activities including respiration, RNA and protein synthesis and trehalose breakdown and changes in cell wall composition can be detected in conidium germination.\" [DOI:10.1128/9781555815523.ch10, PMID:10835388, PMID:11377860, PMID:17950638, PMID:18944978, PMID:25063657, PMID:27355215, PMID:9529886]","metadata":null},{"id":"ad23de30b27845349396d4f7b95fe367","type":"GO_TERM","name":"coniferin beta-glucosidase activity","canonical_id":"go:GO:0047782","description":"\"Catalysis of the reaction: H2O + coniferin = D-glucose + coniferol.\" [EC:3.2.1.126, MetaCyc:CONIFERIN-BETA-GLUCOSIDASE-RXN]","metadata":null},{"id":"d2d86a12cde540a18c352b73582b59bd","type":"GO_TERM","name":"coniferin metabolic process","canonical_id":"go:GO:0033491","description":"\"The chemical reactions and pathways involving coniferin, 4-(3-hydroxyprop-1-en-1-yl)-2-methoxyphenyl beta-D-glucopyranoside.\" [GOC:mah, MetaCyc:PWY-116]","metadata":null},{"id":"d3aff8b82110452da1bafd7328175502","type":"GO_TERM","name":"coniferyl-alcohol dehydrogenase activity","canonical_id":"go:GO:0050268","description":"\"Catalysis of the reaction: coniferyl alcohol + NADP+ = coniferyl aldehyde + NADPH.\" [RHEA:22444]","metadata":null},{"id":"684da51e188a4809b57e438cee111c16","type":"GO_TERM","name":"coniferyl-alcohol glucosyltransferase activity","canonical_id":"go:GO:0047209","description":"\"Catalysis of the reaction: coniferyl alcohol + UDP-D-glucose = coniferin + UDP.\" [EC:2.4.1.111, MetaCyc:2.4.1.111-RXN]","metadata":null},{"id":"fb1834a8928d4c6cbdedd4c46cbb322c","type":"GO_TERM","name":"coniferyl-aldehyde dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0050269","description":"\"Catalysis of the reaction: coniferyl aldehyde + H2O + NAD(P)+ = ferulate + NAD(P)H + H+.\" [EC:1.2.1.68]","metadata":null},{"id":"c4f7e79bd3fa455cbe7a67d08657516b","type":"DRUG","name":"conivaptan","canonical_id":"gtopdb:2203","description":null,"metadata":null},{"id":"a9495f8ae62d46a79ed9715224ac1a5c","type":"DRUG","name":"conivaptan","canonical_id":"mesh:C106389","description":null,"metadata":null},{"id":"a6609761e53d4ca29ec4fd72b3ac4a19","type":"GO_TERM","name":"conjugant formation","canonical_id":"go:GO:0000761","description":"\"During conjugation without cellular fusion, the process that results in pairing complementary mating types. Localized morphological, cytological, and cytoskeletal changes connect the mating types without cytoplasmic mixing.\" [GOC:elh]","metadata":null},{"id":"9d5653ad40004d838c87f1fb0be10e68","type":"DRUG","name":"conjugated estrogens","canonical_id":"mesh:D004966","description":null,"metadata":null},{"id":"ac3107fe039b424fa071bb450fa8ee46","type":"GO_TERM","name":"conjugation with cellular fusion","canonical_id":"go:GO:0000747","description":"\"A conjugation process that results in the union of cellular and genetic information from compatible mating types. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:elh]","metadata":null},{"id":"fca6cae5785649b4a323a4b760308bba","type":"GO_TERM","name":"conjugation with mutual genetic exchange","canonical_id":"go:GO:0000748","description":"\"A conjugation process that results in the mutual exchange and union of only genetic information between compatible mating types. Conjugation without cellular fusion requires direct cellular contact between the organisms without plasma membrane fusion. The organisms involved in conjugation without cellular fusion separate after nuclear exchange.\" [GOC:elh, PMID:22444146]","metadata":null},{"id":"2044ac7ee42c4c99abf7ed68225126c1","type":"DISEASE","name":"conjunctivitis","canonical_id":"mondo:0003799","description":null,"metadata":null},{"id":"985626bb3f4f4a40ab5fdd6cde234f13","type":"GO_TERM","name":"connecting tubule development","canonical_id":"go:GO:0072027","description":"\"The process whose specific outcome is the progression of the connecting tubule over time, from its formation to the mature structure. The connecting tubule is a tubular segment of the nephron; it connects the distal convoluted tubule to the collecting duct.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2a426f66cf4f46b7967e76d476c4d4ba","type":"GO_TERM","name":"connective tissue development","canonical_id":"go:GO:0061448","description":"\"The progression of a connective tissue over time, from its formation to the mature structure.\" [GOC:BHF]","metadata":null},{"id":"0c7e67890efe42fab862694cc7e7eacc","type":"GO_TERM","name":"connective tissue growth factor production","canonical_id":"go:GO:0032601","description":"\"The appearance of connective tissue growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"5ea4da52a63e4882873912fdc72a812d","type":"GO_TERM","name":"connective tissue replacement","canonical_id":"go:GO:0097709","description":"\"The series of events leading to growth of connective tissue when loss of tissues that are incapable of regeneration occurs, or when fibrinous exudate cannot be adequately cleared.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:25590961]","metadata":null},{"id":"6db512ae48d14cf288efc51d4ad6b8ec","type":"GO_TERM","name":"connective tissue replacement involved in inflammatory response wound healing","canonical_id":"go:GO:0002248","description":"\"The series of events leading to growth of connective tissue when loss of tissues that are incapable of regeneration occurs, or when fibrinous exudate cannot be adequately cleared, as part of an inflammatory response.\" [GOC:jal, PMID:9639571]","metadata":null},{"id":"0dfeda1cd22145b0b2aa734048d37058","type":"GO_TERM","name":"connexin binding","canonical_id":"go:GO:0071253","description":"\"Binding to a connexin, any of a group of related proteins that assemble to form gap junctions.\" [GOC:mah, PMID:19864490]","metadata":null},{"id":"13cce39c687f412baa982bdb98a867c3","type":"GO_TERM","name":"connexin complex","canonical_id":"go:GO:0005922","description":"\"An assembly of six molecules of connexin, made in the Golgi apparatus and subsequently transported to the plasma membrane, where docking of two connexons on apposed plasma membranes across the extracellular space forms a gap junction.\" [PMID:11146276]","metadata":null},{"id":"58471fcd565e404686b940db8b5e84fe","type":"GO_TERM","name":"conoid","canonical_id":"go:GO:0020010","description":"\"A spiral cytoskeletal structure located at the apical end of the apical complex in some apicomplexan parasites. Fibers form a left-handed spiral, and are comprised of tubulin protofilaments organized in a ribbon-like structure that differs from the conventional tubular structure characteristic of microtubules.\" [GOC:expert_dr, PMID:11901169, PMID:16518471]","metadata":null},{"id":"c2c1ffc39f4644a99258fe6efe4574de","type":"DISEASE","name":"constipation disorder","canonical_id":"mondo:0002203","description":null,"metadata":null},{"id":"a425115a2ed145539c6d5765da186402","type":"DISEASE","name":"constitutional megaloblastic anemia with severe neurologic disease","canonical_id":"mondo:0013456","description":null,"metadata":null},{"id":"5fb11d40077f4d00819fc524558f23c3","type":"GO_TERM","name":"constitutive heterochromatin formation","canonical_id":"go:GO:0140719","description":"\"The compaction of chromatin into heterochromatin, a conformation that is refractory to transcription and in that involves the methylation of histone H3K9. Constitutive heterochromatin cannot be converted back to euchromatin, the transcriptionally-active conformation.\" [PMID:17936700]","metadata":null},{"id":"e94a244f7eda431c96f4c8bcd8671fd7","type":"GO_TERM","name":"constitutive protein ectodomain proteolysis","canonical_id":"go:GO:0051089","description":"\"The proteolytic cleavage of transmembrane proteins and release of their ectodomain that occurs constantly, regardless of environmental conditions or demands.\" [PMID:12714508]","metadata":null},{"id":"ee7f0dd4f7a84f77b098ace1234251d1","type":"GO_TERM","name":"constitutive secretory pathway","canonical_id":"go:GO:0045054","description":"\"A process of exocytosis found in all eukaryotic cells, in which transport vesicles destined for the plasma membrane leave the trans-Golgi network in a steady stream. Upon exocytosis, the membrane proteins and lipids in these vesicles provide new components for the plasma membrane, and the soluble proteins inside the vesicles are released into the extracellular space.\" [GOC:mah, ISBN:0716731363]","metadata":null},{"id":"5702ba0345c146d492e527a70b3beb1f","type":"GO_TERM","name":"contact chemoreceptor activity","canonical_id":"go:GO:0090684","description":"\"A non-GPCR transmembrane signaling receptor activity that is responsible for contact chemoreception.\" [GOC:hat, GOC:tb]","metadata":null},{"id":"14e4eebd447740f29e56444a2a20f9e6","type":"DISEASE","name":"contact dermatitis","canonical_id":"mondo:0005480","description":null,"metadata":null},{"id":"5409c13c2b3f4146bb2fd796b4fc933c","type":"GO_TERM","name":"contact guidance","canonical_id":"go:GO:0009990","description":"\"Cell recognition involving the deposition of specific pathways in the extracellular matrix that guide migrating cells.\" [ISBN:0824072820]","metadata":null},{"id":"095422f703364804a68408759ebfa258","type":"GO_TERM","name":"contact inhibition","canonical_id":"go:GO:0060242","description":"\"The series of events in which information about the density of cells in a population is received by direct cell-cell contact and is converted into a molecular signal, resulting in the cessation of cell growth or proliferation.\" [GOC:dph, PMID:17376520]","metadata":null},{"id":"8195b879ef95420c846e73c57e2a82e2","type":"DISEASE","name":"contraception","canonical_id":"efo:0009520","description":null,"metadata":null},{"id":"06fcd691639e493ab1400c8478334786","type":"GO_TERM","name":"contractile actin filament bundle","canonical_id":"go:GO:0097517","description":"\"An actin filament bundle in which the filaments are loosely packed (approximately 30-60 nm apart) and arranged with opposing polarities; the loose packing allows myosin (usually myosin-II) to enter the bundle.\" [GOC:cjm, GOC:mah, ISBN:0815316194]","metadata":null},{"id":"a329e295edb041c0a803c7e055ecff06","type":"GO_TERM","name":"contractile actin filament bundle assembly","canonical_id":"go:GO:0030038","description":"\"Assembly of actin filament bundles in which the filaments are loosely packed (approximately 30-60 nm apart) and arranged with opposing polarities; the loose packing allows myosin (usually myosin-II) to enter the bundle.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"d53015bffe4645019566c25ee4d20dfa","type":"GO_TERM","name":"contractile muscle fiber","canonical_id":"go:GO:0043292","description":"\"Fibers, composed of actin, myosin, and associated proteins, found in cells of smooth or striated muscle.\" [GOC:curators, ISBN:0815316194]","metadata":null},{"id":"be1d1327286a48feae308de42a577f02","type":"GO_TERM","name":"contractile ring","canonical_id":"go:GO:0070938","description":"\"A cytoskeletal structure composed of filamentous protein that forms beneath the membrane of many cells or organelles, in the plane of cell or organelle division. Ring contraction is associated with centripetal growth of the membrane that divides the cytoplasm of the two daughter cells or organelles.\" [GOC:mah, ISBN:0123645859, ISBN:0792354923, PMID:10791428, PMID:17913889]","metadata":null},{"id":"918d4934c8e14924b9bed75032c0393b","type":"GO_TERM","name":"contractile ring contraction","canonical_id":"go:GO:0036213","description":"\"The process of an actomyosin ring getting smaller in diameter.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"e7bc14c5334143b59aa0e03529e98eac","type":"GO_TERM","name":"contractile vacuolar membrane","canonical_id":"go:GO:0031164","description":"\"The lipid bilayer surrounding the contractile vacuole.\" [GOC:pg]","metadata":null},{"id":"691d08a33fd84795b15be863ec56729c","type":"GO_TERM","name":"contractile vacuole","canonical_id":"go:GO:0000331","description":"\"A specialized vacuole of eukaryotic cells, especially Protozoa, that fills with water from the cytoplasm and then discharges this externally by the opening of contractile vacuole pores. One of its functions is osmoregulatory.\" [GOC:jl, PMID:10503189, PMID:23890380]","metadata":null},{"id":"eb0e37de5fe24f179a00ccd1b832a3fd","type":"GO_TERM","name":"contractile vacuole complex","canonical_id":"go:GO:0062159","description":"\"A non-membrane-bounded organelle of eukaryotic cells, especially Protozoa, that fills with water from the cytoplasm and then discharges this externally. One of its functions is osmoregulatory.\" [PMID:23890380]","metadata":null},{"id":"d374508fe760453a8d8342c945188121","type":"GO_TERM","name":"contractile vacuole discharge","canonical_id":"go:GO:0070177","description":"\"The regulated release of water from a contractile vacuole to the outside of a cell by fusion of the contractile vacuole membrane with the plasma membrane.\" [GOC:mah, PMID:10369671]","metadata":null},{"id":"5b0c95753adc4fbc8bfd359a310e1dfd","type":"GO_TERM","name":"contractile vacuole dissociation from plasma membrane","canonical_id":"go:GO:0140026","description":"\"The dissociation of the contractile vacuole after discharge, from the plasma membrane. This interaction is mediated by detethering factors that initiate the process of tubulation and fragmentation of the empty contractile vacuole bladder, which is then reincorporated into the CV network.\" [PMID:22323285]","metadata":null},{"id":"bfc0f98ae99542a3a0e8a5ee2b04a8bc","type":"GO_TERM","name":"contractile vacuole localization","canonical_id":"go:GO:0140027","description":"\"The directed movement of the contractile vacuole to a specific location.\" [PMID:19687255]","metadata":null},{"id":"12c54106889e4ca8b34ccbd5fab8e0ff","type":"GO_TERM","name":"contractile vacuole organization","canonical_id":"go:GO:0033298","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a contractile vacuole. A specialized vacuole that fills with water from the cytoplasm and then discharges this externally by the opening of contractile vacuole pores.\" [GOC:mah]","metadata":null},{"id":"e7509ae7fe674257bbcb776749f8be43","type":"GO_TERM","name":"contractile vacuole pore","canonical_id":"go:GO:0031913","description":"\"Stable structure that regulates the flow of liquid between the contractile vacuole and the surrounding medium.\" [PMID:10503189]","metadata":null},{"id":"b6634bfb38664d918262b7c82331cb02","type":"GO_TERM","name":"contractile vacuole-plasma membrane tether activity","canonical_id":"go:GO:7770067","description":"\"The binding activity of a molecule that brings together the contractile vacuolar membrane and the plasma membrane, either via membrane lipid binding or by interacting with a membrane protein, to establish or maintain the localization of the contractile vacuole at a specific plasma membrane discharge site.\" [PMID:22323285]","metadata":null},{"id":"ada505fc636d4f229232257a4bd1b85c","type":"GO_TERM","name":"conus arteriosus development","canonical_id":"go:GO:0003238","description":"\"The progression of the conus arteriosus over time, from its formation to the mature structure. The conus arteriosus is a valved chamber with thick muscular walls stemming from the ventricle and connecting to the pulmonary trunk.\" [GOC:mtg_heart]","metadata":null},{"id":"c01fedbd2366416aa58ca97838b396f8","type":"GO_TERM","name":"conus arteriosus formation","canonical_id":"go:GO:0003240","description":"\"The developmental process pertaining to the initial formation of the conus arteriosus from unspecified parts. The conus arteriosus is a valved chamber with thick muscular walls stemming from the ventricle and connecting to the pulmonary trunk.\" [GOC:mtg_heart]","metadata":null},{"id":"b7011dd00fd14b63ba3927473efa0192","type":"GO_TERM","name":"conus arteriosus morphogenesis","canonical_id":"go:GO:0003239","description":"\"The process in which the conus arteriosus is generated and organized. The conus arteriosus is a valved chamber with thick muscular walls stemming from the ventricle and connecting to the pulmonary trunk.\" [GOC:mtg_heart]","metadata":null},{"id":"ff77e3b380d7486f8d47e05e53fa6b82","type":"GO_TERM","name":"convergent extension","canonical_id":"go:GO:0060026","description":"\"The morphogenetic process in which an epithelium narrows along one axis and lengthens in a perpendicular axis.\" [GOC:dgf, GOC:dph, PMID:12062082]","metadata":null},{"id":"b0338c8f026142179ddf7b4102a0bd90","type":"GO_TERM","name":"convergent extension involved in axis elongation","canonical_id":"go:GO:0060028","description":"\"The morphogenetic process in which an epithelium narrows along one axis and lengthens in a perpendicular axis contributing to the lengthening of the axis of an organism.\" [GOC:dph, PMID:12062082]","metadata":null},{"id":"1ef51df116a24ba8a44838c4613d5121","type":"GO_TERM","name":"convergent extension involved in gastrulation","canonical_id":"go:GO:0060027","description":"\"The morphogenetic process in which an epithelium narrows along one axis and lengthens in a perpendicular axis usually resulting in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm.\" [GOC:dph, PMID:12062082]","metadata":null},{"id":"69bee098ee1c457ead6bf61aeac31cda","type":"GO_TERM","name":"convergent extension involved in nephron morphogenesis","canonical_id":"go:GO:0072045","description":"\"The morphogenetic process in which the renal epithelium narrows along one axis and lengthens in a perpendicular axis that contributes to the shaping of a nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"644d5a4df95c497496e9e5e552e745e0","type":"GO_TERM","name":"convergent extension involved in neural plate elongation","canonical_id":"go:GO:0022007","description":"\"The process of directed cell movement in the neural plate resulting in tissue elongation via intercalation of adjacent cells in an epithelial sheet at the midline, leading to narrowing and lengthening of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:13679871, PMID:15806586]","metadata":null},{"id":"fbc2e990d69e4656908fff21cb3b65e1","type":"GO_TERM","name":"convergent extension involved in notochord morphogenesis","canonical_id":"go:GO:1904126","description":"\"Any convergent extension that is involved in notochord morphogenesis.\" [GO_REF:0000060, GOC:dph, GOC:TermGenie, PMID:24892953]","metadata":null},{"id":"5a0dcea8918247b19e841a2066a0b875","type":"GO_TERM","name":"convergent extension involved in organogenesis","canonical_id":"go:GO:0060029","description":"\"The morphogenetic process in which an epithelium narrows along one axis and lengthens in a perpendicular axis contribution to the shaping of an organ.\" [GOC:dph, PMID:12062082]","metadata":null},{"id":"971ff8409b6040c3b3d8160033fd4594","type":"GO_TERM","name":"convergent extension involved in somitogenesis","canonical_id":"go:GO:0090246","description":"\"The morphogenetic process in which a presomitic mesoderm narrows along the left-right axis and lengthens in the rostral-caudal axis contributing to somitogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d8ff04503a4842f7a0b329339595ecc6","type":"GO_TERM","name":"conversion of O-phosphoseryl-tRNA to cysteinyl-tRNA","canonical_id":"go:GO:0071952","description":"\"The modification process that results in the conversion of O-phosphoserine charged on a tRNA(Cys) to cysteinyl-tRNA.\" [GOC:jsg, PMID:17351629, PMID:18559341]","metadata":null},{"id":"7c71140afbd84591bb95560759239174","type":"GO_TERM","name":"conversion of aspartyl-tRNA to asparaginyl-tRNA","canonical_id":"go:GO:0043688","description":"\"The modification process that results in the conversion of aspartate charged on a tRNA(Asn) to asparaginyl-tRNA.\" [GOC:jsg, PMID:9789001]","metadata":null},{"id":"de01853b546e4f9da03c285ec78b7b2f","type":"GO_TERM","name":"conversion of discoidal high-density lipoprotein particle to spherical high-density lipoprotein particle","canonical_id":"go:GO:0034376","description":"\"The process in which a discoidal high-density lipoprotein (HDL) particle acquires additional lipid or protein molecules, and cholesterol in the particle is converted to tightly bound cholesterol esters by the action of phosphatidylcholine-sterol O-acyltransferase (lecithin cholesterol acyltransferase; LCAT), resulting in the formation of a spherical HDL particle.\" [GOC:BHF, GOC:mah, GOC:pde]","metadata":null},{"id":"3008edc41de2486cb58fc71d9516aa36","type":"GO_TERM","name":"conversion of glutamyl-tRNA to glutaminyl-tRNA","canonical_id":"go:GO:0043685","description":"\"The modification process that results in the conversion of glutamate charged on a tRNA(Gln) to glutaminyl-tRNA.\" [GOC:jsg, PMID:3340166, PMID:9342308]","metadata":null},{"id":"eeec7d8df8e24f3eae46d1971915edb3","type":"GO_TERM","name":"conversion of lysyl-tRNA to pyrrolysyl-tRNA","canonical_id":"go:GO:0001720","description":"\"The modification process that results in the conversion of lysine, carried by a specialized lysine-accepting tRNA (possessing a CUA anticodon), to pyrrolysine (a lysine with an amide linkage to a (4R,5R)-4-substituted pyrroline-5-carboxylate).\" [PMID:12029131, PMID:12029132, PMID:12121639]","metadata":null},{"id":"30c69eb1f3ae4bd594a3303109763917","type":"GO_TERM","name":"conversion of methionyl-tRNA to N-formyl-methionyl-tRNA","canonical_id":"go:GO:0071951","description":"\"The modification process that results in the conversion of methionine charged on a tRNA(fMet) to N-formyl-methionine-tRNA(fMet).\" [GOC:jsg, PMID:5337045]","metadata":null},{"id":"3f4c9912bda046efaf8f46fe0eb7299e","type":"GO_TERM","name":"conversion of seryl-tRNAsec to selenocys-tRNAsec","canonical_id":"go:GO:0001717","description":"\"The modification process that results in the conversion of serine, carried by a specialized tRNA(ser) (which can read a UGA anticodon), to selenocysteine.\" [ISBN:155581073X]","metadata":null},{"id":"41d2527b68744ffc979802e143b6bdf9","type":"DISEASE","name":"convulsion","canonical_id":"efo:0009853","description":null,"metadata":null},{"id":"cc6e22ac4bba466d80ce69b9cae1ae4f","type":"GO_TERM","name":"copal-8-ol diphosphate synthase activity","canonical_id":"go:GO:0102161","description":"\"Catalysis of the reaction: copal-8-ol diphosphate = 2-trans,6-trans,10-trans-geranylgeranyl diphosphate + H2O.\" [EC:4.2.1.133, GOC:pz]","metadata":null},{"id":"3267fdb7fe174740a8d83f67f2c85b7c","type":"GO_TERM","name":"copal-8-ol diphosphate(3-) biosynthetic process","canonical_id":"go:GO:1902243","description":"\"The chemical reactions and pathways resulting in the formation of copal-8-ol diphosphate(3-).\" [GOC:TermGenie, PMID:22672125]","metadata":null},{"id":"09b66a7506464c41b740d255b7857fef","type":"GO_TERM","name":"copal-8-ol diphosphate(3-) catabolic process","canonical_id":"go:GO:1902242","description":"\"The chemical reactions and pathways resulting in the breakdown of copal-8-ol diphosphate(3-).\" [GOC:TermGenie, PMID:22672125]","metadata":null},{"id":"9514a1d0860044ea8712476f5984de41","type":"GO_TERM","name":"copalyl diphosphate synthase activity","canonical_id":"go:GO:0050559","description":"\"Catalysis of the reaction: all-trans-geranylgeranyl diphosphate = (+)-copalyl diphosphate.\" [EC:5.5.1.12, RHEA:24316]","metadata":null},{"id":"60317583ca4a4fdda6fb51f3120a0255","type":"GO_TERM","name":"copper chaperone activity","canonical_id":"go:GO:0016531","description":"\"Directly binding to and delivering copper ions to a target protein.\" [PMID:10790544, PMID:11739376]","metadata":null},{"id":"0a097b0351084aa0a97550c443fa5016","type":"GO_TERM","name":"copper chelate transmembrane transporter activity","canonical_id":"go:GO:0051981","description":"\"Enables the transfer of a copper chelate from one side of a membrane to the other. A copper chelate is a heterocyclic compound having a metal ion attached by coordinate bonds to at least two nonmetal ions.\" [PMID:26512647]","metadata":null},{"id":"d0a5dcab2b254908be48bf603d728b07","type":"GO_TERM","name":"copper import into the mitochondrion","canonical_id":"go:GO:0140636","description":"\"The process in which copper is transported from the cytosol into the mitochondrial matrix.\" [PMID:32979421]","metadata":null},{"id":"6885f081fb384920b3c5d45081357034","type":"GO_TERM","name":"copper incorporation into copper-sulfur cluster","canonical_id":"go:GO:0018428","description":"\"The incorporation of copper into a copper-sulfur cluster.\" [GOC:ai]","metadata":null},{"id":"64d77a5c1a9b4318a92ca4cdf778141d","type":"GO_TERM","name":"copper incorporation into metallo-sulfur cluster","canonical_id":"go:GO:0018427","description":"\"The incorporation of copper into a metallo-sulfur cluster.\" [GOC:ai]","metadata":null},{"id":"4052024ad0e9406f85d0159bb2a10ac0","type":"GO_TERM","name":"copper ion binding","canonical_id":"go:GO:0005507","description":"\"Binding to a copper (Cu) ion.\" [GOC:ai]","metadata":null},{"id":"d593873a149f4a399638a6314f92ea24","type":"GO_TERM","name":"copper ion export","canonical_id":"go:GO:0060003","description":"\"The directed movement of copper ions out of a cell or organelle.\" [GOC:dph]","metadata":null},{"id":"133de5a1c6d940f4b1f083c1bf60b832","type":"GO_TERM","name":"copper ion export from vacuole","canonical_id":"go:GO:0140145","description":"\"The directed movement of copper ions out of the vacuole across the vacuolar membrane.\" [GOC:vw, PMID:12244050]","metadata":null},{"id":"92dc1494afba4b6282ba1b551dac19f4","type":"GO_TERM","name":"copper ion homeostasis","canonical_id":"go:GO:0055070","description":"\"Any process involved in the maintenance of an internal steady state of copper ions within an organism or cell.\" [GOC:ai, GOC:jid, GOC:mah]","metadata":null},{"id":"8ea2750bcaba40d3b10e36f95dcf6ac5","type":"GO_TERM","name":"copper ion import","canonical_id":"go:GO:0015677","description":"\"The directed movement of copper ions into a cell or organelle.\" [GOC:ai]","metadata":null},{"id":"bd6ef5145ebb4f4e99c2669baef387b2","type":"GO_TERM","name":"copper ion import across plasma membrane","canonical_id":"go:GO:0098705","description":"\"The directed movement of copper ions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"0b2623c846504b75b6e78f44593e7983","type":"GO_TERM","name":"copper ion import across prospore membrane","canonical_id":"go:GO:0097430","description":"\"The directed movement of copper ions from outside of a cell, across an ascospore-type prospore membrane and into the cytosol.\" [GOC:al, GOC:vw, PMID:21828039]","metadata":null},{"id":"705e14ed61b5493da76a14d00860929d","type":"GO_TERM","name":"copper ion import into Golgi lumen","canonical_id":"go:GO:7770057","description":"\"The directed import of copper cation from the cytosol across the Golgi membrane into the Golgi lumen.\" [PMID:7708696, PMID:9325307]","metadata":null},{"id":"fed48cd1ea3e4b5599bbd79b79ce6396","type":"GO_TERM","name":"copper ion sensor activity","canonical_id":"go:GO:0097077","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of copper(I) (Cu+).\" [GOC:rs, PMID:19928961]","metadata":null},{"id":"8381ebd5a9ed4638b92fa02518b1e762","type":"GO_TERM","name":"copper ion transmembrane transport","canonical_id":"go:GO:0035434","description":"\"The directed movement of copper cation across a membrane.\" [GOC:vw]","metadata":null},{"id":"4b11b4207f8c4772a290d8ba318cfeb8","type":"GO_TERM","name":"copper ion transmembrane transporter activity","canonical_id":"go:GO:0005375","description":"\"Enables the transfer of copper (Cu) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"6002b5a3369f4b4a91a077d3bbbd44d9","type":"GO_TERM","name":"copper ion transmembrane transporter complex","canonical_id":"go:GO:1903113","description":"\"A protein complex which is capable of copper ion transmembrane transporter activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:23122209]","metadata":null},{"id":"f5d0c479292240acb9165590594d5d11","type":"GO_TERM","name":"copper ion transport","canonical_id":"go:GO:0006825","description":"\"The directed movement of copper (Cu) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"38c57d75b4c844ec8d3f971fc70bdd43","type":"GO_TERM","name":"copper ion transport across blood-brain barrier","canonical_id":"go:GO:0097716","description":"\"The directed movement of copper (Cu) ions passing through the blood-brain barrier.\" [GOC:sl, PMID:24614235]","metadata":null},{"id":"f4be3d3c8cd845969779b7ae4c3ddf6d","type":"GO_TERM","name":"copper ion transport across blood-cerebrospinal fluid barrier","canonical_id":"go:GO:0097717","description":"\"The directed movement of copper (Cu) ions passing through the blood-cerebrospinal fluid barrier.\" [GOC:sl, PMID:24614235]","metadata":null},{"id":"9dc75393844a4084b62b7834986853f0","type":"GO_TERM","name":"copper-dependent protein binding","canonical_id":"go:GO:0032767","description":"\"Binding to a protein or protein complex, in the presence of copper.\" [GOC:ecd, PMID:16884690]","metadata":null},{"id":"d8f20f4c344e46b5a77b96b0aeee31b1","type":"GO_TERM","name":"copper-nicotianamine transmembrane transporter activity","canonical_id":"go:GO:0051982","description":"\"Enables the transfer of the copper chelate copper-nicotianamine (Cu-NA) from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"17e34ff6e1e04376a69e7e0f5e7661e6","type":"GO_TERM","name":"coproporphyrinogen dehydrogenase activity","canonical_id":"go:GO:0051989","description":"\"Catalysis of the reaction: coproporphyrinogen III + 2 S-adenosyl-L-methionine = protoporphyrinogen IX + 2 CO2 + 2 L-methionine + 2 5'-deoxyadenosine.\" [EC:1.3.98.3]","metadata":null},{"id":"e16f78ce9ddc4b45b81dda6a040dac8a","type":"GO_TERM","name":"coproporphyrinogen oxidase activity","canonical_id":"go:GO:0004109","description":"\"Catalysis of the reaction: coproporphyrinogen III + 2 H+ + O2 = 2 CO2 + 2 H2O + protoporphyrinogen IX.\" [EC:1.3.3.3, RHEA:18257]","metadata":null},{"id":"b018d5590a3d41e2a009c9fb31fe0334","type":"GO_TERM","name":"copulation","canonical_id":"go:GO:0007620","description":"\"The act of sexual union between male and female, involving the transfer of sperm.\" [ISBN:0721662544]","metadata":null},{"id":"1960c6e3ad6c4ae1b51ee5a0f1d52649","type":"GO_TERM","name":"corazonin receptor activity","canonical_id":"go:GO:0035237","description":"\"Combining with the neuropeptide corazonin to initiate a change in cell activity.\" [GOC:bf]","metadata":null},{"id":"8b34dda127324751abf8d0bf26e9d4cd","type":"GO_TERM","name":"corazonin receptor binding","canonical_id":"go:GO:0071858","description":"\"Binding to a corazonin receptor.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"a3e32e2afccf4136a721c58ba9e19d3b","type":"GO_TERM","name":"cord factor receptor activity","canonical_id":"go:GO:1990725","description":"\"Combining with a cord factor, an M. tuberculosis cell wall glycolipid, and transmitting a signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:hjd, PMID:23602766]","metadata":null},{"id":"178856036140404e8aa66f1eed6cccef","type":"GO_TERM","name":"core TFIIH complex portion of NEF3 complex","canonical_id":"go:GO:0000440","description":"\"The core TFIIH complex when it is part of the nucleotide-excision repair factor 3 (NEF3).\" [GOC:ew, GOC:krc, PMID:14500720, PMID:22308316, PMID:22572993, PMID:7813015]","metadata":null},{"id":"b2e6533c43e348fe8c6d2f89a4b13958","type":"GO_TERM","name":"core TFIIH complex portion of holo TFIIH complex","canonical_id":"go:GO:0000438","description":"\"The core TFIIH complex when it is part of the general transcription factor TFIIH.\" [GOC:ew, GOC:krc, PMID:14500720, PMID:22308316, PMID:22572993, PMID:7813015]","metadata":null},{"id":"3e7801416a524ec49fb9abb552b7b9c4","type":"GO_TERM","name":"core mediator complex","canonical_id":"go:GO:0070847","description":"\"A protein complex that interacts with the carboxy-terminal domain of the largest subunit of RNA polymerase II and plays an active role in transducing the signal from a transcription factor to the transcriptional machinery. The core mediator complex has a stimulatory effect on basal transcription, and contains most of the same subdomains as the larger form of mediator complex -- a head domain comprising proteins known in Saccharomyces as Srb2, -4, and -5, Med6, -8, and -11, and Rox3 proteins; a middle domain comprising Med1, -4, and -7, Nut1 and -2, Cse2, Rgr1, Soh1, and Srb7 proteins; and a tail consisting of Gal11p, Med2p, Pgd1p, and Sin4p -- but lacks the regulatory subcomplex comprising Ssn2, -3, and -8, and Srb8 proteins. Metazoan core mediator complexes have similar modular structures and include homologs of yeast Srb and Med proteins.\" [PMID:11454195, PMID:16168358, PMID:17870225]","metadata":null},{"id":"bf729fdc56564fd4beab2849fe39bf35","type":"GO_TERM","name":"core primosome complex","canonical_id":"go:GO:1990098","description":"\"A protein-DNA complex containing at least one DNA helicase and one primase. Can also contain associated proteins. The helicase component continues to unwind the double-stranded DNA (dsDNA) and the primase component synthesizes a RNA primer during initiation or restart of replication.\" [GOC:bhm, PMID:21856207]","metadata":null},{"id":"920abc09a340495ead77eed14b91ad14","type":"GO_TERM","name":"core promoter sequence-specific DNA binding","canonical_id":"go:GO:0001046","description":"\"Binding to a sequence of DNA that is part of a core promoter region. The core promoter is composed of the transcription start site and binding sites for the RNA polymerase and the basal transcription machinery. The transcribed region might be described as a gene, cistron, or operon.\" [GOC:pg, GOC:txnOH]","metadata":null},{"id":"36511163d6484395a5cd91b5d66123cb","type":"GO_TERM","name":"core-binding factor complex","canonical_id":"go:GO:0016513","description":"\"A heterodimeric transcription factor complex that contains an alpha subunit (Runx1, Runx2 or Runx3 in human) that binds DNA and a non-DNA-binding beta subunit (CBFbeta), and binds to a consensus sequence 5'-YGYGGTY-3' found in several enhancers and promoters; the beta subunit enhances the DNA binding of the alpha subunit.\" [PMID:15156179, PMID:8497254]","metadata":null},{"id":"ef2488aa995e48f1bda969980c9c5a9b","type":"GO_TERM","name":"coreceptor activity","canonical_id":"go:GO:0015026","description":"\"Combining with an extracellular or intracellular messenger, and in cooperation with a nearby primary receptor, initiating a change in cell activity.\" [GOC:curators]","metadata":null},{"id":"6c19f72c56be410cad1255cb2fe5fa52","type":"GO_TERM","name":"coreceptor-mediated virion attachment to host cell","canonical_id":"go:GO:0046814","description":"\"The process by which a virion attaches to a host cell by binding to a co-receptor on the host cell surface.\" [ISBN:0879694971]","metadata":null},{"id":"af2142a86f5941779c718b7c2a100563","type":"GO_TERM","name":"cornea development in camera-type eye","canonical_id":"go:GO:0061303","description":"\"The progression of the cornea over time, from its formation to the mature structure. The cornea is the transparent structure that covers the anterior of the eye.\" [GOC:dph]","metadata":null},{"id":"0ac48add3f0e447a84eee1f61fcc0c61","type":"DISEASE","name":"corneal disorder","canonical_id":"mondo:0000942","description":null,"metadata":null},{"id":"9de76c67beaa49278e528bfdc52c3f62","type":"GO_TERM","name":"corneal epithelial cell differentiation","canonical_id":"go:GO:0160122","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an corneal epithelial cell, any of the cells making up an corneal epithelium.\" [PMID:32697979, PMID:33414365]","metadata":null},{"id":"a4b8873efc7246409af604d496f2427e","type":"GO_TERM","name":"corneal epithelial cell migration","canonical_id":"go:GO:0061581","description":"\"The orderly movement of a corneal epithelial cell from one site to another, often during the development of a multicellular organism.\" [GOC:dph]","metadata":null},{"id":"4ccd7bbc4b7746b8befc5198e64f5536","type":"GO_TERM","name":"corneocyte desquamation","canonical_id":"go:GO:0003336","description":"\"The delamination process that results in the shedding of a corneocyte from the surface of the epidermis.\" [GOC:dph]","metadata":null},{"id":"13efb63a27134bf38e241fdb642cc1c7","type":"GO_TERM","name":"corneocyte development","canonical_id":"go:GO:0003335","description":"\"The process whose specific outcome is the progression of the corneocyte over time, from its formation to the mature structure. A corneocyte is the last stage of development of a keratinocyte where the keratinocyte flattens, loses its nucleus and eventually delaminates from the epidermis.\" [GOC:dph]","metadata":null},{"id":"daaa2daae2bb42849dc2940b32354dbb","type":"GO_TERM","name":"cornification","canonical_id":"go:GO:0070268","description":"\"A type of programmed cell death that occurs in the epidermis, morphologically and biochemically distinct from apoptosis. It leads to the formation of corneocytes, i.e. dead keratinocytes containing an amalgam of specific proteins (e.g., keratin, loricrin, SPR and involucrin) and lipids (e.g., fatty acids and ceramides), which are necessary for the function of the cornified skin layer (mechanical resistance, elasticity, water repellence and structural stability).\" [GOC:krc, PMID:18846107]","metadata":null},{"id":"a11d72d048ba438c8f799ca464acd89d","type":"GO_TERM","name":"cornified envelope","canonical_id":"go:GO:0001533","description":"\"A type of plasma membrane that has been modified through addition of distinct intracellular and extracellular components, including ceramide, found in cornifying epithelial cells (corneocytes).\" [GOC:add, PMID:11112355, PMID:11590230, PMID:15803139]","metadata":null},{"id":"940db4d372064f849ce981daaf3f4364","type":"GO_TERM","name":"cornified envelope assembly","canonical_id":"go:GO:1903575","description":"\"The aggregation, arrangement and bonding together of a set of components to form a cornified envelope.\" [GO_REF:0000079, GOC:pm, GOC:TermGenie, PMID:22226963, PMID:24794495]","metadata":null},{"id":"a3da43b33b97465ea09cf871409ec707","type":"GO_TERM","name":"corolla development","canonical_id":"go:GO:0048465","description":"\"The process whose specific outcome is the progression of the corolla over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"554b5374e5e945a487bb6012ca49e902","type":"GO_TERM","name":"coronal suture morphogenesis","canonical_id":"go:GO:0060365","description":"\"The process in which the coronal suture is generated and organized.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"4fee63440e114d229d9fc631a6b8f945","type":"DISEASE","name":"coronary artery disorder","canonical_id":"mondo:0005010","description":null,"metadata":null},{"id":"48caf1871bee462ca39c7674b2c88cf3","type":"GO_TERM","name":"coronary artery morphogenesis","canonical_id":"go:GO:0060982","description":"\"The process in which the anatomical structures of coronary arteries are generated and organized. Coronary arteries are blood vessels that transport blood to the heart muscle.\" [GOC:mtg_heart]","metadata":null},{"id":"c932527da3ed4d7b9a42eb6a56ae09ed","type":"DISEASE","name":"coronary atherosclerosis","canonical_id":"mondo:0021661","description":null,"metadata":null},{"id":"99004eb497e54c57ada9fc60e1ee0573","type":"GO_TERM","name":"coronary sinus valve development","canonical_id":"go:GO:0003178","description":"\"The progression of the valve of the coronary sinus over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"242947ef30f046488b4f91398040c55a","type":"GO_TERM","name":"coronary sinus valve formation","canonical_id":"go:GO:0003191","description":"\"The developmental process pertaining to the initial formation of the coronary sinus valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"461e1bf50bbc41e5bce5411ce0108f5a","type":"GO_TERM","name":"coronary sinus valve morphogenesis","canonical_id":"go:GO:0003182","description":"\"The process in which the structure of the coronary sinus valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"1fe48ff19b5240aba54d248953fbabb3","type":"GO_TERM","name":"coronary vasculature development","canonical_id":"go:GO:0060976","description":"\"The process whose specific outcome is the progression of the blood vessels of the heart over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"b981b12bb55044af86a4c117f6cc2709","type":"GO_TERM","name":"coronary vasculature morphogenesis","canonical_id":"go:GO:0060977","description":"\"The process in which the anatomical structures of blood vessels of the heart are generated and organized. The blood vessel is the vasculature carrying blood.\" [GOC:mtg_heart]","metadata":null},{"id":"c300d6140ea14cbd9225cc4fd6e9126b","type":"GO_TERM","name":"coronary vein morphogenesis","canonical_id":"go:GO:0003169","description":"\"The process in which the anatomical structures of veins of the heart are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"be0b6e0e26084807b295f121a322ac01","type":"GO_TERM","name":"corpora quadrigemina development","canonical_id":"go:GO:0061378","description":"\"The progression of the corpora quadrigemina over time, from its formation to the mature structure. The corpora quadrigemina is a part of the midbrain that is made up of the superior and inferior colliculi.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"a6d06b7c13394ccda993b5795a14ab20","type":"GO_TERM","name":"corpus callosum development","canonical_id":"go:GO:0022038","description":"\"The process whose specific outcome is the progression of the corpus callosum over time, from its formation to the mature structure. The corpus callosum is a thick bundle of nerve fibers comprising a commissural plate connecting the two cerebral hemispheres. It consists of contralateral axon projections that provide communication between the right and left cerebral hemispheres.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b9bacced618e43248dae770939cca052","type":"GO_TERM","name":"corpus callosum morphogenesis","canonical_id":"go:GO:0021540","description":"\"The process in which the anatomical structures of the corpus callosum are generated and organized. The corpus callosum is a thick bundle of nerve fibers comprising a commissural plate connecting the two cerebral hemispheres. It consists of contralateral axon projections that provides communications between the right and left cerebral hemispheres.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d8530530baac4bde85f8aa76d9fe788f","type":"GO_TERM","name":"corrin biosynthetic process","canonical_id":"go:GO:0046140","description":"\"The chemical reactions and pathways resulting in the formation of corrin, C19H22N4, the fundamental heterocyclic skeleton of the corrinoids. It consists of four reduced pyrrole rings joined into a macrocyclic ring. Corrin is the core of the vitamin B12 molecule.\" [GOC:ai]","metadata":null},{"id":"018d8236c1ec4ef79bdfd67f15110eef","type":"GO_TERM","name":"corrin catabolic process","canonical_id":"go:GO:0046141","description":"\"The chemical reactions and pathways resulting in the breakdown of corrin, C19H22N4, the fundamental heterocyclic skeleton of the corrinoids. It consists of four reduced pyrrole rings joined into a macrocyclic ring. Corrin is the core of the vitamin B12 molecule.\" [GOC:ai]","metadata":null},{"id":"5ea014d5191f4760a3d5c7c01a330fea","type":"GO_TERM","name":"corrinoid adenosyltransferase activity","canonical_id":"go:GO:0008817","description":"\"Catalysis of the reaction: 2 ATP + 2 corrinoid + reduced [electron-transfer flavoprotein] = 2 adenosylcorrinoid + 3 H+ + oxidized [electron-transfer flavoprotein] + 2 triphosphate. The corrinoid can be cob(II)yrinate a,c diamide, cob(II)inamide or cob(II)alamin.\" [PMID:19933577, PMID:5946606]","metadata":null},{"id":"4aa771773b504b8d97d224a1d433fae1","type":"GO_TERM","name":"cortical Lewy body","canonical_id":"go:GO:0097415","description":"\"Cytoplasmic inclusion similar to a classical Lewy body but lacking a halo of protein fibrils.\" [NIF_Subcellular:sao4040591221]","metadata":null},{"id":"d8d6eca269f74546bcb75ee6d3025708","type":"GO_TERM","name":"cortical actin cytoskeleton","canonical_id":"go:GO:0030864","description":"\"The portion of the actin cytoskeleton, comprising filamentous actin and associated proteins, that lies just beneath the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"4f35c95133d44ba7bf81c9da6fa7c9fa","type":"GO_TERM","name":"cortical actin cytoskeleton organization","canonical_id":"go:GO:0030866","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of actin-based cytoskeletal structures in the cell cortex, i.e. just beneath the plasma membrane.\" [GOC:dph, GOC:jl, GOC:mah, GOC:pf]","metadata":null},{"id":"019eff8f55b540a682ebe447767160b2","type":"GO_TERM","name":"cortical collecting duct development","canonical_id":"go:GO:0072059","description":"\"The process whose specific outcome is the progression of the cortical collecting duct over time, from its formation to the mature structure. The cortical collecting duct is the portion of the collecting duct that resides in the renal cortex.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"844fda0f388f451d8fc2990f9dafeb98","type":"GO_TERM","name":"cortical cytoskeleton","canonical_id":"go:GO:0030863","description":"\"The portion of the cytoskeleton that lies just beneath the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"dd1501e4c49846e19616085e57d1da27","type":"GO_TERM","name":"cortical cytoskeleton organization","canonical_id":"go:GO:0030865","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures in the cell cortex, i.e. just beneath the plasma membrane.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"afc9380972bc4f5a9d49d6c08e212b99","type":"GO_TERM","name":"cortical dynamic polarity patch","canonical_id":"go:GO:0090726","description":"\"A region of the cell cortex that contains a higher concentration of growth polarity factors than the surrounding cortex and that changes position over time. An example is found in fission yeast cells during early mating, in which the GTPase Cdc42 dynamically to discrete zones within the cortex prior to shmoo formation.\" [GOC:mah, PMID:23200991]","metadata":null},{"id":"230a8d8447f5461cab82e8299e85ddc3","type":"GO_TERM","name":"cortical endoplasmic reticulum","canonical_id":"go:GO:0032541","description":"\"A cortical network of highly dynamic tubules that are juxtaposed to the plasma membrane and undergo ring closure and tubule-branching movements.\" [GOC:se, PMID:10931860, PMID:17686782]","metadata":null},{"id":"b12b9b35eb4046cfbb3129c807fee8d8","type":"GO_TERM","name":"cortical endoplasmic reticulum lumen","canonical_id":"go:GO:0099021","description":"\"The volume enclosed by the membranes of the cortical endoplasmic reticulum.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"26bf52723e7545ab91e6123d94cf4d32","type":"GO_TERM","name":"cortical endoplasmic reticulum membrane","canonical_id":"go:GO:0160219","description":"\"The lipid bilayer surrounding the cortical endoplasmic reticulum.\" [PMID:32735772]","metadata":null},{"id":"c793e96717e646a79a5520110a8f108a","type":"GO_TERM","name":"cortical granule","canonical_id":"go:GO:0060473","description":"\"A secretory vesicle that is stored under the cell membrane of an egg. These vesicles fuse with the egg plasma membrane as part of egg activation and are part of the block to polyspermy.\" [GOC:dph]","metadata":null},{"id":"0d0c0ac5d4bf4b28b321b54756fa8713","type":"GO_TERM","name":"cortical granule exocytosis","canonical_id":"go:GO:0060471","description":"\"The process of secretion by a cell that results in the release of intracellular molecules contained within a cortical granule by fusion of the vesicle with the plasma membrane of a cell. A cortical granule is a specialized secretory vesicle that is released during egg activation that changes the surface of the egg to prevent polyspermy.\" [GOC:dph]","metadata":null},{"id":"f5bc0e5c02674a9bb61ad2436e9b8025","type":"GO_TERM","name":"cortical layer of collagen and cuticulin-based cuticle extracellular matrix","canonical_id":"go:GO:0060106","description":"\"The cuticle layer that lies directly beneath the lipid-containing epicuticle. The cortical layer contains collagens and insoluble, non-collagenous cuticulins and is characterized by a distinct annular pattern consisting of regularly spaced annular ridges delineated by annular furrows. An example of this component is found in Caenorhabditis elegans.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"c05fc771df1d458aa1bb76dc835a38eb","type":"GO_TERM","name":"cortical microtubule","canonical_id":"go:GO:0055028","description":"\"Arrays of microtubules underlying and connected to the plasma membrane in the cortical cytosol.\" [GOC:mtg_sensu]","metadata":null},{"id":"b57e368b5cc046e1af1b49d183947fcd","type":"GO_TERM","name":"cortical microtubule cytoskeleton","canonical_id":"go:GO:0030981","description":"\"The portion of the microtubule cytoskeleton that lies just beneath the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"c1e7e83c6db24f9785d782b87e44189a","type":"GO_TERM","name":"cortical microtubule organization","canonical_id":"go:GO:0043622","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures formed of microtubules and associated proteins in the cell cortex, i.e. just beneath the plasma membrane of a cell.\" [GOC:curators, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"65da80dbdccd4eaea9034d7f1a2b9e91","type":"GO_TERM","name":"cortical microtubule plus-end","canonical_id":"go:GO:1903754","description":"\"The plus-end of a cortical microtubule.\" [GO_REF:0000064, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"6dd50ee288314813aff79058cd40ff2e","type":"GO_TERM","name":"cortical microtubule, transverse to long axis","canonical_id":"go:GO:0010005","description":"\"Arrays of microtubules underlying and connected to the plasma membrane, in the cortical cytosol, oriented mainly with their axes transverse to the long axis of the cell (and root in plants). In plants it influences the direction of cellulose microfibril deposition.\" [ISBN:0943088399]","metadata":null},{"id":"dec0573b580340bebe2c059c0a549acd","type":"GO_TERM","name":"cortical rotation","canonical_id":"go:GO:0160174","description":"\"A cellular developmental process by which the outer layer of the cell (the cortex) rotates relative to the inner cytoplasm.\" [PMID:22949618, PMID:25077289, PMID:37983969]","metadata":null},{"id":"328915b39ef24bf6b29fcb1b29ac072a","type":"GO_TERM","name":"corticospinal neuron axon decussation","canonical_id":"go:GO:0021973","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed to cross the midline to the contralateral side.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"817b01740da742149e5a6d43ad132583","type":"GO_TERM","name":"corticospinal neuron axon guidance","canonical_id":"go:GO:0021966","description":"\"The process in which the migration of an axon growth cone of a neuron that is part of the corticospinal tract is directed from the cerebral cortex layer V to the spinal cord dorsal funiculus in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"a2d4f216296a4700a8c71fcdba93451b","type":"GO_TERM","name":"corticospinal neuron axon guidance through spinal cord","canonical_id":"go:GO:0021972","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed after decussation through the spinal cord in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"cef9dc927c8c4620bacc1b030644bc0a","type":"GO_TERM","name":"corticospinal neuron axon guidance through the basilar pons","canonical_id":"go:GO:0021970","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed after exiting the cerebral peduncle through the basilar pons in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"ad7d8f88fea149e796af7b4b3fb7a2cc","type":"GO_TERM","name":"corticospinal neuron axon guidance through the cerebral cortex","canonical_id":"go:GO:0021967","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed from its cell body in layer V through the cerebral cortex in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"772e767eb3464e448692f853faf8aaa6","type":"GO_TERM","name":"corticospinal neuron axon guidance through the cerebral peduncle","canonical_id":"go:GO:0021969","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed after exiting the internal capsule through the cerebral peduncle in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"c27dbe22de584a88a84ca1c6a7156849","type":"GO_TERM","name":"corticospinal neuron axon guidance through the internal capsule","canonical_id":"go:GO:0021968","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed after exiting the cerebral cortex through the internal capsule in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"3d419112fcb4499fb301383da431c93f","type":"GO_TERM","name":"corticospinal neuron axon guidance through the medullary pyramid","canonical_id":"go:GO:0021971","description":"\"The process in which the migration of an axon growth cone of a pyramidal cell that is part of the corticospinal tract is directed after exiting the basilar pons through the medullary pyramid in response to a combination of attractive and repulsive cues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"d387cdeaf81e4d97b2f77ace2a34ce42","type":"GO_TERM","name":"corticospinal tract morphogenesis","canonical_id":"go:GO:0021957","description":"\"Generation of a long process of a pyramidal cell, that carries efferent (outgoing) action potentials from the cell body in cerebral cortex layer V towards target cells in the gray matter of the spinal cord. This axonal process is a member of those that make up the corticospinal tract.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:9878731]","metadata":null},{"id":"5c999849b6a34b40ac9b8f8c7c2cc7ff","type":"GO_TERM","name":"corticosteroid hormone secretion","canonical_id":"go:GO:0035930","description":"\"The regulated release of any corticosteroid hormone into the circulatory system.\" [GOC:sl]","metadata":null},{"id":"c24345e6c961435ab8784c4b7dc82e8d","type":"GO_TERM","name":"corticosteroid side-chain-isomerase activity","canonical_id":"go:GO:0004110","description":"\"Catalysis of the reaction: 11-deoxycorticosterone = 20-hydroxy-3-oxopregn-4-en-21-al.\" [EC:5.3.1.21, RHEA:17861]","metadata":null},{"id":"6c9a290df7854be6a52a82264ec0612c","type":"GO_TERM","name":"corticosterone 18-monooxygenase activity","canonical_id":"go:GO:0047783","description":"\"Catalysis of the reaction: corticosterone + reduced adrenal ferredoxin + O2 = 18-hydroxycorticosterone + oxidized adrenal ferredoxin + H2O.\" [EC:1.14.15.5]","metadata":null},{"id":"b8f0a043d0c34412bd860c754e2a3f40","type":"GO_TERM","name":"corticosterone binding","canonical_id":"go:GO:1903875","description":"\"Binding to corticosterone.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10802282]","metadata":null},{"id":"c288a358e9b34641aa78dc08f6b288b6","type":"GO_TERM","name":"corticosterone secretion","canonical_id":"go:GO:0035934","description":"\"The regulated release of corticosterone into the circulatory system. Corticosterone is a 21-carbon steroid hormone of the corticosteroid type produced in the cortex of the adrenal glands.\" [GOC:sl]","metadata":null},{"id":"76f21ed361034a0dac1b753f00d3aa65","type":"GO_TERM","name":"corticotrophin-releasing factor receptor activity","canonical_id":"go:GO:0015056","description":"\"Combining with the corticotrophin-releasing factor family of ligands, including the urocortins, to initiate a change in cell activity.\" [PMID:12032352]","metadata":null},{"id":"ea280c03bac447d090503baa4d3f2056","type":"GO_TERM","name":"corticotropin hormone receptor binding","canonical_id":"go:GO:0031780","description":"\"Binding to a corticotropin hormone receptor.\" [GOC:dph, GOC:mah, GOC:nln]","metadata":null},{"id":"474139e2df1743d9a7b24ded5027b8c0","type":"GO_TERM","name":"corticotropin hormone secreting cell development","canonical_id":"go:GO:0060131","description":"\"The process whose specific outcome is the progression of a corticotropic hormone secreting cell over time, from its formation to the mature structure. An corticotropic hormone secreting cell is a basophil cell of the anterior pituitary that produces corticotropin.\" [GOC:dph]","metadata":null},{"id":"fb07aa2caf224f84b64abc78666f26d7","type":"GO_TERM","name":"corticotropin hormone secreting cell differentiation","canonical_id":"go:GO:0060128","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a corticotropic hormone secreting cell. An corticotropic hormone secreting cell is a basophil cell of the anterior pituitary that produces corticotropin.\" [GOC:dph]","metadata":null},{"id":"f3d39c20f4af4d7bacac095d2ca55177","type":"GO_TERM","name":"corticotropin receptor activity","canonical_id":"go:GO:0004978","description":"\"Combining with corticotropin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"a98bdd3bbe464f8eb9429e67e37c1064","type":"GO_TERM","name":"corticotropin secretion","canonical_id":"go:GO:0051458","description":"\"The regulated release of corticotropin by a cell. Corticotropin hormone is a polypeptide hormone synthesized and secreted from corticotropes in the anterior lobe of the pituitary gland in response to corticotropin-releasing hormone (CRH) released by the hypothalamus.\" [GOC:cjm, PMID:11027914]","metadata":null},{"id":"45c7e2f960f34beb85c7274b955b78ee","type":"DRUG","name":"corticotropin zinc hydroxide","canonical_id":"gtopdb:6967","description":null,"metadata":null},{"id":"99fb537fed6247218f92d226f39a0d78","type":"DRUG","name":"corticotropin zinc hydroxide","canonical_id":"chembl:CHEMBL1201609","description":null,"metadata":null},{"id":"82542fe7b2f44fdf89f4c18e4dde91bc","type":"GO_TERM","name":"corticotropin-releasing hormone activity","canonical_id":"go:GO:0017045","description":"\"The action characteristic of corticotropin-releasing hormone (CRH), any of a number of peptides released by the mammalian hypothalamus into the hypophyseal-portal circulation in response to neural and/or chemical stimuli. Upon receptor binding, CRH increases the rate of corticotropin secretion by the anterior pituitary.\" [ISBN:0198506732]","metadata":null},{"id":"659ea701775c43d682950fa30b65ccb3","type":"GO_TERM","name":"corticotropin-releasing hormone binding","canonical_id":"go:GO:0051424","description":"\"Binding to corticotropin-releasing hormone, a polypeptide hormone involved in the stress response. It is released by the hypothalamus and stimulates the release of corticotropin by the anterior pituitary gland.\" [PMID:7556876]","metadata":null},{"id":"030a776c449e4e0792f123eb0754f778","type":"GO_TERM","name":"corticotropin-releasing hormone receptor 1 binding","canonical_id":"go:GO:0051430","description":"\"Binding to a corticotropin-releasing hormone receptor 1 (CRHR1). CRHR1 is the major subtype in the pituitary corticotroph, and mediates the stimulatory actions of corticotropin-releasing hormone on corticotropin hormone secretion. CRHR1 are also located in cortical areas of the brain, cerebellum and limbic system.\" [PMID:15134857]","metadata":null},{"id":"06eda0b9f9d246a18c75d2fabdcae82f","type":"GO_TERM","name":"corticotropin-releasing hormone receptor 2 binding","canonical_id":"go:GO:0051431","description":"\"Binding to a corticotropin-releasing hormone receptor type 2 (CRHR2). The CRHR2 has several splice variants that are located in sub-cortical areas of the brain and in the periphery.\" [PMID:15134857]","metadata":null},{"id":"04aff25849e24eee9a419b86b384963d","type":"GO_TERM","name":"corticotropin-releasing hormone receptor activity","canonical_id":"go:GO:0043404","description":"\"Combining with corticotropin-releasing hormone and transmitting the signal to initiate a change in cell activity.\" [GOC:signaling, ISBN:0838577016, PMID:11027914, PMID:15134857]","metadata":null},{"id":"d1018308e21d44cebbd295fef6ed834d","type":"GO_TERM","name":"corticotropin-releasing hormone receptor binding","canonical_id":"go:GO:0051429","description":"\"Binding to a receptor for corticotropin-releasing hormone (CRH), a polypeptide hormone involved in the stress response. It is released by the hypothalamus and stimulates the release of corticotropin by the anterior pituitary gland.\" [GOC:ai]","metadata":null},{"id":"732c0c19e2ed42d88565d681a0c6659a","type":"GO_TERM","name":"corticotropin-releasing hormone secretion","canonical_id":"go:GO:0043396","description":"\"The regulated release of corticotropin-releasing hormone (CRH), a polypeptide hormone involved in the stress response. CRH is produced by the hypothalamus and stimulates corticotropic cells of the anterior lobe of the pituitary to produce corticotropic hormone (CTH) and other biologically active substances e.g. 2-endorphin, release of CRH is affected by serum levels of cortisol, by stress and by the sleep/wake cycle.\" [GOC:curators, PMID:11027914]","metadata":null},{"id":"a076c79d4d3a463585b4aa153b8a9633","type":"DRUG","name":"cortisol","canonical_id":"gtopdb:2868","description":null,"metadata":null},{"id":"7c575526938c446da095625822780c6c","type":"GO_TERM","name":"cortisol O-acetyltransferase activity","canonical_id":"go:GO:0047784","description":"\"Catalysis of the reaction: acetyl-CoA + cortisol = CoA + cortisol 21-acetate.\" [EC:2.3.1.27, RHEA:17073]","metadata":null},{"id":"a6edeb7dcf5b44fe8db4968b9aab79fb","type":"GO_TERM","name":"cortisol binding","canonical_id":"go:GO:1903794","description":"\"Binding to cortisol.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:18483153]","metadata":null},{"id":"d3b5b5a0b5134304bf846724ec23ecd0","type":"GO_TERM","name":"cortisol biosynthetic process","canonical_id":"go:GO:0034651","description":"\"The chemical reactions and pathways resulting in the formation of cortisol, the steroid hormone 11-beta-17,21-trihydroxypregn-4-ene-3,20-dione. Cortisol is synthesized from cholesterol in the adrenal gland and controls carbohydrate, fat and protein metabolism and has anti-inflammatory properties.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"129183a76c3e41bb887ebd9704a33365","type":"GO_TERM","name":"cortisol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0102196","description":"\"Catalysis of the reaction: cortisol + NADP+ = cortisone + NADPH + H+.\" [PMID:16216911, RHEA:68616]","metadata":null},{"id":"ec442b88ab9b429aae97a41330e80daf","type":"GO_TERM","name":"cortisol metabolic process","canonical_id":"go:GO:0034650","description":"\"The chemical reactions and pathways involving cortisol, the steroid hormone 11-beta-17,21-trihydroxypregn-4-ene-3,20-dione. Cortisol is synthesized from cholesterol in the adrenal gland and controls carbohydrate, fat and protein metabolism and has anti-inflammatory properties.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"ff4a37470ce540b09f11fc18afd9c967","type":"GO_TERM","name":"cortisol secretion","canonical_id":"go:GO:0043400","description":"\"The regulated release of cortisol, a steroid hormone that in humans is the major circulating hormone of the cortex, or outer layer, of the adrenal gland.\" [PMID:11027914]","metadata":null},{"id":"4fd99dccadcd456899e8b22a5f1c25bf","type":"GO_TERM","name":"cortisol sulfotransferase activity","canonical_id":"go:GO:0047785","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + cortisol = adenosine 3',5'-diphosphate + cortisol 21-sulfate + H+.\" [EC:2.8.2.18, RHEA:11884]","metadata":null},{"id":"e7fc0b23ca4640029cd3c0d6621dd667","type":"DRUG","name":"cortisone acetate","canonical_id":"mesh:D003348","description":null,"metadata":null},{"id":"6a75b219e3e64f1d92655b6d709b7a6d","type":"GO_TERM","name":"corydaline synthase activity","canonical_id":"go:GO:0050631","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 2 NADPH + palmatine = S-adenosyl-L-homocysteine + corydaline + 2 NADP+.\" [EC:2.1.1.147, RHEA:14773]","metadata":null},{"id":"41559a45316b429bb678647e1ec201e7","type":"DRUG","name":"cosibelimab","canonical_id":"gtopdb:13676","description":null,"metadata":null},{"id":"833d70eb5c454f8a81c1edd7ac48e45c","type":"DRUG","name":"cosibelimab","canonical_id":"chembl:CHEMBL4297729","description":null,"metadata":null},{"id":"c1087b2ee5274ff6a29e2cf528baee22","type":"COMBINATION_TREATMENT","name":"cosibelimab + ublituximab","canonical_id":"ctgov_combo:ctgov-combo-828618a56f782b33","description":null,"metadata":null},{"id":"ac561db019544dc6b1762f49942f3ad0","type":"GO_TERM","name":"costamere","canonical_id":"go:GO:0043034","description":"\"Regular periodic sub membranous arrays of vinculin in skeletal and cardiac muscle cells, these arrays link Z-discs to the sarcolemma and are associated with links to extracellular matrix.\" [GOC:jl, GOC:mtg_muscle, ISBN:0198506732, PMID:6405378]","metadata":null},{"id":"44cd1fbf6feb40c58ee060a948a25934","type":"GO_TERM","name":"costunolide 3beta-hydroxylase activity","canonical_id":"go:GO:0102628","description":"\"Catalysis of the reaction: (+)-costunolide (12,6alpha) + reduced [NADPH-hemoprotein reductase] + dioxygen = 3beta-hydroxycostunolide + oxidized [NADPH-hemoprotein reductase] + H2O.\" [MetaCyc:RXN-15533]","metadata":null},{"id":"c1a9018e6c8645efba69db4d2dc4d0c5","type":"GO_TERM","name":"costunolide synthase activity","canonical_id":"go:GO:0102934","description":"\"Catalysis of the reaction: germacra-1(10),4,11(13)-trien-12-oate + O2 + NADPH + 2 H+ = costunolide + 2 H2O + NADP.\" [GOC:pz, RHEA:28230]","metadata":null},{"id":"0d67eff3c85c4273a696260d1b348a8a","type":"DRUG","name":"cosyntropin","canonical_id":"gtopdb:6965","description":null,"metadata":null},{"id":"ebeb8fbb02b9487abfa9a5e141b6a8dd","type":"DRUG","name":"cosyntropin","canonical_id":"chembl:CHEMBL2103784","description":null,"metadata":null},{"id":"9d74ecd167024e3c88d1e3f573cd0aec","type":"COMBINATION_TREATMENT","name":"cosyntropin + metyrapone","canonical_id":"ctgov_combo:ctgov-combo-5cd7b2360c488aed","description":null,"metadata":null},{"id":"4e89c59cf9fd4e858e3adff4cb3bd847","type":"COMBINATION_TREATMENT","name":"cosyntropin + vigabatrin","canonical_id":"ctgov_combo:ctgov-combo-225ca11979d50f23","description":null,"metadata":null},{"id":"8589e3dd7281477e9ce5872eeabfdf22","type":"GO_TERM","name":"cotranscriptional mitochondrial rRNA nucleotide insertion","canonical_id":"go:GO:0002110","description":"\"The insertion of one or two non-coded nucleotides during the transcription of a mitochondrial rRNA. Such additions are known to occur in myxomycetes such as Physarum, Didymium, and Stemonitis.\" [GOC:curators, ISBN:1555811337, PMID:8306965]","metadata":null},{"id":"717ae3f64f054a3b91a84d1840a7bdaf","type":"GO_TERM","name":"cotranslational protein targeting to membrane","canonical_id":"go:GO:0006613","description":"\"The targeting of proteins to a membrane that occurs during translation. The transport of most secretory proteins, particularly those with more than 100 amino acids, into the endoplasmic reticulum lumen occurs in this manner, as does the import of some proteins into mitochondria.\" [ISBN:0716731363, PMID:10512867, PMID:16896215]","metadata":null},{"id":"10db2682c6e64dc5ba1f4e583f9e28d0","type":"GO_TERM","name":"cotyledon boundary formation","canonical_id":"go:GO:0090451","description":"\"The process in which boundaries between a cotyledon and the surrounding tissue are established and maintained.\" [GOC:tb]","metadata":null},{"id":"0a7a7a92507647219f747ada33ca1ed4","type":"GO_TERM","name":"cotyledon development","canonical_id":"go:GO:0048825","description":"\"The process whose specific outcome is the progression of the cotyledon over time, from its formation to the mature structure. The cotyledon is the modified leaf (seed leaf), found as part of the embryo in plant seeds. It is involved in either storage or absorption of food reserves. Dicotyledonous seeds contain two cotyledons, while monocotyledonous seeds contain only one. The cotyledons may appear above ground and show photosynthetic activity in the seedling.\" [GOC:devbiol, GOC:tb, PO:0020030]","metadata":null},{"id":"5dd071293c4244be859baa3176116eb6","type":"GO_TERM","name":"cotyledon morphogenesis","canonical_id":"go:GO:0048826","description":"\"The process in which the anatomical structures of the cotyledon are generated and organized. The cotyledon is the modified leaf (seed leaf), found as part of the embryo in plant seeds. It is involved in either storage or absorption of food reserves. Dicotyledonous seeds contain two cotyledons, while monocotyledonous seeds contain only one. The cotyledons may appear above ground and show photosynthetic activity in the seedling.\" [GOC:devbiol, GOC:tb, PO:0020030]","metadata":null},{"id":"4ff6dfc98c0a4711b70daee7800c0e49","type":"GO_TERM","name":"cotyledon vascular tissue pattern formation","canonical_id":"go:GO:0010588","description":"\"Vascular tissue pattern formation as it occurs in the cotyledon of vascular plants.\" [PMID:10559439]","metadata":null},{"id":"e8708311aee34fe4b0e671efbbc68ae4","type":"GO_TERM","name":"coumarin 7-hydroxylase activity","canonical_id":"go:GO:0008389","description":"\"Catalysis of the reaction: coumarin + O2 + NADPH + H+ = hydroxycoumarin + H2O + NADP+.\" [PMID:10490589, PMID:2733794]","metadata":null},{"id":"c4ebbf8fc4e34b8f980f1ffa1e7c8053","type":"GO_TERM","name":"coumarin biosynthetic process","canonical_id":"go:GO:0009805","description":"\"The chemical reactions and pathways resulting in the formation of coumarins, a class of compounds derived from the phenylacrylic skeleton of cinnamic acids.\" [GOC:lr, GOC:yl]","metadata":null},{"id":"a83fb1541fc94950b2354e7db3ff0c00","type":"GO_TERM","name":"coumarin catabolic process","canonical_id":"go:GO:0046226","description":"\"The chemical reactions and pathways resulting in the breakdown of coumarins, compounds derived from the phenylacrylic skeleton of cinnamic acids.\" [GOC:ai]","metadata":null},{"id":"3e02f00a47c048e780f095c004530d82","type":"GO_TERM","name":"coumarin metabolic process","canonical_id":"go:GO:0009804","description":"\"The chemical reactions and pathways involving coumarins, compounds derived from the phenylacrylic skeleton of cinnamic acids.\" [GOC:lr, GOC:yl]","metadata":null},{"id":"d39540b71b5141c7b287c65cd26cdb4a","type":"GO_TERM","name":"counting factor complex","canonical_id":"go:GO:0140451","description":"\"A secreted multiprotein complex composed of 4 proteins, regulating group size during aggregation in cooperative development. An example of this complex is found in Dictyostelium discoideum.\" [PMID:10444594, PMID:12117815, PMID:12912898, PMID:16963635, PMID:18426773]","metadata":null},{"id":"f9dcab756b7947a4a0eec4ff7141bc91","type":"GO_TERM","name":"courtship behavior","canonical_id":"go:GO:0007619","description":"\"The behavior of an organism for the purpose of attracting sexual partners.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"7a908d9bab0d4a699c147a96d76ac0ae","type":"DISEASE","name":"covid-19","canonical_id":"mesh:D000086382","description":null,"metadata":null},{"id":"d3e980f72ae741e9ba05cc1b6f059dde","type":"GO_TERM","name":"cranial ganglion development","canonical_id":"go:GO:0061550","description":"\"The process whose specific outcome is the progression of a cranial ganglion over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"e960280c2e8c41d6813904e933d190a6","type":"GO_TERM","name":"cranial ganglion formation","canonical_id":"go:GO:0061560","description":"\"The process that gives rise to a cranial ganglion. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:dph]","metadata":null},{"id":"24bf3ad46b7b49579b85fb2ca8c98e81","type":"GO_TERM","name":"cranial ganglion maturation","canonical_id":"go:GO:0061558","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a cranial ganglion to attain its fully functional state.\" [GOC:dph]","metadata":null},{"id":"9b67e8bd908544c2a1306b926c1d95a1","type":"GO_TERM","name":"cranial ganglion morphogenesis","canonical_id":"go:GO:0061559","description":"\"The process in which the anatomical structure of a cranial ganglion is generated and organized.\" [GOC:dph]","metadata":null},{"id":"0f0e9616fe474162a92c6b7b30afc674","type":"GO_TERM","name":"cranial ganglion structural organization","canonical_id":"go:GO:0061562","description":"\"The process that contributes to creating the structural organization of a cranial ganglion. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dph]","metadata":null},{"id":"56bba44e0d6e4763866e84887f6f2e6f","type":"GO_TERM","name":"cranial nerve development","canonical_id":"go:GO:0021545","description":"\"The process whose specific outcome is the progression of the cranial nerves over time, from its formation to the mature structure. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d29cfbd2d0754112a9f3d2f51504cda0","type":"GO_TERM","name":"cranial nerve formation","canonical_id":"go:GO:0021603","description":"\"The process that gives rise to the cranial nerves. This process pertains to the initial formation of a structure from unspecified parts. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"650ae7eee15846c3a86d71f7170f1280","type":"GO_TERM","name":"cranial nerve maturation","canonical_id":"go:GO:0021605","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a cranial nerve to attain its fully functional state. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"b31ff17e770c4b3596171a7a1dc25dc2","type":"GO_TERM","name":"cranial nerve morphogenesis","canonical_id":"go:GO:0021602","description":"\"The process in which the anatomical structure of the cranial nerves are generated and organized. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"86e6c436e99d41eb9f0d5bb33c7982b0","type":"GO_TERM","name":"cranial nerve structural organization","canonical_id":"go:GO:0021604","description":"\"The process that contributes to the act of creating the structural organization of the cranial nerves. This process pertains to the physical shaping of a rudimentary structure. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"bdd53385e5464a63b655c31f8b0ecf62","type":"GO_TERM","name":"cranial skeletal system development","canonical_id":"go:GO:1904888","description":"\"The process whose specific outcome is the progression of a cranial skeletal system over time, from its formation to the mature structure. The cranial skeletal system is the skeletal subdivision of the head, and includes the skull (cranium plus mandible), pharyngeal and/or hyoid apparatus.\" [GO_REF:0000094, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11262227]","metadata":null},{"id":"ed3847e227fa437889d8e263d196b07a","type":"GO_TERM","name":"cranial suture morphogenesis","canonical_id":"go:GO:0060363","description":"\"The process in which any suture between cranial bones is generated and organized.\" [GOC:dph, GOC:pr, GOC:sl]","metadata":null},{"id":"82e99fd213f044338082ed29ca9a52bf","type":"GO_TERM","name":"craniofacial suture closure","canonical_id":"go:GO:0160048","description":"\"The process of fusing together the edges of a craniofacial suture.\" [PMID:33842480]","metadata":null},{"id":"b0d2598019f14e5a8eb1244dd96d536b","type":"GO_TERM","name":"craniofacial suture morphogenesis","canonical_id":"go:GO:0097094","description":"\"The process in which any suture between cranial and/or facial bones is generated and organized.\" [GOC:pr, GOC:sl, Wikipedia:Cranial_sutures, Wikipedia:Head_and_neck_anatomy#Musculoskeletal_system]","metadata":null},{"id":"efd69fae58b64722b38585dd4b5d9424","type":"DISEASE","name":"craniosynostosis","canonical_id":"mondo:0015469","description":null,"metadata":null},{"id":"1a2e949490fb41d88fcc6284c3ccfcac","type":"GO_TERM","name":"creatinase activity","canonical_id":"go:GO:0016980","description":"\"Catalysis of the reaction: creatine + H2O = sarcosine + urea.\" [EC:3.5.3.3, RHEA:22456]","metadata":null},{"id":"93cda2098f3a4210b449c53c7d57b575","type":"GO_TERM","name":"creatine biosynthetic process","canonical_id":"go:GO:0006601","description":"\"The chemical reactions and pathways resulting in the formation of creatine, N-[amino(imino)methyl]-N-methylglycine. Creatine is formed by a process beginning with amidino group transfer from L-arginine to glycine to form guanidinoacetate, followed by methyl group transfer from S-adenosyl-L-methionine to guanidinoacetate; it is then is phosphorylated to form a pool that stores high energy phosphate for the replenishment of ATP during periods of high, or fluctuating energy demand. In animals, most creatine is transported to and used in muscle.\" [GOC:mah, MetaCyc:GLYCGREAT-PWY]","metadata":null},{"id":"dac7259df9664274a017af3216152af3","type":"GO_TERM","name":"creatine kinase activity","canonical_id":"go:GO:0004111","description":"\"Catalysis of the reaction: ATP + creatine = N-phosphocreatine + ADP + 2 H+.\" [EC:2.7.3.2, RHEA:17157]","metadata":null},{"id":"fee51060d4774c6aa315c50be7e8189c","type":"GO_TERM","name":"creatine kinase complex","canonical_id":"go:GO:0002185","description":"\"A protein complex having creatine kinase activity.\" [GOC:hjd]","metadata":null},{"id":"9ac23eb1d6f94fab9b4722f5f71a3d0d","type":"GO_TERM","name":"creatine metabolic process","canonical_id":"go:GO:0006600","description":"\"The chemical reactions and pathways involving creatine (N-(aminoiminomethyl)-N-methylglycine), a compound synthesized from the amino acids arginine, glycine, and methionine that occurs in muscle.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"afad0224725d45bead78e4f244885836","type":"GO_TERM","name":"creatine transmembrane transport","canonical_id":"go:GO:0015881","description":"\"The directed movement of creatine across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"7c0a511d12e34fca95bde697902137cb","type":"GO_TERM","name":"creatine transmembrane transporter activity","canonical_id":"go:GO:0005308","description":"\"Enables the transfer of creatine from one side of a membrane to the other. Creatine is a compound synthesized from the amino acids arginine, glycine, and methionine that occurs in muscle.\" [GOC:ai]","metadata":null},{"id":"eb3b2e667a9e47dca205434da97f5f08","type":"GO_TERM","name":"creatine:sodium symporter activity","canonical_id":"go:GO:0005309","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: creatine(out) + Na+(out) = creatine(in) + Na+(in).\" [TC:2.A.22.3.4]","metadata":null},{"id":"141e4d11dad547eb9e4daa890a02f640","type":"GO_TERM","name":"creatininase activity","canonical_id":"go:GO:0047789","description":"\"Catalysis of the reaction: creatinine + H2O = creatine.\" [EC:3.5.2.10, RHEA:14533]","metadata":null},{"id":"37c34021fd8b4c6aa7db99e26088fac9","type":"GO_TERM","name":"creatinine catabolic process","canonical_id":"go:GO:0006602","description":"\"The chemical reactions and pathways resulting in the breakdown of creatinine, 2-amino-1,5-dihydro-1-methyl-4H-imidazol-4-one, an end product of creatine metabolism and a normal constituent of urine.\" [ISBN:0198506732]","metadata":null},{"id":"1d1b8807bd8e479792550eb9de75a6e1","type":"GO_TERM","name":"creatinine deaminase activity","canonical_id":"go:GO:0047790","description":"\"Catalysis of the reaction: creatinine + H2O + H+ = N-methylhydantoin + NH4+.\" [RHEA:12681]","metadata":null},{"id":"0f19ea07d6aa4a5ba5696eeb5d8c204a","type":"GO_TERM","name":"creatinine metabolic process","canonical_id":"go:GO:0046449","description":"\"The chemical reactions and pathways involving creatinine, 2-amino-1,5-dihydro-1-methyl-4H-imidazol-4-one, an end product of creatine metabolism and a normal constituent of urine.\" [ISBN:0198506732]","metadata":null},{"id":"113aa25a65794f05a1ff9ccf477c1739","type":"GO_TERM","name":"cresol catabolic process","canonical_id":"go:GO:0046199","description":"\"The chemical reactions and pathways resulting in the breakdown of cresol, a mixture of the aromatic alcohol isoforms o-, p-, and m-cresol, which is obtained from coal tar or petroleum. The isomers are used as disinfectants, textile scouring agents, surfactants and as intermediates in the manufacture of salicylaldehyde, coumarin, and herbicides as well as being a major component of creosote.\" [GOC:ai]","metadata":null},{"id":"7ba81b10f7544a6d8cb40e9ee7fce147","type":"GO_TERM","name":"crinophagy","canonical_id":"go:GO:0160155","description":"\"The autophagic process which involves the direct fusion of abnormal, excess or obsolete secretory granules with lysosomes. This pathway is often associated with maintaining homeostasis in endocrine and exocrine cells.\" [PMID:29066608, PMID:35452619]","metadata":null},{"id":"fe79668dac5447e4b5181a07d8a33700","type":"DRUG","name":"crisaborole","canonical_id":"mesh:C543085","description":null,"metadata":null},{"id":"daa026f8da184e8d85e44df9bf185319","type":"GO_TERM","name":"cristae formation","canonical_id":"go:GO:0042407","description":"\"The assembly of cristae, the inwards folds of the inner mitochondrial membrane.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"4ac94c47b21b459b9f4995d0f0f7c57b","type":"DRUG","name":"crizotinib","canonical_id":"gtopdb:4903","description":null,"metadata":null},{"id":"62645264bffa430883024ca7b6bb2d4e","type":"DRUG","name":"crizotinib","canonical_id":"chembl:CHEMBL601719","description":null,"metadata":null},{"id":"f58a6a6c869a4b1eaf45b8377aab0b93","type":"COMBINATION_TREATMENT","name":"crizotinib + esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-049f3c35e4e88152","description":null,"metadata":null},{"id":"a3ac4db3772f41ac94316ac93815f863","type":"COMBINATION_TREATMENT","name":"crizotinib + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-3b13ae91f40feee8","description":null,"metadata":null},{"id":"21417bac598148a4bd5a7fd89f339609","type":"COMBINATION_TREATMENT","name":"crizotinib + palbociclib + selumetinib","canonical_id":"ctgov_combo:ctgov-combo-bce8ed5e91c6dc80","description":null,"metadata":null},{"id":"b2ffac5b595d4df293bdbe6061221b55","type":"COMBINATION_TREATMENT","name":"crizotinib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-4fc19de5364bede4","description":null,"metadata":null},{"id":"4dba8799e0d74220932bc787e4803ef3","type":"DRUG","name":"crofelemer","canonical_id":"gtopdb:7453","description":null,"metadata":null},{"id":"b694856e93144f96a7d59ee545ee09df","type":"DRUG","name":"crofelemer","canonical_id":"chembl:CHEMBL2108184","description":null,"metadata":null},{"id":"3ebea6c725574614a9d2c9a4785004a5","type":"COMBINATION_TREATMENT","name":"crofelemer + neratinib","canonical_id":"ctgov_combo:ctgov-combo-eca4f6b5db4eb4f8","description":null,"metadata":null},{"id":"9d0258be178a4af7ba5b896e13cbd68d","type":"DRUG","name":"cromoglicic acid","canonical_id":"mesh:D004205","description":null,"metadata":null},{"id":"b71b524e352a4a4db5b20341da70b792","type":"GO_TERM","name":"cross-receptor inhibition within G protein-coupled receptor heterodimer","canonical_id":"go:GO:0038041","description":"\"Inhibition of one protomer of a G protein-coupled receptor (GPCR) heterodimer by the associated subunit. For example, agonist activation of one cytokine receptor can prevent activation of its associated cytokine receptor subunit.\" [GOC:al, GOC:bf, PMID:15979374]","metadata":null},{"id":"54ae7d7320774e9585e6f4ef269c4720","type":"GO_TERM","name":"crossed form four-way junction DNA binding","canonical_id":"go:GO:0000402","description":"\"Binding to a DNA segment containing the crossed form of a four-way junction, also known as a Holliday junction, a structure where two DNA double strands are held together by reciprocal exchange of two of the four strands, one strand each from the two original helices. The crossed form of a four-way junction cannot be diagrammed without any of the strands crossing over, and instead contains a single crossover between two of the strands.\" [GOC:krc, ISBN:0815332181, PMID:15563464]","metadata":null},{"id":"4ae21116e0644e5f960f0121cdd11d95","type":"GO_TERM","name":"crossover junction DNA endonuclease activity","canonical_id":"go:GO:0008821","description":"\"Catalysis of the endonucleolytic cleavage at a junction such as a reciprocal single-stranded crossover between two homologous DNA duplexes (Holliday junction).\" [EC:3.1.21.10]","metadata":null},{"id":"3700d805ee57499c8b99e1ccc2c00145","type":"GO_TERM","name":"crotonobetaine-CoA ligase activity","canonical_id":"go:GO:0051109","description":"\"Catalysis of the reaction: (R)-carnitine + ATP + CoA = (R)-carnitinyl-CoA + AMP + diphosphate. Also catalyzes the transfer of CoA to crotonobetaine and gamma-butyrobetaine.\" [EC:6.2.1.48]","metadata":null},{"id":"73057831a6dc4460bd6a11b0e7929650","type":"GO_TERM","name":"crotonobetainyl-CoA hydratase activity","canonical_id":"go:GO:0140427","description":"\"Catalysis of the reaction: (R)-carnitinyl-CoA = crotonobetainyl-CoA + H2O.\" [RHEA:28338]","metadata":null},{"id":"ba6fe8e47dbc4728a95bf68d8a6e7e37","type":"GO_TERM","name":"crotonyl-CoA reductase activity","canonical_id":"go:GO:0043880","description":"\"Catalysis of the reaction: butanoyl-CoA + NADP+ = (2E)-butenoyl-CoA + NADPH + H+. (2E)-butenoyl-CoA is also called crotonyl-CoA.\" [PMID:11162231, RHEA:27906]","metadata":null},{"id":"acca8436d6324c26b848a01a97fa191a","type":"GO_TERM","name":"crying behavior","canonical_id":"go:GO:0060273","description":"\"The behavior in which an organism sheds tears, often accompanied by non-verbal vocalizations and in response to external or internal stimuli.\" [GOC:dph]","metadata":null},{"id":"3e56f14ad4b8400aa69e40634f1ebe2f","type":"DISEASE","name":"cryopyrin-associated periodic syndrome","canonical_id":"mondo:0016168","description":null,"metadata":null},{"id":"1bc8c0d9837d4ac19e4b1e9d62765689","type":"GO_TERM","name":"crystal cell differentiation","canonical_id":"go:GO:0042688","description":"\"The process in which a hemocyte precursor cell acquires the characteristics of a crystal cell, a class of cells that contain crystalline inclusions and are involved in the melanization of pathogenic material in the hemolymph.\" [GOC:bf, http://sdb.bio.purdue.edu/fly/gene/serpent3.htm]","metadata":null},{"id":"3091b2428e4d423a8ed025cee744aa3c","type":"GO_TERM","name":"crystalloid","canonical_id":"go:GO:0044312","description":"\"A transient, cytoplasmic organelle found in Plasmodium species that resembles a cytoplasmic inclusion body and whose function is poorly understood. Crystalloids form in ookinetes and disappear after ookinete-to-oocyst transformation.\" [GOC:jl, PMID:19932717]","metadata":null},{"id":"f5470f4377ac49a8978f578112cfc32a","type":"GO_TERM","name":"cspyrone B1 biosynthetic process","canonical_id":"go:GO:1900802","description":"\"The chemical reactions and pathways resulting in the formation of cspyrone B1.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e92e79aab3764d5f83eed2c02d2c88b8","type":"GO_TERM","name":"cspyrone B1 catabolic process","canonical_id":"go:GO:1900801","description":"\"The chemical reactions and pathways resulting in the breakdown of cspyrone B1.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8c227afb8dc44a9ba62208ea77b84358","type":"TRIAL","name":"ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab","canonical_id":"clinicaltrials.gov:NCT07504796","description":"Metastatic Melanoma; Advanced Melanoma","metadata":null},{"id":"0745a1991c7a4d1294177ea93638d397","type":"GO_TERM","name":"cucurbitadienol synthase activity","canonical_id":"go:GO:0034076","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = cucurbitadienol.\" [PMID:18033581, RHEA:30999]","metadata":null},{"id":"26f173f7c6a342ebbfd219f1487b5825","type":"GO_TERM","name":"cullin family protein binding","canonical_id":"go:GO:0097602","description":"\"Binding to a member of the cullin family, hydrophobic proteins that act as scaffolds for ubiquitin ligases (E3).\" [GOC:ha, InterPro:IPR016158, PMID:18698375]","metadata":null},{"id":"becd3c9b85764cbdab8c57303184596d","type":"GO_TERM","name":"cullin-RING ubiquitin ligase complex","canonical_id":"go:GO:0031461","description":"\"Any ubiquitin ligase complex in which the catalytic core consists of a member of the cullin family and a RING domain protein; the core is associated with one or more additional proteins that confer substrate specificity.\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"9f27421619b64ae29da2d99312fc7f49","type":"GO_TERM","name":"culmination involved in sorocarp development","canonical_id":"go:GO:0031154","description":"\"The process whose specific outcome is the progression of the culminant over time, from its formation to the mature structure. Culmination begins with a morphogenetic change of the finger-like or migratory slug giving rise to an organized structure containing a stalk and a sorus. This process is the final stage of sorocarp development.\" [GOC:mah, GOC:mtg_sensu, ISBN:0521583640]","metadata":null},{"id":"467eb4483eb74023897f2ab3d398c9b8","type":"GO_TERM","name":"culmorin biosynthetic process","canonical_id":"go:GO:0106210","description":"\"The chemical reactions and pathways resulting in the formation of culmorin, a sesquiterpenoid fungal metabolite and mycotoxin produced by some ascomycete species such as Fusarium culmorum, F. graminearum, F. venenatum and Leptosphaeria oraemaris.\" [GOC:ach, PMID:19880637, PMID:26673640]","metadata":null},{"id":"990150528b934661a475a9fba6c7cda1","type":"GO_TERM","name":"cumulus cell differentiation","canonical_id":"go:GO:0001549","description":"\"The process in which a subpopulation of granulosa cells surrounding the oocyte acquires the specialized features of an ovarian cumulus cell.\" [PMID:30010832]","metadata":null},{"id":"d686ce35ce0246378ee60cb70d61b88e","type":"GO_TERM","name":"cuneatus tract morphogenesis","canonical_id":"go:GO:0021959","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the dorsal root ganglion towards target cells in the medulla. This axonal process is a member of those that make up the cuneatus tract, a group of axons that are from neurons involved in proprioception from the upper trunk and upper limb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12867698]","metadata":null},{"id":"0024988491e04ba1b7121339f4b1bca3","type":"GO_TERM","name":"cupric ion binding","canonical_id":"go:GO:1903135","description":"\"Binding to a cupric ion, copper(2+).\" [GO_REF:0000067, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24567322]","metadata":null},{"id":"b10ff707177c4cc6b406706df50ff98f","type":"GO_TERM","name":"cupric reductase (NADH) activity","canonical_id":"go:GO:0008823","description":"\"Catalysis of the reaction: 2 Cu2+ + NADH = 2 Cu+ + H+ + NAD+.\" [PMID:10510271, RHEA:66848]","metadata":null},{"id":"cf34c04eb0b44490927b2495a8b66dd1","type":"GO_TERM","name":"cuproptosis","canonical_id":"go:GO:0160119","description":"\"A programmed cell death process that is induced by intracellular copper accumulation.\" [PMID:35298263, PMID:35354936]","metadata":null},{"id":"acada7316d9e486e8e0572cb8c272273","type":"GO_TERM","name":"cuprous ion binding","canonical_id":"go:GO:1903136","description":"\"Binding to a cuprous ion, copper(1+).\" [GO_REF:0000067, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24567322]","metadata":null},{"id":"6a65a9a7a4d64d698ee3b6bee6a5adbf","type":"GO_TERM","name":"cupula development","canonical_id":"go:GO:0048887","description":"\"The process whose specific outcome is the progression of the cupula over time, from its formation to the mature structure. The cupula is secreted by mantle cells and the ciliary bundles of all of the hair cells of the neuromast are embedded in it. The cupula provides a mechanical linkage between the hair cells and the external hydrodynamic environment. The cupula of superficial neuromasts grows continuously, while the height of the cupula of canal neuromasts is limited by canal diameter.\" [ISBN:0125296509]","metadata":null},{"id":"0a3ffa6cd63e4919a7de38eb817cc4d7","type":"GO_TERM","name":"curcumin catabolic process","canonical_id":"go:GO:0036040","description":"\"The chemical reactions and pathways resulting in the breakdown of the polyphenol, curcumin.\" [PMID:21467222]","metadata":null},{"id":"8b289b4e1fab4b78b2f5c9fd19ef5e09","type":"GO_TERM","name":"curcumin reductase (NADP+) activity","canonical_id":"go:GO:0052849","description":"\"Catalysis of the reaction: 2 NADP+ + tetrahydrocurcumin = curcumin + 2 H+ + 2 NADPH.\" [RHEA:34815]","metadata":null},{"id":"26514cc59d764928ab7edc7a650546d3","type":"GO_TERM","name":"curcumin synthase activity","canonical_id":"go:GO:0102106","description":"\"Catalysis of the reaction: feruloylacetyl-CoA + feruloyl-CoA(4-) + H2O = curcumin + 2 coenzyme A(4-) + carbon dioxide.\" [EC:2.3.1.217, GOC:pz]","metadata":null},{"id":"1eca10ebb7a44c6a8d22df9f193e6ac8","type":"GO_TERM","name":"curli","canonical_id":"go:GO:0098774","description":"\"A proteinaceous extracellular fiber, produced by an enteric bacterium, that is involved in surface and cell-cell contacts that promote community behavior and host colonization.\" [PMID:16704339]","metadata":null},{"id":"af49ca00e16b48abad13ee46d2906938","type":"GO_TERM","name":"curli assembly","canonical_id":"go:GO:0098775","description":"\"The process of assembly of curli, extracellular fibers produced by enteric bacteria. This process occurs outside the cell, where it is coupled to secretion across the cell outer membrane via nucleation by elements of the transporter complex.\" [PMID:16704339]","metadata":null},{"id":"c84c4ea3d9ac4fe8bfacee9365e59213","type":"GO_TERM","name":"curli secretion complex","canonical_id":"go:GO:0062155","description":"\"A protein-containing complex that serves as a channel for the secretion of curli. Curli are a fibers that serve as a major component of the extracellular matrix of pellicle biofilms.\" [PMID:25219853]","metadata":null},{"id":"cda8834f3c584a28b29fb854296c0006","type":"GO_TERM","name":"curli subunit secretion coupled to curli assembly","canonical_id":"go:GO:0098778","description":"\"The secretion of soluble curli subunits through the outer membrane, coupled to nucleation of curli fiber formation at the membrane surface.\" [PMID:24080089]","metadata":null},{"id":"5d6cdaed4f7f4d28919e475b5701cb40","type":"DISEASE","name":"cutaneous lupus erythematosus","canonical_id":"mondo:0005282","description":null,"metadata":null},{"id":"b0c083345b894612b2d1319e0eaa6e95","type":"DISEASE","name":"cutaneous mastocytosis","canonical_id":"mondo:0019023","description":null,"metadata":null},{"id":"7475c5326eb0410ea14233cfeb93a97c","type":"DISEASE","name":"cutaneous melanoma","canonical_id":"mondo:0005012","description":null,"metadata":null},{"id":"ab5296c938b648c7876ae041a7f99a0c","type":"DISEASE","name":"cutaneous porphyria","canonical_id":"mondo:0009902","description":null,"metadata":null},{"id":"18db126e404d4230a59309c25ff8ff42","type":"DISEASE","name":"cutaneous squamous cell carcinoma","canonical_id":"efo:1001927","description":null,"metadata":null},{"id":"700908b7504d43ab80a66d8903f95a75","type":"GO_TERM","name":"cuticle development","canonical_id":"go:GO:0042335","description":"\"The chemical reactions and pathways resulting in the formation of a cuticle, the outer layer of some animals and plants, which acts to prevent water loss.\" [ISBN:0192800825]","metadata":null},{"id":"887be847723244b2bec6a3033aad106b","type":"GO_TERM","name":"cuticle development involved in chitin-based cuticle molting cycle","canonical_id":"go:GO:0042337","description":"\"The synthesis and deposition of a chitin-based non-cellular, hardened, or membranous secretion from an epithelial sheet, occurring as part of the molting cycle. An example of this is found in Drosophila melanogaster.\" [GOC:dph, GOC:jl, GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"cf47e7f714da4a0fb34e4faf31a35a5b","type":"GO_TERM","name":"cuticle development involved in collagen and cuticulin-based cuticle molting cycle","canonical_id":"go:GO:0042338","description":"\"Synthesis and deposition of a collagen and cuticulin-based noncellular, hardened, or membranous secretion from an epithelial sheet, occurring as part of the molting cycle. An example of this process is found in Caenorhabditis elegans.\" [GOC:mtg_sensu]","metadata":null},{"id":"43a8fea3eb254b07bf64d424c44ce24c","type":"GO_TERM","name":"cuticle hydrocarbon biosynthetic process","canonical_id":"go:GO:0006723","description":"\"The chemical reactions and pathways resulting in the formation of hydrocarbons that make up the cuticle, the outer layer of some animals and plants, which acts to prevent water loss.\" [GOC:ai]","metadata":null},{"id":"a73368fc30c8492badbedd4968d9688c","type":"GO_TERM","name":"cuticle pattern formation","canonical_id":"go:GO:0035017","description":"\"The regionalization process that gives rise to the patterns of cell differentiation in the cuticle.\" [GOC:bf]","metadata":null},{"id":"ee2b2f58bca44610ac2c8981b2e3a83b","type":"GO_TERM","name":"cuticle pigmentation","canonical_id":"go:GO:0048067","description":"\"Establishment of a pattern of pigment in the cuticle of an organism.\" [GOC:jid]","metadata":null},{"id":"2233bac2f83841e0a178f5cdcfe5dcd2","type":"GO_TERM","name":"cuticular extracellular matrix","canonical_id":"go:GO:0060102","description":"\"A collagen and cuticulin-based noncellular, multilayered structure that is synthesized by an underlying ectodermal (hypodermal) cell layer. The cuticle serves essential functions in body morphology, locomotion, and environmental protection. An example of this component is found in Caenorhabditis elegans.\" [GOC:dph, GOC:kmv, ISSN:15518507, PMID:12619137]","metadata":null},{"id":"5718fec6e42d43878774cd3196aaf491","type":"GO_TERM","name":"cuticular plate","canonical_id":"go:GO:0032437","description":"\"A dense network of actin filaments found beneath the apical cell surface of hair cells, and into which stereocilia are inserted.\" [PMID:12485990, PMID:2592408, PMID:8071151]","metadata":null},{"id":"cdeddb0cbacc480aa5361138a4ca17cf","type":"GO_TERM","name":"cutin biosynthetic process","canonical_id":"go:GO:0010143","description":"\"The chemical reactions and pathways resulting in the formation of cutin, a waxy substance, which combined with cellulose forms a substance nearly impervious to water and constituting the cuticle in plants.\" [ISBN:0028623819]","metadata":null},{"id":"3efa7974eef440c1ad937cf877498b4d","type":"GO_TERM","name":"cutin transport","canonical_id":"go:GO:0080051","description":"\"The directed movement of cutin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Cutin, which consists of C16-18 fatty acids, is the major component of the cuticle that covers the plant surface.\" [PMID:17951461]","metadata":null},{"id":"ed3b9ac7d6ed447a93a72e0715faaa06","type":"GO_TERM","name":"cutin-based cuticle development","canonical_id":"go:GO:0160062","description":"\"The process whose specific outcome is the progression of the cutin-based cuticle over time, from its formation to the mature structure. Cutin-based cuticle is an extracellular structure composed of a covalently linked macromolecular scaffold of cutin and a variety of organic solvent-soluble lipids that are collectively termed waxes. Such structures are found on the external face of polysaccharide cell walls in land plants.\" [PMID:23893170]","metadata":null},{"id":"1c19a48b2cb142aa82a46cbb3c87f9a1","type":"GO_TERM","name":"cutinase activity","canonical_id":"go:GO:0050525","description":"\"Catalysis of the reaction: cutin + H2O = cutin monomers.\" [EC:3.1.1.74, MetaCyc:3.1.1.74-RXN]","metadata":null},{"id":"4c8d147184684662aa3ff0c0eba25a2e","type":"GO_TERM","name":"cyanamide hydratase activity","canonical_id":"go:GO:0018820","description":"\"Catalysis of the reaction: urea = cyanamide + H2O.\" [EC:4.2.1.69, RHEA:23056]","metadata":null},{"id":"47837643bcb04d26b35747b65a30e280","type":"GO_TERM","name":"cyanamide metabolic process","canonical_id":"go:GO:0018890","description":"\"The chemical reactions and pathways involving cyanamide, NCNH2, a cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism.\" [GOC:curators]","metadata":null},{"id":"9055830722194121a1f4bc05beaf5680","type":"GO_TERM","name":"cyanate biosynthetic process","canonical_id":"go:GO:0046201","description":"\"The chemical reactions and pathways resulting in the formation of cyanate, NCO-, the anion of cyanic acid.\" [GOC:ai]","metadata":null},{"id":"65b272e0df2f45e596e60709922d1ac3","type":"GO_TERM","name":"cyanate catabolic process","canonical_id":"go:GO:0009440","description":"\"The chemical reactions and pathways resulting in the breakdown of cyanate, NCO-, the anion of cyanic acid.\" [ISBN:0198506732]","metadata":null},{"id":"928d94766c964b7d85a8cb7238c41206","type":"GO_TERM","name":"cyanate hydratase activity","canonical_id":"go:GO:0008824","description":"\"Catalysis of the reaction: cyanate + hydrogencarbonate + 3 H+ = NH4+ + 2 CO2.\" [RHEA:11120]","metadata":null},{"id":"b13b8ec395fc46a0acf339f61ed26db7","type":"GO_TERM","name":"cyanate transmembrane transporter activity","canonical_id":"go:GO:0015110","description":"\"Enables the transfer of cyanate, NCO-, the anion of cyanic acid, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"2559c5831dc64a569d0cbc3bea8c734c","type":"GO_TERM","name":"cyanate transport","canonical_id":"go:GO:0015704","description":"\"The directed movement of cyanate, NCO-, the anion of cyanic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"e00b8bead83d497db4e62e3e7f5ad6ac","type":"GO_TERM","name":"cyanelle","canonical_id":"go:GO:0009842","description":"\"A plastid that contains unstacked, phycobilisome-bearing thylakoid membranes and is surrounded by a double membrane with a peptidoglycan layer in the intermembrane space between the two envelope membranes. Cyanelles are characteristic of algae in the class Glaucophyta, and may represent an ancestral form of plastid.\" [ISBN:0521316871, ISBN:1402001894]","metadata":null},{"id":"103ef8260e1e4ca786e6058f638b8fca","type":"GO_TERM","name":"cyanelle envelope","canonical_id":"go:GO:0033112","description":"\"The double lipid bilayer enclosing the cyanelle and separating its contents from the rest of the cytoplasm; includes the intermembrane space.\" [GOC:mah]","metadata":null},{"id":"f6a4014dab8c4e2da21e1571babfaebe","type":"GO_TERM","name":"cyanelle inner membrane","canonical_id":"go:GO:0036012","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the cyanelle envelope; also faces the cyanelle stroma.\" [GOC:aa, PMID:18976493]","metadata":null},{"id":"5f3cee7fe5da49f69e5cd846e83ae034","type":"GO_TERM","name":"cyanelle intermembrane space","canonical_id":"go:GO:0036014","description":"\"The region between the inner and outer lipid bilayers of the cyanelle envelope; includes the peptidoglycan layer.\" [GOC:aa]","metadata":null},{"id":"60a1e3ac63174865ad5a3ad4bf426be5","type":"GO_TERM","name":"cyanelle membrane","canonical_id":"go:GO:0033113","description":"\"Either of the lipid bilayers that surround a cyanelle and form the cyanelle envelope.\" [GOC:ecd]","metadata":null},{"id":"3e4ff88253834b4b8aa5cf54fda57ca3","type":"GO_TERM","name":"cyanelle outer membrane","canonical_id":"go:GO:0036013","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the cyanelle envelope.\" [GOC:aa]","metadata":null},{"id":"bd0dab670b8b4fdc84b2bd2f55aa8454","type":"GO_TERM","name":"cyanelle ribonuclease P complex","canonical_id":"go:GO:0030679","description":"\"A ribonuclease P complex located in the cyanelle, where it catalyzes the 5' endonucleolytic cleavage of precursor tRNAs to yield mature tRNAs. The best characterized cyanelle ribonuclease P complex, from the alga Cyanophora paradoxa, contains a single RNA molecule that is necessary but not sufficient for catalysis, and several protein molecules.\" [GOC:mah, PMID:12045094]","metadata":null},{"id":"bb183c9a2c1f4b4599896a8621f4356b","type":"GO_TERM","name":"cyanelle stroma","canonical_id":"go:GO:0034060","description":"\"The space enclosed by the double membrane of a cyanelle.\" [GOC:rph]","metadata":null},{"id":"3b1eac04f4c14d8c953036f8db8585d7","type":"GO_TERM","name":"cyanelle thylakoid","canonical_id":"go:GO:0009843","description":"\"A thylakoid found in a cyanelle, which is a type of plastid found in certain algae. The cyanelle contains a photosynthetic membrane resembling that of cyanobacteria.\" [GOC:lr, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"1c3379af922c4f1687fbd3008f0539d0","type":"GO_TERM","name":"cyanelle thylakoid lumen","canonical_id":"go:GO:0033114","description":"\"The volume enclosed by a cyanelle thylakoid membrane.\" [GOC:mah]","metadata":null},{"id":"eeb66a967bcc404ab1a143caa0f02f52","type":"GO_TERM","name":"cyanelle thylakoid membrane","canonical_id":"go:GO:0033115","description":"\"The lipid bilayer membrane of any thylakoid within a cyanelle.\" [GOC:mah]","metadata":null},{"id":"d7a70b590ebe4ba08991ee6b22f48572","type":"GO_TERM","name":"cyanide biosynthetic process","canonical_id":"go:GO:0046202","description":"\"The chemical reactions and pathways resulting in the formation of cyanide, NC-, the anion of hydrocyanic acid. Cyanide is a potent inhibitor of respiration.\" [GOC:ai]","metadata":null},{"id":"ed832c7667de43d4b636252fd3e5c6c5","type":"GO_TERM","name":"cyanide catabolic process","canonical_id":"go:GO:0019500","description":"\"The chemical reactions and pathways resulting in the breakdown of cyanide, NC-, the anion of hydrocyanic acid. Cyanide is a potent inhibitor of respiration.\" [ISBN:0198506732]","metadata":null},{"id":"4a87d0a41b0141a4b7772be79c476c86","type":"GO_TERM","name":"cyanide hydratase activity","canonical_id":"go:GO:0030196","description":"\"Catalysis of the reaction: formamide = H2O + hydrogen cyanide.\" [EC:4.2.1.66, RHEA:21720]","metadata":null},{"id":"19d178af12d8413c83fae453829b5d72","type":"GO_TERM","name":"cyanide metabolic process","canonical_id":"go:GO:0019499","description":"\"The chemical reactions and pathways involving cyanide, NC-, the anion of hydrocyanic acid. Cyanide is a potent inhibitor of respiration, reacting with the ferric form of cytochrome aa3 and thus blocking the electron transport chain.\" [ISBN:0198506732]","metadata":null},{"id":"f39cbd8c10f1433994aa3bcd8eb02ca4","type":"GO_TERM","name":"cyanidin 3-O-[2''-O-(xylosyl)-6''-O-(p-coumaroyl) glucoside] 5-O-glucoside malonyltransferase activity","canonical_id":"go:GO:0102585","description":"\"Catalysis of the reaction: anthocyanin A3 + malonyl-CoA = anthocyanin A5 + CoA.\" [PMID:17292360, RHEA:72871]","metadata":null},{"id":"ea0fd6fe5b9e43baa44a14b703e9ec91","type":"GO_TERM","name":"cyanidin 3-O-galactosyltransferase activity","canonical_id":"go:GO:0102454","description":"\"Catalysis of the reaction: cyanidin + UDP-D-galactose = cyanidin 3-O-beta-D-galactoside betaine + UDP.\" [RHEA:35631]","metadata":null},{"id":"5d2230202ffc422ebcc15b7109099d28","type":"GO_TERM","name":"cyanidin 3-O-glucoside 2-O''-xylosyltransferase activity","canonical_id":"go:GO:0102580","description":"\"Catalysis of the reaction: cyanidin 3-O-beta-D-glucoside betaine + UDP-alpha-D-xylose = cyanidin 3-O-beta-D-sambubioside + UDP.\" [EC:2.4.2.51, GOC:pz]","metadata":null},{"id":"46f8d1ef0aca41879141d088af3e0315","type":"GO_TERM","name":"cyanidin 3-O-glucoside 2-O-glucuronosyltransferase activity","canonical_id":"go:GO:0102160","description":"\"Catalysis of the reaction: cyanidin 3-O-beta-D-glucoside betaine + UDP-alpha-D-glucuronate = H+ + cyanidin 3-O-beta-(2-O-beta-D-glucuronosyl)-beta-D-glucoside + UDP.\" [RHEA:28258]","metadata":null},{"id":"df78afeba5564ee7b96ab57522607676","type":"GO_TERM","name":"cyanidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose) activity","canonical_id":"go:GO:0102506","description":"\"Catalysis of the reaction: cyanidin 3-O-beta-D-glucoside betaine + 1-O-feruloyl-beta-D-glucose = cyanin betaine + ferulate + H+.\" [RHEA:35427]","metadata":null},{"id":"3a5edc19805947939516f37b6f7c1330","type":"GO_TERM","name":"cyanidin 3-O-glucoside 7-O-glucosyltransferase (acyl-glucose) activity","canonical_id":"go:GO:0102457","description":"\"Catalysis of the reaction: 1-O-(4-hydroxy-3-methoxybenzoyl)-beta-D-glucose + cyanidin 3-O-beta-D-glucoside = cyanidin 3,7-di-O-beta-D-glucoside + vanillate.\" [RHEA:35431]","metadata":null},{"id":"167b8b1baeb441eebdc1cc027c94bb7e","type":"GO_TERM","name":"cyanidin 3-O-glucoside biosynthetic process","canonical_id":"go:GO:0033485","description":"\"The chemical reactions and pathways resulting in the formation of cyanidin 3-O-glucoside, a basic anthocyanin responsible for red to magenta coloration of flowers and fruits.\" [GOC:mah, MetaCyc:PWY-5125]","metadata":null},{"id":"a4e5f01f80404dd4818f79b9270f6cc1","type":"GO_TERM","name":"cyanidin 3-O-glucoside metabolic process","canonical_id":"go:GO:1901038","description":"\"The chemical reactions and pathways involving cyanidin 3-O-beta-D-glucoside.\" [GOC:TermGenie, PMID:21899608]","metadata":null},{"id":"5e2ba6e3ec0447699324687fb47f2513","type":"GO_TERM","name":"cyanidin-3-rhamnosylglucoside 5-O-glucosyltransferase activity","canonical_id":"go:GO:0047214","description":"\"Catalysis of the reaction: cyanidin-3-O-D-rhamnosyl-(1,6)-D-glucoside + UDP-D-glucose = cyanidin-3-O-[D-rhamnosyl-(1,6)-D-glucoside]-5-O-D-glucoside + UDP.\" [EC:2.4.1.116, MetaCyc:2.4.1.116-RXN]","metadata":null},{"id":"32ed0cd0199f41d397e7f9a0e8276aea","type":"GO_TERM","name":"cyanoalanine nitrilase activity","canonical_id":"go:GO:0047427","description":"\"Catalysis of the reaction: 3-cyano-L-alanine + 2 H2O + H+ = L-aspartate + NH4.\" [RHEA:11188]","metadata":null},{"id":"f53768906c6c4e0ea2b02437bc110696","type":"GO_TERM","name":"cyanocobalamin reductase (cyanide-eliminating) (NADP+) activity","canonical_id":"go:GO:0033787","description":"\"Catalysis of the reaction: cob(I)alamin + hydrogen cyanide + NADP+ = cyanocob(III)alamin + H+ + NADPH.\" [RHEA:16113]","metadata":null},{"id":"b8c3354b52254413921fe19a14362e5e","type":"GO_TERM","name":"cyanogenic glycoside biosynthetic process","canonical_id":"go:GO:0019756","description":"\"The chemical reactions and pathways resulting in the formation of cyanogenic glycosides, any glycoside containing a cyano group that is released as hydrocyanic acid on acid hydrolysis; such compounds occur in the kernels of various fruits.\" [ISBN:0198506732]","metadata":null},{"id":"3eba3b4a8be04eaeb495d997a7bb3ad2","type":"GO_TERM","name":"cyanogenic glycoside catabolic process","canonical_id":"go:GO:0042342","description":"\"The chemical reactions and pathways resulting in the breakdown of cyanogenic glycosides, any glycoside containing a cyano group that is released as hydrocyanic acid on acid hydrolysis; such compounds occur in the kernels of various fruits.\" [ISBN:0198506732]","metadata":null},{"id":"0a8d990f84a44fbb803de5aa96234c91","type":"GO_TERM","name":"cyanohydrin beta-glucosyltransferase activity","canonical_id":"go:GO:0047792","description":"\"Catalysis of the reaction: UDP-glucose + (S)-4-hydroxymandelonitrile = UDP + (S)-4-hydroxy-mandelonitrile beta-D-glucoside.\" [EC:2.4.1.85]","metadata":null},{"id":"96be3aef99714ad788ff559bd6af626f","type":"GO_TERM","name":"cyanophore differentiation","canonical_id":"go:GO:0048774","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a cyanophore cell. Cyanophores are pigment cells derived from the neural crest. They contain a blue pigment of unknown chemical composition. The pigment is stored in fibrous organelles termed cyanosomes.\" [GOC:jid, GOC:mh]","metadata":null},{"id":"05088c55756d4f769e948a101af620a8","type":"GO_TERM","name":"cyanophycin synthetase activity","canonical_id":"go:GO:0043860","description":"\"Catalysis of the ATP-dependent polymerization of arginine and aspartate to multi-L-arginyl-poly-L-aspartic acid (cyanophycin; a water-insoluble reserve polymer).\" [GOC:jl]","metadata":null},{"id":"83ab998df24744e08be38e4ea32727eb","type":"GO_TERM","name":"cyanophycin synthetase activity (L-arginine-adding)","canonical_id":"go:GO:0071161","description":"\"Catalysis of the reaction: ATP + [L-Asp(4-L-Arg)]n-L-Asp + L-arginine = ADP + phosphate + [L-Asp(4-L-Arg)]n+1.\" [EC:6.3.2.30]","metadata":null},{"id":"ef5b369e6c6e441e8221556afc6cafc6","type":"GO_TERM","name":"cyanophycin synthetase activity (L-aspartate-adding)","canonical_id":"go:GO:0071160","description":"\"Catalysis of the reaction: ATP + [L-Asp(4-L-Arg)]n + L-Asp = ADP + phosphate + [L-Asp(4-L-Arg)]n-L-Asp.\" [EC:6.3.2.29]","metadata":null},{"id":"8d4f1746026947498027d10676fa263e","type":"GO_TERM","name":"cyanosome","canonical_id":"go:GO:0043701","description":"\"A tissue-specific, membrane-bounded cytoplasmic organelle within which an unknown blue pigment is localized. Cyanosomes are synthesized in cyanophores and are blue in appearance.\" [GOC:mh]","metadata":null},{"id":"82799d45987f4e74be8e9b358e7b8346","type":"GO_TERM","name":"cyanuric acid amidohydrolase activity","canonical_id":"go:GO:0018753","description":"\"Catalysis of the reaction: cyanurate + H2O = 1-carboxybiuret + H+.\" [EC:3.5.2.15]","metadata":null},{"id":"b420af5dabc74f6f9f7867eefda282de","type":"GO_TERM","name":"cyanuric acid catabolic process","canonical_id":"go:GO:0042200","description":"\"The chemical reactions and pathways resulting in the breakdown of cyanuric acid, a potential degradation product of triazine herbicides.\" [UM-BBD_pathwayID:cya]","metadata":null},{"id":"82e4c0d795994a73986d04db414e3b07","type":"DRUG","name":"cyclacillin","canonical_id":"mesh:D003493","description":null,"metadata":null},{"id":"541257afb7ec447faba97033ff057565","type":"GO_TERM","name":"cyclamate sulfohydrolase activity","canonical_id":"go:GO:0018789","description":"\"Catalysis of the reaction: cyclohexylsulfamate + H2O = cyclohexylamine + sulfate.\" [EC:3.10.1.2, RHEA:18481]","metadata":null},{"id":"d4cf1bea8a464ede99d678b6dfee9e81","type":"GO_TERM","name":"cyclase activator activity","canonical_id":"go:GO:0010853","description":"\"Binds to and increases the activity of an enzyme that catalyzes a ring closure reaction.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ab6d53f2f49c4c46b734204e951b006e","type":"GO_TERM","name":"cyclase activity","canonical_id":"go:GO:0009975","description":"\"Catalysis of a ring closure reaction.\" [ISBN:0198547684]","metadata":null},{"id":"8ef281992b6c4bb5b19e508a9739ee94","type":"GO_TERM","name":"cyclase inhibitor activity","canonical_id":"go:GO:0010852","description":"\"Binds to and decreases the activity of an enzyme that catalyzes a ring closure reaction.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e86de97cc68044c5be5f77d9ea6972ce","type":"GO_TERM","name":"cyclase regulator activity","canonical_id":"go:GO:0010851","description":"\"Binds to and modulates the activity of an enzyme that catalyzes a ring closure reaction.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d896418994ac4938aa146cde5b2413d4","type":"GO_TERM","name":"cyclic 2,3-bisphospho-D-glycerate biosynthetic process","canonical_id":"go:GO:1901369","description":"\"The chemical reactions and pathways resulting in the formation of cyclic 2,3-bisphospho-D-glyceric acid.\" [GOC:bf, GOC:crds, GOC:TermGenie, PMID:2226838]","metadata":null},{"id":"9d04ed55c7f549aabf335dc4dba9acef","type":"GO_TERM","name":"cyclic 2,3-diphosphoglycerate synthetase activity","canonical_id":"go:GO:0036356","description":"\"Catalysis of the reaction: 2,3-diphosphoglycerate (DPG) + ATP = cyclic 2,3-diphosphoglycerate (cDPG) + ADP + phosphate.\" [GOC:crds, PMID:2226838, PMID:8320225, PMID:9811660]","metadata":null},{"id":"0361614358d8423292fe020091cf63c9","type":"GO_TERM","name":"cyclic GMP-AMP binding","canonical_id":"go:GO:0140702","description":"\"Binding to cyclic GMP-AMP (cGAMP) nucleotide.\" [PMID:23258412]","metadata":null},{"id":"a0b3553d332049d095f43edf43136640","type":"GO_TERM","name":"cyclic GMP-AMP synthase activity","canonical_id":"go:GO:0140699","description":"\"Catalysis of the reaction: ATP + GTP = 2 diphosphate + cyclic GMP-AMP.\" [PMID:23258413]","metadata":null},{"id":"aaef564ad8814da1841c59270e304ad7","type":"DISEASE","name":"cyclic hematopoiesis","canonical_id":"mondo:0008090","description":null,"metadata":null},{"id":"43184e0f76a8469ca5d559ecbfb0f5bf","type":"GO_TERM","name":"cyclic nucleotide binding","canonical_id":"go:GO:0030551","description":"\"Binding to a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.\" [GOC:ai]","metadata":null},{"id":"284b6e96524d42c2bda0455e72942816","type":"GO_TERM","name":"cyclic nucleotide biosynthetic process","canonical_id":"go:GO:0009190","description":"\"The chemical reactions and pathways resulting in the formation of a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"de211a8d8e6e41d4897b9291eaab7753","type":"GO_TERM","name":"cyclic nucleotide catabolic process","canonical_id":"go:GO:0009214","description":"\"The chemical reactions and pathways resulting in the breakdown of a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f5f127afd7e244f9a2737820c7903f80","type":"GO_TERM","name":"cyclic nucleotide metabolic process","canonical_id":"go:GO:0009187","description":"\"The chemical reactions and pathways involving a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"095e02dfee914410aa3deaf7130a5388","type":"GO_TERM","name":"cyclic nucleotide phosphodiesterase activator activity","canonical_id":"go:GO:0170005","description":"\"Binds to and increases the activity of cyclic nucleotide phosphodiesterase.\" [PMID:6087882, PMID:6259174, PMID:6667031]","metadata":null},{"id":"3bb8b1a5697a433593d4c66e846a1543","type":"GO_TERM","name":"cyclic nucleotide transport","canonical_id":"go:GO:0070729","description":"\"The directed movement of a cyclic nucleotide, any nucleotide in which phosphate group is in diester linkage to two positions on the sugar residue, into, out of or within a cell.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"6a17501628bd4e2b986d39e3577e3754","type":"GO_TERM","name":"cyclic nucleotide-activated monoatomic ion channel activity","canonical_id":"go:GO:0043855","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a cyclic nucleotide has been bound by the channel complex or one of its constituent parts.\" [GOC:jl]","metadata":null},{"id":"be155429291b4291a172d79e69d15277","type":"GO_TERM","name":"cyclic nucleotide-dependent protein kinase activity","canonical_id":"go:GO:0004690","description":"\"cNMP-dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein.\" [GOC:mah]","metadata":null},{"id":"9d650bcdc57049bb9e014383d56b31e1","type":"GO_TERM","name":"cyclic nucleotide-gated mechanosensitive monoatomic ion channel activity","canonical_id":"go:GO:0043854","description":"\"Enables the transmembrane transfer of an monoatomic ion by a channel that opens in response to a mechanical stress and when a cyclic nucleotide has been bound by the channel complex or one of its constituent parts.\" [GOC:jl, PMID:22206667]","metadata":null},{"id":"31102771889e4ac7af4183def54b220f","type":"GO_TERM","name":"cyclic photosynthetic phosphorylation","canonical_id":"go:GO:0009778","description":"\"A photosynthetic phosphorylation process in which ATP synthesis is driven by a proton gradient generated across the thylakoid membrane. Involves only photosystem I.\" [ISBN:0198547684]","metadata":null},{"id":"98cf044f6e0349fdab5260655fb807f9","type":"GO_TERM","name":"cyclic purine nucleotide metabolic process","canonical_id":"go:GO:0052652","description":"\"The chemical reactions and pathways involving a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue and the base is a purine.\" [PMID:23911318]","metadata":null},{"id":"9d388f14634546189d9ac2ecc8b24c1f","type":"GO_TERM","name":"cyclic pyranopterin monophosphate synthase activity","canonical_id":"go:GO:0061799","description":"\"Catalysis of the reaction: (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate = cyclic pyranopterin phosphate + diphosphate.\" [GOC:dph, GOC:ik, PMID:25896388]","metadata":null},{"id":"bef1984ba27a41eb9d9074ce0984cb1e","type":"GO_TERM","name":"cyclic threonylcarbamoyladenosine biosynthetic process","canonical_id":"go:GO:0061504","description":"\"The chemical reactions and pathways resulting in the formation of cyclic threonylcarbamoyladenosine, a modified nucleoside found in some tRNA molecules.\" [PMID:23242255]","metadata":null},{"id":"dab3a4153c8d4c54ab1c762a01d7db84","type":"GO_TERM","name":"cyclic-GMP-AMP hydrolase activity","canonical_id":"go:GO:0106177","description":"\"Catalysis of the reaction: cyclic GMP-AMP + 2 H2O = AMP + GMP.\" [GOC:sp, PMID:25344812, RHEA:58808]","metadata":null},{"id":"32eb612ea4d8493c901bf9d2a274d228","type":"GO_TERM","name":"cyclic-GMP-AMP transmembrane import across plasma membrane","canonical_id":"go:GO:0140361","description":"\"The directed movement of cyclic-GMP-AMP from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:31126740]","metadata":null},{"id":"9d8ba51ff82e4645a1484d3c6eeebc3a","type":"GO_TERM","name":"cyclic-GMP-AMP transmembrane transporter activity","canonical_id":"go:GO:0140360","description":"\"Enables the transfer of cyclic-GMP-AMP from one side of a membrane to the other.\" [PMID:31126740]","metadata":null},{"id":"98af0fb844694f45a7c919748128cff4","type":"GO_TERM","name":"cyclic-di-AMP binding","canonical_id":"go:GO:0180001","description":"\"Binding to a cyclic di-AMP nucleotide.\" [PMID:32843560, PMID:36629470]","metadata":null},{"id":"ce8d85a2739e44868f1bb02a38a599f5","type":"GO_TERM","name":"cyclic-di-AMP phosphodiesterase activity","canonical_id":"go:GO:0106409","description":"\"Catalysis of the reaction: 3',3'-c-di-AMP + H2O = 5'-O-phosphonoadenylyl-(3'-5')-adenosine + H+.\" [PMID:21909268, RHEA:54420]","metadata":null},{"id":"b5c712a00af84812a261786b8296c3fe","type":"GO_TERM","name":"cyclic-di-GMP binding","canonical_id":"go:GO:0035438","description":"\"Binding to cyclic-di-GMP, cyclic dimeric guanosine monophosphate.\" [GOC:bf]","metadata":null},{"id":"4f06a6b3d61c4309a45be2260e4b55d7","type":"GO_TERM","name":"cyclic-di-GMP transmembrane transporter activity","canonical_id":"go:GO:0140927","description":"\"Enables the transfer of cyclic-di-GMP from one side of a membrane to the other.\" [PMID:34965418]","metadata":null},{"id":"98a455ad6a0046acb5c4caeb3b174d41","type":"GO_TERM","name":"cyclic-guanylate-specific phosphodiesterase activity","canonical_id":"go:GO:0071111","description":"\"Catalysis of the reaction: cyclic di-3',5'-guanylate + H2O = 5'-phosphoguanylyl(3'->5')guanosine + H+.\" [EC:3.1.4.52, RHEA:24902]","metadata":null},{"id":"8fb85639a6ed4cde9aac0288b4fb949a","type":"GO_TERM","name":"cyclic-nucleotide phosphodiesterase activity","canonical_id":"go:GO:0004112","description":"\"Catalysis of the reaction: a nucleoside cyclic phosphate + H2O = a nucleoside phosphate.\" [GOC:mah]","metadata":null},{"id":"cf3bc731a6474feca228d2b9581588c1","type":"GO_TERM","name":"cyclin A1-CDK1 complex","canonical_id":"go:GO:0097121","description":"\"A protein complex consisting of cyclin A1 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"0cf0ad29b24442029596e42067d550ce","type":"GO_TERM","name":"cyclin A1-CDK2 complex","canonical_id":"go:GO:0097123","description":"\"A protein complex consisting of cyclin A1 and cyclin-dependent kinase 2 (CDK2). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"b551bce857a347b394e802b3b036a7c6","type":"GO_TERM","name":"cyclin A2-CDK1 complex","canonical_id":"go:GO:0097122","description":"\"A protein complex consisting of cyclin A2 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"271ece83a5074e2ab326879d57d5a7c4","type":"GO_TERM","name":"cyclin A2-CDK2 complex","canonical_id":"go:GO:0097124","description":"\"A protein complex consisting of cyclin A2 and cyclin-dependent kinase 2 (CDK2). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"51c35ce55fa6435084da9246373df11a","type":"GO_TERM","name":"cyclin B1-CDK1 complex","canonical_id":"go:GO:0097125","description":"\"A protein complex consisting of cyclin B1 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"f64653bd5173479da0d63f271086b300","type":"GO_TERM","name":"cyclin B2-CDK1 complex","canonical_id":"go:GO:0097126","description":"\"A protein complex consisting of cyclin B2 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"c96720b952c04731af25be48271b6543","type":"GO_TERM","name":"cyclin B3-CDK2 complex","canonical_id":"go:GO:0097127","description":"\"A protein complex consisting of cyclin B3 and cyclin-dependent kinase 2 (CDK2). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"4d0b27bdf7b14d9080a875ef39389cfe","type":"GO_TERM","name":"cyclin D1-CDK4 complex","canonical_id":"go:GO:0097128","description":"\"A protein complex consisting of cyclin D1 and cyclin-dependent kinase 4 (CDK4). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"808d733aac334cc5ad619ee357e88fa3","type":"GO_TERM","name":"cyclin D1-CDK6 complex","canonical_id":"go:GO:0097131","description":"\"A protein complex consisting of cyclin D1 and cyclin-dependent kinase 6 (CDK6). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"338c1fa989864979a0311606b05bf1f9","type":"GO_TERM","name":"cyclin D2-CDK4 complex","canonical_id":"go:GO:0097129","description":"\"A protein complex consisting of cyclin D2 and cyclin-dependent kinase 4 (CDK4). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"c52b47bb42824bd89b447bc1c0248f50","type":"GO_TERM","name":"cyclin D2-CDK6 complex","canonical_id":"go:GO:0097132","description":"\"A protein complex consisting of cyclin D2 and cyclin-dependent kinase 6 (CDK6). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"5b0cd6a798394b688e85360b7c4616be","type":"GO_TERM","name":"cyclin D3-CDK4 complex","canonical_id":"go:GO:0097130","description":"\"A protein complex consisting of cyclin D3 and cyclin-dependent kinase 4 (CDK4). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"1082a0bc0b1f4a459bf5c8c5e47f4f59","type":"GO_TERM","name":"cyclin D3-CDK6 complex","canonical_id":"go:GO:0097133","description":"\"A protein complex consisting of cyclin D3 and cyclin-dependent kinase 6 (CDK6). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"bce22aa0f69c47ae9327d264d1df4f83","type":"GO_TERM","name":"cyclin E1-CDK2 complex","canonical_id":"go:GO:0097134","description":"\"A protein complex consisting of cyclin E1 and cyclin-dependent kinase 2 (CDK2). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"78adebd321c543b4af8dc4c2c6c62dc0","type":"GO_TERM","name":"cyclin E2-CDK2 complex","canonical_id":"go:GO:0097135","description":"\"A protein complex consisting of cyclin E2 and cyclin-dependent kinase 2 (CDK2). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [GOC:so, PMID:15935619]","metadata":null},{"id":"5989fa4bfe774a30a4671a3a051a98b1","type":"GO_TERM","name":"cyclin K-CDK12 complex","canonical_id":"go:GO:0002944","description":"\"A protein complex consisting of cyclin Kand cyclin-dependent kinase 12 (CDK12). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [PMID:22012619]","metadata":null},{"id":"fb51289556194be7973680f64380157a","type":"GO_TERM","name":"cyclin K-CDK13 complex","canonical_id":"go:GO:0002945","description":"\"A protein complex consisting of cyclin Kand cyclin-dependent kinase 13 (CDK13). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [PMID:22012619]","metadata":null},{"id":"27ee093fbbed4400ad9c4f19aa16532f","type":"GO_TERM","name":"cyclin L-CDK11 complex","canonical_id":"go:GO:0180038","description":"\"A protein complex consisting of cyclin L and cyclin-dependent kinase 11 (CDK11). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.\" [PMID:23122962, PMID:32446654]","metadata":null},{"id":"b22e7cc57a084a77a2cc55a4702ec018","type":"GO_TERM","name":"cyclin binding","canonical_id":"go:GO:0030332","description":"\"Binding to cyclins, proteins whose levels in a cell varies markedly during the cell cycle, rising steadily until mitosis, then falling abruptly to zero. As cyclins reach a threshold level, they are thought to drive cells into G2 phase and thus to mitosis.\" [GOC:ai]","metadata":null},{"id":"9c3dd5668c8341eba2fce830cbf09858","type":"GO_TERM","name":"cyclin-dependent protein kinase activity","canonical_id":"go:GO:0097472","description":"\"Cyclin-dependent catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.\" [GOC:pr]","metadata":null},{"id":"2d30fe6874b748fcb9eb516ece72a0d4","type":"GO_TERM","name":"cyclin-dependent protein kinase holoenzyme complex","canonical_id":"go:GO:0000307","description":"\"Cyclin-dependent protein kinases (CDKs) are enzyme complexes that contain a kinase catalytic subunit associated with a regulatory cyclin partner.\" [GOC:krc, PMID:11602261]","metadata":null},{"id":"5ae5c7cd4aa7458b9e53be091bbe6e72","type":"GO_TERM","name":"cyclin-dependent protein kinase regulator activity","canonical_id":"go:GO:0019914","description":"\"Modulation of the activity of the enzyme cyclin-dependent protein kinase activating kinase.\" [GOC:ai]","metadata":null},{"id":"7b01d4d6ba7142b09239f245e887b739","type":"GO_TERM","name":"cyclin-dependent protein serine/threonine kinase activator activity","canonical_id":"go:GO:0061575","description":"\"Binds to and increases the activity of a cyclin-dependent protein serine/threonine kinase.\" [GOC:dph, PMID:2569363, PMID:3322810]","metadata":null},{"id":"c39eee6e55174ee7b15bac322b6dbd42","type":"GO_TERM","name":"cyclin-dependent protein serine/threonine kinase activity","canonical_id":"go:GO:0004693","description":"\"Cyclin-dependent catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.\" [GOC:pr, GOC:rn, PMID:7877684, PMID:9841670]","metadata":null},{"id":"69d0f9bb199f44239e579869ba12f205","type":"GO_TERM","name":"cyclin-dependent protein serine/threonine kinase inhibitor activity","canonical_id":"go:GO:0004861","description":"\"Binds to and stops, prevents or reduces the activity of a cyclin-dependent protein serine/threonine kinase.\" [GOC:mah, GOC:pr]","metadata":null},{"id":"2b3c1bd47fb04725a9a6594a7f19d97b","type":"GO_TERM","name":"cyclin-dependent protein serine/threonine kinase regulator activity","canonical_id":"go:GO:0016538","description":"\"Modulates the activity of a cyclin-dependent protein serine/threonine kinase, enzymes of the protein kinase family that are regulated through association with cyclins and other proteins.\" [GOC:pr, GOC:rn, PMID:7877684, PMID:9442875]","metadata":null},{"id":"51699e7962ff4b8680c0642cce6b97ab","type":"GO_TERM","name":"cyclin/CDK positive transcription elongation factor complex","canonical_id":"go:GO:0008024","description":"\"A transcription elongation factor complex that facilitates the transition from abortive to productive elongation by phosphorylating the CTD domain of the large subunit of DNA-directed RNA polymerase II, holoenzyme. Contains a cyclin and a cyclin-dependent protein kinase catalytic subunit.\" [GOC:bhm, GOC:vw, PMID:10766736, PMID:16721054, PMID:17079683, PMID:19328067, PMID:7759473]","metadata":null},{"id":"808deeee701e4de480e17a38c26b1ee8","type":"DRUG","name":"cyclizine","canonical_id":"gtopdb:7151","description":null,"metadata":null},{"id":"1cee6757b3ea4e5089c30848f94a3310","type":"DRUG","name":"cyclizine","canonical_id":"mesh:D003501","description":null,"metadata":null},{"id":"693fd69236b6430f91c78094d8696fc5","type":"GO_TERM","name":"cyclo-ligase activity","canonical_id":"go:GO:0016882","description":"\"Catalysis of the joining of two groups within a single molecule via a carbon-nitrogen bond, forming heterocyclic ring, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"a42c6f1a070f430c9abbc722f4ab4e80","type":"GO_TERM","name":"cycloartenol 24-C-methyltransferase activity","canonical_id":"go:GO:0030796","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + cycloartenol = (24R)-24-methylcycloart-25-en-3beta-ol + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.142, RHEA:13137]","metadata":null},{"id":"2e2922c1e8c94e14990103adea1244f6","type":"GO_TERM","name":"cycloartenol synthase activity","canonical_id":"go:GO:0016871","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = cycloartenol.\" [EC:5.4.99.8, RHEA:21308]","metadata":null},{"id":"35d9cbdea8e048f98ad0bcd1ff1bd388","type":"DRUG","name":"cyclobenzaprine","canonical_id":"mesh:C004704","description":null,"metadata":null},{"id":"96105396c3c74aa98cb5c3e320274e7e","type":"GO_TERM","name":"cyclodextrin binding","canonical_id":"go:GO:2001073","description":"\"Binding to cyclodextrin.\" [GOC:mengo_curators]","metadata":null},{"id":"90f398069cd640ba95bc98d8b8c955ab","type":"GO_TERM","name":"cyclodextrin catabolic process","canonical_id":"go:GO:2000901","description":"\"The chemical reactions and pathways resulting in the breakdown of a cyclodextrin.\" [GOC:mengo_curators]","metadata":null},{"id":"041049dcafd6450d97c7716e8bfc9203","type":"GO_TERM","name":"cyclodextrin metabolic process","canonical_id":"go:GO:2000900","description":"\"The chemical reactions and pathways involving a cyclodextrin.\" [GOC:mengo_curators]","metadata":null},{"id":"6e6daf323bab41dc9e7d0d089736cbbe","type":"GO_TERM","name":"cycloeucalenol cycloisomerase activity","canonical_id":"go:GO:0047793","description":"\"Catalysis of the reaction: cycloeucalenol = obtusifoliol.\" [EC:5.5.1.9, RHEA:22800]","metadata":null},{"id":"f00ea786dcbe4d41b3032993a1f4a3b5","type":"GO_TERM","name":"cyclohexa-1,5-dienecarbonyl-CoA hydratase activity","canonical_id":"go:GO:0018823","description":"\"Catalysis of the reaction: cyclohexa-1,5-diene-1-carbonyl-CoA + H2O = 6-hydroxycyclohex-1-enecarbonyl-CoA.\" [EC:4.2.1.100, RHEA:21856]","metadata":null},{"id":"7584d3a1246f4b1eafe3e7f21daed726","type":"GO_TERM","name":"cyclohexadienyl dehydrogenase activity","canonical_id":"go:GO:0047794","description":"\"Catalysis of the reaction: L-arogenate + NAD+ = L-tyrosine + NADH + CO2.\" [EC:1.3.1.43]","metadata":null},{"id":"b1a9759ba81d4bd3b6f44605621aa3c3","type":"GO_TERM","name":"cyclohexane-1,2-diol dehydrogenase activity","canonical_id":"go:GO:0047795","description":"\"Catalysis of the reaction: trans-cyclohexane-1,2-diol + NAD+ = 2-hydroxycyclohexan-1-one + NADH.\" [EC:1.1.1.174, MetaCyc:CYCLOHEXANE-12-DIOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"3a482e8674c94cc19554fd07b4d0e910","type":"GO_TERM","name":"cyclohexane-1,3-dione hydrolase activity","canonical_id":"go:GO:0047796","description":"\"Catalysis of the reaction: cyclohexane-1,3-dione + H2O = 5-oxohexanoate + H+.\" [EC:3.7.1.10, RHEA:16473]","metadata":null},{"id":"3819b38c63b54469a7990e83c9c4522a","type":"GO_TERM","name":"cyclohexane-1-carboxylate catabolic process","canonical_id":"go:GO:0010129","description":"\"The chemical reactions and pathways resulting in the breakdown of cyclohexane-1-carboxylate, an alicyclic acid.\" [GOC:pz]","metadata":null},{"id":"553e7e846fd3408f8daa90aec05f0f3c","type":"GO_TERM","name":"cyclohexanol dehydrogenase activity","canonical_id":"go:GO:0018460","description":"\"Catalysis of the reaction: cyclohexanol + NAD+ = cyclohexanone + NADH + H+.\" [EC:1.1.1.245]","metadata":null},{"id":"0b7bb14933a54d1c93a6d5ad416f8e8a","type":"GO_TERM","name":"cyclohexanol oxidation","canonical_id":"go:GO:0019399","description":"\"The cyclohexanol metabolic process in which cyclohexanol is converted to adipate.\" [MetaCyc:CYCLOHEXANOL-OXIDATION-PWY]","metadata":null},{"id":"8ac99cd781514579941886eba761bf75","type":"GO_TERM","name":"cyclohexanone dehydrogenase activity","canonical_id":"go:GO:0047797","description":"\"Catalysis of the reaction: A + cyclohexanone = AH(2) + cyclohex-2-enone.\" [EC:1.3.99.14, RHEA:21780]","metadata":null},{"id":"2263e5e76c8542cda816a877a9fe28b6","type":"GO_TERM","name":"cyclohexanone monooxygenase activity","canonical_id":"go:GO:0018667","description":"\"Catalysis of the reaction: cyclohexanone + NADPH + H+ + O2 = 6-hexanolide + NADP+ + H2O.\" [EC:1.14.13.22]","metadata":null},{"id":"74368b5c6ef24954b9bf62121eaed49f","type":"GO_TERM","name":"cycloheximide transmembrane transporter activity","canonical_id":"go:GO:0015243","description":"\"Enables the transfer of cycloheximide from one side of a membrane to the other. Cycloheximide is an antibiotic produced by Streptomyces which interferes with protein synthesis in eukaryotes.\" [ISBN:0198506732]","metadata":null},{"id":"c706797ead3f4eff8f0cd94a260886e4","type":"GO_TERM","name":"cycloheximide transport","canonical_id":"go:GO:0015901","description":"\"The directed movement of cycloheximide into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Cycloheximide is an antibiotic produced by Streptomyces which interferes with protein synthesis in eukaryotes.\" [ISBN:0198506732]","metadata":null},{"id":"7d8dd2007a5148bb82982a634439c8e1","type":"GO_TERM","name":"cycloheximide:proton antiporter activity","canonical_id":"go:GO:0015309","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + cycloheximide(in) = H+(in) + cycloheximide(out).\" [TC:2.A.1.2.2]","metadata":null},{"id":"6401f9d31ae04685a05bce50336351ef","type":"GO_TERM","name":"cyclohexyl-isocyanide hydratase activity","canonical_id":"go:GO:0050549","description":"\"Catalysis of the reaction: N-cyclohexylformamide + H+ = cyclohexyl isocyanide + H2O.\" [EC:4.2.1.103, RHEA:18197]","metadata":null},{"id":"18379d72c53f42aaaa6380172e69fb86","type":"GO_TERM","name":"cyclohexylamine oxidase activity","canonical_id":"go:GO:0018527","description":"\"Catalysis of the reaction: cyclohexylamine + O2 + H2O = cyclohexanone + H2O2 + NH4+.\" [PMID:18451, RHEA:18433]","metadata":null},{"id":"f72a9ba63b5a4655baae768dcd9e67c0","type":"GO_TERM","name":"cyclohydrolase activity","canonical_id":"go:GO:0019238","description":"\"Catalysis of the hydrolysis of any non-peptide carbon-nitrogen bond in a cyclic amidine, a compound of the form R-C(=NH)-NH2, in a reaction that involves the opening of a ring.\" [GOC:mah]","metadata":null},{"id":"5d1f0405ad224d2e99918dc2af2bb8aa","type":"GO_TERM","name":"cyclomaltodextrin glucanotransferase activity","canonical_id":"go:GO:0043895","description":"\"Catalysis of the cyclization of part of a 1,4-alpha-D-glucan chain by formation of a 1,4-alpha-D-glucosidic bond.\" [EC:2.4.1.19]","metadata":null},{"id":"13c9a16ad7b746fe94b6af2f839ec55f","type":"GO_TERM","name":"cyclomaltodextrinase activity","canonical_id":"go:GO:0047798","description":"\"Catalysis of the reaction: H2O + cyclomaltodextrin = linear maltodextrin.\" [EC:3.2.1.54, MetaCyc:CYCLOMALTODEXTRINASE-RXN]","metadata":null},{"id":"6d61b988a0c54c9d911501f299150747","type":"GO_TERM","name":"cyclooxygenase pathway","canonical_id":"go:GO:0019371","description":"\"The chemical reactions and pathways by which prostaglandins are formed from arachidonic acid, and in which prostaglandin-endoperoxide synthase (cyclooxygenase) catalyzes the committed step in the conversion of arachidonic acid to the prostaglandin-endoperoxides PGG2 and PGH2.\" [PMID:19854273]","metadata":null},{"id":"0683d9448ff94175b7edcbbf876bcdfb","type":"GO_TERM","name":"cyclopentanol biosynthetic process","canonical_id":"go:GO:0033021","description":"\"The chemical reactions and pathways resulting in the formation of cyclopentanol.\" [GOC:mah, PMID:12406764]","metadata":null},{"id":"66fa21abf23140d1a2ba914743fc40a9","type":"GO_TERM","name":"cyclopentanol catabolic process","canonical_id":"go:GO:0033022","description":"\"The chemical reactions and pathways resulting in the breakdown of cyclopentanol.\" [GOC:mah, PMID:12406764]","metadata":null},{"id":"70c758b063a14d8d85e64eca88d52b63","type":"GO_TERM","name":"cyclopentanol dehydrogenase activity","canonical_id":"go:GO:0055041","description":"\"Catalysis of the reaction: cyclopentanol + NAD+ = cyclopentanone + H+ + NADH.\" [EC:1.1.1.163, RHEA:11728]","metadata":null},{"id":"543c47aeee9b4dee876e6f8e648c5a6a","type":"GO_TERM","name":"cyclopentanone monooxygenase activity","canonical_id":"go:GO:0047799","description":"\"Catalysis of the reaction: cyclopentanone + H+ + NADPH + O2 = 5-valerolactone + H2O + NADP+.\" [EC:1.14.13.16, RHEA:15737]","metadata":null},{"id":"dd67aa75336a4af5be1449a79f93328b","type":"GO_TERM","name":"cyclopeptine synthase activity","canonical_id":"go:GO:0047671","description":"\"Catalysis of the reaction: anthranilate + 2 ATP + L-phenylalanine + S-adenosyl-L-methionine = 2 AMP + cyclopeptine + 2 diphosphate + 2 H+ + S-adenosyl-L-homocysteine.\" [EC:6.3.2.40, PMID:2995633, RHEA:35091]","metadata":null},{"id":"02bc4d5e1dee44df9a0507074fbd46fa","type":"DRUG","name":"cyclophosphamide","canonical_id":"mesh:D003520","description":null,"metadata":null},{"id":"0ab82f85418d4ddf9a79902aead189c6","type":"GO_TERM","name":"cyclopropane-fatty-acyl-phospholipid synthase activity","canonical_id":"go:GO:0008825","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + phospholipid olefinic fatty acid = S-adenosyl-L-homocysteine + phospholipid cyclopropane fatty acid.\" [EC:2.1.1.79]","metadata":null},{"id":"718da2d2508645f5b832c2ed15b2023b","type":"DRUG","name":"cyclosporin A","canonical_id":"gtopdb:1024","description":null,"metadata":null},{"id":"9b62df01f0844aba93cbb6c034b729f1","type":"COMBINATION_TREATMENT","name":"cyclosporin A + everolimus + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-88b32858091d5dbf","description":null,"metadata":null},{"id":"ad926c360f1f4e8fbda535ae9cbb7ed7","type":"GO_TERM","name":"cyclosporin A binding","canonical_id":"go:GO:0016018","description":"\"Binding to cyclosporin A, a cyclic undecapeptide that contains several N-methylated and unusual amino acids.\" [GOC:mb]","metadata":null},{"id":"6fc4152d95104657bafad14030d37c5c","type":"DRUG","name":"cyclothiazide","canonical_id":"gtopdb:4167","description":null,"metadata":null},{"id":"6f1a0be200254a8187e1a76fb64048cb","type":"DRUG","name":"cyclothiazide","canonical_id":"chembl:CHEMBL61593","description":null,"metadata":null},{"id":"d36c131ddb074fee8dbe167bdf2733e4","type":"DRUG","name":"cycrimine","canonical_id":"mesh:C012262","description":null,"metadata":null},{"id":"8b3e6398a0ce4d2692f643896cacd8f7","type":"DRUG","name":"cyproheptadine","canonical_id":"gtopdb:277","description":null,"metadata":null},{"id":"bec0ffaa37af4b3c894a46c6bcdb0557","type":"COMBINATION_TREATMENT","name":"cyproheptadine + methylphenidate","canonical_id":"ctgov_combo:ctgov-combo-992c7c4fefd2537f","description":null,"metadata":null},{"id":"581180d6ae0b4750a22f35c05ea9485f","type":"COMBINATION_TREATMENT","name":"cyproheptadine + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-4a003fc8630af466","description":null,"metadata":null},{"id":"a439eaf704f44dd5af09dfd5e0e7436a","type":"DRUG","name":"cyproterone acetate","canonical_id":"gtopdb:2865","description":null,"metadata":null},{"id":"72080f094a8c4c448438f91b71d34864","type":"DRUG","name":"cyproterone acetate","canonical_id":"chembl:CHEMBL139835","description":null,"metadata":null},{"id":"d98f37fdba254ba8b34f1f1259858a3e","type":"COMBINATION_TREATMENT","name":"cyproterone acetate + finasteride","canonical_id":"ctgov_combo:ctgov-combo-64ba3a6e2a28f406","description":null,"metadata":null},{"id":"0676cd6b534644c7ba5f5a68345cb8ee","type":"COMBINATION_TREATMENT","name":"cyproterone acetate + flutamide","canonical_id":"ctgov_combo:ctgov-combo-b9a572c7adfdae85","description":null,"metadata":null},{"id":"07fbb23aa6fd40c8b146dc7cfdcf63c7","type":"COMBINATION_TREATMENT","name":"cyproterone acetate + testolactone","canonical_id":"ctgov_combo:ctgov-combo-5c675ee1d0427aaf","description":null,"metadata":null},{"id":"286ea23f51e54b0f954ee1ef38756bff","type":"GO_TERM","name":"cyst wall","canonical_id":"go:GO:0097570","description":"\"The specialized envelope lying outside the cell membrane of a cyst. A cyst is a resting or dormant stage of a microorganism, usually a bacterium or a protist or rarely an invertebrate animal, that helps the organism to survive in unfavorable environmental conditions. In protists such as protozoan parasites alternating cystic- and non-cystic stages, the cyst wall is usually composed of carbohydrates and proteins.\" [GOC:giardia, PMID:15134259, PMID:2026212, Wikipedia:Microbial_cyst]","metadata":null},{"id":"6fa5e9bf140f436e8a61914ae1094474","type":"GO_TERM","name":"cystathionine beta-synthase activity","canonical_id":"go:GO:0004122","description":"\"Catalysis of the reaction: L-serine + L-homocysteine = cystathionine + H2O.\" [EC:4.2.1.22]","metadata":null},{"id":"ee30a54bda134b5a8de4292807a6812a","type":"GO_TERM","name":"cystathionine gamma-lyase activity","canonical_id":"go:GO:0004123","description":"\"Catalysis of the reaction: L-cystathionine + H2O = 2-oxobutanoate + L-cysteine + NH4+.\" [RHEA:14005]","metadata":null},{"id":"96d1091cf1c4410a8edcd68e07e17416","type":"GO_TERM","name":"cystathionine gamma-synthase activity","canonical_id":"go:GO:0003962","description":"\"Catalysis of the reaction: L-cysteine + O-succinyl-L-homoserine = H+ + L,L-cystathionine + succinate.\" [RHEA:20397]","metadata":null},{"id":"211fca9b20b148ac87c680500db24090","type":"GO_TERM","name":"cysteamine dioxygenase activity","canonical_id":"go:GO:0047800","description":"\"Catalysis of the reaction: cysteamine + O2 = H+ + hypotaurine.\" [EC:1.13.11.19, RHEA:14409]","metadata":null},{"id":"149e0b9fb6904cdd91220a84d50c622b","type":"GO_TERM","name":"cysteate synthase activity","canonical_id":"go:GO:0044686","description":"\"Catalysis of the reaction: O-phospho-L-serine + sulfite + H+ = L-cysteate + phosphate.\" [PMID:19761441, RHEA:26486]","metadata":null},{"id":"cd710fd442f74493886f32be0dab3e6f","type":"GO_TERM","name":"cysteine desulfurase activity","canonical_id":"go:GO:0031071","description":"\"Catalysis of the reaction: L-cysteine + [enzyme]-cysteine = L-alanine + [enzyme]-S-sulfanylcysteine.\" [EC:2.8.1.7]","metadata":null},{"id":"88fa7d6d3e2d4cb886f920a6ca101b46","type":"GO_TERM","name":"cysteine dioxygenase activity","canonical_id":"go:GO:0017172","description":"\"Catalysis of the reaction: L-cysteine + O2 = 3-sulfino-L-alanine + H+.\" [EC:1.13.11.20, RHEA:20441]","metadata":null},{"id":"e39ff5ed44d94ff2a6696b08fa24a706","type":"GO_TERM","name":"cysteine lyase activity","canonical_id":"go:GO:0047803","description":"\"Catalysis of the reaction: L-cysteine + sulfite = L-cysteate + sulfide.\" [EC:4.4.1.10, MetaCyc:CYSTEINE-LYASE-RXN]","metadata":null},{"id":"f5c02544970a431aadb2a288532a5dfb","type":"GO_TERM","name":"cysteine sulfinate desulfinase activity","canonical_id":"go:GO:0008826","description":"\"Catalysis of the reaction: 3-sulfinoalanine = L-alanine + sulfite.\" [RHEA:28278]","metadata":null},{"id":"58fc700422004ca2b21839d35ff8bd10","type":"GO_TERM","name":"cysteine synthase activity","canonical_id":"go:GO:0004124","description":"\"Catalysis of the reaction: O3-acetyl-L-serine + hydrogen sulfide = L-cysteine + acetate.\" [EC:2.5.1.47]","metadata":null},{"id":"6ab736d71c2349eb91a504308e638915","type":"GO_TERM","name":"cysteine synthase activity, acting on O-succinyl-L-serine","canonical_id":"go:GO:0141223","description":"\"Catalysis of the reaction: hydrogen sulfide + O-succinyl-L-serine = L-cysteine + succinate.\" [RHEA:53816]","metadata":null},{"id":"8234a7a609c64532a08712de9ae76607","type":"GO_TERM","name":"cysteine synthase complex","canonical_id":"go:GO:0009333","description":"\"Cysteine synthase is a multienzyme complex made up, in E. coli, of the heteromeric hexamer serine acetyltransferase and the homodimer O-acetylserine (thiol)-lyase A.\" [PMID:10993149]","metadata":null},{"id":"cafee7558aa443e2a393215d3f43e20f","type":"GO_TERM","name":"cysteine-S-conjugate beta-lyase activity","canonical_id":"go:GO:0047804","description":"\"Catalysis of the reaction: S-substituted L-cysteine + H2O = a thiol + NH4+ + pyruvate.\" [RHEA:18121]","metadata":null},{"id":"1257d85b1cbd47648efec203ad115fcd","type":"GO_TERM","name":"cysteine-conjugate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047802","description":"\"Catalysis of the reaction: 2-oxoglutarate + S-(4-bromophenyl)-L-cysteine = (4-bromophenylsulfanyl)pyruvate + L-glutamate.\" [RHEA:13485]","metadata":null},{"id":"9f9cbde6a068471699df3764d99f3300","type":"GO_TERM","name":"cysteine-dependent adenosine diphosphate thiazole synthase activity","canonical_id":"go:GO:0160205","description":"\"Catalysis of the reaction: [ADP-thiazole synthase]-L-cysteine + glycine + NAD(+) = [ADP-thiazole synthase]-dehydroalanine + ADP-5-ethyl-4-methylthiazole-2-carboxylate + 2 H(+) + 3 H2O + nicotinamide.\" [RHEA:55708]","metadata":null},{"id":"c8a2f71486fb4f09bdbc0efe97fac950","type":"GO_TERM","name":"cysteine-glucosaminylinositol ligase activity","canonical_id":"go:GO:0035446","description":"\"Catalysis of the reaction: 1-(2-amino-2-deoxy-alpha-D-glucopyranoside)-1D-myo-inositol + L-cysteine + ATP = 1-D-myo-inosityl-2-L-cysteinylamido-2-deoxy-alpha-D-glucopyranoside + AMP + diphosphate + 2 H+. 1-(2-amino-2-deoxy-alpha-D-glucopyranoside)-1D-myo-inositol is also known as glucosaminyl-inositol or GlcN-Ins, and 1-D-myo-inosityl-2-L-cysteinylamido-2-deoxy-alpha-D-glucopyranoside as desacetylmycothiol or Cys-GlcN-Ins.\" [EC:6.3.1.13, PMID:12033919]","metadata":null},{"id":"fc48d74efba84833bf31b9ed4fdbe570","type":"GO_TERM","name":"cysteine-tRNA ligase activity","canonical_id":"go:GO:0004817","description":"\"Catalysis of the reaction: ATP + L-cysteine + tRNA(Cys) = AMP + diphosphate + L-cysteinyl-tRNA(Cys).\" [EC:6.1.1.16]","metadata":null},{"id":"885b4470ee8744689c065265713ccc19","type":"GO_TERM","name":"cysteine-type aminopeptidase activity","canonical_id":"go:GO:0070005","description":"\"Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#AMINOPEPTIDASE, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"4ade2805ee674f9f862b15490c171140","type":"GO_TERM","name":"cysteine-type carboxypeptidase activity","canonical_id":"go:GO:0016807","description":"\"Catalysis of the hydrolysis of a single C-terminal amino acid residue from a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CARBOXYPEPTIDASE]","metadata":null},{"id":"a008cda857ee40d68ea3737f692028da","type":"GO_TERM","name":"cysteine-type deNEDDylase activity","canonical_id":"go:GO:0140757","description":"\"An thiol-dependent isopeptidase activity that cleaves NEDD8 from a target protein to which it is conjugated.\" [PMID:25628956]","metadata":null},{"id":"ed743bdafdda4aa39cbbeb3ead5aa13d","type":"GO_TERM","name":"cysteine-type deubiquitinase activity","canonical_id":"go:GO:0004843","description":"\"An thiol-dependent isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated.\" [GOC:jh2, PMID:30783221]","metadata":null},{"id":"0e5ceba89bd6486d96fea005f804aa8b","type":"GO_TERM","name":"cysteine-type endopeptidase activator activity","canonical_id":"go:GO:0140608","description":"\"Binds to and increases the activity of a cysteine-type endopeptidase.\" [PMID:32558991]","metadata":null},{"id":"057e22c1edd841248d6466adbb6e14be","type":"GO_TERM","name":"cysteine-type endopeptidase activator activity involved in apoptotic process","canonical_id":"go:GO:0008656","description":"\"Binds to and increases the rate of proteolysis catalyzed by a cysteine-type endopeptidase involved in the apoptotic process.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"972d01b62c9d4a36a3a16fbf1512069a","type":"GO_TERM","name":"cysteine-type endopeptidase activity","canonical_id":"go:GO:0004197","description":"\"Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE]","metadata":null},{"id":"2114a8c2b2364349bac377de446aec88","type":"GO_TERM","name":"cysteine-type endopeptidase inhibitor activity","canonical_id":"go:GO:0004869","description":"\"Binds to and stops, prevents or reduces the activity of a cysteine-type endopeptidase.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1c83e9b947d148c7a5081948a2f04e34","type":"GO_TERM","name":"cysteine-type endopeptidase inhibitor activity involved in apoptotic process","canonical_id":"go:GO:0043027","description":"\"Binds to and stops, prevents or reduces the activity of a cysteine-type endopeptidase involved in the apoptotic process.\" [GOC:jl, GOC:mtg_apoptosis, PMID:14744432, Wikipedia:Caspase]","metadata":null},{"id":"a3d4d1234377455099a60c75ea9d716e","type":"GO_TERM","name":"cysteine-type endopeptidase regulator activity involved in apoptotic process","canonical_id":"go:GO:0043028","description":"\"Binds to and modulates the activity of a cysteine-type endopeptidase involved in the apoptotic process.\" [GOC:jl, GOC:mtg_apoptosis, PMID:14744432, Wikipedia:Caspase]","metadata":null},{"id":"ac6ea04e43f04e36a268d3b5ef56ed76","type":"GO_TERM","name":"cysteine-type exopeptidase activity","canonical_id":"go:GO:0070004","description":"\"Catalysis of the hydrolysis of C- or N-terminal peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#EXOPEPTIDASE]","metadata":null},{"id":"0ac72d63be574e12942d5067759e25ee","type":"GO_TERM","name":"cysteine-type peptidase activity","canonical_id":"go:GO:0008234","description":"\"Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"7583d24b01e1434c90427b7f3242bd0a","type":"GO_TERM","name":"cysteinyl leukotriene receptor activity","canonical_id":"go:GO:0001631","description":"\"Combining with a cysteinyl leukotriene to initiate a change in cell activity. Cysteinyl leukotrienes are leukotrienes that contain a peptide group based on cysteine.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"32c9eb28470d47f4b31f1d0bb9e7e215","type":"GO_TERM","name":"cysteinyl leukotriene receptor binding","canonical_id":"go:GO:0031745","description":"\"Binding to a cysteinyl leukotriene receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"47b6875e63cb4d07bbf660235731d4e8","type":"GO_TERM","name":"cysteinyl-tRNA aminoacylation","canonical_id":"go:GO:0006423","description":"\"The process of coupling L-cysteine to cysteinyl-tRNA, catalyzed by cysteinyl-tRNA synthetase. A cysteinyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a cysteine-accepting tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"6eaba6659cc7490985f9b5f52d73ec9d","type":"GO_TERM","name":"cystic duct development","canonical_id":"go:GO:0035628","description":"\"The progression of the cystic duct over time, from its formation to the mature structure. The cystic duct runs from the gallbladder to the common bile duct.\" [PMID:20614624]","metadata":null},{"id":"7070aea5a3b440d0ba50a2c0f48174f4","type":"DISEASE","name":"cystic fibrosis","canonical_id":"mondo:0009061","description":null,"metadata":null},{"id":"876e08727f374584962f649071e573de","type":"GO_TERM","name":"cystine:glutamate antiporter activity","canonical_id":"go:GO:0015327","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: cystine(out) + glutamate(in) = cystine(in) + glutamate(out).\" [TC:2.A.3.8.5]","metadata":null},{"id":"623590311f1e430a82732b71349c3dc5","type":"GO_TERM","name":"cystoblast division","canonical_id":"go:GO:0007282","description":"\"Any of the rounds of incomplete mitosis undergone by a cystoblast to form a cyst of interconnected cells.\" [PMID:21452446]","metadata":null},{"id":"a6a4c7f2591f4faf8858f5e82705894f","type":"DISEASE","name":"cystoid macular edema","canonical_id":"mondo:0007935","description":null,"metadata":null},{"id":"c61aa18ea2534051b26086457b086ae1","type":"DRUG","name":"cytarabine","canonical_id":"mesh:D003561","description":null,"metadata":null},{"id":"77667ef51e2447d88c759c4f4847a714","type":"GO_TERM","name":"cytidine catabolic process","canonical_id":"go:GO:0006216","description":"\"The chemical reactions and pathways resulting in the breakdown of cytidine, cytosine riboside, a widely distributed nucleoside.\" [GOC:ai]","metadata":null},{"id":"572882f4cca34544951e36e75a9445aa","type":"GO_TERM","name":"cytidine deaminase activity","canonical_id":"go:GO:0004126","description":"\"Catalysis of the reaction: cytidine + H+ + H2O = uridine + NH4 and deoxycytidine + H+ + H2O = deoxyuridine + NH4+.\" [EC:3.5.4.5]","metadata":null},{"id":"7068f4f381db4ed7bf4df9f2b49f02b7","type":"GO_TERM","name":"cytidine kinase activity","canonical_id":"go:GO:0043771","description":"\"Catalysis of the reaction: ATP + cytidine = ADP + CMP.\" [PMID:211379, RHEA:24674]","metadata":null},{"id":"1e239260aeb344469b25c8cbb3f9a7a8","type":"GO_TERM","name":"cytidine metabolic process","canonical_id":"go:GO:0046087","description":"\"The chemical reactions and pathways involving cytidine, cytosine riboside, a widely distributed nucleoside.\" [GOC:curators]","metadata":null},{"id":"e40e0d24cbe045af84436c383f82211f","type":"GO_TERM","name":"cytidine to uridine editing","canonical_id":"go:GO:0016554","description":"\"The conversion of a cytosine residue to uridine in an RNA molecule by deamination.\" [PMID:11092837]","metadata":null},{"id":"390615cc415143338d2ef7e7e93cdfd7","type":"GO_TERM","name":"cytidine transmembrane transporter activity","canonical_id":"go:GO:0015212","description":"\"Enables the transfer of cytidine, cytosine riboside, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"9f25e1b22661478ebc2859a317fe2430","type":"GO_TERM","name":"cytidine transport","canonical_id":"go:GO:0015861","description":"\"The directed movement of cytidine, cytosine riboside, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"e512a9cad865455fb2a79d88200cba84","type":"GO_TERM","name":"cytidylate cyclase activity","canonical_id":"go:GO:0047805","description":"\"Catalysis of the reaction: CTP = 3',5'-cyclic CMP + diphosphate + H+.\" [RHEA:14737]","metadata":null},{"id":"60d74558ad4b4e91be984368d3934444","type":"GO_TERM","name":"cytidylyltransferase activity","canonical_id":"go:GO:0070567","description":"\"Catalysis of the transfer of a cytidylyl group to an acceptor.\" [GOC:mah]","metadata":null},{"id":"093681a23bdf46a7b7aef49ea836bf7a","type":"PROTEIN","name":"cytochrome P450 3A (CYP3A) isoforms","canonical_id":"uniprot:Q9HB55","description":null,"metadata":null},{"id":"82cb66a60d6644b79392c81cab55fe7f","type":"GO_TERM","name":"cytochrome P450 dependent ent-sandaracopimaradiene 3-hydroxylase activity","canonical_id":"go:GO:0102596","description":"\"Catalysis of the reaction: ent-sandaracopimara-8(14),15-diene + NADPH + H+ + O2 = ent-sandaracopimaradien-3beta-ol + NADP + H2O.\" [EC:1.14.14.70, GOC:pz]","metadata":null},{"id":"4cd2283e70e145f9a66d13daa245ab29","type":"GO_TERM","name":"cytochrome b6f complex","canonical_id":"go:GO:0009512","description":"\"Complex that transfers electrons from reduced plastoquinone to oxidized plastocyanin and translocates protons from the stroma to the lumen. The complex contains a core structure of three catalytic subunits: cytochrome b, the Rieske iron sulfur protein (ISP), and cytochrome f, which are arranged in an integral membrane-bound dimeric complex; additional subunits are present, and vary among different species.\" [ISBN:0943088399, PMID:16228398, PMID:16352458]","metadata":null},{"id":"994b50911cfc41a6b68295b3bb028db3","type":"GO_TERM","name":"cytochrome b6f complex assembly","canonical_id":"go:GO:0010190","description":"\"Formation of cytochrome b6f complex, a complex that transfers electrons from reduced plastoquinone to oxidized plastocyanin and translocates protons from the stroma to the lumen, by the aggregation, arrangement and bonding together of its constituents.\" [GOC:tb]","metadata":null},{"id":"f5880b0ca662423ba479f73a35d75b56","type":"GO_TERM","name":"cytochrome biosynthetic process","canonical_id":"go:GO:1903605","description":"\"The chemical reactions and pathways resulting in the formation of a cytochrome.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:19721088]","metadata":null},{"id":"75a2729c725d4543ba051b221414bdc6","type":"GO_TERM","name":"cytochrome bo3 ubiquinol oxidase activity","canonical_id":"go:GO:0009486","description":"\"Catalysis of the reaction: 2 ubiquinol + O2 + 4 H+ = 2 ubiquinone + 2 H2O + 4 H+ [periplasmic space].\" [RHEA:30251]","metadata":null},{"id":"07534da4f7df4125a60bce16935ecfb4","type":"GO_TERM","name":"cytochrome c biosynthetic process","canonical_id":"go:GO:1903607","description":"\"The chemical reactions and pathways resulting in the formation of cytochrome c.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:19721088]","metadata":null},{"id":"341d3c462b1344ffa0ac9b4a41e6609d","type":"GO_TERM","name":"cytochrome c metabolic process","canonical_id":"go:GO:1903606","description":"\"The chemical reactions and pathways involving cytochrome c.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:19721088]","metadata":null},{"id":"c38c334379424a4fa81944fb6dd91f34","type":"GO_TERM","name":"cytochrome c-heme linkage","canonical_id":"go:GO:0018063","description":"\"The linkage of cytochromes and other heme proteins to heme.\" [RESID:AA0134, RESID:AA0135]","metadata":null},{"id":"f45819859cbe4c09878bfc69bd78df3e","type":"GO_TERM","name":"cytochrome complex","canonical_id":"go:GO:0070069","description":"\"A protein complex in which at least one of the proteins is a cytochrome, i.e. a heme-containing protein involved in catalysis of redox reactions.\" [GOC:mah]","metadata":null},{"id":"e08569bf0e794c328fce153f88a4ab3e","type":"GO_TERM","name":"cytochrome complex assembly","canonical_id":"go:GO:0017004","description":"\"The aggregation, arrangement and bonding together of a cytochrome complex. A cytochrome complex is a protein complex in which at least one of the proteins is a cytochrome, i.e. a heme-containing protein involved in catalysis of redox reactions.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"e47c828a8ccf4a3f83ab9c7817aba7c1","type":"GO_TERM","name":"cytochrome metabolic process","canonical_id":"go:GO:1903604","description":"\"The chemical reactions and pathways involving a cytochrome.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:19721088]","metadata":null},{"id":"82c23f2b1eed46b39ca7bbe118f15ac5","type":"GO_TERM","name":"cytochrome o ubiquinol oxidase complex","canonical_id":"go:GO:0009319","description":"\"A protein complex that possesses cytochrome o ubiquinol oxidase activity; consists of four polypeptide subunits and associated prosthetic groups.\" [GOC:mah, MetaCyc:CYT-O-UBIOX-CPLX, PMID:11017202, PMID:3052268]","metadata":null},{"id":"41df7ba7e8174a7b9b3cb055593d68b0","type":"GO_TERM","name":"cytochrome-b5 reductase activity, acting on NAD(P)H","canonical_id":"go:GO:0004128","description":"\"Catalysis of the reaction: 2 Fe(III)-[cytochrome b5] + NAD(P)H = 2 Fe(II)-[cytochrome b5] + NAD(P)+ + H+.\" [GOC:curators]","metadata":null},{"id":"cae5066ce80947668465d2979c61bf55","type":"GO_TERM","name":"cytochrome-b5 reductase activity, acting on NADH","canonical_id":"go:GO:0090524","description":"\"Catalysis of the reaction: 2 Fe(III)-[cytochrome b5] + NADH = 2 Fe(II)-[cytochrome b5] + NAD+ + H+.\" [RHEA:46680]","metadata":null},{"id":"81d7d22bf4584307bb584f59247bb73a","type":"GO_TERM","name":"cytochrome-b5 reductase activity, acting on NADPH","canonical_id":"go:GO:0090523","description":"\"Catalysis of the reaction: 2 Fe(III)-[cytochrome b5] + NADPH = 2 Fe(II)-[cytochrome b5] + NADP+ + H+.\" [RHEA:64576]","metadata":null},{"id":"095d5808a6924615bc64ca8e1b282801","type":"GO_TERM","name":"cytochrome-c oxidase activity","canonical_id":"go:GO:0004129","description":"\"Catalysis of the reaction: 4 Fe(II)-[cytochrome c] + O2 + 8 H+(in) = 4 Fe(III)-[cytochrome c] + 2 H2O + 4 H+(out).\" [RHEA:11436]","metadata":null},{"id":"bb36157cd6b44ba5808dfca4829edc7f","type":"GO_TERM","name":"cytochrome-c peroxidase activity","canonical_id":"go:GO:0004130","description":"\"Catalysis of the reaction: 2 ferrocytochrome c + H2O2 = 2 ferricytochrome c + 2 H2O.\" [EC:1.11.1.5]","metadata":null},{"id":"f9673e3edae2437fb05c7037e87d7139","type":"GO_TERM","name":"cytochrome-c3 hydrogenase activity","canonical_id":"go:GO:0047806","description":"\"Catalysis of the reaction: 2 H2 + ferricytochrome c3 = 4 H+ + ferrocytochrome c3.\" [EC:1.12.2.1, MetaCyc:CYTOCHROME-C3-HYDROGENASE-RXN]","metadata":null},{"id":"dce3185e6cda416b9e7769f8065c7ea7","type":"GO_TERM","name":"cytogamy","canonical_id":"go:GO:0000755","description":"\"A reproductive process in a single-celled organism in which the cytoplasm of two mating cells fuse, resulting in the formation of a single cell containing the combined cellular contents.\" [GOC:vw]","metadata":null},{"id":"8ab058410fdf490689d4bc60c6b56d9e","type":"GO_TERM","name":"cytokine activity","canonical_id":"go:GO:0005125","description":"\"The activity of a soluble extracellular gene product that interacts with a receptor to effect a change in the activity of the receptor to control the survival, growth, differentiation and effector function of tissues and cells.\" [ISBN:0198599471, PMID:11530802]","metadata":null},{"id":"b92c583202c54a82b3622124501b20c9","type":"GO_TERM","name":"cytokine binding","canonical_id":"go:GO:0019955","description":"\"Binding to a cytokine, any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.\" [GOC:ai, GOC:bf, ISBN:0198599471]","metadata":null},{"id":"18e45ceda6b5408fa8fa1175d41e06f0","type":"GO_TERM","name":"cytokine precursor processing","canonical_id":"go:GO:0140447","description":"\"The cleavage of a peptide bond in a precursor form of a cytokine, resulting in the mature (active) form of the cytokine.\" [PMID:29247995]","metadata":null},{"id":"622ba8c7357944c88a47364671b1d74d","type":"GO_TERM","name":"cytokine production","canonical_id":"go:GO:0001816","description":"\"The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"9ccec1168c824955bcd482639f516aab","type":"GO_TERM","name":"cytokine production involved in immune response","canonical_id":"go:GO:0002367","description":"\"The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus contributing to an immune response, resulting in an increase in its intracellular or extracellular levels.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"19ced670b42a48f79fa331de92ed63c5","type":"GO_TERM","name":"cytokine production involved in inflammatory response","canonical_id":"go:GO:0002534","description":"\"The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"cdbf06a0f2294198b4693eff81e620a9","type":"GO_TERM","name":"cytokine receptor activity","canonical_id":"go:GO:0004896","description":"\"Combining with a cytokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:mah]","metadata":null},{"id":"991fd06e12834133a0b345ef337b7f95","type":"GO_TERM","name":"cytokine receptor binding","canonical_id":"go:GO:0005126","description":"\"Binding to a cytokine receptor.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"cb7e4e4ebf8444d8b994880fe9ec0911","type":"GO_TERM","name":"cytokine-mediated signaling pathway","canonical_id":"go:GO:0019221","description":"\"The series of molecular signals initiated by the binding of a cytokine to a receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling, PMID:19295629]","metadata":null},{"id":"0caaa2e0b1a0452f83706b8b81f3db96","type":"GO_TERM","name":"cytokinesis","canonical_id":"go:GO:0000910","description":"\"The division of the cytoplasm and the plasma membrane of a cell and its partitioning into two daughter cells.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"0597a8366876415ebced3b9da5aad4d9","type":"GO_TERM","name":"cytokinesis by cell plate formation","canonical_id":"go:GO:0000911","description":"\"The process of dividing the cytoplasm of a parent cell where a structure forms in the cytoplasm and grows until reaching the plasma membrane, thereby completely separating the cytoplasms of adjacent progeny cells. An example of this is found in Arabidopsis thaliana.\" [GOC:clt]","metadata":null},{"id":"7b6ef9ae2b334f90af2ea8befadd98af","type":"GO_TERM","name":"cytokinesis, division site positioning","canonical_id":"go:GO:0007105","description":"\"The process in which a contractile ring is positioned in a specific location. This process is critical for both for both symmetric and asymmetric cell divisions.\" [PMID:26553932, PMID:28162898]","metadata":null},{"id":"e407d209698e4b45ab0381d49e577f1b","type":"GO_TERM","name":"cytokinetic process","canonical_id":"go:GO:0032506","description":"\"A cellular process that is involved in cytokinesis (the division of the cytoplasm of a cell and its separation into two daughter cells).\" [GOC:bf, GOC:isa_complete, GOC:mah]","metadata":null},{"id":"eb5c32df35c44a029646da2ad5736694","type":"GO_TERM","name":"cytokinin 7-beta-glucosyltransferase activity","canonical_id":"go:GO:0047807","description":"\"Catalysis of the reaction: 6-alkylaminopurine + UDP-D-glucose = 6-alkylamino-7-beta-D-glucosylpurine + H+ + UDP. This reaction is an N-glucosylation event.\" [EC:2.4.1.118, MetaCyc:CYTOKININ-7-BETA-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"68cced8d256341e9b5a574ac38d0168b","type":"GO_TERM","name":"cytokinin 9-beta-glucosyltransferase activity","canonical_id":"go:GO:0080062","description":"\"Catalysis of the reaction: 6-alkylaminopurine + UDP-D-glucose = 6-alkylamino-9-beta-D-glucosylpurine + H+ + UDP. This reaction is an N-glucosylation event.\" [KEGG_REACTION:R08369, PMID:15342621]","metadata":null},{"id":"8aff6aecbe714287b1527c879a50e4f2","type":"GO_TERM","name":"cytokinin binding","canonical_id":"go:GO:0044373","description":"\"Binding to a cytokinin, any of a class of adenine-derived compounds that can function in plants as growth regulators.\" [GOC:jl]","metadata":null},{"id":"5d27a67c908e46e8b0edab1ecb0472e0","type":"GO_TERM","name":"cytokinin biosynthetic process","canonical_id":"go:GO:0009691","description":"\"The chemical reactions and pathways resulting in the formation of cytokinins, a class of adenine-derived compounds that can function in plants as growth regulators.\" [ISBN:0387969845]","metadata":null},{"id":"7a379e050bca48d7808d3f64b41dd2ef","type":"GO_TERM","name":"cytokinin catabolic process","canonical_id":"go:GO:0009823","description":"\"The chemical reactions and pathways resulting in the breakdown of cytokinins, a class of adenine-derived compounds that can function in plants as plant growth regulators.\" [GOC:lr]","metadata":null},{"id":"d1c27c048388441a988ad7923d40b23e","type":"GO_TERM","name":"cytokinin dehydrogenase activity","canonical_id":"go:GO:0019139","description":"\"Catalysis of the reaction: N6-dimethylallyladenine + acceptor + H2O = adenine + 3-methylbut-2-enal + reduced electron acceptor.\" [EC:1.5.99.12]","metadata":null},{"id":"8d4bec05a94d48209a77234f9ad492bf","type":"GO_TERM","name":"cytokinin metabolic process","canonical_id":"go:GO:0009690","description":"\"The chemical reactions and pathways involving cytokinins, a class of adenine-derived compounds that can function in plants as growth regulators.\" [ISBN:0387969845]","metadata":null},{"id":"a0e79bc9b9584908aa4750455afe5260","type":"GO_TERM","name":"cytokinin receptor activity","canonical_id":"go:GO:0009884","description":"\"Combining with a cytokinin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:lr, GOC:signaling]","metadata":null},{"id":"d8539e460ba640f49496f6c45be379d9","type":"GO_TERM","name":"cytokinin riboside 5'-monophosphate phosphoribohydrolase activity","canonical_id":"go:GO:0102682","description":"\"Catalysis of the reaction: N(6)-(dimethylallyl)adenosine 5'-phosphate + H2O = N(6)-dimethylallyladenine + D-ribose 5-phosphate.\" [GOC:pz, RHEA:48560]","metadata":null},{"id":"fc4dab10f0d34d2b8d85bf067f1239ef","type":"GO_TERM","name":"cytokinin transport","canonical_id":"go:GO:0010184","description":"\"The directed movement of cytokinins, a class of adenine-derived compounds that can function in plants as growth regulators, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:lr]","metadata":null},{"id":"e994f71398f148f2a5c0f3b0e4dd9cbc","type":"GO_TERM","name":"cytokinin-activated signaling pathway","canonical_id":"go:GO:0009736","description":"\"The series of molecular signals generated by the binding of a cytokinin to a receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:sm, PMID:24080474]","metadata":null},{"id":"53239f223cc24ae8b63d7c07d6f3715a","type":"GO_TERM","name":"cytolysis","canonical_id":"go:GO:0019835","description":"\"The rupture of cell membranes and the loss of cytoplasm.\" [UniProtKB-KW:KW-0204]","metadata":null},{"id":"251b32d0c0d243dfaf3d16b2c858f512","type":"GO_TERM","name":"cytolysis in another organism","canonical_id":"go:GO:0051715","description":"\"The killing by an organism of a cell in another organism by means of the rupture of cell membranes and the loss of cytoplasm.\" [GOC:ai, PMID:22484288]","metadata":null},{"id":"2d3b425905304beb96414c6ee06dba2c","type":"GO_TERM","name":"cytolytic granule","canonical_id":"go:GO:0044194","description":"\"A specialized secretory lysosome that is present in cells with cytolytic capability such as cytotoxic T lymphocytes and natural killer cells. Cytolytic granules mediate the storage and regulated excretion of lytic molecules for killing of target cells.\" [GOC:jl, PMID:11052265, PMID:12766758]","metadata":null},{"id":"92a68f5665b44c97a6e958978695e89c","type":"GO_TERM","name":"cytolytic granule lumen","canonical_id":"go:GO:1904856","description":"\"Any cytoplasmic membrane-bounded vesicle lumen that is part of a cytolytic granule.\" [GO_REF:0000064, GOC:TermGenie, PMID:17272266, PMID:21247065]","metadata":null},{"id":"9c896ed972bb4b04b5a27d3269c3e3d4","type":"GO_TERM","name":"cytolytic granule membrane","canonical_id":"go:GO:0101004","description":"\"The lipid bilayer surrounding the cytolytic granule.\" [PMID:17272266, PMID:21247065]","metadata":null},{"id":"23a597fea3e14fdabbfea8270f192e03","type":"GO_TERM","name":"cytoneme","canonical_id":"go:GO:0035230","description":"\"A long, thin, polarized cell projection that contains actin and can extend for distances many times the diameter of the cell. Cytonemes represent extensions of cell cytoplasm and typically have a diameter of approximately 0.2um.\" [PMID:10367889, PMID:10675901]","metadata":null},{"id":"5ed852b55e30459fadf600cd8271079f","type":"GO_TERM","name":"cytoneme assembly","canonical_id":"go:GO:0035231","description":"\"Formation of a cytoneme, a long, thin and polarized actin-based cytoplasmic extension that projects from a cell.\" [PMID:10367889, PMID:10675901]","metadata":null},{"id":"b8ba98214a9e44b3b987caf6576f2dbb","type":"GO_TERM","name":"cytoneme morphogenesis","canonical_id":"go:GO:0003399","description":"\"The process in which the anatomical structures of a cytoneme are shaped. A cytoneme is a long, thin and polarized actin-based cytoplasmic extension that projects from a cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"51c431fc708d418387871d267897c092","type":"GO_TERM","name":"cytoophidium","canonical_id":"go:GO:0097268","description":"\"A filamentous, membrane-less subcellular structure composed primarily of polymerized metabolic enzymes, most notably cytidine triphosphate synthase (CTPS). Cytoophidia are evolutionarily conserved structures found across archaea, bacteria, and eukaryotes.\" [PMID:20513629, PMID:21930098, PMID:37248970, Wikipedia:CTP_synthase#Cytoophidium]","metadata":null},{"id":"80ba0b09fce54809a5e2fb2964d07c6d","type":"GO_TERM","name":"cytoophidium organization","canonical_id":"go:GO:0140904","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of a cytoophidium. Cytoophidia are mesoscale, intracellular, filamentous structures that contain metabolic enzymes.\" [PMID:25223282, PMID:27362644]","metadata":null},{"id":"1f80f0321776455ba916325b1ba8a38d","type":"GO_TERM","name":"cytoplasm","canonical_id":"go:GO:0005737","description":"\"The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.\" [ISBN:0198547684]","metadata":null},{"id":"8a86284a61524d929954e0c3135f73a7","type":"GO_TERM","name":"cytoplasm organization","canonical_id":"go:GO:0007028","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the cytoplasm. The cytoplasm is all of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.\" [GOC:curators, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"5ec66d7ba46f44349f326c894f81fe13","type":"GO_TERM","name":"cytoplasm protein quality control","canonical_id":"go:GO:0140455","description":"\"The chemical reactions and pathways resulting in the breakdown of misfolded proteins in the cytoplasm, which are either targeted to cytoplasmic proteasomes for degradation or protected by chaperones to shield thermosensitive proteins from degradation until conditions allow disaggregation and refolding.\" [PMID:32075773]","metadata":null},{"id":"87c3981d9bdc4a8db35ac3744ab85dfd","type":"GO_TERM","name":"cytoplasm protein quality control by the ubiquitin-proteasome system","canonical_id":"go:GO:0071629","description":"\"The chemical reactions and pathways resulting in the breakdown of misfolded proteins in the cytoplasm, which are targeted to cytoplasmic proteasomes for degradation.\" [GOC:mah, GOC:rb, PMID:20080635]","metadata":null},{"id":"3519b32e4a6c4286969fdb0c73849d5c","type":"GO_TERM","name":"cytoplasm to vacuole targeting by the Cvt pathway","canonical_id":"go:GO:0032258","description":"\"A cytoplasm to vacuole targeting pathway that uses machinery common with autophagy. The Cvt vesicle is formed when the receptor protein, Atg19, binds to the complexes of the target protein (aminopeptidase or alpha-mannosidase homododecamers), forming the Cvt complex. Atg11 binds to Atg9 and transports the Cvt complex to the pre-autophagosome (PAS). The phagophore membrane expands around the Cvt complex (excluding bulk cytoplasm) forming the Cvt vesicle. This pathway is mostly observed in yeast.\" [PMID:12865942, PMID:15659643]","metadata":null},{"id":"a59c71628f9241aea4a6fca8e963afd9","type":"GO_TERM","name":"cytoplasm to vacuole targeting by the NVT pathway","canonical_id":"go:GO:0120113","description":"\"A pathway targeting soluble cytosolic proteins to the vacuole lumen. It uses a selective autophagy receptor protein Nbr1, which is an ortholog of mammalian NBR1, and is remotely related to S. cerevisiae Cvt pathway receptor protein Atg19. Similar to the Cvt pathway, the cargos transported by this pathway are hydrolases, which presumably contribute to the hydrolytic activities in the vacuole lumen. Different from the Cvt pathway, this pathway does not require the macroautophagy machinery, but instead relies on the ESCRT machinery for cargo sequestration. This pathway is observed in the fission yeast S. pombe.\" [PMID:26365378]","metadata":null},{"id":"2cc193d712ba45f9bbb90496d48c65f0","type":"GO_TERM","name":"cytoplasmic DNA replication factor C complex","canonical_id":"go:GO:0043598","description":"\"A cytoplasmic complex of two polypeptides that loads the DNA polymerase processivity factor proliferating cell nuclear antigen (PCNA) onto DNA, thereby permitting processive DNA synthesis catalyzed by DNA polymerase. Examples of this component are found in prokaryotic species.\" [GOC:mtg_sensu, PMID:14646196, PMID:16172520]","metadata":null},{"id":"e92edd6ed8714acbbf48ac4191a2afc8","type":"GO_TERM","name":"cytoplasmic RNA surveillance","canonical_id":"go:GO:0071026","description":"\"The set of processes involved in identifying and degrading defective or aberrant RNAs within the cytoplasm.\" [GOC:dgf, GOC:krc, PMID:18644474]","metadata":null},{"id":"4f92c7e1d8d544108efb9dc8ecc0fe2b","type":"GO_TERM","name":"cytoplasmic SCF ubiquitin ligase complex","canonical_id":"go:GO:0043223","description":"\"A ubiquitin ligase complex, located in the cytoplasm, in which a cullin from the Cul1 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by a Skp1 adaptor and an F-box protein. SCF complexes are involved in targeting proteins for degradation by the proteasome. The best characterized complexes are those from yeast and mammals (with core subunits named Cdc53/Cul1, Rbx1/Hrt1/Roc1).\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"f1ff7050a00248f6b4cb5199623b777b","type":"GO_TERM","name":"cytoplasmic U snRNP body","canonical_id":"go:GO:0071254","description":"\"A focus in the cytoplasm that contains uridine-rich small nuclear ribonucleoproteins (U snRNPs) and essential snRNP assembly factors. These U bodies are invariably found in association with P bodies.\" [GOC:sart, PMID:17595295]","metadata":null},{"id":"243a61800ff54306b93d0cf86bf14427","type":"GO_TERM","name":"cytoplasmic U snRNP body assembly","canonical_id":"go:GO:1990194","description":"\"The aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic U snRNP body.\" [PMID:19464282]","metadata":null},{"id":"0f9c7ae352bb4175bb0886a62dc706c1","type":"GO_TERM","name":"cytoplasmic actin-based contraction involved in cell motility","canonical_id":"go:GO:0060327","description":"\"The actin filament-based movement by which cytoplasmic actin filaments slide past one another resulting in a contraction that propels the cell from one place to another.\" [GOC:dph]","metadata":null},{"id":"fbe4e00a225c44d1a54641f5b344c58c","type":"GO_TERM","name":"cytoplasmic actin-based contraction involved in forward cell motility","canonical_id":"go:GO:0060328","description":"\"The actin filament-based movement by which cytoplasmic actin filaments slide past one another resulting in a contraction that propels the cell in the direction that has been defined as the front of the cell.\" [GOC:dph]","metadata":null},{"id":"5a45a212fcd4467b9a2e55cec15dcc53","type":"GO_TERM","name":"cytoplasmic alanyl-tRNA aminoacylation","canonical_id":"go:GO:1990762","description":"\"The process of coupling alanine to alanyl-tRNA, catalyzed by alanyl-tRNA synthetase involved in cytoplasmic translation.\" [GOC:vw]","metadata":null},{"id":"6d23c4dfd655409395f9102dbccbbe5e","type":"GO_TERM","name":"cytoplasmic capsid assembly","canonical_id":"go:GO:0039709","description":"\"The assembly of a virus capsid that occurs in the cytoplasm.\" [VZ:1950]","metadata":null},{"id":"ae023c8f335c4ac9a98dc3ca16f1b48b","type":"GO_TERM","name":"cytoplasmic cyclin-dependent protein kinase holoenzyme complex","canonical_id":"go:GO:0000308","description":"\"Cyclin-dependent protein kinase (CDK) complex found in the cytoplasm.\" [GOC:krc]","metadata":null},{"id":"37c2687a0644456cb897c453d06707a9","type":"GO_TERM","name":"cytoplasmic dynein complex","canonical_id":"go:GO:0005868","description":"\"Any dynein complex with a homodimeric dynein heavy chain core that catalyzes movement along a microtubule. Cytoplasmic dynein complexes participate in many cytoplasmic transport activities in eukaryotes, such as mRNA localization, intermediate filament transport, nuclear envelope breakdown, apoptosis, transport of centrosomal proteins, mitotic spindle assembly, virus transport, kinetochore functions, and movement of signaling and spindle checkpoint proteins. Some complexes participate in intraflagellar transport. Subunits associated with the dynein heavy chain mediate association between dynein heavy chain and cargoes, and may include light chains and light intermediate chains.\" [GOC:cilia, GOC:hla, GOC:krc, GOC:mah, PMID:12600311]","metadata":null},{"id":"7ac18832700f444f8ee21d6d099ef058","type":"GO_TERM","name":"cytoplasmic exosome (RNase complex)","canonical_id":"go:GO:0000177","description":"\"A ribonuclease complex that has 3-prime to 5-prime processive hydrolytic exoribonuclease activity producing 5-prime-phosphomonoesters. Participates in a multitude of cellular RNA processing and degradation events preventing nuclear export and/or translation of aberrant RNAs. Restricted to processing linear and circular single-stranded RNAs (ssRNA) only. RNAs with complex secondary structures may have to be unwound or pre-processed by co-factors prior to entering the complex, esp if the 3-prime end is structured.\" [PMID:17174896, PMID:20531386, PMID:26726035]","metadata":null},{"id":"84f8de0f66274cb8bd4f8fbed6ffd093","type":"GO_TERM","name":"cytoplasmic helical capsid assembly","canonical_id":"go:GO:0039711","description":"\"The assembly of a helical viral capsid in the cytoplasm. Occurs by assembling around the viral genome.\" [VZ:1950]","metadata":null},{"id":"cd65cca0dc6e4cd1acc88d7f21d156ef","type":"GO_TERM","name":"cytoplasmic icosahedral capsid assembly","canonical_id":"go:GO:0039710","description":"\"The assembly of an icosahedral viral capsid in the cytoplasm. Often occurs by assembling around the viral genome.\" [VZ:1950]","metadata":null},{"id":"91026c746a794e63b98843350785201c","type":"GO_TERM","name":"cytoplasmic lattice","canonical_id":"go:GO:0140095","description":"\"Fibrous structures of the mammalian ooplasm that store ribosomes and maternal proteins in insoluble form to prevent their degradation, activation and nuclear transfer.\" [PMID:37922900, PMID:38955588]","metadata":null},{"id":"540261e481404dbca9a94ccd59a64408","type":"GO_TERM","name":"cytoplasmic lattice complex","canonical_id":"go:GO:0140419","description":"\"A protein complex at least composed of PADI6, TLE6, NLRP14 and KHDC3 that forms fibrous structures in the mammalian ooplasm.\" [PMID:41845018, PMID:41917274, PMID:41986725]","metadata":null},{"id":"235516c2d7c94dd7bf4bb6c57edaedd5","type":"GO_TERM","name":"cytoplasmic microtubule","canonical_id":"go:GO:0005881","description":"\"Any microtubule in the cytoplasm of a cell.\" [GOC:mah]","metadata":null},{"id":"d5708210b3914b0b96a2997b860097dd","type":"GO_TERM","name":"cytoplasmic microtubule bundle","canonical_id":"go:GO:1905720","description":"\"Any microtubule bundle that is part of a cytoplasm.\" [GO_REF:0000064, GOC:TermGenie, PMID:11007487, PMID:26124291]","metadata":null},{"id":"7eb2c33bbafd4f8b9b6b12591ddacfdf","type":"GO_TERM","name":"cytoplasmic microtubule depolymerization","canonical_id":"go:GO:0010938","description":"\"The removal of tubulin heterodimers from one or both ends of a cytoplasmic microtubule.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b8e8a77e55a84719aa3f77ac6e0d73d6","type":"GO_TERM","name":"cytoplasmic microtubule minus-end","canonical_id":"go:GO:0062194","description":"\"A microtubule minus end that is part of a cytoplasmic microtubule.\" [PMID:18061564]","metadata":null},{"id":"21e8e0d377fb4119a3e38cf96beff7a9","type":"GO_TERM","name":"cytoplasmic microtubule organization","canonical_id":"go:GO:0031122","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures formed of microtubules and associated proteins in the cytoplasm of a cell.\" [GOC:mah]","metadata":null},{"id":"1d076d7a21c1474d9cdb144bb179d426","type":"GO_TERM","name":"cytoplasmic microtubule plus-end","canonical_id":"go:GO:1904511","description":"\"Any microtubule plus-end that is part of a cytoplasmic microtubule.\" [GO_REF:0000064, GOC:TermGenie, PMID:15772152]","metadata":null},{"id":"84f06158e17a4124a77badec718bb76d","type":"GO_TERM","name":"cytoplasmic origin of replication recognition complex","canonical_id":"go:GO:0000809","description":"\"A multisubunit complex that is located at the replication origins of a chromosome in the cytoplasm.\" [GOC:elh]","metadata":null},{"id":"b9218e03e4f44a3db15eb35859744e75","type":"GO_TERM","name":"cytoplasmic pattern recognition receptor signaling pathway","canonical_id":"go:GO:0002753","description":"\"The series of molecular signals initiated by the binding of a ligand from another organism to a cytoplasmic pattern recognition receptor (PRR). PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species.\" [GOC:add, GOC:ar, ISBN:0781735149, PMID:15199967, PMID:17328678, PMID:18272355, PMID:19531363, PMID:21187438]","metadata":null},{"id":"84d672305b0a4cdc9488b73db46088ae","type":"GO_TERM","name":"cytoplasmic periphery of the nuclear pore complex","canonical_id":"go:GO:1990723","description":"\"Cytoplasm situated in close proximity to a nuclear pore complex.\" [PMID:9398662]","metadata":null},{"id":"d9336d52cd3f425da352451248d92390","type":"GO_TERM","name":"cytoplasmic polyadenylation-dependent RNA catabolic process","canonical_id":"go:GO:0180018","description":"\"The chemical reactions and pathways occurring in the cytoplasm and resulting in the breakdown of an RNA molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target rRNA truncated degradation intermediate.\" [PMID:20368444]","metadata":null},{"id":"3dd28457ebd34ad38e130c4a55513917","type":"GO_TERM","name":"cytoplasmic polyadenylation-dependent rRNA catabolic process","canonical_id":"go:GO:0035760","description":"\"The chemical reactions and pathways occurring in the cytoplasm and resulting in the breakdown of a ribosomal RNA (rRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target rRNA truncated degradation intermediate.\" [PMID:20368444]","metadata":null},{"id":"a8fd1838aa304236974ad8e3de1177b2","type":"GO_TERM","name":"cytoplasmic region","canonical_id":"go:GO:0099568","description":"\"Any (proper) part of the cytoplasm of a single cell of sufficient size to still be considered cytoplasm.\" [GOC:dos]","metadata":null},{"id":"fd8bd116e5a04330a52046bda6cf790d","type":"GO_TERM","name":"cytoplasmic replication fork","canonical_id":"go:GO:0043597","description":"\"The Y-shaped region of a cytoplasmic replicating DNA molecule, resulting from the separation of the DNA strands and in which the synthesis of new strands takes place. Also includes associated protein complexes.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"914b732ae87a41f4b254f83141e55331","type":"GO_TERM","name":"cytoplasmic replisome","canonical_id":"go:GO:0043600","description":"\"A multi-component enzymatic machine at the cytoplasmic replication fork, which mediates DNA replication. Includes DNA primase, DNA polymerase, DNA helicase, and other proteins.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"467751a604de4340b0123e5f30232910","type":"GO_TERM","name":"cytoplasmic ribonucleoprotein granule","canonical_id":"go:GO:0036464","description":"\"A ribonucleoprotein granule located in the cytoplasm.\" [GOC:bf, GOC:PARL, PMID:15121898]","metadata":null},{"id":"cb84f987e8fe4826ab27907c7468e12c","type":"GO_TERM","name":"cytoplasmic side of Golgi membrane","canonical_id":"go:GO:0098548","description":"\"The leaflet of the Golgi membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"18980a0813e94295a32fbc14b0d4ddb1","type":"GO_TERM","name":"cytoplasmic side of apical plasma membrane","canonical_id":"go:GO:0098592","description":"\"The leaflet of the apical region of the plasma membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"7bd8c35da4f34b21a491286dccd74fc8","type":"GO_TERM","name":"cytoplasmic side of cis-Golgi cisternae membrane","canonical_id":"go:GO:0160278","description":"\"The leaflet of the cis-Golgi cisternae membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it. This is the site of interactions with cytosolic proteins, including those involved in vesicle budding, membrane tethering, and lipid or protein trafficking.\" [PMID:10922460, PMID:34597626, PMID:39331042]","metadata":null},{"id":"57c34a7aba1241e7b4621d160677f682","type":"GO_TERM","name":"cytoplasmic side of cis-Golgi network membrane","canonical_id":"go:GO:0140179","description":"\"The leaflet of the cis-Golgi network membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it. This is the site of interactions with cytosolic proteins, including those for vesicle tethering, fusion, and Golgi-associated trafficking activities.\" [PMID:1747103, PMID:23913272, PMID:34080016, PMID:34597626]","metadata":null},{"id":"d8ba2662ba2f439fbc50fe09840d75d3","type":"GO_TERM","name":"cytoplasmic side of dendritic spine plasma membrane","canonical_id":"go:GO:1990780","description":"\"The leaflet of the plasma membrane in the dendritic spine region that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [PMID:9275233]","metadata":null},{"id":"197636857e684fd19545d0ebca307a06","type":"GO_TERM","name":"cytoplasmic side of early endosome membrane","canonical_id":"go:GO:0098559","description":"\"The leaflet of the early endosome membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:lr]","metadata":null},{"id":"fd3683fcfd0e41db813668c81568484e","type":"GO_TERM","name":"cytoplasmic side of endoplasmic reticulum membrane","canonical_id":"go:GO:0098554","description":"\"The leaflet of the endoplasmic reticulum membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"280084ce260d4660bbbf175f3da99e9a","type":"GO_TERM","name":"cytoplasmic side of endosome membrane","canonical_id":"go:GO:0010009","description":"\"The leaflet of the endosome membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:lr]","metadata":null},{"id":"31f11f5930934b7188b4bc4900800a77","type":"GO_TERM","name":"cytoplasmic side of late endosome membrane","canonical_id":"go:GO:0098560","description":"\"The leaflet of the late endosome membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:lr]","metadata":null},{"id":"6db7fcb50f9d45efa62d5cf2693d65a0","type":"GO_TERM","name":"cytoplasmic side of lysosomal membrane","canonical_id":"go:GO:0098574","description":"\"The leaflet of the lysosomal membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"35af8ddb8e1d414d8ea3966eaa0069f3","type":"GO_TERM","name":"cytoplasmic side of medial-Golgi cisterna membrane","canonical_id":"go:GO:0160279","description":"\"The leaflet of the medial-Golgi cisternae membrane that faces the cytoplasm,including any protein embedded in, attached to, or peripherally associated with it. This is the site of interactions with cytosolic proteins involved in membrane trafficking, vesicle docking, and cargo sorting.\" [PMID:28777890, PMID:34597626, PMID:39658747]","metadata":null},{"id":"8b4b2dfbba1e44cc9972f85d5816a50a","type":"GO_TERM","name":"cytoplasmic side of membrane","canonical_id":"go:GO:0098562","description":"\"The leaflet of a membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"3be34d492f3f465f9c2e6651ba1d4a3c","type":"GO_TERM","name":"cytoplasmic side of mitochondrial outer membrane","canonical_id":"go:GO:0032473","description":"\"The leaflet of the mitochondrial outer membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:mah]","metadata":null},{"id":"04a89f833a5f47f4961ad328085c17db","type":"GO_TERM","name":"cytoplasmic side of nuclear pore","canonical_id":"go:GO:1990876","description":"\"The side of the nuclear pore complex (NPC) that faces the cytoplasm.\" [PMID:8422679]","metadata":null},{"id":"370f004115d34abb92b3427fc5f43ef7","type":"GO_TERM","name":"cytoplasmic side of plasma membrane","canonical_id":"go:GO:0009898","description":"\"The leaflet of the plasma membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos, GOC:tb]","metadata":null},{"id":"381b9ef0faab4766ae21060fd215ac46","type":"GO_TERM","name":"cytoplasmic side of plasma membrane, cell tip","canonical_id":"go:GO:0106186","description":"\"The leaflet the plasma membrane at the cell tip that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:vw, PMID:28292899]","metadata":null},{"id":"941c9ae737d54548ba8698ea2b72cfc3","type":"GO_TERM","name":"cytoplasmic side of rough endoplasmic reticulum membrane","canonical_id":"go:GO:0098556","description":"\"The leaflet of the rough endoplasmic reticulum membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"eee58aea72e34a86b8876ac07d2232f7","type":"GO_TERM","name":"cytoplasmic side of smooth endoplasmic reticulum membrane","canonical_id":"go:GO:0098557","description":"\"The leaflet of the smooth endoplasmic reticulum membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"9c8d274a996644949072e0f12179db54","type":"GO_TERM","name":"cytoplasmic side of trans-Golgi cisterna membrane","canonical_id":"go:GO:0160288","description":"\"The leaflet of the trans-Golgi cisternae membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it. This is the site where vesicle formation, and cargo sorting towards post-Golgi destinations such as endosomes, lysosomes and the plasma membrane occur.\" [PMID:23913272, PMID:34597626, PMID:37566051]","metadata":null},{"id":"70a0140a6e274c7c88a386418ad20e3d","type":"GO_TERM","name":"cytoplasmic side of trans-Golgi network membrane","canonical_id":"go:GO:0160281","description":"\"The leaflet of the trans-Golgi network membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it. This is the site of interaction where cytoplasmic proteins interact with proteins involved in vesicle formation and targeting.\" [PMID:10922460, PMID:23913272, PMID:34597626]","metadata":null},{"id":"9bc288d21e5047c0851d31cc2ec290b8","type":"GO_TERM","name":"cytoplasmic side of trans-Golgi network transport vesicle membrane","canonical_id":"go:GO:0098541","description":"\"The leaflet of the trans-Golgi network transport vesicle membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab]","metadata":null},{"id":"da2a8b5a065e4faeb6cdc6518c48548c","type":"GO_TERM","name":"cytoplasmic side of transport vesicle membrane","canonical_id":"go:GO:0098539","description":"\"The leaflet of the transport vesicle membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab]","metadata":null},{"id":"44fd9cd164f74f32afc03fc95bc41882","type":"GO_TERM","name":"cytoplasmic streaming","canonical_id":"go:GO:0099636","description":"\"The directed flow of cytosol (the liquid component of the cytoplasm) and the organelles it contains.\" [GOC:dos, Wikipedia:Cytoplasmic_streaming&oldid=706214009]","metadata":null},{"id":"570052416ec44ff8940995521baaec15","type":"GO_TERM","name":"cytoplasmic stress granule","canonical_id":"go:GO:0010494","description":"\"A dense aggregation in the cytosol composed of proteins and RNAs that appear when the cell is under stress.\" [GOC:ans, PMID:17284590, PMID:17601829, PMID:17967451, PMID:20368989]","metadata":null},{"id":"12cfef5160ca4255a57e54a2a8aa9209","type":"GO_TERM","name":"cytoplasmic stress granule assembly","canonical_id":"go:GO:0034063","description":"\"The aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic stress granule.\" [GOC:mah, PMID:17392519]","metadata":null},{"id":"4c60397f8caf4f38a34289051011a5a4","type":"GO_TERM","name":"cytoplasmic stress granule disassembly","canonical_id":"go:GO:0035617","description":"\"The disaggregation of a cytoplasmic stress granule into its constituent protein and RNA parts.\" [GOC:BHF, PMID:19825938]","metadata":null},{"id":"40aad24d06b141ec8216fad8418baae0","type":"GO_TERM","name":"cytoplasmic translation","canonical_id":"go:GO:0002181","description":"\"The chemical reactions and pathways resulting in the formation of a protein in the cytoplasm. This is a ribosome-mediated process in which the information in messenger RNA (mRNA) is used to specify the sequence of amino acids in the protein.\" [GOC:hjd]","metadata":null},{"id":"08e4909e36534020aed1495fab7b0345","type":"GO_TERM","name":"cytoplasmic translational elongation","canonical_id":"go:GO:0002182","description":"\"The successive addition of amino acid residues to a nascent polypeptide chain during protein biosynthesis in the cytoplasm.\" [GOC:hjd]","metadata":null},{"id":"fe6875a21f4c41d0a9be05daa92827ce","type":"GO_TERM","name":"cytoplasmic translational elongation through polyproline stretches","canonical_id":"go:GO:0097622","description":"\"The successive addition of amino acid residues to a nascent polypeptide chain, proceeding through regions of multiple repeated proline codons, during protein biosynthesis in the cytoplasm.\" [GOC:mcc, PMID:24923804]","metadata":null},{"id":"8621e6daab9648dea705e406c57d9aae","type":"GO_TERM","name":"cytoplasmic translational initiation","canonical_id":"go:GO:0002183","description":"\"The process preceding formation of the peptide bond between the first two amino acids of a protein in the cytoplasm. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA.\" [GOC:hjd]","metadata":null},{"id":"992cf47065f543a2b35bb18bb0565a9f","type":"GO_TERM","name":"cytoplasmic translational termination","canonical_id":"go:GO:0002184","description":"\"The process resulting in the release of a polypeptide chain from the ribosome in the cytoplasm, usually in response to a termination codon.\" [GOC:hjd]","metadata":null},{"id":"3aa0b686c14b47198c228f1519658c3d","type":"GO_TERM","name":"cytoplasmic ubiquitin ligase complex","canonical_id":"go:GO:0000153","description":"\"A ubiquitin ligase complex found in the cytoplasm.\" [GOC:mah]","metadata":null},{"id":"7414cb7ac1bc44e6bfa6d9d69acf5d3e","type":"GO_TERM","name":"cytoplasmic vesicle","canonical_id":"go:GO:0031410","description":"\"A vesicle found in the cytoplasm of a cell.\" [GOC:ai, GOC:mah, GOC:vesicles]","metadata":null},{"id":"7959a4bd1334405aa9986ea195fb17b3","type":"GO_TERM","name":"cytoplasmic vesicle lumen","canonical_id":"go:GO:0060205","description":"\"The volume enclosed by a cytoplasmic vesicle.\" [GOC:dph, GOC:vesicles]","metadata":null},{"id":"3ba73b01f8ce49429b1694837027bff3","type":"GO_TERM","name":"cytoplasmic vesicle membrane","canonical_id":"go:GO:0030659","description":"\"The lipid bilayer surrounding a cytoplasmic vesicle.\" [GOC:mah]","metadata":null},{"id":"5a2856a9090a46bf9a7d6a6756dabab8","type":"GO_TERM","name":"cytoplasmic viral factory","canonical_id":"go:GO:0039714","description":"\"A viral factory located in the cytoplasm of a host cell.\" [VZ:1951]","metadata":null},{"id":"4010a7898d404e5da945a6bcc60998e9","type":"GO_TERM","name":"cytoproct","canonical_id":"go:GO:0031911","description":"\"Stable, specialized structure for extrusion of waste by the cell into the surrounding medium.\" [PMID:10503189, PMID:23317460, PMID:27889663]","metadata":null},{"id":"8e8f74635f0a425081c4146fbafe6541","type":"GO_TERM","name":"cytosine C-5 DNA demethylase activity","canonical_id":"go:GO:0051747","description":"\"Catalysis of the reaction: methyl-dCpdG DNA + H2O = dCpdG DNA + methanol. This reaction is the hydrolytic removal of the methyl group on the 5 position of cytosine in DNA.\" [PMID:10050851]","metadata":null},{"id":"c4674293b4fc436e825edb40652449ef","type":"GO_TERM","name":"cytosine binding","canonical_id":"go:GO:0002056","description":"\"Binding to cytosine.\" [GOC:hjd, GOC:vw]","metadata":null},{"id":"466086baef5a405ebe7872db3bb5bc37","type":"GO_TERM","name":"cytosine catabolic process","canonical_id":"go:GO:0006209","description":"\"The chemical reactions and pathways resulting in the breakdown of cytosine, 4-amino-2-hydroxypyrimidine, a pyrimidine derivative that is one of the five main bases found in nucleic acids; it occurs widely in cytidine derivatives.\" [GOC:curators]","metadata":null},{"id":"fc402c73124d420695c1f7f1d3f78f91","type":"GO_TERM","name":"cytosine deaminase activity","canonical_id":"go:GO:0004131","description":"\"Catalysis of the reaction: cytosine + H2O = uracil + NH4+.\" [RHEA:20605]","metadata":null},{"id":"461782c00f7d4aba9e2f66d601ea923f","type":"GO_TERM","name":"cytosine metabolic process","canonical_id":"go:GO:0019858","description":"\"The chemical reactions and pathways involving cytosine, 4-amino-2-hydroxypyrimidine, a pyrimidine derivative that is one of the five main bases found in nucleic acids; it occurs widely in cytidine derivatives.\" [GOC:ai]","metadata":null},{"id":"3ead23e1df544da98e6e6111bfbffbec","type":"GO_TERM","name":"cytosine transmembrane transporter activity","canonical_id":"go:GO:0015209","description":"\"Enables the transfer of cytosine, 4-amino-2-hydroxypyrimidine from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"84ab16b3c8a8401eacb90af3318a7e22","type":"GO_TERM","name":"cytosine transport","canonical_id":"go:GO:0015856","description":"\"The directed movement of cytosine, 4-amino-2-hydroxypyrimidine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"954fd969dabe43aba3cbd229077d7e73","type":"GO_TERM","name":"cytosine/cytosine mispair binding","canonical_id":"go:GO:0035486","description":"\"Binding to a double-stranded DNA region containing a C/C mispair.\" [GOC:bf, GOC:jh]","metadata":null},{"id":"ca47ab33eaba47e784e398af2a9abac0","type":"GO_TERM","name":"cytosine/thymine mispair binding","canonical_id":"go:GO:0035488","description":"\"Binding to a double-stranded DNA region containing a C/T mispair.\" [GOC:bf, GOC:jh]","metadata":null},{"id":"fd6973d5c08946d0a69da407dddfb71f","type":"GO_TERM","name":"cytosine:proton symporter activity","canonical_id":"go:GO:0015504","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: cytosine(out) + H+(out) = cytosine(in) + H+(in).\" [TC:2.A.39.1.1]","metadata":null},{"id":"0cccc023ef8440c5b2ea358d4dea0d95","type":"GO_TERM","name":"cytoskeletal adaptor activity","canonical_id":"go:GO:0008093","description":"\"The binding activity of a protein that brings together a cytoskeletal protein (either a microtubule or actin filament, spindle pole body, or protein directly bound to them) and one or more other molecules, permitting them to function in a coordinated way.\" [GOC:mtg_MIT_16mar07, PMID:30323238]","metadata":null},{"id":"f04ceec6be634e0da7fa294dd4ecacfa","type":"GO_TERM","name":"cytoskeletal calyx","canonical_id":"go:GO:0033150","description":"\"A large cytoskeletal structure located at the posterior end of the perinuclear theca of a mammalian sperm head. The nucleus is tightly associated with the calyx, which contains calicin and basic cylicin proteins.\" [PMID:12243744, PMID:9184090]","metadata":null},{"id":"9a0136eb724a48ca9147abe9abc6f353","type":"GO_TERM","name":"cytoskeletal matrix organization at active zone","canonical_id":"go:GO:0048789","description":"\"The assembly and arrangement of cytomatrix proteins to form complexes in the cell cortex beneath the active zone, i.e. just beneath the presynaptic plasma membrane.\" [GOC:dh, GOC:ef, GOC:jid, PMID:12812759]","metadata":null},{"id":"5613d86b0b244c62b9b9a9d8cf8b5a8f","type":"GO_TERM","name":"cytoskeletal motor activator activity","canonical_id":"go:GO:0140660","description":"\"Binds to and increases the activity of a motor protein.\" [PMID:33221250]","metadata":null},{"id":"73fad46dc1da4b33983f41cb49d98cfb","type":"GO_TERM","name":"cytoskeletal motor activity","canonical_id":"go:GO:0003774","description":"\"Generation of force resulting in movement, for example along a microfilament or microtubule, or in torque resulting in membrane scission or rotation of a flagellum. The energy required is obtained either from the hydrolysis of a nucleoside triphosphate or by an electrochemical proton gradient (proton-motive force).\" [GOC:mah, GOC:vw, PMID:11242086, PMID:29716949]","metadata":null},{"id":"e77daf9da81044389e5de440329269c0","type":"GO_TERM","name":"cytoskeletal motor inhibitor activity","canonical_id":"go:GO:0140661","description":"\"Binds to and stops, prevents, or reduces the activity of a motor protein.\" [PMID:23142046]","metadata":null},{"id":"2a412212b5f4446bae8867a250c12db0","type":"GO_TERM","name":"cytoskeletal motor regulator activity","canonical_id":"go:GO:0140659","description":"\"Binds to and modulates the activity of a motor protein.\" [PMID:23142046, PMID:33221250]","metadata":null},{"id":"d6529f6c9862443e9749a5841f1321f8","type":"GO_TERM","name":"cytoskeletal protein binding","canonical_id":"go:GO:0008092","description":"\"Binding to a protein component of a cytoskeleton (actin, microtubule, or intermediate filament cytoskeleton).\" [GOC:mah]","metadata":null},{"id":"824d80c5e4034ca6b984a1305f9675a7","type":"GO_TERM","name":"cytoskeletal protein-membrane anchor activity","canonical_id":"go:GO:0106006","description":"\"The binding activity of a molecule that brings together a cytoskeletal protein or protein complex and a plasma membrane lipid or membrane-associated protein, in order to maintain the localization of the cytoskeleton at a specific cortical membrane location.\" [PMID:25736293, PMID:30840879]","metadata":null},{"id":"2991e3ce63904820bdb99b997937d402","type":"GO_TERM","name":"cytoskeletal rearrangement involved in phagocytosis, engulfment","canonical_id":"go:GO:0060097","description":"\"The assembly, arrangement, or disassembly of cytoskeletal structures that is involved in the internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis.\" [GOC:dph]","metadata":null},{"id":"6d0179bd75eb4a0c8ed81196ef70d774","type":"GO_TERM","name":"cytoskeletal regulatory protein binding","canonical_id":"go:GO:0005519","description":"\"Binding to a protein involved in modulating the reorganization of the cytoskeleton.\" [GOC:curators, PMID:15163540]","metadata":null},{"id":"257325467b2f4a9a9f59048120f81923","type":"GO_TERM","name":"cytoskeleton","canonical_id":"go:GO:0005856","description":"\"A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles.\" [GOC:mah, PMID:16959967, PMID:27419875]","metadata":null},{"id":"3740f8aeb3ed45ddbcf5abd890231243","type":"GO_TERM","name":"cytoskeleton of dendritic spine","canonical_id":"go:GO:0098836","description":"\"The portion of the cytoskeleton that lies within a dendritic spine. The actin component of this cytoskeleton is involved in spine head remodeling in response to postsynaptic signaling.\" [PMID:24854120]","metadata":null},{"id":"265b0443f25d4d63941794f1ef0e6436","type":"GO_TERM","name":"cytoskeleton of presynaptic active zone","canonical_id":"go:GO:0048788","description":"\"The specialized cytoskeletal matrix of the presynaptic active zone. It has specialized functions in organizing synaptic events such as immobilisation or translocation of synaptic vesicles, and assembling active zone components. It is believed to form a molecular scaffold that organizes neurotransmitter release sites.\" [GOC:dh, GOC:dl, GOC:ef, GOC:jid, NIF_Subcellular:sao1470121605, PMID:10944438]","metadata":null},{"id":"92ce46bfc06542b4b16233d2cf7dcb20","type":"GO_TERM","name":"cytoskeleton organization","canonical_id":"go:GO:0007010","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"dda5d0e60e9f4f719c2b940a3d24c3e3","type":"GO_TERM","name":"cytoskeleton-dependent cytokinesis","canonical_id":"go:GO:0061640","description":"\"A cytokinesis that involves the function of a set of proteins that are part of the microfilament or microtubule cytoskeleton.\" [GOC:dph]","metadata":null},{"id":"219bde5158ae4627b93af51aa4dabc15","type":"GO_TERM","name":"cytoskeleton-dependent cytoplasmic transport, nurse cell to oocyte","canonical_id":"go:GO:0019749","description":"\"The directed movement of substances along cytoskeletal elements, such as microfilaments or microtubules, from a nurse cell to an oocyte.\" [GOC:ai]","metadata":null},{"id":"c06282138c89441a8c906d30cc93cda4","type":"GO_TERM","name":"cytoskeleton-dependent intracellular transport","canonical_id":"go:GO:0030705","description":"\"The directed movement of substances along cytoskeletal fibers such as microfilaments or microtubules within a cell.\" [GOC:mah]","metadata":null},{"id":"207bb13c9a064bbdbb621d1b9ccc671b","type":"GO_TERM","name":"cytoskeleton-mediated cell swimming","canonical_id":"go:GO:0071979","description":"\"Cell motility in which contractile cytoskeletal elements alter cell shape, resulting in the smooth movement of a cell through a liquid medium.\" [PMID:18461074]","metadata":null},{"id":"2f20f70c9c6347f1bb578fd7d785327e","type":"GO_TERM","name":"cytoskeleton-nuclear membrane anchor activity","canonical_id":"go:GO:0140444","description":"\"The binding activity of a molecule that brings together a cytoskeletal protein or protein complex and a nuclear membrane lipid or membrane-associated protein, in order to maintain the localization of the cytoskeleton at a specific location of the nuclear membrane.\" [PMID:16237665]","metadata":null},{"id":"bb410e227d584776ba3ead67eda80a08","type":"GO_TERM","name":"cytosol","canonical_id":"go:GO:0005829","description":"\"The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.\" [GOC:hjd, GOC:jl]","metadata":null},{"id":"5877089871dd492eae9cbcd87a20377a","type":"GO_TERM","name":"cytosol pyruvate dehydrogenase (lipoamide) phosphatase complex","canonical_id":"go:GO:0045249","description":"\"A cytosolic complex of a regulatory and catalytic subunit that catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex.\" [GOC:mtg_sensu, PMID:9395502]","metadata":null},{"id":"33cb3b062cdb470a917df6be1653388a","type":"GO_TERM","name":"cytosol to ERGIC protein transport","canonical_id":"go:GO:0106273","description":"\"The directed movement of proteins from the cystosol to the endoplasmic reticulum-Golgi intermediate compartment (ERGIC).\" [PMID:32272059]","metadata":null},{"id":"7a6fe9b78f6d40c49dbce5d1e7daae85","type":"GO_TERM","name":"cytosol to Golgi apparatus transport","canonical_id":"go:GO:0140820","description":"\"The directed movement of substances from the cytosol into the Golgi apparatus of a cell.\" [PMID:28373556]","metadata":null},{"id":"0db1fe9d494d4c46a314f903ccd1f04e","type":"GO_TERM","name":"cytosol to endoplasmic reticulum transport","canonical_id":"go:GO:0046967","description":"\"The directed movement of substances from the cytosol to the endoplasmic reticulum of a cell.\" [GOC:ai]","metadata":null},{"id":"1991b37694044af5b6209b8fe3623ec7","type":"GO_TERM","name":"cytosolic DNA-directed RNA polymerase complex","canonical_id":"go:GO:0000345","description":"\"The eubacterial DNA-directed RNA polymerase is a multisubunit complex with a core composed of the essential subunits beta-prime, beta, and two copies of alpha and a fifth nonessential subunit called omega. An additional subunit, a sigma factor, is required for promoter recognition and specificity.\" [PMID:11158566]","metadata":null},{"id":"157635b680f846a98373041fdec0f77c","type":"GO_TERM","name":"cytosolic [4Fe-4S] assembly scaffold complex","canonical_id":"go:GO:1904564","description":"\"A heterotetrameric complex with weak ATPase activity that is capable of scaffolding a 4Fe-4S (iron-sulfur) cluster. In yeast, the subunits are Nbp35 and Cfd1. In humans, the subunits are NUBP1 and NUBP2.\" [GO_REF:0000088, GOC:bhm, GOC:rb, PMID:26195633, PMID:34660592]","metadata":null},{"id":"6f4f3e45e53d4882975c0d31ee958c77","type":"GO_TERM","name":"cytosolic [4Fe-4S] assembly targeting complex","canonical_id":"go:GO:0097361","description":"\"A protein complex capable of condensing two 2Fe-2S clusters into one 4Fe-4S center in the cytoplasm and nucleus. In humans it consists of MMS19, CIAO1, CIAO2A/CIAO2B, CIAO3. MMS19, CIAO1 and CIAO2A/CIAO2B form a tight 'core' complex, whereas CIAO3 is an 'external' component of this complex.\" [PMID:23585563, PMID:23891004, PMID:34660592]","metadata":null},{"id":"e71004e21c5f4949b8784c2d04acba9e","type":"GO_TERM","name":"cytosolic aryl hydrocarbon receptor complex","canonical_id":"go:GO:0034752","description":"\"An aryl hydrocarbon receptor complex found in the cytosol, in which the ligand-binding subunit AhR is not bound to ligand; consists of AhR, two molecules of HSP90, the protein kinase c-Src, and the immunophilin XAP2/AIP.\" [PMID:7598497, PMID:8937476, PMID:9447995]","metadata":null},{"id":"c996dcd16e5e4f59a112e0c2a63bcdab","type":"GO_TERM","name":"cytosolic ciliogenesis","canonical_id":"go:GO:0061824","description":"\"The process in which an axoneme is exposed entirely or partially to the cytoplasm or by which the cytoplasmic portion is assembled or extended. Cytosolic ciliogenesis can occur following compartmentalized ciliogenesis, in which the cilium is formed within a compartment separated from the cytoplasm.\" [PMID:25447994, PMID:26654377]","metadata":null},{"id":"775383bd128244acb63017afdd7cc310","type":"GO_TERM","name":"cytosolic creatine kinase complex","canonical_id":"go:GO:0002186","description":"\"A dimeric protein complex having creatine kinase activity.\" [PMID:173175]","metadata":null},{"id":"6e893cae2a0d4363a2cc64c8b750e999","type":"GO_TERM","name":"cytosolic electron transfer flavoprotein complex","canonical_id":"go:GO:0045247","description":"\"A protein complex located in the cytosol containing flavin adenine dinucleotide (FAD) that, together with an acyl-CoA dehydrogenase, forms a system that oxidizes an acyl-CoA molecule and reduces ubiquinone and other acceptors.\" [GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"89047a203a234d4f829b53eec766fdd1","type":"GO_TERM","name":"cytosolic large ribosomal subunit","canonical_id":"go:GO:0022625","description":"\"The large subunit of a ribosome located in the cytosol.\" [GOC:mtg_sensu]","metadata":null},{"id":"122b51dedef244fba0514728bca54030","type":"GO_TERM","name":"cytosolic large ribosomal subunit assembly","canonical_id":"go:GO:0180023","description":"\"The aggregation, arrangement and bonding together of a set of components to form a cytosolic large ribosomal subunit.\" [PMID:30467428]","metadata":null},{"id":"6473188dc07d4738825e35b32774c07a","type":"GO_TERM","name":"cytosolic lipolysis","canonical_id":"go:GO:0061725","description":"\"The chemical reactions and pathways resulting in the breakdown of lipid droplets and hydrolysis of stored triglycerides occurring through the orchestrated activation of cytosolic lipases.\" [GOC:autophagy]","metadata":null},{"id":"f491713c112b45758bb38acf2a4b7ddd","type":"GO_TERM","name":"cytosolic mRNA polyadenylation","canonical_id":"go:GO:0180011","description":"\"Any process by which dormant, translationally inactive mRNAs become activated, or mRNAs become stabilized, via the elongation of their poly(A) tails in the cytosol.\" [PMID:21536428]","metadata":null},{"id":"d8eadab94a004f3f92bda4956a6db56c","type":"GO_TERM","name":"cytosolic proteasome complex","canonical_id":"go:GO:0031597","description":"\"A proteasome complex found in the cytosol of a cell.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"d951ea779b7e48aa99973bfdf0af70e1","type":"GO_TERM","name":"cytosolic proteasome core complex","canonical_id":"go:GO:0031603","description":"\"The core complex of a proteasome located in the cytosol of a cell.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"3b43b064ff9f4867be30054390b78aab","type":"GO_TERM","name":"cytosolic proteasome core complex, alpha-subunit complex","canonical_id":"go:GO:0031606","description":"\"The proteasome core subcomplex that constitutes the two outer rings of the cytosolic proteasome core complex.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"146db012335d472190f5aad318a654e0","type":"GO_TERM","name":"cytosolic proteasome core complex, beta-subunit complex","canonical_id":"go:GO:0031609","description":"\"The proteasome core subcomplex that constitutes the two inner rings of the cytosolic proteasome core complex.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"51ec4ba75f024a199b2f76f6158597e1","type":"GO_TERM","name":"cytosolic proteasome regulatory particle","canonical_id":"go:GO:0031600","description":"\"A multisubunit complex located in the cytosol of a cell, which caps one or both ends of the proteasome core complex. This complex recognizes, unfolds ubiquitinated proteins and translocates them to the proteasome core complex.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"e3f59f77ff04445c842392813f12617f","type":"GO_TERM","name":"cytosolic proteasome regulatory particle, base subcomplex","canonical_id":"go:GO:0031612","description":"\"The subcomplex of the proteasome regulatory particle that directly associates with the proteasome core complex located in the cytosol of the cell.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"9ff7f9b6a6a0465b9074ce07a99da2ab","type":"GO_TERM","name":"cytosolic proteasome regulatory particle, lid subcomplex","canonical_id":"go:GO:0031615","description":"\"The subcomplex of the cytosolic proteasome regulatory particle that forms the peripheral lid, which is added on top of the base subcomplex.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"51993d5a34f140d8afe32d61ce07a2e6","type":"GO_TERM","name":"cytosolic region","canonical_id":"go:GO:0099522","description":"\"Any (proper) part of the cytosol of a single cell of sufficient size to still be considered cytosol.\" [GOC:dos]","metadata":null},{"id":"1b341e450f404e6f92951af2bee66297","type":"GO_TERM","name":"cytosolic ribosome","canonical_id":"go:GO:0022626","description":"\"A ribosome located in the cytosol.\" [GOC:mtg_sensu]","metadata":null},{"id":"a59499b88d70459aaa4cad56beaedec8","type":"GO_TERM","name":"cytosolic ribosome assembly","canonical_id":"go:GO:0042256","description":"\"The aggregation, arrangement and bonding together of the large and small ribosomal subunits into a functional cytosolic ribosome. Distinct stages of this process take place first in the nucleolus, then in the nucleus and finally in the cytosol.\" [GOC:ma, PMID:30467428]","metadata":null},{"id":"b4f9a08b82a442b8a03838ef110b38a2","type":"GO_TERM","name":"cytosolic ribosome hibernation","canonical_id":"go:GO:0141014","description":"\"A cellular process that results in the silencing of ribosomes in quiescent cells. Quiescence takes place when cells encounter unfavorable conditions and cease to grow in bacteria and yeast. It also takes place in some specialized cells in higher eukaryotes, such as eggs. Ribosomes in a hibernation state are kept silent via association with proteins with inhibitory and protective functions.\" [PMID:28468753, PMID:30177741, PMID:36653451]","metadata":null},{"id":"583f8843d4744b8783ba65f097781a76","type":"GO_TERM","name":"cytosolic small ribosomal subunit","canonical_id":"go:GO:0022627","description":"\"The small subunit of a ribosome located in the cytosol.\" [GOC:mtg_sensu]","metadata":null},{"id":"f9bc7e19bc99439380b3e7453810c832","type":"GO_TERM","name":"cytosolic small ribosomal subunit assembly","canonical_id":"go:GO:0180025","description":"\"The aggregation, arrangement and bonding together of a set of components to form a cytosolic small ribosomal subunit.\" [PMID:30467428]","metadata":null},{"id":"dcc36ae0fe234e9fa4b0b89077baecaa","type":"GO_TERM","name":"cytosolic tRNA wobble base thiouridylase complex","canonical_id":"go:GO:0002144","description":"\"A complex of two proteins involved in the thiolation of uridine 34 (U34) of tRNAs decoding two-family box triplets.\" [PMID:17062623, PMID:18391219]","metadata":null},{"id":"591676fcc0624f20b9f17c216d56f4cb","type":"GO_TERM","name":"cytosolic translation preinitiation complex","canonical_id":"go:GO:0070993","description":"\"A ribonucleoprotein complex that contains the small ribosomal subunit, a translation initiation ternary complex (i.e. an initiator tRNA, GTP, and an IF2 or eIF2 complex), and an mRNA.\" [GOC:hjd, GOC:mah]","metadata":null},{"id":"7821ceb5a7e8417287d8e6e42ebf8986","type":"GO_TERM","name":"cytosolic transport","canonical_id":"go:GO:0016482","description":"\"The directed movement of substances or organelles within the cytosol.\" [GOC:ai]","metadata":null},{"id":"f3f6765b915749dd92cb92f7a5bf0580","type":"GO_TERM","name":"cytosolic valyl-tRNA aminoacylation","canonical_id":"go:GO:0061475","description":"\"The process of coupling valine to valyl-tRNA in the cytosol, catalyzed by valyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:dph]","metadata":null},{"id":"3599981c93b74a2cbcca87b51b12f1ef","type":"GO_TERM","name":"cytospinule","canonical_id":"go:GO:0160231","description":"\"An actin-based cell projection extending laterally from the basolateral membrane of tuft cells in epithelial tissues, including the intestinal epithelium. These thin projections, typically 3-4 per cell and up to 3 micron long, directly contact the nuclei of adjacent epithelial cells, potentially facilitating intercellular communication and molecular exchange.\" [PMID:28490731, PMID:37863104]","metadata":null},{"id":"534e766ef6244ec78ed4b628dec09c20","type":"GO_TERM","name":"cytostome","canonical_id":"go:GO:0031910","description":"\"Stable, specialized structure for the ingestion of food by the cell into phagosomes.\" [PMID:10503189]","metadata":null},{"id":"77d7db1283dd407bab4cd144c3e6a36b","type":"GO_TERM","name":"cytosylglucuronate decarboxylase activity","canonical_id":"go:GO:1990965","description":"\"Catalysis of the reaction: cytosylglucuronic acid + H+ = cytosylarabinopyranose + CO2.\" [GOC:pr, GOC:tb, PMID:23874663]","metadata":null},{"id":"45b40185f96c438498969001b2215e23","type":"GO_TERM","name":"cytotoxic T cell degranulation","canonical_id":"go:GO:0043316","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as perforin and granzymes by a cytotoxic T cell.\" [ISBN:0781735149]","metadata":null},{"id":"9f38a15aecff45ff9f794978789b7f0e","type":"GO_TERM","name":"cytotoxic T cell differentiation","canonical_id":"go:GO:0045065","description":"\"The process in which a relatively unspecialized T cell acquires specialized features of a cytotoxic T cell.\" [GOC:ai]","metadata":null},{"id":"09582f4de56f4457b38715349c2c0238","type":"GO_TERM","name":"cytotoxic T cell pyroptotic cell death","canonical_id":"go:GO:1902483","description":"\"A pyroptotic cell death process that occurs in a cytotoxic T cell.\" [PMID:32299851]","metadata":null},{"id":"00dbd8ec7c96487eacf6c63be8a4580e","type":"GO_TERM","name":"d-4,5 unsaturated beta-glucuronyl hydrolase activity","canonical_id":"go:GO:0052788","description":"\"Catalysis of the hydrolysis of the glycosidic bond in an unsaturated saccharide between the unsaturated glucuronyl residue at the nonreducing terminus and the saccharide linked to the residue.\" [GOC:mengo_curators, PMID:12729728]","metadata":null},{"id":"411a05b7b77d46adac17ae7377826b06","type":"GO_TERM","name":"dADP binding","canonical_id":"go:GO:0032563","description":"\"Binding to dADP, deoxyadenosine diphosphate.\" [GOC:mah]","metadata":null},{"id":"5b4a2d4553954cccbe480bb15e4b0026","type":"GO_TERM","name":"dADP biosynthetic process","canonical_id":"go:GO:0006173","description":"\"The chemical reactions and pathways resulting in the formation of dADP, deoxyadenosine diphosphate (2'-deoxyadenosine 5'-diphosphate).\" [ISBN:0198506732]","metadata":null},{"id":"61b643dc65534e3685215989f83a3589","type":"GO_TERM","name":"dADP catabolic process","canonical_id":"go:GO:0046057","description":"\"The chemical reactions and pathways resulting in the breakdown of dADP, deoxyadenosine diphosphate (2'-deoxyadenosine 5'-diphosphate).\" [GOC:curators]","metadata":null},{"id":"e26006f1f3df4d099923bc7e255b6659","type":"GO_TERM","name":"dADP metabolic process","canonical_id":"go:GO:0046056","description":"\"The chemical reactions and pathways involving dADP, deoxyadenosine diphosphate (2'-deoxyadenosine 5'-diphosphate).\" [GOC:curators]","metadata":null},{"id":"9e95013e6c5d4a7391ec1e2697e1d240","type":"GO_TERM","name":"dAMP binding","canonical_id":"go:GO:0032562","description":"\"Binding to dAMP, deoxyadenosine monophosphate.\" [GOC:mah]","metadata":null},{"id":"af22893927494400b79f88e0563bc8f3","type":"GO_TERM","name":"dAMP biosynthetic process","canonical_id":"go:GO:0006170","description":"\"The chemical reactions and pathways resulting in the formation of dAMP, deoxyadenosine monophosphate (2'-deoxyadenosine 5'-phosphate).\" [ISBN:0198506732]","metadata":null},{"id":"f645227f4c46495a9737c6a9e1b2dc27","type":"GO_TERM","name":"dAMP catabolic process","canonical_id":"go:GO:0046059","description":"\"The chemical reactions and pathways resulting in the breakdown of dAMP, deoxyadenosine monophosphate (2'-deoxyadenosine 5'-phosphate).\" [GOC:curators]","metadata":null},{"id":"93e56e4c8bf048d0a98a5bb883a6fed4","type":"GO_TERM","name":"dAMP kinase activity","canonical_id":"go:GO:0047506","description":"\"Catalysis of the reaction: dAMP + ATP = dADP + ADP.\" [RHEA:23100]","metadata":null},{"id":"e25bd7e290c24fd196354b01d36b9bbc","type":"GO_TERM","name":"dAMP metabolic process","canonical_id":"go:GO:0046053","description":"\"The chemical reactions and pathways involving dAMP, deoxyadenosine monophosphate (2'-deoxyadenosine 5'-phosphate).\" [GOC:curators]","metadata":null},{"id":"0abde0a4ede6499691be2120ff12c479","type":"GO_TERM","name":"dAMP phosphorylation","canonical_id":"go:GO:0061565","description":"\"The process of introducing a phosphate group into dAMP, deoxyadenosine monophosphate, to produce dADP. Addition of two phosphate groups produces dATP.\" [GOC:dph, PMID:23416111]","metadata":null},{"id":"86a47fb1a2b043acafb62d10529284d1","type":"GO_TERM","name":"dAMP salvage","canonical_id":"go:GO:0106383","description":"\"Any process which produces a dAMP from derivatives of it, without de novo synthesis.\" [PMID:21829339, PMID:6605343]","metadata":null},{"id":"b261c0321df448818bfd38b69e9a1b65","type":"GO_TERM","name":"dATP binding","canonical_id":"go:GO:0032564","description":"\"Binding to dATP, deoxyadenosine triphosphate.\" [GOC:mah]","metadata":null},{"id":"d26518bdb123433aa78c37081a411201","type":"GO_TERM","name":"dATP biosynthetic process","canonical_id":"go:GO:0006175","description":"\"The chemical reactions and pathways resulting in the formation of dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate).\" [ISBN:0198506732]","metadata":null},{"id":"72c43565869b46cd83478678d6f50401","type":"GO_TERM","name":"dATP catabolic process","canonical_id":"go:GO:0046061","description":"\"The chemical reactions and pathways resulting in the breakdown of dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate).\" [GOC:curators]","metadata":null},{"id":"5beced1a8b6c471396ad7499449738c0","type":"GO_TERM","name":"dATP diphosphatase activity","canonical_id":"go:GO:0008828","description":"\"Catalysis of the reaction: dATP + H2O = dAMP + H+ + diphosphate.\" [GOC:pde, PMID:11139615, RHEA:28334]","metadata":null},{"id":"d271705fdf8b41f9a74946eb502b375a","type":"GO_TERM","name":"dATP metabolic process","canonical_id":"go:GO:0046060","description":"\"The chemical reactions and pathways involving dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate).\" [GOC:curators]","metadata":null},{"id":"0aeea13d9e8d470299b4b40f119d9c50","type":"GO_TERM","name":"dATP(dGTP)-DNA purinetransferase activity","canonical_id":"go:GO:0047839","description":"\"Catalysis of the reaction: dATP + depurinated DNA = ribose triphosphate + DNA.\" [EC:2.6.99.1]","metadata":null},{"id":"cbe812a038554eed9dadf16fd735f0ec","type":"GO_TERM","name":"dCDP biosynthetic process","canonical_id":"go:GO:0006240","description":"\"The chemical reactions and pathways resulting in the formation of dCDP, deoxycytidine 5'-diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"7b078faf84fa44a080411a918435da82","type":"GO_TERM","name":"dCDP catabolic process","canonical_id":"go:GO:0006251","description":"\"The chemical reactions and pathways resulting in the breakdown of dCDP, deoxycytidine 5'-diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"41f90e721a92460fbbb8989a4de99cdb","type":"GO_TERM","name":"dCDP metabolic process","canonical_id":"go:GO:0046062","description":"\"The chemical reactions and pathways involving dCDP, deoxycytidine 5'-diphosphate.\" [GOC:curators]","metadata":null},{"id":"fea009af83244813a79190f0e92c39b0","type":"GO_TERM","name":"dCMP biosynthetic process","canonical_id":"go:GO:0046064","description":"\"The chemical reactions and pathways resulting in the formation of dCMP, deoxycytidine monophosphate.\" [GOC:curators]","metadata":null},{"id":"e0f2c701f8e9478197fea88093915037","type":"GO_TERM","name":"dCMP catabolic process","canonical_id":"go:GO:0006249","description":"\"The chemical reactions and pathways resulting in the breakdown of dCMP, deoxycytidine monophosphate.\" [ISBN:0198506732]","metadata":null},{"id":"6d4132674fc04d26b84d042e1db3529b","type":"GO_TERM","name":"dCMP deaminase activity","canonical_id":"go:GO:0004132","description":"\"Catalysis of the reaction: dCMP + H2O = dUMP + NH4+.\" [RHEA:22924]","metadata":null},{"id":"ccd941c0551643d5900c0d517975328a","type":"GO_TERM","name":"dCMP kinase activity","canonical_id":"go:GO:0036431","description":"\"Catalysis of the reaction: ATP + dCMP = ADP + dCDP.\" [RHEA:25094]","metadata":null},{"id":"259b8228fdb64fd4a3853234f7e68991","type":"GO_TERM","name":"dCMP metabolic process","canonical_id":"go:GO:0046063","description":"\"The chemical reactions and pathways involving dCMP, deoxycytidine monophosphate.\" [GOC:curators]","metadata":null},{"id":"e2f783abf1144bbd83930777a71281b7","type":"GO_TERM","name":"dCMP phosphorylation","canonical_id":"go:GO:0061567","description":"\"The process of introducing a phosphate group into dCMP, deoxycytidine monophosphate, to produce dCDP. Addition of two phosphate groups produces dCTP.\" [GOC:dph, PMID:23416111]","metadata":null},{"id":"b2eb7b25d60941c0a410fecd5feba724","type":"GO_TERM","name":"dCMP salvage","canonical_id":"go:GO:0006239","description":"\"Any process that generates dCMP, deoxycytidine monophosphate from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"d339b89884a341b19e42ed67b6e05a54","type":"GO_TERM","name":"dCTP biosynthetic process","canonical_id":"go:GO:0006242","description":"\"The chemical reactions and pathways resulting in the formation of dCTP, deoxycytidine triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"b38829a84e4b49c5818d515e5f3e71ca","type":"GO_TERM","name":"dCTP catabolic process","canonical_id":"go:GO:0006253","description":"\"The chemical reactions and pathways resulting in the breakdown of dCTP, deoxycytidine triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"b3edacd3557042eaa90d58eee723a3b3","type":"GO_TERM","name":"dCTP deaminase (dUMP-forming) activity","canonical_id":"go:GO:0033973","description":"\"Catalysis of the reaction: dCTP + 2 H2O = diphosphate + dUMP + H+ + NH4.\" [EC:3.5.4.30, RHEA:19205]","metadata":null},{"id":"9403c7338bff44bd9025c9b998b48fc9","type":"GO_TERM","name":"dCTP deaminase activity","canonical_id":"go:GO:0008829","description":"\"Catalysis of the reaction: dCTP + H2O + H+ = dUTP + NH4+.\" [RHEA:22680]","metadata":null},{"id":"3e008820201347fba8ff294c2b4184e6","type":"GO_TERM","name":"dCTP diphosphatase activity","canonical_id":"go:GO:0047840","description":"\"Catalysis of the reaction: dCTP + H2O = dCMP + H+ + diphosphate.\" [RHEA:22636]","metadata":null},{"id":"4f9ff8dc62dc4af9aa6c57578e57b3af","type":"GO_TERM","name":"dCTP metabolic process","canonical_id":"go:GO:0046065","description":"\"The chemical reactions and pathways involving dCTP, deoxycytidine triphosphate.\" [GOC:curators]","metadata":null},{"id":"d8dcd145d08b4cfdab749105bb9882ee","type":"GO_TERM","name":"dGDP binding","canonical_id":"go:GO:0032566","description":"\"Binding to dGDP, deoxyguanosine diphosphate.\" [GOC:mah]","metadata":null},{"id":"84fdc18e035045f7b3b15e6344989e13","type":"GO_TERM","name":"dGDP biosynthetic process","canonical_id":"go:GO:0006185","description":"\"The chemical reactions and pathways resulting in the formation of dGDP, deoxyguanosine diphosphate, (2'-deoxyguanosine 5'-diphosphate).\" [ISBN:0198506732]","metadata":null},{"id":"be595b7b1f80479eb3f1823a99a19f67","type":"GO_TERM","name":"dGDP catabolic process","canonical_id":"go:GO:0046067","description":"\"The chemical reactions and pathways resulting in the breakdown of dGDP, deoxyguanosine diphosphate, (2'-deoxyguanosine 5'-diphosphate).\" [GOC:curators]","metadata":null},{"id":"ddf272773fbf4e0e9ea37795f9451984","type":"GO_TERM","name":"dGDP metabolic process","canonical_id":"go:GO:0046066","description":"\"The chemical reactions and pathways involving dGDP, deoxyguanosine diphosphate, (2'-deoxyguanosine 5'-diphosphate).\" [GOC:curators]","metadata":null},{"id":"ae581dd19b1143e6b1cd990a8d4b23ac","type":"GO_TERM","name":"dGMP binding","canonical_id":"go:GO:0032565","description":"\"Binding to dGMP, deoxyguanosine monophosphate.\" [GOC:mah]","metadata":null},{"id":"2cdf05bbb5e948b28c0f2298be610f7a","type":"GO_TERM","name":"dGMP biosynthetic process","canonical_id":"go:GO:0006181","description":"\"The chemical reactions and pathways resulting in the formation of dGMP, deoxyguanosine monophosphate (2'-deoxyguanosine 5'-phosphate).\" [ISBN:0198506732]","metadata":null},{"id":"96f026a3b3704f9888c9ad09df8a370e","type":"GO_TERM","name":"dGMP catabolic process","canonical_id":"go:GO:0046055","description":"\"The chemical reactions and pathways resulting in the breakdown of dGMP, deoxyguanosine monophosphate (2'-deoxyguanosine 5'-phosphate).\" [GOC:curators]","metadata":null},{"id":"0d313ed10a3b4aaeaae31546f5ad299e","type":"GO_TERM","name":"dGMP kinase activity","canonical_id":"go:GO:0050316","description":"\"Catalysis of the reaction: dGMP + ATP = dGDP + ADP.\" [RHEA:12697]","metadata":null},{"id":"395828bc1b9e492ca3077ab9fdf46dd9","type":"GO_TERM","name":"dGMP metabolic process","canonical_id":"go:GO:0046054","description":"\"The chemical reactions and pathways involving dGMP, deoxyguanosine monophosphate (2'-deoxyguanosine 5'-phosphate).\" [GOC:curators]","metadata":null},{"id":"18dc82e9a5b34744b6b09464854706cd","type":"GO_TERM","name":"dGMP salvage","canonical_id":"go:GO:0106384","description":"\"Any process which produces a dGMP from derivatives of it, without de novo synthesis.\" [PMID:21829339, PMID:6605343]","metadata":null},{"id":"c2d150bb5161430e91c173cfa1437d6a","type":"GO_TERM","name":"dGTP binding","canonical_id":"go:GO:0032567","description":"\"Binding to dGTP, deoxyguanosine triphosphate.\" [GOC:mah]","metadata":null},{"id":"974d73e25071422e82f8a11611b37e03","type":"GO_TERM","name":"dGTP biosynthetic process","canonical_id":"go:GO:0046071","description":"\"The chemical reactions and pathways resulting in the formation of dGTP, guanosine triphosphate.\" [GOC:curators]","metadata":null},{"id":"b0fb06d30fc04b65b63f133245e1679d","type":"GO_TERM","name":"dGTP catabolic process","canonical_id":"go:GO:0006203","description":"\"The chemical reactions and pathways resulting in the breakdown of dGTP, guanosine triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"e5d91bfdfe2948a9bebc60b424cb228c","type":"GO_TERM","name":"dGTP diphosphatase activity","canonical_id":"go:GO:0036217","description":"\"Catalysis of the reaction: dGTP + H2O = dGMP + H+ + diphosphate.\" [GOC:dgf, PMID:17090528, PMID:22531138, RHEA:28362]","metadata":null},{"id":"29d5e0afd2dc40edb615be7338a48106","type":"GO_TERM","name":"dGTP metabolic process","canonical_id":"go:GO:0046070","description":"\"The chemical reactions and pathways involving dGTP, guanosine triphosphate.\" [GOC:curators]","metadata":null},{"id":"dd121771c2564f2cb60cecf03d81a302","type":"GO_TERM","name":"dGTPase activity","canonical_id":"go:GO:0008832","description":"\"Catalysis of the reaction: dGTP + H2O = 2'-deoxyguanosine + 2 H+ + triphosphate.\" [RHEA:15193]","metadata":null},{"id":"0f431aced9834086887d3d2750ac7a34","type":"GO_TERM","name":"dIDP phosphatase activity","canonical_id":"go:GO:0097383","description":"\"Catalysis of the reaction: dIDP + H2O = dIMP + H+ + phosphate.\" [GOC:pde, PMID:20385596, RHEA:35211]","metadata":null},{"id":"3aff36e021064ee1b5abce7e6f7cace3","type":"GO_TERM","name":"dIMP salvage","canonical_id":"go:GO:0106385","description":"\"Any process which produces a dIMP from derivatives of it, without de novo synthesis.\" [PMID:8692979]","metadata":null},{"id":"d6e67bc6c5a9485799ef66e2bf37fdd1","type":"GO_TERM","name":"dITP catabolic process","canonical_id":"go:GO:0035863","description":"\"The chemical reactions and pathways resulting in the breakdown of dITP, a deoxyinosine phosphate compound having a triphosphate group at the 5'-position.\" [GOC:dgf]","metadata":null},{"id":"7e1ec6848e4746ca972bfcc2715f94d9","type":"GO_TERM","name":"dITP diphosphatase activity","canonical_id":"go:GO:0035870","description":"\"Catalysis of the reaction: dITP + H2O = dIMP + H+ + diphosphate.\" [GOC:dgf, PMID:21548881, RHEA:28342]","metadata":null},{"id":"0cd2f45eae6845a5b0c3213189342f96","type":"GO_TERM","name":"dTDP biosynthetic process","canonical_id":"go:GO:0006233","description":"\"The chemical reactions and pathways resulting in the formation of dTDP, deoxyribosylthymine diphosphate (2'-deoxyribosylthymine5'-diphosphate).\" [ISBN:0198506732]","metadata":null},{"id":"5a102eadc3bb43229dc8bfa6a24484c7","type":"GO_TERM","name":"dTDP catabolic process","canonical_id":"go:GO:0006246","description":"\"The chemical reactions and pathways resulting in the breakdown of dTDP, deoxyribosylthymine diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"62192b0f4bec4d9bbf84fca93bca244f","type":"GO_TERM","name":"dTDP metabolic process","canonical_id":"go:GO:0046072","description":"\"The chemical reactions and pathways involving dTDP, deoxyribosylthymine diphosphate.\" [GOC:curators]","metadata":null},{"id":"47e393d3431c4323bcbca5c9f3465ade","type":"GO_TERM","name":"dTDP-4-amino-4,6-dideoxy-D-glucose:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0019179","description":"\"Catalysis of the reaction: dTDP-4-amino-4,6-dideoxy-D-glucose + 2-oxoglutarate = dTDP-4-dehydro-6-deoxy-D-glucose + L-glutamate.\" [RHEA:19085]","metadata":null},{"id":"f64e97e8dc6b426e8ce17ec891be1704","type":"GO_TERM","name":"dTDP-4-amino-4,6-dideoxygalactose:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0019180","description":"\"Catalysis of the reaction: dTDP-4-amino-4,6-dideoxy-alpha-D-galactose + 2-oxoglutarate = dTDP-4-dehydro-6-deoxy-alpha-D-glucose + L-glutamate.\" [RHEA:10368]","metadata":null},{"id":"4dc6ed7c98e34fc8b709187df5602399","type":"GO_TERM","name":"dTDP-4-dehydro-6-deoxyglucose reductase activity","canonical_id":"go:GO:0050573","description":"\"Catalysis of the reaction: dTDP-D-fucose + NADP+ = dTDP-4-dehydro-6-deoxy-alpha-D-glucose + H+ + NADPH.\" [EC:1.1.1.266, RHEA:36583]","metadata":null},{"id":"70f1366e00cb40a39e07b5b0b2d4aa67","type":"GO_TERM","name":"dTDP-4-dehydrorhamnose 3,5-epimerase activity","canonical_id":"go:GO:0008830","description":"\"Catalysis of the reaction: dTDP-4-dehydro-6-deoxy-alpha-D-glucose = dTDP-4-dehydro-6-deoxy-L-mannose.\" [EC:5.1.3.13, RHEA:16969]","metadata":null},{"id":"b15a9f2c6be04ac9a68314890b8c7566","type":"GO_TERM","name":"dTDP-4-dehydrorhamnose reductase activity","canonical_id":"go:GO:0008831","description":"\"Catalysis of the reaction: dTDP-6-deoxy-L-mannose + NADP+ = dTDP-4-dehydro-6-deoxy-L-mannose + H+ + NADPH.\" [EC:1.1.1.133, RHEA:21796]","metadata":null},{"id":"7959f28691c84d2c9e2e9eac80babe5a","type":"GO_TERM","name":"dTDP-6-deoxy-L-talose 4-dehydrogenase activity","canonical_id":"go:GO:0047003","description":"\"Catalysis of the reaction: dTDP-6-deoxy-L-talose + NADP+ = dTDP-4-dehydro-6-deoxy-L-mannose + H+ + NADPH.\" [EC:1.1.1.134, RHEA:23648]","metadata":null},{"id":"1861c883226245f5a9558c1fc34de5bc","type":"GO_TERM","name":"dTDP-dihydrostreptose-streptidine-6-phosphate dihydrostreptosyltransferase activity","canonical_id":"go:GO:0047282","description":"\"Catalysis of the reaction: dTDP-L-dihydrostreptose + streptidine 6-phosphate = O-(1->4)-alpha-L-dihydrostreptosyl-streptidine 6-phosphate + dTDP + H+.\" [EC:2.4.2.27, RHEA:24392]","metadata":null},{"id":"53012b47540146f29733ef7cf59a483c","type":"GO_TERM","name":"dTDP-galactose 6-dehydrogenase activity","canonical_id":"go:GO:0033701","description":"\"Catalysis of the reaction: dTDP-D-galactose + 2 NADP+ + H2O = dTDP-D-galacturonate + 2 NADPH + 2 H+.\" [EC:1.1.1.186]","metadata":null},{"id":"0032345970784b9f915a5e33054f41fb","type":"GO_TERM","name":"dTDP-glucose 4,6-dehydratase activity","canonical_id":"go:GO:0008460","description":"\"Catalysis of the reaction: dTDP-glucose = dTDP-4-dehydro-6-deoxy-alpha-D-glucose + H2O.\" [EC:4.2.1.46, RHEA:17221]","metadata":null},{"id":"d3d0dfb9dd774be68176b50490a376df","type":"GO_TERM","name":"dTDP-mannose biosynthetic process","canonical_id":"go:GO:0019308","description":"\"The chemical reactions and pathways resulting in the formation of dTDP-mannose, a substance composed of mannose in glycosidic linkage with deoxyribosylthymine diphosphate.\" [GOC:ai]","metadata":null},{"id":"abae31fcb3034c78a5e2d07232baecea","type":"GO_TERM","name":"dTDP-rhamnose biosynthetic process","canonical_id":"go:GO:0019305","description":"\"The chemical reactions and pathways resulting in the formation of dTDP-rhamnose, a substance composed of rhamnose in glycosidic linkage with deoxyribosylthymine diphosphate.\" [GOC:ai]","metadata":null},{"id":"a9ee4837314b4d07863700b79755ec84","type":"GO_TERM","name":"dTMP biosynthetic process","canonical_id":"go:GO:0006231","description":"\"The chemical reactions and pathways resulting in the formation of dTMP, deoxyribosylthymine monophosphate (2'-deoxyribosylthymine 5'-phosphate).\" [ISBN:0198506732]","metadata":null},{"id":"548bb97605df4730b5ea37a11900f263","type":"GO_TERM","name":"dTMP catabolic process","canonical_id":"go:GO:0046074","description":"\"The chemical reactions and pathways resulting in the breakdown of dTMP, deoxyribosylthymine monophosphate.\" [GOC:curators]","metadata":null},{"id":"9f87f0c4ed1442168159267eda235cd8","type":"GO_TERM","name":"dTMP kinase activity","canonical_id":"go:GO:0004798","description":"\"Catalysis of the reaction: dTMP + ATP = dTDP + ADP.\" [RHEA:13517]","metadata":null},{"id":"8bcf20aae3f34f148f0fe2916fa853b0","type":"GO_TERM","name":"dTMP metabolic process","canonical_id":"go:GO:0046073","description":"\"The chemical reactions and pathways involving dTMP, deoxyribosylthymine monophosphate (2'-deoxyribosylthymine 5'-phosphate).\" [GOC:curators]","metadata":null},{"id":"0f6ad6bfaa424fe897ef55cab8851c2e","type":"GO_TERM","name":"dTMP salvage","canonical_id":"go:GO:0036198","description":"\"Any process which produces dTMP, deoxyribosylthymine monophosphate (2'-deoxyribosylthymine 5'-phosphate) without de novo synthesis.\" [GOC:yaf, PMID:5387459]","metadata":null},{"id":"01b8682a004c4b57a8bfb0f977e19bd1","type":"GO_TERM","name":"dTTP biosynthetic process","canonical_id":"go:GO:0006235","description":"\"The chemical reactions and pathways resulting in the formation of dTTP, deoxyribosylthymine triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"3df0991453164f97b9c4f5c510afc2cb","type":"GO_TERM","name":"dTTP catabolic process","canonical_id":"go:GO:0046076","description":"\"The chemical reactions and pathways resulting in the breakdown of dTTP, deoxyribosylthymine triphosphate.\" [GOC:curators]","metadata":null},{"id":"54ca0311ceb94f5d8ea23ed951079185","type":"GO_TERM","name":"dTTP diphosphatase activity","canonical_id":"go:GO:0036218","description":"\"Catalysis of the reaction: dTTP + H2O = dTMP + H+ + diphosphate.\" [GOC:dgf, PMID:22531138, RHEA:28534]","metadata":null},{"id":"83109352bffe41539df8f66410ccabc0","type":"GO_TERM","name":"dTTP metabolic process","canonical_id":"go:GO:0046075","description":"\"The chemical reactions and pathways involving dTTP, deoxyribosylthymine triphosphate.\" [GOC:curators]","metadata":null},{"id":"ca3a95c35ee14369b2ee29b04308fb07","type":"GO_TERM","name":"dUDP biosynthetic process","canonical_id":"go:GO:0006227","description":"\"The chemical reactions and pathways resulting in the formation of dUDP, deoxyuridine diphosphate (2'-deoxy-5'-uridylyl phosphate).\" [ISBN:0198506732]","metadata":null},{"id":"528802bb12ef4e5084c53956a88b44d7","type":"GO_TERM","name":"dUDP catabolic process","canonical_id":"go:GO:0006257","description":"\"The chemical reactions and pathways resulting in the breakdown of dUDP, deoxyuridine (5'-)diphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"fc4f5410b9c44e719e94638346c8d4fa","type":"GO_TERM","name":"dUDP metabolic process","canonical_id":"go:GO:0046077","description":"\"The chemical reactions and pathways involving dUDP, deoxyuridine (5'-)diphosphate.\" [GOC:curators]","metadata":null},{"id":"ed94ff84e0644241a70df72baad47392","type":"GO_TERM","name":"dUMP biosynthetic process","canonical_id":"go:GO:0006226","description":"\"The chemical reactions and pathways resulting in the formation of dUMP, deoxyuridine monophosphate (2'-deoxyuridine 5'-phosphate).\" [ISBN:0198506732]","metadata":null},{"id":"5f99edafd0434b9f8f8317519bf2bd90","type":"GO_TERM","name":"dUMP catabolic process","canonical_id":"go:GO:0046079","description":"\"The chemical reactions and pathways resulting in the breakdown of dUMP, deoxyuridine (5'-)monophosphate.\" [GOC:curators]","metadata":null},{"id":"d87f50bca82c46649e5e101152e97382","type":"GO_TERM","name":"dUMP kinase activity","canonical_id":"go:GO:0120136","description":"\"Catalysis of the reaction: ATP + dUMP = ADP + dUDP.\" [PMID:3010881, RHEA:30655]","metadata":null},{"id":"064d4128de8f4d108cbe97202ac5313e","type":"GO_TERM","name":"dUMP metabolic process","canonical_id":"go:GO:0046078","description":"\"The chemical reactions and pathways involving dUMP, deoxyuridine (5'-)monophosphate (2'-deoxyuridine 5'-phosphate).\" [GOC:curators]","metadata":null},{"id":"8beb2b68f79a4d3399146c4a30af897b","type":"GO_TERM","name":"dUTP biosynthetic process","canonical_id":"go:GO:0006229","description":"\"The chemical reactions and pathways resulting in the formation of dUTP, deoxyuridine (5'-)triphosphate.\" [ISBN:0198506732]","metadata":null},{"id":"6636420163234e3a829e9b2b10bacd5c","type":"GO_TERM","name":"dUTP catabolic process","canonical_id":"go:GO:0046081","description":"\"The chemical reactions and pathways resulting in the breakdown of dUTP, deoxyuridine (5'-)triphosphate.\" [GOC:curators]","metadata":null},{"id":"37736d074acb420cb5a86d110f2f5113","type":"GO_TERM","name":"dUTP diphosphatase activity","canonical_id":"go:GO:0004170","description":"\"Catalysis of the reaction: dUTP + H2O = dUMP + H+ + diphosphate.\" [RHEA:10248]","metadata":null},{"id":"c5033a5d2e06427086014f0933059714","type":"GO_TERM","name":"dUTP metabolic process","canonical_id":"go:GO:0046080","description":"\"The chemical reactions and pathways involving dUTP, deoxyuridine (5'-)triphosphate.\" [GOC:curators]","metadata":null},{"id":"0da47b010f494472b910fac46f8ea8c7","type":"GO_TERM","name":"dUTP pyrophosphatase inhibitor activity","canonical_id":"go:GO:0004858","description":"\"Binds to and stops, prevents or reduces the activity of dUTP pyrophosphatase.\" [GOC:mah]","metadata":null},{"id":"a206baf58ebd42fb86dcf3330e7cad76","type":"DRUG","name":"dabrafenib","canonical_id":"gtopdb:6494","description":null,"metadata":null},{"id":"a7d48835ec7749e39be17bd43d94a543","type":"COMBINATION_TREATMENT","name":"dabrafenib + digoxin + trametinib","canonical_id":"ctgov_combo:ctgov-combo-3a02ad7b6eb132a7","description":null,"metadata":null},{"id":"522041f7dbcc4a72951bd6d726446664","type":"COMBINATION_TREATMENT","name":"dabrafenib + nivolumab + trametinib","canonical_id":"ctgov_combo:ctgov-combo-092765772c4482d1","description":null,"metadata":null},{"id":"a89b1faf358a47cdad933140b9daaf66","type":"COMBINATION_TREATMENT","name":"dabrafenib + panitumumab","canonical_id":"ctgov_combo:ctgov-combo-a625355c78faea33","description":null,"metadata":null},{"id":"a3aef0ac15a74e229febca1fbf38eecc","type":"COMBINATION_TREATMENT","name":"dabrafenib + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-ddc59ec2aa17e0c6","description":null,"metadata":null},{"id":"0ceeb80eef4c4a66950e34ff291b5552","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-671b16b441963f53","description":null,"metadata":null},{"id":"2dbf47236bc64811844b807f8075d9b9","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-0fd695d621de9a7b","description":null,"metadata":null},{"id":"5c3c5b0db10a47b58a7dbff01481b0ad","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-54f369aaa4f316a2","description":null,"metadata":null},{"id":"fcac64ab7cde4674bbc2d5bd8027514b","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-22058362d1f60e1c","description":null,"metadata":null},{"id":"41e7d54637a24652aad060bf0da73060","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-1ec3151c0937c441","description":null,"metadata":null},{"id":"359cffdeb7f24667869ad4de5b474949","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-02a9f1e9d4e99cee","description":null,"metadata":null},{"id":"a9c3caaef2e64c64bf625efa1b523681","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-da17c293ba1c6937","description":null,"metadata":null},{"id":"47c4411da1894900aaaff1d8d40d1028","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-769c05b4add2122c","description":null,"metadata":null},{"id":"1658a472882840ddb6ae05e7d1c530b9","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-ca29abce2a2d2139","description":null,"metadata":null},{"id":"c3bc94d4753c414090888936b9e3b973","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-b8a25f48cabf729a","description":null,"metadata":null},{"id":"078a31e05cf346d1917dd9e49e22621f","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-2f4a204b3d9c9202","description":null,"metadata":null},{"id":"c00c0571170d4ae59b87b3509ba40719","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-9dea2473fc131ea1","description":null,"metadata":null},{"id":"79763a5b614c427886b7d9a1837466d5","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-c1b82d846a99d682","description":null,"metadata":null},{"id":"59615999ec8b443e81811b418df70897","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-7efea5851bf4e130","description":null,"metadata":null},{"id":"1230d1aedb4c40ff9a1626fd05917826","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-f1608e1c7e3cf9f2","description":null,"metadata":null},{"id":"fb4eebbb8ffe449dadef61af301d7fcd","type":"COMBINATION_TREATMENT","name":"dabrafenib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-ac53fbfb623f6053","description":null,"metadata":null},{"id":"2e94559b77374ab0a6f3cb52c5a2575f","type":"COMBINATION_TREATMENT","name":"dabrafenib + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-192242335ec1b8a1","description":null,"metadata":null},{"id":"2d8f33c9c56f4abcbd8563122a6732d9","type":"DRUG","name":"daclatasvir","canonical_id":"mesh:C549273","description":null,"metadata":null},{"id":"7f751d40c12c4c2fa8aa185d37686eec","type":"DRUG","name":"daclizumab","canonical_id":"gtopdb:6880","description":null,"metadata":null},{"id":"b11264cca2194c64a9516b63b4f532b8","type":"DRUG","name":"daclizumab","canonical_id":"mesh:C096001","description":null,"metadata":null},{"id":"6a937f712b374e40a5c554f9d0b4f975","type":"DRUG","name":"daclizumab","canonical_id":"chembl:CHEMBL1201605","description":null,"metadata":null},{"id":"a30e7889ac04429080502e9f72014f61","type":"COMBINATION_TREATMENT","name":"daclizumab + sirolimus + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-40d1677d1ce68e26","description":null,"metadata":null},{"id":"60262085f7da47e4a63fbb3af88eed50","type":"DRUG","name":"dalbavancin","canonical_id":"mesh:C469289","description":null,"metadata":null},{"id":"d27c22c2d2c54f29853787434c0fcca0","type":"GO_TERM","name":"dalcochinase activity","canonical_id":"go:GO:0102954","description":"\"Catalysis of the reaction: dalcochinin-8'-O-beta-glucoside + H2O = dalcochinin + D-glucopyranose.\" [GOC:pz, PMID:16814564]","metadata":null},{"id":"098b3224550a40a6870a84d75dbcbb9c","type":"DRUG","name":"dalfopristin","canonical_id":"mesh:C113826","description":null,"metadata":null},{"id":"4e79869d3d95462397ed20b7fb7b63ec","type":"DRUG","name":"dalteparin","canonical_id":"gtopdb:6803","description":null,"metadata":null},{"id":"4d14331be0e64135b26718f73498e0b8","type":"DRUG","name":"dalteparin","canonical_id":"chembl:CHEMBL1201460","description":null,"metadata":null},{"id":"66d51ac0b47b44199d3c3703103d4e30","type":"COMBINATION_TREATMENT","name":"dalteparin + enoxaparin + nafamostat + tinzaparin","canonical_id":"ctgov_combo:ctgov-combo-b5f70791418b4cbb","description":null,"metadata":null},{"id":"8dd879e87f0e4a46ad8d465d2aaa9522","type":"COMBINATION_TREATMENT","name":"dalteparin + enoxaparin + tinzaparin","canonical_id":"ctgov_combo:ctgov-combo-24b7bbbabbee6f5c","description":null,"metadata":null},{"id":"25c2a36b6f87463f96b08ef4379b4e8d","type":"COMBINATION_TREATMENT","name":"dalteparin + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-ef56fe00d0633e3b","description":null,"metadata":null},{"id":"9bdef3179bb3487e954dc13d8cefeec8","type":"COMBINATION_TREATMENT","name":"dalteparin + heparin","canonical_id":"ctgov_combo:ctgov-combo-18dba187ed42c5e4","description":null,"metadata":null},{"id":"b112161499cd4ee29130f03f0dfef724","type":"COMBINATION_TREATMENT","name":"dalteparin + tinzaparin","canonical_id":"ctgov_combo:ctgov-combo-4587dacf05a548f7","description":null,"metadata":null},{"id":"5c6dea79b276460c976b07984fa5dcf5","type":"GO_TERM","name":"damaged DNA binding","canonical_id":"go:GO:0003684","description":"\"Binding to damaged DNA.\" [GOC:jl]","metadata":null},{"id":"8e43f5cad7cb4f13931b1317d0403202","type":"GO_TERM","name":"dammarenediol 12-hydroxylase activity","canonical_id":"go:GO:0102556","description":"\"Catalysis of the reaction: dammarenediol-II + NADPH + H+ + O2 = (20S)-protopanaxadiol + NADP + H2O.\" [EC:1.14.14.120, GOC:pz]","metadata":null},{"id":"a6a28bc9b85c41589487146bd78057b8","type":"DRUG","name":"danaparoid","canonical_id":"gtopdb:6804","description":null,"metadata":null},{"id":"0b1c5562b1404e0988f8f7b2e82b0fde","type":"DRUG","name":"danaparoid","canonical_id":"chembl:CHEMBL1201534","description":null,"metadata":null},{"id":"35e3ca14763143da9941391b9ad01de0","type":"DRUG","name":"danazol","canonical_id":"gtopdb:6942","description":null,"metadata":null},{"id":"6ad952c64bd248869c897e5ef966c083","type":"DRUG","name":"danazol","canonical_id":"chembl:CHEMBL1479","description":null,"metadata":null},{"id":"c55b5230f7fc40f4b4f05ea15f85247f","type":"COMBINATION_TREATMENT","name":"danazol + momelotinib","canonical_id":"ctgov_combo:ctgov-combo-9e1e04a270360c1d","description":null,"metadata":null},{"id":"7adae088093c4183b873db7b31a78308","type":"COMBINATION_TREATMENT","name":"danazol + romiplostim","canonical_id":"ctgov_combo:ctgov-combo-d638cfd9027937cb","description":null,"metadata":null},{"id":"3cb8c8fbf1164b9dbff5d43a616359cd","type":"COMBINATION_TREATMENT","name":"danazol + terbutaline","canonical_id":"ctgov_combo:ctgov-combo-ea2f87e987967558","description":null,"metadata":null},{"id":"0718d3d0bac54207bc087ec079fb6370","type":"COMBINATION_TREATMENT","name":"danazol + terbutaline","canonical_id":"ctgov_combo:ctgov-combo-8efdbfd0c21f9aff","description":null,"metadata":null},{"id":"e3c48b81e50a468e86ec19e9f6515190","type":"COMBINATION_TREATMENT","name":"danazol + teriflunomide","canonical_id":"ctgov_combo:ctgov-combo-a730d2d81c6e36e2","description":null,"metadata":null},{"id":"e97edd71e4434d9595193cff0d77213a","type":"DRUG","name":"dantrolene","canonical_id":"gtopdb:4172","description":null,"metadata":null},{"id":"c2e5e426b2e9460c9b7b7a96fba09845","type":"COMBINATION_TREATMENT","name":"dantrolene + pindolol","canonical_id":"ctgov_combo:ctgov-combo-ffb52ce312357aa9","description":null,"metadata":null},{"id":"83edaea410ae4afba7dd6cdc5407f823","type":"DRUG","name":"dantron","canonical_id":"mesh:C004315","description":null,"metadata":null},{"id":"2d3bbf2578454994b0062231353b872b","type":"DRUG","name":"dapagliflozin","canonical_id":"gtopdb:4594","description":null,"metadata":null},{"id":"ed87a61e48a74d299edc4309fe5bae2a","type":"DRUG","name":"dapagliflozin","canonical_id":"mesh:C529054","description":null,"metadata":null},{"id":"b95d6bcb37b94a05ac90875cb2589056","type":"DRUG","name":"dapagliflozin","canonical_id":"chembl:CHEMBL429910","description":null,"metadata":null},{"id":"d0349cc10d614fafa21f0e43f11c9a52","type":"COMBINATION_TREATMENT","name":"dapagliflozin + empagliflozin","canonical_id":"ctgov_combo:ctgov-combo-a1335e7c3fcb371e","description":null,"metadata":null},{"id":"5c945230c984440f945c0cd4ed4e2169","type":"COMBINATION_TREATMENT","name":"dapagliflozin + fluoxetine","canonical_id":"ctgov_combo:ctgov-combo-4252fd4e3f50001a","description":null,"metadata":null},{"id":"7b011560f0a34769a10a5535413fc6ba","type":"COMBINATION_TREATMENT","name":"dapagliflozin + linagliptin","canonical_id":"ctgov_combo:ctgov-combo-34652c5b48f0052e","description":null,"metadata":null},{"id":"ce24f90c30b840fcba49a30ec4efabb4","type":"COMBINATION_TREATMENT","name":"dapagliflozin + liraglutide","canonical_id":"ctgov_combo:ctgov-combo-fcee3337d7b998df","description":null,"metadata":null},{"id":"46e56d94bcc941e7b5bca09f9d92c26d","type":"COMBINATION_TREATMENT","name":"dapagliflozin + semaglutide","canonical_id":"ctgov_combo:ctgov-combo-e42eb85ef494dadc","description":null,"metadata":null},{"id":"2737b68e19ff454caecdbe4b0fb08dfc","type":"COMBINATION_TREATMENT","name":"dapagliflozin + sildenafil","canonical_id":"ctgov_combo:ctgov-combo-ee06c120271ab3cd","description":null,"metadata":null},{"id":"1151c72443014728b6d7c0a74ee924dc","type":"COMBINATION_TREATMENT","name":"dapagliflozin + vildagliptin","canonical_id":"ctgov_combo:ctgov-combo-b96c66ef7a9b748b","description":null,"metadata":null},{"id":"8ef06fa0c7594c8c9e616f95a675894f","type":"GO_TERM","name":"daphnetin-8-O-methyltransferase activity","canonical_id":"go:GO:0102358","description":"\"Catalysis of the reaction: 7,8-dihydroxycoumarin + S-adenosyl-L-methionine = 7-hydroxy-8-methoxycoumarin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:68960]","metadata":null},{"id":"16e7d1aca9914222b9d3c1e29dd5d51c","type":"DRUG","name":"dapiprazole","canonical_id":"gtopdb:7155","description":null,"metadata":null},{"id":"418c040debdb475fbb4a38c68fa48f04","type":"DRUG","name":"dapoxetine","canonical_id":"gtopdb:7901","description":null,"metadata":null},{"id":"ac941f28e21749f581e04e78352b269d","type":"DRUG","name":"dapoxetine","canonical_id":"mesh:C080598","description":null,"metadata":null},{"id":"ceef519b55ec4ce6a2651dbfe4aa5401","type":"DRUG","name":"dapoxetine","canonical_id":"chembl:CHEMBL2110900","description":null,"metadata":null},{"id":"77fbc76d25d540f2a5d8a94f6d673f73","type":"DRUG","name":"dapsone","canonical_id":"mesh:D003622","description":null,"metadata":null},{"id":"b744abf4ec9749f481870de1a42cefc1","type":"DRUG","name":"daratumumab","canonical_id":"gtopdb:7395","description":null,"metadata":null},{"id":"07af673647314aeabcf3482c283184d6","type":"DRUG","name":"daratumumab","canonical_id":"mesh:C556306","description":null,"metadata":null},{"id":"30d478ac1fb745c18c89a2a23eb49d9b","type":"DRUG","name":"daratumumab","canonical_id":"chembl:CHEMBL1743007","description":null,"metadata":null},{"id":"401a433e6971448f916e20c5508aae7b","type":"COMBINATION_TREATMENT","name":"daratumumab + dexamethasone","canonical_id":"ctgov_combo:ctgov-combo-e74c680842c274be","description":null,"metadata":null},{"id":"c7ad65b89d7c43259f43faf703dcad8e","type":"COMBINATION_TREATMENT","name":"daratumumab + dexamethasone + diphenhydramine + montelukast + prednisone","canonical_id":"ctgov_combo:ctgov-combo-db117f0f93dbfe8d","description":null,"metadata":null},{"id":"c1dcc4d5c3a14806a2d60212da652aef","type":"COMBINATION_TREATMENT","name":"daratumumab + ibrutinib","canonical_id":"ctgov_combo:ctgov-combo-4b4e9c7feff19e60","description":null,"metadata":null},{"id":"7c35a528e68c4797b99fa0a519f66d51","type":"COMBINATION_TREATMENT","name":"daratumumab + prednisone","canonical_id":"ctgov_combo:ctgov-combo-dfb0513c70d0b8b2","description":null,"metadata":null},{"id":"e0f81bdef5fd45f48347671e4a0e3d82","type":"COMBINATION_TREATMENT","name":"daratumumab + relatlimab","canonical_id":"ctgov_combo:ctgov-combo-0084ad0e73f6a8d1","description":null,"metadata":null},{"id":"64c27c6606fa45d5b8f148830eb16b35","type":"DRUG","name":"darifenacin","canonical_id":"gtopdb:321","description":null,"metadata":null},{"id":"56e8b8b6f5f14bdc9ab6832edd777ded","type":"COMBINATION_TREATMENT","name":"darifenacin + mirabegron + oxybutynin + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-4190f8dec04b9f5d","description":null,"metadata":null},{"id":"822de80626e947349f57e707878301c4","type":"COMBINATION_TREATMENT","name":"darifenacin + oxybutynin","canonical_id":"ctgov_combo:ctgov-combo-832c0b71e2fd850e","description":null,"metadata":null},{"id":"db549f43167449fcaa42cdae5e5699ca","type":"COMBINATION_TREATMENT","name":"darifenacin + oxybutynin","canonical_id":"ctgov_combo:ctgov-combo-0cd985c5d7b47a50","description":null,"metadata":null},{"id":"4810de936f8141f6a063b5f1056ddd6f","type":"GO_TERM","name":"dark adaptation","canonical_id":"go:GO:1990603","description":"\"The process by which the rods of the retina gradually become fully responsive to dim light when no longer exposed to bright light.\" [GOC:hjd, https://www.ncbi.nlm.nih.gov/books/NBK11525/, PMID:11420957, PMID:35268448]","metadata":null},{"id":"433d0088a71d40478e9c02516376befb","type":"DRUG","name":"darolutamide","canonical_id":"gtopdb:10439","description":null,"metadata":null},{"id":"297372bf213947e6a6aa9063f4e14fc9","type":"DRUG","name":"darolutamide","canonical_id":"chembl:CHEMBL4297185","description":null,"metadata":null},{"id":"5b87065fff9e4941a0fea008815dd949","type":"COMBINATION_TREATMENT","name":"darolutamide + enfortumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-8a7109e3d9a5164b","description":null,"metadata":null},{"id":"5c687856500a4f3faa16610b32d1ad07","type":"COMBINATION_TREATMENT","name":"darolutamide + exemestane + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-7954d2cbb88b2f33","description":null,"metadata":null},{"id":"225b5e33537641f4a1ba0c2ba1d3a335","type":"COMBINATION_TREATMENT","name":"darolutamide + flutamide","canonical_id":"ctgov_combo:ctgov-combo-8d40743f6982e0ee","description":null,"metadata":null},{"id":"3f5a3515ebe341afbde72be4a0070414","type":"COMBINATION_TREATMENT","name":"darolutamide + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-0c0d4742bd9e0fca","description":null,"metadata":null},{"id":"abd6d1a35a3746bea7a0f08b2a27bbf3","type":"DRUG","name":"dasatinib","canonical_id":"gtopdb:5678","description":null,"metadata":null},{"id":"a6a9bee8dcdc4b4a94453f7d856caa58","type":"DRUG","name":"dasatinib","canonical_id":"chembl:CHEMBL5416410","description":null,"metadata":null},{"id":"1ced8b0a223c4372a413d565f83723f8","type":"COMBINATION_TREATMENT","name":"dasatinib + dexamethasone","canonical_id":"ctgov_combo:ctgov-combo-f7b45685692149f7","description":null,"metadata":null},{"id":"c837bb17901a49ad9b34277ff2b15ede","type":"COMBINATION_TREATMENT","name":"dasatinib + dexamethasone + methotrexate + prednisone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-b964c9f5787374c2","description":null,"metadata":null},{"id":"a75abd5a847847bc9e45d5e2b97256c7","type":"COMBINATION_TREATMENT","name":"dasatinib + erlotinib + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-c4e4937af62b0ada","description":null,"metadata":null},{"id":"3700ced381f14f2a8baeea8dc739f426","type":"COMBINATION_TREATMENT","name":"dasatinib + imatinib","canonical_id":"ctgov_combo:ctgov-combo-734c72b440effeef","description":null,"metadata":null},{"id":"db7e76274f6b4ab2a218abbf52ea2f97","type":"COMBINATION_TREATMENT","name":"dasatinib + imatinib + nilotinib + ruxolitinib","canonical_id":"ctgov_combo:ctgov-combo-3749420829e1842a","description":null,"metadata":null},{"id":"1db4c4dd2ef3489085c8bbc2f7e1e53a","type":"COMBINATION_TREATMENT","name":"dasatinib + nilotinib","canonical_id":"ctgov_combo:ctgov-combo-97ae14660a5b21e2","description":null,"metadata":null},{"id":"41008928d62a436cb9e875fbe2a811f6","type":"COMBINATION_TREATMENT","name":"dasatinib + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-6b78244f26cc2cbe","description":null,"metadata":null},{"id":"787418be4095468b815c6748fa52cdfc","type":"COMBINATION_TREATMENT","name":"dasatinib + ruxolitinib","canonical_id":"ctgov_combo:ctgov-combo-43f2883269aeeeec","description":null,"metadata":null},{"id":"db42f6adf0dc4a1cbc181d14b5f8fe7b","type":"COMBINATION_TREATMENT","name":"dasatinib + sirolimus + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-3d0f7e1319561c58","description":null,"metadata":null},{"id":"d12ffacfa046418499b3cb559c835e83","type":"COMBINATION_TREATMENT","name":"dasatinib + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-09375eedf9c19466","description":null,"metadata":null},{"id":"7964067ac91f4d9d8891c85f4cc32fda","type":"GO_TERM","name":"dauer entry","canonical_id":"go:GO:0043053","description":"\"Entry into the facultative diapause of the dauer (enduring) larval stage of nematode development.\" [GOC:cab1, GOC:kmv, PMID:10077613]","metadata":null},{"id":"216628c053174cfe82e247b133413d85","type":"GO_TERM","name":"dauer exit","canonical_id":"go:GO:0043054","description":"\"Exit from the facultative diapause of the dauer (enduring) larval stage of nematode development.\" [GOC:cab1, PMID:12620986]","metadata":null},{"id":"6b0031a0354f41df9c0dfad1676c38a7","type":"GO_TERM","name":"dauer larval development","canonical_id":"go:GO:0040024","description":"\"The process whose specific outcome is the progression of the dauer larva over time, through the facultative diapause of the dauer (enduring) larval stage, with specialized traits adapted for dispersal and long-term survival, with elevated stress resistance and without feeding.\" [GOC:ems, ISBN:087969307X]","metadata":null},{"id":"9ead9c9a9fc9418c8c496487ca79e2eb","type":"DRUG","name":"daunorubicin","canonical_id":"mesh:D003630","description":null,"metadata":null},{"id":"3d6a15832c4b4cdfae5f77658649041e","type":"GO_TERM","name":"daunorubicin biosynthetic process","canonical_id":"go:GO:1901771","description":"\"The chemical reactions and pathways resulting in the formation of daunorubicin.\" [GOC:TermGenie, GOC:yaf, PMID:7601857, UniPathway:UPA00054]","metadata":null},{"id":"52db062750c04d91b778868a7504b6fa","type":"GO_TERM","name":"daunorubicin catabolic process","canonical_id":"go:GO:1901770","description":"\"The chemical reactions and pathways resulting in the breakdown of daunorubicin.\" [GOC:TermGenie, GOC:yaf, PMID:7601857]","metadata":null},{"id":"ebe281aefd59488890931ab548755673","type":"GO_TERM","name":"daunorubicin metabolic process","canonical_id":"go:GO:0044597","description":"\"The chemical reactions and pathways involving daunorubicin, a chemotherapeutic of the anthracycline family that is given as a treatment for some types of cancer.\" [PMID:20837989]","metadata":null},{"id":"8030d0b19b5f46dfa300eb1c99ec0312","type":"GO_TERM","name":"daunorubicin transport","canonical_id":"go:GO:0043215","description":"\"The directed movement of daunorubicin, an anthracycline antibiotic produced by Streptomyces coeruleorubidus or S. peucetius and used as an antineoplastic into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, GOC:mlg]","metadata":null},{"id":"6511c87e9da74fedb904d5b2f82ef8f8","type":"GO_TERM","name":"dbTF DNA binding stabilizer activity","canonical_id":"go:GO:0140369","description":"\"A protein binding activity that stimulates and stabilizes the binding of a DNA binding transcription factor to its genomic DNA target, without directly interacting with DNA itself.\" [PMID:40608935]","metadata":null},{"id":"a1bb963f77784540933ad90a57b9dfeb","type":"GO_TERM","name":"de novo centriole assembly","canonical_id":"go:GO:0097742","description":"\"Centriole assembly in which a centriole arises de novo, rather than by replication from an existing centriole. This process may occur via different mechanisms. Examples include the deuterosome pathway in multicilated epithelial animal cells and formation of centrioles during parthenogenesis in some insects.\" [GOC:cilia, PMID:25047614, PMID:25291643]","metadata":null},{"id":"e41b96bb5b8149308085c352c866496b","type":"GO_TERM","name":"de novo centriole assembly involved in multi-ciliated epithelial cell differentiation","canonical_id":"go:GO:0098535","description":"\"Centriole assembly in which a centriole arises de novo by a process involving an electron-dense structure known as a deuterosome, rather than by duplication of an existing centriole, and occurring as part of multi-ciliated epithelial cell differentiation.\" [GOC:cilia, GOC:dos, PMID:24075808, PMID:5111878, PMID:5661997]","metadata":null},{"id":"991fd351b7e642e1a454f2ac59d6a0ac","type":"GO_TERM","name":"de novo centriole assembly via blepharoplast","canonical_id":"go:GO:0097743","description":"\"A de novo centriole assembly process observed in multi-ciliated sperm cells of some primitive land plants, and where centrioles are formed from a blepharoplast, ultimately giving rise to multiple cilia on the sperm surface.\" [GOC:cilia, PMID:25047614]","metadata":null},{"id":"59cc7b32bcf54eecb5e4ad2b45c0d8b3","type":"GO_TERM","name":"de novo tRNA queuosine(34) biosynthetic process","canonical_id":"go:GO:0160253","description":"\"The chemical reactions and pathways resulting in the formation of tRNA queuosine(34) from guanosine triphosphate (GTP).\" [PMID:28208705]","metadata":null},{"id":"64ac8d45cd904a2985504d18c23b67c9","type":"GO_TERM","name":"de-etiolation","canonical_id":"go:GO:0009704","description":"\"The greening response of plants grown in the dark (etiolated) as a result of chloroplast biogenesis and the accumulation of chlorophyll.\" [GOC:lr]","metadata":null},{"id":"00540ec914604859bf9c671ebbd0f4ef","type":"GO_TERM","name":"deNEDDylase activity","canonical_id":"go:GO:0019784","description":"\"An isopeptidase activity that cleaves NEDD8 from a target protein to which it is conjugated.\" [GOC:mah, PMID:25628956]","metadata":null},{"id":"3c6f919136f34e19817ab86f3d6c571a","type":"GO_TERM","name":"deSUMOylase activity","canonical_id":"go:GO:0016929","description":"\"An thiol-dependent isopeptidase activity that cleaves SUMO from a target protein to which it is conjugated.\" [GOC:rn, PMID:10094048, PMID:11031248, PMID:11265250, PMID:23746258]","metadata":null},{"id":"3f0f5190a5224195b7b83785262359be","type":"GO_TERM","name":"deUFMylase activity","canonical_id":"go:GO:0071567","description":"\"A thiol-dependent isopeptidase activity that cleaves UFM1 from a target protein to which it is conjugated.\" [GOC:sp, PMID:17182609, PMID:20018847]","metadata":null},{"id":"a0a5baa29e6d47528e31e7907b860928","type":"GO_TERM","name":"deacetoxycephalosporin-C hydroxylase activity","canonical_id":"go:GO:0045442","description":"\"Catalysis of the reaction: 2-oxoglutarate + deacetoxycephalosporin C + O2 = CO2 + deacetylcephalosporin C + succinate.\" [EC:1.14.11.26, RHEA:16805]","metadata":null},{"id":"0099915a0f5b4f69b635a628062ae175","type":"GO_TERM","name":"deacetoxycephalosporin-C synthase activity","canonical_id":"go:GO:0050599","description":"\"Catalysis of the reaction: 2-oxoglutarate + O2 + penicillin N = CO2 + deacetoxycephalosporin C + H2O + succinate.\" [EC:1.14.20.1, RHEA:20748]","metadata":null},{"id":"e999c3b3bcf248ff9bb64c448740db1a","type":"GO_TERM","name":"deacetyl-[citrate-(pro-3S)-lyase] S-acetyltransferase activity","canonical_id":"go:GO:0047187","description":"\"Catalysis of the reaction: deacetyl-[citrate-oxaloacetate-lyase ((pro-3S)-CH(2)COO(-)-acetate)] + S-acetylphosphopantetheine = [citrate oxaloacetate-lyase ((pro-3S)-CH(2)COO(-)-acetate)] + pantetheine 4'-phosphate.\" [EC:2.3.1.49, MetaCyc:2.3.1.49-RXN]","metadata":null},{"id":"b451b4be1f47414f9a3ad6655b1fc745","type":"GO_TERM","name":"deacetylase activity","canonical_id":"go:GO:0019213","description":"\"Catalysis of the hydrolysis of an acetyl group from a substrate molecule.\" [GOC:jl]","metadata":null},{"id":"ad21992c490d4aaa9396a10480b8cec3","type":"GO_TERM","name":"deacetylcephalosporin-C acetyltransferase activity","canonical_id":"go:GO:0033813","description":"\"Catalysis of the reaction: acetyl-CoA + deacetylcephalosporin C = cephalosporin C + CoA.\" [EC:2.3.1.175, RHEA:23860]","metadata":null},{"id":"f4272d20ecd7427a96fdced7d29b1039","type":"GO_TERM","name":"deacetylipecoside synthase activity","canonical_id":"go:GO:0050557","description":"\"Catalysis of the reaction: deacetylipecoside + H2O = dopamine + secologanin.\" [RHEA:12296]","metadata":null},{"id":"a4e66be7c2e14a2eb3cd044177b6b179","type":"GO_TERM","name":"deacetylisoipecoside synthase activity","canonical_id":"go:GO:0050556","description":"\"Catalysis of the reaction: deacetylisoipecoside + H2O = dopamine + secologanin.\" [RHEA:21756]","metadata":null},{"id":"edba044c7f6c49eca1def63d6e774f5b","type":"GO_TERM","name":"deactivation of mitotic spindle assembly checkpoint","canonical_id":"go:GO:1902426","description":"\"A positive regulation of the mitotic metaphase/anaphase transition that results from deactivation of the mitotic spindle assembly checkpoint.\" [GOC:dph, GOC:TermGenie, GOC:vw, PMID:19075002, PMID:19592249]","metadata":null},{"id":"c01bb6c7e2ee4a6aaa1983f056ae3bdb","type":"GO_TERM","name":"deacylase activity","canonical_id":"go:GO:0160215","description":"\"Catalysis of the reaction: R-CO-X + H2O = R-COOH + HX, hydrolysis of an acyl group or groups from a substrate molecule.\" [PMID:2760018, PMID:29637793, PMID:38355760]","metadata":null},{"id":"4e321512227043cf83992cef5babdb38","type":"GO_TERM","name":"deadenylation-dependent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:0000290","description":"\"Cleavage of the 5'-cap of a nuclear mRNA triggered by shortening of the poly(A) tail to below a minimum functional length.\" [GOC:krc]","metadata":null},{"id":"da8cdd85d54f46e1be4d16d4c73e14dd","type":"GO_TERM","name":"deadenylation-independent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:0031087","description":"\"Cleavage of the 5'-cap of a nuclear-transcribed mRNA that is independent of poly(A) tail shortening.\" [GOC:krc, PMID:15225542, PMID:15225544]","metadata":null},{"id":"d116ecbf1c1f451b851ea31d990a036c","type":"GO_TERM","name":"deaminase activity","canonical_id":"go:GO:0019239","description":"\"Catalysis of the removal of an amino group from a substrate, producing a substituted or nonsubstituted ammonia (NH4+/NH2R).\" [GOC:jl]","metadata":null},{"id":"145a45d562a440e2974754e3f16ce0aa","type":"GO_TERM","name":"deaminase binding","canonical_id":"go:GO:1990827","description":"\"Binding to an enzyme that catalyzes the removal of an amino group from a substrate, producing ammonia (NH3).\" [PMID:9792439]","metadata":null},{"id":"8fa0b1d67dd0462c95f6bc72573a26e4","type":"GO_TERM","name":"deaminated base DNA N-glycosylase activity","canonical_id":"go:GO:0097506","description":"\"DNA N-glycosylase activity acting on deaminated bases.\" [GOC:al, PMID:18789404]","metadata":null},{"id":"0a2f0264669c40d8ac0fc350a689ba90","type":"GO_TERM","name":"deaminated glutathione amidase activity","canonical_id":"go:GO:0110050","description":"\"Catalysis of the reaction: N-(4-oxoglutarate)-L-cysteinylglycine + H2O = 2-oxoglutarate + L-cysteinylglycine.\" [GOC:ka, PMID:28373563, RHEA:54532]","metadata":null},{"id":"8fa97d3875314fde8dd7aca7aa504494","type":"GO_TERM","name":"death domain binding","canonical_id":"go:GO:0070513","description":"\"Binding to a death domain of a protein. The death domain (DD) is a homotypic protein interaction module composed of a bundle of six alpha-helices. DD bind each other forming oligomers. Some DD-containing proteins are involved in the regulation of apoptosis and inflammation through their activation of caspases and NF-kappaB.\" [GOC:BHF, GOC:rl, InterPro:IPR000488, Pfam:PF00531]","metadata":null},{"id":"b7ec3cd1ee2f41039581503364f1538d","type":"GO_TERM","name":"death effector domain binding","canonical_id":"go:GO:0035877","description":"\"Binding to a DED domain (death effector domain) of a protein, a homotypic protein interaction module composed of a bundle of six alpha-helices that is related in structure to the death domain (DD).\" [GOC:ecd, InterPro:IPR001875]","metadata":null},{"id":"842a660fa4b94f54b8b3bf6f2fc81c82","type":"GO_TERM","name":"death receptor activity","canonical_id":"go:GO:0005035","description":"\"Combining with an extracellular messenger (called a death ligand), and transmitting the signal from one side of the plasma membrane to the other to initiate apoptotic or necrotic cell death.\" [GOC:bf, GOC:BHF, GOC:ecd, GOC:mtg_apoptosis, GOC:rl, PMID:10209153]","metadata":null},{"id":"2a193115b6924261b0553b8cebb7d0b9","type":"GO_TERM","name":"death receptor agonist activity","canonical_id":"go:GO:0038177","description":"\"Interacting with a death receptor such that the proportion of death receptors in an active form is increased. Ligand binding to a death receptor often induces a conformational change to activate the receptor.\" [GOC:mtg_apoptosis, GOC:pr]","metadata":null},{"id":"ea95d2377cde4db38d19050282fd6391","type":"GO_TERM","name":"death receptor binding","canonical_id":"go:GO:0005123","description":"\"Binding to a member of the death receptor (DR) family. The DR family falls within the tumor necrosis factor receptor superfamily and is characterized by a cytoplasmic region of ~80 residues termed the death domain (DD).\" [GOC:ceb, GOC:rl, PMID:15654015]","metadata":null},{"id":"b068c235211147efab6f761613b9e22f","type":"GO_TERM","name":"death-inducing signaling complex","canonical_id":"go:GO:0031264","description":"\"A protein complex formed by the association of signaling proteins with a death receptor upon ligand binding. The complex includes procaspases and death domain-containing proteins in addition to the ligand-bound receptor, and may control the activation of caspases 8 and 10.\" [GOC:mtg_apoptosis, PMID:12628743, PMID:12655293, PMID:8521815]","metadata":null},{"id":"43e3a84b4111461a859b57b662ea46c4","type":"GO_TERM","name":"death-inducing signaling complex assembly","canonical_id":"go:GO:0071550","description":"\"A process of protein complex assembly in which the arrangement and bonding together of the set of components that form the protein complex is mediated by a death domain (DD) interaction, as part of the extrinsic apoptotic signaling pathway.\" [GOC:amm, GOC:mtg_apoptosis, InterPro:IPR000488]","metadata":null},{"id":"66f8806ce83c4e829f2d5c8b8f5d202c","type":"GO_TERM","name":"decanoate-CoA ligase activity","canonical_id":"go:GO:0102391","description":"\"Catalysis of the reaction: ATP + decanoate + CoA = AMP + diphosphate + decanoyl-CoA.\" [GOC:pz, RHEA:33627]","metadata":null},{"id":"d03c39d2db9f449c8bfb7ea4d61b52b3","type":"GO_TERM","name":"decaprenyl-N-acetyl-alpha-D-glucosaminyl-pyrophosphate:dTDP-alpha-L-rhamnose rhamnosyltransferase activity","canonical_id":"go:GO:0102096","description":"\"Catalysis of the reaction: dTDP-6-deoxy-beta-L-mannose + N-acetyl-alpha-D-glucosaminyl-diphospho-trans,octacis-decaprenol = dTDP(3-) + alpha-L-Rhap-(1->3)-alpha-D-GlcpNAc-1-diphospho-trans,octacis-decaprenol + H+.\" [EC:2.4.1.289, GOC:pz]","metadata":null},{"id":"05ee5f49180049189795d6a5229a3ee4","type":"GO_TERM","name":"decarboxylation-driven active transmembrane transporter activity","canonical_id":"go:GO:0015451","description":"\"Primary active transport of a solute across a membrane driven by decarboxylation of a cytoplasmic substrate. Primary active transport is catalysis of the transport of a solute across a membrane, up the solute's concentration gradient, by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction and is driven by a primary energy source.\" [GOC:mtg_transport, ISBN:0815340729, TC:3.B.-.-.-]","metadata":null},{"id":"e6793d78500e4de295739769b45e0e3f","type":"GO_TERM","name":"decidualization","canonical_id":"go:GO:0046697","description":"\"The cellular and vascular changes occurring in the endometrium of the pregnant uterus just after the onset of blastocyst implantation. This process involves the proliferation and differentiation of the fibroblast-like endometrial stromal cells into large, polyploid decidual cells that eventually form the maternal component of the placenta.\" [ISBN:0721662544, PMID:11133685]","metadata":null},{"id":"ba840ff8ebf44913af144e0b7ca272eb","type":"DRUG","name":"decitabine","canonical_id":"mesh:D000077209","description":null,"metadata":null},{"id":"508f3d8c01794d37b763839de9da6eaa","type":"GO_TERM","name":"decoy receptor complex","canonical_id":"go:GO:0140368","description":"\"A receptor complex that recognizes, binds and sequesters a specific receptor ligand to prevent it from binding to its regular receptor. May be soluble or membrane bound.\" [GOC:bhm, PMID:30621730, PMID:9168977]","metadata":null},{"id":"b307222926ea44429f4fcf75dde67175","type":"GO_TERM","name":"decylcitrate synthase activity","canonical_id":"go:GO:0050457","description":"\"Catalysis of the reaction: H2O + lauroyl-CoA + oxaloacetate = (2S,3S)-2-hydroxytridecane-1,2,3-tricarboxylate + CoA + H+.\" [RHEA:16605]","metadata":null},{"id":"2edaad1b8d524ceb80323737497c2584","type":"GO_TERM","name":"decylhomocitrate synthase activity","canonical_id":"go:GO:0050458","description":"\"Catalysis of the reaction: 2-oxoglutarate + H2O + lauroyl-CoA = (3S,4S)-3-hydroxytetradecane-1,3,4-tricarboxylate + CoA + H+.\" [RHEA:10364]","metadata":null},{"id":"8761b33da3854a9792c843c1f8909423","type":"GO_TERM","name":"dedifferentiation","canonical_id":"go:GO:0043696","description":"\"The process in which a specialized structure (cell, tissue or organ) loses structural or functional features that characterize it in the mature organism, or some other relatively stable phase of the organism's life history. Under certain conditions, these structures can revert back to the features of their ancestors.\" [GOC:dph, GOC:pg]","metadata":null},{"id":"4fd64a667cee445b9484c55fce7cbd09","type":"GO_TERM","name":"deep fiber","canonical_id":"go:GO:0032123","description":"\"Inward projections of the cytoskeletal structures of the oral apparatus, which form a fiber that extends past the cytostome into the cytoplasm.\" [PMID:10503189]","metadata":null},{"id":"9e0c2e8ca24247a8a48f65a4089bfff2","type":"GO_TERM","name":"deep nuclear neuron cell migration","canonical_id":"go:GO:0021946","description":"\"The directed movement of a deep nuclear neuron from the ventricular zone to the deep hindbrain nuclei.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"3d3612025940475c9e0e6b3b351deb88","type":"GO_TERM","name":"deep nuclear neuron precursor proliferation","canonical_id":"go:GO:0021927","description":"\"The multiplication or reproduction of neuroblasts that will give rise to deep nuclear neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"b1a0442bfd3f4ef9a09c345b2f229d64","type":"DISEASE","name":"deep vein thrombosis","canonical_id":"efo:0003907","description":null,"metadata":null},{"id":"794908f820e24d5c988f77567126d73e","type":"GO_TERM","name":"defasciculation of motor neuron axon","canonical_id":"go:GO:0007415","description":"\"Separation of a motor axon away from a bundle of axons known as a fascicle.\" [GOC:dgh]","metadata":null},{"id":"9f69c3ef449a4cddbf397fd93e8c0cf3","type":"GO_TERM","name":"defecation","canonical_id":"go:GO:0030421","description":"\"The expulsion of feces from the rectum.\" [GOC:mah]","metadata":null},{"id":"bcfe5d4b941745b8888da2e748008d88","type":"GO_TERM","name":"defecation rhythm","canonical_id":"go:GO:0035882","description":"\"The rhythmic process of defecation that consists of an intestinal oscillator which regulates calcium waves. These waves in turn control a stereotypical, three-part pattern of muscle contractions. In some organisms, defecation can recur with a regularity more frequent than every 24 hours. For example, in a well-fed Caenorhabditis elegans, the defecation motor program occurs approximately every 45 seconds, and is temperature- and touch-compensated.\" [GOC:bf, GOC:kmv, PMID:7479775, PMID:8158250, PMID:9066270]","metadata":null},{"id":"573c9900fa704bf9a8b3b57e09e062b2","type":"GO_TERM","name":"defense response","canonical_id":"go:GO:0006952","description":"\"Reactions, triggered in response to the presence of a foreign body or the occurrence of an injury, which result in restriction of damage to the organism attacked or prevention/recovery from the infection caused by the attack.\" [GOC:curators]","metadata":null},{"id":"9bf6543b356545dc8e366fd2bfff5b76","type":"GO_TERM","name":"defense response by callose deposition","canonical_id":"go:GO:0052542","description":"\"Any process in which callose is transported to, and/or maintained in, a specific location during the defense response. Callose is a linear 1,3-beta-d-glucan formed from UDP-glucose and is found in certain plant cell walls.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"783392022cda4877b023de5c58a47ca6","type":"GO_TERM","name":"defense response by callose deposition in cell wall","canonical_id":"go:GO:0052544","description":"\"Any process in which callose is transported to, and/or maintained in, the cell wall during the defense response. Callose is a linear 1,3-beta-d-glucan formed from UDP-glucose and is found in certain plant cell walls.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"2a8fba6684cf42068aad899b467ea50f","type":"GO_TERM","name":"defense response by cell wall thickening","canonical_id":"go:GO:0052482","description":"\"A type of cell wall modification, in which the cell wall is reinforced and made thicker, that occurs as part of the defense response of an organism.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"e885c5d2e55c4d1286e461cc4645b520","type":"GO_TERM","name":"defense response to Gram-negative bacterium","canonical_id":"go:GO:0050829","description":"\"Reactions triggered in response to the presence of a Gram-negative bacterium that act to protect the cell or organism.\" [GOC:ai]","metadata":null},{"id":"7867c785623a4daa819ce52d083a908a","type":"GO_TERM","name":"defense response to Gram-positive bacterium","canonical_id":"go:GO:0050830","description":"\"Reactions triggered in response to the presence of a Gram-positive bacterium that act to protect the cell or organism.\" [GOC:ai]","metadata":null},{"id":"c4e9b3388afa42ef8e792a3560072ac9","type":"GO_TERM","name":"defense response to bacterium","canonical_id":"go:GO:0042742","description":"\"Reactions triggered in response to the presence of a bacterium that act to protect the cell or organism.\" [GOC:jl]","metadata":null},{"id":"c06409a5de9a4d8bae2b3e789a6b27c2","type":"GO_TERM","name":"defense response to fungus","canonical_id":"go:GO:0050832","description":"\"Reactions triggered in response to the presence of a fungus that act to protect the cell or organism.\" [GOC:ai]","metadata":null},{"id":"e2787149efd64c92825c579a67261f15","type":"GO_TERM","name":"defense response to insect","canonical_id":"go:GO:0002213","description":"\"A response to protect an organism from a directly detected or perceived external threat from an insect or insects to that organism.\" [GOC:add]","metadata":null},{"id":"1805b0abb3474e9f9f0b176351c081c8","type":"GO_TERM","name":"defense response to nematode","canonical_id":"go:GO:0002215","description":"\"A response to protect an organism from a directly detected or perceived external threat from a nematode or nematodes, which results in restriction of damage to the organism attacked or prevention/recovery from the infection caused by the attack.\" [GOC:add, PMID:11516579, PMID:14506883]","metadata":null},{"id":"e1967892b9a44da0819a0d1b9c5929a9","type":"GO_TERM","name":"defense response to oomycetes","canonical_id":"go:GO:0002229","description":"\"Reactions triggered in response to the presence of oomycetes that act to protect the cell or organism.\" [GOC:add, PMID:16497589]","metadata":null},{"id":"6eec985f8ef6446f9d7ef1e6709fee25","type":"GO_TERM","name":"defense response to other organism","canonical_id":"go:GO:0098542","description":"\"Reactions triggered in response to the presence of another organism that act to protect the cell or organism from damage caused by that organism.\" [GOC:dos]","metadata":null},{"id":"107682b936c74dac99bef77fa4ab88b8","type":"GO_TERM","name":"defense response to parasitic plant","canonical_id":"go:GO:0002242","description":"\"Reactions triggered in response to the presence of a parasitic plant that act to protect an organism.\" [GOC:add]","metadata":null},{"id":"006690b5f3f8415caa9d28debec7bae3","type":"GO_TERM","name":"defense response to protozoan","canonical_id":"go:GO:0042832","description":"\"Reactions triggered in response to the presence of a protozoan that act to protect the cell or organism.\" [GOC:jl]","metadata":null},{"id":"b5433da012464aab81d8c813627399d4","type":"GO_TERM","name":"defense response to symbiont","canonical_id":"go:GO:0140546","description":"\"Reactions triggered in response to the presence of a symbiont that act to protect or prevent damage to the host.\" [GOC:pg]","metadata":null},{"id":"fccb3ca644be47cbb1163e626fbda4dd","type":"GO_TERM","name":"defense response to tumor cell","canonical_id":"go:GO:0002357","description":"\"Reactions triggered in response to the presence of a tumor cell that act to protect the cell or organism.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"ddac1df8a70d489d98ccf422947e6c24","type":"GO_TERM","name":"defense response to virus","canonical_id":"go:GO:0051607","description":"\"Reactions triggered in response to the presence of a virus that act to protect the cell or organism.\" [GOC:ai]","metadata":null},{"id":"35c92f20c29e4ccfa9e91764b5b3aa2f","type":"DRUG","name":"deferiprone","canonical_id":"mesh:C044919","description":null,"metadata":null},{"id":"f44fdb7966c045048efce936fbe957d5","type":"DRUG","name":"defibrotide","canonical_id":"mesh:C036901","description":null,"metadata":null},{"id":"d043d6595ab0489abc62a90d5b0a1b9c","type":"GO_TERM","name":"definitive erythrocyte differentiation","canonical_id":"go:GO:0060318","description":"\"Erythrocyte differentiation which occurs as part of the process of definitive hemopoiesis.\" [GOC:add, GOC:BHF, GOC:dph]","metadata":null},{"id":"547f00114a554705b28348ea5a64a494","type":"GO_TERM","name":"definitive hemopoiesis","canonical_id":"go:GO:0060216","description":"\"A second wave of blood cell production that, in vertebrates, generates long-term hemopoietic stem cells that continuously provide erythroid, myeloid and lymphoid lineages throughout adulthood.\" [GOC:bf, GOC:dph, PMID:15378083, PMID:15617691]","metadata":null},{"id":"5af6d2471b784849b676da1f8e5fd22a","type":"DRUG","name":"deflazacort","canonical_id":"mesh:C021988","description":null,"metadata":null},{"id":"5de304a40f084dba973335036465467d","type":"DRUG","name":"degarelix","canonical_id":"gtopdb:5585","description":null,"metadata":null},{"id":"68613526eceb4ff8a9d6f8d3d028c117","type":"COMBINATION_TREATMENT","name":"degarelix + enzalutamide","canonical_id":"ctgov_combo:ctgov-combo-9db9e28d9fa7612d","description":null,"metadata":null},{"id":"e6598083f2bf419597516e15ef1c63dc","type":"COMBINATION_TREATMENT","name":"degarelix + goserelin + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-a540b62d429ef2d6","description":null,"metadata":null},{"id":"3d292617309546c8bc373a88dcb556c0","type":"COMBINATION_TREATMENT","name":"degarelix + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-db0393600c9350a3","description":null,"metadata":null},{"id":"1c55c2a7da734e009adf33622f9543d7","type":"COMBINATION_TREATMENT","name":"degarelix + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-901e2b0b0779aa33","description":null,"metadata":null},{"id":"c7915bf811124931a1a2ee6aeccab73d","type":"COMBINATION_TREATMENT","name":"degarelix + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-42573ee5174d994a","description":null,"metadata":null},{"id":"1a84cca8846e40e8b1987c9b1f4e6336","type":"GO_TERM","name":"degradation of host chromosome by virus","canonical_id":"go:GO:0099015","description":"\"The catabolic breakdown of the DNA of a host chromosome by a virus. This occurs during infection of bacteria by some phages. It frees up a large pool of nucleoside 5'-triphophates for use in viral DNA synthesis.\" [PMID:163355, PMID:335083, PMID:3972821, PMID:5263754, VZ:3947]","metadata":null},{"id":"e65fec27d56f47ed8e732380be90f3f5","type":"GO_TERM","name":"dehiscence","canonical_id":"go:GO:0009900","description":"\"The opening of an anther, fruit or other structure, which permits the escape of reproductive bodies contained within it.\" [ISBN:0879015322]","metadata":null},{"id":"64b3c51e94534172bcbe2282d5df6922","type":"GO_TERM","name":"dehydro-D-arabinono-1,4-lactone biosynthetic process","canonical_id":"go:GO:0070485","description":"\"The chemical reactions and pathways resulting in the formation of dehydro-D-arabinono-1,4-lactone, the gamma-lactone (5R)-3,4-dihydroxy-5-(hydroxymethyl)furan-2(5H)-one.\" [GOC:cjk, GOC:mah]","metadata":null},{"id":"8e1ccd21008a4eeda8f21af78b8086ca","type":"GO_TERM","name":"dehydro-L-gulonate decarboxylase activity","canonical_id":"go:GO:0047842","description":"\"Catalysis of the reaction: 3-dehydro-L-gulonate + H+ = L-xylulose + CO2.\" [EC:4.1.1.34, RHEA:11084]","metadata":null},{"id":"2460e24d52ad4a0e979af6ec013dd779","type":"GO_TERM","name":"dehydroascorbic acid transmembrane transporter activity","canonical_id":"go:GO:0033300","description":"\"Enables the transfer of dehydroascorbate, 5-(1,2-dihydroxyethyl)furan-2,3,4(5H)-trione, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"70a85a63ba6547c196283278bd1780b0","type":"GO_TERM","name":"dehydroascorbic acid transport","canonical_id":"go:GO:0070837","description":"\"The directed movement of dehydroascorbate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Dehydroascorbate, 5-(1,2-dihydroxyethyl)furan-2,3,4(5H)-trione, is an oxidized form of vitamin C.\" [GOC:sl]","metadata":null},{"id":"59a9c123cfc94af998b77c42b9c6934c","type":"GO_TERM","name":"dehydroaustinol biosynthetic process","canonical_id":"go:GO:1900563","description":"\"The chemical reactions and pathways resulting in the formation of dehydroaustinol.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"200bd9bcf59442559907303fb56f70d6","type":"GO_TERM","name":"dehydroaustinol catabolic process","canonical_id":"go:GO:1900562","description":"\"The chemical reactions and pathways resulting in the breakdown of dehydroaustinol.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"603e322bea984676b2e5007d33124e06","type":"DRUG","name":"dehydrocholic acid","canonical_id":"mesh:D003685","description":null,"metadata":null},{"id":"6f5a2e6e7489405d9d931a387726ceb8","type":"GO_TERM","name":"dehydrodolichyl diphosphate synthase complex","canonical_id":"go:GO:1904423","description":"\"A protein complex which is capable of dehydrodolichyl diphosphate synthase activity.\" [GO_REF:0000088, GOC:TermGenie, PMID:25066056]","metadata":null},{"id":"ec45e0605226484e871b2e8b54adf403","type":"GO_TERM","name":"dehydroepiandrosterone secretion","canonical_id":"go:GO:0035942","description":"\"The regulated release of dehydroepiandrosterone (3beta-hydroxyandrost-5-en-17-one) into the circulatory system.\" [GOC:sl]","metadata":null},{"id":"3e5f7f76fdd64583a06e067d41a4ed74","type":"GO_TERM","name":"dehydrogluconate dehydrogenase activity","canonical_id":"go:GO:0047843","description":"\"Catalysis of the reaction: 2-dehydro-D-gluconate + A = 2,5-didehydro-D-gluconate + AH(2).\" [RHEA:12368]","metadata":null},{"id":"eb2f26bc4bc5464c8aa39afa16f9e0e7","type":"GO_TERM","name":"dehydrogluconokinase activity","canonical_id":"go:GO:0047841","description":"\"Catalysis of the reaction: 2-dehydro-D-gluconate + ATP = 6-phospho-2-dehydro-D-gluconate + ADP + 2 H+.\" [EC:2.7.1.13, RHEA:10788]","metadata":null},{"id":"53c3f0b9b92b40d8837bd2ae3855dc9d","type":"GO_TERM","name":"dehydropipecolic acid reductase activity","canonical_id":"go:GO:0062046","description":"\"Catalysis of the reaction: dehydropipecolic acid + NAD(P)H + H+ = L-pipecolic acid + NAD(P)+.\" [PMID:27758894, PMID:28330936]","metadata":null},{"id":"d1aa69e1ea2d4184a9b7dd8e43d6660a","type":"GO_TERM","name":"dehydroquinate synthase activity","canonical_id":"go:GO:0102042","description":"\"Catalysis of the reaction: 2-amino-2,3,7-trideoxy-D-lyxo-hept-6-ulosonic acid + H2O + NAD = 3-dehydroquinate + ammonium + NADH + H+.\" [GOC:pz, RHEA:25956]","metadata":null},{"id":"acb3a92e9f6f4ae5a45fd72b808100b9","type":"DRUG","name":"delafloxacin","canonical_id":"mesh:C477891","description":null,"metadata":null},{"id":"9e41e418cc7941cdbe9aa6995e72625f","type":"GO_TERM","name":"delamination","canonical_id":"go:GO:0060232","description":"\"The process of negative regulation of cell adhesion that results in a cell or sheet of cells splitting off from an existing epithelial sheet.\" [GOC:dph, PMID:16962574, PMID:18343170]","metadata":null},{"id":"a5998fee5b8746139496be6e0d7f1f99","type":"GO_TERM","name":"delayed rectifier potassium channel activity","canonical_id":"go:GO:0005251","description":"\"Enables the transmembrane transfer of a potassium ion by a delayed rectifying voltage-gated channel. A delayed rectifying current-voltage relation is one where channel activation kinetics are time-dependent, and inactivation is slow.\" [GOC:mah, PMID:11343411, PMID:2462513]","metadata":null},{"id":"0150d9b014174e579c1639a9b8daab85","type":"DRUG","name":"delgocitinib","canonical_id":"gtopdb:9619","description":null,"metadata":null},{"id":"24e4a377994e4694be481a181ff19473","type":"DRUG","name":"delgocitinib","canonical_id":"chembl:CHEMBL4297507","description":null,"metadata":null},{"id":"51ea1ce5b67c4e1f8d985aa6debd0246","type":"GO_TERM","name":"delphinidin 3-O-glucoside biosynthetic process","canonical_id":"go:GO:0033486","description":"\"The chemical reactions and pathways resulting in the formation of delphinidin 3-O-glucoside, a basic, water-soluble anthocyanin responsible for blue coloration of flowers and fruits.\" [GOC:mah, MetaCyc:PWY-5153]","metadata":null},{"id":"9c941599f5164b03b92bb46eb5e8a2b1","type":"GO_TERM","name":"delta DNA polymerase complex","canonical_id":"go:GO:0043625","description":"\"A multimeric DNA polymerase enzyme complex which differs in composition amongst species; in humans it is a heterotetramer of four subunits of approximately 125, 50, 68 and 12kDa, while in S. cerevisiae, it has three different subunits which form a heterotrimer, and the active enzyme is a dimer of this heterotrimer. Functions in DNA replication, mismatch repair and excision repair.\" [GOC:jl, ISBN:0198547684, PMID:11205330, PMID:12403614]","metadata":null},{"id":"06994c39cc7e4cab85e3b3bca43994dd","type":"GO_TERM","name":"delta(3)-delta(2)-enoyl-CoA isomerase activity","canonical_id":"go:GO:0004165","description":"\"Catalysis of the reactions: a (3Z)-enoyl-CoA = a 4-saturated (2E)-enoyl-CoA or a (3E)-enoyl-CoA = a 4-saturated (2E)-enoyl-CoA.\" [RHEA:45900]","metadata":null},{"id":"ca0b0d4ee3284ca39b0b637e25ad94b6","type":"GO_TERM","name":"delta(3,5)-delta(2,4)-dienoyl-CoA isomerase activity","canonical_id":"go:GO:0051750","description":"\"Catalysis of the reaction: a (3E,5Z)-dienoyl-CoA = a (2E,4E)-(5,6-saturated)-dienoyl-CoA.\" [PMID:11278886, PMID:16040662, RHEA:45240]","metadata":null},{"id":"801b706b568348cda5ba11b785b1efde","type":"GO_TERM","name":"delta-catenin binding","canonical_id":"go:GO:0070097","description":"\"Binding to the delta subunit of the catenin complex.\" [GOC:rph]","metadata":null},{"id":"4322e33a8429401b8ebe126648d7735b","type":"GO_TERM","name":"delta-type opioid receptor binding","canonical_id":"go:GO:0031850","description":"\"Binding to a delta-type opioid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d8c18f55cae24fc6b719be1564234520","type":"GO_TERM","name":"delta1-piperideine-2-carboxylate reductase activity","canonical_id":"go:GO:0047125","description":"\"Catalysis of the reaction: NADP+ + L-pipecolate = NADPH + delta1-piperideine-2-carboxylate.\" [EC:1.5.1.21]","metadata":null},{"id":"41e379c01c684359ae744c99b19a26b5","type":"GO_TERM","name":"delta1-pyrroline-5-carboxylate synthetase (NADP+) activity","canonical_id":"go:GO:0017084","description":"\"Catalysis of the reaction: ATP + H+ + L-glutamate + NADPH = ADP + L-glutamate 5-semialdehyde + NADP+ + phosphate.\" [RHEA:33207]","metadata":null},{"id":"71941a8f576d46da893f4e68f3de6db3","type":"GO_TERM","name":"delta6-acyl-lipid desaturase activity","canonical_id":"go:GO:0102865","description":"\"Catalysis of the reaction: a gamma-linolenoyl-[glycerolipid] + 2 ferrocytochrome b5 + O2 + 2 H+ = a (9Z,12Z)-octadeca-9,12-dien-6-ynoyl-[glycerolipid] + 2 ferricytochrome b5 + 2 H2O.\" [GOC:pz, PMID:10848999, RHEA:46536]","metadata":null},{"id":"76d00fc2d1464f60860ee3d18e8a9c9a","type":"GO_TERM","name":"delta7-sterol 5(6)-desaturase activity","canonical_id":"go:GO:0050046","description":"\"Catalysis of the reaction: a Delta(7)-sterol + 2 Fe(II)-[cytochrome b5] + O2 + 2 H+ = a Delta(5),Delta(7)-sterol + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:54320]","metadata":null},{"id":"400dc7f4eb054a8789a5b70e448b4f7f","type":"GO_TERM","name":"delta9-tetrahydrocannabinolate synthase activity","canonical_id":"go:GO:0102778","description":"\"Catalysis of the reaction: cannabigerolate + O2 = delta(9)-tetrahydrocannabinolic acid +  H2O2.\" [RHEA:34135]","metadata":null},{"id":"723af7ea0de84c23ac7ba5f8b9fcfffc","type":"GO_TERM","name":"deltoid tuberosity development","canonical_id":"go:GO:0035993","description":"\"The process whose specific outcome is the progression of the deltoid tuberosity over time, from its formation to the mature structure. The deltoid tuberosity is the region on the shaft of the humerus to which the deltoid muscle attaches. The deltoid tuberosity develops through endochondral ossification in a two-phase process; an initiating tendon-dependent phase, and a muscle-dependent growth phase.\" [GOC:yaf, PMID:17567668, UBERON:0002498, Wikipedia:Deltoid_tuberosity]","metadata":null},{"id":"a7000990970e42cd88856cfe9d85974b","type":"DRUG","name":"demeclocycline","canonical_id":"mesh:D003707","description":null,"metadata":null},{"id":"ab6e3175a92a4a2183a561f4e599941d","type":"DISEASE","name":"dementia","canonical_id":"mondo:0001627","description":null,"metadata":null},{"id":"6906a96a9f2d4257a7995f099d08641a","type":"GO_TERM","name":"demethoxycurcumin synthase activity","canonical_id":"go:GO:0102103","description":"\"Catalysis of the reaction: (4-coumaroyl)acetyl-CoA + 4-coumaryl-CoA + H2O = bisdemethoxycurcumin + 2 coenzyme A + carbon dioxide.\" [EC:2.3.1.219]","metadata":null},{"id":"db31be0e08614202a4ccc85d7c8705bc","type":"GO_TERM","name":"demethylase activity","canonical_id":"go:GO:0032451","description":"\"Catalysis of the removal of a methyl group from a substrate.\" [GOC:mah]","metadata":null},{"id":"b81354500f644e85b5b27f1bbe083ad7","type":"GO_TERM","name":"demethylation","canonical_id":"go:GO:0070988","description":"\"The process of removing one or more methyl groups from a molecule.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"22f71e26e59e4f25bafde6f7a5c10c56","type":"GO_TERM","name":"demethylkotanin biosynthetic process","canonical_id":"go:GO:1900599","description":"\"The chemical reactions and pathways resulting in the formation of demethylkotanin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1f82f284f00447ff869dec175a33e05c","type":"GO_TERM","name":"demethylkotanin catabolic process","canonical_id":"go:GO:1900598","description":"\"The chemical reactions and pathways resulting in the breakdown of demethylkotanin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1d4e0f091f874c19a60b196a8ff66454","type":"GO_TERM","name":"demethylmacrocin O-methyltransferase activity","canonical_id":"go:GO:0030770","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + demethylmacrocin = S-adenosyl-L-homocysteine + H+ + macrocin.\" [EC:2.1.1.102, RHEA:17573]","metadata":null},{"id":"9465a694b3d64cf38015fecb3b6f5ab5","type":"GO_TERM","name":"demethylmenaquinone methyltransferase activity","canonical_id":"go:GO:0043770","description":"\"Catalysis of the reaction: a 2-demethylmenaquinol + S-adenosyl-L-methionine = a menaquinol + H+ + S-adenosyl-L-homocysteine. Reaction substrates can have varying polyprenyl side chain length.\" [PMID:1444716, PMID:9045837, RHEA:42640]","metadata":null},{"id":"1fc0a621c4ae48648af12cfae8ae8429","type":"GO_TERM","name":"demethylrebeccamycin--D-glucose O-methyltransferase activity","canonical_id":"go:GO:0102082","description":"\"Catalysis of the reaction: 4'-demethylrebeccamycin + S-adenosyl-L-methionine = H+ + rebeccamycin + S-adenosyl-L-homocysteine.\" [EC:2.1.1.164, GOC:pz]","metadata":null},{"id":"e739e71bdb374b61a5e96dca89fc8f73","type":"GO_TERM","name":"demethylsterigmatocystin 6-O-methyltransferase activity","canonical_id":"go:GO:0047145","description":"\"Catalysis of the reaction: 6-demethylsterigmatocystin + S-adenosyl-L-methionine = sterigmatocystin + S-adenosyl-homocysteine.\" [EC:2.1.1.109, MetaCyc:2.1.1.109-RXN]","metadata":null},{"id":"83e5a66c695a46d6a01186918483d776","type":"DRUG","name":"demexiptiline","canonical_id":"mesh:C033781","description":null,"metadata":null},{"id":"c41e518066194bdba354bd1034e90077","type":"GO_TERM","name":"dendriole","canonical_id":"go:GO:0044293","description":"\"Small dendrites that makes up a brush structure found as the terminal specialization of a dendrite of a unipolar brush cell (UBC).\" [GOC:jl, NIF_Subcellular:sao28175134, NIF_Subcellular:sao295057932, PMID:8300904]","metadata":null},{"id":"e795ade90ae442ac82ce0ce63cb54664","type":"GO_TERM","name":"dendrite","canonical_id":"go:GO:0030425","description":"\"A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body.\" [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732]","metadata":null},{"id":"db09247ad57547f68763f9428ec9e443","type":"GO_TERM","name":"dendrite arborization","canonical_id":"go:GO:0140059","description":"\"The process in which the anatomical structures of a dendritic tree are generated and organized into dendritic branches.\" [GOC:aruk, GOC:bc, PMID:23270857]","metadata":null},{"id":"41630f9c30a84af89025d5f69a12a348","type":"GO_TERM","name":"dendrite cytoplasm","canonical_id":"go:GO:0032839","description":"\"All of the contents of a dendrite, excluding the surrounding plasma membrane.\" [GOC:mah]","metadata":null},{"id":"7301964a62924295b3afb99676bad141","type":"GO_TERM","name":"dendrite development","canonical_id":"go:GO:0016358","description":"\"The process whose specific outcome is the progression of the dendrite over time, from its formation to the mature structure.\" [GOC:aruk, GOC:bc, GOC:jl, ISBN:0198506732, PMID:22683681]","metadata":null},{"id":"bc82a47ffbaa43a9b32fe7cf11e3440b","type":"GO_TERM","name":"dendrite development by retrograde extension","canonical_id":"go:GO:0003390","description":"\"The progression of a dendrite over time by the attachment of a part of the neuron to an anchor and the subsequent migration of the cell body away from the anchor point.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b1c20397e570427c9ed312f0b8e7fc10","type":"GO_TERM","name":"dendrite extension","canonical_id":"go:GO:0097484","description":"\"Long distance growth of a single dendrite involved in cellular development.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"fcd9fb39a1a0465a85f451ed214ca064","type":"GO_TERM","name":"dendrite guidance","canonical_id":"go:GO:0070983","description":"\"The process in which the migration of a dendrite is directed to a specific target site in response to a combination of attractive and repulsive cues.\" [GOC:sart, PMID:15046878]","metadata":null},{"id":"07e388287b6e49718a0e02809e4fbd12","type":"GO_TERM","name":"dendrite membrane","canonical_id":"go:GO:0032590","description":"\"The portion of the plasma membrane surrounding a dendrite.\" [GOC:mah]","metadata":null},{"id":"9fd53ddf5f3f49c7b4e595bef19c80e5","type":"GO_TERM","name":"dendrite morphogenesis","canonical_id":"go:GO:0048813","description":"\"The process in which the anatomical structures of a dendrite are generated and organized.\" [GOC:aruk, GOC:bc, GOC:jl, ISBN:0198506732, PMID:22683681]","metadata":null},{"id":"d38f7f8c35934094b147f1c4bad9bea6","type":"GO_TERM","name":"dendrite regeneration","canonical_id":"go:GO:0031104","description":"\"The regrowth of dendrites in response to their loss or damage.\" [GOC:dgh, GOC:dph, GOC:tb]","metadata":null},{"id":"afcb77fddd35410f8e6949cf3f174b87","type":"GO_TERM","name":"dendrite self-avoidance","canonical_id":"go:GO:0070593","description":"\"The process in which dendrites recognize and avoid contact with sister dendrites from the same cell.\" [GOC:sart, PMID:17482551]","metadata":null},{"id":"f1c68b3d951f4496a70c1fcb70b2558a","type":"GO_TERM","name":"dendrite terminus","canonical_id":"go:GO:0044292","description":"\"A structure at the distal end of a dendrite adapted to carry out a specific function, e.g. dendriole.\" [GOC:jl, NIF_Subcellular:sao28175134]","metadata":null},{"id":"2ce61a2da1944773975cfd586a188a05","type":"GO_TERM","name":"dendritic branch","canonical_id":"go:GO:0044307","description":"\"A dendrite arising from another dendrite.\" [GOC:aruk, GOC:bc, NIF_Subcellular:sao884265541]","metadata":null},{"id":"f8bcdf6161b34bbc82b6eb94ae354253","type":"GO_TERM","name":"dendritic branch point","canonical_id":"go:GO:1990033","description":"\"The part of a dendritic tree where it branches, giving rise to a dendritic branch.\" [GOC:aruk, GOC:bc, NIF_Subcellular:sao1348591767]","metadata":null},{"id":"a47ae56d3ef64c70b545284309a96b9d","type":"GO_TERM","name":"dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002468","description":"\"The process in which a dendritic cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"a3f335fd7ee74984bdd4850c1d748661","type":"GO_TERM","name":"dendritic cell apoptotic process","canonical_id":"go:GO:0097048","description":"\"Any apoptotic process in a dendritic cell, a cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation.\" [CL:0000451, GOC:BHF, GOC:mtg_apoptosis, PMID:15059845]","metadata":null},{"id":"76feb75d79ac4977949a606e368fa0d6","type":"GO_TERM","name":"dendritic cell chemotaxis","canonical_id":"go:GO:0002407","description":"\"The movement of a dendritic cell in response to an external stimulus.\" [CL:0000451, GOC:add, ISBN:0781735149, PMID:15814331, PMID:16056255]","metadata":null},{"id":"38d28b69129e4e41b1464afa1fa13783","type":"GO_TERM","name":"dendritic cell cytokine production","canonical_id":"go:GO:0002371","description":"\"Any process that contributes to cytokine production by a dendritic cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"38334283d503463dbf458da2b1798505","type":"GO_TERM","name":"dendritic cell dendrite","canonical_id":"go:GO:0097511","description":"\"A branched cellular projection (or cytoplasmic extension) that is extended from the surface of a dendritic immune cell, and which enables the cell to sample luminal pathogens and increase the surface area for antigen presentation to T cells.\" [CL:0000451, GOC:BHF, GOC:cjm, PMID:12200351]","metadata":null},{"id":"d932f69219e147f7abef7668754cd366","type":"GO_TERM","name":"dendritic cell dendrite assembly","canonical_id":"go:GO:0097026","description":"\"Formation of dendrites, branched cellular projections (or cytoplasmic extension) that are extended from the surface of a dendritic immune cell, and which enable the cell to sample luminal pathogens and increase the surface area for antigen presentation to T cells.\" [CL:0000451, GOC:BHF, PMID:12200351]","metadata":null},{"id":"8a4df98a63db43d496c777a9788a148c","type":"GO_TERM","name":"dendritic cell differentiation","canonical_id":"go:GO:0097028","description":"\"The process in which a precursor cell type acquires the specialized features of a dendritic cell. A dendritic cell is a leukocyte of dendritic lineage specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation.\" [CL:0000451, GOC:pr]","metadata":null},{"id":"e45416979aa3429b897ced7a208f4806","type":"GO_TERM","name":"dendritic cell homeostasis","canonical_id":"go:GO:0036145","description":"\"The process of regulating the proliferation and elimination of dendritic cells such that the total number of dendritic cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [CL:0000451, GOC:uh, PMID:12570827, PMID:19176316]","metadata":null},{"id":"0e3ff3c7f1f246639223bdb861e8c094","type":"GO_TERM","name":"dendritic cell migration","canonical_id":"go:GO:0036336","description":"\"The movement of a dendritic cell within or between different tissues and organs of the body.\" [CL:0000451, GOC:nhn, PMID:19339990]","metadata":null},{"id":"3e146f5f59254d9887bc13add07ee6ab","type":"GO_TERM","name":"dendritic cell proliferation","canonical_id":"go:GO:0044565","description":"\"The expansion of a dendritic cell population by cell division. A dendritic cell is a cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation.\" [CL:0000451, PMID:18469816]","metadata":null},{"id":"3cc7dc71609d45dea5a73feafc124e80","type":"GO_TERM","name":"dendritic filopodium","canonical_id":"go:GO:1902737","description":"\"A small, membranous protrusion found primarily on dendritic stretches of developing neurons. May receive synaptic input, and can develop into dendritic spines.\" [GO_REF:0000064, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24464040, Wikipedia:Dendritic_filopodia]","metadata":null},{"id":"6f3dc92bb38145fb8eb74b5b6a49e95d","type":"GO_TERM","name":"dendritic growth cone","canonical_id":"go:GO:0044294","description":"\"The migrating motile tip of a growing nerve cell dendrite.\" [GOC:jl]","metadata":null},{"id":"55d2b042c87442cc98cb09edf8cbfc99","type":"GO_TERM","name":"dendritic knob","canonical_id":"go:GO:0098788","description":"\"The terminal swelling of an apical dendrite of a ciliated olfactory receptor neuron. Each knob gives rise to 5 to 20 long delicate nonmotile cilia, which extend into the mucus covering the sensory epithelium.\" [PMID:20801626]","metadata":null},{"id":"091c1419450a4520add2a28b5bb04c10","type":"GO_TERM","name":"dendritic lamellar body","canonical_id":"go:GO:1990503","description":"\"A specialized secretory organelle found in neurons and associated with the formation of dendrodendritic gap junctions.\" [PMID:7869120]","metadata":null},{"id":"db222a02f1354223a45e2dfbd2b87ecc","type":"GO_TERM","name":"dendritic microtubule","canonical_id":"go:GO:1901588","description":"\"Any microtubule in a dendrite, a neuron projection.\" [GOC:TermGenie, NIF_Subcellular:sao110773650]","metadata":null},{"id":"2c789be653d542bbb78c58ef55998b45","type":"GO_TERM","name":"dendritic shaft","canonical_id":"go:GO:0043198","description":"\"Cylindric portion of the dendrite, directly stemming from the perikaryon, and carrying the dendritic spines.\" [GOC:nln]","metadata":null},{"id":"adf7c8551e0f420ca9d776a89d7670d3","type":"GO_TERM","name":"dendritic spine","canonical_id":"go:GO:0043197","description":"\"A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity.\" [GOC:nln]","metadata":null},{"id":"e87871c86aa7409eae10dac4318c2102","type":"GO_TERM","name":"dendritic spine cytoplasm","canonical_id":"go:GO:0061846","description":"\"The region of the neuronal cytoplasm located in dendritic spines.\" [PMID:15673667]","metadata":null},{"id":"a99dc9a8b9174df5a16f98a4b8478cef","type":"GO_TERM","name":"dendritic spine development","canonical_id":"go:GO:0060996","description":"\"The process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure. A dendritic spine is a protrusion from a dendrite and a specialized subcellular compartment involved in synaptic transmission.\" [GOC:dph]","metadata":null},{"id":"56e3ca127618433d9b73e42879fdb75f","type":"GO_TERM","name":"dendritic spine head","canonical_id":"go:GO:0044327","description":"\"Distal part of the dendritic spine, that carries the post-synaptic density.\" [GOC:BHF, GOC:nln, GOC:rl]","metadata":null},{"id":"32bf625ef6a14b7bb6b4e3d45e61a3fe","type":"GO_TERM","name":"dendritic spine maintenance","canonical_id":"go:GO:0097062","description":"\"The organization process that preserves a dendritic spine in a stable functional or structural state. A dendritic spine is a specialized protrusion from a neuronal dendrite and is involved in synaptic transmission.\" [GOC:BHF, PMID:20410104]","metadata":null},{"id":"bf62e65c646b46e7be627a4ea5e8a7c1","type":"GO_TERM","name":"dendritic spine membrane","canonical_id":"go:GO:0032591","description":"\"The portion of the plasma membrane surrounding a dendritic spine.\" [GOC:mah]","metadata":null},{"id":"43ebf9d0abc34e0982db659ea39346cb","type":"GO_TERM","name":"dendritic spine morphogenesis","canonical_id":"go:GO:0060997","description":"\"The process in which the anatomical structures of a dendritic spine are generated and organized. A dendritic spine is a protrusion from a dendrite and a specialized subcellular compartment involved in synaptic transmission.\" [GOC:dph]","metadata":null},{"id":"51f91ebb33ea47b883062f1feabb7693","type":"GO_TERM","name":"dendritic spine neck","canonical_id":"go:GO:0044326","description":"\"Part of the dendritic spine that connects the dendritic shaft to the head of the dendritic spine.\" [GOC:nln]","metadata":null},{"id":"00e7d0c2ffef44ffa6a89aeec9d90f12","type":"GO_TERM","name":"dendritic spine organization","canonical_id":"go:GO:0097061","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a dendritic spine. A dendritic spine is a specialized protrusion from a neuronal dendrite and is involved in synaptic transmission.\" [GOC:BHF, PMID:20410104]","metadata":null},{"id":"7291f98bdc244e3597256b2265b99f78","type":"GO_TERM","name":"dendritic spine origin","canonical_id":"go:GO:0150004","description":"\"The part of the dendritic spine neck where the spine arises from the dendritic shaft.\" [GOC:aruk, GOC:bc, PMID:9030614]","metadata":null},{"id":"a0dfb8f34eb447cc9bbb07a2a347b113","type":"GO_TERM","name":"dendritic transport","canonical_id":"go:GO:0098935","description":"\"The directed movement of organelles or molecules along microtubules in dendrites.\" [ISBN:0815316194]","metadata":null},{"id":"ebb02423a0d545f5a2ddef3738ee55ff","type":"GO_TERM","name":"dendritic transport of messenger ribonucleoprotein complex","canonical_id":"go:GO:0098963","description":"\"The directed movement of a messenger ribonucleoprotein complex along microtubules in nerve cell dendrites.\" [GOC:dos]","metadata":null},{"id":"9088ca352daa49caa15c9c5599f14715","type":"GO_TERM","name":"dendritic transport of mitochondrion","canonical_id":"go:GO:0098939","description":"\"The directed movement of mitochondria along microtubules in nerve cell dendrites.\" [GOC:ai]","metadata":null},{"id":"ec2e02ea09e543b392a6c4d6dbd84541","type":"GO_TERM","name":"dendritic transport of ribonucleoprotein complex","canonical_id":"go:GO:0098961","description":"\"The directed movement of a ribonucleoprotein complex along microtubules in nerve cell dendrites.\" [GOC:dos]","metadata":null},{"id":"11a41e36142241df9ae040f38a3b23a0","type":"GO_TERM","name":"dendritic tree","canonical_id":"go:GO:0097447","description":"\"The entire complement of dendrites for a neuron, consisting of each primary dendrite and all its branches.\" [GOC:aruk, GOC:bc, NIF_Subcellular:sao172297168]","metadata":null},{"id":"a9f326c6f53548e8b3fe6daecd0e4956","type":"GO_TERM","name":"dendritic tuft","canonical_id":"go:GO:0044296","description":"\"The terminal specialization found in some types of dendrites which consists of numerous small terminal branches, giving the dendrite a tufted appearance.\" [NIF_Subcellular:sao1340260079]","metadata":null},{"id":"71620e3d1eaf43148f15127758c77719","type":"DRUG","name":"denileukin diftitox","canonical_id":"mesh:C078456","description":null,"metadata":null},{"id":"0c3c8613e90e457391a3a66fd1ffc709","type":"GO_TERM","name":"denitrification pathway","canonical_id":"go:GO:0019333","description":"\"The reduction of nitrate to dinitrogen by four reduction reactions: nitrate reduced to nitrite, then to nitric oxide, then to nitrous oxide, and finally to dinitrogen.\" [MetaCyc:DENITRIFICATION-PWY]","metadata":null},{"id":"8ef66acc4d6d44ada8413fc4d7100b83","type":"DRUG","name":"denosumab","canonical_id":"gtopdb:6886","description":null,"metadata":null},{"id":"e24e898ca172460eb9eb1b71d653383a","type":"DRUG","name":"denosumab","canonical_id":"mesh:D000069448","description":null,"metadata":null},{"id":"dbc603444a5c430c87e59e722789a7f9","type":"DRUG","name":"denosumab","canonical_id":"chembl:CHEMBL1237023","description":null,"metadata":null},{"id":"9d02dd33d9ca4d91975a7cbf0e492648","type":"COMBINATION_TREATMENT","name":"denosumab + lenvatinib","canonical_id":"ctgov_combo:ctgov-combo-944bbea27eaf150f","description":null,"metadata":null},{"id":"e2743c7bd0284b06b493aa8d60e6f30a","type":"COMBINATION_TREATMENT","name":"denosumab + romosozumab","canonical_id":"ctgov_combo:ctgov-combo-3892c8385c71f2dc","description":null,"metadata":null},{"id":"41d173ebf7e748a595ca6d75975e7452","type":"COMBINATION_TREATMENT","name":"denosumab + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-90db08a8559dbd5f","description":null,"metadata":null},{"id":"f3dc2eba4dbe4c24864dc438601374f6","type":"COMBINATION_TREATMENT","name":"denosumab + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-7acc597471b11bd9","description":null,"metadata":null},{"id":"14a6155325af4f4ca04565490bb20a0a","type":"COMBINATION_TREATMENT","name":"denosumab + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-2aeb57b93168c4dd","description":null,"metadata":null},{"id":"1e65a700eb71437bbe86fadc89b77e4d","type":"COMBINATION_TREATMENT","name":"denosumab + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-f8aa23c35e3d99cf","description":null,"metadata":null},{"id":"af474b8137a542a5a1e0c5f5d7a96d02","type":"COMBINATION_TREATMENT","name":"denosumab + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-8c1e85eaf8d6612f","description":null,"metadata":null},{"id":"45f1633e2aa24f9f9b17c428e12720ae","type":"GO_TERM","name":"dense body","canonical_id":"go:GO:0097433","description":"\"An electron dense body which may contain granules.\" [ISBN:0195065719, NIF_Subcellular:sao730872736]","metadata":null},{"id":"4c3d5782e7c1420ca9cc120a475f606e","type":"GO_TERM","name":"dense core granule","canonical_id":"go:GO:0031045","description":"\"Electron-dense organelle with a granular internal matrix; contains proteins destined to be secreted.\" [NIF_Subcellular:sao772007592, PMID:14690495]","metadata":null},{"id":"80e91ae14a004f1192a27b35be1eae75","type":"GO_TERM","name":"dense core granule biogenesis","canonical_id":"go:GO:0061110","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a dense core granule. Includes biosynthesis of constituent macromolecules, and those macromolecular modifications that are involved in synthesis or assembly of the dense core granule.\" [GOC:dph]","metadata":null},{"id":"c0992d2193924ed1a9559ea30d53dfee","type":"GO_TERM","name":"dense core granule cytoskeletal transport","canonical_id":"go:GO:0099519","description":"\"The directed movement of dense core granules along cytoskeletal fibers, such as microtubules or actin filaments.\" [GOC:kmv, PMID:23358451]","metadata":null},{"id":"87938f3f47364095b88d701302f70586","type":"GO_TERM","name":"dense core granule exocytosis","canonical_id":"go:GO:1990504","description":"\"The secretion of molecules (e.g. neuropeptides, insulin-related peptides or neuromodulators such as serotonin and dopamine) contained within a membrane-bounced dense core granule by fusion of the granule with the plasma membrane of a cell in response to increased cytosolic calcium levels.\" [GOC:kmv, PMID:17553987, PMID:24653208]","metadata":null},{"id":"7d5e4e9c3a9e4d1fb87e532fe5d424ad","type":"GO_TERM","name":"dense core granule localization","canonical_id":"go:GO:0032253","description":"\"Any process in which a dense core granule is transported to, and/or maintained in, a specific location within the cell.\" [GOC:mah]","metadata":null},{"id":"9ee71e557ff74ab98a484a7042d42d04","type":"GO_TERM","name":"dense core granule lumen","canonical_id":"go:GO:0098898","description":"\"The volume enclosed by the dense core granule membrane.\" [GOC:dos]","metadata":null},{"id":"9320664376f24c04a226d53f64e81bbd","type":"GO_TERM","name":"dense core granule maturation","canonical_id":"go:GO:1990502","description":"\"Steps required to transform a dense core granule generated at the trans-Golgi network into a fully formed and transmissible dense core granule. Dense core granule maturation proceeds through clathrin-mediated membrane remodeling events and is essential for efficient processing of cargo within dense core granules as well as for removing factors that might otherwise interfere with dense core granule trafficking and exocytosis.\" [GOC:kmv, PMID:22654674]","metadata":null},{"id":"88fa433a3a2147e7b8e619d3674249c8","type":"GO_TERM","name":"dense core granule membrane","canonical_id":"go:GO:0032127","description":"\"The lipid bilayer surrounding a dense core granule.\" [GOC:mah]","metadata":null},{"id":"362f141237c5495487716dcf9a035a37","type":"GO_TERM","name":"dense core granule organization","canonical_id":"go:GO:0061109","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a dense core granule. A dense core granule is a secretory organelle found in endocrine cells.\" [GOC:dph]","metadata":null},{"id":"a99b304caf6e4757aa21a402df434347","type":"GO_TERM","name":"dense core granule priming","canonical_id":"go:GO:0061789","description":"\"A process that converts unprimed dense core granules (DCVs) to a pool of primed vesicles that are capable of fusing with the plasma membrane (fusion-competent) and thereby releasing their contents. Priming typically occurs after docking.\" [GOC:bf, GOC:PARL, PMID:10899113, PMID:26575293]","metadata":null},{"id":"8d9afd3e79d446e48af49c394011eb85","type":"GO_TERM","name":"dense core granule transport","canonical_id":"go:GO:1901950","description":"\"The directed movement a dense core granule within a cell.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"0a2716a519c34613af1a5717942839de","type":"GO_TERM","name":"dense fibrillar component","canonical_id":"go:GO:0001651","description":"\"A structure found in the nucleolus, which contains newly synthesized preribosomal RNA (pre-rRNA) and a collection of proteins.\" [PMID:10754561]","metadata":null},{"id":"5636cab26fd040e18ab4f9a7b2f98e2a","type":"GO_TERM","name":"dense nuclear body","canonical_id":"go:GO:0046818","description":"\"A location in the host cell nucleus where viral proteins colocalize late in infection prior to the onset of viral DNA synthesis. More than one site can be present simultaneously.\" [PMID:10233976]","metadata":null},{"id":"ec41148e701546e98e0a2c5cbc771fb0","type":"GO_TERM","name":"dentate gyrus development","canonical_id":"go:GO:0021542","description":"\"The process whose specific outcome is the progression of the dentate gyrus over time, from its formation to the mature structure. The dentate gyrus is one of two interlocking gyri of the hippocampus. It contains granule cells, which project to the pyramidal cells and interneurons of the CA3 region of the ammon gyrus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8679008b5f384d1badc836e109b82298","type":"GO_TERM","name":"dentate gyrus mossy fiber","canonical_id":"go:GO:0044302","description":"\"Hippocampal mossy fiber produced by dentate gyrus granule cells.\" [NIF_Subcellular:nlx_subcell_20090601, PMID:17765709]","metadata":null},{"id":"73e643e3c16d49b2baf962d560f41b7e","type":"GO_TERM","name":"dentate nucleus development","canonical_id":"go:GO:0021735","description":"\"The process whose specific outcome is the progression of the dentate nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9ad44f8652e045668e722fc197b87d40","type":"GO_TERM","name":"dentin extracellular matrix secretion","canonical_id":"go:GO:0070468","description":"\"The regulated release by odontoblasts of the extracellular matrix constituents, including collagen, that form the basis of dentin.\" [GOC:mah, PMID:12856968]","metadata":null},{"id":"bc7c20d345754ca88dffe58eb9e1bcf9","type":"GO_TERM","name":"dentin mineralization","canonical_id":"go:GO:0097188","description":"\"The process in which calcium salts are deposited into the calcareous tooth structure known as dentin.\" [GOC:sl, PMID:10206335, PMID:21196346]","metadata":null},{"id":"2ee35cb2d54b47279dce9650bc5ef46d","type":"GO_TERM","name":"dentinogenesis","canonical_id":"go:GO:0097187","description":"\"The process whose specific outcome is the formation of dentin, the mineralized tissue that constitutes the major bulk of teeth. Dentin may be one of three types: primary dentin, secondary dentin, and tertiary dentin.\" [GOC:cjm, GOC:sl, PMID:10206335, PMID:21196346]","metadata":null},{"id":"2e99b9f4c55d4c9baec1b3af8a66f21a","type":"GO_TERM","name":"deoxyadenosine biosynthetic process","canonical_id":"go:GO:0046091","description":"\"The chemical reactions and pathways resulting in the formation of deoxyadenosine, 2-deoxyribosyladenine, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"bbc97a1e0f3f4a14968a39021b7e4d7d","type":"GO_TERM","name":"deoxyadenosine catabolic process","canonical_id":"go:GO:0006157","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxyadenosine, 2-deoxyribosyladenine, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"d0898dc7c5784162a299ba614ee9e48a","type":"GO_TERM","name":"deoxyadenosine kinase activity","canonical_id":"go:GO:0004136","description":"\"Catalysis of the reaction: 2'-deoxyadenosine + ATP = ADP + dAMP + 2 H+.\" [EC:2.7.1.76, RHEA:23452]","metadata":null},{"id":"e0740ee75f4b45bd967c815a3ff08007","type":"GO_TERM","name":"deoxyadenosine metabolic process","canonical_id":"go:GO:0046090","description":"\"The chemical reactions and pathways involving deoxyadenosine, 2-deoxyribosyladenine, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"4dcec4e3d78c410fa0864012bdaa7437","type":"GO_TERM","name":"deoxycytidine biosynthetic process","canonical_id":"go:GO:0046093","description":"\"The chemical reactions and pathways resulting in the formation of deoxycytidine, 2-deoxyribosylcytosine, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"5ae892308b4f401ca1c38797c34b84b1","type":"GO_TERM","name":"deoxycytidine catabolic process","canonical_id":"go:GO:0006217","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxycytidine, 2-deoxyribosylcytosine, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"8ace56078ba246f49dd273bda1ccdaeb","type":"GO_TERM","name":"deoxycytidine kinase activity","canonical_id":"go:GO:0004137","description":"\"Catalysis of the reaction: NTP + deoxycytidine = NDP + CMP.\" [EC:2.7.1.74]","metadata":null},{"id":"0af8a15d35a04006a670610a135ee4be","type":"GO_TERM","name":"deoxycytidine metabolic process","canonical_id":"go:GO:0046092","description":"\"The chemical reactions and pathways involving deoxycytidine, 2-deoxyribosylcytosine, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"885858f4bb274861aed5a257ab390808","type":"GO_TERM","name":"deoxycytidine salvage","canonical_id":"go:GO:0006237","description":"\"Any process that generates deoxycytidine, 2-deoxyribosylcytosine, from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"56c6e1006cb944ff9a967d319fd433fd","type":"GO_TERM","name":"deoxycytidyl transferase activity","canonical_id":"go:GO:0017125","description":"\"Catalysis of the insertion of a dCMP residue opposite a template abasic site in DNA.\" [PMID:10535901]","metadata":null},{"id":"5c760cb40e374a73bfd2b5044db7109d","type":"GO_TERM","name":"deoxycytidylate 5-hydroxymethyltransferase activity","canonical_id":"go:GO:0047153","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + dCMP + H2O = (6S)-5,6,7,8-tetrahydrofolate + 5-hydroxymethyldeoxycytidylate.\" [EC:2.1.2.8, RHEA:11280]","metadata":null},{"id":"758d55e80c2847b59daaa8dbec13e79e","type":"GO_TERM","name":"deoxycytidylate C-methyltransferase activity","canonical_id":"go:GO:0050003","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + dCMP = 2'-deoxy-5-methyl-5'-cytidylate + 7,8-dihydrofolate.\" [EC:2.1.1.54, RHEA:11568]","metadata":null},{"id":"756201faa011427aa042f92fc7f09ce6","type":"GO_TERM","name":"deoxyguanosine biosynthetic process","canonical_id":"go:GO:0042452","description":"\"The chemical reactions and pathways resulting in the formation of deoxyguanosine, a nucleoside consisting of the base guanine and the sugar deoxyribose.\" [GOC:jl]","metadata":null},{"id":"12867c564901466596edac94d3c829d7","type":"GO_TERM","name":"deoxyguanosine catabolic process","canonical_id":"go:GO:0006161","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxyguanosine, a nucleoside consisting of the base guanine and the sugar deoxyribose.\" [GOC:jl]","metadata":null},{"id":"fdd7f5e8b8a747938a61b17574ce73e0","type":"GO_TERM","name":"deoxyguanosine kinase activity","canonical_id":"go:GO:0004138","description":"\"Catalysis of the reaction: 2'-deoxyguanosine + ATP = ADP + dGMP + 2 H+.\" [EC:2.7.1.113, RHEA:19201]","metadata":null},{"id":"ddd95e87dbff4e349bce7ef541babe5e","type":"GO_TERM","name":"deoxyguanosine salvage","canonical_id":"go:GO:0006180","description":"\"Any process that generates deoxyguanosine from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"01c0ad5a77d74a76afb7d70ba2198183","type":"GO_TERM","name":"deoxyhypusine monooxygenase activity","canonical_id":"go:GO:0019135","description":"\"Catalysis of the reaction: protein N6-(4-aminobutyl)-L-lysine + donor-H2 + O2 = protein N6-((R)-4-amino-2-hydroxybutyl)-L-lysine + acceptor + H2O.\" [EC:1.14.99.29]","metadata":null},{"id":"141d21abda934416b2b293e7339cbd54","type":"GO_TERM","name":"deoxyhypusine synthase activity","canonical_id":"go:GO:0034038","description":"\"Catalysis of the reaction: [eIF5A-precursor]-lysine + spermidine = [eIF5A-precursor]-deoxyhypusine + propane-1,3-diamine. Four sub-reactions have been identified,in which the intermediates remain tightly associated with the enzyme: spermidine + NAD+ = dehydrospermidine + NADH; dehydrospermidine + [enzyme]-lysine = N-(4-aminobutylidene)-[enzyme]-lysine + propane-1,3-diamine; N-(4-aminobutylidene)-[enzyme]-lysine + [eIF5A-precursor]-lysine = N-(4-aminobutylidene)-[eIF5A-precursor]-lysine + [enzyme]-lysine; N-(4-aminobutylidene)-[eIF5A-precursor]-lysine + NADH + H+ = [eIF5A-precursor]-deoxyhypusine + NAD+.\" [GOC:pde, RHEA:33299]","metadata":null},{"id":"2e3649fe920e4543a2f6888b9920eb2d","type":"GO_TERM","name":"deoxyinosine biosynthetic process","canonical_id":"go:GO:0046095","description":"\"The chemical reactions and pathways resulting in the formation of deoxyinosine, hypoxanthine deoxyriboside.\" [GOC:curators]","metadata":null},{"id":"046416dfc524484f89de31aa55aad11d","type":"GO_TERM","name":"deoxyinosine catabolic process","canonical_id":"go:GO:0006149","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxyinosine, hypoxanthine deoxyriboside.\" [GOC:curators]","metadata":null},{"id":"14675978d5bd490a86af346b5e4c8200","type":"GO_TERM","name":"deoxyinosine metabolic process","canonical_id":"go:GO:0046094","description":"\"The chemical reactions and pathways involving deoxyinosine, hypoxanthine deoxyriboside.\" [GOC:curators]","metadata":null},{"id":"9d70a8e3e6944573964b695f01a0b561","type":"GO_TERM","name":"deoxyinosine salvage","canonical_id":"go:GO:0006191","description":"\"Any process that generates deoxyinosine from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"225ba4e59cdc4871942fff62d6256815","type":"GO_TERM","name":"deoxylimonate A-ring-lactonase activity","canonical_id":"go:GO:0047845","description":"\"Catalysis of the reaction: deoxylimonoate + H2O = deoxylimononate D-ring-lactone + H+.\" [EC:3.1.1.46, RHEA:14997]","metadata":null},{"id":"d43779c39399421ea6480fa15c76e60a","type":"GO_TERM","name":"deoxynucleoside kinase activity","canonical_id":"go:GO:0019136","description":"\"Catalysis of the reaction: ATP + 2'-deoxynucleoside = ADP + 2'-deoxynucleoside 5'-phosphate.\" [EC:2.7.1.145]","metadata":null},{"id":"67269dcb4e224c849be01cf29a59334c","type":"GO_TERM","name":"deoxynucleoside phosphate kinase activity, ATP as phosphate donor","canonical_id":"go:GO:0047507","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-phosphate + ATP = a 2'-deoxyribonucleoside 5'-diphosphate + ADP.\" [RHEA:11216]","metadata":null},{"id":"4fb53bb3252344cfa34e61a1c2f40851","type":"GO_TERM","name":"deoxynucleoside phosphate kinase activity, GTP as phosphate donor","canonical_id":"go:GO:0106369","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-phosphate + GTP = a 2'-deoxyribonucleoside 5'-diphosphate + GDP.\" [PMID:20497505, RHEA:62124]","metadata":null},{"id":"036892823777424cae59532cca7c8cae","type":"GO_TERM","name":"deoxynucleoside phosphate kinase activity, dGTP as phosphate donor","canonical_id":"go:GO:0106367","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-phosphate + dGTP = a 2'-deoxyribonucleoside 5'-diphosphate + dGDP.\" [PMID:20497505, RHEA:62128]","metadata":null},{"id":"03028d9fa6334196bb4fe90ee85ba3cc","type":"GO_TERM","name":"deoxynucleoside phosphate kinase activity, dTTP as phosphate donor","canonical_id":"go:GO:0106368","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-phosphate + dTTP = a 2'-deoxyribonucleoside 5'-diphosphate + dTDP.\" [PMID:20497505, RHEA:62132]","metadata":null},{"id":"117297c1f86f4c88bbe392682657d34f","type":"GO_TERM","name":"deoxynucleoside triphosphate hydrolase activity","canonical_id":"go:GO:0106375","description":"\"Catalysis of the reaction: dNTP + H2O = 2'-deoxynucleoside + H+ + triphosphate.\" [RHEA:46148]","metadata":null},{"id":"cb6e3b0c0ae64e73a9adfc227a84397f","type":"GO_TERM","name":"deoxynucleotide 3'-phosphatase activity","canonical_id":"go:GO:0047846","description":"\"Catalysis of the reaction: a deoxynucleoside 3'-phosphate + H2O = a deoxynucleoside + phosphate.\" [EC:3.1.3.34, MetaCyc:DEOXYNUCLEOTIDE-3-PHOSPHATASE-RXN]","metadata":null},{"id":"df930ad59d234e1eb8ce99cc8bcf3643","type":"GO_TERM","name":"deoxynucleotide transmembrane transporter activity","canonical_id":"go:GO:0030233","description":"\"Catalyzes transport of all four deoxy (d) NDPs, and, less efficiently, the corresponding dNTPs, in exchange for dNDPs, ADP, or ATP.\" [PMID:11226231]","metadata":null},{"id":"1781db41c5aa49b4ab68a7364de37c2c","type":"GO_TERM","name":"deoxynucleotide transport","canonical_id":"go:GO:0030302","description":"\"The directed movement of a deoxynucleotide, a deoxyribonucleoside in ester linkage to phosphate, commonly at the 5' position of deoxyribose, into, out of or within a cell.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"c77315330e1f412c9aa8b30c4de9fb86","type":"GO_TERM","name":"deoxyribodipyrimidine endonucleosidase activity","canonical_id":"go:GO:0033959","description":"\"Catalysis of the cleavage of the N-glycosidic bond between the 5'-pyrimidine residue in cyclobutadipyrimidine (in DNA) and the corresponding deoxy-D-ribose residue.\" [EC:3.2.2.17]","metadata":null},{"id":"f251067828384eb38f18f4d4443f807a","type":"GO_TERM","name":"deoxyribodipyrimidine photo-lyase activity","canonical_id":"go:GO:0003904","description":"\"Catalysis of the reaction: cyclobutadipyrimidine (in DNA) = 2 pyrimidine residues (in DNA). This reaction represents the reactivation of irradiated DNA by light.\" [EC:4.1.99.3]","metadata":null},{"id":"0dee3b5ee68e4f37aa67c4f3a84e933a","type":"GO_TERM","name":"deoxyribonuclease (pyrimidine dimer) activity","canonical_id":"go:GO:0033892","description":"\"Catalysis of the endonucleolytic cleavage near pyrimidine dimers to products with 5'-phosphate.\" [EC:3.1.25.1]","metadata":null},{"id":"1d0a861deeaa4f15808bb9eabed0ffcb","type":"GO_TERM","name":"deoxyribonuclease I activity","canonical_id":"go:GO:0004530","description":"\"Catalysis of the endonucleolytic cleavage of DNA to 5'-phosphodinucleotide and 5'-phosphooligonucleotide end products.\" [EC:3.1.21.1]","metadata":null},{"id":"a3efcd7cc0644abd8d6b5944e0fa1bc3","type":"GO_TERM","name":"deoxyribonuclease II activity","canonical_id":"go:GO:0004531","description":"\"Catalysis of the endonucleolytic cleavage of DNA to nucleoside 3'-phosphates and 3'-phosphooligonucleotide end-products.\" [EC:3.1.22.1]","metadata":null},{"id":"abe37e3cffd0438b94d0a27a8d40459d","type":"GO_TERM","name":"deoxyribonuclease IV (phage-T4-induced) activity","canonical_id":"go:GO:0008833","description":"\"Catalysis of the endonucleolytic cleavage to 5'-phosphooligonucleotide end-products.\" [EC:3.1.21.2]","metadata":null},{"id":"000787c1ba2d45658be83f771e2b917c","type":"GO_TERM","name":"deoxyribonuclease V activity","canonical_id":"go:GO:0043737","description":"\"Catalysis of the endonucleolytic cleavage at apurinic or apyrimidinic sites to products with a 5'-phosphate.\" [EC:3.1.21.7]","metadata":null},{"id":"9d4fc384e1334f6288b2bfaaaeedb53b","type":"GO_TERM","name":"deoxyribonuclease inhibitor activity","canonical_id":"go:GO:0060703","description":"\"Binds to and stops, prevents or reduces the activity of deoxyribonuclease.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ed9c1bf3be2c4afab42ffd89582e540a","type":"GO_TERM","name":"deoxyribonucleoside binding","canonical_id":"go:GO:0032546","description":"\"Binding to a deoxyribonucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked to deoxyribose.\" [GOC:mah]","metadata":null},{"id":"69d688ccdffa49ffa447da58927d9c13","type":"GO_TERM","name":"deoxyribonucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009189","description":"\"The chemical reactions and pathways resulting in the formation of a deoxyribonucleoside diphosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d5f779c9e74a4543bc2927b2b5015d8b","type":"GO_TERM","name":"deoxyribonucleoside diphosphate catabolic process","canonical_id":"go:GO:0009192","description":"\"The chemical reactions and pathways resulting in the breakdown of a deoxyribonucleoside diphosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"e8d88bd5a1b34d91b78f3cf8caae8272","type":"GO_TERM","name":"deoxyribonucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009157","description":"\"The chemical reactions and pathways resulting in the formation of a deoxyribonucleoside monophosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"bde8d3cffb654061b292f7b60cc8261d","type":"GO_TERM","name":"deoxyribonucleoside monophosphate catabolic process","canonical_id":"go:GO:0009159","description":"\"The chemical reactions and pathways resulting in the breakdown of a deoxyribonucleoside monophosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a2748518f6cb42c99c164d88435e303c","type":"GO_TERM","name":"deoxyribonucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009202","description":"\"The chemical reactions and pathways resulting in the formation of a deoxyribonucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f9f91aefbc7844aba0b36c2c61d97fdf","type":"GO_TERM","name":"deoxyribonucleoside triphosphate catabolic process","canonical_id":"go:GO:0009204","description":"\"The chemical reactions and pathways resulting in the breakdown of a deoxyribonucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"7ba978f2da544e12921e1919051fde1c","type":"GO_TERM","name":"deoxyribonucleoside triphosphate metabolic process","canonical_id":"go:GO:0009200","description":"\"The chemical reactions and pathways involving a deoxyribonucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b5f55dc3f26c4aa398d77fdb518f6b2e","type":"GO_TERM","name":"deoxyribonucleotide binding","canonical_id":"go:GO:0032552","description":"\"Binding to a deoxyribonucleotide, any compound consisting of a deoxyribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety.\" [GOC:mah]","metadata":null},{"id":"ad6fae29e5b84cf5bd7e2bf7caae2395","type":"GO_TERM","name":"deoxyribonucleotide biosynthetic process","canonical_id":"go:GO:0009263","description":"\"The chemical reactions and pathways resulting in the formation of a deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators]","metadata":null},{"id":"9cb5f34970104f98a44d080d15dedd68","type":"GO_TERM","name":"deoxyribonucleotide catabolic process","canonical_id":"go:GO:0009264","description":"\"The chemical reactions and pathways resulting in the breakdown of a deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators]","metadata":null},{"id":"6ca1cd3f8438433290779f0f8b6d063c","type":"GO_TERM","name":"deoxyribonucleotide metabolic process","canonical_id":"go:GO:0009262","description":"\"The chemical reactions and pathways involving a deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators]","metadata":null},{"id":"06776b96270e4cfe8a0afdf812da0afc","type":"GO_TERM","name":"deoxyribose phosphate biosynthetic process","canonical_id":"go:GO:0046385","description":"\"The chemical reactions and pathways resulting in the formation of deoxyribose phosphate, the phosphorylated sugar 2-deoxy-erythro-pentose.\" [ISBN:0198506732]","metadata":null},{"id":"b4f08b8c2f3a4148b6a30c81ba5b3d5a","type":"GO_TERM","name":"deoxyribose phosphate catabolic process","canonical_id":"go:GO:0046386","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxyribose phosphate, the phosphorylated sugar 2-deoxy-erythro-pentose.\" [ISBN:0198506732]","metadata":null},{"id":"496c17a4f66641d2a665e27d3ae33c4b","type":"GO_TERM","name":"deoxyribose-phosphate aldolase activity","canonical_id":"go:GO:0004139","description":"\"Catalysis of the reaction: 2-deoxy-D-ribose 5-phosphate = D-glyceraldehyde 3-phosphate + acetaldehyde.\" [EC:4.1.2.4, RHEA:12821]","metadata":null},{"id":"9e2c6b5c0a6845bbb4a8e310f83c49ae","type":"GO_TERM","name":"deoxysarpagine hydroxylase activity","canonical_id":"go:GO:0033775","description":"\"Catalysis of the reaction: 10-deoxysarpagine + H+ + NADPH + O2 = H2O + NADP+ + sarpagine.\" [EC:1.14.14.136, RHEA:14237]","metadata":null},{"id":"87aa4c5ff54c40c68c670ec2141101ef","type":"GO_TERM","name":"deoxyuridine 1'-dioxygenase activity","canonical_id":"go:GO:0047079","description":"\"Catalysis of the reaction: 2'-deoxyuridine + 2-oxoglutarate + O2 = 2-deoxy-D-ribono-1,4-lactone + CO2 + succinate + uracil.\" [EC:1.14.11.10, RHEA:23316]","metadata":null},{"id":"e0401ca52c75490d9aa5464e7452c4fa","type":"GO_TERM","name":"deoxyuridine 2'-dioxygenase activity","canonical_id":"go:GO:0047080","description":"\"Catalysis of the reaction: 2'-deoxyuridine + 2-oxoglutarate + O2 = CO2 + succinate + uridine.\" [EC:1.14.11.3, RHEA:21076]","metadata":null},{"id":"c08d0224216f42b3b00ab42320ac5ec0","type":"GO_TERM","name":"deoxyuridine biosynthetic process","canonical_id":"go:GO:0046097","description":"\"The chemical reactions and pathways resulting in the formation of deoxyuridine, 2-deoxyribosyluracil, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"a900370ecc8047768b6d4c3156438a18","type":"GO_TERM","name":"deoxyuridine catabolic process","canonical_id":"go:GO:0006219","description":"\"The chemical reactions and pathways resulting in the breakdown of deoxyuridine, 2-deoxyribosyluracil, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"95a794886acb4659ba899266b808027c","type":"GO_TERM","name":"deoxyuridine metabolic process","canonical_id":"go:GO:0046096","description":"\"The chemical reactions and pathways involving deoxyuridine, 2-deoxyribosyluracil, one of the four major nucleosides of DNA.\" [GOC:curators]","metadata":null},{"id":"055ae9ca063e4526aee8004a54205cac","type":"GO_TERM","name":"deoxyuridine phosphorylase activity","canonical_id":"go:GO:0047847","description":"\"Catalysis of the reaction: 2'-deoxyuridine + phosphate = 2-deoxy-alpha-D-ribose 1-phosphate + uracil.\" [RHEA:22824]","metadata":null},{"id":"d2d04f7892a744fca2838bad37c6990f","type":"DRUG","name":"depemokimab","canonical_id":"gtopdb:14305","description":null,"metadata":null},{"id":"ad5ddf36897a481aa7edf4d1167b89b4","type":"DRUG","name":"depemokimab","canonical_id":"chembl:CHEMBL4650469","description":null,"metadata":null},{"id":"d6e3bba665174ffca306943ccef488ec","type":"COMBINATION_TREATMENT","name":"depemokimab + mepolizumab","canonical_id":"ctgov_combo:ctgov-combo-661461912e1a994c","description":null,"metadata":null},{"id":"209e09d031494f86a1709196cd2f757d","type":"GO_TERM","name":"dephospho-CoA kinase activity","canonical_id":"go:GO:0004140","description":"\"Catalysis of the reaction: 3'-dephospho-CoA + ATP = ADP + CoA + 2 H+.\" [EC:2.7.1.24, RHEA:18245]","metadata":null},{"id":"035eb609256a485c9b064ec44c337e58","type":"GO_TERM","name":"dephosphorylation","canonical_id":"go:GO:0016311","description":"\"The process of removing one or more phosphoric (ester or anhydride) residues from a molecule.\" [ISBN:0198506732]","metadata":null},{"id":"98d6f757bb274efe84ab944fd85a4a10","type":"GO_TERM","name":"depolarization of postsynaptic membrane","canonical_id":"go:GO:0098819","description":"\"A process that depolarizes a postsynaptic membrane relative to its resting potential. This has an excitatory effect on the post-synaptic cell, moving the membrane potential towards the firing threshold.\" [GOC:dos]","metadata":null},{"id":"3393ea51f37e41dbb3e4458c3d35c4d9","type":"DISEASE","name":"depressive disorder","canonical_id":"mondo:0002050","description":null,"metadata":null},{"id":"8a1b048c317643ffa736eaa3cfbbdbc2","type":"GO_TERM","name":"depsipeptide biosynthetic process","canonical_id":"go:GO:0050763","description":"\"The chemical reactions and pathways resulting in the formation of depsipeptides, a linear or cyclic compound composed of both amino acids and hydroxy acids in peptide and ester bonds respectively.\" [GOC:curators]","metadata":null},{"id":"b66d4d1779e64077918b02a7f4e178ed","type":"GO_TERM","name":"depsipeptide catabolic process","canonical_id":"go:GO:0050762","description":"\"The chemical reactions and pathways resulting in the breakdown of depsipeptides, a linear or cyclic compound composed of both amino acids and hydroxy acids in peptide and ester bonds respectively.\" [GOC:curators]","metadata":null},{"id":"e4122afeb5eb47079b7759be2fafba58","type":"GO_TERM","name":"depsipeptide metabolic process","canonical_id":"go:GO:0050761","description":"\"The chemical reactions and pathways involving depsipeptides, a linear or cyclic compound composed of both amino acids and hydroxy acids in peptide and ester bonds respectively.\" [GOC:curators]","metadata":null},{"id":"7bbd82bdd48e4ba8984511a30b0c0400","type":"GO_TERM","name":"depurination","canonical_id":"go:GO:0045007","description":"\"The disruption of the bond between the sugar in the backbone and the A or G base, causing the base to be removed and leaving a depurinated sugar.\" [GOC:ai]","metadata":null},{"id":"b352bfee73bf4ca69a3e219dc17bd776","type":"GO_TERM","name":"depyrimidination","canonical_id":"go:GO:0045008","description":"\"The disruption of the bond between the sugar in the backbone and the C or T base, causing the base to be removed and leaving a depyrimidinated sugar.\" [GOC:ai]","metadata":null},{"id":"b1ea03ff8ddc4b868935b0074ecb1c88","type":"GO_TERM","name":"dermal bone morphogenesis","canonical_id":"go:GO:0061972","description":"\"The process in which bone which forms superficially in the organism are generated and organized.\" [PMID:12588850, PMID:15003632]","metadata":null},{"id":"4b6d5ffd255344c6a4dd19e2323ad363","type":"GO_TERM","name":"dermatan 2-sulfotransferase activity","canonical_id":"go:GO:0102142","description":"\"Catalysis of the reaction: dermatan-[core protein] + 3'-phosphoadenylyl-sulfate = [dermatan-sulfate] containing 2-O-sulfo-alpha-L-iduronate + adenosine 3',5'-bisphosphate + H+.\" [MetaCyc:RXN-11561]","metadata":null},{"id":"a68dcf28db344a84bf89078bb573dde8","type":"GO_TERM","name":"dermatan 4-sulfotransferase activity","canonical_id":"go:GO:0001537","description":"\"Catalysis of the reaction: n 3'-phosphoadenylyl sulfate + dermatan = n adenosine 3',5'-bisphosphate + dermatan 4'-sulfate + n H+.\" [RHEA:48052]","metadata":null},{"id":"0d6f4f84d81349a79821a7f3e08de251","type":"GO_TERM","name":"dermatan sulfate proteoglycan biosynthetic process","canonical_id":"go:GO:0050651","description":"\"The chemical reactions and pathways resulting in the formation of dermatan sulfate proteoglycans, which consist of a core protein linked to a dermatan sulfate glycosaminoglycan. The dermatan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-hexuronic acid-beta-(1,3)-N-acetyl-D-galactosamine. Tthe former can be a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids, and the latter can be O-sulfated. Dermatan sulfate chains are covalently linked to serine/threonine residues (O-linked) of the core protein via a tetrasaccharide linker sequence (xylose-galactose-galactose-glucuronate).\" [PMID:17239763]","metadata":null},{"id":"a071f975d0ed432c850d836b7e1e04ed","type":"GO_TERM","name":"dermatan sulfate proteoglycan catabolic process","canonical_id":"go:GO:0030209","description":"\"The chemical reactions and pathways resulting in the breakdown of dermatan sulfate proteoglycans, which consist of a core protein linked to a dermatan sulfate glycosaminoglycan. The dermatan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-hexuronic acid-beta-(1,3)-N-acetyl-D-galactosamine. The former can be a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids and the latter can be O-sulfated.\" [PMID:17239763]","metadata":null},{"id":"109b7a7c6d0748659f3b82c5369b9dc7","type":"GO_TERM","name":"dermatan sulfate proteoglycan metabolic process","canonical_id":"go:GO:0050655","description":"\"The chemical reactions and pathways involving dermatan sulfate proteoglycans, which consist of a core protein linked to a dermatan sulfate glycosaminoglycan. The dermatan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-D-hexuronic acid-beta-(1,3)-N-acetyl-D-galactosamine. The former can be a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids, and the latter can be O-sulfated.\" [PMID:17239763]","metadata":null},{"id":"1e0468c18bdf44b7a8c4a851606be5b4","type":"GO_TERM","name":"dermatan sulfotransferase activity","canonical_id":"go:GO:0120534","description":"\"Catalysis of the reaction: 3'-phosphoadenylyl sulfate + dermatan = adenosine 3',5'-bisphosphate + dermatan sulfate.\" [GOC:curators]","metadata":null},{"id":"a93b6f65fc8746fca71454e15b8297d2","type":"DISEASE","name":"dermatitis","canonical_id":"mondo:0002406","description":null,"metadata":null},{"id":"2732359f23754a1cb1619f433753ec6d","type":"DISEASE","name":"dermatitis herpetiformis","canonical_id":"mondo:0015614","description":null,"metadata":null},{"id":"35994835b5f94d81a67230f0beb71057","type":"DISEASE","name":"dermatofibrosarcoma protuberans","canonical_id":"mondo:0011934","description":null,"metadata":null},{"id":"dfb7ff8852b547ac81a8c9ddf3fb4e7d","type":"GO_TERM","name":"dermatome development","canonical_id":"go:GO:0061054","description":"\"The progression of the dermatome over time, from its initial formation to the mature structure. The dermatome is the portion of a somite that will form skin.\" [GOC:dph]","metadata":null},{"id":"4878ffbe825e45e8a968daa330bbc42d","type":"DISEASE","name":"dermatomyositis","canonical_id":"mondo:0016367","description":null,"metadata":null},{"id":"c3731e041e9d4ab68fc3186146bb20b4","type":"GO_TERM","name":"desacetoxyvindoline 4-hydroxylase activity","canonical_id":"go:GO:0050590","description":"\"Catalysis of the reaction: desacetoxyvindoline + 2-oxoglutarate + O2 = desacetylvindoline + succinate + CO2.\" [EC:1.14.11.20, MetaCyc:1.14.11.20-RXN]","metadata":null},{"id":"cbdd1f263fc541c5a30eca1519e72f35","type":"GO_TERM","name":"descending aorta development","canonical_id":"go:GO:0035906","description":"\"The progression of the descending aorta over time, from its initial formation to the mature structure. The descending aorta is the portion of the aorta in a two-pass circulatory system from the arch of aorta to the point where it divides into the common iliac arteries. In a two-pass circulatory system blood passes twice through the heart to supply the body once.\" [GOC:bf, GOC:dgh, MA:0002571, UBERON:0001514, Wikipedia:Descending_aorta]","metadata":null},{"id":"c3a3093b02624143b8bd4e7084736c1d","type":"GO_TERM","name":"descending aorta morphogenesis","canonical_id":"go:GO:0035911","description":"\"The process in which the anatomical structures of the descending aorta are generated and organized. The descending aorta is the portion of the aorta in a two-pass circulatory system from the arch of aorta to the point where it divides into the common iliac arteries. In a two-pass circulatory system blood passes twice through the heart to supply the body once.\" [GOC:bf, GOC:dgh, MA:0002571, UBERON:0001514, Wikipedia:Descending_aorta]","metadata":null},{"id":"2a0ac74594174560b931fb2eaf4eec35","type":"GO_TERM","name":"descending thin limb development","canonical_id":"go:GO:0072022","description":"\"The process whose specific outcome is the progression of the descending thin limb over time, from its formation to the mature structure. The descending thin limb is a part of the loop of Henle situated just after the proximal straight tubule (S3). It extends to the tip of the loop of Henle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8be5c69a66e14e029450ff416b5f7e94","type":"GO_TERM","name":"desensitization of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0002029","description":"\"The process that stops, prevents, or reduces the frequency, rate or extent of G protein-coupled receptor signaling pathway after prolonged stimulation with an agonist of the pathway.\" [PMID:8396717]","metadata":null},{"id":"d5aaca7af4d74c209076b7473e6f5353","type":"DRUG","name":"desipramine","canonical_id":"gtopdb:2399","description":null,"metadata":null},{"id":"99b4c681e5244e00a3d5b0f32462fcde","type":"DRUG","name":"desipramine","canonical_id":"mesh:D003891","description":null,"metadata":null},{"id":"1f12eec5665b4520948d79d03a9c1fdc","type":"COMBINATION_TREATMENT","name":"desipramine + desvenlafaxine","canonical_id":"ctgov_combo:ctgov-combo-89f33e4cb2728e67","description":null,"metadata":null},{"id":"1cd60e9ff8934f23a0d2ddfc9aaa0568","type":"COMBINATION_TREATMENT","name":"desipramine + fluoxetine","canonical_id":"ctgov_combo:ctgov-combo-2b0407e511453826","description":null,"metadata":null},{"id":"e6310905fbd740768c2bf9d00144a060","type":"COMBINATION_TREATMENT","name":"desipramine + fluoxetine","canonical_id":"ctgov_combo:ctgov-combo-771136f0a727d0ce","description":null,"metadata":null},{"id":"5858214a7b4f48f196a12cbd88b21dcf","type":"COMBINATION_TREATMENT","name":"desipramine + nortriptyline","canonical_id":"ctgov_combo:ctgov-combo-e06ba5bf1793a9bf","description":null,"metadata":null},{"id":"cbb85bbccacc4b0d9b1ae54f3a0511f0","type":"COMBINATION_TREATMENT","name":"desipramine + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-b28c7c0f5a5b8ec1","description":null,"metadata":null},{"id":"0fa18f5c4e064e2f8629a3c271519ca7","type":"DRUG","name":"desirudin","canonical_id":"gtopdb:6458","description":null,"metadata":null},{"id":"dc5d42c7ebea4d4bbdf70b81f840867e","type":"DRUG","name":"desirudin","canonical_id":"chembl:CHEMBL1201662","description":null,"metadata":null},{"id":"3e3981a1cdea4c4aa669d64d132c3ced","type":"DRUG","name":"deslanoside","canonical_id":"gtopdb:6806","description":null,"metadata":null},{"id":"6acd25d783bf49aa9fdd478a59f53dd6","type":"DRUG","name":"deslanoside","canonical_id":"chembl:CHEMBL1614","description":null,"metadata":null},{"id":"1303e45238554e73aa0e58f68c7d8de4","type":"DRUG","name":"desloratadine","canonical_id":"gtopdb:7157","description":null,"metadata":null},{"id":"b323bcff2dd445d08232acbf5246f2e8","type":"DRUG","name":"desloratadine","canonical_id":"mesh:C121345","description":null,"metadata":null},{"id":"fbebeb3510b64e5db9bf6b49ba4e490b","type":"DRUG","name":"desloratadine","canonical_id":"chembl:CHEMBL1172","description":null,"metadata":null},{"id":"8ca8f55d125b4fd998e78c51277a00a9","type":"COMBINATION_TREATMENT","name":"desloratadine + dipyridamole","canonical_id":"ctgov_combo:ctgov-combo-e80b2f20c9903eca","description":null,"metadata":null},{"id":"c63185959a09401cb645653dbdae8353","type":"COMBINATION_TREATMENT","name":"desloratadine + fexofenadine","canonical_id":"ctgov_combo:ctgov-combo-1c2b47990b3401b4","description":null,"metadata":null},{"id":"f5db0790244344ba9df07641795ba047","type":"COMBINATION_TREATMENT","name":"desloratadine + fexofenadine","canonical_id":"ctgov_combo:ctgov-combo-9f2d2354f0aa806d","description":null,"metadata":null},{"id":"41967787756e4280b6c934c223214d72","type":"COMBINATION_TREATMENT","name":"desloratadine + ketotifen","canonical_id":"ctgov_combo:ctgov-combo-c8b0cbddf1971622","description":null,"metadata":null},{"id":"5974a4755a304fd5970e69cd2a358179","type":"COMBINATION_TREATMENT","name":"desloratadine + mometasone","canonical_id":"ctgov_combo:ctgov-combo-4511ef3c57f733e7","description":null,"metadata":null},{"id":"ea846cdbcbdb4bc5bdada1b4b23413c1","type":"GO_TERM","name":"desmosome","canonical_id":"go:GO:0030057","description":"\"A cell-cell junction in which: on the cytoplasmic surface of each interacting plasma membrane is a dense plaque composed of a mixture of intracellular anchor proteins; a bundle of keratin intermediate filaments is attached to the surface of each plaque; transmembrane adhesion proteins of the cadherin family bind to the plaques and interact through their extracellular domains to hold the adjacent membranes together by a Ca2+-dependent mechanism.\" [GOC:mah, GOC:mtg_muscle, ISBN:0815332181]","metadata":null},{"id":"7aee661b098143b5a29abde00da10dbf","type":"GO_TERM","name":"desmosome assembly","canonical_id":"go:GO:0002159","description":"\"A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a desmosome. A desmosome is a patch-like intercellular junction found in vertebrate tissues, consisting of parallel zones of two cell membranes, separated by an space of 25-35 nm, and having dense fibrillar plaques in the subjacent cytoplasm.\" [GOC:hjd, ISBN:0198506732]","metadata":null},{"id":"8f6b7533e9f143a78910265f7be5542b","type":"GO_TERM","name":"desmosome disassembly","canonical_id":"go:GO:0035921","description":"\"The controlled breakdown of a desmosome. A desmosome is a patch-like intercellular junction found in vertebrate tissues, consisting of parallel zones of two cell membranes, separated by an space of 25-35 nm, and having dense fibrillar plaques in the subjacent cytoplasm.\" [GOC:BHF, GOC:vk, ISBN:0198506732, PMID:9182671]","metadata":null},{"id":"d4a853fd25034ee29450cf0f42c33c10","type":"GO_TERM","name":"desmosome maintenance","canonical_id":"go:GO:0002160","description":"\"The maintenance of a desmosome. A desmosome is a patch-like intercellular junctions found in vertebrate tissues, consisting of parallel zones of two cell membranes, separated by an interspace of 25-35 nm, and having dense fibrillar plaques in the subjacent cytoplasm.\" [GOC:hjd, ISBN:0198506732]","metadata":null},{"id":"f7fcd37e7ba0419abfbff908d31995f3","type":"GO_TERM","name":"desmosome organization","canonical_id":"go:GO:0002934","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a desmosome. A desmosome is a patch-like intercellular junction found in vertebrate tissues, consisting of parallel zones of two cell membranes, separated by an space of 25-35 nm, and having dense fibrillar plaques in the subjacent cytoplasm.\" [GOC:hjd]","metadata":null},{"id":"5a1ac1fdb67d4d13a672ed1f6a336b92","type":"DRUG","name":"desonide","canonical_id":"mesh:D003898","description":null,"metadata":null},{"id":"368bdb1d6b784eca8259328d564f6b78","type":"DRUG","name":"desoximetasone","canonical_id":"gtopdb:7067","description":null,"metadata":null},{"id":"cd8dc7b8e2294825bb4674032a390efa","type":"DRUG","name":"desoximetasone","canonical_id":"chembl:CHEMBL1766","description":null,"metadata":null},{"id":"feb66f35cc564af1b9abd906a5e81050","type":"DRUG","name":"desvenlafaxine","canonical_id":"gtopdb:7158","description":null,"metadata":null},{"id":"155ec823405c4d2f89dd3c71a88ec7fb","type":"DRUG","name":"desvenlafaxine","canonical_id":"mesh:D000069468","description":null,"metadata":null},{"id":"6d832db02b5044b9b5e86736f3be9a16","type":"DRUG","name":"desvenlafaxine","canonical_id":"chembl:CHEMBL1118","description":null,"metadata":null},{"id":"6f9f6876b4fd4fac84e8fd11d2c3699e","type":"COMBINATION_TREATMENT","name":"desvenlafaxine + fezolinetant","canonical_id":"ctgov_combo:ctgov-combo-158090d56f00f3be","description":null,"metadata":null},{"id":"01f903ececb44d92a3e14adc51074a85","type":"COMBINATION_TREATMENT","name":"desvenlafaxine + fluvoxamine","canonical_id":"ctgov_combo:ctgov-combo-f62f3e79754db036","description":null,"metadata":null},{"id":"d24099ae197849f292fc4fddc474463e","type":"COMBINATION_TREATMENT","name":"desvenlafaxine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-9800b65ba2d50d46","description":null,"metadata":null},{"id":"fd7170c904844af39543b43288f85c97","type":"GO_TERM","name":"detection of UV","canonical_id":"go:GO:0009589","description":"\"The series of events in which an ultraviolet radiation (UV light) stimulus is received and converted into a molecular signal. Ultraviolet radiation is electromagnetic radiation with a wavelength in the range of 10 to 380 nanometers.\" [GOC:curators, GOC:dos, GOC:hb, ISBN:0198506732]","metadata":null},{"id":"9399d87085954d7090a6e38a72413715","type":"GO_TERM","name":"detection of abiotic stimulus","canonical_id":"go:GO:0009582","description":"\"The series of events in which an (non-living) abiotic stimulus is received by a cell and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"54627e3c59064041a35f254528a8cf34","type":"GO_TERM","name":"detection of abscisic acid stimulus","canonical_id":"go:GO:0009724","description":"\"The series of events in which an abscisic acid stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"a6abfa48ab294f0ea67cf8af49f4c958","type":"GO_TERM","name":"detection of activity","canonical_id":"go:GO:0014865","description":"\"The series of events in which an activity stimulus is received by a cell and converted into a molecular signal.\" [GOC:mtg_muscle]","metadata":null},{"id":"e0fefa3c7a574eea9fb0dd83f85c5d86","type":"GO_TERM","name":"detection of auxin stimulus","canonical_id":"go:GO:0009721","description":"\"The series of events in which an auxin stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"abca1f2acb8a47d98950c64af7b7b1cd","type":"GO_TERM","name":"detection of bacterial lipopeptide","canonical_id":"go:GO:0070340","description":"\"The series of events in which a bacterial lipopeptide stimulus is received by a cell and converted into a molecular signal.\" [GOC:add, PMID:12077222]","metadata":null},{"id":"5caa1ecc165f4ce983b91f592aa4f722","type":"GO_TERM","name":"detection of bacterial lipoprotein","canonical_id":"go:GO:0042494","description":"\"The series of events in which a bacterial lipoprotein stimulus is received by a cell and converted into a molecular signal. Bacterial lipoproteins are lipoproteins characterized by the presence of conserved sequence motifs called pathogen-associated molecular patterns (PAMPs).\" [GOC:jl, PMID:12077222]","metadata":null},{"id":"a29c256aeb0544f6a010a06d0b7c446e","type":"GO_TERM","name":"detection of bacterium","canonical_id":"go:GO:0016045","description":"\"The series of events in which a stimulus from a bacterium is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"a9aaa1d97e3e4c4aa14774ab52eaeabb","type":"GO_TERM","name":"detection of biotic stimulus","canonical_id":"go:GO:0009595","description":"\"The series of events in which a biotic stimulus, one caused or produced by a living organism, is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"081acefa720d4e6b8a73b859938e7457","type":"GO_TERM","name":"detection of brassinosteroid stimulus","canonical_id":"go:GO:0009729","description":"\"The series of events in which a brassinosteroid stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"e6d039334aa74a88ae4a247f4f0c7ca3","type":"GO_TERM","name":"detection of cAMP","canonical_id":"go:GO:0031319","description":"\"The series of events in which a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus is received by a cell and converted into a molecular signal; cAMP is the nucleotide cyclic AMP.\" [GOC:pg]","metadata":null},{"id":"4849ccff871b4690a06860da5ba53d16","type":"GO_TERM","name":"detection of calcium ion","canonical_id":"go:GO:0005513","description":"\"The series of events in which a calcium ion stimulus is received by a cell and converted into a molecular signal.\" [GOC:pg]","metadata":null},{"id":"5e39e1d30f3041d7bf650097679c33fe","type":"GO_TERM","name":"detection of carbohydrate stimulus","canonical_id":"go:GO:0009730","description":"\"The series of events in which a carbohydrate stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"7a8b4b44458f4c63bad10ba041e80049","type":"GO_TERM","name":"detection of carbon dioxide","canonical_id":"go:GO:0003031","description":"\"The series of events in which a carbon dioxide stimulus is received by a cell and converted into a molecular signal.\" [GOC:mtg_cardio]","metadata":null},{"id":"dac5d076fc6040999812345dc4e4912f","type":"GO_TERM","name":"detection of carbon dioxide by vasomotor center","canonical_id":"go:GO:0002013","description":"\"The process by a carbon dioxide stimulus is received and converted to a molecular signal by the vasomotor center of the central nervous system.\" [ISBN:0721643949]","metadata":null},{"id":"d3febeee753641fdb8057ab37a69a196","type":"GO_TERM","name":"detection of cell density","canonical_id":"go:GO:0060245","description":"\"The series of events in which information about the density of cells in a population is received and converted into a molecular signal.\" [GOC:dph]","metadata":null},{"id":"c5d641a11f0c4f3b8eb93b1eb31182c5","type":"GO_TERM","name":"detection of chemical stimulus","canonical_id":"go:GO:0009593","description":"\"The series of events in which a chemical stimulus is received by a cell and converted into a molecular signal.\" [GOC:jl]","metadata":null},{"id":"a493d72d24fb4fb69f29713f3e4d5651","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception","canonical_id":"go:GO:0050907","description":"\"The series of events in which a chemical stimulus is received and converted into a molecular signal as part of sensory perception.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"bc3472a6833f433db6a19bfb2adcda25","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception of bitter taste","canonical_id":"go:GO:0001580","description":"\"The series of events required for a bitter taste stimulus to be received and converted to a molecular signal.\" [GOC:curators]","metadata":null},{"id":"d197d77dfa564a91ba6bc35d296f2036","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception of pain","canonical_id":"go:GO:0050968","description":"\"The series of events involved in the perception of pain in which a chemical stimulus is received and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"2ffe8f32c07c424ba5471ad300e8a66e","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception of smell","canonical_id":"go:GO:0050911","description":"\"The series of events involved in the perception of smell in which an olfactory chemical stimulus is received and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"f6c4a0111371410d871c4c233dba2ca5","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception of sour taste","canonical_id":"go:GO:0001581","description":"\"The series of events required for a sour taste stimulus to be received and converted to a molecular signal.\" [GOC:curators]","metadata":null},{"id":"cdaf2b9b223e438d9e4cd6c1c4d0b24f","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception of sweet taste","canonical_id":"go:GO:0001582","description":"\"The series of events required for a sweet taste stimulus to be received and converted to a molecular signal.\" [GOC:curators]","metadata":null},{"id":"682f8d09d74d4f398022867a9bffebfb","type":"GO_TERM","name":"detection of chemical stimulus involved in sensory perception of taste","canonical_id":"go:GO:0050912","description":"\"The series of events involved in the perception of taste in which a gustatory chemical stimulus is received and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"e0b9c05ec3cd46e4b83b6216bf1bdf4c","type":"GO_TERM","name":"detection of cold stimulus involved in thermoception","canonical_id":"go:GO:0120169","description":"\"The series of events in which a cold stimulus is received and converted into a molecular signal as part of thermoception.\" [PMID:21335241]","metadata":null},{"id":"2c440d8b3e23439583fc7102ded49ea6","type":"GO_TERM","name":"detection of cytokinin stimulus","canonical_id":"go:GO:0009722","description":"\"The series of events in which a cytokinin stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"684646d05d824efda0b1ddf8084fe4c4","type":"GO_TERM","name":"detection of diacyl bacterial lipopeptide","canonical_id":"go:GO:0042496","description":"\"The series of events in which a diacylated bacterial lipopeptide stimulus is received by a cell and converted into a molecular signal. Diacylated bacterial lipoproteins are lipopeptides of bacterial origin containing a nonprotein moiety consisting of two acyl groups.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"4853ec8df89043a789050f25cbf12ff3","type":"GO_TERM","name":"detection of dietary excess","canonical_id":"go:GO:0002022","description":"\"The neurological process in which the brain senses excessive caloric intake.\" [PMID:12161655]","metadata":null},{"id":"b91d61d071e74a3a8bcc1736649e16da","type":"GO_TERM","name":"detection of disaccharide stimulus","canonical_id":"go:GO:0034288","description":"\"The series of events in which a stimulus from a disaccharide is received and converted into a molecular signal.\" [GOC:sart]","metadata":null},{"id":"3747115b7f8d4506b0b2f46993168343","type":"GO_TERM","name":"detection of electrical stimulus","canonical_id":"go:GO:0050981","description":"\"The series of events by which an electrical stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"accec02a30374194adc106595e01ffef","type":"GO_TERM","name":"detection of endoplasmic reticulum overloading","canonical_id":"go:GO:0002234","description":"\"The series of events in which a stimulus generated by the accumulation of normal or misfolded proteins in the endoplasmic reticulum is received and converted into a molecular signal.\" [GOC:add, PMID:10390516]","metadata":null},{"id":"f8376fc57f20471ca256b684e683f7dc","type":"GO_TERM","name":"detection of ethylene stimulus","canonical_id":"go:GO:0009727","description":"\"The series of events in which an ethylene (ethene) stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"b1f327a9926e4768b53df94157c3d57f","type":"GO_TERM","name":"detection of external biotic stimulus","canonical_id":"go:GO:0098581","description":"\"The series of events in which an external biotic stimulus is detected and converted into a molecular signal. An external biotic stimulus is defined as one caused or produced by a living organism other than the one being stimulated.\" [GOC:dos]","metadata":null},{"id":"a046cf0fcf1c49828694a07569c464f7","type":"GO_TERM","name":"detection of external stimulus","canonical_id":"go:GO:0009581","description":"\"The series of events in which an external stimulus is received by a cell and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"28e4d02f5b3a4b22b76c3a11c9de23d8","type":"GO_TERM","name":"detection of folic acid","canonical_id":"go:GO:0031318","description":"\"The series of events in which a folic acid stimulus is received by a cell and converted into a molecular signal.\" [GOC:pg]","metadata":null},{"id":"fec4c2f773f146aa9e4df48212d20b2f","type":"GO_TERM","name":"detection of fungus","canonical_id":"go:GO:0016046","description":"\"The series of events in which a stimulus from a fungus is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"d7bb88b2f2ce442ca110417b37d51872","type":"GO_TERM","name":"detection of gibberellic acid stimulus","canonical_id":"go:GO:0009728","description":"\"The series of events in which a gibberellic acid stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"36ea5082302942f08fd61f7e95a4411b","type":"GO_TERM","name":"detection of glucocorticoid hormone stimulus","canonical_id":"go:GO:0051468","description":"\"The series of events by which a glucocorticoid hormone stimulus is received by a cell and converted into a molecular signal. Glucocorticoids are hormonal C21 corticosteroids synthesized from cholesterol with the ability to bind with the cortisol receptor and trigger similar effects. Glucocorticoids act primarily on carbohydrate and protein metabolism, and have anti-inflammatory effects.\" [GOC:ai]","metadata":null},{"id":"249e2033d2c440d8ac1f6d96073c34e6","type":"GO_TERM","name":"detection of glucose","canonical_id":"go:GO:0051594","description":"\"The series of events in which a glucose stimulus is received by a cell and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"f3076c71185141428b0beffee158552d","type":"GO_TERM","name":"detection of gravity","canonical_id":"go:GO:0009590","description":"\"The series of events in which a gravitational stimulus is received and converted into a molecular signal.\" [GOC:dos, GOC:hb]","metadata":null},{"id":"9adeee54844f418787b2eeef3589f119","type":"GO_TERM","name":"detection of hexose stimulus","canonical_id":"go:GO:0009732","description":"\"The series of events in which a stimulus from a hexose is received and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"17ca065fc4b647468b6f37721c155f1d","type":"GO_TERM","name":"detection of high humidity","canonical_id":"go:GO:0098516","description":"\"The series of events in which high humidity is detected and converted into a molecular signal.\" [GOC:dos]","metadata":null},{"id":"5905ac03301e43f2841f0f645bd7aaf2","type":"GO_TERM","name":"detection of hormone stimulus","canonical_id":"go:GO:0009720","description":"\"The series of events in which a hormone stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"647e181c9e5e487bb18487a21f17cf46","type":"GO_TERM","name":"detection of hot stimulus involved in thermoception","canonical_id":"go:GO:0120168","description":"\"The series of events in which a hot stimulus is received and converted into a molecular signal as part of thermoception.\" [PMID:21335241]","metadata":null},{"id":"2c26b4f07bc64213a33e1566cd9250a9","type":"GO_TERM","name":"detection of humidity","canonical_id":"go:GO:0098513","description":"\"The series of events in which a humidity stimulus is received and converted into a molecular signal.\" [GOC:dos]","metadata":null},{"id":"f025de468f7440de8ab0f40ee97fe58c","type":"GO_TERM","name":"detection of humidity stimulus involved in sensory perception","canonical_id":"go:GO:0098512","description":"\"The series of events in which a humidity stimulus is received and converted into a molecular signal as part of the sensory perception of humidity.\" [GOC:dos, PMID:8650222]","metadata":null},{"id":"2ced8000d08d4832a3fa671fe150fddb","type":"GO_TERM","name":"detection of hydrogen ion","canonical_id":"go:GO:0003030","description":"\"The series of events in which a hydrogen ion stimulus is received by a cell and converted into a molecular signal.\" [GOC:mtg_cardio]","metadata":null},{"id":"ca8aa9774da44530b48d427442edb5e1","type":"GO_TERM","name":"detection of hypoxia","canonical_id":"go:GO:0070483","description":"\"The series of events in which a stimulus indicating lowered oxygen tension is received by a cell and converted into a molecular signal. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"4c8c978e0e344d91bb067a36b8e461be","type":"GO_TERM","name":"detection of hypoxic conditions in blood by aortic body chemoreceptor signaling","canonical_id":"go:GO:0003033","description":"\"The process in which information about a lack of oxygen are received and are converted to a molecular signal by chemoreceptors in the aortic bodies.\" [GOC:mtg_cardio]","metadata":null},{"id":"8364d36baa904be5bf9e1c5613b4db6d","type":"GO_TERM","name":"detection of hypoxic conditions in blood by carotid body chemoreceptor signaling","canonical_id":"go:GO:0003029","description":"\"The process in which information about a lack of oxygen are received and are converted to a molecular signal by chemoreceptors in the carotid bodies.\" [GOC:mtg_cardio]","metadata":null},{"id":"676f3874ceef4eaca9f4090ef14774ae","type":"GO_TERM","name":"detection of hypoxic conditions in blood by chemoreceptor signaling","canonical_id":"go:GO:0002007","description":"\"The process in which information about a lack of oxygen are received and are converted to a molecular signal by chemoreceptors in the carotid bodies and the aortic bodies.\" [GOC:dph]","metadata":null},{"id":"580f51577d5844d99135cead51e7e810","type":"GO_TERM","name":"detection of inactivity","canonical_id":"go:GO:0014863","description":"\"The series of events in which a inactivity stimulus is received by a cell or organism and converted into a molecular signal.\" [GOC:mtg_muscle]","metadata":null},{"id":"1bf083f271aa438f8be6ec05a5134d8e","type":"GO_TERM","name":"detection of increased carbon dioxide by aortic body chemoreceptor signaling","canonical_id":"go:GO:0003034","description":"\"The process in which information about the levels of carbon dioxide are received and are converted to a molecular signal by chemoreceptors in an aortic body.\" [GOC:mtg_cardio]","metadata":null},{"id":"7683f137823340b8bee7f4d12c6e5548","type":"GO_TERM","name":"detection of increased carbon dioxide by carotid body chemoreceptor signaling","canonical_id":"go:GO:0003035","description":"\"The process in which information about the levels of carbon dioxide are received and are converted to a molecular signal by chemoreceptors in a carotid body.\" [GOC:mtg_cardio]","metadata":null},{"id":"9a2177a3dc084d99ba5c5a48ab754047","type":"GO_TERM","name":"detection of increased carbon dioxide by chemoreceptor signaling","canonical_id":"go:GO:0003021","description":"\"The process in which information about the levels of carbon dioxide are received and are converted to a molecular signal by chemoreceptors in the carotid bodies and the aortic bodies.\" [GOC:mtg_cardio, ISBN:0323031951]","metadata":null},{"id":"68985d6b8e4245aaa26b7e71cd419d43","type":"GO_TERM","name":"detection of insect","canonical_id":"go:GO:0009601","description":"\"The series of events in which a stimulus from an insect is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"aa915c9525734dfbafa05c0ed97d1c50","type":"GO_TERM","name":"detection of jasmonic acid stimulus","canonical_id":"go:GO:0009754","description":"\"The series of events in which a jasmonic acid stimulus is received by a cell and converted into a molecular signal. Series of events required for a jasmonic acid stimulus to be detected and converted to a signal molecule.\" [GOC:sm]","metadata":null},{"id":"e6db85eaa540457eb68592937170260e","type":"GO_TERM","name":"detection of light stimulus","canonical_id":"go:GO:0009583","description":"\"The series of events in which a light stimulus (in the form of photons) is received and converted into a molecular signal.\" [GOC:curators]","metadata":null},{"id":"89f2f60018734650a9f919d3ca927a30","type":"GO_TERM","name":"detection of light stimulus involved in magnetoreception","canonical_id":"go:GO:0050980","description":"\"The series of events involved in magnetoception in which a light stimulus is received and converted into a molecular signal. Downstream processing of the light information in addition to other sensory data allows organisms to perceive the orientation of a magnetic field.\" [GOC:ai, GOC:dos, PMID:15886990, Wikipedia:Magnetoception]","metadata":null},{"id":"104cdfd797954bc5aeeab4c26bc66686","type":"GO_TERM","name":"detection of light stimulus involved in sensory perception","canonical_id":"go:GO:0050962","description":"\"The series of events in which a light stimulus is received by a cell and converted into a molecular signal as part of the sensory perception of light.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"55a87eaab41345dbb6c8b5b982631646","type":"GO_TERM","name":"detection of light stimulus involved in visual perception","canonical_id":"go:GO:0050908","description":"\"The series of events involved in visual perception in which a light stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"2efb21e066b1449eb4ffea0c42bd7618","type":"GO_TERM","name":"detection of lipopolysaccharide","canonical_id":"go:GO:0032497","description":"\"The series of events in which a lipopolysaccharide stimulus is received by a cell and converted into a molecular signal. Lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.\" [GOC:add, PMID:15998797]","metadata":null},{"id":"9350785da47f47c389a0e679f13031cf","type":"GO_TERM","name":"detection of lipoteichoic acid","canonical_id":"go:GO:0070392","description":"\"The series of events in which a lipoteichoic acid stimulus is received by a cell and converted into a molecular signal; lipoteichoic acid is a major component of the cell wall of gram-positive bacteria and typically consists of a chain of glycerol-phosphate repeating units linked to a glycolipid anchor.\" [GOC:add, PMID:14665680, PMID:16020688]","metadata":null},{"id":"497f78b109dd47ba8da95d3456eb683c","type":"GO_TERM","name":"detection of low humidity","canonical_id":"go:GO:0098517","description":"\"The series of events in which low humidity is detected and converted into a molecular signal.\" [GOC:dos]","metadata":null},{"id":"2e7e386ffe62459ab09f76ba0c8ad13b","type":"GO_TERM","name":"detection of maltose stimulus","canonical_id":"go:GO:0034289","description":"\"The series of events in which a maltose stimulus is received by a cell and converted into a molecular signal.\" [GOC:sart]","metadata":null},{"id":"189b407fb70942f2a187e268332778de","type":"GO_TERM","name":"detection of mechanical stimulus","canonical_id":"go:GO:0050982","description":"\"The series of events by which a mechanical stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"e074f5cf3b4a4f9dabc742166f7ecf1b","type":"GO_TERM","name":"detection of mechanical stimulus involved in equilibrioception","canonical_id":"go:GO:0050973","description":"\"The series of events involved in equilibrioception in which a mechanical stimulus is received and converted into a molecular signal. During equilibrioception, mechanical stimuli may be in the form of input from pressure receptors or from the labyrinth system of the inner ears.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"6af0ecd46fff4d83a54d7f0074ad73f6","type":"GO_TERM","name":"detection of mechanical stimulus involved in sensory perception","canonical_id":"go:GO:0050974","description":"\"The series of events in which a mechanical stimulus is received and converted into a molecular signal as part of sensory perception.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"a1d7be83b9f64f06a66af8bb183a7336","type":"GO_TERM","name":"detection of mechanical stimulus involved in sensory perception of pain","canonical_id":"go:GO:0050966","description":"\"The series of events involved in the perception of pain in which a mechanical stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"3aecd18f07a540299e5960d7468feab9","type":"GO_TERM","name":"detection of mechanical stimulus involved in sensory perception of sound","canonical_id":"go:GO:0050910","description":"\"The series of events involved in the perception of sound vibration in which the vibration is received and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"2a35d00686e14a46ac6287ccfb337b96","type":"GO_TERM","name":"detection of mechanical stimulus involved in sensory perception of touch","canonical_id":"go:GO:0050976","description":"\"The series of events involved in the perception of touch in which a mechanical stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"e09412d4098c40e99228438073bee00f","type":"GO_TERM","name":"detection of misfolded protein","canonical_id":"go:GO:0002236","description":"\"The series of events in which a misfolded protein stimulus is received and converted into a molecular signal.\" [GOC:add, PMID:15226511]","metadata":null},{"id":"9e027cb4b1964e7e9adff21a96542d6b","type":"GO_TERM","name":"detection of molecule of bacterial origin","canonical_id":"go:GO:0032490","description":"\"The series of events in which a stimulus from a molecule of bacterial origin is received and converted into a molecular signal.\" [GOC:add, GOC:rl]","metadata":null},{"id":"6a20283d013c4dd7833f87b73308656b","type":"GO_TERM","name":"detection of molecule of fungal origin","canonical_id":"go:GO:0032491","description":"\"The series of events in which a stimulus from a molecule of fungal origin is received and converted into a molecular signal.\" [GOC:mah, GOC:rl]","metadata":null},{"id":"2786ac97e472489fb165f2145cdcf5dd","type":"GO_TERM","name":"detection of molecule of oomycetes origin","canonical_id":"go:GO:0032492","description":"\"The series of events in which a stimulus from a molecule of oomycetes origin is received and converted into a molecular signal.\" [GOC:mah, GOC:rl]","metadata":null},{"id":"cc6a12090c804378a46315e140765327","type":"GO_TERM","name":"detection of monosaccharide stimulus","canonical_id":"go:GO:0034287","description":"\"The series of events in which a stimulus from a monosaccharide is received and converted into a molecular signal.\" [GOC:mah]","metadata":null},{"id":"9c2b2e61f81c4545aea5e3794ba545cf","type":"GO_TERM","name":"detection of muramyl dipeptide","canonical_id":"go:GO:0032498","description":"\"The series of events in which a muramyl dipeptide stimulus is received by a cell and converted into a molecular signal. Muramyl dipeptide is derived from peptidoglycan.\" [GOC:rl, PMID:15998797]","metadata":null},{"id":"650b42856eb944988205f4b1bd118513","type":"GO_TERM","name":"detection of muscle activity","canonical_id":"go:GO:0014864","description":"\"The series of events in which a muscle activity stimulus is received by a cell and converted into a molecular signal.\" [GOC:mtg_muscle]","metadata":null},{"id":"eaf6e53bb8fd46c781a22f24bec2f6eb","type":"GO_TERM","name":"detection of muscle inactivity","canonical_id":"go:GO:0014869","description":"\"The series of events in which a muscle inactivity stimulus is received by a cell and converted into a molecular signal.\" [GOC:mtg_muscle]","metadata":null},{"id":"f2b3d98834ad4d1699f828aa2df3e995","type":"GO_TERM","name":"detection of muscle stretch","canonical_id":"go:GO:0035995","description":"\"The series of events by which a muscle stretch stimulus is received by a cell and converted into a molecular signal.\" [PMID:14583192]","metadata":null},{"id":"78c215a31e704ef08ba2db7beca4570d","type":"GO_TERM","name":"detection of nematode","canonical_id":"go:GO:0009600","description":"\"The series of events in which a stimulus from a nematode is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"d337d8606e14497c8aa23414b3d6f3de","type":"GO_TERM","name":"detection of nodal flow","canonical_id":"go:GO:0003127","description":"\"The series of events by which an endogenous stimulus is received by a cilium on a cell and converted to a molecular signal contributing to left/right asymmetry.\" [GOC:mtg_heart]","metadata":null},{"id":"25a1b72da1674e01bb8441673d4b1a98","type":"GO_TERM","name":"detection of nuclear:cytoplasmic ratio","canonical_id":"go:GO:0016475","description":"\"The process in which the size of the nucleus with respect to its cytoplasm is sensed by a cell.\" [GOC:jl]","metadata":null},{"id":"87002cf07bad4a38903f791cdb95b140","type":"GO_TERM","name":"detection of nutrient","canonical_id":"go:GO:0009594","description":"\"The series of events in which a nutrient stimulus is received by a cell and converted into a molecular signal.\" [GOC:jl]","metadata":null},{"id":"eef6622250534ab3ae039ae616463c19","type":"GO_TERM","name":"detection of oomycetes","canonical_id":"go:GO:0002231","description":"\"The series of events in which a stimulus from an oomycetes is received and converted into a molecular signal.\" [GOC:add, PMID:15922649]","metadata":null},{"id":"b9b723924d7543e8a11ed0c571732ba8","type":"GO_TERM","name":"detection of osmotic stimulus","canonical_id":"go:GO:0043575","description":"\"The series of events in which a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell is received and converted into a molecular signal.\" [GOC:jl]","metadata":null},{"id":"ca16e6cf70bc4eb089e63655efc84da8","type":"GO_TERM","name":"detection of other organism","canonical_id":"go:GO:0098543","description":"\"The series of events in which a stimulus from another organism is received and converted into a molecular signal.\" [GOC:dos]","metadata":null},{"id":"f9c90310d4f747c6978bdfde332de4d0","type":"GO_TERM","name":"detection of oxidative stress","canonical_id":"go:GO:0070994","description":"\"The series of events in which a stimulus indicating oxidative stress is received and converted into a molecular signal.\" [GOC:mah]","metadata":null},{"id":"0b344c248783471db147d2e1cf3ab10e","type":"GO_TERM","name":"detection of oxygen","canonical_id":"go:GO:0003032","description":"\"The series of events in which an oxygen stimulus is received by a cell and converted into a molecular signal.\" [GOC:mtg_cardio]","metadata":null},{"id":"adf32aa458ad46b7b1d2d0377a391876","type":"GO_TERM","name":"detection of pH by aortic body chemoreceptor signaling","canonical_id":"go:GO:0003036","description":"\"The process in which information about the levels of hydrogen ions are received and are converted to a molecular signal by chemoreceptors in an aortic body.\" [GOC:mtg_cardio]","metadata":null},{"id":"e7587b62572d4c34898ca3fbaf94faa9","type":"GO_TERM","name":"detection of pH by carotid body chemoreceptor signaling","canonical_id":"go:GO:0003037","description":"\"The process in which information about the levels of hydrogen ions are received and are converted to a molecular signal by chemoreceptors in a carotid body.\" [GOC:mtg_cardio]","metadata":null},{"id":"8ce2fde6de6947ac8ea757ecdc4585e0","type":"GO_TERM","name":"detection of pH by chemoreceptor signaling","canonical_id":"go:GO:0003022","description":"\"The process in which information about the levels of hydrogen ions are received and are converted to a molecular signal by chemoreceptors.\" [GOC:mtg_cardio, ISBN:0323031951]","metadata":null},{"id":"c6f82993bbda4a9f91f2e8d66eaedabf","type":"GO_TERM","name":"detection of parasitic plant","canonical_id":"go:GO:0002243","description":"\"The series of events in which a stimulus from a parasitic plant is received and converted into a molecular signal.\" [GOC:add, PMID:16547862]","metadata":null},{"id":"b6f7a169aa50416e84860f5d0343c914","type":"GO_TERM","name":"detection of peptidoglycan","canonical_id":"go:GO:0032499","description":"\"The series of events in which a peptidoglycan stimulus is received by a cell and converted into a molecular signal. Peptidoglycan is a bacterial cell wall macromolecule.\" [GOC:add, ISBN:0721601464]","metadata":null},{"id":"d349f9b7e095498385443938a1f63ac3","type":"GO_TERM","name":"detection of pheromone","canonical_id":"go:GO:0043695","description":"\"The series of events in which a pheromone stimulus is received by a cell and converted into a molecular signal.\" [GOC:mah]","metadata":null},{"id":"3b2947b9f4f94183aaf9057ffc9c798f","type":"GO_TERM","name":"detection of phosphate ion","canonical_id":"go:GO:0010247","description":"\"The series of events in which a phosphate ion stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"2c7a29a9a7584815864ff42a8cc3455e","type":"GO_TERM","name":"detection of protozoan","canonical_id":"go:GO:0001563","description":"\"The series of events in which a stimulus from a protozoan is received and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"54c9eb94d33c4d95b94e26ca4d2e8975","type":"GO_TERM","name":"detection of redox state","canonical_id":"go:GO:0051776","description":"\"The series of events in which a chemical stimulus indicating redox state is received and converted into a molecular signal. Redox state refers to the balance of oxidized versus reduced forms of electron donors and acceptors in an organelle, cell or organ; plastoquinone, glutathione (GSH/GSSG), and nicotinamide nucleotides (NAD+/NADH and NADP+/NADPH) are among the most important.\" [GOC:mah, PMID:15131240, PMID:16987039]","metadata":null},{"id":"16cfbdbe3b4b48dbbae386b27b11b30d","type":"GO_TERM","name":"detection of reduced oxygen by aortic body chemoreceptor signaling","canonical_id":"go:GO:0003038","description":"\"The process in which information about the levels of oxygen are received and are converted to a molecular signal by chemoreceptors in an aortic body.\" [GOC:mtg_cardio]","metadata":null},{"id":"f347ae2d79504279ae879cd3887498b1","type":"GO_TERM","name":"detection of reduced oxygen by carotid body chemoreceptor signaling","canonical_id":"go:GO:0003039","description":"\"The process in which information about the levels of oxygen are received and are converted to a molecular signal by chemoreceptors in a carotid body.\" [GOC:mtg_cardio]","metadata":null},{"id":"c95242b940ee4292a135e93f3b4470f5","type":"GO_TERM","name":"detection of reduced oxygen by chemoreceptor signaling","canonical_id":"go:GO:0003020","description":"\"The process in which information about the levels of oxygen are received and are converted to a molecular signal by chemoreceptors in the carotid bodies and the aortic bodies.\" [GOC:mtg_cardio, ISBN:0323031951]","metadata":null},{"id":"b4f5149223fa454fa6cca0c3b89a43ad","type":"GO_TERM","name":"detection of renal blood flow","canonical_id":"go:GO:0002000","description":"\"The process in which the juxtaglomerular cells of the kidneys receive information about the amount of blood flowing through the arterioles and converts the information to a molecular signal.\" [ISBN:0721643949]","metadata":null},{"id":"e50eda2f6b0142a8bb30f37bc33da991","type":"GO_TERM","name":"detection of salicylic acid stimulus","canonical_id":"go:GO:0009752","description":"\"The series of events in which a salicylic acid stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"60d717a365d545879381821e19ee9c90","type":"GO_TERM","name":"detection of steroid hormone stimulus","canonical_id":"go:GO:0051467","description":"\"The series of events by which a steroid hormone stimulus is received by a cell and converted into a molecular signal.\" [GOC:ai]","metadata":null},{"id":"637b72c94828419dbf79e48f68163d64","type":"GO_TERM","name":"detection of stimulus","canonical_id":"go:GO:0051606","description":"\"The series of events in which a stimulus is received by a cell or organism and converted into a molecular signal.\" [GOC:add, GOC:ai, GOC:dph, GOC:mah]","metadata":null},{"id":"0c7a5e8de49e4e4388bd4d64b6fb2be4","type":"GO_TERM","name":"detection of stimulus involved in sensory perception","canonical_id":"go:GO:0050906","description":"\"The series of events involved in sensory perception in which a sensory stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos, GOC:dph]","metadata":null},{"id":"524d3dcb5ac34d44b926cfcb2f7d6b02","type":"GO_TERM","name":"detection of sucrose stimulus","canonical_id":"go:GO:0009731","description":"\"The series of events in which a sucrose stimulus is received by a cell and converted into a molecular signal.\" [GOC:sm]","metadata":null},{"id":"2dae59084207470eac1d49a83faefca7","type":"GO_TERM","name":"detection of symbiont","canonical_id":"go:GO:0009602","description":"\"The series of events in which a stimulus from a symbiont (an organism living in close physical association with an organism of a different species) is received and converted into a molecular signal. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"05bbd2e2c9f5452b9a1ebcc29d838bd4","type":"GO_TERM","name":"detection of symbiotic bacterium","canonical_id":"go:GO:0009604","description":"\"The series of events in which a stimulus from a symbiotic bacterium, a bacterium living in close physical association with another organism, is received and converted into a molecular signal.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"3f1c17165190417aaee41cc0e238461c","type":"GO_TERM","name":"detection of symbiotic fungus","canonical_id":"go:GO:0009603","description":"\"The series of events in which a stimulus from a symbiotic fungus, a fungus living in close physical association with another organism, is received and converted into a molecular signal.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"461d5537ee2e46359d458c7fc07d2870","type":"GO_TERM","name":"detection of temperature stimulus","canonical_id":"go:GO:0016048","description":"\"The series of events in which a temperature stimulus (hot or cold) is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"6fb46f4fa66940f6b464872cd3e3be8b","type":"GO_TERM","name":"detection of temperature stimulus involved in sensory perception","canonical_id":"go:GO:0050961","description":"\"The series of events in which a temperature stimulus is received and converted into a molecular signal as part of sensory perception.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"05b4c76ce21c44d88a81d8361902ae9c","type":"GO_TERM","name":"detection of temperature stimulus involved in sensory perception of pain","canonical_id":"go:GO:0050965","description":"\"The series of events involved in the perception of pain in which a temperature stimulus is received and converted into a molecular signal.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"0034ef0ca6a0417fb96d69fe9a2a7a3f","type":"GO_TERM","name":"detection of temperature stimulus involved in thermoception","canonical_id":"go:GO:0050960","description":"\"The series of events in which a temperature stimulus is received and converted into a molecular signal as part of thermoception.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"2386fe4ff14f4e60836af7eae88f60c4","type":"GO_TERM","name":"detection of triacyl bacterial lipopeptide","canonical_id":"go:GO:0042495","description":"\"The series of events in which a triacylated bacterial lipoprotein stimulus is received by a cell and converted into a molecular signal. Triacylated bacterial lipoproteins are lipopeptides of bacterial origin containing a nonprotein moiety consisting of three acyl groups.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"cad6de3f5d3f4683a8c17546b5a64e2d","type":"GO_TERM","name":"detection of tumor cell","canonical_id":"go:GO:0002355","description":"\"The series of events in which a stimulus from a tumor cell is received and converted into a molecular signal.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"06150da8ef464de189d62ac426761d9c","type":"GO_TERM","name":"detection of unfolded protein","canonical_id":"go:GO:0002235","description":"\"The series of events in which an unfolded protein stimulus is received and converted into a molecular signal.\" [GOC:add, PMID:15226511, PMID:7765470]","metadata":null},{"id":"b6840bf5adba4f2c8dcc6915cebb7ff0","type":"GO_TERM","name":"detection of virus","canonical_id":"go:GO:0009597","description":"\"The series of events in which a stimulus from a virus is received and converted into a molecular signal.\" [GOC:hb]","metadata":null},{"id":"482877862fed466e83220834cd6bf6dd","type":"GO_TERM","name":"detection of visible light","canonical_id":"go:GO:0009584","description":"\"The series of events in which a visible light stimulus is received by a cell and converted into a molecular signal. A visible light stimulus is electromagnetic radiation that can be perceived visually by an organism; for organisms lacking a visual system, this can be defined as light with a wavelength within the range 380 to 780 nm.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"251c6fa3baf740ed86b8d5155c13a335","type":"GO_TERM","name":"detection of wounding","canonical_id":"go:GO:0014822","description":"\"The series of events by which an injury stimulus is received and converted into a molecular signal.\" [GOC:mtg_muscle]","metadata":null},{"id":"7f3d982c4863428e86cd43e66554a52c","type":"GO_TERM","name":"detection of yeast","canonical_id":"go:GO:0001879","description":"\"The series of events in which a stimulus from a yeast is received and converted into a molecular signal.\" [PMID:14707091]","metadata":null},{"id":"a71d0fa819b34cabb3e21de62cb21c5b","type":"GO_TERM","name":"determinate inflorescence morphogenesis","canonical_id":"go:GO:0048282","description":"\"The process in which the anatomical structures of determinate inflorescences are generated and organized. A determinate inflorescence is one that can only produce a predetermined number of floral meristems.\" [GOC:jid, PMID:9553044]","metadata":null},{"id":"742343fa52b04d72a1658730db976102","type":"GO_TERM","name":"determination of adult lifespan","canonical_id":"go:GO:0008340","description":"\"The pathways that regulate the duration of the adult phase of the life-cycle of an animal.\" [PMID:25561524, PMID:273723695, PMID:3424805]","metadata":null},{"id":"627562a5b02c4b31a47c12129649c1c0","type":"GO_TERM","name":"determination of affect","canonical_id":"go:GO:0050894","description":"\"Any process in which an emotional response is associated with a particular sensory stimulation.\" [GOC:ai, GOC:dph, ISBN:0721662544]","metadata":null},{"id":"74d669878aa14be387bc7ea3c6928c5e","type":"GO_TERM","name":"determination of bilateral symmetry","canonical_id":"go:GO:0009855","description":"\"The establishment of an organism's body plan or part of an organism with respect to a single longitudinal plane. The pattern can either be symmetric, such that the halves are mirror images, or asymmetric where the pattern deviates from this symmetry.\" [GOC:curators]","metadata":null},{"id":"e2a1d24e7f8544a781fad88f7a695550","type":"GO_TERM","name":"determination of digestive tract left/right asymmetry","canonical_id":"go:GO:0071907","description":"\"Determination of the asymmetric location of various parts of the digestive tract with respect to the left and right halves of the organism. The digestive tract is the anatomical structure through which food passes and is processed.\" [GOC:cvs]","metadata":null},{"id":"0a194cae06e04883b067497b0a101f1d","type":"GO_TERM","name":"determination of dorsal identity","canonical_id":"go:GO:0048263","description":"\"Determination of the identity of part of an organism or organ where those parts are of the type that occur in the dorsal region. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:jid]","metadata":null},{"id":"865fe0ddff864d36837004ccade40844","type":"GO_TERM","name":"determination of dorsal/ventral asymmetry","canonical_id":"go:GO:0048262","description":"\"Determination of asymmetry from the dorsal to the ventral side; as, the dorsoventral axis.\" [GOC:jid]","metadata":null},{"id":"81a74a286a4045999bbacc7c9832fd4b","type":"GO_TERM","name":"determination of genital disc primordium","canonical_id":"go:GO:0035225","description":"\"Allocation of embryonic cells to the genital imaginal disc founder populations. Early in development at the blastoderm stage, the anlage of the genital disc of both sexes consists of three primordia: the female genital primoridum lcoated anteriorly, the anal primoridum located posteriorly, and the male gential primordium between the two.\" [GOC:bf, PMID:11494318]","metadata":null},{"id":"34dccc72cf8640688b23cc9c56ccbd73","type":"GO_TERM","name":"determination of heart left/right asymmetry","canonical_id":"go:GO:0061371","description":"\"Determination of the asymmetric location of the heart with respect to the left and right halves of the organism.\" [GOC:dph, GOC:mtg_heart]","metadata":null},{"id":"40ffa2e521774057a7e9b5cdc905b1b3","type":"GO_TERM","name":"determination of imaginal disc primordium","canonical_id":"go:GO:0007445","description":"\"Allocation of embryonic cells to the imaginal disc founder populations, groups of cells that are committed to contribute to the formation of an imaginal disc compartment.\" [ISBN:0879694238]","metadata":null},{"id":"adcc3a097f1f48ee8733171308755403","type":"GO_TERM","name":"determination of intestine left/right asymmetry","canonical_id":"go:GO:0071908","description":"\"Determination of the asymmetric location of the intestine loops with respect to the left and right halves of the organism.\" [GOC:cvs]","metadata":null},{"id":"e263412de85e440b9710aeb81c2e3205","type":"GO_TERM","name":"determination of left/right asymmetry in diencephalon","canonical_id":"go:GO:0035462","description":"\"The establishment of the diencephalon with respect to the left and right halves.\" [GOC:dgh, PMID:15084459]","metadata":null},{"id":"6643166de0cc4383bfe253adcb302e23","type":"GO_TERM","name":"determination of left/right asymmetry in lateral mesoderm","canonical_id":"go:GO:0003140","description":"\"The establishment of the lateral mesoderm with respect to the left and right halves.\" [GOC:mtg_heart]","metadata":null},{"id":"77973429739e48c9823dd4ed8e50668c","type":"GO_TERM","name":"determination of left/right asymmetry in nervous system","canonical_id":"go:GO:0035545","description":"\"The establishment of the nervous system with respect to the left and right halves.\" [GOC:kmv, PMID:17717195, PMID:19641012]","metadata":null},{"id":"37a14db70f274d42a73a8eecea0d8f30","type":"GO_TERM","name":"determination of left/right symmetry","canonical_id":"go:GO:0007368","description":"\"The establishment of an organism's body plan or part of an organism with respect to the left and right halves. The pattern can either be symmetric, such that the halves are mirror images, or asymmetric where the pattern deviates from this symmetry.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"4b1f16f5f1ac43afb0a8216a6a110a56","type":"GO_TERM","name":"determination of liver left/right asymmetry","canonical_id":"go:GO:0071910","description":"\"Determination of the asymmetric location of the liver with respect to the left and right halves of the organism.\" [GOC:cvs]","metadata":null},{"id":"923b291ba36c4bf8a9501caa8107438e","type":"GO_TERM","name":"determination of lung left/right asymmetry","canonical_id":"go:GO:0140969","description":"\"Determination of the asymmetric location of the lungs with respect to the left and right halves of the organism.\" [GOC:BHFL, GOC:rl, PMID:19944405, PMID:20007846, PMID:21131974]","metadata":null},{"id":"4209878dd749408ba02714a185710951","type":"GO_TERM","name":"determination of muscle attachment site","canonical_id":"go:GO:0016204","description":"\"The process that mediates the transfer of information from the cells of a muscle to those of its intended target, thereby identifying the target site.\" [GOC:isa_complete]","metadata":null},{"id":"e86ba41cb817461dadcca2b50e6f64a0","type":"GO_TERM","name":"determination of pancreatic left/right asymmetry","canonical_id":"go:GO:0035469","description":"\"Determination of the asymmetric location of the pancreas with respect to the left and right halves of the organism.\" [GOC:dgh, PMID:12702646]","metadata":null},{"id":"9516715210ea449ab036c068a438d10c","type":"GO_TERM","name":"determination of radial symmetry","canonical_id":"go:GO:0009879","description":"\"The establishment of an organism's body plan or a part of an organism such that it is symmetric around a central axis.\" [GOC:curators]","metadata":null},{"id":"bc9f8de1e8224b69b8f52aa8ecca9ac1","type":"GO_TERM","name":"determination of sensory modality","canonical_id":"go:GO:0050887","description":"\"The determination of the type or quality of a sensation. Sensory modalities include touch, thermal sensation, visual sensation, auditory sensation and pain.\" [ISBN:0721619908]","metadata":null},{"id":"838fc3e4a7794595a5b4bdc163fdb377","type":"GO_TERM","name":"determination of stimulus intensity","canonical_id":"go:GO:0050889","description":"\"The determination of the perceived strength of a sensory stimulus.\" [ISBN:0721619908]","metadata":null},{"id":"c9f5e81f50b2463ebd2a670bfb556099","type":"GO_TERM","name":"determination of stimulus location","canonical_id":"go:GO:0050888","description":"\"The determination of where on the body surface, within the body or in the environment a stimulus originates.\" [ISBN:0721619908]","metadata":null},{"id":"1c56322ebe6c419788f29fd2c3417e44","type":"GO_TERM","name":"determination of stomach left/right asymmetry","canonical_id":"go:GO:0071909","description":"\"Determination of the asymmetric location of the stomach with respect to the left and right halves of the organism.\" [GOC:cvs]","metadata":null},{"id":"72dde3e3e6214519b4bd2498e15998cd","type":"GO_TERM","name":"determination of ventral identity","canonical_id":"go:GO:0048264","description":"\"The regionalization process that results in the determination of the identity of part of an organism or organ where those parts are of the type that occur in the ventral region. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:dph, GOC:isa_complete, GOC:jid]","metadata":null},{"id":"9a7b8846875b40f6ac116cbc72848e0c","type":"GO_TERM","name":"determination of wing disc primordium","canonical_id":"go:GO:0035294","description":"\"Allocation of embryonic cells to the wing disc founder populations, groups of cells that are committed to contribute to the formation of a wing imaginal disc.\" [ISBN:0879694238]","metadata":null},{"id":"6e58462d18e643878e2d90bfb4020340","type":"GO_TERM","name":"dethiobiotin binding","canonical_id":"go:GO:1901602","description":"\"Binding to dethiobiotin.\" [GOC:TermGenie]","metadata":null},{"id":"55651f9f65194f049aa4d38525f110d9","type":"GO_TERM","name":"dethiobiotin import across plasma membrane","canonical_id":"go:GO:1905136","description":"\"The directed movement of dethiobiotin from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:12557275]","metadata":null},{"id":"052019b0a656419a9c0d9f8605d94eac","type":"GO_TERM","name":"dethiobiotin synthase activity","canonical_id":"go:GO:0004141","description":"\"Catalysis of the reaction: 7,8-diaminononanoate + ATP + CO2 = ADP + dethiobiotin + 4 H+ + phosphate.\" [EC:6.3.3.3, RHEA:15805]","metadata":null},{"id":"872a2162b4d24570ac99cb07cd751c25","type":"GO_TERM","name":"dethiobiotin transmembrane transporter activity","canonical_id":"go:GO:1901604","description":"\"Enables the transfer of dethiobiotin from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"2e1a2281c5a548f89e89fae11fe683f0","type":"GO_TERM","name":"detoxification","canonical_id":"go:GO:0098754","description":"\"Any process that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.\" [GOC:dos]","metadata":null},{"id":"458bf3a909824179a79eaaedb0b3828c","type":"GO_TERM","name":"detoxification of aluminum ion","canonical_id":"go:GO:0140982","description":"\"Any process that reduce or remove the toxicity of aluminum ions. These can include transport of the aluminum away from sensitive areas, sequesteration, or chemical modification to an inert form.\" [PMID:10845450, PMID:23888867, PMID:9576769]","metadata":null},{"id":"510a7f895d4a45b4b86e46bfa640cab9","type":"GO_TERM","name":"detoxification of arsenic-containing substance","canonical_id":"go:GO:0071722","description":"\"Any process that reduces or removes the toxicity of compounds containing arsenic, including arsenates, arsenites, and arsenides. These include transport of such compounds away from sensitive areas and to compartments or complexes whose purpose is sequestration of arsenic or arsenic-containing compounds.\" [GOC:kmv, PMID:11313333, PMID:20221439]","metadata":null},{"id":"844aa862935d4f839eaddafcd8aa11ad","type":"GO_TERM","name":"detoxification of cadmium ion","canonical_id":"go:GO:0071585","description":"\"Any process that reduces or removes the toxicity of cadmium ion. These may include transport of cadmium away from sensitive areas and to compartments or complexes whose purpose is sequestration of cadmium ion.\" [GOC:BHF, GOC:kmv, PMID:16741752]","metadata":null},{"id":"f47f888889b04b728a4bc59f3d12e667","type":"GO_TERM","name":"detoxification of cobalt ion","canonical_id":"go:GO:0010299","description":"\"Any process that reduces or removes the toxicity of cobalt ion (Co2+). These include transport of cobalt away from sensitive areas and to compartments or complexes whose purpose is sequestration of cobalt ion.\" [GOC:tair_curators]","metadata":null},{"id":"dc1f243036e84b179f680251e590fa87","type":"GO_TERM","name":"detoxification of copper ion","canonical_id":"go:GO:0010273","description":"\"Any process that reduces or removes the toxicity of copper ion. These include transport of copper away from sensitive areas and to compartments or complexes whose purpose is sequestration of copper ion.\" [GOC:kmv, PMID:16367966]","metadata":null},{"id":"b1679cee56714e85b3c13f863a711172","type":"GO_TERM","name":"detoxification of endogenously produced metabolite","canonical_id":"go:GO:0140729","description":"\"A process that reduces or removes the toxicity of an endogenously produced substance. Mechanisms of resistance to endogenously produced compounds include modification the compound, export, sequestration, or mutations in the target enzyme.\" [PMID:21923907, PMID:29763292]","metadata":null},{"id":"687591c2a16040bf90c0f2d270290cff","type":"GO_TERM","name":"detoxification of free heme","canonical_id":"go:GO:0140725","description":"\"Any process that reduces or removes the toxicity of free heme. These include transport of heme away from sensitive areas and to compartments or complexes whose purpose is sequestration of heme.\" [PMID:26741528, PMID:32983129]","metadata":null},{"id":"f8211c19b49b446e9c2ac60e4b8512ab","type":"GO_TERM","name":"detoxification of hydrogen peroxide","canonical_id":"go:GO:0061691","description":"\"Any process that reduces or removes the toxicity of hydrogen peroxide. These include transport of hydrogen peroxide away from sensitive areas and to compartments or complexes whose purpose is sequestration.\" [GOC:dph]","metadata":null},{"id":"7329a666a1604e39a69e4e931dacfec4","type":"GO_TERM","name":"detoxification of inorganic compound","canonical_id":"go:GO:0061687","description":"\"Any process that reduces or removes the toxicity of inorganic compounds. These include transport of such compounds away from sensitive areas and to compartments or complexes whose purpose is sequestration of inorganic compounds.\" [GOC:vw]","metadata":null},{"id":"79604520493a4dbfa01b9c67ca3692d8","type":"GO_TERM","name":"detoxification of iron ion","canonical_id":"go:GO:1990461","description":"\"Any process that reduces or removes the toxicity of iron ion. These include transport of iron away from sensitive areas and to compartments or complexes whose purpose is sequestration of iron ion.\" [GOC:sart, PMID:23064556]","metadata":null},{"id":"0c5aa65b52b449528dd8f2d5ca75dd26","type":"GO_TERM","name":"detoxification of mercury ion","canonical_id":"go:GO:0050787","description":"\"Any process that reduce or remove the toxicity of mercuric ion. These include transport of mercury away from sensitive areas and to compartments or complexes whose purpose is sequestration of mercury ion and/or reduction of mercury ion (Hg[II]) to metallic mercury (Hg[0]).\" [PMID:10774920]","metadata":null},{"id":"9c33de098aeb4e21bc7ce42cafed3f56","type":"GO_TERM","name":"detoxification of nitrogen compound","canonical_id":"go:GO:0051410","description":"\"Any process that reduces or removes the toxicity of nitrogenous compounds which are dangerous or toxic. This includes the aerobic conversion of toxic compounds to harmless substances.\" [GOC:ai]","metadata":null},{"id":"a6d92a9a1dd44536bb583d3dd117b969","type":"GO_TERM","name":"detoxification of sulfite","canonical_id":"go:GO:0160245","description":"\"Any process that reduces or removes the toxicity of sulfite. These include transport of sulfite away from sensitive areas and to compartments or complexes whose purpose is sequestration of sulfite.\" [PMID:30859719]","metadata":null},{"id":"a64ee167efb749449612c9a6b1ddfa78","type":"GO_TERM","name":"detoxification of zinc ion","canonical_id":"go:GO:0010312","description":"\"Any process that reduces or removes the toxicity of zinc ion. These include transport of zinc away from sensitive areas and to compartments or complexes whose purpose is sequestration of zinc ion.\" [GOC:tair_curators]","metadata":null},{"id":"d0e8d81a76064ca9b43c016702251dd4","type":"GO_TERM","name":"deubiquitinase activator activity","canonical_id":"go:GO:0035800","description":"\"Binds to and increases the activity of a deubiquitinase.\" [GOC:sart, ISBN:0120793709]","metadata":null},{"id":"b0c380065e704f45b864ca9e851862ba","type":"GO_TERM","name":"deubiquitinase activity","canonical_id":"go:GO:0101005","description":"\"An isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated.\" [GOC:mec, PMID:30783221]","metadata":null},{"id":"c9b4453484ab4ccea5fec44a1232e20b","type":"DRUG","name":"deucravacitinib","canonical_id":"gtopdb:10432","description":null,"metadata":null},{"id":"ed502973d9074c628747b359db1a05c6","type":"DRUG","name":"deucravacitinib","canonical_id":"chembl:CHEMBL4435170","description":null,"metadata":null},{"id":"0637f31741d54d8c9873a30137fa2b13","type":"COMBINATION_TREATMENT","name":"deucravacitinib + famotidine","canonical_id":"ctgov_combo:ctgov-combo-caf392b155aa8251","description":null,"metadata":null},{"id":"ae5f3a644f414bc7a81c83a7fbb9b870","type":"COMBINATION_TREATMENT","name":"deucravacitinib + famotidine","canonical_id":"ctgov_combo:ctgov-combo-2eac146e5c6aab6c","description":null,"metadata":null},{"id":"1576a9c0a58d4e1895cfab98036df69e","type":"DRUG","name":"deuruxolitinib","canonical_id":"gtopdb:11410","description":null,"metadata":null},{"id":"4b15e9ba9db34397868ee1abeccad53d","type":"DRUG","name":"deutenzalutamide","canonical_id":"gtopdb:14402","description":null,"metadata":null},{"id":"56593b4846fe46d6ba76cb4ddfa9cf75","type":"GO_TERM","name":"deuterosome","canonical_id":"go:GO:0098536","description":"\"A spherical, electron dense, cytoplasmic structure that is involved in de novo assembly of centrioles.\" [GOC:cilia, GOC:dos, PMID:24075808, PMID:25047614, PMID:5661997]","metadata":null},{"id":"c764a8b04f544a909412e9fcf19d1712","type":"DRUG","name":"deutetrabenazine","canonical_id":"gtopdb:8707","description":null,"metadata":null},{"id":"7c427bf91f914275ab9c5fd3d558231c","type":"DRUG","name":"deutetrabenazine","canonical_id":"chembl:CHEMBL3137326","description":null,"metadata":null},{"id":"17665f72e7324304a252a4dad5a85924","type":"GO_TERM","name":"development of animal secondary female sexual characteristics","canonical_id":"go:GO:0046543","description":"\"The process whose specific outcome is the progression of the secondary female sexual characteristics over time, from their formation to the mature structures. In female mammals, examples include growth of axillary and pubic hair, breast development and menstrual periods. Their development occurs in response to sex hormone secretion.\" [GOC:ai]","metadata":null},{"id":"5092226eeb464e379b333f13801a052c","type":"GO_TERM","name":"development of animal secondary male sexual characteristics","canonical_id":"go:GO:0046544","description":"\"The process whose specific outcome is the progression of the secondary male sexual characteristics over time, from their formation to the mature structures. In male mammals, examples include growth of axillary, chest, and pubic hair, voice changes, and testicular/penile enlargement. Development occurs in response to sex hormone secretion.\" [GOC:ai]","metadata":null},{"id":"c4d5f2ef8d7f4a70bedc2dede818bb2c","type":"GO_TERM","name":"development of animal secondary sexual characteristics","canonical_id":"go:GO:0045136","description":"\"The process whose specific outcome is the progression of the secondary sexual characteristics over time, from their formation to the mature structures. In mammals, examples include growth of axillary, chest, and pubic hair, voice changes, testicular/penile enlargement, breast development and menstrual periods. Development occurs in response to sex hormone secretion.\" [GOC:ai]","metadata":null},{"id":"b0d1647d6339460e8f39b23e2adf7c64","type":"GO_TERM","name":"development of primary female sexual characteristics","canonical_id":"go:GO:0046545","description":"\"The process whose specific outcome is the progression of the primary female sexual characteristics over time, from their formation to the mature structure. The primary female sexual characteristics are the ovaries, and they develop in response to sex hormone secretion.\" [GOC:ai]","metadata":null},{"id":"50b3799ac20d429a9229a02271771494","type":"GO_TERM","name":"development of primary male sexual characteristics","canonical_id":"go:GO:0046546","description":"\"The process whose specific outcome is the progression of the primary male sexual characteristics over time, from their formation to the mature structures. The primary male sexual characteristics are the testes, and they develop in response to sex hormone secretion.\" [GOC:ai]","metadata":null},{"id":"64aadb09a98744beb9b12400ed67089f","type":"GO_TERM","name":"development of primary sexual characteristics","canonical_id":"go:GO:0045137","description":"\"The process whose specific outcome is the progression of the primary sexual characteristics over time, from their formation to the mature structures. The primary sexual characteristics are the testes in males and the ovaries in females and they develop in response to sex hormone secretion.\" [GOC:ai]","metadata":null},{"id":"5c4e3fa2cfc7401bba21bdfe37f8a791","type":"GO_TERM","name":"development of symbiont in host","canonical_id":"go:GO:0044114","description":"\"The progression of an organism from an initial condition to a later condition, occurring within the cells or tissues of the host organism. This may (but not necessarily) include a filamentous growth form, and also can include secretion of proteases and lipases to break down host tissue. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:jl, GOC:pamgo_curators]","metadata":null},{"id":"956b7626afd342c18b2ef72d577b9613","type":"DISEASE","name":"developmental and epileptic encephalopathy","canonical_id":"mondo:0100620","description":null,"metadata":null},{"id":"95810164c9c045d287b638d41ab7e3ee","type":"DISEASE","name":"developmental and epileptic encephalopathy 113","canonical_id":"mondo:0958330","description":null,"metadata":null},{"id":"f6e1c13f7f96405e96a34650130f6e27","type":"DISEASE","name":"developmental and epileptic encephalopathy, 1","canonical_id":"mondo:0010632","description":null,"metadata":null},{"id":"f43c757bd4db492b8809f81c6352fe43","type":"DISEASE","name":"developmental and epileptic encephalopathy, 11","canonical_id":"mondo:0013388","description":null,"metadata":null},{"id":"9de4b19215d7492a98b6ecc1972e11e4","type":"DISEASE","name":"developmental and epileptic encephalopathy, 19","canonical_id":"mondo:0014328","description":null,"metadata":null},{"id":"41dcb865433a40dc8e1f422e26228025","type":"DISEASE","name":"developmental and epileptic encephalopathy, 27","canonical_id":"mondo:0014505","description":null,"metadata":null},{"id":"db207091cf614c0fb3cc03ea76c2321a","type":"DISEASE","name":"developmental and epileptic encephalopathy, 46","canonical_id":"mondo:0014947","description":null,"metadata":null},{"id":"85d1ff43ca3e417fb763a40c0fe7d35f","type":"DISEASE","name":"developmental and/or epileptic encephalopathy with spike-wave activation in sleep","canonical_id":"mondo:0800501","description":null,"metadata":null},{"id":"54a114ccd2164bcaa181d1535e411944","type":"GO_TERM","name":"developmental cell growth","canonical_id":"go:GO:0048588","description":"\"The growth of a cell, where growth contributes to the progression of the cell over time from one condition to another.\" [GOC:curators, GOC:isa_complete]","metadata":null},{"id":"fd94f13a2de94f1cb2fce76303c9144a","type":"GO_TERM","name":"developmental growth","canonical_id":"go:GO:0048589","description":"\"The increase in size or mass of an entire organism, a part of an organism or a cell, where the increase in size or mass has the specific outcome of the progression of the organism over time from one condition to another.\" [GOC:curators]","metadata":null},{"id":"1e9021b78acb49728bcde23817ca5a98","type":"GO_TERM","name":"developmental growth involved in morphogenesis","canonical_id":"go:GO:0060560","description":"\"The increase in size or mass of an anatomical structure that contributes to the structure attaining its shape.\" [GOC:dph]","metadata":null},{"id":"2ace8b757e574786aeb3581e8034fb08","type":"GO_TERM","name":"developmental induction","canonical_id":"go:GO:0031128","description":"\"A developmental process involving two tissues in which one tissue (the inducer) produces a signal that directs cell fate commitment of cells in the second tissue (the responder).\" [GOC:cjm, GOC:dph, GOC:mah, PMID:24503535]","metadata":null},{"id":"c1fc464ffd654931a8b05cb925232f81","type":"GO_TERM","name":"developmental maturation","canonical_id":"go:GO:0021700","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an anatomical structure, cell or cellular component to attain its fully functional state.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d3e28ac450a34626b5d20bceaa8ce6ce","type":"GO_TERM","name":"developmental pigmentation","canonical_id":"go:GO:0048066","description":"\"The developmental process that results in the deposition of coloring matter in an organism, tissue or cell.\" [ISBN:0582227089]","metadata":null},{"id":"d50c2ffd4a2c4a7d892db10fe7361d3e","type":"GO_TERM","name":"developmental process","canonical_id":"go:GO:0032502","description":"\"A biological process whose specific outcome is the progression of an integrated living unit: an anatomical structure (which may be a subcellular structure, cell, tissue, or organ), or organism over time from an initial condition to a later condition.\" [GOC:isa_complete]","metadata":null},{"id":"0bc5c8cb2e3142f89f6d14752700ac56","type":"GO_TERM","name":"developmental process involved in reproduction","canonical_id":"go:GO:0003006","description":"\"A developmental process in which a progressive change in the state of some part of an organism, germline or somatic, specifically contributes to its ability to form offspring.\" [GOC:dph, GOC:isa_complete]","metadata":null},{"id":"331a31d245054571b36e78963b4c3049","type":"GO_TERM","name":"developmental vegetative growth","canonical_id":"go:GO:0080186","description":"\"The increase in size or mass of non-reproductive plant parts.\" [PO:0007134]","metadata":null},{"id":"1f61df0872e2418495fbbefb456327e9","type":"DRUG","name":"dexamethasone","canonical_id":"gtopdb:2768","description":null,"metadata":null},{"id":"e59a4810626543219eeca54d8d6631c9","type":"DRUG","name":"dexamethasone","canonical_id":"mesh:D003907","description":null,"metadata":null},{"id":"0ff3f9dfafae4bc6af0e64c5d251454c","type":"DRUG","name":"dexamethasone","canonical_id":"chembl:CHEMBL384467","description":null,"metadata":null},{"id":"7a9bdb2a2c54496a823189bc734a8f4b","type":"COMBINATION_TREATMENT","name":"dexamethasone + diphenhydramine + famotidine + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-abdfb8148323f764","description":null,"metadata":null},{"id":"1b869c06d30645e1b07d2224ea5f35e3","type":"COMBINATION_TREATMENT","name":"dexamethasone + etoposide + methotrexate + methylprednisolone + prednisolone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-5a1ecc81ede8e2d5","description":null,"metadata":null},{"id":"d4fa4bc6926349da86995362ecdd6a6e","type":"COMBINATION_TREATMENT","name":"dexamethasone + etoposide + methotrexate + prednisolone + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-c8b0646ca4315e68","description":null,"metadata":null},{"id":"d230795bea884d6183a705d6a190f8c9","type":"COMBINATION_TREATMENT","name":"dexamethasone + everolimus + exemestane","canonical_id":"ctgov_combo:ctgov-combo-b5348f78583d6353","description":null,"metadata":null},{"id":"03f90486a8524d99bea93729b91a2e08","type":"COMBINATION_TREATMENT","name":"dexamethasone + gemcitabine + rituximab","canonical_id":"ctgov_combo:ctgov-combo-ba1e6cb0317976e1","description":null,"metadata":null},{"id":"c1e2d3cb74b847f1842b93ae3cf6bf8f","type":"COMBINATION_TREATMENT","name":"dexamethasone + granisetron","canonical_id":"ctgov_combo:ctgov-combo-ace44f1810f22ba1","description":null,"metadata":null},{"id":"74013903489747b78b97bffbd8ce535c","type":"COMBINATION_TREATMENT","name":"dexamethasone + ibrutinib + rituximab","canonical_id":"ctgov_combo:ctgov-combo-a71c518fa7d8d67e","description":null,"metadata":null},{"id":"aa7e6ceb0b31468ebadd05a75f5217a1","type":"COMBINATION_TREATMENT","name":"dexamethasone + imatinib + vincristine","canonical_id":"ctgov_combo:ctgov-combo-440bf0c206f88015","description":null,"metadata":null},{"id":"fc51f284b20b449aac8dbccf8eef566c","type":"COMBINATION_TREATMENT","name":"dexamethasone + irinotecan","canonical_id":"ctgov_combo:ctgov-combo-f1d7de672d25351c","description":null,"metadata":null},{"id":"557b515a53f24a6aa31a71e9dfdc3639","type":"COMBINATION_TREATMENT","name":"dexamethasone + leflunomide","canonical_id":"ctgov_combo:ctgov-combo-2f23de5d16bea17b","description":null,"metadata":null},{"id":"5d944a14f719421381b2f6b5bc3b584c","type":"COMBINATION_TREATMENT","name":"dexamethasone + methotrexate","canonical_id":"ctgov_combo:ctgov-combo-565a286ed885fd38","description":null,"metadata":null},{"id":"b7d53440308c405a9cd091638aaae5dc","type":"COMBINATION_TREATMENT","name":"dexamethasone + methotrexate + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-35382babacc5609e","description":null,"metadata":null},{"id":"84b96c03eb1b4edc8357f4d518d6ea63","type":"COMBINATION_TREATMENT","name":"dexamethasone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-e694378e061bc599","description":null,"metadata":null},{"id":"ec6449b5928546fbaa2c21d3596dc19a","type":"COMBINATION_TREATMENT","name":"dexamethasone + ranitidine","canonical_id":"ctgov_combo:ctgov-combo-5c0a3e2959965865","description":null,"metadata":null},{"id":"a3a34f55bceb4060b76218b0d5a2b77e","type":"DRUG","name":"dexamethasone acetate","canonical_id":"mesh:C018038","description":null,"metadata":null},{"id":"735f0e57d7aa48f4a09c11c0552556ad","type":"DRUG","name":"dexamfetamine","canonical_id":"gtopdb:2147","description":null,"metadata":null},{"id":"51d7b1d1ed8b4a0f998052fd38148f4a","type":"DRUG","name":"dexamfetamine","canonical_id":"chembl:CHEMBL612","description":null,"metadata":null},{"id":"990e1ab27a51479cb1260c0eb5c333fe","type":"DRUG","name":"dexetimide","canonical_id":"gtopdb:354","description":null,"metadata":null},{"id":"dfac09ce7cd745b6881af9480786aed5","type":"DRUG","name":"dexfenfluramine","canonical_id":"mesh:D020372","description":null,"metadata":null},{"id":"0714f1d2ce4b45a6973a684b10a16d77","type":"DRUG","name":"dexibuprofen","canonical_id":"mesh:C539402","description":null,"metadata":null},{"id":"74651695f4214dd39e77a946a8f6f4da","type":"DRUG","name":"dexmedetomidine","canonical_id":"gtopdb:521","description":null,"metadata":null},{"id":"05a70d67f05e41bfa66c3a6fcaffb09a","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + fentanyl","canonical_id":"ctgov_combo:ctgov-combo-baa2d1e79d2340b3","description":null,"metadata":null},{"id":"a2dd5ed29d5945159bc3ceecb201de84","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + fentanyl","canonical_id":"ctgov_combo:ctgov-combo-4357dae5267cccf8","description":null,"metadata":null},{"id":"18723aa7beb2444ea3a4253c1cefba76","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + fentanyl + ketamine","canonical_id":"ctgov_combo:ctgov-combo-25193156539ddd47","description":null,"metadata":null},{"id":"d53bb77fe7674dfdb4b8951e0cf8e080","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-dde72c9ed8f69bce","description":null,"metadata":null},{"id":"3fe38e72978d4aaeaddae24b8f330907","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-f5c3bfd3c9a8d1b4","description":null,"metadata":null},{"id":"6b1611728d0343b8b10ab36755ec3524","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-1836065b93d964f6","description":null,"metadata":null},{"id":"5071460aefbd43f6be07ff3f39eee6a0","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-9b3aa257384a9c89","description":null,"metadata":null},{"id":"b178608b46694626acfa2c8603d1f5d1","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-4c318d817bea3c41","description":null,"metadata":null},{"id":"58f7672ef6b64b939b038fc2c1f06d8c","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + ketamine","canonical_id":"ctgov_combo:ctgov-combo-5d19553b9c7c3beb","description":null,"metadata":null},{"id":"9a78b49f93ba4684a17d80f332afccc6","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + lidocaine","canonical_id":"ctgov_combo:ctgov-combo-d7030dcb619a0274","description":null,"metadata":null},{"id":"4a2e07b3f9c147f58df54a68de78d8eb","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + lidocaine","canonical_id":"ctgov_combo:ctgov-combo-92b878adc76199a1","description":null,"metadata":null},{"id":"40bc834a962c4ee1afd82b487d2bc612","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + morphine","canonical_id":"ctgov_combo:ctgov-combo-7dd4ddf54a70b97d","description":null,"metadata":null},{"id":"42915a500c5145febd0da22a3f0b484f","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + nalbuphine","canonical_id":"ctgov_combo:ctgov-combo-ca304fb84eb2d78c","description":null,"metadata":null},{"id":"66e9ccdfd40d4784bab05ea793c900da","type":"COMBINATION_TREATMENT","name":"dexmedetomidine + nalbuphine","canonical_id":"ctgov_combo:ctgov-combo-649e4a92561185d4","description":null,"metadata":null},{"id":"827021a30b52408ea67b2135405d0026","type":"DRUG","name":"dexmethylphenidate","canonical_id":"gtopdb:7554","description":null,"metadata":null},{"id":"01a5c5564c5f4339bca565fdefa61dcd","type":"COMBINATION_TREATMENT","name":"dexmethylphenidate + methylphenidate","canonical_id":"ctgov_combo:ctgov-combo-3e99b839c16c303e","description":null,"metadata":null},{"id":"ea235a50229b4cf88a649499fad2e2f5","type":"DRUG","name":"dexpanthenol","canonical_id":"mesh:C007288","description":null,"metadata":null},{"id":"eedcffeaa8534ed68fb4c90a4a383d38","type":"GO_TERM","name":"dextran 1,6-alpha-isomaltotriosidase activity","canonical_id":"go:GO:0033924","description":"\"Catalysis of the hydrolysis of (1->6)-alpha-D-glucosidic linkages in dextrans, to remove successive isomaltotriose units from the non-reducing ends of the chains.\" [EC:3.2.1.95]","metadata":null},{"id":"361e23448eb6460f987c67e6e2bd5d2f","type":"GO_TERM","name":"dextranase activity","canonical_id":"go:GO:0033904","description":"\"Catalysis of the endohydrolysis of 1,6-alpha-D-glucosidic linkages in dextran.\" [EC:3.2.1.11]","metadata":null},{"id":"f0ce064d92fc4a71a6f19e62ee76c63c","type":"GO_TERM","name":"dextransucrase activity","canonical_id":"go:GO:0047849","description":"\"Catalysis of the reaction: [(1->6)-alpha-D-glucosyl](n) + sucrose = [(1->6)-alpha-D-glucosyl](n+1) + D-fructose.\" [RHEA:18825]","metadata":null},{"id":"8d931539c285400cb1b13db49552fdb0","type":"GO_TERM","name":"dextrin catabolic process","canonical_id":"go:GO:1901027","description":"\"The chemical reactions and pathways resulting in the breakdown of dextrin.\" [GOC:TermGenie]","metadata":null},{"id":"c8e41a57391d4a388d5a6610332fd72f","type":"GO_TERM","name":"dextrin dextranase activity","canonical_id":"go:GO:0050103","description":"\"Catalysis of the reaction: 1,4-alpha-D-glucosyl(n) + 1,6-alpha-D-glucosyl(m) = 1,4-alpha-D-glucosyl(n-1) + 1,6-alpha-D-glucosyl(m+1).\" [EC:2.4.1.2, MetaCyc:DEXTRIN-DEXTRANASE-RXN]","metadata":null},{"id":"f8e4406053ac4b289221abd456506bbf","type":"GO_TERM","name":"dextrin transmembrane transporter activity","canonical_id":"go:GO:0042957","description":"\"Enables the transfer of dextrin, any one, or the mixture, of the intermediate polysaccharides formed during the hydrolysis of starch, which are dextrorotatory, soluble in water, and precipitable in alcohol, from one side of a membrane to the other.\" [GOC:jl, GOC:vk]","metadata":null},{"id":"00768395873546d6957512864d0f836e","type":"GO_TERM","name":"dextrin transport","canonical_id":"go:GO:0042955","description":"\"The directed movement of dextrin, any one, or the mixture, of the intermediate polysaccharides formed during the hydrolysis of starch, which are dextrorotatory, soluble in water, and precipitable in alcohol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"822e56ac6ec7422db17670714de0a621","type":"DRUG","name":"dextromethorphan","canonical_id":"mesh:D003915","description":null,"metadata":null},{"id":"26447c95691b4c05a8a3819146e7e900","type":"DRUG","name":"dextrothyroxine","canonical_id":"gtopdb:6951","description":null,"metadata":null},{"id":"bd12636c6fd14970bf2fbb56251e5d5f","type":"DRUG","name":"dextrothyroxine","canonical_id":"mesh:D003918","description":null,"metadata":null},{"id":"5d38e9e23fdf4ed99d59d01e2d2b259c","type":"DRUG","name":"dextrothyroxine","canonical_id":"chembl:CHEMBL559","description":null,"metadata":null},{"id":"e8167be3a5d643608eb59ef492c8bc9a","type":"GO_TERM","name":"dhurrin biosynthetic process","canonical_id":"go:GO:0010132","description":"\"The chemical reactions and pathways resulting in the formation of dhurrin, a cyanogenic glucoside which functions as a plant defense compound.\" [GOC:pz]","metadata":null},{"id":"dba9ad8d2e474d1b90be9c0ad6962951","type":"GO_TERM","name":"di-trans, poly-cis-undecaprenol kinase activity","canonical_id":"go:GO:0036433","description":"\"Catalysis of the reaction: di-trans, octa-cis-undecaprenol + ATP = di-trans,octa-cis-undecaprenyl phosphate + ADP + H+.\" [RHEA:28122]","metadata":null},{"id":"69c8769f2a6043daa9bf0f330d1bd9f1","type":"DISEASE","name":"diabetes insipidus","canonical_id":"mondo:0004782","description":null,"metadata":null},{"id":"99be1e5508564d649975b94d9c16ae04","type":"DISEASE","name":"diabetes mellitus","canonical_id":"mondo:0005015","description":null,"metadata":null},{"id":"d8cdcb3accb747bc91b8a7ee674adc08","type":"DISEASE","name":"diabetes mellitus, permanent neonatal 2","canonical_id":"mondo:0030087","description":null,"metadata":null},{"id":"5bc0cbd226b14a57b04077a5d79e7848","type":"DISEASE","name":"diabetes mellitus, permanent neonatal 3","canonical_id":"mondo:0030088","description":null,"metadata":null},{"id":"8224f753473c469db6af158037003738","type":"DISEASE","name":"diabetes mellitus, transient neonatal, 2","canonical_id":"mondo:0012480","description":null,"metadata":null},{"id":"766abcce28b8431a87f87bf2b616edb4","type":"DISEASE","name":"diabetes mellitus, transient neonatal, 3","canonical_id":"mondo:0012522","description":null,"metadata":null},{"id":"94a796e19e544f7da5fefe631c1ec974","type":"DISEASE","name":"diabetic eye disease","canonical_id":"efo:0009486","description":null,"metadata":null},{"id":"6e88c3b1826243ba9859cf14426c33d9","type":"DISEASE","name":"diabetic kidney disease","canonical_id":"mondo:0005016","description":null,"metadata":null},{"id":"5bd7f62ec03146b1b841aa2f476b987f","type":"DISEASE","name":"diabetic macular edema","canonical_id":"mondo:0004728","description":null,"metadata":null},{"id":"b3948229c39041b38d507eddf1e9abce","type":"DISEASE","name":"diabetic neuropathy","canonical_id":"mondo:0006626","description":null,"metadata":null},{"id":"c7543d3632f145cfa87c477dc9d33760","type":"DISEASE","name":"diabetic retinopathy","canonical_id":"mondo:0005266","description":null,"metadata":null},{"id":"e75a5f9e181849bcbaa05c0d138b7ef4","type":"GO_TERM","name":"diacetyl reductase ((R)-acetoin forming) (NAD+) activity","canonical_id":"go:GO:0052587","description":"\"Catalysis of the reaction: (R)-acetoin + NAD+ = diacetyl + H+ + NADH. This reaction is catalyzed in the reverse direction.\" [RHEA:22900]","metadata":null},{"id":"3cd01d20e88e41ffb8fff0603db146fc","type":"GO_TERM","name":"diacetyl reductase ((S)-acetoin forming) (NAD+) activity","canonical_id":"go:GO:0052588","description":"\"Catalysis of the reaction: (S)-acetoin + NAD+ = diacetyl + H+ + NADH. This reaction is catalyzed in the reverse direction.\" [RHEA:27286]","metadata":null},{"id":"37f8d7f1b3b94954b657cc4f48ba72cd","type":"GO_TERM","name":"diacetylchitobiose catabolic process","canonical_id":"go:GO:0052777","description":"\"The chemical reactions and pathways resulting in the breakdown of diacetylchitobiose into simpler products.\" [PMID:22797760]","metadata":null},{"id":"b3ba9814b304446da21f0a054df57655","type":"GO_TERM","name":"diacetylchitobiose deacetylase activity","canonical_id":"go:GO:0052773","description":"\"Catalysis of the reaction: H2O + N,N'-diacetylchitobiose = acetate + beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine.\" [PMID:15136574, PMID:16232910, PMID:16736587, RHEA:62168]","metadata":null},{"id":"8793dc6c35e34f92b82b48e122fa9e32","type":"GO_TERM","name":"diacetylchitobiose metabolic process","canonical_id":"go:GO:0052778","description":"\"The chemical reactions and pathways involving diacetylchitobiose, the N,N'-diacetylated derivative of chitobiose.\" [PMID:22797760]","metadata":null},{"id":"ad8b33e975884cfcb1322a9e052cb62f","type":"GO_TERM","name":"diacyl lipopeptide binding","canonical_id":"go:GO:0042498","description":"\"Binding to a lipopeptide containing a nonprotein moiety consisting of two acyl groups.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"9bb68c5c17294fe28903bbdc0661d3de","type":"GO_TERM","name":"diacylglyceride transfer activity","canonical_id":"go:GO:0140337","description":"\"Directly binding to diacylglyceride and delivering it either to an acceptor molecule or to a specific location.\" [PMID:9132017]","metadata":null},{"id":"d98588558ec342beb1e658b8de0c1bbe","type":"GO_TERM","name":"diacylglycerol O-acyltransferase activity","canonical_id":"go:GO:0004144","description":"\"Catalysis of the reaction: acyl-CoA + 1,2-diacylglycerol = CoA + triacylglycerol.\" [EC:2.3.1.20]","metadata":null},{"id":"131537a7ac264e5bb8a9d548765def33","type":"GO_TERM","name":"diacylglycerol acyl-chain remodeling","canonical_id":"go:GO:0036154","description":"\"Remodeling the acyl chains of diacylglycerol, through sequential deacylation and re-acylation reactions, to generate diacylglycerol containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:15364929]","metadata":null},{"id":"472f6e9a4da340959213759774baf417","type":"GO_TERM","name":"diacylglycerol binding","canonical_id":"go:GO:0019992","description":"\"Binding to a diacylglycerol, a diester of glycerol and two fatty acids.\" [GOC:ma]","metadata":null},{"id":"c7e0dab069974618af06c46c705380ca","type":"GO_TERM","name":"diacylglycerol biosynthetic process","canonical_id":"go:GO:0006651","description":"\"The chemical reactions and pathways resulting in the formation of diacylglycerol, a glyceride in which any two of the R groups (positions not specified) are acyl groups while the remaining R group can be either H or an alkyl group.\" [GOC:curators]","metadata":null},{"id":"208c1508441542d0827e9b6b69f37ec4","type":"GO_TERM","name":"diacylglycerol catabolic process","canonical_id":"go:GO:0046340","description":"\"The chemical reactions and pathways resulting in the breakdown of diacylglycerol, a glyceride in which any two of the R groups (positions not specified) are acyl groups while the remaining R group can be either H or an alkyl group.\" [PMID:11717312]","metadata":null},{"id":"3ad53c3bec094ed0829497d581290980","type":"GO_TERM","name":"diacylglycerol cholinephosphotransferase activity","canonical_id":"go:GO:0004142","description":"\"Catalysis of the reaction: CDP-choline + 1,2-diacylglycerol = CMP + a phosphatidylcholine.\" [EC:2.7.8.2, RHEA:32939]","metadata":null},{"id":"186e8d791f0a425baf27af3f3ace4cd7","type":"GO_TERM","name":"diacylglycerol diphosphate phosphatase activity","canonical_id":"go:GO:0000810","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycerol 3-diphosphate + H2O = a 1,2-diacyl-sn-glycerol 3-phosphate + phosphate.\" [GOC:kad, PMID:8567632, PMID:9452443, RHEA:27449]","metadata":null},{"id":"4d2d3e55ecce4f5a83625821d85fbbd1","type":"GO_TERM","name":"diacylglycerol lipase activity","canonical_id":"go:GO:0120516","description":"\"Catalysis of the reaction: a diacylglycerol + H2O = a fatty acid + a monoacylglycerol + H+.\" [RHEA:32731]","metadata":null},{"id":"f87cf83bfaad47219ab32239b930e9fe","type":"GO_TERM","name":"diacylglycerol metabolic process","canonical_id":"go:GO:0046339","description":"\"The chemical reactions and pathways involving diacylglycerol, a glyceride in which any two of the R groups (positions not specified) are acyl groups while the remaining R group can be either H or an alkyl group.\" [PMID:11481335]","metadata":null},{"id":"5d7f9cf796714c5582c31ffa6c788d0f","type":"GO_TERM","name":"diacylglycerol-dependent serine/threonine kinase activity","canonical_id":"go:GO:0004697","description":"\"Catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein. This reaction requires diacylglycerol.\" [EC:2.7.11.13]","metadata":null},{"id":"9b202d3adfbd4b26b94ff87a8f61756a","type":"GO_TERM","name":"diacylglycerol-dependent, calcium-independent serine/threonine kinase activity","canonical_id":"go:GO:0004699","description":"\"Catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein. This reaction is activated by diacylglycerol but not by calcium.\" [PMID:34834162]","metadata":null},{"id":"01be03589ca24201a15eb497deaf1dd0","type":"GO_TERM","name":"diacylglycerol-sterol O-acyltransferase activity","canonical_id":"go:GO:0047195","description":"\"Catalysis of the reaction: sterol + 1,2-diacylglycerol = sterol ester + acylglycerol.\" [EC:2.3.1.73, MetaCyc:2.3.1.73-RXN]","metadata":null},{"id":"8600f93e52d04c14a33b77f2fbc8faf4","type":"GO_TERM","name":"diadenosine hexaphosphate catabolic process","canonical_id":"go:GO:1901909","description":"\"The chemical reactions and pathways resulting in the breakdown of diadenosine hexaphosphate.\" [GOC:TermGenie, PMID:10090752]","metadata":null},{"id":"4e8f0601138e40f1aaaae1e5bc4f91da","type":"GO_TERM","name":"diadenosine pentaphosphate catabolic process","canonical_id":"go:GO:1901907","description":"\"The chemical reactions and pathways resulting in the breakdown of diadenosine pentaphosphate.\" [GOC:TermGenie, PMID:10090752]","metadata":null},{"id":"4616abb186d7437595ced89084805241","type":"GO_TERM","name":"diadenosine polyphosphate biosynthetic process","canonical_id":"go:GO:0015960","description":"\"The chemical reactions and pathways resulting in the formation of diadenosine polyphosphate, a derivative of the nucleoside adenosine with phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"e6ba1a37f9a244d183aebd5fa178110c","type":"GO_TERM","name":"diadenosine polyphosphate catabolic process","canonical_id":"go:GO:0015961","description":"\"The chemical reactions and pathways resulting in the breakdown of diadenosine polyphosphate, a derivative of the nucleoside adenosine with phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"0c244a7760e745b5b651fd2393e825ea","type":"GO_TERM","name":"diadenosine polyphosphate metabolic process","canonical_id":"go:GO:0015959","description":"\"The chemical reactions and pathways involving diadenosine polyphosphate, a derivative of the nucleoside adenosine with phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"090aea886c884a04887af1d98342c7f8","type":"GO_TERM","name":"diadenosine tetraphosphate biosynthetic process","canonical_id":"go:GO:0015966","description":"\"The chemical reactions and pathways resulting in the formation of diadenosine tetraphosphate, a derivative of the nucleoside adenosine with four phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"209485680d1e4dcbb009ad7c350b0ace","type":"GO_TERM","name":"diadenosine tetraphosphate catabolic process","canonical_id":"go:GO:0015967","description":"\"The chemical reactions and pathways resulting in the breakdown of diadenosine tetraphosphate, a derivative of the nucleoside adenosine with four phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"9404e4aa701d47bf8dda6a89018a7805","type":"GO_TERM","name":"diadenosine triphosphate biosynthetic process","canonical_id":"go:GO:0015963","description":"\"The chemical reactions and pathways resulting in the formation of diadenosine triphosphate, a derivative of the nucleoside adenosine with three phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"38d6eecdac6641dcb0b09768f4e4816c","type":"GO_TERM","name":"diadenosine triphosphate catabolic process","canonical_id":"go:GO:0015964","description":"\"The chemical reactions and pathways resulting in the breakdown of diadenosine triphosphate, a derivative of the nucleoside adenosine with three phosphate groups attached.\" [GOC:ai]","metadata":null},{"id":"79d6570d0eee403e9869caf60539bbe4","type":"GO_TERM","name":"diadenylate cyclase activity","canonical_id":"go:GO:0106408","description":"\"Catalysis of the reaction: 2 ATP = 3',3'-c-di-AMP + 2 diphosphate.\" [PMID:30884174, RHEA:35655]","metadata":null},{"id":"c5be400bc65e4d4dbd31f1ba6a44ecad","type":"GO_TERM","name":"diakinesis","canonical_id":"go:GO:0000241","description":"\"The cell cycle phase which follows diplotene during prophase I of meiosis, the separation of homologous chromosomes is complete and crossing over has occurred.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"502d3dca8c1f412cb29393f9fb0d0163","type":"GO_TERM","name":"diamine N-acetyltransferase activity","canonical_id":"go:GO:0004145","description":"\"Catalysis of the reaction: an alkane-alpha,omega-diamine + acetyl-CoA = an N-acetylalkane-alpha,omega-diamine + CoA + H+.\" [RHEA:11116]","metadata":null},{"id":"1d97b32304534d1a8233d4f32e5a152e","type":"GO_TERM","name":"diamine N-acetyltransferase complex","canonical_id":"go:GO:1990235","description":"\"A protein complex which is capable of diamine N-acetyltransferase activity.\" [GOC:bhm, PMID:8077207]","metadata":null},{"id":"7f64e99e5e0242d7b47b15acd7e844bd","type":"GO_TERM","name":"diamine oxidase activity","canonical_id":"go:GO:0052597","description":"\"Catalysis of the reaction: a diamine + H2O + O2 = a monoamine + NH4+ + H2O2.\" [MetaCyc:RXN-9599]","metadata":null},{"id":"5935a4cdc4fa45b48c5ae4706ec4e72c","type":"GO_TERM","name":"diamine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0019161","description":"\"Catalysis of the reaction: an alpha,omega-diamine + 2-oxoglutarate = an omega-aminoaldehyde + L-glutamate.\" [RHEA:18217]","metadata":null},{"id":"a1b3dff4f8574e30a3666ef0a1bd4f79","type":"GO_TERM","name":"diaminobutyrate acetyltransferase activity","canonical_id":"go:GO:0033816","description":"\"Catalysis of the reaction: L-2,4-diaminobutyrate + acetyl-CoA = N(4)-acetyl-L-2,4-diaminobutyrate + CoA + H+.\" [EC:2.3.1.178, RHEA:16901]","metadata":null},{"id":"55680f46076d4689b87b994af94497c5","type":"GO_TERM","name":"diaminobutyrate decarboxylase activity","canonical_id":"go:GO:0033983","description":"\"Catalysis of the reaction: L-2,4-diaminobutyrate + H+ = 1,3-diaminopropane + CO2.\" [EC:4.1.1.86, RHEA:15689]","metadata":null},{"id":"1017da0cc453402f94fd6757f12893c6","type":"GO_TERM","name":"diaminohydroxyphosphoribosylaminopyrimidine deaminase activity","canonical_id":"go:GO:0008835","description":"\"Catalysis of the reaction: 2,5-diamino-6-hydroxy-4-(5-phosphoribosylamino)-pyrimidine + H2O + H+ = 5-amino-6-(5-phosphoribosylamino)uracil + NH4.\" [EC:3.5.4.26, PMID:11889103, RHEA:21868]","metadata":null},{"id":"b65d894f4b8442bb8342c4c71783264f","type":"GO_TERM","name":"diaminopimelate decarboxylase activity","canonical_id":"go:GO:0008836","description":"\"Catalysis of the reaction: meso-2,6-diaminopimelate + H+ = L-lysine + CO2.\" [EC:4.1.1.20, RHEA:15101]","metadata":null},{"id":"5b02a939b33742a29e445e1cdbcdb71d","type":"GO_TERM","name":"diaminopimelate dehydrogenase activity","canonical_id":"go:GO:0047850","description":"\"Catalysis of the reaction: meso-2,6-diaminopimelate + H2O + NADP+ = L-2-amino-6-oxopimelate + H+ + NADPH + NH4.\" [RHEA:13561]","metadata":null},{"id":"a2a6117eef0d446f99df22b31e1a8289","type":"GO_TERM","name":"diaminopimelate epimerase activity","canonical_id":"go:GO:0008837","description":"\"Catalysis of the reaction: LL-2,6-diaminopimelate = meso-2,6-diaminopimelate.\" [EC:5.1.1.7, RHEA:15393]","metadata":null},{"id":"ddba9a2c89bd41438a775a249b3763bf","type":"GO_TERM","name":"diaminopimelate transport","canonical_id":"go:GO:0015830","description":"\"The directed movement of diaminopimelate, the anion of 2,6-diaminoheptanedioic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"ea4886645acf4c57a0d7ad1ee7e107ed","type":"GO_TERM","name":"diaminopropionate ammonia-lyase activity","canonical_id":"go:GO:0008838","description":"\"Catalysis of the reaction: 2,3-diaminopropanoate + H2O + H+ = pyruvate + 2 NH4+.\" [EC:4.3.1.15]","metadata":null},{"id":"ef4f090155df4b418f66cb78c0de60d6","type":"GO_TERM","name":"diapedesis","canonical_id":"go:GO:0050904","description":"\"The passage of a leukocyte between the tight junctions of endothelial cells lining blood vessels, typically the fourth and final step of cellular extravasation.\" [ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538]","metadata":null},{"id":"a321c55145ca4b29ad9a972b32e1576b","type":"GO_TERM","name":"diaphragm contraction","canonical_id":"go:GO:0002086","description":"\"A process in which force is generated within involuntary skeletal muscle tissue, resulting in a change in muscle geometry. This process occurs in the diaphragm. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The diaphragm is a striated muscle that is necessary for the process of respiratory gaseous exchange.\" [GOC:dph, GOC:mtg_muscle, PMID:12458206]","metadata":null},{"id":"cc1cd50e398945d2a1c4041e5b8abc4e","type":"GO_TERM","name":"diaphragm development","canonical_id":"go:GO:0060539","description":"\"The progression of the diaphragm over time from its initial formation to the mature structure. The diaphragm is a skeletal muscle that is responsible for contraction and expansion of the lungs.\" [GOC:dph]","metadata":null},{"id":"b223bee43e4f485099dabd2b89428fd1","type":"GO_TERM","name":"diaphragm morphogenesis","canonical_id":"go:GO:0060540","description":"\"The process in which the anatomical structures of the diaphragm are generated and organized.\" [GOC:dph]","metadata":null},{"id":"b1781b582b994836b672dfe404e52b43","type":"DISEASE","name":"diarrheal disease","canonical_id":"mondo:0001673","description":null,"metadata":null},{"id":"71d8a75e45b7416fa74ad305052bae1a","type":"GO_TERM","name":"diarylpropane peroxidase activity","canonical_id":"go:GO:0016690","description":"\"Catalysis of the reaction: (3,4-dimethoxyphenyl)methanol + H2O2 = 3,4-dimethoxybenzaldehyde + 2 H2O.\" [EC:1.11.1.14]","metadata":null},{"id":"5f1daea63b5347669e1e70fad4653ce5","type":"DRUG","name":"diazepam","canonical_id":"gtopdb:3364","description":null,"metadata":null},{"id":"55dbe769bb7a42268ccd4c53e2229707","type":"DRUG","name":"diazepam","canonical_id":"chembl:CHEMBL12","description":null,"metadata":null},{"id":"5951efc56d954c1a983cdeb746c22d09","type":"COMBINATION_TREATMENT","name":"diazepam + pethidine","canonical_id":"ctgov_combo:ctgov-combo-4cf376cd70d67c09","description":null,"metadata":null},{"id":"b7822e7f4b4845a7a7a859e717f14891","type":"GO_TERM","name":"diazepam binding","canonical_id":"go:GO:0050809","description":"\"Binding to diazepam, one of the most widely used benzodiazepine drugs. It is used as an anti-anxiety-hypnotic agent and has the proprietary name Valium.\" [ISBN:0198506732]","metadata":null},{"id":"75fd68b72377428783d7fe9ca796662b","type":"DRUG","name":"diazoxide","canonical_id":"mesh:D003981","description":null,"metadata":null},{"id":"dc2908d2e3ad4881816fe570944ca6aa","type":"DISEASE","name":"diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency","canonical_id":"mondo:0017188","description":null,"metadata":null},{"id":"65abe59a7d63494086f96ff49aa9de73","type":"DISEASE","name":"diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency","canonical_id":"mondo:0017187","description":null,"metadata":null},{"id":"1c0eaea2ba7a4e798e749caa72da23f4","type":"GO_TERM","name":"dibasic protein processing","canonical_id":"go:GO:0090472","description":"\"Any protein processing achieved by the cleavage of a peptide bond after two basic amino acids within a protein.\" [GOC:al]","metadata":null},{"id":"d9e7b7557b2340a5a7c45130d38bbca0","type":"GO_TERM","name":"dibenzo-p-dioxin catabolic process","canonical_id":"go:GO:0019341","description":"\"The chemical reactions and pathways resulting in the breakdown of dibenzo-p-dioxin, a substance composed of two benzene rings linked by two ether bonds.\" [GOC:ai]","metadata":null},{"id":"c2ab8bb0dd5646f1b3753592c47005e5","type":"GO_TERM","name":"dibenzo-p-dioxin metabolic process","canonical_id":"go:GO:0018894","description":"\"The chemical reactions and pathways involving dibenzo-p-dioxin, a substance composed of two benzene rings linked by two ether bonds. Dibenzo-p-dioxins are generated as by-products in the manufacturing of herbicides, insecticides, fungicides, paper pulp bleaching, and in incineration, and can accumulate in milk and throughout the food chain, creating significant health concern.\" [UM-BBD_pathwayID:dpd]","metadata":null},{"id":"ddd739972a71407895b66aac28e1fe45","type":"GO_TERM","name":"dibenzofuran 4,4a-dioxygenase activity","canonical_id":"go:GO:0018610","description":"\"Catalysis of the reaction: dibenzofuran + NADH + H+ + O2 = 2,2',3-trihydroxybiphenyl + NAD+.\" [RHEA:42460]","metadata":null},{"id":"3cab183df9fa4fa9b85d366cb420fbee","type":"GO_TERM","name":"dibenzofuran catabolic process","canonical_id":"go:GO:0019340","description":"\"The chemical reactions and pathways resulting in the breakdown of dibenzofuran, a substance composed of two benzene rings linked by one ether bond and one carbon-carbon bond.\" [GOC:ai]","metadata":null},{"id":"bd7eac2c398b4edd811864093822d078","type":"GO_TERM","name":"dibenzofuran metabolic process","canonical_id":"go:GO:0018893","description":"\"The chemical reactions and pathways involving dibenzofuran, a substance composed of two benzene rings linked by one ether bond and one carbon-carbon bond. Dibenzofuran is a white crystalline solid created from the production of coal tar and used as an insecticide and an intermediate in the production of other chemicals.\" [GOC:ai, UM-BBD_pathwayID:dbf]","metadata":null},{"id":"ccb233d78d784e439a169ade8b376b41","type":"GO_TERM","name":"dibenzothiophene catabolic process","canonical_id":"go:GO:0018896","description":"\"The chemical reactions and pathways resulting in the breakdown of dibenzothiophene, a substance composed of two benzene rings linked by one sulfide bond and one carbon-carbon bond.\" [GOC:ai]","metadata":null},{"id":"0e5b4874220746f3a642b8f9429b77f2","type":"GO_TERM","name":"dibenzothiophene dihydrodiol dehydrogenase activity","canonical_id":"go:GO:0018513","description":"\"Catalysis of the reaction: cis-1,2-dihydroxy-1,2-dihydrodibenzothiophene + NAD+ = 1,2-dihydroxydibenzothiophene + H+ + NADH.\" [EC:1.3.1.60, RHEA:24188]","metadata":null},{"id":"f68973d164874a059495451e90678633","type":"GO_TERM","name":"dibenzothiophene monooxygenase activity","canonical_id":"go:GO:0018640","description":"\"Catalysis of the reaction: dibenzothiophene + 2 FMNH2 + 2 O2 = dibenzothiophene 5,5-dioxide + 2 FMN + 2 H2O + 2 H+.\" [RHEA:49076]","metadata":null},{"id":"0071d067497e41c0bfd6f29f40a631c1","type":"GO_TERM","name":"dibenzothiophene sulfone monooxygenase (NADH) activity","canonical_id":"go:GO:0018679","description":"\"Catalysis of the reaction: dibenzothiophene 5,5-dioxide + FMNH2 + NADH + O2 = 2'-hydroxybiphenyl-2-sulfinate + FMN + H+ + H2O + NAD+.\" [RHEA:12312]","metadata":null},{"id":"a300188ef9c54a3795aaa037236fc454","type":"GO_TERM","name":"dibutyl phthalate binding","canonical_id":"go:GO:0035275","description":"\"Binding to dibutyl phthalate, C(16)H(22)O(4).\" [PMID:31954361, PMID:35408690]","metadata":null},{"id":"b42095a0b3eb4d1c9f090a21fdbd12c0","type":"GO_TERM","name":"dicarboxylate-CoA ligase activity","canonical_id":"go:GO:0047851","description":"\"Catalysis of the reaction: ATP + an omega-dicarboxylic acid + CoASH= AMP + diphosphate + an omega-carboxyacyl-CoA.\" [EC:6.2.1.23, MetaCyc:DICARBOXYLATE--COA-LIGASE-RXN]","metadata":null},{"id":"68cbe4d770db431caf26498a4789346a","type":"GO_TERM","name":"dicarboxylate:phosphate antiporter activity","canonical_id":"go:GO:0015364","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: dicarboxylate(out) + phosphate(in) = dicarboxylate(in) +  phosphate(out).\" [TC:2.A.29.2.3]","metadata":null},{"id":"443b07db208a486897a00dc5b466fd0e","type":"GO_TERM","name":"dicarboxylic acid biosynthetic process","canonical_id":"go:GO:0043650","description":"\"The chemical reactions and pathways resulting in the formation of dicarboxylic acids, any organic acid containing two carboxyl (-COOH) groups.\" [ISBN:0198506732]","metadata":null},{"id":"453e9c5859604e2b977c27f73310a1e0","type":"GO_TERM","name":"dicarboxylic acid catabolic process","canonical_id":"go:GO:0043649","description":"\"The chemical reactions and pathways resulting in the breakdown of dicarboxylic acids, any organic acid containing two carboxyl (-COOH) groups.\" [ISBN:0198506732]","metadata":null},{"id":"d7dd1a04ce1f40dd906f09015fa88e88","type":"GO_TERM","name":"dicarboxylic acid metabolic process","canonical_id":"go:GO:0043648","description":"\"The chemical reactions and pathways involving dicarboxylic acids, any organic acid containing two carboxyl (COOH) groups or anions (COO-).\" [ISBN:0198506732]","metadata":null},{"id":"d90740240f4a432db725118478c6d18e","type":"GO_TERM","name":"dicarboxylic acid transmembrane transporter activity","canonical_id":"go:GO:0005310","description":"\"Enables the transfer of dicarboxylic acids from one side of a membrane to the other. A dicarboxylic acid is an organic acid with two COOH groups.\" [GOC:ai]","metadata":null},{"id":"d134a3c66af64d9abc3384c239b29df2","type":"GO_TERM","name":"dicarboxylic acid transport","canonical_id":"go:GO:0006835","description":"\"The directed movement of dicarboxylic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"3068c62bae3d4d7ea310bd6da7eed23a","type":"GO_TERM","name":"dichloromethane dehalogenase activity","canonical_id":"go:GO:0018834","description":"\"Catalysis of the reaction: dichloromethane + H2O = 2 chloride + formaldehyde + 2 H+.\" [EC:4.5.1.3, RHEA:15397]","metadata":null},{"id":"b38e0952d00845f2aabdabddc4f66c79","type":"GO_TERM","name":"dichloromethane metabolic process","canonical_id":"go:GO:0018900","description":"\"The chemical reactions and pathways involving dichloromethane, a dichlorinated derivative of methane. It is a colorless organic liquid with a sweet, chloroform-like odor, often used as a paint remover.\" [UM-BBD_pathwayID:dcm]","metadata":null},{"id":"d02cf7b1158246529c7e62c40c5cddce","type":"GO_TERM","name":"dichloromuconate cycloisomerase activity","canonical_id":"go:GO:0018852","description":"\"Catalysis of the reaction: 2,4-dichloro-2,5-dihydro-5-oxofuran-2-acetate = 2,4-dichloro-cis,cis-muconate.\" [EC:5.5.1.11]","metadata":null},{"id":"63fbc00439fc4ae49e375d459e2eb30e","type":"DRUG","name":"dichlorphenamide","canonical_id":"mesh:D004005","description":null,"metadata":null},{"id":"4ced10e5b7d94f5ba183e3a0d5635b82","type":"GO_TERM","name":"dichotomous subdivision of an epithelial terminal unit","canonical_id":"go:GO:0060600","description":"\"The process in which an epithelial cord, rod or tube bifurcates at its end.\" [GOC:dph]","metadata":null},{"id":"ab4f6b46ee3e4d3780bd94a2c0ebc850","type":"GO_TERM","name":"dichotomous subdivision of prostate epithelial cord terminal unit","canonical_id":"go:GO:0060524","description":"\"The process in which a prostate epithelial cord bifurcates at its end.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"bec28d106a9f4537a4a62705a3c76721","type":"GO_TERM","name":"dichotomous subdivision of terminal units involved in lung branching","canonical_id":"go:GO:0060448","description":"\"The process in which a lung bud bifurcates.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"d4c41f82019241668a68167af02287b1","type":"GO_TERM","name":"dichotomous subdivision of terminal units involved in mammary gland duct morphogenesis","canonical_id":"go:GO:0060598","description":"\"The process in which the terminal end of a mammary duct bifurcates.\" [GOC:dph, PMID:17120154]","metadata":null},{"id":"d7739cd712874ae1ad544f8b901dc9af","type":"GO_TERM","name":"dichotomous subdivision of terminal units involved in salivary gland branching","canonical_id":"go:GO:0060666","description":"\"The process in which a salivary epithelial cord bifurcates at its end.\" [GOC:dph]","metadata":null},{"id":"106b7c30d98b4fec9be6218c73d0df02","type":"GO_TERM","name":"dichotomous subdivision of terminal units involved in ureteric bud branching","canonical_id":"go:GO:0060678","description":"\"The process in which a ureteric bud bifurcates at its end.\" [GOC:dph, PMID:16916378]","metadata":null},{"id":"4468bc98c07041f9bb4d80b738b2233b","type":"DRUG","name":"diclofenac","canonical_id":"gtopdb:2714","description":null,"metadata":null},{"id":"e1bb8cd2ee7c4081b3bf11eb770c3871","type":"DRUG","name":"diclofenac","canonical_id":"chembl:CHEMBL139","description":null,"metadata":null},{"id":"72593c04faff44b5aeb210716baba223","type":"COMBINATION_TREATMENT","name":"diclofenac + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-8a60bc3bcd744c64","description":null,"metadata":null},{"id":"0a5efec3211143aaa18066fc074fef0e","type":"COMBINATION_TREATMENT","name":"diclofenac + naproxen","canonical_id":"ctgov_combo:ctgov-combo-f7239b7c1392e54f","description":null,"metadata":null},{"id":"ea38743e1ac240428d113581fcfadb7b","type":"COMBINATION_TREATMENT","name":"diclofenac + nimesulide","canonical_id":"ctgov_combo:ctgov-combo-274dfae287cfce73","description":null,"metadata":null},{"id":"df68bfa8ca7e4f7f934025f730c0e9c6","type":"COMBINATION_TREATMENT","name":"diclofenac + rofecoxib","canonical_id":"ctgov_combo:ctgov-combo-20c5520006a12329","description":null,"metadata":null},{"id":"468b02819e3f4ff9989db9a4ef89bb3d","type":"DRUG","name":"dicoumarol","canonical_id":"mesh:D001728","description":null,"metadata":null},{"id":"3c682c3142db4dd5a7a67418de271328","type":"GO_TERM","name":"dicoumaroyl monocaffeoyl spermidine meta-hydroxylase activity","canonical_id":"go:GO:0072548","description":"\"Catalysis of the reaction: dicoumaroyl monocaffeoyl spermidine + NADPH + O2 = monocoumaroyl dicaffeoyl spermidine + NADP+ + H2O.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"0e5f49ec6ddc4f8b88cca4b8410c7978","type":"DRUG","name":"dicumarol","canonical_id":"gtopdb:6808","description":null,"metadata":null},{"id":"a82ae9f7edc345beaabf7e0ab57de0e3","type":"DRUG","name":"dicumarol","canonical_id":"chembl:CHEMBL1466","description":null,"metadata":null},{"id":"52100bdeeb0244208e99c171c63a7734","type":"DRUG","name":"dicyclomine","canonical_id":"gtopdb:355","description":null,"metadata":null},{"id":"3ac0cd9bec0b4215bfd7dc2d9876e823","type":"DRUG","name":"didanosine","canonical_id":"mesh:D016049","description":null,"metadata":null},{"id":"1486cca0f5d44d54ad2340b9ea5aaa2b","type":"GO_TERM","name":"diencephalon development","canonical_id":"go:GO:0021536","description":"\"The process whose specific outcome is the progression of the diencephalon over time, from its formation to the mature structure. The diencephalon is the paired caudal parts of the prosencephalon from which the thalamus, hypothalamus, epithalamus and subthalamus are derived; these regions regulate autonomic, visceral and endocrine function, and process information directed to the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d17be667e69447bfbc774b72b1947b2b","type":"GO_TERM","name":"diencephalon morphogenesis","canonical_id":"go:GO:0048852","description":"\"The process in which the anatomical structures of the diencephalon are generated and organized. The diencephalon is the paired caudal parts of the prosencephalon from which the thalamus, hypothalamus, epithalamus and subthalamus are derived; these regions regulate autonomic, visceral and endocrine function, and process information directed to the cerebral cortex.\" [GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"0b7ee1916a614684bb4e12915999e670","type":"DRUG","name":"dienestrol","canonical_id":"mesh:D004028","description":null,"metadata":null},{"id":"a4b4705f55cb42b8bff34d8934c80814","type":"GO_TERM","name":"diestrus","canonical_id":"go:GO:0060207","description":"\"The estrous cycle phase which is a period of sexual quiescence and represents the phase of the mature corpus luteum.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"1416f4c6c7764c94a1727ad1835f4c57","type":"GO_TERM","name":"diet induced thermogenesis","canonical_id":"go:GO:0002024","description":"\"The process that results in increased metabolic rate in tissues of an organism. It is triggered by the detection of dietary excess. This process is achieved via signaling in the sympathetic nervous system.\" [PMID:12161655]","metadata":null},{"id":"7b758a1c70f5468fa633768ac054452a","type":"GO_TERM","name":"diethyl 2-methyl-3-oxosuccinate reductase activity","canonical_id":"go:GO:0047031","description":"\"Catalysis of the reaction: diethyl (2R,3R)-2-methyl-3-hydroxysuccinate + NADP+ = diethyl 2-methyl-3-oxosuccinate + H+ + NADPH.\" [EC:1.1.1.229, RHEA:21008]","metadata":null},{"id":"fa1c30b425e64a029d919c2ef065a802","type":"DRUG","name":"diethylpropion","canonical_id":"mesh:D004053","description":null,"metadata":null},{"id":"9741aeb01ac844a0b65ab490168963dd","type":"DRUG","name":"diethylstilbestrol","canonical_id":"gtopdb:2801","description":null,"metadata":null},{"id":"744b498c1cf448eab578930258c5b58d","type":"DRUG","name":"diethylstilbestrol","canonical_id":"chembl:CHEMBL411","description":null,"metadata":null},{"id":"90c8385d353b4dea9dd7b0d2177cc3fa","type":"DRUG","name":"difelikefalin","canonical_id":"gtopdb:9044","description":null,"metadata":null},{"id":"3077f8f7de0d496996b71404557d25d7","type":"DRUG","name":"difelikefalin","canonical_id":"chembl:CHEMBL3989915","description":null,"metadata":null},{"id":"2ba2eaeeeb854a2f9b21c7d266093e31","type":"DRUG","name":"difenoxin","canonical_id":"mesh:C100010","description":null,"metadata":null},{"id":"f6de4abb545442e8b87b9fcbd45d0e1a","type":"GO_TERM","name":"diferric-transferrin reductase (NAD+) activity","canonical_id":"go:GO:0047852","description":"\"Catalysis of the reaction: transferrin[Fe2+]2 + NAD+ = transferrin[Fe3+]2 + NADH.\" [RHEA:13841]","metadata":null},{"id":"3fb2f870dd1a4d49a10cad6f514c1380","type":"GO_TERM","name":"diferuloyl mono-(hydroxyferuloyl) spermidine meta-hydroxylase activity","canonical_id":"go:GO:0072551","description":"\"Catalysis of the reaction: diferuloyl mono-(hydroxyferuloyl) spermidine + NADPH + O2 = monoferuloyl di-(hydroxyferuloyl) spermidine + NADP+ + H2O.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"a2f2f5f42c954431b61c27eff479b6d1","type":"DISEASE","name":"differentiated thyroid carcinoma","canonical_id":"mondo:0015447","description":null,"metadata":null},{"id":"056e8f9aec7541079cdee3e9615bbee1","type":"DISEASE","name":"diffuse large B-cell lymphoma","canonical_id":"mondo:0018905","description":null,"metadata":null},{"id":"42cf1f2b42b64c629c64d24c0ce2477c","type":"GO_TERM","name":"diffuse secondary thickening","canonical_id":"go:GO:0080193","description":"\"Lateral growth of the older parts of a stem that occurs when the central parenchyma cells and the not yet fully differentiated fiber cells of the bundle sheaths continue to undergo cell division and expansion for a long period of time, leading to an increase in girth of the stem.\" [GOC:dhl]","metadata":null},{"id":"9e2e1c9169c84f3495e1c9cf8b54cecf","type":"DRUG","name":"diflorasone diacetate","canonical_id":"gtopdb:7068","description":null,"metadata":null},{"id":"30546409051c42828724e0ddd56b676f","type":"DRUG","name":"diflorasone diacetate","canonical_id":"chembl:CHEMBL1200545","description":null,"metadata":null},{"id":"d96d019695a4430f991748a989163c8b","type":"DRUG","name":"diflunisal","canonical_id":"mesh:D004061","description":null,"metadata":null},{"id":"364bb3651a7a4244b98fd58baa2a23fb","type":"DRUG","name":"difluprednate","canonical_id":"gtopdb:7474","description":null,"metadata":null},{"id":"1cffd216909b4a9b90130d126b8a4432","type":"DRUG","name":"difluprednate","canonical_id":"chembl:CHEMBL1201749","description":null,"metadata":null},{"id":"f5077c45927f4bee89f83ac01f3b4389","type":"GO_TERM","name":"difructose-anhydride synthase activity","canonical_id":"go:GO:0047853","description":"\"Catalysis of the reaction: H2O + bis-D-fructose 2',1:2,1'-dianhydride = inulobiose.\" [MetaCyc:DIFRUCTOSE-ANHYDRIDE-SYNTHASE-RXN, RHEA:15041]","metadata":null},{"id":"2434fd79fb454299aa44aa93922c4233","type":"GO_TERM","name":"digalactosyldiacylglycerol synthase activity","canonical_id":"go:GO:0046481","description":"\"Catalysis of the reaction: 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol + UDP-D-galactose = 3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-1,2-diacyl-sn-glycerol + H+ + UDP.\" [EC:2.4.1.241, RHEA:10520]","metadata":null},{"id":"9a72df40de2e45f58895f0481c4af863","type":"GO_TERM","name":"digestion","canonical_id":"go:GO:0007586","description":"\"The whole of the physical, chemical, and biochemical processes carried out by multicellular organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.\" [GOC:isa_complete, ISBN:0198506732]","metadata":null},{"id":"9adccf962fbb4a8fa71365dadd3a16e9","type":"GO_TERM","name":"digestive hormone activity","canonical_id":"go:GO:0046659","description":"\"The action characteristic of a hormone that takes part in the digestion process.\" [GOC:ai]","metadata":null},{"id":"168dbc6975a74d6295aa42acc760f2e7","type":"GO_TERM","name":"digestive system development","canonical_id":"go:GO:0055123","description":"\"The process whose specific outcome is the progression of the digestive system over time, from its formation to the mature structure. The digestive system is the entire structure in which digestion takes place. Digestion is all of the physical, chemical, and biochemical processes carried out by multicellular organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.\" [GOC:jid]","metadata":null},{"id":"ff6d91388a45476a83fd4e89138aa6fd","type":"DISEASE","name":"digestive system neuroendocrine tumor, grade 1/2","canonical_id":"mondo:0000386","description":null,"metadata":null},{"id":"7252491f9df94ab9957736c821fa4339","type":"GO_TERM","name":"digestive system process","canonical_id":"go:GO:0022600","description":"\"A physical, chemical, or biochemical process carried out by living organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.\" [GOC:isa_complete, GOC:jid, GOC:mtg_cardio]","metadata":null},{"id":"93a5c079dfec4cbaac26b2e3f9a617c3","type":"GO_TERM","name":"digestive tract development","canonical_id":"go:GO:0048565","description":"\"The process whose specific outcome is the progression of the digestive tract over time, from its formation to the mature structure. The digestive tract is the anatomical structure through which food passes and is processed.\" [GOC:curators]","metadata":null},{"id":"1afc32e5ae1f49ac8d1ed56a71796522","type":"GO_TERM","name":"digestive tract mesoderm development","canonical_id":"go:GO:0007502","description":"\"The process whose specific outcome is the progression of the digestive tract mesoderm over time, from its formation to the mature structure. The digestive tract mesoderm is portion of the middle layer of the three primary germ layers of the embryo which will go on to form part of the digestive tract of the organism.\" [GOC:ai]","metadata":null},{"id":"320927d673f343999fb36e5e1591b5e3","type":"GO_TERM","name":"digestive tract morphogenesis","canonical_id":"go:GO:0048546","description":"\"The process in which the anatomical structures of the digestive tract are generated and organized. The digestive tract is the anatomical structure through which food passes and is processed.\" [GOC:curators, GOC:dph, PMID:12618131]","metadata":null},{"id":"2a5b361664f3429d97d85984745a52c0","type":"DRUG","name":"digitoxin","canonical_id":"gtopdb:6782","description":null,"metadata":null},{"id":"9db10e6c693a4b98bf25c66a16389cef","type":"DRUG","name":"digitoxin","canonical_id":"chembl:CHEMBL254219","description":null,"metadata":null},{"id":"4135370414914b16bfa64ed5c691aeff","type":"GO_TERM","name":"diglucosyl diacylglycerol synthase activity","canonical_id":"go:GO:0047257","description":"\"Catalysis of the reaction: 1,2-diacyl-3-O-(alpha-D-glucopyranosyl)-sn-glycerol + UDP-D-glucose = UDP + 1,2-diacyl-3-O-(alpha-D-glucopyranosyl(1,2)-O-alpha-D-glucopyranosyl)-sn-glycerol.\" [EC:2.4.1.208, MetaCyc:2.4.1.208-RXN]","metadata":null},{"id":"76fd8f22b79e4e06a53559aa2b732bb9","type":"GO_TERM","name":"diglucosylglycerate octanoyltransferase activity","canonical_id":"go:GO:0016414","description":"\"Catalysis of the reaction: (2R)-2-O-[alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-glycerate + octanoyl-CoA = (2R)-2-O-[6-O-octanoyl-alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-glycerate + CoA.\" [RHEA:56868]","metadata":null},{"id":"6e6ebe924ff74c1c802ce27bb5ca910e","type":"DRUG","name":"digoxin","canonical_id":"gtopdb:4726","description":null,"metadata":null},{"id":"252489cd29dc4b4f900429195e7b205d","type":"DRUG","name":"digoxin","canonical_id":"mesh:D004077","description":null,"metadata":null},{"id":"7cc4896720fd4cccb33d3678b84c2a8f","type":"DRUG","name":"digoxin","canonical_id":"chembl:CHEMBL1751","description":null,"metadata":null},{"id":"4fe6ebf3b3b140308e225465ed885f1d","type":"COMBINATION_TREATMENT","name":"digoxin + enfortumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-8fdc2270f72229ce","description":null,"metadata":null},{"id":"62c311137a2c4d08bfbd4de17ab35ec1","type":"COMBINATION_TREATMENT","name":"digoxin + enzalutamide","canonical_id":"ctgov_combo:ctgov-combo-e0667fdb26c654ae","description":null,"metadata":null},{"id":"88b36b8ac9ee4c49898533a2b039940b","type":"COMBINATION_TREATMENT","name":"digoxin + esomeprazole + famotidine + omeprazole + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-76910049c2aec26d","description":null,"metadata":null},{"id":"747116e6349c4601835be188220f3d0e","type":"COMBINATION_TREATMENT","name":"digoxin + fedratinib","canonical_id":"ctgov_combo:ctgov-combo-2f35845a93600262","description":null,"metadata":null},{"id":"0c26717f63664a60a7c82664a3921985","type":"COMBINATION_TREATMENT","name":"digoxin + fexofenadine","canonical_id":"ctgov_combo:ctgov-combo-4eef7ea35cb576fe","description":null,"metadata":null},{"id":"9a850c4f30f345839269f7fb1a942885","type":"COMBINATION_TREATMENT","name":"digoxin + omeprazole + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-1d70b09964b7d8a8","description":null,"metadata":null},{"id":"0ffbaba151fd4903a3b585dbeef6c9bc","type":"COMBINATION_TREATMENT","name":"digoxin + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-c05d792d6c5f9416","description":null,"metadata":null},{"id":"15aefbb859d34991a76fe8843d965c38","type":"COMBINATION_TREATMENT","name":"digoxin + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-5684f2fe89784b66","description":null,"metadata":null},{"id":"792327ad204f41a88020143665570388","type":"COMBINATION_TREATMENT","name":"digoxin + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-746df4d64ab793c6","description":null,"metadata":null},{"id":"002537bdf17b45ec9d84a5e385a9f46d","type":"COMBINATION_TREATMENT","name":"digoxin + retigabine","canonical_id":"ctgov_combo:ctgov-combo-ae1d95a03e3cf3bf","description":null,"metadata":null},{"id":"bce3455f11df44a8a2c7c25fd9f6d28c","type":"COMBINATION_TREATMENT","name":"digoxin + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-8167bf1147b96649","description":null,"metadata":null},{"id":"a0506e9be1d04b6bbc084df8f0294c5a","type":"COMBINATION_TREATMENT","name":"digoxin + tolbutamide","canonical_id":"ctgov_combo:ctgov-combo-0fe27b631cceccc5","description":null,"metadata":null},{"id":"c1efc775499e4a398fe34d5afa8fb219","type":"GO_TERM","name":"diguanidinobutanase activity","canonical_id":"go:GO:0047854","description":"\"Catalysis of the reaction: 1,4-diguanidinobutane + H2O = agmatine + urea.\" [EC:3.5.3.20, RHEA:13597]","metadata":null},{"id":"c7b5f150f3e446c68fee6e22720ac0af","type":"GO_TERM","name":"diguanylate cyclase activity","canonical_id":"go:GO:0052621","description":"\"Catalysis of the reaction: 2 GTP = cyclic di-3',5'-guanylate + 2 diphosphate + 2 H+.\" [EC:2.7.7.65, RHEA:24898]","metadata":null},{"id":"7982a0671c1b455b9623979de55125a6","type":"GO_TERM","name":"dihydrobenzophenanthridine oxidase activity","canonical_id":"go:GO:0047132","description":"\"Catalysis of the reaction: O2 + dihydrosanguinarine = H2O2 + sanguinarine.\" [EC:1.5.3.12]","metadata":null},{"id":"8c844826528740409e237190e0a2c429","type":"GO_TERM","name":"dihydrobiopterin metabolic process","canonical_id":"go:GO:0051066","description":"\"The chemical reactions and pathways involving a dihydrobiopterin, a reduced pteridine derivative related to folic acid; it acts as an electron carrier in tyrosine biosynthesis and its quinoid form is produced by oxidation of tetrahydrobiopterin in several biological hydroxylation reactions.\" [PMID:2557335]","metadata":null},{"id":"8543744f7b7041828dd35d9e6e32adce","type":"GO_TERM","name":"dihydrobunolol dehydrogenase activity","canonical_id":"go:GO:0047855","description":"\"Catalysis of the reaction: dihydrobunolol + NADP+ = bunolol + H+ + NADPH.\" [EC:1.1.1.160, RHEA:15925]","metadata":null},{"id":"51c29657eb014bad95aac3e119074d0f","type":"GO_TERM","name":"dihydrocamalexic acid decarboxylase activity","canonical_id":"go:GO:0010298","description":"\"Catalysis of the reaction: dihydrocamalexic acid = camalexin + CO2 + H+.\" [MetaCyc:RXN-8275, PMID:16766671]","metadata":null},{"id":"e0091bfe793d4e47a89cb779d79a200d","type":"GO_TERM","name":"dihydroceramide fatty acyl 2-hydroxylase activity","canonical_id":"go:GO:0102771","description":"\"Catalysis of the reaction: an N-(1,2-saturated acyl)sphinganine + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = an N-[(2'R)-hydroxyacyl]sphinganine + 2 Fe(III)-[cytochrome b5] + H2O.\" [RHEA:46512]","metadata":null},{"id":"c3294a87f01747ab89530748b1a4baa3","type":"GO_TERM","name":"dihydrochelirubine 12-monooxygenase activity","canonical_id":"go:GO:0047089","description":"\"Catalysis of the reaction: dihydrochelirubine + H+ + NADPH + O2 = 12-hydroxydihydrochelirubine + H2O + NADP+.\" [EC:1.14.14.101, RHEA:10156]","metadata":null},{"id":"2cd752807dc64420807da6b38c627032","type":"DRUG","name":"dihydrocodeine","canonical_id":"mesh:C014481","description":null,"metadata":null},{"id":"f34a224cd6b24c6eb37c0282c71fe820","type":"GO_TERM","name":"dihydrocoumarin hydrolase activity","canonical_id":"go:GO:0047856","description":"\"Catalysis of the reaction: 3,4-dihydrocoumarin + H2O = 3-(2-hydroxyphenyl)propanoate + H+.\" [RHEA:10360]","metadata":null},{"id":"6a8ad3debd264ac7a42baebffa6c59c2","type":"DRUG","name":"dihydroergotamine","canonical_id":"gtopdb:121","description":null,"metadata":null},{"id":"5982a313c50f4e3a9bdde195eb7c73dd","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-a0c54f4fd9fb3dfc","description":null,"metadata":null},{"id":"1d9a58feff4f409c9770d6bd84c1712c","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-d12c953879540c5b","description":null,"metadata":null},{"id":"81b88aa31bb04f869f62bcc3e3707fc5","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-9198a9fbb3250d2f","description":null,"metadata":null},{"id":"2d6dd28f1ab24dfd959560e2af856b9b","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-e67b76e75668bb3e","description":null,"metadata":null},{"id":"6d44a2c1acd7491198572cc7f83d76d7","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-830e9cf38fda7544","description":null,"metadata":null},{"id":"d7ca61f865224dccbc1927dbf4d32070","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-15683c662b7b8bbe","description":null,"metadata":null},{"id":"61eec278623443c5b25a03ba19000109","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-b79a81ba0d7d4054","description":null,"metadata":null},{"id":"87debcf958a54f2aadb04ab4e8f050e1","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-c9577a3d10fd4f51","description":null,"metadata":null},{"id":"a503bed2651142249599ed2feed9dd2f","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-3063f5c895d4fff8","description":null,"metadata":null},{"id":"8e2f8781257e471ba8f1a961c5cffbb0","type":"COMBINATION_TREATMENT","name":"dihydroergotamine + ergotamine","canonical_id":"ctgov_combo:ctgov-combo-809c7127b5127554","description":null,"metadata":null},{"id":"5991408de3b4400f82cfbaa0387cf088","type":"GO_TERM","name":"dihydroflavanol 4-reductase activity","canonical_id":"go:GO:0045552","description":"\"Catalysis of the reaction: a (2R,3S,4S)-leucoanthocyanidin + NADP+ = a (2R,3R)-dihydroflavonol + NADPH + H+.\" [RHEA:54444]","metadata":null},{"id":"a691fa4ea8604e2ea53b112ded396d21","type":"GO_TERM","name":"dihydrofolate biosynthetic process","canonical_id":"go:GO:0006761","description":"\"The chemical reactions and pathways resulting in the formation of dihydrofolate, the dihydroxylated derivative of folate.\" [GOC:ai]","metadata":null},{"id":"31dcf14461f540c88595f139ce085792","type":"GO_TERM","name":"dihydrofolate metabolic process","canonical_id":"go:GO:0046452","description":"\"The chemical reactions and pathways involving dihydrofolate, the dihydroxylated derivative of folate.\" [ISBN:0198506732]","metadata":null},{"id":"2c250fece21d43ce89c17cbac5a4e49b","type":"GO_TERM","name":"dihydrofolate reductase activity","canonical_id":"go:GO:0004146","description":"\"Catalysis of the reaction: 5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+.\" [EC:1.5.1.3]","metadata":null},{"id":"b667fa0db1cf477e90e6b6ec73543359","type":"GO_TERM","name":"dihydrofolate synthase activity","canonical_id":"go:GO:0008841","description":"\"Catalysis of the reaction: ATP + dihydropterate + L-glutamate = ADP + phosphate + dihydrofolate.\" [EC:6.3.2.12]","metadata":null},{"id":"c698d38fd55d4d03a9a990fd61c3cb1a","type":"GO_TERM","name":"dihydrofolic acid binding","canonical_id":"go:GO:0051871","description":"\"Binding to dihydrofolic acid, a folic acid in which the bicyclic pteridine structure is in the dihydro, partially reduced form; they are intermediates in folate metabolism and are reduced to their tetrahydro, reduced forms.\" [ISBN:0721662544]","metadata":null},{"id":"08d74f309bb14d41887a94a7f4b1105d","type":"GO_TERM","name":"dihydrolipoamide branched chain acyltransferase activity","canonical_id":"go:GO:0043754","description":"\"Catalysis of the reaction: N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + 2-methylpropanoyl-CoA = N(6)-[(R)-S(8)-2-methylpropanoyldihydrolipoyl]-L-lysyl-[protein] + CoA. In addition to transferring the 2-methylpropanoyl group when acting on the oxoacid corresponding with valine, this activity also transfers the 3-methylbutanoyl and S-2-methylbutanoyl groups when acting on the oxo acids corresponding with leucine and isoleucine.\" [EC:2.3.1.168]","metadata":null},{"id":"c064f0e3ff3e45c2b763c02654f709fd","type":"GO_TERM","name":"dihydrolipoamide metabolic process","canonical_id":"go:GO:0051068","description":"\"The chemical reactions and pathways involving dihydrolipoamide, the reduced form of lipoamide, produced as an intermediate in the reactions in which lipoamide acts as a cofactor.\" [ISBN:0721601464]","metadata":null},{"id":"4dedbd26c5cb4538aea3f49104525f99","type":"GO_TERM","name":"dihydrolipoyl dehydrogenase (NADH) activity","canonical_id":"go:GO:0004148","description":"\"Catalysis of the reaction: N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + NAD+ = N(6)-[(R)-lipoyl]-L-lysyl-[protein] + NADH + H+.\" [RHEA:15045]","metadata":null},{"id":"388bb2bac8e84e06839f62c9d9e04555","type":"GO_TERM","name":"dihydrolipoyllysine-residue acetyltransferase activity","canonical_id":"go:GO:0004742","description":"\"Catalysis of the reaction: N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + acetyl-CoA = N(6)-[(R)-S(8)-acetyldihydrolipoyl]-L-lysyl-[protein] + CoA.\" [RHEA:17017]","metadata":null},{"id":"293c609f4bd74fd89fef0baecc37d31b","type":"GO_TERM","name":"dihydrolipoyllysine-residue glutaryltransferase activity","canonical_id":"go:GO:0120571","description":"\"Catalysis of the reaction: N6-[(R)-dihydrolipoyl]-L-lysyl-[protein] + glutaryl-CoA = CoA + N6-[(R)-S8-glutaryldihydrolipoyl]-L-lysyl-[protein].\" [PMID:29191460, RHEA:86675]","metadata":null},{"id":"8d5f3ee21a2e48be8f512e16d762bf65","type":"GO_TERM","name":"dihydrolipoyllysine-residue succinyltransferase activity","canonical_id":"go:GO:0004149","description":"\"Catalysis of the reaction: N(6)-[(R)-dihydrolipoyl]-L-lysyl-[2-oxoglutarate dehydrogenase complex component E2] + succinyl-CoA = N(6)-[(R)-S(8)-succinyldihydrolipoyl]-L-lysyl-[2-oxoglutarate dehydrogenase complex component E2] + CoA.\" [RHEA:15213]","metadata":null},{"id":"e830c6a13b4142aba4bcd15f7d670241","type":"GO_TERM","name":"dihydromethanopterin reductase activity","canonical_id":"go:GO:0044684","description":"\"Catalysis of the reaction: 5,6,7,8-tetrahydromethanopterin + acceptor = 7,8-dihydromethanopterin + reduced acceptor.\" [PMID:15028691, RHEA:42804]","metadata":null},{"id":"bafa2a328c1841c6afdb283d2cbcbaee","type":"GO_TERM","name":"dihydromonapterin reductase activity","canonical_id":"go:GO:0071172","description":"\"Catalysis of the reaction: 7,8-dihydromonapterin + NADPH = tetrahydromonapterin + NADP+.\" [PMID:19897652, RHEA:34847]","metadata":null},{"id":"b2ef823144e84fb897efb9467bbe12f1","type":"GO_TERM","name":"dihydroneopterin aldolase activity","canonical_id":"go:GO:0004150","description":"\"Catalysis of the reaction: 2-amino-4-hydroxy-6-(D-erythro-1,2,3-trihydroxypropyl)-7,8-dihydropteridine = 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine + glycolaldehyde.\" [EC:4.1.2.25]","metadata":null},{"id":"9fb26d0fd98a497e9d059b959a29dea5","type":"GO_TERM","name":"dihydroneopterin monophosphate phosphatase activity","canonical_id":"go:GO:0019176","description":"\"Catalysis of the reaction: dihydroneopterin monophosphate = dihydroneopterin + phosphate.\" [MetaCyc:DIHYDRONEOPTERIN-MONO-P-DEPHOS-RXN]","metadata":null},{"id":"607c0f2efedd42aa901b49229c019bc1","type":"GO_TERM","name":"dihydroneopterin triphosphate 2'-epimerase activity","canonical_id":"go:GO:0008719","description":"\"Catalysis of the reaction: 7,8-dihydroneopterin 3'-triphosphate = 7,8-dihydromonapterin 3'-triphosphate.\" [RHEA:28346]","metadata":null},{"id":"6191d6dcde2d4c1992122c074fe58398","type":"GO_TERM","name":"dihydroneopterin triphosphate pyrophosphohydrolase activity","canonical_id":"go:GO:0019177","description":"\"Catalysis of the reaction: dihydroneopterin triphosphate = dihydroneopterin phosphate + diphosphate.\" [RHEA:25302]","metadata":null},{"id":"12ec742693fa4f41b514eaec1c5a69b4","type":"GO_TERM","name":"dihydronicotinamide riboside quinone reductase activity","canonical_id":"go:GO:0001512","description":"\"Catalysis of the reaction: 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone = 1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone.\" [RHEA:12364]","metadata":null},{"id":"c79e14047ef3467a84eca8cef752e05c","type":"GO_TERM","name":"dihydroorotase activity","canonical_id":"go:GO:0004151","description":"\"Catalysis of the reaction: (S)-dihydroorotate + H2O = N-carbamoyl-L-aspartate + H+.\" [EC:3.5.2.3, RHEA:24296]","metadata":null},{"id":"85fd04c034bb42ff87062c5889e1bc46","type":"GO_TERM","name":"dihydroorotate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004589","description":"\"Catalysis of the reaction: (S)-dihydroorotate + NAD+ = H+ + NADH + orotate.\" [RHEA:13513]","metadata":null},{"id":"6f28a33ae81745519f04d060215cc073","type":"GO_TERM","name":"dihydroorotate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050158","description":"\"Catalysis of the reaction: (S)-dihydroorotate + NADP+ = H+ + NADPH + orotate.\" [RHEA:14861]","metadata":null},{"id":"9840342c50424028a3dbd8f5646e006e","type":"GO_TERM","name":"dihydroorotate dehydrogenase (fumarate) activity","canonical_id":"go:GO:1990663","description":"\"Catalysis of the reaction: (S)-dihydroorotate + fumarate = orotate + succinate.\" [PMID:1409592, RHEA:30059]","metadata":null},{"id":"e2e706fd2b294c779a2c797feaa6dbdd","type":"GO_TERM","name":"dihydroorotate dehydrogenase (quinone) activity","canonical_id":"go:GO:0106430","description":"\"(S)-dihydroorotate + a quinone = orotate + a quinol.\" [RHEA:30187]","metadata":null},{"id":"a17964551a5d4592b786ca3b52bf1304","type":"GO_TERM","name":"dihydroorotate dehydrogenase activity","canonical_id":"go:GO:0004152","description":"\"Catalysis of the reaction: (S)-dihydroorotate + A = AH(2) + orotate.\" [RHEA:18073]","metadata":null},{"id":"122e882227c5445ea2c251d12c27da88","type":"GO_TERM","name":"dihydropteridine metabolic process","canonical_id":"go:GO:0051067","description":"\"The chemical reactions and pathways involving 6,7-dihydropteridine, a bicyclic compound with the formula C6H6N4.\" [PMID:2557335]","metadata":null},{"id":"18fe1c118c624e9890f33cacfbc60360","type":"GO_TERM","name":"dihydropterin deaminase activity","canonical_id":"go:GO:0004153","description":"\"Catalysis of the reaction: 7,8-dihydropterin + H2O = 7,8-dihydrolumazine + NH4+.\" [GOC:jl, PMID:19567870, PMID:38786926]","metadata":null},{"id":"8ee4e7af0c7243a7971a01b3326df2c3","type":"GO_TERM","name":"dihydropterin oxidase activity","canonical_id":"go:GO:0004154","description":"\"Catalysis of the reaction: a 7,8-dihydropteridine compound + O2 = an oxidized 7,8-dihydropteridine compound + H2O2. Specific substrates and their fully oxidized products include: 7,8-dihydropteridin/pterin, 7,8-dihydrobiopterin/biopterin, 7,8-dihydroxanthopterin/xanthopterin and sepiapterin/oxidized sepiapterin.\" [GOC:sjm, PMID:1745247, PMID:38786926, PMID:6815189]","metadata":null},{"id":"77437345b04841278f0835ac5f0b9742","type":"GO_TERM","name":"dihydropteroate synthase activity","canonical_id":"go:GO:0004156","description":"\"Catalysis of the reaction: 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine diphosphate + 4-aminobenzoate = diphosphate + dihydropteroate.\" [EC:2.5.1.15]","metadata":null},{"id":"9a48760b965f48948946c5b942feca77","type":"GO_TERM","name":"dihydropyrimidinase activity","canonical_id":"go:GO:0004157","description":"\"Catalysis of the reaction: 5,6-dihydrouracil + H2O = 3-ureidopropionate.\" [EC:3.5.2.2]","metadata":null},{"id":"00b8f2ae345e4fd1ba23d639f3399add","type":"GO_TERM","name":"dihydropyrimidine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004159","description":"\"Catalysis of the reaction: a 5,6-dihydropyrimidine (5,6-dihydrouracil or 5,6-dihydrothymine) + NAD+ = a pyrimidine (uracil or thymine) + NADH + H+.\" [PMID:23150645]","metadata":null},{"id":"d2a7e0b10c8a4ca8981c646e87dd4e7d","type":"GO_TERM","name":"dihydropyrimidine dehydrogenase (NAD+) complex","canonical_id":"go:GO:0140690","description":"\"A heteromultimeric complex capable of dihydropyrimidine dehydrogenase (NAD+); in E. coli, composed of PreA and PreT.\" [PMID:21169495, PMID:34097066]","metadata":null},{"id":"c5a46d113ea2431aaf70aa794dc2b1c5","type":"GO_TERM","name":"dihydropyrimidine dehydrogenase (NADP+) activity","canonical_id":"go:GO:0017113","description":"\"Catalysis of the reaction: 5,6-dihydrouracil + NADP+ = uracil + NADPH + H+.\" [EC:1.3.1.2]","metadata":null},{"id":"900f9235db6648e2969a84192545cf81","type":"GO_TERM","name":"dihydrosanguinarine 10-monooxygenase activity","canonical_id":"go:GO:0047088","description":"\"Catalysis of the reaction: dihydrosanguinarine + H+ + NADPH + O2 = 10-hydroxydihydrosanguinarine + H2O + NADP+.\" [EC:1.14.14.100, RHEA:10528]","metadata":null},{"id":"c9b6c6e9f18d4b3bb6ade0e50a54314a","type":"GO_TERM","name":"dihydrosphingosine-1-P pathway","canonical_id":"go:GO:0006648","description":"\"A phosphatidylethanolamine biosynthetic process that proceeds via the enzymatic action of dihydrosphingosine phosphate lyase.\" [GOC:mah, PMID:15643073]","metadata":null},{"id":"17c8357b365b45f287922a9b795adb9d","type":"GO_TERM","name":"dihydrosphingosine-1-phosphate phosphatase activity","canonical_id":"go:GO:0070780","description":"\"Catalysis of the reaction: dihydrosphingosine 1-phosphate + H2O = dihydrosphingosine + phosphate.\" [GOC:pde, PMID:12815058]","metadata":null},{"id":"9270d08e7c594c809db7cf489375e9f0","type":"GO_TERM","name":"dihydrostreptomycin-6-phosphate 3'-alpha-kinase activity","canonical_id":"go:GO:0047333","description":"\"Catalysis of the reaction: ATP + dihydrostreptomycin 6-phosphate = ADP + dihydrostreptomycin 3'alpha,6-bisphosphate + 2 H+.\" [EC:2.7.1.88, RHEA:16281]","metadata":null},{"id":"6d13343cb0c747edb4b36407badcf4d3","type":"GO_TERM","name":"dihydrouracil oxidase activity","canonical_id":"go:GO:0047857","description":"\"Catalysis of the reaction: 5,6-dihydrouracil + O2 = H2O2 + uracil.\" [EC:1.3.3.7, RHEA:12384]","metadata":null},{"id":"dbc5ca2a05834eb89216bba85118592e","type":"GO_TERM","name":"dihydroxy-acid dehydratase activity","canonical_id":"go:GO:0004160","description":"\"Catalysis of the reaction: (2R)-2,3-dihydroxy-3-methylbutanoate = 3-methyl-2-oxobutanoate + H2O.\" [RHEA:24809]","metadata":null},{"id":"baf0d74d7c514b06a60acade4551d3ea","type":"GO_TERM","name":"dihydroxyfumarate decarboxylase activity","canonical_id":"go:GO:0047858","description":"\"Catalysis of the reaction: dihydroxyfumarate + H+ = 2-hydroxy-3-oxopropanoate + CO2.\" [EC:4.1.1.54, RHEA:13845]","metadata":null},{"id":"c9466ec6d8ea4ee8b5dad0061666b2a8","type":"GO_TERM","name":"dihydroxyphenylalanine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047309","description":"\"Catalysis of the reaction: L-dopa + 2-oxoglutarate = 3-(3,4-dihydroxyphenyl)pyruvate + L-glutamate.\" [RHEA:15273]","metadata":null},{"id":"3b5d9c2353fa4458b5e146a23cc53dc9","type":"GO_TERM","name":"diiodophenylpyruvate reductase (NAD+) activity","canonical_id":"go:GO:0047860","description":"\"Catalysis of the reaction: 3-(3,5-diiodo-4-hydroxyphenyl)lactate + NAD+ = 3-(3,5-diiodo-4-hydroxyphenyl)pyruvate + H+ + NADH.\" [RHEA:20293]","metadata":null},{"id":"34bb06360e2c4d5dac9a13bfce7e0515","type":"GO_TERM","name":"diisopropyl-fluorophosphatase activity","canonical_id":"go:GO:0047862","description":"\"Catalysis of the reaction: diisopropyl fluorophosphate + H2O = diisopropyl phosphate + fluoride + 2 H+.\" [RHEA:24100]","metadata":null},{"id":"fca756924c104f239c46e4648774b67d","type":"DISEASE","name":"dilated cardiomyopathy","canonical_id":"mondo:0005021","description":null,"metadata":null},{"id":"49b814a45f0343b3b12aa93268026c0e","type":"DISEASE","name":"dilated cardiomyopathy 1E","canonical_id":"mondo:0011003","description":null,"metadata":null},{"id":"92cb6116533d480e9345b4cd3a475c0f","type":"DRUG","name":"diloxanide furoate","canonical_id":"mesh:C004932","description":null,"metadata":null},{"id":"64bd8ddca89741ecb28acadf83fcd03e","type":"DRUG","name":"diltiazem","canonical_id":"gtopdb:2298","description":null,"metadata":null},{"id":"36600c4517204287a66c4ba635142ebd","type":"DRUG","name":"diltiazem","canonical_id":"mesh:D004110","description":null,"metadata":null},{"id":"cb22a2fe8e4a4efeaf07f0d4e2e12d82","type":"COMBINATION_TREATMENT","name":"diltiazem + dofetilide + verapamil","canonical_id":"ctgov_combo:ctgov-combo-4f1274ca1600ecc7","description":null,"metadata":null},{"id":"a3303c88def842edad72163af621ee9a","type":"COMBINATION_TREATMENT","name":"diltiazem + esmolol","canonical_id":"ctgov_combo:ctgov-combo-543eeffcc8c9a4ac","description":null,"metadata":null},{"id":"366a5215206146bf8adc4fe7484d3da8","type":"COMBINATION_TREATMENT","name":"diltiazem + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-c489116c9fdbcc46","description":null,"metadata":null},{"id":"1ddd18e507fe4e4bbb88066e07d772d6","type":"COMBINATION_TREATMENT","name":"diltiazem + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-af86ff1e3f2ee613","description":null,"metadata":null},{"id":"0d0423e1a3774f9197a873f7aeac4c3e","type":"COMBINATION_TREATMENT","name":"diltiazem + propafenone + sotalol + verapamil","canonical_id":"ctgov_combo:ctgov-combo-0b351e2024accb6e","description":null,"metadata":null},{"id":"e102e7c2d3b84bd5ad5c7daa8d0279ba","type":"COMBINATION_TREATMENT","name":"diltiazem + verapamil","canonical_id":"ctgov_combo:ctgov-combo-da6f3228998e2fb4","description":null,"metadata":null},{"id":"32bf9aaaf0b64534890832a6aa3dc119","type":"DRUG","name":"dimenhydrinate","canonical_id":"mesh:D004111","description":null,"metadata":null},{"id":"daaf7aca91054325b9c7fbd09eb4cb3f","type":"DRUG","name":"dimercaprol","canonical_id":"mesh:D004112","description":null,"metadata":null},{"id":"5e66f91ab2904998b2c12fae0449cb54","type":"GO_TERM","name":"dimeric IgA immunoglobulin complex","canonical_id":"go:GO:0071750","description":"\"A protein complex composed of two monomeric IgA immunoglobulin complexes linked through both direct disulfide bonds and through a disulfide binded monomer of J chain acting as a bridge. Each IgA monomer consists of two identical immunoglobulin heavy chains of an IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds. Dimeric IgA is sometimes complexed additionally with secretory component, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"03b88fcff4ee44b498d1b9aece193187","type":"GO_TERM","name":"dimeric ribonuclease P complex","canonical_id":"go:GO:0030680","description":"\"A ribonuclease P complex that contains a single RNA molecule that is necessary and usually sufficient for catalysis, and a single protein molecule. Examples of this complex are found in Bacterial species.\" [GOC:mah, PMID:12045094]","metadata":null},{"id":"8ad69a69d76941f0a5f90215c5b8eb62","type":"DRUG","name":"dimethyl fumarate","canonical_id":"mesh:D000069462","description":null,"metadata":null},{"id":"4d13326c18ef406aa0af2bdac523628e","type":"GO_TERM","name":"dimethyl selenide methyltransferase activity","canonical_id":"go:GO:0098615","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + dimethyl selenide = S-adenosyl-L-homocysteine + trimethylselenonium.\" [PMID:17988700, PMID:3350800]","metadata":null},{"id":"b11ca550c84b4b32b7e35821490fec92","type":"GO_TERM","name":"dimethyl sulfide monooxygenase activity","canonical_id":"go:GO:0018633","description":"\"Catalysis of the reaction: dimethyl sulfide + H+ + NADH + O2 = formaldehyde + H2O + methanethiol + NAD+.\" [PMID:21216999, RHEA:31355]","metadata":null},{"id":"6cedd982929646248786d5ff33f6964f","type":"DRUG","name":"dimethyl sulfoxide","canonical_id":"mesh:D004121","description":null,"metadata":null},{"id":"0f2663cac5fe4a33bb089623888ef689","type":"GO_TERM","name":"dimethyl sulfoxide metabolic process","canonical_id":"go:GO:0018907","description":"\"The chemical reactions and pathways involving dimethyl sulfoxide, DMSO (C2H6OS), an alkyl sulfoxide that is practically odorless in its purified form. As a highly polar organic liquid, it is a powerful solvent. Its biological activities include the ability to penetrate plant and animal tissues and to preserve living cells during freezing.\" [GOC:curators]","metadata":null},{"id":"4e74b022041a4661af0f49ba53fff379","type":"GO_TERM","name":"dimethyl sulfoxide reductase activity","canonical_id":"go:GO:0009389","description":"\"Catalysis of the reaction: dimethyl sulfide + a menaquinone + H2O = dimethyl sulfoxide + a menaquinol.\" [PMID:8658134, RHEA:28494]","metadata":null},{"id":"5a34b4e13c5c4825b761986eba0a2d5b","type":"GO_TERM","name":"dimethyl sulfoxide reductase complex","canonical_id":"go:GO:0009390","description":"\"An enzyme complex that catalyzes the formation of dimethyl sulfide from dimethyl sulfoxide.\" [PMID:21357619, PMID:3280546]","metadata":null},{"id":"6f7328fa96cb4f92867e5a6b09941014","type":"GO_TERM","name":"dimethylallyl diphosphate biosynthetic process","canonical_id":"go:GO:0050992","description":"\"The chemical reactions and pathways resulting in the formation of dimethylallyl diphosphate.\" [GOC:ai]","metadata":null},{"id":"51cb355fecc3406d952a17d161e1e125","type":"GO_TERM","name":"dimethylallyl diphosphate metabolic process","canonical_id":"go:GO:0050993","description":"\"The chemical reactions and pathways involving dimethylallyl diphosphate.\" [GOC:ai]","metadata":null},{"id":"5032e0bf523544b69348788373537b63","type":"GO_TERM","name":"dimethylallylcistransferase activity","canonical_id":"go:GO:0047863","description":"\"Catalysis of the reaction: dimethylallyl diphosphate + isopentenyl diphosphate = diphosphate + neryl diphosphate.\" [RHEA:11328]","metadata":null},{"id":"3f47579447244ce49ae4ab6177d0d0dc","type":"GO_TERM","name":"dimethylallyltranstransferase activity","canonical_id":"go:GO:0004161","description":"\"Catalysis of the reaction: dimethylallyl diphosphate + isopentenyl diphosphate = (2E)-geranyl diphosphate + diphosphate.\" [RHEA:22408]","metadata":null},{"id":"a2e2a2d21ee24a09a11bf84ad6fa8c95","type":"GO_TERM","name":"dimethylamine dehydrogenase activity","canonical_id":"go:GO:0047133","description":"\"Catalysis of the reaction: electron-transferring flavoprotein + H2O + dimethylamine = reduced electron-transferring flavoprotein + formaldehyde + methylamine.\" [EC:1.5.8.1, MetaCyc:1.5.8.1-RXN]","metadata":null},{"id":"2b6aca59d7464fbd9d0c811d75fba7d3","type":"GO_TERM","name":"dimethylamine methyltransferase activity","canonical_id":"go:GO:0043791","description":"\"Catalysis of the reaction: dimethylamine + a dimethylamine corrinoid protein = a methylated dimethylamine corrinoid protein + methylamine.\" [PMID:9874228]","metadata":null},{"id":"696595e1fa784a2282e8f1a4f28bece2","type":"GO_TERM","name":"dimethylaniline-N-oxide aldolase activity","canonical_id":"go:GO:0047864","description":"\"Catalysis of the reaction: N,N-dimethylaniline N-oxide = N-methylaniline + formaldehyde.\" [EC:4.1.2.24, RHEA:19321]","metadata":null},{"id":"1f411805113643fda4987dcbe1db59c5","type":"GO_TERM","name":"dimethylargininase activity","canonical_id":"go:GO:0016403","description":"\"Catalysis of the reaction: N(G),N(G)-dimethyl-L-arginine + H2O = dimethylamine + L-citrulline.\" [EC:3.5.3.18]","metadata":null},{"id":"0d8688958e81492fb4e302143c686890","type":"GO_TERM","name":"dimethylarginine transmembrane transporter activity","canonical_id":"go:GO:7770027","description":"\"Enables the transfer of dimethylarginine from one side of a membrane to the other.\" [PMID:41075780, PMID:41075794]","metadata":null},{"id":"e93cee54d57b4235bbe1d79d16adadaf","type":"GO_TERM","name":"dimethylglycine N-methyltransferase activity","canonical_id":"go:GO:0052729","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + N,N-dimethylglycine = S-adenosyl-L-homocysteine + betaine.\" [RHEA:10072]","metadata":null},{"id":"9d31b98c8f384743a8561f69931e600a","type":"GO_TERM","name":"dimethylglycine dehydrogenase activity","canonical_id":"go:GO:0047865","description":"\"Catalysis of the reaction: N,N-dimethylglycine + electron-transfer flavoprotein + H2O = sarcosine + formaldehyde + reduced electron-transfer flavoprotein.\" [EC:1.5.8.4, RHEA:52856]","metadata":null},{"id":"c97bd422c9974b1da75806f67cf46452","type":"GO_TERM","name":"dimethylglycine oxidase activity","canonical_id":"go:GO:0047866","description":"\"Catalysis of the reaction: N,N-dimethylglycine + H2O + O2 = formaldehyde + H2O2 + sarcosine.\" [EC:1.5.3.10, RHEA:17077]","metadata":null},{"id":"d44a70c8a51e4ba3b318e24e8bd67dbb","type":"GO_TERM","name":"dimethylmalate dehydrogenase activity","canonical_id":"go:GO:0047867","description":"\"Catalysis of the reaction: (R)-3,3-dimethylmalate + NAD+ = 3-methyl-2-oxobutanoate + CO2 + NADH.\" [EC:1.1.1.84, RHEA:13321]","metadata":null},{"id":"a30abd148cce43988d896d2f11f2ff59","type":"GO_TERM","name":"dimethylmaleate hydratase activity","canonical_id":"go:GO:0047868","description":"\"Catalysis of the reaction: (2R,3S)-2,3-dimethylmalate = dimethylmaleate + H2O.\" [EC:4.2.1.85, RHEA:20253]","metadata":null},{"id":"1ee5bcf4a0014b039dfd8205702f6049","type":"GO_TERM","name":"dimethylpropiothetin dethiomethylase activity","canonical_id":"go:GO:0047869","description":"\"Catalysis of the reaction: S,S-dimethyl-beta-propiothetin = acrylate + dimethyl sulfide + H+.\" [EC:4.4.1.3, RHEA:19965]","metadata":null},{"id":"4e16196c854f48db9c33436b4da11aff","type":"GO_TERM","name":"dimethylsulfoniopropionate catabolic process","canonical_id":"go:GO:1902087","description":"\"The chemical reactions and pathways resulting in the breakdown of S,S-dimethyl-beta-propiothetin.\" [GOC:jh2, GOC:TermGenie, PMID:19807777]","metadata":null},{"id":"ff6b221926df491a8a38b41e2213a14e","type":"GO_TERM","name":"dimethylsulfoxide oxygenase activity","canonical_id":"go:GO:0103001","description":"\"Catalysis of the reactions: dimethyl sulfoxide + H+ + NADH + O2 = dimethyl sulfone + H2O + NAD+ and dimethyl sulfide + H+ + NADH + O2 = dimethyl sulfoxide + H2O + NAD+.\" [EC:1.14.13.245, PMID:9345770]","metadata":null},{"id":"dbc0a2f2337f4a45bf6b0a04d417fcb9","type":"GO_TERM","name":"dinitrosyl-iron complex binding","canonical_id":"go:GO:0035731","description":"\"Binding to a dinitrosyl-iron complex. Nitric oxide (NO) is stored as dinitrosyl-iron complexes, which form spontaneously from Glutathione (GSH), S-nitrosoglutathione, and trace amounts of ferrous ions, or by reaction of iron-sulfur centers with NO.\" [GOC:BHF, PMID:10534443]","metadata":null},{"id":"ba0cda8efd894290ab95a110bcd93fe1","type":"GO_TERM","name":"dinoflagellate antapex","canonical_id":"go:GO:0097684","description":"\"The anterior most point of a dinoflagellate hypocone.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"4b037ce1fd3a4d14a0683c6621bb51b5","type":"GO_TERM","name":"dinoflagellate antapical horn","canonical_id":"go:GO:0097687","description":"\"A horn-shaped dinoflagellate antapex found in thecate species.\" [GOC:at, PMID:7002229]","metadata":null},{"id":"0fd5b53f64184334a20df4cc009efcb0","type":"GO_TERM","name":"dinoflagellate apex","canonical_id":"go:GO:0097683","description":"\"The anterior most point of a dinoflagellate epicone.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, PMID:7002229, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"e8f8eda10cb3459e9edc36317230977b","type":"GO_TERM","name":"dinoflagellate apical groove","canonical_id":"go:GO:0097685","description":"\"A cell surface furrow (or groove) found on a dinoflagellate apex. It typically loops around the apex.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, PMID:20561119, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"cc7bd669f17648d1a8cecc7a1f04995b","type":"GO_TERM","name":"dinoflagellate apical horn","canonical_id":"go:GO:0097686","description":"\"A horn-shaped dinoflagellate apex found in thecate species.\" [GOC:at, PMID:7002229]","metadata":null},{"id":"0032e78e7d22427b905d3c20f75f89b4","type":"GO_TERM","name":"dinoflagellate cingulum","canonical_id":"go:GO:0097611","description":"\"A cell surface furrow that wraps around a dinoflagellate cell; the transverse flagellum lies in it.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, PMID:7002229, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"a27e7f08d4ab4ecba08332dcbbe9fa8b","type":"GO_TERM","name":"dinoflagellate epicone","canonical_id":"go:GO:0097613","description":"\"The part of a dinoflagellate cell above the cingulum; also referred to as the anterior portion of a dinoflagellate cell. It is separated from the hypocone by the cingulum.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"6fa8b8da9d4a48e3a31ce3166cc65fb2","type":"GO_TERM","name":"dinoflagellate hypocone","canonical_id":"go:GO:0097614","description":"\"The part of a dinoflagellate cell below the cingulum; also referred to as the posterior portion of a dinoflagellate cell. It is separated from the epicone by the cingulum.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"5fac5c3fe4464ad08b4de9bfeadc863a","type":"GO_TERM","name":"dinoflagellate peduncle","canonical_id":"go:GO:1990905","description":"\"A small, flexible, finger-like projection of cytoplasm containing an array of microtubles and located near the flagellar pores in some photosynthetic as well as nonphotosynthetic dinoflagellate species. Its functions are not fully understood, but it has been associated with feeding behavior (phagotrophy).\" [GOC:at, PMID:1480107, Wikipedia:Dinoflagellate]","metadata":null},{"id":"825d9d5399af49e8b0515028b02f95d2","type":"GO_TERM","name":"dinoflagellate sulcal notch","canonical_id":"go:GO:0097618","description":"\"A dinoflagellate sulcus that extends all the way to the posterior end of the cell (also known as antapex). The presence of a sulcal notch makes the dinoflagellate hypocone appear bilobed.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, PMID:7002229, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"eb6dee39f6364f0aa2298aa64491c7cb","type":"GO_TERM","name":"dinoflagellate sulcus","canonical_id":"go:GO:0097612","description":"\"A cell surface furrow that occurs on the ventral side of a dinoflagellate cell. It partially houses the longitudinal flagellum. The sulcus intersects with the cingulum on the ventral side of a dinoflagellate cell.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, PMID:20561119, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"ea4211b944fe4a0cbcd667a8db477683","type":"GO_TERM","name":"dinucleotide insertion or deletion binding","canonical_id":"go:GO:0032139","description":"\"Binding to a double-stranded DNA region containing a dinucleotide insertion or deletion.\" [GOC:vk]","metadata":null},{"id":"67edb7106f57462f8f92d4e5f2e6dc69","type":"GO_TERM","name":"dinucleotide phosphatase activity","canonical_id":"go:GO:0004551","description":"\"Catalysis of the reaction: a dinucleotide + H2O = 2 mononucleotides.\" [PMID:2848456, PMID:4405504]","metadata":null},{"id":"429796e23bd649bd8dcf5a92f3c03078","type":"GO_TERM","name":"dinucleotide repeat insertion binding","canonical_id":"go:GO:0032181","description":"\"Binding to a double-stranded DNA region containing a dinucleotide repeat insertion or a deletion resulting in unpaired dinucleotide repeats.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"7b52ab9494bd453caf8bdf8616490830","type":"DRUG","name":"dinutuximab","canonical_id":"gtopdb:7979","description":null,"metadata":null},{"id":"1a8ada190d8c407bbb5396bd599fcd2c","type":"COMBINATION_TREATMENT","name":"dinutuximab + eflornithine","canonical_id":"ctgov_combo:ctgov-combo-958ce4a6d127c6f9","description":null,"metadata":null},{"id":"711c9517686d4a469ee7308e7237a346","type":"COMBINATION_TREATMENT","name":"dinutuximab + lorlatinib","canonical_id":"ctgov_combo:ctgov-combo-d2cbeb272d38cded","description":null,"metadata":null},{"id":"b47cd4ee9ea84c22ae50e80d7b837e4d","type":"COMBINATION_TREATMENT","name":"dinutuximab + naxitamab","canonical_id":"ctgov_combo:ctgov-combo-385c9ea21b75d6db","description":null,"metadata":null},{"id":"ab3b47e3e47b47ff852fd89f2627e9f8","type":"COMBINATION_TREATMENT","name":"dinutuximab + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-cf936ae1eb42b224","description":null,"metadata":null},{"id":"3ffbb80258c64301a46c090ddf37265f","type":"COMBINATION_TREATMENT","name":"dinutuximab + tretinoin","canonical_id":"ctgov_combo:ctgov-combo-b77d24423a2b0f15","description":null,"metadata":null},{"id":"b5d77cd3760e4703af5010d4469e76a4","type":"GO_TERM","name":"diol biosynthetic process","canonical_id":"go:GO:0034312","description":"\"The chemical reactions and pathways resulting in the formation of a diol, any alcohol containing two hydroxyl groups attached to saturated carbon atoms.\" [GOC:mah]","metadata":null},{"id":"76a95f6dec734b93b16ab0a26ba68e83","type":"GO_TERM","name":"diol catabolic process","canonical_id":"go:GO:0034313","description":"\"The chemical reactions and pathways resulting in the breakdown of a diol, any alcohol containing two hydroxyl groups attached to saturated carbon atoms.\" [GOC:mah]","metadata":null},{"id":"7092083b82e04c46b08098982fdfb377","type":"GO_TERM","name":"diol metabolic process","canonical_id":"go:GO:0034311","description":"\"The chemical reactions and pathways involving a diol, a compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic.\" [GOC:curators]","metadata":null},{"id":"9594b7e709644029a4c81aecf4cb5175","type":"GO_TERM","name":"diolein transacylation activity","canonical_id":"go:GO:0051265","description":"\"Catalysis of the reaction: diolein + mono-olein = triolein + glycerol. Mono-olein, also known as mono-oleoylglycerol, is the monoglyceride formed from oleic acid, 9-octodecenoic acid; diolein is also known as dioleoylglycerol, and triolein as trioleoylglycerol and olein.\" [GOC:ai, PMID:15364929]","metadata":null},{"id":"268880efc20946238048492304f0fd89","type":"GO_TERM","name":"dioxotetrahydropyrimidine phosphoribosyltransferase activity","canonical_id":"go:GO:0047281","description":"\"Catalysis of the reaction: pyrophosphate + a 2,4-dioxotetrahydropyrimidine D-ribonucleotide = PRPP + a 2,4-dioxotetrahydropyrimidine.\" [EC:2.4.2.20, MetaCyc:2.4.2.20-RXN]","metadata":null},{"id":"fe57329d860644db906b19850a7f4f83","type":"GO_TERM","name":"dioxygenase activity","canonical_id":"go:GO:0051213","description":"\"Catalysis of the incorporation of both atoms of molecular oxygen (O2) into the substrate.\" [PMID:1444267]","metadata":null},{"id":"102c2da67af74ada90a0bc3d21da5c6b","type":"GO_TERM","name":"dipeptidase activity","canonical_id":"go:GO:0016805","description":"\"Catalysis of the hydrolysis of a dipeptide.\" [EC:3.4.13.-, https://www.ebi.ac.uk/merops/about/glossary.shtml#DIPEPTIDASE, PMID:19879002]","metadata":null},{"id":"7c4c229a7736488999e35bc8e6a8ac1f","type":"GO_TERM","name":"dipeptide import across plasma membrane","canonical_id":"go:GO:0140206","description":"\"The directed movement of a dipeptide from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:22226946]","metadata":null},{"id":"0a97e681c88943a68fd254f2adfaf9eb","type":"GO_TERM","name":"dipeptide transmembrane transport","canonical_id":"go:GO:0035442","description":"\"The directed movement of a dipeptide across a membrane by means of some agent such as a transporter or pore. A dipeptide is a combination of two amino acids linked together by a peptide (-CO-NH-) bond.\" [GOC:vw]","metadata":null},{"id":"c260d776cab04bfda179f238431f449a","type":"GO_TERM","name":"dipeptide transmembrane transport from lysosomal lumen to cytosol","canonical_id":"go:GO:0141204","description":"\"The directed movement of dipeptide from the lysosomal lumen across the lysosomal membrane and into the cytosol.\" [PMID:38507452]","metadata":null},{"id":"f6529356a1d74270b522c63591e2cbe0","type":"GO_TERM","name":"dipeptide transmembrane transporter activity","canonical_id":"go:GO:0071916","description":"\"Enables the transfer of a dipeptide from one side of a membrane to the other. A dipeptide is a combination of two amino acids linked together by a peptide (-CO-NH-) bond.\" [GOC:mah]","metadata":null},{"id":"bfb7be1e4c594e8fafb421cd43425320","type":"GO_TERM","name":"dipeptide transport","canonical_id":"go:GO:0042938","description":"\"The directed movement of a dipeptide, a combination of two amino acids by means of a peptide (-CO-NH-) link, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"29446e7a9d4948cc86f224f34fec6a54","type":"GO_TERM","name":"dipeptide uniporter activity","canonical_id":"go:GO:0160178","description":"\"Catalysis of the transport of a dipeptide across a membrane; transport is independent of the movement of any other molecular species.\" [PMID:38507452]","metadata":null},{"id":"f9e16ab830e04e45b71f4975196bd6f6","type":"GO_TERM","name":"dipeptidyl-peptidase activity","canonical_id":"go:GO:0008239","description":"\"Catalysis of the hydrolysis of N-terminal dipeptides from a polypeptide chain.\" [GOC:mb, https://www.ebi.ac.uk/merops/about/glossary.shtml#DIPEPTIDYL-PEPTIDASE]","metadata":null},{"id":"eef4fc40776c44e2b7a13d741fd37489","type":"DRUG","name":"diphenhydramine","canonical_id":"gtopdb:1224","description":null,"metadata":null},{"id":"3b23f2d65f4c4c609cba90c1ad5c2ebf","type":"COMBINATION_TREATMENT","name":"diphenhydramine + haloperidol + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-55c3f9995df0dda0","description":null,"metadata":null},{"id":"71d55ec5f7ab445cb5ab5076cbcb64bd","type":"COMBINATION_TREATMENT","name":"diphenhydramine + inotuzumab ozogamicin + methotrexate + methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-a858129083066625","description":null,"metadata":null},{"id":"d409b5c6dea7433b903852b77ca2b0d5","type":"COMBINATION_TREATMENT","name":"diphenhydramine + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-72bf4039a0797a25","description":null,"metadata":null},{"id":"4640dae9f1904dd28778bc47dff4cb12","type":"COMBINATION_TREATMENT","name":"diphenhydramine + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-01dcb974c8e70117","description":null,"metadata":null},{"id":"6a08edee46024e95a315930b9a848f30","type":"COMBINATION_TREATMENT","name":"diphenhydramine + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-687e571edd252eab","description":null,"metadata":null},{"id":"2b578671e8754b2b94f1d3d170a7656c","type":"COMBINATION_TREATMENT","name":"diphenhydramine + ondansetron + prochlorperazine","canonical_id":"ctgov_combo:ctgov-combo-24743436a6c553b9","description":null,"metadata":null},{"id":"ce572a0152184a09a064269415284660","type":"DRUG","name":"diphenidol","canonical_id":"mesh:C004858","description":null,"metadata":null},{"id":"f407717c72664b3b873cfc3118a15aec","type":"DRUG","name":"diphenoxylate","canonical_id":"mesh:D004157","description":null,"metadata":null},{"id":"cab0d3c3086a44be8be9ef16248ac03a","type":"GO_TERM","name":"diphenyl phthalate binding","canonical_id":"go:GO:0035274","description":"\"Binding to diphenyl phthalate, C(20)H(14)O(4).\" [PMID:34697989]","metadata":null},{"id":"087256c2da784a16800476e6217ce825","type":"DRUG","name":"diphenylpyraline","canonical_id":"mesh:C009871","description":null,"metadata":null},{"id":"a18ddc20b1e64bc4a9960cc287371387","type":"GO_TERM","name":"diphosphate hydrolysis-driven proton transmembrane transporter activity","canonical_id":"go:GO:0009678","description":"\"Catalysis of the reaction: diphosphate + H+(in) + H2O = 2 H+(out) + 2 phosphate.\" [GOC:mtg_transport, Wikipedia:Proton-pumping_pyrophosphatase]","metadata":null},{"id":"edcff50b83e343009d8ded268d25e393","type":"GO_TERM","name":"diphosphate metabolic process","canonical_id":"go:GO:0071344","description":"\"The chemical reactions and pathways involving diphosphate, the anion or salt of diphosphoric acid.\" [GOC:pde]","metadata":null},{"id":"ab6bc4acdb6d412f9b57728f6af7f88d","type":"GO_TERM","name":"diphosphate-fructose-6-phosphate 1-phosphotransferase activity","canonical_id":"go:GO:0047334","description":"\"Catalysis of the reaction: fructose-6-phosphate + diphosphate = phosphate + fructose-1,6-bisphosphate.\" [EC:2.7.1.90, MetaCyc:2.7.1.90-RXN]","metadata":null},{"id":"b872b17124ce4f808509507f21749564","type":"GO_TERM","name":"diphosphate-glycerol phosphotransferase activity","canonical_id":"go:GO:0047331","description":"\"Catalysis of the reaction: glycerol + diphosphate = glycerol 1-phosphate + H+ + phosphate.\" [EC:2.7.1.79, RHEA:13689]","metadata":null},{"id":"e5f6a9837fb94882a8f3bd547fdfdbcc","type":"GO_TERM","name":"diphosphate-protein phosphotransferase activity","canonical_id":"go:GO:0047321","description":"\"Catalysis of the reaction: microsomal-membrane protein + diphosphate = diphosphate + O-phospho-microsomal-membrane protein.\" [EC:2.7.99.1, MetaCyc:2.7.99.1-RXN]","metadata":null},{"id":"cede107a98ab4d74a1f14796a99c2db7","type":"GO_TERM","name":"diphosphate-serine phosphotransferase activity","canonical_id":"go:GO:0047332","description":"\"Catalysis of the reaction: L-serine + diphosphate = O-phospho-L-serine + H+ + phosphate.\" [EC:2.7.1.80, RHEA:23764]","metadata":null},{"id":"42b3467bae104fbaa98f1e12ad35c954","type":"GO_TERM","name":"diphosphoinositol pentakisphosphate 5-kinase activity","canonical_id":"go:GO:0033200","description":"\"Catalysis of the reaction: ATP + 4-diphospho-1D-myo-inositol (1,2,3,5,6)pentakisphosphate = ADP + 4,5-bisdiphosphoinositol-1D-myo-inositol (1,2,3,6)tetrakisphosphate, and ATP + 6-diphospho-1D-myo-inositol (1,2,3,4,5)pentakisphosphate = ADP + 5,6-bisdiphosphoinositol-1D-myo-inositol (1,2,3,4)tetrakisphosphate.\" [PMID:17412958]","metadata":null},{"id":"cd8a7b09cf0c410a91729e912a5986b0","type":"GO_TERM","name":"diphosphoinositol pentakisphosphate kinase activity","canonical_id":"go:GO:0000829","description":"\"Catalysis of the reaction: ATP + diphospho-1D-myo-inositol-pentakisphosphate = ADP + bis(diphospho)-1D-myo-inositol-tetrakisphosphate. The isomeric configurations of the diphospho-1D-myo-inositol-pentakisphosphate (PP-IP5) and bis(diphospho)-1D-myo-inositol-tetrakisphosphate (bis-PP-IP4) are unknown.\" [GOC:elh, PMID:16429326]","metadata":null},{"id":"fef6ed8eceb048f2877ae8eec5056b7f","type":"GO_TERM","name":"diphosphoinositol polyphosphate catabolic process","canonical_id":"go:GO:0071544","description":"\"The chemical reactions and pathways resulting in the breakdown of a diphosphoinositol polyphosphate, 1,2,3,4,5,6-cyclohexanehexol with one or more diphosphate groups and multiple monophosphate groups attached.\" [GOC:mah, PMID:12387729]","metadata":null},{"id":"dce99254ce5d4449b730d7a96e066897","type":"GO_TERM","name":"diphosphoinositol polyphosphate metabolic process","canonical_id":"go:GO:0071543","description":"\"The chemical reactions and pathways involving a diphosphoinositol polyphosphate, 1,2,3,4,5,6-cyclohexanehexol with one or more diphosphate groups and multiple monophosphate groups attached.\" [GOC:mah, PMID:12387729]","metadata":null},{"id":"be5d34b546b946f6aca2d1c691f5ea2d","type":"GO_TERM","name":"diphosphoinositol tetrakisphosphate kinase activity","canonical_id":"go:GO:0052839","description":"\"Catalysis of the reaction: ATP + diphospho-1D-myo-inositol tetrakisphosphate = ADP + bis(diphospho)-1D-myo-inositol trisphosphate.\" [PMID:10827188, PMID:11502751, PMID:18355727]","metadata":null},{"id":"8b801e6273ac4bddb65ce366481d0177","type":"GO_TERM","name":"diphosphoinositol-polyphosphate diphosphatase activity","canonical_id":"go:GO:0008486","description":"\"Catalysis of the reaction: diphospho-1D-myo-inositol polyphosphate + H2O = 1D-myo-inositol polyphosphate + phosphate.\" [EC:3.6.1.52]","metadata":null},{"id":"f202db3c8a124046ba601b8ee84ee727","type":"GO_TERM","name":"diphosphomevalonate decarboxylase activity","canonical_id":"go:GO:0004163","description":"\"Catalysis of the reaction: (R)-5-diphosphomevalonate + ATP = ADP + CO2 + H+ + isopentenyl diphosphate + phosphate.\" [EC:4.1.1.33, RHEA:23732]","metadata":null},{"id":"2323dd6b12064284a6aa4348d4af917a","type":"GO_TERM","name":"diphosphoric monoester hydrolase activity","canonical_id":"go:GO:0016794","description":"\"Catalysis of the hydrolysis of a diphosphoester, releasing a diphosphate and a free hydroxyl group.\" [EC:3.1.7.-]","metadata":null},{"id":"c51181e346244dffa39674d5f7c5b426","type":"GO_TERM","name":"diphosphotransferase activity","canonical_id":"go:GO:0016778","description":"\"Catalysis of the transfer of a diphosphate group from one compound (donor) to a another (acceptor).\" [GOC:jl, PMID:1651917]","metadata":null},{"id":"9555b70ca65740289654e3aa94c5e67b","type":"GO_TERM","name":"diphthine methyl ester synthase activity","canonical_id":"go:GO:0141133","description":"\"Catalysis of the reaction: 2-[(3S)-amino-3-carboxypropyl]-L-histidyl-[translation elongation factor 2] + 4 S-adenosyl-L-methionine = diphthine methyl ester-[translation elongation factor 2] + 3 H+ + 4 S-adenosyl-L-homocysteine.\" [PMID:24739148, RHEA:42652]","metadata":null},{"id":"1b0f892267284ef8b7c3b0f667acdea0","type":"GO_TERM","name":"diphthine methylesterase activity","canonical_id":"go:GO:0061685","description":"\"Catalysis of the reaction: diphthine methyl ester + H2O = diphthine + H+ + methanol.\" [GOC:dph, PMID:24739148, RHEA:42656]","metadata":null},{"id":"b8a13404504c473080cddf45b399640d","type":"GO_TERM","name":"diphthine synthase activity","canonical_id":"go:GO:0004164","description":"\"Catalysis of the reaction: 2-[(3S)-amino-3-carboxypropyl]-L-histidyl-[translation elongation factor 2] + 3 S-adenosyl-L-methionine = diphthine-[translation elongation factor 2] + 3 H+ + 3 S-adenosyl-L-homocysteine.\" [PMID:15485916, PMID:20873788, PMID:3042777, RHEA:36415]","metadata":null},{"id":"3995ff0085ef4f0585052066afdae0d5","type":"GO_TERM","name":"diphthine-ammonia ligase activity","canonical_id":"go:GO:0017178","description":"\"Catalysis of the reaction: ATP + diphthine + NH4 = ADP + diphthamide + H+ + phosphate.\" [EC:6.3.1.14, RHEA:19753]","metadata":null},{"id":"620342b2f03d4b518996db1e9bb6e542","type":"DRUG","name":"dipivefrine","canonical_id":"mesh:C015173","description":null,"metadata":null},{"id":"688caa6bbfe143d288f5ea3e3545416f","type":"GO_TERM","name":"diplotene","canonical_id":"go:GO:0000240","description":"\"The cell cycle phase which follows pachytene during prophase I of meiosis, during which the homologous chromosomes begin to separate and the synaptonemal complex dissolves.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"f3424321a7ea41b4be1191933f12a8af","type":"DRUG","name":"dipyridamole","canonical_id":"gtopdb:4807","description":null,"metadata":null},{"id":"ac6773ceffba4baaa2510f26697c9bb8","type":"DRUG","name":"dipyridamole","canonical_id":"chembl:CHEMBL932","description":null,"metadata":null},{"id":"9ed19f4c09d2474cad90040d4340acc8","type":"COMBINATION_TREATMENT","name":"dipyridamole + warfarin","canonical_id":"ctgov_combo:ctgov-combo-a15a587473c9fd3e","description":null,"metadata":null},{"id":"6ab588b6823e4be1960713857b446f20","type":"GO_TERM","name":"direct ossification","canonical_id":"go:GO:0036072","description":"\"The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance, that does not require the replacement of preexisting tissues.\" [GO_REF:0000034]","metadata":null},{"id":"50017f54d9fe479a91d7747604b38032","type":"GO_TERM","name":"directional guidance of interneurons involved in migration from the subpallium to the cortex","canonical_id":"go:GO:0021840","description":"\"The creation and reception of signals that control the direction of migration of interneurons as a component of the process of migration from the subpallium to the cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"ec2679ddfb4a42d88aa33546bee82826","type":"GO_TERM","name":"directional locomotion","canonical_id":"go:GO:0033058","description":"\"Self-propelled movement of a cell or organism from one location to another along an axis.\" [GOC:mtg_MIT_16mar07]","metadata":null},{"id":"f514178f9b9c461a9e16eede82805f2d","type":"GO_TERM","name":"dirigent protein activity","canonical_id":"go:GO:0102910","description":"\"Catalysis of the reaction: 2 H+ + 2 coniferol + O2 = (+)-pinoresinol + 2 H2O. The The protein encoding this activity has been termed 'dirigent protein' because it does not express any catalytic activity and serves only to bind and orientate the coniferyl alcohol-derived free radicals.\" [GOC:pz, MetaCyc:RXN-8677, PMID:37202648]","metadata":null},{"id":"5e368fd739ed49dd9478501633dc1639","type":"DRUG","name":"dirithromycin","canonical_id":"mesh:C053853","description":null,"metadata":null},{"id":"6f8e0156bf084fa7916b486384023978","type":"GO_TERM","name":"disaccharide binding","canonical_id":"go:GO:0048030","description":"\"Binding to a disaccharide. Disaccharides are sugars composed of two monosaccharide units.\" [GOC:jid]","metadata":null},{"id":"d87ed61a0b234ca1bc8080b296f8d7bd","type":"GO_TERM","name":"disaccharide biosynthetic process","canonical_id":"go:GO:0046351","description":"\"The chemical reactions and pathways resulting in the formation of disaccharides, sugars composed of two monosaccharide units.\" [GOC:ai]","metadata":null},{"id":"57967f3774e3457a86d954a11e8d99b3","type":"GO_TERM","name":"disaccharide catabolic process","canonical_id":"go:GO:0046352","description":"\"The chemical reactions and pathways resulting in the breakdown of disaccharides, sugars composed of two monosaccharide units.\" [GOC:ai]","metadata":null},{"id":"093189f10844467f9c99db0142f40b5a","type":"GO_TERM","name":"disaccharide metabolic process","canonical_id":"go:GO:0005984","description":"\"The chemical reactions and pathways involving any disaccharide, sugars composed of two monosaccharide units.\" [GOC:jl, ISBN:0192800981]","metadata":null},{"id":"5fcd2ba2e87048d2823bed528d6cd502","type":"GO_TERM","name":"disaccharide transmembrane transporter activity","canonical_id":"go:GO:0015154","description":"\"Enables the transfer of disaccharide from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"dd89620630284eeeafae0b6584cdf654","type":"GO_TERM","name":"disaccharide transport","canonical_id":"go:GO:0015766","description":"\"The directed movement of disaccharides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Disaccharides are sugars composed of two monosaccharide units.\" [GOC:ai]","metadata":null},{"id":"3ff8fe6f232a4d41be14c6df15244c76","type":"GO_TERM","name":"discadenine synthase activity","canonical_id":"go:GO:0047870","description":"\"Catalysis of the reaction: N(6)-dimethylallyladenine + S-adenosyl-L-methionine(1+) = S-methyl-5'-thioadenosine + discadenine + H+.\" [EC:2.5.1.24, RHEA:19581]","metadata":null},{"id":"776a258a31f3485eab0502011dea3bcf","type":"GO_TERM","name":"discoidal high-density lipoprotein particle","canonical_id":"go:GO:0034365","description":"\"A newly formed high-density lipoprotein particle; consists of a phospholipid bilayer surrounded by two or more APOA1 molecules. The discoidal HDL particle is formed when lipid-free or lipid-poor APOA1 acquires phospholipids and unesterified cholesterol from either cell membranes or triglyceride-rich lipoproteins (undergoing lipolysis by lipoprotein lipase).\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"61dba1ed01a2445a8d90e8591efb180b","type":"DISEASE","name":"disease of the tendon","canonical_id":"mondo:0100010","description":null,"metadata":null},{"id":"f4db962d67c942fc99e3f0e1a687cc4f","type":"GO_TERM","name":"dishabituation","canonical_id":"go:GO:0097270","description":"\"The temporary recovery of response to a stimulus when a novel stimulus is added.\" [GOC:kmv, PMID:11390637, Wikipedia:Habituation]","metadata":null},{"id":"629fe6c7e0974e43b59a5ea8ced29059","type":"DRUG","name":"disitamab vedotin","canonical_id":"gtopdb:13716","description":null,"metadata":null},{"id":"25895012a7b64c2fa1ed0bc912276f5d","type":"DRUG","name":"disitamab vedotin","canonical_id":"chembl:CHEMBL5095273","description":null,"metadata":null},{"id":"659841e65541429281c22e1c9a18ca98","type":"COMBINATION_TREATMENT","name":"disitamab vedotin + enfortumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-4f9d631d53718828","description":null,"metadata":null},{"id":"0618c7f91d054c408d5cc7bd9c6eebb0","type":"COMBINATION_TREATMENT","name":"disitamab vedotin + envafolimab","canonical_id":"ctgov_combo:ctgov-combo-f61a3d9f65fb887c","description":null,"metadata":null},{"id":"630bd6bbfaee48de87c63a680c1cef50","type":"COMBINATION_TREATMENT","name":"disitamab vedotin + famitinib","canonical_id":"ctgov_combo:ctgov-combo-573a483357d55ad8","description":null,"metadata":null},{"id":"7d629a032430404ea655c15791e2c77a","type":"COMBINATION_TREATMENT","name":"disitamab vedotin + fruquintinib","canonical_id":"ctgov_combo:ctgov-combo-6d3b703dc1291afe","description":null,"metadata":null},{"id":"469434cdc0de47aeb7821920beda4958","type":"COMBINATION_TREATMENT","name":"disitamab vedotin + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-4f98ef711953eed6","description":null,"metadata":null},{"id":"f5a15f60e79d4bf293a511ee1278a46e","type":"COMBINATION_TREATMENT","name":"disitamab vedotin + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-41d6daa5d7928758","description":null,"metadata":null},{"id":"9e35472d610e4055b0568e740dffc60b","type":"DISEASE","name":"disorder of glycogen metabolism","canonical_id":"mondo:0002412","description":null,"metadata":null},{"id":"44c220615745476fabcd03c620cfaa7e","type":"DISEASE","name":"disorder of sexual differentiation","canonical_id":"mondo:0002145","description":null,"metadata":null},{"id":"a2efcb0daae54886a585b77fe987bd62","type":"GO_TERM","name":"disordered domain specific binding","canonical_id":"go:GO:0097718","description":"\"Binding to a disordered domain of a protein.\" [GOC:gg, PMID:11746698]","metadata":null},{"id":"09ef81e955ad4663b1794b1f658936b4","type":"GO_TERM","name":"disproportionation of elemental sulfur","canonical_id":"go:GO:0019422","description":"\"The process in which sulfur compounds with an intermediate oxidation state serve as both electron donors and electron acceptors in an energy-generating redox process.\" [MetaCyc:P203-PWY]","metadata":null},{"id":"a66b96562608464aa8a5bda10632f842","type":"GO_TERM","name":"disruption of anatomical structure in another organism","canonical_id":"go:GO:0141060","description":"\"The disruption of an anatomical structure of another organism, leading to damage or temporary subversion of that structure.\" [GOC:pg]","metadata":null},{"id":"e59634cce1f94bbcac26deb2b1e4d490","type":"GO_TERM","name":"disruption of cell in another organism","canonical_id":"go:GO:0141061","description":"\"The disruption of a cell of another organism, leading to damage or temporary subversion of that cell.\" [GOC:pg]","metadata":null},{"id":"0c197356d31a45d5834d3a8587bd38fe","type":"GO_TERM","name":"disruption of cellular anatomical structure in another organism","canonical_id":"go:GO:0140975","description":"\"The disruption of a cellular component of another organism, leading to damage or temporary subversion of that structure. In some cases this can cause malfunctioning of the cells and death of the target organism.\" [GOC:pg]","metadata":null},{"id":"3c585835fa3b420698b19c3ea749e36b","type":"GO_TERM","name":"disruption of plasma membrane integrity in another organism","canonical_id":"go:GO:0051673","description":"\"The disruption of the cell membrane of another organism, leading to damage or temporary subversion of the membrane.\" [GOC:ai]","metadata":null},{"id":"a5dcc454af9b4dd182a46ff2d3700036","type":"GO_TERM","name":"disseminated nephrocyte differentiation","canonical_id":"go:GO:0061322","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a disseminated nephrocyte. A disseminated nephrocyte is an insect renal cell that filters hemolymph and is found at scattered locations in the fat body or other tissues. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.\" [CL:0002524, GOC:19783135, GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"85454d9929d6479c8ef438eeb387ab62","type":"GO_TERM","name":"dissimilatory sulfate reduction","canonical_id":"go:GO:0019420","description":"\"The reduction of sulfate to hydrogen sulfide, which acts as a terminal electron acceptor. Sulfate is activated to adenosine-phosphosulfate (APS) which is then reduced to sulfite, which is in turn reduced to hydrogen sulfide.\" [PMID:25400653, PMID:26680199]","metadata":null},{"id":"7f62bea5605148a4b5b2cb008c3877ec","type":"GO_TERM","name":"dissimilatory sulfite reductase (NADH) activity","canonical_id":"go:GO:0018551","description":"\"Catalysis of the reactions: [DsrC protein]-trisulfide + 3 H2O + NAD+ = [DsrC protein]-dithiol + 3 H+ + NADH + sulfite.\" [RHEA:78943]","metadata":null},{"id":"140ddc6fe2cf45349d6260da5de07c2c","type":"GO_TERM","name":"distal axon","canonical_id":"go:GO:0150034","description":"\"That part of an axon close to and including the growth cone or the axon terminus.\" [GOC:aruk, GOC:bc, PMID:17202468]","metadata":null},{"id":"1cee779708b648328db1e87b3c07ca19","type":"GO_TERM","name":"distal convoluted tubule development","canonical_id":"go:GO:0072025","description":"\"The process whose specific outcome is the progression of the distal convoluted tubule over time, from its formation to the mature structure. The distal convoluted tubule is the first segment of the nephron lying just downstream from the loop of Henle, immediately after the macula densa. Among other functions, in humans it is responsible for the reabsorption of about 5% of filtered sodium via the thiazide-sensitive Na-Cl symporter.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"eeb69b9b8a38443ba269c31ffece4bd0","type":"GO_TERM","name":"distal dendrite","canonical_id":"go:GO:0150002","description":"\"The dendrite of the dendritic tree that is farthest away from the neuronal cell body (the soma).\" [GOC:aruk, GOC:bc, PMID:20629984]","metadata":null},{"id":"82b7ceda3dac4e039e8911cdd0d57505","type":"GO_TERM","name":"distal portion of axoneme","canonical_id":"go:GO:0120135","description":"\"The portion of the axoneme that is close to the tip of the cilium.\" [GOC:krc]","metadata":null},{"id":"40fdd0a524c14013a8d5fb4c56be908e","type":"GO_TERM","name":"distal stomach smooth muscle contraction","canonical_id":"go:GO:0014828","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the distal stomach. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The distal stomach is composed of the lower body and antrum and develops strong peristaltic phasic contractions that increase in amplitude as they propagate toward the pylorus.\" [GOC:mtg_muscle, PMID:30252381]","metadata":null},{"id":"bd4c092a59c440a0a5674f881cd0a748","type":"GO_TERM","name":"distal tip cell migration","canonical_id":"go:GO:0097628","description":"\"The orderly movement of a distal tip cell.\" [CL:0000661, GOC:mm2, PMID:24968003]","metadata":null},{"id":"8930ebd9391541c38a213c68b97b30d1","type":"GO_TERM","name":"distal tubule development","canonical_id":"go:GO:0072017","description":"\"The process whose specific outcome is the progression of the distal tubule over time, from its formation to the mature structure. In mammals, the distal tubule is a nephron tubule that begins at the macula densa and extends to the connecting tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6b5ea802b2f8433c8d48d81eb1cf3d9f","type":"GO_TERM","name":"distal tubule morphogenesis","canonical_id":"go:GO:0072156","description":"\"The process in which the anatomical structures of a distal tubule are generated and organized. The distal tubule is a nephron tubule that begins at the macula densa and extends to the connecting tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"93585b8cef2848968b96ac11fc51749c","type":"GO_TERM","name":"distinct antral spaces stage","canonical_id":"go:GO:0048164","description":"\"The stage in oogenesis when the antral spaces become distinct and the first polar body forms.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"a0210f57886e44fb8349df25b62d7213","type":"GO_TERM","name":"distributive segregation","canonical_id":"go:GO:0032837","description":"\"The cell cycle process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets during a normally chiasmate meiosis under the condition that chiasma have not occurred between a particular pair of homologs. Distributive segregation is a backup mechanism to ensure the segregation of homologs that have failed to cross over - either as a consequence of mutation or not, as, for example, the 4th chromosome of Drosophila melanogaster (which never exchanges, presumably due to its small size) - but nevertheless segregate normally.\" [GOC:expert_rsh, GOC:ma, GOC:sart]","metadata":null},{"id":"156f6fe868284d09927b9ef19e2fc4ad","type":"GO_TERM","name":"disulfide oxidoreductase activity","canonical_id":"go:GO:0015036","description":"\"Catalysis of the reaction: substrate with reduced sulfide groups = substrate with oxidized disulfide bonds.\" [GOC:curators]","metadata":null},{"id":"0df479a1c1cc4fa4bbef5b98c7063143","type":"DRUG","name":"disulfiram","canonical_id":"mesh:D004221","description":null,"metadata":null},{"id":"ccc61f9c9eb940598cb2939f2a7c31f7","type":"GO_TERM","name":"disulfoglucosamine-6-sulfatase activity","canonical_id":"go:GO:0047871","description":"\"Catalysis of the reaction: N(2),6-disulfo-D-glucosamine + H2O = N-sulfo-D-glucosamine + H+ + sulfate.\" [EC:3.1.6.11, RHEA:15517]","metadata":null},{"id":"64e2fb5bf81e415486dfcca5d1700c15","type":"GO_TERM","name":"diterpene phytoalexin biosynthetic process","canonical_id":"go:GO:0051502","description":"\"The chemical reactions and pathways resulting in the formation of diterpene phytoalexins, terpenoids with 20 carbons produced by plants in response to environmental stresses.\" [GOC:ai]","metadata":null},{"id":"c797b4489a8d4de0bd0229ae4e9a3748","type":"GO_TERM","name":"diterpene phytoalexin precursor biosynthetic process","canonical_id":"go:GO:0051504","description":"\"A branched pathway that produces the precursors to four structurally distinct types of polycyclic diterpenes. The pathway starts with the cyclization of geranylgeranyl diphosphate into ent-copalyl diphosphate and syn-copalyl diphosphate. The catalytic conversion by diterpene cyclases of these two compounds produces the four diterpene hydrocarbons which are precursors to the four structurally distinct classes of diterpene phytoalexins.\" [MetaCyc:PWY-2981]","metadata":null},{"id":"938009279bc04c9380335fd8f5c32647","type":"GO_TERM","name":"diterpenoid biosynthetic process","canonical_id":"go:GO:0016102","description":"\"The chemical reactions and pathways resulting in the formation of diterpenoid compounds, terpenoids with four isoprene units.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"131a512fd56c4656a8869bba798e0b46","type":"GO_TERM","name":"diterpenoid catabolic process","canonical_id":"go:GO:0016103","description":"\"The chemical reactions and pathways resulting in the breakdown of diterpenoid compounds, terpenoids with four isoprene units.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"a5dc43d9424740098f57ba7b56c94386","type":"GO_TERM","name":"diterpenoid metabolic process","canonical_id":"go:GO:0016101","description":"\"The chemical reactions and pathways involving diterpenoid compounds, terpenoids with four isoprene units.\" [ISBN:0198547684]","metadata":null},{"id":"edc21d6ff7fa477ebf3f612f8a67f5cb","type":"GO_TERM","name":"ditrans,polycis-polyprenyl diphosphate synthase [(2E,6E)-farnesyl diphosphate specific] activity","canonical_id":"go:GO:0045547","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + n isopentenyl diphosphate = a di-trans,poly-cis-polyprenyl diphosphate + n diphosphate.\" [PMID:9858571, RHEA:53008]","metadata":null},{"id":"7644fbfba3844806bf90cbc4743ab67d","type":"GO_TERM","name":"ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] activity","canonical_id":"go:GO:0008834","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + 8 isopentenyl diphosphate = di-trans,octa-cis-undecaprenyl diphosphate + 8 diphosphate.\" [RHEA:27551]","metadata":null},{"id":"77b674618b6349eaae281978430fcffb","type":"GO_TERM","name":"dityrosine layer of spore wall","canonical_id":"go:GO:0005630","description":"\"The outermost layer of the spore wall, as described in Saccharomyces.\" [ISBN:0879693568]","metadata":null},{"id":"7f2852bc78d44d8087fb0503872b3d7d","type":"GO_TERM","name":"diuretic hormone activity","canonical_id":"go:GO:0008613","description":"\"The action characteristic of a diuretic hormone, a peptide hormone that, upon receptor binding, regulates water balance and fluid secretion.\" [GOC:mah, InterPro:IPR003621, PMID:8618894]","metadata":null},{"id":"19f832afa14c475196d58629b299bb33","type":"GO_TERM","name":"diuretic hormone receptor activity","canonical_id":"go:GO:0008036","description":"\"Combining with a diuretic hormone and transmitting the signal to initiate a change in cell activity.\" [GOC:ai, GOC:signaling]","metadata":null},{"id":"90f19577a7da4dda91c6aaeed8d14978","type":"DISEASE","name":"diverticular disease","canonical_id":"efo:0009959","description":null,"metadata":null},{"id":"611c339c23324dbc811019665fa02c01","type":"GO_TERM","name":"division septum","canonical_id":"go:GO:0000935","description":"\"A cell septum which forms as part of the division site and functions in the compartmentalization of a cell into two daughter cells at division. A division septum spans a cell and does not allow exchange of organelles or cytoplasm between compartments.\" [GOC:clt, GOC:vw]","metadata":null},{"id":"05e53eecd27d4d3b9b48d6516961ffea","type":"GO_TERM","name":"division septum assembly","canonical_id":"go:GO:0000917","description":"\"The assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis. The progeny cells that form a division septum are not able to exchange intracellular material.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"fb67bff0c72c454292df43e9d1500307","type":"GO_TERM","name":"division septum site selection","canonical_id":"go:GO:0000918","description":"\"The process of marking the site where a division septum will form.\" [GOC:clt]","metadata":null},{"id":"07e76a6ea0524654a1da9428c1b815d3","type":"GO_TERM","name":"divisome complex","canonical_id":"go:GO:1990586","description":"\"A protein complex required for prokaryotic cell division (FtsZ-dependent cytokinesis). These complexes are assembled and recruited to the cell septum in a strictly controlled sequence and co-ordinate invagination of the cell membrane, inward growth of the peptidoglycan layer, constriction of the outer membrane and separation of daughter cells.\" [GOC:bhm, PMID:15165235, PMID:21784946]","metadata":null},{"id":"7017ee147d6c40678383521433f83ac3","type":"DRUG","name":"divozilimab","canonical_id":"gtopdb:13087","description":null,"metadata":null},{"id":"b51caeb4f44f45ff8da7be8ddbe31e08","type":"DRUG","name":"dobutamine","canonical_id":"gtopdb:535","description":null,"metadata":null},{"id":"8fff18eef8244569a73127a97daa86fc","type":"DRUG","name":"dobutamine","canonical_id":"mesh:D004280","description":null,"metadata":null},{"id":"67aa4d66576440559c00639efa133af8","type":"COMBINATION_TREATMENT","name":"dobutamine + milrinone","canonical_id":"ctgov_combo:ctgov-combo-a11ee9d0d935ed09","description":null,"metadata":null},{"id":"bd96eeff0c154db785058f3d97c507a9","type":"COMBINATION_TREATMENT","name":"dobutamine + milrinone","canonical_id":"ctgov_combo:ctgov-combo-a0f57f457c685e22","description":null,"metadata":null},{"id":"6b29747c18f8400a84a6a371db2473b9","type":"COMBINATION_TREATMENT","name":"dobutamine + phenylephrine","canonical_id":"ctgov_combo:ctgov-combo-b8891032b2f00747","description":null,"metadata":null},{"id":"8ab93a0acf6b4c0eba1263eb5290534d","type":"DRUG","name":"docetaxel","canonical_id":"gtopdb:6809","description":null,"metadata":null},{"id":"01651c03c82242299677fa0391606243","type":"DRUG","name":"docetaxel","canonical_id":"chembl:CHEMBL3545252","description":null,"metadata":null},{"id":"df32f3c4d8e94844b66de4c5744c56d5","type":"COMBINATION_TREATMENT","name":"docetaxel + durvalumab","canonical_id":"ctgov_combo:ctgov-combo-6f40515e93baec1c","description":null,"metadata":null},{"id":"363a91f6a6d64210aaa91913447c6e03","type":"COMBINATION_TREATMENT","name":"docetaxel + duvelisib","canonical_id":"ctgov_combo:ctgov-combo-1ba076487e11f60e","description":null,"metadata":null},{"id":"35598301c00f45b7a98bbeea4c1e52ec","type":"COMBINATION_TREATMENT","name":"docetaxel + gedatolisib","canonical_id":"ctgov_combo:ctgov-combo-1962ee63a2b3177a","description":null,"metadata":null},{"id":"b9565b5feacf4837b55690f525669af8","type":"COMBINATION_TREATMENT","name":"docetaxel + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-e193d5b40b7a73b0","description":null,"metadata":null},{"id":"bd3794e1b77f47239d1043ca96054d86","type":"COMBINATION_TREATMENT","name":"docetaxel + lapatinib + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-9b2c1f9483762fcd","description":null,"metadata":null},{"id":"861e2130a48e4968a5280e624d987cfd","type":"COMBINATION_TREATMENT","name":"docetaxel + nintedanib","canonical_id":"ctgov_combo:ctgov-combo-0f407ee62622ed41","description":null,"metadata":null},{"id":"64b1a9bcb05d418cbd88af9275292259","type":"COMBINATION_TREATMENT","name":"docetaxel + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-097ef971b1c48324","description":null,"metadata":null},{"id":"3442385bb36e4107a0034191d3f9390b","type":"COMBINATION_TREATMENT","name":"docetaxel + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-ecca464d83286148","description":null,"metadata":null},{"id":"764eceeb115d4e7288cffcbdc1bc5295","type":"COMBINATION_TREATMENT","name":"docetaxel + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-c94a48bab749f3ee","description":null,"metadata":null},{"id":"15f992deae494e4f9b711cd0456090bd","type":"COMBINATION_TREATMENT","name":"docetaxel + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-45e5a02a00fa0ad8","description":null,"metadata":null},{"id":"3223cff8d35c4538b0b4813e56b8cbbc","type":"COMBINATION_TREATMENT","name":"docetaxel + pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-6e93132e3893b012","description":null,"metadata":null},{"id":"b30bf99de293405b8702eeeccf19901d","type":"COMBINATION_TREATMENT","name":"docetaxel + prednisone","canonical_id":"ctgov_combo:ctgov-combo-899fd2684df17080","description":null,"metadata":null},{"id":"58f0fb03a7a94f4e83424e04c128c629","type":"GO_TERM","name":"dodecyl sulfate metabolic process","canonical_id":"go:GO:0018909","description":"\"The chemical reactions and pathways involving dodecyl sulfate, commonly found as sodium dodecyl sulfate (SDS), a component of a variety of synthetic surfactants.\" [UM-BBD_pathwayID:dds]","metadata":null},{"id":"ffbcb013b8dc4cc6bdf5717f24806ed7","type":"DRUG","name":"dofetilide","canonical_id":"gtopdb:2604","description":null,"metadata":null},{"id":"60a90c4e21f3479eb58af51a0eceff0a","type":"DRUG","name":"dofetilide","canonical_id":"mesh:C063533","description":null,"metadata":null},{"id":"088785584d964b5d8471972ddade669a","type":"DRUG","name":"dofetilide","canonical_id":"chembl:CHEMBL473","description":null,"metadata":null},{"id":"9d30ac74836146418c5d6b294f21f8f8","type":"COMBINATION_TREATMENT","name":"dofetilide + mexiletine","canonical_id":"ctgov_combo:ctgov-combo-6f2c3a8f74ca1bba","description":null,"metadata":null},{"id":"48f27d88771e47b399c96db5f796bf70","type":"COMBINATION_TREATMENT","name":"dofetilide + propafenone","canonical_id":"ctgov_combo:ctgov-combo-0a148e72576e1976","description":null,"metadata":null},{"id":"df1b7ad41ef74ec291c8ed5fd2ae9b42","type":"COMBINATION_TREATMENT","name":"dofetilide + propafenone","canonical_id":"ctgov_combo:ctgov-combo-a4a8b9fab16aa387","description":null,"metadata":null},{"id":"4857d15a951d4008a5a40434ce94290b","type":"COMBINATION_TREATMENT","name":"dofetilide + propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-80b5bf42d2843f95","description":null,"metadata":null},{"id":"8aef68786a234138846e643ca0b52990","type":"COMBINATION_TREATMENT","name":"dofetilide + propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-e2036d7c01cb8550","description":null,"metadata":null},{"id":"23e8eddcba11433eb99e0df4e7ad5fd3","type":"COMBINATION_TREATMENT","name":"dofetilide + sotalol","canonical_id":"ctgov_combo:ctgov-combo-744be4a74188c9d5","description":null,"metadata":null},{"id":"03397d0dcb80431b8048a739343301c6","type":"COMBINATION_TREATMENT","name":"dofetilide + sotalol","canonical_id":"ctgov_combo:ctgov-combo-4b24a3e5f827f9d4","description":null,"metadata":null},{"id":"c345439715b74d5a99349d1de6323dcc","type":"GO_TERM","name":"dol-P-Man:GlcN-acyl-PI alpha-1,4-mannosyltransferase activity","canonical_id":"go:GO:0180041","description":"\"Catalysis of the reaction: a 2-acyl-6-alpha-D-glucosaminyl-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol + a di-trans,poly-cis-dolichyl beta-D-mannosyl phosphate = a 2-acyl-6-(alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl)-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol + a di-trans,poly-cis-dolichyl phosphate + H+.\" [PMID:11226175, PMID:15635094, RHEA:60500]","metadata":null},{"id":"427debbfd5e44ce39fdfab1a3dc76b39","type":"GO_TERM","name":"dol-P-Man:Man(1)GlcN-acyl-PI alpha-1,6-mannosyltransferase activity","canonical_id":"go:GO:0120563","description":"\"Catalysis of the transfer of an alpha-D-mannosyl residue from dolichol-P-mannose to Man(1)-GlcN-acyl-PI, forming an alpha-(1->6)-D-mannosyl-D-mannose linkage. This transfers the second mannose to the GPI precursor.\" [PMID:15623507]","metadata":null},{"id":"43385ac20e8041eebc5009527c49f32c","type":"GO_TERM","name":"dol-P-Man:Man(2)GlcN-acyl-PI alpha-1,2-mannosyltransferase activity","canonical_id":"go:GO:0120564","description":"\"Catalysis of the transfer of an alpha-D-mannosyl residue from dolichol-P-mannose to Man(2)-GlcN-acyl-PI, forming an alpha-(1->2)-D-mannosyl-D-mannose linkage. This transfers the third mannose to the GPI precursor.\" [PMID:8861954]","metadata":null},{"id":"069c21de6e49458cb9d9b5b753433d84","type":"GO_TERM","name":"dol-P-Man:Man(3)GlcN-acyl-PI alpha-1,2-mannosyltransferase activity","canonical_id":"go:GO:0120565","description":"\"Catalysis of the transfer of an alpha-D-mannosyl residue from dolichol-P-mannose to Man(3)-GlcN-acyl-PI, forming an alpha-(1->2)-D-mannosyl-D-mannose linkage. This transfers a fourth mannose to the GPI precursor, which is only present in some organisms/cell types.\" [PMID:15208306]","metadata":null},{"id":"5bbdbd2b21e74fa09e0a450e668b403e","type":"GO_TERM","name":"dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase activity","canonical_id":"go:GO:0052925","description":"\"Catalysis of the reaction: an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl beta-D-mannosyl phosphate = an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl phosphate + H+.\" [RHEA:29527]","metadata":null},{"id":"c6bf3a3472d141aeb3c2e6b231572242","type":"GO_TERM","name":"dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity","canonical_id":"go:GO:0052926","description":"\"Catalysis of the reaction: an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl beta-D-mannosyl phosphate = an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl phosphate + H+.\" [RHEA:29531]","metadata":null},{"id":"130fe231a58c460fbe4258668e8113d3","type":"GO_TERM","name":"dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase activity","canonical_id":"go:GO:0052917","description":"\"Catalysis of the reaction: an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl beta-D-mannosyl phosphate = an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl phosphate + H+.\" [PMID:10336995, RHEA:29535]","metadata":null},{"id":"6b982329d9734fc48a58f54d1a99d114","type":"GO_TERM","name":"dol-P-Man:Man(8)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase activity","canonical_id":"go:GO:0052918","description":"\"Catalysis of the reaction: an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl beta-D-mannosyl phosphate = an alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-alpha-D-GlcNAc-diphospho-di-trans,poly-cis-dolichol + a di-trans,poly-cis-dolichyl phosphate + H+.\" [RHEA:29539]","metadata":null},{"id":"7685b581b51d4205b022dfefc60eff19","type":"GO_TERM","name":"dolichal reductase (NADPH) activity","canonical_id":"go:GO:0160197","description":"\"Catalysis of the reaction: a di-trans,poly-cis-dolichol + NADP+ = a di-trans,poly-cis-dolichal + NADPH + H+.\" [PMID:38821050, RHEA:80731]","metadata":null},{"id":"4b45c5a5b8624bf7a80aeb0384df7191","type":"GO_TERM","name":"dolichol O-acyltransferase activity","canonical_id":"go:GO:0047872","description":"\"Catalysis of the reaction: palmitoyl-CoA + dolichol = CoA + dolichyl palmitate.\" [EC:2.3.1.123, MetaCyc:DOLICHOL-O-ACYLTRANSFERASE-RXN]","metadata":null},{"id":"a8c9f0cdd54d4bb799802b57379e3013","type":"GO_TERM","name":"dolichol kinase activity","canonical_id":"go:GO:0004168","description":"\"Catalysis of the reaction: CTP + dolichol = CDP + dolichyl phosphate.\" [EC:2.7.1.108]","metadata":null},{"id":"5fa415f2311841978dc16f6fefaaae3e","type":"GO_TERM","name":"dolichol phosphate mannose biosynthetic process","canonical_id":"go:GO:0180047","description":"\"The chemical reactions and pathways resulting in the formation of dolichol phosphate mannose.\" [PMID:18387370]","metadata":null},{"id":"d811cf99e48c4f8388b45475440790b3","type":"GO_TERM","name":"dolichol-linked oligosaccharide biosynthetic process","canonical_id":"go:GO:0006488","description":"\"The chemical reactions and pathways resulting in the formation of dolichol-linked oligosaccharide, usually by a stepwise addition of glycosyl chains to endoplasmic reticulum membrane-bound dolichol-P.\" [GOC:jl, ISBN:0471331309]","metadata":null},{"id":"b4820ef0a51d4f418bdc0dd9db636420","type":"GO_TERM","name":"dolichol-phosphate-mannose synthase complex","canonical_id":"go:GO:0033185","description":"\"A protein complex that possesses dolichyl-phosphate beta-D-mannosyltransferase activity; contains a catalytic subunit, a regulatory subunit, and a third subunit that stabilizes the complex. In human and several other metazoa, the subunits are named DPM1, DPM2 and DPM3, respectively.\" [PMID:10835346]","metadata":null},{"id":"7f352ac20c2d4af7b8e58751bb0811f8","type":"GO_TERM","name":"dolichol-phosphate-mannose synthase regulator activity","canonical_id":"go:GO:0097713","description":"\"Binds to and modulates the activity of dolichol-phosphate-mannose synthase.\" [GOC:vw, PMID:10835346]","metadata":null},{"id":"7cfd25d128ac4744af377a4601215d58","type":"GO_TERM","name":"dolichyl diphosphate biosynthetic process","canonical_id":"go:GO:0006489","description":"\"The chemical reactions and pathways resulting in the formation of dolichyl diphosphate, a diphosphorylated dolichol derivative.\" [ISBN:0198506732]","metadata":null},{"id":"bef26f0886854ac99480eae3d5efe814","type":"GO_TERM","name":"dolichyl monophosphate biosynthetic process","canonical_id":"go:GO:0043048","description":"\"The chemical reactions and pathways resulting in the formation of dolichyl monophosphate, a phosphorylated dolichol derivative.\" [MetaCyc:PWY-6129, PMID:21384228, PMID:38821050]","metadata":null},{"id":"e73b9df4c8a64323a27e38f683090dc8","type":"GO_TERM","name":"dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase activity","canonical_id":"go:GO:0042283","description":"\"Catalysis of the addition of the second glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation; the transfer of glucose from dolichyl phosphate glucose (Dol-P-Glc) on to the lipid-linked oligosaccharide Glc(1)Man(9)GlcNAc(2)-PP-Dol.\" [MetaCyc:RXN-5471, PMID:12480927]","metadata":null},{"id":"5b85a3bbe6bb47eea9259abd882c738c","type":"GO_TERM","name":"dolichyl pyrophosphate Glc2Man9GlcNAc2 alpha-1,2-glucosyltransferase activity","canonical_id":"go:GO:0106073","description":"\"Catalysis of the addition of the third glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation; the transfer of glucose from dolichyl phosphate glucose (Dol-P-Glc) on to the lipid-linked oligosaccharide Glc(2)Man(9)GlcNAc(2)-PP-Dol.\" [GOC:ha, PMID:9597543]","metadata":null},{"id":"9478c0cfb2bc416080355fa3a47c0e63","type":"GO_TERM","name":"dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase activity","canonical_id":"go:GO:0042281","description":"\"Catalysis of the addition of the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation; the transfer of glucose from dolichyl phosphate glucose (Dol-P-Glc) on to the lipid-linked oligosaccharide Man(9)GlcNAc(2)-PP-Dol.\" [GOC:al, MetaCyc:RXN-5470]","metadata":null},{"id":"8d159a81b019486f846cce518889d752","type":"GO_TERM","name":"dolichyl-diphosphate-polyphosphate phosphotransferase activity","canonical_id":"go:GO:0047337","description":"\"Catalysis of the reaction: dolichyl diphosphate + long-chain-polyphosphate = dolichol-phosphate + long-chain-polyphosphate.\" [EC:2.7.4.20, MetaCyc:2.7.4.20-RXN]","metadata":null},{"id":"aba8b8982b854c86a83d8bb85713aa62","type":"GO_TERM","name":"dolichyl-diphosphooligosaccharide-protein glycotransferase activity","canonical_id":"go:GO:0004579","description":"\"Catalysis of the reaction: dolichyl diphosphooligosaccharide + protein L-asparagine = dolichyl diphosphate + a glycoprotein with the oligosaccharide chain attached by glycosylamine linkage to protein L-asparagine.\" [RHEA:22980]","metadata":null},{"id":"55e26400ab7f470da36c4e7ce23b095b","type":"GO_TERM","name":"dolichyl-phosphatase activity","canonical_id":"go:GO:0047873","description":"\"Catalysis of the reaction: dolichyl phosphate + H2O = dolichol + phosphate.\" [EC:3.1.3.51, MetaCyc:DOLICHYL-PHOSPHATASE-RXN]","metadata":null},{"id":"540ffa0a49e84ed38130837334584492","type":"GO_TERM","name":"dolichyl-phosphate D-xylosyltransferase activity","canonical_id":"go:GO:0047283","description":"\"Catalysis of the reaction: dolichol-phosphate + UDP-D-xylose = dolichyl D-xylosyl phosphate + UDP.\" [EC:2.4.2.32, MetaCyc:2.4.2.32-RXN]","metadata":null},{"id":"b7536f91d5cf4358b9bc0ef9c88204ee","type":"GO_TERM","name":"dolichyl-phosphate alpha-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0004166","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + dolichyl phosphate = UDP + dolichyl N-acetyl-alpha-D-glucosaminyl phosphate.\" [EC:2.4.1.153]","metadata":null},{"id":"37789ed304084bf081ac9ea0e821a3aa","type":"GO_TERM","name":"dolichyl-phosphate beta-D-mannosyltransferase activity","canonical_id":"go:GO:0004582","description":"\"Catalysis of the reaction: GDP-mannose + dolichyl phosphate = GDP + dolichyl D-mannosyl phosphate.\" [EC:2.4.1.83]","metadata":null},{"id":"0395c1e97d894a5cb439d7bb0efcbf72","type":"GO_TERM","name":"dolichyl-phosphate beta-glucosyltransferase activity","canonical_id":"go:GO:0004581","description":"\"Catalysis of the reaction: UDP-glucose + dolichyl phosphate = UDP + dolichyl beta-D-glucosyl phosphate.\" [EC:2.4.1.117]","metadata":null},{"id":"b77a5091ed0345d9b0097e708632d01b","type":"GO_TERM","name":"dolichyl-phosphate-glucose-glycolipid alpha-glucosyltransferase activity","canonical_id":"go:GO:0004583","description":"\"Catalysis of the transfer of an alpha-D-glucosyl residue from dolichyl-phosphate D-glucose into a membrane lipid-linked oligosaccharide.\" [GOC:mah]","metadata":null},{"id":"f2dfb7b7f4024b249dd741faa7cbeab7","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase Pmt1p-Pmt2p dimer complex","canonical_id":"go:GO:0097582","description":"\"A protein dimer complex that possesses dolichyl-phosphate-mannose-protein mannosyltransferase activity and, in S. cerevisiae, is composed of Pmt1p-Pmt2p.\" [GOC:jd, PMID:12551906]","metadata":null},{"id":"400f6fee55e04b778088fc38b82107e7","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase Pmt1p-Pmt3p dimer complex","canonical_id":"go:GO:0097583","description":"\"A protein dimer complex that possesses dolichyl-phosphate-mannose-protein mannosyltransferase activity and, in S. cerevisiae, is composed of Pmt1p-Pmt3p.\" [GOC:jd, PMID:12551906]","metadata":null},{"id":"75de402a1bcb46918bdcf6d9078f2e8a","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase Pmt4p homodimer complex","canonical_id":"go:GO:0097586","description":"\"A protein dimer complex that possesses dolichyl-phosphate-mannose-protein mannosyltransferase activity and, in S. cerevisiae, is composed of Pmt4p.\" [GOC:bhm, GOC:jd, PMID:12551906]","metadata":null},{"id":"f70787272e1c436487e6a92db633bc2d","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase Pmt5p-Pmt2p dimer complex","canonical_id":"go:GO:0097584","description":"\"A protein dimer complex that possesses dolichyl-phosphate-mannose-protein mannosyltransferase activity and, in S. cerevisiae, is composed of Pmt5p-Pmt2p.\" [GOC:jd, PMID:12551906]","metadata":null},{"id":"c48c977e48714542bf149360c86a4368","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase Pmt5p-Pmt3p dimer complex","canonical_id":"go:GO:0097585","description":"\"A protein dimer complex that possesses dolichyl-phosphate-mannose-protein mannosyltransferase activity and, in S. cerevisiae, is composed of Pmt5p-Pmt3p.\" [GOC:jd, PMID:12551906]","metadata":null},{"id":"52529353824343069679ca8eb698f727","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase activity","canonical_id":"go:GO:0004169","description":"\"Catalysis of the reaction: dolichyl phosphate D-mannose + protein = dolichyl phosphate + O-D-mannosylprotein.\" [EC:2.4.1.109, GOC:pr]","metadata":null},{"id":"db8124c1fd8548a4a35e552348a21a51","type":"GO_TERM","name":"dolichyl-phosphate-mannose-protein mannosyltransferase complex","canonical_id":"go:GO:0031502","description":"\"A complex that possesses dolichyl-phosphate-mannose-protein mannosyltransferase activity; usually includes members of the PMT1 and PMT2 protein subfamilies.\" [GOC:mah, GOC:pr, PMID:15948957]","metadata":null},{"id":"763152fcc1c8401b8ed1bb5de9840ccf","type":"GO_TERM","name":"dolichyl-xylosyl-phosphate-protein xylosyltransferase activity","canonical_id":"go:GO:0047284","description":"\"Catalysis of the reaction: dolichyl D-xylosyl phosphate + protein = dolichol-phosphate + D-xylosylprotein.\" [EC:2.4.2.33, MetaCyc:2.4.2.33-RXN]","metadata":null},{"id":"993250c345cc4c008f30703e32e1423a","type":"GO_TERM","name":"dolichyldiphosphatase activity","canonical_id":"go:GO:0047874","description":"\"Catalysis of the reaction: a di-trans,poly-cis-dolichyl diphosphate + H2O = a di-trans,poly-cis-dolichyl phosphate + phosphate + H+.\" [RHEA:14385]","metadata":null},{"id":"cd1a66070a5c409bbbb6cf6b54d1ca91","type":"GO_TERM","name":"dolichylphosphate-glucose phosphodiesterase activity","canonical_id":"go:GO:0047397","description":"\"Catalysis of the reaction: dolichyl beta-D-glucosyl phosphate + H2O = dolichol-phosphate + beta-D-glucose.\" [EC:3.1.4.48, MetaCyc:3.1.4.48-RXN]","metadata":null},{"id":"9b85f248e1c94c21ae1d93b228d7b092","type":"GO_TERM","name":"dolichylphosphate-mannose phosphodiesterase activity","canonical_id":"go:GO:0047398","description":"\"Catalysis of the reaction: dolichyl beta-D-mannosyl phosphate + H2O = dolichol-phosphate + mannose.\" [EC:3.1.4.49, MetaCyc:3.1.4.49-RXN]","metadata":null},{"id":"7cc279cc1b4446d5a2d6f9b7e6bd0617","type":"GO_TERM","name":"dolipore septum","canonical_id":"go:GO:0000937","description":"\"A septum, or cross-wall, between two portions of a cell or hypha; contains a central pore around which the septum is swollen to form a barrel-shaped structure; pore is covered on each side of the septum by a septal pore cap (parenthosome).\" [GOC:clt]","metadata":null},{"id":"2aed3e33da204e599d193b6a7953edd1","type":"DRUG","name":"dolutegravir","canonical_id":"mesh:C562325","description":null,"metadata":null},{"id":"8e2052cb08c94ed0bcd1b37393e7048f","type":"DRUG","name":"domperidone","canonical_id":"gtopdb:965","description":null,"metadata":null},{"id":"99b4ebdbfddd4aec9e7d0163ee121213","type":"DRUG","name":"domperidone","canonical_id":"chembl:CHEMBL219916","description":null,"metadata":null},{"id":"6364e4a99346425da08538c94ff4d08d","type":"COMBINATION_TREATMENT","name":"domperidone + loperamide","canonical_id":"ctgov_combo:ctgov-combo-65122dc3e9213cb9","description":null,"metadata":null},{"id":"18b2bc037cbe4b968769400726089bf6","type":"COMBINATION_TREATMENT","name":"domperidone + sulpiride","canonical_id":"ctgov_combo:ctgov-combo-413fbe23f1a48489","description":null,"metadata":null},{"id":"58e7ee1a6a2e41aca47a8f4362505672","type":"DRUG","name":"donepezil","canonical_id":"gtopdb:6599","description":null,"metadata":null},{"id":"a5f5fb1a182c420c86a416b17884c0ee","type":"DRUG","name":"donepezil","canonical_id":"mesh:C076946","description":null,"metadata":null},{"id":"561fa10d0e3e484f8b3543a53b0cd45a","type":"COMBINATION_TREATMENT","name":"donepezil + duloxetine","canonical_id":"ctgov_combo:ctgov-combo-736c02911f204c49","description":null,"metadata":null},{"id":"eba0918ce3ac4cb08cbadb69a726fc0b","type":"COMBINATION_TREATMENT","name":"donepezil + duloxetine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-36f786e979c75ddd","description":null,"metadata":null},{"id":"7f2b60458fab4c41b383de1c4ffe0ab0","type":"COMBINATION_TREATMENT","name":"donepezil + scopolamine","canonical_id":"ctgov_combo:ctgov-combo-db89f62c8ccfc827","description":null,"metadata":null},{"id":"67d878e92bd34a4ab4aa4bda6ed8e3ea","type":"COMBINATION_TREATMENT","name":"donepezil + selegiline","canonical_id":"ctgov_combo:ctgov-combo-774e849bc63e5966","description":null,"metadata":null},{"id":"22b83101098747a98492bceb8e8c7890","type":"GO_TERM","name":"donor selection","canonical_id":"go:GO:0007535","description":"\"The process that determines which donor locus a cell uses, in preference to another, in mating type switching.\" [GOC:mah, PMID:9928492]","metadata":null},{"id":"0907dac2decd4f9397841dde36433b48","type":"DISEASE","name":"dopa-responsive dystonia","canonical_id":"mondo:0016812","description":null,"metadata":null},{"id":"696ec097c0ca48849d2492c337341f60","type":"GO_TERM","name":"dopachrome isomerase activity","canonical_id":"go:GO:0004167","description":"\"Catalysis of the reaction: L-dopachrome = 5,6-dihydroxyindole-2-carboxylate.\" [EC:5.3.3.12, RHEA:13041]","metadata":null},{"id":"858f68e5689d4fa4b2a7eceeab596044","type":"DRUG","name":"dopamine","canonical_id":"gtopdb:940","description":null,"metadata":null},{"id":"b1661d13986348c3839b3e1482539cd2","type":"DRUG","name":"dopamine","canonical_id":"mesh:D004298","description":null,"metadata":null},{"id":"3f08238c5dd04dcfb74ea894ac4cc231","type":"GO_TERM","name":"dopamine beta-monooxygenase activity","canonical_id":"go:GO:0004500","description":"\"Catalysis of the reaction: L-ascorbate + dopamine + O2 = (R)-noradrenaline + dehydroascorbate + H2O.\" [EC:1.14.17.1, RHEA:19117]","metadata":null},{"id":"e87571a4af224d8cb93162624a68507b","type":"GO_TERM","name":"dopamine binding","canonical_id":"go:GO:0035240","description":"\"Binding to dopamine, a catecholamine neurotransmitter formed by aromatic-L-amino-acid decarboxylase from 3,4-dihydroxy-L-phenylalanine.\" [ISBN:0198506732]","metadata":null},{"id":"c4f64a649c964d1a8ee6450c8296afad","type":"GO_TERM","name":"dopamine biosynthetic process","canonical_id":"go:GO:0042416","description":"\"The chemical reactions and pathways resulting in the formation of dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"61ab3840ce2042eab97f324013e8a69f","type":"GO_TERM","name":"dopamine biosynthetic process from tyrosine","canonical_id":"go:GO:0006585","description":"\"The chemical reactions and pathways resulting in the formation of dopamine (3,4-dihydroxyphenylethylamine) from L-tyrosine, via the metabolic precursor 3,4-dihydroxy-L-phenylalanine (L-dopa). Dopamine is a catecholamine neurotransmitter and a metabolic precursor of norepinephrine and epinephrine.\" [GOC:bf, GOC:jl, ISBN:0198506732]","metadata":null},{"id":"c44ffd1e92ad40f1bc4bccbd69da3363","type":"GO_TERM","name":"dopamine catabolic process","canonical_id":"go:GO:0042420","description":"\"The chemical reactions and pathways resulting in the breakdown of dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"95ba71d0ce894d7a970746c9fa0aefef","type":"GO_TERM","name":"dopamine loading into synaptic vesicle","canonical_id":"go:GO:0160310","description":"\"The active transport of dopamine neurotransmitters into a synaptic vesicle.\" [PMID:29666153]","metadata":null},{"id":"73da23369d47403691b047c497093fe7","type":"GO_TERM","name":"dopamine metabolic process","canonical_id":"go:GO:0042417","description":"\"The chemical reactions and pathways involving dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"ffa2470fad994a36a9763d9142497f83","type":"GO_TERM","name":"dopamine neurotransmitter receptor activity","canonical_id":"go:GO:0004952","description":"\"Combining with the neurotransmitter dopamine to initiate a change in cell activity.\" [GOC:PARL, IUPHAR_GPCR:1282, PMID:21711983]","metadata":null},{"id":"0c2b09c565304d848c26b706d5841eb7","type":"GO_TERM","name":"dopamine neurotransmitter receptor activity, coupled via Gi/Go","canonical_id":"go:GO:0001591","description":"\"Combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gi/Go to initiate a change in cell activity.\" [GOC:mah, ISBN:0953351033, IUPHAR_RECEPTOR:2254, IUPHAR_RECEPTOR:2256, IUPHAR_RECEPTOR:2258]","metadata":null},{"id":"275a9b0204a541118f6136300b695fe3","type":"GO_TERM","name":"dopamine neurotransmitter receptor activity, coupled via Gs","canonical_id":"go:GO:0001588","description":"\"Combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gs to initiate a change in cell activity.\" [GOC:mah, ISBN:0953351033, IUPHAR_RECEPTOR:2252, IUPHAR_RECEPTOR:2260]","metadata":null},{"id":"582bf9d57e214c79a90e4ade4ef59439","type":"GO_TERM","name":"dopamine receptor binding","canonical_id":"go:GO:0050780","description":"\"Binding to a dopamine receptor.\" [GOC:ai]","metadata":null},{"id":"cff0121f0caf4fcea759a09500f4fe88","type":"GO_TERM","name":"dopamine secretion","canonical_id":"go:GO:0014046","description":"\"The regulated release of dopamine by a cell. Dopamine is a catecholamine and a precursor of adrenaline and noradrenaline. It acts as a neurotransmitter in the central nervous system but it is also produced peripherally and acts as a hormone.\" [GOC:ef]","metadata":null},{"id":"e32d5aec331a42e78715d632d4c1fefa","type":"GO_TERM","name":"dopamine secretion, neurotransmission","canonical_id":"go:GO:0061527","description":"\"The regulated release of dopamine by a cell in which the dopamine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"44a57e15e1664103b5f0e613a7ff903f","type":"GO_TERM","name":"dopamine uptake","canonical_id":"go:GO:0090494","description":"\"The directed movement of dopamine into a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"84e67c47345540acaa7698e3718a1dd1","type":"GO_TERM","name":"dopamine uptake involved in synaptic transmission","canonical_id":"go:GO:0051583","description":"\"The directed movement of dopamine into a presynaptic neuron or glial cell. In this context, dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.\" [GOC:ai]","metadata":null},{"id":"f2f8379cbe394c428a6e2c5c905fd033","type":"GO_TERM","name":"dopamine:sodium symporter activity","canonical_id":"go:GO:0005330","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: dopamine(out) + Na+(out) + Cl-(out)= dopamine(in) + Na+(in) + Cl-(in).\" [PMID:21752877, PMID:22519513, TC:2.A.22.1.3]","metadata":null},{"id":"f711cf65a6c64b6b8c0f13f8c159fadc","type":"GO_TERM","name":"dopaminechrome tautomerase activity","canonical_id":"go:GO:0106417","description":"\"Catalysis of the reaction: dopaminechrome = 5,6-dihydroxyindole.\" [PMID:34388859, RHEA:70199]","metadata":null},{"id":"f5949432a00a4494aa9b1e8ec47d3dfc","type":"GO_TERM","name":"dopaminergic neuron axon guidance","canonical_id":"go:GO:0036514","description":"\"The chemotaxis process that directs the migration of an axon growth cone of a dopaminergic neuron to a specific target site in response to a combination of attractive and repulsive cues.\" [GOC:bf, GOC:PARL, PMID:21106844, PMID:23517308]","metadata":null},{"id":"4a76f21770bd4708b783d50eb688e8e8","type":"GO_TERM","name":"dopaminergic neuron differentiation","canonical_id":"go:GO:0071542","description":"\"The process in which a neuroblast acquires the specialized structural and functional features of a dopaminergic neuron, a neuron that secretes dopamine.\" [GOC:rph]","metadata":null},{"id":"ce40525317134867833293ba72ec5c77","type":"GO_TERM","name":"dopaminergic synapse","canonical_id":"go:GO:0098691","description":"\"A synapse that uses dopamine as a neurotransmitter.\" [GOC:dos]","metadata":null},{"id":"d56a7182da804cf6a2fc465a96804ceb","type":"GO_TERM","name":"dormancy entry of symbiont in host","canonical_id":"go:GO:0085014","description":"\"Entry into a dormant state of the symbiont within the host organism.\" [GOC:jl]","metadata":null},{"id":"d3fb03acbda746cdbedf318657401e92","type":"GO_TERM","name":"dormancy exit of symbiont in host","canonical_id":"go:GO:0085016","description":"\"Exit from dormant state, also known as resuscitation, of the symbiont within the host organism.\" [GOC:jl]","metadata":null},{"id":"9f2ee6f6359f44d5809640f6b654a0ec","type":"GO_TERM","name":"dormancy maintenance of symbiont in host","canonical_id":"go:GO:0085015","description":"\"Any process in which a dormant state is maintained by the symbiont within the host organism.\" [GOC:jl]","metadata":null},{"id":"531e0d390826405393cb28ab5790613c","type":"GO_TERM","name":"dormancy process","canonical_id":"go:GO:0022611","description":"\"A developmental process in which dormancy (sometimes called a dormant state) is induced, maintained or broken. Dormancy is a suspension of most physiological activity and growth that can be reactivated.\" [GOC:isa_complete, GOC:PO_curators, PO_REF:00009]","metadata":null},{"id":"5d6e688046f84c8aa3e17b55d430e61b","type":"GO_TERM","name":"dorsal aorta development","canonical_id":"go:GO:0035907","description":"\"The progression of the dorsal aorta over time, from its initial formation to the mature structure. The dorsal aorta is a blood vessel in a single-pass circulatory system that carries oxygenated blood from the gills to the rest of the body. In a single-pass circulatory system blood passes once through the heart to supply the body once.\" [GOC:bf, GOC:dgh, UBERON:0005805, Wikipedia:Aorta, ZFA:0000014]","metadata":null},{"id":"2d57377e773c47ca8bbe35e12ca5d2ca","type":"GO_TERM","name":"dorsal aorta morphogenesis","canonical_id":"go:GO:0035912","description":"\"The process in which the anatomical structures of the dorsal aorta are generated and organized. The dorsal aorta is a blood vessel in a single-pass circulatory system that carries oxygenated blood from the gills to the rest of the body. In a single-pass circulatory system blood passes once through the heart to supply the body once.\" [GOC:bf, GOC:dgh, UBERON:0005805, Wikipedia:Aorta, ZFA:0000014]","metadata":null},{"id":"1025f8d615d449b9915bc7f8a3abf398","type":"GO_TERM","name":"dorsal appendage formation","canonical_id":"go:GO:0046843","description":"\"Establishment of the dorsal filaments, elaborate specializations of the chorion that protrude from the anterior end of the egg and facilitate embryonic respiration.\" [ISBN:0879694238]","metadata":null},{"id":"2099ef504ae945649741519bd4820f0d","type":"GO_TERM","name":"dorsal closure","canonical_id":"go:GO:0007391","description":"\"The process during Drosophila embryogenesis whereby the ectodermal cells of the lateral epithelium stretch in a coordinated fashion to internalize the amnioserosa cells and close the embryo dorsally.\" [PMID:9224720]","metadata":null},{"id":"b543815bc4bd4a71bf9df76bf113a02a","type":"GO_TERM","name":"dorsal closure, amnioserosa morphology change","canonical_id":"go:GO:0046664","description":"\"The changes that occur during dorsal closure of the shape and structure of the amnioserosa, an epithelium that occupies the dorsal side of the embryo.\" [PMID:12147138]","metadata":null},{"id":"6c043ecbcc6142358fa0a4961fa44ad8","type":"GO_TERM","name":"dorsal closure, elongation of leading edge cells","canonical_id":"go:GO:0007394","description":"\"The change in shape of cells at the dorsal-most (leading) edge of the epidermis from being polygonal to being elongated in the dorsal/ventral axis.\" [PMID:12147138]","metadata":null},{"id":"2deeaf733a964c99a74d406aa462e15d","type":"GO_TERM","name":"dorsal closure, leading edge cell differentiation","canonical_id":"go:GO:0046663","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a leading edge cell, the dorsal-most cells of the epidermis that migrates during dorsal closure.\" [GOC:ai, PMID:12147138]","metadata":null},{"id":"50bf1fa2240e4b069ad6d5750648ffe4","type":"GO_TERM","name":"dorsal closure, leading edge cell fate commitment","canonical_id":"go:GO:0035029","description":"\"The commitment of cells to leading edge cell fate during dorsal closure. Leading edge cells are the dorsal-most cells of the migrating epidermis.\" [GOC:bf]","metadata":null},{"id":"47b8c6ee28a848739586c95646f3817d","type":"GO_TERM","name":"dorsal closure, leading edge cell fate determination","canonical_id":"go:GO:0007393","description":"\"The cell fate determination process in which a cell within the dorsal ectoderm becomes capable of differentiating autonomously into a leading edge cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:bf, GOC:curators, PMID:12147138]","metadata":null},{"id":"c9e2be90ab9247a08e0aee69ae706da4","type":"GO_TERM","name":"dorsal closure, spreading of leading edge cells","canonical_id":"go:GO:0007395","description":"\"Dorsally-directed movement of a cell at the leading edge of the epithelium over the amnioserosa.\" [GOC:bf, PMID:12147138]","metadata":null},{"id":"93800330fb864ae4bd73c75b912c2949","type":"GO_TERM","name":"dorsal cochlear nucleus development","canonical_id":"go:GO:0021748","description":"\"The process whose specific outcome is the progression of the dorsal cochlear nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d0d7e38acf604d029b72c7b1d4fca749","type":"GO_TERM","name":"dorsal convergence","canonical_id":"go:GO:0060030","description":"\"The directed migration of individual cells and small groups of cells toward the dorsal midline during gastrulation. This process does not require cell rearrangement.\" [GOC:dgf, GOC:dph, PMID:12062082]","metadata":null},{"id":"350a63aa4c7343e0b25841309db2ab13","type":"GO_TERM","name":"dorsal fin development","canonical_id":"go:GO:0033337","description":"\"The process whose specific outcome is the progression of the dorsal fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"1a49d7d08e6b4cb581d6011ed14ecca4","type":"GO_TERM","name":"dorsal fin morphogenesis","canonical_id":"go:GO:0035142","description":"\"The process in which the anatomical structures of the dorsal fin are generated and organized. A dorsal fin is an unpaired medial fin on the dorsal aspect of fish that provides lateral stability while swimming. Generally fish have one or two dorsal fins.\" [GOC:dgh]","metadata":null},{"id":"5fd75597daab4f239021957c11e18b5d","type":"GO_TERM","name":"dorsal lateral ganglionic eminence cell proliferation","canonical_id":"go:GO:0022019","description":"\"The multiplication or reproduction of dorsal lateral ganglionic eminence cells, resulting in the expansion of the cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"ce40c5ae5c294a8bae7144d80ae3335c","type":"GO_TERM","name":"dorsal motor nucleus of vagus nerve development","canonical_id":"go:GO:0021744","description":"\"The process whose specific outcome is the progression of the dorsal motor nucleus of the vagus nerve over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"fdf34fc1aa0843a5a0be3a61c783c1fe","type":"GO_TERM","name":"dorsal motor nucleus of vagus nerve formation","canonical_id":"go:GO:0035764","description":"\"The process that gives rise to the dorsal motor nucleus of the vagus nerve. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:dgh]","metadata":null},{"id":"d48f9de43d4948bda742edac9212b773","type":"GO_TERM","name":"dorsal motor nucleus of vagus nerve maturation","canonical_id":"go:GO:0035761","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the dorsal motor nucleus of the vagus nerve to attain its fully functional state.\" [GOC:dgh]","metadata":null},{"id":"ae52cb1b61f844ff8f840a8d69bca915","type":"GO_TERM","name":"dorsal motor nucleus of vagus nerve morphogenesis","canonical_id":"go:GO:0035762","description":"\"The process in which the dorsal motor nucleus of the vagus nerve is generated and organized. Morphogenesis pertains to the creation of form.\" [GOC:dgh]","metadata":null},{"id":"5b988f6060f44c609b7c01363ca395a8","type":"GO_TERM","name":"dorsal motor nucleus of vagus nerve structural organization","canonical_id":"go:GO:0035763","description":"\"The process that contributes to the act of creating the structural organization of the dorsal motor nucleus of the vagus nerve. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dgh]","metadata":null},{"id":"eb6fce1ad8984971bc3cc2e8815b82a4","type":"GO_TERM","name":"dorsal root ganglion development","canonical_id":"go:GO:1990791","description":"\"The process whose specific outcome is the progression of a dorsal root ganglion over time, from its formation to the mature structure.\" [PMID:18583150]","metadata":null},{"id":"24872a6815ee4d34a109ee456618dba3","type":"GO_TERM","name":"dorsal root ganglion morphogenesis","canonical_id":"go:GO:1904835","description":"\"The developmental process by which a dorsal root ganglion is generated and organized.\" [GO_REF:0000083, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18936100]","metadata":null},{"id":"412071e3983a42b38fae1dabcc5d73af","type":"GO_TERM","name":"dorsal spinal cord development","canonical_id":"go:GO:0021516","description":"\"The process whose specific outcome is the progression of the dorsal region of the spinal cord over time, from its formation to the mature structure. The dorsal region of the mature spinal cord contains neurons that process and relay sensory input.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11179871]","metadata":null},{"id":"d51a5c3315d4430395d56c04cf7fd00c","type":"GO_TERM","name":"dorsal spinal cord interneuron anterior axon guidance","canonical_id":"go:GO:0097380","description":"\"The process in which the migration of an axon growth cone of a dorsal spinal cord interneuron is directed to a specific target site in the anterior direction along the anterior-posterior body axis in response to a combination of attractive and repulsive cues. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism.\" [GOC:yaf, PMID:19545367]","metadata":null},{"id":"39c20b2889174077a8faa7530a64da19","type":"GO_TERM","name":"dorsal spinal cord interneuron axon guidance","canonical_id":"go:GO:0097378","description":"\"The process in which the migration of an axon growth cone of a dorsal spinal cord interneuron is directed to a specific target site in response to a combination of attractive and repulsive cues. A dorsal spinal cord interneuron is an interneuron located in the dorsal part of the spinal cord.\" [GOC:yaf]","metadata":null},{"id":"be5f7e9ef6c24064a03e609bcb20742d","type":"GO_TERM","name":"dorsal spinal cord interneuron posterior axon guidance","canonical_id":"go:GO:0097379","description":"\"The process in which the migration of an axon growth cone of a dorsal spinal cord interneuron is directed to a specific target site in the posterior direction along the anterior-posterior body axis in response to a combination of attractive and repulsive cues. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism.\" [GOC:yaf, PMID:19545367]","metadata":null},{"id":"07ea5f19919844f896c5ba70ec350182","type":"GO_TERM","name":"dorsal trunk growth, open tracheal system","canonical_id":"go:GO:0035001","description":"\"Growth of epithelial tubes that originate from pits in an open tracheal system and grow towards each other to meet and form a continuous open tube called the dorsal trunk. The dorsal trunk extends from the anterior spiracle to the posterior spiracle of the larva and forms the main airway of the insect tracheal system.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"b8d3906344664f59882e32ce92d335b5","type":"GO_TERM","name":"dorsal vessel aortic cell fate commitment","canonical_id":"go:GO:0035052","description":"\"The commitment of dorsal vessel cardioblast cells to an aortic cell fate and their capacity to differentiate into aortic cells. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, PMID:12397110]","metadata":null},{"id":"8a4700987750438ea48b3b93b5dc9d74","type":"GO_TERM","name":"dorsal vessel heart proper cell fate commitment","canonical_id":"go:GO:0035053","description":"\"The commitment of dorsal vessel cardioblast cells to a heart proper cell fate and their capacity to differentiate into heart cells. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, PMID:12397110]","metadata":null},{"id":"22605028b18b4582808bf9353c7274cd","type":"GO_TERM","name":"dorsal/ventral axis specification","canonical_id":"go:GO:0009950","description":"\"The establishment, maintenance and elaboration of the dorsal/ventral axis. The dorsal/ventral axis is defined by a line that runs orthogonal to both the anterior/posterior and left/right axes. The dorsal end is defined by the upper or back side of an organism. The ventral end is defined by the lower or front side of an organism.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"bc40b837e8e54dfca7d00dcd9d671f12","type":"GO_TERM","name":"dorsal/ventral axis specification, ovarian follicular epithelium","canonical_id":"go:GO:0008069","description":"\"Polarization of the ovarian follicle cells along the dorsal/ventral axis. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:dph, GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"298c1b53eea04cde88287ff6e2041f5d","type":"GO_TERM","name":"dorsal/ventral axon guidance","canonical_id":"go:GO:0033563","description":"\"The process in which the migration of an axon growth cone is directed to a specific target site along the dorsal-ventral body axis in response to a combination of attractive and repulsive cues. The dorsal/ventral axis is defined by a line that runs orthogonal to both the anterior/posterior and left/right axes. The dorsal end is defined by the upper or back side of an organism. The ventral end is defined by the lower or front side of an organism.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"4e118942b3d94f829940419e1dab82a9","type":"GO_TERM","name":"dorsal/ventral lineage restriction, imaginal disc","canonical_id":"go:GO:0007451","description":"\"Formation and/or maintenance of a lineage boundary between dorsal and ventral compartments that cells cannot cross, thus separating the populations of cells in each compartment.\" [GOC:bf, PMID:10625531, PMID:9374402]","metadata":null},{"id":"0f0339b8739b4096b69799a17cec9e37","type":"GO_TERM","name":"dorsal/ventral neural tube patterning","canonical_id":"go:GO:0021904","description":"\"The process in which the neural tube is regionalized in the dorsoventral axis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"083560cf14b542499666be1ba2fde619","type":"GO_TERM","name":"dorsal/ventral pattern formation","canonical_id":"go:GO:0009953","description":"\"The regionalization process in which the areas along the dorsal/ventral axis are established that will lead to differences in cell differentiation. The dorsal/ventral axis is defined by a line that runs orthogonal to both the anterior/posterior and left/right axes. The dorsal end is defined by the upper or back side of an organism. The ventral end is defined by the lower or front side of an organism.\" [GOC:curators, GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"b574f18fad6e4701ba49c152331bd60e","type":"GO_TERM","name":"dorsal/ventral pattern formation, imaginal disc","canonical_id":"go:GO:0007450","description":"\"The establishment, maintenance and elaboration of the dorsal/ventral axis of the imaginal disc. Imaginal disks are masses of hypodermic cells, carried by the larvae of some insects after leaving the egg, from which masses the wings and legs of the adult are subsequently formed.\" [GOC:jid, ISBN:0879694238]","metadata":null},{"id":"e130369f8eed4f9f977e64ff87f3250d","type":"GO_TERM","name":"dorsolateral trunk neural crest cell migration","canonical_id":"go:GO:0036485","description":"\"The movement of trunk neural crest cells from the neural tube, travelling dorso-laterally into the ectoderm and continuing toward the ventral midline of the belly. These migrating trunk neural crest cells become melanocytes, the melanin-forming pigment cells.\" [GOC:bf, GOC:mat, GOC:PARL, PMID:2387238]","metadata":null},{"id":"1483c207824045669931b8dc464c711c","type":"DRUG","name":"dorzolamide","canonical_id":"mesh:C062765","description":null,"metadata":null},{"id":"b6b60009fa7543cc8a76a39a6d2e01ce","type":"GO_TERM","name":"dosage compensation by hyperactivation of X chromosome","canonical_id":"go:GO:0009047","description":"\"Compensating for the two-fold variation in X-chromosome:autosome ratios between sexes by a global hyperactivation of all, or most of, the genes on the X-chromosome in the heterogametic sex, leading to a two-fold increase in gene expression from this chromosome. An example of this is found in Drosophila melanogaster.\" [GOC:jl, GOC:mr, PMID:11498577, PMID:1568251]","metadata":null},{"id":"01675d9740454dc5b4b50e283812ef2b","type":"GO_TERM","name":"dosage compensation by hypoactivation of X chromosome","canonical_id":"go:GO:0042464","description":"\"Compensating for the two-fold variation in X:autosome chromosome ratios between sexes by an inactivation of a proportion of genes on both of the X chromosomes of the XX sex, leading to a decrease, of half, of the levels of gene expression from these chromosomes. An example of this process is found in Caenorhabditis elegans.\" [GOC:jl, GOC:mr, PMID:11102361]","metadata":null},{"id":"b7ecdf635f174ee58d6db513e746e136","type":"GO_TERM","name":"dosage compensation by inactivation of X chromosome","canonical_id":"go:GO:0009048","description":"\"Compensating for the two-fold variation in X-chromosome:autosome ratios between sexes by heterochromatin formation leading to a global inactivation of all, or most of, the genes on one of the X-chromosomes in the XX sex.\" [GOC:jl, GOC:mr, GOC:pr, PMID:11498577, PMID:20622855, Wikipedia:XY_sex-determination_system]","metadata":null},{"id":"d0cb4378c73049658fc2a8416798f5c0","type":"GO_TERM","name":"dosage compensation complex","canonical_id":"go:GO:0046536","description":"\"A protein or protein-RNA complex that localizes to one or more of the sex chromosome(s), where it acts to normalize transcription between different sexes.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"8f774ceb9df140549c23136f6455fec2","type":"GO_TERM","name":"dosage compensation complex assembly","canonical_id":"go:GO:0042714","description":"\"The aggregation, arrangement and bonding together of proteins on DNA or RNA to form the complex that mediates dosage compensation on one or more X chromosomes.\" [GOC:jl, PMID:11102361, PMID:12672493]","metadata":null},{"id":"a7915f4b03754c3e86ff9fedb28d193c","type":"DRUG","name":"dostarlimab","canonical_id":"gtopdb:11518","description":null,"metadata":null},{"id":"4b76217cc4af44088bd741b07ba76886","type":"DRUG","name":"dostarlimab","canonical_id":"chembl:CHEMBL4298124","description":null,"metadata":null},{"id":"ea04c838902042b9a99db4d06951e41b","type":"COMBINATION_TREATMENT","name":"dostarlimab + neratinib + sarilumab + talazoparib + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-660dcbe09ec8bf64","description":null,"metadata":null},{"id":"9886406ac79b49a590606e8905b8a45d","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-100a8c846f45adce","description":null,"metadata":null},{"id":"dbd7feb1bd73433b930ed7e492da7de8","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-75fb5b22b5a7b454","description":null,"metadata":null},{"id":"f61d5092ca134bcab016db1cb9dca4f3","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-54bd3aeb403ff589","description":null,"metadata":null},{"id":"ac3e07e2f8fa4cce8f80ddc0427c8473","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-b5bf5c6c3c2f4857","description":null,"metadata":null},{"id":"572e793d2c514e52a54579f075a1fac6","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-2663b6e4a4573b3c","description":null,"metadata":null},{"id":"e9b3853f7ca646b0acd791eaef3d1d90","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-cb12ac883f74ccfd","description":null,"metadata":null},{"id":"2a2aa163b92f420081922f9b0b19f6e2","type":"COMBINATION_TREATMENT","name":"dostarlimab + niraparib","canonical_id":"ctgov_combo:ctgov-combo-e19f0ea1f316f3fd","description":null,"metadata":null},{"id":"1a99d2b463034a608267fd75160e3ff8","type":"COMBINATION_TREATMENT","name":"dostarlimab + rucaparib","canonical_id":"ctgov_combo:ctgov-combo-dc68034574698f64","description":null,"metadata":null},{"id":"0e8861809de04489b9720149d442612c","type":"DRUG","name":"dosulepin","canonical_id":"gtopdb:7549","description":null,"metadata":null},{"id":"eb93a2778fac43e8ab6a7e44b6897ec1","type":"DRUG","name":"dosulepin","canonical_id":"mesh:D004308","description":null,"metadata":null},{"id":"8dde2fb05b214e808eda8513df613009","type":"DRUG","name":"dotinurad","canonical_id":"gtopdb:11389","description":null,"metadata":null},{"id":"d430d40fd15d4584a3f8524f4d095a56","type":"DRUG","name":"dotinurad","canonical_id":"chembl:CHEMBL4594446","description":null,"metadata":null},{"id":"4af3ecc1056442a6a6892f474590612c","type":"COMBINATION_TREATMENT","name":"dotinurad + febuxostat","canonical_id":"ctgov_combo:ctgov-combo-6c04b1cefaf25d25","description":null,"metadata":null},{"id":"d445684fd192432795d1af5a2c4bcf82","type":"GO_TERM","name":"double fertilization forming a zygote and endosperm","canonical_id":"go:GO:0009567","description":"\"Fertilization where one of the two sperm nuclei from the pollen tube fuses with the egg nucleus to form a 2n zygote, and the other fuses with the two polar nuclei to form the 3n primary endosperm nucleus and then develops into the endosperm. The ploidy level of the 2n zygote and 3n primary endosperm nucleus is determined by the ploidy level of the parents involved. An example of this component is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"d9230c0026fe471fa11c965254d4abc6","type":"GO_TERM","name":"double fertilization forming two zygotes","canonical_id":"go:GO:0009677","description":"\"Rudimentary double fertilization where one of the two sperm nuclei from the pollen tube fuses with the egg nucleus to form a 2n zygote, and the other fuses with the ventral canal cell nucleus to form a second zygote, which soon degenerates. An example of this process is found in the Gnetophytes, such as Welwitschia mirabilis.\" [GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"5c40d355bcf844259a17b5f0224b2f75","type":"GO_TERM","name":"double layer follicle stage","canonical_id":"go:GO:0048161","description":"\"The stage in oogenesis when a double layer of distinct follicle cells surrounds the oocyte. An example of this process is found in Mus musculus.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"a5c63faf5dfa4ce09325c004a3e08e8b","type":"GO_TERM","name":"double membrane vesicle viral factory","canonical_id":"go:GO:0039718","description":"\"A cytoplasmic viral factory that consists of a double-membrane bound vesicle. Has a diameter of 200-300nm and is derived from the endoplasmic reticulum or Golgi apparatus. Produced by Picornaviridae, Nidovirales, Arteriviridae and Coronaviridae.\" [PMID:22440839, VZ:1951]","metadata":null},{"id":"62887df9d7484c91b6877c59e8813338","type":"GO_TERM","name":"double membrane vesicle viral factory assembly","canonical_id":"go:GO:0140526","description":"\"A process that results in the assembly of a cytoplasmic viral factory consisting of a double-membrane bound vesicle.\" [PMID:32555292]","metadata":null},{"id":"da6b8b6109c348feb86afa1b8c9cfb5b","type":"GO_TERM","name":"double membrane vesicle viral factory inner membrane","canonical_id":"go:GO:0062245","description":"\"The inner of the two endoplasmic reticulum-derived lipid bilayer membranes that bound a double membrane vesicle viral factory.\" [PMID:22440839]","metadata":null},{"id":"e34c0c335ce246c0b70041d1b8960e80","type":"GO_TERM","name":"double membrane vesicle viral factory lumen","canonical_id":"go:GO:0062244","description":"\"The volume surrounded by the inner membrane of a double membrane vesicle viral factory.\" [PMID:22440839]","metadata":null},{"id":"4023024513f740b4a03f3c318dfb96c7","type":"GO_TERM","name":"double membrane vesicle viral factory membrane","canonical_id":"go:GO:0062242","description":"\"One of the two endoplasmic reticulum-derived lipid bilayer membranes that bound a double membrane vesicle viral factory.\" [PMID:22440839]","metadata":null},{"id":"6db9a99aabc9430ca2996421be05f703","type":"GO_TERM","name":"double membrane vesicle viral factory outer membrane","canonical_id":"go:GO:0062243","description":"\"The outer of the two endoplasmic reticulum-derived lipid bilayer membranes that bound a double membrane vesicle viral factory.\" [PMID:22440839]","metadata":null},{"id":"e190295e27e44273ad27b4fe48f9295c","type":"GO_TERM","name":"double strand break-nuclear membrane anchor activity","canonical_id":"go:GO:0062241","description":"\"Binding to DNA double strand breaks and the nuclear inner membrane, in order to facilitate DNA repair.\" [PMID:31635174]","metadata":null},{"id":"1f82259f4dfe4182b4798aebbc94c758","type":"GO_TERM","name":"double stranded viral RNA replication","canonical_id":"go:GO:0039691","description":"\"A viral genome replication process where the template genome is double stranded RNA (dsRNA). Genomic dsRNA is first transcribed into single-stranded (ss) mRNA, which is then replicated to ds-genomic RNA.\" [GOC:bf, GOC:jl, VZ:1936]","metadata":null},{"id":"1f979a9caef64b13bd6d5ded0c78c85d","type":"GO_TERM","name":"double-strand break repair","canonical_id":"go:GO:0006302","description":"\"The repair of double-strand breaks in DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix.\" [GOC:elh]","metadata":null},{"id":"5aef0d1bf61d42dfbc7d09a9eca0a29d","type":"GO_TERM","name":"double-strand break repair involved in meiotic recombination","canonical_id":"go:GO:1990918","description":"\"The repair of double-strand breaks in DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix that contributes to reciprocal meiotic recombination.\" [GOC:mah, PMID:15238514]","metadata":null},{"id":"72bba700e1bf448c9b68536c95689576","type":"GO_TERM","name":"double-strand break repair via alternative nonhomologous end joining","canonical_id":"go:GO:0097681","description":"\"An instance of double-strand break repair via nonhomologous end joining that is independent of factors important for V(D)J recombination (as opposed to classical nonhomologous end joining). It often results in a deletion with microhomology (i.e. 5-25bp homology) at the repair junction. Among different subclasses of nonhomologous end joining (NHEJ), alternative NHEJ appears to play a significant role in the etiology of mutations that arise during cancer development and treatment.\" [GOC:rph, PMID:18584027, PMID:21655080, Wikipedia:Microhomology-mediated_end_joining]","metadata":null},{"id":"7d86e2e9326f48ce8a77b485e910da1b","type":"GO_TERM","name":"double-strand break repair via break-induced replication","canonical_id":"go:GO:0000727","description":"\"The error-free repair of a double-strand break in DNA in which the centromere-proximal end of a broken chromosome searches for a homologous region in an intact chromosome. DNA synthesis initiates from the 3' end of the invading DNA strand, using the intact chromosome as the template, and progresses to the end of the chromosome.\" [GOC:elh, PMID:10357855]","metadata":null},{"id":"3a6c2501df194d8da9ab109ac744c0fa","type":"GO_TERM","name":"double-strand break repair via classical nonhomologous end joining","canonical_id":"go:GO:0097680","description":"\"An instance of double-strand break repair via nonhomologous end joining that requires a number of factors important for V(D)J recombination, including the KU70/80 heterodimer (KU), XRCC4, ligase IV, and DNA-PKcs in mammals. It does not produce translocations (as opposed to the alternative nonhomologous end joining).\" [GOC:rph, PMID:18584027]","metadata":null},{"id":"da792c5ee0b94746bdbf4cc9d2e7b446","type":"GO_TERM","name":"double-strand break repair via homologous recombination","canonical_id":"go:GO:0000724","description":"\"The error-free repair of a double-strand break in DNA in which the broken DNA molecule is repaired using homologous sequences. A strand in the broken DNA searches for a homologous region in an intact chromosome to serve as the template for DNA synthesis. The restoration of two intact DNA molecules results in the exchange, reciprocal or nonreciprocal, of genetic material between the intact DNA molecule and the broken DNA molecule.\" [GOC:elh, PMID:10357855]","metadata":null},{"id":"5e239441108b41188e32f9a6aa749dc5","type":"GO_TERM","name":"double-strand break repair via nonhomologous end joining","canonical_id":"go:GO:0006303","description":"\"The repair of a double-strand break in DNA in which the two broken ends are rejoined with little or no sequence complementarity. Information at the DNA ends may be lost due to the modification of broken DNA ends. This term covers instances of separate pathways, called classical (or canonical) and alternative nonhomologous end joining (C-NHEJ and A-NHEJ). These in turn may further branch into sub-pathways, but evidence is still unclear.\" [GOC:rph, PMID:10827453, PMID:24837021]","metadata":null},{"id":"173783bc35d14bdf9f81ad7762425f75","type":"GO_TERM","name":"double-strand break repair via single-strand annealing","canonical_id":"go:GO:0045002","description":"\"Repair of a DSB made between two repeated sequences oriented in the same direction occurs primarily by the single strand annealing pathway. The ends of the break are processed by a 5' to 3' exonuclease, exposing complementary single-strand regions of the direct repeats that can anneal, resulting in a deletion of the unique DNA between the direct repeats.\" [PMID:11606529]","metadata":null},{"id":"1fa75f7afd27498baeb1bb99084bca45","type":"GO_TERM","name":"double-strand break repair via single-strand annealing, removal of nonhomologous ends","canonical_id":"go:GO:0000736","description":"\"During DSBR via single-strand annealing, the removal of nonhomologous sequences at the broken 3' single-strand DNA end before DNA repair synthesis can occur.\" [PMID:10357855]","metadata":null},{"id":"951aea629e1a43ec82081fd97e7c412a","type":"GO_TERM","name":"double-strand break repair via synthesis-dependent strand annealing","canonical_id":"go:GO:0045003","description":"\"SDSA is a major mechanism of double-strand break repair in mitosis which allows for the error-free repair of a double-strand break without the exchange of adjacent sequences. The broken DNA searches for and base pairs with a homologous region in an intact chromosome. DNA synthesis initiates from the 3' end of the invading DNA strand, using the intact chromosome as the template. Newly synthesized DNA is then displaced from the template and anneal with its complement on the other side of the double-strand break.\" [PMID:10357855]","metadata":null},{"id":"e3041a60c79145c8bb8b8b0d64d3aa6d","type":"GO_TERM","name":"double-strand break repair via transcription-associated homologous recombination","canonical_id":"go:GO:0106400","description":"\"A mechanism of homologous recombination and DNA repair in which transcript RNA is used as a template for DSB repair.\" [PMID:25186730]","metadata":null},{"id":"a44879a3b9ac4a729e724c008c0f2664","type":"GO_TERM","name":"double-strand/single-strand DNA junction binding","canonical_id":"go:GO:0000406","description":"\"Binding to a DNA segment that contains double-stranded DNA flanked by a region of single-stranded DNA.\" [GOC:elh, PMID:16781730]","metadata":null},{"id":"e096f487d0d1497480308afc2aac0937","type":"GO_TERM","name":"double-stranded DNA 3'-5' DNA exonuclease activity","canonical_id":"go:GO:0008311","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 3' terminus of a double-stranded DNA molecule.\" [GOC:mah, PMID:22562358]","metadata":null},{"id":"02175ecf87354cc7962c2b3ecc28add8","type":"GO_TERM","name":"double-stranded DNA 5'-3' DNA exonuclease activity","canonical_id":"go:GO:0051908","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' terminus of a double-stranded DNA molecule.\" [GOC:ai]","metadata":null},{"id":"c407ff6b29a54178aa338fd77e2593a7","type":"GO_TERM","name":"double-stranded DNA binding","canonical_id":"go:GO:0003690","description":"\"Binding to double-stranded DNA.\" [GOC:elh, GOC:vw]","metadata":null},{"id":"187e35fcc86843d0acf565742ff50871","type":"GO_TERM","name":"double-stranded DNA endonuclease activity","canonical_id":"go:GO:1990238","description":"\"Catalysis of the hydrolysis of ester linkages within a double-stranded DNA molecule by creating internal breaks.\" [PMID:22885404]","metadata":null},{"id":"71c7e4bcd8184e6785935a4abcc7e1ef","type":"GO_TERM","name":"double-stranded DNA exodeoxyribonuclease activity","canonical_id":"go:GO:0008309","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' or 3' terminus of a double-stranded DNA molecule.\" [GOC:mah]","metadata":null},{"id":"8fade5ebb1a04bbe96ebdb8c3436e5c6","type":"GO_TERM","name":"double-stranded DNA helicase activity","canonical_id":"go:GO:0036121","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate, in the presence of double-stranded DNA; drives the unwinding of a DNA helix.\" [GOC:kmv]","metadata":null},{"id":"d63ecc52f15e4888a327c5547434a548","type":"GO_TERM","name":"double-stranded RNA adenosine deaminase activity","canonical_id":"go:GO:0003726","description":"\"Catalysis of the reaction: adenosine + H2O = inosine + NH4+, in a double-stranded RNA molecule.\" [GOC:mah, RHEA:10120]","metadata":null},{"id":"eaa5440e626e423393acc548c2ee3287","type":"GO_TERM","name":"double-stranded RNA binding","canonical_id":"go:GO:0003725","description":"\"Binding to double-stranded RNA.\" [GOC:jl]","metadata":null},{"id":"19b6f43b767140748479c4b87de11d0c","type":"GO_TERM","name":"double-stranded RNA immune receptor activity","canonical_id":"go:GO:7770072","description":"\"Combining with a double-stranded RNA and transmitting the signal to initiate an innate immune response.\" [PMID:23273991, PMID:33243852, PMID:34678144]","metadata":null},{"id":"1e64b7b826ed427f89548a90479cd481","type":"GO_TERM","name":"double-stranded RNA-specific ribonuclease activity","canonical_id":"go:GO:0032296","description":"\"Catalysis of the hydrolysis of phosphodiester bonds in double-stranded RNA molecules.\" [GOC:mah]","metadata":null},{"id":"07b53884c43e4e2f9130e3a8cbaec7d7","type":"GO_TERM","name":"double-stranded methylated DNA binding","canonical_id":"go:GO:0010385","description":"\"Binding to double-stranded methylated DNA. Methylation of cytosine or adenine in DNA is an important mechanism for establishing stable heritable epigenetic marks.\" [GOC:imk, PMID:17242155]","metadata":null},{"id":"73aac7bb5c6a4ba0ba1460037afe70ea","type":"GO_TERM","name":"double-stranded miRNA binding","canonical_id":"go:GO:0098851","description":"\"Binding to double-stranded miRNA. double-stranded miRNA is formed by processing of pre-miRNA stem-loop structures.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:19966796]","metadata":null},{"id":"48293e6758d647c18d182165090e4fd4","type":"GO_TERM","name":"double-stranded telomeric DNA binding","canonical_id":"go:GO:0003691","description":"\"Binding to double-stranded telomere-associated DNA.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"0205e2fb05a34d55a523fcfe648bbdb2","type":"GO_TERM","name":"double-stranded/single-stranded junction telomeric DNA binding","canonical_id":"go:GO:0090655","description":"\"Binding to a junction formed at the point where double-stranded telomeric DNA becomes a single-stranded G-rich telomeric DNA 3' overhang.\" [GOC:BHF, GOC:BHF_telomere, GOC:bhm, GOC:nc, PMID:21852327]","metadata":null},{"id":"9c212f986cdd45da9b184159798c3cfc","type":"DRUG","name":"doxapram","canonical_id":"mesh:D004315","description":null,"metadata":null},{"id":"96341d291be64cc4a3280b9d09e77ce4","type":"DRUG","name":"doxazosin","canonical_id":"gtopdb:7170","description":null,"metadata":null},{"id":"53ce69028f2c4b3d8139695222f33254","type":"COMBINATION_TREATMENT","name":"doxazosin + finasteride","canonical_id":"ctgov_combo:ctgov-combo-72dcb2d36e4662d5","description":null,"metadata":null},{"id":"c62967af8d33426c9591f4a9426ff4d6","type":"COMBINATION_TREATMENT","name":"doxazosin + perindopril","canonical_id":"ctgov_combo:ctgov-combo-56c4431cfc113b72","description":null,"metadata":null},{"id":"a0c1fba77d1547f488023c8e35cdcc96","type":"COMBINATION_TREATMENT","name":"doxazosin + phenoxybenzamine","canonical_id":"ctgov_combo:ctgov-combo-ac629b689eb89692","description":null,"metadata":null},{"id":"e40af8e9908a46aca2dd62066c60f4cd","type":"COMBINATION_TREATMENT","name":"doxazosin + spirapril","canonical_id":"ctgov_combo:ctgov-combo-56cc3f745fa0058d","description":null,"metadata":null},{"id":"7a2dbc51eb524c89b649d618c5a73349","type":"COMBINATION_TREATMENT","name":"doxazosin + terazosin","canonical_id":"ctgov_combo:ctgov-combo-8fe05d6200a2768a","description":null,"metadata":null},{"id":"b363f1f8bcad4913a3254be1efaf7249","type":"DRUG","name":"doxepin","canonical_id":"gtopdb:1225","description":null,"metadata":null},{"id":"8d3366e2c61e48d0b0e8b224e4120abb","type":"DRUG","name":"doxepin","canonical_id":"mesh:D004316","description":null,"metadata":null},{"id":"6a7653ca24974bbfb0aa63359b3856ed","type":"DRUG","name":"doxepin","canonical_id":"chembl:CHEMBL1628227","description":null,"metadata":null},{"id":"afe3c88466db46abb8d39067cb96a7c8","type":"COMBINATION_TREATMENT","name":"doxepin + melatonin + trazodone + zolpidem","canonical_id":"ctgov_combo:ctgov-combo-0775d01c968ea5f8","description":null,"metadata":null},{"id":"a9fd23908fe440ceb5d57baa0a75c6e9","type":"COMBINATION_TREATMENT","name":"doxepin + nortriptyline","canonical_id":"ctgov_combo:ctgov-combo-44aa108c9d8e2557","description":null,"metadata":null},{"id":"7b48d8ce5c934389be1f4a8fa5f2a206","type":"COMBINATION_TREATMENT","name":"doxepin + ramelteon","canonical_id":"ctgov_combo:ctgov-combo-8417a71d638f6166","description":null,"metadata":null},{"id":"92da278a591a4ec5af15fe4a33cb6e44","type":"COMBINATION_TREATMENT","name":"doxepin + ramelteon","canonical_id":"ctgov_combo:ctgov-combo-c29dcd649c82a78f","description":null,"metadata":null},{"id":"37c512b320de484dbfe42e204db5c121","type":"DRUG","name":"doxorubicin","canonical_id":"mesh:D004317","description":null,"metadata":null},{"id":"d3f4e7daee194eeaa7652bf80e7c7dbf","type":"GO_TERM","name":"doxorubicin metabolic process","canonical_id":"go:GO:0044598","description":"\"The chemical reactions and pathways involving doxorubicin, an anthracycline antibiotic, used in cancer chemotherapy.\" [PMID:10200167]","metadata":null},{"id":"4e5d975dbaf8439f9fc85ce59db60509","type":"GO_TERM","name":"doxorubicin transport","canonical_id":"go:GO:1900753","description":"\"The directed movement of a doxorubicin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie, PMID:12057006, PMID:15090538, PMID:19063901, PMID:19651502, PMID:9651400]","metadata":null},{"id":"0aa621430c1e4a279a4a9ea3e61e5e25","type":"DRUG","name":"doxycycline","canonical_id":"gtopdb:6464","description":null,"metadata":null},{"id":"fcaf09f36e9f44daa678078d66e7e498","type":"DRUG","name":"doxycycline","canonical_id":"mesh:D004318","description":null,"metadata":null},{"id":"704cd47028eb484ab3febd1788cd3e82","type":"DRUG","name":"doxycycline","canonical_id":"chembl:CHEMBL1200699","description":null,"metadata":null},{"id":"fe165a58cf8249f4851af832bceac7d8","type":"COMBINATION_TREATMENT","name":"doxycycline + imiquimod","canonical_id":"ctgov_combo:ctgov-combo-927edbdf14de55f3","description":null,"metadata":null},{"id":"d4dd0b1764fd432784929fc1496d2e4d","type":"COMBINATION_TREATMENT","name":"doxycycline + irbesartan","canonical_id":"ctgov_combo:ctgov-combo-e54662eaebcd0c0a","description":null,"metadata":null},{"id":"99dafdd02cd64c00a32243e8acc2d3b1","type":"COMBINATION_TREATMENT","name":"doxycycline + ketoprofen","canonical_id":"ctgov_combo:ctgov-combo-b49f2828753cf36a","description":null,"metadata":null},{"id":"182717380e904f168c30d1ef3c274157","type":"COMBINATION_TREATMENT","name":"doxycycline + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-c2572eb62e9a23e1","description":null,"metadata":null},{"id":"5d58e2bbbf9e4106882b58ad9bf6ef28","type":"DRUG","name":"doxylamine","canonical_id":"mesh:D004319","description":null,"metadata":null},{"id":"03b74426c7694367bb66eee9945230f3","type":"GO_TERM","name":"drinking behavior","canonical_id":"go:GO:0042756","description":"\"The specific behavior of an organism relating to the intake of liquids, especially water.\" [GOC:curators, GOC:pr]","metadata":null},{"id":"10008d4485c34a6483575f90ef3b7e5a","type":"DRUG","name":"dromostanolone propionate","canonical_id":"gtopdb:6947","description":null,"metadata":null},{"id":"67bfcecae588493caa60eb77bfe7d699","type":"DRUG","name":"dromostanolone propionate","canonical_id":"chembl:CHEMBL1201048","description":null,"metadata":null},{"id":"31d47c8f82e243bca914c04476986c0d","type":"DRUG","name":"dronedarone","canonical_id":"mesh:C118667","description":null,"metadata":null},{"id":"09b974236daa42bbaedbc98b7cb40c95","type":"DRUG","name":"drospirenone","canonical_id":"gtopdb:2874","description":null,"metadata":null},{"id":"890c4e5730c643d6af45f5b0a7b29563","type":"DRUG","name":"drospirenone","canonical_id":"mesh:C035144","description":null,"metadata":null},{"id":"557b56f33dce4ee9a2f03b72feae96d0","type":"DRUG","name":"drospirenone","canonical_id":"chembl:CHEMBL1509","description":null,"metadata":null},{"id":"0085b0cadae545119da7da503e24b402","type":"DRUG","name":"drotrecogin alfa","canonical_id":"gtopdb:6788","description":null,"metadata":null},{"id":"0640c6a02fc44c59addbb7a32b43e566","type":"DRUG","name":"drotrecogin alfa","canonical_id":"chembl:CHEMBL2109065","description":null,"metadata":null},{"id":"14266998364b4a9b86b20d964384c733","type":"GO_TERM","name":"drought recovery","canonical_id":"go:GO:0009819","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of prolonged deprivation of water that restores that organism to a normal (non-stressed) condition.\" [GOC:lr]","metadata":null},{"id":"4d5379641ecc44c59262c766ea9bbbba","type":"DISEASE","name":"drug dependence","canonical_id":"mondo:0005303","description":null,"metadata":null},{"id":"e1dc96eccaf84782b7f25653107defae","type":"DISEASE","name":"dry eye syndrome","canonical_id":"mondo:0006733","description":null,"metadata":null},{"id":"c525ad1c896343bba9895984ba59167e","type":"GO_TERM","name":"ds/ssDNA junction-specific dsDNA endonuclease activity","canonical_id":"go:GO:0106332","description":"\"Catalysis of the endonucleolytic cleavage of double-stranded DNA near a double-strand/single-strand DNA junction.\" [PMID:14528010]","metadata":null},{"id":"b4bb05440dd64370a51bf0e8673644a5","type":"GO_TERM","name":"dsDNA-RNA triple helix-forming chromatin adaptor activity","canonical_id":"go:GO:0141180","description":"\"A chromatin-protein adaptor activity that bridges dsDNA and chromatin proteins to bring regions of a chromosome in proximity. The DNA:DNA:RNA triple-helical structure is formed non-Watson-Crick base-pairing.\" [PMID:35412350]","metadata":null},{"id":"cbf7531e1e5e482b812be8b676f72bc8","type":"GO_TERM","name":"dsRNA transport","canonical_id":"go:GO:0033227","description":"\"The directed movement of dsRNA, double-stranded ribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"003f1e0160bc45459fa869180d36b10e","type":"GO_TERM","name":"ductus arteriosus closure","canonical_id":"go:GO:0097070","description":"\"The morphogenesis process in which the ductus arteriosus changes to no longer permit blood flow after birth. The ductus arteriosus is the shunt between the aorta and the pulmonary artery which allows blood to bypass the fetus' lungs.\" [GOC:hw]","metadata":null},{"id":"6e9a62c8024f46b5a34268e67ef32ec4","type":"GO_TERM","name":"ductus venosus closure","canonical_id":"go:GO:0061116","description":"\"The morphogenesis process in which the ductus venosus changes to no longer permit blood flow after birth.\" [GOC:dph]","metadata":null},{"id":"d188a3618d704bf8b89c6c57ea172869","type":"DRUG","name":"duloxetine","canonical_id":"gtopdb:202","description":null,"metadata":null},{"id":"4fcfd2d8a63d46cd98301ab008b10550","type":"DRUG","name":"duloxetine","canonical_id":"mesh:D000068736","description":null,"metadata":null},{"id":"5c0580c023e74faa93d81f3ca423f170","type":"COMBINATION_TREATMENT","name":"duloxetine + imipramine","canonical_id":"ctgov_combo:ctgov-combo-de9d4d52d64af0db","description":null,"metadata":null},{"id":"803990000c3f4bf4a2f89f796a53fe07","type":"COMBINATION_TREATMENT","name":"duloxetine + methylphenidate","canonical_id":"ctgov_combo:ctgov-combo-a5e57823408a1e87","description":null,"metadata":null},{"id":"294cfff7c0744651afd7e706a8690645","type":"COMBINATION_TREATMENT","name":"duloxetine + morphine","canonical_id":"ctgov_combo:ctgov-combo-4f79c4fe381a03e1","description":null,"metadata":null},{"id":"9f4b4ccf806343f8aef5fb144063683e","type":"COMBINATION_TREATMENT","name":"duloxetine + paroxetine + sertraline + vortioxetine","canonical_id":"ctgov_combo:ctgov-combo-facb622eb209641f","description":null,"metadata":null},{"id":"80b93ca2e0e94b91b781ba2a9fdd3274","type":"COMBINATION_TREATMENT","name":"duloxetine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-3bfd3138c8d94572","description":null,"metadata":null},{"id":"20031b6d232b428dacfea93ebd4fd335","type":"DISEASE","name":"duodenal ulcer","canonical_id":"mondo:0005412","description":null,"metadata":null},{"id":"eff50dbb101743a5b5877490115db6c0","type":"DRUG","name":"dupilumab","canonical_id":"gtopdb:7574","description":null,"metadata":null},{"id":"4ad9985babcf4a4ba3458973064ea89e","type":"DRUG","name":"dupilumab","canonical_id":"mesh:C582203","description":null,"metadata":null},{"id":"54a68246574d46fe895425bdff24965c","type":"DRUG","name":"dupilumab","canonical_id":"chembl:CHEMBL2108675","description":null,"metadata":null},{"id":"f00104e94fc04ab58c7bb9ae6b74c31d","type":"COMBINATION_TREATMENT","name":"dupilumab + fexofenadine + loratadine","canonical_id":"ctgov_combo:ctgov-combo-68773976898bb590","description":null,"metadata":null},{"id":"dbcf979a13af4b3e999f15085ee11147","type":"COMBINATION_TREATMENT","name":"dupilumab + mepolizumab","canonical_id":"ctgov_combo:ctgov-combo-5bbef3876d1b7600","description":null,"metadata":null},{"id":"9cfd6b1dd9bd49a4bd64c4cf493a199a","type":"COMBINATION_TREATMENT","name":"dupilumab + mometasone","canonical_id":"ctgov_combo:ctgov-combo-3e7b72a809c11f4a","description":null,"metadata":null},{"id":"0522360e2af64c71b661dbe9f65ce37e","type":"COMBINATION_TREATMENT","name":"dupilumab + secukinumab + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-65050aad447386bc","description":null,"metadata":null},{"id":"ba46420c0f63441b80fa5d19e0d3f235","type":"COMBINATION_TREATMENT","name":"dupilumab + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-91969b0ae10ebebd","description":null,"metadata":null},{"id":"c01d3999fee5464893f2b8c43f09e714","type":"COMBINATION_TREATMENT","name":"dupilumab + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-220959e161a342d6","description":null,"metadata":null},{"id":"5545d86d16a344cab624c6c0c916ffdb","type":"DRUG","name":"durvalumab","canonical_id":"gtopdb:7985","description":null,"metadata":null},{"id":"d996ed78921e42f98b6109fcec33e284","type":"DRUG","name":"durvalumab","canonical_id":"chembl:CHEMBL3301587","description":null,"metadata":null},{"id":"76db9e3604a3494fa07abbaba81be7ba","type":"COMBINATION_TREATMENT","name":"durvalumab + gemcitabine + paclitaxel + propranolol + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-4523ee62a15a90f9","description":null,"metadata":null},{"id":"ddebf59348b0434ea9b1c4a5c6865f17","type":"COMBINATION_TREATMENT","name":"durvalumab + olaparib","canonical_id":"ctgov_combo:ctgov-combo-81ffa9df2c4b85ab","description":null,"metadata":null},{"id":"98e78f79f6bb4a30bc2b36c81c52cfbf","type":"COMBINATION_TREATMENT","name":"durvalumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-54138d9bb83d8646","description":null,"metadata":null},{"id":"276d774e9d3345ef90509490762887f4","type":"COMBINATION_TREATMENT","name":"durvalumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-6013b01cd11279fa","description":null,"metadata":null},{"id":"1e56a7ceec784c61b15272e2d191d2e3","type":"COMBINATION_TREATMENT","name":"durvalumab + pertuzumab + trastuzumab + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-bec9b1c6ae267845","description":null,"metadata":null},{"id":"ca2da1fd5e2b40e3a1fc54925da2c7f2","type":"COMBINATION_TREATMENT","name":"durvalumab + prednisone + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-86b356d7e6428428","description":null,"metadata":null},{"id":"9cba6e77b1854860bafa0b2fa5ad4f82","type":"COMBINATION_TREATMENT","name":"durvalumab + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-2327b1dd1600eb3f","description":null,"metadata":null},{"id":"d318f329d3ab4a11afa682be9dd79d1a","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-3732eeb105bc7c72","description":null,"metadata":null},{"id":"61f8e39395e04bc4886d48e4ecd333c6","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-1dd340e1e5639c18","description":null,"metadata":null},{"id":"e99f221c06914614b78d2cf8197dd6d7","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-045901e9121ced8a","description":null,"metadata":null},{"id":"d1867998a1a84a58a2f8e40b0f87e5d5","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-c67947fa591ef9ed","description":null,"metadata":null},{"id":"4b7d79c8558043a987b95823d0913d96","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-55519edd689d5403","description":null,"metadata":null},{"id":"88549d00c95e4b8daee7abfbab62b98b","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-47b2dfa8afaf0ba6","description":null,"metadata":null},{"id":"3d4ac00cebc0408a8a8911f2e4993540","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-b2905d2d01709482","description":null,"metadata":null},{"id":"058a8ae95fd24494afebd3c204cb7bd5","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-44d296624f1cfeda","description":null,"metadata":null},{"id":"110390fb36f542a9bccf420aa0cc6816","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-70885c0b5459dd0f","description":null,"metadata":null},{"id":"593eaac6f2d243d0b51fe47e6ae47002","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-7541612573fa3137","description":null,"metadata":null},{"id":"11772278dcb64a5087f962c77f57b566","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-5c45c010f190f59b","description":null,"metadata":null},{"id":"c5bb8eee5bb044f4bcb1d0ae265e8cfd","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-1163f59631164968","description":null,"metadata":null},{"id":"380bf48d0d614140b6160581e519bbff","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-82b56b0dc111f75a","description":null,"metadata":null},{"id":"a7b6be9345cd4e0289bbd645875231cc","type":"COMBINATION_TREATMENT","name":"durvalumab + tremelimumab","canonical_id":"ctgov_combo:ctgov-combo-9f07bf7c055c7d4f","description":null,"metadata":null},{"id":"e5f3f8d314d642e291398e457fa4d48c","type":"DRUG","name":"duvelisib","canonical_id":"gtopdb:7795","description":null,"metadata":null},{"id":"7003595ed96649188756bbf778c31cec","type":"COMBINATION_TREATMENT","name":"duvelisib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-a9c8f01b14c822ae","description":null,"metadata":null},{"id":"3b432adf634d47bc92603155624b9c48","type":"COMBINATION_TREATMENT","name":"duvelisib + romidepsin","canonical_id":"ctgov_combo:ctgov-combo-bcb459df85aa7d4f","description":null,"metadata":null},{"id":"1ab08ac41d114a4cb66086410581b955","type":"DRUG","name":"dyclonine","canonical_id":"mesh:C100063","description":null,"metadata":null},{"id":"9067ec885b4c4d2b891d8d30a273f569","type":"DRUG","name":"dydrogesterone","canonical_id":"gtopdb:2878","description":null,"metadata":null},{"id":"936da65c3cd74eebb14cb2700f934b07","type":"DRUG","name":"dydrogesterone","canonical_id":"chembl:CHEMBL1200853","description":null,"metadata":null},{"id":"22687f9c240a43428bcb5cadff553528","type":"COMBINATION_TREATMENT","name":"dydrogesterone + medroxyprogesterone","canonical_id":"ctgov_combo:ctgov-combo-a7a4d07776fa57ad","description":null,"metadata":null},{"id":"75060d51cef7495db4b507e52ab6a755","type":"COMBINATION_TREATMENT","name":"dydrogesterone + medroxyprogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-ec53501eff164b7e","description":null,"metadata":null},{"id":"ce5a0116d10f4d03aece0b756d752f39","type":"COMBINATION_TREATMENT","name":"dydrogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-c7098850a7c73774","description":null,"metadata":null},{"id":"53571e1809864d5bb0e90c1f0f26f1a7","type":"COMBINATION_TREATMENT","name":"dydrogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-f7fadd8aaf21073b","description":null,"metadata":null},{"id":"138eac68bb86448096e1bb7c5027c034","type":"GO_TERM","name":"dynactin binding","canonical_id":"go:GO:0034452","description":"\"Binding to a dynactin complex; a large protein complex that activates dynein-based motor activity.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"84a150fdf3524e5196cf22c05ef1ea3d","type":"GO_TERM","name":"dynactin complex","canonical_id":"go:GO:0005869","description":"\"A 20S multiprotein assembly of total mass about 1.2 MDa that activates dynein-based activity in vivo. A large structural component of the complex is an actin-like 40 nm filament composed of actin-related protein, to which other components attach.\" [ISBN:0198506732]","metadata":null},{"id":"90e939e72c90448bbf61fba3c2e0ebca","type":"GO_TERM","name":"dynamic microtubule bundle","canonical_id":"go:GO:0099071","description":"\"A microtubule bundle that undergoes changes in length, and in which microtubule sliding takes place.\" [GOC:vw, PMID:26124291]","metadata":null},{"id":"deefa136e9c64ce8b0b5b5d3db1cba97","type":"GO_TERM","name":"dynein axonemal particle","canonical_id":"go:GO:0120293","description":"\"An aggregation of axonemal dyneins, their specific assembly factors, and broadly-acting chaperones that is located in the cytoplasm.\" [GOC:krc, PMID:30561330, PMID:32898505, PMID:33263282]","metadata":null},{"id":"c1183392686c4e22868a79f91fbdd733","type":"GO_TERM","name":"dynein complex","canonical_id":"go:GO:0030286","description":"\"Any of several large complexes that contain two or three dynein heavy chains and several light chains, and have microtubule motor activity.\" [ISBN:0815316194]","metadata":null},{"id":"63eb49a8c8154fddb11402a9b5090193","type":"GO_TERM","name":"dynein complex binding","canonical_id":"go:GO:0070840","description":"\"Binding to a dynein complex, a protein complex that contains two or three dynein heavy chains and several light chains, and has microtubule motor activity.\" [GOC:bf, GOC:BHF, GOC:mah]","metadata":null},{"id":"f2488fc07b104cbd998707b50430a230","type":"GO_TERM","name":"dynein heavy chain binding","canonical_id":"go:GO:0045504","description":"\"Binding to a heavy chain of the dynein complex.\" [GOC:bf]","metadata":null},{"id":"f343fbeb62bf4128b909e42652f0fd45","type":"GO_TERM","name":"dynein intermediate chain binding","canonical_id":"go:GO:0045505","description":"\"Binding to an intermediate chain of the dynein complex.\" [GOC:bf]","metadata":null},{"id":"4c2e52faa44b440bbb0fcbc94e3f89ff","type":"GO_TERM","name":"dynein light chain binding","canonical_id":"go:GO:0045503","description":"\"Binding to a light chain of the dynein complex.\" [GOC:bf]","metadata":null},{"id":"5e0828703461427c8418cb6d355332ac","type":"GO_TERM","name":"dynein light intermediate chain binding","canonical_id":"go:GO:0051959","description":"\"Binding to a light intermediate chain of the dynein complex.\" [GOC:bf]","metadata":null},{"id":"4a7a99e58b5648d3a4ca35635c4bbec2","type":"GO_TERM","name":"dynein-driven meiotic oscillatory nuclear movement","canonical_id":"go:GO:0030989","description":"\"Oscillatory movement of the nucleus involved in meiosis I. This oscillatory movement is led by an astral microtubule array emanating from the spindle pole body, and driven by the microtubule motor cytoplasmic dynein.\" [GOC:vw, PMID:16111942, PMID:9572142]","metadata":null},{"id":"07af59961d594740b640d0828fbac038","type":"GO_TERM","name":"dynorphin receptor activity","canonical_id":"go:GO:0038048","description":"\"Combining with a dynorphin peptide, and transmitting the signal across the membrane by activating an associated G-protein. Dynorphin is any opioid peptide that is generated by cleavage of the precursor protein prodynorphin.\" [GOC:bf, Wikipedia:Dynorphin]","metadata":null},{"id":"b7b0673eca284ca4953820bb1cb81a1e","type":"DISEASE","name":"dysautonomia","canonical_id":"mondo:0044872","description":null,"metadata":null},{"id":"8e8ceb02fdde4e4abb56667bb3d1cf66","type":"DISEASE","name":"dyskeratosis congenita","canonical_id":"mondo:0015780","description":null,"metadata":null},{"id":"bdcdb4a2dcac4a17bb28a1c5e65b166b","type":"DISEASE","name":"dyskeratosis congenita, digenic","canonical_id":"mondo:0031057","description":null,"metadata":null},{"id":"41725feb03b049b89c74b156ff5e460e","type":"DISEASE","name":"dyspepsia","canonical_id":"mondo:0002268","description":null,"metadata":null},{"id":"f1d68baabc994da3b1b0c1d10de562e2","type":"DISEASE","name":"dysplasminogenemia","canonical_id":"mondo:0100538","description":null,"metadata":null},{"id":"9a888d432e8e4fc9a37ea471e5493342","type":"DISEASE","name":"dystonia 5","canonical_id":"mondo:0007495","description":null,"metadata":null},{"id":"8e3dafdf4b85409ab0d23a0ee95bc423","type":"DISEASE","name":"dystonic disorder","canonical_id":"mondo:0003441","description":null,"metadata":null},{"id":"136dfae5251548ffa51a12ce5ab4ed69","type":"GO_TERM","name":"dystrobrevin complex","canonical_id":"go:GO:0016014","description":"\"A protein complex comprising alpha- and beta-dystrobrevin; forms part of the dystrophin glycoprotein complex.\" [PMID:15117830, PMID:16710609]","metadata":null},{"id":"89c8992317d04f979958819983364ea2","type":"GO_TERM","name":"dystroglycan binding","canonical_id":"go:GO:0002162","description":"\"Binding to dystroglycan, a glycoprotein found in non-muscle tissues as well as in muscle tissues, often in association with dystrophin. The native dystroglycan cleaved into two non-covalently associated subunits, alpha (N-terminal) and beta (C-terminal).\" [GOC:hjd]","metadata":null},{"id":"f0d4786e322a4404a3025c812f8c6858","type":"GO_TERM","name":"dystroglycan complex","canonical_id":"go:GO:0016011","description":"\"A protein complex that includes alpha- and beta-dystroglycan, which are alternative products of the same gene; the laminin-binding component of the dystrophin-associated glycoprotein complex, providing a link between the subsarcolemmal cytoskeleton (in muscle cells) and the extracellular matrix. Alpha-dystroglycan is an extracellular protein binding to alpha-laminin and to beta-dystroglycan; beta-dystroglycan is a transmembrane protein which binds alpha-dystroglycan and dystrophin.\" [PMID:15117830, PMID:16710609]","metadata":null},{"id":"2f7e04f0f2f74790873347b100710f01","type":"GO_TERM","name":"dystrophin-associated glycoprotein complex","canonical_id":"go:GO:0016010","description":"\"A multiprotein complex that forms a strong mechanical link between the cytoskeleton and extracellular matrix; typical of, but not confined to, muscle cells. The complex is composed of transmembrane, cytoplasmic, and extracellular proteins, including dystrophin, sarcoglycans, dystroglycan, dystrobrevins, syntrophins, sarcospan, caveolin-3, and NO synthase.\" [PMID:15117830, PMID:16710609]","metadata":null},{"id":"05fa7dd85672443d9cb293e1948c625b","type":"DISEASE","name":"dysuria","canonical_id":"efo:0003901","description":null,"metadata":null},{"id":"e99ca5338fe04853b13cd046a505394d","type":"TRIAL","name":"eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.","canonical_id":"clinicaltrials.gov:NCT04990284","description":"Parkinson Disease","metadata":null},{"id":"6f7d1a38556147a682a26d3f8074e5a2","type":"TRIAL","name":"eGPA and Local Inflammation Within the Ear, Nose and Throat Area","canonical_id":"clinicaltrials.gov:NCT06298448","description":"EGPA - Eosinophilic Granulomatosis With Polyangiitis","metadata":null},{"id":"6b162f1937c24d72a3a1503f87f61ff4","type":"GO_TERM","name":"eIF2alpha dephosphorylation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036497","description":"\"The removal of a phosphate group from the translation initiation factor eIF2alpha, as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL, PMID:16835242]","metadata":null},{"id":"45f6db863621457b81a7a7b6221429aa","type":"GO_TERM","name":"eNoSc complex","canonical_id":"go:GO:0061773","description":"\"A chromatin silencing complex that recruits histone-modifying enzymes and upregulates silencing of rDNA in response to glucose starvation.\" [GOC:BHM, PMID:18485871]","metadata":null},{"id":"7ef8356e69a34613b3243ae891e8ed99","type":"GO_TERM","name":"eRF1 methyltransferase complex","canonical_id":"go:GO:0035657","description":"\"A protein complex required for the methylation of a glutamine (Gln) residue in the protein release factor eRF1. In S. cerevisiae, this complex consists of at least Trm112p and Mtq2p.\" [GOC:rb, PMID:17008308, PMID:20400505]","metadata":null},{"id":"9d22c6f1b4284e31847cd02421aa06b6","type":"TRIAL","name":"eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation","canonical_id":"clinicaltrials.gov:NCT07177339","description":"Pulmonary Disease, Chronic Obstructive","metadata":null},{"id":"67344273e9c04b63b95bca5e434f162a","type":"TRIAL","name":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","canonical_id":"clinicaltrials.gov:NCT02767804","description":"Non-small Cell Lung Cancer","metadata":null},{"id":"18777d3af86647fe8aba18b3911f93a3","type":"GO_TERM","name":"ear development","canonical_id":"go:GO:0043583","description":"\"The process whose specific outcome is the progression of the ear over time, from its formation to the mature structure. The ear is the sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"a40d58554462438a809bd98cac2774a5","type":"GO_TERM","name":"ear morphogenesis","canonical_id":"go:GO:0042471","description":"\"The process in which the anatomical structures of the ear are generated and organized. The ear is the sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"495cc05959f34992a484a965e4fe1463","type":"GO_TERM","name":"early distal convoluted tubule development","canonical_id":"go:GO:0072067","description":"\"The process whose specific outcome is the progression of the early distal convoluted tubule over time, from its formation to the mature structure. The early distal convoluted tubule contains DCT cells and is vasopressin-insensitive.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"39edccb0e0f2439d825f108dc6f530f2","type":"GO_TERM","name":"early endosome","canonical_id":"go:GO:0005769","description":"\"A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways.\" [GOC:mah, NIF_Subcellular:nlx_subcell_20090701, PMID:19696797]","metadata":null},{"id":"fb08fe2e571a48e2a7c6e556b7f247e0","type":"GO_TERM","name":"early endosome lumen","canonical_id":"go:GO:0031905","description":"\"The volume enclosed by the membrane of an early endosome.\" [GOC:mah]","metadata":null},{"id":"8b3405c9732542b98b749d46e2cd6d80","type":"GO_TERM","name":"early endosome membrane","canonical_id":"go:GO:0031901","description":"\"The lipid bilayer surrounding an early endosome.\" [GOC:pz]","metadata":null},{"id":"a1b4915f2f0048b3982e480a337b2c71","type":"GO_TERM","name":"early endosome to Golgi transport","canonical_id":"go:GO:0034498","description":"\"The directed movement of substances from early endosomes to the Golgi.\" [GOC:rb]","metadata":null},{"id":"c321872e5f7a4b7c86978e41c41066df","type":"GO_TERM","name":"early endosome to late endosome transport","canonical_id":"go:GO:0045022","description":"\"The directed movement of substances, in membrane-bounded vesicles, from the early sorting endosomes to the late sorting endosomes.\" [ISBN:0815316194, PMID:29980602]","metadata":null},{"id":"ac710c8fa08449198f4b33ea9752186e","type":"GO_TERM","name":"early meiotic recombination nodule assembly","canonical_id":"go:GO:0042139","description":"\"During meiosis, the aggregation, arrangement and bonding together of strand exchange proteins (recombinases) to form small, electron dense structures in association with meiotic chromosomes during leptotene and zygotene.\" [GOC:jl, PMID:9334324]","metadata":null},{"id":"eb6e4bbf86254d439b0cc9219ba0062f","type":"GO_TERM","name":"early neuron differentiation in forebrain","canonical_id":"go:GO:0021862","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of neurons. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"074fe06d761943458644642e1767cb84","type":"GO_TERM","name":"early neuron fate commitment in forebrain","canonical_id":"go:GO:0021901","description":"\"The commitment of neuroepithelial cell to become a neuron that will reside in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"185fc15b03514d2abb5fa9f6d5195656","type":"GO_TERM","name":"early phagosome","canonical_id":"go:GO:0032009","description":"\"A membrane-bounded intracellular vesicle as initially formed upon the ingestion of particulate material by phagocytosis.\" [GOC:mah, PMID:12388753]","metadata":null},{"id":"eb04dfbce8a54062a12a446db074d4c5","type":"GO_TERM","name":"early phagosome lumen","canonical_id":"go:GO:0062113","description":"\"The volume enclosed by the membrane of an early phagosome.\" [PMID:18813294]","metadata":null},{"id":"ae99a18f99a44b99a4bca39c3312c0bd","type":"GO_TERM","name":"early phagosome membrane","canonical_id":"go:GO:0036186","description":"\"The lipid bilayer surrounding an early phagosome.\" [GOC:phg]","metadata":null},{"id":"ce56731c200b45f7a04cba5db0d30f78","type":"GO_TERM","name":"early recombination nodule","canonical_id":"go:GO:0005714","description":"\"An electron dense structure that is associated with meiotic chromosomes in leptotene or zygotene during meiosis I.\" [GOC:elh]","metadata":null},{"id":"8798a554686549da8ea1724f0931c176","type":"GO_TERM","name":"early stripe melanocyte differentiation","canonical_id":"go:GO:0050933","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an early stripe melanocyte (ESM). In zebrafish, ESMs develop during the first phase (2-3 weeks of development) of the larva to adult transition (2-4 weeks of development).\" [PMID:11858836]","metadata":null},{"id":"e250a78d44ac43e7abfcd6d29ae32d80","type":"GO_TERM","name":"early viral transcription","canonical_id":"go:GO:0019085","description":"\"The first phase of viral transcription that occurs after entry of the virus into the host cell, but prior to viral genome replication. It involves the transcription of genes for non-structural proteins, and for lytic viruses, the early gene products are involved in establishing control over the host cell.\" [GOC:bf, GOC:jh2, GOC:jl]","metadata":null},{"id":"b0d12020609749319f5d2168e8eabda3","type":"DISEASE","name":"early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation","canonical_id":"mondo:0017325","description":null,"metadata":null},{"id":"2b2d5902e5294f54af758735ded79a99","type":"GO_TERM","name":"eating behavior","canonical_id":"go:GO:0042755","description":"\"The specific behavior of an organism relating to the intake of food, any substance (usually solid) that can be metabolized by an organism to give energy and build tissue.\" [GOC:jl, GOC:pr, PMID:19361967]","metadata":null},{"id":"7397df300ab4440c83ebb5ff21683ce0","type":"DRUG","name":"ebastine","canonical_id":"mesh:C058249","description":null,"metadata":null},{"id":"a54a009c2a3340f58939f990bdb09746","type":"DRUG","name":"ebronucimab","canonical_id":"gtopdb:13786","description":null,"metadata":null},{"id":"a8c138d8614a45b5ac63b32d1769acb9","type":"DRUG","name":"ecabet","canonical_id":"mesh:C061681","description":null,"metadata":null},{"id":"33359bda1f71409692be4e8bf44bfdbf","type":"GO_TERM","name":"ecdysiostatic hormone activity","canonical_id":"go:GO:0016087","description":"\"The action characteristic of ecdysiostatic hormone, a peptide hormone that inhibits ecdysone secretion.\" [DOI:10.1002/(SICI)1520-6327(1997)35\\:1, GOC:mah]","metadata":null},{"id":"bcd85c9bdce74624a90545c1f7c5dfe2","type":"GO_TERM","name":"ecdysis, chitin-based cuticle","canonical_id":"go:GO:0018990","description":"\"The shedding of the old chitin-based cuticlar fragments during the molting cycle. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"4e821289b8854b2ebd714c59061486d6","type":"GO_TERM","name":"ecdysis, collagen and cuticulin-based cuticle","canonical_id":"go:GO:0042395","description":"\"The shedding of the old collagen and cuticulin-based cuticle fragments during the molting cycle. Examples of this process are found in invertebrates.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"427c3c09390a4d3bb369329004dcc789","type":"GO_TERM","name":"ecdysis-triggering hormone activity","canonical_id":"go:GO:0008255","description":"\"The action characteristic of ecdysis-triggering hormone, a peptide hormone that, upon receptor binding, initiates pre-ecdysis and ecdysis (i.e. cuticle shedding) through direct action on the central nervous system.\" [GOC:mah, PMID:9020043]","metadata":null},{"id":"4e557514104243e6867f1c17a3b1cf74","type":"GO_TERM","name":"ecdysis-triggering hormone receptor activity","canonical_id":"go:GO:0042654","description":"\"Combining with ecdysis-triggering hormone to initiate a change in cell activity.\" [GOC:ma]","metadata":null},{"id":"ab5cba071e7640d2915f1802b1991fde","type":"GO_TERM","name":"ecdysone 20-monooxygenase activity","canonical_id":"go:GO:0004501","description":"\"Catalysis of the reaction: AH(2) + ecdysone + O2 = 20-hydroxyecdysone + A + H2O.\" [EC:1.14.99.22, RHEA:14021]","metadata":null},{"id":"c5ce5aea26914dc08f87ef0820ce4197","type":"GO_TERM","name":"ecdysone O-acyltransferase activity","canonical_id":"go:GO:0004173","description":"\"Catalysis of the reaction: Ecdysone + palmitoyl-CoA = CoA + ecdysone palmitate.\" [EC:2.3.1.139, RHEA:15217]","metadata":null},{"id":"61d5acfd7b624303bc6bb9d99d70f861","type":"GO_TERM","name":"ecdysone binding","canonical_id":"go:GO:0035100","description":"\"Binding to 20-hydroxyecdysone (ecdysone). Ecdysone is an ecdysteroid produced by the prothoracic glands of immature insects and the ovaries of adult females, which stimulates growth and molting.\" [GOC:bf, ISBN:0198506732, ISBN:0582227089]","metadata":null},{"id":"3dfddda774dd4fd487e09c4e5d6f0d0d","type":"GO_TERM","name":"ecdysone biosynthetic process","canonical_id":"go:GO:0006697","description":"\"The chemical reactions and pathways resulting in the formation of ecdysone, (22R)-2-beta,3-beta,14,22,25-pentahydroxycholest-7-en-6-one, an ecdysteroid found in insects.\" [ISBN:0198506732]","metadata":null},{"id":"ce680b09c1f44c1eb69ee6d455a56a3c","type":"GO_TERM","name":"ecdysone catabolic process","canonical_id":"go:GO:0006708","description":"\"The chemical reactions and pathways resulting in the breakdown of ecdysone, (22R)-2-beta,3-beta,14,22,25-pentahydroxycholest-7-en-6-one, an ecdysteroid found in insects.\" [ISBN:0198506732]","metadata":null},{"id":"9ca9bc9d08224497a8d2f87c36b0b889","type":"GO_TERM","name":"ecdysone metabolic process","canonical_id":"go:GO:0008205","description":"\"The chemical reactions and pathways involving ecdysone, (22R)-2-beta,3-beta,14,22,25-pentahydroxycholest-7-en-6-one, an ecdysteroid found in insects. It is the inactive prohormone of the moulting hormone ecdysterone and may have intrinsic hormonal activity at other stages of insect development.\" [ISBN:0198506732]","metadata":null},{"id":"000e918b1a834d87bf574516c7f8980d","type":"GO_TERM","name":"ecdysone oxidase activity","canonical_id":"go:GO:0047875","description":"\"Catalysis of the reaction: Ecdysone + O2 = 3-dehydroecdysone + H2O2.\" [EC:1.1.3.16, RHEA:11796]","metadata":null},{"id":"f28858a2a6dd4f9b84d5ecae93f38446","type":"GO_TERM","name":"ecdysone receptor holocomplex","canonical_id":"go:GO:0008230","description":"\"A heterodimeric complex containing the products of the insect genes Ecdysone receptor (EcR) and ultraspiracle (usp). Binding of ecdysone promotes association between the two subunits, and the receptor complex then initiates molting and metamorphosis by binding DNA and regulating the transcription of target genes.\" [GOC:bf, PMID:14592980]","metadata":null},{"id":"7250808e3a5b4b26b8584b89326c0abb","type":"GO_TERM","name":"ecdysone receptor signaling pathway","canonical_id":"go:GO:0035076","description":"\"A nuclear receptor-mediated signaling pathway initiated by an ecdysone binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf]","metadata":null},{"id":"0e39da3ca62b405a847843406639584a","type":"GO_TERM","name":"ecdysone-mediated polytene chromosome puffing","canonical_id":"go:GO:0035077","description":"\"The decondensing (loosening) and swelling of the chromosomal sites of hormone-responsive genes on polytene chromosomes in response to increased production of the steroid hormone 20-hydroxyecdysone (ecdysone) in Drosophila larvae approaching pupation.\" [GOC:bf, PMID:12543962]","metadata":null},{"id":"718c839479854f2fb84f4fbc03812e6f","type":"GO_TERM","name":"ecdysteroid 2-hydroxylase activity","canonical_id":"go:GO:0042768","description":"\"Catalysis of the hydroxylation of an ecdysteroid at carbon position 2.\" [PMID:12177427]","metadata":null},{"id":"99e8f3b68f53488ea9c04dad5b2e9320","type":"GO_TERM","name":"ecdysteroid 22-hydroxylase activity","canonical_id":"go:GO:0042767","description":"\"Catalysis of the reaction: 3-dehydro-2,22-dideoxyecdysone + 2 reduced [adrenodoxin] + O2 + 2 H+ = 3-dehydro-2-deoxyecdysone + 2 oxidized [adrenodoxin] + H2O. Other substrates include 3-dehydro-2,22,25-deoxyecdysone and 2,22-dideoxyecdysone.\" [EC:1.14.15.44, PMID:12177427]","metadata":null},{"id":"8b0e994ab0284d61bae4622ee1213d33","type":"GO_TERM","name":"ecdysteroid 22-kinase activity","canonical_id":"go:GO:0106389","description":"\"Catalysis of the reaction: an ecdysteroid + ATP = an ecdysteroid 22-phosphate + ADP + H+.\" [PMID:16899460, RHEA:67972]","metadata":null},{"id":"a69e8359f7e049d1ac222a9faca2786f","type":"GO_TERM","name":"ecdysteroid 25-hydroxylase activity","canonical_id":"go:GO:0035302","description":"\"Catalysis of the hydroxylation of an ecdysteroid at carbon position 25.\" [PMID:15350618]","metadata":null},{"id":"3332baa4f3c64ef28552392aa47ab908","type":"GO_TERM","name":"ecdysteroid UDP-glucosyltransferase activity","canonical_id":"go:GO:0050488","description":"\"Catalysis of the reaction: UDP-glucose + ecdysteroid = UDP + glucosyl-ecdysteroid.\" [GOC:ai, PMID:10073711]","metadata":null},{"id":"da91f4282e3b4610a9ba2d405a9ced75","type":"GO_TERM","name":"ecdysteroid biosynthetic process","canonical_id":"go:GO:0045456","description":"\"The chemical reactions and pathways resulting in the formation of ecdysteroids, a group of polyhydroxylated ketosteroids which initiate post-embryonic development.\" [GOC:curators]","metadata":null},{"id":"50c32c81e5bd4ab182f78860bebb7869","type":"GO_TERM","name":"ecdysteroid catabolic process","canonical_id":"go:GO:0046344","description":"\"The chemical reactions and pathways resulting in the breakdown of ecdysteroids, a group of polyhydroxylated ketosteroids which initiate post-embryonic development.\" [GOC:ai]","metadata":null},{"id":"ed9530bebbf44e28b30ebf647076b7a7","type":"GO_TERM","name":"ecdysteroid metabolic process","canonical_id":"go:GO:0045455","description":"\"The chemical reactions and pathways involving ecdysteroids, a group of polyhydroxylated ketosteroids ubiquitous in insects and other arthropods, in which they initiate post-embryonic development, including the metamorphosis of immature forms and the development of the reproductive system and the maturation of oocytes in adult females.\" [ISBN:0198506732]","metadata":null},{"id":"cdda15bfe22a4e5b94b2247dcc3c0a58","type":"GO_TERM","name":"ecdysteroid secretion","canonical_id":"go:GO:0045457","description":"\"The regulated release of ecdysteroids, a group of polyhydroxylated ketosteroids which initiate post-embryonic development.\" [GOC:curators]","metadata":null},{"id":"510e17e043244c949b79dc2515f3b294","type":"GO_TERM","name":"ecdysteroid-phosphate phosphatase activity","canonical_id":"go:GO:0102531","description":"\"Catalysis of the reaction: H2O + an ecdysteroid 22-phosphate = phosphate + an ecdysteroid. Also has activity towards other ecdysteriod phosphates including 20-hydroxyecdysone 22-phosphate (20E22P) and 2-deoxyecdysone 22-phosphate (2dE22P).\" [MetaCyc:RXN-14734, PMID:12721294]","metadata":null},{"id":"c4321583146c4da6bcd3684c66fc9404","type":"GO_TERM","name":"ecgonine methyl ester biosynthetic process","canonical_id":"go:GO:1901869","description":"\"The chemical reactions and pathways resulting in the formation of ecgonine methyl ester.\" [GOC:TermGenie, PMID:22665766]","metadata":null},{"id":"cdc7b3c0192a41429d274b06a55d30ae","type":"GO_TERM","name":"ecgonine methyl ester catabolic process","canonical_id":"go:GO:1901868","description":"\"The chemical reactions and pathways resulting in the breakdown of ecgonine methyl ester.\" [GOC:TermGenie, PMID:22665766]","metadata":null},{"id":"5a0d1d2329e84d73a1f1c8b66072c41c","type":"GO_TERM","name":"ecgonone methyl ester biosynthetic process","canonical_id":"go:GO:1901872","description":"\"The chemical reactions and pathways resulting in the formation of ecgonone methyl ester.\" [GOC:TermGenie, PMID:22665766]","metadata":null},{"id":"2918d4f426124e3b9cc912fa25142d4e","type":"GO_TERM","name":"ecgonone methyl ester catabolic process","canonical_id":"go:GO:1901871","description":"\"The chemical reactions and pathways resulting in the breakdown of ecgonone methyl ester.\" [GOC:TermGenie, PMID:22665766]","metadata":null},{"id":"2a0beaf1a7434a9295b404f3d2b3b70d","type":"GO_TERM","name":"echolocation","canonical_id":"go:GO:0050959","description":"\"Echolocation is the method used by some animals (e.g. bats, dolphins and some whales) to determine the location of something by measuring the time it takes for an echo to return from it. These animals emit sound waves and listen for the echo, calculating the distance to the object from the time lapse between sound emission and the echo returning.\" [PMID:16005275, Wikipedia:Animal_echolocation]","metadata":null},{"id":"d1a1ce06bbc643f8b2f5e3deea9b9f2d","type":"GO_TERM","name":"eclosion","canonical_id":"go:GO:0007562","description":"\"The emergence of an adult insect from a pupa case.\" [GOC:dgh, GOC:dos, GOC:mah, ISBN:0198600461]","metadata":null},{"id":"948cbc261f63443e9a4dc2c2301e2c60","type":"GO_TERM","name":"eclosion hormone activity","canonical_id":"go:GO:0008031","description":"\"The action characteristic of eclosion hormone, a peptide hormone that, upon receptor binding, triggers the death of certain muscles and neurons during insect metamorphosis.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"aded2fce3b7d4c44a01b53681b1a7b42","type":"GO_TERM","name":"eclosion rhythm","canonical_id":"go:GO:0008062","description":"\"The timing of the emergence of the adult fly from its pupal case, which usually occurs at dawn.\" [PMID:11715043]","metadata":null},{"id":"05850e3543b0438c99a7071daf1aa82e","type":"DRUG","name":"econazole","canonical_id":"mesh:D004464","description":null,"metadata":null},{"id":"dd5444b2905f413c83f5f273f7c13bd8","type":"GO_TERM","name":"ectexine","canonical_id":"go:GO:0043669","description":"\"The outer part of the exine, which stains positively with basic fuchsin in optical microscopy and has higher electron density in conventionally prepared TEM sections.\" [PMID:28904424]","metadata":null},{"id":"91812383d9d04782a4947e92984049f8","type":"GO_TERM","name":"ectoderm and mesoderm interaction","canonical_id":"go:GO:0007499","description":"\"A cell-cell signaling process occurring between the two gastrulation-generated layers of the ectoderm and the mesoderm.\" [GOC:isa_complete]","metadata":null},{"id":"21e5c6c7645a4cf0a34100d51c5ef6ec","type":"GO_TERM","name":"ectoderm development","canonical_id":"go:GO:0007398","description":"\"The process whose specific outcome is the progression of the ectoderm over time, from its formation to the mature structure. In animal embryos, the ectoderm is the outer germ layer of the embryo, formed during gastrulation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"597e57daa1a44589ba170062b26b14a7","type":"GO_TERM","name":"ectoderm formation","canonical_id":"go:GO:0001705","description":"\"The formation of ectoderm during gastrulation.\" [GOC:curators]","metadata":null},{"id":"edab4b6761f640ebbdd13f2c8831d680","type":"GO_TERM","name":"ectodermal cell differentiation","canonical_id":"go:GO:0010668","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an ectodermal cell. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2cc9765c3bdf4ce5ac4e8089ed966517","type":"GO_TERM","name":"ectodermal cell fate commitment","canonical_id":"go:GO:0001712","description":"\"The cell differentiation process that results in commitment of a cell to become part of the ectoderm.\" [GOC:curators, ISBN:0878932437]","metadata":null},{"id":"3286624be513448480ffe9233fc655a1","type":"GO_TERM","name":"ectodermal cell fate determination","canonical_id":"go:GO:0001713","description":"\"The cell fate determination process that results in a cell becoming capable of differentiating autonomously into an ectoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators, ISBN:0878932437]","metadata":null},{"id":"fd48992c15a6468a819155973be7d104","type":"GO_TERM","name":"ectodermal cell fate specification","canonical_id":"go:GO:0001715","description":"\"The cell fate determination process that results in a cell becoming becomes capable of differentiating autonomously into an ectoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:curators]","metadata":null},{"id":"e55756f01f804033ab83c9719841476d","type":"GO_TERM","name":"ectodermal digestive tract development","canonical_id":"go:GO:0007439","description":"\"The process whose specific outcome is the progression of the ectodermal digestive tract over time, from its formation to the mature structure. The ectodermal digestive tract includes those portions that are derived from ectoderm.\" [GOC:curators]","metadata":null},{"id":"18fccd3e9c544efba4ea431719e107d4","type":"GO_TERM","name":"ectodermal digestive tract morphogenesis","canonical_id":"go:GO:0048567","description":"\"The process in which the anatomical structures of the ectodermal digestive tract are generated and organized. The ectodermal digestive tract includes those portions of the digestive tract that are derived from ectoderm.\" [GOC:jid]","metadata":null},{"id":"a99da039435f439180604d4c2504d1d6","type":"DISEASE","name":"ectodermal dysplasia-syndactyly syndrome","canonical_id":"mondo:0013311","description":null,"metadata":null},{"id":"d8f1dd78c8254648bd53df91756c1a69","type":"GO_TERM","name":"ectodermal placode development","canonical_id":"go:GO:0071696","description":"\"The progression of an ectodermal placode over time from its initial formation until its mature state. An ectodermal placode is a thickening of the ectoderm that is the primordium of many structures derived from the ectoderm.\" [GOC:mah]","metadata":null},{"id":"c340f48430274bbcac638e66e4de716c","type":"GO_TERM","name":"ectodermal placode formation","canonical_id":"go:GO:0060788","description":"\"The developmental process in which an ectodermal placode forms. An ectodermal placode is a thickening of the ectoderm that is the primordium of many structures derived from the ectoderm.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"dac1c8af9f8244b2aa3887eec12c53d2","type":"GO_TERM","name":"ectodermal placode morphogenesis","canonical_id":"go:GO:0071697","description":"\"The process in which the anatomical structures of an ectodermal placode are generated and organized. An ectodermal placode is a thickening of the ectoderm that is the primordium of many structures derived from the ectoderm.\" [GOC:mah]","metadata":null},{"id":"2154798c4f1540a3bd9ebca23f823b44","type":"GO_TERM","name":"ectoine binding","canonical_id":"go:GO:0033294","description":"\"Binding to ectoine, 1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid.\" [GOC:mah]","metadata":null},{"id":"d1a7bc79018d40e386ad7407cc84385a","type":"GO_TERM","name":"ectoine biosynthetic process","canonical_id":"go:GO:0019491","description":"\"The chemical reactions and pathways resulting in the formation of ectoine (1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid), a tetrahydropyrimidine commonly synthesized by halophilic bacteria.\" [GOC:jl, PMID:11823218]","metadata":null},{"id":"252447689149460a9eb8d3f8facfd0b9","type":"GO_TERM","name":"ectoine catabolic process","canonical_id":"go:GO:0042400","description":"\"The chemical reactions and pathways resulting in the breakdown of ectoine (1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid), a tetrahydropyrimidine commonly synthesized by halophilic bacteria.\" [GOC:jl, PMID:11823218]","metadata":null},{"id":"04c53e75960d4d92872114c2d3bf9cbd","type":"GO_TERM","name":"ectoine synthase activity","canonical_id":"go:GO:0033990","description":"\"Catalysis of the reaction: N(4)-acetyl-L-2,4-diaminobutyrate = ectoine + H2O.\" [EC:4.2.1.108, RHEA:17281]","metadata":null},{"id":"664718c87b5c4a01a027a11f8014388d","type":"GO_TERM","name":"ectoine transmembrane transport","canonical_id":"go:GO:0051470","description":"\"The directed movement of ectoine across a membrane by means of some agent such as a transporter or a pore. Ectoine (1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid) is a tetrahydropyrimidine commonly synthesized by halophilic bacteria.\" [GOC:ai]","metadata":null},{"id":"533d65c40c0b46689063a21a2f4374e5","type":"GO_TERM","name":"ectopic germ cell programmed cell death","canonical_id":"go:GO:0035234","description":"\"Programmed cell death of an errant germ line cell that is outside the normal migratory path or ectopic to the gonad. This is an important mechanism of regulating germ cell survival within the embryo.\" [PMID:12814944]","metadata":null},{"id":"4d548f882e754cfab40bc6bdbd99c03d","type":"DRUG","name":"eculizumab","canonical_id":"gtopdb:6884","description":null,"metadata":null},{"id":"9b7561fc1ee64d95a858b6558c341faf","type":"DRUG","name":"eculizumab","canonical_id":"chembl:CHEMBL1201828","description":null,"metadata":null},{"id":"c56030d7f4d8408abec5a48bceb2ff5e","type":"COMBINATION_TREATMENT","name":"eculizumab + ravulizumab","canonical_id":"ctgov_combo:ctgov-combo-ff821a4bdd951811","description":null,"metadata":null},{"id":"395469f341294d1d954f418ecb617452","type":"COMBINATION_TREATMENT","name":"eculizumab + ravulizumab","canonical_id":"ctgov_combo:ctgov-combo-3e9bba5bf238bf24","description":null,"metadata":null},{"id":"16833b71af8f4dfea557cb2bfbf86449","type":"COMBINATION_TREATMENT","name":"eculizumab + ravulizumab","canonical_id":"ctgov_combo:ctgov-combo-c9190311d6d8ec22","description":null,"metadata":null},{"id":"1b1ac339734040cda69e8be194446b9c","type":"COMBINATION_TREATMENT","name":"eculizumab + ravulizumab","canonical_id":"ctgov_combo:ctgov-combo-6ff962abde3bcc9b","description":null,"metadata":null},{"id":"79094a70fd884f5987e715f3ab7e4b1a","type":"COMBINATION_TREATMENT","name":"eculizumab + ravulizumab","canonical_id":"ctgov_combo:ctgov-combo-ee92cced94ec4f7f","description":null,"metadata":null},{"id":"37b1ffc8cd164d72af80af9419991c07","type":"DRUG","name":"edaravone","canonical_id":"mesh:C005435","description":null,"metadata":null},{"id":"0d3f81f39e134ea78dc62a0ea397730c","type":"DISEASE","name":"edema","canonical_id":"efo:0009373","description":null,"metadata":null},{"id":"ae4ff330421c4df8bfbcc8ae310cd929","type":"DRUG","name":"edetic acid","canonical_id":"mesh:D004492","description":null,"metadata":null},{"id":"5ff0fcd8d3df4874b638e099ffa6676f","type":"DRUG","name":"edoxaban","canonical_id":"gtopdb:7575","description":null,"metadata":null},{"id":"872957cd224f419e982aca1b69d533a7","type":"COMBINATION_TREATMENT","name":"edoxaban + enoxaparin + warfarin","canonical_id":"ctgov_combo:ctgov-combo-3970b53567c3ae7f","description":null,"metadata":null},{"id":"afa30fe15318437586140309d3df89e6","type":"COMBINATION_TREATMENT","name":"edoxaban + fondaparinux","canonical_id":"ctgov_combo:ctgov-combo-16ed0d0facf7f8c9","description":null,"metadata":null},{"id":"047ab366b67f424db3f2a8151b044985","type":"COMBINATION_TREATMENT","name":"edoxaban + phenprocoumon","canonical_id":"ctgov_combo:ctgov-combo-f468644a7b7259fb","description":null,"metadata":null},{"id":"f313856e3cf84b56b2a536bc7b8a0c01","type":"COMBINATION_TREATMENT","name":"edoxaban + ticagrelor","canonical_id":"ctgov_combo:ctgov-combo-5e5641df1e0fefa5","description":null,"metadata":null},{"id":"1a29b0c02c29484dbd76ae89ae69ff6d","type":"DRUG","name":"efalizumab","canonical_id":"gtopdb:6593","description":null,"metadata":null},{"id":"82788e00bbb94d35aea2124888457739","type":"DRUG","name":"efalizumab","canonical_id":"chembl:CHEMBL1201575","description":null,"metadata":null},{"id":"cc5000b935d04e5882142edee8afd78e","type":"DRUG","name":"efavirenz","canonical_id":"mesh:C098320","description":null,"metadata":null},{"id":"4c8cb5f26cca4dbab9643a500297694d","type":"GO_TERM","name":"effector-mediated activation of host programmed cell death by symbiont","canonical_id":"go:GO:0034055","description":"\"A symbiont process in which a molecule secreted by the symbiont activates a programmed cell death pathway in the host to suppress the host innate immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"14b9f09b446b4885aab287b15a534b76","type":"GO_TERM","name":"effector-mediated activation of plant hypersensitive response by symbiont","canonical_id":"go:GO:0080185","description":"\"A symbiont process in which a molecule secreted by the symbiont activates a resistance gene-dependent defense response signaling pathway in the plant host, in order to activate a hypersensitive response to induce necrosis. In the plant, this process involves the direct or indirect recognition of the symbiont effector protein for example through plant resistance receptor or R proteins (or R genes).\" [PMID:16497589, PMID:22241993, PMID:23411798, PMID:27641772]","metadata":null},{"id":"bf0577f83e104bf9b7e67652306ebb6f","type":"GO_TERM","name":"effector-mediated defense to host-produced reactive oxygen species","canonical_id":"go:GO:0033661","description":"\"A process mediated by a molecule secreted by a symbiont that results in the suppression of reactive oxygen species produced by the host as part of its innate immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"f6f74b58aff9406688d0656738f66acd","type":"GO_TERM","name":"effector-mediated induction of cell cycle reactivation in host","canonical_id":"go:GO:0141017","description":"\"A symbiont process in which a molecule secreted by the symbiont reactivates the host cell cycle, resulting in DNA synthesis and host cell division, and contributing to vegetative tumor formation.\" [PMID:25888589]","metadata":null},{"id":"d03fc3e7502948d2901672a0e5aa6c34","type":"GO_TERM","name":"effector-mediated perturbation of host defenses by symbiont","canonical_id":"go:GO:0140415","description":"\"A process mediated by a molecule secreted by a symbiont that results in the modulation (either activation or suppression) of a defense response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:30610168]","metadata":null},{"id":"c7f226661f9b42828ef802fb9592863d","type":"GO_TERM","name":"effector-mediated perturbation of host innate immune response by symbiont","canonical_id":"go:GO:0140404","description":"\"A process mediated by a molecule secreted by a symbiont that results in the modulation (either activation or suppression) of a host innate immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21467214]","metadata":null},{"id":"56d6efb8797f4655a501742186f07d3f","type":"GO_TERM","name":"effector-mediated perturbation of host process by symbiont","canonical_id":"go:GO:0140418","description":"\"A process mediated by a molecule secreted by a symbiont that results in the modulation (either activation or suppression) of a host structure or process. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21467214]","metadata":null},{"id":"c15ffe7a41704736a4658236697eca5b","type":"GO_TERM","name":"effector-mediated suppression of host defense response","canonical_id":"go:GO:0140590","description":"\"A process mediated by a molecule secreted by a symbiont that results in the suppression of a defense response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:28082413]","metadata":null},{"id":"fb12e9616640449a9c24a576574ab777","type":"GO_TERM","name":"effector-mediated suppression of host innate immune response","canonical_id":"go:GO:0140403","description":"\"A process mediated by a molecule secreted by a symbiont that results in the suppression of a host innate immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21467214, PMID:30584105]","metadata":null},{"id":"d999368ce9c04a59b7e716f2297b51df","type":"GO_TERM","name":"effector-mediated suppression of host pattern-triggered immunity","canonical_id":"go:GO:0052034","description":"\"A process mediated by a molecule secreted by a symbiont that results in the suppression of the innate immune response of the host organism via recognition of a microbe-associated molecular pattern. The innate immune response is the host's first line of defense against infection. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mah]","metadata":null},{"id":"81ed7f8452834c2eb4180b11d2ed211e","type":"GO_TERM","name":"effector-mediated suppression of host pattern-triggered immunity signaling","canonical_id":"go:GO:0140423","description":"\"A process mediated by a molecule secreted by a symbiont that results in the suppression of a pattern-triggered immunity PTI signaling pathway. PTI signaling pathways are found in plants.\" [PMID:30584105]","metadata":null},{"id":"c297012782474521a2577024929ba15b","type":"GO_TERM","name":"effector-mediated suppression of host salicylic acid-mediated innate immune signaling","canonical_id":"go:GO:0140502","description":"\"A process mediated by a molecule secreted by a symbiont that results in the suppression of host salicylic acid-mediated innate immune signaling.\" [PMID:25438793, PMID:30651637]","metadata":null},{"id":"e867ef797a024c17acb32a6f8cf26f9a","type":"GO_TERM","name":"efferent axon development in a lateral line nerve","canonical_id":"go:GO:0048894","description":"\"The process whose specific outcome is the progression of an efferent axon in a lateral line nerve over time from its formation to the mature structure. This process includes axonogenesis and pathfinding of the efferent axons in any lateral line nerve.\" [PMID:15832385]","metadata":null},{"id":"6a862fa5e8104d15a336cdf0b4cb8b18","type":"GO_TERM","name":"efferent axon development in anterior lateral line nerve","canonical_id":"go:GO:0048911","description":"\"The process whose specific outcome is the progression of an efferent axon in the anterior lateral line nerve over time from its formation to the mature structure. This process includes axonogenesis and pathfinding of the efferent axons in the anterior lateral line nerve.\" [PMID:15018940]","metadata":null},{"id":"c18e04102627425e82020eeee362a705","type":"GO_TERM","name":"efferent axon development in posterior lateral line nerve","canonical_id":"go:GO:0048929","description":"\"The process whose specific outcome is the progression of an efferent axon in the posterior lateral line nerve over time from its formation to the mature structure. This process includes axonogenesis and pathfinding of the efferent axons in the posterior lateral line nerve.\" [PMID:15018940]","metadata":null},{"id":"de6f6e99d6e64e19b518d821177ace57","type":"GO_TERM","name":"efflux pump complex","canonical_id":"go:GO:1990281","description":"\"A protein complex that is capable of efflux transmembrane transporter activity.\" [GOC:dos, PMID:21556065, PMID:9417051]","metadata":null},{"id":"36016e5eb905490ab7b2c1a2bf4382bc","type":"GO_TERM","name":"efflux transmembrane transporter activity","canonical_id":"go:GO:0015562","description":"\"Enables the transfer of a specific substance or related group of substances from the inside of the cell to the outside of the cell across a membrane.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"549962ea1a4e4cbea72f8823879c44f6","type":"DRUG","name":"efgartigimod alfa","canonical_id":"gtopdb:9777","description":null,"metadata":null},{"id":"97b5359346314e4eba0527de97a8b2b5","type":"DRUG","name":"efgartigimod alfa","canonical_id":"chembl:CHEMBL4297551","description":null,"metadata":null},{"id":"02bb602eaa6240969e75b8325e75ab21","type":"DRUG","name":"eflornithine","canonical_id":"gtopdb:5176","description":null,"metadata":null},{"id":"a008b6d61383477fb79f087852146087","type":"DRUG","name":"efonidipine","canonical_id":"mesh:C066425","description":null,"metadata":null},{"id":"e046d542e3dc459cae687ce3d1e76180","type":"GO_TERM","name":"egasyn-beta-glucuronidase complex","canonical_id":"go:GO:0070385","description":"\"A protein complex that contains beta-glucuronidase and the carboxyl esterase egasyn; formation of the complex causes beta-glucuronidase to be retained in the endoplasmic reticulum.\" [PMID:7744842]","metadata":null},{"id":"4d59afd87313481dad6094f7c3fec81c","type":"GO_TERM","name":"egg activation","canonical_id":"go:GO:0007343","description":"\"The process in which the egg becomes metabolically active, initiates protein and DNA synthesis and undergoes structural changes to its cortex and/or cytoplasm.\" [GOC:bf, PMID:9630751]","metadata":null},{"id":"d02f4c4b86a2400093a370f6bfa714b1","type":"GO_TERM","name":"egg chorion","canonical_id":"go:GO:0042600","description":"\"A protective, noncellular membrane that surrounds the eggs of various animals including insects and fish.\" [GOC:jl, ISBN:0721662544]","metadata":null},{"id":"1f560847fe8346afafb7806f06adfcba","type":"GO_TERM","name":"egg chorion assembly","canonical_id":"go:GO:0007306","description":"\"Construction of the chorion portion of the egg, which is a protective, noncellular membrane that surrounds the eggs of various animals including insects and fish.\" [GOC:dph, GOC:mtg_sensu, GOC:tb, ISBN:0879694238, PMID:24804966]","metadata":null},{"id":"03844bbf0b1548e3a366b7325bfe558c","type":"GO_TERM","name":"egg coat","canonical_id":"go:GO:0035805","description":"\"A specialized extracellular matrix that surrounds the plasma membrane of the ovum of animals. The egg coat provides structural support and can play an essential role in oogenesis, fertilization and early development.\" [PMID:16944418, PMID:17163408]","metadata":null},{"id":"0da03bd087a24854bb8ae7b0327c9331","type":"GO_TERM","name":"egg coat formation","canonical_id":"go:GO:0035803","description":"\"Construction of an egg coat, a specialized extracellular matrix that surrounds the ovum of animals. The egg coat provides structural support and can play an essential role in oogenesis, fertilization and early development.\" [GOC:bf, GOC:sart, GOC:yaf, PMID:16944418, PMID:17163408]","metadata":null},{"id":"1f6205fec9064b4bb6ad9649cd59e742","type":"GO_TERM","name":"egg deposition","canonical_id":"go:GO:0160027","description":"\"The multicellular organismal reproductive process that results in the movement of an egg from within an organism into the external environment.\" [PMID:18050396, PMID:31164023]","metadata":null},{"id":"edbc98bb549d4e6894015b2567ca38ce","type":"GO_TERM","name":"egg-laying behavior","canonical_id":"go:GO:0018991","description":"\"A reproductive behavior that results in the deposition of eggs (either fertilized or not) upon a surface or into a medium such as water.\" [GOC:ems, PMID:18050396, PMID:31164023]","metadata":null},{"id":"2de79529c3df4bc0a4b28a2aeff200f2","type":"GO_TERM","name":"eggshell chorion gene amplification","canonical_id":"go:GO:0007307","description":"\"Amplification by up to 60-fold of the loci containing the chorion gene clusters. Amplification is necessary for the rapid synthesis of chorion proteins by the follicle cells, and occurs by repeated firing of one or more origins located within each gene cluster.\" [GOC:mtg_sensu, PMID:11157771]","metadata":null},{"id":"9c32c0299e8b4f9899b83736dfd5d87b","type":"GO_TERM","name":"eggshell formation","canonical_id":"go:GO:0030703","description":"\"Construction of the eggshell, a product of the somatic follicle cell epithelium and a structure that supports the egg in a hostile environment, minimizing water loss whilst allowing gas exchanges essential for embryonic respiration.\" [GOC:mtg_sensu, ISBN:0879694238, PMID:10822261]","metadata":null},{"id":"6814fccfa1e94ba38df2d16d508fdefb","type":"GO_TERM","name":"eiF2alpha phosphorylation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036492","description":"\"The addition of a phosphate group on to the translation initiation factor eIF2alpha, as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL, PMID:14676213, PMID:16835242]","metadata":null},{"id":"72646915899948ba874b45aab53350a8","type":"GO_TERM","name":"eif4e-cup complex","canonical_id":"go:GO:1990500","description":"\"A protein complex that causes translational repression in Drosophila. Prevents assembly of ribosomes at the mRNA by interfacing with a sequence-specific RNA-binding protein leading to recruitment of the CCR4 complex and consequently, reduction of the mRNA's poly(A) tail length. The complex is also required for dorso-ventral pattern formation in the embryo.\" [GOC:bhm, PMID:14723848]","metadata":null},{"id":"60fd8a525d2d44eb8577789e3ce7f6a2","type":"GO_TERM","name":"eisosome","canonical_id":"go:GO:0032126","description":"\"A cell part that is composed of the eisosome membrane or MCC domain, a furrow-like plasma membrane sub-domain and associated integral transmembrane proteins, and the proteins (eisosome filaments) that form a scaffolding lattice on the cytoplasmic face. Eisosomes broadly affect overall plasma membrane organization.\" [GOC:al, GOC:vw, PMID:16496001, PMID:22368779]","metadata":null},{"id":"697804a826e24e0a94c1c1cc2abbad49","type":"GO_TERM","name":"eisosome assembly","canonical_id":"go:GO:0070941","description":"\"The aggregation, arrangement and bonding together of a set of components to form an eisosome, a cell part that is composed of the eisosome membrane and eisosome filaments. The eisosome membrane, also called the MCC domain, is a furrow-like plasma membrane sub-domain with associated integral transmembrane proteins. The eisosome filaments form a scaffolding lattice on the cytoplasmic face of the membrane.\" [GOC:al, GOC:jp, GOC:mah, PMID:19564405]","metadata":null},{"id":"7d8a1f1ab81649d59617af8b9398aa1f","type":"GO_TERM","name":"eisosome filament","canonical_id":"go:GO:0036286","description":"\"A filamentous cortical structure formed, in S. pombe, by the eisosome component Pil1.\" [GOC:vw, PMID:21900489, PMID:23722945]","metadata":null},{"id":"c9e186b2c601458790838f8c01d2e2e7","type":"GO_TERM","name":"eisosome membrane domain/MCC","canonical_id":"go:GO:0090512","description":"\"A plasma membrane part that is composed of a furrow-like plasma membrane domain and associated integral transmembrane proteins.\" [GOC:al, GOC:vw, PMID:22368779]","metadata":null},{"id":"9968306d1b80461592474afda239377d","type":"DRUG","name":"elagolix","canonical_id":"gtopdb:8362","description":null,"metadata":null},{"id":"759defd93b404dd68c3c0e078c9664f0","type":"DRUG","name":"elagolix","canonical_id":"chembl:CHEMBL1208155","description":null,"metadata":null},{"id":"6434e80deef34fafa8b3fbb336aefd05","type":"COMBINATION_TREATMENT","name":"elagolix + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-4cf32f30b26967fa","description":null,"metadata":null},{"id":"63ab67fb369145d1be7cd68275a34d15","type":"GO_TERM","name":"elaioplast","canonical_id":"go:GO:0009545","description":"\"A leucoplast in which oil is stored.\" [ISBN:0140514031]","metadata":null},{"id":"af70b66e163f4c5eaa1224eed5d32b73","type":"GO_TERM","name":"elaioplast organization","canonical_id":"go:GO:0043579","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an elaioplast, a leucoplast in which oil is stored.\" [GOC:jl]","metadata":null},{"id":"7f19869768a54238a8ee0b8b79d535b7","type":"GO_TERM","name":"elaioplast stroma","canonical_id":"go:GO:0009577","description":"\"The space enclosed by the double membrane of an elaioplast.\" [GOC:mah]","metadata":null},{"id":"b79ab9f5759846f28fc8953e63edd511","type":"GO_TERM","name":"elastic fiber","canonical_id":"go:GO:0071953","description":"\"An supramolecular fiber that consists of an insoluble core of polymerized tropoelastin monomers and a surrounding mantle of microfibrils. Elastic fibers provide elasticity and recoiling to tissues and organs, and maintain structural integrity against mechanical strain.\" [GOC:BHF, PMID:12082143, PMID:16893474, PMID:20236620]","metadata":null},{"id":"c1d36b2b700b4a358a86063f37c8c5f7","type":"GO_TERM","name":"elastic fiber assembly","canonical_id":"go:GO:0048251","description":"\"Assembly of the extracellular matrix fibers that enables the matrix to recoil after transient stretching.\" [GOC:jid, PMID:10841810, PMID:12615674]","metadata":null},{"id":"d993ac6fa8b24b02b8cee49aba53c204","type":"GO_TERM","name":"elastin catabolic process","canonical_id":"go:GO:0060309","description":"\"The chemical reactions and pathways resulting in the breakdown of elastin. Elastin is a glycoprotein which is randomly coiled and crosslinked to form elastic fibers that are found in connective tissue.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"27c074d2184e49778cc82dc0ee2ef07a","type":"GO_TERM","name":"elastin metabolic process","canonical_id":"go:GO:0051541","description":"\"The chemical reactions and pathways involving elastin, a glycoprotein which is randomly coiled and crosslinked to form elastic fibers that are found in connective tissue.\" [GOC:curators]","metadata":null},{"id":"61aa10c1958c4adcafa35c157b556910","type":"DRUG","name":"elbasvir","canonical_id":"mesh:C000589335","description":null,"metadata":null},{"id":"05b9936300eb492f907cb81246786a83","type":"DRUG","name":"eldecalcitol","canonical_id":"mesh:C547512","description":null,"metadata":null},{"id":"0fb97dc3ad134bde8b0f1bd5166236a7","type":"GO_TERM","name":"electroception","canonical_id":"go:GO:0050956","description":"\"The series of events required for an organism to receive an electrical stimulus, convert it to a molecular signal, and recognize and characterize the signal. Many fish possess an electroception sense; for example, the electric eel uses low voltage pulses of electricity for navigation and prey location.\" [GOC:ai, PMID:10210663, Wikipedia:Electroreception]","metadata":null},{"id":"163b894c9ab94774a1b90a22b97babc1","type":"GO_TERM","name":"electron transfer activity","canonical_id":"go:GO:0009055","description":"\"A molecular function representing the directed movement of electrons from one molecular entity to another, typically mediated by electron carriers or acceptors, resulting in the transfer of energy and/or the reduction-oxidation (redox) transformation of chemical species. This activity is fundamental to various biological processes, including cellular respiration and photosynthesis, as well as numerous enzymatic reactions involved in metabolic pathways.\" [Wikipedia:Electron_transfer]","metadata":null},{"id":"b25e94f6e5f74f63b99d354d3913753e","type":"GO_TERM","name":"electron transfer flavoprotein complex","canonical_id":"go:GO:0045251","description":"\"A protein complex facilitating the electron transfer from an acyl-CoA molecule to ubiquinone via its flavin adenine dinucleotide (FAD) cofactor. Usually contains an alpha and a beta subunit and the structural cofactor adenosine monophosphate (AMP). Part of a system that oxidizes an acyl-CoA molecule and reduces ubiquinone and other acceptors in the electron transport system.\" [GOC:bhm, ISBN:0198506732]","metadata":null},{"id":"ed969be27fc44d6998f4e1cd63873767","type":"GO_TERM","name":"electron transport chain","canonical_id":"go:GO:0022900","description":"\"A process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors.\" [GOC:mtg_electron_transport]","metadata":null},{"id":"51897b8dd84f41968932500bb4853dd0","type":"GO_TERM","name":"electron transport coupled proton transport","canonical_id":"go:GO:0015990","description":"\"The transport of protons against an electrochemical gradient, using energy from electron transport.\" [GOC:mah]","metadata":null},{"id":"8879b7fee99d412f874864c039cf27ff","type":"GO_TERM","name":"electron-transferring-flavoprotein dehydrogenase activity","canonical_id":"go:GO:0004174","description":"\"Catalysis of the reaction: a ubiquinone + reduced [electron-transfer flavoprotein] = a ubiquinol + H+ + oxidized [electron-transfer flavoprotein].\" [RHEA:24052]","metadata":null},{"id":"42bcd5c5b4fb4955ba3debcd2c9a337c","type":"GO_TERM","name":"electrosensory lateral line system development","canonical_id":"go:GO:0048926","description":"\"The process whose specific outcome is the progression of the electrosensory lateral line system over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"fcafeb915b99490f932b163b0bf3a4c4","type":"DRUG","name":"eletriptan","canonical_id":"gtopdb:40","description":null,"metadata":null},{"id":"7f0b0cfd16b44f769ed1429ba92c7016","type":"DRUG","name":"eletriptan","canonical_id":"mesh:C115647","description":null,"metadata":null},{"id":"98a4a859f79c47408a05a8d1bee780a5","type":"COMBINATION_TREATMENT","name":"eletriptan + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-f83ac460cc0929aa","description":null,"metadata":null},{"id":"b41221bb588d419da4aa1b70e9e1fc17","type":"COMBINATION_TREATMENT","name":"eletriptan + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-990d733098e014b9","description":null,"metadata":null},{"id":"56fe99da7bd64f8e85803b9e4d000333","type":"COMBINATION_TREATMENT","name":"eletriptan + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-de207a90a64e45b9","description":null,"metadata":null},{"id":"c8cc0a130fde4b79ac5d8e67535a566a","type":"COMBINATION_TREATMENT","name":"eletriptan + zolmitriptan","canonical_id":"ctgov_combo:ctgov-combo-7d14ee03aab8be8b","description":null,"metadata":null},{"id":"990127c95087431da7cb6e09f39a2f76","type":"DRUG","name":"eliglustat","canonical_id":"mesh:C522917","description":null,"metadata":null},{"id":"3551304bd7fa443da7de704feda03477","type":"PROTEIN","name":"elongation factor g","canonical_id":"uniprot:Q81VT3","description":null,"metadata":null},{"id":"150b7c3c290d40a3a4e7845d99fe48b9","type":"GO_TERM","name":"elongation factor-2 kinase activity","canonical_id":"go:GO:0004686","description":"\"Catalysis of the reaction: ATP + [elongation factor 2] = ADP + [elongation factor 2] phosphate.\" [EC:2.7.11.20, MetaCyc:2.7.11.20-RXN]","metadata":null},{"id":"349c45933c3640e5b7931b76a69235c5","type":"GO_TERM","name":"elongation of arista core","canonical_id":"go:GO:0035015","description":"\"The increase in length of the aristal core. The arista is the terminal segment of the antenna and consists of a central core and a series of lateral extensions.\" [GOC:bf, PMID:11404081]","metadata":null},{"id":"bb6948054e82422598c3e39648316cce","type":"GO_TERM","name":"elongation of arista lateral","canonical_id":"go:GO:0035016","description":"\"The increase in length of the aristal laterals. The arista is the terminal segment of the antenna and consists of a central core and a series of lateral extensions.\" [GOC:bf, PMID:11404081]","metadata":null},{"id":"25863b37dea94384b2be303d03815119","type":"GO_TERM","name":"elongator holoenzyme complex","canonical_id":"go:GO:0033588","description":"\"A heterohexameric protein complex composed two discrete heterotrimeric subcomplexes that is involved in modification of wobble nucleosides in tRNA.\" [GOC:bhm, GOC:jh, GOC:mah, GOC:vw, PMID:11435442, PMID:11689709, PMID:15769872, PMID:17018299, PMID:18755837, PMID:23165209]","metadata":null},{"id":"a2973978fa13474391bfe8aaabe7b048","type":"GO_TERM","name":"elongin complex","canonical_id":"go:GO:0070449","description":"\"A transcription elongation factor complex that suppresses RNA polymerase II pausing, and may act by promoting proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site. Consists of a transcriptionally active Elongin A subunit (about 100 kDa) and two smaller Elongin B (about 18 kDa) and Elongin C (about 15 kDa) subunits.\" [PMID:12676794]","metadata":null},{"id":"e71f2222b9664a31bd6fd030d5cf575c","type":"DRUG","name":"elotuzumab","canonical_id":"gtopdb:8361","description":null,"metadata":null},{"id":"324b1ea261aa4371bce4e77bf6d29e09","type":"DRUG","name":"elotuzumab","canonical_id":"chembl:CHEMBL1743010","description":null,"metadata":null},{"id":"c2ac358f7f5241e49c1bf979431b39ad","type":"COMBINATION_TREATMENT","name":"elotuzumab + isatuximab + ixazomib","canonical_id":"ctgov_combo:ctgov-combo-a87dda4b4cfa58e4","description":null,"metadata":null},{"id":"9012bcc67779470785d7e440cb5d05b8","type":"DRUG","name":"eltrombopag","canonical_id":"gtopdb:6961","description":null,"metadata":null},{"id":"be865b08a39147d692d9ada0789a11a5","type":"COMBINATION_TREATMENT","name":"eltrombopag + romiplostim","canonical_id":"ctgov_combo:ctgov-combo-1f55910f00493bf8","description":null,"metadata":null},{"id":"0797565962524fc8892aa55dfa8510f0","type":"COMBINATION_TREATMENT","name":"eltrombopag + romiplostim","canonical_id":"ctgov_combo:ctgov-combo-7482eb97f312c32b","description":null,"metadata":null},{"id":"6989d73e0949455b9d374aa42d184058","type":"COMBINATION_TREATMENT","name":"eltrombopag + romiplostim","canonical_id":"ctgov_combo:ctgov-combo-26fbba0861724bdb","description":null,"metadata":null},{"id":"651c8ea2c8ae47feb5cd066f96161e90","type":"DRUG","name":"emapalumab","canonical_id":"gtopdb:9295","description":null,"metadata":null},{"id":"a25ddad370f04053992f341b6d059278","type":"DRUG","name":"emapalumab","canonical_id":"chembl:CHEMBL3989977","description":null,"metadata":null},{"id":"4f5a3c7f15514af193b7d2f475aacd34","type":"GO_TERM","name":"emboliform nucleus development","canonical_id":"go:GO:0021737","description":"\"The process whose specific outcome is the progression of the emboliform nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"0075cb20baa44f3b84b6ebfa4a924085","type":"GO_TERM","name":"embryo development","canonical_id":"go:GO:0009790","description":"\"The process whose specific outcome is the progression of an embryo from its formation until the end of its embryonic life stage. The end of the embryonic stage is organism-specific. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant.\" [GOC:curators, GOC:isa_complete, GOC:mtg_sensu]","metadata":null},{"id":"4ceaa84242f8495295deae768eb29cc9","type":"GO_TERM","name":"embryo development ending in birth or egg hatching","canonical_id":"go:GO:0009792","description":"\"The process whose specific outcome is the progression of an embryo over time, from zygote formation until the end of the embryonic life stage. The end of the embryonic life stage is organism-specific and may be somewhat arbitrary; for mammals it is usually considered to be birth, for insects the hatching of the first instar larva from the eggshell.\" [GOC:curators, GOC:isa_complete, GOC:mtg_sensu]","metadata":null},{"id":"3df3bbd7c36842f690418f65e4d94469","type":"GO_TERM","name":"embryo development ending in seed dormancy","canonical_id":"go:GO:0009793","description":"\"The process whose specific outcome is the progression of the embryo over time, from zygote formation to the end of seed dormancy. An example of this process is found in Arabidopsis thaliana.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"12e18be288cd471e8a18db0cc653bb3d","type":"GO_TERM","name":"embryo implantation","canonical_id":"go:GO:0007566","description":"\"Attachment of the blastocyst to the uterine lining.\" [GOC:isa_complete, PMID:10882512]","metadata":null},{"id":"72b7a1c791774e95b6cf719647dee059","type":"GO_TERM","name":"embryo sac cellularization","canonical_id":"go:GO:0009558","description":"\"The process in which the eight-nucleate single celled female gametophyte develops into the seven-celled female gametophyte. This mature structure contains two synergid cells and an egg cell at the micropylar end, and three antipodal cells at the other end. A binucleate endosperm mother cell is formed at the center. An example of this process is found in Arabidopsis thaliana.\" [GOC:jid, GOC:mtg_plant, GOC:mtg_sensu, ISBN:047186840X]","metadata":null},{"id":"881a09da99fa40b498f81ee8423d94da","type":"GO_TERM","name":"embryo sac central cell differentiation","canonical_id":"go:GO:0009559","description":"\"The process in which the two uncellularized polar nuclei cellularize, fuse and acquire the specialized features of a mononucleate diploid central cell.\" [GOC:jid, GOC:mtg_plant]","metadata":null},{"id":"d1b502b2cb06471eabdfcc5cf87a36c1","type":"GO_TERM","name":"embryo sac development","canonical_id":"go:GO:0009553","description":"\"The process whose specific outcome is the progression of the embryo sac over time, from its formation to the mature structure. The process begins with the meiosis of the megasporocyte to form four haploid megaspores. Three of the megaspores disintegrate, and the fourth undergoes mitosis giving rise to a binucleate syncytial embryo sac. The two haploid nuclei migrate to the opposite poles of the embryo sac and then undergo two rounds of mitosis generating four haploid nuclei at each pole. One nucleus from each set of four migrates to the center of the cell. Cellularization occurs, resulting in an eight-nucleate seven-celled structure. This structure contains two synergid cells and an egg cell at the micropylar end, and three antipodal cells at the other end. A binucleate endosperm mother cell is formed at the center. The two polar nuclei fuse resulting in a mononucleate diploid endosperm mother cell. The three antipodal cells degenerate.\" [GOC:mtg_plant, GOC:tb]","metadata":null},{"id":"a3984addbebe4c58b3ab7bb590727a20","type":"GO_TERM","name":"embryo sac egg cell differentiation","canonical_id":"go:GO:0009560","description":"\"The process in which an uncellularized embryo sac nucleus cellularizes and acquires the specialized features of an egg cell. An example of this process is found in Arabidopsis thaliana.\" [GOC:jid, GOC:mtg_plant, GOC:mtg_sensu]","metadata":null},{"id":"2a7caa55f4a84f19b2801e493007546c","type":"GO_TERM","name":"embryo sac morphogenesis","canonical_id":"go:GO:0048314","description":"\"The process in which the anatomical structures of the embryo sac are generated and organized. The embryo sac develops from the megaspore in heterosporous plants.\" [GOC:jid, GOC:mtg_plant, PMID:12271029, PMID:25332875]","metadata":null},{"id":"4946e146450e4516bd69e6ac7453fc7f","type":"GO_TERM","name":"embryo sac nuclear migration","canonical_id":"go:GO:0009562","description":"\"The directed movement of an embryo sac nucleus to the pole or center of the cell.\" [GOC:jl, GOC:mtg_plant]","metadata":null},{"id":"ebf938f811f34d608f923d3ea19c966b","type":"GO_TERM","name":"embryonic anal fin morphogenesis","canonical_id":"go:GO:0035125","description":"\"The process, occurring in the embryo, by which the anatomical structures of the embryonic anal fin are generated and organized. An anal fin is an unpaired medial fin on the ventral aspect near the caudal end of a fish, which provides lateral stability while swimming.\" [GOC:dgh]","metadata":null},{"id":"c29e0c1674ee41ce93b1bd78128cc6a0","type":"GO_TERM","name":"embryonic anterior midgut (ectodermal) morphogenesis","canonical_id":"go:GO:0048615","description":"\"The process in which the anatomical structures of the anterior midgut (ectodermal) are generated and organized, during the embryonic phase.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"5cbfe40e55d64887b3ae0848eb4ff5ba","type":"GO_TERM","name":"embryonic appendage morphogenesis","canonical_id":"go:GO:0035113","description":"\"The process, occurring in the embryo, by which the anatomical structures of the appendage are generated and organized. An appendage is an organ or part that is attached to the trunk of an organism, such as a limb or a branch.\" [ISBN:0582227089]","metadata":null},{"id":"25d322f4ae4d4612a20c56cea5258c8e","type":"GO_TERM","name":"embryonic axis specification","canonical_id":"go:GO:0000578","description":"\"The establishment, maintenance and elaboration of a pattern along a line or a point in an embryo.\" [GOC:curators, GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"1ad4b9468614462e9957a52d649f1f47","type":"GO_TERM","name":"embryonic body morphogenesis","canonical_id":"go:GO:0010172","description":"\"The process in which the anatomical structures of the embryonic soma are generated and organized.\" [GOC:ems]","metadata":null},{"id":"f9c2a1890c1e43b6a7370c3cd918f438","type":"GO_TERM","name":"embryonic brain development","canonical_id":"go:GO:1990403","description":"\"The process occurring during the embryonic phase whose specific outcome is the progression of the brain over time, from its formation to the mature structure.\" [PMID:15918910]","metadata":null},{"id":"0fa998b9cc274789a54c8418559ed747","type":"GO_TERM","name":"embryonic camera-type eye development","canonical_id":"go:GO:0031076","description":"\"The process occurring during the embryonic phase whose specific outcome is the progression of the eye over time, from its formation to the mature structure.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"56773c44abeb4a5cb1a49e2156d2a76f","type":"GO_TERM","name":"embryonic camera-type eye formation","canonical_id":"go:GO:0060900","description":"\"The developmental process pertaining to the initial formation of a camera-type eye from unspecified neurectoderm. This process begins with the differentiation of cells that form the optic field and ends when the optic cup has attained its shape.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"565e9100177745c09b25bd5bcc88fca4","type":"GO_TERM","name":"embryonic camera-type eye morphogenesis","canonical_id":"go:GO:0048596","description":"\"The process in which the anatomical structures of the eye are generated and organized during embryonic development.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"793a687457964f12bad8e3fed3dcb259","type":"GO_TERM","name":"embryonic caudal fin morphogenesis","canonical_id":"go:GO:0035124","description":"\"The process, occurring in the embryo, by which the anatomical structures of the caudal fin are generated and organized. The caudal fin is an unpaired medial fin mounted at the caudal end of the fish and is the main fin used for propulsion.\" [GOC:dgh]","metadata":null},{"id":"0250c26c153e487e9822087f67ede654","type":"GO_TERM","name":"embryonic cleavage","canonical_id":"go:GO:0040016","description":"\"The first few specialized divisions of an activated animal egg.\" [GOC:clt, ISBN:0070524300]","metadata":null},{"id":"2c841457cebf45e8b8b939d4d8c1e567","type":"GO_TERM","name":"embryonic cranial skeleton morphogenesis","canonical_id":"go:GO:0048701","description":"\"The process in which the anatomical structures of the cranial skeleton are generated and organized during the embryonic phase.\" [GOC:dsf, GOC:jid, PMID:16049113]","metadata":null},{"id":"98a2c349f0284f2fb03b7d5aeaabf2ed","type":"GO_TERM","name":"embryonic crystal cell differentiation","canonical_id":"go:GO:0035165","description":"\"The process in which an embryonic mesoderm-derived hemocyte precursor cell acquires the specialized features of a crystal cell. Crystal cells are a class of cells that contain crystalline inclusions and are involved in the melanization of pathogenic material in the hemolymph.\" [GOC:bf, http://sdb.bio.purdue.edu/fly/gene/serpent3.htm]","metadata":null},{"id":"894f611be1994f68922344ef5306bb9d","type":"GO_TERM","name":"embryonic development via the syncytial blastoderm","canonical_id":"go:GO:0001700","description":"\"The process whose specific outcome is the progression of the embryo over time, from zygote formation through syncytial blastoderm to the hatching of the first instar larva. An example of this process is found in Drosophila melanogaster.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"ee62f77e20254908a98dbdc5a70aacb1","type":"GO_TERM","name":"embryonic digestive tract development","canonical_id":"go:GO:0048566","description":"\"The process whose specific outcome is the progression of the gut over time, from its formation to the mature structure during embryonic development. The gut is the region of the digestive tract extending from the beginning of the intestines to the anus.\" [GOC:curators]","metadata":null},{"id":"64f3e99f1cd04dd5b6d6ee4bccee7558","type":"GO_TERM","name":"embryonic digestive tract morphogenesis","canonical_id":"go:GO:0048557","description":"\"The process in which the anatomical structures of the digestive tract are generated and organized during embryonic development. The digestive tract is the anatomical structure through which food passes and is processed.\" [GOC:curators]","metadata":null},{"id":"ce934ae6ac1042089a97397060de3c20","type":"GO_TERM","name":"embryonic digit morphogenesis","canonical_id":"go:GO:0042733","description":"\"The process, occurring in the embryo, by which the anatomical structures of the digit are generated and organized. A digit is one of the terminal divisions of an appendage, such as a finger or toe.\" [GOC:bf, GOC:jl, UBERON:0002544]","metadata":null},{"id":"8463b35e88804c4f903719a6e43e57fd","type":"GO_TERM","name":"embryonic dorsal fin morphogenesis","canonical_id":"go:GO:0035123","description":"\"The process, occurring in the embryo, by which the anatomical structures of the dorsal fin are generated and organized. A dorsal fin is an unpaired medial fin on the dorsal aspect of a fish that provides lateral stability while swimming. Generally fish have one or two dorsal fins.\" [GOC:dgh]","metadata":null},{"id":"cf1ab02f8f484c5aa264b9c2112718c0","type":"GO_TERM","name":"embryonic ectodermal digestive tract development","canonical_id":"go:GO:0048611","description":"\"The process, occurring during the embryonic phase, whose specific outcome is the progression of the ectodermal gut over time, from its formation to the mature structure.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"427bc5fcc20c47c8988e7029c9562450","type":"GO_TERM","name":"embryonic ectodermal digestive tract morphogenesis","canonical_id":"go:GO:0048613","description":"\"The process, occurring during the embryonic phase, by which the anatomical structures of the ectodermal digestive tract are generated and organized.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"4ecc5145bcf34e198ae3ffe0ce4b9870","type":"GO_TERM","name":"embryonic epithelial tube formation","canonical_id":"go:GO:0001838","description":"\"The morphogenesis of an embryonic epithelium into a tube-shaped structure.\" [GOC:dph, ISBN:0824072820]","metadata":null},{"id":"b8a368f33c604897ad6de4da52e192de","type":"GO_TERM","name":"embryonic eye morphogenesis","canonical_id":"go:GO:0048048","description":"\"The process occurring in the embryo by which the anatomical structures of the post-embryonic eye are generated and organized.\" [GOC:jid]","metadata":null},{"id":"eaf2f597d4c34a29ad93144a371764d2","type":"GO_TERM","name":"embryonic foregut morphogenesis","canonical_id":"go:GO:0048617","description":"\"The process in which the anatomical structures of the foregut are generated and organized, during the embryonic phase.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"c813f1305d0e47eebaced32f8c85b768","type":"GO_TERM","name":"embryonic forelimb morphogenesis","canonical_id":"go:GO:0035115","description":"\"The process, occurring in the embryo, by which the anatomical structures of the forelimb are generated and organized. The forelimbs are the front limbs of an animal, e.g. the arms of a human.\" [ISBN:0198612001]","metadata":null},{"id":"a85c84fcb3d44b86bbde69f42667a806","type":"GO_TERM","name":"embryonic genitalia morphogenesis","canonical_id":"go:GO:0030538","description":"\"The process, occurring in the embryo, by which the anatomical structures of the genitalia are generated and organized.\" [GOC:bf]","metadata":null},{"id":"32c6f241b20340e38e1328184d267769","type":"GO_TERM","name":"embryonic heart tube anterior/posterior pattern specification","canonical_id":"go:GO:0035054","description":"\"The establishment, maintenance and elaboration of cell differentiation that results in the anterior/posterior subdivision of the embryonic heart tube. In Drosophila this results in subdivision of the dorsal vessel into to the posterior heart proper and the anterior aorta.\" [GOC:bf, PMID:12435360]","metadata":null},{"id":"3d48878a43074392a79a4ce186d6c01b","type":"GO_TERM","name":"embryonic heart tube development","canonical_id":"go:GO:0035050","description":"\"The process whose specific outcome is the progression of the embryonic heart tube over time, from its formation to the mature structure. The heart tube forms as the heart rudiment from the heart field.\" [GOC:curators]","metadata":null},{"id":"fa7a90c1be2a4328a018a0e318d75324","type":"GO_TERM","name":"embryonic heart tube dorsal/ventral pattern formation","canonical_id":"go:GO:0060970","description":"\"The regionalization process in which the areas along the dorsal/ventral axis of the embryonic heart tube are established. This process will determine the patterns of cell differentiation along the axis.\" [GOC:mtg_heart]","metadata":null},{"id":"55fdcf51a5b9410d90976cd947b1e721","type":"GO_TERM","name":"embryonic heart tube elongation","canonical_id":"go:GO:0036306","description":"\"The developmental growth that results in the increase in length of the embryonic heart tube. The embryonic heart tube is an epithelial tube that will give rise to the mature heart.\" [GOC:BHF, GOC:gr, PMID:15901664]","metadata":null},{"id":"75a720270cda420abb2b952c5fc597e3","type":"GO_TERM","name":"embryonic heart tube formation","canonical_id":"go:GO:0003144","description":"\"The process that gives rise to the embryonic heart tube. This process pertains to the initial formation of a structure from unspecified parts. The embryonic heart tube is an epithelial tube that will give rise to the mature heart.\" [GOC:mtg_heart]","metadata":null},{"id":"27bc27f79857410990501a6cb8ba4959","type":"GO_TERM","name":"embryonic heart tube formation via epithelial folding","canonical_id":"go:GO:0003145","description":"\"The process that gives rise to the embryonic heart tube by the cells of the heart field along a linear axis.\" [GOC:mtg_heart]","metadata":null},{"id":"659bfb78d02d4d32b76b17ca11626b67","type":"GO_TERM","name":"embryonic heart tube left/right pattern formation","canonical_id":"go:GO:0060971","description":"\"The pattern specification process that results in the subdivision of the left/right axis of the embryonic heart tube in space to define an area or volume in which specific patterns of cell differentiation will take place.\" [GOC:mtg_heart]","metadata":null},{"id":"3a5c862b69a4467ab1701cdf9fdaa483","type":"GO_TERM","name":"embryonic heart tube morphogenesis","canonical_id":"go:GO:0003143","description":"\"The process in which the anatomical structures of the embryonic heart tube are generated and organized. The embryonic heart tube is an epithelial tube that will give rise to the mature heart.\" [GOC:mtg_heart]","metadata":null},{"id":"488d6c18fdd54bdeb4e0c697f1673d1e","type":"GO_TERM","name":"embryonic hemocyte differentiation","canonical_id":"go:GO:0035163","description":"\"The process in which a relatively unspecialized cell derived from the embryonic head mesoderm acquires the specialized features of a mature hemocyte. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen.\" [GOC:bf, GOC:mtg_sensu, PMID:14602069]","metadata":null},{"id":"be6ec539537046a5848d6d9cda3bf7fb","type":"GO_TERM","name":"embryonic hemopoiesis","canonical_id":"go:GO:0035162","description":"\"The stages of blood cell formation that take place within the embryo.\" [GOC:bf]","metadata":null},{"id":"6e7053a54d7d401eb0d6fad7bf103802","type":"GO_TERM","name":"embryonic hindgut morphogenesis","canonical_id":"go:GO:0048619","description":"\"The process in which the anatomical structures of the hindgut are generated and organized, during the embryonic phase.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"8903c0c6943c433b92329f945781557d","type":"GO_TERM","name":"embryonic hindlimb morphogenesis","canonical_id":"go:GO:0035116","description":"\"The process, occurring in the embryo, by which the anatomical structures of the hindlimbs are generated and organized. The hindlimbs are the posterior limbs of an animal.\" [ISBN:0198612001]","metadata":null},{"id":"02ecfab98ff7425fa1de701330182b58","type":"GO_TERM","name":"embryonic limb morphogenesis","canonical_id":"go:GO:0030326","description":"\"The process, occurring in the embryo, by which the anatomical structures of the limb are generated and organized. A limb is an appendage of an animal used for locomotion or grasping.\" [GOC:bf, GOC:jl, ISBN:0395825172]","metadata":null},{"id":"5a41efeb994942db94117cecbe1d1d61","type":"GO_TERM","name":"embryonic liver development","canonical_id":"go:GO:1990402","description":"\"The process occurring during the embryonic phase whose specific outcome is the progression of the liver over time, from its formation to the mature structure.\" [PMID:15918910]","metadata":null},{"id":"3627b00639dc49a1a1f5e0508bcf869a","type":"GO_TERM","name":"embryonic lung development","canonical_id":"go:GO:1990401","description":"\"The process occurring during the embryonic phase whose specific outcome is the progression of the lung over time, from its formation to the mature structure.\" [PMID:24785085]","metadata":null},{"id":"132c999bd5bd4f279a8d33072690fb91","type":"GO_TERM","name":"embryonic medial fin morphogenesis","canonical_id":"go:GO:0035122","description":"\"The process, occurring in the embryo, by which the anatomical structures of the medial fin are generated and organized. Medial fins are unpaired fins of fish, usually located dorsomedially or ventromedially and primarily used for stability while swimming.\" [GOC:dgh]","metadata":null},{"id":"d6cfeac4cda94968b840149fc38f1545","type":"GO_TERM","name":"embryonic meristem development","canonical_id":"go:GO:0048508","description":"\"The process whose specific outcome is the progression of the embryonic meristem over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"23e340cc0c4d4c94b6b3b7ff309585f9","type":"GO_TERM","name":"embryonic meristem initiation","canonical_id":"go:GO:0090421","description":"\"Initiation of a region of tissue in a plant embryo that is composed of one or more undifferentiated cells capable of undergoing mitosis and differentiation.\" [GOC:tb]","metadata":null},{"id":"a40350fe59ee402f91fcee45c81b7972","type":"GO_TERM","name":"embryonic morphogenesis","canonical_id":"go:GO:0048598","description":"\"The process in which anatomical structures are generated and organized during the embryonic phase. The embryonic phase begins with zygote formation. The end of the embryonic phase is organism-specific. For example, it would be at birth for mammals, larval hatching for insects and seed dormancy in plants.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"07a9076df4e54747a61fe466939e5df7","type":"GO_TERM","name":"embryonic nail plate morphogenesis","canonical_id":"go:GO:0035880","description":"\"The process, occurring in the embryo, by which the anatomical structures of a nail plate are generated and organized. The nail plate is the hard and translucent portion of the nail, composed of keratin, and serves to protect the tips of digits.\" [GOC:BHF, GOC:vk, ISBN:0323025781, PMID:11369996, UBERON:0008198, Wikipedia:Nail_(anatomy)]","metadata":null},{"id":"3a011fe93ba04803857cdbef300b3185","type":"GO_TERM","name":"embryonic neurocranium morphogenesis","canonical_id":"go:GO:0048702","description":"\"The process in which the anatomical structures of the neurocranium are generated and organized during the embryonic phase. The neurocranium is the portion of the vertebrate skull surrounding the brain.\" [GOC:dsf, GOC:jid, PMID:16049113]","metadata":null},{"id":"28c08cc410284e81958e47de1053372c","type":"GO_TERM","name":"embryonic olfactory bulb interneuron precursor migration","canonical_id":"go:GO:0021831","description":"\"The directed movement of individual interneuron precursors during the embryonic development of the olfactory bulb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"5bc2ea3caf83402b91a4c6ee645d7ce0","type":"GO_TERM","name":"embryonic organ development","canonical_id":"go:GO:0048568","description":"\"Development, taking place during the embryonic phase, of a tissue or tissues that work together to perform a specific function or functions. Development pertains to the process whose specific outcome is the progression of a structure over time, from its formation to the mature structure. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:jid]","metadata":null},{"id":"f7fcdedbc30b498da27dfc5b89eb2404","type":"GO_TERM","name":"embryonic organ morphogenesis","canonical_id":"go:GO:0048562","description":"\"Morphogenesis, during the embryonic phase, of a tissue or tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:jid]","metadata":null},{"id":"da1dc32da09c4dddade09c0ebdbd14b5","type":"GO_TERM","name":"embryonic pattern specification","canonical_id":"go:GO:0009880","description":"\"The process that results in the patterns of cell differentiation that will arise in an embryo.\" [GOC:curators, ISBN:0521436125]","metadata":null},{"id":"76e7aef0c096425491feb65776311bb8","type":"GO_TERM","name":"embryonic pectoral fin morphogenesis","canonical_id":"go:GO:0035118","description":"\"The process, occurring in the embryo, by which the anatomical structures of the pectoral fin are generated and organized. Pectoral fins are bilaterally paired fins mounted laterally and located behind the gill covers of fish. These fins are used for lateral mobility and propulsion.\" [GOC:dgh]","metadata":null},{"id":"f440fe09b59147c8a03ddc46c511e2b5","type":"GO_TERM","name":"embryonic pelvic fin morphogenesis","canonical_id":"go:GO:0035119","description":"\"The process, occurring in the embryo, by which the anatomical structures of the pelvic fin are generated and organized. The pelvic fins are bilaterally paired fins mounted in a ventral-lateral position on most fish. These fins are used primarily for lateral mobility and propulsion.\" [GOC:dgh]","metadata":null},{"id":"e4ab3c59d2c742fb883fda01739c8212","type":"GO_TERM","name":"embryonic placenta development","canonical_id":"go:GO:0001892","description":"\"The embryonically driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.\" [GOC:add, ISBN:068340007X]","metadata":null},{"id":"d25cee0e4b284ed491302176b4450ae8","type":"GO_TERM","name":"embryonic placenta morphogenesis","canonical_id":"go:GO:0060669","description":"\"The process in which the embryonic placenta is generated and organized.\" [GOC:dph]","metadata":null},{"id":"babec1f9e31742e0bf9c153613379d7e","type":"GO_TERM","name":"embryonic plasmatocyte differentiation","canonical_id":"go:GO:0035164","description":"\"The process in which an embryonic mesoderm-derived hemocyte precursor cell acquires the specialized features of the phagocytic blood-cell type, the plasmatocyte.\" [GOC:bf, PMID:11921077, PMID:8174791]","metadata":null},{"id":"bc32ec2370e74d688172bc966f27e2ad","type":"GO_TERM","name":"embryonic process involved in female pregnancy","canonical_id":"go:GO:0060136","description":"\"A reproductive process occurring in the embryo or fetus that allows the embryo or fetus to develop within the mother.\" [GOC:dph]","metadata":null},{"id":"724aac015e564035a876b8da8aadf1d7","type":"GO_TERM","name":"embryonic retina morphogenesis in camera-type eye","canonical_id":"go:GO:0060059","description":"\"The process in which the anatomical structure of the retina is generated and organized in a camera-type eye during the embryonic life stage.\" [GOC:dgh, GOC:dph]","metadata":null},{"id":"b1b6d3a662774d2eb52a9de13a23703d","type":"GO_TERM","name":"embryonic root morphogenesis","canonical_id":"go:GO:0010086","description":"\"The process in which the anatomical structures of the embryonic root are generated and organized.\" [GOC:tb]","metadata":null},{"id":"a9798fa2dd9a4a7d9d3365a2e4b065ac","type":"GO_TERM","name":"embryonic sheath","canonical_id":"go:GO:0140400","description":"\"A specialized, transient apical extracellular matrix (aECM) that overlays the apical surface of the embryonic epidermis in Caenorhabditis elegans. It is secreted just prior to the start of embryonic elongation and acts as a mechanical scaffold to maintain embryonic integrity, distribute actomyosin-dependent stress, and anchor developing muscles.\" [PMID:22278925, PMID:25798732, PMID:28526752, PMID:33036165]","metadata":null},{"id":"d622f6ef76be4abcb7c70d097b0d0ec3","type":"GO_TERM","name":"embryonic shoot morphogenesis","canonical_id":"go:GO:0010064","description":"\"The process in which the anatomical structures of embryonic shoot are generated and organized.\" [GOC:tb]","metadata":null},{"id":"5181f8cd74b84a90a5512acaa416906f","type":"GO_TERM","name":"embryonic skeletal joint development","canonical_id":"go:GO:0072498","description":"\"The process, occurring during the embryonic phase, whose specific outcome is the progression of the skeletal joints over time, from formation to mature structure.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"85e7d37bb73c410498d16049d191332e","type":"GO_TERM","name":"embryonic skeletal joint morphogenesis","canonical_id":"go:GO:0060272","description":"\"The process in which the anatomical structures of skeletal joints are generated and organized during the embryonic phase. A skeletal joint is the connecting structure between the bones of the skeleton.\" [GOC:bf, GOC:BHF, GOC:dph, UBERON:0000982]","metadata":null},{"id":"7d979e14b7a941879ad0c94570cd20d8","type":"GO_TERM","name":"embryonic skeletal limb joint morphogenesis","canonical_id":"go:GO:0036023","description":"\"The process, occurring in the embryo, in which the anatomical structures of a skeletal limb joint are generated and organized. A skeletal limb joint is the connecting structure between the bones of a limb.\" [GOC:bf, Wikipedia:Joint]","metadata":null},{"id":"e226b3bcf4024f2a9a464429ba7a0aed","type":"GO_TERM","name":"embryonic skeletal system development","canonical_id":"go:GO:0048706","description":"\"The process, occurring during the embryonic phase, whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure.\" [GOC:dph, GOC:dsf, GOC:jid, GOC:tb, PMID:16049113]","metadata":null},{"id":"8aefb83cc41d4a7b94651929c1d0f0d9","type":"GO_TERM","name":"embryonic skeletal system morphogenesis","canonical_id":"go:GO:0048704","description":"\"The process in which the anatomical structures of the skeleton are generated and organized during the embryonic phase.\" [GOC:dph, GOC:dsf, GOC:jid, GOC:tb, PMID:16049113]","metadata":null},{"id":"44b3b541896c4e11a9a6aaf2f7b69063","type":"GO_TERM","name":"embryonic viscerocranium morphogenesis","canonical_id":"go:GO:0048703","description":"\"The process in which the anatomical structures of the viscerocranium are generated and organized during the embryonic phase. The viscerocranium is the part of the skull comprising the facial bones.\" [GOC:dsf, GOC:jid, PMID:16049113]","metadata":null},{"id":"b4ad201329a3436c9e6c0fded774f5de","type":"GO_TERM","name":"emericellamide A biosynthetic process","canonical_id":"go:GO:1900617","description":"\"The chemical reactions and pathways resulting in the formation of emericellamide A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4db0b5b1b73940938a75d54cd3d3e95e","type":"GO_TERM","name":"emericellamide A catabolic process","canonical_id":"go:GO:1900616","description":"\"The chemical reactions and pathways resulting in the breakdown of emericellamide A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f6a74b79a49f479e80059fd50c3e05ed","type":"GO_TERM","name":"emericellamide biosynthetic process","canonical_id":"go:GO:1900557","description":"\"The chemical reactions and pathways resulting in the formation of emericellamide.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f0956a7d301749f5b2851fa34c86bb81","type":"GO_TERM","name":"emericellamide catabolic process","canonical_id":"go:GO:1900556","description":"\"The chemical reactions and pathways resulting in the breakdown of emericellamide.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"059293eea58f42d287b27cf58edf5148","type":"GO_TERM","name":"emericellin biosynthetic process","canonical_id":"go:GO:1900766","description":"\"The chemical reactions and pathways resulting in the formation of emericellin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"fadb6e9c636f4dab9063b9b31d193121","type":"GO_TERM","name":"emericellin catabolic process","canonical_id":"go:GO:1900765","description":"\"The chemical reactions and pathways resulting in the breakdown of emericellin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a5e242eb2ca24f6f9194899db8b3f5a8","type":"GO_TERM","name":"emodin biosynthetic process","canonical_id":"go:GO:1900575","description":"\"The chemical reactions and pathways resulting in the formation of emodin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"403874c40e4841b1b53f37bab63a10e3","type":"GO_TERM","name":"emodin catabolic process","canonical_id":"go:GO:1900574","description":"\"The chemical reactions and pathways resulting in the breakdown of emodin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4edab4f01d5f41e3a86dcc4a8f4f092b","type":"DRUG","name":"empagliflozin","canonical_id":"gtopdb:4754","description":null,"metadata":null},{"id":"2aca3aa8b628401f8d4b4970c1491502","type":"DRUG","name":"empagliflozin","canonical_id":"mesh:C570240","description":null,"metadata":null},{"id":"d0fbd9df64d344d1bc278df1a4c99edb","type":"DRUG","name":"empagliflozin","canonical_id":"chembl:CHEMBL2107830","description":null,"metadata":null},{"id":"aabbf75d02ba45249fb8ae39823334de","type":"COMBINATION_TREATMENT","name":"empagliflozin + enalapril","canonical_id":"ctgov_combo:ctgov-combo-130f4a2c6eedc210","description":null,"metadata":null},{"id":"17a3a90ce56f4b189585857c70a131bd","type":"COMBINATION_TREATMENT","name":"empagliflozin + ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-cbb5a2e6882c432a","description":null,"metadata":null},{"id":"421e6a3499244d159ef3ca8877218f67","type":"COMBINATION_TREATMENT","name":"empagliflozin + linagliptin","canonical_id":"ctgov_combo:ctgov-combo-4db1e0879a5770e6","description":null,"metadata":null},{"id":"503f18bdf944442892ee5570a3b88a2b","type":"COMBINATION_TREATMENT","name":"empagliflozin + linagliptin","canonical_id":"ctgov_combo:ctgov-combo-4f630148831324a0","description":null,"metadata":null},{"id":"701ce57636a0408ba856ff1eaa8c7b94","type":"COMBINATION_TREATMENT","name":"empagliflozin + linagliptin + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-a43626c0f6339f89","description":null,"metadata":null},{"id":"feece27a3d274b96b031c9a1078d7a0e","type":"COMBINATION_TREATMENT","name":"empagliflozin + losartan","canonical_id":"ctgov_combo:ctgov-combo-b961aa864224312a","description":null,"metadata":null},{"id":"b39ee0cea56c452286f4195f19edf4f3","type":"COMBINATION_TREATMENT","name":"empagliflozin + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-9b35d0fbb2728dcf","description":null,"metadata":null},{"id":"08c467d7a7e54ec28bca35a4251c2db2","type":"DRUG","name":"emtricitabine","canonical_id":"mesh:D000068679","description":null,"metadata":null},{"id":"08e27677a2b3403fbba519b6b2469e75","type":"DRUG","name":"enalapril","canonical_id":"gtopdb:6322","description":null,"metadata":null},{"id":"5fee1b0a9668483b8af5f8e76220c7a6","type":"COMBINATION_TREATMENT","name":"enalapril + enalaprilat","canonical_id":"ctgov_combo:ctgov-combo-0526be200fc87807","description":null,"metadata":null},{"id":"d3ccffacbaec44a395e2c5032fe1f567","type":"COMBINATION_TREATMENT","name":"enalapril + enalaprilat","canonical_id":"ctgov_combo:ctgov-combo-1bb5b00025bfa5c6","description":null,"metadata":null},{"id":"f37c3fc3143c43afbff87e1767347908","type":"COMBINATION_TREATMENT","name":"enalapril + enalaprilat + esmolol + labetalol + phentolamine","canonical_id":"ctgov_combo:ctgov-combo-58ba09349c20000f","description":null,"metadata":null},{"id":"f905c50ee0e7423abe793fee00b8e859","type":"COMBINATION_TREATMENT","name":"enalapril + enalaprilat + sitagliptin + valsartan","canonical_id":"ctgov_combo:ctgov-combo-0f9e789f099689c9","description":null,"metadata":null},{"id":"1f9a6d239ed3484082ceb399666f885b","type":"COMBINATION_TREATMENT","name":"enalapril + ertugliflozin + lisinopril + semaglutide + sotagliflozin","canonical_id":"ctgov_combo:ctgov-combo-f1d31458665c1fad","description":null,"metadata":null},{"id":"20e158a9f63d47e198bf842fc631a93e","type":"COMBINATION_TREATMENT","name":"enalapril + icatibant + valsartan","canonical_id":"ctgov_combo:ctgov-combo-9a9009362332dcef","description":null,"metadata":null},{"id":"7ffb786afcd4430cb18c1b2719665e6d","type":"COMBINATION_TREATMENT","name":"enalapril + labetalol","canonical_id":"ctgov_combo:ctgov-combo-a33fe44bc5e24434","description":null,"metadata":null},{"id":"9e9a7f62cabb42d1bbd0dd28a80bdb26","type":"COMBINATION_TREATMENT","name":"enalapril + labetalol","canonical_id":"ctgov_combo:ctgov-combo-d7989a1b4946605c","description":null,"metadata":null},{"id":"803c0c00e34f446aa1cc624e1d75af1f","type":"COMBINATION_TREATMENT","name":"enalapril + lisinopril","canonical_id":"ctgov_combo:ctgov-combo-5a009e1500ac2be1","description":null,"metadata":null},{"id":"0f54d3ffe4f9428f84892a4a155d4733","type":"COMBINATION_TREATMENT","name":"enalapril + losartan","canonical_id":"ctgov_combo:ctgov-combo-dc6659e96f2e0569","description":null,"metadata":null},{"id":"39c6637be36a4d7395e6e6a2493b535c","type":"COMBINATION_TREATMENT","name":"enalapril + losartan","canonical_id":"ctgov_combo:ctgov-combo-59f9dc788d0b6d10","description":null,"metadata":null},{"id":"9b15b86898114ad9b4408a84e26c149e","type":"COMBINATION_TREATMENT","name":"enalapril + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-c846dd1d5d4c59e7","description":null,"metadata":null},{"id":"a3b4847198d04579a2a2a1928093503f","type":"COMBINATION_TREATMENT","name":"enalapril + valsartan","canonical_id":"ctgov_combo:ctgov-combo-5177cd985b1b2101","description":null,"metadata":null},{"id":"1a95754d71404549941bba845d7ff7ed","type":"DRUG","name":"enalaprilat","canonical_id":"gtopdb:6332","description":null,"metadata":null},{"id":"3b77eb36bef24f999a785eb3eec3ce88","type":"DRUG","name":"enalaprilat","canonical_id":"chembl:CHEMBL3989406","description":null,"metadata":null},{"id":"a1ce9b2733664ca0884d34281dfc624c","type":"GO_TERM","name":"enamel mineralization","canonical_id":"go:GO:0070166","description":"\"The process in which calcium salts, mainly carbonated hydroxyapatite, are deposited in tooth enamel.\" [GOC:BHF, GOC:mah, GOC:sl, PMID:10206335, PMID:16931858, PMID:21196346]","metadata":null},{"id":"da387bd40448497a903805b4be1a06ce","type":"GO_TERM","name":"enamidase activity","canonical_id":"go:GO:0043792","description":"\"Catalysis of the reaction: 1,4,5,6-tetrahydro-6-oxonicotinate + 2 H2O = 2-formylglutarate + NH4.\" [EC:3.5.2.18, RHEA:17209]","metadata":null},{"id":"eb26e7c136604de9b045f5fd73e6a4c0","type":"DRUG","name":"encainide","canonical_id":"mesh:D016700","description":null,"metadata":null},{"id":"717f59cdce2d4f459c1e3c0268106e07","type":"GO_TERM","name":"encapsulation of foreign target","canonical_id":"go:GO:0035010","description":"\"Events resulting in the formation of a multilayered cellular sheath surrounding an invader and thus preventing its development. This defense mechanism is often seen in insects in response to nematodes or parasitoids, which are too large to be phagocytosed by individual hemocytes. In some organisms the capsule is blackened due to melanization.\" [GO_REF:0000022, GOC:bf, PMID:11846478, PMID:12225920]","metadata":null},{"id":"6314e605018f42338cb3d23b4acfa226","type":"GO_TERM","name":"encapsulin nanocompartment","canonical_id":"go:GO:0140737","description":"\"Intracellular non-membrane bound organelle, consisting of proteinaceous polyhedral shells that encapsulate enzymes, protecting the contents from their surrounding milieu and/or the milieu from reactants in their interior. The self-assembling, 25-42 nm nanocompartment shell, unlike larger bacterial microcompartments, is made of only one protein, and has only a few proteins inside. Shells about vary from about 25-42 nm in diameter. The shell protein has an HK97-like fold and probably evolved from a viral protein. Artificial encapsulin nanocompartments can be expressed and filled with cargo proteins for biotechnological uses. They are found in many bacterial and a few archaeal phyla.\" [PMID:32918485]","metadata":null},{"id":"51d2c5267acf464b84eb1719e3b5e8ad","type":"DISEASE","name":"encephalocraniocutaneous lipomatosis","canonical_id":"mondo:0013074","description":null,"metadata":null},{"id":"30ac987b5d4b4c9f81998fd2ba2cd8c9","type":"DISEASE","name":"encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy","canonical_id":"mondo:0014960","description":null,"metadata":null},{"id":"12e52b9c9a2d45aa9c52e26055592cb5","type":"GO_TERM","name":"encysted zoospore germination","canonical_id":"go:GO:0075226","description":"\"The physiological, developmental and morphological changes that occur in an encysted zoospore, that germinates by developing a germ tube that may penetrate the host directly or indirectly through an appressorium. An encysted zoospore is a zoospore which has shed its flagellum and whose membrane has fused to form a walled cyst. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"1b9613e5967e4a3fa2f3b3365e4ecd53","type":"GO_TERM","name":"endexine","canonical_id":"go:GO:0043671","description":"\"The inner part of the exine, which stains.\" [PMID:28904424]","metadata":null},{"id":"df3c9906d15b45058a6c72cc1d2b9025","type":"GO_TERM","name":"endo-1,3(4)-beta-glucanase activity","canonical_id":"go:GO:0052861","description":"\"Catalysis of the endohydrolysis of (1->3)- or (1->4)-linkages in beta-D-glucans when the glucose residue whose reducing group is involved in the linkage to be hydrolyzed is itself substituted at C-3. Substrates include laminarin, lichenin and cereal D-glucans.\" [EC:3.2.1.6]","metadata":null},{"id":"adacf3038fdf4219a108611ca7111573","type":"GO_TERM","name":"endo-1,3-alpha-L-rhamnosidase activity","canonical_id":"go:GO:0052775","description":"\"Catalysis of the reaction: R1-L-rhamnose-(1->3)-alpha-L-rhamnose-R2 + H2O = R1-L-rhamnose + L-rhamnose-R2. This reaction is the hydrolysis of an alpha-(1->3) linkage between two rhamnose residues in a polysaccharide chain.\" [GOC:mengo_curators, PMID:10439404]","metadata":null},{"id":"49addff549214fef8694df72ca32b974","type":"GO_TERM","name":"endo-1,4-beta-xylanase activity","canonical_id":"go:GO:0031176","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-xylosidic linkages in xylans.\" [EC:3.2.1.8]","metadata":null},{"id":"40d5d8a025054b8182fd437e4966fe08","type":"GO_TERM","name":"endo-alpha-(2,8)-sialidase activity","canonical_id":"go:GO:0016996","description":"\"Catalysis of the endohydrolysis of (2->8)-alpha-sialosyl linkages in oligo- or poly(sialic) acids.\" [EC:3.2.1.129]","metadata":null},{"id":"8e4efd2f714e4181b8b0639145c79a7f","type":"GO_TERM","name":"endo-alpha-N-acetylgalactosaminidase activity","canonical_id":"go:GO:0033926","description":"\"Catalysis of the reactions : D-galactosyl-3-(N-acetyl-beta-D-galactosaminyl)-L-serine + H2O = D-galactosyl-3-N-acetyl-beta-D-galactosamine + L-serine and D-galactosyl-3-(N-acetyl-beta-D-galactosaminyl)-L-threonyl + H2O = D-galactosyl-3-N-acetyl-beta-D-galactosamine + L-threonyl.\" [EC:3.2.1.97]","metadata":null},{"id":"19e821567b084a248c3fab96edb81bf1","type":"GO_TERM","name":"endo-alpha-bergamotene synthase activity","canonical_id":"go:GO:0102060","description":"\"Catalysis of the reaction: 2-cis,6-cis-farnesyl diphosphate = (-)-endo-alpha-bergamotene + diphosphoric acid.\" [GOC:pz, RHEA:30471]","metadata":null},{"id":"d6baa664739d47b2b1e6202f9a36c757","type":"GO_TERM","name":"endo-beta-bergamotene synthase activity","canonical_id":"go:GO:0102061","description":"\"Catalysis of the reaction: 2-cis,6-cis-farnesyl diphosphate = (+)-endo-beta-bergamotene + diphosphoric acid.\" [GOC:pz, RHEA:30467]","metadata":null},{"id":"3448da00a8994429b331b0baf8e7cb53","type":"GO_TERM","name":"endo-xylogalacturonan hydrolase activity","canonical_id":"go:GO:0052792","description":"\"Catalysis of the endohydrolysis of xylogalacturonate by cleavage of the alpha-(1,4)-linkage. Xylogalacturonate (XGA) is composed of a chain of alpha-(1,4)-linked D-galacturonic acid residues with beta-D-xylose substituted at the O3 position.\" [GOC:mengo_curators, PMID:10618200]","metadata":null},{"id":"2aead44fc3b1440ea6a74b7c602e378e","type":"GO_TERM","name":"endobrevin-SNAP-25-syntaxin-1a complex","canonical_id":"go:GO:0070048","description":"\"A SNARE complex that contains endobrevin (VAMP8), SNAP-25, and syntaxin 1a (or orthologs thereof).\" [PMID:10336434]","metadata":null},{"id":"0775232f60a24e62bc79aefaa55ac8d8","type":"GO_TERM","name":"endobrevin-SNAP-25-syntaxin-2 complex","canonical_id":"go:GO:0070049","description":"\"A SNARE complex that contains endobrevin (VAMP8), SNAP-25, and syntaxin 2 (or orthologs thereof).\" [PMID:10336434]","metadata":null},{"id":"5e034cf7a54647ca9f3cb1fd758d057c","type":"GO_TERM","name":"endobrevin-synaptobrevin 2-alpha-SNAP-NSF-syntaxin-4 complex","canonical_id":"go:GO:0070766","description":"\"A SNARE complex that contains endobrevin (VAMP8), synaptobrevin 2 (VAMP2), alpha-SNAP, NSF, and syntaxin 4 (or orthologs thereof).\" [PMID:8973549]","metadata":null},{"id":"6aae7e8bf12940898a07ddc8674b4b91","type":"GO_TERM","name":"endocannabinoid signaling pathway","canonical_id":"go:GO:0071926","description":"\"The series of molecular signals generated as a consequence of an endocannabinoid binding to a cell surface receptor. The pathway proceeds with the receptor transmitting the signal to a heterotrimeric G-protein complex and ends with regulation of a downstream cellular process, e.g. transcription. Endocannabinoids are small molecules derived from arachidonic acid, anandamide (arachidonoylethanolamide) and 2-arachidonoylglycerol.\" [GOC:bf, GOC:mah, PMID:15550444]","metadata":null},{"id":"6d9ddba6ab724abb993836672e4f8600","type":"GO_TERM","name":"endocardial cell development","canonical_id":"go:GO:0060958","description":"\"The progression of an endocardial cell over time, from its formation to the mature cell. An endocardial cell is a specialized endothelial cell that makes up the endocardium portion of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"54ccc173fc6645df95497dea367ba476","type":"GO_TERM","name":"endocardial cell differentiation","canonical_id":"go:GO:0060956","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of an endocardial cell. An endocardial cell is a specialized endothelial cell that makes up the endocardium portion of the heart. The endocardium is the innermost layer of tissue of the heart, and lines the heart chambers.\" [GOC:mtg_heart]","metadata":null},{"id":"086379137aba410ba26f00c244981dc1","type":"GO_TERM","name":"endocardial cell fate commitment","canonical_id":"go:GO:0060957","description":"\"The commitment of a cell to an endocardial cell fate and its capacity to differentiate into an endocardial cell. An endocardial cell is a specialized endothelial cell that makes up the endocardium portion of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"caf21fa395b6470e888fdf1ea62f4bd7","type":"GO_TERM","name":"endocardial cushion cell development","canonical_id":"go:GO:0061444","description":"\"The process whose specific outcome is the progression of an endocardial cushion cell over time, from its formation to the mature state.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"0a9dcf847e9d478fb75002c4c5ce4c18","type":"GO_TERM","name":"endocardial cushion cell differentiation","canonical_id":"go:GO:0061443","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of an endocardial cushion cell.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"3025c86a357943ea8fa4bab28b22258b","type":"GO_TERM","name":"endocardial cushion cell fate commitment","canonical_id":"go:GO:0061445","description":"\"The commitment of a cell to an endocardial cushion cell fate and its capacity to differentiate into an endocardial cushion cell.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"7e746181961e4f17b6d82fa1d739b46e","type":"GO_TERM","name":"endocardial cushion cell fate determination","canonical_id":"go:GO:0061446","description":"\"The process involved in endocardial cushion cell fate commitment. Once determination has taken place, a cell becomes committed to differentiate down a particular pathway regardless of its environment.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"09d221deba7d4a46921610593d9895d7","type":"GO_TERM","name":"endocardial cushion cell fate specification","canonical_id":"go:GO:0061447","description":"\"The process involved in the specification of endocardial cushion cell identity. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"ccf4a8da83474d20a953e0bd5c8e2150","type":"GO_TERM","name":"endocardial cushion development","canonical_id":"go:GO:0003197","description":"\"The progression of a cardiac cushion over time, from its initial formation to the mature structure. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.\" [GOC:mtg_heart]","metadata":null},{"id":"959c9f6e1f1e430895b91df8cfc83b9d","type":"GO_TERM","name":"endocardial cushion formation","canonical_id":"go:GO:0003272","description":"\"The developmental process pertaining to the initial formation of an endocardial cushion. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.\" [GOC:mtg_heart, PMID:15797462]","metadata":null},{"id":"3239f5cab5354c559f32ca12c5344fe6","type":"GO_TERM","name":"endocardial cushion fusion","canonical_id":"go:GO:0003274","description":"\"The cell-cell adhesion process of mesenchymal cardiac cushion cells that contributes to the process of cushion shaping.\" [GOC:mtg_heart]","metadata":null},{"id":"eb28dba27bca493aae19ad9c7b874176","type":"GO_TERM","name":"endocardial cushion morphogenesis","canonical_id":"go:GO:0003203","description":"\"The process in which the anatomical structure of the endocardial cushion is generated and organized. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.\" [GOC:mtg_heart]","metadata":null},{"id":"8f7fa38f11524920911d1626ba671df7","type":"GO_TERM","name":"endocardial cushion to mesenchymal transition","canonical_id":"go:GO:0090500","description":"\"A transition where an endocardial cushion cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"59ac424826b74edeb98eafa062a75cc1","type":"GO_TERM","name":"endocardial cushion to mesenchymal transition involved in heart valve formation","canonical_id":"go:GO:0003199","description":"\"A transition where an endocardial cushion cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell that will contribute to the formation of a cardiac valve.\" [GOC:mtg_heart]","metadata":null},{"id":"7ccfbea3e3d64971ae5c35c3fad813dc","type":"GO_TERM","name":"endocardial endothelium development","canonical_id":"go:GO:0061147","description":"\"The progression of the endocardial endothelium over time, from its initial formation to the mature structure. The endocardium is an anatomical structure comprised of an endothelium and an extracellular matrix that forms the innermost layer of tissue of the heart, and lines the heart chambers.\" [GOC:dph]","metadata":null},{"id":"83589574fddc4e40b821e4f75a088f61","type":"GO_TERM","name":"endocardial precursor cell differentiation","canonical_id":"go:GO:0003255","description":"\"The process in which a relatively unspecialized mesodermal cell acquires the specialized structural and/or functional features of an endocardial precursor cell. A endocardial precursor cell is a cell that has been committed to a endocardial cell fate, but will undergo further cell divisions rather than terminally differentiate.\" [GOC:mtg_heart]","metadata":null},{"id":"be3e0d516f564755a5c95b6fec11d82c","type":"GO_TERM","name":"endocardial progenitor cell migration to the midline involved in heart field formation","canonical_id":"go:GO:0003262","description":"\"The orderly movement of an endocardial progenitor cell toward the midline to form the heart field. Cardiac muscle progenitor cells are non-terminally differentiated, mesoderm-derived cells that are committed to differentiate into endocardial cells of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"619bce6dfbdd4df8bcb3cb66cf1d9600","type":"DISEASE","name":"endocarditis","canonical_id":"mondo:0005025","description":null,"metadata":null},{"id":"eae05f074aba4647839d7e87e516056b","type":"GO_TERM","name":"endocardium development","canonical_id":"go:GO:0003157","description":"\"The process whose specific outcome is the progression of the endocardium over time, from its formation to the mature structure. The endocardium is an anatomical structure comprised of an endothelium and an extracellular matrix that forms the innermost layer of tissue of the heart, and lines the heart chambers.\" [GOC:mtg_heart]","metadata":null},{"id":"d701689b23944093a3fecef2c7ffabc4","type":"GO_TERM","name":"endocardium formation","canonical_id":"go:GO:0060214","description":"\"Formation of the endocardium of the heart. The endocardium is an anatomical structure comprised of an endothelium and an extracellular matrix that forms the innermost layer of tissue of the heart, and lines the heart chambers.\" [GOC:bf, GOC:dph, PMID:17722983]","metadata":null},{"id":"d8f28839b7b94c0199f30b868c1193fb","type":"GO_TERM","name":"endocardium morphogenesis","canonical_id":"go:GO:0003160","description":"\"The process in which the anatomical structure of the endocardium is generated and organized. The endocardium is an anatomical structure comprised of an endothelium and an extracellular matrix that forms the innermost layer of tissue of the heart, and lines the heart chambers.\" [GOC:mtg_heart]","metadata":null},{"id":"30a3955585e145ee89cfb076809d49d5","type":"GO_TERM","name":"endochitinase activity","canonical_id":"go:GO:0008843","description":"\"Catalysis of the hydrolysis of nonterminal (1->4)-beta linkages of N-acetyl-D-glucosamine (GlcNAc) polymers of chitin and chitodextrins. Typically, endochitinases cleave randomly within the chitin chain.\" [EC:3.2.1.14, GOC:bf, GOC:kah, GOC:pde, PMID:11468293]","metadata":null},{"id":"26c5d7f48b8f4910b4499fa1f0d56056","type":"GO_TERM","name":"endochondral bone growth","canonical_id":"go:GO:0003416","description":"\"The increase in size or mass of an endochondral bone that contributes to the shaping of the bone.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"ddbac6de7e90418fa72a9b3de2c4fecb","type":"GO_TERM","name":"endochondral bone morphogenesis","canonical_id":"go:GO:0060350","description":"\"The process in which bones are generated and organized as a result of the conversion of initial cartilaginous anlage into bone.\" [GOC:dph, PMID:11680679]","metadata":null},{"id":"450c5e6faa374b779ad3a13538b916ba","type":"GO_TERM","name":"endochondral ossification","canonical_id":"go:GO:0001958","description":"\"Replacement ossification wherein bone tissue replaces cartilage.\" [GO_REF:0000034, ISBN:0878932437]","metadata":null},{"id":"f2314b338ff741a5920709a53c46e2db","type":"GO_TERM","name":"endocrine pancreas development","canonical_id":"go:GO:0031018","description":"\"The process whose specific outcome is the progression of the endocrine pancreas over time, from its formation to the mature structure. The endocrine pancreas is made up of islet cells that produce insulin, glucagon and somatostatin.\" [GOC:cvs]","metadata":null},{"id":"5fb949af80114861b9a78f5c80c04b6e","type":"GO_TERM","name":"endocrine process","canonical_id":"go:GO:0050886","description":"\"The process that involves the secretion of or response to endocrine hormones. An endocrine hormone is a hormone released into the circulatory system.\" [ISBN:0721662544]","metadata":null},{"id":"5bb1ac729c984f7eaad176dd1e818b3b","type":"GO_TERM","name":"endocrine signaling","canonical_id":"go:GO:0038002","description":"\"The transfer of information from one cell to another, where an endocrine hormone is transported from the signal-producing cell to the receiving cell via the circulatory system (via blood, lymph or cerebrospinal fluid). The signaling cell and the receiving cell are often distant to each other.\" [GOC:mtg_signaling_feb11, ISBN:0199264678, ISBN:3527303782]","metadata":null},{"id":"2e6b7d489eed48b4b179a52ccfbd500f","type":"GO_TERM","name":"endocrine system development","canonical_id":"go:GO:0035270","description":"\"Progression of the endocrine system over time, from its formation to a mature structure. The endocrine system is a system of hormones and ductless glands, where the glands release hormones directly into the blood, lymph or other intercellular fluid, and the hormones circulate within the body to affect distant organs. The major glands that make up the human endocrine system are the hypothalamus, pituitary, thyroid, parathryoids, adrenals, pineal body, and the reproductive glands which include the ovaries and testes.\" [GOC:bf, Wikipedia:Development_of_the_endocrine_system]","metadata":null},{"id":"2a57a47a63e9476f9d24d03cae377505","type":"DISEASE","name":"endocrine system disorder","canonical_id":"mondo:0005151","description":null,"metadata":null},{"id":"ccd360c376c14d4e9396fdc831a44445","type":"GO_TERM","name":"endocrocin biosynthetic process","canonical_id":"go:GO:1900602","description":"\"The chemical reactions and pathways resulting in the formation of endocrocin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ee3406d3a2834c5f8fd9242e5824ef7f","type":"GO_TERM","name":"endocrocin catabolic process","canonical_id":"go:GO:1900601","description":"\"The chemical reactions and pathways resulting in the breakdown of endocrocin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e26173419a7d4578ad4817fdb2c8cada","type":"GO_TERM","name":"endocytic heme import into cell","canonical_id":"go:GO:0140421","description":"\"The directed movement into cell of externally available heme by receptor-mediated endocytosis.\" [PMID:28193844]","metadata":null},{"id":"5d7995666c164f6cbb1e534eb9197824","type":"GO_TERM","name":"endocytic hemoglobin import into cell","canonical_id":"go:GO:0020028","description":"\"The directed movement of hemoglobin into a cell by receptor-mediated endocytosis.\" [GOC:mb]","metadata":null},{"id":"fa8187a28e2649c3b19c03bb2a576bd4","type":"GO_TERM","name":"endocytic iron import into cell","canonical_id":"go:GO:0140298","description":"\"Uptake of iron into a cell via binding to an extracellular receptor, which is internalized by endocytosis.\" [PMID:23092063]","metadata":null},{"id":"396482403b30404a92e3bcdffac89785","type":"GO_TERM","name":"endocytic patch","canonical_id":"go:GO:0061645","description":"\"The part of the cell cortex consisting of an aggregation of proteins that will give rise to an endocytic vesicle.\" [GOC:dph, PMID:22949647]","metadata":null},{"id":"7e88d75b8a9a4aae895e8d22f02fcde8","type":"GO_TERM","name":"endocytic recycling","canonical_id":"go:GO:0032456","description":"\"The directed movement of membrane-bounded vesicles from endosomes back to the plasma membrane, a trafficking pathway that promotes the recycling of internalized transmembrane proteins.\" [PMID:16473635, PMID:23563491]","metadata":null},{"id":"502da9987c2a412591fe3773449ffd70","type":"GO_TERM","name":"endocytic targeting sequence binding","canonical_id":"go:GO:0089710","description":"\"Binding to a endocytic signal sequence, a specific peptide sequence, of 4-6 amino acids with an essential tyrosine (Y), found on cytoplasmic tails of some cell surface membrane proteins, which directs internalization by clathrin-coated pits.\" [PMID:8918456]","metadata":null},{"id":"173857dd945c496ba6e3785680935b2d","type":"GO_TERM","name":"endocytic vesicle","canonical_id":"go:GO:0030139","description":"\"A membrane-bounded intracellular vesicle formed by invagination of the plasma membrane around an extracellular substance. Endocytic vesicles fuse with early endosomes to deliver the cargo for further sorting.\" [GOC:curators, PMID:19696797]","metadata":null},{"id":"77609afa54e04dcc800c53bb7a77eda5","type":"GO_TERM","name":"endocytic vesicle lumen","canonical_id":"go:GO:0071682","description":"\"The volume enclosed by the membrane of an endocytic vesicle.\" [GOC:pde]","metadata":null},{"id":"5357fd61362e4297933b49c2e8069c63","type":"GO_TERM","name":"endocytic vesicle membrane","canonical_id":"go:GO:0030666","description":"\"The lipid bilayer surrounding an endocytic vesicle.\" [GOC:mah]","metadata":null},{"id":"91a2d2a1e8f24b3f9b711a40aed4439e","type":"GO_TERM","name":"endocytosed protein transport to vacuole","canonical_id":"go:GO:0007038","description":"\"The directed movement of proteins imported into a cell by endocytosis to the vacuole.\" [GOC:ai]","metadata":null},{"id":"6c2f879554ca4247950ada28883e7209","type":"GO_TERM","name":"endocytosed synaptic vesicle processing via endosome","canonical_id":"go:GO:0099592","description":"\"The process in which endocytosed synaptic vesicles fuse to the presynaptic endosome followed by sorting of synaptic vesicle components and budding of new synaptic vesicles.\" [GOC:dos]","metadata":null},{"id":"5f8fe2bdebf94d158c17538aaad71f58","type":"GO_TERM","name":"endocytosed synaptic vesicle to endosome fusion","canonical_id":"go:GO:0099593","description":"\"Fusion of an endocytosed synaptic vesicle with an endosome.\" [GOC:dos]","metadata":null},{"id":"e356f3313e8b47b2b314eb50af5749fb","type":"GO_TERM","name":"endocytosis","canonical_id":"go:GO:0006897","description":"\"A cellular process in which cells take up external materials or membrane constituents by the invagination of a part of the plasma membrane to form a new membrane-bounded vesicle.\" [GOC:mah, ISBN:0198506732, ISBN:0716731363, Wikipedia:Endocytosis]","metadata":null},{"id":"2b20322272844ea984ae82f18b3f766b","type":"GO_TERM","name":"endocytosis involved in viral entry into host cell","canonical_id":"go:GO:0075509","description":"\"Any endocytosis that is involved in the uptake of a virus into a host cell.\" [GOC:bf, GOC:jl, VZ:977]","metadata":null},{"id":"53b3ccebf74b4460b246f8b5bbf2bded","type":"GO_TERM","name":"endocytosis, site selection","canonical_id":"go:GO:0120207","description":"\"The process of selecting and or marking the position where endocytosis will occur.\" [GOC:vw, PMID:30044717]","metadata":null},{"id":"ab170afe234d4da3ae99de4093cfe87c","type":"GO_TERM","name":"endodeoxyribonuclease activator activity","canonical_id":"go:GO:0140656","description":"\"Binds to and increases the activity of an endodeoxyribonuclease.\" [PMID:33836577]","metadata":null},{"id":"b5e44ed754024edb9e4779f6fbf6540f","type":"GO_TERM","name":"endodeoxyribonuclease complex","canonical_id":"go:GO:1905347","description":"\"A protein complex which is capable of endodeoxyribonuclease activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:18413719]","metadata":null},{"id":"1873e088e1e3487c927d254b27662aa8","type":"GO_TERM","name":"endoderm development","canonical_id":"go:GO:0007492","description":"\"The process whose specific outcome is the progression of the endoderm over time, from its formation to the mature structure. The endoderm is the innermost germ layer that develops into the gastrointestinal tract, the lungs and associated tissues.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"620643d0ba7d4e7e86e5fac7d26f8fe6","type":"GO_TERM","name":"endoderm formation","canonical_id":"go:GO:0001706","description":"\"The formation of the endoderm during gastrulation.\" [GOC:curators]","metadata":null},{"id":"fffcfadcf6b04a3ba2b02c55f8e04118","type":"GO_TERM","name":"endodermal cell differentiation","canonical_id":"go:GO:0035987","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an endoderm cell, a cell of the inner of the three germ layers of the embryo.\" [CL:0000223, GOC:yaf, PMID:17624332]","metadata":null},{"id":"32c780a7fbce4ebaa7c6fd38e7c10734","type":"GO_TERM","name":"endodermal cell fate commitment","canonical_id":"go:GO:0001711","description":"\"The cell differentiation process that results in commitment of a cell to become part of the endoderm.\" [GOC:curators, ISBN:0878932437]","metadata":null},{"id":"e9ef1318da0f4f8a89c377ca160de9ca","type":"GO_TERM","name":"endodermal cell fate determination","canonical_id":"go:GO:0007493","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into an endoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators, ISBN:0878932437]","metadata":null},{"id":"88f7bba812314242b2e4ddcebbe2bc8f","type":"GO_TERM","name":"endodermal cell fate specification","canonical_id":"go:GO:0001714","description":"\"The cell fate determination process that results in a cell becoming capable of differentiating autonomously into an endoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:curators]","metadata":null},{"id":"0a34285c07df4007bfaf0ce752593f5f","type":"GO_TERM","name":"endodermal digestive tract morphogenesis","canonical_id":"go:GO:0061031","description":"\"The process in which the anatomical structures of the endodermal digestive tract are generated and organized. The endodermal digestive tract includes those portions of the digestive tract that are derived from endoderm.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"7960b2d2e17f496fb8f9d69c52542aa2","type":"GO_TERM","name":"endodermal-mesodermal cell signaling","canonical_id":"go:GO:0003133","description":"\"Any process that mediates the transfer of information from endodermal cells to mesodermal cells.\" [GOC:mtg_heart]","metadata":null},{"id":"6dcc4d14d8324654b931426266a15130","type":"GO_TERM","name":"endogalactosaminidase activity","canonical_id":"go:GO:0033931","description":"\"Catalysis of the endohydrolysis of (1->4)-alpha-D-galactosaminidic linkages in poly(D-galactosamine).\" [EC:3.2.1.109]","metadata":null},{"id":"1185e54128c84e3aba5d8d0ef35e8fde","type":"GO_TERM","name":"endogenous antibiotic catabolic process","canonical_id":"go:GO:0042741","description":"\"The chemical reactions and pathways resulting in the breakdown of an antibiotic that has originated internally within the cell or organism.\" [GOC:jl]","metadata":null},{"id":"4038032949924644940ea12f19350d3c","type":"GO_TERM","name":"endogenous lipid antigen binding","canonical_id":"go:GO:0030883","description":"\"Binding to an endogenous cellular lipid antigen.\" [PMID:14500461]","metadata":null},{"id":"4c74787acd844de9907011953c894655","type":"GO_TERM","name":"endoglycosylceramidase activity","canonical_id":"go:GO:0047876","description":"\"Catalysis of the reaction: H2O + oligoglycosylglucosylceramide = ceramide + oligoglycosylglucose.\" [EC:3.2.1.123, MetaCyc:ENDOGLYCOSYLCERAMIDASE-RXN]","metadata":null},{"id":"c5285e75cf94477d8c87fe5930254427","type":"GO_TERM","name":"endolysosomal intralumenal vesicle","canonical_id":"go:GO:0160316","description":"\"A membrane-bounded vesicle that is located within the lumen of an endolysosome.\" [PMID:31854087, PMID:38706230]","metadata":null},{"id":"d45fbbb0baa44399b7afe2d91b4daaea","type":"GO_TERM","name":"endolysosomal intralumenal vesicle lumen","canonical_id":"go:GO:0160318","description":"\"The volume enclosed by the membrane of an intraluminal vesicle within an endolysosome.\" [PMID:31854087, PMID:38706230]","metadata":null},{"id":"45bc062fbe3146e6abcf7ad88da2cc78","type":"GO_TERM","name":"endolysosomal intralumenal vesicle membrane","canonical_id":"go:GO:0160317","description":"\"The lipid bilayer surrounding an intraluminal vesicle within an endolysosome.\" [PMID:31854087, PMID:38706230]","metadata":null},{"id":"0c03508312304f4494cc27931c2d1968","type":"GO_TERM","name":"endolysosomal toll-like receptor signaling pathway","canonical_id":"go:GO:0140894","description":"\"The series of molecular signals initiated by a ligand binding to an endolysosomal pattern recognition receptor (PRR) of the toll-like family. PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species.\" [PMID:29679565]","metadata":null},{"id":"ed5cde36f82f4448b92bc769bc7eaae3","type":"GO_TERM","name":"endolysosome","canonical_id":"go:GO:0036019","description":"\"An transient hybrid organelle formed by fusion of a late endosome with a lysosome, and in which active degradation takes place.\" [GOC:pde, PMID:21878991]","metadata":null},{"id":"e3deddc2e77343fbaa541b7f67ce7931","type":"GO_TERM","name":"endolysosome lumen","canonical_id":"go:GO:0036021","description":"\"The volume enclosed by the membrane of an endolysosome. An endolysosome is a transient hybrid organelle formed by fusion of a late endosome with a lysosome.\" [GOC:pde]","metadata":null},{"id":"9b3b8468a2534f4daf3234b689debdee","type":"GO_TERM","name":"endolysosome membrane","canonical_id":"go:GO:0036020","description":"\"The lipid bilayer surrounding an endolysosome. An endolysosome is a transient hybrid organelle formed by fusion of a late endosome with a lysosome.\" [GOC:pde]","metadata":null},{"id":"2af0b917689f4fa4bb8ab9f9122ed3b6","type":"GO_TERM","name":"endomembrane system","canonical_id":"go:GO:0012505","description":"\"A collection of membranous structures involved in transport within the cell. The main components of the endomembrane system are endoplasmic reticulum, Golgi bodies, vesicles, cell membrane and nuclear envelope. Members of the endomembrane system pass materials through each other or though the use of vesicles.\" [GOC:lh]","metadata":null},{"id":"d98dbfd06c424b90aa8f0bb2a6ef30dc","type":"GO_TERM","name":"endomembrane system organization","canonical_id":"go:GO:0010256","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the endomembrane system.\" [GOC:mah, GOC:sm]","metadata":null},{"id":"e6564f143e4046779b81c79c86647c46","type":"DISEASE","name":"endometrial cancer","canonical_id":"mondo:0011962","description":null,"metadata":null},{"id":"dfdf90e641fc442eaf661367633b2ec3","type":"DISEASE","name":"endometrial carcinoma","canonical_id":"mondo:0002447","description":null,"metadata":null},{"id":"25dd36a9f919407799e4cf8468c56b3d","type":"DISEASE","name":"endometrial neoplasm","canonical_id":"efo:0004230","description":null,"metadata":null},{"id":"b5bbfc27a5fa4c2a9d1009ab4d7566a9","type":"DISEASE","name":"endometriosis","canonical_id":"mondo:0005133","description":null,"metadata":null},{"id":"6c6e0d5173a240afbe5641bcc591e056","type":"GO_TERM","name":"endomitotic cell cycle","canonical_id":"go:GO:0007113","description":"\"A mitotic cell cycle in which chromosomes are replicated and sister chromatids separate, but spindle formation, nuclear membrane breakdown and nuclear division do not occur, resulting in an increased number of chromosomes in the cell.\" [GOC:curators, GOC:dos, GOC:expert_vm]","metadata":null},{"id":"2571848f378d455e9cd3941fc40257d8","type":"GO_TERM","name":"endonuclear canal","canonical_id":"go:GO:0035843","description":"\"A membrane-bound structure present in the nucleus of a spermatozoon. There is variation in the number of endonuclear canals between sperm of different organisms, and some species lack these structures altogether. The endonuclear canal may provide a supporting role for the sperm nucleus, and originates during spermiogenesis from an invagination of the nuclear envelope.\" [GOC:bf, PMID:18359585]","metadata":null},{"id":"2248aedf3d594af5b75a0ecceda02568","type":"GO_TERM","name":"endonuclease activity","canonical_id":"go:GO:0004519","description":"\"Catalysis of the cleavage of ester linkages within nucleic acids by creating internal breaks.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"eb0b623fe6804405a117f60c81717258","type":"GO_TERM","name":"endonuclease complex","canonical_id":"go:GO:1905348","description":"\"A protein complex which is capable of endonuclease activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:18413719]","metadata":null},{"id":"2caa21b0872f4eff948bde169a1a467e","type":"GO_TERM","name":"endonucleolytic cleavage between LSU-rRNA and 5S rRNA of tricistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 5S)","canonical_id":"go:GO:0000458","description":"\"Endonucleolytic cleavage to separate a pre-LSU-rRNA from a pre-5S rRNA originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the Large Subunit (LSU) rRNA, and the 5S rRNA, in that order, from 5' to 3' along the primary transcript. Note that the use of the word tricistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"07b81338e55e4f1880f11b1bc4ab18cb","type":"GO_TERM","name":"endonucleolytic cleavage between SSU-rRNA and LSU-rRNA of tricistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 5S)","canonical_id":"go:GO:0000457","description":"\"Endonucleolytic cleavage to separate a pre-SSU-rRNA from a pre-LSU-rRNA originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the Large Subunit (LSU) rRNA, and the 5S rRNA, in that order, from 5' to 3' along the primary transcript. Note that the use of the word tricistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"f0c185e67423452faa3ce0e1662301cf","type":"GO_TERM","name":"endonucleolytic cleavage in 3'-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000471","description":"\"Endonucleolytic cleavage within the 3'-External Transcribed Spacer (ETS) of a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript. In S. cerevisiae, endonucleolytic cleavage within the 3'-ETS of the pre-RNA, which may occur cotranscriptionally, is the first step in rRNA processing, and initiates a cascade of subsequent processing and modification events.\" [GOC:krc, PMID:10690410]","metadata":null},{"id":"af4af9964efe49d7b3ae33d2c98f9c9a","type":"GO_TERM","name":"endonucleolytic cleavage in 5'-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000480","description":"\"Endonucleolytic cleavage within the 5'-External Transcribed Spacer (ETS) of a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript. Endonucleolytic cleavage within the 5'-ETS of the pre-RNA is conserved as one of the early steps of rRNA processing in all eukaryotes, but the specific position of cleavage is variable.\" [GOC:curators, PMID:10690410, PMID:15282326]","metadata":null},{"id":"0705a124a9484bbba09ce394c2e31323","type":"GO_TERM","name":"endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000447","description":"\"Endonucleolytic cleavage between the SSU-rRNA and the 5.8S rRNA of an rRNA molecule originally produced as a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators, PMID:10690410]","metadata":null},{"id":"1a727a650f51420e9128702b9083e7fa","type":"GO_TERM","name":"endonucleolytic cleavage in ITS1 upstream of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000464","description":"\"Endonucleolytic cleavage within Internal Transcribed Spacer 1 (ITS1) upstream of the 5.8S rRNA derived from an originally tricistronic rRNA transcript that contained the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript. In S. cerevisiae, this endonucleolytic cleavage within ITS1 initiates the maturation of the LSU and the 5.8S rRNAs.\" [GOC:krc, PMID:10690410]","metadata":null},{"id":"2246917e550b4755bf989aa24dc58ba3","type":"GO_TERM","name":"endonucleolytic cleavage of tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000483","description":"\"Endonucleolytic cleavage of a pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small SubUnit (SSU) rRNA, the 5.8S rRNA, 2S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript. Primary ribosomal RNA transcripts with four genes, in this order, are produced in the nuclei of D. melanogaster as well as in those of other dipteran species.\" [GOC:curators]","metadata":null},{"id":"d6d74b108ff34894ae1103828959eb34","type":"GO_TERM","name":"endonucleolytic cleavage of tetracistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 4.5S-rRNA, 5S-rRNA)","canonical_id":"go:GO:0002103","description":"\"Endonucleolytic cleavage of a pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript. Primary ribosomal RNA transcripts with four genes, in this order, are produced in the chloroplasts of vascular plants. Note that the use of the word tetracistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"fee76c87df3d43f9a0c466f684c0574c","type":"GO_TERM","name":"endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000479","description":"\"Endonucleolytic cleavage of a pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript. Primary ribosomal RNA transcripts with three genes, in this order, are produced in the nuclei of many eukaryotic species, including S. cerevisiae.\" [GOC:curators, PMID:10690410]","metadata":null},{"id":"2630ff1a7a464de191d53d473c43dca6","type":"GO_TERM","name":"endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 5S)","canonical_id":"go:GO:0000449","description":"\"Endonucleolytic cleavage of a pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the Large Subunit (LSU) rRNA, and the 5S rRNA, in that order, from 5' to 3' along the primary transcript. For example, primary ribosomal RNA transcripts containing three genes, in this order, are produced in E. coli and other prokaryotic species. Note that the use of the word tricistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"626af26e13b54e8f915451175cd86331","type":"GO_TERM","name":"endonucleolytic cleavage to generate mature 3'-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000461","description":"\"Endonucleolytic cleavage at the 3'-end of the SSU-rRNA from an originally tricistronic rRNA transcript that contained the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript, to produce the mature end of the SSU-rRNA.\" [GOC:krc, PMID:10690410]","metadata":null},{"id":"ac9c39b0177c4b528f4bde5f8b10f4cd","type":"GO_TERM","name":"endonucleolytic cleavage to generate mature 5'-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000472","description":"\"Endonucleolytic cleavage between the 5'-External Transcribed Spacer (5'-ETS) and the 5' end of the SSU-rRNA of a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript, to produce the mature end of the SSU-rRNA.\" [GOC:curators, PMID:10690410]","metadata":null},{"id":"0496f81d840e4ecb903a0ad04736c5f6","type":"GO_TERM","name":"endonucleolytic cleaveage between 4.5S rRNA and 5S rRNA of tetracistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 4.5S-rRNA, 5S-rRNA)","canonical_id":"go:GO:0002104","description":"\"Endonucleolytic cleavage between the 5S rRNA and the 4.5S rRNA of an rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript. Note that the use of the word tetracistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"c568eb235eaf427babd0f7e353e69061","type":"GO_TERM","name":"endonucleolytic cleaveage between LSU-rRNA and 4.5S rRNA of tetracistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 4.5S-rRNA, 5S-rRNA)","canonical_id":"go:GO:0002105","description":"\"Endonucleolytic cleavage between the LSU-rRNA and the 4.5S rRNA of an rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript. Note that the use of the word tetracistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"0ec68e3c1f434837b3d1236ca91fb687","type":"GO_TERM","name":"endonucleolytic cleaveage between SSU-rRNA and LSU-rRNA of tetracistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 4.5S-rRNA, 5S-rRNA)","canonical_id":"go:GO:0002106","description":"\"Endonucleolytic cleavages between the SSU-rRNA and the LSU-rRNA of an rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript. These cleavages liberate tRNAs from the polycistronic transcript as well as separating the SSU and LSU containing transcript. Note that the use of the word tetracistronic refers only to the number of mature rRNA molecules which will be produced from the primary transcript and ignores tRNAs that may also be present within the primary transcript.\" [GOC:curators]","metadata":null},{"id":"d08bd9407298446e9e17002f4aea2edc","type":"GO_TERM","name":"endopeptidase Clp complex","canonical_id":"go:GO:0009368","description":"\"A protein complex comprised of members of the ClpX, ClpC, ClpD, ClpP or ClpR protein families. ClpPs are the proteolytic subunit of active complexes, and ClpA and ClpX form the regulatory subunits. Enzymatically active and inactive complexes can form.\" [GOC:mah, PMID:11352464]","metadata":null},{"id":"93afac21b2134fa892f17476c6d404cd","type":"GO_TERM","name":"endopeptidase activator activity","canonical_id":"go:GO:0061133","description":"\"Binds to and increases the activity of an endopeptidase.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c6cb7e402ba448fd9a8212cbfa6160fa","type":"GO_TERM","name":"endopeptidase activity","canonical_id":"go:GO:0004175","description":"\"Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain.\" [http://merops.sanger.ac.uk/about/glossary.htm#ENDOPEPTIDASE]","metadata":null},{"id":"d6bca3e5ab554db1870673cd3c1c05ff","type":"GO_TERM","name":"endopeptidase complex","canonical_id":"go:GO:1905369","description":"\"A protein complex which is capable of endopeptidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:1689240]","metadata":null},{"id":"9957bef460c248a0914c9b81b744298c","type":"GO_TERM","name":"endopeptidase inhibitor activity","canonical_id":"go:GO:0004866","description":"\"Binds to and stops, prevents or reduces the activity of an endopeptidase.\" [GOC:jl]","metadata":null},{"id":"548d65ea38734a51acb82fc4cd47b26f","type":"GO_TERM","name":"endopeptidase regulator activity","canonical_id":"go:GO:0061135","description":"\"Binds to and modulates the activity of a peptidase, any enzyme that hydrolyzes nonterminal peptide bonds in polypeptides.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b5d2c5be11674cdb9e2d066c371a7a8a","type":"GO_TERM","name":"endoplasmic reticulum","canonical_id":"go:GO:0005783","description":"\"The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).\" [ISBN:0198506732]","metadata":null},{"id":"be875383dbd7474885fac8248c191743","type":"GO_TERM","name":"endoplasmic reticulum N-glycan trimming","canonical_id":"go:GO:0140277","description":"\"The trimming, in the ER, of the protein newly attached N-glycan by glucosidases and mannosidases to produce high mannose-type N-glycans.\" [PMID:30858582]","metadata":null},{"id":"9e683994ac1345ca99d68300f2145e4b","type":"GO_TERM","name":"endoplasmic reticulum Sec complex","canonical_id":"go:GO:0031205","description":"\"An endoplasmic reticulum membrane-associated complex involved in the translocation of proteins that are targeted to the ER. In yeast, this complex consists of two subcomplexes, namely, the Sec61 complex and the Sec62/Sec63 complex.\" [GOC:mtg_sensu, PMID:14617809]","metadata":null},{"id":"ed12fa9ca6f447babc3e38f889657ef7","type":"GO_TERM","name":"endoplasmic reticulum calcium ion homeostasis","canonical_id":"go:GO:0032469","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions within the endoplasmic reticulum of a cell or between the endoplasmic reticulum and its surroundings.\" [GOC:mah]","metadata":null},{"id":"7db2209ad2cf453582345c502aecd0ee","type":"GO_TERM","name":"endoplasmic reticulum chaperone complex","canonical_id":"go:GO:0034663","description":"\"A protein complex that is located in the endoplasmic reticulum and is composed of chaperone proteins, including BiP, GRP94; CaBP1, protein disulfide isomerase (PDI), ERdj3, cyclophilin B, ERp72, GRP170, UDP-glucosyltransferase, and SDF2-L1.\" [PMID:12475965]","metadata":null},{"id":"5795d047a4864bd5b9a6bcfb0d0eefe2","type":"GO_TERM","name":"endoplasmic reticulum cisternal network","canonical_id":"go:GO:0071781","description":"\"A subcompartment of the endoplasmic reticulum consisting of flattened, disc-shaped domains known as cisternae. These are typically found close to the nucleus and are generally more prominent in secretory cells.\" [GOC:vw, PMID:16469703, PMID:20434336]","metadata":null},{"id":"a9b5de82f3c4472dbcda925603a2928c","type":"GO_TERM","name":"endoplasmic reticulum cisternal network assembly","canonical_id":"go:GO:0071784","description":"\"The aggregation, arrangement and bonding together of a set of components to form the endoplasmic reticulum (ER) cisternal network. The ER cisternal network is the ER part that comprises the membranes with low curvature in cross-section.\" [GOC:mah, PMID:16469703, PMID:20434336]","metadata":null},{"id":"d72a2328886c45bc857b1a2b49f133a7","type":"GO_TERM","name":"endoplasmic reticulum cisternal network maintenance","canonical_id":"go:GO:0071785","description":"\"The organization process that preserves the endoplasmic reticulum (ER) cisternal network in a stable functional or structural state. The ER cisternal network is the ER part that comprises the membranes with low curvature in cross-section.\" [GOC:mah, PMID:16469703, PMID:20434336]","metadata":null},{"id":"1e6a5ec12b604538b0def1725e8c53ae","type":"GO_TERM","name":"endoplasmic reticulum cisternal network organization","canonical_id":"go:GO:0071783","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the endoplasmic reticulum (ER) cisternal network. The ER cisternal network is the ER part that comprises the membranes with low curvature in cross-section.\" [GOC:vw, PMID:16469703, PMID:20434336]","metadata":null},{"id":"04b930e0fe534e2087214b329735927c","type":"GO_TERM","name":"endoplasmic reticulum disassembly","canonical_id":"go:GO:1905692","description":"\"The disaggregation of an endoplasmic reticulum into its constituent components.\" [GO_REF:0000079, GOC:autophagy, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"45330a5ad3a840cb89c5ef913b91c1b8","type":"GO_TERM","name":"endoplasmic reticulum exit site","canonical_id":"go:GO:0070971","description":"\"An endoplasmic reticulum part at which COPII-coated vesicles are produced.\" [NIF_Subcellular:sao124393998, PMID:15623529, PMID:16957052]","metadata":null},{"id":"2aa8dac2d79b4f97bd9e1672dc864478","type":"GO_TERM","name":"endoplasmic reticulum inheritance","canonical_id":"go:GO:0048309","description":"\"The partitioning of endoplasmic reticulum between daughter cells at cell division.\" [GOC:jid]","metadata":null},{"id":"26de4010de7a4d10a9c15102cd099359","type":"GO_TERM","name":"endoplasmic reticulum localization","canonical_id":"go:GO:0051643","description":"\"Any process in which endoplasmic reticulum is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"678a49eed0db470fa7d41509c60b9846","type":"GO_TERM","name":"endoplasmic reticulum lumen","canonical_id":"go:GO:0005788","description":"\"The volume enclosed by the membranes of the endoplasmic reticulum.\" [ISBN:0198547684]","metadata":null},{"id":"fd9f465850a4408381546f0d0cb3b281","type":"GO_TERM","name":"endoplasmic reticulum mannose trimming","canonical_id":"go:GO:1904380","description":"\"Any protein alpha-1,2-demannosylation that takes place in the endoplasmic reticulum quality control compartment (ERQC).\" [GO_REF:0000062, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24519966]","metadata":null},{"id":"6e5824db707e422d90172140b8d96861","type":"GO_TERM","name":"endoplasmic reticulum membrane","canonical_id":"go:GO:0005789","description":"\"The lipid bilayer surrounding the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"a8fa2acb85e4413995ba5b674eac1d56","type":"GO_TERM","name":"endoplasmic reticulum membrane biogenesis","canonical_id":"go:GO:0160031","description":"\"The process in which an endoplasmic reticulum membrane is synthesized, aggregates, and bonds together.\" [PMID:19825355, PMID:24373967, PMID:34617598]","metadata":null},{"id":"b49b21525d60484da6f4198b08aab5ed","type":"GO_TERM","name":"endoplasmic reticulum membrane fusion","canonical_id":"go:GO:0016320","description":"\"The joining of 2 or more lipid bilayer membranes that surround the endoplasmic reticulum.\" [GOC:elh, GOC:jid]","metadata":null},{"id":"b7473d634f074e90932e0944b1a006c1","type":"GO_TERM","name":"endoplasmic reticulum membrane organization","canonical_id":"go:GO:0090158","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an endoplasmic reticulum membrane.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"ae2d11dd8ba84adc95c6519203080efb","type":"GO_TERM","name":"endoplasmic reticulum membrane-lipid droplet contact site","canonical_id":"go:GO:0160259","description":"\"A membrane contact site between the endoplasmic reticulum (ER) membrane and the lipid droplet.\" [PMID:24497546, PMID:30523332, PMID:37150040]","metadata":null},{"id":"a921df4695e542ffbce786e9638fee0f","type":"GO_TERM","name":"endoplasmic reticulum organization","canonical_id":"go:GO:0007029","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the endoplasmic reticulum.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"629226b8f3b54d499734e4b7010a1183","type":"GO_TERM","name":"endoplasmic reticulum palmitoyltransferase complex","canonical_id":"go:GO:0031211","description":"\"A complex of the endoplasmic reticulum that catalyzes S-palmitoylation, the addition of palmitate (C16:0) or other long-chain fatty acids to proteins at a cysteine residue.\" [GOC:jh]","metadata":null},{"id":"957cef47e0b54176a416ad5fab48968e","type":"GO_TERM","name":"endoplasmic reticulum polarization","canonical_id":"go:GO:0061163","description":"\"The endoplasmic reticulum organization process that results in the structure of the endoplasmic reticulum being oriented in the cell. Endoplasmic reticulum polarization serves as a mechanism to compartmentalize cellular activities and to establish cell polarity.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"38d394e0d7c448d2bf14ea2693d8d80a","type":"GO_TERM","name":"endoplasmic reticulum protein-containing complex","canonical_id":"go:GO:0140534","description":"\"A protein complex that is part of an endoplasmic reticulum.\" [GOC:pg]","metadata":null},{"id":"64af71c8d6024cd3b0f778c282fe4ea0","type":"GO_TERM","name":"endoplasmic reticulum quality control compartment","canonical_id":"go:GO:0044322","description":"\"A subcompartment of the endoplasmic reticulum in which proteins with improper or incorrect folding accumulate. Enzymes in this compartment direct proteins with major folding problems to translocation to the cytosol and degradation, and proteins with minor folding problems to the ER, to interact with chaperon proteins.\" [PMID:11408579]","metadata":null},{"id":"ff4ec300ad61470c9a0e89cb2566bbd0","type":"GO_TERM","name":"endoplasmic reticulum signal sequence receptor activity","canonical_id":"go:GO:0030942","description":"\"Binding to an endoplasmic reticulum signal peptide, a short stretch of amino acids found in a protein that acts as a signal to localize the protein to the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"601f425ca97048f8b9a8ccd27a67b553","type":"GO_TERM","name":"endoplasmic reticulum stress-induced pre-emptive quality control","canonical_id":"go:GO:0061857","description":"\"The response to endoplasimic reticulum stress in which nascent proteins are degraded by attenuation of their translocation into the ER followed by rerouting to the cytosol without cleavage of the signal peptide, and subsequent degradation by the proteasome.\" [PMID:17129784, PMID:26565908]","metadata":null},{"id":"80697aee0a30419496ff8c5b9b62a2cf","type":"GO_TERM","name":"endoplasmic reticulum subcompartment","canonical_id":"go:GO:0098827","description":"\"A distinct region of the endoplasmic reticulum.\" [GOC:dos]","metadata":null},{"id":"91077f5ce1014b3780c0e1ebdfcf395f","type":"GO_TERM","name":"endoplasmic reticulum to Golgi vesicle-mediated transport","canonical_id":"go:GO:0006888","description":"\"The directed movement of substances from the endoplasmic reticulum (ER) to the Golgi, mediated by COP II vesicles. Small COP II coated vesicles form from the ER and then fuse directly with the cis-Golgi. Larger structures are transported along microtubules to the cis-Golgi.\" [GOC:ascb_2009, GOC:dph, GOC:jp, GOC:tb, ISBN:0716731363]","metadata":null},{"id":"b5a11cc5634f4f4481e81e1a3651066b","type":"GO_TERM","name":"endoplasmic reticulum to chloroplast transport","canonical_id":"go:GO:1901965","description":"\"The directed movement of substances from endoplasmic reticulum to chloroplast.\" [GOC:TermGenie, PMID:18689504]","metadata":null},{"id":"86113460dfec4394bb516058b576b7ac","type":"GO_TERM","name":"endoplasmic reticulum to cytosol auxin transport","canonical_id":"go:GO:0080162","description":"\"The directed movement of auxins from endoplasmic reticulum to cytosol.\" [PMID:19506555]","metadata":null},{"id":"496cd911bba34a8082d212fde65bca89","type":"GO_TERM","name":"endoplasmic reticulum to cytosol transport","canonical_id":"go:GO:1903513","description":"\"The directed movement of substances from endoplasmic reticulum to cytosol.\" [GO_REF:0000076, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:16402920]","metadata":null},{"id":"6a2b80388bf44b76a0b7e860ef236b01","type":"GO_TERM","name":"endoplasmic reticulum tubular network","canonical_id":"go:GO:0071782","description":"\"A subcompartment of the endoplasmic reticulum consisting of tubules having membranes with high curvature in cross-section.\" [GOC:vw, PMID:16469703, PMID:20434336]","metadata":null},{"id":"4d3957b6c2644140aa4741e50e6f21be","type":"GO_TERM","name":"endoplasmic reticulum tubular network formation","canonical_id":"go:GO:0071787","description":"\"The aggregation, arrangement and bonding together of a set of components to form the endoplasmic reticulum (ER) tubular network. The ER tubular network is the ER part that comprises the membranes with high curvature in cross-section.\" [GOC:mah, GOC:vw, PMID:16469703, PMID:20434336]","metadata":null},{"id":"cf276072e5034bbc8a06f8ace007f91d","type":"GO_TERM","name":"endoplasmic reticulum tubular network maintenance","canonical_id":"go:GO:0071788","description":"\"The organization process that preserves the endoplasmic reticulum (ER) tubular network in a stable functional or structural state. The ER tubular network is the ER part that comprises the membranes with high curvature in cross-section.\" [GOC:mah, PMID:16469703, PMID:20434336]","metadata":null},{"id":"a4c870ec99d6438bb56bcd6219165db9","type":"GO_TERM","name":"endoplasmic reticulum tubular network membrane","canonical_id":"go:GO:0098826","description":"\"The membrane of the endoplasmic reticulum tubular network.\" [PMID:16469703]","metadata":null},{"id":"c1e574766027484f86c84e9d9da48435","type":"GO_TERM","name":"endoplasmic reticulum tubular network membrane organization","canonical_id":"go:GO:1990809","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the endoplasmic reticulum (ER) tubular network membrane.\" [PMID:20434336]","metadata":null},{"id":"3920fadceddb4afba643efe18b244d01","type":"GO_TERM","name":"endoplasmic reticulum tubular network organization","canonical_id":"go:GO:0071786","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the endoplasmic reticulum (ER) tubular network. The ER tubular network is the ER part that that has membranes with high curvature in cross-section.\" [GOC:vw, PMID:16469703, PMID:20434336]","metadata":null},{"id":"bcb51dfb4a0543a2b9707349e325448d","type":"GO_TERM","name":"endoplasmic reticulum unfolded protein response","canonical_id":"go:GO:0030968","description":"\"The series of molecular signals generated as a consequence of the presence of unfolded proteins in the endoplasmic reticulum (ER) or other ER-related stress; results in changes in the regulation of transcription and translation.\" [GOC:mah, PMID:12042763]","metadata":null},{"id":"118787b5070b4bfc815bfe39f1fd8031","type":"GO_TERM","name":"endoplasmic reticulum-Golgi intermediate compartment","canonical_id":"go:GO:0005793","description":"\"A complex system of membrane-bounded compartments located between endoplasmic reticulum (ER) and the Golgi complex, with a distinctive membrane protein composition; involved in ER-to-Golgi and Golgi-to-ER transport.\" [GOC:pr, PMID:16723730]","metadata":null},{"id":"f7258e8a6abb41009b52c23db7779922","type":"GO_TERM","name":"endoplasmic reticulum-Golgi intermediate compartment (ERGIC) derived vesicle fusion with Golgi cis cisterna membrane","canonical_id":"go:GO:1990689","description":"\"The joining of the lipid bilayer membrane around an ERGIC-derived vesicle to the lipid bilayer membrane around the Golgi cis cisterna. Such vesicles include COPII-coated transport vesicles involved in anterograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"d6724fd74d5042d180bdc6d715a99cd1","type":"GO_TERM","name":"endoplasmic reticulum-Golgi intermediate compartment (ERGIC) derived vesicle fusion with endoplasmic reticulum membrane","canonical_id":"go:GO:1990669","description":"\"The joining of the lipid bilayer membrane around an ERGIC-derived vesicle to the lipid bilayer membrane of the ER. Such vesicles include COPI-coated transport vesicles involved in retrograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"41343e150a304a32be0f30f57e343f15","type":"GO_TERM","name":"endoplasmic reticulum-Golgi intermediate compartment membrane","canonical_id":"go:GO:0033116","description":"\"The lipid bilayer surrounding any of the compartments of the endoplasmic reticulum (ER)-Golgi intermediate compartment system.\" [GOC:mah, GOC:pr, PMID:16723730]","metadata":null},{"id":"f9de2b2e0e9340acb6d71e462f3d32b7","type":"GO_TERM","name":"endoplasmic reticulum-Golgi intermediate compartment organization","canonical_id":"go:GO:0097111","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the endoplasmic reticulum (ER)-Golgi intermediate compartment.\" [GOC:br, PMID:18287528]","metadata":null},{"id":"c5b5a433ed5d4a7d8ef2b6007bb11714","type":"GO_TERM","name":"endoplasmic reticulum-autophagosome adaptor activity","canonical_id":"go:GO:0140506","description":"\"The binding activity of a molecule that brings together an ER membrane and an autophagosome membrane during reticulophagy.\" [PMID:32735772]","metadata":null},{"id":"ef44909c42a147a99211b8dd3711b68e","type":"GO_TERM","name":"endoplasmic reticulum-derived vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane","canonical_id":"go:GO:1990687","description":"\"The joining of the lipid bilayer membrane around an endoplasmic reticulum-derived vesicle to the lipid bilayer membrane of the ERGIC. Such vesicles include COPII-coated transport vesicles involved in anterograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"41f5c74bf1284366bbe809708fef6e7d","type":"GO_TERM","name":"endoplasmic reticulum-endolysosomal membrane contact site","canonical_id":"go:GO:7770088","description":"\"A membrane contact site between the endoplasmic reticulum membrane and the membrane of an organelle of the endolysosomal system, such as an endosome or lysosome.\" [PMID:31678515]","metadata":null},{"id":"584e86493ce3409e929e2abf84c8b9d7","type":"GO_TERM","name":"endoplasmic reticulum-endosome membrane contact site","canonical_id":"go:GO:0140284","description":"\"A contact site between the endoplasmic reticulum membrane and the endosome membrane.\" [PMID:24105263, PMID:30220460]","metadata":null},{"id":"30f82d42e6f644d7acabdc71edaa660b","type":"GO_TERM","name":"endoplasmic reticulum-endosome tether activity","canonical_id":"go:GO:0170016","description":"\"The binding activity of a molecule that brings together an endosome membrane and an ER membrane either via membrane lipid binding or by interacting with an endosome protein, to establish and facilitate organelle exchange.\" [PMID:33124732]","metadata":null},{"id":"6de9553f8a4c4848be0d8bca4de17e5a","type":"GO_TERM","name":"endoplasmic reticulum-lipid droplet tether activity","canonical_id":"go:GO:0170007","description":"\"The binding activity of a molecule that brings together a lipid droplet with an endoplasmic reticulum membrane, via membrane lipid binding, to establish membrane contact sites and mediate exchange and communication.\" [PMID:35389430]","metadata":null},{"id":"c2bb248b5caa4ce58bf709c8c05550ed","type":"GO_TERM","name":"endoplasmic reticulum-lysosome membrane contact site","canonical_id":"go:GO:7770052","description":"\"An organelle membrane contact site between the endoplasmic reticulum membrane and the lysosomal membrane.\" [PMID:31537798, PMID:39370902]","metadata":null},{"id":"14c59dcdc72244ef8b22c7b8d863a2ec","type":"GO_TERM","name":"endoplasmic reticulum-organelle membrane tether activity","canonical_id":"go:GO:0170009","description":"\"The binding activity of a molecule that brings together two membranes, either via membrane lipid binding or by interacting with a membrane protein, to establish or maintain membrane contact sites and mediate organelle exchange and communication.\" [PMID:29858488]","metadata":null},{"id":"c3632a1ebf654b319ecfdae52487ece9","type":"GO_TERM","name":"endoplasmic reticulum-plasma membrane adaptor activity","canonical_id":"go:GO:0160214","description":"\"The binding activity of a molecule that brings together a plasma membrane with an endoplasmic reticulum membrane, via membrane lipid binding, to establish membrane contact sites and mediate exchange and communication.\" [PMID:23041194, PMID:39239853]","metadata":null},{"id":"5b5ee31d9d4346d0aac7614f55e003e1","type":"GO_TERM","name":"endoplasmic reticulum-plasma membrane contact site","canonical_id":"go:GO:0140268","description":"\"A contact site between the endoplasmic reticulum membrane and the plasma membrane, structured by bridging complexes.\" [PMID:23041194, PMID:27955928, PMID:29290560, PMID:29782498, PMID:30012696]","metadata":null},{"id":"fb8e0b191c7949548a3da3e605c8ce91","type":"GO_TERM","name":"endoplasmic reticulum-trans-Golgi network membrane contact site","canonical_id":"go:GO:0160258","description":"\"An organelle membrane contact site between the endoplasmic reticulum (ER) membrane and the trans-Golgi network (TGN) membrane.\" [PMID:30275117, PMID:31732717]","metadata":null},{"id":"e5fdfe50ec8b456baa2c0641f936740d","type":"GO_TERM","name":"endoplasmic reticulum-vacuole membrane contact site","canonical_id":"go:GO:0098853","description":"\"A zone of apposition between endoplasmic-reticulum and lytic vacuole membranes, structured by bridging complexes.\" [GOC:dos, PMID:26283797]","metadata":null},{"id":"1e9941c6cd1449cf97a93e18fd16ca22","type":"GO_TERM","name":"endoplasmic reticulum-vacuole tether activity","canonical_id":"go:GO:7770066","description":"\"The binding activity of a molecule that brings together an endoplasmic reticulum membrane and a vacuole membrane either via membrane lipid binding or by interacting with a membrane protein, to establish or maintain membrane contact sites.\" [PMID:26283797]","metadata":null},{"id":"88f07eeaeeb948f9b8203d36a1d2f3b5","type":"GO_TERM","name":"endopolyphosphatase activity","canonical_id":"go:GO:0000298","description":"\"Catalysis of the reaction: polyphosphate + n H2O = (n+1) oligophosphate. The product contains 4 or 5 phosphate residues.\" [EC:3.6.1.10]","metadata":null},{"id":"b761f43d12a04818b0489d6126e447cf","type":"GO_TERM","name":"endoribonuclease activity, cleaving miRNA-paired mRNA","canonical_id":"go:GO:0090624","description":"\"Catalysis of the endonucleolytic cleavage of the mRNA in a double-stranded RNA molecule formed by the base pairing of an mRNA with an miRNA.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:15260970, PMID:19239888]","metadata":null},{"id":"8722fc4c0719418387bcf23f949a64c6","type":"GO_TERM","name":"endoribonuclease activity, cleaving siRNA-paired mRNA","canonical_id":"go:GO:0070551","description":"\"Catalysis of the endonucleolytic cleavage of the mRNA in a double-stranded RNA molecule formed by the base pairing of an mRNA with an siRNA, yielding 5'-phosphomonoesters.\" [GOC:mah, PMID:15105377]","metadata":null},{"id":"3e26618976dc44fc9722db49599b675d","type":"GO_TERM","name":"endoribonuclease complex","canonical_id":"go:GO:1902555","description":"\"A protein complex which is capable of endoribonuclease activity.\" [GOC:bhm, GOC:TermGenie, PMID:18191223]","metadata":null},{"id":"1d55e625efe04dbdb53e7a4ce56178ed","type":"GO_TERM","name":"endoribonuclease inhibitor activity","canonical_id":"go:GO:0060698","description":"\"Binds to and stops, prevents or reduces the activity of endoribonuclease.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f09a8783c9ef46feb62f97207f38523c","type":"GO_TERM","name":"endosomal intralumenal vesicle","canonical_id":"go:GO:0160313","description":"\"A membrane-bounded vesicle that is located within the lumen of an endosome.\" [PMID:21878991, PMID:31854087]","metadata":null},{"id":"0972732bb2ff43b5bcecd65fb1531ab8","type":"GO_TERM","name":"endosomal intralumenal vesicle lumen","canonical_id":"go:GO:0160315","description":"\"The volume enclosed by the membrane of an intraluminal vesicle within an endosome.\" [PMID:31854087, PMID:38706230]","metadata":null},{"id":"8b4f6659fd3846739e6765534041881e","type":"GO_TERM","name":"endosomal intralumenal vesicle membrane","canonical_id":"go:GO:0160314","description":"\"The lipid bilayer surrounding an intraluminal vesicle within an endososome.\" [PMID:31854087, PMID:38706230]","metadata":null},{"id":"96ca17a81b424c7f9aa75593686276aa","type":"GO_TERM","name":"endosomal lumen acidification","canonical_id":"go:GO:0048388","description":"\"Any process that reduces the pH of the endosomal lumen, corresponding to an increase in hydrogen ion concentration.\" [GOC:jid]","metadata":null},{"id":"dbdeaf806e9c4966bc58111a3aacfa21","type":"GO_TERM","name":"endosomal pattern recognition receptor signaling pathway","canonical_id":"go:GO:0002754","description":"\"The series of molecular signals initiated by the binding of a ligand to an intracellular vesicle pattern recognition receptor (PRR). PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species.\" [GOC:add, GOC:ar, ISBN:0781735149, PMID:15199967]","metadata":null},{"id":"de0d455efd3a4f2c86b4969269c41135","type":"GO_TERM","name":"endosomal scaffold complex","canonical_id":"go:GO:0032969","description":"\"A protein complex that contains MAPKSP1 (MP1, Map2k1ip1) and ROBLD3 (p14, Mapbpip), is anchored to late endosomes, and is involved in selective activation of the ERK1 in ERK/MAPK signaling.\" [PMID:15263099, PMID:16227978, PMID:17496910]","metadata":null},{"id":"5a37b976f6c347ed827163f83a9cf637","type":"GO_TERM","name":"endosomal transport","canonical_id":"go:GO:0016197","description":"\"The directed movement of substances mediated by an endosome, a membrane-bounded organelle that carries materials enclosed in the lumen or located in the endosomal membrane.\" [ISBN:0198506732]","metadata":null},{"id":"34835b86083e4bfa9319d449fb2f3a9d","type":"GO_TERM","name":"endosomal vesicle fusion","canonical_id":"go:GO:0034058","description":"\"The homotypic fusion of endocytic vesicles to form or add to an early endosome.\" [PMID:11964142, PMID:9422733]","metadata":null},{"id":"0569e90ba9654104bf76506e0be8f106","type":"GO_TERM","name":"endosome","canonical_id":"go:GO:0005768","description":"\"A vacuole to which materials ingested by endocytosis are delivered.\" [ISBN:0198506732, PMID:19696797]","metadata":null},{"id":"3c9db14c69ad4e1397f1033e381ce143","type":"GO_TERM","name":"endosome fission","canonical_id":"go:GO:0140285","description":"\"The process by which early and late endosomes undergo budding and fission reactions that separate regions destined for lysosomal degradation from carriers to be recycled to the plasma membrane.\" [PMID:25416943, PMID:30220460]","metadata":null},{"id":"3d4cc8fdebe9400f8a8461842e950bc1","type":"GO_TERM","name":"endosome lumen","canonical_id":"go:GO:0031904","description":"\"The volume enclosed by the membrane of an endosome.\" [GOC:mah]","metadata":null},{"id":"124c13712a954372a7daa93f5635aa83","type":"GO_TERM","name":"endosome lysis involved in viral entry into host cell","canonical_id":"go:GO:0075514","description":"\"Viral-induced lysis of the endosome involved in uptake of a virus into a host cell. Occurs after internalization of the virus through the endosomal pathway, and results in release of the viral contents from the endosome into the host cell cytoplasm.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"cc5a0bb80c904734a43236cbcb2e52a4","type":"GO_TERM","name":"endosome membrane","canonical_id":"go:GO:0010008","description":"\"The lipid bilayer surrounding an endosome.\" [GOC:mah]","metadata":null},{"id":"a84e2b49ab1b4f95b532b4601490c38c","type":"GO_TERM","name":"endosome membrane permeabilization involved in viral entry into host cell","canonical_id":"go:GO:0075502","description":"\"Induction of endosome membrane permeabilization triggered by an interaction between the host membrane and a membrane-penetration protein associated with the capsid. Occurs after internalization of the virus through the endosomal pathway, and results in delivery of the virus contents into the host cell cytoplasm.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"ccc17f691b304a8899642484590991af","type":"GO_TERM","name":"endosome membrane tubulation","canonical_id":"go:GO:0097750","description":"\"A membrane tubulation process occurring in an endosome membrane.\" [GOC:bc, GOC:PARL, PMID:26911690]","metadata":null},{"id":"9d3d147032374f63a24ee97fa9a508d6","type":"GO_TERM","name":"endosome organization","canonical_id":"go:GO:0007032","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of endosomes.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"cbf2b44287ec43f09e08897078bcc637","type":"GO_TERM","name":"endosome to lysosome transport","canonical_id":"go:GO:0008333","description":"\"The directed movement of substances from endosomes to lysosomes.\" [GOC:ai, ISBN:0716731363]","metadata":null},{"id":"f2c010af4c874b3fa87bbcf73330d72d","type":"GO_TERM","name":"endosome to lysosome transport of low-density lipoprotein particle","canonical_id":"go:GO:0090117","description":"\"The directed movement of low-density lipoprotein particle from endosomes to lysosomes.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"330ff959383b47cea963c555da2e45be","type":"GO_TERM","name":"endosome to lysosome transport via multivesicular body sorting pathway","canonical_id":"go:GO:0032510","description":"\"The directed movement of substances from endosomes to lysosomes by a pathway in which molecules are sorted into multivesicular bodies, which then fuse with the lysosome.\" [GOC:mah, PMID:12461556, PMID:16689637]","metadata":null},{"id":"3945ac83f3644e07ac118072883b4e45","type":"GO_TERM","name":"endosome to melanosome transport","canonical_id":"go:GO:0035646","description":"\"The directed movement of substances from endosomes to the melanosome, a specialised lysosome-related organelle.\" [PMID:16162817]","metadata":null},{"id":"5550d1b638804591abd1830aa1e11b21","type":"GO_TERM","name":"endosome to pigment granule transport","canonical_id":"go:GO:0043485","description":"\"The directed movement of substances from endosomes to pigment granules.\" [GOC:jl]","metadata":null},{"id":"b5670f44ce124594898925596a94e2cf","type":"GO_TERM","name":"endosome to plasma membrane protein transport","canonical_id":"go:GO:0099638","description":"\"The directed movement of proteins from the endosome to the plasma membrane in transport vesicles.\" [GOC:dos]","metadata":null},{"id":"c268892d030b46c68b6d0a9c18438a96","type":"GO_TERM","name":"endosome to plasma membrane transport vesicle","canonical_id":"go:GO:0070381","description":"\"A transport vesicle that mediates transport from the endosome to the plasma membrane, and fuses with the plasma membrane to deliver lipids and membrane proteins to the plasma membrane and to release various cargo molecules, such as proteins or hormones, by exocytosis.\" [GOC:kad, GOC:mah, PMID:10679016, PMID:12110576]","metadata":null},{"id":"2fde81033bf84797a72ca72e1f91e6b2","type":"GO_TERM","name":"endosome transport via multivesicular body sorting pathway","canonical_id":"go:GO:0032509","description":"\"The directed movement of substances from endosomes to lysosomes or vacuoles by a pathway in which molecules are sorted into multivesicular bodies, which then fuse with the target compartment.\" [GOC:mah, PMID:12461556, PMID:16689637]","metadata":null},{"id":"12181396ccdb4ed99d1a505381a6b1a1","type":"GO_TERM","name":"endosperm cellularization","canonical_id":"go:GO:0010342","description":"\"The separation of the multi-nucleate endosperm into individual cells. In many plant species, the endosperm that nurtures the embryo in the seed initially develops as a syncytium. This syncytial phase ends with simultaneous partitioning of the multi-nucleate cytoplasm into individual cells, a process referred to as cellularization.\" [PMID:12421698]","metadata":null},{"id":"5f38a8ad310c4acaa5dfbd412760379b","type":"GO_TERM","name":"endosperm development","canonical_id":"go:GO:0009960","description":"\"The process whose specific outcome is the progression of the endosperm over time, from its formation to the mature structure. The endosperm is formed during fertilization and provides nutrients to the developing embryo.\" [GOC:sm]","metadata":null},{"id":"e6c671b944474ff5b845dacb3fb1e073","type":"GO_TERM","name":"endosperm protein body","canonical_id":"go:GO:0042735","description":"\"A membrane-bounded plant organelle found in the developing endosperm, contains storage proteins.\" [GOC:jl, PMID:7704047]","metadata":null},{"id":"1d870e3f87894491b66ad748b3291ece","type":"GO_TERM","name":"endospore coat","canonical_id":"go:GO:0043593","description":"\"The layer in a bacterial endospore that lies under the exosporium, and is impermeable to many toxic molecules. The coat may also contain enzymes that are involved in endospore germination.\" [GOC:mlg]","metadata":null},{"id":"0869b68ef9f94aba9f957677b48ba011","type":"GO_TERM","name":"endospore core","canonical_id":"go:GO:0070477","description":"\"An intracellular part that represents the innermost portion of an endospore; the endospore core is dehydrated, enriched in dipicolinic acid and divalent cations, and metabolically inactive.\" [GOC:mah, PMID:15035041, PMID:18035610]","metadata":null},{"id":"f4af7b7383a5404bbc696421e1940172","type":"GO_TERM","name":"endospore cortex","canonical_id":"go:GO:0043595","description":"\"A layer surrounding a bacterial endospore found inside the outer endospore membrane, but outside the membrane surrounding the endospore core. It consists of peptidoglycan of a different chemical nature than that found in vegetative cell walls which results in less cross-linking of peptidoglycan.\" [GOC:mlg]","metadata":null},{"id":"449de235d3bf4a12995f564977b22e72","type":"GO_TERM","name":"endospore external encapsulating structure","canonical_id":"go:GO:0043591","description":"\"The structures that lie outside the inner membrane and surround the entire endospore; consists of a peptidoglycan-containing inner layer (the endospore cortex) surrounded by a multilayered proteinaceous coat. An exosporium may be present as an extreme outer layer.\" [GOC:curators, PMID:15035041]","metadata":null},{"id":"f3287af8dc2e4e459cadece0ecdcf14f","type":"GO_TERM","name":"endospore formation","canonical_id":"go:GO:0034301","description":"\"The process in which a cell gives rise to an endospore, a dormant, highly resistant spore with a thick wall that forms within the mother cell. Endospores are produced by some low G+C Gram-positive bacteria in response to harsh conditions.\" [GOC:ds, GOC:mah, ISBN:0470090278]","metadata":null},{"id":"b55c8a6fa84a441fa79eee4888914060","type":"GO_TERM","name":"endospore-forming forespore","canonical_id":"go:GO:0042601","description":"\"Portion of the cell formed during the process of bacterial sporulation that will ultimately become the core of the endospore. An endospore is a type of dormant cell that is resistant to adverse conditions.\" [GOC:jl, GOC:mtg_sensu, ISBN:0697286029]","metadata":null},{"id":"65e899312f054703b1bf6ff803cb98f7","type":"GO_TERM","name":"endothelial cell activation","canonical_id":"go:GO:0042118","description":"\"The change in morphology and behavior of an endothelial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149, PMID:12851652, PMID:14581484]","metadata":null},{"id":"a4f33a32bf0a406ba39c16af084387f0","type":"GO_TERM","name":"endothelial cell activation involved in immune response","canonical_id":"go:GO:0002264","description":"\"A change in the morphology or behavior of an endothelial cell resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b8e6d96aa47e4d608bce5895e5c33939","type":"GO_TERM","name":"endothelial cell apoptotic process","canonical_id":"go:GO:0072577","description":"\"Any apoptotic process in an endothelial cell. An endothelial cell comprises the outermost layer or lining of anatomical structures and can be squamous or cuboidal.\" [CL:0000115, GOC:BHF, GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"2f29f727f87943fa826037b9f4206b3e","type":"GO_TERM","name":"endothelial cell chemotaxis","canonical_id":"go:GO:0035767","description":"\"The directed movement of an endothelial cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [CL:0000115, GOC:BHF]","metadata":null},{"id":"00cedf97a8474ddcb7be0e99a839d6b9","type":"GO_TERM","name":"endothelial cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:0035768","description":"\"The directed movement of an endothelial cell in response to the presence of fibroblast growth factor (FGF).\" [CL:0000115, GOC:BHF]","metadata":null},{"id":"3076f5ca8b794d9492253552ed12133f","type":"GO_TERM","name":"endothelial cell chemotaxis to vascular endothelial growth factor","canonical_id":"go:GO:0090668","description":"\"The directed movement of an endothelial cell in response to the presence of vascular endothelial growth factor (VEGF).\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:21885851]","metadata":null},{"id":"d9edb47927034564ac7cf621f349e1f5","type":"GO_TERM","name":"endothelial cell development","canonical_id":"go:GO:0001885","description":"\"The progression of an endothelial cell over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"e3461b9bc6824a7cb22ea7fcc6b44eab","type":"GO_TERM","name":"endothelial cell differentiation","canonical_id":"go:GO:0045446","description":"\"The process in which a mesodermal, bone marrow or neural crest cell acquires specialized features of an endothelial cell, a thin flattened cell. A layer of such cells lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium.\" [CL:0000115, GOC:curators]","metadata":null},{"id":"be19dd42ee534929a9cd2f0111e730e9","type":"GO_TERM","name":"endothelial cell fate commitment","canonical_id":"go:GO:0060839","description":"\"The commitment of a cell to an endothelial cell fate and its capacity to differentiate into an endothelial cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"677eaf4b9db345308c86c72c96f5fecd","type":"GO_TERM","name":"endothelial cell fate determination","canonical_id":"go:GO:0060848","description":"\"A process involved in cell fate commitment of an endothelial cell. Once determination has taken place, a cell becomes committed to differentiate down a particular pathway regardless of its environment.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3d3e283b90b841a9a4a1b8c0f946128b","type":"GO_TERM","name":"endothelial cell fate specification","canonical_id":"go:GO:0060847","description":"\"The process involved in the specification of identity of an endothelial cell. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"11e232910386403799be9538d36a9e38","type":"GO_TERM","name":"endothelial cell migration","canonical_id":"go:GO:0043542","description":"\"The orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.\" [GOC:curators]","metadata":null},{"id":"70d27a6c252d4c408195a1e25805d427","type":"GO_TERM","name":"endothelial cell morphogenesis","canonical_id":"go:GO:0001886","description":"\"The change in form (cell shape and size) that occurs during the differentiation of an endothelial cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"43deffeb92d6407f88e8f61a7faf0344","type":"GO_TERM","name":"endothelial cell proliferation","canonical_id":"go:GO:0001935","description":"\"The multiplication or reproduction of endothelial cells, resulting in the expansion of a cell population. Endothelial cells are thin flattened cells which line the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"dff83e4a09d44772a16dcdc26f7d61df","type":"GO_TERM","name":"endothelial cell-cell adhesion","canonical_id":"go:GO:0071603","description":"\"The attachment of an endothelial cell to another endothelial cell via adhesion molecules.\" [GOC:BHF]","metadata":null},{"id":"cd9e54d758ed4b34afdf410113bad18c","type":"GO_TERM","name":"endothelial cell-matrix adhesion","canonical_id":"go:GO:0090673","description":"\"The binding of an endothelial cell to the extracellular matrix via adhesion molecules.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:19460962]","metadata":null},{"id":"c7e81bc184434af5a052383cfe90dcef","type":"GO_TERM","name":"endothelial differentiation G protein-coupled receptor binding","canonical_id":"go:GO:0031753","description":"\"Binding to an endothelial differentiation G protein-coupled receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ba629b7a3dd247b1a9a6f41f825c78e3","type":"GO_TERM","name":"endothelial microparticle","canonical_id":"go:GO:0072563","description":"\"A blood microparticle that is derived from, and contains membrane receptors as well as other proteins characteristic of, an endothelial cell.\" [GOC:BHF, GOC:mah, PMID:16373184]","metadata":null},{"id":"dc11b52273aa422c8c5678f5b64cdc26","type":"GO_TERM","name":"endothelial microparticle formation","canonical_id":"go:GO:0072565","description":"\"The cellular component organization process in which microparticles bud off from an endothelial cell.\" [GOC:BHF, GOC:mah, PMID:16373184]","metadata":null},{"id":"9c3bf3ebdcf54ece919dfe76f7871ca3","type":"GO_TERM","name":"endothelial stalk cell fate specification","canonical_id":"go:GO:0097103","description":"\"The process involved in the specification of identity of an endothelial stalk cell. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment. An endothelial stalk cell is a specialized endothelial cell which follows behind the tip cell of an angiogenic sprout.\" [CL:0002671, GOC:dgh, PMID:21521739]","metadata":null},{"id":"fc514e2d2b0248f299666890625de784","type":"GO_TERM","name":"endothelial tip cell fate specification","canonical_id":"go:GO:0097102","description":"\"The process involved in the specification of identity of an endothelial tip cell. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment. An endothelial tip cell is a specialized endothelial cell localized to the leading edge of an angiogenic sprout that senses extracellular signals and guides the directed growth of blood vessels.\" [CL:0000704, GOC:dgh, PMID:21521739]","metadata":null},{"id":"b50aa297dc314341bb4bf2491419a806","type":"GO_TERM","name":"endothelial tip cell filopodium assembly","canonical_id":"go:GO:0120084","description":"\"The assembly of a filopodium, a thin, stiff protrusion extended by the endothelial tip cell of a vascular sprout.\" [GOC:cvs, PMID:28264837]","metadata":null},{"id":"7de623406ffd4b64a55cfd32059624a4","type":"GO_TERM","name":"endothelial to hematopoietic transition","canonical_id":"go:GO:0098508","description":"\"The generation of hematopoietic stem cells from hemogenic endothelial cells by a process that includes tight-junction dissolution and loss of cell polarity followed by delamination from the endothelium.\" [PMID:20154732, PMID:22521721]","metadata":null},{"id":"ea74796e8598497c801ef00b64036f70","type":"GO_TERM","name":"endothelial tube formation","canonical_id":"go:GO:0120331","description":"\"The developmental process pertaining to the initial formation of an endothelial tube.\" [GOC:sl, PMID:23239824]","metadata":null},{"id":"b511871162ca4135ae555dd03c43d5f6","type":"GO_TERM","name":"endothelial tube lumen extension","canonical_id":"go:GO:0097498","description":"\"Any endothelial tube morphogenesis process by which the tube is increased in length.\" [GOC:dgh, PMID:23698350]","metadata":null},{"id":"e2d1b39be3fa482ba0376e4d41605775","type":"GO_TERM","name":"endothelial tube lumen extension involved in blood vessel lumen ensheathment","canonical_id":"go:GO:1902355","description":"\"Any endothelial tube lumen extension that is involved in blood vessel lumen ensheathment.\" [GOC:dgh, GOC:TermGenie, PMID:23698350]","metadata":null},{"id":"594be099c9eb48bb9032addd7c6c6d67","type":"GO_TERM","name":"endothelial tube morphogenesis","canonical_id":"go:GO:0061154","description":"\"The process in which the anatomical structures of a tube are generated and organized from an endothelium. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"6fbf561b8c6e46298352a330796d6416","type":"GO_TERM","name":"endothelin A receptor binding","canonical_id":"go:GO:0031707","description":"\"Binding to an endothelin A receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"32ebd7ec8c2e4c11b3743e2acaa2adfa","type":"GO_TERM","name":"endothelin B receptor binding","canonical_id":"go:GO:0031708","description":"\"Binding to an endothelin B receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"8ed9491e982643189731c27bfa7e783b","type":"GO_TERM","name":"endothelin maturation","canonical_id":"go:GO:0034959","description":"\"The process leading to the attainment of the full functional capacity of endothelin by conversion of Big-endothelin substrate into mature endothelin.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"6a7473706d474f97b01c701b4bbdcd74","type":"GO_TERM","name":"endothelin production","canonical_id":"go:GO:1990775","description":"\"The appearance of a endothelin due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Endothelins are endothelium-derived vasoactive peptides involved in a variety of biological functions.\" [PMID:15560120]","metadata":null},{"id":"c31837d22b3c4da3bae28f65bdf48e72","type":"GO_TERM","name":"endothelin receptor activity","canonical_id":"go:GO:0004962","description":"\"Combining with endothelin and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:bf, GOC:dph, GOC:signaling, IUPHAR_GPCR:1283, IUPHAR_RECEPTOR:2263, IUPHAR_RECEPTOR:2265]","metadata":null},{"id":"481588cf8efd438089e63e5135f54002","type":"GO_TERM","name":"endothelin receptor signaling pathway","canonical_id":"go:GO:0086100","description":"\"A G protein-coupled receptor signaling pathway initiated by endothelin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, PMID:10977869]","metadata":null},{"id":"d57e0e937959474ca84494ac0e56e97b","type":"GO_TERM","name":"endothelin receptor signaling pathway involved in heart process","canonical_id":"go:GO:0086101","description":"\"An endothelin receptor signaling pathway which contributes to a circulatory system process carried out by the heart.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, PMID:17376402]","metadata":null},{"id":"dc5c984c52a14e1d842e728cb99dd76d","type":"GO_TERM","name":"endothelium development","canonical_id":"go:GO:0003158","description":"\"The process whose specific outcome is the progression of an endothelium over time, from its formation to the mature structure. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells.\" [GOC:mtg_heart]","metadata":null},{"id":"19bd6bafe071434dbb854bbab3e05fd4","type":"GO_TERM","name":"energy coupled proton transmembrane transport, against electrochemical gradient","canonical_id":"go:GO:0015988","description":"\"The transport of protons across a membrane and against an electrochemical gradient, using energy from a source such as ATP hydrolysis, light, or electron transport.\" [GOC:mah]","metadata":null},{"id":"e8f1499195d348fdaf083938f2c0dc4f","type":"GO_TERM","name":"energy coupled proton transport, down electrochemical gradient","canonical_id":"go:GO:0015985","description":"\"The transport of protons across a membrane to generate an electrochemical gradient (proton-motive force) that provides energy for the synthesis of ATP or GTP.\" [GOC:mah]","metadata":null},{"id":"659c1c60afd942be940a5c79cf132727","type":"GO_TERM","name":"energy derivation by oxidation of organic compounds","canonical_id":"go:GO:0015980","description":"\"The chemical reactions and pathways by which a cell derives energy from organic compounds; results in the oxidation of the compounds from which energy is released.\" [GOC:mah]","metadata":null},{"id":"7125bb1499414d5f9dee208407da5ef5","type":"GO_TERM","name":"energy derivation by oxidation of reduced inorganic compounds","canonical_id":"go:GO:0015975","description":"\"The chemical reactions and pathways by which a cell derives energy from inorganic compounds; results in the oxidation of the compounds from which energy is released.\" [GOC:mah]","metadata":null},{"id":"405c20693f39402e954170158dbc1da4","type":"GO_TERM","name":"energy homeostasis","canonical_id":"go:GO:0097009","description":"\"Any process involved in the balance between food intake (energy input) and energy expenditure.\" [GOC:yaf, PMID:15919751]","metadata":null},{"id":"1b65098b9053459c96ffcea2e5b20d9e","type":"GO_TERM","name":"energy quenching","canonical_id":"go:GO:1990066","description":"\"The process by which excess light energy absorbed by chlorophyll and not used to drive photosynthesis is emitted by nonphotochemical quenching or chlorophyll fluorescence.\" [PMID:10938857]","metadata":null},{"id":"cb86835d996c4c828407f313e7426043","type":"GO_TERM","name":"energy reserve metabolic process","canonical_id":"go:GO:0006112","description":"\"The chemical reactions and pathways by which a cell derives energy from stored compounds such as fats or glycogen.\" [GOC:mah]","metadata":null},{"id":"3bee51c6ccf945c5ad805dfeb73977ed","type":"GO_TERM","name":"energy taxis","canonical_id":"go:GO:0009453","description":"\"The directed movement of a motile cell or organism in response to physical parameters involved in energy generation, such as light, oxygen, and oxidizable substrates.\" [GOC:jl, PMID:11029423]","metadata":null},{"id":"c47a734351d84d78b1164a03f933d142","type":"GO_TERM","name":"energy transducer activity","canonical_id":"go:GO:0031992","description":"\"The biological transducer activity that accepts energy and converts it to another form, often by transfer to another molecule within the cell.\" [GOC:curators]","metadata":null},{"id":"c1ab0baf424e49a6a21f10891d8527b8","type":"DRUG","name":"enfortumab vedotin","canonical_id":"gtopdb:10738","description":null,"metadata":null},{"id":"ab7a154902214caa81a6a7ea5ef9d8d0","type":"DRUG","name":"enfortumab vedotin","canonical_id":"chembl:CHEMBL3301589","description":null,"metadata":null},{"id":"f83b36a0f5cc42099e61c0462756f7f5","type":"COMBINATION_TREATMENT","name":"enfortumab vedotin + izalontamab brengitecan","canonical_id":"ctgov_combo:ctgov-combo-c2beacfa97f87d64","description":null,"metadata":null},{"id":"8ed7650b19bf40e085797872d3dd6462","type":"COMBINATION_TREATMENT","name":"enfortumab vedotin + niraparib + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-7ecbce66ef398d8a","description":null,"metadata":null},{"id":"3c4b586d680a47ff80254c2f96834425","type":"COMBINATION_TREATMENT","name":"enfortumab vedotin + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-771804422a4157b6","description":null,"metadata":null},{"id":"901a819fe26049dbb9c8518a1260ea56","type":"COMBINATION_TREATMENT","name":"enfortumab vedotin + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-47158a134880c49e","description":null,"metadata":null},{"id":"54005bd74964476da04af5af6cacb621","type":"DRUG","name":"enfuvirtide","canonical_id":"mesh:C105196","description":null,"metadata":null},{"id":"24256ec9b47e46308300e3a693f4315d","type":"GO_TERM","name":"engulfment of apoptotic cell","canonical_id":"go:GO:0043652","description":"\"The removal of the apoptotic cell by phagocytosis, by a neighboring cell or by a phagocyte.\" [GOC:rk, PMID:15536015]","metadata":null},{"id":"5a04c0bdb17d4283a59639e3ad73864c","type":"GO_TERM","name":"engulfment of target by autophagosome","canonical_id":"go:GO:0061736","description":"\"The membrane invagination process by which an autophagosomal membrane surrounds an object that will be degraded by macroautophagy.\" [GOC:autophagy, GOC:dph, GOC:pad, GOC:PARL]","metadata":null},{"id":"0dc3d11e7a8844ffbf5afd68f893729c","type":"GO_TERM","name":"enhanceosome","canonical_id":"go:GO:0034206","description":"\"A protein-DNA complex formed by the association of a distinct set of general and specific transcription factors with a region of enhancer DNA. The cooperative assembly of an enhanceosome confers specificity of transcriptional regulation.\" [PMID:11250145, PMID:17574024]","metadata":null},{"id":"e3d449ab496241059263d4dc9f17e281","type":"GO_TERM","name":"enkephalin processing","canonical_id":"go:GO:0034230","description":"\"The formation of mature enkephalin, a pentapeptide hormone involved in regulating pain and nociception in the body by proteolytic processing of enkephalin propeptide.\" [GOC:BHF, GOC:mah, GOC:rl, PMID:8262946]","metadata":null},{"id":"5d1221088a4745e283825700295b4a12","type":"DRUG","name":"enlonstobart","canonical_id":"gtopdb:13789","description":null,"metadata":null},{"id":"e86afc842b93444da235ae728900aeef","type":"GO_TERM","name":"enniatin biosynthetic process","canonical_id":"go:GO:0046585","description":"\"The chemical reactions and pathways resulting in the formation of enniatins, any of various cyclodepsipeptide antibiotics from Fusarium species that function as ionophores.\" [ISBN:0198506732]","metadata":null},{"id":"ab9636d1d7ae409aabd09178c8a8f84f","type":"GO_TERM","name":"enone reductase activity","canonical_id":"go:GO:0035671","description":"\"Catalysis of the reaction: an enone + NADPH + H+ = a ketone + NADP+.\" [GOC:kad, PMID:17945329, PMID:19166903]","metadata":null},{"id":"399b6d7c13cc4dd796a6a98e50b7ae1f","type":"DRUG","name":"enoxacin","canonical_id":"mesh:D015365","description":null,"metadata":null},{"id":"54c57f1ee63a485da3b0d09870ab2079","type":"DRUG","name":"enoxaparin","canonical_id":"gtopdb:6811","description":null,"metadata":null},{"id":"7ad1d09940a54f17a8090f7e5792e667","type":"COMBINATION_TREATMENT","name":"enoxaparin + fondaparinux","canonical_id":"ctgov_combo:ctgov-combo-fa9e70eb4edbef0d","description":null,"metadata":null},{"id":"728690f939944c2e9b87382d4c2f0af2","type":"COMBINATION_TREATMENT","name":"enoxaparin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-57d4e956ec8fad03","description":null,"metadata":null},{"id":"a4ce89965587495da172c403e6ef6233","type":"COMBINATION_TREATMENT","name":"enoxaparin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-bba9cd26db82a98d","description":null,"metadata":null},{"id":"f21b179f669c41cba7b454267c57ea62","type":"COMBINATION_TREATMENT","name":"enoxaparin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-67d109ed7c6dd32f","description":null,"metadata":null},{"id":"10f46bf9afc94d24a70a4d11f522055b","type":"COMBINATION_TREATMENT","name":"enoxaparin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-d02146b9fe841231","description":null,"metadata":null},{"id":"74abd270694342028574f89da3d1e6fc","type":"COMBINATION_TREATMENT","name":"enoxaparin + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-5de4ddeafdb146aa","description":null,"metadata":null},{"id":"0fad058476bd4053b4fa1b03f52258ec","type":"DRUG","name":"enoximone","canonical_id":"gtopdb:9063","description":null,"metadata":null},{"id":"7d9cf645eca44d47bd37ce2af3bb301e","type":"DRUG","name":"enoximone","canonical_id":"chembl:CHEMBL249856","description":null,"metadata":null},{"id":"2978ba51c8554e79a8da8f77cd303ccc","type":"GO_TERM","name":"enoyl-CoA hydratase activity","canonical_id":"go:GO:0004300","description":"\"Catalysis of the reaction: a 3-hydroxy-fatty acyl-CoA = a enoyl-CoA + H2O. This reaction usually occurs in the reverse direction, leading to the reduction of the double bound of enoyl-CoA in position 2 or 3. Specific reactions catalyzed include: a 4-saturated-(3S)-3-hydroxyacyl-CoA = a (3E)-enoyl-CoA + H2O and a (3S)-3-hydroxyacyl-CoA = a (2E)-enoyl-CoA + H2O.\" [EC:4.2.1.17]","metadata":null},{"id":"ad20a7a8e2364994b06bfc7681ac8aac","type":"GO_TERM","name":"enoyl-[acyl-carrier-protein] reductase (NADH) activity","canonical_id":"go:GO:0004318","description":"\"Catalysis of the reaction: a 2,3-saturated acyl-[ACP] + NAD+ = a (2E)-enoyl-[ACP] + H+ + NADH.\" [RHEA:10240]","metadata":null},{"id":"57f032ad90204e598ab10a71474b2fc6","type":"GO_TERM","name":"enoyl-[acyl-carrier-protein] reductase (NADPH) activity","canonical_id":"go:GO:0141148","description":"\"Catalysis of the reaction: a 2,3-saturated acyl-[ACP] + NADP+ = a (2E)-enoyl-[ACP] + H+ + NADPH.\" [RHEA:22564]","metadata":null},{"id":"eda0058be47b4ac1bf213b36528301cf","type":"GO_TERM","name":"enoyl-[acyl-carrier-protein] reductase [NAD(P)H] activity","canonical_id":"go:GO:0016631","description":"\"Catalysis of the reaction: acyl-[acyl-carrier protein] + NAD(P)+ = trans-2,3-dehydroacyl-[acyl-carrier protein] + NAD(P)H + H+.\" [GOC:rb]","metadata":null},{"id":"42a50af39ebb47a29a5f0146352a67d8","type":"GO_TERM","name":"ensheathing process","canonical_id":"go:GO:1990015","description":"\"A cell projection (often from glial cells such as Schwann cells) that surrounds an unmyelinated axon or cell soma.\" [NIF_Subcellular:sao1376748732]","metadata":null},{"id":"158ab7f6ef7943d5b434300ad8ca6ed0","type":"GO_TERM","name":"ensheathment of neuronal cell bodies","canonical_id":"go:GO:0032295","description":"\"The process in which satellite glial cells isolate neuronal cell bodies.\" [GOC:dgh]","metadata":null},{"id":"1b2849c8aba8456a9995f01885388a3a","type":"GO_TERM","name":"ensheathment of neurons","canonical_id":"go:GO:0007272","description":"\"The process in which glial cells envelop neuronal cell bodies and/or axons to form an insulating layer. This can take the form of myelinating or non-myelinating ensheathment.\" [GOC:dgh, GOC:dph, GOC:tb]","metadata":null},{"id":"3d9f163ae7324481aebf1b938c5885a4","type":"GO_TERM","name":"ent-cassa-12,15-diene 11-hydroxylase activity","canonical_id":"go:GO:0036202","description":"\"Catalysis of the reaction: ent-cassa-12,15-diene + O2 + NADPH + H+ = ent-11beta-hydroxycassa-12,15-diene + NADP+ + H2O.\" [EC:1.14.14.112]","metadata":null},{"id":"43902374cd044a23b6daec867277c7c7","type":"GO_TERM","name":"ent-cassa-12,15-diene synthase activity","canonical_id":"go:GO:0034277","description":"\"Catalysis of the reaction: ent-copalyl diphosphate = ent-cassa-12,15-diene + diphosphate.\" [EC:4.2.3.28, RHEA:25532]","metadata":null},{"id":"adf4f21630fb4858af619443457578a7","type":"GO_TERM","name":"ent-copalyl diphosphate synthase activity","canonical_id":"go:GO:0009905","description":"\"Catalysis of the reaction: all-trans-geranylgeranyl diphosphate = ent-copalyl diphosphate.\" [EC:5.5.1.13, RHEA:14841]","metadata":null},{"id":"54e8297c5d1b43e1be9447f10533d0c8","type":"GO_TERM","name":"ent-isokaurene C2-hydroxylase activity","canonical_id":"go:GO:0036201","description":"\"Catalysis of the reaction: ent-isokaurene + O2 + NADPH + H+ = ent-2alpha-hydroxyisokaurene + H2O + NADP+.\" [EC:1.14.14.76]","metadata":null},{"id":"ab87987a0e5946e08857f7b150f3b4da","type":"GO_TERM","name":"ent-isokaurene synthase activity","canonical_id":"go:GO:0034281","description":"\"Catalysis of the reaction: ent-copalyl diphosphate = ent-isokaurene + diphosphate.\" [PMID:17141283, RHEA:25759]","metadata":null},{"id":"a327f2ef2c2b433cb0316c67d7006130","type":"GO_TERM","name":"ent-kaurene biosynthetic process","canonical_id":"go:GO:0033332","description":"\"The chemical reactions and pathways resulting in the formation of ent-kaurene. Ent-kaurene is a tetracyclic diterpenoid that is a precursor of several plant isoprenoids, including gibberellins.\" [GOC:mah, MetaCyc:PWY-5032, PMID:17064690]","metadata":null},{"id":"e6aca0b84f4a4e8abed4615282b8eab0","type":"GO_TERM","name":"ent-kaurene metabolic process","canonical_id":"go:GO:0033331","description":"\"The chemical reactions and pathways involving ent-kaur-16-ene. Ent-kaurene is a tetracyclic diterpenoid that is a precursor of several plant isoprenoids, including gibberellins.\" [GOC:mah, PMID:17064690]","metadata":null},{"id":"b9dd3da31a7a4e9cbdf137619a053dfd","type":"GO_TERM","name":"ent-kaurene oxidase activity","canonical_id":"go:GO:0052615","description":"\"Catalysis of the reaction: ent-kaur-16-ene + 3 O2 + 3 reduced [NADPH--hemoprotein reductase] = ent-kaur-16-en-19-oate + 4 H+ + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase].\" [RHEA:32323]","metadata":null},{"id":"4c09250230fd4a9c879bedd219213398","type":"GO_TERM","name":"ent-kaurene synthase activity","canonical_id":"go:GO:0009899","description":"\"Catalysis of the reaction: ent-copalyl diphosphate = ent-kaur-16-ene + diphosphate.\" [EC:4.2.3.19, RHEA:22220]","metadata":null},{"id":"27249ac345f24ab69b95b1d406e8cc6b","type":"GO_TERM","name":"ent-kaurenoic acid monooxygenase activity","canonical_id":"go:GO:0051777","description":"\"Catalysis of the reaction:ent-kaur-16-en-19-oate + 3 O2 + 3 reduced [NADPH--hemoprotein reductase] = gibberellin A12 + 4 H+ + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase]. Catalyzes three successive oxidations of ent-kaurenoic acid.\" [RHEA:33219]","metadata":null},{"id":"6cd4ea18234e406e8fe61ac13dd663ee","type":"GO_TERM","name":"ent-pimara-8(14),15-diene biosynthetic process","canonical_id":"go:GO:1901541","description":"\"The chemical reactions and pathways resulting in the formation of ent-pimara-8(14),15-diene.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8ec6fd58bb264e5e8d7f2845e2d9ed61","type":"GO_TERM","name":"ent-pimara-8(14),15-diene catabolic process","canonical_id":"go:GO:1901540","description":"\"The chemical reactions and pathways resulting in the breakdown of ent-pimara-8(14),15-diene.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5d856deb28694d6aa295eb53524fa8c4","type":"GO_TERM","name":"ent-pimara-8(14),15-diene synthase activity","canonical_id":"go:GO:0034282","description":"\"Catalysis of the reaction: ent-copalyl diphosphate = ent-pimara-8(14),15-diene + diphosphate.\" [RHEA:25540]","metadata":null},{"id":"89c44b10d5b347feb47fc7b2b66129e4","type":"GO_TERM","name":"ent-pimara-9(11),15-diene synthase activity","canonical_id":"go:GO:0052674","description":"\"Catalysis of the reaction: ent-copalyl diphosphate = ent-pimara-9(11),15-diene + diphosphate.\" [RHEA:25544]","metadata":null},{"id":"7aef38a08043431f90bd2815cac505d3","type":"GO_TERM","name":"ent-sandaracopimaradiene synthase activity","canonical_id":"go:GO:0034280","description":"\"Catalysis of the reaction: ent-copalyl diphosphate = ent-sandaracopimara-8(14),15-diene + diphosphate.\" [RHEA:25536]","metadata":null},{"id":"f14aef9eee3a4dbcb37d424b73768a60","type":"DRUG","name":"entacapone","canonical_id":"gtopdb:6647","description":null,"metadata":null},{"id":"d42fe311a51541c79cc525f90debc09a","type":"DRUG","name":"entacapone","canonical_id":"mesh:C071192","description":null,"metadata":null},{"id":"46387821db914e0e9f1f79b0f235fcce","type":"DRUG","name":"entacapone","canonical_id":"chembl:CHEMBL953","description":null,"metadata":null},{"id":"0dd7f4a4aa5641a0a4c1d07139d25266","type":"COMBINATION_TREATMENT","name":"entacapone + mecamylamine","canonical_id":"ctgov_combo:ctgov-combo-7fc14bfdc5b6b64c","description":null,"metadata":null},{"id":"369cb6b243c242ab88b6aa2fee68343a","type":"COMBINATION_TREATMENT","name":"entacapone + tolcapone","canonical_id":"ctgov_combo:ctgov-combo-3ce8f9ed7491ee52","description":null,"metadata":null},{"id":"c002958c26c5442ab189e2b43b8c9203","type":"GO_TERM","name":"enteric nervous system development","canonical_id":"go:GO:0048484","description":"\"The process whose specific outcome is the progression of the enteric nervous system over time, from its formation to the mature structure. The enteric nervous system is composed of two ganglionated neural plexuses in the gut wall which form one of the three major divisions of the autonomic nervous system. The enteric nervous system innervates the gastrointestinal tract, the pancreas, and the gallbladder. It contains sensory neurons, interneurons, and motor neurons. Thus the circuitry can autonomously sense the tension and the chemical environment in the gut and regulate blood vessel tone, motility, secretions, and fluid transport. The system is itself governed by the central nervous system and receives both parasympathetic and sympathetic innervation.\" [FMA:66070, GOC:jid, GOC:sr]","metadata":null},{"id":"640939e9ac504d1793f537eda7a5a770","type":"GO_TERM","name":"enteric smooth muscle cell differentiation","canonical_id":"go:GO:0035645","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell of the intestine.\" [CL:0002504, GOC:BHF]","metadata":null},{"id":"02e6c9cbddce4bd5bae43594fb366ec1","type":"GO_TERM","name":"enterobacterial common antigen biosynthetic process","canonical_id":"go:GO:0009246","description":"\"The chemical reactions and pathways resulting in the formation of the enterobacterial common antigen, an acidic polysaccharide containing N-acetyl-D-glucosamine, N-acetyl-D-mannosaminouronic acid, and 4-acetamido-4,6-dideoxy-D-galactose. A major component of the cell wall outer membrane of Gram-negative bacteria.\" [GOC:ma]","metadata":null},{"id":"ab993aec99f44eb4892f72b88968df63","type":"GO_TERM","name":"enterobacterial common antigen metabolic process","canonical_id":"go:GO:0046378","description":"\"The chemical reactions and pathways involving enterobacterial common antigen, an acidic polysaccharide containing N-acetyl-D-glucosamine, N-acetyl-D-mannosaminouronic acid, and 4-acetamido-4,6-dideoxy-D-galactose. A major component of the cell wall outer membrane of Gram-negative bacteria.\" [GOC:ma]","metadata":null},{"id":"ae0b0f2061ef4ee09fd6d09ccef0e88a","type":"GO_TERM","name":"enterobactin binding","canonical_id":"go:GO:1903981","description":"\"Binding to enterobactin.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:21951132]","metadata":null},{"id":"08caeb65f3fa4f1484bbe404c0ccb843","type":"GO_TERM","name":"enterobactin biosynthetic process","canonical_id":"go:GO:0009239","description":"\"The chemical reactions and pathways resulting in the formation of enterobactin, a catechol-derived siderochrome of Enterobacteria; enterobactin (N',N',N''-(2,6,10-trioxo-1,5,9-triacyclodecane-3,7,11-triyl)tris(2,3-dihydroxy)benzamide) is a self-triester of 2,3-dihydroxy-N-benzoyl-L-serine and a product of the shikimate pathway.\" [GOC:curators]","metadata":null},{"id":"891964d1e19547e3b0ad6f9e67e68d50","type":"GO_TERM","name":"enterobactin catabolic process","canonical_id":"go:GO:0046214","description":"\"The chemical reactions and pathways resulting in the breakdown of enterobactin, a catechol-derived siderochrome of Enterobacteria; enterobactin (N',N',N''-(2,6,10-trioxo-1,5,9-triacyclodecane-3,7,11-triyl)tris(2,3-dihydroxy)benzamide) is a self-triester of 2,3-dihydroxy-N-benzoyl-L-serine and a product of the shikimate pathway.\" [GOC:ai]","metadata":null},{"id":"054bcc1714f04e5b96bb290ef6ab09f2","type":"GO_TERM","name":"enterobactin synthetase complex","canonical_id":"go:GO:0009366","description":"\"A multienzyme complex usually composed of four proteins, EntB, EntD, EntE and EntF. Plays a role in the enterobactin biosynthesis pathway.\" [PMID:9485415]","metadata":null},{"id":"b4351b09531042ce9484d29f1ec68e9b","type":"GO_TERM","name":"enterobactin transmembrane transporter activity","canonical_id":"go:GO:0042931","description":"\"Enables the directed movement of the siderochrome enterochelin, a cyclic trimer of 2, 3 dihydroxybenzoylserine from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"8aaa73c666af46df80e26e621b4ff030","type":"GO_TERM","name":"enterobactin transport","canonical_id":"go:GO:0042930","description":"\"The directed movement of the siderochrome enterobactin, a cyclic trimer of 2, 3 dihydroxybenzoylserine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"c1553eb2f9fa4a8bbcc775789a084a25","type":"GO_TERM","name":"enterochelin esterase activity","canonical_id":"go:GO:0008849","description":"\"Catalysis of the reaction: enterobactin + 3 H2O = 3 N-23-dihydroxybenzoyl-L-serine + 3 H+.\" [MetaCyc:RXN0-1661, PMID:4565531]","metadata":null},{"id":"23f61b74309c43aa8c62bb8fb137276c","type":"GO_TERM","name":"enterocyte differentiation","canonical_id":"go:GO:1903703","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an enterocyte.\" [GO_REF:0000086, GOC:TermGenie, PMID:16782882, Wikipedia:List_of_intestinal_epithelial_differentiation_genes]","metadata":null},{"id":"747afb35e9e54ec0a974e4c64c228470","type":"GO_TERM","name":"enteroendocrine cell differentiation","canonical_id":"go:GO:0035883","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of an enteroendocrine cell. Enteroendocrine cells are hormonally active epithelial cells in the gut that constitute the diffuse neuroendocrine system.\" [CL:0000164, GOC:bf]","metadata":null},{"id":"c4dc6f442c0b499aa62c7291dbb94f92","type":"GO_TERM","name":"entrainment of circadian clock","canonical_id":"go:GO:0009649","description":"\"The synchronization of a circadian rhythm to environmental time cues such as light.\" [GOC:jid]","metadata":null},{"id":"10b70cbf1b7140ca96f0ed8f92c50812","type":"GO_TERM","name":"entrainment of circadian clock by photoperiod","canonical_id":"go:GO:0043153","description":"\"The synchronization of a circadian rhythm to photoperiod, the intermittent cycle of light (day) and dark (night).\" [GOC:jl]","metadata":null},{"id":"d668b344e61c499d80254d80301c5f80","type":"GO_TERM","name":"entry into diapause","canonical_id":"go:GO:0055115","description":"\"The dormancy process that results in entry into diapause. Diapause is a neurohormonally mediated, dynamic state of low metabolic activity. Associated characteristics of this form of dormancy include reduced morphogenesis, increased resistance to environmental extremes, and altered or reduced behavioral activity. Full expression develops in a species-specific manner, usually in response to a number of environmental stimuli that precede unfavorable conditions. Once diapause has begun, metabolic activity is suppressed even if conditions favorable for development prevail. Once initiated, only certain stimuli are capable of releasing the organism from this state, and this characteristic is essential in distinguishing diapause from hibernation.\" [GOC:ds, GOC:jid, GOC:mah]","metadata":null},{"id":"ebec6a252707412693205be1adc50668","type":"GO_TERM","name":"entry into dormancy","canonical_id":"go:GO:0097436","description":"\"The dormancy process that results in entry into dormancy. Dormancy (sometimes called a dormant state) is a suspension of most physiological activity and growth that can be reactivated.\" [GOC:PO_curators, PO_REF:00009]","metadata":null},{"id":"9c1fcd80716f426494f5cbe91b1bd156","type":"GO_TERM","name":"entry into host cell by a symbiont-containing vacuole","canonical_id":"go:GO:0085017","description":"\"The invasion by a symbiont of a cell of a host organism, forming a vacuole in which the symbiont resides. The vacuole membrane is formed from lipids and proteins derived from both host and symbiont. Begins when the symbiont attaches on to the host cell membrane which invaginates and deepens as the symbiont enters, and ends when the host cell membrane closes behind the newly-formed vacuole.\" [GOC:jl, PMID:18665841, PMID:8690024, PMID:9580555]","metadata":null},{"id":"f2169aeeedb3491893a98874a42eac0a","type":"GO_TERM","name":"entry into host through the stromata","canonical_id":"go:GO:0140717","description":"\"Entry of a symbiont into host plant tissue via the stromata, microscopic pores in the epidermis of the aerial parts of terrestrial plants. These pores are essential for photosynthesis, as they allow CO2 to diffuse into the plant. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:16959560, PMID:17419713, PMID:29307013]","metadata":null},{"id":"6100a632289e4ba68b2801bf2485a60e","type":"GO_TERM","name":"entry into reproductive diapause","canonical_id":"go:GO:0055116","description":"\"The dormancy process that results in entry into reproductive diapause. Reproductive diapause is a form of diapause where the organism itself will remain fully active, including feeding and other routine activities, but the reproductive organs experience a tissue-specific reduction in metabolism, with characteristic triggering and releasing stimuli.\" [GOC:ds, GOC:jid, GOC:mah]","metadata":null},{"id":"02549d2a364e4620b300ad8eec8ab6f0","type":"GO_TERM","name":"entry of bacterium into host cell","canonical_id":"go:GO:0035635","description":"\"The process in which a bacterium enters a host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, PMID:21187937]","metadata":null},{"id":"fbce3fbe0e774553a941971d11f5fe95","type":"GO_TERM","name":"entry of intact viral capsid into host nucleus through nuclear pore complex","canonical_id":"go:GO:0075505","description":"\"Viral penetration into the host nucleus where a viral capsid passes intact through the host nuclear pore complex (NPC).\" [PMID:22929056, VZ:989]","metadata":null},{"id":"3a7c1896b9314abd94181a4006d73e13","type":"GO_TERM","name":"entry of viral genome into host nucleus through nuclear pore complex via importin","canonical_id":"go:GO:0075506","description":"\"Viral penetration into the host nucleus where the viral genome passes through the nuclear pore complex (NPC) using the cellular importin transport machinery.\" [PMID:22929056, VZ:989]","metadata":null},{"id":"4023b71c35c849f995bdd4799760aae5","type":"GO_TERM","name":"entry of viral genome into host nucleus via docking of viral capsid to the nuclear pore complex and injection of viral genome","canonical_id":"go:GO:0075507","description":"\"Viral penetration into the host nucleus where the where a viral capsid docks on the cytoplasmic side of the nuclear pore complex (NPC) and ejects the viral genome through the pore into the nucleoplasm.\" [PMID:22929056, VZ:989]","metadata":null},{"id":"591d5445786943f7a7effff23e615857","type":"GO_TERM","name":"entry of viral genome into host nucleus via retainment of capsid in nuclear pore complex and release of genome into nucleoplasm","canonical_id":"go:GO:0075508","description":"\"Viral penetration into the host nucleus where a viral capsid enters the host nuclear pore complex (NPC) but remains attached to the pore on the nuclear side. The capsid then disassembles, releasing the viral genome into the nucleoplasm.\" [PMID:22929056, VZ:989]","metadata":null},{"id":"d6c8fe9192764b1891ff40cd80047676","type":"GO_TERM","name":"entry receptor-mediated virion attachment to host cell","canonical_id":"go:GO:0098670","description":"\"The process by which a virion attaches to a host cell by binding to a receptor on the host cell surface that mediates/triggers viral entry by endocytosis/pinocytosis or by inducing fusion/penetration.\" [PMID:18351291, VZ:3942]","metadata":null},{"id":"f1d172f73f1848e1a5e0448309dd5202","type":"GO_TERM","name":"enucleate erythrocyte development","canonical_id":"go:GO:0048822","description":"\"The process aimed at the progression of an enucleate erythrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:devbiol]","metadata":null},{"id":"398de49b3f784782acdd802402743f45","type":"GO_TERM","name":"enucleate erythrocyte differentiation","canonical_id":"go:GO:0043353","description":"\"The process in which a myeloid precursor cell acquires specialized features of an erythrocyte without a nucleus. An example of this process is found in Mus musculus.\" [GOC:curators]","metadata":null},{"id":"dbadfedea90d48b991f74a67f0ba15c9","type":"GO_TERM","name":"enucleate erythrocyte maturation","canonical_id":"go:GO:0043354","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an enucleate erythrocyte to attain its fully functional state. An enucleate erythrocyte is an erythrocyte without a nucleus.\" [GOC:curators]","metadata":null},{"id":"0f4a6d5c728e4a9b99d14c3380b5eea6","type":"GO_TERM","name":"enucleation","canonical_id":"go:GO:0090601","description":"\"The process in which nucleated precursor cells lose their nucleus.\" [GOC:tb]","metadata":null},{"id":"0c0ee48a500b4a92a84a825553b1bcde","type":"DISEASE","name":"enuresis","canonical_id":"mondo:0024290","description":null,"metadata":null},{"id":"0a17e7bcf5944a73a6e1d9b18d2acc06","type":"DRUG","name":"envafolimab","canonical_id":"gtopdb:10492","description":null,"metadata":null},{"id":"776a1d09c6e44d13b5ab9470c021c114","type":"DRUG","name":"envafolimab","canonical_id":"chembl:CHEMBL4298006","description":null,"metadata":null},{"id":"8717d1bb28e04ac48e7b55c574b56f40","type":"COMBINATION_TREATMENT","name":"envafolimab + fruquintinib","canonical_id":"ctgov_combo:ctgov-combo-fb8940e157732b07","description":null,"metadata":null},{"id":"5bd20a562f9e48a1b78d64494cfe6943","type":"DRUG","name":"enzalutamide","canonical_id":"gtopdb:6812","description":null,"metadata":null},{"id":"35873598a48b405c8d9eec49958a6140","type":"DRUG","name":"enzalutamide","canonical_id":"mesh:C540278","description":null,"metadata":null},{"id":"4919ea369225449dafda16e93c47f51b","type":"DRUG","name":"enzalutamide","canonical_id":"chembl:CHEMBL1082407","description":null,"metadata":null},{"id":"40f13c2d3a374e65b726f479f1c13283","type":"COMBINATION_TREATMENT","name":"enzalutamide + fludrocortisone","canonical_id":"ctgov_combo:ctgov-combo-23841b012ab0b067","description":null,"metadata":null},{"id":"4dc8f2e30a6c4911abfe44eeab36b794","type":"COMBINATION_TREATMENT","name":"enzalutamide + olaparib","canonical_id":"ctgov_combo:ctgov-combo-4d3f3dcd13e8a782","description":null,"metadata":null},{"id":"0d8e538e0fcc4e3492283f6621aa7dec","type":"COMBINATION_TREATMENT","name":"enzalutamide + pegfilgrastim","canonical_id":"ctgov_combo:ctgov-combo-302bc5ec1e016a9e","description":null,"metadata":null},{"id":"aa9033c57d924a4db06f933c10ac48c6","type":"COMBINATION_TREATMENT","name":"enzalutamide + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-8b9760b0aac7b826","description":null,"metadata":null},{"id":"298f7855c5614304884f1ba02977ac89","type":"COMBINATION_TREATMENT","name":"enzalutamide + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-e022bcbfa4e28806","description":null,"metadata":null},{"id":"9470017ff14f4d0ab539de0fef0b829d","type":"GO_TERM","name":"enzyme IIA-maltose transporter complex","canonical_id":"go:GO:1990154","description":"\"A protein complex consisting of the pentameric maltose transporter complex bound to two enzyme IIA (EIIA) molecules. EIIA is a component of the glucose-specific phosphotransferase system that inhibits maltose transport from the periplasm to the cytoplasm. When EIIA-bound, the maltose transporter remains in the open, inward-facing conformation, which prevents binding of maltose-loaded maltose binding protein (MBP) to the transporter.\" [GOC:bf, GOC:bhm, PMID:23770568]","metadata":null},{"id":"1e9234d3c6b24797806121a4f1e03742","type":"GO_TERM","name":"enzyme activator activity","canonical_id":"go:GO:0008047","description":"\"A molecular function regulator that increases a catalytic activity.\" [GOC:pdt]","metadata":null},{"id":"85c7400eac044204857d541efdd203b7","type":"GO_TERM","name":"enzyme activator complex","canonical_id":"go:GO:0150005","description":"\"A protein complex capable of activating an enzyme. Activating subunits may dissociate from the catalytic unit before the enzyme is active.\" [GOC:bhm, PMID:16244137, PMID:28710280]","metadata":null},{"id":"241a01a5024349c18afee90e48e3a66b","type":"GO_TERM","name":"enzyme binding","canonical_id":"go:GO:0019899","description":"\"Binding to an enzyme, a protein with catalytic activity.\" [GOC:jl]","metadata":null},{"id":"5a49c83db93042a7ba3fcc0915881a72","type":"GO_TERM","name":"enzyme inhibitor activity","canonical_id":"go:GO:0004857","description":"\"A molecular function regulator that reduces a catalytic activity.\" [GOC:ai, GOC:ebc]","metadata":null},{"id":"2f9e706d0c4446098719d0649e1f2076","type":"GO_TERM","name":"enzyme regulator activity","canonical_id":"go:GO:0030234","description":"\"A molecular function regulator that modulates a catalytic activity.\" [GOC:pdt]","metadata":null},{"id":"c46d56b5a79645deaf1b9924a9faa2a9","type":"GO_TERM","name":"enzyme-directed rRNA pseudouridine synthesis","canonical_id":"go:GO:0000455","description":"\"The intramolecular conversion of uridine to pseudouridine during ribosome biogenesis where the enzyme specifies the site that becomes pseudouridylated without using a guide RNA.\" [GOC:curators, ISBN:1555811337]","metadata":null},{"id":"d8639038d9d24f70bee2e079ba8231c2","type":"GO_TERM","name":"enzyme-linked receptor protein signaling pathway","canonical_id":"go:GO:0007167","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell, where the receptor possesses catalytic activity or is closely associated with an enzyme such as a protein kinase, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling, ISBN:0815316194]","metadata":null},{"id":"d92c018f050d4d8d976e746b434a1207","type":"GO_TERM","name":"enzyme-substrate adaptor activity","canonical_id":"go:GO:0140767","description":"\"An adaptor that brings together an enzyme and its substrate. Adaptors recruit the substrate to its enzyme, thus contributing to substrate selection and specificity.\" [PMID:16250895, PMID:34358446]","metadata":null},{"id":"f07544448e2f4e21bd7ba76934b959ad","type":"GO_TERM","name":"enzyme-thiol transhydrogenase (glutathione-disulfide) activity","canonical_id":"go:GO:0047142","description":"\"Catalysis of the reaction: oxidized glutathione + [xanthine dehydrogenase] = reduced glutathione + xanthine-oxidase.\" [EC:1.8.4.7, MetaCyc:1.8.4.7-RXN]","metadata":null},{"id":"0d3f4abe3510418f85670b6aba28c240","type":"GO_TERM","name":"eosinophil activation","canonical_id":"go:GO:0043307","description":"\"The change in morphology and behavior of a eosinophil resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"124dad8be45f47d98c998dcabc32cb58","type":"GO_TERM","name":"eosinophil activation involved in immune response","canonical_id":"go:GO:0002278","description":"\"The change in morphology and behavior of a eosinophil resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"af13214e744241878ab6434e4cb49b7e","type":"GO_TERM","name":"eosinophil chemotaxis","canonical_id":"go:GO:0048245","description":"\"The movement of an eosinophil in response to an external stimulus.\" [GOC:jid, PMID:11292027, PMID:12391252]","metadata":null},{"id":"332fac4b9a9742f487dcf5f94f077278","type":"GO_TERM","name":"eosinophil degranulation","canonical_id":"go:GO:0043308","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as major basic protein, eosinophil peroxidase, and eosinophil cationic protein by an eosinophil.\" [ISBN:0781735149]","metadata":null},{"id":"45b17507ee584d23b19d3603e40149c0","type":"GO_TERM","name":"eosinophil differentiation","canonical_id":"go:GO:0030222","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires the specializes features of an eosinophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"3d1ff588f3ee4f938e90925a54659e41","type":"GO_TERM","name":"eosinophil extravasation","canonical_id":"go:GO:0072682","description":"\"The migration of an eosinophil from the blood vessels into the surrounding tissue.\" [CL:0000771, GOC:BHF, GOC:mah]","metadata":null},{"id":"5a6293f76c184dcdb9af2d18d83a3bec","type":"GO_TERM","name":"eosinophil fate commitment","canonical_id":"go:GO:0035854","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a eosinophil cell. A eosinophil is any of the immature or mature forms of a granular leukocyte with a nucleus that usually has two lobes connected by one or more slender threads of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and which can be stained by the dye eosin.\" [CL:0000771, GOC:BHF, GOC:vk]","metadata":null},{"id":"fe9cd646eeae42118c6d860dc2dd0db6","type":"GO_TERM","name":"eosinophil fate determination","canonical_id":"go:GO:0035858","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into an eosinophil cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [CL:0000771, GOC:BHF, GOC:vk]","metadata":null},{"id":"e25cc0667d66438daa2b80bd7ee96139","type":"GO_TERM","name":"eosinophil fate specification","canonical_id":"go:GO:0035857","description":"\"The process involved in the specification of identity of an eosinophil cell. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment.\" [CL:0000771, GOC:BHF, GOC:vk]","metadata":null},{"id":"68995a59dc0b485b980d75afb4bdf1ab","type":"GO_TERM","name":"eosinophil homeostasis","canonical_id":"go:GO:1990959","description":"\"The process of regulating the proliferation and elimination of eosinophils such that the total number of eosinophils within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [PMID:10606160]","metadata":null},{"id":"f714addb0e20483eaa4251ec9d6322c1","type":"GO_TERM","name":"eosinophil mediated immunity","canonical_id":"go:GO:0002447","description":"\"Any process involved in the carrying out of an immune response by an eosinophil.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"995e560cec6842fcad25b476f129ecdc","type":"GO_TERM","name":"eosinophil migration","canonical_id":"go:GO:0072677","description":"\"The movement of an eosinophil within or between different tissues and organs of the body.\" [CL:0000771, GOC:BHF, GOC:mah]","metadata":null},{"id":"0045817454b8489f9dc2b6d6ef3b984f","type":"DISEASE","name":"eosinophilic pneumonia","canonical_id":"mondo:0005749","description":null,"metadata":null},{"id":"12e3cc0f89ef47c18887179db02affe7","type":"GO_TERM","name":"eoxin C4 synthase activity","canonical_id":"go:GO:0097261","description":"\"Catalysis of the reaction: eoxin A4 + glutathione = eoxin C4.\" [GOC:mw, PMID:18184802, PMID:18647347]","metadata":null},{"id":"096c140e152d4368bd4e4006735be871","type":"GO_TERM","name":"eoxin D4 synthase activity","canonical_id":"go:GO:0097262","description":"\"Catalysis of the reaction: eoxin C4 = eoxin D4 + 5-L-glutamyl amino acid.\" [GOC:mw, PMID:18184802, PMID:18647347]","metadata":null},{"id":"1df071a003484ac794f45bcec44407f2","type":"GO_TERM","name":"eoxin E4 synthase activity","canonical_id":"go:GO:0097263","description":"\"Catalysis of the reaction: eoxin D4 + H20 = eoxin E4 + glycine.\" [GOC:mw, PMID:18184802, PMID:18647347]","metadata":null},{"id":"6e7a26cd43164088afb2b9f00d6256ca","type":"DISEASE","name":"ependymoma","canonical_id":"mondo:0016698","description":null,"metadata":null},{"id":"ec6cdf68020341999809aeb95e528e4f","type":"DRUG","name":"eperisone","canonical_id":"mesh:C030848","description":null,"metadata":null},{"id":"c6bfbd40ca524ca89cfa2817fd2a3d5e","type":"GO_TERM","name":"ephedrine dehydrogenase activity","canonical_id":"go:GO:0047877","description":"\"Catalysis of the reaction: (1R,2S)-ephedrine + NAD+ = (R)-2-methylimino-1-phenylpropan-1-ol + 2 H+ + NADH.\" [EC:1.5.1.18, RHEA:16289]","metadata":null},{"id":"6cdb2873b996466ebae9dee959156f57","type":"GO_TERM","name":"ephrin receptor activity","canonical_id":"go:GO:0005003","description":"\"Combining with an ephrin receptor ligand to initiate a change in cell activity.\" [GOC:mah, PMID:9530499]","metadata":null},{"id":"f78da397912d47d2bd7c4e09f886311f","type":"GO_TERM","name":"ephrin receptor binding","canonical_id":"go:GO:0046875","description":"\"Binding to an ephrin receptor.\" [GOC:ai]","metadata":null},{"id":"708bd0e1f1b74c0e9a82949fcf0a3f25","type":"GO_TERM","name":"ephrin receptor signaling pathway","canonical_id":"go:GO:0048013","description":"\"The series of molecular signals initiated by ephrin binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb]","metadata":null},{"id":"387a669297f54a2fb9d60f66969a71d2","type":"GO_TERM","name":"epi-cedrol synthase activity","canonical_id":"go:GO:0052682","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate + H2O = epi-cedrol + diphosphate.\" [RHEA:26115]","metadata":null},{"id":"7756b5c92062445eb1fc483d02678754","type":"GO_TERM","name":"epi-isozizaene synthase activity","canonical_id":"go:GO:0052680","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (+)-epi-isozizaene + diphosphate.\" [RHEA:25992]","metadata":null},{"id":"653d2066e1574623a2bf61c26d26f246","type":"GO_TERM","name":"epiblast cell-extraembryonic ectoderm cell signaling","canonical_id":"go:GO:0060802","description":"\"Any process that mediates the transfer of information from an epiblast cell to an extraembryonic ectoderm cell.\" [GOC:dph, GOC:tb, PMID:14511481, PMID:31391456]","metadata":null},{"id":"d3b958d9c254418fb517f105dec834f1","type":"GO_TERM","name":"epiboly","canonical_id":"go:GO:0090504","description":"\"The expansion of one cell sheet over other cells or yolk.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d0bd44117e4d402bbae3abaeda109cbf","type":"GO_TERM","name":"epiboly involved in gastrulation with mouth forming second","canonical_id":"go:GO:0055113","description":"\"The expansion of one cell sheet over other cells involved in deuterostomic gastrulation.\" [ISBN:0878932437]","metadata":null},{"id":"1bb9158b84ed4433b46b846340ff66ae","type":"GO_TERM","name":"epiboly involved in wound healing","canonical_id":"go:GO:0090505","description":"\"The expansion of one cell sheet over other cells involved in wound healing.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0b4d7bd1f59a49329a874df564aa27b5","type":"GO_TERM","name":"epicardial cell to mesenchymal cell transition","canonical_id":"go:GO:0003347","description":"\"A transition where an epicardial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. The epicardium is a part of the pericardium.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"df954eb490db4a478f3ae2ed70e5a85a","type":"GO_TERM","name":"epicardium morphogenesis","canonical_id":"go:GO:1905223","description":"\"The developmental process by which an epicardium is generated and organized.\" [GO_REF:0000083, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"baf5ace5a48b44bf8b654f55d3974c90","type":"GO_TERM","name":"epicardium-derived cardiac endothelial cell differentiation","canonical_id":"go:GO:0003349","description":"\"The process in which an epicardial cell acquires the specialized structural and/or functional features of a cardiac endothelial cell.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"34a2b43d3b7045f392306c54a0396c8c","type":"GO_TERM","name":"epicardium-derived cardiac fibroblast cell development","canonical_id":"go:GO:0060939","description":"\"The process whose specific outcome is the progression of an epicardial-derived cardiac fibroblast over time, from its formation to the mature state. A epicardial-derived cardiac fibroblast is a connective tissue cell of the heart that arises from the epicardium and secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"34ed53749b9647df9b5b09815ee7d997","type":"GO_TERM","name":"epicardium-derived cardiac fibroblast cell differentiation","canonical_id":"go:GO:0060938","description":"\"The process in which an epicardial cell acquires the specialized structural and/or functional features of a cardiac fibroblast. A cardiac fibroblast is a connective tissue cell in the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"af943d30dce241a3b11051cbfbdfc0e3","type":"GO_TERM","name":"epicardium-derived cardiac fibroblast cell fate commitment","canonical_id":"go:GO:0060941","description":"\"The commitment of an epicardial cell to a cardiac fibroblast cell fate and its capacity to differentiate into a cardiac fibroblast. A cardiac fibroblast is a connective tissue cell in the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"3120bbe2381f408ba159c61e12700824","type":"GO_TERM","name":"epicardium-derived cardiac vascular smooth muscle cell development","canonical_id":"go:GO:0060984","description":"\"The process whose specific outcome is the progression of a cardiac vascular smooth muscle cell that was derived from the epicardium over time, from its formation to the mature state.\" [GOC:mtg_heart]","metadata":null},{"id":"0920a31ba67344ba9b4e3e14a577a636","type":"GO_TERM","name":"epicardium-derived cardiac vascular smooth muscle cell differentiation","canonical_id":"go:GO:0060983","description":"\"The process in which a relatively unspecialized cell derived from the epicardium acquires specialized features of a cardiac vascular smooth muscle cell. A cardiac vascular smooth muscle cell covers the heart vasculature and lacks transverse striations in its constituent fibers.\" [GOC:mtg_heart]","metadata":null},{"id":"1a247627558b4bc0bcdd047ce1c12a13","type":"GO_TERM","name":"epicardium-derived cardiac vascular smooth muscle cell fate commitment","canonical_id":"go:GO:0060985","description":"\"The commitment of an epicardial cell to a cardiac vascular smooth muscle cell fate and its capacity to differentiate into a cardiac vascular smooth muscle cell.\" [GOC:mtg_heart]","metadata":null},{"id":"8723f3f2ccfc43e3827d9b124288f4d7","type":"GO_TERM","name":"epicardium-derived cell migration to the myocardium","canonical_id":"go:GO:0003346","description":"\"The orderly movement of a cell that have undergone an epithelial to mesenchymal transition from the epicardium into the myocardium.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"2797783af5f24cecb8f83f8dcc5747fd","type":"GO_TERM","name":"epicuticle of collagen and cuticulin-based cuticle extracellular matrix","canonical_id":"go:GO:0060105","description":"\"A lipid-containing layer of cuticle that lies between the cortical layer and the surface coat. An example of this component is found in Caenorhabditis elegans.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"cc3052d43bda47029009c95d90a8534b","type":"GO_TERM","name":"epidermal cell differentiation","canonical_id":"go:GO:0009913","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an epidermal cell, any of the cells making up the epidermis.\" [GOC:curators, GOC:dph, GOC:mtg_sensu, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"46fb73da3ceb4c3986769d2ae65bf841","type":"GO_TERM","name":"epidermal cell division","canonical_id":"go:GO:0010481","description":"\"Any process resulting in the physical partitioning and separation of an epidermal cell, any of the cells making up the epidermis, into daughter cells.\" [PMID:17450124]","metadata":null},{"id":"32fa3e945a20459790a68916651407c5","type":"GO_TERM","name":"epidermal cell fate specification","canonical_id":"go:GO:0009957","description":"\"The process in which a cell becomes capable of differentiating autonomously into an epidermal cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:mtg_sensu, GOC:sm]","metadata":null},{"id":"f91f048a688a419fb40be280f69a5a88","type":"GO_TERM","name":"epidermal growth factor binding","canonical_id":"go:GO:0048408","description":"\"Binding to epidermal growth factor.\" [GOC:dgh]","metadata":null},{"id":"776bf1b5ea714352a27f110cb80b2dde","type":"GO_TERM","name":"epidermal growth factor catabolic process","canonical_id":"go:GO:0007174","description":"\"The chemical reactions and pathways resulting in the breakdown of epidermal growth factor (EGF), following internalization of the receptor-bound ligand into the signal-receiving cell. Full breakdown of epidermal growth factor results in a ligand that is unable to bind and activate its receptor.\" [GOC:bf, GOC:signaling, PMID:2985587]","metadata":null},{"id":"2bf9bbc1aa3241f49f0876f02780fb0b","type":"GO_TERM","name":"epidermal growth factor receptor activity","canonical_id":"go:GO:0005006","description":"\"Combining with an epidermal growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:bf]","metadata":null},{"id":"a964e4832ac845d7af8e0d2e3066783c","type":"GO_TERM","name":"epidermal growth factor receptor binding","canonical_id":"go:GO:0005154","description":"\"Binding to an epidermal growth factor receptor.\" [GOC:ai]","metadata":null},{"id":"0bd8546b11b94812a5d1204b5ea95351","type":"GO_TERM","name":"epidermal growth factor receptor ligand maturation","canonical_id":"go:GO:0038004","description":"\"Any process leading to the attainment of the full functional capacity of a ligand for an epidermal growth factor receptor. The ligand is functional when it can bind to and activate an epidermal growth factor receptor.\" [GOC:signaling, PMID:11672524, PMID:11672525]","metadata":null},{"id":"04c2032348df46e680c66747947f2603","type":"GO_TERM","name":"epidermal growth factor receptor signaling pathway","canonical_id":"go:GO:0007173","description":"\"The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb]","metadata":null},{"id":"30331bfe83e242fb8765f742aff9b918","type":"GO_TERM","name":"epidermal lamellar body","canonical_id":"go:GO:0097209","description":"\"A specialized secretory organelle found in keratinocytes and involved in the formation of an impermeable, lipid-containing membrane that serves as a water barrier and is required for correct skin barrier function.\" [GOC:cjm, Wikipedia:Lamellar_granule]","metadata":null},{"id":"b3d16f77b6e3414ca3d21142c87acc56","type":"GO_TERM","name":"epidermal lamellar body membrane","canonical_id":"go:GO:0097234","description":"\"The lipid bilayer surrounding an epidermal lamellar body, a specialized secretory organelle found in keratinocytes and involved in the formation of an impermeable, lipid-containing membrane that serves as a water barrier and is required for correct skin barrier function.\" [GOC:sl, PMID:11940594]","metadata":null},{"id":"dc1bb840a2694b11be73753ba4558a9b","type":"GO_TERM","name":"epidermal stem cell homeostasis","canonical_id":"go:GO:0036334","description":"\"Any biological process involved in the maintenance of the steady-state number of epidermal stem cells within a population of cells.\" [CL:1000428, GOC:nhn, PMID:17666529]","metadata":null},{"id":"4f738c9b9dce49e58643a17bfc1fca78","type":"GO_TERM","name":"epidermis development","canonical_id":"go:GO:0008544","description":"\"The process whose specific outcome is the progression of the epidermis over time, from its formation to the mature structure. The epidermis is the outer epithelial layer of an animal, it may be a single layer that produces an extracellular material (e.g. the cuticle of arthropods) or a complex stratified squamous epithelium, as in the case of many vertebrate species.\" [GOC:curators, UBERON:0001003]","metadata":null},{"id":"34b47b0cadb14cfe8ebe18cb3c252f77","type":"GO_TERM","name":"epidermis morphogenesis","canonical_id":"go:GO:0048730","description":"\"The process in which the anatomical structures of the epidermis are generated and organized. The epidermis is the outer epithelial layer of an animal, it may be a single layer that produces an extracellular material (e.g. the cuticle of arthropods) or a complex stratified squamous epithelium, as in the case of many vertebrate species.\" [GOC:jid, UBERON:0001003]","metadata":null},{"id":"f6e1f7d01dbe44e69c00a70b30871bd6","type":"DISEASE","name":"epidermolytic palmoplantar keratoderma, 1","canonical_id":"mondo:0007758","description":null,"metadata":null},{"id":"db58e0fbf52f4ca29df08cd9f97ccc1f","type":"GO_TERM","name":"epididymis development","canonical_id":"go:GO:1905867","description":"\"The process whose specific outcome is the progression of an epididymis over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, PMID:12388089]","metadata":null},{"id":"df6e8dfe65f144c7b1a3fa79ec12c72e","type":"GO_TERM","name":"epididymosome","canonical_id":"go:GO:0098875","description":"\"A microvesicle of the epididymal fluid, from which spermatozoa acquire membrane proteins.\" [GOC:dos, GOC:mg, PMID:23177142, PMID:26112475]","metadata":null},{"id":"7f71335e367f494587bb3747b23d75f6","type":"GO_TERM","name":"epigallocatechin 3-gallate binding","canonical_id":"go:GO:0097247","description":"\"Binding to epigallocatechin 3-gallate, a compound that is a gallic acid ester of a catechin.\" [GOC:sl, PMID:21307292]","metadata":null},{"id":"3737afdbda864b4f9a4c3571afc09a32","type":"GO_TERM","name":"epigenetic programing of female pronucleus","canonical_id":"go:GO:0044726","description":"\"The global programming of epigenetic modifications in the female pronucleus of the newly fertilized zygote. The maternal genome is protected from global DNA demethylation before the first division of the zygote, and instead undergoes passive, replication-dependent demethylation during early embryogenesis, arising from inhibition of the DNA maintenance methyltransferase Dnmt1.\" [GOC:sp, PMID:22868271]","metadata":null},{"id":"b82b68a035494a4b9c6057ab823e4fc4","type":"GO_TERM","name":"epigenetic programing of male pronucleus","canonical_id":"go:GO:0044727","description":"\"The global programming of epigenetic modifications in the male pronucleus of the newly fertilized zygote. The most major change in the paternal genome is DNA demethylation, which takes place before the first cell division.\" [GOC:sp, PMID:22868271]","metadata":null},{"id":"5d10c49fafa34749b36e958240dcfaf1","type":"GO_TERM","name":"epigenetic programming in the central cell","canonical_id":"go:GO:0141063","description":"\"The establishment of epigenetic modifications (imprints) in a plant central cell, leading to an asymmetry between the two maternal alleles and the paternal allele, and differential expression of the corresponding alleles in the developing endosperm. This can happen through heterochromatin formation or differential chromatin loop formation.\" [PMID:28118754]","metadata":null},{"id":"7058d0f2003a4e42a29df4032c9622eb","type":"GO_TERM","name":"epigenetic programming in the endosperm","canonical_id":"go:GO:0141044","description":"\"The global programming of epigenetic modifications following binucleate central cell fertilization. This involves DNA methylation at the silent allele. In the endosperm, maternal genomes are hypomethylated compared with the paternal genome.\" [PMID:10580004, PMID:16469697, PMID:16527743, PMID:18700816, PMID:28118754]","metadata":null},{"id":"5e56dbd697bb4c2d823f5f55d0cd9b2c","type":"GO_TERM","name":"epigenetic programming in the zygotic pronuclei","canonical_id":"go:GO:0044725","description":"\"The global programming of epigenetic modifications in the zygote following fertilization. The paternal genome undergoes active DNA demethylation before the first cell division, while the adjacent maternal genome is protected from this process.\" [GOC:sp, PMID:22868271]","metadata":null},{"id":"94a0e95830ed4bc8b5a2f78e3f2c100f","type":"GO_TERM","name":"epigenetic programming of gene expression","canonical_id":"go:GO:0043045","description":"\"A epigenetic process that happens during embryonic development that modulates gene expression potential at later stages of development of the organism, including the adult. Epigenetic regulation takes place via chromatin remodeling either by modifying higher order chromatin fiber structure, nucleosomal histones, or cytosine DNA methylation.\" [GOC:curators, PMID:12138111, PMID:22868271]","metadata":null},{"id":"7ca76abed13a4e0aa59585d5eafe0c49","type":"GO_TERM","name":"epigenetic regulation of gene expression","canonical_id":"go:GO:0040029","description":"\"A process that modulates the frequency, rate or extent of gene expression through chromatin remodeling either by modifying higher order chromatin fiber structure, nucleosomal histones, or cytosine methylation of DNA. Once established, this regulation may be maintained over many cell divisions. It can also be heritable in the absence of the instigating signal.\" [PMID:10521337, PMID:11498582, PMID:22243696, PMID:34414474]","metadata":null},{"id":"8cce0bc159b8420089d3be3cee2189bc","type":"DISEASE","name":"epilepsy","canonical_id":"mondo:0005027","description":null,"metadata":null},{"id":"4949c0b7edc745b5a36904ec387bc28b","type":"DISEASE","name":"epilepsy with myoclonic atonic seizures","canonical_id":"mondo:0014633","description":null,"metadata":null},{"id":"4e70d3584d284b1eaade74c37eb8c65f","type":"DISEASE","name":"epilepsy, X-linked 2, with or without impaired intellectual development and dysmorphic features","canonical_id":"mondo:0859564","description":null,"metadata":null},{"id":"5b8235e4d9404c1e8531670b0f883e7b","type":"DRUG","name":"epinastine","canonical_id":"gtopdb:7176","description":null,"metadata":null},{"id":"68419db98ace41cbac291b85151b269e","type":"DRUG","name":"epinephrine","canonical_id":"mesh:D004837","description":null,"metadata":null},{"id":"2c9f53f5bbe14a679a904eb6adf7d46e","type":"GO_TERM","name":"epinephrine binding","canonical_id":"go:GO:0051379","description":"\"Binding to epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine.\" [GOC:ai]","metadata":null},{"id":"29e62e1832e44db08b21dda32a9a36a2","type":"GO_TERM","name":"epinephrine biosynthetic process","canonical_id":"go:GO:0042418","description":"\"The chemical reactions and pathways resulting in the formation of epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine.\" [GOC:jl, ISBN:0192801023, ISBN:0198506732]","metadata":null},{"id":"d5a4692c58a54425b0257e6c0caee34f","type":"GO_TERM","name":"epinephrine catabolic process","canonical_id":"go:GO:0042419","description":"\"The chemical reactions and pathways resulting in the breakdown of epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine.\" [GOC:jl, ISBN:0192801023, ISBN:0198506732]","metadata":null},{"id":"5de8bff9391540e38d76fad1c0453c1e","type":"GO_TERM","name":"epinephrine metabolic process","canonical_id":"go:GO:0042414","description":"\"The chemical reactions and pathways involving epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine.\" [GOC:jl, ISBN:0192801023, ISBN:0198506732]","metadata":null},{"id":"954357bc67e540f783f6208a762a716f","type":"GO_TERM","name":"epinephrine secretion","canonical_id":"go:GO:0048242","description":"\"The regulated release of epinephrine by a cell. Epinephrine is a catecholamine hormone secreted by the adrenal medulla and a neurotransmitter, released by certain neurons and active in the central nervous system.\" [GOC:ef, GOC:jid]","metadata":null},{"id":"51a5c71320ca46a5bb8d5056806a7bda","type":"GO_TERM","name":"epinephrine secretion, neurotransmission","canonical_id":"go:GO:0061529","description":"\"The regulated release of epinephrine by a cell in which the epinephrine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"161c08cd9ee944f9b9bbf7bd1bf38662","type":"GO_TERM","name":"epinephrine uptake","canonical_id":"go:GO:0051625","description":"\"The directed movement of epinephrine into a cell, typically presynaptic neurons or glial cells. Epinephrine is a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine.\" [GOC:ai]","metadata":null},{"id":"c9291be1ed434ff9bb0625b22792c4b8","type":"GO_TERM","name":"epinephrine-mediated vasodilation","canonical_id":"go:GO:0003121","description":"\"A vasodilation process resulting from secretion of epinephrine into the bloodstream or released by nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"28fabec612c44cc28c4f0c6ec46ca739","type":"GO_TERM","name":"epiplastidial membrane","canonical_id":"go:GO:7770040","description":"\"The outermost lipid bilayer surrounding complex plastids in organisms that acquired their plastids through secondary endosymbiosis. This membrane is derived from the host cell's endomembrane system and is continuous with the rough endoplasmic reticulum and the outer nuclear envelope. In some species, the cytoplasmic face may be studded with ribosomes.\" [PMID:15937721, PMID:27179349, PMID:39383259]","metadata":null},{"id":"bd577a80376940ed9f61ec337ce084dd","type":"DRUG","name":"epirubicin","canonical_id":"mesh:D015251","description":null,"metadata":null},{"id":"95cc91d5b56643cdacbca4c919145216","type":"DISEASE","name":"episodic ataxia, type 9","canonical_id":"mondo:0030064","description":null,"metadata":null},{"id":"06dac364c04949b7be5401dc708f3a3a","type":"GO_TERM","name":"epistomal sclerite development","canonical_id":"go:GO:0048724","description":"\"The process whose specific outcome is the progression of the epistomal sclerite over time, from its formation to the mature structure.\" [GOC:rc]","metadata":null},{"id":"f262310218924b3aa5b1ed406eb54bf4","type":"GO_TERM","name":"epistomal sclerite morphogenesis","canonical_id":"go:GO:0048719","description":"\"The process in which the anatomical structures of the epistomal sclerite are generated and organized.\" [GOC:rc]","metadata":null},{"id":"459a7f8fc6814a6c9fe7fbd9034f31c6","type":"GO_TERM","name":"epithalamus development","canonical_id":"go:GO:0021538","description":"\"The progression of the epithalamus over time from its initial formation until its mature state. The epithalamus is the small dorsomedial area of the thalamus including the habenular nuclei and associated fiber bundles, the pineal body, and the epithelial roof of the third ventricle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"c1e80d5a820244f2b54e55b3f6cdb829","type":"GO_TERM","name":"epithelial cell apoptotic process","canonical_id":"go:GO:1904019","description":"\"Any apoptotic process in an epithelial cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:19137015]","metadata":null},{"id":"721db343ba8443eb9360c4cd731a2b45","type":"GO_TERM","name":"epithelial cell apoptotic process involved in palatal shelf morphogenesis","canonical_id":"go:GO:1990134","description":"\"An apoptotic process in a palatal shelf epithelial cell that contributes to the shaping of the palatal shelf.\" [GOC:dph, GOC:mtg_apoptosis, PMID:16607638]","metadata":null},{"id":"86b71c32f1a545eabd9ce213d200dc85","type":"GO_TERM","name":"epithelial cell development","canonical_id":"go:GO:0002064","description":"\"The process whose specific outcome is the progression of an epithelial cell over time, from its formation to the mature structure. An epithelial cell is a cell usually found in a two-dimensional sheet with a free surface.\" [GOC:dph]","metadata":null},{"id":"d2a9448aeb8343c1a4b573265efbf432","type":"GO_TERM","name":"epithelial cell differentiation","canonical_id":"go:GO:0030855","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell, any of the cells making up an epithelium.\" [GOC:ecd, PMID:11839751]","metadata":null},{"id":"b841786ddfcc4e43a265d9c596be7d7f","type":"GO_TERM","name":"epithelial cell differentiation involved in embryonic placenta development","canonical_id":"go:GO:0060671","description":"\"The process in which a trophoblast cell acquires specialized features of an epithelial cell of the placental labyrinthine layer.\" [GOC:dph, PMID:16916377]","metadata":null},{"id":"fe8d0e75a43c46bea6dd80d1d153e87f","type":"GO_TERM","name":"epithelial cell differentiation involved in kidney development","canonical_id":"go:GO:0035850","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an epithelial cell that characterize the cells of the kidney as it progresses from its formation to the mature state.\" [GOC:bf, GOC:mtg_kidney_jan10, GOC:yaf, PMID:16216236]","metadata":null},{"id":"d267de4b6e9b41ef8fccf3448ff5ea8c","type":"GO_TERM","name":"epithelial cell differentiation involved in mammary gland alveolus development","canonical_id":"go:GO:0061030","description":"\"The process in which a relatively unspecialized epithelial cell becomes a more specialized epithelial cell of the mammary gland alveolus.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"c6b0a8aa86f84fbba96a5c1bf05636e6","type":"GO_TERM","name":"epithelial cell differentiation involved in prostate gland development","canonical_id":"go:GO:0060742","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell of the prostate gland.\" [GOC:dph]","metadata":null},{"id":"3411a43e66bc444e8c794be3b14adf56","type":"GO_TERM","name":"epithelial cell differentiation involved in salivary gland development","canonical_id":"go:GO:0060690","description":"\"The process in which a relatively unspecialized cell acquire specialized structural and/or functional features of an epithelial cell of the salivary gland.\" [GOC:dph]","metadata":null},{"id":"09b005223a424b0abb83c51e8edb7fad","type":"GO_TERM","name":"epithelial cell fate commitment","canonical_id":"go:GO:0072148","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an epithelial cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3e2fb610d765491791abc460d3948c6e","type":"GO_TERM","name":"epithelial cell fate determination, open tracheal system","canonical_id":"go:GO:0007425","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into an epithelial cell within an open tracheal system regardless of its environment; upon determination, the cell fate cannot be reversed. Tracheal cells are set aside as 10 clusters of approximately 80 cells on each side of the embryo (termed tracheal placodes). An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11063940]","metadata":null},{"id":"860b0bfd49ce46b588350add3d842d90","type":"GO_TERM","name":"epithelial cell maturation","canonical_id":"go:GO:0002070","description":"\"The developmental process, independent of morphogenetic (shape) change, that is required for an epithelial cell to attain its fully functional state. An epithelial cell is a cell usually found in a two-dimensional sheet with a free surface.\" [GOC:dph]","metadata":null},{"id":"ec2ddf139ecb4e86983fff4dac954da0","type":"GO_TERM","name":"epithelial cell maturation involved in prostate gland development","canonical_id":"go:GO:0060743","description":"\"The developmental process, independent of morphogenetic (shape) change, that is required for an epithelial cell of the prostate gland to attain its fully functional state. An epithelial cell is a cell usually found in a two-dimensional sheet with a free surface.\" [GOC:dph]","metadata":null},{"id":"164663c7979a4c6c82b71611f93fd7e6","type":"GO_TERM","name":"epithelial cell maturation involved in salivary gland development","canonical_id":"go:GO:0060691","description":"\"The developmental process, independent of morphogenetic (shape) change, that is required for an epithelial cell of the salivary gland to attain its fully functional state.\" [GOC:dph]","metadata":null},{"id":"e14c890ae2c04580b17df723e1892582","type":"GO_TERM","name":"epithelial cell migration","canonical_id":"go:GO:0010631","description":"\"The orderly movement of an epithelial cell from one site to another, often during the development of a multicellular organism.\" [GOC:ascb_2009, GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"33256ac3facb4ff98de2e28a0eb89226","type":"GO_TERM","name":"epithelial cell migration, open tracheal system","canonical_id":"go:GO:0007427","description":"\"The orderly movement of epithelial cells during development of an open tracheal system. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"8fd6aff371df494fb760eccac609ade2","type":"GO_TERM","name":"epithelial cell morphogenesis","canonical_id":"go:GO:0003382","description":"\"The change in form that occurs when an epithelial cell progresses from its initial formation to its mature state.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b7271e3522144e39b2a1a3d0b37f6e02","type":"GO_TERM","name":"epithelial cell morphogenesis involved in gastrulation","canonical_id":"go:GO:0003381","description":"\"The change in form that occurs when an epithelial cell progresses from it initial formation to its mature state, contributing to the process of gastrulation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"8eb3f10f0e944d2995bedb7b6865bdab","type":"GO_TERM","name":"epithelial cell morphogenesis involved in placental branching","canonical_id":"go:GO:0060672","description":"\"The change in form (cell shape and size) that occurs when a trophoblast cell elongates to contribute to the branching of the placenta.\" [GOC:ascb_2009, GOC:dph, GOC:tb, PMID:16916377]","metadata":null},{"id":"1589dff8f4004e0d90ec4563099227c2","type":"GO_TERM","name":"epithelial cell proliferation","canonical_id":"go:GO:0050673","description":"\"The multiplication or reproduction of epithelial cells, resulting in the expansion of a cell population. Epithelial cells make up the epithelium, the covering of internal and external surfaces of the body, including the lining of vessels and other small cavities. It consists of cells joined by small amounts of cementing substances.\" [ISBN:0721662544]","metadata":null},{"id":"f617dc6380c14513a799ee8ff2d91921","type":"GO_TERM","name":"epithelial cell proliferation involved in Malpighian tubule morphogenesis","canonical_id":"go:GO:0061331","description":"\"The multiplication or reproduction of epithelial cells, resulting in the expansion of a cell population and contributing to the shaping of a Malpighian tubule.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"f2128436a8e646bdbde9de2cc78887fc","type":"GO_TERM","name":"epithelial cell proliferation involved in lung morphogenesis","canonical_id":"go:GO:0060502","description":"\"The multiplication or reproduction of epithelial cells, resulting in the expansion of a cell population that contributes to the shaping of the lung.\" [GOC:dph]","metadata":null},{"id":"c7b17ae6d9e6487a9ccf7f129010ef63","type":"GO_TERM","name":"epithelial cell proliferation involved in mammary gland duct elongation","canonical_id":"go:GO:0060750","description":"\"The multiplication or reproduction of mammary gland branch epithelial cells, resulting in the elongation of the branch. The mammary gland branch differs from the bud in that it is not the initial curved portion of the outgrowth.\" [GOC:dph]","metadata":null},{"id":"1f7a68d2a40f48a7bae32223167fd855","type":"GO_TERM","name":"epithelial cell proliferation involved in prostate gland development","canonical_id":"go:GO:0060767","description":"\"The multiplication or reproduction of epithelial cells, resulting in the expansion of a cell population that contributes to the progression of the prostate gland over time.\" [GOC:dph]","metadata":null},{"id":"874ffc6824344128a5291fadba886bc5","type":"GO_TERM","name":"epithelial cell proliferation involved in prostatic bud elongation","canonical_id":"go:GO:0060517","description":"\"The multiplication of epithelial cells, contributing to the expansion of the primary prostatic bud.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"c66fc899e852455caa5485bb4541d727","type":"GO_TERM","name":"epithelial cell proliferation involved in renal tubule morphogenesis","canonical_id":"go:GO:2001013","description":"\"Any epithelial cell proliferation that is involved in renal tubule morphogenesis.\" [GOC:obol]","metadata":null},{"id":"6d9d7191fbc04d0cb7766882b8913c2b","type":"GO_TERM","name":"epithelial cell proliferation involved in salivary gland morphogenesis","canonical_id":"go:GO:0060664","description":"\"The multiplication or reproduction of epithelial cells of the submandibular salivary gland, resulting in the expansion of a cell population and the shaping of the gland.\" [GOC:dph, PMID:17336109]","metadata":null},{"id":"a605a3c30fe2439a9f095669292d87fc","type":"GO_TERM","name":"epithelial cell type specification, open tracheal system","canonical_id":"go:GO:0035153","description":"\"Allocation of epithelial cells within each migrating branch in an open tracheal system to distinct tracheal cell fates. During the migration phase each branch forms a well-defined number of cell types (including fusion cells, terminal cells and branch cells) at precise positions.\" [GOC:mtg_sensu, PMID:10684581, PMID:11063940]","metadata":null},{"id":"6e4fb44e8b61426d9fff59686e6cfc96","type":"GO_TERM","name":"epithelial cell-cell adhesion","canonical_id":"go:GO:0090136","description":"\"The attachment of an epithelial cell to another epithelial cell via adhesion molecules.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"37e13c1e458a4c3fbda6b5f4047cbfb9","type":"GO_TERM","name":"epithelial cilium movement involved in determination of left/right asymmetry","canonical_id":"go:GO:0060287","description":"\"The movement of cilia of epithelial cells of the Left Right Organizer (LRO), also referred to as the node in mouse or the Kupffer's vesicle in zebrafish, resulting in the leftward fluid flow across the LRO and generation or transport of a signal which determines asymmetry in an organism's body plan with respect to the left and right halves.\" [GOC:dgh, GOC:dph, GOC:krc, GOC:mlg, PMID:28559696, PMID:29367579]","metadata":null},{"id":"5be5adba33e64660b6f27f755685d480","type":"GO_TERM","name":"epithelial cilium movement involved in extracellular fluid movement","canonical_id":"go:GO:0003351","description":"\"The directed, self-propelled movement of cilia of epithelial cells. Depending on the type of cell, there may be one or many cilia per cell. This movement is usually coordinated between many epithelial cells, and serves to move extracellular fluid.\" [GOC:dph, GOC:krc]","metadata":null},{"id":"9ca48825afcc45b2aef8f42179548c6b","type":"GO_TERM","name":"epithelial fluid transport","canonical_id":"go:GO:0042045","description":"\"The directed movement of fluid across epithelia.\" [GOC:jl, PMID:11390830]","metadata":null},{"id":"e49143837b624e0790fc03df839438d3","type":"GO_TERM","name":"epithelial structure maintenance","canonical_id":"go:GO:0010669","description":"\"A tissue homeostatic process required for the maintenance of epithelial structure.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"461f5c3a2c3a4ea0a92a4aedccd440df","type":"GO_TERM","name":"epithelial to mesenchymal transition","canonical_id":"go:GO:0001837","description":"\"A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:dph, PMID:14701881]","metadata":null},{"id":"ece327bb3f5549eeb6ade4a10b720d30","type":"GO_TERM","name":"epithelial to mesenchymal transition involved in cardiac fibroblast development","canonical_id":"go:GO:0060940","description":"\"A transition where an epicardial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell that will mature into a cardiac fibroblast.\" [GOC:mtg_heart]","metadata":null},{"id":"a9d652ac81e74318abd6d023ea151bdf","type":"GO_TERM","name":"epithelial to mesenchymal transition involved in coronary vasculature morphogenesis","canonical_id":"go:GO:0003201","description":"\"A transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell that will contribute to the shaping of the coronary vasculature.\" [GOC:mtg_heart]","metadata":null},{"id":"e21fb6467da145eea712cbebbdbc3c0f","type":"GO_TERM","name":"epithelial to mesenchymal transition involved in endocardial cushion formation","canonical_id":"go:GO:0003198","description":"\"A transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell that will contribute to the formation of the endocardial cushion.\" [GOC:mtg_heart]","metadata":null},{"id":"59356c2218284d04965b7f0e8ed10891","type":"GO_TERM","name":"epithelial tube branching involved in lung morphogenesis","canonical_id":"go:GO:0060441","description":"\"The process in which a highly ordered sequence of patterning events generates the branched epithelial tubes of the lung, consisting of reiterated combinations of bud outgrowth, elongation, and dichotomous subdivision of terminal units.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"1e1832a8de2a48e9872e89ac235f0126","type":"GO_TERM","name":"epithelial tube formation","canonical_id":"go:GO:0072175","description":"\"The developmental process pertaining to the initial formation of an epithelial tube.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"77b7321c4d904930adf08a26e2ef0c62","type":"GO_TERM","name":"epithelial tube morphogenesis","canonical_id":"go:GO:0060562","description":"\"The process in which the anatomical structures of a tube are generated and organized from an epithelium. Epithelial tubes transport gases, liquids and cells from one site to another and form the basic structure of many organs and tissues, with tube shape and organization varying from the single-celled excretory organ in Caenorhabditis elegans to the branching trees of the mammalian kidney and insect tracheal system.\" [GOC:dph]","metadata":null},{"id":"572c099ab4324e5a8aa459b6169930e7","type":"GO_TERM","name":"epithelial-mesenchymal cell signaling","canonical_id":"go:GO:0060684","description":"\"Any process that results in the transfer of information from an epithelial cell to a mesenchymal cell where it is interpreted.\" [GOC:dph]","metadata":null},{"id":"b69f3561f49042abab9ca30749da4c32","type":"GO_TERM","name":"epithelial-mesenchymal signaling involved in prostate gland development","canonical_id":"go:GO:0060738","description":"\"Any process that results in the transfer of information from an epithelial cell to a mesenchymal cell where it is interpreted and contributes to the progression of the prostate gland over time.\" [GOC:dph]","metadata":null},{"id":"259f273e569840569b028e9676e1e23d","type":"GO_TERM","name":"epithelium development","canonical_id":"go:GO:0060429","description":"\"The process whose specific outcome is the progression of an epithelium over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"1f0d940946e34bd8a9de85fdceb88e47","type":"GO_TERM","name":"epithelium migration","canonical_id":"go:GO:0090132","description":"\"The process in which the population of cells that make up an epithelium undergo directed movement.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"a2fcff759bea4f168b18b0ac32ff953c","type":"GO_TERM","name":"epithelium regeneration","canonical_id":"go:GO:1990399","description":"\"The regrowth of lost or destroyed epithelium.\" [GOC:sl, PMID:19845688]","metadata":null},{"id":"aeea65934af44e29bf5e31ecd29bbea7","type":"GO_TERM","name":"epithelium-like organization","canonical_id":"go:GO:0140509","description":"\"The organization of a polarized cell layer during morphogenesis in protozoa; an example is found during culmination in D. discoideum, involving alpha and beta catenins.\" [PMID:21393547, PMID:22902739]","metadata":null},{"id":"3122e2ad1394425a8be73695dfff4ab1","type":"DRUG","name":"eplerenone","canonical_id":"gtopdb:2876","description":null,"metadata":null},{"id":"e724cd56da534841b2eaa62f6658fe65","type":"DRUG","name":"eplerenone","canonical_id":"chembl:CHEMBL1095097","description":null,"metadata":null},{"id":"ae963ddcbd934d53ac219ef60fbc2a8d","type":"DRUG","name":"epoetin theta","canonical_id":"mesh:C555712","description":null,"metadata":null},{"id":"b75ed30f19ec478db318a869820904a2","type":"DRUG","name":"epoprostenol","canonical_id":"mesh:D011464","description":null,"metadata":null},{"id":"ef85cb7410524416881610d27ff18902","type":"GO_TERM","name":"epothilone biosynthetic process","canonical_id":"go:GO:0050814","description":"\"The chemical reactions and pathways resulting in the formation of epothilone, a drug obtained from the myxobacteria Sporangium cellulosum that interferes with cell division. Some epothilones are being studied as treatments for cancer.\" [GOC:ai]","metadata":null},{"id":"bb85fab900ee4e57b4d184b21f4ab712","type":"GO_TERM","name":"epoxide hydrolase activity","canonical_id":"go:GO:0004301","description":"\"Catalysis of the reaction: an epoxide + H2O = an ethanediol.\" [EC:3.3.2.10]","metadata":null},{"id":"c277cafa3ac54be8bc5cee4d17f7c810","type":"GO_TERM","name":"epoxide metabolic process","canonical_id":"go:GO:0097176","description":"\"The chemical reactions and pathways involving epoxides, compounds in which an oxygen atom is directly attached to two adjacent or non-adjacent carbon atoms of a carbon chain or ring system; thus cyclic ethers.\" [GOC:rs, PMID:15822179]","metadata":null},{"id":"26ce688983674b72a352b3ccfec9e7cd","type":"GO_TERM","name":"epoxygenase P450 pathway","canonical_id":"go:GO:0019373","description":"\"The chemical reactions and pathways by which arachidonic acid is converted to other compounds including epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids.\" [GOC:mah, PMID:17979511]","metadata":null},{"id":"1759201b3b7a4c31bfbebf042dcb161e","type":"GO_TERM","name":"epoxyqueuosine reductase activity","canonical_id":"go:GO:0052693","description":"\"Catalysis of the reaction: epoxyqueuosine in tRNA + reductant = queuosine in tRNA + oxidised reductant.\" [PMID:21502530, RHEA:32159]","metadata":null},{"id":"00345b6dced041ca905ff0755ee5dfe7","type":"DRUG","name":"eprosartan","canonical_id":"gtopdb:588","description":null,"metadata":null},{"id":"9907598d830f461faa3e40dbf09a0d4c","type":"COMBINATION_TREATMENT","name":"eprosartan + losartan + propranolol","canonical_id":"ctgov_combo:ctgov-combo-8e51d97bd8e6dad9","description":null,"metadata":null},{"id":"8e4d8f7e294f4601b55a778886766f97","type":"GO_TERM","name":"epsilon DNA polymerase complex","canonical_id":"go:GO:0008622","description":"\"A heterotetrameric DNA polymerase complex that catalyzes processive DNA synthesis in the absence of PCNA, but is further stimulated in the presence of PCNA. The complex contains a large catalytic subunit and three small subunits, and is best characterized in Saccharomyces, in which the subunits are named Pol2p, Dpb2p, Dpb3p, and Dpb4p. Some evidence suggests that DNA polymerase epsilon is the leading strand polymerase; it is also involved in nucleotide-excision repair and mismatch repair.\" [PMID:15814431, PMID:9745046]","metadata":null},{"id":"c5b10b94a0b14cd7915a49249d76ff93","type":"DRUG","name":"eptacog alfa (activated)","canonical_id":"mesh:C103587","description":null,"metadata":null},{"id":"156b77997fb5457bbc215792d4fc576e","type":"DRUG","name":"eptifibatide","canonical_id":"gtopdb:6585","description":null,"metadata":null},{"id":"43a789f55a7c46e0a9c4c7323e17d0ef","type":"DRUG","name":"eptifibatide","canonical_id":"chembl:CHEMBL1174","description":null,"metadata":null},{"id":"7a950afeec1f4d74b5c379aa64c1c9d1","type":"DRUG","name":"eptinezumab","canonical_id":"gtopdb:10694","description":null,"metadata":null},{"id":"7dd436a2d94f4951a1f0f0c452bdd879","type":"DRUG","name":"eptinezumab","canonical_id":"chembl:CHEMBL3833320","description":null,"metadata":null},{"id":"cac1c3076b37449a842190e0ef222db7","type":"COMBINATION_TREATMENT","name":"eptinezumab + erenumab","canonical_id":"ctgov_combo:ctgov-combo-f247b04bc7a3a5b0","description":null,"metadata":null},{"id":"dded7f0b1416487bbe4b4534419a6b8e","type":"COMBINATION_TREATMENT","name":"eptinezumab + erenumab + fremanezumab + galcanezumab","canonical_id":"ctgov_combo:ctgov-combo-9f79a7dcc0621180","description":null,"metadata":null},{"id":"2337746960d14becaf260f38603e66ce","type":"COMBINATION_TREATMENT","name":"eptinezumab + erenumab + fremanezumab + galcanezumab + rimegepant","canonical_id":"ctgov_combo:ctgov-combo-f072b22f5f299935","description":null,"metadata":null},{"id":"650ca7799a744ee0a2e17fb73fafa5a5","type":"COMBINATION_TREATMENT","name":"eptinezumab + galcanezumab + nortriptyline","canonical_id":"ctgov_combo:ctgov-combo-bbd540052e90a58e","description":null,"metadata":null},{"id":"9283ab7f1cd540f0b997fe7846144d05","type":"GO_TERM","name":"equator specification","canonical_id":"go:GO:0045317","description":"\"The formation and development of the equator that forms the boundary between the photoreceptors in the dorsal sector of the eye and those in the ventral sector, dividing the eye into dorsal and ventral halves.\" [GOC:bf]","metadata":null},{"id":"9fa03e60dbe64d68af0bb3c08e4153c9","type":"GO_TERM","name":"equatorial cell cortex","canonical_id":"go:GO:1990753","description":"\"The region of the cell cortex in a mitotically dividing cell that flanks the central spindle and corresponds to the site of actomyosin ring formation that results in cleavage furrow formation and ingression.\" [GOC:kmv, PMID:16352658, PMID:22552143, PMID:23750214, PMID:25898168]","metadata":null},{"id":"56f7a4026fd64c27820a7d940b5a9cc9","type":"GO_TERM","name":"equatorial microtubule organization","canonical_id":"go:GO:0031121","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures formed of microtubules and associated proteins at the midpoint of a cell.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"4a51acd1f5aa4aa796048434bb6990fe","type":"GO_TERM","name":"equatorial microtubule organizing center","canonical_id":"go:GO:0000923","description":"\"A microtubule organizing center formed by a band of gamma-tubulin that is recruited to a circumferential band of F-actin at the midpoint of a cell and which nucleates microtubules from the cell division site at the end of mitosis.\" [PMID:11792817]","metadata":null},{"id":"ff9e4bc70ed8476ea97165b1051526fd","type":"GO_TERM","name":"equatorial microtubule organizing center assembly","canonical_id":"go:GO:1904185","description":"\"The aggregation, arrangement and bonding together of a set of components to form an equatorial microtubule organizing center.\" [GO_REF:0000079, GOC:TermGenie, PMID:15004232]","metadata":null},{"id":"ce1bd25dfbb04f02a3742da9cb4e7f90","type":"GO_TERM","name":"equatorial microtubule organizing center disassembly","canonical_id":"go:GO:0031025","description":"\"The process in which the equatorial microtubule organizing center is disassembled at the end of mitosis.\" [GOC:mah, PMID:15068790]","metadata":null},{"id":"81e729dcd92c461ca1b79c1947b0d52e","type":"GO_TERM","name":"equilibrioception","canonical_id":"go:GO:0050957","description":"\"The series of events required for an organism to receive an orientational stimulus, convert it to a molecular signal, and recognize and characterize the signal. Equilibrioception refers to a combination of processes by which an organism can perceive its orientation with respect to gravity. In animals, stimuli come from labyrinth system of the inner ears, monitoring the direction of motion; visual stimuli, with information on orientation and motion; pressure receptors, which tell the organism which body surfaces are in contact with the ground; and proprioceptive cues, which report which parts of the body are in motion.\" [PMID:29303967]","metadata":null},{"id":"d9a0c9875bc04c21b89a1609222f4155","type":"DISEASE","name":"erectile dysfunction","canonical_id":"mondo:0005362","description":null,"metadata":null},{"id":"aa72b23c12d94ca2b168cc35ceb0b087","type":"DRUG","name":"erenumab","canonical_id":"gtopdb:9250","description":null,"metadata":null},{"id":"2b468e2fb3b14dfd91432025aa6044fd","type":"DRUG","name":"erenumab","canonical_id":"chembl:CHEMBL3833329","description":null,"metadata":null},{"id":"fe4fb5b8af2f41cf9a62c581f514944e","type":"COMBINATION_TREATMENT","name":"erenumab + fremanezumab + galcanezumab","canonical_id":"ctgov_combo:ctgov-combo-cb4d9821efb6e118","description":null,"metadata":null},{"id":"31b98534cce8462abb2170056794b979","type":"COMBINATION_TREATMENT","name":"erenumab + fremanezumab + galcanezumab","canonical_id":"ctgov_combo:ctgov-combo-85009b859366b57a","description":null,"metadata":null},{"id":"4ed401333f024a3fbe5851b961097bf7","type":"COMBINATION_TREATMENT","name":"erenumab + galcanezumab","canonical_id":"ctgov_combo:ctgov-combo-1efb25a5d9faf44f","description":null,"metadata":null},{"id":"632021a65f7d40b89d483d592231f01c","type":"COMBINATION_TREATMENT","name":"erenumab + galcanezumab","canonical_id":"ctgov_combo:ctgov-combo-581934aee0219b6d","description":null,"metadata":null},{"id":"c7c680549db14fbc876f157ab4b8f14f","type":"COMBINATION_TREATMENT","name":"erenumab + siltuximab","canonical_id":"ctgov_combo:ctgov-combo-72c504adc2bcafef","description":null,"metadata":null},{"id":"e7335827ac16457f824de76b781a2159","type":"DRUG","name":"ergometrine","canonical_id":"mesh:D004874","description":null,"metadata":null},{"id":"7dff97db6b9944e9b7abd5f1d1f0e9ae","type":"GO_TERM","name":"ergosterol O-acyltransferase activity","canonical_id":"go:GO:0034737","description":"\"Catalysis of the reaction: acyl-CoA + ergosterol = CoA + ergosterol ester.\" [GOC:mah]","metadata":null},{"id":"8134e9de94964f00af38ea110207b161","type":"GO_TERM","name":"ergosterol biosynthetic process","canonical_id":"go:GO:0006696","description":"\"The chemical reactions and pathways resulting in the formation of ergosterol, (22E)-ergosta-5,7,22-trien-3-beta-ol, a sterol found in ergot, yeast and moulds.\" [ISBN:0198506732]","metadata":null},{"id":"4844372c9428437faa3acda7102505e4","type":"GO_TERM","name":"ergosterol metabolic process","canonical_id":"go:GO:0008204","description":"\"The chemical reactions and pathways involving ergosterol, (22E)-ergosta-5,7,22-trien-3-beta-ol, a sterol found in ergot, yeast and moulds. It is the most important of the D provitamins and is converted to vitamin D2 on irradiation with UV light.\" [ISBN:0198506732]","metadata":null},{"id":"3a6d8dfe0f864afdab82cbfd578ee05a","type":"GO_TERM","name":"ergosteryl 3-beta-D-glucoside biosynthetic process","canonical_id":"go:GO:1904463","description":"\"The chemical reactions and pathways resulting in the formation of ergosteryl 3-beta-D-glucoside.\" [GO_REF:0000068, GOC:TermGenie, PMID:26116408]","metadata":null},{"id":"4c12aae2e42a48ebaee82822a96aef93","type":"GO_TERM","name":"ergosteryl 3-beta-D-glucoside catabolic process","canonical_id":"go:GO:1904462","description":"\"The chemical reactions and pathways resulting in the breakdown of ergosteryl 3-beta-D-glucoside.\" [GO_REF:0000068, GOC:TermGenie, PMID:26116408]","metadata":null},{"id":"fe4ccb5b22c74a91be0eaef7ded5a66c","type":"GO_TERM","name":"ergot alkaloid biosynthetic process","canonical_id":"go:GO:0035837","description":"\"The chemical reactions and pathways resulting in the formation of an ergot alkaloid.\" [GOC:yaf]","metadata":null},{"id":"0e5bfde27b26470aae544c9f6368f01f","type":"DRUG","name":"ergotamine","canonical_id":"gtopdb:149","description":null,"metadata":null},{"id":"eca1c49977d8444ab0463343bb1c7001","type":"DRUG","name":"ergotamine","canonical_id":"mesh:D004878","description":null,"metadata":null},{"id":"5f3147fc014f4b60a82a2fb7792d633d","type":"COMBINATION_TREATMENT","name":"ergotamine + tranylcypromine + yohimbine","canonical_id":"ctgov_combo:ctgov-combo-d762e173864784f2","description":null,"metadata":null},{"id":"0accd8461a764a8ea051e022c1d9090d","type":"GO_TERM","name":"ergothioneine biosynthetic process","canonical_id":"go:GO:0052699","description":"\"The chemical reactions and pathways resulting in the formation of ergothioneine, a naturally occurring metabolite of histidine with antioxidant properties.\" [Wikipedia:Ergothioneine]","metadata":null},{"id":"4dd89d6b1a4c463b88b52de140dbe10b","type":"GO_TERM","name":"ergothioneine catabolic process","canonical_id":"go:GO:0052700","description":"\"The chemical reactions and pathways resulting in the breakdown of ergothioneine, a naturally occurring metabolite of histidine with antioxidant properties.\" [Wikipedia:Ergothioneine]","metadata":null},{"id":"ddfe98751c0348a09547921c7caa046e","type":"GO_TERM","name":"ergothioneine transmembrane transporter activity","canonical_id":"go:GO:0170001","description":"\"Enables the transfer of ergothioneine from one side of a membrane to the other.\" [PMID:15795384, PMID:20601551, PMID:29530864]","metadata":null},{"id":"86688a1aa93f446090f497e5bcf1987d","type":"DRUG","name":"eribulin","canonical_id":"gtopdb:6813","description":null,"metadata":null},{"id":"b217e1b2a5314268bdd393e5d1ddb587","type":"DRUG","name":"eribulin","canonical_id":"mesh:C490954","description":null,"metadata":null},{"id":"cfeb3d1ab20643f3b22b16ed57980868","type":"COMBINATION_TREATMENT","name":"eribulin + fulvestrant + neratinib","canonical_id":"ctgov_combo:ctgov-combo-d112da89ba706ddf","description":null,"metadata":null},{"id":"57eb3c9d896e4691bfdb14d9982f86bf","type":"COMBINATION_TREATMENT","name":"eribulin + ixabepilone","canonical_id":"ctgov_combo:ctgov-combo-01344b53af7478b0","description":null,"metadata":null},{"id":"7e788a61ad7a432381260172e51313ff","type":"COMBINATION_TREATMENT","name":"eribulin + ixabepilone","canonical_id":"ctgov_combo:ctgov-combo-b1b5848dddea291b","description":null,"metadata":null},{"id":"80b2092d2eb34de5aedf688ce09d0405","type":"COMBINATION_TREATMENT","name":"eribulin + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-dff806ee10f56a97","description":null,"metadata":null},{"id":"19c32ddaccba4b7083fb3a278278fe14","type":"COMBINATION_TREATMENT","name":"eribulin + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-baeb920ffb5dd2fa","description":null,"metadata":null},{"id":"38d41f5c572e41b890ca44dad7a5edb9","type":"COMBINATION_TREATMENT","name":"eribulin + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-0b3f01e79fd0d431","description":null,"metadata":null},{"id":"f8f67cc32c90447f85e6ea2c07e2055f","type":"COMBINATION_TREATMENT","name":"eribulin + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-97a7ce44a862ef48","description":null,"metadata":null},{"id":"2bde34129ea54dbea574007d64f21a6d","type":"GO_TERM","name":"eriodictyol 3'-O-methyltransferase activity","canonical_id":"go:GO:0102761","description":"\"Catalysis of the reaction: (S)-eriodictyol + S-adenosyl-L-methionine = (S)-homoeriodictyol + H+ + S-adenosyl-L-homocysteine.\" [RHEA:60948]","metadata":null},{"id":"3fa51977255f4dee9ff3b880fcc91032","type":"DRUG","name":"erlotinib","canonical_id":"gtopdb:4920","description":null,"metadata":null},{"id":"8fd2fc4b467e4622a38ee5b3344b9ee7","type":"DRUG","name":"erlotinib","canonical_id":"mesh:D000069347","description":null,"metadata":null},{"id":"def81071918c4d3c84666e193acc02f0","type":"COMBINATION_TREATMENT","name":"erlotinib + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-5d9fa920b7c2d8e5","description":null,"metadata":null},{"id":"632558917385435a9705a83f926740a2","type":"COMBINATION_TREATMENT","name":"erlotinib + gefitinib","canonical_id":"ctgov_combo:ctgov-combo-d536a900052a2ed7","description":null,"metadata":null},{"id":"9930b093565d488b8e741487b1e6af3b","type":"COMBINATION_TREATMENT","name":"erlotinib + gefitinib","canonical_id":"ctgov_combo:ctgov-combo-add6d0bc3d198d02","description":null,"metadata":null},{"id":"5b57b74044304d659585ef76ebc06c58","type":"COMBINATION_TREATMENT","name":"erlotinib + gefitinib + icotinib","canonical_id":"ctgov_combo:ctgov-combo-32c4ec6d74b0106b","description":null,"metadata":null},{"id":"45e7ea7e8680442daf51ea5eb84d615e","type":"COMBINATION_TREATMENT","name":"erlotinib + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-b05b2302f537f756","description":null,"metadata":null},{"id":"dbf41f806e414bb49ff36177dbaa8ba9","type":"COMBINATION_TREATMENT","name":"erlotinib + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-8e97d8ff77379ec3","description":null,"metadata":null},{"id":"45a173287a7444cb96ee05afcd7b93ca","type":"COMBINATION_TREATMENT","name":"erlotinib + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-2aa4d51699cffedc","description":null,"metadata":null},{"id":"acc442bcc4d4473f84bc7350ae7360b5","type":"COMBINATION_TREATMENT","name":"erlotinib + icotinib","canonical_id":"ctgov_combo:ctgov-combo-98cc53cec4d5235e","description":null,"metadata":null},{"id":"b90955c7ef354f478f7a5026fa8d6cc5","type":"COMBINATION_TREATMENT","name":"erlotinib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-1bd7c36bec31dc5d","description":null,"metadata":null},{"id":"9ed58a33820448efa9593841f29f7589","type":"COMBINATION_TREATMENT","name":"erlotinib + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-94758eceeb142f51","description":null,"metadata":null},{"id":"8c612f6f7a6c45c48f647bc7f23314ad","type":"COMBINATION_TREATMENT","name":"erlotinib + tretinoin","canonical_id":"ctgov_combo:ctgov-combo-c45c68c752f03b96","description":null,"metadata":null},{"id":"97ed145f935948b38bd0326c9eb3a10c","type":"GO_TERM","name":"error-free postreplication DNA repair","canonical_id":"go:GO:0042275","description":"\"The conversion of DNA-damage induced single-stranded gaps into large molecular weight DNA via processes such as template switching, which does not remove the replication-blocking lesions but does not increase the endogenous mutation rate.\" [GOC:elh, GOC:jl, PMID:11459630]","metadata":null},{"id":"1c0eaa31d5494acfa66d7bce719184d4","type":"GO_TERM","name":"error-free translesion synthesis","canonical_id":"go:GO:0070987","description":"\"The conversion of DNA-damage induced single-stranded gaps into large molecular weight DNA after replication by using a specialized DNA polymerase or replication complex to insert a defined nucleotide across the lesion. This process does not remove the replication-blocking lesions but does not causes an increase in the endogenous mutation level. For S. cerevisiae, RAD30 encodes DNA polymerase eta, which incorporates two adenines. When incorporated across a thymine-thymine dimer, it does not increase the endogenous mutation level.\" [GOC:elh]","metadata":null},{"id":"5ab65be63eb84261b75667b4f77197ce","type":"GO_TERM","name":"error-prone translesion synthesis","canonical_id":"go:GO:0042276","description":"\"The conversion of DNA-damage induced single-stranded gaps into large molecular weight DNA after replication by using a specialized DNA polymerase or replication complex to insert a defined nucleotide across the lesion. This process does not remove the replication-blocking lesions and causes an increase in the endogenous mutation level. For example, in E. coli, a low fidelity DNA polymerase, pol V, copies lesions that block replication fork progress. This produces mutations specifically targeted to DNA template damage sites, but it can also produce mutations at undamaged sites.\" [GOC:elh, GOC:jl, PMID:11485998]","metadata":null},{"id":"20eab83fa7e84e35857fa0993e2f6669","type":"DRUG","name":"ertapenem","canonical_id":"mesh:D000077727","description":null,"metadata":null},{"id":"60619add1b774987bc13b9684b3306ee","type":"DRUG","name":"ertapenem","canonical_id":"mesh:C446479","description":null,"metadata":null},{"id":"f190cdf1712d4c998ef50e7bc497d088","type":"DRUG","name":"ertugliflozin","canonical_id":"gtopdb:8376","description":null,"metadata":null},{"id":"1761b7f7e5e64c77a8f9117b9685d726","type":"DRUG","name":"ertugliflozin","canonical_id":"chembl:CHEMBL1770248","description":null,"metadata":null},{"id":"56da487db43b4c4eaf9ecc3bfabea75c","type":"COMBINATION_TREATMENT","name":"ertugliflozin + metolazone","canonical_id":"ctgov_combo:ctgov-combo-86726e4bfc6804c6","description":null,"metadata":null},{"id":"70b04aac24e345e2880022e7f2e0abe3","type":"COMBINATION_TREATMENT","name":"ertugliflozin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-ef5d6477e9f7476d","description":null,"metadata":null},{"id":"eb57ba6c445b499aad6e48373e295e72","type":"COMBINATION_TREATMENT","name":"ertugliflozin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-f50ea354233c0db0","description":null,"metadata":null},{"id":"867552f8b3d143e0a84948061b6d5da1","type":"COMBINATION_TREATMENT","name":"ertugliflozin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-9271566d321282c8","description":null,"metadata":null},{"id":"9cfab3806b224cdcb1c1d50200718079","type":"DISEASE","name":"erythema multiforme","canonical_id":"mondo:0006545","description":null,"metadata":null},{"id":"769e216182a3464aa079f73bee190010","type":"GO_TERM","name":"erythritol kinase activity","canonical_id":"go:GO:0047878","description":"\"Catalysis of the reaction: ATP + erythritol = D-erythritol 4-phosphate + ADP + 2 H+.\" [EC:2.7.1.27, RHEA:20708]","metadata":null},{"id":"eab7a585389941208a90e54478f98175","type":"GO_TERM","name":"erythro-3-hydroxyaspartate ammonia-lyase activity","canonical_id":"go:GO:0047447","description":"\"Catalysis of the reaction: 3-hydroxy-L-aspartate = oxaloacetate + NH4+.\" [RHEA:19757]","metadata":null},{"id":"ae43a1f8c64e4121be61267829c8a81f","type":"GO_TERM","name":"erythrocyte aggregation","canonical_id":"go:GO:0034117","description":"\"The adhesion of one erythrocyte to one or more other erythrocytes via adhesion molecules.\" [GOC:add, PMID:14631543]","metadata":null},{"id":"949b87019fd84914a2d8fc8e924d7163","type":"GO_TERM","name":"erythrocyte apoptotic process","canonical_id":"go:GO:1902217","description":"\"Any apoptotic process in an erythrocyte.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"4fd8fe461ed84f498b766f38e30e4a76","type":"GO_TERM","name":"erythrocyte clearance","canonical_id":"go:GO:0034102","description":"\"The selective elimination of erythrocytes from the body by autoregulatory mechanisms.\" [GOC:add, PMID:12905029, PMID:14754397]","metadata":null},{"id":"c960220018c145b28f58eb51f659a969","type":"GO_TERM","name":"erythrocyte development","canonical_id":"go:GO:0048821","description":"\"The process whose specific outcome is the progression of an erythrocyte over time, from its formation to the mature structure.\" [GOC:devbiol]","metadata":null},{"id":"36de7a73904c4e7488541f7b33f19a9d","type":"GO_TERM","name":"erythrocyte differentiation","canonical_id":"go:GO:0030218","description":"\"The process in which a myeloid precursor cell acquires specializes features of an erythrocyte.\" [GOC:mah]","metadata":null},{"id":"440dbe97a694461b8c4a4fb9895090f7","type":"GO_TERM","name":"erythrocyte enucleation","canonical_id":"go:GO:0043131","description":"\"The process in which nucleated precursor cells lose their nucleus during erythrocyte maturation.\" [GOC:hjd]","metadata":null},{"id":"6659835bfb6342bc8c3dc6141db89a97","type":"GO_TERM","name":"erythrocyte homeostasis","canonical_id":"go:GO:0034101","description":"\"Any process of regulating the production and elimination of erythrocytes within an organism.\" [GOC:add, PMID:10694114, PMID:14754397]","metadata":null},{"id":"1524d0021f304531b65067a308286b5a","type":"GO_TERM","name":"erythrocyte maturation","canonical_id":"go:GO:0043249","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an erythrocyte to attain its fully functional state.\" [GOC:devbiol, GOC:jl]","metadata":null},{"id":"87d087baa93346c5a317fa36eebda8fc","type":"DISEASE","name":"erythroleukemia, familial, susceptibility to","canonical_id":"mondo:0007573","description":null,"metadata":null},{"id":"2576206aebe745b79ee3f357990ca406","type":"DRUG","name":"erythromycin","canonical_id":"mesh:D004917","description":null,"metadata":null},{"id":"759a78674fe242399730bebeaa2c5948","type":"GO_TERM","name":"erythromycin 3''-o-methyltransferase activity","canonical_id":"go:GO:0102307","description":"\"Catalysis of the reaction: erythromycin C + S-adenosyl-L-methionine = erythromycin A + H+ + S-adenosyl-L-homocysteine. Also converts erythromycin D into erythromycin B.\" [EC:2.1.1.254]","metadata":null},{"id":"eba2ac2dc3e942d1a70fed36989f62a5","type":"GO_TERM","name":"erythromycin biosynthetic process","canonical_id":"go:GO:1901115","description":"\"The chemical reactions and pathways resulting in the formation of erythromycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00240]","metadata":null},{"id":"7fe7ed558b76413a8531a16bfaf4bd4b","type":"GO_TERM","name":"erythromycin catabolic process","canonical_id":"go:GO:1901114","description":"\"The chemical reactions and pathways resulting in the breakdown of erythromycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00240]","metadata":null},{"id":"6e65f58a062940c58bd1a33f33e0686e","type":"DRUG","name":"erythromycin ethylsuccinate","canonical_id":"mesh:D015643","description":null,"metadata":null},{"id":"3f67d46ee33e4085bfbad89815e8feec","type":"GO_TERM","name":"erythronolide synthase activity","canonical_id":"go:GO:0047879","description":"\"Catalysis of the reaction: 6 malonyl-CoA + propionyl-CoA = 7 CoA + 6-deoxyerythronolide B.\" [EC:2.3.1.94, MetaCyc:ERYTHRONOLIDE-SYNTHASE-RXN]","metadata":null},{"id":"afe6f52f3d2d40929860dfeaf1453906","type":"GO_TERM","name":"erythrophore differentiation","canonical_id":"go:GO:0048773","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an erythrophore cell. Erythrophores are pigment cells derived from the neural crest. They contain pteridine and/or carotenoid pigments in structures called pterinosomes or erythrosomes. This gives them an orange to red appearance.\" [GOC:jid, GOC:mh]","metadata":null},{"id":"b669c198affc406aafc3191d81a9fc14","type":"GO_TERM","name":"erythropoietin receptor activity","canonical_id":"go:GO:0004900","description":"\"Combining with erythropoietin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:ai, GOC:signaling]","metadata":null},{"id":"e4bc58e7738d450cac4d58db36530ceb","type":"GO_TERM","name":"erythropoietin receptor binding","canonical_id":"go:GO:0005128","description":"\"Binding to an erythropoietin receptor.\" [GOC:ai]","metadata":null},{"id":"1423bbeb0e8949208930e63a3656929b","type":"GO_TERM","name":"erythropoietin-mediated signaling pathway","canonical_id":"go:GO:0038162","description":"\"The series of molecular signals initiated by erythropoietin (EPO) binding to the erythropoietin receptor (EPO-R) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, PMID:12489509]","metadata":null},{"id":"fb2f0d5063064aca94b96ba6f7e80a16","type":"GO_TERM","name":"erythrose 4-phosphate/phosphoenolpyruvate family amino acid biosynthetic process","canonical_id":"go:GO:1902223","description":"\"The chemical reactions and pathways resulting in the formation of an L-amino acid derived from erythrose 4-phosphate and phosphoenolpyruvate (L-phenylalanine, L-tyrosine and L-tryptophan).\" [GOC:curators]","metadata":null},{"id":"cd7afe54bc2541e4b635559743fa3de0","type":"GO_TERM","name":"erythrose-4-phosphate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0048001","description":"\"Catalysis of the reaction: D-erythrose 4-phosphate + H2O + NAD+ = 4-phospho-D-erythronate + 2 H+ + NADH.\" [EC:1.2.1.72, RHEA:12056]","metadata":null},{"id":"ac83d13d89ea4bd9ae830b23f42c6493","type":"GO_TERM","name":"erythrulose reductase activity","canonical_id":"go:GO:0047880","description":"\"Catalysis of the reaction: D-threitol + NADP+ = D-erythrulose + H+ + NADPH.\" [EC:1.1.1.162, RHEA:18005]","metadata":null},{"id":"548652c301a642ca912392993d53b3cf","type":"GO_TERM","name":"esBAF complex","canonical_id":"go:GO:0140093","description":"\"An embryonic stem cell-specific SWI/SNF-type complex that contains eight or nine proteins, including both conserved (core) and nonconserved components; contains the ATPase product of either the SMARCA4/BAF190A/BRG1 gene, the mammalian ortholog of the yeast SNF2 gene, or an ortholog thereof. Compared to many other BAF complexes never contains ACTL6B/BAF53B, ARID1B/BAF250B, SMARCA2/BRM, SMARCC2/BAF170 or SMARCD3/BAF60C but contains PHF10/BAF45A, DPF2/BAF45D and possibly one of BCL7A/B/C.\" [GOC:bhm, PMID:19279218, PMID:19279220, PMID:2620226, PMID:8804307, PMID:8895581]","metadata":null},{"id":"58c0775ce824400088e13610b898e5fc","type":"DRUG","name":"escitalopram","canonical_id":"gtopdb:7177","description":null,"metadata":null},{"id":"6a15ce2317a14e6eaa77f5e4345d92e7","type":"GO_TERM","name":"esculetin biosynthetic process","canonical_id":"go:GO:0033493","description":"\"The chemical reactions and pathways resulting in the formation of esculetin, 6,7-dihydroxycoumarin.\" [GOC:mah]","metadata":null},{"id":"1c134233cc0c44b18fbce4a2bfd52ebe","type":"GO_TERM","name":"esculin beta-glucosidase activity","canonical_id":"go:GO:0080082","description":"\"Catalysis of the hydrolysis of glucosidic link in esculin.\" [PMID:15604686]","metadata":null},{"id":"0c5a0f63284c4c2d8fc16e1d52f8a554","type":"DRUG","name":"eslicarbazepine acetate","canonical_id":"mesh:C416835","description":null,"metadata":null},{"id":"5763120aa9ce4b42a69e522c688e75cd","type":"DRUG","name":"esmolol","canonical_id":"gtopdb:7178","description":null,"metadata":null},{"id":"daf775cf7b24453aa98013b7244b6d10","type":"DRUG","name":"esmolol","canonical_id":"mesh:C036604","description":null,"metadata":null},{"id":"0073c6d9c32e4467a75131d68fa39e9b","type":"COMBINATION_TREATMENT","name":"esmolol + labetalol","canonical_id":"ctgov_combo:ctgov-combo-4d3ec1692d5cfed0","description":null,"metadata":null},{"id":"56319cc871334933b88273b69fc88c74","type":"COMBINATION_TREATMENT","name":"esmolol + labetalol","canonical_id":"ctgov_combo:ctgov-combo-2dbf6762833cca4d","description":null,"metadata":null},{"id":"6f645ccda4d84e78b194e78383b72eed","type":"COMBINATION_TREATMENT","name":"esmolol + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-45b83c5958ad84c8","description":null,"metadata":null},{"id":"9f8d0b9988a44ac5bfc8d88909b62e6d","type":"COMBINATION_TREATMENT","name":"esmolol + phentolamine","canonical_id":"ctgov_combo:ctgov-combo-00f147a8b36b24ab","description":null,"metadata":null},{"id":"bd22159ef47b436688fdfca38318ba4b","type":"DRUG","name":"esomeprazole","canonical_id":"gtopdb:5488","description":null,"metadata":null},{"id":"be8451490722497b9d44a0e1c5910b93","type":"DRUG","name":"esomeprazole","canonical_id":"mesh:D064098","description":null,"metadata":null},{"id":"fffa82cb125c4c6db8488da2fdb398e2","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-3c059c4a8da6cb50","description":null,"metadata":null},{"id":"a57d19d82b9b4832a23fa9f56c7e7b34","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-4d3a8fb42ff1f1a8","description":null,"metadata":null},{"id":"20ad66d1d22345b995da64ca9da5376a","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-e7f81435acad37e8","description":null,"metadata":null},{"id":"3a818f71404f4f2f89d9a90279ddab7c","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-5a42306e6d86a297","description":null,"metadata":null},{"id":"c469f8e7f51c4bdb8edeef4ececadb88","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-21481ce0a944cb9e","description":null,"metadata":null},{"id":"fdf95d275b154d03b7dad108cf9cb97c","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-0424d4cdca24e47e","description":null,"metadata":null},{"id":"59a5c57da8bc444cada3e88f32ed1861","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-ce55526b4d7f99de","description":null,"metadata":null},{"id":"d03ebb3b8fee4042bc43252557e84502","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-10f2beca433eccb1","description":null,"metadata":null},{"id":"012c092b3ead4d1da8a215b943fddf95","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-3f6345dff69a03cc","description":null,"metadata":null},{"id":"6b71f9a8238f4d75bf9622bb31500db7","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-8fd52a6f3d495cfc","description":null,"metadata":null},{"id":"336ebd57174a42b6a5e10f7f3d2bd726","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-80c3560b9486f8fe","description":null,"metadata":null},{"id":"eb9d0587c2664799a24089e51fb5310d","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-d64d0858b61b3202","description":null,"metadata":null},{"id":"4b98820e7027411ba9422a7ea78c0df6","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-57356f0eb238dd75","description":null,"metadata":null},{"id":"aae9725e068843df9eb6e8d7a79219cb","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-0058c363d9df6550","description":null,"metadata":null},{"id":"130bf6f471834e74b2ce7885389f9d09","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-7db5f3d48b13f73d","description":null,"metadata":null},{"id":"6fac933a915d4b679d5b859477c124fa","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-0349d2dac84be60f","description":null,"metadata":null},{"id":"5faed4bd701a492da4894f2fe89a1fd0","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-c2d255a861d9e6f2","description":null,"metadata":null},{"id":"c3a0c52837764dc1a513d6cee889405a","type":"COMBINATION_TREATMENT","name":"esomeprazole + omeprazole + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-9f78ba2e09f619fb","description":null,"metadata":null},{"id":"fa67f0f6df7844f8b43e98e67e9e223e","type":"DISEASE","name":"esophageal cancer","canonical_id":"mondo:0007576","description":null,"metadata":null},{"id":"a07a673e122e41b2be1e0386b20507e6","type":"DISEASE","name":"esophageal disorder","canonical_id":"mondo:0003749","description":null,"metadata":null},{"id":"79e13f90254943889a127f091cb88e0f","type":"DISEASE","name":"esophageal squamous cell carcinoma","canonical_id":"mondo:0005580","description":null,"metadata":null},{"id":"2a10ce25b34d453ca9b2c689a64d624f","type":"DISEASE","name":"esophagitis","canonical_id":"mondo:0001409","description":null,"metadata":null},{"id":"d3ea4e6384d44702839e8c61b551868a","type":"GO_TERM","name":"esophagus development","canonical_id":"go:GO:1903702","description":"\"The process whose specific outcome is the progression of an esophagus over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, ISBN:0-683-40008-8]","metadata":null},{"id":"e2fa64c7c5e14bc1a6988e8bcb75e820","type":"GO_TERM","name":"esophagus smooth muscle contraction","canonical_id":"go:GO:0014846","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the esophagus. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The esophagus is the muscular membranous segment between the pharynx and the stomach in the upper gastrointestinal tract.\" [GOC:ef, GOC:mtg_muscle, MA:0001573, MSH:D041742]","metadata":null},{"id":"87d4ad52deab4ebbae0a3588b62b2ade","type":"DISEASE","name":"essential hypertension","canonical_id":"mondo:0001134","description":null,"metadata":null},{"id":"a665a4447ec842f5be26e5ba9c4ec1ba","type":"DISEASE","name":"essential hypertension, genetic","canonical_id":"mondo:0007781","description":null,"metadata":null},{"id":"285dc08453724d8f8b488727916e1066","type":"DISEASE","name":"essential thrombocythemia","canonical_id":"mondo:0005029","description":null,"metadata":null},{"id":"36db2096a4214c2fa14cfb4a7ed61bde","type":"GO_TERM","name":"establishment of B cell polarity","canonical_id":"go:GO:0001769","description":"\"The directed orientation of B cell signaling molecules and associated membrane rafts towards a chemokine gradient of a contact point with an antigen displaying cell.\" [GOC:mgi_curators, PMID:12615889, PMID:9692889]","metadata":null},{"id":"22a36d1222b94f3b9c158a4479930b1e","type":"GO_TERM","name":"establishment of ER localization","canonical_id":"go:GO:0051686","description":"\"The directed movement of the endoplasmic reticulum to a specific location.\" [GOC:ai]","metadata":null},{"id":"b8b44b5e5e9d43edbbd7dfc229afe827","type":"GO_TERM","name":"establishment of Golgi localization","canonical_id":"go:GO:0051683","description":"\"The directed movement of the Golgi to a specific location.\" [GOC:ai]","metadata":null},{"id":"c11b41069ce24ddeb4f2550b4bb727d1","type":"GO_TERM","name":"establishment of RNA localization","canonical_id":"go:GO:0051236","description":"\"The directed movement of RNA to a specific location.\" [GOC:ai]","metadata":null},{"id":"6ad2bc93e2ba441d8cbc56b6db878cc2","type":"GO_TERM","name":"establishment of RNA localization to telomere","canonical_id":"go:GO:0097694","description":"\"The directed movement of RNA to a specific location in the telomeric region of a chromosome.\" [GOC:BHF, GOC:BHF_telomere, GOC:rph, PMID:26586433]","metadata":null},{"id":"9c59955a5a2a46d49f7c235cc5a0bfb8","type":"GO_TERM","name":"establishment of Sertoli cell barrier","canonical_id":"go:GO:0097368","description":"\"Establishment of a structure near the basement membrane in adjacent Sertoli cells of the seminiferous epithelium for maintaining spermatogenesis. The structure consists of tight junctions, basal ectoplasmic specializations, and desmosome-like junctions.\" [GOC:sl, PMID:19509333, Wikipedia:Blood-testis_barrier]","metadata":null},{"id":"1429a97e06284ed88acc5d92e9284507","type":"GO_TERM","name":"establishment of T cell polarity","canonical_id":"go:GO:0001768","description":"\"The directed orientation of T cell signaling molecules and associated membrane rafts towards a chemokine gradient or a contact point with antigen presenting cell.\" [GOC:mgi_curators, PMID:11244041, PMID:12615889]","metadata":null},{"id":"0f1699f29fb34aa9b0c9d184683de28a","type":"GO_TERM","name":"establishment of anatomical structure orientation","canonical_id":"go:GO:0048560","description":"\"The process that determines the orientation of an anatomical structure with reference to an axis.\" [GOC:jid]","metadata":null},{"id":"c4d287d74de24623a74fb8508d4ad865","type":"GO_TERM","name":"establishment of animal organ orientation","canonical_id":"go:GO:0048561","description":"\"The process that determines the orientation of an animal organ or tissue with reference to an axis.\" [GOC:jid]","metadata":null},{"id":"9b221a153a8d4435934312bd52ae62b9","type":"GO_TERM","name":"establishment of apical/basal cell polarity","canonical_id":"go:GO:0035089","description":"\"The specification and formation of the polarity of a cell along its apical/basal axis.\" [GOC:bf]","metadata":null},{"id":"998d69d8948942719927d6d06bf002fc","type":"GO_TERM","name":"establishment of bipolar cell polarity","canonical_id":"go:GO:0061171","description":"\"The specification and formation of bipolar intracellular organization or cell growth patterns. Bipolar organization is the organization that is a mirror image along an axis from a plane.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"411113d0224342acabe693bc7cc27e68","type":"GO_TERM","name":"establishment of bipolar cell polarity involved in cell morphogenesis","canonical_id":"go:GO:0061159","description":"\"The specification and formation of bipolar intracellular organization or cell growth patterns that contribute to cell morphogenesis. Bipolar organization is the organization that is a mirror image along an axis from a plane.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"271a9dca257c4f9ba186e0a35c6b4d35","type":"GO_TERM","name":"establishment of blood-brain barrier","canonical_id":"go:GO:0060856","description":"\"Establishment of the barrier between the blood and the brain. The cells in the brain are packed tightly together preventing the passage of most molecules from the blood into the brain. Only lipid soluble molecules or those that are actively transported can pass through the blood-brain barrier.\" [GOC:aruk, GOC:dph, GOC:sart, PMID:20080302, PMID:30280653]","metadata":null},{"id":"c540703725774e0885eda088ca010397","type":"GO_TERM","name":"establishment of blood-nerve barrier","canonical_id":"go:GO:0008065","description":"\"The establishment of the barrier between the perineurium of peripheral nerves and the vascular endothelium of endoneurial capillaries. The perineurium acts as a diffusion barrier, but ion permeability at the blood-nerve barrier is still higher than at the blood-brain barrier.\" [GOC:dgh]","metadata":null},{"id":"a45708fab576418b81d0aaa3dc84e2c6","type":"GO_TERM","name":"establishment of blood-retinal barrier","canonical_id":"go:GO:1990963","description":"\"Establishment of the barrier between the blood and the retina. The blood-retinal barrier is located at two levels, forming an outer barrier in the retinal pigment epithelium and an inner barrier in the endothelial membrane of the retinal vessels. Both these membranes have tight junctions of the 'nonleaky' type.\" [PMID:25053619]","metadata":null},{"id":"aa4f86b880c446f69df2ce0ac91964d9","type":"GO_TERM","name":"establishment of body hair or bristle planar orientation","canonical_id":"go:GO:0048104","description":"\"Orientation of hairs or sensory bristles that cover the body surface of an adult, such that they all point in a uniform direction along the plane of the epithelium from which they project.\" [GOC:ascb_2009, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"8c2bb8e7ed794252b6aeb2a736c6ae23","type":"GO_TERM","name":"establishment of body hair planar orientation","canonical_id":"go:GO:0048105","description":"\"Orientation of body hairs, projections from the surface of an organism, such that the hairs all point in a uniform direction along the surface.\" [GOC:ascb_2009, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"2349728db8044f0899caa96b1587a06d","type":"GO_TERM","name":"establishment of cell polarity","canonical_id":"go:GO:0030010","description":"\"The specification and formation of anisotropic intracellular organization or cell growth patterns.\" [GOC:mah]","metadata":null},{"id":"d68ced7a16fb46b09d94a18940faa37e","type":"GO_TERM","name":"establishment of cell polarity involved in ameboidal cell migration","canonical_id":"go:GO:0003365","description":"\"The specification and formation of anisotropic intracellular organization that contributes to the self-propelled directed movement of an ameboid cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"409e0388e0a646a89c500e5ca854479e","type":"GO_TERM","name":"establishment of cell polarity involved in gastrulation cell migration","canonical_id":"go:GO:0003379","description":"\"The specification and formation of anisotropic intracellular organization that contributes to the self-propelled directed movement of an ameboid cell taking part in gastrulation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"06a7a6ef2d8242e2843182a94687db38","type":"GO_TERM","name":"establishment of cell polarity involved in mesendodermal cell migration","canonical_id":"go:GO:0003369","description":"\"The specification and formation of anisotropic intracellular organization that contributes to the self-propelled directed movement of a mesendodermal cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"5cf95f2863e2450e9a3cbd3496b30504","type":"GO_TERM","name":"establishment of cell polarity regulating cell shape","canonical_id":"go:GO:0071964","description":"\"Any cellular process that results in the specification or formation of a polarized intracellular organization or cell growth pattern that regulates the shape of a cell.\" [GOC:mah]","metadata":null},{"id":"25ea70ddef0a4becb70a407cadf14993","type":"GO_TERM","name":"establishment of centrosome localization","canonical_id":"go:GO:0051660","description":"\"The directed movement of the centrosome to a specific location.\" [GOC:ai]","metadata":null},{"id":"6c31d7152cc041919aa7a2cd25397b1f","type":"GO_TERM","name":"establishment of competence for transformation","canonical_id":"go:GO:0030420","description":"\"The process in which a naturally transformable bacterium acquires the ability to take up exogenous DNA. This term should be applied only to naturally transformable bacteria, and should not be used in the context of artificially induced bacterial transformation.\" [GOC:mah, ISBN:1555811027]","metadata":null},{"id":"73c0c77778fe422aa52258b0f37dd962","type":"GO_TERM","name":"establishment of dense core granule localization","canonical_id":"go:GO:0032256","description":"\"The directed movement of a dense core granule to a specific location.\" [GOC:mah]","metadata":null},{"id":"babd79da1bc04e4ba68f8c7ccf7fdb36","type":"GO_TERM","name":"establishment of endoplasmic reticulum localization to postsynapse","canonical_id":"go:GO:0099089","description":"\"The directed movement of endoplasmic reticulum into a postsynaptic compartment such as a dendritic spine.\" [GOC:dos, PMID:21151132]","metadata":null},{"id":"dc0578afb644472288d0f69fee96d367","type":"GO_TERM","name":"establishment of endothelial barrier","canonical_id":"go:GO:0061028","description":"\"The establishment of a barrier between endothelial cell layers, such as those in the brain, lung or intestine, to exert specific and selective control over the passage of water and solutes, thus allowing formation and maintenance of compartments that differ in fluid and solute composition.\" [GOC:dph]","metadata":null},{"id":"60bba807806f461caf61a3f2d5e1c9e4","type":"GO_TERM","name":"establishment of endothelial blood-brain barrier","canonical_id":"go:GO:0014045","description":"\"Establishment of the endothelial barrier between the blood and the brain. The endothelial cells in the brain capillaries are packed tightly together preventing the passage of most molecules from the blood into the brain. Only lipid soluble molecules or those that are actively transported can pass through the blood-brain barrier.\" [GOC:aruk, GOC:dgh, GOC:dph, GOC:sart, PMID:20080302, PMID:30280653]","metadata":null},{"id":"270c3a1617604bb39709260f14d3015c","type":"GO_TERM","name":"establishment of endothelial intestinal barrier","canonical_id":"go:GO:0090557","description":"\"The establishment of a barrier between endothelial cell layers of the intestine to exert specific and selective control over the passage of water and solutes, thus allowing formation and maintenance of compartments that differ in fluid and solute composition.\" [GOC:krc, PMID:22155109]","metadata":null},{"id":"e6029d988de3430fb684c04f17ba8add","type":"GO_TERM","name":"establishment of episomal latency","canonical_id":"go:GO:0075720","description":"\"A process by which a virus establishes a latent state within its host as an episome, where the viral genome remains silent in the cytoplasm or nucleus as a distinct genetic entity.\" [GOC:jl]","metadata":null},{"id":"d0505e2521174e65bceb724457b914c4","type":"GO_TERM","name":"establishment of epithelial cell apical/basal polarity","canonical_id":"go:GO:0045198","description":"\"The specification and formation of the apicobasal polarity of an epithelial cell.\" [GOC:ascb_2009, GOC:bf, GOC:dph, GOC:tb]","metadata":null},{"id":"18d808d580ef48a19a718394b70de587","type":"GO_TERM","name":"establishment of epithelial cell apical/basal polarity involved in camera-type eye morphogenesis","canonical_id":"go:GO:0003412","description":"\"The specification and formation of the apicobasal polarity of an epithelial cell that contributes to the shaping of a camera-type eye.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"00bdfe64518348288babaf5930f2e3bb","type":"GO_TERM","name":"establishment of epithelial cell planar polarity","canonical_id":"go:GO:0090163","description":"\"The specification and formation of the polarity of an epithelial cell along the plane of the epithelial tissue.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b1a04399876444bba426857b8a5445c4","type":"GO_TERM","name":"establishment of epithelial cell polarity","canonical_id":"go:GO:0090162","description":"\"The specification and formation of anisotropic intracellular organization of an epithelial cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"7db02d34cfa1493c9b929f3012c071f5","type":"GO_TERM","name":"establishment of floral organ orientation","canonical_id":"go:GO:0048559","description":"\"The process that determines the orientation of the floral organs with reference to the central axis of the flower.\" [GOC:jid]","metadata":null},{"id":"e04e9601d71241e698cdfa15550bc5e6","type":"GO_TERM","name":"establishment of germ plasm mRNA localization","canonical_id":"go:GO:0046595","description":"\"Any process that results in the directed movement of mRNA to the germ plasm.\" [GOC:bf]","metadata":null},{"id":"e0089273929b4c858a4857a997de0ee3","type":"GO_TERM","name":"establishment of glial blood-brain barrier","canonical_id":"go:GO:0060857","description":"\"Establishment of the glial barrier between the blood and the brain. The glial cells in the brain are packed tightly together preventing the passage of most molecules from the blood into the brain. Only lipid soluble molecules or those that are actively transported can pass through the blood-brain barrier.\" [GOC:dph, GOC:sart, PMID:20080302]","metadata":null},{"id":"741d1b6ce1604b399b19775e84b42f22","type":"GO_TERM","name":"establishment of granzyme B localization to T cell secretory granule","canonical_id":"go:GO:0033381","description":"\"The directed movement of the protease granzyme B to a location within a secretory granule in a T cell.\" [GOC:mah]","metadata":null},{"id":"6088b4de1a924b0a894c86a69981c274","type":"GO_TERM","name":"establishment of imaginal disc-derived wing hair orientation","canonical_id":"go:GO:0001737","description":"\"Orientation of hairs in the imaginal disc-derived wing along a proximal-distal axis, such that each cell of the wing produces one wing hair which points in a distal direction.\" [GOC:ascb_2009, GOC:dph, GOC:mtg_sensu, GOC:tb, PMID:11239465]","metadata":null},{"id":"2c879e74882545c680326478a5a6c7bc","type":"GO_TERM","name":"establishment of integrated proviral latency","canonical_id":"go:GO:0075713","description":"\"A process by which the virus integrates into the host genome and establishes as a stable provirus or prophage.\" [GOC:jl]","metadata":null},{"id":"bbc452a4c8d843899926549f563867ce","type":"GO_TERM","name":"establishment of latency as a circular episome","canonical_id":"go:GO:0075529","description":"\"A process by which a virus establishes a latent state within its host as an episome, where the viral genome remains silent in the cytoplasm or nucleus as a circular structure.\" [GOC:jl]","metadata":null},{"id":"f8bc16db8e1b41399ec0cffe4e849085","type":"GO_TERM","name":"establishment of latency as a linear episome","canonical_id":"go:GO:0075530","description":"\"A process by which a virus establishes a latent state within its host as an episome, where the viral genome remains silent in the cytoplasm or nucleus as linear structure.\" [GOC:jl]","metadata":null},{"id":"32dc374e848440e5a5636169496c4f78","type":"GO_TERM","name":"establishment of left sidedness","canonical_id":"go:GO:0061967","description":"\"The initial formation of the type asymmetry in an organism's body plan or part of an organism that established the pattern characteristic to its left side.\" [GOC:18629866, GOC:BHF]","metadata":null},{"id":"441c52dc38a044b4915397c0651a38a0","type":"GO_TERM","name":"establishment of left/right asymmetry","canonical_id":"go:GO:0061966","description":"\"The initial formation of the type asymmetry in an organism's body plan or part of an organism with respect to the left and right halves.\" [GOC:BHF, PMID:18629866]","metadata":null},{"id":"e31952c0c028481595946264eb9270e7","type":"GO_TERM","name":"establishment of localization","canonical_id":"go:GO:0051234","description":"\"Any process that localizes a substance or cellular component. This may occur via movement, tethering or selective degradation.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"e5a8090aa62e4250a57cfacb474402af","type":"GO_TERM","name":"establishment of localization in cell","canonical_id":"go:GO:0051649","description":"\"Any process, occurring in a cell, that localizes a substance or cellular component. This may occur via movement, tethering or selective degradation.\" [GOC:ai, GOC:dos, GOC:dph, GOC:tb]","metadata":null},{"id":"7579aede4f4d454999949b5ed1e62465","type":"GO_TERM","name":"establishment of lymphocyte polarity","canonical_id":"go:GO:0001767","description":"\"The directed orientation of lymphocyte signaling molecules and associated membrane rafts towards a chemokine gradient or a contact point with an appropriate activating cell.\" [GOC:mgi_curators, PMID:11244041, PMID:12615889]","metadata":null},{"id":"f4ad9f06045f4d689c18fdf246d2cf70","type":"GO_TERM","name":"establishment of meiotic sister chromatid cohesion","canonical_id":"go:GO:0034089","description":"\"The process in which the sister chromatids of a replicated chromosome become joined along the entire length of the chromosome during S phase during a meiotic cell cycle.\" [GOC:mah]","metadata":null},{"id":"77f2951273ad4ace9d0784c1e9f7da3d","type":"GO_TERM","name":"establishment of meiotic spindle localization","canonical_id":"go:GO:0051295","description":"\"The cell cycle process in which the directed movement of the meiotic spindle to a specific location in the cell occurs.\" [GOC:ai]","metadata":null},{"id":"9a65ef2bb5ba4174a88a588a7967704d","type":"GO_TERM","name":"establishment of meiotic spindle orientation","canonical_id":"go:GO:0051296","description":"\"Any process that set the alignment of meiotic spindle relative to other cellular structures.\" [GOC:ai]","metadata":null},{"id":"3b2a2a6785e641029adbcaa8157ddbf8","type":"GO_TERM","name":"establishment of melanosome localization","canonical_id":"go:GO:0032401","description":"\"The directed movement of a melanosome to a specific location.\" [GOC:mah]","metadata":null},{"id":"172bd222a46e4b859850b8006ba120fa","type":"GO_TERM","name":"establishment of mitochondrion localization","canonical_id":"go:GO:0051654","description":"\"The directed movement of the mitochondrion to a specific location.\" [GOC:ai]","metadata":null},{"id":"e864aa0cddbd42cebcd05eb1a78f27d7","type":"GO_TERM","name":"establishment of mitochondrion localization by microtubule attachment","canonical_id":"go:GO:0034640","description":"\"The directed movement of a mitochondrion by attachment to a microtubule, followed by elongation of the microtubule by tubulin polymerization.\" [GOC:mah, PMID:12972644]","metadata":null},{"id":"51af6b2368b641a09e0cc48c81e4c95b","type":"GO_TERM","name":"establishment of mitochondrion localization, microtubule-mediated","canonical_id":"go:GO:0034643","description":"\"The directed movement of the mitochondrion to a specific location, by a process involving microtubules.\" [GOC:mah, PMID:12972644, PMID:15979253, PMID:16306220]","metadata":null},{"id":"083d3fa7e3f546d281852ca141209e03","type":"GO_TERM","name":"establishment of mitotic sister chromatid cohesion","canonical_id":"go:GO:0034087","description":"\"The process in which the sister chromatids of a replicated chromosome become joined along the entire length of the chromosome during S phase during a mitotic cell cycle.\" [GOC:mah]","metadata":null},{"id":"7c5a3c79cb8243b7849739c056aecbe7","type":"GO_TERM","name":"establishment of mitotic spindle asymmetry","canonical_id":"go:GO:0061867","description":"\"The mitotic spindle organization process by which a mitotic spindle becomes asymmetric either in position or structure.\" [PMID:26659188]","metadata":null},{"id":"fe5f1cc6aa2e46c9b077a4afe0319883","type":"GO_TERM","name":"establishment of mitotic spindle localization","canonical_id":"go:GO:0040001","description":"\"The cell cycle process in which the directed movement of the mitotic spindle to a specific location in the cell occurs.\" [GOC:ai]","metadata":null},{"id":"a6bf3edc34694ea298627b527f800894","type":"GO_TERM","name":"establishment of mitotic spindle orientation","canonical_id":"go:GO:0000132","description":"\"A cell cycle process that sets the alignment of mitotic spindle relative to other cellular structures.\" [GOC:ems]","metadata":null},{"id":"b3b8f0d174e24479affa750a17e86619","type":"GO_TERM","name":"establishment of monopolar cell polarity","canonical_id":"go:GO:0061162","description":"\"The specification and formation of monopolar intracellular organization or cell growth patterns. Monopolar cell organization is directional organization along an axis.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"9bae50d54fda412e86f9bfa95be72121","type":"GO_TERM","name":"establishment of myocardial progenitor cell apical/basal polarity","canonical_id":"go:GO:0003316","description":"\"The specification and formation of the apicobasal polarity of an myocardial progenitor cell that contributes to the formation of the heart rudiment.\" [GOC:mtg_heart]","metadata":null},{"id":"d4e181bbb0a648be844b1f15215fe79a","type":"GO_TERM","name":"establishment of natural killer cell polarity","canonical_id":"go:GO:0001770","description":"\"The directed orientation of natural killer cell signaling molecules and associated membrane rafts towards a chemokine gradient or a contact point with a cell displaying natural killer cell activating ligands.\" [GOC:mgi_curators, PMID:12615886, PMID:9759849]","metadata":null},{"id":"44ce626c03a54a4791c77905f3b3ef97","type":"GO_TERM","name":"establishment of neuroblast polarity","canonical_id":"go:GO:0045200","description":"\"The specification and formation of the apicobasal polarity of a neuroblast cell, a progenitor of the central nervous system.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"cdab22e5d8ab48af8f39e5fae9c31b69","type":"GO_TERM","name":"establishment of ommatidial planar polarity","canonical_id":"go:GO:0042067","description":"\"The specification of polarized ommatidia. Ommatidia occur in two chiral forms. The trapezoidal arrangement of photoreceptors in the dorsal part of the eye is the mirror image of that in the ventral part.\" [GOC:ascb_2009, GOC:dph, GOC:tb, PMID:3076112, PMID:3937883]","metadata":null},{"id":"f731c3ae039b4dfc93cb95e83ddc0be5","type":"GO_TERM","name":"establishment of organelle localization","canonical_id":"go:GO:0051656","description":"\"The directed movement of an organelle to a specific location.\" [GOC:ai]","metadata":null},{"id":"e890e93e9a534c5c92cae3817ef165b8","type":"GO_TERM","name":"establishment of petal orientation","canonical_id":"go:GO:0048498","description":"\"The process that determines the orientation of petals with reference to the central axis.\" [GOC:tb, PMID:10572040]","metadata":null},{"id":"c013d26dd3ea401b96e53a7f0ef65155","type":"GO_TERM","name":"establishment of pigment granule localization","canonical_id":"go:GO:0051905","description":"\"The directed movement of a pigment granule to a specific location.\" [GOC:ai]","metadata":null},{"id":"63d3e3a69e124c42a6c1f676338df7cc","type":"GO_TERM","name":"establishment of planar polarity","canonical_id":"go:GO:0001736","description":"\"Coordinated organization of groups of cells in the plane of an epithelium, such that they all orient to similar coordinates.\" [GOC:dph]","metadata":null},{"id":"038a13cc97d94081b34d844cbe994361","type":"GO_TERM","name":"establishment of planar polarity involved in nephron morphogenesis","canonical_id":"go:GO:0072046","description":"\"Coordinated organization of groups of cells in the plane of an epithelium that contributes to the shaping of a nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"80e496cd8a354ecfb8a03c84827ec593","type":"GO_TERM","name":"establishment of planar polarity involved in neural tube closure","canonical_id":"go:GO:0090177","description":"\"Coordinated organization of groups of cells in the plane of an epithelium that contributes to the closure of the neural tube.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b0e23620119e429db3a0b14016b7093e","type":"GO_TERM","name":"establishment of planar polarity of embryonic epithelium","canonical_id":"go:GO:0042249","description":"\"Coordinated organization of groups of cells in the plane of an embryonic epithelium, such that they all orient to similar coordinates.\" [GOC:ascb_2009, GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"5e0f0fb047dd4e7a85a28e4c6927803d","type":"GO_TERM","name":"establishment of planar polarity of follicular epithelium","canonical_id":"go:GO:0042247","description":"\"Coordinated organization of groups of cells in the plane of a follicular epithelium, such that they all orient to similar coordinates.\" [GOC:ascb_2009, GOC:bf, GOC:dph, GOC:tb]","metadata":null},{"id":"bd094d49d3524ad289cfef4c94527710","type":"GO_TERM","name":"establishment of planar polarity of larval imaginal disc epithelium","canonical_id":"go:GO:0042252","description":"\"Coordinated organization of groups of cells in the plane of a larval imaginal disc epithelium, such that they all orient to similar coordinates.\" [GOC:jl]","metadata":null},{"id":"55be3c4ae1464db7b7da07ac4109931e","type":"GO_TERM","name":"establishment of plant organ orientation","canonical_id":"go:GO:0090707","description":"\"The process that determines the orientation of a plant organ or tissue with reference to an axis.\" [GOC:tb]","metadata":null},{"id":"5dab9f096c1641189e19b892bed71a5f","type":"GO_TERM","name":"establishment of plastid localization","canonical_id":"go:GO:0051667","description":"\"The directed movement of a plastid to a specific location in the cell.\" [GOC:ai]","metadata":null},{"id":"0e63feaa7efa48b39d1ec222c4605ef5","type":"GO_TERM","name":"establishment of protease localization to T cell secretory granule","canonical_id":"go:GO:0033378","description":"\"The directed movement of a protease to a location within a secretory granule in a T cell.\" [GOC:mah]","metadata":null},{"id":"3d2db50aaa5f412a9fd6cdff68c4404f","type":"GO_TERM","name":"establishment of protease localization to mast cell secretory granule","canonical_id":"go:GO:0033372","description":"\"The directed movement of a protease to a location within a secretory granule in a mast cell.\" [GOC:mah]","metadata":null},{"id":"ea2d3823ba62404aaee51e1242f7c098","type":"GO_TERM","name":"establishment of protein localization","canonical_id":"go:GO:0045184","description":"\"The directed movement of a protein to a specific location.\" [GOC:bf]","metadata":null},{"id":"8b9bc1a4ca0a4bd8932bfd5571bcc6c8","type":"GO_TERM","name":"establishment of protein localization to T cell secretory granule","canonical_id":"go:GO:0033376","description":"\"The directed movement of a protein to a location within a secretory granule in a T cell.\" [GOC:mah]","metadata":null},{"id":"0cb10c51a4454ffca3500713c3052587","type":"GO_TERM","name":"establishment of protein localization to chloroplast","canonical_id":"go:GO:0072596","description":"\"The directed movement of a protein to a specific location in a chloroplast.\" [GOC:mah]","metadata":null},{"id":"4c55e860da5d4b5098bdd2c89555971f","type":"GO_TERM","name":"establishment of protein localization to chromatin","canonical_id":"go:GO:0071169","description":"\"The directed movement of a protein to a part of a chromosome that is organized into chromatin.\" [GOC:mah]","metadata":null},{"id":"8379419125174715aeebce0f47eb4193","type":"GO_TERM","name":"establishment of protein localization to chromosome","canonical_id":"go:GO:0070199","description":"\"The directed movement of a protein to a specific location on a chromosome.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"30ac757e606b43af914fd0604c78592e","type":"GO_TERM","name":"establishment of protein localization to endoplasmic reticulum","canonical_id":"go:GO:0072599","description":"\"The directed movement of a protein to a specific location in the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"c1735a3cab464933b0032a8150f6f0a6","type":"GO_TERM","name":"establishment of protein localization to endoplasmic reticulum membrane","canonical_id":"go:GO:0097051","description":"\"The directed movement of a protein to a specific location in the endoplasmic reticulum membrane.\" [GOC:rb, PMID:9388185]","metadata":null},{"id":"8e50f0bcd9fd434b8c24e1289e86f253","type":"GO_TERM","name":"establishment of protein localization to euchromatin","canonical_id":"go:GO:1905633","description":"\"The directed movement of a protein to a specific location in an euchromatin.\" [GO_REF:0000087, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"54e585c51e504d9184b622e1bb4a9800","type":"GO_TERM","name":"establishment of protein localization to extracellular region","canonical_id":"go:GO:0035592","description":"\"The directed movement of a protein to a specific location within the extracellular region.\" [GOC:bf, GOC:BHF]","metadata":null},{"id":"4c722054d6334d96bd1948471f08bf65","type":"GO_TERM","name":"establishment of protein localization to juxtaparanode region of axon","canonical_id":"go:GO:0071206","description":"\"The directed movement of a protein to the juxtaparanode region of an axon.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"e9c67176363343dfaf724af9b0e2f274","type":"GO_TERM","name":"establishment of protein localization to mast cell secretory granule","canonical_id":"go:GO:0033369","description":"\"The directed movement of a protein to a location within a secretory granule in a mast cell.\" [GOC:mah]","metadata":null},{"id":"8beabf5d92ee4c0eb59700f60a49a334","type":"GO_TERM","name":"establishment of protein localization to membrane","canonical_id":"go:GO:0090150","description":"\"The directed movement of a protein to a specific location in a membrane.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"6b10e6cf86d040d888b4e4a9bcd84466","type":"GO_TERM","name":"establishment of protein localization to organelle","canonical_id":"go:GO:0072594","description":"\"The directed movement of a protein to a specific location on or in an organelle. Encompasses establishment of localization in the membrane or lumen of a membrane-bounded organelle.\" [GOC:mah]","metadata":null},{"id":"e7078ae714374c7f9f8a1b58573039d9","type":"GO_TERM","name":"establishment of protein localization to peroxisome","canonical_id":"go:GO:0072663","description":"\"The directed movement of a protein to a specific location in a peroxisome.\" [GOC:mah]","metadata":null},{"id":"d9aa30db554d4d4a869fbf7abcd5aa2e","type":"GO_TERM","name":"establishment of protein localization to plasma membrane","canonical_id":"go:GO:0061951","description":"\"The directed movement of a protein to a specific location in a plasma membrane.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"66fccee9990c429e8bd20336b3dcbda6","type":"GO_TERM","name":"establishment of protein localization to postsynaptic membrane","canonical_id":"go:GO:1903540","description":"\"The directed movement of a protein to a specific location in a postsynaptic membrane.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:9753322]","metadata":null},{"id":"a27abc7afa934d20bd6bde76ef8f82fa","type":"GO_TERM","name":"establishment of protein localization to spindle pole body","canonical_id":"go:GO:0071989","description":"\"The directed movement of a protein to a specific location at the spindle pole body.\" [GOC:mah]","metadata":null},{"id":"d68446dfad92441eb511a71b88fcc9e3","type":"GO_TERM","name":"establishment of protein localization to telomere","canonical_id":"go:GO:0070200","description":"\"The directed movement of a protein to a specific location in the telomeric region of a chromosome.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"0eb9924e1ca64f77826bb1d04c701013","type":"GO_TERM","name":"establishment of protein localization to vacuole","canonical_id":"go:GO:0072666","description":"\"The directed movement of a protein to a specific location in a vacuole.\" [GOC:mah]","metadata":null},{"id":"31289d93a26c4f1f804bc319df46c45e","type":"GO_TERM","name":"establishment of protein-containing complex localization to telomere","canonical_id":"go:GO:0097695","description":"\"The directed movement of a protein-containing macromolecular complex to a specific location in the telomeric region of a chromosome.\" [GOC:BHF, GOC:BHF_telomere, GOC:rph, PMID:26586433]","metadata":null},{"id":"32b1698372054927be7d84724e572127","type":"GO_TERM","name":"establishment of proximal/distal cell polarity","canonical_id":"go:GO:0022606","description":"\"The specification and formation of the polarity of a cell along its proximal/distal axis.\" [GOC:isa_complete]","metadata":null},{"id":"ee9944b850904c978258de567e724335","type":"GO_TERM","name":"establishment of secretory granule localization","canonical_id":"go:GO:0032254","description":"\"The directed movement of a secretory granule to a specific location.\" [GOC:mah]","metadata":null},{"id":"a190b141800143259c0cd02390dc354c","type":"GO_TERM","name":"establishment of sister chromatid cohesion","canonical_id":"go:GO:0034085","description":"\"The process in which the sister chromatids of a replicated chromosome become associated with each other during S phase.\" [GOC:jh, GOC:mah, PMID:14623866]","metadata":null},{"id":"531c4bafef7d40da93d1212cdfe625ba","type":"GO_TERM","name":"establishment of skin barrier","canonical_id":"go:GO:0061436","description":"\"Establishment of the epithelial barrier, the functional barrier in the skin that limits its permeability.\" [GOC:dph]","metadata":null},{"id":"d7353108f04d44db82ce9b915c24aa60","type":"GO_TERM","name":"establishment of spindle localization","canonical_id":"go:GO:0051293","description":"\"The directed movement of the spindle to a specific location in the cell.\" [GOC:ai]","metadata":null},{"id":"5c058458a8484508824070cb8cf3f619","type":"GO_TERM","name":"establishment of spindle orientation","canonical_id":"go:GO:0051294","description":"\"Any process that set the alignment of spindle relative to other cellular structures.\" [GOC:ai]","metadata":null},{"id":"d9127b4c5e3c4cf99cacf81a84f37213","type":"GO_TERM","name":"establishment of synaptic specificity at neuromuscular junction","canonical_id":"go:GO:0007529","description":"\"The biological process in which a synapse between a motor neuron and a muscle is initially formed.\" [GOC:isa_complete]","metadata":null},{"id":"d1dee7bb49fd4afda303001b39ef1af5","type":"GO_TERM","name":"establishment of synaptic vesicle localization","canonical_id":"go:GO:0097480","description":"\"The directed movement of a synaptic vesicle or vesicles to a specific location.\" [GOC:pr]","metadata":null},{"id":"6770b56a6a5d45dd8da5b2ea63d0ade3","type":"GO_TERM","name":"establishment of thoracic bristle planar orientation","canonical_id":"go:GO:0048106","description":"\"Orientation along the body surface of bristles, sensory organs originating from a sensory organ precursor cell, such that they all point in a uniform direction.\" [FBbt:00004298, FBbt:00004408, GOC:ascb_2009, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"537c1f892aed41d8a70e94e6c695e2fb","type":"GO_TERM","name":"establishment of tissue polarity","canonical_id":"go:GO:0007164","description":"\"Coordinated organization of groups of cells in a tissue, such that they all orient to similar coordinates.\" [GOC:jid]","metadata":null},{"id":"e471be121c7d4b73b330e0f6c1548097","type":"GO_TERM","name":"establishment of turgor in appressorium","canonical_id":"go:GO:0075039","description":"\"The process in which hydrostatic pressure is increased within the symbiont appressorium to breach the cuticle of the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"eb184fef79a641ca835327b18f9587c7","type":"GO_TERM","name":"establishment of vesicle localization","canonical_id":"go:GO:0051650","description":"\"The directed movement of a vesicle to a specific location.\" [GOC:ai]","metadata":null},{"id":"64a8fbde8eab4baf9e89e96ae818a80a","type":"GO_TERM","name":"establishment of viral latency","canonical_id":"go:GO:0019043","description":"\"A process by which a virus establishes a latent state within its host, either as an integrated provirus within the host genome or as an episome, where viral genome remains in the cytoplasm or nucleus as distinct objects.\" [GOC:jl]","metadata":null},{"id":"398bcd946d404289a2de37e6e17e2c44","type":"GO_TERM","name":"establishment or maintenance of actin cytoskeleton polarity","canonical_id":"go:GO:0030950","description":"\"Any cellular process that results in the specification, formation or maintenance of polarized actin-based cytoskeletal structures.\" [GOC:mah]","metadata":null},{"id":"62e68b284e394c60b756a6901d0855e5","type":"GO_TERM","name":"establishment or maintenance of apical/basal cell polarity","canonical_id":"go:GO:0035088","description":"\"Any cellular process that results in the specification, formation or maintenance polarization of a cell's architecture along its apical/basal axis so that the apical and basal regions of the cell have different membrane, extracellular matrix and sub-membrane cellular components.\" [GOC:bf, GOC:mah, PMID:10934483]","metadata":null},{"id":"093f112ea46d43d39517b38c0211315c","type":"GO_TERM","name":"establishment or maintenance of bipolar cell polarity","canonical_id":"go:GO:0061245","description":"\"Any cellular process that results in the specification, formation or maintenance of a bipolar intracellular organization or cell growth patterns.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"4e033f0b659f405680a49f171a36b2ae","type":"GO_TERM","name":"establishment or maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:0061246","description":"\"Any cellular process that results in the specification, formation or maintenance of a bipolar intracellular organization or cell growth patterns that regulates the shaping of a cell.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"005fe98e792e4195950f0cf409548496","type":"GO_TERM","name":"establishment or maintenance of cell polarity","canonical_id":"go:GO:0007163","description":"\"Any cellular process that results in the specification, formation or maintenance of anisotropic intracellular organization or cell growth patterns.\" [GOC:mah]","metadata":null},{"id":"334a2231a5c1452a8f843634cc7dc040","type":"GO_TERM","name":"establishment or maintenance of cell polarity regulating cell shape","canonical_id":"go:GO:0071963","description":"\"Any cellular process that results in the specification, formation or maintenance of a polarized intracellular organization or cell growth patterns that regulate the shape of a cell.\" [GOC:mah]","metadata":null},{"id":"f66894c6813d45c0aa327c5d24a9d8ef","type":"GO_TERM","name":"establishment or maintenance of cell type involved in phenotypic switching","canonical_id":"go:GO:0044663","description":"\"A cellular process of the specification, formation or maintenance of an alternative cell type, occurring as part of the process of phenotypic switching. Phenotypic switching begins with changes in cell morphology and altered gene expression patterns and ends when the morphology of a population of cells has reverted back to the default state, accompanied by altered expression patterns.\" [GOC:jl]","metadata":null},{"id":"385215e802c441ebae1f1fbd72620831","type":"GO_TERM","name":"establishment or maintenance of cytoskeleton polarity","canonical_id":"go:GO:0030952","description":"\"Any cellular process that results in the specification, formation or maintenance of polarized cytoskeletal structures.\" [GOC:mah]","metadata":null},{"id":"e92184c9701742f2925ca2770b5de5f5","type":"GO_TERM","name":"establishment or maintenance of cytoskeleton polarity involved in ameboidal cell migration","canonical_id":"go:GO:0003371","description":"\"Any cellular process that results in the specification, formation or maintenance of polarized cytoskeletal structures that contribute to the cell polarity of a migrating ameboid cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"ae76d90b705246e992d56d0f92164e20","type":"GO_TERM","name":"establishment or maintenance of cytoskeleton polarity involved in gastrulation","canonical_id":"go:GO:0003380","description":"\"Any cellular process that results in the specification, formation or maintenance of polarized cytoskeletal structures that contribute to the cell polarity of a migrating ameboid cell taking part in gastrulation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"28842fd075444a09a88e6526b86ff5d2","type":"GO_TERM","name":"establishment or maintenance of epithelial cell apical/basal polarity","canonical_id":"go:GO:0045197","description":"\"Any cellular process that results in the specification, formation or maintenance of the apicobasal polarity of an epithelial cell.\" [GOC:bf, GOC:mah]","metadata":null},{"id":"5baa994910144018b12570dc9d41742c","type":"GO_TERM","name":"establishment or maintenance of microtubule cytoskeleton polarity","canonical_id":"go:GO:0030951","description":"\"Any cellular process that results in the specification, formation or maintenance of polarized microtubule-based cytoskeletal structures.\" [GOC:mah]","metadata":null},{"id":"6aa6bcc2a6924dc1b82ee38b5d39e716","type":"GO_TERM","name":"establishment or maintenance of monopolar cell polarity","canonical_id":"go:GO:0061339","description":"\"Any cellular process that results in the specification, formation or maintenance of monopolar intracellular organization or cell growth patterns. Monopolar cell organization is directional organization along an axis.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"61b4be04078a464dab4082976f6edd91","type":"GO_TERM","name":"establishment or maintenance of monopolar cell polarity regulating cell shape","canonical_id":"go:GO:0061340","description":"\"Any cellular process that results in the specification, formation or maintenance of a monopolar intracellular organization or cell growth patterns that regulate the shape of a cell.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"2096a13d4dd347a48f2227f396d74878","type":"GO_TERM","name":"establishment or maintenance of neuroblast polarity","canonical_id":"go:GO:0045196","description":"\"Any cellular process that results in the specification, formation or maintenance of the apicobasal polarity of a neuroblast cell, a progenitor of the central nervous system.\" [GOC:bf, GOC:mah, GOC:mtg_sensu, PMID:19375318, PMID:20066083]","metadata":null},{"id":"15a0655acfb146169256afe3b7cdc404","type":"GO_TERM","name":"establishment or maintenance of polarity of embryonic epithelium","canonical_id":"go:GO:0016332","description":"\"Any cellular process that results in the specification, formation or maintenance of anisotropic intracellular organization of epithelial cells in an embryo.\" [GOC:isa_complete, GOC:mah]","metadata":null},{"id":"4e99ec3107df4f338706c62e9abd7701","type":"GO_TERM","name":"establishment or maintenance of polarity of follicular epithelium","canonical_id":"go:GO:0016334","description":"\"Any cellular process that results in the specification, formation or maintenance of a polarized follicular epithelial sheet.\" [GOC:bf, GOC:mah]","metadata":null},{"id":"a22faff8d96a4b6eb9643335237c84ef","type":"GO_TERM","name":"establishment or maintenance of polarity of larval imaginal disc epithelium","canonical_id":"go:GO:0016336","description":"\"Any cellular process that results in the specification, formation or maintenance of a polarized larval imaginal disc epithelium.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"8697bf4eeeb2450594a82d9de10bd337","type":"GO_TERM","name":"establishment or maintenance of transmembrane electrochemical gradient","canonical_id":"go:GO:0010248","description":"\"The directed movement of ions to establish or maintain an electrochemical gradient across a membrane by means of some agent such as a transporter or pore.\" [GOC:mah, GOC:sm]","metadata":null},{"id":"a92b625a63104acc9b3e147f79a18632","type":"GO_TERM","name":"esterosome","canonical_id":"go:GO:0033117","description":"\"A vesicle filled with crystalline protein that shows sequence similarities with various esterases.\" [GOC:ecd, PMID:2307702]","metadata":null},{"id":"07339bd4b1e04c40b7db3b814647aad9","type":"GO_TERM","name":"esterosome lumen","canonical_id":"go:GO:0034467","description":"\"The volume enclosed by the membrane of an esterosome.\" [GOC:rph]","metadata":null},{"id":"b295653913b4469bb30dca40018a065b","type":"GO_TERM","name":"esterosome membrane","canonical_id":"go:GO:0033118","description":"\"The lipid bilayer surrounding an esterosome. This membrane has characteristics of rough endoplasmic reticulum (RER) membranes.\" [GOC:ecd, PMID:2307702]","metadata":null},{"id":"ea14679a7bb747c59f0e9f775185bd46","type":"GO_TERM","name":"estivation","canonical_id":"go:GO:0042751","description":"\"Any process in which an organism enters and maintains a period of dormancy, similar to hibernation, but that occurs during the summer. It insulates against heat to prevent the harmful effects of the season.\" [GOC:jl, PMID:12443930, Wikipedia:Estivation]","metadata":null},{"id":"e3af9d985e644e9884a87e698b08c0eb","type":"GO_TERM","name":"estradiol 17-alpha-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0047881","description":"\"Catalysis of the reaction: estradiol-17-alpha + NAD(P)+ = estrone + NAD(P)H + H+.\" [EC:1.1.1.148]","metadata":null},{"id":"ad8961d314034c50ad682b81221cf310","type":"GO_TERM","name":"estradiol 17-beta-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0004303","description":"\"Catalysis of the reaction: estradiol-17-beta + NAD(P)+ = estrone + NAD(P)H + H+. The activity can use NAD+ or NADP+ as the acceptor.\" [EC:1.1.1.62]","metadata":null},{"id":"669a9b8b911e4a068288a67d481d350b","type":"GO_TERM","name":"estradiol 6-beta-monooxygenase activity","canonical_id":"go:GO:0047882","description":"\"Catalysis of the reaction: AH(2) + estradiol-17beta + O2 = 6beta-hydroxyestradiol-17beta + A + H2O.\" [EC:1.14.99.11, RHEA:19137]","metadata":null},{"id":"fa5b772a12124ed3a8e44da49417a0d5","type":"GO_TERM","name":"estradiol binding","canonical_id":"go:GO:1903924","description":"\"Binding to estradiol.\" [GO_REF:0000067, GOC:TermGenie, PMID:9048584]","metadata":null},{"id":"1980f24c2c8148f49095f8138368e658","type":"GO_TERM","name":"estradiol secretion","canonical_id":"go:GO:0035938","description":"\"The regulated release of estradiol into the circulatory system.\" [GOC:sl, PMID:21632818]","metadata":null},{"id":"0b2b46774eca4940bd163ef2f3a988a2","type":"DRUG","name":"estriol","canonical_id":"gtopdb:2821","description":null,"metadata":null},{"id":"048d601a69484a868a2931b74db72a2f","type":"DRUG","name":"estriol","canonical_id":"chembl:CHEMBL193482","description":null,"metadata":null},{"id":"c11f872869b14c04b5af8d4f35b992df","type":"GO_TERM","name":"estrogen 16-alpha-hydroxylase activity","canonical_id":"go:GO:0101020","description":"\"Catalysis of the reaction: estrogen + reduced [NADPH--hemoprotein reductase] + O2 = 16-alpha-hydroxyestrogen + oxidized [NADPH--hemoprotein reductase] + H2O.\" [GOC:BHF]","metadata":null},{"id":"a1fa21d2aeb040d28d5d509a68293cb9","type":"GO_TERM","name":"estrogen 2-hydroxylase activity","canonical_id":"go:GO:0101021","description":"\"Catalysis of the reaction: estrogen + reduced [NADPH--hemoprotein reductase] + O2 = 2-hydroxyestrogen + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [GOC:BHF, GOC:rl, PMID:14559847]","metadata":null},{"id":"fe9733fc5b9d4824b8fb8c76ec734ed3","type":"GO_TERM","name":"estrogen binding","canonical_id":"go:GO:0099130","description":"\"Binding to an estrogen.\" [GOC:dos]","metadata":null},{"id":"0dc550e0d11448108c3dcbfb334e26cd","type":"GO_TERM","name":"estrogen biosynthetic process","canonical_id":"go:GO:0006703","description":"\"The chemical reactions and pathways resulting in the formation of estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants.\" [ISBN:0198506732]","metadata":null},{"id":"c048213741d0495bbff7febd7c39156d","type":"GO_TERM","name":"estrogen catabolic process","canonical_id":"go:GO:0006711","description":"\"The chemical reactions and pathways resulting in the breakdown of estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants.\" [ISBN:0198506732]","metadata":null},{"id":"daea3ecd21414ea3834397fadcd38912","type":"GO_TERM","name":"estrogen metabolic process","canonical_id":"go:GO:0008210","description":"\"The chemical reactions and pathways involving estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants.\" [ISBN:0198506732]","metadata":null},{"id":"3847b119e95c4beaa9c5eee2a6ea02c4","type":"GO_TERM","name":"estrogen receptor signaling pathway","canonical_id":"go:GO:0030520","description":"\"A nuclear receptor-mediated signaling pathway initiated by an estrogen binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling]","metadata":null},{"id":"92d5c59f95654dc38ee52abbdc1d3507","type":"GO_TERM","name":"estrogen response element binding","canonical_id":"go:GO:0034056","description":"\"Binding to an estrogen response element (ERE), a conserved sequence found in the promoters of genes whose expression is regulated in response to estrogen.\" [GOC:ecd, PMID:15036253, PMID:17975005]","metadata":null},{"id":"21604350c90242a4ad613aad9289b069","type":"GO_TERM","name":"estrogen secretion","canonical_id":"go:GO:0035937","description":"\"The regulated release of estrogen into the circulatory system. Estrogen is a steroid hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals.\" [GOC:sl]","metadata":null},{"id":"920a7b1ae2f54faab085e340b9de9e0d","type":"DRUG","name":"estrone","canonical_id":"gtopdb:2818","description":null,"metadata":null},{"id":"c6d56c89c03f42f6881398c6326b0a4c","type":"DRUG","name":"estrone","canonical_id":"mesh:D004970","description":null,"metadata":null},{"id":"d614e6bb00d34e1c852204c4caa4c0bc","type":"GO_TERM","name":"estrone secretion","canonical_id":"go:GO:0035943","description":"\"The regulated release of estrone into the circulatory system.\" [GOC:sl, PMID:8395854]","metadata":null},{"id":"4aacd06b48d943899392d2f0ac42bfb5","type":"GO_TERM","name":"estrone sulfotransferase activity","canonical_id":"go:GO:0004304","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + estrone = adenosine 3',5'-bisphosphate + estrone 3-sulfate.\" [EC:2.8.2.4]","metadata":null},{"id":"76ebb57ebdb3410283231598d845e0f2","type":"GO_TERM","name":"estrous cycle","canonical_id":"go:GO:0044849","description":"\"A type of ovulation cycle, which occurs in most mammalian therian females, where the endometrium is resorbed if pregnancy does not occur.\" [GOC:jl, Wikipedia:Estrous_cycle]","metadata":null},{"id":"328f20ce9cc445e1aa80c8be1a97f250","type":"GO_TERM","name":"estrous cycle phase","canonical_id":"go:GO:0060206","description":"\"The progression of physiological phases, occurring in the endometrium during the estrous cycle that recur at regular intervals during the reproductive years. The estrous cycle is an ovulation cycle where the endometrium is resorbed if pregnancy does not occur.\" [GOC:dph]","metadata":null},{"id":"9aa96005413a4abcb8597211f2b6e6bc","type":"GO_TERM","name":"estrus","canonical_id":"go:GO:0060209","description":"\"The estrous cycle phase in which a female is sexually receptive.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"6926c320ca684fc4b46c1533ac8845a6","type":"DRUG","name":"etanercept","canonical_id":"gtopdb:6789","description":null,"metadata":null},{"id":"dbc700f336404cb6bdf34fae7eec3b13","type":"DRUG","name":"etanercept","canonical_id":"chembl:CHEMBL1201572","description":null,"metadata":null},{"id":"42aba09b66fe4ec79fd5f1616a9969de","type":"COMBINATION_TREATMENT","name":"etanercept + golimumab","canonical_id":"ctgov_combo:ctgov-combo-7a35d744d25d1347","description":null,"metadata":null},{"id":"2d92277bdcaa4eeda43b546092845b00","type":"COMBINATION_TREATMENT","name":"etanercept + golimumab + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-0d7ce2ce3389c567","description":null,"metadata":null},{"id":"51accb2f2efd4245bacaeb8dfacfaf9f","type":"COMBINATION_TREATMENT","name":"etanercept + hydroxychloroquine","canonical_id":"ctgov_combo:ctgov-combo-ba10141bdf94e548","description":null,"metadata":null},{"id":"72a974255cdc4b108ca2aaa50f9e49fc","type":"COMBINATION_TREATMENT","name":"etanercept + ixekizumab","canonical_id":"ctgov_combo:ctgov-combo-9ca7c854f82aface","description":null,"metadata":null},{"id":"efc84361d617467f8bf617952d861d84","type":"COMBINATION_TREATMENT","name":"etanercept + tocilizumab + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-191e50cc817a47a5","description":null,"metadata":null},{"id":"2aff95c743924167aebc02dae849d479","type":"COMBINATION_TREATMENT","name":"etanercept + tofacitinib","canonical_id":"ctgov_combo:ctgov-combo-9a3564dac82bf338","description":null,"metadata":null},{"id":"b0a43ceea2d44352858580605a3ed381","type":"DRUG","name":"etelcalcetide","canonical_id":"mesh:C583569","description":null,"metadata":null},{"id":"4b5384cd36bf4aa2869f3d3495819ba6","type":"DRUG","name":"ethacrynic acid","canonical_id":"mesh:D004976","description":null,"metadata":null},{"id":"16fb792087264e9d849eb83765ac0ab9","type":"GO_TERM","name":"ethanol binding","canonical_id":"go:GO:0035276","description":"\"Binding to ethanol, CH(3)-CH(2)-OH.\" [ISBN:0198506732]","metadata":null},{"id":"be20bf4c74bc444ebf87985980232deb","type":"GO_TERM","name":"ethanol biosynthetic process","canonical_id":"go:GO:0006115","description":"\"The chemical reactions and pathways resulting in the formation of ethanol, CH3-CH2-OH, a colorless, water-miscible, flammable liquid produced by alcoholic fermentation.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"e8d8259da921407dae52b48845c383c5","type":"GO_TERM","name":"ethanol catabolic process","canonical_id":"go:GO:0006068","description":"\"The chemical reactions and pathways resulting in the breakdown of ethanol, CH3-CH2-OH, a colorless, water-miscible, flammable liquid produced by alcoholic fermentation.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"c80851e6ec6c47aca80023e6afca4790","type":"GO_TERM","name":"ethanol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0120542","description":"\"Catalysis of the reaction: ethanol + NAD+ = acetaldehyde + NADH + H+.\" [RHEA:25290]","metadata":null},{"id":"90c425aaf7834b69a55a240b64832b35","type":"GO_TERM","name":"ethanol metabolic process","canonical_id":"go:GO:0006067","description":"\"The chemical reactions and pathways involving ethanol, CH3-CH2-OH, a colorless, water-miscible, flammable liquid produced by alcoholic fermentation.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"c6d43fb77e03462493fa7ba6c8824e23","type":"GO_TERM","name":"ethanolamine ammonia-lyase activity","canonical_id":"go:GO:0008851","description":"\"Catalysis of the reaction: ethanolamine = acetaldehyde + NH4+.\" [RHEA:15313]","metadata":null},{"id":"4e96de129f5b43038b7ed87209b6bff2","type":"GO_TERM","name":"ethanolamine ammonia-lyase complex","canonical_id":"go:GO:0009350","description":"\"An enzyme complex that catalyzes the breakdown of ethanolamine to form acetaldehyde and ammonia.\" [PMID:1550360]","metadata":null},{"id":"73b6fc42e26f49d183a8c12169530922","type":"GO_TERM","name":"ethanolamine biosynthetic process","canonical_id":"go:GO:0046335","description":"\"The chemical reactions and pathways resulting in the formation of ethanolamine (2-aminoethanol), an important water-soluble base of phospholipid (phosphatidylethanolamine).\" [GOC:ai]","metadata":null},{"id":"397d2784043445aca68ef1919c45c41e","type":"GO_TERM","name":"ethanolamine catabolic process","canonical_id":"go:GO:0046336","description":"\"The chemical reactions and pathways resulting in the breakdown of ethanolamine (2-aminoethanol), an important water-soluble base of phospholipid (phosphatidylethanolamine).\" [GOC:ai]","metadata":null},{"id":"6c36758d49bc4c53a7e8751f7fb7380a","type":"GO_TERM","name":"ethanolamine degradation polyhedral organelle","canonical_id":"go:GO:0031471","description":"\"An organelle found in bacteria consisting of a proteinaceous coat containing enzymes for the degradation of ethanolamine whose purpose is the protection of the rest of the cell from the toxic acetaldehyde product of the enzyme ethanolamine ammonia lyase.\" [GOC:js, PMID:11844753]","metadata":null},{"id":"d076637238864362ac7a270977146e90","type":"GO_TERM","name":"ethanolamine kinase activity","canonical_id":"go:GO:0004305","description":"\"Catalysis of the reaction: ATP + ethanolamine = ADP + 2 H+ + phosphoethanolamine.\" [EC:2.7.1.82, RHEA:13069]","metadata":null},{"id":"e1a2ff89ec1449a78474386e23316970","type":"GO_TERM","name":"ethanolamine metabolic process","canonical_id":"go:GO:0006580","description":"\"The chemical reactions and pathways involving ethanolamine (2-aminoethanol), an important water-soluble base of phospholipid (phosphatidylethanolamine).\" [ISBN:0192800981]","metadata":null},{"id":"bca2050a8a10447da7b43a8215ae6818","type":"GO_TERM","name":"ethanolamine oxidase activity","canonical_id":"go:GO:0047883","description":"\"Catalysis of the reaction: ethanolamine + O2 + H2O = glycolaldehyde + H2O2 + NH4+.\" [RHEA:18581]","metadata":null},{"id":"4bfcec70a8d849a08bcb33c11e33d04d","type":"GO_TERM","name":"ethanolamine transmembrane transporter activity","canonical_id":"go:GO:0034228","description":"\"Enables the transfer of ethanolamine from one side of a membrane to the other. Ethanolamine (2-aminoethanol, monoethanolamine) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids, such as phosphatidylethanolamine.\" [GOC:rn, PMID:3514579]","metadata":null},{"id":"901a0e941ec143eeb9e6aaa5f1274348","type":"GO_TERM","name":"ethanolamine transport","canonical_id":"go:GO:0034229","description":"\"The directed movement of ethanolamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Ethanolamine (2-aminoethanol, monoethanolamine) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids, such as phosphatidylethanolamine.\" [GOC:rn, PMID:3514579]","metadata":null},{"id":"11cee4bd27da4763a0e4252b8266639c","type":"GO_TERM","name":"ethanolamine-phosphate cytidylyltransferase activity","canonical_id":"go:GO:0004306","description":"\"Catalysis of the reaction: CTP + ethanolamine phosphate = diphosphate + CDP-ethanolamine.\" [EC:2.7.7.14]","metadata":null},{"id":"569d4741c68f43bf9f88df56290cc058","type":"GO_TERM","name":"ethanolamine-phosphate phospho-lyase activity","canonical_id":"go:GO:0050459","description":"\"Catalysis of the reaction: H2O + phosphoethanolamine = acetaldehyde + NH4 + phosphate.\" [EC:4.2.3.2, RHEA:17889]","metadata":null},{"id":"167faf8b42004c78b684e891931c0730","type":"GO_TERM","name":"ethanolaminephosphotransferase activity","canonical_id":"go:GO:0004307","description":"\"Catalysis of the reaction: CDP-ethanolamine + 1,2-diacylglycerol = CMP + a phosphatidylethanolamine.\" [EC:2.7.8.1, RHEA:32943]","metadata":null},{"id":"d571ebfa35974528bedcc49d86de0ae6","type":"GO_TERM","name":"ether biosynthetic process","canonical_id":"go:GO:1901503","description":"\"The chemical reactions and pathways resulting in the formation of ether.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"1c8bf8336c924defbcebd621593090e7","type":"GO_TERM","name":"ether catabolic process","canonical_id":"go:GO:1901502","description":"\"The chemical reactions and pathways resulting in the breakdown of ether.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"df9c82dd5142494988dc651419b84bc5","type":"GO_TERM","name":"ether hydrolase activity","canonical_id":"go:GO:0016803","description":"\"Catalysis of the hydrolysis of an ether bond, -O-.\" [EC:3.3.2.-, GOC:ai]","metadata":null},{"id":"ae64c54bbeec483987f204412a3abf40","type":"GO_TERM","name":"ether lipid biosynthetic process","canonical_id":"go:GO:0008611","description":"\"The chemical reactions and pathways resulting in the formation of ether lipids, lipids that contain (normally) one lipid alcohol in ether linkage to one of the carbon atoms (normally C-1) of glycerol.\" [GOC:ma, ISBN:0198547684, PMID:15337120]","metadata":null},{"id":"c957f7e7295a4ac5be47db834d60e254","type":"GO_TERM","name":"ether lipid metabolic process","canonical_id":"go:GO:0046485","description":"\"The chemical reactions and pathways involving ether lipids, lipids that contain (normally) one lipid alcohol in ether linkage to one of the carbon atoms (normally C-1) of glycerol.\" [ISBN:0198506732, PMID:15337120]","metadata":null},{"id":"688b7d71dcc847f2876f3e1cc849efa6","type":"DRUG","name":"ethinylestradiol","canonical_id":"gtopdb:7071","description":null,"metadata":null},{"id":"8c49139c6efa45db9984344a1022c193","type":"COMBINATION_TREATMENT","name":"ethinylestradiol + levonorgestrel + ulipristal acetate","canonical_id":"ctgov_combo:ctgov-combo-6f14467259866fa4","description":null,"metadata":null},{"id":"397e548699bf427f8b1256e34f85fd2d","type":"DRUG","name":"ethotoin","canonical_id":"mesh:C084606","description":null,"metadata":null},{"id":"580ae2747f684b4caad44672e0eb9ab4","type":"DRUG","name":"ethoxzolamide","canonical_id":"gtopdb:6814","description":null,"metadata":null},{"id":"c372030f7c9343b7aff011de6aa88d2c","type":"DRUG","name":"ethoxzolamide","canonical_id":"chembl:CHEMBL18","description":null,"metadata":null},{"id":"83a04d1af3e84c89939ab677a057fa18","type":"GO_TERM","name":"ethyl acetate biosynthetic process","canonical_id":"go:GO:1902819","description":"\"The chemical reactions and pathways resulting in the formation of ethyl acetate.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:16013377]","metadata":null},{"id":"80a3270eecce4358857fc70c484140d6","type":"GO_TERM","name":"ethylbenzene catabolic process","canonical_id":"go:GO:0018915","description":"\"The chemical reactions and pathways resulting in the breakdown of ethylbenzene (phenylethane), a benzene derivative with an ethyl group attached to the ring. It is a colorless liquid with a pungent odor used as a solvent and as a component of automotive and aviation fuels.\" [PMID:8795196]","metadata":null},{"id":"11bf5d79600b47b0917f16581a87649c","type":"GO_TERM","name":"ethylbenzene hydroxylase activity","canonical_id":"go:GO:0018693","description":"\"Catalysis of the reaction: A + ethylbenzene + H2O = (S)-1-phenylethanol + AH(2).\" [EC:1.17.99.2, RHEA:17897]","metadata":null},{"id":"a920808a906343b99b023852eb8ae359","type":"GO_TERM","name":"ethylene binding","canonical_id":"go:GO:0051740","description":"\"Binding to ethylene (C2-H4, ethene), a simple hydrocarbon gas that can function in plants as a growth regulator.\" [GOC:ai]","metadata":null},{"id":"a4bbbc17aa0543d49b6f1170d94528e8","type":"GO_TERM","name":"ethylene biosynthetic process","canonical_id":"go:GO:0009693","description":"\"The chemical reactions and pathways resulting in the formation of ethylene (C2-H4, ethene), a simple hydrocarbon gas that can function in plants as a growth regulator.\" [ISBN:0387969845]","metadata":null},{"id":"8512edab5f04496eaff629d93acaf027","type":"GO_TERM","name":"ethylene catabolic process","canonical_id":"go:GO:0042457","description":"\"The chemical reactions and pathways resulting in the breakdown of ethylene (C2-H4, ethene), a simple hydrocarbon gas that can function in plants as a growth regulator.\" [GOC:jl, ISBN:0387969845]","metadata":null},{"id":"04d9596f8f3d4b909c27a4c06fb535d7","type":"GO_TERM","name":"ethylene metabolic process","canonical_id":"go:GO:0009692","description":"\"The chemical reactions and pathways involving ethylene (C2-H4, ethene), a simple hydrocarbon gas that can function in plants as a growth regulator.\" [ISBN:0387969845]","metadata":null},{"id":"d46c03b774384a82a9f836cc8f31a362","type":"GO_TERM","name":"ethylene receptor activity","canonical_id":"go:GO:0038199","description":"\"Combining with ethylene and transmitting the signal in the cell to initiate a change in cell activity.\" [GOC:signaling, PMID:22467798, PMID:24012247]","metadata":null},{"id":"5f92f840b9d44eb3be3cc2d01cd7e6d6","type":"GO_TERM","name":"ethylene receptor histidine kinase activity","canonical_id":"go:GO:0038200","description":"\"Combining with ethylene and transmitting the signal within the cell to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-histidine = ADP + a protein-L-histidine phosphate.\" [GOC:signaling, PMID:22467798]","metadata":null},{"id":"1321596d0f3e440684059f1ca25a0458","type":"GO_TERM","name":"ethylene-activated signaling pathway","canonical_id":"go:GO:0009873","description":"\"The series of molecular signals generated by the reception of ethylene (ethene, C2H4) by a receptor and ending with modulation of a cellular process, e.g. transcription.\" [GOC:jy, PMID:24012247]","metadata":null},{"id":"d15a7d23c8924956b3a6ba2f9cb45080","type":"DRUG","name":"ethylestrenol","canonical_id":"gtopdb:6948","description":null,"metadata":null},{"id":"6b8a448da61b458198200640d7cced61","type":"DRUG","name":"ethylestrenol","canonical_id":"chembl:CHEMBL1200623","description":null,"metadata":null},{"id":"7427140bd0b44fbbb13698f11ef4b488","type":"DRUG","name":"etidronic acid","canonical_id":"mesh:D012968","description":null,"metadata":null},{"id":"94da7bc335d84b28a6935531d346651a","type":"GO_TERM","name":"etioplast","canonical_id":"go:GO:0009513","description":"\"A plastid arrested in the development of chloroplasts from proplastids due to absence of light or low light conditions.\" [ISBN:0943088399]","metadata":null},{"id":"e4b0da20dd374a88a7b7ed9ba2c8ace9","type":"GO_TERM","name":"etioplast envelope","canonical_id":"go:GO:0034425","description":"\"The double lipid bilayer enclosing the etioplast and separating its contents from the rest of the cytoplasm; includes the intermembrane space.\" [GOC:mah]","metadata":null},{"id":"d5e833b31abc4764952751bf4a88337e","type":"GO_TERM","name":"etioplast membrane","canonical_id":"go:GO:0034426","description":"\"Either of the lipid bilayers that surround a etioplast and form the etioplast envelope.\" [GOC:rph]","metadata":null},{"id":"98a6560902bc404996bcb96f9cd90a6e","type":"GO_TERM","name":"etioplast organization","canonical_id":"go:GO:0009662","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an etioplast. An etioplast is a plastid arrested in the development of chloroplasts from proplastids due to absence of light or low light conditions.\" [GOC:jid]","metadata":null},{"id":"a118b4bf2eeb4817aee3d9c78cf71b28","type":"GO_TERM","name":"etioplast prolamellar body","canonical_id":"go:GO:0009541","description":"\"A three dimensional regular lattice found in etioplasts. It is composed of a continuous system of tubules but when exposed to light the symmetrical arrangement is rapidly lost as tubules become pinched off into two dimensional sections of lattice. These for perforated sheets of membrane that move apart, extend and increase, finally establishing the typical granal and intergranal lamellae of the mature chloroplast.\" [ISBN:0140514031]","metadata":null},{"id":"e7baad8200184ae6b03f5b2af9ec6658","type":"GO_TERM","name":"etioplast stroma","canonical_id":"go:GO:0009578","description":"\"The space enclosed by the double membrane of an etioplast but excluding the prothylakoid space. It contains the etioplast DNA.\" [GOC:jl]","metadata":null},{"id":"324b380bb38a4014bb8ac3ed8ffafb97","type":"DRUG","name":"etizolam","canonical_id":"mesh:C044610","description":null,"metadata":null},{"id":"36c7ba7ff86f4bd3ba0b7084a18a6d4d","type":"DRUG","name":"etodolac","canonical_id":"gtopdb:7185","description":null,"metadata":null},{"id":"043ac66265894d09a937c1ec0a03332b","type":"DRUG","name":"etodolac","canonical_id":"mesh:D017308","description":null,"metadata":null},{"id":"aa7f7c08967f45a7bcb97c85f5449f61","type":"DRUG","name":"etodolac","canonical_id":"chembl:CHEMBL622","description":null,"metadata":null},{"id":"184ddcaa7730428199a76821acf3b341","type":"COMBINATION_TREATMENT","name":"etodolac + meloxicam","canonical_id":"ctgov_combo:ctgov-combo-3cc4580ca1cc3d90","description":null,"metadata":null},{"id":"d01cbf5bbc5843ab8d42fc1495e605e3","type":"COMBINATION_TREATMENT","name":"etodolac + propranolol","canonical_id":"ctgov_combo:ctgov-combo-5e6f4aa2001cbc3a","description":null,"metadata":null},{"id":"8fa604eb0c14425b824b5b54f91e1bdb","type":"COMBINATION_TREATMENT","name":"etodolac + propranolol","canonical_id":"ctgov_combo:ctgov-combo-4ab1839f86fdfe15","description":null,"metadata":null},{"id":"1dc868eea8514c97888455b8facaca12","type":"DRUG","name":"etofenamate","canonical_id":"mesh:C015207","description":null,"metadata":null},{"id":"00816733ade44322a1c8730c5e0445a5","type":"DRUG","name":"etoposide","canonical_id":"gtopdb:6815","description":null,"metadata":null},{"id":"94bdc49ce57a427db684dc10dd7d9cd4","type":"DRUG","name":"etoposide","canonical_id":"mesh:D005047","description":null,"metadata":null},{"id":"97ff90b30ba349fe9dfba3ba60532bc7","type":"DRUG","name":"etoposide","canonical_id":"chembl:CHEMBL44657","description":null,"metadata":null},{"id":"48d97bd0419945deb136955d107a52af","type":"COMBINATION_TREATMENT","name":"etoposide + fludarabine","canonical_id":"ctgov_combo:ctgov-combo-928e00f5adb64a8a","description":null,"metadata":null},{"id":"5c5b7cdd27174815856f8897758913d3","type":"COMBINATION_TREATMENT","name":"etoposide + fludarabine + methotrexate + sirolimus + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-ab5feac8ff434265","description":null,"metadata":null},{"id":"4c0653574dfd4b46b0fc05285ed79746","type":"COMBINATION_TREATMENT","name":"etoposide + fludarabine + mycophenolate mofetil + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-bd14780b05092ab7","description":null,"metadata":null},{"id":"551ba5f929c7464089cc3a0e36ad4404","type":"COMBINATION_TREATMENT","name":"etoposide + irinotecan + vincristine","canonical_id":"ctgov_combo:ctgov-combo-6b2f2dc1dd996a0d","description":null,"metadata":null},{"id":"f455472d3d3f4d05a7039d40e84d64c0","type":"COMBINATION_TREATMENT","name":"etoposide + methotrexate","canonical_id":"ctgov_combo:ctgov-combo-3e3807b55e79c69b","description":null,"metadata":null},{"id":"9febb88372ff47a7a7cfe9cd6ad69267","type":"COMBINATION_TREATMENT","name":"etoposide + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-099256ea5cd529f5","description":null,"metadata":null},{"id":"6c3b0241381d497fbc42d98455ae68f0","type":"COMBINATION_TREATMENT","name":"etoposide + prednisone + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-46bc0d645f9a6151","description":null,"metadata":null},{"id":"689411fb6f124319b0e7b5a35d33a50c","type":"COMBINATION_TREATMENT","name":"etoposide + prednisone + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-75005148e3905247","description":null,"metadata":null},{"id":"c51b1b91b9bb4708ba2d843db02fe1ec","type":"COMBINATION_TREATMENT","name":"etoposide + prednisone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-dd71cc3e77619ec9","description":null,"metadata":null},{"id":"07fee9cb3c994ab8b6b4afa63158e873","type":"COMBINATION_TREATMENT","name":"etoposide + rituximab + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-31e6868184ed3f68","description":null,"metadata":null},{"id":"7cd4cd709eaa43819037b27d1d03dfed","type":"COMBINATION_TREATMENT","name":"etoposide + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-d8c68b9e89612bfb","description":null,"metadata":null},{"id":"b2836c38812d414799fe1ed590686ce3","type":"COMBINATION_TREATMENT","name":"etoposide + vincristine","canonical_id":"ctgov_combo:ctgov-combo-e59f07b3cf93c05e","description":null,"metadata":null},{"id":"781883673522461fa9cfd74a65c58aec","type":"COMBINATION_TREATMENT","name":"etoposide + vincristine","canonical_id":"ctgov_combo:ctgov-combo-26d5e2deaa3f1c02","description":null,"metadata":null},{"id":"0cb57481fc9044f5a4f94f62878ce9ac","type":"COMBINATION_TREATMENT","name":"etoposide + vincristine","canonical_id":"ctgov_combo:ctgov-combo-b6d5310a4562ca0b","description":null,"metadata":null},{"id":"555d7a56855e4e258643330ecd2f7423","type":"COMBINATION_TREATMENT","name":"etoposide + vincristine","canonical_id":"ctgov_combo:ctgov-combo-f2a15965f9b1673b","description":null,"metadata":null},{"id":"27ceea96902c43fe90e58bbb224d1ddc","type":"DRUG","name":"etoricoxib","canonical_id":"gtopdb:2896","description":null,"metadata":null},{"id":"e97bac1b9d004c80ae4a38661dbb8a70","type":"DRUG","name":"etoricoxib","canonical_id":"chembl:CHEMBL416146","description":null,"metadata":null},{"id":"4df3b03be4f94947b02d408877f1b11a","type":"COMBINATION_TREATMENT","name":"etoricoxib + meloxicam","canonical_id":"ctgov_combo:ctgov-combo-75e84805fd2611e6","description":null,"metadata":null},{"id":"42b17d700288421487f504e71597f8a1","type":"COMBINATION_TREATMENT","name":"etoricoxib + valdecoxib","canonical_id":"ctgov_combo:ctgov-combo-b2d4489f9862c87a","description":null,"metadata":null},{"id":"a3ba96c3744a4a698e055a8cb0096fba","type":"DRUG","name":"etrasimod","canonical_id":"gtopdb:9331","description":null,"metadata":null},{"id":"94f17a83853047fb9dfb96c5530cedc5","type":"DRUG","name":"etrasimod","canonical_id":"chembl:CHEMBL3358920","description":null,"metadata":null},{"id":"6e2d18c660ad4787b10eec3a2e63b058","type":"COMBINATION_TREATMENT","name":"etrasimod + mesalazine","canonical_id":"ctgov_combo:ctgov-combo-837890e311b25df9","description":null,"metadata":null},{"id":"6ff822ee746148fd970e67b9bad4657c","type":"GO_TERM","name":"euchromatin","canonical_id":"go:GO:0000791","description":"\"A dispersed and relatively uncompacted form of chromatin that is in a transcription-competent conformation.\" [PMID:32017156]","metadata":null},{"id":"c6725e5aff254b40abc2d1da70d36660","type":"GO_TERM","name":"euchromatin binding","canonical_id":"go:GO:1990188","description":"\"Binding to euchromatin, a dispersed and relatively uncompacted form of chromatin.\" [GOC:vw, PMID:22431512]","metadata":null},{"id":"6a8575760b1843699d8bdb8031f41de8","type":"GO_TERM","name":"euchromatin-nuclear membrane anchor activity","canonical_id":"go:GO:0062240","description":"\"Binding to euchromatin and the nuclear inner membrane, in order to establish and maintain the euchromatin location and organization.\" [PMID:31635174]","metadata":null},{"id":"5c375b091cdd4ad18331212d5ee023a1","type":"GO_TERM","name":"eugenol biosynthetic process","canonical_id":"go:GO:0042855","description":"\"The chemical reactions and pathways resulting in the formation of eugenol, a colorless, aromatic, liquid hydrocarbon (C10H12O2) found in clove oil.\" [GOC:jl]","metadata":null},{"id":"250466b2d26341fc95ff097ff4874e2f","type":"GO_TERM","name":"eugenol catabolic process","canonical_id":"go:GO:0042856","description":"\"The chemical reactions and pathways resulting in the breakdown of eugenol, a colorless, aromatic, liquid hydrocarbon (C10H12O2) found in clove oil.\" [GOC:jl]","metadata":null},{"id":"cb2b0d64399a48b89e9b1dc0306519c2","type":"GO_TERM","name":"eugenol metabolic process","canonical_id":"go:GO:0042854","description":"\"The chemical reactions and pathways involving eugenol, a colorless, aromatic, liquid hydrocarbon (C10H12O2) found in clove oil.\" [GOC:jl]","metadata":null},{"id":"255edc4fd3814e84ace5baa8139f037d","type":"GO_TERM","name":"eukaryotic 43S preinitiation complex","canonical_id":"go:GO:0016282","description":"\"A protein complex composed of the 40S ribosomal subunit plus eIF1, eIF1A, eIF3, eIF5, and eIF2-GTP-bound methionyl-initiator methionine tRNA.\" [GOC:hjd, PMID:15145049, PMID:16510876, PMID:25742741, PMID:29735639]","metadata":null},{"id":"97c310dd78bc46bba4d89a4641d5aefe","type":"GO_TERM","name":"eukaryotic 48S preinitiation complex","canonical_id":"go:GO:0033290","description":"\"The protein-ribosome-tRNA complex that has just recognized the start codon of a capped mRNA. It is composed of the small ribosomal subunit, eukaryote initiation factors (eIF) eIF3 complex, eIF1, eIF1A, eIF2-GDP, eIF4 complex and initiatior-methionine-tRNA. Recognition of the start codon triggers downstream steps in the pathway, including eIF1 dissociation; Pi release from eIF2; and conversion to the closed, scanning-arrested conformation of the PIC.\" [GOC:hjd, PMID:16510876, PMID:24319994, PMID:24499181, PMID:29735639]","metadata":null},{"id":"aad0da262d5b46b29e27aeb37f224bfb","type":"GO_TERM","name":"eukaryotic 80S initiation complex","canonical_id":"go:GO:0033291","description":"\"A protein complex composed of the large and small ribosomal subunits, methionyl-initiatior tRNA, and the capped mRNA. The initiator tRNA is positioned at the ribosomal P site at the AUG codon corresponding to the beginning of the coding region.\" [GOC:hjd, PMID:15145049]","metadata":null},{"id":"f779ad702d274abaa391adc21d112a37","type":"GO_TERM","name":"eukaryotic elongation factor-2 kinase activator activity","canonical_id":"go:GO:0042557","description":"\"Binds to and increases the activity of the enzyme eukaryotic elongation factor-2 kinase.\" [GOC:jl, PMID:11904175]","metadata":null},{"id":"59fe516849f84888b956e533cb8b42e7","type":"GO_TERM","name":"eukaryotic elongation factor-2 kinase regulator activity","canonical_id":"go:GO:0042556","description":"\"Modulates the activity of the enzyme eukaryotic elongation factor-2 kinase.\" [GOC:jl, PMID:11904175]","metadata":null},{"id":"fa53ffcef55c4ee7bf0d3af7d6089802","type":"GO_TERM","name":"eukaryotic initiation factor 4E binding","canonical_id":"go:GO:0008190","description":"\"Binding to eukaryotic initiation factor 4E, a polypeptide factor involved in the initiation of ribosome-mediated translation.\" [ISBN:0198506732]","metadata":null},{"id":"c35b91afc0444e87b8271f940e1be38f","type":"GO_TERM","name":"eukaryotic initiation factor 4G binding","canonical_id":"go:GO:0031370","description":"\"Binding to eukaryotic initiation factor 4G, a polypeptide factor involved in the initiation of ribosome-mediated translation.\" [GOC:mah]","metadata":null},{"id":"7ee78b41132248ae85fb0bfe29be5236","type":"GO_TERM","name":"eukaryotic initiation factor eIF2 binding","canonical_id":"go:GO:0071074","description":"\"Binding to eukaryotic initiation factor eIF2, a protein complex involved in the initiation of ribosome-mediated translation.\" [GOC:hjd]","metadata":null},{"id":"370ba1d8c58f4e959982fa9bf7e08578","type":"GO_TERM","name":"eukaryotic translation elongation factor 1 complex","canonical_id":"go:GO:0005853","description":"\"A multisubunit nucleotide exchange complex that binds GTP and aminoacyl-tRNAs, and catalyzes their codon-dependent placement at the A-site of the ribosome. In humans, the complex is composed of four subunits, alpha, beta, delta and gamma.\" [GOC:jl, PMID:10216950]","metadata":null},{"id":"df767c4cdbe34057a2dbc3ff4bf51676","type":"GO_TERM","name":"eukaryotic translation initiation factor 2 complex","canonical_id":"go:GO:0005850","description":"\"Complex of three heterogeneous polypeptide chains, that form a ternary complex with initiator methionyl-tRNA and GTP. This ternary complex binds to free 40S subunit, which subsequently binds the 5' end of mRNA.\" [PMID:10216940]","metadata":null},{"id":"3644d3867e9846988fe86a7c25f10ddd","type":"GO_TERM","name":"eukaryotic translation initiation factor 2 complex assembly","canonical_id":"go:GO:1905143","description":"\"The aggregation, arrangement and bonding together of a set of components to form an eukaryotic translation initiation factor 2 complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:23775072]","metadata":null},{"id":"497d6a6aebc24ef0abc8ff95c5e8ad7a","type":"GO_TERM","name":"eukaryotic translation initiation factor 2B complex","canonical_id":"go:GO:0005851","description":"\"A multisubunit guanine nucleotide exchange factor which catalyzes the exchange of GDP bound to initiation factor eIF2 for GTP, generating active eIF2-GTP. In humans, it is composed of five subunits, alpha, beta, delta, gamma and epsilon.\" [PMID:9438375]","metadata":null},{"id":"8423993b6b004423911be53e7f6274f1","type":"GO_TERM","name":"eukaryotic translation initiation factor 2B complex assembly","canonical_id":"go:GO:1905173","description":"\"The aggregation, arrangement and bonding together of a set of components to form an eukaryotic translation initiation factor 2B complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:27023709]","metadata":null},{"id":"06a147207637420ebd024e9a1a71ab91","type":"GO_TERM","name":"eukaryotic translation initiation factor 2alpha kinase activity","canonical_id":"go:GO:0004694","description":"\"Catalysis of the reaction: ATP + [eukaryotic translation initiation factor 2 alpha subunit] = ADP + [eukaryotic translation initiation factor 2 alpha subunit] phosphate.\" [GOC:mah, InterPro:IPR015516]","metadata":null},{"id":"c33ed55a621e4233833fe64a63dbd720","type":"GO_TERM","name":"eukaryotic translation initiation factor 3 complex","canonical_id":"go:GO:0005852","description":"\"A complex of several polypeptides that plays at least two important roles in protein synthesis: First, eIF3 binds to the 40S ribosome and facilitates loading of the Met-tRNA/eIF2.GTP ternary complex to form the 43S preinitiation complex. Subsequently, eIF3 apparently assists eIF4 in recruiting mRNAs to the 43S complex. The eIF3 complex contains five conserved core subunits, and may contain several additional proteins; the non-core subunits are thought to mediate association of the complex with specific sets of mRNAs.\" [PMID:15904532]","metadata":null},{"id":"d27f9ce4bc794818ae62404b9654b628","type":"GO_TERM","name":"eukaryotic translation initiation factor 3 complex assembly","canonical_id":"go:GO:0070196","description":"\"The aggregation, arrangement and bonding together of a set of components to form the eukaryotic translation initiation factor 3 complex.\" [GOC:mah]","metadata":null},{"id":"964c056509414e349446f7ed3c992935","type":"GO_TERM","name":"eukaryotic translation initiation factor 3 complex, eIF3e","canonical_id":"go:GO:0071540","description":"\"An eukaryotic translation initiation factor 3 complex that contains the PCI-domain protein eIF3e.\" [PMID:15904532, PMID:19061185]","metadata":null},{"id":"8d246c3d3d5d41969154f9ca16737856","type":"GO_TERM","name":"eukaryotic translation initiation factor 3 complex, eIF3m","canonical_id":"go:GO:0071541","description":"\"An eukaryotic translation initiation factor 3 complex that contains the PCI-domain protein eIF3m.\" [PMID:15904532, PMID:19061185]","metadata":null},{"id":"2b98c346f2554030a76244ac58505adc","type":"GO_TERM","name":"eukaryotic translation initiation factor 4F complex","canonical_id":"go:GO:0016281","description":"\"The eukaryotic translation initiation factor 4F complex is composed of eIF4E, eIF4A and eIF4G; it is involved in the recognition of the mRNA cap, ATP-dependent unwinding of the 5'-terminal secondary structure and recruitment of the mRNA to the ribosome.\" [GOC:hb, PMID:32883864, PMID:8449919]","metadata":null},{"id":"12a753b5c690427b89a525f6b82490bc","type":"GO_TERM","name":"eukaryotic translation initiation factor 4F complex assembly","canonical_id":"go:GO:0097010","description":"\"The aggregation, arrangement and bonding together of a set of components to form the eukaryotic translation initiation factor 4F complex.\" [GOC:BHF, GOC:ebc, PMID:18337562]","metadata":null},{"id":"04e7a9f5d07d4ef3bcca8abcf4662603","type":"GO_TERM","name":"eupatolide synthase activity","canonical_id":"go:GO:0106244","description":"\"Catalysis of the reaction: 8beta-hydroxygermacra-1(10),4,11(13)-trien-12-oate + O2 + reduced [NADPH--hemoprotein reductase] = eupatolide + 2 H2O + oxidized [NADPH--hemoprotein reductase].\" [GOC:eab, PMID:29758164, RHEA:57972]","metadata":null},{"id":"6a07326e5b3b4ef0a743b8a0d2534ddc","type":"GO_TERM","name":"eurydendroid cell differentiation","canonical_id":"go:GO:0021755","description":"\"The process in which neuroblasts acquire specialized structural and/or functional features that characterize the mature eurydendroid cell. Differentiation includes the processes involved in commitment of a neuroblast to a eurydendroid cell fate. A eurydendroid cell is an efferent neuron found in the cerebellar cortex of teleosts.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15892096]","metadata":null},{"id":"cb958131b024477c988b1b1b74d1ce97","type":"DRUG","name":"everolimus","canonical_id":"gtopdb:5889","description":null,"metadata":null},{"id":"053f612e854749f2abf9d80f0b041649","type":"DRUG","name":"everolimus","canonical_id":"mesh:D000068338","description":null,"metadata":null},{"id":"9981bf237b214fb3ba63bc62b0964006","type":"DRUG","name":"everolimus","canonical_id":"chembl:CHEMBL1908360","description":null,"metadata":null},{"id":"2c37d210a59048dfa4d6158e87f1a04a","type":"COMBINATION_TREATMENT","name":"everolimus + exemestane + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-b2eed228ad1b4346","description":null,"metadata":null},{"id":"053ddf6920614ca490bab1b8c4503b47","type":"COMBINATION_TREATMENT","name":"everolimus + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-c0d6e4563f81c293","description":null,"metadata":null},{"id":"1fb728bb12294b0a88fff3dc3eee698b","type":"COMBINATION_TREATMENT","name":"everolimus + gemcitabine","canonical_id":"ctgov_combo:ctgov-combo-88a8d41d6a90d403","description":null,"metadata":null},{"id":"faba68075e524f648dbc6a01fd3e34ff","type":"COMBINATION_TREATMENT","name":"everolimus + irinotecan + pazopanib + temsirolimus + vincristine","canonical_id":"ctgov_combo:ctgov-combo-e1198e4030ef7acd","description":null,"metadata":null},{"id":"8f82fdfb0acd42e18971c9a2358c228d","type":"COMBINATION_TREATMENT","name":"everolimus + lenvatinib","canonical_id":"ctgov_combo:ctgov-combo-04c9b0eb50911981","description":null,"metadata":null},{"id":"73390e73f6cb446d98d0f1b4a96619c8","type":"COMBINATION_TREATMENT","name":"everolimus + methotrexate + prednisone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-318e7e042d735dda","description":null,"metadata":null},{"id":"74195277da054e6a980b5229fefc7583","type":"COMBINATION_TREATMENT","name":"everolimus + mycophenolic acid + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-f96633a26c69b613","description":null,"metadata":null},{"id":"6fcd5c9378094c249ea8de740d7d5e23","type":"COMBINATION_TREATMENT","name":"everolimus + pasireotide","canonical_id":"ctgov_combo:ctgov-combo-880c3ae57de4f4d5","description":null,"metadata":null},{"id":"049f8f3d1c03451eba7406476eb7d386","type":"COMBINATION_TREATMENT","name":"everolimus + pasireotide","canonical_id":"ctgov_combo:ctgov-combo-250a9475028a291d","description":null,"metadata":null},{"id":"10e8171c51fc4bcf947e778f56b2d725","type":"COMBINATION_TREATMENT","name":"everolimus + pasireotide","canonical_id":"ctgov_combo:ctgov-combo-66a170f769d5f398","description":null,"metadata":null},{"id":"8353a49f1451415cb1eadc8c0968a537","type":"COMBINATION_TREATMENT","name":"everolimus + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-19ee96a8c58674fe","description":null,"metadata":null},{"id":"c056a8c7662f480ab7a03c3981d6caed","type":"COMBINATION_TREATMENT","name":"everolimus + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-c45c1ee8a13c497f","description":null,"metadata":null},{"id":"0b37b760b8ef496c968e8a401da99f0e","type":"COMBINATION_TREATMENT","name":"everolimus + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-e1771e85c1ff3615","description":null,"metadata":null},{"id":"f7c8401148f2483c9b35277ad5fe8242","type":"COMBINATION_TREATMENT","name":"everolimus + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-afd1a91a86bb2768","description":null,"metadata":null},{"id":"a516ff73aac743f3a7cd57856f755283","type":"COMBINATION_TREATMENT","name":"everolimus + vandetanib","canonical_id":"ctgov_combo:ctgov-combo-97f0eb14883db361","description":null,"metadata":null},{"id":"81aed32192d948bb906df740917fe97d","type":"DRUG","name":"evinacumab","canonical_id":"gtopdb:8717","description":null,"metadata":null},{"id":"245d4ae0922545de9451caa3ec40aba1","type":"DRUG","name":"evinacumab","canonical_id":"chembl:CHEMBL3545191","description":null,"metadata":null},{"id":"196650a22c534011820b9649e3198e67","type":"DRUG","name":"evocalcet","canonical_id":"gtopdb:9042","description":null,"metadata":null},{"id":"cb922f0bcb3b46f3abd9bb0c37e3e054","type":"DRUG","name":"evocalcet","canonical_id":"chembl:CHEMBL4297621","description":null,"metadata":null},{"id":"86f93a3176d3403b910beadaed7720b5","type":"DRUG","name":"evogliptin","canonical_id":"mesh:C557982","description":null,"metadata":null},{"id":"ba178e01c6304d1d99a320aef7445f46","type":"GO_TERM","name":"evoked excitatory postsynaptic potential","canonical_id":"go:GO:0098817","description":"\"A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell induced by the evoked release of many vesicles of excitatory neurotransmitter at the synapse.\" [GOC:dos]","metadata":null},{"id":"ad5f52e74734438dbff88511965e3f40","type":"GO_TERM","name":"evoked neurotransmitter secretion","canonical_id":"go:GO:0061670","description":"\"Neurotransmitter secretion that occurs in the presence of the action of a secretagogue or a presynaptic action potential.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:21334193]","metadata":null},{"id":"f5093ef4346f4c628df5b94ee6f819c7","type":"DRUG","name":"evolocumab","canonical_id":"gtopdb:7343","description":null,"metadata":null},{"id":"be27691359244b5c94600144e0aae0fc","type":"DRUG","name":"evolocumab","canonical_id":"chembl:CHEMBL2364655","description":null,"metadata":null},{"id":"01750098163a4a2590f88ae7f9265154","type":"COMBINATION_TREATMENT","name":"evolocumab + ezetimibe","canonical_id":"ctgov_combo:ctgov-combo-961a01de74234d93","description":null,"metadata":null},{"id":"c5b45cfaa60c4e7692bd690ae2b735b9","type":"COMBINATION_TREATMENT","name":"evolocumab + ezetimibe","canonical_id":"ctgov_combo:ctgov-combo-fb63c0c8a2224141","description":null,"metadata":null},{"id":"d129de2033e94b0397b4a7ff685ef529","type":"COMBINATION_TREATMENT","name":"evolocumab + ezetimibe","canonical_id":"ctgov_combo:ctgov-combo-4fd860fc56f028c0","description":null,"metadata":null},{"id":"a6b7f9cd760040dbba55b0dff42e2a49","type":"COMBINATION_TREATMENT","name":"evolocumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-9231099adc605399","description":null,"metadata":null},{"id":"653dcf93f5a74801ae0bc9c2249888e1","type":"DISEASE","name":"exanthem","canonical_id":"mondo:0006547","description":null,"metadata":null},{"id":"a21731227e7c475f9fc047ba72c68bb8","type":"GO_TERM","name":"excinuclease ABC activity","canonical_id":"go:GO:0009381","description":"\"Catalysis of the hydrolysis of ester linkages within deoxyribonucleic acid at sites flanking regions of damaged DNA to which the Uvr ABC excinuclease complexes bind.\" [GOC:mah, PMID:15192705]","metadata":null},{"id":"53c78ac35b0f452581188edf695806c7","type":"GO_TERM","name":"excinuclease repair complex","canonical_id":"go:GO:0009380","description":"\"Any of the protein complexes formed by the UvrABC excinuclease system, which carries out nucleotide excision repair. Three different complexes are formed by the 3 proteins as they proceed through the excision repair process. First a complex consisting of two A subunits and two B subunits bind DNA and unwind it around the damaged site. Then, the A subunits disassociate leaving behind a stable complex between B subunits and DNA. Now, subunit C binds to this B+DNA complex and causes subunit B to nick the DNA on one side of the complex while subunit C nicks the DNA on the other side of the complex. DNA polymerase I and DNA ligase can then repair the resulting gap.\" [GOC:mah, GOC:mlg, PMID:12145219, PMID:15192705]","metadata":null},{"id":"a0b6e405bea94317b1c8c2f65cbc69c6","type":"GO_TERM","name":"excitation of vasomotor center by aortic body chemoreceptor signaling","canonical_id":"go:GO:0003040","description":"\"The process in which the molecular signal from an aortic body is relayed to the vasomotor center, causing it to signal an increase arterial pressure.\" [GOC:mtg_cardio]","metadata":null},{"id":"05016179c8824a8da095c6c98a187a49","type":"GO_TERM","name":"excitation of vasomotor center by baroreceptor signaling","canonical_id":"go:GO:0002010","description":"\"The process in which the molecular signal from the arterial baroreceptors is relayed to the vasomotor center causing it to signal increase arterial pressure.\" [GOC:dph]","metadata":null},{"id":"9fd4994a0dcb424f94bd7103e1029ce0","type":"GO_TERM","name":"excitation of vasomotor center by carotid body chemoreceptor signaling","canonical_id":"go:GO:0003041","description":"\"The process in which the molecular signal from a carotid body is relayed to the vasomotor center, causing it to signal an increase arterial pressure.\" [GOC:mtg_cardio]","metadata":null},{"id":"601fba55969042948a54122b37914e94","type":"GO_TERM","name":"excitation of vasomotor center by chemoreceptor signaling","canonical_id":"go:GO:0002008","description":"\"The process in which the molecular signal from the carotid and aortic bodies is relayed to the vasomotor center, causing it to signal an increase arterial pressure.\" [GOC:dph]","metadata":null},{"id":"1f6f57cac9de4a56ae9625a111fa59f9","type":"GO_TERM","name":"excitatory chemical synaptic transmission","canonical_id":"go:GO:0098976","description":"\"Synaptic transmission that results in an excitatory postsynaptic potential.\" [GOC:dos]","metadata":null},{"id":"e65a985b3185430babcb8899e592e81c","type":"GO_TERM","name":"excitatory extracellular ligand-gated monoatomic ion channel activity","canonical_id":"go:GO:0005231","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific extracellular ligand has been bound by the channel complex or one of its constituent parts, where channel opening contributes to an increase in membrane potential.\" [GOC:mah, ISBN:0323037070]","metadata":null},{"id":"4eb2ecf9bf7f41f29f7b0f57139098b3","type":"GO_TERM","name":"excitatory neuromuscular junction","canonical_id":"go:GO:0098520","description":"\"The junction between the axon of a motor neuron and a muscle fiber. In response to the arrival of action potentials, the presynaptic button releases molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane of the muscle fiber, leading to a post-synaptic potential responsible for muscle contraction.\" [GOC:dos]","metadata":null},{"id":"00f2a814f7984c91a2fd6a421abf1d01","type":"GO_TERM","name":"excitatory neuromuscular junction of somatic myotube","canonical_id":"go:GO:0098525","description":"\"A neuromuscular junction that functions in the excitation of somatic muscle myotubes, such as an arthropod somatic muscle cells.\" [GOC:dos]","metadata":null},{"id":"5557a917512849b78612a496dc9a1029","type":"GO_TERM","name":"excitatory postsynaptic potential","canonical_id":"go:GO:0060079","description":"\"A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"42de5a6db9ca413aba2163c76201f839","type":"GO_TERM","name":"excitatory synapse","canonical_id":"go:GO:0060076","description":"\"A synapse in which an action potential in the presynaptic cell increases the probability of an action potential occurring in the postsynaptic cell.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"6b6f80c4d8e546c8adcd464f1e08ef97","type":"GO_TERM","name":"excitatory synapse assembly","canonical_id":"go:GO:1904861","description":"\"The aggregation, arrangement and bonding together of a set of components to form an excitatory synapse.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21670302]","metadata":null},{"id":"260f43cbad8648eb9fdf5eed5f0e64a7","type":"GO_TERM","name":"excitatory synapse pruning","canonical_id":"go:GO:1905805","description":"\"The disaggregation of an excitatory synapse into its constituent components.\" [GO_REF:0000079, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"10a732e2c23a40859be4c083bd12ce9c","type":"GO_TERM","name":"excretion","canonical_id":"go:GO:0007588","description":"\"The elimination by an organism of the waste products that arise as a result of metabolic activity. These products include water, carbon dioxide (CO2), and nitrogenous compounds.\" [ISBN:0192801023]","metadata":null},{"id":"cc193a397389402eb827fd5b27d53b4c","type":"GO_TERM","name":"execution phase of apoptosis","canonical_id":"go:GO:0097194","description":"\"A stage of the apoptotic process that starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules (e.g. cathepsins, calpains etc.). Key steps of the execution phase are rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.\" [GOC:mtg_apoptosis, PMID:21760595]","metadata":null},{"id":"2c331c3c59404e96b9f95c3813b663fb","type":"GO_TERM","name":"execution phase of necroptosis","canonical_id":"go:GO:0097528","description":"\"A stage of the necroptotic process that starts after a necroptotic signal has been relayed to the execution machinery. Key steps of the execution phase are swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. The execution phase ends when the cell has died.\" [GOC:mtg_apoptosis, PMID:20823910]","metadata":null},{"id":"3eaac0245d464d36af37745299c0f3a0","type":"DRUG","name":"exemestane","canonical_id":"gtopdb:7073","description":null,"metadata":null},{"id":"88f2b3578ac94eecb67d7814b0adeaf9","type":"DRUG","name":"exemestane","canonical_id":"chembl:CHEMBL1200374","description":null,"metadata":null},{"id":"409a6a40470349ada2fd9c4216dfe8ef","type":"COMBINATION_TREATMENT","name":"exemestane + fulvestrant","canonical_id":"ctgov_combo:ctgov-combo-d32d1699fbc4dbeb","description":null,"metadata":null},{"id":"ca3f72ef5bf64610abf89d6738f321e5","type":"COMBINATION_TREATMENT","name":"exemestane + goserelin","canonical_id":"ctgov_combo:ctgov-combo-51344a514d8b6f00","description":null,"metadata":null},{"id":"087c5f7f17024e6690eb81a7bb741960","type":"COMBINATION_TREATMENT","name":"exemestane + palbociclib + pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-bb41a9fce2f877db","description":null,"metadata":null},{"id":"3ee69a058d604c1aab4136ba6fb383ac","type":"COMBINATION_TREATMENT","name":"exemestane + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-5d8e8dccf7cf26e8","description":null,"metadata":null},{"id":"07d76989024e41ed9798f6489029ffff","type":"COMBINATION_TREATMENT","name":"exemestane + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-880f9af5552a4f56","description":null,"metadata":null},{"id":"cdd7ae8ebf8f4ddd8ebe9844f3976ccd","type":"DRUG","name":"exendin-4","canonical_id":"gtopdb:1135","description":null,"metadata":null},{"id":"6d7f4b68237042c9a301b263fb8980fb","type":"DISEASE","name":"exfoliative dermatitis","canonical_id":"mondo:0043233","description":null,"metadata":null},{"id":"f7e16850dd3a4196b22d38a0997d44a4","type":"GO_TERM","name":"exhausted T cell differentiation","canonical_id":"go:GO:0160083","description":"\"The process in which an activated T cell acquires specialized features of an exhausted T cell.\" [PMID:21739672, PMID:31570879]","metadata":null},{"id":"7e8046ec14724dddb71fd6103cc4a75d","type":"GO_TERM","name":"exine","canonical_id":"go:GO:0043668","description":"\"The outer layer of the pollen grain wall which is composed primarily of sporopollenin.\" [https://doi.org/10.1038/220389a0]","metadata":null},{"id":"d2c9c27c732149abaf4251ab80060287","type":"GO_TERM","name":"exit from diapause","canonical_id":"go:GO:0071981","description":"\"The dormancy process that results in exit from diapause. Diapause is a neurohormonally mediated, dynamic state of low metabolic activity. Associated characteristics of this form of dormancy include reduced morphogenesis, increased resistance to environmental extremes, and altered or reduced behavioral activity. Full expression develops in a species-specific manner, usually in response to a number of environmental stimuli that precede unfavorable conditions. Once diapause has begun, metabolic activity is suppressed even if conditions favorable for development prevail. Once initiated, only certain stimuli are capable of releasing the organism from this state, and this characteristic is essential in distinguishing diapause from hibernation.\" [GOC:mah]","metadata":null},{"id":"f516462f0076491986d44ed10b96e52e","type":"GO_TERM","name":"exit from dormancy","canonical_id":"go:GO:0097438","description":"\"The dormancy process that results in exit from dormancy. Dormancy (sometimes called a dormant state) is a suspension of most physiological activity and growth that can be reactivated.\" [GOC:PO_curators, PO_REF:00009]","metadata":null},{"id":"07464de909594f71a7d02508c79716d6","type":"GO_TERM","name":"exit from host cell","canonical_id":"go:GO:0035891","description":"\"The movement of an organism out of a cell of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:rs, PMID:19325115]","metadata":null},{"id":"e1d145fa8fdd428bbae6470b4ff9e91e","type":"GO_TERM","name":"exit from meiosis","canonical_id":"go:GO:1990947","description":"\"Any process involved in the progression from anaphase/telophase of meiosis II to the creation of end products of meiosis, in which ploidy is reduced by half.\" [PMID:21389117]","metadata":null},{"id":"efc54d0fd3484f89a63de9d5859660d9","type":"GO_TERM","name":"exit from mitosis","canonical_id":"go:GO:0010458","description":"\"The cell cycle transition where a cell leaves M phase and enters a new G1 phase. M phase is the part of the mitotic cell cycle during which mitosis and cytokinesis take place.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"5ad9a22d0e574b5580962e50076edcb4","type":"GO_TERM","name":"exit from reproductive diapause","canonical_id":"go:GO:0071983","description":"\"The dormancy process that results in exit from reproductive diapause. Reproductive diapause is a form of diapause where the organism itself will remain fully active, including feeding and other routine activities, but the reproductive organs experience a tissue-specific reduction in metabolism, with characteristic triggering and releasing stimuli.\" [GOC:mah]","metadata":null},{"id":"103f976c12724935a519464f2809170a","type":"GO_TERM","name":"exit of virus from host cell nucleus","canonical_id":"go:GO:0039674","description":"\"The directed movement of the viral genome or a viral particle out of the host cell nucleus.\" [VZ:2177]","metadata":null},{"id":"7de8ded0471942d3a7ba14d482ded120","type":"GO_TERM","name":"exit of virus from host cell nucleus by nuclear egress","canonical_id":"go:GO:0046802","description":"\"The directed movement of an assembled viral particle out of the host cell nucleus by budding and fusion through the nuclear membranes. In this process, enveloped viral particles are formed by budding through the inner nuclear membrane. These perinuclear enveloped particles then fuse with the outer nuclear membrane to deliver a naked capsid into the host cytoplasm.\" [PMID:21494278, PMID:22858153, PMID:9601512, PMID:9765421, VZ:1952]","metadata":null},{"id":"b2deed0dfcfb4b128272309596f1df37","type":"GO_TERM","name":"exit of virus from host cell nucleus through nuclear pore","canonical_id":"go:GO:0039675","description":"\"The directed movement of the viral genome or a viral particle out of the host cell nucleus through the nuclear pore.\" [PMID:12921991, VZ:1953]","metadata":null},{"id":"40ae9f3ef6054794bb3ba0bac09960f4","type":"GO_TERM","name":"exit of virus from host cell nucleus via nuclear envelope disassembly","canonical_id":"go:GO:0039677","description":"\"The directed movement of the viral genome or a viral particle out of the host cell nucleus that involves disruption of the nuclear membrane envelope by the virus.\" [VZ:2176]","metadata":null},{"id":"d093df23643d4a6085ee3caf32af6f78","type":"GO_TERM","name":"exo-(1,4)-alpha-D-glucan lyase activity","canonical_id":"go:GO:0047457","description":"\"Catalysis of the reaction: linear alpha-D-glucan = 1,5-anhydro-D-fructose + beta-D-glucose.\" [EC:4.2.2.13, MetaCyc:4.2.2.13-RXN]","metadata":null},{"id":"c30304ab4f304564b0b7759394d6dd02","type":"GO_TERM","name":"exo-1,4-beta-D-glucosaminidase activity","canonical_id":"go:GO:0052761","description":"\"Catalysis of the reaction: [beta-(1->4)-D-glucosamine]n-[N-acetyl-D-glucosamine]m = D-glucosamine + [beta-(1->4)-D-glucosamine](n-1)-[N-acetyl-D-glucosamine]m. This reaction is the hydrolysis of chitosan or chitosan oligosaccharides to remove a D-glucosamine residue from the non-reducing termini; chitosan is a linear polysaccharide composed of randomly distributed beta-(1->4)-linked D-glucosamine and N-acetyl-D-glucosamine units.\" [EC:3.2.1.165, GOC:mengo_curators, MetaCyc:3.2.1.165-RXN]","metadata":null},{"id":"3f7ba62502964e73b1db2e1960aaac93","type":"GO_TERM","name":"exo-alpha-sialidase activity","canonical_id":"go:GO:0004308","description":"\"Catalysis of the hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)-glycosidic linkages of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates.\" [EC:3.2.1.18]","metadata":null},{"id":"44d0a9232c7d4a74a1abb7dfbbbd51b7","type":"GO_TERM","name":"exo-oligoalginate lyase activity","canonical_id":"go:GO:0052764","description":"\"Catalysis of the cleavage of glycosidic bonds through a beta-elimination reaction on alginate, a linear polysaccharide consisting of guluronate (G) and mannuronate (M) as the monomer constituents. An oligoalginate is a linear polymer of two, three or four units of (1->4)-alpha-L-guluronic acid and beta-D-mannuronic acid, releasing monosaccharides with 4-deoxy-alpha-L-erythro-hex-4-enopyranuronosyl groups at their ends.\" [GOC:mengo_curators, PMID:20925655]","metadata":null},{"id":"f6c4b2bb7f7949e59bdfd5033d23a994","type":"GO_TERM","name":"exo-poly-alpha-galacturonosidase activity","canonical_id":"go:GO:0033917","description":"\"Catalysis of the hydrolysis of pectic acid from the non-reducing end, releasing digalacturonate.\" [EC:3.2.1.82]","metadata":null},{"id":"3d3f62e0c18c4bc0919145330d11bc34","type":"GO_TERM","name":"exochitinase activity","canonical_id":"go:GO:0035885","description":"\"Catalysis of the hydrolysis of terminal 1,4-beta-linkages of N-acetyl-D-glucosamine (GlcNAc) polymers of chitin and chitodextrins. Typically, exochitinases progressively cleave off two subunits from the reducing or non-reducing ends of the chitin chain.\" [GOC:bf, GOC:kah, GOC:pde, PMID:11468293, PMID:16298970, PMID:21390509]","metadata":null},{"id":"5f613a033c2a40aaad4cdb353de42d77","type":"GO_TERM","name":"exocrine pancreas development","canonical_id":"go:GO:0031017","description":"\"The process whose specific outcome is the progression of the exocrine pancreas over time, from its formation to the mature structure. The exocrine pancreas produces and store zymogens of digestive enzymes, such as chymotrypsinogen and trypsinogen in the acinar cells.\" [GOC:cvs]","metadata":null},{"id":"3f81e4dc5c35484eab9872ee99440ad6","type":"DISEASE","name":"exocrine pancreatic carcinoma","canonical_id":"mondo:0005192","description":null,"metadata":null},{"id":"354d02ca5a2749f6b5a305ed0c5c7f47","type":"GO_TERM","name":"exocrine system development","canonical_id":"go:GO:0035272","description":"\"Progression of the exocrine system over time, from its formation to a mature structure. The exocrine system is a system of hormones and glands, where the glands secrete straight to a target site via ducts or tubes. The human exocrine system includes the salivary glands, sweat glands and many glands of the digestive system.\" [GOC:bf, Wikipedia:Exocrine_gland]","metadata":null},{"id":"a8b41d14235d45edb344b8797144f711","type":"GO_TERM","name":"exocyst","canonical_id":"go:GO:0000145","description":"\"A vesicle tethering complex peripherally associated with the plasma membrane that determines where vesicles dock and fuse. At least eight complex components are conserved between yeast and mammals.\" [GOC:cilia, PMID:15292201, PMID:27243008, PMID:9700152]","metadata":null},{"id":"34aec23f74544554969b0fefe3b41de1","type":"GO_TERM","name":"exocyst assembly","canonical_id":"go:GO:0001927","description":"\"The aggregation, arrangement and bonding together of various polypeptides into the exocyst complex.\" [GOC:hjd, PMID:9700152, Wikipedia:Exocyst]","metadata":null},{"id":"63b2463b2a0e4946b46b235f0532d3f3","type":"GO_TERM","name":"exocyst localization","canonical_id":"go:GO:0051601","description":"\"Any process in which an exocyst is transported to, or maintained in, a specific location. An exocyst is a protein complex peripherally associated with the plasma membrane that determines where vesicles dock and fuse.\" [GOC:ai]","metadata":null},{"id":"880f9c776f7e4fc694c69de1554b47da","type":"GO_TERM","name":"exocytic insertion of neurotransmitter receptor to postsynaptic membrane","canonical_id":"go:GO:0098967","description":"\"The exocytic fusion of neurotransmitter receptor containing vesicles with the postsynaptic membrane resulting in the integration of NT receptors, enabling them to participate in neurotransmitter reception. This process includes tethering and docking steps that prepare vesicles for fusion.\" [PMID:19503082]","metadata":null},{"id":"4c0f782d310c409bbaca894035d46810","type":"GO_TERM","name":"exocytic process","canonical_id":"go:GO:0140029","description":"\"The cellular processes that contribute to exocytosis.\" [Wikipedia:Exocytosis]","metadata":null},{"id":"5eccd5aa03bf46919d36d24729cd5949","type":"GO_TERM","name":"exocytic vesicle","canonical_id":"go:GO:0070382","description":"\"A transport vesicle that mediates transport from an intracellular compartment to the plasma membrane, and fuses with the plasma membrane to release various cargo molecules, such as proteins or hormones, by exocytosis.\" [GOC:kad, GOC:mah]","metadata":null},{"id":"901babc2d11e4d0ba80fa536a01c9823","type":"GO_TERM","name":"exocytic vesicle lumen","canonical_id":"go:GO:0062246","description":"\"The volume enclosed by an exocytic vesicle.\" [PMID:27384577]","metadata":null},{"id":"08b7e98063444d00be274e1019744267","type":"GO_TERM","name":"exocytic vesicle membrane","canonical_id":"go:GO:0099501","description":"\"The lipid bilayer surrounding an exocytic vesicle.\" [GOC:dos]","metadata":null},{"id":"31bec637319f4a00a6c996427077ad78","type":"GO_TERM","name":"exocytosis","canonical_id":"go:GO:0006887","description":"\"A process of secretion by a cell that results in the release of intracellular molecules (e.g. hormones, matrix proteins) contained within a membrane-bounded vesicle. Exocytosis can occur either by full fusion, when the vesicle collapses into the plasma membrane, or by a kiss-and-run mechanism that involves the formation of a transient contact, a pore, between a granule (for example of chromaffin cells) and the plasma membrane. The latter process most of the time leads to only partial secretion of the granule content. Exocytosis begins with steps that prepare vesicles for fusion with the membrane (tethering and docking) and ends when molecules are secreted from the cell.\" [GOC:mah, ISBN:0716731363, PMID:22323285]","metadata":null},{"id":"08b84b59291a48939e45e6613871eb86","type":"GO_TERM","name":"exodeoxyribonuclease V activity","canonical_id":"go:GO:0008854","description":"\"Catalysis of the exonucleolytic cleavage (in the presence of ATP) in either 5' to 3' or 3' to 5' direction to yield 5'-phosphooligonucleotides.\" [EC:3.1.11.5]","metadata":null},{"id":"2de76604870043859da28a674461eb76","type":"GO_TERM","name":"exodeoxyribonuclease V complex","canonical_id":"go:GO:0009338","description":"\"An enzyme complex that catalyzes exonucleolytic cleavage (in the presence of ATP) in either 5' to 3' or 3' to 5' direction to yield 5'-phosphooligonucleotides. Exodeoxyribonuclease V shows a preference for double-stranded DNA and possesses DNA-dependent ATPase activity. It acts endonucleolytically on single-stranded circular DNA.\" [PMID:1618858]","metadata":null},{"id":"eb292bc228b540d6a16abdc93556f3da","type":"GO_TERM","name":"exodeoxyribonuclease VII activity","canonical_id":"go:GO:0008855","description":"\"Catalysis of the exonucleolytic cleavage in either 5' to 3' or 3' to 5' direction to yield 5'-phosphomononucleotides.\" [EC:3.1.11.6]","metadata":null},{"id":"2e43f3f0456d4a23b441a3efcbaa4abd","type":"GO_TERM","name":"exodeoxyribonuclease VII complex","canonical_id":"go:GO:0009318","description":"\"An enzyme complex that catalyzes exonucleolytic cleavage in either 5' to 3' or 3' to 5' direction to yield nucleoside 5'-phosphates; it prefers single-stranded DNA.\" [PMID:6284744]","metadata":null},{"id":"1b8c677bfd7a44dfb33e971ed086513a","type":"GO_TERM","name":"exogen","canonical_id":"go:GO:0042638","description":"\"The shedding phase of the hair cycle.\" [PMID:12230507]","metadata":null},{"id":"4f4b397e44e0480ca9c1c0f8c04caf9d","type":"GO_TERM","name":"exogenous antibiotic catabolic process","canonical_id":"go:GO:0042740","description":"\"The chemical reactions and pathways resulting in the breakdown of an antibiotic that has originated externally to the cell or organism.\" [GOC:jl]","metadata":null},{"id":"c4a57a662d9d48139ee6e882697acb80","type":"GO_TERM","name":"exogenous lipid antigen binding","canonical_id":"go:GO:0030884","description":"\"Binding to an exogenous lipid antigen (examples include microbial lipids and glycolipids).\" [PMID:14500461]","metadata":null},{"id":"5d6ffe432fce41aa95331ce41b9c12e2","type":"GO_TERM","name":"exogenous protein binding","canonical_id":"go:GO:0140272","description":"\"Binding to a protein or protein complex from a different species, for example a pathogen molecule binding to a host protein.\" [PMID:28861068]","metadata":null},{"id":"6cc808ef4fe548439bf2a53e262786eb","type":"GO_TERM","name":"exomer complex","canonical_id":"go:GO:0034044","description":"\"A protein complex that acts as a selective cargo adaptor mediating the selective transport of specific membrane proteins from the trans-Golgi network (TGN) to the plasma membrane.\" [GOC:vw, PMID:16498409, PMID:17000877]","metadata":null},{"id":"eb6d7402e4ea4900895e5579d3ab29ba","type":"GO_TERM","name":"exon-exon junction complex","canonical_id":"go:GO:0035145","description":"\"A multi-subunit complex deposited by the spliceosome upstream of messenger RNA exon-exon junctions. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay.\" [PMID:11532962, PMID:11743026]","metadata":null},{"id":"098ea6a6f9d54ca1b1715df443f89d38","type":"GO_TERM","name":"exon-exon junction complex assembly","canonical_id":"go:GO:1903040","description":"\"The aggregation, arrangement and bonding together of a set of components to form an exon-exon junction complex.\" [GO_REF:0000079, GOC:sart, GOC:TermGenie, PMID:17606899]","metadata":null},{"id":"758510791fdd4a70887b4569d970a003","type":"GO_TERM","name":"exon-exon junction complex binding","canonical_id":"go:GO:1990448","description":"\"Binding to an exon-exon junction complex, a protein complex deposited by the spliceosome upstream of messenger RNA exon-exon junctions. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay.\" [GOC:sart, PMID:24967911]","metadata":null},{"id":"947ebb065bda418b900a04d8698957f3","type":"GO_TERM","name":"exon-exon junction complex disassembly","canonical_id":"go:GO:1903259","description":"\"The disaggregation of an exon-exon junction complex into its constituent components.\" [GO_REF:0000079, GOC:sart, GOC:TermGenie, PMID:24967911]","metadata":null},{"id":"fbe7ee97625846c1a69d87f4880f36b9","type":"GO_TERM","name":"exon-exon junction subcomplex mago-y14","canonical_id":"go:GO:1990501","description":"\"Component of the core exon-exon-junction complex (EJC). Fairly conserved in eukaryotes; in Drosophila, consists of the Mago and Y14 (tsunagi) gene products. Important for coupling nuclear and cytoplasmic events in gene expression. Inhibits the ATPase activity of eIF4AIII (Q9VHS8) to ensure a stable association of the EJC core with the mRNA.\" [GOC:bhm, PMID:12730685]","metadata":null},{"id":"be761d2abb804515946e60eda5016c57","type":"GO_TERM","name":"exoneme","canonical_id":"go:GO:0044311","description":"\"A dense granule-like organelle of the apical complex of merozoites, released into the parasitophorous vacuole, mediating protease-dependent rupture and parasite exit from the infected erythrocyte.\" [GOC:jl, PMID:18083092, PMID:18083098]","metadata":null},{"id":"1e59873a0d9e4bc6a53103715fbfc75e","type":"GO_TERM","name":"exonuclease activity","canonical_id":"go:GO:0004527","description":"\"Catalysis of the hydrolysis of ester linkages within nucleic acids by removing nucleotide residues from the 3' or 5' end.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"122dd8c067564840ab7b763603238705","type":"GO_TERM","name":"exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000467","description":"\"Exonucleolytic digestion of a pre-rRNA molecule to generate the mature 3'-end of a 5.8S rRNA molecule derived from an originally tricistronic pre-rRNA transcript that contained the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:krc, PMID:10690410]","metadata":null},{"id":"62ecd0ee235147b0a6fb32b962cd978a","type":"GO_TERM","name":"exonucleolytic trimming to generate mature 5'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000465","description":"\"Exonucleolytic digestion of a pre-rRNA molecule to generate the mature 5'-end of a 5.8S rRNA molecule derived from an originally tricistronic pre-rRNA transcript that contained the Small Subunit (SSU) rRNA, the 5.8S rRNA, and the Large Subunit (LSU) rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:krc, PMID:10690410]","metadata":null},{"id":"1a60ec437e8e440aa3d821d36f92befa","type":"GO_TERM","name":"exopeptidase activity","canonical_id":"go:GO:0008238","description":"\"Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain, in a reaction that requires a free N-terminal amino group, C-terminal carboxyl group or both.\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#EXOPEPTIDASE]","metadata":null},{"id":"236f00ce84ca46509c8b6deb5766f92b","type":"GO_TERM","name":"exopher","canonical_id":"go:GO:0160014","description":"\"An extracellular vesicle that is approximately four microns in diameter, released by budding out of cells into the extracellular space, and hypothesized to be a mechanism for disposal of unwanted cellular material including protein aggregates and damaged organelles.\" [PMID:28178240, PMID:33016946, PMID:33027673, PMID:33659873, PMID:34288362, PMID:34475208]","metadata":null},{"id":"269e7658675f44a381799fcb88d2ea84","type":"GO_TERM","name":"exopolyphosphatase activity","canonical_id":"go:GO:0004309","description":"\"Catalysis of the reaction: polyphosphate(n) + H2O = polyphosphate(n-1) + phosphate.\" [EC:3.6.1.11]","metadata":null},{"id":"5be8185dec5443509cbdc97186a1c567","type":"GO_TERM","name":"exoribonuclease H activity","canonical_id":"go:GO:0004533","description":"\"Catalysis of the exonucleolytic cleavage of RNA to 5'-phosphomonoester oligonucleotides in both 5' to 3' and 3' to 5' directions.\" [EC:3.1.13.2]","metadata":null},{"id":"2804b2b3232d4a2faf0d751ab40ff117","type":"GO_TERM","name":"exoribonuclease II activity","canonical_id":"go:GO:0008859","description":"\"Catalysis of the reaction: RNA + H2O = 5'-phosphomononucleotides. Cleaves RNA in the 3' to 5' direction.\" [EC:3.1.13.1]","metadata":null},{"id":"7881b3a542104d9abdbd68e2f05585e1","type":"GO_TERM","name":"exoribonuclease activator activity","canonical_id":"go:GO:0044692","description":"\"Binds to and increases the activity of an exoribonuclease.\" [GOC:rb, PMID:22570495]","metadata":null},{"id":"e732dc74677a4ea7b1df63a22a95928a","type":"GO_TERM","name":"exoribonuclease complex","canonical_id":"go:GO:1905354","description":"\"A protein complex which is capable of exoribonuclease activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:17174896]","metadata":null},{"id":"aeb0bc1f31114fad90d5211ba5d027b5","type":"GO_TERM","name":"exosomal secretion","canonical_id":"go:GO:1990182","description":"\"The process whereby a membrane-bounded vesicle is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane.\" [GOC:hjd, PMID:10572093, PMID:12154376, PMID:16773132, PMID:18617898]","metadata":null},{"id":"2044e728208048f4b513c29fe3129731","type":"GO_TERM","name":"exosome (RNase complex)","canonical_id":"go:GO:0000178","description":"\"A ribonuclease complex that has 3-prime to 5-prime exoribonuclease activity and possibly endoribonuclease activity, producing 5-prime-phosphomonoesters. Participates in a multitude of cellular RNA processing and degradation events preventing nuclear export and/or translation of aberrant RNAs. Restricted to processing linear and circular single-stranded RNAs (ssRNA) only. RNAs with complex secondary structures may have to be unwound or pre-processed by co-factors prior to entering the complex, esp if the 3-prime end is structured.\" [PMID:17174896, PMID:20531386, PMID:26726035]","metadata":null},{"id":"de80af7f537b4abe9b4665964b044f4a","type":"GO_TERM","name":"exosporium","canonical_id":"go:GO:0043592","description":"\"The outermost layer of a bacterial endospore, which is loosely attached and located outside of the endospore coat. It is generally composed of protein, carbohydrate, and perhaps lipid.\" [GOC:mlg]","metadata":null},{"id":"dac390b438614b6695987dde241aac61","type":"GO_TERM","name":"exosporium assembly","canonical_id":"go:GO:0070499","description":"\"A process that is carried out at the cellular level which results in the formation of an exosporium, the outermost layer of a bacterial endospore.\" [GOC:mah]","metadata":null},{"id":"285e12e63d5e48f587b5ccd020d1b61a","type":"GO_TERM","name":"exoxylanase activity","canonical_id":"go:GO:0097600","description":"\"A xylanase activity that acts on one of the ends of a xylan polymer which does not contain side chains.\" [GOC:jh2, ISBN:81-7736-269-0, PMID:16535010]","metadata":null},{"id":"f9308b626d894558bbf4ba2367f3a2f2","type":"GO_TERM","name":"exploration behavior","canonical_id":"go:GO:0035640","description":"\"The specific behavior of an organism in response to a novel environment or stimulus.\" [GOC:BHF, GOC:pr, PMID:11682103, PMID:9767169]","metadata":null},{"id":"525abc17c6944a918fc90566064d10aa","type":"GO_TERM","name":"export across cell outer membrane","canonical_id":"go:GO:0140317","description":"\"The directed movement of a substance across the outer membrane in cells with two membranes.\" [PMID:15968039]","metadata":null},{"id":"a302aac5ecbd40ba9b18b8c033111f38","type":"GO_TERM","name":"export across plasma membrane","canonical_id":"go:GO:0140115","description":"\"The directed movement of some substance from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:pg]","metadata":null},{"id":"a292143dbca24155b49a681d587e71e0","type":"GO_TERM","name":"export from cell","canonical_id":"go:GO:0140352","description":"\"The directed movement of some substance from a cell, into the extracellular region. This may occur via transport across the plasma membrane or via exocytosis.\" [GOC:pg]","metadata":null},{"id":"8a29773ef8254344ad8e54c6f605be7a","type":"GO_TERM","name":"export from the mitochondrion","canonical_id":"go:GO:0170037","description":"\"The directed movement of substances from the mitochondrion to the cytosol.\" [GOC:ew]","metadata":null},{"id":"5525dc1d6bb14652a0aeb4da8f36c5ca","type":"GO_TERM","name":"extension of a leading process involved in cell motility in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021816","description":"\"The rearrangements of the microtubule cytoskeleton that result in the extension of a leading process, where this process is involved in the movement of cells along radial glial cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"9946f6fb6bc74c44a602e5161337d78f","type":"GO_TERM","name":"extension of leading cell process to pial surface","canonical_id":"go:GO:0021803","description":"\"The extension of a long process to the pial surface as a cell leaves the ventricular zone.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"328603d0c02e4a55b1cbd11570fb27fd","type":"GO_TERM","name":"external encapsulating structure","canonical_id":"go:GO:0030312","description":"\"A structure that lies outside the plasma membrane and surrounds the entire cell or cells. This does not include the periplasmic space.\" [GOC:curators]","metadata":null},{"id":"40356f12f6764ac38fec38c0da7689e2","type":"GO_TERM","name":"external encapsulating structure organization","canonical_id":"go:GO:0045229","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of external structures that lie outside the plasma membrane and surround the entire cell.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"09438c48131f4a02a14392454401b3bf","type":"GO_TERM","name":"external genitalia morphogenesis","canonical_id":"go:GO:0035261","description":"\"The process in which the anatomical structures of the external genitalia are generated and organized. The external genitalia are the outer sex organs, such as the penis or vulva in mammals.\" [PMID:24793987, PMID:25247640]","metadata":null},{"id":"1b4f6b6fac8e45e9a017cf27ed06720b","type":"GO_TERM","name":"external side of apical plasma membrane","canonical_id":"go:GO:0098591","description":"\"The leaflet the apical region of the plasma membrane that faces the extracellular side of the cell, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"ffc434ffcab14a1e9c8e623c7db353e9","type":"GO_TERM","name":"external side of cell outer membrane","canonical_id":"go:GO:0031240","description":"\"The leaflet of the outer membrane that is opposite to the side that faces the periplasm of the cell, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"b1b64f65723c41289c9210a7a36ac33b","type":"GO_TERM","name":"external side of cell wall","canonical_id":"go:GO:0010339","description":"\"The side of the cell wall that is opposite to the side that faces the cell and its contents.\" [GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"c907dd9f264b4fbcb75d0047534374fb","type":"GO_TERM","name":"external side of fungal-type cell wall","canonical_id":"go:GO:0070263","description":"\"The side of the fungal-type cell wall that is opposite to the side that faces the cell and its contents.\" [GOC:mah]","metadata":null},{"id":"8147f5edf95e4d0794db849b102c66d9","type":"GO_TERM","name":"external side of mycolate outer membrane","canonical_id":"go:GO:0098568","description":"\"The leaflet of the mycolate outer membrane that faces the periplasm of the cell, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos, PMID:18316738, PMID:18567661]","metadata":null},{"id":"488c884a88124f97b9be4be86f046ad4","type":"GO_TERM","name":"external side of plasma membrane","canonical_id":"go:GO:0009897","description":"\"The leaflet of the plasma membrane that faces the extracellular side of the cell, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos, GOC:tb]","metadata":null},{"id":"bf65a203158a4435879d9e2f6ef75c01","type":"GO_TERM","name":"extracellular ATP signaling","canonical_id":"go:GO:0106167","description":"\"The series of molecular signals mediated by the detection of extracellular ATP.\" [GOC:tb, PMID:12948585, PMID:20817461, PMID:29274390]","metadata":null},{"id":"ce3a5aea1328438e8c1f5d4ff4c6095a","type":"GO_TERM","name":"extracellular amino acid transport","canonical_id":"go:GO:0006860","description":"\"The directed extracellular movement of amino acids.\" [GOC:ai]","metadata":null},{"id":"bc92cfbb23c848a38992e9b157ebbbea","type":"GO_TERM","name":"extracellular ammonia-gated monoatomic ion channel activity","canonical_id":"go:GO:0036081","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when extracellular ammonia (NH4+) has been bound by the channel complex or one of its constituent parts.\" [GOC:sart, PMID:19135896]","metadata":null},{"id":"685a88f982b748ecb8ea7a819befb4ae","type":"GO_TERM","name":"extracellular core region of desmosome","canonical_id":"go:GO:0090635","description":"\"The desmosomal part containing the desmosomal cadherins, desmogleins and desmocollins, that establish contact and adhere to neighboring cells in a Ca2+-dependent manner.\" [PMID:20066089]","metadata":null},{"id":"9ac86a8cd7014922a50ed8ad3fe52a76","type":"GO_TERM","name":"extracellular exosome","canonical_id":"go:GO:0070062","description":"\"A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm.\" [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894]","metadata":null},{"id":"230aa052ee7a4ee68ab0ada7cf0032cd","type":"GO_TERM","name":"extracellular exosome assembly","canonical_id":"go:GO:0071971","description":"\"The aggregation, arrangement and bonding together of a set of components to form an extracellular vesicular exosome, a membrane-bounded vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Exosomes are defined by their size, which generally ranges from 30 nm to 100 nm.\" [GOC:mah, GOC:tfm, PMID:19442504, PMID:27462458]","metadata":null},{"id":"28da7b88650f4cc892dbce3595d0a544","type":"GO_TERM","name":"extracellular exosome biogenesis","canonical_id":"go:GO:0097734","description":"\"The assembly and secretion of an extracellular exosome, a membrane-bounded vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane.\" [GOC:bf, GOC:PARL, PMID:19442504, PMID:25392495]","metadata":null},{"id":"c0cd80513dc24978b15d131b8375b9c8","type":"GO_TERM","name":"extracellular exosome complex","canonical_id":"go:GO:1990563","description":"\"A protein complex that is wholly or partially contained within the lumen or membrane of the extracellular vesicular exosome.\" [GOC:bhm, PMID:22660413]","metadata":null},{"id":"498f658359fa49dc8c58bd14b47a069d","type":"GO_TERM","name":"extracellular exosome macropinocytosis","canonical_id":"go:GO:0061707","description":"\"The single-organism macropinocytosis process that results in the uptake of an extracellular exosome.\" [GOC:dph, PMID:24951588]","metadata":null},{"id":"b1aa51ad60b74369bcd81e45b3a93938","type":"GO_TERM","name":"extracellular isoamylase complex","canonical_id":"go:GO:0010367","description":"\"A protein complex whose composition varies amongst species; in rice it probably exists in a homo-tetramer to homo-hexamer form and in Gram negative bacteria as a dimer. Functions in the hydrolysis of alpha-(1,6)-D-glucosidic branch linkages. Isoamylases in animals are localized in the extracellular space.\" [GOC:tair_curators]","metadata":null},{"id":"ba1fce8008164921bad4bfb739d3a34b","type":"GO_TERM","name":"extracellular ligand-gated monoatomic ion channel activity","canonical_id":"go:GO:0005230","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific extracellular ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"8586feca43114ac19a0438ae94b0addb","type":"GO_TERM","name":"extracellular matrix","canonical_id":"go:GO:0031012","description":"\"A structure lying external to one or more cells, which provides structural support, biochemical or biomechanical cues for cells or tissues.\" [GOC:BHF, GOC:mah, GOC:rph, PMID:21123617, PMID:28089324, PMID:33605520]","metadata":null},{"id":"678aecccab7b4a7ea7d972b57b20abb2","type":"GO_TERM","name":"extracellular matrix assembly","canonical_id":"go:GO:0085029","description":"\"The aggregation, arrangement and bonding together of the extracellular matrix.\" [GOC:jl]","metadata":null},{"id":"a62e08764e334c6aa3f0ef133468ca5c","type":"GO_TERM","name":"extracellular matrix binding","canonical_id":"go:GO:0050840","description":"\"Binding to a component of the extracellular matrix.\" [GOC:ai]","metadata":null},{"id":"6fe9cf63d1a2408e86580955da7ef28f","type":"GO_TERM","name":"extracellular matrix constituent conferring elasticity","canonical_id":"go:GO:0030023","description":"\"A component of the extracellular matrix that enables the matrix to recoil after transient stretching.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"6845496a303e447cbbeb939dbfe3c58c","type":"GO_TERM","name":"extracellular matrix constituent secretion","canonical_id":"go:GO:0070278","description":"\"The controlled release of molecules that form the extracellular matrix, including carbohydrates and glycoproteins by a cell.\" [GOC:mah]","metadata":null},{"id":"604b71908cc74a97b5b00e7e1f4c140a","type":"GO_TERM","name":"extracellular matrix constituent, lubricant activity","canonical_id":"go:GO:0030197","description":"\"Functions as a lubricant for an extracellular matrix, such as a mucous membrane.\" [GOC:mah]","metadata":null},{"id":"a7e892cdb34440cb8f9fafa253aabf19","type":"GO_TERM","name":"extracellular matrix disassembly","canonical_id":"go:GO:0022617","description":"\"A process that results in the breakdown of the extracellular matrix.\" [GOC:jid]","metadata":null},{"id":"5bb77b3376b14dba93d66482f5ecffc3","type":"GO_TERM","name":"extracellular matrix of synaptic cleft","canonical_id":"go:GO:0098965","description":"\"The portion of the extracellular matrix that lies within the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"c519c51cfc204c839ce263c7eb0dcaef","type":"GO_TERM","name":"extracellular matrix organization","canonical_id":"go:GO:0030198","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an extracellular matrix.\" [GOC:mah]","metadata":null},{"id":"92f1c6e15f004cc6a8f604a46fd42b36","type":"GO_TERM","name":"extracellular matrix organization involved in endocardium development","canonical_id":"go:GO:0061148","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of an extracellular matrix of the endocardium. The endocardium is an anatomical structure comprised of an endothelium and an extracellular matrix that forms the innermost layer of tissue of the heart, and lines the heart chambers.\" [GOC:dph]","metadata":null},{"id":"35b7a83f454a4f329daf29bd2b715424","type":"GO_TERM","name":"extracellular matrix protein binding","canonical_id":"go:GO:1990430","description":"\"Binding to a protein that is part of an extracellular matrix.\" [PMID:22355679]","metadata":null},{"id":"84737a69a2754bdabb830e6e56f1ccd1","type":"GO_TERM","name":"extracellular matrix structural constituent","canonical_id":"go:GO:0005201","description":"\"The action of a molecule that contributes to the structural integrity of the extracellular matrix.\" [GOC:mah]","metadata":null},{"id":"6d26e0ba6383463da45b941db75ee83a","type":"GO_TERM","name":"extracellular matrix structural constituent conferring compression resistance","canonical_id":"go:GO:0030021","description":"\"A constituent of the extracellular matrix that enables the matrix to resist compressive forces; often a proteoglycan.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"9e427215e24a45ddbb68aaaa0a029504","type":"GO_TERM","name":"extracellular matrix structural constituent conferring tensile strength","canonical_id":"go:GO:0030020","description":"\"A constituent of the extracellular matrix that enables the matrix to resist longitudinal stress.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"2a3f8e2ad4364cc1aaa5adbe1abc9fd0","type":"GO_TERM","name":"extracellular matrix-cell signaling","canonical_id":"go:GO:0035426","description":"\"Any process that mediates the transfer of information between the extracellular matrix and a cell.\" [GOC:bf]","metadata":null},{"id":"00f8135e5e5f4b03b035b896c9a02515","type":"GO_TERM","name":"extracellular matrix-dependent thymocyte migration","canonical_id":"go:GO:0072680","description":"\"The movement of a thymocyte through distinct intrathymic niches (e.g. medulla, cortex), where it receives a unique set of developmental cues required for T-cell development, dependent on extracellular matrix components including fibronectin, collagen and laminin.\" [CL:0000893, GOC:BHF, GOC:mah, PMID:20856819]","metadata":null},{"id":"e7b5928fd01b455b837d4275f18d81b2","type":"GO_TERM","name":"extracellular membrane-bounded organelle","canonical_id":"go:GO:0065010","description":"\"Organized structure of distinctive morphology and function, bounded by a lipid bilayer membrane and occurring outside the cell.\" [GOC:isa_complete]","metadata":null},{"id":"e92c3e41e34c447f8f83eaf3452b8daa","type":"GO_TERM","name":"extracellular membraneless organelle","canonical_id":"go:GO:0043264","description":"\"Organized structure of distinctive morphology and function, not bounded by a lipid bilayer membrane and occurring outside the cell.\" [GOC:jl]","metadata":null},{"id":"4ec0b763006d4b908fa0b77ba86eff10","type":"GO_TERM","name":"extracellular microvesicle biogenesis","canonical_id":"go:GO:0140113","description":"\"The assembly and secretion of a set of components to form an extracellular microvesicule, a membrane-bounded vesicle that ranges in size 100 nm to 1 micron in size) and exits the cell by budding.\" [PMID:28736435]","metadata":null},{"id":"a3bf87dad441499283fdf619577119c9","type":"GO_TERM","name":"extracellular negative regulation of signal transduction","canonical_id":"go:GO:1900116","description":"\"Any negative regulation of signal transduction that takes place in extracellular region.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"9e46620877364a19b51498dd1d0989d5","type":"GO_TERM","name":"extracellular organelle","canonical_id":"go:GO:0043230","description":"\"Organized structure of distinctive morphology and function, occurring outside the cell. Includes, for example, extracellular membrane vesicles (EMVs) and the cellulosomes of anaerobic bacteria and fungi.\" [GOC:jl, PMID:9914479]","metadata":null},{"id":"771562b155d84a0d9087bfef0486c3a9","type":"GO_TERM","name":"extracellular phenylacetaldehyde-gated monoatomic ion channel activity","canonical_id":"go:GO:0036082","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when extracellular phenylacetaldehyde has been bound by the channel complex or one of its constituent parts.\" [GOC:sart, PMID:19135896]","metadata":null},{"id":"bdfca8b584ef4896b93bcfaccd044ac1","type":"GO_TERM","name":"extracellular protein-containing complex","canonical_id":"go:GO:0140392","description":"\"A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together outside a cell.\" [GOC:curators]","metadata":null},{"id":"13bc315d072442d89340c60aa43999c9","type":"GO_TERM","name":"extracellular region","canonical_id":"go:GO:0005576","description":"\"The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.\" [GOC:curators]","metadata":null},{"id":"f8a2058dfa5e4026870a691c5fca385b","type":"GO_TERM","name":"extracellular regulation of signal transduction","canonical_id":"go:GO:1900115","description":"\"Any regulation of signal transduction that takes place in the extracellular region.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"9cc20ea98ba44675aa4491ff4533b6cd","type":"GO_TERM","name":"extracellular structure organization","canonical_id":"go:GO:0043062","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"d0c547d52fd44c3080fa98810115f9ea","type":"GO_TERM","name":"extracellular transport","canonical_id":"go:GO:0006858","description":"\"The transport of substances that occurs outside cells.\" [GOC:curators]","metadata":null},{"id":"abd9c69acfc54f299d72942d6309b36b","type":"GO_TERM","name":"extracellular vesicle","canonical_id":"go:GO:1903561","description":"\"Any vesicle that is part of the extracellular region.\" [GO_REF:0000064, GOC:pm, GOC:TermGenie, PMID:24769233]","metadata":null},{"id":"8b9d3681ccdd44699d0847743eb68698","type":"GO_TERM","name":"extracellular vesicle biogenesis","canonical_id":"go:GO:0140112","description":"\"The assembly and secretion a set of components to form an extracellular vesicule, a membrane-bounded vesicle that is released into the extracellular region. Extracellular vesicles include exosomes, microvesicles and apoptotic bodies, based on the mechanism by which they are released from cells and differentiated based on their size and content.\" [PMID:28736435]","metadata":null},{"id":"65b067bf3e214cea80df68a5739a958a","type":"GO_TERM","name":"extracellularly ATP-gated monoatomic cation channel activity","canonical_id":"go:GO:0004931","description":"\"Enables the transmembrane transfer of a monoatomic cation by a channel that opens when ATP is bound by the channel complex or one of its constituent parts on the extracellular side of the plasma membrane.\" [GOC:bf, GOC:mah, PMID:9755289]","metadata":null},{"id":"9ff9fe41a559442b8477c7e49ecc4bd6","type":"GO_TERM","name":"extracellularly glutamate-gated chloride channel activity","canonical_id":"go:GO:0008068","description":"\"Enables the transmembrane transfer of a chloride ion by a channel that opens when glutamate is bound by the channel complex or one of its constituent parts on the extracellular side of the plasma membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e32954cb92a54e3f95ec31d1532d1db3","type":"GO_TERM","name":"extracellularly glutamate-gated ion channel activity","canonical_id":"go:GO:0005234","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when glutamate is bound by the channel complex or one of its constituent parts on the extracellular side of the plasma membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"170c04973099486eb1253fcd0192779d","type":"GO_TERM","name":"extracellularly glycine-gated chloride channel activity","canonical_id":"go:GO:0016934","description":"\"Enables the transmembrane transfer of a chloride ion by a channel that opens when glycine is bound by the channel complex or one of its constituent parts on the extracellular side of the plasma membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"6b0faec3fc8d4ad0bf69832a811f5a40","type":"GO_TERM","name":"extracellularly glycine-gated ion channel activity","canonical_id":"go:GO:0016933","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when glycine is bound by the channel complex or one of its constituent parts on the extracellular side of the plasma membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"849226068c214c55879cf17846bc92cd","type":"GO_TERM","name":"extrachromosomal DNA","canonical_id":"go:GO:0046821","description":"\"DNA structures that are not part of a chromosome.\" [GOC:ai]","metadata":null},{"id":"a2daddb45f6f43239dadc91755563800","type":"GO_TERM","name":"extrachromosomal circular DNA","canonical_id":"go:GO:0005727","description":"\"Circular DNA structures that are not part of a chromosome.\" [GOC:ai]","metadata":null},{"id":"53e97b8edcc34850a8ff24d44353d959","type":"GO_TERM","name":"extrachromosomal rDNA circle","canonical_id":"go:GO:0005728","description":"\"Circular DNA molecules encoding ribosomal RNA that are replicated independently of chromosomal replication. These molecules originate in the chromosome but are excised and circularized, often by intramolecular homologous recombination between direct tandem repeats.\" [GOC:mah, PMID:12044934]","metadata":null},{"id":"2f1de97af52846b1a231126e3074ce7f","type":"GO_TERM","name":"extraction of mislocalized protein from ER membrane","canonical_id":"go:GO:0140569","description":"\"The removal of a mislocalized protein from the endoplasmic reticulum (ER) membrane.\" [PMID:32973005]","metadata":null},{"id":"bd91548afd524c13a8273e7abe9a068d","type":"GO_TERM","name":"extraction of mislocalized protein from membrane","canonical_id":"go:GO:0140568","description":"\"The removal of a mislocalized protein from a cellular membrane.\" [PMID:24821790, PMID:28712723, PMID:32973005]","metadata":null},{"id":"3cadfc090c824728bb2263dd39a5fb63","type":"GO_TERM","name":"extraction of mislocalized protein from mitochondrial outer membrane","canonical_id":"go:GO:0140570","description":"\"The removal of a mislocalized protein from the mitochondrial outer membrane.\" [PMID:32973005]","metadata":null},{"id":"55f4d28428e74a64a70e791154e9eac9","type":"GO_TERM","name":"extraembryonic membrane development","canonical_id":"go:GO:1903867","description":"\"The process whose specific outcome is the progression of an extraembryonic membrane over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, ISBN:0073040584]","metadata":null},{"id":"b49b2bf4d3504d32853b793c6cf2a53b","type":"GO_TERM","name":"extraglomerular mesangial cell proliferation","canonical_id":"go:GO:0072122","description":"\"The multiplication or reproduction of extraglomerular glomerular mesangium cells by cell division, resulting in the expansion of their population. Extraglomerular mesangial cells (also known as lacis cells, Goormaghtigh cells) are light-staining cells in the kidney found outside the glomerulus, near the vascular pole and macula densa.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6998641ccd564f8483329054d4f4232a","type":"GO_TERM","name":"extrahaustorial matrix","canonical_id":"go:GO:0085036","description":"\"The space between the symbiont plasma membrane and the extrahaustorial membrane of the host.\" [GOC:pamgo_curators]","metadata":null},{"id":"73a0dc55b6dd4703a71b8c38716be31c","type":"GO_TERM","name":"extrahaustorial membrane","canonical_id":"go:GO:0085037","description":"\"The membrane surrounding the symbiont haustorium during symbiosis, derived from the host plasma membrane.\" [GOC:pamgo_curators]","metadata":null},{"id":"187915ae9b344bb0b2ce3aa816b189fa","type":"GO_TERM","name":"extraocular skeletal muscle development","canonical_id":"go:GO:0002074","description":"\"The process whose specific outcome is the progression of the extraocular skeletal muscle over time, from its formation to the mature structure. The extraocular muscle is derived from cranial mesoderm and controls eye movements. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle. An example of this process is found in Mus musculus.\" [GOC:dph, GOC:mtg_muscle, GOC:mtg_sensu, MA:0001271, PMID:16638982]","metadata":null},{"id":"545a77e4ce5449d4ba63775e52a9ecd2","type":"GO_TERM","name":"extraorganismal space","canonical_id":"go:GO:0043245","description":"\"The environmental space outside of an organism; this may be a host organism in the case of parasitic and symbiotic organisms.\" [GOC:jl]","metadata":null},{"id":"d8e29c7f0d114b778847a5f18b1edc76","type":"GO_TERM","name":"extrasynaptic signaling via GABA","canonical_id":"go:GO:0160001","description":"\"Cell-cell signaling that starts with the activation of extrasynaptic GABA receptors in neurons through binding of ambient gamma-aminobutyric acid present in the extracellular fluid.\" [PMID:23038269, PMID:9364051]","metadata":null},{"id":"ba8b5ce394334f42901a33a533fb13aa","type":"GO_TERM","name":"extrathymic T cell differentiation","canonical_id":"go:GO:0033078","description":"\"The process in which a precursor cell type acquires the specialized features of a T cell via a differentiation pathway independent of the thymus.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5bbc4c7dafa4426b9f1d8993938dbf6b","type":"GO_TERM","name":"extrathymic T cell selection","canonical_id":"go:GO:0045062","description":"\"The process of T cell selection that occurs in extrathymic locations, often resulting T cells of distinct specificities from those selected in the thymus.\" [ISBN:0781735149, PMID:7880383]","metadata":null},{"id":"1a0dccb53dc04aeba1188c4dc1f72b89","type":"GO_TERM","name":"extrinsic apoptotic signaling pathway","canonical_id":"go:GO:0097191","description":"\"The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with either a ligand binding to a cell surface receptor, or a ligand being withdrawn from a cell surface receptor (e.g. in the case of signaling by dependence receptors), and ends when the execution phase of apoptosis is triggered.\" [GOC:mtg_apoptosis, GOC:yaf, PMID:17340152]","metadata":null},{"id":"98117da6b4ea476ea24b4bb0858bbfc3","type":"GO_TERM","name":"extrinsic apoptotic signaling pathway in absence of ligand","canonical_id":"go:GO:0097192","description":"\"The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with withdrawal of a ligand from a cell surface receptor, and ends when the execution phase of apoptosis is triggered.\" [GOC:mtg_apoptosis, PMID:15044679, PMID:20816705]","metadata":null},{"id":"3f2ccbd6f6a84593baeaff1bd5ca4973","type":"GO_TERM","name":"extrinsic apoptotic signaling pathway via death domain receptors","canonical_id":"go:GO:0008625","description":"\"The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"73f48f242e564b3d801b205127b20b7a","type":"GO_TERM","name":"extrinsic component of Golgi membrane","canonical_id":"go:GO:0090498","description":"\"The component of a Golgi membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, PMID:21337012]","metadata":null},{"id":"5014368e8b5743f39aa6160858059476","type":"GO_TERM","name":"extrinsic component of cell outer membrane","canonical_id":"go:GO:0031244","description":"\"The component of the cell outer membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"cfa578c53b7448a1aba7e27bb6f8c7a6","type":"GO_TERM","name":"extrinsic component of cytoplasmic side of plasma membrane","canonical_id":"go:GO:0031234","description":"\"The component of a plasma membrane consisting of gene products and protein complexes that are loosely bound to its cytoplasmic surface, but not integrated into the hydrophobic region.\" [GOC:mah]","metadata":null},{"id":"d72cb3b355bd4801b69e9be4a1b6f940","type":"GO_TERM","name":"extrinsic component of dense core granule membrane","canonical_id":"go:GO:0098922","description":"\"The component of the dense core granule membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos]","metadata":null},{"id":"5ffb1d14907a42d8af57bf076bec07ea","type":"GO_TERM","name":"extrinsic component of endoplasmic reticulum membrane","canonical_id":"go:GO:0042406","description":"\"The component of the endoplasmic reticulum membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:curators, GOC:dos]","metadata":null},{"id":"43640cb404b141219263696a75c529d1","type":"GO_TERM","name":"extrinsic component of endosome membrane","canonical_id":"go:GO:0031313","description":"\"The component of an endosome membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"bf21f0b5231a4d55bb8eb50b39ca4606","type":"GO_TERM","name":"extrinsic component of external side of cell outer membrane","canonical_id":"go:GO:0031242","description":"\"The component of a cell outer membrane consisting of gene products and protein complexes that are loosely bound to its external surface, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"3a4db053c78547d1a9ffa671f2de583c","type":"GO_TERM","name":"extrinsic component of external side of mycolate outer membrane","canonical_id":"go:GO:0036421","description":"\"The component of mycolate membrane consisting of gene products and protein complexes that are loosely bound to its external surface, but not integrated into the hydrophobic region.\" [GOC:md]","metadata":null},{"id":"2ca59bac151f400384eb989c75deb78e","type":"GO_TERM","name":"extrinsic component of external side of plasma membrane","canonical_id":"go:GO:0031232","description":"\"The component of a plasma membrane consisting of gene products and protein complexes that are loosely bound to its external surface, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"8a652d65dac84edd96ada6163af9e152","type":"GO_TERM","name":"extrinsic component of intraperoxisomal membrane","canonical_id":"go:GO:0005780","description":"\"The component of the intraperoxisomal membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:jl, GOC:mah]","metadata":null},{"id":"baa700fed81f44358820b52e244c271f","type":"GO_TERM","name":"extrinsic component of lumenal side of plastid thylakoid membrane","canonical_id":"go:GO:0035450","description":"\"The component of a plastid thylakoid membrane consisting of gene products and protein complexes that are loosely bound to its lumenal surface, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"d0ca5c3b4b094ddd8631bade6672f850","type":"GO_TERM","name":"extrinsic component of matrix side of mitochondrial inner membrane","canonical_id":"go:GO:0099616","description":"\"The component of the matrix side of the mitochondrial inner membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos]","metadata":null},{"id":"99075e4e1f6c4e628d5efb0ed073e809","type":"GO_TERM","name":"extrinsic component of membrane","canonical_id":"go:GO:0019898","description":"\"The component of a membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:jl, GOC:mah]","metadata":null},{"id":"8e20bb58fc834ffc94ddd131162e947f","type":"GO_TERM","name":"extrinsic component of mitochondrial inner membrane","canonical_id":"go:GO:0031314","description":"\"The component of mitochondrial inner membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"c622d620b6e24ebe92bfd73c985a7ea8","type":"GO_TERM","name":"extrinsic component of mitochondrial outer membrane","canonical_id":"go:GO:0031315","description":"\"The component of a mitochondrial outer membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"513a7634698e4cf9a2bfdc9a68d3fe5a","type":"GO_TERM","name":"extrinsic component of mycolate outer membrane","canonical_id":"go:GO:0036420","description":"\"The component of mycolate outer membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:md]","metadata":null},{"id":"ac59a0f40d5d4b55a8bf773fcf854826","type":"GO_TERM","name":"extrinsic component of neuronal dense core vesicle membrane","canonical_id":"go:GO:0098674","description":"\"The component of the neuronal dense core vesicle membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos]","metadata":null},{"id":"efee8170acc246c2b9c5406686da67bc","type":"GO_TERM","name":"extrinsic component of nuclear outer membrane","canonical_id":"go:GO:0031316","description":"\"The component of a nuclear outer membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"b59f55c34af742c4a04708e269b070ed","type":"GO_TERM","name":"extrinsic component of omegasome membrane","canonical_id":"go:GO:0097629","description":"\"The component of the omegasome membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:mf, PMID:18725538, PMID:24591649]","metadata":null},{"id":"522db7cdcd834acd9329e3b7b81bb536","type":"GO_TERM","name":"extrinsic component of organelle membrane","canonical_id":"go:GO:0031312","description":"\"The component of an organelle membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"4934235131844ee48c8dbff0a4bdfde1","type":"GO_TERM","name":"extrinsic component of periplasmic side of cell outer membrane","canonical_id":"go:GO:0031245","description":"\"The component of the cell outer membrane consisting of gene products and protein complexes that are loosely bound to periplasmic surface, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"2df04efe1407445db749273a7e0c1507","type":"GO_TERM","name":"extrinsic component of periplasmic side of plasma membrane","canonical_id":"go:GO:0031236","description":"\"The component of a plasma membrane consisting of gene products and protein complexes that are loosely bound to its periplasmic surface, but not integrated into the hydrophobic region.\" [GOC:dos, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"b1b4364c959145a8ac727dec221b2898","type":"GO_TERM","name":"extrinsic component of phagophore assembly site membrane","canonical_id":"go:GO:0097632","description":"\"The component of the phagophore assembly site membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:mf]","metadata":null},{"id":"10c792e2a17d487fb37095f266befb29","type":"GO_TERM","name":"extrinsic component of plasma membrane","canonical_id":"go:GO:0019897","description":"\"The component of a plasma membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:curators, GOC:dos]","metadata":null},{"id":"4513a92aa1cf4985b93c37561137e9dd","type":"GO_TERM","name":"extrinsic component of plastid inner membrane","canonical_id":"go:GO:0035453","description":"\"The component of a plastid inner membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"7a529e72de764e6d9cf0663cb3c58453","type":"GO_TERM","name":"extrinsic component of plastid membrane","canonical_id":"go:GO:0035452","description":"\"The component of a plastid membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"ea5364b334a248fea8002f5f885f5d75","type":"GO_TERM","name":"extrinsic component of plastid thylakoid membrane","canonical_id":"go:GO:0035449","description":"\"The component of a plastid thylakoid membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"9e93d1ae57224a69b2d3096e64601210","type":"GO_TERM","name":"extrinsic component of postsynaptic density membrane","canonical_id":"go:GO:0099147","description":"\"The component of the postsynaptic density membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"53647a3f618945a8beb7213cfc087da1","type":"GO_TERM","name":"extrinsic component of postsynaptic early endosome membrane","canonical_id":"go:GO:0098998","description":"\"The component of the postsynaptic early endosome membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"ea5818246cb14b0892b59495fce79805","type":"GO_TERM","name":"extrinsic component of postsynaptic endocytic zone","canonical_id":"go:GO:0098893","description":"\"The component of the postsynaptic endocytic zone membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"d5d9fe856b504d0790df2b579f148fcf","type":"GO_TERM","name":"extrinsic component of postsynaptic endosome membrane","canonical_id":"go:GO:0098999","description":"\"The component of the postsynaptic endosome membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"80867837a34544e8b2e16267be866510","type":"GO_TERM","name":"extrinsic component of postsynaptic membrane","canonical_id":"go:GO:0098890","description":"\"The component of the postsynaptic membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"f51bc6f8bf844bb1931c41b030de1c66","type":"GO_TERM","name":"extrinsic component of postsynaptic recycling endosome membrane","canonical_id":"go:GO:0099005","description":"\"The component of the postsynaptic recycling endosome membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"95dbdb70a6b541de9a8f62717d2d9533","type":"GO_TERM","name":"extrinsic component of postsynaptic specialization membrane","canonical_id":"go:GO:0098892","description":"\"The component of the postsynaptic specialization membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"777ce7f76cfe44b19234775ed344ff00","type":"GO_TERM","name":"extrinsic component of presynaptic active zone membrane","canonical_id":"go:GO:0098891","description":"\"The component of the presynaptic active zone membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"e90f8b263cad46a1a297a397fbfe68ba","type":"GO_TERM","name":"extrinsic component of presynaptic endocytic zone membrane","canonical_id":"go:GO:0098894","description":"\"The component of the presynaptic endocytic zone membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"87813655449f4e1a84bfd70c99222ca1","type":"GO_TERM","name":"extrinsic component of presynaptic endosome membrane","canonical_id":"go:GO:0099007","description":"\"The component of the presynaptic endosome membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"d5d86077d6284e89affbc786cdea1375","type":"GO_TERM","name":"extrinsic component of presynaptic membrane","canonical_id":"go:GO:0098888","description":"\"The component of the presynaptic membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:autophagy, GOC:mf]","metadata":null},{"id":"47102132a366423abd8d1dd23775ddc1","type":"GO_TERM","name":"extrinsic component of stromal side of plastid inner membrane","canonical_id":"go:GO:0035454","description":"\"The component of a plastid inner membrane consisting of gene products and protein complexes that are loosely bound to its stromal surface, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"e5a4e3a34ad547348d43ad4ecc78ab95","type":"GO_TERM","name":"extrinsic component of stromal side of plastid thylakoid membrane","canonical_id":"go:GO:0035451","description":"\"The component of a plastid thylakoid membrane consisting of gene products and protein complexes that are loosely bound to its stromal surface, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"3134050b8216404ab023555fccc68e3c","type":"GO_TERM","name":"extrinsic component of synaptic membrane","canonical_id":"go:GO:0099243","description":"\"The component of the synaptic membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos]","metadata":null},{"id":"7e2ec7ddf2cb4432a9ff0827ce2dfbb6","type":"GO_TERM","name":"extrinsic component of synaptic vesicle membrane","canonical_id":"go:GO:0098850","description":"\"The component of the synaptic vesicle membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:dos]","metadata":null},{"id":"77f1e8a918d8449f97eed6581e3a56ac","type":"GO_TERM","name":"extrinsic component of thylakoid membrane","canonical_id":"go:GO:0035448","description":"\"The component of a thylakoid membrane consisting of gene products and protein complexes that are loosely bound to one of its surfaces, but not integrated into the hydrophobic region.\" [GOC:bf, GOC:dos]","metadata":null},{"id":"87c9ff9d2bf54b31a2f4105e0dbdb7fc","type":"DISEASE","name":"eye allergy","canonical_id":"mondo:0005551","description":null,"metadata":null},{"id":"4fd29347da9e4a78b53e7e82f4c0279b","type":"GO_TERM","name":"eye blink reflex","canonical_id":"go:GO:0060082","description":"\"The reflex process in which a mechanical stimulus applied to the eye elicits a response of the eyelid closing.\" [GOC:dph, PMID:2913208]","metadata":null},{"id":"0d99bfd6e3cc46ca92f78e25aa019afe","type":"GO_TERM","name":"eye development","canonical_id":"go:GO:0001654","description":"\"The process whose specific outcome is the progression of the eye over time, from its formation to the mature structure. The eye is the organ of sight.\" [GOC:jid, GOC:jl]","metadata":null},{"id":"8e58d14d23294cd78cef64578406fe58","type":"DISEASE","name":"eye disorder","canonical_id":"mondo:0005328","description":null,"metadata":null},{"id":"d848779773f34c45b5b1c4d74a4aa353","type":"GO_TERM","name":"eye field cell fate commitment involved in camera-type eye formation","canonical_id":"go:GO:0060898","description":"\"The commitment of neurectodermal cells to cells of the eye field and their capacity to differentiate into eye field cells. Eye field cells are neurectodermal cells that will form the optic placode.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"50f4b2c723b148f18399d0efd0d2f86c","type":"DISEASE","name":"eye inflammation","canonical_id":"efo:0005752","description":null,"metadata":null},{"id":"0a72c593546e4c2b8fe72f679e21ecc4","type":"GO_TERM","name":"eye morphogenesis","canonical_id":"go:GO:0048592","description":"\"The process in which the anatomical structures of the eye are generated and organized.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"245b6c84ace84c46bdb4dc75f2a4a5a9","type":"GO_TERM","name":"eye photoreceptor cell development","canonical_id":"go:GO:0042462","description":"\"Development of a photoreceptor, a sensory cell in the eye that reacts to the presence of light. They usually contain a pigment that undergoes a chemical change when light is absorbed, thus stimulating a nerve.\" [GOC:jl, ISBN:0192800981]","metadata":null},{"id":"c444a201ef5d4fc19ad6c362882c6841","type":"GO_TERM","name":"eye photoreceptor cell differentiation","canonical_id":"go:GO:0001754","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a photoreceptor cell, as found in the eye, the primary visual organ of most organisms.\" [GOC:curators]","metadata":null},{"id":"27120c19d0bb4d9e8125e10ff3b84956","type":"GO_TERM","name":"eye photoreceptor cell fate commitment","canonical_id":"go:GO:0042706","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an eye photoreceptor cell. A photoreceptor cell is a cell that responds to incident electromagnetic radiation. Different classes of photoreceptor have different spectral sensitivities and express different photosensitive pigments.\" [GOC:mtg_sensu]","metadata":null},{"id":"3de9d9ed4b034356847b5f38e077bad6","type":"GO_TERM","name":"eye pigment biosynthetic process","canonical_id":"go:GO:0006726","description":"\"The chemical reactions and pathways resulting in the formation of eye pigments, any general or particular coloring matter in living organisms, found or utilized in the eye.\" [GOC:ai]","metadata":null},{"id":"132715b0c9d74801b798c3c1961da19c","type":"GO_TERM","name":"eye pigment catabolic process","canonical_id":"go:GO:0046151","description":"\"The chemical reactions and pathways resulting in the breakdown of eye pigments, any general or particular coloring matter in living organisms, found or utilized in the eye.\" [GOC:ai]","metadata":null},{"id":"a7de26fd94564ff8aec567261ff9a8b7","type":"GO_TERM","name":"eye pigment granule organization","canonical_id":"go:GO:0008057","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of intracellular pigment storage granules in the eye.\" [PMID:9303295]","metadata":null},{"id":"5bdd0f2a02d943448ebd9c9032e29c98","type":"GO_TERM","name":"eye pigment metabolic process","canonical_id":"go:GO:0042441","description":"\"The chemical reactions and pathways involving eye pigments, any general or particular coloring matter in living organisms, found or utilized in the eye.\" [GOC:ai]","metadata":null},{"id":"f500ca249bec4f1e952168116c136141","type":"GO_TERM","name":"eye pigment precursor transport","canonical_id":"go:GO:0006856","description":"\"The directed movement of eye pigment precursors, the inactive forms of visual pigments, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"a7a6afeb46b74ebfa5ced27a4f53ddcf","type":"GO_TERM","name":"eye pigmentation","canonical_id":"go:GO:0048069","description":"\"Establishment of a pattern of pigment in the eye of an organism.\" [GOC:jid]","metadata":null},{"id":"e6ca749898b94b92aa146bf4d67025d3","type":"GO_TERM","name":"eye-antennal disc development","canonical_id":"go:GO:0035214","description":"\"Progression of the eye-antennal imaginal disc over time, from its initial formation through to its metamorphosis to form adult structures including the eye, antenna, head capsule and maxillary palps.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"8eb21c8bd7534215973762eb6323d5ad","type":"GO_TERM","name":"eye-antennal disc morphogenesis","canonical_id":"go:GO:0007455","description":"\"The process in which the anatomical structures derived from the eye-antennal disc are generated and organized. This includes the transformation of an eye-antennal imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into recognizable adult structures including the eye, antenna, head capsule and maxillary palps.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"db350313ae6342d2a4f2284c9b41cfea","type":"GO_TERM","name":"eyelid development in camera-type eye","canonical_id":"go:GO:0061029","description":"\"The progression of the eyelid in a camera-type eye from its formation to the mature state. The eyelid is a membranous cover that helps protect and lubricate the eye.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"098d52e1f22d4fe89e1a32bf484a6025","type":"GO_TERM","name":"eyespot apparatus","canonical_id":"go:GO:1990413","description":"\"A small pigmented organelle used in single-celled organisms to detect light.\" [Wikipedia:Eyespot_apparatus]","metadata":null},{"id":"545b586ad93e420d8bca2e09c9b90c6c","type":"DRUG","name":"ezetimibe","canonical_id":"gtopdb:6816","description":null,"metadata":null},{"id":"c26ca93f619348a383b7eafc239d498f","type":"DRUG","name":"ezetimibe","canonical_id":"mesh:D000069438","description":null,"metadata":null},{"id":"245c18c5307049a7b94d137443df1894","type":"DRUG","name":"ezetimibe","canonical_id":"chembl:CHEMBL1138","description":null,"metadata":null},{"id":"508f59fb8c9f4db7ac5ff940f69d1197","type":"COMBINATION_TREATMENT","name":"ezetimibe + fluvastatin","canonical_id":"ctgov_combo:ctgov-combo-1956384444ee1287","description":null,"metadata":null},{"id":"2f1a27291a6042178ba0d7ac6191d353","type":"COMBINATION_TREATMENT","name":"ezetimibe + fluvastatin + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-79dbdf950b22eb8e","description":null,"metadata":null},{"id":"f25e06f1155c465980edd39f8186659d","type":"COMBINATION_TREATMENT","name":"ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-82186db8856cde7d","description":null,"metadata":null},{"id":"5bbab1533919498d825b3693aef6d662","type":"COMBINATION_TREATMENT","name":"ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-68f7ed05d9e7ad73","description":null,"metadata":null},{"id":"88acd1f612724d3bb9eb3f153d000e6e","type":"COMBINATION_TREATMENT","name":"ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-85f44181f45b7266","description":null,"metadata":null},{"id":"741410f403b946e8b0318c97b58d9891","type":"COMBINATION_TREATMENT","name":"ezetimibe + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-18e0c73e39e872dc","description":null,"metadata":null},{"id":"a3c3e675668e46de97ebbf940dc5a7a1","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-4f9257f816207323","description":null,"metadata":null},{"id":"2f0838c21e464726ae03aaecc9eaa105","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-8bcdce87614fdf4e","description":null,"metadata":null},{"id":"3b14fdcba6f24a6d9ab22712dcc5df82","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-ddfc10957d90c1ce","description":null,"metadata":null},{"id":"aed6bf10165246e8b9b154c218ee0c97","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-8977177b322431f6","description":null,"metadata":null},{"id":"22dbffd235df46939b87eba0ddbfccd8","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-1190635e428af8e4","description":null,"metadata":null},{"id":"2806538642f940c2a28597858b694423","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-7e31b92e3fe2bbd4","description":null,"metadata":null},{"id":"0a0cbf1b7aca4e8f9914aee99f379d12","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-c185c496d073f03b","description":null,"metadata":null},{"id":"70c53fd7adde49eeb5a81a0b858134b2","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-08745731adfc156f","description":null,"metadata":null},{"id":"8ee6e62f2d35471ea55ceabe367de74b","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-c4b80b8193168885","description":null,"metadata":null},{"id":"e90f3fc31069477cba31458fc98f1d08","type":"COMBINATION_TREATMENT","name":"ezetimibe + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-88a5b7042fd8924d","description":null,"metadata":null},{"id":"74e682adda874c20979d4f99394a7419","type":"TRIAL","name":"fFN & E3 in the Prediction of PTB in Women With Twin Pregnancies Receiving 17OHP or Placebo","canonical_id":"clinicaltrials.gov:NCT00156000","description":"Preterm Delivery; Preterm Birth","metadata":null},{"id":"f8b8fde999c44f788f78e211b6e14abe","type":"GO_TERM","name":"fMet-Leu-Phe receptor binding","canonical_id":"go:GO:0031761","description":"\"Binding to a fMet-Leu-Phe receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"746c6d692a7d405b92b38032d87b59cb","type":"GO_TERM","name":"face development","canonical_id":"go:GO:0060324","description":"\"The biological process whose specific outcome is the progression of a face from an initial condition to its mature state. The face is the ventral division of the head.\" [GOC:dph]","metadata":null},{"id":"a9bb304d944743b1aa54d40dea6df692","type":"GO_TERM","name":"face morphogenesis","canonical_id":"go:GO:0060325","description":"\"The process in which the anatomical structures of the face are generated and organized. The face is the ventral division of the head.\" [GOC:dph]","metadata":null},{"id":"d748ccbf31614187976a674cc13860f0","type":"GO_TERM","name":"facial nerve development","canonical_id":"go:GO:0021561","description":"\"The process whose specific outcome is the progression of the facial nerve over time, from its formation to the mature structure. This sensory and motor nerve supplies the muscles of facial expression and the expression and taste at the anterior two-thirds of the tongue. The principal branches are the superficial ophthalmic, buccal, palatine and hyomandibular. The main trunk synapses within pterygopalatine ganglion in the parotid gland and this ganglion then gives off nerve branches which supply the lacrimal gland and the mucous secreting glands of the nasal and oral cavities.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"985306093f584e08a7fbd3f615cf9fb7","type":"GO_TERM","name":"facial nerve formation","canonical_id":"go:GO:0021611","description":"\"The process that gives rise to the facial nerve. This process pertains to the initial formation of a structure from unspecified parts. This sensory and motor nerve supplies the muscles of facial expression and the expression and taste at the anterior two-thirds of the tongue. The principal branches are the superficial ophthalmic, buccal, palatine and hyomandibular. The main trunk synapses within pterygopalatine ganglion in the parotid gland and this ganglion then gives of nerve branches which supply the lacrimal gland and the mucous secreting glands of the nasal and oral cavities.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"e144e7fa896547d494f6d7ed18b75b54","type":"GO_TERM","name":"facial nerve maturation","canonical_id":"go:GO:0021613","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the facial nerve to attain its fully functional state. This sensory and motor nerve supplies the muscles of facial expression and the expression and taste at the anterior two-thirds of the tongue. The principal branches are the superficial ophthalmic, buccal, palatine and hyomandibular. The main trunk synapses within pterygopalatine ganglion in the parotid gland and this ganglion then gives of nerve branches which supply the lacrimal gland and the mucous secreting glands of the nasal and oral cavities.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"aa8232b35a1a4759a9c711ca87babc0e","type":"GO_TERM","name":"facial nerve morphogenesis","canonical_id":"go:GO:0021610","description":"\"The process in which the anatomical structure of the facial nerve is generated and organized. This sensory and motor nerve supplies the muscles of facial expression and the expression and taste at the anterior two-thirds of the tongue. The principal branches are the superficial ophthalmic, buccal, palatine and hyomandibular. The main trunk synapses within pterygopalatine ganglion in the parotid gland and this ganglion then gives of nerve branches which supply the lacrimal gland and the mucous secreting glands of the nasal and oral cavities.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"09484683bacc4304983d0bb016f2cd9d","type":"GO_TERM","name":"facial nerve structural organization","canonical_id":"go:GO:0021612","description":"\"The process that contributes to the act of creating the structural organization of the facial nerve. This process pertains to the physical shaping of a rudimentary structure. This sensory and motor nerve supplies the muscles of facial expression and the expression and taste at the anterior two-thirds of the tongue. The principal branches are the superficial ophthalmic, buccal, palatine and hyomandibular. The main trunk synapses within pterygopalatine ganglion in the parotid gland and this ganglion then gives of nerve branches which supply the lacrimal gland and the mucous secreting glands of the nasal and oral cavities.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d017b8b1a69048c0b4fdf2837963cd7b","type":"GO_TERM","name":"facial nucleus development","canonical_id":"go:GO:0021754","description":"\"The process whose specific outcome is the progression of the facial nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"060fccfc9e0c4b9fba702f8f7b4c8b92","type":"GO_TERM","name":"facial suture morphogenesis","canonical_id":"go:GO:0097096","description":"\"The process in which any suture between facial bones is generated and organized.\" [GOC:pr, GOC:sl, Wikipedia:Cranial_sutures, Wikipedia:Head_and_neck_anatomy#Musculoskeletal_system]","metadata":null},{"id":"8181adbcd23241c3a6bf278c3748b26e","type":"GO_TERM","name":"facioacoustic ganglion development","canonical_id":"go:GO:1903375","description":"\"The process whose specific outcome is the progression of an acoustico-facial VII-VIII ganglion complex over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:bf, GOC:mat, GOC:PARL, GOC:TermGenie, PMID:18356247]","metadata":null},{"id":"01bde1ee600943fe8bc6345ea74722fb","type":"GO_TERM","name":"facioacoustic ganglion morphogenesis","canonical_id":"go:GO:1904836","description":"\"The developmental process by which an acoustico-facial VII-VIII ganglion complex is generated and organized.\" [GO_REF:0000083, GOC:bf, GOC:mat, GOC:PARL, GOC:TermGenie, PMID:18356247]","metadata":null},{"id":"5f17f2dcbefc4342bef475a4d0b929e1","type":"DISEASE","name":"factor V deficiency","canonical_id":"mondo:0020586","description":null,"metadata":null},{"id":"7a235f58b58142129d610e7542a5ad13","type":"DISEASE","name":"factor X deficiency","canonical_id":"mondo:0002247","description":null,"metadata":null},{"id":"fd5633241f054982af171d9d102a76c1","type":"GO_TERM","name":"facultative heterochromatin formation","canonical_id":"go:GO:0140718","description":"\"The compaction of chromatin into a conformation that is refractory to transcription but that can be converted to euchromatin and allow transcription in specific contexts. These can be temporal (e.g., developmental states or specific cell-cycle stages), spatial (e.g., nuclear localization changes from the center to the periphery or vice versa due to exogenous factors/signals), or parental/heritable (e.g., monoallelic gene expression). In metazoa, this involves the methylation of histone H3K27, and in certain cases methylation of H3K9. On the other hand, in unicellular eukaryotes, only methylation of H3K9 is involved and H3K27 is not methylated.\" [PMID:17936700]","metadata":null},{"id":"97c3982e344d44b497accfce1f151a59","type":"DRUG","name":"fadrozole","canonical_id":"gtopdb:8311","description":null,"metadata":null},{"id":"de6d21cab5e84237ae949a06406ddf3b","type":"DISEASE","name":"fallopian tube cancer","canonical_id":"mondo:0002158","description":null,"metadata":null},{"id":"90e13f0104424a428c23de8f23e80e78","type":"DISEASE","name":"fallopian tube carcinoma","canonical_id":"mondo:0006206","description":null,"metadata":null},{"id":"8a8b4860d7e541ccb480f05867e4ca12","type":"DISEASE","name":"fallopian tube neoplasm","canonical_id":"mondo:0021092","description":null,"metadata":null},{"id":"ecdd228edcbb451db0e688a2a75f5ce0","type":"DRUG","name":"famciclovir","canonical_id":"mesh:D000077595","description":null,"metadata":null},{"id":"9520d3aeba734fbc8823fe3355a605f7","type":"DISEASE","name":"familial Mediterranean fever","canonical_id":"mondo:0018088","description":null,"metadata":null},{"id":"598577d3b0044016bd549193a9fa5454","type":"DISEASE","name":"familial adenomatous polyposis 4","canonical_id":"mondo:0044300","description":null,"metadata":null},{"id":"6a94f6e1e6494b3099e1e9434b1ec50e","type":"DISEASE","name":"familial amyotrophic lateral sclerosis","canonical_id":"mondo:0005144","description":null,"metadata":null},{"id":"a1130e3c8a524ec1a4f5a93573f2d035","type":"DISEASE","name":"familial atypical multiple mole melanoma syndrome","canonical_id":"mondo:0018453","description":null,"metadata":null},{"id":"17a2c13d8d2f49d182d5ba2f0d7fae4d","type":"DISEASE","name":"familial cold autoinflammatory syndrome","canonical_id":"mondo:0018768","description":null,"metadata":null},{"id":"7455b3709934452e91d03ac096d6ead6","type":"DISEASE","name":"familial gestational hyperthyroidism","canonical_id":"mondo:0011309","description":null,"metadata":null},{"id":"4aa2e362227946a6ad613bfd6af384c6","type":"DISEASE","name":"familial glucocorticoid deficiency","canonical_id":"mondo:0008733","description":null,"metadata":null},{"id":"827be0951fd045a7bbd3309aecac0e5c","type":"DISEASE","name":"familial hyperaldosteronism type II","canonical_id":"mondo:0011576","description":null,"metadata":null},{"id":"68f1c2d7a94844deab0c4f474804c53e","type":"DISEASE","name":"familial hypercholesterolemia","canonical_id":"mondo:0005439","description":null,"metadata":null},{"id":"34e9104bee4d4479855bd608529fe3d8","type":"DISEASE","name":"familial hyperinsulinism","canonical_id":"mondo:0017182","description":null,"metadata":null},{"id":"8f6d96da44c6433f80e5139bc7b504fb","type":"DISEASE","name":"familial hyperlipidemia","canonical_id":"mondo:0001336","description":null,"metadata":null},{"id":"2459571c0bf44219ab79149473ffee81","type":"DISEASE","name":"familial hyperthyroidism due to mutations in TSH receptor","canonical_id":"mondo:0012203","description":null,"metadata":null},{"id":"3b673d246c8141959e57dab6a08e4bfe","type":"DISEASE","name":"familial hypocalciuric hypercalcemia","canonical_id":"mondo:0018458","description":null,"metadata":null},{"id":"304c2d88871348ff83ea0819293686f9","type":"DISEASE","name":"familial hypocalciuric hypercalcemia 1","canonical_id":"mondo:0007791","description":null,"metadata":null},{"id":"0e6981a580fb476499632ffd1e6a72cb","type":"DISEASE","name":"familial hypoparathyroidism","canonical_id":"mondo:0016390","description":null,"metadata":null},{"id":"8afa4783eba540d891d9062c2d438f22","type":"DISEASE","name":"familial isolated dilated cardiomyopathy","canonical_id":"mondo:0700335","description":null,"metadata":null},{"id":"42a452518d7e4b06b798bbb5c55fdf29","type":"DISEASE","name":"familial juvenile hyperuricemic nephropathy type 2","canonical_id":"mondo:0013128","description":null,"metadata":null},{"id":"0358f37f286c479bb9758c382fd03ef1","type":"DISEASE","name":"familial long QT syndrome","canonical_id":"mondo:0019171","description":null,"metadata":null},{"id":"32e1c3e468d54def94cc088cd550b411","type":"DISEASE","name":"familial male-limited precocious puberty","canonical_id":"mondo:0008303","description":null,"metadata":null},{"id":"46341d5d5a8849529a479c27039eb71f","type":"DISEASE","name":"familial medullary thyroid carcinoma","canonical_id":"mondo:0007958","description":null,"metadata":null},{"id":"78ccfad0abff4fbea476afe29e5eae4a","type":"DISEASE","name":"familial melanoma","canonical_id":"mondo:0018961","description":null,"metadata":null},{"id":"8d51d32ad20d4b0eb6a49eedcf108e9d","type":"DISEASE","name":"familial pancreatic carcinoma","canonical_id":"mondo:0015278","description":null,"metadata":null},{"id":"c877a590008b4ec9a85696029b11a909","type":"DISEASE","name":"familial primary hypomagnesemia","canonical_id":"mondo:0018100","description":null,"metadata":null},{"id":"96b25051b12447ae8dd52dae17bf4e1f","type":"DISEASE","name":"familial primary localized cutaneous amyloidosis","canonical_id":"mondo:0007101","description":null,"metadata":null},{"id":"7ef5bb9e070d4b42a01409c761ad015c","type":"DISEASE","name":"familial scaphocephaly syndrome, McGillivray type","canonical_id":"mondo:0012307","description":null,"metadata":null},{"id":"8537fce42b96499da4690e365217e793","type":"DISEASE","name":"familial sleep-related hypermotor epilepsy","canonical_id":"mondo:0000030","description":null,"metadata":null},{"id":"4f9b21ad35db4bc1b467533793f348d5","type":"DISEASE","name":"familial thyroid dyshormonogenesis","canonical_id":"mondo:0010132","description":null,"metadata":null},{"id":"20bd0e2e85c74c9a93a0e18bac720e6d","type":"DRUG","name":"famitinib","canonical_id":"gtopdb:7886","description":null,"metadata":null},{"id":"45ec76e4fa9d4ab79b73620bc9e766a5","type":"DRUG","name":"famitinib","canonical_id":"chembl:CHEMBL1278146","description":null,"metadata":null},{"id":"23a25d96b9f442e6903bf0aa4dc226f8","type":"DRUG","name":"famotidine","canonical_id":"gtopdb:7074","description":null,"metadata":null},{"id":"142fcdbb9667481bbcfa4293c7c6b4cc","type":"DRUG","name":"famotidine","canonical_id":"chembl:CHEMBL902","description":null,"metadata":null},{"id":"07b8cd04932c43d79a8ecdec58608d68","type":"COMBINATION_TREATMENT","name":"famotidine + flurbiprofen","canonical_id":"ctgov_combo:ctgov-combo-52c03d3f2ad29e44","description":null,"metadata":null},{"id":"003f1ef733a24c7cb0edca62b1ad7137","type":"COMBINATION_TREATMENT","name":"famotidine + loratadine","canonical_id":"ctgov_combo:ctgov-combo-7d222e8f90121aa7","description":null,"metadata":null},{"id":"8edf96a51b7c4395ae7303564d1b3927","type":"COMBINATION_TREATMENT","name":"famotidine + loratadine","canonical_id":"ctgov_combo:ctgov-combo-24f238b275530c84","description":null,"metadata":null},{"id":"1f3d4b04218d4cd1ad67b31cc32507bc","type":"COMBINATION_TREATMENT","name":"famotidine + moxetumomab pasudotox","canonical_id":"ctgov_combo:ctgov-combo-c1e543cdf1370c93","description":null,"metadata":null},{"id":"0896c50e1ff64292a51c2b2c9530ca2b","type":"COMBINATION_TREATMENT","name":"famotidine + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-16174f904ae3a124","description":null,"metadata":null},{"id":"703bb373472748e8a74142b1627d9222","type":"COMBINATION_TREATMENT","name":"famotidine + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-7afa7fc9217dd4db","description":null,"metadata":null},{"id":"ac96f7d6d79c48e69312937ee79eeb02","type":"COMBINATION_TREATMENT","name":"famotidine + omeprazole","canonical_id":"ctgov_combo:ctgov-combo-2d6f9e7e1d2aacfe","description":null,"metadata":null},{"id":"38da3d8917c8420aa1923cb23949b25d","type":"COMBINATION_TREATMENT","name":"famotidine + ranitidine","canonical_id":"ctgov_combo:ctgov-combo-fa6d4254877a3a11","description":null,"metadata":null},{"id":"0f36ccb731db4947a3d642fef4a69b8d","type":"DRUG","name":"fampridine","canonical_id":"gtopdb:2416","description":null,"metadata":null},{"id":"aa870462880f47d4ab1012f3bec99faa","type":"DRUG","name":"fampridine","canonical_id":"mesh:D015761","description":null,"metadata":null},{"id":"981a739a0844493b8ea2d7d5db158a33","type":"DRUG","name":"fampridine","canonical_id":"chembl:CHEMBL284348","description":null,"metadata":null},{"id":"c89ef2f42c824388af7a0e37d5a981f8","type":"GO_TERM","name":"far-red light photoreceptor activity","canonical_id":"go:GO:0031516","description":"\"The function of absorbing and responding to electromagnetic radiation with a wavelength of approximately 730nm. The response may involve a change in conformation.\" [GOC:nln]","metadata":null},{"id":"45a0eb1b2d7e48ca841ccb80f506c02b","type":"GO_TERM","name":"far-red light signaling pathway","canonical_id":"go:GO:0010018","description":"\"The series of molecular signals initiated upon sensing of far red light by a photoreceptor molecule. Far red light is electromagnetic radiation of wavelength 700-800nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:lr, GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"236c507ee4e24a89852e34d8613992f3","type":"DRUG","name":"faricimab","canonical_id":"gtopdb:11420","description":null,"metadata":null},{"id":"edbb9ef3456a4d41928b7f17d73b6a23","type":"DRUG","name":"faricimab","canonical_id":"chembl:CHEMBL4297750","description":null,"metadata":null},{"id":"33e25ea4e56d4f4a8e4448b5eb7bd8d5","type":"GO_TERM","name":"farnesal dehydrogenase (NAD+) activity","canonical_id":"go:GO:0120553","description":"\"Catalysis of the reaction: (2E,6E)-farnesal + NAD+ + H2O = (2E,6E)-farnesoate + NADH + 2 H+.\" [PMID:23639754, RHEA:24216]","metadata":null},{"id":"e6c8765aa038469595bc3a66bdbdeda7","type":"GO_TERM","name":"farnesoate epoxidase activity","canonical_id":"go:GO:0120512","description":"\"Catalysis of the reaction: (2E,6E)-farnesoate + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + juvenile hormone III carboxylate + oxidized [NADPH--hemoprotein reductase].\" [PMID:22412378, PMID:38741075, RHEA:43724]","metadata":null},{"id":"8599b0d723fc4aec992b20dfb64f3434","type":"GO_TERM","name":"farnesoic acid O-methyltransferase activity","canonical_id":"go:GO:0019010","description":"\"Catalysis of the reaction: (2E,6E)-farnesoate + S-adenosyl-L-methionine = methyl (2E,6E)-farnesoate + S-adenosyl-L-homocysteine. Also converts juvenile hormone III carboxylate into juvenile hormone-III.\" [EC:2.1.1.325, PMID:12135499, PMID:14530389, PMID:18549957]","metadata":null},{"id":"cc3fc43565a74dca97c8c7d3f814ffcc","type":"GO_TERM","name":"farnesol 2-isomerase activity","canonical_id":"go:GO:0047885","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesol = 2-cis,6-trans-farnesol.\" [EC:5.2.1.9, RHEA:13401]","metadata":null},{"id":"b8a497cfd0094a0a98b6cebbc5ad209f","type":"GO_TERM","name":"farnesol biosynthetic process","canonical_id":"go:GO:0006715","description":"\"The chemical reactions and pathways resulting in the formation of the sesquiterpenoid alcohol farnesol, 3,7,11-trimethyl-2,6,10,dodecatrien-1-ol.\" [ISBN:0198547684]","metadata":null},{"id":"78cefd28999a4e9c99c2b7f80dbbb05e","type":"GO_TERM","name":"farnesol catabolic process","canonical_id":"go:GO:0016488","description":"\"The chemical reactions and pathways resulting in the breakdown of the sesquiterpenoid alcohol farnesol, 3,7,11-trimethyl-2,6,10,dodecatrien-1-ol.\" [GOC:curators]","metadata":null},{"id":"d1ea440e865542ecbcfd1db3c2ad0455","type":"GO_TERM","name":"farnesol dehydrogenase activity","canonical_id":"go:GO:0047886","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesol + NADP+ = 2-trans,6-trans-farnesal + H+ + NADPH.\" [EC:1.1.1.216, RHEA:14697]","metadata":null},{"id":"5c7a13657b1442c7ab9c10dcd081d520","type":"GO_TERM","name":"farnesol metabolic process","canonical_id":"go:GO:0016487","description":"\"The chemical reactions and pathways involving the sesquiterpenoid alcohol farnesol, 3,7,11-trimethyl-2,6,10,dodecatrien-1-ol.\" [GOC:curators]","metadata":null},{"id":"74b12bbf353d48508fa34bbaf5e1fe73","type":"GO_TERM","name":"farnesyl diphosphatase activity","canonical_id":"go:GO:0120557","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + H2O = (2E,6E)-farnesyl phosphate + phosphate + H+.\" [PMID:19168029, RHEA:48128]","metadata":null},{"id":"3a6f2dafa79e4ca4b99da39061d62190","type":"GO_TERM","name":"farnesyl diphosphate catabolic process","canonical_id":"go:GO:0045339","description":"\"The chemical reactions and pathways resulting in the breakdown of farnesyl diphosphate.\" [GOC:curators]","metadata":null},{"id":"4ed968bc1a0741ab951fa69109631729","type":"GO_TERM","name":"farnesyl diphosphate kinase activity","canonical_id":"go:GO:0047887","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate + ATP = 2-trans,6-trans-farnesyl triphosphate + ADP.\" [RHEA:21544]","metadata":null},{"id":"98ce221ae6014432943e3c9c45a01c7c","type":"GO_TERM","name":"farnesyl diphosphate metabolic process","canonical_id":"go:GO:0045338","description":"\"The chemical reactions and pathways involving farnesyl diphosphate, an intermediate in carotenoid, sesquiterpene, squalene and sterol biosynthesis, as well as a substrate in protein farnesylation.\" [GOC:curators]","metadata":null},{"id":"034ac51d4e994211b7ace2fd6331f13f","type":"GO_TERM","name":"farnesylated protein binding","canonical_id":"go:GO:0001918","description":"\"Binding to a farnesylated protein.\" [GOC:add, PMID:14555765]","metadata":null},{"id":"74671916cd78412d83ced71d318ada64","type":"GO_TERM","name":"farnesylcysteine lyase activity","canonical_id":"go:GO:0102149","description":"\"Catalysis of the reaction: S-[(2E,6E)-farnesyl]-L-cysteine + O2 + H2O = (2-trans,6-trans)-farnesal + L-cysteine + H2O2.\" [EC:1.8.3.6]","metadata":null},{"id":"8080d4f284704713a892a6ad1582b802","type":"DRUG","name":"faropenem","canonical_id":"mesh:C107057","description":null,"metadata":null},{"id":"e8bcbd82f6f94c0bbb31f341320ef666","type":"GO_TERM","name":"fascia adherens","canonical_id":"go:GO:0005916","description":"\"A cell-cell junction that contains the transmembrane protein N-cadherin, which interacts with identical molecules from neighbouring cells to form a tight mechanical intercellular link; forms a large portion of the intercalated disc, the structure at which myofibrils terminate in cardiomyocytes.\" [GOC:aruk, GOC:bc, GOC:mtg_muscle, PMID:11732910]","metadata":null},{"id":"f5817db1f33344c5a3c1d7d7884450e0","type":"GO_TERM","name":"fasciculation of motor neuron axon","canonical_id":"go:GO:0097156","description":"\"The collection of motor neuron axons into a bundle of rods, known as a fascicle.\" [GOC:lb, PMID:18403711]","metadata":null},{"id":"e4ee97dd897f4d9b96c14444fdd54109","type":"GO_TERM","name":"fasciculation of sensory neuron axon","canonical_id":"go:GO:0097155","description":"\"The collection of sensory neuron axons into a bundle of rods, known as a fascicle.\" [GOC:lb, PMID:18403711]","metadata":null},{"id":"6373123c55cb46fba55d7bdb23b4bef6","type":"GO_TERM","name":"fast endocytic recycling","canonical_id":"go:GO:0032457","description":"\"The directed movement of membrane-bounded vesicles from peripheral endocytic compartments back to the plasma membrane where they are recycled for further rounds of transport.\" [GOC:ecd, PMID:16473635]","metadata":null},{"id":"205e72a80fba4b128e0919c5b3749167","type":"GO_TERM","name":"fast endophilin-mediated endocytosis","canonical_id":"go:GO:7770083","description":"\"An endocytosis process in which plasma membrane cargo is internalized through endophilin-enriched, clathrin-uncoated invaginations.\" [PMID:25517094]","metadata":null},{"id":"af29aa9e433644e292628d5280fd5502","type":"GO_TERM","name":"fast, calcium ion-dependent exocytosis of neurotransmitter","canonical_id":"go:GO:0098746","description":"\"The fast, initial phase of calcium ion-induced neurotransmitter release, via exocytosis, into the synaptic cleft. This depends on low affinity calcium sensors and typically begins a fraction of a millisecond after Ca2+ influx, and decays rapidly (1-10ms) with a decay constant of around 5-10ms. The underlying molecular mechanisms of this process are distinct from those of the later, slow phase of release.\" [GOC:dos, GOC:pad, GOC:PARL, PMID:4405553, PMID:7809151, PMID:7954835]","metadata":null},{"id":"9dd09854658f4a7cbc6b6996e8e6f275","type":"GO_TERM","name":"fast-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031443","description":"\"A process in which force is generated within fast-twitch skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The fast-twitch skeletal muscle is characterized by fast time parameters, high force development and fatiguability.\" [GOC:ef, GOC:mah, GOC:mtg_muscle]","metadata":null},{"id":"7686e08247454edbaa97ac91a2f51fd7","type":"GO_TERM","name":"fastigial nucleus development","canonical_id":"go:GO:0021738","description":"\"The process whose specific outcome is the progression of the fastigial nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"4f60ae7a915240c5aaef7794b5044d6e","type":"DRUG","name":"fasudil","canonical_id":"gtopdb:5181","description":null,"metadata":null},{"id":"12862d7ffb6145ed9f97b402d966fce1","type":"DRUG","name":"fasudil","canonical_id":"mesh:C049347","description":null,"metadata":null},{"id":"3a3ca17b50ac4f319a11daad87f379dd","type":"DRUG","name":"fasudil","canonical_id":"chembl:CHEMBL38380","description":null,"metadata":null},{"id":"ca41bbad6ff14860b56e958f9ae500d5","type":"GO_TERM","name":"fat body development","canonical_id":"go:GO:0007503","description":"\"The process whose specific outcome is the progression of the fat body over time, from its formation to the mature structure. A fat body is an insect gland dorsal to the insect gut, with a function analogous to that of the vertebrate liver. It is a storage organ for fats, glycogen and protein and is a major site of intermediary metabolism.\" [ISBN:0582227089]","metadata":null},{"id":"7cd1db2a64a44613a9081a38619b6f2a","type":"GO_TERM","name":"fat cell apoptotic process","canonical_id":"go:GO:1904606","description":"\"Any apoptotic process in a fat cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:17024416]","metadata":null},{"id":"2be9e7a243a8467581ba6ed5d9550f27","type":"GO_TERM","name":"fat cell differentiation","canonical_id":"go:GO:0045444","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an adipocyte, an animal connective tissue cell specialized for the synthesis and storage of fat.\" [CL:0000136, GOC:curators]","metadata":null},{"id":"b963dda0733046dbbaa751f135352327","type":"GO_TERM","name":"fat cell proliferation","canonical_id":"go:GO:0070341","description":"\"The multiplication or reproduction of fat cells by cell division, resulting in the expansion of their population. A fat cell is an animal connective tissue cell specialized for the synthesis and storage of fat.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"1fee5f7046fa419cbef50120212e6713","type":"GO_TERM","name":"fat pad development","canonical_id":"go:GO:0060613","description":"\"The progression of a fat pad from its initial formation to its mature structure. A fat pad is an accumulation of adipose tissue.\" [GOC:dph]","metadata":null},{"id":"126f0c63e12b4876ba83e779ccfd5580","type":"GO_TERM","name":"fat-soluble vitamin biosynthetic process","canonical_id":"go:GO:0042362","description":"\"The chemical reactions and pathways resulting in the formation of any of a diverse group of vitamins that are soluble in organic solvents and relatively insoluble in water.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"85fa493e46744f00840aa06e200b8fe0","type":"GO_TERM","name":"fat-soluble vitamin catabolic process","canonical_id":"go:GO:0042363","description":"\"The chemical reactions and pathways resulting in the breakdown of any of a diverse group of vitamins that are soluble in organic solvents and relatively insoluble in water.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"fff364f166ba4659832d362e6c22bcfa","type":"GO_TERM","name":"fatty acid 2-hydroxylase activity","canonical_id":"go:GO:0080132","description":"\"Catalysis of the hydroxylation of the C-2 position in a fatty acid. The 2-hydroxylation may occur on free fatty acids or within the fatty acyl chain of a sphingolipid.\" [PMID:36902339]","metadata":null},{"id":"92e77e3bd5e44b1c9ae4e0cab2baa587","type":"GO_TERM","name":"fatty acid O-methyltransferase activity","canonical_id":"go:GO:0030733","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a fatty acid = S-adenosyl-L-homocysteine + a fatty acid methyl ester.\" [EC:2.1.1.15]","metadata":null},{"id":"7fda1c2de1064df28365911e71460de5","type":"GO_TERM","name":"fatty acid alpha-dioxygenase activity","canonical_id":"go:GO:0102672","description":"\"Catalysis of the reaction: a 1,2-saturated fatty acid + O2 = a (2R)-2-hydroperoxy fatty acid.\" [RHEA:63508]","metadata":null},{"id":"e26fd0e1f9934a80b4f613f066297539","type":"GO_TERM","name":"fatty acid alpha-oxidation","canonical_id":"go:GO:0001561","description":"\"A metabolic pathway by which 3-methyl branched fatty acids are degraded. These compounds are not degraded by the normal peroxisomal beta-oxidation pathway, because the 3-methyl blocks the dehydrogenation of the hydroxyl group by hydroxyacyl-CoA dehydrogenase. The 3-methyl branched fatty acid is converted in several steps to pristenic acid, which can then feed into the beta-oxidative pathway.\" [PMID:10198260]","metadata":null},{"id":"8abfff471bc24af0958009d405ae512f","type":"GO_TERM","name":"fatty acid amide hydrolase activity","canonical_id":"go:GO:0017064","description":"\"Catalysis of the hydrolysis of a fatty acid amide to yield a fatty acid.\" [PMID:15952893]","metadata":null},{"id":"953ab36b223649718d6715e9a632404c","type":"GO_TERM","name":"fatty acid beta-oxidation","canonical_id":"go:GO:0006635","description":"\"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"5d9616a1d8664e1f811ba0935664ee98","type":"GO_TERM","name":"fatty acid beta-oxidation multienzyme complex","canonical_id":"go:GO:0036125","description":"\"A multienzyme complex possessing three kinds of enzymes that catalyze the chain reactions in the fatty acid beta-oxidation cycle, enoyl-CoA hydratase (ECH), 3-hydroxyacyl-CoA dehydrogenase (HACD), and acetyl-CoA C-acyltransferase (KACT).\" [GOC:imk, PMID:12115060, PMID:16472743]","metadata":null},{"id":"2edd2502ec1b412fbfed2b5e94bf9015","type":"GO_TERM","name":"fatty acid beta-oxidation using acyl-CoA dehydrogenase","canonical_id":"go:GO:0033539","description":"\"A fatty acid beta-oxidation pathway in which the initial step of each oxidation cycle, which converts an acyl-CoA to a trans-2-enoyl-CoA, is catalyzed by acyl-CoA dehydrogenase; the electrons removed by oxidation pass through the respiratory chain to oxygen and leave H2O as the product. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and ends when only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).\" [GOC:mah, MetaCyc:FAO-PWY]","metadata":null},{"id":"fdc76d84f73440418108d088bd6e32b5","type":"GO_TERM","name":"fatty acid beta-oxidation using acyl-CoA oxidase","canonical_id":"go:GO:0033540","description":"\"A fatty acid beta-oxidation pathway in which the initial step, which converts an acyl-CoA to a trans-2-enoyl-CoA, is catalyzed by acyl-CoA oxidase; the electrons removed by oxidation pass directly to oxygen and produce hydrogen peroxide, which is cleaved by peroxisomal catalases. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and ends when only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).\" [GOC:mah, MetaCyc:PWY-5136]","metadata":null},{"id":"4b34b1606bd349da88b2d8cc6d55e1a1","type":"GO_TERM","name":"fatty acid binding","canonical_id":"go:GO:0005504","description":"\"Binding to a fatty acid, an aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.\" [ISBN:0198506732]","metadata":null},{"id":"65e9aa1493644508847f8665e4f5911d","type":"GO_TERM","name":"fatty acid biosynthetic process","canonical_id":"go:GO:0006633","description":"\"The chemical reactions and pathways resulting in the formation of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"7211feeda6b243d5bf303935050afcfb","type":"GO_TERM","name":"fatty acid catabolic process","canonical_id":"go:GO:0009062","description":"\"The chemical reactions and pathways resulting in the breakdown of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.\" [GOC:curators]","metadata":null},{"id":"06c20efac38d465d9571fa5df800e066","type":"GO_TERM","name":"fatty acid derivative binding","canonical_id":"go:GO:1901567","description":"\"Binding to fatty acid derivative.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"d17c3bbc8ff6421fb16afb691352fdb6","type":"GO_TERM","name":"fatty acid derivative biosynthetic process","canonical_id":"go:GO:1901570","description":"\"The chemical reactions and pathways resulting in the formation of fatty acid derivative.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"50ebab0ddf5245cabfd15e1e7c8b0819","type":"GO_TERM","name":"fatty acid derivative catabolic process","canonical_id":"go:GO:1901569","description":"\"The chemical reactions and pathways resulting in the breakdown of fatty acid derivative.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"d2cfceac2a3c4a13b05f5af10afd89a6","type":"GO_TERM","name":"fatty acid derivative metabolic process","canonical_id":"go:GO:1901568","description":"\"The chemical reactions and pathways involving fatty acid derivative.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"c1a86e8f8d8644d09b5096c83b6fcc7c","type":"GO_TERM","name":"fatty acid derivative transport","canonical_id":"go:GO:1901571","description":"\"The directed movement of a fatty acid derivative into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"9db21d9684d94a149da5b510d7b9c872","type":"GO_TERM","name":"fatty acid elongase activity","canonical_id":"go:GO:0009922","description":"\"Catalysis of the reaction: a very-long-chain acyl-CoA + H+ + malonyl-CoA = a very-long-chain 3-oxoacyl-CoA + CO2 + CoA. This reaction is the first (condensation) step of the four-step fatty acid elongation cycle in the endoplasmic reticulum that extends fatty acids of C-16 or longer with an additional 2-C unit.\" [PMID:16564093, PMID:19763486, RHEA:32727]","metadata":null},{"id":"4032a3ad16a74b63a5216a496628e768","type":"GO_TERM","name":"fatty acid elongase complex","canonical_id":"go:GO:0009923","description":"\"A tetrameric complex of four different subunits which catalyzes the elongation of a fatty acid chain 2 carbon units at a time in the synthesis of very long chain fatty acids.\" [GOC:tb]","metadata":null},{"id":"56ff0fe5631f43b8b5bce0d393741122","type":"GO_TERM","name":"fatty acid elongation","canonical_id":"go:GO:0030497","description":"\"The elongation of a fatty acid chain by the sequential addition of two-carbon units.\" [ISBN:0716720094]","metadata":null},{"id":"8c8663c9f77d4d5fa44624f745f7a664","type":"GO_TERM","name":"fatty acid elongation, monounsaturated fatty acid","canonical_id":"go:GO:0034625","description":"\"Elongation of a fatty acid chain into which one C-C double bond has been introduced.\" [GOC:mah]","metadata":null},{"id":"82a4cd796bb74fcbaf902b012b3e0616","type":"GO_TERM","name":"fatty acid elongation, polyunsaturated fatty acid","canonical_id":"go:GO:0034626","description":"\"Elongation of a fatty acid chain into which two or more C-C double bonds have been introduced.\" [GOC:mah]","metadata":null},{"id":"f3fe4efc840d4c30b181e756873751e4","type":"GO_TERM","name":"fatty acid elongation, saturated fatty acid","canonical_id":"go:GO:0019367","description":"\"Elongation of a saturated fatty acid chain.\" [GOC:mah]","metadata":null},{"id":"7db7f8cb7172471985c863a6dae44017","type":"GO_TERM","name":"fatty acid elongation, unsaturated fatty acid","canonical_id":"go:GO:0019368","description":"\"Elongation of a fatty acid chain into which one or more C-C double bonds have been introduced.\" [GOC:mah]","metadata":null},{"id":"b2478d7ae9274551aa32c5c0705a2905","type":"GO_TERM","name":"fatty acid homeostasis","canonical_id":"go:GO:0055089","description":"\"Any process involved in the maintenance of an internal steady state of fatty acid within an organism or cell.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"9483e2cf7f3c4a20b602ec63916e3c92","type":"GO_TERM","name":"fatty acid in-chain hydroxylase activity","canonical_id":"go:GO:0052722","description":"\"Catalysis of the reaction: fatty acid + O2 + 2 NADPH + H+ = fatty acid with in-chain hydroxy group + 2 NADP+ + H2O.\" [MetaCyc:RXN-12186]","metadata":null},{"id":"721cd5909e2f4d5f84e19f44453f35ad","type":"GO_TERM","name":"fatty acid ligase activity","canonical_id":"go:GO:0015645","description":"\"Catalysis of the ligation of a fatty acid to an acceptor, coupled to the hydrolysis of ATP.\" [GOC:cjk, GOC:mah]","metadata":null},{"id":"2a4a65edea7e4542b7c6d3735b6909d0","type":"GO_TERM","name":"fatty acid metabolic process","canonical_id":"go:GO:0006631","description":"\"The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.\" [ISBN:0198547684]","metadata":null},{"id":"50c889494869432d9167b92437e51e73","type":"GO_TERM","name":"fatty acid methyl ester biosynthetic process","canonical_id":"go:GO:1902899","description":"\"The chemical reactions and pathways resulting in the formation of fatty acid methyl ester.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:16570218]","metadata":null},{"id":"ad7d7f8fc14645bfbc0ef7f83333d7f1","type":"GO_TERM","name":"fatty acid methyl ester metabolic process","canonical_id":"go:GO:1902898","description":"\"The chemical reactions and pathways involving fatty acid methyl ester.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:16570218]","metadata":null},{"id":"d907b6d4885b42728dbaf0d294ddd5b4","type":"GO_TERM","name":"fatty acid omega-1 hydroxylase activity","canonical_id":"go:GO:0120502","description":"\"Catalysis of the reaction: an (omega-1)-ethyl fatty acid + O2 + reduced [NADPH--hemoprotein reductase] = an (omega-1)-hydroxy fatty acid + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:44548]","metadata":null},{"id":"3f1d38c74bd74ea7929e6eb174bd677d","type":"GO_TERM","name":"fatty acid omega-hydroxylase activity","canonical_id":"go:GO:0120250","description":"\"Catalysis of the reaction: an omega-methyl fatty acid + O2 + reduced [NADPH--hemoprotein reductase] = an omega-hydroxy fatty acid + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [GOC:krc, RHEA:39023]","metadata":null},{"id":"f3afe40dce964fa48cb83b311cb9b064","type":"GO_TERM","name":"fatty acid omega-oxidation","canonical_id":"go:GO:0010430","description":"\"A fatty acid oxidation process in which the methyl group at the end of the fatty acid molecule (the omega carbon) is first oxidized to a hydroxyl group, then to an oxo group, and finally to a carboxyl group. The long chain dicarboxylates derived from omega-oxidation then enter the beta-oxidation pathway for further degradation.\" [MetaCyc:PWY-2724, PMID:16404574]","metadata":null},{"id":"a87277fea52b415c922fa050c15bd214","type":"GO_TERM","name":"fatty acid oxidation","canonical_id":"go:GO:0019395","description":"\"The removal of one or more electrons from a fatty acid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen.\" [ISBN:0198506732]","metadata":null},{"id":"da9c96e975a6430cbaec0c8655fc9c02","type":"GO_TERM","name":"fatty acid peroxidase activity","canonical_id":"go:GO:0047888","description":"\"Catalysis of the reaction: 2 H2O2 + H+ + palmitate = CO2 + 3 H2O + pentadecanal.\" [EC:1.11.1.3, RHEA:23960]","metadata":null},{"id":"089effa2b7a640f2a2c351c6823188b3","type":"GO_TERM","name":"fatty acid primary amide biosynthetic process","canonical_id":"go:GO:0062112","description":"\"The chemical reactions and pathways resulting in the formation of a fatty acid primary amide.\" [PMID:10079066, PMID:15952893]","metadata":null},{"id":"61b65a9e8d9b45d6886b0a7fe9ad858d","type":"GO_TERM","name":"fatty acid primary amide catabolic process","canonical_id":"go:GO:0062127","description":"\"The chemical reactions and pathways resulting in the breakdown of primary fatty amides.\" [PMID:11128635]","metadata":null},{"id":"75f1dade451144ac97387a60d6e3673e","type":"GO_TERM","name":"fatty acid primary amide metabolic process","canonical_id":"go:GO:0062126","description":"\"The chemical reactions and pathways, including anabolism and catabolism, by which living organisms transform primary fatty amides.\" [PMID:11128635]","metadata":null},{"id":"f9febcd0f7cc4ca4bad80c7ad3e4b705","type":"GO_TERM","name":"fatty acid synthase activity","canonical_id":"go:GO:0004312","description":"\"Catalysis of the reaction: acetyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+ = long-chain fatty acid + n+1 CoA + n CO2 + 2n NADP+.\" [EC:2.3.1.85]","metadata":null},{"id":"0ece015a840e44718542ced2787de8ca","type":"GO_TERM","name":"fatty acid synthase complex","canonical_id":"go:GO:0005835","description":"\"A multienzyme complex that catalyses the synthesis of fatty acids from acetyl CoA.\" [GOC:pde, GOC:sgd_curators, ISBN:0716746840]","metadata":null},{"id":"2a232b0ea58e41aea9439eeb2e0d41ef","type":"GO_TERM","name":"fatty acid transmembrane transport","canonical_id":"go:GO:1902001","description":"\"The process in which a fatty acid is transported across a membrane.\" [GOC:rb, GOC:TermGenie, PMID:9395310]","metadata":null},{"id":"b66b1aaf5ef34da199f6a73aa27b8757","type":"GO_TERM","name":"fatty acid transmembrane transporter activity","canonical_id":"go:GO:0015245","description":"\"Enables the transfer of fatty acids from one side of a membrane to the other. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.\" [ISBN:0198506732]","metadata":null},{"id":"60ccaffb961946459ac29c067dfe6bb5","type":"GO_TERM","name":"fatty acid transport","canonical_id":"go:GO:0015908","description":"\"The directed movement of fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.\" [GOC:ai]","metadata":null},{"id":"3d76ea921d334dbc8f477c701b3af247","type":"GO_TERM","name":"fatty acid-CoA ligase activity","canonical_id":"go:GO:0120515","description":"\"Catalysis of the reaction: a fatty acid + ATP + CoA = a fatty acyl-CoA + AMP + diphosphate.\" [RHEA:38883]","metadata":null},{"id":"c85d479b87ee4176907a172fc7350d00","type":"GO_TERM","name":"fatty acyl-CoA hydrolase activity","canonical_id":"go:GO:0047617","description":"\"Catalysis of the reaction: a fatty acyl-CoA + H2O = a fatty acid + CoA + H+.\" [RHEA:16781]","metadata":null},{"id":"79af45be1b304cb29769014494eddf3b","type":"GO_TERM","name":"fatty acyl-[ACP] hydrolase activity","canonical_id":"go:GO:0016297","description":"\"Catalysis of the reaction: a fatty acyl-[ACP] + H2O = a fatty acid + H+ + holo-[acyl-carrier protein].\" [RHEA:44596]","metadata":null},{"id":"074b335a0c2a429d8b00bc78be4f1821","type":"GO_TERM","name":"fatty alcohol biosynthetic process","canonical_id":"go:GO:1903175","description":"\"The chemical reactions and pathways resulting in the formation of fatty alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:24036493]","metadata":null},{"id":"18f7d4fb53754581948d8757c5ae0e73","type":"GO_TERM","name":"fatty alcohol catabolic process","canonical_id":"go:GO:1903174","description":"\"The chemical reactions and pathways resulting in the breakdown of fatty alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:24036493]","metadata":null},{"id":"d67a1187993548428ce10542410dfe75","type":"GO_TERM","name":"fatty alcohol metabolic process","canonical_id":"go:GO:1903173","description":"\"The chemical reactions and pathways involving fatty alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:24036493]","metadata":null},{"id":"71afd8c0f23e4863a3f97c71e4862d5d","type":"GO_TERM","name":"fatty aldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0102673","description":"\"Catalysis of the reaction: a fatty aldehyde + H2O + NAD+ = a fatty acid + 2 H+ + NADH.\" [RHEA:49832]","metadata":null},{"id":"80540481ede7453689f989fc4505dfdc","type":"GO_TERM","name":"fatty-acyl-CoA binding","canonical_id":"go:GO:0000062","description":"\"Binding to a fatty-acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty acyl group.\" [GOC:jl, GOC:krc, ISBN:0198506732]","metadata":null},{"id":"e26af2d3e74b4157a3abe803114f703b","type":"GO_TERM","name":"fatty-acyl-CoA biosynthetic process","canonical_id":"go:GO:0046949","description":"\"The chemical reactions and pathways resulting in the formation of a fatty-acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty-acyl group.\" [ISBN:0198506732]","metadata":null},{"id":"0e4735cc7c654c38b7032b776e31f347","type":"GO_TERM","name":"fatty-acyl-CoA catabolic process","canonical_id":"go:GO:0036115","description":"\"The chemical reactions and pathways resulting in the breakdown of a fatty-acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty-acyl group.\" [PMID:10578051]","metadata":null},{"id":"bf3a54a3368e46de90d38e5abf6aebfa","type":"GO_TERM","name":"fatty-acyl-CoA metabolic process","canonical_id":"go:GO:0035337","description":"\"The chemical reactions and pathways involving a fatty-acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty-acyl group.\" [ISBN:0198506732]","metadata":null},{"id":"37bbc8c08bd144f0a6a66b137af13564","type":"GO_TERM","name":"fatty-acyl-CoA synthase activity","canonical_id":"go:GO:0004321","description":"\"Catalysis of the reaction: acetyl-CoA + n malonyl-CoA + 2n NADH + 2n NADPH + 4n H+ = a long-chain acyl-CoA + n CoA + n CO2 + 2n NAD+ + 2n NADP+.\" [EC:2.3.1.86]","metadata":null},{"id":"c00b0aa730624897b82d1c6dfdbc0c25","type":"GO_TERM","name":"fatty-acyl-CoA synthase complex","canonical_id":"go:GO:0005836","description":"\"A protein complex that possesses fatty-acyl-CoA synthase activity.\" [GOC:mah]","metadata":null},{"id":"bc872118ee3a4b29a659dd4c71f420b2","type":"GO_TERM","name":"fatty-acyl-CoA transport","canonical_id":"go:GO:0015916","description":"\"The directed movement of fatty acyl coenzyme A into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acyl coenzyme A is an acyl group linked to 3'-phosphoadenosine-(5')diphospho(4')pantatheine (coenzyme A).\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"c81dfa8d7bfd49a38ea7ca6f140dabb8","type":"GO_TERM","name":"fatty-acyl-ethyl-ester synthase activity","canonical_id":"go:GO:0030339","description":"\"Catalysis of the reaction: a long-chain-acyl ethyl ester + H2O = a long-chain carboxylic acid + ethanol.\" [EC:3.1.1.67]","metadata":null},{"id":"90f9710abc554a9f92030ff14c3547fa","type":"DRUG","name":"favipiravir","canonical_id":"mesh:C462182","description":null,"metadata":null},{"id":"5fa17a5d55a040d1b6a54caf4d96d91b","type":"GO_TERM","name":"fear response","canonical_id":"go:GO:0042596","description":"\"The response of an organism to a perceived external threat.\" [GOC:curators]","metadata":null},{"id":"f57c579f46f0455681aa7f8343f32b2f","type":"GO_TERM","name":"fear-induced aggressive behavior","canonical_id":"go:GO:0002122","description":"\"Aggressive behavior associated with attempts to flee from a threat.\" [GOC:hjd]","metadata":null},{"id":"1f890a7e93714e7b9b7a1110e68bc99d","type":"DRUG","name":"febuxostat","canonical_id":"gtopdb:6817","description":null,"metadata":null},{"id":"5fee7bbae8fe408782fe375472f3650f","type":"DRUG","name":"febuxostat","canonical_id":"chembl:CHEMBL1164729","description":null,"metadata":null},{"id":"1d9ae71b19804cf6bbff757b620953d5","type":"DISEASE","name":"fecal incontinence","canonical_id":"efo:0009523","description":null,"metadata":null},{"id":"2bf53ecd881f4858a6fe79c4bfd56b08","type":"DRUG","name":"fedratinib","canonical_id":"gtopdb:5716","description":null,"metadata":null},{"id":"17902f93226449128badd2eca5ef8a2a","type":"DRUG","name":"fedratinib","canonical_id":"chembl:CHEMBL1287853","description":null,"metadata":null},{"id":"63101fd41e384faea5a2b5776c526228","type":"COMBINATION_TREATMENT","name":"fedratinib + ivosidenib","canonical_id":"ctgov_combo:ctgov-combo-d788b271d2a3883b","description":null,"metadata":null},{"id":"846a504247844c8a8fb2a4515d68b3c2","type":"COMBINATION_TREATMENT","name":"fedratinib + momelotinib + ruxolitinib","canonical_id":"ctgov_combo:ctgov-combo-bba4c6c508799289","description":null,"metadata":null},{"id":"ce783e2deb97497e9dcaa2974086647e","type":"COMBINATION_TREATMENT","name":"fedratinib + pacritinib","canonical_id":"ctgov_combo:ctgov-combo-e6c8cc1a8f4e8ffb","description":null,"metadata":null},{"id":"35fca8fb637a4e0883190986709c4f70","type":"GO_TERM","name":"feeding behavior","canonical_id":"go:GO:0007631","description":"\"Behavior associated with the intake of food.\" [GOC:mah]","metadata":null},{"id":"df27fb5bbd3e4dc7bdf97dd7df7889ec","type":"DRUG","name":"felodipine","canonical_id":"mesh:D015736","description":null,"metadata":null},{"id":"a3c377eb5fbf4738baa5f43063fa413c","type":"GO_TERM","name":"female analia development","canonical_id":"go:GO:0045497","description":"\"The process whose specific outcome is the progression of the analia of the female over time, from formation to the mature structure. The analia is the posterior-most vertral appendage that develops from the genital disc. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11494318]","metadata":null},{"id":"d7cba28702184e6c9ea7a780a7166f51","type":"GO_TERM","name":"female analia morphogenesis","canonical_id":"go:GO:0048810","description":"\"The process in which the anatomical structures of the analia of the female are generated and organized. The analia is the posterior-most vertral appendage that develops from the genital disc. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11494318]","metadata":null},{"id":"2b7760946f8a4503b10415838ed28f54","type":"GO_TERM","name":"female courtship behavior","canonical_id":"go:GO:0008050","description":"\"The behavior of a female, for the purpose of attracting a sexual partner.\" [GOC:bf, GOC:pr]","metadata":null},{"id":"5968ac86c83a4fb58ceaf01cc8a1b0ce","type":"GO_TERM","name":"female gamete generation","canonical_id":"go:GO:0007292","description":"\"Generation of the female gamete; specialised haploid cells produced by meiosis and along with a male gamete takes part in sexual reproduction.\" [GOC:dph, ISBN:0198506732]","metadata":null},{"id":"3d41a60495654e36b1e4f27da80fc1b2","type":"GO_TERM","name":"female genitalia development","canonical_id":"go:GO:0030540","description":"\"The process whose specific outcome is the progression of the female genitalia over time, from formation to the mature structure.\" [GOC:mah]","metadata":null},{"id":"5352d1487c954052b76e8c5cd043998b","type":"GO_TERM","name":"female genitalia morphogenesis","canonical_id":"go:GO:0048807","description":"\"The process in which the anatomical structures of female genitalia are generated and organized.\" [GOC:mah]","metadata":null},{"id":"93d513a9d5d84b9b82c4287579ff40a7","type":"GO_TERM","name":"female germ cell nucleus","canonical_id":"go:GO:0001674","description":"\"The nucleus of the female germ cell, a reproductive cell in females.\" [CL:0000021, GOC:hjd]","metadata":null},{"id":"201b50fc9bc64e79a09f697fe36777af","type":"GO_TERM","name":"female germ-line cyst encapsulation","canonical_id":"go:GO:0048139","description":"\"Formation of a single follicular epithelium around the germ-line derived cells of a cyst formed in the female gonad.\" [GOC:jid]","metadata":null},{"id":"7554808650444058a545098a4b4250af","type":"GO_TERM","name":"female germ-line cyst formation","canonical_id":"go:GO:0048135","description":"\"Formation of a group of interconnected cells derived from a single female gonial founder cell.\" [GOC:jid, PMID:10370240]","metadata":null},{"id":"bb1166a1afa14623be64d9d0ec7e546a","type":"GO_TERM","name":"female germ-line sex determination","canonical_id":"go:GO:0019099","description":"\"The determination of sex and sexual phenotype in a female organism's germ line.\" [GOC:mah]","metadata":null},{"id":"24e7684e041649ccb74d8a8f562cfbd5","type":"GO_TERM","name":"female germ-line stem cell asymmetric division","canonical_id":"go:GO:0048132","description":"\"The self-renewing division of a germline stem cell in the female gonad, to produce a daughter stem cell and a daughter germ cell, which will divide to form the female gametes.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"2b2c18edab6143f2a3aea4f073d61fca","type":"GO_TERM","name":"female germ-line stem cell population maintenance","canonical_id":"go:GO:0036099","description":"\"The process by which an organism or tissue maintains a population of female germ-line stem cells.\" [GOC:sart]","metadata":null},{"id":"e45cab53d0464c119ac7bac9e3884391","type":"GO_TERM","name":"female germline ring canal","canonical_id":"go:GO:0035324","description":"\"An intercellular bridge that connects the germline cells of a female cyst.\" [PMID:9635420]","metadata":null},{"id":"fc94bb427e52442ca77afbfdd7ab0b80","type":"GO_TERM","name":"female germline ring canal formation","canonical_id":"go:GO:0007301","description":"\"Assembly of the intercellular bridges that connect the germ-line cells of a female cyst.\" [ISBN:0879694238]","metadata":null},{"id":"c85c25beb927486b8829d499353eb089","type":"GO_TERM","name":"female germline ring canal formation, actin assembly","canonical_id":"go:GO:0008302","description":"\"Recruitment and organization of actin filaments in female germline ring canals.\" [ISBN:0879694238]","metadata":null},{"id":"938364438f004f519fa2a89f940aafd0","type":"GO_TERM","name":"female germline ring canal inner rim","canonical_id":"go:GO:0035183","description":"\"A proteinaceous actin-rich layer of the insect ovarian ring canal that forms subcortically to the outer rim. The electron dense inner rim accumulates after the final mitotic division of each germline syncytia, and contains actin, a phosphotyrosine protein, and a number of cytoskeletal proteins.\" [PMID:10556087, PMID:7925006, PMID:9093858]","metadata":null},{"id":"03ef1ab8645640e681e1ea1265689c35","type":"GO_TERM","name":"female germline ring canal outer rim","canonical_id":"go:GO:0035182","description":"\"An electron opaque backbone of the insect ovarian ring canal that is a part of or adjacent to the plasma membrane. The outer rim is established as the cleavage furrow is arrested, and contains F-actin, anillin, glycoproteins and at least one a protein with a high content of phosphorylated tyrosine residues.\" [PMID:12435357, PMID:7925006]","metadata":null},{"id":"d9b564cbf38e42a38cbee426b10751cc","type":"GO_TERM","name":"female germline ring canal stabilization","canonical_id":"go:GO:0008335","description":"\"Maintenance of the structural integrity of the ring canals connecting the female germline cyst.\" [GOC:curators]","metadata":null},{"id":"dea3017381c84a23ab717c47e40753f7","type":"GO_TERM","name":"female germline stem cell symmetric division","canonical_id":"go:GO:0062102","description":"\"Division of a female germline stem cell to produce two germline stem cells of the same type as the parent.\" [GOC:ha, PMID:30248087]","metadata":null},{"id":"655e28baee5140b9ad4e46f6452e5b67","type":"GO_TERM","name":"female gonad development","canonical_id":"go:GO:0008585","description":"\"The process whose specific outcome is the progression of the female gonad over time, from its formation to the mature structure.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"3344fc1275af4827b89fb0b5874bbfa2","type":"GO_TERM","name":"female gonad morphogenesis","canonical_id":"go:GO:0061040","description":"\"The process in which a female gonad is generated and organized.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"9e7844abb2a4450ea4faeee2e22a57f3","type":"DISEASE","name":"female infertility","canonical_id":"mondo:0021124","description":null,"metadata":null},{"id":"e925c6a25dc743228e5a5815a4d1454a","type":"GO_TERM","name":"female mating behavior","canonical_id":"go:GO:0060180","description":"\"The specific behavior of a female organism that is associated with reproduction.\" [GOC:dph, GOC:pr, GOC:tb]","metadata":null},{"id":"f07342008a934d2eb92f92644b779182","type":"GO_TERM","name":"female meiosis I","canonical_id":"go:GO:0007144","description":"\"The cell cycle process in which the first meiotic division occurs in the female germline.\" [GOC:mah]","metadata":null},{"id":"7119fd71ec8b4eca94ed2fe5d573e48a","type":"GO_TERM","name":"female meiosis II","canonical_id":"go:GO:0007147","description":"\"The cell cycle process in which the second meiotic division occurs in the female germline.\" [GOC:mah]","metadata":null},{"id":"196461b56ea04e59b7ee37de02d38890","type":"GO_TERM","name":"female meiosis chromosome segregation","canonical_id":"go:GO:0016321","description":"\"The cell cycle process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets during the meiotic cell cycle in a female.\" [GOC:ai]","metadata":null},{"id":"009a9cefa68c48beb1d57fee61fe4a85","type":"GO_TERM","name":"female meiosis chromosome separation","canonical_id":"go:GO:0051309","description":"\"The process in which paired chromosomes are physically detached from each other during female meiosis.\" [GOC:ai]","metadata":null},{"id":"0cf1db830f3548529543f876ee2686af","type":"GO_TERM","name":"female meiosis sister chromatid cohesion","canonical_id":"go:GO:0007066","description":"\"The joining of the sister chromatids of a replicated chromosome along the entire length of the chromosome that occurs during meiosis in a female.\" [GOC:ai]","metadata":null},{"id":"93abce7742f746eb9708a11f712db8ca","type":"GO_TERM","name":"female meiotic chromosome movement towards spindle pole","canonical_id":"go:GO:0016345","description":"\"The directed movement of chromosomes in the center of the spindle towards the spindle poles, mediated by the shortening of microtubules attached to the chromosomes, during female meiosis.\" [GOC:ai]","metadata":null},{"id":"5f6d85eadf0d463e93e2a4b664222ad2","type":"GO_TERM","name":"female meiotic nuclear division","canonical_id":"go:GO:0007143","description":"\"A cell cycle process by which the cell nucleus divides as part of a meiotic cell cycle in the female germline.\" [GOC:dph, GOC:ems, GOC:mah, GOC:vw]","metadata":null},{"id":"fd9704f662bf461999a122894406ac52","type":"GO_TERM","name":"female pigmentation","canonical_id":"go:GO:0048095","description":"\"Establishment of a pattern of pigment in females.\" [GOC:jid]","metadata":null},{"id":"fbf6c26b2857437e991374477b92c384","type":"GO_TERM","name":"female pregnancy","canonical_id":"go:GO:0007565","description":"\"The set of physiological processes that allow an embryo or foetus to develop within the body of a female animal. It covers the time from fertilization of a female ovum by a male spermatozoon until birth.\" [ISBN:0192800825]","metadata":null},{"id":"782f901fe3fe42bbaebf701f4f5ba221","type":"GO_TERM","name":"female pronucleus","canonical_id":"go:GO:0001939","description":"\"The pronucleus originating from the ovum that is being fertilized.\" [GOC:hjd, ISBN:0198506732]","metadata":null},{"id":"d6a3106cb491411483c84b226d8a16d2","type":"GO_TERM","name":"female pronucleus assembly","canonical_id":"go:GO:0035038","description":"\"Assembly of the haploid nucleus of the unfertilized egg.\" [GOC:bf, ISBN:0582227089]","metadata":null},{"id":"fcc769b4bf364a838db7df0a83ebac33","type":"GO_TERM","name":"female sex determination","canonical_id":"go:GO:0030237","description":"\"The specification of female sex of an individual organism.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"78c8939ac823470985e116142fc3b25d","type":"GO_TERM","name":"female sex differentiation","canonical_id":"go:GO:0046660","description":"\"The establishment of the sex of a female organism by physical differentiation.\" [GOC:bf]","metadata":null},{"id":"eb7d8183c2f04f4297e74a99ceb01e89","type":"GO_TERM","name":"female somatic sex determination","canonical_id":"go:GO:0019101","description":"\"The determination of sex and sexual phenotypes in a female organism's soma.\" [GOC:mah]","metadata":null},{"id":"0f96f0a9e7354eaa8e37bb3abcf93a78","type":"GO_TERM","name":"female urethra development","canonical_id":"go:GO:0061070","description":"\"The progression of the female urethra over time from its initial formation to the mature structure. The female urethra is a renal system organ that carries urine from the bladder to outside the body, exiting above the vaginal opening.\" [GOC:dph]","metadata":null},{"id":"a071a8279a0b4ed6a8a5bb0e8dd3e855","type":"GO_TERM","name":"feminization of hermaphrodite soma","canonical_id":"go:GO:0042004","description":"\"Promotion of female sex and sexual phenotypes in the hermaphroditic soma. An example of this is found in Caenorhabditis elegans.\" [GOC:ems]","metadata":null},{"id":"5e2bdb09571240ddb4db2150082759f3","type":"GO_TERM","name":"feminization of hermaphroditic germ-line","canonical_id":"go:GO:0040022","description":"\"The determination of female sex and sexual phenotype in the germ-line of the hermaphrodite.\" [GOC:ems]","metadata":null},{"id":"e9439480717348618f69071ded35dbb8","type":"GO_TERM","name":"femoral head articular cartilage development","canonical_id":"go:GO:0061979","description":"\"The process whose specific outcome is the progression of femoral head articular cartilage over time, from its formation to the mature structure.\" [PMID:20097540]","metadata":null},{"id":"825bc11fb56442a0bbecdf6a0af9e848","type":"DRUG","name":"fendiline","canonical_id":"mesh:D005275","description":null,"metadata":null},{"id":"b3f51a6a2fc1495eb7a670ed46b22e51","type":"DRUG","name":"fenofibrate","canonical_id":"gtopdb:7186","description":null,"metadata":null},{"id":"f8daf61d9ecb4a17a4b5d3e1dffd7297","type":"DRUG","name":"fenofibrate","canonical_id":"chembl:CHEMBL672","description":null,"metadata":null},{"id":"e4731ea29f7549a09c5d8c17bd5b06c3","type":"COMBINATION_TREATMENT","name":"fenofibrate + irbesartan + orlistat + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-a608337e66161591","description":null,"metadata":null},{"id":"1a9209a321a04aca87545435120a7671","type":"COMBINATION_TREATMENT","name":"fenofibrate + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-c915fc5af787178a","description":null,"metadata":null},{"id":"f5d81e64b5c3426db87fa227324da1c6","type":"COMBINATION_TREATMENT","name":"fenofibrate + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-89a9cea7d3228e4f","description":null,"metadata":null},{"id":"04075af66ad140cbaa5a0500c8dbf149","type":"DRUG","name":"fenoldopam","canonical_id":"gtopdb:939","description":null,"metadata":null},{"id":"541e24a6a00f4c48bf9343d6b74c8430","type":"COMBINATION_TREATMENT","name":"fenoldopam + furosemide","canonical_id":"ctgov_combo:ctgov-combo-66f6ca7121f51b3f","description":null,"metadata":null},{"id":"db6fa5cb1f2a4f848a7791db230cfcce","type":"DRUG","name":"fenoprofen","canonical_id":"gtopdb:4820","description":null,"metadata":null},{"id":"1bc607a2c03146d3858a517b7f224ae4","type":"DRUG","name":"fenoprofen","canonical_id":"mesh:D005279","description":null,"metadata":null},{"id":"c3852fa1dfd84a1fb35ed90d78fbc033","type":"DRUG","name":"fenoterol","canonical_id":"gtopdb:557","description":null,"metadata":null},{"id":"56fa6c300997427fafdf8f165ef6758c","type":"DRUG","name":"fenoterol","canonical_id":"chembl:CHEMBL32800","description":null,"metadata":null},{"id":"170b556a214e4e95893da3198fa04047","type":"COMBINATION_TREATMENT","name":"fenoterol + ipratropium","canonical_id":"ctgov_combo:ctgov-combo-05f396d6946f821e","description":null,"metadata":null},{"id":"ecacac36aaf14899b5901777e9f04dcc","type":"DRUG","name":"fenproporex","canonical_id":"mesh:C026013","description":null,"metadata":null},{"id":"b8a17032ce46455eafbdb9e546c00568","type":"DRUG","name":"fentanyl","canonical_id":"gtopdb:1626","description":null,"metadata":null},{"id":"8f406e12fbaf452db16f0349dbaa8910","type":"DRUG","name":"fentanyl","canonical_id":"mesh:D005283","description":null,"metadata":null},{"id":"66f1bac086fd43118a51d5ff79fbf2a4","type":"DRUG","name":"fentanyl","canonical_id":"chembl:CHEMBL596","description":null,"metadata":null},{"id":"2a62234bdb304e6b94209754aa36d090","type":"COMBINATION_TREATMENT","name":"fentanyl + ketamine","canonical_id":"ctgov_combo:ctgov-combo-c942476ae248d38b","description":null,"metadata":null},{"id":"e4c70a62e77842908f6bea2ace0c3004","type":"COMBINATION_TREATMENT","name":"fentanyl + ketamine","canonical_id":"ctgov_combo:ctgov-combo-ec7facdd35c6854f","description":null,"metadata":null},{"id":"7afdb9b0890e455eb1b5380ddf99c0df","type":"COMBINATION_TREATMENT","name":"fentanyl + ketamine + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-37a13dff1421155b","description":null,"metadata":null},{"id":"a3f0f037e7db4627b01f6e36d4564437","type":"COMBINATION_TREATMENT","name":"fentanyl + morphine","canonical_id":"ctgov_combo:ctgov-combo-d23e863db12d1ff4","description":null,"metadata":null},{"id":"a74e3908fc0b496aade21e8ceb8d1011","type":"COMBINATION_TREATMENT","name":"fentanyl + morphine","canonical_id":"ctgov_combo:ctgov-combo-7ee9b2017cb27619","description":null,"metadata":null},{"id":"53507612cf844815ae3902572ebab4b4","type":"COMBINATION_TREATMENT","name":"fentanyl + sufentanil","canonical_id":"ctgov_combo:ctgov-combo-467616eac008e132","description":null,"metadata":null},{"id":"035e75de8831417c8f676283f8d0ad42","type":"GO_TERM","name":"fermentation","canonical_id":"go:GO:0006113","description":"\"The metabolic process that uses oxidation-reduction reactions of organic compounds and substrate-level phosphorylation for the generation of adenosine triphosphate (ATP), without consuming oxygen and is independent of electron transport chains.\" [PMID:25617754, PMID:38821505]","metadata":null},{"id":"07584dbdcad449c2810dfb1a02019141","type":"GO_TERM","name":"ferredoxin hydrogenase activity","canonical_id":"go:GO:0008901","description":"\"Catalysis of the reaction: 2 reduced ferredoxin + 2 H+ = 2 oxidized ferredoxin + H2.\" [EC:1.12.7.2]","metadata":null},{"id":"83c3409e47814f3c9f944eb94e2a9317","type":"GO_TERM","name":"ferredoxin hydrogenase complex","canonical_id":"go:GO:0009375","description":"\"An enzyme complex that catalyzes the oxidation of reduced ferredoxin. Hydrogenase contains iron-sulfur clusters, and some contain nickel; it can use molecular hydrogen for the reduction of a variety of substances.\" [PMID:12792025, PMID:9836629]","metadata":null},{"id":"8ac6d05c84084d819f041b7e87132d14","type":"GO_TERM","name":"ferredoxin metabolic process","canonical_id":"go:GO:0006124","description":"\"The chemical reactions and pathways involving ferredoxin, any simple, nonenzymatic iron-sulfur protein that is characterized by having equal numbers of atoms of iron and labile sulfur. Iron and sulfur atoms are present in one or two clusters of two or four atoms of each.\" [ISBN:0198506732]","metadata":null},{"id":"26529fbaa2b14026881869ea9073d371","type":"GO_TERM","name":"ferredoxin-NAD+ reductase activity","canonical_id":"go:GO:0008860","description":"\"Catalysis of the reaction: 2 reduced [2Fe-2S]-[ferredoxin] + NAD+ + H+ = 2 oxidized [2Fe-2S]-[ferredoxin] + NADH.\" [RHEA:16521]","metadata":null},{"id":"9a039b058fbd476f9d9255174dc1687f","type":"GO_TERM","name":"ferredoxin-NADP+ reductase activity","canonical_id":"go:GO:0004324","description":"\"Catalysis of the reaction: 2 reduced [2Fe-2S]-[ferredoxin] + NADP+ + H+ = 2 oxidized [2Fe-2S]-[ferredoxin] + NADPH.\" [RHEA:20125]","metadata":null},{"id":"0c6a1974bc0244ae910fe5e93d251ee3","type":"GO_TERM","name":"ferredoxin-[NAD(P)H] reductase activity","canonical_id":"go:GO:0008937","description":"\"Catalysis of the reaction: reduced ferredoxin + NAD(P)+ = oxidized ferredoxin + NAD(P)H + H+.\" [GOC:curators]","metadata":null},{"id":"11064a65dd45475297bd9914e98c723f","type":"GO_TERM","name":"ferredoxin-nitrate reductase activity","canonical_id":"go:GO:0047889","description":"\"Catalysis of the reaction: nitrite + 2 oxidized [2Fe-2S]-[ferredoxin] + H2O = nitrate + 2 reduced [2Fe-2S]-[ferredoxin] + 2 H+.\" [RHEA:21828]","metadata":null},{"id":"1bcfb12771224392b22d9350cbac0636","type":"GO_TERM","name":"ferredoxin-nitrite reductase activity","canonical_id":"go:GO:0048307","description":"\"Catalysis of the reaction: 2 H2O + NH4+ + 6 oxidized [2Fe-2S]-[ferredoxin] = 8 H+ + nitrite + 6 reduced [2Fe-2S]-[ferredoxin].\" [RHEA:18041]","metadata":null},{"id":"e845c77d8180481eb57a7a6becc9ae45","type":"GO_TERM","name":"ferredoxin-thioredoxin reductase activity","canonical_id":"go:GO:0103012","description":"\"Catalysis of the reaction: 2 H+ + 2 a reduced ferredoxin + an oxidized thioredoxin = 2 an oxidized ferredoxin + a reduced thioredoxin, involving a 4Fe-4S cluster and an adjacent active-site disulfide.\" [GOC:pz, PMID:14769790, RHEA:42336]","metadata":null},{"id":"2971eae3925a4bdf8e020349ec7e412d","type":"GO_TERM","name":"ferredoxin-thioredoxin reductase complex","canonical_id":"go:GO:0030386","description":"\"A protein complex that possesses ferredoxin-thioredoxin reductase activity.\" [GOC:mah]","metadata":null},{"id":"3931e144199f41dc8d931db00bc1e75b","type":"DRUG","name":"ferric citrate","canonical_id":"mesh:C025314","description":null,"metadata":null},{"id":"bcec51bfb0ff449b83c1fbebb9cfda7d","type":"GO_TERM","name":"ferric enterobactin:proton symporter activity","canonical_id":"go:GO:0015345","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ferric enterobactin(out) + H+(out) = ferric enterobactin(in) + H+(in).\" [TC:2.A.1.16.2]","metadata":null},{"id":"bdc029140b834081b38d954d153323b6","type":"GO_TERM","name":"ferric iron binding","canonical_id":"go:GO:0008199","description":"\"Binding to a ferric iron ion, Fe(III).\" [GOC:ai]","metadata":null},{"id":"bb06ef7cdc6d4435a28e6c5aebfd5b1b","type":"GO_TERM","name":"ferric iron reductase activity","canonical_id":"go:GO:7770068","description":"\"Catalysis of the reaction: 2 Fe2+ + NADP+ + H+ = 2 Fe3+ + NADPH.\" [PMID:34614242, PMID:39940646, PMID:8321236, RHEA:71767]","metadata":null},{"id":"0317d028d847406abd16e1300d65e724","type":"GO_TERM","name":"ferric iron transmembrane transporter activity","canonical_id":"go:GO:0015091","description":"\"Enables the transfer of ferric iron (Fe(III) or Fe3+) ions from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"b4f2edcc03bd412c8ea6c04ecc4c4346","type":"GO_TERM","name":"ferric triacetylfusarinine C import into cell","canonical_id":"go:GO:0015686","description":"\"The directed movement of ferric triacetylfusarinine C into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"7fc91e345b0d44ed97f9fb15dcc4170f","type":"GO_TERM","name":"ferric triacetylfusarinine C transmembrane transporter activity","canonical_id":"go:GO:0015621","description":"\"Enables the transfer of ferric triacetylfusarinine C from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"804bbb5bb8b24958a412c181d89bf7c0","type":"GO_TERM","name":"ferric triacetylfusarinine C:proton symporter activity","canonical_id":"go:GO:0015346","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ferric triacetylfusarinine C(out) + H+(out) = ferric triacetylfusarinine C(in) + H+(in).\" [TC:2.A.1.16.3]","metadata":null},{"id":"d36f6b9cc9c94c4fa26dcb2ae6657a94","type":"GO_TERM","name":"ferric-chelate reductase (NADH) activity","canonical_id":"go:GO:0140618","description":"\"Catalysis of the reaction: 2 a Fe(II)-siderophore + NAD+ + H+ = 2 a Fe(III)-siderophore + NADH.\" [RHEA:15061]","metadata":null},{"id":"2c776a4f21f0461b95dea5d9dfc08970","type":"GO_TERM","name":"ferric-chelate reductase (NADPH) activity","canonical_id":"go:GO:0052851","description":"\"Catalysis of the reaction: 2 a Fe(II)-siderophore + NADP+ + H+ = 2 a Fe(III)-siderophore + NADPH.\" [RHEA:28795]","metadata":null},{"id":"59cfbe5eb3fa432c81a63277b24b38e8","type":"GO_TERM","name":"ferric-chelate reductase activity","canonical_id":"go:GO:0000293","description":"\"Catalysis of the reaction: 2 Fe3+-chelate + electron donor = 2 Fe2+-chelate + electron acceptor.\" [PMID:33559753]","metadata":null},{"id":"d721c88c766245829f34e92be39473ed","type":"GO_TERM","name":"ferric-enterobactin import into cell","canonical_id":"go:GO:0015685","description":"\"A process in which ferric-enterobactin, the iron-bound form of the siderophore enterobactin, is transported into the cell by specific cell surface receptors.\" [GOC:pg, PMID:23192658]","metadata":null},{"id":"d7a248f59d5c4e78b8dfbc630cf861b5","type":"GO_TERM","name":"ferric-enterobactin transmembrane transporter activity","canonical_id":"go:GO:0015620","description":"\"Enables the transfer of ferric-enterobactin from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"95aba11dda2c476f8cad62e3842b0c4f","type":"GO_TERM","name":"ferric-hydroxamate import into cell","canonical_id":"go:GO:0015687","description":"\"A process in which ferric-hydroxamate, the iron-bound form of the iron chelator hydroxamate, is transported into the cell by specific cell surface receptors.\" [GOC:pg, PMID:23192658]","metadata":null},{"id":"62e84707a61c44f6966c1764c0ec8f82","type":"GO_TERM","name":"ferric-vibriobactin transmembrane transporter activity","canonical_id":"go:GO:0019535","description":"\"Enables the transfer of ferric-vibriobactin ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"2ac0ce76c8e5408087afce784bdf7333","type":"GO_TERM","name":"ferrichrome biosynthetic process","canonical_id":"go:GO:0031169","description":"\"The chemical reactions and pathways resulting in the formation of a ferrichrome. Ferrichromes are any of a group of growth-promoting Fe(III) chelates formed by various genera of microfungi. They are homodetic cyclic hexapeptides made up of a tripeptide of glycine (or other small neutral amino acids) and a tripeptide of an N'acyl-N4-hydroxy-L-ornithine.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"1c0bb91bc7614274a2bc22596cfa7de6","type":"GO_TERM","name":"ferrichrome import into cell","canonical_id":"go:GO:0042928","description":"\"A process in which ferrichrome is transported into the cell by specific cell surface receptors. Ferrichromes are any of a group of growth-promoting Fe(III) chelates formed by various genera of microfungi. They are homodetic cyclic hexapeptides made up of a tripeptide of glycine (or other small neutral amino acids) and a tripeptide of an N'acyl-N4-hydroxy-L-ornithine.\" [GOC:jl, ISBN:0198506732, PMID:23192658]","metadata":null},{"id":"688a223484394a918220befefaf91079","type":"GO_TERM","name":"ferrichrome transmembrane transporter activity","canonical_id":"go:GO:0042929","description":"\"Enables the directed movement of a ferrichrome from one side of a membrane to the other. Ferrichromes are any of a group of growth-promoting Fe(III) chelates formed by various genera of microfungi. They are homodetic cyclic hexapeptides made up of a tripeptide of glycine (or other small neutral amino acids) and a tripeptide of an N'acyl-N4-hydroxy-L-ornithine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f8baae1862df436c960be10122a1625f","type":"GO_TERM","name":"ferricrocin biosynthetic process","canonical_id":"go:GO:0031171","description":"\"The chemical reactions and pathways resulting in the formation of ferricrocin, a cyclic hexapeptide siderophore with the structure Gly-Ser-Gly-(N5-acetyl-N5-hydroxyornithine)3.\" [GOC:mah, PMID:12828635]","metadata":null},{"id":"7888093babac4e588748fde675b31985","type":"GO_TERM","name":"ferritin complex","canonical_id":"go:GO:0070288","description":"\"A protein complex that binds iron and acts as a major iron storage system. There are three major subclasses of ferritins: the classical ferritins (Ftn), the heme-containing bacterioferritins (Bfr) and the DNA-binding proteins from starved cells (Dps). Ftn and Bfr are made of 24 subunits, whereas Dps are smaller with 12 subunits. Ftn is found in most kindoms, while Bfr and Dps are restricted to prokaryotes.\" [PMID:19154717, PMID:33881539]","metadata":null},{"id":"c15580961bad4296b055f9f4ace84c43","type":"GO_TERM","name":"ferritin receptor activity","canonical_id":"go:GO:0070287","description":"\"Combining with ferritin, and delivering ferritin into the cell via endocytosis.\" [GOC:bf, PMID:17459943, PMID:19154717]","metadata":null},{"id":"eeb7aaba0d844262b52aa467f1a4bce2","type":"GO_TERM","name":"ferritinophagy","canonical_id":"go:GO:7770069","description":"\"The selective degradation of ferritin to release iron by macroautophagy.\" [PMID:25327288, PMID:26436293, PMID:38714719]","metadata":null},{"id":"6a909603fdc045c1b7f865feb327f11a","type":"GO_TERM","name":"ferroptosis","canonical_id":"go:GO:0097707","description":"\"A programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism. Glutathione peroxidase 4 (GPX4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes.\" [GOC:mtg_apoptosis, PMID:25236395, PMID:26794443]","metadata":null},{"id":"76f5965832184031bf2708af5345f22f","type":"DRUG","name":"ferrous gluconate","canonical_id":"mesh:C011819","description":null,"metadata":null},{"id":"45668deafd0c40a5ad9c322dc5ea0275","type":"GO_TERM","name":"ferrous iron binding","canonical_id":"go:GO:0008198","description":"\"Binding to a ferrous iron ion, Fe(II).\" [GOC:ai]","metadata":null},{"id":"0ca26580e727449aaa041b58cf82db1a","type":"GO_TERM","name":"ferrous iron transmembrane transporter activity","canonical_id":"go:GO:0015093","description":"\"Enables the transfer of ferrous iron (Fe(II) or Fe2+) ions from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"6e5d5eb0abe14be8b1e6799fa66dc57e","type":"GO_TERM","name":"ferroxidase activity","canonical_id":"go:GO:0004322","description":"\"Catalysis of the reaction: 4 Fe2+ + 4 H+ + O2 = 4 Fe3+ + 2 H2O.\" [RHEA:11148]","metadata":null},{"id":"32abf8ab31a94f92ae316d72b348c4e1","type":"GO_TERM","name":"ferroxidase complex","canonical_id":"go:GO:1905862","description":"\"A protein complex which is capable of ferroxidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16522632]","metadata":null},{"id":"aabfe91202314c71b53d4d56b6fda4d7","type":"GO_TERM","name":"fertilization","canonical_id":"go:GO:0009566","description":"\"The union of gametes of opposite sexes during the process of sexual reproduction to form a zygote. It involves the fusion of the gametic nuclei (karyogamy) and cytoplasm (plasmogamy).\" [GOC:tb, ISBN:0198506732]","metadata":null},{"id":"4d7521117ece464d89970de1aa7d6299","type":"GO_TERM","name":"fertilization envelope","canonical_id":"go:GO:0060387","description":"\"A structure that lies outside the plasma membrane and surrounds the egg. The fertilization envelope forms from the vitelline membrane after fertilization as a result of cortical granule release.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"dacf67559d7a42ffb75654fc42a53679","type":"GO_TERM","name":"ferulate 5-hydroxylase activity","canonical_id":"go:GO:0046424","description":"\"Catalysis of the reaction: ferulic acid + NADPH + H+ + O2 = 5-hydroxyferulic acid + H2O + NADP+.\" [PMID:8692910, PMID:9880351]","metadata":null},{"id":"cbe885ceece74607a0d5f0553804a21b","type":"GO_TERM","name":"ferulate biosynthetic process","canonical_id":"go:GO:0033495","description":"\"The chemical reactions and pathways resulting in the formation of ferulate, (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate.\" [GOC:mah]","metadata":null},{"id":"3ee371ad74184933b9ecdf3c11ae063e","type":"GO_TERM","name":"ferulate catabolic process","canonical_id":"go:GO:1901067","description":"\"The chemical reactions and pathways resulting in the breakdown of ferulate.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4506847371d74becaeeed582ca3a5bfc","type":"GO_TERM","name":"ferulate metabolic process","canonical_id":"go:GO:0033494","description":"\"The chemical reactions and pathways involving ferulate, (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate.\" [GOC:mah]","metadata":null},{"id":"12d4548067bb401bb03a9627ceb06731","type":"GO_TERM","name":"feruloyl esterase activity","canonical_id":"go:GO:0030600","description":"\"Catalysis of the reaction: feruloyl-polysaccharide + H2O = ferulate + polysaccharide.\" [EC:3.1.1.73]","metadata":null},{"id":"72d3e97329ab45e6ba7db78481b3a15e","type":"GO_TERM","name":"feruloyl-CoA hydratase/lyase activity","canonical_id":"go:GO:0050547","description":"\"Catalysis of the reaction: (E)-feruloyl-CoA + H2O = acetyl-CoA + vanillin.\" [RHEA:62412]","metadata":null},{"id":"f63278b331374dbda1d6e45fcf0b108b","type":"DISEASE","name":"fetal akinesia deformation sequence 1","canonical_id":"mondo:0100101","description":null,"metadata":null},{"id":"24a7ff7e4e224f2e802f005516f59d8c","type":"GO_TERM","name":"fetal process involved in parturition","canonical_id":"go:GO:0060138","description":"\"A reproductive process occurring in the fetus that results in birth.\" [GOC:dph]","metadata":null},{"id":"130c69713da94a33a3c2ca7d57effdc4","type":"GO_TERM","name":"fever generation","canonical_id":"go:GO:0001660","description":"\"The heat generation process that results in a rise in body temperature above the normal, often as a response to infection.\" [GOC:dph, GOC:jl]","metadata":null},{"id":"ab9a2668c9fc4b138de9e4fbd3d5a258","type":"DRUG","name":"fexofenadine","canonical_id":"gtopdb:4819","description":null,"metadata":null},{"id":"8b6405716c6b46b2a3bca13890f1b511","type":"COMBINATION_TREATMENT","name":"fexofenadine + flurbiprofen","canonical_id":"ctgov_combo:ctgov-combo-2e2a613fa579d687","description":null,"metadata":null},{"id":"dc53c82bc5304926bd126d5f5254debc","type":"COMBINATION_TREATMENT","name":"fexofenadine + loratadine","canonical_id":"ctgov_combo:ctgov-combo-7c51a982c49231b3","description":null,"metadata":null},{"id":"e11751df9eb14ff9b5a2496474ee024b","type":"COMBINATION_TREATMENT","name":"fexofenadine + montelukast","canonical_id":"ctgov_combo:ctgov-combo-19f5f62499890ed8","description":null,"metadata":null},{"id":"781b53eb26c34eabbba3abe364bce282","type":"DRUG","name":"fezolinetant","canonical_id":"gtopdb:10422","description":null,"metadata":null},{"id":"13259aa212b9441388c6b746607b4df5","type":"DRUG","name":"fezolinetant","canonical_id":"chembl:CHEMBL3608680","description":null,"metadata":null},{"id":"82f7237e2e894dd0a5bea20a6bb694fb","type":"GO_TERM","name":"fibrillar center","canonical_id":"go:GO:0001650","description":"\"A structure found most metazoan nucleoli, but not usually found in lower eukaryotes; surrounded by the dense fibrillar component; the zone of transcription from multiple copies of the pre-rRNA genes is in the border region between these two structures.\" [PMID:10754561]","metadata":null},{"id":"21132c2e1f7c4bd99376906bf7b3abe7","type":"GO_TERM","name":"fibrillar collagen complex","canonical_id":"go:GO:0098643","description":"\"A supramolecular assembly of fibrillar collagen complexes in the form of a long fiber (fibril) with transverse striations (bands).\" [GOC:dos, PMID:20386646, PMID:21421911, PMID:29853175]","metadata":null},{"id":"e6f209e0bb6a4863afd4d881c4dade68","type":"GO_TERM","name":"fibrillar collagen trimer","canonical_id":"go:GO:0005583","description":"\"Any triple helical collagen trimer that forms fibrils.\" [PMID:21421911]","metadata":null},{"id":"9c84c7647b524485923b2fbf91ab3d19","type":"GO_TERM","name":"fibrillary inclusion","canonical_id":"go:GO:0097408","description":"\"Cellular inclusion consisting of circular areas filled with fine slender filaments about 10 nanometers in diameter, delimited by a wall of varying complexity (either a single continuous membrane or a tubular network consisting of a fine filamentous material giving the wall a honeycomb appearance). Fibrillary inclusions are found in the cytoplasm of giant cells of Dieters in the lateral vestibular nucleus of the rat; similar structures have been described in the ventral cochlear nucleus, spinal cord, and substantia nigra.\" [NIF_Subcellular:sao967812059]","metadata":null},{"id":"27ca680b90cf4d0ebf7996aabc82bd33","type":"GO_TERM","name":"fibrinogen binding","canonical_id":"go:GO:0070051","description":"\"Binding to fibrinogen, a highly soluble hexameric glycoprotein complex that is found in blood plasma and is converted to fibrin by thrombin in the coagulation cascade.\" [GOC:BHF, GOC:mah, GOC:vk]","metadata":null},{"id":"a941195b4c43444cb15d009d128f3b0d","type":"GO_TERM","name":"fibrinogen complex","canonical_id":"go:GO:0005577","description":"\"A highly soluble, elongated protein complex found in blood plasma and involved in clot formation. It is converted into fibrin monomer by the action of thrombin. In the mouse, fibrinogen is a hexamer, 46 nm long and 9 nm maximal diameter, containing two sets of nonidentical chains (alpha, beta, and gamma) linked together by disulfide bonds.\" [ISBN:0198547684]","metadata":null},{"id":"75a0a6555625464cbeacc023e7427014","type":"GO_TERM","name":"fibrinolysis","canonical_id":"go:GO:0042730","description":"\"A process that solubilizes fibrin in the bloodstream of a multicellular organism, chiefly by the proteolytic action of plasmin.\" [GOC:jl, PMID:15842654]","metadata":null},{"id":"c54c9789ae7b49ae9dac4484d30225d8","type":"GO_TERM","name":"fibroblast activation","canonical_id":"go:GO:0072537","description":"\"A change in the morphology or behavior of a fibroblast resulting from exposure to an activating factor such as a cellular or soluble ligand.\" [CL:0000057, GOC:BHF, GOC:mah]","metadata":null},{"id":"82e1ea2f6ee24443a70aeca8281c45c3","type":"GO_TERM","name":"fibroblast apoptotic process","canonical_id":"go:GO:0044346","description":"\"Any apoptotic process in a fibroblast, a connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules.\" [CL:0000057, GOC:jl, GOC:mtg_apoptosis, GOC:yaf]","metadata":null},{"id":"b99b20a8b77a426bb5ef915518e1e6e0","type":"GO_TERM","name":"fibroblast chemotaxis","canonical_id":"go:GO:1990956","description":"\"The directed movement of a fibroblast guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [GOC:dph, PMID:8760137]","metadata":null},{"id":"54423feeb7bc49729a1e2a3a41842f4d","type":"GO_TERM","name":"fibroblast growth factor binding","canonical_id":"go:GO:0017134","description":"\"Binding to a fibroblast growth factor.\" [PMID:9806903]","metadata":null},{"id":"c0f607d6e9db4837b95536b55a1d1d11","type":"GO_TERM","name":"fibroblast growth factor production","canonical_id":"go:GO:0090269","description":"\"The appearance of a fibroblast growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"125323580ff244069710b3c9c6771830","type":"GO_TERM","name":"fibroblast growth factor receptor activity","canonical_id":"go:GO:0005007","description":"\"Combining with a fibroblast growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"8a4aece5d10b44b6a08e636c9505e514","type":"GO_TERM","name":"fibroblast growth factor receptor antagonist activity","canonical_id":"go:GO:0030353","description":"\"Interacts with the fibroblast growth factor receptor to reduce the action of another ligand, the agonist.\" [GOC:mah]","metadata":null},{"id":"6a5b56d74acc4e918fcd523adfd59611","type":"GO_TERM","name":"fibroblast growth factor receptor apoptotic signaling pathway","canonical_id":"go:GO:1902178","description":"\"An apoptotic signaling pathway that starts with a ligand binding to, or being withdrawn from, a fibroblast growth factor receptor (FGFR).\" [GOC:mtg_apoptosis, GOC:pm, GOC:pr, GOC:TermGenie, PMID:17561467]","metadata":null},{"id":"29f3b33d35e147119026590362946185","type":"GO_TERM","name":"fibroblast growth factor receptor binding","canonical_id":"go:GO:0005104","description":"\"Binding to a fibroblast growth factor receptor (FGFR).\" [GOC:ceb]","metadata":null},{"id":"da6e21f89b9f43a385409bcf23a7433d","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0008543","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.\" [GOC:ceb]","metadata":null},{"id":"df7effd08ffe4374ae97a25c5e83a05a","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in forebrain neuron fate commitment","canonical_id":"go:GO:0021899","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands that contributes to the commitment of a neuroblast to a neuronal fate. The neuron will reside in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"6830855b65764e7fa8247692c145f7ad","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in hemopoiesis","canonical_id":"go:GO:0035603","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands, which contributes to hemopoiesis.\" [GOC:yaf]","metadata":null},{"id":"cf759b06aee64da3a23a493bfdf5bb12","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in mammary gland specification","canonical_id":"go:GO:0060595","description":"\"The series of molecular signals initiated by binding of a fibroblast growth factor to its receptor on the surface of al cell in the epidermis resulting in the formation of the mammary line. The mammary line is a ridge of epidermal cells that will form the mammary placodes.\" [GOC:dph, PMID:16168142]","metadata":null},{"id":"ebac5c1a16f8461db165839a82493b9f","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell","canonical_id":"go:GO:0035602","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands, which stops, prevents, or reduces the frequency, rate or extent of the occurrence or rate of cell death by apoptotic process in the bone marrow.\" [GOC:mtg_apoptosis, GOC:yaf]","metadata":null},{"id":"f0f8437cdfa14aa99155926ed591f059","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development","canonical_id":"go:GO:0035607","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor-type receptor binding to one of its physiological ligands, which contributes to the progression of the orbitofrontal cortex over time from its initial formation until its mature state.\" [GOC:yaf]","metadata":null},{"id":"1978be495f4a499f816a8c24b4a71113","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow","canonical_id":"go:GO:0035604","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands, which activates or increases the frequency, rate or extent of cell proliferation in the bone marrow.\" [GOC:yaf]","metadata":null},{"id":"c10aed35a65f42d18828101947fe7005","type":"GO_TERM","name":"fibroblast growth factor receptor signaling pathway involved in somitogenesis","canonical_id":"go:GO:0090243","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands that contributes to somitogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"a7686f6c1faa41ba94938aa24a8e01a1","type":"GO_TERM","name":"fibroblast migration","canonical_id":"go:GO:0010761","description":"\"Cell migration that is accomplished by extension and retraction of a fibroblast pseudopodium. A fibroblast is a connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d7afc7cca7844cf38aa7bcaabaa718b4","type":"GO_TERM","name":"fibroblast proliferation","canonical_id":"go:GO:0048144","description":"\"The multiplication or reproduction of fibroblast cells, resulting in the expansion of the fibroblast population.\" [GOC:jid]","metadata":null},{"id":"7fabe523701446f1956537f8597325af","type":"DISEASE","name":"fibrodysplasia ossificans progressiva","canonical_id":"mondo:0007606","description":null,"metadata":null},{"id":"4cad8e5e5917431d947fc55661f50c00","type":"DISEASE","name":"fibromyalgia","canonical_id":"mondo:0005546","description":null,"metadata":null},{"id":"f12c86b746fc420d96f69a76aa59e8ea","type":"GO_TERM","name":"fibronectin binding","canonical_id":"go:GO:0001968","description":"\"Binding to a fibronectin, a group of related adhesive glycoproteins of high molecular weight found on the surface of animal cells, connective tissue matrices, and in extracellular fluids.\" [GOC:hjd]","metadata":null},{"id":"3a5d31f2bdc54b22b4fc3d5394def328","type":"GO_TERM","name":"fibronectin fibril","canonical_id":"go:GO:0061800","description":"\"A supramolecular fiber formed from fibronectin molecules. The fibrils are 5 to 25nm in diameter and can form branched meshworks.\" [PMID:20690820, PMID:26041410, PMID:34572092]","metadata":null},{"id":"af54028f3735480a853ec3aef80af735","type":"GO_TERM","name":"fibronectin fibril organization","canonical_id":"go:GO:1905590","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a fibronectin fibril.\" [GOC:dph, GOC:TermGenie, PMID:20690820]","metadata":null},{"id":"350fc99112f6491eb9162399a2fcbaca","type":"GO_TERM","name":"fibronectin-dependent thymocyte migration","canonical_id":"go:GO:0072681","description":"\"The movement of a thymocyte through distinct intrathymic niches (e.g. medulla, cortex), where it receives a unique set of developmental cues required for T-cell development, dependent on fibronectin in the extracellular matrix.\" [CL:0000893, GOC:BHF, GOC:mah, PMID:20856819]","metadata":null},{"id":"99917b2d18164f43b1779c079c237db5","type":"GO_TERM","name":"fibronectin-tissue transglutaminase complex","canonical_id":"go:GO:0071078","description":"\"A protein complex that consists of fibronectin bound to tissue transglutaminase, and is involved in cell adhesion.\" [PMID:10684262]","metadata":null},{"id":"c5d76c342eab4bd7a4359a794734e174","type":"DISEASE","name":"fibrosis","canonical_id":"efo:0006890","description":null,"metadata":null},{"id":"9a6aec35d7b041618853eeb96fa2c31b","type":"GO_TERM","name":"fibrous body-membranous organelle","canonical_id":"go:GO:0160208","description":"\"A Golgi-derived organelle that forms in primary spermatocytes during spermatogenesis of some nematodes including C. elegans. This 'double organelle' consists of a fibrous body containing major sperm protein and a membranous organelle that envelops the developing fibrous body.\" [PMID:18050478, PMID:8004009]","metadata":null},{"id":"51a4a4b23fcc4bac8bdb5703ee588503","type":"GO_TERM","name":"fibrous ring of heart morphogenesis","canonical_id":"go:GO:1905285","description":"\"The developmental process by which a fibrous ring of heart is generated and organized.\" [GO_REF:0000083, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16037571]","metadata":null},{"id":"fc5834dd73cb451180218aa9d883de76","type":"GO_TERM","name":"ficolin-1-rich granule","canonical_id":"go:GO:0101002","description":"\"Highly exocytosable gelatinase-poor granules found in neutrophils and rich in ficolin-1. Ficolin-1 is released from neutrophil granules by stimulation with fMLP or PMA, and the majority becomes associated with the surface membrane of the cells and can be detected by flow cytometry.\" [GOC:mec, PMID:19741154]","metadata":null},{"id":"1f4068fd20db4d6ca0d1a8378c66f4f2","type":"GO_TERM","name":"ficolin-1-rich granule lumen","canonical_id":"go:GO:1904813","description":"\"Any membrane-enclosed lumen that is part of a ficolin-1-rich granule.\" [GO_REF:0000064, GOC:TermGenie, PMID:23650620]","metadata":null},{"id":"8ab9e2cb9b8748c6bf1fac2a24c9881a","type":"GO_TERM","name":"ficolin-1-rich granule membrane","canonical_id":"go:GO:0101003","description":"\"The lipid bilayer surrounding a ficolin-1-rich granule.\" [GOC:mec, PMID:23650620]","metadata":null},{"id":"a5c1f47a54484272a29531c0d2ea662f","type":"GO_TERM","name":"filamentous actin","canonical_id":"go:GO:0031941","description":"\"A two-stranded helical polymer of the protein actin.\" [GOC:mah]","metadata":null},{"id":"4b228a9f2a2c4a01b7a148d4835f1721","type":"GO_TERM","name":"filamentous growth","canonical_id":"go:GO:0030447","description":"\"The process in which a multicellular organism, a unicellular organism or a group of unicellular organisms grow in a threadlike, filamentous shape.\" [GOC:mcc, PMID:11729141]","metadata":null},{"id":"c49886000e8e45ca853ae2415bcde4cc","type":"GO_TERM","name":"filamentous growth MAPK cascade","canonical_id":"go:GO:0062031","description":"\"A MAPK cascade containing at least the Kss1 MAP kinase. It starts with the activation of Ste20, a MAP4K, which activates Ste11, a MAP3K, which in turn activate Ste7, a MAP2K, which activates Kss1. The kinases in each tier phosphorylate and activate the kinases in the downstream tier. The filamentous growth MAPK cascade is activated as a result of partial nutrient deprivation and  results in filamentous growth.\" [PMID:17604854, PMID:33335117, PMID:38187743]","metadata":null},{"id":"c5b6314c469e4c13a5e9965d7f790127","type":"GO_TERM","name":"filamentous growth of a multicellular organism","canonical_id":"go:GO:0044181","description":"\"The process in which a multicellular organism grows in a threadlike, filamentous shape.\" [GOC:mtg_cambridge_2009]","metadata":null},{"id":"dd9e6f0e221d491e8e4022415952ad2b","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms","canonical_id":"go:GO:0044182","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape.\" [GOC:mtg_cambridge_2009]","metadata":null},{"id":"e98a2ea68bb74bb699beff85e213594b","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms in response to biotic stimulus","canonical_id":"go:GO:0036180","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape in response to a biotic (living) stimulus.\" [GOC:di]","metadata":null},{"id":"2595818333e846fa937fc63b986646a5","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms in response to chemical stimulus","canonical_id":"go:GO:0036171","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape in response to a chemical stimulus.\" [GOC:di, PMID:17554048]","metadata":null},{"id":"faa081a2485e4884a29ed27f2cd1ae4c","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms in response to heat","canonical_id":"go:GO:0036168","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape in response to an increase in temperature.\" [GOC:di, PMID:17554048]","metadata":null},{"id":"1a95c83d86c64f13a3dbf297a6524e01","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms in response to neutral pH","canonical_id":"go:GO:0036178","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape in response to a neutral pH (pH close to 7) stimulus.\" [GOC:di, PMID:6374461]","metadata":null},{"id":"8115a103bc27440281d0f429aa49c995","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms in response to pH","canonical_id":"go:GO:0036177","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape in response to a pH stimulus. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:di, Wikipedia:PH]","metadata":null},{"id":"99a797acee364998bd5d38708d48d328","type":"GO_TERM","name":"filamentous growth of a population of unicellular organisms in response to starvation","canonical_id":"go:GO:0036170","description":"\"The process in which a group of unicellular organisms grow in a threadlike, filamentous shape in response to deprivation of nourishment.\" [GOC:di, PMID:17554048]","metadata":null},{"id":"6d7292afd03c41ee9c3092140aa2baac","type":"GO_TERM","name":"filamentous growth of a unicellular organism","canonical_id":"go:GO:0044180","description":"\"The process in which a unicellular organism grows in a threadlike, filamentous shape.\" [GOC:mtg_cambridge_2009]","metadata":null},{"id":"f37a39c63a714aa1bf00f18845513dcf","type":"GO_TERM","name":"filamin binding","canonical_id":"go:GO:0031005","description":"\"Binding to a filamin, any member of a family of high molecular mass cytoskeletal proteins that crosslink actin filaments to form networks and stress fibers. Filamins contain an amino-terminal alpha-actinin-like actin binding domain, which is followed by a rod-domain composed of 4 to 24 100-residue repetitive segments including a carboxy-terminal dimerization domain.\" [GOC:mah, PMID:11336782]","metadata":null},{"id":"759db9a025e345dda8adca6ff8515744","type":"DRUG","name":"filgotinib","canonical_id":"gtopdb:7913","description":null,"metadata":null},{"id":"33107a3799754986b94c1d9f59cb9822","type":"DRUG","name":"filgotinib","canonical_id":"chembl:CHEMBL3301607","description":null,"metadata":null},{"id":"fbd4bb50e2f141ba8c5298c1cb96c9d5","type":"COMBINATION_TREATMENT","name":"filgotinib + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-63824d22adc53ad4","description":null,"metadata":null},{"id":"a0943eda85c6433dab4195655528be87","type":"COMBINATION_TREATMENT","name":"filgotinib + tirabrutinib","canonical_id":"ctgov_combo:ctgov-combo-8cd3c7f577f67308","description":null,"metadata":null},{"id":"61d4a22702954c9696801a85aa1339ad","type":"GO_TERM","name":"filiform apparatus","canonical_id":"go:GO:0043680","description":"\"A complex of cell wall invaginations in a synergid cell, similar to those in transfer cells.\" [ISBN:0471245208]","metadata":null},{"id":"bab3c4a709014696a4784afd9a0a9eec","type":"GO_TERM","name":"filopodium","canonical_id":"go:GO:0030175","description":"\"Thin, stiff, actin-based protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal or dendritic growth cone, or a dendritic shaft.\" [GOC:mah, GOC:pr, ISBN:0815316194]","metadata":null},{"id":"0b4494e5c8fc4c4da7a32229c77d8d5d","type":"GO_TERM","name":"filopodium assembly","canonical_id":"go:GO:0046847","description":"\"The assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone.\" [GOC:dph, GOC:mah, GOC:tb, PMID:16337369, PMID:18464790]","metadata":null},{"id":"aac672113ef244459d7f43af532b5026","type":"GO_TERM","name":"filopodium membrane","canonical_id":"go:GO:0031527","description":"\"The portion of the plasma membrane surrounding a filopodium.\" [GOC:mah]","metadata":null},{"id":"bed72207dd1840c4867fd5e51cec36ce","type":"GO_TERM","name":"filopodium tip","canonical_id":"go:GO:0032433","description":"\"The end of a filopodium distal to the body of the cell.\" [GOC:mah]","metadata":null},{"id":"dafe08979bc14c64aff13f3cc6649246","type":"GO_TERM","name":"filtration diaphragm","canonical_id":"go:GO:0036056","description":"\"A specialized cell-cell junction found between the cells of the excretory system, which provides a barrier for filtration of blood or hemolymph.\" [GOC:mtg_kidney_jan10, GOC:sart, PMID:18971929]","metadata":null},{"id":"6b839eca401b498e8717ab7e3c47f134","type":"GO_TERM","name":"filtration diaphragm assembly","canonical_id":"go:GO:0036058","description":"\"The aggregation, arrangement and bonding together of a set of components to form a filtration diaphragm, a specialized cell-cell junction found between the cells of the excretory system, which provides a barrier for filtration of blood or hemolymph.\" [GOC:mtg_kidney_jan10, PMID:18971929]","metadata":null},{"id":"7fab66d3cb6447d481c3287f33b85a55","type":"DRUG","name":"fimasartan","canonical_id":"mesh:C558933","description":null,"metadata":null},{"id":"f31a24d6800444ef801ae88c064f9786","type":"GO_TERM","name":"fimbrial usher porin activity","canonical_id":"go:GO:0015473","description":"\"A porin that acts in the assembly of fimbria together with fimbrial chaperone.\" [TC:1.B.11.-.-]","metadata":null},{"id":"6138e5ed20084ad49ed21aff26a821bd","type":"GO_TERM","name":"fin development","canonical_id":"go:GO:0033333","description":"\"The process whose specific outcome is the progression of a fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"17babe4d88df4e5e95f287f3f2c9398e","type":"GO_TERM","name":"fin morphogenesis","canonical_id":"go:GO:0033334","description":"\"The process in which the anatomical structures of a fin are generated and organized.\" [GOC:dgh]","metadata":null},{"id":"6f24954aec154c09baa8525a548759cd","type":"GO_TERM","name":"fin regeneration","canonical_id":"go:GO:0031101","description":"\"The regrowth of fin tissue following its loss or destruction.\" [GOC:dgh]","metadata":null},{"id":"4ddd9504bf604b6c889cd54c526eea15","type":"DRUG","name":"finasteride","canonical_id":"gtopdb:6818","description":null,"metadata":null},{"id":"3d75da05ef8f4d0e889e57e258224fe6","type":"DRUG","name":"finasteride","canonical_id":"chembl:CHEMBL710","description":null,"metadata":null},{"id":"01ea22285e8944ff8ee8f50cd2b52467","type":"COMBINATION_TREATMENT","name":"finasteride + flutamide","canonical_id":"ctgov_combo:ctgov-combo-249fe621ac0a22ea","description":null,"metadata":null},{"id":"47c63affe7034a408ba5e4eade2de0b0","type":"COMBINATION_TREATMENT","name":"finasteride + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-a47a14a8f874de61","description":null,"metadata":null},{"id":"15ec65b849ed41f0b047487e316552fc","type":"COMBINATION_TREATMENT","name":"finasteride + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-498903cd6e67cdd0","description":null,"metadata":null},{"id":"08527e29aab346ddb567680bdf826e6c","type":"DRUG","name":"fingolimod","canonical_id":"gtopdb:2407","description":null,"metadata":null},{"id":"8fb0872743324c62964436bfef86d9c4","type":"COMBINATION_TREATMENT","name":"fingolimod + fluoxetine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-3b8f5eb4fef8b3ce","description":null,"metadata":null},{"id":"65fda802ba7a4b1cb49448c13f5c2320","type":"COMBINATION_TREATMENT","name":"fingolimod + natalizumab + ocrelizumab + ofatumumab + ponesimod + teriflunomide","canonical_id":"ctgov_combo:ctgov-combo-cf366d44496ff1c8","description":null,"metadata":null},{"id":"f233062b1009400a9aa41a105565b0d4","type":"COMBINATION_TREATMENT","name":"fingolimod + ocrelizumab","canonical_id":"ctgov_combo:ctgov-combo-8be82d5142d3151e","description":null,"metadata":null},{"id":"fbe4116da69648b5a9636f9f9f614221","type":"COMBINATION_TREATMENT","name":"fingolimod + ozanimod","canonical_id":"ctgov_combo:ctgov-combo-ef4a91a7b8d377d4","description":null,"metadata":null},{"id":"e9350ade531448d5872bfb87dbc31211","type":"DRUG","name":"finotonlimab","canonical_id":"gtopdb:14401","description":null,"metadata":null},{"id":"54498201a2984410923cc4c4fb1ced82","type":"DRUG","name":"finotonlimab","canonical_id":"chembl:CHEMBL4650516","description":null,"metadata":null},{"id":"7bd63df790fd4b6cb3f88bc780051417","type":"COMBINATION_TREATMENT","name":"finotonlimab + stapokibart","canonical_id":"ctgov_combo:ctgov-combo-876b900222df7121","description":null,"metadata":null},{"id":"e331ce4d08344500a19b2e8206dd4ace","type":"GO_TERM","name":"first cell cycle pseudocleavage","canonical_id":"go:GO:0030590","description":"\"A process that occurs during the first cell cycle in an embryo, in which anterior cortical contractions culminate in a single partial constriction of the embryo called the pseudocleavage furrow. An example of this process is found in nematode worms.\" [GOC:mtg_sensu, PMID:7729583]","metadata":null},{"id":"5cf90410acb944b8a68d26c8cad986be","type":"GO_TERM","name":"first spliceosomal transesterification activity","canonical_id":"go:GO:0000384","description":"\"Catalysis of the first transesterification reaction of spliceosomal mRNA splicing. The intron branch site adenosine is the nucleophile attacking the 5' splice site, resulting in cleavage at this position. In cis splicing, this is the step that forms a lariat structure of the intron RNA, while it is still joined to the 3' exon.\" [GOC:krc, ISBN:0879695897, PMID:19239890]","metadata":null},{"id":"e539861ce9b04c879084ff03f999dafb","type":"GO_TERM","name":"flagella connector","canonical_id":"go:GO:0120118","description":"\"A mobile transmembrane junction at the tip of the flagellum of some kinetoplastid species linking the tip of a new growing flagellum to an older flagellum.\" [PMID:11641501, PMID:15075226, PMID:16954145, PMID:26820516]","metadata":null},{"id":"5c0402f0c83948b4b0c4b57e18ac7158","type":"GO_TERM","name":"flagellated sperm motility","canonical_id":"go:GO:0030317","description":"\"The directed, self-propelled movement of a cilium (aka flagellum) that contributes to the movement of a flagellated sperm.\" [GO_REF:0000060, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:26680031]","metadata":null},{"id":"cad74ff92b12412b90f43f48e54e55e0","type":"GO_TERM","name":"flagellum attachment zone","canonical_id":"go:GO:0120119","description":"\"A network of cytoskeletal and membranous connections responsible for the lateral attachment of the cilium to the cell body in some trypanosomatid species.\" [PMID:10361731, PMID:16414276, PMID:17945531, PMID:20541452, PMID:25972344, PMID:2606941, PMID:26746239, PMID:26776656]","metadata":null},{"id":"6adc601bd0a9448d95d907dcf52c1beb","type":"GO_TERM","name":"flagellum attachment zone organization","canonical_id":"go:GO:0110140","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a flagellum attachment zone. FAZ is a network of cytoskeletal and membranous connections responsible for the lateral attachment of the cilium to the cell body in some trypanosomatid species.\" [GOC:ach, PMID:26776656]","metadata":null},{"id":"1b4937c386f7419abaa6f17b80efa69a","type":"GO_TERM","name":"flap endonuclease activity","canonical_id":"go:GO:0048256","description":"\"Catalysis of the cleavage of a flap structure in DNA, but not other DNA structures; processes the ends of Okazaki fragments in lagging strand DNA synthesis.\" [GOC:jid]","metadata":null},{"id":"2336db8d41bb43bd8fe76ab5d3fe7e6b","type":"GO_TERM","name":"flap-structured DNA binding","canonical_id":"go:GO:0070336","description":"\"Binding to a flap structure in DNA. A DNA flap structure is one in which a single-stranded length of DNA or RNA protrudes from a double-stranded DNA molecule.\" [GOC:mah, PMID:15189154]","metadata":null},{"id":"f35d4d9d4e414f82b5e3d9a8699cbdf9","type":"GO_TERM","name":"flavanol binding","canonical_id":"go:GO:0097245","description":"\"Binding to a flavanol.\" [GOC:sl]","metadata":null},{"id":"9cd5ea7a1e97464aa8e78bdd2d7778eb","type":"GO_TERM","name":"flavanone 2-hydroxylase activity","canonical_id":"go:GO:0033771","description":"\"Catalysis of the reaction: a flavanone + O2 + reduced [NADPH--hemoprotein reductase] = a 2-hydroxyflavanone + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [EC:1.14.14.162, RHEA:57584]","metadata":null},{"id":"3c6ab247ddff40a38e72aec6b7a6b77b","type":"GO_TERM","name":"flavanone 3-dioxygenase activity","canonical_id":"go:GO:0045486","description":"\"Catalysis of the reaction: 2-oxoglutarate + a (2S)-flavan-4-one + O2 = a (2R,3R)-dihydroflavonol + CO2 + succinate.\" [RHEA:18621]","metadata":null},{"id":"cda948f07ca144868a4508a5d4292da0","type":"GO_TERM","name":"flavanone 4'-O-methyltransferase activity","canonical_id":"go:GO:0102767","description":"\"Catalysis of the reaction: (S)-naringenin + S-adenosyl-L-methionine = 2 H+ + ponciretin + S-adenosyl-L-homocysteine.\" [EC:2.1.1.231, GOC:pz]","metadata":null},{"id":"20f145b4f1b7423c9c661ee49282e5fe","type":"GO_TERM","name":"flavanone 4-reductase activity","canonical_id":"go:GO:0047890","description":"\"Catalysis of the reaction: (2S)-flavan-4-ol + NADP+ = (2S)-flavanone + NADPH.\" [EC:1.1.1.234, MetaCyc:FLAVANONE-4-REDUCTASE-RXN]","metadata":null},{"id":"1e053f9a104d42b6a46d82f6428bd0d0","type":"GO_TERM","name":"flavanone 7-O-beta-glucosyltransferase activity","canonical_id":"go:GO:0047243","description":"\"Catalysis of the reaction: a flavanone + UDP-D-glucose = a flavanone 7-O-beta-D-glucoside + UDP.\" [EC:2.4.1.185, MetaCyc:2.4.1.185-RXN]","metadata":null},{"id":"fc611cbd424d41f3aea34c5594d81647","type":"GO_TERM","name":"flavanone 7-O-glucoside 2''-O-beta-L-rhamnosyltransferase activity","canonical_id":"go:GO:0033835","description":"\"Catalysis of the reaction: UDP-L-rhamnose + a flavanone 7-O-glucoside = UDP + a flavanone 7-O-[beta-L-rhamnosyl-(1->2)-beta-D-glucoside].\" [EC:2.4.1.236]","metadata":null},{"id":"ecc65d32a83c42d7b709490957f0f3cc","type":"GO_TERM","name":"flavin adenine dinucleotide binding","canonical_id":"go:GO:0050660","description":"\"Binding to FAD, flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes, in either the oxidized form, FAD, or the reduced form, FADH2.\" [GOC:ai, GOC:imk, ISBN:0198506732]","metadata":null},{"id":"eabd0e1fdfed4862a189bc6cf9823de2","type":"GO_TERM","name":"flavin adenine dinucleotide biosynthetic process","canonical_id":"go:GO:0072388","description":"\"The chemical reactions and pathways resulting in the formation of flavin adenine dinucleotide, which acts as a coenzyme or prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:mah]","metadata":null},{"id":"9fe8296cd94b48a181c7292181263c78","type":"GO_TERM","name":"flavin adenine dinucleotide catabolic process","canonical_id":"go:GO:0072389","description":"\"The chemical reactions and pathways resulting in the breakdown of flavin adenine dinucleotide, which acts as a coenzyme or prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:mah]","metadata":null},{"id":"de0e68aaf44346c28c37fa3f3dbf8257","type":"GO_TERM","name":"flavin adenine dinucleotide metabolic process","canonical_id":"go:GO:0072387","description":"\"The chemical reactions and pathways involving flavin adenine dinucleotide, which acts as a coenzyme or prosthetic group of various flavoprotein oxidoreductase enzymes.\" [GOC:mah]","metadata":null},{"id":"3500e2a7847a49628aa9b820910ec24f","type":"GO_TERM","name":"flavin prenyltransferase activity","canonical_id":"go:GO:0106141","description":"\"Catalysis of the reaction: dimethylallyl phosphate + FMNH2 = phosphate + prenyl-FMNH2.\" [PMID:26083743, RHEA:37743]","metadata":null},{"id":"e0a5346378d84874b925df7d39ea9c0e","type":"GO_TERM","name":"flavin reductase (NADH) activity","canonical_id":"go:GO:0036382","description":"\"Catalysis of the reaction: a reduced flavin + NAD+ = an oxidized flavin + 2 H+ + NADH.\" [GOC:rs, RHEA:31303]","metadata":null},{"id":"330ad7ae7e2141e89855f093c80c14af","type":"GO_TERM","name":"flavin transferase activity","canonical_id":"go:GO:7770036","description":"\"Catalysis of the reaction: L-threonyl-[protein] + FAD = FMN-L-threonyl-[protein] + AMP + H+.\" [RHEA:36847]","metadata":null},{"id":"040c5e2ad6174f079c2015d5a9d720b2","type":"GO_TERM","name":"flavin-containing compound biosynthetic process","canonical_id":"go:GO:0042727","description":"\"The chemical reactions and pathways resulting in the formation of a flavin, any derivative of the dimethylisoalloxazine (7,8-dimethylbenzo[g]pteridine-2,4(3H,10H)-dione) skeleton, with a substituent on the 10 position.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"f3d580ecb0ce4124a9cab556c24e7e3f","type":"GO_TERM","name":"flavin-containing compound catabolic process","canonical_id":"go:GO:0042728","description":"\"The chemical reactions and pathways resulting in the breakdown of a flavin, any derivative of the dimethylisoalloxazine (7,8-dimethylbenzo[g]pteridine-2,4(3H,10H)-dione) skeleton, with a substituent on the 10 position.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"f479555e7b624502bd316ab7cfbbc13b","type":"GO_TERM","name":"flavin-containing compound metabolic process","canonical_id":"go:GO:0042726","description":"\"The chemical reactions and pathways involving a flavin, any derivative of the dimethylisoalloxazine (7,8-dimethylbenzo[g]pteridine-2,4(3H,10H)-dione) skeleton, with a substituent on the 10 position.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"6621973524574738b393e73970d7f0fe","type":"GO_TERM","name":"flavin-dependent halogenase activity","canonical_id":"go:GO:0140907","description":"\"Catalysis of the reaction: R-CH + a halogen + FADH2 + O2 = R-C-halogen + FAD + H2O.\" [PMID:28466644, PMID:34368824]","metadata":null},{"id":"d0e2502da59a4fa68f1d2f91c8d2c730","type":"GO_TERM","name":"flavin-dependent sulfhydryl oxidase activity","canonical_id":"go:GO:0016971","description":"\"Catalysis of the reaction: [protein]-dithiol + O2 = [protein]-disulfide + H2O2 using FAD as a cofactor, leading to formation of disulfide bridges in proteins.\" [PMID:10899311, PMID:19679655, PMID:35495482]","metadata":null},{"id":"506deb1426bc40b097a8a6121962902e","type":"GO_TERM","name":"flavone 3'-O-methyltransferase activity","canonical_id":"go:GO:0102822","description":"\"Catalysis of the reaction: a 3'-hydroxyflavone + S-adenosyl-L-methionine = a 3'-methoxyflavone + H+ + S-adenosyl-L-homocysteine.\" [RHEA:55332]","metadata":null},{"id":"1974bac1a0cf439b93bd505c72f53463","type":"GO_TERM","name":"flavone 7-O-beta-glucosyltransferase activity","canonical_id":"go:GO:0047891","description":"\"Catalysis of the reaction: UDP-glucose + 5,7,3',4'-tetrahydroxyflavone = UDP + 7-O-beta-D-glucosyl-5,7,3',4'-tetrahydroxyflavone.\" [EC:2.4.1.81, MetaCyc:FLAVONE-7-O-BETA-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"9e6f418097c34aacb9963735b855506b","type":"GO_TERM","name":"flavone apiosyltransferase activity","canonical_id":"go:GO:0047892","description":"\"Catalysis of the reaction: UDP-apiose + 7-O-beta-D-glucosyl-5,7,4'-trihydroxyflavone = UDP + 7-O-(beta-D-apiofuranosyl-1,2-beta-D-glucosyl)-5,7,4'-trihydroxyflavone.\" [EC:2.4.2.25, MetaCyc:FLAVONE-APIOSYLTRANSFERASE-RXN]","metadata":null},{"id":"2293c68ebc7a41f0a4c2d234684dbc18","type":"GO_TERM","name":"flavone biosynthetic process","canonical_id":"go:GO:0051553","description":"\"The chemical reactions and pathways resulting in the formation of flavones, a class of pigmented plant compounds based on 2-phenyl-4H-1-benzopyran-4-one (2-phenylchromone).\" [GOC:ai, PMID:18567791]","metadata":null},{"id":"fba36b2b0d904445868de3ef4cab1210","type":"GO_TERM","name":"flavone metabolic process","canonical_id":"go:GO:0051552","description":"\"The chemical reactions and pathways involving flavones, a class of pigmented plant compounds based on 2-phenyl-4H-1-benzopyran-4-one (2-phenylchromone).\" [PMID:18567791]","metadata":null},{"id":"8123eef567c046e7b2a92c8c94d8a20e","type":"GO_TERM","name":"flavone synthase activity","canonical_id":"go:GO:0033759","description":"\"Catalysis of the reaction: a flavanone + 2-oxoglutarate + O2 = a flavone + succinate + CO2 + H2O.\" [EC:1.14.20.5]","metadata":null},{"id":"0c1bfe4b2d184b2ca3cbdb79a7b47803","type":"GO_TERM","name":"flavonoid 3',5'-hydroxylase activity","canonical_id":"go:GO:0033772","description":"\"Catalysis of the reaction: a 3',5'-unsubstituted flavanone + 2 O2 + 2 reduced [NADPH--hemoprotein reductase] = a 3',5'-dihydroxyflavanone + 2 H+ + 2 H2O + 2 oxidized [NADPH--hemoprotein reductase].\" [RHEA:55448]","metadata":null},{"id":"c3c7a45ab0bc4f1985c78bbd65190ee5","type":"GO_TERM","name":"flavonoid 3'-monooxygenase activity","canonical_id":"go:GO:0016711","description":"\"Catalysis of the reaction: a flavonoid + NADPH + H+ + O2 = 3'-hydroxyflavonoid + NADP+ + H2O.\" [EC:1.14.14.82]","metadata":null},{"id":"440fe2e3ed1b4cb1bded5e79704cb48b","type":"GO_TERM","name":"flavonoid binding","canonical_id":"go:GO:0097243","description":"\"Binding to a flavonoid, a compound containing two or more aromatic rings, each bearing at least one aromatic hydroxyl and connected with a carbon bridge.\" [GOC:sl, PMID:20599706]","metadata":null},{"id":"4303bd50a3ca49888992744152088f3d","type":"GO_TERM","name":"flavonoid biosynthetic process","canonical_id":"go:GO:0009813","description":"\"The chemical reactions and pathways resulting in the formation of flavonoids, a group of phenolic derivatives containing a flavan skeleton.\" [GOC:tair_curators, ISBN:0198547684]","metadata":null},{"id":"96a6714bfd684b80b042d96de7e5feea","type":"GO_TERM","name":"flavonoid catabolic process","canonical_id":"go:GO:0046275","description":"\"The chemical reactions and pathways resulting in the breakdown of flavonoids, a group of phenolic derivatives containing a flavan skeleton.\" [GOC:ai]","metadata":null},{"id":"97d2537557cf44c5b3a50c6b68583db1","type":"GO_TERM","name":"flavonoid metabolic process","canonical_id":"go:GO:0009812","description":"\"The chemical reactions and pathways involving flavonoids, a group of water-soluble phenolic derivatives containing a flavan skeleton including flavones, flavonols and flavanoids, and anthocyanins.\" [GOC:tair_curators, ISBN:0198547684]","metadata":null},{"id":"6926955906c74ab1b34bdabf9e2401b0","type":"GO_TERM","name":"flavonoid phytoalexin biosynthetic process","canonical_id":"go:GO:0009716","description":"\"The chemical reactions and pathways resulting in the formation of flavonoid phytoalexins, a group of water-soluble phenolic derivatives containing a flavan skeleton, which possess antibiotic activity and are produced by plant tissues in response to infection.\" [ISBN:0198506732]","metadata":null},{"id":"0661198882774d74bfb292342c34182f","type":"GO_TERM","name":"flavonoid phytoalexin catabolic process","canonical_id":"go:GO:0046286","description":"\"The chemical reactions and pathways resulting in the breakdown of flavonoid phytoalexins, a group of water-soluble phenolic derivatives containing a flavan skeleton, which possess antibiotic activity and are produced by plant tissues in response to infection.\" [GOC:ai]","metadata":null},{"id":"44a5c188cce64dfda657b33dec6e8ea5","type":"GO_TERM","name":"flavonoid sulfotransferase activity","canonical_id":"go:GO:1990135","description":"\"Catalysis of the reaction: a flavonoid + 3'-phosphoadenosine-5'-phosphosulfate = sulfated flavonoid + adenosine-3',5'-diphosphate. This reaction is the transfer of a sulfate group to the hydroxyl group of a flavonoid acceptor, producing the sulfated flavonoid derivative.\" [PMID:23611783]","metadata":null},{"id":"f8bac81bb4774e919207cd0aa0f79c3c","type":"GO_TERM","name":"flavonoid transport from endoplasmic reticulum to plant-type vacuole","canonical_id":"go:GO:1903415","description":"\"The directed movement of flavonoid from endoplasmic reticulum to plant-type vacuole.\" [GO_REF:0000078, GOC:tb, GOC:TermGenie, PMID:25116949]","metadata":null},{"id":"ff197d850a86400b9623010c5bd6f5a0","type":"GO_TERM","name":"flavonol 3-O-arabinosyltransferase activity","canonical_id":"go:GO:0080059","description":"\"Catalysis of the reaction: UDP-arabinose + a flavonol = UDP + a flavonol 3-O-D-arabinoside.\" [PMID:18757557]","metadata":null},{"id":"1b17ed1063ac46f78272da0979b1ae28","type":"GO_TERM","name":"flavonol 3-O-glucosyltransferase activity","canonical_id":"go:GO:0047893","description":"\"Catalysis of the reaction: UDP-glucose + a flavonol = UDP + a flavonol 3-O-D-glucoside.\" [EC:2.4.1.91, MetaCyc:FLAVONOL-3-O-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"afdcef06407141398c2d998e681f2e03","type":"GO_TERM","name":"flavonol 3-sulfotransferase activity","canonical_id":"go:GO:0047894","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + quercetin = adenosine 3',5'-diphosphate + H+ + quercetin 3-sulfate.\" [EC:2.8.2.25, RHEA:13453]","metadata":null},{"id":"389ed6c0798846a6875f08fbeb634cc7","type":"GO_TERM","name":"flavonol 7-O-beta-glucosyltransferase activity","canonical_id":"go:GO:0033836","description":"\"Catalysis of the reaction: UDP-glucose + a flavonol = UDP + a flavonol 7-O-beta-D-glucoside.\" [EC:2.4.1.237]","metadata":null},{"id":"ca67e66597e7435e9cd25b4e1c4ac7de","type":"GO_TERM","name":"flavonol binding","canonical_id":"go:GO:0097244","description":"\"Binding to a flavonol, a flavonoid that contains a 3-hydroxy-2-phenylchromen-4-one backbone.\" [GOC:sl]","metadata":null},{"id":"01c7b286784148cbaf2f1fa35c883e50","type":"GO_TERM","name":"flavonol biosynthetic process","canonical_id":"go:GO:0051555","description":"\"The chemical reactions and pathways resulting in the formation of flavonols, a member of a class of vascular pigments formed by consecutive oxidative processes from the flavonoid intermediates flavanones and dihydroflavonols. Flavonols are the most widespread of the flavonoids and have a wide array of physiological activities.\" [GOC:ai]","metadata":null},{"id":"96ea19fb4d01495585ae03105dd79216","type":"GO_TERM","name":"flavonol metabolic process","canonical_id":"go:GO:0051554","description":"\"The chemical reactions and pathways involving flavonols, a member of a class of vascular pigments formed by consecutive oxidative processes from the flavonoid intermediates flavanones and dihydroflavonols. Flavonols are the most widespread of the flavonoids and have a wide array of physiological activities.\" [PMID:11402179]","metadata":null},{"id":"8533f3cb06a742168519e9010f2f0aec","type":"GO_TERM","name":"flavonol synthase activity","canonical_id":"go:GO:0045431","description":"\"Catalysis of the reaction: a dihydroflavonol + 2-oxoglurate + O2 = a flavonol + succinate + CO2 + H2O.\" [EC:1.14.20.6, ISBN:0943088372, PMID:7904213]","metadata":null},{"id":"73c22367c9784c45b5209cddf517adfd","type":"GO_TERM","name":"flavonol-3-O-beta-glucoside O-malonyltransferase activity","canonical_id":"go:GO:0047165","description":"\"Catalysis of the reaction: flavonol 3-O-beta-D-glucoside + malonyl-CoA = malonyl-flavonol 3-O-beta-D-glucoside + CoA.\" [EC:2.3.1.116, MetaCyc:2.3.1.116-RXN]","metadata":null},{"id":"c61c9f1f9de3412ab2da95c65b34e82b","type":"GO_TERM","name":"flavonol-3-O-glucoside L-rhamnosyltransferase activity","canonical_id":"go:GO:0047230","description":"\"Catalysis of the reaction: flavonol 3-O-D-glucoside + UDP-L-rhamnose = flavonol 3-O-L-rhamnosylglucoside + UDP.\" [EC:2.4.1.159, MetaCyc:2.4.1.159-RXN]","metadata":null},{"id":"f6144378258c43dc9e944a3e92dea384","type":"GO_TERM","name":"flavonol-3-O-glucoside glucosyltransferase activity","canonical_id":"go:GO:0033838","description":"\"Catalysis of the reaction: UDP-glucose + a flavonol 3-O-beta-D-glucoside = UDP + a flavonol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside.\" [EC:2.4.1.239]","metadata":null},{"id":"86058a54739240f49403457e4a3812d7","type":"GO_TERM","name":"flavonol-3-O-glycoside glucosyltransferase activity","canonical_id":"go:GO:0033839","description":"\"Catalysis of the reaction: UDP-glucose + a flavonol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside = UDP + a flavonol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside.\" [EC:2.4.1.240]","metadata":null},{"id":"f9b565ef17904e0885fac2b7b21ff9d7","type":"GO_TERM","name":"flavonol-3-O-glycoside xylosyltransferase activity","canonical_id":"go:GO:0047285","description":"\"Catalysis of the reaction: flavonol 3-O-glycoside + UDP-D-xylose = flavonol 3-O-D-xylosylglycoside + UDP.\" [EC:2.4.2.35, MetaCyc:2.4.2.35-RXN]","metadata":null},{"id":"4f3d4e07621443e2b0259a1b56372b1d","type":"GO_TERM","name":"flavonol-3-O-triglucoside O-coumaroyltransferase activity","canonical_id":"go:GO:0033811","description":"\"Catalysis of the reaction: 4-coumaroyl-CoA + a flavonol 3-O-[beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside] = CoA + a flavonol 3-O-[6-(4-coumaroyl)-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside].\" [EC:2.3.1.173]","metadata":null},{"id":"e2bceeda57204c1cabe896e852b7241c","type":"DRUG","name":"flibanserin","canonical_id":"gtopdb:8182","description":null,"metadata":null},{"id":"7dbd960978a146bcb8014e77b7ff2cc9","type":"DRUG","name":"flibanserin","canonical_id":"mesh:C098107","description":null,"metadata":null},{"id":"97f4405ec71246a4a09fdaae9be45a20","type":"GO_TERM","name":"flight","canonical_id":"go:GO:0060361","description":"\"Self-propelled movement of an organism from one location to another through the air, usually by means of active wing movement.\" [GOC:dph]","metadata":null},{"id":"c4d3e27f2b574adfa9d3fd8782231dcb","type":"GO_TERM","name":"flight behavior","canonical_id":"go:GO:0007629","description":"\"The response to external or internal stimuli that results in the locomotory process of flight. Flight is the self-propelled movement of an organism through the air.\" [GOC:jid, ISBN:0198606907]","metadata":null},{"id":"20eff5e45f26414c9195e184f7abe62f","type":"GO_TERM","name":"flippase activity","canonical_id":"go:GO:0140327","description":"\"Catalysis of the movement of lipids from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:20043909, PMID:25284293, Wikipedia:Flippase]","metadata":null},{"id":"f031090215cf4296bbd3a136b8cf3985","type":"GO_TERM","name":"flocculation","canonical_id":"go:GO:0000128","description":"\"The reversible, non-sexual aggregation of single-celled organisms in suspension to form aggregates of many cells known as flocs.\" [GOC:jl, GOC:vw, PMID:11472912, PMID:21114594, PMID:8740415]","metadata":null},{"id":"dd8ff0fd2ec7456595a81dc514986664","type":"GO_TERM","name":"floor plate development","canonical_id":"go:GO:0033504","description":"\"The progression of the floor plate over time from its initial formation until its mature state.\" [GOC:dh]","metadata":null},{"id":"bc5b775b03c84845b3e875f004f95bd3","type":"GO_TERM","name":"floor plate formation","canonical_id":"go:GO:0021508","description":"\"The formation of a ventral region of glial cells in the neural tube that provides inductive signals for the specification of neuronal cell types. The floor plate is evident at the ventral midline by the neural fold stage.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"387a1020d53445ea9ec9c35889a0922c","type":"GO_TERM","name":"floor plate morphogenesis","canonical_id":"go:GO:0033505","description":"\"The process in which the anatomical structure of the floor plate is generated and organized.\" [GOC:dh]","metadata":null},{"id":"f14d02dc5e524d20b79a566b04002aad","type":"GO_TERM","name":"floppase activity","canonical_id":"go:GO:0140328","description":"\"Catalysis of the movement of a lipid from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:20043909, PMID:25284293, Wikipedia:Flippase]","metadata":null},{"id":"160595203b294dc3bd0fc36a19c1f985","type":"GO_TERM","name":"floral meristem determinacy","canonical_id":"go:GO:0010582","description":"\"The process in which a floral meristem becomes determinate (i.e. ceases to produce lateral organs and may or may not terminally differentiate).\" [PMID:18441215]","metadata":null},{"id":"ee33de9ff34143f080b79b33c8890cff","type":"GO_TERM","name":"floral meristem growth","canonical_id":"go:GO:0010451","description":"\"The increase in size or mass of a floral meristem, a population of undifferentiated cells in a plant that gives rise to a flower.\" [GOC:tb]","metadata":null},{"id":"6d91372a909c4a4db24edfa5b52e6aae","type":"GO_TERM","name":"floral organ abscission","canonical_id":"go:GO:0010227","description":"\"The controlled shedding of floral organs.\" [GOC:PO_curators, PMID:12972671, PO:0025395]","metadata":null},{"id":"978316a956f045e09958f0030d6810ec","type":"GO_TERM","name":"floral organ development","canonical_id":"go:GO:0048437","description":"\"The process whose specific outcome is the progression of the floral organ over time, from its formation to the mature structure.\" [GOC:curators, GOC:PO_curators, PO:0025395]","metadata":null},{"id":"10b1ab2b95d44541b10f6b1a93cdbd65","type":"GO_TERM","name":"floral organ formation","canonical_id":"go:GO:0048449","description":"\"The process that gives rise to floral organs. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid, GOC:PO_curators, PO:0025395]","metadata":null},{"id":"d48529e434954e779c71fa95ce4941b3","type":"GO_TERM","name":"floral organ morphogenesis","canonical_id":"go:GO:0048444","description":"\"The process in which the anatomical structures of the floral organ are generated and organized.\" [GOC:curators, GOC:PO_curators, PO:0025395]","metadata":null},{"id":"673d4cb8e1d14ed1a7a549df0e61cdcf","type":"GO_TERM","name":"floral organ senescence","canonical_id":"go:GO:0080187","description":"\"The last stage of flower development during which programmed degradation of macromolecules and nutrient recycling take place.\" [PMID:19380421, PMID:21689171]","metadata":null},{"id":"5de304194b7d465ab9d1250aaeaf0ac7","type":"GO_TERM","name":"floral organ structural organization","canonical_id":"go:GO:0048450","description":"\"The process that contributes to the act of creating the structural organization of floral organs. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid, GOC:PO_curators, PO:0025395]","metadata":null},{"id":"2da4bd177f9a4070b57b32694b12fb78","type":"GO_TERM","name":"floral whorl development","canonical_id":"go:GO:0048438","description":"\"The process whose specific outcome is the progression of a floral whorl over time, from its formation to the mature structure. A floral whorl is a circular arrangement of parts of a flower arising from a stem of a plant.\" [GOC:curators, GOC:dph, GOC:PO_curators, GOC:tb, PO:0025023]","metadata":null},{"id":"ec814d038db64060a67dbe4c43bc43df","type":"GO_TERM","name":"floral whorl formation","canonical_id":"go:GO:0048458","description":"\"The process that gives rise to the floral whorl. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid, GOC:PO_curators, PO:0025023]","metadata":null},{"id":"5fc2833d838e470bb89daf3ec0b01b4c","type":"GO_TERM","name":"floral whorl morphogenesis","canonical_id":"go:GO:0048457","description":"\"The process in which the anatomical structures of the floral whorl are generated and organized.\" [GOC:curators, GOC:PO_curators, PO:0025023]","metadata":null},{"id":"3c0e2682e2874434a0a19b292620efb9","type":"GO_TERM","name":"floral whorl structural organization","canonical_id":"go:GO:0048459","description":"\"The process that contributes to the act of creating the structural organization of the floral whorl. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid, GOC:PO_curators, PO:0025023]","metadata":null},{"id":"daf3baccb77844d58f2ccfad91115429","type":"DRUG","name":"florbetaben","canonical_id":"gtopdb:7769","description":null,"metadata":null},{"id":"31638e0bacf64611a703cfbbf0b1050f","type":"COMBINATION_TREATMENT","name":"florbetaben + florbetapir","canonical_id":"ctgov_combo:ctgov-combo-6c5ea7bb932d8258","description":null,"metadata":null},{"id":"083e7ad334d14bfd82aea08273538d38","type":"COMBINATION_TREATMENT","name":"florbetaben + flutemetamol","canonical_id":"ctgov_combo:ctgov-combo-6778091343cf54bf","description":null,"metadata":null},{"id":"0e5076b0bd72424c8ab1fdf325a5a22e","type":"DRUG","name":"florbetapir","canonical_id":"gtopdb:7344","description":null,"metadata":null},{"id":"b6aadba5a4934f64ab0b52e6206ff046","type":"COMBINATION_TREATMENT","name":"florbetapir + flutemetamol","canonical_id":"ctgov_combo:ctgov-combo-b201042a7f1dd79a","description":null,"metadata":null},{"id":"da2ae3bb5d6a48d1a750dda4e8de9e6c","type":"GO_TERM","name":"flotillin complex","canonical_id":"go:GO:0016600","description":"\"A protein complex that contains flotillin-1 and flotillin-2, and may contain associated proteins. Flotillins associate into membrane microdomains resembling caveolae.\" [PMID:17206938, PMID:17600709]","metadata":null},{"id":"5732aee33eb7466288f3a091e4f04f0d","type":"GO_TERM","name":"flower calyx development","canonical_id":"go:GO:0048464","description":"\"The process whose specific outcome is the progression of the flower calyx over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"14e484eee8894d5b8b5fd2d0974dca53","type":"GO_TERM","name":"flower development","canonical_id":"go:GO:0009908","description":"\"The process whose specific outcome is the progression of the flower over time, from its formation to the mature structure. The flower is the reproductive structure in a plant, and its development begins with the transition of the vegetative or inflorescence meristem into a floral meristem.\" [GOC:tb, ISBN:0879015322]","metadata":null},{"id":"d4e8cb22335742df9061b6d9ab14dd5f","type":"GO_TERM","name":"flower formation","canonical_id":"go:GO:0048460","description":"\"The process that gives rise to the flower. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid]","metadata":null},{"id":"cbbb4fd1657a42718509286d9b779b7e","type":"GO_TERM","name":"flower morphogenesis","canonical_id":"go:GO:0048439","description":"\"The process in which the anatomical structures of the flower are generated and organized.\" [GOC:curators]","metadata":null},{"id":"dac0898f30244aba8e8944a3377a37e0","type":"GO_TERM","name":"flower phyllotactic patterning","canonical_id":"go:GO:0060773","description":"\"The radial pattern formation process that results in the formation of floral organ primordia around a central axis in a flower primordium.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"062fbefe57b348ca858339f957acb8b0","type":"GO_TERM","name":"flower structural organization","canonical_id":"go:GO:0048461","description":"\"The process that contributes to the act of creating the structural organization of the flower. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid]","metadata":null},{"id":"3b59329803214dbb8bef92ead4584f80","type":"DRUG","name":"floxuridine","canonical_id":"mesh:D005467","description":null,"metadata":null},{"id":"5107031a32554094a0f326240d971c3f","type":"GO_TERM","name":"fluconazole transmembrane transporter activity","canonical_id":"go:GO:0015244","description":"\"Enables the transfer of fluconazole from one side of a membrane to the other. Fluconazole is an antifungal drug used for oral candidiasis and cryptococcal meningitis; it is still under study for treatment of vaginal candidiasis and other fungal infections.\" [GOC:curators]","metadata":null},{"id":"70eb4c1ccbf84b7287ab37ef84a8284d","type":"GO_TERM","name":"fluconazole transport","canonical_id":"go:GO:0015903","description":"\"The directed movement of fluconazole into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fluconazole is an antifungal drug used for oral candidiasis and cryptococcal meningitis; it is still under study for treatment of vaginal candidiasis and other fungal infections.\" [GOC:curators]","metadata":null},{"id":"76902fad42434e3aaae4c8c1379dbcc4","type":"GO_TERM","name":"fluconazole:proton antiporter activity","canonical_id":"go:GO:0015313","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + fluconazole(in) = H+(in) + fluconazole(out).\" [TC:2.A.1.2.17]","metadata":null},{"id":"d28f9f213dc046d59b9d20ff7473b214","type":"DRUG","name":"fludarabine","canonical_id":"gtopdb:4802","description":null,"metadata":null},{"id":"468873c9fdad4bbaa37ab04cce5a0ead","type":"COMBINATION_TREATMENT","name":"fludarabine + gemcitabine + methotrexate + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-e7c808bd32d5ddd7","description":null,"metadata":null},{"id":"f0995206d6b34796a102980b8fa09027","type":"COMBINATION_TREATMENT","name":"fludarabine + ibrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-3f608227fa57a2b4","description":null,"metadata":null},{"id":"4fd3c30267c946d09307f833a0e83e45","type":"COMBINATION_TREATMENT","name":"fludarabine + ipilimumab","canonical_id":"ctgov_combo:ctgov-combo-7946fdb9f711e0a3","description":null,"metadata":null},{"id":"7915d40bf79b4291a7e2be2d7a23ce1a","type":"COMBINATION_TREATMENT","name":"fludarabine + methotrexate","canonical_id":"ctgov_combo:ctgov-combo-7781a0264dee5fa0","description":null,"metadata":null},{"id":"7290a2002d33436f98fd04ed6113f7fd","type":"COMBINATION_TREATMENT","name":"fludarabine + methotrexate + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-7bd97d90c2317aa6","description":null,"metadata":null},{"id":"cb534af1de30439799fc19256535e3e1","type":"COMBINATION_TREATMENT","name":"fludarabine + methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-3141175d5e786298","description":null,"metadata":null},{"id":"44e8f6e167e14298aa01045116bc0509","type":"COMBINATION_TREATMENT","name":"fludarabine + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-b77fbb2e37391173","description":null,"metadata":null},{"id":"1ef3572a5ffc408f9db5a8bcb0502d54","type":"COMBINATION_TREATMENT","name":"fludarabine + mycophenolate mofetil + sirolimus","canonical_id":"ctgov_combo:ctgov-combo-e002d08a6429c874","description":null,"metadata":null},{"id":"a74ab92757b94500ba327094d5ff14ad","type":"COMBINATION_TREATMENT","name":"fludarabine + prednisone + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-8bfb4f9b66d1c3b3","description":null,"metadata":null},{"id":"a3ed4a5fd07d4a94b1c3f8e798444838","type":"COMBINATION_TREATMENT","name":"fludarabine + rituximab","canonical_id":"ctgov_combo:ctgov-combo-1640a4c2e3a8f72e","description":null,"metadata":null},{"id":"f9d3b434d14d41359250c6b0660ac050","type":"COMBINATION_TREATMENT","name":"fludarabine + rituximab","canonical_id":"ctgov_combo:ctgov-combo-3583735fc2bf40ab","description":null,"metadata":null},{"id":"78ab6f15b61f4e2da08b4e656aa9bc97","type":"COMBINATION_TREATMENT","name":"fludarabine + rituximab","canonical_id":"ctgov_combo:ctgov-combo-757c7e46ec892690","description":null,"metadata":null},{"id":"7c2942d1a12845aaaaec6698593d4d5a","type":"COMBINATION_TREATMENT","name":"fludarabine + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-78e0484e3f59c62c","description":null,"metadata":null},{"id":"19345d9ee91744b6ba2a624144b1df1b","type":"COMBINATION_TREATMENT","name":"fludarabine + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-fa4db47d173a0160","description":null,"metadata":null},{"id":"0a09fc4b7542450d816cbce78d7e42fe","type":"DRUG","name":"fludarabine phosphate","canonical_id":"mesh:C042382","description":null,"metadata":null},{"id":"daeb0fb86177499c9fe00753aef055f2","type":"DRUG","name":"fludrocortisone","canonical_id":"gtopdb:2873","description":null,"metadata":null},{"id":"122146be5dc946f2af5caa54cf9c7d51","type":"COMBINATION_TREATMENT","name":"fludrocortisone + flutamide + testolactone","canonical_id":"ctgov_combo:ctgov-combo-58ae4251c1dc1ac5","description":null,"metadata":null},{"id":"a023503171d24709a2938ce3d3af3ed8","type":"COMBINATION_TREATMENT","name":"fludrocortisone + sivelestat","canonical_id":"ctgov_combo:ctgov-combo-9d867a8c3d68a427","description":null,"metadata":null},{"id":"315dad0460c8407ab9347c51f9e390c1","type":"COMBINATION_TREATMENT","name":"fludrocortisone + vamorolone","canonical_id":"ctgov_combo:ctgov-combo-76afeb5670d4e968","description":null,"metadata":null},{"id":"d4e18282fc964d41af9af2c36be1960b","type":"DRUG","name":"flufenamic acid","canonical_id":"mesh:D005439","description":null,"metadata":null},{"id":"ea3c53500b2d4a87a1e25f084fe92bfe","type":"GO_TERM","name":"fluid transport","canonical_id":"go:GO:0042044","description":"\"The directed movement of substances that are in liquid form in normal living conditions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"7566330b74a04b41b25ce63be3ebcafe","type":"DRUG","name":"flumazenil","canonical_id":"gtopdb:4192","description":null,"metadata":null},{"id":"a2205b36518942fdb5d6083770c006d6","type":"DRUG","name":"flumazenil","canonical_id":"chembl:CHEMBL407","description":null,"metadata":null},{"id":"58dbd834d82f45db91cd7f5324864057","type":"COMBINATION_TREATMENT","name":"flumazenil + tiagabine","canonical_id":"ctgov_combo:ctgov-combo-bae985ea22c1404d","description":null,"metadata":null},{"id":"2ab8cfeb819a4178987e6dff7331368e","type":"DRUG","name":"flunisolide","canonical_id":"gtopdb:7076","description":null,"metadata":null},{"id":"40e3ff2f666f468c976489be04135a3c","type":"DRUG","name":"flunisolide","canonical_id":"chembl:CHEMBL1512","description":null,"metadata":null},{"id":"954372124d1a4519ab4b9a93b83980b9","type":"DRUG","name":"flunitrazepam","canonical_id":"gtopdb:4193","description":null,"metadata":null},{"id":"aef0c929bccd4019a048d21108233128","type":"DRUG","name":"flunitrazepam","canonical_id":"chembl:CHEMBL13280","description":null,"metadata":null},{"id":"73f3d93a699e4db685ea05591373a703","type":"DRUG","name":"fluocinolone acetonide","canonical_id":"gtopdb:7077","description":null,"metadata":null},{"id":"0d4a09d5eef0440b90dfa9a8e7405eb9","type":"DRUG","name":"fluocinolone acetonide","canonical_id":"mesh:D005446","description":null,"metadata":null},{"id":"427de77131a3420a8fbd7b0cd5629c7d","type":"DRUG","name":"fluocinolone acetonide","canonical_id":"chembl:CHEMBL989","description":null,"metadata":null},{"id":"f1c9e64700b04d86b26e849f9550732a","type":"DRUG","name":"fluocinonide","canonical_id":"gtopdb:7078","description":null,"metadata":null},{"id":"555090b6d64a4738acc3c84a702a8e76","type":"DRUG","name":"fluocinonide","canonical_id":"chembl:CHEMBL1501","description":null,"metadata":null},{"id":"3b934c9eedb6410396a500130caf3b0f","type":"COMBINATION_TREATMENT","name":"fluocinonide + tazarotene","canonical_id":"ctgov_combo:ctgov-combo-3559eea52ccad560","description":null,"metadata":null},{"id":"0abcb006a93d4cf9a6441628b27dfd01","type":"GO_TERM","name":"fluoren-9-ol dehydrogenase activity","canonical_id":"go:GO:0018461","description":"\"Catalysis of the reaction: fluoren-9-ol + 2 NADP+ = fluoren-9-one + 2 NADPH + 2 H+.\" [EC:1.1.1.256]","metadata":null},{"id":"bc4ed80e5bc241a5bc5d547b999da7b5","type":"GO_TERM","name":"fluorene catabolic process","canonical_id":"go:GO:0019429","description":"\"The chemical reactions and pathways resulting in the breakdown of fluorene, a tricyclic polycyclic aromatic hydrocarbon containing a five-membered ring. It is a major component of fossil fuels and their derivatives and is also a by-product of coal-conversion and energy-related industries. It is commonly found in vehicle exhaust emissions, crude oils, motor oils, coal and oil combustion products, waste incineration, and industrial effluents.\" [PMID:15317800]","metadata":null},{"id":"40bedac5f2e848fb90a343c0d5ee2c0b","type":"GO_TERM","name":"fluorescent chlorophyll catabolite monooxygenase (deformylase) activity","canonical_id":"go:GO:0106371","description":"\"Catalysis of the reaction: O2 + primary fluorescent chlorophyll catabolite + reduced [NADPH--hemoprotein reductase] = formate + 2 H+ + oxidized [NADPH--hemoprotein reductase] + primary fluorescent dioxobilin-type chlorophyll catabolite.\" [PMID:23723324, RHEA:67172]","metadata":null},{"id":"34bc7563937741dc8b8907960fb7ce0b","type":"GO_TERM","name":"fluoride channel activity","canonical_id":"go:GO:0062054","description":"\"Enables the energy-independent facilitated diffusion of a fluoride ion through a transmembrane aqueous pore or channel.\" [PMID:23991286, PMID:25156118]","metadata":null},{"id":"72559c24099e4216be8f3a202c513877","type":"GO_TERM","name":"fluoride export across plasma membrane","canonical_id":"go:GO:0140116","description":"\"The directed movement of fluoride ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:vw, PMID:27327046]","metadata":null},{"id":"7218cdc01ce84becb00c553fbc7b3987","type":"GO_TERM","name":"fluoride transmembrane transport","canonical_id":"go:GO:1903424","description":"\"The process in which fluoride is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:24173035]","metadata":null},{"id":"880bd688f4e7410994b473ae5155daa0","type":"GO_TERM","name":"fluoride transmembrane transporter activity","canonical_id":"go:GO:1903425","description":"\"Enables the transfer of fluoride from one side of a membrane to the other.\" [GO_REF:0000070, GOC:TermGenie, PMID:24173035]","metadata":null},{"id":"aa0224b4db2948368b111d5b572e7ae2","type":"GO_TERM","name":"fluoroacetaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0033723","description":"\"Catalysis of the reaction: fluoroacetaldehyde + NAD+ + H2O = fluoroacetate + NADH + 2 H+.\" [EC:1.2.1.69]","metadata":null},{"id":"dc57a07945ec482086a8468a5416a931","type":"DRUG","name":"fluorometholone","canonical_id":"gtopdb:7079","description":null,"metadata":null},{"id":"425b679b7930478495491987713953f6","type":"DRUG","name":"fluorometholone","canonical_id":"chembl:CHEMBL1200600","description":null,"metadata":null},{"id":"aaae6e0b178a46bcb04bc3671f5ac123","type":"GO_TERM","name":"fluorothreonine transaldolase activity","canonical_id":"go:GO:0033806","description":"\"Catalysis of the reaction: L-threonine + fluoroacetaldehyde = acetaldehyde + 4-fluoro-L-threonine.\" [RHEA:11748]","metadata":null},{"id":"904d30bdc73e40649bc265dcee45f9d4","type":"DRUG","name":"fluoxetine","canonical_id":"gtopdb:203","description":null,"metadata":null},{"id":"83a782c2f5324576bf4b34d23f8a2e81","type":"DRUG","name":"fluoxetine","canonical_id":"mesh:D005473","description":null,"metadata":null},{"id":"6a416b2b97884d4d8a39027174f8429d","type":"COMBINATION_TREATMENT","name":"fluoxetine + imipramine","canonical_id":"ctgov_combo:ctgov-combo-7343760da0a80ccb","description":null,"metadata":null},{"id":"582b5fbe200043399905e3bb6fab82d7","type":"COMBINATION_TREATMENT","name":"fluoxetine + levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-3b0e54ea2de4d2fb","description":null,"metadata":null},{"id":"78cfb8bf6b2f4bf1a62df07996913acf","type":"COMBINATION_TREATMENT","name":"fluoxetine + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-c58c82fbb35f52ad","description":null,"metadata":null},{"id":"8b0b16a7c2be49da87ed0a5ee253dbd4","type":"COMBINATION_TREATMENT","name":"fluoxetine + valsartan","canonical_id":"ctgov_combo:ctgov-combo-37617b65d39e9db6","description":null,"metadata":null},{"id":"e72824dadbc5476bbdf5a39148cfb751","type":"DRUG","name":"fluoxymesterone","canonical_id":"gtopdb:2861","description":null,"metadata":null},{"id":"92a715a9d52e4dfeb09dbe88c47548d0","type":"DRUG","name":"fluoxymesterone","canonical_id":"chembl:CHEMBL1445","description":null,"metadata":null},{"id":"7cf6f51156ad4ee3a59c252e146339d2","type":"DRUG","name":"flupentixol","canonical_id":"gtopdb:948","description":null,"metadata":null},{"id":"12c84fa745dd45e9888b0859da136b00","type":"COMBINATION_TREATMENT","name":"flupentixol + haloperidol","canonical_id":"ctgov_combo:ctgov-combo-49096072201f07c6","description":null,"metadata":null},{"id":"57796d1837e543d493cf0812762176a6","type":"DRUG","name":"fluphenazine","canonical_id":"gtopdb:204","description":null,"metadata":null},{"id":"74016f420f2d4069b54df2889aee740b","type":"DRUG","name":"fluphenazine","canonical_id":"mesh:D005476","description":null,"metadata":null},{"id":"c11755bb7d624520821a34736d0e82de","type":"COMBINATION_TREATMENT","name":"fluphenazine + quetiapine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-01f5f725df144656","description":null,"metadata":null},{"id":"97f575db312e46949842f26268d5a9b8","type":"DRUG","name":"fluphenazine decanoate","canonical_id":"mesh:C011825","description":null,"metadata":null},{"id":"5d13ec357d604638819099ef94b344b6","type":"DRUG","name":"fluphenazine enanthate","canonical_id":"mesh:C017610","description":null,"metadata":null},{"id":"f80e62a0fff34539ba3a6157aab1cadf","type":"DRUG","name":"flurbiprofen","canonical_id":"gtopdb:4194","description":null,"metadata":null},{"id":"5d74500e20664fb6952f8e034952cb80","type":"DRUG","name":"flurbiprofen","canonical_id":"mesh:D005480","description":null,"metadata":null},{"id":"6e1ea12a37b44c5f9189c0297d829028","type":"DRUG","name":"flurbiprofen","canonical_id":"chembl:CHEMBL563","description":null,"metadata":null},{"id":"9e00882f68c94740ae03cf44c5ed780b","type":"COMBINATION_TREATMENT","name":"flurbiprofen + hydromorphone","canonical_id":"ctgov_combo:ctgov-combo-ba3fd459f1486fa1","description":null,"metadata":null},{"id":"e67a3414f32247bdbe66082b11834eec","type":"COMBINATION_TREATMENT","name":"flurbiprofen + ketoprofen + tolbutamide","canonical_id":"ctgov_combo:ctgov-combo-0acf42a91758a731","description":null,"metadata":null},{"id":"9878f6e9ef34493b826b5cde54d1a2dc","type":"COMBINATION_TREATMENT","name":"flurbiprofen + lidocaine","canonical_id":"ctgov_combo:ctgov-combo-56cf466563f2ed18","description":null,"metadata":null},{"id":"260fa5de5a22418eafe059df569d9d75","type":"COMBINATION_TREATMENT","name":"flurbiprofen + nalbuphine","canonical_id":"ctgov_combo:ctgov-combo-364dcf3949e5d016","description":null,"metadata":null},{"id":"c09f95c862fc4213862e59b581a77798","type":"COMBINATION_TREATMENT","name":"flurbiprofen + nalbuphine","canonical_id":"ctgov_combo:ctgov-combo-c8aa2989e4fd02db","description":null,"metadata":null},{"id":"91c9ebc3533044a68035955fa8396957","type":"COMBINATION_TREATMENT","name":"flurbiprofen + pravastatin","canonical_id":"ctgov_combo:ctgov-combo-26b0bd1802d217ea","description":null,"metadata":null},{"id":"2fe96e2918f84624ae7fa4652d19b3f8","type":"COMBINATION_TREATMENT","name":"flurbiprofen + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-1e4a2fcf6a6bd006","description":null,"metadata":null},{"id":"a309c7ef6b3346c28fdbae87e2ae4be4","type":"COMBINATION_TREATMENT","name":"flurbiprofen + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-64c4ab8896438ed6","description":null,"metadata":null},{"id":"8c9be148a00e4487a847b705afb0d562","type":"COMBINATION_TREATMENT","name":"flurbiprofen + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-7a7c3e665dbc160a","description":null,"metadata":null},{"id":"27daf96c188b4e2194b28ae088322280","type":"GO_TERM","name":"flurbiprofen binding","canonical_id":"go:GO:0035923","description":"\"Binding to flurbiprofen.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"a6d43d735a2e46beb71966aac46b9945","type":"DRUG","name":"fluspirilene","canonical_id":"mesh:D005484","description":null,"metadata":null},{"id":"5cdf472fcee941a2b4d5b0f7af8ed6ef","type":"DRUG","name":"flutamide","canonical_id":"gtopdb:6943","description":null,"metadata":null},{"id":"04bea38a8b264216b2e07bf7265d28a3","type":"DRUG","name":"flutamide","canonical_id":"mesh:D005485","description":null,"metadata":null},{"id":"f4755d2dd7fe4d1fa16a676c7673c832","type":"DRUG","name":"flutamide","canonical_id":"chembl:CHEMBL806","description":null,"metadata":null},{"id":"a17c987e851f429888938864a8c082b9","type":"COMBINATION_TREATMENT","name":"flutamide + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-27f806060ab47a08","description":null,"metadata":null},{"id":"9059ed4f923b433490a5a814ede66e4a","type":"COMBINATION_TREATMENT","name":"flutamide + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-5e0fa89621426169","description":null,"metadata":null},{"id":"ebd1b9bc2be5412ba9501700c2a5d55e","type":"COMBINATION_TREATMENT","name":"flutamide + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-307ff48bc4a33b17","description":null,"metadata":null},{"id":"f9afc99aeb194c3eaa19f345848489a8","type":"COMBINATION_TREATMENT","name":"flutamide + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-30b32758590cc9cd","description":null,"metadata":null},{"id":"8852c1757b5c44d8be4cf65a67183da0","type":"COMBINATION_TREATMENT","name":"flutamide + nilutamide","canonical_id":"ctgov_combo:ctgov-combo-4d4dded816e88710","description":null,"metadata":null},{"id":"fa364ddf6a4847ca9ef57aab66972a5e","type":"DRUG","name":"flutemetamol","canonical_id":"gtopdb:7342","description":null,"metadata":null},{"id":"82d19f8355fd43fa8bc14956d61724f3","type":"DRUG","name":"fluticasone","canonical_id":"gtopdb:6699","description":null,"metadata":null},{"id":"2fd8eb5cf10348a69eef755882c95ec2","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-c92eb8db7b4796ca","description":null,"metadata":null},{"id":"b84a019fc2df43e3b69e09562f6efc25","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-5277f660cdb97cf0","description":null,"metadata":null},{"id":"4977ee4efeae4f2cabcb4f8df2e32747","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-a1b96087872afa16","description":null,"metadata":null},{"id":"a850273d675a4ccd9860574c4fa18606","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-63151bca15241cb5","description":null,"metadata":null},{"id":"42bbebb82fcb461daaedf2b28b777458","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-3b252ba8cdbdd9dc","description":null,"metadata":null},{"id":"f567250eed2c40128a7f9ce650f38eaa","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-ffcbfe0014c7afeb","description":null,"metadata":null},{"id":"4912f0b5d4e0497496ce2feda0ba464f","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate","canonical_id":"ctgov_combo:ctgov-combo-a6d909b4ae889449","description":null,"metadata":null},{"id":"c407d0a3d3f04c1aa5947a81549927ca","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + formoterol + indacaterol","canonical_id":"ctgov_combo:ctgov-combo-3f4278216d259612","description":null,"metadata":null},{"id":"a95beb5ade584066a173bd0cc8a61301","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + oxymetazoline","canonical_id":"ctgov_combo:ctgov-combo-4527faee83665219","description":null,"metadata":null},{"id":"38353968a3f9480691d3d5d6c5e32ea6","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-647ea7f13addd3ab","description":null,"metadata":null},{"id":"82b1c4cc52034ca18be72cbff67c458b","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-bba25dbeffbf95e3","description":null,"metadata":null},{"id":"4a62e4c9204b4899b602bd7e4a7a40a1","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-d4535781820d86fa","description":null,"metadata":null},{"id":"05b82b42aec946bebad3bc8e1ff57d41","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-19c1a4444129eebd","description":null,"metadata":null},{"id":"6d7c38cf6ffa44d596e1476530b4ff02","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-907ce047d3719420","description":null,"metadata":null},{"id":"4800557fe9004157b3fe9535047c967a","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-295f01bd153bf770","description":null,"metadata":null},{"id":"7e165005197a4e6a84f08f1c7c07fa29","type":"COMBINATION_TREATMENT","name":"fluticasone + fluticasone propionate + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-90d9537a55d9fc07","description":null,"metadata":null},{"id":"14acad4c0ca94a21a1bd938dd4d6dcf3","type":"COMBINATION_TREATMENT","name":"fluticasone + indacaterol + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-ac8b980e5c7ac82b","description":null,"metadata":null},{"id":"dfa29ff5089c463e96972e07702b426d","type":"COMBINATION_TREATMENT","name":"fluticasone + ipratropium + montelukast + salmeterol + theophylline","canonical_id":"ctgov_combo:ctgov-combo-920239b8705de153","description":null,"metadata":null},{"id":"6921b71fa4894aff9efb37362908eda2","type":"COMBINATION_TREATMENT","name":"fluticasone + loratadine + mometasone","canonical_id":"ctgov_combo:ctgov-combo-822fce553f343660","description":null,"metadata":null},{"id":"07df5f6979384d22832bb2b11ffe0a79","type":"COMBINATION_TREATMENT","name":"fluticasone + mometasone","canonical_id":"ctgov_combo:ctgov-combo-ee22545139f187b8","description":null,"metadata":null},{"id":"b931575884b541758e100490bbabe5ce","type":"COMBINATION_TREATMENT","name":"fluticasone + mometasone + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-c91d9d88572b5b6f","description":null,"metadata":null},{"id":"8b713093ab4549148842ae7130eca7a8","type":"COMBINATION_TREATMENT","name":"fluticasone + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-d05a0ffbd158fc99","description":null,"metadata":null},{"id":"1474aa481db74cf0bacea82b81b7e6a5","type":"COMBINATION_TREATMENT","name":"fluticasone + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-e1b884797a659ec3","description":null,"metadata":null},{"id":"908709e4b0434820b57daca42a51deae","type":"COMBINATION_TREATMENT","name":"fluticasone + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-1ca23fb7b2ae0906","description":null,"metadata":null},{"id":"8d33a1e48fd64a4d8ef5e41d1f3c0d68","type":"COMBINATION_TREATMENT","name":"fluticasone + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-5ad38de787aed32f","description":null,"metadata":null},{"id":"bc25768dac2f46518d889773d4705428","type":"COMBINATION_TREATMENT","name":"fluticasone + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-e4fe12134ec81a1d","description":null,"metadata":null},{"id":"e5e67c552ad943f1b4dc6f4213f634cf","type":"DRUG","name":"fluticasone propionate","canonical_id":"gtopdb:7080","description":null,"metadata":null},{"id":"d469b9f4ac1f4d9d822a1286d59cbbff","type":"DRUG","name":"fluticasone propionate","canonical_id":"mesh:D000068298","description":null,"metadata":null},{"id":"bd0918aa1f0942768e7ebb96dd51b83d","type":"DRUG","name":"fluticasone propionate","canonical_id":"chembl:CHEMBL1473","description":null,"metadata":null},{"id":"3f58a3cc199c48fc850124f63890e853","type":"DRUG","name":"fluvastatin","canonical_id":"gtopdb:2951","description":null,"metadata":null},{"id":"4eaf82202ea747ddb19ecf3ff7544432","type":"DRUG","name":"fluvastatin","canonical_id":"mesh:C065180","description":null,"metadata":null},{"id":"01e1863c579845738c22ebe718b1d2b0","type":"DRUG","name":"fluvoxamine","canonical_id":"gtopdb:7189","description":null,"metadata":null},{"id":"9ff41ae7980f452cad2a8ebf1b959297","type":"DRUG","name":"fluvoxamine","canonical_id":"mesh:D016666","description":null,"metadata":null},{"id":"b11f0eef891444dba466a8b2040341c2","type":"COMBINATION_TREATMENT","name":"fluvoxamine + labetalol + sumatriptan + trazodone","canonical_id":"ctgov_combo:ctgov-combo-17945e11aab41d56","description":null,"metadata":null},{"id":"bce0fa0197ed48d49a76032cab14bb98","type":"COMBINATION_TREATMENT","name":"fluvoxamine + mirtazapine","canonical_id":"ctgov_combo:ctgov-combo-bd5169987f43d808","description":null,"metadata":null},{"id":"6f7c2f290474426cbafc2e1b4dd3c0ed","type":"COMBINATION_TREATMENT","name":"fluvoxamine + paroxetine","canonical_id":"ctgov_combo:ctgov-combo-58b6a892081d31c9","description":null,"metadata":null},{"id":"e27e1951dcb84998a7ec6601126dca90","type":"GO_TERM","name":"foam cell differentiation","canonical_id":"go:GO:0090077","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.\" [GOC:add, GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"bc911f42b5564d8db1e27309aed06ee3","type":"GO_TERM","name":"focal adhesion","canonical_id":"go:GO:0005925","description":"\"A cell-substrate junction that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. In insects focal adhesion has also been referred to as hemi-adherens junction (HAJ).\" [GOC:aruk, GOC:bc, ISBN:0124325653, ISBN:0815316208, PMID:10419689, PMID:12191915, PMID:15246682, PMID:1643657, PMID:16805308, PMID:19197329, PMID:23033047, PMID:26923917, PMID:28796323, PMID:8314002]","metadata":null},{"id":"d35a588c2f2e441cb06e79aef649eba1","type":"GO_TERM","name":"focal adhesion assembly","canonical_id":"go:GO:0048041","description":"\"The aggregation and bonding together of a set of components to form a focal adhesion, a complex of intracellular signaling and structural proteins that provides a structural link between the internal actin cytoskeleton and the ECM, and also function as a locus of signal transduction activity.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"eaee85de097b40b4a86fb644b1221cc3","type":"GO_TERM","name":"focal adhesion disassembly","canonical_id":"go:GO:0120181","description":"\"The disaggregation of a focal adhesion into its constituent components. A focal adhesion is a complex of intracellular signaling and structural proteins that provides a structural link between the internal actin cytoskeleton and the ECM, and also functions as a locus of signal transduction activity.\" [PMID:25490267]","metadata":null},{"id":"162535da9942433dad8a1735e6d57249","type":"DISEASE","name":"focal epilepsy","canonical_id":"mondo:0005384","description":null,"metadata":null},{"id":"c48df70971734a8eb100b5c78f0bb6e5","type":"GO_TERM","name":"folate import across plasma membrane","canonical_id":"go:GO:1904447","description":"\"The directed movement of folic acid from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:19762432]","metadata":null},{"id":"6c36a3d574e34cff9604c59d6d4cc6d7","type":"GO_TERM","name":"folate import into mitochondrion","canonical_id":"go:GO:1904947","description":"\"The process in which folic acid is transported from the cytosol into the mitochondrial matrix.\" [GO_REF:0000075, GOC:BHF, GOC:rph, GOC:TermGenie, PMID:15140890]","metadata":null},{"id":"363459d1502a4bbcbf3bcc3ac1b98cdd","type":"GO_TERM","name":"folate reductase activity","canonical_id":"go:GO:0033560","description":"\"Catalysis of the reaction: 7,8-dihydrofolate + NADP+ = folate + NADPH + H+.\" [GOC:pde]","metadata":null},{"id":"3eb4a5ed5ac14a26b0b67043bba095d6","type":"GO_TERM","name":"folate transmembrane transport","canonical_id":"go:GO:0098838","description":"\"The process in which a folic acid, or one of its derivatives (dihydrofolate, tetrahydrofolate, methylene-tetrahydrofolate or methyl-tetrahydrofolate) is transported across a membrane.\" [PMID:24745983]","metadata":null},{"id":"6f76ed2029c44d28a114b47e6e88ff2d","type":"GO_TERM","name":"folate:monoatomic anion antiporter activity","canonical_id":"go:GO:0008518","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Folate derivative (out) + anion (in) = folate derivative (in) + anion (out). The Reduced Folate Carrier (RCF(SLC19A1) acts by an antiport mechanism. RCF carries several folate derivatives: MTX, PMX, ratitrexed, pralatrexate, 5-methyl THF, and 5-formyl THF.\" [GOC:mtg_transport, PMID:21568705, PMID:24745983, TC:2.A.48]","metadata":null},{"id":"ebbc8b515e014cf39f64c2bc083074b7","type":"GO_TERM","name":"folic acid binding","canonical_id":"go:GO:0005542","description":"\"Binding to folic acid, pteroylglutamic acid. Folic acid is widely distributed as a member of the vitamin B complex and is essential for the synthesis of purine and pyrimidines.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"65de3b64b10841268ac0e606c77e24e8","type":"GO_TERM","name":"folic acid biosynthetic process","canonical_id":"go:GO:0046656","description":"\"The chemical reactions and pathways resulting in the formation of folic acid, pteroylglutamic acid.\" [GOC:ai]","metadata":null},{"id":"47cbd0ad5fa4482f90238760943c7c41","type":"GO_TERM","name":"folic acid catabolic process","canonical_id":"go:GO:0046657","description":"\"The chemical reactions and pathways resulting in the breakdown of folic acid, pteroylglutamic acid.\" [GOC:ai]","metadata":null},{"id":"154b2560c4bc4ac89fc5487c9feb73b1","type":"GO_TERM","name":"folic acid metabolic process","canonical_id":"go:GO:0046655","description":"\"The chemical reactions and pathways involving folic acid, pteroylglutamic acid. Folic acid is widely distributed as a member of the vitamin B complex and is essential for the synthesis of purine and pyrimidines.\" [ISBN:0198506732]","metadata":null},{"id":"9b918512c1074a3588af6e4195b9919f","type":"GO_TERM","name":"folic acid receptor activity","canonical_id":"go:GO:0061714","description":"\"Combining selectively with extracellular folic acid and delivering it into the cell via endocytosis.\" [GOC:BHF, GOC:hal]","metadata":null},{"id":"15d070546cda46be8de4c3aacc81ad75","type":"GO_TERM","name":"folic acid transmembrane transporter activity","canonical_id":"go:GO:0008517","description":"\"Enables the transfer of folic acid (pteroylglutamic acid) from one side of a membrane to the other. Folic acid is widely distributed as a member of the vitamin B complex and is essential for the synthesis of purine and pyrimidines.\" [GOC:ai]","metadata":null},{"id":"3b1bc187eefb440ab3f6d6ae6d552edb","type":"GO_TERM","name":"folic acid transport","canonical_id":"go:GO:0015884","description":"\"The directed movement of folic acid (pteroylglutamic acid) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Folic acid is widely distributed as a member of the vitamin B complex and is essential for the synthesis of purine and pyrimidines.\" [GOC:ai]","metadata":null},{"id":"3fd5a4fadcd647bf8ab19cd7baff1035","type":"GO_TERM","name":"folic acid-containing compound biosynthetic process","canonical_id":"go:GO:0009396","description":"\"The chemical reactions and pathways resulting in the formation of folic acid and its derivatives.\" [GOC:ai]","metadata":null},{"id":"500a9d7c62034fd2952fa293286f1867","type":"GO_TERM","name":"folic acid-containing compound catabolic process","canonical_id":"go:GO:0009397","description":"\"The chemical reactions and pathways resulting in the breakdown of folic acid and its derivatives.\" [GOC:ai]","metadata":null},{"id":"1c28f0596a0f430482241b9bf0d7e9b1","type":"GO_TERM","name":"folic acid-containing compound metabolic process","canonical_id":"go:GO:0006760","description":"\"The chemical reactions and pathways involving a folic acid-containing compound, i.e. any of a group of heterocyclic compounds based on the pteroic acid skeleton conjugated with one or more L-glutamic acid or L-glutamate units.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"46528179abc9423a8515f403ebca9dd4","type":"GO_TERM","name":"folic acid:proton symporter activity","canonical_id":"go:GO:0140211","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: folic acid(out) + H+(out) = folic acid(in) + H+(in). The main folic acid symporter is the Proton-Coupled Folate Transporter (PCFT/SLC46A1), which has similar affinity for transport of reduced folates (5-methyl THF, 5-formyl THF) and folic acid.\" [PMID:24745983]","metadata":null},{"id":"00af7ec524aa4d9483a132238ae0b9e6","type":"GO_TERM","name":"follicle cell microvillus organization","canonical_id":"go:GO:0032529","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a microvillus on a follicle cell. A microvillus is a thin cylindrical membrane-covered projection on the surface of an animal cell containing a core bundle of actin filaments.\" [GOC:sart, PMID:16507588]","metadata":null},{"id":"01ea8893dd5543709f716002bb5a07bd","type":"GO_TERM","name":"follicle cell of egg chamber development","canonical_id":"go:GO:0030707","description":"\"The process that occurs during oogenesis involving the ovarian follicle cells, somatic cells which surround the germ cells of an ovary. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:10822261]","metadata":null},{"id":"f018562eae134c89890881c4c523c463","type":"GO_TERM","name":"follicle cell of egg chamber migration","canonical_id":"go:GO:0007297","description":"\"The directed movement of an ovarian follicle cell that takes place during oogenesis. During egg chamber formation, follicle cells migrate to envelop the germ-line cysts and move in between cysts. At stage 10B, follicle cells migrate centripetally between the nurse cells and the oocyte, enclosing the anterior of the egg. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:10822261]","metadata":null},{"id":"030f3c8706724cfdbc132a796da68108","type":"GO_TERM","name":"follicle cell of egg chamber stalk formation","canonical_id":"go:GO:0030713","description":"\"Development of ovarian follicle cells to create the interfollicular stalks that connect the egg chambers of progressive developmental stages. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:10822261]","metadata":null},{"id":"6b430cdd4a144ad9894b4527a046283d","type":"GO_TERM","name":"follicle cell of egg chamber-cell adhesion","canonical_id":"go:GO:0007299","description":"\"The attachment of a somatic follicle cell to another somatic follicle cell or to its substratum, the germline cells. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, PMID:12642496]","metadata":null},{"id":"f9a0812709b04b57b1b4fc0c0afd80e3","type":"GO_TERM","name":"follicle-stimulating hormone activity","canonical_id":"go:GO:0016913","description":"\"The action characteristic of follicle-stimulating hormone (FSH), a gonadotrophic glycoprotein hormone secreted, in mammals, by the anterior pituitary gland. Upon receptor binding, FSH stimulates growth of Graafian follicles in the ovaries in females, and stimulates the epithelium of the seminiferous tubules to increase spermatogenesis.\" [ISBN:0198547684]","metadata":null},{"id":"31e91ffea5194b98b0af171db8339e20","type":"GO_TERM","name":"follicle-stimulating hormone complex","canonical_id":"go:GO:0016914","description":"\"A gonadotrophic glycoprotein hormone secreted, in mammals, by the anterior pituitary gland; consists of alpha and beta subunits, the latter of which confers hormonal specificity.\" [ISBN:0198547684]","metadata":null},{"id":"e1c5f30118e0403db39ede7746ef79af","type":"GO_TERM","name":"follicle-stimulating hormone receptor activity","canonical_id":"go:GO:0004963","description":"\"Combining with follicle-stimulating hormone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"4db6d30b95c54bf4a4ba0a942ee978e1","type":"GO_TERM","name":"follicle-stimulating hormone receptor binding","canonical_id":"go:GO:0031762","description":"\"Binding to a follicle-stimulating hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cc78a41cfc254e6296cc47ea209d6f26","type":"GO_TERM","name":"follicle-stimulating hormone secretion","canonical_id":"go:GO:0046884","description":"\"The regulated release of follicle-stimulating hormone, a gonadotropic glycoprotein hormone secreted by the anterior pituitary.\" [ISBN:0198506732]","metadata":null},{"id":"def36f8e7c7e4ddda05e2fbddf7ca8ef","type":"GO_TERM","name":"follicle-stimulating hormone signaling pathway","canonical_id":"go:GO:0042699","description":"\"A G protein-coupled receptor signaling pathway initiated by follicle-stimulating hormone binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:dph]","metadata":null},{"id":"3984848e4cc04555acd5208dc4abd758","type":"GO_TERM","name":"follicular B cell differentiation","canonical_id":"go:GO:0002316","description":"\"The process in which a B cell in the spleen acquires the specialized features of a follicular B cell. Follicular B cells are major population of mature recirculating B cells in the spleen and are located in the B-cell follicle region.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"e025192b7edb49848f7a96338a0ec6de","type":"GO_TERM","name":"follicular dendritic cell activation","canonical_id":"go:GO:0002266","description":"\"A change in the morphology or behavior of a follicular dendritic cell resulting from exposure to an activating factor such as a cellular or soluble ligand.\" [GOC:add, PMID:15606789]","metadata":null},{"id":"4ff1a6ce982646c290011b33a4111e9e","type":"GO_TERM","name":"follicular dendritic cell differentiation","canonical_id":"go:GO:0002268","description":"\"The process in which a relatively unspecialized precursor cell acquires the specialized features of a follicular dendritic cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"aa81e08f4fa24a2fa4be0a983ff43a24","type":"GO_TERM","name":"follicular fluid formation in ovarian follicle antrum","canonical_id":"go:GO:0001548","description":"\"The menstrual cycle process that results in the formation of one central cavity separating the oocyte/cumulus complex from mural granulosa and theca cells during the various stages of oogenesis.\" [GOC:dph, GOC:tb, https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"f4715bc6cfbb4a5dafa10785cf9fb60d","type":"DISEASE","name":"follicular lymphoma","canonical_id":"mondo:0018906","description":null,"metadata":null},{"id":"bca3fac4b2434a48b7a28c56fc2c423b","type":"DRUG","name":"follitropin","canonical_id":"mesh:D005640","description":null,"metadata":null},{"id":"26820b3f239e451ba6d349e69918f5b4","type":"DRUG","name":"fomepizole","canonical_id":"mesh:D000077604","description":null,"metadata":null},{"id":"8b6c09a01aaf4ef1b5f301825df873c9","type":"DRUG","name":"fondaparinux","canonical_id":"gtopdb:6819","description":null,"metadata":null},{"id":"4368300c2328402e8e5c0771eca9d31a","type":"DRUG","name":"fondaparinux","canonical_id":"mesh:D000077425","description":null,"metadata":null},{"id":"13bc6c68ae53483781d70b6c5cb79878","type":"COMBINATION_TREATMENT","name":"fondaparinux + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-37b24e671f26ed18","description":null,"metadata":null},{"id":"33e2c2e4a785490582c762af0db72a44","type":"COMBINATION_TREATMENT","name":"fondaparinux + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-cb96b8882bb9f248","description":null,"metadata":null},{"id":"39924f7fb0464e01b16b4c7bd766201c","type":"COMBINATION_TREATMENT","name":"fondaparinux + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-bb3b608c241b79f7","description":null,"metadata":null},{"id":"4ae8f7599e2046259096580ef858e787","type":"COMBINATION_TREATMENT","name":"fondaparinux + tirofiban","canonical_id":"ctgov_combo:ctgov-combo-b31cddbfc584d8b8","description":null,"metadata":null},{"id":"8e8e0692cc0e4055a5ddcf953ee10884","type":"GO_TERM","name":"fonsecin biosynthetic process","canonical_id":"go:GO:1900769","description":"\"The chemical reactions and pathways resulting in the formation of fonsecin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6805220e912b4f5b856b7598c51ca632","type":"GO_TERM","name":"fonsecin catabolic process","canonical_id":"go:GO:1900768","description":"\"The chemical reactions and pathways resulting in the breakdown of fonsecin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c6375d13744f479ab7456eb9d574afc8","type":"GO_TERM","name":"food vacuole","canonical_id":"go:GO:0020020","description":"\"Vacuole within a parasite used for digestion of the host cell cytoplasm. An example of this component is found in the Apicomplexa.\" [GOC:mb]","metadata":null},{"id":"483925115ad144b7b536711239edfee2","type":"GO_TERM","name":"foot layer","canonical_id":"go:GO:0043670","description":"\"The inner layer of the ectexine.\" [PMID:28904424]","metadata":null},{"id":"6e8d191253a74a558588fe897c45df0e","type":"GO_TERM","name":"foraging behavior","canonical_id":"go:GO:0060756","description":"\"Behavior by which an organism locates food.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8b26d2566a294a34b8a3627e1024436f","type":"GO_TERM","name":"foraging behavior by probing substrate","canonical_id":"go:GO:0060758","description":"\"Foraging behavior in which an anatomical part of the organism is inserted into the substrate to locate food.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"29267a2de2524d43b65081b0480b2b9f","type":"GO_TERM","name":"foramen ovale closure","canonical_id":"go:GO:0035922","description":"\"The morphogenetic process in which the foramen ovale closes after birth, to prevent blood flow between the right and left atria. In the fetal heart, the foramen ovale allows blood to enter the left atrium from the right atrium. Closure of the foramen ovale after birth stops this blood flow.\" [GOC:BHF, GOC:vk, PMID:19762328, UBERON:0004754, Wikipedia:Foramen_ovale_(heart)]","metadata":null},{"id":"e7d94bd2a0ab4f2b9cf42f6141439cd9","type":"GO_TERM","name":"forebrain anterior/posterior pattern specification","canonical_id":"go:GO:0021797","description":"\"The creation of specific areas of progenitor domains along the anterior-posterior axis of the developing forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"58155d7597df419eb8e9912b60ad5a29","type":"GO_TERM","name":"forebrain astrocyte development","canonical_id":"go:GO:0021897","description":"\"The process aimed at the progression of an astrocyte that resides in the forebrain, from initial commitment of the cell to its fate, to the fully functional differentiated cell. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b60b50174a274b22aa561d028985ac58","type":"GO_TERM","name":"forebrain astrocyte differentiation","canonical_id":"go:GO:0021896","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an astrocyte residing in the forebrain. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"026cea2e02c74b1ca0721550c67d36be","type":"GO_TERM","name":"forebrain astrocyte fate commitment","canonical_id":"go:GO:0021878","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an astrocyte that resides in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"9f1500ca79b347b29e897e181f6dae63","type":"GO_TERM","name":"forebrain cell migration","canonical_id":"go:GO:0021885","description":"\"The orderly movement of a cell from one site to another at least one of which is located in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"73bc8758a969419ca0a3d7e1001c64d7","type":"GO_TERM","name":"forebrain development","canonical_id":"go:GO:0030900","description":"\"The process whose specific outcome is the progression of the forebrain over time, from its formation to the mature structure. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions).\" [PMID:4975589, PMID:4992177]","metadata":null},{"id":"4556e01f27d3438d857e1cc54a132d99","type":"GO_TERM","name":"forebrain dorsal/ventral pattern formation","canonical_id":"go:GO:0021798","description":"\"The formation of specific regional progenitor domains along the dorsal-ventral axis in the developing forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3ffb14d7634645219b4305f04efe4f7e","type":"GO_TERM","name":"forebrain generation of neurons","canonical_id":"go:GO:0021872","description":"\"The process in which nerve cells are generated in the forebrain. This includes the production of neuroblasts from and their differentiation into neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b041d666a4ba42d08a8ee9a167bf7f23","type":"GO_TERM","name":"forebrain induction by the anterior neural ridge","canonical_id":"go:GO:0022000","description":"\"The close range interaction of the anterior neural ridge to the caudal region of the neural plate that specifies the forebrain fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a2c73c00616f46538817fe2073ab82a6","type":"GO_TERM","name":"forebrain morphogenesis","canonical_id":"go:GO:0048853","description":"\"The process in which the anatomical structures of the forebrain are generated and organized. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions).\" [GOC:cvs, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"60f02aba855c446aa3a2f8cfd9147621","type":"GO_TERM","name":"forebrain neuroblast differentiation","canonical_id":"go:GO:0021863","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of basal progenitor cells, neuroblasts that lose their contacts with the ventricular surface. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"8124372976dd4d0abe074e13e9aa7013","type":"GO_TERM","name":"forebrain neuroblast division","canonical_id":"go:GO:0021873","description":"\"The division of a neuroblast located in the forebrain. Neuroblast division gives rise to at least another neuroblast.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"33b25af736984a20a494b4d84d496609","type":"GO_TERM","name":"forebrain neuron development","canonical_id":"go:GO:0021884","description":"\"The process whose specific outcome is the progression of a neuron that resides in the forebrain, from its initial commitment to its fate, to the fully functional differentiated cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b1ff96c74d714998907edf3f852a215f","type":"GO_TERM","name":"forebrain neuron differentiation","canonical_id":"go:GO:0021879","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron that will reside in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"011f152db576434e8f0f473a90d69beb","type":"GO_TERM","name":"forebrain neuron fate commitment","canonical_id":"go:GO:0021877","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a neuron that resides in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"775fa54f39034f1fa0191d41f1162023","type":"GO_TERM","name":"forebrain radial glial cell differentiation","canonical_id":"go:GO:0021861","description":"\"The process in which neuroepithelial cells of the neural tube give rise to radial glial cells, specialized bipotential progenitors cells of the forebrain. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"1b2257545e4241ceacc812b7135dcde5","type":"GO_TERM","name":"forebrain regionalization","canonical_id":"go:GO:0021871","description":"\"The regionalization process resulting in the creation of areas within the forebrain that will direct the behavior of cell migration in differentiation as the forebrain develops.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:isa_complete, GOC:jid, PMID:16226447]","metadata":null},{"id":"f75123adc4e24ba99341b6b6f9860add","type":"GO_TERM","name":"forebrain ventricular zone progenitor cell division","canonical_id":"go:GO:0021869","description":"\"The mitotic division of a basal progenitor giving rise to two neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"e36771ef4f59412cabcea971cd85832f","type":"GO_TERM","name":"forebrain-midbrain boundary formation","canonical_id":"go:GO:0021905","description":"\"The process whose specific outcome is the creation of the forebrain-midbrain boundary.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"15e40d777f0b44a298bcc042d33afd96","type":"GO_TERM","name":"foregut morphogenesis","canonical_id":"go:GO:0007440","description":"\"The process in which the anatomical structures of the foregut are generated and organized.\" [GOC:jid]","metadata":null},{"id":"b2c261e32e7f449f8e08947ea831b6b5","type":"GO_TERM","name":"foregut regionalization","canonical_id":"go:GO:0060423","description":"\"The pattern specification process that results in the spatial subdivision of an axis or axes along the foregut to define an area or volume in which specific patterns of cell differentiation will take place.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"8cd978759c3c4228bec08fe2ea923efb","type":"GO_TERM","name":"forelimb morphogenesis","canonical_id":"go:GO:0035136","description":"\"The process in which the anatomical structures of the forelimb are generated and organized. The forelimbs are the front limbs of an animal, e.g. the arms of a human.\" [GOC:curators]","metadata":null},{"id":"c9032ea301e04d648cc940bfca10ce8e","type":"GO_TERM","name":"forked DNA-dependent helicase activity","canonical_id":"go:GO:0061749","description":"\"Unwinding a DNA helix containing forked DNA, driven by ATP hydrolysis.\" [GOC:dph, PMID:26277776]","metadata":null},{"id":"c8ac562ae834489d804132f1891f3654","type":"DRUG","name":"formaldehyde","canonical_id":"mesh:D005557","description":null,"metadata":null},{"id":"b393e65d723549bbb00d66caf119af4c","type":"GO_TERM","name":"formaldehyde assimilation","canonical_id":"go:GO:0019649","description":"\"The pathways in which formaldehyde is processed and used as a carbon source for the cell.\" [GOC:ai]","metadata":null},{"id":"47fa42b09a334d09b5f1439f4a6615f8","type":"GO_TERM","name":"formaldehyde biosynthetic process","canonical_id":"go:GO:0046293","description":"\"The chemical reactions and pathways resulting in the formation of formaldehyde (methanal, H2C=O), the simplest aldehyde.\" [GOC:ai]","metadata":null},{"id":"d5e42ac12f14465794b5b721af6678d3","type":"GO_TERM","name":"formaldehyde catabolic process","canonical_id":"go:GO:0046294","description":"\"The chemical reactions and pathways resulting in the breakdown of formaldehyde (methanal, H2C=O), the simplest aldehyde.\" [GOC:ai]","metadata":null},{"id":"d06fde7ddb7e42398665128aa2653125","type":"GO_TERM","name":"formaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018467","description":"\"Catalysis of the reaction: formaldehyde + H2O + NAD+ = formate + 2 H+ + NADH.\" [RHEA:16425]","metadata":null},{"id":"ac131c9bc9d94b419f7abafd9f3e0254","type":"GO_TERM","name":"formaldehyde dismutase activity","canonical_id":"go:GO:0047895","description":"\"Catalysis of the reaction: 2 formaldehyde + H2O = methanol + formate.\" [EC:1.2.98.1]","metadata":null},{"id":"2196a254f7624dec89a47e1519bdce0d","type":"GO_TERM","name":"formaldehyde metabolic process","canonical_id":"go:GO:0046292","description":"\"The chemical reactions and pathways involving formaldehyde (methanal, H2C=O), a colorless liquid or gas with a pungent odor, commonly used as a fixative or an antibacterial agent.\" [GOC:ai]","metadata":null},{"id":"6a7c688451384e4bae9622595da70a8c","type":"GO_TERM","name":"formaldehyde transketolase activity","canonical_id":"go:GO:0047896","description":"\"Catalysis of the reaction: D-xylulose 5-phosphate + formaldehyde = glyceraldehyde 3-phosphate + glycerone.\" [EC:2.2.1.3, MetaCyc:FORMALDEHYDE-TRANSKETOLASE-RXN]","metadata":null},{"id":"8753d5f397b244358d8d2be5f4443dd1","type":"GO_TERM","name":"formamidase activity","canonical_id":"go:GO:0004328","description":"\"Catalysis of the reaction: formamide + H2O = formate + NH4.\" [RHEA:21948]","metadata":null},{"id":"ee7ef76f5c74484086b8af2b9f51b145","type":"GO_TERM","name":"formate C-acetyltransferase activity","canonical_id":"go:GO:0008861","description":"\"Catalysis of the reaction: acetyl-CoA + formate = CoA + pyruvate.\" [RHEA:11844]","metadata":null},{"id":"edd3beb09c86412c97e023e9c6381973","type":"GO_TERM","name":"formate biosynthetic process","canonical_id":"go:GO:0015943","description":"\"The chemical reactions and pathways resulting in the formation of formate, also known as methanoate, the anion HCOO- derived from methanoic (formic) acid.\" [ISBN:0198506732]","metadata":null},{"id":"c4536d0caa5e4b3a88cefa2c585e2cff","type":"GO_TERM","name":"formate catabolic process","canonical_id":"go:GO:0042183","description":"\"The chemical reactions and pathways resulting in the breakdown of formate, also known as methanoate, the anion HCOO- derived from methanoic (formic) acid.\" [ISBN:0198506732]","metadata":null},{"id":"e0c7622615564eb686c9de1ea4d75dfe","type":"GO_TERM","name":"formate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008863","description":"\"Catalysis of the reaction: formate + NAD+ = CO2 + NADH.\" [EC:1.17.1.9, RHEA:15985]","metadata":null},{"id":"f5d0b70a4f3d492d8b83170296674ff4","type":"GO_TERM","name":"formate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047899","description":"\"Catalysis of the reaction: formate + NADP+ = CO2 + NADPH.\" [EC:1.17.1.10, RHEA:12000]","metadata":null},{"id":"5083314b9f56487e9b363cce6ca6ba38","type":"GO_TERM","name":"formate dehydrogenase (coenzyme F420) activity","canonical_id":"go:GO:0043794","description":"\"Catalysis of the reaction: formate + 2 H+ + oxidized coenzyme F420-(gamma-L-Glu)(n) = CO2 + reduced coenzyme F420-(gamma-L-Glu)(n).\" [PMID:3801411, RHEA:42764]","metadata":null},{"id":"b9371c28902048ec8c4cb54ee9df1d24","type":"GO_TERM","name":"formate dehydrogenase (cytochrome) activity","canonical_id":"go:GO:0047898","description":"\"Catalysis of the reaction: formate + ferricytochrome b1 = CO2 + ferrocytochrome b1.\" [EC:1.2.2.1, MetaCyc:FORMATE-DEHYDROGENASE-CYTOCHROME-RXN]","metadata":null},{"id":"a306ba944d2942da91260316f842bb04","type":"GO_TERM","name":"formate dehydrogenase (cytochrome-c-553) activity","canonical_id":"go:GO:0047111","description":"\"Catalysis of the reaction: ferricytochrome C-553 + formate = ferrocytochrome C-553 + CO2.\" [EC:1.17.2.3, MetaCyc:1.2.2.3-RXN]","metadata":null},{"id":"3e2c9f0757f6460989b6bc94f6896b52","type":"GO_TERM","name":"formate dehydrogenase (quinone) activity","canonical_id":"go:GO:0036397","description":"\"Catalysis of the reaction: formate + a quinone = CO2 + a quinol.\" [GOC:bhm, RHEA:48592]","metadata":null},{"id":"785a76d53cea44619ef8cc890a9c0a2d","type":"GO_TERM","name":"formate dehydrogenase complex","canonical_id":"go:GO:0009326","description":"\"An enzyme complex that catalyzes the dehydrogenation of formate to produce carbon dioxide (CO2).\" [PMID:1504073, PMID:8566699]","metadata":null},{"id":"e37706a06a784c8cbe22412f79eedf44","type":"GO_TERM","name":"formate efflux transmembrane transporter activity","canonical_id":"go:GO:0015660","description":"\"Enables the transfer of formate from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"09e8014fcf6b4771ad60401e7bb12356","type":"GO_TERM","name":"formate kinase activity","canonical_id":"go:GO:0047900","description":"\"Catalysis of the reaction: ATP + formate = ADP + formyl phosphate + H+.\" [EC:2.7.2.6, RHEA:16009]","metadata":null},{"id":"6a0c6107663440fcaa7ab7e8539c2dc7","type":"GO_TERM","name":"formate metabolic process","canonical_id":"go:GO:0015942","description":"\"The chemical reactions and pathways involving formate, also known as methanoate, the anion HCOO- derived from methanoic (formic) acid.\" [ISBN:0198506732]","metadata":null},{"id":"417a5a3d4ff24e6390055231b671dd04","type":"GO_TERM","name":"formate oxidation","canonical_id":"go:GO:0015944","description":"\"The chemical reactions and pathways by which formate is converted to CO2.\" [MetaCyc:PWY-1881]","metadata":null},{"id":"c5ec3f8aa66f4f69974849a0848850e5","type":"GO_TERM","name":"formate transmembrane transporter activity","canonical_id":"go:GO:0015499","description":"\"Enables the transfer of formate from one side of a membrane to the other. Formate is also known as methanoate, the anion HCOO- derived from methanoic (formic) acid.\" [GOC:ai]","metadata":null},{"id":"65c6ff41b95f49a69bef73050b30b896","type":"GO_TERM","name":"formate transport","canonical_id":"go:GO:0015724","description":"\"The directed movement of formate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"2e381658b3ee4f808bddce7d8f0d8fb7","type":"GO_TERM","name":"formate-dihydrofolate ligase activity","canonical_id":"go:GO:0047897","description":"\"Catalysis of the reaction: 7,8-dihydrofolate + ATP + formate = 10-formyldihydrofolate + ADP + H+ + phosphate.\" [EC:6.3.4.17, RHEA:24328]","metadata":null},{"id":"502574ee6201464c94057486b84afb38","type":"GO_TERM","name":"formate-tetrahydrofolate ligase activity","canonical_id":"go:GO:0004329","description":"\"Catalysis of the reaction: ATP + formate + tetrahydrofolate = ADP + phosphate + 10-formyltetrahydrofolate.\" [EC:6.3.4.3]","metadata":null},{"id":"f900b660cacc4b1ba40309cd2a938823","type":"GO_TERM","name":"formation by host of specialized structure for nutrient acquisition from symbiont","canonical_id":"go:GO:0052098","description":"\"The assembly by an organism of a cellular component or anatomical structure for the purpose of obtaining nutrients from a symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"0b05f832266341ad984c23b4aadeb0df","type":"GO_TERM","name":"formation of a compartment boundary","canonical_id":"go:GO:0060288","description":"\"Formation of a lineage restriction boundary within a developing tissue which does not correspond to some morphological barrier.\" [GOC:dph]","metadata":null},{"id":"63fad7baef24490893976bae9ff64523","type":"GO_TERM","name":"formation of anatomical boundary","canonical_id":"go:GO:0048859","description":"\"The process in which the limits of an anatomical structure are generated. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.\" [GO_REF:0000021]","metadata":null},{"id":"c6429081d75c42ed9a6763b7c31bec5b","type":"GO_TERM","name":"formation of animal organ boundary","canonical_id":"go:GO:0010160","description":"\"The regionalization process that specifies animal organ primordium boundaries resulting in a restriction of organogenesis to a limited spatial domain and keeping the organ separate from surrounding tissues.\" [GOC:dph, GOC:isa_complete, PMID:9611175]","metadata":null},{"id":"3fcd3774d49c45cfbedf7eeac1ca3cc7","type":"GO_TERM","name":"formation of appressorium germ tube hook structure","canonical_id":"go:GO:0075029","description":"\"The development of a swollen tip at the growing end of a symbiont spore which usually flattens against the host cell surface prior to appressorium formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"2ce96e72d7e34cd7be823223feb82d26","type":"GO_TERM","name":"formation of arbuscule for nutrient acquisition","canonical_id":"go:GO:0075328","description":"\"The assembly of an arbuscule, a fine, tree-like hyphal symbiont structure projected into the host cell for the purpose of obtaining nutrients. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"b53088f69fb64799acd6f5aa32d92df1","type":"GO_TERM","name":"formation of cytoplasmic translation initiation complex","canonical_id":"go:GO:0001732","description":"\"Joining of the large ribosomal subunit with the translation preinitiation complex, with release of IF2/eIF2 and IF3/eIF3 or IF5B/eIF5B. This leaves the functional ribosome at the AUG, with the methionyl/formyl-methionyl-tRNA positioned at the P site.\" [GOC:hjd, PMID:29735639]","metadata":null},{"id":"9f743ead9f3047e7971d67c9e109fd35","type":"GO_TERM","name":"formation of extrachromosomal circular DNA","canonical_id":"go:GO:0001325","description":"\"Excision from the chromosome and circularization of a region of chromosomal DNA, generally, but not always, via homologous recombination between direct tandem repeats.\" [GOC:jh, PMID:12044938]","metadata":null},{"id":"82f7500668ad4be190efec0d26c3aad3","type":"GO_TERM","name":"formation of growth cone in injured axon","canonical_id":"go:GO:0048689","description":"\"The formation of a growth cone in an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"3bd30af81638415f8ccdcd723d77e7a0","type":"GO_TERM","name":"formation of haustorium for nutrient acquisition","canonical_id":"go:GO:0052094","description":"\"The assembly of a haustorium, a projection from a symbiotic cell or tissue that penetrates the host's tissues for the purpose of obtaining nutrients. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"0992436076314fd8bd4a47928bed16e6","type":"GO_TERM","name":"formation of infection structure","canonical_id":"go:GO:0075015","description":"\"The formation of a symbiont structure that serves to infect its host organism. It includes physiological, developmental, and morphological changes of the symbiont. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"869f4ac5c8364a0dade53726612c6e26","type":"GO_TERM","name":"formation of plant organ boundary","canonical_id":"go:GO:0090691","description":"\"The regionalization process that specifies plant organ primordium boundaries resulting in a restriction of organogenesis to a limited spatial domain and keeping the organ separate from surrounding tissues.\" [GOC:tb]","metadata":null},{"id":"7b0c96d5d2d34963b80c663717ddfd57","type":"GO_TERM","name":"formation of primary germ layer","canonical_id":"go:GO:0001704","description":"\"The formation of the ectoderm, mesoderm and endoderm during gastrulation.\" [GOC:curators]","metadata":null},{"id":"8f4575561d0a4f9882a685e6a860f4ca","type":"GO_TERM","name":"formation of quadruple SL/U4/U5/U6 snRNP","canonical_id":"go:GO:0000353","description":"\"Formation of a quadruple snRNP complex composed of the spliced leader (SL) RNA along with the U4/U6-U5 tri-snRNP complex. Interactions that may facilitate this include a duplex between the SL and U6 RNAs and interactions between the U5 RNA and the exon sequence at the 5' splice site within the SL RNA.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"701eb8d03a1044dbbf9627b7e51cf348","type":"GO_TERM","name":"formation of radial glial scaffolds","canonical_id":"go:GO:0021943","description":"\"The formation of scaffolds from a radial glial cell. The scaffolds are used as a substrate for the radial migration of cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"e6522301738f499f807bd86a5048bc7b","type":"GO_TERM","name":"formation of specialized structure for nutrient acquisition","canonical_id":"go:GO:0052093","description":"\"The assembly of a symbiotic cellular or anatomical structure for the purpose of obtaining nutrients from its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"f22be8910d694b0a84d6842b8fc9f99d","type":"GO_TERM","name":"formation of structure involved in a symbiotic process","canonical_id":"go:GO:0044111","description":"\"The progression of an organism from an initial condition to a later condition, occurring when the organism is in a symbiotic interaction.\" [GO:jl, GOC:pamgo_curators]","metadata":null},{"id":"b605b7b050004d4eaf15c43af2381d38","type":"GO_TERM","name":"formation of stylet for nutrient acquisition","canonical_id":"go:GO:0085001","description":"\"The assembly of a stylet, a hollow protrusible spear-like symbiont structure projected into the host cell for the purpose of obtaining nutrients. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"bb22672b3c1641e89fe48d76b2e7f990","type":"GO_TERM","name":"formation of syncytium involving giant cell for nutrient acquisition","canonical_id":"go:GO:0052096","description":"\"The assembly of a syncytium, a multi-nucleate and physiologically active aggregation of fused root cells induced by a symbiotic nematode in a plant host. The syncytium exclusively provides the nematode with nourishment during its sedentary life, for the purpose of obtaining nutrients from its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"7574f7e2e96540498b92ed8396a61e9e","type":"GO_TERM","name":"formation of translation initiation ternary complex","canonical_id":"go:GO:0001677","description":"\"Formation of a complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2 (either eIF2 in eukaryotes, or IF2 in prokaryotes). In prokaryotes, fMet-tRNA (initiator) is used rather than Met-tRNA (initiator).\" [GOC:hjd]","metadata":null},{"id":"a96651f79d64425286074c77bc6c4440","type":"GO_TERM","name":"formation of translation preinitiation complex","canonical_id":"go:GO:0001731","description":"\"The joining of the small ribosomal subunit, ternary complex, and mRNA.\" [GOC:hjd]","metadata":null},{"id":"fc28e4df93a849399abea514f9746b36","type":"GO_TERM","name":"formation of tubovesicular network for nutrient acquisition","canonical_id":"go:GO:0085019","description":"\"The assembly of a symbiont-induced complex organelle that comprises of multiple protein and lipid domains for the purpose of obtaining nutrients from its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"7cc087cd9b674e009a8b2ff6e8a1d76f","type":"GO_TERM","name":"formic acid secretion","canonical_id":"go:GO:0046721","description":"\"The controlled release of formic acid, HCOOH, by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"c2993d9156f8451e82bc36f5dc5ec3c1","type":"GO_TERM","name":"formimidoylaspartate deiminase activity","canonical_id":"go:GO:0050414","description":"\"Catalysis of the reaction: N-formimidoyl-L-aspartate + H2O = N-formyl-L-aspartate + NH4+.\" [RHEA:13661]","metadata":null},{"id":"2fae0294406d490682980a3aff513ceb","type":"GO_TERM","name":"formimidoylglutamase activity","canonical_id":"go:GO:0050415","description":"\"Catalysis of the reaction: N-formimidoyl-L-glutamate + H2O = L-glutamate + formamide.\" [EC:3.5.3.8, RHEA:22492]","metadata":null},{"id":"0147080ac8c442cd8714a275f51bac24","type":"GO_TERM","name":"formimidoylglutamate deiminase activity","canonical_id":"go:GO:0050416","description":"\"Catalysis of the reaction: N-formimidoyl-L-glutamate + H2O = N-formyl-L-glutamate + NH4+.\" [RHEA:22832]","metadata":null},{"id":"a86241970dd34dec906969f044292368","type":"GO_TERM","name":"formimidoyltetrahydrofolate cyclodeaminase activity","canonical_id":"go:GO:0030412","description":"\"Catalysis of the reaction: 5-formimidoyltetrahydrofolate + 2 H+ = 5,10-methenyltetrahydrofolate + NH4.\" [EC:4.3.1.4, RHEA:22736]","metadata":null},{"id":"4b112d116dab4940ba64136abce36ab5","type":"GO_TERM","name":"formin-nucleated actin cable","canonical_id":"go:GO:0070648","description":"\"An actin filament bundle that consists of short filaments organized into bundles of uniform polarity, and is nucleated by formins. In fungal cells, myosin motors transport cargo along actin cables toward sites of polarized cell growth; actin cables may play a similar role in pollen tube growth.\" [PMID:14671023, PMID:16959963]","metadata":null},{"id":"d44a5f3575af424598aaed39d01ab862","type":"GO_TERM","name":"formin-nucleated actin cable assembly","canonical_id":"go:GO:0070649","description":"\"The aggregation, arrangement and bonding together of a set of components to form a formin-nucleated actin cable. A formin-nucleated actin cable is an actin filament bundle that consists of short filaments organized into bundles of uniform polarity, and is nucleated by formins.\" [GOC:mah, PMID:14671023, PMID:16959963]","metadata":null},{"id":"bae2650aed204b5386551794483b0ebb","type":"GO_TERM","name":"formin-nucleated actin cable organization","canonical_id":"go:GO:0110009","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of a formin-nucleated actin cable.\" [GOC:mah]","metadata":null},{"id":"dff16db364604ea7b8c19290e8cb9c35","type":"DRUG","name":"formoterol","canonical_id":"gtopdb:3465","description":null,"metadata":null},{"id":"d604f652cc914271b5bd8812724a2cec","type":"DRUG","name":"formoterol","canonical_id":"mesh:D000068759","description":null,"metadata":null},{"id":"4d475e4221fe42f7acfaf1bd66e2285e","type":"COMBINATION_TREATMENT","name":"formoterol + glycopyrrolate","canonical_id":"ctgov_combo:ctgov-combo-a18cc50060453329","description":null,"metadata":null},{"id":"6e9d951a63ba4ab3814fee5d36d7bf3d","type":"COMBINATION_TREATMENT","name":"formoterol + mometasone","canonical_id":"ctgov_combo:ctgov-combo-e9e7bae18ac52951","description":null,"metadata":null},{"id":"c61a76d4ab51471fa643f7e82961304f","type":"COMBINATION_TREATMENT","name":"formoterol + olodaterol","canonical_id":"ctgov_combo:ctgov-combo-15b4a48a68189976","description":null,"metadata":null},{"id":"f007e804b6544bf29a5a5bb5df5428be","type":"COMBINATION_TREATMENT","name":"formoterol + olodaterol","canonical_id":"ctgov_combo:ctgov-combo-53d347877cb0d6e6","description":null,"metadata":null},{"id":"d2df931bb4184bf19b381ebf934a8e98","type":"COMBINATION_TREATMENT","name":"formoterol + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-f9b3a9f889308a68","description":null,"metadata":null},{"id":"1880073f901f429d8732f97576bf751f","type":"COMBINATION_TREATMENT","name":"formoterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-1ba09994c59144b2","description":null,"metadata":null},{"id":"d3abf564a1e2480f90523d409078c283","type":"COMBINATION_TREATMENT","name":"formoterol + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-7dcaa8d161ddbf14","description":null,"metadata":null},{"id":"67e6b641299a4fe19a961e34b8c4d4da","type":"GO_TERM","name":"formyl-CoA transferase activity","canonical_id":"go:GO:0033608","description":"\"Catalysis of the reaction: formyl-CoA + oxalate = formate + oxalyl-CoA.\" [RHEA:16545]","metadata":null},{"id":"4d0678577d614dde90b0f5685daec4be","type":"GO_TERM","name":"formyl-methanofuran dehydrogenase (molybdenum enzyme) complex","canonical_id":"go:GO:0044676","description":"\"A protein complex consisting of three polypeptides which also contains molybdenum, a molybdopterin guanine dinucleotide and iron-sulfur clusters. This protein complex catalyzes the reversible conversion of CO2 and methanofuran to formylmethanofuran during methanogenesis.\" [GOC:mengo_curators, PMID:1915887, PMID:8954165]","metadata":null},{"id":"c473476cd27b47de941b1257cd5d6e99","type":"GO_TERM","name":"formyl-methanofuran dehydrogenase (tungsten enzyme) complex","canonical_id":"go:GO:0044675","description":"\"A protein complex consisting of four polypeptides which also contains tungsten, a molybdopterin guanine dinucleotide, and iron-sulfur clusters. This protein complex catalyzes the reversible conversion of CO2 and methanofuran to formylmethanofuran during methanogenesis.\" [GOC:mengo_curators, PMID:8125106, PMID:8575452]","metadata":null},{"id":"7c23aca7898944538ebc271843bc3148","type":"GO_TERM","name":"formylaspartate deformylase activity","canonical_id":"go:GO:0047902","description":"\"Catalysis of the reaction: N-formyl-L-aspartate + H2O = formate + L-aspartate.\" [EC:3.5.1.8, MetaCyc:FORMYLASPARTATE-DEFORMYLASE-RXN]","metadata":null},{"id":"99ddc3df4ad84a949afc59f6ed3d1e0c","type":"GO_TERM","name":"formylglycine-generating oxidase activity","canonical_id":"go:GO:0120147","description":"\"Catalysis of the reaction: A [sulfatase]-L-cysteine + O2 + 2 a thiol = a [sulfatase]-3-oxo-L-alanine + hydrogen sulfide + a disulfide + H2O.\" [EC:1.8.3.7, RHEA:51152]","metadata":null},{"id":"ff93e48153464d35b925ceb108a4b905","type":"GO_TERM","name":"formylmethanofuran dehydrogenase activity","canonical_id":"go:GO:0018493","description":"\"Catalysis of the reaction: N-formylmethanofuran + A + H2O + H+ = AH(2) + CO2 + methanofuran.\" [EC:1.2.7.12, RHEA:19841]","metadata":null},{"id":"47d3c42232c04e5d92075b2f87a4e3c7","type":"GO_TERM","name":"formylmethanofuran-tetrahydromethanopterin N-formyltransferase activity","canonical_id":"go:GO:0030270","description":"\"Catalysis of the reaction: 5,6,7,8-tetrahydromethanopterin + N-formylmethanofuran + H+ = N(5)-formyl-5,6,7,8-tetrahydromethanopterin + methanofuran.\" [EC:2.3.1.101, RHEA:18061]","metadata":null},{"id":"65626b996be7490f9bb06a043e923f47","type":"GO_TERM","name":"formylmethionine deformylase activity","canonical_id":"go:GO:0008463","description":"\"Catalysis of the reaction: N-formyl-L-methionine + H2O = L-methionine + formate.\" [EC:3.5.1.31, RHEA:17781]","metadata":null},{"id":"781a2875a9d646698bdefb852af118ba","type":"GO_TERM","name":"formyltetrahydrofolate deformylase activity","canonical_id":"go:GO:0008864","description":"\"Catalysis of the reaction: 10-formyltetrahydrofolate + H2O = (6S)-5,6,7,8-tetrahydrofolate + formate + H+.\" [EC:3.5.1.10, RHEA:19833]","metadata":null},{"id":"dd41fc95c3a54cafb5a916e304c4e79e","type":"GO_TERM","name":"formyltetrahydrofolate dehydrogenase activity","canonical_id":"go:GO:0016155","description":"\"Catalysis of the reaction: 10-formyltetrahydrofolate + H2O + NADP+ = (6S)-5,6,7,8-tetrahydrofolate + CO2 + H+ + NADPH.\" [EC:1.5.1.6, RHEA:10180]","metadata":null},{"id":"53a8358286ad414cadcbbef33e7ca827","type":"GO_TERM","name":"forward locomotion","canonical_id":"go:GO:0043056","description":"\"Anterior movement of an organism, following the direction of the head of the animal.\" [GOC:curators]","metadata":null},{"id":"a532391118b94a83b1f216858f933ec2","type":"DRUG","name":"fosamprenavir","canonical_id":"mesh:C426859","description":null,"metadata":null},{"id":"350f5d09f0c04d14b5dac2e587df66b9","type":"DRUG","name":"foscarnet","canonical_id":"mesh:D017245","description":null,"metadata":null},{"id":"991508a2d26741bab2b2493da973c781","type":"DRUG","name":"fosfomycin","canonical_id":"mesh:D005578","description":null,"metadata":null},{"id":"3759f4a67be746bcaafd875cfe7754c6","type":"DRUG","name":"fosinopril","canonical_id":"gtopdb:6456","description":null,"metadata":null},{"id":"7a211040644d43e58f1f1795c3419702","type":"DRUG","name":"fosinopril","canonical_id":"mesh:D017328","description":null,"metadata":null},{"id":"db7112adc00a4a95b5a3e0ce50fddb93","type":"GO_TERM","name":"fosmidomycin transmembrane transporter activity","canonical_id":"go:GO:0042898","description":"\"Enables the transfer of fosmidomycin, a phosphonic acid derivative with potent activity against Gram-negative organisms, from one side of a membrane to the other.\" [GOC:jl, PMID:12543685]","metadata":null},{"id":"1843fd4b4a1b4519b1e3760056749d0c","type":"GO_TERM","name":"fosmidomycin transport","canonical_id":"go:GO:0042894","description":"\"The directed movement of fosmidomycin, a phosphonic acid derivative with potent activity against Gram-negative organisms, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:12543685]","metadata":null},{"id":"3a044b222543424586f485e9f7e3d37f","type":"DRUG","name":"fosphenytoin","canonical_id":"mesh:C043114","description":null,"metadata":null},{"id":"c22369d020ef4118a747a639788a51fe","type":"GO_TERM","name":"four-way junction DNA binding","canonical_id":"go:GO:0000400","description":"\"Binding to a DNA segment containing four-way junctions, also known as Holliday junctions, a structure where two DNA double strands are held together by reciprocal exchange of two of the four strands, one strand each from the two original helices.\" [GOC:krc, ISBN:0815332181, PMID:15563464]","metadata":null},{"id":"696645ff52c54017b2a026c300a51edc","type":"GO_TERM","name":"four-way junction helicase activity","canonical_id":"go:GO:0009378","description":"\"Unwinding a DNA helix of DNA containing four-way junctions, including Holliday junctions, driven by ATP hydrolysis.\" [GOC:al, PMID:22723423, PMID:9442895]","metadata":null},{"id":"75cbbfc2c8ec42d5a666febba99e7ace","type":"GO_TERM","name":"fourth ventricle development","canonical_id":"go:GO:0021592","description":"\"The process whose specific outcome is the progression of the fourth ventricle over time, from its formation to the mature structure. The fourth ventricle is an irregularly shaped cavity in the rhombencephalon, between the medulla oblongata, the pons, and the isthmus in front, and the cerebellum behind. It is continuous with the central canal of the cord below and with the cerebral aqueduct above, and through its lateral and median apertures it communicates with the subarachnoid space.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"140b80f8c4654706bf77db1fd9504b65","type":"DISEASE","name":"foveal hypoplasia 3","canonical_id":"mondo:0975805","description":null,"metadata":null},{"id":"a6a4d458bd354227921ca9064a0844b2","type":"GO_TERM","name":"fractalkine production","canonical_id":"go:GO:0032603","description":"\"The appearance of fractalkine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:12729461]","metadata":null},{"id":"9920f36f94494d678901b0f8a8d282e3","type":"GO_TERM","name":"fraxetin 5-hydroxylase activity","canonical_id":"go:GO:0106144","description":"\"Catalyzes the reaction fraxetin+ NAD(P)H + 02= sideretin + NAD(P)(+) + H20.\" [GOC:lr, PMID:29581584, RHEA:57844]","metadata":null},{"id":"b719b9ce464e4bc3861c2cd77d5540e4","type":"GO_TERM","name":"fraxetin biosynthesis","canonical_id":"go:GO:0106147","description":"\"The chemical reactions and pathways resulting in the formation of fraxetin.\" [GOC:lr, PMID:29581584]","metadata":null},{"id":"1aab042ed3f045d4aa9d03f2187616cd","type":"DISEASE","name":"freckles","canonical_id":"efo:0003963","description":null,"metadata":null},{"id":"0476909ae59646f8ab952dcb3024a007","type":"GO_TERM","name":"free fatty acid 2-hydroxylase activity","canonical_id":"go:GO:0120520","description":"\"Catalysis of the reaction: a 1,2-saturated fatty acid + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = a (R)-2-hydroxy fatty acid + 2 Fe(III)-[cytochrome b5] + H2O. Note that the substrate is a free fatty acid, not a fatty acyl chain within a sphingolipid.\" [GOC:sjm, RHEA:38855]","metadata":null},{"id":"3f88d12073a148cbb4fd349918bfa303","type":"GO_TERM","name":"free sarcoplasmic reticulum membrane","canonical_id":"go:GO:0014702","description":"\"The part of the sarcoplasmic reticulum membrane that contains calcium pumps and is devoted to calcium uptake. The free sarcoplasmic reticulum membrane consists of the longitudinal sarcoplasmic reticulum membrane and the non-junctional region of the terminal cisterna membrane.\" [GOC:mtg_muscle]","metadata":null},{"id":"c77e043172c8455dbef651295f4c6c53","type":"GO_TERM","name":"free ubiquitin chain depolymerization","canonical_id":"go:GO:0010995","description":"\"The process in which free ubiquitin chains, compounds composed of a large number of ubiquitin monomers, are broken down.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"338fe2018f414ffcbb5e191366dbd93e","type":"GO_TERM","name":"free ubiquitin chain polymerization","canonical_id":"go:GO:0010994","description":"\"The process of creating free ubiquitin chains, compounds composed of a large number of ubiquitin monomers. These chains are not conjugated to a protein.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"b91eab051c7b42a0a11e6435aaa2937e","type":"DRUG","name":"fremanezumab","canonical_id":"gtopdb:9208","description":null,"metadata":null},{"id":"9e7f3867a1424c4cbaf4f8a903c67fce","type":"DRUG","name":"fremanezumab","canonical_id":"chembl:CHEMBL4297756","description":null,"metadata":null},{"id":"c9ed12ae16174cc8ba8d669785060280","type":"GO_TERM","name":"frizzled binding","canonical_id":"go:GO:0005109","description":"\"Binding to a frizzled (fz) receptor.\" [GOC:ceb]","metadata":null},{"id":"ce2aab80600546a693e8d59b1b4c75ee","type":"GO_TERM","name":"frontal suture morphogenesis","canonical_id":"go:GO:0060364","description":"\"The process in which the frontal suture is generated and organized.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"e7ac7483d3214f93aecdc4e18009ff5a","type":"GO_TERM","name":"frontonasal suture morphogenesis","canonical_id":"go:GO:0097095","description":"\"The process in which the frontonasal suture, between frontal and nasal bones, is generated and organized.\" [GOC:pr, GOC:sl, PMID:12416537, Wikipedia:Cranial_sutures, Wikipedia:Head_and_neck_anatomy#Musculoskeletal_system]","metadata":null},{"id":"33dcfc7a0a93437eb4165eeba695594c","type":"DISEASE","name":"frontotemporal dementia with motor neuron disease","canonical_id":"mondo:0017161","description":null,"metadata":null},{"id":"db535fb24b814bd9877cd35c13108af8","type":"DRUG","name":"frovatriptan","canonical_id":"gtopdb:7191","description":null,"metadata":null},{"id":"2f02a4ad853249d7ae7fd6f727291f30","type":"DRUG","name":"frovatriptan","canonical_id":"mesh:C108128","description":null,"metadata":null},{"id":"f2b83f7560904630b9a3e94baf212759","type":"DISEASE","name":"frozen shoulder","canonical_id":"mondo:0006763","description":null,"metadata":null},{"id":"17b99a947941449b99fcb126c7717f95","type":"GO_TERM","name":"fructan beta-(2,1)-fructosidase activity","canonical_id":"go:GO:0033948","description":"\"Catalysis of the hydrolysis of terminal, non-reducing (2->1) linked beta-D-fructofuranose residues in fructans.\" [EC:3.2.1.153]","metadata":null},{"id":"3a68e5dc29694c8e8b35a601be4f8815","type":"GO_TERM","name":"fructan beta-(2,6)-fructosidase activity","canonical_id":"go:GO:0033949","description":"\"Catalysis of the hydrolysis of terminal, non-reducing (2->6) linked beta-D-fructofuranose residues in fructans.\" [EC:3.2.1.154]","metadata":null},{"id":"e77797dac000446b84885b0f8d707840","type":"GO_TERM","name":"fructan beta-fructosidase activity","canonical_id":"go:GO:0051669","description":"\"Catalysis of the hydrolysis of terminal, non-reducing 2,1- and 2,6-linked beta-D-fructofuranose residues in fructans.\" [EC:3.2.1.80]","metadata":null},{"id":"0d889434ed5044c2b2d287b556f65202","type":"GO_TERM","name":"fructan biosynthetic process","canonical_id":"go:GO:0010146","description":"\"The chemical reactions and pathways resulting in the formation of fructan a polysaccharide consisting of fructose residues.\" [GOC:pz]","metadata":null},{"id":"b5abd8f404a04040853b1a404e912a91","type":"GO_TERM","name":"fructan catabolic process","canonical_id":"go:GO:0010147","description":"\"The chemical reactions and pathways resulting in the breakdown of fructan, a polysaccharide consisting of fructose residues.\" [GOC:pz]","metadata":null},{"id":"f21308215b1446e6826c745e939f0640","type":"GO_TERM","name":"fructokinase activity","canonical_id":"go:GO:0008865","description":"\"Catalysis of the reaction: ATP + D-fructose = ADP + D-fructose 6-phosphate.\" [EC:2.7.1.4]","metadata":null},{"id":"ed6f30be10ca4b0eb20f04cbd526646a","type":"GO_TERM","name":"fructosamine biosynthetic process","canonical_id":"go:GO:0030391","description":"\"The chemical reactions and pathways resulting in the formation of fructosamine, a fructose molecule containing an amino group in place of a hydroxyl group.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"f9a4097a69514708b021e650d919f4ff","type":"GO_TERM","name":"fructosamine catabolic process","canonical_id":"go:GO:0030392","description":"\"The chemical reactions and pathways resulting in the breakdown of fructosamine, a fructose molecule containing an amino group in place of a hydroxyl group.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"facddf08625542cfab0308029034f563","type":"GO_TERM","name":"fructosamine metabolic process","canonical_id":"go:GO:0030389","description":"\"The chemical reactions and pathways involving fructosamine, a fructose molecule containing an amino group in place of a hydroxyl group.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"a01c420d0fd644d3959071cf7480e3d0","type":"GO_TERM","name":"fructose 1,6-bisphosphate 1-phosphatase activity","canonical_id":"go:GO:0042132","description":"\"Catalysis of the reaction: D-fructose 1,6-bisphosphate + H2O = D-fructose 6-phosphate + phosphate.\" [EC:3.1.3.11]","metadata":null},{"id":"ce0db0330377426f940627a1478f1410","type":"GO_TERM","name":"fructose 1,6-bisphosphate metabolic process","canonical_id":"go:GO:0030388","description":"\"The chemical reactions and pathways involving fructose 1,6-bisphosphate, also known as FBP. The D enantiomer is a metabolic intermediate in glycolysis and gluconeogenesis.\" [ISBN:0198506732]","metadata":null},{"id":"25ce781677a149bebbf6f116f396cb03","type":"GO_TERM","name":"fructose 2,6-bisphosphate metabolic process","canonical_id":"go:GO:0006003","description":"\"The chemical reactions and pathways involving fructose 2,6-bisphosphate. The D enantiomer is an important regulator of the glycolytic and gluconeogenic pathways. It inhibits fructose 1,6-bisphosphatase and activates phosphofructokinase.\" [ISBN:0198506732]","metadata":null},{"id":"e76439ad44a248c883254cec95a6457c","type":"GO_TERM","name":"fructose 5-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047903","description":"\"Catalysis of the reaction: D-fructose + NADP+ = 5-dehydro-D-fructose + NADPH.\" [EC:1.1.1.124, MetaCyc:FRUCTOSE-5-DEHYDROGENASE-NADP+-RXN]","metadata":null},{"id":"0791f7b823b2486799656d4ccabac55a","type":"GO_TERM","name":"fructose 5-dehydrogenase activity","canonical_id":"go:GO:0047904","description":"\"Catalysis of the reaction: a ubiquinone + keto-D-fructose = 5-dehydro-D-fructose + a ubiquinol.\" [RHEA:22304]","metadata":null},{"id":"597a7328f21a4642aaa8d6839e2ef8f9","type":"GO_TERM","name":"fructose 6-phosphate aldolase activity","canonical_id":"go:GO:0097023","description":"\"Catalysis of the reaction: D-fructose-6-phosphate = dihydroxyacetone + D-glyceraldehyde-3-phosphate.\" [GOC:imk, PMID:11120740, PMID:21290439]","metadata":null},{"id":"1e843804d41746dbb0e9e5904f757e48","type":"GO_TERM","name":"fructose 6-phosphate metabolic process","canonical_id":"go:GO:0006002","description":"\"The chemical reactions and pathways involving fructose 6-phosphate, also known as F6P. The D-enantiomer is an important intermediate in glycolysis, gluconeogenesis, and fructose metabolism.\" [ISBN:0198506732]","metadata":null},{"id":"14697304f4804c63af208445989ed6d6","type":"GO_TERM","name":"fructose binding","canonical_id":"go:GO:0070061","description":"\"Binding to the D- or L-enantiomer of fructose, the ketohexose arabino-hex-2-ulose.\" [CHEBI:28757, GOC:BHF, GOC:mah]","metadata":null},{"id":"173e8fd225f0424eb898e2129ee40164","type":"GO_TERM","name":"fructose biosynthetic process","canonical_id":"go:GO:0046370","description":"\"The chemical reactions and pathways resulting in the formation of fructose, the ketohexose arabino-2-hexulose.\" [GOC:ai]","metadata":null},{"id":"e8f4ea9c15ed4fcc8681592ef3fbbb24","type":"GO_TERM","name":"fructose catabolic process","canonical_id":"go:GO:0006001","description":"\"The chemical reactions and pathways resulting in the breakdown of fructose, the ketohexose arabino-2-hexulose.\" [GOC:ai]","metadata":null},{"id":"7b475b1820794f50ac7fd48e77153598","type":"GO_TERM","name":"fructose export from vacuole to cytoplasm","canonical_id":"go:GO:1902334","description":"\"The directed movement of fructose from vacuole to cytoplasm.\" [GOC:TermGenie, PMID:23583552]","metadata":null},{"id":"a8251057cb78475da41980c5bfef2bb2","type":"GO_TERM","name":"fructose import across plasma membrane","canonical_id":"go:GO:1990539","description":"\"The directed movement of fructose substance from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:10735857]","metadata":null},{"id":"5d542aac62f24e20907de8b1a3b19388","type":"GO_TERM","name":"fructose metabolic process","canonical_id":"go:GO:0006000","description":"\"The chemical reactions and pathways involving fructose, the ketohexose arabino-2-hexulose. Fructose exists in a open chain form or as a ring compound. D-fructose is the sweetest of the sugars and is found free in a large number of fruits and honey.\" [ISBN:0198506732]","metadata":null},{"id":"aac0af3875284496b9f5f1eefbc74c50","type":"GO_TERM","name":"fructose transmembrane transport","canonical_id":"go:GO:0015755","description":"\"The directed movement of fructose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fructose exists in a open chain form or as a ring compound. D-fructose is the sweetest of the sugars and is found free in a large number of fruits and honey.\" [GOC:ai]","metadata":null},{"id":"3c039ce97ff04f4d97a1865701d3cf09","type":"GO_TERM","name":"fructose transmembrane transporter activity","canonical_id":"go:GO:0005353","description":"\"Enables the transfer of fructose from one side of a membrane to the other. Fructose exists in a open chain form or as a ring compound. D-fructose is the sweetest of the sugars and is found free in a large number of fruits and honey.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"28ba73a79fd444e49b030d003cbf202a","type":"GO_TERM","name":"fructose uniporter activity","canonical_id":"go:GO:0015284","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: fructose(out) = fructose(in).\" [TC:2.A.1.1.13]","metadata":null},{"id":"314d86e0f3094378a9b06849a64b3459","type":"GO_TERM","name":"fructose-1-phosphatase activity","canonical_id":"go:GO:0103026","description":"\"Catalysis of the reaction: beta-D-fructose 1-phosphate + H2O = D-fructose + phosphate.\" [RHEA:35603]","metadata":null},{"id":"98d481ea54b54a95a002bb137d91969b","type":"GO_TERM","name":"fructose-1-phosphate aldolase activity","canonical_id":"go:GO:0061609","description":"\"Catalysis of the reaction: beta-D-fructose-1-phosphate = D-glyceraldehyde + dihydroxyacetone phosphate.\" [GOC:dph, GOC:glycolysis, ISBN:0201090910, RHEA:30851]","metadata":null},{"id":"de19b4f352df4c088f532ad7f08f93ba","type":"GO_TERM","name":"fructose-2,6-bisphosphate 2-phosphatase activity","canonical_id":"go:GO:0004331","description":"\"Catalysis of the reaction: D-fructose 2,6-bisphosphate + H2O = D-fructose-6-phosphate + phosphate.\" [EC:3.1.3.46]","metadata":null},{"id":"6f9a8547652d408e8cb7cb42e4202341","type":"GO_TERM","name":"fructose-2,6-bisphosphate 6-phosphatase activity","canonical_id":"go:GO:0047386","description":"\"Catalysis of the reaction: beta-D-fructose 2,6-bisphosphate + H2O = beta-D-fructofuranose 2-phosphate + phosphate.\" [EC:3.1.3.54, RHEA:13333]","metadata":null},{"id":"83a0a198725e41c2b298adf3671ea98d","type":"GO_TERM","name":"fructose-6-phosphate binding","canonical_id":"go:GO:0070095","description":"\"Binding to fructose 6-phosphate.\" [GOC:mah]","metadata":null},{"id":"fa7104ab65994b108c603dfc4c1d24aa","type":"GO_TERM","name":"fructose-6-phosphate phosphoketolase activity","canonical_id":"go:GO:0047905","description":"\"Catalysis of the reaction: D-fructose 6-phosphate + phosphate = acetyl phosphate + D-erythrose 4-phosphate + H2O.\" [EC:4.1.2.22, MetaCyc:FRUCTOSE-6-PHOSPHATE-PHOSPHOKETOLASE-RXN]","metadata":null},{"id":"e997f7b7424a4015bb2e2732c433184e","type":"GO_TERM","name":"fructose-bisphosphate aldolase activity","canonical_id":"go:GO:0004332","description":"\"Catalysis of the reaction: beta-D-fructose 1,6-bisphosphate = D-glyceraldehyde 3-phosphate + dihydroxyacetone phosphate.\" [EC:4.1.2.13]","metadata":null},{"id":"fe0f4ea71d9c4ea3ac1f3eadd165a881","type":"GO_TERM","name":"fructose:proton symporter activity","canonical_id":"go:GO:0055054","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: fructose + H+ = fructose + H+.\" [GOC:ct]","metadata":null},{"id":"ebb6c5148b02425690b7717a1361e118","type":"GO_TERM","name":"fructose:sodium symporter activity","canonical_id":"go:GO:0140930","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-fructose(out) + Na+(out) = D-fructose(in) + Na+(in).\" [PMID:22212718, PMID:23451068]","metadata":null},{"id":"f13f742fb1e64b55a46cd413afcbad29","type":"GO_TERM","name":"fructoselysine biosynthetic process","canonical_id":"go:GO:1901282","description":"\"The chemical reactions and pathways resulting in the formation of fructoselysine.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00784]","metadata":null},{"id":"a65a708734f641459504e0b79969f36a","type":"GO_TERM","name":"fructoselysine catabolic process","canonical_id":"go:GO:1901281","description":"\"The chemical reactions and pathways resulting in the breakdown of fructoselysine.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00784]","metadata":null},{"id":"9094985cc4164409bfbd7af12f5e46df","type":"GO_TERM","name":"fructoselysine metabolic process","canonical_id":"go:GO:0030393","description":"\"The chemical reactions and pathways involving fructoselysine, a fructose molecule containing a lysine group in place of a hydroxyl group.\" [GOC:ai]","metadata":null},{"id":"355beb16597c4ba3ade9e30da17f9a83","type":"GO_TERM","name":"fructosyl-amino acid oxidase activity","canonical_id":"go:GO:0051700","description":"\"Catalysis of the reaction: fructosyl-amino acid + O2 = corresponding amino acid + glucosone + H2O2.\" [PMID:16233628]","metadata":null},{"id":"c43c321e131f46269be6b3fafc9e72fb","type":"GO_TERM","name":"fructosyltransferase activity","canonical_id":"go:GO:0050738","description":"\"Catalysis of the transfer of a fructosyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [GOC:ai]","metadata":null},{"id":"208569008a2d489a967b24876fca2770","type":"GO_TERM","name":"fructuronate reductase activity","canonical_id":"go:GO:0008866","description":"\"Catalysis of the reaction: D-mannonate + NAD+ = D-fructuronate + H+ + NADH.\" [EC:1.1.1.57, RHEA:15729]","metadata":null},{"id":"62cb75425caf4acf942d81740b72086c","type":"GO_TERM","name":"fruit abscission","canonical_id":"go:GO:0060867","description":"\"The controlled shedding of a fruit.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"b4e7726faf554be897e38579e4c2265b","type":"GO_TERM","name":"fruit dehiscence","canonical_id":"go:GO:0010047","description":"\"The process leading to the spontaneous opening of the fruit permitting the escape of seeds.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"7d34336ad67f4dff98340ffbad5e356c","type":"GO_TERM","name":"fruit development","canonical_id":"go:GO:0010154","description":"\"The process whose specific outcome is the progression of the fruit over time, from its formation to the mature structure. The fruit is a reproductive body of a seed plant.\" [GOC:sm]","metadata":null},{"id":"b3adbb8b822147339fec03bf8559ebbc","type":"GO_TERM","name":"fruit morphogenesis","canonical_id":"go:GO:0048530","description":"\"The process in which the anatomical structures of a fruit are generated and organized. A fruit is a reproductive body of a seed plant.\" [GOC:sm]","metadata":null},{"id":"9859075f7bab416cb05fd5c0fd310934","type":"GO_TERM","name":"fruit replum development","canonical_id":"go:GO:1990058","description":"\"The process whose specific outcome is the progression of the fruit replum over time, from its formation to the mature structure. The fruit replum is a portion of fruit placenta tissue that divides a fruit into two or more chambers and develops from a replum.\" [PMID:23133401, PO:0025267]","metadata":null},{"id":"b066402c2218435f83ac55ea0168dbd6","type":"GO_TERM","name":"fruit ripening","canonical_id":"go:GO:0009835","description":"\"An developmental maturation process that has as participant a fruit. Ripening causes changes in one or more characteristics of a fruit (color, aroma, flavor, texture, hardness, cell wall structure) and may make it more attractive to animals and aid in seed dispersal.\" [GOC:lr]","metadata":null},{"id":"5c0e3b84d6a54368a44b518952a03ef4","type":"GO_TERM","name":"fruit ripening, climacteric","canonical_id":"go:GO:0009836","description":"\"A fruit ripening process that involves a burst of respiration and ethylene (ethene) evolution at the onset.\" [GOC:lr, ISBN:0521587840]","metadata":null},{"id":"8596fb33fc5e4b5a8026bf6e34158b9b","type":"GO_TERM","name":"fruit ripening, non-climacteric","canonical_id":"go:GO:0009837","description":"\"A fruit ripening process that does not involve a respiratory burst.\" [GOC:lr, ISBN:0521587840]","metadata":null},{"id":"34c7bb30e41f41d5853a8b5c184c0346","type":"GO_TERM","name":"fruit septum development","canonical_id":"go:GO:0080127","description":"\"The process whose specific outcome is the progression of the fruit septum over time, from its formation to the mature structure. The fruit septum is a thin partition or membrane that divides a cavity or a mass of tissue in the fruit.\" [GOC:dhl, PO:0005008]","metadata":null},{"id":"551c63a001554537ab833f92fd3dda61","type":"GO_TERM","name":"fruit valve development","canonical_id":"go:GO:1990059","description":"\"The process whose specific outcome is the progression of the fruit valve over time, from its formation to the mature structure. The fruit valve is a part of a fruit that splits apart when the fruit dehisces.\" [PMID:23133401, PO:0000033]","metadata":null},{"id":"a081aa1fbd5c46e1930e2333565e0c4b","type":"DRUG","name":"fruquintinib","canonical_id":"gtopdb:9428","description":null,"metadata":null},{"id":"25f9e27f29bc41bc9dcfab939494c82d","type":"DRUG","name":"fruquintinib","canonical_id":"chembl:CHEMBL4303214","description":null,"metadata":null},{"id":"c6f11a07a25a48c8832fbbbee7b14cfb","type":"COMBINATION_TREATMENT","name":"fruquintinib + iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-0dae4abec47a409f","description":null,"metadata":null},{"id":"81027e2a6e704a1787e44421d2727a4e","type":"COMBINATION_TREATMENT","name":"fruquintinib + raltitrexed","canonical_id":"ctgov_combo:ctgov-combo-665a00d221b609a6","description":null,"metadata":null},{"id":"6ce26738fbd14c6d8dd52bfb1aa50df5","type":"COMBINATION_TREATMENT","name":"fruquintinib + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-c91ff28443aef5b8","description":null,"metadata":null},{"id":"62554403dde34f67a42fa082b255f194","type":"COMBINATION_TREATMENT","name":"fruquintinib + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-0a03c4c3fd3db772","description":null,"metadata":null},{"id":"81de7a7c106d4895a5060ebca6f18897","type":"COMBINATION_TREATMENT","name":"fruquintinib + serplulimab","canonical_id":"ctgov_combo:ctgov-combo-72c57a120f41578a","description":null,"metadata":null},{"id":"f5481ae32b714892ba1e4d8f9ee344dc","type":"COMBINATION_TREATMENT","name":"fruquintinib + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-8de4953a492ff772","description":null,"metadata":null},{"id":"48e00cd95657498782939e69aeb16492","type":"COMBINATION_TREATMENT","name":"fruquintinib + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-e6a2ab1c0dba56f7","description":null,"metadata":null},{"id":"95f513824edc4ee18178309a93d18689","type":"COMBINATION_TREATMENT","name":"fruquintinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-a3d3f0a28a3f8514","description":null,"metadata":null},{"id":"3f7de3c9fd52482e84a4241d325fe1fb","type":"COMBINATION_TREATMENT","name":"fruquintinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-bac639d21612a065","description":null,"metadata":null},{"id":"748d87228b53431fb8732eed9b25384e","type":"COMBINATION_TREATMENT","name":"fruquintinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-31d48e59d1b34cae","description":null,"metadata":null},{"id":"7ea4bb0fd7be45ed93bf01e5f7442fb2","type":"COMBINATION_TREATMENT","name":"fruquintinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-e025dd3bbb920f12","description":null,"metadata":null},{"id":"f7df172ef0fb4e59828ca26a1fee8254","type":"GO_TERM","name":"fucoidanase activity","canonical_id":"go:GO:0033909","description":"\"Catalysis of the endohydrolysis of 1,2-alpha-L-fucoside linkages in fucoidan without release of sulfate.\" [PMID:11910806, PMID:6417453]","metadata":null},{"id":"806345dc8eea45bdbb2f9e5071a14b49","type":"GO_TERM","name":"fucokinase activity","canonical_id":"go:GO:0050201","description":"\"Catalysis of the reaction: L-fucose + ATP = beta-L-fucose 1-phosphate + ADP + 2 H+.\" [EC:2.7.1.52, RHEA:13241]","metadata":null},{"id":"013f55f01af84370a3267b6b5563ab69","type":"GO_TERM","name":"fucose binding","canonical_id":"go:GO:0042806","description":"\"Binding to fucose, the pentose 6-deoxygalactose.\" [ISBN:0582227089]","metadata":null},{"id":"3b4d5fb18dfa41c7b256b44b0e5a05ae","type":"GO_TERM","name":"fucose biosynthetic process","canonical_id":"go:GO:0042353","description":"\"The chemical reactions and pathways resulting in the formation of fucose (6-deoxygalactose).\" [GOC:jl]","metadata":null},{"id":"249b07e03ffa4fc8baba0050d1fc8e9c","type":"GO_TERM","name":"fucose metabolic process","canonical_id":"go:GO:0006004","description":"\"The chemical reactions and pathways involving fucose, or 6-deoxygalactose, which has two enantiomers, D-fucose and L-fucose.\" [ISBN:0198506732]","metadata":null},{"id":"8190dfdfbb374886845cbe4d9eb11273","type":"GO_TERM","name":"fucose transmembrane transport","canonical_id":"go:GO:0015756","description":"\"The process in which fucose is transported across a lipid bilayer, from one side of a membrane to the other. Fucose is 6-deoxygalactose and has two enantiomers, D-fucose and L-fucose.\" [GOC:ai]","metadata":null},{"id":"dc4db49e81084f28b2210950164a7721","type":"GO_TERM","name":"fucose transmembrane transporter activity","canonical_id":"go:GO:0015150","description":"\"Enables the transfer of fucose from one side of a membrane to the other. Fucose is 6-deoxygalactose and has two enantiomers, D-fucose and L-fucose.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ada62016e6844555bdefdeacb2724adc","type":"GO_TERM","name":"fucose-1-phosphate guanylyltransferase activity","canonical_id":"go:GO:0047341","description":"\"Catalysis of the reaction: beta-L-fucose 1-phosphate + GTP + H+ = diphosphate + GDP-beta-L-fucose.\" [RHEA:13549]","metadata":null},{"id":"84cd5cca595443e0b6d1a250b1364545","type":"GO_TERM","name":"fucose:proton symporter activity","canonical_id":"go:GO:0015535","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: fucose(out) + H+(out) = fucose(in) + H+(in).\" [TC:2.A.1.7.1]","metadata":null},{"id":"1ef34a16c68444129f6aa8e3f0750084","type":"GO_TERM","name":"fucosidase activity","canonical_id":"go:GO:0015928","description":"\"Catalysis of the hydrolysis of fucosyl compounds, substances containing a group derived from a cyclic form of fucose or a fucose derivative.\" [GOC:ai]","metadata":null},{"id":"e2cf02616b894a2e9219751d273b91db","type":"GO_TERM","name":"fucosterol-epoxide lyase activity","canonical_id":"go:GO:0047906","description":"\"Catalysis of the reaction: (24R,24'R)-fucosterol epoxide = acetaldehyde + desmosterol.\" [EC:4.1.2.33, RHEA:10884]","metadata":null},{"id":"13eee1a5ccb24743ab4eb4f511981fff","type":"GO_TERM","name":"fucosylgalactoside 3-alpha-galactosyltransferase activity","canonical_id":"go:GO:0004381","description":"\"Catalysis of the reaction: UDP-galactose + glycoprotein-alpha-L-fucosyl-(1,2)-D-galactose = UDP + glycoprotein-alpha-D-galactosyl-(1,3)-(alpha-L-fucosyl-(1,2))-D-galactose.\" [EC:2.4.1.37]","metadata":null},{"id":"6c787f52dad64e37a223752f5b119de1","type":"GO_TERM","name":"fucosyltransferase activity","canonical_id":"go:GO:0008417","description":"\"Catalysis of the transfer of a fucosyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [GOC:ai]","metadata":null},{"id":"4a5ee21d75b8418abb9ec64c640098c5","type":"DRUG","name":"fulvestrant","canonical_id":"gtopdb:1015","description":null,"metadata":null},{"id":"cf002ed755de4fdbb3545327c494ce31","type":"DRUG","name":"fulvestrant","canonical_id":"chembl:CHEMBL1358","description":null,"metadata":null},{"id":"a4e46522ff154093aa28d50175128284","type":"COMBINATION_TREATMENT","name":"fulvestrant + gedatolisib + palbociclib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-82a75f0a9659c237","description":null,"metadata":null},{"id":"48b1c7b9ccc8412a901a1f3de2220f13","type":"COMBINATION_TREATMENT","name":"fulvestrant + letrozole","canonical_id":"ctgov_combo:ctgov-combo-d957c4da3aec8774","description":null,"metadata":null},{"id":"63f6ed5cdcc349d1b97bce1b4df1fe61","type":"COMBINATION_TREATMENT","name":"fulvestrant + letrozole","canonical_id":"ctgov_combo:ctgov-combo-32e4091f02f71e3b","description":null,"metadata":null},{"id":"6f29e6d6e4274f3ca8ff723d19e88750","type":"COMBINATION_TREATMENT","name":"fulvestrant + letrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-9c6e502939571902","description":null,"metadata":null},{"id":"b31ce32dace44c05b5b4ad107ff5337a","type":"COMBINATION_TREATMENT","name":"fulvestrant + neratinib","canonical_id":"ctgov_combo:ctgov-combo-c1ef7077d6efff44","description":null,"metadata":null},{"id":"6d6c9a8d9caf4480bb6a15879ed696ba","type":"COMBINATION_TREATMENT","name":"fulvestrant + olaparib + palbociclib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-63c174dae1fc04d8","description":null,"metadata":null},{"id":"85132e23c9eb46b0a787d55b4199fb1a","type":"COMBINATION_TREATMENT","name":"fulvestrant + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-5e2b2df642cb2db6","description":null,"metadata":null},{"id":"b369c82aaec54514a63fca63e14be381","type":"COMBINATION_TREATMENT","name":"fulvestrant + palbociclib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-b0b0f57b86d3e805","description":null,"metadata":null},{"id":"665c13d9dbd246368a939f207f69b806","type":"COMBINATION_TREATMENT","name":"fulvestrant + palbociclib + sirolimus","canonical_id":"ctgov_combo:ctgov-combo-e198c19880e46f82","description":null,"metadata":null},{"id":"635dc62def364e5293b3be8631cc49de","type":"COMBINATION_TREATMENT","name":"fulvestrant + pertuzumab","canonical_id":"ctgov_combo:ctgov-combo-4540afb2a1619336","description":null,"metadata":null},{"id":"4c4e01c4cbf24c43b78ee94c5a933917","type":"COMBINATION_TREATMENT","name":"fulvestrant + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-37514c61aee5cf75","description":null,"metadata":null},{"id":"ab0a50c409d04484818ab988afc2bb3c","type":"COMBINATION_TREATMENT","name":"fulvestrant + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-99942cd0a6dbdb79","description":null,"metadata":null},{"id":"958d7a2336d1456487cfeb8bff06703c","type":"COMBINATION_TREATMENT","name":"fulvestrant + vandetanib","canonical_id":"ctgov_combo:ctgov-combo-ac0356001a4d1097","description":null,"metadata":null},{"id":"d92bd1eafe3946b09bc48d6c84acca72","type":"GO_TERM","name":"fumagillin biosynthetic process","canonical_id":"go:GO:1902086","description":"\"The chemical reactions and pathways resulting in the formation of fumagillin.\" [GOC:di, GOC:TermGenie, PMID:23488861]","metadata":null},{"id":"97465d0f5fd340219716cd1f4164860a","type":"GO_TERM","name":"fumagillin catabolic process","canonical_id":"go:GO:1902085","description":"\"The chemical reactions and pathways resulting in the breakdown of fumagillin.\" [GOC:di, GOC:TermGenie, PMID:23488861]","metadata":null},{"id":"44943334cdd847feb1537d321753b8e0","type":"GO_TERM","name":"fumarate hydratase activity","canonical_id":"go:GO:0004333","description":"\"Catalysis of the reaction: (S)-malate = fumarate + H2O.\" [EC:4.2.1.2, RHEA:12460]","metadata":null},{"id":"a56ea927ade0408ab112a81993a72812","type":"GO_TERM","name":"fumarate metabolic process","canonical_id":"go:GO:0006106","description":"\"The chemical reactions and pathways involving fumarate, the anion of trans-1,2-ethenedicarboxylic acid, the diastereoisomer of maleate. It is a key intermediate in metabolism and is formed in the TCA cycle from succinate and converted into malate.\" [ISBN:0198506732]","metadata":null},{"id":"ca7b88ab503a4b1f836705f3e048ff54","type":"GO_TERM","name":"fumarate reductase (NADH) activity","canonical_id":"go:GO:0016156","description":"\"Catalysis of the reaction: NAD+ + succinate = fumarate + H+ + NADH.\" [RHEA:18281]","metadata":null},{"id":"b1217b1a1df4422ab0908c95f0bf63db","type":"GO_TERM","name":"fumarate reductase complex","canonical_id":"go:GO:0045283","description":"\"A membrane-bound flavoenzyme complex consisting of four subunits, A, B, C, and D. A and B comprise the membrane-extrinsic catalytic domain and C (InterPro:IPR003510; InterPro:IPR004224) and D (InterPro:IPR003418) link the catalytic centers to the electron-transport chain. This family consists of the 13 kDa hydrophobic subunit D. This component may be required to anchor the catalytic components of the fumarate reductase complex to the cytoplasmic membrane. Fumarate reductase couples the reduction of fumarate to succinate to the oxidation of quinol to quinone, in a reaction opposite to that catalyzed by the related complex II of the respiratory chain (succinate dehydrogenase-(ubiquinone)).\" [InterPro:IPR003418, InterPro:IPR004224]","metadata":null},{"id":"e0eb3faeaa064389be9c3a9511be8cee","type":"GO_TERM","name":"fumarate transmembrane transporter activity","canonical_id":"go:GO:0015138","description":"\"Enables the transfer of fumarate from one side of a membrane to the other. Fumarate is a key intermediate in metabolism and is formed in the TCA cycle from succinate and converted into malate.\" [GOC:ai]","metadata":null},{"id":"cd5d34ebb6db431689b1b06dc4d1fbc5","type":"GO_TERM","name":"fumarate transport","canonical_id":"go:GO:0015741","description":"\"The directed movement of fumarate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"69468dec05d745c5b59c66797f57c04b","type":"GO_TERM","name":"fumarylacetoacetase activity","canonical_id":"go:GO:0004334","description":"\"Catalysis of the reaction: 4-fumarylacetoacetate + H2O = acetoacetate + fumarate + H+.\" [EC:3.7.1.2, RHEA:10244]","metadata":null},{"id":"494d2875ebfe4e4cb0c3dfb50b813f8f","type":"GO_TERM","name":"fumarylpyruvate hydrolase activity","canonical_id":"go:GO:0034545","description":"\"Catalysis of the reaction: fumarylpyruvate + H2O = fumarate + pyruvate + H+.\" [UM-BBD_reactionID:r0811]","metadata":null},{"id":"5b455fe99d7d439891f4b699d85a8eea","type":"GO_TERM","name":"fumigaclavine C biosynthetic process","canonical_id":"go:GO:1900809","description":"\"The chemical reactions and pathways resulting in the formation of fumigaclavine C, a fungal ergot alkaloid.\" [GOC:di, GOC:TermGenie, PMID:15933009, PMID:23435153, PMID:26972831]","metadata":null},{"id":"e12718d670214e7b904f3d62854c6708","type":"GO_TERM","name":"fumigermin biosynthetic process","canonical_id":"go:GO:0140446","description":"\"The chemical reactions and pathways resulting in the formation of fumigermin, an alpha-pyrone secondary metabolite found in some species of fungi such as Aspergillus fumigatus.\" [PMID:32083553]","metadata":null},{"id":"eff8958d0c9a444b933aed788dae8291","type":"GO_TERM","name":"fumiquinazoline C biosynthetic process","canonical_id":"go:GO:1900781","description":"\"The chemical reactions and pathways resulting in the formation of the indole alkaloid fumiquinazoline C.\" [GOC:di, GOC:TermGenie, PMID:20225828]","metadata":null},{"id":"f37d6c28595645dba98fd98877a42f07","type":"GO_TERM","name":"fumitremorgin B biosynthetic process","canonical_id":"go:GO:1900772","description":"\"The chemical reactions and pathways resulting in the formation of the indole alkaloid fumitremorgin B.\" [GOC:di, GOC:TermGenie, PMID:18683158]","metadata":null},{"id":"2c025a3ba24b4123835be46261a7a42c","type":"GO_TERM","name":"fumonisin biosynthetic process","canonical_id":"go:GO:1900541","description":"\"The chemical reactions and pathways resulting in the formation of fumonisin.\" [GOC:TermGenie]","metadata":null},{"id":"6990c127f6f4480b9995355390d23f37","type":"GO_TERM","name":"fumonisin catabolic process","canonical_id":"go:GO:1900540","description":"\"The chemical reactions and pathways resulting in the breakdown of fumonisin.\" [GOC:TermGenie]","metadata":null},{"id":"90b6ce75435e4e678b3c457ef67687af","type":"GO_TERM","name":"funalenone biosynthetic process","canonical_id":"go:GO:1901366","description":"\"The chemical reactions and pathways resulting in the formation of funalenone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ff67b2dd4d9f4a97a3f88ab46c1cc75d","type":"GO_TERM","name":"funalenone catabolic process","canonical_id":"go:GO:1901365","description":"\"The chemical reactions and pathways resulting in the breakdown of funalenone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"822448166d2c4cd3b69f256e0f88297e","type":"DISEASE","name":"functional neutrophil defect","canonical_id":"mondo:0015978","description":null,"metadata":null},{"id":"2bf5a71f0d064136b149025fb4dca434","type":"GO_TERM","name":"fungal biofilm matrix","canonical_id":"go:GO:0062040","description":"\"An extracellular matrix lying external to fungal cells. The fungal biofilm matrix consists of polysaccharides, proteins, lipids, and nucleic acids. Fungal biofilms mediate adherence to host tissues, and provide protection from host immune defenses.\" [GOC:BHF, PMID:27129222, PMID:28516088]","metadata":null},{"id":"200433a1bb4d4d8ca6e6a6680973672e","type":"GO_TERM","name":"fungal sorus development","canonical_id":"go:GO:0099121","description":"\"The process whose specific outcome is the progression of a fungal sorus over time, from its formation to the mature structure. A fungal sorus is a spore containing structure.\" [GOC:dos]","metadata":null},{"id":"b8efaca775f84c78adbdc859e921998b","type":"GO_TERM","name":"fungal-type cell wall","canonical_id":"go:GO:0009277","description":"\"A rigid yet dynamic structure surrounding the plasma membrane that affords protection from stresses and contributes to cell morphogenesis, consisting of extensively cross-linked glycoproteins and carbohydrates. The glycoproteins may be modified with N- or O-linked carbohydrates, or glycosylphosphatidylinositol (GPI) anchors; the polysaccharides are primarily branched glucans, including beta-linked and alpha-linked glucans, and may also include chitin and other carbohydrate polymers, but not cellulose or pectin. Enzymes involved in cell wall biosynthesis are also found in the cell wall. Note that some forms of fungi develop a capsule outside of the cell wall under certain circumstances; this is considered a separate structure.\" [GOC:mcc, GOC:mtg_sensu, ISBN:3540601864, PMID:11283274, PMID:16927300, PMID:3319422, PMID:36266346]","metadata":null},{"id":"48007e8821f44b4db25cd4cf1fa2b720","type":"GO_TERM","name":"fungal-type cell wall (1->3)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070600","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-alpha-D-glucans, compounds composed of glucose residues linked by (1->3)-alpha-D-glucosidic bonds, found in fungal-type cell walls, including those of ascospores.\" [GOC:mah]","metadata":null},{"id":"abe820f81f5d4e0d84906f31bf8582fe","type":"GO_TERM","name":"fungal-type cell wall (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0071970","description":"\"The chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in fungal cell walls.\" [GOC:mah]","metadata":null},{"id":"18f4338de4f54a3db28782326a491b0e","type":"GO_TERM","name":"fungal-type cell wall (1->3)-beta-D-glucan metabolic process","canonical_id":"go:GO:0071969","description":"\"The chemical reactions and pathways involving (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in the walls of fungi.\" [GOC:mah]","metadata":null},{"id":"179c65d9a4544c108949a8941d14245c","type":"GO_TERM","name":"fungal-type cell wall assembly","canonical_id":"go:GO:0071940","description":"\"The aggregation, arrangement and bonding together of a set of components to form a fungal-type cell wall.\" [GOC:mah, GOC:vw, PMID:19646873]","metadata":null},{"id":"7d6f92da7e9e4b3d86147e183e449c7c","type":"GO_TERM","name":"fungal-type cell wall beta-glucan biosynthetic process","canonical_id":"go:GO:0070880","description":"\"The chemical reactions and pathways resulting in the formation of beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of fungal cells.\" [GOC:mah]","metadata":null},{"id":"97dfe5c9f18f43ee9652f7930c3fcb6f","type":"GO_TERM","name":"fungal-type cell wall beta-glucan metabolic process","canonical_id":"go:GO:0070879","description":"\"The chemical reactions and pathways involving beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of fungal cells.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"72f1cd0cd9a04aa2ae74a5e977e522db","type":"GO_TERM","name":"fungal-type cell wall biogenesis","canonical_id":"go:GO:0009272","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a fungal-type cell wall. The fungal-type cell wall contains beta-glucan and may contain chitin.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"fdcde7c265cd4ed9a74db55bab6aa2ce","type":"GO_TERM","name":"fungal-type cell wall disassembly","canonical_id":"go:GO:0071853","description":"\"A cellular process that results in the breakdown of a fungal-type cell wall.\" [GOC:mah]","metadata":null},{"id":"da069770e23d45618ec919496ea03e9c","type":"GO_TERM","name":"fungal-type cell wall organization","canonical_id":"go:GO:0031505","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the fungal-type cell wall.\" [GOC:dph, GOC:jl, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"6c152bcf175a4dffbd7401144d0147fc","type":"GO_TERM","name":"fungal-type cell wall organization or biogenesis","canonical_id":"go:GO:0071852","description":"\"A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a fungal-type cell wall.\" [GOC:mah]","metadata":null},{"id":"7decd58deaff4549af1964ab6bb2c958","type":"GO_TERM","name":"fungal-type cell wall polysaccharide biosynthetic process","canonical_id":"go:GO:0051278","description":"\"The chemical reactions and pathways resulting in the formation of the polysaccharides which make up the fungal-type cell wall.\" [GOC:ai, GOC:mtg_sensu]","metadata":null},{"id":"c0d564d312114c5d91647b7c55fd383b","type":"GO_TERM","name":"fungal-type cell wall polysaccharide metabolic process","canonical_id":"go:GO:0071966","description":"\"The chemical reactions and pathways involving the polysaccharides which make up the fungal-type cell wall.\" [GOC:mah]","metadata":null},{"id":"07052cd929a54e82ab13d8b748ffb82f","type":"GO_TERM","name":"fungal-type vacuole","canonical_id":"go:GO:0000324","description":"\"A vacuole that has both lytic and storage functions. The fungal vacuole is a large, membrane-bounded organelle that functions as a reservoir for the storage of small molecules (including polyphosphate, amino acids, several divalent cations (e.g. calcium), other ions, and other small molecules) as well as being the primary compartment for degradation. It is an acidic compartment, containing an ensemble of acid hydrolases. At least in S. cerevisiae, there are indications that the morphology of the vacuole is variable and correlated with the cell cycle, with logarithmically growing cells having a multilobed, reticulated vacuole, while stationary phase cells contain a single large structure.\" [GOC:mah, GOC:mtg_sensu, ISBN:0879693649]","metadata":null},{"id":"d5c71ad484db45e99b9faf4e0ae2b3a1","type":"GO_TERM","name":"fungal-type vacuole lumen","canonical_id":"go:GO:0000328","description":"\"The volume enclosed within the vacuolar membrane of a vacuole, the shape of which correlates with cell cycle phase. An example of this structure is found in Saccharomyces cerevisiae.\" [GOC:krc, GOC:mtg_sensu]","metadata":null},{"id":"6e48890d8f3e4bdda5abc947695fcfa3","type":"GO_TERM","name":"fungal-type vacuole membrane","canonical_id":"go:GO:0000329","description":"\"The lipid bilayer surrounding a vacuole, the shape of which correlates with cell cycle phase. The membrane separates its contents from the cytoplasm of the cell. An example of this structure is found in Saccharomyces cerevisiae.\" [GOC:krc, GOC:mtg_sensu]","metadata":null},{"id":"85b29492e8a8462ab5812edd6f490339","type":"GO_TERM","name":"fungiform papilla development","canonical_id":"go:GO:0061196","description":"\"The progression of the fungiform papilla over time, from its formation to the mature structure. The fungiform papilla is a mushroom-shaped papilla of the tongue.\" [GOC:dph]","metadata":null},{"id":"2ff683bc4b6c472dbb9e27dc996fc1e6","type":"GO_TERM","name":"fungiform papilla formation","canonical_id":"go:GO:0061198","description":"\"The developmental process pertaining to the initial formation of a spongiform papilla from unspecified parts. The fungiform papilla is a mushroom-shaped papilla of the tongue.\" [GOC:dph]","metadata":null},{"id":"e66b066f759346ae9fd46820e6c7119e","type":"GO_TERM","name":"fungiform papilla morphogenesis","canonical_id":"go:GO:0061197","description":"\"The process in which the anatomical structures of the fungiform papilla are generated and organized. The fungiform papilla is a mushroom-shaped papilla of the tongue.\" [GOC:dph]","metadata":null},{"id":"f07b6905c78e4f078e134bbdc3885096","type":"GO_TERM","name":"furaldehyde metabolic process","canonical_id":"go:GO:0033859","description":"\"The chemical reactions and pathways involving furaldehyde, a furan ring-containing aldehyde compound which can be formed from the thermal decomposition of biomass.\" [GOC:jp, PMID:15338422, PMID:16652391]","metadata":null},{"id":"f0a1a1c639684f10b0ecef5f55366765","type":"GO_TERM","name":"furaneol oxidoreductase activity","canonical_id":"go:GO:0102978","description":"\"Catalysis of the reaction: 4-hydroxy-2,5-dimethylfuran-3-one + NADP = 4-hydroxy-5-methyl-2-methylenefuran-3-one + NADPH + H+.\" [EC:1.3.1.105, GOC:pz]","metadata":null},{"id":"7466d74bbb5b4fa3b5e9d32a7a43ad01","type":"DRUG","name":"furosemide","canonical_id":"gtopdb:4839","description":null,"metadata":null},{"id":"2beff91b29a642fa891e02ec70406ba1","type":"DRUG","name":"furosemide","canonical_id":"mesh:D005665","description":null,"metadata":null},{"id":"7e5865396c344be287c562fdab38340a","type":"DRUG","name":"furosemide","canonical_id":"chembl:CHEMBL35","description":null,"metadata":null},{"id":"46212500f51c41d99e0f7e6b453ef86b","type":"COMBINATION_TREATMENT","name":"furosemide + losartan + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-da7a0eb9950452a1","description":null,"metadata":null},{"id":"84cb76aa8cdf40afaa2a77d307033712","type":"COMBINATION_TREATMENT","name":"furosemide + metolazone","canonical_id":"ctgov_combo:ctgov-combo-f229d7a70fcaadb0","description":null,"metadata":null},{"id":"d341913469e04274b7e84aed4f091810","type":"COMBINATION_TREATMENT","name":"furosemide + metolazone + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-689432ec14293dd3","description":null,"metadata":null},{"id":"caf823763e3840f1b0f5e0e9114e4675","type":"COMBINATION_TREATMENT","name":"furosemide + ribavirin + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-ad8246f91e068ba5","description":null,"metadata":null},{"id":"863119b0feed4b5eb1c3110c814a257f","type":"COMBINATION_TREATMENT","name":"furosemide + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-6f7a940e88fc1f22","description":null,"metadata":null},{"id":"c65197252ddc477cbf310fb09e12c3b7","type":"COMBINATION_TREATMENT","name":"furosemide + spironolactone","canonical_id":"ctgov_combo:ctgov-combo-4621d543a5ec5365","description":null,"metadata":null},{"id":"f5945b154f9947548f553df3b0db9319","type":"COMBINATION_TREATMENT","name":"furosemide + tolvaptan","canonical_id":"ctgov_combo:ctgov-combo-3334b1fc844e38ea","description":null,"metadata":null},{"id":"660b1b9700cc4a46ab99222691c5b330","type":"GO_TERM","name":"furylfuramide isomerase activity","canonical_id":"go:GO:0047907","description":"\"Catalysis of the reaction: (E)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide = (Z)-2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide.\" [EC:5.2.1.6, RHEA:21848]","metadata":null},{"id":"b2900fd652e740019e427b965e15aff3","type":"GO_TERM","name":"fusarinine-C ornithinesterase activity","canonical_id":"go:GO:0047908","description":"\"Catalysis of the reaction: N5-acyl-L-ornithine ester + H2O = N5-acyl-L-ornithine + an alcohol.\" [EC:3.1.1.48, MetaCyc:FUSARININE-C-ORNITHINESTERASE-RXN]","metadata":null},{"id":"1380d913933248aa848dc604fe61a002","type":"GO_TERM","name":"fused antrum stage","canonical_id":"go:GO:0048165","description":"\"The stage in oogenesis when the antral spaces fuse to form a single antral space. The oocyte is suspended in the cumulus oophorous and the first polar body in the perivitelline space.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"0baa0091202b4983a65729f563cd4961","type":"DRUG","name":"fusidic acid","canonical_id":"mesh:D005672","description":null,"metadata":null},{"id":"8aeae499ba2c4795bb06a34f5dae7435","type":"GO_TERM","name":"fusiform vesicle","canonical_id":"go:GO:0120002","description":"\"A cytoplasmic vesicle which contains two urothelial plaques and can deliver these plaques to the apical plasma membrane of urothelial superficial (umbrella) cells. It can also be formed by endocytosis of apical plasma membrane during contractions of the urinary bladder.\" [GOC:krc, PMID:21468280, PMID:21887288]","metadata":null},{"id":"134a95c7a8944c4fab76aba5530c8eaf","type":"GO_TERM","name":"fusion cell fate specification","canonical_id":"go:GO:0035156","description":"\"The process in which a cell becomes capable of differentiating autonomously into a fusion cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. Fusion cells allow the interconnection of adjacent tracheal metameres during tracheal tube fusion.\" [PMID:11063940]","metadata":null},{"id":"6df8fd5ec5c146e4b8afaf4e6014da9a","type":"GO_TERM","name":"fusion of sperm to egg plasma membrane involved in double fertilization forming a zygote and endosperm","canonical_id":"go:GO:0061936","description":"\"The binding and fusion of a sperm, with the plasma membrane of the oocyte as part of the process of double fertilization forming a zygote and endosperm.\" [PMID:21123745]","metadata":null},{"id":"7ce613bc40a947829888b9c1bd7a2abf","type":"GO_TERM","name":"fusion of sperm to egg plasma membrane involved in single fertilization","canonical_id":"go:GO:0007342","description":"\"The binding and fusion of a sperm, with the plasma membrane of the oocyte as part of the process of single fertilization. In sperm with flagella, binding occurs at the posterior (post-acrosomal) region of the sperm head.\" [GOC:dph, GOC:jl, PMID:17644969]","metadata":null},{"id":"9735732bc92c4ba38cae344b1642d6ad","type":"GO_TERM","name":"fusion of viral membrane with host outer nuclear membrane","canonical_id":"go:GO:0039700","description":"\"Fusion of a viral primary envelope with the host outer nuclear membrane during nuclear egress. The transitory primary envelope is acquired by the virus as it buds at the inner nuclear membrane and gains access to the perinuclear space. This membrane is lost by fusing with the host outer nuclear membrane during nuclear exit.\" [PMID:23057731, UniProtKB-KW:KW-1181]","metadata":null},{"id":"3dba43eeffd24454ada6c77fef1b4cb6","type":"GO_TERM","name":"fusion of virus membrane with host endosome membrane","canonical_id":"go:GO:0039654","description":"\"Fusion of a virus membrane with a host endosome membrane. Occurs after internalization of the virus through the endosomal pathway, and results in release of the virus contents into the cell.\" [GOC:bf, UniProtKB-KW:KW-1170, VZ:992]","metadata":null},{"id":"9f2f2593871b4ec3915cd7a7b09549d2","type":"GO_TERM","name":"fusion of virus membrane with host macropinosome membrane","canonical_id":"go:GO:0075503","description":"\"Fusion of a viral membrane with a host macropinosome membrane, that occurs after internalization of the virus through the endosomal pathway, and results in release of the viral contents into the host cell cytoplasm.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"8031f9bcb494497fa1399ff3b873b14d","type":"GO_TERM","name":"fusion of virus membrane with host outer membrane","canonical_id":"go:GO:0098997","description":"\"Fusion of a viral membrane with the host cell outer membrane during viral entry.\" [GOC:dos, VZ:3941]","metadata":null},{"id":"fcf9ea353bbb4ce69a4264fca9f84f8a","type":"GO_TERM","name":"fusion of virus membrane with host plasma membrane","canonical_id":"go:GO:0019064","description":"\"Fusion of a viral membrane with the host cell membrane during viral entry. Results in release of the virion contents into the cytoplasm.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"6ae8be9d65eb4e839e82a10cac57550f","type":"GO_TERM","name":"fusogenic activity","canonical_id":"go:GO:0140522","description":"\"The activity of joining two lipid bilayers to form a single membrane.\" [PMID:10332732, PMID:11493675, PMID:12600315, PMID:32100701, PMID:32641474]","metadata":null},{"id":"bf322b09c01445dea4dd4bb65d4790a6","type":"GO_TERM","name":"fusome","canonical_id":"go:GO:0045169","description":"\"A large intracellular spectrin-rich structure that has been found in insect germline cells and mammalian hematopoietic cells. The fusome is an elongated, branched structure, formed from the spherical spectrosome organelle.\" [GOC:bf, PMID:12655376]","metadata":null},{"id":"c864051d9b744beab785bf54d4c6d19a","type":"GO_TERM","name":"fusome organization","canonical_id":"go:GO:0045478","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the fusome, a large intracellular spectrin-rich structure found in insect germline cells and mammalian hematopoietic cells.\" [GOC:curators, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"0ae99652409b4671940d207d1dfa4ae9","type":"GO_TERM","name":"futile creatine cycle","canonical_id":"go:GO:0140651","description":"\"The phosphorylation and dephosphorylation of creatine in a futile cycle, which dissipates the high energy charge of phosphocreatine as heat without performing any mechanical or chemical work. The futile creatine cycle takes place in thermogenic fat cells and is part of adaptive thermogenesis.\" [PMID:33597756, PMID:33981039]","metadata":null},{"id":"2cff0ef32b2d4c219df6cb7351591fa4","type":"DRUG","name":"gabexate","canonical_id":"gtopdb:7863","description":null,"metadata":null},{"id":"9c68936ed53f4cc599daafea78dd63f1","type":"GO_TERM","name":"galactan 1,3-beta-galactosidase activity","canonical_id":"go:GO:0033943","description":"\"Catalysis of the hydrolysis of terminal, non-reducing beta-D-galactose residues in (1->3)-beta-D-galactopyranans.\" [EC:3.2.1.145]","metadata":null},{"id":"bb88fd01ba364aff93128ec725c32077","type":"GO_TERM","name":"galactarate O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047169","description":"\"Catalysis of the reaction: feruloyl-CoA + galactarate = 2-(E)-O-feruloyl-D-galactarate + CoA.\" [EC:2.3.1.130, RHEA:12997]","metadata":null},{"id":"6bf53d6ddd6946d996039b3584f6d21f","type":"GO_TERM","name":"galactarate dehydratase activity","canonical_id":"go:GO:0008867","description":"\"Catalysis of the reaction: galactarate = 5-dehydro-4-deoxy-D-glucarate + H2O.\" [EC:4.2.1.42, RHEA:16005]","metadata":null},{"id":"fc86d427485547b480bf13eea02188b7","type":"GO_TERM","name":"galactarate metabolic process","canonical_id":"go:GO:0019580","description":"\"The chemical reactions and pathways involving galactarate, an anion of galactaric acid, the meso-aldaric acid derived from both D- and L-galactose.\" [GOC:pr, ISBN:0198506732]","metadata":null},{"id":"343d19da0546490cb9963508cd394a2f","type":"GO_TERM","name":"galactarate transmembrane transport","canonical_id":"go:GO:1902300","description":"\"The process in which galactaric acid anion (galactarate) is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"073dfa7855934094bdd95db271dbd777","type":"GO_TERM","name":"galactarate transmembrane transporter activity","canonical_id":"go:GO:1902301","description":"\"Enables the transfer of galactaric acid anion (galactarate) from one side of a membrane to the other.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"4d152573ea1a4798a392e74cf76f8a84","type":"GO_TERM","name":"galactinol-raffinose galactosyltransferase activity","canonical_id":"go:GO:0047268","description":"\"Catalysis of the reaction: raffinose + 1-alpha-D-galactosyl-myo-inositol = stachyose + myo-inositol.\" [EC:2.4.1.67, MetaCyc:2.4.1.67-RXN]","metadata":null},{"id":"f152cfffdd214ac6926f40cef2c1f4c6","type":"GO_TERM","name":"galactinol-sucrose galactosyltransferase activity","canonical_id":"go:GO:0047274","description":"\"Catalysis of the reaction: sucrose + 1-alpha-D-galactosyl-myo-inositol = raffinose + myo-inositol.\" [EC:2.4.1.82, MetaCyc:2.4.1.82-RXN]","metadata":null},{"id":"1782430e9f91427d98ba7944e7eaae80","type":"GO_TERM","name":"galactitol 2-dehydrogenase activity","canonical_id":"go:GO:0047713","description":"\"Catalysis of the reaction: galactitol + NAD+ = D-tagatose + H+ + NADH.\" [RHEA:20685]","metadata":null},{"id":"3569b49bcdf849a0a0ad29f22987598a","type":"GO_TERM","name":"galactitol biosynthetic process","canonical_id":"go:GO:0019403","description":"\"The chemical reactions and pathways resulting in the formation of galactitol, the hexitol derived by the reduction of the aldehyde group of either D- or L-galactose.\" [ISBN:0198506732]","metadata":null},{"id":"6e28aa4a16e94940a476a84a364bd84c","type":"GO_TERM","name":"galactitol catabolic process","canonical_id":"go:GO:0019404","description":"\"The chemical reactions and pathways resulting in the breakdown of galactitol, the hexitol derived by the reduction of the aldehyde group of either D- or L-galactose.\" [ISBN:0198506732]","metadata":null},{"id":"52f0175d16984f6da7cb3ac1de185f02","type":"GO_TERM","name":"galactitol metabolic process","canonical_id":"go:GO:0019402","description":"\"The chemical reactions and pathways involving galactitol, the hexitol derived by the reduction of the aldehyde group of either D- or L-galactose.\" [ISBN:0198506732]","metadata":null},{"id":"668c1332d2944e16a69a2efd38236314","type":"GO_TERM","name":"galactitol transmembrane transport","canonical_id":"go:GO:0015796","description":"\"The directed movement of galactitol across a membrane. Galactitol is the hexitol derived by the reduction of the aldehyde group of either D- or L-galactose.\" [GOC:ai]","metadata":null},{"id":"aee1c63c268a4e618326f689d7a7aa66","type":"GO_TERM","name":"galactitol transmembrane transporter activity","canonical_id":"go:GO:0015577","description":"\"Enables the transfer of a galactitol from one side of a membrane to the other. Galactitol is the hexitol derived by the reduction of the aldehyde group of either D- or L-galactose.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"85b79ba8d7724525a94dfb2aed1713e7","type":"GO_TERM","name":"galactitol-1-phosphate 5-dehydrogenase activity","canonical_id":"go:GO:0008868","description":"\"Catalysis of the reaction: galactitol-1-phosphate + NAD+ = D-tagatose 6-phosphate + NADH + H+.\" [EC:1.1.1.251]","metadata":null},{"id":"95b587d9f2a247ee85ae2c3965293981","type":"GO_TERM","name":"galactogen 6-beta-galactosyltransferase activity","canonical_id":"go:GO:0047255","description":"\"Catalysis of the reaction: galactogen + UDP-galactose = 1,6-beta-D-galctosylgalactogen + UDP.\" [EC:2.4.1.205, MetaCyc:2.4.1.205-RXN]","metadata":null},{"id":"42fd2c6c61e84cf5990f325e90313f07","type":"GO_TERM","name":"galactoglucomannan catabolic process","canonical_id":"go:GO:2000885","description":"\"The chemical reactions and pathways resulting in the breakdown of a galactoglucomannan.\" [GOC:mengo_curators]","metadata":null},{"id":"87b6269333224079be56ff43f7dfe273","type":"GO_TERM","name":"galactoglucomannan metabolic process","canonical_id":"go:GO:0010392","description":"\"The chemical reactions and pathways involving galactoglucomannan, a polysaccharide composed of D-glucose, D-galactose and D-mannose. The mannose units form the backbone structure (a linear main chain) decorated with a mixture of D-glucose and D-galactose side-units.\" [GOC:tair_curators]","metadata":null},{"id":"274fa7044be042cdbe32523a24122e33","type":"GO_TERM","name":"galactokinase activity","canonical_id":"go:GO:0004335","description":"\"Catalysis of the reaction: D-galactose + ATP = alpha-D-galactose 1-phosphate + ADP + 2 H+.\" [EC:2.7.1.6, RHEA:13553]","metadata":null},{"id":"a95409924f1a41438708bf37d1ebac44","type":"GO_TERM","name":"galactolipase activity","canonical_id":"go:GO:0047714","description":"\"Catalysis of the reaction: a 1,2-diacyl-3-O-(beta-D-galactosyl)-sn-glycerol + 2 H2O = 3-beta-D-galactosyl-sn-glycerol + 2 a fatty acid + 2 H+.\" [RHEA:13189]","metadata":null},{"id":"c59621ec06814aabb3c6f2ed788bea83","type":"GO_TERM","name":"galactolipid O-acyltransferase activity","canonical_id":"go:GO:0047909","description":"\"Catalysis of the reaction: 2 mono-beta-D-galactosyldiacylglycerol = acylmono-beta-D-galactosyl-diacylglycerol + mono-beta-D-galactosylacylglycerol.\" [EC:2.3.1.134, MetaCyc:GALACTOLIPID-O-ACYLTRANSFERASE-RXN]","metadata":null},{"id":"a881e7c1f2e04d1493176f51f108df31","type":"GO_TERM","name":"galactolipid biosynthetic process","canonical_id":"go:GO:0019375","description":"\"The chemical reactions and pathways resulting in the formation of galactolipids, any glycolipid containing one of more residues of galactose and/or N-acetylgalactosamine.\" [ISBN:0198506732]","metadata":null},{"id":"4eae609244bf4f01b517b877b7398fa5","type":"GO_TERM","name":"galactolipid catabolic process","canonical_id":"go:GO:0019376","description":"\"The chemical reactions and pathways resulting in the breakdown of galactolipids, any glycolipid containing one of more residues of galactose and/or N-acetylgalactosamine.\" [ISBN:0198506732]","metadata":null},{"id":"beb44e8b0f534678af9cf1b880148fe4","type":"GO_TERM","name":"galactolipid galactosyltransferase activity","canonical_id":"go:GO:0046480","description":"\"Catalysis of the reaction: 2 mono-beta-D-galactosyldiacylglycerol = alpha-D-galactosyl-beta-D-galactosyldiacylglycerol + 1,2-diacylglycerol.\" [EC:2.4.1.184]","metadata":null},{"id":"261d60783f1a4fcfba18d3bcd0152eea","type":"GO_TERM","name":"galactolipid metabolic process","canonical_id":"go:GO:0019374","description":"\"The chemical reactions and pathways involving galactolipids, any glycolipid containing one of more residues of galactose and/or N-acetylgalactosamine.\" [ISBN:0198506732]","metadata":null},{"id":"83ce8c5e9e354f4ab828f485635c2555","type":"GO_TERM","name":"galactomannan binding","canonical_id":"go:GO:2001072","description":"\"Binding to galactomannan.\" [GOC:mengo_curators]","metadata":null},{"id":"63089429cba24c87877b22bc0463d74c","type":"GO_TERM","name":"galactomannan biosynthetic process","canonical_id":"go:GO:0051070","description":"\"The chemical reactions and pathways resulting in the formation of galactomannan, a polysaccharide composed of D-galactosyl and D-mannosyl. The mannosyl units form the backbone structure (a linear main chain) with the D-galactosyl as single side units.\" [GOC:ai]","metadata":null},{"id":"2f61e6c5694f4e6e92861fe72a6058d4","type":"GO_TERM","name":"galactomannan catabolic process","canonical_id":"go:GO:0051682","description":"\"The chemical reactions and pathways resulting in the breakdown of galactomannan, a polysaccharide composed of D-galactosyl and D-mannosyl. The mannosyl units form the backbone structure (a linear main chain) with the D-galactosyl as single side units.\" [GOC:ai]","metadata":null},{"id":"8a6d06a1572146959de9136885156b0b","type":"GO_TERM","name":"galactomannan metabolic process","canonical_id":"go:GO:0051069","description":"\"The chemical reactions and pathways involving galactomannan, a polysaccharide composed of D-galactose and D-mannose. The mannose units form the backbone structure (a linear main chain) with the D-galactose as single side units.\" [PMID:30701316, PMID:33012173]","metadata":null},{"id":"a9d6474e810649549c06fd867325bfb2","type":"GO_TERM","name":"galactonate dehydratase activity","canonical_id":"go:GO:0008869","description":"\"Catalysis of the reaction: D-galactonate = 2-dehydro-3-deoxy-D-galactonate + H2O.\" [EC:4.2.1.6, RHEA:18649]","metadata":null},{"id":"e6dab49aab2f4f0ca6b9052742f911ce","type":"GO_TERM","name":"galactonolactone dehydrogenase activity","canonical_id":"go:GO:0016633","description":"\"Catalysis of the reaction: L-galactono-1,4-lactone + 2 ferricytochrome c = L-ascorbate + 2 ferrocytochrome c.\" [EC:1.3.2.3]","metadata":null},{"id":"4cbc6bbb09a14261850fffc2cbe42977","type":"GO_TERM","name":"galactosamine transmembrane transporter activity","canonical_id":"go:GO:0019196","description":"\"Enables the transfer of galactosamine from one side of a membrane to the other. Galactosamine is an aminodeoxysugar; D-galactosamine is a constituent of some glycolipids and glycosaminoglycans, commonly as its N-acetyl derivative.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"1c3840f6b44348aa8379f2840a12adcf","type":"GO_TERM","name":"galactosamine-6-phosphate isomerase activity","canonical_id":"go:GO:0043877","description":"\"Catalysis of the reaction: D-galactosamine 6-phosphate + H2O = D-tagatose 6-phosphate + NH4+.\" [PMID:10931310]","metadata":null},{"id":"a44cfd6a12eb4f7ea5b1d3e582385dd2","type":"GO_TERM","name":"galactosaminogalactan biosynthetic process","canonical_id":"go:GO:0106218","description":"\"The chemical reactions and pathways resulting in the formation of the exopolysaccharide galactosaminogalactan. GAG is a heteropolysaccharide composed of alpha-1,4 linked galactose, N-acetyl galactosamine (GalNAc) and galactosamine (GalN).\" [PMID:173713, PMID:22102815, PMID:24257745, PMID:26492565, PMID:26932183, PMID:27048799, PMID:30667338]","metadata":null},{"id":"026a63c60d0b4945b632079876da5526","type":"GO_TERM","name":"galactose 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047910","description":"\"Catalysis of the reaction: D-galactose + NADP+ = D-galactonolactone + NADPH.\" [EC:1.1.1.120, MetaCyc:GALACTOSE-1-DEHYDROGENASE-NADP+-RXN]","metadata":null},{"id":"fc940a8206614671a2edad9a7de2bff6","type":"GO_TERM","name":"galactose 1-dehydrogenase activity","canonical_id":"go:GO:0019151","description":"\"Catalysis of the reaction: D-galactose + NAD+ = D-galactono-1,4-lactone + NADH + H+.\" [EC:1.1.1.48]","metadata":null},{"id":"7f40fb5040a642bda89bd480c97506ec","type":"GO_TERM","name":"galactose 3-O-sulfotransferase activity","canonical_id":"go:GO:0050694","description":"\"Catalysis of the reaction: N-acetyllactosamine + 3'-phosphoadenosine 5'-phosphosulfate = 3-sulfo-N-acetyllactosamine + adenosine 3',5'-bisphosphate. N-acetyllactosamine residues are found in a number of different carbohydrate types. N-acetyllactosamine can also be written as Gal-beta-(1,4)-GlcNAc.\" [GOC:ai, PMID:11323440, PMID:11356829]","metadata":null},{"id":"5b5c97b5070f45afb739d27f256ad5e6","type":"GO_TERM","name":"galactose binding","canonical_id":"go:GO:0005534","description":"\"Binding to aldohexose galactose (galacto-hexose), a common constituent of many oligo- and polysaccharides.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"497a119f63264089a4c27a3196b5adeb","type":"GO_TERM","name":"galactose biosynthetic process","canonical_id":"go:GO:0046369","description":"\"The chemical reactions and pathways resulting in the formation of galactose, the aldohexose galacto-hexose.\" [ISBN:0198506732]","metadata":null},{"id":"c841c6c9b2c94214bb479ace614dc589","type":"GO_TERM","name":"galactose catabolic process","canonical_id":"go:GO:0019388","description":"\"The chemical reactions and pathways resulting in the breakdown of galactose, the aldohexose galacto-hexose.\" [ISBN:0198506732]","metadata":null},{"id":"66d12029278145c89d6f24383c76e45f","type":"GO_TERM","name":"galactose catabolic process via D-galactonate","canonical_id":"go:GO:0033498","description":"\"The chemical reactions and pathways resulting in the breakdown of galactose, via the intermediate D-galactonate.\" [GOC:mah, MetaCyc:GALDEG-PWY]","metadata":null},{"id":"6691c53011b64f0ba30e774d21bd6508","type":"GO_TERM","name":"galactose import across plasma membrane","canonical_id":"go:GO:0140425","description":"\"The directed movement of galactose from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:21621292, PMID:23254763]","metadata":null},{"id":"bd565d8b5a85425eb98ceec7273f3c99","type":"GO_TERM","name":"galactose metabolic process","canonical_id":"go:GO:0006012","description":"\"The chemical reactions and pathways involving galactose, the aldohexose galacto-hexose. D-galactose is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides; it also occurs in galactolipids and as its glucoside in lactose and melibiose.\" [ISBN:0198506732]","metadata":null},{"id":"dab894c05db648c1817cfecb9e82361f","type":"GO_TERM","name":"galactose oxidase activity","canonical_id":"go:GO:0045480","description":"\"Catalysis of the reaction: D-galactose + O2 = D-galacto-hexodialdose + H2O2.\" [RHEA:24160]","metadata":null},{"id":"6ecf4b2e251b438586177b17a8c0c98b","type":"GO_TERM","name":"galactose transmembrane transport","canonical_id":"go:GO:0015757","description":"\"The process in which galactose is transported across a lipid bilayer, from one side of a membrane to the other. D-galactose is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides; it also occurs in galactolipids and as its glucoside in lactose and melibiose.\" [GOC:ai]","metadata":null},{"id":"b02bad37432b4a5584a44137468307db","type":"GO_TERM","name":"galactose transmembrane transporter activity","canonical_id":"go:GO:0005354","description":"\"Enables the transfer of galactose from one side of a membrane to the other. D-galactose is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides; it also occurs in galactolipids and as its glucoside in lactose and melibiose.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"5214272868984ecb88be5d50c5cd8f32","type":"GO_TERM","name":"galactose uniporter activity","canonical_id":"go:GO:0050782","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: galactose (out) = galactose(in).\" [GOC:ai, TC:2.A.1.1.6]","metadata":null},{"id":"b214da751fa344ed95b6f37fb95889d3","type":"GO_TERM","name":"galactose-1-phosphate phosphatase activity","canonical_id":"go:GO:0070456","description":"\"Catalysis of the reaction: galactose-1-phosphate + H2O = galactose + phosphate.\" [GOC:mah]","metadata":null},{"id":"96426b6d8b53496b82c6e6f5408f737b","type":"GO_TERM","name":"galactose-1-phosphate thymidylyltransferase activity","canonical_id":"go:GO:0047342","description":"\"Catalysis of the reaction: alpha-D-galactose 1-phosphate + dTTP = diphosphate + dTDP-D-galactose.\" [EC:2.7.7.32, RHEA:17165]","metadata":null},{"id":"b1486c5a3f1b4e2c83cb76d19f9bc1e9","type":"GO_TERM","name":"galactose-6-phosphate isomerase activity","canonical_id":"go:GO:0050044","description":"\"Catalysis of the reaction: D-galactose 6-phosphate = D-tagatose 6-phosphate.\" [EC:5.3.1.26, RHEA:13033]","metadata":null},{"id":"06b9d36a2c734f08bd603413991d8010","type":"GO_TERM","name":"galactose-6-sulfurylase activity","canonical_id":"go:GO:0033844","description":"\"Catalysis of the elimination of sulfate from the D-galactose 6-sulfate residues of porphyran, producing 3,6-anhydrogalactose residues.\" [EC:2.5.1.5]","metadata":null},{"id":"bdd97ff2877842d38fc08602536ef657","type":"GO_TERM","name":"galactose-specific flocculation","canonical_id":"go:GO:0036349","description":"\"The non-sexual aggregation of single-celled organisms mediated by the binding of cell wall proteins on one cell to galactose residues on the other.\" [GOC:vw, PMID:22098069]","metadata":null},{"id":"6f5c91451e9e4287902a522d1d667b3b","type":"GO_TERM","name":"galactose:proton symporter activity","canonical_id":"go:GO:0015517","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: galactose(out) + H+(out) = galactose(in) + H+(in).\" [TC:2.A.1.1.1, TC:2.A.1.1.9]","metadata":null},{"id":"7422ff6f495e4224871fca0c353e634b","type":"GO_TERM","name":"galactose:sodium symporter activity","canonical_id":"go:GO:0015371","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: galactose(out) + Na+(out) = glucose(in) + Na+(in).\" [TC:2.A.21.3.-]","metadata":null},{"id":"672cde6aee054ca79f0e84ac7c0edca1","type":"GO_TERM","name":"galactosidase activity","canonical_id":"go:GO:0015925","description":"\"Catalysis of the hydrolysis of galactosyl compounds, substances containing a group derived from a cyclic form of galactose or a galactose derivative.\" [GOC:ai]","metadata":null},{"id":"9d785693baf345f2807483b56eb45e90","type":"GO_TERM","name":"galactoside 2-alpha-L-fucosyltransferase activity","canonical_id":"go:GO:0008107","description":"\"Catalysis of the reaction: GDP-L-fucose + beta-D-galactosyl-R = GDP + alpha-L-fucosyl-(1,2)-beta-D-galactosyl-R.\" [EC:2.4.1.69, RHEA:50664]","metadata":null},{"id":"b674900a00ca44b09e6dfe4068f30248","type":"GO_TERM","name":"galactoside 6-L-fucosyltransferase activity","canonical_id":"go:GO:0046702","description":"\"Catalysis of the transfer of an L-fucosyl group from GDP-beta-L-fucose to a galactoside acceptor molecule, usually an N-glycan, to form an alpha(1,6)-fucosylated galactoside.\" [PMID:12413479]","metadata":null},{"id":"fd1c6b94ecd24a839f40c968826ebfbf","type":"GO_TERM","name":"galactoside O-acetyltransferase activity","canonical_id":"go:GO:0008870","description":"\"Catalysis of the reaction: acetyl-CoA + a beta-D-galactoside = CoA + a 6-acetyl-beta-D-galactoside.\" [EC:2.3.1.18]","metadata":null},{"id":"99629a41737e4b9f9c5f9b72ec04b314","type":"GO_TERM","name":"galactoside binding","canonical_id":"go:GO:0016936","description":"\"Binding to a glycoside in which the sugar group is galactose.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"4f5c436cdc554d62801043b8f32c98a2","type":"GO_TERM","name":"galactosyl beta-1,3 N-acetylgalactosamine beta-1,3-glucuronosyltransferase activity","canonical_id":"go:GO:0046989","description":"\"Catalysis of the transfer, in a beta 1,3 linkage, of D-glucuronic acid (GlcUA) from UDP-GlcUA to the disaccharide galactosyl beta-1,3 N-acetylgalactosamine, a common component of glycoproteins and glycolipids.\" [GOC:bf, PMID:12511570]","metadata":null},{"id":"f61e879d802d4768ab4d7b19e6cf3676","type":"GO_TERM","name":"galactosylacylglycerol O-acyltransferase activity","canonical_id":"go:GO:0047175","description":"\"Catalysis of the reaction: sn-3-D-galactosyl-sn-2-acylglycerol + acyl-[acyl-carrier protein] = D-galactosyldiacylglycerol + [acyl-carrier protein].\" [EC:2.3.1.141, MetaCyc:2.3.1.141-RXN]","metadata":null},{"id":"1ce40557975e461c8249048567b243de","type":"GO_TERM","name":"galactosylceramidase activity","canonical_id":"go:GO:0004336","description":"\"Catalysis of the reaction: D-galactosyl-N-acylsphingosine + H2O = D-galactose + N-acylsphingosine.\" [EC:3.2.1.46]","metadata":null},{"id":"3a011766e72b4153bfafe36608dce03b","type":"GO_TERM","name":"galactosylceramide biosynthetic process","canonical_id":"go:GO:0006682","description":"\"The chemical reactions and pathways resulting in the formation of galactosylceramides, any composed of a ceramide backbone covalently linked to a galactose. The galactose can be sulfated or further elongated with one more monosaccharide often a sialic acid.\" [PMID:34071409]","metadata":null},{"id":"da235876b31c4beaa45ab0f36515994c","type":"GO_TERM","name":"galactosylceramide catabolic process","canonical_id":"go:GO:0006683","description":"\"The chemical reactions and pathways resulting in the breakdown of galactosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of galactose by a ceramide group.\" [GOC:ai]","metadata":null},{"id":"11fe396a1750405190fe34e9094f01c1","type":"GO_TERM","name":"galactosylceramide metabolic process","canonical_id":"go:GO:0006681","description":"\"The chemical reactions and pathways involving galactosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of galactose by a ceramide group.\" [GOC:ai]","metadata":null},{"id":"4867840ba3f24b558031b778c1a39c87","type":"GO_TERM","name":"galactosylceramide sulfotransferase activity","canonical_id":"go:GO:0001733","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + a galactosylceramide = adenosine 3',5'-bisphosphate + a galactosylceramidesulfate.\" [EC:2.8.2.11, PMID:10727929, RHEA:20613]","metadata":null},{"id":"c02bcf4800df483da48509b009cd3e24","type":"GO_TERM","name":"galactosyldiacylglycerol alpha-2,3-sialyltransferase activity","canonical_id":"go:GO:0047289","description":"\"Catalysis of the reaction: 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol + CMP-N-acetyl-beta-neuraminate = 1,2-diacyl-3-[3-(alpha-D-N-acetylneuraminyl)-beta-D-galactosyl]-sn-glycerol + CMP + H+.\" [EC:2.4.3.5]","metadata":null},{"id":"c4305320a7094bc080bc63cce0c206f8","type":"GO_TERM","name":"galactosylgalactosylglucosylceramide beta-D-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0047273","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-galactosamine + alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide = UDP + beta-N-acetyl-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide.\" [EC:2.4.1.79]","metadata":null},{"id":"2a5476e9a76f442bbd21c3fafb04ef36","type":"GO_TERM","name":"galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity","canonical_id":"go:GO:0015018","description":"\"Catalysis of the reaction: 3-O-(beta-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-xylosyl)-L-seryl-[protein] + UDP-alpha-D-glucuronate = 3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + H+ + UDP.\" [EC:2.4.1.135]","metadata":null},{"id":"4fb73b26283849c5a223d0922f65a8b4","type":"GO_TERM","name":"galactosyltransferase activity","canonical_id":"go:GO:0008378","description":"\"Catalysis of the transfer of a galactosyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [ISBN:0198506732]","metadata":null},{"id":"cc98c59905f441feb392944cf4780218","type":"GO_TERM","name":"galactosylxylosylprotein 3-beta-galactosyltransferase activity","canonical_id":"go:GO:0047220","description":"\"Catalysis of the reaction: 4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP-galactose = 3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein + UDP.\" [EC:2.4.1.134, MetaCyc:2.4.1.134-RXN]","metadata":null},{"id":"41af9f85258c43358a3b981227e94444","type":"GO_TERM","name":"galactotriose transport","canonical_id":"go:GO:2001093","description":"\"The directed movement of a galactotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"4e5695734c4e4826be67af8f0052fbc7","type":"GO_TERM","name":"galactoxylomannan biosynthetic process","canonical_id":"go:GO:0062191","description":"\"The chemical reactions and pathways resulting in the formation of the exopolysaccharide galactoxylomannan. Galactoxylomannan is produced by a pathogenic fungus and causes paralysis in some animals.\" [PMID:16441437, PMID:18952901, PMID:19684080, PMID:21843086]","metadata":null},{"id":"7ed8910619574a73a5bdde3812913c98","type":"GO_TERM","name":"galacturan 1,4-alpha-galacturonidase activity","canonical_id":"go:GO:0047911","description":"\"Catalysis of the reaction: [(1->4)-alpha-D-galacturonide](n) + H2O = [(1->4)-alpha-D-galacturonide](n-1) + D-galacturonate.\" [EC:3.2.1.67, MetaCyc:GALACTURAN-14-ALPHA-GALACTURONIDASE-RXN]","metadata":null},{"id":"07a046c841da4cc696f8958afadfaf20","type":"GO_TERM","name":"galacturonan binding","canonical_id":"go:GO:0048028","description":"\"Binding to a simple or complex galacturonan. Galacturonan is any glycan composed solely of galacturonic acid residues, a specific type of glycuronan, and a constituent of some pectins.\" [GOC:jid]","metadata":null},{"id":"9cacdc7515d141eea4467453148665a7","type":"GO_TERM","name":"galacturonan metabolic process","canonical_id":"go:GO:0010393","description":"\"The chemical reactions and pathways involving galacturonan, a pectin polymer containing a backbone of alpha-(1->4)-linked D-galacturonic acid residues.\" [GOC:tair_curators]","metadata":null},{"id":"a9ad0d3f127f4168b87e3bae373d118e","type":"GO_TERM","name":"galacturonate binding","canonical_id":"go:GO:0048032","description":"\"Binding to a galacturonate. Galacturonate is the anion of galacturonic acid, the uronic acid formally derived from galactose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group.\" [GOC:jid]","metadata":null},{"id":"97865ef83ce246619d1f64f4f677035e","type":"GO_TERM","name":"galacturonate biosynthetic process","canonical_id":"go:GO:0033481","description":"\"The chemical reactions and pathways resulting in the formation of galacturonate, the anion of galacturonic acid.\" [GOC:mah]","metadata":null},{"id":"c39a2b3f98b445f7b76e0232abc24ae3","type":"GO_TERM","name":"galacturonate catabolic process","canonical_id":"go:GO:0046397","description":"\"The chemical reactions and pathways resulting in the breakdown of galacturonate, the anion of galacturonic acid.\" [GOC:ai]","metadata":null},{"id":"1bb4cbff29464f419d321fac01793320","type":"GO_TERM","name":"galacturonate transmembrane transport","canonical_id":"go:GO:0015737","description":"\"The process in which galacturonate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"fe221a48035b4d27b2bed85541804266","type":"GO_TERM","name":"galacturonate transmembrane transporter activity","canonical_id":"go:GO:0015550","description":"\"Enables the transfer of galacturonate from one side of a membrane to the other. Galacturonate is the uronic acid formally derived from galactose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group.\" [GOC:ai]","metadata":null},{"id":"970342de94d04a8d893a70a0b0b7df51","type":"GO_TERM","name":"galacturonokinase activity","canonical_id":"go:GO:0047912","description":"\"Catalysis of the reaction: alpha-D-galacturonate + ATP = 1-phospho-alpha-D-galacturonate + ADP + 2 H+.\" [EC:2.7.1.44, RHEA:12965]","metadata":null},{"id":"fc0f775176974a14ad4e6917c9da12f7","type":"GO_TERM","name":"galanin receptor activity","canonical_id":"go:GO:0004966","description":"\"Combining with galanin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"ebc45f3df39c4bed8d68eacfdb5a1155","type":"GO_TERM","name":"galanin receptor binding","canonical_id":"go:GO:0031763","description":"\"Binding to a galanin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e8d6f0080be14b4685bc02bd478f0b0c","type":"GO_TERM","name":"galanin-activated signaling pathway","canonical_id":"go:GO:0090663","description":"\"The series of molecular signals generated as a consequence of the peptide neurotransmitter galanin binding to a cell surface receptor.\" [GOC:lb, PMID:25691535]","metadata":null},{"id":"d6b62fc458324bd49604205e6673bb6e","type":"DRUG","name":"galantamine","canonical_id":"mesh:D005702","description":null,"metadata":null},{"id":"79fbe3468fea40d182182a00d6e36da4","type":"DRUG","name":"galcanezumab","canonical_id":"gtopdb:8967","description":null,"metadata":null},{"id":"290610c5bc6644089e6ad7f93f71db7e","type":"DRUG","name":"galcanezumab","canonical_id":"chembl:CHEMBL3707328","description":null,"metadata":null},{"id":"334b1d7b548f4bf598d5700dcb1f6bf5","type":"COMBINATION_TREATMENT","name":"galcanezumab + rimegepant","canonical_id":"ctgov_combo:ctgov-combo-58f38ac238b865a6","description":null,"metadata":null},{"id":"5b1db1a5bb094e339ed8e1507230f557","type":"GO_TERM","name":"galectin complex","canonical_id":"go:GO:1990724","description":"\"A homodimeric protein complex that is capable of binding a range of carbohydrates and is involved in anti-inflammatory and pro-apoptotic processes.\" [GOC:bhm, PMID:15476813, PMID:18777589, PMID:8262940]","metadata":null},{"id":"c8faf580c30a442da9f3ba30ea3910f5","type":"GO_TERM","name":"galectin lattice","canonical_id":"go:GO:0140366","description":"\"A non-stoichiometric protein complex formed by several galectins crosslinking glycosylated ligands to form a dynamic lattice. The galectin lattice modulates receptor kinase signaling and the functionality of membrane receptors, by regulating the diffusion, compartmentalization and endocytosis of plasma membrane glycoproteins and glycolipids.\" [PMID:19021578, PMID:26092931, PMID:28893908, PMID:30951647]","metadata":null},{"id":"6f61049161644f8dbcb49667a4374000","type":"GO_TERM","name":"gallate 1-beta-glucosyltransferase activity","canonical_id":"go:GO:0047913","description":"\"Catalysis of the reaction: gallate + UDP-D-glucose = 1-O-galloyl-beta-D-glucose + UDP.\" [EC:2.4.1.136, RHEA:15249]","metadata":null},{"id":"a8cf089ce4e44e7cb9197dd241bde4e7","type":"GO_TERM","name":"gallate catabolic process","canonical_id":"go:GO:0019396","description":"\"The chemical reactions and pathways resulting in the breakdown of gallate, the anion of gallic acid (3,4,5-trihydroxybenzoic acid).\" [GOC:jl]","metadata":null},{"id":"d6145c1f59384f24a9532f8fa1d8a67f","type":"GO_TERM","name":"gallate decarboxylase activity","canonical_id":"go:GO:0018798","description":"\"Catalysis of the reaction: gallate + H+ = CO2 + pyrogallol.\" [EC:4.1.1.59, RHEA:12749]","metadata":null},{"id":"adb3ad3fb1d1499d89b7bfd7a0078bc9","type":"GO_TERM","name":"gallate dioxygenase activity","canonical_id":"go:GO:0036238","description":"\"Catalysis of the reaction: gallate + O2 = (1E)-4-oxobut-1-ene-1,2,4-tricarboxylate.\" [EC:1.13.11.57, PMID:16030014]","metadata":null},{"id":"6b4168d56ac34dea91b2d4141c5a12d5","type":"GO_TERM","name":"gallbladder development","canonical_id":"go:GO:0061010","description":"\"The progression of the gallbladder over time, from its initial formation to the mature structure. The gallbladder is a cavitated organ that stores bile.\" [GOC:dph]","metadata":null},{"id":"a147dec28b184d769bf3786c624c172e","type":"DISEASE","name":"gallstones","canonical_id":"mondo:0005346","description":null,"metadata":null},{"id":"c21d7abaaca64479a57e4eae8ef92336","type":"GO_TERM","name":"gamete generation","canonical_id":"go:GO:0007276","description":"\"The generation and maintenance of gametes in a multicellular organism. A gamete is a haploid reproductive cell.\" [GOC:ems, GOC:mtg_sensu]","metadata":null},{"id":"19124309b56142b5a79e3460934d987f","type":"GO_TERM","name":"gametophyte development","canonical_id":"go:GO:0048229","description":"\"The process whose specific outcome is the progression of the gametophyte over time, from its formation to the mature structure. The gametophyte is the gamete-producing individual or phase in the life cycle having alternation of generations. An example of this process is found in Arabidopsis thaliana.\" [GOC:jid, PO:0009004]","metadata":null},{"id":"f69b4564deef4f13afd9e3eaceea0eb9","type":"GO_TERM","name":"gamma DNA polymerase complex","canonical_id":"go:GO:0005760","description":"\"A DNA polymerase complex consisting of a large subunit, responsible for the catalytic activities, and a small accessory subunit. Functions in the replication and repair of mitochondrial DNA.\" [GOC:jl, PMID:12045093]","metadata":null},{"id":"68ed0d4e0a6347779f538f2926197450","type":"GO_TERM","name":"gamma-1,2,3,4,5,6-hexachlorocyclohexane catabolic process","canonical_id":"go:GO:0018919","description":"\"The chemical reactions and pathways  resulting in the breakdown of  gamma-1,2,3,4,5,6-hexachlorocyclohexane (also known as Lindane), the most common form of hexachlorohexane, a halogenated organic insecticide that has been used worldwide for agriculture and public health.\" [MetaCyc:GAMMAHEXCHLORDEG-PWY]","metadata":null},{"id":"bed877df7abb42738ab9799b2a3b6c7f","type":"GO_TERM","name":"gamma-aminobutyric acid import","canonical_id":"go:GO:0051939","description":"\"The directed movement of gamma-aminobutyric acid (GABA, 4-aminobutyrate) into a cell or organelle.\" [GOC:ai]","metadata":null},{"id":"5022cf3579404719ae46045e38811eef","type":"GO_TERM","name":"gamma-aminobutyric acid receptor clustering","canonical_id":"go:GO:0097112","description":"\"The receptor clustering process in which gamma-aminobutyric acid (GABA) receptors are localized to distinct domains in the cell membrane.\" [GOC:BHF, GOC:sjp, PMID:15620359]","metadata":null},{"id":"75787006e445470a815d9f7f0cfee37a","type":"GO_TERM","name":"gamma-aminobutyric acid reuptake","canonical_id":"go:GO:0051936","description":"\"The uptake of gamma-aminobutyric acid (GABA, 4-aminobutyrate) by neurons or glial cells. This process leads to inactivation and recycling of neurotransmitters.\" [ISBN:0123668387]","metadata":null},{"id":"dd91cf9413bd42d690fcab028fe27849","type":"GO_TERM","name":"gamma-aminobutyric acid secretion","canonical_id":"go:GO:0014051","description":"\"The regulated release of gamma-aminobutyric acid by a cell or a tissue. The gamma-aminobutyric acid is the principal inhibitory neurotransmitter in the brain but is also found in several extraneural tissues.\" [GOC:ef]","metadata":null},{"id":"27dea1f0951c47539bd46d8d31e4f48f","type":"GO_TERM","name":"gamma-aminobutyric acid secretion, neurotransmission","canonical_id":"go:GO:0061534","description":"\"The regulated release of gamma-aminobutyric acid by a cell, in which the gamma-aminobutyric acid acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"3e75f138a3c84120ac185875b071fc1c","type":"GO_TERM","name":"gamma-aminobutyric acid signaling pathway","canonical_id":"go:GO:0007214","description":"\"The series of molecular signals generated by the binding of gamma-aminobutyric acid (GABA, 4-aminobutyrate), an amino acid which acts as a neurotransmitter in some organisms, to its receptor on the surface of a target cell.\" [GOC:mah]","metadata":null},{"id":"dcf7c0ff58784bc0a5b4bb414471cde0","type":"GO_TERM","name":"gamma-aminobutyric acid transmembrane transporter activity","canonical_id":"go:GO:0015185","description":"\"Enables the transfer of gamma-aminobutyric acid from one side of a membrane to the other. Gamma-aminobutyric acid is 4-aminobutyrate (GABA).\" [GOC:curators, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"17fccad9364a4f62961779fefa8b6744","type":"GO_TERM","name":"gamma-aminobutyric acid transport","canonical_id":"go:GO:0015812","description":"\"The directed movement of gamma-aminobutyric acid (GABA, 4-aminobutyrate), an amino acid which acts as a neurotransmitter in some organisms, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c3755c9368ba427d8997c7974f0abf05","type":"GO_TERM","name":"gamma-aminobutyric acid:proton antiporter activity","canonical_id":"go:GO:0140800","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: 4-aminobutanoate(out) + H+(in) = 4-aminobutanoate(in) + H+(out).\" [PMID:16701208, PMID:26912364, PMID:27601664]","metadata":null},{"id":"4c1429dd752a456996f172a50b15ed87","type":"GO_TERM","name":"gamma-aminobutyric acid:proton symporter activity","canonical_id":"go:GO:0015495","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: gamma-aminobutyric acid(out) + H+(out) = gamma-aminobutyric acid(in) + H+(in).\" [TC:2.A.18.5.1, TC:2.A.3.1.4, TC:2.A.3.4.2]","metadata":null},{"id":"4c683417439c4fa2a7c5759d3b17f777","type":"GO_TERM","name":"gamma-aminobutyric acid:sodium:chloride symporter activity","canonical_id":"go:GO:0005332","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: gamma-aminobutyric acid(out) + Na+(out) + Cl-(out) = gamma-aminobutyric acid(in) + Na+(in) + Cl(in).\" [PMID:7589472, PMID:7861179]","metadata":null},{"id":"735421ddfe58446ab08174aa89237240","type":"GO_TERM","name":"gamma-butyrobetaine dioxygenase activity","canonical_id":"go:GO:0008336","description":"\"Catalysis of the reaction: 2-oxoglutarate + 4-(trimethylammonio)butanoate + O2 = carnitine + CO2 + succinate.\" [EC:1.14.11.1, RHEA:24028]","metadata":null},{"id":"6003879451d54e65b9d1060e73aaf443","type":"GO_TERM","name":"gamma-catenin binding","canonical_id":"go:GO:0045295","description":"\"Binding to catenin complex gamma subunit.\" [GOC:bf]","metadata":null},{"id":"aa43abdd0254428fbf40fa2f990eedbd","type":"GO_TERM","name":"gamma-catenin-TCF7L2 complex","canonical_id":"go:GO:0071665","description":"\"A protein complex that contains gamma-catenin and TCF7L2 (TCF4), binds to the TCF DNA motif within a promoter element, and is involved in the regulation of WNT target gene transcription.\" [GOC:BHF, GOC:vk, PMID:14661054]","metadata":null},{"id":"4e3126b22d724d99acec0d2b824448fe","type":"GO_TERM","name":"gamma-curcumene synthase activity","canonical_id":"go:GO:0102064","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = gamma-curcumene + diphosphoric acid.\" [EC:4.2.3.94, GOC:pz]","metadata":null},{"id":"9556a7749c8c41dd9720f4bd2c2d6143","type":"GO_TERM","name":"gamma-delta T cell activation","canonical_id":"go:GO:0046629","description":"\"The change in morphology and behavior of a gamma-delta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [GOC:add]","metadata":null},{"id":"f6e65dcda1d241f9a9759c020cc012c6","type":"GO_TERM","name":"gamma-delta T cell differentiation","canonical_id":"go:GO:0042492","description":"\"The process in which a relatively unspecialized hemopoietic cell acquires specialized features of a gamma-delta T cell. A gamma-delta T cell is a T cell that expresses a gamma-delta T cell receptor complex.\" [CL:0000798, GOC:jl]","metadata":null},{"id":"f6dfd4eaf3de4deba2334d71495c51f0","type":"GO_TERM","name":"gamma-delta T cell lineage commitment","canonical_id":"go:GO:0002365","description":"\"The process in which a pro-T cell becomes committed to becoming a gamma-delta T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0be6258959a4460794210ec2fcc32bb6","type":"GO_TERM","name":"gamma-delta T cell proliferation","canonical_id":"go:GO:0046630","description":"\"The expansion of a gamma-delta T cell population by cell division.\" [GOC:ai]","metadata":null},{"id":"5dc21178cffc400baa1debfb229873c3","type":"GO_TERM","name":"gamma-delta T cell receptor complex","canonical_id":"go:GO:0042106","description":"\"A T cell receptor complex in which the TCR heterodimer comprises gamma and delta chains, associated with the CD3 complex; recognizes antigen directly, without a requirement for processing and presentation by an MHC protein.\" [GOC:mah, ISBN:0781735149]","metadata":null},{"id":"319685e27b5a4f75b6aed0bdd79779b6","type":"GO_TERM","name":"gamma-delta intraepithelial T cell differentiation","canonical_id":"go:GO:0002304","description":"\"The process in which a precursor cell type acquires the specialized features of a gamma-delta intraepithelial T cell. Intraepithelial T cells are found among epithelial cells in mucosal areas and have distinct phenotypes and developmental pathways.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"17fc4ceca2784f5fb158d8fe3485f63b","type":"GO_TERM","name":"gamma-glutamyl carboxylase activity","canonical_id":"go:GO:0008488","description":"\"Catalysis of the reaction: peptidyl-glutamate + reduced vitamin K + CO2 + O2 = peptidyl-gamma-carboxyglutamate + vitamin K epoxide.\" [PMID:18374194]","metadata":null},{"id":"5e654fc91cd945ccad22209e4961b1d3","type":"GO_TERM","name":"gamma-glutamyl hercynylcysteine sulfoxide synthase activity","canonical_id":"go:GO:0044875","description":"\"Catalysis of the reaction: gamma-glutamyl cysteine + hercynine + O2 = gamma-glutamyl-hercynyl cysteine sulfoxide + H2O.\" [GOC:jl, PMID:24828577, RHEA:42672]","metadata":null},{"id":"d149684f14ea41f1bc817007eb06fecb","type":"GO_TERM","name":"gamma-glutamyl-gamma-aminobutyrate hydrolase activity","canonical_id":"go:GO:0033969","description":"\"Catalysis of the reaction: 4-(L-gamma-glutamylamino)butanoate + H2O = 4-aminobutanoate + L-glutamate.\" [EC:3.5.1.94, RHEA:19737]","metadata":null},{"id":"8933c29c89d943a6a1978428fe7d1c64","type":"GO_TERM","name":"gamma-glutamyl-peptidase activity","canonical_id":"go:GO:0034722","description":"\"Catalysis of the cleavage of a gamma-linked glutamate bond.\" [EC:3.4.19.9, MEROPS_fam:C26]","metadata":null},{"id":"9c2e929945544b39a5d42d98b03bc7c1","type":"GO_TERM","name":"gamma-glutamylaminecyclotransferase activity","canonical_id":"go:GO:0061929","description":"\"Catalysis of the reaction: epsilon-(L-gamma-glutamyl)-L-lysine = L-lysine + 5-oxo-L-proline.\" [PMID:20110353, PMID:6107907]","metadata":null},{"id":"a7cc29c062964d5eb251dabd84105f32","type":"GO_TERM","name":"gamma-glutamylcyclotransferase activity","canonical_id":"go:GO:0003839","description":"\"Catalysis of the reaction: (5-L-glutamyl)-L-amino acid = 5-oxoproline + L-amino acid.\" [PMID:18515354]","metadata":null},{"id":"676cabaaa17649ff9e9019de504a5b72","type":"GO_TERM","name":"gamma-glutamylhistamine synthase activity","canonical_id":"go:GO:0047914","description":"\"Catalysis of the reaction: histamine + L-glutamate + ATP = N(alpha)-gamma-L-glutamylhistamine + products of ATP breakdown.\" [EC:6.3.2.18, MetaCyc:GAMMA-GLUTAMYLHISTAMINE-SYNTHASE-RXN]","metadata":null},{"id":"43829ee10b5c472bb759e7dc59ad3ba1","type":"GO_TERM","name":"gamma-guanidinobutyraldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047107","description":"\"Catalysis of the reaction: 4-guanidinobutanal + H2O + NAD+ = 4-guanidinobutanoate + 2 H+ + NADH.\" [RHEA:14381]","metadata":null},{"id":"3b790b2257164e7b851c5b3e258ec516","type":"GO_TERM","name":"gamma-secretase complex","canonical_id":"go:GO:0070765","description":"\"A protein complex that has aspartic-type endopeptidase activity and contains a presenilin catalytic subunit (either PSEN1 or PSEN2), an APH1 subunit (multiple genes and splice variants exist), nicastrin (NCT), and presenilin enhancer (aka PEN-2 or Psenen), as the core complex. Variants of the complex with different subunit compositions differ in localization and specific substrates. Additionally, variants of the complex exist that contain a additional regulatory subunit as well as the four core subunits; known regulatory subunits include gamma-secretase-activating protein (aka gSAP), TMP1 (aka TMED10), and CD147 antigen (aka basigin). Gamma-secretase cleaves type I transmembrane protein substrates, including the cell surface receptor Notch and the amyloid-beta precursor protein.\" [GOC:krc, PMID:15286082, PMID:15890777, PMID:17047368, PMID:22122073, PMID:25565961, PMID:28320827, PMID:32616437]","metadata":null},{"id":"aacab5653765400284cd850165fe8a84","type":"GO_TERM","name":"gamma-secretase-Delta1 complex","canonical_id":"go:GO:0070764","description":"\"A protein complex that is formed by the association of the Notch ligand Delta1 with the gamma-secretase complex.\" [PMID:12794186]","metadata":null},{"id":"b687823b16a848d1841db18f257df12d","type":"GO_TERM","name":"gamma-terpinene synthase activity","canonical_id":"go:GO:0102903","description":"\"Catalysis of the reaction: geranyl diphosphate = gamma-terpinene + diphosphoric acid.\" [GOC:pz, RHEA:32559]","metadata":null},{"id":"9964be441d97437f999e1ef8de7b6118","type":"GO_TERM","name":"gamma-tubulin binding","canonical_id":"go:GO:0043015","description":"\"Binding to the microtubule constituent protein gamma-tubulin.\" [GOC:jl]","metadata":null},{"id":"2ebb4d85495a42be99cbb42cd070b998","type":"GO_TERM","name":"gamma-tubulin complex","canonical_id":"go:GO:0000930","description":"\"A multiprotein complex composed of gamma-tubulin and other non-tubulin proteins. Gamma-tubulin complexes are localized to microtubule organizing centers, and play an important role in the nucleation of microtubules. The number and complexity of non-tubulin proteins associated with these complexes varies between species.\" [GOC:clt, PMID:12134075]","metadata":null},{"id":"a890a1a9c383441e850f4eeaf61f258d","type":"GO_TERM","name":"gamma-tubulin complex assembly","canonical_id":"go:GO:1902481","description":"\"The aggregation, arrangement and bonding together of a set of components to form a gamma-tubulin complex.\" [GOC:TermGenie, PMID:23885124]","metadata":null},{"id":"9b27bf1293054bf39319682ab8aba31e","type":"GO_TERM","name":"gamma-tubulin complex binding","canonical_id":"go:GO:0140496","description":"\"Binding to a gamma-tubulin complex.\" [PMID:30174135]","metadata":null},{"id":"6e4fcc95c5ea4dadb35cdae41dc3e91b","type":"GO_TERM","name":"gamma-tubulin complex localization","canonical_id":"go:GO:0033566","description":"\"Any process in which a gamma-tubulin complex is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"5b5d951bf8b143abba6cdff8d61a16ed","type":"GO_TERM","name":"gamma-tubulin complex localization to cytoplasmic side of mitotic spindle pole body","canonical_id":"go:GO:0110121","description":"\"Any process in which a gamma-tubulin complex is transported to, or maintained in, a specific location at the cytoplasmic side of the mitotic spindle pole body.\" [GOC:vw, PMID:19001497]","metadata":null},{"id":"35087a952c7b412fa55f11b799bc2a41","type":"GO_TERM","name":"gamma-tubulin complex localization to mitotic spindle pole body","canonical_id":"go:GO:1990735","description":"\"Any process in which a gamma-tubulin complex is transported to, or maintained in, a specific location at a mitotic spindle pole body.\" [GOC:dos, GOC:mah, PMID:11080156]","metadata":null},{"id":"b5b41875214d4a928ee19f0fa9a01fad","type":"GO_TERM","name":"gamma-tubulin complex localization to nuclear side of mitotic spindle pole body","canonical_id":"go:GO:0110120","description":"\"Any process in which a gamma-tubulin complex is transported to, or maintained in, a specific location at the nuclear side of the mitotic spindle pole body.\" [GOC:vw, PMID:19942852]","metadata":null},{"id":"f0a5a08655df4f2eafb76e332d66ffac","type":"GO_TERM","name":"gamma-tubulin ring complex","canonical_id":"go:GO:0000931","description":"\"A complex of gamma tubulin and associated proteins thought to be formed by multimerization of gamma-tubulin small complexes. An example of this structure is found in Schizosaccharomyces pombe.\" [GOC:mtg_sensu, PMID:12134075, PMID:17021256]","metadata":null},{"id":"c7681de931d942a4ae5ddf19bd95d7e9","type":"GO_TERM","name":"gamma-tubulin small complex","canonical_id":"go:GO:0008275","description":"\"A complex usually comprising two gamma-tubulin molecules and two conserved non-tubulin proteins. Some gamma-tubulin small complexes are thought to be the repeating unit making up the core of the gamma-tubulin ring complex.\" [PMID:11297925, PMID:12134075]","metadata":null},{"id":"ffdfd5118cba47ebbdc0a6b155c7a225","type":"GO_TERM","name":"ganglion development","canonical_id":"go:GO:0061548","description":"\"The process whose specific outcome is the progression of a ganglion over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"b7fedc73271346eea2e3c819c7cb1eb2","type":"GO_TERM","name":"ganglion formation","canonical_id":"go:GO:0061554","description":"\"The process that gives rise to ganglion. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:dph]","metadata":null},{"id":"57fcd1a2909647c0ac2b95db84a53381","type":"GO_TERM","name":"ganglion maturation","canonical_id":"go:GO:0061553","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for ganglion to attain its fully functional state.\" [GOC:dph]","metadata":null},{"id":"e89d5159a3284b2bafdc8515c9bed408","type":"GO_TERM","name":"ganglion morphogenesis","canonical_id":"go:GO:0061552","description":"\"The process in which the anatomical structures of ganglion are generated and organized.\" [GOC:dph]","metadata":null},{"id":"51b6980bc53043718b6a191bc37c36bd","type":"GO_TERM","name":"ganglion mother cell fate determination","canonical_id":"go:GO:0007402","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a ganglion mother cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators]","metadata":null},{"id":"0e741c0b86914b249ad6f3786b53a1db","type":"GO_TERM","name":"ganglion structural organization","canonical_id":"go:GO:0061555","description":"\"The process that contributes to creating the structural organization of a ganglion. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dph]","metadata":null},{"id":"3ad20aee83214161a0aeb8e51eb5edf5","type":"GO_TERM","name":"ganglioside GM1 binding","canonical_id":"go:GO:1905573","description":"\"Binding to ganglioside GM1.\" [GO_REF:0000067, GOC:TermGenie, PMID:1454804]","metadata":null},{"id":"a1432aa31efa4231a60b43cc49fd7499","type":"GO_TERM","name":"ganglioside GM1 transport to membrane","canonical_id":"go:GO:1905572","description":"\"The directed movement of ganglioside GM1 to membrane.\" [GO_REF:0000078, GOC:TermGenie, PMID:1454804]","metadata":null},{"id":"3077353d780d4792b478831de1023d32","type":"GO_TERM","name":"ganglioside GM2 binding","canonical_id":"go:GO:1905574","description":"\"Binding to ganglioside GM2.\" [GO_REF:0000067, GOC:TermGenie, PMID:1454804]","metadata":null},{"id":"af72018f7d474263a60d55424f1d8a65","type":"GO_TERM","name":"ganglioside GM3 binding","canonical_id":"go:GO:1905575","description":"\"Binding to ganglioside GM3.\" [GO_REF:0000067, GOC:TermGenie, PMID:1454804]","metadata":null},{"id":"c8d252fda964488392612bbfa1895937","type":"GO_TERM","name":"ganglioside GP1c binding","canonical_id":"go:GO:1905577","description":"\"Binding to ganglioside GP1c.\" [GO_REF:0000067, GOC:TermGenie, PMID:1454804]","metadata":null},{"id":"16a5e7b111a246cf8190d7c6b8bf0358","type":"GO_TERM","name":"ganglioside GT1b binding","canonical_id":"go:GO:1905576","description":"\"Binding to ganglioside GT1b.\" [GO_REF:0000067, GOC:TermGenie, PMID:1454804]","metadata":null},{"id":"3b56245bf0434934a7b0d8b757ae2625","type":"GO_TERM","name":"ganglioside binding","canonical_id":"go:GO:0035594","description":"\"Binding to a ganglioside, a ceramide oligosaccharide carrying in addition to other sugar residues, one or more sialic acid residues.\" [GOC:yaf]","metadata":null},{"id":"66fc4a37c22449f5b86ccc78e9c373f7","type":"GO_TERM","name":"ganglioside biosynthetic process","canonical_id":"go:GO:0001574","description":"\"The chemical reactions and pathways resulting in the formation of gangliosides that begins with the synthesis of a tetrasaccharide core Gal-beta-1,3-GalNAc-beta-1,4-Gal-beta-1,4-Glc-ceramide. This core can be further elongated with the sequential addition of various carbohydrate units including the addition of one or more sialic acid residues.\" [PMID:35536927]","metadata":null},{"id":"017866ee90934a0ba363cfa354d5ed73","type":"GO_TERM","name":"ganglioside catabolic process","canonical_id":"go:GO:0006689","description":"\"The chemical reactions and pathways resulting in the breakdown of ganglioside, a ceramide oligosaccharide carrying, in addition to other sugar residues, one or more sialic residues.\" [ISBN:0198547684]","metadata":null},{"id":"1b7facfb541f482f984e56ea8acc726f","type":"GO_TERM","name":"ganglioside galactosyltransferase activity","canonical_id":"go:GO:0047915","description":"\"Catalysis of the reaction: UDP-galactose + N-acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-1,4-beta-D-glucosyl-N-acylsphingosine = UDP + D-galactosyl-1,3-beta-N-acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-D-glucosyl-N-acylsphingosine.\" [EC:2.4.1.62, MetaCyc:GANGLIOSIDE-GALACTOSYLTRANSFERASE-RXN]","metadata":null},{"id":"47b445b5c92240b5a3982dad38e0aa02","type":"GO_TERM","name":"ganglioside metabolic process","canonical_id":"go:GO:0001573","description":"\"The chemical reactions and pathways involving ceramide oligosaccharides carrying in addition to other sugar residues, one or more sialic acid residues.\" [ISBN:0198506732]","metadata":null},{"id":"e325fbd7526449c08789d2d47ceb74af","type":"DRUG","name":"ganirelix","canonical_id":"mesh:C061018","description":null,"metadata":null},{"id":"7c112259549f4c279c271ef22ace5de7","type":"GO_TERM","name":"gap filling involved in double-strand break repair via nonhomologous end joining","canonical_id":"go:GO:0061674","description":"\"Repair of the gaps in the DNA helix using a discontinuous template during double-strand break repair via nonhomologous end joining.\" [GOC:dph]","metadata":null},{"id":"c298db6b5fe146b1bcba0a38a821cbf4","type":"GO_TERM","name":"gap junction","canonical_id":"go:GO:0005921","description":"\"A cell-cell junction composed of pannexins or innexins and connexins, two different families of channel-forming proteins.\" [GOC:mah, GOC:mtg_muscle, ISBN:0815332181, PMID:22366062, Wikipedia:Gap_junction]","metadata":null},{"id":"6089c8e4e6e34f23821db01b471f1076","type":"GO_TERM","name":"gap junction assembly","canonical_id":"go:GO:0016264","description":"\"Assembly of gap junctions, which are found in most animal tissues, and serve as direct connections between the cytoplasms of adjacent cells. They provide open channels through the plasma membrane, allowing ions and small molecules (less than approximately a thousand daltons) to diffuse freely between neighboring cells, but preventing the passage of proteins and nucleic acids.\" [GOC:jid, ISBN:0716731363]","metadata":null},{"id":"242042b1d7954a6db722f30c57371fbe","type":"GO_TERM","name":"gap junction channel activity","canonical_id":"go:GO:0005243","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from one cell to an adjacent cell. The gap junction can pass large solutes as well as electrical signals between cells. Gap junctions consist of two gap junction hemi-channels, or connexons, one contributed by each membrane through which the gap junction passes.\" [GOC:dgh, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"55df45156e75417aa0f567326bb3ca96","type":"GO_TERM","name":"gap junction channel activity involved in AV node cell-bundle of His cell electrical coupling","canonical_id":"go:GO:0086077","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from an AV node cell to a bundle of His cell. The gap junction passes electrical signals between the cells contributing to cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"13a02ca5cd814667bb46fce3ce5e4fd9","type":"GO_TERM","name":"gap junction channel activity involved in Purkinje myocyte-ventricular cardiac muscle cell electrical coupling","canonical_id":"go:GO:0086079","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from a Purkinje myocyte to a ventricular cardiac muscle cell. The gap junction passes electrical signals between the cells contributing to cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"2ecd8e8fe26a419ea19ff7e0411a2452","type":"GO_TERM","name":"gap junction channel activity involved in SA node cell-atrial cardiac muscle cell electrical coupling","canonical_id":"go:GO:0086020","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from an SA node cell to an atrial cardiomyocyte. The gap junction passes electrical signals between the cells contributing to cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"124a148cdb114d59a8c9d634256d25ac","type":"GO_TERM","name":"gap junction channel activity involved in atrial cardiac muscle cell-AV node cell electrical coupling","canonical_id":"go:GO:0086076","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from an atrial cardiomyocyte to an AV node cell. The gap junction passes electrical signals between the cells contributing to cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"69ac9cc4e11746408bfbf693bc182bff","type":"GO_TERM","name":"gap junction channel activity involved in bundle of His cell-Purkinje myocyte electrical coupling","canonical_id":"go:GO:0086078","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from a bundle of His cell to a Purkinje myocyte. The gap junction passes electrical signals between the cells contributing to cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"82a223ed8a8543329a5dd409c1cabebd","type":"GO_TERM","name":"gap junction channel activity involved in cardiac conduction electrical coupling","canonical_id":"go:GO:0086075","description":"\"A wide pore channel activity that enables a direct cytoplasmic connection from one cardiomyocyte to an adjacent cardiomyocyte. The gap junction passes electrical signals between the cells contributing to cardiac conduction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"a113df37e78c4dabbf741477849a80d3","type":"GO_TERM","name":"gap junction channel activity involved in cell communication by electrical coupling","canonical_id":"go:GO:1903763","description":"\"Any gap junction channel activity that is involved in cell communication by electrical coupling.\" [GO_REF:0000061, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:24587307]","metadata":null},{"id":"953efc92eb3e4cf894fe2d940d8bbacb","type":"GO_TERM","name":"gap junction hemi-channel activity","canonical_id":"go:GO:0055077","description":"\"A wide pore channel activity that enables the transport of a solute across a membrane via a gap junction hemi-channel. Two gap junction hemi-channels coupled together form a complete gap junction.\" [GOC:dgh]","metadata":null},{"id":"bbfc8c2119d64d2c97eee3e12705ca8c","type":"GO_TERM","name":"gap junction-mediated intercellular transport","canonical_id":"go:GO:1990349","description":"\"The movement of substances between cells via gap junctions. A gap junction is a fine cytoplasmic channel, found in animal cells, that connects the cytoplasm of one cell to that of an adjacent cell, allowing ions and other molecules to pass freely between the two cells.\" [GOC:hjd, PMID:14506308, PMID:23261543, Wikipedia:Gap_junction]","metadata":null},{"id":"a50993cd9da74e2fab95813c86d28436","type":"GO_TERM","name":"garland nephrocyte differentiation","canonical_id":"go:GO:0061321","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a garland nephrocyte. A garland nephrocyte is an insect renal cell that filters hemolymph and forms a ring with other garland nephrocytes around the esophagus. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.\" [CL:0000486, GOC:dph, GOC:mtg_kidney_jan10, GOC:sart, PMID:19783135]","metadata":null},{"id":"755eec7a85994a2e8a539ae6a50fe3f5","type":"DRUG","name":"garsorasib","canonical_id":"gtopdb:13767","description":null,"metadata":null},{"id":"cba967d0b71a4b19b29c9374873b599c","type":"GO_TERM","name":"gas transport","canonical_id":"go:GO:0015669","description":"\"The directed movement of substances that are gaseous in normal living conditions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"8d06e0f793f04078adacb7a7dcd41a81","type":"GO_TERM","name":"gas vesicle","canonical_id":"go:GO:0031411","description":"\"An intracellular non-membrane-bounded organelle; a hollow structure made of protein, which usually has the form of a cylindrical tube closed by conical end caps. By regulating their relative gas vesicle content, aquatic microbes are able to perform vertical migrations.\" [PMID:22147705, PMID:8177173]","metadata":null},{"id":"b38d1e42f48e4218904ab42899eb0db5","type":"GO_TERM","name":"gas vesicle organization","canonical_id":"go:GO:0031412","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a gas vesicle. A gas vesicle is a hollow structure made of protein, which usually has the form of a cylindrical tube closed by conical end caps.\" [GOC:mah]","metadata":null},{"id":"1f7764e16b95499ea709a0c977a0277e","type":"GO_TERM","name":"gas vesicle shell","canonical_id":"go:GO:0033172","description":"\"The proteinaceous structure surrounding a gas vesicle.\" [GOC:ecd]","metadata":null},{"id":"6629f3ed57e24e339701571fcce9d852","type":"GO_TERM","name":"gastric acid secretion","canonical_id":"go:GO:0001696","description":"\"The regulated release of gastric acid (hydrochloric acid) by parietal or oxyntic cells during digestion.\" [GOC:hjd]","metadata":null},{"id":"f6d01b270a3f4ec3b74d1ce6ad760af5","type":"DISEASE","name":"gastric adenocarcinoma","canonical_id":"mondo:0005036","description":null,"metadata":null},{"id":"f0f74a25b4fc4d338df4ab68e803c71e","type":"DISEASE","name":"gastric cancer","canonical_id":"mondo:0001056","description":null,"metadata":null},{"id":"cb3afad013564b49b83e4e5040b32a4e","type":"DISEASE","name":"gastric carcinoma","canonical_id":"mondo:0004950","description":null,"metadata":null},{"id":"c5bda0166a854b3eb3f36c042490ef62","type":"GO_TERM","name":"gastric emptying","canonical_id":"go:GO:0035483","description":"\"The process in which the liquid and liquid-suspended solid contents of the stomach exit through the pylorus into the duodenum.\" [GOC:cy, ISBN:9781416032458]","metadata":null},{"id":"bd383fef73e34a60a78855a4b38d33b0","type":"GO_TERM","name":"gastric inhibitory peptide receptor activity","canonical_id":"go:GO:0016519","description":"\"Combining with gastric inhibitory peptide (GIP) and transmitting the signal across the membrane to activate an associated G-protein.\" [GOC:mah, PMID:8243312]","metadata":null},{"id":"3ccc2de493ab43fca31bf75e4999f376","type":"GO_TERM","name":"gastric inhibitory peptide signaling pathway","canonical_id":"go:GO:0038192","description":"\"A G protein-coupled receptor signaling pathway initiated by gastric inhibitory peptide (GIP) binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, PMID:15955806]","metadata":null},{"id":"ca163173ad5d4c2b8601c33a49acb521","type":"GO_TERM","name":"gastric inhibitory polypeptide receptor binding","canonical_id":"go:GO:0031767","description":"\"Binding to a gastric inhibitory polypeptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"4b89bd9d73db468886595f6c49ae4680","type":"GO_TERM","name":"gastric motility","canonical_id":"go:GO:0035482","description":"\"The spontaneous peristaltic movements of the stomach that aid in digestion, moving food through the stomach and out through the pyloric sphincter into the duodenum.\" [GOC:cy, ISBN:9781416032458, PMID:16139031]","metadata":null},{"id":"e71069b7a6174619af7076fe5738b940","type":"DISEASE","name":"gastric mucosa-associated lymphoid tissue lymphoma","canonical_id":"mondo:0006226","description":null,"metadata":null},{"id":"a0138fa032fd41908c6f46630276bd6f","type":"GO_TERM","name":"gastric mucosal blood circulation","canonical_id":"go:GO:1990768","description":"\"The flow of blood through the gastric mucosa of an animal, enabling the transport of nutrients and the removal of waste products.\" [PMID:10807413]","metadata":null},{"id":"d2f639cda9d647cf9f647e2f5fbcd01c","type":"DISEASE","name":"gastric neoplasm","canonical_id":"mondo:0021085","description":null,"metadata":null},{"id":"d1a82ad8ac1541f79d188a9fee7d5d18","type":"DISEASE","name":"gastric ulcer","canonical_id":"mondo:0001126","description":null,"metadata":null},{"id":"ad9ed6c654544caea782c6a03a67a10f","type":"GO_TERM","name":"gastrin receptor activity","canonical_id":"go:GO:0015054","description":"\"Combining with gastrin and transmitting the signal across the membrane by activating an associated G-protein to initiate a change in cell activity.\" [GOC:ai, GOC:signaling]","metadata":null},{"id":"d0ce7c10960443b6933974736c25c23e","type":"GO_TERM","name":"gastrin-induced gastric acid secretion","canonical_id":"go:GO:0001698","description":"\"The regulated release of gastric acid induced by the interaction of gastrin with its receptor.\" [GOC:hjd]","metadata":null},{"id":"166ede7d2f5e40458d59f719899003d4","type":"DISEASE","name":"gastrin-producing neuroendocrine tumor","canonical_id":"mondo:0003523","description":null,"metadata":null},{"id":"c15b4cbe4081464293e611a92aa37af1","type":"GO_TERM","name":"gastrin-releasing peptide receptor binding","canonical_id":"go:GO:0031709","description":"\"Binding to a gastrin-releasing peptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"4b53ea96d6994ef28597a106cb21dba7","type":"DISEASE","name":"gastritis","canonical_id":"mondo:0004966","description":null,"metadata":null},{"id":"1e31ca297b8e4b5d94420449fbb76fa5","type":"GO_TERM","name":"gastro-intestinal system smooth muscle contraction","canonical_id":"go:GO:0014831","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the gastro-intestinal system. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The gastro-intestinal system generally refers to the digestive structures stretching from the mouth to anus, but does not include the accessory glandular organs (liver, pancreas and biliary tract).\" [GOC:mtg_muscle, MA:0001523, MSH:D041981]","metadata":null},{"id":"4b25e736eb5542ee8da2c4ebcd9e2ee3","type":"DISEASE","name":"gastroesophageal junction adenocarcinoma","canonical_id":"mondo:0003219","description":null,"metadata":null},{"id":"d07979848be7400eaca16aa82d0267e6","type":"DISEASE","name":"gastroesophageal reflux disease","canonical_id":"mondo:0007186","description":null,"metadata":null},{"id":"ff664a24ae3642418ee098d1094550c4","type":"DISEASE","name":"gastrointestinal disease","canonical_id":"efo:0010282","description":null,"metadata":null},{"id":"e134b638e77747c0b64fe539bc4ad046","type":"DISEASE","name":"gastrointestinal stromal tumor","canonical_id":"mondo:0011719","description":null,"metadata":null},{"id":"81ef26b577f0482dbd06702eefc85edc","type":"DISEASE","name":"gastroparesis","canonical_id":"mondo:0006769","description":null,"metadata":null},{"id":"c16ebafba38e474d9bfcc6d87cef7eda","type":"GO_TERM","name":"gastrulation","canonical_id":"go:GO:0007369","description":"\"A complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals. The details of gastrulation vary from species to species, but usually result in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm.\" [GOC:curators, ISBN:9780878933846]","metadata":null},{"id":"245960616dea475989865ece4a76ae6d","type":"GO_TERM","name":"gastrulation involving germ band extension","canonical_id":"go:GO:0010004","description":"\"A complex and coordinated series of cellular movements, including germ band extension, that occurs at the end of cleavage during embryonic development. An example of this process is found in Drosophila melanogaster.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"7aef8563319244dcb07609eb80363d8e","type":"GO_TERM","name":"gastrulation with mouth forming first","canonical_id":"go:GO:0001703","description":"\"A gastrulation process in which the initial invagination becomes the mouth and the anus forms second.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"5fb2c141b9d94615a78543b7ecc5ef70","type":"GO_TERM","name":"gastrulation with mouth forming second","canonical_id":"go:GO:0001702","description":"\"A gastrulation process in which the initial invagination becomes the anus and the mouth forms second.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"7a4fdb57568b49c78d1c8f4f5dcdf3f9","type":"GO_TERM","name":"gated channel activity","canonical_id":"go:GO:0022836","description":"\"Enables the transmembrane transfer of a solute by a channel that opens in response to a specific stimulus.\" [GOC:mtg_transport]","metadata":null},{"id":"4779d9789865432c967c7db18451467b","type":"DRUG","name":"gedatolisib","canonical_id":"gtopdb:7940","description":null,"metadata":null},{"id":"daf7e4e73dfd4194a934cef81d13a31b","type":"DRUG","name":"gedatolisib","canonical_id":"chembl:CHEMBL592445","description":null,"metadata":null},{"id":"b854f4f875ef47d889a60313996148b0","type":"DRUG","name":"gefitinib","canonical_id":"gtopdb:4941","description":null,"metadata":null},{"id":"21e0b5fc0c4d4f3b8d15a091a7e5efcd","type":"DRUG","name":"gefitinib","canonical_id":"chembl:CHEMBL939","description":null,"metadata":null},{"id":"a64d16dab48e433d89174b40d1c2ffb8","type":"COMBINATION_TREATMENT","name":"gefitinib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-829865dbde361a52","description":null,"metadata":null},{"id":"ac00d4dabb20411cbb7b69c082be1f37","type":"COMBINATION_TREATMENT","name":"gefitinib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-46095f2a5e5ba940","description":null,"metadata":null},{"id":"ccfa789ca9474708bfffa605bc09ff7c","type":"COMBINATION_TREATMENT","name":"gefitinib + ribociclib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-7dbc70ebe614d0a0","description":null,"metadata":null},{"id":"243f972fb9a3476289112c6367d6ffef","type":"GO_TERM","name":"geissoschizine dehydrogenase activity","canonical_id":"go:GO:0047920","description":"\"Catalysis of the reaction: geissoschizine + NADP+ = 4,21-dehydrogeissoschizine + H+ + NADPH.\" [EC:1.3.1.36, RHEA:11376]","metadata":null},{"id":"6ab417fe68d047beb4d7b89a6b3d6f88","type":"GO_TERM","name":"gel phase of basement membrane","canonical_id":"go:GO:0140148","description":"\"Gel formed of proteglycans filling the basement membrane ECM space.\" [PMID:21421915, PMID:28324731]","metadata":null},{"id":"06f6cb5a00014402a19bf6ff498a0a5d","type":"GO_TERM","name":"gel phase of interstitial matrix","canonical_id":"go:GO:0140150","description":"\"Hydrogel filling the interstitial extracellular matrix space. Composed of proteoglycans such as hyaluronan and lectin-binding proteoglycans, SPOCK proteoglycans and small leucin-rich proteoglycan (SLRP).\" [PMID:21123617, PMID:25701227, PMID:33605520, PMID:39223427]","metadata":null},{"id":"8a46e0804e864bcb914b035ed02dcdfe","type":"DISEASE","name":"gelatinous drop-like corneal dystrophy","canonical_id":"mondo:0008777","description":null,"metadata":null},{"id":"91bba760a23044d7930cb096033c65b9","type":"GO_TERM","name":"gellan lyase activity","canonical_id":"go:GO:0052762","description":"\"Catalysis of the reaction: gellan = n beta-D-4-deoxy-delta4,5-GlcAp-(1->4)-beta-D-Glcp-(1->4)-alpha-L-Rhap-(1->3)-beta-D-Glcp. This reaction is the eliminative cleavage of beta-D-glucopyranosyl-(1->4)-beta-D-glucopyranosyluronate bonds of gellan backbone, releasing tetrasaccharides containing a 4-deoxy-4,5-unsaturated D-glucopyranosyluronic acid at the non-reducing end; in the product, the abbreviations are D-glucose (Glc), D-glucuronic acid (GlcA), and L-rhamnose (Rha).\" [GOC:mengo_curators, MetaCyc:RXN-12269]","metadata":null},{"id":"7304237a5a3d437390bde68677342725","type":"DRUG","name":"gemcitabine","canonical_id":"gtopdb:4793","description":null,"metadata":null},{"id":"eeb65d64683943889c0b193f591fe5f3","type":"DRUG","name":"gemcitabine","canonical_id":"mesh:C056507","description":null,"metadata":null},{"id":"6bd652410326413a99abcf95cb4a3873","type":"COMBINATION_TREATMENT","name":"gemcitabine + irinotecan + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-a5268cb6383ad606","description":null,"metadata":null},{"id":"8a611c6435514c62a3eee5cb885de053","type":"COMBINATION_TREATMENT","name":"gemcitabine + naxitamab","canonical_id":"ctgov_combo:ctgov-combo-47366dedf1e98932","description":null,"metadata":null},{"id":"fd439f0bac44454292bd49653c89e6c6","type":"COMBINATION_TREATMENT","name":"gemcitabine + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-078be801cbc65900","description":null,"metadata":null},{"id":"3d02abdd76af4460a18797560c6286a1","type":"COMBINATION_TREATMENT","name":"gemcitabine + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-b8907457c3d71610","description":null,"metadata":null},{"id":"e4d3a1a1c3f34d1da2e12f7158cb84d1","type":"COMBINATION_TREATMENT","name":"gemcitabine + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-3008788312336ca9","description":null,"metadata":null},{"id":"b078d9d034e44dca88a7d666877c53b7","type":"COMBINATION_TREATMENT","name":"gemcitabine + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-89b8410ba463419e","description":null,"metadata":null},{"id":"073e1f481f764fa28dd6b10493ac3001","type":"COMBINATION_TREATMENT","name":"gemcitabine + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-c13a1df88beaac3e","description":null,"metadata":null},{"id":"9586cd388c074f168c3d8e736d76c6bb","type":"COMBINATION_TREATMENT","name":"gemcitabine + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-c86121bb29afd29e","description":null,"metadata":null},{"id":"4aa5b3a5b52c4f099af7abe5ecbd1161","type":"COMBINATION_TREATMENT","name":"gemcitabine + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-a77c40b18e7e077c","description":null,"metadata":null},{"id":"285ab67c3b604742ad6ef669b321190f","type":"COMBINATION_TREATMENT","name":"gemcitabine + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-fedbcda0787ac109","description":null,"metadata":null},{"id":"0ef479eb25474c9f989691422eb5d512","type":"DRUG","name":"gemfibrozil","canonical_id":"gtopdb:3439","description":null,"metadata":null},{"id":"93a995b6a6b24294b4d542b01cf61b28","type":"DRUG","name":"gemfibrozil","canonical_id":"chembl:CHEMBL457","description":null,"metadata":null},{"id":"d8e411a991d346168f683979f6c974da","type":"COMBINATION_TREATMENT","name":"gemfibrozil + ozanimod","canonical_id":"ctgov_combo:ctgov-combo-b18311f963505741","description":null,"metadata":null},{"id":"adef2e1ae41e494da9861abe886def1d","type":"COMBINATION_TREATMENT","name":"gemfibrozil + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-a0ca816cd9abfa93","description":null,"metadata":null},{"id":"9f3bfe52d8f34c8b9dbdb5b61df63d6e","type":"COMBINATION_TREATMENT","name":"gemfibrozil + pravastatin + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-0f437c188f68609a","description":null,"metadata":null},{"id":"4466993beb4e41c888ae7aad66d411ba","type":"COMBINATION_TREATMENT","name":"gemfibrozil + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-adb6e753d34be038","description":null,"metadata":null},{"id":"6508b63dd9ca467ea98677dd7524e4a1","type":"COMBINATION_TREATMENT","name":"gemfibrozil + repaglinide","canonical_id":"ctgov_combo:ctgov-combo-f48bd3db45fcff77","description":null,"metadata":null},{"id":"2ba88ca97ca14904ac129bae6c9a6097","type":"COMBINATION_TREATMENT","name":"gemfibrozil + tolbutamide + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-4a9cb99c6a3f21d3","description":null,"metadata":null},{"id":"c655e89cfa1b4ccb919e02c52ac34a60","type":"DRUG","name":"gemifloxacin","canonical_id":"mesh:D000077735","description":null,"metadata":null},{"id":"2152dec98183401281e05e0a71813d60","type":"DRUG","name":"gemigliptin","canonical_id":"mesh:C534891","description":null,"metadata":null},{"id":"0618a2a6d8b542ef8b230f6c1d7f7ead","type":"GO_TERM","name":"gemmule","canonical_id":"go:GO:0097463","description":"\"Spine-like process found on some neurons, e.g., periglomerular cells of olfactory cortex.\" [NIF_Subcellular:nlx_subcell_1005003]","metadata":null},{"id":"adf7018ec10046f2a646ab60ac88dc50","type":"DRUG","name":"gemtuzumab ozogamicin","canonical_id":"gtopdb:6775","description":null,"metadata":null},{"id":"74a9df34c06b4763a2fda07c64cc9753","type":"DRUG","name":"gemtuzumab ozogamicin","canonical_id":"chembl:CHEMBL1201506","description":null,"metadata":null},{"id":"a2cdebfdfd35454692bf06c88ed99d0f","type":"COMBINATION_TREATMENT","name":"gemtuzumab ozogamicin + glasdegib","canonical_id":"ctgov_combo:ctgov-combo-598b8a790a7ccee7","description":null,"metadata":null},{"id":"931b3b0e998e437784a377d0ab1819e1","type":"COMBINATION_TREATMENT","name":"gemtuzumab ozogamicin + glasdegib","canonical_id":"ctgov_combo:ctgov-combo-3e8a3194c7f6d62b","description":null,"metadata":null},{"id":"efcfd4c436224f58957b8957b81f1b8c","type":"COMBINATION_TREATMENT","name":"gemtuzumab ozogamicin + quizartinib","canonical_id":"ctgov_combo:ctgov-combo-19231f5223c7de8f","description":null,"metadata":null},{"id":"9f0e57b1837d452599c30234522bfdbd","type":"COMBINATION_TREATMENT","name":"gemtuzumab ozogamicin + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-67d78fc4ed54ffa7","description":null,"metadata":null},{"id":"04b92d4dd845488694dc055f1dbea11a","type":"GO_TERM","name":"gene conversion","canonical_id":"go:GO:0035822","description":"\"A DNA recombination process that results in the unidirectional transfer of genetic material from a donor sequence to a highly homologous acceptor. The resulting acceptor sequence is identical to that of the donor.\" [GOC:mah, PMID:17846636]","metadata":null},{"id":"f26625aed501411db7d2169663d710e1","type":"GO_TERM","name":"gene conversion at mating-type locus","canonical_id":"go:GO:0007534","description":"\"The conversion of the mating-type locus from one allele to another resulting from the recombinational repair of a site-specific double-strand break at the mating-type locus with information from a silent donor sequence. There is no reciprocal exchange of information because the mating-type locus copies information from the donor sequence and the donor sequence remains unchanged.\" [GOC:elh, PMID:10716938, PMID:7646483, PMID:9928492]","metadata":null},{"id":"02a6bb4ec98b495093866b8a9f22c82f","type":"GO_TERM","name":"gene conversion of immunoglobulin genes","canonical_id":"go:GO:0002206","description":"\"The somatic process in which immunoglobulin genes are diversified through the mechanism of gene conversion.\" [GOC:add, PMID:14991701]","metadata":null},{"id":"924f1c3ef522469886703812f80442f0","type":"GO_TERM","name":"gene expression","canonical_id":"go:GO:0010467","description":"\"The process in which a gene's sequence is converted into a mature gene product (protein or RNA). This includes the production of an RNA transcript and its processing, as well as translation and maturation for protein-coding genes.\" [GOC:txnOH-2018, PMID:25934543, PMID:31580950]","metadata":null},{"id":"a12b6f428cab422596f801c54ee1785d","type":"GO_TERM","name":"gene expression involved in extracellular matrix organization","canonical_id":"go:GO:1901148","description":"\"Any gene expression that is involved in extracellular matrix organization. Gene expression includes both transcription to produce an RNA transcript, and the translation of that mRNA into protein. Protein maturation is included in gene expression when required to form an active form of a product from an inactive precursor form.\" [GOC:pg, GOC:TermGenie, PMID:18668558]","metadata":null},{"id":"c8f6dbf1a11a4713a2e6a90a5aa5e431","type":"GO_TERM","name":"gene silencing by piRNA-directed DNA methylation","canonical_id":"go:GO:0141176","description":"\"A small RNA-based gene silencing process in which Piwi-associated RNAs (piRNAs) guide de novo DNA methylation. This results in a heterochromatin assembly, a chromatin conformation that is refractory to transcription.\" [PMID:32674113, PMID:38359823]","metadata":null},{"id":"ce0717ca0d49423ea67a4bb9527aa6fe","type":"GO_TERM","name":"gene silencing by siRNA-directed DNA methylation","canonical_id":"go:GO:0080188","description":"\"A small RNA-based gene silencing process in which small interfering RNAs (siRNAs) guide DNA methylation to the siRNA-generating genomic loci and other loci that are homologous to the siRNAs for de novo DNA methylation. This results in a heterochromatin assembly, a chromatin conformation that is refractory to transcription. In general this process consists of three phases: biogenesis of siRNAs, scaffold RNA production, and the formation of the guiding complex that recruits de novo DNA methyltransferases to the target loci. Transposable elements are silenced by this mechanism.\" [PMID:21420348, PMID:33031395]","metadata":null},{"id":"78b7a3e0fbbf4509bbe4581e5719630c","type":"GO_TERM","name":"general adaptation syndrome","canonical_id":"go:GO:0051866","description":"\"General adaptation syndrome is the set of changes in various organ systems of the body, especially the pituitary-endocrine system, in response to a wide range of strong external stimuli, both physiological and psychological. It is described as having three stages: alarm reaction, where the body detects the external stimulus; adaptation, where the body engages defensive countermeasures against the stressor; and exhaustion, where the body begins to run out of defenses.\" [PMID:14847556, Wikipedia:General_adaptation_syndrome]","metadata":null},{"id":"a9b30a88120541479e5b7330373c82a2","type":"GO_TERM","name":"general adaptation syndrome, behavioral process","canonical_id":"go:GO:0051867","description":"\"The set of behavioral processes that occur as part of the general adaptation syndrome, the response of the body to a strong, stressful stimulus.\" [GOC:ai]","metadata":null},{"id":"1a6dff5b783842098c6d3d8e0fd42149","type":"GO_TERM","name":"general transcription initiation factor activity","canonical_id":"go:GO:0140223","description":"\"A molecular function required for core promoter activity that mediates the assembly of the RNA polymerase holoenzyme at promoter DNA to form the pre-initiation complex (PIC). General transcription factors (GTFs) bind to and open promoter DNA, initiate RNA synthesis and stimulate the escape of the polymerase from the promoter. Not all subunits of the general transcription factor are necessarily present at all promoters to initiate transcription. GTFs act at each promoter, although the exact subunit composition at individual promoters may vary.\" [GOC:txnOH-2018]","metadata":null},{"id":"ef01fddf763042a08b735e26f7a19c80","type":"GO_TERM","name":"general transcription initiation factor binding","canonical_id":"go:GO:0140296","description":"\"Binding to a general transcription initiation factor, a protein that contributes to transcription start site selection and transcription initiation.\" [GOC:txnOH-2018]","metadata":null},{"id":"0f72be265c1048e290ac056d8cd11ecb","type":"DISEASE","name":"generalized anxiety disorder","canonical_id":"mondo:0001942","description":null,"metadata":null},{"id":"af03452dc4e241998d04180a009a6716","type":"DISEASE","name":"generalized resistance to thyroid hormone","canonical_id":"mondo:0009043","description":null,"metadata":null},{"id":"d65c6e73a674462f97ddc038c514a49e","type":"GO_TERM","name":"generation of catalytic spliceosome for first transesterification step","canonical_id":"go:GO:0000349","description":"\"Formation of a catalytic spliceosome complex ready to perform the first splicing reaction. This occurs by an ATP-dependent conformational change of the pre-catalytic spliceosome.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"1365fdb009b049d587f2aace5b9c5286","type":"GO_TERM","name":"generation of catalytic spliceosome for second transesterification step","canonical_id":"go:GO:0000350","description":"\"Conformational rearrangement of the spliceosomal complex containing the RNA products from the 1st step of splicing to form the catalytic site for the second step of splicing.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"1914ee4b72554da8bb7a11f02bdf77a6","type":"GO_TERM","name":"generation of mature 3'-end of 5S rRNA generated by RNA polymerase III","canonical_id":"go:GO:0002107","description":"\"The removal of extra uridine residues from the 3' end of a 5S pre-rRNA generated by transcription by RNA polymerase III to generate the mature 3'-end.\" [GOC:hjd, PMID:16387655, PMID:1748637, PMID:1902221, PMID:8389357]","metadata":null},{"id":"fe24fdf944a94198843e4f5769e2e59e","type":"GO_TERM","name":"generation of mature 3'-end of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000468","description":"\"Any process involved in generating the mature 3'-end of an LSU-rRNA derived from a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:krc, PMID:10690410]","metadata":null},{"id":"8d15fb3b2f4c4e70b12594155c5f8ef1","type":"GO_TERM","name":"generation of mature 5'-end of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000477","description":"\"Cleavage within ITS2 to generate the mature 5'-end of an LSU-rRNA derived from a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators, PMID:10690410]","metadata":null},{"id":"db1d5c837e774c85b14c89adeec72421","type":"GO_TERM","name":"generation of neurons","canonical_id":"go:GO:0048699","description":"\"The process in which nerve cells are generated. This includes the production of neuroblasts and their differentiation into neurons.\" [GOC:nln]","metadata":null},{"id":"d978ee346b0f45009bfbceabd5a557ab","type":"GO_TERM","name":"generation of ovulation cycle rhythm","canonical_id":"go:GO:0060112","description":"\"The process which controls the timing of the type of sexual cycle seen in female mammals.\" [GOC:dph]","metadata":null},{"id":"f37da286716b49e7b7e3c76bd8536b93","type":"GO_TERM","name":"generation of precursor metabolites and energy","canonical_id":"go:GO:0006091","description":"\"The chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and any process involved in the liberation of energy from these substances.\" [GOC:jl]","metadata":null},{"id":"e43c9fd042c54ecfbf3ca5020c196a3d","type":"GO_TERM","name":"generative cell differentiation","canonical_id":"go:GO:0022619","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a generative cell. The generative cell gives rise to the sperm cells in the male gametophyte.\" [GOC:isa_complete]","metadata":null},{"id":"a8d487e48a2140caac8e8c2dba199080","type":"GO_TERM","name":"generative cell mitosis","canonical_id":"go:GO:0055047","description":"\"The process in which the generative cell divides by mitosis to form two haploid cells. These will subsequently differentiate into sperm cells.\" [GOC:mtg_plant]","metadata":null},{"id":"5d050d6866674bd2ac20c8f612208fc8","type":"GO_TERM","name":"generative cell nucleus","canonical_id":"go:GO:0048555","description":"\"The nucleus of the generative cell, a cell contained within the pollen grain that will divide to produce two haploid sperm cells.\" [GOC:tair_curators]","metadata":null},{"id":"a2b0f8d83f044390ab16d520cd9cf491","type":"DISEASE","name":"genetic developmental and epileptic encephalopathy","canonical_id":"mondo:0100062","description":null,"metadata":null},{"id":"d4b177eaa10843589757a8ce08c02cda","type":"DISEASE","name":"genetic non-acquired premature ovarian failure","canonical_id":"efo:0010646","description":null,"metadata":null},{"id":"47dac1f3add1448bb473eac04948dfca","type":"GO_TERM","name":"genital disc anterior/posterior pattern formation","canonical_id":"go:GO:0035224","description":"\"The establishment, maintenance and elaboration of the anterior/posterior axis of the genital disc. An anterior and posterior compartment form in each of the three genital disc primoridia (the female genital disc primordium, the male genital disc primordium and the anal primordium).\" [PMID:11494318]","metadata":null},{"id":"811137482920490fbcb10cb23156fba9","type":"GO_TERM","name":"genital disc development","canonical_id":"go:GO:0035215","description":"\"Progression of the genital imaginal disc over time, from its initial formation through to its metamorphosis to form the adult terminalia, comprising the entire set of internal and external genitalia and analia. Both sexes of Drosophila have a single genital disc formed from the female and male genital primordia, and the anal primordium. The anal primordium develops in both sexes, forming either male or female analia. However, only one of the genital primordia develops in each sex, forming either the male or the female genitalia.\" [GOC:bf, ISBN:0879694238, PMID:11494318]","metadata":null},{"id":"a356b945a1224aaeb732cf792e06fb7a","type":"GO_TERM","name":"genital disc morphogenesis","canonical_id":"go:GO:0007483","description":"\"The process in which the anatomical structures derived from the genital disc are generated and organized. This includes the transformation of a genital imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into the recognizable adult genital structures, the anal plates and the hind gut.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"cf44721235064cf382e699a34c01acfa","type":"GO_TERM","name":"genital disc pattern formation","canonical_id":"go:GO:0035221","description":"\"The process that gives rise to the patterns of cell differentiation that will arise in the genital imaginal disc.\" [GOC:bf]","metadata":null},{"id":"9dd9338254084f0cbf998482c13f621f","type":"GO_TERM","name":"genital disc sexually dimorphic development","canonical_id":"go:GO:0035263","description":"\"The sex-specific patterns of primoridia growth and differentiation in the genital imaginal disc. The anal primordium of the genital disc develops in both sexes, but depending on the genetic sex gives rise to either male or female analia. Depending on the genetic sex, only one of the two genital primordia develop. In females the female genital primordium develops and gives rise to the female genitalia whereas the male primordium is repressed. Conversely, in males the male genital primordium develops and gives rise to the male genitalia whereas the female genital primordium is repressed.\" [PMID:11290302, PMID:11494318, PMID:11702781]","metadata":null},{"id":"d59cc791a616414793ef6dffa0356833","type":"GO_TERM","name":"genitalia development","canonical_id":"go:GO:0048806","description":"\"The process whose specific outcome is the progression of the genitalia over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"25bb0f4aec9d4cd78c41bd74f7a30d65","type":"GO_TERM","name":"genitalia morphogenesis","canonical_id":"go:GO:0035112","description":"\"The process in which the anatomical structures of genitalia are generated and organized. The genitalia are the organs of reproduction or generation, external and internal.\" [GOC:bf]","metadata":null},{"id":"fb3951b648814d7f804780dcd8026b73","type":"GO_TERM","name":"genkwanin 4'-O-methyltransferase activity","canonical_id":"go:GO:0102533","description":"\"Catalysis of the reaction: genkwanin + S-adenosyl-L-methionine = apigenin 4',7-dimethyl ether + S-adenosyl-L-homocysteine.\" [RHEA:73263]","metadata":null},{"id":"aac0d4513a7843dcb4460e80bce70136","type":"GO_TERM","name":"genkwanin 6-hydroxylase activity","canonical_id":"go:GO:0102532","description":"\"Catalysis of the reaction: genkwanin + O2 + reduced [NADPH--hemoprotein reductase] = H2O + oxidized [NADPH--hemoprotein reductase] + scutellarein 7-methyl ether.\" [RHEA:73427]","metadata":null},{"id":"995b6c7af15c467b9ad5183cfa91d5ae","type":"GO_TERM","name":"genomic imprinting","canonical_id":"go:GO:0071514","description":"\"The establishment of epigenetic modifications (imprints) during gametogenesis, and propagation of these imprints during the organism's life. Genomic imprinting leads to an asymmetry between the maternal and paternal alleles and differential expression of the corresponding alleles. This can happen through heterochromatin formation or differential chromatin loop formation.\" [PMID:24492710, PMID:31896690, PMID:31965998]","metadata":null},{"id":"6a712a3d046f48c0bfd2d7576767f3c5","type":"DRUG","name":"gentamicin","canonical_id":"mesh:D005839","description":null,"metadata":null},{"id":"90d2087897644f74a9cbaed42b06fd6e","type":"GO_TERM","name":"gentamycin biosynthetic process","canonical_id":"go:GO:1901130","description":"\"The chemical reactions and pathways resulting in the formation of gentamycin.\" [GOC:TermGenie, MetaCyc:PWY-7025]","metadata":null},{"id":"04c503cbb4654e8786b79c5177095e0c","type":"DRUG","name":"gentian violet","canonical_id":"mesh:D005840","description":null,"metadata":null},{"id":"dc91fbe010054a0c90eb169423d9a70f","type":"GO_TERM","name":"gentisate 1,2-dioxygenase activity","canonical_id":"go:GO:0047922","description":"\"Catalysis of the reaction: 2,5-dihydroxybenzoate + O2 = 3-maleylpyruvate + H+.\" [EC:1.13.11.4, RHEA:18237]","metadata":null},{"id":"91e342c911644ede9d4d17af712cb25e","type":"GO_TERM","name":"gentisate decarboxylase activity","canonical_id":"go:GO:0047923","description":"\"Catalysis of the reaction: 2,5-dihydroxybenzoate + H+ = CO2 + hydroquinone.\" [EC:4.1.1.62, RHEA:21312]","metadata":null},{"id":"751252703e4043578a2221c82a0f00f2","type":"GO_TERM","name":"gephyrin clustering involved in postsynaptic density assembly","canonical_id":"go:GO:0097116","description":"\"The clustering process in which gephyrin molecules are localized to distinct domains in the postsynaptic density as part of postsynaptic density assembly. Gephyrin is a component of the postsynaptic protein network of inhibitory synapses.\" [GOC:BHF, GOC:sjp, PMID:15620359, PMID:24552784, PMID:25772192]","metadata":null},{"id":"cc2ad6da1fee4f7ea1b5ebc2d6c4b009","type":"DRUG","name":"gepirone","canonical_id":"mesh:C039979","description":null,"metadata":null},{"id":"022ae1257a9741efb9e2666f099ad159","type":"GO_TERM","name":"geranial dehydrogenase (NAD+) activity","canonical_id":"go:GO:0034832","description":"\"Catalysis of the reaction: (2E)-geranial + H2O + NAD+ = geranate + 2 H+ + NADH.\" [RHEA:34351]","metadata":null},{"id":"2c0e3be603ff40ad9d401137fadc5bbb","type":"GO_TERM","name":"geraniol 10-hydroxylase activity","canonical_id":"go:GO:0102811","description":"\"Catalysis of the reaction: geraniol + O2 + NADPH + H+ = (6E)-8-hydroxygeraniol + NADP + H2O.\" [EC:1.14.14.83, GOC:pz]","metadata":null},{"id":"73e53e89cd65439cbcb3949b4271286b","type":"GO_TERM","name":"geraniol biosynthetic process","canonical_id":"go:GO:1903448","description":"\"The chemical reactions and pathways resulting in the formation of geraniol.\" [GO_REF:0000068, GOC:di, GOC:TermGenie, PMID:23200656]","metadata":null},{"id":"fe4d42fefa8f45778b694d30555950fd","type":"GO_TERM","name":"geraniol catabolic process","canonical_id":"go:GO:1903447","description":"\"The chemical reactions and pathways resulting in the breakdown of geraniol.\" [GO_REF:0000068, GOC:di, GOC:TermGenie, PMID:23200656]","metadata":null},{"id":"df2261014c6c41fbaeb461748a77166b","type":"GO_TERM","name":"geraniol dehydrogenase activity","canonical_id":"go:GO:0047924","description":"\"Catalysis of the reaction: geraniol + NADP+ = geranial + NADPH.\" [EC:1.1.1.183, MetaCyc:GERANIOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"a6c61c8bb17e43689f672293de6c2b63","type":"GO_TERM","name":"geranoyl-CoA carboxylase activity","canonical_id":"go:GO:0047925","description":"\"Catalysis of the reaction: ATP + bicarbonate + geranoyl-CoA = 3-(4-methylpent-3-en-1-yl)pent-2-enedioyl-CoA + ADP + 2 H+ + phosphate.\" [EC:6.4.1.5, RHEA:17701]","metadata":null},{"id":"6987a9015156485db40988ae9640e706","type":"GO_TERM","name":"geranyl diphosphate biosynthetic process","canonical_id":"go:GO:0033384","description":"\"The chemical reactions and pathways resulting in the formation of geranyl diphosphate.\" [GOC:mah, MetaCyc:PWY-5122]","metadata":null},{"id":"822df45de1584b21aa2e41a820f5fe98","type":"GO_TERM","name":"geranyl diphosphate metabolic process","canonical_id":"go:GO:0033383","description":"\"The chemical reactions and pathways involving geranyl diphosphate, the universal precursor of the monoterpenes.\" [GOC:mah]","metadata":null},{"id":"aa089e93372d4f3eb720876facbb123d","type":"GO_TERM","name":"geranyl-diphosphate cyclase activity","canonical_id":"go:GO:0047926","description":"\"Catalysis of the reaction: geranyl diphosphate = (2S)-bornyl diphosphate.\" [PMID:42357, RHEA:18209]","metadata":null},{"id":"37a2c5d0c2a04d27a5177067d1867944","type":"GO_TERM","name":"geranylfarnesyl diphosphate synthase activity","canonical_id":"go:GO:0044687","description":"\"Catalysis of the reaction: (2E,6E,10E)-geranylgeranyl diphosphate + isopentenyl diphosphate = (2E,6E,10E,14E)-geranylfarnesyl diphosphate + diphosphate.\" [PMID:20097171, RHEA:25694]","metadata":null},{"id":"8f1e4bd799e54a45bdfb73903a8f238b","type":"GO_TERM","name":"geranylgeranyl diphosphate biosynthetic process","canonical_id":"go:GO:0033386","description":"\"The chemical reactions and pathways resulting in the formation of geranylgeranyl diphosphate.\" [GOC:mah]","metadata":null},{"id":"f8b077fa200c4b59ae9bfbb7572b750a","type":"GO_TERM","name":"geranylgeranyl diphosphate catabolic process","canonical_id":"go:GO:1902247","description":"\"The chemical reactions and pathways resulting in the breakdown of geranylgeranyl diphosphate.\" [GOC:TermGenie, PMID:22672125]","metadata":null},{"id":"adc1bdb444db421f8709ba858aedca16","type":"GO_TERM","name":"geranylgeranyl diphosphate metabolic process","canonical_id":"go:GO:0033385","description":"\"The chemical reactions and pathways involving geranylgeranyl diphosphate, a polyprenol compound involved in the biosynthesis of a variety of terpenoids including chlorophylls, carotenoids, tocopherols, plastoquinones, and the plant hormones gibberellins.\" [GOC:mah]","metadata":null},{"id":"ba301b9b908942ecac82d7ab6c5c14d7","type":"GO_TERM","name":"geranylgeranyl diphosphate reductase activity","canonical_id":"go:GO:0102067","description":"\"Catalysis of the reaction: phytyl diphosphate + 3 NADP+ = geranylgeranyl diphosphate + 3 NADPH + 3 H+. This enzyme also catalyzes the reduction of geranylgeranyl-chlorophyll a into phytyl-chlorophyll a.\" [EC:1.3.1.83, PMID:9492312, RHEA:26229]","metadata":null},{"id":"8090b230153c46d9bb68f5b26e5e816c","type":"GO_TERM","name":"geranylgeranyl diphosphate synthase activity","canonical_id":"go:GO:0004311","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + isopentenyl diphosphate = (2E,6E,10E)-geranylgeranyl diphosphate + diphosphate.\" [RHEA:17653]","metadata":null},{"id":"78408099fed74eb78c3c738f9c3f9ad7","type":"GO_TERM","name":"geranylgeranylglycerol-phosphate geranylgeranyltransferase activity","canonical_id":"go:GO:0047295","description":"\"Catalysis of the reaction: (2E,6E,10E)-geranylgeranyl diphosphate + sn-3-O-(geranylgeranyl)glycerol 1-phosphate = 2,3-bis-O-(geranylgeranyl)-sn-glycerol 1-phosphate + diphosphate.\" [PMID:15356000, PMID:16494480, RHEA:18109]","metadata":null},{"id":"08f52dbe801f4d1bbfb7daadc4fe8f83","type":"GO_TERM","name":"geranylgeranyltransferase type III activity","canonical_id":"go:GO:0170068","description":"\"Catalyzes the covalent addition of a geranylgeranyl group to a mono-farnesylated substrate via a thioether linkage to a cysteine residue located within a conserved C-terminal tandem cysteine motif (CCAIM or CCIIM) that is used in substrate recognition. Known substrates include mono-farnesylated Golgi SNARE proteins.\" [PMID:32128853, PMID:33035318, PMID:35628237, PMID:40049413]","metadata":null},{"id":"1a70ae6fa85b43599e0e108a9eb5bf43","type":"GO_TERM","name":"geranylgeranyltransferase-III complex","canonical_id":"go:GO:0170069","description":"\"A protein-containing complex that catalyzes the transfer of a geranyl-geranyl group from geranylgeranyl pyrophosphate to a mono-farnsylated substrate. In humans, the complex is comprised of a prenyltransferase alpha subunit, PTAR1 and beta subunit, RabGGTB, while in budding yeast the prenyltransferase complex contains Ecm9p, the alpha subunit and Bet2p, the beta subunit.\" [PMID:32128853, PMID:33035318, PMID:35628237, PMID:40049413]","metadata":null},{"id":"7c5090ee3b8d41d4ad7234fbd5a8d025","type":"GO_TERM","name":"gerfelin biosynthetic process","canonical_id":"go:GO:1900578","description":"\"The chemical reactions and pathways resulting in the formation of gerfelin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4f52f23019b3447fa27d6d844f46d64e","type":"GO_TERM","name":"gerfelin catabolic process","canonical_id":"go:GO:1900577","description":"\"The chemical reactions and pathways resulting in the breakdown of gerfelin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ff0cd5671bfe491eb7ca3170709d2aed","type":"GO_TERM","name":"germ cell attraction","canonical_id":"go:GO:0035232","description":"\"The directed movement of a germ cell from their site of production to the gonad, through the attraction of cells towards their target.\" [PMID:12885551]","metadata":null},{"id":"653ffcb2f3cc4dcab06088e6abddf0b7","type":"GO_TERM","name":"germ cell development","canonical_id":"go:GO:0007281","description":"\"The process whose specific outcome is the progression of an immature germ cell over time, from its formation to the mature structure (gamete). A germ cell is any reproductive cell in a multicellular organism.\" [GOC:curators]","metadata":null},{"id":"42f1ebee5f0b4d319f731ea7402dbb13","type":"GO_TERM","name":"germ cell nucleus","canonical_id":"go:GO:0043073","description":"\"The nucleus of a germ cell, a reproductive cell in multicellular organisms.\" [CL:0000586, GOC:curators]","metadata":null},{"id":"afc3a5d743874d62aebef98c4cdb28b7","type":"GO_TERM","name":"germ cell proliferation","canonical_id":"go:GO:0036093","description":"\"The multiplication or reproduction of germ cells, reproductive cells in multicellular organisms, resulting in the expansion of a cell population.\" [CL:0000586, GOC:kmv]","metadata":null},{"id":"4b504b7694c9409b91eac367fb586401","type":"GO_TERM","name":"germ cell repulsion","canonical_id":"go:GO:0035233","description":"\"The directed movement of a germ cell from their site of production to the gonad, through the repulsion of cells away from a tissue.\" [PMID:12885551]","metadata":null},{"id":"6d15e1f9016d4ca99ed0fff63c2acbb5","type":"GO_TERM","name":"germ plasm","canonical_id":"go:GO:0060293","description":"\"Differentiated cytoplasm associated with an oocyte, egg or early embryo that will be inherited by the cells that will give rise to the germ line.\" [GOC:dph, PMID:16168720]","metadata":null},{"id":"365971c7e76441db98f85a2836452226","type":"GO_TERM","name":"germ plasm RNA localization","canonical_id":"go:GO:0007316","description":"\"Any process in which RNA is transported to, or maintained in, the germ plasm.\" [GOC:ai]","metadata":null},{"id":"d5d01621322b488dbf387b8a4a141b47","type":"GO_TERM","name":"germ plasm assembly","canonical_id":"go:GO:0007315","description":"\"The aggregation, arrangement and bonding together of a set of components to form the germ plasm, the differentiated cytoplasm associated with an oocyte, egg or early embryo that will be inherited by the cells that will give rise to the germ line.\" [GOC:mtg_sensu]","metadata":null},{"id":"c97886908cbc4b4ca46b3142c371dcff","type":"GO_TERM","name":"germ plasm mRNA localization","canonical_id":"go:GO:0019094","description":"\"Any process in which mRNA is transported to, or maintained in, the germ plasm.\" [GOC:ai]","metadata":null},{"id":"4547dcc0d09648be8284d9503028cf42","type":"GO_TERM","name":"germ plasm mitochondrial lrRNA localization","canonical_id":"go:GO:0019096","description":"\"Any process in which mitochondrial large ribosomal RNA is transported to, or maintained in, the germ plasm.\" [ISBN:0879694238]","metadata":null},{"id":"10e7f0c303314e72a9c3de65cd4f6678","type":"GO_TERM","name":"germ plasm mitochondrial rRNA localization","canonical_id":"go:GO:0019095","description":"\"Any process in which mitochondrial ribosomal RNA is transported to, or maintained in, the germ plasm.\" [ISBN:0879694238]","metadata":null},{"id":"55c5cf33c6e449a4b2df886fc9815528","type":"GO_TERM","name":"germ plasm mitochondrial srRNA localization","canonical_id":"go:GO:0019097","description":"\"Any process in which mitochondrial small ribosomal RNA is transported to, or maintained in, the germ plasm.\" [ISBN:0879694238]","metadata":null},{"id":"9d5b1a6bf2a04180a87efc9e297ae8cf","type":"GO_TERM","name":"germ plasm oskar mRNA localization","canonical_id":"go:GO:0045451","description":"\"Any process in which oskar mRNA is transported to, or maintained in, the germ plasm.\" [GOC:curators]","metadata":null},{"id":"0fbaff8a918e457d8a24336c974d1671","type":"GO_TERM","name":"germ plasm protein localization","canonical_id":"go:GO:0007318","description":"\"Any process in which a protein is transported to, or maintained in, the germ plasm.\" [GOC:ai]","metadata":null},{"id":"d2e3c3cfb8a24efb8e824c8b97c891ed","type":"GO_TERM","name":"germ tube","canonical_id":"go:GO:0032179","description":"\"The slender tubular outgrowth first produced by most spores in germination.\" [ISBN:0877799148]","metadata":null},{"id":"29de1a1cbd8346c3970f1c0fb441c11a","type":"GO_TERM","name":"germ tube formation","canonical_id":"go:GO:0075009","description":"\"Development of slender tubular outgrowth first produced by most symbiont spores immediately following germination on or near its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"e7f25a65a63942cfbb3f6840c7973513","type":"GO_TERM","name":"germ tube septin cap","canonical_id":"go:GO:0032171","description":"\"A faint structure formed of septins found at the leading edge of growth in germ tubes of fungal cells growing filamentously. This cap of septins colocalizes with a region of the plasma membrane that is rich in ergosterol.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"b17b0402a97c4abba9f7388becab97d1","type":"GO_TERM","name":"germ tube septin ring","canonical_id":"go:GO:0032172","description":"\"A tight ring-shaped structure that forms in the division plane within the germ tube of filamentous fungi at sites where a septum will form; composed of septins as well as septin-associated proteins.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"b72ddaa0e3fe48e5882998bda7ed6742","type":"GO_TERM","name":"germ-band extension","canonical_id":"go:GO:0007377","description":"\"Elongation of the germ band on the ventral side of the embryo, accompanied by a halving in width. The elongation process pushes the posterior midgut invagination closed and compresses the amnioserosa further.\" [ISBN:0879694238]","metadata":null},{"id":"9120605ff34d43dab6744753242b44b4","type":"GO_TERM","name":"germ-band shortening","canonical_id":"go:GO:0007390","description":"\"The spreading of the amnioserosa from its compressed state to cover the whole of the dorsal surface. Initiating in the thorax and spreading posteriorly, it is accompanied by the transition from a parasegmental to segmental division of the embryo.\" [GOC:bf, PMID:12147138]","metadata":null},{"id":"69bbc69c56bb4fb798b971c4e6e17d2a","type":"GO_TERM","name":"germ-line cyst encapsulation","canonical_id":"go:GO:0048138","description":"\"Formation of a single follicular epithelium around the germ-line derived cells of a cyst.\" [GOC:jid]","metadata":null},{"id":"f79124c97fa4419a961af552f6a6a210","type":"GO_TERM","name":"germ-line cyst formation","canonical_id":"go:GO:0048134","description":"\"Formation of a group of interconnected cells derived from a single gonial founder cell.\" [GOC:jid, PMID:10370240, PMID:21681920]","metadata":null},{"id":"408ecc1338ce4bc59d337e314a9be5f6","type":"GO_TERM","name":"germ-line sex determination","canonical_id":"go:GO:0018992","description":"\"The determination of sex and sexual phenotype in an organism's germ line.\" [GOC:ems]","metadata":null},{"id":"4f2c70c1f47745dab5e822aa6b021d11","type":"GO_TERM","name":"germ-line stem cell division","canonical_id":"go:GO:0042078","description":"\"The self-renewing division of a germline stem cell to produce a daughter stem cell and a daughter germ cell, which will divide to form the gametes.\" [GOC:jid, PMID:2279698]","metadata":null},{"id":"c151054491074edba737a2f8d5aa0e82","type":"GO_TERM","name":"germ-line stem cell population maintenance","canonical_id":"go:GO:0030718","description":"\"Any process by which an organism or tissue maintains a population of germ-line stem cells.\" [ISBN:0879694238]","metadata":null},{"id":"184ec6504ceb438b809e2d87dbed5edb","type":"GO_TERM","name":"germ-line stem-cell niche homeostasis","canonical_id":"go:GO:0060250","description":"\"A homeostatic process involved in the maintenance of an internal steady state within the germ-line stem-cell niche. This includes control of cellular proliferation and death and control of metabolic function that allows the niche to continue to function. A gem-line stem-cell niche is an anatomical structure that regulates how germ-line stem-cells are used and saves them from depletion.\" [GOC:dph]","metadata":null},{"id":"9017966f30c94ce08358c8d4bff5952a","type":"GO_TERM","name":"germacradienol synthase activity","canonical_id":"go:GO:0034004","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate + H2O = (1E,4S,5E,7R)-germacra-1(10),5-dien-11-ol + diphosphate.\" [EC:4.2.3.22]","metadata":null},{"id":"54a8ee70f67e49d29bcfed6da5a184af","type":"GO_TERM","name":"germacrene A acid 8beta-hydroxylase activity","canonical_id":"go:GO:0102614","description":"\"Catalysis of the reaction: germacra-1(10),4,11(13)-trien-12-oate + O2 + reduced [NADPH--hemoprotein reductase] = 8beta-hydroxygermacra-1(10),4,11(13)-trien-12-oate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:57964]","metadata":null},{"id":"17ba16880acc4590b0babdd9ef2b0b55","type":"GO_TERM","name":"germacrene A hydroxylase activity","canonical_id":"go:GO:0106223","description":"\"Catalysis of the reaction:(+)-(R)-germacrene A + 3 O2 + 3 reduced [NADPH--hemoprotein reductase] = germacra-1(10),4,11(13)-trien-12-oate + 4 H+ + 4 H2O + 3 oxidized [NADPH--hemoprotein reductase].\" [PMID:11299372, PMID:20351109, RHEA:30303]","metadata":null},{"id":"235edd59d239494fb3728d5d11d6405b","type":"GO_TERM","name":"germacrene C synthase activity","canonical_id":"go:GO:0102904","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = germacrene C + diphosphoric acid.\" [EC:4.2.3.60, GOC:pz]","metadata":null},{"id":"e32b6da611b2462fb96765a7acaeb6b9","type":"GO_TERM","name":"germacrene-A synthase activity","canonical_id":"go:GO:0034005","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = (+)-(R)-germacrene A + diphosphate.\" [EC:4.2.3.23, RHEA:12516]","metadata":null},{"id":"c8280310c65e48a793dabd757b561639","type":"GO_TERM","name":"germacrene-D synthase activity","canonical_id":"go:GO:0052577","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate = (-)-germacrene D + diphosphate.\" [RHEA:12016]","metadata":null},{"id":"e13d9e4009f54f98804cc611d82bfe3d","type":"GO_TERM","name":"germarium-derived cystoblast division","canonical_id":"go:GO:0048142","description":"\"The four rounds of incomplete mitosis undergone by a cystoblast to form a 16-cell cyst of interconnected cells within a germarium. Within the cyst, one cell differentiates into an oocyte while the rest become nurse cells. An example of this process is found in Drosophila melanogaster.\" [GOC:jid, GOC:mtg_sensu, PMID:11131529]","metadata":null},{"id":"a49e6c4e38e9446e96187ecc9ad6c951","type":"GO_TERM","name":"germarium-derived egg chamber formation","canonical_id":"go:GO:0007293","description":"\"Construction of a stage-1 egg chamber in the anterior part of the germarium, from the progeny of germ-line and somatic stem cells. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"fb94637a81dc48d3b2f3ebae0c63815c","type":"GO_TERM","name":"germarium-derived female germ-line cyst encapsulation","canonical_id":"go:GO:0030708","description":"\"Formation of a single follicular epithelium around the germ-line derived cells of a cyst formed in the germarium. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11591336]","metadata":null},{"id":"f723644851874bceb368008883f1d973","type":"GO_TERM","name":"germarium-derived female germ-line cyst formation","canonical_id":"go:GO:0030727","description":"\"Formation, in a germarium, of a group of interconnected cells derived from a single female gonial founder cell (a cystoblast). The germarium is the most anterior portion of an insect ovariole. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:10370240, PMID:9442902]","metadata":null},{"id":"0fa3f2b810b94ca1925dd2fad8618fb4","type":"GO_TERM","name":"germarium-derived oocyte differentiation","canonical_id":"go:GO:0030706","description":"\"The process in which one relatively unspecialized immature cystocyte of the germ-line cyst in the germarium acquires the specialized features of an oocyte. An example of this process can be found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"3d08d858745c4f12885d26f9f1def19a","type":"GO_TERM","name":"germarium-derived oocyte fate determination","canonical_id":"go:GO:0007294","description":"\"The cell fate determination process in which a germarium-derived cell becomes capable of differentiating autonomously into an oocyte cell regardless of its environment; upon determination, the cell fate cannot be reversed. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"b93c15bbc93f47f0ba317006a3db1c4f","type":"GO_TERM","name":"germinal center B cell differentiation","canonical_id":"go:GO:0002314","description":"\"The process in which a B cell in the spleen acquires the specialized features of a germinal center B cell. Germinal center B cells are rapidly cycling B cells which have downregulated IgD expression and exhibit high levels of binding by peanut agglutinin (PNA).\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"5e0468c00e5141c9ac62cf7dc786a334","type":"GO_TERM","name":"germinal center formation","canonical_id":"go:GO:0002467","description":"\"The process in which germinal centers form. A germinal center is a specialized microenvironment formed when activated B cells enter lymphoid follicles. Germinal centers are the foci for B cell proliferation and somatic hypermutation.\" [GO_REF:0000022, GOC:jal, ISBN:081533642X]","metadata":null},{"id":"e3c211a0cc2741f2818cfbf3963cfbd0","type":"GO_TERM","name":"germinal vesicle","canonical_id":"go:GO:0042585","description":"\"The enlarged, fluid filled nucleus of a primary oocyte, the development of which is suspended in prophase I of the first meiotic division between embryohood and sexual maturity.\" [GOC:jl, GOC:mtg_sensu, PMID:19019837]","metadata":null},{"id":"09782a32bae046f7bc5c6dc6508ef8f9","type":"GO_TERM","name":"germline cell cycle switching, mitotic to meiotic cell cycle","canonical_id":"go:GO:0051729","description":"\"The process in which a germline cell switches cell cycle mode from mitotic to meiotic division.\" [GOC:ai]","metadata":null},{"id":"eaab12530fc949f6ab62db8ac57f5e86","type":"GO_TERM","name":"germline ring canal","canonical_id":"go:GO:0045172","description":"\"Germline specific intercellular bridge. During cyst formation in insects, ring canals interconnect the cells of the cyst, facilitating the passage of cytoplasmic components between cells.\" [GOC:mtg_sensu, PMID:9635420, PMID:9655801]","metadata":null},{"id":"38e410f349364034800c3b96aae7049f","type":"GO_TERM","name":"germline ring canal formation","canonical_id":"go:GO:0030725","description":"\"Assembly of the cytoplasmic bridges between developing spermatogonial or oogonial cysts.\" [ISBN:0879694238]","metadata":null},{"id":"9a65c0b186834d4f96898d4e422e5881","type":"GO_TERM","name":"germline stem cell asymmetric division","canonical_id":"go:GO:0098728","description":"\"The self-renewing division of a germline stem cell, to produce a daughter stem cell and a daughter germ cell which will divide to form one or more gametes.\" [GOC:dos]","metadata":null},{"id":"1d6b9ea8950a4d6ba295c0b8ed7fc89c","type":"GO_TERM","name":"germline stem cell symmetric division","canonical_id":"go:GO:0098729","description":"\"Division of a germline stem cell to produce two germline stem cells of the same type as the parent.\" [GOC:dos, PMID:19948499]","metadata":null},{"id":"14d664cf710648b8a2451be41820bb47","type":"GO_TERM","name":"gerontoplast","canonical_id":"go:GO:0034400","description":"\"A plastid found in senescing, formerly green tissues that is derived from a chloroplast that undergoes an organized developmental program of senescence.\" [PMID:12654863, PMID:24668747]","metadata":null},{"id":"b2df5bcfd1004c2fa7883eb203ecf108","type":"GO_TERM","name":"gerontoplast stroma","canonical_id":"go:GO:1905506","description":"\"Any plastid stroma that is part of a gerontoplast.\" [GO_REF:0000064, GOC:mag, GOC:TermGenie, PMID:11212360]","metadata":null},{"id":"2b3f7082942c493b8aa5273f3c03b851","type":"DISEASE","name":"gestational diabetes","canonical_id":"mondo:0005406","description":null,"metadata":null},{"id":"551a9e289a224e3dbd0fa8646ed7ce85","type":"GO_TERM","name":"ghrelin receptor binding","canonical_id":"go:GO:0031768","description":"\"Binding to a ghrelin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"37f8c654fe2a4cd9a30a30a5a4a682cd","type":"GO_TERM","name":"ghrelin secretion","canonical_id":"go:GO:0036321","description":"\"The regulated release of ghrelin from a cell. Ghrelin is a 28 amino acid hunger-stimulating peptide hormone.\" [GOC:cjm, PMID:14610293, Wikipedia:Ghrelin]","metadata":null},{"id":"15051d2d20f9498b96f46769034af7ba","type":"GO_TERM","name":"giant axon","canonical_id":"go:GO:0042757","description":"\"Extremely large, unmyelinated axon found in invertebrates. Has high conduction speeds and is usually involved in panic or escape responses.\" [GOC:jl, PMID:9705477]","metadata":null},{"id":"75bde2b3d31e4f91974081615d14448a","type":"DISEASE","name":"giant cell tumor","canonical_id":"mondo:0002171","description":null,"metadata":null},{"id":"d9a1b588a07c4cf6be846677a4b71187","type":"GO_TERM","name":"gibberellic acid homeostasis","canonical_id":"go:GO:0010336","description":"\"Any biological process involved in the maintenance of an internal steady state of gibberellic acid; may involve transport, biosynthesis, catabolism or conjugation.\" [PMID:17194763]","metadata":null},{"id":"595faea0e88e49f2a02e3edbe443a146","type":"GO_TERM","name":"gibberellic acid mediated signaling pathway","canonical_id":"go:GO:0009740","description":"\"The series of molecular signals mediated by the detection of gibberellic acid.\" [GOC:sm]","metadata":null},{"id":"f74912792831420caabbeef9a012bbb8","type":"GO_TERM","name":"gibberellic acid mediated signaling pathway, G-alpha-dependent","canonical_id":"go:GO:0042388","description":"\"The series of molecular signals mediated by the detection of gibberellic acid and dependent on the coupling of the alpha subunit of G proteins to the hormone receptors.\" [GOC:pj, PMID:11027362]","metadata":null},{"id":"498eb3345fcd4376a05a3219088585bd","type":"GO_TERM","name":"gibberellic acid mediated signaling pathway, G-alpha-independent","canonical_id":"go:GO:0042390","description":"\"The series of molecular signals mediated by the detection of gibberellic acid and not dependent on the coupling of the alpha subunit of G proteins to the hormone receptors.\" [GOC:pj, PMID:11027362]","metadata":null},{"id":"e9459354cb9b4f099c470c721b840fd7","type":"GO_TERM","name":"gibberellic acid transmembrane transport","canonical_id":"go:GO:1905200","description":"\"The directed movement of gibberellic acid across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:27139299]","metadata":null},{"id":"7ba561adbd114b6b862d2484e317f45f","type":"GO_TERM","name":"gibberellin 12 biosynthetic process","canonical_id":"go:GO:0033470","description":"\"The chemical reactions and pathways resulting in the formation of gibberellin 12, (1R,2S,3S,4R,8S,9S,12R)-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylic acid 1meta,4a-dimethyl-8-methylidene-4aalpha,4bbeta-gibbane-1alpha,10beta-dicarboxylic acid.\" [GOC:mah]","metadata":null},{"id":"a0221c9d392046ecbc14f60e8e4fc00e","type":"GO_TERM","name":"gibberellin 2-beta-dioxygenase activity","canonical_id":"go:GO:0045543","description":"\"Catalysis of the reaction: a gibberellin + 2-oxoglutarate + O2 = a 2-beta-hydroxygibberellin + succinate + CO2.\" [EC:1.14.11.13, PMID:32652020]","metadata":null},{"id":"c3a148e326c44716a05dcc1ec29fe3f9","type":"GO_TERM","name":"gibberellin 20-oxidase activity","canonical_id":"go:GO:0045544","description":"\"Catalysis of the reaction: 2 2-oxoglutarate + gibberellin A12 (GA12) + H+ + 3 O2 = 3 CO2 + gibberellin A9 (GA9) + 2 H2O + 2 succinate. This reaction results in the oxidation of C-20 gibberellins to form the corresponding C-19 lactones, via a three-step oxidation at C-20 of the GA skeleton. Also converts GA53 to GA20. GA25 is also formed as a minor product.\" [PMID:32652020, PMID:7604047]","metadata":null},{"id":"7c614074ba3647618507eae83a85ef2d","type":"GO_TERM","name":"gibberellin 3-beta-dioxygenase activity","canonical_id":"go:GO:0016707","description":"\"Catalysis of the reaction: a gibberellin + 2-oxoglutarate + O2 = a 3-beta-hydroxy-gibberellin + succinate + CO2.\" [EC:1.14.11.15, PMID:32652020]","metadata":null},{"id":"5526cac14bad49d78c4d6945c3cd6331","type":"GO_TERM","name":"gibberellin A4 carboxyl methyltransferase activity","canonical_id":"go:GO:0102118","description":"\"Catalysis of the reaction: gibberellin A4 + S-adenosyl-L-methionine = gibberellin A4 methyl ester + S-adenosyl-L-homocysteine.\" [EC:2.1.1.276, GOC:pz]","metadata":null},{"id":"aebcd01db4af40a88e8d239ea3a32c51","type":"GO_TERM","name":"gibberellin A9 carboxyl methyltransferase activity","canonical_id":"go:GO:0102117","description":"\"Catalysis of the reaction: gibberellin A9 + S-adenosyl-L-methionine = gibberellin A9 methyl ester + S-adenosyl-L-homocysteine.\" [EC:2.1.1.275, GOC:pz]","metadata":null},{"id":"fd7c0320c48b454db615c61c60ac16f1","type":"GO_TERM","name":"gibberellin beta-D-glucosyltransferase activity","canonical_id":"go:GO:0047928","description":"\"Catalysis of the reaction: UDP-glucose + gibberellin = UDP + gibberellin 2-O-beta-D-glucoside.\" [EC:2.4.1.176, MetaCyc:GIBBERELLIN-BETA-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"ab4edbfd207049f190c8f9f9f291595b","type":"GO_TERM","name":"gibberellin binding","canonical_id":"go:GO:0010331","description":"\"Binding to a gibberellin, a plant hormone that regulates aspects of plant growth.\" [GOC:tair_curators]","metadata":null},{"id":"195d8d7128a24863927d65e5e56cce89","type":"GO_TERM","name":"gibberellin biosynthetic process","canonical_id":"go:GO:0009686","description":"\"The chemical reactions and pathways resulting in the formation of gibberellin. Gibberellins are a class of highly modified terpenes that function as plant growth regulators.\" [ISBN:0387969845]","metadata":null},{"id":"4faad6d1ef5141d8a347276f8e223d6b","type":"GO_TERM","name":"gibberellin carboxyl-O-methyltransferase activity","canonical_id":"go:GO:0010341","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a gibberellin = S-adenosyl-L-homocysteine + a gibberellin methyl ester.\" [PMID:17220201]","metadata":null},{"id":"15a8bc34158344a9a8a7e8f30b7094a0","type":"GO_TERM","name":"gibberellin catabolic process","canonical_id":"go:GO:0045487","description":"\"The chemical reactions and pathways resulting in the breakdown of gibberellin. Gibberellins are a class of highly modified terpenes that function as plant growth regulators.\" [GOC:curators]","metadata":null},{"id":"4e8e578d36334a69841f467cff051385","type":"GO_TERM","name":"gibberellin mediated signaling pathway","canonical_id":"go:GO:0010476","description":"\"The series of molecular signals generated as a consequence of gibberellin stimulus.\" [PMID:17521411]","metadata":null},{"id":"834d6c1b5d10472b9b6ba7d19e72067e","type":"GO_TERM","name":"gibberellin metabolic process","canonical_id":"go:GO:0009685","description":"\"The chemical reactions and pathways involving gibberellin. Gibberellins are a class of highly modified terpenes that function as plant growth regulators.\" [ISBN:0387969845]","metadata":null},{"id":"1bde2a763be94e00a61c4f0cc616e228","type":"GO_TERM","name":"gibberellin transmembrane transporter activity","canonical_id":"go:GO:1905201","description":"\"Enables the transfer of gibberellin from one side of a membrane to the other.\" [GO_REF:0000070, GOC:TermGenie, PMID:27139299]","metadata":null},{"id":"8ee153e7b13c481b8c9cd38cf0a63935","type":"GO_TERM","name":"gland development","canonical_id":"go:GO:0048732","description":"\"The process whose specific outcome is the progression of a gland over time, from its formation to the mature structure. A gland is an organ specialised for secretion.\" [GOC:jid]","metadata":null},{"id":"5a7da206731e4a76820be6dd8d238a27","type":"GO_TERM","name":"gland morphogenesis","canonical_id":"go:GO:0022612","description":"\"The process in which the anatomical structures of a gland are generated and organized.\" [GOC:isa_complete]","metadata":null},{"id":"ca80102423fc416980f068b5b2e0dc9c","type":"GO_TERM","name":"glandular epithelial cell development","canonical_id":"go:GO:0002068","description":"\"The process whose specific outcome is the progression of a glandular epithelial cell over time, from its formation to the mature structure. A glandular epithelial cell is a columnar/cuboidal epithelial cell is a cell found in a two dimensional sheet with a free surface exposed to the lumen of a gland.\" [GOC:dph]","metadata":null},{"id":"c9cb4523b62445099c96240fd227abb9","type":"GO_TERM","name":"glandular epithelial cell differentiation","canonical_id":"go:GO:0002067","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glandular epithelial cell. A glandular epithelial cell is a columnar/cuboidal epithelial cell found in a two dimensional sheet with a free surface exposed to the lumen of a gland.\" [GOC:dph]","metadata":null},{"id":"1f955167f6a4456e97650768160cf6fa","type":"GO_TERM","name":"glandular epithelial cell maturation","canonical_id":"go:GO:0002071","description":"\"The developmental process, independent of morphogenetic (shape) change, that is required for a glandular epithelial cell to attain its fully functional state. A glandular epithelial cell is a columnar/cuboidal epithelial cell is a cell found in a two dimensional sheet with a free surface exposed to the lumen of a gland.\" [GOC:dph]","metadata":null},{"id":"de89a80b089b4f71a6e36cd499b2e265","type":"DRUG","name":"glasdegib","canonical_id":"gtopdb:8201","description":null,"metadata":null},{"id":"163acd79b8df42258ed1b3ee682fdbe8","type":"DRUG","name":"glasdegib","canonical_id":"chembl:CHEMBL2043437","description":null,"metadata":null},{"id":"a1f4ab92a0d3470b9599333272fe34d5","type":"COMBINATION_TREATMENT","name":"glasdegib + ivosidenib","canonical_id":"ctgov_combo:ctgov-combo-1b77215376841439","description":null,"metadata":null},{"id":"35b04419655f42c391eb849b5e42d464","type":"DISEASE","name":"glaucoma","canonical_id":"mondo:0005041","description":null,"metadata":null},{"id":"5a51e54adf0844188880fbb19c7b194c","type":"GO_TERM","name":"glial cell activation","canonical_id":"go:GO:0061900","description":"\"A change in morphology and behavior of a glial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:aruk, GOC:bc, PMID:18723082]","metadata":null},{"id":"89a5c18770b9447fad4cec2e95f7040a","type":"GO_TERM","name":"glial cell apoptotic process","canonical_id":"go:GO:0034349","description":"\"Any apoptotic process in a glial cell, a non-neuronal cell of the nervous system.\" [CL:0000125, GOC:mtg_apoptosis, GOC:sart]","metadata":null},{"id":"ea788c9e742f4045901cc0e5ccb45316","type":"GO_TERM","name":"glial cell development","canonical_id":"go:GO:0021782","description":"\"The process aimed at the progression of a glial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5638d4a6b32546188209e72fd8a8f54d","type":"GO_TERM","name":"glial cell differentiation","canonical_id":"go:GO:0010001","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a glial cell.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"377722443edb4198b324bfe87055ff8f","type":"GO_TERM","name":"glial cell differentiation involved in amphid sensory organ development","canonical_id":"go:GO:0003398","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a glial cell of the amphid sensory organ.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"26a70ed1ea0340aeb6f83d62bb8531b8","type":"GO_TERM","name":"glial cell fate commitment","canonical_id":"go:GO:0021781","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a glial cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6a60c8ceb87e48338ee49b39d8f680c9","type":"GO_TERM","name":"glial cell fate determination","canonical_id":"go:GO:0007403","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a glial cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"c4208b29a527461484eba2b298fba828","type":"GO_TERM","name":"glial cell fate specification","canonical_id":"go:GO:0021780","description":"\"The process in which a cell becomes capable of differentiating autonomously into a glial cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6885aa9c501248d5939e92dd8ba0655a","type":"GO_TERM","name":"glial cell growth","canonical_id":"go:GO:0042065","description":"\"Growth of glial cells, non-neuronal cells that provide support and nutrition, maintain homeostasis, form myelin, and participate in signal transmission in the nervous system.\" [GOC:dph, GOC:isa_complete, GOC:jid]","metadata":null},{"id":"d7974688271c42428552eb00ba184910","type":"GO_TERM","name":"glial cell migration","canonical_id":"go:GO:0008347","description":"\"The orderly movement of a glial cell, non-neuronal cells that provide support and nutrition, maintain homeostasis, form myelin, and participate in signal transmission in the nervous system.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"2cf0059e50f5447391d98779e0561a18","type":"GO_TERM","name":"glial cell migration in anterior lateral line nerve","canonical_id":"go:GO:0048912","description":"\"The movement of a glial cell along the axons in the anterior lateral line nerve.\" [PMID:12062041]","metadata":null},{"id":"7c1adfc02cd54826b7f20a9671d1ed70","type":"GO_TERM","name":"glial cell migration in posterior lateral line nerve","canonical_id":"go:GO:0048930","description":"\"The movement of a glial cell along the axons in the posterior lateral line nerve.\" [PMID:12062041]","metadata":null},{"id":"74c4914d730445b680e232c439b39492","type":"GO_TERM","name":"glial cell projection","canonical_id":"go:GO:0097386","description":"\"A prolongation or process extending from a glial cell.\" [GOC:mc]","metadata":null},{"id":"3ae0c6d85a974ce09d74b85c6cd99597","type":"GO_TERM","name":"glial cell projection elongation","canonical_id":"go:GO:0106091","description":"\"The process of creating an elongation or projection from a glial cell.\" [GOC:ha, PMID:27131624]","metadata":null},{"id":"069ccc6d107b451bb9d543cb7a974747","type":"GO_TERM","name":"glial cell proliferation","canonical_id":"go:GO:0014009","description":"\"The multiplication or reproduction of glial cells by cell division, resulting in the expansion of their population. Glial cells exist throughout the nervous system, and include Schwann cells, astrocytes, and oligodendrocytes among others.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"cfec14b43b4f42b0837657b1fcc78230","type":"GO_TERM","name":"glial cell-derived neurotrophic factor production","canonical_id":"go:GO:0044467","description":"\"The regulated release of glial cell line-derived neurotrophic factor from a cell. Glial cell-derived neurotrophic factor (GDNF) is a small protein that potently promotes the survival of many types of neurons, notably dopaminergic and motor neurons.\" [GOC:yaf, PMID:17505307]","metadata":null},{"id":"dabac31ea51f4fb393515909ff1ed7c4","type":"GO_TERM","name":"glial cell-derived neurotrophic factor receptor activity","canonical_id":"go:GO:0016167","description":"\"Combining with glial cell line-derived neurotrophic factor and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"ede0a590de024e77aee91b936517f549","type":"GO_TERM","name":"glial cell-derived neurotrophic factor receptor binding","canonical_id":"go:GO:0030116","description":"\"A growth factor that binds selectively and non-covalently to glial cell-derived neurotrophic factor receptors.\" [GOC:vw, PMID:11476867]","metadata":null},{"id":"74f3ac4c372e4f0483442a473d502a77","type":"GO_TERM","name":"glial cell-derived neurotrophic factor receptor signaling pathway","canonical_id":"go:GO:0035860","description":"\"The series of molecular signals initiated by a ligand binding to a glial cell-derived neurotrophic factor receptor.\" [GOC:yaf, PMID:12953054, PMID:29245123]","metadata":null},{"id":"5ed45b285d444ac7bf28e7549684f20f","type":"GO_TERM","name":"glial cell-neuron signaling","canonical_id":"go:GO:0150098","description":"\"Cell-cell signaling that mediates the transfer of information from a glial cell to a neuron. This signaling has been shown to be mediated by various molecules, depending on which glial cells release them, and in which tissues the signaling occurs, e.g. microglial cell-derived nerve growth factor (NGF) in the retina, or microglial cell-derived superoxide ions in the cerebellum.\" [GOC:aruk, GOC:bc, PMID:14980203, PMID:16144764, PMID:16547515, PMID:18685038, PMID:27788368, PMID:9459440]","metadata":null},{"id":"48c1fb21d1714132a7603a1999040dda","type":"GO_TERM","name":"glial cytoplasmic inclusion","canonical_id":"go:GO:0097409","description":"\"Non-membrane-bound cytoplasmic inclusions composed of 10-40 nm granule-coated fibrils. These inclusions have an abnormal accumulation of alpha-synuclein protein and are found in association with multiple system atrophy.\" [NIF_Subcellular:nlx_subcell_20090703, PMID:21562886, PMID:2559165]","metadata":null},{"id":"b21de1161dda45e4b1ff7772136f41cf","type":"GO_TERM","name":"glial filament","canonical_id":"go:GO:0097426","description":"\"An intermediate filament composed of glial fibrillary acidic protein (GFAP) and found in astrocytes.\" [NIF_Subcellular:sao1863852493]","metadata":null},{"id":"7cd03ede68ff44bc92f379a39f07e474","type":"GO_TERM","name":"glial limiting end-foot","canonical_id":"go:GO:0097451","description":"\"Terminal process of astrocyte that extends to the surface of the central nervous system. Together, glial limiting end-feet form the glial limiting membrane or glia limitans.\" [NIF_Subcellular:sao181458425]","metadata":null},{"id":"ea4c47de57354bc49243f58fcbf3daf6","type":"GO_TERM","name":"glial scar formation","canonical_id":"go:GO:7770037","description":"\"The process by which central nervous system glial and associated cells assemble and stabilize a dense, organized glial border at the site of injury. This involves proliferation and reorganization of reactive astrocytes and NG2 glia (oligodendrocyte precursor cells), deposition of extracellular matrix components, and formation of a barrier that modulates inflammation and regeneration.\" [PMID:20012068, PMID:23904622, PMID:27027288]","metadata":null},{"id":"36485fe8f873411d95a8bcb2e9b9bbd0","type":"DRUG","name":"glibenclamide","canonical_id":"gtopdb:2414","description":null,"metadata":null},{"id":"2bd1fcda16e245f99c0de951d230e315","type":"DRUG","name":"glibenclamide","canonical_id":"mesh:D005905","description":null,"metadata":null},{"id":"17b5f489ccec4082a98dc7764c3919a3","type":"DRUG","name":"glibenclamide","canonical_id":"chembl:CHEMBL472","description":null,"metadata":null},{"id":"e683fc69841a4de5a03bf2f7915d9e5c","type":"COMBINATION_TREATMENT","name":"glibenclamide + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-3027070f126b2839","description":null,"metadata":null},{"id":"4ac8b87f7fb94e07b247cf6173b47926","type":"COMBINATION_TREATMENT","name":"glibenclamide + vildagliptin","canonical_id":"ctgov_combo:ctgov-combo-ae5fa4aca055e835","description":null,"metadata":null},{"id":"49cfdad896f24544b52790e8af04f373","type":"GO_TERM","name":"glideosome","canonical_id":"go:GO:0160055","description":"\"A protein complex composed of at least GAP45 (gliding-associated protein), GAP50 and myosin heavy and light chains. Anchored via GAP50 to the inner membrane complex of motile and invasive forms of apicomplexan parasites and regulates parasite gliding motility and invasion of host cells.\" [PMID:12139608, PMID:15123738, PMID:19577950]","metadata":null},{"id":"d4b37cecb7004867a893c5024faa6401","type":"DRUG","name":"glimepiride","canonical_id":"mesh:C057619","description":null,"metadata":null},{"id":"c091aa3e10b243808dcda33258aa1caf","type":"GO_TERM","name":"glioblast division","canonical_id":"go:GO:0048860","description":"\"The process resulting in the physical partitioning and separation of a glioblast into daughter cells.\" [GOC:devbiol]","metadata":null},{"id":"cda1a48ba6754a1db51b66233e9f8b92","type":"DISEASE","name":"glioblastoma","canonical_id":"mondo:0018177","description":null,"metadata":null},{"id":"74e0e3b91a0e4718a01309c53ec10e4e","type":"GO_TERM","name":"gliogenesis","canonical_id":"go:GO:0042063","description":"\"The process that results in the generation of glial cells. This includes the production of glial progenitors and their differentiation into mature glia.\" [GOC:dgh, GOC:jid]","metadata":null},{"id":"73b1261a6cbf40a685e79432807e3e8b","type":"DISEASE","name":"glioma","canonical_id":"mondo:0021042","description":null,"metadata":null},{"id":"f655a3e9e6444bc2a0b4a45f140bc3f5","type":"DISEASE","name":"glioma susceptibility 1","canonical_id":"mondo:0024498","description":null,"metadata":null},{"id":"a69aba49d2264e50910d37b8a2ea2a87","type":"GO_TERM","name":"gliotoxin biosynthetic process","canonical_id":"go:GO:2001310","description":"\"The chemical reactions and pathways resulting in the formation of the epipolythiodioxopiperazine gliotoxin, a poisonous substance produced by some species of fungi.\" [GOC:di, PMID:16333108, PMID:17574915, PMID:18272357, PMID:29966253]","metadata":null},{"id":"0a6e431bceb0481782566f140943fb0d","type":"GO_TERM","name":"gliotoxin catabolic process","canonical_id":"go:GO:2001309","description":"\"The chemical reactions and pathways resulting in the breakdown of the epipolythiodioxopiperazine gliotoxin, a poisonous substance produced by some species of fungi.\" [GOC:di, PMID:16333108, PMID:17574915, PMID:18272357]","metadata":null},{"id":"2bf46475ef1642ad9ef50c8b49286881","type":"DRUG","name":"glipizide","canonical_id":"mesh:D005913","description":null,"metadata":null},{"id":"f25c6e48fd4e43c297f63c670992f91e","type":"DRUG","name":"gliquidone","canonical_id":"mesh:C010969","description":null,"metadata":null},{"id":"1e890e4d544b4e2ea220d62bf106e625","type":"GO_TERM","name":"global gene silencing by mRNA cleavage","canonical_id":"go:GO:0098795","description":"\"A posttranscriptional gene silencing pathway that involves the cleavage of mRNAs in a non-gene-specific manner.\" [PMID:15009896]","metadata":null},{"id":"f1aa3d1dc77f4d6dbd3c8c6375f071cd","type":"GO_TERM","name":"global genome nucleotide-excision repair","canonical_id":"go:GO:0070911","description":"\"The nucleotide-excision repair process in which DNA lesions are removed from nontranscribed strands and from transcriptionally silent regions over the entire genome.\" [PMID:10197977, PMID:18794354]","metadata":null},{"id":"348cd5a510e34a9d994f7bb031152d4f","type":"GO_TERM","name":"globose nucleus development","canonical_id":"go:GO:0021736","description":"\"The process whose specific outcome is the progression of the globose nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7ef6c86a27c54d59a4521d4299244fd8","type":"GO_TERM","name":"globoside alpha-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0047277","description":"\"Catalysis of the reaction: N-acetyl-D-galactosaminyl-(1,3)-D-galactosyl-(1,4)-D-galactosyl-(1,4)-D-glucosylceramide + UDP-N-acetylgalactosamine = N-acetyl-D-galactosaminyl-N-acetyl-D-galactosaminyl-(1,3)-D-galactosyl-(1,4)-D-galactosyl-(1,4)-D-glucosylceramide + UDP.\" [EC:2.4.1.88, MetaCyc:2.4.1.88-RXN]","metadata":null},{"id":"c8f55d0f36bb4adf895f7bc29fd674ce","type":"GO_TERM","name":"globoside biosynthetic process","canonical_id":"go:GO:0001576","description":"\"The chemical reactions and pathways resulting in the formation of gobliosides that begins with the synthesis of a tetrasaccharide core GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide. This core can be further elongated with the sequential addition of various carbohydrate units.\" [PMID:35536927]","metadata":null},{"id":"3a70aecc5f6044118e23bcc686a855d0","type":"GO_TERM","name":"globoside metabolic process","canonical_id":"go:GO:0001575","description":"\"The chemical reactions and pathways involving globosides, globotetraosylceramides, ceramides containing a core structure of GalNAc-beta-(1->3)-Gal-alpha-(1->4)-Glc(I). Globosides are the major neutral glycosphingolipid in normal kidneys and erythrocytes.\" [ISBN:0198506732]","metadata":null},{"id":"eccb7c183a374f6596986f7cc9690c2f","type":"GO_TERM","name":"globus pallidus development","canonical_id":"go:GO:0021759","description":"\"The progression of the globus pallidus over time from its initial formation until its mature state. The globus pallidus is one of the basal ganglia involved with control of voluntary movement in the brain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"61547ca686534e0b995e7ae7f725f455","type":"GO_TERM","name":"glomerular basement membrane development","canonical_id":"go:GO:0032836","description":"\"The process whose specific outcome is the progression of the glomerular basement membrane over time, from its formation to the mature structure. The glomerular basement membrane is the basal laminal portion of the glomerulus which performs the actual filtration.\" [GOC:sr]","metadata":null},{"id":"75acad614ee84e569f90688cdf2bdce4","type":"GO_TERM","name":"glomerular capillary formation","canonical_id":"go:GO:0072104","description":"\"The process that gives rise to a glomerular capillary. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c0c1d13537b940578eb7f1bd050e57fa","type":"GO_TERM","name":"glomerular endothelium development","canonical_id":"go:GO:0072011","description":"\"The process whose specific outcome is the progression of the glomerular endothelium over time, from its formation to the mature structure. The glomerular endothelium is an epithelial tissue that covers the internal surfaces of the glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2a90a24023b64bcc99719e25712b6c7c","type":"GO_TERM","name":"glomerular endothelium fenestra","canonical_id":"go:GO:0036053","description":"\"A large plasma membrane-lined circular pore that perforates the flattened glomerular endothelium and, unlike those of other fenestrated capillaries, is not spanned by diaphragms; the density and size of glomerular fenestrae account, at least in part, for the high permeability of the glomerular capillary wall to water and small solutes.\" [GOC:cjm, MP:0011454, PMID:19129259]","metadata":null},{"id":"6c6591f7031c4daabc35a33a238744fc","type":"GO_TERM","name":"glomerular epithelial cell development","canonical_id":"go:GO:0072310","description":"\"The process whose specific outcome is the progression of a glomerular epithelial cell over time, from its formation to the mature structure. Glomerular epithelial cells are specialized epithelial cells that form part of the glomerulus; there are two types, glomerular parietal epithelial cells and glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"7803639e184d497e8448c93b7bdab1c6","type":"GO_TERM","name":"glomerular epithelial cell differentiation","canonical_id":"go:GO:0072311","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glomerular epithelial cell. Glomerular epithelial cells are specialized epithelial cells that form part of the glomerulus; there are two types, glomerular parietal epithelial cells and glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"694ad6ca180a4f6a83cb7275e1d38436","type":"GO_TERM","name":"glomerular epithelial cell fate commitment","canonical_id":"go:GO:0072314","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a glomerular epithelial cell. Glomerular epithelial cells are specialized epithelial cells that form part of the glomerulus; there are two types, glomerular parietal epithelial cells and glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4de092c0e2614550acad74e2f29c92da","type":"GO_TERM","name":"glomerular epithelium development","canonical_id":"go:GO:0072010","description":"\"The process whose specific outcome is the progression of the glomerular epithelium over time, from its formation to the mature structure. The glomerular epithelium is an epithelial tissue that covers the outer surfaces of the glomerulus. The glomerular epithelium consists of both parietal and visceral epithelium. Metanephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport. A metanephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"afc90e91b8294dc3bc85cc3e245e39bc","type":"GO_TERM","name":"glomerular filtration","canonical_id":"go:GO:0003094","description":"\"The process in which plasma is filtered through the glomerular membrane which consists of capillary endothelial cells, the basement membrane, and epithelial cells. The glomerular filtrate is the same as plasma except it has no significant amount of protein.\" [GOC:mtg_cardio, GOC:sart, ISBN:0721643949]","metadata":null},{"id":"f55f39f3fd2f4db5b04b9c6897bc662e","type":"GO_TERM","name":"glomerular mesangial cell development","canonical_id":"go:GO:0072144","description":"\"The process whose specific outcome is the progression of a glomerular mesangial cell in the kidney over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c335ec207cf648e4b53f93027b073fa9","type":"GO_TERM","name":"glomerular mesangial cell differentiation","canonical_id":"go:GO:0072008","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the glomerular mesangial cells of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c647e28571934abf9d651e704adc2e11","type":"GO_TERM","name":"glomerular mesangial cell fate commitment","canonical_id":"go:GO:0072152","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a glomerular mesangial cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"47643c4511884a6d9df9dd4d391b8cc7","type":"GO_TERM","name":"glomerular mesangial cell proliferation","canonical_id":"go:GO:0072110","description":"\"The multiplication or reproduction of glomerular mesangial cells, resulting in the expansion of the population.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ed13788bdddd4710b4c64347b1cf6e4c","type":"GO_TERM","name":"glomerular mesangium development","canonical_id":"go:GO:0072109","description":"\"The process whose specific outcome is the progression of the glomerular mesangium over time, from its formation to the mature structure. The glomerular mesangium is the thin membrane connective tissue composed of mesangial cells, which helps to support the capillary loops in a renal glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"70b7b6b077f04813856fb3e0fb19fa4e","type":"GO_TERM","name":"glomerular parietal epithelial cell development","canonical_id":"go:GO:0072016","description":"\"The process whose specific outcome is the progression of a glomerular parietal epithelial cell over time, from its formation to the mature structure. Glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0c4352b8c2534ffa95fc447fda187e42","type":"GO_TERM","name":"glomerular parietal epithelial cell differentiation","canonical_id":"go:GO:0072139","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glomerular parietal epithelial cell. Glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"58321afbb16642fa84386ae4137bc627","type":"GO_TERM","name":"glomerular parietal epithelial cell fate commitment","canonical_id":"go:GO:0072147","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a glomerular parietal epithelial cell. Glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport. These cells may also give rise to podocytes.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a9fd953a021d401ba0fe6aa3cff8d95d","type":"DISEASE","name":"glomerulonephritis","canonical_id":"mondo:0002462","description":null,"metadata":null},{"id":"fcbe4f8ae10d42e8945f8f06512d841d","type":"GO_TERM","name":"glomerulus development","canonical_id":"go:GO:0032835","description":"\"The progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft which forms a close network with the visceral epithelium (podocytes) and the mesangium to form the filtration barrier and is surrounded by Bowman's capsule in nephrons of the vertebrate kidney. The glomerulus is part of the nephron and is restricted to one body segment.\" [GOC:mah, GOC:mtg_kidney_jan10]","metadata":null},{"id":"a667a8494e3942b6971c12371f1900c2","type":"GO_TERM","name":"glomerulus morphogenesis","canonical_id":"go:GO:0072102","description":"\"The process in which the anatomical structures of the glomerulus are generated and organized. The glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"965a8b131afc4df9af04130b1fd47ba8","type":"GO_TERM","name":"glomerulus vasculature development","canonical_id":"go:GO:0072012","description":"\"The biological process whose specific outcome is the progression of a glomerulus vasculature from an initial condition to its mature state. This process begins with the formation of the glomerulus vasculature and ends with the mature structure. The glomerulus vasculature is composed of the tubule structures that carry blood or lymph in the glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2688be3d13154b46a048dc13b9236e73","type":"GO_TERM","name":"glomerulus vasculature morphogenesis","canonical_id":"go:GO:0072103","description":"\"The process in which the anatomical structures of the glomerulus vasculature are generated and organized. The glomerulus vasculature is composed of the tubule structures that carry blood or lymph in the glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b6219a382ac2442399986ff5b1d6c70c","type":"GO_TERM","name":"glomus development","canonical_id":"go:GO:0072013","description":"\"The progression of the glomus over time from its initial formation until its mature state. The glomus forms from the splanchnic intermediate mesoderm and is the vascularized filtration unit, filtering the blood before it enters the tubules. The glomus is external to the nephron and extends over more than one body segment.\" [GOC:mtg_kidney_jan10, PMID:10572058, PMID:15647339, PMID:9268568, XAO:0000318]","metadata":null},{"id":"8ccdb64e870d4443b08e00559fb0b2a1","type":"GO_TERM","name":"glossopharyngeal nerve development","canonical_id":"go:GO:0021563","description":"\"Various sensory and motor branches of the glossopharyngeal nerve supply nerve connections to the pharynx and back of the tongue. The branchial motor component contains motor fibers that innervate muscles that elevate the pharynx and larynx, and the tympanic branch supplies parasympathetic fibers to the otic ganglion.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d5f2b3aebc5b44af85af13014ba31546","type":"GO_TERM","name":"glossopharyngeal nerve formation","canonical_id":"go:GO:0021616","description":"\"The process that gives rise to the glossopharyngeal nerve. This process pertains to the initial formation of a structure from unspecified parts. Various sensory and motor branches of the glossopharyngeal nerve supply nerve connections to the pharynx and back of the tongue. The branchial motor component contains motor fibers that innervate muscles that elevate the pharynx and larynx, and the tympanic branch supplies parasympathetic fibers to the otic ganglion.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"095fd7f0779b46df9f67b9e5e9dec12d","type":"GO_TERM","name":"glossopharyngeal nerve maturation","canonical_id":"go:GO:0021614","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the glossopharyngeal nerve to attain its fully functional state. Various sensory and motor branches of the glossopharyngeal nerve supply nerve connections to the pharynx and back of the tongue. The branchial motor component contains motor fibers that innervate muscles that elevate the pharynx and larynx, and the tympanic branch supplies parasympathetic fibers to the otic ganglion.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"ac8ae378cc204bec9ed90872d6bb0997","type":"GO_TERM","name":"glossopharyngeal nerve morphogenesis","canonical_id":"go:GO:0021615","description":"\"The process in which the anatomical structure of the glossopharyngeal nerve is generated and organized. Various sensory and motor branches of the glossopharyngeal nerve supply nerve connections to the pharynx and back of the tongue. The branchial motor component contains motor fibers that innervate muscles that elevate the pharynx and larynx, and the tympanic branch supplies parasympathetic fibers to the otic ganglion.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"f0d6385465614e479e29403ebbb9a072","type":"GO_TERM","name":"glossopharyngeal nerve structural organization","canonical_id":"go:GO:0021617","description":"\"The process that contributes to the act of creating the structural organization of the glossopharyngeal nerve. This process pertains to the physical shaping of a rudimentary structure. Various sensory and motor branches of the glossopharyngeal nerve supply nerve connections to the pharynx and back of the tongue. The branchial motor component contains motor fibers that innervate muscles that elevate the pharynx and larynx, and the tympanic branch supplies parasympathetic fibers to the otic ganglion.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"cf70c0d0c5424c1fa80eae3bf131d8f5","type":"DRUG","name":"glucagon","canonical_id":"gtopdb:1136","description":null,"metadata":null},{"id":"80c23629d53e4647b0719c881ce4017f","type":"DRUG","name":"glucagon","canonical_id":"chembl:CHEMBL5314342","description":null,"metadata":null},{"id":"b515c763f859445d973317fffca715fd","type":"GO_TERM","name":"glucagon family peptide binding","canonical_id":"go:GO:0120022","description":"\"Binding to a member of the glucagon family peptide hormone (e.g. glucagon, glucagon-like peptides, oxyntomodulin, glicentin, ADCYAP1, GHRH, secretin, VIP, GIP).\" [PMID:17715056]","metadata":null},{"id":"bdd4c778ee544ccf902ed73324d97334","type":"GO_TERM","name":"glucagon processing","canonical_id":"go:GO:0120116","description":"\"The formation of mature glucagon by proteolysis of the precursor proglucagon.\" [PMID:28719828]","metadata":null},{"id":"a5beb2cc5ca54bd58096eb65337a6a97","type":"GO_TERM","name":"glucagon receptor activity","canonical_id":"go:GO:0004967","description":"\"Combining with glucagon and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.\" [GOC:mah, GOC:signaling, PMID:22438981]","metadata":null},{"id":"87664a225c0448aa8ab98786564d3776","type":"GO_TERM","name":"glucagon receptor binding","canonical_id":"go:GO:0031769","description":"\"Binding to a glucagon receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a72a019c81c94a2d9fc40a6340b239b9","type":"GO_TERM","name":"glucagon secretion","canonical_id":"go:GO:0070091","description":"\"The regulated release of glucagon from secretory granules in the A (alpha) cells of the pancreas (islets of Langerhans).\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"603094d260634934abd2c5050640f3f2","type":"GO_TERM","name":"glucagon-like peptide 1 receptor activity","canonical_id":"go:GO:0044508","description":"\"Combining with glucagon-like peptide 1 and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:jl, PMID:12529935]","metadata":null},{"id":"eff208de507f4e879cc2b3fdc10d73f3","type":"GO_TERM","name":"glucan 1,3-alpha-glucosidase activity","canonical_id":"go:GO:0033919","description":"\"Catalysis of the hydrolysis of terminal (1->3)-alpha-D-glucosidic links in 1,3-alpha-D-glucans.\" [EC:3.2.1.84]","metadata":null},{"id":"0cbe96a949ac44e794dedefcefc9715a","type":"GO_TERM","name":"glucan 1,4-alpha-glucosidase activity","canonical_id":"go:GO:0004339","description":"\"Catalysis of the hydrolysis of terminal (1->4)-linked alpha-D-glucose residues successively from non-reducing ends of the chains with release of beta-D-glucose.\" [EC:3.2.1.3]","metadata":null},{"id":"8e1fd0cbfd20407ebb6d6d89ff8fcd6f","type":"GO_TERM","name":"glucan 1,4-alpha-maltohexaosidase activity","canonical_id":"go:GO:0033927","description":"\"Catalysis of the hydrolysis of (1->4)-alpha-D-glucosidic linkages in amylaceous polysaccharides, to remove successive maltohexaose residues from the non-reducing chain ends.\" [EC:3.2.1.98]","metadata":null},{"id":"3adce5eab2684170bc49233b8c9381d9","type":"GO_TERM","name":"glucan 1,4-alpha-maltohydrolase activity","canonical_id":"go:GO:0043897","description":"\"Catalysis of the hydrolysis of (1->4)-alpha-D-glucosidic linkages in polysaccharides so as to remove successive alpha-maltose residues from the non-reducing ends of the chains.\" [EC:3.2.1.133]","metadata":null},{"id":"c321eea04bbf4245a32456d028faa5ff","type":"GO_TERM","name":"glucan 1,4-alpha-maltotetraohydrolase activity","canonical_id":"go:GO:0033910","description":"\"Catalysis of the hydrolysis of (1->4)-alpha-D-glucosidic linkages in amylaceous polysaccharides, to remove successive maltotetraose residues from the non-reducing chain ends.\" [EC:3.2.1.60]","metadata":null},{"id":"46d5aa26a13e4020adc874e575d6d55a","type":"GO_TERM","name":"glucan 1,4-alpha-maltotriohydrolase activity","canonical_id":"go:GO:0033934","description":"\"Catalysis of the hydrolysis of (1->4)-alpha-D-glucosidic linkages in amylaceous polysaccharides, to remove successive maltotriose residues from the non-reducing chain ends.\" [EC:3.2.1.116]","metadata":null},{"id":"1b4b2096f4ef4ae98bceba63d1b9acbe","type":"GO_TERM","name":"glucan 1,4-beta-glucosidase activity","canonical_id":"go:GO:0031217","description":"\"Catalysis of the hydrolysis of (1->4) linkages in (1->4)-beta-D-glucans, to remove successive glucose units.\" [EC:3.2.1.74, GOC:mlg]","metadata":null},{"id":"90b729be673f40a2b80714e67cde66fe","type":"GO_TERM","name":"glucan 1,6-alpha-glucosidase activity","canonical_id":"go:GO:0043896","description":"\"Catalysis of the hydrolysis of (1->6)-alpha-D-glucosidic linkages in (1->6)-alpha-D-glucans and derived oligosaccharides.\" [EC:3.2.1.70]","metadata":null},{"id":"03bf4ebfc3bc47788b8d952a45a303b6","type":"GO_TERM","name":"glucan 1,6-alpha-isomaltosidase activity","canonical_id":"go:GO:0033923","description":"\"Catalysis of the hydrolysis of (1->6)-alpha-D-glucosidic linkages in polysaccharides, to remove successive isomaltose units from the non-reducing ends of the chains.\" [EC:3.2.1.94]","metadata":null},{"id":"ec3258f764f146bc9d0ec5615acc0dc8","type":"GO_TERM","name":"glucan biosynthetic process","canonical_id":"go:GO:0009250","description":"\"The chemical reactions and pathways resulting in the formation of glucans, polysaccharides consisting only of glucose residues.\" [GOC:curators]","metadata":null},{"id":"93c5966dd176450197d90e3f065c78dc","type":"GO_TERM","name":"glucan catabolic process","canonical_id":"go:GO:0009251","description":"\"The chemical reactions and pathways resulting in the breakdown of glucans, polysaccharides consisting only of glucose residues.\" [GOC:curators]","metadata":null},{"id":"3989b5a28ed9405483e40effa184cfdc","type":"GO_TERM","name":"glucan endo-1,2-beta-glucosidase activity","canonical_id":"go:GO:0033913","description":"\"Catalysis of the random hydrolysis of (1->2)-glucosidic linkages in (1->2)-beta-D-glucans.\" [EC:3.2.1.71]","metadata":null},{"id":"b42b6ebb27be470c8bf66279557a5ae6","type":"GO_TERM","name":"glucan endo-1,3-alpha-glucosidase activity","canonical_id":"go:GO:0051118","description":"\"Catalysis of the endohydrolysis of (1->3)-alpha-D-glucosidic linkages in isolichenin, pseudonigeran and nigeran.\" [EC:3.2.1.59]","metadata":null},{"id":"1a202f9a35b8443e976a20cdf63fb114","type":"GO_TERM","name":"glucan endo-1,3-beta-D-glucosidase activity","canonical_id":"go:GO:0042973","description":"\"Catalysis of the hydrolysis of (1->3)-beta-D-glucosidic linkages in (1->3)-beta-D-glucans.\" [EC:3.2.1.39]","metadata":null},{"id":"dbd29de6d3f44818b35ea70f755521d4","type":"GO_TERM","name":"glucan endo-1,6-beta-glucosidase activity","canonical_id":"go:GO:0046557","description":"\"Catalysis of the random hydrolysis of (1->6) linkages in (1->6)-beta-D-glucans.\" [EC:3.2.1.75]","metadata":null},{"id":"97e4cfdc24534a5099b73509b37c47fd","type":"GO_TERM","name":"glucan exo-1,3-beta-glucosidase activity","canonical_id":"go:GO:0004338","description":"\"Catalysis of the successive hydrolysis of beta-D-glucose units from the non-reducing ends of (1->3)-beta-D-glucans, releasing alpha-glucose.\" [EC:3.2.1.58]","metadata":null},{"id":"b5cece24a6d64831892387381612cd5e","type":"GO_TERM","name":"glucan metabolic process","canonical_id":"go:GO:0044042","description":"\"The chemical reactions and pathways involving glucans, polysaccharides consisting only of glucose residues.\" [GOC:jl]","metadata":null},{"id":"2da7ba6566f44bdc872642cf63cfab6b","type":"GO_TERM","name":"glucanosyltransferase activity","canonical_id":"go:GO:0042123","description":"\"Catalysis of the splitting and linkage of glucan molecules, resulting in glucan chain elongation.\" [GOC:jl]","metadata":null},{"id":"be652d116ef24b83bf6001cdbf187203","type":"GO_TERM","name":"glucarate O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047170","description":"\"Catalysis of the reaction: D-glucarate + sinapoyl-CoA = 2-O-sinapoyl-D-glucarate + CoA.\" [EC:2.3.1.131, RHEA:23308]","metadata":null},{"id":"590c12d8a7374cab9435b8ef4bd5229b","type":"GO_TERM","name":"glucarate dehydratase activity","canonical_id":"go:GO:0008872","description":"\"Catalysis of the reaction: D-glucarate = 5-dehydro-4-deoxy-D-glucarate + H2O.\" [EC:4.2.1.40]","metadata":null},{"id":"5176f67d035f45bf91f79f383be5f1a1","type":"GO_TERM","name":"glucarolactone O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047171","description":"\"Catalysis of the reaction: glucarolactone + sinapoyl-CoA = O-sinapoylglucarolactone + CoA.\" [EC:2.3.1.132, MetaCyc:2.3.1.132-RXN]","metadata":null},{"id":"3edc91f6e3ff46c49f4afc36b1c17c6c","type":"GO_TERM","name":"glucocorticoid biosynthetic process","canonical_id":"go:GO:0006704","description":"\"The chemical reactions and pathways resulting in the formation of glucocorticoids, hormonal C21 corticosteroids synthesized from cholesterol.\" [ISBN:0198506732]","metadata":null},{"id":"5b4d7de9e5364238b957cde311b5387f","type":"GO_TERM","name":"glucocorticoid catabolic process","canonical_id":"go:GO:0006713","description":"\"The chemical reactions and pathways resulting in the breakdown of glucocorticoids, hormonal C21 corticosteroids synthesized from cholesterol.\" [ISBN:0198506732]","metadata":null},{"id":"54cc53719f954e4dabaa4dbfff9d57ce","type":"GO_TERM","name":"glucocorticoid metabolic process","canonical_id":"go:GO:0008211","description":"\"The chemical reactions and pathways involving glucocorticoids, hormonal C21 corticosteroids synthesized from cholesterol. Glucocorticoids act primarily on carbohydrate and protein metabolism, and have anti-inflammatory effects.\" [ISBN:0198506732]","metadata":null},{"id":"11755a85f44a49e680488f057b6b7894","type":"DISEASE","name":"glucocorticoid resistance","canonical_id":"mondo:0014421","description":null,"metadata":null},{"id":"2231be436e944bc4ac998c10f7c4c85f","type":"GO_TERM","name":"glucocorticoid secretion","canonical_id":"go:GO:0035933","description":"\"The regulated release of any glucocorticoid hormone into the circulatory system. Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.\" [GOC:sl]","metadata":null},{"id":"87627fefacd440b99cbe0d7bcfede3b8","type":"DISEASE","name":"glucocorticoid-remediable aldosteronism","canonical_id":"mondo:0007080","description":null,"metadata":null},{"id":"a3afa04a7b6f4ec38fdf48843090f2d5","type":"GO_TERM","name":"glucokinase activity","canonical_id":"go:GO:0004340","description":"\"Catalysis of the reaction: ATP + D-glucose = ADP + D-glucose-6-phosphate.\" [EC:2.7.1.2]","metadata":null},{"id":"ac4cfa2bf9ce4a0aa4f3d4ccc4191053","type":"GO_TERM","name":"glucomannan 4-beta-mannosyltransferase activity","canonical_id":"go:GO:0047259","description":"\"Catalysis of the reaction: glucomannan(n) + GDP-mannose = glucomannan(n+1) + GDP.\" [EC:2.4.1.32, MetaCyc:2.4.1.32-RXN]","metadata":null},{"id":"376cccee55324bdea1bc3ec81701ad23","type":"GO_TERM","name":"glucomannan binding","canonical_id":"go:GO:2001063","description":"\"Binding to glucomannan.\" [GOC:mengo_curators]","metadata":null},{"id":"b2bb1a844e6144679006421a2d85bda4","type":"GO_TERM","name":"glucomannan catabolic process","canonical_id":"go:GO:2000884","description":"\"The chemical reactions and pathways resulting in the breakdown of a glucomannan.\" [GOC:mengo_curators]","metadata":null},{"id":"d68df01879e6421c9f088e62df490980","type":"GO_TERM","name":"glucomannan metabolic process","canonical_id":"go:GO:0010391","description":"\"The chemical reactions and pathways involving glucomannan, a polysaccharide composed of D-glucose and D-mannose. The mannose units form the backbone structure (a linear main chain) with the D-glucose as single side-units.\" [GOC:tair_curators]","metadata":null},{"id":"82c5dbf756f44c20a2be60e1ab8429b7","type":"GO_TERM","name":"gluconate 2-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0008873","description":"\"Catalysis of the reaction: D-gluconate + NADP+ = 2-dehydro-D-gluconate + NADPH + H+.\" [EC:1.1.1.215]","metadata":null},{"id":"8e319d6aaac84245bddddb2b0bff3c71","type":"GO_TERM","name":"gluconate 2-dehydrogenase (acceptor) activity","canonical_id":"go:GO:0033717","description":"\"Catalysis of the reaction: D-gluconate + acceptor = 2-dehydro-D-gluconate + reduced acceptor.\" [RHEA:12769]","metadata":null},{"id":"261fdee779c241cc89179e2a3c1e1b69","type":"GO_TERM","name":"gluconate 5-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0008874","description":"\"Catalysis of the reaction: D-gluconate + NAD(P)+ = 5-dehydro-D-gluconate + NAD(P)H + H+.\" [EC:1.1.1.69]","metadata":null},{"id":"eee75cf9b8fb4532846dca6a41446fd6","type":"GO_TERM","name":"gluconate dehydratase activity","canonical_id":"go:GO:0047929","description":"\"Catalysis of the reaction: D-gluconate = 2-dehydro-3-deoxy-D-gluconate + H2O.\" [EC:4.2.1.39, RHEA:21612]","metadata":null},{"id":"ec9d93a5afaa41828139456760d9003c","type":"GO_TERM","name":"gluconate import across plasma membrane","canonical_id":"go:GO:0140270","description":"\"The directed movement of gluconate from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:10735857]","metadata":null},{"id":"b9189320094344ab9f2e67f5caa88379","type":"GO_TERM","name":"gluconate transmembrane transport","canonical_id":"go:GO:0035429","description":"\"The process in which gluconate is transported across a membrane. Gluconate is the aldonic acid derived from glucose.\" [GOC:vw, ISBN:0198506732]","metadata":null},{"id":"4c5b09fdcc5b4bc1bd8549cdda50e480","type":"GO_TERM","name":"gluconate transmembrane transporter activity","canonical_id":"go:GO:0015128","description":"\"Enables the transfer of gluconate from one side of a membrane to the other. Gluconate is the aldonic acid derived from glucose.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"79aa8fd0991148da856fb6089226f34c","type":"GO_TERM","name":"gluconeogenesis","canonical_id":"go:GO:0006094","description":"\"The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol.\" [MetaCyc:GLUCONEO-PWY]","metadata":null},{"id":"e58c424993e34e1b8d243b468dc9a1c6","type":"GO_TERM","name":"gluconokinase activity","canonical_id":"go:GO:0046316","description":"\"Catalysis of the reaction: D-gluconate + ATP = 6-phospho-D-gluconate + ADP + 2 H+.\" [EC:2.7.1.12, RHEA:19433]","metadata":null},{"id":"f89fc1859aa54d4199b15fe40c322b56","type":"GO_TERM","name":"gluconolactonase activity","canonical_id":"go:GO:0004341","description":"\"Catalysis of the reaction: D-glucono-1,5-lactone + H2O = D-gluconate.\" [EC:3.1.1.17]","metadata":null},{"id":"2bd0b4f7cfa64d369be8edd43ec5fbd8","type":"GO_TERM","name":"glucosaminate ammonia-lyase activity","canonical_id":"go:GO:0047930","description":"\"Catalysis of the reaction: 2-amino-2-deoxy-D-gluconate = 2-dehydro-3-deoxy-D-gluconate + NH4+.\" [RHEA:12488]","metadata":null},{"id":"bfcd4691f2a24e95803f2a31fec80d14","type":"GO_TERM","name":"glucosamine 6-phosphate N-acetyltransferase activity","canonical_id":"go:GO:0004343","description":"\"Catalysis of the reaction: D-glucosamine 6-phosphate + acetyl-CoA = N-acetyl-D-glucosamine 6-phosphate + CoA + H+.\" [EC:2.3.1.4, RHEA:10292]","metadata":null},{"id":"5bbd663e02a248d5807ea7f605b7da6a","type":"GO_TERM","name":"glucosamine N-acetyltransferase activity","canonical_id":"go:GO:0047932","description":"\"Catalysis of the reaction: D-glucosamine + acetyl-CoA = N-acetyl-D-glucosamine + CoA + H+.\" [EC:2.3.1.3, RHEA:21332]","metadata":null},{"id":"c291766c3dd44e3688b4b4f0353b9c84","type":"GO_TERM","name":"glucosamine kinase activity","canonical_id":"go:GO:0047931","description":"\"Catalysis of the reaction: ATP + D-glucosamine = ADP + D-glucosamine 6-phosphate + H+.\" [RHEA:10948]","metadata":null},{"id":"0911eb29c58a41cc890384aa9f2c5d48","type":"GO_TERM","name":"glucosamine-1-phosphate N-acetyltransferase activity","canonical_id":"go:GO:0019134","description":"\"Catalysis of the reaction: alpha-D-glucosamine 1-phosphate + acetyl-CoA = N-acetyl-alpha-D-glucosamine 1-phosphate + CoA + H+.\" [EC:2.3.1.157, RHEA:13725]","metadata":null},{"id":"2ad4c5a96e6e4d67be811c46777fcc85","type":"GO_TERM","name":"glucosamine-6-phosphate deaminase activity","canonical_id":"go:GO:0004342","description":"\"Catalysis of the reaction: D-glucosamine 6-phosphate + H2O = beta-D-fructose 6-phosphate + NH4.\" [EC:3.5.99.6, RHEA:12172]","metadata":null},{"id":"cf0c4fdae4c34b3ca5907197a9b07f11","type":"GO_TERM","name":"glucosamine-containing compound biosynthetic process","canonical_id":"go:GO:1901073","description":"\"The chemical reactions and pathways resulting in the formation of glucosamine-containing compounds (glucosamines).\" [GOC:TermGenie]","metadata":null},{"id":"a6b7965ec874431b8fd6796c4d11be90","type":"GO_TERM","name":"glucosamine-containing compound catabolic process","canonical_id":"go:GO:1901072","description":"\"The chemical reactions and pathways resulting in the breakdown of glucosamine-containing compounds (glucosamines).\" [GOC:TermGenie]","metadata":null},{"id":"db729e146bf445febdc3020893e19c9a","type":"GO_TERM","name":"glucosaminyl-phosphatidylinositol O-acyltransferase activity","canonical_id":"go:GO:0032216","description":"\"Catalysis of the reaction: 6-(alpha-D-glucosaminyl)-1-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol + fatty acyl-CoA = 2-acyl-6-(alpha-D-glucosaminyl)-1-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol + CoA.\" [PMID:29484956, RHEA:60496]","metadata":null},{"id":"6626ac9254c74bfcae27dd375ac70edb","type":"GO_TERM","name":"glucose 1-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047934","description":"\"Catalysis of the reaction: D-glucose + NAD+ = D-glucono-1,5-lactone + NADH.\" [EC:1.1.1.118, MetaCyc:GLUCOSE-1-DEHYDROGENASE-NAD+-RXN]","metadata":null},{"id":"e64b7540ba624def86d85936ae0437d2","type":"GO_TERM","name":"glucose 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047935","description":"\"Catalysis of the reaction: D-glucose + NADP+ = D-glucono-1,5-lactone + NADPH.\" [EC:1.1.1.119, MetaCyc:GLUCOSE-1-DEHYDROGENASE-NADP+-RXN]","metadata":null},{"id":"9383aa4e5f42473eafb1805f5474adf2","type":"GO_TERM","name":"glucose 1-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0047936","description":"\"Catalysis of the reaction: beta-D-glucose + NAD(P)+ = D-glucono-1,5-lactone + NAD(P)H.\" [EC:1.1.1.47]","metadata":null},{"id":"053b216df8144f5da156aa3eaedcdffc","type":"GO_TERM","name":"glucose 1-phosphate metabolic process","canonical_id":"go:GO:0019255","description":"\"The chemical reactions and pathways involving glucose 1-phosphate, a monophosphorylated derivative of glucose with the phosphate group attached to C-1.\" [GOC:ai]","metadata":null},{"id":"535ba7cd988a4c55ac3539a8728f6e7d","type":"GO_TERM","name":"glucose 1-phosphate phosphorylation","canonical_id":"go:GO:0006009","description":"\"The process of introducing a phosphate group into glucose 1-phosphate to produce glucose bisphosphate.\" [GOC:ai]","metadata":null},{"id":"ec5915295e5c4c989893cdb52bcc421c","type":"GO_TERM","name":"glucose 6-phosphate metabolic process","canonical_id":"go:GO:0051156","description":"\"The chemical reactions and pathways involving glucose 6-phosphate, a monophosphorylated derivative of glucose with the phosphate group attached to C-6.\" [GOC:ai]","metadata":null},{"id":"b85e953448d44a3a8fad1f787468a22d","type":"GO_TERM","name":"glucose 6-phosphate:phosphate antiporter activity","canonical_id":"go:GO:0061513","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose 6-phosphate(out) + phosphate(in) = glucose 6-phosphate(in) + phosphate(out).\" [GOC:dph, PMID:18337460]","metadata":null},{"id":"302b8f13304346b9b963a5af242479b4","type":"GO_TERM","name":"glucose catabolic process","canonical_id":"go:GO:0006007","description":"\"The chemical reactions and pathways resulting in the breakdown of glucose, the aldohexose gluco-hexose.\" [GOC:ai]","metadata":null},{"id":"b47c54acaffd4bddad67d5e6dac013a6","type":"GO_TERM","name":"glucose catabolic process to pyruvate","canonical_id":"go:GO:0061718","description":"\"The chemical reactions and pathways resulting in the breakdown of glucose, with the production of pyruvate.\" [GOC:dph]","metadata":null},{"id":"187e6630e6de4071bc36eae9e3dc193d","type":"GO_TERM","name":"glucose dehydrogenase (FAD, quinone) activity","canonical_id":"go:GO:0140762","description":"\"Catalysis of the reaction: a quinone + D-glucose = a quinol + D-glucono-1,5-lactone.\" [RHEA:47372]","metadata":null},{"id":"2e81bf6a6bf1498a83bfa0cd2bf18b34","type":"GO_TERM","name":"glucose dehydrogenase activity","canonical_id":"go:GO:0004344","description":"\"Catalysis of the reaction: D-glucose + acceptor = D-glucono-1,5-lactone + reduced acceptor.\" [PMID:22027299]","metadata":null},{"id":"678a42f12263492abf3272d6507bec85","type":"GO_TERM","name":"glucose homeostasis","canonical_id":"go:GO:0042593","description":"\"Any process involved in the maintenance of an internal steady state of glucose within an organism or cell.\" [GOC:curators]","metadata":null},{"id":"177f77e921d54509ac224cb1aeb2d75f","type":"GO_TERM","name":"glucose import in response to insulin stimulus","canonical_id":"go:GO:0044381","description":"\"The directed movement of the hexose monosaccharide glucose into a cell as a result of an insulin stimulus.\" [GOC:BHF, PMID:19079291]","metadata":null},{"id":"da13ca3b592e41febf80e63edb30cfdd","type":"GO_TERM","name":"glucose mediated signaling pathway","canonical_id":"go:GO:0010255","description":"\"The process in which a change in the level of mono- and disaccharide glucose trigger the expression of genes controlling metabolic and developmental processes.\" [GOC:sm]","metadata":null},{"id":"5458eb315d984199b9c5d2044013cfa5","type":"GO_TERM","name":"glucose metabolic process","canonical_id":"go:GO:0006006","description":"\"The chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. D-glucose is dextrorotatory and is sometimes known as dextrose; it is an important source of energy for living organisms and is found free as well as combined in homo- and hetero-oligosaccharides and polysaccharides.\" [ISBN:0198506732]","metadata":null},{"id":"504a05ee4a1342588c591b9c53a81129","type":"DISEASE","name":"glucose metabolism disease","canonical_id":"mondo:0002908","description":null,"metadata":null},{"id":"1fc462ff59bb4d95b18bbb6654d13136","type":"GO_TERM","name":"glucose sensor activity","canonical_id":"go:GO:0141089","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of glucose.\" [PMID:17470517]","metadata":null},{"id":"5a231eabb61e4ce3bc1f98d69ae3cc31","type":"GO_TERM","name":"glucose transporter complex","canonical_id":"go:GO:1990350","description":"\"A protein complex facilitating glucose transport into, out of or within a cell, or between cells.\" [GOC:bhm, PMID:15449578]","metadata":null},{"id":"14b9916fc6514109970594c9fe200d9e","type":"GO_TERM","name":"glucose-1,6-bisphosphate synthase activity","canonical_id":"go:GO:0047933","description":"\"Catalysis of the reaction: 3-phospho-D-glyceroyl phosphate + alpha-D-glucose 1-phosphate = 3-phospho-D-glycerate + alpha-D-glucose 1,6-bisphosphate + H+.\" [EC:2.7.1.106, RHEA:16769]","metadata":null},{"id":"a30746379e2845b18590078e2343a126","type":"GO_TERM","name":"glucose-1-phosphatase activity","canonical_id":"go:GO:0008877","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + H2O = D-glucose + phosphate.\" [EC:3.1.3.10]","metadata":null},{"id":"6963de18376c493abc388db3e18d7e3e","type":"GO_TERM","name":"glucose-1-phosphate adenylyltransferase activity","canonical_id":"go:GO:0008878","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + ATP = ADP-glucose + diphosphate.\" [EC:2.7.7.27, RHEA:12120]","metadata":null},{"id":"99553e4fc86d48d186de6428a1f2a12c","type":"GO_TERM","name":"glucose-1-phosphate adenylyltransferase complex","canonical_id":"go:GO:0010170","description":"\"Complex that catalyzes the synthesis of ADP-glucose and pyrophosphate from glucose-1-phosphate and ATP. In plants, the complex is a heterotetramer composed of two types of subunits (small and large). In bacteria, the enzyme complex is composed of four identical subunits.\" [GOC:tb, PMID:12748181]","metadata":null},{"id":"ef6e96a32a0e48dc83e3fccf2831a123","type":"GO_TERM","name":"glucose-1-phosphate cytidylyltransferase activity","canonical_id":"go:GO:0047343","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + CTP = CDP-D-glucose + diphosphate.\" [RHEA:18213]","metadata":null},{"id":"dc5d96a4efef47998525a5dd970f5e56","type":"GO_TERM","name":"glucose-1-phosphate guanylyltransferase activity","canonical_id":"go:GO:0047344","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + GTP = diphosphate + GDP-D-glucose.\" [RHEA:10708]","metadata":null},{"id":"0579aed848e94eb7b763c15205300559","type":"GO_TERM","name":"glucose-1-phosphate phosphodismutase activity","canonical_id":"go:GO:0047937","description":"\"Catalysis of the reaction: 2 D-glucose 1-phosphate = D-glucose + D-glucose 1,6-bisphosphate.\" [EC:2.7.1.41, MetaCyc:GLUCOSE-1-PHOSPHATE-PHOSPHODISMUTASE-RXN]","metadata":null},{"id":"c1e4222fcae6474b80c14f0811b585b3","type":"GO_TERM","name":"glucose-1-phosphate thymidylyltransferase activity","canonical_id":"go:GO:0008879","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + dTTP = diphosphate + dTDP-glucose.\" [EC:2.7.7.24, RHEA:15225]","metadata":null},{"id":"3f72bc253d264d3c8c5075d7f0947fa9","type":"GO_TERM","name":"glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase activity","canonical_id":"go:GO:0047399","description":"\"Catalysis of the reaction: H2O + 6-(D-glucose-1-phospho)-D-mannosylglycoprotein = D-mannosylglycoprotein + D-glucose-alpha-1-phosphate.\" [EC:3.1.4.51, MetaCyc:3.1.4.51-RXN]","metadata":null},{"id":"207c89fe75b746b9be52ce933c6cb59c","type":"GO_TERM","name":"glucose-6-phosphatase activity","canonical_id":"go:GO:0004346","description":"\"Catalysis of the reaction: D-glucopyranose 6-phosphate + H2O = D-glucose + phosphate. D-glucopyranose is also known as D-glucose 6-phosphate.\" [EC:3.1.3.9, RHEA:16689]","metadata":null},{"id":"3016b7f2732b41b4b535ba61d7fee87c","type":"GO_TERM","name":"glucose-6-phosphate 1-epimerase activity","canonical_id":"go:GO:0047938","description":"\"Catalysis of the reaction: alpha-D-glucose 6-phosphate = beta-D-glucose 6-phosphate.\" [EC:5.1.3.15, MetaCyc:GLUCOSE-6-PHOSPHATE-1-EPIMERASE-RXN]","metadata":null},{"id":"fd91b9d56a544abba2947c938fce1484","type":"GO_TERM","name":"glucose-6-phosphate 3-dehydrogenase activity","canonical_id":"go:GO:0103074","description":"\"Catalysis of the reaction: NAD + D-glucopyranose 6-phosphate = NADH + H+ + 3-dehydro-D-glucose 6-phosphate.\" [GOC:pz, RHEA:37547]","metadata":null},{"id":"c5cc5931f71744db9664bf0353cdc573","type":"GO_TERM","name":"glucose-6-phosphate dehydrogenase (coenzyme F420) activity","canonical_id":"go:GO:0052749","description":"\"Catalysis of the reaction: beta-D-glucose 6-phosphate + coenzyme F420 + H+ = 6-O-phosphono-D-glucono-1,5-lactone + reduced coenzyme F420.\" [EC:1.1.98.2, GOC:mengo_curators, RHEA:27294]","metadata":null},{"id":"04898be4065e441c8c8a84bfc0819245","type":"GO_TERM","name":"glucose-6-phosphate dehydrogenase activity","canonical_id":"go:GO:0004345","description":"\"Catalysis of the reaction: D-glucose 6-phosphate + NADP+ = D-glucono-1,5-lactone 6-phosphate + NADPH + H+.\" [EC:1.1.1.49]","metadata":null},{"id":"0646479142374e5e9b5334ec0e71351f","type":"GO_TERM","name":"glucose-6-phosphate isomerase activity","canonical_id":"go:GO:0004347","description":"\"Catalysis of the reaction: alpha-D-glucose 6-phosphate = beta-D-fructose 6-phosphate.\" [RHEA:11816]","metadata":null},{"id":"3dae7d16e79245948f1236ff0aa77546","type":"GO_TERM","name":"glucose-6-phosphate transmembrane transporter activity","canonical_id":"go:GO:0015152","description":"\"Enables the transfer of glucose-6-phosphate from one side of a membrane to the other. Glucose-6-phosphate is a monophosphorylated derivative of glucose with the phosphate group attached to C-6.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"08c9d13e32604b40a7f0d6a229b6b123","type":"GO_TERM","name":"glucose-6-phosphate transport","canonical_id":"go:GO:0015760","description":"\"The directed movement of glucose-6-phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Glucose-6-phosphate is a monophosphorylated derivative of glucose with the phosphate group attached to C-6.\" [GOC:ai]","metadata":null},{"id":"469cbe22ddac4b618e8db6ad2ec56920","type":"GO_TERM","name":"glucose-fructose oxidoreductase activity","canonical_id":"go:GO:0047061","description":"\"Catalysis of the reaction: D-fructose + D-glucose = D-glucitol + D-glucono-1,5-lactone.\" [EC:1.1.99.28, RHEA:20637]","metadata":null},{"id":"7cae1e7ad05644d8851eedcff3d0d8d1","type":"DISEASE","name":"glucose-galactose malabsorption","canonical_id":"mondo:0011731","description":null,"metadata":null},{"id":"3e3c08acb0fa40cf9308d551529834af","type":"GO_TERM","name":"glucosidase II complex","canonical_id":"go:GO:0017177","description":"\"A heterodimeric complex that catalyzes the trimming of glucose residues from N-linked core glycans on newly synthesized glycoproteins.\" [PMID:10464333, PMID:8910335]","metadata":null},{"id":"4663031181714bafa3e9c8ac887b66de","type":"GO_TERM","name":"glucosidase activity","canonical_id":"go:GO:0015926","description":"\"Catalysis of the hydrolysis of glucosyl compounds, substances containing a group derived from a cyclic form of glucose or a glucose derivative.\" [ISBN:0198506732]","metadata":null},{"id":"1905f6cfe0024eaa92faff29a7e28545","type":"GO_TERM","name":"glucosidase complex","canonical_id":"go:GO:1902687","description":"\"A protein complex which is capable of glucosidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:23826932]","metadata":null},{"id":"17ee00713374426ab20d4e7c92c8cafd","type":"GO_TERM","name":"glucoside 3-dehydrogenase activity","canonical_id":"go:GO:0033757","description":"\"Catalysis of the reaction: sucrose + acceptor = 3-dehydro-alpha-D-glucosyl-beta-D-fructofuranoside + reduced acceptor.\" [EC:1.1.99.13]","metadata":null},{"id":"c053946c519b4c58a8265cc45370b550","type":"GO_TERM","name":"glucoside transmembrane transporter activity","canonical_id":"go:GO:0042947","description":"\"Enables the transfer of glucosides from one side of a membrane to the other. Glucosides are glycosides in which the sugar group is a glucose residue.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"630f7f19e23c4a16877bc0331ee57b4a","type":"GO_TERM","name":"glucoside transport","canonical_id":"go:GO:0042946","description":"\"The directed movement of glucosides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Glucosides are glycosides in which the sugar group is a glucose residue.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"315d4a6a03fe4e218caa572ccd63594c","type":"GO_TERM","name":"glucosinolate biosynthetic process","canonical_id":"go:GO:0019761","description":"\"The chemical reactions and pathways resulting in the formation of glucosinolates, substituted thioglucosides found in rapeseed products and related cruciferae.\" [GOC:ai]","metadata":null},{"id":"a9a319a3ff114743930ac816477bbd82","type":"GO_TERM","name":"glucosinolate catabolic process","canonical_id":"go:GO:0019762","description":"\"The chemical reactions and pathways resulting in the breakdown of glucosinolates, substituted thioglucosides found in rapeseed products and related cruciferae.\" [GOC:ai]","metadata":null},{"id":"4c9dca1199454c71acdc8539ff700f07","type":"GO_TERM","name":"glucosinolate metabolic process","canonical_id":"go:GO:0019760","description":"\"The chemical reactions and pathways involving glucosinolates, substituted thioglucosides found in rapeseed products and related cruciferae. They are metabolized to a variety of toxic products which are most likely the cause of hepatocytic necrosis in animals and humans.\" [GOC:curators]","metadata":null},{"id":"e069da0ecb9d4c1998f355bb6f0592a9","type":"GO_TERM","name":"glucosinolate transmembrane transporter activity","canonical_id":"go:GO:0141165","description":"\"Enables the transfer of a glucosinolate across a membrane.\" [PMID:37076627]","metadata":null},{"id":"86e4ef54e656478facd7e1947cfb6525","type":"GO_TERM","name":"glucosinolate transport","canonical_id":"go:GO:1901349","description":"\"The directed movement of a glucosinolate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie]","metadata":null},{"id":"18772f05bbd746e0bebbaf5d42988647","type":"GO_TERM","name":"glucosinolate:proton symporter activity","canonical_id":"go:GO:0090448","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucosinolate(out) + H+(out) = glucosinolate(in) + H+(in).\" [PMID:22864417]","metadata":null},{"id":"0e0899b035bb41ddac3e70f7e54bd750","type":"GO_TERM","name":"glucosyl-DNA beta-glucosyltransferase activity","canonical_id":"go:GO:0033822","description":"\"Catalysis of the transfer of a beta-D-glucosyl residue from UDP-glucose to a glucosylhydroxymethylcytosine residue in DNA.\" [EC:2.4.1.28]","metadata":null},{"id":"0ea9d225f66b4ab1844d5e18606b1a2b","type":"GO_TERM","name":"glucosyl-N-acetylglucosamine glucosaminidase activity","canonical_id":"go:GO:0052774","description":"\"Catalysis of the reaction: glucosyl-N-acetylglucosamine + H2O = glucosamine + N-acetylglucosamine.\" [GOC:mengo_curators, PMID:15136574, PMID:16232910, PMID:16736587]","metadata":null},{"id":"2b4eb6e249e241c991e00248ec286a2e","type":"GO_TERM","name":"glucosylceramidase activity","canonical_id":"go:GO:0004348","description":"\"Catalysis of the reaction: D-glucosyl-N-acylsphingosine + H2O = D-glucose + N-acylsphingosine.\" [EC:3.2.1.45]","metadata":null},{"id":"fe633d572d4a48bf9cfe9298ce46fb3e","type":"GO_TERM","name":"glucosylceramide biosynthetic process","canonical_id":"go:GO:0006679","description":"\"The chemical reactions and pathways resulting in the formation of glucosylceramides, any compound composed of a ceramide backbone covalently linked to a glucose. The glucose can be further elongated with the sequential addition of various carbohydrate units.\" [PMID:35536927]","metadata":null},{"id":"4cca4a42250f411f935fab9ba478c14d","type":"GO_TERM","name":"glucosylceramide catabolic process","canonical_id":"go:GO:0006680","description":"\"The chemical reactions and pathways resulting in the breakdown of glucosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of glucose by a ceramide group.\" [GOC:ai]","metadata":null},{"id":"5aea6d6f959c4e7a8d6f509515b35cf6","type":"GO_TERM","name":"glucosylceramide metabolic process","canonical_id":"go:GO:0006678","description":"\"The chemical reactions and pathways involving glucosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of glucose by a ceramide group. They are neutral glycolipids containing equimolar amounts of fatty acid, glucose, and sphingosine or a sphingosine derivative.\" [ISBN:0198506732]","metadata":null},{"id":"18a1350e9c804b8b9e273df5546db1e7","type":"GO_TERM","name":"glucosylglycerate hydrolase activity","canonical_id":"go:GO:0102547","description":"\"Catalysis of the reaction: (2R)-2-O-(alpha-D-glucopyranosyl)-glycerate + H2O = (R)-glycerate + D-glucose.\" [RHEA:32059]","metadata":null},{"id":"b6494ae6d2ae4480add963bae3689164","type":"GO_TERM","name":"glucosylglycerate phosphorylase activity","canonical_id":"go:GO:0110068","description":"\"Catalysis of the reaction: (2R)-2-O-(alpha-D-glucopyranosyl)-glycerate + phosphate = (R)-glycerate + alpha-D-glucose 1-phosphate.\" [PMID:28754708, RHEA:55268]","metadata":null},{"id":"81f93289c55d4b9498a634e3dcfbdf6b","type":"GO_TERM","name":"glucosylglycerol 3-phosphatase activity","canonical_id":"go:GO:0050530","description":"\"Catalysis of the reaction: 2-O-(beta-D-glucosyl)-sn-glycerol 3-phosphate + H2O = 2-O-(beta-D-glucosyl)-sn-glycerol + phosphate.\" [EC:3.1.3.69, RHEA:22652]","metadata":null},{"id":"fedc03e0975349a6847d956075cff4ac","type":"GO_TERM","name":"glucosylglycerol biosynthetic process","canonical_id":"go:GO:0051473","description":"\"The chemical reactions and pathways resulting in the formation of glucosylglycerol, alpha-D-glucopyranosyl-alpha-(1,2)-glycerol.\" [GOC:ai]","metadata":null},{"id":"e6b581999ecd4bdcb7eccb2919207578","type":"GO_TERM","name":"glucosylglycerol metabolic process","canonical_id":"go:GO:0051472","description":"\"The chemical reactions and pathways involving glucosylglycerol, alpha-D-glucopyranosyl-alpha-(1,2)-glycerol.\" [GOC:ai]","metadata":null},{"id":"ef1e1218beea42b49ba056b121419782","type":"GO_TERM","name":"glucosylglycerol transmembrane transport","canonical_id":"go:GO:0051475","description":"\"The directed movement of glucosylglycerol, alpha-D-glucopyranosyl-alpha-(1,2)-glycerol, across a membrane.\" [GOC:ai]","metadata":null},{"id":"7561f11c44414c37ae2436b827d3bc5c","type":"GO_TERM","name":"glucosylglycerol transmembrane transporter activity","canonical_id":"go:GO:0051474","description":"\"Enables the transfer of a glucosylglycerol from one side of a membrane to the other. A glucosylglycerol is an alpha-D-glucopyranosyl-alpha-(1,2)-glycerol.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"5d6475b056ee493abe8bf49115276d02","type":"GO_TERM","name":"glucosylglycerol-phosphate synthase activity","canonical_id":"go:GO:0033828","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + ADP-glucose = 2-O-(beta-D-glucosyl)-sn-glycerol 3-phosphate + ADP + H+.\" [EC:2.4.1.213, RHEA:12881]","metadata":null},{"id":"d122207997e847118ee52a07605b473e","type":"GO_TERM","name":"glucosyltransferase activity","canonical_id":"go:GO:0046527","description":"\"Catalysis of the transfer of a glucosyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [ISBN:0198506732]","metadata":null},{"id":"824c9e0c65d0473aabb911853adb62e6","type":"GO_TERM","name":"glucuronan lyase activity","canonical_id":"go:GO:0033994","description":"\"Catalysis of the reaction: (1->4)-beta-D-glucuronan = an oligosaccharide with 4-deoxy-beta-D-gluc-4-enuronosyl end + (1->4)-beta-D-glucuronan. This reaction is the eliminative cleavage of (1->4)-beta-D-glucuronans to give oligosaccharides with 4-deoxy-beta-D-gluc-4-enuronosyl groups at their non-reducing ends. Complete degradation of glucuronans results in the formation of tetrasaccharides.\" [EC:4.2.2.14]","metadata":null},{"id":"ac8c4f279cc34eb1be6c87846507a726","type":"GO_TERM","name":"glucuronate biosynthetic process","canonical_id":"go:GO:0046399","description":"\"The chemical reactions and pathways resulting in the formation of glucuronate, the anion of glucuronic acid.\" [GOC:ai]","metadata":null},{"id":"477766444a1149158e8f4f519a19061b","type":"GO_TERM","name":"glucuronate catabolic process","canonical_id":"go:GO:0006064","description":"\"The chemical reactions and pathways resulting in the breakdown of glucuronate, any salt or ester of glucuronic acid.\" [GOC:curators]","metadata":null},{"id":"afe38aaaa2a54a7d9f2b94adb19be5f4","type":"GO_TERM","name":"glucuronate isomerase activity","canonical_id":"go:GO:0008880","description":"\"Catalysis of the reaction: D-glucuronate = D-fructuronate. Also converts D-galacturonate to D-tagaturonate.\" [EC:5.3.1.12]","metadata":null},{"id":"2a54f0a86b504f0cbe1f1f573e2dd7dd","type":"GO_TERM","name":"glucuronate metabolic process","canonical_id":"go:GO:0019585","description":"\"The chemical reactions and pathways involving glucuronate, any salt or ester of glucuronic acid, the uronic acid formally derived from glucose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"bd969e6e3d264631abfe5cf5b8a5bd16","type":"GO_TERM","name":"glucuronate transmembrane transport","canonical_id":"go:GO:0015738","description":"\"The process in which glucuronate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"0776b62cb32b4a20b15c3e96838a6bf3","type":"GO_TERM","name":"glucuronate transmembrane transporter activity","canonical_id":"go:GO:0015135","description":"\"Enables the transfer of glucuronate from one side of a membrane to the other. Glucuronate is the uronic acid formally derived from glucose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group.\" [GOC:ai]","metadata":null},{"id":"69831ba54d1045319069e48b21da9a88","type":"GO_TERM","name":"glucuronate-1-phosphate uridylyltransferase activity","canonical_id":"go:GO:0047350","description":"\"Catalysis of the reaction: 1-phospho-alpha-D-glucuronate + UTP = diphosphate + UDP-alpha-D-glucuronate.\" [EC:2.7.7.44, RHEA:16325]","metadata":null},{"id":"dfc44d74f64642d7b0460e70b2f3fa2b","type":"GO_TERM","name":"glucuronate-2-sulfatase activity","canonical_id":"go:GO:0015024","description":"\"Catalysis of the hydrolysis of the 2-sulfate groups of the 2-O-sulfo-D-glucuronate residues of chondroitin sulfate, heparin and heparitin sulfate.\" [EC:3.1.6.18]","metadata":null},{"id":"95a6b594cf7746dbbdc30fc96f9b6a0e","type":"GO_TERM","name":"glucuronidase activity","canonical_id":"go:GO:0046574","description":"\"Catalysis of the hydrolysis of glucuronosides, yielding free glucuronic acid.\" [PMID:10441389, PMID:12044176]","metadata":null},{"id":"f15f2e0667e94ddfae0d9954ec2f3bbb","type":"GO_TERM","name":"glucuronide:cation symporter activity","canonical_id":"go:GO:0015488","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucuronide(out) + monovalent cation(out) = glucuronide(in) + monovalent cation(in).\" [TC:2.A.2.3.1]","metadata":null},{"id":"993471f097f540d38d4b64be7b896232","type":"GO_TERM","name":"glucuronoarabinoxylan catabolic process","canonical_id":"go:GO:2000887","description":"\"The chemical reactions and pathways resulting in the breakdown of a glucuronoarabinoxylan.\" [GOC:mengo_curators]","metadata":null},{"id":"702489460ee24bf8930869b45046a652","type":"GO_TERM","name":"glucuronoarabinoxylan endo-1,4-beta-xylanase activity","canonical_id":"go:GO:0033940","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-xylosyl links in some glucuronoarabinoxylans.\" [EC:3.2.1.136]","metadata":null},{"id":"b31c15c7844744b5ac6861c6a3057c87","type":"GO_TERM","name":"glucuronokinase activity","canonical_id":"go:GO:0047940","description":"\"Catalysis of the reaction: D-glucuronate + ATP = 1-phospho-alpha-D-glucuronate + ADP + 2 H+.\" [EC:2.7.1.43, RHEA:17005]","metadata":null},{"id":"1b857e7795c6466aa315564492794b96","type":"GO_TERM","name":"glucuronolactone reductase activity","canonical_id":"go:GO:0047941","description":"\"Catalysis of the reaction: L-gulono-1,4-lactone + NADP+ = D-glucurono-3,6-lactone + H+ + NADPH.\" [EC:1.1.1.20, RHEA:18925]","metadata":null},{"id":"5cb0ffe1055a4b4cbf697301aecf8eb3","type":"GO_TERM","name":"glucuronoside catabolic process","canonical_id":"go:GO:0019391","description":"\"The chemical reactions and pathways resulting in the breakdown of glucuronosides, compound composed of a hydroxy compound linked to a glucuronate residue.\" [PMID:28389557]","metadata":null},{"id":"1cdffedd0d194065b0ec5e1a69b354b4","type":"GO_TERM","name":"glucuronoside transmembrane transporter activity","canonical_id":"go:GO:0015164","description":"\"Enables the transfer of a glucuronosides from one side of a membrane to the other. Glucuronosides are any compound formed by combination of glycosidic linkage of a hydroxy compound (e.g. an alcohol or a saccharide) with the anomeric carbon atom of glucuronate.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"d4d38d0f6d9942e2b17abdfb74747495","type":"GO_TERM","name":"glucuronoside transport","canonical_id":"go:GO:0015779","description":"\"The directed movement of glucuronosides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Glucuronosides are any compound formed by combination of glycosidic linkage of a hydroxy compound (e.g. an alcohol or a saccharide) with the anomeric carbon atom of glucuronate.\" [GOC:ai]","metadata":null},{"id":"88282e754bf14fec90238cfa74d41faf","type":"GO_TERM","name":"glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0047238","description":"\"Catalysis of the reaction: D-glucuronyl-N-acetyl-1,3-beta-D-galactosaminylproteoglycan + UDP-N-acetylgalactosamine = N-acetyl-D-galactosaminyl-1,4-beta-D-glucuronyl-N-acetyl-1,3-beta-D-galactosaminylproteoglycan + UDP.\" [EC:2.4.1.175]","metadata":null},{"id":"f89ca8d1ff0446c696309c92a94fbce3","type":"GO_TERM","name":"glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0050508","description":"\"Catalysis of the reaction: 3-O-{[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n)-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-seryl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = 3-O-{alpha-D-GlcNAc-[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n)-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-seryl-[protein] + H+ + UDP.\" [EC:2.4.1.224, MetaCyc:2.4.1.224-RXN, RHEA:16213]","metadata":null},{"id":"fb78db721aa046e9b353eb51244678e5","type":"GO_TERM","name":"glucuronosyl-disulfoglucosamine glucuronidase activity","canonical_id":"go:GO:0047404","description":"\"Catalysis of the reaction: H2O + 3-D-glucuronosyl-N2-,6-disulfo-beta-D-glucosamine = glucuronate + N2,6-disulfo-D-glucosamine.\" [EC:3.2.1.56]","metadata":null},{"id":"8b988606223f403f9a459a32eb9a7306","type":"GO_TERM","name":"glucuronosyltransferase activity","canonical_id":"go:GO:0015020","description":"\"Catalysis of the reaction: glucuronate acceptor + UDP-alpha-D-glucuronate = acceptor beta-D-glucuronoside + H+ + UDP.\" [RHEA:21032]","metadata":null},{"id":"9cfc0abd84f14cb0a96161e5ad32f194","type":"GO_TERM","name":"glucuronoxylan 4-O-methyltransferase activity","canonical_id":"go:GO:0030775","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + glucuronoxylan D-glucuronate = S-adenosyl-L-homocysteine + glucuronoxylan 4-O-methyl-D-glucuronate.\" [EC:2.1.1.112]","metadata":null},{"id":"ac3089114fff49c9add1d1cad1d66051","type":"GO_TERM","name":"glucuronoxylan biosynthetic process","canonical_id":"go:GO:0010417","description":"\"The chemical reactions and pathways resulting in the formation of glucuronoxylan, a polymer containing a beta-1,4-linked D-xylose backbone substituted with glucuronic acid residues.\" [GOC:tair_curators]","metadata":null},{"id":"14a989e008ed43839aea2233c5e29e33","type":"GO_TERM","name":"glucuronoxylan catabolic process","canonical_id":"go:GO:2000886","description":"\"The chemical reactions and pathways resulting in the breakdown of a glucuronoxylan.\" [GOC:mengo_curators]","metadata":null},{"id":"e41b502685404dcfbd7c6b6a93bddbfc","type":"GO_TERM","name":"glucuronoxylan glucuronosyltransferase activity","canonical_id":"go:GO:0080116","description":"\"Catalysis of the transfer of glucuronate to the xylan backbone of glucuronoxylan molecule.\" [PMID:18980649]","metadata":null},{"id":"edbe415247cb48c0a4eb5f329a89193f","type":"GO_TERM","name":"glucuronoxylan metabolic process","canonical_id":"go:GO:0010413","description":"\"The chemical reactions and pathways involving xylan, a polymer containing a beta-(1->4)-linked D-xylose backbone decorated with glucuronic acid side units.\" [GOC:tair_curators]","metadata":null},{"id":"a20a401859ee4f65a78ff801c3fe421e","type":"GO_TERM","name":"glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0001888","description":"\"Catalysis of the reaction: 3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = 3-O-(alpha-D-GlcNAc-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + H+ + UDP.\" [EC:2.4.1.223, RHEA:16221]","metadata":null},{"id":"c03cb7fa845e431ba8cacd60122108d8","type":"GO_TERM","name":"glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0047237","description":"\"Catalysis of the reaction: D-glucuronyl-1,3-beta-D-galactosylproteoglycan + UDP-N-acetylgalactosamine = N-acetyl-D-galactosaminyl-1,4-beta-D-glucuronyl-1,3-beta-D-galactosylproteoglycan + UDP.\" [EC:2.4.1.174, MetaCyc:2.4.1.174-RXN]","metadata":null},{"id":"00d158f96b9d4a22a1a0d24621383fa1","type":"GO_TERM","name":"glutaconate CoA-transferase activity","canonical_id":"go:GO:0018730","description":"\"Catalysis of the reaction: trans-glutaconate + acetyl-CoA = (2E)-glutaconyl-CoA + acetate.\" [RHEA:23208]","metadata":null},{"id":"c2e94043f6a94bd9b7c5804b734c02bf","type":"GO_TERM","name":"glutaconyl-CoA decarboxylase activity","canonical_id":"go:GO:0018801","description":"\"Catalysis of the reaction: (2E)-glutaconyl-CoA + Na+(in) + H+ = (2E)-butenoyl-CoA + Na+(out) + CO2.\" [PMID:11248185, RHEA:23972]","metadata":null},{"id":"07110df3c7564e268ca0061e06bab55c","type":"GO_TERM","name":"glutamate 5-kinase activity","canonical_id":"go:GO:0004349","description":"\"Catalysis of the reaction: L-glutamate + ATP = L-glutamyl 5-phosphate + ADP + H+.\" [EC:2.7.2.11, RHEA:14877]","metadata":null},{"id":"62fa6c616abb4226b7c8eba08221adb2","type":"GO_TERM","name":"glutamate binding","canonical_id":"go:GO:0016595","description":"\"Binding to glutamate, the anion of 2-aminopentanedioic acid.\" [GOC:ai]","metadata":null},{"id":"d1374ebd71104129878e6e75b2ad9630","type":"GO_TERM","name":"glutamate decarboxylase activity","canonical_id":"go:GO:0004351","description":"\"Catalysis of the reaction: L-glutamate = 4-aminobutanoate + CO2.\" [EC:4.1.1.15]","metadata":null},{"id":"ce195c2e06114798bd217bf889542468","type":"GO_TERM","name":"glutamate decarboxylase complex","canonical_id":"go:GO:1902793","description":"\"A protein complex which is capable of glutamate decarboxylase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:17384644]","metadata":null},{"id":"a79cf8cab14344088d7bfd6e522afffc","type":"GO_TERM","name":"glutamate dehydrogenase complex","canonical_id":"go:GO:1990148","description":"\"A homomeric protein complex that possesses glutamate dehydrogenase activity. This complex is evolutionarily conserved except that the number of homoprotomers per complex varies.\" [GOC:bhm, PMID:22393408, PMID:23412807]","metadata":null},{"id":"a24fdbe4502a43f38127e17cfe71de00","type":"GO_TERM","name":"glutamate family amino acid biosynthetic process","canonical_id":"go:GO:0009084","description":"\"The chemical reactions and pathways resulting in the formation of L-glutamate or any of the amino acids synthesised from it (L-glutamine, L-proline and L-arginine).\" [GOC:curators]","metadata":null},{"id":"ff2676e943c24a8b80ff32bc432a52e6","type":"GO_TERM","name":"glutamate formimidoyltransferase activity","canonical_id":"go:GO:0030409","description":"\"Catalysis of the reaction: 5-formimidoyltetrahydrofolate + L-glutamate = tetrahydrofolate + N-formimidoyl-L-glutamate.\" [RHEA:15097]","metadata":null},{"id":"7116f5d842c54f9e86bb08b0508a22fe","type":"GO_TERM","name":"glutamate metabolic process","canonical_id":"go:GO:0006536","description":"\"The chemical reactions and pathways involving glutamate, the anion of 2-aminopentanedioic acid.\" [GOC:curators]","metadata":null},{"id":"881d3afab7914241a8c86cc2c7209e4a","type":"GO_TERM","name":"glutamate racemase activity","canonical_id":"go:GO:0008881","description":"\"Catalysis of the reaction: L-glutamate = D-glutamate.\" [EC:5.1.1.3, RHEA:12813]","metadata":null},{"id":"ed5c0fd26d254461bb1ca4d81d17339d","type":"GO_TERM","name":"glutamate receptor activity","canonical_id":"go:GO:0008066","description":"\"Combining with glutamate and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:ai, GOC:signaling]","metadata":null},{"id":"ca0311762975419b98439a35b3d90b7b","type":"GO_TERM","name":"glutamate receptor binding","canonical_id":"go:GO:0035254","description":"\"Binding to a glutamate receptor.\" [GOC:bf]","metadata":null},{"id":"dc9a67fc6a5d4f32b2af207295c6d742","type":"GO_TERM","name":"glutamate receptor clustering","canonical_id":"go:GO:0097688","description":"\"The neurotransmitter-gated ion channel clustering process in which glutamate receptors are localized to distinct domains in the cell membrane.\" [GOC:krc, PMID:19723286]","metadata":null},{"id":"013cae6f4d5246e5a6a518dff1ea43a6","type":"GO_TERM","name":"glutamate receptor signaling pathway","canonical_id":"go:GO:0007215","description":"\"The series of molecular signals initiated by the binding of glutamate to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling, PMID:9131252]","metadata":null},{"id":"eaa9bc5831d343798496f9883a296781","type":"GO_TERM","name":"glutamate reuptake","canonical_id":"go:GO:0051935","description":"\"The uptake of L-glutamate by neurons or glial cells. This process leads to inactivation and recycling of neurotransmitters.\" [ISBN:0123668387, Wikipedia:Glutamate_transporter]","metadata":null},{"id":"0c14b2cd229c4bd09637acb5f77e8f7d","type":"GO_TERM","name":"glutamate secretion","canonical_id":"go:GO:0014047","description":"\"The controlled release of glutamate by a cell. The glutamate is the most abundant excitatory neurotransmitter in the nervous system.\" [GOC:ef]","metadata":null},{"id":"03946cf29fcf4551af34868b43e816f1","type":"GO_TERM","name":"glutamate secretion, neurotransmission","canonical_id":"go:GO:0061535","description":"\"The controlled release of glutamate by a cell, in which the glutamate acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"cdc3804b0d12452185a99cbf6fe4a9af","type":"GO_TERM","name":"glutamate synthase (NADH) activity","canonical_id":"go:GO:0016040","description":"\"Catalysis of the reaction: 2 L-glutamate + NAD+ = 2-oxoglutarate + L-glutamine + H+ + NADH.\" [RHEA:13753]","metadata":null},{"id":"5e9113e5e2274df5901e71d2781cf8a8","type":"GO_TERM","name":"glutamate synthase (NADPH) activity","canonical_id":"go:GO:0004355","description":"\"Catalysis of the reaction: 2 L-glutamate + NADP+ = 2-oxoglutarate + L-glutamine + H+ + NADPH. This is a two-step reaction: (a) L-glutamate + NH4+ = L-glutamine + H2O, (b) L-glutamate + NADP+ + H2O = NH4+ + 2-oxoglutarate + NADPH + H+.\" [RHEA:15501]","metadata":null},{"id":"1af349f506474c93bf8ebba24bfe4fc4","type":"GO_TERM","name":"glutamate synthase (ferredoxin) activity","canonical_id":"go:GO:0016041","description":"\"Catalysis of the reaction: 2 L-glutamate + 2 oxidized ferredoxin = L-glutamine + 2-oxoglutarate + 2 reduced ferredoxin + 2 H+. This is a two-step reaction: (a) L-glutamate + NH4+ = L-glutamine + H2O, (b) L-glutamate + 2 oxidized ferredoxin + H2O = NH4+ + 2-oxoglutarate + 2 reduced ferredoxin + 2 H+.\" [EC:1.4.7.1]","metadata":null},{"id":"bbf6d82b62b04b7fa838c924a594b36f","type":"GO_TERM","name":"glutamate synthase activity","canonical_id":"go:GO:0015930","description":"\"Catalysis of the formation of L-glutamine and 2-oxoglutarate from L-glutamate, using NADH, NADPH or ferredoxin as hydrogen acceptors.\" [GOC:curators]","metadata":null},{"id":"7f92a4833d24441a889dec00573daefe","type":"GO_TERM","name":"glutamate synthase complex","canonical_id":"go:GO:0031026","description":"\"A complex that possesses glutamate synthase activity.\" [GOC:mah]","metadata":null},{"id":"c3bba61b189f4fc9919044e51c9922b6","type":"GO_TERM","name":"glutamate synthase complex (NADH)","canonical_id":"go:GO:0031027","description":"\"A protein complex that in yeast consists of a large and a small subunit. Possesses glutamate synthase (NADH) activity.\" [GOC:jl, PMID:7047525]","metadata":null},{"id":"5b49d1f065d649c7a799a821a255baf9","type":"GO_TERM","name":"glutamate synthase complex (NADPH)","canonical_id":"go:GO:0009342","description":"\"A complex that possesses glutamate synthase (NADPH) activity.\" [GOC:mah, PMID:4565085]","metadata":null},{"id":"445ded5c0431464eabedb1fb344274de","type":"GO_TERM","name":"glutamate transmembrane import into vacuole","canonical_id":"go:GO:0090454","description":"\"The directed movement of glutamate into the vacuole across the vacuolar membrane.\" [GOC:tb]","metadata":null},{"id":"e8f5a95e1cae4c79a2c9d86a0244a30f","type":"GO_TERM","name":"glutamate-1-semialdehyde 2,1-aminomutase activity","canonical_id":"go:GO:0042286","description":"\"Catalysis of the reaction: (S)-4-amino-5-oxopentanoate = 5-aminolevulinate.\" [RHEA:14265]","metadata":null},{"id":"8eebc0fae9f14895a7e9d5aafffecdd3","type":"GO_TERM","name":"glutamate-5-semialdehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004350","description":"\"Catalysis of the reaction: L-glutamate 5-semialdehyde + NADP+ + phosphate = L-glutamyl 5-phosphate + H+ + NADPH.\" [EC:1.2.1.41, RHEA:19541]","metadata":null},{"id":"51b3dbcc6bf541eb87d9baf04760a246","type":"GO_TERM","name":"glutamate-cysteine ligase activity","canonical_id":"go:GO:0004357","description":"\"Catalysis of the reaction: L-cysteine + L-glutamate + ATP = L-gamma-glutamyl-L-cysteine + ADP + 2 H+ + phosphate.\" [EC:6.3.2.2, RHEA:13285]","metadata":null},{"id":"d1d746690239481bbc4f5e3c60e1aa8a","type":"GO_TERM","name":"glutamate-cysteine ligase catalytic subunit binding","canonical_id":"go:GO:0035226","description":"\"Binding to the catalytic subunit of glutamate-cysteine ligase.\" [PMID:12954617]","metadata":null},{"id":"4e4f1d7461b442dbb37aabb0f2ceef23","type":"GO_TERM","name":"glutamate-cysteine ligase complex","canonical_id":"go:GO:0017109","description":"\"An enzyme complex that catalyzes the ligation of L-glutamate to L-cysteine, forming gamma-L-glutamyl-L-cysteine.\" [PMID:9675072]","metadata":null},{"id":"4c0be6d149204749b2d288e450f0faf7","type":"GO_TERM","name":"glutamate-cysteine ligase regulator activity","canonical_id":"go:GO:1990609","description":"\"Binds to and modulates the activity of glutamate-cysteine ligase.\" [PMID:8103521]","metadata":null},{"id":"4b95e0c617a844dcb2784fdee68bb1df","type":"GO_TERM","name":"glutamate-ethylamine ligase activity","canonical_id":"go:GO:0047942","description":"\"Catalysis of the reaction: L-glutamate + ATP + ethylamine = N(5)-ethyl-L-glutamine + ADP + 2 H+ + phosphate.\" [EC:6.3.1.6, RHEA:20525]","metadata":null},{"id":"a5d92da0765742538844ee29bbc608bb","type":"GO_TERM","name":"glutamate-gated calcium ion channel activity","canonical_id":"go:GO:0022849","description":"\"Enables the transmembrane transfer of a calcium ion by a channel that opens when glutamate has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"50226d4a91584df89225b7fe14abe26f","type":"GO_TERM","name":"glutamate-gated receptor activity","canonical_id":"go:GO:0004970","description":"\"Catalysis of the transmembrane transfer of an ion by a channel that opens when glutamate has been bound by the channel complex or one of its constituent parts.\" [ISBN:0198506732]","metadata":null},{"id":"c2060e80fb8b4167b676f8f225f65927","type":"GO_TERM","name":"glutamate-methylamine ligase activity","canonical_id":"go:GO:0047943","description":"\"Catalysis of the reaction: L-glutamate + ATP + methylammonium = N(5)-methyl-L-glutamine + ADP + 2 H+ + phosphate.\" [EC:6.3.4.12, RHEA:17117]","metadata":null},{"id":"3c2bd56adfe74b1787aea179ad7c22b8","type":"GO_TERM","name":"glutamate-putrescine ligase activity","canonical_id":"go:GO:0034024","description":"\"Catalysis of the reaction: L-glutamate + ATP + putrescine = gamma-L-glutamylputrescine + ADP + 2 H+ + phosphate.\" [EC:6.3.1.11, RHEA:13633]","metadata":null},{"id":"0e63ac605ffe4b868b3a1af5559b4d8a","type":"GO_TERM","name":"glutamate-tRNA ligase activity","canonical_id":"go:GO:0004818","description":"\"Catalysis of the reaction: ATP + L-glutamate + tRNA(Glu) = AMP + diphosphate + L-glutamyl-tRNA(Glu).\" [EC:6.1.1.17]","metadata":null},{"id":"8b2747307c624d0a9e6634260749bab8","type":"GO_TERM","name":"glutamate-tRNA ligase complex","canonical_id":"go:GO:0009332","description":"\"An enzyme complex that catalyzes the ligation of glutamate and tRNA(Glu) to form glutamyl-tRNA(Glu).\" [PMID:29679766]","metadata":null},{"id":"60dcb48cf7da4a6cbff00c81142860b4","type":"GO_TERM","name":"glutamate-tRNA(Gln) ligase activity","canonical_id":"go:GO:0050561","description":"\"Catalysis of the reaction: tRNA(Glx) + L-glutamate + ATP = glutamyl-tRNA(Glx) + diphosphate + AMP.\" [EC:6.1.1.24, MetaCyc:6.1.1.24-RXN]","metadata":null},{"id":"605cc9f339db4fecbc373f09f1bb5a39","type":"GO_TERM","name":"glutamate:gamma-aminobutyric acid antiporter activity","canonical_id":"go:GO:0070909","description":"\"Catalysis of the reaction: glutamate(out) + gamma-aminobutyric acid(in) = glutamate(in) + gamma-aminobutyric acid(out).\" [GOC:dh]","metadata":null},{"id":"d5dc9b33301d4e1b8b0a1e6838548877","type":"GO_TERM","name":"glutamate:sodium symporter activity","canonical_id":"go:GO:0015501","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glutamate(out) + Na+(out) = glutamate(in) + Na+(in).\" [TC:2.A.27.1.1]","metadata":null},{"id":"18aa7db0b2b5453bb796398a3e596f47","type":"GO_TERM","name":"glutamatergic neuron differentiation","canonical_id":"go:GO:1905962","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a glutamatergic neuron.\" [GO_REF:0000086, GOC:TermGenie, PMID:24030726]","metadata":null},{"id":"28b346836d4d4aacbd8a7a29dc1265aa","type":"GO_TERM","name":"glutamatergic postsynaptic density","canonical_id":"go:GO:0099573","description":"\"The post-synaptic specialization of a glutamatergic excitatory synapse.\" [GOC:dos]","metadata":null},{"id":"1a6ac9210f3e449886c63c4d03aa94b0","type":"GO_TERM","name":"glutamatergic synapse","canonical_id":"go:GO:0098978","description":"\"A synapse that uses glutamate as a neurotransmitter.\" [GOC:dos]","metadata":null},{"id":"e405cc9592ae46f29ed4e58fb1901951","type":"GO_TERM","name":"glutamic-type endopeptidase activity","canonical_id":"go:GO:0070007","description":"\"Catalysis of the hydrolysis of internal peptide bonds in a polypeptide chain by a mechanism involving a glutamate/glutamine catalytic dyad.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE]","metadata":null},{"id":"b667f2571b9d4c01b92d3c562bc25223","type":"GO_TERM","name":"glutamic-type peptidase activity","canonical_id":"go:GO:0070002","description":"\"Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a mechanism involving a glutamate/glutamine catalytic dyad.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"672f92642b714a5a9100b8b0a1441575","type":"GO_TERM","name":"glutamin-(asparagin-)ase activity","canonical_id":"go:GO:0050417","description":"\"Catalysis of the reactions: H2O + L-glutamine = NH4 + L-glutamate; and H2O + L-asparagine = NH4 + L-aspartate.\" [EC:3.5.1.38]","metadata":null},{"id":"b9b5ab6430124a4bba466980ddd3c3c4","type":"GO_TERM","name":"glutaminase activity","canonical_id":"go:GO:0004359","description":"\"Catalysis of the reaction: L-glutamine + H2O = L-glutamate + NH4+.\" [RHEA:15889]","metadata":null},{"id":"3991e0ab6dd04d9490a02f14e0e11da5","type":"GO_TERM","name":"glutaminase complex","canonical_id":"go:GO:1903600","description":"\"A protein complex which is capable of glutaminase activity.\" [GO_REF:0000088, GOC:TermGenie, PMID:14764090]","metadata":null},{"id":"917fdb3022804b15bba724ef7ed28595","type":"DRUG","name":"glutamine","canonical_id":"mesh:D005973","description":null,"metadata":null},{"id":"0669a83824404ba5b87b45ec9f8c88d4","type":"GO_TERM","name":"glutamine N-phenylacetyltransferase activity","canonical_id":"go:GO:0047947","description":"\"Catalysis of the reaction: phenylacetyl-CoA + L-glutamine = CoA + alpha-N-phenylacetyl-L-glutamine.\" [EC:2.3.1.14, MetaCyc:GLUTAMINE-N-PHENYLACETYLTRANSFERASE-RXN]","metadata":null},{"id":"059ceb13d19a4da7b68b6ca678df49a0","type":"GO_TERM","name":"glutamine sensor activity","canonical_id":"go:GO:0140786","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of glutamine.\" [PMID:34535752]","metadata":null},{"id":"4caf8b31a04345e495139a4e3ed82c8e","type":"GO_TERM","name":"glutamine synthetase activity","canonical_id":"go:GO:0004356","description":"\"Catalysis of the reaction: ATP + L-glutamate + NH4+ = ADP + H+ + L-glutamine + phosphate.\" [RHEA:16169]","metadata":null},{"id":"d4a38fd5c61d4ecea6debc45cb68928d","type":"GO_TERM","name":"glutamine-tRNA ligase activity","canonical_id":"go:GO:0004819","description":"\"Catalysis of the reaction: ATP + L-glutamine + tRNA(Gln) = AMP + diphosphate + L-glutaminyl-tRNA(Gln).\" [EC:6.1.1.18]","metadata":null},{"id":"a612c0023eb64f179a6e244a890cb5dc","type":"GO_TERM","name":"glutaminyl-peptide cyclotransferase activity","canonical_id":"go:GO:0016603","description":"\"Catalysis of the reaction: N-terminal L-glutaminyl-[peptide] = N-terminal 5-oxo-L-prolyl-[peptide] + NH4+.\" [RHEA:23652]","metadata":null},{"id":"77f4aa2a64844551b2f1a695e9758c4e","type":"GO_TERM","name":"glutaminyl-tRNA aminoacylation","canonical_id":"go:GO:0006425","description":"\"The process of coupling glutamine to glutaminyl-tRNA, catalyzed by glutaminyl-tRNA synthetase. The glutaminyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a glutamine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"426c3f30fcf04c3ea365970f0385bb1f","type":"GO_TERM","name":"glutaminyl-tRNA synthase (glutamine-hydrolyzing) activity","canonical_id":"go:GO:0050567","description":"\"Catalysis of the reaction: L-glutamine + glutamyl-tRNA(Gln) + ATP = L-glutamate + glutaminyl-tRNA(Gln) + phosphate + ADP.\" [EC:6.3.5.7, MetaCyc:6.3.5.7-RXN]","metadata":null},{"id":"60f0ea1ff1084669b6ad66e9550c764a","type":"GO_TERM","name":"glutaminyl-tRNAGln biosynthesis via transamidation","canonical_id":"go:GO:0070681","description":"\"A tRNA aminoacylation process in which glutaminyl-tRNAGln is formed by a tRNA-dependent two-step pathway. In the first step a non-discriminating glutamyl-tRNAGlx synthetase generates the misacylated L-glutamyl-tRNAGln species, and in the second step it is amidated to the correctly charged L-glutaminyl-tRNAGln by a glutamyl-tRNAGln amidotransferase.\" [GOC:mah, MetaCyc:PWY-5921]","metadata":null},{"id":"c5ab0accefb245659dd408dc22fb91c2","type":"GO_TERM","name":"glutamyl aminopeptidase activity","canonical_id":"go:GO:0004230","description":"\"Catalysis of the release of a N-terminal glutamate (and to a lesser extent aspartate) from a peptide.\" [EC:3.4.11.7]","metadata":null},{"id":"efd66eaeebbd4bcbac20b4978ada3b00","type":"GO_TERM","name":"glutamyl-tRNA aminoacylation","canonical_id":"go:GO:0006424","description":"\"The process of coupling glutamate to glutamyl-tRNA, catalyzed by glutamyl-tRNA synthetase. The glutamyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a glutamic acid-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"6a3c792938034e99a7504dc1cb285711","type":"GO_TERM","name":"glutamyl-tRNA reductase (NADP+) activity","canonical_id":"go:GO:0008883","description":"\"Catalysis of the reaction: (S)-4-amino-5-oxopentanoate + NADP+ + tRNA(Glu) = L-glutamyl-tRNA(Glu) + H+ + NADPH.\" [EC:1.2.1.70, RHEA:12344]","metadata":null},{"id":"670b84173c504281bf54216826cdc85b","type":"GO_TERM","name":"glutamyl-tRNA(Gln) amidotransferase complex","canonical_id":"go:GO:0030956","description":"\"A protein complex that possesses glutamyl-tRNA(Gln) amidotransferase activity, and therefore creates Gln-tRNA by amidating Glu-tRNA; usually composed of 3 subunits: A, B, and C. Note that the C subunit may not be required in all organisms.\" [GOC:mlg]","metadata":null},{"id":"5d5bc4f0b4214da5864e123674fa3c18","type":"GO_TERM","name":"glutarate dioxygenase activity","canonical_id":"go:GO:0106343","description":"\"Catalysis of the reaction glutarate + 2-oxoglutarate + O2 = (S)-2-hydroxyglutarate + succinate + CO2.\" [PMID:30498244, RHEA:13821]","metadata":null},{"id":"4019b3be43f84dd191b4f4967893640e","type":"GO_TERM","name":"glutarate-CoA ligase activity","canonical_id":"go:GO:0047948","description":"\"Catalysis of the reaction: ATP + CoA + glutarate = ADP + glutaryl-CoA + H+ + phosphate.\" [EC:6.2.1.6, RHEA:14169]","metadata":null},{"id":"6aa123b2595b45ddb14aec2c7ea406db","type":"GO_TERM","name":"glutarate-semialdehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0102810","description":"\"Catalysis of the reaction: 5-oxopentanoate + NADP + H2O = glutarate + NADPH + 2 H+.\" [RHEA:57832]","metadata":null},{"id":"3a78cdd520b54d1980318056fab2b5e2","type":"GO_TERM","name":"glutaryl-7-aminocephalosporanic-acid acylase activity","canonical_id":"go:GO:0033968","description":"\"Catalysis of the reaction: (7R)-7-(4-carboxybutanamido)cephalosporanate + H2O = (7R)-7-aminocephalosporanate + glutarate.\" [EC:3.5.1.93]","metadata":null},{"id":"db6a443fc1c546d09bfe6f87b354043f","type":"GO_TERM","name":"glutaryl-CoA dehydrogenase activity","canonical_id":"go:GO:0004361","description":"\"Catalysis of the reaction: glutaryl-CoA + 2 H+ + oxidized [electron-transfer flavoprotein] = (2E)-butenoyl-CoA + CO2 + reduced [electron-transfer flavoprotein].\" [RHEA:13389]","metadata":null},{"id":"fe040f0d505048c3b98fc0348a975f9c","type":"GO_TERM","name":"glutathione S-conjugate carboxypeptidase activity","canonical_id":"go:GO:0102274","description":"\"Catalysis of the reaction: an S-substituted glutathione + H2O = glycine + S-substituted gamma-glutamyl-L-cysteine. Patricipates in glutathione-mediated detoxification.\" [RHEA:60448]","metadata":null},{"id":"186ffb4f366d41098c4fc585136d2cf3","type":"GO_TERM","name":"glutathione binding","canonical_id":"go:GO:0043295","description":"\"Binding to glutathione; a tripeptide composed of the three amino acids cysteine, glutamic acid and glycine.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"a2a764ac71c849d496c310d1b7fd25e4","type":"GO_TERM","name":"glutathione biosynthetic process","canonical_id":"go:GO:0006750","description":"\"The chemical reactions and pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.\" [GOC:ai, GOC:al, GOC:pde, ISBN:0198506732]","metadata":null},{"id":"93ac1ac282e0443cb1b2b4120b85152d","type":"GO_TERM","name":"glutathione catabolic process","canonical_id":"go:GO:0006751","description":"\"The chemical reactions and pathways resulting in the breakdown of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"d04ce76d52ea4d3d98f73e660f5406b3","type":"GO_TERM","name":"glutathione dehydrogenase (ascorbate) activity","canonical_id":"go:GO:0045174","description":"\"Catalysis of the reaction: dehydroascorbate + 2 glutathione = L-ascorbate + glutathione disulfide.\" [RHEA:24424]","metadata":null},{"id":"bff2b869eb384d71afbec458a7f114d2","type":"GO_TERM","name":"glutathione derivative biosynthetic process","canonical_id":"go:GO:1901687","description":"\"The chemical reactions and pathways resulting in the formation of glutathione derivative.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"c44505f13cdb465192da0f3543d859f8","type":"GO_TERM","name":"glutathione derivative catabolic process","canonical_id":"go:GO:1901686","description":"\"The chemical reactions and pathways resulting in the breakdown of glutathione derivative.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"3f30730c9aa141c0a846a20fbebec3f8","type":"GO_TERM","name":"glutathione disulfide oxidoreductase activity","canonical_id":"go:GO:0015038","description":"\"Catalysis of the reaction: 2 glutathione + electron acceptor = glutathione disulfide + electron donor.\" [GOC:mah]","metadata":null},{"id":"bb6e9bca80a849aab89f693e56998ebf","type":"GO_TERM","name":"glutathione gamma-glutamate hydrolase","canonical_id":"go:GO:0036374","description":"\"Catalysis of the reaction: glutathione + H2O = L-cysteinylglycine + L-glutamate.\" [EC:3.4.19.13, GOC:imk]","metadata":null},{"id":"eeccbd6eb3be4f7aa4cebb2f1843211c","type":"GO_TERM","name":"glutathione gamma-glutamylcysteinyltransferase activity","canonical_id":"go:GO:0016756","description":"\"Catalysis of the reaction: glutathione + Glu(-Cys)(n)-Gly = Gly + Glu(-Cys)(n+1)-Gly.\" [EC:2.3.2.15]","metadata":null},{"id":"c375a35b0f3d4a288a49a984f382b4e1","type":"GO_TERM","name":"glutathione hydrolase complex","canonical_id":"go:GO:0061672","description":"\"Enzyme complex that in S. cerevisiae has components Dug2/Dug3 and is able to catalyze the cleavage of glutathione into glutamate and Cys-Gly.\" [GOC:dph]","metadata":null},{"id":"7056614fb8f7403188b855d3015a8c20","type":"GO_TERM","name":"glutathione import across plasma membrane","canonical_id":"go:GO:0098709","description":"\"The directed movement of glutathione from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"ae992ae4126c408cb4b8b97b1353af46","type":"GO_TERM","name":"glutathione import into mitochondrion","canonical_id":"go:GO:0160007","description":"\"The process in which glutathione is transported from the cytosol into the mitochondrial matrix.\" [PMID:34707288]","metadata":null},{"id":"6342cd863e644c3ea927c00abb8723d3","type":"GO_TERM","name":"glutathione metabolic process","canonical_id":"go:GO:0006749","description":"\"The chemical reactions and pathways involving glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins; it has a specific role in the reduction of hydrogen peroxide (H2O2) and oxidized ascorbate, and it participates in the gamma-glutamyl cycle.\" [ISBN:0198506732]","metadata":null},{"id":"bf9d9f8b16394726904ad3961fb5e781","type":"GO_TERM","name":"glutathione oxidase activity","canonical_id":"go:GO:0047950","description":"\"Catalysis of the reaction: 2 glutathione + O2 = glutathione disulfide + H2O2.\" [RHEA:24112]","metadata":null},{"id":"bce41789d14b4679ac76018eabe1c519","type":"GO_TERM","name":"glutathione peroxidase activity","canonical_id":"go:GO:0004602","description":"\"Catalysis of the reaction: 2 glutathione + H2O2 = oxidized glutathione + 2 H2O.\" [EC:1.11.1.9, PMID:36771108]","metadata":null},{"id":"5856294ef43e465aaf5385936f215df5","type":"GO_TERM","name":"glutathione specific gamma-glutamylcyclotransferase activity","canonical_id":"go:GO:0061928","description":"\"Catalysis of the reaction: glutathione = 5-oxoproline + L-cysteinylglycine.\" [PMID:23070364, PMID:27913623]","metadata":null},{"id":"8a2722151cd74de0afaeacbf64c8b313","type":"GO_TERM","name":"glutathione synthase activity","canonical_id":"go:GO:0004363","description":"\"Catalysis of the reaction: L-gamma-glutamyl-L-cysteine + ATP + glycine = ADP + glutathione + 2 H+ + phosphate.\" [EC:6.3.2.3, RHEA:13557]","metadata":null},{"id":"307216c3ee0d498fa2c8b8f83380d6d0","type":"GO_TERM","name":"glutathione synthase complex","canonical_id":"go:GO:0036087","description":"\"A protein complex composed of two or more polypeptide subunits, and which possesses glutathione synthase activity (catalysis of the reaction: L-gamma-glutamyl-L-cysteine + ATP + glycine = ADP + glutathione + 2 H+ + phosphate). In eukaryotes, the complex is homodimeric, in E. coli glutathione synthase exists as a tetramer, and in S. pombe the complex exists as a homodimer or a heterotetramer.\" [GOC:al, PMID:12734194, PMID:14990577, PMID:1958212]","metadata":null},{"id":"86e8ea5e025045808dc8f198c271fd69","type":"GO_TERM","name":"glutathione thiolesterase activity","canonical_id":"go:GO:0047951","description":"\"Catalysis of the reaction: S-acylglutathione + H2O = a carboxylate + glutathione + H+.\" [EC:3.1.2.7, RHEA:22708]","metadata":null},{"id":"0193e23c5d944ed39e09484a76d669ab","type":"GO_TERM","name":"glutathione transferase activity","canonical_id":"go:GO:0004364","description":"\"Catalysis of the reaction: RX + glutathione = an S-substituted glutathione + a halide anion + H+.\" [RHEA:16437]","metadata":null},{"id":"12e60abdea2c4f7fa40bbb82cd92589b","type":"GO_TERM","name":"glutathione transmembrane import into vacuole","canonical_id":"go:GO:0071996","description":"\"The directed movement of glutathione into the vacuole across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"0bbe4d08f62e4d7094f1d816f83af863","type":"GO_TERM","name":"glutathione transmembrane transport","canonical_id":"go:GO:0034775","description":"\"A process in which glutathione is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"d50b4c4736ae4b44b15f56b3e33e90ba","type":"GO_TERM","name":"glutathione transmembrane transporter activity","canonical_id":"go:GO:0034634","description":"\"Enables the transfer of glutathione, the tripeptide glutamylcysteinylglycine, from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"81073b452cec4cc890da79d46312f85c","type":"GO_TERM","name":"glutathione transport","canonical_id":"go:GO:0034635","description":"\"The directed movement of glutathione, the tripeptide glutamylcysteinylglycine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"61843fb933d24001a2dd17c949e47fad","type":"GO_TERM","name":"glutathione-CoA-glutathione transhydrogenase activity","canonical_id":"go:GO:0047140","description":"\"Catalysis of the reaction: oxidized glutathione + CoA = reduced glutathione + CoA-glutathione.\" [EC:1.8.4.3, MetaCyc:1.8.4.3-RXN]","metadata":null},{"id":"95380efe68ba498b88af06213ed37141","type":"GO_TERM","name":"glutathione-cystine transhydrogenase activity","canonical_id":"go:GO:0047141","description":"\"Catalysis of the reaction: cystine + 2 reduced glutathione = oxidized glutathione + 2 L-cysteine.\" [EC:1.8.4.4, MetaCyc:1.8.4.4-RXN]","metadata":null},{"id":"4fd2dcd6efda43ddac7e8d17677947e6","type":"GO_TERM","name":"glutathione-dependent sulfide quinone oxidoreductase activity","canonical_id":"go:GO:0106436","description":"\"Catalysis of the reaction: a quinone + glutathione + H+ + hydrogen sulfide = a quinol + S-sulfanylglutathione.\" [RHEA:55156]","metadata":null},{"id":"96ea58da1756480dafbef76b54d21992","type":"GO_TERM","name":"glutathione-disulfide reductase (NADPH) activity","canonical_id":"go:GO:0004362","description":"\"Catalysis of the reaction: 2 glutathione + NADP+ = glutathione disulfide + NADPH + H+.\" [PMID:36771108, RHEA:11740]","metadata":null},{"id":"da5707c32a7e4c089880bd27677536eb","type":"GO_TERM","name":"glutathione-homocystine transhydrogenase activity","canonical_id":"go:GO:0047139","description":"\"Catalysis of the reaction: homocystine + 2 reduced glutathione = oxidized glutathione + 2 homocysteine.\" [EC:1.8.4.1, MetaCyc:1.8.4.1-RXN]","metadata":null},{"id":"03cbd214ca77416ca63e1ae0529beea0","type":"GO_TERM","name":"glutathione-regulated potassium exporter activity","canonical_id":"go:GO:0015503","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: K+(in) + H+(out) = K+(out) + H+(in), where glutathione maintains the closed state.\" [PMID:11053405, TC:2.A.37.1.1, TC:2.A.37.1.2]","metadata":null},{"id":"27835196778d45a89bcee365e2c31410","type":"GO_TERM","name":"glutathionylspermidine amidase activity","canonical_id":"go:GO:0008884","description":"\"Catalysis of the reaction: N1-(gamma-L-glutamyl-L-cysteinyl-glycyl)-spermidine + H2O = gamma-L-glutamyl-L-cysteinyl-glycine + spermidine.\" [EC:3.5.1.78]","metadata":null},{"id":"8ca51bbfce81410f965223b011fb0a1f","type":"GO_TERM","name":"glutathionylspermidine synthase activity","canonical_id":"go:GO:0008885","description":"\"Catalysis of the reaction: gamma-L-glutamyl-L-cysteinyl-glycine + spermidine + ATP = N1-(gamma-L-glutamyl-L-cysteinyl-glycyl)-spermidine + ADP + phosphate.\" [EC:6.3.1.8]","metadata":null},{"id":"f959b5c4e055462da15715537dbc7ffc","type":"DRUG","name":"glutethimide","canonical_id":"mesh:D005984","description":null,"metadata":null},{"id":"27bfdf0bfe044e46ba041bc95e620288","type":"GO_TERM","name":"glyceollin synthase activity","canonical_id":"go:GO:0033769","description":"\"Catalysis of the reactions: 2-dimethylallyl-(6aS,11aS)-3,6a,9-trihydroxypterocarpan + NADPH + H+ + O2 = glyceollin II or glyceollin III + NADP+ + 2 H2O, and 4-dimethylallyl-(6aS,11aS)-3,6a,9-trihydroxypterocarpan + NADPH + H+ + O2 = glyceollin I + NADP+ + 2 H2O.\" [EC:1.14.14.135]","metadata":null},{"id":"0ff45af0873e484380299f05fd350a2a","type":"GO_TERM","name":"glyceraldehyde 3-phosphate:phosphate antiporter activity","canonical_id":"go:GO:0051408","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glyceraldehyde 3-phosphate(out) + phosphate(in) = glyceraldehyde 3-phosphate(in) + phosphate(out).\" [GOC:ai]","metadata":null},{"id":"b4b94088ca714fc0bd0d771a15b66033","type":"GO_TERM","name":"glyceraldehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0043796","description":"\"Catalysis of the reaction: D-glyceraldehyde + H2O + NADP+ = D-glycerate + NADPH + H+.\" [RHEA:40163]","metadata":null},{"id":"5f89a4d77b874f5d92f45138199e7d83","type":"GO_TERM","name":"glyceraldehyde oxidoreductase activity","canonical_id":"go:GO:0043795","description":"\"Catalysis of the reaction: A + D-glyceraldehyde + H2O = (R)-glycerate + AH2 + H+.\" [PMID:10095793, RHEA:36047]","metadata":null},{"id":"2edd27c7f0f644a88f11377739b93c46","type":"GO_TERM","name":"glyceraldehyde-3-phosphate biosynthetic process","canonical_id":"go:GO:0046166","description":"\"The chemical reactions and pathways resulting in the formation of glyceraldehyde-3-phosphate, an important intermediate in glycolysis.\" [GOC:ai]","metadata":null},{"id":"d723255ce0c24a66b35adf24f2858bef","type":"GO_TERM","name":"glyceraldehyde-3-phosphate catabolic process","canonical_id":"go:GO:0019683","description":"\"The chemical reactions and pathways resulting in the breakdown of glyceraldehyde-3-phosphate, an important intermediate in glycolysis.\" [ISBN:0198506732]","metadata":null},{"id":"0d11fbadfb394dcd8877b41dd3958e3e","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity","canonical_id":"go:GO:0043878","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + NAD+ + H2O = 3-phospho-D-glycerate + NADH + H+.\" [PMID:9497334]","metadata":null},{"id":"f206257da9eb4a29bc085bab8ce952fb","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity","canonical_id":"go:GO:0004365","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + phosphate + NAD+ = 3-phospho-D-glyceroyl phosphate + NADH + H+.\" [EC:1.2.1.12]","metadata":null},{"id":"61f931b853824677a21c37e8a4003cd1","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (NADP+) (non-phosphorylating) activity","canonical_id":"go:GO:0008886","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + H2O + NADP+ = 3-phospho-D-glycerate + 2 H+ + NADPH.\" [RHEA:14669]","metadata":null},{"id":"edecbf7237a543c795d3d4359a44f367","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (NADP+) (phosphorylating) activity","canonical_id":"go:GO:0047100","description":"\"Catalysis of the reaction: phosphate + NADP+ + glyceraldehyde-3-phosphate = NADPH + 3-phospho-D-glyceroyl-phosphate.\" [EC:1.2.1.13, MetaCyc:1.2.1.13-RXN]","metadata":null},{"id":"50bc3d5391674a5690c68107c405a14a","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (ferredoxin) activity","canonical_id":"go:GO:0043797","description":"\"Catalysis of the reaction: D-glyceraldehyde-3-phosphate + H2O + 2 oxidized ferredoxin = 3-phospho-D-glycerate + 2 H+ + 2 reduced ferredoxin.\" [PMID:11265456, PMID:7721730, RHEA:24148]","metadata":null},{"id":"ce9ef1dc3402499d8f0001e412972ab4","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (non-phosphorylating, [NAD(P)+] ) activity","canonical_id":"go:GO:0120533","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + NAD(P)+ + H2O = (2R)-3-phosphoglycerate + NAD(P)H + 2 H+.\" [EC:1.2.1.90]","metadata":null},{"id":"91be0f7ed4ef419c989cb39b43943b72","type":"GO_TERM","name":"glyceraldehyde-3-phosphate dehydrogenase (phosphorylating, [NAD(P)+] ) activity","canonical_id":"go:GO:0043891","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate + phosphate + NAD(P)+ = 3-phospho-D-glyceroyl phosphate + NAD(P)H + H+.\" [EC:1.2.1.59]","metadata":null},{"id":"bc311512c3084cf6af3ed9197b58d743","type":"GO_TERM","name":"glyceraldehyde-3-phosphate metabolic process","canonical_id":"go:GO:0019682","description":"\"The chemical reactions and pathways involving glyceraldehyde-3-phosphate, an important intermediate in glycolysis.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"d9252e386ce94d0a973b6152ef186f1a","type":"GO_TERM","name":"glycerate 2-kinase activity","canonical_id":"go:GO:0043798","description":"\"Catalysis of the reaction: D-glycerate + ATP = 2-phospho-D-glycerate + ADP.\" [PMID:14413719, RHEA:27377]","metadata":null},{"id":"2804d2c3ddca4a0288943a15b78e9104","type":"GO_TERM","name":"glycerate kinase activity","canonical_id":"go:GO:0008887","description":"\"Catalysis of the reaction: D-glycerate + ATP = 3-phospho-D-glycerate + ADP + 2 H+.\" [EC:2.7.1.31, RHEA:23516]","metadata":null},{"id":"05782760a84b45cea350e65f34607f61","type":"GO_TERM","name":"glycerate transmembrane transport","canonical_id":"go:GO:1901975","description":"\"The process in which glycerate is transported across a membrane.\" [GOC:TermGenie, PMID:23382251]","metadata":null},{"id":"294f5213cd2b455aa64254a0691c4927","type":"GO_TERM","name":"glycerate transmembrane transporter activity","canonical_id":"go:GO:1901974","description":"\"Enables the transfer of glycerate from one side of a membrane to the other.\" [GOC:TermGenie, PMID:23382251]","metadata":null},{"id":"2b17b8474ea24326ab14a0c5ddcc8a9a","type":"GO_TERM","name":"glycero-3-phosphocholine acyltransferase activity","canonical_id":"go:GO:0106158","description":"\"Catalysis of the reaction:acyl-CoA + glycerophosphocholine = CoA + 1-acyl-sn-glycero-3-phosphocholine.\" [PMID:18430972, PMID:27758859, RHEA:58476]","metadata":null},{"id":"c2f118a662934d13ad8e02cb79f10e9a","type":"DRUG","name":"glycerol","canonical_id":"mesh:D005990","description":null,"metadata":null},{"id":"3245610b949b4989970493af5c6cc30b","type":"GO_TERM","name":"glycerol 2-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047953","description":"\"Catalysis of the reaction: glycerol + NADP+ = dihydroxyacetone + NADPH + H+.\" [RHEA:12753]","metadata":null},{"id":"a9f9f306a25849ff8d98066c60599d4e","type":"GO_TERM","name":"glycerol biosynthetic process","canonical_id":"go:GO:0006114","description":"\"The chemical reactions and pathways resulting in the formation of glycerol, 1,2,3-propanetriol, a sweet, hygroscopic, viscous liquid, widely distributed in nature as a constituent of many lipids.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"e3fc5c79ecf249b786b22b20cb044ca9","type":"GO_TERM","name":"glycerol catabolic process","canonical_id":"go:GO:0019563","description":"\"The chemical reactions and pathways resulting in the breakdown of glycerol, 1,2,3-propanetriol, a sweet, hygroscopic, viscous liquid, widely distributed in nature as a constituent of many lipids.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"ffde4cbcdcf24a52b81ebd17a2eb9545","type":"GO_TERM","name":"glycerol channel activity","canonical_id":"go:GO:0015254","description":"\"Enables the energy-independent facilitated diffusion of glycerol through a transmembrane aqueous pore or channel.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"7bd3bb9364e34ffb9644d42438851b13","type":"GO_TERM","name":"glycerol dehydratase activity","canonical_id":"go:GO:0046405","description":"\"Catalysis of the reaction: glycerol = 3-hydroxypropanal + H2O.\" [EC:4.2.1.30, PMID:18307109]","metadata":null},{"id":"6eb23fa8713543a3bf1bc9c343c6ad96","type":"GO_TERM","name":"glycerol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008888","description":"\"Catalysis of the reaction: glycerol + NAD+ = glycerone + H+ + NADH.\" [RHEA:13769]","metadata":null},{"id":"42599a85137c47dc9a266ccc83393e23","type":"GO_TERM","name":"glycerol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047956","description":"\"Catalysis of the reaction: glycerol + NADP+ = D-glyceraldehyde + NADPH.\" [RHEA:23592]","metadata":null},{"id":"2549af453acc4f0392345f8b0b2b6d1a","type":"GO_TERM","name":"glycerol dehydrogenase (acceptor) activity","canonical_id":"go:GO:0047955","description":"\"Catalysis of the reaction: A + glycerol = AH(2) + glycerone.\" [EC:1.1.99.22, RHEA:17493]","metadata":null},{"id":"448e2e1fb5884979b95e9c6494f67ba4","type":"GO_TERM","name":"glycerol ether biosynthetic process","canonical_id":"go:GO:0046504","description":"\"The chemical reactions and pathways resulting in the formation of glycerol ethers, any anhydride formed between two organic hydroxy compounds, one of which is glycerol.\" [GOC:ai]","metadata":null},{"id":"569100b6644b485db0396c1605b2e316","type":"GO_TERM","name":"glycerol ether catabolic process","canonical_id":"go:GO:0044269","description":"\"The chemical reactions and pathways resulting in the breakdown of glycerol ethers, any anhydride formed between two organic hydroxy compounds, one of which is glycerol.\" [GOC:jl]","metadata":null},{"id":"33dabc65a4494a5c84be440ad9d55547","type":"GO_TERM","name":"glycerol kinase activity","canonical_id":"go:GO:0004370","description":"\"Catalysis of the reaction: ATP + glycerol = sn-glycerol 3-phosphate + ADP + 2 H+.\" [EC:2.7.1.30, RHEA:21644]","metadata":null},{"id":"1e6d6489aca742af9468a21f83e2f9f6","type":"GO_TERM","name":"glycerol metabolic process","canonical_id":"go:GO:0006071","description":"\"The chemical reactions and pathways involving glycerol, 1,2,3-propanetriol, a sweet, hygroscopic, viscous liquid, widely distributed in nature as a constituent of many lipids.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"20a844eec3904a07be2f2e8fd12ec22e","type":"DRUG","name":"glycerol phenylbutyrate","canonical_id":"mesh:C570223","description":null,"metadata":null},{"id":"dfefa11e8cf04e7a9d2cfb740e6c0e65","type":"GO_TERM","name":"glycerol transmembrane transport","canonical_id":"go:GO:0015793","description":"\"The directed movement of glycerol across a membrane. Glycerol is 1,2,3-propanetriol, a sweet, hygroscopic, viscous liquid, widely distributed in nature as a constituent of many lipids.\" [GOC:ai]","metadata":null},{"id":"42d5f2a3930e479db6887286d92a8128","type":"GO_TERM","name":"glycerol transmembrane transporter activity","canonical_id":"go:GO:0015168","description":"\"Enables the transfer of glycerol from one side of a membrane to the other. Glycerol is 1,2,3-propanetriol, a sweet, hygroscopic, viscous liquid, widely distributed in nature as a constituent of many lipids.\" [GOC:ai]","metadata":null},{"id":"ce740528356247b0a52a200c625c99e4","type":"GO_TERM","name":"glycerol-1,2-cyclic-phosphate 2-phosphodiesterase activity","canonical_id":"go:GO:0047393","description":"\"Catalysis of the reaction: glycerol 1,2-cyclic phosphate + H2O = glycerol 1-phosphate + H+.\" [EC:3.1.4.42, RHEA:16493]","metadata":null},{"id":"b75ec7d7c8014abdb83fe89181d1960f","type":"GO_TERM","name":"glycerol-1-phosphate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106357","description":"\"Catalysis of the reaction: NAD+ + sn-glycerol 1-phosphate = dihydroxyacetone phosphate + H+ + NADH.\" [RHEA:21412]","metadata":null},{"id":"6fe6237214d341c59a41d361c67f612b","type":"GO_TERM","name":"glycerol-1-phosphate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0106358","description":"\"Catalysis of the reaction: NADP+ + sn-glycerol 1-phosphate = dihydroxyacetone phosphate + H+ + NADPH.\" [RHEA:21416]","metadata":null},{"id":"7f86ecf4b45d4ae680004bd01130f821","type":"GO_TERM","name":"glycerol-1-phosphate dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0050492","description":"\"Catalysis of the reaction: NAD(P)+ + sn-glycerol-1-phosphate = NAD(P)H + H+ + dihydroxy-acetone-phosphate.\" [EC:1.1.1.261]","metadata":null},{"id":"966472661f8d45239ed060928eb5861f","type":"GO_TERM","name":"glycerol-2-phosphatase activity","canonical_id":"go:GO:0047954","description":"\"Catalysis of the reaction: glycerol 2-phosphate + H2O = glycerol + phosphate.\" [EC:3.1.3.19, RHEA:13105]","metadata":null},{"id":"abbc673fcdf7405aa71ef04eec71d06c","type":"GO_TERM","name":"glycerol-2-phosphate transmembrane transport","canonical_id":"go:GO:0070811","description":"\"The process in which glycerol-2-phosphate is transported across a membrane. Glycerol-2-phosphate is a phosphoric monoester of glycerol.\" [GOC:mah]","metadata":null},{"id":"06420210562b4daaa6f287d8bb313d5a","type":"GO_TERM","name":"glycerol-3-phosphate 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047014","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + NADP+ = D-glyceraldehyde 3-phosphate + H+ + NADPH.\" [RHEA:19773]","metadata":null},{"id":"89d0228889f74f50aca289dfe08f109d","type":"GO_TERM","name":"glycerol-3-phosphate 2-O-acyltransferase activity","canonical_id":"go:GO:0090447","description":"\"Catalysis of the reaction: an acyl-CoA + sn-glycerol 3-phosphate = CoA + a 2-acyl-sn-glycerol 3-phosphate.\" [RHEA:33559]","metadata":null},{"id":"6753a3696c994ceba3ff1a7f9f0f804c","type":"GO_TERM","name":"glycerol-3-phosphate O-acyltransferase activity","canonical_id":"go:GO:0004366","description":"\"Catalysis of the reaction: an acyl-CoA + sn-glycerol 3-phosphate = a 1-acyl-sn-glycero-3-phosphate + CoA.\" [RHEA:15325]","metadata":null},{"id":"07feac091a124bcbbe6c15ce7193e72c","type":"GO_TERM","name":"glycerol-3-phosphate biosynthetic process","canonical_id":"go:GO:0046167","description":"\"The chemical reactions and pathways resulting in the formation of glycerol-3-phosphate, a phosphoric monoester of glycerol.\" [GOC:ai]","metadata":null},{"id":"19291c0565cf4eb7848703c706746ffc","type":"GO_TERM","name":"glycerol-3-phosphate catabolic process","canonical_id":"go:GO:0046168","description":"\"The chemical reactions and pathways resulting in the breakdown of glycerol-3-phosphate, a phosphoric monoester of glycerol.\" [GOC:ai]","metadata":null},{"id":"d4790df8bb994930ad31e83fb45fe3cf","type":"GO_TERM","name":"glycerol-3-phosphate cytidylyltransferase activity","canonical_id":"go:GO:0047348","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + CTP = CDP-glycerol + diphosphate.\" [RHEA:13361]","metadata":null},{"id":"2470a3e436294ec392b17df7f258b8be","type":"GO_TERM","name":"glycerol-3-phosphate dehydrogenase (FAD) complex","canonical_id":"go:GO:0009331","description":"\"An enzyme complex that catalyzes the oxidation of sn-glycerol 3-phosphate to dihydroxyacetone phosphate, with concurrent reduction of flavin adenine dinucleotide (FAD) to FADH2. In E. coli, the complex is either a GlpA-GlpB-GlpC heterotrimer that functions in anaerobic conditions, or a GlpD homodimer that functions in aerobic conditions.\" [PMID:18296637, PMID:3286606, PMID:7576488]","metadata":null},{"id":"b63fc65feb4e46d8a102d9c3a1acc08b","type":"GO_TERM","name":"glycerol-3-phosphate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0141152","description":"\"Catalysis of the reaction: NAD+ + sn-glycerol 3-phosphate = dihydroxyacetone phosphate + H+ + NADH.\" [RHEA:11092]","metadata":null},{"id":"d24d8722c4874ea4843e89acd34bc1b7","type":"GO_TERM","name":"glycerol-3-phosphate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0141153","description":"\"NADP+ + sn-glycerol 3-phosphate = dihydroxyacetone phosphate + H+ + NADPH.\" [PMID:15557260, RHEA:11096]","metadata":null},{"id":"60897a0f01ff4ba2aa6664e2ca80180e","type":"GO_TERM","name":"glycerol-3-phosphate dehydrogenase (quinone) activity","canonical_id":"go:GO:0004368","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + a quinone = glycerone phosphate + a quinol.\" [EC:1.1.5.3]","metadata":null},{"id":"2f63eb538de049c798384e54bf4fcc60","type":"GO_TERM","name":"glycerol-3-phosphate dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0047952","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + NAD(P)+ = glycerone phosphate + NAD(P)H + H+.\" [EC:1.1.1.94, PMID:28326]","metadata":null},{"id":"24a886ab57ee4f74aa8438f87bea0cce","type":"GO_TERM","name":"glycerol-3-phosphate metabolic process","canonical_id":"go:GO:0006072","description":"\"The chemical reactions and pathways involving glycerol-3-phosphate, a phosphoric monoester of glycerol.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a54019f916eb4909837ecb26a57ca0d4","type":"GO_TERM","name":"glycerol-3-phosphate oxidase activity","canonical_id":"go:GO:0004369","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + O2 = glycerone phosphate + H2O2.\" [EC:1.1.3.21, RHEA:18369]","metadata":null},{"id":"e451f89060044b91a14a505a8882f711","type":"GO_TERM","name":"glycerol-3-phosphate shuttle","canonical_id":"go:GO:0006127","description":"\"The process of transferring reducing equivalents from NADH in the cytosol into the mitochondria via glycerol-3-phosphate. Cytosolic glycerol-3-phosphate dehydrogenase uses NADH to convert dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P) in the cytosol; G3P then diffuses into the mitochondria where mitochondrial glycerol-3-phosphate dehydrogenase uses FAD to convert G3P back to DHAP; the electrons on the reduced FADH2 are then available for use in the electron transport chain, and DHAP returns to the cytosol to complete the cycle.\" [GOC:sjm, PMID:16368075]","metadata":null},{"id":"7e19054e34ae425f9e0b3299890ac18b","type":"GO_TERM","name":"glycerol-3-phosphate transmembrane transport","canonical_id":"go:GO:0015794","description":"\"The process in which glycerol-3-phosphate is transported across a membrane. Glycerol-3-phosphate is a phosphoric monoester of glycerol.\" [GOC:ai]","metadata":null},{"id":"a4e48452ed14435683d69684fd6259d2","type":"GO_TERM","name":"glycerol-3-phosphate transmembrane transporter activity","canonical_id":"go:GO:0015169","description":"\"Enables the transfer of glycerol-3-phosphate from one side of a membrane to the other. Glycerol-3-phosphate is a phosphoric monoester of glycerol.\" [GOC:ai]","metadata":null},{"id":"8ec027970dd64fcfa0e6e88ad349c0fd","type":"GO_TERM","name":"glycerol-3-phosphate-glucose phosphotransferase activity","canonical_id":"go:GO:0047327","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + D-glucose = D-glucose 6-phosphate + glycerol.\" [EC:2.7.1.142, RHEA:21288]","metadata":null},{"id":"efd9ef4bbaab44f6836bd53182511d11","type":"GO_TERM","name":"glycerol-3-phosphate-transporting ATPase complex","canonical_id":"go:GO:1902517","description":"\"A protein complex which is capable of glycerol-3-phosphate-transporting ATPase activity.\" [GOC:bhm, GOC:TermGenie, PMID:23013274]","metadata":null},{"id":"1ad7a5974c9f45adb8ff2073c3c288a0","type":"GO_TERM","name":"glycerol-phosphate:phosphate antiporter activity","canonical_id":"go:GO:0015527","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glycerol phosphate(out) + phosphate(in) = glycerol phosphate(in) + phosphate(out).\" [TC:2.A.1.4.3]","metadata":null},{"id":"87dfd3b4abd24972a9f279b7c0586af8","type":"GO_TERM","name":"glycerolipid biosynthetic process","canonical_id":"go:GO:0045017","description":"\"The chemical reactions and pathways resulting in the formation of glycerolipids, any lipid with a glycerol backbone.\" [GOC:ai]","metadata":null},{"id":"57ad78dac4d0421b9be117124f83b031","type":"GO_TERM","name":"glycerolipid catabolic process","canonical_id":"go:GO:0046503","description":"\"The chemical reactions and pathways resulting in the breakdown of glycerolipids, any lipid with a glycerol backbone.\" [GOC:ai]","metadata":null},{"id":"55410df4a8de4042a233b0005e415e88","type":"GO_TERM","name":"glycerolipid metabolic process","canonical_id":"go:GO:0046486","description":"\"The chemical reactions and pathways involving glycerolipids, any lipid with a glycerol backbone. Diacylglycerol and phosphatidate are key lipid intermediates of glycerolipid biosynthesis.\" [GOC:ai, PMID:8906569]","metadata":null},{"id":"42eb420343414c10ba51b51c98d41504","type":"GO_TERM","name":"glycerone kinase activity","canonical_id":"go:GO:0004371","description":"\"Catalysis of the reaction: ATP + glycerone = ADP + glycerone phosphate + 2 H+.\" [EC:2.7.1.29, RHEA:15773]","metadata":null},{"id":"dde719c476184f6eb0d915089eb62c1a","type":"GO_TERM","name":"glycerone phosphate:phosphate antiporter activity","canonical_id":"go:GO:0051407","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glycerone phosphate(out) + phosphate(in) = glycerone phosphate(in) + phosphate(out).\" [GOC:ai]","metadata":null},{"id":"fd88f125fed54f56a0348cdff54d74a4","type":"GO_TERM","name":"glycerone-phosphate O-acyltransferase activity","canonical_id":"go:GO:0016287","description":"\"Catalysis of the reaction: acyl-CoA + glycerone phosphate = 1-acylglycerone 3-phosphate + CoA.\" [EC:2.3.1.42, RHEA:17657]","metadata":null},{"id":"7217394e0c754f7ca30f066ce9efed67","type":"GO_TERM","name":"glycerophosphocholine cholinephosphodiesterase activity","canonical_id":"go:GO:0047390","description":"\"Catalysis of the reaction: sn-glycero-3-phosphocholine + H2O = choline phosphate + glycerol + H+.\" [EC:3.1.4.38, RHEA:19545]","metadata":null},{"id":"265effd96bef44c3bf830597e0a4ef99","type":"GO_TERM","name":"glycerophosphocholine phosphodiesterase activity","canonical_id":"go:GO:0047389","description":"\"Catalysis of the reaction: H2O + L-1-glycero-3-phosphocholine = glycerol-3-phosphate + choline.\" [EC:3.1.4.2, MetaCyc:3.1.4.2-RXN]","metadata":null},{"id":"07cdbcdfcb9b4020a07dbaf689d4e23e","type":"GO_TERM","name":"glycerophosphodiester phosphodiesterase activity","canonical_id":"go:GO:0008889","description":"\"Catalysis of the reaction: a glycerophosphodiester + H2O = an alcohol + sn-glycerol 3-phosphate.\" [EC:3.1.4.46]","metadata":null},{"id":"23ed90dc726b438c8af0186e5b71bcbe","type":"GO_TERM","name":"glycerophosphodiester transmembrane transport","canonical_id":"go:GO:0001407","description":"\"The process in which a glycerophosphodiester is transported across a membrane. Glycerophosphodiesters are small molecules composed of glycerol-3-phosphate and an alcohol, for example, glycerophosphoinositol.\" [GOC:mcc, PMID:12912892]","metadata":null},{"id":"3fda9769d79c499eb39e181a66bd2982","type":"GO_TERM","name":"glycerophosphodiester transmembrane transporter activity","canonical_id":"go:GO:0001406","description":"\"Enables the transfer of glycerophosphodiesters from one side of a membrane to the other. Glycerophosphodiesters are small molecules composed of glycerol-3-phosphate and an alcohol, for example, glycerophosphoinositol.\" [GOC:mcc, PMID:12912892]","metadata":null},{"id":"a24a8282e9e24eeaa64a151a2694c543","type":"GO_TERM","name":"glycerophosphoinositol glycerophosphodiesterase activity","canonical_id":"go:GO:0047395","description":"\"Catalysis of the reaction: 1-(sn-glycero-3-phospho)-1D-myo-inositol + H2O = sn-glycerol 3-phosphate + myo-inositol + H+.\" [EC:3.1.4.44, RHEA:16501]","metadata":null},{"id":"a125455155c4471f8262ab5e6cb69918","type":"GO_TERM","name":"glycerophosphoinositol inositolphosphodiesterase activity","canonical_id":"go:GO:0047394","description":"\"Catalysis of the reaction: H2O + 1-(sn-glycero-3-phospho)-1D-myoinositol = 1D-myo-inositol 1-phosphate + glycerol.\" [EC:3.1.4.43, MetaCyc:3.1.4.43-RXN]","metadata":null},{"id":"0b168b49202b414b8ce889ec9fc26903","type":"GO_TERM","name":"glycerophospholipase activity","canonical_id":"go:GO:0004620","description":"\"Catalysis of the hydrolysis of a glycerophospholipid.\" [PMID:30109646]","metadata":null},{"id":"2fb1ff0eda824ee28850babdcfb4ed36","type":"GO_TERM","name":"glycerophospholipid acyltransferase (CoA-dependent) activity","canonical_id":"go:GO:0047178","description":"\"Catalysis of the reaction: 1-radyl-2-lyso-sn-glycero-3-phosphoethanolamine + 1-radyl-2-acyl-sn-glycero-3-phosphocholine = 1-radyl-2-lyso-sn-glycero-3-phosphocholine + 1-radyl-2-acyl-sn-glycero-3-phosphoethanolamine.\" [EC:2.3.1.148, MetaCyc:2.3.1.148-RXN]","metadata":null},{"id":"1d145569094a4acdad4ad538749512d3","type":"GO_TERM","name":"glycerophospholipid arachidonoyl-transferase (CoA-independent) activity","canonical_id":"go:GO:0047177","description":"\"Catalysis of the reaction: 1-alkyl-2-lyso-sn-glycero-3-phosphoethanolamine + 1-alkyl-2-arachidonyl-sn-glycero-3-phosphocholine = 1-alkyl-2-lyso-sn-glycero-3-phosphocholine + 1-alkyl-2-arachidonyl-sn-glycero-3-phosphoethanolamine.\" [EC:2.3.1.147, MetaCyc:2.3.1.147-RXN]","metadata":null},{"id":"79df71ea1d4848bcac2ddf1f0a2b031c","type":"GO_TERM","name":"glycerophospholipid biosynthetic process","canonical_id":"go:GO:0046474","description":"\"The chemical reactions and pathways resulting in the formation of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.\" [ISBN:0198506732]","metadata":null},{"id":"7a5ec36c284b441f9851f65cc38f9a00","type":"GO_TERM","name":"glycerophospholipid catabolic process","canonical_id":"go:GO:0046475","description":"\"The chemical reactions and pathways resulting in the breakdown of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.\" [ISBN:0198506732]","metadata":null},{"id":"10e8d1a0de2e458b881ed9957a5c8f9f","type":"GO_TERM","name":"glycerophospholipid flippase activity","canonical_id":"go:GO:0140333","description":"\"Catalysis of the movement of a glycerophospholipid from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:26212235]","metadata":null},{"id":"47bdd283832141aa80359f4eec239e71","type":"GO_TERM","name":"glycerophospholipid metabolic process","canonical_id":"go:GO:0006650","description":"\"The chemical reactions and pathways involving glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.\" [ISBN:0198506732]","metadata":null},{"id":"9ee859a59f944e4689c74c4e31f6f36d","type":"GO_TERM","name":"glycerophospholipid phospholipase A1 activity","canonical_id":"go:GO:0008970","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospholipid + H2O = a 2-acyl-sn-glycero-3-phospholipid + a fatty acid + H+. Note that the substrate has a diacyl group attached to the glycerol group.\" [RHEA:67424]","metadata":null},{"id":"80e926b61a4046b2b8ce8640275b1445","type":"DRUG","name":"glyceryl trinitrate","canonical_id":"mesh:D005996","description":null,"metadata":null},{"id":"33a021a8685a46bc88ebfe8849617c95","type":"GO_TERM","name":"glyceryl-ether monooxygenase activity","canonical_id":"go:GO:0050479","description":"\"Catalysis of the reaction: 1-alkyl-sn-glycerol + O2 + (tetrahydrobiopterin/tetrahydropteridine) = 1-hydroxyalkyl-sn-glycerol + H2O + (dihydrobiopterin/dihydropteridine).\" [EC:1.14.16.5, MetaCyc:GLYCERYL-ETHER-MONOOXYGENASE-RXN]","metadata":null},{"id":"8749c57de2014fc7832ffd024a44a8c7","type":"GO_TERM","name":"glycine C-acetyltransferase activity","canonical_id":"go:GO:0008890","description":"\"Catalysis of the reaction: acetyl-CoA + glycine = L-2-amino-3-oxobutanoate + CoA.\" [EC:2.3.1.29, RHEA:20736]","metadata":null},{"id":"8e5326af8dd34390b02a0eb024ca4301","type":"GO_TERM","name":"glycine N-acyltransferase activity","canonical_id":"go:GO:0047961","description":"\"Catalysis of the reaction: acyl-CoA + glycine = CoA + N-acylglycine.\" [RHEA:19869]","metadata":null},{"id":"933d975e1fa54e44bd5a5b3b25646f5b","type":"GO_TERM","name":"glycine N-benzoyltransferase activity","canonical_id":"go:GO:0047962","description":"\"Catalysis of the reaction: benzoyl-CoA + glycine = N-benzoylglycine + CoA + H+.\" [EC:2.3.1.71, RHEA:18493]","metadata":null},{"id":"3897d49d612b447798f36a473a05d90d","type":"GO_TERM","name":"glycine N-choloyltransferase activity","canonical_id":"go:GO:0047963","description":"\"Catalysis of the reaction: choloyl-CoA + glycine = CoA + glycocholate.\" [EC:2.3.1.65, MetaCyc:GLYCINE-N-CHOLOYLTRANSFERASE-RXN]","metadata":null},{"id":"be149b803d114bf287e1a069a94b3323","type":"GO_TERM","name":"glycine N-methyltransferase activity","canonical_id":"go:GO:0017174","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + glycine = S-adenosyl-L-homocysteine + sarcosine.\" [EC:2.1.1.20]","metadata":null},{"id":"06feca904d7a41edb5f114d6615e6e89","type":"GO_TERM","name":"glycine amidinotransferase activity","canonical_id":"go:GO:0015068","description":"\"Catalysis of the reaction: L-arginine + glycine = L-ornithine + guanidinoacetate.\" [RHEA:13201]","metadata":null},{"id":"fd58b128896a4d848635cb402cfbc891","type":"GO_TERM","name":"glycine betaine biosynthetic process","canonical_id":"go:GO:0031456","description":"\"The chemical reactions and pathways resulting in the formation of glycine betaine, N-trimethylglycine.\" [GOC:mah]","metadata":null},{"id":"96d0a4ea391842aaa4165d79a3f851a3","type":"GO_TERM","name":"glycine betaine catabolic process","canonical_id":"go:GO:0031457","description":"\"The chemical reactions and pathways resulting in the breakdown of glycine betaine, N-trimethylglycine.\" [GOC:mah]","metadata":null},{"id":"799951ac3b4a4549980e09c295a06261","type":"GO_TERM","name":"glycine betaine transport","canonical_id":"go:GO:0031460","description":"\"The directed movement of glycine betaine, N-trimethylglycine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"c6c7c97d30b24a25b7d285b06fccbf7f","type":"GO_TERM","name":"glycine betaine-activated nonselective monoatomic cation channel activity","canonical_id":"go:GO:0090686","description":"\"Enables the transmembrane transfer of a monoatomic cation by a channel that opens when glycine betaine has been bound by the channel complex or one of its constituent parts.\" [GOC:kmv, PMID:24212673]","metadata":null},{"id":"face0e2b3b744190860bbe5d8b7f3232","type":"GO_TERM","name":"glycine betaine:proton symporter activity","canonical_id":"go:GO:0015653","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glycine betaine(out) + H+(out) = glycine betaine(in) + H+(in).\" [TC:2.A.15.1.1]","metadata":null},{"id":"60b9aa45adb14a609a7f56ec99fc30b9","type":"GO_TERM","name":"glycine betaine:sodium:chloride symporter activity","canonical_id":"go:GO:0140814","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glycine betaine(out) + Na+(out) + Cl-(out)= glycine betaine(in) + Na+(in) + Cl-(in).\" [PMID:10358010]","metadata":null},{"id":"013c17676a0348f3aeebcb105c47dfa8","type":"GO_TERM","name":"glycine binding","canonical_id":"go:GO:0016594","description":"\"Binding to glycine, aminoethanoic acid.\" [GOC:ai]","metadata":null},{"id":"9c3a96f6310141f495bcb3fcbabceb26","type":"GO_TERM","name":"glycine biosynthetic process","canonical_id":"go:GO:0006545","description":"\"The chemical reactions and pathways resulting in the formation of glycine, aminoethanoic acid.\" [GOC:curators, MetaCyc:GLYCINE-SYN2-PWY]","metadata":null},{"id":"ba02b33936214aae8b61a2773d2bc83e","type":"GO_TERM","name":"glycine catabolic process","canonical_id":"go:GO:0006546","description":"\"The chemical reactions and pathways resulting in the breakdown of glycine.\" [GOC:curators]","metadata":null},{"id":"438fcc41b8404b80b0de48f093eb9187","type":"GO_TERM","name":"glycine cleavage complex","canonical_id":"go:GO:0005960","description":"\"A protein complex that catalyzes the reversible oxidation of glycine. In E. coli, it has four components: dihydrolipoamide dehydrogenase, glycine dehydrogenase (decarboxylating), lipoyl-GcvH-protein and aminomethyltransferase, also known as L, P, H, and T.\" [GOC:mah]","metadata":null},{"id":"1694e745796f488188fdc8204c492aa6","type":"GO_TERM","name":"glycine decarboxylation via glycine cleavage system","canonical_id":"go:GO:0019464","description":"\"The chemical reactions and pathways resulting in the breakdown of glycine by oxidative cleavage to carbon dioxide, ammonia, and a methylene group, mediated by enzymes of the glycine cleavage complex.\" [MetaCyc:GLYCLEAV-PWY]","metadata":null},{"id":"668d23536b7a449cbbbcf2834321c056","type":"GO_TERM","name":"glycine dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047960","description":"\"Catalysis of the reaction: glycine + NAD+ + H2O = glyoxylate + NH4+ + NADH + H+.\" [RHEA:15721]","metadata":null},{"id":"d90feae563a14b51be858f5339c176ca","type":"GO_TERM","name":"glycine dehydrogenase (cyanide-forming) activity","canonical_id":"go:GO:0050622","description":"\"Catalysis of the reaction: glycine + 2 A = HCN + CO2 + 2 AH2.\" [RHEA:15821]","metadata":null},{"id":"ba98f198726240698f5dc41984343fbb","type":"GO_TERM","name":"glycine dehydrogenase (cytochrome) activity","canonical_id":"go:GO:0047959","description":"\"Catalysis of the reaction: 2 Fe(III)-[cytochrome c] + glycine + H2O = 2 Fe(II)-[cytochrome c] + glyoxylate + NH4+ + 2 H+.\" [RHEA:16909]","metadata":null},{"id":"da8e81915f6e4884b78f096c6609eb47","type":"GO_TERM","name":"glycine dehydrogenase (decarboxylating) activity","canonical_id":"go:GO:0004375","description":"\"Catalysis of the reaction: N(6)-[(R)-lipoyl]-L-lysyl-[glycine-cleavage complex H protein] + glycine + H+ = N(6)-[(R)-S(8)-aminomethyldihydrolipoyl]-L-lysyl-[glycine-cleavage complex H protein] + CO2.\" [RHEA:24304]","metadata":null},{"id":"db794b7c25c94c258611307c504c8f6b","type":"GO_TERM","name":"glycine fermentation","canonical_id":"go:GO:0019669","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of glycine, yielding energy in the form of ATP.\" [MetaCyc:PWY-8015]","metadata":null},{"id":"6b4cf6ece3a14189bd7c70be12158142","type":"GO_TERM","name":"glycine formimidoyltransferase activity","canonical_id":"go:GO:0030408","description":"\"Catalysis of the reaction: 5-formimidoyltetrahydrofolate + glycine = (6S)-5,6,7,8-tetrahydrofolate + N-formimidoylglycine.\" [RHEA:24288]","metadata":null},{"id":"5976612d1cbb4bc0aec43eb82d092ccf","type":"GO_TERM","name":"glycine hydroxymethyltransferase activity","canonical_id":"go:GO:0004372","description":"\"Catalysis of the reaction: (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + glycine + H2O = (6S)-5,6,7,8-tetrahydrofolate + L-serine.\" [RHEA:15481]","metadata":null},{"id":"447129a230ba4911ba245a307f10eeac","type":"GO_TERM","name":"glycine import across plasma membrane","canonical_id":"go:GO:1903804","description":"\"The directed movement of glycine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:23895341]","metadata":null},{"id":"8d04e1b0867045fc87ff7ff428afe6d8","type":"GO_TERM","name":"glycine import into mitochondrion","canonical_id":"go:GO:1904983","description":"\"The process in which glycine is transported from the cytosol into the mitochondrial matrix.\" [GO_REF:0000078, GOC:TermGenie, PMID:26821380]","metadata":null},{"id":"4064931e231c42ab9b8e1bcc2aff5d7e","type":"GO_TERM","name":"glycine metabolic process","canonical_id":"go:GO:0006544","description":"\"The chemical reactions and pathways involving glycine, aminoethanoic acid.\" [GOC:curators]","metadata":null},{"id":"968467ebeadf4d369fd4c52ac95a6079","type":"GO_TERM","name":"glycine oxidase activity","canonical_id":"go:GO:0043799","description":"\"Catalysis of the reactions: (1) glycine + H2O + O2 = glyoxylate + NH4+ + H2O2; (2) D-alanine + H2O + O2 = pyruvate + NH4+ + H2O2; (3) sarcosine + H2O + O2 = glyoxylate + methylamine + H2O2; (4) N-ethylglycine + H2O + O2 = glyoxylate + ethylamine + H2O2.\" [EC:1.4.3.19]","metadata":null},{"id":"26d937c9b5fe407a89c1383320914c6b","type":"GO_TERM","name":"glycine receptor clustering","canonical_id":"go:GO:0072579","description":"\"The receptor clustering process in which glycine receptors are localized to distinct domains in the cell membrane.\" [GOC:dsf, GOC:mah, GOC:pr, PMID:20843816]","metadata":null},{"id":"6fd3d50001ad40fa843566ad6beb7c53","type":"GO_TERM","name":"glycine reductase activity","canonical_id":"go:GO:0030699","description":"\"Catalysis of the reaction: acetyl phosphate + H2O + NH4 + thioredoxin disulfide = glycine + H+ + phosphate + thioredoxin.\" [EC:1.21.4.2, RHEA:12232]","metadata":null},{"id":"5b98145cdd45457a8452d866ea5e7fad","type":"GO_TERM","name":"glycine reductase complex","canonical_id":"go:GO:0030700","description":"\"Complex that possesses glycine reductase activity; usually comprises three subunits, of which two are selenoproteins; the subunits are typically designated selenoprotein A, selenoprotein B and protein C.\" [GOC:mah, PMID:2018775]","metadata":null},{"id":"efaa8e5677854ba7bda7c41a37818a6a","type":"GO_TERM","name":"glycine secretion","canonical_id":"go:GO:0061536","description":"\"The controlled release of glycine by a cell.\" [GOC:dph]","metadata":null},{"id":"7c050c5d02a946dc8a4b2e8d62793c75","type":"GO_TERM","name":"glycine secretion, neurotransmission","canonical_id":"go:GO:0061537","description":"\"The controlled release of glycine by a cell, in which glycine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"fb00dc62f5c84399b3aea7e64554574f","type":"GO_TERM","name":"glycine transmembrane transporter activity","canonical_id":"go:GO:0015187","description":"\"Enables the transfer of glycine from one side of a membrane to the other. Glycine is aminoethanoic acid.\" [GOC:ai]","metadata":null},{"id":"c8f3e2fd4cbb42f8ab35ee77ea1b1cc5","type":"GO_TERM","name":"glycine transport","canonical_id":"go:GO:0015816","description":"\"The directed movement of glycine, aminoethanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"90e6f88c3080427ca83b6101f0a96d51","type":"GO_TERM","name":"glycine-gated cation channel activity","canonical_id":"go:GO:0160212","description":"\"Enables the transmembrane transfer of a cation by a channel that opens when glycine is bound by the channel complex or one of its constituent parts on the extracellular side of the plasma membrane.\" [PMID:11823786]","metadata":null},{"id":"9875c852a46b4c58813700507e14d5d8","type":"GO_TERM","name":"glycine-gated chloride channel complex","canonical_id":"go:GO:0016935","description":"\"A protein complex that forms a transmembrane channel through which chloride ions may pass in response to glycine binding to the channel complex or one of its constituent parts.\" [GOC:mah]","metadata":null},{"id":"3c2cab0314244eafa94c5ec7770e17cb","type":"GO_TERM","name":"glycine-gated chloride ion channel activity","canonical_id":"go:GO:0022852","description":"\"Enables the transmembrane transfer of a chloride ion by a channel that opens when glycine has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"c8c33b63fca34ec8a0ee9f7b1b09af3d","type":"GO_TERM","name":"glycine-tRNA ligase activity","canonical_id":"go:GO:0004820","description":"\"Catalysis of the reaction: ATP + glycine + tRNA(Gly) = AMP + diphosphate + glycyl-tRNA(Gly).\" [EC:6.1.1.14]","metadata":null},{"id":"343afa4b82f8473c831c882c14c9fc1e","type":"GO_TERM","name":"glycine-tRNA ligase complex","canonical_id":"go:GO:0009345","description":"\"A multimeric enzyme complex which, in bacteria, is usually a tetramer of two alpha and two beta chains and in eukaryotes, is usually a homodimer. Functions in the ligation of glycine and tRNA(Gly) to form glycyl-tRNA(Gly).\" [PMID:15733854]","metadata":null},{"id":"7cc17be4997b4690bd33479d2369cfcd","type":"GO_TERM","name":"glycine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0047958","description":"\"Catalysis of the reaction: glycine + 2-oxoglutarate = glyoxylate + L-glutamate.\" [RHEA:14089]","metadata":null},{"id":"7275c35da9e741ecb6708d6c75ddf77d","type":"GO_TERM","name":"glycine:oxaloacetate transaminase activity","canonical_id":"go:GO:0047303","description":"\"Catalysis of the reaction: glycine + oxaloacetate = L-aspartate + glyoxylate.\" [RHEA:17141]","metadata":null},{"id":"7c332df715bd435698fe75993a1b83d6","type":"GO_TERM","name":"glycine:proton antiporter activity","canonical_id":"go:GO:0140799","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glycine(out) + H+(in) = glycine(in) + H+(out).\" [PMID:16701208, PMID:26912364]","metadata":null},{"id":"4fd30850dc9e4f34ab55453391bc9d8f","type":"GO_TERM","name":"glycine:sodium symporter activity","canonical_id":"go:GO:0015375","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glycine(out) + Na+(out) = glycine(in) + Na+(in).\" [GOC:ai]","metadata":null},{"id":"c95ed5fa98bd4b3888ab24f9751d33a9","type":"GO_TERM","name":"glycinergic synapse","canonical_id":"go:GO:0098690","description":"\"A synapse that uses glycine as a neurotransmitter.\" [GOC:dos]","metadata":null},{"id":"cf11667a27184c8a8a97450002014f54","type":"GO_TERM","name":"glycoRNA biosynthetic process","canonical_id":"go:GO:0141217","description":"\"The posttranscriptional addition of a carbohydrate or carbohydrate derivative unit to residues in an RNA molecule. GlycoRNA consists of RNAs modified with secretory N-glycans that are presented on the cell surface.\" [PMID:34004145, PMID:39173631]","metadata":null},{"id":"1040349dc54545c0b2d7dfc28a21935c","type":"GO_TERM","name":"glycocalyx","canonical_id":"go:GO:0030112","description":"\"A carbohydrate rich layer at the outermost periphery of a cell.\" [GOC:krc, GOC:mlg, ISBN:0815316208, PMID:28876829]","metadata":null},{"id":"9bf760309eab452ab51d359ead64ea74","type":"GO_TERM","name":"glycochenodeoxycholate sulfotransferase activity","canonical_id":"go:GO:0033876","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + glycochenodeoxycholate = adenosine 3',5'-diphosphate + glycochenodeoxycholate 7-sulfate + H+.\" [EC:2.8.2.34, RHEA:17689]","metadata":null},{"id":"5d0616e9473147f09bcfc53b972822b5","type":"GO_TERM","name":"glycogen binding","canonical_id":"go:GO:2001069","description":"\"Binding to glycogen.\" [GOC:mengo_curators]","metadata":null},{"id":"a2837f828ea54e179b70b96b160a957a","type":"GO_TERM","name":"glycogen biosynthetic process","canonical_id":"go:GO:0005978","description":"\"The chemical reactions and pathways resulting in the formation of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.\" [ISBN:0198506732]","metadata":null},{"id":"4b0e0638729b4ba1ad5e421b1c3313d2","type":"GO_TERM","name":"glycogen catabolic process","canonical_id":"go:GO:0005980","description":"\"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.\" [ISBN:0198506732]","metadata":null},{"id":"356115dfc60b48538e26754b8fdcb38b","type":"GO_TERM","name":"glycogen cell differentiation involved in embryonic placenta development","canonical_id":"go:GO:0060709","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glycogen cell of the placenta. A glycogen cell is a vacuolated glycogen-rich cell that appears in compact cell islets of the spongiotrophoblast layer.\" [GOC:dph, PMID:16269175]","metadata":null},{"id":"a6e40c400d054ef6bbd1c505db355bd9","type":"GO_TERM","name":"glycogen granule","canonical_id":"go:GO:0042587","description":"\"Cytoplasmic bead-like structures of animal cells, visible by electron microscope. Each granule is a functional unit with the biosynthesis and catabolism of glycogen being catalyzed by enzymes bound to the granule surface.\" [GOC:jl, PMID:12179957]","metadata":null},{"id":"d53edd35be634404b98093e5e4a0ba2f","type":"GO_TERM","name":"glycogen metabolic process","canonical_id":"go:GO:0005977","description":"\"The chemical reactions and pathways involving glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues in alpha-(1->4) glycosidic linkage, joined together by alpha-(1->6) glycosidic linkages.\" [ISBN:0198506732]","metadata":null},{"id":"641a9ccda2aa42d394fae75bff79815a","type":"GO_TERM","name":"glycogen phosphorylase activity","canonical_id":"go:GO:0008184","description":"\"Catalysis of the reaction: glycogen + phosphate = maltodextrin + alpha-D-glucose 1-phosphate.\" [MetaCyc:GLYCOPHOSPHORYL-RXN]","metadata":null},{"id":"5517dd084fe84d7a8ffabb6ee4ab54a1","type":"DISEASE","name":"glycogen storage disease II","canonical_id":"mondo:0009290","description":null,"metadata":null},{"id":"8d7ed05300c146c9a173a9f83e65610e","type":"DISEASE","name":"glycogen storage disease due to acid maltase deficiency, infantile onset","canonical_id":"mondo:0017694","description":null,"metadata":null},{"id":"6ac564644926484d8dbc900c68f723e4","type":"DISEASE","name":"glycogen storage disease due to acid maltase deficiency, late-onset","canonical_id":"mondo:0018485","description":null,"metadata":null},{"id":"c167a6cdb69d444d959536e56b7315b7","type":"DISEASE","name":"glycogen storage disease due to glycogen branching enzyme deficiency","canonical_id":"mondo:0009292","description":null,"metadata":null},{"id":"0457a6343edc4e7cb20359672858222a","type":"GO_TERM","name":"glycogen synthase activity, transferring glucose-1-phosphate","canonical_id":"go:GO:0061547","description":"\"Catalysis of the reaction: UDP-glucose + (1,4)-alpha-D-glucosyl(n) = UMP + (1,4)-alpha-D-glucosyl(n)-glucose-1-phosphate.\" [GOC:dph, PMID:21356517]","metadata":null},{"id":"d18c18de920b40d88b70b11ff13f8621","type":"GO_TERM","name":"glycogenin glucosyltransferase activity","canonical_id":"go:GO:0008466","description":"\"Catalysis of the reaction: UDP-glucose + glycogenin = UDP + glucosylglycogenin. This first reaction is a self glucosylation. Further UDP-glucose goups are added to the [1,4-alpha-D-glucosyl](n) group of glycogenin until a length of about 5-13 residues.\" [EC:2.4.1.186]","metadata":null},{"id":"8603514f674546168d838c5d20acb0f0","type":"GO_TERM","name":"glycol biosynthetic process","canonical_id":"go:GO:0042845","description":"\"The chemical reactions and pathways resulting in the formation of glycol, a diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent.\" [GOC:curators]","metadata":null},{"id":"f6efd45db42d4170a1517745ee9210a1","type":"GO_TERM","name":"glycol catabolic process","canonical_id":"go:GO:0042846","description":"\"The chemical reactions and pathways resulting in the breakdown of glycol, a diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent.\" [Wikipedia:Ethylene_glycol]","metadata":null},{"id":"6f16f41da6424d1b871998a5479d2355","type":"GO_TERM","name":"glycol metabolic process","canonical_id":"go:GO:0042844","description":"\"The chemical reactions and pathways involving glycol, a diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent.\" [PMID:9851711]","metadata":null},{"id":"3f9232ce596347e5a0ef19bda656f0cf","type":"GO_TERM","name":"glycolaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050569","description":"\"Catalysis of the reaction: glycolaldehyde + H2O + NAD+ = glycolate + 2 H+ + NADH.\" [RHEA:20001]","metadata":null},{"id":"41e8e1a038ba4e2fa2b697761de328c8","type":"GO_TERM","name":"glycolate biosynthetic process","canonical_id":"go:GO:0046295","description":"\"The chemical reactions and pathways resulting in the formation of glycolate, the anion of hydroxyethanoic acid (glycolic acid).\" [GOC:ai]","metadata":null},{"id":"be3bd763c1ed420999b1131bb9cd3dfd","type":"GO_TERM","name":"glycolate catabolic process","canonical_id":"go:GO:0046296","description":"\"The chemical reactions and pathways resulting in the breakdown of glycolate, the anion of hydroxyethanoic acid (glycolic acid).\" [GOC:ai]","metadata":null},{"id":"5e965e7c640b4bb3a88cdce753a6c022","type":"GO_TERM","name":"glycolate dehydrogenase activity","canonical_id":"go:GO:0019154","description":"\"Catalysis of the reaction: A + glycolate = AH(2) + glyoxylate.\" [EC:1.1.99.14, RHEA:21264]","metadata":null},{"id":"a91aa89a64ac4852bc78e4a6533f03f2","type":"GO_TERM","name":"glycolate metabolic process","canonical_id":"go:GO:0009441","description":"\"The chemical reactions and pathways involving glycolate, the anion of hydroxyethanoic acid (glycolic acid).\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"d9144b2be327450fb2385dee5cec4797","type":"GO_TERM","name":"glycolate oxidase complex","canonical_id":"go:GO:0009339","description":"\"An enzyme complex that catalyzes the oxidation of 2-hydroxy acid to form 2-oxo acid and H2O2. The enzyme is a flavoprotein (FMN).\" [PMID:4557653, PMID:8606183]","metadata":null},{"id":"017b31332f5b4c21bdf9d5ec05fd56e5","type":"GO_TERM","name":"glycolate transmembrane transport","canonical_id":"go:GO:0097339","description":"\"The process in which glycolate is transported across a membrane. Glycolate is the anion of hydroxyethanoic acid (glycolic acid).\" [GOC:am, PMID:11283302, PMID:11785976]","metadata":null},{"id":"0963f456ed81437eb75d1cc515cd344e","type":"GO_TERM","name":"glycolate transmembrane transporter activity","canonical_id":"go:GO:0043879","description":"\"Enables the transfer of glycolate from one side of a membrane to the other. Glycolate is the smallest alpha-hydroxy acid (AHA).\" [GOC:jl]","metadata":null},{"id":"ef07423f1c5145848baec2f718c77a2f","type":"GO_TERM","name":"glycolate transport","canonical_id":"go:GO:1900866","description":"\"The directed movement of a glycolate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"392e35c93d9b4fc2916e8aa3b65e9f43","type":"GO_TERM","name":"glycolipid binding","canonical_id":"go:GO:0051861","description":"\"Binding to a glycolipid, any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic group such as an acylglycerol, a sphingoid, a ceramide (N-acylsphingoid) or a prenyl phosphate.\" [PMID:19635802]","metadata":null},{"id":"0f1c1e4e02ca43f0b13c6d04f71a3fa7","type":"GO_TERM","name":"glycolipid biosynthetic process","canonical_id":"go:GO:0009247","description":"\"The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).\" [GOC:curators]","metadata":null},{"id":"1bbd0de1eaae4ed493fe7581719d0548","type":"GO_TERM","name":"glycolipid catabolic process","canonical_id":"go:GO:0019377","description":"\"The chemical reactions and pathways resulting in the breakdown of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).\" [GOC:curators]","metadata":null},{"id":"e71740c86b394a7e9cc61b628638f6e5","type":"GO_TERM","name":"glycolipid floppase activity","canonical_id":"go:GO:0034202","description":"\"Catalysis of the movement of a glycolipid from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [GOC:krc, PMID:11807558]","metadata":null},{"id":"d653106990b847fbbb5379519f558fc7","type":"GO_TERM","name":"glycolipid metabolic process","canonical_id":"go:GO:0006664","description":"\"The chemical reactions and pathways involving glycolipids, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide). Some substances classified as bacterial glycolipids have the sugar group acylated by one or more fatty acids and the glycerol group may be absent.\" [ISBN:0198547684]","metadata":null},{"id":"2b5cda7825ef40a1bae918a8cb992e95","type":"GO_TERM","name":"glycolipid transfer activity","canonical_id":"go:GO:0017089","description":"\"Removes a glycolipid from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle. A glycolipid is a compound usually containing 1-4 linked monosaccharide residues joined by a glycosyl linkage to a lipid.\" [PMID:30337668]","metadata":null},{"id":"97518c28c7dc479f8bd5e0ff9083aa9b","type":"GO_TERM","name":"glycolipid translocation","canonical_id":"go:GO:0034203","description":"\"The translocation, or flipping, of glycolipid molecules from one monolayer of a membrane bilayer to the opposite monolayer.\" [GOC:curators, PMID:11807558]","metadata":null},{"id":"eee0f8f51a144a928c7eea25fc2aab8f","type":"GO_TERM","name":"glycolipid transport","canonical_id":"go:GO:0046836","description":"\"The directed movement of glycolipids, compounds containing (usually) 1-4 linked monosaccharide residues joined by a glycosyl linkage to a lipid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"759e417c75674d0898ecf8d391efc4f2","type":"GO_TERM","name":"glycolysis from storage polysaccharide through glucose-1-phosphate","canonical_id":"go:GO:0093001","description":"\"The chemical reactions and pathways resulting in the breakdown of a storage polysaccharide into pyruvate through a glucose-1-phosphate intermediate, with the concomitant production of a small amount of ATP and the reduction of NAD to NADH.\" [GOC:dph, GOC:glycolysis]","metadata":null},{"id":"7c14aa6c248942c79d8654531edc05b8","type":"GO_TERM","name":"glycolytic process","canonical_id":"go:GO:0006096","description":"\"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.\" [GOC:bf, GOC:dph, ISBN:0201090910, ISBN:0716720094, ISBN:0879010479, Wikipedia:Glycolysis]","metadata":null},{"id":"e3215a355d3b42b1b6b2abc555f91fb5","type":"GO_TERM","name":"glycolytic process from fructose through fructose-6-phosphate","canonical_id":"go:GO:0061616","description":"\"The glycolytic process through fructose-6-phosphate in which fructose is catabolized into pyruvate.\" [GOC:dph, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"bcb9638cb05f4a249870c108c51616c8","type":"GO_TERM","name":"glycolytic process from galactose","canonical_id":"go:GO:0061623","description":"\"The chemical reactions and pathways resulting in the breakdown of galactose into pyruvate, with the concomitant production of a small amount of ATP.\" [GOC:dph, ISBN:0201090910]","metadata":null},{"id":"27bcef31923b4bc197fefd4fa4110bc7","type":"GO_TERM","name":"glycolytic process from mannose through fructose-6-phosphate","canonical_id":"go:GO:0061619","description":"\"The chemical reactions and pathways resulting in the breakdown of mannose into pyruvate, occurring through a fructose-6-phosphate intermediate, with the concomitant production of ATP and NADH.\" [GOC:dph, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"26791f1da2474bdb9d06cf0216df4f56","type":"GO_TERM","name":"glycolytic process from sucrose","canonical_id":"go:GO:0061704","description":"\"The chemical reactions and pathways resulting in the breakdown of a sucrose into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.\" [GOC:dph, GOC:glycolysis, PMID:15012287]","metadata":null},{"id":"f64f500c8fd9412e9c28a5dcb3d516c5","type":"GO_TERM","name":"glycolytic process from sucrose through glucose and fructose","canonical_id":"go:GO:0061706","description":"\"The chemical reactions and pathways resulting in the breakdown of sucrose into pyruvate through both glucose and fructose intermediates, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.\" [GOC:dph, GOC:glycolysis, MetaCyc:PWY-1042, PMID:15012287]","metadata":null},{"id":"2fc2a7e798904e989f119bcb5b72e266","type":"GO_TERM","name":"glycolytic process through fructose-1-phosphate","canonical_id":"go:GO:0061625","description":"\"The chemical reactions and pathways resulting in the breakdown of fructose into pyruvate through a fructose-1-phosphate intermediate, with the concomitant production of ATP and NADH.\" [GOC:dph, ISBN:0201090910]","metadata":null},{"id":"3b0e9751827441bca847334b9bd21ebc","type":"GO_TERM","name":"glycolytic process through fructose-6-phosphate","canonical_id":"go:GO:0061615","description":"\"The chemical reactions and pathways resulting in the breakdown of a monosaccharide into pyruvate, occurring through a fructose-6-phosphate intermediate, with the concomitant production of ATP and NADH.\" [GOC:dph, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"1122c97d56c64ebfa93d4346a0bcec12","type":"GO_TERM","name":"glycolytic process through glucose-1-phosphate","canonical_id":"go:GO:0061622","description":"\"The chemical reactions and pathways through a glucose-1-phosphate intermediate that result in the catabolism of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP.\" [GOC:dph, ISBN:0201090910]","metadata":null},{"id":"f4f2ee6cf1974b18a9372836263f5e8b","type":"GO_TERM","name":"glycolytic process through glucose-6-phosphate","canonical_id":"go:GO:0061620","description":"\"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, occurring through a glucose-6-phosphate intermediate, with the concomitant production of a small amount of ATP.\" [GOC:dph, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"b1806f99f5a942d39af5d273536af197","type":"GO_TERM","name":"glycopeptide catabolic process","canonical_id":"go:GO:0009050","description":"\"The chemical reactions and pathways resulting in the breakdown of glycopeptides, a compound in which carbohydrate is covalently attached to an oligopeptide composed of residues of L and/or D-amino acids. The term usually denotes a product of proteolytic degradation of a glycoprotein but includes glycated peptide.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b5779534635044ebb8d9b6dec0dece52","type":"GO_TERM","name":"glycophagy","canonical_id":"go:GO:0061723","description":"\"The selective degradation of glycogen by macroautophagy.\" [GOC:autophagy, PMID:21893048]","metadata":null},{"id":"8dbd358f3a454f01ba272c1705bc33ba","type":"GO_TERM","name":"glycoprotein 2-beta-D-xylosyltransferase activity","canonical_id":"go:GO:0050513","description":"\"Catalysis of the reaction: N(4)-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl}-L-asparagine + UDP-alpha-D-xylose = N(4)-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl}-L-asparagine + H+ + UDP.\" [EC:2.4.2.38, RHEA:10612]","metadata":null},{"id":"039bb95454894d719dbe1a2dd4ec48ad","type":"GO_TERM","name":"glycoprotein 3-alpha-L-fucosyltransferase activity","canonical_id":"go:GO:0018392","description":"\"Catalysis of the reaction: N(4)-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl}-L-asparagine + GDP-L-fucose = N(4)-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl}-L-asparagine + GDP + H+.\" [EC:2.4.1.214, RHEA:24444]","metadata":null},{"id":"47782bf2c5fd4b5a9e1069120db446f0","type":"GO_TERM","name":"glycoprotein 6-alpha-L-fucosyltransferase activity","canonical_id":"go:GO:0008424","description":"\"Catalysis of the reaction: N(4)-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl}-L-asparagine + GDP-L-fucose = N(4)-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-beta-D-glucosaminyl}asparagine + GDP + H+.\" [EC:2.4.1.68, RHEA:12985]","metadata":null},{"id":"9794512102754f6a8d367895f50ce697","type":"GO_TERM","name":"glycoprotein Ib-IX-V complex","canonical_id":"go:GO:1990779","description":"\"A transmembrane signaling receptor complex found exclusively on platelets. Involved in haemostasis and thrombosis where it aids blood coagulation.\" [GOC:bhm, PMID:1730602, PMID:23336709, PMID:25297919]","metadata":null},{"id":"768318655a09429ba559c74b2fb533e3","type":"GO_TERM","name":"glycoprotein O-fatty-acyltransferase activity","canonical_id":"go:GO:0047965","description":"\"Catalysis of the reaction: palmitoyl-CoA + mucus glycoprotein = CoA + O-palmitoylglycoprotein.\" [EC:2.3.1.142, MetaCyc:GLYCOPROTEIN-O-FATTY-ACYLTRANSFERASE-RXN]","metadata":null},{"id":"77924047afd04794bcea2b6e78a9b45c","type":"GO_TERM","name":"glycoprotein biosynthetic process","canonical_id":"go:GO:0009101","description":"\"The chemical reactions and pathways resulting in the formation of glycoproteins, a protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.\" [PMID:35536965]","metadata":null},{"id":"609af9f710aa4011ab64fb0b0a0465ff","type":"GO_TERM","name":"glycoprotein catabolic process","canonical_id":"go:GO:0006516","description":"\"The chemical reactions and pathways resulting in the breakdown of a glycoprotein, a protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"7631d2c919034f538763eb4053e5c738","type":"GO_TERM","name":"glycoprotein complex","canonical_id":"go:GO:0090665","description":"\"A protein complex containing at least one glycosylated protein, may be held together by both covalent and noncovalent bonds.\" [GOC:pf, PMID:7693675, PMID:8662961]","metadata":null},{"id":"6a046b5f7aa546b9a5ffeea4d4f9df9f","type":"GO_TERM","name":"glycoprotein endo-alpha-1,2-mannosidase activity","canonical_id":"go:GO:0004569","description":"\"Catalysis of the hydrolysis of the terminal alpha-glucosyl-(1,3)-mannosyl unit from Glc-Man(9)-(GlcNAc)(2) oligosaccharide component of the glycoprotein produced in the Golgi membrane.\" [EC:3.2.1.130]","metadata":null},{"id":"c63677030c214bf7b3aea544c7a8f39a","type":"GO_TERM","name":"glycoprotein metabolic process","canonical_id":"go:GO:0009100","description":"\"The chemical reactions and pathways involving glycoproteins, a protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"481709522ab24a9ea289e0d32944aad7","type":"GO_TERM","name":"glycoprotein network","canonical_id":"go:GO:0048222","description":"\"An extracellular matrix part that consists of cross-linked glycoproteins.\" [GOC:mah, PMID:18508691, PMID:7048321]","metadata":null},{"id":"a2353e84c3e841c6a220a394e48093a0","type":"GO_TERM","name":"glycoprotein transport","canonical_id":"go:GO:0034436","description":"\"The directed movement of a glycoprotein, a protein that contains covalently bound glycose (i.e. monosaccharide) residues, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"e255ad93a6df498fb7dee2ec31ba4f0f","type":"GO_TERM","name":"glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0004380","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-galactosamine + glycoprotein-alpha-L-fucosyl-(1,2)-D-galactose = UDP + glycoprotein-N-acetyl-alpha-D-galactosaminyl-(1,3)-(alpha-L-fucosyl-(1,2))-D-galactose.\" [EC:2.4.1.40]","metadata":null},{"id":"ded05d68e0ff40acbb383d59be1df72f","type":"DRUG","name":"glycopyrrolate","canonical_id":"gtopdb:7459","description":null,"metadata":null},{"id":"24019b8552454457b5d09774675d4beb","type":"COMBINATION_TREATMENT","name":"glycopyrrolate + indacaterol","canonical_id":"ctgov_combo:ctgov-combo-a142210de79effed","description":null,"metadata":null},{"id":"e755130f2e704df288ea6393140429dc","type":"GO_TERM","name":"glycosaminoglycan binding","canonical_id":"go:GO:0005539","description":"\"Binding to a glycan (polysaccharide) containing a substantial proportion of aminomonosaccharide residues.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"894b1c64f4624fe1a77692da55528d9f","type":"GO_TERM","name":"glycosaminoglycan biosynthetic process","canonical_id":"go:GO:0006024","description":"\"The chemical reactions and pathways resulting in the formation of glycosaminoglycans, any one of a group of linear polysaccharides composed of repeating disaccharide units.\" [PMID:38500384]","metadata":null},{"id":"66cd7b914cf24acfa3290d870e890373","type":"GO_TERM","name":"glycosaminoglycan catabolic process","canonical_id":"go:GO:0006027","description":"\"The chemical reactions and pathways resulting in the breakdown of glycosaminoglycans, any one of a group of linear polysaccharides composed of repeating disaccharide units.\" [PMID:38500384]","metadata":null},{"id":"8ac347466200478391a6049c383dc9fc","type":"GO_TERM","name":"glycosaminoglycan galactosyltransferase activity","canonical_id":"go:GO:0047271","description":"\"Catalysis of the reaction: glycosaminoglycan + UDP-galactose = D-galactosylglycosaminoglycan + UDP.\" [EC:2.4.1.74, MetaCyc:2.4.1.74-RXN]","metadata":null},{"id":"55986082b7d3438f882abca0e3a9ac42","type":"GO_TERM","name":"glycosaminoglycan metabolic process","canonical_id":"go:GO:0030203","description":"\"The chemical reactions and pathways involving glycosaminoglycans, any of a group of linear polysaccharides composed of repeating disaccharide units.\" [PMID:38500384]","metadata":null},{"id":"75288f8e87544238b60b6c82f963d005","type":"GO_TERM","name":"glycosaminoglycan-protein linkage region biosynthetic process","canonical_id":"go:GO:0120532","description":"\"The formation of a tetrasaccharide linker sequence (xylose-galactose-galactose-glucuronate) on specific serine residues of a core protein, on to which dermatan sulfate, chondroitin sulfate, heparan sulfate or heparin glycosaminoglycans may be assembled to synthesise the corresponding proteoglycan.\" [MetaCyc:PWY-6557]","metadata":null},{"id":"a6f34facd213444ba6b46499180a45f0","type":"GO_TERM","name":"glycoside biosynthetic process","canonical_id":"go:GO:0016138","description":"\"The chemical reactions and pathways resulting in the formation of glycosides, compounds in which a glycosyl group is substituted into a hydroxyl, thiol or selenol group in another compound.\" [GOC:curators]","metadata":null},{"id":"50724609a06149bd928899475cdd4b85","type":"GO_TERM","name":"glycoside catabolic process","canonical_id":"go:GO:0016139","description":"\"The chemical reactions and pathways resulting in the breakdown of glycosides, compounds in which a glycosyl group is substituted into a hydroxyl, thiol or selenol group in another compound.\" [GOC:curators]","metadata":null},{"id":"33af562b7fe5487983500c37af8480ab","type":"GO_TERM","name":"glycoside metabolic process","canonical_id":"go:GO:0016137","description":"\"The chemical reactions and pathways involving glycosides, compounds in which a glycosyl group is substituted into a hydroxyl, thiol or selenol group in another compound.\" [ISBN:0198547684]","metadata":null},{"id":"ac124f4ee18f478889aab9a47a759d3a","type":"GO_TERM","name":"glycoside transport","canonical_id":"go:GO:1901656","description":"\"The directed movement of a glycoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"a48e15a244d842da8b8bc2c7b6a1211e","type":"GO_TERM","name":"glycoside-pentoside-hexuronide:cation symporter activity","canonical_id":"go:GO:0015486","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: (glycoside, pentoside or hexuronide)(out) + monovalent cation(out) = (glycoside, pentoside or hexuronide)(in) + monovalent cation(in). The cation is Na+, Li+ or H+.\" [TC:2.A.2.-.-]","metadata":null},{"id":"1149744a2306477888e247c13a329321","type":"GO_TERM","name":"glycosome","canonical_id":"go:GO:0020015","description":"\"A membrane-bounded organelle found in organisms from the order Kinetoplastida that houses the enzymes of glycolysis.\" [GOC:mb]","metadata":null},{"id":"919821dab8c14536a2c5cbaf3daf5c1b","type":"GO_TERM","name":"glycosome lumen","canonical_id":"go:GO:0034468","description":"\"The volume enclosed by the membrane of a glycosome.\" [GOC:rph]","metadata":null},{"id":"e6bdb82704ae4e3cad8c3238e2e448b2","type":"GO_TERM","name":"glycosome membrane","canonical_id":"go:GO:0046860","description":"\"The lipid bilayer surrounding a glycosome.\" [GOC:ai]","metadata":null},{"id":"fae5bdeac00d48a3a5f9e92860f5465f","type":"GO_TERM","name":"glycosome organization","canonical_id":"go:GO:0106233","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a glycosome, a membrane-bounded organelle found in organisms from the order Kinetoplastida that houses the enzymes of glycolysis.\" [GOC:ach, PMID:15539076, PMID:28426655, PMID:31341002, PMID:8056787]","metadata":null},{"id":"6c48c6f929b94d608fcdbb12e7cfa620","type":"GO_TERM","name":"glycosphingolipid binding","canonical_id":"go:GO:0043208","description":"\"Binding to glycosphingolipid, a compound with residues of sphingoid and at least one monosaccharide.\" [GOC:jl]","metadata":null},{"id":"87ba5dc0420b44b0b6d8df238312e2fd","type":"GO_TERM","name":"glycosphingolipid biosynthetic process","canonical_id":"go:GO:0006688","description":"\"The chemical reactions and pathways resulting in the formation of a glycosphingolipid, a compound composed of a ceramide backbone covalently linked to at least one carbohydrate moiety.\" [PMID:35536927]","metadata":null},{"id":"e2b41f18e6624a259d15d89dbd527665","type":"GO_TERM","name":"glycosphingolipid catabolic process","canonical_id":"go:GO:0046479","description":"\"The chemical reactions and pathways resulting in the breakdown of glycosphingolipid, a compound with residues of sphingoid and at least one monosaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"baef8f7d3f814c328346da3d7eb859ef","type":"GO_TERM","name":"glycosphingolipid deacylase activity","canonical_id":"go:GO:0033964","description":"\"Catalysis of the hydrolysis of gangliosides and neutral glycosphingolipids, releasing fatty acids to form the lyso-derivatives.\" [EC:3.5.1.69]","metadata":null},{"id":"571d07eb796d4ad1bf47f97be3095905","type":"GO_TERM","name":"glycosphingolipid metabolic process","canonical_id":"go:GO:0006687","description":"\"The chemical reactions and pathways involving glycosphingolipids, any compound with residues of sphingoid and at least one monosaccharide.\" [ISBN:0198547684]","metadata":null},{"id":"d95fd2e852bb4e778c6e12fbb5c5ba36","type":"GO_TERM","name":"glycosulfatase activity","canonical_id":"go:GO:0047966","description":"\"Catalysis of the reaction: D-glucose 6-sulfate + H2O = D-glucose + H+ + sulfate.\" [EC:3.1.6.3, RHEA:19145]","metadata":null},{"id":"123ae3fc094d4a8d84e9fd10757b4127","type":"GO_TERM","name":"glycosyl compound biosynthetic process","canonical_id":"go:GO:1901659","description":"\"The chemical reactions and pathways resulting in the formation of glycosyl compound.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"de67b69e0e8546ceaa205472b10ad107","type":"GO_TERM","name":"glycosyl compound catabolic process","canonical_id":"go:GO:1901658","description":"\"The chemical reactions and pathways resulting in the breakdown of glycosyl compound.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"08570cc061334efe97e0ac09ee6f0ed2","type":"GO_TERM","name":"glycosylated region protein binding","canonical_id":"go:GO:0140081","description":"\"Binding to a glycosylated region of a protein.\" [GOC:pg]","metadata":null},{"id":"908ba53509d4486bba09d936732642e1","type":"GO_TERM","name":"glycosylation-dependent protein binding","canonical_id":"go:GO:0140032","description":"\"Binding to a protein upon glycosylation of the target protein.\" [PMID:26060076]","metadata":null},{"id":"4863380d2f284bd384391d67b406c67c","type":"GO_TERM","name":"glycosylceramidase activity","canonical_id":"go:GO:0017042","description":"\"Catalysis of the reaction: glycosyl-N-acylsphingosine + H2O = a sugar + N-acylsphingosine.\" [EC:3.2.1.62, PMID:10692580, PMID:9762914]","metadata":null},{"id":"24959b7fdb234971a47c8c821af36363","type":"GO_TERM","name":"glycosylceramide catabolic process","canonical_id":"go:GO:0046477","description":"\"The chemical reactions and pathways resulting in the breakdown of glycosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of a monosaccharide (or derivative) by a ceramide group.\" [GOC:ai]","metadata":null},{"id":"c8fc55b3938c465eb5ee13323f053686","type":"GO_TERM","name":"glycosylceramide flippase activity","canonical_id":"go:GO:0140351","description":"\"Catalysis of the movement of glycosylceramide from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP. Glycosylceramides are ceramides containing a functional group derived from a sugar.\" [PMID:30530492]","metadata":null},{"id":"b74607ba69bb4e86b74719e49dc20ebe","type":"GO_TERM","name":"glycosylceramide metabolic process","canonical_id":"go:GO:0006677","description":"\"The chemical reactions and pathways involving glycosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of a monosaccharide (or derivative) by a ceramide group.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"2caad1bb41d44bf9abc7ef507ba64c06","type":"GO_TERM","name":"glycosylphosphatidylinositol diacylglycerol-lyase activity","canonical_id":"go:GO:0047396","description":"\"Catalysis of the reaction: 6-(alpha-D-glucosaminyl)-1-phosphatidyl-1D-myo-inositol = 1,2-diacyl-sn-glycerol + 6-(alpha-D-glucosaminyl)-1D-myo-inositol 1,2-cyclic phosphate.\" [EC:4.6.1.14, MetaCyc:3.1.4.47-RXN]","metadata":null},{"id":"bfacbb54838b4181913aabe757f493c6","type":"GO_TERM","name":"glycosylphosphatidylinositol phospholipase D activity","canonical_id":"go:GO:0140336","description":"\"Catalysis of the reaction: a 6-(alpha-D-glucosaminyl)-1-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol + H2O = 6-(alpha-D-glucosaminyl)-1D-myo-inositol + a 1,2-diacyl-sn-glycero-3-phosphate + H+.\" [RHEA:10832]","metadata":null},{"id":"7f9154e92ae14517824e631d2f3ccc1f","type":"GO_TERM","name":"glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex","canonical_id":"go:GO:0000506","description":"\"An enzyme complex that catalyzes the transfer of GlcNAc from UDP-GlcNAc to an acceptor phosphatidylinositol, the first step in the production of GPI anchors for cell surface proteins. The complex contains PIG-A, PIG-C, PIG-H, PIG-Q, PIG-P, and DPM2 in human, and Eri1p, Gpi1p, Gpi2p, Gpi15p, Gpi19p, and Spt14p in budding yeast.\" [GOC:kp, GOC:rb, PMID:10944123, PMID:15163411]","metadata":null},{"id":"928b4ceeab244d4c9d611b9b282e891f","type":"GO_TERM","name":"glycosylphosphatidylinositol-mannosyltransferase I complex","canonical_id":"go:GO:1990529","description":"\"A protein complex that is involved in the transfer of the four mannoses in the GPI-anchor precursor. In yeast S. cerevisiae this complex consists of Pbn1p and Gpi14p and in rat this complex consists of PIG-X and PIG-M.\" [GOC:dph, GOC:rb, PMID:15635094]","metadata":null},{"id":"30bce6431b2849acbe28777c7b4b3772","type":"GO_TERM","name":"glycosylphosphatidylinositol-mannosyltransferase II complex","canonical_id":"go:GO:0120097","description":"\"A protein complex that is involved in the transfer of the second mannose to the glycosylphosphatidylinositol (GPI) during GPI precursor assembly. In yeast S. cerevisiae this complex consists of GPI18p and PGA1p.\" [GOC:bhm, PMID:17615295]","metadata":null},{"id":"0a6d09791163441eaba7d9bf977a8e48","type":"GO_TERM","name":"glycosyltransferase activity","canonical_id":"go:GO:0016757","description":"\"Catalysis of the transfer of a glycosyl group from one compound (donor) to another (acceptor).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a9af24be5a684b9d81486dd7c13c11ec","type":"GO_TERM","name":"glycyl-radical enzyme activating activity","canonical_id":"go:GO:0043364","description":"\"Catalyzes the activation of an enzyme by generating an organic free radical on a glycine residue via a homolytic cleavage of S-adenosyl-L-methionine (SAM).\" [GOC:jl, PMID:24486374]","metadata":null},{"id":"6ea94adf2ca44e2ea32065604330e662","type":"GO_TERM","name":"glycyl-tRNA aminoacylation","canonical_id":"go:GO:0006426","description":"\"The process of coupling glycine to glycyl-tRNA, catalyzed by glycyl-tRNA synthetase. The glycyll-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of a glycine-accepting tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"a00c9f34d1bc4a1b9fbc47c1540a5369","type":"GO_TERM","name":"glycylpeptide N-tetradecanoyltransferase activity","canonical_id":"go:GO:0004379","description":"\"Catalysis of the reaction: tetradecanoyl-CoA + glycyl-peptide = CoA + N-tetradecanoylglycyl-peptide.\" [EC:2.3.1.97]","metadata":null},{"id":"28fa9213d977499db5193c8f29656ad7","type":"GO_TERM","name":"glycyrrhetinate biosynthetic process","canonical_id":"go:GO:1902386","description":"\"The chemical reactions and pathways resulting in the formation of glycyrrhetinate.\" [GOC:TermGenie, PMID:22128119]","metadata":null},{"id":"df4ca0d271e1465d86421939848b3ec6","type":"GO_TERM","name":"glycyrrhetinate catabolic process","canonical_id":"go:GO:1902385","description":"\"The chemical reactions and pathways resulting in the breakdown of glycyrrhetinate.\" [GOC:TermGenie, PMID:22128119]","metadata":null},{"id":"1a54b2c6a81a4fa983df83970ad28cc1","type":"GO_TERM","name":"glycyrrhizinate beta-glucuronidase activity","canonical_id":"go:GO:0047967","description":"\"Catalysis of the reaction: glycyrrhizate + H2O = 2-(beta-D-glucuronosyl)-D-glucuronate + glycyrrhetinate.\" [EC:3.2.1.128, RHEA:17369]","metadata":null},{"id":"f91f096f3a094867a713f485e729b088","type":"GO_TERM","name":"glyoxal biosynthetic process","canonical_id":"go:GO:1903191","description":"\"The chemical reactions and pathways resulting in the formation of glyoxal.\" [GO_REF:0000068, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"ef424550fa9a42fd968a880344519e25","type":"GO_TERM","name":"glyoxal catabolic process","canonical_id":"go:GO:1903190","description":"\"The chemical reactions and pathways resulting in the breakdown of glyoxal.\" [GO_REF:0000068, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22523093, PMID:23651081]","metadata":null},{"id":"e0125651d9194e9d8b8a919643e19c1a","type":"GO_TERM","name":"glyoxal metabolic process","canonical_id":"go:GO:1903189","description":"\"The chemical reactions and pathways involving glyoxal.\" [GO_REF:0000068, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"e036aa1d3e064f5e93aa6f418dcfce52","type":"GO_TERM","name":"glyoxal oxidase activity","canonical_id":"go:GO:0046569","description":"\"Catalysis of the reaction: glyoxal + O2 + H2O = glyoxalate + H2O2.\" [PMID:11733005]","metadata":null},{"id":"256f9647327348369627faecb5b2064a","type":"GO_TERM","name":"glyoxalase (glycolic acid-forming) activity","canonical_id":"go:GO:1990422","description":"\"Catalysis of the reaction: glyoxal + H2O = glycolic acid. Catalysis occurs in the absence of a cofactor.\" [GOC:bf, GOC:PARL, PMID:22523093]","metadata":null},{"id":"ce9bcce2707349ae8ad07ab81ff0ba78","type":"GO_TERM","name":"glyoxalase III activity","canonical_id":"go:GO:0019172","description":"\"Catalysis of the reaction: methylglyoxal + H2O = D-lactate.\" [GOC:mcc, PMID:21696459, PMID:7848303, RHEA:27754]","metadata":null},{"id":"06cb642e9fc34237853deca0c0cad835","type":"GO_TERM","name":"glyoxylate catabolic process","canonical_id":"go:GO:0009436","description":"\"The chemical reactions and pathways resulting in the breakdown of glyoxylate, the anion of glyoxylic acid, HOC-COOH.\" [ISBN:0198506732]","metadata":null},{"id":"30bcd5d86abb43b7958dc1ab9a46d0c2","type":"GO_TERM","name":"glyoxylate cycle","canonical_id":"go:GO:0006097","description":"\"A modification of the TCA cycle occurring in some plants and microorganisms, in which isocitrate is cleaved to glyoxylate and succinate. Glyoxylate can then react with acetyl-CoA to form malate.\" [ISBN:0198506732]","metadata":null},{"id":"9345045af25e4031a66308074b00004a","type":"GO_TERM","name":"glyoxylate dehydrogenase (acylating, NADP+) activity","canonical_id":"go:GO:0047968","description":"\"Catalysis of the reaction: CoA + glyoxylate + NADP+ = H+ + NADPH + oxalyl-CoA.\" [RHEA:21024]","metadata":null},{"id":"0bc87b8bbc524ce893b61b43b833d2f8","type":"GO_TERM","name":"glyoxylate metabolic process","canonical_id":"go:GO:0046487","description":"\"The chemical reactions and pathways involving glyoxylate, the anion of glyoxylic acid, HOC-COOH.\" [ISBN:0198506732]","metadata":null},{"id":"d808d3814db040d48e50159065fde80e","type":"GO_TERM","name":"glyoxylate oxidase activity","canonical_id":"go:GO:0047969","description":"\"Catalysis of the reaction: glyoxylate + H2O + O2 = H2O2 + H+ + oxalate.\" [RHEA:14837]","metadata":null},{"id":"c356b635a2414f048d368c6e596fbd2c","type":"GO_TERM","name":"glyoxylate reductase (NADH) activity","canonical_id":"go:GO:0047964","description":"\"Catalysis of the reaction: glycolate + NAD+ = glyoxylate + NADH.\" [RHEA:18229]","metadata":null},{"id":"1d13f7d4e1e84250af9eab069765a2e2","type":"GO_TERM","name":"glyoxylate reductase (NADPH) activity","canonical_id":"go:GO:0030267","description":"\"Catalysis of the reaction: glycolate + NADP+ = glyoxylate + NADPH + H+.\" [RHEA:10992]","metadata":null},{"id":"788d002f27e04002bd9df1a99c8bcb05","type":"GO_TERM","name":"glyoxylate reductase activity","canonical_id":"go:GO:0106345","description":"\"Catalysis of the reaction: glycolate + NAD(P)+ = glyoxylate + NAD(P)H.\" [GOC:curators, PMID:3548703]","metadata":null},{"id":"840d5feee40a48168f439eae14f02185","type":"GO_TERM","name":"glyoxysomal lumen","canonical_id":"go:GO:0031908","description":"\"The volume enclosed by the membranes of a glyoxysome.\" [GOC:mah]","metadata":null},{"id":"cbc237d136a540aa83b94c2e002ce0a0","type":"GO_TERM","name":"glyoxysomal membrane","canonical_id":"go:GO:0046861","description":"\"The lipid bilayer surrounding a glyoxysome.\" [GOC:ai]","metadata":null},{"id":"44f89743e172498cbccce3003aaa359d","type":"GO_TERM","name":"glyoxysome","canonical_id":"go:GO:0009514","description":"\"A specialized form of peroxisome that contains the enzymes of the glyoxylate pathway. The glyoxysome is found in some plant cells, notably the cells of germinating seeds.\" [GOC:dhl, ISBN:0140514031]","metadata":null},{"id":"947334a1c9f84da89a2dda3a77cbe91a","type":"GO_TERM","name":"glyoxysome organization","canonical_id":"go:GO:0010111","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the glyoxysome. A glyoxysome is a microbody that contains the enzymes of the glyoxylate pathway.\" [GOC:tb]","metadata":null},{"id":"4d3c6df733ab4f1ab9ed6afdd04fe598","type":"GO_TERM","name":"glyphosate metabolic process","canonical_id":"go:GO:0018920","description":"\"The chemical reactions and pathways involving glyphosate, a broad-spectrum herbicide also known by the trade name Roundup. It is a member of a broad class of compounds known as phosphonic acids, which contain a direct carbon-to-phosphorus (C-P) bond.\" [UM-BBD_pathwayID:gly]","metadata":null},{"id":"cfa86239e5d940afa75aeb0ca95f67a7","type":"GO_TERM","name":"goblet cell theca","canonical_id":"go:GO:0098593","description":"\"A cup shaped specialization of the cytoskeleton that forms a thin layer located just below the apical mass of mature mucin secretory granules in the cytoplasm of goblet cells of the intestinal epithelium. It consists of an orderly network of intermediate filaments and microtubules. Microtubules are arranged vertically, like barrel staves, along the inner aspect of the theta. Intermediate filaments form two networks: an inner, basketlike network and an outer series of circumferential bundles resembling the hoops of a barrel.\" [PMID:6541604]","metadata":null},{"id":"a17f3014044844f3a809942977f2b94e","type":"DRUG","name":"golimumab","canonical_id":"gtopdb:6776","description":null,"metadata":null},{"id":"056513242a6b4b999d22e132f7073ff7","type":"DRUG","name":"golimumab","canonical_id":"chembl:CHEMBL1201833","description":null,"metadata":null},{"id":"0fbbe6698f184b9f827d5fdc5288d9f2","type":"COMBINATION_TREATMENT","name":"golimumab + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-55202441effaca77","description":null,"metadata":null},{"id":"deb7586dc7c54b279b18fa646246fa37","type":"GO_TERM","name":"gonad development","canonical_id":"go:GO:0008406","description":"\"The process whose specific outcome is the progression of the gonad over time, from its formation to the mature structure. The gonad is an animal organ that produces gametes; in some species it also produces hormones.\" [GOC:ems, ISBN:0198506732]","metadata":null},{"id":"4a856d27883c4040883796b0cda27805","type":"GO_TERM","name":"gonad morphogenesis","canonical_id":"go:GO:0035262","description":"\"The process in which the anatomical structures of the gonads are generated and organized. A gonad is an animal organ producing gametes, e.g. the testes or the ovary in mammals.\" [ISBN:0198612001]","metadata":null},{"id":"1a7bc272e97943d08b6e4b69cb0a4e06","type":"DISEASE","name":"gonadal dysgenesis","canonical_id":"mondo:0001967","description":null,"metadata":null},{"id":"57c8a07179d94e2688699d1c8a1f6b1f","type":"GO_TERM","name":"gonadal mesoderm development","canonical_id":"go:GO:0007506","description":"\"The process whose specific outcome is the progression of the gonadal mesoderm over time, from its formation to the mature structure. The gonadal mesoderm is the middle layer of the three primary germ layers of the embryo which will go on to form the gonads of the organism.\" [GOC:ai]","metadata":null},{"id":"8092f2651f504ee2935568f0202bbb03","type":"GO_TERM","name":"gonadotrophin-releasing hormone neuronal migration to the hypothalamus","canonical_id":"go:GO:0021828","description":"\"The directional movement of a gonadotrophin-releasing hormone producing neuron from the nasal placode to the hypothalamus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"2255033939214ce1a5643250b4db8bc7","type":"GO_TERM","name":"gonadotropin hormone-releasing hormone activity","canonical_id":"go:GO:0005183","description":"\"The action characteristic of gonadotropin hormone-releasing hormone (GnRH), any of a family of decapeptide amide hormones that are released by the hypothalamus in response to neural and/or chemical stimuli. In at least mammals, upon receptor binding, GnRH causes the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary.\" [ISBN:0198506732, PMID:11026571, Wikipedia:Gonadotropin-releasing_hormone]","metadata":null},{"id":"93d1f04fc9a94eaf85dffcac2bda2b91","type":"GO_TERM","name":"gonadotropin secretion","canonical_id":"go:GO:0032274","description":"\"The regulated release of a gonadotropin, any hormone that stimulates the gonads, especially follicle-stimulating hormone and luteinizing hormone.\" [GOC:mah, ISBN:0721662544]","metadata":null},{"id":"2708d7ab73644927ae3fa59adfb09033","type":"GO_TERM","name":"gonadotropin-releasing hormone binding","canonical_id":"go:GO:0051448","description":"\"Binding to gonadotropin-releasing hormone (GnRH), a peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released by the hypothalamus.\" [GOC:pr, PMID:1984190]","metadata":null},{"id":"8c9ebfdcdeb8457eb18cb96ace0b4319","type":"GO_TERM","name":"gonadotropin-releasing hormone receptor activity","canonical_id":"go:GO:0004968","description":"\"Combining with gonadotropin-releasing hormone to initiate a change in cell activity. Gonadotropin-releasing hormone (GnRH) is a peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released by the hypothalamus.\" [GOC:mah]","metadata":null},{"id":"b82438a02ca64373ba9bdb40e29152f2","type":"GO_TERM","name":"gonadotropin-releasing hormone receptor binding","canonical_id":"go:GO:0031530","description":"\"Binding to a receptor for gonadotropin-releasing hormone (GnRH), a peptide hormone that is synthesized and released by the hypothalamus and is responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary.\" [GOC:pr, PMID:15196882]","metadata":null},{"id":"91e1d37cd1a14e609327b7c9293b1cd7","type":"DISEASE","name":"gonorrhea","canonical_id":"mondo:0004277","description":null,"metadata":null},{"id":"17fab50ffcd14fb1aecb2033d728cf87","type":"DRUG","name":"goserelin","canonical_id":"gtopdb:3879","description":null,"metadata":null},{"id":"a2b339048c514ea58e421e17d0a9acc4","type":"COMBINATION_TREATMENT","name":"goserelin + letrozole + leuprolide + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-3413d7413efc760b","description":null,"metadata":null},{"id":"000d433e5be6442db4a118cdf00ce521","type":"COMBINATION_TREATMENT","name":"goserelin + leuprolide","canonical_id":"ctgov_combo:ctgov-combo-6a959eaed857b25c","description":null,"metadata":null},{"id":"9aae8278469b4666bb6888c396f268f3","type":"COMBINATION_TREATMENT","name":"goserelin + leuprolide + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-393594290c5324f5","description":null,"metadata":null},{"id":"5710150d2d4749ad99c05ce4811a6cde","type":"COMBINATION_TREATMENT","name":"goserelin + pertuzumab","canonical_id":"ctgov_combo:ctgov-combo-80cb7f1121775a22","description":null,"metadata":null},{"id":"4dc5fdc8952d40668f5d298ff6eeab8b","type":"COMBINATION_TREATMENT","name":"goserelin + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-af49f6835dc3a73a","description":null,"metadata":null},{"id":"07662395c9a94c55941a5225437222c6","type":"DISEASE","name":"gout","canonical_id":"mondo:0005393","description":null,"metadata":null},{"id":"d32abe69adeb4375b4642b5e56f4ec45","type":"GO_TERM","name":"gracilis tract morphogenesis","canonical_id":"go:GO:0021958","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the dorsal root ganglion towards target cells in the medulla. This axonal process is a member of those that make up the gracilis tract, a group of axons that are from neurons involved in proprioception from the lower trunk and lower limb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12867698]","metadata":null},{"id":"8a5cc8128c7f45f79dfd02cd6e11dc7e","type":"DISEASE","name":"graft versus host disease","canonical_id":"mondo:0013730","description":null,"metadata":null},{"id":"89b693591e62447aa186d7c2b02f32d1","type":"DISEASE","name":"gram-negative bacterial infections","canonical_id":"mondo:0021678","description":null,"metadata":null},{"id":"ab705e66a0fe4dff9d68ae58d6488627","type":"GO_TERM","name":"gramicidin S biosynthetic process","canonical_id":"go:GO:1901103","description":"\"The chemical reactions and pathways resulting in the formation of gramicidin S.\" [GOC:TermGenie, GOC:yaf, PMID:7534306]","metadata":null},{"id":"e815d81b228f42ad989f457f7aa14d91","type":"GO_TERM","name":"granal stacked thylakoid","canonical_id":"go:GO:0009515","description":"\"Appressed thylakoid membranes that are part of a granum (stacked regions). A characteristic of these appressed regions is the preferential localization of photosystem II.\" [GOC:lr]","metadata":null},{"id":"9e2ef867964344f49707c029040cceb4","type":"GO_TERM","name":"granaticin biosynthetic process","canonical_id":"go:GO:1901109","description":"\"The chemical reactions and pathways resulting in the formation of granaticin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00175]","metadata":null},{"id":"6a5a8871341c4a78b8db4db935516484","type":"GO_TERM","name":"granaticin catabolic process","canonical_id":"go:GO:1901108","description":"\"The chemical reactions and pathways resulting in the breakdown of granaticin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00175]","metadata":null},{"id":"bc19fb2a307c4d28ae46e00078883326","type":"DRUG","name":"granisetron","canonical_id":"gtopdb:2300","description":null,"metadata":null},{"id":"8d34a1f023d0467ab92a522902fd235b","type":"DRUG","name":"granisetron","canonical_id":"chembl:CHEMBL289469","description":null,"metadata":null},{"id":"b0f7f20bae494608aa1779cd51f58f62","type":"COMBINATION_TREATMENT","name":"granisetron + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-df0920fea983800f","description":null,"metadata":null},{"id":"65994a6f1bdf42c78825989caa7ac47b","type":"COMBINATION_TREATMENT","name":"granisetron + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-9d864943ba3a15e0","description":null,"metadata":null},{"id":"d91eaf66a6ba4aaeb55fade25c91ad53","type":"COMBINATION_TREATMENT","name":"granisetron + ondansetron + prochlorperazine","canonical_id":"ctgov_combo:ctgov-combo-7a7ee954b8486482","description":null,"metadata":null},{"id":"e4518de1638042ee81037039ed151a54","type":"COMBINATION_TREATMENT","name":"granisetron + palonosetron","canonical_id":"ctgov_combo:ctgov-combo-a7abd278f300f9d1","description":null,"metadata":null},{"id":"4d9358f854ec49f28632cb22d4f149ba","type":"COMBINATION_TREATMENT","name":"granisetron + palonosetron","canonical_id":"ctgov_combo:ctgov-combo-c0d8fcd0faa04fbe","description":null,"metadata":null},{"id":"2afc693ee1f74f01bd8979bc244c4b71","type":"COMBINATION_TREATMENT","name":"granisetron + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-4dab890503e15a39","description":null,"metadata":null},{"id":"d73f33b6d3ef4f08bd6e0935ba658c83","type":"COMBINATION_TREATMENT","name":"granisetron + tropisetron","canonical_id":"ctgov_combo:ctgov-combo-4a0e2b7eea0b4804","description":null,"metadata":null},{"id":"dfc878d2aa844c57981a82913d153390","type":"GO_TERM","name":"granular component","canonical_id":"go:GO:0001652","description":"\"A structure found in the nucleolus, which contains nearly completed preribosomal particles destined for the cytoplasm.\" [PMID:10754561]","metadata":null},{"id":"846740fba36f401296409b6e69353d9f","type":"GO_TERM","name":"granular vesicle","canonical_id":"go:GO:1990005","description":"\"A cytoplasmic membrane-bounded vesicle of varying size, but usually larger than 45 nm, with an electron dense granular core, found in noradrenergic and peptidergic cells.\" [NIF_Subcellular:sao478230652]","metadata":null},{"id":"3e86c4521b5143c3b1652300cc7af4bd","type":"GO_TERM","name":"granulocyte activation","canonical_id":"go:GO:0036230","description":"\"The change in morphology and behavior of a granulocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [CL:0000094, GOC:nhn]","metadata":null},{"id":"d496fc279aa248f2b4a42b6838c931a9","type":"GO_TERM","name":"granulocyte chemotaxis","canonical_id":"go:GO:0071621","description":"\"The movement of a granulocyte in response to an external stimulus.\" [GOC:rph]","metadata":null},{"id":"17636e1aecbc4c36bbbd629602dba051","type":"GO_TERM","name":"granulocyte colony-stimulating factor binding","canonical_id":"go:GO:0051916","description":"\"Binding to granulocyte colony-stimulating factor, G-CSF.\" [GOC:ai]","metadata":null},{"id":"a66ea2704c0a49a98cfb906644fb4264","type":"GO_TERM","name":"granulocyte colony-stimulating factor production","canonical_id":"go:GO:0071611","description":"\"The appearance of granulocyte colony-stimulating factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"4c7ed56b966942f1998a703d2fbf9477","type":"GO_TERM","name":"granulocyte colony-stimulating factor receptor activity","canonical_id":"go:GO:0004902","description":"\"Combining with granulocyte colony-stimulating factor (G-CSF) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"deb5f05a74744e59817c93d8e9bfbe47","type":"GO_TERM","name":"granulocyte colony-stimulating factor receptor binding","canonical_id":"go:GO:0005130","description":"\"Binding to a granulocyte colony-stimulating factor receptor.\" [GOC:ai]","metadata":null},{"id":"f57546a8fe8a46f2ac35c86372002799","type":"GO_TERM","name":"granulocyte colony-stimulating factor signaling pathway","canonical_id":"go:GO:0038158","description":"\"The series of molecular signals initiated by the binding of the cytokine granulocyte colony-stimulating factor (G-CSF) to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. G-CSF binds to the receptor (CSF3R).\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"0ee4f4081e9140f09f1d021c313a8cbe","type":"GO_TERM","name":"granulocyte differentiation","canonical_id":"go:GO:0030851","description":"\"The process in which a myeloid precursor cell acquires the specialized features of a granulocyte. Granulocytes are a class of leukocytes characterized by the presence of granules in their cytoplasm. These cells are active in allergic immune reactions such as arthritic inflammation and rashes. This class includes basophils, eosinophils and neutrophils.\" [GOC:ecd, http://life.nthu.edu.tw/~g864204/dict-search1.htm]","metadata":null},{"id":"c6ba54c414ae4fd8b5967fd5a5ddd9ef","type":"GO_TERM","name":"granulocyte macrophage colony-stimulating factor complex binding","canonical_id":"go:GO:0042021","description":"\"Binding to a granulocyte macrophage colony-stimulating factor complex.\" [GOC:ai]","metadata":null},{"id":"17b2fde048294428bfd7b5db090bfb49","type":"GO_TERM","name":"granulocyte macrophage colony-stimulating factor production","canonical_id":"go:GO:0032604","description":"\"The appearance of granulocyte macrophage colony-stimulating factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"89ae6e82ca8b455cadc8b0e83799b33d","type":"GO_TERM","name":"granulocyte macrophage colony-stimulating factor receptor activity","canonical_id":"go:GO:0004901","description":"\"Combining with granulocyte macrophage colony-stimulating factor (GM-CSF) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"3c9b1de10cfe40d496167922854d1879","type":"GO_TERM","name":"granulocyte macrophage colony-stimulating factor receptor binding","canonical_id":"go:GO:0005129","description":"\"Binding to a granulocyte macrophage colony-stimulating factor receptor.\" [GOC:ai]","metadata":null},{"id":"52a8bae9663346f1aa278d0327a94145","type":"GO_TERM","name":"granulocyte macrophage colony-stimulating factor receptor complex","canonical_id":"go:GO:0030526","description":"\"The heterodimeric receptor for granulocyte macrophage colony-stimulating factor.\" [GOC:mah]","metadata":null},{"id":"6bd0029e186b42b9b9dacddea897ca88","type":"GO_TERM","name":"granulocyte migration","canonical_id":"go:GO:0097530","description":"\"The movement of a granulocyte within or between different tissues and organs of the body.\" [GOC:cvs, PMID:24163421, PMID:24193336]","metadata":null},{"id":"d9d58d640cfb44cf83d1d58155f5e880","type":"GO_TERM","name":"granulocyte-macrophage colony-stimulating factor signaling pathway","canonical_id":"go:GO:0038157","description":"\"The series of molecular signals initiated by the binding of the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF) to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. GM-CSF binds to a heterodimer receptor (CSF2R) consisting of an alpha ligand-binding subunit, and a common beta subunit that is shared with other cytokine receptors.\" [GOC:nhn, GOC:signaling, PMID:17027509]","metadata":null},{"id":"b2fc790fdba54791ac7fc7f954ca36bc","type":"GO_TERM","name":"granuloma formation","canonical_id":"go:GO:0002432","description":"\"The formation of nodular inflammatory lesions, usually small or granular, firm, persistent, well-structured, and containing compactly grouped T lymphocytes and modified phagocytes such as epithelioid cells, giant cells, and other macrophages. Granuloma formation represents a chronic inflammatory response initiated by various infectious and noninfectious agents. The center of a granuloma consists of fused macrophages, which can become necrotic.\" [GO_REF:0000022, GOC:add, ISBN:068340007X, ISBN:0721601464, ISBN:081533642X]","metadata":null},{"id":"a0cba80e3a404a85a0fac3012c32b9e0","type":"DISEASE","name":"granulomatosis with polyangiitis","canonical_id":"mondo:0012105","description":null,"metadata":null},{"id":"58950e46297247b78b061528c86421d0","type":"GO_TERM","name":"granulosa cell apoptotic process","canonical_id":"go:GO:1904700","description":"\"Any apoptotic process in a granulosa cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:19208546]","metadata":null},{"id":"e5e899f18d87477887d3b2707259fe63","type":"GO_TERM","name":"granulosa cell development","canonical_id":"go:GO:0060016","description":"\"The process whose specific outcome is the progression of a granulosa cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a granulosa cell fate.\" [GOC:dph]","metadata":null},{"id":"0175a82c3f2843cdaae18b74a5130f1b","type":"GO_TERM","name":"granulosa cell differentiation","canonical_id":"go:GO:0060014","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a granulosa cell, a supporting cell for the developing female gamete in the ovary of mammals.\" [GOC:dph]","metadata":null},{"id":"087ff39b4579493eb0472130ab1a67dc","type":"GO_TERM","name":"granulosa cell fate commitment","canonical_id":"go:GO:0060015","description":"\"The cell fate commitment of precursor cells that will become granulosa cells.\" [GOC:dph]","metadata":null},{"id":"f85b5edb12174f6596565c11a8543aba","type":"GO_TERM","name":"granulosa cell proliferation","canonical_id":"go:GO:1990739","description":"\"The multiplication or reproduction of granulosa cells, resulting in the expansion of the granulosa cells population. A granulosa cell is a supporting cell for the developing female gamete in the ovary of mammals. They develop from the coelomic epithelial cells of the gonadal ridge.\" [PMID:22383759]","metadata":null},{"id":"239b4979681f4dacb2fcf075410a712d","type":"GO_TERM","name":"granulysin production","canonical_id":"go:GO:0036262","description":"\"The appearance of granulysin due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"16ab0b0c427c46f28e17937f54024650","type":"GO_TERM","name":"granum","canonical_id":"go:GO:0009542","description":"\"Distinct stack of lamellae seen within chloroplasts. Grana contain the pigments, electron transfer compounds, and enzymes essential to the light-dependent reactions of photosynthesis.\" [ISBN:0140514031]","metadata":null},{"id":"7b7d71fa615c4576b9050a455253559a","type":"GO_TERM","name":"granum assembly","canonical_id":"go:GO:0090391","description":"\"A process that is carried out at the cellular level which results in the assembly of a granum. A granum is a distinct stack of lamellae seen within chloroplasts.\" [GOC:tb]","metadata":null},{"id":"f8136485cd1c41f091b833b2365f8999","type":"GO_TERM","name":"granzyme A production","canonical_id":"go:GO:0035746","description":"\"The appearance of granzyme A due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"e31f583d9bd8497cad8a0e68547de432","type":"GO_TERM","name":"granzyme B localization to T cell secretory granule","canonical_id":"go:GO:0033380","description":"\"Any process in which the protease granzyme B is transported to, or maintained in, a location within a secretory granule in a T cell.\" [GOC:mah]","metadata":null},{"id":"a7c9e505730b42f0a219bb25a87f41df","type":"GO_TERM","name":"granzyme B production","canonical_id":"go:GO:0071613","description":"\"The appearance of granzyme B due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"6e9546f5686d47d78031eeff30ab0fe7","type":"GO_TERM","name":"granzyme-mediated apoptotic signaling pathway","canonical_id":"go:GO:0008626","description":"\"The series of molecular signals induced by granzymes which triggers the apoptotic death of a cell. The pathway starts with reception of a granzyme signal, and ends when the execution phase of apoptosis is triggered. Granzymes are serine proteases that are secreted by cytotoxic T cells and natural killer cells to induce apoptosis in target cells.\" [GOC:mtg_apoptosis, PMID:17158907]","metadata":null},{"id":"28c15d354790487b831735c4dbb7e358","type":"GO_TERM","name":"granzyme-mediated programmed cell death signaling pathway","canonical_id":"go:GO:0140507","description":"\"The series of molecular signals induced by granzymes which triggers the cell death of a cell. The pathway starts with reception of a granzyme signal, and ends when the execution phase of cell death is triggered. Granzymes are serine proteases that are secreted by cytotoxic T cells and natural killer cells to induce cell death in target cells.\" [PMID:32299851]","metadata":null},{"id":"ccf8f218862f44768ddee3875a67970f","type":"GO_TERM","name":"gravitaxis","canonical_id":"go:GO:0042332","description":"\"The directed movement of a motile cell or organism in response to gravity.\" [GOC:jid, GOC:jl]","metadata":null},{"id":"f9fb090884e64740aadf39bdb7df0406","type":"GO_TERM","name":"gravitropism","canonical_id":"go:GO:0009630","description":"\"The orientation of plant parts under the stimulation of gravity.\" [ISBN:0198547684]","metadata":null},{"id":"6598a8ea7dc54db18261083d9bcefdaa","type":"DRUG","name":"grazoprevir","canonical_id":"mesh:C578009","description":null,"metadata":null},{"id":"a947717e062042caa577f8d94bde6b27","type":"GO_TERM","name":"green leaf volatile biosynthetic process","canonical_id":"go:GO:0010597","description":"\"The chemical reactions and pathways resulting in the formation of volatile molecules emitted from green plants, such as hexenal, hexenol and hexenyl acetate, from linoleic acid or linolenic acid.\" [PMID:17163881]","metadata":null},{"id":"60bf7c8532a249e58c169c7e12cb0052","type":"GO_TERM","name":"griseofulvin biosynthetic process","canonical_id":"go:GO:0140878","description":"\"The chemical reactions and pathways resulting in the formation of griseofulvin, an important antifungal drug that has been in use for a long time for treating dermatophyte infections.\" [PMID:20534346, PMID:23978092]","metadata":null},{"id":"50f2eaf4bfc2423ea77ccd6e476f6efd","type":"GO_TERM","name":"grooming behavior","canonical_id":"go:GO:0007625","description":"\"The specific behavior of an organism relating to grooming, cleaning and brushing to remove dirt and parasites.\" [GOC:jl, GOC:pr]","metadata":null},{"id":"47c8750e535743cf819c414f3b4a7d61","type":"GO_TERM","name":"ground meristem histogenesis","canonical_id":"go:GO:0010066","description":"\"The formation of the primary meristem or meristematic tissue that gives rise to the ground tissues.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"128126da40554a62bfc9835ce6aec8a0","type":"GO_TERM","name":"ground tissue pattern formation","canonical_id":"go:GO:1990064","description":"\"The regionalization process that gives rise to the patterning of the ground tissue.\" [PMID:23444357]","metadata":null},{"id":"fcb6826a685841449a1babef21d685c2","type":"GO_TERM","name":"group A colicin transmembrane transporter activity","canonical_id":"go:GO:0042913","description":"\"Enables the transfer of group A colicins (colicins E1, E2, E3, A, K, and N) from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729, PMID:9171417]","metadata":null},{"id":"dac72f909b1549d7b0120694e1021305","type":"GO_TERM","name":"group A colicin transport","canonical_id":"go:GO:0042915","description":"\"The directed movement of group A colicins (colicins E1, E2, E3, A, K, and N) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:9171417]","metadata":null},{"id":"4ee2014c7b124a928e87f11fad07328c","type":"GO_TERM","name":"group II metabotropic glutamate receptor activity","canonical_id":"go:GO:0001641","description":"\"A G protein-coupled receptor that is activated by trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) and inhibits adenylate cyclase activity.\" [GOC:dph]","metadata":null},{"id":"df51e71e4e984c9b82aa506f1c0a6282","type":"GO_TERM","name":"group III metabotropic glutamate receptor activity","canonical_id":"go:GO:0001642","description":"\"A G protein-coupled receptor that is activated by L-AP-4 and inhibits adenylate cyclase activity.\" [PMID:9016303]","metadata":null},{"id":"616b4b9a105d4b17bc7a53034d312587","type":"GO_TERM","name":"growing cell tip","canonical_id":"go:GO:0035838","description":"\"The region at either end of the longest axis of a cylindrical or elongated cell, where polarized growth occurs.\" [GOC:mah]","metadata":null},{"id":"1a3554ad48ae4fdfb5c263eb70486fc9","type":"GO_TERM","name":"growth","canonical_id":"go:GO:0040007","description":"\"The increase in size or mass of an entire organism, a part of an organism or a cell.\" [GOC:bf, GOC:ma]","metadata":null},{"id":"2fabf04c70694daa81864b65619a8cb7","type":"DISEASE","name":"growth","canonical_id":"go:0040007","description":null,"metadata":null},{"id":"f2445ab77dca4736bbc8bbf6fbceefc7","type":"GO_TERM","name":"growth cone","canonical_id":"go:GO:0030426","description":"\"The migrating motile tip of a growing neuron projection, where actin accumulates, and the actin cytoskeleton is the most dynamic.\" [GOC:aruk, GOC:bc, ISBN:0815316194, PMID:10082468]","metadata":null},{"id":"ae36468dbdf5479c849c7301c9c4fdc8","type":"GO_TERM","name":"growth cone filopodium","canonical_id":"go:GO:1990812","description":"\"A thin, stiff protrusion extended by the leading edge of an axonal or dendritic growth cone.\" [PMID:25598228]","metadata":null},{"id":"64f9c837f34f42f7841d29bf2140e960","type":"GO_TERM","name":"growth cone lamellipodium","canonical_id":"go:GO:1990761","description":"\"A thin sheetlike process extended by the leading edge of an axonal or dendritic growth cone; contains a dense meshwork of actin filaments.\" [GOC:dos, PMID:25598228]","metadata":null},{"id":"2f6f4e03d7cd464a9fa48722cbc8728a","type":"GO_TERM","name":"growth cone leading edge","canonical_id":"go:GO:0061850","description":"\"That part of the growth cone which represents the distal part of the structure.\" [PMID:10797548]","metadata":null},{"id":"3addd9a3e7cc414abeb8b3cb315ffc90","type":"GO_TERM","name":"growth cone membrane","canonical_id":"go:GO:0032584","description":"\"The portion of the plasma membrane surrounding a growth cone.\" [GOC:mah]","metadata":null},{"id":"1a1704c7ad2342aba39297fa53672d5e","type":"DISEASE","name":"growth delay due to insulin-like growth factor I resistance","canonical_id":"mondo:0010038","description":null,"metadata":null},{"id":"75b7d7127f964eeda208c492620228ee","type":"GO_TERM","name":"growth factor activity","canonical_id":"go:GO:0008083","description":"\"The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.\" [ISBN:0815316194]","metadata":null},{"id":"b7ea134dc42f4ad2b277faf2e00cc6f8","type":"GO_TERM","name":"growth factor binding","canonical_id":"go:GO:0019838","description":"\"Binding to a growth factor, proteins or polypeptides that stimulate a cell or organism to grow or proliferate.\" [GOC:curators]","metadata":null},{"id":"b720496e702241a7a10bd2473462cbe0","type":"GO_TERM","name":"growth factor complex","canonical_id":"go:GO:0036454","description":"\"A protein complex that has growth factor activity.\" [GOC:bhm]","metadata":null},{"id":"1e08d88ace1d415fba00a88b1501dcad","type":"GO_TERM","name":"growth factor dependent regulation of skeletal muscle satellite cell proliferation","canonical_id":"go:GO:0014843","description":"\"Any process that modulates the frequency, rate or extent of satellite cell proliferation; dependent on specific growth factor activity such as fibroblast growth factors and transforming growth factor beta.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"ead3116570ab4e288e21f6f633accb41","type":"GO_TERM","name":"growth factor receptor binding","canonical_id":"go:GO:0070851","description":"\"Binding to a growth factor receptor.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"f1966bd6e7644660a04d0d3f30bd4f16","type":"DRUG","name":"growth hormone 1","canonical_id":"gtopdb:4943","description":null,"metadata":null},{"id":"5f8b6b7f87304895b8b8708b94c93a65","type":"GO_TERM","name":"growth hormone activity","canonical_id":"go:GO:0070186","description":"\"The action characteristic of growth hormone, a peptide hormone that is secreted by the anterior pituitary or the placenta into the circulation, and binds to membrane receptors in target tissues to stimulate body growth.\" [GOC:BHF, GOC:mah, PMID:11445442]","metadata":null},{"id":"aeb83b9da1eb4b818d9e9b4556a120b7","type":"DISEASE","name":"growth hormone insensitivity syndrome","canonical_id":"mondo:0015892","description":null,"metadata":null},{"id":"dea47e4eb8804704bddbdd2c12ba3426","type":"GO_TERM","name":"growth hormone receptor activity","canonical_id":"go:GO:0004903","description":"\"Combining with a growth hormone and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:ai, GOC:signaling]","metadata":null},{"id":"8544862c433947cfb316c47536884a52","type":"GO_TERM","name":"growth hormone receptor binding","canonical_id":"go:GO:0005131","description":"\"Binding to a growth hormone receptor.\" [GOC:ai]","metadata":null},{"id":"c72ac4b22d3c4267a1562bd62ee20703","type":"GO_TERM","name":"growth hormone receptor complex","canonical_id":"go:GO:0070195","description":"\"A receptor complex that consists of two identical subunits and binds growth hormone.\" [GOC:BHF, GOC:mah, GOC:vk, PMID:11445442]","metadata":null},{"id":"4935cc042eca4594bed9d48f0630ac1b","type":"GO_TERM","name":"growth hormone receptor signaling pathway","canonical_id":"go:GO:0060396","description":"\"The series of molecular signals generated as a consequence of growth hormone receptor binding to its physiological ligand.\" [GOC:BHF, GOC:dph, PMID:11445442]","metadata":null},{"id":"4958ee2bca1b45f38535a3bb92b87403","type":"GO_TERM","name":"growth hormone receptor signaling pathway via JAK-STAT","canonical_id":"go:GO:0060397","description":"\"The process in which STAT proteins (Signal Transducers and Activators of Transcription) are activated by members of the JAK (janus activated kinase) family of tyrosine kinases, following the binding of physiological ligands to the growth hormone receptor. Once activated, STATs dimerize and translocate to the nucleus and modulate the expression of target genes.\" [GOC:BHF, GOC:dph, PMID:11445442]","metadata":null},{"id":"cd11c5b22c8242f4adb7935c7d0a79db","type":"GO_TERM","name":"growth hormone secretagogue receptor activity","canonical_id":"go:GO:0001616","description":"\"Combining with ghrelin to initiate a change in cell activity.\" [GOC:mah, PMID:17983853]","metadata":null},{"id":"37a000168b904ed1b0d5aa39088dfe06","type":"GO_TERM","name":"growth hormone secretion","canonical_id":"go:GO:0030252","description":"\"The regulated release of growth hormone from secretory granules into the blood.\" [GOC:mah]","metadata":null},{"id":"1dbed9cecec14e8a8ea73b4e33acb668","type":"GO_TERM","name":"growth hormone-releasing hormone activity","canonical_id":"go:GO:0016608","description":"\"The action characteristic of growth hormone-releasing hormone, any of a family of peptide hormones that act on the anterior pituitary to stimulate the secretion of growth hormone and exert a trophic effect on the gland.\" [ISBN:0198506732]","metadata":null},{"id":"d9b05be549c04a6392a3b1f7697918bc","type":"GO_TERM","name":"growth hormone-releasing hormone receptor activity","canonical_id":"go:GO:0016520","description":"\"Combining with growth hormone-releasing hormone to initiate a change in cell activity.\" [PMID:12529933]","metadata":null},{"id":"6892aa6290c44fffb76afd2837f3adb9","type":"GO_TERM","name":"growth hormone-releasing hormone receptor binding","canonical_id":"go:GO:0031770","description":"\"Binding to a growth hormone-releasing hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e87a8f21462c4fff8e0bb23a30b371e4","type":"GO_TERM","name":"growth involved in heart morphogenesis","canonical_id":"go:GO:0003241","description":"\"Developmental growth that contributes to the shaping of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"0a5f12fada4648e0a83db1cbdeeb245b","type":"GO_TERM","name":"growth of a germarium-derived egg chamber","canonical_id":"go:GO:0007295","description":"\"Growth of the egg chamber between the time it leaves the germarium and the onset of vitellogenesis. During this time both nurse cells and the oocyte undergo developmental changes including nuclear organization and cytoplasmic growth. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"03ba4a7855f345ddbf7454a37c868603","type":"GO_TERM","name":"growth of unicellular organism as a thread of attached cells","canonical_id":"go:GO:0070783","description":"\"A filamentous growth process in which cells remain attached after division and form thread-like filaments that may penetrate into a solid growth medium such as an agar plate, exhibited by unicellular fungi under certain growth conditions.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"ca0f152ff24f4abca1e58d20675d6cdc","type":"GO_TERM","name":"growth plate cartilage axis specification","canonical_id":"go:GO:0003421","description":"\"The establishment, maintenance and elaboration of the columnar cartilage along the axis of a long bone that contributes to bone growth.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1ece58e12734403590cac54ebbaeb7fa","type":"GO_TERM","name":"growth plate cartilage chondrocyte development","canonical_id":"go:GO:0003431","description":"\"The progression of a growth plate cartilage chondrocyte over time from after its fate commitment to the mature cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"346de90081024d26911d43328e21f9a5","type":"GO_TERM","name":"growth plate cartilage chondrocyte differentiation","canonical_id":"go:GO:0003418","description":"\"The process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte that will contribute to the growth of a bone. A chondrocyte is a polymorphic cell that forms cartilage.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d17eb48d0da74271b3d2397a9a9e1c24","type":"GO_TERM","name":"growth plate cartilage chondrocyte division","canonical_id":"go:GO:0003423","description":"\"The process resulting in the oriented physical partitioning and separation of a chondrocytes in the growth plate.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"c7c36d4b089442f09ee9eaf675ccb07c","type":"GO_TERM","name":"growth plate cartilage chondrocyte growth","canonical_id":"go:GO:0003430","description":"\"The growth of a growth plate cartilage chondrocyte, where growth contributes to the progression of the chondrocyte over time from one condition to another.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0eadcc4a3e414dc99bb00cc94d4f8da9","type":"GO_TERM","name":"growth plate cartilage chondrocyte morphogenesis","canonical_id":"go:GO:0003429","description":"\"The process in which the structures of a chondrocyte in the growth plate cartilage are generated and organized.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0fded33db535478dbc4e56398506a2f6","type":"GO_TERM","name":"growth plate cartilage chondrocyte proliferation","canonical_id":"go:GO:0003419","description":"\"The multiplication or reproduction of chondrocytes in a growing endochondral bone, resulting in the expansion of a cell population.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"8ff20c3f25fc4bcebf4fe1eba8488df4","type":"GO_TERM","name":"growth plate cartilage development","canonical_id":"go:GO:0003417","description":"\"The process whose specific outcome is the progression of the cartilage that will provide a scaffold for mineralization of endochondral bones as they elongate or grow.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"46797630103740abaea3d0b45f55eaf2","type":"GO_TERM","name":"growth plate cartilage morphogenesis","canonical_id":"go:GO:0003422","description":"\"The process in which the anatomical structures of growth plate cartilage are generated and organized.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"4f12cae7fd374579b93b1f5a7f2efb45","type":"DRUG","name":"guaiacol","canonical_id":"mesh:D006139","description":null,"metadata":null},{"id":"fb4ee04bae834bbf8c0cda454ea35dc6","type":"GO_TERM","name":"guaiacyl lignin biosynthetic process","canonical_id":"go:GO:1901063","description":"\"The chemical reactions and pathways resulting in the formation of guaiacyl lignin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4343826ebf2c41fe840b8cf1d79cd513","type":"GO_TERM","name":"guaiacyl lignin catabolic process","canonical_id":"go:GO:1901062","description":"\"The chemical reactions and pathways resulting in the breakdown of guaiacyl lignin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"64993b39366c480083d104d6c06cad61","type":"DRUG","name":"guanabenz","canonical_id":"gtopdb:5443","description":null,"metadata":null},{"id":"bbd598e3022e448fb27630ab0aa6f468","type":"DRUG","name":"guanfacine","canonical_id":"gtopdb:522","description":null,"metadata":null},{"id":"06b140f1964b4a3293b03802a82ce832","type":"COMBINATION_TREATMENT","name":"guanfacine + sertraline","canonical_id":"ctgov_combo:ctgov-combo-48eb526b756a29c8","description":null,"metadata":null},{"id":"f2b98fc374f54eea84728821fdb3c7d6","type":"DRUG","name":"guanidine","canonical_id":"mesh:D019791","description":null,"metadata":null},{"id":"1f63a087a0e54f96bfb23528b055138c","type":"GO_TERM","name":"guanidinoacetase activity","canonical_id":"go:GO:0047970","description":"\"Catalysis of the reaction: guanidinoacetate + H2O = glycine + urea.\" [EC:3.5.3.2, RHEA:23268]","metadata":null},{"id":"25df2bfee3044a718c052d163f2f7dbf","type":"GO_TERM","name":"guanidinoacetate N-methyltransferase activity","canonical_id":"go:GO:0030731","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanidinoacetate = S-adenosyl-L-homocysteine + creatine + H+.\" [EC:2.1.1.2, RHEA:10656]","metadata":null},{"id":"b6ec3e578f044ce398110163eb052af7","type":"GO_TERM","name":"guanidinoacetate kinase activity","canonical_id":"go:GO:0047973","description":"\"Catalysis of the reaction: ATP + guanidinoacetate = ADP + 2 H+ + phosphoguanidinoacetate.\" [EC:2.7.3.1, RHEA:14145]","metadata":null},{"id":"236c8eb915d2453495879e1e420c8e3a","type":"GO_TERM","name":"guanidinobutyrase activity","canonical_id":"go:GO:0047971","description":"\"Catalysis of the reaction: 4-guanidinobutanoate + H2O = 4-aminobutanoate + urea.\" [EC:3.5.3.7, RHEA:19501]","metadata":null},{"id":"d9c57455e53247b0960fe887844451a4","type":"GO_TERM","name":"guanidinodeoxy-scyllo-inositol-4-phosphatase activity","canonical_id":"go:GO:0047383","description":"\"Catalysis of the reaction: 1-guanidino-1-deoxy-scyllo-inositol 4-phosphate + H2O = 1-guanidino-1-deoxy-scyllo-inositol + phosphate.\" [EC:3.1.3.40, RHEA:15777]","metadata":null},{"id":"3ae9e4d4131e4d2dab836939d76f0854","type":"GO_TERM","name":"guanidinopropionase activity","canonical_id":"go:GO:0047972","description":"\"Catalysis of the reaction: 3-guanidinopropanoate + H2O = beta-alanine + urea.\" [EC:3.5.3.17, RHEA:16029]","metadata":null},{"id":"a17dd6f087e943908cbe19d9c46034ca","type":"GO_TERM","name":"guanine binding","canonical_id":"go:GO:0002057","description":"\"Binding to guanine.\" [GOC:hjd]","metadata":null},{"id":"cc742a1fb64c442aba9352c8bbc00241","type":"GO_TERM","name":"guanine biosynthetic process","canonical_id":"go:GO:0046099","description":"\"The chemical reactions and pathways resulting in the formation of guanine, 2-amino-6-hydroxypurine, a purine that is one of the five main bases found in nucleic acids and a component of a number of phosphorylated guanosine derivatives whose metabolic or regulatory functions are important.\" [GOC:curators]","metadata":null},{"id":"6c2528ae04654111983d5aeb76ecafe6","type":"GO_TERM","name":"guanine catabolic process","canonical_id":"go:GO:0006147","description":"\"The chemical reactions and pathways resulting in the breakdown of guanine, 2-amino-6-hydroxypurine, a purine that is one of the five main bases found in nucleic acids and a component of a number of phosphorylated guanosine derivatives whose metabolic or regulatory functions are important.\" [GOC:curators]","metadata":null},{"id":"29dd9236375b4fea83a28334cac40ba6","type":"GO_TERM","name":"guanine deaminase activity","canonical_id":"go:GO:0008892","description":"\"Catalysis of the reaction: guanine + H2O + H+ = xanthine + NH4+.\" [RHEA:14665]","metadata":null},{"id":"173c364915124c588df6f534fa1b96c4","type":"GO_TERM","name":"guanine deglycation","canonical_id":"go:GO:0106044","description":"\"The removal of a sugar or dicarbonyl from a glycated guanine.\" [PMID:28596309]","metadata":null},{"id":"997c157c1796455b99b0d1913de4b29d","type":"GO_TERM","name":"guanine deglycation, glyoxal removal","canonical_id":"go:GO:0106046","description":"\"The removal of glyoxal from a glycated guanine, to form glycolate and a deglycated guanine.\" [PMID:28596309]","metadata":null},{"id":"0d3ea15c0b19461f90e720aae90284ca","type":"GO_TERM","name":"guanine import across plasma membrane","canonical_id":"go:GO:0098710","description":"\"The directed movement of guanine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"a7d74e2997604d6883ffb2642809f1d5","type":"GO_TERM","name":"guanine metabolic process","canonical_id":"go:GO:0046098","description":"\"The chemical reactions and pathways involving guanine, 2-amino-6-hydroxypurine, a purine that is one of the five main bases found in nucleic acids and a component of a number of phosphorylated guanosine derivatives whose metabolic or regulatory functions are important.\" [GOC:curators]","metadata":null},{"id":"348e666f1fd54efab49c0c25e676a86e","type":"GO_TERM","name":"guanine nucleotide transmembrane transport","canonical_id":"go:GO:1903790","description":"\"The process in which a guanyl nucleotide is transported across a membrane.\" [GO_REF:0000069, GOC:dph, GOC:TermGenie, GOC:vw, PMID:25320081]","metadata":null},{"id":"0a2faf61c6224d458b5dec85c3cd67bc","type":"GO_TERM","name":"guanine nucleotide transmembrane transporter activity","canonical_id":"go:GO:0001409","description":"\"Enables the transfer of guanine nucleotides (GMP, GDP, and GTP) from one side of a membrane to the other.\" [GOC:mcc]","metadata":null},{"id":"0b89167db125420eb221bb0824516a40","type":"GO_TERM","name":"guanine nucleotide transport","canonical_id":"go:GO:0001408","description":"\"The directed movement of guanine nucleotides, GTP, GDP, and/or GMP, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mcc]","metadata":null},{"id":"a7c80452b9234373b7954c618aca1bbd","type":"GO_TERM","name":"guanine phosphoribosyltransferase activity","canonical_id":"go:GO:0052657","description":"\"Catalysis of the reaction: GMP + diphosphate = guanine + 5-phospho-alpha-D-ribose 1-diphosphate.\" [RHEA:25424]","metadata":null},{"id":"6d8b925a7c394a1f956496350bf9e776","type":"GO_TERM","name":"guanine salvage","canonical_id":"go:GO:0006178","description":"\"Any process that generates guanine, 2-amino-6-hydroxypurine, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"7283e70c37404221af9d7d8ec890ea46","type":"GO_TERM","name":"guanine transmembrane transport","canonical_id":"go:GO:1903716","description":"\"The process in which guanine is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:14998997]","metadata":null},{"id":"d9691b6e8d7c4be3a633544358c3618b","type":"GO_TERM","name":"guanine transmembrane transporter activity","canonical_id":"go:GO:0015208","description":"\"Enables the transfer of guanine, 2-amino-6-hydroxypurine, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"09cd177501a2486eb1a68e415cd21118","type":"GO_TERM","name":"guanine transport","canonical_id":"go:GO:0015854","description":"\"The directed movement of guanine, 2-amino-6-hydroxypurine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"34b09571f12e434095ccdaad8ee574fd","type":"GO_TERM","name":"guanine/guanine mispair binding","canonical_id":"go:GO:0035489","description":"\"Binding to a double-stranded DNA region containing a G/G mispair.\" [GOC:bf, GOC:jh]","metadata":null},{"id":"a4fa00a0096944ada13a1c3129596ab2","type":"GO_TERM","name":"guanine/thymine mispair binding","canonical_id":"go:GO:0032137","description":"\"Binding to a double-stranded DNA region containing a G/T mispair.\" [GOC:vk]","metadata":null},{"id":"bce1f1d1260b42879095a6a091b79eda","type":"GO_TERM","name":"guanosine binding","canonical_id":"go:GO:1905108","description":"\"Binding to guanosine.\" [GO_REF:0000067, GOC:TermGenie, PMID:26007660]","metadata":null},{"id":"106afec7ada94ab0b215567e656b156d","type":"GO_TERM","name":"guanosine biosynthetic process","canonical_id":"go:GO:0046114","description":"\"The chemical reactions and pathways resulting in the formation of guanine, guanine riboside, a nucleoside with a wide species distribution.\" [GOC:curators]","metadata":null},{"id":"44398409b8df4f45a4dea135feb2cf5c","type":"GO_TERM","name":"guanosine catabolic process","canonical_id":"go:GO:0046115","description":"\"The chemical reactions and pathways resulting in the breakdown of guanine, guanine riboside, a nucleoside with a wide species distribution.\" [GOC:curators]","metadata":null},{"id":"9acca69f8afd4dceb125163bca71dfd6","type":"GO_TERM","name":"guanosine deaminase activity","canonical_id":"go:GO:0047974","description":"\"Catalysis of the reaction: guanosine + H2O + H+ = xanthosine + NH4+.\" [RHEA:12861]","metadata":null},{"id":"3aea84df74a545c5862a462399eb00b4","type":"GO_TERM","name":"guanosine kinase activity","canonical_id":"go:GO:0106366","description":"\"Catalysis of the reaction: ATP + guanosine = ADP + GMP.\" [PMID:10879466, PMID:7665468, RHEA:27710]","metadata":null},{"id":"11ca4024816944a1b079b7e05fbf6d02","type":"GO_TERM","name":"guanosine metabolic process","canonical_id":"go:GO:0008617","description":"\"The chemical reactions and pathways involving guanine, guanine riboside, a nucleoside with a wide species distribution.\" [ISBN:0198506732]","metadata":null},{"id":"99fac67aaa234a44b2ed8bff1598c393","type":"GO_TERM","name":"guanosine pentaphosphate biosynthetic process","canonical_id":"go:GO:0015973","description":"\"The chemical reactions and pathways resulting in the formation of guanine pentaphosphate (5'-pppGpp-3'), a derivative of guanine riboside with five phosphates.\" [GOC:ai]","metadata":null},{"id":"509772fa21b940989d1a03ab063e5ba8","type":"GO_TERM","name":"guanosine pentaphosphate catabolic process","canonical_id":"go:GO:0015974","description":"\"The chemical reactions and pathways resulting in the breakdown of guanine pentaphosphate (5'-pppGpp-3'), a derivative of guanine riboside with five phosphates.\" [GOC:ai]","metadata":null},{"id":"22620da6db8e4757aa38e7635f4fa06a","type":"GO_TERM","name":"guanosine pentaphosphate metabolic process","canonical_id":"go:GO:0015972","description":"\"The chemical reactions and pathways involving guanine pentaphosphate (5'-pppGpp-3'), a derivative of guanine riboside with five phosphates.\" [GOC:ai]","metadata":null},{"id":"457ce664d0f4403195e0851a3c073910","type":"GO_TERM","name":"guanosine phosphorylase activity","canonical_id":"go:GO:0047975","description":"\"Catalysis of the reaction: guanosine + phosphate = alpha-D-ribose 1-phosphate + guanine.\" [RHEA:13233]","metadata":null},{"id":"e6e0b209c83b415e9cba4475d3484a5d","type":"GO_TERM","name":"guanosine salvage","canonical_id":"go:GO:0006179","description":"\"Any process that generates guanosine, guanine riboside, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"3ca5fd838fc546589491f25b1df13c27","type":"GO_TERM","name":"guanosine tetraphosphate binding","canonical_id":"go:GO:0097216","description":"\"Binding to guanosine tetraphosphate (5'-ppGpp-3'), a guanosine bisphosphate having diphosphate groups at both the 3' and 5'-positions.\" [GOC:imk, PMID:15109491, PMID:16968770, PMID:18359660]","metadata":null},{"id":"0725aa58eeb14c45a02d2a4c18430b14","type":"GO_TERM","name":"guanosine tetraphosphate biosynthetic process","canonical_id":"go:GO:0015970","description":"\"The chemical reactions and pathways resulting in the formation of guanine tetraphosphate (5'-ppGpp-3'), a derivative of guanine riboside with four phosphates.\" [GOC:ai]","metadata":null},{"id":"7cbf028bacd048d989b19071eca1b9e1","type":"GO_TERM","name":"guanosine tetraphosphate catabolic process","canonical_id":"go:GO:0015971","description":"\"The chemical reactions and pathways resulting in the breakdown of guanine tetraphosphate (5'-ppGpp-3'), a derivative of guanine riboside with four phosphates.\" [GOC:ai]","metadata":null},{"id":"b894beece7604fa6b62e5fb4135d35dc","type":"GO_TERM","name":"guanosine tetraphosphate metabolic process","canonical_id":"go:GO:0015969","description":"\"The chemical reactions and pathways involving guanine tetraphosphate (5'-ppGpp-3'), a derivative of guanine riboside with four phosphates.\" [GOC:ai]","metadata":null},{"id":"b55ef35448ee4d83a2b22193da9bf8dd","type":"GO_TERM","name":"guanosine-3',5'-bis(diphosphate) 3'-diphosphatase activity","canonical_id":"go:GO:0008893","description":"\"Catalysis of the reaction: guanosine 3',5'-bis(diphosphate) + H2O = diphosphate + GDP + H+.\" [RHEA:14253]","metadata":null},{"id":"6118b0c668694a2e843135a59f902713","type":"GO_TERM","name":"guanosine-5'-triphosphate,3'-diphosphate diphosphatase activity","canonical_id":"go:GO:0008894","description":"\"Catalysis of the reaction: guanosine 5'-triphosphate,3'-diphosphate + H2O = guanosine 5'-diphosphate,3'-diphosphate + phosphate.\" [EC:3.6.1.40]","metadata":null},{"id":"e1ab7f7d15e743ab8581aaeeced86398","type":"GO_TERM","name":"guanosine-containing compound biosynthetic process","canonical_id":"go:GO:1901070","description":"\"The chemical reactions and pathways resulting in the formation of guanosine-containing compounds (guanosines).\" [GOC:TermGenie]","metadata":null},{"id":"7681621fa2ac4519b859a6f7bbc23118","type":"GO_TERM","name":"guanosine-containing compound catabolic process","canonical_id":"go:GO:1901069","description":"\"The chemical reactions and pathways resulting in the breakdown of guanosine-containing compounds (guanosines).\" [GOC:TermGenie]","metadata":null},{"id":"4a2a339af92a48eb9f8c2ef985b82e07","type":"GO_TERM","name":"guanyl deoxyribonucleotide binding","canonical_id":"go:GO:0032560","description":"\"Binding to a guanyl deoxyribonucleotide, any compound consisting of guanosine esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety.\" [GOC:mah]","metadata":null},{"id":"87848090f1114636b75ee3ffd0519d4a","type":"GO_TERM","name":"guanyl nucleotide binding","canonical_id":"go:GO:0019001","description":"\"Binding to a guanyl nucleotide, consisting of guanosine esterified with (ortho)phosphate.\" [ISBN:0198506732]","metadata":null},{"id":"ee1eb8a7e6704b4a809969ac769e95d8","type":"GO_TERM","name":"guanyl nucleotide exchange factor activator activity","canonical_id":"go:GO:0160124","description":"\"Binds to and increases the activity of a guanyl nucleotide exchange factor.\" [PMID:37463208]","metadata":null},{"id":"18865bd48aef41b48a95bb536fe535d6","type":"GO_TERM","name":"guanyl nucleotide exchange factor inhibitor activity","canonical_id":"go:GO:1990624","description":"\"Binds to and stops, prevents or reduces the activity of a guanyl nucleotide exchange factor.\" [GOC:vw, PMID:25635048]","metadata":null},{"id":"d08c2a3505ff4e4cb26d1b1b25ec60f4","type":"GO_TERM","name":"guanyl ribonucleotide binding","canonical_id":"go:GO:0032561","description":"\"Binding to a guanyl ribonucleotide, any compound consisting of guanosine esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety.\" [GOC:mah]","metadata":null},{"id":"84762dbae14b46298338034573978c1d","type":"GO_TERM","name":"guanyl-nucleotide exchange factor activity","canonical_id":"go:GO:0005085","description":"\"Stimulates the exchange of GDP to GTP on a signaling GTPase, changing its conformation to its active form. Guanine nucleotide exchange factors (GEFs) act by stimulating the release of guanosine diphosphate (GDP) to allow binding of guanosine triphosphate (GTP), which is more abundant in the cell under normal cellular physiological conditions.\" [GOC:kd, GOC:mah, PMID:23303910, PMID:27218782]","metadata":null},{"id":"df2b07b4647d4350a4c50c538fec0260","type":"GO_TERM","name":"guanyl-nucleotide exchange factor adaptor activity","canonical_id":"go:GO:0005091","description":"\"The binding activity of a molecule that brings together a guanyl-nucleotide exchange factor and one or more other proteins, permitting them to function in a coordinated way.\" [GOC:mtg_MIT_16mar07, GOC:vw]","metadata":null},{"id":"9f080c0bf3524fa7babe010dbc18cb80","type":"GO_TERM","name":"guanyl-nucleotide exchange factor complex","canonical_id":"go:GO:0032045","description":"\"A protein complex that stimulates the exchange of guanyl nucleotides associated with a GTPase.\" [GOC:mah]","metadata":null},{"id":"d1dbb45fed2c4caeb8cd8736a9519175","type":"GO_TERM","name":"guanylate cyclase activator activity","canonical_id":"go:GO:0030250","description":"\"Binds to and increases the activity of guanylate cyclase.\" [GOC:mah]","metadata":null},{"id":"8e9b4bee591a46d791b0991fb73cce13","type":"GO_TERM","name":"guanylate cyclase activity","canonical_id":"go:GO:0004383","description":"\"Catalysis of the reaction: GTP = 3',5'-cyclic GMP + diphosphate.\" [EC:4.6.1.2]","metadata":null},{"id":"192e3c1573834ed484cd9d7cd0a78826","type":"GO_TERM","name":"guanylate cyclase complex, soluble","canonical_id":"go:GO:0008074","description":"\"Complex that possesses guanylate cyclase activity and is not bound to a membrane.\" [GOC:mah]","metadata":null},{"id":"9d86578b822245e683f85430425393e5","type":"GO_TERM","name":"guanylate cyclase inhibitor activity","canonical_id":"go:GO:0030251","description":"\"Binds to and stops, prevents or reduces the activity of guanylate cyclase.\" [GOC:mah]","metadata":null},{"id":"24abfa0229ef4fd19bc5631d992d8797","type":"GO_TERM","name":"guanylate cyclase regulator activity","canonical_id":"go:GO:0030249","description":"\"Modulates the activity of guanylate cyclase.\" [GOC:mah]","metadata":null},{"id":"3384936a419d4fb58411523010e3114e","type":"GO_TERM","name":"guanylate kinase-associated protein clustering","canonical_id":"go:GO:0097117","description":"\"The clustering process in which guanylate kinase-associated proteins (GKAPs) are localized to distinct domains in the cell membrane. GKAP facilitates assembly of the post synaptic density of neurons.\" [GOC:BHF, GOC:sjp, PMID:15620359]","metadata":null},{"id":"064d0a7f2cac4bcc8d05848a69e10ee8","type":"GO_TERM","name":"guanylylpyridinol adenylase activity","canonical_id":"go:GO:0160301","description":"\"Catalysis of the reaction: guanylylpyridinol + ATP + H+ = guanylylpyridinol-AMP + diphosphate.\" [PMID:25882909, RHEA:85487]","metadata":null},{"id":"272b0ec4c04e4f398c7b7c4e3ea7a6bc","type":"GO_TERM","name":"guanylyltransferase activity","canonical_id":"go:GO:0070568","description":"\"Catalysis of the transfer of a guanylyl group to an acceptor.\" [GOC:mah]","metadata":null},{"id":"24dba43db50c467194e834beee4ee958","type":"GO_TERM","name":"guard cell development","canonical_id":"go:GO:0010441","description":"\"The process whose specific outcome is the progression of the guard cell over time, from its formation to the mature structure.\" [GOC:tb]","metadata":null},{"id":"ce9d867fee3849cda8550e086f6b9a06","type":"GO_TERM","name":"guard cell differentiation","canonical_id":"go:GO:0010052","description":"\"The process in which a guard mother cell acquires the specialized features of a guard cell.\" [GOC:expert_db, GOC:tb]","metadata":null},{"id":"0ee936a6ff3d4e249e79e5848a5d96de","type":"GO_TERM","name":"guard cell fate commitment","canonical_id":"go:GO:0010377","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a stomatal guard cell. Guard cells are located in the leaf epidermis and pairwise surround stomatal pores, which allow CO2 influx for photosynthetic carbon fixation and water loss via transpiration to the atmosphere.\" [PMID:17259259]","metadata":null},{"id":"d548db4d8abf42ccbb5f9fb72a0dac5c","type":"GO_TERM","name":"guard cell morphogenesis","canonical_id":"go:GO:0010442","description":"\"Generation and organization of the polarized cell that is capable of turgor driven movement.\" [GOC:expert_db, GOC:tb]","metadata":null},{"id":"15fb0f9371ce4fbc81a56e7f82620d31","type":"GO_TERM","name":"guard mother cell cytokinesis","canonical_id":"go:GO:0010235","description":"\"The stereotyped symmetric cell division by which guard mother cell give rise to stomatal guard cells.\" [GOC:tb]","metadata":null},{"id":"d91b496323224f7398e2b27336bdeb97","type":"GO_TERM","name":"guard mother cell differentiation","canonical_id":"go:GO:0010444","description":"\"The process in which a meristemoid acquires the specialized features of a guard mother cell.\" [GOC:expert_db, GOC:tb]","metadata":null},{"id":"c24b1ebb472e41e2858fca14a6f12fe9","type":"GO_TERM","name":"guiding stereospecific synthesis activity","canonical_id":"go:GO:0042349","description":"\"The orientation of free radical substrates in such a way that only a particular stereoisomer is synthesized by an enzyme. Best characterized as a function during lignan biosynthesis.\" [GOC:ma]","metadata":null},{"id":"b863205963074b2b9846e7d829ba0a77","type":"GO_TERM","name":"gut granule","canonical_id":"go:GO:0044840","description":"\"A lysosome-related organelle contained within the intestinal cells of the nematode C. elegans. Gut granules are acidified, birefringent, autofluorescent, and contain the vacuolar H+-ATPase. They also serve as sites of cellular zinc storage.\" [GOC:kmv, PMID:22916203, PMID:24204312]","metadata":null},{"id":"e36be9c4ada3462186cc22f37f3b10c6","type":"GO_TERM","name":"gut granule assembly","canonical_id":"go:GO:1902900","description":"\"The aggregation, arrangement and bonding together of a set of components to form a gut granule.\" [GO_REF:0000079, GOC:kmv, GOC:TermGenie, PMID:17202409]","metadata":null},{"id":"c8889bd8a9eb457dbdfc4c187abdcdac","type":"GO_TERM","name":"gut granule lumen","canonical_id":"go:GO:0044842","description":"\"The lumen of a gut granule, a lysosome-related organelle contained within the intestinal cells of the nematode C. elegans.\" [GOC:kmv, PMID:22916203, PMID:24204312]","metadata":null},{"id":"a9fe924d29f94415b7788e083ccb6f31","type":"GO_TERM","name":"gut granule membrane","canonical_id":"go:GO:0044841","description":"\"The membrane of a gut granule, a lysosome-related organelle contained within the intestinal cells of the nematode C. elegans.\" [GOC:kmv, PMID:22916203, PMID:24204312]","metadata":null},{"id":"f87c8a12a32745c8890d5d13ee862b46","type":"GO_TERM","name":"gynoecium development","canonical_id":"go:GO:0048467","description":"\"The process whose specific outcome is the progression of the gynoecium over time, from its formation to the mature structure. The gynoecium is the collective name for the carpels of a flower.\" [GOC:curators, PO:0008062]","metadata":null},{"id":"e9f9151e09a74b41ab89c0b4f5fbd03b","type":"TRIAL","name":"hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study\"","canonical_id":"clinicaltrials.gov:NCT03824691","description":"Bladder Carcinoma","metadata":null},{"id":"d03d075af36849598a420212171d7605","type":"GO_TERM","name":"habenula development","canonical_id":"go:GO:0021986","description":"\"The progression of the habenula over time from its initial formation until its mature state. The habenula is the group of nuclei that makes up the stalk of the pineal gland.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:9780721601465]","metadata":null},{"id":"5e2924aa452e418ebb2d62d95c8df3b2","type":"GO_TERM","name":"habituation","canonical_id":"go:GO:0046959","description":"\"A decrease in a behavioral response to a repeated stimulus. This is exemplified by the failure of a person to show a startle response to a loud noise that has been repeatedly presented.\" [ISBN:0582227089]","metadata":null},{"id":"b73fe7e928ee4e24beef2c23873e5ce6","type":"GO_TERM","name":"hair cell differentiation","canonical_id":"go:GO:0035315","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a hair cell.\" [GOC:bf]","metadata":null},{"id":"1409e428700040afb0e984558faf9ad3","type":"DISEASE","name":"hair color","canonical_id":"efo:0003924","description":null,"metadata":null},{"id":"de2296da070d4ddb9c9706c25eff2e02","type":"GO_TERM","name":"hair cycle","canonical_id":"go:GO:0042633","description":"\"The cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair; one of the collection or mass of filaments growing from the skin of an animal, and forming a covering for a part of the head or for any part or the whole of the body.\" [GOC:curators, PMID:12230507]","metadata":null},{"id":"809258283fb34f86a620d4e9dc58d7fb","type":"GO_TERM","name":"hair cycle phase","canonical_id":"go:GO:0044851","description":"\"The cyclical periods of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair; one of the collection or mass of filaments growing from the skin of an animal, and forming a covering for a part of the head or for any part or the whole of the body.\" [GOC:jl]","metadata":null},{"id":"62ad0f723a264f9ca3adee4a09051afa","type":"GO_TERM","name":"hair cycle process","canonical_id":"go:GO:0022405","description":"\"A multicellular organismal process involved in the cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair; one of the collection or mass of filaments growing from the skin of an animal, and forming a covering for a part of the head or for any part or the whole of the body.\" [GOC:isa_complete]","metadata":null},{"id":"11f36a7d89d0462a8b18b11c6e0fe1b6","type":"GO_TERM","name":"hair follicle cell proliferation","canonical_id":"go:GO:0071335","description":"\"The multiplication or reproduction of hair follicle cells, resulting in the expansion of a cell population.\" [GOC:rph, PMID:16086254]","metadata":null},{"id":"c97193b499c74e3ebae82c2745724ef3","type":"GO_TERM","name":"hair follicle development","canonical_id":"go:GO:0001942","description":"\"The process whose specific outcome is the progression of the hair follicle over time, from its formation to the mature structure. A hair follicle is a tube-like opening in the epidermis where the hair shaft develops and into which the sebaceous glands open.\" [GOC:dph, UBERON:0002073]","metadata":null},{"id":"98c2026eaf29483788fc11043555f067","type":"GO_TERM","name":"hair follicle maturation","canonical_id":"go:GO:0048820","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a hair follicle to attain its fully functional state.\" [GOC:devbiol]","metadata":null},{"id":"cc490dfa22984d9c8bb50fc9f284e8c1","type":"GO_TERM","name":"hair follicle morphogenesis","canonical_id":"go:GO:0031069","description":"\"The process in which the anatomical structures of the hair follicle are generated and organized.\" [GOC:ln]","metadata":null},{"id":"92b5a5ccae134f5d8906fdaf514e16ed","type":"GO_TERM","name":"hair follicle placode formation","canonical_id":"go:GO:0060789","description":"\"The developmental process in which a hair placode forms. An hair follicle placode is a thickening of the ectoderm that will give rise to the hair follicle bud.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"920de485aae043188218cc200b9275e4","type":"DISEASE","name":"hairy cell leukemia","canonical_id":"mondo:0018935","description":null,"metadata":null},{"id":"5bab0997e5774326babf5b7f2bae7a5e","type":"DRUG","name":"halazepam","canonical_id":"mesh:C010175","description":null,"metadata":null},{"id":"41f985635c4b41a69acb1b6024582442","type":"DRUG","name":"halcinonide","canonical_id":"mesh:D006206","description":null,"metadata":null},{"id":"4a64aee2e5234fcfb57e31b999367012","type":"GO_TERM","name":"half bridge of mitotic spindle pole body","canonical_id":"go:GO:0061496","description":"\"Structure adjacent to the plaques of the mitotic spindle pole body.\" [GOC:dph]","metadata":null},{"id":"82841dcbd0af46c8b4b44d0bfe66cf9d","type":"GO_TERM","name":"half bridge of spindle pole body","canonical_id":"go:GO:0005825","description":"\"Structure adjacent to the plaques of the spindle pole body.\" [ISBN:0879693568]","metadata":null},{"id":"63a7ba42747245beb65f77c1f122968a","type":"GO_TERM","name":"halimadienyl-diphosphate synthase activity","canonical_id":"go:GO:0035439","description":"\"Catalysis of the reaction: geranylgeranyl diphosphate = halima-5(6),13-dien-15-yl diphosphate.\" [EC:5.5.1.16]","metadata":null},{"id":"953aef61aaac4f75b2c8c042ee8da054","type":"GO_TERM","name":"haloacetate dehalogenase activity","canonical_id":"go:GO:0018785","description":"\"Catalysis of the reaction: haloacetate + H2O = glycolate + halide.\" [EC:3.8.1.3]","metadata":null},{"id":"9efab538e6224fe1ad90dead86ebef87","type":"GO_TERM","name":"haloalkane dehalogenase activity","canonical_id":"go:GO:0018786","description":"\"Catalysis of the reaction: 1-haloalkane + H2O = a primary alcohol + halide.\" [PMID:3624201, RHEA:19081]","metadata":null},{"id":"c94619c3493a45d8afc74ff4939db168","type":"DRUG","name":"halofantrine","canonical_id":"mesh:C023768","description":null,"metadata":null},{"id":"09e47064318b400e852d100907b5b50d","type":"GO_TERM","name":"halogen metabolic process","canonical_id":"go:GO:0070276","description":"\"The chemical reactions and pathways involving any halogen, elements of Group VII; includes metabolism of halogen-containing compounds.\" [GOC:mah]","metadata":null},{"id":"3df0d743027a4d219f2b83381939cd2b","type":"GO_TERM","name":"halogenase activity","canonical_id":"go:GO:0140906","description":"\"Catalysis of the reaction: R-CH + a halogen + oxygen donor = R-C-halogen +H2O.\" [PMID:28466644, PMID:34368824]","metadata":null},{"id":"1008720cfb2d4e15b11b7cb271d146c6","type":"GO_TERM","name":"halogenated hydrocarbon catabolic process","canonical_id":"go:GO:0042206","description":"\"The chemical reactions and pathways resulting in the breakdown of halogenated hydrocarbons, compounds derived from hydrocarbons by replacing one or more hydrogen atoms with halogen atoms.\" [GOC:ai, GOC:krc]","metadata":null},{"id":"5b1c6c553e464dadba48841697b7d056","type":"GO_TERM","name":"halogenated hydrocarbon metabolic process","canonical_id":"go:GO:0042197","description":"\"The chemical reactions and pathways involving halogenated hydrocarbons, compounds derived from hydrocarbons by replacing one or more hydrogen atoms with halogen atoms. Halogens include fluorine, chlorine, bromine and iodine.\" [GOC:ai, GOC:krc]","metadata":null},{"id":"9945289b14f94aadb5494e92c17410b6","type":"GO_TERM","name":"halohydrin hydrogen-halide-lyase activity","canonical_id":"go:GO:0019181","description":"\"Catalysis of the reaction: a halohydrin = an epoxide + a hydrogen halide.\" [PMID:8017917]","metadata":null},{"id":"310fe3533887430e8af23171cc04375a","type":"DRUG","name":"haloperidol","canonical_id":"gtopdb:86","description":null,"metadata":null},{"id":"42fe5f9e475f4fed9fc3942c49777d6f","type":"DRUG","name":"haloperidol","canonical_id":"mesh:D006220","description":null,"metadata":null},{"id":"5ea7b58cd59a459d899417eb55ce47ee","type":"DRUG","name":"haloperidol","canonical_id":"chembl:CHEMBL1200986","description":null,"metadata":null},{"id":"20c076e2b0114c089682a522fe393ad3","type":"COMBINATION_TREATMENT","name":"haloperidol + ketamine","canonical_id":"ctgov_combo:ctgov-combo-40f7f6654a4ab24e","description":null,"metadata":null},{"id":"6255ac49a0c04326b7680c40f5876ce2","type":"COMBINATION_TREATMENT","name":"haloperidol + ketamine","canonical_id":"ctgov_combo:ctgov-combo-93b19452ce02cac8","description":null,"metadata":null},{"id":"3a1c83b858794cbeb2bf9c6e178c9716","type":"COMBINATION_TREATMENT","name":"haloperidol + lurasidone + perphenazine","canonical_id":"ctgov_combo:ctgov-combo-f8d4a9e19641748f","description":null,"metadata":null},{"id":"5a97104397004f8d8532257f162cdf02","type":"COMBINATION_TREATMENT","name":"haloperidol + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-db1597e73f9b0584","description":null,"metadata":null},{"id":"e192109f1c844c88ad6fd89550aac136","type":"COMBINATION_TREATMENT","name":"haloperidol + olanzapine","canonical_id":"ctgov_combo:ctgov-combo-298551888ae28851","description":null,"metadata":null},{"id":"b1d4b75f66ed4cda9b03bbb908022509","type":"COMBINATION_TREATMENT","name":"haloperidol + ondansetron","canonical_id":"ctgov_combo:ctgov-combo-36fbf89eb9984aed","description":null,"metadata":null},{"id":"872ba640bcda4975a3170e4c094a59d7","type":"COMBINATION_TREATMENT","name":"haloperidol + perphenazine","canonical_id":"ctgov_combo:ctgov-combo-249a680d6dee6dab","description":null,"metadata":null},{"id":"66cdc964212f468eb2845bbb41482ef3","type":"COMBINATION_TREATMENT","name":"haloperidol + pethidine","canonical_id":"ctgov_combo:ctgov-combo-39c7bd80357a2283","description":null,"metadata":null},{"id":"021f224363134efe8a970ce1050db155","type":"COMBINATION_TREATMENT","name":"haloperidol + quetiapine","canonical_id":"ctgov_combo:ctgov-combo-41c72c17fca084a4","description":null,"metadata":null},{"id":"427bbc55bf92497ea07b4ee51b2ac398","type":"COMBINATION_TREATMENT","name":"haloperidol + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-d15b3dcc90355ffc","description":null,"metadata":null},{"id":"a9f6341f112149d8805f8d1fbe6983b5","type":"GO_TERM","name":"haloperoxidase activity","canonical_id":"go:GO:0140905","description":"\"Catalysis of the reaction: R-CH + a halogen + H2O2 = R-C-halogen + H2O.\" [PMID:28466644, PMID:34368824]","metadata":null},{"id":"524aa8ba788d400e809c0d86b170b2a0","type":"DRUG","name":"halothane","canonical_id":"gtopdb:2401","description":null,"metadata":null},{"id":"ba00c87fe9964578886269cb39ac8431","type":"DRUG","name":"halothane","canonical_id":"chembl:CHEMBL931","description":null,"metadata":null},{"id":"7945d6f2f7b04cbbb9ce17f5f38546f2","type":"GO_TERM","name":"halotropism","canonical_id":"go:GO:0170002","description":"\"A sodium-specific negative tropism that is crucial for surviving and thriving under high salinity.\" [PMID:36243013]","metadata":null},{"id":"71d0a377bab04bb887e3effcfc0465a2","type":"GO_TERM","name":"haltere development","canonical_id":"go:GO:0007482","description":"\"The process whose specific outcome is the progression of the haltere over time, from its formation to the mature structure. The haltere is the club-shaped 'balancers' found on each side of the metathorax among the true flies (Diptera). They are the much-modified hind wings.\" [GOC:jid, PMID:32659004]","metadata":null},{"id":"575c0f04398c469e8d9dc6f333565a58","type":"GO_TERM","name":"haltere disc development","canonical_id":"go:GO:0035216","description":"\"Progression of the haltere imaginal disc over time, from its initial formation through to its metamorphosis to form the adult capitellum, pedicel, haltere sclerite, metathoracic spiracle and metanotum.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"8106308ce02f4b009cf95b6de140779d","type":"GO_TERM","name":"haltere disc morphogenesis","canonical_id":"go:GO:0007481","description":"\"The process in which the anatomical structures derived from the haltere disc are generated and organized. This includes the transformation of a haltere imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into the recognizable adult capitellum, pedicel, haltere sclerite, metathoracic spiracle and metanotum.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"c96fbb61556a4d53866a9850b5f59da5","type":"GO_TERM","name":"haltere morphogenesis","canonical_id":"go:GO:0048735","description":"\"The process in which the anatomical structures of a haltere are generated and organized.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"10748e758088483fb14945214f063f05","type":"GO_TERM","name":"hamamelose kinase activity","canonical_id":"go:GO:0047976","description":"\"Catalysis of the reaction: D-hamamelose + ATP = D-hamamelose 2'-phosphate + ADP + 2 H+.\" [EC:2.7.1.102, RHEA:22796]","metadata":null},{"id":"2d4a2101eb8646ec8d6a4dc3e9314a82","type":"DISEASE","name":"hamartoma","canonical_id":"mondo:0006499","description":null,"metadata":null},{"id":"c3f6eee015fc4746976dbb9a21db2e77","type":"GO_TERM","name":"haptoglobin binding","canonical_id":"go:GO:0031720","description":"\"Binding to a haptoglobin, any alpha2 globulin of blood plasma that can combine with free oxyhemoglobin to form a stable complex.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"9ca202a6ed79497bb50fba02dfec736a","type":"GO_TERM","name":"haptoglobin-hemoglobin complex","canonical_id":"go:GO:0031838","description":"\"A protein complex formed by the stable binding of a haptoglobin to hemoglobin.\" [GOC:mah]","metadata":null},{"id":"595b5ee7b1564c90acc42fccced49990","type":"GO_TERM","name":"hard palate development","canonical_id":"go:GO:0060022","description":"\"The biological process whose specific outcome is the progression of the hard palate from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure, whatever form that may be including its natural destruction. The hard palate is the anterior portion of the palate consisting of bone and mucous membranes.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"ab54d9d6900f497688d0a47b256e0752","type":"GO_TERM","name":"hard palate morphogenesis","canonical_id":"go:GO:1905748","description":"\"The developmental process by which a hard palate is generated and organized.\" [GO_REF:0000083, GOC:TermGenie, PMID:23419067]","metadata":null},{"id":"24494f7d2a8a4e188310622abbaa95ea","type":"GO_TERM","name":"hatching","canonical_id":"go:GO:0035188","description":"\"The emergence of an immature organism from a protective structure.\" [GOC:dgh, GOC:isa_complete, ISBN:0198612001]","metadata":null},{"id":"f95eda9fb8824b3fa6d7933cd6d24227","type":"GO_TERM","name":"hatching behavior","canonical_id":"go:GO:0035187","description":"\"The specific behavior of an organism during the emergence from an egg shell. In Drosophila for example, the larva swings its head reiteratively through a semicircular arc, using its mouth hooks to tear apart the chorion in front of it and thus free itself from within the egg shell.\" [GOC:pr, PMID:10436051]","metadata":null},{"id":"7f243b18e76f4f099c0d37a5166a91fe","type":"GO_TERM","name":"hatching gland development","canonical_id":"go:GO:0048785","description":"\"The process whose specific outcome is the progression of the hatching gland over time, from its formation to the mature structure. The cells of the hatching gland contain enzymes responsible for solubilization of the egg chorion, facilitating the hatching process.\" [GOC:bf, GOC:dh, GOC:jid]","metadata":null},{"id":"495bcd7e85ba4fd599f3bb4e6674a4ab","type":"GO_TERM","name":"haustorium","canonical_id":"go:GO:0085035","description":"\"A projection from a cell or tissue that penetrates the host's cell wall and invaginates the host cell membrane.\" [GOC:pamgo_curators]","metadata":null},{"id":"1a0101fdabbd4613a53c2c3eac37e475","type":"GO_TERM","name":"haustorium mother cell formation","canonical_id":"go:GO:0075192","description":"\"The process in which a symbiont cell is formed, separated from the tip of an infection hypha by a septum. The haustorium mother cell usually contains 2-4 fungal nuclei, and its function is to attach and penetrate the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"84d04b8a860d48acbe33343f52badb8d","type":"GO_TERM","name":"haustorium neck formation","canonical_id":"go:GO:0075197","description":"\"The assembly by the symbiont of a neck-like structure for the purpose of penetration into its host organism. The neck-like structure connects haustorium mother cell and haustorium. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators, Wikipedia:Haustorium]","metadata":null},{"id":"1d3abcb1d53440de8a409300259223ac","type":"DISEASE","name":"hawkinsinuria","canonical_id":"mondo:0007700","description":null,"metadata":null},{"id":"37d90ac2e61c47ec93b2f3af96f76e7c","type":"DISEASE","name":"head and neck cancer","canonical_id":"mondo:0005627","description":null,"metadata":null},{"id":"221cc861ad7e4c4f8cd586cac53f373f","type":"DISEASE","name":"head and neck neoplasm","canonical_id":"mondo:0005586","description":null,"metadata":null},{"id":"fc6e625e2ed448c5be24dcfba61a472d","type":"DISEASE","name":"head and neck squamous cell carcinoma","canonical_id":"mondo:0010150","description":null,"metadata":null},{"id":"ed21c70bed7d49bc9ed8471198cde1b5","type":"GO_TERM","name":"head development","canonical_id":"go:GO:0060322","description":"\"The biological process whose specific outcome is the progression of a head from an initial condition to its mature state. The head is the anterior-most division of the body.\" [GOC:dph]","metadata":null},{"id":"7df483f046b54daabd5f4b855104fd5b","type":"DISEASE","name":"head injury","canonical_id":"efo:0009505","description":null,"metadata":null},{"id":"008e16d6a5774794899ec254253e5afc","type":"GO_TERM","name":"head involution","canonical_id":"go:GO:0008258","description":"\"Movement of the anterior ectoderm to the interior of the embryo.\" [ISBN:0879694238]","metadata":null},{"id":"d529b3b44f4a40d0a2232b69fc5be8f0","type":"GO_TERM","name":"head kidney development","canonical_id":"go:GO:0072113","description":"\"The process whose specific outcome is the progression of the head kidney over time, from its formation to the mature structure. The head kidney is a pronephros that consists of fused bilateral lobes located in the anterior part of the kidney. It is analogous to the mammalian bone marrow and the primary site of definitive hematopoiesis.\" [GOC:mtg_kidney_jan10, ZFA:0000669]","metadata":null},{"id":"8fda2900f559481084c85320151da8d4","type":"GO_TERM","name":"head kidney formation","canonical_id":"go:GO:0072117","description":"\"The developmental process pertaining to the initial formation of the head kidney. The head kidney is a pronephros that consists of fused bilateral lobes located in the anterior part of the kidney.\" [GOC:mtg_kidney_jan10, ZFA:0000669]","metadata":null},{"id":"9d4297a09138452ebd8363fddd9bd464","type":"GO_TERM","name":"head kidney maturation","canonical_id":"go:GO:0072121","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the head kidney to attain its fully functional state. The head kidney is a pronephros that consists of fused bilateral lobes located in the anterior part of the kidney.\" [GOC:mtg_kidney_jan10, ZFA:0000669]","metadata":null},{"id":"612d9b0cdd01402ba30e23ea75c2f02e","type":"GO_TERM","name":"head kidney morphogenesis","canonical_id":"go:GO:0072115","description":"\"The process in which the anatomical structures of the head kidney are generated and organized. The head kidney is a pronephros that consists of fused bilateral lobes located in the anterior part of the kidney.\" [GOC:mtg_kidney_jan10, ZFA:0000669]","metadata":null},{"id":"64cca94c7df743f59d9724d88bc0e417","type":"GO_TERM","name":"head kidney structural organization","canonical_id":"go:GO:0072119","description":"\"The process that contributes to the act of creating the structural organization of the head kidney. This process pertains to the physical shaping of a rudimentary structure. The head kidney is a pronephros that consists of fused bilateral lobes located in the anterior part of the kidney.\" [GOC:mtg_kidney_jan10, ZFA:0000669]","metadata":null},{"id":"b329f220abfc40878f8c91e49290fd7a","type":"GO_TERM","name":"head morphogenesis","canonical_id":"go:GO:0060323","description":"\"The process in which the anatomical structures of the head are generated and organized. The head is the anterior-most division of the body.\" [GOC:dph]","metadata":null},{"id":"8f1849f55cbe4179bc26c849d002aa33","type":"GO_TERM","name":"head segmentation","canonical_id":"go:GO:0035287","description":"\"Partitioning the insect head anlage into a fixed number of segmental units. The number of segments composing the insect head has long been a subject of debate, but it is generally agreed that there are 6 or 7 segments. From anterior to posterior the head segments are the procephalic segments (labral, (ocular), antennal and intercalary) and the gnathal segments (mandibular, maxillary and labial).\" [PMID:10477305, PMID:7915837]","metadata":null},{"id":"12521c23047840ffb175e5c9962df507","type":"GO_TERM","name":"heart capillary growth","canonical_id":"go:GO:0003248","description":"\"The increase in heart capillaries that accompanies physiological hypertrophy of cardiac muscle.\" [GOC:mtg_heart]","metadata":null},{"id":"fbbf2e2129d243e18ba59ba00d13d7e7","type":"GO_TERM","name":"heart contraction","canonical_id":"go:GO:0060047","description":"\"The multicellular organismal process in which the heart decreases in volume in a characteristic way to propel blood through the body.\" [GOC:dph]","metadata":null},{"id":"30e1a5b769144ebcab5e83ff5ece5dac","type":"GO_TERM","name":"heart development","canonical_id":"go:GO:0007507","description":"\"The process whose specific outcome is the progression of the heart over time, from its formation to the mature structure. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.\" [GOC:jid, UBERON:0000948]","metadata":null},{"id":"85f4435a82364ffda6caa66b63cd1142","type":"DISEASE","name":"heart disorder","canonical_id":"mondo:0005267","description":null,"metadata":null},{"id":"54a8bb3a1e894e51a1aaee56893a7054","type":"DISEASE","name":"heart failure","canonical_id":"mondo:0005252","description":null,"metadata":null},{"id":"2511a706662144e7827a3c30e566752c","type":"GO_TERM","name":"heart field specification","canonical_id":"go:GO:0003128","description":"\"The process that results in the delineation of a specific region of the lateral mesoderm into the area in which the heart will develop.\" [GOC:mtg_heart]","metadata":null},{"id":"790618dc04f94cc0b6d4542133232337","type":"GO_TERM","name":"heart formation","canonical_id":"go:GO:0060914","description":"\"The developmental process pertaining to the initial formation of the heart from unspecified parts. This process begins with the specific processes that contribute to the appearance of the heart field and the arrival of cardiac neural crest to the heart region. The process ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"2c48de5ec22b444e89a66fa88a4ced99","type":"GO_TERM","name":"heart growth","canonical_id":"go:GO:0060419","description":"\"The increase in size or mass of the heart.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"370dccb5a38e43709d8a269ad0f47fb8","type":"GO_TERM","name":"heart induction","canonical_id":"go:GO:0003129","description":"\"The close range interaction between mesoderm and endoderm or ectoderm that causes cells to change their fates and specify the development of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"d514e0c16736479ab3d6d75cecfff32d","type":"GO_TERM","name":"heart jogging","canonical_id":"go:GO:0003146","description":"\"The morphogenetic process in which the heart cone is displaced to the left with respect to the vector of the anterior-posterior axis.\" [GOC:mtg_heart, PMID:9334285]","metadata":null},{"id":"d3c75d290a394659be1d534609c2c34c","type":"GO_TERM","name":"heart looping","canonical_id":"go:GO:0001947","description":"\"The tube morphogenesis process in which the primitive heart tube loops asymmetrically. This looping brings the primitive heart chambers into alignment preceding their future integration. Heart looping begins with dextral-looping and ends when the main regional divisions of the mature heart and primordium of the great arterial trunks become established preceding septation.\" [GOC:dph, PMID:12094232]","metadata":null},{"id":"4ec45290141f4556b10e36d21db7e544","type":"GO_TERM","name":"heart morphogenesis","canonical_id":"go:GO:0003007","description":"\"The developmental process in which the heart is generated and organized. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.\" [GOC:dph, GOC:isa_complete]","metadata":null},{"id":"3e6b5085d89245afbed6e74f94510d09","type":"GO_TERM","name":"heart process","canonical_id":"go:GO:0003015","description":"\"A circulatory system process carried out by the heart. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.\" [GOC:mtg_cardio]","metadata":null},{"id":"159999308b274237bbf99564aa65d17e","type":"GO_TERM","name":"heart rudiment development","canonical_id":"go:GO:0003313","description":"\"The progression of the heart rudiment over time, from its initial formation to the mature structure. The heart rudiment is a cone-like structure that is formed when myocardial progenitor cells of the heart field fuse at the midline. The heart rudiment is the first structure of the heart tube.\" [GOC:mtg_heart]","metadata":null},{"id":"c35b177dbd0d44529d5899ee9bd2051c","type":"GO_TERM","name":"heart rudiment formation","canonical_id":"go:GO:0003315","description":"\"The developmental process pertaining to the initial formation of the heart rudiment.\" [GOC:mtg_heart]","metadata":null},{"id":"f4decd5e177a476390fdd0901fc56c21","type":"GO_TERM","name":"heart rudiment involution","canonical_id":"go:GO:0003320","description":"\"The inward folding of myocardial tissue derived from the right half of the heart rudiment that will form the future ventral part of the heart tube.\" [GOC:mtg_heart]","metadata":null},{"id":"82b5fbe1dba5497bb3c6975563e85dc1","type":"GO_TERM","name":"heart rudiment morphogenesis","canonical_id":"go:GO:0003314","description":"\"The process in which the anatomical structures of the heart rudiment are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"a8343bd6321a4a0bb6d68d4c8e2b6eb4","type":"DISEASE","name":"heart septal defect","canonical_id":"mondo:0002078","description":null,"metadata":null},{"id":"9a3e32b047704dcf986d6a9853525479","type":"GO_TERM","name":"heart trabecula formation","canonical_id":"go:GO:0060347","description":"\"The process of creating a trabecula in the heart. A trabecula is a tissue element in the form of a small beam, strut or rod.\" [GOC:dph]","metadata":null},{"id":"47835f0bde3745c997925a0f2a72769d","type":"GO_TERM","name":"heart trabecula morphogenesis","canonical_id":"go:GO:0061384","description":"\"The process of shaping a trabecula in the heart. A trabecula is a small, often microscopic, tissue element in the form of a small beam, strut or rod, which generally has a mechanical function. Trabecula are usually but not necessarily, composed of dense collagenous tissue.\" [GOC:dph]","metadata":null},{"id":"4e41e6a608cb4fa3b8852023b3f1ced1","type":"GO_TERM","name":"heart valve cell differentiation","canonical_id":"go:GO:0003293","description":"\"The process in which an endocardial cushion cell give rise to a cell that is part of a heart valve.\" [GOC:mtg_heart]","metadata":null},{"id":"593dec5ca2324b93b5435d8888c7ced6","type":"GO_TERM","name":"heart valve development","canonical_id":"go:GO:0003170","description":"\"The progression of a heart valve over time, from its formation to the mature structure. A heart valve is a structure that restricts the flow of blood to different regions of the heart and forms from an endocardial cushion.\" [GOC:mtg_heart]","metadata":null},{"id":"919a90512772426a85305dd6c6ed91d5","type":"GO_TERM","name":"heart valve formation","canonical_id":"go:GO:0003188","description":"\"The developmental process pertaining to the initial formation of a heart valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"e85764c418b346faadfe80c943cace9c","type":"GO_TERM","name":"heart valve morphogenesis","canonical_id":"go:GO:0003179","description":"\"The process in which the structure of a heart valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"0d2194b05ed8482c9fecf67b076515fa","type":"GO_TERM","name":"heart wedging","canonical_id":"go:GO:0003297","description":"\"The morphogenetic process in which the aorta inserts between the atrioventricular valves, contributing to the shaping of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"3d82bed7d7c04f28b000ed361f5d82e7","type":"GO_TERM","name":"heat acclimation","canonical_id":"go:GO:0010286","description":"\"Any process that increases heat tolerance of an organism in response to high temperatures.\" [GOC:tair_curators]","metadata":null},{"id":"0882f6222d4349b2a54b77d2b9c658ae","type":"GO_TERM","name":"heat dissipation","canonical_id":"go:GO:0031653","description":"\"Any homeostatic process in which an organism releases excess heat to the environment, thereby lowering its internal temperature.\" [GOC:mah]","metadata":null},{"id":"52a73841003d4fb28a566cba23a2e946","type":"GO_TERM","name":"heat generation","canonical_id":"go:GO:0031649","description":"\"Any homeostatic process in which an organism produces heat, thereby raising its internal temperature.\" [GOC:mah]","metadata":null},{"id":"3cbb4d69d5e54d53a7a3ed364712eacf","type":"GO_TERM","name":"heat shock protein binding","canonical_id":"go:GO:0031072","description":"\"Binding to a heat shock protein, a protein synthesized or activated in response to heat shock.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"c1456cf5c60648cbb087b39a8cd85d0f","type":"GO_TERM","name":"heat shock-mediated polytene chromosome puffing","canonical_id":"go:GO:0035080","description":"\"The decondensing (loosening) and swelling of the chromosomal sites of heat shock genes on polytene chromosomes in response to a heat shock stimulus.\" [GOC:bf, PMID:12543962]","metadata":null},{"id":"7b8e7f84307f4a75b02676843dd1f399","type":"GO_TERM","name":"heavy chain immunoglobulin complex","canonical_id":"go:GO:0071762","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of the IgNAR isotype held together by disulfide bonds and lacking immunoglobulin light chains.\" [GOC:add, ISBN:0781765196, PMID:12543123, PMID:16051357]","metadata":null},{"id":"bea6fc13e70a4456a32cb45be28e47d1","type":"GO_TERM","name":"hedgehog family protein binding","canonical_id":"go:GO:0097108","description":"\"Binding to a member of the hedgehog protein family, signaling proteins involved in development.\" [GOC:BHF, GOC:pr, PMID:10050855]","metadata":null},{"id":"89c851c2163a4dd19473d62b07d91c0f","type":"GO_TERM","name":"hedgehog receptor activity","canonical_id":"go:GO:0008158","description":"\"Combining with a member of the hedgehog protein family and transmitting the signal across the membrane to initiate a change in cell activity.\" [GOC:bf, GOC:curators, PMID:9278137]","metadata":null},{"id":"1b30a32c69644595ae7a5e35b280aad9","type":"GO_TERM","name":"helical viral capsid","canonical_id":"go:GO:0019029","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles; the subunits are arranged to form a protein helix with the genetic material contained within. Tobacco mosaic virus has such a capsid structure.\" [ISBN:071673706X, UniProtKB-KW:KW-1139, VZ:885]","metadata":null},{"id":"07680459800945db946254b0aa7bf6c6","type":"GO_TERM","name":"helicase activity","canonical_id":"go:GO:0004386","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate, to drive the unwinding of a DNA or RNA helix.\" [GOC:jl]","metadata":null},{"id":"99c39ce2855842c7a82657b22b050b5c","type":"GO_TERM","name":"helper T cell chemotaxis","canonical_id":"go:GO:0035704","description":"\"The directed movement of a helper T cell in response to an external stimulus.\" [CL:0000912, GOC:BHF]","metadata":null},{"id":"367d54e099e34ae1990d62883caeafa1","type":"GO_TERM","name":"helper T cell diapedesis","canonical_id":"go:GO:0035685","description":"\"The passage of a helper T cell between the tight junctions of endothelial cells lining blood vessels, typically the fourth and final step of cellular extravasation.\" [CL:0000912, GOC:BHF]","metadata":null},{"id":"847b0d8c32d345e28192fea86eaa0686","type":"GO_TERM","name":"helper T cell enhancement of B cell mediated immune response","canonical_id":"go:GO:0035399","description":"\"Positive regulation of a B cell mediated immune response mediated via cytokine production by a helper T cell.\" [GOC:add]","metadata":null},{"id":"7d93bedd66f24ec5b3a1f0cd49b89fa9","type":"GO_TERM","name":"helper T cell enhancement of T cell mediated immune response","canonical_id":"go:GO:0035398","description":"\"Positive regulation of a T cell mediated immune response mediated via cytokine production by a helper T cell.\" [GOC:add]","metadata":null},{"id":"b1ff534d38b74e348681d0f61972ffa2","type":"GO_TERM","name":"helper T cell enhancement of adaptive immune response","canonical_id":"go:GO:0035397","description":"\"Positive regulation of an adaptive immune response mediated via cytokine production by helper T cell.\" [GOC:add]","metadata":null},{"id":"96e76a12b5ef4a1396d5e61a0adfcda0","type":"GO_TERM","name":"helper T cell extravasation","canonical_id":"go:GO:0035684","description":"\"The migration of a helper T cell from the blood vessels into the surrounding tissue. A helper T-cell is an effector T cell that provides help in the form of secreted cytokines to other immune cells.\" [CL:0000912, GOC:BHF]","metadata":null},{"id":"075405093d8241b780f812df8703ff82","type":"GO_TERM","name":"helvolic acid biosynthetic process","canonical_id":"go:GO:1900812","description":"\"The chemical reactions and pathways resulting in the formation of helvolic acid.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ffcdfbdf8c2b4768a3e1294aa5493e72","type":"GO_TERM","name":"helvolic acid catabolic process","canonical_id":"go:GO:1900811","description":"\"The chemical reactions and pathways resulting in the breakdown of helvolic acid.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"786db66bfbda47609a467905a7e29d97","type":"GO_TERM","name":"hemangioblast cell differentiation","canonical_id":"go:GO:0060217","description":"\"The process in which a relatively unspecialized cell acquires the characteristics of a mature hemangioblast. Hemangioblasts are the proposed common precursor of blood and endothelial lineages.\" [GOC:bf, GOC:dph, PMID:15378083, PMID:9670018]","metadata":null},{"id":"f008ac89c4574ebead4706b3f97e47db","type":"DISEASE","name":"hemangioendothelioma","canonical_id":"mondo:0021121","description":null,"metadata":null},{"id":"a4bda463eca94706b1ce11a2d66881b7","type":"DISEASE","name":"hemangioma","canonical_id":"mondo:0006500","description":null,"metadata":null},{"id":"1bdca58ea62344c09a2cb5014a4786d3","type":"DISEASE","name":"hematologic disorder","canonical_id":"mondo:0005570","description":null,"metadata":null},{"id":"ac59fd683dcc422bb33511c631fff16d","type":"GO_TERM","name":"hematophagy","canonical_id":"go:GO:0140106","description":"\"A feeding behavior that involves the ingestion of blood. Hematophagous animals have mouth parts and chemical agents for penetrating vascular structures in the skin of hosts. To overcome natural hemostasis, vasoconstriction, inflammation, and pain sensation in the host, hematophagous animals pre-inject chemical substances with anesthetic and/or anticoagulant properties.\" [Wikipedia:Hematophagy]","metadata":null},{"id":"4551b71af8984c5c9cbe633d17aea6b9","type":"GO_TERM","name":"hematopoietic or lymphoid organ development","canonical_id":"go:GO:0048534","description":"\"The process whose specific outcome is the progression of any organ involved in hematopoiesis (also known as hemopoiesis) or lymphoid cell activation over time, from its formation to the mature structure. Such development includes differentiation of resident cell types (stromal cells) and of migratory cell types dependent on the unique microenvironment afforded by the organ for their proper differentiation.\" [GOC:add, GOC:rl, ISBN:0781735149]","metadata":null},{"id":"6882cc95689142908d129082faf08ba6","type":"GO_TERM","name":"hematopoietic progenitor cell differentiation","canonical_id":"go:GO:0002244","description":"\"The process in which precursor cell type acquires the specialized features of a hematopoietic progenitor cell, a class of cell types including myeloid progenitor cells and lymphoid progenitor cells.\" [GOC:add, GOC:rl, ISBN:0781735149, PMID:16551251]","metadata":null},{"id":"1d53391ca9e14e618a9125d3404bb860","type":"GO_TERM","name":"hematopoietic stem cell differentiation","canonical_id":"go:GO:0060218","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a hematopoietic stem cell. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.\" [GOC:bf, GOC:BHF, GOC:dph, GOC:rl, PMID:15378083]","metadata":null},{"id":"e944689f12ca4633af230b8e573f99b8","type":"GO_TERM","name":"hematopoietic stem cell homeostasis","canonical_id":"go:GO:0061484","description":"\"Any biological process involved in the maintenance of the steady-state number of hematopoietic stem cells within a population of cells.\" [GOC:dph, PMID:21508411]","metadata":null},{"id":"96f344bbd0854241b1257484aded52b5","type":"GO_TERM","name":"hematopoietic stem cell migration","canonical_id":"go:GO:0035701","description":"\"The orderly movement of a hematopoietic stem cell from one site to another. A hematopoietic stem cell is a cell from which all cells of the lymphoid and myeloid lineages develop, including blood cells and cells of the immune system.\" [CL:0000037, GOC:BHF, PMID:20234092]","metadata":null},{"id":"6e0a12b5ec494966a199006c3c5a3160","type":"GO_TERM","name":"hematopoietic stem cell migration to bone marrow","canonical_id":"go:GO:0097241","description":"\"The orderly movement of a hematopoietic stem cell into the bone marrow, and its subsequent positioning within defined functional compartments in that microenvironment. A hematopoietic stem cell is a cell from which all cells of the lymphoid and myeloid lineages develop, including blood cells and cells of the immune system.\" [CL:0000037, GOC:yaf, PMID:17368745]","metadata":null},{"id":"9e8d41ad45d64a5b980be21ad1088789","type":"GO_TERM","name":"hematopoietic stem cell proliferation","canonical_id":"go:GO:0071425","description":"\"The expansion of a hematopoietic stem cell population by cell division. A hematopoietic stem cell is a stem cell from which all cells of the lymphoid and myeloid lineages develop.\" [CL:0000037, GOC:add, GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"6c2ef9b93d42451c84d846988e3ec534","type":"GO_TERM","name":"heme A biosynthetic process","canonical_id":"go:GO:0006784","description":"\"The chemical reactions and pathways resulting in the formation of heme A, a derivative of heme found in cytochrome aa3.\" [GOC:ai, PMID:11788607]","metadata":null},{"id":"789a84d89849402f8ca5af4d4ece06e4","type":"GO_TERM","name":"heme A synthase activity","canonical_id":"go:GO:0120547","description":"\"Catalysis of the reaction: Fe(II)-heme o + 2 acceptor + H2O = Fe(II)-heme a + 2 acceptor-H2. The conversion of heme o to heme a occcurs by two successive hydroxylations of the methyl group at C8 using water as the oxygen source. The first hydroxylation forms heme i, the second hydroxylation results in an unstable dihydroxymethyl group, which spontaneously dehydrates, resulting in the formyl group of heme A.\" [PMID:30397130, RHEA:63388]","metadata":null},{"id":"7bce5a128c7549aab84aee9c027afe93","type":"GO_TERM","name":"heme B biosynthetic process","canonical_id":"go:GO:0006785","description":"\"The chemical reactions and pathways resulting in the formation of heme B, a Fe(II) porphyrin complex readily isolated from the hemoglobin of beef blood, but also found in other proteins including other hemoglobins, myoglobins, cytochromes P-450, catalases, peroxidases as well as b type cytochromes.\" [GOC:yaf, PMID:29414780]","metadata":null},{"id":"ba0eae680af6460e8481ede9282325d2","type":"GO_TERM","name":"heme B catabolic process","canonical_id":"go:GO:1900548","description":"\"The chemical reactions and pathways resulting in the breakdown of heme b, a Fe(II) porphyrin complex readily isolated from the hemoglobin of beef blood, but also found in other proteins including other hemoglobins, myoglobins, cytochromes P-450, catalases, peroxidases as well as b type cytochromes.\" [GOC:TermGenie, GOC:yaf, PMID:28352909]","metadata":null},{"id":"20e5a7f97cd147b1be63c0cb1580cc97","type":"GO_TERM","name":"heme B transmembrane transporter activity","canonical_id":"go:GO:0170003","description":"\"Enables the transfer of heme B from one side of a membrane to the other.\" [PMID:15369674, PMID:20610401, PMID:32121449, PMID:9657107]","metadata":null},{"id":"f6ebec5682da4061b1395be5d1fad979","type":"GO_TERM","name":"heme C biosynthetic process","canonical_id":"go:GO:0006786","description":"\"The chemical reactions and pathways resulting in the formation of heme c, a derivative of heme found in cytochromes c, b4, and f.\" [GOC:curators, PubChem_Compound:122208]","metadata":null},{"id":"57c28d943bb941458ba1a77ac42fd2b0","type":"GO_TERM","name":"heme C catabolic process","canonical_id":"go:GO:0046163","description":"\"The chemical reactions and pathways resulting in the breakdown of heme C, a derivative of heme found in cytochromes c, b4, and f.\" [GOC:curators]","metadata":null},{"id":"484de91cf166491c88a4cf1aea8f27bd","type":"GO_TERM","name":"heme O biosynthetic process","canonical_id":"go:GO:0048034","description":"\"The chemical reactions and pathways resulting in the formation of heme O, a derivative of heme containing a 17-carbon hydroxyethylfarnesyl side chain at position 8 of the tetrapyrrole macrocycle.\" [GOC:jid]","metadata":null},{"id":"4d63b76e00964ba795ca8b74c6d784c8","type":"GO_TERM","name":"heme O catabolic process","canonical_id":"go:GO:0048035","description":"\"The chemical reactions and pathways resulting in the breakdown of heme O, a derivative of heme containing a 17-carbon hydroxyethylfarnesyl side chain at position 8 of the tetrapyrrole macrocycle.\" [GOC:jid]","metadata":null},{"id":"08c4f34f2a144e22b66b04a73601ee3e","type":"GO_TERM","name":"heme a catabolic process","canonical_id":"go:GO:0046161","description":"\"The chemical reactions and pathways resulting in the breakdown of heme a, a derivative of heme found in cytochrome aa3.\" [GOC:curators, PMID:28352909]","metadata":null},{"id":"e0ba65d706414486a16af74c7ea73028","type":"GO_TERM","name":"heme binding","canonical_id":"go:GO:0020037","description":"\"Binding to a heme, a compound composed of iron complexed in a porphyrin (tetrapyrrole) ring.\" [GOC:ai]","metadata":null},{"id":"ec9bbd69cf6245148fd1e31b8895c699","type":"GO_TERM","name":"heme biosynthetic process","canonical_id":"go:GO:0006783","description":"\"The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors.\" [GOC:jl, PMID:11788607]","metadata":null},{"id":"ada7bda22a754ae5ab0d81bc02bfa1cf","type":"GO_TERM","name":"heme catabolic process","canonical_id":"go:GO:0042167","description":"\"The chemical reactions and pathways resulting in the breakdown of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.\" [GOC:jl]","metadata":null},{"id":"2d1686e11fa34aa2819365c0f1f431a8","type":"GO_TERM","name":"heme export","canonical_id":"go:GO:0097037","description":"\"The directed movement of heme out of a cell or organelle.\" [GOC:lf, PMID:15369674, PMID:20610401]","metadata":null},{"id":"89724cd3784a4d1e865ce4b2420aaa1c","type":"GO_TERM","name":"heme export from vacuole to cytoplasm","canonical_id":"go:GO:0140357","description":"\"The directed movement of heme from inside the vacuole across the vacuolar membrane and into the cytosol.\" [PMID:28193844]","metadata":null},{"id":"6694da8e597f4e08a802bfc312eca2ea","type":"GO_TERM","name":"heme import across plasma membrane","canonical_id":"go:GO:1904334","description":"\"The directed movement of heme from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:25733668]","metadata":null},{"id":"8110add04a0842439fda9aed1fde219e","type":"GO_TERM","name":"heme import into cell","canonical_id":"go:GO:0140420","description":"\"The directed movement of a heme from outside of a cell into a cell. This may occur via transport across the plasma membrane or via endocytosis.\" [PMID:28193844]","metadata":null},{"id":"42b54c8f9c3a4388a01750b5407ee743","type":"GO_TERM","name":"heme metabolic process","canonical_id":"go:GO:0042168","description":"\"The chemical reactions and pathways involving heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.\" [GOC:jl, ISBN:0124325653]","metadata":null},{"id":"6cd04b37a93c4bffa75a8cfa9fdc8571","type":"GO_TERM","name":"heme oxidation","canonical_id":"go:GO:0006788","description":"\"The chemical reactions and pathways resulting in the loss of electrons from one or more atoms in heme.\" [GOC:mah]","metadata":null},{"id":"0704d1b97a6244d4b86351816f8699e3","type":"GO_TERM","name":"heme oxygenase (decyclizing) activity","canonical_id":"go:GO:0004392","description":"\"Catalysis of the reaction: heme b + 3 O2 + 3 reduced [NADPH-hemoprotein reductase] = biliverdin + CO + Fe2+ + H+ + 3 H2O + 3 oxidized [NADPH-hemoprotein reductase].\" [RHEA:21764]","metadata":null},{"id":"0d29c55f152e4f4184894ad55d34eed1","type":"GO_TERM","name":"heme receptor activity","canonical_id":"go:GO:0140488","description":"\"Binding specifically to heme to deliver it to a transport vesicle.\" [PMID:28193844, PMID:32185489]","metadata":null},{"id":"00fb1c8ca1d54635ac706352240ac609","type":"GO_TERM","name":"heme transmembrane transport","canonical_id":"go:GO:0035351","description":"\"The process in which heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"1b47145317f94e95920bf03795df90ed","type":"GO_TERM","name":"heme transmembrane transporter activity","canonical_id":"go:GO:0015232","description":"\"Enables the transfer of heme from one side of a membrane to the other.\" [PMID:29549126]","metadata":null},{"id":"ae92d54ac8b94d9c83a2751ecf59bc07","type":"GO_TERM","name":"heme transport","canonical_id":"go:GO:0015886","description":"\"The directed movement of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"145816b352d84b779c452b6333d971f8","type":"GO_TERM","name":"hemi-methylated DNA-binding","canonical_id":"go:GO:0044729","description":"\"Binding to double-stranded hemi-methylated DNA at replication foci (one strand methylated, while the other strand is unmethylated). Methylation of cytosine or adenine in DNA is an important mechanism for establishing stable heritable epigenetic marks.\" [GOC:imk, GOC:sp, PMID:18772889]","metadata":null},{"id":"3f20d4d25edf4343b4892925824d5d81","type":"GO_TERM","name":"hemicellulose catabolic process","canonical_id":"go:GO:2000895","description":"\"The chemical reactions and pathways resulting in the breakdown of a hemicellulose.\" [GOC:mengo_curators]","metadata":null},{"id":"db3fe6cbf815410db9ad4e8369d7dfd6","type":"GO_TERM","name":"hemicellulose network","canonical_id":"go:GO:0048223","description":"\"Network composed of hemicelluloses; members of a class of plant cell wall polysaccharide that cannot be extracted from the wall by hot water or chelating agents, but can be extracted by aqueous alkali. Includes xylan, glucuronoxylan, arabinoxylan, arabinogalactan II, glucomannan, xyloglucan and galactomannan.\" [DOI:10.1016/j.foodchem.2008.11.065, GOC:jid]","metadata":null},{"id":"e4a668bfa2f5490e8675738c0f74fbbc","type":"GO_TERM","name":"hemidesmosome","canonical_id":"go:GO:0030056","description":"\"A cell-substrate junction (attachment structure) found in epithelial cells that links intermediate filaments to extracellular matrices via transmembrane complexes. In vertebrates, hemidesmosomes mediate contact between the basal side of epithelial cells and the basal lamina. In C. elegans, hemidesmosomes connect epithelial cells to distinct extracellular matrices on both the apical and basal cell surfaces.\" [GOC:kmv, ISBN:0815316208, PMID:20205195]","metadata":null},{"id":"79d9bad4f1bc407f8aac01f7c58a07cf","type":"GO_TERM","name":"hemidesmosome assembly","canonical_id":"go:GO:0031581","description":"\"Assembly of hemidesmosomes, integrin-containing protein complexes that bind to laminin in the basal lamina. Hemidesmosomes form the contact between the basal surface of epithelial cells and the underlying basal lamina.\" [GOC:dgh, PMID:15983403]","metadata":null},{"id":"da2939c087da4572a2c9fe1ac67e1d37","type":"GO_TERM","name":"hemidesmosome associated protein complex","canonical_id":"go:GO:0098733","description":"\"Any protein complex that is part of or has some part in a hemidesmosome.\" [GOC:dos]","metadata":null},{"id":"443d247b5f464f34bf2c9cb71c4b17e3","type":"DRUG","name":"hemin","canonical_id":"mesh:D006427","description":null,"metadata":null},{"id":"120ed796d69b4df8a8a6a4f37af173db","type":"GO_TERM","name":"hemocyte development","canonical_id":"go:GO:0007516","description":"\"The process whose specific outcome is the progression of the hemocyte over time, from its formation to the mature structure. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"08a3731ede684f47a6ad7a886c404cf7","type":"GO_TERM","name":"hemocyte differentiation","canonical_id":"go:GO:0042386","description":"\"The process in which a relatively unspecialized cell acquires the characteristics of a mature hemocyte. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen.\" [CL:0000387, GOC:jl, GOC:mtg_sensu, PMID:9550723]","metadata":null},{"id":"29cff7e6bede4ecf8d71e0d1f42e4630","type":"GO_TERM","name":"hemocyte migration","canonical_id":"go:GO:0035099","description":"\"The directed movement of a hemocyte within the embryo. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen. In Drosophila, embryonic hemocytes originate from the head mesoderm as a cluster of cells. The cluster splits into two and one group of cells crosses the amnioserosa. Both populations then spread toward the middle of the embryo and then disperse evenly throughout the embryo.\" [GOC:bf, GOC:mtg_sensu, PMID:12885551]","metadata":null},{"id":"b8c5d8ebfa024068adb36ec107ab6daa","type":"GO_TERM","name":"hemocyte proliferation","canonical_id":"go:GO:0035172","description":"\"The multiplication or reproduction of hemocytes, resulting in the expansion of the cell population. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"07eaf361efe74527a5cccda4ffdc9706","type":"GO_TERM","name":"hemoglobin alpha binding","canonical_id":"go:GO:0031721","description":"\"Binding to a hemoglobin alpha chain.\" [GOC:mah]","metadata":null},{"id":"23df2d5bfec445c695b33865f508246e","type":"GO_TERM","name":"hemoglobin beta binding","canonical_id":"go:GO:0031722","description":"\"Binding to a hemoglobin beta chain.\" [GOC:mah]","metadata":null},{"id":"868a7b3cf6a24ffebdb8fef8a14f6e05","type":"GO_TERM","name":"hemoglobin binding","canonical_id":"go:GO:0030492","description":"\"Binding to hemoglobin, an oxygen carrying, conjugated protein containing four heme groups and globin.\" [GOC:jl]","metadata":null},{"id":"77340193280d4201b0f92713683bce9a","type":"GO_TERM","name":"hemoglobin biosynthetic process","canonical_id":"go:GO:0042541","description":"\"The chemical reactions and pathways resulting in the formation of hemoglobin, an oxygen carrying, conjugated protein containing four heme groups and globin.\" [GOC:jl]","metadata":null},{"id":"3bb4cedb205941d09a6399eb2125e14c","type":"GO_TERM","name":"hemoglobin catabolic process","canonical_id":"go:GO:0042540","description":"\"The chemical reactions and pathways resulting in the breakdown of hemoglobin, an oxygen carrying, conjugated protein containing four heme groups and globin; especially, the proteolytic cleavage of hemoglobin to yield free heme, peptides, and amino acids.\" [GOC:jl, GOC:mb]","metadata":null},{"id":"e8821827eece4e3f9aaa0ea5e71c5566","type":"GO_TERM","name":"hemoglobin complex","canonical_id":"go:GO:0005833","description":"\"An iron-containing, oxygen carrying complex. In vertebrates it is made up of two pairs of associated globin polypeptide chains, each chain carrying a noncovalently bound heme prosthetic group.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"585e310630e149abb2f9969ce3ce97b7","type":"GO_TERM","name":"hemoglobin metabolic process","canonical_id":"go:GO:0020027","description":"\"The chemical reactions and pathways involving hemoglobin, including its uptake and utilization.\" [GOC:curators, GOC:jl]","metadata":null},{"id":"16702d692dbd4d9284c0792df2ca1900","type":"GO_TERM","name":"hemolymph coagulation","canonical_id":"go:GO:0042381","description":"\"Any process in which factors in the hemolymph (the invertebrate equivalent of vertebrate blood and lymph) precipitate into insoluble clots in order to prevent loss of body fluid, and at the same time prevent the movement of microbes. Hemolymph coagulation is also part of the invertebrate humoral immune response.\" [GOC:jl, ISBN:0198506732, PMID:10561606, PMID:11915949]","metadata":null},{"id":"b12e6ad8e78e4f24a9cfc8acc087c000","type":"DISEASE","name":"hemolysis","canonical_id":"efo:0009473","description":null,"metadata":null},{"id":"1cacbff85728443397c06dc8485d2357","type":"GO_TERM","name":"hemolysis in another organism","canonical_id":"go:GO:0044179","description":"\"The cytolytic destruction of red blood cells, with the release of intracellular hemoglobin, in one organism by another.\" [GOC:jl, PMID:21590705]","metadata":null},{"id":"5521cdc87ed24b6cbce4cb0cedb54d8c","type":"DISEASE","name":"hemolytic anemia due to glutathione reductase deficiency","canonical_id":"mondo:0019531","description":null,"metadata":null},{"id":"8cac099fd1664b9b84a29a5428d07c94","type":"DISEASE","name":"hemolytic-uremic syndrome","canonical_id":"mondo:0001549","description":null,"metadata":null},{"id":"0feb1418ef0c4d15af05f89adc47a946","type":"DISEASE","name":"hemophilia","canonical_id":"mondo:0018660","description":null,"metadata":null},{"id":"86df8d91f2c243c28ca56388596eccc9","type":"DISEASE","name":"hemophilia A","canonical_id":"mondo:0010602","description":null,"metadata":null},{"id":"435c714526a14cd694b0a6e89aeba652","type":"DISEASE","name":"hemophilia B","canonical_id":"mondo:0010604","description":null,"metadata":null},{"id":"dcad023d93304fb794c5d19c0c091dde","type":"GO_TERM","name":"hemopoiesis","canonical_id":"go:GO:0030097","description":"\"The process whose specific outcome is the progression of the myeloid and lymphoid derived organ/tissue systems of the blood and other parts of the body over time, from formation to the mature structure. The site of hemopoiesis is variable during development, but occurs primarily in bone marrow or kidney in many adult vertebrates.\" [GOC:dgh, ISBN:0198506732]","metadata":null},{"id":"f8fd526881394ece88b0ff3383e82e33","type":"DISEASE","name":"hemorrhage","canonical_id":"mp:0001914","description":null,"metadata":null},{"id":"5c306bf0267d4c689f6b197b3e406964","type":"DISEASE","name":"hemorrhagic disease","canonical_id":"mondo:0002243","description":null,"metadata":null},{"id":"835cf221363c475d87735e7ccec447d9","type":"DISEASE","name":"hemorrhoid","canonical_id":"mondo:0004872","description":null,"metadata":null},{"id":"5a6fb4b6ed4947fd8be711e1b49ecf8d","type":"GO_TERM","name":"hemostasis","canonical_id":"go:GO:0007599","description":"\"The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.\" [ISBN:0198506732]","metadata":null},{"id":"34216e07a2ef481892d13b0c4c1ac692","type":"GO_TERM","name":"hemozoin formation complex","canonical_id":"go:GO:0160092","description":"\"A protein-containing complex involved in hemoglobin degradation and detoxification of heme in the food vacuole during the asexual blood stage of a Plasmodium. It is composed of at least falcipains FP2A and/or FP2B, plasmepsins PMII, PMIII/HAP and PMIV, heme detoxifying protein HDP and falcilysin FLN.\" [PMID:23471987]","metadata":null},{"id":"c13cea81b7ac41cbb71aeefa195e019f","type":"GO_TERM","name":"heparan sulfate 2-sulfotransferase activity","canonical_id":"go:GO:0004394","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + heparan sulfate = adenosine 3',5'-bisphosphate + heparan sulfate 2-O-sulfate; results in 2-O-sulfation of iduronic acid residues in heparan sulfate.\" [PMID:9153262]","metadata":null},{"id":"57c7161f91bc4f7e90b4cb6a5f1429b6","type":"GO_TERM","name":"heparan sulfate 6-sulfotransferase activity","canonical_id":"go:GO:0017095","description":"\"Catalysis of the reaction: alpha-D-glucosaminyl-[heparan sulfate](n) + 3'-phosphoadenylyl sulfate = 6-sulfo-alpha-D-glucosaminyl-[heparan sulfate](n) + adenosine 3',5'-bisphosphate + H+.\" [PMID:8631808, RHEA:56604]","metadata":null},{"id":"3b23b67fdb6f41a3a44a7a38cf0300f8","type":"GO_TERM","name":"heparan sulfate N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0042328","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + heparan sulfate = UDP + (N-acetyl-D-glucosaminyl)-heparan sulfate.\" [GOC:ma]","metadata":null},{"id":"e4f48a47845c4fd1ba609d4ccbb5b5ca","type":"GO_TERM","name":"heparan sulfate N-deacetylase activity","canonical_id":"go:GO:0102140","description":"\"Catalysis of the reaction: H2O + [heparan sulfate]-N-acetyl-alpha-D-glucosamine = acetate + H+ + [heparan sulfate]-alpha-D-glucosamine.\" [RHEA:70587]","metadata":null},{"id":"092e88aabced4de98a1c646cc3a59b3d","type":"GO_TERM","name":"heparan sulfate N-sulfotransferase activity","canonical_id":"go:GO:0015016","description":"\"Catalysis of the reaction: 3'-phosphoadenylyl sulfate + alpha-D-glucosaminyl-[heparan sulfate](n) = adenosine 3',5'-bisphosphate + 2 H+ + N-sulfo-alpha-D-glucosaminyl-[heparan sulfate](n).\" [EC:2.8.2.8, RHEA:21980]","metadata":null},{"id":"a3d2ee4f204841f4bcd21d96c60c5aa1","type":"GO_TERM","name":"heparan sulfate binding","canonical_id":"go:GO:1904399","description":"\"Binding to heparan sulfate.\" [GO_REF:0000067, GOC:TermGenie, PMID:8567685]","metadata":null},{"id":"2c0b38124e3c45ff9a5bf1082c4fa2b0","type":"GO_TERM","name":"heparan sulfate proteoglycan binding","canonical_id":"go:GO:0043395","description":"\"Binding to a heparan sulfate proteoglycan, any proteoglycan containing heparan sulfate as the glycosaminoglycan carbohydrate unit.\" [ISBN:0198506732]","metadata":null},{"id":"b093f1b0e26b4057bbec62e3c56269fd","type":"GO_TERM","name":"heparan sulfate proteoglycan biosynthetic process","canonical_id":"go:GO:0015012","description":"\"The chemical reactions and pathways resulting in the formation of heparan sulfate proteoglycans, which consist of a core protein linked to a heparan sulfate glycosaminoglycan. The heparan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid, the former being either sulfated or deacetylated on its amino group as well as sulfated on one of its hydroxyl groups, and the latter being e a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids. Heparan sulfate chains are covalently linked to serine/threonine residues (O-linked) of the core protein via a tetrasaccharide linker sequence (xylose-galactose-galactose-glucuronate).\" [PMID:27241222]","metadata":null},{"id":"1f21215bc5044ad18deeb91f288ab4f3","type":"GO_TERM","name":"heparan sulfate proteoglycan catabolic process","canonical_id":"go:GO:0030200","description":"\"The chemical reactions and pathways resulting in the breakdown of heparan sulfate proteoglycans, which consist of a core protein linked to a heparan sulfate glycosaminoglycan. The heparan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid, the former being either sulfated or deacetylated on its amino group as well as sulfated on one of its hydroxyl groups, and the latter being a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids.\" [PMID:35536982]","metadata":null},{"id":"a597bf35bb2e43089c80aa6393467cf9","type":"GO_TERM","name":"heparan sulfate proteoglycan metabolic process","canonical_id":"go:GO:0030201","description":"\"The chemical reactions and pathways involving heparan sulfate proteoglycans, which consist of a core protein linked to a heparan sulfate glycosaminoglycan. The heparan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid, the former being either sulfated or deacetylated on its amino group as well as sulfated on one of its hydroxyl groups, and the latter being a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids.\" [PMID:27241222]","metadata":null},{"id":"54c8185a1c914ac19c1d58d85a193e70","type":"GO_TERM","name":"heparan sulfate sulfotransferase activity","canonical_id":"go:GO:0034483","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + heparan sulfate = adenosine 3',5'-bisphosphate + sulfated heparan sulfate.\" [GOC:mah]","metadata":null},{"id":"f10fc1f085c34100ba374ca1f5e758ed","type":"GO_TERM","name":"heparan-alpha-glucosaminide N-acetyltransferase activity","canonical_id":"go:GO:0015019","description":"\"Catalysis of the reaction: alpha-D-glucosaminyl-[heparan sulfate](n) + acetyl-CoA = N-acetyl-alpha-D-glucosaminyl-[heparan sulfate](n) + CoA + H+.\" [RHEA:15125]","metadata":null},{"id":"7582d892ef62473e83841f4eeb377ba7","type":"GO_TERM","name":"heparanase activity","canonical_id":"go:GO:0030305","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-glycosidic bonds of heparan sulfate chains in heparan sulfate proteoglycan.\" [EC:3.2.1.166, PMID:10916150]","metadata":null},{"id":"fa456c3c2010407996d9163fd7ee3c2d","type":"GO_TERM","name":"heparanase complex","canonical_id":"go:GO:1904974","description":"\"A protein complex which is capable of heparanase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:12927802]","metadata":null},{"id":"fb89333f6d8849db8a0b1f02127084c1","type":"DRUG","name":"heparin","canonical_id":"gtopdb:4214","description":null,"metadata":null},{"id":"a547a40a2cdd4b8ea5815cfb77e4b853","type":"DRUG","name":"heparin","canonical_id":"chembl:CHEMBL4650299","description":null,"metadata":null},{"id":"4e3b972efa884158aad6c528939b3109","type":"COMBINATION_TREATMENT","name":"heparin + lidocaine","canonical_id":"ctgov_combo:ctgov-combo-eb615d413c00b395","description":null,"metadata":null},{"id":"04103009d74a48f4945c2ffdd227f2c3","type":"COMBINATION_TREATMENT","name":"heparin + nafamostat","canonical_id":"ctgov_combo:ctgov-combo-20c2faf2c1e39962","description":null,"metadata":null},{"id":"e389f366e7b64e4ea9314043e216db41","type":"COMBINATION_TREATMENT","name":"heparin + rivaroxaban","canonical_id":"ctgov_combo:ctgov-combo-0ca4f4a1c9fd0ddd","description":null,"metadata":null},{"id":"6303369e84574f3f98cbd747ee12aa61","type":"GO_TERM","name":"heparin binding","canonical_id":"go:GO:0008201","description":"\"Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"c13c098fe1b84868a9bd5b358bed9066","type":"GO_TERM","name":"heparin lyase activity","canonical_id":"go:GO:0047488","description":"\"Catalysis of the eliminative cleavage of polysaccharides containing 1,4-linked D-glucuronate or L-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-D-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-D-gluc-4-enuronosyl groups at their nonreducing ends.\" [EC:4.2.2.7, MetaCyc:4.2.2.7-RXN]","metadata":null},{"id":"0d0423398ef2433a97af21866c3051a5","type":"GO_TERM","name":"heparin proteoglycan biosynthetic process","canonical_id":"go:GO:0030210","description":"\"The chemical reactions and pathways resulting in the formation of heparin proteoglycans, which consist of a core protein linked to a heparin glycosaminoglycan. The heparin chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid, the former being either sulfated or deacetylated on its amino group as well as sulfated on one of its hydroxyl groups, and the latter being a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids. Heparin is similar to heparan sulfate but it contains more N-sulfate and O-sulfate groups. Heparin chains are covalently linked to serine/threonine residues (O-linked) of the core protein via a tetrasaccharide linker sequence (xylose-galactose-galactose-glucuronate).\" [PMID:22566225]","metadata":null},{"id":"c031d80908ba4fd78550f3e643370d54","type":"GO_TERM","name":"heparin proteoglycan catabolic process","canonical_id":"go:GO:0030211","description":"\"The chemical reactions and pathways resulting in the breakdown of heparin proteoglycans, which consist of a core protein linked to a heparin glycosaminoglycan. The heparin chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid, the former being either sulfated or deacetylated on its amino group as well as sulfated on one of its hydroxyl groups and the latter being a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids. Heparin is similar to heparan sulfate but it contains more N-sulfate and O-sulfate groups.\" [PMID:35536982]","metadata":null},{"id":"a4ae6d3bde4347ec8bfadd4ac999e474","type":"GO_TERM","name":"heparin proteoglycan metabolic process","canonical_id":"go:GO:0030202","description":"\"The chemical reactions and pathways involving heparin proteoglycans, which consist of a core protein linked to a heparin glycosaminoglycan. The heparin chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid, the former being either sulfated or deacetylated on its amino group as well as sulfated on one of its hydroxyl groups, and the latter being e a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids. Heparin is similar to heparan sulfate but it contains more N-sulfate and O-sulfate groups. Heparin proteoglycans are stored selectively in the secretory granules of mammalian mast cells.\" [PMID:22566225]","metadata":null},{"id":"f38bfc68848f49aaaa141eeecc56741d","type":"GO_TERM","name":"heparin-sulfate lyase activity","canonical_id":"go:GO:0015021","description":"\"Catalysis of the elimination of sulfate; appears to act on linkages between N-acetyl-D-glucosamine and uronate. Product is an unsaturated sugar.\" [EC:4.2.2.8]","metadata":null},{"id":"e8f43332877c424a8870cec4006d107d","type":"GO_TERM","name":"heparosan-N-sulfate-glucuronate 5-epimerase activity","canonical_id":"go:GO:0047464","description":"\"Catalysis of the reaction: (heparosan-N-sulfate)(n) = (heparan-N-sulfate)(n). Converts D-glucosyluronate residues to L-iduronate residues.\" [EC:5.1.3.17, MetaCyc:5.1.3.17-RXN]","metadata":null},{"id":"dba497d921154cf7899bb4f41c0ee7b9","type":"GO_TERM","name":"hepatic duct development","canonical_id":"go:GO:0061011","description":"\"The progression of the hepatic duct over time, from its formation to the mature structure. The hepatic duct is the duct that leads from the liver to the common bile duct.\" [GOC:dph, PMID:20614624]","metadata":null},{"id":"3f3e07d88063400d8520b4f0bb56ff3a","type":"GO_TERM","name":"hepatic immune response","canonical_id":"go:GO:0002384","description":"\"An immune response taking place in the liver.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"20b9341216784c1bae9c3e9524e10c19","type":"GO_TERM","name":"hepatic stellate cell activation","canonical_id":"go:GO:0035733","description":"\"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.\" [CL:0000632, GOC:bf]","metadata":null},{"id":"3211eeb9a9194aed89c4c3c0a24d7a2d","type":"GO_TERM","name":"hepatic stellate cell contraction","canonical_id":"go:GO:0061872","description":"\"The actin filament-based process in which cytoplasmic actin filaments slide past one another resulting in contraction of a hepatic stellate cell.\" [PMID:24204762]","metadata":null},{"id":"d69d3f089fa347eabf2616df7fbd3349","type":"GO_TERM","name":"hepatic stellate cell differentiation","canonical_id":"go:GO:0061521","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a hepatic stellate cell.\" [GOC:dph, PMID:9407545]","metadata":null},{"id":"e9964ba23a2d45a18cf6aee3efc15ce8","type":"GO_TERM","name":"hepatic stellate cell migration","canonical_id":"go:GO:0061868","description":"\"The orderly movement of a hepatic stellate cell from one site to another.\" [PMID:24204762]","metadata":null},{"id":"1d012a223fd647ef873df1b8e9d81719","type":"GO_TERM","name":"hepatic stellate cell proliferation","canonical_id":"go:GO:1990922","description":"\"The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver.\" [GOC:sl, PMID:15358192, PMID:18466260]","metadata":null},{"id":"d802dcf1223b407ea66f0ef3da320e55","type":"DISEASE","name":"hepatic veno-occlusive disease","canonical_id":"mondo:0019514","description":null,"metadata":null},{"id":"2629682b0f1d4e77810e6b835d438e35","type":"GO_TERM","name":"hepaticobiliary system development","canonical_id":"go:GO:0061008","description":"\"The progression of the hepaticobiliary system over time, from its formation to the mature structure. The hepaticobiliary system is responsible for metabolic and catabolic processing of small molecules absorbed from the blood or gut, hormones and serum proteins, detoxification, storage of glycogen, triglycerides, metals and lipid soluble vitamins and excretion of bile. Included are the synthesis of albumin, blood coagulation factors, complement, and specific binding proteins.\" [GOC:dph]","metadata":null},{"id":"631f5ac096c247f7b4b197ad52df6345","type":"GO_TERM","name":"hepaticobiliary system process","canonical_id":"go:GO:0061007","description":"\"A system process carried out by any of the organs or tissues of the hepaticobiliary system. The hepaticobiliary system is responsible for metabolic and catabolic processing of small molecules absorbed from the blood or gut, hormones and serum proteins, detoxification, storage of glycogen, triglycerides, metals and lipid soluble vitamins and excretion of bile. Included are the synthesis of albumin, blood coagulation factors, complement, and specific binding proteins.\" [GOC:dph]","metadata":null},{"id":"726008006a7843969f93a4d4b4511375","type":"DISEASE","name":"hepatitis B virus infection","canonical_id":"mondo:0005344","description":null,"metadata":null},{"id":"cd200449f50648e48374be5e8ad34802","type":"DISEASE","name":"hepatitis C virus infection","canonical_id":"mondo:0005231","description":null,"metadata":null},{"id":"b512efd6040745d88ad8457909014f4f","type":"GO_TERM","name":"hepatoblast apoptotic process","canonical_id":"go:GO:1902489","description":"\"Any apoptotic process in a hepatoblast.\" [GOC:TermGenie, PMID:22412967]","metadata":null},{"id":"43f40e8993de4e13a4c167b4d074415b","type":"GO_TERM","name":"hepatoblast differentiation","canonical_id":"go:GO:0061017","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a hepatoblast. A hepatoblast is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into hepatocytes and cholangiocytes.\" [GOC:dph, PMID:15226394]","metadata":null},{"id":"6fc712572ea043df85b19063635b7637","type":"DISEASE","name":"hepatocellular carcinoma","canonical_id":"mondo:0007256","description":null,"metadata":null},{"id":"2e2c40ea46b94f46beeb47e471da6f84","type":"GO_TERM","name":"hepatocyte apoptotic process","canonical_id":"go:GO:0097284","description":"\"Any apoptotic process in a hepatocyte, the main structural component of the liver.\" [CL:0000182, GOC:jc, GOC:mtg_apoptosis, PMID:15856020]","metadata":null},{"id":"2834631ff8f34b4ab8d66287c16e4a8c","type":"GO_TERM","name":"hepatocyte cell migration","canonical_id":"go:GO:0002194","description":"\"The orderly movement of a hepatocyte during the development of the liver. Hepatocytes emerge from the hepatic epithelium, populating the septum transversum and lateral mesenchymal areas of the hepatic lobes.\" [CL:0000182, PMID:9794819]","metadata":null},{"id":"7beebfa7599e4eae8b7e3fa7f769601c","type":"GO_TERM","name":"hepatocyte dedifferentiation","canonical_id":"go:GO:1990828","description":"\"The process in which a hepatocyte (specialized epithelial cell of the liver) loses the structural or functional features that characterize it in the mature organism, or some other relatively stable phase of the organism's life history. Under certain conditions, these cells can revert back to the features of the stem cells that were their ancestors.\" [PMID:20102719]","metadata":null},{"id":"0f7f8d26e69c43ceae663430015e7c19","type":"GO_TERM","name":"hepatocyte differentiation","canonical_id":"go:GO:0070365","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a hepatocyte. A hepatocyte is specialized epithelial cell that is organized into interconnected plates called lobules, and is the main structural component of the liver.\" [CL:0000182, PMID:7588884]","metadata":null},{"id":"cd4e75c90f90413089a9adb2e101d2ac","type":"GO_TERM","name":"hepatocyte growth factor binding","canonical_id":"go:GO:0036458","description":"\"Binding to a hepatocyte growth factor.\" [GOC:curators]","metadata":null},{"id":"baf003bbcf6246ff9bd107557d8bc58d","type":"GO_TERM","name":"hepatocyte growth factor production","canonical_id":"go:GO:0032605","description":"\"The appearance of hepatocyte growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:1838014]","metadata":null},{"id":"85d17c0522f24b63ad58172f0e7697e0","type":"GO_TERM","name":"hepatocyte growth factor receptor activity","canonical_id":"go:GO:0005008","description":"\"Combining with hepatocyte growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"3479feef16a142ca94d2497716954a91","type":"GO_TERM","name":"hepatocyte growth factor receptor binding","canonical_id":"go:GO:0005171","description":"\"Binding to an hepatocyte growth factor receptor.\" [GOC:ai]","metadata":null},{"id":"74c366a98e27443084a28d6130fe8d7f","type":"GO_TERM","name":"hepatocyte growth factor receptor signaling pathway","canonical_id":"go:GO:0048012","description":"\"The series of molecular signals initiated by a ligand binding to a hepatocyte growth factor receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb]","metadata":null},{"id":"b94d4a62ec5d43259d9613312f069da6","type":"GO_TERM","name":"hepatocyte homeostasis","canonical_id":"go:GO:0036333","description":"\"Any biological process involved in the maintenance of the steady-state number of hepatocytes within a population of cells. Hepatocytes are specialized epithelial cells of the liver that are organized into interconnected plates called lobules.\" [CL:0000182, GOC:nhn, PMID:19878874]","metadata":null},{"id":"9ac09715301743758873581828d863af","type":"GO_TERM","name":"hepatocyte proliferation","canonical_id":"go:GO:0072574","description":"\"The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.\" [CL:0000182, GOC:BHF, GOC:mah]","metadata":null},{"id":"ff747c9691794613ac768935f37177f0","type":"DISEASE","name":"hepatorenal syndrome","canonical_id":"mondo:0001382","description":null,"metadata":null},{"id":"95057bd1ddfb4bb6be4971b9ad834342","type":"GO_TERM","name":"hepoxilin biosynthetic process","canonical_id":"go:GO:0051122","description":"\"The chemical reactions and pathways resulting in the formation of hepoxilins, a class of bioactive icosanoids with roles in the regulation of cell physiology.\" [GOC:ai]","metadata":null},{"id":"ccc44dab837940ecae137310228aa2a2","type":"GO_TERM","name":"hepoxilin-epoxide hydrolase activity","canonical_id":"go:GO:0047977","description":"\"Catalysis of the reaction: (5Z,9E,14Z)-(8x,11R,12S)-11,12-epoxy-8-hydroxyicosa-5,9,14-trienoate + H2O = (5Z,9E,14Z)-(8x,11x,12S)-8,11,12-trihydroxyicosa-5,9,14-trienoate.\" [EC:3.3.2.7, MetaCyc:HEPOXILIN-EPOXIDE-HYDROLASE-RXN]","metadata":null},{"id":"6a4d8676144a42eaa7ed4f6ac7fe062f","type":"GO_TERM","name":"heptadec-1-ene biosynthetic process","canonical_id":"go:GO:1900875","description":"\"The chemical reactions and pathways resulting in the formation of heptadec-1-ene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"5fadb3e746204fa6a82c77766f01e3cb","type":"GO_TERM","name":"heptadecane biosynthetic process","canonical_id":"go:GO:1900636","description":"\"The chemical reactions and pathways resulting in the formation of heptadecane.\" [GOC:mengo_curators, GOC:TermGenie, MetaCyc:PWY-6622]","metadata":null},{"id":"76bf18525c0d440ca8580c5e9c0a8220","type":"GO_TERM","name":"heptaprenyl diphosphate synthase activity","canonical_id":"go:GO:0000010","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + 4 isopentenyl diphosphate = 4 diphosphate + all-trans-heptaprenyl diphosphate.\" [PMID:9708911, RHEA:27794]","metadata":null},{"id":"a85a3c5e93f647dd9b1628c74fee2623","type":"GO_TERM","name":"heptaprenylglyceryl phosphate synthase activity","canonical_id":"go:GO:0120536","description":"\"Catalysis of the reaction: sn-glycerol 1-phosphate + all-trans-heptaprenyl diphosphate = 3-heptaprenyl-sn-glycero-1-phosphate + diphosphate.\" [PMID:21761520, RHEA:33495]","metadata":null},{"id":"452c860e801b4cea8f774c3ca1957f40","type":"GO_TERM","name":"heptasaccharide transport","canonical_id":"go:GO:2001104","description":"\"The directed movement of a heptasaccharideacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"f08ddcb80f304f5d85f5be6a7db00149","type":"GO_TERM","name":"heptose 7-phosphate kinase activity","canonical_id":"go:GO:0033785","description":"\"Catalysis of the reaction: D-alpha,beta-D-heptose-7-phosphate + ATP = D-beta-D-heptose-1,7-bisphosphate + ADP.\" [RHEA:27473]","metadata":null},{"id":"759b29be1b5a49e3a9de0f254d3734ef","type":"GO_TERM","name":"heptose-1-phosphate adenylyltransferase activity","canonical_id":"go:GO:0033786","description":"\"Catalysis of the reaction: D-beta-D-heptose-1-phosphate + ATP = ADP-D-glycero-D-manno-heptose.\" [MetaCyc:RXN0-4342]","metadata":null},{"id":"2bd441043ec0405ea334333af22abac4","type":"GO_TERM","name":"hercynylcysteine sulfoxide lyase activity (ergothioneine-forming)","canonical_id":"go:GO:1990411","description":"\"Catalysis of the reaction: hercynylcysteine sulfoxide + 2H+ = ergothioneine + pyruvate + ammonium.\" [PMID:24828577]","metadata":null},{"id":"0cad538b6b51428881b0d7f1b48ccc7e","type":"GO_TERM","name":"hercynylcysteine sulfoxide synthase activity","canonical_id":"go:GO:0061686","description":"\"Catalysis of the reaction: L-cysteine + N-alpha,N-alpha,N-alpha-trimethyl-L-histidine (hercynine) + O2 = hercynylcysteine sulfoxide + H2O.\" [GOC:dph, PMID:24828577, PMID:4276459, RHEA:42704]","metadata":null},{"id":"8b6d0cc6151a476c8acebe5f63d44437","type":"DISEASE","name":"hereditary angioedema","canonical_id":"mondo:0019623","description":null,"metadata":null},{"id":"6638c02772d6448f8ed23ce36962340b","type":"DISEASE","name":"hereditary angioneurotic edema","canonical_id":"mesh:D054179","description":null,"metadata":null},{"id":"ac5cfacd140842b3be3ac9f8911f6050","type":"DISEASE","name":"hereditary antithrombin deficiency","canonical_id":"mondo:0013144","description":null,"metadata":null},{"id":"87a3f23d409245c8825cd65920603621","type":"DISEASE","name":"hereditary chronic pancreatitis","canonical_id":"mondo:0008185","description":null,"metadata":null},{"id":"cc9f85a1fd214f9098bafae55de8bf94","type":"DISEASE","name":"hereditary disease","canonical_id":"mondo:0003847","description":null,"metadata":null},{"id":"5008982572f04414b072f6255a9e16b3","type":"DISEASE","name":"hereditary hemorrhagic telangiectasia","canonical_id":"mondo:0019180","description":null,"metadata":null},{"id":"c4182ec53b454c33b818dd1aedd09d43","type":"DISEASE","name":"hereditary neoplastic syndrome","canonical_id":"mondo:0015356","description":null,"metadata":null},{"id":"3f0f86935b8f40d7b04f940a9d1e753d","type":"DISEASE","name":"hereditary neutrophilia","canonical_id":"mondo:0008092","description":null,"metadata":null},{"id":"1c02e97e5e0b4c2a94b4ad1f54f768d1","type":"DISEASE","name":"hereditary palmoplantar keratoderma","canonical_id":"mondo:0019272","description":null,"metadata":null},{"id":"c09d86c4dd274dc78e32294d753bfb4a","type":"DISEASE","name":"hereditary pheochromocytoma-paraganglioma","canonical_id":"mondo:0017366","description":null,"metadata":null},{"id":"a6e24259815e4b20a6ebf3dee1486995","type":"DISEASE","name":"hereditary renal hypouricemia","canonical_id":"mondo:0009071","description":null,"metadata":null},{"id":"6758c296062b433b8a6060f00ab51a01","type":"DISEASE","name":"hereditary sensory and autonomic neuropathy type 2","canonical_id":"mondo:0019941","description":null,"metadata":null},{"id":"fab358d3637648219c356c9594e921b0","type":"GO_TERM","name":"hermaphrodite germ-line sex determination","canonical_id":"go:GO:0040021","description":"\"The determination of sex and sexual phenotype in the germ line of a hermaphrodite.\" [GOC:ems]","metadata":null},{"id":"a2fb91fd582e4cf582cf50d1287355f6","type":"GO_TERM","name":"hermaphrodite somatic sex determination","canonical_id":"go:GO:0042001","description":"\"The determination of sex and sexual phenotypes in a hermaphroditic organism's soma. An example of this is found in Caenorhabditis elegans.\" [GOC:ems]","metadata":null},{"id":"99959fdf386b440e963b1f433503d611","type":"DISEASE","name":"herpes labialis","canonical_id":"mondo:0043653","description":null,"metadata":null},{"id":"30225eeb098746c4a3c4aba93522b671","type":"DISEASE","name":"herpes simplex infectious disease","canonical_id":"mondo:0004609","description":null,"metadata":null},{"id":"dd0934ff6a2041d6bfddcdcee667aa25","type":"GO_TERM","name":"heterochromatin","canonical_id":"go:GO:0000792","description":"\"A compact and highly condensed form of chromatin that is refractory to transcription.\" [PMID:32017156]","metadata":null},{"id":"8c5913655f9c4cce9080236438bf18d6","type":"GO_TERM","name":"heterochromatin boundary formation","canonical_id":"go:GO:0033696","description":"\"A process that forms a boundary that limits the spreading of heterochromatin along a chromosome.\" [GOC:mah]","metadata":null},{"id":"dd7264c5ddd74fe6bef1bb8be2d73663","type":"GO_TERM","name":"heterochromatin domain","canonical_id":"go:GO:1990343","description":"\"A region of heterochromatin that is formed dynamically under specific growth conditions by a process that requires RNAi, and is enriched in histone H3 methylated on lysine 9 (H3K9me).\" [PMID:23151475, PMID:24210919]","metadata":null},{"id":"2bf0834d679e49d89ffca970fcece1cd","type":"GO_TERM","name":"heterochromatin formation","canonical_id":"go:GO:0031507","description":"\"An epigenetic gene silencing mechanism in which chromatin is compacted into heterochromatin, resulting in a chromatin conformation refractory to transcription. This process starts with heterochromatin nucleation, its spreading, and ends with heterochromatin boundary formation.\" [PMID:25192661, PMID:33827924]","metadata":null},{"id":"12b7e57142b0431ba67efa4ed82e9101","type":"GO_TERM","name":"heterochromatin island","canonical_id":"go:GO:1990342","description":"\"A region of facultative heterochromatin formed dynamically at specific loci in response to environmental signals, independently of RNAi.\" [PMID:22144463, PMID:24210919]","metadata":null},{"id":"2c10f455952e4d9aaa113ba68ecc55a8","type":"GO_TERM","name":"heterochromatin organization","canonical_id":"go:GO:0070828","description":"\"Any process that results in the specification, formation or maintenance of the physical structure of eukaryotic heterochromatin, a compact and highly condensed form of chromatin.\" [GOC:mah]","metadata":null},{"id":"027646abb80b46899c1844eb57bbc2fa","type":"GO_TERM","name":"heterochromatin-nuclear membrane anchor activity","canonical_id":"go:GO:0062239","description":"\"Binding to heterochromatin and the nuclear inner membrane, in order to establish and maintain the heterochromatin location and organization.\" [PMID:31635174]","metadata":null},{"id":"5e51c5da0446467eadcfd6c4f3b076f1","type":"GO_TERM","name":"heterocyclic compound binding","canonical_id":"go:GO:1901363","description":"\"Binding to heterocyclic compound.\" [GOC:TermGenie]","metadata":null},{"id":"0b1e36a1acc94ab79102f5c32b11af4b","type":"GO_TERM","name":"heterocyst development","canonical_id":"go:GO:0043158","description":"\"The cellular developmental process by which a cell becomes a heterocyst, a cell that carries out nitrogen fixation. This process involves changes to the cell wall, expression of nitrogenase and other proteins involved in nitrogen fixation, and degradation of photosystem II, which produces oxygen. This process is known to occur in some cyanobacteria.\" [PMID:11121783, PMID:35744626]","metadata":null},{"id":"90a599c3b40b45f5bd893ccb01dfad3f","type":"GO_TERM","name":"heteroduplex DNA loop binding","canonical_id":"go:GO:0000404","description":"\"Binding to a DNA segment containing a loop. A loop occurs when DNA contains a large insertion or deletion that causes a region of unpaired single-stranded DNA to loop out, while the rest of the DNA is in a paired double-stranded configuration.\" [GOC:elh, PMID:16781730]","metadata":null},{"id":"032b9bf8f06f4ae4aaa3e70abd249f6d","type":"GO_TERM","name":"heteroduplex formation","canonical_id":"go:GO:0030491","description":"\"The formation of a stable duplex DNA that contains one strand from each of the two recombining DNA molecules.\" [GOC:elh, PMID:10357855]","metadata":null},{"id":"54393b06793e417686a17b07ee1ccc34","type":"GO_TERM","name":"heteroduplex formation involved in double-strand break repair via synthesis-dependent strand annealing","canonical_id":"go:GO:0010709","description":"\"The formation of a stable duplex DNA that contains one strand from each of the two recombining DNA molecules resulting in the error-free repair of a double-strand break without the exchange of adjacent sequences.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"00742d9415624950b8878609512f8271","type":"GO_TERM","name":"heteroglycan alpha-mannosyltransferase activity","canonical_id":"go:GO:0047264","description":"\"Catalysis of the reaction: heteroglycan + GDP-mannose = alpha-D-mannosylheteroglycan + GDP. 1,2- and 1,3-mannosyl bonds are formed.\" [EC:2.4.1.48]","metadata":null},{"id":"cd747cc5e34d4627baa15bf8e9c4405d","type":"GO_TERM","name":"heteromeric SMAD protein complex","canonical_id":"go:GO:0071144","description":"\"A protein complex composed of SMAD family proteins, a transcription factor complex which binds to the promoters of target genes and recruits co-activators and histone acetyltransferases, facilitating transcription. Phosphorylation of the non-SMAD4 subunit(s) enables binding of SMAD4 to form heteromeric complexes that enter the nucleus to initiate gene transcription. DNA-binding specificity is conferred by other transcription factors binding to SMAD complexes. Interactions with coactivators or corepressors modulate their transcriptional activity. Can be heterotrimeric or heterodimeric.\" [GOC:bhm, GOC:mah, PMID:11779505, PMID:15350224, PMID:16322555, PMID:9389648, PMID:9670020]","metadata":null},{"id":"04cfa8a3a1554ff5bd22283bb074d749","type":"GO_TERM","name":"heterophilic cell-cell adhesion","canonical_id":"go:GO:0007157","description":"\"The attachment of an adhesion molecule in one cell to a nonidentical adhesion molecule in an adjacent cell.\" [ISBN:0198506732]","metadata":null},{"id":"d29ea7c57193418ba281681c75c7ae3c","type":"GO_TERM","name":"heteropolysaccharide binding","canonical_id":"go:GO:0010297","description":"\"Binding to a heteropolysaccharide, a glycan composed of more than one type of monosaccharide residue.\" [PMID:16640603]","metadata":null},{"id":"5dca9b88835e4327a7823af872198203","type":"GO_TERM","name":"heterotetrameric ADPG pyrophosphorylase complex","canonical_id":"go:GO:0030931","description":"\"A protein complex composed of four different subunits that possesses ADPG pyrophosphorylase activity. An example of this process is found in Mus musculus.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"2a1e26ee2e2e440a89650110c9cc3752","type":"GO_TERM","name":"heterotetrameric polyprenyl diphosphate synthase complex","canonical_id":"go:GO:0032478","description":"\"A heterotetrameric complex located in the mitochondrial inner membrane that possesses polyprenyl diphosphate synthase activity involved in the synthesis of the isoprenoid chain of ubiquinone whose length varies between organisms. In S. pombe it is a heterotetramer of Dlp1 and Dps1.\" [PMID:14519123, PMID:16262699]","metadata":null},{"id":"e09c88f6f9f242d3b825ac0983f57b4f","type":"GO_TERM","name":"heterotrimeric G-protein binding","canonical_id":"go:GO:0032795","description":"\"Binding to a heterotrimeric G-protein.\" [GOC:nln]","metadata":null},{"id":"c2e2e18110954bde8100ddc88adb1193","type":"GO_TERM","name":"heterotrimeric G-protein complex","canonical_id":"go:GO:0005834","description":"\"Any of a family of heterotrimeric GTP-binding and hydrolyzing proteins; they belong to a superfamily of GTPases that includes monomeric proteins such as EF-Tu and RAS. Heterotrimeric G-proteins consist of three subunits; the alpha subunit contains the guanine nucleotide binding site and possesses GTPase activity; the beta and gamma subunits are tightly associated and function as a beta-gamma heterodimer; extrinsic plasma membrane proteins (cytoplasmic face) that function as a complex to transduce signals from G protein-coupled receptors to an effector protein.\" [ISBN:0198547684]","metadata":null},{"id":"89c23ee5f79c4b97835ccbbff5763c72","type":"GO_TERM","name":"heterotrimeric G-protein complex assembly","canonical_id":"go:GO:1902605","description":"\"The aggregation, arrangement and bonding together of a set of components to form a heterotrimeric G-protein complex.\" [GO_REF:0000079, GOC:dph, GOC:TermGenie, PMID:23637185]","metadata":null},{"id":"3590b8bcb3f5463fad63abf52d3cc7bf","type":"GO_TERM","name":"heterotypic cell-cell adhesion","canonical_id":"go:GO:0034113","description":"\"The attachment of a cell to a cell of a different type via adhesion molecules.\" [GOC:add]","metadata":null},{"id":"3353afd4ad5d424288e082155631707b","type":"GO_TERM","name":"hexachlorocyclohexane metabolic process","canonical_id":"go:GO:0019497","description":"\"The chemical reactions and pathways involving hexachlorocyclohexane, a cyclohexane derivative with 6 chlorine atoms attached to the hexane ring. Hexachlorocyclohexane consists of a mixture of 8 different isomers and was used a commercial insecticide. It is persistent in the environment, causing serious soil pollution.\" [UM-BBD_pathwayID:ghch, UM-BBD_pathwayID:hch]","metadata":null},{"id":"f3e2fdbfdca44709a9687b97a45ed70e","type":"GO_TERM","name":"hexadecanal biosynthetic process","canonical_id":"go:GO:0006634","description":"\"The chemical reactions and pathways resulting in the formation of hexadecanal, the C16 straight chain aldehyde.\" [https://en.wikipedia.org/wiki/Hexadecanal]","metadata":null},{"id":"936591b6759f45d7bdaf11466fcd12ca","type":"GO_TERM","name":"hexadecanal dehydrogenase (acylating) activity","canonical_id":"go:GO:0047104","description":"\"Catalysis of the reaction: CoA + NAD+ + palmitaldehyde = H+ + NADH + palmitoyl-CoA.\" [EC:1.2.1.42, RHEA:19705]","metadata":null},{"id":"904037c7ee5842099454bcb393613816","type":"GO_TERM","name":"hexadecanal metabolic process","canonical_id":"go:GO:0046458","description":"\"The chemical reactions and pathways involving hexadecanal, the C16 straight chain aldehyde.\" [PMID:25047030]","metadata":null},{"id":"494750aef7b14ea994e2e337f1dec790","type":"GO_TERM","name":"hexadecanol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047978","description":"\"Catalysis of the reaction: hexadecanol + NAD+ = hexadecanal + NADH.\" [EC:1.1.1.164, MetaCyc:HEXADECANOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"21e599aad86a446a8d42d264169251d7","type":"GO_TERM","name":"hexagonal collagen network","canonical_id":"go:GO:0098646","description":"\"A hexagonal-shaped collagen network formed by collagen type X trimer or collagen type VIII trimers. Collagen type X trimers are mostly found in the cartilage hyaline matrix, which is located in the interstitial area. Note that collagen type VIII has been found in the basement membrane, but the localization is not definitive.\" [PMID:21421911, PMID:3047147, PMID:31387942, PMID:34948124]","metadata":null},{"id":"8cbf6f466cbf4b83bc7cb9fdfff18eb9","type":"GO_TERM","name":"hexameric IgM immunoglobulin complex","canonical_id":"go:GO:0071757","description":"\"A circulating form of IgM consisting of a hexamer of IgM core units with a single J chain polypeptide.\" [GOC:add, ISBN:0781765196, PMID:20176268]","metadata":null},{"id":"ff7a30b564dc479c8bd056b147f2c352","type":"DRUG","name":"hexamidine","canonical_id":"mesh:C018961","description":null,"metadata":null},{"id":"dbd5032a0e7e4ccaa90f151c8a4d46ab","type":"GO_TERM","name":"hexaprenyl diphosphate synthase (geranylgeranyl-diphosphate specific) activity","canonical_id":"go:GO:0052922","description":"\"Catalysis of the reaction: 2 isopentenyl diphosphate + (2E,6E,10E)-geranylgeranyl diphosphate = all-trans-hexaprenyl diphosphate + 2 diphosphate.\" [RHEA:27555]","metadata":null},{"id":"5a38897c06104a1eaa840c1f88d62b29","type":"GO_TERM","name":"hexaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific) activity","canonical_id":"go:GO:0036423","description":"\"Catalysis of the reaction: (2E,6E)-farnesyl diphosphate + 3 isopentenyl diphosphate = 3 diphosphate + all-trans-hexaprenyl diphosphate.\" [RHEA:27559]","metadata":null},{"id":"b67b2918009e4be6a39a3444231a81e4","type":"GO_TERM","name":"hexasaccharide transport","canonical_id":"go:GO:2001102","description":"\"The directed movement of a hexasaccharideacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"a461548b4d8b4ae2a17c5c786046687f","type":"GO_TERM","name":"hexitol biosynthetic process","canonical_id":"go:GO:0019406","description":"\"The chemical reactions and pathways resulting in the formation of hexitols, any alditol with a chain of six carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"414ccdfa60e94ca7a93dee2acc2407a7","type":"GO_TERM","name":"hexitol catabolic process","canonical_id":"go:GO:0019407","description":"\"The chemical reactions and pathways resulting in the breakdown of hexitols, any alditol with a chain of six carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"55ac63b35f4347b58a0f4e9900d6fcc6","type":"GO_TERM","name":"hexitol dehydrogenase activity","canonical_id":"go:GO:0031320","description":"\"Catalysis of the reaction: hexitol + acceptor = hexose + reduced acceptor.\" [GOC:mah]","metadata":null},{"id":"10a692304ba047eb8b8e4c28b8f0c2b2","type":"GO_TERM","name":"hexitol metabolic process","canonical_id":"go:GO:0006059","description":"\"The chemical reactions and pathways involving hexitols, any alditol with a chain of six carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"5a67d225e7484fc585fd47235063b793","type":"GO_TERM","name":"hexokinase activity","canonical_id":"go:GO:0004396","description":"\"Catalysis of the reaction: ATP + D-hexose = ADP + D-hexose 6-phosphate.\" [EC:2.7.1.1]","metadata":null},{"id":"b02ffce221984941b826bcfbb616b77c","type":"GO_TERM","name":"hexokinase-dependent signaling","canonical_id":"go:GO:0009747","description":"\"The series of molecular signals mediated by hexose and dependent on the detection of hexokinase.\" [GOC:mah, GOC:sm]","metadata":null},{"id":"a7f58e796db947a093c15ca9a72aec61","type":"GO_TERM","name":"hexokinase-independent signaling","canonical_id":"go:GO:0009748","description":"\"The series of molecular signals mediated by hexose and independent of hexokinase.\" [GOC:mah, GOC:sm]","metadata":null},{"id":"e9dab2d6e8a64db5a9e1c5456653a035","type":"GO_TERM","name":"hexon binding","canonical_id":"go:GO:0031423","description":"\"Binding to a hexon, the major protein component of the icosahedral capsid of an adenovirus.\" [GOC:mah, PMID:12915569]","metadata":null},{"id":"d29df75b656c436c829a62ec3276166e","type":"GO_TERM","name":"hexosaminidase activity","canonical_id":"go:GO:0015929","description":"\"Catalysis of the cleavage of hexosamine or N-acetylhexosamine residues (e.g. N-acetylglucosamine) residues from gangliosides or other glycoside oligosaccharides.\" [ISBN:0721662544]","metadata":null},{"id":"62bcb2dc8bf8428aa0f0d42276a1a6d3","type":"GO_TERM","name":"hexose biosynthetic process","canonical_id":"go:GO:0019319","description":"\"The chemical reactions and pathways resulting in the formation of hexose, any monosaccharide with a chain of six carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"60c30aa8ca96420196fe035915bbe3da","type":"GO_TERM","name":"hexose catabolic process","canonical_id":"go:GO:0019320","description":"\"The chemical reactions and pathways resulting in the breakdown of hexose, any monosaccharide with a chain of six carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"aa31ac500d89426886b3c151d8ec77d6","type":"GO_TERM","name":"hexose import across plasma membrane","canonical_id":"go:GO:0140271","description":"\"The directed movement of hexose from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:10735857]","metadata":null},{"id":"7db2e82f31614894946d10d59ec35103","type":"GO_TERM","name":"hexose mediated signaling","canonical_id":"go:GO:0009757","description":"\"The series of molecular signals mediated by the detection of hexose.\" [GOC:sm]","metadata":null},{"id":"b9c57e2c487b4cbfa5bb40251a70d90c","type":"GO_TERM","name":"hexose metabolic process","canonical_id":"go:GO:0019318","description":"\"The chemical reactions and pathways involving a hexose, any monosaccharide with a chain of six carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"aae6025ae2904e3aae534d7cb35738e6","type":"GO_TERM","name":"hexose oxidase activity","canonical_id":"go:GO:0047979","description":"\"Catalysis of the reaction: hexose + O2 = aldono-1,5-lactone + H202.\" [EC:1.1.3.5]","metadata":null},{"id":"614da7fbc94044e7b7cb144ddf68bc33","type":"GO_TERM","name":"hexose phosphate transmembrane transporter activity","canonical_id":"go:GO:0015119","description":"\"Enables the transfer of hexose phosphate from one side of a membrane to the other. Hexose phosphates is any of a group of monophosphorylated aldoses with a chain of six carbon atoms in the molecule.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"116a7eccdb8342a19e72e06b1a2e8846","type":"GO_TERM","name":"hexose phosphate transport","canonical_id":"go:GO:0015712","description":"\"The directed movement of hexose phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"5037a6cc9840493eb220aaf68bcd532a","type":"GO_TERM","name":"hexose transmembrane transport","canonical_id":"go:GO:0008645","description":"\"The process in which hexose is transported across a membrane. Hexoses are aldoses with a chain of six carbon atoms in the molecule.\" [GOC:vw]","metadata":null},{"id":"18f3ce5c3b4f4e649b5d4dbabbc3c7a8","type":"GO_TERM","name":"hexose transmembrane transporter activity","canonical_id":"go:GO:0015149","description":"\"Enables the transfer of a hexose sugar, a monosaccharide with 6 carbon atoms, from one side of a membrane to the other.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"550a7efcfe7c4a02a7a9dcd10c1ba872","type":"GO_TERM","name":"hexose uniporter activity","canonical_id":"go:GO:0008516","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: hexose(out) = hexose(in).\" [TC:2.A.1.1.5]","metadata":null},{"id":"517c7524288d43fc905521fe6cf44d10","type":"GO_TERM","name":"hexose-phosphate:phosphate antiporter activity","canonical_id":"go:GO:0015526","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: hexose phosphate(out) + phosphate(in) = hexose phosphate(in) +  phosphate(out).\" [TC:2.A.1.4.1]","metadata":null},{"id":"91b14c95315a422798cfef8db90f4a52","type":"GO_TERM","name":"hexose:proton symporter activity","canonical_id":"go:GO:0009679","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: hexose(out) + H+(out) = hexose(in) + H+(in).\" [TC:2.A.1.-.-]","metadata":null},{"id":"c8a90333b82f44bbac2b87b2238ea6dc","type":"GO_TERM","name":"hexosyltransferase activity","canonical_id":"go:GO:0016758","description":"\"Catalysis of the transfer of a hexosyl group from one compound (donor) to another (acceptor).\" [EC:2.4.1.-]","metadata":null},{"id":"0cc439e504aa40869001f20a617ede41","type":"GO_TERM","name":"hexulose-6-phosphate synthase activity","canonical_id":"go:GO:0043801","description":"\"Catalysis of the reaction: D-ribulose 5-phosphate + formaldehyde = D-arabino-3-hexulose 6-phosphate.\" [PMID:16075199]","metadata":null},{"id":"16c2f885638844d28d1ffa0b99e83832","type":"GO_TERM","name":"hexuronate transmembrane transport","canonical_id":"go:GO:0015736","description":"\"The process in which hexuronate is transported across a lipid bilayer, from one side of a membrane to the other. A hexuronate is any monocarboxylic acid derived from a hexose by oxidation of C-6.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"9df75e1dad714df6b9324d3d1bc9b562","type":"GO_TERM","name":"hexuronate transmembrane transporter activity","canonical_id":"go:GO:0015134","description":"\"Enables the transfer of hexuronates from one side of a membrane to the other. A hexuronate is any monocarboxylic acid derived from a hexose by oxidation of C-6.\" [GOC:ai, GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"39150d3346644323bb36620f183003bd","type":"GO_TERM","name":"hexuronate:monoatomic cation symporter activity","canonical_id":"go:GO:0015539","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: hexuronate(out) + cation(out) = hexuronate(in) + cation(in). The hexuronate may be glucuronate or galacturonate.\" [TC:2.A.1.14.2]","metadata":null},{"id":"0e35a9823d5e406c9b90637e49eef2f6","type":"GO_TERM","name":"hexuronide transmembrane transport","canonical_id":"go:GO:0015778","description":"\"The directed movement of hexuronide across a membrane. Hexuronides are any compound formed by combination of glycosidic linkage of a hydroxy compound (e.g. an alcohol or a saccharide) with the anomeric carbon atom of a hexuronate.\" [GOC:ai]","metadata":null},{"id":"50e2a4268d514017a9e3679c7329db54","type":"GO_TERM","name":"hibernation","canonical_id":"go:GO:0042750","description":"\"Any process in which an organism enters and maintains a period of dormancy in which to pass the winter. It is characterized by narcosis and by sharp reduction in body temperature and metabolic activity and by a depression of vital signs.\" [GOC:jl, PMID:1945046]","metadata":null},{"id":"51cf5d1ee9a04a68a894df655487c2e8","type":"DISEASE","name":"hidradenitis suppurativa","canonical_id":"mondo:0006559","description":null,"metadata":null},{"id":"4132e4f2c78e48d5aa86520e590f96b1","type":"GO_TERM","name":"high density lipoprotein particle mediated signaling","canonical_id":"go:GO:0055097","description":"\"The series of molecular signals mediated by the detection of high density lipoprotein particle.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"228a3965a0b840ef8f016702d4fed025","type":"GO_TERM","name":"high mobility group box 1 binding","canonical_id":"go:GO:0070379","description":"\"Binding to high mobility group box 1 (HMBGB1).\" [GOC:add, PMID:18431461]","metadata":null},{"id":"4a0b183a768d4e288306367bdf255fa2","type":"GO_TERM","name":"high mobility group box 1 receptor activity","canonical_id":"go:GO:0070380","description":"\"Combining with high mobility group box 1 (HMBGB1) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, PMID:18431461]","metadata":null},{"id":"1b769423ca604d709a374a839079f666","type":"GO_TERM","name":"high molecular weight B cell growth factor receptor activity","canonical_id":"go:GO:0030373","description":"\"Combining with a high molecular weight B cell growth factor and transmitting the signal to initiate a change in cell activity.\" [GOC:ai, GOC:signaling, PMID:2681271]","metadata":null},{"id":"fca8767f5f954f5b8d0f77a9e26136bb","type":"GO_TERM","name":"high molecular weight B cell growth factor receptor binding","canonical_id":"go:GO:0030372","description":"\"Binding to a high molecular weight B cell growth factor receptor.\" [GOC:ai]","metadata":null},{"id":"f7f4af145a6b4716badda39a5fe83118","type":"GO_TERM","name":"high molecular weight kininogen binding","canonical_id":"go:GO:0030985","description":"\"Binding to a kininogen of high molecular mass.\" [GOC:mah, PMID:9520414]","metadata":null},{"id":"4375eacef13b4ed684d1ac9cf14c6882","type":"GO_TERM","name":"high molecular weight kininogen receptor binding","canonical_id":"go:GO:0030987","description":"\"Binding to a high molecular weight kininogen receptor.\" [GOC:mah]","metadata":null},{"id":"4b9ec89f95ea496c9e1acd3692ed6bd3","type":"GO_TERM","name":"high molecular weight kininogen receptor complex","canonical_id":"go:GO:0030988","description":"\"A protein complex that acts as a receptor for high molecular weight kininogens. In humans, this receptor includes the CK1 and uPAR proteins.\" [GOC:mah, PMID:11290596]","metadata":null},{"id":"b5d7af0dd34a48f6a995c3966476b17b","type":"GO_TERM","name":"high voltage-gated calcium channel activity","canonical_id":"go:GO:0008331","description":"\"Enables the transmembrane transfer of a calcium ion by a high voltage-gated channel. A high voltage-gated channel is a channel whose open state is dependent on high voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729, PMID:16382099]","metadata":null},{"id":"7c94782665f340b3916e1877247c2f89","type":"GO_TERM","name":"high-affinity D-glucose transmembrane transporter activity","canonical_id":"go:GO:0140108","description":"\"Enables the transfer of D-glucose from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [PMID:25411338]","metadata":null},{"id":"2f6ff6cfd2ca46b48a1fd1efeb4f0e00","type":"GO_TERM","name":"high-affinity D-glucose:proton symporter activity","canonical_id":"go:GO:0005358","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose + H+ = glucose + H+. This activity is constitutive and therefore always present, regardless of demand. Symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"304c8fbabd1d4ce6b97f9361c81ca677","type":"GO_TERM","name":"high-affinity IgA receptor activity","canonical_id":"go:GO:0002170","description":"\"Combining with high affinity with an immunoglobulin of an IgA isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:hjd, GOC:signaling]","metadata":null},{"id":"997ee0ef01024f95ba68a0c148182ecb","type":"GO_TERM","name":"high-affinity IgE receptor activity","canonical_id":"go:GO:0019768","description":"\"Combining with high affinity with an immunoglobulin of the IgE isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"5331a15c8f94490b9cee580adbca5139","type":"GO_TERM","name":"high-affinity IgG receptor activity","canonical_id":"go:GO:0019771","description":"\"Combining with high affinity with an immunoglobulin of an IgG isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"445949b130604b7580980cb7d4d6e129","type":"GO_TERM","name":"high-affinity IgM receptor activity","canonical_id":"go:GO:0002172","description":"\"Combining with high affinity with an immunoglobulin of an IgM isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:hjd, GOC:signaling]","metadata":null},{"id":"5fc070a257a94abd973f69c2f39f7daf","type":"GO_TERM","name":"high-affinity L-arginine transmembrane transporter activity","canonical_id":"go:GO:0005289","description":"\"Enables the transfer of arginine from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"2d2375285ff14226b71705f7a8354555","type":"GO_TERM","name":"high-affinity L-glutamate transmembrane transporter activity","canonical_id":"go:GO:0005314","description":"\"Enables the transfer of glutamate from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [TC:2.A.3.10.5]","metadata":null},{"id":"deb1ba4ac53c467c91466f91716d797e","type":"GO_TERM","name":"high-affinity L-histidine transmembrane transporter activity","canonical_id":"go:GO:0005291","description":"\"Enables the transfer of L-histidine from one side of a membrane to the other. L-histidine is 2-amino-3-(1H-imidazol-4-yl)propanoic acid. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"8b0916f246ff4204bbe1d73f0e991cb7","type":"GO_TERM","name":"high-affinity L-ornithine transmembrane transporter activity","canonical_id":"go:GO:0097627","description":"\"Enables the transfer of L-ornithine from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:krc, PMID:8195186]","metadata":null},{"id":"65a47cc7863f40088d12710d300ca83a","type":"GO_TERM","name":"high-affinity basic amino acid transmembrane transporter activity","canonical_id":"go:GO:0005287","description":"\"Enables the transfer of basic amino acids from one side of a membrane to the other. Acidic amino acids have a pH above 7. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"932f7fba673847ddb346d147b6138c6d","type":"GO_TERM","name":"high-affinity copper ion transmembrane transporter activity","canonical_id":"go:GO:0015089","description":"\"Enables the transfer of a copper ions (Cu2+) from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [TC:9.A.11.1.1]","metadata":null},{"id":"46630211995546e9ab9f01133ec43f8f","type":"GO_TERM","name":"high-affinity ferric iron transmembrane transporter activity","canonical_id":"go:GO:0015092","description":"\"Enables the transfer of ferric iron (Fe(III) or Fe3+) ions from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:ai, PMID:1447137]","metadata":null},{"id":"fd727fcb5e844205adc4871b7705eb27","type":"GO_TERM","name":"high-affinity ferrous iron transmembrane transporter activity","canonical_id":"go:GO:0061840","description":"\"Enables the transfer of ferrous iron (Fe(II) or Fe2+) ions from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:bhm, PMID:9413439]","metadata":null},{"id":"1744d81b4f604ca28142b517e2574ee4","type":"GO_TERM","name":"high-affinity fructose transmembrane transporter activity","canonical_id":"go:GO:0061486","description":"\"Enables the transfer of fructose from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:dph, PMID:10735857]","metadata":null},{"id":"ef7cfcea917c4017a1bdd8d11b8901aa","type":"GO_TERM","name":"high-affinity glutamine transmembrane transporter activity","canonical_id":"go:GO:0015330","description":"\"Enables the transfer of glutamine from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"977e10ad20ae453382c142c19d8cd874","type":"GO_TERM","name":"high-affinity iron exporter complex","canonical_id":"go:GO:0061841","description":"\"A protein complex which transports ferrous iron (Fe(III) or Fe3+) ions from the vacuole, the main storage component of intracellular free iron, into the cytoplasm in a low iron environment.\" [GOC:bhm, PMID:10608875, PMID:9413439]","metadata":null},{"id":"b403b7ce746d4e1182381f2bbb445cf5","type":"GO_TERM","name":"high-affinity iron permease complex","canonical_id":"go:GO:0033573","description":"\"A protein complex composed of a multicopper ferroxidase that oxidizes Fe(II) to Fe(III), and a ferric iron permease that transports the produced Fe(III) into the cell. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:jp, PMID:16522632, PMID:8599111]","metadata":null},{"id":"8ff822629d5a488a940f5f0b0e3dc25a","type":"GO_TERM","name":"high-affinity lysine transmembrane transporter activity","canonical_id":"go:GO:0005292","description":"\"Enables the transfer of lysine from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"1eb9f0fc359444c596d9e4423a9fa91f","type":"GO_TERM","name":"high-affinity nickel cation transmembrane transporter activity","canonical_id":"go:GO:0044750","description":"\"Catalysis of the high-affinity transfer of nickel (Ni) cations from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:jl]","metadata":null},{"id":"86366c40e63e4bdf86a69088891ea571","type":"GO_TERM","name":"high-affinity oligopeptide transmembrane transporter activity","canonical_id":"go:GO:0015334","description":"\"Enables the transfer of oligopeptide from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations. Oligopeptides are molecules that contain a small number (2 to 20) of amino-acid residues connected by peptide linkages.\" [GOC:mtg_transport]","metadata":null},{"id":"47995ed2f46f41eeabd294cdfd9ebc34","type":"GO_TERM","name":"high-affinity phosphate transmembrane transporter activity","canonical_id":"go:GO:0048249","description":"\"Enables the transfer of phosphate from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:jid, PMID:8709965]","metadata":null},{"id":"c30ad260742d4743b6a07e5403ee9ff2","type":"GO_TERM","name":"high-affinity phosphate:sodium symporter activity","canonical_id":"go:GO:0005316","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction:phosphate(out) + Na+(out) = phosphate(in) + Na+(in). In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [TC:2.A.20.2.2]","metadata":null},{"id":"17b62bcf3909483e800612321fbd4387","type":"GO_TERM","name":"high-affinity potassium ion transmembrane transporter activity","canonical_id":"go:GO:0140107","description":"\"Enables the transfer of potassium ions from one side of a membrane to the other. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [PMID:10629185]","metadata":null},{"id":"cce43b4a2ca74af2a30b60aa2bfbc375","type":"GO_TERM","name":"high-affinity secondary active nitrite transmembrane transporter activity","canonical_id":"go:GO:0015513","description":"\"Catalysis of the transfer of nitrite from one side of the membrane to the other, up the solute's concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. In high affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e6119c5e2fda43139dfd8fcbe9faa8e9","type":"GO_TERM","name":"high-affinity sodium:dicarboxylate symporter activity","canonical_id":"go:GO:0015362","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: dicarboxylate(out) + Na+(out) = dicarboxylate(in) + Na+(in). In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [TC:2.A.47.1.4]","metadata":null},{"id":"19750a559d9140d0aa58214489530a39","type":"GO_TERM","name":"high-affinity sulfate transmembrane transporter activity","canonical_id":"go:GO:0015381","description":"\"Enables the secondary active high affinity transfer of sulfate from one side of a membrane to the other. Secondary active transport is the transfer of a solute across a membrane, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters. In high-affinity transport the transporter is able to bind thesolute even if it is only present at very low concentrations.\" [GOC:mtg_transport]","metadata":null},{"id":"b11a8d008680468e91d0da38f161bc28","type":"GO_TERM","name":"high-affinity sulfate:proton symporter activity","canonical_id":"go:GO:0009675","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sulfate(out) + H+(out) = sulfate(in) + H+(in). In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mah]","metadata":null},{"id":"1127740ba8334db8850e17143ebf3a0d","type":"GO_TERM","name":"high-affinity thiamine:proton symporter activity","canonical_id":"go:GO:0034216","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: thiamine(out) + H+(out) = thiamine(in) + H+(in). In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mah]","metadata":null},{"id":"f4b7183c44bb441396678e80cc3ba890","type":"GO_TERM","name":"high-affinity tryptophan transmembrane transporter activity","canonical_id":"go:GO:0005300","description":"\"Catalysis of the high-affinity transfer of L-tryptophan from one side of a membrane to the other. Tryptophan is 2-amino-3-(1H-indol-3-yl)propanoic acid. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b76ad5de56334001a694df5556397f0b","type":"GO_TERM","name":"high-affinity zinc transmembrane transporter activity","canonical_id":"go:GO:0000006","description":"\"Enables the transfer of zinc ions (Zn2+) from one side of a membrane to the other, probably powered by proton motive force. In high-affinity transport the transporter is able to bind the solute even if it is only present at very low concentrations.\" [TC:2.A.5.1.1]","metadata":null},{"id":"a0d822068ce0487c9447aead2090916b","type":"GO_TERM","name":"high-density lipoprotein particle","canonical_id":"go:GO:0034364","description":"\"A lipoprotein particle with a high density (typically 1.063-1.21 g/ml) and a diameter of 5-10 nm that contains APOAs and may contain APOCs and APOE; found in blood and carries lipids from body tissues to the liver as part of the reverse cholesterol transport process.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:pde, GOC:rl]","metadata":null},{"id":"e14f58a986624c45b713487241479c75","type":"GO_TERM","name":"high-density lipoprotein particle assembly","canonical_id":"go:GO:0034380","description":"\"The non-covalent aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"03c4cb7b264f41bd86b5a1ef2383a9da","type":"GO_TERM","name":"high-density lipoprotein particle binding","canonical_id":"go:GO:0008035","description":"\"Binding to high-density lipoprotein particle, a lipoprotein particle with a high density (typically 1.063-1.21 g/ml) and a diameter of 5-10 nm that contains APOAs and may contain APOCs and APOE.\" [GOC:mah]","metadata":null},{"id":"aa81174871254b54af8087a0f05d47b8","type":"GO_TERM","name":"high-density lipoprotein particle clearance","canonical_id":"go:GO:0034384","description":"\"The process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1e3373c90d7f4f578d1aebf44808b375","type":"GO_TERM","name":"high-density lipoprotein particle receptor activity","canonical_id":"go:GO:0070506","description":"\"Combining with a high-density lipoprotein particle and delivering the high-density lipoprotein into the cell via endocytosis.\" [GOC:bf, GOC:BHF, GOC:rl, PMID:9211901]","metadata":null},{"id":"44aaac29f78f4623ba1ca58f64ae914a","type":"GO_TERM","name":"high-density lipoprotein particle receptor binding","canonical_id":"go:GO:0070653","description":"\"Binding to a high-density lipoprotein receptor.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"8a73893f94954c9ba45fd1213714cdce","type":"GO_TERM","name":"high-density lipoprotein particle remodeling","canonical_id":"go:GO:0034375","description":"\"The acquisition, loss or modification of a protein or lipid within a high-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase, with the subsequent loss of free fatty acid, and the transfer of cholesterol esters from LDL to a triglyceride-rich lipoprotein particle by cholesteryl ester transfer protein (CETP), with the simultaneous transfer of triglyceride to LDL.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"4a83eab84c4e41a4a167bddeab6d488e","type":"GO_TERM","name":"high-mannose-oligosaccharide beta-1,4-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0033827","description":"\"Catalysis of the transfer of an N-acetyl-D-glucosamine residue from UDP-N-acetyl-D-glucosamine to the 4-position of a mannose linked alpha-1,6 to the core mannose of high-mannose oligosaccharides produced by Dictyostelium discoideum.\" [EC:2.4.1.197]","metadata":null},{"id":"aba1b2c2f58c49fe8c47761550699c17","type":"GO_TERM","name":"hindbrain development","canonical_id":"go:GO:0030902","description":"\"The process whose specific outcome is the progression of the hindbrain over time, from its formation to the mature structure. The hindbrain is the posterior of the three primary divisions of the developing chordate brain, or the corresponding part of the adult brain (in vertebrates, includes the cerebellum, pons, and medulla oblongata and controls the autonomic functions and equilibrium).\" [PMID:4975589, PMID:4992177]","metadata":null},{"id":"6ff11ad18c334d089f0d6023ed54b9f6","type":"GO_TERM","name":"hindbrain formation","canonical_id":"go:GO:0021576","description":"\"The process that gives rise to the hindbrain. This process pertains to the initial formation of a structure from unspecified parts. The hindbrain is the region consisting of the medulla, pons and cerebellum. Areas of the hindbrain control motor and autonomic functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"32df2debf8b6457788d9ff7c3301fecb","type":"GO_TERM","name":"hindbrain maturation","canonical_id":"go:GO:0021578","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the hindbrain to attain its fully functional state. The hindbrain is the region consisting of the medulla, pons and cerebellum. Areas of the hindbrain control motor and autonomic functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"721e842314b54a8ab75c474de9e78c4f","type":"GO_TERM","name":"hindbrain morphogenesis","canonical_id":"go:GO:0021575","description":"\"The process in which the anatomical structure of the hindbrain is generated and organized. The hindbrain is the region consisting of the medulla, pons and cerebellum. Areas of the hindbrain control motor and autonomic functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"9acfb15caf13436d8ea01e7ef28575ad","type":"GO_TERM","name":"hindbrain radial glia guided cell migration","canonical_id":"go:GO:0021932","description":"\"The radially directed movement of a cell along radial glial cells in the hindbrain. Radial migration refers to a directed movement from the internal ventricular area to the outer surface of the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"7f3b5693fae54cb2a26fc296830d4759","type":"GO_TERM","name":"hindbrain structural organization","canonical_id":"go:GO:0021577","description":"\"The process that contributes to the act of creating the structural organization of the hindbrain. This process pertains to the physical shaping of a rudimentary structure. The hindbrain is the region consisting of the medulla, pons and cerebellum. Areas of the hindbrain control motor and autonomic functions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"7c793360f07a48b7ae9a09073e133394","type":"GO_TERM","name":"hindbrain tangential cell migration","canonical_id":"go:GO:0021934","description":"\"The migration of a cell in the hindbrain in which cells move orthogonal to the direction of radial migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"1a8899c8ffe74ae4b8a17e266d4cea88","type":"GO_TERM","name":"hindbrain-spinal cord boundary formation","canonical_id":"go:GO:0021906","description":"\"The process whose specific outcome is the formation of the hindbrain-spinal cord boundary.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"42d06f6bb727488f8d8b8518391d9bbe","type":"GO_TERM","name":"hindgut contraction","canonical_id":"go:GO:0043133","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the hindgut. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The hindgut is the posterior part of the alimentary canal, including the rectum, and the large intestine.\" [GOC:jl, GOC:mtg_muscle, UBERON:0001046]","metadata":null},{"id":"d95a1e87915d4ef28f38ed5f2785f1bc","type":"GO_TERM","name":"hindgut development","canonical_id":"go:GO:0061525","description":"\"The process whose specific outcome is the progression of the hindgut over time, from its formation to the mature structure. The hindgut is part of the alimentary canal that lies posterior to the midgut.\" [GOC:dph]","metadata":null},{"id":"58f209f611224670a213cb4e3159865b","type":"GO_TERM","name":"hindgut morphogenesis","canonical_id":"go:GO:0007442","description":"\"The process in which the anatomical structures of the hindgut are generated and organized.\" [GOC:jid]","metadata":null},{"id":"2c9817cf85d4412fa29a090dd927f4d9","type":"GO_TERM","name":"hindlimb morphogenesis","canonical_id":"go:GO:0035137","description":"\"The process in which the anatomical structures of the hindlimb are generated and organized.\" [GOC:curators]","metadata":null},{"id":"71415745ea5b4f7c95f422d33d655345","type":"GO_TERM","name":"hinge region between urothelial plaques of apical plasma membrane","canonical_id":"go:GO:0120003","description":"\"A narrow rim of non-thickened membrane in between urothelial plaques in apical plasma membrane.\" [GOC:krc, PMID:21468280, PMID:21887288]","metadata":null},{"id":"dcb635e3daac461480c146a621ac187e","type":"DISEASE","name":"hip fracture","canonical_id":"mondo:0005327","description":null,"metadata":null},{"id":"5b023f25661f484da5d40e48e6a14a8a","type":"GO_TERM","name":"hip joint articular cartilage development","canonical_id":"go:GO:0061977","description":"\"The process whose specific outcome is the progression of hip joint articular cartilage over time, from its formation to the mature structure.\" [PMID:20097540]","metadata":null},{"id":"fbba6c97ed8446f2bd496cf486f83ffc","type":"GO_TERM","name":"hippo signaling","canonical_id":"go:GO:0035329","description":"\"An intracellular signaling cascade that starts with the activation of hippo (STK4/MST1 and STK3/MST2 in mammals and hpo kinase in Drosophila). Hippo then phosphorylates LATS1/2, which in turn phosphoylates the transcriptional co-activator YAP1 (yki in Drosophila), leading to its cytosolic retention and/or degradation.\" [PMID:17318211, PMID:18328423, PMID:36347846]","metadata":null},{"id":"2979cf47da38438ca66b2f0006d1daf8","type":"GO_TERM","name":"hippocampal interneuron differentiation","canonical_id":"go:GO:0097410","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a hippocampal interneuron.\" [CL:1001569, GOC:jc, PMID:19655320]","metadata":null},{"id":"f3c8df373f754bdc89150bf8db24e019","type":"GO_TERM","name":"hippocampal mossy fiber","canonical_id":"go:GO:0097457","description":"\"An axon of a hippocampal granule cell, including dentate gyrus granule cell and CA3 granule cell, characterized by expansions (mossy fiber expansions) giving the fibers a mossy appearance. These unmyelinated axons were first described by Ramon y Cajal.\" [NIF_Subcellular:nlx_subcell_100312, PMID:17765709, PMID:20554881, PMID:24336151]","metadata":null},{"id":"af52a9b29f0b483f8f4a8c67fa484b6a","type":"GO_TERM","name":"hippocampal mossy fiber expansion","canonical_id":"go:GO:1990026","description":"\"Synaptic expansion of hippocampal mossy fiber axon that makes contact with the thorny excrescences of hippocampal CA3 pyramidal cell dendrites.\" [NIF_Subcellular:nlx_subcell_1005002]","metadata":null},{"id":"1e6340b7d23544bf83454fffbe9b452f","type":"GO_TERM","name":"hippocampal mossy fiber to CA3 synapse","canonical_id":"go:GO:0098686","description":"\"One of the giant synapses that form between the mossy fiber axons of dentate gyrus granule cells and the large complex spines of CA3 pyramidal cells. It consists of a giant bouton known as the mossy fiber expansion, synapsed to the complex, multiheaded spine (thorny excresence) of a CA3 pyramidal cell.\" [DOI:10.1002/1096-9861, PMID:13869693, PMID:23264762]","metadata":null},{"id":"c30475ee3be94e21b2094a322f33f03d","type":"GO_TERM","name":"hippocampal neuron apoptotic process","canonical_id":"go:GO:0110088","description":"\"Any apoptotic process that occurs in a hippocampal neuron.\" [GOC:sl, PMID:18940801]","metadata":null},{"id":"74542dd46f9d41c8a3290ac9f1ab339a","type":"GO_TERM","name":"hippocampal pyramidal neuron differentiation","canonical_id":"go:GO:0097432","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a hippocampal pyramidal neuron, a pyramidal cell of the hippocampus.\" [CL:1001571, GOC:jc, PMID:19342486]","metadata":null},{"id":"2477403584e84263a21e242b47e46f32","type":"GO_TERM","name":"hippocampus development","canonical_id":"go:GO:0021766","description":"\"The progression of the hippocampus over time from its initial formation until its mature state.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420, UBERON:0002421]","metadata":null},{"id":"2628de88efcc441996541110af10ba78","type":"GO_TERM","name":"hippurate hydrolase activity","canonical_id":"go:GO:0047980","description":"\"Catalysis of the reaction: N-benzoylglycine + H2O = benzoate + glycine.\" [EC:3.5.1.32, RHEA:10424]","metadata":null},{"id":"6f3312220861479b9abf1aa53322dea4","type":"DRUG","name":"histamine","canonical_id":"mesh:D006632","description":null,"metadata":null},{"id":"7effa372471942e992404fc29592bebf","type":"GO_TERM","name":"histamine N-methyltransferase activity","canonical_id":"go:GO:0046539","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + histamine = N(tau)-methylhistamine + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.8, RHEA:19301]","metadata":null},{"id":"8328b114613340b290a757c4a82b220c","type":"GO_TERM","name":"histamine binding","canonical_id":"go:GO:0051381","description":"\"Binding to histamine, a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:ai]","metadata":null},{"id":"646cc2850b50480486e89ce162b8132a","type":"GO_TERM","name":"histamine biosynthetic process","canonical_id":"go:GO:0001694","description":"\"The chemical reactions and pathways resulting in the formation of histamine, a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"1544066d449f4acd8dad064c8851790b","type":"GO_TERM","name":"histamine catabolic process","canonical_id":"go:GO:0001695","description":"\"The chemical reactions and pathways resulting in the breakdown of histamine, a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"e3eacabb7c38440c869cb340763ff7a1","type":"GO_TERM","name":"histamine metabolic process","canonical_id":"go:GO:0001692","description":"\"The chemical reactions and pathways involving histamine, a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"cb2d52c6ca1b43958892eae4ec3abe01","type":"GO_TERM","name":"histamine oxidase activity","canonical_id":"go:GO:0052598","description":"\"Catalysis of the reaction: H2O + histamine + O2 = H2O2 + imidazole-4-acetaldehyde + NH4+.\" [RHEA:25625]","metadata":null},{"id":"1864f98d33554f61ab909ce59d9aeca1","type":"GO_TERM","name":"histamine production involved in inflammatory response","canonical_id":"go:GO:0002349","description":"\"The synthesis or release of histamine following a stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"6b9496cea99348e79a54943f3190ec14","type":"GO_TERM","name":"histamine receptor activity","canonical_id":"go:GO:0004969","description":"\"Combining with histamine to initiate a change in cell activity. Histamine is a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:ai]","metadata":null},{"id":"af57ed51bbf448f1967641779a6e966d","type":"GO_TERM","name":"histamine secretion","canonical_id":"go:GO:0001821","description":"\"The regulated release of histamine by a cell or tissue. It is formed by decarboxylation of histidine and it acts through receptors in smooth muscle and in secretory systems.\" [GOC:mah, ISBN:0198506732, ISBN:0781735149]","metadata":null},{"id":"dc197c1296ac48b0af6ad8b268564ad1","type":"GO_TERM","name":"histamine secretion by basophil","canonical_id":"go:GO:0002557","description":"\"The regulated release of histamine by a basophil or group of basophils.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b2c36eea1c19442ebec235f41ffe53eb","type":"GO_TERM","name":"histamine secretion by mast cell","canonical_id":"go:GO:0002553","description":"\"The regulated release of histamine by a mast cell or group of mast cells.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"895d96f0e8184496b6f4edc7255d0c6d","type":"GO_TERM","name":"histamine secretion by platelet","canonical_id":"go:GO:0002555","description":"\"The regulated release of histamine by a platelet or group of platelets.\" [GOC:add, PMID:9117517]","metadata":null},{"id":"cbfea0b14f6f45f2b5f44d2521feea9a","type":"GO_TERM","name":"histamine secretion involved in inflammatory response","canonical_id":"go:GO:0002441","description":"\"The regulated release of histamine by a cell as part of an inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"bc4f168195374590b0c3626cdde7779d","type":"GO_TERM","name":"histamine secretion mediated by IgE immunoglobulin","canonical_id":"go:GO:0097279","description":"\"Histamine release triggered by the binding of an antigen to an IgE immunoglobulin bound to the cell surface. An example is mast cell histamine degranulation as a result of exposure of mast cell-bound IgE to alder tree pollen.\" [GOC:add, GOC:rv]","metadata":null},{"id":"d48f205dfbc44368a98897e75ea21bc6","type":"GO_TERM","name":"histamine secretion mediated by immunoglobulin","canonical_id":"go:GO:0097280","description":"\"Histamine release triggered by the binding of an antigen to an immunoglobulin bound to the cell surface.\" [GOC:add, GOC:rv, PMID:11490155, PMID:1719184]","metadata":null},{"id":"55001aa3d3434155bfb11738f547650c","type":"GO_TERM","name":"histamine secretion, neurotransmission","canonical_id":"go:GO:0061538","description":"\"The controlled release of histamine by a cell, in which the histamine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"879d654117a04395bfe9985a16fc8af2","type":"GO_TERM","name":"histamine transmembrane transporter activity","canonical_id":"go:GO:0160173","description":"\"Enables the transfer of histamine from one side of a membrane to the other.\" [PMID:36288320]","metadata":null},{"id":"4f5adbc8ce134ecc8b187125fefefd51","type":"GO_TERM","name":"histamine transport","canonical_id":"go:GO:0051608","description":"\"The directed movement of histamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Histamine is a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:ai]","metadata":null},{"id":"943197953dea4360afd8f21126f41d8b","type":"GO_TERM","name":"histamine uptake","canonical_id":"go:GO:0051615","description":"\"The directed movement of histamine into a cell, typically presynaptic neurons or glial cells. Histamine is a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans.\" [GOC:ai]","metadata":null},{"id":"f990f5af6a7a4919b094eec88c12bceb","type":"GO_TERM","name":"histamine-gated chloride channel activity","canonical_id":"go:GO:0019182","description":"\"Enables the energy-independent facilitated diffusion of a chloride ion through a transmembrane channel that opens when bound to histamine.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b1d6bf7b61cd49d6b1841c3587cbbfea","type":"GO_TERM","name":"histamine-gated chloride channel complex","canonical_id":"go:GO:0019183","description":"\"A protein complex that forms a transmembrane channel through which chloride ions may pass in response to histamine binding to the channel complex or one of its constituent parts.\" [GOC:mah]","metadata":null},{"id":"d2307bec7e2548b4a4046980aa3827cb","type":"GO_TERM","name":"histamine-induced gastric acid secretion","canonical_id":"go:GO:0001697","description":"\"The regulated release of gastric acid induced by the interaction of histamine with H2 type receptor receptors with subsequent activation of adenylate cyclase and elevation of intracellular cyclic AMP.\" [GOC:hjd]","metadata":null},{"id":"5faf0d66e29e43b1b2231a2b2fb47979","type":"GO_TERM","name":"histidine ammonia-lyase activity","canonical_id":"go:GO:0004397","description":"\"Catalysis of the reaction: L-histidine = trans-urocanate + NH4+.\" [RHEA:21232]","metadata":null},{"id":"f35610b912cd4444898d9ce5a201b8c6","type":"GO_TERM","name":"histidine decarboxylase activity","canonical_id":"go:GO:0004398","description":"\"Catalysis of the reaction: L-histidine = histamine + CO2.\" [EC:4.1.1.22]","metadata":null},{"id":"4c6b812ed2aa4e57ab2778f390d99409","type":"GO_TERM","name":"histidine phosphotransfer kinase activity","canonical_id":"go:GO:0009927","description":"\"Serves as a phospho-His intermediate enabling the transfer of phospho group between a hybrid kinase and a response regulator.\" [PMID:11842140, PMID:31386843]","metadata":null},{"id":"a52ec5bb135e40cf862ae6711bbe160e","type":"GO_TERM","name":"histidine transport","canonical_id":"go:GO:0015817","description":"\"The directed movement of histidine, 2-amino-3-(1H-imidazol-4-yl)propanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"cdafcb3fd3fe4ac3ac2c86ce95efde9a","type":"GO_TERM","name":"histidine-tRNA ligase activity","canonical_id":"go:GO:0004821","description":"\"Catalysis of the reaction: ATP + L-histidine + tRNA(His) = AMP + diphosphate + L-histidyl-tRNA(His).\" [EC:6.1.1.21]","metadata":null},{"id":"7fb1a62cdb80476e9fb8a77eb7b8919e","type":"GO_TERM","name":"histidinol dehydrogenase activity","canonical_id":"go:GO:0004399","description":"\"Catalysis of the reaction: H2O + L-histidinol + 2 NAD+ = 3 H+ + L-histidine + 2 NADH.\" [RHEA:20641]","metadata":null},{"id":"da42639ed71b4923821aa27c55c00228","type":"GO_TERM","name":"histidinol-phosphatase activity","canonical_id":"go:GO:0004401","description":"\"Catalysis of the reaction: L-histidinol phosphate + H2O = L-histidinol + phosphate.\" [EC:3.1.3.15, RHEA:14465]","metadata":null},{"id":"992b699e9376401c8eb9e433907a5149","type":"GO_TERM","name":"histidyl-tRNA aminoacylation","canonical_id":"go:GO:0006427","description":"\"The process of coupling histidine to histidyl-tRNA, catalyzed by histidyl-tRNA synthetase. The histidyl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3''-OH group of a histidine-accetping tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"fb86df359b5a4f5ba93f3a02b8930adb","type":"GO_TERM","name":"histoblast morphogenesis","canonical_id":"go:GO:0007488","description":"\"The process in which the anatomical structures derived from the histoblast disc are generated and organized. This includes the transformation of histoblast cells into adult structures during pupal metamorphosis. Histoblast cells are cells founded in the embryo that are the progenitors to the adult abdomen.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"501649d4bb1941daae7871f280ee7f45","type":"GO_TERM","name":"histone H1 acetyltransferase activity","canonical_id":"go:GO:0160262","description":"\"Catalysis of the reaction: acetyl-CoA + histone H1 = CoA + acetyl-histone H1.\" [PMID:40240600]","metadata":null},{"id":"4f5b7256fe94441ca2693dfd316159ca","type":"GO_TERM","name":"histone H1 asparagine deamidase activity","canonical_id":"go:GO:0160261","description":"\"Catalysis of the reaction: histone H1 L-asparagine + H2O = histone H1 L-aspartate + NH4+.\" [PMID:40240600]","metadata":null},{"id":"f781970fbaa94eb283c26d58e03626bc","type":"GO_TERM","name":"histone H1 demethylase activity","canonical_id":"go:GO:0160243","description":"\"Catalysis of the removal of a methyl group from a modified lysine residue of the histone H1 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:19144645]","metadata":null},{"id":"7574781dafbf4f9ebf178351118b52d5","type":"GO_TERM","name":"histone H1 kinase activity","canonical_id":"go:GO:0140190","description":"\"Catalysis of the transfer of a phosphate group to a histone H1.\" [PMID:21511733, PMID:21852232, PMID:33238524]","metadata":null},{"id":"a52d79f764c446ada3688ec4a7c57812","type":"GO_TERM","name":"histone H1 methyltransferase activity","canonical_id":"go:GO:0140188","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a histone H1 = S-adenosyl-L-homocysteine + a methylated histone H1.\" [PMID:19144645]","metadata":null},{"id":"6912efdedce74922a423e51b3ee66a38","type":"GO_TERM","name":"histone H1 reader activity","canonical_id":"go:GO:0140128","description":"\"A histone reader that specifically binds either to an unmodified histone H1 or a form modified by a post-translational modification on a specific residue. The most common PTMs on histones are methylation, acetylation and phosphorylation.\" [PMID:17540172]","metadata":null},{"id":"a19da58381884f26b4541c39b2daf64b","type":"GO_TERM","name":"histone H1-4K34 acetyltransferase activity","canonical_id":"go:GO:0140187","description":"\"Catalysis of the reaction: acetyl-CoA + histone H1-4 L-lysine (position 34) = CoA + histone H1-4 N6-acetyl-L-lysine (position 34).\" [PMID:22465951]","metadata":null},{"id":"c41807bc32fd44e086a2a6d2ba0c5f4e","type":"GO_TERM","name":"histone H1-4S187 kinase activity","canonical_id":"go:GO:0140191","description":"\"Catalysis of the reaction: histone H1-4-serine (position 27) + ATP = histone H1-4-phosphoserine (position 27) + ADP.\" [PMID:21511733]","metadata":null},{"id":"c3ced6ce74214596856c2cfdd1f54241","type":"GO_TERM","name":"histone H1-4S27 kinase activity","canonical_id":"go:GO:0140197","description":"\"Catalysis of the reaction: histone H1-4-serine (position 187) + ATP = histone H1-4-phosphoserine (position 187) + ADP.\" [PMID:21511733, PMID:21852232, PMID:33238524]","metadata":null},{"id":"9117c338ba5a4f679310dfa107e6a292","type":"GO_TERM","name":"histone H1-4S35 kinase activity","canonical_id":"go:GO:0140198","description":"\"Catalysis of the reaction: histone H1-4-serine (position 35) + ATP = histone H1-4-phosphoserine (position 35) + ADP.\" [PMID:21852232]","metadata":null},{"id":"8fd4e60d1e8345f89eef011241ee3a7d","type":"GO_TERM","name":"histone H1K26me1 reader activity","canonical_id":"go:GO:0160267","description":"\"A histone reader that recognizes a histone H1 monomethylated at lysine 26.\" [PMID:17540172]","metadata":null},{"id":"186bfb922356473db7c4274d4882fe75","type":"GO_TERM","name":"histone H1K26me2 reader activity","canonical_id":"go:GO:0160268","description":"\"A histone reader that recognizes a histone H1 dimethylated at lysine 26.\" [PMID:17540172]","metadata":null},{"id":"202948fee6904ec0887164e181d66aaa","type":"GO_TERM","name":"histone H1K75 acetyltransferase activity","canonical_id":"go:GO:0160263","description":"\"Catalysis of the reaction: acetyl-CoA + histone H1 L-lysine (position 75) = CoA + histone H1 N6-acetyl-L-lysine (position 75).\" [PMID:40240600]","metadata":null},{"id":"b8e8a34242c5433da93d03525e1946e2","type":"GO_TERM","name":"histone H1N76/N77 asparagine deamidase activity","canonical_id":"go:GO:0160264","description":"\"Catalysis of the reaction: histone H1 L-asparagine [positions 76 and 77] + H2O = histone H1 L-aspartate [positions 76 and 77] + NH4+.\" [PMID:40240600]","metadata":null},{"id":"e82787e3d27c4a7f83bd35c96240d2ae","type":"GO_TERM","name":"histone H1R54 arginine deiminase activity","canonical_id":"go:GO:0140810","description":"\"Catalysis of the reaction: H2O + histone H1 L-arginyl (position 54)= histone H1 L-citrullyl (position 54) + NH4+, resulting in histone H1 citrullination at position 54.\" [PMID:24463520]","metadata":null},{"id":"6a0d222ec4fe46489187c3706a54f61a","type":"GO_TERM","name":"histone H2A acetyltransferase activity","canonical_id":"go:GO:0043998","description":"\"Catalysis of the reaction: acetyl-CoA + histone H2A L-lysine = CoA + histone H2A N6-acetyl-L-lysine.\" [PMID:19056256]","metadata":null},{"id":"ece3b9664daf46d3b51589d004395229","type":"GO_TERM","name":"histone H2A deubiquitinase activity","canonical_id":"go:GO:0140950","description":"\"A histone deubiquitinase that cleaves ubiquitin from a histone H2A protein to which it is conjugated.\" [PMID:18226187, PMID:20436459]","metadata":null},{"id":"ab99c09c58984bcc93928aabb28c269b","type":"GO_TERM","name":"histone H2A kinase activity","canonical_id":"go:GO:0140995","description":"\"Catalysis of the transfer of a phosphate group to a histone H2A.\" [PMID:25303536]","metadata":null},{"id":"37ed077f3f9a4f1aa42e7d2a858d9745","type":"GO_TERM","name":"histone H2A methyltransferase activity","canonical_id":"go:GO:0140940","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a histone H2 = S-adenosyl-L-homocysteine + a methylated histone H2A. Histone methylation generally occurs on either an arginine or a lysine residue.\" [PMID:28450737]","metadata":null},{"id":"20e50d5e5f604010bef0eed24bbf45cb","type":"GO_TERM","name":"histone H2A reader activity","canonical_id":"go:GO:0140054","description":"\"A histone reader that specifically binds either to an unmodified histone H2A or a form modified by a post-translational modification on a specific residue. The most common PTMs on histones are methylation, acetylation and phosphorylation.\" [PMID:11498575, PMID:25688442, PMID:31082667, PMID:34726351]","metadata":null},{"id":"68a9197393e249029a13c27746f40ee1","type":"GO_TERM","name":"histone H2A ubiquitin ligase activity","canonical_id":"go:GO:0141053","description":"\"Catalysis of the transfer of ubiquitin to a histone H2A substrate.\" [PMID:25303536]","metadata":null},{"id":"1bef1236bd0d45a387b938c386dbfe6d","type":"GO_TERM","name":"histone H2AK119 ubiquitin ligase activity","canonical_id":"go:GO:0140862","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 2A at the lysine-119 residue.\" [PMID:22844243, PMID:25470042, PMID:28624371]","metadata":null},{"id":"06921d65bf13461c97053c11fd308e96","type":"GO_TERM","name":"histone H2AK127 ubiquitin ligase activity","canonical_id":"go:GO:0140863","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 2A at the lysine-127 residue.\" [PMID:28624371]","metadata":null},{"id":"67e850e6b4bf465b945df852ce43d33b","type":"GO_TERM","name":"histone H2AK129 ubiquitin ligase activity","canonical_id":"go:GO:0140864","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 2A at the lysine-129 residue.\" [PMID:28624371]","metadata":null},{"id":"56517dd3242c4d0ba981e16e8d626701","type":"GO_TERM","name":"histone H2AK13 ubiquitin ligase activity","canonical_id":"go:GO:0140856","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 2A at the lysine-13 residue.\" [PMID:22980979, PMID:28624371]","metadata":null},{"id":"0fc4187d17db4c09bb8c96c3500432d6","type":"GO_TERM","name":"histone H2AK15 ubiquitin ligase activity","canonical_id":"go:GO:0140858","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 2A at the lysine-15 residue.\" [PMID:22980979, PMID:28624371]","metadata":null},{"id":"1a920276d4e64e32b3e059d0b887023a","type":"GO_TERM","name":"histone H2AK15ac reader activity","canonical_id":"go:GO:0140126","description":"\"A histone reader that recognizes a histone H2A acetylated at lysine 15.\" [PMID:27153538]","metadata":null},{"id":"6f8e6611bdc14ae8a84695421e8529e1","type":"GO_TERM","name":"histone H2AK15ub reader activity","canonical_id":"go:GO:0140120","description":"\"A histone reader that recognizes a histone H2A ubiquitinated at lysine 15.\" [PMID:23760478]","metadata":null},{"id":"a227921073ac4b63b142b6f490d8f7ad","type":"GO_TERM","name":"histone H2AK5 acetyltransferase activity","canonical_id":"go:GO:0043999","description":"\"Catalysis of the reaction: acetyl-CoA + histone H2A L-lysine (position 5) = CoA + histone H2A N6-acetyl-L-lysine (position 5).\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"356e29db4b7a4e6c8dd6af5977d8f142","type":"GO_TERM","name":"histone H2AK5ac reader activity","canonical_id":"go:GO:0140130","description":"\"A histone reader that recognizes a histone H2A acetylated at lysine 5.\" [PMID:18469222]","metadata":null},{"id":"4367b24c3193420594fc3883860d8312","type":"GO_TERM","name":"histone H2AK9 acetyltransferase activity","canonical_id":"go:GO:0044012","description":"\"Catalysis of the reaction: acetyl-CoA + histone H2A L-lysine (position 9) = CoA + histone H2A N6-acetyl-L-lysine (position 9).\" [PMID:18552846]","metadata":null},{"id":"b85cf6400eaa4ecfb62997c07ab5b505","type":"GO_TERM","name":"histone H2AQ104 methyltransferase activity","canonical_id":"go:GO:1990259","description":"\"Catalysis of the reaction: L-glutamine(104)-[histone H2A] + S-adenosyl-L-methionine = N(5)-methyl-L-glutamine(104)-[histone H2A] + S-adenosyl-L-homocysteine + H+. Note that this corresponds to Q105 in yeast.\" [PMID:24352239, RHEA:43228]","metadata":null},{"id":"5327df4281e34636b1d4ba399dcda009","type":"GO_TERM","name":"histone H2AR3 arginine deiminase activity","canonical_id":"go:GO:0140811","description":"\"Catalysis of the reaction: H2O + histone 2A L-arginyl (position 3)= histone 2A L-citrullyl (position 3) + NH4+, resulting in histone H2A citrullination at position 3.\" [PMID:15823041]","metadata":null},{"id":"3c02321905564dba8e565a32cb06b5f0","type":"GO_TERM","name":"histone H2AR3 methyltransferase activity","canonical_id":"go:GO:0070612","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (histone H2A)-arginine (position 3) = S-adenosyl-L-homocysteine + (histone H2A)-N-methyl-arginine (position 3). This reaction is the addition of a methyl group to the arginine residue at position 3 of histone H2A.\" [GOC:mah, PMID:17898714, PMID:23451136]","metadata":null},{"id":"add0f110aa4a4a0f881128b39f4ab100","type":"GO_TERM","name":"histone H2AS1 kinase activity","canonical_id":"go:GO:0044024","description":"\"Catalysis of the reaction: histone H2A-serine (position 1) + ATP = histone H2A-phosphoserine (position 1) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 1 of histone H2A.\" [GOC:jl]","metadata":null},{"id":"b2adda2ea37e4665adeda5bcf7158cde","type":"GO_TERM","name":"histone H2AS121 kinase activity","canonical_id":"go:GO:0072371","description":"\"Catalysis of the reaction: histone H2A-serine (position 121) + ATP = histone H2A-phosphoserine (position 121) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 121 of histone H2A. This serine residue is present inthe histone H2A of fungi and Tetrahymena. This position corresponds to T120 in metazoa.\" [PMID:19965387]","metadata":null},{"id":"7638d6f538d5453583d10fbb98bd9307","type":"GO_TERM","name":"histone H2AS139pho reader activity","canonical_id":"go:GO:0140173","description":"\"A histone reader that recognizes a histone H2A phosphorylated at serine 139.\" [PMID:20679485]","metadata":null},{"id":"e4b48f124d4241d1a75c70be6ee282a7","type":"GO_TERM","name":"histone H2AT120 kinase activity","canonical_id":"go:GO:1990244","description":"\"Catalysis of the reaction: histone H2A-threonine (position 120) + ATP = histone H2A-phosphothreonine (position 120) + ADP. This reaction is the addition of a phosphate group to the threonine residue at position 120 of histone H2A.\" [PMID:24140421]","metadata":null},{"id":"3c864814e02f4ca08001234243a7cf9d","type":"GO_TERM","name":"histone H2AT120pho reader activity","canonical_id":"go:GO:0140172","description":"\"A histone reader that recognizes a histone H2A phosphorylated at threonine 120.\" [PMID:19965387, PMID:20679485]","metadata":null},{"id":"2dba7d2925924a948a042ad3968fd6f3","type":"GO_TERM","name":"histone H2AX kinase activity","canonical_id":"go:GO:0141003","description":"\"Catalysis of the transfer of a phosphate group to a histone variant H2AX.\" [GOC:bf]","metadata":null},{"id":"a360538a1d7b4b9f9259f0736b8fb62b","type":"GO_TERM","name":"histone H2AXS139 kinase activity","canonical_id":"go:GO:0035979","description":"\"Catalysis of the reaction: histone H2AX-serine (position 139) + ATP = histone H2AX-phosphoserine (position 139) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 139 of histone variant H2AX.\" [PMID:11893489, PMID:16061642]","metadata":null},{"id":"7bb7164545364d7b8ff1f7d9bf422892","type":"GO_TERM","name":"histone H2AXS139 phosphatase activity","canonical_id":"go:GO:0140791","description":"\"Catalysis of the reaction: histone H2AX serine phosphate (position 139) + H2O = histone H2AX serine (position 139) + phosphate.\" [PMID:18614045]","metadata":null},{"id":"4afc66c2671b46398e5f210d8f34823e","type":"GO_TERM","name":"histone H2AXY142 kinase activity","canonical_id":"go:GO:0140801","description":"\"Catalysis of the reaction: histone H2AX-tyrosine (position 142) + ATP = (histone H2AX-phosphotyrosine (position 142) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 142 of histone variant H2AX.\" [PMID:19092802]","metadata":null},{"id":"ee3fcbeb41dc4b849636ffe223e95be8","type":"GO_TERM","name":"histone H2AXY142 phosphatase activity","canonical_id":"go:GO:0140793","description":"\"Catalysis of the reaction: histone H2AX tyrosine phosphate (position 142) + H2O = histone H2AX tyrosine (position 142) + phosphate.\" [PMID:19234442, PMID:19351884]","metadata":null},{"id":"cfca6c2ccb9a49f9b253a82dde60f643","type":"GO_TERM","name":"histone H2B C-terminal K residue ubiquitin ligase activity","canonical_id":"go:GO:0140850","description":"\"Catalysis of the transfer of a ubiquitin molecule to a histone 2B at the conserved C-terminal lysine (K) residue. The last K residue is at position 119 in fission yeast, 123 in budding yeast, and 120 in mammals.\" [PMID:17363370, PMID:28624371]","metadata":null},{"id":"0fd4be1641f248ef8676361825fa8185","type":"GO_TERM","name":"histone H2B acetyltransferase activity","canonical_id":"go:GO:0044013","description":"\"Catalysis of the reaction: acetyl-CoA + histone H2B L-lysine = CoA + histone H2B N6-acetyl-L-lysine.\" [PMID:19056256]","metadata":null},{"id":"8daf63de2b5942debb15e5dde5794765","type":"GO_TERM","name":"histone H2B conserved C-terminal lysine deubiquitinase activity","canonical_id":"go:GO:0140935","description":"\"A histone deubiquitinase that cleaves ubiquitin from the conserved C-terminal lysine residue of a histone H2B protein to which it is conjugated. The conserved lysine residue is K119 in fission yeast, K123 in budding yeast, and K120 in mammals.\" [PMID:15657442]","metadata":null},{"id":"6af1b91fa4f04bc7a7aaec10b15ef1e6","type":"GO_TERM","name":"histone H2B deubiquitinase activity","canonical_id":"go:GO:0140936","description":"\"A histone deubiquitinase that cleaves ubiquitin from a histone H2B protein to which it is conjugated.\" [PMID:18206972, PMID:29352077]","metadata":null},{"id":"674650472cda40d1aa2c9acbff1f50a0","type":"GO_TERM","name":"histone H2B kinase activity","canonical_id":"go:GO:0140998","description":"\"Catalysis of the transfer of a phosphate group to a histone H2B.\" [PMID:25303536]","metadata":null},{"id":"21330009fa204af4a4c41d399e48a6e0","type":"GO_TERM","name":"histone H2B reader activity","canonical_id":"go:GO:0140071","description":"\"A histone reader that specifically binds either to an unmodified histone H2B or a form modified by a post-translational modification on a specific residue. The most common PTMs on histones are methylation, acetylation and phosphorylation.\" [PMID:11498575, PMID:25688442, PMID:31082667, PMID:34726351]","metadata":null},{"id":"48e650816d83419e85d8dcba08374165","type":"GO_TERM","name":"histone H2B ubiquitin ligase activity","canonical_id":"go:GO:0141054","description":"\"Catalysis of the transfer of ubiquitin to a histone H2B substrate.\" [PMID:25303536]","metadata":null},{"id":"f6039bdd1c424f7097229d13dbac1a33","type":"GO_TERM","name":"histone H2BK12 acetyltransferase activity","canonical_id":"go:GO:0044015","description":"\"Catalysis of the reaction: acetyl-CoA + histone H2B L-lysine (position 12) = CoA + histone H2B N6-acetyl-L-lysine (position 12).\" [PMID:18552846]","metadata":null},{"id":"80dc0207ec784f3d92486adc9b4060a7","type":"GO_TERM","name":"histone H2BK5 acetyltransferase activity","canonical_id":"go:GO:0044014","description":"\"Catalysis of the reaction: acetyl-CoA + histone H2B L-lysine (position 5) = CoA + histone H2B N6-acetyl-L-lysine (position 5).\" [PMID:18552846]","metadata":null},{"id":"55907e68dc6a45cdaf2050b3e7e392b8","type":"GO_TERM","name":"histone H2BS14 kinase activity","canonical_id":"go:GO:0044025","description":"\"Catalysis of the reaction: histone H2B-serine (position 14) + ATP = histone H2B-phosphoserine (position 14) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 14 of histone H2B.\" [PMID:15652479]","metadata":null},{"id":"28b95c63fdea4963a6cb185b83f24ac0","type":"GO_TERM","name":"histone H2BS36 kinase activity","canonical_id":"go:GO:0140823","description":"\"Catalysis of the reaction: histone H2B-serine (position 36) + ATP = histone H2B-phosphoserine (position 36) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 36 of histone H2B.\" [PMID:32822587]","metadata":null},{"id":"06207cefc1c14a72aedcaa1ccef315c7","type":"GO_TERM","name":"histone H3 acetyltransferase activity","canonical_id":"go:GO:0010484","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 = CoA + acetyl-histone H3.\" [PMID:19056256]","metadata":null},{"id":"2a7c7b2f0bf64282ad3d3719889eff6e","type":"GO_TERM","name":"histone H3 arginine deiminase activity","canonical_id":"go:GO:0141057","description":"\"Catalysis of the reaction: H2O + histone H3 L-arginyl = histone H3 L-citrullyl + NH4+, resulting in histone H3 citrullination.\" [PMID:25303536]","metadata":null},{"id":"54fde25f4ce24dbe8c43ea40ee51b7c5","type":"GO_TERM","name":"histone H3 demethylase activity","canonical_id":"go:GO:0141052","description":"\"Catalysis of the removal of a methyl group from a modified lysine residue of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:17947579]","metadata":null},{"id":"400c092b654241afa93adc592b5fc1d8","type":"GO_TERM","name":"histone H3 kinase activity","canonical_id":"go:GO:0140996","description":"\"Catalysis of the transfer of a phosphate group to a histone H3.\" [PMID:25303536]","metadata":null},{"id":"1010225f4e7f44bda70740af722b3d44","type":"GO_TERM","name":"histone H3 methyltransferase activity","canonical_id":"go:GO:0140938","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a histone H3 = S-adenosyl-L-homocysteine + a methylated histone H3. Histone methylation generally occurs on either an arginine or a lysine residue.\" [PMID:28450737]","metadata":null},{"id":"e3e0170e9b28437994267be4aec4e1a2","type":"GO_TERM","name":"histone H3 reader activity","canonical_id":"go:GO:0140006","description":"\"A histone reader that specifically binds either to an unmodified histone H3 or a form modified by a post-translational modification on a specific residue. The most common PTMs on histones are methylation, acetylation and phosphorylation.\" [PMID:11498575, PMID:25688442, PMID:31082667, PMID:34726351]","metadata":null},{"id":"e6375625ca174494a65b047f4edbc111","type":"GO_TERM","name":"histone H3 ubiquitin ligase activity","canonical_id":"go:GO:0141055","description":"\"Catalysis of the transfer of ubiquitin to a histone H3 substrate.\" [PMID:25303536]","metadata":null},{"id":"419f37e1ee3f4e299b3f9d49fab93870","type":"GO_TERM","name":"histone H3-K14 acetyltransferase complex","canonical_id":"go:GO:0036409","description":"\"A protein complex that can catalyze the acetylation of lysine at position 14 in histone H3.\" [GOC:vw, PMID:21289066]","metadata":null},{"id":"55d703364e0d4be8bd24a15895c86096","type":"GO_TERM","name":"histone H3-containing nucleosome","canonical_id":"go:GO:0140573","description":"\"A complex comprised of DNA wound around a multisubunit core and associated proteins containing the histone H3, which forms the primary packing unit of DNA into higher order structures.\" [PMID:33155135]","metadata":null},{"id":"7376019fd4d94802b70c6cf25579b52f","type":"GO_TERM","name":"histone H3K deacetylase activity","canonical_id":"go:GO:0141050","description":"\"Removal of an acetyl group from a lysine residue in a histone H3.\" [GOC:pg, PMID:9893272]","metadata":null},{"id":"0e3855e03b634857ad895d6721ac0c7f","type":"GO_TERM","name":"histone H3K122 acetyltransferase activity","canonical_id":"go:GO:0140908","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 122) = CoA + histone H3 N6-acetyl-L-lysine (position 122).\" [PMID:23415232]","metadata":null},{"id":"350ecdda879d4542ae8fb0ba5c194bca","type":"GO_TERM","name":"histone H3K14 acetyltransferase activity","canonical_id":"go:GO:0036408","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 14) = CoA + histone H3 N6-acetyl-L-lysine (position 14).\" [GOC:vw, PMID:18552846, PMID:19056256, PMID:21289066]","metadata":null},{"id":"d4e5d708c1e54754b0c3b78d8a555804","type":"GO_TERM","name":"histone H3K14 deacetylase activity, NAD-dependent","canonical_id":"go:GO:0032041","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 14) + NAD+ + H2O = histone H3 L-lysine (position 14) + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group attached to a lysine residue in H3K14 to NAD, producing nicotinamide.\" [PMID:28450737]","metadata":null},{"id":"05cedf9497484bf594d977ad6688b749","type":"GO_TERM","name":"histone H3K14 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0031078","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 14) + H2O = histone H3 L-lysine (position 14) + acetate. This reaction represents the removal of an acetyl group from lysine at position 14 of the histone H3 protein.\" [PMID:28450737]","metadata":null},{"id":"5cf00653d8e341b6a3f98b1df7264caf","type":"GO_TERM","name":"histone H3K14 ubiquitin ligase activity","canonical_id":"go:GO:0140851","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 3 at the lysine-14 residue.\" [PMID:28624371, PMID:31468675, PMID:34010645]","metadata":null},{"id":"2332d372b05c425ca31cd73ce1e01049","type":"GO_TERM","name":"histone H3K14ac reader activity","canonical_id":"go:GO:0140015","description":"\"A histone reader that recognizes a histone H3 acetylated at lysine 14.\" [PMID:30110338]","metadata":null},{"id":"78e0c5d5cbb94012b7414120634b5713","type":"GO_TERM","name":"histone H3K14ub reader activity","canonical_id":"go:GO:0140258","description":"\"A histone reader that recognizes a histone H3 ubiquitinated at lysine 14.\" [PMID:29053958, PMID:34524082]","metadata":null},{"id":"40325c3f88114d04a6b7c5d9fca3ec43","type":"GO_TERM","name":"histone H3K18 acetyltransferase activity","canonical_id":"go:GO:0043993","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 18) = CoA + histone H3 N6-acetyl-L-lysine (position 18).\" [PMID:18552846]","metadata":null},{"id":"b19136e9ab1d4bf199971549f4ffa17c","type":"GO_TERM","name":"histone H3K18 deacetylase activity, NAD-dependent","canonical_id":"go:GO:0097372","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 18) + NAD+ + H2O = histone H3 L-lysine (position 18) + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group attached to a lysine residue in H3K18 to NAD, producing nicotinamide.\" [GOC:sp, PMID:22722849, PMID:28450737]","metadata":null},{"id":"06d81bd95ccd41768525c341feb1dc3f","type":"GO_TERM","name":"histone H3K18 decrotonylase activity","canonical_id":"go:GO:0170012","description":"\"Catalysis of the reaction: H2O + N6-(2E)-butenoyl-L-lysyl-[histone H3 position 18] + NAD+ = 2''-O-(2E)-but-2-enoyl-ADP-D-ribose + L-lysyl-[histone H3] + nicotinamide.\" [PMID:34927582]","metadata":null},{"id":"e51afb39cfbb4af69b77ac1a95fd79cb","type":"GO_TERM","name":"histone H3K18 ubiquitin ligase activity","canonical_id":"go:GO:0140248","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 3 at the lysine-18 residue.\" [PMID:27595565]","metadata":null},{"id":"ff691de0c2e14447b8ff3d602db8f5c9","type":"GO_TERM","name":"histone H3K18ac reader activity","canonical_id":"go:GO:0140044","description":"\"A histone reader that recognizes a histone H3 acetylated at lysine 18.\" [PMID:30110338]","metadata":null},{"id":"4a4ecade1076451986bb0dae694f4819","type":"GO_TERM","name":"histone H3K18cr reader activity","canonical_id":"go:GO:0140017","description":"\"A histone reader that recognizes a histone H3 crotonylated at lysine 18.\" [PMID:27105114]","metadata":null},{"id":"7786bbc3b2874e609e6d15f15439c79a","type":"GO_TERM","name":"histone H3K18ub reader activity","canonical_id":"go:GO:0140254","description":"\"A histone reader that recognizes a histone H3 ubiquitinated at lysine 18.\" [PMID:29053958]","metadata":null},{"id":"19594385b7e44f3fac6db8206e91b8fb","type":"GO_TERM","name":"histone H3K23 acetyltransferase activity","canonical_id":"go:GO:0043994","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 23) = CoA + histone H3 N6-acetyl-L-lysine (position 23).\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"b5f401cc98de4b7d8ba41eaabca21292","type":"GO_TERM","name":"histone H3K23 ubiquitin ligase activity","canonical_id":"go:GO:0140234","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 3 at the lysine-23 residue.\" [PMID:40680746]","metadata":null},{"id":"19ae59632eb34e53b0d7ddd6ad25f1fc","type":"GO_TERM","name":"histone H3K23ac reader activity","canonical_id":"go:GO:0140118","description":"\"A histone reader that recognizes a histone H3 acetylated at lysine 23.\" [PMID:21164480]","metadata":null},{"id":"398c60c721b24559ab8871905f026233","type":"GO_TERM","name":"histone H3K23ub reader activity","canonical_id":"go:GO:0140257","description":"\"A histone reader that recognizes a histone H3 ubiquitinated at lysine 23.\" [PMID:29053958]","metadata":null},{"id":"3d84cc6b81a24cd29abfb57b87854b91","type":"GO_TERM","name":"histone H3K27 acetyltransferase activity","canonical_id":"go:GO:0044017","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 27) = CoA + histone H3 N6-acetyl-L-lysine (position 27).\" [PMID:18552846]","metadata":null},{"id":"0f3600b7f1e045ae913dc84b4978140d","type":"GO_TERM","name":"histone H3K27 dimethyltransferase activity","canonical_id":"go:GO:0140952","description":"\"Catalysis of the reaction: L-lysyl27-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl27-[histone H3] + 2 S-adenosyl-L-homocysteine. This reaction is the successive addition of two methyl groups to the unmethylated lysine residue at position 27 of histone H3, producing histone H3K27me2.\" [RHEA:64452]","metadata":null},{"id":"78dffed3b60e44d0b21dd8211baa1075","type":"GO_TERM","name":"histone H3K27 methyltransferase activity","canonical_id":"go:GO:0046976","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 27) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 27). This reaction is the addition of a methyl group to the lysine residue at position 27 of the histone H3 protein.\" [GOC:ai]","metadata":null},{"id":"7e05ae60e9ba4d8486b9dd0a456f757f","type":"GO_TERM","name":"histone H3K27 monomethyltransferase activity","canonical_id":"go:GO:0140953","description":"\"Catalysis of the reaction: L-lysyl27-[histone H3] + S-adenosyl-L-methionine = H+ + N6-methyl-L-lysyl27-[histone H3] + S-adenosyl-L-homocysteine. This reaction is the addition of a single methyl group to the unmethylated lysine residue at position 27 of histone H3, producing histone H3K27me.\" [RHEA:60296]","metadata":null},{"id":"3b10ea7b215c4438af66e8d0a117ce9a","type":"GO_TERM","name":"histone H3K27 trimethyltransferase activity","canonical_id":"go:GO:0140951","description":"\"Catalysis of the reaction: L-lysyl27-[histone H3] + 3 S-adenosyl-L-methionine = 3 H+ + N6,N6,N6-trimethyl-L-lysyl27-[histone H3] + 3 S-adenosyl-L-homocysteine. This reaction is the successive addition of three methyl groups to the unmethylated lysine residue at position 27 of histone H3, producing histone H3K27me3.\" [RHEA:60292]","metadata":null},{"id":"9a83e9333cbf45e2a763c636a852bb5d","type":"GO_TERM","name":"histone H3K27ac reader activity","canonical_id":"go:GO:0140119","description":"\"A histone reader that recognizes a histone H3 acetylated at lysine 27.\" [PMID:25417107]","metadata":null},{"id":"c1f818fb2964410eb77a954b503f378a","type":"GO_TERM","name":"histone H3K27cr reader activity","canonical_id":"go:GO:0140038","description":"\"A histone reader that recognizes a histone H3 crotonylated at lysine 27.\" [PMID:27105114]","metadata":null},{"id":"62a0ab58442944c2bcf195ebe8d47359","type":"GO_TERM","name":"histone H3K27me2/H3K27me3 demethylase activity","canonical_id":"go:GO:0071558","description":"\"Catalysis of the removal of a methyl group from a tri- or a dimethyl-lysine residue at position 27 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [GOC:sp, PMID:20622853]","metadata":null},{"id":"7cd11b1efdd34e918d49ecaa0f500d8c","type":"GO_TERM","name":"histone H3K27me3 reader activity","canonical_id":"go:GO:0061628","description":"\"A histone reader that recognizes a histone H3 trimethylated at lysine 27.\" [GOC:dph, PMID:23948251]","metadata":null},{"id":"6373f3e4e30f4ce08b8f7ec341c3e719","type":"GO_TERM","name":"histone H3K36 acetyltransferase activity","canonical_id":"go:GO:0044018","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 36) = CoA + histone H3 N6-acetyl-L-lysine (position 36).\" [PMID:18552846]","metadata":null},{"id":"c9bfafa4361241c4ad51ac96234ba9fd","type":"GO_TERM","name":"histone H3K36 demethylase activity","canonical_id":"go:GO:0051864","description":"\"Catalysis of the removal of a methyl group from a modified lysine residue at position 36 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:16362057]","metadata":null},{"id":"7d0f5829ee6347ef9eeae41944002a13","type":"GO_TERM","name":"histone H3K36 dimethyltransferase activity","canonical_id":"go:GO:0140954","description":"\"Catalysis of the reaction: L-lysyl36-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl36-[histone H3] + 2 S-adenosyl-L-homocysteine. This reaction is the successive addition of two methyl groups to the lysine residue at position 36 of histone H3, producing histone H3K36me2.\" [RHEA:60308]","metadata":null},{"id":"10e38c925bb94d99a496a541baf9040f","type":"GO_TERM","name":"histone H3K36 methyltransferase activity","canonical_id":"go:GO:0046975","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 36) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 36). This reaction is the addition of a methyl group to the lysine residue at position 36 of the histone H3 protein.\" [GOC:ai]","metadata":null},{"id":"9262d8c27a074cb89f5cd8dcf8849e14","type":"GO_TERM","name":"histone H3K36 trimethyltransferase activity","canonical_id":"go:GO:0140955","description":"\"Catalysis of the reaction: L-lysyl36-[histone H3] + 3 S-adenosyl-L-methionine = 3 H+ + N6,N6,N6-trimethyl-L-lysyl36-[histone H3] + 3 S-adenosyl-L-homocysteine. This reaction is the successive addition of three methyl groups to the lysine residue at position 36 of histone H3, producing histone H3K36me3.\" [RHEA:60324]","metadata":null},{"id":"04a5ec2791ab4a51b97d6481588278ec","type":"GO_TERM","name":"histone H3K36me/H3K36me2 demethylase activity","canonical_id":"go:GO:0140680","description":"\"Catalysis of the removal of a methyl group from a di- or a monomethyl-lysine residue at position 36 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:20531378]","metadata":null},{"id":"6afe802802384445ad49e3b2cb1fb769","type":"GO_TERM","name":"histone H3K36me2/H3K36me3 demethylase activity","canonical_id":"go:GO:0140681","description":"\"Catalysis of the removal of a methyl group from a tri- or a dimethyl-lysine residue at position 36 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:21914792]","metadata":null},{"id":"98dc4e1a24984172adf4d6a5a4ddced1","type":"GO_TERM","name":"histone H3K36me3 reader activity","canonical_id":"go:GO:0140003","description":"\"A histone reader that recognizes a histone H3 trimethylated at lysine 36.\" [PMID:15489290, PMID:16364921]","metadata":null},{"id":"d3ac50c27ad740a9b2fa3924927be972","type":"GO_TERM","name":"histone H3K37 methyltransferase activity","canonical_id":"go:GO:0062122","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 37) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 37). This reaction is the addition of a methyl group to the lysine residue at position 37 of the histone H3 protein.\" [PMID:30773398]","metadata":null},{"id":"52d44a922b2e43fea2f00af3e62907a5","type":"GO_TERM","name":"histone H3K4 acetyltransferase activity","canonical_id":"go:GO:0044016","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 4) = CoA + histone H3 N6-acetyl-L-lysine (position 4).\" [PMID:18552846]","metadata":null},{"id":"3d9f477c3046403782a50a9c7ef05fa5","type":"GO_TERM","name":"histone H3K4 deacetylase activity, NAD-dependent","canonical_id":"go:GO:0141222","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 14) + NAD+ + H2O = histone H3 L-lysine (position 14) + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group attached to a lysine residue in H3K4 to NAD, producing nicotinamide.\" [PMID:20299449, PMID:23771057]","metadata":null},{"id":"ea5612a1c76b425d9ead5de2ed585038","type":"GO_TERM","name":"histone H3K4 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:1990162","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 4) + H2O = histone H3 L-lysine (position 4) + acetate. This reaction represents the removal of an acetyl group from lysine at position 4 of the histone H3 protein.\" [GOC:al, PMID:23771057, PMID:28450737]","metadata":null},{"id":"572309fadec747739ac7faa972b1bc44","type":"GO_TERM","name":"histone H3K4 demethylase activity","canonical_id":"go:GO:0032453","description":"\"Catalysis of the removal of a methyl group from a modified lysine residue at position 4 of the histone H3 protein.\" [GOC:mah]","metadata":null},{"id":"ada1db5a4205435681a8b9c572e24574","type":"GO_TERM","name":"histone H3K4 dimethyltransferase activity","canonical_id":"go:GO:0140946","description":"\"Catalysis of the reaction: L-lysyl4-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl4-[histone H3] + 2 S-adenosyl-L-homocysteine. This reaction is the successive addition of two methyl groups to the unmethylated lysine residue at position 4 of histone H3, producing histone H3K4me2.\" [RHEA:64448]","metadata":null},{"id":"d56b3f21d2da4411b136cc29105da811","type":"GO_TERM","name":"histone H3K4 methyltransferase activity","canonical_id":"go:GO:0042800","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 4) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 4). This reaction is the addition of up to three methyl groups to the lysine residue at position 4 of the histone H3 protein.\" [PMID:12086618]","metadata":null},{"id":"331f8d7e1b5b413095d9f3b10bd109e9","type":"GO_TERM","name":"histone H3K4 monomethyltransferase activity","canonical_id":"go:GO:0140945","description":"\"Catalysis of the reaction: L-lysyl4-[histone H3] + S-adenosyl-L-methionine = H+ + N6-methyl-L-lysyl4-[histone H3] + S-adenosyl-L-homocysteine. This reaction is the addition of a single methyl group to the unmethylated lysine residue at position 4 of histone H3, producing histone H3K4me.\" [RHEA:60264]","metadata":null},{"id":"5041deac8c5f4b96ac70612f14bdae2b","type":"GO_TERM","name":"histone H3K4 trimethyltransferase activity","canonical_id":"go:GO:0140999","description":"\"Catalysis of the reaction: L-lysyl4-[histone H3] + 3 S-adenosyl-L-methionine = 2 H+ + N6,N6-trimethyl-L-lysyl4-[histone H3] + 3 S-adenosyl-L-homocysteine. This reaction is the successive addition of three methyl groups to the unmethylated lysine residue at position 4 of histone H3, producing histone H3K4me3.\" [PMID:18375658, RHEA:60260]","metadata":null},{"id":"5513e8eccb814a9e9173a3ff677ce012","type":"GO_TERM","name":"histone H3K4me/H3K4me2/H3K4me3 demethylase activity","canonical_id":"go:GO:0034647","description":"\"Catalysis of the removal of a methyl group from a tri, a di or a monomethyl-lysine residue at position 4 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:17550896, PMID:22473470]","metadata":null},{"id":"3a769df438c946c9836743c0c423fc54","type":"GO_TERM","name":"histone H3K4me1 reader activity","canonical_id":"go:GO:0140109","description":"\"A histone reader that recognizes a histone H3 monomethylated at lysine 4.\" [PMID:18840606, PMID:29255264]","metadata":null},{"id":"06720ed645d94e4eb68ba55324b5e3f3","type":"GO_TERM","name":"histone H3K4me3 reader activity","canonical_id":"go:GO:0140002","description":"\"A histone reader that recognizes a histone H3 trimethylated at lysine 4.\" [PMID:15647753, PMID:23318260]","metadata":null},{"id":"03edf14b899b40909618a81925eda462","type":"GO_TERM","name":"histone H3K56 acetyltransferase activity","canonical_id":"go:GO:0032931","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 56) = CoA + histone H3 N6-acetyl-L-lysine (position 56).\" [PMID:19056256]","metadata":null},{"id":"5550cdd1efa44e21a47a4f5f63d08a77","type":"GO_TERM","name":"histone H3K56 deacetylase activity, NAD-dependent","canonical_id":"go:GO:0140765","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 56) + NAD+ + H2O = histone H3 L-lysine (position 56) + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group attached to a lysine residue in H3K56 to NAD, producing nicotinamide.\" [PMID:23911928, PMID:30374165]","metadata":null},{"id":"8e4f358634014c39a563b9acf4917d61","type":"GO_TERM","name":"histone H3K56 methyltransferase activity","canonical_id":"go:GO:0140759","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 56) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 56). This reaction is the addition of a methyl group to the lysine residue at position 56 of the histone H3 protein.\" [PMID:23451023, PMID:28743002, RHEA:85519]","metadata":null},{"id":"993d69b84dd44d8f8fca8409b0a179a3","type":"GO_TERM","name":"histone H3K56ac reader activity","canonical_id":"go:GO:0140129","description":"\"A histone reader that recognizes a histone H3 acetylated at lysine 56.\" [PMID:23798425]","metadata":null},{"id":"671d5f8961534596ba11a0d5d3697bef","type":"GO_TERM","name":"histone H3K56me2/H3K56me3 demethylase activity","canonical_id":"go:GO:0140760","description":"\"Catalysis of the removal of a methyl group from a tri or a dimethyl-lysine residue at position 56 of the histone H3 protein.\" [PMID:23451023, PMID:28743002]","metadata":null},{"id":"8cf065f5a32b4e8393ab3ef27a2da508","type":"GO_TERM","name":"histone H3K79 dimethyltransferase activity","canonical_id":"go:GO:0120506","description":"\"Catalysis of the reaction: L-lysyl79-[histone H3] + 2 S-adenosyl-L-methionine = 2H+ + N6,N6-methyl-L-lysyl79-[histone H3] + 2 S-adenosyl-L-homocysteine.\" [PMID:14732680, PMID:15371351]","metadata":null},{"id":"296b358495474c7b9697f839a840bee0","type":"GO_TERM","name":"histone H3K79 methyltransferase activity","canonical_id":"go:GO:0031151","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 79) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 79). This reaction is the addition of a methyl group to the lysine residue at position 79 of the histone H3 protein.\" [PMID:15371351]","metadata":null},{"id":"6e68be013db34702a679a0d9b01577b6","type":"GO_TERM","name":"histone H3K79 monomethyltransferase activity","canonical_id":"go:GO:0120505","description":"\"Catalysis of the reaction: L-lysyl79-[histone H3] + S-adenosyl-L-methionine = H+ + N6-methyl-L-lysyl79-[histone H3] + S-adenosyl-L-homocysteine.\" [PMID:14732680, PMID:15371351, RHEA:60332]","metadata":null},{"id":"c874ece31a114e5fbb2d6f271b6b3b75","type":"GO_TERM","name":"histone H3K79 trimethyltransferase activity","canonical_id":"go:GO:0140956","description":"\"Catalysis of the reaction: L-lysyl79-[histone H3] + 3 S-adenosyl-L-methionine = 3 H+ + N6,N6,N6-trimethyl-L-lysyl79-[histone H3] + 3 S-adenosyl-L-homocysteine. This reaction is the successive addition of up to three methyl group to the lysine residue at position 79 of the histone H3 protein, producing H3K79me3.\" [PMID:15371351, RHEA:60328]","metadata":null},{"id":"59f66990ed88469f92651d4dbec2289d","type":"GO_TERM","name":"histone H3K9 acetyltransferase activity","canonical_id":"go:GO:0043992","description":"\"Catalysis of the reaction: acetyl-CoA + histone H3 L-lysine (position 9) = CoA + histone H3 N6-acetyl-L-lysine (position 9).\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"69877e785c76435e99bc4b16bcc52821","type":"GO_TERM","name":"histone H3K9 deacetylase activity, NAD-dependent","canonical_id":"go:GO:0046969","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 9) + NAD+ + H2O = histone H3 L-lysine (position 9) + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group attached to a lysine residue in H3K9 to NAD, producing nicotinamide.\" [PMID:28450737]","metadata":null},{"id":"55dff74143b24bd4a2f8a3f82d086bad","type":"GO_TERM","name":"histone H3K9 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0032129","description":"\"Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 9) + H2O = histone H3 L-lysine (position 9) + acetate. This reaction represents the removal of an acetyl group from lysine at position 9 of the histone H3 protein.\" [PMID:28450737]","metadata":null},{"id":"bc37780fa16d4fcdb7e7dc2973c69d81","type":"GO_TERM","name":"histone H3K9 demethylase activity","canonical_id":"go:GO:0032454","description":"\"Catalysis of the removal of a methyl group from a modified lysine residue at position 9 of the histone H3 protein.\" [PMID:16362057]","metadata":null},{"id":"4d71766b2f404daaacb8fc80af567fef","type":"GO_TERM","name":"histone H3K9 dimethyltransferase activity","canonical_id":"go:GO:0140942","description":"\"Catalysis of the reaction: L-lysyl9-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl9-[histone H3] + 2 S-adenosyl-L-homocysteine. This reaction is the successive addition of two methyl groups to the unmethylated lysine residue at position 9 of histone H3, producing histone H3K9me2.\" [RHEA:64444]","metadata":null},{"id":"588dc4416b9d4cd0bd9ec4d8101ba470","type":"GO_TERM","name":"histone H3K9 methyltransferase activity","canonical_id":"go:GO:0046974","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 9) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 9). This reaction is the addition of up to three methyl groups to the lysine residue at position 9 of the histone H3 protein.\" [GOC:ai]","metadata":null},{"id":"1ab8b5d8c6f248e59579340ff74c1f26","type":"GO_TERM","name":"histone H3K9 monomethyltransferase activity","canonical_id":"go:GO:0140948","description":"\"Catalysis of the reaction: L-lysyl9-[histone H3] + S-adenosyl-L-methionine = H+ + N6-methyl-L-lysyl9-[histone H3] + S-adenosyl-L-homocysteine. This reaction is the addition of a methyl group to the unmethylated lysine residue at position 9 of histone H3, producing histone H3K9me.\" [RHEA:60280]","metadata":null},{"id":"cab63b0a74ea4ee3a50b6ef242cc9bc5","type":"GO_TERM","name":"histone H3K9 trimethyltransferase activity","canonical_id":"go:GO:0140949","description":"\"Catalysis of the reaction: L-lysyl9-[histone H3] + 3 S-adenosyl-L-methionine = 3 H+ + N6,N6,N6-trimethyl-L-lysyl9-[histone H3] + 3 S-adenosyl-L-homocysteine. This reaction is the successive addition of three methyl groups to the unmethylated lysine residue at position 9 of histone H3, producing histone H3K9me3.\" [RHEA:60276]","metadata":null},{"id":"16c640dc616f4606bea3f1df33ac0311","type":"GO_TERM","name":"histone H3K9ac reader activity","canonical_id":"go:GO:0140072","description":"\"A histone reader that recognizes a histone H3 acetylated at lysine 9.\" [PMID:26067602]","metadata":null},{"id":"27ad350a9a2e4bcf8a17505e6bb5b78d","type":"GO_TERM","name":"histone H3K9cr reader activity","canonical_id":"go:GO:0140019","description":"\"A histone reader that recognizes a histone H3 crotonylated at lysine 9.\" [PMID:27105114]","metadata":null},{"id":"34e571609af64a0782ba1a3e391fa783","type":"GO_TERM","name":"histone H3K9me/H3K9me2 demethylase activity","canonical_id":"go:GO:0140683","description":"\"Catalysis of the removal of a methyl group from a di or a monomethyl-lysine residue at position 9 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:16603238]","metadata":null},{"id":"b4c3fed95a7d49739078f1d94a40a787","type":"GO_TERM","name":"histone H3K9me2 methyltransferase activity","canonical_id":"go:GO:0140947","description":"\"Catalysis of the reaction: N6,N6-dimethyl-L-lysyl9-[histone H3] + S-adenosyl-L-methionine = H+ + N6,N6,N6-trimethyl-L-lysyl9-[histone H3] + S-adenosyl-L-homocysteine. This reaction is the addition of a single methyl group to the dimethylated lysine residue at position 9 of histone H3, producing histone H3K9me3.\" [RHEA:60288]","metadata":null},{"id":"7e71bb8910de4cb69008b80301c594f8","type":"GO_TERM","name":"histone H3K9me2/3 reader activity","canonical_id":"go:GO:0062072","description":"\"A histone reader that recognizes a histone H3 trimethylated at lysine 9. In some organisms, there is only H3K9me2, not H3K9me3, but this modification is recognized by homologous readers.\" [PMID:30110338]","metadata":null},{"id":"5d50f850050d426fb5c0a682f52bb754","type":"GO_TERM","name":"histone H3K9me2/H3K9me3 demethylase activity","canonical_id":"go:GO:0140684","description":"\"Catalysis of the removal of a methyl group from a tri or a dimethyl-lysine residue at position 9 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:20208542, PMID:20531378]","metadata":null},{"id":"5764f8fc1fe6475399368126f910e524","type":"GO_TERM","name":"histone H3Q5ser reader activity","canonical_id":"go:GO:0140004","description":"\"A histone reader that recognizes a histone H3 serotonylated at glutamine 5.\" [PMID:34144982]","metadata":null},{"id":"98c9766c0f8640c990c7f5b628211c41","type":"GO_TERM","name":"histone H3R17 arginine deiminase activity","canonical_id":"go:GO:0140797","description":"\"Catalysis of the reaction: H2O + histone H3 L-arginyl (position 17)= histone H3 L-citrullyl (position 17) + NH4+, resulting in histone H3 citrullination at position 17.\" [PMID:15339660]","metadata":null},{"id":"5d08108205314e839c6190dd92c3814f","type":"GO_TERM","name":"histone H3R17 methyltransferase activity","canonical_id":"go:GO:0035642","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (histone H3)-arginine (position 17) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 17). This reaction is the addition of a methyl group to the arginine residue at position 17 of histone H3.\" [PMID:11341840]","metadata":null},{"id":"c40cbb624d114880b92b25c1eccbf5bd","type":"GO_TERM","name":"histone H3R2 arginine deiminase activity","canonical_id":"go:GO:0140795","description":"\"Catalysis of the reaction: H2O + histone H3 L-arginyl (position 2)= histone H3 L-citrullyl (position 2) + NH4+, resulting in histone H3 citrullination at position 2.\" [PMID:15339660]","metadata":null},{"id":"3f9b15e00d874e54a4f5479b5605716c","type":"GO_TERM","name":"histone H3R2 demethylase activity","canonical_id":"go:GO:0033746","description":"\"Catalysis of the removal of the methyl group from a modified arginine residue at position 2 of the histone H3 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:17947579, PMID:22483719, PMID:29233856]","metadata":null},{"id":"38ba25afc67b405f82fa23cef29fb7a4","type":"GO_TERM","name":"histone H3R2 methyltransferase activity","canonical_id":"go:GO:0070611","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (histone H3)-arginine (position 2) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 2). This reaction is the addition of a methyl group to the arginine residue at position 2 of histone H3.\" [PMID:17898714]","metadata":null},{"id":"a7ad7b6bd5f24af3982fe5937908c46e","type":"GO_TERM","name":"histone H3R26 arginine deiminase activity","canonical_id":"go:GO:0140798","description":"\"Catalysis of the reaction: H2O + histone H3 L-arginyl (position 26)= histone H3 L-citrullyl (position 26) + NH4+, resulting in histone H3 citrullination at position 26.\" [PMID:15339660]","metadata":null},{"id":"fdb092910f0e4981a7fc67d3f8579171","type":"GO_TERM","name":"histone H3R26 methyltransferase activity","canonical_id":"go:GO:0140903","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (histone H3)-arginine (position 26) = S-adenosyl-L-homocysteine + (histone H3)-N-methyl-arginine (position 26). This reaction is the addition of a methyl group to the arginine residue at position 26 of histone H3.\" [PMID:17882261]","metadata":null},{"id":"9571a58b648b4f7bae12a284ee3595c3","type":"GO_TERM","name":"histone H3R8 arginine deiminase activity","canonical_id":"go:GO:0140796","description":"\"Catalysis of the reaction: H2O + histone H3 L-arginyl (position 8)= histone H3 L-citrullyl (position 8) + NH4+, resulting in histone H3 citrullination at position 8.\" [PMID:15339660]","metadata":null},{"id":"adadec7eef414564bbb341caf9d27a4a","type":"GO_TERM","name":"histone H3R8 methyltransferase activity","canonical_id":"go:GO:0140592","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (histone H3)-arginine (position 8) = S-adenosyl-L-homocysteine + (histone H3-N-methyl-arginine (position 8). This reaction is the addition of a methyl group to the arginine residue at position 8 of histone H3.\" [PMID:20708585, PMID:31533925]","metadata":null},{"id":"ffbfa4e6065e49a8a0697e4bd12ee930","type":"GO_TERM","name":"histone H3R8me2 reader activity","canonical_id":"go:GO:0140127","description":"\"A histone reader that recognizes a histone H3 dimethylate at arginine 8. The methylation can be symmetrical or asymmetrical.\" [PMID:24589551]","metadata":null},{"id":"d2fa352f18ef443c8dd930801083fa14","type":"GO_TERM","name":"histone H3S10 kinase activity","canonical_id":"go:GO:0035175","description":"\"Catalysis of the reaction: histone H3-serine (position 10) + ATP = histone H3-phosphoserine (position 10) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 10 of histone H3.\" [GOC:bf, PMID:15041176]","metadata":null},{"id":"c60ef5afb36c463987961b0859ea72a1","type":"GO_TERM","name":"histone H3S28 kinase activity","canonical_id":"go:GO:0044022","description":"\"Catalysis of the reaction: histone H3-serine (position 28) + ATP = histone H3-phosphoserine (position 28) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 28 of histone H3.\" [GOC:jl]","metadata":null},{"id":"9bcfcf43e0f146dcbe453f92791ebf1c","type":"GO_TERM","name":"histone H3S57 kinase activity","canonical_id":"go:GO:0140855","description":"\"Catalysis of the reaction: histone H3-serine (position 57) + ATP = histone H3-phosphoserine (position 57) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 57 of histone H3.\" [PMID:24820035]","metadata":null},{"id":"6f3d1e4b88c84d8cb8fc1eb6d5c1be39","type":"GO_TERM","name":"histone H3T11 kinase activity","canonical_id":"go:GO:0035402","description":"\"Catalysis of the reaction: histone H3-threonine (position 11) + ATP = histone H3-phosphothreonine (position 11) + ADP. This reaction is the addition of a phosphate group to the threonine residue at position 11 of histone H3.\" [GOC:bf]","metadata":null},{"id":"921c7c38ff664c66b156842bd97972ab","type":"GO_TERM","name":"histone H3T3 kinase activity","canonical_id":"go:GO:0072354","description":"\"Catalysis of the reaction: histone H3-threonine (position 3) + ATP = histone H3-phosphothreonine (position 3) + ADP. This reaction is the addition of a phosphate group to the threonine residue at position 3 of histone H3.\" [GOC:mah]","metadata":null},{"id":"98162b10b3eb47a3a588dc41a38c9520","type":"GO_TERM","name":"histone H3T45 kinase activity","canonical_id":"go:GO:0140857","description":"\"Catalysis of the reaction: histone H3-threonine (position 45) + ATP = histone H3-phosphothreonine (position 45) + ADP. This reaction is the addition of a phosphate group to the threonine residue at position 45 of histone H3.\" [PMID:24820035]","metadata":null},{"id":"4cf54e3053004325b326c0b5abd46b7d","type":"GO_TERM","name":"histone H3T6 kinase activity","canonical_id":"go:GO:0035403","description":"\"Catalysis of the reaction: histone H3-threonine (position 6) + ATP = histone H3-phosphothreonine (position 6) + ADP. This reaction is the addition of a phosphate group to the threonine residue at position 6 of histone H3.\" [GOC:bf]","metadata":null},{"id":"f7265f7acca24579a74f88ae1120f6d6","type":"GO_TERM","name":"histone H3Y41 kinase activity","canonical_id":"go:GO:0035401","description":"\"Catalysis of the reaction: histone H3-tyrosine (position 41) + ATP = histone H3-phosphotyrosine (position 41) + ADP. This reaction is the addition of a phosphate group to the tyrosine residue at position 41 of histone H3.\" [GOC:bf]","metadata":null},{"id":"325c97d720ba4ab9b8843f1ec62270d4","type":"GO_TERM","name":"histone H4 acetyltransferase activity","canonical_id":"go:GO:0010485","description":"\"Catalysis of the reaction: acetyl-CoA + histone H4 = CoA + acetyl-histone H4.\" [PMID:19056256]","metadata":null},{"id":"a730a48fcec8492ca5fbb65702f3573f","type":"GO_TERM","name":"histone H4 demethylase activity","canonical_id":"go:GO:0141058","description":"\"Catalysis of the removal of a methyl group from a modified lysine residue of the histone H4 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:17947579]","metadata":null},{"id":"1f78586dfcbd4ac6ae494a1d27ad4fcd","type":"GO_TERM","name":"histone H4 kinase activity","canonical_id":"go:GO:0140997","description":"\"Catalysis of the transfer of a phosphate group to a histone H4.\" [PMID:25303536]","metadata":null},{"id":"db80877f71674059b4a2b1b24c148508","type":"GO_TERM","name":"histone H4 methyltransferase activity","canonical_id":"go:GO:0140939","description":"\"Catalysis of the reaction: Catalysis of the reaction: S-adenosyl-L-methionine + a histone H4 = S-adenosyl-L-homocysteine + a methylated histone H4. Histone methylation generally occurs on either an arginine or a lysine residue.\" [PMID:28450737]","metadata":null},{"id":"abdf6130f5754207a827d065b561aa90","type":"GO_TERM","name":"histone H4 reader activity","canonical_id":"go:GO:0140008","description":"\"A histone reader that specifically binds either to an unmodified histone H4 or a form modified by a post-translational modification on a specific residue. The most common PTMs on histones are methylation, acetylation and phosphorylation.\" [PMID:11498575, PMID:25688442, PMID:31082667, PMID:34726351]","metadata":null},{"id":"54c42d58d7db45f7a59e19b74fc2f68e","type":"GO_TERM","name":"histone H4 ubiquitin ligase activity","canonical_id":"go:GO:0141056","description":"\"Catalysis of the transfer of ubiquitin to a histone H4 substrate.\" [PMID:25303536]","metadata":null},{"id":"d72718b395eb4a8c8aaeb1d8489bcf91","type":"GO_TERM","name":"histone H4K deacetylase activity","canonical_id":"go:GO:0141051","description":"\"Removal of an acetyl group from a lysine residue in a histone H4.\" [PMID:12590135]","metadata":null},{"id":"5c5148fc83bf4b58bf7ac3378b2e9ced","type":"GO_TERM","name":"histone H4K12 acetyltransferase activity","canonical_id":"go:GO:0043997","description":"\"Catalysis of the reaction: acetyl-CoA + histone H4 L-lysine (position 12) = CoA + histone H4 N6-acetyl-L-lysine (position 12).\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"3a25ff8d4d0b44d79341cc86ab92c8cd","type":"GO_TERM","name":"histone H4K12 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0140937","description":"\"Catalysis of the reaction: histone H4 N6-acetyl-L-lysine (position 12) + H2O = histone H4 L-lysine (position 12) + acetate. This reaction represents the removal of an acetyl group from lysine at position 12 of the histone H4 protein.\" [GOC:vw, PMID:15293224]","metadata":null},{"id":"840f55c1f9fb448db0b188361c2da941","type":"GO_TERM","name":"histone H4K12 methyltransferase activity","canonical_id":"go:GO:0140984","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H4 L-lysine (position 12) = S-adenosyl-L-homocysteine + histone H4 N6-methyl-L-lysine (position 12). This reaction is the addition of a methyl group to the lysine residue at position 12 of the histone H4 protein.\" [PMID:12086618]","metadata":null},{"id":"629c5ce914aa443f8a0310168855f311","type":"GO_TERM","name":"histone H4K12ac reader activity","canonical_id":"go:GO:0140011","description":"\"A histone reader that recognizes a histone H4 acetylated at lysine 12.\" [PMID:14731392]","metadata":null},{"id":"04e82db8b2c043afba376e56dde5d327","type":"GO_TERM","name":"histone H4K16 acetyltransferase activity","canonical_id":"go:GO:0046972","description":"\"Catalysis of the reaction: acetyl-CoA + histone H4 L-lysine (position 16) = CoA + histone H4 N6-acetyl-L-lysine (position 16). This reaction represents the addition of an acetyl group to the lysine at position 16 of histone H4.\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"431577a413054f9d9e0ccdfc87e17c10","type":"GO_TERM","name":"histone H4K16 deacetylase activity, NAD-dependent","canonical_id":"go:GO:0046970","description":"\"Catalysis of the reaction: histone H4 N6-acetyl-L-lysine (position 16) + NAD+ + H2O = histone H4 L-lysine (position 16) + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group attached to a lysine residue in H4K16 to NAD, producing nicotinamide.\" [GOC:vw, PMID:28450737]","metadata":null},{"id":"4cc9293f79664435a1a46ee40b3230aa","type":"GO_TERM","name":"histone H4K16 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0034739","description":"\"Catalysis of the reaction: histone H4 N6-acetyl-L-lysine (position 16) + H2O = histone H4 L-lysine (position 16) + acetate. This reaction represents the removal of an acetyl group from lysine at position 16 of the histone H4 protein.\" [GOC:vw, PMID:28450737]","metadata":null},{"id":"831b6b9bf0c94eff9a5f2bca821db1a1","type":"GO_TERM","name":"histone H4K16 propionyltransferase activity","canonical_id":"go:GO:0141002","description":"\"Catalysis of the reaction: histone H4 L-lysine (position 16) + propionyl-CoA = CoA + H+ + histone H3 N6-propionyl-L-lysyl (position 16).\" [PMID:17267393, PMID:29321206, PMID:31794431]","metadata":null},{"id":"dd48c05cec214b6aadd3c315e42ffd47","type":"GO_TERM","name":"histone H4K16ac reader activity","canonical_id":"go:GO:0140046","description":"\"A histone reader that recognizes a histone H4 acetylated at lysine 16.\" [PMID:16085498]","metadata":null},{"id":"0b905c8fae4e4322a4b83c6f7f7c8c6a","type":"GO_TERM","name":"histone H4K20 demethylase activity","canonical_id":"go:GO:0035575","description":"\"Catalysis of the removal of the methyl group from a modified lysine residue at position 20 of the histone H4 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:20622853, PMID:26214369, PMID:32209475]","metadata":null},{"id":"22bed584ba84475b9402d5c41116d4c8","type":"GO_TERM","name":"histone H4K20 methyltransferase activity","canonical_id":"go:GO:0042799","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone H4 L-lysine (position 20) = S-adenosyl-L-homocysteine + histone H4 N6-methyl-L-lysine (position 20). This reaction is the addition of a methyl group to the lysine residue at position 20 of the histone H4 protein.\" [PMID:12086618]","metadata":null},{"id":"96a40956fcb74c10a7c72fcfa134a8ee","type":"GO_TERM","name":"histone H4K20 monomethyltransferase activity","canonical_id":"go:GO:0140944","description":"\"Catalysis of the reaction: L-lysyl20-[histone H4] + S-adenosyl-L-methionine = H+ + N6-methyl-L-lysyl20-[histone H4] + S-adenosyl-L-homocysteine. This reaction is the addition of a methyl group to the unmethylated lysine residue at position 20 of histone H4, producing histone H4K20me.\" [RHEA:60344]","metadata":null},{"id":"923a05b5d78d4c59b7d8ac78b692d934","type":"GO_TERM","name":"histone H4K20 trimethyltransferase activity","canonical_id":"go:GO:0140943","description":"\"Catalysis of the reaction: L-lysyl(20)-[histone H4] + 3 S-adenosyl-L-methionine = 3 H+ + N(6),N(6),N(6)-trimethyl-L-lysyl(20)-[histone H4] + 3 S-adenosyl-L-homocysteine. This reaction is the addition of three methyl groups to the lysine residue at position 20 of the histone H4 protein, producing histone H4K20me3.\" [RHEA:64456]","metadata":null},{"id":"fe7008ba4fe14fdaad071544a01736c1","type":"GO_TERM","name":"histone H4K20me methyltransferase activity","canonical_id":"go:GO:0140941","description":"\"Catalysis of the reaction: N(6)-methyl-L-lysyl(20)-[histone H4] + S-adenosyl-L-methionine = H+ + N(6),N(6)-dimethyl-L-lysyl(20)-[histone H4] + S-adenosyl-L-homocysteine. This reaction is the addition of a methyl group to the monomethylated lysine residue at position 20 of histone H4, producing H4K20me2.\" [RHEA:60348]","metadata":null},{"id":"09196c12d572464baf935eb9fec64a84","type":"GO_TERM","name":"histone H4K20me1 reader activity","canonical_id":"go:GO:0140117","description":"\"A histone reader that recognizes a histone H4 monomethylated at lysine 20.\" [PMID:19494831]","metadata":null},{"id":"167d89050661489ebcf44604d0301b69","type":"GO_TERM","name":"histone H4K20me2 reader activity","canonical_id":"go:GO:0140005","description":"\"A histone reader that recognizes a histone H4 dimethylated at lysine 20.\" [PMID:22150589]","metadata":null},{"id":"99e3a7d8d33548fc932247d85848f524","type":"GO_TERM","name":"histone H4K20me3 reader activity","canonical_id":"go:GO:1990889","description":"\"A histone reader that recognizes a histone H4 trimethylated at lysine 20.\" [PMID:20943666, PMID:22150589]","metadata":null},{"id":"9828e70b16004dc09e14ca8676468051","type":"GO_TERM","name":"histone H4K5 acetyltransferase activity","canonical_id":"go:GO:0043995","description":"\"Catalysis of the reaction: acetyl-CoA + histone H4 L-lysine (position 5) = CoA + histone H4 N6-acetyl-L-lysine (position 5).\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"70d4c86c6df443a39a7da2d0130cce4f","type":"GO_TERM","name":"histone H4K5 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0180032","description":"\"Catalysis of the reaction: histone H4 N6-acetyl-L-lysine (position 5) + H2O = histone H4 L-lysine (position 5) + acetate. This reaction represents the removal of an acetyl group from lysine at position 5 of the histone H4 protein.\" [PMID:37459529]","metadata":null},{"id":"7ad5de8b328a41e69e96c415ccf2809f","type":"GO_TERM","name":"histone H4K5ac reader activity","canonical_id":"go:GO:0140012","description":"\"A histone reader that recognizes a histone H4 acetylated at lysine 5.\" [PMID:18406326, PMID:20709061]","metadata":null},{"id":"c1d12b69a9ac4abfa0d5889aa2c09987","type":"GO_TERM","name":"histone H4K8 acetyltransferase activity","canonical_id":"go:GO:0043996","description":"\"Catalysis of the reaction: acetyl-CoA + histone H4 L-lysine (position 8) = CoA + histone H4 N6-acetyl-L-lysine (position 8).\" [PMID:18552846, PMID:19056256]","metadata":null},{"id":"0ae33cca291d4596aaa0ce142e48d14a","type":"GO_TERM","name":"histone H4K8 deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0180033","description":"\"Catalysis of the reaction: histone H4 N6-acetyl-L-lysine (position 8) + H2O = histone H4 L-lysine (position 8) + acetate. This reaction represents the removal of an acetyl group from lysine at position 8 of the histone H4 protein.\" [PMID:37459529]","metadata":null},{"id":"22cd8ae926d84e278e18809d322bf4f8","type":"GO_TERM","name":"histone H4K8ac reader activity","canonical_id":"go:GO:0140055","description":"\"A histone reader that recognizes a histone H4 acetylated at lysine 8.\" [PMID:17996705]","metadata":null},{"id":"cdec517819d045c2990c8818ebe78866","type":"GO_TERM","name":"histone H4K91 ubiquitin ligase activity","canonical_id":"go:GO:0141000","description":"\"Catalysis of the transfer of a ubiquitin molecule to histone 4 at the lysine-91 residue.\" [PMID:19818714]","metadata":null},{"id":"3236a1bf42904095921fa05a9eab6514","type":"GO_TERM","name":"histone H4R3 arginine deiminase activity","canonical_id":"go:GO:0140809","description":"\"Catalysis of the reaction: H2O + histone H4 L-arginyl (position 3)= histone H4 L-citrullyl (position 3) + NH4+, resulting in histone H4 citrullination at position 3.\" [PMID:16567635]","metadata":null},{"id":"cef05a62bb5e47acba4054346e3a9975","type":"GO_TERM","name":"histone H4R3 demethylase activity","canonical_id":"go:GO:0033749","description":"\"Catalysis of the removal of the methyl group from a modified arginine residue at position 3 of the histone H4 protein. This is a dioxygenase reaction that is dependent on Fe(II) and 2-oxoglutarate.\" [PMID:17947579]","metadata":null},{"id":"0cda440f4de74e0c8b768b10887d441c","type":"GO_TERM","name":"histone H4R3 methyltransferase activity","canonical_id":"go:GO:0044020","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (histone H4)-arginine (position 3) = S-adenosyl-L-homocysteine + (histone H4)-N-methyl-arginine (position 3). This reaction is the addition of a methyl group to the arginine residue at position 3 of histone H4, producing histone H4R3me.\" [GOC:mah, PMID:17898714]","metadata":null},{"id":"d99953f274104759a190b0a556826d36","type":"GO_TERM","name":"histone H4S1 kinase activity","canonical_id":"go:GO:0044023","description":"\"Catalysis of the reaction: histone H4-serine (position 1) + ATP = histone H4-phosphoserine (position 1) + ADP. This reaction is the addition of a phosphate group to the serine residue at position 1 of histone H4.\" [GOC:jl]","metadata":null},{"id":"2703dde303be45d49c75f65dfbc8f00d","type":"GO_TERM","name":"histone acetyltransferase activity","canonical_id":"go:GO:0004402","description":"\"Catalysis of the reaction: L-lysyl-[histone] + acetyl-CoA = N6-acetyl-L-lysyl-[histone] + CoA + H+.\" [PMID:19056256, RHEA:21992]","metadata":null},{"id":"26a9a7aafb25427192f76786dbce0c00","type":"GO_TERM","name":"histone acetyltransferase binding","canonical_id":"go:GO:0035035","description":"\"Binding to an histone acetyltransferase.\" [GOC:bf]","metadata":null},{"id":"008528938a984479a012c0b8c45d5722","type":"GO_TERM","name":"histone acetyltransferase complex","canonical_id":"go:GO:0000123","description":"\"A protein complex that possesses histone acetyltransferase activity.\" [GOC:mah]","metadata":null},{"id":"46b70c3d76434ae6828a70d3819d221a","type":"GO_TERM","name":"histone acetyltransferase regulator activity","canonical_id":"go:GO:0035034","description":"\"Binds to and modulates the activity of histone acetyltransferase.\" [GOC:bf]","metadata":null},{"id":"1d7559133d0b40da81c90d60cd4bdec7","type":"GO_TERM","name":"histone arginine deiminase activity","canonical_id":"go:GO:0140794","description":"\"Catalysis of the reaction: H2O + histone 3 L-arginyl = histone 3 L-citrullyl + NH4+, resulting in histone citrullination.\" [PMID:15339660]","metadata":null},{"id":"fe40a33a8aea447b89b60c6eba3eb0e5","type":"GO_TERM","name":"histone benzoyllysine debenzoylase activity","canonical_id":"go:GO:0140228","description":"\"Catalysis of the reaction: N(6)-benzoyl-L-lysyl-[protein] + NAD+ + H2O = 2''-O-benzoyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein].\" [PMID:34961760]","metadata":null},{"id":"59475be8594a428693b39587960e74f3","type":"GO_TERM","name":"histone binding","canonical_id":"go:GO:0042393","description":"\"Binding to a histone, any of a group of water-soluble proteins found in association with the DNA of eukaryotic or archaeal chromosomes. They are involved in the condensation and coiling of chromosomes during cell division and have also been implicated in gene regulation and DNA replication. They may be chemically modified (methylated, acetlyated and others) to regulate gene transcription.\" [GOC:jl, PMID:16209651, PMID:30212449, PMID:9305837]","metadata":null},{"id":"aed3e9d48f0c444c9553db32baa8d0e3","type":"GO_TERM","name":"histone butyryltransferase activity","canonical_id":"go:GO:0140069","description":"\"Catalysis of the reaction: butyryl-CoA + histone = CoA + butyryl-histone.\" [PMID:27105113]","metadata":null},{"id":"eecc397874ea495394b2c9176f76c272","type":"GO_TERM","name":"histone catabolic process","canonical_id":"go:GO:0036205","description":"\"The chemical reactions and pathways resulting in the breakdown of a histone protein by individual cells.\" [GOC:krc]","metadata":null},{"id":"2feebb3c102a4887aa9083d94ea375c8","type":"GO_TERM","name":"histone chaperone activity","canonical_id":"go:GO:0140713","description":"\"Binding to and carrying a histone or a histone complex to unload or deposit it as a nucleosome. The histone can be newly synthesized or result from nucleosome disassembly (either spontaneously, or by a histone chaperone).\" [PMID:26459557]","metadata":null},{"id":"5cb4fb69e4d040ec845bdd8acd048eb2","type":"GO_TERM","name":"histone crotonyltransferase activity","canonical_id":"go:GO:0140068","description":"\"Catalysis of the reaction: crotonyl-CoA + histone = CoA + crotonyl-histone.\" [PMID:25818647]","metadata":null},{"id":"1adc83766c164ebcbb9f2dcaea16723d","type":"GO_TERM","name":"histone deacetylase activity","canonical_id":"go:GO:0004407","description":"\"Removal of an acetyl group from a lysine residue in a histone.\" [PMID:24691964, PMID:9893272]","metadata":null},{"id":"77533751d16147e29024b9909ee857ad","type":"GO_TERM","name":"histone deacetylase activity, NAD-dependent","canonical_id":"go:GO:0017136","description":"\"Catalysis of the reaction: N(6)-acetyl-L-lysyl-[histone] + NAD+ + H2O = L-lysyl-[protein] + 2''-O-acetyl-ADP-D-ribose + nicotinamide. This reaction transfers an acetyl group from a histone to NAD, producing nicotinamide.\" [PMID:24691964, PMID:28450737]","metadata":null},{"id":"7976b45e53434c7393276bcf493e07cc","type":"GO_TERM","name":"histone deacetylase activity, hydrolytic mechanism","canonical_id":"go:GO:0141221","description":"\"Catalysis of the reaction: H2O + N6-acetyl-L-lysyl-[histone] = acetate + L-lysyl-[histone].\" [PMID:24691964, PMID:28450737, RHEA:58196]","metadata":null},{"id":"7f1df5316f594acfb41182063c8b4f61","type":"GO_TERM","name":"histone deacetylase binding","canonical_id":"go:GO:0042826","description":"\"Binding to histone deacetylase.\" [GOC:jl]","metadata":null},{"id":"78337a11ae25468bb93093dd65f37457","type":"GO_TERM","name":"histone deacetylase complex","canonical_id":"go:GO:0000118","description":"\"A protein complex that possesses histone deacetylase activity.\" [GOC:mah]","metadata":null},{"id":"530c227d61964edc9d87913ffae4cf8c","type":"GO_TERM","name":"histone deacetylase inhibitor activity","canonical_id":"go:GO:0046811","description":"\"Binds to and stops, prevents or reduces the activity of histone deacetylase, which catalyzes of the removal of acetyl groups from histones, proteins complexed to DNA in chromatin and chromosomes.\" [GOC:ai, PMID:10482575]","metadata":null},{"id":"711090dc59f644eeb20509a4d0b991ec","type":"GO_TERM","name":"histone deacetylase regulator activity","canonical_id":"go:GO:0035033","description":"\"Binds to and modulates the activity of histone deacetylase.\" [GOC:bf]","metadata":null},{"id":"b548a5a076d7411b8e4cbc3c22d7f503","type":"PROTEIN","name":"histone deactylase (HDAC)","canonical_id":"uniprot:Q9UKV0","description":null,"metadata":null},{"id":"51f348bbfa5343a1a6254db025143029","type":"GO_TERM","name":"histone decrotonylase activity","canonical_id":"go:GO:0160009","description":"\"Catalysis of the reaction: H2O + N6-(2E)-butenoyl-L-lysyl-[histone] = (2E)-2-butenoate + L-lysyl-[histone].\" [PMID:28497810]","metadata":null},{"id":"3694d33f8fee4873acc6949fce831d1a","type":"GO_TERM","name":"histone decrotonylase activity, NAD-dependent","canonical_id":"go:GO:0160012","description":"\"Catalysis of the reaction: H2O + N6-(2E)-butenoyl-L-lysyl-[histone] + NAD+ = 2''-O-(2E)-but-2-enoyl-ADP-D-ribose + L-lysyl-[histone] + nicotinamide.\" [PMID:28497810]","metadata":null},{"id":"e896800544b24bc094e08acb10867a85","type":"GO_TERM","name":"histone demethylase activity","canonical_id":"go:GO:0032452","description":"\"Catalysis of the removal of a methyl group from a histone.\" [GOC:mah]","metadata":null},{"id":"6ee92a87c5de4ba7af4ca53ee373f148","type":"GO_TERM","name":"histone deubiquitinase activity","canonical_id":"go:GO:0140934","description":"\"A deubiquitinase that cleaves ubiquitin from a histone protein to which it is conjugated.\" [PMID:18206972, PMID:18226187]","metadata":null},{"id":"a70c2b6ed6eb4a8f81fdceb34b7f7b0d","type":"GO_TERM","name":"histone dopaminyltransferase activity","canonical_id":"go:GO:0120297","description":"\"Catalysis of the reaction: dopamine + L-glutaminyl-[histone] = 5-dopaminyl-L-glutamyl-[histone] + NH4+.\" [GOC:sp, PMID:32273471]","metadata":null},{"id":"ab09a618ae8f444ca9d047e3f21a5671","type":"GO_TERM","name":"histone glutaryltransferase activity","canonical_id":"go:GO:0106229","description":"\"Catalysis of the reaction: glutaryl-CoA + histone = CoA + H+ + N6-glutaryl-histone.\" [GOC:sp, PMID:31542297]","metadata":null},{"id":"f817c16fc3774ff3ac35d0465dafe84d","type":"GO_TERM","name":"histone isonicotinyllysine deisonicotinylase activity","canonical_id":"go:GO:0140229","description":"\"Catalysis of the reaction: N(6)-isonicotinyl-L-lysyl-[protein] + H2O = isonicotinate + L-lysyl-[protein].\" [PMID:34545082]","metadata":null},{"id":"ba5d3599b7734cd09cbc493cfe0dcfb2","type":"GO_TERM","name":"histone isonicotinyltransferase activity","canonical_id":"go:GO:0140230","description":"\"Catalysis of the reaction: isonicotinyl-CoA + histone = coA + N(6)-isonicotinyl-histone.\" [PMID:34545082]","metadata":null},{"id":"e9ac4c8ffb834bfd896514c9977632f9","type":"GO_TERM","name":"histone kinase activity","canonical_id":"go:GO:0035173","description":"\"Catalysis of the transfer of a phosphate group to a histone.\" [GOC:bf]","metadata":null},{"id":"2d381b813b8d4521b72f11b563e85d93","type":"GO_TERM","name":"histone lactyltransferase (CoA-dependent) activity","canonical_id":"go:GO:0120301","description":"\"Catalysis of the reaction: (L-lysyl-[histone] + lactoyl-CoA = CoA + H+ + N(6)-lactoyl-L-lysyl-[histone].\" [GOC:sp, PMID:31645732]","metadata":null},{"id":"828bea0fc771459e949503df3c3070f0","type":"GO_TERM","name":"histone locus body","canonical_id":"go:GO:0035363","description":"\"A nuclear body associated with the histone gene locus that is thought to contain all of the factors necessary for histone mRNA transcription and pre-mRNA processing. In Drosophila, U7 snRNP is located in the histone locus body rather than the distinct Cajal body.\" [GOC:sart, PMID:16533947, PMID:18927579, PMID:19620235]","metadata":null},{"id":"ddf98cd42d494b55866abed55fc25feb","type":"GO_TERM","name":"histone locus body assembly","canonical_id":"go:GO:0140167","description":"\"The aggregation, arrangement and bonding together of a set of components to form a histone locus body.\" [PMID:21576393, PMID:32401666]","metadata":null},{"id":"d18a8462ff904ec8921d20a410ca3f15","type":"GO_TERM","name":"histone mRNA catabolic process","canonical_id":"go:GO:0071044","description":"\"The chemical reactions and pathways resulting in the breakdown of histone messenger RNA (mRNA).\" [GOC:dgf, GOC:krc, PMID:17179095, PMID:17855393]","metadata":null},{"id":"a1f32f135b274f56a2d21a59c720c544","type":"GO_TERM","name":"histone mRNA metabolic process","canonical_id":"go:GO:0008334","description":"\"The chemical reactions and pathways involving an mRNA encoding a histone.\" [GOC:krc, GOC:mah, PMID:17855393]","metadata":null},{"id":"3b0c901dca9049a6acf797681f7a797b","type":"GO_TERM","name":"histone mRNA stem-loop binding complex","canonical_id":"go:GO:0062073","description":"\"A protein-containing complex composed of a stem-loop binding protein (in most species SLBP) and its interacting partner (SLIP1 or MIF4GD in most species) that binds to the histone mRNA (hmRNA) 3-prime-stem-loop structure. Facilitates hmRNA translation initiation and may also be involved in its processing and nuclear export.\" [GOC:bhm, PMID:18025107, PMID:23286197]","metadata":null},{"id":"7844255f3d9340ed87d51811ff7766ab","type":"GO_TERM","name":"histone methacryllysine demethacrylase activity","canonical_id":"go:GO:0140219","description":"\"Catalysis of the reaction: N6-methacrylyl-L-lysyl-[histone] + H2O = 2-methylprop-2-enoate + L-lysyl-[histone].\" [PMID:34961760]","metadata":null},{"id":"df65b8b019464fe5a1fbce44f2b4fec8","type":"GO_TERM","name":"histone methacryltransferase activity","canonical_id":"go:GO:0140218","description":"\"Catalysis of the reaction: 2-methylpropenoyl-CoA + L-lysyl-[protein] = N6-methacrylyl-L-lysyl-[protein] + CoA + H+. Methacryl-CoA is a synonym of 2-methylpropenoyl-CoA.\" [PMID:34961760, PMID:40339582]","metadata":null},{"id":"6fbe525c41724c76a952252e6cc61060","type":"GO_TERM","name":"histone methyltransferase activity","canonical_id":"go:GO:0042054","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + histone = S-adenosyl-L-homocysteine + methyl-histone. Histone methylation generally occurs on either an arginine or a lysine residue.\" [GOC:curators]","metadata":null},{"id":"8a58f576cfba4e4fa5f972cf0e81c222","type":"GO_TERM","name":"histone methyltransferase binding","canonical_id":"go:GO:1990226","description":"\"Binding to a histone methyltransferase enzyme.\" [GOC:ame, GOC:BHF, PMID:19486527]","metadata":null},{"id":"5268c95295ec4f4ab8a2cc5e6fcff505","type":"GO_TERM","name":"histone methyltransferase complex","canonical_id":"go:GO:0035097","description":"\"A multimeric complex that is able to catalyze the addition of methyl groups to histone proteins.\" [GOC:bf]","metadata":null},{"id":"a17e6a3007a442c191fb102560479e5d","type":"GO_TERM","name":"histone methyltransferase inhibitor activity","canonical_id":"go:GO:0180000","description":"\"Binds to and stops, prevents or reduces the activity of a histone methyltransferase.\" [PMID:30923826]","metadata":null},{"id":"0f4827b6ea1647ceb19191674023470f","type":"GO_TERM","name":"histone modifying activity","canonical_id":"go:GO:0140993","description":"\"A catalytic activity that acts on a histone protein. Reversible histone modifications contribute to regulation of gene expression.\" [GOC:pg]","metadata":null},{"id":"9bc7d2b810fe40ac9726e5fa6993210e","type":"GO_TERM","name":"histone octamer slider activity","canonical_id":"go:GO:0140751","description":"\"A chromatin remodeler activity that slides core histone octamers along chromosomal DNA.\" [PMID:10466730]","metadata":null},{"id":"cdf4c4faca44423eb77c588839aa3604","type":"GO_TERM","name":"histone phosphatase activity","canonical_id":"go:GO:0140789","description":"\"Catalysis of the reaction: a phosphorylated histone + H2O = a protein + phosphate.\" [PMID:19351884]","metadata":null},{"id":"d30f38654fa142a3b76c65c93840b460","type":"GO_TERM","name":"histone pre-mRNA 3'end processing complex","canonical_id":"go:GO:0071204","description":"\"A ribonucleoprotein that binds to specific sites in, and is required for cleavage of, the 3'-end of histone pre-mRNAs. The complex contains the U7 snRNP and additional proteins, including the stem-loop binding protein (SLBP) and the exonuclease 3'hExo/Eri-1.\" [GOC:mah, PMID:19470752]","metadata":null},{"id":"386a09feb26c40739972500b0f55b73e","type":"GO_TERM","name":"histone pre-mRNA DCP binding","canonical_id":"go:GO:0071208","description":"\"Binding to the downstream cleavage product (DCP) generated by histone pre-mRNA 3'-end processing.\" [PMID:19470752]","metadata":null},{"id":"50c0f0d89ab3474992476ddd88595637","type":"GO_TERM","name":"histone pre-mRNA stem-loop binding","canonical_id":"go:GO:0071207","description":"\"Binding to a conserved stem-loop structure found in histone pre-mRNAs.\" [PMID:19470752]","metadata":null},{"id":"dbaace00296b4d2daf11bac21bbba914","type":"GO_TERM","name":"histone propionyltransferase activity","canonical_id":"go:GO:0061922","description":"\"Catalysis of the reaction: propionyl-CoA + histone = CoA + propionyl-histone.\" [PMID:17267393]","metadata":null},{"id":"da32d7a6cb6a49929069b82e906a6be5","type":"GO_TERM","name":"histone reader activity","canonical_id":"go:GO:0140566","description":"\"A chromatin adaptor activity that brings together a protein and a specific form of histone, either modified by a post-translational modification, or the unmodified form. Histone readers have roles in many processes, including in centromere function or in modulating the accessibility of cis-regulatory regions to the transcription machinery.\" [PMID:11498575, PMID:25688442, PMID:31082667, PMID:34726351]","metadata":null},{"id":"9a63cb545bda49ddb2e3066193f04c67","type":"GO_TERM","name":"histone serotonyltransferase activity","canonical_id":"go:GO:0120295","description":"\"Catalysis of the reaction: L-glutaminyl-[histone] + serotonin = 5-serotonyl-L-glutamyl-[histone] + NH4+.\" [GOC:sp, PMID:30867594]","metadata":null},{"id":"170bf61409724249ba733b9c9833ed28","type":"GO_TERM","name":"histone succinyltransferase activity","canonical_id":"go:GO:0106078","description":"\"Catalysis of the reaction: succinyl-CoA + histone = CoA + succinyl-histone.\" [PMID:29211711]","metadata":null},{"id":"e8a3eab409a2482280054f4bc8c3f300","type":"GO_TERM","name":"histone ubiquitin ligase activity","canonical_id":"go:GO:0140852","description":"\"Catalysis of the transfer of ubiquitin to a histone substrate.\" [GOC:curators]","metadata":null},{"id":"fe8a234d93a047ada27b3ea7c8ceba44","type":"GO_TERM","name":"histone-dependent DNA binding","canonical_id":"go:GO:0099077","description":"\"DNA-binding activity that is dependent on binding to a histone.\" [PMID:11691835]","metadata":null},{"id":"ee39aff67448412bad264804d75456f6","type":"GO_TERM","name":"holo-[acyl-carrier-protein] biosynthetic process","canonical_id":"go:GO:0031108","description":"\"The chemical reactions and pathways resulting in the formation of holo-[acyl-carrier protein].\" [GOC:mlg]","metadata":null},{"id":"376edfc87ca543cdbc3df3978d50d93e","type":"GO_TERM","name":"holo-[acyl-carrier-protein] synthase activity","canonical_id":"go:GO:0008897","description":"\"Catalysis of the reaction: CoA + substrate-serine = adenosine 3',5'-bisphosphate + substrate-serine-4'-phosphopantetheine. The transfer of the 4'-phosphopantetheine (Ppant) co-factor from coenzyme A to the hydroxyl side chain of the serine residue of acyl- or peptidyl-carrier protein (ACP or PCP) to convert them from the apo to the holo form.\" [EC:2.7.8.7, PMID:10320345, PMID:11867633, PMID:8939709]","metadata":null},{"id":"9cda43dca6a840c2b481382b19d36d00","type":"GO_TERM","name":"holo-citrate lyase synthase activity","canonical_id":"go:GO:0050519","description":"\"Catalysis of the reaction: apo-citrate lyase + 2'-(5''-triphosphoribosyl)-3'-dephospho-CoA = diphosphate + holo-citrate lyase.\" [EC:2.7.7.61, MetaCyc:2.7.7.61-RXN]","metadata":null},{"id":"8d2ba02d68a44591b5114c5700380ba9","type":"GO_TERM","name":"holocytochrome-c synthase activity","canonical_id":"go:GO:0004408","description":"\"Catalysis of the reaction: holocytochrome c = apocytochrome c + heme.\" [EC:4.4.1.17]","metadata":null},{"id":"40b4b8e98db94bfbadfc9755ca185a3d","type":"GO_TERM","name":"homeostasis of number of cells","canonical_id":"go:GO:0048872","description":"\"Any biological process involved in the maintenance of the steady-state number of cells within a population of cells.\" [GOC:isa_complete]","metadata":null},{"id":"f2ccd7cb15c44e8fbe325001eb656c8e","type":"GO_TERM","name":"homeostasis of number of cells within a tissue","canonical_id":"go:GO:0048873","description":"\"Any biological process involved in the maintenance of the steady-state number of cells within a population of cells in a tissue.\" [GOC:isa_complete]","metadata":null},{"id":"0dd6cb4846fd4c73bdf9a50c2eb10b47","type":"GO_TERM","name":"homeostasis of number of meristem cells","canonical_id":"go:GO:0007639","description":"\"Any biological process involved in the maintenance of the steady-state number of cells within a population of cells in the meristem.\" [GOC:isa_complete]","metadata":null},{"id":"2afbb314c66845c1b3fb2a65e7fa3d0d","type":"GO_TERM","name":"homeostasis of number of retina cells","canonical_id":"go:GO:0048877","description":"\"Any biological process involved in the maintenance of the steady-state number of cells within a population of cells in the retina.\" [GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"eaf9779dcdcd4634811a6950f3126e94","type":"GO_TERM","name":"homeostatic process","canonical_id":"go:GO:0042592","description":"\"Any biological process involved in the maintenance of an internal steady state. Homeostasis allows cells and organisms to maintain stable internal conditions despite varying external conditions.\" [PMID:26265027]","metadata":null},{"id":"f65a3e99d5114fd79a38b496258715de","type":"GO_TERM","name":"homing of group II introns","canonical_id":"go:GO:0006315","description":"\"Lateral transfer of a group II intron to a homologous allele that lacks the intron, mediated by a site-specific endonuclease encoded within the mobile intron; group II introns are self-splicing introns with a conserved secondary structure.\" [GOC:mcc, ISBN:0716743663, PMID:10487208]","metadata":null},{"id":"a24e93e2e04d470e801b11268bf74e81","type":"GO_TERM","name":"homoaconitate hydratase activity","canonical_id":"go:GO:0004409","description":"\"Catalysis of the reaction: (-)-homoisocitrate = cis-homoaconitate + H2O.\" [EC:4.2.1.36, RHEA:15485]","metadata":null},{"id":"64345f504a374a72a8caae2571279a2c","type":"GO_TERM","name":"homocarnosine synthase activity","canonical_id":"go:GO:0102102","description":"\"Catalysis of the reaction: gamma-aminobutyric acid + L-histidine + ATP = H+ + homocarnosine + ADP + hydrogenphosphate.\" [GOC:pz]","metadata":null},{"id":"28b99079bcbe402599d59ff4116f433b","type":"GO_TERM","name":"homocitrate synthase activity","canonical_id":"go:GO:0004410","description":"\"Catalysis of the reaction: 2-oxoglutarate + acetyl-CoA + H2O = CoA + H+ + homocitrate.\" [RHEA:12929]","metadata":null},{"id":"af920b24012a44f9acf74c30cd58ad0f","type":"GO_TERM","name":"homocysteine desulfhydrase activity","canonical_id":"go:GO:0047982","description":"\"Catalysis of the reaction: L-homocysteine + H2O = 2-oxobutanoate + hydrogen sulfide + NH4+ + H+.\" [RHEA:14501]","metadata":null},{"id":"23e8230693104e3e9900c0e64d38ba2f","type":"GO_TERM","name":"homocysteine metabolic process","canonical_id":"go:GO:0050667","description":"\"The chemical reactions and pathways involving homocysteine, the amino acid alpha-amino-gamma-mercaptobutanoic acid. Homocysteine is an important intermediate in the metabolic reactions of its S-methyl derivative, methionine.\" [ISBN:0198506732]","metadata":null},{"id":"fb70f7a3724e4e84824189a8ce98af6b","type":"GO_TERM","name":"homodimeric polyprenyl diphosphate synthase complex","canonical_id":"go:GO:0032477","description":"\"A homodimeric complex that possesses polyprenyl diphosphate synthase activity involved in the synthesis of the isoprenoid chain of ubiquinone whose length varies between organisms.\" [PMID:14519123]","metadata":null},{"id":"72c95d0005fb4ca8903c2e7cbb0ffe1c","type":"GO_TERM","name":"homodimeric serine palmitoyltransferase complex","canonical_id":"go:GO:0002179","description":"\"A homodimeric complex which transfers a palmitoyl group onto serine, forming 3-dehydro-D-sphinganine.\" [GOC:hjd]","metadata":null},{"id":"e4cfacd7462b46d88946d1d797284232","type":"GO_TERM","name":"homogalacturonan biosynthetic process","canonical_id":"go:GO:0010289","description":"\"The chemical reactions and pathways resulting in the formation of the pectidic homogalacturonan, characterized by a backbone of (1->4)-linked alpha-D-GalpA residues that can be methyl-esterified at C-6 and carry acetyl groups on O-2 and O-3.\" [PMID:12913136, PMID:16540543]","metadata":null},{"id":"098a4c4769e9482e95f8c151e1bf38c6","type":"GO_TERM","name":"homogalacturonan metabolic process","canonical_id":"go:GO:0010394","description":"\"The chemical reactions and pathways involving homogalacturonan, a pectin characterized by a backbone of alpha-(1->4)-linked D-galacturonic acid residues that can be methyl-esterified at C-6 and carry acetyl groups on O-2 and O-3.\" [GOC:tair_curators]","metadata":null},{"id":"76fccbf31b304e76bf4871b5dd7d13b7","type":"GO_TERM","name":"homogentisate 1,2-dioxygenase activity","canonical_id":"go:GO:0004411","description":"\"Catalysis of the reaction: homogentisate + O2 = 4-maleylacetoacetate + H+.\" [EC:1.13.11.5, RHEA:15449]","metadata":null},{"id":"4837972352994db6984790153c6986a0","type":"GO_TERM","name":"homogentisate catabolic process","canonical_id":"go:GO:1902000","description":"\"The chemical reactions and pathways resulting in the breakdown of homogentisate.\" [GOC:TermGenie, PMID:22980205]","metadata":null},{"id":"09294bcc26ce4f9f80e8b5a889573716","type":"GO_TERM","name":"homogentisate farnesyltransferase activity","canonical_id":"go:GO:0010355","description":"\"Catalysis of the reaction: homogentisic acid + farnesyl diphosphate = 2-methyl-6-farnesylplastoquinol.\" [PMID:16989822]","metadata":null},{"id":"81d2fb789dbc454f97c5739720db1406","type":"GO_TERM","name":"homogentisate geranylgeranyltransferase activity","canonical_id":"go:GO:0010356","description":"\"Catalysis of the reaction: (2E,6E,10E)-geranylgeranyl diphosphate + H+ + homogentisate = 6-geranylgeranyl-2-methylbenzene-1,4-diol + CO2 + diphosphate.\" [EC:2.5.1.116, GOC:pz, PMID:16989822]","metadata":null},{"id":"0d160e3cee15475b8d8c7f02665be2ba","type":"GO_TERM","name":"homogentisate phytyltransferase activity","canonical_id":"go:GO:0010176","description":"\"Catalysis of the reaction: homogentisate + phytyl diphosphate + H+ = 2-methyl-6-phytyl-1,4-benzoquinone + CO2 + diphosphate. 2-methyl-6-phytyl-1,4-benzoquinone is also known as 2-methyl-6-phytylplastoquinol.\" [MetaCyc:RXN-2541, PMID:14512521]","metadata":null},{"id":"c14d8c5d926a4d819a992c2e70bdc840","type":"GO_TERM","name":"homogentisate prenyltransferase activity","canonical_id":"go:GO:0010354","description":"\"Catalysis of the transfer of a prenyl group from one compound (donor) to homogentisic acid.\" [PMID:16989822]","metadata":null},{"id":"e5e652c9ed484e71b8f2e8cc5515ce36","type":"GO_TERM","name":"homogentisate solanesyltransferase activity","canonical_id":"go:GO:0010357","description":"\"Catalysis of the reaction: all-trans-nonaprenyl diphosphate + H+ + homogentisate = 2-methyl-6-all-trans-nonaprenylbenzene-1,4-diol + CO2 + diphosphate. 2-methyl-6-solanyl-1,4-benzoquinonone is also known as 2-methyl-6-solanesylplastoquinol and all-trans-nonaprenyl diphosphate as solanesyl diphosphate.\" [PMID:16989822, RHEA:37995]","metadata":null},{"id":"952e019bc50548c0a810f9613ad57c4d","type":"GO_TERM","name":"homoglutathione synthase activity","canonical_id":"go:GO:0047983","description":"\"Catalysis of the reaction: beta-alanine + L-gamma-glutamyl-L-cysteine + ATP = gamma-L-glutamyl-L-cysteinyl-beta-alanine + ADP + 2 H+ + phosphate.\" [EC:6.3.2.23, RHEA:17993]","metadata":null},{"id":"4fe61d996040412fbce261ccbddebbf4","type":"GO_TERM","name":"homoiothermy","canonical_id":"go:GO:0042309","description":"\"Any homoeostatic process in which an organism maintains its internal body temperature at a relatively constant value. This is achieved by using metabolic processes to counteract fluctuations in the temperature of the environment.\" [ISBN:0192801023]","metadata":null},{"id":"eda6cda41fdc4350ae594cbfe03ec8f8","type":"GO_TERM","name":"homoisocitrate dehydrogenase activity","canonical_id":"go:GO:0047046","description":"\"Catalysis of the reaction: NAD+ + 3-carboxy-2-hydroxyadipate = NADH + H+ + CO2 + 2-keto-adipate.\" [EC:1.1.1.87]","metadata":null},{"id":"af9c0c568e6d42838736d5470f16897c","type":"GO_TERM","name":"homologous chromosome movement towards spindle pole in meiosis I anaphase","canonical_id":"go:GO:0051758","description":"\"The directed movement of homologous chromosomes from the center of the spindle towards the spindle poles, mediated by the shortening of microtubules attached to the chromosomes, during meiosis I anaphase.\" [GOC:ai]","metadata":null},{"id":"1545ba0396ae4f9bb1bd6c030e9bd7fe","type":"GO_TERM","name":"homologous chromosome orientation in meiotic metaphase I","canonical_id":"go:GO:0031619","description":"\"The cell cycle process in which the sister centromeres and kinetochores of one chromosome are fused and orientated so the chromosomes attach to microtubules that emanate from the same spindle pole. This process ensures that homologous l chromosomes are segregated at anaphase of meiosis I.\" [PMID:15062096]","metadata":null},{"id":"662f28ca2f8444afa442e7a1b5d293be","type":"GO_TERM","name":"homologous chromosome pairing at meiosis","canonical_id":"go:GO:0007129","description":"\"The meiotic cell cycle process where side by side pairing and physical juxtaposition of homologous chromosomes is created during meiotic prophase. Homologous chromosome pairing begins when the chromosome arms begin to pair from the clustered telomeres and ends when synaptonemal complex or linear element assembly is complete.\" [GOC:mtg_cell_cycle, PMID:22582262, PMID:23117617, PMID:31811152]","metadata":null},{"id":"01b17995905c411ebaa283146de4e9ce","type":"GO_TERM","name":"homologous chromosome segregation","canonical_id":"go:GO:0045143","description":"\"The cell cycle process in which replicated homologous chromosomes are organized and then physically separated and apportioned to two sets during the first division of the meiotic cell cycle. Each replicated chromosome, composed of two sister chromatids, aligns at the cell equator, paired with its homologous partner; this pairing off, referred to as synapsis, permits genetic recombination. One homolog (both sister chromatids) of each morphologic type goes into each of the resulting chromosome sets.\" [GOC:ai, ISBN:0815316194]","metadata":null},{"id":"2f47c792f27a4265a9231e19b3e01e20","type":"GO_TERM","name":"homologous recombination","canonical_id":"go:GO:0035825","description":"\"A DNA recombination process that results in the exchange of an equal amount of genetic material between highly homologous DNA molecules.\" [GOC:mah, PMID:11139492, PMID:17304215]","metadata":null},{"id":"6d28b305e10042eba25f5a8eee946167","type":"GO_TERM","name":"homomeric SMAD protein complex","canonical_id":"go:GO:0071142","description":"\"A protein complex composed of a single type of SMAD family proteins. In the absence of Smad4, phosphorylation of R-SMADs results in their homotrimerization. However, these complexes do not appear to import into the nucleus and are assumed to be transcriptionally inactive.\" [GOC:bhm, GOC:mah, PMID:11779505, PMID:16322555, PMID:9670020]","metadata":null},{"id":"4d08dc4cf8b44d4a99734dbf964e8e07","type":"GO_TERM","name":"homomethionine N-monooxygenase activity","canonical_id":"go:GO:0120526","description":"\"Catalysis of the reaction: an L-polyhomomethionine + 2 O2 + 2 reduced [NADPH--hemoprotein reductase] = an (E)-omega-(methylsulfanyl)-alkanal oxime + CO2 + 2 H(+) + 3 H2O + 2 oxidized [NADPH--hemoprotein reductase].\" [RHEA:51972]","metadata":null},{"id":"88e87f3a462f45c58b6895e69673b1a0","type":"GO_TERM","name":"homophilic cell-cell adhesion","canonical_id":"go:GO:0007156","description":"\"The attachment of an adhesion molecule in one cell to an identical molecule in an adjacent cell.\" [ISBN:0198506732]","metadata":null},{"id":"80280c7fc36146e8bd804dc04e4d0b84","type":"GO_TERM","name":"homoserine O-acetyltransferase activity","canonical_id":"go:GO:0004414","description":"\"Catalysis of the reaction: L-homoserine + acetyl-CoA = O-acetyl-L-homoserine + CoA.\" [EC:2.3.1.31, RHEA:13701]","metadata":null},{"id":"98ea7a8b2375439bbdce04edd5c56f6e","type":"GO_TERM","name":"homoserine O-succinyltransferase activity","canonical_id":"go:GO:0008899","description":"\"Catalysis of the reaction: L-homoserine + succinyl-CoA = O-succinyl-L-homoserine + CoA.\" [EC:2.3.1.46, RHEA:22008]","metadata":null},{"id":"169d5f7d9c3040a0bbfc06da294416a0","type":"GO_TERM","name":"homoserine dehydrogenase activity","canonical_id":"go:GO:0004412","description":"\"Catalysis of the reaction: L-homoserine + NADP+ = L-aspartate-4-semialdehyde + NADPH + H+.\" [EC:1.1.1.3]","metadata":null},{"id":"49615025290a4bb390c87e16932e026f","type":"GO_TERM","name":"homoserine kinase activity","canonical_id":"go:GO:0004413","description":"\"Catalysis of the reaction: L-homoserine + ATP = O-phospho-L-homoserine + ADP + 2 H+.\" [EC:2.7.1.39, RHEA:13985]","metadata":null},{"id":"526bf44b42584dc7bd1980d71222afb2","type":"GO_TERM","name":"homospermidine synthase (spermidine-specific) activity","canonical_id":"go:GO:0050514","description":"\"Catalysis of the reaction: spermidine + putrescine = sym-homospermidine + propane-1,3-diamine.\" [RHEA:11236]","metadata":null},{"id":"d4a208026ea042e6bed358e79988884b","type":"GO_TERM","name":"homospermidine synthase activity","canonical_id":"go:GO:0047296","description":"\"Catalysis of the reaction: 2 putrescine = sym-homospermidine + NH4+.\" [RHEA:18645]","metadata":null},{"id":"6269a3ca5bdd4eeab15f1e278811b562","type":"GO_TERM","name":"homotetrameric ADPG pyrophosphorylase complex","canonical_id":"go:GO:0030930","description":"\"A protein complex composed of four identical subunits that possesses ADPG pyrophosphorylase activity. Examples of this component are found in Bacterial species.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"3be0efd362f646e89b1ea9d89b9ba99b","type":"GO_TERM","name":"homotypic cell-cell adhesion","canonical_id":"go:GO:0034109","description":"\"The attachment of a cell to a second cell of the identical type via adhesion molecules.\" [GOC:add]","metadata":null},{"id":"a59f437f868a4039a28e804ba4b37ab4","type":"DISEASE","name":"homozygous familial hypercholesterolemia","canonical_id":"mondo:0018328","description":null,"metadata":null},{"id":"52eefa70936748e0ad5aa44a635d3417","type":"GO_TERM","name":"hopanoid biosynthetic process","canonical_id":"go:GO:0019746","description":"\"The chemical reactions and pathways resulting in the formation of hopanoids, pentacyclic sterol-like compounds based on the hopane nucleus.\" [ISBN:0198547684]","metadata":null},{"id":"65b1f0991d57464593c48825f399e506","type":"GO_TERM","name":"hopanoid catabolic process","canonical_id":"go:GO:0019743","description":"\"The chemical reactions and pathways resulting in the breakdown of hopanoids, pentacyclic sterol-like compounds based on the hopane nucleus.\" [ISBN:0198547684]","metadata":null},{"id":"e4de3f2a4c5446a3aec6d75139f466b1","type":"GO_TERM","name":"horizontal cell localization","canonical_id":"go:GO:0035852","description":"\"Any process in which a horizontal cell is transported to, and/or maintained in, a specific location within the inner nuclear layer (INL) of the retina. A horizontal cell is a neuron that laterally connects other neurons in the inner nuclear layer (INL) of the retina. Targeting of retinal neurons to the appropriate lamina is vital to establish the architecture of the retina.\" [CL:0000745, GOC:bf, GOC:yaf, PMID:18094249]","metadata":null},{"id":"2c916922e8ba42a18406174e4c801d51","type":"GO_TERM","name":"horizontal gene transfer","canonical_id":"go:GO:0009292","description":"\"The introduction of genetic information into a cell to create a genetically different individual, without production of new individuals.\" [PMID:26184597]","metadata":null},{"id":"c03290ab09234c7e89a61d53f2af190a","type":"GO_TERM","name":"hormonal regulation of the force of heart contraction","canonical_id":"go:GO:0003058","description":"\"The process in which the hormones modulates the force of heart muscle contraction. A hormone is one of a group of substances formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells, in the same organism, upon which they have a specific regulatory action.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"7858b7b0e48040fd942b15e716daf53e","type":"GO_TERM","name":"hormone activity","canonical_id":"go:GO:0005179","description":"\"The action characteristic of a hormone, any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action. The term was originally applied to agents with a stimulatory physiological action in vertebrate animals (as opposed to a chalone, which has a depressant action). Usage is now extended to regulatory compounds in lower animals and plants, and to synthetic substances having comparable effects; all bind receptors and trigger some biological process.\" [GOC:dph, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"0ad1cea027864aa196b9343123fbcf60","type":"GO_TERM","name":"hormone binding","canonical_id":"go:GO:0042562","description":"\"Binding to an hormone, a naturally occurring substance secreted by specialized cells that affect the metabolism or behavior of cells possessing functional receptors for the hormone. Hormones may be produced by the same, or different, cell as express the receptor.\" [GOC:jl]","metadata":null},{"id":"57520fbf2a1042999e637f0ad024e0d1","type":"GO_TERM","name":"hormone biosynthetic process","canonical_id":"go:GO:0042446","description":"\"The chemical reactions and pathways resulting in the formation of any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.\" [GOC:jl]","metadata":null},{"id":"5d95da4f3d1842c3983e0fe382d2848e","type":"GO_TERM","name":"hormone catabolic process","canonical_id":"go:GO:0042447","description":"\"The chemical reactions and pathways resulting in the breakdown of any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.\" [GOC:jl]","metadata":null},{"id":"37dc668b392b4443ae582a427bdfa623","type":"GO_TERM","name":"hormone metabolic process","canonical_id":"go:GO:0042445","description":"\"The chemical reactions and pathways involving any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.\" [GOC:jl]","metadata":null},{"id":"39a04cac71b2417a97884ce5cd3f679c","type":"GO_TERM","name":"hormone receptor binding","canonical_id":"go:GO:0051427","description":"\"Binding to a receptor for a hormone.\" [GOC:ai]","metadata":null},{"id":"e22c43b44ca1453ca6710235ea30a95a","type":"GO_TERM","name":"hormone secretion","canonical_id":"go:GO:0046879","description":"\"The regulated release of hormones, substances with a specific regulatory effect on a particular organ or group of cells.\" [ISBN:0198506732]","metadata":null},{"id":"74908f60790247c18c2e1478399f96a8","type":"GO_TERM","name":"hormone transport","canonical_id":"go:GO:0009914","description":"\"The directed movement of hormones into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:tb]","metadata":null},{"id":"50464e0a653a4a85a9d214e3a8423eaa","type":"GO_TERM","name":"hormone-mediated apoptotic signaling pathway","canonical_id":"go:GO:0008628","description":"\"The series of molecular signals mediated by the detection of a hormone, and which triggers the apoptotic signaling pathway in a cell. The pathway starts with reception of a hormone signal, and ends when the execution phase of apoptosis is triggered.\" [GOC:bf, GOC:mtg_apoptosis]","metadata":null},{"id":"1f42ebe8214c490caa2d6b7d13f26ba5","type":"GO_TERM","name":"hormone-mediated signaling pathway","canonical_id":"go:GO:0009755","description":"\"The series of molecular signals mediated by the detection of a hormone.\" [GOC:sm]","metadata":null},{"id":"7cfd63c776444a4cb4ebaf143595be4b","type":"GO_TERM","name":"horsetail-astral microtubule array","canonical_id":"go:GO:0032117","description":"\"An array of astral microtubules that emanates from the spindle pole body during meiosis and facilitates horsetail nuclear movement.\" [GOC:mah, PMID:16111942]","metadata":null},{"id":"00093dc6dbd643ca828a9f8b37862aab","type":"GO_TERM","name":"horsetail-astral microtubule organization","canonical_id":"go:GO:0032118","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the horsetail-astral array, a structure of astral microtubules that emanates from the spindle pole body during meiosis.\" [GOC:mah]","metadata":null},{"id":"2a8be01fa13a4bdb9b20d4bf820bd239","type":"GO_TERM","name":"host apoplast","canonical_id":"go:GO:0140593","description":"\"The apoplast region surrounding a host plant cell. Plants may be described as having two major compartments: the living symplast and the non-living apoplast. The apoplast is external to the plasma membrane and includes cell walls, intercellular spaces and the lumen of dead structures such as xylem vessels. Water and solutes pass freely through it. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:28082413]","metadata":null},{"id":"2f383476c4744c27b6fcb2ec678ab766","type":"GO_TERM","name":"host bacteroid-containing symbiosome","canonical_id":"go:GO:0043663","description":"\"A symbiosome containing any of various structurally modified bacteria, such as those occurring on the root nodules of leguminous plants, of a host cell.\" [GOC:cc]","metadata":null},{"id":"3446aac0e6074f34a58b3c3bd0f05ec4","type":"GO_TERM","name":"host caveola","canonical_id":"go:GO:0044155","description":"\"A small pit, depression, or invagination, such as any of the minute pits or incuppings of the host cell membrane formed during pinocytosis, that communicates with the outside of a host cell and extends inward, indenting the host cytoplasm and the host cell membrane. Such caveolae may be pinched off to form free vesicles within the host cytoplasm. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:rph]","metadata":null},{"id":"aa96945dbadb4c869076cff921a1fce1","type":"GO_TERM","name":"host cell","canonical_id":"go:GO:0043657","description":"\"A cell within a host organism. Includes the host plasma membrane and any external encapsulating structures such as the host cell wall and cell envelope.\" [GOC:jl]","metadata":null},{"id":"e8a497cc3ea64da582df4cc955641793","type":"GO_TERM","name":"host cell Cajal body","canonical_id":"go:GO:0072495","description":"\"A class of nuclear body in the eukaryotic host cell, first seen after silver staining by Ramon y Cajal in 1903, enriched in small nuclear ribonucleoproteins, and certain general RNA polymerase II transcription factors; ultrastructurally, they appear as a tangle of coiled, electron-dense threads roughly 0.5 micrometers in diameter; involved in aspects of snRNP biogenesis; the protein coilin serves as a marker for Cajal bodies. Some argue that Cajal bodies are the sites for preassembly of transcriptosomes, unitary particles involved in transcription and processing of RNA. The host is the larger of the organisms involved in a symbiotic interaction.\" [GOC:rph]","metadata":null},{"id":"75addd61fa5a4fcab0316fc3a1be2512","type":"GO_TERM","name":"host cell Golgi apparatus","canonical_id":"go:GO:0044177","description":"\"A compound membranous cytoplasmic organelle of eukaryotic host cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack.\" [GOC:jl]","metadata":null},{"id":"37f59957884140d7b729c64e52709a27","type":"GO_TERM","name":"host cell Golgi membrane","canonical_id":"go:GO:0044178","description":"\"The lipid bilayer surrounding any of the compartments of the host cell Golgi apparatus.\" [GOC:jl]","metadata":null},{"id":"2394fd67897048a682c0941af66b93d2","type":"GO_TERM","name":"host cell PML body","canonical_id":"go:GO:0075341","description":"\"A nuclear body that reacts against SP100 auto-antibodies (PML = promyelocytic leukemia) located within a cell of a host organism.\" [GOC:BHF, GOC:jl]","metadata":null},{"id":"c08c56bd7b4c4325bbf53961d6c5818f","type":"GO_TERM","name":"host cell centrosome","canonical_id":"go:GO:0120148","description":"\"A structure in a host cell comprised of a core structure (in most organisms, a pair of centrioles) and peripheral material from which a microtubule-based structure, such as a spindle apparatus, is organized. Centrosomes occur close to the nucleus during interphase in many eukaryotic cells, though in animal cells it changes continually during the cell-division cycle.\" [ISBN:0198547684]","metadata":null},{"id":"b2f82a715da941bbaf5ee8d085fe2e03","type":"GO_TERM","name":"host cell chloroplast","canonical_id":"go:GO:0033652","description":"\"A chlorophyll-containing plastid as found within host cells with thylakoids organized into grana and frets, or stroma thylakoids, and embedded in a stroma. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"b50c86e78ed44ec49a9d0d2c6b509b8b","type":"GO_TERM","name":"host cell chloroplast part","canonical_id":"go:GO:0033653","description":"\"Any constituent part of a chloroplast as it is found in host cells and which are a chlorophyll-containing plastid with thylakoids organized into grana and frets, or stroma thylakoids, and embedded in a stroma. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"24d6d81f98d047f88d2caa361be79962","type":"GO_TERM","name":"host cell chloroplast thylakoid membrane","canonical_id":"go:GO:0033654","description":"\"Any sac-like membranous structures (cisternae) in a chloroplast found in host cells, combined into stacks (grana) and present singly in the stroma (stroma thylakoids or frets) as interconnections between grana. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"485606ae9e2d4a3f8bd73a5ebfeaf1ea","type":"GO_TERM","name":"host cell cytoplasm","canonical_id":"go:GO:0030430","description":"\"The cytoplasm of a host cell.\" [GOC:mah]","metadata":null},{"id":"0fffb56f08db43959bfda5a739cd185c","type":"GO_TERM","name":"host cell cytoplasm part","canonical_id":"go:GO:0033655","description":"\"Any constituent part of the host cell cytoplasm, all of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"f76cc581ca9b432eb6269386cd52c5d4","type":"GO_TERM","name":"host cell cytoplasmic vesicle","canonical_id":"go:GO:0044161","description":"\"A vesicle formed of membrane or protein, found in the cytoplasm of a host cell.\" [GOC:rph]","metadata":null},{"id":"d3419c4a84e74114be5f9dc52c8830f0","type":"GO_TERM","name":"host cell cytoplasmic vesicle membrane","canonical_id":"go:GO:0044162","description":"\"The lipid bilayer surrounding a host cell cytoplasmic vesicle.\" [GOC:rph]","metadata":null},{"id":"92b905a7d9ae4158934affe544a9e592","type":"GO_TERM","name":"host cell cytosol","canonical_id":"go:GO:0044164","description":"\"The part of the host cell cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.\" [GOC:jl]","metadata":null},{"id":"56d5a51154fa41ee9861a85aac90c029","type":"GO_TERM","name":"host cell endocytic vesicle membrane","canonical_id":"go:GO:0097348","description":"\"The lipid bilayer surrounding a host cell endocytic vesicle.\" [GOC:ecd]","metadata":null},{"id":"405160cbbf5e46fea3f0769ea30a0ebd","type":"GO_TERM","name":"host cell endomembrane system","canonical_id":"go:GO:0033645","description":"\"A collection of membranous structures involved in transport within the host cell. The main components of the endomembrane system are endoplasmic reticulum, Golgi bodies, vesicles, cell membrane and nuclear envelope. Members of the endomembrane system pass materials through each other or though the use of vesicles. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"e57f6abfec094b73b4bd450cfa7c4414","type":"GO_TERM","name":"host cell endoplasmic reticulum","canonical_id":"go:GO:0044165","description":"\"The irregular network of unit membranes, visible only by electron microscopy, that occurs in the host cell cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The host ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).\" [GOC:jl]","metadata":null},{"id":"83e1d5a61f2649cf8ba1f70e74a74867","type":"GO_TERM","name":"host cell endoplasmic reticulum lumen","canonical_id":"go:GO:0044166","description":"\"The volume enclosed by the membranes of the host cell endoplasmic reticulum.\" [GOC:jl]","metadata":null},{"id":"337fac116a6d45c997fb301b3d4ed6c5","type":"GO_TERM","name":"host cell endoplasmic reticulum membrane","canonical_id":"go:GO:0044167","description":"\"The lipid bilayer surrounding the host cell endoplasmic reticulum.\" [GOC:jl]","metadata":null},{"id":"155c1329accc40be9262955b498b3a9f","type":"GO_TERM","name":"host cell endoplasmic reticulum-Golgi intermediate compartment","canonical_id":"go:GO:0044172","description":"\"A complex system of membrane-bounded compartments located between host cell endoplasmic reticulum (ER) and the host Golgi complex, with a distinctive membrane protein composition; involved in ER-to-Golgi transport.\" [GOC:jl, GOC:pr]","metadata":null},{"id":"a8c5fb5d5d6f4273a2eebd044a013043","type":"GO_TERM","name":"host cell endoplasmic reticulum-Golgi intermediate compartment membrane","canonical_id":"go:GO:0044173","description":"\"The lipid bilayer surrounding any of the compartments of the host cell ER-Golgi intermediate compartment system.\" [GOC:jl]","metadata":null},{"id":"6850b84270354193a8b707ebb507b615","type":"GO_TERM","name":"host cell endosome","canonical_id":"go:GO:0044174","description":"\"A membrane-bounded organelle that carries materials newly ingested by endocytosis. It passes many of the materials to host cell lysosomes for degradation.\" [GOC:jl]","metadata":null},{"id":"05c132a5b4a549ed9ec62d2c578d1fde","type":"GO_TERM","name":"host cell endosome lumen","canonical_id":"go:GO:0072493","description":"\"The volume enclosed by the membranes of the host cell endosome.\" [GOC:ecd]","metadata":null},{"id":"b9446add38c840518d5d1b61806671a8","type":"GO_TERM","name":"host cell endosome membrane","canonical_id":"go:GO:0044175","description":"\"The lipid bilayer surrounding a host cell endosome.\" [GOC:jl]","metadata":null},{"id":"02c5b957553745a0a00f022e677e3f62","type":"GO_TERM","name":"host cell envelope","canonical_id":"go:GO:0044230","description":"\"An envelope that surrounds a bacterial host cell and includes the host cytoplasmic membrane and everything external, encompassing the host periplasmic space, host cell wall, and host outer membrane if present.\" [GOC:rph]","metadata":null},{"id":"8aa90cb1675e4de1a79dfe14456a353b","type":"GO_TERM","name":"host cell extracellular matrix binding","canonical_id":"go:GO:0046810","description":"\"Binding to the extracellular matrix of a host cell.\" [PMID:7996163]","metadata":null},{"id":"17c05255303c4b91ba6714ce7bba4e26","type":"GO_TERM","name":"host cell filopodium","canonical_id":"go:GO:0044176","description":"\"Thin, stiff protrusion extended by the leading edge of a motile host cell such as a crawling fibroblast or amoeba, or an axonal growth cone; usually approximately 0.1 um wide, 5-10 um long, can be up to 50 um long in axon growth cones; contains a loose bundle of about 20 actin filaments oriented with their plus ends pointing outward.\" [GOC:jl]","metadata":null},{"id":"aba272735d2243aca3f99192cedac44d","type":"GO_TERM","name":"host cell junction","canonical_id":"go:GO:0044156","description":"\"A plasma membrane part that forms a specialized region of connection between two host cells or between a host cell and the host extracellular matrix. At a host cell junction, anchoring proteins extend through the host plasma membrane to link cytoskeletal proteins in one cell to cytoskeletal proteins in neighboring cells or to proteins in the extracellular matrix.\" [GOC:rph]","metadata":null},{"id":"25c7be46c31a406b913e9487a91f1f73","type":"GO_TERM","name":"host cell late endosome","canonical_id":"go:GO:0044184","description":"\"A prelysosomal endocytic organelle differentiated from host early endosomes by lower lumenal pH and different protein composition. Host late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center.\" [GOC:jl]","metadata":null},{"id":"bbb5319d39fb478893cfcba3c6de00e2","type":"GO_TERM","name":"host cell late endosome membrane","canonical_id":"go:GO:0044185","description":"\"The lipid bilayer surrounding a host cell late endosome.\" [GOC:jl]","metadata":null},{"id":"f2ff8706bf334f64bdbde592225340cc","type":"GO_TERM","name":"host cell lipid droplet","canonical_id":"go:GO:0044186","description":"\"Any particle of coalesced lipids in the cytoplasm of a host cell. May include associated proteins.\" [GOC:jl]","metadata":null},{"id":"19b1e1256dfa41aea3cb9eae95194d71","type":"GO_TERM","name":"host cell lysosomal membrane","canonical_id":"go:GO:0044188","description":"\"The lipid bilayer surrounding the host cell lysosome and separating its contents from the host cell cytoplasm.\" [GOC:jl]","metadata":null},{"id":"3668724bee2448bf8f21982062472eb7","type":"GO_TERM","name":"host cell lysosome","canonical_id":"go:GO:0044187","description":"\"A small lytic vacuole that has cell cycle-independent morphology and is found in most host animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and host cell lysosomes have a great variety of morphologies and functions.\" [GOC:jl]","metadata":null},{"id":"f61a1846c00c40ec9525466c9ec0ce91","type":"GO_TERM","name":"host cell membrane","canonical_id":"go:GO:0033644","description":"\"Double layer of lipid molecules as it encloses host cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"b0552c17a89142c0943288e31afed36c","type":"GO_TERM","name":"host cell membrane pore complex","canonical_id":"go:GO:0044084","description":"\"Any small opening in a host cell membrane that allows the passage of gases and/or liquids, composed of host proteins.\" [MITRE:tk]","metadata":null},{"id":"856bc27ca5e348b8ae5c6464b94eabe2","type":"GO_TERM","name":"host cell mitochondrial envelope","canonical_id":"go:GO:0044190","description":"\"The double lipid bilayer enclosing the host cell mitochondrion and separating its contents from the host cell cytoplasm; includes the intermembrane space.\" [GOC:jl]","metadata":null},{"id":"2468684a604d494aaeb32d554f3fc4b0","type":"GO_TERM","name":"host cell mitochondrial inner membrane","canonical_id":"go:GO:0044192","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the host cell mitochondrial envelope. It is highly folded to form cristae.\" [GOC:jl]","metadata":null},{"id":"c8b40f6bf08b4086900324ff98364313","type":"GO_TERM","name":"host cell mitochondrial intermembrane space","canonical_id":"go:GO:0072492","description":"\"The region between the inner and outer lipid bilayers of the host cell mitochondrial envelope.\" [GOC:ecd]","metadata":null},{"id":"7f9376f429784011b850917300a26313","type":"GO_TERM","name":"host cell mitochondrial membrane","canonical_id":"go:GO:0044191","description":"\"Either of the lipid bilayers that surround the host cell mitochondrion and form the host cell mitochondrial envelope.\" [GOC:jl]","metadata":null},{"id":"86801fc14f3448fc91d592a31cb70596","type":"GO_TERM","name":"host cell mitochondrial outer membrane","canonical_id":"go:GO:0044193","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the host cell mitochondrial envelope.\" [GOC:jl]","metadata":null},{"id":"19120553199d44ccbd162c76248e503a","type":"GO_TERM","name":"host cell mitochondrion","canonical_id":"go:GO:0033650","description":"\"A semiautonomous, self replicating organelle as found in host cells that occurs in varying numbers, shapes, and sizes in the cell cytoplasm. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"f03655ed5dac46ff97009dcb18ea1cb0","type":"GO_TERM","name":"host cell nuclear envelope","canonical_id":"go:GO:0044199","description":"\"The double lipid bilayer that encloses the host cell nucleus, separating its contents from the cytoplasm. It consists of an inner and outer nuclear membrane, with an intermembrane space (20-40 nm wide, also called the perinuclear space) between them. The envelope is supported by the nuclear lamina and contains nuclear pore complexes, which regulate molecular transport.\" [GOC:jl, GOC:rynl]","metadata":null},{"id":"62bf754c21cc414dab85d807770701cf","type":"GO_TERM","name":"host cell nuclear inner membrane","canonical_id":"go:GO:0044201","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the host nuclear envelope.\" [GOC:jl]","metadata":null},{"id":"04538047878945a987736fe51afcc091","type":"GO_TERM","name":"host cell nuclear lamina","canonical_id":"go:GO:0044203","description":"\"The fibrous, electron-dense layer lying on the nucleoplasmic side of the inner membrane of a host cell nucleus, composed of lamin filaments.\" [GOC:jl]","metadata":null},{"id":"ddd94a6558b04f0a866364f75609464b","type":"GO_TERM","name":"host cell nuclear matrix","canonical_id":"go:GO:0044204","description":"\"A dynamic, proteinaceous framework within the nucleus of host eukaryotic cells, composed of proteins and RNA, that provides structural support for chromatin organization, gene regulation, and nuclear processes.\" [GOC:jl, GOC:rynl]","metadata":null},{"id":"1065508c08f643cf89840c2a84f773db","type":"GO_TERM","name":"host cell nuclear membrane","canonical_id":"go:GO:0044200","description":"\"Either of the lipid bilayers that surround the host nucleus and form the nuclear envelope; excludes the intermembrane space.\" [GOC:jl]","metadata":null},{"id":"d8a5b70da3b1430094911fb5859fec5b","type":"GO_TERM","name":"host cell nuclear outer membrane","canonical_id":"go:GO:0044202","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the host nuclear envelope; continuous with the endoplasmic reticulum of the host cell and sometimes studded with ribosomes.\" [GOC:jl]","metadata":null},{"id":"8f7003a8e30b4ad59691cb39f0ae4b8e","type":"GO_TERM","name":"host cell nuclear part","canonical_id":"go:GO:0044094","description":"\"Any constituent part of a host cell's nucleus, a membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. The host is the larger of the organisms involved in a symbiotic interaction.\" [GOC:ecd]","metadata":null},{"id":"81a3698459c44cc182192c66c7a460d2","type":"GO_TERM","name":"host cell nucleolus","canonical_id":"go:GO:0044196","description":"\"A small, dense body one or more of which are present in the nucleus of eukaryotic host cells.\" [GOC:jl]","metadata":null},{"id":"ca9771a9a5664eaf80a57c79544b63a2","type":"GO_TERM","name":"host cell nucleoplasm","canonical_id":"go:GO:0044095","description":"\"That part of a host cell's nuclear content other than the chromosomes or the nucleolus. The host is the larger of the organisms involved in a symbiotic interaction.\" [GOC:ecd]","metadata":null},{"id":"0c7e02d22a964c32b67c836ee4c1285c","type":"GO_TERM","name":"host cell nucleus","canonical_id":"go:GO:0042025","description":"\"A membrane-bounded organelle as it is found in the host cell in which chromosomes are housed and replicated. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"bdbbb06a0fec4e758ae727b288460ed8","type":"GO_TERM","name":"host cell outer membrane","canonical_id":"go:GO:0039662","description":"\"A lipid bilayer that forms the outermost layer of the cell envelope, occurring in a host cell.\" [GOC:bf, GOC:ch]","metadata":null},{"id":"eefd0f6748094ce48e9289ccc5c81765","type":"GO_TERM","name":"host cell part","canonical_id":"go:GO:0033643","description":"\"Any constituent part of a host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"b5a32ec9e86b45f59fcfdf39519608da","type":"GO_TERM","name":"host cell perinuclear region of cytoplasm","canonical_id":"go:GO:0044220","description":"\"The host cell cytoplasm situated near, or occurring around, the host nucleus.\" [GOC:rph]","metadata":null},{"id":"2f15021995774088a3d83c7bdeeb926d","type":"GO_TERM","name":"host cell periphery","canonical_id":"go:GO:0044538","description":"\"The part of a cell encompassing the cell cortex, the plasma membrane, and any external encapsulating structures of a host cell.\" [GOC:jl, PMID:20463076]","metadata":null},{"id":"164126e086514ceda4200a2f071b74ac","type":"GO_TERM","name":"host cell periplasmic space","canonical_id":"go:GO:0044229","description":"\"The region between the inner (cytoplasmic) and outer host membrane (Gram-negative Bacteria) or inner host membrane and host cell wall (Fungi).\" [GOC:rph]","metadata":null},{"id":"bb459c87ef5b435b83bce1533baea885","type":"GO_TERM","name":"host cell peroxisome","canonical_id":"go:GO:0120149","description":"\"A small host cell organelle enclosed by a single membrane, and found in most eukaryotic cells. Contains peroxidases and other enzymes involved in a variety of metabolic processes including free radical detoxification, lipid catabolism and biosynthesis, and hydrogen peroxide metabolism.\" [PMID:9302272]","metadata":null},{"id":"597ce76d5070409d8c412ef968a56049","type":"GO_TERM","name":"host cell plasma membrane","canonical_id":"go:GO:0020002","description":"\"The plasma membrane surrounding a host cell.\" [GOC:mb]","metadata":null},{"id":"903c681c58804667978b74e31bf87d0f","type":"GO_TERM","name":"host cell plasmodesma","canonical_id":"go:GO:0044219","description":"\"A fine cytoplasmic channel, found in all higher plants, that connects the cytoplasm of one host cell to that of an adjacent host cell.\" [GOC:rph, PMID:16903353]","metadata":null},{"id":"5a2bffd29f204099aebb9b34aa43b77c","type":"GO_TERM","name":"host cell plastid","canonical_id":"go:GO:0033651","description":"\"Any member of a family of organelles as found in the cytoplasm of host cells, which are membrane-bounded and contain DNA. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"65dfc89944674dcd82c094c78caa4997","type":"GO_TERM","name":"host cell postsynaptic membrane","canonical_id":"go:GO:0035792","description":"\"A postsynaptic membrane that is part of a host cell. A postsynaptic membrane is a specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters transmit the signal across the synaptic cleft to the postsynaptic membrane.\" [GOC:ecd]","metadata":null},{"id":"e17013d9dbf74815b95558d82ba78d52","type":"GO_TERM","name":"host cell presynaptic membrane","canonical_id":"go:GO:0044231","description":"\"A specialized area of membrane of the host axon terminal that faces the plasma membrane of the host neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many host synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane.\" [GOC:rph]","metadata":null},{"id":"39fb55b45bd94afe8f2e40aa0f68250b","type":"GO_TERM","name":"host cell projection","canonical_id":"go:GO:0044157","description":"\"A prolongation or process extending from a host cell, e.g. a flagellum or axon.\" [GOC:rph]","metadata":null},{"id":"9fca9b0a3b924de8b2de92487374a994","type":"GO_TERM","name":"host cell rough endoplasmic reticulum","canonical_id":"go:GO:0044168","description":"\"The irregular network of unit membranes, visible only by electron microscopy, that occurs in the host cell cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The host rough ER has ribosomes adhering to the outer surface.\" [GOC:jl]","metadata":null},{"id":"c3fc9e5d292b49f7965288e371ea48a5","type":"GO_TERM","name":"host cell rough endoplasmic reticulum membrane","canonical_id":"go:GO:0044169","description":"\"The lipid bilayer surrounding the host cell rough endoplasmic reticulum.\" [GOC:jl]","metadata":null},{"id":"1ef99931497b48e7bbdc29cd2b7d3f38","type":"GO_TERM","name":"host cell smooth endoplasmic reticulum","canonical_id":"go:GO:0044170","description":"\"The irregular network of unit membranes, visible only by electron microscopy, that occurs in the host cell cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The host smooth ER has no ribosomes adhering to the outer surface.\" [GOC:jl]","metadata":null},{"id":"7b5515da81034885a4aa76bcdec58250","type":"GO_TERM","name":"host cell smooth endoplasmic reticulum membrane","canonical_id":"go:GO:0044171","description":"\"The lipid bilayer surrounding the host cell smooth endoplasmic reticulum.\" [GOC:jl]","metadata":null},{"id":"3c7e35c9b51643fab3a10ee5bfed4c41","type":"GO_TERM","name":"host cell surface","canonical_id":"go:GO:0044228","description":"\"The external part of the host cell wall and/or host plasma membrane.\" [GOC:rph]","metadata":null},{"id":"afadf4a9dade4a2ea324bbcc2320bf4f","type":"GO_TERM","name":"host cell surface binding","canonical_id":"go:GO:0046812","description":"\"Binding to the surface of a host cell.\" [GOC:ai]","metadata":null},{"id":"a7fa7eff405c44339d5019ff601c1d9f","type":"GO_TERM","name":"host cell surface receptor binding","canonical_id":"go:GO:0046789","description":"\"Binding to a receptor on the host cell surface.\" [GOC:ai, PMID:11511370]","metadata":null},{"id":"d9861d792db34490951647e06d8b9d15","type":"GO_TERM","name":"host cell synapse","canonical_id":"go:GO:0044221","description":"\"The junction between a nerve fiber of one host neuron and another host neuron or muscle fiber or glial cell; the site of interneuronal communication.\" [GOC:rph]","metadata":null},{"id":"e948421282994df69c6f16f44913feda","type":"GO_TERM","name":"host cell synaptic vesicle","canonical_id":"go:GO:0098584","description":"\"A secretory organelle of a host cell, some 50 nm in diameter, of presynaptic nerve terminals; accumulates in high concentrations of neurotransmitters and secretes these into the synaptic cleft by fusion with the 'active zone' of the presynaptic plasma membrane.\" [GOC:dos]","metadata":null},{"id":"e653c0e8d10f43328b1d840dd0e8c865","type":"GO_TERM","name":"host cell synaptic vesicle membrane","canonical_id":"go:GO:0098585","description":"\"The lipid bilayer surrounding a host synaptic vesicle.\" [GOC:dos]","metadata":null},{"id":"4edf31f1459f4d24afd98eb18f926fff","type":"GO_TERM","name":"host cell uropod","canonical_id":"go:GO:0120026","description":"\"A host cell membrane projection with related cytoskeletal components at the trailing edge of a cell in the process of migrating or being activated, found on the opposite side of the cell from the leading edge or immunological synapse, respectively.\" [PMID:24965475]","metadata":null},{"id":"2b2e1d0dc20445578318dc3a5cc39767","type":"GO_TERM","name":"host cell viral assembly compartment","canonical_id":"go:GO:0072517","description":"\"A membrane-bounded compartment that forms in the cytoplasm of the host cell, in which virus assembly takes place.\" [GOC:BHF, PMID:20374631]","metadata":null},{"id":"1e04db74cca8473eb69b7ce878ff2aa3","type":"GO_TERM","name":"host cell viral nucleoid","canonical_id":"go:GO:0039643","description":"\"The region of a host cell that contains the viral genome.\" [GOC:bf, GOC:bm, GOC:jl]","metadata":null},{"id":"a0589d4d05264e14bae70766a8c03368","type":"GO_TERM","name":"host cell wall","canonical_id":"go:GO:0044158","description":"\"The rigid or semi-rigid envelope lying outside the host cell membrane of plant, fungal, and most prokaryotic cells, maintaining their shape and protecting them from osmotic lysis. In plants it is made of cellulose and, often, lignin; in fungi it is composed largely of polysaccharides; in bacteria it is composed of peptidoglycan.\" [GOC:rph]","metadata":null},{"id":"8b52c325522942b59e4687ade93a1d67","type":"GO_TERM","name":"host cellular component","canonical_id":"go:GO:0018995","description":"\"Any cellular component of a host cell. The host is an organism in which another organism, for instance a parasite or symbiont, spends part or all of its life cycle and from which it obtains nourishment and/or protection.\" [ISBN:0198506732]","metadata":null},{"id":"b9e845fa51ef4639b47db1f4d79241f3","type":"GO_TERM","name":"host chromosome","canonical_id":"go:GO:0044383","description":"\"A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information, occurring within a host cell.\" [GOC:jl]","metadata":null},{"id":"b6028765e45b40f892416bfe723efd51","type":"GO_TERM","name":"host cytoskeleton","canonical_id":"go:GO:0044163","description":"\"A cellular structure that forms the internal framework of eukaryotic and prokaryotic host cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles.\" [GOC:rph]","metadata":null},{"id":"240c4f1b350b4933a7b6466af3211be5","type":"GO_TERM","name":"host defense response against symbiont-mediated perturbation of plasma membrane integrity","canonical_id":"go:GO:0140976","description":"\"The cellular processes and signaling pathways by which a cell responds to disruption of the integrity of its plasma membrane by another organism. Some toxins produced by other organisms can form pores in membranes, or affect the membrane permeability.\" [PMID:17234446, PMID:21518219]","metadata":null},{"id":"f3d7d7bf6f4a429eb24fb68290a1cc5f","type":"GO_TERM","name":"host extracellular region","canonical_id":"go:GO:0043655","description":"\"The space within a host but external to the plasma membrane of host cells, e.g. host bloodstream.\" [GOC:cc]","metadata":null},{"id":"11f0086a7fbd4d6f8d705c220f8a82e5","type":"GO_TERM","name":"host interaction involved in quorum sensing","canonical_id":"go:GO:0120218","description":"\"A quorum sensing process that is modulated by some interaction with a host cell or organism.\" [GOC:krc, GOC:mlg, PMID:11780122, PMID:16630813]","metadata":null},{"id":"bbf7f7ae09344404b5fc3e096733d2d9","type":"GO_TERM","name":"host intracellular membrane-bounded organelle","canonical_id":"go:GO:0033648","description":"\"Organized structure of distinctive morphology and function, as found in host cells, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"05be9cbbff874a29a4957491cdd6333f","type":"GO_TERM","name":"host intracellular organelle","canonical_id":"go:GO:0033647","description":"\"Organized structure of distinctive morphology and function, occurring within the host cell. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. Excludes the plasma membrane. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"3dc4877b35c94430bcb7de3c4b4ae19f","type":"GO_TERM","name":"host intracellular part","canonical_id":"go:GO:0033646","description":"\"Any constituent part of the living contents of a host cell; the matter contained within (but not including) the plasma membrane, usually taken to exclude large vacuoles and masses of secretory or ingested material. In eukaryotes it includes the nucleus and cytoplasm. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"e0e8d1ad0bd84170965c488b78699874","type":"GO_TERM","name":"host intracellular region","canonical_id":"go:GO:0043656","description":"\"That space within the plasma membrane of a host cell.\" [GOC:cc]","metadata":null},{"id":"44d9e4c933464d0cad6052168eca5c61","type":"GO_TERM","name":"host multivesicular body","canonical_id":"go:GO:0072494","description":"\"A late endosome in which regions of the limiting host cell endosomal membrane invaginate to form internal vesicles; host membrane proteins that enter the internal vesicles are sequestered from the host cytoplasm.\" [GOC:rph]","metadata":null},{"id":"8eb7beb3fa2f44759498b352667fbde2","type":"GO_TERM","name":"host organelle outer membrane","canonical_id":"go:GO:0039661","description":"\"The outer, i.e. cytoplasm-facing in a cellular organelle, lipid bilayer of an organelle envelope, occurring in a host cell.\" [GOC:bf, GOC:ch]","metadata":null},{"id":"3efc2e6741dd406b971d3c00ccbdd37c","type":"GO_TERM","name":"host outer membrane","canonical_id":"go:GO:0044384","description":"\"The external membrane of Gram-negative bacteria or certain organelles such as mitochondria and chloroplasts; freely permeable to most ions and metabolites, occurring in a host cell.\" [GOC:jl]","metadata":null},{"id":"a520ceaae9a34f4caf4c931093fda511","type":"GO_TERM","name":"host peribacteroid fluid","canonical_id":"go:GO:0043665","description":"\"The soluble material inside the peribacteroid membrane, but outside of the bacteroid, within a bacteroid-containing symbiosome of a host cell.\" [GOC:cc]","metadata":null},{"id":"9f25dfb53ccf417586b166b0eebf2d8e","type":"GO_TERM","name":"host peribacteroid membrane","canonical_id":"go:GO:0043664","description":"\"A host-derived membrane that surrounds one or more bacteroids (such as nitrogen-fixing bacteroids within legume root nodule cells).\" [GOC:cc]","metadata":null},{"id":"d3e3f0f201e046c2a371e4049d600d2f","type":"GO_TERM","name":"host response to induction by symbiont of tumor, nodule or growth in host","canonical_id":"go:GO:0080034","description":"\"Any process that results in a change in the state or activity of a host cell or organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the formation of an abnormal mass of cells in the host organism, induced by a symbiont. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18836040]","metadata":null},{"id":"1a9cc3bafc5f410984db7e039f264e5f","type":"GO_TERM","name":"host symbiosome","canonical_id":"go:GO:0043658","description":"\"A double-enveloped cell compartment, composed of the endosymbiont with its plasmalemma (as inner envelope) and an outer envelope (the perisymbiontic membrane) derived from the host cell.\" [GOC:cc]","metadata":null},{"id":"956fde78715741208588f651d2126415","type":"GO_TERM","name":"host thylakoid","canonical_id":"go:GO:0044159","description":"\"A membranous cellular structure within the host cell that bears the photosynthetic pigments in plants, algae, and cyanobacteria. In cyanobacteria thylakoids are of various shapes and are attached to, or continuous with, the host plasma membrane. In eukaryotic host cells they are flattened, membrane-bounded disk-like structures located in the chloroplasts; in the chloroplasts of higher plants the thylakoids form dense stacks called grana. Isolated thylakoid preparations can carry out photosynthetic electron transport and the associated phosphorylation.\" [GOC:rph]","metadata":null},{"id":"471257c5435d4116a3d97989a30268d7","type":"GO_TERM","name":"host thylakoid membrane","canonical_id":"go:GO:0044160","description":"\"The pigmented membrane of any host thylakoid.\" [GOC:rph]","metadata":null},{"id":"213b9030f96a4727a1fc0faae14fe37d","type":"GO_TERM","name":"host-mediated activation of viral RNA-templated transcription","canonical_id":"go:GO:0140181","description":"\"A process in which a host organism initiates, promotes, or enhances the normal execution of viral RNA-templated transcription, the synthesis of either RNA on a RNA template.\" [PMID:18836083]","metadata":null},{"id":"c7db76ce41a94b8b932f48507bd98cdf","type":"GO_TERM","name":"host-mediated activation of viral genome replication","canonical_id":"go:GO:0044829","description":"\"A process in which a host organism initiates, promotes, or enhances the normal execution of viral genome replication.\" [GOC:jl]","metadata":null},{"id":"a52c71c164ff4ceb9a55dfbb97ffc33a","type":"GO_TERM","name":"host-mediated activation of viral process","canonical_id":"go:GO:0044794","description":"\"A process in which a host organism initiates, promotes, or enhances the normal execution of a biological process being mediated by a virus with which it is infected.\" [GOC:jl]","metadata":null},{"id":"739a907710f14beea66c7ae8cd49c36e","type":"GO_TERM","name":"host-mediated activation of viral transcription","canonical_id":"go:GO:0043923","description":"\"A process in which a host organism initiates, promotes, or enhances the normal execution of viral transcription, the synthesis of either RNA on a template of DNA or DNA on a template of RNA.\" [GOC:jl]","metadata":null},{"id":"579a1fb768bb4c4db53f2b20a1d5f7cd","type":"GO_TERM","name":"host-mediated modulation of intestinal microbiota composition","canonical_id":"go:GO:0048874","description":"\"The biological process involved in maintaining the steady-state number of cells within a population of free-living cells such as the bacteria in the gut.\" [PMID:25757720]","metadata":null},{"id":"bb0a41594ab240bcac249267ad30021f","type":"GO_TERM","name":"host-mediated modulation of oral microbiota composition","canonical_id":"go:GO:0120332","description":"\"The biological process involved in maintaining the steady-state number of cells within a population of free-living cells, such as the bacteria, in the mouth.\" [PMID:31882545]","metadata":null},{"id":"7230e9d76b994e18b016e4e15cb1d1ac","type":"GO_TERM","name":"host-mediated perturbation of symbiont process","canonical_id":"go:GO:0051851","description":"\"The process in which an host alters or subverts a process in a symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"8362d8b9cfcf4138b56e346560e6c043","type":"GO_TERM","name":"host-mediated perturbation of viral RNA genome replication","canonical_id":"go:GO:0044830","description":"\"A process in which a host organism alters or subverts viral RNA genome replication.\" [GOC:jl]","metadata":null},{"id":"2a04f0cf4ec14dbb97258eb898b086be","type":"GO_TERM","name":"host-mediated perturbation of viral genome replication","canonical_id":"go:GO:0044827","description":"\"A process in which a host organism alters or subverts viral genome replication.\" [GOC:jl]","metadata":null},{"id":"94ec8ad6a306484d9e8fbfe2f607cb3e","type":"GO_TERM","name":"host-mediated perturbation of viral process","canonical_id":"go:GO:0044788","description":"\"A process in which a host organism alters or subverts a biological process being mediated by a virus with which it is infected.\" [GOC:jl]","metadata":null},{"id":"63d0a52480ee477a8058cf604cf5ede9","type":"GO_TERM","name":"host-mediated perturbation of viral transcription","canonical_id":"go:GO:0043921","description":"\"A process in which a host organism alters or subverts viral transcription.\" [GOC:jl]","metadata":null},{"id":"fb213881931346d09b628f678fe12d94","type":"GO_TERM","name":"host-mediated suppression of symbiont invasion","canonical_id":"go:GO:0046597","description":"\"A process in which a host inhibits or disrupts the entry of a symbiont into a host cell.\" [PMID:23544079]","metadata":null},{"id":"a00d7aa2da0e4756b0c4fe03036d259e","type":"GO_TERM","name":"host-mediated suppression of viral genome replication","canonical_id":"go:GO:0044828","description":"\"A process in which a host organism interferes with, inhibits or disrupts viral genome replication.\" [GOC:jl]","metadata":null},{"id":"0f234f3993f84af1860784bc1957eef4","type":"GO_TERM","name":"host-mediated suppression of viral proces","canonical_id":"go:GO:0044793","description":"\"A process in which a host organism interferes with, inhibits or disrupts a process being mediated by a virus with which it is infected.\" [GOC:jl]","metadata":null},{"id":"49b218911e0144df81e4ebe22577d1c4","type":"GO_TERM","name":"host-mediated suppression of viral transcription","canonical_id":"go:GO:0043922","description":"\"A process in which a host organism interferes with, inhibits or disrupts viral transcription.\" [GOC:jl]","metadata":null},{"id":"213ebff56bb94c4f96136b144197ba06","type":"GO_TERM","name":"host-seeking behavior","canonical_id":"go:GO:0032537","description":"\"The specific behavior of an organism that are associated with finding a host organism; may include behavioral responses to light, temperature, or chemical emanations from the prospective host.\" [GOC:mah, GOC:pr, PMID:11931033]","metadata":null},{"id":"60b785ee4d6d478baf8ba82d60eafa19","type":"GO_TERM","name":"host-symbiont bicellular tight junction","canonical_id":"go:GO:0044647","description":"\"An occluding cell-cell junction formed between the membranes of the apical end of an invading cell (e.g. a merozoite in Plasmodium) and a host target cell (e.g. erythrocyte for Plasmodium infection). The junction is a stable yet dynamic structure that moves around the symbiont cell during invasion, enclosing it in a vacuole surrounded by a membrane.\" [GOC:jl, PMID:21803641]","metadata":null},{"id":"71acb3ec46154c8e9517d56a14cdbc64","type":"DISEASE","name":"human African trypanosomiasis","canonical_id":"mondo:0005459","description":null,"metadata":null},{"id":"92e542ef0c4441488a86789d02e4f33a","type":"GO_TERM","name":"humanin receptor complex","canonical_id":"go:GO:7770013","description":"\"A protein complex that acts as a receptor for the neuroprotective peptide humanin (HN). In humans the receptor complex is a trimer composed of CNTFR, IL6ST and IL27RA. HN binding to IL27RA and CNTFR induces oligomerization of the three subunits.\" [PMID:19386761]","metadata":null},{"id":"9e36432f140e4ca886a67afcbdc4e3cc","type":"GO_TERM","name":"humoral immune response","canonical_id":"go:GO:0006959","description":"\"An immune response mediated through a body fluid.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"510a24cb59344696b585ac24db03f147","type":"GO_TERM","name":"humoral immune response mediated by circulating immunoglobulin","canonical_id":"go:GO:0002455","description":"\"An immune response dependent upon secreted immunoglobulin. An example of this process is found in Mus musculus.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"5edec5995fbf47a6babf0e2d55386100","type":"GO_TERM","name":"hyaline inclusion","canonical_id":"go:GO:0097412","description":"\"A glass-like, pale intracellular inclusion.\" [NIF_Subcellular:nlx_subcell_20090104]","metadata":null},{"id":"fc267145cdbe438292fc231b938a76b1","type":"GO_TERM","name":"hyaline layer","canonical_id":"go:GO:0033166","description":"\"A multilayered extraembryonic matrix that functions as a substrate for cell adhesion through early development. It is thought to protect and lubricate the embryo, stabilize the blastomeres during morphogenesis, and regulate nutrient intake. The major constituent of the hyaline layer is the protein hyalin. This matrix has been found in echinoderms.\" [PMID:1721506, PMID:9473317]","metadata":null},{"id":"abc62d1b00f346d19124fe43aa5b4139","type":"GO_TERM","name":"hyaloid vascular plexus regression","canonical_id":"go:GO:1990384","description":"\"The developmental process in which the hyaloid vascular plexus is destroyed as a part of its normal progression.\" [GOC:hjd, PMID:18841878]","metadata":null},{"id":"35e99d3239824c0f96cd02be75d3a6d5","type":"GO_TERM","name":"hyaluranon cable","canonical_id":"go:GO:0036117","description":"\"A cable structure, surrounding some cell types (e.g. proximal or bronchial tubular epithelial cells), and composed of hyaluranon (HA), a ubiquitous connective tissue glycosaminoglycan.\" [GOC:yaf, PMID:16900089]","metadata":null},{"id":"f60c00931a7d4a5cb571c0e37cfe7390","type":"GO_TERM","name":"hyaluranon cable assembly","canonical_id":"go:GO:0036118","description":"\"A process that results in the aggregation, arrangement and bonding together of a hyaluranon cable, a cable structure, surrounding some cell types (e.g. proximal or bronchial tubular epithelial cells), and composed of hyaluranon (HA), a ubiquitous connective tissue glycosaminoglycan.\" [GOC:yaf, PMID:16900089]","metadata":null},{"id":"96d39471d4d042d19624dec73cc8d783","type":"GO_TERM","name":"hyaluronan biosynthetic process","canonical_id":"go:GO:0030213","description":"\"The chemical reactions and pathways resulting in the formation of hyaluronan, the naturally occurring anionic form of hyaluronic acid. Hyaluronan is a type of non-sulfated glycosaminoglycan composed of the repeating disaccharide unit beta(1,4)-D-glucuronic acid-beta(1,3)-N-acetyl-D-glucosamine.\" [PMID:33171800, PMID:35536932]","metadata":null},{"id":"d8f920f80e2842eb9255f3197822f995","type":"GO_TERM","name":"hyaluronan catabolic process","canonical_id":"go:GO:0030214","description":"\"The chemical reactions and pathways resulting in the breakdown of hyaluronan, the naturally occurring anionic form of hyaluronic acid. Hyaluronan is a type of non-sulfated glycosaminoglycan composed of the repeating disaccharide unit beta(1,4)-D-glucuronic acid-beta(1,3)-N-acetyl-D-glucosamine.\" [PMID:33171800, PMID:35536932]","metadata":null},{"id":"860cb02539ba46fd974dc73fe8248918","type":"GO_TERM","name":"hyaluronan metabolic process","canonical_id":"go:GO:0030212","description":"\"The chemical reactions and pathways involving hyaluronan, the naturally occurring anionic form of hyaluronic acid. Hyaluronan is a type of non-sulfated glycosaminoglycan composed of the repeating disaccharide unit beta(1,4)-D-glucuronic acid-beta(1,3)-N-acetyl-D-glucosamine.\" [PMID:33171800, PMID:35536932]","metadata":null},{"id":"af2c525e4d0541b1be6dec3f4d9c5a3c","type":"GO_TERM","name":"hyaluronan synthase activity","canonical_id":"go:GO:0050501","description":"\"Catalysis of the reaction: UDP-D-glucuronate + UDP-N-acetyl-D-glucosamine = [beta-N-acetyl-D-glucosaminyl-(1->4)-beta-D-glucuronosyl-(1->3)](n) + 2n UDP.\" [EC:2.4.1.212, MetaCyc:2.4.1.212-RXN]","metadata":null},{"id":"40747be78d7946b38f0778fde7fd2191","type":"GO_TERM","name":"hyaluronate lyase activity","canonical_id":"go:GO:0030340","description":"\"Catalysis of the reaction: hyaluronate(n) = n 3-(4-deoxy-beta-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine + H2O.\" [RHEA:50240]","metadata":null},{"id":"f53bbcbef5d04ef591f420702753a6f7","type":"GO_TERM","name":"hyaluronic acid binding","canonical_id":"go:GO:0005540","description":"\"Binding to hyaluronic acid, a polymer composed of repeating dimeric units of glucuronic acid and N-acetyl glucosamine.\" [GOC:jl]","metadata":null},{"id":"112c0c4f52af4eb78fb9839b82df0ca4","type":"GO_TERM","name":"hyaluronoglucuronidase activity","canonical_id":"go:GO:0033906","description":"\"Catalysis of the random hydrolysis of 1,3-linkages between beta-D-glucuronate and N-acetyl-D-glucosamine residues in hyaluronate.\" [EC:3.2.1.36]","metadata":null},{"id":"91961c647abe452b96abf56edbc5e545","type":"GO_TERM","name":"hyalurononglucosaminidase activity","canonical_id":"go:GO:0004415","description":"\"Catalysis of the random hydrolysis of (1->4) linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate.\" [EC:3.2.1.35]","metadata":null},{"id":"613c8d216b8a441c9a52cdb369689ba0","type":"GO_TERM","name":"hydantoin racemase activity","canonical_id":"go:GO:0036348","description":"\"Catalysis of the reaction: D-5-monosubstituted hydantoin = L-5-monosubstituted hydantoin.\" [EC:5.1.99.5, InterPro:IPR015942]","metadata":null},{"id":"fc0333841c6c41e0a9c75fd66d2a8eed","type":"DRUG","name":"hydralazine","canonical_id":"mesh:D006830","description":null,"metadata":null},{"id":"3ab67f04fef549dea6b5834a39a00159","type":"GO_TERM","name":"hydrazine dehydrogenase activity","canonical_id":"go:GO:0140287","description":"\"Catalysis of the reaction: hydrazine + 4 Fe(III)-[cytochrome c] = N2 + 4 Fe(II)-[cytochrome c] + 4 H+.\" [RHEA:23232]","metadata":null},{"id":"74f23fe422bb47508b3bee8480f0a4ac","type":"GO_TERM","name":"hydrazine synthase activity","canonical_id":"go:GO:0140304","description":"\"Catalysis of the reaction: hydrazine + 3 Fe(III)-[cytochrome c] + H2O = nitric oxide + 3 Fe(II)-[cytochrome c] + NH4+ + 2 H+.\" [RHEA:49816]","metadata":null},{"id":"448d7cad002c4afe8ae506f8a1be57ea","type":"GO_TERM","name":"hydro-lyase activity","canonical_id":"go:GO:0016836","description":"\"Catalysis of the cleavage of a carbon-oxygen bond by elimination of water.\" [EC:4.2.1.-]","metadata":null},{"id":"cd8aede0137b4ff0bfa8a521a5ef96de","type":"GO_TERM","name":"hydrocarbon biosynthetic process","canonical_id":"go:GO:0120251","description":"\"The chemical reactions and pathways resulting in the formation of a hydrocarbon, a compound consisting of carbon and hydrogen only.\" [GOC:krc, Wikipedia:Hydrocarbon]","metadata":null},{"id":"5abb445ac499485baf06748c5820325c","type":"GO_TERM","name":"hydrocarbon catabolic process","canonical_id":"go:GO:0120253","description":"\"The chemical reactions and pathways resulting in the breakdown of a hydrocarbon, a compound consisting of carbon and hydrogen only.\" [GOC:krc, Wikipedia:Hydrocarbon]","metadata":null},{"id":"8cd818cdcb0c46399490bf7a92372283","type":"GO_TERM","name":"hydrocarbon metabolic process","canonical_id":"go:GO:0120252","description":"\"The chemical reactions and pathways involving a hydrocarbon, a compound consisting of carbon and hydrogen only.\" [GOC:krc, Wikipedia:Hydrocarbon]","metadata":null},{"id":"c75ec46edae140d89233ce8c7027e39e","type":"DRUG","name":"hydrochlorothiazide","canonical_id":"gtopdb:4836","description":null,"metadata":null},{"id":"a339f470d42a4105b220020e33d993b6","type":"DRUG","name":"hydrochlorothiazide","canonical_id":"chembl:CHEMBL435","description":null,"metadata":null},{"id":"522bcb734f504bd6a76620b51db4a7c2","type":"COMBINATION_TREATMENT","name":"hydrochlorothiazide + irbesartan","canonical_id":"ctgov_combo:ctgov-combo-d331c22caddf4f7c","description":null,"metadata":null},{"id":"0936a6053f9c4f9686e0728ee8908081","type":"DRUG","name":"hydrocodone","canonical_id":"gtopdb:7081","description":null,"metadata":null},{"id":"5431bdb6079b445fb9d9e789ac080fa0","type":"DRUG","name":"hydrocodone","canonical_id":"mesh:D006853","description":null,"metadata":null},{"id":"b44f25cafec2434bba541efe72f22a45","type":"COMBINATION_TREATMENT","name":"hydrocodone + hydromorphone","canonical_id":"ctgov_combo:ctgov-combo-580a01b2aaa93516","description":null,"metadata":null},{"id":"3c0b8086058e43ce93b2d01d16a3cb22","type":"COMBINATION_TREATMENT","name":"hydrocodone + levorphanol","canonical_id":"ctgov_combo:ctgov-combo-46d0703bf7e71517","description":null,"metadata":null},{"id":"71c76c18c5164cbe899836898f444f4a","type":"COMBINATION_TREATMENT","name":"hydrocodone + naproxen","canonical_id":"ctgov_combo:ctgov-combo-c127b27c4dc433c5","description":null,"metadata":null},{"id":"bc120d2815e2425da53e32756158c196","type":"DRUG","name":"hydrocortisone","canonical_id":"mesh:D006854","description":null,"metadata":null},{"id":"08a5266a60744cf38b764bbd55a9b417","type":"DRUG","name":"hydroflumethiazide","canonical_id":"mesh:D006857","description":null,"metadata":null},{"id":"51fde1511e584a03927a282619da6a67","type":"GO_TERM","name":"hydrogen biosynthetic process","canonical_id":"go:GO:1902422","description":"\"The chemical reactions and pathways resulting in the formation of H2 (dihydrogen).\" [GOC:mengo_curators, GOC:TermGenie, PMID:20395274, PMID:20692761]","metadata":null},{"id":"34c7c0596c194e9297a4953a355a871b","type":"GO_TERM","name":"hydrogen dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050583","description":"\"Catalysis of the reaction: NADP+ + H2 = NADPH + H+.\" [EC:1.12.1.3, MetaCyc:1.12.1.3-RXN]","metadata":null},{"id":"4fc84f22f8eb44fe993e706470e07c4f","type":"GO_TERM","name":"hydrogen dehydrogenase activity","canonical_id":"go:GO:0047985","description":"\"Catalysis of the reaction: H2 + NAD+ = H+ + NADH.\" [EC:1.12.1.2, MetaCyc:HYDROGEN-DEHYDROGENASE-RXN]","metadata":null},{"id":"1d1e7bd5875649a8b6feb9cff8e2367d","type":"GO_TERM","name":"hydrogen generation via biophotolysis","canonical_id":"go:GO:0044817","description":"\"The production of hydrogen which results from the dissociation by light of water into molecular hydrogen and oxygen. This process is observed in cyanobacteria and microalgae.\" [GOC:mengo_curators, PMID:20395274, PMID:20692761]","metadata":null},{"id":"66ad332a4f8e42f5a3634ac8f2d1854a","type":"GO_TERM","name":"hydrogen generation via nitrogenase","canonical_id":"go:GO:0044835","description":"\"The chemical reactions and pathways resulting in the formation of H2 (dihydrogen) which involve a nitrogenase activity as one of the steps. This process is observed in cyanobacteria.\" [GOC:mengo_curators, PMID:22128188]","metadata":null},{"id":"915aef4e065a49d18e22bafcefc4b6ae","type":"GO_TERM","name":"hydrogen metabolic process","canonical_id":"go:GO:1902421","description":"\"The chemical reactions and pathways involving H2 (dihydrogen).\" [GOC:mengo_curators, GOC:TermGenie, PMID:20395274, PMID:20692761]","metadata":null},{"id":"141374d38c3e403093e1b213e4ab781b","type":"GO_TERM","name":"hydrogen peroxide biosynthetic process","canonical_id":"go:GO:0050665","description":"\"The chemical reactions and pathways resulting in the formation of hydrogen peroxide (H2O2), a potentially harmful byproduct of aerobic cellular respiration which can cause damage to DNA.\" [GOC:ai]","metadata":null},{"id":"67d462fdefb6498085952be594e73357","type":"GO_TERM","name":"hydrogen peroxide catabolic process","canonical_id":"go:GO:0042744","description":"\"The chemical reactions and pathways resulting in the breakdown of hydrogen peroxide (H2O2).\" [GOC:jl]","metadata":null},{"id":"651667d4d5d444fc8d5272f6156dbb38","type":"GO_TERM","name":"hydrogen peroxide channel activity","canonical_id":"go:GO:0140070","description":"\"Enables the energy-independent facilitated diffusion of H2O2 through a transmembrane aqueous pore or channel.\" [PMID:23541115, PMID:27256569]","metadata":null},{"id":"c6b6577dd0cd4ed3bfdb30a01f3dcb38","type":"GO_TERM","name":"hydrogen peroxide mediated signaling pathway","canonical_id":"go:GO:0071588","description":"\"The series of molecular signals mediated by the detection of hydrogen peroxide (H2O2).\" [GOC:mah, PMID:17043891]","metadata":null},{"id":"3adf2a9e3ebf4d0c83e4734fbd8bbe8f","type":"GO_TERM","name":"hydrogen peroxide metabolic process","canonical_id":"go:GO:0042743","description":"\"The chemical reactions and pathways involving hydrogen peroxide (H2O2), a potentially harmful byproduct of aerobic cellular respiration which can cause damage to DNA.\" [GOC:jl, PMID:21734470]","metadata":null},{"id":"250fbb7844b44956ae0d89599311ac96","type":"GO_TERM","name":"hydrogen peroxide transmembrane transport","canonical_id":"go:GO:0080170","description":"\"The process in which H2O2 is transported across a membrane.\" [GOC:tb]","metadata":null},{"id":"fc855bb4779349088766469186081334","type":"GO_TERM","name":"hydrogen peroxide-mediated programmed cell death","canonical_id":"go:GO:0010421","description":"\"Programmed cell death induced by hydrogen peroxide. Programmed cell death is the cell death resulting from activation of endogenous cellular processes.\" [GOC:mtg_apoptosis, PMID:16036580]","metadata":null},{"id":"adcd927c99754a92a9d0c84cc5a9f692","type":"GO_TERM","name":"hydrogen selenide methyltransferase activity","canonical_id":"go:GO:0098614","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + hydrogen selenide = S-adenosyl-L-homocysteine + methaneselenol.\" [PMID:14705, PMID:17988700]","metadata":null},{"id":"3c6c794dbcd141af803d5681936db38d","type":"GO_TERM","name":"hydrogen sulfide biosynthetic process","canonical_id":"go:GO:0070814","description":"\"The chemical reactions and pathways resulting in the formation of hydrogen sulfide, H2S.\" [GOC:mah]","metadata":null},{"id":"f1e2e99e99a94d0abb198f302da1a53b","type":"GO_TERM","name":"hydrogen sulfide metabolic process","canonical_id":"go:GO:0070813","description":"\"The chemical reactions and pathways involving hydrogen sulfide, H2S.\" [GOC:mah]","metadata":null},{"id":"2d7fdff2517c40aa985818904cf55c35","type":"GO_TERM","name":"hydrogen-sulfide S-acetyltransferase activity","canonical_id":"go:GO:0047986","description":"\"Catalysis of the reaction: acetyl-CoA + S(2-) = CoA + thioacetate.\" [EC:2.3.1.10, RHEA:16625]","metadata":null},{"id":"4d852c982a854af8b7c4f8c2c9cef02d","type":"GO_TERM","name":"hydrogen:quinone oxidoreductase activity","canonical_id":"go:GO:0047067","description":"\"Catalysis of the reaction: H(2) + menaquinone = reduced menaquinone.\" [EC:1.12.5.1, RHEA:18641]","metadata":null},{"id":"8e72970f50ec4302b014f0fdb4655cd6","type":"GO_TERM","name":"hydrogenase (acceptor) activity","canonical_id":"go:GO:0033748","description":"\"Catalysis of the reaction: H2 + A = AH2.\" [EC:1.12.99.6]","metadata":null},{"id":"ba41c652831a4ff7a6d8c68199095143","type":"GO_TERM","name":"hydrogenase activity (NAD+, ferredoxin)","canonical_id":"go:GO:0102220","description":"\"Catalysis of the reaction: 2 dihydrogen + NAD + 2 an oxidized ferredoxin = NADH + 3 H+ + 2 a reduced ferredoxin.\" [GOC:pz, RHEA:30279]","metadata":null},{"id":"37d4d000e2474d1c81f99808d6eb0d0c","type":"GO_TERM","name":"hydrogenobyrinic acid a,c-diamide synthase (glutamine-hydrolysing) activity","canonical_id":"go:GO:0043802","description":"\"Catalysis of the reaction: 2 L-glutamine + 2 ATP + 2 H2O + hydrogenobyrinate = 2 L-glutamate + 2 ADP + 4 H+ + hydrogenobyrinate a,c-diamide + 2 phosphate.\" [EC:6.3.5.9, RHEA:12544]","metadata":null},{"id":"24cd9bb3addf4db5ae25e578c990d742","type":"GO_TERM","name":"hydrogenosomal membrane","canonical_id":"go:GO:0046859","description":"\"The lipid bilayer surrounding a hydrogenosome.\" [GOC:ai]","metadata":null},{"id":"ca6a43fca82d4db688661eea3d89b3a3","type":"GO_TERM","name":"hydrogenosome","canonical_id":"go:GO:0042566","description":"\"A spherical, membrane-bounded organelle found in some anaerobic protozoa, which participates in ATP and molecular hydrogen formation.\" [GOC:jl, PMID:11197234, PMID:11293569]","metadata":null},{"id":"d7a5d1abd1a344248ebd7e7c728b56a6","type":"GO_TERM","name":"hydrogenosome lumen","canonical_id":"go:GO:0034492","description":"\"The volume enclosed by the hydrogenosome membrane.\" [GOC:rph]","metadata":null},{"id":"2efb8ecc6d574bbca841b5a5b7b5e534","type":"GO_TERM","name":"hydrolase activity","canonical_id":"go:GO:0016787","description":"\"Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc.\" [ISBN:0198506732]","metadata":null},{"id":"3fef1887c8e9454ebb2ed20eef528be3","type":"GO_TERM","name":"hydrolase activity, acting on acid anhydrides","canonical_id":"go:GO:0016817","description":"\"Catalysis of the hydrolysis of any acid anhydride.\" [GOC:jl]","metadata":null},{"id":"dc63a44e484a496f92e0ddeee218bd99","type":"GO_TERM","name":"hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides","canonical_id":"go:GO:0016818","description":"\"Catalysis of the hydrolysis of any acid anhydride which contains phosphorus.\" [GOC:jl]","metadata":null},{"id":"8c6a08d64c364b5485ad89bc243ab40b","type":"GO_TERM","name":"hydrolase activity, acting on acid anhydrides, in sulfonyl-containing anhydrides","canonical_id":"go:GO:0016819","description":"\"Catalysis of the hydrolysis of any acid anhydride which contains a sulfonyl group, -SO2-.\" [GOC:ai]","metadata":null},{"id":"18cdb99a1dea44a298247c9d395f6c5d","type":"GO_TERM","name":"hydrolase activity, acting on carbon-carbon bonds","canonical_id":"go:GO:0016822","description":"\"Catalysis of the hydrolysis of any carbon-carbon bond.\" [EC:3.7.-.-]","metadata":null},{"id":"c6e05aeca8e9430085952ed9a7c72c82","type":"GO_TERM","name":"hydrolase activity, acting on carbon-carbon bonds, in ketonic substances","canonical_id":"go:GO:0016823","description":"\"Catalysis of the hydrolysis of any carbon-carbon bond in a ketonic substance, a substance containing a keto (C=O) group.\" [EC:3.7.1.-]","metadata":null},{"id":"0e7308da90b248aca51ad28699b88a96","type":"GO_TERM","name":"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds","canonical_id":"go:GO:0016810","description":"\"Catalysis of the hydrolysis of any carbon-nitrogen bond, C-N, with the exception of peptide bonds.\" [EC:3.5.-.-]","metadata":null},{"id":"dd41e2856ffc45b587b9ee20754d52f3","type":"GO_TERM","name":"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides","canonical_id":"go:GO:0016812","description":"\"Catalysis of the hydrolysis of any non-peptide carbon-nitrogen bond in a cyclic amide.\" [EC:3.5.2.-]","metadata":null},{"id":"a99d0615fdcf4a43b4f947ac4d3baf93","type":"GO_TERM","name":"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines","canonical_id":"go:GO:0016814","description":"\"Catalysis of the hydrolysis of any non-peptide carbon-nitrogen bond in a cyclic amidine, a compound of the form R-C(=NH)-NH2.\" [EC:3.5.4.-]","metadata":null},{"id":"8f53128f3f484086bee852e0e82d49ac","type":"GO_TERM","name":"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides","canonical_id":"go:GO:0016811","description":"\"Catalysis of the hydrolysis of any non-peptide carbon-nitrogen bond in a linear amide.\" [EC:3.5.1.-]","metadata":null},{"id":"d09339323d0c424bbb7ff33084ec2f84","type":"GO_TERM","name":"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidines","canonical_id":"go:GO:0016813","description":"\"Catalysis of the hydrolysis of any non-peptide carbon-nitrogen bond in a linear amidine, a compound of the form R-C(=NH)-NH2.\" [EC:3.5.3.-]","metadata":null},{"id":"7665ba80370d4553aa309bc10b54a2e3","type":"GO_TERM","name":"hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in nitriles","canonical_id":"go:GO:0016815","description":"\"Catalysis of the hydrolysis of any non-peptide carbon-nitrogen bond in a nitrile, a compound containing the cyano radical, -CN.\" [GOC:curators]","metadata":null},{"id":"2172fc1a731d4a838aa780213f58f136","type":"GO_TERM","name":"hydrolase activity, acting on carbon-phosphorus bonds","canonical_id":"go:GO:0016827","description":"\"Catalysis of the hydrolysis of any carbon-phosphorus bond.\" [EC:3.11.-.-]","metadata":null},{"id":"adaf250753374558a9135793e11c734d","type":"GO_TERM","name":"hydrolase activity, acting on carbon-sulfur bonds","canonical_id":"go:GO:0046508","description":"\"Catalysis of the hydrolysis of any carbon-sulfur bond, C-S.\" [GOC:jl]","metadata":null},{"id":"3130cdf9827044b79af4c286bb99628c","type":"GO_TERM","name":"hydrolase activity, acting on ester bonds","canonical_id":"go:GO:0016788","description":"\"Catalysis of the hydrolysis of any ester bond.\" [GOC:jl]","metadata":null},{"id":"f68cd79688ee46889bf949de20e3e8f0","type":"GO_TERM","name":"hydrolase activity, acting on ether bonds","canonical_id":"go:GO:0016801","description":"\"Catalysis of the hydrolysis of any ether or thioether bond, -O- or -S- respectively.\" [GOC:ai, GOC:jl]","metadata":null},{"id":"5408ddc70f1240f1a766650c0a68ff49","type":"GO_TERM","name":"hydrolase activity, acting on glycosyl bonds","canonical_id":"go:GO:0016798","description":"\"Catalysis of the hydrolysis of any glycosyl bond.\" [GOC:jl]","metadata":null},{"id":"78218a3cf6494cc1af59cb8a08601ce8","type":"GO_TERM","name":"hydrolase activity, acting on halide bonds","canonical_id":"go:GO:0016824","description":"\"Catalysis of the hydrolysis of any halide bond.\" [EC:3.8.-.-]","metadata":null},{"id":"c52e898d14804ea6bf7041d5f22e2cc1","type":"GO_TERM","name":"hydrolase activity, acting on halide bonds, in C-halide compounds","canonical_id":"go:GO:0019120","description":"\"Catalysis of the hydrolysis of any halide bond in substances containing halogen atoms in organic linkage.\" [EC:3.8.1.-]","metadata":null},{"id":"5c071ebce464481a8c234a7789405dc4","type":"GO_TERM","name":"hydrolase activity, acting on phosphorus-nitrogen bonds","canonical_id":"go:GO:0016825","description":"\"Catalysis of the hydrolysis of any phosphorus-nitrogen bond.\" [EC:3.9.1.-]","metadata":null},{"id":"10ae44e9bb74419bbee8eb3f7efb95bb","type":"GO_TERM","name":"hydrolase activity, acting on sulfur-nitrogen bonds","canonical_id":"go:GO:0016826","description":"\"Catalysis of the hydrolysis of any sulfur-nitrogen bond.\" [EC:3.10.-.-]","metadata":null},{"id":"35ad3aef08f3418792bffc35bdd9384b","type":"GO_TERM","name":"hydrolase activity, acting on sulfur-sulfur bonds","canonical_id":"go:GO:0016828","description":"\"Catalysis of the hydrolysis of any sulfur-sulfur bond.\" [EC:3.12.-.-]","metadata":null},{"id":"7910f691c6514b05820293edb9d816b3","type":"GO_TERM","name":"hydrolase activity, hydrolyzing N-glycosyl compounds","canonical_id":"go:GO:0016799","description":"\"Catalysis of the hydrolysis of any N-glycosyl bond.\" [GOC:jl]","metadata":null},{"id":"d74ed598dde3488bbcbef14f1ca4b5cc","type":"GO_TERM","name":"hydrolase activity, hydrolyzing O-glycosyl compounds","canonical_id":"go:GO:0004553","description":"\"Catalysis of the hydrolysis of any O-glycosyl bond.\" [GOC:mah]","metadata":null},{"id":"298d6594658a401981c4c92b70073530","type":"DRUG","name":"hydromorphone","canonical_id":"gtopdb:7082","description":null,"metadata":null},{"id":"eeb401ba37254844839a32305ad2be6b","type":"COMBINATION_TREATMENT","name":"hydromorphone + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-20892acf95f91988","description":null,"metadata":null},{"id":"a4c32d7a50854420a99d982e0e162e49","type":"COMBINATION_TREATMENT","name":"hydromorphone + methadone","canonical_id":"ctgov_combo:ctgov-combo-9a4eed239251de65","description":null,"metadata":null},{"id":"1bc30382acf8475db57599f53915ad06","type":"COMBINATION_TREATMENT","name":"hydromorphone + morphine","canonical_id":"ctgov_combo:ctgov-combo-91a2d9d828d837b4","description":null,"metadata":null},{"id":"0ea3cc39aa234538b7de47559e40bfca","type":"COMBINATION_TREATMENT","name":"hydromorphone + naloxone","canonical_id":"ctgov_combo:ctgov-combo-32fcd791611180e6","description":null,"metadata":null},{"id":"6473fa805dc549959e56d63202659481","type":"COMBINATION_TREATMENT","name":"hydromorphone + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-a1c7cecc38381667","description":null,"metadata":null},{"id":"bfccb94555ff486ab92177cfe54e00a7","type":"COMBINATION_TREATMENT","name":"hydromorphone + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-489ca92cfd1e7db8","description":null,"metadata":null},{"id":"51e1bb14e65d43ffb6814d2af5984e72","type":"COMBINATION_TREATMENT","name":"hydromorphone + sufentanil","canonical_id":"ctgov_combo:ctgov-combo-9164af5d1a2d388e","description":null,"metadata":null},{"id":"9673564c849f43f4ad49ca70275e1211","type":"COMBINATION_TREATMENT","name":"hydromorphone + tapentadol","canonical_id":"ctgov_combo:ctgov-combo-9152604962a9c7d0","description":null,"metadata":null},{"id":"aba96a7a77a5464bbdeca7b2537aa47f","type":"GO_TERM","name":"hydroperoxy icosatetraenoate dehydratase activity","canonical_id":"go:GO:0106256","description":"\"A hydroperoxy icosatetraenoate = an oxoicosatetraenoate + H2O.\" [PMID:12881489, RHEA:55556]","metadata":null},{"id":"1357357dd3a0450987d6d1eb21109834","type":"GO_TERM","name":"hydroperoxy icosatetraenoate isomerase activity","canonical_id":"go:GO:0106255","description":"\"A hydroperoxy icosatetraenoate = a hydroxy epoxy icosatrienoate.\" [PMID:12881489, RHEA:55560]","metadata":null},{"id":"3e2d78d10415452f832af0e9cfa6b656","type":"DRUG","name":"hydroquinone","canonical_id":"mesh:C031927","description":null,"metadata":null},{"id":"625ce26736d241a4a26603fe6181d5a3","type":"GO_TERM","name":"hydroquinone binding","canonical_id":"go:GO:1902314","description":"\"Binding to hydroquinone.\" [GOC:bhm, GOC:TermGenie, PMID:15667223]","metadata":null},{"id":"2c298192c8aa444da9859c0d61b6312e","type":"GO_TERM","name":"hydroquinone glucosyltransferase activity","canonical_id":"go:GO:0050505","description":"\"Catalysis of the reaction: hydroquinone + UDP-D-glucose = H+ + hydroquinone O-beta-D-glucopyranoside + UDP.\" [EC:2.4.1.218, RHEA:12560]","metadata":null},{"id":"b1567783488849c99aa1429ccb836111","type":"GO_TERM","name":"hydroquinone:oxygen oxidoreductase activity","canonical_id":"go:GO:0052716","description":"\"Catalysis of the reaction: 4 hydroquinone + O2 = 4 benzosemiquinone + 4 H2O.\" [EC:1.10.3.2]","metadata":null},{"id":"7f60b4785e6142bab79bb908d465db6a","type":"GO_TERM","name":"hydrotropism","canonical_id":"go:GO:0010274","description":"\"Growth or movement in a sessile organism toward or away from water, as of the roots of a plant.\" [ISBN:0395825172]","metadata":null},{"id":"dbe9b5831cf0416dbd4ff0dc33a793f2","type":"DRUG","name":"hydroxocobalamin","canonical_id":"mesh:D006879","description":null,"metadata":null},{"id":"ddfb6bc81836417a86551ba77d3f7ad7","type":"GO_TERM","name":"hydroxyacid-oxoacid transhydrogenase activity","canonical_id":"go:GO:0047988","description":"\"Catalysis of the reaction: (S)-3-hydroxybutanoate + 2-oxoglutarate = acetoacetate + (R)-2-hydroxyglutarate.\" [EC:1.1.99.24, MetaCyc:HYDROXYACID-OXOACID-TRANSHYDROGENASE-RXN]","metadata":null},{"id":"ae2ec576b89e4635b6d225b74dc21b9c","type":"GO_TERM","name":"hydroxyacylglutathione hydrolase activity","canonical_id":"go:GO:0004416","description":"\"Catalysis of the reaction: an S-(2-hydroxyacyl)glutathione + H2O = a 2-hydroxy carboxylate + glutathione + H+.\" [RHEA:21864]","metadata":null},{"id":"651ed1750d024dfabd5ad32f62027103","type":"GO_TERM","name":"hydroxyanthraquinone glucosyltransferase activity","canonical_id":"go:GO:0047242","description":"\"Catalysis of the reaction: a hydroxyanthraquinone + UDP-D-glucose = a glucosyloxyanthraquinone + UDP.\" [EC:2.4.1.181]","metadata":null},{"id":"1d3c1faddff54b9c80cdbcf541684c87","type":"GO_TERM","name":"hydroxyapatite binding","canonical_id":"go:GO:0046848","description":"\"Binding to hydroxyapatite, the calcium phosphate mineral of formula Ca10(PO4)6(OH)2 found both in rocks of nonorganic origin and as a component of bone and dentin.\" [PMID:2438276]","metadata":null},{"id":"72406432f3e14b29b30c24afe634ea6e","type":"GO_TERM","name":"hydroxybutyrate-dimer hydrolase activity","canonical_id":"go:GO:0047989","description":"\"Catalysis of the reaction: (R)-3-[(R)-3-hydroxybutanoyloxy]butanoate + H2O = 2 (R)-3-hydroxybutanoate + H+.\" [EC:3.1.1.22, RHEA:10172]","metadata":null},{"id":"542b3604d36c4e41afa9b17f9defc37e","type":"DRUG","name":"hydroxychloroquine","canonical_id":"gtopdb:7198","description":null,"metadata":null},{"id":"072c816bdf494488bd360f1e5ac4d3b4","type":"DRUG","name":"hydroxychloroquine","canonical_id":"mesh:D006886","description":null,"metadata":null},{"id":"50cabba489de4ccca199ffd21b222954","type":"COMBINATION_TREATMENT","name":"hydroxychloroquine + ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-f07fc3c612efedfb","description":null,"metadata":null},{"id":"50dc2eb4095c46019f0dd2f0d1e81399","type":"COMBINATION_TREATMENT","name":"hydroxychloroquine + leflunomide","canonical_id":"ctgov_combo:ctgov-combo-1b7795bc1e63ac57","description":null,"metadata":null},{"id":"6ef77ebb92b14b76a84ac223e5285f87","type":"COMBINATION_TREATMENT","name":"hydroxychloroquine + letrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-973ee8b7dd2e2312","description":null,"metadata":null},{"id":"15f777a3c4b94c52ad2b3335280913fc","type":"COMBINATION_TREATMENT","name":"hydroxychloroquine + montelukast","canonical_id":"ctgov_combo:ctgov-combo-b2b422caebabc50d","description":null,"metadata":null},{"id":"a49f84df889747aeb2748ce01f8667b2","type":"COMBINATION_TREATMENT","name":"hydroxychloroquine + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-e656266582d4cc6f","description":null,"metadata":null},{"id":"1018299618d74bd5a4028815ba2efa65","type":"GO_TERM","name":"hydroxycinnamate 4-beta-glucosyltransferase activity","canonical_id":"go:GO:0047218","description":"\"Catalysis of the reaction: 4-coumarate + UDP-D-glucose = 4-O-beta-D-glucosyl-4-hydroxycinnamate + UDP. Also acts on ferulate, caffeate and sinapate, forming a mixture of 4-glucosides and glucose esters.\" [EC:2.4.1.126]","metadata":null},{"id":"a1792a327c184d798b6725582657233f","type":"GO_TERM","name":"hydroxycinnamic acid transport","canonical_id":"go:GO:1904952","description":"\"The directed movement of a hydroxycinnamic acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GO_REF:0000065, GOC:TermGenie, PMID:26744218]","metadata":null},{"id":"79d1df90dbbf4a00bbeb4004c65f8e61","type":"GO_TERM","name":"hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0050734","description":"\"Catalysis of the transfer of a hydroxycinnamoyl group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"6fd76d69b9d44624b6d6a64a4392f61c","type":"GO_TERM","name":"hydroxycyclohexanecarboxylate dehydrogenase activity","canonical_id":"go:GO:0047010","description":"\"Catalysis of the reaction: (1S,3R,4S)-3,4-dihydroxycyclohexane-1-carboxylate + NAD+ = (1S,4S)-4-hydroxy-3-oxocyclohexane-1-carboxylate + H+ + NADH.\" [EC:1.1.1.166, RHEA:10516]","metadata":null},{"id":"cd03395868c847a5a914c2939f8df864","type":"GO_TERM","name":"hydroxydechloroatrazine ethylaminohydrolase activity","canonical_id":"go:GO:0018763","description":"\"Catalysis of the reaction: 4-(ethylamino)-2-hydroxy-6-(isopropylamino)-1,3,5-triazine + H2O = N-isopropylammelide + ethylamine.\" [EC:3.5.4.43]","metadata":null},{"id":"b85fe422eab64cb1a0ff47499633a9dc","type":"GO_TERM","name":"hydroxyectoine binding","canonical_id":"go:GO:0033295","description":"\"Binding to hydroxyectoine.\" [GOC:mlg]","metadata":null},{"id":"500c3d52fbea40338c227603f4c4210a","type":"GO_TERM","name":"hydroxyectoine transmembrane transport","canonical_id":"go:GO:0033308","description":"\"The directed movement of hydroxyectoine across a membrane by means of some agent such as a transporter or a pore.\" [GOC:mlg]","metadata":null},{"id":"302fbbc33d6a4b10a75ae1b2b4026335","type":"GO_TERM","name":"hydroxyethylthiazole kinase activity","canonical_id":"go:GO:0004417","description":"\"Catalysis of the reaction: 5-(2-hydroxyethyl)-4-methylthiazole + ATP = 4-methyl-5-(2-phosphoethyl)-thiazole + ADP + 2 H+.\" [EC:2.7.1.50, RHEA:24212]","metadata":null},{"id":"f5ca9566d5ed4ba9832d6db4769ee4aa","type":"GO_TERM","name":"hydroxyglutamate decarboxylase activity","canonical_id":"go:GO:0047990","description":"\"Catalysis of the reaction: 3-hydroxy-L-glutamate + H+ = 4-amino-3-hydroxybutanoate + CO2.\" [EC:4.1.1.16, RHEA:14073]","metadata":null},{"id":"885b641344a944f2bf871bed8a7e2bbc","type":"GO_TERM","name":"hydroxyisourate hydrolase activity","canonical_id":"go:GO:0033971","description":"\"Catalysis of the reaction: 5-hydroxyisourate + H2O = 5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate + H+.\" [EC:3.5.2.17, RHEA:23736]","metadata":null},{"id":"3eaa0fe0b91a4f6684fc2f673b807b30","type":"GO_TERM","name":"hydroxyisourate hydrolase complex","canonical_id":"go:GO:0106232","description":"\"A hydrolase complex that converts 5-hydroxyisourate (HIU) to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline. This is the second step of the three-step enzymatic reaction that degrades uric acid to (S)-allantoin.\" [GOC:bhm, PMID:21795808]","metadata":null},{"id":"fd94e57bf7db46d982f32f52a61c2a58","type":"GO_TERM","name":"hydroxyjasmonate sulfotransferase activity","canonical_id":"go:GO:0080131","description":"\"Catalysis of the reaction: a hydroxyjasmonate + 3'-phosphoadenosine-5'-phosphosulfate = a hydroxyjasmonate sulfate + adenosine-3',5'-diphosphate.\" [EC:2.8.2.39, PMID:12637544]","metadata":null},{"id":"dd43cd70f8d04fcfa3b0a58cc6f96a33","type":"GO_TERM","name":"hydroxylamine dehydrogenase activity","canonical_id":"go:GO:0140305","description":"\"Catalysis of the reaction: hydroxylamine + 4 Fe(III)-[cytochrome c] + H2O = 4 Fe(II)-[cytochrome c] + nitrite + 5 H+.\" [RHEA:45032]","metadata":null},{"id":"92a03a4301df4d73a15e8dbf6f16a277","type":"GO_TERM","name":"hydroxylamine oxidase activity","canonical_id":"go:GO:0047991","description":"\"Catalysis of the reaction: hydroxylamine + O2 = H2O + H+ + nitrite.\" [RHEA:19969]","metadata":null},{"id":"359402720bcd49bc81bb83a34509e368","type":"GO_TERM","name":"hydroxylamine oxidoreductase activity","canonical_id":"go:GO:0033740","description":"\"Catalysis of the reaction: hydroxylamine + 3 Fe(III)-[cytochrome c] = nitric oxide + 3 Fe(II)-[cytochrome c] + 3 H+.\" [RHEA:45036]","metadata":null},{"id":"af8f85af5eda4ea4a89258c67d615f77","type":"GO_TERM","name":"hydroxylamine reductase (NADH) activity","canonical_id":"go:GO:0050460","description":"\"Catalysis of the reaction: NH4+ + NAD+ + H2O = hydroxylamine + NADH + 2 H+.\" [RHEA:20581]","metadata":null},{"id":"359afe02cd60450abd28e29f5cc97559","type":"GO_TERM","name":"hydroxylamine reductase activity","canonical_id":"go:GO:0050418","description":"\"Catalysis of the reaction: an acceptor + NH4+ + H2O = hydroxylamine + a reduced acceptor + H+.\" [RHEA:22052]","metadata":null},{"id":"133f85580b284d2583ba181c51a11257","type":"GO_TERM","name":"hydroxylysine kinase activity","canonical_id":"go:GO:0047992","description":"\"Catalysis of the reaction: erythro-5-hydroxy-L-lysine + GTP = 5-phosphonooxy-L-lysine + GDP + 2 H+.\" [EC:2.7.1.81, RHEA:19049]","metadata":null},{"id":"f06cd719cad8401d9bbb659eac781deb","type":"GO_TERM","name":"hydroxymalonate dehydrogenase activity","canonical_id":"go:GO:0047993","description":"\"Catalysis of the reaction: hydroxymalonate + NAD+ = H+ + NADH + oxomalonate.\" [EC:1.1.1.167, RHEA:11284]","metadata":null},{"id":"e22e43789565475eb8b928b15ae6248d","type":"GO_TERM","name":"hydroxymandelonitrile glucosyltransferase activity","canonical_id":"go:GO:0047239","description":"\"Catalysis of the reaction: 4-hydroxymandelonitrile + UDP-D-glucose = H+ + taxiphyllin + UDP.\" [EC:2.4.1.178, RHEA:15961]","metadata":null},{"id":"3f1f62fadc584ab1a031c79d0d78d836","type":"GO_TERM","name":"hydroxymandelonitrile lyase activity","canonical_id":"go:GO:0050419","description":"\"Catalysis of the reaction: 4-hydroxymandelonitrile = 4-hydroxybenzaldehyde + hydrocyanate.\" [RHEA:15977]","metadata":null},{"id":"a70b9421acef4538884dc7b43470cb60","type":"GO_TERM","name":"hydroxymate-containing siderophore biosynthetic process","canonical_id":"go:GO:0019539","description":"\"The chemical reactions and pathways resulting in the formation of a siderophore from other compounds, including hydroxamic acid. Hydroxamate is one of the three major chemical groups incorporated into siderophore structures with catechol and a-hydroxycarboxylate, each having a high selectivity for iron(3+).\" [PMID:20376388]","metadata":null},{"id":"b8f21189d995482eacfb0d11dfdbc39d","type":"GO_TERM","name":"hydroxymethyl-, formyl- and related transferase activity","canonical_id":"go:GO:0016742","description":"\"Catalysis of the transfer of a hydroxymethyl- or formyl group from one compound (donor) to another (acceptor).\" [EC:2.1.2.-, GOC:mah]","metadata":null},{"id":"694bfed60223427092f6cdc6e0af739d","type":"GO_TERM","name":"hydroxymethylbilane synthase activity","canonical_id":"go:GO:0004418","description":"\"Catalysis of the reaction: H2O + 4 porphobilinogen = hydroxymethylbilane + 4 NH4.\" [EC:2.5.1.61, RHEA:13185]","metadata":null},{"id":"d9ea795dc694440bb3f798513ba225b7","type":"GO_TERM","name":"hydroxymethylfurfural reductase (NADH) activity","canonical_id":"go:GO:0033833","description":"\"Catalysis of the reaction: 5-hydroxymethylfurfural + NADH + H+ = 2,5-bis-hydroxymethylfuran + NAD+.\" [GOC:jp, GOC:mah, PMID:15338422, PMID:16652391]","metadata":null},{"id":"49ce0c7d795c48558185784f32fc6d53","type":"GO_TERM","name":"hydroxymethylfurfural reductase (NADPH) activity","canonical_id":"go:GO:0033845","description":"\"Catalysis of the reaction: 5-hydroxymethylfurfural + NADPH + H+ = 2,5-bis-hydroxymethylfuran + NADP+.\" [GOC:jp, GOC:mah, PMID:15338422, PMID:16652391]","metadata":null},{"id":"3587741bb0ab4d63855bb9ad1dba4595","type":"GO_TERM","name":"hydroxymethylglutaryl-CoA hydrolase activity","canonical_id":"go:GO:0047994","description":"\"Catalysis of the reaction: (S)-3-hydroxy-3-methylglutaryl-CoA + H2O = 3-hydroxy-3-methylglutarate + CoA + H+.\" [EC:3.1.2.5, RHEA:16305]","metadata":null},{"id":"3d260cae31224f918a4e4e0ff0fcfd5a","type":"GO_TERM","name":"hydroxymethylglutaryl-CoA lyase activity","canonical_id":"go:GO:0004419","description":"\"Catalysis of the reaction: (S)-3-hydroxy-3-methylglutaryl-CoA = acetoacetate + acetyl-CoA.\" [EC:4.1.3.4, RHEA:24404]","metadata":null},{"id":"117e9efbdcdc45179fed360c78a5ba67","type":"GO_TERM","name":"hydroxymethylglutaryl-CoA reductase (NADH) activity","canonical_id":"go:GO:0140643","description":"\"Catalysis of the reaction: (R)-mevalonate + CoA + 2 NAD+ = 3-hydroxy-3-methylglutaryl-CoA + 2 NADH.\" [PMID:29224355, RHEA:14833]","metadata":null},{"id":"6d805a81b4dd4f6a9475d4b863149c82","type":"GO_TERM","name":"hydroxymethylglutaryl-CoA reductase (NADPH) activity","canonical_id":"go:GO:0004420","description":"\"Catalysis of the reaction: (R)-mevalonate + CoA + 2 NADP+ = (S)-3-hydroxy-3-methylglutaryl-CoA + 2 H+ + 2 NADPH.\" [PMID:29224355, RHEA:15989]","metadata":null},{"id":"9718ceff4b8d4b24bbfb3cf2d0d122a8","type":"GO_TERM","name":"hydroxymethylglutaryl-CoA synthase activity","canonical_id":"go:GO:0004421","description":"\"Catalysis of the reaction: acetoacetyl-CoA + acetyl-CoA + H2O = (S)-3-hydroxy-3-methylglutaryl-CoA + CoA + H+.\" [RHEA:10188]","metadata":null},{"id":"d53959ad808f40449b8c83f118d3da3c","type":"GO_TERM","name":"hydroxymethylpyrimidine kinase activity","canonical_id":"go:GO:0008902","description":"\"Catalysis of the reaction: 4-amino-5-hydroxymethyl-2-methylpyrimidine + ATP = 4-amino-2-methyl-5-phosphomethylpyrimidine + ADP + 2 H+.\" [EC:2.7.1.49, RHEA:23096]","metadata":null},{"id":"50b2c1ed16a7424387786ea6005fd750","type":"GO_TERM","name":"hydroxyneurosporene-O-methyltransferase activity","canonical_id":"go:GO:0043803","description":"\"Catalysis of the reaction: demethylspheroidene + S-adenosyl-L-methionine = H+ + S-adenosyl-L-homocysteine + spheroidene.\" [PMID:12664193, PMID:12770713, PMID:7358679, RHEA:30903]","metadata":null},{"id":"e99875cdd15b4d778fd729828470dab6","type":"GO_TERM","name":"hydroxyphenylacetonitrile 2-monooxygenase activity","canonical_id":"go:GO:0047085","description":"\"Catalysis of the reaction: 4-hydroxyphenylacetonitrile + H+ + NADPH + O2 = 4-hydroxymandelonitrile + H2O + NADP+.\" [RHEA:50732]","metadata":null},{"id":"fddd9937937349afa3d0fe8052d341dd","type":"GO_TERM","name":"hydroxyproline O-arabinosyltransferase activity","canonical_id":"go:GO:1990585","description":"\"Catalysis of the reaction: trans-4-hydroxy-L-prolyl-[protein] + UDP-beta-L-arabinofuranose = H+ + O-(beta-L-arabinofuranosyl)-trans-4-hydroxy-L-prolyl-[protein] + UDP.\" [PMID:24036508, RHEA:49472]","metadata":null},{"id":"0541586c0e85496c8be11ddbd1fbe3d7","type":"GO_TERM","name":"hydroxyproline O-galactosyltransferase activity","canonical_id":"go:GO:1990714","description":"\"Catalysis of the transfer of galactose from UDP-galactose to hydroxyproline residues present in the peptide backbone.\" [PMID:25600942]","metadata":null},{"id":"b4f58f5594644d51a4bd5deec3cd35a8","type":"GO_TERM","name":"hydroxyproline transport","canonical_id":"go:GO:0034589","description":"\"The directed movement of hydroxyproline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah, PMID:14502423]","metadata":null},{"id":"1ba1d97aacf644fdb85e0f80b070a3d8","type":"GO_TERM","name":"hydroxypyruvate decarboxylase activity","canonical_id":"go:GO:0047997","description":"\"Catalysis of the reaction: 3-hydroxypyruvate + H+ = CO2 + glycolaldehyde.\" [EC:4.1.1.40, RHEA:20561]","metadata":null},{"id":"aa6ebc413a78409aadc18d50dc182e3a","type":"GO_TERM","name":"hydroxypyruvate isomerase activity","canonical_id":"go:GO:0008903","description":"\"Catalysis of the reaction: 3-hydroxypyruvate = 2-hydroxy-3-oxopropanoate.\" [EC:5.3.1.22, RHEA:11952]","metadata":null},{"id":"ff2ee395e8ee4551bf55f99cc8b4a64e","type":"GO_TERM","name":"hydroxypyruvate reductase (NADH) activity","canonical_id":"go:GO:0008465","description":"\"Catalysis of the reaction: (R)-glycerate + NAD+ = 3-hydroxypyruvate + NADH + H+.\" [EC:1.1.1.29]","metadata":null},{"id":"18fde6d120f84715a87f3aa319559f2e","type":"GO_TERM","name":"hydroxypyruvate reductase (NADPH) activity","canonical_id":"go:GO:0120509","description":"\"Catalysis of the reaction: (R)-glycerate + NADP+ = 3-hydroxypyruvate + NADPH + H+.\" [RHEA:18657]","metadata":null},{"id":"59b9a52374f541969a4abac6e8d89887","type":"GO_TERM","name":"hydroxypyruvate reductase [NAD(P)H] activity","canonical_id":"go:GO:0016618","description":"\"Catalysis of the reaction: (R)-glycerate + NAD(P)+ = 3-hydroxypyruvate + NAD(P)H + H+.\" [EC:1.1.1.81]","metadata":null},{"id":"8300b5faf19d45e29eb1d1e89f7938fc","type":"GO_TERM","name":"hydroxyquinol 1,2-dioxygenase activity","canonical_id":"go:GO:0047074","description":"\"Catalysis of the reaction: benzene-1,2,4-triol + O2 = maleylacetate + 2 H+.\" [RHEA:35595]","metadata":null},{"id":"9dca443ebdf34ab3b71c8ad4d47218f6","type":"GO_TERM","name":"hydroxytrimethyllysine aldolase activity","canonical_id":"go:GO:0120567","description":"\"Catalysis of the reaction: (3S)-3-hydroxy-N(6),N(6),N(6)-trimethyl-L-lysine = 4-(trimethylamino)butanal + glycine.\" [PMID:38615009, RHEA:79695]","metadata":null},{"id":"b5cc34774de24fd8bf8c6f77da40fa06","type":"DRUG","name":"hydroxyurea","canonical_id":"gtopdb:6822","description":null,"metadata":null},{"id":"34e2c96dd14d4ff68c7e6c04dd5aa024","type":"DRUG","name":"hydroxyurea","canonical_id":"chembl:CHEMBL467","description":null,"metadata":null},{"id":"be404e4d6d4d406e807d90f46aeffae0","type":"GO_TERM","name":"hydroxyversicolorone reductase activity","canonical_id":"go:GO:0102974","description":"\"Catalysis of the reaction: versicolorone + NADP = hydroxyversicolorone + NADPH.\" [RHEA:35691]","metadata":null},{"id":"56556fd4a6c24535a0340adc6aa0ea8d","type":"DRUG","name":"hydroxyzine","canonical_id":"gtopdb:7199","description":null,"metadata":null},{"id":"dbd2272115e74cb7a8291d46f0030aec","type":"COMBINATION_TREATMENT","name":"hydroxyzine + rupatadine","canonical_id":"ctgov_combo:ctgov-combo-56332749a599e11a","description":null,"metadata":null},{"id":"fbd6ca377fd74d138f942f37b4dc0a65","type":"GO_TERM","name":"hygromycin-B 7''-O-phosphotransferase activity","canonical_id":"go:GO:0008904","description":"\"Catalysis of the reaction: ATP + hygromycin B = 7''-O-phosphohygromycin B + ADP + 2 H+.\" [EC:2.7.1.119, RHEA:23388]","metadata":null},{"id":"41f382fe40d445e39338ca5eff993666","type":"GO_TERM","name":"hyoscyamine (6S)-dioxygenase activity","canonical_id":"go:GO:0047998","description":"\"Catalysis of the reaction: 2-oxoglutarate + L-hyoscyamine + O2 = (6S)-6-hydroxyhyoscyamine + CO2 + succinate.\" [EC:1.14.11.11, RHEA:12629]","metadata":null},{"id":"6213390ed5fe40619202980f551cf0e1","type":"DISEASE","name":"hyper-IgE recurrent infection syndrome 5, autosomal recessive","canonical_id":"mondo:0030069","description":null,"metadata":null},{"id":"5c502ae113a040d7849d1321fbf466b2","type":"DISEASE","name":"hyperaldosteronism","canonical_id":"mondo:0003009","description":null,"metadata":null},{"id":"2fe52c174bf945cc9655c47ba23c4338","type":"DISEASE","name":"hypercalcemia disease","canonical_id":"mondo:0001566","description":null,"metadata":null},{"id":"97b8e4f86f794f9e8cb270ca0ed471a0","type":"DISEASE","name":"hypercholesterolemia, autosomal dominant, 3","canonical_id":"mondo:0011369","description":null,"metadata":null},{"id":"818f68020ffd437f869c0b79e37cde58","type":"DISEASE","name":"hypercholesterolemia, familial, 1","canonical_id":"mondo:0007750","description":null,"metadata":null},{"id":"1ad02761f57e4248aa46587047aa14cc","type":"DISEASE","name":"hypereosinophilic syndrome","canonical_id":"mondo:0015691","description":null,"metadata":null},{"id":"2d51682c12864f2998b65aae3e8494a1","type":"DISEASE","name":"hyperinsulinemic hypoglycemia","canonical_id":"mondo:0005803","description":null,"metadata":null},{"id":"ee600169114648338e7030a200b33177","type":"DISEASE","name":"hyperinsulinemic hypoglycemia, familial, 1","canonical_id":"mondo:0009734","description":null,"metadata":null},{"id":"a0a10a06dd804d249c43a5171ab9d327","type":"DISEASE","name":"hyperinsulinemic hypoglycemia, familial, 2","canonical_id":"mondo:0011153","description":null,"metadata":null},{"id":"60fa782734c34a66a4e47debae55e2c9","type":"DISEASE","name":"hyperinsulinism","canonical_id":"mondo:0002177","description":null,"metadata":null},{"id":"6588c720d3c844c8a8401b06437ca2f4","type":"DISEASE","name":"hyperinsulinism due to INSR deficiency","canonical_id":"mondo:0012381","description":null,"metadata":null},{"id":"123cc127a66b4b6db4a8fc4a19084c71","type":"DISEASE","name":"hyperkalemic periodic paralysis","canonical_id":"mondo:0008224","description":null,"metadata":null},{"id":"4f088b1472344da1863c13e2e50ab440","type":"DISEASE","name":"hyperlipidemia","canonical_id":"mondo:0021187","description":null,"metadata":null},{"id":"a02545b09b454b68b261cde34fd381df","type":"DISEASE","name":"hyperlipoproteinemia","canonical_id":"mondo:0037748","description":null,"metadata":null},{"id":"1374bd9796404fd2a36efb1b4173306e","type":"DISEASE","name":"hyperlipoproteinemia type 3","canonical_id":"mondo:0018473","description":null,"metadata":null},{"id":"5d068a44d38440bc95f8fec3c7766435","type":"GO_TERM","name":"hyperosmotic response","canonical_id":"go:GO:0006972","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hyperosmotic environment, i.e. an environment with a higher concentration of solutes than the organism or cell.\" [GOC:jl, PMID:12142009]","metadata":null},{"id":"a78e6a70a8c14da29f8b32307d36faae","type":"GO_TERM","name":"hyperosmotic salinity response","canonical_id":"go:GO:0042538","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, an increase in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.\" [GOC:jl]","metadata":null},{"id":"d9e487e5a30343cfaf6250bd6bec4225","type":"DISEASE","name":"hyperparathyroidism","canonical_id":"mondo:0001741","description":null,"metadata":null},{"id":"8be74764bd074656866eb357ff1ef892","type":"DISEASE","name":"hyperphenylalaninemia due to tetrahydrobiopterin deficiency","canonical_id":"mondo:0016543","description":null,"metadata":null},{"id":"e65cecc7c6d34f79969e9e2ae89182ac","type":"DISEASE","name":"hyperpigmentation of the skin","canonical_id":"mondo:0019289","description":null,"metadata":null},{"id":"c708d5293c73403c9a87dbcf898cdd63","type":"DISEASE","name":"hyperplasia","canonical_id":"mondo:0005043","description":null,"metadata":null},{"id":"ef6fa826e5f1404ab95fb175df646531","type":"GO_TERM","name":"hyperpolarization of postsynaptic membrane","canonical_id":"go:GO:0098818","description":"\"A process that hyerpolarizes a postsynaptic membrane relative to its resting potential. This has an inhibitory effect on the post-synaptic cell, moving the membrane potential away from the firing threshold.\" [GOC:dos]","metadata":null},{"id":"14199f3fc44149c291ebdc49b75a1494","type":"DISEASE","name":"hyperprolactinemia","canonical_id":"mondo:0005804","description":null,"metadata":null},{"id":"f324c124e3034d909c2b5d624f7d3e5e","type":"GO_TERM","name":"hypersensitivity","canonical_id":"go:GO:0002524","description":"\"An inflammatory response to an exogenous environmental antigen or an endogenous antigen initiated by the adaptive immune system.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"d24b79fb203547d6bf73a6243c552a42","type":"DISEASE","name":"hypersensitivity","canonical_id":"go:0002524","description":null,"metadata":null},{"id":"2e72d4eb771740a18707c753d4b8965b","type":"DISEASE","name":"hypertensive disorder","canonical_id":"mondo:0005044","description":null,"metadata":null},{"id":"734ca32c11904111b228ff5399f0d411","type":"DISEASE","name":"hyperthyroidism","canonical_id":"mondo:0004425","description":null,"metadata":null},{"id":"6ec9409ae2a245af9da0b71d0804f364","type":"DISEASE","name":"hypertriglyceridemia","canonical_id":"mondo:0005347","description":null,"metadata":null},{"id":"030ba9d9c1f24fad854bcd90fd4ec65c","type":"DISEASE","name":"hypertrophic cardiomyopathy","canonical_id":"mondo:0005045","description":null,"metadata":null},{"id":"b2b55efab2504bd0b70fb27c2d6f5a53","type":"DISEASE","name":"hyperuricemia","canonical_id":"efo:0009104","description":null,"metadata":null},{"id":"df99639a9bcb4a0ba5139be7737133b8","type":"GO_TERM","name":"hyphae septin collar","canonical_id":"go:GO:0062140","description":"\"A septin collar in pathogenic fungi involved in the constriction of hyphae at the plant plasmodesma enabling penetration of an adjacent cell.\" [PMID:29567712]","metadata":null},{"id":"521ead5fb1fa4920a91394e7cea3cf94","type":"GO_TERM","name":"hyphal cell wall","canonical_id":"go:GO:0030446","description":"\"The cell wall surrounding a fungal hypha.\" [GOC:mah, PMID:36266346]","metadata":null},{"id":"c72cab99058a4da3af56ab66137193cd","type":"GO_TERM","name":"hyphal growth","canonical_id":"go:GO:0030448","description":"\"Growth of fungi as threadlike, tubular structures that may contain multiple nuclei and may or may not be divided internally by septa, or cross-walls.\" [GOC:mcc, ISBN:0471522295]","metadata":null},{"id":"38e329396ec14315a5b5175e8b8e02ea","type":"GO_TERM","name":"hyphal membrane","canonical_id":"go:GO:0085039","description":"\"A host-derived membrane surrounding the symbiont hypha during infection.\" [GOC:pamgo_curators]","metadata":null},{"id":"cc35dbfc4d4543a99d88ff74cca67541","type":"GO_TERM","name":"hyphal septin band","canonical_id":"go:GO:0032163","description":"\"A septin band, i.e. a diffuse ring composed of a series of septin bars running parallel to the long axis of the cell, located at the junction between the mother cell and the germ tube (hypha) of a fungal cell growing filamentously.\" [GOC:krc, GOC:mah, PMID:16151244]","metadata":null},{"id":"4f27497617544af3bacf8555f39dc9ab","type":"GO_TERM","name":"hyphal septin cap","canonical_id":"go:GO:0032164","description":"\"A faint structure formed of septins found at the leading edge of growth in hyphae of fungal cells growing filamentously. This cap of septins colocalizes with a region of the plasma membrane that is rich in ergosterol.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"5f8fe54bc10e4c2faf1554344c4d71dd","type":"GO_TERM","name":"hyphal septin ring","canonical_id":"go:GO:0032168","description":"\"A tight ring-shaped structure that forms in the division plane within hyphae of filamentous fungi at sites where a septum will form; composed of septins as well as septin-associated proteins.\" [GOC:krc, GOC:mah, PMID:16151244]","metadata":null},{"id":"578f8ca6ee654a94bf6fc7283f03c32f","type":"GO_TERM","name":"hyphal tip","canonical_id":"go:GO:0001411","description":"\"The end, or tip, of a fungal hypha, where polarized growth occurs during hyphal elongation.\" [GOC:mcc]","metadata":null},{"id":"78c99a42cc4a42c08e5a31382500e3fd","type":"GO_TERM","name":"hyphal tip polarisome","canonical_id":"go:GO:0031562","description":"\"Protein complex that has a role in determining cell polarity, found at the tip of a growing fungal hypha.\" [PMID:15976451]","metadata":null},{"id":"fddcafbf0283441da526aba780c7d6bf","type":"GO_TERM","name":"hyphopodium formation","canonical_id":"go:GO:0075187","description":"\"The process in which a specialized structure, consisted of stalked, thick-walled, lobed cells of vegetative epiphytic hyphae, is formed, to attach and penetrate the host surface. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"4c78866be21e43f3bbbe3a5e964e0310","type":"GO_TERM","name":"hypoblast development","canonical_id":"go:GO:0090008","description":"\"The process whose specific outcome is the progression of the hypoblast over time, from its formation to the mature structure. The hypoblast is a tissue formed from the inner cell mass that lies beneath the epiblast.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"a85c289b9da84b918d6251ca68e59ad3","type":"DISEASE","name":"hypocalcemia","canonical_id":"mesh:D006996","description":null,"metadata":null},{"id":"adce75d3c47843609addeab66cddc3e1","type":"GO_TERM","name":"hypochlorite binding","canonical_id":"go:GO:1901531","description":"\"Binding to hypochlorite.\" [GOC:pr, GOC:TermGenie, PMID:22223481]","metadata":null},{"id":"567a29f983c94025816eb7b78f272904","type":"DISEASE","name":"hypochondroplasia","canonical_id":"mondo:0007793","description":null,"metadata":null},{"id":"50f0118bb4de42e789bb74d82884840c","type":"GO_TERM","name":"hypochord development","canonical_id":"go:GO:0055016","description":"\"The process whose specific outcome is the progression of the hypochord over time, from its formation to the mature structure. The hypochord is a transient rod-like structure in the embryos of fish, lampreys and amphibians that is located immediately ventral to the notochord. The hypochord may play a role in positioning the dorsal aorta.\" [GOC:devbiol, GOC:lb]","metadata":null},{"id":"5caf7d05359e40499a72011c819444ff","type":"GO_TERM","name":"hypoglossal nerve development","canonical_id":"go:GO:0021566","description":"\"The process whose specific outcome is the progression of the hypoglossal nerve over time, from its formation to the mature structure. This motor nerve innervates all the intrinsic and all but one of the extrinsic muscles of the tongue.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"cd585cacbace4b2490a1f3f115d12fba","type":"GO_TERM","name":"hypoglossal nerve formation","canonical_id":"go:GO:0021620","description":"\"The process that gives rise to the hypoglossal nerve. This process pertains to the initial formation of a structure from unspecified parts. This motor nerve innervates all the intrinsic and all but one of the extrinsic muscles of the tongue.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"c02db20cea0645fdaa5463f5e9a6402f","type":"GO_TERM","name":"hypoglossal nerve maturation","canonical_id":"go:GO:0021619","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the hypoglossal nerve to attain its fully functional state. This motor nerve innervates all the intrinsic and all but one of the extrinsic muscles of the tongue.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"ffa2def190c9470f945435e8fd310886","type":"GO_TERM","name":"hypoglossal nerve morphogenesis","canonical_id":"go:GO:0021618","description":"\"The process in which the anatomical structure of the hypoglossal nerve is generated and organized. This motor nerve innervates all the intrinsic and all but one of the extrinsic muscles of the tongue.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d4e4c9f637b74f439e44a04b6aab1173","type":"GO_TERM","name":"hypoglossal nerve structural organization","canonical_id":"go:GO:0021621","description":"\"The process that contributes to the act of creating the structural organization of the hypoglossal nerve. This process pertains to the physical shaping of a rudimentary structure. This motor nerve innervates all the intrinsic and all but one of the extrinsic muscles of the tongue.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"92454aeec93b405a82afa8b7e9a50b7b","type":"GO_TERM","name":"hypoglossal nucleus development","canonical_id":"go:GO:0021743","description":"\"The process whose specific outcome is the progression of the hypoglossal nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5a0691e55c5849e0a05636e3aad08b66","type":"DISEASE","name":"hypogonadism","canonical_id":"mondo:0002146","description":null,"metadata":null},{"id":"675a8b368421493489218d2841cc8e51","type":"DISEASE","name":"hypogonadotropic hypogonadism","canonical_id":"mondo:0018555","description":null,"metadata":null},{"id":"067aec0917934cf990cb58517b1b5cf3","type":"DISEASE","name":"hypogonadotropic hypogonadism 11 with or without anosmia","canonical_id":"mondo:0013913","description":null,"metadata":null},{"id":"64f85e819f5e4cc5a40bb72e5cadea28","type":"DISEASE","name":"hypogonadotropic hypogonadism 2 with or without anosmia","canonical_id":"mondo:0007844","description":null,"metadata":null},{"id":"bb1acc34537f4252b58bc4ab9c735881","type":"DISEASE","name":"hypoinsulinemic hypoglycemia and body hemihypertrophy","canonical_id":"mondo:0009416","description":null,"metadata":null},{"id":"98585f04bc634c90922a04535cb5f84d","type":"DISEASE","name":"hypokalemic periodic paralysis","canonical_id":"mondo:0008223","description":null,"metadata":null},{"id":"2577f7f7aeb543d8a4bf69f22b36be1c","type":"DISEASE","name":"hypokalemic periodic paralysis, type 1","canonical_id":"mondo:0042979","description":null,"metadata":null},{"id":"a44a871de62f412d840ff4e2581089a1","type":"DISEASE","name":"hypokalemic periodic paralysis, type 2","canonical_id":"mondo:0013234","description":null,"metadata":null},{"id":"9a60b58cdb5347c6a22815cd4f572564","type":"GO_TERM","name":"hypolemmal cisterna","canonical_id":"go:GO:1990039","description":"\"Specialized part of the smooth endoplasmic reticulum that closely underlies the plasma membrane, usually within 60 nm or closer.\" [ISBN:0195065719, NIF_Subcellular:sao1634374950]","metadata":null},{"id":"c3cf340a5d2648e0a718bf6c4d4c7698","type":"DISEASE","name":"hypomagnesemia, seizures, and intellectual disability 2","canonical_id":"mondo:0020788","description":null,"metadata":null},{"id":"3c3ffa6e3efd441bbe84d955fcf5166e","type":"GO_TERM","name":"hyponitrite reductase (NADH) activity","canonical_id":"go:GO:0047999","description":"\"Catalysis of the reaction: 2 hydroxylamine + 2 NAD+ = 2 H+ + hyponitrous acid + 2 NADH.\" [RHEA:19337]","metadata":null},{"id":"c9e5b943eee54adaa46cc487fe2750bc","type":"DISEASE","name":"hypoparathyroidism","canonical_id":"mondo:0001220","description":null,"metadata":null},{"id":"ec8b62cc5b4f40ed8d6c1e7bf2c17c21","type":"DISEASE","name":"hypophosphatemia","canonical_id":"mondo:0000313","description":null,"metadata":null},{"id":"92f8c914780e46728f32c95d52e96919","type":"DISEASE","name":"hypophosphatemic rickets","canonical_id":"mondo:0024300","description":null,"metadata":null},{"id":"ab7f689e74624119b31a9ce5a704074d","type":"GO_TERM","name":"hypophysis formation","canonical_id":"go:GO:0048851","description":"\"The process in which the anatomical structures of the hypophysis are generated and organized. The hypophysis is an endocrine gland that secretes hormones that regulate many other glands.\" [GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6c8d7e3eabe3485f9323242a0aefd139","type":"GO_TERM","name":"hypophysis morphogenesis","canonical_id":"go:GO:0048850","description":"\"The process in which the anatomical structures of the hypophysis are generated and organized. The pituitary gland is an endocrine gland that secretes hormones that regulate many other glands.\" [GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e3abe30d581d42c5a97e4d21e9c72d47","type":"DISEASE","name":"hypopituitarism","canonical_id":"mondo:0005152","description":null,"metadata":null},{"id":"698073f933f345df9a7574e28068e6f9","type":"DISEASE","name":"hypoplasminogenemia","canonical_id":"mondo:0009009","description":null,"metadata":null},{"id":"760bc0c8ec9945e8a67648d755587f48","type":"DISEASE","name":"hypospadias","canonical_id":"mondo:0005345","description":null,"metadata":null},{"id":"6cc9b25eaba54d0bbad7ce86cfc1cecd","type":"GO_TERM","name":"hypotaurine monooxygenase activity","canonical_id":"go:GO:0047822","description":"\"Catalysis of the reaction: H+ + hypotaurine + NADPH + O2 = H2O + NADP+ + taurine.\" [RHEA:69819]","metadata":null},{"id":"089f80b63fc94562908d1696dae99046","type":"GO_TERM","name":"hypotaurocyamine kinase activity","canonical_id":"go:GO:0047715","description":"\"Catalysis of the reaction: ATP + hypotaurocyamine = N(omega)-phosphohypotaurocyamine + ADP + 2 H+.\" [EC:2.7.3.6, RHEA:24008]","metadata":null},{"id":"6316d2adbf3648149064ff88be3f1718","type":"DISEASE","name":"hypotensive disorder","canonical_id":"mondo:0005468","description":null,"metadata":null},{"id":"55853bce1e434068a7150cb6d97b55db","type":"DISEASE","name":"hypothalamic neoplasm","canonical_id":"mondo:0006799","description":null,"metadata":null},{"id":"96ff6b6c90264ef0ad1ca1acc0b5c36c","type":"GO_TERM","name":"hypothalamic tangential migration using cell-axon interactions","canonical_id":"go:GO:0021856","description":"\"The movement of a hypothalamic neuronal precursor tangentially through the forebrain using an interaction of the migrating cells with axons of other neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d55b22261e994139bc52bbdc07664da9","type":"GO_TERM","name":"hypothalamus cell differentiation","canonical_id":"go:GO:0021979","description":"\"The differentiation of cells that will contribute to the structure and function of the hypothalamus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:mgi_curators]","metadata":null},{"id":"0e716392f1754682a774e8033b549c36","type":"GO_TERM","name":"hypothalamus cell migration","canonical_id":"go:GO:0021855","description":"\"The directed movement of a cell into the hypothalamus region of the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"38111df6ed264a27a78ee24e14f36d9d","type":"GO_TERM","name":"hypothalamus development","canonical_id":"go:GO:0021854","description":"\"The progression of the hypothalamus region of the forebrain, from its initial formation to its mature state.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"623b69d90bb04aa980583d8398ba2e54","type":"GO_TERM","name":"hypothalamus gonadotrophin-releasing hormone neuron development","canonical_id":"go:GO:0021888","description":"\"The process whose specific outcome is the progression of a hypothalamus gonadotrophin-releasing hormone neuron over time, from initial commitment of its fate, to the fully functional differentiated cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"6dbd08de83494799b3c2302b5c885328","type":"GO_TERM","name":"hypothalamus gonadotrophin-releasing hormone neuron differentiation","canonical_id":"go:GO:0021886","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron located in the hypothalamus. These neurons release gonadotrophin-releasing hormone as a neural transmitter.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"67b69d39efad427ca63ccb00b23ac590","type":"GO_TERM","name":"hypothalamus gonadotrophin-releasing hormone neuron fate commitment","canonical_id":"go:GO:0021887","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a hypothalamus neuron that releases gonadotrophin-releasing hormone.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"8b126741f30a45dfa4465479e9020ade","type":"DISEASE","name":"hypothyroidism","canonical_id":"mondo:0005420","description":null,"metadata":null},{"id":"2147427893e34e0db93ba2973b0ecbb4","type":"DISEASE","name":"hypothyroidism due to TSH receptor mutations","canonical_id":"mondo:0010142","description":null,"metadata":null},{"id":"e4b96fa8bca0486db61fa328b97a58b8","type":"DISEASE","name":"hypothyroidism, congenital, nongoitrous, 7","canonical_id":"mondo:0032819","description":null,"metadata":null},{"id":"2e11250e670142b1a0b3ce137f78e601","type":"GO_TERM","name":"hypotonic response","canonical_id":"go:GO:0006971","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hypotonic environment, i.e. an environment with a lower concentration of solutes than the organism or cell.\" [GOC:jl, PMID:12598593]","metadata":null},{"id":"a130d22f101e443393a67b98368889a3","type":"GO_TERM","name":"hypotonic salinity response","canonical_id":"go:GO:0042539","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a decrease in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.\" [GOC:jl]","metadata":null},{"id":"9b160c02d969434398487d62dd32286a","type":"DISEASE","name":"hypotrichosis","canonical_id":"mondo:0003037","description":null,"metadata":null},{"id":"fe9153f4390d491bb8408fd549b0e587","type":"DISEASE","name":"hypotrichosis simplex","canonical_id":"mondo:0018914","description":null,"metadata":null},{"id":"fb44ea5e650f4b969b55a1441b21b917","type":"DISEASE","name":"hypouricemia, renal","canonical_id":"mondo:0968951","description":null,"metadata":null},{"id":"e9cb6052c2a34377b4448e962918e6b4","type":"GO_TERM","name":"hypoxanthine DNA N-glycosylase activity","canonical_id":"go:GO:0097507","description":"\"DNA N-glycosylase activity acting on deaminated adenine (hypoxanthine).\" [GOC:al, PMID:18789404]","metadata":null},{"id":"401ceb9df4a144a78b2e3025d44e03bb","type":"GO_TERM","name":"hypoxanthine biosynthetic process","canonical_id":"go:GO:0046101","description":"\"The chemical reactions and pathways resulting in the formation of hypoxanthine, 6-hydroxy purine, an intermediate in the degradation of adenylate. Its ribonucleoside is known as inosine and its ribonucleotide as inosinate.\" [GOC:curators]","metadata":null},{"id":"2d2e88e6a3db48b3931cc6af937a53db","type":"GO_TERM","name":"hypoxanthine catabolic process","canonical_id":"go:GO:0009114","description":"\"The chemical reactions and pathways resulting in the breakdown of hypoxanthine, 6-hydroxy purine, an intermediate in the degradation of adenylate. Its ribonucleoside is known as inosine and its ribonucleotide as inosinate.\" [PMID:3196295]","metadata":null},{"id":"42f0b4ff477e4f6191d8e6db0cccee82","type":"GO_TERM","name":"hypoxanthine dehydrogenase activity","canonical_id":"go:GO:0070674","description":"\"Catalysis of the reaction: hypoxanthine + NAD+ + H2O = xanthine + NADH + H+.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"41b8c418111a4ffbb9a60b2b3c92492b","type":"GO_TERM","name":"hypoxanthine metabolic process","canonical_id":"go:GO:0046100","description":"\"The chemical reactions and pathways involving hypoxanthine, 6-hydroxy purine, an intermediate in the degradation of adenylate. Its ribonucleoside is known as inosine and its ribonucleotide as inosinate.\" [GOC:curators]","metadata":null},{"id":"f737e79dfd9c4e2081f71154d1ff059a","type":"GO_TERM","name":"hypoxanthine oxidase activity","canonical_id":"go:GO:0070675","description":"\"Catalysis of the reaction: hypoxanthine + H2O + O2 = xanthine + H2O2.\" [RHEA:68012]","metadata":null},{"id":"00e51792748b4615857e3c4dbb2d16fe","type":"GO_TERM","name":"hypoxanthine phosphoribosyltransferase activity","canonical_id":"go:GO:0004422","description":"\"Catalysis of the reaction: IMP + diphosphate = hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate.\" [RHEA:17973]","metadata":null},{"id":"05ca7a444bf84c25897c48ef4a94e132","type":"GO_TERM","name":"hypoxanthine salvage","canonical_id":"go:GO:0043103","description":"\"Any process that generates hypoxanthine, 6-hydroxy purine, from derivatives of it without de novo synthesis.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"8018a49961ae461cb31de5481eacf79a","type":"GO_TERM","name":"hypoxanthine transport","canonical_id":"go:GO:0035344","description":"\"The directed movement of hypoxanthine, 6-hydroxypurine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:sl]","metadata":null},{"id":"7f71f1afb2d14bd897fe0a3aa27552fa","type":"GO_TERM","name":"hypoxia-inducible factor-1alpha signaling pathway","canonical_id":"go:GO:0097411","description":"\"The series of molecular signals mediated by hypoxia-inducible factor (HIF1) in response to lowered oxygen levels (hypoxia). Under hypoxic conditions, the oxygen-sensitive alpha-subunit of hypoxia-inducible factor (HIF)-1 dimerizes with a HIF1-beta subunit (also called ARNT or aryl-hydrocarbon-receptor nuclear translocator), translocates to the nucleus and activates transcription of genes whose products participate in responding to hypoxia.\" [GOC:bf, GOC:jc, PMID:16887934, PMID:26579469]","metadata":null},{"id":"16c4291b8d1c41489b3edfcb2389be3b","type":"GO_TERM","name":"hypoxia-inducible factor-proline dioxygenase activity","canonical_id":"go:GO:0160082","description":"\"Catalysis of the reaction: 2-oxoglutarate + L-prolyl-[hypoxia-inducible factor alpha subunit] + O2 = CO2 + succinate + trans-4-hydroxy-L-prolyl-[hypoxia-inducible factor alpha subunit].\" [PMID:11595184, PMID:11598268]","metadata":null},{"id":"8ccef68052444513840a7e2030ca15b2","type":"GO_TERM","name":"i-AAA complex","canonical_id":"go:GO:0031942","description":"\"Protease complex of the mitochondrial inner membrane whose catalytic residues lie on the intermembrane space side of the inner membrane; involved in mitochondrial protein turnover. Contains a subunit belonging to the AAA family of ATP-dependent metalloproteases.\" [PMID:16247555, PMID:16267274]","metadata":null},{"id":"bd83e99a8c274dc39e894730d9dc6654","type":"TRIAL","name":"iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray","canonical_id":"clinicaltrials.gov:NCT03192501","description":"Lung Cancer; Gene Abnormality; Gene Product Sequence Variation; Cancer","metadata":null},{"id":"17d23f5749234b2c9958c1181108c5f3","type":"TRIAL","name":"iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)","canonical_id":"clinicaltrials.gov:NCT03207334","description":"Acute Myeloid Leukemia","metadata":null},{"id":"3eb6d85f0e8b45c3ac55584d59d7380d","type":"TRIAL","name":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","canonical_id":"clinicaltrials.gov:NCT06671587","description":"Type 2 Diabetes (T2D)","metadata":null},{"id":"014acad6095c431282da4c11e258206c","type":"TRIAL","name":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","canonical_id":"clinicaltrials.gov:NCT05413369","description":"Type 2 Diabetes Mellitus","metadata":null},{"id":"09ef272ced264091b01976fff543403a","type":"GO_TERM","name":"iNOS-S100A8/A9 complex","canonical_id":"go:GO:1990657","description":"\"A protein complex capable of stimulus-inducible nitric-oxide synthase activity. S-nitrosylates cysteine residues in target proteins, a principal mechanism of nitric oxide (NO)-mediated signal transduction. In mammals consists of NOS2, S100A8 and S100A9. S100A9 acts both as an adaptor linking NOS2 to its target and as a transnitrosylase that transfers the nitric oxide moiety from NOS2 to its target, via its own S-nitrosylated cysteine.\" [GOC:bhm, PMID:25417112]","metadata":null},{"id":"db9c6e4a3e7d419c9c42e88ca1c5f499","type":"GO_TERM","name":"iRhom2/ADAM17 sheddase complex","canonical_id":"go:GO:0140910","description":"\"A complex consisting of ADAM17 in complex with regulatory iRhoms and FERM domain containing proteins.\" [PMID:29897336]","metadata":null},{"id":"b85b37e39550479fac94c07353db377c","type":"TRIAL","name":"iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL","canonical_id":"clinicaltrials.gov:NCT02802943","description":"Leukemia, Chronic Lymphatic","metadata":null},{"id":"31a3c5f2375141579934fdd5b8385af9","type":"DRUG","name":"ibalizumab","canonical_id":"gtopdb:10208","description":null,"metadata":null},{"id":"caf5792bf83140e6a5adef126b5a761d","type":"DRUG","name":"ibalizumab","canonical_id":"chembl:CHEMBL1743029","description":null,"metadata":null},{"id":"813b5b0dcb8c4298a907771d91794acf","type":"DRUG","name":"ibandronic acid","canonical_id":"gtopdb:3059","description":null,"metadata":null},{"id":"d077af7f453144028a5bee2427112fd4","type":"DRUG","name":"ibandronic acid","canonical_id":"mesh:C073007","description":null,"metadata":null},{"id":"3325eb9cc61847e1992f9e6a112d07f1","type":"DRUG","name":"ibritumomab tiuxetan","canonical_id":"gtopdb:6777","description":null,"metadata":null},{"id":"064e494756f14ef3afc8b893ef252bc6","type":"DRUG","name":"ibritumomab tiuxetan","canonical_id":"mesh:C422802","description":null,"metadata":null},{"id":"8dbfa21557914efdabef06a6ab131ec1","type":"COMBINATION_TREATMENT","name":"ibritumomab tiuxetan + oprelvekin","canonical_id":"ctgov_combo:ctgov-combo-a4afe40d14b1755d","description":null,"metadata":null},{"id":"fa0ee4c70fb04bee88597e5a64ddaa7a","type":"COMBINATION_TREATMENT","name":"ibritumomab tiuxetan + tositumomab","canonical_id":"ctgov_combo:ctgov-combo-8785514afa183693","description":null,"metadata":null},{"id":"5297de41d7ff4945a4e626e3fc163e59","type":"DRUG","name":"ibrutinib","canonical_id":"gtopdb:6912","description":null,"metadata":null},{"id":"c3b9e44be41b452a8d794a5465c720ab","type":"DRUG","name":"ibrutinib","canonical_id":"mesh:C551803","description":null,"metadata":null},{"id":"8fd85db8357a41b3996ef3042d634aba","type":"DRUG","name":"ibrutinib","canonical_id":"chembl:CHEMBL1873475","description":null,"metadata":null},{"id":"4d0d8f75c96f4fa0ba7096afec3a4213","type":"COMBINATION_TREATMENT","name":"ibrutinib + idelalisib + obinutuzumab + rituximab","canonical_id":"ctgov_combo:ctgov-combo-5430571a0bac06a9","description":null,"metadata":null},{"id":"b8c2447f0e0d4f3d8218eb6c8276ef67","type":"COMBINATION_TREATMENT","name":"ibrutinib + methotrexate + rituximab + venetoclax + vincristine","canonical_id":"ctgov_combo:ctgov-combo-adce5254494a6663","description":null,"metadata":null},{"id":"a016393be364436c96a81c852e468c76","type":"COMBINATION_TREATMENT","name":"ibrutinib + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-8f87323e2a6a79be","description":null,"metadata":null},{"id":"622f6c3a15064b6cab96c03dc3522902","type":"COMBINATION_TREATMENT","name":"ibrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-2911fb6c9c789eae","description":null,"metadata":null},{"id":"c9281075a0944e88aa92fbb87243e0b8","type":"COMBINATION_TREATMENT","name":"ibrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-6ae94ad8d99b50b9","description":null,"metadata":null},{"id":"d0a699e40116468fbd208099f6844a50","type":"COMBINATION_TREATMENT","name":"ibrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-67288d3a4a5321ec","description":null,"metadata":null},{"id":"7205d12a00bd48c5a30863263cb91c26","type":"COMBINATION_TREATMENT","name":"ibrutinib + obinutuzumab","canonical_id":"ctgov_combo:ctgov-combo-bcca3dcbb3fedae7","description":null,"metadata":null},{"id":"7b837baacbd04951bdea31c8ccdc0d75","type":"COMBINATION_TREATMENT","name":"ibrutinib + obinutuzumab + prednisone + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-b25c27c5b76a6fbb","description":null,"metadata":null},{"id":"0dbef849ccd845829044f3168645854a","type":"COMBINATION_TREATMENT","name":"ibrutinib + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-d9c6625bb05538a1","description":null,"metadata":null},{"id":"8c15c667477d48f2a0de51b77e4c9920","type":"COMBINATION_TREATMENT","name":"ibrutinib + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-3e48695fc2c88ece","description":null,"metadata":null},{"id":"8cc5302c9ff34fe0bca2630889054593","type":"DRUG","name":"ibudilast","canonical_id":"gtopdb:7399","description":null,"metadata":null},{"id":"f442d3c6979f43d885788c2f82fef387","type":"DRUG","name":"ibudilast","canonical_id":"chembl:CHEMBL19449","description":null,"metadata":null},{"id":"ad3a8dccfb7140628aedb0acd0866792","type":"DRUG","name":"ibuprofen","canonical_id":"gtopdb:2713","description":null,"metadata":null},{"id":"82abc8edd12941f2a1ec38810707fb7f","type":"DRUG","name":"ibuprofen","canonical_id":"chembl:CHEMBL521","description":null,"metadata":null},{"id":"1fb51596f684403288ec2e4c92e766b8","type":"COMBINATION_TREATMENT","name":"ibuprofen + ketoprofen","canonical_id":"ctgov_combo:ctgov-combo-167507e346aae522","description":null,"metadata":null},{"id":"ce58657a85f3494392bb8a4482276290","type":"COMBINATION_TREATMENT","name":"ibuprofen + ketorolac","canonical_id":"ctgov_combo:ctgov-combo-aa734c2ab353a775","description":null,"metadata":null},{"id":"1e4917b44f234085af0b6e51f13eafd7","type":"COMBINATION_TREATMENT","name":"ibuprofen + lacosamide","canonical_id":"ctgov_combo:ctgov-combo-5bfea9183ffb98e9","description":null,"metadata":null},{"id":"b9bd0a573bdf4a6e8a595745801bbdd7","type":"DRUG","name":"ibutilide","canonical_id":"gtopdb:7200","description":null,"metadata":null},{"id":"cd69be66d126491bb491a840b0fd15bd","type":"DRUG","name":"icatibant","canonical_id":"gtopdb:667","description":null,"metadata":null},{"id":"0a93ba8fcea04bc6b5c4ae695a5338ad","type":"DRUG","name":"icatibant","canonical_id":"mesh:C065679","description":null,"metadata":null},{"id":"0d068e6394e14167a0053adfdbc9b9c9","type":"COMBINATION_TREATMENT","name":"icatibant + narsoplimab","canonical_id":"ctgov_combo:ctgov-combo-c5e9a4f77097f555","description":null,"metadata":null},{"id":"3988bf272f5c4515aca58fc68219c79a","type":"GO_TERM","name":"ice binding","canonical_id":"go:GO:0050825","description":"\"Binding to ice, water reduced to the solid state by cold temperature. It is a white or transparent colorless substance, crystalline, brittle, and viscoidal.\" [GOC:curators]","metadata":null},{"id":"ad5c7a0deba0428e9a47cc3b50dbb6f3","type":"GO_TERM","name":"ice nucleation activity","canonical_id":"go:GO:0019833","description":"\"Catalysis of the formation of ice crystals in extracellular fluid at relatively high temperatures (up to -2 degrees Celsius) to protect the organism from damage by intracellular ice formation. This process is commonly found in certain bacteria, such as Pseudomonas syringae, and plays roles in environmental adaptation and plant pathogenesis.\" [GOC:cjm, PMID:35551271, UniProt:KW-0387]","metadata":null},{"id":"22c6486e94b641d682c155fe24e325e2","type":"GO_TERM","name":"icosahedral viral capsid","canonical_id":"go:GO:0019030","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles; the subunits are arranged to form an icosahedron, a solid with 20 faces and 12 vertices. Icosahedral capsids have 12 pentamers plus 10(T-1) hexamers, where T is the triangulation number. Tobacco satellite necrosis virus has such a capsid structure.\" [GOC:bm, ISBN:0198506732, ISBN:071673706X, VZ:885, Wikipedia:Capsid]","metadata":null},{"id":"55a35586a066463399e7d10a703cad49","type":"GO_TERM","name":"icosahedral viral capsid, collar","canonical_id":"go:GO:0098031","description":"\"A small disk located at the base of some icosahedral virus capsids.\" [GOC:bm]","metadata":null},{"id":"36dd771fb84845b6902a27bbcc7fba22","type":"GO_TERM","name":"icosahedral viral capsid, collar fiber","canonical_id":"go:GO:0098032","description":"\"A fiber attached to the collar structure of some icosahedral viral capsids.\" [GOC:bm]","metadata":null},{"id":"179392fe7d3c42b697089008f99ec73a","type":"GO_TERM","name":"icosahedral viral capsid, neck","canonical_id":"go:GO:0098030","description":"\"A region of constriction located below the head and above the tail sheath of viruses with contractile tails (Myoviridae).\" [GOC:bm]","metadata":null},{"id":"e55b003b5ab44d1bbd94f3ad833834a7","type":"GO_TERM","name":"icosahedral viral capsid, neck fiber","canonical_id":"go:GO:0098033","description":"\"A fiber attached to the neck at the base of some icosahedral viral capsids.\" [GOC:bm]","metadata":null},{"id":"7695c2635f8b42009323e9f1942efc96","type":"GO_TERM","name":"icosahedral viral capsid, spike","canonical_id":"go:GO:0098029","description":"\"A short structure attached to an icosahedral virion capsid, and used for attachment to the host cell.\" [GOC:bm]","metadata":null},{"id":"95d0f275d49c41f385fb6d05ac5a8e8c","type":"GO_TERM","name":"icosanoid binding","canonical_id":"go:GO:0050542","description":"\"Binding to icosanoids, any C20 polyunsaturated fatty acids or their derivatives, including the leukotrienes and the prostanoids.\" [ISBN:0198506732]","metadata":null},{"id":"3d5808c0b480402282e7bf65d870764d","type":"GO_TERM","name":"icosanoid biosynthetic process","canonical_id":"go:GO:0046456","description":"\"The chemical reactions and pathways resulting in the formation of icosanoids, any of a group of C20 polyunsaturated fatty acids.\" [ISBN:0198506732]","metadata":null},{"id":"ca354ccdd8244ab4a2a7511a5450c735","type":"GO_TERM","name":"icosanoid catabolic process","canonical_id":"go:GO:1901523","description":"\"The chemical reactions and pathways resulting in the breakdown of icosanoid.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"4ff75390fcd74c41b337e9cb92d619f6","type":"GO_TERM","name":"icosanoid metabolic process","canonical_id":"go:GO:0006690","description":"\"The chemical reactions and pathways involving icosanoids, any of a group of C20 polyunsaturated fatty acids.\" [GOC:ma]","metadata":null},{"id":"3af4cb723aee4591ade07bcdc44aa2e2","type":"GO_TERM","name":"icosanoid receptor activity","canonical_id":"go:GO:0004953","description":"\"Combining with an icosanoid to initiate a change in cell activity.\" [GOC:dph]","metadata":null},{"id":"086a2c9f884b4427871e9cb6e309b2a6","type":"GO_TERM","name":"icosanoid secretion","canonical_id":"go:GO:0032309","description":"\"The controlled release of icosanoids, any of a group of C20 polyunsaturated fatty acids from a cell or a tissue.\" [GOC:mah]","metadata":null},{"id":"666939036fb64d42a52b2e2246041ac2","type":"GO_TERM","name":"icosanoid transmembrane transporter activity","canonical_id":"go:GO:0071714","description":"\"Enables the transfer of icosanoids from one side of a membrane to the other.\" [GOC:sl]","metadata":null},{"id":"5f324bb1dec24023993951f3680d9225","type":"GO_TERM","name":"icosanoid transport","canonical_id":"go:GO:0071715","description":"\"The directed movement of icosanoids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Icosanoids are unsaturated C20 fatty acids and skeletally related compounds.\" [GOC:mah]","metadata":null},{"id":"0c43dd93821b4840b5b355aefee6cacd","type":"GO_TERM","name":"icosatetraenoic acid binding","canonical_id":"go:GO:0050543","description":"\"Binding to icosatetraenoic acid, any straight-chain fatty acid with twenty carbon atoms and four double bonds per molecule.\" [ISBN:0198506732]","metadata":null},{"id":"884183047a4f4770a4b7dc592b18d188","type":"DRUG","name":"icotinib","canonical_id":"gtopdb:7641","description":null,"metadata":null},{"id":"ae73c0f95012408092196a150bc7833d","type":"DRUG","name":"icotinib","canonical_id":"chembl:CHEMBL2087361","description":null,"metadata":null},{"id":"f279ac04c1ae4841b60a6b1045518eb1","type":"COMBINATION_TREATMENT","name":"icotinib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-75d12d5e2739bdf0","description":null,"metadata":null},{"id":"891b6a537a9049ae9b5b1dac249d4ee1","type":"COMBINATION_TREATMENT","name":"icotinib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-e7093de55324935d","description":null,"metadata":null},{"id":"e39dc663688b4042b4d37c98c4a71e73","type":"DRUG","name":"icotrokinra","canonical_id":"gtopdb:14181","description":null,"metadata":null},{"id":"f71a179c86ae4413b8aee61f436fcdce","type":"DRUG","name":"idarubicin","canonical_id":"mesh:D015255","description":null,"metadata":null},{"id":"51a3ad046c6543f9be3afb2c81cdc2e3","type":"DRUG","name":"idarucizumab","canonical_id":"gtopdb:8298","description":null,"metadata":null},{"id":"c79d250f9eb24906b023aa40df1f6ecc","type":"DRUG","name":"idelalisib","canonical_id":"gtopdb:6741","description":null,"metadata":null},{"id":"e2d517b16b9645c0b7153d0d01ac79a7","type":"DRUG","name":"idelalisib","canonical_id":"chembl:CHEMBL2216870","description":null,"metadata":null},{"id":"96f8635fda2842a2b924a1edfc32df46","type":"COMBINATION_TREATMENT","name":"idelalisib + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-951d08847950ca50","description":null,"metadata":null},{"id":"d8b89bb9093d4bf490da6dfed6db126d","type":"COMBINATION_TREATMENT","name":"idelalisib + rituximab","canonical_id":"ctgov_combo:ctgov-combo-7c7184b785ff1ad3","description":null,"metadata":null},{"id":"3986817672c44e33a8af0b17fd3b296a","type":"COMBINATION_TREATMENT","name":"idelalisib + tafasitamab","canonical_id":"ctgov_combo:ctgov-combo-4576fe833f9a8ba0","description":null,"metadata":null},{"id":"399d16875fb54e01991a8ae0f2869bd0","type":"COMBINATION_TREATMENT","name":"idelalisib + tirabrutinib","canonical_id":"ctgov_combo:ctgov-combo-d6a782090685a0b1","description":null,"metadata":null},{"id":"90647b267ed04c5eaf2a487d4f92fddf","type":"COMBINATION_TREATMENT","name":"idelalisib + tirabrutinib","canonical_id":"ctgov_combo:ctgov-combo-13d552da3ea3d243","description":null,"metadata":null},{"id":"2312acb16da1498aa6f5fce60448c237","type":"GO_TERM","name":"identical protein binding","canonical_id":"go:GO:0042802","description":"\"Binding to an identical protein or proteins.\" [GOC:jl]","metadata":null},{"id":"d77b410fb5a549e6b1ddf02334fbf46b","type":"DISEASE","name":"idiopathic generalized epilepsy","canonical_id":"mondo:0005579","description":null,"metadata":null},{"id":"0257f06d2cb54401b0125ca21ef7df4f","type":"DISEASE","name":"idiopathic multicentric Castleman disease","canonical_id":"mondo:0035838","description":null,"metadata":null},{"id":"2b91b29253814cc1a3e5eafa6f4a0aae","type":"DISEASE","name":"idiopathic pulmonary arterial hypertension","canonical_id":"mondo:0001999","description":null,"metadata":null},{"id":"5ee33e17dd2940a784d44c27852cc870","type":"DISEASE","name":"idiopathic pulmonary fibrosis","canonical_id":"efo:0000768","description":null,"metadata":null},{"id":"c43d9aab986742f1baa2b50808abaa66","type":"DRUG","name":"idoxuridine","canonical_id":"mesh:D007065","description":null,"metadata":null},{"id":"52a16101f45b40db810a5a0d5cbb62b0","type":"GO_TERM","name":"iduronate-2-sulfatase activity","canonical_id":"go:GO:0004423","description":"\"Catalysis of the hydrolysis of the 2-sulfate groups of the L-iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and heparin.\" [EC:3.1.6.13]","metadata":null},{"id":"c98363a32c2440b4b3835fe32591bd26","type":"DRUG","name":"ifupinostat","canonical_id":"gtopdb:14249","description":null,"metadata":null},{"id":"83c254bcff25431780fb45f24492cc18","type":"DRUG","name":"iguratimod","canonical_id":"mesh:C519076","description":null,"metadata":null},{"id":"8594a9a049e441d487f51d33047adc8d","type":"DRUG","name":"ilaprazole","canonical_id":"mesh:C119615","description":null,"metadata":null},{"id":"9eb6139e2a6d4ea0b0f8a0e02c0a92de","type":"GO_TERM","name":"ilicicolin H biosynthetic process","canonical_id":"go:GO:0140781","description":"\"The chemical reactions and pathways resulting in the formation of ilicicolin H, a 4-hydroxy-2-pyridone alkaloid that has potent and broad antifungal activities by inhibiting the mitochondrial respiration chain.\" [PMID:30905148, PMID:31216742, PMID:34947016]","metadata":null},{"id":"208f5deabac84e5380a2841b218261cc","type":"DRUG","name":"iloprost","canonical_id":"gtopdb:1895","description":null,"metadata":null},{"id":"d73e1b160aca41d997defe4e990917d6","type":"DRUG","name":"iloprost","canonical_id":"mesh:D016285","description":null,"metadata":null},{"id":"16872481dda4465a9f28bd699a58d9a6","type":"DRUG","name":"iloprost","canonical_id":"chembl:CHEMBL494","description":null,"metadata":null},{"id":"7c106689023f4a84ae59af00202adf3c","type":"GO_TERM","name":"imaginal disc development","canonical_id":"go:GO:0007444","description":"\"The process whose specific outcome is the progression of the imaginal disc over time, from its formation to the metamorphosis to form adult structures. Imaginal discs are epithelial infoldings in the larvae of holometabolous insects that develop into adult structures (legs, antennae, wings, etc.).\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"14c2601bcc9f49a78ce02a76a8a12297","type":"GO_TERM","name":"imaginal disc eversion","canonical_id":"go:GO:0007561","description":"\"The eversion (turning inside out) of imaginal discs from their peripodial sacs, resulting in movement of the epithelium to the outside of the larval epidermis.\" [PMID:11494317]","metadata":null},{"id":"572810c5ebc345fd80d97f9b3f48d37f","type":"GO_TERM","name":"imaginal disc fusion","canonical_id":"go:GO:0046528","description":"\"The process following disc eversion whereby imaginal discs fuse with adjacent disc derivatives to form a continuous adult epidermis.\" [PMID:11494317]","metadata":null},{"id":"4585be117389481aa1c92b955bb5bb36","type":"GO_TERM","name":"imaginal disc fusion, thorax closure","canonical_id":"go:GO:0046529","description":"\"The joining of the parts of the wing imaginal discs, giving rise to the adult thorax.\" [http://sdb.bio.purdue.edu/fly/gene/fos4.htm]","metadata":null},{"id":"1740cbeb50af4b46844b7e4a13845f34","type":"GO_TERM","name":"imaginal disc growth","canonical_id":"go:GO:0007446","description":"\"The increase in mass of imaginal discs by cell proliferation prior to metamorphosis. Imaginal discs are epithelial infoldings in the larvae of holometabolous insects that develop into adult structures (legs, antennae, wings, etc.) during metamorphosis from larval to adult form.\" [GOC:bf, GOC:jid, PMID:10679387]","metadata":null},{"id":"a5e87b90aff24ae7b11d0336679d70ad","type":"GO_TERM","name":"imaginal disc growth factor receptor binding","canonical_id":"go:GO:0008084","description":"\"Binding to an imaginal disc growth factor receptor.\" [GOC:mah]","metadata":null},{"id":"b577b288d71646cab5dde321ab337485","type":"GO_TERM","name":"imaginal disc lineage restriction","canonical_id":"go:GO:0035161","description":"\"Formation and/or maintenance of a lineage boundary between compartments in an imaginal disc that cells cannot cross, thus separating the populations of cells in each compartment.\" [GOC:bf, PMID:10625531, PMID:9374402]","metadata":null},{"id":"28c6d683ff23473cb47c72826e2a293e","type":"GO_TERM","name":"imaginal disc morphogenesis","canonical_id":"go:GO:0007560","description":"\"The process in which the anatomical structures derived from an imaginal disc are generated and organized. The imaginal discs are epithelial infoldings in the larvae of holometabolous insects that develop into adult appendages (legs, antennae, wings, etc.) during metamorphosis from larval to adult form.\" [GOC:jid]","metadata":null},{"id":"ad10a89332314383b82175a05afbf579","type":"GO_TERM","name":"imaginal disc pattern formation","canonical_id":"go:GO:0007447","description":"\"The regionalization process that results in defined areas of the imaginal disc that will undergo specific cell differentaiton. Imaginal discs are epithelial infoldings in the larvae of holometabolous insects that develop into adult appendages (legs, antennae, wings, etc.) during metamorphosis from larval to adult form.\" [GOC:dph, GOC:isa_complete, GOC:jid]","metadata":null},{"id":"ea2e9f4d2ee34f64b3699639ba8503fd","type":"GO_TERM","name":"imaginal disc-derived appendage development","canonical_id":"go:GO:0048737","description":"\"The process whose specific outcome is the progression of an appendage over time, from its formation in the imaginal disc to the mature structure. An appendage is an organ or part that is attached to the trunk of an organism.\" [GOC:jid, GOC:mtg_sensu, GOC:rc]","metadata":null},{"id":"bc701cb2a8294d63aef4e10051134da5","type":"GO_TERM","name":"imaginal disc-derived appendage morphogenesis","canonical_id":"go:GO:0035114","description":"\"The process in which the anatomical structures of appendages are generated and organized. An appendage is an organ or part that is attached to the trunk of an organism.\" [GOC:mtg_sensu, ISBN:0582227089]","metadata":null},{"id":"45f2b74c4c394412a1e8e6d8a4d4093a","type":"GO_TERM","name":"imaginal disc-derived female genitalia development","canonical_id":"go:GO:0007486","description":"\"The process whose specific outcome is the progression of the female genitalia over time, from formation as part of the genital disc to the mature structure. An example of this is found in Drosophila melanogaster.\" [GOC:ai, GOC:sensu]","metadata":null},{"id":"bc731573a2fb45a7b0ae8904f455e711","type":"GO_TERM","name":"imaginal disc-derived female genitalia morphogenesis","canonical_id":"go:GO:0048804","description":"\"The process in which the anatomical structures of female genitalia are generated and organized from the genital disc.\" [GOC:ai, GOC:sensu]","metadata":null},{"id":"d738e5b11e8e43cb809d423037699ba5","type":"GO_TERM","name":"imaginal disc-derived genitalia development","canonical_id":"go:GO:0007484","description":"\"The process whose specific outcome is the progression of the genitalia over time, from formation as part of the genital disc to the mature structure. An example of this is found in Drosophila melanogaster.\" [GOC:ai, GOC:sensu]","metadata":null},{"id":"ee10a02528e84bf58bc1ca1293089655","type":"GO_TERM","name":"imaginal disc-derived genitalia morphogenesis","canonical_id":"go:GO:0048805","description":"\"The process in which the anatomical structures of genitalia are generated and organized from the genital imaginal disc.\" [GOC:ai, GOC:sensu]","metadata":null},{"id":"03b3e25e3e6b49498d9b5eeb0c234fbe","type":"GO_TERM","name":"imaginal disc-derived leg joint morphogenesis","canonical_id":"go:GO:0016348","description":"\"The process in which the anatomical structures of an imaginal disc-derived leg joint are generated and organized. The leg joint is a flexible region that separates the rigid sections of a leg to allow movement in a controlled manner. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"02965d7d2bb94372b3da394a2e8fbb10","type":"GO_TERM","name":"imaginal disc-derived leg morphogenesis","canonical_id":"go:GO:0007480","description":"\"The process in which the anatomical structures of a leg derived from an imaginal disc are generated and organized. A leg is a limb on which an animal walks and stands. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"699f9d6e648d4246a686256a93c13487","type":"GO_TERM","name":"imaginal disc-derived leg segmentation","canonical_id":"go:GO:0036011","description":"\"Division of an imaginal disc-derived leg into a series of semi-repetitive parts or segments. The Drosophila leg, for example, has nine segments, each separated from the next by a flexible joint.\" [GOC:bf]","metadata":null},{"id":"408f6f521c294d799da593df36d5b0fd","type":"GO_TERM","name":"imaginal disc-derived male genitalia development","canonical_id":"go:GO:0007485","description":"\"The process whose specific outcome is the progression of the male genitalia over time, from formation as part of the genital disc to the mature structure. An example of this is found in Drosophila melanogaster.\" [GOC:ai, GOC:sensu]","metadata":null},{"id":"e18a34c7ee73440e81c43f1cf90b8b6a","type":"GO_TERM","name":"imaginal disc-derived male genitalia morphogenesis","canonical_id":"go:GO:0048803","description":"\"The process in which the anatomical structures of male genitalia are generated and organized from the genital imaginal disc.\" [GOC:ai, GOC:sensu]","metadata":null},{"id":"e92dce4c3d884bf887260008272122e9","type":"GO_TERM","name":"imaginal disc-derived wing expansion","canonical_id":"go:GO:0048526","description":"\"The process of expanding or inflating the folded imaginal disc-derived pupal wing, and the adhering of the dorsal and ventral surfaces, to form the mature adult wing.\" [GOC:mtg_sensu, GOC:rc]","metadata":null},{"id":"9a2dabb7e91747e9be13740762b98a66","type":"GO_TERM","name":"imaginal disc-derived wing hair elongation","canonical_id":"go:GO:0035319","description":"\"Growth of a prehair in the approximately 10 hour period following its emergence from an epidermal cell in an imaginal disc-derived wing. Prehair elongation is guided and/or driven by the polymerization of actin filaments and the orderly crosslinking of filaments into bundles.\" [GOC:mtg_sensu, PMID:11832234]","metadata":null},{"id":"d2fb411afd644562907751f0ca775a1d","type":"GO_TERM","name":"imaginal disc-derived wing hair organization","canonical_id":"go:GO:0035317","description":"\"A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of an imaginal disc-derived wing hair. A wing hair is an actin-rich, polarized, non-sensory apical projection that protrudes from each of the approximately 30,000 wing epithelial cells. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11064425, PMID:12540853]","metadata":null},{"id":"d146fc7d1f4f4225bb462ec01b0c934a","type":"GO_TERM","name":"imaginal disc-derived wing hair outgrowth","canonical_id":"go:GO:0035318","description":"\"Extrusion of a cellular projection from the apical membrane of an epithelial cell in an imaginal disc-derived wing. Outgrowth initiates approximately 35 hours after puparium formation from the distal side of the cell, and at this stage the cellular extension is termed a prehair.\" [GOC:mtg_sensu, PMID:11064425, PMID:8947551]","metadata":null},{"id":"d292037e87dc4bd680c49daa4700be67","type":"GO_TERM","name":"imaginal disc-derived wing hair site selection","canonical_id":"go:GO:0035320","description":"\"Determination of the site in the cell of an imaginal disc-derived wing at which a prehair initiates outgrowth. Restriction of prehair initiation to the distalmost part of a cell is essential to ensure that each wing epithelial cell produces one adult hair that points distally.\" [GOC:mtg_transport, ISBN:0815340729, PMID:8947551]","metadata":null},{"id":"d6d2ed09a426404faa956ef9828dd109","type":"GO_TERM","name":"imaginal disc-derived wing margin morphogenesis","canonical_id":"go:GO:0008587","description":"\"The process in which the anatomical structures of the imaginal disc-derived wing margin are generated and organized. The wing margin is a strip of cells in the third instar disc at the boundary between the presumptive dorsal and ventral surfaces of the wing blade.\" [GOC:bf, GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"57cfc6353ec34efd82a7f44ac15fd904","type":"GO_TERM","name":"imaginal disc-derived wing morphogenesis","canonical_id":"go:GO:0007476","description":"\"The process in which the anatomical structures of the imaginal disc-derived wing are generated and organized. The wing is an appendage modified for flying.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"52f12093408048e7aebc6a1fb3b34024","type":"GO_TERM","name":"imaginal disc-derived wing vein morphogenesis","canonical_id":"go:GO:0008586","description":"\"The process in which anatomical structures of the veins on an imaginal disc-derived wing are generated and organized.\" [GOC:mtg_sensu]","metadata":null},{"id":"b7f352e5c2e04823854a8aac97728b63","type":"GO_TERM","name":"imaginal disc-derived wing vein specification","canonical_id":"go:GO:0007474","description":"\"The regionalization process in which the area of a imaginal disc-derived wing that will form a wing vein is specified.\" [GOC:dph, GOC:isa_complete, GOC:mtg_sensu]","metadata":null},{"id":"66d9a593a45141f7b957537c4ec75a8f","type":"DRUG","name":"imatinib","canonical_id":"gtopdb:5687","description":null,"metadata":null},{"id":"6852b97cc3284bed8a5a19c2cc64edf4","type":"DRUG","name":"imatinib","canonical_id":"mesh:D000068877","description":null,"metadata":null},{"id":"b696153ae2b8418e9711d23f6db20138","type":"COMBINATION_TREATMENT","name":"imatinib + nilotinib","canonical_id":"ctgov_combo:ctgov-combo-751adc1f08e77070","description":null,"metadata":null},{"id":"e45301511d764ac49317c43d87b750b3","type":"COMBINATION_TREATMENT","name":"imatinib + nilotinib","canonical_id":"ctgov_combo:ctgov-combo-737453b596d7406f","description":null,"metadata":null},{"id":"1aa1b469e02f45e3b1c3e48a992468d9","type":"COMBINATION_TREATMENT","name":"imatinib + ranibizumab","canonical_id":"ctgov_combo:ctgov-combo-a9f9a7cbdd384843","description":null,"metadata":null},{"id":"b911b98d6fac417596efa00c113c4aed","type":"DRUG","name":"imidapril","canonical_id":"gtopdb:6377","description":null,"metadata":null},{"id":"ca2f4f513d4049b69396063899b03463","type":"DRUG","name":"imidapril","canonical_id":"mesh:C065166","description":null,"metadata":null},{"id":"cf5b3e5da182433fbccab9bbe9843cf3","type":"DRUG","name":"imidapril","canonical_id":"chembl:CHEMBL317094","description":null,"metadata":null},{"id":"347920c0ae354df88b3d32a3ba2e391e","type":"DRUG","name":"imidaprilat","canonical_id":"gtopdb:6378","description":null,"metadata":null},{"id":"18a05f9943e04df1944b702ea4cac6db","type":"GO_TERM","name":"imidazole N-acetyltransferase activity","canonical_id":"go:GO:0047716","description":"\"Catalysis of the reaction: 1H-imidazole + acetyl-CoA = N-acetylimidazole + CoA.\" [EC:2.3.1.2, RHEA:15813]","metadata":null},{"id":"42763617208546769eb240a8377534e1","type":"GO_TERM","name":"imidazole-containing compound catabolic process","canonical_id":"go:GO:0052805","description":"\"The chemical reactions and pathways resulting in the breakdown of imidazoles, five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.\" [GOC:curators]","metadata":null},{"id":"81c62f8ec8714498bfb33b13f732f965","type":"GO_TERM","name":"imidazole-containing compound metabolic process","canonical_id":"go:GO:0052803","description":"\"The chemical reactions and pathways involving imidazoles, five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.\" [GOC:curators]","metadata":null},{"id":"eda9df03d4fc42a890f4fb38146ee4d3","type":"GO_TERM","name":"imidazoleacetate 4-monooxygenase activity","canonical_id":"go:GO:0047717","description":"\"Catalysis of the reaction: H+ + imidazol-4-ylacetate + NADH + O2 = 5-hydroxyimidazole-4-acetate + H2O + NAD+.\" [EC:1.14.13.5, RHEA:19425]","metadata":null},{"id":"b26057bab6f3458dab3f1092ba77da90","type":"GO_TERM","name":"imidazoleacetate-phosphoribosyldiphosphate ligase activity","canonical_id":"go:GO:0047483","description":"\"Catalysis of the reaction: 5-phospho-alpha-D-ribose 1-diphosphate + ATP + H2O + imidazol-4-ylacetate = 1-(5-phosphoribosyl)imidazol-4-ylacetate + ADP + diphosphate + 2 H+ + phosphate.\" [EC:6.3.4.8, RHEA:16485]","metadata":null},{"id":"af015b9f96284cd788e5aa66bd25a698","type":"GO_TERM","name":"imidazoleglycerol-phosphate dehydratase activity","canonical_id":"go:GO:0004424","description":"\"Catalysis of the reaction: D-erythro-1-(imidazol-4-yl)glycerol 3-phosphate = 3-(imidazol-4-yl)-2-oxopropyl phosphate + H2O.\" [EC:4.2.1.19, RHEA:11040]","metadata":null},{"id":"3a2111bd115340e7960b4314e6bc2f74","type":"GO_TERM","name":"imidazoleglycerol-phosphate synthase activity","canonical_id":"go:GO:0000107","description":"\"Catalysis of the reaction: phosphoribulosylformimino-AICAR-P + L-glutamine = D-erythro-imidazole-glycerol-phosphate + aminoimidazole carboxamide ribonucleotide + L-glutamate + 2 H+.\" [RHEA:24793]","metadata":null},{"id":"88895ca779a94fd290871bda1a9c839c","type":"GO_TERM","name":"imidazoleglycerol-phosphate synthase complex","canonical_id":"go:GO:0009382","description":"\"Complex that possesses imidazoleglycerol-phosphate synthase activity.\" [GOC:mah]","metadata":null},{"id":"defa060babcd4d82b7ef7c6c004ae956","type":"GO_TERM","name":"imidazolone hydrolase activity","canonical_id":"go:GO:0043804","description":"\"Catalysis of the reaction: imidazol-4-one + H2O = N-formimidoylglycine.\" [PMID:27286964, RHEA:24935]","metadata":null},{"id":"973b25db4b874bd98b01504df229aed6","type":"GO_TERM","name":"imidazolonepropionase activity","canonical_id":"go:GO:0050480","description":"\"Catalysis of the reaction: (S)-3-(4-oxo-4,5-dihydro-1H-imidazol-5-yl)propanoic acid + H2O = N-formimidoyl-L-glutamate + H+.\" [EC:3.5.2.7, RHEA:23660]","metadata":null},{"id":"b1aab6295e0a4e758827e19e6299960e","type":"DRUG","name":"imiglucerase","canonical_id":"mesh:C090568","description":null,"metadata":null},{"id":"5a5cd96e172a41d095da4070f92855d7","type":"DRUG","name":"imipenem","canonical_id":"mesh:D015378","description":null,"metadata":null},{"id":"52b854a645ad41a9aea2b7fd851b2b74","type":"DRUG","name":"imipramine","canonical_id":"gtopdb:357","description":null,"metadata":null},{"id":"6b513a8c7ece459cb680f2a24ece2449","type":"COMBINATION_TREATMENT","name":"imipramine + mexiletine + propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-4b63fc77aff19e6c","description":null,"metadata":null},{"id":"864d4d0843a64de3aaa1feb9901d4714","type":"COMBINATION_TREATMENT","name":"imipramine + mexiletine + sotalol","canonical_id":"ctgov_combo:ctgov-combo-79d06b99ae8a3b0b","description":null,"metadata":null},{"id":"74ffe9856b334704b545a548a7945aef","type":"COMBINATION_TREATMENT","name":"imipramine + propranolol","canonical_id":"ctgov_combo:ctgov-combo-a1ed7b1190a6e0bd","description":null,"metadata":null},{"id":"5c9230e48a0446fc91e46c34be76a984","type":"COMBINATION_TREATMENT","name":"imipramine + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-d33082dc3c4520e8","description":null,"metadata":null},{"id":"091ce94ef7ce4df1879a7aac969d855a","type":"DRUG","name":"imiquimod","canonical_id":"gtopdb:5003","description":null,"metadata":null},{"id":"91c1625ef77f458eabb1ee94e87f14d4","type":"DRUG","name":"imiquimod","canonical_id":"mesh:C056493","description":null,"metadata":null},{"id":"ab997089e5584f62af60f9da2024b616","type":"DRUG","name":"imiquimod","canonical_id":"chembl:CHEMBL1282","description":null,"metadata":null},{"id":"8e3afd93596e40c98a794cfe08b5e5ab","type":"COMBINATION_TREATMENT","name":"imiquimod + tazarotene","canonical_id":"ctgov_combo:ctgov-combo-108f2c3315de6527","description":null,"metadata":null},{"id":"966df9e1bac44b1aa5fd8464640a7840","type":"GO_TERM","name":"imitative learning","canonical_id":"go:GO:0098596","description":"\"Learning in which new behaviors are acquired through imitation.\" [GOC:dos, Wikipedia:Imitative_learning&oldid=593192364]","metadata":null},{"id":"8fce884e6ce542f6888104aa931ea989","type":"GO_TERM","name":"immature B cell differentiation","canonical_id":"go:GO:0002327","description":"\"The process in which a precursor cell type acquires the specialized features of an immature B cell.\" [GOC:jal, ISBN:0781735149, PMID:16551251]","metadata":null},{"id":"853620936bc54d25b04dd40e61d6ecf7","type":"GO_TERM","name":"immature T cell proliferation","canonical_id":"go:GO:0033079","description":"\"The expansion of an immature T cell population by cell division.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"3bc056bda5f84c3ea5e052c6af3bf617","type":"GO_TERM","name":"immature T cell proliferation in thymus","canonical_id":"go:GO:0033080","description":"\"The expansion of an immature T cell population by cell division in the thymus.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"98a965c9def742799184de793184fc5d","type":"GO_TERM","name":"immune complex clearance","canonical_id":"go:GO:0002434","description":"\"A process directed at removing immune complexes from the body. Immune complexes are clusters of antibodies bound to antigen, to which complement may also be fixed, and which may precipitate or remain in solution.\" [GO_REF:0000022, GOC:add, ISBN:068340007X]","metadata":null},{"id":"d2a72aa9580340989b5e1b535aaad1a1","type":"GO_TERM","name":"immune complex clearance by erythrocytes","canonical_id":"go:GO:0002435","description":"\"The process of immune complex clearance by erythrocytes. The process often starts with binding of complement receptor 1 (CR1) on the surface of erythrocytes to a complement coated immune complex. The complex bound to erythrocyte CR1 is then transported to the liver or spleen where it is presented to phagocytes. The process ends when the complex is removed from CR1, allowing the erythrocyte to return to general circulation.\" [GOC:add, PMID:11414352, PMID:24022490]","metadata":null},{"id":"9ed79275f6de48a798df8aa580c5c560","type":"GO_TERM","name":"immune complex clearance by monocytes and macrophages","canonical_id":"go:GO:0002436","description":"\"The process of immune complex clearance by monocytes or macrophages.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1e17da98c49f460aa068f96f392ec2d8","type":"GO_TERM","name":"immune complex formation","canonical_id":"go:GO:0097281","description":"\"The process that gives rise to an immune complex. Immune complexes are clusters of antibodies bound to antigen, to which complement may also be fixed, and which may precipitate or remain in solution. Examples are the clumping of cells such as bacteria or red blood cells in the presence of an antibody, precipitation of a toxin after an antibody binds to it, and clumping of viral particles as a result of antibody binding to the virus.\" [GOC:add, GOC:rv]","metadata":null},{"id":"6a14aa9bf01d4a28930112d4514a7fa5","type":"GO_TERM","name":"immune effector process","canonical_id":"go:GO:0002252","description":"\"Any process of the immune system that executes a component of an immune response. An effector immune process takes place after its activation.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"dc1c999590674ad1abfbe8c72e2081f6","type":"GO_TERM","name":"immune receptor activity","canonical_id":"go:GO:0140375","description":"\"Receiving a signal and transmitting it in a cell to initiate an immune response.\" [PMID:31415752, Wikipedia:Immune_receptor]","metadata":null},{"id":"41624917f9ab4f1c9f6b8e0c2d574c34","type":"GO_TERM","name":"immune response","canonical_id":"go:GO:0006955","description":"\"Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.\" [GO_REF:0000022, GOC:add]","metadata":null},{"id":"6ebad850e65d46b098777bffa7b4e3b7","type":"GO_TERM","name":"immune response in Peyer's patch","canonical_id":"go:GO:0002388","description":"\"Immune response taking place in the Peyer's patch, nodular lymphoid structures on the serosal surface of the small intestine.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"db8bb8ee71c540559e7acc02b926ac68","type":"GO_TERM","name":"immune response in brain or nervous system","canonical_id":"go:GO:0002383","description":"\"An immune response taking place in the brain or nervous system.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"1e0ef288705e417c8f46a29f26798199","type":"GO_TERM","name":"immune response in gut-associated lymphoid tissue","canonical_id":"go:GO:0002387","description":"\"Immune response taking place in the gut-associated lymphoid tissue (GALT). GALT includes Peyer's patches, appendix, and solitary lymph nodules.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"e2f49894dfd74f3b9f7421faf99527e5","type":"GO_TERM","name":"immune response in nasopharyngeal-associated lymphoid tissue","canonical_id":"go:GO:0002395","description":"\"An immune response taking place in the nasopharyngeal-associated lymphoid tissue (NALT). NALT includes the tonsils and adenoids.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"c6167bac91204e648e7c2baaf033b821","type":"GO_TERM","name":"immune response involved in response to exogenous dsRNA","canonical_id":"go:GO:1902615","description":"\"Any immune response that is involved in response to exogenous dsRNA.\" [GO_REF:0000060, GOC:pg, GOC:TermGenie, PMID:21266579]","metadata":null},{"id":"716b13bf881e4d5895b5d4d281773e9a","type":"GO_TERM","name":"immune response to tumor cell","canonical_id":"go:GO:0002418","description":"\"An immune system process that functions in the response of an organism to a tumor cell.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"ed9608dda7dd4e53aaec1328e4739b78","type":"GO_TERM","name":"immune response-activating cell surface receptor signaling pathway","canonical_id":"go:GO:0002429","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of a cell, leading to the activation or perpetuation of an immune response.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"efdb3f31e0a840828e1350ffc3772fbb","type":"GO_TERM","name":"immune response-activating signaling pathway","canonical_id":"go:GO:0002757","description":"\"The series of molecular signals generated by a ligand binding to its receptor that lead to the activation or perpetuation of an immune response.\" [GOC:add]","metadata":null},{"id":"06e596375bc74b3491a77f411e72c35e","type":"GO_TERM","name":"immune response-inhibiting cell surface receptor signaling pathway","canonical_id":"go:GO:0002767","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell capable of inhibiting an immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"8b7068a37b5546ec88fc9ca3983a912d","type":"GO_TERM","name":"immune response-inhibiting signal transduction","canonical_id":"go:GO:0002765","description":"\"The cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to inhibition of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f8f1561f085b4bc38eeef9c82032b8b1","type":"GO_TERM","name":"immune response-regulating cell surface receptor signaling pathway","canonical_id":"go:GO:0002768","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell capable of activating, perpetuating, or inhibiting an immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"6b1bb3abce95450092183c6303b8f693","type":"GO_TERM","name":"immune response-regulating signaling pathway","canonical_id":"go:GO:0002764","description":"\"The cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to the activation, perpetuation, or inhibition of an immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"e00b0cbee93842f89972260aaf87ea93","type":"GO_TERM","name":"immune system development","canonical_id":"go:GO:0002520","description":"\"The process whose specific outcome is the progression of an organismal system whose objective is to provide calibrated responses by an organism to a potential internal or invasive threat, over time, from its formation to the mature structure. A system is a regularly interacting or interdependent group of organs or tissues that work together to carry out a given biological process.\" [GOC:add, GOC:dph]","metadata":null},{"id":"75c43d57c03a4fe6bccfc6f78263c5b2","type":"DISEASE","name":"immune system disorder","canonical_id":"mondo:0005046","description":null,"metadata":null},{"id":"50cd559e10ad4a50930ea6062b72eb8d","type":"GO_TERM","name":"immune system process","canonical_id":"go:GO:0002376","description":"\"Any process involved in the development or functioning of the immune system, an organismal system for calibrated responses to potential internal or invasive threats.\" [GO_REF:0000022, GOC:add]","metadata":null},{"id":"38bc098a0a1346a6b787c59d22c3e1c5","type":"DISEASE","name":"immunodeficiency 106, susceptibility to viral infections","canonical_id":"mondo:0030970","description":null,"metadata":null},{"id":"e061e2c788a64ad4a0f7ac66a43e7b8f","type":"DISEASE","name":"immunodeficiency 14b, autosomal recessive","canonical_id":"mondo:0023655","description":null,"metadata":null},{"id":"d18c3ff080764a01a2a6038c839b0c4a","type":"DISEASE","name":"immunodeficiency 18","canonical_id":"mondo:0014278","description":null,"metadata":null},{"id":"50776e584ad245b881425141c2e7fe1c","type":"DISEASE","name":"immunodeficiency 35","canonical_id":"mondo:0012682","description":null,"metadata":null},{"id":"1f0f712368a041c78d956b277922cf36","type":"DISEASE","name":"immunodeficiency 51","canonical_id":"mondo:0013500","description":null,"metadata":null},{"id":"e68cbee8b2824576ab0c22ed4581b897","type":"DISEASE","name":"immunodeficiency 74, COVID-19-related, X-linked","canonical_id":"mondo:0026767","description":null,"metadata":null},{"id":"892068f49a614d8386652da5c009c0f5","type":"DISEASE","name":"immunodeficiency 79","canonical_id":"mondo:0030981","description":null,"metadata":null},{"id":"a111ade228914f03ad93cde57ec315a2","type":"DISEASE","name":"immunodeficiency disease","canonical_id":"mondo:0021094","description":null,"metadata":null},{"id":"e681f5fa155140efaf92025cbde2738a","type":"DISEASE","name":"immunodeficiency due to CD25 deficiency","canonical_id":"mondo:0011664","description":null,"metadata":null},{"id":"ec63c79495ca4e75902029d18bdf7716","type":"DISEASE","name":"immunodeficiency due to MASP-2 deficiency","canonical_id":"mondo:0013423","description":null,"metadata":null},{"id":"01851720914c4ddab8e8cb1b2a06e460","type":"DISEASE","name":"immunodeficiency due to a classical component pathway complement deficiency","canonical_id":"mondo:0015699","description":null,"metadata":null},{"id":"14fc8898a1724f58b0f63fae239bc34d","type":"DISEASE","name":"immunodeficiency, common variable, 3","canonical_id":"mondo:0013283","description":null,"metadata":null},{"id":"8b3295d2dfa94e60ad4cf062fc7dfaed","type":"GO_TERM","name":"immunoglobulin V(D)J recombination","canonical_id":"go:GO:0033152","description":"\"The process in which immunoglobulin gene segments are recombined within a single locus utilizing the conserved heptamer and nonomer recombination signal sequences (RSS). For immunoglobulin heavy chains V, D, and J gene segments are joined, and for immunoglobulin light chains V and J gene segments are joined.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d54e8c684ebb453badbc473f85f9473d","type":"GO_TERM","name":"immunoglobulin binding","canonical_id":"go:GO:0019865","description":"\"Binding to an immunoglobulin.\" [GOC:ma]","metadata":null},{"id":"05d55065b19e4bf39d3350fa522fb193","type":"GO_TERM","name":"immunoglobulin complex","canonical_id":"go:GO:0019814","description":"\"A protein complex that in its canonical form is composed of two identical immunoglobulin heavy chains and two identical immunoglobulin light chains, held together by disulfide bonds and sometimes complexed with additional proteins. An immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, GOC:jl, ISBN:0781765196]","metadata":null},{"id":"39f081cfb9b746d9b3ebe0471caec59d","type":"GO_TERM","name":"immunoglobulin complex, circulating","canonical_id":"go:GO:0042571","description":"\"An immunoglobulin complex that is secreted into extracellular space and found in mucosal areas or other tissues or circulating in the blood or lymph. In its canonical form, a circulating immunoglobulin complex is composed of two identical heavy chains and two identical light chains, held together by disulfide bonds. Some forms of are polymers of the basic structure and contain additional components such as J-chain and the secretory component.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"49e3514b0ed7446f8f8c37b1291a7011","type":"GO_TERM","name":"immunoglobulin heavy chain V-D-J recombination","canonical_id":"go:GO:0071707","description":"\"The process in which immunoglobulin heavy chain V, D, and J gene segments are recombined within a single locus utilizing the conserved heptamer and nonomer recombination signal sequences (RSS).\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"24a8121d3af84812b0ceb27fc86231a3","type":"GO_TERM","name":"immunoglobulin light chain V-J recombination","canonical_id":"go:GO:0071708","description":"\"The process in which immunoglobulin light chain V and J gene segments are recombined within a single locus utilizing the conserved heptamer and nonomer recombination signal sequences (RSS).\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"27875ba3318f4d49ad7aa5b512172040","type":"GO_TERM","name":"immunoglobulin mediated immune response","canonical_id":"go:GO:0016064","description":"\"An immune response mediated by immunoglobulins, whether cell-bound or in solution.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"a20645a0c7974264808cf2aeddf7de55","type":"GO_TERM","name":"immunoglobulin production","canonical_id":"go:GO:0002377","description":"\"The appearance of immunoglobulin due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"4af92fe148d74d748a4052376481e0da","type":"GO_TERM","name":"immunoglobulin production in mucosal tissue","canonical_id":"go:GO:0002426","description":"\"The synthesis and release of immunoglobulin in the mucosal tissue.\" [GOC:jal]","metadata":null},{"id":"03171e87b4954ca0a53f5f0d1dc932bd","type":"GO_TERM","name":"immunoglobulin production involved in immunoglobulin-mediated immune response","canonical_id":"go:GO:0002381","description":"\"The appearance of immunoglobulin due to biosynthesis or secretion following a cellular stimulus during an immune response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149, PMID:9185563]","metadata":null},{"id":"274ca1683685486093e43a883b88ea81","type":"GO_TERM","name":"immunoglobulin receptor activity","canonical_id":"go:GO:0019763","description":"\"Combining with the Fc region of an immunoglobulin protein and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:signaling, ISBN:0198547684]","metadata":null},{"id":"886aac8e1fd74672b4f2092c46d981cf","type":"GO_TERM","name":"immunoglobulin receptor binding","canonical_id":"go:GO:0034987","description":"\"Binding to one or more specific sites on an immunoglobulin receptor molecule.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"1fb883c4431a4a6184346f6cda873c13","type":"GO_TERM","name":"immunoglobulin transcytosis in epithelial cells","canonical_id":"go:GO:0002414","description":"\"The process of transporting immunoglobulin, via transcytosis, from one side of an epithelial cell to the other.\" [GOC:add, ISBN:0781735149, ISBN:081533642X, PMID:16048543]","metadata":null},{"id":"4bf8180a6fe1404c997cceaa1e0ecbb5","type":"GO_TERM","name":"immunoglobulin transcytosis in epithelial cells mediated by polymeric immunoglobulin receptor","canonical_id":"go:GO:0002415","description":"\"The process of transporting polymeric IgA and polymeric IgM immunoglobulin, via transcytosis mediated by the polymeric immunoglobulin receptor (pIgR), from the basolateral surface to apical surface of an epithelial cell. At the apical surface the immunoglobulin binding portion of the pIgRis cleaved and remains bound to the transported immunoglobulin as secretory component (SC). The same process is used for the transport and excretion of IgA immune complexes to the luminal surface of the mucosa.\" [GOC:add, ISBN:0781735149, ISBN:081533642X, PMID:16048543]","metadata":null},{"id":"1a72b929c46845dd96ad7a660992eb2e","type":"GO_TERM","name":"immunoglobulin-mediated neutralization","canonical_id":"go:GO:0097282","description":"\"The inhibition of an antigen's biological effects by antibody binding to it. An example is neutralization of diphtheria toxin by preventing its entry into human cells via the binding of antibody specific for diphtheria toxin.\" [GOC:add, GOC:rv]","metadata":null},{"id":"9d8a030076584fa4a5b1c42799cbb811","type":"GO_TERM","name":"immunological memory formation process","canonical_id":"go:GO:0090715","description":"\"Any immunological memory process that can contribute to the formation of immunological memory.\" [GOC:add, PMID:26086132, PMID:26831526]","metadata":null},{"id":"cf5455d02d904fffa4977c790e945987","type":"GO_TERM","name":"immunological memory process","canonical_id":"go:GO:0090713","description":"\"Any process of the immune system that can contribute to the formation of immunological memory or an immune response based upon activation of immunological memory.\" [GOC:add, PMID:26086132, PMID:26831526]","metadata":null},{"id":"738384b0f7a9440f965b42323fbf9724","type":"GO_TERM","name":"immunological synapse","canonical_id":"go:GO:0001772","description":"\"An area of close contact between a lymphocyte (T-, B-, or natural killer cell) and a target cell formed through the clustering of particular signaling and adhesion molecules and their associated membrane rafts on both the lymphocyte and the target cell and facilitating activation of the lymphocyte, transfer of membrane from the target cell to the lymphocyte, and in some situations killing of the target cell through release of secretory granules and/or death-pathway ligand-receptor interaction.\" [GOC:mgi_curators, PMID:11244041, PMID:11376300]","metadata":null},{"id":"ab7927b17d304d0d85787e0b906ca9c2","type":"GO_TERM","name":"immunological synapse formation","canonical_id":"go:GO:0001771","description":"\"The formation of an area of close contact between a lymphocyte (T-, B-, or natural killer cell) and a target cell through the clustering of particular signaling and adhesion molecules and their associated membrane rafts on both the lymphocyte and target cell, which facilitates activation of the lymphocyte, transfer of membrane from the target cell to the lymphocyte, and in some situations killing of the target cell through release of secretory granules and/or death-pathway ligand-receptor interaction.\" [GOC:mgi_curators, PMID:11244041, PMID:11376330]","metadata":null},{"id":"d1d5a43cdeb243ddb32c27010f46d049","type":"DRUG","name":"imolamine","canonical_id":"mesh:C002787","description":null,"metadata":null},{"id":"639407bab3ff409eb47b3390ed2c1430","type":"GO_TERM","name":"import across plasma membrane","canonical_id":"go:GO:0098739","description":"\"The directed movement of some substance from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"a28acb5b876a4226a0e8c92dea74aa40","type":"GO_TERM","name":"import into cell","canonical_id":"go:GO:0098657","description":"\"The directed movement of some substance from outside of a cell into a cell. This may occur via transport across the plasma membrane or via endocytosis.\" [GOC:dos]","metadata":null},{"id":"72a57bc50348472a8af8a964f71fbe1e","type":"GO_TERM","name":"import into nucleus","canonical_id":"go:GO:0051170","description":"\"The directed movement of substances into the nucleus.\" [GOC:ai]","metadata":null},{"id":"ff3e1fcd1d6c483aa78efc7fb31aaaae","type":"GO_TERM","name":"import into the mitochondrion","canonical_id":"go:GO:0170036","description":"\"The directed movement of substances from the cytosol into the mitochondrion.\" [GOC:ew]","metadata":null},{"id":"5213c0d51f9d4aa0a5c9ed5904ccfd58","type":"GO_TERM","name":"importin-alpha family protein binding","canonical_id":"go:GO:0061676","description":"\"Binding to a member of the importin-alpha family.\" [PMID:15350979, PMID:17170104, PMID:23734157]","metadata":null},{"id":"1665bad657084639bbb01bf94380b4b9","type":"GO_TERM","name":"in utero embryonic development","canonical_id":"go:GO:0001701","description":"\"The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"74f074d0baf44ef49768c29d8f10a45a","type":"GO_TERM","name":"inaD signaling complex","canonical_id":"go:GO:0016027","description":"\"A complex of proteins that are involved in phototransduction and attached to the transient receptor potential (TRP) channel. The protein connections are mediated through inaD.\" [GOC:hb, PMID:9010208, PMID:9796815]","metadata":null},{"id":"aef605c6c95847b4aba3cffc7b83ec2b","type":"GO_TERM","name":"inactivation of paternal X chromosome by genomic imprinting","canonical_id":"go:GO:0060818","description":"\"Compensating for the two-fold variation in X-chromosome:autosome ratios between sexes by a global inactivation of all, or most of, the genes on the paternal X-chromosome in the XX sex by genomic imprinting.\" [GOC:dph, GOC:sdb_2009, GOC:tb, PMID:11743158, PMID:16789828, PMID:18425126, PMID:23578369]","metadata":null},{"id":"61b5f183905d4c51a5d71f5ffddddacb","type":"GO_TERM","name":"inactivation of recombination (HML)","canonical_id":"go:GO:0007537","description":"\"The inactivation of recombination at sequences around a mating type donor locus, with the consequence that the other donor is the only one available for mating type switching; exemplified by the HML locus and surrounding sequences on Chromosome III in Saccharomyces cerevisiae.\" [GOC:mah, PMID:9928492]","metadata":null},{"id":"c519abdbfc3d42f498676821226e5b05","type":"GO_TERM","name":"inactive sex chromosome","canonical_id":"go:GO:0098577","description":"\"A sex chromosome that has been inactivated.\" [GOC:dos]","metadata":null},{"id":"68ed40a7f78b45838123237aa84050f3","type":"DRUG","name":"inamrinone","canonical_id":"gtopdb:7202","description":null,"metadata":null},{"id":"7eb2415473784195a0c49e3698556d6f","type":"DISEASE","name":"inappropriate ADH syndrome","canonical_id":"mondo:0006802","description":null,"metadata":null},{"id":"706a0335fded4b47ae581f8364f5916f","type":"DRUG","name":"inavolisib","canonical_id":"gtopdb:9636","description":null,"metadata":null},{"id":"056b1c30fc46423aa9002ebe7fb6087d","type":"DRUG","name":"inavolisib","canonical_id":"chembl:CHEMBL4650215","description":null,"metadata":null},{"id":"da88ac4d3849430d94a6403ee863bb48","type":"COMBINATION_TREATMENT","name":"inavolisib + letrozole","canonical_id":"ctgov_combo:ctgov-combo-88d7f14317b8e970","description":null,"metadata":null},{"id":"00da6811e2254de7866e070333205f1e","type":"COMBINATION_TREATMENT","name":"inavolisib + pralsetinib + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-d86020ce84c2d724","description":null,"metadata":null},{"id":"fc1b50d1f99a455b9c560d3d4347a7ee","type":"COMBINATION_TREATMENT","name":"inavolisib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-eb614e8afd45e102","description":null,"metadata":null},{"id":"881e5e756bec409694cced1b80a2b987","type":"DISEASE","name":"inborn disorder of amino acid metabolism","canonical_id":"mondo:0004736","description":null,"metadata":null},{"id":"8d7820de22c64f88bae1b27b9c1f18c8","type":"DISEASE","name":"inborn error of immunity","canonical_id":"mondo:0003778","description":null,"metadata":null},{"id":"4082e00753fb41fa963a70657fcb34c3","type":"DISEASE","name":"inborn errors of metabolism","canonical_id":"mondo:0019052","description":null,"metadata":null},{"id":"0ee5688be400411383072b195d5e590e","type":"DRUG","name":"incadronic acid","canonical_id":"mesh:C071542","description":null,"metadata":null},{"id":"7428b2141b9141a7aec0a23d2ea79582","type":"GO_TERM","name":"inchworm-type cell migration","canonical_id":"go:GO:0140350","description":"\"A type of amoeboid cell migration involving minimal contact between the cell and the surface, with the cell body standing upright and twisting, followed by rapid reattachment for directed movement.\" [PMID:40712579]","metadata":null},{"id":"2dde3e5d0fe7438583b301bd15972a47","type":"GO_TERM","name":"incipient cellular bud site","canonical_id":"go:GO:0000131","description":"\"The portion of the budding yeast plasma membrane where a daughter cell will emerge. The yeast marks this spot with bud-site selection proteins before bud emergence occurs. Actin is polarized to this spot just prior to and during bud emergence.\" [GOC:clt]","metadata":null},{"id":"288b6e0abfd344f8a6cd1c2a431da1e6","type":"GO_TERM","name":"inclusion body","canonical_id":"go:GO:0016234","description":"\"A discrete intracellular part formed of aggregated molecules such as proteins or other biopolymers.\" [GOC:mah, PMID:11121744]","metadata":null},{"id":"c15fb362e022494ea57507a16afe318e","type":"GO_TERM","name":"inclusion body assembly","canonical_id":"go:GO:0070841","description":"\"The aggregation, arrangement and bonding together of a set of components to form an inclusion body.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"9ddf0a9358654dda9f5f6b3f125993d6","type":"DRUG","name":"indacaterol","canonical_id":"gtopdb:7455","description":null,"metadata":null},{"id":"2ce840466d0944339b4308a933392f16","type":"COMBINATION_TREATMENT","name":"indacaterol + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-5615c940b0baaf72","description":null,"metadata":null},{"id":"b0eca7ba718f46a5b07eabedd25f4802","type":"COMBINATION_TREATMENT","name":"indacaterol + theophylline","canonical_id":"ctgov_combo:ctgov-combo-68c9573345bc7e3d","description":null,"metadata":null},{"id":"5fad886066db40228e709488be26350b","type":"COMBINATION_TREATMENT","name":"indacaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-74ed6aa8d4eb0ade","description":null,"metadata":null},{"id":"ea1f0c9dd71547af87a6d87287b49e6d","type":"COMBINATION_TREATMENT","name":"indacaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-de1d9591a3bb3fac","description":null,"metadata":null},{"id":"fab638b211834fc4b7d98c6ffc00d888","type":"COMBINATION_TREATMENT","name":"indacaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-788e1599e4aa4e50","description":null,"metadata":null},{"id":"862875c5c7764d3594d9f5acc77bc109","type":"COMBINATION_TREATMENT","name":"indacaterol + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-fc7008a37399e882","description":null,"metadata":null},{"id":"e4d968faae3b43548396e0137162ac2b","type":"GO_TERM","name":"indanol dehydrogenase activity","canonical_id":"go:GO:0047718","description":"\"Catalysis of the reaction: indan-1-ol + NAD(P)+ = indanone + NAD(P)H + H+.\" [EC:1.1.1.112, MetaCyc:INDANOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"16b04a2af1994ec984397bbf465ba9d8","type":"GO_TERM","name":"indeterminate inflorescence morphogenesis","canonical_id":"go:GO:0048283","description":"\"The process in which the anatomical structures of determinate inflorescences are generated and organized. A determinate inflorescence is one that can produce an undefined number of floral meristems.\" [GOC:jid]","metadata":null},{"id":"71e9486357b541a8ac83e92c7f98e0ee","type":"DRUG","name":"indinavir","canonical_id":"mesh:D019469","description":null,"metadata":null},{"id":"4137e08c11cb46f68eeb402b8da90c64","type":"GO_TERM","name":"indolalkylamine biosynthetic process","canonical_id":"go:GO:0046219","description":"\"The chemical reactions and pathways resulting in the formation of indolalkylamines, indole or indole derivatives containing a primary, secondary, or tertiary amine group.\" [GOC:curators]","metadata":null},{"id":"476795b38d43415da50cab9546a267c6","type":"GO_TERM","name":"indole 2,3-dioxygenase activity","canonical_id":"go:GO:0047719","description":"\"Catalysis of the reaction: indole + O2 = 2-formamidobenzaldehyde.\" [EC:1.13.11.17, RHEA:11212]","metadata":null},{"id":"aa774283d60b4dbb90668fcccbce1bea","type":"GO_TERM","name":"indole acetic acid carboxyl methyltransferase activity","canonical_id":"go:GO:0051749","description":"\"Catalysis of the reaction: indole acetic acid + S-adenosyl-methionine = methyl indole acetic acid ester + S-adenosyl-homocysteine.\" [PMID:16169896]","metadata":null},{"id":"ba459626ade745678e28e26a7d7a3004","type":"GO_TERM","name":"indole alkaloid biosynthetic process","canonical_id":"go:GO:0035835","description":"\"The chemical reactions and pathways resulting in the formation of an indole alkaloid, an alkaloid containing an indole skeleton.\" [GOC:yaf]","metadata":null},{"id":"b8b76cd4e8d340cdb8d8651a20d5a0d7","type":"GO_TERM","name":"indole alkaloid metabolic process","canonical_id":"go:GO:0035834","description":"\"The chemical reactions and pathways involving an indole alkaloid, an alkaloid containing an indole skeleton.\" [GOC:yaf]","metadata":null},{"id":"5e8f50e405a8488da3405d708e0b341b","type":"GO_TERM","name":"indole biosynthetic process","canonical_id":"go:GO:0042432","description":"\"The chemical reactions and pathways resulting in the formation of indole (2,3-benzopyrrole), the basis of many biologically active substances (e.g. serotonin, tryptophan).\" [GOC:jl]","metadata":null},{"id":"8a2025f1486647dd8d566fd82648ca2e","type":"GO_TERM","name":"indole catabolic process","canonical_id":"go:GO:0042433","description":"\"The chemical reactions and pathways resulting in the breakdown of indole (2,3-benzopyrrole), the basis of many biologically active substances (e.g. serotonin, tryptophan).\" [GOC:jl]","metadata":null},{"id":"12e56001bb19466a82e658bdb4df4b63","type":"GO_TERM","name":"indole glucosinolate biosynthetic process","canonical_id":"go:GO:0009759","description":"\"The chemical reactions and pathways resulting in the formation of indole glucosinolates, sulfur-containing compounds that have a common structure linked to an R group derived from tryptophan.\" [GOC:ai]","metadata":null},{"id":"2aba2d50944a48c39f7b6447e924fcbc","type":"GO_TERM","name":"indole glucosinolate catabolic process","canonical_id":"go:GO:0042344","description":"\"The chemical reactions and pathways resulting in the breakdown of indole glucosinolates, sulfur-containing compounds that have a common structure linked to an R group derived from tryptophan.\" [PMID:29122987]","metadata":null},{"id":"9f74d06886a04109a1b62dcfc08d3c92","type":"GO_TERM","name":"indole glucosinolate metabolic process","canonical_id":"go:GO:0042343","description":"\"The chemical reactions and pathways resulting in the formation of indole glucosinolates. Glucosinolates are sulfur-containing compounds that have a common structure linked to an R group derived from tryptophan; indoles are biologically active substances based on 2,3-benzopyrrole, formed during the catabolism of tryptophan.\" [GOC:curators]","metadata":null},{"id":"6748c760ec0d47f6ae3f6264cfaf1290","type":"GO_TERM","name":"indole metabolic process","canonical_id":"go:GO:0042431","description":"\"The chemical reactions and pathways involving indole (2,3-benzopyrrole), the basis of many biologically active substances (e.g. serotonin, tryptophan).\" [GOC:jl]","metadata":null},{"id":"1f3a53e181644e23ae9ebe6eb10b5190","type":"GO_TERM","name":"indole phytoalexin biosynthetic process","canonical_id":"go:GO:0009700","description":"\"The chemical reactions and pathways resulting in the formation of indole phytoalexins, any indole compound produced by plants as part of their defense response.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"a821314216964d5baf06d97cad235e53","type":"GO_TERM","name":"indole phytoalexin catabolic process","canonical_id":"go:GO:0046216","description":"\"The chemical reactions and pathways resulting in the breakdown of indole phytoalexins, any indole compound produced by plants as part of their defense response.\" [GOC:ai]","metadata":null},{"id":"762e80290124471cbf79bb64bb59a409","type":"GO_TERM","name":"indole-2-monooxygenase activity","canonical_id":"go:GO:0036190","description":"\"Catalysis of the reaction: indole + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + indolin-2-one + oxidized [NADPH--hemoprotein reductase].\" [RHEA:31899]","metadata":null},{"id":"092216008a2643c4b805db71eef4f5ab","type":"GO_TERM","name":"indole-3-acetaldehyde oxidase activity","canonical_id":"go:GO:0050302","description":"\"Catalysis of the reaction: H2O + indole-3-acetaldehyde + O2 = (indol-3-yl)acetate + H+ + H2O2.\" [RHEA:16277]","metadata":null},{"id":"18005a33785c40dbb53d301a92aa42cc","type":"GO_TERM","name":"indole-3-acetaldehyde reductase (NADH) activity","canonical_id":"go:GO:0047018","description":"\"Catalysis of the reaction: indole-3-ethanol + NAD+ = (indol-3-yl)acetaldehyde + H+ + NADH.\" [EC:1.1.1.190, RHEA:14873]","metadata":null},{"id":"2f7d54eb32814a2bbafb06e21b4d132b","type":"GO_TERM","name":"indole-3-acetaldehyde reductase (NADPH) activity","canonical_id":"go:GO:0047019","description":"\"Catalysis of the reaction: indole-3-ethanol + NADP+ = (indol-3-yl)acetaldehyde + H+ + NADPH.\" [EC:1.1.1.191, RHEA:17037]","metadata":null},{"id":"b8de663ea2cf46e6b03abe3ba9c54e04","type":"GO_TERM","name":"indole-3-acetate beta-glucosyltransferase activity","canonical_id":"go:GO:0047215","description":"\"Catalysis of the reaction: (indol-3-yl)acetate + UDP-D-glucose = 1-O-(indol-3-ylacetyl)-beta-D-glucose + UDP.\" [EC:2.4.1.121, RHEA:14921]","metadata":null},{"id":"53e3d43ef61c4d95872145721dd3ca19","type":"GO_TERM","name":"indole-3-acetate carboxyl methyltransferase activity","canonical_id":"go:GO:0103007","description":"\"Catalysis of the reaction: indole-3-acetate + S-adenosyl-L-methionine = methyl (indol-3-yl)acetate + S-adenosyl-L-homocysteine.\" [EC:2.1.1.278, GOC:pz]","metadata":null},{"id":"4d7b9a8b5402402697b9d1839fe0ebc1","type":"GO_TERM","name":"indole-3-acetic acid amido synthetase activity","canonical_id":"go:GO:0010279","description":"\"Catalysis of the reaction: indole-3-acetic acid + an amino acid = an indole-3-acetic acid amide conjugate.\" [PMID:15659623]","metadata":null},{"id":"460b08eb20f743219564bdce90978bfa","type":"GO_TERM","name":"indole-3-acetonitrile nitrilase activity","canonical_id":"go:GO:0080061","description":"\"Catalysis of the reaction: (indol-3-yl)acetonitrile + 2 H2O = (indol-3-yl)acetate + NH4+.\" [RHEA:45776]","metadata":null},{"id":"c40d05dd36594d30825a0cd1cc12c7f1","type":"GO_TERM","name":"indole-3-acetonitrile nitrile hydratase activity","canonical_id":"go:GO:0080109","description":"\"Catalysis of the reaction: indole-3-acetonitrile + H2O = indole-3-acetamide.\" [MetaCyc:RXN-7567, PMID:11607511, PMID:12430025]","metadata":null},{"id":"c226244bd0f242a68571b80ce01aee83","type":"GO_TERM","name":"indole-3-acetyl-glycine synthetase activity","canonical_id":"go:GO:0102047","description":"\"Catalysis of the reaction: indole-3-acetate + glycine + ATP(4-) = H+ + indole-3-acetyl-glycine + AMP(2-) + diphosphoric acid.\" [GOC:pz, PMID:15659623]","metadata":null},{"id":"4f4a535b865f4719abcb7754cdc9462a","type":"GO_TERM","name":"indole-3-acetyl-isoleucine synthetase activity","canonical_id":"go:GO:0102048","description":"\"Catalysis of the reaction: indole-3-acetate + L-isoleucine + ATP(4-) = H+ + indole-3-acetyl-isoleucine + AMP(2-) + diphosphoric acid.\" [GOC:pz, PMID:15659623]","metadata":null},{"id":"4a6cd84c326d49fa9c7b03809f03be24","type":"GO_TERM","name":"indole-3-acetyl-methionine synthetase activity","canonical_id":"go:GO:0102049","description":"\"Catalysis of the reaction: indole-3-acetate + L-methionine + ATP(4-) = H+ + indole-3-acetyl-methionine + AMP(2-) + diphosphoric acid.\" [GOC:pz, PMID:15659623]","metadata":null},{"id":"780f4170f0394e238a2f030a3fc95a61","type":"GO_TERM","name":"indole-3-butyrate beta-glucosyltransferase activity","canonical_id":"go:GO:0052638","description":"\"Catalysis of the reaction: indole-3-butyrate + UDP-D-glucose = indole-3-butyryl-beta-1-D-glucose + UDP.\" [MetaCyc:RXN-11655, RHEA:62708]","metadata":null},{"id":"635b8a1368e743c28aca19a1ab03c802","type":"GO_TERM","name":"indole-3-carbonyl nitrile 4-hydroxylase activity","canonical_id":"go:GO:0106149","description":"\"Catalysis of the reaction: indole-3-carbonyl nitrile + NADPH +O2=4-hydroxyindole-3- carbonyl nitrile + NADP+ + H20.\" [GOC:lr, PMID:26352477, RHEA:57864]","metadata":null},{"id":"ba676038e4fa40e2a07640628277c206","type":"GO_TERM","name":"indole-3-glycerol-phosphate lyase activity","canonical_id":"go:GO:0033984","description":"\"Catalysis of the reaction: (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate = indole + D-glyceraldehyde 3-phosphate.\" [EC:4.1.2.8]","metadata":null},{"id":"ac4f78b20bf642088f78e326fec55bd0","type":"GO_TERM","name":"indole-3-glycerol-phosphate synthase activity","canonical_id":"go:GO:0004425","description":"\"Catalysis of the reaction: 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate = 1-(indol-3-yl)glycerol 3-phosphate + CO2 + H2O.\" [EC:4.1.1.48]","metadata":null},{"id":"7f3dff5c710f419bb7424dec4ce892a6","type":"GO_TERM","name":"indole-3-pyruvate monooxygenase activity","canonical_id":"go:GO:0103075","description":"\"Catalysis of the reaction: 3-(indol-3-yl)pyruvate + NADPH + O2 + H+ = indole-3-acetate + carbon dioxide + NADP + H2O.\" [EC:1.14.13.168, GOC:pz]","metadata":null},{"id":"35fdc7b2864e44929b2be65c77d3e30b","type":"GO_TERM","name":"indole-containing compound biosynthetic process","canonical_id":"go:GO:0042435","description":"\"The chemical reactions and pathways resulting in the formation of compounds that contain an indole (2,3-benzopyrrole) skeleton.\" [GOC:jl]","metadata":null},{"id":"b8beb9bfc8a6449cbc551c999b475161","type":"GO_TERM","name":"indole-containing compound catabolic process","canonical_id":"go:GO:0042436","description":"\"The chemical reactions and pathways resulting in the breakdown of compounds that contain an indole (2,3-benzopyrrole) skeleton.\" [GOC:jl]","metadata":null},{"id":"85465df9adc24fd5b3d0a578aa3942d4","type":"GO_TERM","name":"indole-containing compound metabolic process","canonical_id":"go:GO:0042430","description":"\"The chemical reactions and pathways involving compounds that contain an indole (2,3-benzopyrrole) skeleton.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"6d709096bd96490fb1b2d84bb362ebab","type":"GO_TERM","name":"indoleacetaldoxime dehydratase activity","canonical_id":"go:GO:0047720","description":"\"Catalysis of the reaction: (indol-3-yl)acetaldehyde oxime = (indol-3-yl)acetonitrile + H2O.\" [RHEA:23156]","metadata":null},{"id":"1d15a013e9874d0e8da9276baebb49ac","type":"GO_TERM","name":"indoleacetamide hydrolase activity","canonical_id":"go:GO:0043864","description":"\"Catalysis of the reaction: iH2O + indole-3-acetamide = (indol-3-yl)acetate + NH4+. Indole-3-acetamide is known as IAM and indole-3-acetate as IAA.\" [GOC:jl, RHEA:34371]","metadata":null},{"id":"349a38caa25b45ffa145903aeae5a4bf","type":"GO_TERM","name":"indoleacetate-lysine synthetase activity","canonical_id":"go:GO:0047721","description":"\"Catalysis of the reaction: (indol-3-yl)acetate + L-lysine + ATP = N(6)-[(indole-3-yl)acetyl]-L-lysine + ADP + 2 H+ + phosphate.\" [EC:6.3.2.20, RHEA:14857]","metadata":null},{"id":"92ce0cc22d51430aa455fd3c34d00a44","type":"GO_TERM","name":"indoleacetic acid amide conjugate biosynthetic process","canonical_id":"go:GO:0033475","description":"\"The chemical reactions and pathways resulting in the formation of an indole-3-acetic acid amide conjugate, a form of indoleacetic acid covalently bound to an amino acid or polypeptide through an amide bond.\" [GOC:mah, MetaCyc:PWY-1782]","metadata":null},{"id":"4e5841d17d614099aa71b37eeb5a2355","type":"GO_TERM","name":"indoleacetic acid biosynthetic process","canonical_id":"go:GO:0009684","description":"\"The chemical reactions and pathways resulting in the formation of indole-3-acetic acid, a compound which functions as a growth regulator in plants.\" [PMID:12620340]","metadata":null},{"id":"f9b15c80d3364521aa727f64caa6dfcc","type":"GO_TERM","name":"indoleacetic acid catabolic process","canonical_id":"go:GO:0042437","description":"\"The chemical reactions and pathways resulting in the breakdown of indole-3-acetic acid, a compound which functions as a growth regulator in plants.\" [GOC:jl]","metadata":null},{"id":"3abaff6a11f149598d970c60ed7f2f37","type":"GO_TERM","name":"indoleacetic acid conjugate biosynthetic process","canonical_id":"go:GO:0033474","description":"\"The chemical reactions and pathways resulting in the formation of an indole-3-acetic acid conjugate, a form of indoleacetic acid covalently bound to another molecule.\" [GOC:mah]","metadata":null},{"id":"6e06092918d8486cbd7e2372803bea18","type":"GO_TERM","name":"indoleacetic acid conjugate metabolic process","canonical_id":"go:GO:0033473","description":"\"The chemical reactions and pathways involving any indole-3-acetic acid conjugate, a form of indoleacetic acid covalently bound to another molecule.\" [GOC:mah]","metadata":null},{"id":"6296f1b69d0f40ecacaa39bff886c487","type":"GO_TERM","name":"indoleacetylglucose-inositol O-acyltransferase activity","canonical_id":"go:GO:0047194","description":"\"Catalysis of the reaction: 1-O-(indol-3-ylacetyl)-beta-D-glucose + myo-inositol = 1L-1-O-(indol-3-yl)acetyl-myo-inositol + D-glucose.\" [EC:2.3.1.72, RHEA:21180]","metadata":null},{"id":"cc0b8c9a0a2c48c196247924772d927b","type":"GO_TERM","name":"indoleamine 2,3-dioxygenase activity","canonical_id":"go:GO:0033754","description":"\"Catalysis of the reaction: D-tryptophan + O2 = N-formyl-D-kynurenine.\" [RHEA:14189]","metadata":null},{"id":"672e3ff12c2149648cc86efb1adc5cb2","type":"GO_TERM","name":"indolebutyric acid metabolic process","canonical_id":"go:GO:0080024","description":"\"The chemical reactions and pathways involving indolebutyric acid, a compound that serves as an active or storage form of the hormone indole-3-acetic acid (an auxin) in many plants.\" [PMID:18725356]","metadata":null},{"id":"6e7e55646e3b41a6990fc66f5bf14ece","type":"GO_TERM","name":"indolelactate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047722","description":"\"Catalysis of the reaction: 3-(indol-3-yl)lactate + NAD+ = 3-(indol-3-yl)pyruvate + H+ + NADH.\" [RHEA:20133]","metadata":null},{"id":"833bd78801cc429784aaf2ce9f6fb4a8","type":"GO_TERM","name":"indolepyruvate C-methyltransferase activity","canonical_id":"go:GO:0030747","description":"\"Catalysis of the reaction: indole-3-pyruvate + S-adenosyl-L-methionine = (R)-3-(indol-3-yl)-2-oxobutanoate + H+ + S-adenosyl-L-homocysteine.\" [EC:2.1.1.47]","metadata":null},{"id":"2645b271306f471091aa4f999cdedecc","type":"GO_TERM","name":"indolepyruvate decarboxylase activity","canonical_id":"go:GO:0047434","description":"\"Catalysis of the reaction: indolepyruvate = CO2 + indole acetaldehyde.\" [EC:4.1.1.74, MetaCyc:4.1.1.74-RXN]","metadata":null},{"id":"512af20acd5e49c68e5fde15fb826247","type":"GO_TERM","name":"indolepyruvate ferredoxin oxidoreductase activity","canonical_id":"go:GO:0043805","description":"\"Catalysis of the reaction: (indol-3-yl)pyruvate + CoA + oxidized ferredoxin = S-2-(indol-3-yl)acetyl-CoA + CO2 + reduced ferredoxin.\" [EC:1.2.7.8]","metadata":null},{"id":"a8e3c05dbb9946b0a74f003fb9f7e360","type":"GO_TERM","name":"indolin-2-one monooxygenase activity","canonical_id":"go:GO:0036191","description":"\"Catalysis of the reaction: ndolin-2-one + reduced [NADPH-hemoprotein reductase] + O2 = 3-hydroxyindolin-2-one + oxidized [NADPH-hemoprotein reductase] + H2O + H+.\" [RHEA:31919]","metadata":null},{"id":"c0a12897e15542ed82348e17fddd4a31","type":"GO_TERM","name":"indolylacetyl-myo-inositol galactosyltransferase activity","canonical_id":"go:GO:0047227","description":"\"Catalysis of the reaction: 1L-1-O-(indol-3-yl)acetyl-myo-inositol + UDP-D-galactose = 5-O-(indol-3-ylacetyl)-myo-inositol D-galactoside + H+ + UDP.\" [EC:2.4.1.156, RHEA:21148]","metadata":null},{"id":"1a0b038c10104ded990a504ec247f8b3","type":"GO_TERM","name":"indolylacetylinositol arabinosyltransferase activity","canonical_id":"go:GO:0050409","description":"\"Catalysis of the reaction: 1L-1-O-(indol-3-yl)acetyl-myo-inositol + UDP-L-arabinose = (indol-3-yl)acetyl-myo-inositol 3-L-arabinoside + H+ + UDP.\" [EC:2.4.2.34, RHEA:19505]","metadata":null},{"id":"c1934b011ea342d9be74c7bb8ceb913a","type":"DRUG","name":"indomethacin","canonical_id":"mesh:D007213","description":null,"metadata":null},{"id":"b2647f15c93f436c93d642568a440088","type":"GO_TERM","name":"indoxyl-UDPG glucosyltransferase activity","canonical_id":"go:GO:0050507","description":"\"Catalysis of the reaction: indoxyl + UDP-D-glucose = H+ + indican + UDP.\" [EC:2.4.1.220, RHEA:12004]","metadata":null},{"id":"89e7d8ab92724355b2a737eb415f6ec7","type":"GO_TERM","name":"induced systemic resistance","canonical_id":"go:GO:0009682","description":"\"A response to non-pathogenic bacteria that confers broad spectrum systemic resistance to disease that does not depend upon salicylic acid signaling.\" [PMID:10234273, PMID:15233292, PMID:23386685]","metadata":null},{"id":"e92959ee98674c05901ac0adaa88dcea","type":"GO_TERM","name":"induced systemic resistance, ethylene mediated signaling pathway","canonical_id":"go:GO:0009866","description":"\"The series of molecular signals mediated by ethylene (ethene) involved in induced systemic resistance.\" [GOC:jy]","metadata":null},{"id":"fecfce5a84ac49c2ac8cceb44289d7fd","type":"GO_TERM","name":"induced systemic resistance, jasmonic acid mediated signaling pathway","canonical_id":"go:GO:0009864","description":"\"The series of molecular signals mediated by jasmonic acid involved in induced systemic resistance.\" [GOC:jy]","metadata":null},{"id":"6de739f2143a49c59767c51e8cb4c04b","type":"GO_TERM","name":"induction of bacterial agglutination","canonical_id":"go:GO:0043152","description":"\"Any process in which infecting bacteria are clumped together by a host organism.\" [GOC:jl]","metadata":null},{"id":"145bb1352e6646d49a65e218abdb7427","type":"GO_TERM","name":"induction of conjugation upon carbon starvation","canonical_id":"go:GO:0031141","description":"\"The process in which a cell initiates conjugation with cellular fusion upon carbon starvation.\" [GOC:mah]","metadata":null},{"id":"220ad3c29ef943c8bc7b49c7203a3d76","type":"GO_TERM","name":"induction of conjugation upon nitrogen starvation","canonical_id":"go:GO:0031142","description":"\"The process in which a cell initiates conjugation with cellular fusion upon nitrogen starvation.\" [GOC:mah]","metadata":null},{"id":"0a8315944c9748cda18317e4677b439c","type":"GO_TERM","name":"induction of conjugation upon nutrient starvation","canonical_id":"go:GO:0031140","description":"\"The process in which a cell initiates conjugation with cellular fusion upon starvation for one or more nutrients.\" [GOC:mah]","metadata":null},{"id":"4465a90cd3944885975acdbe1fcb6af0","type":"GO_TERM","name":"induction of negative chemotaxis","canonical_id":"go:GO:0050929","description":"\"Any process that initiates the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"7bb93490d721452ba910108b8a1565fc","type":"GO_TERM","name":"induction of positive chemotaxis","canonical_id":"go:GO:0050930","description":"\"Any process that initiates the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"3289efe1868a496aadcdf6c47e2ab0f8","type":"GO_TERM","name":"induction of programmed cell death","canonical_id":"go:GO:0012502","description":"\"A process which directly activates any of the steps required for programmed cell death.\" [GOC:lr]","metadata":null},{"id":"74734aa014a3454d8714082863001896","type":"GO_TERM","name":"induction of programmed cell death by ecdysone","canonical_id":"go:GO:0035078","description":"\"Any process induced by the steroid hormone 20-hydroxyecdysone (ecdysone) that directly activates any of the steps required for programmed cell death.\" [GOC:bf]","metadata":null},{"id":"2df36827c7b14a85b0b1c0caf6d81f33","type":"GO_TERM","name":"induction of programmed cell death by hormones","canonical_id":"go:GO:0035081","description":"\"Any process induced by hormones that directly activates any of the steps required for programmed cell death.\" [GOC:bf]","metadata":null},{"id":"4306694b996546d29335060bc1472350","type":"GO_TERM","name":"induction of synaptic plasticity by chemical substance","canonical_id":"go:GO:0051915","description":"\"The process in which a chemical substance activates synaptic plasticity, the ability of synapses to change as circumstances require.\" [GOC:ai]","metadata":null},{"id":"714d36772ff24746825c4226c4c60dca","type":"GO_TERM","name":"induction of synaptic vesicle exocytosis by positive regulation of presynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:0099703","description":"\"The induction of synaptic vesicle release by any process that leads to a rise in intracellular calcium ion concentration at the presynapse. This is the first step in synaptic transmission.\" [GOC:dos, ISBN:9780071120005]","metadata":null},{"id":"11c46e85d4cb4851a33a47d80953f885","type":"GO_TERM","name":"inductive cell migration","canonical_id":"go:GO:0040039","description":"\"Migration of a cell in a multicellular organism that, having changed its location, is required to induce normal properties in one or more cells at its new location. An example of this would be the distal tip cells of Caenorhabditis elegans.\" [ISBN:087969307X, ISBN:0879694882]","metadata":null},{"id":"2ec4781250f24e4881b2f53cd56a9ed6","type":"GO_TERM","name":"inductive cell-cell signaling","canonical_id":"go:GO:0031129","description":"\"Signaling at short range between cells of different ancestry and developmental potential that results in one cell or group of cells effecting a developmental change in the other. This is often done by secretion of proteins by one cell which affects the neighboring cells and causes them to adopt a certain fate.\" [GOC:mah]","metadata":null},{"id":"5e785aed2d744521acaf0e0e2b408685","type":"GO_TERM","name":"inductive cell-cell signaling between paraxial mesoderm and motor neuron precursors","canonical_id":"go:GO:0021916","description":"\"Short range signaling between cells of the paraxial mesoderm and motor neuron precursors in the spinal cord that specifies the fate of the motor column neuron precursors along the anterior-posterior axis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"a158f659ce18465c9c5e0b7fc427d24a","type":"GO_TERM","name":"inductive mesenchymal to epithelial cell signaling","canonical_id":"go:GO:0060522","description":"\"Signaling at short range from mesenchymal cells to cells of an epithelium that results in a developmental change in the epithelial cells.\" [GOC:dph]","metadata":null},{"id":"0cce8b8f072b4f919f2146d7d8c0ae0d","type":"GO_TERM","name":"inductive mesenchymal-endodermal cell signaling","canonical_id":"go:GO:0060494","description":"\"Any process that mediates the transfer of information from a mesenchymal cell to an endodermal cell changing the fate of the endodermal cell.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"20f328c3c032410ea2797cc862257f9a","type":"DRUG","name":"inebilizumab","canonical_id":"gtopdb:7992","description":null,"metadata":null},{"id":"f8247ff444904683aed98bab56cab1c7","type":"DRUG","name":"inebilizumab","canonical_id":"chembl:CHEMBL2109334","description":null,"metadata":null},{"id":"07663847835d43258efaca17bbcc7881","type":"COMBINATION_TREATMENT","name":"inebilizumab + ravulizumab + satralizumab","canonical_id":"ctgov_combo:ctgov-combo-0b9cdb3256df2024","description":null,"metadata":null},{"id":"55b7c08f510d439fbac6871da51ac017","type":"DISEASE","name":"infantile epileptic encephalopathy","canonical_id":"efo:1000643","description":null,"metadata":null},{"id":"c96ecefeac0e4fbbb8c67d51d54ff76b","type":"DISEASE","name":"infantile myofibromatosis","canonical_id":"mondo:0016824","description":null,"metadata":null},{"id":"1c316b6df21d4adfaf2b0d4e930f7d98","type":"DISEASE","name":"infantile spasms","canonical_id":"mondo:0018097","description":null,"metadata":null},{"id":"34c04a0bb6724827a946810fc354e100","type":"GO_TERM","name":"infected host cell surface knob","canonical_id":"go:GO:0020030","description":"\"Protrusion that develops in the plasma membrane of a parasitized erythrocyte. An example of this component is found in Plasmodium species.\" [GOC:mb]","metadata":null},{"id":"8ad1598ab6d84211a8b962918f7decbf","type":"DISEASE","name":"infection","canonical_id":"efo:0000544","description":null,"metadata":null},{"id":"ddb977ea8103472b9679c0b438bd64f8","type":"GO_TERM","name":"infection cushion formation","canonical_id":"go:GO:0075183","description":"\"The process in which an organized mass of hyphae is formed and numerous infective hyphae develop from the hyphae mass.\" [GOC:pamgo_curators]","metadata":null},{"id":"3497ccd2566748af97beaf4d485bd808","type":"DISEASE","name":"infectious disease","canonical_id":"mondo:0005550","description":null,"metadata":null},{"id":"3ca7d3f9b6404f13ba4f2e6d4ec35557","type":"GO_TERM","name":"inferior colliculus development","canonical_id":"go:GO:0061379","description":"\"The process whose specific outcome is the progression of the inferior colliculus over time, from its formation to the mature structure. The inferior colliculus (IC) (Latin, lower hill) is the principal midbrain nucleus of the auditory pathway and receives input from several more peripheral brainstem nuclei in the auditory pathway, as well as inputs from the auditory cortex. The inferior colliculus has three subdivisions: the central nucleus (CIC), a dorsal cortex (DCIC) by which it is surrounded, and an external cortex (ICX) which is located laterally.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"4fd80e72071644e6862f5477a5711b5c","type":"GO_TERM","name":"inferior endocardial cushion morphogenesis","canonical_id":"go:GO:1905317","description":"\"The developmental process by which an inferior endocardial cushion is generated and organized.\" [GO_REF:0000083, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17050629]","metadata":null},{"id":"c4d14a5f1d714f24b80de7fc5fb17df7","type":"GO_TERM","name":"inferior olivary nucleus development","canonical_id":"go:GO:0021713","description":"\"The process whose specific outcome is the progression of the inferior olivary nucleus over time, from its formation to the mature structure. The inferior olivary nucleus is a capsule-shaped structure in the ventral medulla located just lateral and dorsal to the medullary pyramids. Neurons in the inferior olivary nucleus are the source of climbing fiber input to the cerebellar cortex; these neurons have been implicated in various functions, such as learning and timing of movements.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"73b680f0f9964cd099f72bb0b0e7a570","type":"GO_TERM","name":"inferior olivary nucleus formation","canonical_id":"go:GO:0021715","description":"\"The process that gives rise to the inferior olivary nucleus. This process pertains to the initial formation of a structure from unspecified parts. The inferior olivary nucleus is a capsule-shaped structure in the ventral medulla located just lateral and dorsal to the medullary pyramids. Neurons in the inferior olivary nucleus are the source of climbing fiber input to the cerebellar cortex; these neurons have been implicated in various functions, such as learning and timing of movements.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"faaa76b5b1b64e6daf33ba85b8c4a7dd","type":"GO_TERM","name":"inferior olivary nucleus maturation","canonical_id":"go:GO:0021717","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the inferior olivary nucleus to attain its fully functional state. The inferior olivary nucleus is a capsule-shaped structure in the ventral medulla located just lateral and dorsal to the medullary pyramids. Neurons in the inferior olivary nucleus are the source of climbing fiber input to the cerebellar cortex; these neurons have been implicated in various functions, such as learning and timing of movements.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"3d8c6a11efcb41d393af9b696404fac7","type":"GO_TERM","name":"inferior olivary nucleus morphogenesis","canonical_id":"go:GO:0021714","description":"\"The process in which the anatomical structure of the inferior olivary nucleus is generated and organized. The inferior olivary nucleus is a capsule-shaped structure in the ventral medulla located just lateral and dorsal to the medullary pyramids. Neurons in the inferior olivary nucleus are the source of climbing fiber input to the cerebellar cortex; these neurons have been implicated in various functions, such as learning and timing of movements.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"c6c4e5117fbb4d6c993797d35ed08356","type":"GO_TERM","name":"inferior olivary nucleus structural organization","canonical_id":"go:GO:0021716","description":"\"The process that contributes to the act of creating the structural organization of the inferior olivary nucleus structure. The inferior olivary nucleus is a capsule-shaped structure in the ventral medulla located just lateral and dorsal to the medullary pyramids. Neurons in the inferior olivary nucleus are the source of climbing fiber input to the cerebellar cortex; these neurons have been implicated in various functions, such as learning and timing of movements.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"0b69de5d6cd34b1eb22905e0c84049bc","type":"GO_TERM","name":"inferior raphe nucleus development","canonical_id":"go:GO:0021724","description":"\"The process whose specific outcome is the progression of the inferior raphe nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cjm, GOC:cls, GOC:curators, GOC:cvs, GOC:dgh, GOC:dph, GOC:jid, PMID:19003874, ZFA:0000366]","metadata":null},{"id":"740368836f884bfc8e35f69ad8946f9e","type":"GO_TERM","name":"inferior reticular formation development","canonical_id":"go:GO:0021728","description":"\"The process whose specific outcome is the progression of the inferior reticular formation over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"f0c8fb7bc0a143059983886f011fd607","type":"GO_TERM","name":"inferior salivary nucleus development","canonical_id":"go:GO:0021752","description":"\"The process whose specific outcome is the progression of the inferior salivary nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e0941916516e440ba19b5338a94c230c","type":"DISEASE","name":"infertility disorder","canonical_id":"mondo:0005047","description":null,"metadata":null},{"id":"4684865868e2498dae1ea17054a4d677","type":"DRUG","name":"infigratinib","canonical_id":"gtopdb:7877","description":null,"metadata":null},{"id":"8811d5f4cc374629954d43026990ec45","type":"DRUG","name":"infigratinib","canonical_id":"chembl:CHEMBL1852688","description":null,"metadata":null},{"id":"fb8fc77fdd2c4bd88abff2fa8c04c9d5","type":"GO_TERM","name":"inflammasome-mediated signaling pathway","canonical_id":"go:GO:0141084","description":"\"An intracellular signal transduction pathway that starts with a ligand binding to a pattern recognition receptor (PRR), assembly of the inflammasome complex, leading to the activation of CASP1 and inducing an inflammatory response. In some cases, inflammasome-mediated signal transduction can lead to programmed cell death, such as pyroptosis.\" [PMID:35883561]","metadata":null},{"id":"6f7be71dad1c4e84be26b88a1f0d344d","type":"DISEASE","name":"inflammation","canonical_id":"mp:0001845","description":null,"metadata":null},{"id":"82e06b9a3ec846549328e16d90d0bbdc","type":"DISEASE","name":"inflammatory bowel disease","canonical_id":"mondo:0005265","description":null,"metadata":null},{"id":"db71b221ce2242d6a981020786cc1a92","type":"GO_TERM","name":"inflammatory cell apoptotic process","canonical_id":"go:GO:0006925","description":"\"Any apoptotic process in an inflammatory cell, any cell participating in the inflammatory response to a foreign substance e.g. neutrophil, macrophage.\" [GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"9680fbbb9e5347bd84f51a18157a0438","type":"DISEASE","name":"inflammatory myofibroblastic tumor","canonical_id":"mondo:0015798","description":null,"metadata":null},{"id":"35482aeb59e14e8c9dfa9caf29ff9484","type":"GO_TERM","name":"inflammatory response","canonical_id":"go:GO:0006954","description":"\"The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.\" [GO_REF:0000022, ISBN:0198506732]","metadata":null},{"id":"f3d7a4b546fe4504a1ca7777a98ba440","type":"GO_TERM","name":"inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002437","description":"\"An inflammatory response to an antigenic stimulus, which can be include any number of T cell or B cell epitopes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"e2cebcb3488d4580899b4140199a7d16","type":"GO_TERM","name":"inflammatory response to wounding","canonical_id":"go:GO:0090594","description":"\"The immediate defensive reaction by vertebrate tissue to injury caused by chemical or physical agents.\" [GOC:add]","metadata":null},{"id":"e5fd9951f63e4a4988e05bff150fd48e","type":"DISEASE","name":"inflammatory skin and bowel disease, neonatal, 2","canonical_id":"mondo:0014481","description":null,"metadata":null},{"id":"d11c2a187a894b4387195f8930381c31","type":"DRUG","name":"infliximab","canonical_id":"gtopdb:5004","description":null,"metadata":null},{"id":"906dc7c8906441c19f8182e2270fe597","type":"DRUG","name":"infliximab","canonical_id":"chembl:CHEMBL1201581","description":null,"metadata":null},{"id":"096b347d15d34726a16e8870f11d68c8","type":"COMBINATION_TREATMENT","name":"infliximab + relatlimab","canonical_id":"ctgov_combo:ctgov-combo-e8113bcf8c057c3f","description":null,"metadata":null},{"id":"ae4ae383667448c38051dac250ec0786","type":"COMBINATION_TREATMENT","name":"infliximab + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-a2d4ee9cd947490f","description":null,"metadata":null},{"id":"79f77a2b531647a9b0a5f600e0788336","type":"GO_TERM","name":"inflorescence development","canonical_id":"go:GO:0010229","description":"\"The process whose specific outcome is the progression of an inflorescence over time, from its formation to the mature structure.\" [GOC:tb]","metadata":null},{"id":"3d0f20f1b7e944579ad750820b118cb8","type":"GO_TERM","name":"inflorescence meristem growth","canonical_id":"go:GO:0010450","description":"\"The increase in size or mass of an inflorescence meristem, a population of undifferentiated cells in a plant shoot which produces small leaves and then floral meristems, which will give rise to flowers.\" [GOC:tb]","metadata":null},{"id":"36305cabd3504d1f8cdd0b2508ffb025","type":"GO_TERM","name":"inflorescence morphogenesis","canonical_id":"go:GO:0048281","description":"\"The process in which the anatomical structures of inflorescences are generated and organized. An inflorescence is the part of a seed plant body that is usually above ground and that can bear flowers.\" [GOC:jid]","metadata":null},{"id":"87831934be4c4160bccc476945762d36","type":"GO_TERM","name":"inflorescence phyllotactic patterning","canonical_id":"go:GO:0090643","description":"\"The radial pattern formation process that results in the formation of flowers around a central axis in an inflorescence meristem.\" [PMID:25352850]","metadata":null},{"id":"41b3a438a315471d99b5ab6bff33f5b0","type":"DRUG","name":"ingenol mebutate","canonical_id":"gtopdb:7443","description":null,"metadata":null},{"id":"0c323e7e0a0241d5a26f31944794faac","type":"GO_TERM","name":"ingression involved in gastrulation with mouth forming second","canonical_id":"go:GO:0055111","description":"\"The migration of individual cells into the embryo involved in deuterostomic gastrulation.\" [ISBN:0878932437]","metadata":null},{"id":"d4761c62a6e048f89484316be0f42ec8","type":"DISEASE","name":"inherited lipid metabolism disorder","canonical_id":"mondo:0002525","description":null,"metadata":null},{"id":"34305b46c9584fd5a36b97ead39c4cdc","type":"DISEASE","name":"inherited obesity","canonical_id":"mondo:0019182","description":null,"metadata":null},{"id":"46c91fba7e1b4e599b5ff310d99c50fb","type":"DISEASE","name":"inherited prekallikrein deficiency","canonical_id":"mondo:0012901","description":null,"metadata":null},{"id":"106c1ab290fc410bbc01d64f7fde43f9","type":"DISEASE","name":"inherited retinal dystrophy","canonical_id":"mondo:0019118","description":null,"metadata":null},{"id":"2b590864c8364acf8a53cffe5d30c939","type":"GO_TERM","name":"inhibin A complex","canonical_id":"go:GO:0043512","description":"\"Heterodimeric hormone composed of an inhibin alpha subunit complexed with an inhibin beta-A subunit.\" [GOC:jl]","metadata":null},{"id":"a54a2f396cd740989fb30c2d57b3c1fc","type":"GO_TERM","name":"inhibin B complex","canonical_id":"go:GO:0043513","description":"\"Heterodimeric hormone composed of an inhibin alpha subunit complexed with an inhibin beta-B subunit.\" [GOC:jl]","metadata":null},{"id":"daf6f3523602442180dc5f6d44f59a26","type":"GO_TERM","name":"inhibin binding","canonical_id":"go:GO:0034711","description":"\"Binding to an inhibin monomer, any of the polypeptides that combine to form activin and inhibin dimers.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"2e19c646ede6463e9d179b0486e36ddd","type":"GO_TERM","name":"inhibin complex","canonical_id":"go:GO:0043511","description":"\"Heterodimeric hormone composed of an inhibin alpha subunit complexed with either an inhibin beta-A subunit, to form inhibin A, or an inhibin beta-B subunit, to form inhibin B.\" [GOC:jl]","metadata":null},{"id":"6ed3d24fe7b043318730081a4fa2a2e2","type":"GO_TERM","name":"inhibin complex binding","canonical_id":"go:GO:0034710","description":"\"Binding to an inhibin complex, a dimer of one inhibin-alpha subunit and one inhibin-beta subunit.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a0c605ca392643a5b6533de9c9c8e87f","type":"GO_TERM","name":"inhibin secretion","canonical_id":"go:GO:0032334","description":"\"The regulated release of an inhibin, either of two glycoproteins (designated A and B), secreted by the gonads and present in seminal plasma and follicular fluid, that inhibit pituitary production of follicle-stimulating hormone.\" [GOC:mah]","metadata":null},{"id":"15d2687b1baa495fafe5f1da34aa0acb","type":"GO_TERM","name":"inhibin-betaglycan-ActRII complex","canonical_id":"go:GO:0034673","description":"\"A protein complex that consists of inhibin, type III transforming growth factor beta receptor (also known as betaglycan), and the type II activin receptor ActRII. The complex is thought to negatively regulate the activity of activin B.\" [GOC:BHF, PMID:10746731]","metadata":null},{"id":"b461855025e740739b126593c10c519e","type":"GO_TERM","name":"inhibition of acetylcholine uptake","canonical_id":"go:GO:0051634","description":"\"Any process that prevents the activation of the directed movement of acetylcholine into a cell.\" [GOC:ai]","metadata":null},{"id":"90c8a95f293b4271bacc9c39c1f14444","type":"GO_TERM","name":"inhibition of epinephrine uptake","canonical_id":"go:GO:0051629","description":"\"Any process that prevents the activation of the directed movement of epinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"be41a90541a349b9bd5ec99621f13891","type":"GO_TERM","name":"inhibition of histamine uptake","canonical_id":"go:GO:0051619","description":"\"Any process that prevents the activation of the directed movement of histamine into a cell.\" [GOC:ai]","metadata":null},{"id":"bd34d845a53049f38aea77fecb1e0768","type":"GO_TERM","name":"inhibition of neuroepithelial cell differentiation","canonical_id":"go:GO:0002085","description":"\"Any process that prevents the activation of neuroepithelial cell differentiation. Neuroepithelial cell differentiation is the process in which epiblast cells acquire specialized features of neuroepithelial cells.\" [GOC:dph, PMID:16678814]","metadata":null},{"id":"157b1e437dc54e4b9626b99de64c0dbe","type":"GO_TERM","name":"inhibition of neurotransmitter uptake","canonical_id":"go:GO:0051609","description":"\"Any process that prevents the activation of the directed movement of a neurotransmitter into a cell.\" [GOC:ai]","metadata":null},{"id":"b24ba3c065aa4f1cb8a18644c9decc30","type":"GO_TERM","name":"inhibition of non-skeletal tissue mineralization","canonical_id":"go:GO:0140928","description":"\"A homeostatic process involved in the maintenance of non-mineral tissue, by preventing mineralization of non-skeletal tissue.\" [PMID:21490328, PMID:30030150]","metadata":null},{"id":"fae293d4bf7b487cbc6189fc2585a5e3","type":"GO_TERM","name":"inhibition of norepinephrine uptake","canonical_id":"go:GO:0051624","description":"\"Any process that prevents the activation of the directed movement of norepinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"229814fa5eb747a6af2b23a723e887e4","type":"GO_TERM","name":"inhibition of serotonin uptake","canonical_id":"go:GO:0051614","description":"\"Any process that prevents the activation of the directed movement of serotonin into a cell.\" [GOC:ai]","metadata":null},{"id":"ab2fdeb512fb44228659de01f955e037","type":"GO_TERM","name":"inhibitory C-type lectin receptor signaling pathway","canonical_id":"go:GO:0002772","description":"\"The series of molecular signals initiated by an extracellular ligand binding to an inhibitory C-type lectin receptor capable of inhibiting an immune effector process contributing to an immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"97087f02b0cd4189ae3f7398ac234000","type":"GO_TERM","name":"inhibitory G protein-coupled receptor phosphorylation","canonical_id":"go:GO:0002030","description":"\"The process that inhibits the signaling function of a G protein-coupled receptor by addition of a phosphate group to its third intracellular loop consensus site.\" [PMID:8396717]","metadata":null},{"id":"2371c94531ac41c3be5abcd6702dff20","type":"GO_TERM","name":"inhibitory MHC class I receptor activity","canonical_id":"go:GO:0032396","description":"\"Combining with a MHC class I protein complex to mediate signaling that inhibits activation of a lymphocyte.\" [GOC:add, PMID:11858820, PMID:9368779, PMID:9597134]","metadata":null},{"id":"d274484efda640278431986759efb506","type":"GO_TERM","name":"inhibitory MHC class Ib receptor activity","canonical_id":"go:GO:0062080","description":"\"Combining with a MHC class Ib protein complex to mediate signaling that inhibits activation of a lymphocyte.\" [DOI:10.1002/9780470015902.a0024246]","metadata":null},{"id":"ef0acf8d009a451792349b8f782cfa5e","type":"GO_TERM","name":"inhibitory chemical synaptic transmission","canonical_id":"go:GO:0098977","description":"\"Synaptic transmission that results in an inhibitory postsynaptic potential.\" [GOC:dos]","metadata":null},{"id":"53f569bbc43c458c9e2abe0c098f641b","type":"GO_TERM","name":"inhibitory extracellular ligand-gated monoatomic ion channel activity","canonical_id":"go:GO:0005237","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific extracellular inhibitory ligand has been bound by the channel complex or one of its constituent parts. Inhibitory ligands, such as GABA or glycine, open chloride-selective channels.\" [GOC:mah, ISBN:0323037070]","metadata":null},{"id":"b0f799371db84d2e94b1242ce39e14ca","type":"GO_TERM","name":"inhibitory killer cell immunoglobulin-like receptor signaling pathway","canonical_id":"go:GO:0002771","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a inhibitory killer cell immunoglobulin-like receptor capable of inhibiting an immune effector process contributing to an immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"2099394073a64c44aa07cefd0427fc0b","type":"GO_TERM","name":"inhibitory neuromuscular junction","canonical_id":"go:GO:0098521","description":"\"The junction between the axon of a motor neuron and a muscle fiber. In response to the arrival of action potentials, the presynaptic button releases molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane of the muscle fiber, leading to a change in post-synaptic potential that inhibits muscle contraction.\" [GOC:dos]","metadata":null},{"id":"eba9f4423dc94f479189080ef543416d","type":"GO_TERM","name":"inhibitory neuromuscular junction of somatic myotube","canonical_id":"go:GO:0098526","description":"\"A neuromuscular junction that functions in the inhibition of somatic muscle myotube contraction. Examples of somatic muscle myotubes include the somatic muscle cells of arthropods.\" [GOC:dos]","metadata":null},{"id":"7cfedb9be89b4295b09906256e862e5f","type":"GO_TERM","name":"inhibitory postsynaptic potential","canonical_id":"go:GO:0060080","description":"\"A process that causes a temporary decrease in postsynaptic membrane potential due to the flow of negatively charged ions into the postsynaptic cell. The flow of ions that causes an IPSP is an inhibitory postsynaptic current (IPSC) and makes it more difficult for the neuron to fire an action potential.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"1d5730386d5d4d3e9fabda4e5c90a33c","type":"GO_TERM","name":"inhibitory synapse","canonical_id":"go:GO:0060077","description":"\"A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"f635d2788c2a43f983ffb908bd5386b5","type":"GO_TERM","name":"inhibitory synapse assembly","canonical_id":"go:GO:1904862","description":"\"The aggregation, arrangement and bonding together of a set of components to form an inhibitory synapse.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"82a0419e65374326aec07425da34cf88","type":"GO_TERM","name":"initial meiotic spindle pole body separation","canonical_id":"go:GO:0140456","description":"\"The release of duplicated meiotic spindle pole bodies (SPBs).\" [PMID:31532702]","metadata":null},{"id":"3d9cb936a8da4f54bdd57ab113342166","type":"GO_TERM","name":"initial mitotic spindle pole body separation","canonical_id":"go:GO:0000073","description":"\"The release of duplicated mitotic spindle pole bodies (SPBs) that begins with the nucleation of microtubules from each SPB within the nucleus, leading to V-shaped spindle microtubules. Interpolar microtubules that elongate from each pole are interconnected, forming overlapping microtubules. Capturing and antiparallel sliding apart of microtubules promotes the initial separation of the SPB.\" [GOC:sgd_curators, GOC:vw]","metadata":null},{"id":"05e5a0d3ddd74f30b8bab186774a1c44","type":"GO_TERM","name":"initiation of appressorium formation","canonical_id":"go:GO:0075025","description":"\"The process in which a relatively unspecialized cell starts to acquire specialized features of the symbiont appressorium to aid in infection of the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"487d398300fa48489110428c31242602","type":"GO_TERM","name":"initiation of dorsal closure","canonical_id":"go:GO:0007392","description":"\"Events that occur at the start of dorsal closure.\" [GOC:bf]","metadata":null},{"id":"4effa0e72d2e4d329dd4d41493e8b93d","type":"GO_TERM","name":"initiation of neural tube closure","canonical_id":"go:GO:0021993","description":"\"The process in which closure points are established at multiple points and along the neural rostrocaudal axis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"efcc02b391734f4ca9a2f31b702ed325","type":"GO_TERM","name":"initiation of primordial ovarian follicle growth","canonical_id":"go:GO:0001544","description":"\"Increase in size of primordial follicles including proliferation and shape changes of granulosa and/or theca cells until oocyte is surrounded by one layer of cuboidal shaped granulosa cells (primary follicle).\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"332602dd05d84da089fc87b676b8c56d","type":"GO_TERM","name":"initiation-specific glycolipid 1,6-alpha-mannosyltransferase activity","canonical_id":"go:GO:0033164","description":"\"Catalysis of the transfer of an alpha-D-mannosyl residue from GDP-mannose to Man(8)GlcNAc or Man(9)GlcNAc via an alpha-(1->6)-D-mannosyl-D-mannose linkage to form Man(9)GlcNAc or Man(10)GlcNAc, respectively. This is the first step specific to the biosynthesis of the outer chain of yeast mannoproteins.\" [EC:2.4.1.232, PMID:2644248]","metadata":null},{"id":"740c35476fba40909d7029b25735b923","type":"GO_TERM","name":"initiator methionyl aminopeptidase activity","canonical_id":"go:GO:0004239","description":"\"Catalysis of the release of N-terminal initiator methionine from peptides.\" [EC:3.4.11.18]","metadata":null},{"id":"707cbbf168d340899fd14e990ffec31c","type":"DISEASE","name":"injury","canonical_id":"mondo:0021178","description":null,"metadata":null},{"id":"cd3948d3638b436fb2e6374462516689","type":"GO_TERM","name":"innate immune receptor activity","canonical_id":"go:GO:0140376","description":"\"Receiving a signal and transmitting it in a cell to initiate an innate immune response.\" [PMID:28921463, PMID:31415752]","metadata":null},{"id":"c07d8d295f434fa09eba0c97502cd1ed","type":"GO_TERM","name":"innate immune response","canonical_id":"go:GO:0045087","description":"\"Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.\" [GO_REF:0000022, GOC:add, GOC:ebc, GOC:mtg_sensu]","metadata":null},{"id":"21363d33d25b4de494b86070c835c2b9","type":"GO_TERM","name":"innate immune response activating cell surface receptor signaling pathway","canonical_id":"go:GO:0002220","description":"\"The series of molecular signals initiated by a ligand binding to a cell surface receptor that leads to the activation of an innate immune response.\" [GOC:add, ISBN:0781735149, PMID:15199967]","metadata":null},{"id":"ffa8f360e4fd4733a02113c9ebc7931b","type":"GO_TERM","name":"innate immune response in mucosa","canonical_id":"go:GO:0002227","description":"\"Any process of the innate immune response that takes place in the mucosal tissues.\" [GOC:add, PMID:10719665, PMID:15971105]","metadata":null},{"id":"ffc239e7e37d475bba4d81bae7691004","type":"GO_TERM","name":"innate immune response-activating signaling pathway","canonical_id":"go:GO:0002758","description":"\"The series of molecular signals generated by a ligand binding to its receptor that lead to the activation or perpetuation of an innate immune response.\" [GOC:jy, GOC:mah, PMID:11418339, PMID:28105028]","metadata":null},{"id":"3d4b2dcb0b334b72b6c400695024c0bc","type":"GO_TERM","name":"innate immune response-inhibiting signal transduction","canonical_id":"go:GO:0002766","description":"\"The cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately leading to inhibition of an innate immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"0a7e0394644d40408919c833ccffb328","type":"GO_TERM","name":"innate immunity memory response","canonical_id":"go:GO:0090714","description":"\"An immune response mediated by the innate immune system and directed against a previously encountered immunologic stimulus, being quicker and quantitatively better compared with the initial response to that stimulus.\" [GOC:add, PMID:26086132]","metadata":null},{"id":"87e1a21c0c2d4eb98aa3ec1d751f6858","type":"GO_TERM","name":"innate vocalization behavior","canonical_id":"go:GO:0098582","description":"\"A vocalisation behavior that is innate, i.e. that does not need to be learned in order to occur.\" [GOC:BHF, GOC:dos, GOC:rl]","metadata":null},{"id":"e4bb87df71ed4a799b6ba4540bb52734","type":"GO_TERM","name":"inner acrosomal membrane","canonical_id":"go:GO:0002079","description":"\"The acrosomal membrane region that underlies the acrosomal vesicle and is located toward the sperm nucleus. This region is responsible for molecular interactions allowing the sperm to penetrate the zona pellucida and fuses with the egg plasma membrane.\" [GOC:dph, PMID:3899643, PMID:8936405]","metadata":null},{"id":"687dbc8f5e2f441ba4c14d91c9edcfa4","type":"GO_TERM","name":"inner cell mass cell differentiation","canonical_id":"go:GO:0001826","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an inner cell mass cell.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"21aac3e5ace649c4bf504fae3e1c867e","type":"GO_TERM","name":"inner cell mass cell fate commitment","canonical_id":"go:GO:0001827","description":"\"The cell fate commitment of precursor cells that will become inner cell mass cells.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"457695e2b3914b47b65c4555fee71f87","type":"GO_TERM","name":"inner cell mass cell proliferation","canonical_id":"go:GO:0001833","description":"\"The proliferation of cells in the inner cell mass.\" [GOC:dph, GOC:isa_complete, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"6c8a5b7109aa4dc1bcec5fcb123131bf","type":"GO_TERM","name":"inner cell mass cellular morphogenesis","canonical_id":"go:GO:0001828","description":"\"The morphogenesis of cells in the inner cell mass.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"441759711c054179b02eaac159c520a5","type":"GO_TERM","name":"inner dense plaque of desmosome","canonical_id":"go:GO:0090637","description":"\"The desmosomal part containing the C-termini of desmoplakins which interact with the keratin intermediate filaments, serving to tether the intermediate filaments to the plasma membrane.\" [PMID:20066089]","metadata":null},{"id":"623c277d64c9429c95f8e7b92c475024","type":"GO_TERM","name":"inner dynein arm","canonical_id":"go:GO:0036156","description":"\"Inner arm structure present on the outer doublet microtubules of ciliary and flagellar axonemes. The structure of inner dynein arms is complex and may vary within the axoneme. Inner dynein arms are heteromeric, comprising 8 different heavy chains and various subunits. Inner and outer dynein arms have different functions in the generation of microtubule-based motility.\" [GOC:BHF, GOC:vk, PMID:19347929, PMID:2557057, PMID:7962092]","metadata":null},{"id":"452e5d6dfd0845faafc63814a24f39e4","type":"GO_TERM","name":"inner dynein arm assembly","canonical_id":"go:GO:0036159","description":"\"The aggregation, arrangement and bonding together of a set of components to form an axonemal dynein inner arm, an inner arm structure present on the outer doublet microtubules of ciliary and flagellar axonemes.\" [GOC:BHF, GOC:vk, PMID:19944400]","metadata":null},{"id":"b6c84832a5294c85883a56b70415ccdd","type":"GO_TERM","name":"inner ear auditory receptor cell differentiation","canonical_id":"go:GO:0042491","description":"\"The process in which a relatively unspecialized inner cell acquires specialized features of an auditory hair cell.\" [CL:0000201, GOC:jl]","metadata":null},{"id":"e2db0a29bd9b455d815304b58f0015b1","type":"GO_TERM","name":"inner ear development","canonical_id":"go:GO:0048839","description":"\"The process whose specific outcome is the progression of the inner ear over time, from its formation to the mature structure.\" [GOC:sr]","metadata":null},{"id":"4f2c3306b58f4df1bcc5daa3ce484407","type":"GO_TERM","name":"inner ear morphogenesis","canonical_id":"go:GO:0042472","description":"\"The process in which the anatomical structures of the inner ear are generated and organized. The inner ear is the structure in vertebrates that contains the organs of balance and hearing. It consists of soft hollow sensory structures (the membranous labyrinth) containing fluid (endolymph) surrounded by fluid (perilymph) and encased in a bony cavity (the bony labyrinth). It consists of two chambers, the sacculus and utriculus, from which arise the cochlea and semicircular canals respectively.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"df7150ac45514344b9359239ab249035","type":"GO_TERM","name":"inner ear receptor cell development","canonical_id":"go:GO:0060119","description":"\"The process whose specific outcome is the progression of an inner ear receptor cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:dph]","metadata":null},{"id":"48c0f3ed47a141bea6e993b7387fbd6e","type":"GO_TERM","name":"inner ear receptor cell differentiation","canonical_id":"go:GO:0060113","description":"\"The process in which relatively unspecialized cells, acquire specialized structural and/or functional features of inner ear receptor cells. Inner ear receptor cells are mechanorecptors found in the inner ear responsible for transducing signals involved in balance and sensory perception of sound.\" [GOC:dph]","metadata":null},{"id":"6fd71420e82646558c763724cf8cd1b4","type":"GO_TERM","name":"inner ear receptor cell differentiation involved in inner ear sensory epithelium regeneration","canonical_id":"go:GO:0070660","description":"\"Differentiation of new inner ear sensory hair cells to replace those lost or destroyed by injury.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"f90bda659a1049e4965b87e0c3afd513","type":"GO_TERM","name":"inner ear receptor cell fate commitment","canonical_id":"go:GO:0060120","description":"\"The process in which a cell becomes committed to become an inner ear receptor cell.\" [GOC:dph]","metadata":null},{"id":"da6691756db24dd79726ed04df4ad243","type":"GO_TERM","name":"inner ear receptor cell stereocilium organization","canonical_id":"go:GO:0060122","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a stereocilium. A stereocilium is an actin-based protrusion from the apical surface of inner ear receptor cells.\" [GOC:dph]","metadata":null},{"id":"6d2947ceadbc4d11898fdb6b0af3b5d0","type":"GO_TERM","name":"inner ear sensory epithelium regeneration","canonical_id":"go:GO:0070659","description":"\"The regrowth of lost or destroyed inner ear sensory epithelia.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"43ca17c2bc3e45968f203d15c242b20e","type":"GO_TERM","name":"inner kinetochore","canonical_id":"go:GO:0000939","description":"\"The region of a kinetochore closest to centromeric DNA which contains many CENP proteins organized in various subcomplexes including CENP-C, CENP-LN, CENP-HIKM, CENP-OPQUR and CENP-TWSX, but excluding the CENP-A containing heterochromatin.\" [GOC:clt, PMID:10619130, PMID:11483983, PMID:32516549]","metadata":null},{"id":"dc317d923a97477e94285ddca5a6da96","type":"GO_TERM","name":"inner layer of spore wall","canonical_id":"go:GO:0005632","description":"\"Either of the two innermost layers of the spore wall, as described in Saccharomyces.\" [ISBN:0879693568]","metadata":null},{"id":"4a619bd218614117a76ec1c734a1d10a","type":"GO_TERM","name":"inner medullary collecting duct development","canonical_id":"go:GO:0072061","description":"\"The process whose specific outcome is the progression of the inner medullary collecting duct over time, from its formation to the mature structure. The inner medullary collecting duct is the portion of the collecting duct that lies in the renal inner medulla.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"93f4233df9fe42e3ae7f3961577ca0e9","type":"GO_TERM","name":"inner membrane pellicle complex","canonical_id":"go:GO:0070258","description":"\"A membrane structure formed of two closely aligned lipid bilayers that lie beneath the plasma membrane and form part of the pellicle surrounding an apicomplexan parasite cell.\" [GOC:mah, PMID:12456714]","metadata":null},{"id":"e18c21084bba4004b12e94694c1bc9ed","type":"GO_TERM","name":"inner mitochondrial membrane organization","canonical_id":"go:GO:0007007","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the mitochondrial inner membrane.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"6e6a6dcab36545ebbf0bc2c2d849c4fe","type":"GO_TERM","name":"inner mitochondrial membrane protein complex","canonical_id":"go:GO:0098800","description":"\"Any protein complex that is part of the inner mitochondrial membrane.\" [GOC:dos]","metadata":null},{"id":"0a8e25d5b2c84f2da0c0a442f5f8cd61","type":"GO_TERM","name":"inner mucus layer","canonical_id":"go:GO:0070702","description":"\"The inner of two mucus layers secreted by epithelial cells in the colon; the inner mucus layer is firmly attached to the epithelium, is densely packed with a compact stratified appearance and is devoid of bacteria.\" [GOC:mah, GOC:mm2, PMID:18806221, PMID:19432394]","metadata":null},{"id":"dd3fe7b120764c658e676b98da9bbbb4","type":"GO_TERM","name":"inner nuclear membrane-associated protein degradation pathway","canonical_id":"go:GO:0180027","description":"\"A protein quality control pathway that removes ubiquitinated proteins from the nuclear inner membrane before transferring them to the proteasome for degradation.\" [PMID:37694715]","metadata":null},{"id":"b7dfd3c60b2e4d65a996eca6df965efb","type":"GO_TERM","name":"inner plaque of mitotic spindle pole body","canonical_id":"go:GO:0061497","description":"\"One of three laminate structures that form the mitotic spindle pole body; the inner plaque is in the nucleus.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"9831268a1ea248909c75ae407b1583be","type":"GO_TERM","name":"inner plaque of spindle pole body","canonical_id":"go:GO:0005822","description":"\"One of three laminate structures that form the spindle pole body; the inner plaque is in the nucleus.\" [ISBN:0879693568]","metadata":null},{"id":"747650c90a7c451cb57dc38aa6335c4e","type":"GO_TERM","name":"inner stripe development","canonical_id":"go:GO:0072057","description":"\"The process whose specific outcome is the progression of the inner stripe over time, from its formation to the mature structure. The inner stripe is a deep, centrally located portion of the renal outer medulla and is traversed by thin descending and thick ascending portions of the loops of Henle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1e1af5ca52f949c298baada888029750","type":"GO_TERM","name":"innervation","canonical_id":"go:GO:0060384","description":"\"The process in which a nerve invades a tissue and makes functional synaptic connection within the tissue.\" [GOC:dph, GOC:sart]","metadata":null},{"id":"3456eb040e5544c296000134b30dac97","type":"GO_TERM","name":"inorganic anion import across plasma membrane","canonical_id":"go:GO:0098658","description":"\"The directed movement of inorganic anions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"b089f32587c7424b9bbb6d90054e0801","type":"GO_TERM","name":"inorganic anion transport","canonical_id":"go:GO:0015698","description":"\"The directed movement of inorganic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Inorganic anions are atoms or small molecules with a negative charge which do not contain carbon in covalent linkage.\" [GOC:krc]","metadata":null},{"id":"6577beb9b5674f1aaaec72038a007223","type":"GO_TERM","name":"inorganic cation import across plasma membrane","canonical_id":"go:GO:0098659","description":"\"The directed movement of inorganic cations from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"d4bf63a0c46a44ec8a6e5d319d81d08b","type":"GO_TERM","name":"inorganic diphosphate phosphatase activity","canonical_id":"go:GO:0004427","description":"\"Catalysis of the reaction: diphosphate + H2O = H+ + 2 phosphate.\" [EC:3.6.1.1, RHEA:24576]","metadata":null},{"id":"fcbd009cb10c424fb6c950113ddabdc5","type":"GO_TERM","name":"inorganic diphosphate transport","canonical_id":"go:GO:0030505","description":"\"The directed movement of inorganic diphosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"c90837ffea3f4387bc14bbb5bd4b9e14","type":"GO_TERM","name":"inorganic ion homeostasis","canonical_id":"go:GO:0098771","description":"\"Any process involved in the maintenance of an internal steady state of inorganic ions within an organism or cell.\" [GOC:dos]","metadata":null},{"id":"249433a0488d438ea43d0399455d4b0b","type":"GO_TERM","name":"inorganic ion import across plasma membrane","canonical_id":"go:GO:0099587","description":"\"The directed movement of inorganic ions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"7f8570a4bd3049da8db538ad5398d9e3","type":"GO_TERM","name":"inorganic triphosphate phosphatase activity","canonical_id":"go:GO:0050355","description":"\"Catalysis of the reaction: H2O + inorganic triphosphate = diphosphate + phosphate.\" [EC:3.6.1.25, RHEA:14157]","metadata":null},{"id":"54a272b2b059429faf79c6bcc5e767b3","type":"GO_TERM","name":"inosinate nucleosidase activity","canonical_id":"go:GO:0047723","description":"\"Catalysis of the reaction: H2O + IMP = D-ribose 5-phosphate + hypoxanthine.\" [EC:3.2.2.12, RHEA:20469]","metadata":null},{"id":"6b065c42e5ba4920b78ee9e8ef88ff93","type":"GO_TERM","name":"inosine biosynthetic process","canonical_id":"go:GO:0046103","description":"\"The chemical reactions and pathways resulting in the formation of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs.\" [GOC:curators]","metadata":null},{"id":"d189c9acfc094f1b8ed150cbbbb7da78","type":"GO_TERM","name":"inosine catabolic process","canonical_id":"go:GO:0006148","description":"\"The chemical reactions and pathways resulting in the breakdown of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs.\" [GOC:curators]","metadata":null},{"id":"a868a9fd51fc4db89725c91690b86eb4","type":"GO_TERM","name":"inosine kinase activity","canonical_id":"go:GO:0008906","description":"\"Catalysis of the reaction: ATP + inosine = ADP + IMP.\" [EC:2.7.1.73]","metadata":null},{"id":"aa7fe89238f04f25bb2c81472eb8444d","type":"GO_TERM","name":"inosine metabolic process","canonical_id":"go:GO:0046102","description":"\"The chemical reactions and pathways involving inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs.\" [GOC:curators]","metadata":null},{"id":"29ef2a9b20114ec88b6fbaae1e2f6066","type":"GO_TERM","name":"inosine nucleosidase activity","canonical_id":"go:GO:0047724","description":"\"Catalysis of the reaction: inosine + H2O = D-ribose + hypoxanthine.\" [EC:3.2.2.2, MetaCyc:INOSINE-NUCLEOSIDASE-RXN]","metadata":null},{"id":"a7194cad555d4b4684c3c6b58919e4a8","type":"GO_TERM","name":"inosine salvage","canonical_id":"go:GO:0006190","description":"\"Any process that generates inosine, hypoxanthine riboside, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"959703738ebf406db43c029e824a506b","type":"GO_TERM","name":"inosine transport","canonical_id":"go:GO:0035340","description":"\"The directed movement of the purine ribonucleoside inosine, also known as hypoxanthine riboside, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [PMID:19135251]","metadata":null},{"id":"e055449d28d44c23b7df31c7eed46e33","type":"GO_TERM","name":"inositol 1,3,4,5 tetrakisphosphate binding","canonical_id":"go:GO:0043533","description":"\"Binding to inositol 1,3,4,5 tetrakisphosphate.\" [GOC:curators]","metadata":null},{"id":"f9852f15ddde4cfb9978b8552efdd5ff","type":"GO_TERM","name":"inositol 1,4,5 trisphosphate binding","canonical_id":"go:GO:0070679","description":"\"Binding to inositol 1,4,5 trisphosphate.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"2984a9a44485453b9c9d9b74848b6e3f","type":"GO_TERM","name":"inositol 1,4,5-trisphosphate receptor activity involved in regulation of postsynaptic cytosolic calcium levels","canonical_id":"go:GO:0098695","description":"\"Any inositol 1,4,5-trisphosphate receptor activity that is involved in regulation of postsynaptic cytosolic calcium ion concentration.\" [GOC:dos]","metadata":null},{"id":"6175c397848d443b9d71e04d0f2706bc","type":"GO_TERM","name":"inositol 1,4,5-trisphosphate-gated calcium channel activity","canonical_id":"go:GO:0005220","description":"\"Enables the transmembrane transfer of a calcium ion by a channel that opens when inositol 1,4,5-trisphosphate (IP3) has been bound by the channel complex or one of its constituent parts.\" [GOC:mah, GOC:signaling, PMID:28416699, PMID:8660280, Wikipedia:Inositol_trisphosphate_receptor]","metadata":null},{"id":"beb8ca2b71fe42bcaff0932b4d4ca8f4","type":"GO_TERM","name":"inositol 1-methyltransferase activity","canonical_id":"go:GO:0030741","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + myo-inositol = 1D-1-O-methyl-myo-inositol + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.40, RHEA:17565]","metadata":null},{"id":"fb085c79cffb4e2e90ecc30fb471983c","type":"GO_TERM","name":"inositol 2-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050112","description":"\"Catalysis of the reaction: myo-inositol + NAD+ = 2,4,6/3,5-pentahydroxycyclohexanone + H+ + NADH.\" [EC:1.1.1.18, RHEA:16949]","metadata":null},{"id":"45201f6774e84d91814fce21ec5943fa","type":"GO_TERM","name":"inositol 3-alpha-galactosyltransferase activity","canonical_id":"go:GO:0047216","description":"\"Catalysis of the reaction: myo-inositol + UDP-galactose = O-alpha-D-galactosyl-(1,3)-1D-myo-inositol + UDP.\" [EC:2.4.1.123, MetaCyc:2.4.1.123-RXN]","metadata":null},{"id":"1709281337384c978ec7deaba39cefc5","type":"GO_TERM","name":"inositol 3-kinase activity","canonical_id":"go:GO:0019140","description":"\"Catalysis of the reaction: ATP + myo-inositol = ADP + 1D-myo-inositol 3-phosphate.\" [EC:2.7.1.64]","metadata":null},{"id":"922dfc2c5541498c943a3eebe99aa146","type":"GO_TERM","name":"inositol 3-methyltransferase activity","canonical_id":"go:GO:0030740","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + myo-inositol = 1D-3-O-methyl-myo-inositol + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.39, RHEA:18877]","metadata":null},{"id":"0c0c963b9cf54ac5a765bd74b995567c","type":"GO_TERM","name":"inositol 4-methyltransferase activity","canonical_id":"go:GO:0030787","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + myo-inositol = 1D-4-O-methyl-myo-inositol + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.129, RHEA:23248]","metadata":null},{"id":"fc2aa754a06e4b368df4a37653578c10","type":"GO_TERM","name":"inositol 5-diphosphate pentakisphosphate 5-kinase activity","canonical_id":"go:GO:0052836","description":"\"Catalysis of the reaction: ATP + 5-diphospho-1D-myo-inositol pentakisphosphate = ADP + 5-triphospho-1D-myo-inositol pentakisphosphate.\" [PMID:11502751, PMID:18355727]","metadata":null},{"id":"bed04746ef8c473ea0b922d5dacf596a","type":"GO_TERM","name":"inositol biosynthetic process","canonical_id":"go:GO:0006021","description":"\"The chemical reactions and pathways resulting in the formation of inositol, 1,2,3,4,5,6-cyclohexanehexol, a growth factor for animals and microorganisms.\" [ISBN:0198547684]","metadata":null},{"id":"bf0cd99904824ff983527f6b7e27ad6e","type":"GO_TERM","name":"inositol bisdiphosphate tetrakisphosphate diphosphatase activity","canonical_id":"go:GO:0052841","description":"\"Catalysis of the reaction: bisdiphospho-1D-myo-inositol tetrakisphosphate + H2O = diphospho-1D-myo-inositol pentakisphosphate + phosphate.\" [PMID:10827188, PMID:11502751]","metadata":null},{"id":"f16b23732f3542adb794d237c11ffb01","type":"GO_TERM","name":"inositol bisphosphate phosphatase activity","canonical_id":"go:GO:0016312","description":"\"Catalysis of the reaction: myo-inositol bisphosphate + H2O = myo-inositol phosphate + phosphate.\" [GOC:hb]","metadata":null},{"id":"0c1d0f7618da4e4e9e5577f6a5019286","type":"GO_TERM","name":"inositol catabolic process","canonical_id":"go:GO:0019310","description":"\"The chemical reactions and pathways resulting in the breakdown of inositol, 1,2,3,4,5,6-cyclohexanehexol, a growth factor for animals and microorganisms.\" [GOC:curators]","metadata":null},{"id":"867207428eb843bebbb89d3daa17a33b","type":"GO_TERM","name":"inositol diphosphate pentakisphosphate diphosphatase activity","canonical_id":"go:GO:0052842","description":"\"Catalysis of the reaction: diphospho-1D-myo-inositol pentakisphosphate + H2O = 1D-myo-inositol hexakisphosphate + phosphate.\" [PMID:10827188, PMID:11502751]","metadata":null},{"id":"4c2dc321918e49199cb619a524f74c6d","type":"GO_TERM","name":"inositol diphosphate tetrakisphosphate diphosphatase activity","canonical_id":"go:GO:0052840","description":"\"Catalysis of the reaction: diphospho-1D-myo-inositol tetrakisphosphate + H2O = 1D-myo-inositol pentakisphosphate + phosphate.\" [PMID:10827188, PMID:11502751]","metadata":null},{"id":"28d2831640564fd0ae6399f5b2d8f2ae","type":"GO_TERM","name":"inositol hexakisphosphate 1-kinase activity","canonical_id":"go:GO:0052723","description":"\"Catalysis of the reaction: 1D-myo-inositol hexakisphosphate + ATP = 1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate + ADP.\" [PMID:18981179, RHEA:37459]","metadata":null},{"id":"1d66425762494eb4a15e5bab1f46afeb","type":"GO_TERM","name":"inositol hexakisphosphate 3-kinase activity","canonical_id":"go:GO:0052724","description":"\"Catalysis of the reaction: ATP + 1D-myo-inositol hexakisphosphate = ADP + 3-diphospho-1D-myo-inositol (1,2,4,5,6)pentakisphosphate.\" [MetaCyc:RXN-10971, PMID:18981179]","metadata":null},{"id":"a301a7e3e42746768d18c22b54747e89","type":"GO_TERM","name":"inositol hexakisphosphate 3-phosphatase activity","canonical_id":"go:GO:0016158","description":"\"Catalysis of the reaction: myo-inositol hexakisphosphate + H2O = D-myo-inositol 1,2,4,5,6-pentakisphosphate + phosphate.\" [EC:3.1.3.8]","metadata":null},{"id":"e019e577abe946d0b1a0cf2a17f070da","type":"GO_TERM","name":"inositol hexakisphosphate 4-kinase activity","canonical_id":"go:GO:0000830","description":"\"Catalysis of the reaction: ATP + 1D-myo-inositol hexakisphosphate = ADP + 4-diphospho-1D-myo-inositol (1,2,3,5,6)pentakisphosphate.\" [GOC:elh, PMID:16429326]","metadata":null},{"id":"348cd6d1d8154b75b29bba1ba6b5e2ff","type":"GO_TERM","name":"inositol hexakisphosphate 4-phosphatase activity","canonical_id":"go:GO:0008707","description":"\"Catalysis of the reaction: myo-inositol hexakisphosphate + H2O = 1-myo-inositol 1,2,3,4,5-pentakisphosphate + phosphate.\" [EC:3.1.3.26]","metadata":null},{"id":"68c637a4b71d45bd83a4f0023a75d25c","type":"GO_TERM","name":"inositol hexakisphosphate 5-kinase activity","canonical_id":"go:GO:0000832","description":"\"Catalysis of the reaction: 1D-myo-inositol hexakisphosphate + ATP = 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate + ADP.\" [RHEA:12793]","metadata":null},{"id":"1cf01b8245e44e2896027fc6082b1e1d","type":"GO_TERM","name":"inositol hexakisphosphate 5-phosphatase activity","canonical_id":"go:GO:0050533","description":"\"Catalysis of the reaction: 1D-myo-inositol hexakisphosphate + H2O = 1D-myo-inositol 1,2,3,4,6-pentakisphosphate + phosphate.\" [RHEA:13001]","metadata":null},{"id":"8293f9bd61c04108a1285fb6fcb704a3","type":"GO_TERM","name":"inositol hexakisphosphate 6-kinase activity","canonical_id":"go:GO:0000831","description":"\"Catalysis of the reaction: ATP + 1D-myo-inositol hexakisphosphate = ADP + 6-diphospho-1D-myo-inositol (1,2,3,4,5)pentakisphosphate.\" [GOC:elh, PMID:16429326]","metadata":null},{"id":"0eac4cb523b744a598132e10114c2f7c","type":"GO_TERM","name":"inositol hexakisphosphate binding","canonical_id":"go:GO:0000822","description":"\"Binding to inositol hexakisphosphate.\" [GOC:curators]","metadata":null},{"id":"0356a29ed44a4f5680947a8f684811c0","type":"GO_TERM","name":"inositol hexakisphosphate kinase activity","canonical_id":"go:GO:0000828","description":"\"Catalysis of the reaction: ATP + 1D-myo-inositol hexakisphosphate = ADP + diphospho-1D-myo-inositol-pentakisphosphate. The isomeric configuration of diphospho-1D-myo-inositol-pentakisphosphate (PP-IP5) is unknown.\" [GOC:elh, GOC:vw, PMID:16429326]","metadata":null},{"id":"3c13cc8ce05f44b69fb98aa42372477d","type":"GO_TERM","name":"inositol hexakisphosphate phosphatase activity","canonical_id":"go:GO:0004446","description":"\"Catalysis of the reaction: myo-inositol hexakisphosphate + H2O = myo-inositol pentakisphosphate + phosphate.\" [GOC:curators]","metadata":null},{"id":"b9882f70ccb44c16b61859a379906dc0","type":"GO_TERM","name":"inositol metabolic process","canonical_id":"go:GO:0006020","description":"\"The chemical reactions and pathways involving inositol, 1,2,3,4,5,6-cyclohexanehexol, a growth factor for animals and microorganisms.\" [ISBN:0198547684]","metadata":null},{"id":"a9d609cc49ca4429bc382c8240649c58","type":"GO_TERM","name":"inositol monophosphate 1-phosphatase activity","canonical_id":"go:GO:0008934","description":"\"Catalysis of the reaction: 1D-myo-inositol 1-phosphate + H2O = myo-inositol + phosphate.\" [RHEA:27670]","metadata":null},{"id":"05bf96ee20ab4808a61873259c158fbe","type":"GO_TERM","name":"inositol monophosphate 3-phosphatase activity","canonical_id":"go:GO:0052832","description":"\"Catalysis of the reaction: 1D-myo-inositol 3-phosphate + H2O = myo-inositol + phosphate.\" [RHEA:30739]","metadata":null},{"id":"ebf3fc64513b4baab49d3dfbde504c54","type":"GO_TERM","name":"inositol monophosphate 4-phosphatase activity","canonical_id":"go:GO:0052833","description":"\"Catalysis of the reaction:1D-myo-inositol 4-phosphate + H2O = myo-inositol + phosphate.\" [RHEA:30735]","metadata":null},{"id":"01bb2682086143b8ac47ad68c0d62c6c","type":"GO_TERM","name":"inositol monophosphate phosphatase activity","canonical_id":"go:GO:0052834","description":"\"Catalysis of the reaction: myo-inositol phosphate + H2O = myo-inositol + phosphate.\" [EC:3.1.3.25]","metadata":null},{"id":"a83289bda3e44837aac6fffd9793b596","type":"GO_TERM","name":"inositol oxygenase activity","canonical_id":"go:GO:0050113","description":"\"Catalysis of the reaction: myo-inositol + O2 = D-glucuronate + H2O + H+.\" [RHEA:23696]","metadata":null},{"id":"9178a13cb5304c8bb0a2918089b1886d","type":"GO_TERM","name":"inositol pentakisphosphate kinase activity","canonical_id":"go:GO:0120517","description":"\"Catalysis of the reaction: inositol pentakisphosphate + ATP = inositol hexakisphosphate + ADP + H+.\" [GOC:curators]","metadata":null},{"id":"795466633eec4fcd8d096f8f87ced246","type":"GO_TERM","name":"inositol pentakisphosphate phosphatase activity","canonical_id":"go:GO:0052827","description":"\"Catalysis of the reaction: myo-inositol pentakisphosphate + H2O = myo-inositol tetrakisphosphate + phosphate.\" [GOC:bf]","metadata":null},{"id":"815c9f891bae40e89101f4a52b46c19f","type":"GO_TERM","name":"inositol phosphate biosynthetic process","canonical_id":"go:GO:0032958","description":"\"The chemical reactions and pathways resulting in the formation of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.\" [GOC:mah]","metadata":null},{"id":"4b7d55eb852248619f5970c56321aae9","type":"GO_TERM","name":"inositol phosphate catabolic process","canonical_id":"go:GO:0071545","description":"\"The chemical reactions and pathways resulting in the breakdown of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.\" [GOC:mah]","metadata":null},{"id":"7f029ec0975048198a19c529c3f170ee","type":"GO_TERM","name":"inositol phosphate kinase activity","canonical_id":"go:GO:0180030","description":"\"Catalysis of the reaction: inositol phosphate + ATP = inositol phosphate + ADP.\" [PMID:35536002]","metadata":null},{"id":"5446dc896edd481ca46d25d5138c679a","type":"GO_TERM","name":"inositol phosphate metabolic process","canonical_id":"go:GO:0043647","description":"\"The chemical reactions and pathways involving inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.\" [GOC:jl]","metadata":null},{"id":"cff620514ee84599b95762544d2f850d","type":"GO_TERM","name":"inositol phosphate phosphatase activity","canonical_id":"go:GO:0052745","description":"\"Catalysis of the reaction: inositol phosphate(n) + H2O = inositol phosphate(n-1) + phosphate. This reaction is the removal of a phosphate group from an inositol phosphate.\" [GOC:ai]","metadata":null},{"id":"32764db37a204e059bf52127516dc34a","type":"GO_TERM","name":"inositol phosphoceramide metabolic process","canonical_id":"go:GO:0006673","description":"\"The chemical reactions and pathways involving inositol phosphoceramides, any lipid with a phosphodiester bridge between an inositol residue and the ceramide group.\" [PMID:19726565]","metadata":null},{"id":"3bc6ac64d5c6418285bb99ce4cd9412a","type":"GO_TERM","name":"inositol phosphoceramide synthase activity","canonical_id":"go:GO:0045140","description":"\"Catalysis of the reaction: phytoceramide + inositol phosphate = inositol phosphoceramide + diacylglycerol.\" [PMID:9405490, PMID:9614099]","metadata":null},{"id":"220d679213a54b7cb65ac87ccf689323","type":"GO_TERM","name":"inositol phosphoceramide synthase complex","canonical_id":"go:GO:0070916","description":"\"A protein complex that possesses inositol phosphoceramide synthase activity and contains a catalytic subunit and a regulatory subunit (Aur1p and Kei1p, respectively, in Saccharomyces).\" [GOC:mah, PMID:19726565]","metadata":null},{"id":"3492d26532da4a36a1cee60a92760f84","type":"GO_TERM","name":"inositol phosphoceramide synthase regulator activity","canonical_id":"go:GO:0070917","description":"\"Binds to and modulates the activity of inositol phosphoceramide synthase.\" [GOC:mah]","metadata":null},{"id":"f9a35a9751594054b813f7a16a653e0a","type":"GO_TERM","name":"inositol phosphorylceramide mannosyltransferase activity","canonical_id":"go:GO:0103064","description":"\"Catalysis of the reaction: a 1D-myo-inositol-1-phospho-N-[(R)-2-hydroxy-very-long-chain fatty acyl]-(R)-4-hydroxysphingoid base + GDP-alpha-D-mannose = an alpha-D-mannosyl-(1,6)-1D-myo-inositol-1-phospho-N-[(R)-2-hydroxy-very-long-chain fatty acyl]-(R)-4-hydroxysphingoid base + GDP + H+.\" [GOC:pz, RHEA:64596]","metadata":null},{"id":"148b8290030944708721bc354d9abfab","type":"GO_TERM","name":"inositol phosphorylceramide phospholipase activity","canonical_id":"go:GO:0052713","description":"\"Catalysis of the reaction: inositol phosphorylceramide + H2O = C26-phytoceramide + phosphorylinositol.\" [GOC:ai]","metadata":null},{"id":"b7a0d04c17ec4ee6939307cb6ee42df3","type":"GO_TERM","name":"inositol phosphorylceramide synthase activity","canonical_id":"go:GO:0102770","description":"\"Catalysis of the reaction: an L-1-phosphatidyl-inositol + a dihydroceramide = an inositol phosphodihydroceramide + a 1,2-diacyl-sn-glycerol.\" [MetaCyc:RXN-7795]","metadata":null},{"id":"b38a5f9bc9b946fe8c829891e1bb64a4","type":"GO_TERM","name":"inositol phosphosphingolipid phospholipase activity","canonical_id":"go:GO:0052712","description":"\"Catalysis of the reaction: inositol phosphosphingolipid + H2O = sphingolipid + phosphorylinositol.\" [GOC:ai]","metadata":null},{"id":"ea336f86330d4829b9548cc632863eaa","type":"GO_TERM","name":"inositol pyrophosphate sensor activity","canonical_id":"go:GO:0180043","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of an inositol pyrophosphate.\" [PMID:37949217]","metadata":null},{"id":"90eb075d07c6416aa318b2bcea101167","type":"GO_TERM","name":"inositol tetrakisphosphate kinase activity","canonical_id":"go:GO:0051765","description":"\"Catalysis of the reaction: inositol tetrakisphosphate + ATP = inositol pentakisphosphate + ADP.\" [GOC:ai]","metadata":null},{"id":"eff5537773f24a7b893a7842200c22b5","type":"GO_TERM","name":"inositol tetrakisphosphate phosphatase activity","canonical_id":"go:GO:0052743","description":"\"Catalysis of the reaction: myo-inositol tetrakisphosphate + H2O = myo-inositol trisphosphate + phosphate.\" [GOC:ai]","metadata":null},{"id":"84c5fb063cc84c9984db28992f74bc6a","type":"GO_TERM","name":"inositol trisphosphate biosynthetic process","canonical_id":"go:GO:0032959","description":"\"The chemical reactions and pathways resulting in the formation of inositol trisphosphate, 1,2,3,4,5,6-cyclohexanehexol, with three phosphate groups attached.\" [GOC:mah]","metadata":null},{"id":"6276d72590a34370b62d357980791e9d","type":"GO_TERM","name":"inositol trisphosphate kinase activity","canonical_id":"go:GO:0051766","description":"\"Catalysis of the reaction: inositol trisphosphate + ATP = inositol tetrakisphosphate + ADP + H+.\" [GOC:ai]","metadata":null},{"id":"8c91d40ab2fe46ca972a9d7c898e7efb","type":"GO_TERM","name":"inositol trisphosphate metabolic process","canonical_id":"go:GO:0032957","description":"\"The chemical reactions and pathways involving myo-inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with three phosphate groups attached.\" [GOC:mah]","metadata":null},{"id":"2442d2051cc84208a9bf1ba79334ae32","type":"GO_TERM","name":"inositol trisphosphate phosphatase activity","canonical_id":"go:GO:0046030","description":"\"Catalysis of the reaction: myo-inositol trisphosphate + H2O = myo-inositol bisphosphate + phosphate.\" [GOC:bf]","metadata":null},{"id":"be37dccf2d3d4c889ba110584c2aeaf5","type":"GO_TERM","name":"inositol-1,2,3,4,6-pentakisphosphate 5-kinase activity","canonical_id":"go:GO:0102732","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,2,3,4,6-pentakisphosphate + ATP = 1D-myo-inositol hexakisphosphate + ADP + H+.\" [MetaCyc:RXN-7186, PMID:12226109]","metadata":null},{"id":"e47fedd0cf60439598516bde434cf90f","type":"GO_TERM","name":"inositol-1,2,4,5,6-pentakisphosphate 5-phosphatase activity","canonical_id":"go:GO:1990651","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,2,4,5,6-pentakisphosphate + H2O = 1D-myo-inositol 1,2,4,6-tetrakisphosphate + phosphate.\" [GOC:al, PMID:15316017]","metadata":null},{"id":"e184e94f255e47a5b14bf838d25b9caf","type":"GO_TERM","name":"inositol-1,2,4,5-tetrakisphosphate 5-phosphatase activity","canonical_id":"go:GO:1990649","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,2,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,2,4-trisphosphate + phosphate.\" [GOC:al, PMID:15316017]","metadata":null},{"id":"f36b555810814c8787ac4ce62b07ea22","type":"GO_TERM","name":"inositol-1,3,4,5,6-pentakisphosphate 1-phosphatase activity","canonical_id":"go:GO:0052825","description":"\"Catalysis of the reaction: inositol-1,3,4,5,6-pentakisphosphate + H2O = inositol-3,4,5,6-tetrakisphosphate + phosphate.\" [GOC:ai]","metadata":null},{"id":"f7361c54f53b4cda81d781b2789ae4bb","type":"GO_TERM","name":"inositol-1,3,4,5,6-pentakisphosphate 2-kinase activity","canonical_id":"go:GO:0035299","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + ATP = 1D-myo-inositol hexakisphosphate + ADP + H+.\" [RHEA:20313]","metadata":null},{"id":"b8e49d8b8df442fbb4257cf08aacc194","type":"GO_TERM","name":"inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity","canonical_id":"go:GO:0030351","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo-inositol 1,4,5,6-tetrakisphosphate + phosphate.\" [RHEA:77143]","metadata":null},{"id":"38a8e11ce698404ca6fcb17c4a896197","type":"GO_TERM","name":"inositol-1,3,4,5,6-pentakisphosphate kinase activity","canonical_id":"go:GO:0000827","description":"\"Catalysis of the reaction: ATP + 1D-myo-inositol 1,3,4,5,6-pentakisphosphate = ADP + diphospho-1D-myo-inositol tetrakisphosphate. The isomeric configuration of diphospho-1D-myo-inositol tetrakisphosphate is unknown.\" [GOC:elh, PMID:11311242]","metadata":null},{"id":"cfee911c03b449bea18cc4137b75d788","type":"GO_TERM","name":"inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity","canonical_id":"go:GO:0051717","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + phosphate.\" [RHEA:77155]","metadata":null},{"id":"1dc88b7cc867453889cd0aaf5ce8403f","type":"GO_TERM","name":"inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity","canonical_id":"go:GO:0052659","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,3,4-trisphosphate + phosphate.\" [RHEA:11392]","metadata":null},{"id":"e90051f558984f1f8ee1f9acdad53145","type":"GO_TERM","name":"inositol-1,3,4,5-tetrakisphosphate 6-kinase activity","canonical_id":"go:GO:0000825","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,5-tetrakisphosphate + ATP = 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + ADP + H+.\" [MetaCyc:RXN-7184]","metadata":null},{"id":"673d277ac1c54775a97e95f3f82e12b2","type":"GO_TERM","name":"inositol-1,3,4,6-tetrakisphosphate 1-phosphatase activity","canonical_id":"go:GO:0052831","description":"\"Catalysis of the reaction: inositol-1,3,4,6-tetrakisphosphate + H2O = inositol-3,4,6-trisphosphate + phosphate.\" [GOC:ai]","metadata":null},{"id":"8c21f86fbda347a99e1de76d34abdedb","type":"GO_TERM","name":"inositol-1,3,4,6-tetrakisphosphate 2-kinase activity","canonical_id":"go:GO:0102731","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,6-tetrakisphosphate + ATP = 1D-myo-inositol 1,2,3,4,6-pentakisphosphate + ADP + H+.\" [MetaCyc:RXN-7185, PMID:16107538]","metadata":null},{"id":"b93ea012063843dda9eabacb5f22c1fa","type":"GO_TERM","name":"inositol-1,3,4,6-tetrakisphosphate 5-kinase activity","canonical_id":"go:GO:0047326","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4,6-tetrakisphosphate + ATP = 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + ADP + H+.\" [RHEA:12717]","metadata":null},{"id":"ca9dc2b865f4434b88a0bfea77f6df6e","type":"GO_TERM","name":"inositol-1,3,4,6-tetrakisphosphate 6-phosphatase activity","canonical_id":"go:GO:0052830","description":"\"Catalysis of the reaction: inositol-1,3,4,6-tetrakisphosphate + H2O = inositol-1,3,4-trisphosphate + phosphate.\" [GOC:ai]","metadata":null},{"id":"0e785c239adb459784136b9d12f403de","type":"GO_TERM","name":"inositol-1,3,4-trisphosphate 1-phosphatase activity","canonical_id":"go:GO:0052829","description":"\"Catalysis of the reaction: D-myo-inositol 1,3,4-trisphosphate + H2O = myo-inositol 3,4-bisphosphate + phosphate.\" [GOC:ai]","metadata":null},{"id":"2d243c158397406f8ecd160c8cbd35e2","type":"GO_TERM","name":"inositol-1,3,4-trisphosphate 4-phosphatase activity","canonical_id":"go:GO:0017161","description":"\"Catalysis of the reaction: D-myo-inositol 1,3,4-trisphosphate + H2O = myo-inositol 1,3-bisphosphate + phosphate.\" [GOC:ai]","metadata":null},{"id":"a94b220142634558af9de70b344e7360","type":"GO_TERM","name":"inositol-1,3,4-trisphosphate 5-kinase activity","canonical_id":"go:GO:0052726","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4-trisphosphate + ATP = 1D-myo-inositol 1,3,4,5-tetrakisphosphate + ADP + H+.\" [RHEA:13253]","metadata":null},{"id":"dbcdc475312a4ba490609efdea8e349a","type":"GO_TERM","name":"inositol-1,3,4-trisphosphate 6-kinase activity","canonical_id":"go:GO:0052725","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,3,4-trisphosphate + ATP = 1D-myo-inositol 1,3,4,6-tetrakisphosphate + ADP + H+.\" [RHEA:20940]","metadata":null},{"id":"6fe749d157554272b42e78383314750e","type":"GO_TERM","name":"inositol-1,4,5,6-tetrakisphosphate 2-kinase activity","canonical_id":"go:GO:0032942","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4,5,6-tetrakisphosphate + ATP = 1D-myo-inositol 1,2,4,5,6-pentakisphosphate + ADP + H+.\" [MetaCyc:RXN-7182, PMID:16107538]","metadata":null},{"id":"92136e4e94fa4b10bd868ba1894a4342","type":"GO_TERM","name":"inositol-1,4,5,6-tetrakisphosphate 3-kinase activity","canonical_id":"go:GO:0000824","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4,5,6-tetrakisphosphate + ATP = 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + ADP + H+.\" [RHEA:11856]","metadata":null},{"id":"6607869b510642568b11aa4fa7811402","type":"GO_TERM","name":"inositol-1,4,5,6-tetrakisphosphate 6-phosphatase activity","canonical_id":"go:GO:0030352","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4,5,6-tetrakisphosphate + H2O = 1D-myo-inositol 1,4,5-trisphosphate + phosphate.\" [RHEA:77147]","metadata":null},{"id":"9a1790ca07994d17a530573baaf29915","type":"GO_TERM","name":"inositol-1,4,5-trisphosphate 3-kinase activity","canonical_id":"go:GO:0008440","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4,5-trisphosphate + ATP = 1D-myo-inositol 1,3,4,5-tetrakisphosphate + ADP + H+.\" [RHEA:11020]","metadata":null},{"id":"b29331b759084b2682275944fb820db5","type":"GO_TERM","name":"inositol-1,4,5-trisphosphate 5-phosphatase activity","canonical_id":"go:GO:0052658","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4,5-trisphosphate + H2O = 1D-myo-inositol 1,4-bisphosphate + phosphate.\" [RHEA:19797]","metadata":null},{"id":"dd50a0733b454aed8e376b3071a9b752","type":"GO_TERM","name":"inositol-1,4,5-trisphosphate 6-kinase activity","canonical_id":"go:GO:0000823","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4,5-trisphosphate + ATP = 1D-myo-inositol 1,4,5,6-tetrakisphosphate + ADP + H+.\" [RHEA:17717]","metadata":null},{"id":"2efe4eea3980411b81d00130a8d7d0d4","type":"GO_TERM","name":"inositol-1,4-bisphosphate 1-phosphatase activity","canonical_id":"go:GO:0004441","description":"\"Catalysis of the reaction: 1D-myo-inositol 1,4-bisphosphate + H2O = 1D-myo-inositol 4-phosphate + phosphate.\" [EC:3.1.3.57, GOC:hb]","metadata":null},{"id":"b658e0648634451a97a6e0ddf98c8255","type":"GO_TERM","name":"inositol-1,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 1-diphosphatase activity","canonical_id":"go:GO:0052846","description":"\"Catalysis of the reaction: 1,5-bisdiphospho-1D-myo-inositol 2,3,4,6-tetrakisphosphate + H2O = 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate + phosphate + H+.\" [PMID:10827188, PMID:11502751, PMID:26422458]","metadata":null},{"id":"40d56dd2eb57466c947bf8dc8e84b4a1","type":"GO_TERM","name":"inositol-1,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 5-diphosphatase activity","canonical_id":"go:GO:0052847","description":"\"Catalysis of the reaction: 1,5-bisdiphospho-1D-myo-inositol 2,3,4,6-tetrakisphosphate + H2O = 1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate + phosphate + H+.\" [MetaCyc:RXN-10975, PMID:10827188, PMID:11502751]","metadata":null},{"id":"98802f9a4bfd4af79f15cd8250d7cb13","type":"GO_TERM","name":"inositol-1-diphosphate-2,3,4,5,6-pentakisphosphate diphosphatase activity","canonical_id":"go:GO:0052843","description":"\"Catalysis of the reaction: 1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate + H2O = 1D-myo-inositol 1,2,3,4,5,6-hexakisphosphate + phosphate + 2 H+.\" [PMID:10827188, PMID:11502751, PMID:26422458]","metadata":null},{"id":"5355e7d8a7944786af415d7fae3ea6df","type":"GO_TERM","name":"inositol-2,4,5,6-tetrakisphosphate 5-phosphatase activity","canonical_id":"go:GO:1990650","description":"\"Catalysis of the reaction: 1D-myo-inositol 2,4,5,6-tetrakisphosphate + H2O = 1D-myo-inositol 2,4,6-trisphosphate + phosphate.\" [GOC:al, PMID:15316017]","metadata":null},{"id":"5aaa7cfb2e23455793cb7386f34f8e6c","type":"GO_TERM","name":"inositol-2,4,5-triphosphate 5-phosphatase activity","canonical_id":"go:GO:1990640","description":"\"Catalysis of the reaction: 1D-myo-inositol 2,4,5-trisphosphate + H2O = 1D-myo-inositol 2,4-bisphosphate + phosphate.\" [PMID:15316017]","metadata":null},{"id":"72da75fa8a7647b39dacb298a2f45aab","type":"GO_TERM","name":"inositol-3,4,5,6-tetrakisphosphate 1-kinase activity","canonical_id":"go:GO:0047325","description":"\"Catalysis of the reaction: 1D-myo-inositol 3,4,5,6-tetrakisphosphate + ATP = 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + ADP + H+.\" [RHEA:12452]","metadata":null},{"id":"10ee79abbc07480fbd45bd802be8d679","type":"GO_TERM","name":"inositol-3,4,6-trisphosphate 1-kinase activity","canonical_id":"go:GO:0052835","description":"\"Catalysis of the reaction: 1D-myo-inositol 3,4,6-trisphosphate + ATP = 1D-myo-inositol 1,3,4,6-tetrakisphosphate + ADP + H+.\" [PMID:11909533, RHEA:70287]","metadata":null},{"id":"e74658c05441459197ed3472c7f86526","type":"GO_TERM","name":"inositol-3,4-bisphosphate 4-phosphatase activity","canonical_id":"go:GO:0052828","description":"\"Catalysis of the reaction: 1D-myo-inositol 3,4-bisphosphate + H2O = 1D-myo-inositol 3-phosphate + phosphate.\" [GOC:mah]","metadata":null},{"id":"9516735c21d74c0ea8c984d0b6e58f11","type":"GO_TERM","name":"inositol-3,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 5-diphosphatase activity","canonical_id":"go:GO:0052848","description":"\"Catalysis of the reaction: 3,5-bisdiphospho-1D-myo-inositol 2,3,4,6-tetrakisphosphate + H2O = 3-diphospho-1D-myo-inositol 1,2,4,5,6-pentakisphosphate + phosphate + 2 H+.\" [PMID:10827188, PMID:11502751, RHEA:56312]","metadata":null},{"id":"db12d3a727f14c4d8bdc5d097c17f322","type":"GO_TERM","name":"inositol-3-diphosphate-1,2,4,5,6-pentakisphosphate diphosphatase activity","canonical_id":"go:GO:0052844","description":"\"Catalysis of the reaction: 3-diphospho-1D-myo-inositol 1,2,4,5,6-pentakisphosphate + H2O = 1D-myo-inositol 1,2,3,4,5,6-hexakisphosphate + phosphate + 2 H+.\" [PMID:10827188, PMID:11502751]","metadata":null},{"id":"67abe43611de4e97a2f2fdd0e3187b3f","type":"GO_TERM","name":"inositol-3-phosphate synthase activity","canonical_id":"go:GO:0004512","description":"\"Catalysis of the reaction: D-glucose 6-phosphate = 1D-myo-inositol 3-phosphate. This reaction requires NAD, which dehydrogenates the CHOH group to CO at C-5 of the glucose 6-phosphate, making C-6 into an active methylene, able to condense with the aldehyde at C-1. Finally, the enzyme-bound NADH reconverts C-5 into the CHOH form.\" [EC:5.5.1.4, RHEA:10716]","metadata":null},{"id":"4b1b43a312eb44c495566e554908e4df","type":"GO_TERM","name":"inositol-4,5,6-triphosphate 5-phosphatase activity","canonical_id":"go:GO:1990648","description":"\"Catalysis of the reaction: 1D-myo-inositol 4,5,6-trisphosphate + H2O = 1D-myo-inositol 4,6-bisphosphate + phosphate.\" [GOC:al, PMID:15316017]","metadata":null},{"id":"d594f393c6804f249823b8f0113ee148","type":"GO_TERM","name":"inositol-4,5-bisphosphate 5-phosphatase activity","canonical_id":"go:GO:0030487","description":"\"Catalysis of the reaction: 1D-myo-inositol 4,5-bisphosphate + H2O = 1D-myo-inositol 4-phosphate + phosphate.\" [GOC:mah]","metadata":null},{"id":"48c7d158de1b43e299d2a3e68e1870e3","type":"GO_TERM","name":"inositol-5-diphosphate-1,2,3,4,6-pentakisphosphate diphosphatase activity","canonical_id":"go:GO:0052845","description":"\"Catalysis of the reaction: 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate + H2O = 1D-myo-inositol 1,2,3,4,5,6-hexakisphosphate + phosphate + H+.\" [PMID:10827188, PMID:11502751, RHEA:22384]","metadata":null},{"id":"0523ce82468e41e9aa84d08a961f038e","type":"GO_TERM","name":"inositol-5-diphosphate-1,3,4,6-tetrakisphosphate diphosphatase activity","canonical_id":"go:GO:0106211","description":"\"Catalysis of the reaction: 5-diphospho-1D-myo-inositol 1,3,4,6-tetrakisphosphate + H2O = 1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H+ + phosphate.\" [GOC:rn, PMID:29540476]","metadata":null},{"id":"e6593b9cc450456eadd201c56a77478b","type":"GO_TERM","name":"inositol-polyphosphate 5-phosphatase activity","canonical_id":"go:GO:0004445","description":"\"Catalysis of the reactions: D-myo-inositol 1,4,5-trisphosphate + H2O = myo-inositol 1,4-bisphosphate + phosphate, and 1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-inositol 1,3,4-trisphosphate + phosphate.\" [EC:3.1.3.56]","metadata":null},{"id":"60a40cc104f642eaa817e9425f806a3e","type":"DRUG","name":"inotuzumab ozogamicin","canonical_id":"gtopdb:8266","description":null,"metadata":null},{"id":"475ebf63f9c94cb9a99ef33d6de286a3","type":"DRUG","name":"inotuzumab ozogamicin","canonical_id":"chembl:CHEMBL2108611","description":null,"metadata":null},{"id":"e1d3e3e4551e49abaebf27860dfa4e65","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-8266876307e6f579","description":null,"metadata":null},{"id":"7624d6c10ecb4343b943487d992a8c6c","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-65db9b6668b6f587","description":null,"metadata":null},{"id":"c181781ba41b4ced8a92db5df1dbd990","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-86f91bca3d741a36","description":null,"metadata":null},{"id":"fc79633e02154819b0091367f6025a19","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-b2da9c73154fab61","description":null,"metadata":null},{"id":"575d1b9a0e6a4cc8a10212405cd6950d","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-0e8ae10195a56916","description":null,"metadata":null},{"id":"9567c576c8e941ab87d92c9a36c1a4d3","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + thioguanine","canonical_id":"ctgov_combo:ctgov-combo-f48111fa4cc06c6e","description":null,"metadata":null},{"id":"cf8bfc4301fb4996b02fd57ab65da1ac","type":"COMBINATION_TREATMENT","name":"inotuzumab ozogamicin + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-82634a214a3d7529","description":null,"metadata":null},{"id":"6563d9a308384e9dbb219ec1b9d71b1a","type":"GO_TERM","name":"insect pharynx development","canonical_id":"go:GO:0160095","description":"\"The process whose specific outcome is the progression of insect pharynx over time, from its formation to the mature structure.\" [PMID:10952900]","metadata":null},{"id":"2c91e80eeeb347f5b8f4595fd7da636a","type":"GO_TERM","name":"insect visual primordium development","canonical_id":"go:GO:0001748","description":"\"The process whose specific outcome is the progression of the optic placode over time, from its formation to the mature structure. During embryonic stage 12 the placode starts to invaginate, forming a pouch. Cells that will form Bolwig's organ segregate from the ventral lip of this pouch, remaining in the head epidermis. The remainder of the invagination loses contact with the outer surface and becomes the optic lobe. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:8402833]","metadata":null},{"id":"fadc6f88495c4b758453f366749de609","type":"GO_TERM","name":"insect visual primordium formation","canonical_id":"go:GO:0001744","description":"\"Establishment of the optic lobe placode. In Drosophila, for example, the placode appears in the dorsolateral region of the head in late stage 11 embryos and is the precursor to the larval visual system.\" [GOC:mtg_sensu, PMID:8402833]","metadata":null},{"id":"c1fb7e5ee3d44936833f5f3f0ee35ac8","type":"GO_TERM","name":"insecticide catabolic process","canonical_id":"go:GO:0046701","description":"\"The chemical reactions and pathways resulting in the breakdown of insecticides, chemicals used to kill insects.\" [GOC:ai]","metadata":null},{"id":"2b6a8fd7b4d64a7eb531193cd3f2d769","type":"GO_TERM","name":"insecticide metabolic process","canonical_id":"go:GO:0017143","description":"\"The chemical reactions and pathways involving insecticides, chemicals used to kill insects.\" [GOC:ai]","metadata":null},{"id":"a560b3a6b6df4b0d9bee5c96b8dc0bee","type":"GO_TERM","name":"insemination","canonical_id":"go:GO:0007320","description":"\"The introduction of semen or sperm into the genital tract of a female.\" [ISBN:0582227089]","metadata":null},{"id":"c39ef0f3d425455baf0cd77c7507454f","type":"DISEASE","name":"insomnia","canonical_id":"mondo:0013600","description":null,"metadata":null},{"id":"5e3b676d06994273bdd0c64cffe7b606","type":"GO_TERM","name":"instar larval development","canonical_id":"go:GO:0002168","description":"\"The process whose specific outcome is the progression of the larva over time, from its formation to the mature structure. This begins with the newly hatched first-instar larva, through its maturation to the end of the last larval stage. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"5b05a64ef67f4a86935de12d2a166d18","type":"GO_TERM","name":"instar larval or pupal development","canonical_id":"go:GO:0002165","description":"\"The process whose specific outcome is the progression of the instar larva or pupa over time, from its formation to the mature structure. An example of this process is found in Drosophila melanogaster.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"f5e7f7f444044e1f801de34cc9b859fc","type":"GO_TERM","name":"instar larval or pupal morphogenesis","canonical_id":"go:GO:0048707","description":"\"The process, occurring during instar larval or pupal development, by which anatomical structures are generated and organized.\" [GOC:mtg_sensu, GOC:rc]","metadata":null},{"id":"7a8d3b4e334e4ff199966aa36291d197","type":"GO_TERM","name":"instrumental aggressive behavior","canonical_id":"go:GO:0002126","description":"\"Aggressive behavior directed towards obtaining some goal, considered to be a learned response to a situation.\" [GOC:hjd]","metadata":null},{"id":"cee372b87c1f403d9eb3891a63015dd8","type":"DRUG","name":"insulin","canonical_id":"gtopdb:5012","description":null,"metadata":null},{"id":"08247565832541029e5809959ca788f1","type":"DRUG","name":"insulin","canonical_id":"chembl:CHEMBL1201631","description":null,"metadata":null},{"id":"d19edb6dc0574e7b8c7a82899129c73f","type":"COMBINATION_TREATMENT","name":"insulin + liraglutide","canonical_id":"ctgov_combo:ctgov-combo-0c25e6bf5910d424","description":null,"metadata":null},{"id":"0f04b59f36984de0886078f67159ece9","type":"GO_TERM","name":"insulin binding","canonical_id":"go:GO:0043559","description":"\"Binding to insulin, a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.\" [ISBN:0198506732]","metadata":null},{"id":"e3dde0fceb8943f9bb6ab160acee36ea","type":"GO_TERM","name":"insulin catabolic process","canonical_id":"go:GO:1901143","description":"\"The chemical reactions and pathways resulting in the breakdown of insulin.\" [GOC:TermGenie]","metadata":null},{"id":"ffd3f1a84a4d44669d20b4c54ce7e8cc","type":"GO_TERM","name":"insulin control element activator complex","canonical_id":"go:GO:0030232","description":"\"Transcription factor complex that binds to the insulin control element (ICE), a DNA sequence element found within the 5'-flanking region of the insulin gene, and activates ICE-mediated transcription.\" [PMID:7935390]","metadata":null},{"id":"1eadbdc06cea4e1aafd10d8cbdfe93df","type":"DRUG","name":"insulin degludec","canonical_id":"mesh:C571886","description":null,"metadata":null},{"id":"3e5bafee93ad48f0a261ec459d8d1e35","type":"DRUG","name":"insulin detemir","canonical_id":"mesh:D000069057","description":null,"metadata":null},{"id":"305d2d83f79843479f45d4cf4dbe8cf3","type":"DRUG","name":"insulin detemir","canonical_id":"mesh:D061267","description":null,"metadata":null},{"id":"3fd2d734b34f4c3f9615c7ce6e3bed4a","type":"DRUG","name":"insulin glulisine","canonical_id":"mesh:C479079","description":null,"metadata":null},{"id":"99501a19b6214be5adc320ac7eea5932","type":"DRUG","name":"insulin lispro","canonical_id":"mesh:D061268","description":null,"metadata":null},{"id":"4f6fa53002d542c1944476753fc8d63b","type":"GO_TERM","name":"insulin metabolic process","canonical_id":"go:GO:1901142","description":"\"The chemical reactions and pathways involving insulin.\" [GOC:TermGenie]","metadata":null},{"id":"8c75077d79404f058a2806a921014d08","type":"GO_TERM","name":"insulin processing","canonical_id":"go:GO:0030070","description":"\"The formation of mature insulin by proteolysis of the precursor preproinsulin. The signal sequence is first cleaved from preproinsulin to form proinsulin; proinsulin is then cleaved to release the C peptide, leaving the A and B chains of mature insulin linked by disulfide bridges.\" [ISBN:0198506732]","metadata":null},{"id":"1b021cbb19e540b58efad3a7f19ef2d6","type":"GO_TERM","name":"insulin receptor activity","canonical_id":"go:GO:0005009","description":"\"Combining with insulin receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"67ce61bca6344994bb83e9a652e7c563","type":"GO_TERM","name":"insulin receptor binding","canonical_id":"go:GO:0005158","description":"\"Binding to an insulin receptor.\" [GOC:ai]","metadata":null},{"id":"0fb2f7eb37944af0a23d8ea6f179843f","type":"GO_TERM","name":"insulin receptor complex","canonical_id":"go:GO:0005899","description":"\"A disulfide-bonded, heterotetrameric receptor complex. The alpha chains are entirely extracellular, while each beta chain has one transmembrane domain. The ligand binds to the alpha subunit extracellular domain and the kinase is associated with the beta subunit intracellular domain.\" [ISBN:0198506732]","metadata":null},{"id":"6e4f52cce0b24dfca7cd1cad5a2a626a","type":"GO_TERM","name":"insulin receptor internalization","canonical_id":"go:GO:0038016","description":"\"A receptor-mediated endocytosis process that results in the movement of an insulin receptor from the plasma membrane to the inside of the cell.\" [GOC:bf, PMID:3907718, PMID:9609114]","metadata":null},{"id":"a5d44f673c1947e1896a923a2eb2f460","type":"GO_TERM","name":"insulin receptor recycling","canonical_id":"go:GO:0038020","description":"\"The process that results in the return of an insulin receptor to an active state at the plasma membrane. An active state is when the receptor is ready to receive an insulin signal. Internalized insulin receptors can be recycled to the plasma membrane or sorted to lysosomes for protein degradation.\" [GOC:bf, GOC:signaling, PMID:3907718]","metadata":null},{"id":"a11aa6d89e8746a3a34590941145c083","type":"GO_TERM","name":"insulin receptor signaling pathway","canonical_id":"go:GO:0008286","description":"\"The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.\" [GOC:ceb]","metadata":null},{"id":"a7e8dc02b0df47498a8fc262c27338cb","type":"GO_TERM","name":"insulin receptor substrate binding","canonical_id":"go:GO:0043560","description":"\"Binding to an insulin receptor substrate (IRS) protein, an adaptor protein that bind to the transphosphorylated insulin and insulin-like growth factor receptors, are themselves phosphorylated and in turn recruit SH2 domain-containing signaling molecules to form a productive signaling complex.\" [PMID:12829233]","metadata":null},{"id":"9215e4a4efc1493196a4b3e15ca7ff59","type":"GO_TERM","name":"insulin secretion","canonical_id":"go:GO:0030073","description":"\"The regulated release of proinsulin from secretory granules accompanied by cleavage of proinsulin to form mature insulin. In vertebrates, insulin is secreted from B granules in the B cells of the vertebrate pancreas and from insulin-producing cells in insects.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"b23b61222fad4b71ac204d1ac4ab91bf","type":"GO_TERM","name":"insulin secretion involved in cellular response to glucose stimulus","canonical_id":"go:GO:0035773","description":"\"The regulated release of proinsulin from secretory granules (B granules) in the B cells of the pancreas; accompanied by cleavage of proinsulin to form mature insulin, in response to a glucose stimulus.\" [GOC:bf, GOC:yaf, PMID:8492079]","metadata":null},{"id":"2e31f29730974f96a9759d1b368dc9ca","type":"GO_TERM","name":"insulin-like growth factor I binding","canonical_id":"go:GO:0031994","description":"\"Binding to insulin-like growth factor I.\" [GOC:mah]","metadata":null},{"id":"21caa9461c3042618dc9fdce30e498c7","type":"GO_TERM","name":"insulin-like growth factor II binding","canonical_id":"go:GO:0031995","description":"\"Binding to insulin-like growth factor II.\" [GOC:mah]","metadata":null},{"id":"d5440bc6fa9e410b94979bd1d2474093","type":"GO_TERM","name":"insulin-like growth factor binary complex","canonical_id":"go:GO:0042568","description":"\"A complex of two proteins, which in animals is 50kDa and consists of the insulin-like growth factor (IGF) and one of the insulin-like growth factor binding protein-1 (IGFBP-1), -2 (IGFBP-2), -4 (IGFBP-4) and -6 (IGFBP-6). The complex plays a role in growth and development.\" [GOC:jl, PMID:12239079]","metadata":null},{"id":"2d8efdd1c71147ff92e703d670cf20e0","type":"GO_TERM","name":"insulin-like growth factor binding","canonical_id":"go:GO:0005520","description":"\"Binding to an insulin-like growth factor, any member of a group of polypeptides that are structurally homologous to insulin and share many of its biological activities, but are immunologically distinct from it.\" [ISBN:0198506732]","metadata":null},{"id":"739dbd41c00b4095a701ae2866e3ebb7","type":"GO_TERM","name":"insulin-like growth factor binding protein complex","canonical_id":"go:GO:0016942","description":"\"A complex of proteins which includes the insulin-like growth factor (IGF) and a number of IGF-binding proteins. The complex plays a role in growth and development.\" [GOC:jl]","metadata":null},{"id":"307099e3fcbb4312b335e4e013fa3316","type":"GO_TERM","name":"insulin-like growth factor binding receptor complex","canonical_id":"go:GO:0140308","description":"\"A plasma membrane-localized protein complex that binds insulin-like growth factors (IGF1 or IGF2). This class includes both signaling receptor complexes, such as the insulin-like growth factor 1 receptor (IGF1R) complex, which possesses intrinsic tyrosine kinase activity and initiates intracellular signaling cascades upon ligand binding, and non-signaling receptor complexes such as the insulin-like growth factor 2 receptor (IGF2R), which functions to sequester IGF2 and regulate its bioavailability by directing it to lysosomal degradation. These complexes regulate cell growth, proliferation, survival, and development by modulating IGF signaling.\" [PMID:17475626, PMID:27140600, PMID:31594955, PMID:35749888]","metadata":null},{"id":"3102554626494cc88dfb68b849c52767","type":"GO_TERM","name":"insulin-like growth factor receptor activity","canonical_id":"go:GO:0005010","description":"\"Combining with insulin-like growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"9c8e4d1091a34fe3920e1c1bdadb516c","type":"GO_TERM","name":"insulin-like growth factor receptor binding","canonical_id":"go:GO:0005159","description":"\"Binding to an insulin-like growth factor receptor.\" [GOC:jl]","metadata":null},{"id":"00b13d3f22334138b7900fd8f9eefaec","type":"GO_TERM","name":"insulin-like growth factor receptor signaling pathway","canonical_id":"go:GO:0048009","description":"\"The series of molecular signals initiated by a ligand binding to an insulin-like growth factor receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb]","metadata":null},{"id":"c9871fb03a3c411ba73c980d460bcc00","type":"GO_TERM","name":"insulin-like growth factor ternary complex","canonical_id":"go:GO:0042567","description":"\"A complex of three proteins, which in animals is approximately 150kDa and consists of the insulin-like growth factor (IGF), the insulin-like growth factor binding protein-3 (IGFBP-3), or -5 (IGFBP-5) and an acid-labile subunit (ALS). The complex plays a role in growth and development.\" [GOC:jl, PMID:12239079]","metadata":null},{"id":"1785785691b544e28df399f09866d69f","type":"DISEASE","name":"insulin-resistance syndrome type A","canonical_id":"mondo:0012520","description":null,"metadata":null},{"id":"35f7063f7d7c403195b03221d5fd58a5","type":"GO_TERM","name":"insulin-responsive D-glucose:proton symporter activity","canonical_id":"go:GO:0005360","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + H(out)+ = glucose(in) + H(in)+, in response to a stimulus by insulin. Symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy.\" [GOC:mtg_transport]","metadata":null},{"id":"166be3b1bc69420e84f26fe1f1468fc4","type":"GO_TERM","name":"insulin-responsive compartment","canonical_id":"go:GO:0032593","description":"\"A small membrane-bounded vesicle that releases its contents by exocytosis in response to insulin stimulation; the contents are enriched in GLUT4, IRAP and VAMP2.\" [PMID:17644329]","metadata":null},{"id":"85b1950f00714f6b8df00372b478cb27","type":"GO_TERM","name":"integrase activity","canonical_id":"go:GO:0008907","description":"\"Catalysis of the integration of one DNA segment into another.\" [GOC:mah]","metadata":null},{"id":"3bc6806159ae478e8311c625d75d0f2b","type":"GO_TERM","name":"integrated stress response signaling","canonical_id":"go:GO:0140467","description":"\"The series of molecular signals generated in response to diverse stress stimuli required to restore cellular homeostasis. The core event in this pathway is the phosphorylation of eIF2 alpha by one of four members of the eIF2a kinase family (EIF2AK1/HRI, EIF2AK2/PKR, EIF2AK3/PERK and EIF2AK4/GCN2), which leads to a decrease in global protein synthesis and the induction of selected genes, including the transcription factor ATF4, that together promote cellular recovery.\" [PMID:27629041]","metadata":null},{"id":"ccc66301107a4e7d81bdbebd654decff","type":"GO_TERM","name":"integrator complex","canonical_id":"go:GO:0032039","description":"\"A protein complex that stably associates with the C-terminus of RNA polymerase II and mediates 3'-end processing of small nuclear RNAs generated by RNA polymerase II.\" [PMID:16239144]","metadata":null},{"id":"d1229dbeeef943a182232ab311d1ed7c","type":"GO_TERM","name":"integrator complex assembly","canonical_id":"go:GO:0160234","description":"\"The aggregation, arrangement and bonding together of a set of components to form the integrator complex.\" [PMID:39032489, PMID:39032490]","metadata":null},{"id":"8f430410761547818ee2b45774fb5001","type":"GO_TERM","name":"integrin activation","canonical_id":"go:GO:0033622","description":"\"The aggregation, arrangement and bonding together of an integrin, a heterodimeric adhesion receptor formed by the non-covalent association of particular alpha and beta subunits, that lead to the increased affinity of the integrin for its extracellular ligands.\" [GOC:add, PMID:12213832, PMID:14754902]","metadata":null},{"id":"36d5f41f0ea34f728d10635d563ef881","type":"GO_TERM","name":"integrin alpha1-beta1 complex","canonical_id":"go:GO:0034665","description":"\"An integrin complex that comprises one alpha1 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"817e8401e46741a4b3aaaa48ad9352f0","type":"GO_TERM","name":"integrin alpha10-beta1 complex","canonical_id":"go:GO:0034680","description":"\"An integrin complex that comprises one alpha10 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"75c5b3463342494486fad0de6628ae17","type":"GO_TERM","name":"integrin alpha11-beta1 complex","canonical_id":"go:GO:0034681","description":"\"An integrin complex that comprises one alpha11 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"1448604a11a644d2a05d526dc2e1047e","type":"GO_TERM","name":"integrin alpha2-beta1 complex","canonical_id":"go:GO:0034666","description":"\"An integrin complex that comprises one alpha2 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"bc793b3b70db40db93ae2656ff545b2f","type":"GO_TERM","name":"integrin alpha3-beta1 complex","canonical_id":"go:GO:0034667","description":"\"An integrin complex that comprises one alpha3 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"30ce285f53cf47fb8bedcc6fc8518e9a","type":"GO_TERM","name":"integrin alpha4-beta1 complex","canonical_id":"go:GO:0034668","description":"\"An integrin complex that comprises one alpha4 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"11521ea2e9e848549853b37f990eb39d","type":"GO_TERM","name":"integrin alpha4-beta7 complex","canonical_id":"go:GO:0034669","description":"\"An integrin complex that comprises one alpha4 subunit and one beta7 subunit.\" [PMID:12297042]","metadata":null},{"id":"c71ab221a395425799dfaa501a8bcf41","type":"GO_TERM","name":"integrin alpha5-beta1 complex","canonical_id":"go:GO:0034674","description":"\"An integrin complex that comprises one alpha5 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"c7ca9f26f6784dfc95eaf09183c7a18b","type":"GO_TERM","name":"integrin alpha6-beta1 complex","canonical_id":"go:GO:0034675","description":"\"An integrin complex that comprises one alpha6 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"84c39238b2694b748ddbeede10010a88","type":"GO_TERM","name":"integrin alpha6-beta4 complex","canonical_id":"go:GO:0034676","description":"\"An integrin complex that comprises one alpha6 subunit and one beta4 subunit.\" [PMID:12297042]","metadata":null},{"id":"d6e189ab74a147089b2a1fe925668493","type":"GO_TERM","name":"integrin alpha7-beta1 complex","canonical_id":"go:GO:0034677","description":"\"An integrin complex that comprises one alpha7 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"3684261cf76b47c294ace063c1d6fc34","type":"GO_TERM","name":"integrin alpha8-beta1 complex","canonical_id":"go:GO:0034678","description":"\"An integrin complex that comprises one alpha8 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"266aff41feac47fbbfd8ed9bfbbb93f3","type":"GO_TERM","name":"integrin alpha9-beta1 complex","canonical_id":"go:GO:0034679","description":"\"An integrin complex that comprises one alpha9 subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"c719047470834cf58bf0ec7dec46d037","type":"GO_TERM","name":"integrin alphaD-beta2 complex","canonical_id":"go:GO:0034690","description":"\"An integrin complex that comprises one alphaD subunit and one beta2 subunit.\" [PMID:12297042]","metadata":null},{"id":"a3b9ae19e26b4c9c80471a0bc6e09825","type":"GO_TERM","name":"integrin alphaE-beta7 complex","canonical_id":"go:GO:0034691","description":"\"An integrin complex that comprises one alphaE subunit and one beta7 subunit.\" [PMID:12297042]","metadata":null},{"id":"9aed32d69cc647f19ae4b1ab9e36affb","type":"GO_TERM","name":"integrin alphaIIb-beta3 complex","canonical_id":"go:GO:0070442","description":"\"An integrin complex that comprises one alphaIIb subunit and one beta3 subunit.\" [PMID:12297042]","metadata":null},{"id":"586509d76db44d988e414543cd43a6b3","type":"GO_TERM","name":"integrin alphaL-beta2 complex","canonical_id":"go:GO:0034687","description":"\"An integrin complex that comprises one alphaL subunit and one beta2 subunit.\" [PMID:12297042]","metadata":null},{"id":"562526a820dc47fdbdef2a857a362902","type":"GO_TERM","name":"integrin alphaM-beta2 complex","canonical_id":"go:GO:0034688","description":"\"An integrin complex that comprises one alphaM subunit and one beta2 subunit.\" [PMID:12297042]","metadata":null},{"id":"e6ebc15c868142b986f981c1d03dd011","type":"GO_TERM","name":"integrin alphaX-beta2 complex","canonical_id":"go:GO:0034689","description":"\"An integrin complex that comprises one alphaX subunit and one beta2 subunit.\" [PMID:12297042]","metadata":null},{"id":"5ab153868463493daeb21c099f715542","type":"GO_TERM","name":"integrin alphav-beta1 complex","canonical_id":"go:GO:0034682","description":"\"An integrin complex that comprises one alphav subunit and one beta1 subunit.\" [PMID:12297042]","metadata":null},{"id":"3768d30ec77b4308bd01ba45690cc9ef","type":"GO_TERM","name":"integrin alphav-beta3 complex","canonical_id":"go:GO:0034683","description":"\"An integrin complex that comprises one alphav subunit and one beta3 subunit.\" [PMID:12297042]","metadata":null},{"id":"9f9c35cb6c6f4fa1ac578389808c92dd","type":"GO_TERM","name":"integrin alphav-beta5 complex","canonical_id":"go:GO:0034684","description":"\"An integrin complex that comprises one alphav subunit and one beta5 subunit.\" [PMID:12297042]","metadata":null},{"id":"9a298ae8ab6541fb8e55be2a3acbd207","type":"GO_TERM","name":"integrin alphav-beta6 complex","canonical_id":"go:GO:0034685","description":"\"An integrin complex that comprises one alphav subunit and one beta6 subunit.\" [PMID:12297042]","metadata":null},{"id":"6634e3d0e69346cc8517b86875198bcc","type":"GO_TERM","name":"integrin alphav-beta8 complex","canonical_id":"go:GO:0034686","description":"\"An integrin complex that comprises one alphav subunit and one beta8 subunit.\" [PMID:12297042]","metadata":null},{"id":"460635a0a6144d96bf533fe631628f53","type":"GO_TERM","name":"integrin binding","canonical_id":"go:GO:0005178","description":"\"Binding to an integrin.\" [GOC:ceb]","metadata":null},{"id":"e145e69804074bc8836d4b04680dfba4","type":"GO_TERM","name":"integrin binding involved in cell-matrix adhesion","canonical_id":"go:GO:0098640","description":"\"Any integrin binding that occurs as part of the process of cell-matrix adhesion.\" [GOC:dos]","metadata":null},{"id":"6ac346de157b4842adf9f0c7f5a15473","type":"GO_TERM","name":"integrin biosynthetic process","canonical_id":"go:GO:0045112","description":"\"The chemical reactions and pathways resulting in the formation of integrins, a large family of transmembrane proteins that act as receptors for cell-adhesion molecules.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c633ae7d755c4309a7c8fc8d163ae78c","type":"GO_TERM","name":"integrin complex","canonical_id":"go:GO:0008305","description":"\"A protein complex that is composed of one alpha subunit and one beta subunit, both of which are members of the integrin superfamily of cell adhesion receptors; the complex spans the plasma membrane and binds to extracellular matrix ligands, cell-surface ligands, and soluble ligands.\" [PMID:17543136]","metadata":null},{"id":"6f77e9b5dc9d496283a37eb817247f0a","type":"GO_TERM","name":"integrin-mediated signaling pathway","canonical_id":"go:GO:0007229","description":"\"The series of molecular signals initiated by an extracellular ligand binding to an integrin on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"ee02bd19717c42a7b7213bacae17973e","type":"GO_TERM","name":"integument development","canonical_id":"go:GO:0080060","description":"\"The process whose specific outcome is the progression of the integument over time, from its formation to the mature structure. Integument is one of the layers of tissue that usually covers the ovule, enveloping the nucellus and forming the micropyle at the apex.\" [PMID:19054366, PO:0020021]","metadata":null},{"id":"716b9aa911e34d098b412ac808430cf1","type":"GO_TERM","name":"integument-mediated background adaptation","canonical_id":"go:GO:0120304","description":"\"Any process in which an organism changes its pigmentation (lightening in response to a brighter environment or darkening in response to a dimmer environment) in response to a change in light intensity detected by light sensitive cells in the integument.\" [GOC:cvs, GOC:krc, PMID:29239123, PMID:32898924]","metadata":null},{"id":"1efe60e7da45458085e5e9aa726500fa","type":"GO_TERM","name":"intein-mediated protein splicing","canonical_id":"go:GO:0016539","description":"\"The removal of an internal amino acid sequence (an intein) from a protein during protein maturation; the excision of inteins is precise and the N- and C-terminal exteins are joined by a normal peptide bond. Protein splicing involves 4 nucleophilic displacements by the 3 conserved splice junction residues.\" [GOC:ma, PMID:16305544]","metadata":null},{"id":"fbfcbf81cf9d4e539e565f4cbd50aae5","type":"DISEASE","name":"intellectual disability, autosomal dominant 46","canonical_id":"mondo:0030911","description":null,"metadata":null},{"id":"398b87c541ab494189184365a551478c","type":"DISEASE","name":"intellectual disability, autosomal dominant 48","canonical_id":"efo:0009156","description":null,"metadata":null},{"id":"c1e27b9e496f4e7c89abb1eaf4b533d8","type":"DISEASE","name":"intellectual disability, autosomal dominant 6","canonical_id":"mondo:0013509","description":null,"metadata":null},{"id":"958b1cb10e6649b0b3a7ddc80a395790","type":"DISEASE","name":"intellectual disability, autosomal recessive 59","canonical_id":"mondo:0015020","description":null,"metadata":null},{"id":"0b5406fbe3a3458b903d3284f3fe7af0","type":"GO_TERM","name":"inter-Golgi cisterna vesicle-mediated transport","canonical_id":"go:GO:0048219","description":"\"The directed movement of substances from one Golgi cisterna to another, mediated by small transport vesicles.\" [GOC:jid, GOC:mah, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"c8cf7526fe8c49e887ca620af49fd7a4","type":"GO_TERM","name":"inter-Golgi transport vesicle membrane","canonical_id":"go:GO:0012509","description":"\"The lipid bilayer surrounding a vesicle transporting substances within the Golgi.\" [GOC:ai]","metadata":null},{"id":"ee80f8f1a19040d3b4f9851da3e5e3d8","type":"GO_TERM","name":"inter-male aggressive behavior","canonical_id":"go:GO:0002121","description":"\"Aggressive behavior based on competition between males of the same species over access to resources such as females, dominance, status, etc. and characterized by noise, threats, and is often less injurious.\" [GOC:hjd]","metadata":null},{"id":"9ca035ecb3e144c8a330df7b66c30f88","type":"GO_TERM","name":"intercalary heterochromatin","canonical_id":"go:GO:0005725","description":"\"Any of the regions of heterochromatin that form a reproducible set of dense bands scattered along the euchromatic arms in polytene chromosomes.\" [PMID:14579245]","metadata":null},{"id":"addb1acdc1b7469aa2c7c865ad0a7dba","type":"GO_TERM","name":"intercalary leaflet morphogenesis","canonical_id":"go:GO:0060780","description":"\"The process in which the intercalary leaflet attains its shape. An intercalary leaflet is a leaflet that develops between primary leaflets.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"1f29fd6de3174380977c7c9255923c68","type":"GO_TERM","name":"intercalated disc","canonical_id":"go:GO:0014704","description":"\"A complex cell-cell junction at which myofibrils terminate in cardiomyocytes; mediates mechanical and electrochemical integration between individual cardiomyocytes. The intercalated disc contains regions of tight mechanical attachment (fasciae adherentes and desmosomes) and electrical coupling (gap junctions) between adjacent cells.\" [GOC:mtg_muscle, PMID:11732910]","metadata":null},{"id":"363c62aa5ffc4e21b4dca824d9387653","type":"GO_TERM","name":"intercellular adhesion molecule-3 receptor binding","canonical_id":"go:GO:0030370","description":"\"Binding to a receptor for intercellular adhesion molecule-3 (ICAM-3), such as DC-SIGN and LFA-1.\" [GOC:ceb, PMID:11473836]","metadata":null},{"id":"59c2cfe806d64a6c952327e47b9cd3ca","type":"GO_TERM","name":"intercellular bridge","canonical_id":"go:GO:0045171","description":"\"A direct connection between the cytoplasm of two cells that is formed following the completion of cleavage furrow ingression during cell division. They are usually present only briefly prior to completion of cytokinesis. However, in some cases, such as the bridges between germ cells during their development, they become stabilised.\" [PMID:9635420]","metadata":null},{"id":"5fc1b68e83224faaad219e32747889e2","type":"GO_TERM","name":"intercellular bridge organization","canonical_id":"go:GO:0043063","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the intracellular bridge. An intracellular bridge is a direct link between the cytoplasms of sister cells that allows cells to communicate with one another.\" [GOC:jid]","metadata":null},{"id":"3bbd7ef8f1f447adb14991628498df37","type":"GO_TERM","name":"intercellular canaliculus","canonical_id":"go:GO:0046581","description":"\"An extremely narrow tubular channel located between adjacent cells. An instance of this is the secretory canaliculi occurring between adjacent parietal cells in the gastric mucosa of vertebrates.\" [ISBN:0721662544]","metadata":null},{"id":"852f250da934460aac2c87494560fc2c","type":"GO_TERM","name":"intercellular transport","canonical_id":"go:GO:0010496","description":"\"The movement of substances between cells.\" [GOC:dhl]","metadata":null},{"id":"7a2a3b8c8430458cb42b01cf34855432","type":"GO_TERM","name":"interchromatin granule","canonical_id":"go:GO:0035061","description":"\"A class of nuclear body measuring 20-25 nm in diameter and distributed throughout the interchromatin space, linked together by thin fibrils. They are believed to be storage centers for various snRNAs, snRNPs, serine/arginine-rich proteins and RNA polymerase II. A typical mammalian cell contains 25-50 clusters of interchromatin granules. Interchromatin granule clusters do not contain the heterogeneous nuclear RNA-binding proteins (hnRNPs).\" [GOC:bf, PMID:10984439]","metadata":null},{"id":"bc95d5d2048c4b7f9e964a18aeb4bed1","type":"DRUG","name":"interferon alfa-2b","canonical_id":"mesh:C554127","description":null,"metadata":null},{"id":"357d9b11bf464e739ef7ea55c5b1ef21","type":"GO_TERM","name":"interferon binding","canonical_id":"go:GO:0019961","description":"\"Binding to an interferon, a protein produced by the immune systems of many animals in response to a challenge by a foreign agent.\" [PMID:9607096, Wikipedia:Interferon]","metadata":null},{"id":"7b00de5a592e45aea22c7203f3db1574","type":"GO_TERM","name":"interferon receptor activity","canonical_id":"go:GO:0004904","description":"\"Combining with an interferon and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:ai, GOC:signaling, PMID:9607096]","metadata":null},{"id":"b83a62e42fcb48609fdecd4c518b0a28","type":"GO_TERM","name":"interferon regulatory factor 3 complex","canonical_id":"go:GO:0097072","description":"\"An interferon regulatory factor complex that consists of a homodimer of interferon regulatory factor 3.\" [GOC:cna, PMID:12855817, PMID:14556004]","metadata":null},{"id":"af22d14e33ac4c408cbae141a993465e","type":"GO_TERM","name":"interferon regulatory factor 3-interferon regulatory factor 5 complex","canonical_id":"go:GO:0097085","description":"\"An interferon regulatory factor complex that consists of a heterodimer of interferon regulatory factor 3 and interferon regulatory factor 5.\" [GOC:cna, PMID:12138184]","metadata":null},{"id":"978b120075b74b9bb5aa7fb29127457b","type":"GO_TERM","name":"interferon regulatory factor 3-interferon regulatory factor 7 complex","canonical_id":"go:GO:0097075","description":"\"An interferon regulatory factor complex that consists of a heterodimer of interferon regulatory factor 3 and interferon regulatory factor 7.\" [GOC:cna, PMID:18068231]","metadata":null},{"id":"1d80e68b25aa4166954b0c2d84e0b766","type":"GO_TERM","name":"interferon regulatory factor 5 complex","canonical_id":"go:GO:0097073","description":"\"An interferon regulatory factor complex that consists of a homodimer of interferon regulatory factor 5.\" [GOC:cna, PMID:12138184, PMID:16751392]","metadata":null},{"id":"65926530dd124a8987251f550d450908","type":"GO_TERM","name":"interferon regulatory factor 7 complex","canonical_id":"go:GO:0097074","description":"\"An interferon regulatory factor complex that consists of a homodimer of interferon regulatory factor 7.\" [GOC:cna, PMID:18068231]","metadata":null},{"id":"4a93876745be499b85f9a70b0362c88c","type":"GO_TERM","name":"interferon regulatory factor complex","canonical_id":"go:GO:0097071","description":"\"A protein complex that consists of two interferon regulatory proteins (IRFs); may be homodimeric or heterodimeric. The activation of a latent closed conformation of IRF in the cytoplasm is triggered by phosphorylation of Ser/Thr residues in a C-terminal region. Phosphorylation stimulates the C-terminal autoinhibitory domain to attain a highly extended conformation triggering dimerization through extensive contacts to a second subunit.\" [GOC:cna, PMID:20043992]","metadata":null},{"id":"69a5395eba9a4e64b25e34b1846d9519","type":"GO_TERM","name":"interferon-alpha production","canonical_id":"go:GO:0032607","description":"\"The appearance of interferon-alpha due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"bc2bcc32bffa4b3e85393a6b75fee9e4","type":"GO_TERM","name":"interferon-beta production","canonical_id":"go:GO:0032608","description":"\"The appearance of interferon-beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"8a6c432b8c844a2dbf33b007e4b20944","type":"GO_TERM","name":"interferon-delta production","canonical_id":"go:GO:0072645","description":"\"The appearance of interferon-delta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"7f5f9e597540479b8bd703be85852dbc","type":"GO_TERM","name":"interferon-epsilon production","canonical_id":"go:GO:0072647","description":"\"The appearance of interferon-epsilon due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"89ff966a66a24bde885940a11facce6c","type":"GO_TERM","name":"interferon-kappa production","canonical_id":"go:GO:0072649","description":"\"The appearance of interferon-kappa due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"8db28ab1e89f4fdbbbd9f2d1606181e7","type":"GO_TERM","name":"interferon-mediated signaling pathway","canonical_id":"go:GO:0140888","description":"\"The series of molecular signals initiated by type II interferon binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Type II interferon is also known as interferon-gamma.\" [GOC:add, GOC:dph, GOC:signaling, PMID:32464097]","metadata":null},{"id":"bf6f0b1e6fa74f258ea8f4586873b426","type":"GO_TERM","name":"interferon-omega production","canonical_id":"go:GO:0072653","description":"\"The appearance of interferon-omega due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"f3069570f5ba4e59b6780963e4392d16","type":"GO_TERM","name":"interferon-tau production","canonical_id":"go:GO:0072651","description":"\"The appearance of interferon-tau due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"03a85959fa4d4009b6d61c38bfb9fb3d","type":"GO_TERM","name":"interkinetic nuclear migration","canonical_id":"go:GO:0022027","description":"\"The movement of the nucleus of the ventricular zone cell between the apical and the basal zone surfaces. Mitosis occurs when the nucleus is near the apical surface, that is, the lumen of the ventricle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"de5a648cb34f4e2d99619d595dafc771","type":"GO_TERM","name":"interleukin-1 alpha production","canonical_id":"go:GO:0032610","description":"\"The appearance of interleukin-1 alpha due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"f6f1c35d34734053b77d78e324a56acf","type":"GO_TERM","name":"interleukin-1 beta production","canonical_id":"go:GO:0032611","description":"\"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"1bc4b59a986d4fafa7ab01031ac65227","type":"GO_TERM","name":"interleukin-1 binding","canonical_id":"go:GO:0019966","description":"\"Binding to interleukin-1.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f8239de345c04acbb50f94272c629e1e","type":"GO_TERM","name":"interleukin-1 production","canonical_id":"go:GO:0032612","description":"\"The appearance of interleukin-1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"9b7e229148764b3c9b064178c11a1215","type":"GO_TERM","name":"interleukin-1 receptor activity","canonical_id":"go:GO:0004908","description":"\"Combining with interleukin-1 to initiate a change in cell activity. Interleukin-1 is produced mainly by activated macrophages and is involved in the inflammatory response.\" [GOC:jl]","metadata":null},{"id":"26309d36db0f40dab4066e1b260c4439","type":"GO_TERM","name":"interleukin-1 receptor antagonist activity","canonical_id":"go:GO:0005152","description":"\"Blocks the binding of interleukin-1 to the interleukin-1 receptor complex.\" [GOC:ebc]","metadata":null},{"id":"2ca3b2a1a148403fb75dd01e3b02e0cd","type":"GO_TERM","name":"interleukin-1 receptor binding","canonical_id":"go:GO:0005149","description":"\"Binding to an interleukin-1 receptor.\" [GOC:curators]","metadata":null},{"id":"b7d5e3b29d5b4381b4fc755dbb746ad1","type":"GO_TERM","name":"interleukin-1 receptor complex","canonical_id":"go:GO:0045323","description":"\"A protein complex that binds interleukin-1; comprises an alpha and a beta subunit.\" [GOC:mah, InterPro:IPR004075]","metadata":null},{"id":"a3e5cdbb6d1a43418edd059f1def00d9","type":"GO_TERM","name":"interleukin-1 type I receptor antagonist activity","canonical_id":"go:GO:0045352","description":"\"Blocks the binding of interleukin-1 to interleukin-1 type I receptors.\" [GOC:ebc]","metadata":null},{"id":"97f0a6b244774b239473280d66a3cfda","type":"GO_TERM","name":"interleukin-1 type II receptor antagonist activity","canonical_id":"go:GO:0045353","description":"\"Blocks the binding of interleukin-1 to interleukin-1 type II receptors.\" [GOC:ebc]","metadata":null},{"id":"2ac492ec7af2456b870c5232578d68f7","type":"GO_TERM","name":"interleukin-1, type I receptor binding","canonical_id":"go:GO:0005150","description":"\"Binding to a Type I interleukin-1 receptor.\" [GOC:ai]","metadata":null},{"id":"2101cc1687a64c6692a6ba3a37bb8d37","type":"GO_TERM","name":"interleukin-1, type I, activating receptor activity","canonical_id":"go:GO:0004909","description":"\"Combining with interleukin-1 to initiate a change in cell activity via signaling pathways and mediated by adaptor proteins.\" [PMID:15062641, PMID:18613828]","metadata":null},{"id":"ad80d6e3498a4565b1712b71a00c4d90","type":"GO_TERM","name":"interleukin-1, type II receptor binding","canonical_id":"go:GO:0005151","description":"\"Binding to a Type II interleukin-1 receptor.\" [GOC:ai]","metadata":null},{"id":"14acf008faa6430cbdb5fc56a497410d","type":"GO_TERM","name":"interleukin-1, type II, blocking receptor activity","canonical_id":"go:GO:0004910","description":"\"Combining with interleukin-1 to initiate a change in cell activity by inhibiting the activity of type I interleukin receptors.\" [PMID:15062641, PMID:18613828]","metadata":null},{"id":"d702490423e74a939c088b52b9d3cc80","type":"GO_TERM","name":"interleukin-1-mediated signaling pathway","canonical_id":"go:GO:0070498","description":"\"The series of molecular signals initiated by interleukin-1 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"3cf5ec7641d7438ca77b16ea6fb31565","type":"GO_TERM","name":"interleukin-10 binding","canonical_id":"go:GO:0019969","description":"\"Binding to interleukin-10.\" [GOC:jl]","metadata":null},{"id":"2d47d92cb0204a45a0af44126a974389","type":"GO_TERM","name":"interleukin-10 production","canonical_id":"go:GO:0032613","description":"\"The appearance of interleukin-10 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"a611b309ab424fe096d8cd83c0289193","type":"GO_TERM","name":"interleukin-10 receptor activity","canonical_id":"go:GO:0004920","description":"\"Combining with interleukin-10 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"8093217f7dc04df9a80bc52129231373","type":"GO_TERM","name":"interleukin-10 receptor binding","canonical_id":"go:GO:0005141","description":"\"Binding to an interleukin-10 receptor.\" [GOC:ai]","metadata":null},{"id":"21b72366ddc548bbb52b2b1f5a0e99e0","type":"GO_TERM","name":"interleukin-10 receptor complex","canonical_id":"go:GO:1905571","description":"\"A protein complex that binds interleukin-10 (IL-10) and that consists of, at a minimum, a dimeric interleukin, an alpha and a beta chain as well as optional additional kinase subunits. The alpha chain binds IL-10 with high affinity and subsequently binds the common beta receptor chain that forms part of multiple interleukin receptors.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16982608]","metadata":null},{"id":"eab20451012945b1b5cb7a36090a3b1a","type":"GO_TERM","name":"interleukin-10-mediated signaling pathway","canonical_id":"go:GO:0140105","description":"\"The series of molecular signals initiated by interleukin-10 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:11244051]","metadata":null},{"id":"9394e326f96845fc8dab680afb1253e7","type":"GO_TERM","name":"interleukin-11 binding","canonical_id":"go:GO:0019970","description":"\"Binding to interleukin-11.\" [GOC:jl]","metadata":null},{"id":"1184e599b1a2406f9ad293f7de7c98a0","type":"GO_TERM","name":"interleukin-11 production","canonical_id":"go:GO:0032614","description":"\"The appearance of interleukin-11 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"1b082047b918435c9b172fa3aa2fa08e","type":"GO_TERM","name":"interleukin-11 receptor activity","canonical_id":"go:GO:0004921","description":"\"Combining with interleukin-11 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"0f846a32c814467fa17a4913111e1a1d","type":"GO_TERM","name":"interleukin-11 receptor binding","canonical_id":"go:GO:0005142","description":"\"Binding to an interleukin-11 receptor.\" [GOC:ai]","metadata":null},{"id":"c55ee818497d4819a8f1a60c5df083ca","type":"GO_TERM","name":"interleukin-11-mediated signaling pathway","canonical_id":"go:GO:0038154","description":"\"The series of molecular signals initiated by the binding of interleukin-11 to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"680add6c21074c22823b7d5d11170dab","type":"GO_TERM","name":"interleukin-12 alpha subunit binding","canonical_id":"go:GO:0042164","description":"\"Binding to the alpha subunit of interleukin-12.\" [GOC:mah]","metadata":null},{"id":"2bef034bcb984343b055227b2ee2e697","type":"GO_TERM","name":"interleukin-12 beta subunit binding","canonical_id":"go:GO:0042163","description":"\"Binding to the beta subunit of interleukin-12.\" [GOC:mah]","metadata":null},{"id":"7792535ed7fa4c2fa899c6bfff52064f","type":"GO_TERM","name":"interleukin-12 binding","canonical_id":"go:GO:0019972","description":"\"Binding to interleukin-12.\" [GOC:jl]","metadata":null},{"id":"0a7ef6eb6a454dfea475066fa99a0331","type":"GO_TERM","name":"interleukin-12 complex","canonical_id":"go:GO:0043514","description":"\"A protein complex that is composed of an interleukin-12 alpha (p35, product of the IL12A gene) and an interleukin-12 beta subunit (p40, product of the IL12B gene) and is secreted into the extracellular space.\" [GOC:add, GOC:ebc, GOC:mah, PMID:12948519, PMID:1381512]","metadata":null},{"id":"63febbe7b9aa4f1f8c8d564caa146a3d","type":"GO_TERM","name":"interleukin-12 production","canonical_id":"go:GO:0032615","description":"\"The appearance of interleukin-12 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"2d839efc14314a0d8866924bfc5e1672","type":"GO_TERM","name":"interleukin-12 receptor activity","canonical_id":"go:GO:0016517","description":"\"Combining with interleukin-12 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"1bfd955fff294cc3bed995f4728d9822","type":"GO_TERM","name":"interleukin-12 receptor binding","canonical_id":"go:GO:0005143","description":"\"Binding to an interleukin-12 receptor.\" [GOC:ai]","metadata":null},{"id":"51cda716f3044d26a3bb53af1c5ce414","type":"GO_TERM","name":"interleukin-12 receptor complex","canonical_id":"go:GO:0042022","description":"\"A protein complex that binds interleukin-12 and that consists of, at a minimum, a dimeric interleukin and its two receptor subunits as well as optional additional kinase subunits.\" [GOC:ebc, GOC:mah, PMID:10971505]","metadata":null},{"id":"9a85033ad7634d269da773e3a14b3899","type":"GO_TERM","name":"interleukin-12-interleukin-12 receptor complex","canonical_id":"go:GO:0070023","description":"\"A protein complex that is formed by the association of a heterodimeric interleukin-12 receptor complex with an interleukin-12 heterodimer.\" [PMID:11900991]","metadata":null},{"id":"7c26a0bf77f74aac950952e838f90085","type":"GO_TERM","name":"interleukin-12-mediated signaling pathway","canonical_id":"go:GO:0035722","description":"\"The series of molecular signals initiated by interleukin-12 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:signaling]","metadata":null},{"id":"46cfc9df48cf457ea2a7ed9f99862469","type":"GO_TERM","name":"interleukin-13 binding","canonical_id":"go:GO:0019973","description":"\"Binding to interleukin-13.\" [GOC:jl]","metadata":null},{"id":"882b84f052494e06b7528c6216e1c3af","type":"GO_TERM","name":"interleukin-13 production","canonical_id":"go:GO:0032616","description":"\"The appearance of interleukin-13 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"9d870005128f41d3badcdc33b8e4235c","type":"GO_TERM","name":"interleukin-13 receptor activity","canonical_id":"go:GO:0016515","description":"\"Combining with interleukin-13 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"020d3d84263e4251a407f4cc655455ae","type":"GO_TERM","name":"interleukin-13 receptor binding","canonical_id":"go:GO:0005144","description":"\"Binding to an interleukin-13 receptor.\" [GOC:ai]","metadata":null},{"id":"8f708ad405a141aa9f8f4a6cff14bb8a","type":"GO_TERM","name":"interleukin-13 receptor complex","canonical_id":"go:GO:0005898","description":"\"A protein complex that binds interleukin-13; consists of two chains, interleukin-13 receptor alpha1 chain and interleukin-4 receptor alpha chain.\" [PMID:8552669, PMID:9013879]","metadata":null},{"id":"5592aad70680449eacda7e62973c0cab","type":"GO_TERM","name":"interleukin-13-mediated signaling pathway","canonical_id":"go:GO:0035772","description":"\"The series of molecular signals initiated by interleukin-13 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:signaling]","metadata":null},{"id":"b24d32b6e1874249903dec22736492b6","type":"GO_TERM","name":"interleukin-15 binding","canonical_id":"go:GO:0042009","description":"\"Binding to interleukin-15.\" [GOC:jl]","metadata":null},{"id":"4702767f38af40f18742699deac59c01","type":"GO_TERM","name":"interleukin-15 production","canonical_id":"go:GO:0032618","description":"\"The appearance of interleukin-15 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"bd68ff036440414381787df8d8adb9ea","type":"GO_TERM","name":"interleukin-15 receptor activity","canonical_id":"go:GO:0042010","description":"\"Combining with interleukin-15 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"6e9275d257904a0eacaa55309b1f2d59","type":"GO_TERM","name":"interleukin-15 receptor binding","canonical_id":"go:GO:0016170","description":"\"Binding to an interleukin-15 receptor.\" [GOC:ai]","metadata":null},{"id":"22dd8a2ae07e49f496a19a66da7fa009","type":"GO_TERM","name":"interleukin-15 receptor complex","canonical_id":"go:GO:1905543","description":"\"A protein complex that binds interleukin-15 (IL-15) and that consists of, at a minimum, an interleukin, an alpha, beta and gamma chain as well as optional additional kinase subunits. The alpha chain is unique to binds IL-15 while it shares the beta chain with the IL-2 receptor and the cytokine receptor common gamma chain with multiple interleukin receptors.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:23104097]","metadata":null},{"id":"8dfb4ff584fe4d599c7bc80c0511d327","type":"GO_TERM","name":"interleukin-15-mediated signaling pathway","canonical_id":"go:GO:0035723","description":"\"The series of molecular signals initiated by interleukin-15 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:signaling]","metadata":null},{"id":"f8669aeb24b545e3a144e1f1451c5e4c","type":"GO_TERM","name":"interleukin-16 binding","canonical_id":"go:GO:0042011","description":"\"Binding to interleukin-16.\" [GOC:jl]","metadata":null},{"id":"a3e9a780c1954646af80450df5fa86c8","type":"GO_TERM","name":"interleukin-16 production","canonical_id":"go:GO:0032619","description":"\"The appearance of interleukin-16 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"1e856bea8b1648a29e17b7049721a221","type":"GO_TERM","name":"interleukin-16 receptor activity","canonical_id":"go:GO:0042012","description":"\"Combining with interleukin-16 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"7580c8cec8ec4a028f2a301b75389baf","type":"GO_TERM","name":"interleukin-16 receptor binding","canonical_id":"go:GO:0045514","description":"\"Binding to an interleukin-16 receptor.\" [GOC:curators]","metadata":null},{"id":"01efe2d829ff40ffb62e40c7d24ab79e","type":"GO_TERM","name":"interleukin-17 binding","canonical_id":"go:GO:0019975","description":"\"Binding to a member of the interleukin-17 family of cytokines.\" [GOC:add, GOC:jl]","metadata":null},{"id":"52673de4227b40c587538e328200607a","type":"GO_TERM","name":"interleukin-17 production","canonical_id":"go:GO:0032620","description":"\"The appearance of any member of the interleukin-17 family of cytokines due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, GOC:rv, Wikipedia:Interleukin_17]","metadata":null},{"id":"8737d0e90426492792ccb41077f610c0","type":"GO_TERM","name":"interleukin-17 receptor activity","canonical_id":"go:GO:0030368","description":"\"Combining with any member of the interleukin-17 family of cytokines and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:jl, GOC:signaling]","metadata":null},{"id":"23adc5274c114339876b5892bac08977","type":"GO_TERM","name":"interleukin-17 receptor binding","canonical_id":"go:GO:0030367","description":"\"Binding to an interleukin-17 receptor.\" [GOC:ai]","metadata":null},{"id":"a37b9fc0ed554a4796ef87e74c078cb1","type":"GO_TERM","name":"interleukin-17-mediated signaling pathway","canonical_id":"go:GO:0097400","description":"\"The series of molecular signals initiated by interleukin-17 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ic, PMID:21602493]","metadata":null},{"id":"6670e9543d764471a43a6321858c3cb2","type":"GO_TERM","name":"interleukin-17A production","canonical_id":"go:GO:0097087","description":"\"The appearance of interleukin-17A due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv, PMID:27901018]","metadata":null},{"id":"d050ad454ec8450b84baa14181a76dd4","type":"GO_TERM","name":"interleukin-17A receptor activity","canonical_id":"go:GO:0038174","description":"\"Combining with the cytokine interleukin-17A and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:jc, GOC:signaling]","metadata":null},{"id":"670c043b539c410ca7f9ba3e98f001e6","type":"GO_TERM","name":"interleukin-17A-mediated signaling pathway","canonical_id":"go:GO:0038173","description":"\"The series of molecular signals initiated by interleukin-17A binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:jc, GOC:signaling]","metadata":null},{"id":"f0289fe7070c481e929a95668436329a","type":"GO_TERM","name":"interleukin-17E receptor binding","canonical_id":"go:GO:0030380","description":"\"Binding to an interleukin-17E receptor.\" [GOC:ai]","metadata":null},{"id":"e42d0585d726436f9cb302862c822b07","type":"GO_TERM","name":"interleukin-17F production","canonical_id":"go:GO:0097088","description":"\"The appearance of interleukin-17F due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv, Wikipedia:Interleukin_17]","metadata":null},{"id":"3e05ccfa97ea48369ce23500a3183824","type":"GO_TERM","name":"interleukin-18 binding","canonical_id":"go:GO:0042007","description":"\"Binding to interleukin-18.\" [GOC:jl]","metadata":null},{"id":"8563193fea3a483bad5bc4da97a7994d","type":"GO_TERM","name":"interleukin-18 production","canonical_id":"go:GO:0032621","description":"\"The appearance of interleukin-18 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"65ed99ffa3a54055964edcf7aa4a482c","type":"GO_TERM","name":"interleukin-18 receptor activity","canonical_id":"go:GO:0042008","description":"\"Combining with interleukin-18 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"494660ecc30d411783de139cff094ac4","type":"GO_TERM","name":"interleukin-18 receptor binding","canonical_id":"go:GO:0045515","description":"\"Binding to an interleukin-18 receptor.\" [GOC:curators]","metadata":null},{"id":"01209a14c2924e42a82e9c360d877d33","type":"GO_TERM","name":"interleukin-18 receptor complex","canonical_id":"go:GO:0045092","description":"\"A protein complex that binds interleukin-18; comprises an alpha and a beta subunit.\" [GOC:mah, PMID:12759435]","metadata":null},{"id":"617ca2cbe59e48e48bcbe7155b58acd1","type":"GO_TERM","name":"interleukin-18-mediated signaling pathway","canonical_id":"go:GO:0035655","description":"\"The series of molecular signals initiated by interleukin-18 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:BHF, GOC:signaling]","metadata":null},{"id":"8cec35dd72f04312aba99765b42d2b08","type":"GO_TERM","name":"interleukin-19 binding","canonical_id":"go:GO:0042013","description":"\"Binding to interleukin-19.\" [GOC:jl]","metadata":null},{"id":"5983e5cbf461437a9032c39ecf3d5f05","type":"GO_TERM","name":"interleukin-19 production","canonical_id":"go:GO:0032622","description":"\"The appearance of interleukin-19 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"748e0d09120c40f2b0695344533d2900","type":"GO_TERM","name":"interleukin-19 receptor activity","canonical_id":"go:GO:0042014","description":"\"Combining with interleukin-19 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"e78f2f10e0fe462a844d535bd64d2928","type":"GO_TERM","name":"interleukin-19 receptor binding","canonical_id":"go:GO:0045516","description":"\"Binding to an interleukin-19 receptor.\" [GOC:curators]","metadata":null},{"id":"852ea986b1624990b1136bac467d7553","type":"GO_TERM","name":"interleukin-19-mediated signaling pathway","canonical_id":"go:GO:0140854","description":"\"The series of molecular signals initiated by interleukin-19 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:34052656]","metadata":null},{"id":"9accdf5c402c4671914678e8a8e3d301","type":"GO_TERM","name":"interleukin-2 binding","canonical_id":"go:GO:0019976","description":"\"Binding to interleukin-2.\" [GOC:jl]","metadata":null},{"id":"14b295d3fa17496fad777f061b4904f6","type":"GO_TERM","name":"interleukin-2 production","canonical_id":"go:GO:0032623","description":"\"The appearance of interleukin-2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"c148cc51aab043adbe7b4853fb44584e","type":"GO_TERM","name":"interleukin-2 receptor activity","canonical_id":"go:GO:0004911","description":"\"Combining with interleukin-2 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"2d9cc260ada24c98a1ca75bb0537cb71","type":"GO_TERM","name":"interleukin-2 receptor binding","canonical_id":"go:GO:0005134","description":"\"Binding to an interleukin-2 receptor.\" [GOC:ai]","metadata":null},{"id":"7f7eebdbc93f4cccae6440ff5be4fdec","type":"GO_TERM","name":"interleukin-2 receptor complex","canonical_id":"go:GO:0005893","description":"\"A protein complex that binds interleukin-2; comprises alpha, beta, and gamma subunits.\" [GOC:mah, PMID:3116143, PMID:8266078]","metadata":null},{"id":"5617c40b9ac94b988378f801cc429a8a","type":"GO_TERM","name":"interleukin-2-mediated signaling pathway","canonical_id":"go:GO:0038110","description":"\"The series of molecular signals initiated by interleukin-2 binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"63f75e6e648941f5abe54bd95ada071d","type":"GO_TERM","name":"interleukin-20 binding","canonical_id":"go:GO:0042015","description":"\"Binding to interleukin-20.\" [GOC:jl]","metadata":null},{"id":"402366c64ec841b19577d2e155b7acb2","type":"GO_TERM","name":"interleukin-20 production","canonical_id":"go:GO:0032624","description":"\"The appearance of interleukin-20 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"e65b777f14d34f2babaf3fe61a5718ab","type":"GO_TERM","name":"interleukin-20 receptor activity","canonical_id":"go:GO:0042016","description":"\"Combining with interleukin-20 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"6f15bbe2da294954be9e40fc32841af2","type":"GO_TERM","name":"interleukin-20 receptor binding","canonical_id":"go:GO:0045517","description":"\"Binding to an interleukin-20 receptor.\" [GOC:curators]","metadata":null},{"id":"11498686f4524efa93a5b6580c64f8d9","type":"GO_TERM","name":"interleukin-20 receptor complex","canonical_id":"go:GO:0030876","description":"\"A protein complex composed of an alpha and a beta receptor subunit and an interleukin ligand. In human, Interleukin-19, -20 and -24 bind IL20RA/IL20RB receptor subunits and Interleukin-20 and -24 bind IL22RA1/IL20RB receptor subunits.\" [PMID:12351624]","metadata":null},{"id":"5544eb7b18444417989f13b1b4d786a5","type":"GO_TERM","name":"interleukin-20-mediated signaling pathway","canonical_id":"go:GO:0140866","description":"\"The series of molecular signals initiated by interleukin-20 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:34755534]","metadata":null},{"id":"15634afd740a477cac8b1f3eab872fdc","type":"GO_TERM","name":"interleukin-21 binding","canonical_id":"go:GO:0019977","description":"\"Binding to interleukin-21.\" [GOC:jl]","metadata":null},{"id":"c3d4eeb40b3a43568f24ff759c6b6b71","type":"GO_TERM","name":"interleukin-21 production","canonical_id":"go:GO:0032625","description":"\"The appearance of interleukin-21 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"f470b7fa582c454a98fef0e41e43b862","type":"GO_TERM","name":"interleukin-21 receptor activity","canonical_id":"go:GO:0001532","description":"\"Combining with interleukin-21 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"a9435c5661964e10aff917b364d6ae1e","type":"GO_TERM","name":"interleukin-21 receptor binding","canonical_id":"go:GO:0001531","description":"\"Binding to an interleukin-21 receptor.\" [GOC:ai]","metadata":null},{"id":"b63c197d91d44ceab51dad4f855b1e0c","type":"GO_TERM","name":"interleukin-21-mediated signaling pathway","canonical_id":"go:GO:0038114","description":"\"The series of molecular signals initiated by interleukin-21 binding to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"361b5a2ff4c44a169a93150152f00672","type":"GO_TERM","name":"interleukin-22 binding","canonical_id":"go:GO:0042017","description":"\"Binding to interleukin-22.\" [GOC:jl]","metadata":null},{"id":"1ae30cf8ed8c42e485e5ad245355ba66","type":"GO_TERM","name":"interleukin-22 production","canonical_id":"go:GO:0032626","description":"\"The appearance of interleukin-22 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"1ab9fe656f1241c2ac260c6e035672e0","type":"GO_TERM","name":"interleukin-22 receptor activity","canonical_id":"go:GO:0042018","description":"\"Combining with interleukin-22 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"55d51c8674ac45fe86873d3eb6d4ec74","type":"GO_TERM","name":"interleukin-22 receptor binding","canonical_id":"go:GO:0045518","description":"\"Binding to an interleukin-22 receptor.\" [GOC:curators]","metadata":null},{"id":"5ac11648377a4fe79155f37f517a6b85","type":"GO_TERM","name":"interleukin-22-mediated signaling pathway","canonical_id":"go:GO:0140865","description":"\"The series of molecular signals initiated by interleukin-22 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:34755534]","metadata":null},{"id":"e60db31928b84ddcb800c6e4f90657a8","type":"GO_TERM","name":"interleukin-23 binding","canonical_id":"go:GO:0042019","description":"\"Binding to interleukin-23.\" [GOC:jl]","metadata":null},{"id":"90df5d5dde04414ea0ddfb3ed206a222","type":"GO_TERM","name":"interleukin-23 complex","canonical_id":"go:GO:0070743","description":"\"A protein complex that is composed of an interleukin-23 alpha (p19, product of the IL23A gene) and an interleukin-12 beta (p40, product of the IL12B gene) subunit and is secreted into the extracellular space.\" [GOC:add, PMID:11114383, PMID:15999093]","metadata":null},{"id":"2b4a8bdbe1354c609afe9d26a58e1287","type":"GO_TERM","name":"interleukin-23 production","canonical_id":"go:GO:0032627","description":"\"The appearance of interleukin-23 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"ee9ff12c449642c3bd02f3908832d9de","type":"GO_TERM","name":"interleukin-23 receptor activity","canonical_id":"go:GO:0042020","description":"\"Combining with interleukin-23 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"2c1d4f20c67648599ca8b50268f1a41a","type":"GO_TERM","name":"interleukin-23 receptor binding","canonical_id":"go:GO:0045519","description":"\"Binding to an interleukin-23 receptor.\" [GOC:curators]","metadata":null},{"id":"bb7c5422f5fa479f962cb7f6fe9171e5","type":"GO_TERM","name":"interleukin-23 receptor complex","canonical_id":"go:GO:0072536","description":"\"A protein complex that binds interleukin-23 and that consists of, at a minimum, a dimeric interleukin and its two receptor subunits as well as optional additional kinase subunits.\" [GOC:BHF, GOC:mah, PMID:12023369]","metadata":null},{"id":"2790074a7c5d49589f78ca40dd29c128","type":"GO_TERM","name":"interleukin-23-mediated signaling pathway","canonical_id":"go:GO:0038155","description":"\"The series of molecular signals initiated by interleukin-23 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"851bc88f1b314d92a7b2463e0214a8bf","type":"GO_TERM","name":"interleukin-24 binding","canonical_id":"go:GO:0045510","description":"\"Binding to interleukin-24.\" [GOC:curators]","metadata":null},{"id":"3b38e86c8df94288b55944ae6dc9c31d","type":"GO_TERM","name":"interleukin-24 production","canonical_id":"go:GO:0032628","description":"\"The appearance of interleukin-24 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"14538a551a7a444796792fecc9508163","type":"GO_TERM","name":"interleukin-24 receptor activity","canonical_id":"go:GO:0045506","description":"\"Combining with interleukin-24 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"f43a359b6dfd4de98d37dc8ec6149f0d","type":"GO_TERM","name":"interleukin-24 receptor binding","canonical_id":"go:GO:0045520","description":"\"Binding to an interleukin-24 receptor.\" [GOC:curators]","metadata":null},{"id":"c7b16c6c9db049bcb040c467999b8329","type":"GO_TERM","name":"interleukin-25 binding","canonical_id":"go:GO:0045511","description":"\"Binding to interleukin-25.\" [GOC:curators]","metadata":null},{"id":"e06068b90e5b4257a5a09071a3232f7b","type":"GO_TERM","name":"interleukin-25 production","canonical_id":"go:GO:0032629","description":"\"The appearance of interleukin-25 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"1ea415dd51ca43deba3832c405039eed","type":"GO_TERM","name":"interleukin-25 receptor activity","canonical_id":"go:GO:0045507","description":"\"Combining with interleukin-25 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"d6b10344302d434ea56a826753ddf445","type":"GO_TERM","name":"interleukin-25 receptor binding","canonical_id":"go:GO:0045521","description":"\"Binding to an interleukin-25 receptor.\" [GOC:curators]","metadata":null},{"id":"8a0a33863e674e55974bb695b917782f","type":"GO_TERM","name":"interleukin-26 binding","canonical_id":"go:GO:0045512","description":"\"Binding to interleukin-26.\" [GOC:curators]","metadata":null},{"id":"1332b61e926b460bae3ea10999f3e8b5","type":"GO_TERM","name":"interleukin-26 production","canonical_id":"go:GO:0032630","description":"\"The appearance of interleukin-26 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"d6faf2fdc0f845f7a422b2b9ef71f811","type":"GO_TERM","name":"interleukin-26 receptor activity","canonical_id":"go:GO:0045508","description":"\"Combining with interleukin-26 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"a3cc517feeef48f598ee2ec8f720906b","type":"GO_TERM","name":"interleukin-26 receptor binding","canonical_id":"go:GO:0045522","description":"\"Binding to an interleukin-26 receptor.\" [GOC:curators]","metadata":null},{"id":"ef88922bdaaf4998a878a413e3f233e2","type":"GO_TERM","name":"interleukin-27 binding","canonical_id":"go:GO:0045513","description":"\"Binding to interleukin-27.\" [GOC:curators]","metadata":null},{"id":"fe2fd8c60b234ec0adac0a39e38f9de3","type":"GO_TERM","name":"interleukin-27 complex","canonical_id":"go:GO:0070744","description":"\"A protein complex that is composed of an interleukin-27p28 subunit (product of the IL27 gene) and an EBI3 subunit and is secreted into the extracellular space.\" [GOC:add, PMID:15999093, PMID:19161428]","metadata":null},{"id":"e7103d93dc3a43c8b77927c9dd3e3fcd","type":"GO_TERM","name":"interleukin-27 production","canonical_id":"go:GO:0032631","description":"\"The appearance of interleukin-27 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"c453ebecc6f2487fbefe18be159a6556","type":"GO_TERM","name":"interleukin-27 receptor activity","canonical_id":"go:GO:0045509","description":"\"Combining with interleukin-27 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"76842c716894457fbb82bfcceeaf6d79","type":"GO_TERM","name":"interleukin-27 receptor binding","canonical_id":"go:GO:0045523","description":"\"Binding to an interleukin-27 receptor.\" [GOC:curators]","metadata":null},{"id":"a3609da16d884042b4ed95438ae1fd69","type":"GO_TERM","name":"interleukin-27-mediated signaling pathway","canonical_id":"go:GO:0070106","description":"\"The series of molecular signals initiated by interleukin-27 binding to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:add, GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"0fda366eb9104941b5702e2fe74696a8","type":"GO_TERM","name":"interleukin-28 receptor binding","canonical_id":"go:GO:0032003","description":"\"Binding to an interleukin-28 receptor.\" [GOC:rph]","metadata":null},{"id":"05f53af4d75c4748bd7982bcc085eed0","type":"GO_TERM","name":"interleukin-28 receptor complex","canonical_id":"go:GO:0032002","description":"\"A protein complex that binds interleukin-28 and interleukin-29. It is composed of an alpha and a beta receptor subunit (in human IFNLR1/IL28Ralpha & IL10RB) and either Interleukin-28 (IFNL2 or IFNL3) or Interleukin-29 (IFNL1).\" [GOC:rph]","metadata":null},{"id":"853a4a6a13974fb4a8924458cce70369","type":"GO_TERM","name":"interleukin-28A production","canonical_id":"go:GO:0072627","description":"\"The appearance of interleukin-28A due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"58c43d2910664ee78c5bf9f107f7afb9","type":"GO_TERM","name":"interleukin-28B production","canonical_id":"go:GO:0072629","description":"\"The appearance of interleukin-28B due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"9bc71dd5119b429186459f99ef09a028","type":"GO_TERM","name":"interleukin-29 production","canonical_id":"go:GO:0072631","description":"\"The appearance of interleukin-29 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:15546383]","metadata":null},{"id":"857a35bf89b843c38254709c4e463528","type":"GO_TERM","name":"interleukin-3 binding","canonical_id":"go:GO:0019978","description":"\"Binding to interleukin-3.\" [GOC:jl]","metadata":null},{"id":"dfe55e94f39548d4ad019346bc29368c","type":"GO_TERM","name":"interleukin-3 production","canonical_id":"go:GO:0032632","description":"\"The appearance of interleukin-3 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"031e1a92d7584af886c4a9d9f1f63502","type":"GO_TERM","name":"interleukin-3 receptor activity","canonical_id":"go:GO:0004912","description":"\"Combining with interleukin-3 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"15b0644a31a54ed0adcce4a7c69a93c0","type":"GO_TERM","name":"interleukin-3 receptor binding","canonical_id":"go:GO:0005135","description":"\"Binding to an interleukin-3 receptor.\" [GOC:ai]","metadata":null},{"id":"b4898ef627014992b5c83b9cae2362d9","type":"GO_TERM","name":"interleukin-3 receptor complex","canonical_id":"go:GO:0005894","description":"\"A protein complex that binds interleukin-3; comprises an alpha and a beta subunit. The alpha chain is specific to the interleukin-3 receptor, whereas the beta chain is shared with the receptors for granulocyte-macrophage colony-stimulating factor and interleukin-5.\" [PMID:11839579]","metadata":null},{"id":"b727b85ae7c14d2bb2cc33ad91e2335b","type":"GO_TERM","name":"interleukin-3-mediated signaling pathway","canonical_id":"go:GO:0038156","description":"\"The series of molecular signals initiated by interleukin-3 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"691fd76e806b4206b910bc5c1bda132c","type":"GO_TERM","name":"interleukin-30 production","canonical_id":"go:GO:0072633","description":"\"The appearance of interleukin-30 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:30328794]","metadata":null},{"id":"13e20f4566624ffbb7396d43733464ad","type":"GO_TERM","name":"interleukin-31 production","canonical_id":"go:GO:0072635","description":"\"The appearance of interleukin-31 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:30328794]","metadata":null},{"id":"b04ad4a5399049f4a0e726cc9b616079","type":"GO_TERM","name":"interleukin-32 production","canonical_id":"go:GO:0072637","description":"\"The appearance of interleukin-32 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:23729669]","metadata":null},{"id":"dcd0845f1bf44a51a862917569c298d3","type":"GO_TERM","name":"interleukin-32-mediated signaling pathway","canonical_id":"go:GO:0097399","description":"\"The series of molecular signals initiated by interleukin-32 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ic, PMID:21602493]","metadata":null},{"id":"02e3b28a2b0d4a36835af5985d5f4ac8","type":"GO_TERM","name":"interleukin-33 binding","canonical_id":"go:GO:0002113","description":"\"Binding to interleukin-33.\" [GOC:hjd]","metadata":null},{"id":"eec921c08c344b8bac9d2a6128f49b30","type":"GO_TERM","name":"interleukin-33 production","canonical_id":"go:GO:0072639","description":"\"The appearance of interleukin-33 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah, PMID:29778524]","metadata":null},{"id":"c1f84715720c4f0292be1e6dec5ccc61","type":"GO_TERM","name":"interleukin-33 receptor activity","canonical_id":"go:GO:0002114","description":"\"Combining with interleukin-33 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:hjd, GOC:signaling]","metadata":null},{"id":"a28e642e5d3c4c418c961015f5606681","type":"GO_TERM","name":"interleukin-33 receptor binding","canonical_id":"go:GO:0002112","description":"\"Binding to an interleukin-33 receptor.\" [GOC:hjd]","metadata":null},{"id":"cd15a96f53934fb3ac5aef4ef77af150","type":"GO_TERM","name":"interleukin-33-mediated signaling pathway","canonical_id":"go:GO:0038172","description":"\"The series of molecular signals initiated by interleukin-33 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:jc, GOC:signaling]","metadata":null},{"id":"6c1eae696b604aa3af073addad2ba6d0","type":"GO_TERM","name":"interleukin-34 production","canonical_id":"go:GO:0150155","description":"\"The appearance of interleukin-34 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:aruk, PMID:26754294]","metadata":null},{"id":"7c02d791dd74437e9079a0b4e327a0f1","type":"GO_TERM","name":"interleukin-34-mediated signaling pathway","canonical_id":"go:GO:0061514","description":"\"The series of molecular signals initiated by interleukin-34 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dph, PMID:18467591]","metadata":null},{"id":"dddc86e1c52c4164aa5d71607ea90e54","type":"GO_TERM","name":"interleukin-35 binding","canonical_id":"go:GO:0070746","description":"\"Binding to interleukin-35.\" [GOC:add]","metadata":null},{"id":"ba8c5cc72b0548339744835abb35d256","type":"GO_TERM","name":"interleukin-35 complex","canonical_id":"go:GO:0070745","description":"\"A protein complex that is composed of an interleukin-12 alpha subunit (p35, product of the IL12A gene) and an EBI3 subunit and is secreted into the extracellular space.\" [GOC:add, PMID:19161428, PMID:19161429]","metadata":null},{"id":"6be7ff2ceb734d508c2890db21baf3b8","type":"GO_TERM","name":"interleukin-35 production","canonical_id":"go:GO:0070753","description":"\"The appearance of interleukin-35 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"1548fd1c23fc4a43b93498971bc6c4f9","type":"GO_TERM","name":"interleukin-35 receptor activity","canonical_id":"go:GO:0070747","description":"\"Combining with interleukin-35 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling]","metadata":null},{"id":"e6764ccfa0074abc96de45eed4dbf8c9","type":"GO_TERM","name":"interleukin-35 receptor binding","canonical_id":"go:GO:0070748","description":"\"Binding to an interleukin-35 receptor.\" [GOC:add]","metadata":null},{"id":"ee10458c0a03485fa10216da1e883b5c","type":"GO_TERM","name":"interleukin-35-mediated signaling pathway","canonical_id":"go:GO:0070757","description":"\"The series of molecular signals initiated by interleukin-35 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:add, GOC:mah, GOC:signaling]","metadata":null},{"id":"79388e1ee1004b128d3910b5f27217ce","type":"GO_TERM","name":"interleukin-37 production","canonical_id":"go:GO:0150137","description":"\"The appearance of interleukin-37 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:aruk, PMID:30362558]","metadata":null},{"id":"8316daf686c444af88df32ab1438be9e","type":"GO_TERM","name":"interleukin-4 binding","canonical_id":"go:GO:0019979","description":"\"Binding to interleukin-4.\" [GOC:jl]","metadata":null},{"id":"2c50ec9652e74215ab35642ae354f1ed","type":"GO_TERM","name":"interleukin-4 production","canonical_id":"go:GO:0032633","description":"\"The appearance of interleukin-4 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"a36c0f63fef4460699119380d2355610","type":"GO_TERM","name":"interleukin-4 receptor activity","canonical_id":"go:GO:0004913","description":"\"Combining with interleukin-4 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"4c00070d38b244d08f2e0a928149d443","type":"GO_TERM","name":"interleukin-4 receptor binding","canonical_id":"go:GO:0005136","description":"\"Binding to an interleukin-4 receptor.\" [GOC:ai]","metadata":null},{"id":"d5faacb4c52b42eeb8475aa9dcaa221b","type":"GO_TERM","name":"interleukin-4 receptor complex","canonical_id":"go:GO:0016516","description":"\"A protein complex that binds interleukin-4 (IL-4) and consists of an alpha chain that binds IL-4 with high affinity and a gamma common chain that also forms part of the interleukin-2 receptor.\" [PMID:10358772]","metadata":null},{"id":"0de03cf30bca46d69e970f186e9fe114","type":"GO_TERM","name":"interleukin-4-dependent isotype switching to IgE isotypes","canonical_id":"go:GO:0035708","description":"\"The switching of activated B cells from IgM biosynthesis to IgE biosynthesis, accomplished through a recombination process involving an intrachromosomal deletion between switch regions that reside 5' of the IgM and IgE constant region gene segments in the immunoglobulin heavy chain locus, that is dependent on the activity of interleukin 4 (IL-4).\" [GOC:BHF, PMID:12496423]","metadata":null},{"id":"82442415b67b4d54a3427097611dcc3a","type":"GO_TERM","name":"interleukin-4-mediated signaling pathway","canonical_id":"go:GO:0035771","description":"\"The series of molecular signals initiated by interleukin-4 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:signaling]","metadata":null},{"id":"b6cf95a1bbd447178d7041a90f615710","type":"GO_TERM","name":"interleukin-5 binding","canonical_id":"go:GO:0019980","description":"\"Binding to interleukin-5.\" [GOC:jl]","metadata":null},{"id":"f763d5292f8f4dffb75bf35b96be4e51","type":"GO_TERM","name":"interleukin-5 production","canonical_id":"go:GO:0032634","description":"\"The appearance of interleukin-5 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"df028c88cf19447c8da3a0f8cf2ff795","type":"GO_TERM","name":"interleukin-5 receptor activity","canonical_id":"go:GO:0004914","description":"\"Combining with interleukin-5 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"9826db5cb68147eebe4d720cc11aafa8","type":"GO_TERM","name":"interleukin-5 receptor binding","canonical_id":"go:GO:0005137","description":"\"Binding to an interleukin-5 receptor.\" [GOC:ai]","metadata":null},{"id":"a705b6a2a49341db854ff4aed5b337d8","type":"GO_TERM","name":"interleukin-5 receptor complex","canonical_id":"go:GO:0005895","description":"\"A protein complex that binds interleukin-3; comprises an alpha and a beta subunit. The alpha chain is specific to the interleukin-5 receptor, whereas the beta chain is shared with the receptors for granulocyte-macrophage colony-stimulating factor and interleukin-3.\" [GOC:mah, PMID:11312115, PMID:11839579]","metadata":null},{"id":"acbd45905db1476d93cdeed2d500e237","type":"GO_TERM","name":"interleukin-5-mediated signaling pathway","canonical_id":"go:GO:0038043","description":"\"The series of molecular signals initiated by interleukin-5 binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling]","metadata":null},{"id":"24dd142ce5da4808a317fd534851e6a2","type":"GO_TERM","name":"interleukin-6 binding","canonical_id":"go:GO:0019981","description":"\"Binding to interleukin-6.\" [GOC:jl]","metadata":null},{"id":"58176eee7235417eb66db335fef4723a","type":"GO_TERM","name":"interleukin-6 production","canonical_id":"go:GO:0032635","description":"\"The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"10b89fc1ba5b4d41aab3b0fad244aa30","type":"GO_TERM","name":"interleukin-6 receptor activity","canonical_id":"go:GO:0004915","description":"\"Combining with interleukin-6 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"6eb0a7794c5141d0a62debe9db9cae09","type":"GO_TERM","name":"interleukin-6 receptor binding","canonical_id":"go:GO:0005138","description":"\"Binding to an interleukin-6 receptor.\" [GOC:ai]","metadata":null},{"id":"81b4214604cb4414a00bdc4aaa800d33","type":"GO_TERM","name":"interleukin-6 receptor complex","canonical_id":"go:GO:0005896","description":"\"A hexameric protein complex consisting of two molecules each of interleukin-6, interleukin-6 receptor alpha chain, and gp-130.\" [PMID:8083235]","metadata":null},{"id":"a5b6539328254571b0a9ce217c0453a3","type":"GO_TERM","name":"interleukin-6-mediated signaling pathway","canonical_id":"go:GO:0070102","description":"\"The series of molecular signals initiated by interleukin-6 binding to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:add, GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"49b48b93ef604a4aa5c015186401c64d","type":"GO_TERM","name":"interleukin-7 binding","canonical_id":"go:GO:0019982","description":"\"Binding to interleukin-7.\" [GOC:jl]","metadata":null},{"id":"9144c02cba94487a8af7cbc1966fd1c4","type":"GO_TERM","name":"interleukin-7 production","canonical_id":"go:GO:0032636","description":"\"The appearance of interleukin-7 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"55024ae8fef846688d004173b467a237","type":"GO_TERM","name":"interleukin-7 receptor activity","canonical_id":"go:GO:0004917","description":"\"Combining with interleukin-7 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"bf574bc7cd084f6dae55d3d63ecf770e","type":"GO_TERM","name":"interleukin-7 receptor binding","canonical_id":"go:GO:0005139","description":"\"Binding to an interleukin-7 receptor.\" [GOC:ai]","metadata":null},{"id":"c4e1b977911e4f4a86526529f2e07f98","type":"GO_TERM","name":"interleukin-7 receptor complex","canonical_id":"go:GO:1905540","description":"\"A protein complex that binds interleukin-7 (IL-7) and that consists of, at a minimum, an interleukin, an alpha and a gamma chain as well as optional additional kinase subunits. The alpha chain binds IL-7 with high affinity and subsequently binds the cytokine receptor common gamma chain that forms part of multiple interleukin receptors.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:19141282]","metadata":null},{"id":"480bc61b498e4e15aa87d67d52a5ee67","type":"GO_TERM","name":"interleukin-7-mediated signaling pathway","canonical_id":"go:GO:0038111","description":"\"The series of molecular signals initiated by interleukin-7 binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"e137f2207b98426db2b4f1167d76eebe","type":"GO_TERM","name":"interleukin-8 binding","canonical_id":"go:GO:0019959","description":"\"Binding to interleukin-8.\" [GOC:jl]","metadata":null},{"id":"0706b05a619f4cd88761d50fc0f709c6","type":"GO_TERM","name":"interleukin-8 production","canonical_id":"go:GO:0032637","description":"\"The appearance of interleukin-8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"3b96a64f118144489c5a43189e60b91c","type":"GO_TERM","name":"interleukin-8 receptor activity","canonical_id":"go:GO:0004918","description":"\"Combining with interleukin-8 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"389ab3d9034645f2aeea83b5bd1c0567","type":"GO_TERM","name":"interleukin-8 receptor binding","canonical_id":"go:GO:0005153","description":"\"Binding to an interleukin-8 receptor.\" [GOC:curators]","metadata":null},{"id":"91a58a137f2a402bb8d39c9721eced16","type":"GO_TERM","name":"interleukin-8-mediated signaling pathway","canonical_id":"go:GO:0038112","description":"\"The series of molecular signals initiated by interleukin-8 binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"e52dca0da996462bb4ebb88992b896c1","type":"GO_TERM","name":"interleukin-9 binding","canonical_id":"go:GO:0019983","description":"\"Binding to interleukin-9.\" [GOC:jl]","metadata":null},{"id":"f7692c0e590e4dc49e23fde3e96c9bb7","type":"GO_TERM","name":"interleukin-9 production","canonical_id":"go:GO:0032638","description":"\"The appearance of interleukin-9 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"a8f6c9964374423aa80f01d1cdc6c8ab","type":"GO_TERM","name":"interleukin-9 receptor activity","canonical_id":"go:GO:0004919","description":"\"Combining with interleukin-9 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"f0a8cb4e5a7c4abcb34497c41a64ee6d","type":"GO_TERM","name":"interleukin-9 receptor binding","canonical_id":"go:GO:0005140","description":"\"Binding to an interleukin-9 receptor.\" [GOC:ai]","metadata":null},{"id":"51d8fca6018947fa8d4d6b9f4b3a1815","type":"GO_TERM","name":"interleukin-9 receptor complex","canonical_id":"go:GO:0005897","description":"\"A protein complex that binds interleukin-9; comprises an alpha and a beta subunit. The alpha chain is specific to the interleukin-9 receptor, whereas the beta chain is shared with the receptors for several other interleukins.\" [GOC:mah, PMID:10642536]","metadata":null},{"id":"dac4b85d5c9048a181778528b470c300","type":"GO_TERM","name":"interleukin-9-mediated signaling pathway","canonical_id":"go:GO:0038113","description":"\"The series of molecular signals initiated by interleukin-9 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling]","metadata":null},{"id":"d5de653eaec7432086cc008466ba7b34","type":"GO_TERM","name":"interleukin4-interleukin-4 receptor complex","canonical_id":"go:GO:0070450","description":"\"A protein complex that is formed by the association of a heterodimeric interleukin-4 receptor complex with an interleukin-4 molecule.\" [GOC:mah, PMID:10358772]","metadata":null},{"id":"5f8da7c157a54ce4a46913bd4cc2b986","type":"GO_TERM","name":"intermediate conductance calcium-activated potassium channel activity","canonical_id":"go:GO:0022894","description":"\"Enables the transmembrane transfer of potassium by a channel with a unit conductance of 20 to 85 picoSiemens that opens in response to stimulus by internal calcium ions. Intermediate conductance calcium-activated potassium channels are more sensitive to calcium than are large conductance calcium-activated potassium channels. Transport by a channel involves catalysis of facilitated diffusion of a solute (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel, without evidence for a carrier-mediated mechanism.\" [GOC:mtg_transport, OMIM:602754]","metadata":null},{"id":"fd6d65ac6f8d48fd8d32bf1caed1a864","type":"DISEASE","name":"intermediate coronary syndrome","canonical_id":"mondo:0006805","description":null,"metadata":null},{"id":"8197859a3c40438c95cc3d52df721fd7","type":"GO_TERM","name":"intermediate filament","canonical_id":"go:GO:0005882","description":"\"A cytoskeletal structure that forms a distinct elongated structure, characteristically 10 nm in diameter, that occurs in the cytoplasm of eukaryotic cells. Intermediate filaments form a fibrous system, composed of chemically heterogeneous subunits and involved in mechanically integrating the various components of the cytoplasmic space. Intermediate filaments may be divided into five chemically distinct classes: Type I, acidic keratins; Type II, basic keratins; Type III, including desmin, vimentin and others; Type IV, neurofilaments and related filaments; and Type V, lamins.\" [ISBN:0198506732, PMID:17493611, PMID:17551517, PMID:7979242]","metadata":null},{"id":"bc74895465cb41aea56d4cf5e903b1aa","type":"GO_TERM","name":"intermediate filament binding","canonical_id":"go:GO:0019215","description":"\"Binding to an intermediate filament, a distinct elongated structure, characteristically 10 nm in diameter, that occurs in the cytoplasm of higher eukaryotic cells. Intermediate filaments form a fibrous system, composed of chemically heterogeneous subunits and involved in mechanically integrating the various components of the cytoplasmic space.\" [ISBN:0198506732]","metadata":null},{"id":"592456dff07f4189aa0cf7d52c4f0425","type":"GO_TERM","name":"intermediate filament bundle assembly","canonical_id":"go:GO:0045110","description":"\"The formation of the bundles of intermediate filaments. Intermediate filament-associated proteins (IFAPs) cross-link intermediate filaments with one another, forming a bundle or a network, and with other cell structures, including the plasma membrane. The organization of intermediate filaments and their supportive function in various cells types depends in large part on their linkage to other cell structures via IFAPs.\" [ISBN:0716731363]","metadata":null},{"id":"adaeb08ba25242028cd7f618d9ba66e0","type":"GO_TERM","name":"intermediate filament cytoskeleton","canonical_id":"go:GO:0045111","description":"\"Cytoskeletal structure made from intermediate filaments, typically organized in the cytosol as an extended system that stretches from the nuclear envelope to the plasma membrane. Some intermediate filaments run parallel to the cell surface, while others traverse the cytosol; together they form an internal framework that helps support the shape and resilience of the cell.\" [ISBN:0716731363]","metadata":null},{"id":"6e32cd92289f43f694a412fc86cbcf48","type":"GO_TERM","name":"intermediate filament cytoskeleton organization","canonical_id":"go:GO:0045104","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising intermediate filaments and their associated proteins.\" [GOC:ai]","metadata":null},{"id":"8a702c05f90e4eb2b955cdf991a9d502","type":"GO_TERM","name":"intermediate filament depolymerization","canonical_id":"go:GO:0045106","description":"\"Disassembly of intermediate filaments by the removal of component monomers from a filament.\" [GOC:mah, ISBN:0716731363]","metadata":null},{"id":"2a1686d2ba484d1eaedd798d19021062","type":"GO_TERM","name":"intermediate filament organization","canonical_id":"go:GO:0045109","description":"\"Control of the spatial distribution of intermediate filaments; includes organizing filaments into meshworks, bundles, or other structures, as by cross-linking.\" [GOC:ai]","metadata":null},{"id":"e906d2b424e44c54bca4a742177c3253","type":"GO_TERM","name":"intermediate filament polymerization","canonical_id":"go:GO:0045107","description":"\"Assembly of intermediate filaments by the addition of component monomers to a filament. Polymerization of intermediate filament proteins results from interactions among several distinct binding sites on the constituent proteins. Nuclear lamin head-to-tail polymers arise from one such interaction. Deletion analysis localized the binding sites to the ends of the rod domain that are highly conserved among all intermediate filament proteins. Data indicate that one type of interaction in intermediate filament protein polymerization is the longitudinal binding of dimers via the conserved end segments of the coiled-coil rod domain.\" [GOC:mah, PMID:8776884]","metadata":null},{"id":"500cf8f4f99040b68782ebe0d9edf113","type":"GO_TERM","name":"intermediate filament polymerization or depolymerization","canonical_id":"go:GO:0045105","description":"\"Assembly or disassembly of intermediate filaments by the addition or removal of component parts from a filament.\" [GOC:ai]","metadata":null},{"id":"e339464b02004513bba1eb82f2709dc1","type":"GO_TERM","name":"intermediate filament-based process","canonical_id":"go:GO:0045103","description":"\"Any cellular process that depends upon or alters the intermediate filament cytoskeleton, that part of the cytoskeleton comprising intermediate filaments and their associated proteins.\" [GOC:ai]","metadata":null},{"id":"dd4e0b285863499f85cc33a5184d3dc4","type":"GO_TERM","name":"intermediate layer of mitotic spindle pole body","canonical_id":"go:GO:0061498","description":"\"Structure between the central and outer plaques of the mitotic spindle pole body.\" [GOC:dph]","metadata":null},{"id":"353240b421a7478783e43ec85edcc29a","type":"GO_TERM","name":"intermediate layer of spindle pole body","canonical_id":"go:GO:0005821","description":"\"Structure between the central and outer plaques of the spindle pole body.\" [PMID:9215630]","metadata":null},{"id":"f1a26d19312f4dc6a8eb60cc40c39a5c","type":"GO_TERM","name":"intermediate mesoderm development","canonical_id":"go:GO:0048389","description":"\"The process whose specific outcome is the progression of the intermediate mesoderm over time, from its formation to the mature structure. The intermediate mesoderm is located between the lateral mesoderm and the paraxial mesoderm. It develops into the kidney and gonads.\" [GOC:dgh]","metadata":null},{"id":"fadbaca44af341a998d1ac9d4ff7b62c","type":"GO_TERM","name":"intermediate mesoderm formation","canonical_id":"go:GO:0048391","description":"\"The process that gives rise to the intermediate mesoderm. This process pertains to the initial formation of the structure from unspecified parts.\" [GOC:dgh]","metadata":null},{"id":"853a8e1848b64099bc26042fede53082","type":"GO_TERM","name":"intermediate mesoderm morphogenesis","canonical_id":"go:GO:0048390","description":"\"The process in which the anatomical structures of the intermediate mesoderm are generated and organized.\" [GOC:curators]","metadata":null},{"id":"4fee1673ba4a42e3b055825b05d148b4","type":"GO_TERM","name":"intermediate mesoderm structural organization","canonical_id":"go:GO:0048402","description":"\"The process that contributes to the act of creating the structural organization of the intermediate mesoderm. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dgh]","metadata":null},{"id":"140716839c034fc28f0bae536ccd43fe","type":"GO_TERM","name":"intermediate mesodermal cell differentiation","canonical_id":"go:GO:0048392","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an intermediate mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"0aaae7a5b52a474b9830746887268008","type":"GO_TERM","name":"intermediate mesodermal cell fate commitment","canonical_id":"go:GO:0048393","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an intermediate mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"75213962103d4a42a4ab9f397820b2eb","type":"GO_TERM","name":"intermediate mesodermal cell fate determination","canonical_id":"go:GO:0048394","description":"\"The process in which a cell becomes capable of differentiating autonomously into a intermediate mesoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:dgh]","metadata":null},{"id":"f407ece7f170429d8284533f574a2539","type":"GO_TERM","name":"intermediate mesodermal cell fate specification","canonical_id":"go:GO:0048398","description":"\"The process in which a cell becomes capable of differentiating autonomously into an intermediate mesoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dgh]","metadata":null},{"id":"e23b747e2c564113a4ab3945174db6af","type":"GO_TERM","name":"intermediate reticular formation development","canonical_id":"go:GO:0021727","description":"\"The process whose specific outcome is the progression of the intermediate reticular formation over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7d22944056f743c683c114847ddc42f9","type":"GO_TERM","name":"intermediate voltage-gated calcium channel activity","canonical_id":"go:GO:1990028","description":"\"Enables the transmembrane transfer of a calcium ion by an intermediate voltage-gated channel. An intermediate voltage-gated channel is a channel whose open state is dependent on intermediate voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:rl, PMID:16382099, Wikipedia:Calcium_channel]","metadata":null},{"id":"c6173ed96154451083bde21d48daa3b4","type":"GO_TERM","name":"intermediate-density lipoprotein particle","canonical_id":"go:GO:0034363","description":"\"A triglyceride-rich lipoprotein particle that typically contains APOB100, APOE and APOCs and has a density of 1.006-1.019 g/ml and a diameter of between 25-30 nm. IDL particles are found in blood and are formed by the delipidation of very-low-density lipoprotein particles (VLDL). IDL particles are removed from blood by the liver, following binding to the APOE receptor, or are converted to low-density lipoprotein (LDL).\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"de8738024ffe4d969e6d51db0b77a37d","type":"GO_TERM","name":"intermediate-density lipoprotein particle binding","canonical_id":"go:GO:0071815","description":"\"Binding to a intermediate-density lipoprotein particle, a triglyceride-rich lipoprotein particle that typically contains APOB100, APOE and APOCs and has a density of 1.006-1.019 g/ml and a diameter of between 25-30 nm.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d0fda749bdee44febb0434a0422e8aab","type":"GO_TERM","name":"intermediate-density lipoprotein particle clearance","canonical_id":"go:GO:0071831","description":"\"The process in which a intermediate-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF]","metadata":null},{"id":"2ada2c6016d94244ad34f2022e479c9d","type":"GO_TERM","name":"intermediate-density lipoprotein particle remodeling","canonical_id":"go:GO:0034373","description":"\"The acquisition, loss or modification of a protein or lipid within an intermediate-density lipoprotein particle.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"3684c115dbfc4e0cb552c64d5d835363","type":"GO_TERM","name":"intermembrane lipid transfer","canonical_id":"go:GO:0120009","description":"\"The transport of lipids between membranes in which a lipid molecule is transported through an aqueous phase from the outer leaflet of a donor membrane to the outer leaflet of an acceptor membrane. This process does not require metabolic energy and can be either spontaneous or mediated by lipid transfer proteins (LTPs).\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"403c7ec1bbb1462aa18b72905806bd49","type":"GO_TERM","name":"intermembrane lipid transporter complex","canonical_id":"go:GO:7770015","description":"\"A protein complex that mediates the transport of lipids between membranes, in which a lipid molecule or molecules is transferred through an aqueous phase from the outer leaflet of a donor membrane to the outer leaflet of an acceptor membrane.\" [PMID:39106189, PMID:40269155]","metadata":null},{"id":"33c83d9ab6c541b59cb2bcb6eca57e45","type":"GO_TERM","name":"intermembrane phospholipid transfer","canonical_id":"go:GO:0120010","description":"\"The transport of phospholipids between membranes in which a phospholipid molecule is transported through an aqueous phase from the outer leaflet of a donor membrane to the outer leaflet of an acceptor membrane.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"3ad33066b78f42548610335f23039da5","type":"GO_TERM","name":"intermembrane sphingolipid transfer","canonical_id":"go:GO:0120012","description":"\"The transport of sphingolipids between membranes in which a sphingolipid molecule is transported through an aqueous phase from the outer leaflet of a donor membrane to the outer leaflet of an acceptor membrane. This process does not require metabolic energy and can be either spontaneous or mediated by lipid transfer proteins (LTPs).\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"d1d8643d34d04a5983f3ed476e5fa5c7","type":"GO_TERM","name":"intermembrane sterol transfer","canonical_id":"go:GO:0120011","description":"\"The transport of sterols between membranes in which a sterol molecule is transported through an aqueous phase from the outer leaflet of a donor membrane to the outer leaflet of an acceptor membrane. This process does not require metabolic energy and can be either spontaneous or mediated by lipid transfer proteins (LTPs).\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"4f908f868bd645768953b3344bb98444","type":"GO_TERM","name":"intermicrovillar adhesion","canonical_id":"go:GO:0090675","description":"\"The cell-cell adhesion process by which adjacent microvilli attach to each other through Ca(2+)-dependent adhesion links made of protocadherin-24 and mucin-like protocadherin.\" [GOC:lb, PMID:24725409]","metadata":null},{"id":"b9c1de278941431fa9f5ebf0c1672d88","type":"DISEASE","name":"intermittent vascular claudication","canonical_id":"mondo:0005295","description":null,"metadata":null},{"id":"039923356c1e4802a773cd1bc7133934","type":"GO_TERM","name":"internal N(7)-methylguanine-containing RNA reader activity","canonical_id":"go:GO:0160089","description":"\"A protein adaptor that recognizes and binds an RNA molecule modified by N(7)-methylguanine (m7G), a modification present at internal sites of mRNAs and some non-coding RNAs.\" [PMID:37379838]","metadata":null},{"id":"459c92e6e03c48948ec7fcd4946cf4e5","type":"GO_TERM","name":"internal genitalia morphogenesis","canonical_id":"go:GO:0035260","description":"\"The process in which the anatomical structures of the internal genitalia are generated and organized. The internal genitalia are the internal sex organs such as the uterine tube, the uterus and the vagina in female mammals, and the testis, seminal vesicle, ejaculatory duct and prostate in male mammals.\" [PMID:24793987, PMID:25247640]","metadata":null},{"id":"2f1748448f2a4e29abeda860b3ff5c04","type":"GO_TERM","name":"internal mRNA (guanine-N7-)-methyltransferase activity","canonical_id":"go:GO:0160090","description":"\"Catalysis of the reaction: a guanosine in mRNA + S-adenosyl-L-methionine = an N(7)-methylguanosine in mRNA + S-adenosyl-L-homocysteine.\" [PMID:31031084, PMID:37379838, RHEA:60508]","metadata":null},{"id":"3cc0515ded22464b8ed844eb2cdf1853","type":"GO_TERM","name":"internal mammary gland bud epithelial cell differentiation","canonical_id":"go:GO:0060646","description":"\"The process in which a relatively unspecialized epithelial cell of the mammary placode becomes an internal epithelial cell of the mammary gland bud. Internal cells are small and of irregular shape.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"f5e3a44fadce462f842f0c76fa11970e","type":"GO_TERM","name":"internal peptidyl-lysine acetylation","canonical_id":"go:GO:0018393","description":"\"The addition of an acetyl group to a non-terminal lysine residue in a protein.\" [GOC:mah]","metadata":null},{"id":"d52799d8c39747f69936ae3e8630b2d6","type":"GO_TERM","name":"internal protein amino acid acetylation","canonical_id":"go:GO:0006475","description":"\"The addition of an acetyl group to a non-terminal amino acid in a protein.\" [GOC:mah]","metadata":null},{"id":"3b0e5652171e4c7783e15942aa3c496b","type":"GO_TERM","name":"internal side of mycolate outer membrane","canonical_id":"go:GO:0098569","description":"\"The leaflet of the mycolate outer membrane that faces the cell wall peptidoglycan, including any protein embedded in, attached to, or peripherally associated with it. It is rich in long-chain mycolic acids (hydroxylated branched-chain fatty acids) that are covalently linked to the cell wall peptidoglycan via an arabinogalactan network.\" [GOC:dos, PMID:18316738, PMID:18567661]","metadata":null},{"id":"1bcfc34a18ce4fbc8f2ca5e210ea2b33","type":"GO_TERM","name":"interneuron axon guidance","canonical_id":"go:GO:0097376","description":"\"The process in which the migration of an axon growth cone of an interneuron is directed to a specific target site in response to a combination of attractive and repulsive cues. An interneuron is any neuron which is not motor or sensory. Interneurons may also refer to neurons whose axons remain within a particular brain region, as contrasted with projection neurons which have axons projecting to other brain regions.\" [CL:0000099, GOC:pr]","metadata":null},{"id":"0e447b40d88240e28e9f6d31cca5b077","type":"GO_TERM","name":"interneuron migration","canonical_id":"go:GO:1904936","description":"\"The orderly movement of an interneuron from one site to another.\" [GO_REF:0000091, GOC:ah, GOC:TermGenie, PMID:18622031]","metadata":null},{"id":"22184129f9c84da8b7fd240f26553bef","type":"GO_TERM","name":"interneuron migration from the subpallium to the cortex","canonical_id":"go:GO:0021830","description":"\"The directed movement of interneurons from the subpallium to the cortex during forebrain development.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"adaf2f08feed402384e7cf4133ec3494","type":"GO_TERM","name":"internode patterning","canonical_id":"go:GO:0080006","description":"\"Determines the spacing between two shoot nodes. A shoot node is the region of the shoot where the spikelet, flower, floret, branch, bud and/or leaves are attached.\" [GOC:tb]","metadata":null},{"id":"68dbda1c7dab4c57bb98ac82f52dd3a0","type":"GO_TERM","name":"internode region of axon","canonical_id":"go:GO:0033269","description":"\"An axon part that is located between the nodes of Ranvier and surrounded by compact myelin sheath.\" [GOC:mah, GOC:mh]","metadata":null},{"id":"44b4f0b2d8ff4183b10aefcc5ce6c145","type":"GO_TERM","name":"interphase","canonical_id":"go:GO:0051325","description":"\"The cell cycle phase following cytokinesis which begins with G1 phase, proceeds through S phase and G2 phase and ends when prophase of meiosis or mitosis begins. During interphase the cell readies itself for meiosis or mitosis and the replication of its DNA occurs.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"96970fc39b4b47e18f1bc5bd85cf1b70","type":"GO_TERM","name":"interphase SIN signaling complex","canonical_id":"go:GO:0160066","description":"\"A SIN signaling complex associated with the old mitotic spindle pole body during interphase and early M-phase and characterised by the presence active ubiquitin ligase (Dma1 in fission yeast) and GTPase activator (Spg1 in fission yeast) to inactivate SIN signaling.\" [PMID:21131906]","metadata":null},{"id":"b261249bd8e94581a261c019d2509e8a","type":"GO_TERM","name":"interphase microtubule organizing center","canonical_id":"go:GO:0031021","description":"\"A microtubule organizing center found in interphase cells, which organize a longitudinal array of three to five MT bundles from the nuclear envelope during interphase. Each MT bundle is composed of two to seven MTs arranged in an antiparallel configuration, with the dynamic MT plus ends extending toward the cell tips and stable minus ends near the nucleus.\" [PMID:15068790]","metadata":null},{"id":"c6f747ba25fc4ceeb20d437b90e097d2","type":"GO_TERM","name":"interphase microtubule organizing center assembly","canonical_id":"go:GO:0031024","description":"\"The aggregation, arrangement and bonding together of a set of components, including gamma-tubulin and other proteins, to form an interphase microtubule organizing center.\" [GOC:mah, PMID:15068790]","metadata":null},{"id":"96c32c3bc4a14655b39cf9fac1849c74","type":"GO_TERM","name":"interphase mitotic telomere clustering","canonical_id":"go:GO:0120110","description":"\"The process whereby the mitotic telomeres are gathered together during, or prior to, attachment to the nuclear envelope.\" [PMID:25778919]","metadata":null},{"id":"bc077ed4a9f84c9d8ba6bd3e7ab0f1c1","type":"GO_TERM","name":"interphotoreceptor matrix","canonical_id":"go:GO:0033165","description":"\"A specialized extracellularc matrix that surrounds the photoreceptors of the retina and lies between them and the apical surface of the retinal pigment epithelium. The IPM has been implicated in several important activities required for photoreceptor function and maintenance.\" [PMID:1862095, PMID:2194288]","metadata":null},{"id":"591a51ff111b485ea5f92a88701f1691","type":"GO_TERM","name":"interstitial cell of Cajal differentiation","canonical_id":"go:GO:0061453","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an interstitial cell of Cajal. An interstitial cell of Cajal is an intestinal neuroepithelial cell that serves as a pacemaker to trigger gut contraction.\" [GOC:dph]","metadata":null},{"id":"49d8c627a87441c9a34bfb0d6bd11255","type":"DISEASE","name":"interstitial lung disease","canonical_id":"mondo:0015925","description":null,"metadata":null},{"id":"7df53c11ba164e65a972c81628574844","type":"GO_TERM","name":"interstitial matrix","canonical_id":"go:GO:0005614","description":"\"A type of extracellular matrix found in interstitial connective tissue, characterized by the presence of fibronectins, proteoglycans, and types I, III, V, VI, VII and XII collagens.\" [PMID:33605520, PMID:39223427, PMID:8450001]","metadata":null},{"id":"25d055b99a5c409dbf8a05120fa8b112","type":"GO_TERM","name":"interstrand cross-link repair","canonical_id":"go:GO:0036297","description":"\"Removal of a DNA interstrand crosslink (a covalent attachment of DNA bases on opposite strands of the DNA) and restoration of the DNA. DNA interstrand crosslinks occur when both strands of duplex DNA are covalently tethered together (e.g. by an exogenous or endogenous agent), thus preventing the strand unwinding necessary for essential DNA functions such as transcription and replication.\" [GOC:vw, PMID:16464006, PMID:22064477]","metadata":null},{"id":"2818d5566b5c4e48bc4f0a28a4dc299a","type":"GO_TERM","name":"intestinal D-glucose absorption","canonical_id":"go:GO:0001951","description":"\"Uptake of D-glucose into the blood by absorption from the small intestine.\" [GOC:mgi_curators, PMID:5601832]","metadata":null},{"id":"1bc26525ebd04b9b8f2951d37aa0ce75","type":"GO_TERM","name":"intestinal absorption","canonical_id":"go:GO:0050892","description":"\"A process in which nutrients are taken up from the contents of the intestine.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"0697f4f64a44480b938de5d6b216d97a","type":"GO_TERM","name":"intestinal cholesterol absorption","canonical_id":"go:GO:0030299","description":"\"Uptake of cholesterol into the blood by absorption from the small intestine.\" [GOC:mah]","metadata":null},{"id":"80654c0054614973986381967836ebc0","type":"GO_TERM","name":"intestinal enterochromaffin enteroendocrine cell differentiation","canonical_id":"go:GO:7770020","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an intestinal enterochromaffin enteroendocrine cell. Enterochromaffin enteroendocrine cells are found in the gastrointestinal mucosa and secrete serotonin and some neurotransmitters including enkephalins and substance P.\" [PMID:37883554]","metadata":null},{"id":"ea8e3818636f4e9482bdeeb69a1d2b82","type":"GO_TERM","name":"intestinal epithelial cell development","canonical_id":"go:GO:0060576","description":"\"The process whose specific outcome is the progression of a columnar/cuboidal epithelial cell of the intestine over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"c30426c5673a4dc3ab97316d35f4a173","type":"GO_TERM","name":"intestinal epithelial cell differentiation","canonical_id":"go:GO:0060575","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a columnar/cuboidal epithelial cell of the intestine.\" [GOC:dph]","metadata":null},{"id":"456c78eefa4f49219b5b3e7bb328c1e6","type":"GO_TERM","name":"intestinal epithelial cell maturation","canonical_id":"go:GO:0060574","description":"\"The developmental process, independent of morphogenetic (shape) change, that is required for a columna/cuboidal epithelial cell of the intestine to attain its fully functional state. A columnar/cuboidal epithelial cell of the intestine mature as they migrate from the intestinal crypt to the villus.\" [GOC:dph, PMID:18824147]","metadata":null},{"id":"5787ff7c8954416f8d8a959a36b111a7","type":"GO_TERM","name":"intestinal epithelial cell migration","canonical_id":"go:GO:0061582","description":"\"The orderly movement of an intestinal epithelial cell from one site to another, often during the development of a multicellular organism.\" [GOC:dph]","metadata":null},{"id":"872da409380c482a98bca74434d9ec97","type":"GO_TERM","name":"intestinal epithelial structure maintenance","canonical_id":"go:GO:0060729","description":"\"A tissue homeostatic process required for the maintenance of the structure of the intestinal epithelium.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"4d906fb94dda4a5f88a392210801100b","type":"GO_TERM","name":"intestinal folate absorption","canonical_id":"go:GO:0098829","description":"\"Uptake of folic into the blood by absorption from the small intestine.\" [GOC:BHF, GOC:dos, GOC:hal, PMID:19762432]","metadata":null},{"id":"d86dc0b8fe474a1bbbc5829c922493a4","type":"GO_TERM","name":"intestinal hexose absorption","canonical_id":"go:GO:0106001","description":"\"Uptake of hexoses, notably D-glucose, fructose, and galactose, into the blood by absorption from the small intestine.\" [GOC:hjd]","metadata":null},{"id":"c7064f8e4bb643fd9ae8ebfc4df721a2","type":"GO_TERM","name":"intestinal iron absorption","canonical_id":"go:GO:0160179","description":"\"A process in which iron is taken up from the contents of the intestine.\" [PMID:16054062, PMID:17729393]","metadata":null},{"id":"d4c3e1a03f8042c5b3083c23c715dbb9","type":"GO_TERM","name":"intestinal lipid absorption","canonical_id":"go:GO:0098856","description":"\"A process in which lipids are taken up from the contents of the intestine.\" [GOC:dos, GOC:sl, PMID:18768481]","metadata":null},{"id":"ff2c09e9090c4eafac064dd5615ddcdc","type":"GO_TERM","name":"intestinal lipid catabolic process","canonical_id":"go:GO:0044258","description":"\"The chemical reactions and pathways resulting in the breakdown into fatty acids and monoglycerides of lipids in the small intestine. Lipids are broken down by lipases released by the pancreas.\" [GOC:jl, PMID:7018485]","metadata":null},{"id":"acbbb9f3a802456a8489a9c1601b07ca","type":"GO_TERM","name":"intestinal lumen acidification","canonical_id":"go:GO:7770055","description":"\"Any process that reduces the pH of the intestinal lumen, corresponding to an increase in hydrogen ion concentration.\" [PMID:19741196]","metadata":null},{"id":"7c33b7c3eb394ee1ac8987c41cbb64ea","type":"GO_TERM","name":"intestinal motility","canonical_id":"go:GO:0120054","description":"\"Contractions of the intestinal tract that include peristalsis (moving contents onward) and non-peristaltic movement (moving contents back and forth).\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"4770a3c8f7874dc9967433a36f1a3f82","type":"DISEASE","name":"intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency","canonical_id":"mondo:0013843","description":null,"metadata":null},{"id":"1c6f90eceda24975a2db03501554b46d","type":"GO_TERM","name":"intestinal phytosterol absorption","canonical_id":"go:GO:0060752","description":"\"A process in which phytosterols are taken up from the contents of the intestine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"19e27b29837742fa9f7bb899e12a0d5c","type":"GO_TERM","name":"intestinal stem cell homeostasis","canonical_id":"go:GO:0036335","description":"\"Any biological process involved in the maintenance of the steady-state number of intestinal stem cells within a population of cells.\" [GOC:nhn, PMID:22042863, PMID:22608824]","metadata":null},{"id":"71656dcc768d497fa58466166bfa276d","type":"GO_TERM","name":"intestinal type D enteroendocrine cell differentiation","canonical_id":"go:GO:7770025","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an intestinal type D enteroendocrine cell. Intestinal type D enteroendocrine cells are found in the gastrointestinal tract and in the pancreas and secrete somatostatin.\" [PMID:37883554]","metadata":null},{"id":"e74884e70cd74f58be9f1e368b56f790","type":"GO_TERM","name":"intestinal type G enteroendocrine cell differentiation","canonical_id":"go:GO:7770021","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an intestinal type G enteroendocrine cell. Intestinal type G enteroendocrine cells are found in the stomach and duodenum and are responsible for the secretion of gastrin and enkephalin.\" [PMID:37883554]","metadata":null},{"id":"5456470dc85a465bb37543d9fe18613d","type":"GO_TERM","name":"intestinal type I enteroendocrine cell differentiation","canonical_id":"go:GO:7770022","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an intestinal type I enteroendocrine cell. Intestinal type I enteroendocrine cells are found in the duodenum and jejunum and secrete cholecystokinin.\" [GOC:TermGenie, PMID:37883554]","metadata":null},{"id":"fa8bbff61c4a4139a502d636fb57fa93","type":"GO_TERM","name":"intestinal type L enteroendocrine cell differentiation","canonical_id":"go:GO:7770023","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an intestinal type L enteroendocrine cell. Intestinal type L enteroendocrine cells are found in ileum and large intestine and secrete glucagon-like peptides.\" [PMID:37883554]","metadata":null},{"id":"eaee1b758f5c4067a82ae4da6ebc3edd","type":"GO_TERM","name":"intestinal type N enteroendocrine cell differentiation","canonical_id":"go:GO:7770024","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of an intestinal type N enteroendocrine cell. Intestinal type N enteroendocrine cells are found in the ileum and jejunum and secrete neurotensin.\" [PMID:37883554]","metadata":null},{"id":"298fae75bbc74456b64fc0edbcd1ece8","type":"GO_TERM","name":"intestine smooth muscle contraction","canonical_id":"go:GO:0014827","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the intestine. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The intestine is the section of the alimentary canal from the stomach to the anal canal. It includes the large intestine and small intestine.\" [GOC:mtg_muscle, MA:0001539, MSH:D007422]","metadata":null},{"id":"8f7d9cf4341d48b2b90e5f49b3d48801","type":"GO_TERM","name":"intine","canonical_id":"go:GO:0043678","description":"\"The innermost of the major layers of the pollen grain wall which underlies the exine and borders the cytoplasm.\" [PMID:33706055]","metadata":null},{"id":"318a73f02dd94d00a8085cac1a239e5d","type":"GO_TERM","name":"intra-Golgi vesicle-mediated transport","canonical_id":"go:GO:0006891","description":"\"The directed movement of substances within the Golgi, mediated by small transport vesicles. These either fuse with the cis-Golgi or with each other to form the membrane stacks known as the cis-Golgi reticulum (network).\" [ISBN:0716731363]","metadata":null},{"id":"109d9ea2bff7460392a158f1d63855fc","type":"GO_TERM","name":"intracellular abscisic acid homeostasis","canonical_id":"go:GO:1902266","description":"\"A homeostatic process involved in the maintenance of a steady state level of abscisic acid within a cell.\" [GOC:TermGenie, PMID:23252460]","metadata":null},{"id":"851af89d42fb4fe8bd90cfc8a7ff2381","type":"GO_TERM","name":"intracellular accumulation of glycerol","canonical_id":"go:GO:0006973","description":"\"The accumulation of glycerol within a cell, for example by increased glycerol biosynthesis combined with decreased permeability of the cell membrane to glycerol, in response to the detection of a hyperosmotic environment.\" [GOC:jl, PMID:11752666]","metadata":null},{"id":"0e9a502aec414d678d2597b7530d0431","type":"GO_TERM","name":"intracellular acyl-CoA homeostasis","canonical_id":"go:GO:0042049","description":"\"A homeostatic process involved in the maintenance of a steady state level of acyl-CoA within a cell.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"65c18484b092464ba79dc48743cc39a6","type":"GO_TERM","name":"intracellular amino acid homeostasis","canonical_id":"go:GO:0080144","description":"\"A homeostatic process involved in the maintenance of a steady state level of amino acids within a cell.\" [PMID:19955263]","metadata":null},{"id":"1cffe8a90a4d43ec932cc97c42882bb8","type":"GO_TERM","name":"intracellular ammonium homeostasis","canonical_id":"go:GO:0097275","description":"\"A homeostatic process involved in the maintenance of a steady state level of ammonium within a cell.\" [GOC:yaf, PMID:12695560]","metadata":null},{"id":"7269f616fe794081ac166ffbd1a30978","type":"GO_TERM","name":"intracellular anatomical structure","canonical_id":"go:GO:0005622","description":"\"A component of a cell contained within (but not including) the plasma membrane. In eukaryotes it includes the nucleus and cytoplasm.\" [ISBN:0198506732]","metadata":null},{"id":"05b032d7332d48f7a9759542feb4c97b","type":"GO_TERM","name":"intracellular arginine homeostasis","canonical_id":"go:GO:0090465","description":"\"A homeostatic process involved in the maintenance of a steady state level of arginine within a cell.\" [GOC:tb]","metadata":null},{"id":"6681d634856742558aeb7869f7320745","type":"GO_TERM","name":"intracellular aspartate homeostasis","canonical_id":"go:GO:0090459","description":"\"A homeostatic process involved in the maintenance of a steady state level of aspartate within a cell.\" [GOC:tb]","metadata":null},{"id":"fa4e5ef43b9e4d67937666a4e7bc88a7","type":"GO_TERM","name":"intracellular auxin homeostasis","canonical_id":"go:GO:0140964","description":"\"A homeostatic process involved in the maintenance of a steady state level of auxin within a cell.\" [PMID:19506555, PMID:22314799]","metadata":null},{"id":"1a5cc7c840f24e3386b87691027431d1","type":"GO_TERM","name":"intracellular borate homeostasis","canonical_id":"go:GO:0160070","description":"\"A homeostatic process involved in the maintenance of a steady state level of tetrahydroxoborate within a cell.\" [PMID:15525507]","metadata":null},{"id":"d0ea978000fc44c8bd25aad2fcf01764","type":"GO_TERM","name":"intracellular calcium ion homeostasis","canonical_id":"go:GO:0006874","description":"\"A homeostatic process involved in the maintenance of a steady state level of calcium ions within a cell.\" [GOC:ceb, GOC:mah]","metadata":null},{"id":"df75e1297b10452dae5df46ade98bd5a","type":"GO_TERM","name":"intracellular canaliculus","canonical_id":"go:GO:0046691","description":"\"An apical plasma membrane part that forms a narrow enfolded luminal membrane channel, lined with numerous microvilli, that appears to extend into the cytoplasm of the cell. A specialized network of intracellular canaliculi is a characteristic feature of parietal cells of the gastric mucosa in vertebrates.\" [GOC:mah, ISBN:0721662544, PMID:10700045]","metadata":null},{"id":"c4e420e1b0e44bc69ac50afcd1cba96d","type":"GO_TERM","name":"intracellular chemical homeostasis","canonical_id":"go:GO:0055082","description":"\"A homeostatic process involved in the maintenance of a steady state level of a chemical within a cell.\" [GOC:isa_complete, GOC:jid]","metadata":null},{"id":"c05ac6cbc674478bb5d0f239750b0ed4","type":"GO_TERM","name":"intracellular chloride ion homeostasis","canonical_id":"go:GO:0030644","description":"\"A homeostatic process involved in the maintenance of a steady state level of chloride ions within a cell.\" [GOC:mah]","metadata":null},{"id":"678156bc226e47f3904d0a7bde98df22","type":"GO_TERM","name":"intracellular cholesterol transport","canonical_id":"go:GO:0032367","description":"\"The directed movement of cholesterol, cholest-5-en-3-beta-ol, within cells.\" [GOC:mah]","metadata":null},{"id":"237687caac6241d99092e31c8606c52e","type":"GO_TERM","name":"intracellular cobalt ion homeostasis","canonical_id":"go:GO:0006877","description":"\"A homeostatic process involved in the maintenance of a steady state level of cobalt (Co2+) ions within a cell.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"4241c45d14e540949bca4513cbfc27b8","type":"GO_TERM","name":"intracellular copper ion homeostasis","canonical_id":"go:GO:0006878","description":"\"A homeostatic process involved in the maintenance of a steady state level of copper ions within a cell.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"47a03061509a4f95b3daebb804c897e7","type":"GO_TERM","name":"intracellular cyclic nucleotide activated cation channel complex","canonical_id":"go:GO:0017071","description":"\"A protein complex that forms a transmembrane channel through which cations ions may pass in response to an intracellular cyclic nucleotide binding to the channel complex or one of its constituent parts.\" [GOC:mah]","metadata":null},{"id":"2727b7ff1f024ad7871854ff420e5f96","type":"GO_TERM","name":"intracellular cysteine homeostasis","canonical_id":"go:GO:0080145","description":"\"A homeostatic process involved in the maintenance of a steady state level of L-cysteine within a cell.\" [PMID:19955263]","metadata":null},{"id":"cf9d92a221394ac38b49964338206abe","type":"GO_TERM","name":"intracellular distribution of mitochondria","canonical_id":"go:GO:0048312","description":"\"Any process that establishes the spatial arrangement of mitochondria within the cell.\" [GOC:jid]","metadata":null},{"id":"45ec7a874be148e0aad98dd4f99ac842","type":"GO_TERM","name":"intracellular glucose homeostasis","canonical_id":"go:GO:0001678","description":"\"A homeostatic process involved in the maintenance of a steady state level of glucose within a cell.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"7deb98b454664e75806df82b9f0dec79","type":"GO_TERM","name":"intracellular glutamate homeostasis","canonical_id":"go:GO:0090461","description":"\"A homeostatic process involved in the maintenance of a steady state level of glutamate within a cell.\" [GOC:tb]","metadata":null},{"id":"bcb6e82e85bd4e23807e084ce33acded","type":"GO_TERM","name":"intracellular histidine homeostasis","canonical_id":"go:GO:0090464","description":"\"A homeostatic process involved in the maintenance of a steady state level of histidine within a cell.\" [GOC:tb]","metadata":null},{"id":"dcb241d64a4f4ee4bedd62751cea25d7","type":"GO_TERM","name":"intracellular immature spore","canonical_id":"go:GO:0042763","description":"\"A cell or part of the cell that constitutes an early developmental stage of a spore, a small reproductive body that is highly resistant to desiccation and heat and is capable of growing into a new organism, produced especially by certain bacteria, fungi, algae, and nonflowering plants.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"de8fa03d4bff452e85dc129d5c17ba32","type":"GO_TERM","name":"intracellular iron ion homeostasis","canonical_id":"go:GO:0006879","description":"\"A homeostatic process involved in the maintenance of a steady state level of iron ions within a cell.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"6bfdb72e3b864e4d9111fecaf39e5601","type":"GO_TERM","name":"intracellular lipid transport","canonical_id":"go:GO:0032365","description":"\"The directed movement of lipids within cells.\" [GOC:mah]","metadata":null},{"id":"95a7c36a52f849248ed2fa67e42a2212","type":"GO_TERM","name":"intracellular lysine homeostasis","canonical_id":"go:GO:0090463","description":"\"A homeostatic process involved in the maintenance of a steady state level of lysine within a cell.\" [GOC:tb]","metadata":null},{"id":"2fafcf9222724f3eba40d137457f6bf4","type":"GO_TERM","name":"intracellular mRNA localization","canonical_id":"go:GO:0008298","description":"\"Any process in which mRNA is transported to, or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"c43215fd2e0840949c070f312d1df3ea","type":"GO_TERM","name":"intracellular mRNA localization involved in anterior/posterior axis specification","canonical_id":"go:GO:0060811","description":"\"Any process in which mRNA is transported to, or maintained in, a specific location within the oocyte and/or syncytial embryo that contributes to the specification of the anterior/posterior axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"834bd291b9494633ae9302b05aef0b0d","type":"GO_TERM","name":"intracellular mRNA localization involved in pattern specification process","canonical_id":"go:GO:0060810","description":"\"Any process in which mRNA is transported to, or maintained in, a specific location within an oocyte that results in a pattern being established in the embryo.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"5ac13dc989764567adfccb73944b3ad4","type":"GO_TERM","name":"intracellular magnesium ion homeostasis","canonical_id":"go:GO:0010961","description":"\"A homeostatic process involved in the maintenance of a steady state level of magnesium ions within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"90f65b1df067423a8dc9c7af5b0fff67","type":"GO_TERM","name":"intracellular manganese ion homeostasis","canonical_id":"go:GO:0030026","description":"\"A homeostatic process involved in the maintenance of a steady state level of manganese ions within a cell.\" [GOC:mah]","metadata":null},{"id":"60394a9c528f49acba9968d8ceb4b734","type":"GO_TERM","name":"intracellular membrane-bounded organelle","canonical_id":"go:GO:0043231","description":"\"Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane.\" [GOC:curators]","metadata":null},{"id":"27c9dcda2b144b6d93fadd0bf305b4dc","type":"GO_TERM","name":"intracellular membraneless organelle","canonical_id":"go:GO:0043232","description":"\"Organized structure of distinctive morphology and function, not bounded by a lipid bilayer membrane and occurring within the cell. Includes ribosomes, the cytoskeleton and chromosomes.\" [GOC:curators]","metadata":null},{"id":"c812b1366b464cef815e33dfd29aa4e1","type":"GO_TERM","name":"intracellular monoatomic anion homeostasis","canonical_id":"go:GO:0030002","description":"\"A homeostatic process involved in the maintenance of a steady state level of monoatomic anions within a cell. Monatomic anions (also called simple anions) are anions consisting of exactly one atom.\" [GOC:ceb, GOC:mah]","metadata":null},{"id":"d9abf023ebf34ef99b4d24cfb2b5256b","type":"GO_TERM","name":"intracellular monoatomic cation homeostasis","canonical_id":"go:GO:0030003","description":"\"A homeostatic process involved in the maintenance of a steady state level of monoatomic cations within a cell. Monatomic cations (also called simple cations) are cations consisting of exactly one atom.\" [GOC:ceb, GOC:mah]","metadata":null},{"id":"f745f1addf6241e7843f19558ee65111","type":"GO_TERM","name":"intracellular monoatomic ion homeostasis","canonical_id":"go:GO:0006873","description":"\"A homeostatic process involved in the maintenance of a steady state level of monoatomic ions within a cell. Monatomic ions (also called simple ions) are ions consisting of exactly one atom.\" [GOC:mah]","metadata":null},{"id":"a3629e9ead4b4d3a95174b713d7a3d30","type":"GO_TERM","name":"intracellular nickel ion homeostasis","canonical_id":"go:GO:0035785","description":"\"A homeostatic process involved in the maintenance of a steady state level of nickel ions within a cell.\" [GOC:kmv]","metadata":null},{"id":"bf54f8c40af84b5fa3dc4da3444b124a","type":"GO_TERM","name":"intracellular nitric oxide homeostasis","canonical_id":"go:GO:0033484","description":"\"A homeostatic process involved in the maintenance of a steady state level of nitric oxide within a cell.\" [GOC:mah]","metadata":null},{"id":"259e79742c8f4751af5ebd8605bf8f32","type":"GO_TERM","name":"intracellular nitrogen homeostasis","canonical_id":"go:GO:0141067","description":"\"A homeostatic process involved in the maintenance of a steady state level of nitrogen within a cell.\" [GOC:tb]","metadata":null},{"id":"9922d63270674a9a8b13162a5e2b5908","type":"GO_TERM","name":"intracellular nucleoside homeostasis","canonical_id":"go:GO:0140980","description":"\"A homeostatic process involved in the maintenance of a steady state level of nucleosides within a cell.\" [PMID:23416111, PMID:34880500]","metadata":null},{"id":"95978886d70440a6a8298053fc522212","type":"GO_TERM","name":"intracellular nucleoside transport","canonical_id":"go:GO:0015859","description":"\"The directed movement of a nucleoside, a nucleobase linked to either beta-D-ribofuranose (ribonucleoside) or 2-deoxy-beta-D-ribofuranose, (a deoxyribonucleotide), within a cell.\" [GOC:ai]","metadata":null},{"id":"f0c9293a524b402fa2f8d33bfaf0ec27","type":"GO_TERM","name":"intracellular nucleotide homeostasis","canonical_id":"go:GO:0140979","description":"\"A homeostatic process involved in the maintenance of a steady state level of nucleotides within a cell.\" [PMID:23416111, PMID:34880500]","metadata":null},{"id":"22271ece6a104ebfae28fe4f1b9b63cf","type":"GO_TERM","name":"intracellular organelle","canonical_id":"go:GO:0043229","description":"\"Organized structure of distinctive morphology and function, occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. Excludes the plasma membrane.\" [GOC:curators]","metadata":null},{"id":"6cfd899d4c8f4af6a6d537ab1ef07a8c","type":"GO_TERM","name":"intracellular organelle lumen","canonical_id":"go:GO:0070013","description":"\"An organelle lumen that is part of an intracellular organelle.\" [GOC:mah]","metadata":null},{"id":"2a4be5b074134f7095db7ae31f6c8477","type":"GO_TERM","name":"intracellular ornithine homeostasis","canonical_id":"go:GO:0090462","description":"\"A homeostatic process involved in the maintenance of a steady state level of orthinine within a cell.\" [GOC:tb]","metadata":null},{"id":"3f9a5069f5774138a83df33ab065a16b","type":"GO_TERM","name":"intracellular oxygen homeostasis","canonical_id":"go:GO:0032364","description":"\"A homeostatic process involved in the maintenance of a steady state level of oxygen within a cell.\" [GOC:rph]","metadata":null},{"id":"a45d0d76c62b4308a06d81709e9b0ce5","type":"GO_TERM","name":"intracellular pH elevation","canonical_id":"go:GO:0051454","description":"\"Any process that increases the internal pH of a cell, corresponding to a decrease in hydrogen ion concentration.\" [GOC:ai]","metadata":null},{"id":"eb5da409853d498892c4cc9c73cf9cb3","type":"GO_TERM","name":"intracellular pH reduction","canonical_id":"go:GO:0051452","description":"\"Any process that reduces the internal pH of a cell, corresponding to an increase in hydrogen ion concentration.\" [GOC:ai]","metadata":null},{"id":"62839a8423aa4ceb8c9d2d2052f6182d","type":"GO_TERM","name":"intracellular phosphate ion homeostasis","canonical_id":"go:GO:0030643","description":"\"A homeostatic process involved in the maintenance of a steady state level of phosphate ions within a cell.\" [GOC:mah]","metadata":null},{"id":"d56b1e5ff5844a9ba9fd3f816af4095c","type":"GO_TERM","name":"intracellular polyamine homeostasis","canonical_id":"go:GO:0010509","description":"\"A homeostatic process involved in the maintenance of a steady state level of polyamine within a cell.\" [GOC:dph, GOC:rph, GOC:tb, PMID:11161802, PMID:9761731]","metadata":null},{"id":"838648eed758491fb92c4e469b1eb25f","type":"GO_TERM","name":"intracellular potassium ion homeostasis","canonical_id":"go:GO:0030007","description":"\"A homeostatic process involved in the maintenance of a steady state level of potassium ions within a cell.\" [GOC:mah]","metadata":null},{"id":"be26121e37e64956a18429ebf05b03f0","type":"GO_TERM","name":"intracellular protein localization","canonical_id":"go:GO:0008104","description":"\"Any process in which a protein is transported to, or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"79324a3fe42c420292f348d3e544f6d2","type":"GO_TERM","name":"intracellular protein transmembrane transport","canonical_id":"go:GO:0065002","description":"\"The directed movement of proteins in a cell, from one side of a membrane to another by means of some agent such as a transporter or pore.\" [GOC:isa_complete]","metadata":null},{"id":"cfd7286e64eb4c2eb850e982d5ea4a5a","type":"GO_TERM","name":"intracellular protein transport","canonical_id":"go:GO:0006886","description":"\"The directed movement of proteins in a cell, including the movement of proteins between specific compartments or structures within a cell, such as organelles of a eukaryotic cell.\" [GOC:mah]","metadata":null},{"id":"24e8cf2cf0c14136b28f3bb5e88140b1","type":"GO_TERM","name":"intracellular protein-containing complex","canonical_id":"go:GO:0140535","description":"\"A protein-containing complex located intracellularly.\" [GOC:pg]","metadata":null},{"id":"11bca664885749d98e3c2fb12325809f","type":"GO_TERM","name":"intracellular receptor signaling pathway","canonical_id":"go:GO:0030522","description":"\"The series of molecular signals initiated by a ligand binding to a receptor located within a cell.\" [GOC:bf, GOC:mah]","metadata":null},{"id":"fdc9aa5d690a40ee9f7d6a5acaec6207","type":"GO_TERM","name":"intracellular signal transduction","canonical_id":"go:GO:0035556","description":"\"The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell.\" [GOC:bf, GOC:jl, GOC:signaling, ISBN:3527303782]","metadata":null},{"id":"c2ad584fd735475c872dea42dc92117a","type":"GO_TERM","name":"intracellular signaling cassette","canonical_id":"go:GO:0141124","description":"\"An intracellular signaling module that is part of larger signaling pathways that can be initiated either intracellularly or by cell surface receptors. Intracellular signaling cassettes are discrete signaling units that are often shared by multiple signaling pathways.\" [GOC:ha, GOC:pg]","metadata":null},{"id":"5f61b2dcc34645f0abf83cbb4a14769f","type":"GO_TERM","name":"intracellular sodium ion homeostasis","canonical_id":"go:GO:0006883","description":"\"A homeostatic process involved in the maintenance of a steady state level of sodium ions within a cell.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"4446178ddf8e4838a8973a6960fff165","type":"GO_TERM","name":"intracellular sodium-activated potassium channel activity","canonical_id":"go:GO:0005228","description":"\"Enables the transmembrane transfer of potassium by a channel that opens in response to stimulus by a sodium ion or ions. Transport by a channel involves facilitated diffusion of a solute (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel, without evidence for a carrier-mediated mechanism. Sodium activated potassium channels have distinctive properties, including a large single channel conductance, subconductance states, and a block of single channel currents at positive potentials, similar to inward rectification.\" [GOC:mtg_transport, PMID:12628167]","metadata":null},{"id":"b98d66e3819341e3af1838b5c4714ef7","type":"GO_TERM","name":"intracellular sphingolipid homeostasis","canonical_id":"go:GO:0090156","description":"\"A homeostatic process involved in the maintenance of a steady state level of sphingolipids within a cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"5c936e5ddd9a4a5ea33b87a5d77fd7db","type":"GO_TERM","name":"intracellular sterol transport","canonical_id":"go:GO:0032366","description":"\"The directed movement of sterols within cells.\" [GOC:mah]","metadata":null},{"id":"6536c9440ffc4f4abcc0a17e69e72a3f","type":"GO_TERM","name":"intracellular sulfate ion homeostasis","canonical_id":"go:GO:0030642","description":"\"A homeostatic process involved in the maintenance of a steady state level of sulfate ions within a cell.\" [GOC:mah, PMID:24193406]","metadata":null},{"id":"94a5bf5bf7534ef3bf117ee1146e7883","type":"GO_TERM","name":"intracellular threonine homeostasis","canonical_id":"go:GO:0090460","description":"\"A homeostatic process involved in the maintenance of a steady state level of threonine within a cell.\" [GOC:tb]","metadata":null},{"id":"3fc1e30807bf4368811458093b7d3faf","type":"GO_TERM","name":"intracellular transport","canonical_id":"go:GO:0046907","description":"\"The directed movement of substances within a cell.\" [GOC:ai]","metadata":null},{"id":"fdb79dda7b754553afb492795457c51b","type":"GO_TERM","name":"intracellular transport of viral protein in host cell","canonical_id":"go:GO:0019060","description":"\"The directed movement of a viral protein within the host cell.\" [GOC:ai, ISBN:0781702534, ISBN:0781718325, PMID:11581394, PMID:9188566]","metadata":null},{"id":"be4630bbc3bd4010a42389056393a993","type":"GO_TERM","name":"intracellular transport of virus","canonical_id":"go:GO:0075733","description":"\"The directed movement of a virus, or part of a virus, within the host cell.\" [GOC:ai, GOC:bf, GOC:jl, PMID:11733033]","metadata":null},{"id":"f930931861014f8680c330e08a13d77f","type":"GO_TERM","name":"intracellular triglyceride homeostasis","canonical_id":"go:GO:0035356","description":"\"A homeostatic process involved in the maintenance of a steady state level of triglyceride within a cell.\" [GOC:BHF]","metadata":null},{"id":"4ad39023da7945daa7d90f6a335a3074","type":"GO_TERM","name":"intracellular vesicle","canonical_id":"go:GO:0097708","description":"\"Any vesicle that is part of the intracellular region.\" [GOC:vesicles]","metadata":null},{"id":"52be8e0470de496280469b5b279823e3","type":"GO_TERM","name":"intracellular water homeostasis","canonical_id":"go:GO:0009992","description":"\"A homeostatic process involved in the maintenance of a steady state level of water within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"358a932dc1e44a0ab6ceaad90284b95e","type":"GO_TERM","name":"intracellular zinc ion homeostasis","canonical_id":"go:GO:0006882","description":"\"A homeostatic process involved in the maintenance of a steady state level of zinc ions within a cell.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"34201aadcc474bdd844a5aff95279711","type":"GO_TERM","name":"intracellularly ATP-gated calcium channel activity","canonical_id":"go:GO:0140417","description":"\"Enables the transmembrane transfer of a calcium ion from intracellular stores by a channel that opens when a ATP has been bound by the channel complex or one of its constituent parts.\" [PMID:22736763]","metadata":null},{"id":"dc1da36f0aaa43c4991ff0a3868020ba","type":"GO_TERM","name":"intracellularly ATP-gated chloride channel activity","canonical_id":"go:GO:0005260","description":"\"Enables passage of a chloride ion through a transmembrane channel that opens when ATP is bound by the channel complex or one of its constituent parts on the intracellular side of the plasma membrane.\" [PMID:24727426, PMID:9922375]","metadata":null},{"id":"b0f30b72b9024eb4892a38ce681a89b3","type":"GO_TERM","name":"intracellularly ATP-gated ion channel activity","canonical_id":"go:GO:0099142","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when ATP has been bound by the channel complex or one of its constituent parts on the intracellular side of the plasma membrane.\" [PMID:9755289]","metadata":null},{"id":"5aeb53c6b871496a89b2e199237a87c4","type":"GO_TERM","name":"intracellularly cAMP-activated cation channel activity","canonical_id":"go:GO:0005222","description":"\"Enables the transmembrane transfer of a cation by a channel that opens when intracellular cAMP has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport]","metadata":null},{"id":"045d952b857d42fd9c0ddc96bba023d2","type":"GO_TERM","name":"intracellularly cGMP-activated cation channel activity","canonical_id":"go:GO:0005223","description":"\"Enables the transmembrane transfer of a cation by a channel that opens when intracellular cGMP has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport]","metadata":null},{"id":"1cebf647b1a140e78e068096ecfa5995","type":"GO_TERM","name":"intracellularly calcium-gated channel activity","canonical_id":"go:GO:0141147","description":"\"Enables the transmembrane transfer of a solute by a channel that opens when calcium ions bind on the intracellular side of the channel complex or one of its constituent parts.\" [PMID:20929730, PMID:23021213]","metadata":null},{"id":"8a83bc120090402586f8e31dfa302ddc","type":"GO_TERM","name":"intracellularly calcium-gated chloride channel activity","canonical_id":"go:GO:0005229","description":"\"Enables the transmembrane transfer of chloride by a channel that opens in response to stimulus by a calcium ion or ions. Transport by a channel involves catalysis of facilitated diffusion of a solute (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel, without evidence for a carrier-mediated mechanism.\" [GOC:mtg_transport, PMID:29236691]","metadata":null},{"id":"67795bd489744e848d2a0426bee2e716","type":"GO_TERM","name":"intracellularly cyclic nucleotide-activated monoatomic cation channel activity","canonical_id":"go:GO:0005221","description":"\"Enables the transmembrane transfer of a monoatomic cation by a channel that opens when intracellular cyclic nucleotide has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport]","metadata":null},{"id":"aaa0119addee46a38b0d2a60bb9c5b54","type":"GO_TERM","name":"intracellularly gated calcium channel activity","canonical_id":"go:GO:0015278","description":"\"Enables the transmembrane transfer of a calcium ion by a channel that opens when a specific intracellular ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mah]","metadata":null},{"id":"d57d455c4ad840d2afd9f53950c92c97","type":"GO_TERM","name":"intracellularly ligand-gated monoatomic ion channel activity","canonical_id":"go:GO:0005217","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific intracellular ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"9f7cc783f4c84a66ad9a38a4b45a105b","type":"GO_TERM","name":"intracellularly phosphatidylinositol-3,5-bisphosphate-gated monatomic cation channel activity","canonical_id":"go:GO:0097682","description":"\"Enables the transmembrane transfer of cations by a channel that opens when phosphatidylinositol-3,5-bisphosphate has been bound by the channel complex or one of its constituent parts.\" [GOC:ha, PMID:24375408]","metadata":null},{"id":"ba9992670a8245869f6ee51b2fb1f3b6","type":"GO_TERM","name":"intrachromosomal DNA recombination","canonical_id":"go:GO:1990067","description":"\"The process of DNA recombination occurring within a single chromosome.\" [PMID:7748165]","metadata":null},{"id":"f77ad3d39c7140c58097d7645d733610","type":"GO_TERM","name":"intraciliary anterograde transport","canonical_id":"go:GO:0035720","description":"\"The directed movement of large protein complexes along microtubules from the cell body toward the tip of a cilium (also called flagellum), mediated by motor proteins.\" [GOC:BHF, GOC:cilia, PMID:17895364]","metadata":null},{"id":"7227b7bee4cb464499ada265bb5ff782","type":"GO_TERM","name":"intraciliary retrograde transport","canonical_id":"go:GO:0035721","description":"\"The directed movement of large protein complexes along microtubules from the tip of a cilium (also called flagellum) toward the cell body, mediated by motor proteins.\" [GOC:BHF, GOC:cilia]","metadata":null},{"id":"26d68a9e298b41aebb3ac95a1ce14043","type":"GO_TERM","name":"intraciliary transport","canonical_id":"go:GO:0042073","description":"\"The bidirectional movement of large protein complexes along microtubules within a cilium, mediated by motor proteins.\" [GOC:cilia, GOC:kmv, PMID:17981739, PMID:18180368, PMID:22869374]","metadata":null},{"id":"bde2efff93c749fc9b7f2b8182674b29","type":"GO_TERM","name":"intraciliary transport involved in cilium assembly","canonical_id":"go:GO:0035735","description":"\"The bidirectional movement of large protein complexes along microtubules within a cilium that contributes to cilium assembly.\" [GOC:bf, GOC:cilia]","metadata":null},{"id":"435f181f76814ddd9944d5dc30e6b429","type":"GO_TERM","name":"intraciliary transport particle","canonical_id":"go:GO:0030990","description":"\"A nonmembrane-bound oligomeric protein complex that participates in bidirectional transport of molecules (cargo) along axonemal microtubules.\" [GOC:cilia, GOC:kmv, PMID:14570576, PMID:22118932, PMID:23945166]","metadata":null},{"id":"edccde9a55154db3a59557f54ab2f8ef","type":"GO_TERM","name":"intraciliary transport particle A","canonical_id":"go:GO:0030991","description":"\"The smaller subcomplex of the intraciliary transport particle; characterized complexes have molecular weights of 710-760 kDa.\" [GOC:cilia, GOC:kmv, PMID:14570576]","metadata":null},{"id":"0984be25039e478f934faedca382df79","type":"GO_TERM","name":"intraciliary transport particle A binding","canonical_id":"go:GO:0120160","description":"\"Binding to an intraciliary transport particle A (IFT A) complex.\" [PMID:20889716]","metadata":null},{"id":"20f02ee5d984405fb5feaffce79a3205","type":"GO_TERM","name":"intraciliary transport particle B","canonical_id":"go:GO:0030992","description":"\"The larger subcomplex of the intraciliary transport particle; characterized complexes have molecular weights around 550 kDa.\" [GOC:cilia, GOC:kmv, PMID:14570576, PMID:19253336]","metadata":null},{"id":"f975a83c1c744cdcbd328a602c8753c7","type":"GO_TERM","name":"intraciliary transport particle B binding","canonical_id":"go:GO:0120170","description":"\"Binding to an intraciliary transport particle B (IFT B) complex.\" [PMID:20889716]","metadata":null},{"id":"1916c27d85f849a3968ef544a40fb137","type":"GO_TERM","name":"intraconoid microtubule","canonical_id":"go:GO:0033289","description":"\"A microtubule located such that it threads through the conoid and projects through the polar ring.\" [GOC:mah, PMID:11901169, PMID:16518471]","metadata":null},{"id":"7359a718fe084d59b34dd87fd7ef8377","type":"GO_TERM","name":"intraglomerular mesangial cell proliferation","canonical_id":"go:GO:0072123","description":"\"The multiplication or reproduction of intraglomerular glomerular mesangium cells by cell division, resulting in the expansion of their population. Intraglomerular mesangial cells are specialized pericytes located among the glomerular capillaries within a renal corpuscle of a kidney. They are required for filtration, structural support and phagocytosis.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6538d0965fcb42948f68165a5ba591a3","type":"GO_TERM","name":"intrahepatic bile duct development","canonical_id":"go:GO:0035622","description":"\"The progression of the intrahepatic bile ducts over time, from their formation to the mature structure. Intrahepatic bile ducts (bile ducts within the liver) collect bile from bile canaliculi in the liver, and connect to the extrahepatic bile ducts (bile ducts outside the liver).\" [GOC:bf, PMID:20614624]","metadata":null},{"id":"762004230a2643a5b0d08f70b5216f58","type":"DISEASE","name":"intrahepatic cholestasis","canonical_id":"mondo:0019072","description":null,"metadata":null},{"id":"28282e10a5114f74acf14c4d0a44d5ac","type":"GO_TERM","name":"intralumenal vesicle formation","canonical_id":"go:GO:0070676","description":"\"The invagination of the endosome membrane and resulting formation of a vesicle within the lumen of the endosome.\" [GOC:jp, PMID:19234443]","metadata":null},{"id":"492369a769204d68a861260b35a99edd","type":"GO_TERM","name":"intramanchette transport","canonical_id":"go:GO:1990953","description":"\"The movement of vesicles and protein complexes carried out by molecular motors, kinesins and dynein, along the microtubule tracks within the manchette and by myosin along actin filaments.\" [GOC:krc, PMID:22319670, PMID:24440897, PMID:26792866]","metadata":null},{"id":"c60f958f84ec4d0494a49fe2080d0efd","type":"GO_TERM","name":"intramembrane lipid carrier activity","canonical_id":"go:GO:0140303","description":"\"Enables the transport of a lipid from a region of a membrane to a different region on the same membrane.\" [PMID:16828084]","metadata":null},{"id":"2a89e3c925e84740af2c918afd4586fc","type":"GO_TERM","name":"intramembranous bone growth","canonical_id":"go:GO:0098867","description":"\"The increase in size or mass of an intramembranous bone that contributes to the shaping of the bone.\" [PMID:26399686]","metadata":null},{"id":"6eff0e12b6964c4d83f2826af7088c08","type":"GO_TERM","name":"intramembranous bone morphogenesis","canonical_id":"go:GO:1904770","description":"\"The developmental process by which an intramembranous bone is generated and organized.\" [GO_REF:0000083, GOC:TermGenie, PMID:26399686]","metadata":null},{"id":"78167dc3ceb44380b2838be39b04c3a6","type":"GO_TERM","name":"intramembranous ossification","canonical_id":"go:GO:0001957","description":"\"Direct ossification that occurs within mesenchyme or an accumulation of relatively unspecialized cells.\" [ISBN:0878932437]","metadata":null},{"id":"20c0721a7403424aa3d7dbbd07d0ce86","type":"GO_TERM","name":"intramolecular acyltransferase activity","canonical_id":"go:GO:0016867","description":"\"Catalysis of the transfer of an acyl group from one position to another within a single molecule.\" [GOC:mah]","metadata":null},{"id":"dda32092c8724a259a097d703a7b7230","type":"GO_TERM","name":"intramolecular aminotransferase activity","canonical_id":"go:GO:0016869","description":"\"Catalysis of the transfer of an amino group from one position to another within a single molecule.\" [GOC:mah]","metadata":null},{"id":"08a5e3c205f943f08e2e55a17ab0e0cf","type":"GO_TERM","name":"intramolecular hydroxytransferase activity","canonical_id":"go:GO:0050486","description":"\"Catalysis of the transfer of a hydroxyl group from one position to another within a single molecule.\" [GOC:mah]","metadata":null},{"id":"14426401ce3846cab8c7538f31b47175","type":"GO_TERM","name":"intramolecular lyase activity","canonical_id":"go:GO:0016872","description":"\"The catalysis of certain rearrangements of a molecule to break or form a ring.\" [GOC:jl]","metadata":null},{"id":"79f35d785b354e618ca0bacfe4ddfc22","type":"GO_TERM","name":"intramolecular oxidoreductase activity","canonical_id":"go:GO:0016860","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which the hydrogen donor and acceptor are the same molecule, and no oxidized product appears.\" [EC:5.3.-.-, GOC:curators]","metadata":null},{"id":"47237b9255b8414b9c22ff2ec2b3675d","type":"GO_TERM","name":"intramolecular oxidoreductase activity, interconverting aldoses and ketoses","canonical_id":"go:GO:0016861","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which the hydrogen donor and acceptor, which is an aldose or a ketose, are the same molecule, and no oxidized product appears.\" [EC:5.3.1.-, GOC:jl]","metadata":null},{"id":"91afa84ab5ff4d7682b9af862c56aff3","type":"GO_TERM","name":"intramolecular oxidoreductase activity, interconverting keto- and enol-groups","canonical_id":"go:GO:0016862","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which the hydrogen donor and acceptor, which is a keto- or an enol-group, are the same molecule, and no oxidized product appears.\" [EC:5.3.2.-, GOC:jl]","metadata":null},{"id":"9fd8607063b74dbf8ea8e552aa2a1746","type":"GO_TERM","name":"intramolecular oxidoreductase activity, transposing C=C bonds","canonical_id":"go:GO:0016863","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which the hydrogen donor and acceptor are the same molecule, one or more carbon-carbon double bonds in the molecule are rearranged, and no oxidized product appears.\" [EC:5.3.3.-, GOC:mah]","metadata":null},{"id":"34955fc1174a404d9aded63aac986d8b","type":"GO_TERM","name":"intramolecular oxidoreductase activity, transposing S-S bonds","canonical_id":"go:GO:0016864","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which the hydrogen donor and acceptor are the same molecule, one or more sulfur-sulfur bonds in the molecule are rearranged, and no oxidized product appears.\" [EC:5.3.4.-, GOC:mah]","metadata":null},{"id":"08f0ae61dd0e4ab09349923960232f54","type":"GO_TERM","name":"intramolecular phosphotransferase activity","canonical_id":"go:GO:0016868","description":"\"Catalysis of the transfer of a phosphate group from one position to another within a single molecule.\" [GOC:mah]","metadata":null},{"id":"8d40ea68a4054f8dbc03bf6f7b5ea9da","type":"GO_TERM","name":"intramolecular phosphotransferase complex","canonical_id":"go:GO:1990233","description":"\"A protein complex capable of catalyzing the transfer of a phosphate group from one position to another within a single molecule.\" [GOC:bhm, PMID:16540464]","metadata":null},{"id":"9d2049dfb0d4418c91e3d35fb2452363","type":"GO_TERM","name":"intramolecular transferase activity","canonical_id":"go:GO:0016866","description":"\"Catalysis of the transfer of a functional group from one position to another within a single molecule.\" [GOC:mah]","metadata":null},{"id":"79287f7689954134a0d4e425661db4d2","type":"GO_TERM","name":"intranuclear rod","canonical_id":"go:GO:0061836","description":"\"A macromolecular fiber consisting of actin and cofilin that is formed in the nucleus as a consequence of chemical or mechanical stress conditions.\" [PMID:28074884]","metadata":null},{"id":"8a0eb2c27ce04f1694b31955efa1923c","type":"GO_TERM","name":"intranuclear rod assembly","canonical_id":"go:GO:1905861","description":"\"The aggregation, arrangement and bonding together of a set of components to form an intranuclear rod.\" [GO_REF:0000079, GOC:TermGenie, PMID:28074884]","metadata":null},{"id":"d4dc632a40ea4f8380312f904ff2b967","type":"GO_TERM","name":"intratendonous ossification","canonical_id":"go:GO:0036077","description":"\"Ossification wherein bone tissue forms within tendonous tissue.\" [GO_REF:0000034]","metadata":null},{"id":"be4a54a43a11412a9a7f59832b60328e","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway","canonical_id":"go:GO:0097193","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).\" [GOC:mtg_apoptosis, GOC:yaf, PMID:11919192, PMID:17340152, PMID:18852119]","metadata":null},{"id":"032aad9ba3594f798ab18256656eddc3","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway by p53 class mediator","canonical_id":"go:GO:0072332","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, and ends when the execution phase of apoptosis is triggered.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"f513c330ceb24f5cacdf9cb2bc40c389","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to DNA damage","canonical_id":"go:GO:0008630","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the detection of DNA damage, and ends when the execution phase of apoptosis is triggered.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"ed1615336a5842c9b75fa7a0c5efebe3","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator","canonical_id":"go:GO:0042771","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage, and ends when the execution phase of apoptosis is triggered.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"e75a8381d4a04d18aebf2c391d2aa2d6","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress","canonical_id":"go:GO:0070059","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to a stimulus indicating endoplasmic reticulum (ER) stress, and ends when the execution phase of apoptosis is triggered. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.\" [GOC:mah, GOC:mtg_apoptosis, PMID:18701708]","metadata":null},{"id":"a32162f85b1e4537868dd24171996c6c","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to hydrogen peroxide","canonical_id":"go:GO:0036481","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to hydrogen peroxide (H2O2).\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"0aab45bb6d774442ae9fc6cce15dae55","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to hypoxia","canonical_id":"go:GO:1990144","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to hypoxia (lowered oxygen tension). Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. The pathway ends when the execution phase of apoptosis is triggered.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, PMID:20436456]","metadata":null},{"id":"e9008e207af74a209893061cce6c2d52","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to nitrosative stress","canonical_id":"go:GO:1990442","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to nitrosative stress; a state often resulting from exposure to high levels of nitric oxide (NO) or the highly reactive oxidant peroxynitrite, which is produced following interaction of NO with superoxide anions.\" [GOC:bf, GOC:PARL, PMID:23985028]","metadata":null},{"id":"e3223187d82e4bd9803b55d3eae224f7","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to osmotic stress","canonical_id":"go:GO:0008627","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to changes in intracellular ion homeostasis, and ends when the execution phase of apoptosis is triggered.\" [GOC:mtg_apoptosis, PMID:11454444, PMID:16483738]","metadata":null},{"id":"76e4c1a43e724beb95a8bb6fa34142ab","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator","canonical_id":"go:GO:1990127","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of osmotic stress, and ends when the execution phase of apoptosis is triggered.\" [GOC:krc, GOC:mtg_apoptosis, PMID:16571598]","metadata":null},{"id":"3138670a2cbc4bc6a51ecd14dd149fef","type":"GO_TERM","name":"intrinsic apoptotic signaling pathway in response to oxidative stress","canonical_id":"go:GO:0008631","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, and ends when the execution phase of apoptosis is triggered.\" [GOC:ai, GOC:mtg_apoptosis]","metadata":null},{"id":"2291827458694066bc602ccded20258d","type":"GO_TERM","name":"intron homing","canonical_id":"go:GO:0006314","description":"\"Lateral transfer of an intron to a homologous allele that lacks the intron, mediated by a site-specific endonuclease encoded within the mobile intron.\" [PMID:10487208]","metadata":null},{"id":"d734bf772ec84c8caab59cc539723266","type":"GO_TERM","name":"intronic box C/D snoRNA processing","canonical_id":"go:GO:0034965","description":"\"Any process involved in the conversion of a primary box C/D type small nucleolar RNA (snoRNA) transcript that resides within, and is processed from, the intron of a pre-mRNA into a mature box C/D snoRNA.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"26cda6f975bb41eabfe09629d1a04443","type":"GO_TERM","name":"intronic box H/ACA snoRNA processing","canonical_id":"go:GO:0034966","description":"\"Any process involved in the conversion of a primary box H/ACA type small nucleolar RNA (snoRNA) transcript that resides within, and is processed from, the intron of a pre-mRNA into a mature box H/ACA snoRNA.\" [GOC:mah]","metadata":null},{"id":"1202bb8dbb314b5e96ef7d79c4df7fe1","type":"GO_TERM","name":"intronic snoRNA processing","canonical_id":"go:GO:0031070","description":"\"The biogenesis of a snoRNA molecule which resides within, and is processed from, the intron of a pre-mRNA.\" [GOC:vw]","metadata":null},{"id":"a8ba5f343bd94fe3bf5269a41498ece1","type":"GO_TERM","name":"intronic transcription regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0001161","description":"\"Binding to an intronic DNA sequence that regulates the transcription of the transcript it is contained within.\" [GOC:txnOH]","metadata":null},{"id":"c2e39e80b27b47faa9d76a080759f365","type":"GO_TERM","name":"intussusceptive angiogenesis","canonical_id":"go:GO:0002041","description":"\"The formation of new blood vessels as a result of the insertion and extension of lumenal tissue pillars.\" [PMID:16391003]","metadata":null},{"id":"13a3e5e0b2f34b7d9f45eb3331c236ff","type":"DRUG","name":"inulin","canonical_id":"mesh:D007444","description":null,"metadata":null},{"id":"95cba6da79f74ae3804df6e1cd46e436","type":"GO_TERM","name":"inulin binding","canonical_id":"go:GO:2001082","description":"\"Binding to inulin.\" [GOC:mengo_curators]","metadata":null},{"id":"b0bce581a3804337884feac6f92a0e11","type":"GO_TERM","name":"inulin biosynthetic process","canonical_id":"go:GO:1902928","description":"\"The chemical reactions and pathways resulting in the formation of inulin.\" [GO_REF:0000068, GOC:TermGenie, PMID:23104410]","metadata":null},{"id":"f899a3d30fef485c9302aa7507df3eda","type":"GO_TERM","name":"inulin catabolic process","canonical_id":"go:GO:1902927","description":"\"The chemical reactions and pathways resulting in the breakdown of inulin.\" [GO_REF:0000068, GOC:TermGenie, PMID:23104410]","metadata":null},{"id":"536c6abe97bb4d899bd1b326bfcf0097","type":"GO_TERM","name":"inulin fructotransferase (DFA-I-forming) activity","canonical_id":"go:GO:0033997","description":"\"Catalysis of the reaction: [(2->1)-beta-D-fructosyl](n) = [(2->1)-beta-D-fructosyl](n-1) + alpha-D-fructofuranose-beta-D-fructofuranose 1,2':1,2'-dianhydride. This reaction is the production of alpha-D-fructofuranose beta-D-fructofuranose 1,2':2,1'-dianhydride (DFA I) by successively eliminating the diminishing (2->1)-beta-D-fructan (inulin) chain from the terminal D-fructosyl-D-fructosyl disaccharide.\" [EC:4.2.2.17]","metadata":null},{"id":"b4315a9320df49a2bf87b3203d46adfd","type":"GO_TERM","name":"inulin fructotransferase (DFA-III-forming) activity","canonical_id":"go:GO:0033998","description":"\"Catalysis of the reaction: [(2->1)-beta-D-fructosyl](n) = [(2->1)-beta-D-fructosyl](n-1) + alpha-D-fructofuranose beta-D-fructofuranose 1,2':2,3'-dianhydride. This reaction is the production of alpha-D-fructofuranose beta-D-fructofuranose 1,2':2,3'-dianhydride (DFA III) by successively eliminating the diminishing (2->1)-beta-D-fructan (inulin) chain from the terminal D-fructosyl-D-fructosyl disaccharide.\" [EC:4.2.2.18]","metadata":null},{"id":"a90a693d752c49178fe1d3f195f4bdb2","type":"GO_TERM","name":"inulinase activity","canonical_id":"go:GO:0051670","description":"\"Catalysis of the endohydrolysis of 2,1-beta-D-fructosidic linkages in inulin.\" [EC:3.2.1.7]","metadata":null},{"id":"3b4d59da190748cda4b9c6b3958c7459","type":"GO_TERM","name":"inulosucrase activity","canonical_id":"go:GO:0047725","description":"\"Catalysis of the reaction: sucrose + 2,1-beta-D-fructosyl(n) = glucose + 2,1-beta-D-fructosyl(n+1).\" [EC:2.4.1.9]","metadata":null},{"id":"671b5d5abc184775a97aa66013fce3bb","type":"GO_TERM","name":"invagination involved in gastrulation with mouth forming second","canonical_id":"go:GO:0055109","description":"\"The infolding of the epithelial sheet into the embryo involved in deuterostomic gastrulation.\" [ISBN:0878932437]","metadata":null},{"id":"96f0f90a6ea749aeaf7b5db6e1709ad4","type":"GO_TERM","name":"invasive filamentous growth","canonical_id":"go:GO:0036267","description":"\"The growth of colonies in filamentous chains of cells into a substrate.\" [GOC:di, PMID:22276126]","metadata":null},{"id":"686213868c644c5b8f1aa6d334f94fe1","type":"GO_TERM","name":"invasive growth in response to abiotic stimulus","canonical_id":"go:GO:0097318","description":"\"The growth of colonies in filamentous chains of cells as a result of a abiotic stimulus. An example of this process is found in Candida albicans.\" [GOC:di, PMID:18679170]","metadata":null},{"id":"16ab648a2195497cb70959d9f303b55e","type":"GO_TERM","name":"invasive growth in response to biotic stimulus","canonical_id":"go:GO:0097317","description":"\"The growth of colonies in filamentous chains of cells as a result of a biotic stimulus. An example of this is Candida albicans forming invasive filaments in agar medium in response to a serum stimulus.\" [GOC:di, PMID:18679170]","metadata":null},{"id":"c1b1b78a7c7341f7ab8ff4316ce38511","type":"GO_TERM","name":"invasive growth in response to glucose limitation","canonical_id":"go:GO:0001403","description":"\"A growth pattern exhibited by budding haploid cells under certain growth conditions, in which cells retain the typical axial budding pattern of haploids, but become elongated and fail to separate after division; during growth on a solid substrate, this results in penetration of cells into the agar medium. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:mcc, PMID:9728395]","metadata":null},{"id":"905bdae5784a4ae1a73c1eef9e2a15d8","type":"GO_TERM","name":"invasive growth in response to heat","canonical_id":"go:GO:0036165","description":"\"The growth of colonies in filamentous chains of cells as a result of an increase in temperature.\" [GOC:di, PMID:22365851]","metadata":null},{"id":"a1899c79b37c473a9bf6c742f6e643ed","type":"GO_TERM","name":"invasive growth in response to pheromone","canonical_id":"go:GO:0045311","description":"\"The growth of colonies in filamentous chains of cells as a result of a pheromone stimulus.\" [GOC:ai, GOC:dph, GOC:mcc]","metadata":null},{"id":"49249a729fca448482c64a331f583189","type":"GO_TERM","name":"invertasome","canonical_id":"go:GO:0031421","description":"\"A complex formed by a recombinase, a regulatory protein, and the DNA sequences bound by each protein; catalyzes a reversible site-specific recombination reaction that results in the alternate expression of one or more genes in various contexts.\" [PMID:11114897, PMID:9732277]","metadata":null},{"id":"4126533675174c0b95b9f44f43cc84be","type":"GO_TERM","name":"investment cone","canonical_id":"go:GO:0070865","description":"\"A cytoskeletal part that consists of a microfilament-rich cone that forms round each nucleus in a spermatogenic cyst and translocates the length of the cyst during sperm individualization.\" [GOC:sart, PMID:15829565, PMID:9550716]","metadata":null},{"id":"c5750de2ab974bb1bf21881c7ba8b947","type":"GO_TERM","name":"involuntary skeletal muscle contraction","canonical_id":"go:GO:0003011","description":"\"A process in which force is generated within involuntary skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Involuntary skeletal muscle is skeletal muscle that is not under conscious control.\" [GOC:mtg_cardio, GOC:mtg_muscle]","metadata":null},{"id":"59fd06846ebe4b668b4003e9eb5d9c8c","type":"GO_TERM","name":"involution involved in gastrulation with mouth forming second","canonical_id":"go:GO:0055110","description":"\"The inturning of an epithelial sheet over the basal surface of an outer layer involved in deuterostomic gastrulation.\" [ISBN:0878932437]","metadata":null},{"id":"520e4bb2b4ac4572af2e7ba2b0c0f468","type":"GO_TERM","name":"inward migration of deep nuclear neurons","canonical_id":"go:GO:0021948","description":"\"The directed movement of a deep nuclear neuron from the rostrodorsal region of the cerebellar plate to their final more ventral position.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"deaaa73f78754d5d9b4c5882d408d67e","type":"GO_TERM","name":"inward rectifier potassium channel activity","canonical_id":"go:GO:0005242","description":"\"Enables the transmembrane transfer of a potassium ion by an inwardly-rectifying voltage-gated channel. An inwardly rectifying current-voltage relation is one where at any given driving force the inward flow of K+ ions exceeds the outward flow for the opposite driving force. The inward-rectification is due to a voltage-dependent block of the channel pore by a specific ligand or ligands, and as a result the macroscopic conductance depends on the difference between membrane voltage and the K+ equilibrium potential rather than on membrane voltage itself.\" [GOC:cb, GOC:mah, PMID:14977398]","metadata":null},{"id":"017e43ac73824f0ebda20a6ef7b71555","type":"GO_TERM","name":"inward rectifier potassium channel complex","canonical_id":"go:GO:1902937","description":"\"A protein complex which is capable of inward rectifier potassium channel activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16834334]","metadata":null},{"id":"cbc41fd85bc4454a8007a8b8eb94219d","type":"GO_TERM","name":"inward rectifier potassium channel inhibitor activity","canonical_id":"go:GO:0070320","description":"\"Binds to and stops, prevents, or reduces the activity of an inwardly rectifying potassium channel.\" [GOC:mah]","metadata":null},{"id":"3642055fbb734cbca22879a81cf2df28","type":"GO_TERM","name":"inward rectifying potassium channel","canonical_id":"go:GO:0008282","description":"\"A protein complex that comprises four pore-forming (Kir6.x) and four regulatory sulphonylurea receptor (SURx) subunits and forms a transmembrane channel through which ions may pass. The opening and closing of the channel is regulated by ATP: binding of ATP to the Kir6.x subunit inhibits channel activity, whereas binding of Mg2+-complexed ATP or ADP to the SURx subunit stimulates channel activity.\" [GOC:bhm, PMID:16308567, PMID:16956886]","metadata":null},{"id":"1d943dd585ca4ccfa9030afab8852d4c","type":"GO_TERM","name":"iodide channel activity","canonical_id":"go:GO:0160081","description":"\"Enables the energy-independent facilitated diffusion of iodide through a transmembrane aqueous pore or channel.\" [PMID:34910516]","metadata":null},{"id":"272f22c03286456a95f55bd69944fa89","type":"GO_TERM","name":"iodide peroxidase activity","canonical_id":"go:GO:0004447","description":"\"Catalysis of the reactions: (1) 2 iodide + H2O2 + 2 H+ = diiodine + 2 H2O; (2) [thyroglobulin]-L-tyrosine + iodide + H2O2 + H+ = [thyroglobulin]-3-iodo-L-tyrosine + 2 H2O; (3) [thyroglobulin]-3-iodo-L-tyrosine + iodide + H2O2 + H+ = [thyroglobulin]-3,5-diiodo-L-tyrosine + 2 H2O; (4) 2 [thyroglobulin]-3,5-diiodo-L-tyrosine + H2O2 = [thyroglobulin]-L-thyroxine + [thyroglobulin]-dehydroalanine + 2 H2O; (5) [thyroglobulin]-3-iodo-L-tyrosine + [thyroglobulin]-3,5-diiodo-L-tyrosine + H2O2 = [thyroglobulin]-3,3',5-triiodo-L-thyronine + [thyroglobulin]-dehydroalanine + 2 H2O.\" [EC:1.11.1.8, PMID:8651700]","metadata":null},{"id":"c6b81dc782f44061a70ca821a90341cd","type":"GO_TERM","name":"iodide transmembrane transport","canonical_id":"go:GO:1904200","description":"\"The process in which iodide is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"010734a161f646368a01ff30078e0d26","type":"GO_TERM","name":"iodide transmembrane transporter activity","canonical_id":"go:GO:0015111","description":"\"Enables the transfer of iodide ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"120f178dd8234bf6938287a7ad5b979c","type":"GO_TERM","name":"iodide transport","canonical_id":"go:GO:0015705","description":"\"The directed movement of iodide into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"c9c8c7d3bd464bae93bab848af333f23","type":"GO_TERM","name":"iodophenol O-methyltransferase activity","canonical_id":"go:GO:0030737","description":"\"Catalysis of the reaction: 2-iodophenol + S-adenosyl-L-methionine = 1-iodo-2-methoxybenzene + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.26, RHEA:14313]","metadata":null},{"id":"09bffe5fcc094cfbb1d3a334162484f4","type":"GO_TERM","name":"iodotyrosine deiodinase activity","canonical_id":"go:GO:0140616","description":"\"Catalyzes the reaction: 2 iodide + L-tyrosine + 2 NADP+ = 3,5-diiodo-L-tyrosine + H+ + 2 NADPH. Note that this activity has only been demonstrated in the direction of 3-deiodination. 3-bromo-L-tyrosine and 3-chloro-L-tyrosine can also be used as substrates.\" [PMID:15289438, PMID:18434651, PMID:25395621, PMID:27643701, RHEA:32479]","metadata":null},{"id":"9cb89a4fe8844d2895b75e2a5c8caa4c","type":"GO_TERM","name":"ion binding","canonical_id":"go:GO:0043167","description":"\"Binding to an ion, a charged atoms or groups of atoms.\" [GOC:jl]","metadata":null},{"id":"6edb367cd77444a58ab787ac914ce3fd","type":"GO_TERM","name":"ion channel inhibitor activity","canonical_id":"go:GO:0008200","description":"\"Binds to and stops, prevents, or reduces the activity of an ion channel.\" [GOC:mah]","metadata":null},{"id":"83f7947e8f574acdb07b07dd8a8d65eb","type":"GO_TERM","name":"ion channel regulator activity","canonical_id":"go:GO:0099106","description":"\"Modulates the activity of a channel via direct interaction with it. A channel catalyzes energy-independent facilitated diffusion, mediated by passage of a solute through a transmembrane aqueous pore or channel.\" [GOC:dos]","metadata":null},{"id":"5bb6ff77d08d4b518e26e5ea33b1380e","type":"GO_TERM","name":"ionocyte differentiation","canonical_id":"go:GO:0062236","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of an ionocyte. Ionocytes are specialized epithelial cells that contribute to osmotic homeostasis.\" [PMID:17555741]","metadata":null},{"id":"0f63e99840a8483bbc99d3360f83280f","type":"GO_TERM","name":"ionotropic bitter taste receptor activity","canonical_id":"go:GO:0170022","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific bitter compound has been bound by the channel complex or one of its constituent parts.\" [PMID:21262465]","metadata":null},{"id":"92789448974b44e9980c1926b19c95ce","type":"GO_TERM","name":"ionotropic glutamate receptor binding","canonical_id":"go:GO:0035255","description":"\"Binding to an ionotropic glutamate receptor. Ionotropic glutamate receptors bind glutamate and exert an effect through the regulation of ion channels.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"af66403b470d402e9a20b6fdd0f618e1","type":"GO_TERM","name":"ionotropic glutamate receptor complex","canonical_id":"go:GO:0008328","description":"\"A multimeric assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand-gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex.\" [PMID:20716669, PMID:34753794]","metadata":null},{"id":"41e6e89f8ac14499a7da2088c50ce80d","type":"GO_TERM","name":"ionotropic glutamate receptor signaling pathway","canonical_id":"go:GO:0035235","description":"\"The series of molecular signals initiated by glutamate binding to a glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, ISBN:0198506732]","metadata":null},{"id":"2e3f49ab9978474d80b3259846f200dc","type":"GO_TERM","name":"ionotropic olfactory receptor activity","canonical_id":"go:GO:0170020","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific odorant has been bound by the channel complex or one of its constituent parts.\" [PMID:21857978, PMID:24661599]","metadata":null},{"id":"919c960d6bc64b26ba233d0e48423dbc","type":"GO_TERM","name":"ionotropic salty taste receptor activity","canonical_id":"go:GO:0033039","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a soluble salty compound has been bound by the channel complex or one of its constituent parts.\" [GOC:mah, PMID:36332657]","metadata":null},{"id":"99d14d94fbd4426ba67902b9f987cdb7","type":"GO_TERM","name":"ionotropic sweet taste receptor activity","canonical_id":"go:GO:0170023","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific soluble sweet compound has been bound by the channel complex or one of its constituent parts.\" [PMID:24474785]","metadata":null},{"id":"29c2d5472385477cb15062c21c8c18d2","type":"GO_TERM","name":"ionotropic taste receptor activity","canonical_id":"go:GO:0170021","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a soluble compound has been bound by the channel complex or one of its constituent parts.\" [PMID:36828965]","metadata":null},{"id":"bed8006709724f83bb4edd510058bba1","type":"GO_TERM","name":"iota-carrageenase activity","canonical_id":"go:GO:0033952","description":"\"Catalysis of the endohydrolysis of 1,4-beta-D-linkages between D-galactose 4-sulfate and 3,6-anhydro-D-galactose-2-sulfate in iota-carrageenans.\" [EC:3.2.1.157]","metadata":null},{"id":"cfcbcdc241394c95bf91cd68f241b1fb","type":"DRUG","name":"iparomlimab","canonical_id":"gtopdb:13792","description":null,"metadata":null},{"id":"92647533fd9f40d684bd1984007836f9","type":"COMBINATION_TREATMENT","name":"iparomlimab + regorafenib + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-93f6f188c0472525","description":null,"metadata":null},{"id":"409f7740d0454e9192f4e359020ec2f4","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-33c73cad8a5a90e1","description":null,"metadata":null},{"id":"95494c3387dc464b9dff929256b658b9","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-1f399a4f9ccc3fcf","description":null,"metadata":null},{"id":"989e4670e9754524a0ac182b707ce582","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-03af2dda04497e23","description":null,"metadata":null},{"id":"80dfc161a7f84bd6a8e66f08672cf3b2","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-c49a877aa471dee9","description":null,"metadata":null},{"id":"136f3b90255c4674954054abb0ce6ca3","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-941a8f3c484be1ff","description":null,"metadata":null},{"id":"0ae392af9c0c4a799eb00b98b007d82b","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-b2230c071686e2bb","description":null,"metadata":null},{"id":"6bcf6dcb24ad417ab597dfa19e0fb599","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-38bdfaa8bddffb65","description":null,"metadata":null},{"id":"e8a10a211f3a4d868afea86b34eb39b0","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-65b84549a534e4da","description":null,"metadata":null},{"id":"61dd3307ada64ca5af5ca907d6bd8555","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-4e6265641fcc1ff7","description":null,"metadata":null},{"id":"51e250d454bc44a28460574609557a94","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-2d7d66c4fd4a7b94","description":null,"metadata":null},{"id":"9a8227c8e53049f8a72ebf2a7237ac6b","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-1bea429d2825630b","description":null,"metadata":null},{"id":"85f606e30ec441f992dbf3a9215c5c7e","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-e7eb0317e145b443","description":null,"metadata":null},{"id":"7f80f2664e63464c9ba78c94d7345ee6","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-c02cada079859b7a","description":null,"metadata":null},{"id":"87b16e20018a41248470b128c7f4c121","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-226e373b0c1e261a","description":null,"metadata":null},{"id":"0ac72c8b150d437d8b4b9fd91bd7c257","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-1dc0051ff21be361","description":null,"metadata":null},{"id":"279e53897eb74f55b72e0b8256e0c434","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-aa64a27ac2dbe2c3","description":null,"metadata":null},{"id":"4f5636e0f5cc49838ca74781d4dad000","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-0545c30aa072f6e3","description":null,"metadata":null},{"id":"57f08a5c15da4773b162ddf5d08ae10d","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-74ccb19b4799bde1","description":null,"metadata":null},{"id":"f848f809d7f54d8eb160b49237cc4a4f","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-b7182ef433eed585","description":null,"metadata":null},{"id":"31277f529b53462b9faa05dbeb04903b","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-45aed0e2c56af205","description":null,"metadata":null},{"id":"d930b71a7eb7495eb3bef6d686ddf314","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-ee98ef6e60fb03d3","description":null,"metadata":null},{"id":"af02bc892ef5415c87ecb5ed0aba3a77","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-910c37d11e71201e","description":null,"metadata":null},{"id":"6adb8d6a3d0244e8b5ee74d2c15a4d84","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-c359c5a3ba9ff355","description":null,"metadata":null},{"id":"f81beaa20e4f49b39978a006fe372ac2","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-82d4923eacdb60f9","description":null,"metadata":null},{"id":"05cf2f19b3434789a6d72c1629fca238","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-cdaf1418567d6ae1","description":null,"metadata":null},{"id":"a98d59f966e2424e877f0c0d4ee28f3f","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-0616765bd818e0a9","description":null,"metadata":null},{"id":"193f2a20329a4dad857fe3afd9dbc187","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-e66a5ce295754aeb","description":null,"metadata":null},{"id":"df01abeab9eb43ccae65fc71cf089c80","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-2ddbc79f9406ab69","description":null,"metadata":null},{"id":"7146486f77ee497d8a55927dfbc2ab47","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-e770393590090af3","description":null,"metadata":null},{"id":"6c33de7bc7dd42658d386d3a0e38bb26","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-77185c7a0971a343","description":null,"metadata":null},{"id":"e9de67fb44aa40dfb92513536516e87f","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-f5973bfba7de1089","description":null,"metadata":null},{"id":"df83840e59a64897bd9a7e1e060b4b37","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-9e8c877d10d1c7c6","description":null,"metadata":null},{"id":"baf904b723094932811d8eedf7d93b82","type":"COMBINATION_TREATMENT","name":"iparomlimab + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-008cb3080b3d4171","description":null,"metadata":null},{"id":"16d36b0c1d76418c81cb81cfeeb41344","type":"DRUG","name":"ipilimumab","canonical_id":"gtopdb:6888","description":null,"metadata":null},{"id":"70e5c6d50e5246ea8d09ea253e55e890","type":"DRUG","name":"ipilimumab","canonical_id":"chembl:CHEMBL1789844","description":null,"metadata":null},{"id":"32cea58146934b13a00990eedc249039","type":"COMBINATION_TREATMENT","name":"ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-a82338c3ecad39d7","description":null,"metadata":null},{"id":"61bfd891e5b54b218b9e6920e8ff7a4e","type":"COMBINATION_TREATMENT","name":"ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-9f90cf596fc669d2","description":null,"metadata":null},{"id":"0861001e05c441d3a9d65deb3cd097eb","type":"COMBINATION_TREATMENT","name":"ipilimumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-18bc77e85e9e5e9e","description":null,"metadata":null},{"id":"5aa8602ed9e84823ae64643ec99ae2cc","type":"COMBINATION_TREATMENT","name":"ipilimumab + nivolumab + pembrolizumab + relatlimab","canonical_id":"ctgov_combo:ctgov-combo-c9a0e4823bd3cfdc","description":null,"metadata":null},{"id":"7b7c2cfac6b8450583624b9c64d7b9df","type":"COMBINATION_TREATMENT","name":"ipilimumab + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-5898a689f48ea0f8","description":null,"metadata":null},{"id":"4aa41df9ac34483fa73b74c64b9f2c5c","type":"COMBINATION_TREATMENT","name":"ipilimumab + relatlimab","canonical_id":"ctgov_combo:ctgov-combo-d1c131d59f6feb47","description":null,"metadata":null},{"id":"044db37e0c894ef2bb3d3fa8cfd9b78b","type":"COMBINATION_TREATMENT","name":"ipilimumab + relatlimab","canonical_id":"ctgov_combo:ctgov-combo-a168dd2fb4778086","description":null,"metadata":null},{"id":"f505ee624c9f4d3f960955ed2a14f06c","type":"DRUG","name":"ipragliflozin","canonical_id":"gtopdb:9394","description":null,"metadata":null},{"id":"a15ba9821d15473d9d6be4eeb3db607f","type":"DRUG","name":"ipragliflozin","canonical_id":"mesh:C572941","description":null,"metadata":null},{"id":"40096e907036419bbaae533a4da719ed","type":"DRUG","name":"ipragliflozin","canonical_id":"chembl:CHEMBL2018096","description":null,"metadata":null},{"id":"9e66f14db83445b99bfd33843292577a","type":"DRUG","name":"ipratropium","canonical_id":"gtopdb:325","description":null,"metadata":null},{"id":"e2ecfe40872444e8b4276d554359a946","type":"DRUG","name":"ipratropium","canonical_id":"mesh:D009241","description":null,"metadata":null},{"id":"53f8d4333f2f4b2bb3950f662b2314bd","type":"COMBINATION_TREATMENT","name":"ipratropium + salbutamol","canonical_id":"ctgov_combo:ctgov-combo-591372555ec2bb4a","description":null,"metadata":null},{"id":"0df97b8175f34b42b3f52336bf1dd9fe","type":"COMBINATION_TREATMENT","name":"ipratropium + salbutamol","canonical_id":"ctgov_combo:ctgov-combo-c797eae1d3ae8d81","description":null,"metadata":null},{"id":"ae3800911f954e5b9f1c0fb782f0a2cd","type":"COMBINATION_TREATMENT","name":"ipratropium + salbutamol","canonical_id":"ctgov_combo:ctgov-combo-48bd98bc911b9a09","description":null,"metadata":null},{"id":"9c6b931421a04fe4bee5f282b14ec07b","type":"COMBINATION_TREATMENT","name":"ipratropium + salbutamol","canonical_id":"ctgov_combo:ctgov-combo-733297e519bc021a","description":null,"metadata":null},{"id":"4ab88fc9d99741879bfe43fe34ab6c26","type":"COMBINATION_TREATMENT","name":"ipratropium + salbutamol","canonical_id":"ctgov_combo:ctgov-combo-1575ad3ffe6be008","description":null,"metadata":null},{"id":"48ea40bd56e140cc9c007558ef47dcc6","type":"COMBINATION_TREATMENT","name":"ipratropium + theophylline","canonical_id":"ctgov_combo:ctgov-combo-d060c9ae638857cb","description":null,"metadata":null},{"id":"9973bf11c34b4fc984e0d0511731ed75","type":"DRUG","name":"irbesartan","canonical_id":"gtopdb:589","description":null,"metadata":null},{"id":"69f60ac6c0ff431f9a4751bc69d4810c","type":"DRUG","name":"irbesartan","canonical_id":"chembl:CHEMBL1513","description":null,"metadata":null},{"id":"45b9b4317260439dab21e5d318490816","type":"COMBINATION_TREATMENT","name":"irbesartan + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-f93735d71847bee9","description":null,"metadata":null},{"id":"5f0ee87876ad4066bae8052244dd39b4","type":"COMBINATION_TREATMENT","name":"irbesartan + ramipril","canonical_id":"ctgov_combo:ctgov-combo-d1f160ac0b6d0ab8","description":null,"metadata":null},{"id":"b332e8102faf418185a578c2b7813d69","type":"COMBINATION_TREATMENT","name":"irbesartan + ramipril","canonical_id":"ctgov_combo:ctgov-combo-c47f46b2e1f41528","description":null,"metadata":null},{"id":"9af999ded532477c94f755d35e069fa8","type":"DISEASE","name":"iridocyclitis","canonical_id":"mondo:0004773","description":null,"metadata":null},{"id":"4be1a00f179c4b36bf8cd87dcb2c1249","type":"GO_TERM","name":"iridophore differentiation","canonical_id":"go:GO:0050935","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an iridophore. Iridophores are pigment cells derived from the neural crest. They contain guanidine or other purine crystals deposited in stacks called reflecting platets or iridisomes. This gives them a silver, gold, or iridescent appearance.\" [GOC:jid, GOC:mh, PMID:11858836]","metadata":null},{"id":"3112bae6807a4858a0a5090351841284","type":"GO_TERM","name":"iridosome","canonical_id":"go:GO:0043698","description":"\"A tissue-specific, membrane-bounded cytoplasmic organelle within which purines crystalize in reflective stacks. Iridosomes are synthesized in iridophore cells and are silver, gold or iridescent in appearance.\" [GOC:mh]","metadata":null},{"id":"28897bcc26904cb7bebb82172152c050","type":"DRUG","name":"irinotecan","canonical_id":"gtopdb:6823","description":null,"metadata":null},{"id":"78c812062ae1452296efbd80422bf7a2","type":"COMBINATION_TREATMENT","name":"irinotecan + sirolimus + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-ed53d9c043c2b5d5","description":null,"metadata":null},{"id":"85302098ef63416c89e9ece59cee42dd","type":"COMBINATION_TREATMENT","name":"irinotecan + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-c9c0549d2daff1d0","description":null,"metadata":null},{"id":"d7f093c3703747fc9426078e4be70aab","type":"GO_TERM","name":"iris morphogenesis","canonical_id":"go:GO:0061072","description":"\"The process in which the iris is generated and organized. The iris is an anatomical structure in the eye whose opening forms the pupil. The iris is responsible for controlling the diameter and size of the pupil and the amount of light reaching the retina.\" [GOC:dph]","metadata":null},{"id":"1ec9abfeaaa645328f5f6f9f74e9d76c","type":"DISEASE","name":"iritis","canonical_id":"mondo:0006814","description":null,"metadata":null},{"id":"a4c2660ad90740fb84aad70b9f950b9c","type":"DRUG","name":"iron","canonical_id":"mesh:D007501","description":null,"metadata":null},{"id":"e7f45f652c3e4df4a0e57e3d63a003ab","type":"GO_TERM","name":"iron acquisition from host","canonical_id":"go:GO:0044847","description":"\"The process by which a symbiont acquires iron from its host, either from heme or other iron containing molecules such as transferrin and lactoferrin. Begins with either the secretion of symbiont gene products that bind iron- or heme-containing molecules (siderophores and hemophores) from the symbiont cell into the host, or by expression of receptors that bind iron- or heme-containing molecules on the symbiont cell surface. Ends when the iron-containing compound is transported into the symbiont cell.\" [PMID:15487950, PMID:22865843]","metadata":null},{"id":"36fad34e459944039f5810df2884d04a","type":"GO_TERM","name":"iron chaperone activity","canonical_id":"go:GO:0034986","description":"\"Directly binding to and delivering iron ions to a target protein.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"ea64348657144577afbd72d0686df312","type":"GO_TERM","name":"iron chelate transmembrane transporter activity","canonical_id":"go:GO:0015603","description":"\"Enables the transfer of an iron chelate from one side of a membrane to the other. An iron chelate is a heterocyclic compound having a metal ion attached by coordinate bonds to at least two nonmetal ions.\" [PMID:17660286]","metadata":null},{"id":"a26fcd18e9ba4afba328f9e7ac06c3a4","type":"GO_TERM","name":"iron coordination entity transport","canonical_id":"go:GO:1901678","description":"\"The directed movement of an iron coordination entity into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"c6178bebc2c44f67a26901ba73d62f41","type":"GO_TERM","name":"iron import into cell","canonical_id":"go:GO:0033212","description":"\"The directed movement of iron ions from outside of a cell into the cytoplasmic compartment. This may occur via transport across the plasma membrane or via endocytosis.\" [PMID:18622392, PMID:23192658, Wikipedia:Human_iron_metabolism]","metadata":null},{"id":"a05fb2260bb142a7bee4b393c1d71701","type":"GO_TERM","name":"iron import into the mitochondrion","canonical_id":"go:GO:0048250","description":"\"The process in which iron is transported from the cytosol into the mitochondrial matrix.\" [GOC:jid, PMID:12006577]","metadata":null},{"id":"ffb4531c11814557b3dc55d73d9d930b","type":"GO_TERM","name":"iron incorporation into metallo-sulfur cluster","canonical_id":"go:GO:0018283","description":"\"The incorporation of iron into a metallo-sulfur cluster.\" [GOC:ai]","metadata":null},{"id":"5ac2f9677e84441a9e05132be3f81d7a","type":"GO_TERM","name":"iron ion binding","canonical_id":"go:GO:0005506","description":"\"Binding to an iron (Fe) ion.\" [GOC:ai]","metadata":null},{"id":"37cd17ecc62a4751b4763845e0f9dc3c","type":"GO_TERM","name":"iron ion export across plasma membrane","canonical_id":"go:GO:1903988","description":"\"The directed movement of iron ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GO_REF:0000074, GOC:BHF, GOC:kom, GOC:rl, GOC:TermGenie, PMID:15514116]","metadata":null},{"id":"eb76fe92c3b1415ab9e1d0c2bb46879f","type":"GO_TERM","name":"iron ion import across cell outer membrane","canonical_id":"go:GO:0098706","description":"\"The directed movement of iron ions from outside of a cell, across the cell outer membrane and into the periplasmic space.\" [GOC:mah, PMID:23192658]","metadata":null},{"id":"fd33e01a9af845b9bff615edd5275922","type":"GO_TERM","name":"iron ion import across plasma membrane","canonical_id":"go:GO:0098711","description":"\"The directed movement of iron ions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:mah, PMID:8321236]","metadata":null},{"id":"2c6a46462de24bdbba9769998c3707e4","type":"GO_TERM","name":"iron ion sequestering activity","canonical_id":"go:GO:0140315","description":"\"Binding to an iron ion to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:27780864]","metadata":null},{"id":"aff183d82154407b9b423e32e472eb51","type":"GO_TERM","name":"iron ion transmembrane transport","canonical_id":"go:GO:0034755","description":"\"A process in which an iron ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah, PMID:11390404]","metadata":null},{"id":"fa7ab3051a5440898ff7a1ee9d0517c1","type":"GO_TERM","name":"iron ion transmembrane transporter activity","canonical_id":"go:GO:0005381","description":"\"Enables the transfer of iron (Fe) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"0624824b6d944bb28994338a01a703e7","type":"GO_TERM","name":"iron ion transmembrane transporter inhibitor activity","canonical_id":"go:GO:0097690","description":"\"Binds to and stops, prevents, or reduces the activity of an iron ion transmembrane transporter.\" [GOC:BHF, GOC:kom, PMID:15514116]","metadata":null},{"id":"885373bdaa6546af997a32a1bce7f27c","type":"GO_TERM","name":"iron ion transport","canonical_id":"go:GO:0006826","description":"\"The directed movement of iron (Fe) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"7d794527ceb841388aafade376b85592","type":"GO_TERM","name":"iron sensor activity","canonical_id":"go:GO:0140482","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of iron.\" [PMID:11956219, PMID:25806539]","metadata":null},{"id":"d8b53eb6799149409428efcc640a9530","type":"GO_TERM","name":"iron-cytochrome-c reductase activity","canonical_id":"go:GO:0047726","description":"\"Catalysis of the reaction: Fe3+ + Fe(II)-[cytochrome c] = Fe2+ + Fe(III)-[cytochrome c].\" [EC:1.16.2.1, RHEA:15617]","metadata":null},{"id":"4602e115325a434dbd5d37e53291d918","type":"GO_TERM","name":"iron-guanylylpyridinol cofactor biosynthetic process","canonical_id":"go:GO:0160300","description":"\"The chemical reactions and pathways resulting in the formation of iron-guanylylpyridinol cofactor, in which mononuclear Fe(II) is ligated with a pyridinol and two CO ligands.\" [PMID:37671838]","metadata":null},{"id":"a5be5bf9598f466b987eb7432cb3b62e","type":"GO_TERM","name":"iron-iron nitrogenase complex","canonical_id":"go:GO:0016611","description":"\"An enzyme complex containing an iron-iron cluster found in species such as the photosynthetic bacterium Rhodobacter capsulatus. It is composed of two main subunits, dinitrogenase and nitrogenase reductase. Dinitrogenase, the iron-iron containing subunit, has an alpha1-beta2 or alpha2-beta2 structure, and the nitrogenase reductase subunit is a homodimer. Functions in the catalysis of the formation of oxidized ferredoxin and ammonia from reduced ferredoxin and nitrogen.\" [GOC:jl, PMID:11848850]","metadata":null},{"id":"cec8eca1b79f4d7dab8b75fd2d8295c3","type":"GO_TERM","name":"iron-nicotianamine transmembrane transporter activity","canonical_id":"go:GO:0051980","description":"\"Enables the transfer of the iron chelate iron-nicotianamine (Fe-NA) from one side of a membrane to the other.\" [GOC:ai, PMID:20625001]","metadata":null},{"id":"f855e52569ff4bc59a1afc409033b5e1","type":"GO_TERM","name":"iron-responsive element binding","canonical_id":"go:GO:0030350","description":"\"Binding to an iron-responsive element, a regulatory sequence found in the 5'- and 3'-untranslated regions of mRNAs encoding many iron-binding proteins.\" [PMID:3198610, PMID:8710843]","metadata":null},{"id":"f2b6479527674fddad7b71240164c1f9","type":"GO_TERM","name":"iron-sulfur cluster assembly","canonical_id":"go:GO:0016226","description":"\"The incorporation of iron and exogenous sulfur into a metallo-sulfur cluster.\" [GOC:jl, GOC:mah, GOC:pde, GOC:vw]","metadata":null},{"id":"8049b84903f341ac88ce485af950095c","type":"GO_TERM","name":"iron-sulfur cluster assembly complex","canonical_id":"go:GO:1990229","description":"\"A protein complex capable of assembling an iron-sulfur (Fe-S) cluster.\" [GOC:bhm, PMID:17350958]","metadata":null},{"id":"648b177b215043f4b627a15f17584d1c","type":"GO_TERM","name":"iron-sulfur cluster binding","canonical_id":"go:GO:0051536","description":"\"Binding to an iron-sulfur cluster, a combination of iron and sulfur atoms.\" [GOC:ai]","metadata":null},{"id":"dd308d987a3f4caabdc6ec92148fa802","type":"GO_TERM","name":"iron-sulfur cluster chaperone activity","canonical_id":"go:GO:0140132","description":"\"Binding to an iron-sulfur cluster and delivering it to an acceptor molecule.\" [PMID:22966982, PMID:29051382]","metadata":null},{"id":"308b5af9456042e784ac0db4f241dbf4","type":"GO_TERM","name":"iron-sulfur cluster export from the mitochondrion","canonical_id":"go:GO:0140466","description":"\"The directed movement of iron sulfur clusters from inside the mitochondrion into the cytosol by crossing the inner mitochondrial membrane.\" [PMID:31040179]","metadata":null},{"id":"df036d7633004417ad6f077427571f72","type":"GO_TERM","name":"iron-sulfur cluster transfer complex","canonical_id":"go:GO:1990230","description":"\"A protein complex capable of catalyzing the transfer of an iron-sulfur (Fe-S) cluster from one compound (donor) to another (acceptor), which may be a target protein or another Fe-S assembly complex. In humans, it consists of HSPA9, HSCB, GLRX5, ABCB7 and GFER.\" [GOC:bhm, PMID:19810706, PMID:34660592]","metadata":null},{"id":"ffe02fbe1c464fbfb20168eb67996a6e","type":"GO_TERM","name":"iron-sulfur cluster transmembrane transport","canonical_id":"go:GO:1902497","description":"\"A process in which an iron-sulfur cluster is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:TermGenie, PMID:19810706]","metadata":null},{"id":"160fd5a65997443cb927257ac159fe67","type":"GO_TERM","name":"iron-sulfur transferase activity","canonical_id":"go:GO:0036455","description":"\"Catalysis of the transfer of a iron-sulfur cluster from one compound (donor) to another (acceptor).\" [GOC:bhm]","metadata":null},{"id":"0ca1db5a63204893ba70660b706fe394","type":"GO_TERM","name":"iron-sulfur-molybdenum cofactor assembly","canonical_id":"go:GO:0044593","description":"\"The chemical reactions and pathways resulting in the formation of iron-sulfur-molybdenum cofactor, the cofactor located at the active site of the molybdenum nitrogenase.\" [GOC:mengo_curators, GOC:tt, PMID:18429691]","metadata":null},{"id":"35986cc667694c6f8833cb9af7934425","type":"GO_TERM","name":"iron-sulfur-molybdenum cofactor binding","canonical_id":"go:GO:0044590","description":"\"Binding to iron molybdenum cofactor, the cofactor located at the active site of the molybdenum nitrogenase.\" [GOC:mengo_curators, GOC:tt, PMID:18429691]","metadata":null},{"id":"a65cd5f6abaf418da39857cdd6617dbc","type":"GO_TERM","name":"iron-sulfur-molybdenum cofactor biosynthetic process","canonical_id":"go:GO:1901288","description":"\"The chemical reactions and pathways resulting in the formation of iron-sulfur-molybdenum cofactor.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00782]","metadata":null},{"id":"cef220e9233345069215c026c3fb7d7a","type":"GO_TERM","name":"iron-sulfur-molybdenum cofactor catabolic process","canonical_id":"go:GO:1901287","description":"\"The chemical reactions and pathways resulting in the breakdown of iron-sulfur-molybdenum cofactor.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00782]","metadata":null},{"id":"a36423a981fc4d9587746dca53b0177b","type":"GO_TERM","name":"iron-sulfur-molybdenum cofactor metabolic process","canonical_id":"go:GO:1901286","description":"\"The chemical reactions and pathways involving iron-sulfur-molybdenum cofactor.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00782]","metadata":null},{"id":"2a4c1e41f8f5414589934905edbeff4e","type":"GO_TERM","name":"irritable aggressive behavior","canonical_id":"go:GO:0002123","description":"\"Aggressive behavior induced by frustration and directed against an available target.\" [GOC:hjd]","metadata":null},{"id":"b67aade969fb423cb8ece007e11f4633","type":"DISEASE","name":"irritable bowel syndrome","canonical_id":"mondo:0005052","description":null,"metadata":null},{"id":"e5a9820f3ea54b58afeacfe261d1ee71","type":"DRUG","name":"isatuximab","canonical_id":"gtopdb:8719","description":null,"metadata":null},{"id":"28b1f5bb65a04f6c877a6b60577aead0","type":"DRUG","name":"isatuximab","canonical_id":"chembl:CHEMBL3545131","description":null,"metadata":null},{"id":"ac643fb5be114b5aacfce345e21f0260","type":"COMBINATION_TREATMENT","name":"isatuximab + montelukast","canonical_id":"ctgov_combo:ctgov-combo-e78263f4f63742e5","description":null,"metadata":null},{"id":"8191a3fb37b74698ba02e16d3a9cafcd","type":"DRUG","name":"isavuconazonium","canonical_id":"mesh:C508735","description":null,"metadata":null},{"id":"76885c683bb846ffa799455f15692bb1","type":"DISEASE","name":"ischemia","canonical_id":"efo:0000556","description":null,"metadata":null},{"id":"df06b70c7c67469f814b3a20f2ee94f4","type":"DISEASE","name":"ischemic stroke","canonical_id":"mondo:1060198","description":null,"metadata":null},{"id":"f2d5a21ecb544b67a3ffd6f17f08b0a0","type":"GO_TERM","name":"islet amyloid polypeptide processing","canonical_id":"go:GO:0034231","description":"\"The formation of mature islet amyloid polypeptide (IAPP) by posttranslational processing of pro-islet amyloid polypeptide (pro-IAPP).\" [GOC:BHF, GOC:rl, PMID:15983213, PMID:8262946]","metadata":null},{"id":"573cd3e0265f4faf856d5bf32b76078f","type":"GO_TERM","name":"isoamylase activity","canonical_id":"go:GO:0019156","description":"\"Catalysis of the hydrolysis of alpha-(1,6)-D-glucosidic branch linkages in glycogen, amylopectin and their beta-limits dextrins.\" [EC:3.2.1.68]","metadata":null},{"id":"5fe568cb8a1b4e8c8047674cc17969fa","type":"GO_TERM","name":"isoamylase complex","canonical_id":"go:GO:0043033","description":"\"A protein complex whose composition varies amongst species; in rice it probably exists in a homo-tetramer to homo-hexamer form and in Gram-negative bacteria as a dimer. Functions in the hydrolysis of alpha-(1,6)-D-glucosidic branch linkages.\" [GOC:jl, PMID:10333591]","metadata":null},{"id":"8c2adad171284095bcdc368a10c2acfe","type":"GO_TERM","name":"isobutanol biosynthetic process","canonical_id":"go:GO:1901961","description":"\"The chemical reactions and pathways resulting in the formation of isobutanol.\" [GOC:mengo_curators, GOC:TermGenie, PMID:22224870]","metadata":null},{"id":"c31332b9b0e2497d8b5b429d730ef3a3","type":"GO_TERM","name":"isobutyraldoxime O-methyltransferase activity","canonical_id":"go:GO:0030763","description":"\"Catalysis of the reaction: 2-methylpropanal oxime + S-adenosyl-L-methionine = 2-methylpropanal O-methyloxime + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.91, RHEA:10996]","metadata":null},{"id":"e6af48ef50764260a45668de0f7c086d","type":"GO_TERM","name":"isobutyryl-CoA mutase activity","canonical_id":"go:GO:0047727","description":"\"Catalysis of the reaction: isobutyryl-CoA = butanoyl-CoA.\" [EC:5.4.99.13, RHEA:13141]","metadata":null},{"id":"346c1ae2aa2542c5971eccf204e41a85","type":"DRUG","name":"isocarboxazid","canonical_id":"mesh:D007520","description":null,"metadata":null},{"id":"cca0192ad81d437ba43713adaaf350bd","type":"GO_TERM","name":"isochorismatase activity","canonical_id":"go:GO:0008908","description":"\"Catalysis of the reaction: H2O + isochorismate = 2,3-dihydroxy-2,3-dihydrobenzoate + pyruvate.\" [EC:3.3.2.1, RHEA:11112]","metadata":null},{"id":"bb22c4280e174d27ac96219a57b21365","type":"GO_TERM","name":"isochorismate pyruvate lyase activity","canonical_id":"go:GO:0043904","description":"\"Catalysis of the reaction: isochorismate = salicylate + pyruvate.\" [GOC:jl, PMID:16248620]","metadata":null},{"id":"11f01bb7b3f14719a2a7396da2e815ea","type":"GO_TERM","name":"isochorismate synthase activity","canonical_id":"go:GO:0008909","description":"\"Catalysis of the reaction: chorismate = isochorismate.\" [EC:5.4.4.2, RHEA:18985]","metadata":null},{"id":"742e58c5635c4f65a08d1dc93dfad525","type":"GO_TERM","name":"isocitrate O-dihydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047168","description":"\"Catalysis of the reaction: caffeoyl-CoA + isocitrate = 2-caffeoylisocitrate + CoA.\" [EC:2.3.1.126, RHEA:20756]","metadata":null},{"id":"67147f1af3c64bc0aab8f4770bf45b52","type":"GO_TERM","name":"isocitrate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004449","description":"\"Catalysis of the reaction: isocitrate + NAD+ = 2-oxoglutarate + CO2 + NADH.\" [RHEA:23632]","metadata":null},{"id":"ca48acb074c14996bf057d2fd84f7540","type":"GO_TERM","name":"isocitrate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004450","description":"\"Catalysis of the reaction: isocitrate + NADP+ = 2-oxoglutarate + CO2 + NADPH.\" [RHEA:19629]","metadata":null},{"id":"5dde148c8d79491aaf3405c1f41edce4","type":"GO_TERM","name":"isocitrate dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0004448","description":"\"Catalysis of the reaction: isocitrate + NAD(P)+ = 2-oxoglutarate + CO2 + NAD(P)H.\" [GOC:curators]","metadata":null},{"id":"efc588ba7487474e99e4f056472fea07","type":"GO_TERM","name":"isocitrate dehydrogenase complex (NAD+)","canonical_id":"go:GO:0045242","description":"\"Complex that possesses isocitrate dehydrogenase (NAD+) activity.\" [GOC:mah]","metadata":null},{"id":"57925ba87eff4bc188fffd1b7970811f","type":"GO_TERM","name":"isocitrate epimerase activity","canonical_id":"go:GO:0047755","description":"\"Catalysis of the reaction: D-threo-isocitrate = D-erythro-isocitrate.\" [EC:5.1.2.6, RHEA:10820]","metadata":null},{"id":"723621596a89417896ab4903a9f6d894","type":"GO_TERM","name":"isocitrate lyase activity","canonical_id":"go:GO:0004451","description":"\"Catalysis of the reaction: isocitrate = glyoxylate + succinate.\" [EC:4.1.3.1, RHEA:13245]","metadata":null},{"id":"341d79d813b9480790182e28b993b7c5","type":"GO_TERM","name":"isocitrate metabolic process","canonical_id":"go:GO:0006102","description":"\"The chemical reactions and pathways involving isocitrate, the anion of isocitric acid, 1-hydroxy-1,2,3-propanetricarboxylic acid. Isocitrate is an important intermediate in the TCA cycle and the glycoxylate cycle.\" [ISBN:0198506732]","metadata":null},{"id":"623de425d16246d8be343f02d48e59c0","type":"GO_TERM","name":"isocitrate-homoisocitrate dehydrogenase activity","canonical_id":"go:GO:0033708","description":"\"Catalysis of the reactions: isocitrate + NAD+ = 2-oxoglutarate + CO2 + NADH, and (1R,2S)-1-hydroxybutane-1,2,4-tricarboxylate + NAD+ = 2-oxoadipate + CO2 + NADH + H+.\" [EC:1.1.1.286]","metadata":null},{"id":"951997620a124fbeb93f7bd95ec0a4b4","type":"GO_TERM","name":"isoflavone 2'-hydroxylase activity","canonical_id":"go:GO:0033773","description":"\"Catalysis of the reaction: an isoflavone + O2 + reduced [NADPH-hemoprotein reductase] = a 2'-hydroxyisoflavone + H+ + H2O + oxidized [NADPH-hemoprotein reductase].\" [RHEA:18849]","metadata":null},{"id":"6d45689f30eb4e9fbe72df59277ca419","type":"GO_TERM","name":"isoflavone 3'-hydroxylase activity","canonical_id":"go:GO:0048000","description":"\"Catalysis of the reaction: formononetin + NADPH + O2 = calycosin + NADP+ + H2O.\" [EC:1.14.14.88]","metadata":null},{"id":"2663951c39b24604934dd52ba59d0de5","type":"GO_TERM","name":"isoflavone 4'-O-methyltransferase activity","canonical_id":"go:GO:0030746","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + isoflavone = S-adenosyl-L-homocysteine + 4'-O-methylisoflavone.\" [EC:2.1.1.46]","metadata":null},{"id":"9c6d9ae243214906bc277b22c91fc015","type":"GO_TERM","name":"isoflavone 7-O-glucosyltransferase activity","canonical_id":"go:GO:0050004","description":"\"Catalysis of the reaction: UDP-glucose + isoflavone = UDP + isoflavone 7-O-beta-D-glucoside.\" [EC:2.4.1.170, MetaCyc:ISOFLAVONE-7-O-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"5d8477607ed4439b9675a01c466292aa","type":"GO_TERM","name":"isoflavone 7-O-methyltransferase activity","canonical_id":"go:GO:0033800","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a 7-hydroxyisoflavone = S-adenosyl-L-homocysteine + a 7-methoxyisoflavone.\" [EC:2.1.1.150]","metadata":null},{"id":"57fd53a10bcc4209b614909f547c17ab","type":"GO_TERM","name":"isoflavone-7-O-beta-glucoside 6''-O-malonyltransferase activity","canonical_id":"go:GO:0047164","description":"\"Catalysis of the reaction: biochanin-A + malonyl-CoA = 6'-malonyl-biochanin A + CoA.\" [EC:2.3.1.115]","metadata":null},{"id":"16d2c962ef7d4771a72fc74a95b81f7a","type":"GO_TERM","name":"isoflavonoid biosynthetic process","canonical_id":"go:GO:0009717","description":"\"The chemical reactions and pathways resulting in the formation of isoflavonoids, a group of water-soluble phenolic derivatives, isomeric with flavonoids.\" [GOC:ai]","metadata":null},{"id":"b75f631d46c644c7933a6697bba766e0","type":"GO_TERM","name":"isoflavonoid catabolic process","canonical_id":"go:GO:0046288","description":"\"The chemical reactions and pathways resulting in the breakdown of isoflavonoids, a group of water-soluble phenolic derivatives, isomeric with flavonoids.\" [GOC:ai]","metadata":null},{"id":"a5fb9db46868428a8ff94d4f5c237e5a","type":"GO_TERM","name":"isoflavonoid metabolic process","canonical_id":"go:GO:0046287","description":"\"The chemical reactions and pathways involving isoflavonoids, a group of water-soluble phenolic derivatives, isomeric with flavonoids, containing a flavan skeleton. They are differentiated from flavonoids by the point of attachment of the aromatic ring group.\" [GOC:ai, PMID:15734910]","metadata":null},{"id":"e27c66c7ed424494bf77b6afcd8c0b86","type":"GO_TERM","name":"isoflavonoid phytoalexin biosynthetic process","canonical_id":"go:GO:0009701","description":"\"The chemical reactions and pathways resulting in the formation of isoflavonoid phytoalexins, a group of water-soluble phenolic derivatives isomeric with flavonoids that possess antibiotic activity and are produced by plant tissues in response to infection.\" [GOC:ai]","metadata":null},{"id":"721fa6b9c24540848692f0ca4a26ba15","type":"GO_TERM","name":"isoflavonoid phytoalexin catabolic process","canonical_id":"go:GO:0046290","description":"\"The chemical reactions and pathways resulting in the breakdown of isoflavonoid phytoalexins, a group of water-soluble phenolic derivatives isomeric with flavonoids that possess antibiotic activity and are produced by plant tissues in response to infection.\" [GOC:ai]","metadata":null},{"id":"cf297dcc619847088c88618397ea04e4","type":"GO_TERM","name":"isogloboside biosynthetic process","canonical_id":"go:GO:1990387","description":"\"The chemical reactions and pathways resulting in the formation of isogobliosides that begins with the synthesis of a tetrasaccharide core GalNAc-beta-1,3Gal-alpha-1,3Gal-beta-1,4Glc-ceramide. This core can be further elongated with the sequential addition of various carbohydrate units.\" [PMID:35536927]","metadata":null},{"id":"d3dd77db034b45ff8d12150246b9b36b","type":"GO_TERM","name":"isoguanine deaminase activity","canonical_id":"go:GO:0035888","description":"\"Catalysis of the reaction: H+ + H2O + isoguanine = NH4+ + xanthine.\" [PMID:21604715, RHEA:47720]","metadata":null},{"id":"275ec2bf6fea45409be618083ee47cbb","type":"GO_TERM","name":"isohexenylglutaconyl-CoA hydratase activity","canonical_id":"go:GO:0050005","description":"\"Catalysis of the reaction: 3-hydroxy-3-(4-methylpent-3-en-1-yl)glutaryl-CoA = 3-(4-methylpent-3-en-1-yl)pent-2-enedioyl-CoA + H2O.\" [EC:4.2.1.57, RHEA:24144]","metadata":null},{"id":"7724743eda064955aa773b53d7de7049","type":"DISEASE","name":"isolated agammaglobulinemia","canonical_id":"mondo:0016462","description":null,"metadata":null},{"id":"13e8ef642459452aa9f46d1626c6a339","type":"DISEASE","name":"isolated congenital growth hormone deficiency","canonical_id":"mondo:0000050","description":null,"metadata":null},{"id":"2ae067fc1cfc43beb25075f95e966efe","type":"DISEASE","name":"isolated congenital hypogonadotropic hypogonadism","canonical_id":"mondo:0016553","description":null,"metadata":null},{"id":"d39541ddd0e048ae901207f3d1726394","type":"DISEASE","name":"isolated focal cortical dysplasia type II","canonical_id":"mondo:0011818","description":null,"metadata":null},{"id":"89d009e07d764d2e8aa7484464d51d43","type":"DISEASE","name":"isolated growth hormone deficiency type IB","canonical_id":"mondo:0013006","description":null,"metadata":null},{"id":"9ab378b5ba9645f8a9f84d462b659dde","type":"DISEASE","name":"isolated growth hormone deficiency type III","canonical_id":"mondo:0010615","description":null,"metadata":null},{"id":"399338a51dac49079539036c29f6f211","type":"DISEASE","name":"isolated growth hormone deficiency, type 4","canonical_id":"mondo:0032567","description":null,"metadata":null},{"id":"170e25674b344b46a01414a9ce5603ea","type":"DISEASE","name":"isolated thyroid-stimulating hormone deficiency","canonical_id":"mondo:0010139","description":null,"metadata":null},{"id":"fa138f08dedb43bc85fc8640d203f2bd","type":"DISEASE","name":"isolated trigonocephaly","canonical_id":"mondo:0018065","description":null,"metadata":null},{"id":"6a72f4704d774952af33713bb094482e","type":"GO_TERM","name":"isoleucine N-monooxygenase (oxime forming) activity","canonical_id":"go:GO:0102001","description":"\"Catalysis of the reaction: L-isoleucine + 2 O2 + 2 NADPH(4-) + 2 H+ = (E)-2-methylbutanal oxime + 2 NADP(3-) + carbon dioxide + 3 H2O.\" [EC:1.14.14.39]","metadata":null},{"id":"73100bfcd53745039bc3571149fc49ef","type":"GO_TERM","name":"isoleucine transmembrane transport","canonical_id":"go:GO:1903714","description":"\"The directed movement of isoleucine across a membrane by means of some agent such as a transporter or a pore.\" [GO_REF:0000069, GOC:TermGenie, PMID:18503766]","metadata":null},{"id":"924e4b415e6744dab3867325fa97cb56","type":"GO_TERM","name":"isoleucine transport","canonical_id":"go:GO:0015818","description":"\"The directed movement of isoleucine, (2R*,3R*)-2-amino-3-methylpentanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"14b2616a49c845da8f48dc0a6bd08b07","type":"GO_TERM","name":"isoleucine-tRNA ligase activity","canonical_id":"go:GO:0004822","description":"\"Catalysis of the reaction: L-isoleucine + ATP + tRNA(Ile) = L-isoleucyl-tRNA(Ile) + AMP + diphosphate + 2 H+.\" [EC:6.1.1.5, RHEA:11060]","metadata":null},{"id":"d3658c009c0f445184bfb8cd9f59bf8d","type":"GO_TERM","name":"isoleucyl-tRNA aminoacylation","canonical_id":"go:GO:0006428","description":"\"The process of coupling isoleucine to isoleucyl-tRNA, catalyzed by isoleucyl-tRNA synthetase. The isoleucyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a isoleucine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"df1bea1857b64a9ebb5072bb5b21dd8f","type":"GO_TERM","name":"isoliquiritigenin 2'-O-methyltransferase activity","canonical_id":"go:GO:0033802","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + isoliquiritigenin = 2'-O-methylisoliquiritigenin + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.154, RHEA:21608]","metadata":null},{"id":"62fda73a12564aa8bb46a4e99ed16e5d","type":"GO_TERM","name":"isomaltulose synthase activity","canonical_id":"go:GO:0050006","description":"\"Catalysis of the reaction: sucrose = 6-O-alpha-D-glucopyranosyl-D-fructofuranose.\" [EC:5.4.99.11, MetaCyc:ISOMALTULOSE-SYNTHASE-RXN]","metadata":null},{"id":"42eae98a180b49678d95e7a484643bc7","type":"GO_TERM","name":"isomerase activity","canonical_id":"go:GO:0016853","description":"\"Catalysis of the geometric or structural changes within one molecule. Isomerase is the systematic name for any enzyme of EC class 5.\" [ISBN:0198506732]","metadata":null},{"id":"c066d1db5d154f0083e09b92fa52a71a","type":"GO_TERM","name":"isonocardicin synthase activity","canonical_id":"go:GO:0050007","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + nocardicin E = S-methyl-5'-thioadenosine + H+ + isonocardicin A.\" [EC:2.5.1.38, RHEA:19845]","metadata":null},{"id":"7fec2855450f4aa98a944eb9a9bcc1fb","type":"GO_TERM","name":"isoorientin 3'-O-methyltransferase activity","canonical_id":"go:GO:0030756","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + isoorientin = S-adenosyl-L-homocysteine + H+ + isoscoparin.\" [EC:2.1.1.78, RHEA:24096]","metadata":null},{"id":"b16feead97b24ad78ef15d107134efd6","type":"GO_TERM","name":"isopenicillin-N N-acyltransferase activity","canonical_id":"go:GO:0050640","description":"\"Catalysis of the reaction: phenylacetyl-CoA + isopenicillin N + H2O = CoA + penicillin G + L-2-aminoadipate.\" [RHEA:20720]","metadata":null},{"id":"fcf2d79ce49d4c3b915f91ac9fb7d154","type":"GO_TERM","name":"isopenicillin-N epimerase activity","canonical_id":"go:GO:0045439","description":"\"Catalysis of the reaction: isopenicillin N = penicillin N.\" [EC:5.1.1.17, RHEA:20033]","metadata":null},{"id":"9a000234f7fe45ddb6ac91d348b5aa9d","type":"GO_TERM","name":"isopenicillin-N synthase activity","canonical_id":"go:GO:0016216","description":"\"Catalysis of the reaction: N-[(5S)-5-amino-5-carboxypentanoyl]-L-cysteinyl-D-valine + O2 = 2 H2O + isopenicillin N.\" [EC:1.21.3.1, RHEA:22428]","metadata":null},{"id":"e5faa29501e844b8ba6c3e9bda010602","type":"GO_TERM","name":"isopentadecanoic acid binding","canonical_id":"go:GO:1904769","description":"\"Binding to isopentadecanoic acid.\" [GO_REF:0000067, GOC:kmv, GOC:TermGenie, PMID:19828452]","metadata":null},{"id":"47e33155e1334bc59b27733acd474559","type":"GO_TERM","name":"isopentenol biosynthetic process","canonical_id":"go:GO:1902934","description":"\"The chemical reactions and pathways resulting in the formation of isopentenol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:17693564]","metadata":null},{"id":"84672d00ddc548beb83ead95319aea93","type":"GO_TERM","name":"isopentenyl adenine biosynthetic process","canonical_id":"go:GO:0034265","description":"\"The chemical reactions and pathways resulting in the formation of the cytokinin 6-isopentenyladenine.\" [GOC:mah, PMID:18216168]","metadata":null},{"id":"94d674f659b7457f9ba8f974ceee3fe8","type":"GO_TERM","name":"isopentenyl adenine catabolic process","canonical_id":"go:GO:0034266","description":"\"The chemical reactions and pathways resulting in the breakdown of the cytokinin 6-isopentenyladenine.\" [GOC:mah, PMID:18216168]","metadata":null},{"id":"45034d8405cb44a79e0b045d137f831a","type":"GO_TERM","name":"isopentenyl diphosphate biosynthetic process","canonical_id":"go:GO:0009240","description":"\"The chemical reactions and pathways resulting in the formation of isopentenyl diphosphate, an isomer of dimethylallyl diphosphate and the key precursor of all isoprenoids.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"02ea651cc28d4b06b06e5a06cb07dcc8","type":"GO_TERM","name":"isopentenyl diphosphate biosynthetic process, methylerythritol phosphate pathway","canonical_id":"go:GO:0019288","description":"\"The chemical reactions and pathways resulting in the formation of isopentenyl diphosphate by the methylerythritol phosphate pathway, also known as the mevalonate-independent pathway. Isopentenyl diphosphate (IPP) is the fundamental unit in isoprenoid biosynthesis and is produced from pyruvate and glyceraldehyde 3-phosphate via intermediates, including methylerythritol 4-phosphate.\" [MetaCyc:NONMEVIPP-PWY, PMID:18948055]","metadata":null},{"id":"560581d1aaac44619c699853e205d6a2","type":"GO_TERM","name":"isopentenyl diphosphate biosynthetic process, mevalonate pathway","canonical_id":"go:GO:0019287","description":"\"The chemical reactions and pathways resulting in the formation of isopentenyl diphosphate, via the intermediate mevalonate. This pathway converts acetate, in the form of acetyl-CoA, to isopentenyl diphosphate (IPP), the fundamental unit in isoprenoid biosynthesis, through a series of mevalonate intermediates.\" [GOC:curators, MetaCyc:PWY-922]","metadata":null},{"id":"c7fb11990d6b4b42a65dc5771532c2c8","type":"GO_TERM","name":"isopentenyl diphosphate metabolic process","canonical_id":"go:GO:0046490","description":"\"The chemical reactions and pathways involving isopentenyl diphosphate, an isomer of dimethylallyl diphosphate and the key precursor of all isoprenoids.\" [ISBN:0198506732]","metadata":null},{"id":"90159d2ec24649d286d58d4becc89495","type":"GO_TERM","name":"isopentenyl phosphate kinase activity","canonical_id":"go:GO:0102043","description":"\"Catalysis of the reaction: isopentenyl phosphate(2-) + ATP(4-) = isopentenyl diphosphate(3-) + ADP(3-).\" [GOC:pz, PMID:19928876, RHEA:33963]","metadata":null},{"id":"5544b31c42f9488193799e7b7e8fb9dc","type":"GO_TERM","name":"isopentenyl pyrophosphate import into mitochondrion","canonical_id":"go:GO:0170046","description":"\"The process in which isopentenyl pyrophosphate is transported across a membrane into the mitochondrion.\" [GOC:ew, PMID:37813972]","metadata":null},{"id":"0a14e5c28b184a7cb554558b2140ff38","type":"GO_TERM","name":"isopentenyl pyrophosphate transmembrane transporter activity","canonical_id":"go:GO:0170045","description":"\"Enables the transfer of isopentenyl pyrophosphate from one side of a membrane to the other.\" [GOC:ew, PMID:37813972]","metadata":null},{"id":"c5ad4b317f8541f88222e242bd9e2afc","type":"GO_TERM","name":"isopentenyl-diphosphate delta-isomerase activity","canonical_id":"go:GO:0004452","description":"\"Catalysis of the reaction: isopentenyl diphosphate = dimethylallyl diphosphate.\" [RHEA:23284]","metadata":null},{"id":"1a092e3c34504a38ac6826991a63ba5a","type":"GO_TERM","name":"isopeptide cross-linking","canonical_id":"go:GO:0018262","description":"\"The formation of a covalent cross-link between or within peptide chains, where either the amino group or the carboxyl group, or both, are not attached to the alpha carbon.\" [GOC:jsg]","metadata":null},{"id":"d0722b36cce245468572980421d5a97f","type":"GO_TERM","name":"isopeptide cross-linking via N6-(L-isoglutamyl)-L-lysine","canonical_id":"go:GO:0018153","description":"\"The formation of an isopeptide cross-link between peptidyl-lysine and peptidyl-glutamine to produce N6-(L-isoglutamyl)-L-lysine.\" [RESID:AA0124]","metadata":null},{"id":"80b8f5b553434c8fb6f7aa7a14c24bbd","type":"GO_TERM","name":"isopiperitenol dehydrogenase activity","canonical_id":"go:GO:0018458","description":"\"Catalysis of the reaction: (1S,6R)-isopiperitenol + NAD+ = (6R)-isoperitenone + H+ + NADH.\" [EC:1.1.1.223, RHEA:20860]","metadata":null},{"id":"9ffdf6bbf8cd4871afb0b575c292a8a5","type":"GO_TERM","name":"isopiperitenone delta-isomerase activity","canonical_id":"go:GO:0050008","description":"\"Catalysis of the reaction: isopiperitenone = piperitenone.\" [RHEA:21516]","metadata":null},{"id":"96cabcd8adf34d519f717c6cfcea2052","type":"DRUG","name":"isoprenaline","canonical_id":"gtopdb:536","description":null,"metadata":null},{"id":"ad8caa056809484685dc229bf6031cbe","type":"GO_TERM","name":"isoprene catabolic process","canonical_id":"go:GO:0043613","description":"\"The chemical reactions and pathways resulting in the breakdown of isoprene, C5H8.\" [GOC:jl]","metadata":null},{"id":"a6d8df97ddb045b491a6397246a202eb","type":"GO_TERM","name":"isoprene synthase activity","canonical_id":"go:GO:0034009","description":"\"Catalysis of the reaction: dimethylallyl diphosphate = diphosphate + isoprene.\" [RHEA:13369]","metadata":null},{"id":"25a46af1fabc4541bfacb90100adbf1f","type":"GO_TERM","name":"isoprenoid binding","canonical_id":"go:GO:0019840","description":"\"Binding to an isoprenoid compound, isoprene (2-methylbuta-1,3-diene) or compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues.\" [GOC:jl]","metadata":null},{"id":"755ed08a8167483e9f53b6083accec9c","type":"GO_TERM","name":"isoprenoid biosynthetic process","canonical_id":"go:GO:0008299","description":"\"The chemical reactions and pathways resulting in the formation of an isoprenoid compound, isoprene (2-methylbuta-1,3-diene) or compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues.\" [ISBN:0198506732]","metadata":null},{"id":"60c01ad0ee2245fd96ed769bcd5eecaf","type":"GO_TERM","name":"isoprenoid catabolic process","canonical_id":"go:GO:0008300","description":"\"The chemical reactions and pathways resulting in the breakdown of an isoprenoid compound, isoprene (2-methylbuta-1,3-diene) or compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues.\" [ISBN:0198506732]","metadata":null},{"id":"a011ff069a27428a9f0b18ce5f8668e6","type":"GO_TERM","name":"isoprenoid diphosphate phosphatase activity","canonical_id":"go:GO:0106405","description":"\"Catalysis of the dephosphorylation of isoprenoid diphosphates.\" [PMID:33246356]","metadata":null},{"id":"f41491d0285d4cb3a5ee0b3fe3903cca","type":"GO_TERM","name":"isoprenoid metabolic process","canonical_id":"go:GO:0006720","description":"\"The chemical reactions and pathways involving isoprenoid compounds, isoprene (2-methylbuta-1,3-diene) or compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues.\" [ISBN:0198547684]","metadata":null},{"id":"1916701500d54398994c18f46868c1a9","type":"GO_TERM","name":"isoprenoid transport","canonical_id":"go:GO:0046864","description":"\"The directed movement of isoprenoids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Isoprenoids comprise a group of compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues.\" [GOC:ai]","metadata":null},{"id":"d81fb276f8cc492e99aeb9e268dee3fd","type":"GO_TERM","name":"isopropanol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050009","description":"\"Catalysis of the reaction: NADP+ + propan-2-ol = acetone + H+ + NADPH.\" [EC:1.1.1.80, RHEA:21792]","metadata":null},{"id":"858ddfe67dc14eb395297e8ba0c1f39a","type":"GO_TERM","name":"isopropylmalate transmembrane transporter activity","canonical_id":"go:GO:0034658","description":"\"Enables the transfer of isopropylmalate from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"c818184cecc6474b83e0dad3165f5624","type":"GO_TERM","name":"isopropylmalate transport","canonical_id":"go:GO:0034659","description":"\"The directed movement of isopropylmalate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"ec20e370a0ef4bea9264251aaede17df","type":"GO_TERM","name":"isopullulanase activity","canonical_id":"go:GO:0051675","description":"\"Catalysis of the hydrolysis of pullulan to isopanose (6-alpha-maltosylglucose).\" [EC:3.2.1.57]","metadata":null},{"id":"5777cdf33214438fa2dbccf4376d5ff4","type":"GO_TERM","name":"isoquinoline 1-oxidoreductase activity","canonical_id":"go:GO:0047121","description":"\"Catalysis of the reaction: A + H2O + isoquinoline = AH(2) + isoquinolin-1(2H)-one.\" [EC:1.3.99.16, RHEA:11588]","metadata":null},{"id":"dedea848577346e7967b697830b5ff5c","type":"GO_TERM","name":"isoquinoline alkaloid biosynthetic process","canonical_id":"go:GO:0033075","description":"\"The chemical reactions and pathways resulting in the formation of isoquinoline alkaloids, alkaloid compounds that contain bicyclic N-containing aromatic rings and are derived from a 3,4-dihydroxytyramine (dopamine) precursor that undergoes a Schiff base addition with aldehydes of different origin.\" [GOC:mah, PMID:26503307]","metadata":null},{"id":"c01a77135ba6493bb9eddcbb309457f7","type":"GO_TERM","name":"isoquinoline alkaloid catabolic process","canonical_id":"go:GO:0071274","description":"\"The chemical reactions and pathways resulting in the breakdown of isoquinoline alkaloids, alkaloid compounds that contain bicyclic N-containing aromatic rings and are derived from a 3,4-dihydroxytyramine (dopamine) precursor that undergoes a Schiff base addition with aldehydes of different origin.\" [GOC:mah, PMID:23666088]","metadata":null},{"id":"69c894d3260d4f8c8587164695c7f7d9","type":"GO_TERM","name":"isoquinoline alkaloid metabolic process","canonical_id":"go:GO:0033076","description":"\"The chemical reactions and pathways involving isoquinoline alkaloids, alkaloid compounds that contain bicyclic N-containing aromatic rings and are derived from a 3,4-dihydroxytyramine (dopamine) precursor that undergoes a Schiff base addition with aldehydes of different origin.\" [GOC:mah, PMID:26503307]","metadata":null},{"id":"6bab6378d7f34da9b000b782ea0d30fd","type":"GO_TERM","name":"isorhamnetin 3-O-methyltransferase activity","canonical_id":"go:GO:0102444","description":"\"Catalysis of the reaction: isorhamnetin + S-adenosyl-L-methionine = 3,3'-O-dimethylquercetin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74759]","metadata":null},{"id":"60736a62650249d79b238b6602066171","type":"DRUG","name":"isosorbide mononitrate","canonical_id":"mesh:C030397","description":null,"metadata":null},{"id":"d78c9e42fe7e472d9241ced219c7015c","type":"GO_TERM","name":"isotropic cell growth","canonical_id":"go:GO:0051210","description":"\"The process in which a cell irreversibly increases in size uniformly in all directions. In general, a rounded cell morphology reflects isotropic cell growth.\" [GOC:ai, GOC:jid]","metadata":null},{"id":"a80321b03987407294d68e6e9e269751","type":"GO_TERM","name":"isotype switching","canonical_id":"go:GO:0045190","description":"\"The switching of activated B cells from IgM biosynthesis to biosynthesis of other isotypes of immunoglobulin, accomplished through a recombination process involving an intrachromosomal deletion involving switch regions that reside 5' of each constant region gene segment in the immunoglobulin heavy chain locus.\" [ISBN:0781735149]","metadata":null},{"id":"d07a742110c141a0820d82d411c02ad7","type":"GO_TERM","name":"isotype switching to IgA isotypes","canonical_id":"go:GO:0048290","description":"\"The switching of activated B cells from IgM biosynthesis to biosynthesis of an IgA isotype, accomplished through a recombination process involving an intrachromosomal deletion between switch regions that reside 5' of the IgM and one of the IgA constant region gene segments in the immunoglobulin heavy chain locus.\" [ISBN:0781735149, PMID:12370374, PMID:2113175, PMID:9186655]","metadata":null},{"id":"9cbd4cdd43a54ca5b3c4aeafac68456c","type":"GO_TERM","name":"isotype switching to IgD isotypes","canonical_id":"go:GO:0048292","description":"\"The switching of activated B cells from IgM biosynthesis to IgD biosynthesis, accomplished through a recombination process involving an intrachromosomal deletion between switch regions that reside 5' of the IgM and IgD constant region gene segments in the immunoglobulin heavy chain locus.\" [ISBN:0781735149, PMID:12370374, PMID:2113175, PMID:9186655]","metadata":null},{"id":"cd7906d5aa6c4326992b9e45d03982b7","type":"GO_TERM","name":"isotype switching to IgE isotypes","canonical_id":"go:GO:0048289","description":"\"The switching of activated B cells from IgM biosynthesis to IgE biosynthesis, accomplished through a recombination process involving an intrachromosomal deletion between switch regions that reside 5' of the IgM and IgE constant region gene segments in the immunoglobulin heavy chain locus.\" [ISBN:0781735149, PMID:12370374, PMID:2113175, PMID:9186655]","metadata":null},{"id":"b614b08f9d4642c19a4741fbb66aa566","type":"GO_TERM","name":"isotype switching to IgG isotypes","canonical_id":"go:GO:0048291","description":"\"The switching of activated B cells from IgM biosynthesis to biosynthesis of an IgG isotype, accomplished through a recombination process involving an intrachromosomal deletion between switch regions that reside 5' of the IgM and one of the IgG constant region gene segments in the immunoglobulin heavy chain locus.\" [ISBN:0781735149, PMID:12370374, PMID:2113175, PMID:9186655]","metadata":null},{"id":"73117b9c555e4e978aabfb6f45d951d3","type":"GO_TERM","name":"isoursodeoxycholate 7-beta-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106282","description":"\"Catalysis of the reaction: 3-beta,7-beta-dihydroxy-5-beta-cholan-24-oate + NAD+ = 3-beta-hydroxy-7-oxo-5-beta-cholan-24-oate + H+ + NADH.\" [PMID:12917011, RHEA:42024]","metadata":null},{"id":"b796c88a730d4d109cf8ab9c1b8f35b9","type":"GO_TERM","name":"isovaleryl-CoA(4-) biosynthetic process","canonical_id":"go:GO:1902197","description":"\"The chemical reactions and pathways resulting in the formation of isovaleryl-CoA(4-).\" [GOC:TermGenie, PMID:11231285]","metadata":null},{"id":"04d02821f69b48aa83e284d4dc58155b","type":"GO_TERM","name":"isovaleryl-CoA(4-) catabolic process","canonical_id":"go:GO:1902196","description":"\"The chemical reactions and pathways resulting in the breakdown of isovaleryl-CoA(4-).\" [GOC:TermGenie, PMID:11231285]","metadata":null},{"id":"0d925e8a201e4d9da5b5acc788c1f884","type":"GO_TERM","name":"isovitexin beta-glucosyltransferase activity","canonical_id":"go:GO:0050010","description":"\"Catalysis of the reaction: isovitexin + UDP-D-glucose = H+ + isovitexin 2''-O-beta-D-glucoside + UDP.\" [EC:2.4.1.106, RHEA:19529]","metadata":null},{"id":"070dd2326c28430b93eb9a3b0b9ae1fa","type":"GO_TERM","name":"itaconyl-CoA hydratase activity","canonical_id":"go:GO:0050011","description":"\"Catalysis of the reaction: citramalyl-CoA = itaconyl-CoA + H2O.\" [EC:4.2.1.56, MetaCyc:ITACONYL-COA-HYDRATASE-RXN]","metadata":null},{"id":"8a89ba292e9d4cc192cb31101d6a942f","type":"DRUG","name":"itolizumab","canonical_id":"gtopdb:9421","description":null,"metadata":null},{"id":"623bcb853a374db9b1d8c9c3d9390365","type":"DRUG","name":"itolizumab","canonical_id":"chembl:CHEMBL1743033","description":null,"metadata":null},{"id":"05922f5e6e1c4605a2d6fc6b987b738a","type":"DRUG","name":"ivabradine","canonical_id":"mesh:C088408","description":null,"metadata":null},{"id":"5cb18638a1e14bcc87f10a8a519d0b11","type":"DRUG","name":"ivermectin","canonical_id":"mesh:D007559","description":null,"metadata":null},{"id":"3835b9949017420b92120b677af9a99d","type":"DRUG","name":"ivosidenib","canonical_id":"gtopdb:9217","description":null,"metadata":null},{"id":"b2016bf3b14e4e48b1ca5c5e7ad96afc","type":"DRUG","name":"ivosidenib","canonical_id":"chembl:CHEMBL3989958","description":null,"metadata":null},{"id":"fe667447477148a99893ceca5071ea38","type":"COMBINATION_TREATMENT","name":"ivosidenib + neratinib","canonical_id":"ctgov_combo:ctgov-combo-111502e3ec6c4b30","description":null,"metadata":null},{"id":"98fe8102d28441d9a3142a9e20623de3","type":"COMBINATION_TREATMENT","name":"ivosidenib + olaparib + palbociclib + selumetinib + tazemetostat + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-5a159dbc737c1660","description":null,"metadata":null},{"id":"b041eb4066414b4c8193b81b6fd01200","type":"COMBINATION_TREATMENT","name":"ivosidenib + quizartinib","canonical_id":"ctgov_combo:ctgov-combo-782534b92a58eef7","description":null,"metadata":null},{"id":"3aa0011e34da4669864d48763315913c","type":"COMBINATION_TREATMENT","name":"ivosidenib + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-654230fbe6d3e1dd","description":null,"metadata":null},{"id":"c3af2229c9c84c7d80660b7e01ae43f0","type":"DRUG","name":"ixabepilone","canonical_id":"gtopdb:6824","description":null,"metadata":null},{"id":"985175a2bd7a48eb8c1d6674958f4d94","type":"DRUG","name":"ixabepilone","canonical_id":"mesh:C430592","description":null,"metadata":null},{"id":"2ce5ddab16354001b5213e0c11f9c4ab","type":"DRUG","name":"ixabepilone","canonical_id":"chembl:CHEMBL1201752","description":null,"metadata":null},{"id":"ce129525351c49389735ae1e9d97d414","type":"COMBINATION_TREATMENT","name":"ixabepilone + paricalcitol","canonical_id":"ctgov_combo:ctgov-combo-450d40b583afe4e2","description":null,"metadata":null},{"id":"a2d328bb3b494020aa9229914dc55524","type":"COMBINATION_TREATMENT","name":"ixabepilone + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-dad989aa4084013a","description":null,"metadata":null},{"id":"b79c2e2ca3ec4626bb1321083bfd736e","type":"DRUG","name":"ixazomib","canonical_id":"gtopdb:8450","description":null,"metadata":null},{"id":"e23aba19ee424cb6b25ebf48d374f1f3","type":"DRUG","name":"ixazomib","canonical_id":"chembl:CHEMBL2141296","description":null,"metadata":null},{"id":"7ac55b0562434e45994aaedbb78f3f90","type":"COMBINATION_TREATMENT","name":"ixazomib + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-b6c3047c92612c00","description":null,"metadata":null},{"id":"e1ba7642984647ed84135bcffed7cbba","type":"DRUG","name":"ixekizumab","canonical_id":"gtopdb:7541","description":null,"metadata":null},{"id":"ce437e05f2e74251b27a9acbd4ea02c2","type":"DRUG","name":"ixekizumab","canonical_id":"chembl:CHEMBL1743034","description":null,"metadata":null},{"id":"552cf2919e1d44ca82d38e5faa00a007","type":"COMBINATION_TREATMENT","name":"ixekizumab + secukinumab","canonical_id":"ctgov_combo:ctgov-combo-dd4d7715f32737db","description":null,"metadata":null},{"id":"fa1d5178e4ec4e1cb11a6592b8e16c48","type":"DRUG","name":"izalontamab brengitecan","canonical_id":"gtopdb:14566","description":null,"metadata":null},{"id":"1e0f0d6b935a4bffa3c4ca53d7467442","type":"DISEASE","name":"janus kinase-3 deficiency","canonical_id":"mondo:0005511","description":null,"metadata":null},{"id":"4ffe0919ee2744138a7ffbb3255b3d89","type":"GO_TERM","name":"jasmonic acid and ethylene-dependent systemic resistance","canonical_id":"go:GO:0009861","description":"\"The jasmonic acid and ethylene (ethene) dependent process that confers broad spectrum systemic resistance to disease in response to wounding or a pathogen.\" [GOC:jy, PMID:10234273]","metadata":null},{"id":"5b05749b91cd4c77a17935479b4c2515","type":"GO_TERM","name":"jasmonic acid and ethylene-dependent systemic resistance, ethylene mediated signaling pathway","canonical_id":"go:GO:0009871","description":"\"The series of molecular signals mediated by ethylene (ethene) involved in jasmonic acid/ethylene dependent systemic resistance.\" [GOC:jy]","metadata":null},{"id":"e7216746af5d4df39dbe20224d188182","type":"GO_TERM","name":"jasmonic acid and ethylene-dependent systemic resistance, jasmonic acid mediated signaling pathway","canonical_id":"go:GO:0009868","description":"\"The series of molecular signals mediated by jasmonic acid involved in jasmonic acid/ethylene (ethene) dependent systemic resistance.\" [GOC:jy]","metadata":null},{"id":"ef9e09fdab38449284868a7fdb1fc864","type":"GO_TERM","name":"jasmonic acid biosynthetic process","canonical_id":"go:GO:0009695","description":"\"The chemical reactions and pathways resulting in the formation of jasmonic acid, a fatty acid derivative.\" [PMID:33821356]","metadata":null},{"id":"abe37c3084ab4be683ddfb97b480b90e","type":"GO_TERM","name":"jasmonic acid hydrolase activity","canonical_id":"go:GO:0120091","description":"\"Catalysis of the reaction: jasmonate + 2-oxoglutarate + O2 = (1R,2R)-12-hydroxyjasmonate + succinate + CO2.\" [PMID:28559313, PMID:28760569, RHEA:67144]","metadata":null},{"id":"e3d4db72a4e64455ae7836bebb7124d1","type":"GO_TERM","name":"jasmonic acid mediated signaling pathway","canonical_id":"go:GO:0009867","description":"\"The series of molecular signals mediated by jasmonic acid.\" [GOC:jy, PMID:16478936, PMID:19522558, PMID:20159850]","metadata":null},{"id":"3bdda9d4d6804aceaaf455cd9c74399d","type":"GO_TERM","name":"jasmonic acid metabolic process","canonical_id":"go:GO:0009694","description":"\"The chemical reactions and pathways involving jasmonic acid, a fatty acid derivative with the formula (1R-(1 alpha, 2 beta(Z)))-3-oxo-2-(2-pentenyl)cyclopentaneacetic acid.\" [ISBN:0387969845]","metadata":null},{"id":"9bd7e6bd06944b37a2455eae58759c0d","type":"GO_TERM","name":"jasmonoyl-L-amino acid ligase activity","canonical_id":"go:GO:0080123","description":"\"Catalysis of the reaction: a jasmonate + an L-alpha-amino acid + ATP = a jasmonyl-L-amino acid + AMP + diphosphate + H+. In Arabidopsis, isoleucine is the principal amino acid that conjugates with JA to form JA (JA-Ile). Other amino acid can be conjugated with JA such as valine, leucine, and phenylalanine.\" [PMID:15258265, PMID:17291501, PMID:33821356, RHEA:55772]","metadata":null},{"id":"7121ddbcd1524081b6ece7779f6f9f9d","type":"GO_TERM","name":"jasmonoyl-isoleucine-12-hydroxylase activity","canonical_id":"go:GO:0052694","description":"\"Catalysis of the reaction: jasmonoyl-isoleucine + NADPH + H+ + O2 = 12-hydroxy-jasmonoyl-isoleucine + NADP+ + H2O.\" [MetaCyc:RXN-12421, PMID:21576464]","metadata":null},{"id":"f0aa48c6702b4d6caad828a15fdf01f0","type":"GO_TERM","name":"jasmonyl-Ile conjugate hydrolase activity","canonical_id":"go:GO:1990206","description":"\"Catalysis of the reaction: jasmonyl-Ile + H2O = jasmonic acid + L-isoleucine.\" [PMID:23943861]","metadata":null},{"id":"991dea1b649f41699a87f378ab2fb3d3","type":"GO_TERM","name":"juglone 3-hydroxylase activity","canonical_id":"go:GO:0050012","description":"\"Catalysis of the reaction: 2 juglone + O2 = 2 3,5-dihydroxy-1,4-naphthoquinone + 2 H+.\" [PMID:4041238, RHEA:18745]","metadata":null},{"id":"db1fbd1da4004b98a05547698cf97518","type":"GO_TERM","name":"jump response","canonical_id":"go:GO:0007630","description":"\"The sudden, usually upward, movement off the ground or other surface through sudden muscular effort in the legs, following exposure to an external stimulus.\" [GOC:jid, ISBN:0198606907]","metadata":null},{"id":"d198177ca8274e54a525f6b127f162a9","type":"GO_TERM","name":"junctional membrane complex","canonical_id":"go:GO:0030314","description":"\"Complex formed in muscle cells between the membrane of the sarcoplasmic reticulum and invaginations of the plasma membrane (T-tubules).\" [PMID:11535622]","metadata":null},{"id":"23bc0852c6dc49c29a5917a25624ddac","type":"GO_TERM","name":"junctional sarcoplasmic reticulum membrane","canonical_id":"go:GO:0014701","description":"\"The part of the sarcoplasmic reticulum membrane that contains calcium release channels, is devoted to calcium release and is juxtaposed to transverse tubule membrane. The junctional sarcoplasmic reticulum membrane consists of the junctional region of the terminal cisterna membrane.\" [GOC:mtg_muscle]","metadata":null},{"id":"77c8a326cb72426cac066a065e00b42a","type":"DISEASE","name":"juvenile amyotrophic lateral sclerosis","canonical_id":"mondo:0017593","description":null,"metadata":null},{"id":"642fe7e78acf482e86fd74b2db54c84e","type":"DISEASE","name":"juvenile dermatomyositis","canonical_id":"mondo:0008054","description":null,"metadata":null},{"id":"1d2a0069fbf445c4a7968b21b9dd8d6f","type":"GO_TERM","name":"juvenile hormone binding","canonical_id":"go:GO:0005500","description":"\"Binding to a juvenile hormone, a sesquiterpenoid derivative that function to maintain the larval state of insects at molting and that may be required for other processes, e.g. oogenesis.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"6935b459756646b09f114bc1bd6d2575","type":"GO_TERM","name":"juvenile hormone biosynthetic process","canonical_id":"go:GO:0006718","description":"\"The chemical reactions and pathways resulting in the formation of juvenile hormones, the three sesquiterpenoid derivatives that function to maintain the larval state of insects at molting and that may be required for other processes, e.g. oogenesis.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"f72ebb9bbf684306a8ade52463c85015","type":"GO_TERM","name":"juvenile hormone catabolic process","canonical_id":"go:GO:0006719","description":"\"The chemical reactions and pathways resulting in the breakdown of juvenile hormones, the three sesquiterpenoid derivatives that function to maintain the larval state of insects at molting and that may be required for other processes, e.g. oogenesis.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"f07b224b76ed4792a42da182e93540f8","type":"GO_TERM","name":"juvenile hormone epoxide hydrolase activity","canonical_id":"go:GO:0008096","description":"\"Catalysis of the hydrolysis of the epoxide in a juvenile hormone to the corresponding diol.\" [GOC:mah, PMID:8396141]","metadata":null},{"id":"8f32dfecd56f4f16afe18891d39c8110","type":"GO_TERM","name":"juvenile hormone mediated signaling pathway","canonical_id":"go:GO:0035626","description":"\"The series of molecular signals initiated by a juvenile hormone binding to its receptor, a bHLH-PAS transcription factor, to regulate gene expression.\" [PMID:28285758, PMID:29888456]","metadata":null},{"id":"d9a9040d0c7946709034196dd8c9ef2c","type":"GO_TERM","name":"juvenile hormone metabolic process","canonical_id":"go:GO:0006716","description":"\"The chemical reactions and pathways involving juvenile hormones, the three sesquiterpenoid derivatives that function to maintain the larval state of insects at molting and that may be required for other processes, e.g. oogenesis.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"23fd57f9946f4dc7971276f506c54704","type":"GO_TERM","name":"juvenile hormone response element binding","canonical_id":"go:GO:0070594","description":"\"Binding to a juvenile hormone response element (JHRE), a conserved sequence found in the promoters of genes whose expression is regulated in response to juvenile hormone.\" [GOC:sart, PMID:17956872]","metadata":null},{"id":"2564bf97230a4a40871642bd1600efd1","type":"GO_TERM","name":"juvenile hormone secretion","canonical_id":"go:GO:0045443","description":"\"The regulated release of juvenile hormones, the three sesquiterpenoid derivatives that function to maintain the larval state of insects at molting and that may be required for other processes, e.g. oogenesis.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"e3508fd0d51f4a2ebcb8d66e0941b658","type":"DISEASE","name":"juvenile idiopathic arthritis","canonical_id":"mondo:0011429","description":null,"metadata":null},{"id":"006a8eebc3a746dd883067d53285c759","type":"DISEASE","name":"juvenile myelomonocytic leukemia","canonical_id":"mondo:0011908","description":null,"metadata":null},{"id":"fb03f744f6bd4f9ebf5afbf20fa03a47","type":"DISEASE","name":"juvenile myoclonic epilepsy","canonical_id":"mondo:0009696","description":null,"metadata":null},{"id":"25413862224142c2ac49ae50f03e3d6a","type":"GO_TERM","name":"juvenile-hormone esterase activity","canonical_id":"go:GO:0004453","description":"\"Catalysis of the reaction: methyl (2E,6E)-(10R,11S)-10,11-epoxy-3,7,11-trimethyltrideca-2,6-dienoate + H2O = (2E,6E)-(10R,11S)-10,11-epoxy-3,7,11-trimethyltrideca-2,6-dienoate + methanol. A carboxylesterase that hydrolyzes the ester linkage of juvenile hormone.\" [PMID:11267890, RHEA:16393]","metadata":null},{"id":"c1d2b72286bb4e01b6ea727763d2477e","type":"GO_TERM","name":"juxtaglomerular apparatus development","canonical_id":"go:GO:0072051","description":"\"The process whose specific outcome is the progression of the juxtaglomerular apparatus over time, from its formation to the mature structure. The juxtaglomerular apparatus is an anatomical structure that lies adjacent to the glomerulus and regulates kidney function.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ec25e6b27c1440eaaf7b1de368298d2c","type":"GO_TERM","name":"juxtaglomerulus cell development","canonical_id":"go:GO:0072142","description":"\"The process whose specific outcome is the progression of a juxtaglomerulus cell over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e141f92f8c1a45f1989d5f0df5321d03","type":"GO_TERM","name":"juxtaglomerulus cell differentiation","canonical_id":"go:GO:0072052","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1449bf5b957745f1ab126a6c6c0a59e7","type":"GO_TERM","name":"juxtaglomerulus cell fate commitment","canonical_id":"go:GO:0072150","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a juxtaglomerulus cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"04692b12d282439284bff043016d6100","type":"GO_TERM","name":"juxtaparanode region of axon","canonical_id":"go:GO:0044224","description":"\"A region of an axon near a node of Ranvier that is between the paranode and internode regions.\" [GOC:BHF, GOC:jl, PMID:10624965, PMID:14682359]","metadata":null},{"id":"b39d53cf2b454646b762eb79cdac2ef2","type":"GO_TERM","name":"kaempferide 3-O-methyltransferase activity","canonical_id":"go:GO:0102451","description":"\"Catalysis of the reaction: kaempferide + S-adenosyl-L-methionine = 3,4'-O-dimethylkaempferol + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74755]","metadata":null},{"id":"dc97312526bb4190a515cf4dfa2d6a2b","type":"GO_TERM","name":"kaempferide 7-O-methyltransferase activity","canonical_id":"go:GO:0102450","description":"\"Catalysis of the reaction: kaempferide + S-adenosyl-L-methionine = 7,4'-O-dimethylkaempferol + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74775]","metadata":null},{"id":"8b22c764d79747138f9d4fbfcb17f879","type":"GO_TERM","name":"kaempferol 3-O-galactosyltransferase activity","canonical_id":"go:GO:0033834","description":"\"Catalysis of the reaction: UDP-galactose + kaempferol = UDP + kaempferol 3-O-beta-D-galactoside.\" [RHEA:15709]","metadata":null},{"id":"d7c62cff56f045dd86d4d587c2a51c28","type":"GO_TERM","name":"kaempferol 3-O-methyltransferase activity","canonical_id":"go:GO:0102449","description":"\"Catalysis of the reaction: kaempferol + S-adenosyl-L-methionine = 3-O-methylkaempferol + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74743]","metadata":null},{"id":"18f5367b13b2477b83891cf9b8cf3de7","type":"GO_TERM","name":"kaempferol 4'-O-methyltransferase activity","canonical_id":"go:GO:0033803","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + kaempferol = S-adenosyl-L-homocysteine + H+ + kaempferide.\" [RHEA:15105]","metadata":null},{"id":"cca1416b4c044080ba7623f9b4d9d537","type":"GO_TERM","name":"kaempferol O-glucoside biosynthetic process","canonical_id":"go:GO:0033330","description":"\"The chemical reactions and pathways leading to the formation of O-glucosylated derivatives of kaempferol.\" [GOC:mah, MetaCyc:PWY-5320]","metadata":null},{"id":"c378ae811d26440789a6dd3c09d28ef5","type":"GO_TERM","name":"kainate selective glutamate receptor activity","canonical_id":"go:GO:0015277","description":"\"An ionotropic glutamate receptor activity that exhibits fast gating by glutamate, acts by opening a cation channel permeable to sodium and potassium, and for which kainate is an agonist.\" [GOC:mah, PMID:10049997, PMID:8804111]","metadata":null},{"id":"7919dc236aca4ce19b00e39d6c51fc04","type":"GO_TERM","name":"kainate selective glutamate receptor complex","canonical_id":"go:GO:0032983","description":"\"An assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex. Kainate receptors are multimeric assemblies of GluK1-3 (also called GluR5-7), GluK4 (KA1) and GluK5 (KA2) subunits.\" [GOC:bf, PMID:18655795]","metadata":null},{"id":"af574ec52ed840e8b0ca852b99626a77","type":"GO_TERM","name":"kainate selective glutamate receptor signaling pathway","canonical_id":"go:GO:0098991","description":"\"The series of molecular signals initiated by glutamate binding to an kainate-selective glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, ISBN:9780071120005]","metadata":null},{"id":"fc7977baff6142c3abbdba125eec23d3","type":"DRUG","name":"kanamycin","canonical_id":"mesh:D007612","description":null,"metadata":null},{"id":"247bd6e65b4e4a3bb5ded6832d3e5224","type":"GO_TERM","name":"kanamycin biosynthetic process","canonical_id":"go:GO:1901133","description":"\"The chemical reactions and pathways resulting in the formation of kanamycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00965]","metadata":null},{"id":"37ead79289a149beb8773c9f6994086b","type":"GO_TERM","name":"kanamycin catabolic process","canonical_id":"go:GO:1901132","description":"\"The chemical reactions and pathways resulting in the breakdown of kanamycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00965]","metadata":null},{"id":"6c88b265163543b59ca3cf40ca60d5b2","type":"GO_TERM","name":"kanamycin kinase activity","canonical_id":"go:GO:0008910","description":"\"Catalysis of the reaction: ATP + kanamycin = ADP + 2 H+ + kanamycin 3'-phosphate.\" [EC:2.7.1.95, RHEA:24256]","metadata":null},{"id":"7e8999e2661b4f4f9b4d155022cf695c","type":"GO_TERM","name":"kappa-carrageenase activity","canonical_id":"go:GO:0033918","description":"\"Catalysis of the endohydrolysis of 1,4-beta-D-linkages between D-galactose 4-sulfate and 3,6-anhydro-D-galactose in kappa-carrageenans.\" [EC:3.2.1.83]","metadata":null},{"id":"81d70bfa07754dcb86525197ac003977","type":"GO_TERM","name":"kappa-type opioid receptor binding","canonical_id":"go:GO:0031851","description":"\"Binding to a kappa-type opioid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7b97f0080b614df6bd227bf8dd8f3756","type":"GO_TERM","name":"karyogamy","canonical_id":"go:GO:0000741","description":"\"The creation of a single nucleus from multiple nuclei as a result of fusing the lipid bilayers that surround each nuclei.\" [GOC:elh]","metadata":null},{"id":"9a3a9eef395d4ca793d944941b45aaf1","type":"GO_TERM","name":"karyogamy involved in conjugation with cellular fusion","canonical_id":"go:GO:0000742","description":"\"During sexual reproduction, the creation of a single nucleus from multiple nuclei as a result of fusing the lipid bilayers that surround each nuclei. This occurs after cytogamy.\" [GOC:elh]","metadata":null},{"id":"9b956dbe867a4944836c29f1aec901f9","type":"GO_TERM","name":"karyomere","canonical_id":"go:GO:0061468","description":"\"A membrane-bound intermediate cleavage-stage structure of individual or groups of chromosomes that coalesces and fuses with other karyomeres to form a nucleus during interphase. Karyomere formation occurs in blastomeres undergoing rapid cell division.\" [GOC:dph, PMID:12734396, PMID:22863006]","metadata":null},{"id":"65a706c7d6494437b2f0a6786ce5fdb6","type":"GO_TERM","name":"karyomere assembly","canonical_id":"go:GO:0061471","description":"\"The process where the nuclear membrane engulfs condensed chromosomes to form karyomeres during M phase of the mitotic cell cycle.\" [GOC:dph, PMID:9732278]","metadata":null},{"id":"9835de1ed3344b93b41fe03b6be2ef91","type":"GO_TERM","name":"karyomere membrane fusion","canonical_id":"go:GO:0061472","description":"\"Process whereby karyomere membranes fuse during interphase to form a single lobed nucleus.\" [GOC:dph, PMID:2734396]","metadata":null},{"id":"220e01d7d19648c5873cba44862f1c61","type":"GO_TERM","name":"karyosome formation","canonical_id":"go:GO:0061988","description":"\"The chromosome organization process in which meiotic chromosomes in the germ cell nucleus cluster together to form a compact spherical structure called the karyosome.\" [PMID:19696886]","metadata":null},{"id":"2afaefab786d4feda822e25c89c9cc60","type":"GO_TERM","name":"katanin complex","canonical_id":"go:GO:0008352","description":"\"A complex possessing an activity that couples ATP hydrolysis to the severing of microtubules; usually a heterodimer comprising a catalytic subunit (often 60kDa) and a regulatory subunit (often 80 kDa).\" [PMID:10910766]","metadata":null},{"id":"608483f5a39247ec9086f29430e33354","type":"GO_TERM","name":"keratan sulfate proteoglycan biosynthetic process","canonical_id":"go:GO:0018146","description":"\"The chemical reactions and pathways resulting in the formation of keratan sulfate proteoglycans, which consist of a core protein linked to a keratan sulfate glycosaminoglycan. The keratan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-beta-(1,3)-galactose, both of which can be sulfated. Keratan sulfate chains can be covalently linked either to an asparagine residue (N-linked) of the core protein via a high mannose oligasacccharide linker or to serine/threonine residues (O-linked) of the core protein via a core 2 type-linker.\" [PMID:29340594]","metadata":null},{"id":"2d0b358631024473b7a8950848aa8479","type":"GO_TERM","name":"keratan sulfate proteoglycan catabolic process","canonical_id":"go:GO:0042340","description":"\"The chemical reactions and pathways resulting in the breakdown of keratan sulfate proteoglycans, which consist of a core protein linked to a keratan sulfate glycosaminoglycan. The keratan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-beta-(1,3)-galactose, both of which can be sulfated.\" [PMID:35536982]","metadata":null},{"id":"a05caa94e9144a6aa4989cc3740e197e","type":"GO_TERM","name":"keratan sulfate proteoglycan metabolic process","canonical_id":"go:GO:0042339","description":"\"The chemical reactions and pathways involving keratan sulfate proteoglycans, which consist of a core protein linked to a keratan sulfate glycosaminoglycan. The keratan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-beta-(1,3)-galactose, both of which can be sulfated.\" [PMID:29340594]","metadata":null},{"id":"087124a1846d4e53be20937654394f02","type":"GO_TERM","name":"keratan sulfate-I proteoglycan biosynthetic process","canonical_id":"go:GO:0140263","description":"\"The chemical reactions and pathways resulting in the formation of keratan sulfate I (KS-I), N-linked via a GlcNAc attached to an asparigine residue in the target protein.\" [PMID:29340594]","metadata":null},{"id":"4930dc95985641078c315c15112ef9f2","type":"GO_TERM","name":"keratan sulfate-II proteoglycan biosynthetic process","canonical_id":"go:GO:0140264","description":"\"The chemical reactions and pathways resulting in the formation of keratan sulfate II (KS-II), O-linked via a GalNAc attached to a serine or a threonine residue in the target protein.\" [PMID:29340594]","metadata":null},{"id":"5b995d622b7047a1acaefb3d7917bfa1","type":"GO_TERM","name":"keratan sulfate-III proteoglycan biosynthetic process","canonical_id":"go:GO:0140265","description":"\"The chemical reactions and pathways resulting in the formation of keratan sulfate III (KS-III), O-linked via a mannose attached to a serine or a threonine residue in the target protein.\" [PMID:29340594]","metadata":null},{"id":"15e3bbb7c8ad480093e6332e87746d0d","type":"GO_TERM","name":"keratan sulfotransferase activity","canonical_id":"go:GO:0045130","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + keratan = adenosine 3',5'-bisphosphate + keratan 6'-sulfate.\" [EC:2.8.2.21]","metadata":null},{"id":"fca15502679b475eaf5b22f6bdf417fb","type":"GO_TERM","name":"keratan-sulfate endo-1,4-beta-galactosidase activity","canonical_id":"go:GO:0033930","description":"\"Catalysis of the endohydrolysis of (1->4)-beta-D-galactosidic linkages in keratan sulfate.\" [EC:3.2.1.103]","metadata":null},{"id":"31b0da8629eb4f079eee5159120de832","type":"GO_TERM","name":"keratin filament","canonical_id":"go:GO:0045095","description":"\"A filament composed of acidic and basic keratins (types I and II), typically expressed in epithelial cells. The keratins are the most diverse classes of IF proteins, with a large number of keratin isoforms being expressed. Each type of epithelium always expresses a characteristic combination of type I and type II keratins.\" [ISBN:0716731363]","metadata":null},{"id":"e3eb2030acd64557b380b3d3fd3a84f5","type":"GO_TERM","name":"keratin filament binding","canonical_id":"go:GO:1990254","description":"\"Binding to a keratin filament, an intermediate filament composed of acidic and basic keratins (types I and II), typically expressed in epithelial cells.\" [GOC:krc, PMID:6170061]","metadata":null},{"id":"e29f8bb718aa406facffd84f2bfaa52a","type":"GO_TERM","name":"keratinization","canonical_id":"go:GO:0031424","description":"\"The process in which the cytoplasm of the outermost cells of the vertebrate epidermis is replaced by keratin. Keratinization occurs in the stratum corneum, feathers, hair, claws, nails, hooves, and horns.\" [GOC:dph, GOC:ebc, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"cfabcdd9d8684bfd9a653fc6d49a530a","type":"GO_TERM","name":"keratinocyte activation","canonical_id":"go:GO:0032980","description":"\"A change in the morphology or behavior of a keratinocyte resulting from exposure to an activating factor such as a cellular or soluble ligand. Upon activation, keratinocytes become migratory and hyperproliferative, and produce growth factors and cytokines.\" [GOC:mah, PMID:15737202]","metadata":null},{"id":"1b940316f8b141318b09893cdf8606ac","type":"GO_TERM","name":"keratinocyte apoptotic process","canonical_id":"go:GO:0097283","description":"\"Any apoptotic process in a keratinocyte. A keratinocyte is an epidermal cell which synthesizes keratin and undergoes a characteristic change as it moves upward from the basal layers of the epidermis to the cornified (horny) layer of the skin.\" [CL:0000312, GOC:jc, GOC:mtg_apoptosis, PMID:10201527]","metadata":null},{"id":"1670f521dd7c42fb8d891e5dca954874","type":"GO_TERM","name":"keratinocyte development","canonical_id":"go:GO:0003334","description":"\"The process whose specific outcome is the progression of a keratinocyte over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"0fa79299a69c4718acf5c6d6cc34c21f","type":"GO_TERM","name":"keratinocyte differentiation","canonical_id":"go:GO:0030216","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a keratinocyte.\" [GOC:dph, GOC:mah, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"210a01eeea0d44638e23c408ebbd4b34","type":"GO_TERM","name":"keratinocyte migration","canonical_id":"go:GO:0051546","description":"\"The directed movement of a keratinocyte, epidermal cells which synthesize keratin, from one site to another.\" [ISBN:0721662544]","metadata":null},{"id":"d4115f9305434970a283078b26ad7591","type":"GO_TERM","name":"keratinocyte proliferation","canonical_id":"go:GO:0043616","description":"\"The multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population. Keratinocytes are epidermal cells which synthesize keratin and undergo a characteristic change as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin.\" [CL:0000311]","metadata":null},{"id":"6e43ff5ea30f47608c44ff4aec28d63d","type":"DISEASE","name":"keratitis","canonical_id":"mondo:0003085","description":null,"metadata":null},{"id":"e6c443a3e084465d86b255fa75cd6294","type":"DISEASE","name":"keratoconjunctivitis","canonical_id":"mondo:0004768","description":null,"metadata":null},{"id":"7151204e7d1b43158bd554ad77e03e29","type":"GO_TERM","name":"keratohyalin granule","canonical_id":"go:GO:0036457","description":"\"A cytoplasmic, non-membrane bound granule of, at least, keratinocyte. Associated to keratin intermediate filaments and partially crosslinked to the cell envelope.\" [GOC:krc, PMID:15854042]","metadata":null},{"id":"f521382eebad4905886f3e5af50f0312","type":"DISEASE","name":"keratosis","canonical_id":"mondo:0006566","description":null,"metadata":null},{"id":"d25e85f3c1c84bfcad20b7e76b2f1c8f","type":"DRUG","name":"ketamine","canonical_id":"gtopdb:4233","description":null,"metadata":null},{"id":"cf2af06c9852485b9fb8ab0ee27ce83c","type":"COMBINATION_TREATMENT","name":"ketamine + sufentanil","canonical_id":"ctgov_combo:ctgov-combo-4c3a7801ae79bdcd","description":null,"metadata":null},{"id":"9dfd700d160a40f2b381bab87ec2357c","type":"DRUG","name":"ketanserin","canonical_id":"mesh:D007650","description":null,"metadata":null},{"id":"d2ac9ffb87384eea849e61463a43a618","type":"GO_TERM","name":"keto-3-deoxy-D-manno-octulosonic acid biosynthetic process","canonical_id":"go:GO:0019294","description":"\"The chemical reactions and pathways resulting in the formation of keto-3-deoxy-D-manno-octulosonic acid, an acidic sugar present in lipopolysaccharides of the outer membranes of some Gram-negative bacteria.\" [ISBN:0198506732]","metadata":null},{"id":"4a0b1eb4f43a4f4f9165a306b74e38cb","type":"GO_TERM","name":"keto-D-gluconate biosynthetic process","canonical_id":"go:GO:0046179","description":"\"The chemical reactions and pathways resulting in the formation of keto-D-gluconate, the anion of keto-D-gluconic acid, an aldonic acid derived from glucose.\" [ISBN:0198506732]","metadata":null},{"id":"46c8247780ee4a08a20c2627b2d537d7","type":"GO_TERM","name":"keto-D-gluconate catabolic process","canonical_id":"go:GO:0019524","description":"\"The chemical reactions and pathways resulting in the breakdown of keto-D-gluconate, the anion of keto-D-gluconic acid, an aldonic acid derived from glucose.\" [ISBN:0198506732]","metadata":null},{"id":"12f5fa02109242ceb0a364bc4989ea29","type":"GO_TERM","name":"keto-deoxynonulosonic acid (KDN) cytidylyltransferase activity","canonical_id":"go:GO:0090633","description":"\"Catalysis of the reaction: CTP + KDN = diphosphate + CMP-KDN.\" [ISBN:978-1-60805-067-3, PMID:11479279, PMID:8381411]","metadata":null},{"id":"1018afc8dd2c4ead861f888eb2896744","type":"DRUG","name":"ketoconazole","canonical_id":"mesh:D007654","description":null,"metadata":null},{"id":"275726d0e5da40d3a53db04e5b8b1222","type":"GO_TERM","name":"ketohexokinase activity","canonical_id":"go:GO:0004454","description":"\"Catalysis of the reaction: ATP + D-fructose = ADP + D-fructose 1-phosphate.\" [EC:2.7.1.3]","metadata":null},{"id":"f965140b047547afb05d7d0f78589459","type":"GO_TERM","name":"ketol-acid reductoisomerase activity","canonical_id":"go:GO:0004455","description":"\"Catalysis of the reaction: (R)-2,3-dihydroxy-3-methylbutanoate + NADP+ = (S)-2-hydroxy-2-methyl-3-oxobutanoate + NADPH + H+.\" [EC:1.1.1.86]","metadata":null},{"id":"da8d7e58ef274eee87314633e7a11af2","type":"GO_TERM","name":"ketone biosynthetic process","canonical_id":"go:GO:0042181","description":"\"The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.\" [GOC:curators]","metadata":null},{"id":"d0b13bed60d349e28db4d7e1e7a62c76","type":"GO_TERM","name":"ketone body biosynthetic process","canonical_id":"go:GO:0046951","description":"\"The chemical reactions and pathways resulting in the formation of ketone bodies, any one of the three substances: acetoacetate, D-3-hydroxybutyrate (beta-hydroxybutyrate) or acetone. Biosynthesis involves the formation of hydroxymethylglutaryl-CoA, which is cleaved to acetate and acetyl-CoA.\" [MetaCyc:PWY66-367]","metadata":null},{"id":"3e6c4f96770a4b9c965d39fa46289336","type":"GO_TERM","name":"ketone body catabolic process","canonical_id":"go:GO:0046952","description":"\"The chemical reactions and pathways resulting in the breakdown of ketone bodies, any one of the three substances: acetoacetate, D-3-hydroxybutyrate (beta-hydroxybutyrate) or acetone. Ketone bodies can be used as an energy source as an alternative to glucose. Utilization of ketone bodies in peripheral tissues involves conversion of acetoacetate to acetoacetyl-CoA, which is then converted to two molecules of acetyl-CoA.\" [MetaCyc:PWY66-368]","metadata":null},{"id":"e80af0105a0d4deca0064e2867f7b9e6","type":"GO_TERM","name":"ketone catabolic process","canonical_id":"go:GO:0042182","description":"\"The chemical reactions and pathways resulting in the breakdown of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.\" [GOC:curators]","metadata":null},{"id":"6b452254ae3e478db3db8c8b5a9f3c50","type":"GO_TERM","name":"ketone metabolic process","canonical_id":"go:GO:0042180","description":"\"The chemical reactions and pathways involving any of a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms, as carried out by individual cells. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.\" [GOC:jl, ISBN:0787650153]","metadata":null},{"id":"720af8fc52b94b118919b1db96a66b23","type":"DRUG","name":"ketoprofen","canonical_id":"gtopdb:4795","description":null,"metadata":null},{"id":"fd17fc7b873a41d3a72730fc52f69799","type":"DRUG","name":"ketoprofen","canonical_id":"mesh:D007660","description":null,"metadata":null},{"id":"05a648c8fd954498890b32851465639f","type":"DRUG","name":"ketoprofen","canonical_id":"chembl:CHEMBL571","description":null,"metadata":null},{"id":"6af3b903297843e8ad913bc25444a307","type":"GO_TERM","name":"ketoreductase activity","canonical_id":"go:GO:0045703","description":"\"Catalysis of the reduction of a ketone group to form the corresponding alcohol.\" [GOC:curators]","metadata":null},{"id":"769e9f001fcd4609ab4fa98085e57b46","type":"DRUG","name":"ketorolac","canonical_id":"gtopdb:6661","description":null,"metadata":null},{"id":"19c0150d9018460b80f4e8f08a880862","type":"DRUG","name":"ketorolac","canonical_id":"mesh:D020910","description":null,"metadata":null},{"id":"01bd3a31927444fdaccc74d4d7a7590a","type":"COMBINATION_TREATMENT","name":"ketorolac + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-1700e78f2b4a6ba3","description":null,"metadata":null},{"id":"d7b1378eee5a41ffa16018e1370c0938","type":"COMBINATION_TREATMENT","name":"ketorolac + morphine","canonical_id":"ctgov_combo:ctgov-combo-f80ce4b81c009912","description":null,"metadata":null},{"id":"aa7963fad70b4cb2b43ab7792296da5c","type":"COMBINATION_TREATMENT","name":"ketorolac + morphine","canonical_id":"ctgov_combo:ctgov-combo-99f9560043a5524e","description":null,"metadata":null},{"id":"6467482622df42cb9789adb847b2f306","type":"COMBINATION_TREATMENT","name":"ketorolac + naproxen","canonical_id":"ctgov_combo:ctgov-combo-0a9dc5b3adbfa015","description":null,"metadata":null},{"id":"99ade2f143e14656a86f5c19a636ee5b","type":"COMBINATION_TREATMENT","name":"ketorolac + naproxen","canonical_id":"ctgov_combo:ctgov-combo-e338da034cbc17a7","description":null,"metadata":null},{"id":"d523abc8430b474e9f6dba9a318faa99","type":"COMBINATION_TREATMENT","name":"ketorolac + pethidine","canonical_id":"ctgov_combo:ctgov-combo-6d3ddc335aea5d64","description":null,"metadata":null},{"id":"b48e129f1a314e95a1486e9c7a844555","type":"COMBINATION_TREATMENT","name":"ketorolac + sufentanil","canonical_id":"ctgov_combo:ctgov-combo-70c13ce3d0c4e310","description":null,"metadata":null},{"id":"573ee25059a74b8e97d90571aadc875f","type":"GO_TERM","name":"ketosteroid monooxygenase activity","canonical_id":"go:GO:0047086","description":"\"Catalysis of the reaction: O2 + NADPH + progesterone = H2O + NADP+ + testosterone acetate.\" [EC:1.14.13.54, MetaCyc:1.14.13.54-RXN]","metadata":null},{"id":"9e37b7a820744c4c91c88168aee983b9","type":"GO_TERM","name":"ketotetrose-phosphate aldolase activity","canonical_id":"go:GO:0050014","description":"\"Catalysis of the reaction: L-erythrulose 1-phosphate = formaldehyde + glycerone phosphate.\" [EC:4.1.2.2, RHEA:20932]","metadata":null},{"id":"fdeb17049c744c04bca94474653df51d","type":"DRUG","name":"ketotifen","canonical_id":"gtopdb:7206","description":null,"metadata":null},{"id":"a63ef16553644cc58fe6628b0c0cd7bb","type":"DISEASE","name":"kidney angiomyolipoma","canonical_id":"mondo:0004555","description":null,"metadata":null},{"id":"fcd69e6be5a8424ab1cd00054cbe575c","type":"GO_TERM","name":"kidney cortex tubule cell dedifferentiation","canonical_id":"go:GO:0160029","description":"\"The process in which a kidney cortex tubule cell (specialized epithelial cell of the kidney) loses the structural or functional features that characterize it in the mature organism, or some other relatively stable phase of the organism's life history. Under certain conditions, these cells can revert back to the features of the stem cells that were their ancestors.\" [PMID:18987110, PMID:31847447]","metadata":null},{"id":"cd8fd40a14ca484e88540dd4f767a928","type":"GO_TERM","name":"kidney development","canonical_id":"go:GO:0001822","description":"\"The process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and/or excretes the end products of body metabolism in the form of urine.\" [GOC:dph, GOC:mtg_kidney_jan10, ISBN:0124020607, ISBN:0721662544]","metadata":null},{"id":"eccca05e29e5419abfbd9d2e5a23b22d","type":"DISEASE","name":"kidney disorder","canonical_id":"mondo:0005240","description":null,"metadata":null},{"id":"d0526728744841df8db43b1f80a051d6","type":"GO_TERM","name":"kidney epithelium development","canonical_id":"go:GO:0072073","description":"\"The process whose specific outcome is the progression of an epithelium in the kidney over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f8acfd54dc1e445393537a56a1090ff5","type":"DISEASE","name":"kidney failure","canonical_id":"mondo:0001106","description":null,"metadata":null},{"id":"19aa4462babf4298ae681e6fe67d3c1c","type":"GO_TERM","name":"kidney field specification","canonical_id":"go:GO:0072004","description":"\"The process that results in the delineation of regions of the embryo into the area in which the kidney rudiment will develop.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6028d742c85f4493b833d491cb68eb2d","type":"GO_TERM","name":"kidney interstitial fibroblast differentiation","canonical_id":"go:GO:0072071","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the interstitial fibroblast of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"07c6da97acce46978b7a355019a84612","type":"GO_TERM","name":"kidney mesenchymal cell proliferation","canonical_id":"go:GO:0072135","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population in the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"dbd644aeb6284923aa3552511a1dfbc6","type":"GO_TERM","name":"kidney mesenchyme development","canonical_id":"go:GO:0072074","description":"\"The biological process whose specific outcome is the progression of a kidney mesenchyme from an initial condition to its mature state. This process begins with the formation of kidney mesenchyme and ends with the mature structure. Kidney mesenchyme is the tissue made up of loosely connected mesenchymal cells in the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"43ec1e7d1e8a4dcb9ec5e7d0f203c390","type":"GO_TERM","name":"kidney mesenchyme morphogenesis","canonical_id":"go:GO:0072131","description":"\"The process in which the anatomical structures of a kidney mesenchymal tissue are generated and organized. Kidney mesenchyme is the tissue made up of loosely connected mesenchymal cells in the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"77464c4cee8c487d9b32ad73cf76179b","type":"GO_TERM","name":"kidney morphogenesis","canonical_id":"go:GO:0060993","description":"\"Morphogenesis of a kidney. A kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"91eca401495d40fea6bd4a2105f74139","type":"GO_TERM","name":"kidney rudiment formation","canonical_id":"go:GO:0072003","description":"\"The developmental process pertaining to the initial formation of a kidney rudiment from unspecified parts. A kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"95968278ca4d4d1f9644cabda8310e7b","type":"GO_TERM","name":"kidney smooth muscle cell differentiation","canonical_id":"go:GO:0072195","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell in the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cd6829f9342f4e4b9d0bd30249ce1880","type":"GO_TERM","name":"kidney smooth muscle tissue development","canonical_id":"go:GO:0072194","description":"\"The process whose specific outcome is the progression of smooth muscle in the kidney over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"724d0c680f244ff19fb7a3a9a96ec2b8","type":"GO_TERM","name":"kidney stroma development","canonical_id":"go:GO:0072072","description":"\"The process whose specific outcome is the progression of the kidney stroma over time, from its formation to the mature structure. The kidney stroma is the mesenchyme of the mature kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"dc8e6f9c041b43a1b4f9ba7cfbc5392f","type":"DISEASE","name":"kidney transplant","canonical_id":"efo:0010134","description":null,"metadata":null},{"id":"5809ff7ca5c2461db2f055492d6f567f","type":"GO_TERM","name":"kidney vasculature development","canonical_id":"go:GO:0061440","description":"\"The process whose specific outcome is the progression of the vasculature of the kidney over time, from its formation to the mature structure.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:11891195]","metadata":null},{"id":"9a392a895df74e54874ab9b3ee78096e","type":"GO_TERM","name":"kidney vasculature morphogenesis","canonical_id":"go:GO:0061439","description":"\"The process in which the kidney vasculature is generated and organized. Morphogenesis pertains to the creation of form.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"41ba56009cf14dce81c57e2b00c76427","type":"GO_TERM","name":"kievitone hydratase activity","canonical_id":"go:GO:0050015","description":"\"Catalysis of the reaction: kievitone hydrate = H2O + H+ + kievitone.\" [EC:4.2.1.95, RHEA:23604]","metadata":null},{"id":"3ac7bd70847b4c2782d133e76ee627e2","type":"GO_TERM","name":"killing by virus of host cell by post-segregational killing","canonical_id":"go:GO:0044696","description":"\"The process by which a virus causes the death of daughter cells which do not contain its genes after host cell division, by a mechanism of post-segregational killing (PSK). The extrachromosomal viral DNA consist of two genes; the product of the second is long lived and toxic, while the product of the first is short lived and antagonizes the lethal action of the toxin. Daughter cells that do not contain the viral extrachromosomal element are killed by the long lived toxin, while daughter cells that do contain the viral extrachromosomal element are protected by the action of the short lived antitoxin it encodes.\" [GOC:bf, GOC:jl, PMID:11222604, Wikipedia:Toxin-antitoxin_system]","metadata":null},{"id":"c56dc2566fef4e8687bf2a0ee761a876","type":"GO_TERM","name":"killing by virus of host cell during superinfection exclusion","canonical_id":"go:GO:0039634","description":"\"The viral-killing of a host cell by a pre-existing virus in response to a subsequent infection of the host cell by second virus.\" [GOC:bf, GOC:bm, GOC:jl, PMID:22398285]","metadata":null},{"id":"e3ef9770321640f1ae0a6f9b774a8b0b","type":"GO_TERM","name":"killing of cells of another organism","canonical_id":"go:GO:0031640","description":"\"Any process in an organism that results in the killing of cells of another organism, including in some cases the death of the other organism. Killing here refers to the induction of death in one cell by another cell, not cell-autonomous death due to internal or other environmental conditions.\" [GOC:add]","metadata":null},{"id":"ea153bf8b2f849c4b79d45f32cc90ac8","type":"GO_TERM","name":"kinase activator activity","canonical_id":"go:GO:0019209","description":"\"Binds to and increases the activity of a kinase, an enzyme which catalyzes of the transfer of a phosphate group, usually from ATP, to a substrate molecule.\" [GOC:ai]","metadata":null},{"id":"ed9f2302092a4c919395be65f3cb2016","type":"GO_TERM","name":"kinase activity","canonical_id":"go:GO:0016301","description":"\"Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.\" [ISBN:0198506732]","metadata":null},{"id":"3fa60d004f0640b7bbb80c56d92195e6","type":"GO_TERM","name":"kinase binding","canonical_id":"go:GO:0019900","description":"\"Binding to a kinase, any enzyme that catalyzes the transfer of a phosphate group.\" [GOC:jl]","metadata":null},{"id":"b9d2bedef3814423adeb2e447e4dd455","type":"GO_TERM","name":"kinase inhibitor activity","canonical_id":"go:GO:0019210","description":"\"Binds to and stops, prevents or reduces the activity of a kinase.\" [GOC:mah]","metadata":null},{"id":"0735b3f2cf8b44da8ce8f38c9284f8b1","type":"GO_TERM","name":"kinase regulator activity","canonical_id":"go:GO:0019207","description":"\"Modulates the activity of a kinase, an enzyme which catalyzes of the transfer of a phosphate group, usually from ATP, to a substrate molecule.\" [GOC:ai]","metadata":null},{"id":"9e097b537d2445a8a107e6c1e71f0dd3","type":"GO_TERM","name":"kinesin I complex","canonical_id":"go:GO:0016938","description":"\"A complex of two kinesin heavy chains and two kinesin light chains.\" [PMID:20930137]","metadata":null},{"id":"9871fba9f9a247d2ac3bddbaa8909bb8","type":"GO_TERM","name":"kinesin II complex","canonical_id":"go:GO:0016939","description":"\"A complex consisting of two distinct motor subunits that form a heterodimer complexed with a third non-motor accessory subunit, the kinesin associated protein or KAP; the KIF3 heterodimer interacts via its C-terminal portion with KAP, which is thought to regulate the binding of the motor to cargo membranes.\" [PMID:20930137]","metadata":null},{"id":"a48789506eed4e0aadbfe5519a20ee5d","type":"GO_TERM","name":"kinesin binding","canonical_id":"go:GO:0019894","description":"\"Interacting selectively and non-covalently and stoichiometrically with kinesin, a member of a superfamily of microtubule-based motor proteins that perform force-generating tasks such as organelle transport and chromosome segregation.\" [GOC:curators, PMID:8606779]","metadata":null},{"id":"4e5cdf8d87ab45399a04fade84479b75","type":"GO_TERM","name":"kinesin complex","canonical_id":"go:GO:0005871","description":"\"Any complex that includes a dimer of molecules from the kinesin superfamily, a group of related proteins that contain an extended region of predicted alpha-helical coiled coil in the main chain that likely produces dimerization. The native complexes of several kinesin family members have also been shown to contain additional peptides, often designated light chains as all of the noncatalytic subunits that are currently known are smaller than the chain that contains the motor unit. Kinesin complexes generally possess a force-generating enzymatic activity, or motor, which converts the free energy of the gamma phosphate bond of ATP into mechanical work.\" [GOC:mah, PMID:32842864]","metadata":null},{"id":"6cb47c8cd83a424c95ed718431466130","type":"GO_TERM","name":"kinesis","canonical_id":"go:GO:0042465","description":"\"The movement of a cell or organism in response to a stimulus in which the rate of movement depends on the intensity (rather than the direction) of the stimulus.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"a56f13115c284d8fa0904d96c1e88ecd","type":"GO_TERM","name":"kinetochore","canonical_id":"go:GO:0000776","description":"\"A multisubunit complex that is located at the centromeric region of DNA and provides an attachment point for the spindle microtubules.\" [GOC:elh]","metadata":null},{"id":"298d979001a348378f29fc1c96c92807","type":"GO_TERM","name":"kinetochore adaptor activity","canonical_id":"go:GO:0140483","description":"\"The binding activity of a protein that brings the kinetochore and another molecule into contact, permitting those molecules to function in a coordinated way.\" [PMID:22521786]","metadata":null},{"id":"68a66056fee34fcf979cfc0a4745863a","type":"GO_TERM","name":"kinetochore assembly","canonical_id":"go:GO:0051382","description":"\"The aggregation, arrangement and bonding together of a set of components to form the kinetochore, a multisubunit complex that is located at the centromeric region of DNA and provides an attachment point for the spindle microtubules.\" [GOC:ai]","metadata":null},{"id":"0a0730a97fbb470eb75282dc19a6c7bf","type":"GO_TERM","name":"kinetochore binding","canonical_id":"go:GO:0043515","description":"\"Binding to a kinetochore, a proteinaceous structure on a condensed chromosome, beside the centromere, to which the spindle fibers are attached.\" [GOC:jl]","metadata":null},{"id":"0aef460cace940498e35603f4626a9a4","type":"GO_TERM","name":"kinetochore disassembly","canonical_id":"go:GO:0062096","description":"\"The disaggregation of a kinetochore into its constituent components.\" [GOC:mah, PMID:27611693]","metadata":null},{"id":"d70e7005c51649598bb71e0f2f7ea822","type":"GO_TERM","name":"kinetochore microtubule","canonical_id":"go:GO:0005828","description":"\"Any of the spindle microtubules that attach to the kinetochores of chromosomes by their plus ends, and maneuver the chromosomes during mitotic or meiotic chromosome segregation.\" [ISBN:0815316194]","metadata":null},{"id":"cebb95772a944d2da86dba916bd323a0","type":"GO_TERM","name":"kinetochore organization","canonical_id":"go:GO:0051383","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the kinetochore, a multisubunit complex that is located at the centromeric region of DNA and provides an attachment point for the spindle microtubules.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"b1a050e1759740c584bb87a700f5af32","type":"GO_TERM","name":"kinetoplast","canonical_id":"go:GO:0020023","description":"\"A sub-structure within the large single mitochondrion of kinetoplastid parasites and which is closely associated with the flagellar pocket and basal body of the flagellum.\" [GOC:mb]","metadata":null},{"id":"b32d8faf280d4ec8981e97a9b250ff7f","type":"GO_TERM","name":"kinetoplast DNA replication","canonical_id":"go:GO:0140909","description":"\"The process of doubling of the number of maxicircles and minicircles and distribution of the progeny into two daughter networks, which are identical to the parent kinetoplast DNA network.\" [GOC:ach, PMID:12455998, PMID:15967722, PMID:17462016, PMID:8045928, PMID:8561456]","metadata":null},{"id":"24ef8dff022d48fbb0b806ff79c8463f","type":"GO_TERM","name":"kinin cascade","canonical_id":"go:GO:0002254","description":"\"A series of reactions that takes place outside the cell that occur as a result of by-products of tissue damage, including collagen, cartilage, and basement membrane. The ultimate product of the kinin cascade include kallidin and bradykinin, agents known to induce smooth muscle contraction, vasoconstriction, and increased vascular permeability.\" [GOC:jal, ISBN:0721601871, PMID:11842287, PMID:14501145]","metadata":null},{"id":"1c94b519785a4ac7ae9bc4201a6ea50e","type":"GO_TERM","name":"kininogen binding","canonical_id":"go:GO:0030984","description":"\"Binding to a kininogen, a kinin precursor.\" [GOC:mah, PMID:9520414]","metadata":null},{"id":"3be3be207a1843faaa48478b8a40ec2b","type":"GO_TERM","name":"kinociliary basal body","canonical_id":"go:GO:1902636","description":"\"A ciliary basal body that is part of a kinocilium.\" [GO_REF:0000064, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:15855039, PMID:15882574]","metadata":null},{"id":"fa3c9a6ce6b54c88b47b11f195c9a318","type":"GO_TERM","name":"kinocilium","canonical_id":"go:GO:0060091","description":"\"A nonmotile primary cilium that is found at the apical surface of auditory receptor cells. The kinocilium is surrounded by actin-based stereocilia.\" [GOC:cilia, GOC:dph, PMID:15882574]","metadata":null},{"id":"d73252ad1dce4eab8b9c430d7d8ac121","type":"GO_TERM","name":"kisspeptin receptor binding","canonical_id":"go:GO:0031773","description":"\"Binding to a kisspeptin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"32a3cfa3f58b42c8a635119678b7e75e","type":"GO_TERM","name":"klinokinesis","canonical_id":"go:GO:0042468","description":"\"The movement of a cell or organism in response to a stimulus in which the frequency or magnitude of turning behavior is altered.\" [GOC:jl, PMID:2790068]","metadata":null},{"id":"1cbad78304004f19a26ce728c9709749","type":"GO_TERM","name":"kojibiose phosphorylase activity","canonical_id":"go:GO:0033831","description":"\"Catalysis of the reaction: kojibiose + phosphate = beta-D-glucose 1-phosphate + D-glucose.\" [EC:2.4.1.230, RHEA:11176]","metadata":null},{"id":"268e3e5b90d444bba526d41b9cd9a4e2","type":"GO_TERM","name":"kojic acid biosynthetic process","canonical_id":"go:GO:2001317","description":"\"The chemical reactions and pathways resulting in the formation of kojic acid.\" [GOC:di]","metadata":null},{"id":"e53f2a5bf7f0462d9a6b4705c7267c2f","type":"GO_TERM","name":"kolavenyl diphosphate synthase activity","canonical_id":"go:GO:0106242","description":"\"Catalysis of the reaction: all-trans-geranylgeranyl diphosphate = (+)-kolavenyl diphosphate.\" [GOC:eab, PMID:29315936, RHEA:54676]","metadata":null},{"id":"8010c0a8e4e545e5b477943972d9f662","type":"GO_TERM","name":"kringle domain binding","canonical_id":"go:GO:0036143","description":"\"Binding to a kringle domain. Kringle domains are protein domains that fold into large loops stabilized by 3 disulfide linkages, and are important in protein-protein interactions with blood coagulation factors.\" [GOC:yaf, Wikipedia:Kringle_domain]","metadata":null},{"id":"fe742d72baca467b9cb9024bef614bc5","type":"GO_TERM","name":"kynurenate-7,8-dihydrodiol dehydrogenase activity","canonical_id":"go:GO:0047114","description":"\"Catalysis of the reaction: 7,8-dihydro-7,8-dihydroxykynurenate + NAD+ = 7,8-dihydroxykynurenate + H+ + NADH.\" [EC:1.3.1.18, RHEA:22248]","metadata":null},{"id":"aa1ff6e518714dbe8dd38824474931e3","type":"GO_TERM","name":"kynurenic acid biosynthetic process","canonical_id":"go:GO:0034276","description":"\"The chemical reactions and pathways resulting in the formation of kynurenic acid, 4-hydroxyquinoline-2-carboxylic acid.\" [GOC:mah]","metadata":null},{"id":"a15c916e22d3486c87a7e8524b3a885b","type":"GO_TERM","name":"kynurenic acid metabolic process","canonical_id":"go:GO:0034275","description":"\"The chemical reactions and pathways involving kynurenic acid, 4-hydroxyquinoline-2-carboxylic acid.\" [GOC:mah]","metadata":null},{"id":"6945a5eb7fdd4467b7ff02d9a4c6366c","type":"GO_TERM","name":"kynureninase activity","canonical_id":"go:GO:0030429","description":"\"Catalysis of the reaction: L-kynurenine + H2O = anthranilate + L-alanine + H+. Also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)- alanines.\" [EC:3.7.1.3, PMID:17300176]","metadata":null},{"id":"04574403d1da4ac09b0623dc0073f3b1","type":"GO_TERM","name":"kynurenine 3-monooxygenase activity","canonical_id":"go:GO:0004502","description":"\"Catalysis of the reaction: L-kynurenine + H+ + NADPH + O2 = 3-hydroxy-L-kynurenine + H2O + NADP+.\" [EC:1.14.13.9, RHEA:20545]","metadata":null},{"id":"7f2605b138754606abccd7e3a6c7ffab","type":"GO_TERM","name":"kynurenine 7,8-hydroxylase activity","canonical_id":"go:GO:0050016","description":"\"Catalysis of the reaction: kynurenate + donor-H2 + O2 = 7,8-dihydro-7,8-dihydroxykynurenate + acceptor.\" [EC:1.14.99.2]","metadata":null},{"id":"8162447a18684ebda33266ad2b64ccaa","type":"GO_TERM","name":"labd-13Z-ene-9,15,16-triol synthase activity","canonical_id":"go:GO:0106240","description":"\"Catalysis of the reaction: O2 + peregrinol + reduced [NADPH--hemoprotein reductase] = H+ + H2O + labd-13Z-ene-9,15,16-triol + oxidized [NADPH--hemoprotein reductase].\" [GOC:eab, PMID:29315936, RHEA:62192]","metadata":null},{"id":"911079db4f2d4cac9ae34729dc5aadee","type":"DRUG","name":"labetalol","canonical_id":"gtopdb:7207","description":null,"metadata":null},{"id":"6b3b55deb3704393928369e22a20e11c","type":"DRUG","name":"labetalol","canonical_id":"mesh:D007741","description":null,"metadata":null},{"id":"7f12b03a77f34a72ab013d260b765d48","type":"GO_TERM","name":"labial disc development","canonical_id":"go:GO:0035217","description":"\"Progression of the labial imaginal disc over time, from its initial formation through to its metamorphosis to form adult structures including parts of the proboscis.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"7b03af9017c04809b1c159d7d133a2c0","type":"GO_TERM","name":"labial disc morphogenesis","canonical_id":"go:GO:0007454","description":"\"The process in which the anatomical structures derived from the labial disc are generated and organized. This includes the transformation of a labial imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into recognizable adult structures including parts of the proboscis.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"04afd315bd0c4c398528737e70fbb061","type":"GO_TERM","name":"labrum development","canonical_id":"go:GO:0048726","description":"\"The process whose specific outcome is the progression of the labrum over time, from its formation to the mature structure.\" [GOC:rc]","metadata":null},{"id":"d5886e60a67c43ed9e510896e5264568","type":"GO_TERM","name":"labrum morphogenesis","canonical_id":"go:GO:0048716","description":"\"The process in which the anatomical structures of labrum are generated and organized.\" [GOC:rc]","metadata":null},{"id":"a365f4c8982b40c086edd3a95229b98d","type":"GO_TERM","name":"labyrinthine layer blood vessel development","canonical_id":"go:GO:0060716","description":"\"The process whose specific outcome is the progression of a blood vessel of the labyrinthine layer of the placenta over time, from its formation to the mature structure. The embryonic vessels grow through the layer to come in close contact with the maternal blood supply.\" [GOC:dph]","metadata":null},{"id":"23c6fc66f68144ea8359cb3c38f6c5ca","type":"GO_TERM","name":"labyrinthine layer development","canonical_id":"go:GO:0060711","description":"\"The process in which the labyrinthine layer of the placenta progresses, from its formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"b49821246104452abd9790db8e4b53f1","type":"GO_TERM","name":"labyrinthine layer formation","canonical_id":"go:GO:0060714","description":"\"The developmental process pertaining to the initial formation of the labyrinthine layer of the placenta.\" [GOC:dph]","metadata":null},{"id":"e16d759d63f7489f805c5e4f9d8667eb","type":"GO_TERM","name":"labyrinthine layer morphogenesis","canonical_id":"go:GO:0060713","description":"\"The process in which the labyrinthine layer of the placenta is generated and organized.\" [GOC:dph]","metadata":null},{"id":"bb59b3f2c7d2428eba9e8bb7ee1c0ed4","type":"DRUG","name":"lacosamide","canonical_id":"gtopdb:7472","description":null,"metadata":null},{"id":"7d53d1ac3eb24c509a1ac10ded36620c","type":"DRUG","name":"lacosamide","canonical_id":"chembl:CHEMBL58323","description":null,"metadata":null},{"id":"5a10582505ff4eb7a29fb0e3a4a36a62","type":"COMBINATION_TREATMENT","name":"lacosamide + levetiracetam + phenytoin + tiagabine + vigabatrin","canonical_id":"ctgov_combo:ctgov-combo-227548b7c87caca8","description":null,"metadata":null},{"id":"2c75bf2b7c874ef4aaf7f76a5b7a79cf","type":"COMBINATION_TREATMENT","name":"lacosamide + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-64bd51bef94c537b","description":null,"metadata":null},{"id":"a45a1706e5334bb99e4ee7bee72a8a0a","type":"COMBINATION_TREATMENT","name":"lacosamide + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-070c2554354108c6","description":null,"metadata":null},{"id":"83bfe0dd15c34a90965bdfd8f1b23419","type":"GO_TERM","name":"lacrimal gland development","canonical_id":"go:GO:0032808","description":"\"The process whose specific outcome is the progression of the lacrimal gland over time, from its formation to the mature structure. The lacrimal gland produces secretions that lubricate and protect the cornea of the eye.\" [GOC:ln]","metadata":null},{"id":"0563bfe0c34e413a8ce57efc43ff2221","type":"GO_TERM","name":"lactaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008911","description":"\"Catalysis of the reaction: (S)-lactaldehyde + NAD+ + H2O = (S)-lactate + NADH + H+.\" [RHEA:14277]","metadata":null},{"id":"dc28291bf72346eda6620e3d2fb50fb8","type":"GO_TERM","name":"lactaldehyde reductase (NADPH) activity","canonical_id":"go:GO:0050039","description":"\"Catalysis of the reaction: NADP+ + propane-1,2-diol = (S)-lactaldehyde + H+ + NADPH.\" [RHEA:15885]","metadata":null},{"id":"6006cb7a674d446c94711375a8f29261","type":"GO_TERM","name":"lactaldehyde reductase activity","canonical_id":"go:GO:0008912","description":"\"Catalysis of the reaction: propane-1,2-diol + NAD+ = lactaldehyde + NADH + H+.\" [EC:1.1.1.77]","metadata":null},{"id":"9990e98091724bbcb211ee4897c44170","type":"GO_TERM","name":"lactam biosynthetic process","canonical_id":"go:GO:0072339","description":"\"The chemical reactions and pathways resulting in the formation of lactams, any cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.\" [GOC:mah]","metadata":null},{"id":"06b723daf74846f1aa519aa911e3c45a","type":"GO_TERM","name":"lactam catabolic process","canonical_id":"go:GO:0072340","description":"\"The chemical reactions and pathways resulting in the breakdown of lactams, any cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.\" [GOC:mah]","metadata":null},{"id":"49ccbba8b98b4f2a909060caf8d467e0","type":"GO_TERM","name":"lactam metabolic process","canonical_id":"go:GO:0072338","description":"\"The chemical reactions and pathways involving lactams, any cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.\" [GOC:mah]","metadata":null},{"id":"412c79716e25498e93856a2b4b0146f1","type":"GO_TERM","name":"lactase activity","canonical_id":"go:GO:0000016","description":"\"Catalysis of the reaction: lactose + H2O = D-glucose + D-galactose.\" [PMID:12023280]","metadata":null},{"id":"dafb197f1d3e4da985c754d85848bbb5","type":"GO_TERM","name":"lactate 2-monooxygenase activity","canonical_id":"go:GO:0050040","description":"\"Catalysis of the reaction: (S)-lactate + O2 = acetate + CO2 + H2O.\" [EC:1.13.12.4, RHEA:16513]","metadata":null},{"id":"becd2c2749fd494c9118a3d38bd9072e","type":"GO_TERM","name":"lactate aldolase activity","canonical_id":"go:GO:0050041","description":"\"Catalysis of the reaction: (S)-lactate = acetaldehyde + formate.\" [EC:4.1.2.36, RHEA:17909]","metadata":null},{"id":"abe3bddfb80b42cda1c80ae3d26af91d","type":"GO_TERM","name":"lactate biosynthetic process","canonical_id":"go:GO:0019249","description":"\"The chemical reactions and pathways resulting in the formation of lactate, the anion of lactic acid.\" [GOC:curators]","metadata":null},{"id":"4174598205ff4fbdb961f2da46c128fe","type":"GO_TERM","name":"lactate catabolic process","canonical_id":"go:GO:1903457","description":"\"The chemical reactions and pathways resulting in the breakdown of lactate.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:8941775]","metadata":null},{"id":"47122c550ef2498ea2a4652d240ddf52","type":"GO_TERM","name":"lactate dehydrogenase activity","canonical_id":"go:GO:0004457","description":"\"Catalysis of the reaction: lactate + NAD+ = H+ + NADH + pyruvate.\" [GOC:ai, GOC:bf]","metadata":null},{"id":"259601f6b1f34ca1a9bae7d8fd4da0b3","type":"GO_TERM","name":"lactate metabolic process","canonical_id":"go:GO:0006089","description":"\"The chemical reactions and pathways involving lactate, the anion of lactic acid.\" [ISBN:0198547684]","metadata":null},{"id":"360c64928eab4d3fb167894e55b78fa9","type":"GO_TERM","name":"lactate racemase activity","canonical_id":"go:GO:0050043","description":"\"Catalysis of the reaction: (S)-lactate = (R)-lactate.\" [EC:5.1.2.1, RHEA:10960]","metadata":null},{"id":"245d9f77f59f487da6339c1d6cd5b2e4","type":"GO_TERM","name":"lactate racemization","canonical_id":"go:GO:0019247","description":"\"Partial conversion of one lactate enantiomer into another so that the specific optical rotation is decreased, or even reduced to zero, in the resulting mixture.\" [GOC:curators, PMID:16166538]","metadata":null},{"id":"5362e607dab14f3d89fe77deecddbd3a","type":"GO_TERM","name":"lactate transmembrane transport","canonical_id":"go:GO:0035873","description":"\"The process in which lactate is transported across a membrane. Lactate is 2-hydroxypropanoate, CH3-CHOH-COOH; L(+)-lactate is formed by anaerobic glycolysis in animal tissues, and DL-lactate is found in sour milk, molasses and certain fruit juices.\" [GOC:mcc, ISBN:0198506732]","metadata":null},{"id":"ccb72adc17b6405295c7a8948d97664f","type":"GO_TERM","name":"lactate transmembrane transporter activity","canonical_id":"go:GO:0015129","description":"\"Enables the transfer of lactate from one side of a membrane to the other. Lactate is 2-hydroxypropanoate, CH3-CHOH-COOH; L(+)-lactate is formed by anaerobic glycolysis in animal tissues, and DL-lactate is found in sour milk, molasses and certain fruit juices.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"4b74f0c8722e493c87d5a24dc91f0cbe","type":"GO_TERM","name":"lactate transport","canonical_id":"go:GO:0015727","description":"\"The directed movement of lactate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lactate is 2-hydroxypropanoate, CH3-CHOH-COOH; L(+)-lactate is formed by anaerobic glycolysis in animal tissues, and DL-lactate is found in sour milk, molasses and certain fruit juices.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"02827347a9bc4e44a9f2c1b7d608005b","type":"GO_TERM","name":"lactate-malate transhydrogenase activity","canonical_id":"go:GO:0050042","description":"\"Catalysis of the reaction: (S)-lactate + oxaloacetate = malate + pyruvate.\" [EC:1.1.99.7, RHEA:10984]","metadata":null},{"id":"5c8654ff75044570a672e8a6674a6fc5","type":"GO_TERM","name":"lactate:proton symporter activity","canonical_id":"go:GO:0015650","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: lactate (out) + H+ (out) = lactate (in) + H+ (in).\" [TC:2.A.14.1.1]","metadata":null},{"id":"05e63657dbb04b0da7c3bbc052eff274","type":"GO_TERM","name":"lactation","canonical_id":"go:GO:0007595","description":"\"The regulated release of milk from the mammary glands and the period of time that a mother lactates to feed her young.\" [ISBN:0198506732]","metadata":null},{"id":"6be8076c98ee44f29d6be0098cdc848c","type":"DRUG","name":"lactic acid","canonical_id":"mesh:D019344","description":null,"metadata":null},{"id":"760e1225207b4f9eb0286edd75ba5dcd","type":"GO_TERM","name":"lactic acid secretion","canonical_id":"go:GO:0046722","description":"\"The controlled release of lactic acid, 2-hydroxypropanoic acid, by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"a99b430c5bae432c94ef93041ad9fe59","type":"GO_TERM","name":"lacto-N-biosidase activity","canonical_id":"go:GO:0047403","description":"\"Catalysis of the reaction: H2O + beta-D-Gal-(1,3)-beta-D-GlcNAc-(1,3)-beta-D-Gal-(1,4)-D-Glc = beta-D-Gal-(1,4)-D-Glc + beta-D-Gal-(1,3)-D-GlcNAc.\" [EC:3.2.1.140]","metadata":null},{"id":"e651633a55d34121b8b4e7f77d5c30d2","type":"GO_TERM","name":"lactoferrin receptor activity","canonical_id":"go:GO:0033568","description":"\"Combining with lactoferrin and delivering lactoferrin into the cell via endocytosis. Lactoferrin is an iron-binding glycoprotein which binds ferric iron most efficiently at low pH.\" [GOC:bf, GOC:mlg, PMID:16261254]","metadata":null},{"id":"bc2879b7ecf64c178f030162a9b5bd2d","type":"GO_TERM","name":"lactoferrin transmembrane transporter activity","canonical_id":"go:GO:0033569","description":"\"Enables the transfer of lactoferrin from one side of a membrane to the other.\" [GOC:mlg]","metadata":null},{"id":"c7f166261acd4ab88b65c4aadb5c8782","type":"GO_TERM","name":"lactoferrin transport","canonical_id":"go:GO:0033571","description":"\"The directed movement of lactoferrin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mlg]","metadata":null},{"id":"081cee3c8ed246fd805cd2ff6d436d04","type":"GO_TERM","name":"lactone biosynthetic process","canonical_id":"go:GO:1901336","description":"\"The chemical reactions and pathways resulting in the formation of lactone.\" [GOC:TermGenie]","metadata":null},{"id":"09060e086286421c8c242bb0e72a4ff3","type":"GO_TERM","name":"lactone catabolic process","canonical_id":"go:GO:1901335","description":"\"The chemical reactions and pathways resulting in the breakdown of lactone.\" [GOC:TermGenie]","metadata":null},{"id":"64ba696272f6499c947a0f4ea1b7f3cb","type":"GO_TERM","name":"lactone metabolic process","canonical_id":"go:GO:1901334","description":"\"The chemical reactions and pathways involving lactone.\" [GOC:TermGenie]","metadata":null},{"id":"77ad21a30d724441a256e50a1b5060b0","type":"GO_TERM","name":"lactonohydrolase activity","canonical_id":"go:GO:0046573","description":"\"Catalysis of the hydrolysis of lactone rings (intramolecular cyclic esters) to produce a hydroxyl group and a carboxyl group.\" [PMID:11640988]","metadata":null},{"id":"85e041e3f2154d95aacdd1a5ef51047f","type":"GO_TERM","name":"lactoperoxidase activity","canonical_id":"go:GO:0140825","description":"\"Catalysis of the reaction: 2 a phenolic donor + H2O2 = 2 a phenolic radical donor + 2 H2O.\" [PMID:19339248, RHEA:56136]","metadata":null},{"id":"048c27d49216428db5efef6260f6cf3e","type":"GO_TERM","name":"lactose binding","canonical_id":"go:GO:0030395","description":"\"Binding to lactose, a disaccharide of glucose and galactose, the carbohydrate of milk.\" [GOC:jl, ISBN:0192800981]","metadata":null},{"id":"7bc7635745f141e39d86d03f1af0bf6e","type":"GO_TERM","name":"lactose biosynthetic process","canonical_id":"go:GO:0005989","description":"\"The chemical reactions and pathways resulting in the formation of lactose, the disaccharide galactopyranosyl-glucose.\" [GOC:curators]","metadata":null},{"id":"ad4931e2b96749f097f62f24323f7cfe","type":"GO_TERM","name":"lactose catabolic process","canonical_id":"go:GO:0005990","description":"\"The chemical reactions and pathways resulting in the breakdown of lactose, the disaccharide galactopyranosyl-glucose.\" [GOC:curators]","metadata":null},{"id":"9c0b755b283047679756b65073aa54c2","type":"GO_TERM","name":"lactose metabolic process","canonical_id":"go:GO:0005988","description":"\"The chemical reactions and pathways involving lactose, the disaccharide galactopyranosyl-glucose.\" [GOC:curators]","metadata":null},{"id":"4ce0d1cf9b584ed681de08aaf8047117","type":"GO_TERM","name":"lactose synthase activity","canonical_id":"go:GO:0004461","description":"\"Catalysis of the reaction: UDP-galactose + D-glucose = UDP + lactose.\" [EC:2.4.1.22]","metadata":null},{"id":"62e2a69aae9644a5b757c236c56e06b6","type":"GO_TERM","name":"lactose transmembrane transporter activity","canonical_id":"go:GO:0015155","description":"\"Enables the transfer of lactose from one side of a membrane to the other. Lactose is a disaccharide 4-O-beta-D-galactopyranosyl-D-glucose, and constitutes roughly 5% of the milk in almost all mammals.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"592469cbb90d49bc8491ab0d04947676","type":"GO_TERM","name":"lactose transport","canonical_id":"go:GO:0015767","description":"\"The directed movement of lactose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lactose is a disaccharide 4-O-beta-D-galactopyranosyl-D-glucose, and constitutes roughly 5% of the milk in almost all mammals.\" [GOC:ai]","metadata":null},{"id":"61a37c5baac04810a5d72ee72ae08348","type":"GO_TERM","name":"lactose:proton symporter activity","canonical_id":"go:GO:0015528","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: lactose(out) + H+(out) = lactose(in) + H+(in).\" [TC:2.A.1.1.9, TC:2.A.1.5.1]","metadata":null},{"id":"d94a07da1e554b45a248c2219cab7205","type":"GO_TERM","name":"lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase activity","canonical_id":"go:GO:0047256","description":"\"Catalysis of the reaction: a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + UDP-N-acetyl-alpha-D-glucosamine = a beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + H+ + UDP.\" [RHEA:13905]","metadata":null},{"id":"52ca364d88804be1ae9ad3d70001f4ff","type":"GO_TERM","name":"lactosylceramide 4-alpha-galactosyltransferase activity","canonical_id":"go:GO:0050512","description":"\"Catalysis of the reaction: beta-D-galactosyl-(1,4)-D-glucosylceramide + UDP-galactose = alpha-D-galactosyl-(1,4)-beta-D-galactosyl-(1,4)-D-glucosylceramide + UDP.\" [EC:2.4.1.228, MetaCyc:2.4.1.228-RXN]","metadata":null},{"id":"70d6a9908c2b4b679153427420a3ce5e","type":"GO_TERM","name":"lactosylceramide alpha-2,3-sialyltransferase activity","canonical_id":"go:GO:0047291","description":"\"Catalysis of the reaction: cytolipin-H + CMP-N-acetylneuraminate = alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide + CMP. Alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1,4-beta-D-glucosylceramide is also known as GM3.\" [EC:2.4.3.9, MetaCyc:2.4.99.9-RXN]","metadata":null},{"id":"489906dc6b4148eab9fd847cfacf0671","type":"GO_TERM","name":"lactosylceramide beta-1,3-galactosyltransferase activity","canonical_id":"go:GO:0047240","description":"\"Catalysis of the reaction: D-galactosyl-(1->4)-beta-D-glucosyl-R + UDP-D-galactose = D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-R + H+ + UDP.\" [EC:2.4.1.179, RHEA:18413]","metadata":null},{"id":"875a6888c92b4bd18663fe5e11498f26","type":"GO_TERM","name":"lactosylceramide biosynthetic process","canonical_id":"go:GO:0001572","description":"\"The chemical reactions and pathways resulting in the formation of lactosylceramides that begins with the synthesis of a disaccharide core 4-Gal-beta-1,4-Glc-ceramide. This core can be further elongated with the sequential addition of various carbohydrate units and is also the precursor for the synthesis of gangliosides, globosides and isoglobosides.\" [PMID:35536927]","metadata":null},{"id":"4b946e8dac7d48f88efc26e782c24e2c","type":"GO_TERM","name":"lactoyl-CoA dehydratase activity","canonical_id":"go:GO:0018819","description":"\"Catalysis of the reaction: (R)-lactoyl-CoA = acryloyl-CoA + H2O.\" [RHEA:34691]","metadata":null},{"id":"8365e117f8214126b740b839a7994d37","type":"GO_TERM","name":"lactoylglutathione lyase activity","canonical_id":"go:GO:0004462","description":"\"Catalysis of the reaction: (R)-S-lactoylglutathione = glutathione + methylglyoxal.\" [EC:4.4.1.5, RHEA:19069]","metadata":null},{"id":"92d8548cd3a64206a492702667753c5a","type":"DRUG","name":"lactulose","canonical_id":"mesh:D007792","description":null,"metadata":null},{"id":"c6a2a9c546124d509db7a1664309f556","type":"GO_TERM","name":"ladanein 6-O-methyltransferase activity","canonical_id":"go:GO:0102535","description":"\"Catalysis of the reaction: ladanein + S-adenosyl-L-methionine = H+ + S-adenosyl-L-homocysteine + salvigenin.\" [RHEA:73247]","metadata":null},{"id":"cdcf5b2b228f42c99953045771eef11b","type":"DRUG","name":"lafutidine","canonical_id":"mesh:C076948","description":null,"metadata":null},{"id":"b0403297b6cd40b6b66b07168c184fc6","type":"GO_TERM","name":"lagging strand elongation","canonical_id":"go:GO:0006273","description":"\"The process in which an existing DNA strand is extended in a net 3' to 5' direction by activities including the addition of nucleotides to the 3' end of the strand, complementary to an existing template, as part of DNA replication. Lagging strand DNA elongation proceeds by discontinuous synthesis of short stretches of DNA, known as Okazaki fragments, from RNA primers; these fragments are then joined by DNA ligase. Although each segment of nascent DNA is synthesized in the 5' to 3' direction, the overall direction of lagging strand synthesis is 3' to 5', mirroring the progress of the replication fork.\" [GOC:mah, ISBN:071673706X, ISBN:0815316194]","metadata":null},{"id":"361c8bcd26df454fb329364e518e8449","type":"GO_TERM","name":"lagging strand initiation","canonical_id":"go:GO:0090629","description":"\"The process in which the synthesis of DNA from a template strand in a net 3' to 5' direction is started.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"292111a146264d8fb616bff8c787e148","type":"GO_TERM","name":"lambda-carrageenase activity","canonical_id":"go:GO:0033957","description":"\"Catalysis of the endohydrolysis of beta-1,4-linkages in the backbone of lambda-carrageenan, resulting in the tetrasaccharide alpha-D-Galp2,6S2-(1->3)-beta-D-Galp2S-(1->4)-alpha-D-Galp2,6S2-(1->3)-D-Galp2S.\" [EC:3.2.1.162]","metadata":null},{"id":"0e95b4fd77f0434ca2b31dda0576c3cf","type":"GO_TERM","name":"lambdoid suture morphogenesis","canonical_id":"go:GO:0060366","description":"\"The process in which the lambdoid suture is generated and organized.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"af43cb5c6c2541279ec798cb435de221","type":"GO_TERM","name":"lamellar body","canonical_id":"go:GO:0042599","description":"\"A membrane-bounded organelle, specialized for the storage and secretion of various substances (surfactant phospholipids, glycoproteins and acid phosphates) which are arranged in the form of tightly packed, concentric, membrane sheets or lamellae. Has some similar properties to, but is distinct from, a lysosome.\" [GOC:cjm, GOC:jl, PMID:12243725, Wikipedia:Lamellar_granule]","metadata":null},{"id":"4c244f0a255c4f6287ad4b99ee4aedf4","type":"GO_TERM","name":"lamellar body membrane","canonical_id":"go:GO:0097232","description":"\"The lipid bilayer surrounding a lamellar body. A lamellar body is a membrane-bounded organelle, specialized for the storage and secretion of various substances (surfactant phospholipids, glycoproteins and acid phosphates) which are arranged in the form of tightly packed, concentric, membrane sheets or lamellae. Has some similar properties to, but is distinct from, a lysosome.\" [GOC:sl, PMID:11940594]","metadata":null},{"id":"c807ad96000d4d17acbfa7623d502173","type":"GO_TERM","name":"lamellipodium","canonical_id":"go:GO:0030027","description":"\"A thin sheetlike process extended by the leading edge of a migrating cell or extending cell process; contains a dense meshwork of actin filaments.\" [ISBN:0815316194]","metadata":null},{"id":"8776fc63667641b6940c9bdb17819eab","type":"GO_TERM","name":"lamellipodium assembly","canonical_id":"go:GO:0030032","description":"\"Formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"7e31433e3aba4f8ebb840d1fa885adc5","type":"GO_TERM","name":"lamellipodium assembly involved in ameboidal cell migration","canonical_id":"go:GO:0003363","description":"\"Formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell that contributes to the directed self propelled movement of a cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"f6cbac1bff70449aa1b465d49795d24e","type":"GO_TERM","name":"lamellipodium membrane","canonical_id":"go:GO:0031258","description":"\"The portion of the plasma membrane surrounding a lamellipodium.\" [GOC:mah]","metadata":null},{"id":"eb5a5ffc0e114804ac287f6a205ada70","type":"GO_TERM","name":"lamellipodium morphogenesis","canonical_id":"go:GO:0072673","description":"\"A process that is carried out at the cellular level and in which the structure of a lamellipodium is organized.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"f149bd3a81a24cd49d4066fb99c90801","type":"GO_TERM","name":"lamellipodium organization","canonical_id":"go:GO:0097581","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lamellipodium. A lamellipodium is a thin sheetlike process extended by the leading edge of a crawling fibroblast; contains a dense meshwork of actin filaments.\" [GOC:als, PMID:16054028]","metadata":null},{"id":"588743d47cc04a95807b045104a14f35","type":"GO_TERM","name":"lamellocyte differentiation","canonical_id":"go:GO:0035171","description":"\"The process in which a relatively unspecialized hemocyte precursor cell acquires the specialized features of a lamellocyte. Lamellocytes are a hemocyte lineage that exists only in larvae, but are seldom observed in healthy animals. Lamellocytes differentiate massively in the lymph glands after parasitization and are large flat cells devoted to encapsulation of invaders too large to be phagocytosed by plasmatocytes.\" [GOC:bf, PMID:14734104]","metadata":null},{"id":"28c3ce83e1e04aebbd245c96ae89880d","type":"GO_TERM","name":"lamin binding","canonical_id":"go:GO:0005521","description":"\"Binding to lamin; any of a group of intermediate-filament proteins that form the fibrous matrix on the inner surface of the nuclear envelope.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"6dee413dc9e04f45a399898f07fa6d3d","type":"GO_TERM","name":"lamin depolymerization","canonical_id":"go:GO:0007078","description":"\"The cell cycle process in which lamin is depolymerized.\" [GOC:jid]","metadata":null},{"id":"52d0250d22f84679913eb10f317fc3fe","type":"GO_TERM","name":"lamin filament","canonical_id":"go:GO:0005638","description":"\"Any of a group of intermediate-filament proteins that form the fibrous matrix on the inner surface of the nuclear envelope. They are classified as lamins A, B and C.\" [ISBN:0198547684]","metadata":null},{"id":"972e092aa79a4510af310228e7945d1b","type":"GO_TERM","name":"lamina terminalis formation","canonical_id":"go:GO:0021996","description":"\"The process in which the anterior-most portion of the neural axis is formed by closure of the anterior neuropore.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e4a4387aaa314a939adcb76e11661f4a","type":"GO_TERM","name":"laminaribiose binding","canonical_id":"go:GO:0044588","description":"\"Binding to laminaribiose, a disaccharide.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"2bfb5ef6332a4f27bbde2987e4c698f0","type":"GO_TERM","name":"laminaribiose phosphorylase activity","canonical_id":"go:GO:0050045","description":"\"Catalysis of the reaction: 3-beta-D-glucosyl-D-glucose + phosphate = D-glucose + alpha-D-glucose 1-phosphate.\" [EC:2.4.1.31]","metadata":null},{"id":"6af918a8bbd947a098ab15c750536f91","type":"GO_TERM","name":"laminaritriose transport","canonical_id":"go:GO:2001097","description":"\"The directed movement of a laminaritrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"befd1d39778248f08665bd822a483872","type":"GO_TERM","name":"laminated body","canonical_id":"go:GO:1990011","description":"\"Inclusion body characterized by regularly spaced sheets of tubules arranged in a whorl pattern resembling a fingerprint. Laminated bodies have been observed in neurons of the lateral geniculate nucleus.\" [ISBN:0195065719, NIF_Subcellular:sao506721981]","metadata":null},{"id":"48180b29e4bb499fa334a91cd078a2ab","type":"GO_TERM","name":"laminin binding","canonical_id":"go:GO:0043236","description":"\"Binding to a laminin, a major glycoprotein constituent of the basement membrane of cells.\" [GOC:ecd]","metadata":null},{"id":"9ea9b9492db94de19ed48ccfecc7e7d6","type":"GO_TERM","name":"laminin binding involved in cell-matrix adhesion","canonical_id":"go:GO:0098638","description":"\"Any laminin protein binding that occurs as part of cell-matrix adhesion.\" [GOC:dos]","metadata":null},{"id":"1724fa2c4fda4c9386ab34f634b83e90","type":"GO_TERM","name":"laminin network","canonical_id":"go:GO:0140349","description":"\"A supramolecular network that forms mainly through linkages of the short laminin arms between the N-terminal regions of one alpha, one beta, and one gamma chain. The laminin network associates with the collagen network to create the stable, sheet-like structure of the basement membrane ECM.\" [PMID:1577869, PMID:21421915, PMID:23263632, PMID:28187500]","metadata":null},{"id":"c26900479fb34775a8aee7febe4d6c2d","type":"GO_TERM","name":"laminin receptor activity","canonical_id":"go:GO:0005055","description":"\"Combining with a laminin, a glycoprotein that constitutes the majority of proteins in the basement membrane, to initiate a change in cell activity.\" [GOC:ai, PMID:2970671]","metadata":null},{"id":"f79b0468c17e4fedb2b6b21c9891dbe4","type":"GO_TERM","name":"laminin trimer","canonical_id":"go:GO:0043256","description":"\"A large, extracellular glycoprotein complex composed of three different polypeptide chains, alpha, beta and gamma. Provides an integral part of the structural scaffolding of basement membranes.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"745c9bfcc1d14de1b4a1d37d98688e84","type":"GO_TERM","name":"laminin-1 binding","canonical_id":"go:GO:0043237","description":"\"Binding to laminin-1, a glycoprotein trimer with the subunit composition alpha1, beta1, gamma1.\" [GOC:curators]","metadata":null},{"id":"63ccbb7faa184ff89df246d60f10e99e","type":"GO_TERM","name":"laminin-111 trimer","canonical_id":"go:GO:0005606","description":"\"A laminin complex composed of alpha1, beta1 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"3038efe7932e4d549d28f7a626d61ba3","type":"GO_TERM","name":"laminin-121 trimer","canonical_id":"go:GO:0005608","description":"\"A laminin complex composed of alpha1, beta2 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"7fbb92a456464e508ff3d369afaa2db9","type":"GO_TERM","name":"laminin-211 trimer","canonical_id":"go:GO:0005607","description":"\"A laminin complex composed of alpha2, beta1 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"ec3ce47525e34b81843fb7f2f5630d91","type":"GO_TERM","name":"laminin-213 trimer","canonical_id":"go:GO:0043261","description":"\"A laminin complex composed of alpha2, beta1 and gamma3 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"32214760f965405eaa6eda3fe2bab9c6","type":"GO_TERM","name":"laminin-221 trimer","canonical_id":"go:GO:0005609","description":"\"A laminin complex composed of alpha2, beta2 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"37c2b53107b7411dbfbfababb2244bc3","type":"GO_TERM","name":"laminin-311 trimer","canonical_id":"go:GO:0005611","description":"\"A laminin complex composed of alpha3, beta1 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"77d3debf17064c3d93c92039da0bb51e","type":"GO_TERM","name":"laminin-321 trimer","canonical_id":"go:GO:0005612","description":"\"A laminin complex composed of alpha3, beta2 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"971f759134364c3ba5cacc10cb1ab401","type":"GO_TERM","name":"laminin-332 trimer","canonical_id":"go:GO:0005610","description":"\"A laminin complex composed of alpha3, beta3 and gamma2 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"0b1f1241bcb649de99bd048847198636","type":"GO_TERM","name":"laminin-3B32 trimer","canonical_id":"go:GO:0061801","description":"\"A laminin complex composed of alpha3B, beta3 and gamma2 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"adcf5c9085264b17841d1443ffcca2bf","type":"GO_TERM","name":"laminin-411 trimer","canonical_id":"go:GO:0043257","description":"\"A laminin complex composed of alpha4, beta1 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"ed9fecb317444ef9bcc21aebaeac8337","type":"GO_TERM","name":"laminin-421 trimer","canonical_id":"go:GO:0043258","description":"\"A laminin complex composed of alpha4, beta2 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"5548ee4846994cd0876f1a5b1ed28a4b","type":"GO_TERM","name":"laminin-423 trimer","canonical_id":"go:GO:1990338","description":"\"A laminin complex composed of alpha4, beta2 and gamma3 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"b99eb4435b42400d897d045543f436ce","type":"GO_TERM","name":"laminin-511 trimer","canonical_id":"go:GO:0043259","description":"\"A laminin complex composed of alpha5, beta1 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"7740a23885fe43f1bca00c1162d264e7","type":"GO_TERM","name":"laminin-521 trimer","canonical_id":"go:GO:0043260","description":"\"A laminin complex composed of alpha5, beta2 and gamma1 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"1aeb5e62144f42ab8acf4c8e509780d4","type":"GO_TERM","name":"laminin-522 trimer","canonical_id":"go:GO:1990339","description":"\"A laminin complex composed of alpha5, beta2 and gamma2 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"c7b9ced3e21c4cb998b2697f902c856f","type":"GO_TERM","name":"laminin-523 trimer","canonical_id":"go:GO:1990340","description":"\"A laminin complex composed of alpha5, beta2 and gamma3 polypeptide chains.\" [PMID:15979864, PMID:21421915, PMID:23263632]","metadata":null},{"id":"0679857486b6482d87edd7e8de170c1a","type":"DRUG","name":"lamivudine","canonical_id":"mesh:D019259","description":null,"metadata":null},{"id":"ebab39e60c7449e58a8233c859b71383","type":"DRUG","name":"lamotrigine","canonical_id":"mesh:C047781","description":null,"metadata":null},{"id":"17ae95cb08954b8996bb6ae48b10d357","type":"DRUG","name":"lanadelumab","canonical_id":"gtopdb:9094","description":null,"metadata":null},{"id":"42b26ee62ac44d11a228dd2eb872648d","type":"DRUG","name":"lanadelumab","canonical_id":"chembl:CHEMBL3545189","description":null,"metadata":null},{"id":"d41271dc5f7a41fbb229556e80c6ad25","type":"DRUG","name":"landiolol","canonical_id":"mesh:C077049","description":null,"metadata":null},{"id":"a4f500388f8446d5b86290cfbd83fd92","type":"GO_TERM","name":"lanosterol O-acyltransferase activity","canonical_id":"go:GO:0034738","description":"\"Catalysis of the reaction: acyl-CoA + lanosterol = CoA + lanosterol ester.\" [GOC:mah]","metadata":null},{"id":"fb8cab27eccd4a1599383876fa8ed85e","type":"GO_TERM","name":"lanosterol synthase activity","canonical_id":"go:GO:0000250","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = lanosterol. This is a cyclization reaction that forms the sterol nucleus.\" [EC:5.4.99.7, RHEA:14621]","metadata":null},{"id":"ba41033b7ac246518ea7873e6456002e","type":"DRUG","name":"lanreotide","canonical_id":"gtopdb:2031","description":null,"metadata":null},{"id":"3dc8e1bb650d4abe849d7300516006ee","type":"DRUG","name":"lanreotide","canonical_id":"mesh:C060347","description":null,"metadata":null},{"id":"391b59cd325849d3a72bb3c42109c5e1","type":"COMBINATION_TREATMENT","name":"lanreotide + pasireotide","canonical_id":"ctgov_combo:ctgov-combo-7b91c12a0a5b162d","description":null,"metadata":null},{"id":"bd2cd7ddb628400f932b759966a04ea4","type":"COMBINATION_TREATMENT","name":"lanreotide + pegvisomant","canonical_id":"ctgov_combo:ctgov-combo-9dcb74a59249ea10","description":null,"metadata":null},{"id":"f86853d690654d379b9e66ce47049f61","type":"COMBINATION_TREATMENT","name":"lanreotide + pegvisomant","canonical_id":"ctgov_combo:ctgov-combo-544103b4d43e4aa4","description":null,"metadata":null},{"id":"33fd5e48d0f748d48b7581a4eb83e830","type":"DRUG","name":"lansoprazole","canonical_id":"mesh:D064747","description":null,"metadata":null},{"id":"9f90efb116524e4ba57776de4273e7c1","type":"DRUG","name":"lapatinib","canonical_id":"gtopdb:5692","description":null,"metadata":null},{"id":"99a201c605174235b4c485e199a605c3","type":"COMBINATION_TREATMENT","name":"lapatinib + neratinib","canonical_id":"ctgov_combo:ctgov-combo-feba5d54a95016ed","description":null,"metadata":null},{"id":"020498f09eb64ca5b3c55b69aae15261","type":"COMBINATION_TREATMENT","name":"lapatinib + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-0d80d720ec25df16","description":null,"metadata":null},{"id":"9dae38bc836f4600bcad9eb60b5f7291","type":"COMBINATION_TREATMENT","name":"lapatinib + pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-843af787ca8280fd","description":null,"metadata":null},{"id":"43639ff9483b4842a74f979d821168ba","type":"COMBINATION_TREATMENT","name":"lapatinib + pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-95ece97f7a5cc5dd","description":null,"metadata":null},{"id":"136b6d3c7ef545a5a0c811b513a225e5","type":"COMBINATION_TREATMENT","name":"lapatinib + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-a4ef25cfd1397221","description":null,"metadata":null},{"id":"339b2f910bd44b5c930d4a1c40730edb","type":"COMBINATION_TREATMENT","name":"lapatinib + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-81e32e8f5aa224b4","description":null,"metadata":null},{"id":"e89bad0682fb4191a4b05a97d2aa1ef9","type":"DRUG","name":"laquinimod","canonical_id":"mesh:C476223","description":null,"metadata":null},{"id":"7b3a2cccfcd94963abbc830db74ed700","type":"GO_TERM","name":"large conductance calcium-activated potassium channel activity","canonical_id":"go:GO:0060072","description":"\"Enables the transmembrane transfer of potassium by a channel with a unit conductance of 100 to 220 picoSiemens that opens in response to stimulus by concerted actions of internal calcium ions and membrane potential. Large conductance calcium-activated potassium channels are less sensitive to calcium than are small or intermediate conductance calcium-activated potassium channels. Transport by a channel involves catalysis of facilitated diffusion of a solute (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel, without evidence for a carrier-mediated mechanism.\" [GOC:mtg_transport, ISBN:0815340729, PMID:17115074]","metadata":null},{"id":"0287405bd9f542c2af3509e3ca7585b9","type":"GO_TERM","name":"large intestinal transit","canonical_id":"go:GO:0120056","description":"\"Migration of ingested material along the length of the large intestine.\" [GOC:sl, PMID:28157109]","metadata":null},{"id":"716f3f6e98654d6a9451ff57bb46f1c0","type":"GO_TERM","name":"large latent transforming growth factor-beta complex","canonical_id":"go:GO:0038045","description":"\"A protein complex containing latency-associated proteins (LAPs), mature disulphide-linked dimeric TGF-beta, and latent TGF-beta binding proteins (LTBPs). TGF-beta is mostly secreted as part of the large latent complex, and must be subsequently released from the LLC in order to bind to cell surface receptors.\" [GOC:bf, PMID:2350783, PMID:8680476, PMID:9805445]","metadata":null},{"id":"19f225439ee84aa8adfadc15cdba0924","type":"GO_TERM","name":"large ribosomal subunit","canonical_id":"go:GO:0015934","description":"\"The larger of the two subunits of a ribosome. Two sites on the ribosomal large subunit are involved in translation, namely the aminoacyl site (A site) and peptidyl site (P site).\" [ISBN:0198506732]","metadata":null},{"id":"5337feccea214c07a2577aa9f04e99e1","type":"GO_TERM","name":"large ribosomal subunit pre-assembly complex","canonical_id":"go:GO:0140714","description":"\"A protein complex that assists early maturation of nascent 60S ribosomal subunits. The complex interacts with the large ribosomal subunit rRNA via one of the components (Urb2 in S. cerevisiae) and requires a RNA helicase (Dbp6 in S. cerevisiae).\" [GOC:lnp, PMID:17145778, PMID:9528757]","metadata":null},{"id":"a0abca837f3f4b308822c1547a9669b6","type":"GO_TERM","name":"large ribosomal subunit rRNA binding","canonical_id":"go:GO:0070180","description":"\"Binding to large ribosomal subunit RNA (LSU rRNA), a constituent of the large ribosomal subunit. In S. cerevisiae, this is the 25S rRNA.\" [GOC:elh]","metadata":null},{"id":"f34d6205a1c44675b560039f37919c71","type":"GO_TERM","name":"lariciresinol reductase activity","canonical_id":"go:GO:0010284","description":"\"Catalysis of the reaction: lariciresinol + NADPH + H+ = secoisolariciresinol + NADP+.\" [PMID:10066819, PMID:7592828]","metadata":null},{"id":"14f9057b851d428690acc3a4d5270864","type":"GO_TERM","name":"laricitrin 5'-O-methyltransferase activity","canonical_id":"go:GO:0070448","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + laricitrin = S-adenosyl-L-homocysteine + syringetin.\" [RHEA:25633]","metadata":null},{"id":"0b6c63b6f0894938bd156fa11a5ba8e5","type":"GO_TERM","name":"larval behavior","canonical_id":"go:GO:0030537","description":"\"Behavior in a larval form of an organism, an immature organism that must undergo metamorphosis to assume adult characteristics.\" [GOC:mah, ISBN:0877797099]","metadata":null},{"id":"0e7e762fc2464c92ab51c810a7a84d2f","type":"GO_TERM","name":"larval burrowing behavior","canonical_id":"go:GO:0035181","description":"\"Digging into the substrate by non-feeding larvae in search for food-free sites suitable for pupation.\" [PMID:12848927, PMID:12848939]","metadata":null},{"id":"f51fddc7941f4f20bd8a46af8134829d","type":"GO_TERM","name":"larval central nervous system remodeling","canonical_id":"go:GO:0035193","description":"\"Reorganization of the pre-existing, functional larval central nervous system into one that can serve the novel behavioral needs of the adult. An example of this process is found in Drosophila melanogaster.\" [GOC:sensu, PMID:9647692]","metadata":null},{"id":"e5a727a95da14b0ca31614370165ec1f","type":"GO_TERM","name":"larval chitin-based cuticle development","canonical_id":"go:GO:0008363","description":"\"Synthesis and deposition of a chitin-based larval cuticle. The insect larval cuticle is a secretion from epidermal cells that is shed at each molt. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"cea29eb818cd4d9a9998374421d5056e","type":"GO_TERM","name":"larval development","canonical_id":"go:GO:0002164","description":"\"The process whose specific outcome is the progression of the larva over time, from its formation to the mature structure. The larva is the early, immature form of an that at birth or hatching is fundamentally unlike its parent and must metamorphose before assuming the adult characters.\" [GOC:jid, ISBN:0877795088]","metadata":null},{"id":"44ab6b517bdc4231af659bbad48692b4","type":"GO_TERM","name":"larval fat body development","canonical_id":"go:GO:0007504","description":"\"The process whose specific outcome is the progression of the larval fat body over time, from its formation to the mature structure. The larval fat body consists of a bilaterally symmetrical monolayer of cells lying between the gut and the muscles of the body wall. As in other tissues of the larva, the cells of the fat body complete their divisions in the embryo and increase in size and ploidy during larval life.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"eefdd001891045cb8111165eb4776716","type":"GO_TERM","name":"larval feeding behavior","canonical_id":"go:GO:0030536","description":"\"Feeding behavior in a larval (immature) organism.\" [GOC:mah]","metadata":null},{"id":"81e33cd9b1bb48de865df176535454bf","type":"GO_TERM","name":"larval foraging behavior","canonical_id":"go:GO:0035177","description":"\"The movement of a larva through a feeding substrate whilst feeding on food.\" [PMID:12848927]","metadata":null},{"id":"5047055346d046209617d7a052b71ee0","type":"GO_TERM","name":"larval heart development","canonical_id":"go:GO:0007508","description":"\"The process whose specific outcome is the progression of the larval heart over time, from its formation to the mature structure. In Drosophila the larval heart (dorsal vessel) is a continuous tube of mesodormal cells that runs beneath the dorsal midline of the epidermis, divided into an anterior aorta and a posterior heart proper.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"04e4fdf9780a4a0c986df919d041ed48","type":"GO_TERM","name":"larval locomotory behavior","canonical_id":"go:GO:0008345","description":"\"Locomotory behavior in a larval (immature) organism.\" [GOC:ai]","metadata":null},{"id":"5f1d10399c7747d2a4a7c2b67920d92f","type":"GO_TERM","name":"larval lymph gland hemocyte differentiation","canonical_id":"go:GO:0035168","description":"\"The process in which a relatively unspecialized cell derived from the larval lymph gland acquires the specialized features of a mature hemocyte. The lymph gland consists of three to six bilaterally paired lobes that are attached to the cardioblasts during larval stages, and it degenerates during pupal stages. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, PMID:14602069]","metadata":null},{"id":"bf7b31325b7c4e84a74d24b88795b66a","type":"GO_TERM","name":"larval lymph gland hemopoiesis","canonical_id":"go:GO:0035167","description":"\"The production of blood cells from the larval lymph gland. The lymph gland consists of three to six bilaterally paired lobes that are attached to the cardioblasts during larval stages, and it degenerates during pupal stages.\" [GOC:bf, GOC:mtg_sensu, PMID:12445385]","metadata":null},{"id":"4c6c3b5e25d84d71af20979bc59d5a27","type":"GO_TERM","name":"larval midgut cell programmed cell death","canonical_id":"go:GO:0035096","description":"\"The stage-specific programmed cell death of cells of the larval midgut, during histolysis of the larval organ.\" [GOC:bf, GOC:mtg_apoptosis]","metadata":null},{"id":"8fc9e693f9d64275af7116ffcc4b0206","type":"GO_TERM","name":"larval midgut histolysis","canonical_id":"go:GO:0035069","description":"\"The stage-specific break down of the larval midgut during Drosophila metamorphosis, to allow replacement of larval structures by tissues and structures that form the adult fly.\" [GOC:bf, GOC:dph, GOC:mtg_apoptosis, PMID:9409683]","metadata":null},{"id":"b172e06800c648baa53f968a9f52c02e","type":"GO_TERM","name":"larval salivary gland boundary specification","canonical_id":"go:GO:0007433","description":"\"Determination in a larval organism of where the salivary gland forms, the total number of salivary gland cells and how many cells are allocated to each of the specialised cell types within the salivary gland.\" [GOC:tb, PMID:11598957]","metadata":null},{"id":"d36c280b76b14c9ca854e3593142fd47","type":"GO_TERM","name":"larval salivary gland morphogenesis","canonical_id":"go:GO:0007436","description":"\"The process, occurring in the larva, by which the anatomical structures of the salivary gland are generated and organized.\" [GOC:jid]","metadata":null},{"id":"eecd1ae8452a4908a8a0991f66c38060","type":"GO_TERM","name":"larval serum protein complex","canonical_id":"go:GO:0005616","description":"\"A multisubunit protein complex which, in Drosophila, is a heterohexamer of three subunits, alpha, beta and gamma. The complex is thought to store amino acids for synthesis of adult proteins.\" [GOC:jl, PMID:6781759]","metadata":null},{"id":"6468681ec9f54d6888ee83c8af41755c","type":"GO_TERM","name":"larval somatic muscle development","canonical_id":"go:GO:0007526","description":"\"The process whose specific outcome is the progression of the larval somatic muscle over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"374d8246a4e6433886697e941486389a","type":"GO_TERM","name":"larval visceral muscle development","canonical_id":"go:GO:0007523","description":"\"The process whose specific outcome is the progression of the larval visceral muscle over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"6ed1fa5271f04588af85b06bb4f98b19","type":"GO_TERM","name":"larval walking behavior","canonical_id":"go:GO:0008346","description":"\"The behavior of a larval organism relating to the progression of that organism along the ground by the process of lifting and setting down each leg.\" [GOC:curators, GOC:pr]","metadata":null},{"id":"9681001c2f64422ab06cde00135b2e85","type":"GO_TERM","name":"larval wandering behavior","canonical_id":"go:GO:0035180","description":"\"The movement of a third instar larva through a substrate in search of a pupation site. This movement occurs without feeding and is characterized by short bursts of forward movement, separated by stops and repeated side-to-side head probes, followed normally by a change in direction.\" [PMID:12848927, PMID:12956960]","metadata":null},{"id":"764b08f1997341ee8f531f46b640e06d","type":"GO_TERM","name":"larynx development","canonical_id":"go:GO:0120224","description":"\"The biological process whose specific outcome is the progression of a larynx from an initial condition to its mature state. This process begins with the formation of the larynx and ends with the mature structure. A larynx is a continuation of the pharynx that is involved in breathing, sound production, and protecting the trachea against food aspiration.\" [GOC:krc, PMID:28177282]","metadata":null},{"id":"4d5ed32f63f04f23bc8dfa7d2feaea4d","type":"GO_TERM","name":"larynx morphogenesis","canonical_id":"go:GO:0120223","description":"\"The process in which the larynx is generated and organized. The larynx is a continuation of the pharynx that is involved in breathing, sound production, and protecting the trachea against food aspiration.\" [GOC:krc, PMID:28177282]","metadata":null},{"id":"b69ca25f164f42f6a5a96ffa060076f0","type":"DRUG","name":"lasofoxifene","canonical_id":"mesh:C111332","description":null,"metadata":null},{"id":"3a778a88fbcd4e588f2c4a0b6b585503","type":"DRUG","name":"latanoprost (free acid form)","canonical_id":"gtopdb:1960","description":null,"metadata":null},{"id":"fdb5e4d5dc2543fd8fea23313fdc0a98","type":"DRUG","name":"latanoprost (isopropyl ester)","canonical_id":"gtopdb:1961","description":null,"metadata":null},{"id":"6e727ad87ecd46bf95f795c328a612a1","type":"DRUG","name":"latanoprost (isopropyl ester)","canonical_id":"chembl:CHEMBL1051","description":null,"metadata":null},{"id":"c8d58a8fec254561b37c75d15f6223b0","type":"GO_TERM","name":"late distal convoluted tubule development","canonical_id":"go:GO:0072068","description":"\"The process whose specific outcome is the progression of the late distal convoluted tubule over time, from its formation to the mature structure. The late distal convoluted tubule contains DCT cells and intercalated (IC) alpha and beta cells and is vasopressin-sensitive.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f79d5e830b9747c0908f0800d1b157af","type":"GO_TERM","name":"late endosomal microautophagy","canonical_id":"go:GO:0061738","description":"\"The autophagy process by which cytosolic proteins targeted for degradation are tagged with a chaperone and are directly transferred into and degraded in a late endosomal compartment.\" [GOC:autophagy, GOC:dph, GOC:pad, GOC:PARL, PMID:21238931]","metadata":null},{"id":"1d39e3374a924f70a4798be5c9998d09","type":"GO_TERM","name":"late endosome","canonical_id":"go:GO:0005770","description":"\"A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center.\" [NIF_Subcellular:nlx_subcell_20090702, PMID:11964142, PMID:2557062]","metadata":null},{"id":"6efcd55e9c544463a2823a1d1f2dfdc7","type":"GO_TERM","name":"late endosome lumen","canonical_id":"go:GO:0031906","description":"\"The volume enclosed by the membrane of a late endosome.\" [GOC:mah]","metadata":null},{"id":"f82f382f1d3c4a3abac4ba73525d48f9","type":"GO_TERM","name":"late endosome membrane","canonical_id":"go:GO:0031902","description":"\"The lipid bilayer surrounding a late endosome.\" [GOC:pz]","metadata":null},{"id":"6b6fe594e50841d88732ac3dccf7457f","type":"GO_TERM","name":"late endosome to Golgi transport","canonical_id":"go:GO:0034499","description":"\"The directed movement of substances from late endosomes to the Golgi.\" [GOC:rb]","metadata":null},{"id":"89bb575a7a214b8abe73f477e41d6a90","type":"GO_TERM","name":"late endosome to lysosome transport","canonical_id":"go:GO:1902774","description":"\"The directed movement of substances from late endosome to lysosome.\" [GO_REF:0000076, GOC:TermGenie, PMID:23949442]","metadata":null},{"id":"6735ce9a58d84cdcbf842264a63b7f58","type":"GO_TERM","name":"late endosome to lysosome transport via multivesicular body sorting pathway","canonical_id":"go:GO:0061764","description":"\"The directed movement of substances from late endosomes to lysosomes by a pathway in which molecules are sorted into multivesicular bodies, which then fuse with the lysosome.\" [GOC:dph]","metadata":null},{"id":"e33b8e7e3c554ba9bb0a984290929fd4","type":"GO_TERM","name":"late endosome to vacuole transport","canonical_id":"go:GO:0045324","description":"\"The directed movement of substances from late endosomes to the vacuole. In yeast, after transport to the prevacuolar compartment, endocytic content is delivered to the late endosome and on to the vacuole. This pathway is analogous to endosome to lysosome transport.\" [PMID:11872141]","metadata":null},{"id":"3f513d570dee403a9d661ada1329c354","type":"GO_TERM","name":"late endosome to vacuole transport via multivesicular body sorting pathway","canonical_id":"go:GO:0032511","description":"\"The directed movement of substances from endosomes to vacuoles by a pathway in which molecules are sorted into multivesicular bodies, which then fuse with the vacuole.\" [GOC:mah, PMID:12461556, PMID:16689637]","metadata":null},{"id":"04c46ed60670431f8cad3cf97502330f","type":"GO_TERM","name":"late meiotic recombination nodule assembly","canonical_id":"go:GO:0042140","description":"\"During meiosis, the aggregation, arrangement and bonding together of strand exchange proteins (recombinases) to form small, electron dense structures in association with meiotic chromosomes during pachytene. Involved in the catalysis crossing over.\" [GOC:jl, PMID:9334324]","metadata":null},{"id":"186b77555aa74394a1eda6cdb1783b18","type":"GO_TERM","name":"late recombination nodule","canonical_id":"go:GO:0005715","description":"\"An electron dense structure that is associated with meiotic chromosomes in pachytene during meiosis I.\" [GOC:elh]","metadata":null},{"id":"d4e0bec3c11f4c089d26076a6b01f7fc","type":"GO_TERM","name":"late stripe melanocyte differentiation","canonical_id":"go:GO:0050934","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a late stripe melanocyte (LSM). In zebrafish, LSMs develop during the second phase (3-4 weeks of development) of the larva-to-adult transition (2-4 weeks of development).\" [PMID:11858836]","metadata":null},{"id":"1946bdff71a94369b96d4ff547fc5e6e","type":"GO_TERM","name":"late viral transcription","canonical_id":"go:GO:0019086","description":"\"The transcription of the final group of viral genes of the viral life cycle, following middle transcription, or where middle transcription doesn't occur, following early transcription. Involves the transcription of genes encoding structural proteins.\" [GOC:bf, GOC:jh2, GOC:jl]","metadata":null},{"id":"3bf287aa1c62460f88b80a90f6eba340","type":"GO_TERM","name":"latency-replication decision","canonical_id":"go:GO:0098689","description":"\"The process by which a virus switches on its replication cycle in an infected cell. The process is typically controlled by a genetic switch controlled by environmental factors such as cell type, cell shape, the availability of nutrients, superinfection or exposure of infected cells to UV or various chemical stimuli.\" [PMID:19416825, PMID:24339346, VZ:3964]","metadata":null},{"id":"06d10ae8cb0f4ed28b923490bf3afb43","type":"GO_TERM","name":"latent virus replication","canonical_id":"go:GO:0019045","description":"\"Any process required for latent viral replication in a cell.\" [ISBN:0781702534]","metadata":null},{"id":"0afbee15327744fabe20c447e11044ec","type":"GO_TERM","name":"lateral attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:0099607","description":"\"The cellular process in which sister chromatids become laterally attached to spindle microtubules as part of mitotic metaphase plate congression. Attachment precedes migration along microtubules towards the spindle equator (metaphase plate).\" [PMID:26258632, PMID:26705896]","metadata":null},{"id":"dc5a0b2e0ec743d7bdf3b7cbcc01e7d7","type":"GO_TERM","name":"lateral cell cortex","canonical_id":"go:GO:0097575","description":"\"The region directly beneath the plasma membrane of the lateral portion of the cell.\" [GOC:mah, PMID:24146635]","metadata":null},{"id":"9a5da127f11446a3b5f1850e7fd43f2c","type":"GO_TERM","name":"lateral cortical node","canonical_id":"go:GO:1990463","description":"\"A protein complex that is anchored at the cortical face of the plasma membrane, and contains proteins involved in regulating cell cycle progression. In Schizosaccharomyces pombe, lateral cortical nodes are several megadaltons in size, and contain Slf1, which anchors the complex at the membrane, and the methyltransferase Skb1 in stoichiometric quantities, and may contain other proteins.\" [GOC:mah, PMID:25009287]","metadata":null},{"id":"b6beb9ba068d4c0f8144d5c03e15fe1a","type":"GO_TERM","name":"lateral cortical node assembly","canonical_id":"go:GO:1903359","description":"\"The aggregation, arrangement and bonding together of a set of components to form a lateral cortical node.\" [GO_REF:0000079, GOC:TermGenie, PMID:25009287]","metadata":null},{"id":"d7778d42344d4b8c8c752b525613cdef","type":"GO_TERM","name":"lateral element","canonical_id":"go:GO:0000800","description":"\"A proteinaceous core found between sister chromatids during meiotic prophase.\" [GOC:elh]","metadata":null},{"id":"33f6adb0374c49c28bae609eb94d8b9a","type":"GO_TERM","name":"lateral element assembly","canonical_id":"go:GO:0051878","description":"\"The cell cycle process in which lateral elements are formed. Axial elements form a proteinaceous core between the two sister chromatids of each chromosome; the two axial elements then connect along their entire lengths by fine fibers known as transverse filaments, forming the lateral elements.\" [PMID:11463847]","metadata":null},{"id":"6214fa0c5c294f2fadefd21520cd7af3","type":"DISEASE","name":"lateral epicondylitis","canonical_id":"efo:1001896","description":null,"metadata":null},{"id":"800fa073f31c4af685d91d4a2e460fb5","type":"GO_TERM","name":"lateral ganglionic eminence cell proliferation","canonical_id":"go:GO:0022018","description":"\"The multiplication or reproduction of lateral ganglionic eminence cells, resulting in the expansion of the cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7d51ee6d7fbd492b9c4e5546de5c7c7e","type":"GO_TERM","name":"lateral geniculate nucleus development","canonical_id":"go:GO:0021771","description":"\"The progression of the lateral geniculate nucleus over time from its initial formation until its mature state. The lateral geniculate nucleus is the primary processor of visual information received from the retina.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"a190ee30200e4c4cb46f387cbaa03bb7","type":"GO_TERM","name":"lateral growth","canonical_id":"go:GO:0080190","description":"\"Growth of a plant axis (shoot axis or root) that originates from a lateral meristem.\" [PO:0020145]","metadata":null},{"id":"cfffbbc098a24c29a942c58f6dcb856a","type":"GO_TERM","name":"lateral inhibition","canonical_id":"go:GO:0046331","description":"\"Signaling between cells of equivalent developmental potential that results in these cells adopting different developmental fates. An example is the suppression by cells with a particular fate of the adoption of the same fate by surrounding cells.\" [GOC:bf, GOC:kmv]","metadata":null},{"id":"d6a48e24233d4cb096d15b7153675c34","type":"GO_TERM","name":"lateral line development","canonical_id":"go:GO:0048882","description":"\"The process whose specific outcome is the progression of the lateral line over time, from its formation to the mature structure. The lateral line consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head and body of all fishes and most amphibians. The lateral line develops from cranial ectodermal placodes situated behind the ear and between the eye and ear.\" [ISBN:0125296509]","metadata":null},{"id":"3f2cb8e91ea04343bc4cb7a5d88e068d","type":"GO_TERM","name":"lateral line ganglion development","canonical_id":"go:GO:0048890","description":"\"The process whose specific outcome is the progression of the lateral line ganglion over time, from its formation to the mature structure. The lateral line ganglion develops from cranial ectodermal placodes situated between the eye and ear and behind the ear.\" [ISBN:0125296509, ISBN:0387968377]","metadata":null},{"id":"c8f05f8e300b411f8b54bbd328023fba","type":"GO_TERM","name":"lateral line ganglion neuron differentiation","canonical_id":"go:GO:0048891","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a lateral line ganglion neuron.\" [PMID:15018940]","metadata":null},{"id":"df0d53dc5a7248c2acab2b78f91ec62e","type":"GO_TERM","name":"lateral line nerve development","canonical_id":"go:GO:0048892","description":"\"The process whose specific outcome is the progression of the lateral line nerve over time, form its formation to the mature structure. Lateral line nerves project primarily to an octavolateralis column in the hindbrain that consists of the medial octavolateralis nucleus (MON), the caudal octavolateralis nucleus, and the magnocellular nucleus.\" [ISBN:0125296509]","metadata":null},{"id":"c24f492fc1034e499b81c2b7df1480e7","type":"GO_TERM","name":"lateral line nerve glial cell development","canonical_id":"go:GO:0048937","description":"\"The process aimed at the progression of a lateral line glial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dgh]","metadata":null},{"id":"c7bac0d17aa243f695aacf69743e7684","type":"GO_TERM","name":"lateral line nerve glial cell differentiation","canonical_id":"go:GO:0048895","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glial cell in a lateral line nerve.\" [PMID:12062041]","metadata":null},{"id":"2861a30ffe8747be8a32ad01d6763753","type":"GO_TERM","name":"lateral line nerve glial cell migration","canonical_id":"go:GO:0048896","description":"\"The movement of a glial cell along the axons in a lateral line nerve.\" [PMID:12062041]","metadata":null},{"id":"f43aa82ea1604d9690a71b56a46ce5a1","type":"GO_TERM","name":"lateral line system development","canonical_id":"go:GO:0048925","description":"\"The process whose specific outcome is the progression of the lateral line system over time, from its formation to the mature structure. The lateral line system is a network of sensory organs (neuromasts) and lateral line nerves located superficially on the skin or just under the skin in fluid-filled canals on the head and body of all fishes and most amphibians. The lateral line system develops from cranial ectodermal placodes situated between the eye and ear.\" [GOC:dgh, ISBN:0125296509]","metadata":null},{"id":"f0b61e9268ba426e8f910bc92702568a","type":"GO_TERM","name":"lateral loop","canonical_id":"go:GO:0043219","description":"\"Non-compact myelin located adjacent to the nodes of Ranvier in a myelin segment. These non-compact regions include cytoplasm from the cell responsible for synthesizing the myelin. Lateral loops are found in the paranodal region adjacent to the nodes of Ranvier, while Schmidt-Lantermann clefts are analogous structures found within the compact myelin internode.\" [GOC:dgh]","metadata":null},{"id":"45fb91329d6a4ac8906e381a6fbaca05","type":"GO_TERM","name":"lateral mesoderm development","canonical_id":"go:GO:0048368","description":"\"The process whose specific outcome is the progression of the lateral mesoderm over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"4a87534a52c54f34b127a11ad54beb79","type":"GO_TERM","name":"lateral mesoderm formation","canonical_id":"go:GO:0048370","description":"\"The process that gives rise to the lateral mesoderm. This process pertains to the initial formation of the structure from unspecified parts.\" [GOC:jid]","metadata":null},{"id":"0832b81b76f64e47b8f4eaed629b570e","type":"GO_TERM","name":"lateral mesoderm morphogenesis","canonical_id":"go:GO:0048369","description":"\"The process in which the anatomical structures of the lateral mesoderm are generated and organized.\" [GOC:curators]","metadata":null},{"id":"2788964a7a634de6a02cc5d3086c80e3","type":"GO_TERM","name":"lateral mesoderm structural organization","canonical_id":"go:GO:0048381","description":"\"The process that contributes to the act of creating the structural organization of the lateral mesoderm. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid]","metadata":null},{"id":"d5ac65cdc3bd427a8f34e12e97d99aeb","type":"GO_TERM","name":"lateral mesodermal cell differentiation","canonical_id":"go:GO:0048371","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a lateral mesoderm cell.\" [GOC:jid]","metadata":null},{"id":"f7ab7285a12141dfb801ccbb23b05d41","type":"GO_TERM","name":"lateral mesodermal cell fate commitment","canonical_id":"go:GO:0048372","description":"\"The process in which a cell becomes committed to become a lateral mesoderm cell.\" [GOC:jid]","metadata":null},{"id":"c54edfc070724ddaa1a07ac2bfd70ed3","type":"GO_TERM","name":"lateral mesodermal cell fate determination","canonical_id":"go:GO:0048373","description":"\"The process in which a cell becomes capable of differentiating autonomously into a lateral mesoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:jid]","metadata":null},{"id":"0ca5cacdbde64734a90783bc594539d2","type":"GO_TERM","name":"lateral mesodermal cell fate specification","canonical_id":"go:GO:0048377","description":"\"The process in which a cell becomes capable of differentiating autonomously into a lateral mesoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:jid]","metadata":null},{"id":"d6fc4fd3a86540bfa9c26428c388b897","type":"GO_TERM","name":"lateral motor column neuron differentiation","canonical_id":"go:GO:0021525","description":"\"The process in which differentiating motor neurons in the neural tube acquire the specialized structural and/or functional features of lateral motor column neurons. Lateral motor column neurons are generated only on limb levels and send axons into the limb mesenchyme. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"9672d040e69f414a9a0dc8b395ce2127","type":"GO_TERM","name":"lateral motor column neuron migration","canonical_id":"go:GO:0097477","description":"\"The orderly movement of a lateral motor column neuron from one site to another. A lateral motor column neuron is a motor neuron that is generated only on limb levels and send axons into the limb mesenchyme.\" [CL:0011002, GOC:yaf, PMID:20711475]","metadata":null},{"id":"00fb304d6c8149508d8f56382c775944","type":"GO_TERM","name":"lateral part of cell","canonical_id":"go:GO:0097574","description":"\"The region of a polarized cell other than its tips or ends (in some cell types, one end may be called the apex and the other the base). For example, in a polarized epithelial cell, the lateral part includes the cell sides which interface adjacent cells.\" [GOC:pr]","metadata":null},{"id":"d5afd41d3187497a95a027ba38dedd9a","type":"GO_TERM","name":"lateral part of motile cell","canonical_id":"go:GO:0031255","description":"\"The area of a motile cell perpendicular to the direction of movement.\" [GOC:pg, GOC:pr]","metadata":null},{"id":"c25daa70f24a40dab9e31bdc062f0936","type":"GO_TERM","name":"lateral plasma membrane","canonical_id":"go:GO:0016328","description":"\"The portion of the plasma membrane at the lateral side of the cell. In epithelial cells, lateral plasma membranes are on the sides of cells which lie at the interface of adjacent cells.\" [GOC:hb, GOC:mah, GOC:pr]","metadata":null},{"id":"834f06ae16ee4733ae9ce316644b0d4a","type":"GO_TERM","name":"lateral pseudopodium assembly","canonical_id":"go:GO:0031271","description":"\"The extension of a pseudopodium from the lateral area of a cell.\" [GOC:dph, GOC:mah, GOC:pg, GOC:tb]","metadata":null},{"id":"cfbfeb1d2ba14db3a2236c7692a4cd0b","type":"GO_TERM","name":"lateral pseudopodium retraction","canonical_id":"go:GO:0120320","description":"\"The myosin-based contraction and retraction of a lateral pseudopodium.\" [GOC:krc, GOC:pf, PMID:12953059, PMID:15483055, PMID:17623773]","metadata":null},{"id":"35c20bcc6dc046f384e388111176fd82","type":"GO_TERM","name":"lateral reticular nucleus development","canonical_id":"go:GO:0021726","description":"\"The process whose specific outcome is the progression of the lateral reticular nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"20de7c074db049088f329f0eb855f7d6","type":"GO_TERM","name":"lateral root branching","canonical_id":"go:GO:0080181","description":"\"Any process involved in the formation of branches in lateral roots.\" [GOC:tb]","metadata":null},{"id":"160a993e680142d1b49c16ac79823a1c","type":"GO_TERM","name":"lateral root development","canonical_id":"go:GO:0048527","description":"\"The process whose specific outcome is the progression of the lateral root over time, from its formation to the mature structure. A lateral root is one formed from pericycle cells located on the xylem radius of the root, as opposed to the initiation of the main root from the embryo proper.\" [GOC:tb]","metadata":null},{"id":"9febf5c119914d0ea62f64b9d58e42bb","type":"GO_TERM","name":"lateral root formation","canonical_id":"go:GO:0010311","description":"\"The process that gives rise to a lateral root. This process pertains to the initial formation of a structure from unspecified parts. A lateral root primordium represents an organized group of cells derived from the root pericycle that will differentiate into a new root, as opposed to the initiation of the main root from the embryo proper.\" [GOC:tair_curators, PMID:17259263]","metadata":null},{"id":"5eff956956c04258ab6576b180813d55","type":"GO_TERM","name":"lateral root morphogenesis","canonical_id":"go:GO:0010102","description":"\"The process in which the anatomical structures of a lateral root are generated and organized. A lateral root is one formed from pericycle cells located on the xylem radius of the root, as opposed to the initiation of the main root from the embryo proper.\" [GOC:tair_curators]","metadata":null},{"id":"b312feb3bac94217bfd2ec9af8d9eb32","type":"GO_TERM","name":"lateral semicircular canal development","canonical_id":"go:GO:0060875","description":"\"The progession of the lateral semicircular canal from its initial formation to the mature structure.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"4ba4574bc2234f28a42044deb4182013","type":"GO_TERM","name":"lateral shield","canonical_id":"go:GO:0097569","description":"\"Region of the ventral side of the cell body found in Giardia species (trophozoite stage). It is located posterior on either side of the ventral groove; the upper boundary is the ventral disc, and the lower boundary is marked by the posteriolateral flagella.\" [GOC:giardia, ISBN:9780124260207]","metadata":null},{"id":"2aa3b313c0ba4cc6ab225a320b164d5a","type":"GO_TERM","name":"lateral sprouting from an epithelium","canonical_id":"go:GO:0060601","description":"\"The process in which a branch forms along the side of an epithelium.\" [GOC:dph]","metadata":null},{"id":"17423e3bf0fe4470bd900e44360c807a","type":"GO_TERM","name":"lateral sprouting involved in lung morphogenesis","canonical_id":"go:GO:0060490","description":"\"The process in which a branch forms along the side of the lung epithelial tube.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"d60b182d1d37438db24c20db9c80b44e","type":"GO_TERM","name":"lateral sprouting involved in mammary gland duct morphogenesis","canonical_id":"go:GO:0060599","description":"\"The process in which a branch forms along the side of a mammary duct.\" [GOC:dph, PMID:17120154]","metadata":null},{"id":"63b8fb3ee2b3476186f820970f64f839","type":"GO_TERM","name":"lateral ventricle development","canonical_id":"go:GO:0021670","description":"\"The process whose specific outcome is the progression of the lateral ventricles over time, from the formation to the mature structure. The two lateral ventricles are a cavity in each of the cerebral hemispheres derived from the cavity of the embryonic neural tube. They are separated from each other by the septum pellucidum, and each communicates with the third ventricle by the foramen of Monro, through which also the choroid plexuses of the lateral ventricles become continuous with that of the third ventricle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"7d7cddc06f9e4f7c91029ce7d2b4de18","type":"GO_TERM","name":"lateral wall of outer hair cell","canonical_id":"go:GO:0120249","description":"\"The lateral wall of an outer hair cell (OHC) is a unique trilaminate composite consisting of the plasma membrane, an underlying cytoskeletal network containing an actin-spectrin cortical lattice, and an adjacent system of circumferential lamellar organelles known as the subsurface cisternae.\" [GOC:krc, PMID:26352669, PMID:31920560, PMID:9412485]","metadata":null},{"id":"389541a91dd0457abe26715b4582c9fd","type":"GO_TERM","name":"latrotoxin receptor activity","canonical_id":"go:GO:0016524","description":"\"Combining with alpha-latrotoxin, a potent presynaptic neurotoxin, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:jl, GOC:signaling, PMID:10025961]","metadata":null},{"id":"83c4ae68957c42fa872efc22445e66a7","type":"GO_TERM","name":"lauric acid metabolic process","canonical_id":"go:GO:0048252","description":"\"The chemical reactions and pathways involving lauric acid, a fatty acid with the formula CH3(CH2)10COOH. Derived from vegetable sources.\" [GOC:jid, PMID:15555597]","metadata":null},{"id":"1a33362a3d144d799e65d7b8369e9137","type":"GO_TERM","name":"lavandulyl diphosphate synthase activity","canonical_id":"go:GO:0033851","description":"\"Catalysis of the reaction: 2 dimethylallyl diphosphate = diphosphate + lavandulyl diphosphate.\" [EC:2.5.1.69, RHEA:21676]","metadata":null},{"id":"ffd64e10504441c18ea11092d4161d5c","type":"GO_TERM","name":"layer formation in cerebral cortex","canonical_id":"go:GO:0021819","description":"\"The detachment of cells from radial glial fibers at the appropriate time when they cease to migrate and form distinct layer in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"b658bfd6cc11446697a8573a0b46be3c","type":"GO_TERM","name":"lead ion binding","canonical_id":"go:GO:0032791","description":"\"Binding to lead (Pb) ions.\" [GOC:mah]","metadata":null},{"id":"d266e192dbe54efc9144239d272cb156","type":"GO_TERM","name":"lead ion transmembrane transporter activity","canonical_id":"go:GO:0015094","description":"\"Enables the transfer of lead (Pb) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"74279273e3e84a84bace4ffa13c35fd3","type":"GO_TERM","name":"lead ion transport","canonical_id":"go:GO:0015692","description":"\"The directed movement of lead (Pb) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"79912fd319ef4603a8aca471a9d65463","type":"GO_TERM","name":"lead sulfide oxidation","canonical_id":"go:GO:0019327","description":"\"The chemical reactions and pathways resulting in the conversion of lead sulfide to lead sulfate.\" [MetaCyc:P301-PWY]","metadata":null},{"id":"721c924f295944d0a36b60410d179f94","type":"GO_TERM","name":"leading edge cell differentiation","canonical_id":"go:GO:0035026","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of leading edge cells, cells at the front of a migrating epithelial sheet.\" [GOC:bf]","metadata":null},{"id":"f0783b78e5b142f3b70ce368b01f1383","type":"GO_TERM","name":"leading edge cell fate commitment","canonical_id":"go:GO:0035027","description":"\"The commitment of cells to leading edge cell fate and their capacity to differentiate into leading edge cells. Leading edge cells are found at the front of a migrating epithelial sheet.\" [GOC:bf]","metadata":null},{"id":"3da51bd1134b4ad28fdc4efd54ded856","type":"GO_TERM","name":"leading edge cell fate determination","canonical_id":"go:GO:0035028","description":"\"The process in which a cell becomes capable of differentiating autonomously into a leading edge cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:bf]","metadata":null},{"id":"9b1fd0d6907643ffbde5fef5c241c910","type":"GO_TERM","name":"leading edge membrane","canonical_id":"go:GO:0031256","description":"\"The portion of the plasma membrane surrounding the leading edge of a motile cell.\" [GOC:mah]","metadata":null},{"id":"7b7e3591356e45adaaa373e2c4fd192f","type":"GO_TERM","name":"leading edge of axonal growth cone","canonical_id":"go:GO:0061916","description":"\"That part of the axonal growth cone which represents the distal part of the structure.\" [PMID:16098134]","metadata":null},{"id":"310ee06060644e34bdf3cf9680ae2eda","type":"GO_TERM","name":"leading edge of dendritic growth cone","canonical_id":"go:GO:0061917","description":"\"That part of the dendritic growth cone which represents the distal part of the structure.\" [PMID:16098134]","metadata":null},{"id":"4a446e239c56411fa8d14506e0c8c6ab","type":"GO_TERM","name":"leading edge of lamellipodium","canonical_id":"go:GO:0061851","description":"\"That part of the lamellipodium which represents the distal part of the structure.\" [PMID:22339865]","metadata":null},{"id":"a819601e748e45fa8f1d077c25aeafb6","type":"GO_TERM","name":"leading strand elongation","canonical_id":"go:GO:0006272","description":"\"The process in which an existing DNA strand is extended continuously in a 5' to 3' direction by activities including the addition of nucleotides to the 3' end of the strand, complementary to an existing template, as part of DNA replication. Leading strand elongation proceeds in the same direction as the replication fork.\" [GOC:mah, ISBN:071673706X, ISBN:0815316194]","metadata":null},{"id":"0454c81db8df4b8eb871cc5c7700a3b2","type":"GO_TERM","name":"leaf abscission","canonical_id":"go:GO:0060866","description":"\"The controlled shedding of a leaf.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"9b9b537490894ba0821e0c5db9e5ef8f","type":"GO_TERM","name":"leaf development","canonical_id":"go:GO:0048366","description":"\"The process whose specific outcome is the progression of the leaf over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"eba7a829f4f04fdab1124d39f69a1317","type":"GO_TERM","name":"leaf formation","canonical_id":"go:GO:0010338","description":"\"The process that gives rise to a leaf. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:tair_curators]","metadata":null},{"id":"efc1f87cf39149d18e69bdf7f57ade8b","type":"GO_TERM","name":"leaf morphogenesis","canonical_id":"go:GO:0009965","description":"\"The process in which the anatomical structures of the leaf are generated and organized.\" [GOC:curators]","metadata":null},{"id":"c7d1114d742e405488b0a38148711351","type":"GO_TERM","name":"leaf papilla","canonical_id":"go:GO:0090396","description":"\"A plant cell papilla that is part of a leaf papilla cell.\" [GOC:tb]","metadata":null},{"id":"81088e3855ef4709a1252fa1fc026228","type":"GO_TERM","name":"leaf pavement cell development","canonical_id":"go:GO:0090436","description":"\"The process whose specific outcome is the progression of an leaf pavement cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a leaf pavement cell fate.\" [GOC:tb]","metadata":null},{"id":"0334ff481c8a48fe8e99c816c6335a89","type":"GO_TERM","name":"leaf phyllotactic patterning","canonical_id":"go:GO:0060772","description":"\"The radial pattern formation process that results in the formation of leaf primordia around the center of a shoot apical meristem.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"0f2b934f53e342a4815b7cfe068e7032","type":"GO_TERM","name":"leaf proximal/distal pattern formation","canonical_id":"go:GO:0010589","description":"\"The regionalization process within a leaf by which specific areas of cell differentiation are determined along a proximal/distal axis.\" [PMID:18398054]","metadata":null},{"id":"30975848776d43c79d0c8f5d1829e3a6","type":"GO_TERM","name":"leaf senescence","canonical_id":"go:GO:0010150","description":"\"The last stage of leaf development during which programmed degradation of macromolecules and nutrient recycling take place.\" [ISBN:0387987819, PMID:17177638, PMID:34938309]","metadata":null},{"id":"146433e9bdaa4198a86dd524f7f877d1","type":"GO_TERM","name":"leaf shaping","canonical_id":"go:GO:0010358","description":"\"The developmental process that pertains to the organization of a leaf in three-dimensional space once the structure has initially formed.\" [GOC:tb, PMID:16971475]","metadata":null},{"id":"4b99f2ea192f42a8a74894a5042a8032","type":"GO_TERM","name":"leaf vascular tissue pattern formation","canonical_id":"go:GO:0010305","description":"\"Vascular tissue pattern formation as it occurs in the leaf of vascular plants.\" [GOC:tair_curators]","metadata":null},{"id":"3b386adde94d4a718d1ec7adfb6af0de","type":"GO_TERM","name":"leaflet formation","canonical_id":"go:GO:0090014","description":"\"The developmental process pertaining to the initial formation of a leaflet from unspecified parts. A leaflet is one of the ultimate segments of a compound leaf.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"dc9266e3226f4eee94ce1d8472fdff99","type":"GO_TERM","name":"leaflet morphogenesis","canonical_id":"go:GO:0060794","description":"\"The process in which the anatomical structures of the leaflet are generated and organized.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"5a6c510fe8ef4d7ca674f77dd55d6ff6","type":"GO_TERM","name":"leaflet of membrane bilayer","canonical_id":"go:GO:0097478","description":"\"Any of the two layers of lipid molecules that constitute a membrane.\" [GOC:cjm]","metadata":null},{"id":"387fcd393a6a41cb8d5fe41437a72823","type":"GO_TERM","name":"leak channel activity","canonical_id":"go:GO:0022840","description":"\"Enables the transport of a solute across a membrane via a narrow pore channel that is open even in an unstimulated or 'resting' state.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"3fba727ab6cd48f2862a0413fb444189","type":"GO_TERM","name":"learned vocalization behavior","canonical_id":"go:GO:0098583","description":"\"A vocalization behavior that is the result of learning.\" [GOC:BHF, GOC:dos, GOC:rl, PMID:16418265, PMID:17035521]","metadata":null},{"id":"5380a634aa6647ad8235bf8acd66c7d4","type":"GO_TERM","name":"learned vocalization behavior or vocal learning","canonical_id":"go:GO:0098598","description":"\"Vocalisation behavior that is the result of learning, or the process by which new vocalizations are learned.\" [GOC:BHF, GOC:dos, GOC:rl, PMID:16418265, PMID:17035521]","metadata":null},{"id":"7e685244166441de83b81a5d4d61771e","type":"GO_TERM","name":"learning","canonical_id":"go:GO:0007612","description":"\"Any process in an organism in which a relatively long-lasting adaptive behavioral change occurs as the result of experience.\" [ISBN:0582227089, ISBN:0721662544]","metadata":null},{"id":"b7ae31ab427146dcb861ab4ca96c5afa","type":"GO_TERM","name":"learning or memory","canonical_id":"go:GO:0007611","description":"\"The acquisition and processing of information and/or the storage and retrieval of this information over time.\" [GOC:jid, PMID:8938125]","metadata":null},{"id":"ff91ee004f444cf4b546fd032f54d7e3","type":"GO_TERM","name":"lectin-induced modified bacterial internalization","canonical_id":"go:GO:0106136","description":"\"The process in which an organism effects a change in the structure or function of a symbiont organism, mediated by secretion of lectins which bind to the bacterial surface. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:rjd, PMID:30049880]","metadata":null},{"id":"436e51a489914d078e66cdf6ccd269e7","type":"DRUG","name":"ledipasvir","canonical_id":"mesh:C586541","description":null,"metadata":null},{"id":"6d8f5e910e574f19ae01604f56aa6903","type":"DRUG","name":"leflunomide","canonical_id":"gtopdb:6825","description":null,"metadata":null},{"id":"e0b2d814bfd84901a99e14a2269944ec","type":"DRUG","name":"leflunomide","canonical_id":"chembl:CHEMBL960","description":null,"metadata":null},{"id":"efda6096ac224ff6af27e9b056925d5d","type":"COMBINATION_TREATMENT","name":"leflunomide + methotrexate","canonical_id":"ctgov_combo:ctgov-combo-0f645f5fcbee1f4d","description":null,"metadata":null},{"id":"9727e2a40031449183348a509fb87d29","type":"COMBINATION_TREATMENT","name":"leflunomide + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-e3012b9769b9e9b4","description":null,"metadata":null},{"id":"5b6d816f931e4d81b3ff178f53e82d0f","type":"COMBINATION_TREATMENT","name":"leflunomide + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-5433f6ec8ad92fb0","description":null,"metadata":null},{"id":"df3ec541ae914972a4c6581f125d2ef2","type":"COMBINATION_TREATMENT","name":"leflunomide + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-54ff32264dbf5df7","description":null,"metadata":null},{"id":"10188874f2c04ec8b9503ee9d067d2bb","type":"GO_TERM","name":"left anterior basal body","canonical_id":"go:GO:1902671","description":"\"Any ciliary basal body that is part of a left anterior flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"77f353fb9a1b4402a55c1e224c6941aa","type":"GO_TERM","name":"left anterior flagellum","canonical_id":"go:GO:0097554","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It originates at the left anterior basal body, extends laterally through the cytoplasm, crosses the right anterior axoneme, and exits as a membrane-bound flagellum on the anterior left side of the cell.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"2c810ba64e6e47e1b634d3c6972f43d3","type":"GO_TERM","name":"left caudal basal body","canonical_id":"go:GO:1902677","description":"\"Any ciliary basal body that is part of a left caudal flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"3e9a3f6aefcb44269ad9501d1dcc10c1","type":"GO_TERM","name":"left caudal flagellum","canonical_id":"go:GO:0097560","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It is nucleated by the left caudal basal body, extending cytoplasmically and exiting at the posterior end of the cell body.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"17a7c3f3729e42cf95bb9f305d6adad3","type":"GO_TERM","name":"left horn of sinus venosus development","canonical_id":"go:GO:0061079","description":"\"The progression of the left horn of the sinus venosus from its initial formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"0c34641cd8364d8bb2d3373ff80d2569","type":"GO_TERM","name":"left lateral basal body pair","canonical_id":"go:GO:0097562","description":"\"Set of two basal bodies found in Giardia species (trophozoite stage). It comprises the anterior and ventral basal bodies located to the right of the left nucleus of the trophozoite when viewed dorsally.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"0bddaef6b27a4b7a843d870b0af994e0","type":"GO_TERM","name":"left lung development","canonical_id":"go:GO:0060459","description":"\"The biological process whose specific outcome is the progression of a left lung from an initial condition to its mature state. This process begins with the formation of the left lung and ends with the mature structure. The left lung is the lung which is on the left side of the anterior posterior axis looking from a dorsal to ventral aspect.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"648574bc3b504539925cfa4775e9e5d2","type":"GO_TERM","name":"left lung morphogenesis","canonical_id":"go:GO:0060460","description":"\"The process in which anatomical structures of the left lung are generated and organized.\" [GOC:dph]","metadata":null},{"id":"7e06bf0fc3d24c88a0511c9ae47c84c9","type":"GO_TERM","name":"left middle basal body pair","canonical_id":"go:GO:0097563","description":"\"Set of two basal bodies found in Giardia species (trophozoite stage). It comprises the caudal and posteriolateral basal bodies located to the right of the left nucleus of the trophozoite when viewed dorsally.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"36f4c287afca49c89f99d7ca3a15881c","type":"GO_TERM","name":"left nucleus","canonical_id":"go:GO:0097571","description":"\"One of the two nuclei found in Giardia species (trophozoite stage). It is located on the left side of the cell when viewed from the dorsal side.\" [GOC:giardia, ISBN:0-444-81258-X]","metadata":null},{"id":"d9ca7cc7426d44b9889e871c54d2df78","type":"GO_TERM","name":"left posteriolateral basal body","canonical_id":"go:GO:1902673","description":"\"Any ciliary basal body that is part of a left posteriolateral flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"2fd25f27b49d4e919fc00a276e9c7b36","type":"GO_TERM","name":"left posteriolateral flagellum","canonical_id":"go:GO:0097556","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It is nucleated by the left posteriolateral basal body and extends cytoplasmically toward the cell posterior, marking the left anterior boundary of the lateral shield and the left lateral region of the funis before exiting at the left lateral region of the cell body.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"be2382315d52444bbd509178d1bb20ca","type":"GO_TERM","name":"left tetrad","canonical_id":"go:GO:0097566","description":"\"Set of four basal bodies found in Giardia species (trophozoite stage). It comprises the left lateral basal body pair and the left middle basal body pair (i.e. the anterior, ventral, caudal and posteriolateral basal bodies located to the right of the left nucleus of the trophozoite when viewed dorsally).\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"e6326939e5fb426e9b711e042c3dec40","type":"GO_TERM","name":"left ventral basal body","canonical_id":"go:GO:1902675","description":"\"Any ciliary basal body that is part of a left ventral flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"2fe77d24b5e24f7faa07b672e1c93b92","type":"GO_TERM","name":"left ventral flagellum","canonical_id":"go:GO:0097558","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It is nucleated by the left ventral basal body and exits the cell body proximally and dorsal to the ventral disc.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"f905adcb2ada430599abd990debe4ec8","type":"GO_TERM","name":"left ventricular cardiac muscle tissue morphogenesis","canonical_id":"go:GO:0003220","description":"\"The process in which the anatomical structures of left cardiac ventricle muscle are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"09c98dbafc324c6c9f12f9992a4bb9f7","type":"GO_TERM","name":"left ventricular compact myocardium morphogenesis","canonical_id":"go:GO:0003224","description":"\"The process in which the anatomical structures of cardiac left ventricular compact myocardium are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"e76a1593c40c43fd89ee3afb4c2db5a9","type":"GO_TERM","name":"left ventricular trabecular myocardium morphogenesis","canonical_id":"go:GO:0003225","description":"\"The process in which the anatomical structures of cardiac left ventricular trabecular myocardium are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"b033fdd511b64debbf1776e911ea7bfd","type":"GO_TERM","name":"left-handed Z-DNA binding","canonical_id":"go:GO:0003692","description":"\"Binding to DNA in the Z form, i.e. a left-handed helix in which the phosphate backbone zigzags.\" [ISBN:0716720094]","metadata":null},{"id":"263a5abea42f4e09a6ccccc68dcf6f84","type":"GO_TERM","name":"left-handed Z-RNA immune receptor activity","canonical_id":"go:GO:7770073","description":"\"Combining with a left-handed Z-RNA and transmitting the signal to initiate an innate immune response. Z-RNA is a left-handed double-helical conformation of RNA in which the phosphate backbone zigzags.\" [PMID:32200799]","metadata":null},{"id":"63172c0751a2420cb28e812850cc603d","type":"GO_TERM","name":"left/right axis specification","canonical_id":"go:GO:0070986","description":"\"The establishment, maintenance and elaboration of the left/right axis. The left/right axis is defined by a line that runs orthogonal to both the anterior/posterior and dorsal/ventral axes. Each side is defined from the viewpoint of the organism rather of the observer (as per anatomical axes).\" [GOC:dph, GOC:gvg, GOC:mah]","metadata":null},{"id":"be6494fe46444947b4435ab8ff1b283c","type":"GO_TERM","name":"left/right pattern formation","canonical_id":"go:GO:0060972","description":"\"The pattern specification process that results in the subdivision of the left/right axis in space to define an area or volume in which specific patterns of cell differentiation will take place or in which cells interpret a specific environment.\" [GOC:mtg_heart]","metadata":null},{"id":"62669b0deefa4b448cc8bced63907332","type":"GO_TERM","name":"leg disc anterior/posterior lineage restriction","canonical_id":"go:GO:0035201","description":"\"Formation and/or maintenance of a lineage boundary between anterior and posterior compartments of the leg disc that cells cannot cross, thus separating the populations of cells in each compartment.\" [GOC:bf]","metadata":null},{"id":"f8a482f81c644eeba43bbfd3b9261c45","type":"GO_TERM","name":"leg disc anterior/posterior pattern formation","canonical_id":"go:GO:0035200","description":"\"The establishment, maintenance and elaboration of the anterior/posterior axis of the leg imaginal disc.\" [GOC:bf]","metadata":null},{"id":"df336b398baf4d3b8b51215454e7da17","type":"GO_TERM","name":"leg disc development","canonical_id":"go:GO:0035218","description":"\"Progression of the leg imaginal disc over time, from its initial formation through to its metamorphosis to form adult structures including the leg, coxa and ventral thoracic pleura.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"488d2e7c059147b783de3bd756e487b5","type":"GO_TERM","name":"leg disc morphogenesis","canonical_id":"go:GO:0007478","description":"\"The process in which the anatomical structures derived from the leg disc are generated and organized. This includes the transformation of a leg imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into recognizable adult structures including the leg, coxa and ventral thoracic pleura.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"8a66adf3470d4052a56fedda72bd8326","type":"GO_TERM","name":"leg disc pattern formation","canonical_id":"go:GO:0035223","description":"\"The process that gives rise to the patterns of cell differentiation in the leg imaginal disc.\" [GOC:bf]","metadata":null},{"id":"395d4576fc1143a9bb5e46a602dd7293","type":"GO_TERM","name":"leg disc proximal/distal pattern formation","canonical_id":"go:GO:0007479","description":"\"The establishment, maintenance and elaboration of the proximal/distal axis of the leg imaginal disc, a precursor to the adult leg.\" [GOC:bf]","metadata":null},{"id":"19c54055cecc4f4ba6ac894b80c03461","type":"GO_TERM","name":"leghemoglobin reductase [NAD(P)H] activity","canonical_id":"go:GO:0015043","description":"\"Catalysis of the reaction: 2 Fe(III)-[leghemoglobin] + NAD(P)H = 2 Fe(II)-[leghemoglobin] + NAD(P)+ + H+.\" [EC:1.6.2.6]","metadata":null},{"id":"f1aea58ec4d041938d8e75c0d51c6437","type":"DISEASE","name":"leiomyoma","canonical_id":"mondo:0001572","description":null,"metadata":null},{"id":"f93b39296f1a4782aa34385ac42d88ab","type":"DISEASE","name":"leishmaniasis","canonical_id":"mondo:0011989","description":null,"metadata":null},{"id":"1d92a218589547c4add11c632d0fa14a","type":"DRUG","name":"lemborexant","canonical_id":"gtopdb:9302","description":null,"metadata":null},{"id":"5e62777690564a9390e0995ecc0cec7f","type":"DRUG","name":"lemborexant","canonical_id":"chembl:CHEMBL3545367","description":null,"metadata":null},{"id":"c90194d7fc6344f2914378d292b37940","type":"COMBINATION_TREATMENT","name":"lemborexant + suvorexant","canonical_id":"ctgov_combo:ctgov-combo-20491216bf06ff51","description":null,"metadata":null},{"id":"b49f2ff6c0c04526815c75eaf1d988c5","type":"DRUG","name":"leniolisib","canonical_id":"gtopdb:9424","description":null,"metadata":null},{"id":"3854f4211437434b9163ce3b18c6f94c","type":"DRUG","name":"leniolisib","canonical_id":"chembl:CHEMBL3643413","description":null,"metadata":null},{"id":"fc04ff066fe540d6999def0998b864eb","type":"GO_TERM","name":"lens development in camera-type eye","canonical_id":"go:GO:0002088","description":"\"The process whose specific outcome is the progression of the lens over time, from its formation to the mature structure. The lens is a transparent structure in the eye through which light is focused onto the retina. An example of this process is found in Mus musculus.\" [GOC:dph, ISBN:0582064333]","metadata":null},{"id":"30ab77ce96464f12ad233b4ed82d949f","type":"GO_TERM","name":"lens epithelial cell proliferation","canonical_id":"go:GO:0097166","description":"\"The multiplication or reproduction of lens epithelial cells, resulting in the expansion of a cell population. Lens epithelial cells make up the lens epithelium, which is located in the anterior portion of the lens between the lens capsule and the lens fibers and is a simple cuboidal epithelium. The epithelial cells of the lens regulate most of the homeostatic functions of the lens such as osmolarity and liquid volume. The lens epithelial cells also serve as the progenitors for new lens fibers. The lens epithelium constantly lays down fibers in the embryo, fetus, infant, and adult, and continues to lay down fibers for lifelong growth.\" [CL:0002224, GOC:yaf, PMID:18423449, Wikipedia:Lens_%28anatomy%29#Lens_epithelium]","metadata":null},{"id":"2ce51432ef594d409ca70a7fb3230916","type":"GO_TERM","name":"lens fiber cell apoptotic process","canonical_id":"go:GO:1990086","description":"\"Any apoptotic process in a lens fiber cell. Lens fiber cells are elongated, tightly packed cells that make up the bulk of the mature lens in a camera-type eye.\" [CL:0011004, GOC:hjd, PMID:11095619]","metadata":null},{"id":"e2242979bdcb452bac183f8d794f4184","type":"GO_TERM","name":"lens fiber cell development","canonical_id":"go:GO:0070307","description":"\"The process whose specific outcome is the progression of a lens fiber cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a lens fiber cell fate. A lens fiber cell is any of the elongated, tightly packed cells that make up the bulk of the mature lens in a camera-type eye.\" [GOC:mah, PMID:7693735]","metadata":null},{"id":"bab201061ec843058e2080850ebae743","type":"GO_TERM","name":"lens fiber cell differentiation","canonical_id":"go:GO:0070306","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a lens fiber cell, any of the elongated, tightly packed cells that make up the bulk of the mature lens in the camera-type eye. The cytoplasm of a lens fiber cell is devoid of most intracellular organelles including the cell nucleus, and contains primarily crystallins, a group of water-soluble proteins expressed in vary large quantities.\" [GOC:mah, PMID:7693735]","metadata":null},{"id":"b04e20b5f41e42f184bf5da0e46367a7","type":"GO_TERM","name":"lens fiber cell fate commitment","canonical_id":"go:GO:0070308","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a lens fiber cell. A lens fiber cell is any of the elongated, tightly packed cells that make up the bulk of the mature lens in a camera-type eye.\" [GOC:mah, PMID:7693735]","metadata":null},{"id":"0eb652b41fae457c9758e18dc18fd4f4","type":"GO_TERM","name":"lens fiber cell morphogenesis","canonical_id":"go:GO:0070309","description":"\"The process in which the structures of a lens fiber cell are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of a lens fiber cell. A lens fiber cell is any of the elongated, tightly packed cells that make up the bulk of the mature lens in a camera-type eye.\" [GOC:mah, PMID:7693735]","metadata":null},{"id":"bdd32ecf97ee4953b9658d82ccccf5eb","type":"GO_TERM","name":"lens induction in camera-type eye","canonical_id":"go:GO:0060235","description":"\"Signaling at short range between the head ectoderm and the optic vesicle that results in the head ectoderm forming a lens.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"177519fc4b1b4868a82ec50dc0496c85","type":"GO_TERM","name":"lens morphogenesis in camera-type eye","canonical_id":"go:GO:0002089","description":"\"The process in which the anatomical structures of the lens are generated and organized. The lens is a transparent structure in the eye through which light is focused onto the retina. An example of this process is found in Mus musculus.\" [GOC:dph, GOC:mtg_sensu]","metadata":null},{"id":"66322be54e014bdd853d28f7f9e37cde","type":"GO_TERM","name":"lens placode formation","canonical_id":"go:GO:0001743","description":"\"The initial developmental process that will lead to the formation of an eye.\" [GOC:dph]","metadata":null},{"id":"eb4eb887ab1244b28ce723c167009543","type":"GO_TERM","name":"lens placode formation involved in camera-type eye formation","canonical_id":"go:GO:0046619","description":"\"Establishment and formation of the optic placode, paired ectodermal placodes that become invaginated to form the embryonic lens vesicles.\" [GOC:dph, GOC:mtg_sensu, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"6ad9ed11bb2a4c0e94018aa5eb9779cf","type":"DRUG","name":"lenvatinib","canonical_id":"gtopdb:7426","description":null,"metadata":null},{"id":"436228a4c04341d7b6975ba68e513266","type":"DRUG","name":"lenvatinib","canonical_id":"mesh:C531958","description":null,"metadata":null},{"id":"1c0d081662df4312a2040d594a3621ba","type":"COMBINATION_TREATMENT","name":"lenvatinib + letrozole","canonical_id":"ctgov_combo:ctgov-combo-bc111b391124fbaa","description":null,"metadata":null},{"id":"5ba2f9e937264be482699410babfac8d","type":"COMBINATION_TREATMENT","name":"lenvatinib + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-28139cab7b9a80f7","description":null,"metadata":null},{"id":"82f28ca949894aef8b1caee641475590","type":"COMBINATION_TREATMENT","name":"lenvatinib + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-6e266285cb7d8063","description":null,"metadata":null},{"id":"79e760bd616048fe9fa14ca1a976bc6f","type":"COMBINATION_TREATMENT","name":"lenvatinib + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-e36b735381aaba37","description":null,"metadata":null},{"id":"d6c83606c9e3402d82e41a6fa73c3013","type":"COMBINATION_TREATMENT","name":"lenvatinib + pembrolizumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-322b4adb58f3f1c9","description":null,"metadata":null},{"id":"9682445f15874b8185f9df01a0759c82","type":"COMBINATION_TREATMENT","name":"lenvatinib + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-9a4a0af57393a2f2","description":null,"metadata":null},{"id":"6c1f37e898af4e22bf6cff1c93eb3f8a","type":"COMBINATION_TREATMENT","name":"lenvatinib + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-575aca843a569f48","description":null,"metadata":null},{"id":"7e026476a06442e99082dc69a9851322","type":"COMBINATION_TREATMENT","name":"lenvatinib + sintilimab + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-856ffcfa74f87a7e","description":null,"metadata":null},{"id":"e87c2d9596134083b79f3e489b8405d4","type":"COMBINATION_TREATMENT","name":"lenvatinib + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-a7d4c1879b988175","description":null,"metadata":null},{"id":"d5f085ba04af4c8b96e9b61c10618ca7","type":"COMBINATION_TREATMENT","name":"lenvatinib + sorafenib","canonical_id":"ctgov_combo:ctgov-combo-b94771c56e331f8f","description":null,"metadata":null},{"id":"eb51baf535bc40b28e42550c1d53d616","type":"COMBINATION_TREATMENT","name":"lenvatinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-e7cf3399b0779838","description":null,"metadata":null},{"id":"30c1870b400047a9adf822528715f3c2","type":"COMBINATION_TREATMENT","name":"lenvatinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-3facbc4f9e707834","description":null,"metadata":null},{"id":"61d8aeadefd3420fa01938283b23cf6d","type":"COMBINATION_TREATMENT","name":"lenvatinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-2bb4634c6989ae56","description":null,"metadata":null},{"id":"0c14514742ea4855953471ce0ce61edb","type":"COMBINATION_TREATMENT","name":"lenvatinib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-1abcfc9a65a809f4","description":null,"metadata":null},{"id":"39c6ac4b07824eaba29783e76f925041","type":"DRUG","name":"lepirudin","canonical_id":"gtopdb:6469","description":null,"metadata":null},{"id":"b8bbcaee7ade45b097cc12b8e9a41b80","type":"DRUG","name":"lepirudin","canonical_id":"chembl:CHEMBL1201666","description":null,"metadata":null},{"id":"aa97c3f3ac4d412eae4abad4b4e85191","type":"PROTEIN","name":"leptin receptor","canonical_id":"uniprot:P48357","description":null,"metadata":null},{"id":"9c3c0929df2542e1ac02de27f4a76de5","type":"GO_TERM","name":"leptin receptor activity","canonical_id":"go:GO:0038021","description":"\"Combining with the fat-cell specific hormone leptin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:signaling, PMID:9102398, Wikipedia:Leptin_receptor]","metadata":null},{"id":"9cd1d9beeb8f4a0f9daab60be7ae159e","type":"GO_TERM","name":"leptin receptor binding","canonical_id":"go:GO:1990460","description":"\"Binding to a leptin receptor.\" [GOC:pm, PMID:22405007]","metadata":null},{"id":"4aead55958dd4046817ef8449bb4be78","type":"GO_TERM","name":"leptin-mediated signaling pathway","canonical_id":"go:GO:0033210","description":"\"The series of molecular signals initiated by leptin binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Leptin is a hormone manufactured primarily in the adipocytes of white adipose tissue, and the level of circulating leptin is directly proportional to the total amount of fat in the body.\" [GOC:mah, GOC:signaling, GOC:yaf]","metadata":null},{"id":"144e3c6c01a446c7b8211b0a37bcd302","type":"DISEASE","name":"leptomeningeal metastasis","canonical_id":"efo:1001012","description":null,"metadata":null},{"id":"6b0a7b695f644a7dac5b6f1f0b46d715","type":"GO_TERM","name":"leptomycin B binding","canonical_id":"go:GO:1901707","description":"\"Binding to leptomycin B.\" [GOC:TermGenie]","metadata":null},{"id":"c285fcd8b4b042b69ea32f4d7815ecce","type":"GO_TERM","name":"leptotene","canonical_id":"go:GO:0000237","description":"\"The cell cycle phase which is the first stage of prophase I in meiosis, and during which the chromosomes first become visible.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"dc6215b711dd453ba73fa966221a5e0c","type":"DRUG","name":"lercanidipine","canonical_id":"mesh:C060343","description":null,"metadata":null},{"id":"0601ffb700cf42a2ac6ba406aea35fdd","type":"DISEASE","name":"lethal congenital contracture syndrome 2","canonical_id":"mondo:0011868","description":null,"metadata":null},{"id":"a22182a92147425fa6f381c6184d3af8","type":"DISEASE","name":"lethal multiple pterygium syndrome","canonical_id":"mondo:0009668","description":null,"metadata":null},{"id":"9f7950e44c70447aa76f377c9e5912c3","type":"DRUG","name":"letrozole","canonical_id":"gtopdb:5209","description":null,"metadata":null},{"id":"2f42addad399450fb0064ed3a70661c6","type":"DRUG","name":"letrozole","canonical_id":"chembl:CHEMBL1444","description":null,"metadata":null},{"id":"eb03ea9ef3384a6485d71f1d1e55975e","type":"COMBINATION_TREATMENT","name":"letrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-90de189d8ebc5739","description":null,"metadata":null},{"id":"1c07ce3329314430a4f11d77dfb51116","type":"COMBINATION_TREATMENT","name":"letrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-78c17a3fec17353a","description":null,"metadata":null},{"id":"664594a2a51a4145b0741fbdb663f9c9","type":"COMBINATION_TREATMENT","name":"letrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-d8082561aed99d05","description":null,"metadata":null},{"id":"0fab7492296745e88149619287dae1e6","type":"COMBINATION_TREATMENT","name":"letrozole + palbociclib","canonical_id":"ctgov_combo:ctgov-combo-f58207f330a777bb","description":null,"metadata":null},{"id":"c6ef0bb98e4742e5a3ae280197537b77","type":"COMBINATION_TREATMENT","name":"letrozole + palbociclib + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-25dc678f28b31939","description":null,"metadata":null},{"id":"ca80c45149044ef498ccda57f3df265f","type":"COMBINATION_TREATMENT","name":"letrozole + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-62906708479edde0","description":null,"metadata":null},{"id":"6c45c79b66d44f2997a59ef507dfd4d2","type":"COMBINATION_TREATMENT","name":"letrozole + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-35cac69459252669","description":null,"metadata":null},{"id":"e3dd6c5bb6504d57b4ab718c76e1c8bf","type":"COMBINATION_TREATMENT","name":"letrozole + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-db41a31c36c015dd","description":null,"metadata":null},{"id":"bfda0032f253417583592e8e78ce37bc","type":"GO_TERM","name":"leucine zipper domain binding","canonical_id":"go:GO:0043522","description":"\"Binding to a leucine zipper domain, a protein secondary structure exhibiting a periodic repetition of leucine residues at every seventh position over a distance covering eight helical turns.\" [GOC:jl, InterPro:IPR002158]","metadata":null},{"id":"636dcae8483e41e0b39f35d063b536d8","type":"DISEASE","name":"leucine-induced hypoglycemia","canonical_id":"efo:0006856","description":null,"metadata":null},{"id":"c7735470e419479390165bf963d47431","type":"GO_TERM","name":"leucine-tRNA ligase activity","canonical_id":"go:GO:0004823","description":"\"Catalysis of the reaction: leucine + ATP + tRNA(Leu) = AMP + diphosphate + 2 H+ + Leu-tRNA(Leu).\" [RHEA:11688]","metadata":null},{"id":"37734edd203844399f0d0d24e4dd4b62","type":"GO_TERM","name":"leucoanthocyanidin reductase activity","canonical_id":"go:GO:0033788","description":"\"Catalysis of the reaction: (2R,3S)-catechin + NADP+ + H2O = 2,3-trans-3,4-cis-leucocyanidin + NADPH + H+.\" [EC:1.17.1.3]","metadata":null},{"id":"8d627121a2b142498ad96f84891ad6ad","type":"GO_TERM","name":"leucocyanidin oxygenase activity","canonical_id":"go:GO:0050589","description":"\"Catalysis of the reaction: leucocyanidin + 2-oxoglutarate + O2 = cis- or trans-dihydroquercetin + succinate + CO2 + 2 H2O.\" [EC:1.14.20.4]","metadata":null},{"id":"40690cb8505946fca27eb2da07b14b4f","type":"GO_TERM","name":"leucokinin receptor activity","canonical_id":"go:GO:0042071","description":"\"Combining with a leucokinin, any of several octapeptide hormones found in insects, and transmitting the signal to initiate a change in cell activity.\" [GOC:mah, GOC:signaling, PMID:2716741]","metadata":null},{"id":"63f1940462ef46719441845714fb5468","type":"GO_TERM","name":"leucophore differentiation","canonical_id":"go:GO:0048772","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a leucophore cell. Leucophores are pigment cells derived from the neural crest. They contain uric acid or other purine crystals, deposited in stacks called leucosomes. This gives them a white appearance.\" [GOC:jid, GOC:mh]","metadata":null},{"id":"d524c16cdcb94bd48c7304edeffe7bf6","type":"GO_TERM","name":"leucoplast","canonical_id":"go:GO:0009516","description":"\"A colorless plastid involved in the synthesis of monoterpenes.\" [ISBN:0943088399]","metadata":null},{"id":"452dcb9f454d481c806b688f479d500a","type":"GO_TERM","name":"leucoplast fission","canonical_id":"go:GO:0043573","description":"\"The creation of two or more leucoplasts by division of one leucoplast. A leucoplast is a colorless plastid involved in the synthesis of monoterpenes.\" [GOC:jl]","metadata":null},{"id":"b7e9bd9a979c40769ede99b7519e320f","type":"GO_TERM","name":"leucoplast organization","canonical_id":"go:GO:0009659","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a leucoplast. A leucoplast is a colorless plastid involved in the synthesis of monoterpenes.\" [GOC:jid]","metadata":null},{"id":"9a64e5a7ed4d4ce6aeff5d42a08e5bd4","type":"GO_TERM","name":"leucoplast stroma","canonical_id":"go:GO:0009576","description":"\"The space enclosed by the double membrane of a leucoplast.\" [GOC:mah]","metadata":null},{"id":"d647ebfabec6494f90b31a004f5c25b1","type":"GO_TERM","name":"leucosome","canonical_id":"go:GO:0043699","description":"\"A tissue-specific, membrane-bounded cytoplasmic organelle within which uric acid and/or purines crystalize in reflective stacks. Leucosomes are synthesized in leucophore cells and have a whitish cast.\" [GOC:mh]","metadata":null},{"id":"94fe3571aa7845e08b14e0ff22c5b704","type":"DRUG","name":"leucovorin","canonical_id":"mesh:D002955","description":null,"metadata":null},{"id":"9f04b2fcf80845dd81b7f591788bd85b","type":"GO_TERM","name":"leucyl-tRNA aminoacylation","canonical_id":"go:GO:0006429","description":"\"The process of coupling leucine to leucyl-tRNA, catalyzed by leucyl-tRNA synthetase. The leucyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a leucine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"82a7933d7b5f4b6bbadffeb15b8cbcea","type":"GO_TERM","name":"leucyl-tRNA--protein transferase activity","canonical_id":"go:GO:0008914","description":"\"Catalysis of the reaction: L-leucyl-tRNA(Leu) + N-terminal L-arginyl-[protein] = H+ + N-terminal L-leucyl-L-arginyl-[protein] + tRNA(Leu). Can also transfer the leucyl residue on an N-terminal L-lysyl residue.\" [EC:2.3.2.6]","metadata":null},{"id":"39eb388cf0774138bdf4a98775352719","type":"DISEASE","name":"leukemia","canonical_id":"mondo:0005059","description":null,"metadata":null},{"id":"f11f8eb81b8a445a88ded11546bd80f7","type":"GO_TERM","name":"leukemia inhibitory factor receptor activity","canonical_id":"go:GO:0004923","description":"\"Combining with leukemia inhibitory factor (LIF) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:mah, GOC:signaling]","metadata":null},{"id":"6b13371861924a3886aeb46e0fd98293","type":"GO_TERM","name":"leukemia inhibitory factor receptor binding","canonical_id":"go:GO:0005146","description":"\"Binding to an leukemia inhibitory factor receptor.\" [GOC:ai]","metadata":null},{"id":"5312afe8ec1d4cdea7a6644314b1eb50","type":"GO_TERM","name":"leukemia inhibitory factor signaling pathway","canonical_id":"go:GO:0048861","description":"\"The series of molecular signals initiated by the binding of a leukemia inhibitory factor to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:devbiol, GOC:signaling]","metadata":null},{"id":"bac3bcf04eef4adf8a24604a96a7099a","type":"GO_TERM","name":"leukocyte activation","canonical_id":"go:GO:0045321","description":"\"A change in morphology and behavior of a leukocyte resulting from exposure to a specific antigen, mitogen, cytokine, cellular ligand, or soluble factor.\" [GOC:add]","metadata":null},{"id":"3ce09345320340a1ba16f3ec5684a1ce","type":"GO_TERM","name":"leukocyte activation involved in immune response","canonical_id":"go:GO:0002366","description":"\"A change in morphology and behavior of a leukocyte resulting from exposure to a specific antigen, mitogen, cytokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"401375cd19774d36b08c05401b5e0d1d","type":"GO_TERM","name":"leukocyte activation involved in inflammatory response","canonical_id":"go:GO:0002269","description":"\"A change in the morphology or behavior of a leukocyte resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f78c583f82064cd294b8ede4acaca8e1","type":"GO_TERM","name":"leukocyte activation-dependent arrest","canonical_id":"go:GO:0050903","description":"\"The formation of an integrin-dependent strong adhesive bond between leukocytes and blood vessel endothelial cells which is dependent on prior activation of the leukocyte and leads to the firm attachment of the leukocyte to the endothelial surface, typically the third step in cellular extravasation.\" [ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538]","metadata":null},{"id":"20855ba17fd54f74be07b15ef622dc69","type":"GO_TERM","name":"leukocyte adhesion to arterial endothelial cell","canonical_id":"go:GO:0061757","description":"\"The attachment of a leukocyte to an arterial endothelial cell via adhesion molecules.\" [GOC:add, GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:22267480]","metadata":null},{"id":"bc03c4c239924c858f25d82d22ff38f7","type":"GO_TERM","name":"leukocyte adhesion to vascular endothelial cell","canonical_id":"go:GO:0061756","description":"\"The attachment of a leukocyte to vascular endothelial cell via adhesion molecules.\" [GOC:add, GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:23897866]","metadata":null},{"id":"af16bfbd942245d3b4026f9df5337412","type":"GO_TERM","name":"leukocyte adhesive activation","canonical_id":"go:GO:0050902","description":"\"The activation of loosely bound or rolling leukocytes by signals displayed on blood vessel endothelial cells, which is typically the second step in cellular extravasation.\" [ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538]","metadata":null},{"id":"cb9a4466ce134f209d4f4319aa58bfcf","type":"GO_TERM","name":"leukocyte aggregation","canonical_id":"go:GO:0070486","description":"\"The adhesion of one leukocyte to one or more other leukocytes via adhesion molecules.\" [GOC:sl, PMID:12972508]","metadata":null},{"id":"5eaef2800b144aa884fea10e5a8688a6","type":"GO_TERM","name":"leukocyte apoptotic process","canonical_id":"go:GO:0071887","description":"\"Any apoptotic process in a leukocyte, an achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.\" [CL:0000738, GOC:BHF, GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"4dbfd766659c45cebd4fb7778620db25","type":"GO_TERM","name":"leukocyte cell-cell adhesion","canonical_id":"go:GO:0007159","description":"\"The attachment of a leukocyte to another cell via adhesion molecules.\" [GOC:curators]","metadata":null},{"id":"27639a0fe9754d82b5f3885b65096b41","type":"GO_TERM","name":"leukocyte chemotaxis","canonical_id":"go:GO:0030595","description":"\"The movement of a leukocyte in response to an external stimulus.\" [GOC:add, GOC:jl]","metadata":null},{"id":"d9237bf084c348288862b5a6ccdc82f2","type":"GO_TERM","name":"leukocyte chemotaxis involved in immune response","canonical_id":"go:GO:0002233","description":"\"The movement of an immune cell in response to an external stimulus a part of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"18ae14b22f67444693ae065c9bf4a858","type":"GO_TERM","name":"leukocyte chemotaxis involved in inflammatory response","canonical_id":"go:GO:0002232","description":"\"The movement of an immune cell in response to an external stimulus contributing to an inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"95714a16e7fd4d1a8786e5cc94a3362d","type":"GO_TERM","name":"leukocyte degranulation","canonical_id":"go:GO:0043299","description":"\"The regulated exocytosis of secretory granules by a leukocyte.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"00943656984a4d30922771e568858920","type":"GO_TERM","name":"leukocyte differentiation","canonical_id":"go:GO:0002521","description":"\"The process in which a relatively unspecialized hemopoietic precursor cell acquires the specialized features of a leukocyte. A leukocyte is an achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.\" [CL:0000738, GOC:add, PMID:16551264]","metadata":null},{"id":"ea8f4f597cad4fd891788545b70930a5","type":"GO_TERM","name":"leukocyte homeostasis","canonical_id":"go:GO:0001776","description":"\"The process of regulating the proliferation and elimination of cells of the immune system such that the total number of cells of a particular cell type within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d70fa384b3c34f75948f1c24233382f1","type":"GO_TERM","name":"leukocyte mediated cytotoxicity","canonical_id":"go:GO:0001909","description":"\"The directed killing of a target cell by a leukocyte.\" [GO_REF:0000022, GOC:add, ISBN:0781735149, PMID:11911826]","metadata":null},{"id":"001ab85207fa4a79832ab9571e861f63","type":"GO_TERM","name":"leukocyte mediated immunity","canonical_id":"go:GO:0002443","description":"\"Any process involved in the carrying out of an immune response by a leukocyte.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"d25ef0d7396e4cc3983af48e2d17f4c7","type":"GO_TERM","name":"leukocyte migration","canonical_id":"go:GO:0050900","description":"\"The movement of a leukocyte within or between different tissues and organs of the body.\" [GOC:add, ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538]","metadata":null},{"id":"3804d4aed6864c47baaabc3fb89ba349","type":"GO_TERM","name":"leukocyte migration involved in immune response","canonical_id":"go:GO:0002522","description":"\"The movement of a leukocyte within or between different tissues and organs of the body as part of an immune response.\" [GOC:add, ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538]","metadata":null},{"id":"566211b397a34dee8b5d6c670aeb6309","type":"GO_TERM","name":"leukocyte migration involved in inflammatory response","canonical_id":"go:GO:0002523","description":"\"The movement of a leukocyte within or between different tissues and organs of the body contributing to an inflammatory response.\" [GOC:add, ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538]","metadata":null},{"id":"d893915c87814fd9ae8096926bddca07","type":"GO_TERM","name":"leukocyte proliferation","canonical_id":"go:GO:0070661","description":"\"The expansion of a leukocyte population by cell division.\" [GOC:add]","metadata":null},{"id":"c703f6c049c446feb2193098af5a8c2a","type":"GO_TERM","name":"leukocyte tethering or rolling","canonical_id":"go:GO:0050901","description":"\"Transient adhesive interactions between leukocytes and endothelial cells lining blood vessels. Carbohydrates on circulating leukocytes bind selectins on the vessel wall causing the leukocytes to slow down and roll along the inner surface of the vessel wall. During this rolling motion, transitory bonds are formed and broken between selectins and their ligands. Typically the first step in cellular extravasation (the movement of leukocytes out of the circulatory system, towards the site of tissue damage or infection).\" [GOC:bf, ISBN:0781735149, PMID:14680625, PMID:14708592, PMID:7507411, PMID:8600538, Wikipedia:Leukocyte_extravasation]","metadata":null},{"id":"9e9b22ecd8e54e30a0a08795e8638e78","type":"DISEASE","name":"leukoencephalopathy with mild cerebellar ataxia and white matter edema","canonical_id":"mondo:0014292","description":null,"metadata":null},{"id":"40bbc7d23c83465eb009492facdac7ef","type":"DISEASE","name":"leukoencephalopathy, diffuse hereditary, with spheroids 1","canonical_id":"mondo:0800027","description":null,"metadata":null},{"id":"2dc2cfb02b64486aa3f15fc8a46cf22f","type":"DISEASE","name":"leukoencephalopathy, hereditary diffuse, with spheroids","canonical_id":"mondo:0030796","description":null,"metadata":null},{"id":"5d78c74a786b4b6cbba7284da2dc0f17","type":"GO_TERM","name":"leukotriene A4 biosynthetic process","canonical_id":"go:GO:1901753","description":"\"The chemical reactions and pathways resulting in the formation of leukotriene A4.\" [GOC:TermGenie, GOC:yaf, PMID:23242647]","metadata":null},{"id":"8e108db8f4c4485786e3441c61214ee0","type":"GO_TERM","name":"leukotriene A4 catabolic process","canonical_id":"go:GO:1901752","description":"\"The chemical reactions and pathways resulting in the breakdown of leukotriene A4.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"6dd6081315e84e8587875ca7e10081c5","type":"GO_TERM","name":"leukotriene A4 metabolic process","canonical_id":"go:GO:1901751","description":"\"The chemical reactions and pathways involving leukotriene A4.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"24ced0e2238d448ba9102815da17cf3b","type":"GO_TERM","name":"leukotriene B4 12-hydroxy dehydrogenase activity","canonical_id":"go:GO:0097257","description":"\"Catalysis of the reaction: leukotriene B4 + NADP+ = 12-oxo-leukotriene B4 + NADPH + H+.\" [GOC:mw, KEGG_REACTION:R03864, PMID:8394361, PMID:9461497]","metadata":null},{"id":"4349fb8772444468a8424583f0cb16a9","type":"GO_TERM","name":"leukotriene B4 biosynthetic process","canonical_id":"go:GO:0097251","description":"\"The chemical reactions and pathways resulting in the formation of leukotriene B4, a leukotriene composed of (6Z,8E,10E,14Z)-eicosatetraenoic acid having (5S)- and (12R)-hydroxy substituents.\" [GOC:yaf]","metadata":null},{"id":"4dc016b79e61407ea1ba527e8c3ee8c3","type":"GO_TERM","name":"leukotriene B4 catabolic process","canonical_id":"go:GO:0036101","description":"\"The chemical reactions and pathways resulting in the breakdown of leukotriene B4, a leukotriene composed of (6Z,8E,10E,14Z)-eicosatetraenoic acid having (5S)- and (12R)-hydroxy substituents.\" [GOC:yaf, PMID:9799565]","metadata":null},{"id":"c08927dbc072444d883089afdb8cfc87","type":"GO_TERM","name":"leukotriene B4 metabolic process","canonical_id":"go:GO:0036102","description":"\"The chemical reactions and pathways involving leukotriene B4, a leukotriene composed of (6Z,8E,10E,14Z)-eicosatetraenoic acid having (5S)- and (12R)-hydroxy substituents.\" [GOC:bf]","metadata":null},{"id":"16ca365c366b4e7eb7cc9ee01decb4c8","type":"GO_TERM","name":"leukotriene B4 receptor activity","canonical_id":"go:GO:0001632","description":"\"Combining with leukotriene B4, LTB4, to initiate a change in cell activity. Leukotriene B4 is also known as (6Z, 8E, 10E, 14Z)-(5S, 12R)-5,12-dihydroxyicosa-6,8,10,14-tetraen-1-oate.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"41897f53786945f595ff258d2b391cab","type":"GO_TERM","name":"leukotriene D4 biosynthetic process","canonical_id":"go:GO:1901750","description":"\"The chemical reactions and pathways resulting in the formation of leukotriene D4.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00880]","metadata":null},{"id":"124dd88f34a44b6e89f0dede9ff0b4a6","type":"GO_TERM","name":"leukotriene D4 catabolic process","canonical_id":"go:GO:1901749","description":"\"The chemical reactions and pathways resulting in the breakdown of leukotriene D4.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"aae27589090d4d0db2ea60266537a6fd","type":"GO_TERM","name":"leukotriene biosynthetic process","canonical_id":"go:GO:0019370","description":"\"The chemical reactions and pathways resulting in the formation of leukotriene, a pharmacologically active substance derived from a polyunsaturated fatty acid, such as arachidonic acid.\" [GOC:curators]","metadata":null},{"id":"db118d013a654ef09d1748c478d19c8d","type":"GO_TERM","name":"leukotriene catabolic process","canonical_id":"go:GO:0036100","description":"\"The chemical reactions and pathways resulting in the breakdown of a leukotriene, a pharmacologically active substance derived from a polyunsaturated fatty acid, such as arachidonic acid.\" [GOC:yaf]","metadata":null},{"id":"b60a3f33273047ff86c3c6293c2d4761","type":"GO_TERM","name":"leukotriene metabolic process","canonical_id":"go:GO:0006691","description":"\"The chemical reactions and pathways involving leukotriene, a pharmacologically active substance derived from a polyunsaturated fatty acid, such as arachidonic acid.\" [GOC:ma]","metadata":null},{"id":"f85816f36cdb42a3892e7d812f1c0873","type":"GO_TERM","name":"leukotriene production involved in inflammatory response","canonical_id":"go:GO:0002540","description":"\"The synthesis or release of any leukotriene following a stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"bbd7f8b697a249449d0f8de3ecb50817","type":"GO_TERM","name":"leukotriene receptor activity","canonical_id":"go:GO:0004974","description":"\"Combining with a leukotriene to initiate a change in cell activity. Leukotrienes are pharmacologically active substances with a set of three conjugated double bonds; some contain a peptide group based on cysteine.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"690e20dd963641ecb82ad9fe9ccbc53e","type":"GO_TERM","name":"leukotriene receptor binding","canonical_id":"go:GO:0031774","description":"\"Binding to a leukotriene receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"713fd65adc7546ec846b3485bd14ec75","type":"GO_TERM","name":"leukotriene signaling pathway","canonical_id":"go:GO:0061737","description":"\"A G protein-coupled receptor signaling pathway initiated by leukotriene binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:dph, PMID:21771892]","metadata":null},{"id":"73eb11a80941423a942f7928319187ed","type":"GO_TERM","name":"leukotriene transport","canonical_id":"go:GO:0071716","description":"\"The directed movement of leukotrienes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Leukotrienes are linear C20 endogenous metabolites of arachidonic acid (icosa-5,8,11,14-tetraenoic acid) containing a terminal carboxy function and four or more double bonds (three or more of which are conjugated) as well as other functional groups.\" [GOC:mah]","metadata":null},{"id":"456f54c93b2d4b678efd4aba56062eac","type":"GO_TERM","name":"leukotriene-A4 hydrolase activity","canonical_id":"go:GO:0004463","description":"\"Catalysis of the reaction: H2O + leukotriene A(4) = leukotriene B(4).\" [EC:3.3.2.6, RHEA:22324]","metadata":null},{"id":"4f16496d5c3049e29e66edf15f130559","type":"GO_TERM","name":"leukotriene-B4 20-monooxygenase activity","canonical_id":"go:GO:0050051","description":"\"Catalysis of the reaction: leukotriene B4 + O2 + reduced [NADPH-hemoprotein reductase] = 20-hydroxy-leukotriene B4 + H+ + H2O + oxidized [NADPH-hemoprotein reductase].\" [PMID:11461919, PMID:15364545, PMID:8486631, PMID:9675028, RHEA:22176]","metadata":null},{"id":"bee10323dcb44b418834f5d1fb41f6cc","type":"GO_TERM","name":"leukotriene-C(4) hydrolase activity","canonical_id":"go:GO:0002951","description":"\"Catalysis of the reaction leukotriene C(4) + H2O= leukotriene D(4) + L-glutamate.\" [PMID:9774450, RHEA:31563]","metadata":null},{"id":"75ea2741518d4fc4ab77aaf67bc52f76","type":"GO_TERM","name":"leukotriene-C4 synthase activity","canonical_id":"go:GO:0004464","description":"\"Catalysis of the reaction: leukotriene C(4) = glutathione + leukotriene A(4).\" [EC:4.4.1.20, RHEA:17617]","metadata":null},{"id":"d0ca9abc28044b7faaf8f2eea4e6cc52","type":"GO_TERM","name":"leukotriene-E4 20-monooxygenase activity","canonical_id":"go:GO:0050052","description":"\"Catalysis of the reaction: H+ + leukotriene E(4) + NADPH + O2 = 20-hydroxy-leukotriene E(4) + H2O + NADP+.\" [EC:1.14.13.34, RHEA:24120]","metadata":null},{"id":"7b672b3b9f8345a097a610a2153cc577","type":"DRUG","name":"leuprolide","canonical_id":"gtopdb:1175","description":null,"metadata":null},{"id":"9008cfd970f04f9e9df722e001b42653","type":"DRUG","name":"levallorphan","canonical_id":"gtopdb:7209","description":null,"metadata":null},{"id":"136d66b322114c8f9f5dd067808f7947","type":"GO_TERM","name":"levan fructotransferase (DFA-IV-forming) activity","canonical_id":"go:GO:0033996","description":"\"Catalysis of the reaction: beta-D-fructopyranosyl-(2->6)-[D-fructofuranosyl-(2->6)]n-D-fructofuranoside = beta-D-fructopyranosyl-(2->6)-[D-fructofuranosyl-(2->6)](n-1)-D-fructofuranoside + di-beta-D-fructofuranose 2,6':2',6-dianhydride. This reaction is the production of di-beta-D-fructofuranose 2,6':2',6-dianhydride (DFA IV) by successively eliminating the diminishing (2->6)-beta-D-fructan (levan) chain from the terminal D-fructosyl-D-fructosyl disaccharide.\" [EC:4.2.2.16]","metadata":null},{"id":"4710085b3f084b358c6af9eb18083960","type":"GO_TERM","name":"levanase activity","canonical_id":"go:GO:0031219","description":"\"Catalysis of the random hydrolysis of 2,6-beta-D-fructofuranosidic linkages in 2,6-beta-D-fructans (levans) containing more than 3 fructose units.\" [EC:3.2.1.65, GOC:mlg]","metadata":null},{"id":"d49e80249df44750b5bd8accf16f7a16","type":"GO_TERM","name":"levansucrase activity","canonical_id":"go:GO:0050053","description":"\"Catalysis of the reaction: sucrose + 2,6-beta-D-fructosyl(n) = glucose + 2,6-beta-D-fructosyl(n+1).\" [EC:2.4.1.10, MetaCyc:LEVANSUCRASE-RXN]","metadata":null},{"id":"a432852a1109420bbff42a71b709c343","type":"DRUG","name":"levetiracetam","canonical_id":"gtopdb:6826","description":null,"metadata":null},{"id":"3cb0294c9cd24d609dc2919aecff3700","type":"DRUG","name":"levetiracetam","canonical_id":"mesh:C026098","description":null,"metadata":null},{"id":"72c3700350a54c46879ba61a91702540","type":"DRUG","name":"levetiracetam","canonical_id":"chembl:CHEMBL1286","description":null,"metadata":null},{"id":"3f4753358c7d4e8db1613056d962c741","type":"COMBINATION_TREATMENT","name":"levetiracetam + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-96e89304848d04a5","description":null,"metadata":null},{"id":"d291d98b3af84829bf4c04129676560c","type":"COMBINATION_TREATMENT","name":"levetiracetam + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-683a1c318837415c","description":null,"metadata":null},{"id":"346b54b294a34413a21b3c7ff82f1331","type":"COMBINATION_TREATMENT","name":"levetiracetam + sertraline","canonical_id":"ctgov_combo:ctgov-combo-b7d0d442f237b87a","description":null,"metadata":null},{"id":"12aac43eb876484e8863ba23f487006c","type":"DRUG","name":"levocabastine","canonical_id":"mesh:C047340","description":null,"metadata":null},{"id":"fcf73e69ca1b478092c5d87a1a79542e","type":"DRUG","name":"levodopa","canonical_id":"mesh:D007980","description":null,"metadata":null},{"id":"fca95ae9bda94e12b68eede67cc36801","type":"DRUG","name":"levofloxacin","canonical_id":"mesh:D064704","description":null,"metadata":null},{"id":"dde58d7260da415db9c6dc84e9618dae","type":"DRUG","name":"levofolinic acid","canonical_id":"mesh:D058766","description":null,"metadata":null},{"id":"8f1aa3b70a834f6ba58fd55176aeb2e1","type":"DRUG","name":"levomefolic acid","canonical_id":"mesh:C569381","description":null,"metadata":null},{"id":"4ab2e3358b054589b99991a5a928acf9","type":"DRUG","name":"levomilnacipran","canonical_id":"gtopdb:7435","description":null,"metadata":null},{"id":"d24f205c86b04f7297f8dc26c699c886","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-43b7aadfeed2653f","description":null,"metadata":null},{"id":"a1084c5758fe4328bc490cf271ccdbf1","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-5164f327bff4e699","description":null,"metadata":null},{"id":"f71d62c9b121454fad7c5c61e73dbfa1","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-df807c8154d148b5","description":null,"metadata":null},{"id":"9245ecb7b66c43979f95b079f660b605","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-c377548f99cb768b","description":null,"metadata":null},{"id":"a6a9474f7ca4497e840fd6228f45f95f","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-7f434fb900ee182e","description":null,"metadata":null},{"id":"38865be7225e44359fa531c1ff7130b1","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-45213345b367aaff","description":null,"metadata":null},{"id":"470ee13a7f6c4923afac705751fdbe4f","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-5356725edf539d3a","description":null,"metadata":null},{"id":"66cd7ba38714464eb81e33f5f5585247","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-4df7d268b25085a6","description":null,"metadata":null},{"id":"59d744da0ce940129465bdfea34cb22f","type":"COMBINATION_TREATMENT","name":"levomilnacipran + milnacipran","canonical_id":"ctgov_combo:ctgov-combo-5a2395183f44701a","description":null,"metadata":null},{"id":"fbc689178d98454a8e6e0c9853b0678d","type":"DRUG","name":"levonorgestrel","canonical_id":"gtopdb:2881","description":null,"metadata":null},{"id":"ab5936df17f0415f890b2d3b8a1dc307","type":"DRUG","name":"levonorgestrel","canonical_id":"mesh:D016912","description":null,"metadata":null},{"id":"064b1a9e1a584e8d9ad6194f77edb24c","type":"DRUG","name":"levonorgestrel","canonical_id":"chembl:CHEMBL1389","description":null,"metadata":null},{"id":"27385bf1032f4070b489ad9ecb6a64df","type":"COMBINATION_TREATMENT","name":"levonorgestrel + mifepristone","canonical_id":"ctgov_combo:ctgov-combo-806412afa96e0901","description":null,"metadata":null},{"id":"7abced4c48314daa98ddf5e480fe9b5e","type":"COMBINATION_TREATMENT","name":"levonorgestrel + progesterone","canonical_id":"ctgov_combo:ctgov-combo-9c8749e12fb93d73","description":null,"metadata":null},{"id":"1af4a3aa407643b8b1fbcd67f7d41e70","type":"GO_TERM","name":"levopimaradiene synthase activity","canonical_id":"go:GO:0052678","description":"\"Catalysis of the reaction: (+)-copalyl diphosphate = abieta-8(14),12-diene + diphosphate.\" [RHEA:25548]","metadata":null},{"id":"f0b7b38694654c0990a320557bdc2680","type":"DRUG","name":"levorphanol","canonical_id":"gtopdb:7595","description":null,"metadata":null},{"id":"d50708b009be4b21a0aa8637806f2049","type":"DRUG","name":"levorphanol","canonical_id":"mesh:D007981","description":null,"metadata":null},{"id":"4cc6597a7a2f4780aea45630d269dc8d","type":"DRUG","name":"levosalbutamol","canonical_id":"mesh:D064412","description":null,"metadata":null},{"id":"81ee5cb1cc0340a79dce9e5eaa796642","type":"GO_TERM","name":"licheninase activity","canonical_id":"go:GO:0042972","description":"\"Catalysis of the hydrolysis of (1->4)-beta-D-glucosidic linkages in beta-D-glucans containing (1->3) and (1->4) bonds.\" [EC:3.2.1.73]","metadata":null},{"id":"d2b1ebefc8614ee1879474d65d80710b","type":"GO_TERM","name":"licodione 2'-O-methyltransferase activity","canonical_id":"go:GO:0030751","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + licodione = 2'-O-methyllicodione + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.65, RHEA:18521]","metadata":null},{"id":"4e330022b3654119bcef993e8eab4044","type":"DRUG","name":"lidocaine","canonical_id":"gtopdb:2623","description":null,"metadata":null},{"id":"329cf96f31c24502b690e468690e6a74","type":"DRUG","name":"lidocaine","canonical_id":"mesh:D008012","description":null,"metadata":null},{"id":"5c5a38d770d44b1b9166833f9b63b25b","type":"DRUG","name":"lidocaine","canonical_id":"chembl:CHEMBL79","description":null,"metadata":null},{"id":"b19e7ecc1f684d13a010742f1c7176a6","type":"GO_TERM","name":"lifelong otolith mineralization","canonical_id":"go:GO:0031174","description":"\"The formation and growth of otoliths throughout the life of the organism. Otoliths are the large extracellular ear-stones of the fish inner ear, produced by precipitation of specific crystal forms of calcium carbonate on organic matrices. The otolith enlarges throughout the life of the fish, as layers of calcium carbonate are added.\" [GOC:dsf, PMID:15581873]","metadata":null},{"id":"9cf32c4285ee43c7a84cdb2b5f5c3fa9","type":"DRUG","name":"lifitegrast","canonical_id":"gtopdb:7533","description":null,"metadata":null},{"id":"f5132c9b47d9419f8fe3140fd145feae","type":"DRUG","name":"lifitegrast","canonical_id":"chembl:CHEMBL2048028","description":null,"metadata":null},{"id":"69397362720543b6ab1ac6111bbdcd82","type":"GO_TERM","name":"ligamentous ossification","canonical_id":"go:GO:0036076","description":"\"Ossification wherein bone tissue forms within ligamentous tissue.\" [GO_REF:0000034]","metadata":null},{"id":"82aaec910a9e49fcb523dec30d04ab6a","type":"GO_TERM","name":"ligand-gated calcium channel activity","canonical_id":"go:GO:0099604","description":"\"Enables the transmembrane transfer of a calcium ions by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:dos]","metadata":null},{"id":"dc2c169fbc2f4077bf49a7b7cc27eebb","type":"GO_TERM","name":"ligand-gated channel activity","canonical_id":"go:GO:0022834","description":"\"Enables the transmembrane transfer of a solute by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e85d6494c0db4317bad1e18d69bf06c0","type":"GO_TERM","name":"ligand-gated ion channel signaling pathway","canonical_id":"go:GO:1990806","description":"\"The series of molecular signals initiated by activation of a ligand-gated ion channel on the surface of a cell. The pathway begins with binding of an extracellular ligand to a ligand-gated ion channel and ends with a molecular function that directly regulates a downstream cellular process, e.g. transcription.\" [GOC:bhm, PMID:25869137]","metadata":null},{"id":"73fcf6705c1e4bb39b371b0df099bfdd","type":"GO_TERM","name":"ligand-gated monoatomic anion channel activity","canonical_id":"go:GO:0099095","description":"\"Enables the transmembrane transfer of an inorganic anion by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"7fa771c77a894f0392a76e35c0a72541","type":"GO_TERM","name":"ligand-gated monoatomic cation channel activity","canonical_id":"go:GO:0099094","description":"\"Enables the transmembrane transfer of an inorganic cation by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e4650bf4d0664007b3b407a77e019eea","type":"GO_TERM","name":"ligand-gated monoatomic ion channel activity","canonical_id":"go:GO:0015276","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"1b613e8188434e2ca43eab3ed3d66fb7","type":"GO_TERM","name":"ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential","canonical_id":"go:GO:0099507","description":"\"Any ligand-gated ion channel activity, occurring in the presynaptic membrane, that is involved in regulation of presynaptic membrane potential.\" [GOC:dos, PMID:15145529, PMID:19558451]","metadata":null},{"id":"57ffe01a231747caad11faa7e6cdcdf4","type":"GO_TERM","name":"ligand-gated sodium channel activity","canonical_id":"go:GO:0015280","description":"\"Enables the transmembrane transfer of a sodium ion by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:mah]","metadata":null},{"id":"1c7da6b6bc4345c59318596a4e56bfb4","type":"GO_TERM","name":"ligand-independent adenylate cyclase-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0038035","description":"\"A G protein-coupled receptor signaling pathway in which the receptor constitutively activates adenylate cyclase, without binding to an agonist.\" [PMID:12402500, PMID:17629961]","metadata":null},{"id":"a9b1bdaaef9e4567990ff4248b0acc3c","type":"GO_TERM","name":"ligand-modulated transcription activator activity","canonical_id":"go:GO:0141097","description":"\"A DNA-binding transcription activator activity regulated by binding to a ligand and that activates the transcription of specific genes and gene sets.\" [GOC:pg]","metadata":null},{"id":"dbfe362c293c450c8981b9f2bd303817","type":"GO_TERM","name":"ligand-modulated transcription factor activity","canonical_id":"go:GO:0098531","description":"\"A DNA-binding transcription factor activity regulated by binding to a ligand and that modulates the transcription of specific genes and gene sets. Examples include the lac and trp repressors in E.coli and steroid hormone receptors.\" [GOC:dos, PMID:25568920, PMID:8735275]","metadata":null},{"id":"960c3f7965f74cdf95ff67b140ddc013","type":"GO_TERM","name":"ligand-modulated transcription repressor activity","canonical_id":"go:GO:0141096","description":"\"A DNA-binding transcription repressor activity regulated by binding to a ligand and that inhibits the transcription of specific genes and gene sets.\" [PMID:21555518]","metadata":null},{"id":"47c91ee3b6f9478e88acb58de69ad116","type":"GO_TERM","name":"ligase activity","canonical_id":"go:GO:0016874","description":"\"Catalysis of the joining of two molecules, or two groups within a single molecule, using the energy from the hydrolysis of ATP, a similar triphosphate, or a pH gradient.\" [EC:6.-.-.-]","metadata":null},{"id":"c685d2795c90437bad2e618f77bd6929","type":"GO_TERM","name":"ligase activity, forming carbon-carbon bonds","canonical_id":"go:GO:0016885","description":"\"Catalysis of the joining of two molecules via a carbon-carbon bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.4.-.-]","metadata":null},{"id":"be57c112feb94b07bd775e0650f56239","type":"GO_TERM","name":"ligase activity, forming carbon-nitrogen bonds","canonical_id":"go:GO:0016879","description":"\"Catalysis of the joining of two molecules, or two groups within a single molecule, via a carbon-nitrogen bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.3.-.-]","metadata":null},{"id":"fd175556ef154f8f95d0b2c65a9d11e7","type":"GO_TERM","name":"ligase activity, forming carbon-oxygen bonds","canonical_id":"go:GO:0016875","description":"\"Catalysis of the joining of two molecules via a carbon-oxygen bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.1.-.-]","metadata":null},{"id":"aedd5e1b21854102b58f05aba4c9dbbe","type":"GO_TERM","name":"ligase activity, forming carbon-sulfur bonds","canonical_id":"go:GO:0016877","description":"\"Catalysis of the joining of two molecules via a carbon-sulfur bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.2.-.-]","metadata":null},{"id":"04cbfdc93e864e2591133be02535b185","type":"GO_TERM","name":"ligase activity, forming nitrogen-metal bonds","canonical_id":"go:GO:0051002","description":"\"Catalysis of the joining of a metal ion to a molecule via a nitrogen-metal bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.6.-.-]","metadata":null},{"id":"f64d4c2005cb4ddc8716a428508d3074","type":"GO_TERM","name":"ligase activity, forming nitrogen-metal bonds, forming coordination complexes","canonical_id":"go:GO:0051003","description":"\"Catalysis of the ligation of two substances via a nitrogen-metal bond, forming a coordination complex.\" [EC:6.6.1.-]","metadata":null},{"id":"ddabae757e4c4eb39435761b3889f07f","type":"GO_TERM","name":"ligase activity, forming phosphoric ester bonds","canonical_id":"go:GO:0016886","description":"\"Catalysis of the joining of two molecules, or two groups within a single molecule, via a phosphoric ester bond, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.\" [EC:6.5.-.-]","metadata":null},{"id":"d0e1e3f09454428d9dd2413c3692df45","type":"GO_TERM","name":"ligase inhibitor activity","canonical_id":"go:GO:0055104","description":"\"Binds to and stops, prevents or reduces the activity of a ligase.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"90d8043eed7f461092c5109556816aec","type":"GO_TERM","name":"ligase regulator activity","canonical_id":"go:GO:0055103","description":"\"Binds to and modulates the activity of a ligase.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"779c90c25fde44d4949ce68d22b616e6","type":"GO_TERM","name":"light absorption","canonical_id":"go:GO:0016037","description":"\"The reception of a photon by a cell.\" [GOC:curators]","metadata":null},{"id":"570c2a08cbcb4fe5a9d9448cc3085303","type":"GO_TERM","name":"light adaption","canonical_id":"go:GO:0036367","description":"\"The ability of a photoreceptor to adjust to varying levels of light.\" [GOC:gap, PMID:16039565]","metadata":null},{"id":"e6025892696f476e8f9893f4c99eaead","type":"GO_TERM","name":"light transducer activity","canonical_id":"go:GO:0031993","description":"\"Absorbing energy from one or more photons and transferring their energy to another molecule, usually a protein, within the cell.\" [GOC:mah, GOC:mlg]","metadata":null},{"id":"c28e5187f93945028560264b7a2d4b69","type":"GO_TERM","name":"light-activated monoatomic ion channel activity","canonical_id":"go:GO:0010461","description":"\"Enables the transmembrane transfer of a monoatomic ion by a channel that opens in response to a light stimulus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8ff93901d887491dac8a6222785e5f2f","type":"GO_TERM","name":"light-activated voltage-gated calcium channel activity","canonical_id":"go:GO:0008086","description":"\"Enables the transmembrane transfer of a calcium ion by a voltage-gated channel that is activated in response to light. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport]","metadata":null},{"id":"38cb7ef6e9ae422598424c776a7eb580","type":"GO_TERM","name":"light-activated voltage-gated calcium channel complex","canonical_id":"go:GO:0008087","description":"\"A protein complex that forms a transmembrane channel through which calcium ions may cross a cell membrane in response to changes in membrane potential generated in response to a light stimulus.\" [GOC:mah, PMID:9223679]","metadata":null},{"id":"4f7b582153fd4dbb96015f9d58e745cc","type":"GO_TERM","name":"light-dependent bacteriochlorophyll biosynthetic process","canonical_id":"go:GO:0036069","description":"\"The chemical reactions and pathways resulting in the formation of a bacteriochlorophyll, which occur in the presence of light. Bacteriochlorophylls are any of the chlorophylls of photosynthetic bacteria; they differ structurally from the chlorophylls of higher plants.\" [GOC:yaf, PMID:12242396]","metadata":null},{"id":"41def246af18468da8298a84eebd386e","type":"GO_TERM","name":"light-dependent chlorophyll biosynthetic process","canonical_id":"go:GO:0036067","description":"\"The chemical reactions and pathways resulting in the formation of chlorophyll, any compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment, from less complex precursors, which occur in the presence of light.\" [GOC:yaf, PMID:12242396]","metadata":null},{"id":"31eda5bc8bad4f89ba1676fbbba36157","type":"GO_TERM","name":"light-driven active monoatomic ion transmembrane transporter activity","canonical_id":"go:GO:0015454","description":"\"Active transport of an ion across a membrane, driven by light.\" [GOC:mtg_transport, PMID:23994288, PMID:26442282]","metadata":null},{"id":"05832d02b3e64282b788a16f31ad6d82","type":"GO_TERM","name":"light-harvesting complex","canonical_id":"go:GO:0030076","description":"\"A protein-pigment complex that may be closely or peripherally associated to photosynthetic reaction centers that participate in harvesting and transferring radiant energy to the reaction center.\" [GOC:lr]","metadata":null},{"id":"3b15d467a97845fead6b43f8efe3bd9d","type":"GO_TERM","name":"light-harvesting complex, core complex","canonical_id":"go:GO:0030078","description":"\"Light harvesting complex associated with the reaction complex of photosynthetic purple bacteria.\" [GOC:lr]","metadata":null},{"id":"6a7c223fba064caa84c8f1014bd6f8a1","type":"GO_TERM","name":"light-harvesting complex, peripheral complex","canonical_id":"go:GO:0030079","description":"\"Bacteriochlorophyll a binding complex that is peripherally associated to the bacterial reaction center.\" [GOC:lr]","metadata":null},{"id":"c3654a051d7f47f78a039a3d9f8e5761","type":"GO_TERM","name":"light-independent bacteriochlorophyll biosynthetic process","canonical_id":"go:GO:0036070","description":"\"The chemical reactions and pathways resulting in the formation of a bacteriochlorophyll, which occur in the absence of light. Bacteriochlorophylls are any of the chlorophylls of photosynthetic bacteria; they differ structurally from the chlorophylls of higher plants.\" [GOC:yaf, PMID:12242396]","metadata":null},{"id":"474afbc8a85e46859d15528e2629b534","type":"GO_TERM","name":"light-independent chlorophyll biosynthetic process","canonical_id":"go:GO:0036068","description":"\"The chemical reactions and pathways resulting in the formation of chlorophyll, any compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment, from less complex precursors, which occur in the absence of light.\" [GOC:yaf, PMID:12242396]","metadata":null},{"id":"32cad0c586eb488f82a9832e683efd4c","type":"GO_TERM","name":"lignan biosynthetic process","canonical_id":"go:GO:0009807","description":"\"The chemical reactions and pathways resulting in the formation of lignans, any member of a class of plant metabolites related to lignins. Lignans are usually found as phenylpropanoid dimers in which the phenylpropanoid units are linked tail to tail and thus having a 2,3 dibenzylbutane skeleton, but higher oligomers can also exist.\" [GOC:jl, PMID:10074466]","metadata":null},{"id":"eb376bc9dcfa421b92c3de74a3ce3557","type":"GO_TERM","name":"lignan catabolic process","canonical_id":"go:GO:0046273","description":"\"The chemical reactions and pathways resulting in the breakdown of lignans, any member of a class of plant metabolites related to lignins. Lignans are usually found as phenylpropanoid dimers in which the phenylpropanoid units are linked tail to tail and thus having a 2,3 dibenzylbutane skeleton, but higher oligomers can also exist.\" [GOC:jl, PMID:10074466]","metadata":null},{"id":"9fad7854981545a0bf943d63be2827f7","type":"GO_TERM","name":"lignan metabolic process","canonical_id":"go:GO:0009806","description":"\"The chemical reactions and pathways involving lignans, any member of a class of plant metabolites related to lignins. Lignans are usually found as phenylpropanoid dimers in which the phenylpropanoid units are linked tail to tail and thus having a 2,3 dibenzylbutane skeleton, but higher oligomers can also exist.\" [GOC:jl, PMID:10074466]","metadata":null},{"id":"f96548aef04c47a5b667c379f5fb3597","type":"GO_TERM","name":"lignin biosynthetic process","canonical_id":"go:GO:0009809","description":"\"The chemical reactions and pathways resulting in the formation of lignins, a class of polymers formed by the dehydrogenetive radical polymerization of various phenylpropanoid monomers.\" [GOC:tair_curators, ISBN:0198547684]","metadata":null},{"id":"6d940eb432da4a1b9d0539f0a8f4e5b8","type":"GO_TERM","name":"lignin catabolic process","canonical_id":"go:GO:0046274","description":"\"The chemical reactions and pathways resulting in the breakdown of lignins, a class of polymers of phenylpropanoid units.\" [GOC:ai]","metadata":null},{"id":"e7bcde4411db4842bf4463243e2a0fbe","type":"GO_TERM","name":"lignin metabolic process","canonical_id":"go:GO:0009808","description":"\"The chemical reactions and pathways involving lignins, a class of polymers of phenylpropanoid units.\" [GOC:lr, GOC:yl]","metadata":null},{"id":"b23100343d334c2595bc8497e8e1a438","type":"GO_TERM","name":"lignin network","canonical_id":"go:GO:0048224","description":"\"An extracellular matrix part that consists of lignin in the form of a three-dimensional polymeric network. Lignins are complex racemic aromatic heteropolymers derived from a variety of phenylpropane monomers coupled together by an assortment of carbon-carbon and ether linkages. Lignin is crucial for structural integrity of the cell wall and stiffness and strength of the stem. In addition, lignin waterproofs the cell wall, enabling transport of water and solutes through the vascular system, and plays a role in protecting plants against pathogens.\" [GOC:jid, GOC:mah, PMID:14503002, PMID:16662709]","metadata":null},{"id":"be9bba96255c45c4ae42e9029cf5b176","type":"GO_TERM","name":"lignostilbene alpha beta-dioxygenase activity","canonical_id":"go:GO:0050054","description":"\"Catalysis of the reaction: 1,2-bis(4-hydroxy-3-methoxyphenyl)ethylene + O2 = 2 vanillin.\" [EC:1.13.11.43, RHEA:21340]","metadata":null},{"id":"ec578a850f0a4780940841605cf47f34","type":"GO_TERM","name":"limb basal epidermal cell differentiation","canonical_id":"go:GO:0060889","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a limb epidermal basal cell. A epidermal basal cell cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into more specialized cell of the limb epidermis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"d36897db6b8d4ecab013aec1d7047f17","type":"GO_TERM","name":"limb basal epidermal cell fate specification","canonical_id":"go:GO:0060892","description":"\"The process in which a cell becomes capable of differentiating autonomously into an limb basal epidermal cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"786915df2d774527b60f12165c48a617","type":"GO_TERM","name":"limb bud formation","canonical_id":"go:GO:0060174","description":"\"The process pertaining to the initial formation of a limb bud from unspecified parts. This process begins with the formation of a local condensation of mesenchyme cells within the prospective limb field, and ends when a limb bud is recognizable.\" [GOC:dgh, GOC:dph]","metadata":null},{"id":"31a0e168ba9e440fa135732a0d60eb7f","type":"GO_TERM","name":"limb development","canonical_id":"go:GO:0060173","description":"\"The process whose specific outcome is the progression of a limb over time, from its formation to the mature structure. A limb is an appendage of an animal used for locomotion or grasping. Examples include legs, arms or some types of fin.\" [GOC:dgh, GOC:dph, PMID:11487378]","metadata":null},{"id":"05f1f8af04524f568c25f4d040c22e04","type":"GO_TERM","name":"limb epidermis development","canonical_id":"go:GO:0060887","description":"\"The process whose specific outcome is the progression of the epidermis of the limb over time, from its formation to the mature structure. The limb epidermis is the outer epithelial layer of the limb, it is a complex stratified squamous epithelium.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"78bb54dd7b794a7c9827d8c05ac2ea70","type":"GO_TERM","name":"limb epidermis stratification","canonical_id":"go:GO:0060888","description":"\"The pattern specification process that results in the subdivision of the epidermis of the limb in space to define a volume in which specific patterns of basal cell, spinous cell and granular cells will differentiate giving rise to the layers of the limb epidermis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"7e962eca41884114aae23a6f54f4e59e","type":"GO_TERM","name":"limb granular cell differentiation","canonical_id":"go:GO:0060891","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a limb epidermal granular cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"38d6bfa825b244e4bc4212e20691fa7b","type":"GO_TERM","name":"limb granular cell fate specification","canonical_id":"go:GO:0060893","description":"\"The process in which a cell becomes capable of differentiating autonomously into an limb granular cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"6984b68b4bc2418f84456bfcd422d198","type":"GO_TERM","name":"limb joint morphogenesis","canonical_id":"go:GO:0036022","description":"\"The process in which the anatomical structures of a limb joint are generated and organized. A limb joint is a flexible region that separates the rigid sections of a limb to allow movement in a controlled manner.\" [GOC:bf]","metadata":null},{"id":"e4284d7dda184552970c3c11d731b4c3","type":"GO_TERM","name":"limb morphogenesis","canonical_id":"go:GO:0035108","description":"\"The process in which the anatomical structures of a limb are generated and organized. A limb is a paired appendage of a tetrapod used for locomotion or grasping.\" [UBERON:0002101]","metadata":null},{"id":"3d0ddfa3c9304c45935942a09ff1bf3b","type":"GO_TERM","name":"limb spinous cell differentiation","canonical_id":"go:GO:0060890","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a limb epidermal spinous cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"d84b2abab6fb41df9a21e21ca18c42b9","type":"GO_TERM","name":"limb spinous cell fate specification","canonical_id":"go:GO:0060894","description":"\"The process in which a cell becomes capable of differentiating autonomously into a limb spinous cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"86d373f4648c4fbc976b5088e683985d","type":"GO_TERM","name":"limbic system development","canonical_id":"go:GO:0021761","description":"\"The progression of the limbic system over time from its initial formation until its mature state. The limbic system is a collection of structures in the brain involved in emotion, motivation and emotional aspects of memory.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"2c2b681459e042b09fe57361674ffcae","type":"GO_TERM","name":"limit dextrin alpha-1,6-maltotetraose-hydrolase activity","canonical_id":"go:GO:0120549","description":"\"Catalysis of the hydrolysis of (1->6)-alpha-D-glucosidic linkages to branches with degrees of polymerization of three or four glucose residues in limit dextrin.\" [EC:3.2.1.196]","metadata":null},{"id":"4179b7d1f2754793b15861c1b9eb3c3e","type":"GO_TERM","name":"limit dextrinase activity","canonical_id":"go:GO:0010303","description":"\"Catalysis of the hydrolysis of (1,6)-alpha-D-glucosidic linkages in alpha- and beta-limit dextrins of amylopectin and glycogen, and in amylopectin and pullulan.\" [EC:3.2.1.142]","metadata":null},{"id":"861e6087072a423e9f6b88c575b8dd73","type":"GO_TERM","name":"limonene 1,2-monooxygenase [NAD(P)H) activity","canonical_id":"go:GO:0052601","description":"\"Catalysis of the reaction: limonene + NAD(P)H + H+ + O2 = NAD(P)+ + H2O + limonene-1,2-epoxide. Can use either (4S)-limonene or (4R)-limonene as substrate. NADPH can act instead of NADH, although more slowly.\" [EC:1.14.13.107, PMID:8820855]","metadata":null},{"id":"fe09bc51d88d4201ae2e6aa3a4430dd4","type":"GO_TERM","name":"limonene biosynthetic process","canonical_id":"go:GO:0046250","description":"\"The chemical reactions and pathways resulting in the formation of limonene (4-isopropenyl-1-methyl-cyclohexene), a monocyclic monoterpene.\" [GOC:ai]","metadata":null},{"id":"db9d5a4f89a845039319a122296963e9","type":"GO_TERM","name":"limonene catabolic process","canonical_id":"go:GO:0046251","description":"\"The chemical reactions and pathways resulting in the breakdown of limonene (4-isopropenyl-1-methyl-cyclohexene), a monocyclic monoterpene.\" [PMID:10224006]","metadata":null},{"id":"2c003490e29d491caed14ead9b356f21","type":"GO_TERM","name":"limonene monooxygenase activity","canonical_id":"go:GO:0019113","description":"\"Catalysis of a monooxygenase reaction in which oxygen is incorporated into limonene.\" [GOC:mah]","metadata":null},{"id":"ab78fa9ea01e4a9da4186c5c31308954","type":"GO_TERM","name":"limonene-1,2-epoxide hydrolase activity","canonical_id":"go:GO:0018744","description":"\"Catalysis of the reaction: limonene-1,2-epoxide + H2O = limonene-1,2-diol. Other substrates include alicyclic and 1-methyl-substituted epoxides, such as 1-methylcyclohexene oxide, indene oxide and cyclohexene oxide.\" [EC:3.3.2.8]","metadata":null},{"id":"f396db065036428295323afa5c62be9c","type":"GO_TERM","name":"limonin-D-ring-lactonase activity","canonical_id":"go:GO:0050055","description":"\"Catalysis of the reaction: limonoate D-ring-lactone + H2O = limonoate.\" [EC:3.1.1.36, MetaCyc:LIMONIN-D-RING-LACTONASE-RXN]","metadata":null},{"id":"881aec736bf145e89487994bfbcf8172","type":"GO_TERM","name":"limonoid glucosyltransferase activity","canonical_id":"go:GO:0050645","description":"\"Catalysis of the reaction: UDP-glucose + limonin = glucosyl-limonin + UDP.\" [EC:2.4.1.210]","metadata":null},{"id":"e6027b4846a549f19c4a9a6f2d82a19b","type":"DRUG","name":"linaclotide","canonical_id":"gtopdb:5017","description":null,"metadata":null},{"id":"e4811a375821497ab5adfd551d2d3cec","type":"DRUG","name":"linaclotide","canonical_id":"mesh:C523483","description":null,"metadata":null},{"id":"bfca944b168a4c94b2be76f7965aa643","type":"DRUG","name":"linaclotide","canonical_id":"chembl:CHEMBL3301675","description":null,"metadata":null},{"id":"7313e43d1e1c4b96be91f41eaca0d0e9","type":"DRUG","name":"linagliptin","canonical_id":"gtopdb:6318","description":null,"metadata":null},{"id":"76fb172cd10a4058a727819199d6ca09","type":"DRUG","name":"linagliptin","canonical_id":"chembl:CHEMBL237500","description":null,"metadata":null},{"id":"026ec5fb231b4a59a1e81642746db6b0","type":"GO_TERM","name":"linalool 8-monooxygenase activity","canonical_id":"go:GO:0050056","description":"\"Catalysis of the reaction: linalool + 2 O2 + 2 reduced [NADPH--hemoprotein reductase] = (6E)-8-oxolinalool + 2 H+ + 3 H2O + 2 oxidized [NADPH--hemoprotein reductase].\" [RHEA:32635]","metadata":null},{"id":"eb4f9275370540908a4a73b8b3a120e4","type":"GO_TERM","name":"linamarin synthase activity","canonical_id":"go:GO:0050057","description":"\"Catalysis of the reaction: UDP-glucose + 2-hydroxy-2-methylpropanenitrile = UDP + linamarin.\" [EC:2.4.1.63, MetaCyc:LINAMARIN-SYNTHASE-RXN]","metadata":null},{"id":"dd473dc370ad42ef86b0b97a262e1457","type":"DRUG","name":"lincomycin","canonical_id":"mesh:D008034","description":null,"metadata":null},{"id":"c737a95cf16a46a8af897007e9192a66","type":"GO_TERM","name":"lincomycin biosynthetic process","canonical_id":"go:GO:1901774","description":"\"The chemical reactions and pathways resulting in the formation of lincomycin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-6955, PMID:8577249, UniPathway:UPA00161]","metadata":null},{"id":"0dfbadb963964abda5427167b82848f9","type":"GO_TERM","name":"lincomycin catabolic process","canonical_id":"go:GO:1901773","description":"\"The chemical reactions and pathways resulting in the breakdown of lincomycin.\" [GOC:TermGenie, GOC:yaf, PMID:8577249]","metadata":null},{"id":"55c5b8af45f24eb5939fb34a841807df","type":"GO_TERM","name":"linear 1,3-beta-D-glucan synthase activity","canonical_id":"go:GO:0140753","description":"\"Catalysis of the reaction: UDP-glucose + [(1->3)-beta-D-glucosyl](n) = UDP + a linear [(1->3)-beta-D-glucosyl](n+1).\" [PMID:34959732]","metadata":null},{"id":"696467c207f943dba30d429fed899405","type":"GO_TERM","name":"linear element","canonical_id":"go:GO:0030998","description":"\"A proteinaceous scaffold associated with fission yeast chromosomes during meiotic prophase. Linear elements consist of a protein complex, LinE, with four main structural components (Rec10, Rec25, Rec27, and Mug20 in S. pombe) associated with chromatin. The resulting structure is related to but not equivalent to the synaptonemal complex.\" [DOI:10.2323/jgam.28.263, GOC:jb, PMID:12665553, PMID:30640914]","metadata":null},{"id":"fa04e8f17ebe46f796b150d0628f245a","type":"GO_TERM","name":"linear element assembly","canonical_id":"go:GO:0030999","description":"\"The cell cycle process in which linear elements are assembled in association with fission yeast chromosomes during meiotic prophase. Linear element assembly begins with LinE complex formation and ends when LinE complexes are associated with chromatin in structures visible as nuclear foci. A linear element is a proteinaceous scaffold related to the synaptonemal complex.\" [GOC:jb, GOC:mah, PMID:30640914]","metadata":null},{"id":"9d006da5bbc5473a844773658bed4588","type":"GO_TERM","name":"linear element maturation","canonical_id":"go:GO:0062121","description":"\"The meiotic cell cycle chromosome organization process in which LinE complexes closely associate with chromatin during meiotic prophase to form mature linear elements.\" [PMID:30640914]","metadata":null},{"id":"e54ef363c91a4b79a39821c610eee4fc","type":"DISEASE","name":"linear nevus sebaceous syndrome","canonical_id":"mondo:0008097","description":null,"metadata":null},{"id":"125226fc85c14fd5a40ab27f4e23f72e","type":"GO_TERM","name":"linear polyubiquitin binding","canonical_id":"go:GO:1990450","description":"\"Binding to a linear polymer of ubiquitin. Linear ubiquitin polymers are formed by linking the amino-terminal methionine (M1) of one ubiquitin molecule to the carboxy-terminal glycine (G76) of the next.\" [GOC:bf, GOC:PARL, PMID:23453807]","metadata":null},{"id":"4d32b574714042e3926277857ecbf5c4","type":"GO_TERM","name":"linear primary-alkylsulfatase activity","canonical_id":"go:GO:0018741","description":"\"Catalysis of the reaction: a primary linear alkyl sulfate ester + H2O = a primary alcohol + H+ + sulfate.\" [RHEA:67908]","metadata":null},{"id":"8726f1177abe4b8dbf35667cef6e7f4e","type":"GO_TERM","name":"linear vestibuloocular reflex","canonical_id":"go:GO:0060007","description":"\"A vestibular reflex by which a response to a linear acceleration stimulus begins with an afferent nerve impulse from a receptor in the otolith and ends with the compensatory action of eye muscles. Signaling never reaches a level of consciousness.\" [GOC:dph, PMID:11784757]","metadata":null},{"id":"3bddb099dc3b42db80d96d50e54bfa1e","type":"DRUG","name":"linerixibat","canonical_id":"gtopdb:14439","description":null,"metadata":null},{"id":"89fad30c323f47bab79a606bf1c5ea56","type":"DRUG","name":"linerixibat","canonical_id":"chembl:CHEMBL2387408","description":null,"metadata":null},{"id":"dadef65c2c474a9295fa7fc73f8fa4bc","type":"COMBINATION_TREATMENT","name":"linerixibat + obeticholic acid","canonical_id":"ctgov_combo:ctgov-combo-bc64af060ddc7ccb","description":null,"metadata":null},{"id":"16faea96000e4e979c51015bc0039e78","type":"COMBINATION_TREATMENT","name":"linerixibat + obeticholic acid","canonical_id":"ctgov_combo:ctgov-combo-847aa46b5c15c234","description":null,"metadata":null},{"id":"d3a6a4656afd4d4dbfaf34bd5ec9d6a8","type":"GO_TERM","name":"linoleate 11-lipoxygenase activity","canonical_id":"go:GO:0050584","description":"\"Catalysis of the reaction: linoleate + O2 = (9Z,11S,12Z)-11-hydroperoxyoctadeca-9,12-dienoate.\" [EC:1.13.11.45, RHEA:18993]","metadata":null},{"id":"eea0d49391a74a06a27d0b5e228b0648","type":"GO_TERM","name":"linoleate 13S-lipoxygenase activity","canonical_id":"go:GO:0016165","description":"\"Catalysis of the reaction: linoleate + O2 = (9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate.\" [EC:1.13.11.12, GOC:lb]","metadata":null},{"id":"0df15e49cc574971a75785208a728448","type":"GO_TERM","name":"linoleate 8R-lipoxygenase activity","canonical_id":"go:GO:0052878","description":"\"Catalysis of the reaction: O2 + linoleate = (8R,9Z,12Z)-8-hydroperoxyoctadeca-9,12-dienoate.\" [RHEA:25395]","metadata":null},{"id":"2d4e5f6ec4464fa493764f698a7923d9","type":"GO_TERM","name":"linoleate 9S-lipoxygenase activity","canonical_id":"go:GO:1990136","description":"\"Catalysis of the reaction: linoleate + O2 = (9S,10E,12Z)-9-hydroperoxy-10,12-octadecadienoate.\" [GOC:rph, RHEA:30291]","metadata":null},{"id":"fef85abfc73e445398e074d6e3e51659","type":"GO_TERM","name":"linoleate isomerase activity","canonical_id":"go:GO:0050058","description":"\"Catalysis of the reaction: linoleate = 9-cis,11-trans-octadecadienoate.\" [EC:5.2.1.5, RHEA:17381]","metadata":null},{"id":"bae1a20424374afabd7a28f1aa04030b","type":"GO_TERM","name":"linoleic acid binding","canonical_id":"go:GO:0070539","description":"\"Binding to linoleic acid, the 18-carbon unsaturated fatty acid (9Z,12Z)-octadeca-9,12-dienoic acid.\" [GOC:lp, GOC:mah]","metadata":null},{"id":"6bae101238df48ed981c76cceec0f7f7","type":"GO_TERM","name":"linoleic acid epoxygenase activity","canonical_id":"go:GO:0071614","description":"\"Catalysis of an NADPH- and oxygen-dependent reaction that converts linoleic acid to a cis-epoxyoctadecenoic acid.\" [GOC:BHF, PMID:11042099]","metadata":null},{"id":"0b830b4e846449ffbec5a683ed94105f","type":"GO_TERM","name":"linoleic acid metabolic process","canonical_id":"go:GO:0043651","description":"\"The chemical reactions and pathways involving linoleic acid, an unsaturated omega-6 fatty acid that has the molecular formula C18H32O2.\" [Wikipedia:Linoleic_Acid]","metadata":null},{"id":"ffc833604cec48d8beb798cbd75380e9","type":"GO_TERM","name":"linolenate 9R-lipoxygenase activity","canonical_id":"go:GO:0102299","description":"\"Catalysis of the reaction: (9Z,12Z,15Z)-octadecatrienoate + O2 = (9R,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate. Also converts linoleate to (9R,10E,12Z)-9- hydroperoxyoctadeca-10,12-dienoate.\" [EC:1.13.11.61]","metadata":null},{"id":"0089f4cda3184cc4b547acaa5b88e152","type":"GO_TERM","name":"lipase activator activity","canonical_id":"go:GO:0060229","description":"\"Binds to and increases the activity of a lipase, an enzyme that catalyzes of the hydrolysis of a lipid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"a7a635e67dac4a69a6fdac29cf10dc58","type":"GO_TERM","name":"lipase activity","canonical_id":"go:GO:0016298","description":"\"Catalysis of the hydrolysis of a lipid.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"970252027628428f9625d1085cafc6d3","type":"GO_TERM","name":"lipase binding","canonical_id":"go:GO:0035473","description":"\"Binding to a lipase.\" [GOC:BHF]","metadata":null},{"id":"739ad4d4053f40fb85e4ea46b5ea01c6","type":"GO_TERM","name":"lipase inhibitor activity","canonical_id":"go:GO:0055102","description":"\"Binds to and stops, prevents or reduces the activity of a lipase, an enzyme that catalyzes of the hydrolysis of a lipid.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"1270578a1d3441b8818a8687916a4e92","type":"GO_TERM","name":"lipid A biosynthetic process","canonical_id":"go:GO:0009245","description":"\"The chemical reactions and pathways resulting in the formation of lipid A, the glycolipid group of bacterial lipopolysaccharides, consisting of four to six fatty acyl chains linked to two glucosamine residues. Further modifications of the backbone are common.\" [ISBN:0198506732, PMID:20974832, PMID:22216004]","metadata":null},{"id":"30e765ae35544e019006dcbfd9cb5474","type":"GO_TERM","name":"lipid A metabolic process","canonical_id":"go:GO:0046493","description":"\"The chemical reactions and pathways involving lipid A, the glycolipid group of bacterial lipopolysaccharides, consisting of four to six fatty acyl chains linked to two glucosamine residues. Further modifications of the backbone are common.\" [ISBN:0198506732, PMID:20974832, PMID:22216004]","metadata":null},{"id":"631516778e36446bb9b3898a06a84541","type":"GO_TERM","name":"lipid A phosphate methyltransferase activity","canonical_id":"go:GO:0043839","description":"\"Catalysis of the transfer of a methyl group from S-adenosylmethionine (SAM) to the 1-phosphate group of lipid A.\" [PMID:15994324]","metadata":null},{"id":"e5ef8b7c8d2d4f9ca5c6effd6b7421d4","type":"GO_TERM","name":"lipid A-core heptosyltransferase activity","canonical_id":"go:GO:0071968","description":"\"Catalysis of the reaction: galactosyl-glucosyl3-heptosyl3-KDO2-lipid A-bisphosphate + ADP-L-glycero-beta-D-manno-heptose = lipid A-core + ADP + H+.\" [MetaCyc:RXN0-5127]","metadata":null},{"id":"55af1b3848b94c19b503d79dbbb6f288","type":"GO_TERM","name":"lipid III floppase activity","canonical_id":"go:GO:0015161","description":"\"Enables the transbilayer of capsular-polysaccharides (Und-PP-GlcNAc-ManNAcA-Fuc4NAc (lipid III)) from the inner to the outer leaflet of the cytoplasmic membrane during the assembly of ECA. Capsular polysaccharides make up the capsule, a protective structure surrounding some species of bacteria and fungi.\" [GOC:ai, GOC:mtg_transport, PMID:12621029, PMID:16816184]","metadata":null},{"id":"b9c032ad6bee46209627318540db9186","type":"GO_TERM","name":"lipid X metabolic process","canonical_id":"go:GO:2001289","description":"\"The chemical reactions and pathways involving lipid X, 2,3-diacylglucosamine 1-phosphate.\" [GOC:obol]","metadata":null},{"id":"7bf8d2417bea45189672738eb3b47344","type":"GO_TERM","name":"lipid antigen assembly with MHC class Ib protein complex","canonical_id":"go:GO:0002493","description":"\"The binding of a lipid antigen to the antigen binding groove of an MHC class Ib protein complex. Class Ib here refers to non-classical class I molecules, such as those of the CD1 gene family.\" [GOC:add, PMID:15928678, PMID:15928680]","metadata":null},{"id":"41cf10fd8532434f90a0494ff85b6a26","type":"GO_TERM","name":"lipid antigen binding","canonical_id":"go:GO:0030882","description":"\"Binding to a lipid antigen.\" [PMID:14500461]","metadata":null},{"id":"1a4b9e9b07fa428b9b24b12dd5fd5d03","type":"GO_TERM","name":"lipid antigen transport","canonical_id":"go:GO:0002494","description":"\"The directed movement of a lipid antigen into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:add, PMID:15928678, PMID:15928680]","metadata":null},{"id":"ad63fdc10a0949a5ae766f7b554b977a","type":"GO_TERM","name":"lipid binding","canonical_id":"go:GO:0008289","description":"\"Binding to a lipid.\" [GOC:ai]","metadata":null},{"id":"d8205aa225b1484bbeb76537646da5c5","type":"GO_TERM","name":"lipid biosynthetic process","canonical_id":"go:GO:0008610","description":"\"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.\" [GOC:curators]","metadata":null},{"id":"f93ec13df7154df59919cb501a6c2c18","type":"GO_TERM","name":"lipid carrier activity","canonical_id":"go:GO:0005319","description":"\"Directly binding to a specific lipid and delivering it either to an acceptor molecule or to a specific location.\" [GOC:curators]","metadata":null},{"id":"73ff8c9f6d5246e58d7a7ecbc5ce2ee4","type":"GO_TERM","name":"lipid catabolic process","canonical_id":"go:GO:0016042","description":"\"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.\" [GOC:curators]","metadata":null},{"id":"bd1e49ffe9b94354b5e501905a3359a8","type":"GO_TERM","name":"lipid chaperone activity","canonical_id":"go:GO:7770043","description":"\"Binding to a lipid and delivering it to an acceptor protein, including enzymes, nuclear receptors, and other lipid-binding proteins. The lipid may be presented while bound to the chaperone for enzymatic modification or signaling, or fully transferred to the acceptor protein.\" [PMID:16216074, PMID:18511927, PMID:25847235, PMID:26658141]","metadata":null},{"id":"f9aad534ba484c04b2c4c0e92022dfd3","type":"GO_TERM","name":"lipid digestion","canonical_id":"go:GO:0044241","description":"\"The whole of the physical, chemical, and biochemical processes carried out by living organisms to break down ingested lipids into components that may be easily absorbed and directed into metabolism.\" [GOC:curators]","metadata":null},{"id":"41691469e3244820b9f3f8ef401f5518","type":"GO_TERM","name":"lipid droplet","canonical_id":"go:GO:0005811","description":"\"An intracellular non-membrane-bounded organelle comprising a matrix of coalesced lipids surrounded by a phospholipid monolayer. May include associated proteins.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"eabf52a7b2464ad8bd76fda5104c2495","type":"GO_TERM","name":"lipid droplet disassembly","canonical_id":"go:GO:1905691","description":"\"The disaggregation of a lipid particle into its constituent components.\" [GO_REF:0000079, GOC:autophagy, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"4eb2513355474959bf11643ee94db1bc","type":"GO_TERM","name":"lipid droplet formation","canonical_id":"go:GO:0140042","description":"\"A process that results in the assembly, arrangement of constituent parts of a lipid droplet.\" [PMID:28011631]","metadata":null},{"id":"f43c3932202946eda689e32c337b33e8","type":"GO_TERM","name":"lipid droplet fusion","canonical_id":"go:GO:0160077","description":"\"The process by which a single lipid droplet is created from the fusion of two or more lipid droplets.\" [PMID:34508658, PMID:36477540]","metadata":null},{"id":"82d44283bc65412ca77791671320f67e","type":"GO_TERM","name":"lipid droplet localization to prospore membrane leading edge","canonical_id":"go:GO:0140043","description":"\"Any process in which a lipid droplet is transported to, or maintained to the prospore membrane leading edge.\" [PMID:28011631]","metadata":null},{"id":"f2e52e19932c41f5a0e3c743736fa943","type":"GO_TERM","name":"lipid droplet organization","canonical_id":"go:GO:0034389","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lipid particle.\" [GOC:dph, GOC:jl, GOC:mah, PMID:18093937, PMID:18250201]","metadata":null},{"id":"f94cc6fe5a3e48f792417c9f98cbd88c","type":"GO_TERM","name":"lipid droplet transport along microtubule","canonical_id":"go:GO:0031887","description":"\"The directed movement of a lipid droplet along a microtubule, mediated by motor proteins.\" [PMID:9491895]","metadata":null},{"id":"aa2d4e8fe1a946cab09cf9a42ec877db","type":"GO_TERM","name":"lipid exchange activity","canonical_id":"go:GO:7770011","description":"\"Enables the transfer of a specific lipid molecule from one membrane to another, coupled with the simultaneous counter-transfer of a different lipid molecule in the opposite direction.\" [PMID:32793602]","metadata":null},{"id":"fc03f0d75e2442a7905e4786d24d1d68","type":"GO_TERM","name":"lipid export from cell","canonical_id":"go:GO:0140353","description":"\"The directed movement of a lipid from a cell, into the extracellular region.\" [GOC:pg]","metadata":null},{"id":"8c04feaffc6642c0805c0292a080aa08","type":"GO_TERM","name":"lipid homeostasis","canonical_id":"go:GO:0055088","description":"\"Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"e1afcdd114dd42c8b2711be238824be0","type":"GO_TERM","name":"lipid hydroperoxide transport","canonical_id":"go:GO:1901373","description":"\"The directed movement of a lipid hydroperoxide into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie]","metadata":null},{"id":"ea14bf123fdf4a0098dd1b6b5de78a89","type":"GO_TERM","name":"lipid hydroxylation","canonical_id":"go:GO:0002933","description":"\"The covalent attachment of a hydroxyl group to one or more fatty acids in a lipid.\" [GOC:hjd, PMID:15658937]","metadata":null},{"id":"39082c0c37364ddf8f5c1e399c6232f5","type":"GO_TERM","name":"lipid import into cell","canonical_id":"go:GO:0140354","description":"\"The directed movement of a lipid from outside of a cell into a cell. This may occur via transport across the plasma membrane or via endocytosis.\" [GOC:pg]","metadata":null},{"id":"aaf4cbf10d2f4b1398f76f44e59f2a4f","type":"GO_TERM","name":"lipid kinase activity","canonical_id":"go:GO:0001727","description":"\"Catalysis of the phosphorylation of a simple or complex lipid.\" [GOC:hjd]","metadata":null},{"id":"3900d15952df4d799ae698a539f69f3f","type":"GO_TERM","name":"lipid localization","canonical_id":"go:GO:0010876","description":"\"Any process in which a lipid is transported to, or maintained in, a specific location.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"227d8400ff7149bea99a132f0082718c","type":"GO_TERM","name":"lipid metabolic process","canonical_id":"go:GO:0006629","description":"\"The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids.\" [GOC:ma]","metadata":null},{"id":"411d60e7203a41c6a81d7629055f6ef3","type":"GO_TERM","name":"lipid modification","canonical_id":"go:GO:0030258","description":"\"The covalent alteration of one or more fatty acids in a lipid, resulting in a change in the properties of the lipid.\" [GOC:mah]","metadata":null},{"id":"b9f5a314c43947c8b37cbebe7ecfea7a","type":"GO_TERM","name":"lipid modification by small protein conjugation","canonical_id":"go:GO:0120322","description":"\"A lipid modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to a target lipid.\" [GOC:sp, PMID:34012115]","metadata":null},{"id":"b674b30b24a84cf7a0f4a89985198d8b","type":"GO_TERM","name":"lipid oxidation","canonical_id":"go:GO:0034440","description":"\"The removal of one or more electrons from a lipid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"696a186a5d884730b694917cd4e82ac2","type":"GO_TERM","name":"lipid phosphatase activity","canonical_id":"go:GO:0042577","description":"\"Catalysis of the reaction: a phospholipid + H2O = a lipid + phosphate.\" [GOC:jl]","metadata":null},{"id":"af6bcf27368e4daa8a61261043de936b","type":"GO_TERM","name":"lipid phosphorylation","canonical_id":"go:GO:0046834","description":"\"The process of introducing one or more phosphate groups into a lipid, any member of a group of substances soluble in lipid solvents but only sparingly soluble in aqueous solvents.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"3f7880cd5ed74a80b505ebae0b9b472e","type":"GO_TERM","name":"lipid sensor activity","canonical_id":"go:GO:0106254","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of a lipid.\" [GOC:vw, PMID:30075144]","metadata":null},{"id":"52bb3b53dd4a42ce9fe2521d342799d1","type":"GO_TERM","name":"lipid storage","canonical_id":"go:GO:0019915","description":"\"The accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.\" [GOC:dph, GOC:mah, GOC:tb, PMID:11102830]","metadata":null},{"id":"e64aae02f80e41698fcc32be5861557e","type":"GO_TERM","name":"lipid transfer activity","canonical_id":"go:GO:0120013","description":"\"Removes a lipid from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle. This results in intermembrane transfer of lipids.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"2180bb939e6b486ca863d6345ee69dde","type":"GO_TERM","name":"lipid translocation","canonical_id":"go:GO:0034204","description":"\"The translocation, or flipping, of lipid molecules from one monolayer of a membrane bilayer to the opposite monolayer.\" [GOC:mah]","metadata":null},{"id":"dc6780a9e4064f98ae3d5aedd303ece8","type":"GO_TERM","name":"lipid transmembrane transporter activity","canonical_id":"go:GO:0170055","description":"\"Enables the transfer of a lipid from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"e4038e2d8c7c4923a76c31a556e7726c","type":"GO_TERM","name":"lipid transport","canonical_id":"go:GO:0006869","description":"\"The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.\" [ISBN:0198506732]","metadata":null},{"id":"056344af3c4c4ed2ab9da3ce96bf8644","type":"GO_TERM","name":"lipid transport across blood-brain barrier","canonical_id":"go:GO:1990379","description":"\"The directed movement of lipid molecules passing through the blood-brain barrier.\" [GOC:sjp, PMID:24345162]","metadata":null},{"id":"6660673757ab4de3ba943a2947fa033e","type":"GO_TERM","name":"lipid transport involved in lipid storage","canonical_id":"go:GO:0010877","description":"\"The directed movement of lipids into cells that is part of their accumulation and maintenance.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1330da85d1214c32b4237c8ed1811041","type":"GO_TERM","name":"lipid tube","canonical_id":"go:GO:0060987","description":"\"A macromolecular complex that contains a tube of lipid surrounded by a protein coat.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1de753db70a9418abd8afa5523b8b174","type":"GO_TERM","name":"lipid tube assembly","canonical_id":"go:GO:0060988","description":"\"The aggregation, arrangement and bonding together of a set of macromolecules to form a macromolecular complex that contains a tube of lipid surrounded by a protein coat involved in membrane shaping of vesicle membranes as they fuse or undergo fission.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"daf0875b82cf42d9a52104dc0f6640f1","type":"GO_TERM","name":"lipid tube assembly involved in organelle fission","canonical_id":"go:GO:0060990","description":"\"The aggregation, arrangement and bonding together of a set of macromolecules to form a macromolecular complex that contains a tube of lipid surrounded by a protein coat involved in membrane shaping of vesicle membranes as organelles undergo fission.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"8528c2e8b047408c9edefca3eafb940d","type":"GO_TERM","name":"lipid tube assembly involved in organelle fusion","canonical_id":"go:GO:0060989","description":"\"The aggregation, arrangement and bonding together of a set of macromolecules to form a macromolecular complex that contains a tube of lipid surrounded by a protein coat involved in membrane shaping of vesicle membranes as organelles fuse.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0bdfa919d30d42f2a7d32a7028eef148","type":"GO_TERM","name":"lipid ubiquitination","canonical_id":"go:GO:0120323","description":"\"The process in which one or more ubiquitin groups are added to a lipid.\" [GOC:sp, PMID:34012115]","metadata":null},{"id":"c92d5a4df8f44bd9b377c3785c5d4d80","type":"GO_TERM","name":"lipid-A 4'-kinase activity","canonical_id":"go:GO:0009029","description":"\"Catalysis of the reaction: a lipid A disaccharide + ATP = a lipid IVA + ADP + H+.\" [RHEA:67840]","metadata":null},{"id":"e97565ba72354847942741efef9da69f","type":"GO_TERM","name":"lipid-A-disaccharide synthase activity","canonical_id":"go:GO:0008915","description":"\"Catalysis of the reaction: a lipid X + a UDP-2-N,3-O-bis[(3R)-3-hydroxyacyl]-alpha-D-glucosamine = a lipid A disaccharide + UDP + H+.\" [RHEA:67828]","metadata":null},{"id":"c42ccee395474d4387904281f9978592","type":"GO_TERM","name":"lipid-linked peptidoglycan transport","canonical_id":"go:GO:0015836","description":"\"The directed movement of lipid-linked peptidoglycans into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"2fd4263e18004bddba05922f382e003e","type":"GO_TERM","name":"lipid-linked peptidoglycan transporter activity","canonical_id":"go:GO:0015648","description":"\"Enables the directed movement of lipid-linked peptidoglycans into, out of or within a cell, or between cells.\" [GOC:mah]","metadata":null},{"id":"9ac5dd194f0941baa4565b2b64b572a5","type":"GO_TERM","name":"lipo-chitin oligosaccharide transmembrane transporter activity","canonical_id":"go:GO:1901513","description":"\"Enables the transfer of lipo-chitin oligosaccharide from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"662914443927438baec14e52906ecf57","type":"GO_TERM","name":"lipoamidase activity","canonical_id":"go:GO:0061690","description":"\"Catalysis of the reaction: H2O + N(6)-[(R)-lipoyl]-L-lysyl-[lipoyl-carrier protein] = (R)-lipoate + L-lysyl-[lipoyl-carrier protein].\" [PMID:14086741, RHEA:76519]","metadata":null},{"id":"a5b5c23a312f40729aeed3d22c71a742","type":"GO_TERM","name":"lipoamide binding","canonical_id":"go:GO:0043544","description":"\"Binding to lipoamide, the functional form of lipoic acid in which the carboxyl group is attached to protein by an amide linkage to a lysine amino group.\" [GOC:curators]","metadata":null},{"id":"818eb7bb8aa1438d9047129077bc34e8","type":"GO_TERM","name":"lipoarabinomannan binding","canonical_id":"go:GO:0001876","description":"\"Binding to lipoarabinomannan.\" [PMID:10586073]","metadata":null},{"id":"1db5c630ee9443ccb6a6f0c029e11897","type":"GO_TERM","name":"lipoarabinomannan immune receptor activity","canonical_id":"go:GO:0001877","description":"\"Combining with lipoarabinomannan and transmitting the signal to initiate an innate immune response.\" [PMID:10586073]","metadata":null},{"id":"46da3011c8124df4852db89585d06ee3","type":"GO_TERM","name":"lipoate biosynthetic process","canonical_id":"go:GO:0009107","description":"\"The chemical reactions and pathways resulting in the formation of lipoate, 1,2-dithiolane-3-pentanoate, the anion derived from lipoic acid.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"6189869e221348ef865b259050b9a7d0","type":"GO_TERM","name":"lipoate catabolic process","canonical_id":"go:GO:0032323","description":"\"The chemical reactions and pathways resulting in the breakdown of lipoate.\" [GOC:mah]","metadata":null},{"id":"2469ac801ae04600ac722374da550706","type":"GO_TERM","name":"lipoate metabolic process","canonical_id":"go:GO:0009106","description":"\"The chemical reactions and pathways involving lipoate, 1,2-dithiolane-3-pentanoate, the anion derived from lipoic acid.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"454d1984241540968b5437f6f67145b6","type":"GO_TERM","name":"lipoate synthase activity","canonical_id":"go:GO:0016992","description":"\"Catalysis of the reaction: [[Fe-S] cluster scaffold protein carrying a second [4Fe-4S]2+ cluster] + N(6)-octanoyl-L-lysyl-[protein] + 2 oxidized [2Fe-2S]-[ferredoxin] + 2 S-adenosyl-L-methionine + 4 H+ = [[Fe-S] cluster scaffold protein] + N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + 4 Fe3+ + 2 hydrogen sulfide + 2 5'-deoxyadenosine + 2 L-methionine + 2 reduced [2Fe-2S]-[ferredoxin].\" [RHEA:16585]","metadata":null},{"id":"3e86b2c40be94c5d804e4bfef76efc05","type":"GO_TERM","name":"lipoate transmembrane transport","canonical_id":"go:GO:0170006","description":"\"The process in which lipoate is transported across a membrane.\" [PMID:20980265, PMID:25971966]","metadata":null},{"id":"0e9a7f8e99984676b16be0668f53d55a","type":"GO_TERM","name":"lipoate transmembrane transporter activity","canonical_id":"go:GO:0170004","description":"\"Enables the transfer of lipoate from one side of a membrane to the other.\" [PMID:20980265, PMID:25971966]","metadata":null},{"id":"6e9b31a3374f46218c1dfb9b3f80a454","type":"GO_TERM","name":"lipoate-protein ligase activity","canonical_id":"go:GO:0016979","description":"\"Catalysis of the lipoylation of a protein in two steps: ATP + (R)-lipoate + a [lipoyl-carrier protein]-L-lysine = a [lipoyl-carrier protein]-N6-(lipoyl)lysine + AMP + diphosphate (overall reaction): (1) ATP + (R)-lipoate = lipoyl-AMP + diphosphate; (2) lipoyl-AMP + a [lipoyl-carrier protein]-L-lysine = a [lipoyl-carrier protein]-N6-(lipoyl)lysine + AMP.\" [PMID:16141198, PMID:17570395, RHEA:49288]","metadata":null},{"id":"80de82e442eb460ba6481883d4b4e424","type":"DISEASE","name":"lipodystrophy","canonical_id":"mondo:0006573","description":null,"metadata":null},{"id":"5e4e93545a3d4eedb99943d8fdb44279","type":"DISEASE","name":"lipodystrophy","canonical_id":"mesh:D008060","description":null,"metadata":null},{"id":"272f644911b149c4af686544adb4e567","type":"GO_TERM","name":"lipoic acid binding","canonical_id":"go:GO:0031405","description":"\"Binding to lipoic acid, 1,2-dithiolane-3-pentanoic acid.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"80334c695cb14f478656ee8b1bafd487","type":"DISEASE","name":"lipoma","canonical_id":"mondo:0005106","description":null,"metadata":null},{"id":"33db158db32045cf89e6504ed6d4e9da","type":"GO_TERM","name":"lipooligosaccharide binding","canonical_id":"go:GO:1990458","description":"\"Binding to lipooligosaccharide. Lipooligosaccharides (LOSs) are the major glycolipids expressed on mucosal Gram-negative bacteria.\" [GOC:hjd, PMID:8894399]","metadata":null},{"id":"d58fe9a7e509429b99d752ee39b61e69","type":"GO_TERM","name":"lipooligosaccharide biosynthetic process","canonical_id":"go:GO:1901271","description":"\"The chemical reactions and pathways resulting in the formation of lipooligosaccharide.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00501]","metadata":null},{"id":"cc047f3657cf4bbd866793f5c8751ad3","type":"GO_TERM","name":"lipooligosaccharide catabolic process","canonical_id":"go:GO:1901270","description":"\"The chemical reactions and pathways resulting in the breakdown of lipooligosaccharide.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00501]","metadata":null},{"id":"63858a8b0fbc48eaac5b81a4be823477","type":"GO_TERM","name":"lipooligosaccharide metabolic process","canonical_id":"go:GO:1901269","description":"\"The chemical reactions and pathways involving lipooligosaccharide.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00501]","metadata":null},{"id":"cef58e905bc840c7a9badf05aacdb4e9","type":"GO_TERM","name":"lipopeptide binding","canonical_id":"go:GO:0071723","description":"\"Binding to a lipopeptide, any of a group of organic compounds comprising two or more amino acids linked by peptide bonds and containing a nonprotein group consisting of a lipid or lipids.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"9a803301373f49d8b4cc9cadf71792f1","type":"GO_TERM","name":"lipophagy","canonical_id":"go:GO:0061724","description":"\"The selective degradation of lipid droplets by macroautophagy.\" [GOC:autophagy, PMID:23708524, PMID:26076903]","metadata":null},{"id":"9efe044a0ca945c193dbed6c2a6a027a","type":"GO_TERM","name":"lipopolysaccharide 3-alpha-galactosyltransferase activity","canonical_id":"go:GO:0008918","description":"\"Catalysis of the reaction: UDP-galactose + lipopolysaccharide = UDP + 1,3 alpha-D-galactosyl-lipopolysaccharide.\" [EC:2.4.1.44, GOC:mr]","metadata":null},{"id":"9e3ef2f568dd43e8a9bd6366a4b473c5","type":"GO_TERM","name":"lipopolysaccharide N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0008917","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + lipopolysaccharide = UDP + N-acetyl-D-glucosaminyl-lipopolysaccharide.\" [EC:2.4.1.56, GOC:mr]","metadata":null},{"id":"dc55872b14ec47809ee66dcf5c1dc072","type":"GO_TERM","name":"lipopolysaccharide N-acetylmannosaminouronosyltransferase activity","canonical_id":"go:GO:0047241","description":"\"Catalysis of the reaction: lipopolysaccharide + UDP-N-acetylmannosaminouronate = N-acetyl-beta-D-mannosaminouronosyl-1,4-lipopolysaccharide + UDP.\" [RHEA:28366]","metadata":null},{"id":"c31bc477606a4f7f954f41507234fdaf","type":"GO_TERM","name":"lipopolysaccharide binding","canonical_id":"go:GO:0001530","description":"\"Binding to a lipopolysaccharide.\" [PMID:11079463]","metadata":null},{"id":"1a9f07c61852420680fd6e63757f2b00","type":"GO_TERM","name":"lipopolysaccharide biosynthetic process","canonical_id":"go:GO:0009103","description":"\"The chemical reactions and pathways resulting in the formation of lipopolysaccharides, any of a group of related, structurally complex components of the outer membrane of Gram-negative bacteria.\" [GOC:ai, GOC:mr]","metadata":null},{"id":"964a098309b64f609c955d623e184bd5","type":"GO_TERM","name":"lipopolysaccharide catabolic process","canonical_id":"go:GO:0009104","description":"\"The chemical reactions and pathways resulting in the breakdown of lipopolysaccharides, any of a group of related, structurally complex components of the outer membrane of Gram-negative bacteria.\" [GOC:ai]","metadata":null},{"id":"208cbdddf5b140689cf2460e8929a346","type":"GO_TERM","name":"lipopolysaccharide core heptosyltransferase activity","canonical_id":"go:GO:0071967","description":"\"Catalysis of the reaction: glucosyl-heptosyl2-KDO2-lipid A-phosphate + ADP-L-glycero-beta-D-manno-heptose = glucosyl-heptosyl3-KDO2-lipid A-phosphate + ADP + H+.\" [MetaCyc:RXN0-5122]","metadata":null},{"id":"04c73a259ddd411e884394349a631c87","type":"GO_TERM","name":"lipopolysaccharide core region biosynthetic process","canonical_id":"go:GO:0009244","description":"\"The chemical reactions and pathways resulting in the formation of the core region of bacterial lipopolysaccharides, which contains ten saccharide residues.\" [ISBN:0198506732]","metadata":null},{"id":"9932c9cb82a146cba64f4da04fe43a1d","type":"GO_TERM","name":"lipopolysaccharide floppase activity","canonical_id":"go:GO:0015437","description":"\"Enables the transfer of a lipopolysaccharide from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [EC:7.5.2.5]","metadata":null},{"id":"ad65979b00b341c5bec44360c6026715","type":"GO_TERM","name":"lipopolysaccharide glucosyltransferase I activity","canonical_id":"go:GO:0008919","description":"\"Catalysis of the reaction: UDP-glucose + lipopolysaccharide = UDP + D-glucosyl-lipopolysaccharide.\" [EC:2.4.1.58]","metadata":null},{"id":"2d39de37ceec4912963268b9fa43791c","type":"GO_TERM","name":"lipopolysaccharide glucosyltransferase II activity","canonical_id":"go:GO:0047270","description":"\"Catalysis of the reaction: UDP-glucose + lipopolysaccharide = UDP + alpha-D-glucosyl-lipopolysaccharide.\" [EC:2.4.1.73]","metadata":null},{"id":"0c2e1ee6aaf54a008e91ccd29ef28f1f","type":"GO_TERM","name":"lipopolysaccharide heptosyltransferase activity","canonical_id":"go:GO:0008920","description":"\"Catalysis of the reaction: a lipopolysaccharide + ADP-L-glycero-beta-D-manno-heptose = a heptosylated lipopolysaccharide + ADP + H+.\" [GOC:curators]","metadata":null},{"id":"cf123dc98bc24979a292b2ba63938a76","type":"GO_TERM","name":"lipopolysaccharide immune receptor activity","canonical_id":"go:GO:0001875","description":"\"Combining with a lipopolysaccharide and transmitting the signal across the cell membrane to initiate an innate immune response. Lipopolysaccharides (LPS) are major components of the outer membrane of Gram-negative bacteria, making them prime targets for recognition by the immune system.\" [PMID:14609719, PMID:15379975]","metadata":null},{"id":"6daec782997c4ab7b25c18ac169f5268","type":"GO_TERM","name":"lipopolysaccharide localization to cell outer membrane","canonical_id":"go:GO:0140334","description":"\"A process in which a lipopolysaccharide is transported to the cell outer membrane.\" [PMID:24639492]","metadata":null},{"id":"404a74da05274ca8a68b5d0831a25b03","type":"GO_TERM","name":"lipopolysaccharide metabolic process","canonical_id":"go:GO:0008653","description":"\"The chemical reactions and pathways involving lipopolysaccharides, a group of related, structurally complex components of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consist three covalently linked regions, lipid A, core oligosaccharide, and an O side chain. Lipid A is responsible for the toxicity of the lipopolysaccharide.\" [ISBN:0198506732]","metadata":null},{"id":"efc4b0dc18ad4c9a9fff59b4bb4dda3b","type":"GO_TERM","name":"lipopolysaccharide receptor complex","canonical_id":"go:GO:0046696","description":"\"A multiprotein complex that consists of at least three proteins, CD14, TLR4, and MD-2, each of which is glycosylated and which functions as a lipopolysaccharide (LPS) receptor that primes the innate immune response against bacterial pathogens.\" [PMID:11706042, PMID:9665271]","metadata":null},{"id":"bcdcb7178e594e4ea3f1e1268b3e8e63","type":"GO_TERM","name":"lipopolysaccharide transfer activity","canonical_id":"go:GO:0140332","description":"\"Removes a lipopolysaccharide (LPS) from the outer leaflet of a donor membrane, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to the outer leaflet of an acceptor membrane.\" [PMID:24639492]","metadata":null},{"id":"797445d1ccf84fa4813be1d1acd57bf4","type":"GO_TERM","name":"lipopolysaccharide transmembrane transporter activity","canonical_id":"go:GO:0015221","description":"\"Enables the transfer of lipopolysaccharides from one side of a membrane to the other. A lipopolysaccharide is any of a group of related, structurally complex components of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consist three covalently linked regions, lipid A, core oligosaccharide, and an O side chain. Lipid A is responsible for the toxicity of the lipopolysaccharide.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"32636cad199b42ceab7532182c7ee484","type":"GO_TERM","name":"lipopolysaccharide transport","canonical_id":"go:GO:0015920","description":"\"The directed movement of lipopolysaccharides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A lipopolysaccharide is any of a group of related, structurally complex components of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consist three covalently linked regions, lipid A, core oligosaccharide, and an O side chain. Lipid A is responsible for the toxicity of the lipopolysaccharide.\" [GOC:ai]","metadata":null},{"id":"20004b7f211a4889a6a1123652a20523","type":"GO_TERM","name":"lipopolysaccharide transport system","canonical_id":"go:GO:0062051","description":"\"A protein-containing complex that functions to transport lipopolysaccharide from its site of synthesis at the cytoplasmic membrane across the periplasm to the outer membrane in an ATP-dependent manner.\" [PMID:29449493]","metadata":null},{"id":"a50ecdf84b9f4ba9b6aecb6c1805c2da","type":"GO_TERM","name":"lipopolysaccharide-1,5-galactosyltransferase activity","canonical_id":"go:GO:0035496","description":"\"Catalysis of the reaction: UDP-galactose + lipopolysaccharide = UDP + 1,5 alpha-D-galactosyl-lipopolysaccharide.\" [PMID:11304545]","metadata":null},{"id":"78fabb86b88246b49ce707dac36fe8e3","type":"GO_TERM","name":"lipopolysaccharide-1,6-galactosyltransferase activity","canonical_id":"go:GO:0008921","description":"\"Catalysis of the reaction: UDP-galactose + lipopolysaccharide = UDP + 1,6 alpha-D-galactosyl-lipopolysaccharide.\" [GOC:ai]","metadata":null},{"id":"5f3192e779514c20b6ebc7c75fa2d294","type":"GO_TERM","name":"lipopolysaccharide-mediated signaling pathway","canonical_id":"go:GO:0031663","description":"\"The series of molecular signals initiated by the binding of a lipopolysaccharide (LPS) to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Lipopolysaccharides are major components of the outer membrane of Gram-negative bacteria, making them prime targets for recognition by the immune system.\" [GOC:mah, GOC:signaling, PMID:15379975]","metadata":null},{"id":"5a7ad5642c0e442689c2ef73c5bc25ad","type":"GO_TERM","name":"lipopolysaccharide-mediated virion attachment to host cell","canonical_id":"go:GO:0039638","description":"\"The process by which a virion attaches to a host cell by binding to a lipopolysaccharide (LPS) on the host cell surface.\" [GOC:bf, GOC:bm, PMID:12837775]","metadata":null},{"id":"797beb09fb5b49f191942780bb12933d","type":"GO_TERM","name":"lipoprotein biosynthetic process","canonical_id":"go:GO:0042158","description":"\"The chemical reactions and pathways resulting in the formation of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids.\" [ISBN:0198506732]","metadata":null},{"id":"f278d21899884fe4aca35e3698717583","type":"GO_TERM","name":"lipoprotein carrier activity","canonical_id":"go:GO:0140598","description":"\"Binding to and carrying a lipoprotein between two different cellular locations by moving along with the target lipoprotein.\" [PMID:7628437]","metadata":null},{"id":"bf98c67c98ff46c19768d82fbb374e31","type":"GO_TERM","name":"lipoprotein catabolic process","canonical_id":"go:GO:0042159","description":"\"The chemical reactions and pathways resulting in the breakdown of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids.\" [ISBN:0198506732]","metadata":null},{"id":"41a67e112ee8401ca08501011b08ff54","type":"GO_TERM","name":"lipoprotein lipase activator activity","canonical_id":"go:GO:0060230","description":"\"Binds to and increases the activity of a lipoprotein lipase, an enzyme that catalyzes of the hydrolysis of a lipid within a lipoprotein.\" [GOC:BHF, GOC:dph, GOC:tb, PMID:10727238]","metadata":null},{"id":"401fcca42a524f278fa90e8cf24455c6","type":"GO_TERM","name":"lipoprotein lipase activity","canonical_id":"go:GO:0004465","description":"\"Catalysis of the reaction: triacylglycerol + H2O = diacylglycerol + a carboxylate, where the triacylglycerol is part of a lipoprotein. May also hydrolyze diacylglycerol and phospholipids present in lipoproteins.\" [EC:3.1.1.34, GOC:bf]","metadata":null},{"id":"5745f86e3bbd47bca4519f87dd3a342a","type":"GO_TERM","name":"lipoprotein lipid oxidation","canonical_id":"go:GO:0034439","description":"\"The modification of a lipoprotein by oxidation of the lipid group.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"00b2c4a739ba4b0a966fe9f855c2ec38","type":"GO_TERM","name":"lipoprotein localization","canonical_id":"go:GO:0044872","description":"\"Any process in which a lipoprotein is transported to, or maintained in, a specific location.\" [GOC:jl]","metadata":null},{"id":"8a213456cd864554b89a323a587e1b94","type":"GO_TERM","name":"lipoprotein localization to membrane","canonical_id":"go:GO:0044873","description":"\"A process in which a lipoprotein is transported to, or maintained in, a specific location in a membrane.\" [GOC:jl]","metadata":null},{"id":"c2a6c0500b034b36aa46c2f3af06b11a","type":"GO_TERM","name":"lipoprotein localization to outer membrane","canonical_id":"go:GO:0044874","description":"\"A process in which a lipoprotein is transported to, or maintained in, a specific location in an outer membrane.\" [GOC:jl]","metadata":null},{"id":"26fbfe8d57f14a3e8c42598fbcccb460","type":"GO_TERM","name":"lipoprotein metabolic process","canonical_id":"go:GO:0042157","description":"\"The chemical reactions and pathways involving any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids.\" [ISBN:0198506732]","metadata":null},{"id":"4b81fe0571904deeb849b77fac34fe5f","type":"GO_TERM","name":"lipoprotein modification","canonical_id":"go:GO:0042160","description":"\"The chemical reactions and pathways resulting in the covalent alteration of one or more amino acid or lipid residues occurring in a lipoprotein, any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.\" [GOC:mah]","metadata":null},{"id":"4de54d3d431f46108e18a57fb9697171","type":"GO_TERM","name":"lipoprotein oxidation","canonical_id":"go:GO:0042161","description":"\"The modification of a lipoprotein by oxidation of one or more amino acids or the lipid group.\" [GOC:mah]","metadata":null},{"id":"1961b1a559e5408587e057702315b1cc","type":"GO_TERM","name":"lipoprotein particle","canonical_id":"go:GO:1990777","description":"\"A spherical particle containing non-covalently associated proteins and lipids. Examples are plasma lipoprotein particles which transport lipids in the blood or lymph.\" [GOC:vesicles]","metadata":null},{"id":"87afda946b18401284cfd5ec9f740066","type":"GO_TERM","name":"lipoprotein particle binding","canonical_id":"go:GO:0071813","description":"\"Binding to a lipoprotein particle. A lipoprotein particle, also known as a lipoprotein, is a clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"0b92f2e5faa842ed8fcb0c9771d02238","type":"GO_TERM","name":"lipoprotein particle mediated signaling","canonical_id":"go:GO:0055095","description":"\"The series of molecular signals mediated by the detection of a lipoprotein particle.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"607554f5af6b4db8843aa2dd626375f1","type":"GO_TERM","name":"lipoprotein particle receptor activity","canonical_id":"go:GO:0030228","description":"\"Combining with a lipoprotein particle and delivering the lipoprotein particle into the cell via endocytosis. A lipoprotein particle, also known as a lipoprotein, is a clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids.\" [GOC:bf, GOC:mah, PMID:12827279]","metadata":null},{"id":"12b3c7c1dbfc425180810cb6ede8f3b8","type":"GO_TERM","name":"lipoprotein particle receptor binding","canonical_id":"go:GO:0070325","description":"\"Binding to a lipoprotein particle receptor.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"6a2334f95104419aa5c6808286af37ea","type":"GO_TERM","name":"lipoprotein releasing activity","canonical_id":"go:GO:0140306","description":"\"The activity of recognizing mature outer membrane lipoproteins in the inner membrane and releasing from the inner membrane so that they can be transported across the periplasmic space to their target location, the outer membrane. This function exists in diderm bacteria, mediated by the LolCDE complex.\" [PMID:10783239, PMID:21670534]","metadata":null},{"id":"984d09ded9624f6f861e3742067b3476","type":"GO_TERM","name":"lipoprotein transport","canonical_id":"go:GO:0042953","description":"\"The directed movement of any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"89c74d7e7784460bb51912ed97d59d43","type":"GO_TERM","name":"liposaccharide metabolic process","canonical_id":"go:GO:1903509","description":"\"The chemical reactions and pathways involving liposaccharide.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:9452964]","metadata":null},{"id":"4cf0c132e5884f8d91789de704cffcb7","type":"DISEASE","name":"liposarcoma","canonical_id":"mondo:0005060","description":null,"metadata":null},{"id":"e2bc3b90b97c480983c3535799cedcc4","type":"GO_TERM","name":"lipoteichoic acid D-alanylation","canonical_id":"go:GO:0036358","description":"\"The formation of a D-alanyl ester of lipoteichoic acid by transfer of D-Ala onto a membrane-associated lipoteichoic acid (LTA).\" [GOC:crds, PMID:22750871, PMID:8682792]","metadata":null},{"id":"2ac8bb7d327a42b7a735b9b62c44a909","type":"GO_TERM","name":"lipoteichoic acid binding","canonical_id":"go:GO:0070891","description":"\"Binding to lipoteichoic acid.\" [GOC:add, PMID:14665680]","metadata":null},{"id":"6df35246fac249eba5135b2e425a807b","type":"GO_TERM","name":"lipoteichoic acid biosynthetic process","canonical_id":"go:GO:0070395","description":"\"The chemical reactions and pathways resulting in the formation of lipoteichoic acid, which is a major component of the cell wall of gram-positive bacteria and typically consists of a chain of glycerol-phosphate repeating units linked to a glycolipid anchor.\" [GOC:add, PMID:14665680, PMID:16020688]","metadata":null},{"id":"32cee48d09e943ea821ff4b32685348d","type":"GO_TERM","name":"lipoteichoic acid catabolic process","canonical_id":"go:GO:0070396","description":"\"The chemical reactions and pathways resulting in the breakdown of lipoteichoic acid, which is a major component of the cell wall of gram-positive bacteria and typically consists of a chain of glycerol-phosphate repeating units linked to a glycolipid anchor.\" [GOC:add, PMID:14665680]","metadata":null},{"id":"817641270d584499bd04810e41a70931","type":"GO_TERM","name":"lipoteichoic acid immune receptor activity","canonical_id":"go:GO:0070892","description":"\"Combining with lipoteichoic acid and transmitting the signal to initiate an innate immune response.\" [GOC:add, PMID:14665680]","metadata":null},{"id":"e2497fbd3ba64f80a5bb60c7f7e3a1d7","type":"GO_TERM","name":"lipoxin A4 biosynthetic process","canonical_id":"go:GO:2001303","description":"\"The chemical reactions and pathways resulting in the formation of lipoxin A4. Lipoxin A4 is a C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.\" [GOC:mw]","metadata":null},{"id":"c878127a98d04fa396e0c36d71a6c507","type":"GO_TERM","name":"lipoxin A4 metabolic process","canonical_id":"go:GO:2001302","description":"\"The chemical reactions and pathways involving lipoxin A4. Lipoxin A4 is a C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.\" [GOC:mw]","metadata":null},{"id":"4ca3162d78c44605956d3f51c20b7651","type":"GO_TERM","name":"lipoxin B4 biosynthetic process","canonical_id":"go:GO:2001306","description":"\"The chemical reactions and pathways resulting in the formation of lipoxin B4. Lipoxin B4 is a C20 hydroxy fatty acid having (5S)-, (14R)- and (15S)-hydroxy groups as well as (6E)- (8Z)-, (10E)- and (12E)-double bonds.\" [GOC:mw]","metadata":null},{"id":"5257e3d4eeb14fafbc8dacbf402acca3","type":"GO_TERM","name":"lipoxin B4 metabolic process","canonical_id":"go:GO:2001304","description":"\"The chemical reactions and pathways involving lipoxin B4. Lipoxin B4 is a C20 hydroxy fatty acid having (5S)-, (14R)- and (15S)-hydroxy groups as well as (6E)- (8Z)-, (10E)- and (12E)-double bonds.\" [GOC:mw]","metadata":null},{"id":"3107ddd5ec164a809c0e1dc1af3f7ffa","type":"GO_TERM","name":"lipoxin biosynthetic process","canonical_id":"go:GO:2001301","description":"\"The chemical reactions and pathways resulting in the formation of a lipoxin. A lipoxin is a non-classic eicosanoid and signaling molecule that has four conjugated double bonds and is derived from arachidonic acid.\" [GOC:mw]","metadata":null},{"id":"ccfe25b6c85a4779b435b1297c2caf9f","type":"GO_TERM","name":"lipoxygenase pathway","canonical_id":"go:GO:0019372","description":"\"The chemical reactions and pathways by which an unsaturated fatty acid (such as arachidonic acid or linolenic acid) is converted to other compounds, and in which the first step is hydroperoxide formation catalyzed by lipoxygenase.\" [GOC:mah, PMID:17163881]","metadata":null},{"id":"0629a3f49b71455e8dfe93229b600490","type":"GO_TERM","name":"lipoyl(octanoyl) transferase activity","canonical_id":"go:GO:0033819","description":"\"Catalysis of the reaction: L-lysyl-[protein] + octanoyl-[ACP] = H+ + holo-[ACP] + N6-octanoyl-L-lysyl-[protein].\" [RHEA:17665]","metadata":null},{"id":"2ed359f3e5604325aa722383fc3dbff5","type":"GO_TERM","name":"lipoyl-dependent peroxiredoxin activity","canonical_id":"go:GO:0160319","description":"\"Catalysis of the reaction: N(6)-[(R)-dihydrolipoyl]-L-lysyl-[lipoyl-carrier protein] + a hydroperoxide = N(6)-[(R)-lipoyl]-L-lysyl-[lipoyl-carrier protein] + an alcohol + H2O.\" [EC:1.11.1.28, RHEA:62636]","metadata":null},{"id":"161c9577312442d08bf18ffc9d6e5d49","type":"GO_TERM","name":"lipoyltransferase activity","canonical_id":"go:GO:0017118","description":"\"Catalysis of the reaction: (R)-lipoyl-5'-AMP + L-lysyl-[lipoyl-carrier protein] = (R)-N6-lipoyl-L-lysyl-[lipoyl-carrier protein] + AMP + 2 H+.\" [PMID:10103005, RHEA:20473]","metadata":null},{"id":"d0f64c314ee44657b54797024127e694","type":"GO_TERM","name":"liquid clearance, open tracheal system","canonical_id":"go:GO:0035002","description":"\"The clearance of liquid from the epithelial tubes of an open tracheal system, shortly before the emergence of the larva, to generate an air-filled tubule system.\" [GOC:mtg_sensu, PMID:12571352]","metadata":null},{"id":"f5c2da6b90fa4003a9c9f4df17e5fa21","type":"DRUG","name":"liraglutide","canonical_id":"gtopdb:1133","description":null,"metadata":null},{"id":"43d0ea25f2b3468ba64b99d3418cd90d","type":"DRUG","name":"liraglutide","canonical_id":"chembl:CHEMBL4084119","description":null,"metadata":null},{"id":"8a6be4461a6946bf86609efb33c80f87","type":"COMBINATION_TREATMENT","name":"liraglutide + orlistat","canonical_id":"ctgov_combo:ctgov-combo-fcc268290d4ecbb0","description":null,"metadata":null},{"id":"e38e80bef75b4c8185b2831b6a82e812","type":"COMBINATION_TREATMENT","name":"liraglutide + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-6bd9d475a9570446","description":null,"metadata":null},{"id":"d4f7f994a0934d57afad1bca22cba2f4","type":"COMBINATION_TREATMENT","name":"liraglutide + semaglutide","canonical_id":"ctgov_combo:ctgov-combo-3155ae5ad15e6041","description":null,"metadata":null},{"id":"535c2e57a8404d9e9b468035fe8edb34","type":"COMBINATION_TREATMENT","name":"liraglutide + semaglutide","canonical_id":"ctgov_combo:ctgov-combo-a3e7fb5d15103799","description":null,"metadata":null},{"id":"2094128d03da4748b7cab08d6e3338a8","type":"COMBINATION_TREATMENT","name":"liraglutide + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-500590ae20375d01","description":null,"metadata":null},{"id":"63c4c4a0689e4bcb9bc77dcf39928993","type":"DRUG","name":"lisdexamfetamine","canonical_id":"mesh:D000069478","description":null,"metadata":null},{"id":"9de3aba6f6864dad8cd1a7694fc7eb24","type":"DRUG","name":"lisinopril","canonical_id":"gtopdb:6360","description":null,"metadata":null},{"id":"a84989a71503497fac749aaf1d792ae7","type":"DRUG","name":"lisinopril","canonical_id":"mesh:D017706","description":null,"metadata":null},{"id":"0382726491274272a6eefec9ec2bc144","type":"DRUG","name":"lisinopril","canonical_id":"chembl:CHEMBL419213","description":null,"metadata":null},{"id":"ac82132a03e04cadabdd19a257813c97","type":"COMBINATION_TREATMENT","name":"lisinopril + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-6f32e70847a6890b","description":null,"metadata":null},{"id":"57847e2082a74cb692450758d13dfcac","type":"COMBINATION_TREATMENT","name":"lisinopril + valsartan","canonical_id":"ctgov_combo:ctgov-combo-8ea748ca2e277e82","description":null,"metadata":null},{"id":"738c978a9ad24d8dbeb1388452836167","type":"GO_TERM","name":"lithium ion binding","canonical_id":"go:GO:0031403","description":"\"Binding to a lithium ion (Li+).\" [GOC:mah]","metadata":null},{"id":"3f3001df0fc04e65921cc7cf6a9b1a14","type":"GO_TERM","name":"lithium ion export across the plasma membrane","canonical_id":"go:GO:0010352","description":"\"The directed movement of lithium ion out of a cell or organelle.\" [PMID:17270011]","metadata":null},{"id":"da928e389fbd40b796c3a0f961b569b9","type":"GO_TERM","name":"lithium ion transmembrane transport","canonical_id":"go:GO:0090452","description":"\"The directed movement of lithium ions (Li+) across a membrane.\" [GOC:tb]","metadata":null},{"id":"74dc9366e34842159442807b15cbb259","type":"GO_TERM","name":"lithium ion transport","canonical_id":"go:GO:0010351","description":"\"The directed movement of lithium ion into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [PMID:17270011]","metadata":null},{"id":"fac2dc0a61de4276957691f715843690","type":"GO_TERM","name":"lithium:proton antiporter activity","canonical_id":"go:GO:0010348","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Li+(in) + H+(out) = Li+(out) + H+(in).\" [PMID:17270011]","metadata":null},{"id":"9b42d01a8bf34feba25c74fd8f797e23","type":"GO_TERM","name":"lithocholate 6beta-hydroxylase activity","canonical_id":"go:GO:0033777","description":"\"Catalysis of the reaction: H+ + lithocholate + NADPH + O2 = 6-beta-hydroxylithocholate + H2O + NADP+.\" [EC:1.14.14.138, RHEA:18857]","metadata":null},{"id":"698677e169434069886c48fb07c88d71","type":"GO_TERM","name":"lithocholic acid binding","canonical_id":"go:GO:1902121","description":"\"Binding to lithocholic acid.\" [GOC:bf, GOC:TermGenie, PMID:20371703]","metadata":null},{"id":"e3d04a6581964ed398c0f8ff3937857e","type":"DISEASE","name":"liver cancer","canonical_id":"mondo:0002691","description":null,"metadata":null},{"id":"694417c32350458b9dbd21de06c9e941","type":"GO_TERM","name":"liver development","canonical_id":"go:GO:0001889","description":"\"The process whose specific outcome is the progression of the liver over time, from its formation to the mature structure. The liver is an exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes.\" [GOC:add, ISBN:068340007X]","metadata":null},{"id":"daa88b80bb494a1e82a13e0478ee1e44","type":"DISEASE","name":"liver failure","canonical_id":"mondo:0100192","description":null,"metadata":null},{"id":"3857d6a7d614431f83b583173dcfa7ea","type":"GO_TERM","name":"liver morphogenesis","canonical_id":"go:GO:0072576","description":"\"The process in which the anatomical structures of the liver are generated and organized.\" [GOC:mah]","metadata":null},{"id":"1d99e40f4ee64584b7e2dddebbf1191e","type":"GO_TERM","name":"liver regeneration","canonical_id":"go:GO:0097421","description":"\"The regrowth of lost or destroyed liver.\" [GOC:gap, PMID:19447520]","metadata":null},{"id":"4c03e2eac2094174a78a756ef3bd9cf4","type":"GO_TERM","name":"liver trabecula formation","canonical_id":"go:GO:0060344","description":"\"The process of creating a trabecula in the liver. A trabecula is a tissue element in the form of a small beam, strut or rod.\" [GOC:dph]","metadata":null},{"id":"96cfadb7fe1644928c2460146fbcd2ab","type":"DISEASE","name":"liver transplant","canonical_id":"efo:0010682","description":null,"metadata":null},{"id":"c4c5acfe29184f2c982cc2c44574e229","type":"DRUG","name":"lixisenatide","canonical_id":"gtopdb:7387","description":null,"metadata":null},{"id":"47b82241d49b4c48a570cf73937aac5a","type":"DRUG","name":"lixisenatide","canonical_id":"mesh:C479460","description":null,"metadata":null},{"id":"7d29ff6144ac4c6096cd7db53e04a549","type":"DRUG","name":"lixisenatide","canonical_id":"chembl:CHEMBL2108336","description":null,"metadata":null},{"id":"b6d7957120ac4bba9530176711fe0915","type":"GO_TERM","name":"lncRNA binding","canonical_id":"go:GO:0106222","description":"\"Binding to a long noncoding RNA (lncRNA).\" [PMID:25578728]","metadata":null},{"id":"f14d70b57ea94599a089d1903aff745e","type":"GO_TERM","name":"lncRNA catabolic process","canonical_id":"go:GO:0110064","description":"\"The chemical reactions and pathways resulting in the breakdown of lncRNAs, non-coding RNAs over 200 nucleotides in length.\" [GOC:al, PMID:24493644]","metadata":null},{"id":"bd725e74003d44e1a191365ed4aac6cf","type":"GO_TERM","name":"lncRNA processing","canonical_id":"go:GO:0180035","description":"\"Any process involved in the conversion of one or more primary lncRNA transcripts into one or more mature lncRNA molecules.\" [PMID:31276588]","metadata":null},{"id":"96870be0fc65495c958b1c7244d52750","type":"GO_TERM","name":"lncRNA transcription","canonical_id":"go:GO:0140742","description":"\"The transcription of lncRNAs, non-coding RNAs over 200 nucleotides in length, from a DNA template.\" [PMID:33767452, PMID:33913806]","metadata":null},{"id":"fa945e5d2640460fac7a4dcc4136a57d","type":"GO_TERM","name":"lncRNA-mediated post-transcriptional gene silencing","canonical_id":"go:GO:0000512","description":"\"A post-transcriptional gene silencing pathway in which regulatory long noncoding RNAs (lncRNAs) elicit silencing of specific target genes, often miRNAs or mRNAs.\" [PMID:34454184, PMID:35055152]","metadata":null},{"id":"1e1eadfe67fc4405a1adf25dd058a3cc","type":"GO_TERM","name":"lobar bronchus development","canonical_id":"go:GO:0060482","description":"\"The biological process whose specific outcome is the progression of a lobar bronchus from an initial condition to its mature state. This process begins with the formation of the lobar bronchus and ends with the mature structure. The lobar bronchus is the major airway within the respiratory tree that starts by division of the principal bronchi on both sides and ends at the point of its own subdivision into tertiary or segmental bronchi.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"e169b4558684457ea27fcf3d3da34acd","type":"GO_TERM","name":"lobar bronchus epithelium development","canonical_id":"go:GO:0060481","description":"\"The biological process whose specific outcome is the progression of a lobar bronchus epithelium from an initial condition to its mature state. This process begins with the formation of the lobar bronchus epithelium and ends with the mature structure. The lobar bronchus epithelium is the tissue made up of epithelial cells that lines the inside of the lobar bronchus.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"a122de8152274b42808699fc03aed333","type":"GO_TERM","name":"lobar bronchus mesenchyme development","canonical_id":"go:GO:0060483","description":"\"The biological process whose specific outcome is the progression of a lobar bronchus mesenchyme from an initial condition to its mature state. This process begins with the formation of the lobar bronchus mesenchyme and ends with the mature structure. The lobar bronchus mesenchyme is the mass of tissue composed of mesenchymal cells in the lobar bronchus.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"aa017f8748524fb28734164c91ed8d72","type":"DRUG","name":"lobeglitazone","canonical_id":"mesh:C546215","description":null,"metadata":null},{"id":"ffa94ec0dc6a48c5ad99d412292e72d4","type":"GO_TERM","name":"localization","canonical_id":"go:GO:0051179","description":"\"Any process in which a cell, a substance, or a cellular entity, such as a protein complex or organelle, is transported, tethered to or otherwise maintained in a specific location. In the case of substances, localization may also be achieved via selective degradation.\" [GOC:ai, GOC:dos]","metadata":null},{"id":"7aabde86b8944a49a464651c82b3db6d","type":"GO_TERM","name":"localization of cell","canonical_id":"go:GO:0051674","description":"\"Any process in which a cell is transported to, and/or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"ab017e71aadb4289870d840867e1e1e1","type":"GO_TERM","name":"localization within membrane","canonical_id":"go:GO:0051668","description":"\"Any process in which a substance or cellular entity, such as a protein complex or organelle, is transported to, and/or maintained in, a specific location within a membrane.\" [GOC:ai]","metadata":null},{"id":"4df0c47fc0d64e8a98cf07af98280fce","type":"GO_TERM","name":"locomotion","canonical_id":"go:GO:0040011","description":"\"Self-propelled movement of a cell or organism from one location to another.\" [GOC:dgh]","metadata":null},{"id":"1fc6b2272bc245bdb1eb33bc4fda19f0","type":"GO_TERM","name":"locomotion involved in locomotory behavior","canonical_id":"go:GO:0031987","description":"\"Self-propelled movement of a cell or organism from one location to another in a behavioral context; the aspect of locomotory behavior having to do with movement.\" [GOC:mah]","metadata":null},{"id":"1493d6e6e87b4d6eaa5b4ccebc7f06f1","type":"GO_TERM","name":"locomotor rhythm","canonical_id":"go:GO:0045475","description":"\"The rhythm of the locomotor activity of an organism during its 24 hour activity cycle.\" [GOC:curators]","metadata":null},{"id":"92c554e502eb4cb893ca60e726a4b940","type":"GO_TERM","name":"locomotory behavior","canonical_id":"go:GO:0007626","description":"\"The specific movement from place to place of an organism in response to external or internal stimuli. Locomotion of a whole organism in a manner dependent upon some combination of that organism's internal state and external conditions.\" [GOC:dph]","metadata":null},{"id":"d376e7288c834b21b1ee3b5c9e64d013","type":"GO_TERM","name":"locomotory exploration behavior","canonical_id":"go:GO:0035641","description":"\"The specific movement from place to place of an organism in response to a novel environment.\" [GOC:sart, PMID:17151232]","metadata":null},{"id":"7dd3ca8ee67a401291d0139a89c702e9","type":"GO_TERM","name":"locus ceruleus development","canonical_id":"go:GO:0021703","description":"\"The process whose specific outcome is the progression of the locus ceruleus over time, from its formation to the mature structure. The locus ceruleus is a dense cluster of neurons within the dorsorostral pons. This nucleus is the major location of neurons that release norepinephrine throughout the brain, and is responsible for physiological responses to stress and panic.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"ee47603deb27477e8f1b4a80157f65f1","type":"GO_TERM","name":"locus ceruleus formation","canonical_id":"go:GO:0021705","description":"\"The process that gives rise to the locus ceruleus. This process pertains to the initial formation of a structure from unspecified parts. In mice, the locus ceruleus is a dense cluster of neurons within the dorsorostral pons. This nucleus is the major location of neurons that release norepinephrine throughout the brain, and is responsible for physiological responses to stress and panic.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"ff4bfa320ca140e5a945adb7f6e7ad04","type":"GO_TERM","name":"locus ceruleus maturation","canonical_id":"go:GO:0021706","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the locus ceruleus to attain its fully functional state. The locus ceruleus is a dense cluster of neurons within the dorsorostral pons. This nucleus is the major location of neurons that release norepinephrine throughout the brain, and is responsible for physiological responses to stress and panic.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"55cb2ef9abbc43a28e1f4b8fdd3ea8d1","type":"GO_TERM","name":"locus ceruleus morphogenesis","canonical_id":"go:GO:0021704","description":"\"The process in which the anatomical structure of the locus ceruleus is generated and organized. In mice, the locus ceruleus is a dense cluster of neurons within the dorsorostral pons. This nucleus is the major location of neurons that release norepinephrine throughout the brain, and is responsible for physiological responses to stress and panic.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d05d50ddf3c041fc892e2035deb60547","type":"DRUG","name":"lofepramine","canonical_id":"gtopdb:7551","description":null,"metadata":null},{"id":"0960f799bc754323a7684a1d83f26485","type":"GO_TERM","name":"loganate O-methyltransferase activity","canonical_id":"go:GO:0030749","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + loganate = S-adenosyl-L-homocysteine + loganin.\" [EC:2.1.1.50]","metadata":null},{"id":"a5ad0ff408e54b8f84c06ae463326e29","type":"GO_TERM","name":"lombricine kinase activity","canonical_id":"go:GO:0050059","description":"\"Catalysis of the reaction: ATP + lombricine = ADP + N-phospholombricine.\" [EC:2.7.3.5, MetaCyc:LOMBRICINE-KINASE-RXN]","metadata":null},{"id":"b9d6d57646644a5ea3c909b57f163422","type":"DISEASE","name":"long QT syndrome 3","canonical_id":"mondo:0011377","description":null,"metadata":null},{"id":"b8317f18cf654866b3d07e95d71d9812","type":"DISEASE","name":"long QT syndrome 8","canonical_id":"mondo:0032756","description":null,"metadata":null},{"id":"3303fd88c1ad40799c4f3e8d5553d7fe","type":"GO_TERM","name":"long descending thin limb bend development","canonical_id":"go:GO:0072065","description":"\"The process whose specific outcome is the progression of the long descending thin limb bend over time, from its formation to the mature structure. The long descending thin limb bend is a part of the descending thin limb of a long nephron that lies beyond the prebend segment.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f525fc92738b46248ac3b89ace8eba47","type":"GO_TERM","name":"long descending thin limb development","canonical_id":"go:GO:0072064","description":"\"The process whose specific outcome is the progression of the long descending thin limb over time, from its formation to the mature structure. The long descending thin limb is the descending thin limb of a long nephron that has a squamous epithelial morphology. The long descending limb starts in the inner stripe of the outer medulla and extends into the inner medulla.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8b955ea81e884fc586cc326443227eb9","type":"GO_TERM","name":"long nephron development","canonical_id":"go:GO:0072029","description":"\"The process whose specific outcome is the progression of a long nephron over time, from its formation to the mature structure. Long nephrons are associated with juxtamedullary glomeruli and extend into the inner medulla.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"15f9c217ae2e4b0eba82d9636b824377","type":"GO_TERM","name":"long tract gene conversion","canonical_id":"go:GO:0035824","description":"\"A gene conversion process in which a segment of more than 1000 base pairs is transferred from the donor to the acceptor.\" [GOC:mah, PMID:16954385]","metadata":null},{"id":"832a65a155684e9a81b581981101f4a1","type":"GO_TERM","name":"long-chain (3S)-3-hydroxyacyl-CoA dehydrogenase (NAD+) activity","canonical_id":"go:GO:0016509","description":"\"Catalysis of the reaction: a long-chain (3S)-3-hydroxy fatty acyl-CoA + NAD+ = a long-chain 3-oxo-fatty acyl-CoA + H+ + NADH. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [RHEA:52656]","metadata":null},{"id":"ce889a88b97c4357bc592fb811306237","type":"GO_TERM","name":"long-chain fatty acid [acyl-carrier-protein] ligase activity","canonical_id":"go:GO:0008922","description":"\"Catalysis of the reaction: a long-chain fatty acid + ATP + holo-[ACP] = a long-chain fatty acyl-[ACP] + AMP + diphosphate. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [EC:6.2.1.20]","metadata":null},{"id":"769948fb60ae446698f5ccaffeea8d09","type":"GO_TERM","name":"long-chain fatty acid binding","canonical_id":"go:GO:0036041","description":"\"Binding to a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:pm, PMID:12641450]","metadata":null},{"id":"48af998d8f0a45dc899c8ef3dcd0962e","type":"GO_TERM","name":"long-chain fatty acid biosynthetic process","canonical_id":"go:GO:0042759","description":"\"The chemical reactions and pathways resulting in the formation of a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [PMID:18390550]","metadata":null},{"id":"4438a5193a864ef1b8a3d5cad68db757","type":"GO_TERM","name":"long-chain fatty acid catabolic process","canonical_id":"go:GO:0042758","description":"\"The chemical reactions and pathways resulting in the breakdown of a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [PMID:20043225]","metadata":null},{"id":"1e1e53f4228f417cb76cd71799671b6b","type":"GO_TERM","name":"long-chain fatty acid import across plasma membrane","canonical_id":"go:GO:0015911","description":"\"The directed movement of a long-chain fatty acid from outside of a cell, across the plasma membrane and into the cytosol. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:ai]","metadata":null},{"id":"5c7c4e5ac0b24b92bfc37622851e40a3","type":"GO_TERM","name":"long-chain fatty acid import into cell","canonical_id":"go:GO:0044539","description":"\"The directed movement of a long-chain fatty acid from outside of a cell into a cell. This may occur via transport across the plasma membrane or via endocytosis. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:jl, GOC:pm, PMID:22022213]","metadata":null},{"id":"0d3292ba38f94a679c17cdbabe2cb345","type":"GO_TERM","name":"long-chain fatty acid import into peroxisome","canonical_id":"go:GO:0015910","description":"\"The directed movement of a long-chain fatty acid into a peroxisome. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:ai]","metadata":null},{"id":"d49bccb664e347878cf38ed1b53664dc","type":"GO_TERM","name":"long-chain fatty acid metabolic process","canonical_id":"go:GO:0001676","description":"\"The chemical reactions and pathways involving a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:ajp]","metadata":null},{"id":"6dd215ebd3084fe2a5fadf88289ba28b","type":"GO_TERM","name":"long-chain fatty acid omega-1 hydroxylase activity","canonical_id":"go:GO:0120319","description":"\"Catalysis of the reaction: an (omega-1)-ethyl long-chain fatty acid + O2 + reduced [NADPH-hemoprotein reductase] = an (omega-1)-hydroxy-long-chain fatty acid + H+ + H2O + oxidized [NADPH-hemoprotein reductase. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:nhn, PMID:18577768, PMID:22772592, PMID:24242247, RHEA:60936]","metadata":null},{"id":"a750c5d8275943eaa9c0190f5d67fecc","type":"GO_TERM","name":"long-chain fatty acid omega-hydroxylase activity","canonical_id":"go:GO:0102033","description":"\"Catalysis of the reaction: an omega-methyl-long-chain fatty acid + O2 + reduced [NADPH--hemoprotein reductase] = an omega-hydroxy-long-chain fatty acid + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:krc, PMID:18544608, RHEA:56748]","metadata":null},{"id":"c71f6afa713c4242a73b8287c8531c3f","type":"GO_TERM","name":"long-chain fatty acid transmembrane transporter activity","canonical_id":"go:GO:0005324","description":"\"Enables the transfer of a long-chain fatty acid from one side of a membrane to the other. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [ISBN:0198506732]","metadata":null},{"id":"eb1047d01c394e56b45504858b343c6b","type":"GO_TERM","name":"long-chain fatty acid transport","canonical_id":"go:GO:0015909","description":"\"The directed movement of a long-chain fatty acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:ai]","metadata":null},{"id":"b00702aaa93a4ef0951418e1d373d6b9","type":"GO_TERM","name":"long-chain fatty acid transporting porin activity","canonical_id":"go:GO:0015483","description":"\"Enables the transfer of a long-chain fatty acid from one side of a membrane to the other. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons. This transporter is a porin and so enables the energy independent passage of substances, sized less than 1000 Da, across a membrane. The transmembrane portions of porins consist exclusively of beta-strands which form a beta-barrel. They are found in the outer membranes of Gram-negative bacteria, mitochondria, plastids and possibly acid-fast Gram-positive bacteria.\" [GOC:mtg_transport, TC:1.B.9.1.1]","metadata":null},{"id":"58a97fcba0494315a8d2c6280dfdd989","type":"GO_TERM","name":"long-chain fatty acid--protein ligase activity","canonical_id":"go:GO:0047474","description":"\"Catalysis of the reaction: a long-chain fatty acid + ATP + L-cysteinyl-[protein] = AMP + diphosphate + S-(long-chain fatty acyl)-L-cysteinyl-[protein]. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [EC:6.2.1.19, MetaCyc:6.2.1.19-RXN]","metadata":null},{"id":"76fea169cc2347a2bba2bff2d741a156","type":"GO_TERM","name":"long-chain fatty acid-CoA ligase activity","canonical_id":"go:GO:0004467","description":"\"Catalysis of the reaction: a long-chain fatty acid + ATP + CoA = a long-chain fatty acyl-CoA + AMP + diphosphate. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [RHEA:15421]","metadata":null},{"id":"8b5ba8572358402d8eab0f3d8935ff0a","type":"GO_TERM","name":"long-chain fatty acyl-CoA binding","canonical_id":"go:GO:0036042","description":"\"Binding to a long-chain fatty acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:krc, GOC:pm]","metadata":null},{"id":"b7d641c7a88f45039c7330cd0b221b23","type":"GO_TERM","name":"long-chain fatty acyl-CoA dehydrogenase activity","canonical_id":"go:GO:0004466","description":"\"Catalysis of the reaction: a long-chain 2,3-saturated fatty acyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = a long-chain (2E)-enoyl-CoA + reduced [electron-transfer flavoprotein]. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [RHEA:17721]","metadata":null},{"id":"dec4a2fbe61a4fadbc5852ab5c720695","type":"GO_TERM","name":"long-chain fatty acyl-CoA hydrolase activity","canonical_id":"go:GO:0052816","description":"\"Catalysis of the reaction: a long-chain fatty acyl-CoA + H2O = a long-chain fatty acid + CoA + H+. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [RHEA:67680]","metadata":null},{"id":"23e92338333144c68b672412bb917ad0","type":"GO_TERM","name":"long-chain fatty acyl-CoA oxidase activity","canonical_id":"go:GO:0120524","description":"\"Catalysis of the reaction: a long-chain 2,3-saturated fatty acyl-CoA + O2 = a long-chain (2E)-enoyl-CoA + H2O2.\" [RHEA:78851]","metadata":null},{"id":"eaa4b7ede94641e39a6ae83aba04cc96","type":"GO_TERM","name":"long-chain fatty aldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050061","description":"\"Catalysis of the reaction: a long-chain fatty aldehyde + H2O + NAD+ = a long-chain fatty acid + 2 H+ + NADH.\" [RHEA:10652]","metadata":null},{"id":"591e4cafced34888b39e49cbdb4e4ef0","type":"GO_TERM","name":"long-chain fatty aldehyde oxidative decarbonylase activity","canonical_id":"go:GO:0160238","description":"\"Catalysis of the reaction: reduced [NADPH-hemoprotein reductase] + O2 + a long-chain fatty aldehyde = oxidized [NADPH-hemoprotein reductase] + CO2 + H2O + H+ + a long-chain alkane.\" [PMID:22927409, RHEA:83563]","metadata":null},{"id":"810d13ea8a7c4356b7940d41b0be2800","type":"GO_TERM","name":"long-chain fatty-acyl-CoA biosynthetic process","canonical_id":"go:GO:0035338","description":"\"The chemical reactions and pathways resulting in the formation of a long-chain fatty-acyl-CoA any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [ISBN:0198506732]","metadata":null},{"id":"8432d0a9e9c8433eb3a5cbb03a19c186","type":"GO_TERM","name":"long-chain fatty-acyl-CoA catabolic process","canonical_id":"go:GO:0036116","description":"\"The chemical reactions and pathways resulting in the breakdown of long-chain fatty-acyl-CoAs, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:pm]","metadata":null},{"id":"42aac09d08e3427cb6f58ca5809c756f","type":"GO_TERM","name":"long-chain fatty-acyl-CoA metabolic process","canonical_id":"go:GO:0035336","description":"\"The chemical reactions and pathways involving long-chain fatty-acyl-CoAs, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [ISBN:0198506732]","metadata":null},{"id":"1d08c0310b774f019e3b38fb97127a3a","type":"GO_TERM","name":"long-chain fatty-acyl-glutamate deacylase activity","canonical_id":"go:GO:0008421","description":"\"Catalysis of the reaction: N-long-chain-fatty-acyl-L-glutamate + H2O = a fatty acid anion + L-glutamate.\" [EC:3.5.1.55]","metadata":null},{"id":"74e9735c061d4b2ab60718e09acb51aa","type":"GO_TERM","name":"long-chain-alcohol O-fatty-acyltransferase activity","canonical_id":"go:GO:0047196","description":"\"Catalysis of the reaction: a long-chain-alcohol + acyl-CoA = a long-chain ester + CoA.\" [EC:2.3.1.75, MetaCyc:2.3.1.75-RXN]","metadata":null},{"id":"93518bbf7ba4452595e29b852d11198d","type":"GO_TERM","name":"long-chain-alcohol dehydrogenase activity","canonical_id":"go:GO:0050060","description":"\"Catalysis of the reaction: a long-chain alcohol + 2 NAD+ + H2O = a long-chain carboxylate + 2 NADH.\" [EC:1.1.1.192, MetaCyc:LONG-CHAIN-ALCOHOL-DEHYDROGENASE-RXN]","metadata":null},{"id":"9db6e6889d2848baaa29126b800fa097","type":"GO_TERM","name":"long-chain-alcohol oxidase activity","canonical_id":"go:GO:0046577","description":"\"Catalysis of the reaction: 2 long-chain alcohol + O2 = 2 long-chain aldehyde + 2 H2O.\" [EC:1.1.3.20]","metadata":null},{"id":"ba70f14d53a347218c03e041193d582a","type":"GO_TERM","name":"long-chain-fatty-acyl-CoA reductase (NADP+) activity","canonical_id":"go:GO:0050062","description":"\"Catalysis of the reaction: a long-chain fatty aldehyde + CoA + NADP+ = a long-chain fatty acyl-CoA + NADPH.\" [RHEA:15437]","metadata":null},{"id":"ef2d54aaed0d4cc3973ad40ebebecfd1","type":"GO_TERM","name":"long-day photoperiodism","canonical_id":"go:GO:0048571","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a day length that exceeds a particular duration known as the 'critical day length'. The critical day length varies between species. Although the term long-day is used, most species actually respond to the duration of the night, so that the response will occur when a period of darkness falls short of the number of hours defined by 24 hours minus the critical day length.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"02cfebc8265f4948b1b885f35a21f198","type":"GO_TERM","name":"long-day photoperiodism, flowering","canonical_id":"go:GO:0048574","description":"\"A change from the vegetative to the reproductive phase as a result of detection of, or exposure to, a period of light that exceeds the critical day length. The critical day length varies between species. Although the term is long-day is used, most species actually respond to the duration of the night, so that the response will occur when a period of darkness falls short of the number of hours defined by 24 minus the critical day length.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"b52beb9a2d5f486cb3e2cff9c950740d","type":"GO_TERM","name":"long-term memory","canonical_id":"go:GO:0007616","description":"\"The memory process that deals with the storage, retrieval and modification of information a long time (typically weeks, months or years) after receiving that information. This type of memory is typically dependent on gene transcription regulated by second messenger activation.\" [http://hebb.mit.edu/courses/9.03/lecture4.html, ISBN:0582227089]","metadata":null},{"id":"12333d3f38754bd69087653595301ce6","type":"GO_TERM","name":"long-term strengthening of neuromuscular junction","canonical_id":"go:GO:0042062","description":"\"Any process that results in an increase in the efficacy of transmission at a neuromuscular synapse.\" [GO_REF:0000021]","metadata":null},{"id":"6615b37b6ad54ddbbdc2d264a01bd11c","type":"GO_TERM","name":"long-term synaptic depression","canonical_id":"go:GO:0060292","description":"\"A process that modulates synaptic plasticity such that synapses are changed resulting in the decrease in the rate, or frequency of synaptic transmission at the synapse.\" [GOC:dgh, GOC:dph]","metadata":null},{"id":"0fe798b9911d4009b50645c8936955f6","type":"GO_TERM","name":"long-term synaptic potentiation","canonical_id":"go:GO:0060291","description":"\"A process that modulates synaptic plasticity such that synapses are changed resulting in the increase in the rate, or frequency of synaptic transmission at the synapse.\" [GOC:dgh, GOC:dph]","metadata":null},{"id":"4856b10366784c1ea260dec3c4b9bf3d","type":"GO_TERM","name":"longitudinal axis specification","canonical_id":"go:GO:0009942","description":"\"The establishment, maintenance and elaboration of the longitudinal axis. In plants, this is the axis that runs from the shoot to the root.\" [GOC:tb]","metadata":null},{"id":"418fab8570a84e5a92f554dca1a1eaf0","type":"GO_TERM","name":"longitudinal flagellum","canonical_id":"go:GO:0097609","description":"\"A motile cilium found in dinoflagellates. It trails the cell and acts as a steering rudder. It is often partially contained in a furrow called the sulcus, and emerges from a flagellar pore located in the sulcus.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, https://doi.org/10.1508/cytologia.88.321, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"84378e1387024706b9836978eddf98fd","type":"GO_TERM","name":"longitudinal sarcoplasmic reticulum","canonical_id":"go:GO:0014801","description":"\"The portion of the free sarcoplasmic reticulum consisting of longitudinal tubules that connect terminal cisternae.\" [GOC:mtg_muscle]","metadata":null},{"id":"05f24d09257c414bb5a71345832ff18b","type":"GO_TERM","name":"longitudinal sarcoplasmic reticulum lumen","canonical_id":"go:GO:0014803","description":"\"The region between the inner and outer lipid bilayers of the longitudinal sarcoplasmic reticulum envelope. The longitudinal sarcoplasmic reticulum lumen is continuous with the lumen contained within the terminal cisternae.\" [GOC:mtg_muscle]","metadata":null},{"id":"fee4d10f7e81488791f04e608a87fa30","type":"GO_TERM","name":"longitudinal side of cell surface","canonical_id":"go:GO:0009930","description":"\"The side of the cell parallel to the zygotic axis.\" [GOC:mtg_sensu, GOC:sm]","metadata":null},{"id":"3729ace8c1d24ed4a5d99bf96b212711","type":"GO_TERM","name":"loop of Henle development","canonical_id":"go:GO:0072070","description":"\"The process whose specific outcome is the progression of the loop of Henle over time, from its formation to the mature structure. The loop of Henle is a nephron tubule that connects the proximal convoluted tubule to the distal convoluted tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ba9538341a3c4ccc88f3f969458bab33","type":"DRUG","name":"loperamide","canonical_id":"gtopdb:7215","description":null,"metadata":null},{"id":"90ed99a726ae40e3a01b6580f1dfe19c","type":"COMBINATION_TREATMENT","name":"loperamide + metoclopramide","canonical_id":"ctgov_combo:ctgov-combo-9d64e8eb20e152bc","description":null,"metadata":null},{"id":"6e094042563e4b15b51d9e382cb94f37","type":"COMBINATION_TREATMENT","name":"loperamide + neratinib","canonical_id":"ctgov_combo:ctgov-combo-3fb508ae027a73f1","description":null,"metadata":null},{"id":"0991789324054fa1b65b61ae9b3bf428","type":"COMBINATION_TREATMENT","name":"loperamide + neratinib","canonical_id":"ctgov_combo:ctgov-combo-ba1fe681d824fdab","description":null,"metadata":null},{"id":"71c55c7ecb6a4809bf2eaac9321f452c","type":"COMBINATION_TREATMENT","name":"loperamide + prochlorperazine","canonical_id":"ctgov_combo:ctgov-combo-545c3f96c9f233e0","description":null,"metadata":null},{"id":"7cf9da944b3e480ba6594977d16386d2","type":"DRUG","name":"lopinavir","canonical_id":"mesh:D061466","description":null,"metadata":null},{"id":"b77aa598e6e64d95969ba7e8a80ce1b4","type":"DRUG","name":"loracarbef","canonical_id":"mesh:C054920","description":null,"metadata":null},{"id":"e6c854f5c1c44ebb9aca6a741835df96","type":"DRUG","name":"loratadine","canonical_id":"gtopdb:7216","description":null,"metadata":null},{"id":"9c0c9177370f4d1eb7e0c0b663c48d5d","type":"DRUG","name":"loratadine","canonical_id":"mesh:D017336","description":null,"metadata":null},{"id":"a234908e40dc4f949f3328e5b4546604","type":"DRUG","name":"loratadine","canonical_id":"chembl:CHEMBL998","description":null,"metadata":null},{"id":"98166a930d2a4412b38e337672533b2a","type":"COMBINATION_TREATMENT","name":"loratadine + montelukast","canonical_id":"ctgov_combo:ctgov-combo-ec2d1487c0b4ffab","description":null,"metadata":null},{"id":"024dd06ccd604ef1a24d82bd377078da","type":"COMBINATION_TREATMENT","name":"loratadine + naproxen + pegfilgrastim","canonical_id":"ctgov_combo:ctgov-combo-d0db06f0e284bf60","description":null,"metadata":null},{"id":"77eac977af464c8a9b852303dc588dce","type":"DRUG","name":"lorcaserin","canonical_id":"gtopdb:2941","description":null,"metadata":null},{"id":"e91cd4bc3e2146f98a5ccb7bd31c58c9","type":"DRUG","name":"lorlatinib","canonical_id":"gtopdb:7476","description":null,"metadata":null},{"id":"7df11f5e8d524f9ea8b34653dbc034e8","type":"DRUG","name":"lorlatinib","canonical_id":"chembl:CHEMBL3286830","description":null,"metadata":null},{"id":"7ec68b546efb40129dc7aad56ee822eb","type":"DRUG","name":"lornoxicam","canonical_id":"mesh:C059451","description":null,"metadata":null},{"id":"c92a5dbbba914e6b9dcd369485e6e827","type":"DRUG","name":"losartan","canonical_id":"gtopdb:590","description":null,"metadata":null},{"id":"8786cfd46398463dbdcbfa6a39021671","type":"COMBINATION_TREATMENT","name":"losartan + metoprolol","canonical_id":"ctgov_combo:ctgov-combo-ca55834cabcb98cb","description":null,"metadata":null},{"id":"40bfb45c1f9646959e4a2708bbe9697a","type":"COMBINATION_TREATMENT","name":"losartan + mycophenolate mofetil","canonical_id":"ctgov_combo:ctgov-combo-c6b9dea1a675d7d6","description":null,"metadata":null},{"id":"734e333c83274fd6bbc4c657d66501c3","type":"COMBINATION_TREATMENT","name":"losartan + olmesartan","canonical_id":"ctgov_combo:ctgov-combo-3b4920b2927792a8","description":null,"metadata":null},{"id":"d7e40a3573ed4cf2b92397512ae174cd","type":"COMBINATION_TREATMENT","name":"losartan + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-ac9c6eaf04e0b2d4","description":null,"metadata":null},{"id":"c945b65d7f7540f199711ed8586ec86c","type":"COMBINATION_TREATMENT","name":"losartan + pioglitazone + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-48a842eb31decf75","description":null,"metadata":null},{"id":"b4c5fdbfee394e58ac602415a46c4cc2","type":"COMBINATION_TREATMENT","name":"losartan + valsartan","canonical_id":"ctgov_combo:ctgov-combo-a9be82330de75a7d","description":null,"metadata":null},{"id":"2d7ccf149cd14ca7992f30c6426eb49d","type":"DRUG","name":"lovastatin","canonical_id":"gtopdb:2739","description":null,"metadata":null},{"id":"f57b3b736dd842c3807ed4d2d747d53a","type":"DRUG","name":"lovastatin","canonical_id":"mesh:D008148","description":null,"metadata":null},{"id":"17197954f65646438c95a02545cba1b0","type":"COMBINATION_TREATMENT","name":"lovastatin + warfarin","canonical_id":"ctgov_combo:ctgov-combo-bbdadfe088b48fe1","description":null,"metadata":null},{"id":"6d8b7a5b83b04fbc9f7c144ef9115198","type":"GO_TERM","name":"lovastatin biosynthetic process","canonical_id":"go:GO:0140735","description":"\"The chemical reactions and pathways resulting in the formation of lovastatin (also known as mevinolin, mevacor or monacolin K), a hypolipidemic inhibitor of (3S)-hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR).\" [PMID:10334994, PMID:10381407]","metadata":null},{"id":"c29428b75dd34f71a12fea419f8f8171","type":"GO_TERM","name":"lovastatin nonaketide synthase activity","canonical_id":"go:GO:0050637","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + acetyl-CoA + 18 H+ + 8 malonyl-CoA + 11 NADPH = S-adenosyl-L-homocysteine + 8 CO2 + 9 CoA + dihydromonacolin L + 6 H2O + 11 NADP+.\" [EC:2.3.1.161, RHEA:18565]","metadata":null},{"id":"5c4185a836ea4192bc897acc67150766","type":"DISEASE","name":"low grade glioma","canonical_id":"mondo:0021637","description":null,"metadata":null},{"id":"a05ca0f215ff4831a98f37d10c83611f","type":"GO_TERM","name":"low molecular weight kininogen binding","canonical_id":"go:GO:0030986","description":"\"Binding to a kininogen of low molecular mass.\" [GOC:mah, PMID:9520414]","metadata":null},{"id":"3af74435ec364adca34fbc2353f42e06","type":"GO_TERM","name":"low voltage-gated calcium channel activity","canonical_id":"go:GO:0008332","description":"\"Enables the transmembrane transfer of a calcium ion by a low voltage-gated channel. A low voltage-gated channel is a channel whose open state is dependent on low voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729, PMID:16382099]","metadata":null},{"id":"4e7c740c6d29493cb8cb062f78ae741b","type":"GO_TERM","name":"low-affinity D-glucose:proton symporter activity","canonical_id":"go:GO:0005359","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: glucose(out) + H(out)+ = glucose(in) + H(in)+. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations. Symporter activity enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy.\" [GOC:mtg_transport]","metadata":null},{"id":"dcd1ef5d35004d85b457dec9eb6cc389","type":"GO_TERM","name":"low-affinity D-glucose:sodium symporter activity","canonical_id":"go:GO:0005362","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-glucose(out) + Na+(out) = D-glucose(in) + Na+(in). In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [TC:2.A.21.3.-]","metadata":null},{"id":"1efe302bb3614a328804c2cafecdaa61","type":"GO_TERM","name":"low-affinity IgA receptor activity","canonical_id":"go:GO:0002171","description":"\"Combining with low affinity with an immunoglobulin of an IgA isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:hjd, GOC:signaling]","metadata":null},{"id":"72d6752f40fb4e3ab605e963edd80639","type":"GO_TERM","name":"low-affinity IgE receptor activity","canonical_id":"go:GO:0019769","description":"\"Combining with low affinity with an immunoglobulin of the IgE isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"2470c5891c9c493e93080e2694aca6de","type":"GO_TERM","name":"low-affinity IgG receptor activity","canonical_id":"go:GO:0019772","description":"\"Combining with low affinity with an immunoglobulin of an IgG isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"ca42876407ee4938ae2f7cd2d3e0cd64","type":"GO_TERM","name":"low-affinity IgM receptor activity","canonical_id":"go:GO:0002173","description":"\"Combining with low affinity with an immunoglobulin of an IgM isotype via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:hjd, GOC:signaling]","metadata":null},{"id":"19f42e97a50842aa9ea1b9708de79a56","type":"GO_TERM","name":"low-affinity L-arginine transmembrane transporter activity","canonical_id":"go:GO:0097626","description":"\"Enables the transfer of L-arginine from one side of a membrane to the other. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [GOC:krc, PMID:8195186]","metadata":null},{"id":"fe415bb0cc2b4ca3a39cecfca2a8a310","type":"GO_TERM","name":"low-affinity basic amino acid transmembrane transporter activity","canonical_id":"go:GO:0097625","description":"\"Enables the transfer of basic amino acids from one side of a membrane to the other. Basic amino acids have a pH above 7. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [GOC:pr]","metadata":null},{"id":"ff26034d82a84f65b85908605a6cebd6","type":"GO_TERM","name":"low-affinity ferric iron ion transmembrane transporter activity","canonical_id":"go:GO:0015090","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Fe2+(out) = Fe2+(in). In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [TC:9.A.9.1.1]","metadata":null},{"id":"2a780968056746aba5aee1de953ae584","type":"GO_TERM","name":"low-affinity nitrate transmembrane transporter activity","canonical_id":"go:GO:0080054","description":"\"Enables the transfer of nitrate ions (NO3-) from one side of a membrane to the other. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [PMID:19050168]","metadata":null},{"id":"eee7f53fba754c60b3099ab086b2bac2","type":"GO_TERM","name":"low-affinity phosphate transmembrane transporter activity","canonical_id":"go:GO:0009673","description":"\"Enables the transfer of phosphate from one side of a membrane to the other. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [TC:2.A.20.-.-]","metadata":null},{"id":"845bc66825414157a1e44df88395ec48","type":"GO_TERM","name":"low-affinity sodium:dicarboxylate symporter activity","canonical_id":"go:GO:0015361","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: dicarboxylate(out) + Na+(out) = dicarboxylate(in) + Na+(in). In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [TC:2.A.47.1.1]","metadata":null},{"id":"3ec4875b85f54149b6027fcc2acd6e7b","type":"GO_TERM","name":"low-affinity sulfate:proton symporter activity","canonical_id":"go:GO:0009676","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sulfate(out) + H+(out) = sulfate(in) + H+(in). In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [GOC:mah, PMID:7568135]","metadata":null},{"id":"29716e854d4e45c8b4bb57e4675e1e7b","type":"GO_TERM","name":"low-affinity tryptophan transmembrane transporter activity","canonical_id":"go:GO:0022893","description":"\"Catalysis of the low-affinity transfer of L-tryptophan from one side of a membrane to the other. Tryptophan is 2-amino-3-(1H-indol-3-yl)propanoic acid. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"bfadffae9313497f941646dea116eba4","type":"GO_TERM","name":"low-affinity zinc ion transmembrane transporter activity","canonical_id":"go:GO:0000007","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Zn2+ = Zn2+, probably powered by proton motive force. In low-affinity transport the transporter is able to bind the solute only if it is present at very high concentrations.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ed6bdb7737bd42268dd63255ecdc585f","type":"GO_TERM","name":"low-density lipoprotein particle","canonical_id":"go:GO:0034362","description":"\"A lipoprotein particle, rich in cholesterol esters and low in triglycerides that is typically composed of APOB100 and APOE and has a density of 1.02-1.06 g/ml and a diameter of between 20-25 nm. LDL particles are formed from VLDL particles (via IDL) by the loss of triglyceride and gain of cholesterol ester. They transport endogenous cholesterol (and to some extent triglycerides) from peripheral tissues back to the liver.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"0de52178040747e78d00cac20da99f9b","type":"GO_TERM","name":"low-density lipoprotein particle binding","canonical_id":"go:GO:0030169","description":"\"Binding to a low-density lipoprotein particle, a lipoprotein particle that is rich in cholesterol esters and low in triglycerides, is typically composed of APOB100 and APOE, and has a density of 1.02-1.06 g/ml and a diameter of between 20-25 nm.\" [GOC:mah]","metadata":null},{"id":"47a8b8d6db1d42a994faa3e5d27e87e6","type":"GO_TERM","name":"low-density lipoprotein particle clearance","canonical_id":"go:GO:0034383","description":"\"The process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"578f831ec1a34a5996a8a37b6d93acca","type":"GO_TERM","name":"low-density lipoprotein particle disassembly","canonical_id":"go:GO:0090495","description":"\"The disaggregation of a low-density lipoprotein particle into its constituent components.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f369e5d387e44a4ba6005824de53c7dd","type":"GO_TERM","name":"low-density lipoprotein particle mediated signaling","canonical_id":"go:GO:0055096","description":"\"The series of molecular signals mediated by the detection of low-density lipoprotein particle.\" [GOC:BHF, GOC:rl, PMID:16013438]","metadata":null},{"id":"d25404f0ccf545c7862673728db7fd0c","type":"GO_TERM","name":"low-density lipoprotein particle receptor activity","canonical_id":"go:GO:0005041","description":"\"Combining with a low-density lipoprotein particle and delivering the low-density lipoprotein particle into the cell via endocytosis.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"09b5a58fdd5146b285c19e7d04ed58d2","type":"GO_TERM","name":"low-density lipoprotein particle receptor binding","canonical_id":"go:GO:0050750","description":"\"Binding to a low-density lipoprotein receptor.\" [GOC:ai]","metadata":null},{"id":"177f994065a842debfdf590ac3ac4e44","type":"GO_TERM","name":"low-density lipoprotein particle receptor catabolic process","canonical_id":"go:GO:0032802","description":"\"The chemical reactions and pathways resulting in the breakdown of a low-density lipoprotein particle receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.\" [GOC:mah]","metadata":null},{"id":"b28ab7266d2d4f3cac539e5149e1709a","type":"GO_TERM","name":"low-density lipoprotein particle remodeling","canonical_id":"go:GO:0034374","description":"\"The acquisition, loss or modification of a protein or lipid within a low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase, with the subsequent loss of free fatty acid, and the transfer of cholesterol esters from LDL to a triglyceride-rich lipoprotein particle by cholesteryl ester transfer protein (CETP), with the simultaneous transfer of triglyceride to LDL.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"b421fc1cb41b4740a0e62bb32a80cae2","type":"GO_TERM","name":"low-density lipoprotein receptor complex","canonical_id":"go:GO:0062136","description":"\"A plasma membrane protein complex capable of low-density lipoprotein particle receptor activity. It may also bind xenobiotic toxins and deliver them into the cell via endocytosis. While most substrates get degraded via the endosome the receptor is recycled to the plasma membrane. It may also act as a transducer of intracellular signal pathways and often acts in corporation with other cell-surface receptors.\" [GOC:bhm, PMID:26005850]","metadata":null},{"id":"ef9adadf40fb4a97a88e822c957e5d15","type":"GO_TERM","name":"low-density lipoprotein receptor particle metabolic process","canonical_id":"go:GO:0032799","description":"\"The chemical reactions and pathways involving low-density lipoprotein receptors.\" [GOC:vk]","metadata":null},{"id":"ffdb4717a0604dc6b738b4c028258900","type":"DISEASE","name":"lower respiratory tract disorder","canonical_id":"mondo:0000270","description":null,"metadata":null},{"id":"2b2dd0ac5cc24a819bd3174b0e0750ef","type":"GO_TERM","name":"lower tip-link density","canonical_id":"go:GO:1990434","description":"\"An electron-dense plaque at the lower end of a stereocilia tip link that provides the anchor in the stereocilia membrane at the tip of the stereocilium from which the tip link rises.\" [PMID:19447093]","metadata":null},{"id":"6f3de8547a1646ad951f909e194f71bf","type":"DRUG","name":"loxapine","canonical_id":"gtopdb:205","description":null,"metadata":null},{"id":"e816108e1a764856aaad91c3db0c24b0","type":"DRUG","name":"loxapine","canonical_id":"mesh:D008152","description":null,"metadata":null},{"id":"c7906cc883504e41b4da231b16c6446a","type":"DRUG","name":"loxapine","canonical_id":"chembl:CHEMBL831","description":null,"metadata":null},{"id":"299d9b359595434bac0c6e11caeccf61","type":"DRUG","name":"loxoprofen","canonical_id":"mesh:C040656","description":null,"metadata":null},{"id":"d10abc9f8ae340b3b4821f4ffa6125cd","type":"GO_TERM","name":"lsiRNA processing","canonical_id":"go:GO:0010599","description":"\"A process leading to the generation of a functional long small interfering RNA (lsiRNA). lsiRNAs are class of siRNAs 30 to 40 nt in length. lsiRNAs are induced by pathogen infection or under specific growth conditions.\" [PMID:18003861, PMID:20687832]","metadata":null},{"id":"5221a66a4a824e5097fe6c34833e5b89","type":"DRUG","name":"lubiprostone","canonical_id":"gtopdb:4242","description":null,"metadata":null},{"id":"b6dcfe1b0f4d4a4b85e585a677937d87","type":"DRUG","name":"lubiprostone","canonical_id":"chembl:CHEMBL1201134","description":null,"metadata":null},{"id":"7248f4bbf2414529bd0e2f5469c568c5","type":"COMBINATION_TREATMENT","name":"lubiprostone + naldemedine","canonical_id":"ctgov_combo:ctgov-combo-c731309ecb6b8a04","description":null,"metadata":null},{"id":"2198e833cda84674a9e74d0d18e35b9a","type":"GO_TERM","name":"luciferin monooxygenase activity","canonical_id":"go:GO:0045289","description":"\"Catalysis of the generalized reaction: luciferin + O2 = oxidized luciferin + CO2 + light. There may be additional substrates and reactants involved in the reaction. The reaction results in light emission as luciferin returns to the ground state after enzymatic oxidation.\" [GOC:bf]","metadata":null},{"id":"7c06b59368e64014828a706558c2ea03","type":"DRUG","name":"lucinactant","canonical_id":"mesh:C502722","description":null,"metadata":null},{"id":"1363b0ec7267450a871ea9af6cd05c3c","type":"DRUG","name":"luliconazole","canonical_id":"mesh:C112528","description":null,"metadata":null},{"id":"96f255b03830489c81cdbea875361c4e","type":"DRUG","name":"lumefantrine","canonical_id":"mesh:C102070","description":null,"metadata":null},{"id":"2c526472af974d5ca096fc102d74c971","type":"GO_TERM","name":"lumen formation, open tracheal system","canonical_id":"go:GO:0035149","description":"\"Creation of the central hole of a tube in an open tracheal system through which gases flow.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"682c5921224b41d8b2aee1cf0be3c1d0","type":"GO_TERM","name":"lumenal side of Golgi membrane","canonical_id":"go:GO:0098547","description":"\"The leaflet of the Golgi membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"eacce2b9ae9146ef955cdbdfc397f38e","type":"GO_TERM","name":"lumenal side of cis-Golgi cisternae membrane","canonical_id":"go:GO:0160277","description":"\"The leaflet of the cis-Golgi cisternae membrane that faces the Golgi lumen, including any protein embedded in, attached to, or peripherally associated with it. This is the site where glycosylation and lumen-facing cargo recognition occur.\" [PMID:23913272, PMID:34597626]","metadata":null},{"id":"1ff31ae8693644c583a5255b748008a7","type":"GO_TERM","name":"lumenal side of cis-Golgi network membrane","canonical_id":"go:GO:0140178","description":"\"The leaflet of the cis-Golgi network membrane directly contacts the Golgi lumen, including any protein embedded in, attached to, or peripherally associated with it. This is the site where glycosylation, cargo sorting, or interactions with resident Golgi proteins occur.\" [PMID:1747103, PMID:29802621, PMID:34080016]","metadata":null},{"id":"77bd404aaa0841049d5d708610cbce0e","type":"GO_TERM","name":"lumenal side of early endosome membrane","canonical_id":"go:GO:0098550","description":"\"The leaflet of the early endosome membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:lr]","metadata":null},{"id":"0409ced6021547c5bb7cb30af4f37771","type":"GO_TERM","name":"lumenal side of endoplasmic reticulum membrane","canonical_id":"go:GO:0098553","description":"\"The leaflet of the endoplasmic reticulum membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"a7f0b97d893947ad9c957304846c6504","type":"GO_TERM","name":"lumenal side of endosome membrane","canonical_id":"go:GO:0098565","description":"\"The leaflet of the endosome membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"93ec0c03eb334296b40b113002e78e92","type":"GO_TERM","name":"lumenal side of late endosome membrane","canonical_id":"go:GO:0098551","description":"\"The leaflet of the late endosomal membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:lr]","metadata":null},{"id":"082f0090ade5494cb5b08e7222011b5c","type":"GO_TERM","name":"lumenal side of lysosomal membrane","canonical_id":"go:GO:0098575","description":"\"The leaflet of the lysosomal membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"921262fbe32245bc83e2efd0451fd393","type":"GO_TERM","name":"lumenal side of medial-Golgi cisterna membrane","canonical_id":"go:GO:0160280","description":"\"The leaflet of the medial-Golgi cisternae membrane that faces the Golgi lumen, including any protein embedded in, attached to, or peripherally associated with it. This is the site where protein glycosylation occur.\" [PMID:28777890, PMID:34597626, PMID:36658747, PMID:39331042]","metadata":null},{"id":"38ef722fe2d0482bb47f26b565971944","type":"GO_TERM","name":"lumenal side of membrane","canonical_id":"go:GO:0098576","description":"\"The leaflet of an organelle membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"2483681a9561401d8b95d95e64ab8217","type":"GO_TERM","name":"lumenal side of plastid thylakoid membrane","canonical_id":"go:GO:0098571","description":"\"The leaflet of a plastid thylakoid membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"b47965f2ed7d4839aa2fd5cbe473abe5","type":"GO_TERM","name":"lumenal side of rough endoplasmic reticulum membrane","canonical_id":"go:GO:0098555","description":"\"The leaflet of the rough endoplasmic reticulum membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"3523dd07f50c4dfbbafea033117746d3","type":"GO_TERM","name":"lumenal side of smooth endoplasmic reticulum membrane","canonical_id":"go:GO:0098558","description":"\"The leaflet of the smooth endoplasmic reticulum membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab, GOC:dos]","metadata":null},{"id":"ae6d9022824b481d9396cb66bffdae65","type":"GO_TERM","name":"lumenal side of trans-Golgi cisternae membrane","canonical_id":"go:GO:0160289","description":"\"The leaflet of the trans-Golgi cisternae membrane that faces the Golgi lumen, including any protein embedded in, attached to, or peripherally associated with it. This is the site where the final steps of glycan processing, proteolytic modification, and cargo maturation prior to sorting at the trans-Golgi network occur.\" [PMID:34597626, PMID:38307322, PMID:6121819]","metadata":null},{"id":"1e95a98745ae402ab454af816555d330","type":"GO_TERM","name":"lumenal side of trans-Golgi network membrane","canonical_id":"go:GO:0160282","description":"\"The leaflet of the trans-Golgi network membrane that faces the Golgi lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [PMID:23913272, PMID:34597626, PMID:38307322]","metadata":null},{"id":"27e5a27f54c84b22b5f8a1fd1328e68a","type":"GO_TERM","name":"lumenal side of trans-Golgi network transport vesicle membrane","canonical_id":"go:GO:0098540","description":"\"The leaflet of a trans-Golgi network transport vesicle membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab]","metadata":null},{"id":"f70b584f0ac841be8c66fa98dd50823e","type":"GO_TERM","name":"lumenal side of transport vesicle membrane","canonical_id":"go:GO:0098538","description":"\"The leaflet of a transport vesicle membrane that faces the lumen, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:ab]","metadata":null},{"id":"e9c8891a61b64e74969298362429afde","type":"GO_TERM","name":"luminal surveillance complex","canonical_id":"go:GO:0034099","description":"\"A multiprotein complex that recognizes ERAD-luminal misfolded substrates and brings them to the ubiquitination/extraction machinery. In yeast, this complex consists of Yos9p, Kar2p and Hrd3p proteins.\" [PMID:16873065]","metadata":null},{"id":"4534acd844414dfe821d81e37edda4f4","type":"DRUG","name":"lumiracoxib","canonical_id":"gtopdb:2897","description":null,"metadata":null},{"id":"703cf49486414acd84eafb3df37dff2d","type":"DRUG","name":"lumiracoxib","canonical_id":"mesh:C473384","description":null,"metadata":null},{"id":"b14db6144da94313aec3d7901850fbd1","type":"DRUG","name":"lumiracoxib","canonical_id":"chembl:CHEMBL404108","description":null,"metadata":null},{"id":"11900f8fde784410b0ae557edc511fb2","type":"COMBINATION_TREATMENT","name":"lumiracoxib + rofecoxib","canonical_id":"ctgov_combo:ctgov-combo-4fb8a3cebc69fc01","description":null,"metadata":null},{"id":"005cae289bfd48c3808b5f14d12200d8","type":"DISEASE","name":"lung adenocarcinoma","canonical_id":"mondo:0005061","description":null,"metadata":null},{"id":"abafdf4bf8d24254b1913720047b7113","type":"GO_TERM","name":"lung alveolus development","canonical_id":"go:GO:0048286","description":"\"The process whose specific outcome is the progression of the alveolus over time, from its formation to the mature structure. The alveolus is a sac for holding air in the lungs; formed by the terminal dilation of air passageways.\" [GOC:mtg_lung, PMID:9751757]","metadata":null},{"id":"e1110d5946b840f79e32f495ab2901f3","type":"GO_TERM","name":"lung basal cell differentiation","canonical_id":"go:GO:0060508","description":"\"The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features of a mature basal cell found in the lung. Differentiation includes the processes involved in commitment of a cell to a specific fate. A basal cell is an epithelial stem cell.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"6a02e77ac07242b499003629244813e0","type":"DISEASE","name":"lung cancer","canonical_id":"mondo:0008903","description":null,"metadata":null},{"id":"910b77452454493f9600f470083a9505","type":"DISEASE","name":"lung carcinoma","canonical_id":"mondo:0005138","description":null,"metadata":null},{"id":"374d3bf74d9c4f28ac0ff28164469e3b","type":"GO_TERM","name":"lung cell differentiation","canonical_id":"go:GO:0060479","description":"\"The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features of a mature cell found in the lung. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"6060616fbae74b3d98b572881ee481be","type":"GO_TERM","name":"lung ciliated cell differentiation","canonical_id":"go:GO:0061141","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a lung ciliated cell. A lung ciliated cell is a specialized lung epithelial cell that contains cilia for moving substances released from lung secretory cells.\" [GOC:cilia, GOC:dph, GOC:krc]","metadata":null},{"id":"8a73c47c266f4cefb973f6a6d2f48310","type":"GO_TERM","name":"lung connective tissue development","canonical_id":"go:GO:0060427","description":"\"The biological process whose specific outcome is the progression of lung connective tissue from an initial condition to its mature state. This process begins with the formation of lung connective tissue and ends with the mature structure. The lung connective tissue is a material made up of fibers forming a framework and support structure for the lungs.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"2e337ab690d84cfb9235d59e6dea068c","type":"GO_TERM","name":"lung development","canonical_id":"go:GO:0030324","description":"\"The process whose specific outcome is the progression of the lung over time, from its formation to the mature structure. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax.\" [GOC:jid, UBERON:0002048]","metadata":null},{"id":"a86f8b2e159f4a97ae10e33271d30d70","type":"DISEASE","name":"lung disorder","canonical_id":"mondo:0005275","description":null,"metadata":null},{"id":"4141a23a86aa4e5cad1634ddae1a5d74","type":"GO_TERM","name":"lung epithelial cell differentiation","canonical_id":"go:GO:0060487","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell that contributes to the epithelium of the lung.\" [GOC:dph]","metadata":null},{"id":"6d26c8ca0b194654b671178291bf54d2","type":"GO_TERM","name":"lung epithelium development","canonical_id":"go:GO:0060428","description":"\"The biological process whose specific outcome is the progression of the lung epithelium from an initial condition to its mature state. This process begins with the formation of lung epithelium and ends with the mature structure. The lung epithelium is the specialized epithelium that lines the inside of the lung.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"848214d4a1554812869f4c24b8476bfa","type":"GO_TERM","name":"lung field specification","canonical_id":"go:GO:0060424","description":"\"The process that results in the delineation of a specific region of the foregut into the area in which the lung will develop.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"cdec363b15d64fd0b357c971dcebde24","type":"GO_TERM","name":"lung goblet cell differentiation","canonical_id":"go:GO:0060480","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a lung goblet cell. A goblet cell is a cell of the epithelial lining that produces and secretes mucins.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"c672255bd69848c3ab216b36b745b992","type":"GO_TERM","name":"lung growth","canonical_id":"go:GO:0060437","description":"\"The increase in size or mass of a lung. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax.\" [GOC:dph]","metadata":null},{"id":"30a2bb08528a4326bd95ab661f313d7b","type":"GO_TERM","name":"lung induction","canonical_id":"go:GO:0060492","description":"\"The close range interaction of two or more cells or tissues that causes the cells of the foregut to change their fates and specify the development of the lung.\" [GOC:dph]","metadata":null},{"id":"d254826b9f9c4a639edacee4b1d79acb","type":"GO_TERM","name":"lung lobe development","canonical_id":"go:GO:0060462","description":"\"The biological process whose specific outcome is the progression of a lung lobe from an initial condition to its mature state. This process begins with the formation of a lung lobe by branching morphogenesis and ends with the mature structure. A lung lobe is one of the rounded projections that compose the lung.\" [GOC:dph]","metadata":null},{"id":"b3a728496fa1451aaf330e6e3c34a465","type":"GO_TERM","name":"lung lobe formation","canonical_id":"go:GO:0060464","description":"\"The developmental process pertaining to the initial formation of a lung lobe from unspecified parts. This process begins with the specific processes that contribute to the appearance of the lobe and ends when the structural rudiment is recognizable. A lung lobe is a projection that extends from the lung.\" [GOC:dph]","metadata":null},{"id":"19420cf91cb6403fb764ad033b84555a","type":"GO_TERM","name":"lung lobe morphogenesis","canonical_id":"go:GO:0060463","description":"\"The process in which the anatomical structures of a lung lobe are generated and organized. A lung lobe is a projection that extends from the lung.\" [GOC:dph]","metadata":null},{"id":"8c4c5e0e65bf4ea0a15c77160fa1ac56","type":"GO_TERM","name":"lung morphogenesis","canonical_id":"go:GO:0060425","description":"\"The process in which the anatomical structures of the lung are generated and organized.\" [GOC:dph]","metadata":null},{"id":"7978e6ffb3a8421d977a8c51939847e6","type":"GO_TERM","name":"lung neuroendocrine cell differentiation","canonical_id":"go:GO:0061100","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuroendocrine cell of the lung epithelium.\" [GOC:dph, PMID:9126746]","metadata":null},{"id":"349a06f4230f48a9b40189d96fc632d1","type":"GO_TERM","name":"lung pattern specification process","canonical_id":"go:GO:0060432","description":"\"Any developmental process that results in the creation of defined areas or spaces within the lung, to which cells respond and eventually are instructed to differentiate.\" [GOC:dph]","metadata":null},{"id":"937d3ec150aa4d06b408e8efea9cdc00","type":"GO_TERM","name":"lung proximal/distal axis specification","canonical_id":"go:GO:0061115","description":"\"The establishment, maintenance and elaboration of the proximal/distal axis of the lung. The proximal/distal axis of the lung is defined by a line that runs from the trachea to the alveoli.\" [GOC:dph]","metadata":null},{"id":"531bdca971b4444482a026706f98fca0","type":"GO_TERM","name":"lung saccule development","canonical_id":"go:GO:0060430","description":"\"The biological process whose specific outcome is the progression of a lung saccule from an initial condition to its mature state. The lung saccule is the primitive gas exchange portion of the lung composed of type I and type II cells.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"5dc6b4c78ba142249c08cdb3a50cceda","type":"GO_TERM","name":"lung secretory cell differentiation","canonical_id":"go:GO:0061140","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a lung secretory cell. A lung secretory cell is a specialized epithelial cell of the lung that contains large secretory granules in its apical part.\" [GOC:dph]","metadata":null},{"id":"a6f5f7a1a4f34740ac1621fe811445a1","type":"GO_TERM","name":"lung smooth muscle development","canonical_id":"go:GO:0061145","description":"\"The process whose specific outcome is the progression of smooth muscle in the lung over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"ceab8639053d44b9ac0aeb1f93ce4e43","type":"GO_TERM","name":"lung vasculature development","canonical_id":"go:GO:0060426","description":"\"The biological process whose specific outcome is the progression of a lung vasculature from an initial condition to its mature state. This process begins with the formation of the lung vasculature and ends with the mature structure. The lung vasculature is composed of the tubule structures that carry blood or lymph in the lungs.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"8efc94a80ab6470499022052472df351","type":"GO_TERM","name":"lung-associated mesenchyme development","canonical_id":"go:GO:0060484","description":"\"The biological process whose specific outcome is the progression of a lung-associated mesenchyme from an initial condition to its mature state. This process begins with the formation of lung-associated mesenchyme and ends with the mature structure. Lung-associated mesenchyme is the tissue made up of loosely connected mesenchymal cells in the lung.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"3ddbf157a2d243e2a13b6a8e351fdf73","type":"GO_TERM","name":"lupan-3beta,20-diol synthase activity","canonical_id":"go:GO:0102245","description":"\"Catalysis of the reaction: lupan-3beta,20-diol = (S)-2,3-epoxysqualene + H2O.\" [EC:4.2.1.128, GOC:pz]","metadata":null},{"id":"26cdf8e4b4a04ee190090f12adf898e2","type":"GO_TERM","name":"lupeol synthase activity","canonical_id":"go:GO:0042299","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = lupeol. This reaction is the cyclization of (S)-2,3-epoxysqualene (2,3-oxidosqualene) to lupeol.\" [MetaCyc:RXN-111, PMID:9883589]","metadata":null},{"id":"998796ec57b542babcc05b0b75164b59","type":"DISEASE","name":"lupus nephritis","canonical_id":"mondo:0005556","description":null,"metadata":null},{"id":"279b0b2c74cb477ea73e9672023bc852","type":"DRUG","name":"lurasidone","canonical_id":"gtopdb:7461","description":null,"metadata":null},{"id":"c9ca61c68edf45eabfb49e53b85a130a","type":"DRUG","name":"lurasidone","canonical_id":"mesh:D000069056","description":null,"metadata":null},{"id":"0e6b85080d2a4450a07f982c13452270","type":"COMBINATION_TREATMENT","name":"lurasidone + risperidone","canonical_id":"ctgov_combo:ctgov-combo-a0068b1309eb48d9","description":null,"metadata":null},{"id":"0f17f14c3ab8403c8c8f3512532be129","type":"DRUG","name":"luseogliflozin","canonical_id":"mesh:C549343","description":null,"metadata":null},{"id":"399fb98da33e4e08bbc88d9d4b07876b","type":"DRUG","name":"lusutrombopag","canonical_id":"gtopdb:10032","description":null,"metadata":null},{"id":"ea29e277057e42bd9187eebcd764fc22","type":"DRUG","name":"lusutrombopag","canonical_id":"mesh:C000611387","description":null,"metadata":null},{"id":"9bf7b879c0ec4c4cbecf274098ec310b","type":"DRUG","name":"lusutrombopag","canonical_id":"chembl:CHEMBL2107831","description":null,"metadata":null},{"id":"48b6ba8fcffe41e49c37e95ecf42d831","type":"GO_TERM","name":"luteal cell differentiation","canonical_id":"go:GO:1903728","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a luteal cell. Large luteal cells develop from granulosa cells. Small luteal cells develop from theca cells.\" [GO_REF:0000086, GOC:TermGenie, MP:0001133]","metadata":null},{"id":"0281593e9a09477ab837912bf14c47f7","type":"DRUG","name":"lutein","canonical_id":"mesh:D014975","description":null,"metadata":null},{"id":"b0379e75801f407abf558ad443ebf988","type":"GO_TERM","name":"lutein biosynthetic process","canonical_id":"go:GO:0062171","description":"\"The chemical reactions and pathways resulting in the formation of lutein.\" [PMID:24397433]","metadata":null},{"id":"78a63be5c9cc4c62a372013c8f98332f","type":"GO_TERM","name":"lutein catabolic process","canonical_id":"go:GO:0062172","description":"\"The chemical reactions and pathways resulting in the breakdown of lutein.\" [PMID:24397433]","metadata":null},{"id":"66ed346510454958a18d8e21ece24ac5","type":"GO_TERM","name":"luteinization","canonical_id":"go:GO:0001553","description":"\"The set of processes resulting in differentiation of theca and granulosa cells into luteal cells and in the formation of a corpus luteum after ovulation.\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"b5d36198e46d45e8966819042116d88b","type":"GO_TERM","name":"luteinizing hormone receptor activity","canonical_id":"go:GO:0004964","description":"\"Combining with luteinizing hormone (also called lutropin) to initiate a change in cell activity.\" [ISBN:0198506732, PMID:18848524, PMID:1922095]","metadata":null},{"id":"8c637d3bcc2c4c9e843189d68d8d6d46","type":"GO_TERM","name":"luteinizing hormone secretion","canonical_id":"go:GO:0032275","description":"\"The regulated release of luteinizing hormone, a gonadotropic glycoprotein hormone secreted by the anterior pituitary.\" [ISBN:0198506732]","metadata":null},{"id":"3b0e53458c344d2fb4d373251cfc0d19","type":"GO_TERM","name":"luteinizing hormone signaling pathway","canonical_id":"go:GO:0042700","description":"\"A G protein-coupled receptor signaling pathway initiated by luteinizing hormone binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:dph]","metadata":null},{"id":"115229081a4847ed8c0800e9f67ebdc3","type":"GO_TERM","name":"luteinizing hormone signaling pathway involved in ovarian follicle development","canonical_id":"go:GO:0035471","description":"\"The series of molecular signals initiated by luteinizing hormone binding to a receptor, where the activated receptor signals via downstream effectors that contribute to progression of the ovarian follicle over time, from its formation to the mature structure.\" [GOC:bf]","metadata":null},{"id":"11f964735e3e4a4db46b0e9d6a68242b","type":"GO_TERM","name":"luteolin 7-O-glucuronosyltransferase activity","canonical_id":"go:GO:0050064","description":"\"Catalysis of the reaction: luteolin + UDP-alpha-D-glucuronate = luteolin 7-O-beta-D-glucosiduronate + UDP.\" [EC:2.4.1.189, RHEA:10568]","metadata":null},{"id":"04ae471d41994e338ee3862779f74834","type":"GO_TERM","name":"luteolin biosynthetic process","canonical_id":"go:GO:0033511","description":"\"The chemical reactions and pathways resulting in the formation of luteolin, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one.\" [GOC:mah]","metadata":null},{"id":"4a532e16cae64a5f8835399663955d35","type":"GO_TERM","name":"luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity","canonical_id":"go:GO:0047247","description":"\"Catalysis of the reaction: luteolin 7-O-[(beta-D-glucosiduronate)-(1->2)-(beta-D-glucosiduronate)] + UDP-alpha-D-glucuronate = H+ + luteolin 7-O-[(beta-D-glucosiduronate)-(1->2)-(beta-D-glucosiduronate)] 4'-O-beta-D-glucosiduronate + UDP.\" [EC:2.4.1.191, RHEA:22116]","metadata":null},{"id":"6e0957b06e604bd28a687dcfcc950d47","type":"GO_TERM","name":"luteolin-7-O-glucuronide 7-O-glucuronosyltransferase activity","canonical_id":"go:GO:0047246","description":"\"Catalysis of the reaction: luteolin 7-O-beta-D-glucosiduronate + UDP-alpha-D-glucuronate = H+ + luteolin 7-O-[(beta-D-glucosiduronate)-(1->2)-(beta-D-glucosiduronate)] + UDP.\" [EC:2.4.1.190, RHEA:14149]","metadata":null},{"id":"28aa6302bb524dada9ba58df5b4fc99d","type":"GO_TERM","name":"luteolysis","canonical_id":"go:GO:0001554","description":"\"The lysis or structural demise of the corpus luteum. During normal luteolysis, two closely related events occur. First, there is loss of the capacity to synthesize and secrete progesterone (functional luteolysis) followed by loss of the cells that comprise the corpus luteum (structural luteolysis). Preventing luteolysis is crucial to maintain pregnancy.\" [PMID:10617764]","metadata":null},{"id":"385b6c51d2c0400eb85a1d89bb92afa6","type":"GO_TERM","name":"lutropin-choriogonadotropic hormone receptor binding","canonical_id":"go:GO:0031775","description":"\"Binding to a lutropin-choriogonadotropic hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"1ef37513f7054ae69064a55d456cc5e8","type":"GO_TERM","name":"lyase activity","canonical_id":"go:GO:0016829","description":"\"Catalysis of the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond. They differ from other enzymes in that two substrates are involved in one reaction direction, but only one in the other direction. When acting on the single substrate, a molecule is eliminated and this generates either a new double bond or a new ring.\" [EC:4.-.-.-]","metadata":null},{"id":"739fa81be253406aa572a1a52df36442","type":"GO_TERM","name":"lycopene beta cyclase activity","canonical_id":"go:GO:0045436","description":"\"Catalysis of the cyclization of beta rings at one or both ends of the lycopene molecule (psi, psi-carotene) to form gamma-carotene or the bicyclic beta-carotene (beta, beta-carotene), respectively.\" [PMID:8837512]","metadata":null},{"id":"76ba366e3efc480c8b2b0c2082778505","type":"GO_TERM","name":"lycopene biosynthetic process","canonical_id":"go:GO:1901177","description":"\"The chemical reactions and pathways resulting in the formation of lycopene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00803]","metadata":null},{"id":"c6445f6989f4476bb5c74b8c73ea98f3","type":"GO_TERM","name":"lycopene catabolic process","canonical_id":"go:GO:1901176","description":"\"The chemical reactions and pathways resulting in the breakdown of lycopene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00803]","metadata":null},{"id":"f749146c32e843c1b37f8e9834080983","type":"GO_TERM","name":"lycopene epsilon cyclase activity","canonical_id":"go:GO:0045435","description":"\"Catalysis of the cyclization of an epsilon ring at one end of the lycopene molecule (psi, psi-carotene) to form delta-carotene (epsilon, psi-carotene).\" [PMID:8837512]","metadata":null},{"id":"569b06e60bbe423382f54f6a149c5092","type":"GO_TERM","name":"lymph circulation","canonical_id":"go:GO:0003017","description":"\"The flow of lymph through the body of an animal.\" [GOC:mtg_cardio]","metadata":null},{"id":"3046cb5ef4f94c2cb8e70a7ef69109e4","type":"GO_TERM","name":"lymph gland crystal cell differentiation","canonical_id":"go:GO:0035170","description":"\"The process in which a relatively unspecialized larval lymph gland-derived hemocyte precursor cell acquires the specialized features of a crystal cell. Crystal cells are a class of cells that contain crystalline inclusions and are involved in the melanization of pathogenic material in the hemolymph.\" [GOC:bf, http://sdb.bio.purdue.edu/fly/gene/serpent3.htm]","metadata":null},{"id":"1b5f2b00a7b045e0ae4f599976d723fb","type":"GO_TERM","name":"lymph gland development","canonical_id":"go:GO:0048542","description":"\"The process whose specific outcome is the progression of the lymph gland over time, from its formation to the mature structure. The lymph gland is one of the sites of hemocyte differentiation. It consists of three to six bilaterally paired lobes that are attached to the cardioblasts during larval stages, and it degenerates during pupal stages.\" [GOC:mtg_sensu, GOC:rc]","metadata":null},{"id":"4824ffd7b86f45c1ad34b78c79eb796e","type":"GO_TERM","name":"lymph gland plasmatocyte differentiation","canonical_id":"go:GO:0035169","description":"\"The process in which a relatively unspecialized larval lymph gland-derived hemocyte precursor cell acquires the specialized features of the phagocytic blood-cell type, the plasmatocyte.\" [GOC:bf, PMID:11921077, PMID:8174791]","metadata":null},{"id":"83820c550dbd43dea94d464feec58425","type":"GO_TERM","name":"lymph node development","canonical_id":"go:GO:0048535","description":"\"The process whose specific outcome is the progression of lymph nodes over time, from their formation to the mature structure. A lymph node is a round, oval, or bean shaped structure localized in clusters along the lymphatic vessels, with a distinct internal structure including specialized vasculature and B- and T-zones for the activation of lymphocytes.\" [GOC:add, ISBN:068340007X, ISBN:0781735149]","metadata":null},{"id":"645fd73556c84aee91dffbdadeeef246","type":"GO_TERM","name":"lymph vessel development","canonical_id":"go:GO:0001945","description":"\"The process whose specific outcome is the progression of a lymph vessel over time, from its formation to the mature structure.\" [GOC:dph, UBERON:0001473]","metadata":null},{"id":"35a1dcd1ac4e4cb794653fa6e688167d","type":"GO_TERM","name":"lymph vessel morphogenesis","canonical_id":"go:GO:0036303","description":"\"The process in which the anatomical structures of lymph vessels are generated and organized. The lymph vessel is the vasculature carrying lymph.\" [GOC:BHF, GOC:gr, PMID:18093989]","metadata":null},{"id":"9dc62f2a7dc8461c8fb29dbe98724a25","type":"DISEASE","name":"lymphangiectasis","canonical_id":"mondo:0006840","description":null,"metadata":null},{"id":"2c0ff63386384fb6a9acd99a3bbe4825","type":"GO_TERM","name":"lymphangiogenesis","canonical_id":"go:GO:0001946","description":"\"Lymph vessel formation when new vessels emerge from the proliferation of pre-existing vessels.\" [GOC:dph, PMID:11596157]","metadata":null},{"id":"f3ebf4e16025497ab4a462d29d6d6a26","type":"DISEASE","name":"lymphangioleiomyomatosis","canonical_id":"mondo:0011705","description":null,"metadata":null},{"id":"feaf63bd72564f4a9abca2df9344ff54","type":"DISEASE","name":"lymphangioma","canonical_id":"mondo:0002013","description":null,"metadata":null},{"id":"c8c3f9ebc4c94af29fb99509052fe7b0","type":"GO_TERM","name":"lymphatic endothelial cell differentiation","canonical_id":"go:GO:0060836","description":"\"The process in which a venous blood vessel endothelial cell acquires specialized features of a lymphatic vessel endothelial cell, a thin flattened cell that lines the inside surfaces of lymph vessels.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"eddf64937891438ba6610344510ece00","type":"GO_TERM","name":"lymphatic endothelial cell fate commitment","canonical_id":"go:GO:0060838","description":"\"The commitment of a venous blood vessel endothelial cell to a lymphatic endothelial cell fate and its capacity to differentiate into a lymphatic endothelial cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"5add36a5925e46dcab3f3f1d199dec66","type":"GO_TERM","name":"lymphatic endothelial cell migration","canonical_id":"go:GO:1904977","description":"\"The orderly movement of a lymphatic endothelial cell from one site to another in the wall of a lymphatic vessel.\" [GO_REF:0000091, GOC:TermGenie, PMID:25745057]","metadata":null},{"id":"80d26c44af16433aad2490498a19b43d","type":"DISEASE","name":"lymphatic malformation","canonical_id":"mondo:0019313","description":null,"metadata":null},{"id":"4c42dc162d46458ebdf5329ebf511fc3","type":"DISEASE","name":"lymphatic malformation 1","canonical_id":"mondo:0007919","description":null,"metadata":null},{"id":"bedaa436713d4b1d9b9d3ccff97475ff","type":"GO_TERM","name":"lymphatic vascular process in circulatory system","canonical_id":"go:GO:1990183","description":"\"A circulatory process that occurs at the level of the lymphatic vasculature.\" [PMID:21576390]","metadata":null},{"id":"ebcfb857411a4f938f6efac1ddfe6f8b","type":"GO_TERM","name":"lymphocyte activation","canonical_id":"go:GO:0046649","description":"\"A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"e801617d1d414fb6b8544068d41cb1f3","type":"GO_TERM","name":"lymphocyte activation involved in immune response","canonical_id":"go:GO:0002285","description":"\"A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"cf35b94521f44c45b0e3a47b8b69d2ee","type":"GO_TERM","name":"lymphocyte adhesion to endothelial cell of high endothelial venule","canonical_id":"go:GO:0036339","description":"\"The attachment of a lymphocyte to an endothelial cell of a high endothelial venule (HEV) via adhesion molecules. A HEV cell is an endothelial cell that is cuboidal, expresses leukocyte-specific receptors, and allows for passage of lymphocytes into bloodstream.\" [CL:0000542, CL:0002652, GOC:nhn, PMID:19339990, PMID:7679710, Wikipedia:High_endothelial_venules]","metadata":null},{"id":"9ce9b8375eca48f2b374d1d862bc3415","type":"GO_TERM","name":"lymphocyte aggregation","canonical_id":"go:GO:0071593","description":"\"The adhesion of one lymphocyte to one or more other lymphocytes via adhesion molecules.\" [GOC:sl]","metadata":null},{"id":"bb06280d55c14644a200cbd45c06ea6e","type":"GO_TERM","name":"lymphocyte anergy","canonical_id":"go:GO:0002249","description":"\"Any process contributing to lymphocyte anergy, a state of functional inactivation.\" [GOC:add]","metadata":null},{"id":"312d3943980e479abb3728fd39d675a9","type":"GO_TERM","name":"lymphocyte apoptotic process","canonical_id":"go:GO:0070227","description":"\"Any apoptotic process in a lymphocyte, a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.\" [CL:0000542, GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"3b71c06f00e0489a9cf8fea0a73b94c6","type":"GO_TERM","name":"lymphocyte chemotaxis","canonical_id":"go:GO:0048247","description":"\"The directed movement of a lymphocyte in response to an external stimulus.\" [GOC:hjd, GOC:jid, PMID:12391252]","metadata":null},{"id":"5b5ba16f8877498693ac5c5a275e4988","type":"GO_TERM","name":"lymphocyte chemotaxis across high endothelial venule","canonical_id":"go:GO:0002518","description":"\"The movement of a lymphocyte to cross a high endothelial venule in response to an external stimulus.\" [GOC:add, ISBN:0781735149, PMID:15122201]","metadata":null},{"id":"0516b9c711e741de828787768b7ec65d","type":"GO_TERM","name":"lymphocyte costimulation","canonical_id":"go:GO:0031294","description":"\"The process of providing, via surface-bound receptor-ligand pairs, a second, antigen-independent, signal in addition to that provided by the B- or T cell receptor to augment B- or T cell activation.\" [ISBN:0781735149]","metadata":null},{"id":"21da6195209b4436bfefb9315d29d3c2","type":"GO_TERM","name":"lymphocyte differentiation","canonical_id":"go:GO:0030098","description":"\"The process in which a relatively unspecialized precursor cell acquires specialized features of a lymphocyte. A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.\" [CL:0000542, GOC:curators]","metadata":null},{"id":"2b6b9109f5124aaeb506544e99cf9e19","type":"GO_TERM","name":"lymphocyte homeostasis","canonical_id":"go:GO:0002260","description":"\"The process of regulating the proliferation and elimination of lymphocytes such that the total number of lymphocytes within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:add, PMID:15826826, PMID:16319493, PMID:16551252, PMID:16551262]","metadata":null},{"id":"97abb1290b554f4ea53a204c237dcade","type":"GO_TERM","name":"lymphocyte mediated immunity","canonical_id":"go:GO:0002449","description":"\"Any process involved in the carrying out of an immune response by a lymphocyte.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"a1fd1302f1a346e08d714c4bc529490c","type":"GO_TERM","name":"lymphocyte migration","canonical_id":"go:GO:0072676","description":"\"The movement of a lymphocyte within or between different tissues and organs of the body.\" [CL:0000542, GOC:BHF, GOC:mah]","metadata":null},{"id":"d9b3b8b4c02c4c7ca1cb0be407278f23","type":"GO_TERM","name":"lymphocyte migration into lymph node","canonical_id":"go:GO:0097022","description":"\"The movement of a lymphocyte within the lymphatic system into a lymph node, and its subsequent positioning within defined functional compartments such as sites of cell activation by antigen.\" [GOC:BHF, GOC:pr, PMID:18379575]","metadata":null},{"id":"fd7c48fd4eac497a8d5141ec425033d5","type":"GO_TERM","name":"lymphocyte migration into lymphoid organs","canonical_id":"go:GO:0097021","description":"\"The movement of a lymphocyte within the lymphatic system into lymphoid organs such as lymph nodes, spleen or Peyer's patches, and its subsequent positioning within defined functional compartments such as sites of cell activation by antigen.\" [GOC:BHF, GOC:pr, PMID:18379575]","metadata":null},{"id":"a68c25d42cd246d09e36d9b0adfdeb74","type":"GO_TERM","name":"lymphocyte proliferation","canonical_id":"go:GO:0046651","description":"\"The expansion of a lymphocyte population by cell division.\" [GOC:ai]","metadata":null},{"id":"34b0161800f74d04b26036d053fc2aa7","type":"DISEASE","name":"lymphoid leukemia","canonical_id":"mondo:0005402","description":null,"metadata":null},{"id":"ec62bb6b60074d8c83ebe6bb9ac589e7","type":"GO_TERM","name":"lymphoid lineage cell migration","canonical_id":"go:GO:0097534","description":"\"The orderly movement of a lymphoid lineage cell from one site to another. A lymphoid lineage cell, also called a lymphoid lineage restricted progenitor cell, is a progenitor cell restricted to the lymphoid lineage.\" [GOC:pr, PMID:22342843]","metadata":null},{"id":"538930fbb7e246e4ae4ac1c96a7997d4","type":"GO_TERM","name":"lymphoid lineage cell migration into thymus","canonical_id":"go:GO:0097535","description":"\"The movement of a lymphoid lineage cell (also called a lymphoid lineage restricted progenitor cell) into the thymus. Lymphoid lineage cells enter and exit the thymus several times as part of this process.\" [GOC:cvs, PMID:22342843]","metadata":null},{"id":"86ba465955f84de491f12da3128c59ae","type":"DISEASE","name":"lymphoid neoplasm","canonical_id":"mondo:0005157","description":null,"metadata":null},{"id":"738e8262198e4982bf34c321cff918e6","type":"GO_TERM","name":"lymphoid progenitor cell differentiation","canonical_id":"go:GO:0002320","description":"\"The process in which a precursor cell type acquires the specialized features of a lymphoid progenitor cell. Lymphoid progenitor cells include progenitor cells for any of the lymphoid lineages.\" [GOC:add, PMID:16551251, PMID:16551264]","metadata":null},{"id":"d2eae651cfca4687b2375df7bc78ba22","type":"DISEASE","name":"lymphoma","canonical_id":"mondo:0005062","description":null,"metadata":null},{"id":"018835be68754232993a24261c467431","type":"DISEASE","name":"lymphoplasmacytic lymphoma","canonical_id":"mondo:0000432","description":null,"metadata":null},{"id":"088b37caab6346f282f57212f8851d03","type":"GO_TERM","name":"lymphotoxin A production","canonical_id":"go:GO:0032641","description":"\"The chemical reactions and pathways resulting in the formation of the cytokine lymphotoxin A.\" [GOC:jl]","metadata":null},{"id":"05341e8fbdf04b8f978ecd98bb88c48b","type":"GO_TERM","name":"lymphotoxin complex","canonical_id":"go:GO:0062048","description":"\"A homo- or heterotrimeric protein containing complex consisting of alpha and beta lymphotoxin subunits in different stoichiometric combinations.\" [PMID:1733951]","metadata":null},{"id":"f5707e8734d24c90a5244111b20d9bc9","type":"GO_TERM","name":"lys-arg specific dibasic protein processing","canonical_id":"go:GO:0090473","description":"\"Any protein processing achieved by the cleavage of a peptide bond after a lysine-arginine amino acid residue combination within a protein.\" [GOC:al]","metadata":null},{"id":"1c1a55de02384e4296b901d1afb5ac92","type":"GO_TERM","name":"lys-lys specific dibasic protein processing","canonical_id":"go:GO:0090475","description":"\"Any protein processing achieved by the cleavage of a peptide bond after two consecutive lysine amino acid residues within a protein.\" [GOC:al]","metadata":null},{"id":"6224862e3aee46aba9907ce645d57b1d","type":"GO_TERM","name":"lysine N-methyltransferase activity","canonical_id":"go:GO:0016278","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the epsilon-amino group of a lysine residue.\" [GOC:mah]","metadata":null},{"id":"8025e171069744a4b90514677368eb04","type":"GO_TERM","name":"lysine carbamoyltransferase activity","canonical_id":"go:GO:0050068","description":"\"Catalysis of the reaction: L-lysine + carbamoyl phosphate = L-homocitrulline + H+ + phosphate.\" [EC:2.1.3.8, RHEA:17121]","metadata":null},{"id":"645e65ea5dc540328d1b9be27405ddd9","type":"GO_TERM","name":"lysine decarboxylase activity","canonical_id":"go:GO:0008923","description":"\"Catalysis of the reaction: L-lysine + H+ = cadaverine + CO2.\" [RHEA:22352]","metadata":null},{"id":"827bb7d93df34409ab4e5cbde5417596","type":"GO_TERM","name":"lysine racemase activity","canonical_id":"go:GO:0018113","description":"\"Catalysis of the reaction: L-lysine = D-lysine.\" [EC:5.1.1.5]","metadata":null},{"id":"049281831d0d43e19551772ff2c78dd5","type":"GO_TERM","name":"lysine transport","canonical_id":"go:GO:0015819","description":"\"The directed movement of lysine, 2,6-diaminohexanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"a414d86447d44cd7aa71b2cab4828f28","type":"GO_TERM","name":"lysine-tRNA ligase activity","canonical_id":"go:GO:0004824","description":"\"Catalysis of the reaction: ATP + L-lysine + tRNA(Lys) = AMP + diphosphate + L-lysyl-tRNA(Lys).\" [EC:6.1.1.6]","metadata":null},{"id":"8c25c4313b1f4c499ca3bb848848723e","type":"GO_TERM","name":"lysine:cadaverine antiporter activity","canonical_id":"go:GO:0043872","description":"\"Catalysis of the reaction: lysine(out) + cadaverine(in) = lysine(in) + cadaverine(out).\" [GOC:jl, PMID:10986235, TC:2.A.3.2.2]","metadata":null},{"id":"be8388084b094c1c9c0638bd1558ab62","type":"GO_TERM","name":"lysine:proton symporter activity","canonical_id":"go:GO:0015493","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: lysine(out) + H+(out) = lysine(in) + H+(in).\" [TC:2.A.3.1.2]","metadata":null},{"id":"1f6308fdbdce47689c2ccc3c2f766dde","type":"GO_TERM","name":"lysis of host organelle involved in viral entry into host cell","canonical_id":"go:GO:0039664","description":"\"The viral-induced lysis of an organelle (endosome, lysosome, or caveosome) that is involved in the uptake of a virus into a host cell. Occurs once the virus is within the organelle, and results in transfer of the viral contents from the organelle compartment into the cytoplasm.\" [GOC:bf, GOC:jl, UniProtKB-KW:KW-1174, VZ:984]","metadata":null},{"id":"605acc53b92b48919a2548e13b846d28","type":"GO_TERM","name":"lyso-ornithine lipid acyltransferase activity","canonical_id":"go:GO:0043808","description":"\"Catalysis of the reaction: lyso-ornithine lipid + acyl-[acyl-carrier protein] = ornithine lipid + [acyl-carrier protein].\" [PMID:15341653]","metadata":null},{"id":"bd3966f940a642019d14187823da1a04","type":"GO_TERM","name":"lysobisphosphatidic acid biosynthetic process","canonical_id":"go:GO:2001312","description":"\"The chemical reactions and pathways resulting in the formation of a lysobisphosphatidic acid. A lysobisphosphatidic acid is a lysophosphatidic acid having the unusual property of a phosphodiester moiety linked to positions sn-1 and sn1' of glycerol; and two additional fatty acids esterified to the glycerol head group.\" [GOC:mw]","metadata":null},{"id":"770626e9a0b94061b70413c63f849512","type":"GO_TERM","name":"lysobisphosphatidic acid metabolic process","canonical_id":"go:GO:2001311","description":"\"The chemical reactions and pathways involving a lysobisphosphatidic acid. A lysobisphosphatidic acid is a lysophosphatidic acid having the unusual property of a phosphodiester moiety linked to positions sn-1 and sn1' of glycerol; and two additional fatty acids esterified to the glycerol head group.\" [GOC:mw]","metadata":null},{"id":"ef7abe1d7dcb4d74b4bd45910a099237","type":"GO_TERM","name":"lysolecithin acylmutase activity","canonical_id":"go:GO:0050070","description":"\"Catalysis of the reaction: 1-acyl-sn-glycero-3-phosphocholine = 2-acyl-sn-glycero-3-phosphocholine.\" [EC:5.4.1.1, RHEA:24356]","metadata":null},{"id":"0c241c13e6664a1ab89764f19e444751","type":"GO_TERM","name":"lysophagy","canonical_id":"go:GO:0062093","description":"\"The selective autophagy process in which a damaged lysosome is degraded by macroautophagy.\" [PMID:28743755]","metadata":null},{"id":"5ac6773f14674bb2857a0b5bae028939","type":"GO_TERM","name":"lysophosphatidic acid acyltransferase activity","canonical_id":"go:GO:0042171","description":"\"Catalysis of the transfer of acyl groups from an acyl-CoA to lysophosphatidic acid to form phosphatidic acid.\" [GOC:ab, PMID:16369050]","metadata":null},{"id":"588beb1a828b47a381b28ba4003d00b8","type":"GO_TERM","name":"lysophosphatidic acid binding","canonical_id":"go:GO:0035727","description":"\"Binding to lysophosphatidic acid (LPA), a phospholipid derivative that acts as a potent mitogen due to its activation of high-affinity G protein-coupled receptors.\" [GOC:curators]","metadata":null},{"id":"1b71cf9ff57a4d4ab0d0853a220890f6","type":"GO_TERM","name":"lysophosphatidic acid phosphatase activity","canonical_id":"go:GO:0052642","description":"\"Catalysis of the reaction: lysophosphatidic acid + H2O = phosphate + monoacylglycerol.\" [PMID:20045079, PMID:7966317]","metadata":null},{"id":"ad43418c4df24e09966cd010d994c149","type":"GO_TERM","name":"lysophosphatidic acid receptor activity","canonical_id":"go:GO:0070915","description":"\"Combining with the phospholipid derivative lysophosphatidic acid, and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:bf, GOC:mah, PMID:15755723]","metadata":null},{"id":"33ce9fd8cc574eeb9d37988bba754e00","type":"GO_TERM","name":"lysophosphatidylcholine flippase activity","canonical_id":"go:GO:0140348","description":"\"Catalysis of the movement of lysophosphatidylcholine from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:26945070]","metadata":null},{"id":"3787bb3aca3544f5950d8d4009047101","type":"GO_TERM","name":"lysophosphatidylethanolamine acyltransferase activity","canonical_id":"go:GO:0071618","description":"\"Catalysis of the transfer of acyl groups from an acyl-CoA to lysophosphatidylethanolamine.\" [GOC:cjk]","metadata":null},{"id":"08b1dde4107540878d77f5ee4a48db2e","type":"GO_TERM","name":"lysophosphatidylserine flippase activity","canonical_id":"go:GO:0180013","description":"\"Catalysis of the movement of a lysophosphatidylserine from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:34645814]","metadata":null},{"id":"59993328358a4b2f96b677fb7f2ff763","type":"GO_TERM","name":"lysophospholipase A1 activity","canonical_id":"go:GO:0120558","description":"\"Catalysis of the hydrolysis of a lysoglycerophospholipid, removing the acyl chain at the sn-1 position to yield a glycerophospho-compound and a free fatty acid.\" [GOC:curators]","metadata":null},{"id":"c39c313c31cc4cc09fcc1fb818c0ff51","type":"GO_TERM","name":"lysophospholipase C activity","canonical_id":"go:GO:0140324","description":"\"Hydrolysis of a lysoglycerophospholipid at the first phosphodiester bond between the phosphate and glycerol.\" [PMID:32917725]","metadata":null},{"id":"0160cf6e5e2a45208463e4e01bafc8fe","type":"GO_TERM","name":"lysophospholipid acyltransferase activity","canonical_id":"go:GO:0071617","description":"\"Catalysis of the transfer of acyl groups from an acyl-CoA to a lysophospholipid.\" [GOC:cjk]","metadata":null},{"id":"2f9b26fb783c4544ab9334d2bd76c6a1","type":"GO_TERM","name":"lysophospholipid translocation","canonical_id":"go:GO:0140329","description":"\"The movement of a lysophospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet.\" [PMID:15661733]","metadata":null},{"id":"737581ef10734964ac0a5407badeb31a","type":"GO_TERM","name":"lysophospholipid transport","canonical_id":"go:GO:0051977","description":"\"The directed movement of phospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A lysophospholipid is a phospholipid that lacks one of its fatty acyl chains; it is an intermediate formed during digestion of dietary and biliary phospholipids.\" [GOC:ai]","metadata":null},{"id":"525189a2a5124705af4250478b69bd2c","type":"GO_TERM","name":"lysophospholipid:sodium symporter activity","canonical_id":"go:GO:0051978","description":"\"Enables the directed movement of lysophospholipids from one side of a membrane to the other. A lysophospholipid is a phospholipid that lacks one of its fatty acyl chains; it is an intermediate formed during digestion of dietary and biliary phospholipids.\" [GOC:ai]","metadata":null},{"id":"150cf8dd07a749ee94709943d85083e6","type":"GO_TERM","name":"lysosomal HOPS complex","canonical_id":"go:GO:1902501","description":"\"Any HOPS complex that is part of a lysosomal membrane.\" [GOC:TermGenie, PMID:23645161]","metadata":null},{"id":"3f09ea00792547b99bb3a5bd8450a83f","type":"GO_TERM","name":"lysosomal glycocalyx","canonical_id":"go:GO:0090123","description":"\"The polysaccharide-based coating on the inner side of a lysosomal membrane. It may be involved in protecting the membrane from digestion by lysosomal enzymes.\" [GOC:ascb_2009, GOC:dph, GOC:krc, GOC:tb, PMID:10521503, PMID:22809326, PMID:29367433]","metadata":null},{"id":"1703ce19a0624bf3a66a68c81fc0a178","type":"GO_TERM","name":"lysosomal lumen","canonical_id":"go:GO:0043202","description":"\"The volume enclosed within the lysosomal membrane.\" [GOC:jl, PMID:15213228]","metadata":null},{"id":"2a8301a17b4d47bc9a103c6ffc32995b","type":"GO_TERM","name":"lysosomal lumen acidification","canonical_id":"go:GO:0007042","description":"\"Any process that reduces the pH of the lysosomal lumen, corresponding to an increase in hydrogen ion concentration.\" [GOC:jid]","metadata":null},{"id":"1c4109b49c244569aee011c3adcb435e","type":"GO_TERM","name":"lysosomal lumen pH elevation","canonical_id":"go:GO:0035752","description":"\"Any process that increases the pH of the lysosomal lumen, corresponding to a decrease in hydrogen ion concentration.\" [GOC:bf, GOC:rph]","metadata":null},{"id":"513ed2bcb97f48179a2811c016b41da2","type":"GO_TERM","name":"lysosomal matrix","canonical_id":"go:GO:1990836","description":"\"A matrix composed of supramolecular assemblies of lysosomal enzymes and lipids which forms at a pH of 5.0 within the lysosome.\" [PMID:9395337]","metadata":null},{"id":"720bb724c5504f78b3dbbd128897dcee","type":"GO_TERM","name":"lysosomal membrane","canonical_id":"go:GO:0005765","description":"\"The lipid bilayer surrounding the lysosome and separating its contents from the cell cytoplasm.\" [GOC:ai]","metadata":null},{"id":"1bf1fd5e190045c7a4e44317bc33326f","type":"GO_TERM","name":"lysosomal membrane organization","canonical_id":"go:GO:0097212","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lysosomal membrane. A lysosomal membrane is the lipid bilayer surrounding the lysosome and separating its contents from the cell cytoplasm.\" [GOC:yaf, PMID:20544854]","metadata":null},{"id":"47dd0422739b46ac995661c7f0bb772e","type":"GO_TERM","name":"lysosomal multienzyme complex","canonical_id":"go:GO:0070559","description":"\"A protein complex found in the lysosome that contains beta-galactosidase, cathepsin A, alpha-neuraminidase and N-acetylgalactosamine-6-sulfate sulfatase, and is involved in glycosaminoglycan catabolism.\" [GOC:mah, PMID:8910459]","metadata":null},{"id":"eb97f361877e453a874c8ea128ee6f2a","type":"GO_TERM","name":"lysosomal protein catabolic process","canonical_id":"go:GO:1905146","description":"\"Any cellular protein catabolic process that takes place in a lysosome.\" [GO_REF:0000062, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24334770]","metadata":null},{"id":"745aec8d2cfb4ef48b851fc772fabc39","type":"GO_TERM","name":"lysosomal proton-transporting V-type ATPase complex","canonical_id":"go:GO:0046611","description":"\"A proton-transporting two-sector ATPase complex found in the lysosomal membrane, where it acts as a proton pump to mediate acidification of the lysosomal lumen.\" [GOC:mah, ISBN:0716743663, PMID:16449553]","metadata":null},{"id":"18a244c84cae4ed8b8e2fd8f0fb34448","type":"GO_TERM","name":"lysosomal proton-transporting V-type ATPase, V0 domain","canonical_id":"go:GO:0046610","description":"\"The V0 domain of a proton-transporting V-type ATPase found in the lysosomal membrane.\" [GOC:mah]","metadata":null},{"id":"a4cb8c8f603e4d64851268742dbb13c5","type":"GO_TERM","name":"lysosomal proton-transporting V-type ATPase, V1 domain","canonical_id":"go:GO:0046612","description":"\"The V1 domain of a proton-transporting V-type ATPase found in the lysosomal membrane.\" [GOC:mah]","metadata":null},{"id":"4af0c28385d04169993341d840bf8da1","type":"DISEASE","name":"lysosomal storage disease","canonical_id":"mondo:0002561","description":null,"metadata":null},{"id":"4e85b10c68bf44758396ba5a936d0ac7","type":"GO_TERM","name":"lysosomal transport","canonical_id":"go:GO:0007041","description":"\"The directed movement of substances into, out of or within a lysosome.\" [GOC:ai]","metadata":null},{"id":"d46e164dcf194bc8b761535608d0f429","type":"GO_TERM","name":"lysosome","canonical_id":"go:GO:0005764","description":"\"A small lytic vacuole that has cell cycle-independent morphology found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"3ab810bf2e5b438891e318daece28df9","type":"GO_TERM","name":"lysosome fission","canonical_id":"go:GO:0170064","description":"\"The process by which lysosomes undergo budding and fission to maintain their steady-state number, shape, size, composition and function, and to accomplish regeneration.\" [PMID:31171420, PMID:38538795]","metadata":null},{"id":"e67792a26e6f4ed597e54fa00bf4e6f1","type":"GO_TERM","name":"lysosome localization","canonical_id":"go:GO:0032418","description":"\"Any process in which a lysosome is transported to, and/or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"3da2ec591b594dae92067c35e197cb96","type":"GO_TERM","name":"lysosome organization","canonical_id":"go:GO:0007040","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lysosome. A lysosome is a cytoplasmic, membrane-bounded organelle that is found in most animal cells and that contains a variety of hydrolases.\" [GOC:mah]","metadata":null},{"id":"112fe50401404b3c9360d76ab059b071","type":"GO_TERM","name":"lysosome to ER cholesterol transport","canonical_id":"go:GO:0090120","description":"\"The directed movement of cholesterol, cholest-5-en-3-beta-ol, or cholesterol-containing compounds, from the lysosome to the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"e3a006d57f444d078791c0e66caa731f","type":"GO_TERM","name":"lysozyme activity","canonical_id":"go:GO:0003796","description":"\"Catalysis of the hydrolysis of the beta-(1->4) linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in a peptidoglycan.\" [EC:3.2.1.17, PMID:22748813]","metadata":null},{"id":"4b3c544f98684b49a1bd50cd626290d7","type":"GO_TERM","name":"lysozyme inhibitor activity","canonical_id":"go:GO:0060241","description":"\"Binds to and stops, prevents or reduces the activity of lysozyme.\" [GOC:dph]","metadata":null},{"id":"72f5a6221c58480a97135bc60e7b3751","type":"GO_TERM","name":"lysyl-tRNA aminoacylation","canonical_id":"go:GO:0006430","description":"\"The process of coupling lysine to lysyl-tRNA, catalyzed by lysyl-tRNA synthetase. The lysyl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of a lysine-accetping tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"626d68ca4d7b4a679b5c499a50309197","type":"GO_TERM","name":"lytic endotransglycosylase activity","canonical_id":"go:GO:0008932","description":"\"Catalysis of the endolytic cleavage of the (1->4)-beta-glycosidic linkage between N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) residues in peptidoglycan with concomitant formation of a 1,6-anhydrobond in the MurNAc residue.\" [EC:4.2.2.n2, PMID:10964424, PMID:9642199]","metadata":null},{"id":"bc6b929045434c49b327488159d94104","type":"GO_TERM","name":"lytic exotransglycosylase activity","canonical_id":"go:GO:0140100","description":"\"Catalysis of the exolytic cleavage of the (1->4)-beta-glycosidic linkage between N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) residues in peptidoglycan, from either the reducing or the non-reducing ends of the peptidoglycan chains, with concomitant formation of a 1,6-anhydrobond in the MurNAc residue.\" [EC:4.2.2.n1]","metadata":null},{"id":"561061e68c6b4c77a61d1fc8d8647bba","type":"GO_TERM","name":"lytic vacuole","canonical_id":"go:GO:0000323","description":"\"A vacuole that is maintained at an acidic pH and which contains degradative enzymes, including a wide variety of acid hydrolases.\" [GOC:krc]","metadata":null},{"id":"f27c0f205007459cb3f2ff70a9e8e27e","type":"GO_TERM","name":"lytic vacuole membrane","canonical_id":"go:GO:0098852","description":"\"The lipid bilayer surrounding a lytic vacuole and separating its contents from the cytoplasm of the cell.\" [GOC:dos]","metadata":null},{"id":"551b5fec850943c393795bfdbbae2637","type":"GO_TERM","name":"lytic vacuole organization","canonical_id":"go:GO:0080171","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lytic vacuole.\" [PMID:20729380]","metadata":null},{"id":"4c02491b53c04a2b8e1930b3acf8b359","type":"GO_TERM","name":"lytic vacuole within protein storage vacuole","canonical_id":"go:GO:0000327","description":"\"A membrane-bounded compartment containing crystals of phytic acid and proteins characteristic of a lytic vacuole, found within a storage vacuole.\" [PMID:11739490]","metadata":null},{"id":"17c64454aed04ff3813855b301fc8593","type":"GO_TERM","name":"m-AAA complex","canonical_id":"go:GO:0005745","description":"\"Protease complex of the mitochondrial inner membrane that is involved in mitochondrial protein turnover and in processing of proteins imported into mitochondria.\" [GOC:mcc, PMID:12417197, PMID:21147776]","metadata":null},{"id":"41a0f454e12e4808b68762de97e57958","type":"GO_TERM","name":"m-cresol catabolic process","canonical_id":"go:GO:0042213","description":"\"The chemical reactions and pathways resulting in the breakdown of m-cresol (3-hydroxytoluene), the meta-isoform of cresol.\" [GOC:jl]","metadata":null},{"id":"2304529e7feb47758c2011ce6d7f6d42","type":"GO_TERM","name":"m-xylene catabolic process","canonical_id":"go:GO:0042185","description":"\"The chemical reactions and pathways resulting in the breakdown of m-xylene, 1,3-dimethylbenzene, a colorless, liquid aromatic hydrocarbon.\" [GOC:curators, GOC:jl]","metadata":null},{"id":"94e3eb7c48a5459da1898102bba8de50","type":"GO_TERM","name":"m7G(5')pppN diphosphatase complex","canonical_id":"go:GO:0106095","description":"\"A homodimeric protein complex that catalyzes the reaction: 7-methylguanosine-5'-triphospho-5'-pholynucleotide + H20 = 7-methylguanosine-5'-phosphate + polynucleotide.\" [GOC:lnp, PMID:22985415, PMID:26258763]","metadata":null},{"id":"8645341f37494ec3a0f5296502cc756f","type":"GO_TERM","name":"mBAF complex","canonical_id":"go:GO:0140091","description":"\"A muscle cell-specific SWI/SNF-type complex that contains eight to fourteen proteins, including both conserved (core) and nonconserved components; contains the ATPase product of either the SMARCA4/BAF190A/BRG1 gene, the mammalian ortholog of the yeast SNF2 gene, or the SMARCA2/BAF190B/BRM gene, the mammalian ortholog of the Drosophila brm (brahma) gene, or an ortholog of either of these genes, and the muscle-specific product of the DPF3/BAF45C gene or an ortholog thereof.\" [GO:bhm, PMID:11175787, PMID:12620226, PMID:15525990, PMID:8804307, PMID:8895581]","metadata":null},{"id":"7ff084038530413ba6e4ce4bb05c1f9b","type":"GO_TERM","name":"mCRD-mediated mRNA stability complex","canonical_id":"go:GO:0106002","description":"\"A protein complex that binds to, and promotes stabilization of, mRNA molecules containing the major coding region instability determinant (mCRD) by bridging the mCRD domain and the poly(A) tail of the mRNA. In human, it consists of CSDE1, HNRPD, PABPC1, PAIP1 and SYNCRIP.\" [GOC:bhm, PMID:11051545]","metadata":null},{"id":"5bbe71134de24012b6528e619f7b5965","type":"TRIAL","name":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","canonical_id":"clinicaltrials.gov:NCT04251715","description":"Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma","metadata":null},{"id":"f248ac3d9adc4165a30a77ddc2b4b228","type":"GO_TERM","name":"mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity","canonical_id":"go:GO:0016422","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + m(7)G(5')pppAm = S-adenosyl-L-homocysteine + m(7)G(5')pppm(6)Am.\" [EC:2.1.1.62]","metadata":null},{"id":"c912473cf5ca4a0596d119d0d2043028","type":"GO_TERM","name":"mRNA (adenine-N1-)-methyltransferase activity","canonical_id":"go:GO:0061953","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + adenine in mRNA = S-adenosyl-L-homocysteine + N(1)-methyladenine in mRNA.\" [PMID:29072297]","metadata":null},{"id":"b0ff6d1ea0794a2ca5251741b76028ea","type":"GO_TERM","name":"mRNA (cytidine-5-)-methyltransferase activity","canonical_id":"go:GO:0062152","description":"\"Catalysis of the reaction: a cytidine in mRNA + S-adenosyl-L-methionine = a 5-methylcytidine in mRNA + H+ + S-adenosyl-L-homocysteine.\" [PMID:22395603, PMID:23871666, RHEA:61464]","metadata":null},{"id":"5a821c5e137e465c851c0abf8edd7bfb","type":"GO_TERM","name":"mRNA 3'-UTR AU-rich region binding","canonical_id":"go:GO:0035925","description":"\"Binding to a region containing frequent adenine and uridine bases within the 3' untranslated region of a mRNA molecule or in pre-mRNA intron. The ARE-binding element consensus is UUAUUUAUU. ARE-binding proteins control the stability and/or translation of mRNAs.\" [GOC:vw, PMID:31511872, PMID:7892223, PMID:8578590]","metadata":null},{"id":"d180f3fd0bff4c3f80675a5718935aa9","type":"GO_TERM","name":"mRNA 3'-UTR binding","canonical_id":"go:GO:0003730","description":"\"Binding to a 3' untranslated region of an mRNA molecule.\" [GOC:mah]","metadata":null},{"id":"8128aa5139c64a4b8ceb4a400f826c7b","type":"GO_TERM","name":"mRNA 3'-end processing","canonical_id":"go:GO:0031124","description":"\"Any process involved in forming the mature 3' end of an mRNA molecule.\" [GOC:mah]","metadata":null},{"id":"63b7be335176408cbcb513a7e6d081b0","type":"GO_TERM","name":"mRNA 3'-end processing by stem-loop binding and cleavage","canonical_id":"go:GO:0006398","description":"\"Any mRNA 3'-end processing that involves the binding to and cleavage of a stem-loop structure. For example, histone mRNAs contain a highly conserved stem-loop sequence at the 3' end of the mRNA with a 6 base pairs (bp) stem and a 4-nt loop. The mRNA is cleaved between these two elements, after the fourth or fifth nucleotide, which is typically an adenosine.\" [GOC:mah, GOC:tb, PMID:17998288]","metadata":null},{"id":"98905ee996b5431ba350b62f0fa93e67","type":"GO_TERM","name":"mRNA 3'-splice site recognition","canonical_id":"go:GO:0000389","description":"\"Recognition of the intron 3'-splice site by components of the assembling U2- or U12-type spliceosome.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"17c806c0efe94a2188fad9c3e550b5b6","type":"GO_TERM","name":"mRNA 5'-UTR binding","canonical_id":"go:GO:0048027","description":"\"Binding to an mRNA molecule at its 5' untranslated region.\" [GOC:jid]","metadata":null},{"id":"81c3e768ccbb4389bc8daf1bf74363e1","type":"GO_TERM","name":"mRNA 5'-cap (guanine-N7-)-methyltransferase activity","canonical_id":"go:GO:0004482","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + G(5')pppR-RNA = S-adenosyl-L-homocysteine + m7G(5')pppR-RNA. m7G(5')pppR-RNA is mRNA containing an N7-methylguanine cap; R may be guanosine or adenosine.\" [EC:2.1.1.56]","metadata":null},{"id":"fab4499d183f4b2d917a65c8cb7475ea","type":"GO_TERM","name":"mRNA 5'-diphosphatase activity","canonical_id":"go:GO:0034353","description":"\"Catalysis of the removal of a 5' terminal diphosphate from the 5'-triphosphate end of an mRNA, leaving a 5'-monophosphate end.\" [GOC:jh2, PMID:17612492, PMID:18202662]","metadata":null},{"id":"91b067853e3045ba8648be09885ee0eb","type":"GO_TERM","name":"mRNA 5'-splice site recognition","canonical_id":"go:GO:0000395","description":"\"Recognition of the intron 5'-splice site by components of the assembling spliceosome.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"8e8fdc16348d4ab2a61da4d2cf62ca1e","type":"GO_TERM","name":"mRNA 5'-triphosphate monophosphatase activity","canonical_id":"go:GO:0140818","description":"\"A 5'-end triphospho-[mRNA] + H2O = a 5'-end diphospho-[mRNA] + H+ + phosphate.\" [PMID:9473487]","metadata":null},{"id":"88701ac9c555474493252f0e591f7d0a","type":"GO_TERM","name":"mRNA CDS binding","canonical_id":"go:GO:1990715","description":"\"Binding to an mRNA molecule coding sequence (CDS).\" [GOC:kmv, PMID:25805859, SO:0000316]","metadata":null},{"id":"b2843c80d882492586f591d57a4cff1f","type":"GO_TERM","name":"mRNA N1-methyladenosine dioxygenase activity","canonical_id":"go:GO:1990930","description":"\"Catalysis of the oxidative demethylation of N1-methyladenosine RNA, with concomitant decarboxylation of 2-oxoglutarate and releases oxidized methyl group on N1-methyladenosine as formaldehyde.\" [PMID:26863196, PMID:26863410]","metadata":null},{"id":"37c88d0d5d4f41188764f5f47efc7cd3","type":"GO_TERM","name":"mRNA N6-methyladenosine dioxygenase activity","canonical_id":"go:GO:1990931","description":"\"Catalysis of the oxidative demethylation of N6-methyladenosine RNA, with concomitant decarboxylation of 2-oxoglutarate and releases oxidized methyl group on N6-methyladenosine as formaldehyde.\" [PMID:22002720, PMID:26458103]","metadata":null},{"id":"9cdb7d27e87145259a36861b0552c68d","type":"GO_TERM","name":"mRNA alternative polyadenylation","canonical_id":"go:GO:0110104","description":"\"The process of generating multiple mRNA molecules with variable 3'-end length formation from a given pre-mRNA by differential use of cleavage and polyadenylation signals (pA signals).\" [GOC:ans, PMID:28453393, PMID:29276085]","metadata":null},{"id":"eeaa9c8a05df4ad0bccb6f7ffce00284","type":"GO_TERM","name":"mRNA alternative trans-splicing","canonical_id":"go:GO:0000366","description":"\"The joining together of two independently transcribed RNAs from two different genes, each of which also produces mRNA(s) via cis-splicing.\" [GOC:krc, PMID:11726664, PMID:12110900]","metadata":null},{"id":"76fb3052b0604f11847832b0a862f1f7","type":"GO_TERM","name":"mRNA base-pairing post-transcriptional repressor activity","canonical_id":"go:GO:1903231","description":"\"A post-transcriptional repressor activity that acts by base-pairing with an mRNA to prevent gene expression. The binding can result in targeting the mRNA for degradation or interfering with mRNA translation resulting in post-transcriptional gene silencing.\" [GOC:BHF, GOC:BHF_miRNA, GOC:ha, GOC:vw, PMID:18197166, PMID:20533884]","metadata":null},{"id":"f14aed55b7f7410a9a62d196f67a6bee","type":"GO_TERM","name":"mRNA binding","canonical_id":"go:GO:0003729","description":"\"Binding to messenger RNA (mRNA), an intermediate molecule between DNA and protein. mRNA includes UTR and coding sequences, but does not contain introns.\" [GOC:kmv, GOC:pr, SO:0000234]","metadata":null},{"id":"e3ff8241168947bb998b4fd0f89cfedf","type":"GO_TERM","name":"mRNA branch site recognition","canonical_id":"go:GO:0000348","description":"\"Recognition of the pre-mRNA branch site sequence by components of the assembling spliceosome.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"7b1bb2d1fa5244f3b0f99c5ac62b1a8c","type":"GO_TERM","name":"mRNA cap binding","canonical_id":"go:GO:0098808","description":"\"Binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an mRNA molecule.\" [GOC:dos]","metadata":null},{"id":"8295d3b3665b4a3dbae149308234fa1f","type":"GO_TERM","name":"mRNA cap binding complex binding","canonical_id":"go:GO:0140262","description":"\"Binding to a mRNA cap binding complex.\" [PMID:16938833]","metadata":null},{"id":"27e9420be4db46a8a05d15181075c8da","type":"GO_TERM","name":"mRNA cap methyltransferase RNMT:RAMAC complex","canonical_id":"go:GO:0160130","description":"\"A protein complex that consists of RNA guanine-7 methyltransferase (RNMT) and RNA guanine-7 methyltransferase activating subunit (RAMAC) and is involved in mRNA cap methylation.\" [PMID:22099306]","metadata":null},{"id":"5816a2084afd4141b550c608d9baeb9c","type":"GO_TERM","name":"mRNA capping enzyme complex","canonical_id":"go:GO:0031533","description":"\"A protein complex that consists of an RNA 5' triphosphatase and a guanyl transferase (Cet1p and Ceg1p in S. cerevisiae; Pct1 and Ceg1 in S. pombe) and is involved in mRNA capping.\" [GOC:vw, PMID:10347220, PMID:12455993, PMID:9345280]","metadata":null},{"id":"47f4690bcfa04cc4a2efbb6132834985","type":"GO_TERM","name":"mRNA catabolic process","canonical_id":"go:GO:0006402","description":"\"The chemical reactions and pathways resulting in the breakdown of mRNA, messenger RNA, which is responsible for carrying the coded genetic 'message', transcribed from DNA, to sites of protein assembly at the ribosomes.\" [ISBN:0198506732]","metadata":null},{"id":"89eeffb24f0e48a58f5ab68128b6bd52","type":"GO_TERM","name":"mRNA cis splicing, via spliceosome","canonical_id":"go:GO:0045292","description":"\"The joining together, after removal of an intervening sequence composed of one or more introns, of two segments of the same RNA molecule via spliceosomal catalysis to produce an mRNA composed only of exon sequences that all came from the same primary transcript.\" [GOC:krc, ISBN:0879695897, PMID:18458335]","metadata":null},{"id":"7797080e79f94fe8acaa67dd345d5598","type":"GO_TERM","name":"mRNA cleavage and polyadenylation specificity factor complex","canonical_id":"go:GO:0005847","description":"\"A multisubunit complex that binds to the canonical AAUAAA hexamer and to U-rich upstream sequence elements on the pre-mRNA, thereby stimulating the otherwise weakly active and nonspecific polymerase to elongate efficiently RNAs containing a poly(A) signal.\" [PMID:14749727]","metadata":null},{"id":"9358526441634b54be0611ba7be96ca0","type":"GO_TERM","name":"mRNA cleavage and polyadenylation specificity factor complex assembly","canonical_id":"go:GO:0110105","description":"\"The aggregation, arrangement and bonding together of a set of components to form the mRNA cleavage and polyadenylation specificity factor complex.\" [GOC:mah, PMID:27401558]","metadata":null},{"id":"bde9506ef5fc4255907e3ee023804f62","type":"GO_TERM","name":"mRNA cleavage factor complex","canonical_id":"go:GO:0005849","description":"\"Any macromolecular complex involved in cleavage or polyadenylation of mRNA molecules.\" [GOC:mah, PMID:10357856]","metadata":null},{"id":"34903e1e4f1c4824b0298bb10a2f50e7","type":"GO_TERM","name":"mRNA cleavage stimulating factor complex","canonical_id":"go:GO:0005848","description":"\"A protein complex required for mRNA cleavage but not for poly(A) addition.\" [GOC:mah, PMID:10357856]","metadata":null},{"id":"42c671041a4b450eac8e337b114e3655","type":"GO_TERM","name":"mRNA cytidine N-acetyltransferase activity","canonical_id":"go:GO:0106162","description":"\"Catalysis of the reaction: a cytidine in mRNA + acetyl-CoA + ATP + H2O = ADP + an N(4)-acetylcytidine in mRNA + CoA + H+ + phosphate.\" [GOC:sp, PMID:30449621, RHEA:58480]","metadata":null},{"id":"c9ef987ed6674f5785e1dfb1ac577f37","type":"GO_TERM","name":"mRNA destabilization","canonical_id":"go:GO:0061157","description":"\"Any process that decreases the stability of an mRNA molecule, making it more vulnerable to degradative processes. Messenger RNA is the intermediate molecule between DNA and protein. It includes UTR and coding sequences. It does not contain introns.\" [GOC:dph, GOC:jh]","metadata":null},{"id":"247106f69cca46678b158d2e8aff66ad","type":"GO_TERM","name":"mRNA dihydrouridine synthase activity","canonical_id":"go:GO:0106414","description":"\"Catalysis of the reaction: mRNA-uracil + NAD(P)+ = mRNA-dihydrouridine + NAD(P)H+ + H+.\" [PMID:34798057]","metadata":null},{"id":"3f4776ebeaea461790194b0360afb99b","type":"GO_TERM","name":"mRNA editing complex","canonical_id":"go:GO:0045293","description":"\"A protein complex that posttranscriptionally catalyzes insertion, deletion or substitution of nucleotides at multiple sites within nascent mRNA transcripts to produce mature mRNAs in eukaryotes.\" [PMID:11564867, PMID:12139607, PMID:24316715]","metadata":null},{"id":"b8fd07a899a045e19af463590f4ab897","type":"GO_TERM","name":"mRNA export from nucleus","canonical_id":"go:GO:0006406","description":"\"The directed movement of mRNA from the nucleus to the cytoplasm.\" [GOC:ma]","metadata":null},{"id":"413f22fbcdb44d27839f159b9d8ebc2b","type":"GO_TERM","name":"mRNA export from nucleus in response to heat stress","canonical_id":"go:GO:0031990","description":"\"The directed movement of mRNA from the nucleus to the cytoplasm during a heat stimulus, a temperature stimulus above the optimal temperature for the organism; in particular, a process that enables an organism withstand exposure to temperatures that would otherwise lethally impair poly(A)+ mRNA-nucleus export.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"fe46e70a7b0d49aba5302f536e29ff13","type":"GO_TERM","name":"mRNA guanylyltransferase activity","canonical_id":"go:GO:0004484","description":"\"Catalysis of the reaction: GTP + (5')pp-Pur-mRNA = diphosphate + G(5')ppp-Pur-mRNA; G(5')ppp-Pur-mRNA is mRNA containing a guanosine residue linked 5' through three phosphates to the 5' position of the terminal residue.\" [EC:2.7.7.50]","metadata":null},{"id":"dec09fffac024faca1e0042e34df0f22","type":"GO_TERM","name":"mRNA localization resulting in post-transcriptional regulation of gene expression","canonical_id":"go:GO:0010609","description":"\"Any process that modulates the frequency, rate or extent of gene expression after the production of a mRNA transcript by its transport into, or maintenance in, a specific location within the cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f98c829f38964a95822e6e5f217fad74","type":"GO_TERM","name":"mRNA m(6)A methyltransferase activity","canonical_id":"go:GO:0001734","description":"\"Catalysis of the reaction: an adenosine in mRNA + S-adenosyl-L-methionine = an N(6)-methyladenosine in mRNA + H+ + S-adenosyl-L-homocysteine. This activity is the methylation of adenines in mRNA with the consensus sequence RRACH, where R is a purine, and H is C, A, or U.\" [EC:2.1.1.348, GOC:hjd]","metadata":null},{"id":"8756de761b674834921e1992101b7dac","type":"GO_TERM","name":"mRNA metabolic process","canonical_id":"go:GO:0016071","description":"\"The chemical reactions and pathways involving mRNA, messenger RNA, which is responsible for carrying the coded genetic 'message', transcribed from DNA, to sites of protein assembly at the ribosomes.\" [ISBN:0198506732]","metadata":null},{"id":"2a67ca93cb3b4747afad608f7539894b","type":"GO_TERM","name":"mRNA methylguanosine-cap decapping","canonical_id":"go:GO:0110156","description":"\"Cleavage of the 5'-methylguanosine-cap of an mRNA. The methylguanosine-cap is present at the 5'-end of eukaryotic mRNAs. Decapping inactivates translation initiation and promotes 5'-to-3' decay of mRNA.\" [PMID:23287066]","metadata":null},{"id":"5df469ccd7974a308236a25eaf988462","type":"GO_TERM","name":"mRNA methyltransferase activity","canonical_id":"go:GO:0008174","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to a nucleoside residue in an mRNA molecule.\" [GOC:mah]","metadata":null},{"id":"dcc2a0dcd4fa48aa9f34f133f46e6521","type":"GO_TERM","name":"mRNA modification","canonical_id":"go:GO:0016556","description":"\"The covalent alteration of one or more nucleotides within an mRNA molecule to produce an mRNA molecule with a sequence that differs from that coded genetically.\" [GOC:curators]","metadata":null},{"id":"97dfaf0460564940bad3d5375af3f48a","type":"GO_TERM","name":"mRNA phosphatase activator activity","canonical_id":"go:GO:0170008","description":"\"Binds to and increases the activity of mRNA phosphatase.\" [PMID:22323607]","metadata":null},{"id":"7253d611c5f7457cbb6dd11385dbd80f","type":"GO_TERM","name":"mRNA processing","canonical_id":"go:GO:0006397","description":"\"Any process involved in the conversion of a primary mRNA transcript into one or more mature mRNA(s) prior to translation into polypeptide.\" [GOC:mah]","metadata":null},{"id":"4849e4b8e3a3447cb2be7c40fbbb4b49","type":"GO_TERM","name":"mRNA pseudouridine synthesis","canonical_id":"go:GO:1990481","description":"\"The intramolecular conversion of uridine to pseudouridine in an mRNA molecule.\" [PMID:25192136]","metadata":null},{"id":"db56ffcf6cb5487cb1025accd2ec94ec","type":"GO_TERM","name":"mRNA regulatory element binding translation repressor activity","canonical_id":"go:GO:0000900","description":"\"Antagonizes the ribosome-mediated translation of mRNA into a polypeptide via direct binding (through a selective and non-covalent interaction) to nucleic acid.\" [GOC:clt, GOC:vw, PMID:29061112, PMID:7523370]","metadata":null},{"id":"5905a33ff11a495490c3b816d0e61198","type":"GO_TERM","name":"mRNA splice site recognition","canonical_id":"go:GO:0006376","description":"\"Selection of a splice site by components of the assembling spliceosome.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"2fa2ebaef5e64ac385fc987b9f967046","type":"GO_TERM","name":"mRNA splicing, via endonucleolytic cleavage and ligation","canonical_id":"go:GO:0070054","description":"\"Splicing of mRNA substrates via recognition of the folded RNA structure that brings the 5' and 3' splice sites into proximity and cleavage of the RNA at both the 3' and 5' splice sites by an endonucleolytic mechanism, followed by ligation of the exons.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"6f58c02171cc47d28fa44f9cd407f597","type":"GO_TERM","name":"mRNA splicing, via spliceosome","canonical_id":"go:GO:0000398","description":"\"The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.\" [GOC:krc, ISBN:0198506732, ISBN:0879695897]","metadata":null},{"id":"4cd58704534143228472b5c6d95ffb32","type":"GO_TERM","name":"mRNA stabilization","canonical_id":"go:GO:0048255","description":"\"Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules.\" [GOC:jid]","metadata":null},{"id":"1794c470c2c04e4f931f09625cf780e6","type":"GO_TERM","name":"mRNA trans splicing, SL addition","canonical_id":"go:GO:0045291","description":"\"The joining together of two independently transcribed RNAs, where the one that provides the 5' portion of the final mRNA is from a splice leader RNA (SL-RNA). The SL-RNA, or mini-exon donor sequence, is added to the 5'-end of the acceptor RNA molecule which provides the mRNA body.\" [GOC:krc, ISBN:0879695897, PMID:2675423]","metadata":null},{"id":"4618f6b5e1744ee48625b62788bf33da","type":"GO_TERM","name":"mRNA trans splicing, via spliceosome","canonical_id":"go:GO:0000365","description":"\"The joining together of exons from two different primary transcripts of messenger RNA (mRNA) via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.\" [GOC:krc, ISBN:0879695897, PMID:18458335]","metadata":null},{"id":"351fca2fca004bc6bef2fb6a74477820","type":"GO_TERM","name":"mRNA transcription","canonical_id":"go:GO:0009299","description":"\"The cellular synthesis of messenger RNA (mRNA) from a DNA template.\" [GOC:jl]","metadata":null},{"id":"ef5a8f2667164977ba756340462f6670","type":"GO_TERM","name":"mRNA transcription by RNA polymerase II","canonical_id":"go:GO:0042789","description":"\"The cellular synthesis of messenger RNA (mRNA) from a DNA template by RNA polymerase II, originating at an RNA polymerase II promoter.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"ad2819d7a1464e9f8315c198c2c6c563","type":"GO_TERM","name":"mRNA transport","canonical_id":"go:GO:0051028","description":"\"The directed movement of mRNA, messenger ribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"c44b313ebce946a193e45c77a25efbf9","type":"DRUG","name":"macimorelin","canonical_id":"gtopdb:9745","description":null,"metadata":null},{"id":"629ea1fd71ad414db744d4706a577cf7","type":"DRUG","name":"macimorelin","canonical_id":"chembl:CHEMBL278623","description":null,"metadata":null},{"id":"0bd1479b86ce4286b78fbcfd55bcb997","type":"DRUG","name":"macitentan","canonical_id":"gtopdb:7352","description":null,"metadata":null},{"id":"69fc79c4df9d40fd9912188667a0c4e7","type":"DRUG","name":"macitentan","canonical_id":"mesh:C533860","description":null,"metadata":null},{"id":"e64c59c30518446d90b5a0f88defd95c","type":"DRUG","name":"macitentan","canonical_id":"chembl:CHEMBL2103873","description":null,"metadata":null},{"id":"58299772285c4778bb42d9e3700f8937","type":"COMBINATION_TREATMENT","name":"macitentan + sildenafil","canonical_id":"ctgov_combo:ctgov-combo-fbcd07ca52da4270","description":null,"metadata":null},{"id":"2deeb159e1af4176b13ca1196463ed6f","type":"COMBINATION_TREATMENT","name":"macitentan + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-e5a526a56cf7ec63","description":null,"metadata":null},{"id":"bec86ce241c6424dbf4e118d7a294301","type":"COMBINATION_TREATMENT","name":"macitentan + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-cf2eff7e0a1665ec","description":null,"metadata":null},{"id":"26f041adf46b4033aa216b3df90d2dc0","type":"COMBINATION_TREATMENT","name":"macitentan + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-0d1ab2cf851127a9","description":null,"metadata":null},{"id":"10bbf5c27092431c85e1927fac4a9a9b","type":"COMBINATION_TREATMENT","name":"macitentan + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-09bcf6674e4c46fd","description":null,"metadata":null},{"id":"a8a3134b1326450f8e7eb66485539f91","type":"GO_TERM","name":"macroautophagy","canonical_id":"go:GO:0016236","description":"\"The autophagic process that proceeds via the formation of an autophagosome.\" [PMID:24366339]","metadata":null},{"id":"be4f6ab0ffeb4e1f8ff9ab4efdfaca63","type":"GO_TERM","name":"macrocin O-methyltransferase activity","canonical_id":"go:GO:0030769","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + macrocin = S-adenosyl-L-homocysteine + H+ + tylosin.\" [EC:2.1.1.101, RHEA:17269]","metadata":null},{"id":"48036a513f8c434aa5f33d3c4f10ef0a","type":"DISEASE","name":"macroglobulinemia","canonical_id":"efo:0002616","description":null,"metadata":null},{"id":"10cd7c6741924a1394683769c61a6bc1","type":"GO_TERM","name":"macrolide 2'-kinase activity","canonical_id":"go:GO:0050073","description":"\"Catalysis of the reaction: ATP + a macrolide = ADP + 2 H+ + a macrolide-2'-O-phosphate. Substrates include oleandomycin, erythromycin, spiramycin and other macrolide antibiotics.\" [EC:2.7.1.136]","metadata":null},{"id":"6aecf9ed150d4cd785c7e6eac9cf1b41","type":"GO_TERM","name":"macrolide binding","canonical_id":"go:GO:0005527","description":"\"Binding to a macrolide, any of a large group of structurally related antibiotics produced by Streptomyces species.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"1bb93f9a07da4f70937a8ddea19b17cb","type":"GO_TERM","name":"macrolide biosynthetic process","canonical_id":"go:GO:0033068","description":"\"The chemical reactions and pathways leading to the formation of macrolides, any of a large group of polyketide compounds that contain a large lactone ring with few or no double bonds and no nitrogen atoms, linked glycosidically to one or more sugar groups. The macrolides include the carbomycins, the erythromycins, oleandomycin, oligomycins, and the spiramycins, and act as antibiotics, mainly against Gram-positive bacteria.\" [ISBN:0198506732, PMID:17298179]","metadata":null},{"id":"af4c791d7f1244a9af058bb8a7637d19","type":"GO_TERM","name":"macrolide metabolic process","canonical_id":"go:GO:0033067","description":"\"The chemical reactions and pathways involving macrolides, any of a large group of polyketide compounds that contain a large lactone ring with few or no double bonds and no nitrogen atoms, linked glycosidically to one or more sugar groups. The macrolides include the carbomycins, the erythromycins, oleandomycin, oligomycins, and the spiramycins, and act as antibiotics, mainly against Gram-positive bacteria.\" [ISBN:0198506732, PMID:17298179]","metadata":null},{"id":"5db8b40ed5254365aac3b0a8d311a07a","type":"GO_TERM","name":"macrolide transmembrane transporter complex","canonical_id":"go:GO:1990195","description":"\"A bacterial transmembrane transporter complex that spans the entire cell membrane system and possesses ATP-dependent xenobiotic transport activity pumping drugs (typically antibiotics) and other toxins directly from the cytosol out of the bacterial cell. Typically, it is trimeric consisting of a inner membrane ATPase (IMP), a periplasmic membrane fusion protein (MFP) and an outer membrane factor (OMF). In E. coli, macrolide transporter complexes may consists of MacB (IMP), MacA (MFP) and TolC (OMF) or AcrB (IMP), AcrA (MFP) and TolC (OMF). Trimeric TolC is a common OMF found in many macrolide transporter complexes.\" [GOC:bhm, PMID:10879525, PMID:18955484, PMID:19254725]","metadata":null},{"id":"50bae29f8ffd4689b5d038e30db0cc7b","type":"GO_TERM","name":"macromolecular conformation isomerase activity","canonical_id":"go:GO:0120543","description":"\"Catalysis of a reaction that alters the macromolecular conformation of a molecule.\" [EC:5.6.-.-]","metadata":null},{"id":"0812e7b44f574b16a13e631066ec10f3","type":"GO_TERM","name":"macromolecule biosynthetic process","canonical_id":"go:GO:0009059","description":"\"The chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:mah]","metadata":null},{"id":"1ff6f9c7b9374ccf95b8e8db25ce8607","type":"GO_TERM","name":"macromolecule catabolic process","canonical_id":"go:GO:0009057","description":"\"The chemical reactions and pathways resulting in the breakdown of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:mah]","metadata":null},{"id":"b522c5e0e0f84f85a3e03736ca88b6a9","type":"GO_TERM","name":"macromolecule deacylation","canonical_id":"go:GO:0098732","description":"\"The removal of an acyl group, any group or radical of the form RCO- where R is an organic group, from a macromolecule.\" [GOC:dos]","metadata":null},{"id":"184b3705840d4754aba7e24edd7ed673","type":"GO_TERM","name":"macromolecule depalmitoylation","canonical_id":"go:GO:0098734","description":"\"The removal of palymitoyl groups from a macromolecule.\" [GOC:dos]","metadata":null},{"id":"919bc66fc48b41d6a48abb7d2c411ceb","type":"GO_TERM","name":"macromolecule localization","canonical_id":"go:GO:0033036","description":"\"Any process in which a macromolecule is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"0e6991ba25664e75bf0ae050af2725de","type":"GO_TERM","name":"macromolecule metabolic process","canonical_id":"go:GO:0043170","description":"\"The chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:mah]","metadata":null},{"id":"0e02ed7488f64166badb37ac7c36e743","type":"GO_TERM","name":"macromolecule methylation","canonical_id":"go:GO:0043414","description":"\"The covalent attachment of a methyl residue to one or more monomeric units in a polypeptide, polynucleotide, polysaccharide, or other biological macromolecule.\" [GOC:curators]","metadata":null},{"id":"1609e773118444f9a388b305065febdd","type":"GO_TERM","name":"macromolecule modification","canonical_id":"go:GO:0043412","description":"\"The covalent alteration of one or more monomeric units in a polypeptide, polynucleotide, polysaccharide, or other biological macromolecule, resulting in a change in its properties.\" [GOC:curators]","metadata":null},{"id":"40831f2bf2b64db580b54f1151d5c0bd","type":"GO_TERM","name":"macromolecule transmembrane transporter activity","canonical_id":"go:GO:0022884","description":"\"Enables the transfer of a macromolecule from one side of a membrane to the other.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"5721087203e54c6c9d847cb464b805e6","type":"GO_TERM","name":"macronucleus","canonical_id":"go:GO:0031039","description":"\"A membrane-bounded organelle of ciliated protozoan cells that contains polyploid copies of a portion of the cell's complete genome. Transcription of genes occurs in macronuclei. Some ciliate species may contain multiple macronuclei per cell.\" [GOC:ns]","metadata":null},{"id":"c406d21dadef4f71a40d618231713c84","type":"GO_TERM","name":"macronucleus organization","canonical_id":"go:GO:0032124","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the macronucleus.\" [GOC:dph, GOC:jl, GOC:mah, PMID:10503190]","metadata":null},{"id":"96810fff6e70481fa079b7ab45139b09","type":"GO_TERM","name":"macrophage activation","canonical_id":"go:GO:0042116","description":"\"A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149, PMID:14506301]","metadata":null},{"id":"acda783370954aa0b95f845c84f42d1e","type":"GO_TERM","name":"macrophage activation involved in immune response","canonical_id":"go:GO:0002281","description":"\"A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"4d8a0650b9964a5eaa7c4208bbbfbdf4","type":"GO_TERM","name":"macrophage antigen processing and presentation","canonical_id":"go:GO:0002472","description":"\"The process in which a macrophage expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"2fc3db6c54c247c6bb1d2981cf96129b","type":"GO_TERM","name":"macrophage apoptotic process","canonical_id":"go:GO:0071888","description":"\"Any apoptotic process in a macrophage, a mononuclear phagocyte present in a variety of tissues.\" [CL:0000235, GOC:BHF, GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"e89cf77c9c914351aebe936fb57d1bde","type":"GO_TERM","name":"macrophage chemotaxis","canonical_id":"go:GO:0048246","description":"\"The movement of a macrophage in response to an external stimulus.\" [GOC:jid]","metadata":null},{"id":"30a41d9a8c284628b8a6bc61b0321839","type":"GO_TERM","name":"macrophage colony-stimulating factor production","canonical_id":"go:GO:0036301","description":"\"The appearance of macrophage colony-stimulating factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"2dea0815ff6746389f6380f9ba899907","type":"GO_TERM","name":"macrophage colony-stimulating factor receptor activity","canonical_id":"go:GO:0005011","description":"\"Combining with macrophage colony-stimulating factor (M-CSF) receptor ligand and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"08aa7dac9d014e7b8ad690adfc766b65","type":"GO_TERM","name":"macrophage colony-stimulating factor receptor binding","canonical_id":"go:GO:0005157","description":"\"Binding to a macrophage colony-stimulating factor receptor.\" [GOC:ai]","metadata":null},{"id":"2f52c7f841454e57898b5161cac9b05f","type":"GO_TERM","name":"macrophage colony-stimulating factor signaling pathway","canonical_id":"go:GO:0038145","description":"\"The series of molecular signals initiated by the binding of the cytokine macrophage colony-stimulating factor (M-CSF) to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, GOC:uh, PMID:12138890, Wikipedia:Macrophage_colony-stimulating_factor]","metadata":null},{"id":"a69759c2cd8b467e9271caa961fdd942","type":"GO_TERM","name":"macrophage cytokine production","canonical_id":"go:GO:0010934","description":"\"The appearance of a macrophage cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"28cc9a3d844841a4be5fcd17bebf6e69","type":"GO_TERM","name":"macrophage derived foam cell differentiation","canonical_id":"go:GO:0010742","description":"\"The process in which a monocyte acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"04595a1047a64648b277dd86610cf9fb","type":"GO_TERM","name":"macrophage differentiation","canonical_id":"go:GO:0030225","description":"\"The process in which a relatively unspecialized monocyte acquires the specialized features of a macrophage.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6f888d6647174d85b9396106affd4652","type":"GO_TERM","name":"macrophage fusion","canonical_id":"go:GO:0034238","description":"\"The binding and fusion of a macrophage to one or more other cells to form a multinucleated cell.\" [GOC:sl]","metadata":null},{"id":"f77f8958327843839caea80e829b8210","type":"GO_TERM","name":"macrophage homeostasis","canonical_id":"go:GO:0061519","description":"\"The process of regulating the proliferation and elimination of macrophage cells such that the total number of myeloid cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:dph, PMID:21727904]","metadata":null},{"id":"8076b812133d4630b5e74e98ecb336a9","type":"GO_TERM","name":"macrophage inflammatory protein-1 alpha production","canonical_id":"go:GO:0071608","description":"\"The appearance of macrophage inflammatory protein 1 alpha due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"fd6e8c4d206643e2a6f482b076004fc5","type":"GO_TERM","name":"macrophage inflammatory protein-1 gamma production","canonical_id":"go:GO:0071607","description":"\"The appearance of macrophage inflammatory protein-1 gamma due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"a58616e278834030acefc24dda28e959","type":"GO_TERM","name":"macrophage migration","canonical_id":"go:GO:1905517","description":"\"The orderly movement of a macrophage from one site to another.\" [GO_REF:0000091, GOC:TermGenie, PMID:25749876]","metadata":null},{"id":"1377ae8530c54c5b8f3a37bce9916cfc","type":"GO_TERM","name":"macrophage migration inhibitory factor binding","canonical_id":"go:GO:0035718","description":"\"Binding to the cytokine, macrophage migration inhibitory factor.\" [GOC:BHF, PMID:19601712]","metadata":null},{"id":"9b4ae7faa23e4b438c7cb396326fa827","type":"GO_TERM","name":"macrophage migration inhibitory factor production","canonical_id":"go:GO:0044807","description":"\"The appearance of macrophage migration inhibitory factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"1351ab327f3a4fec8de786dd98a2a12f","type":"GO_TERM","name":"macrophage migration inhibitory factor receptor complex","canonical_id":"go:GO:0035692","description":"\"A protein complex that binds macrophage migration inhibitory factor. Comprises CD74 and CD44 cell surface proteins.\" [GOC:BHF, PMID:12782713, PMID:17045821]","metadata":null},{"id":"4194e19b59b74953aaf8605d75def9ad","type":"GO_TERM","name":"macrophage migration inhibitory factor signaling pathway","canonical_id":"go:GO:0035691","description":"\"The series of molecular signals initiated by macrophage migration inhibitory factor binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:signaling, PMID:12782713, PMID:19413900]","metadata":null},{"id":"17f618858c4c4137883793876fccbc1f","type":"GO_TERM","name":"macrophage proliferation","canonical_id":"go:GO:0061517","description":"\"The expansion of a macrophage population by cell division.\" [GOC:dph, PMID:12614284, PMID:19466391]","metadata":null},{"id":"ea5480a66b594ca3bcfc1c49086044ef","type":"GO_TERM","name":"macrophage tolerance induction","canonical_id":"go:GO:0010931","description":"\"A process involving any mechanism for tolerance induction in macrophages.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"c334cb963a3d4f8ebd372db19bf0bb3b","type":"GO_TERM","name":"macrophomate synthase activity","canonical_id":"go:GO:0033191","description":"\"Catalysis of the reaction: a 2-pyrone + oxalacetate = macrophomate.\" [GOC:cb, PMID:10984474]","metadata":null},{"id":"b14b82870c2d4b6bbe0ecf7dbf0ee68f","type":"GO_TERM","name":"macropinocytic cup","canonical_id":"go:GO:0070685","description":"\"A cell projection that forms at the site of macropinocytosis, a form of endocytosis that results in the uptake of relatively large amounts of extracellular fluid. The macropinocytic cup membrane selectively excludes certain proteins, such as H36 or PM4C4 in Dictyostelium, and the underlying cytoskeleton is enriched in F-actin and coronin.\" [PMID:12538772, PMID:16968738, PMID:9044041]","metadata":null},{"id":"2fa46ee01ee4425386596966bff7840d","type":"GO_TERM","name":"macropinocytic cup cytoskeleton","canonical_id":"go:GO:0070687","description":"\"The part of the cortical actin cytoskeleton that forms part of a macropinocytic cup.\" [GOC:mah]","metadata":null},{"id":"f4e9dbe7355b4cda9b19ec08da44a32c","type":"GO_TERM","name":"macropinocytic cup membrane","canonical_id":"go:GO:0070686","description":"\"The portion of the plasma membrane surrounding a macropinocytic cup.\" [GOC:mah]","metadata":null},{"id":"ef3d0f2c32e848d6beb7e4f3f86b0d47","type":"GO_TERM","name":"macropinocytosis","canonical_id":"go:GO:0044351","description":"\"An endocytosis process that results in the uptake of liquid material by cells from their external environment by the 'ruffling' of the cell membrane to form heterogeneously sized intracellular vesicles called macropinosomes, which can be up to 5 micrometers in size.\" [PMID:14732047]","metadata":null},{"id":"b0bb7faaacdd46218a4394685ed6cb84","type":"GO_TERM","name":"macropinocytosis involved in viral entry into host cell","canonical_id":"go:GO:0075510","description":"\"Any macropinocytosis that is involved in the uptake of a virus into a host cell.\" [GOC:jl, GOC:sp, PMID:17077125, PMID:19404330, VZ:800]","metadata":null},{"id":"d8e26521e2ac478eb7751508e3503ce6","type":"GO_TERM","name":"macropinosomal membrane permeabilization involved in viral entry into host cell","canonical_id":"go:GO:0075504","description":"\"Induction of macropinosome membrane permeabilization triggered by an interaction between the host membrane and a membrane-penetration protein associated with the capsid. Occurs after internalization of the virus in a macropinosome, and results in release of the viral contents from the macropinosome into the host cell cytoplasm.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"2bd38a938dd74ab6adf6c8c31198652b","type":"GO_TERM","name":"macropinosome","canonical_id":"go:GO:0044354","description":"\"A membrane-bounded, uncoated intracellular vesicle formed by the process of macropinocytosis.\" [PMID:14732047]","metadata":null},{"id":"3a8a5136637d40a0adb670366ce0d9df","type":"GO_TERM","name":"macropinosome lysis involved in viral entry into host cell","canonical_id":"go:GO:0075511","description":"\"Viral-induced lysis of the macropinosome involved in the uptake of a virus into a host cell. Occurs after internalization of the virus in a macropinosome, and results in the release of viral contents from the macropinosome into the host cell cytoplasm.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"427b7976a5854b109f3b6d19982c7388","type":"GO_TERM","name":"macropinosome membrane","canonical_id":"go:GO:0160056","description":"\"The lipid bilayer surrounding a macropinosome.\" [PMID:19690049]","metadata":null},{"id":"0583eae0b5bd4628bdc0afe0a64d1433","type":"GO_TERM","name":"macula densa development","canonical_id":"go:GO:0072024","description":"\"The process whose specific outcome is the progression of the macula densa over time, from its formation to the mature structure. The macula densa is an area of specialized cells in the distal tubule that makes contact with the vascular pole of the glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"014364590a534d0695483908dc321e66","type":"DISEASE","name":"macular degeneration","canonical_id":"mondo:0003004","description":null,"metadata":null},{"id":"98e7880b7de3493095828ef166ca2cab","type":"DISEASE","name":"macular retinal edema","canonical_id":"mondo:0003005","description":null,"metadata":null},{"id":"19d43f282df44ea295978c83baf521a6","type":"DISEASE","name":"maculopapular cutaneous mastocytosis","canonical_id":"mondo:0019316","description":null,"metadata":null},{"id":"f19c56dd06ae4a1080597e30a0d8a9df","type":"DRUG","name":"magnesium carbonate","canonical_id":"mesh:C005479","description":null,"metadata":null},{"id":"f9217490825b482283cabfe0f062938e","type":"GO_TERM","name":"magnesium chelatase activity","canonical_id":"go:GO:0016851","description":"\"Catalysis of the reaction: ATP + H2O + Mg2+ + protoporphyrin IX = ADP + 3 H+ + Mg-protoporphyrin IX + phosphate.\" [RHEA:13961]","metadata":null},{"id":"5c6c783b784149699003c293761946aa","type":"GO_TERM","name":"magnesium chelatase complex","canonical_id":"go:GO:0010007","description":"\"A heterotrimeric enzyme complex composed of three subunits, all of which are required for enzyme activity, which catalyzes the chelation of Mg by proto IX in an ATP-dependent manner.\" [PMID:11842180]","metadata":null},{"id":"53c45c13c20e4a10a23dc71d6248bbb0","type":"DRUG","name":"magnesium hydroxide","canonical_id":"mesh:D008276","description":null,"metadata":null},{"id":"8696096d83fc4379a3fe82b062e8a56b","type":"GO_TERM","name":"magnesium ion binding","canonical_id":"go:GO:0000287","description":"\"Binding to a magnesium (Mg) ion.\" [GOC:ai]","metadata":null},{"id":"43336f2a56004e9c8f95fa5947015c3f","type":"GO_TERM","name":"magnesium ion export from mitochondrion","canonical_id":"go:GO:1990616","description":"\"The directed movement of magnesium ions out of mitochondrial matrix into the cytosol by means of some agent such as a transporter or pore.\" [PMID:25585246]","metadata":null},{"id":"5c46f81c0cad4584b04a8708201355b1","type":"GO_TERM","name":"magnesium ion homeostasis","canonical_id":"go:GO:0010960","description":"\"Any process involved in the maintenance of an internal steady state of magnesium ions within an organism or cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"315d593f2c5b4c31b5e8e7cfb2270603","type":"GO_TERM","name":"magnesium ion transmembrane transport","canonical_id":"go:GO:1903830","description":"\"The directed movement of magnesium ion across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:11254124]","metadata":null},{"id":"f85d4cbf9c554ba583a467c8009d1d12","type":"GO_TERM","name":"magnesium ion transmembrane transporter activity","canonical_id":"go:GO:0015095","description":"\"Enables the transfer of magnesium (Mg) ions from one side of a membrane to the other.\" [GOC:dgf]","metadata":null},{"id":"d92074fb9c3248cebd6ab80a327b11b4","type":"GO_TERM","name":"magnesium ion transport","canonical_id":"go:GO:0015693","description":"\"The directed movement of magnesium (Mg) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"4dba65f1dbc34374b7ef556791e82298","type":"GO_TERM","name":"magnesium ion transport from cytosol to endoplasmic reticulum","canonical_id":"go:GO:0160176","description":"\"The directed movement of magnesium ion from cytosol to endoplasmic reticulum.\" [PMID:38513662]","metadata":null},{"id":"62d9e4b63db9484da9c4016ab0089c46","type":"GO_TERM","name":"magnesium protoporphyrin IX methyltransferase activity","canonical_id":"go:GO:0046406","description":"\"Catalysis of the reaction: Mg-protoporphyrin IX + S-adenosyl-L-methionine = Mg-protoporphyrin IX 13-monomethyl ester + S-adenosyl-L-homocysteine.\" [RHEA:17809]","metadata":null},{"id":"c6eae03787c84e29acc8c91e973aaaa2","type":"DRUG","name":"magnesium sulfate","canonical_id":"mesh:D008278","description":null,"metadata":null},{"id":"a807c79b0ea445cfb237ba0f26f07d61","type":"GO_TERM","name":"magnesium-dependent protein serine/threonine phosphatase complex","canonical_id":"go:GO:0005963","description":"\"An intracellular enzyme complex that catalyzes the removal of serine- or threonine-bound phosphate groups from a wide range of phosphoproteins, including a number of enzymes that have been phosphorylated under the action of a kinase.\" [PMID:17517611, PMID:22343722]","metadata":null},{"id":"42a4940dc079464496079c6389d5a553","type":"GO_TERM","name":"magnesium-protoporphyrin IX monomethyl ester (oxidative) cyclase activity","canonical_id":"go:GO:0048529","description":"\"Catalysis of the reaction: magnesium protoporphyrin IX 13-monomethyl ester + 3 NADPH + 3 H+ + 3 O2 = divinylprotochlorophyllide + 3 NADP+ + 5 H2O.\" [EC:1.14.13.81, RHEA:33235]","metadata":null},{"id":"be22e7e6501f4da1a97a612fd405fb76","type":"GO_TERM","name":"magnesium:sodium antiporter activity","canonical_id":"go:GO:0061768","description":"\"Catalysis of the reaction: Na+(in) + Mg2+(out) = Na+(out) + Mg2+(in).\" [GOC:pad, GOC:PARL, PMID:22031603]","metadata":null},{"id":"bb24fdd1434a4a868fc35507c3114263","type":"GO_TERM","name":"magnetoreception","canonical_id":"go:GO:0050958","description":"\"The series of events required for an organism to receive a stimulus relating to a magnetic field, convert it to a molecular signal, and recognize and characterize the signal. Stimuli may be chemical, mechanical or electrical and interpreting these stimuli allows an organism to determine the orientation of a magnetic field. Magnetoreception also involves the perception of light; birds cannot orient without the presence of short wavelength (blue/green) light.\" [GOC:ai, PMID:15886990, Wikipedia:Magnetoception]","metadata":null},{"id":"0acb1879b84b43c9a8e57a9c534d161b","type":"GO_TERM","name":"magnetoreception by sensory perception of chemical stimulus","canonical_id":"go:GO:0050977","description":"\"The series of events required for an organism to receive a chemical stimulus relating to a magnetic field, convert it to a molecular signal, and recognize and characterize the signal. It is believed that organisms such as birds and salamanders use a 'chemical compass': chemical reactions that involve transitions between different spin states can be influenced by magnetic fields and by detecting the different product ratios, these organisms can perceive the direction of the magnetic field. The mechanism by which this is detected is not certain but it may also involve light stimuli.\" [GOC:ai, PMID:15886990, Wikipedia:Magnetoception]","metadata":null},{"id":"e6d7e343d73e4c618c9b3c6903681d3c","type":"GO_TERM","name":"magnetoreception by sensory perception of electrical stimulus","canonical_id":"go:GO:0050978","description":"\"The series of events required for an organism to receive an electrical stimulus relating to a magnetic field, convert it to a molecular signal, and recognize and characterize the signal. Movement in a magnetic field results in an induced electric field, which can be perceived by organisms such as elasmobranch fish.\" [GOC:ai, PMID:15886990, Wikipedia:Magnetoception]","metadata":null},{"id":"146fe6804e264af89c0bc0983fdb322b","type":"GO_TERM","name":"magnetoreception by sensory perception of mechanical stimulus","canonical_id":"go:GO:0050979","description":"\"The series of events required for an organism to receive a mechanical stimulus relating to a magnetic field, convert it to a molecular signal, and recognize and characterize the signal. A magnetic field exerts a torque on a ferromagnetic material (e.g. magnetite) or on a material with diamagnetic anisotropy; organisms that can detect this torque can use it to determine the orientation of the magnetic field.\" [GOC:ai, PMID:15886990, Wikipedia:Magnetoception]","metadata":null},{"id":"80ec793229b64303bd704af5af7508c9","type":"GO_TERM","name":"magnetosome","canonical_id":"go:GO:0110143","description":"\"A membrane-bound organelle that envelops particles of magnetic iron minerals in magnetotactic bacteria. Magnetosomes form linear chains that align along the cellular motility axis at midcell and function in bacterial navigation along the Earth's magnetic field. They are formed by invagination of the cell inner membrane; in some species they remain connected to the inner membrane, in others they pinch off to form independent intracellular vesicles.\" [GOC:aa, PMID:27620945]","metadata":null},{"id":"552a3cbec35f491b9dab23c0c05538fc","type":"GO_TERM","name":"magnetosome assembly","canonical_id":"go:GO:0140923","description":"\"The aggregation, arrangement and bonding together of a set of components to form a magnetosome. Magnetosomes are specialized organelles for magnetic navigation that comprise membrane-enveloped, nano-sized crystals of a magnetic iron mineral; they are formed by a diverse group of magnetotactic bacteria (MTB).\" [PMID:19575557, PMID:34723168]","metadata":null},{"id":"ff5739b598e3490c92d52a2ece3b6811","type":"GO_TERM","name":"magnetosome lumen","canonical_id":"go:GO:0110145","description":"\"The volume enclosed by the membrane of a magnetosome.\" [GOC:aa, PMID:27620945]","metadata":null},{"id":"7605852b49de483aae98882619f03bf5","type":"GO_TERM","name":"magnetosome membrane","canonical_id":"go:GO:0110146","description":"\"The lipid bilayer surrounding a magnetosome.\" [GOC:aa, PMID:27620945]","metadata":null},{"id":"2fbaf6d48bf848c9ab83e01766365d71","type":"GO_TERM","name":"main axon","canonical_id":"go:GO:0044304","description":"\"The main axonal trunk, as opposed to the collaterals; i.e., excluding collaterals, terminal, spines, or dendrites.\" [NIF_Subcellular:sao1596975044]","metadata":null},{"id":"d6c443d2527a44ad898d950104d4d848","type":"GO_TERM","name":"main body follicle cell migration","canonical_id":"go:GO:0060270","description":"\"The ovarian follicle cell migration process in which follicle cells migrate posteriorly to form a columnar epithelium over the oocyte.\" [GOC:dph]","metadata":null},{"id":"5668e7ad42cc4ef7a90ee61aeb92c7d0","type":"GO_TERM","name":"maintenance of CRISPR repeat elements","canonical_id":"go:GO:0043571","description":"\"Any process involved in sustaining CRISPR repeat clusters, including capture of new spacer elements, expansion or contraction of clusters, propagation of the leader sequence and repeat clusters within a genome, transfer of repeat clusters and CRISPR-associated (cas) genes to new genomes, transcription of the CRISPR repeat arrays into RNA and processing, and interaction of CRISPR/cas loci with the host genome. CRISPR (clustered regularly interspaced short palindromic repeat) elements are a family of sequence elements containing multiple direct repeats of 24-48 bp with weak dyad symmetry which are separated by regularly sized nonrepetitive spacer sequences.\" [PMID:16292354]","metadata":null},{"id":"ace1343964dc47ffb0fd316d076290da","type":"GO_TERM","name":"maintenance of DNA repeat elements","canonical_id":"go:GO:0043570","description":"\"Any process involved in sustaining the fidelity and copy number of DNA repeat elements.\" [GOC:jl]","metadata":null},{"id":"b4847abd77984609baf42f1414a2a5e1","type":"GO_TERM","name":"maintenance of DNA trinucleotide repeats","canonical_id":"go:GO:0035753","description":"\"Any process involved in sustaining the fidelity and copy number of DNA trinucleotide repeats. DNA trinucleotide repeats are naturally occurring runs of three base-pairs.\" [GOC:rb, PMID:21347277, SO:0000291]","metadata":null},{"id":"9aaf36a33f0347e899bbee41d9be0e8f","type":"GO_TERM","name":"maintenance of ER location","canonical_id":"go:GO:0051685","description":"\"Any process in which the endoplasmic reticulum is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"53f809a05f234585ab595cebfd568f38","type":"GO_TERM","name":"maintenance of Golgi location","canonical_id":"go:GO:0051684","description":"\"Any process in which the Golgi is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"7b1bd8df299f4182bf95bef6b6b0cdd7","type":"GO_TERM","name":"maintenance of RNA location","canonical_id":"go:GO:0051237","description":"\"Any process in which RNA is maintained in a location and prevented from moving elsewhere.\" [GOC:ai]","metadata":null},{"id":"8ff05bd94df34edcb6a9b5ec1aa1287a","type":"GO_TERM","name":"maintenance of alignment of postsynaptic density and presynaptic active zone","canonical_id":"go:GO:0099559","description":"\"The process by which alignment between postsynaptic density and presynaptic active zone is maintained.\" [GOC:dos]","metadata":null},{"id":"2ea40130bc884a26a4c8d89d0db9dd27","type":"GO_TERM","name":"maintenance of animal organ identity","canonical_id":"go:GO:0048496","description":"\"The process in which the identity of an animal organ is maintained. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tb]","metadata":null},{"id":"4e211a05faeb4fc98cac724008380efe","type":"GO_TERM","name":"maintenance of apical/basal cell polarity","canonical_id":"go:GO:0035090","description":"\"Retaining the established polarization of a cell along its apical/basal axis.\" [GOC:bf]","metadata":null},{"id":"3227c7c102ca4246907443ae84746ce9","type":"GO_TERM","name":"maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:0061305","description":"\"The maintenance of established bipolar anisotropic intracellular organization or cell growth patterns that results in the shaping of a cell.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"646b82dbe3ad4655bc2baef3cf3d7036","type":"GO_TERM","name":"maintenance of blood vessel diameter homeostasis by renin-angiotensin","canonical_id":"go:GO:0002034","description":"\"The process in which the diameter of a blood vessel is changed due to activity of the renin-angiotensin system.\" [GOC:dph, GOC:pr, GOC:tb]","metadata":null},{"id":"793042a401df41e2b22f1feab23bedeb","type":"GO_TERM","name":"maintenance of blood-brain barrier","canonical_id":"go:GO:0035633","description":"\"Maintaining the structure and function of the blood-brain barrier, thus ensuring specific regulated transport of substances (e.g. macromolecules, small molecules, ions) into the brain, and out of the brain into the blood circulation.\" [GOC:aruk, GOC:bc, GOC:bf, GOC:sl, PMID:20080302, PMID:30280653]","metadata":null},{"id":"f35b8e9f81cb48fd8163f29207a565f2","type":"GO_TERM","name":"maintenance of cell number","canonical_id":"go:GO:0098727","description":"\"Any process by which the numbers of cells of a particular type or in a tissue are maintained.\" [GOC:dos]","metadata":null},{"id":"05f3762c8030406f9ae83aaf31a960b3","type":"GO_TERM","name":"maintenance of cell polarity","canonical_id":"go:GO:0030011","description":"\"The maintenance of established anisotropic intracellular organization or cell growth patterns.\" [GOC:mah]","metadata":null},{"id":"5d130d2d7d2a4046b3e911d522ecb002","type":"GO_TERM","name":"maintenance of centrosome location","canonical_id":"go:GO:0051661","description":"\"Any process in which a centrosome is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"8f16e095305f49b5bbcafcc92326e385","type":"GO_TERM","name":"maintenance of ciliary planar beating movement pattern","canonical_id":"go:GO:0120221","description":"\"Any process involved in maintaining the planar beating pattern of ciliary movement pattern. Connection between the outer doublets and the central pair via the radial spokes constrains ciliary movement to the planar beating pattern. Cilia that lack this connection, such as those in the embryonic node or Kupfer's vesicle, display radial movement.\" [GOC:krc, PMID:26506310]","metadata":null},{"id":"9e510c16547a491ba2f37f25495d9eef","type":"GO_TERM","name":"maintenance of dauer","canonical_id":"go:GO:0043055","description":"\"Maintenance of a nematode during the facultative diapause of the dauer (enduring) larval stage of nematode development.\" [GOC:cab1, WB_REF:wm2003ab740]","metadata":null},{"id":"6072127ea2de46efa616a9a1589d0276","type":"GO_TERM","name":"maintenance of dense core granule location","canonical_id":"go:GO:0032257","description":"\"Any process in which a dense core granule is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"14cfe4698ce342dd977a1b2418442047","type":"GO_TERM","name":"maintenance of diapause","canonical_id":"go:GO:0071982","description":"\"The dormancy process that results an organism remaining in diapause. Diapause is a neurohormonally mediated, dynamic state of low metabolic activity. Associated characteristics of this form of dormancy include reduced morphogenesis, increased resistance to environmental extremes, and altered or reduced behavioral activity. Full expression develops in a species-specific manner, usually in response to a number of environmental stimuli that precede unfavorable conditions. Once diapause has begun, metabolic activity is suppressed even if conditions favorable for development prevail. Once initiated, only certain stimuli are capable of releasing the organism from this state, and this characteristic is essential in distinguishing diapause from hibernation.\" [GOC:mah]","metadata":null},{"id":"1e594008964b4e81b973712f3e4ea557","type":"GO_TERM","name":"maintenance of dormancy","canonical_id":"go:GO:0097437","description":"\"The dormancy process that results in an organism remaining in dormancy. Dormancy (sometimes called a dormant state) is a suspension of most physiological activity and growth that can be reactivated.\" [GOC:PO_curators, PO_REF:00009]","metadata":null},{"id":"53593111d9784c94b4b781d9545d7f67","type":"GO_TERM","name":"maintenance of epithelial cell apical/basal polarity","canonical_id":"go:GO:0045199","description":"\"The maintenance of the apicobasal polarity of an epithelial cell.\" [GOC:bf]","metadata":null},{"id":"6357031faf5543259367b60fb890c8dc","type":"GO_TERM","name":"maintenance of epithelial integrity, open tracheal system","canonical_id":"go:GO:0035160","description":"\"Ensuring that tracheal tubes in an open tracheal system maintain their epithelial structure during the cell shape changes and movements that occur during the branching process.\" [GOC:mtg_sensu, PMID:10694415, PMID:14681183]","metadata":null},{"id":"9543359fbf7045aca3c00770d9965447","type":"GO_TERM","name":"maintenance of floral meristem identity","canonical_id":"go:GO:0010076","description":"\"The process in which an organism retains a population of floral meristem cells, preventing the commitment of all stem cell progeny to a differentiated cell fate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4182e2385f4c45a1bb4f8430615515fc","type":"GO_TERM","name":"maintenance of floral organ identity","canonical_id":"go:GO:0048497","description":"\"The process in which the identity of a floral organ is maintained. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:PO_curators, GOC:tair_curators, PMID:9090883, PO:0025395]","metadata":null},{"id":"7afe9b7225dc4ab69681c2216c668caa","type":"GO_TERM","name":"maintenance of gastrointestinal epithelium","canonical_id":"go:GO:0030277","description":"\"Protection of epithelial surfaces of the gastrointestinal tract from proteolytic and caustic digestive agents.\" [GOC:mah]","metadata":null},{"id":"3f1040b8eb164718a44abd45e7021361","type":"GO_TERM","name":"maintenance of germ plasm mRNA location","canonical_id":"go:GO:0046594","description":"\"The process of maintaining mRNA in a specific location in the germ plasm.\" [GOC:bf, GOC:dph, GOC:tb]","metadata":null},{"id":"e29009d0fea34cf898387306dac692ef","type":"GO_TERM","name":"maintenance of granzyme B location in T cell secretory granule","canonical_id":"go:GO:0033382","description":"\"A process in which the protease granyme B is maintained in a secretory granule in a T cell and prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"f5c3c6253c1b460d935941f38fbf197b","type":"GO_TERM","name":"maintenance of imaginal disc-derived wing hair orientation","canonical_id":"go:GO:0035321","description":"\"Ensuring that hairs in the imaginal disc-derived wing continue to point distally during development, following the initial establishment of wing hair polarity.\" [GOC:mtg_sensu, PMID:15501220]","metadata":null},{"id":"4d749238f5bf4d3dbdfdff02b1a655fc","type":"GO_TERM","name":"maintenance of imaginal histoblast diploidy","canonical_id":"go:GO:0007489","description":"\"The negative regulation of the differentiation of polytenized larval hypodermal cells from abdominal histoblasts. The abdominal histoblasts remain a small cluster of diploid cells among the polytenized larval hypodermal cells.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"3104c1e92a364af1988f93349834f714","type":"GO_TERM","name":"maintenance of inflorescence meristem identity","canonical_id":"go:GO:0010077","description":"\"The process in which an organism retains a population of inflorescence meristem cells, preventing the commitment of all stem cell progeny to a differentiated cell fate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"81e80b34b6a8443b8136ce1c9f425d1c","type":"GO_TERM","name":"maintenance of kidney identity","canonical_id":"go:GO:0072005","description":"\"The process in which the identity of a kidney is maintained. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c11bce4bf05b40d6917ec8ce01e050a4","type":"GO_TERM","name":"maintenance of left sidedness","canonical_id":"go:GO:0061969","description":"\"The organization process that preserves the left sidedness in an organism's body plan or part of an organism with respect to the left and right halves.\" [GOC:BHF, PMID:18629866]","metadata":null},{"id":"827ab6f50f294a948a4703de15c0544d","type":"GO_TERM","name":"maintenance of left/right asymmetry","canonical_id":"go:GO:0061968","description":"\"The organization process that preserves the asymmetry in an organism's body plan or part of an organism with respect to the left and right halves.\" [GOC:BHF, PMID:18629866]","metadata":null},{"id":"9cc42390c01b488fbb3a41d72d21eaf3","type":"GO_TERM","name":"maintenance of lens transparency","canonical_id":"go:GO:0036438","description":"\"A homeostatic process in which the lens is maintained in a highly refractive, transparent state to allow for optimal focusing of light on the retina.\" [GOC:nhn, PMID:22095752]","metadata":null},{"id":"38655fa154e9480eb2e02f6f23fd7f2d","type":"GO_TERM","name":"maintenance of location","canonical_id":"go:GO:0051235","description":"\"Any process in which a cell, substance or cellular entity, such as a protein complex or organelle, is maintained in a location and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"8d9935d68139446384f2ff79873f1a50","type":"GO_TERM","name":"maintenance of location in cell","canonical_id":"go:GO:0051651","description":"\"Any process in which a substance or cellular entity, such as a protein complex or organelle, is maintained in a specific location within, or in the membrane of, a cell, and is prevented from moving elsewhere.\" [GOC:ai]","metadata":null},{"id":"c6da0af877df4b9c97276a5110a85da8","type":"GO_TERM","name":"maintenance of meiotic sister chromatid cohesion","canonical_id":"go:GO:0034090","description":"\"The process in which the association between sister chromatids of a replicated chromosome is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate during a meiotic cell cycle.\" [GOC:mah]","metadata":null},{"id":"b7fb539582384a46be7e6240986b1162","type":"GO_TERM","name":"maintenance of meiotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:0035875","description":"\"The process in which the association between sister chromatids of a replicated chromosome along the length of the centromeric region is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate during a meiotic cell cycle.\" [GOC:vw, PMID:1708436]","metadata":null},{"id":"73af9f21558344489516b0d03d76811d","type":"GO_TERM","name":"maintenance of membrane potential in photoreceptor cell by rhodopsin mediated signaling","canonical_id":"go:GO:0016058","description":"\"Maintenance of the excited state of a photoreceptor cell to produce a steady-state current as a result of signals generated by rhodopsin activation by a photon.\" [GOC:dph, GOC:hb, GOC:tb]","metadata":null},{"id":"1096a0e65f12432dac7d0f3c44a4c6a5","type":"GO_TERM","name":"maintenance of meristem identity","canonical_id":"go:GO:0010074","description":"\"The process in which an organism retains a population of meristem cells, preventing the commitment of all stem cell progeny to a differentiated cell fate.\" [GOC:tb]","metadata":null},{"id":"a730f936bc2143b5b1727de63cffb5e8","type":"GO_TERM","name":"maintenance of mitochondrion location","canonical_id":"go:GO:0051659","description":"\"Any process in which a mitochondrion is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"cc531ecc17704d5e9adf82cb82659049","type":"GO_TERM","name":"maintenance of mitotic sister chromatid cohesion","canonical_id":"go:GO:0034088","description":"\"The process in which the association between sister chromatids of a replicated chromosome is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate during a mitotic cell cycle.\" [GOC:mah]","metadata":null},{"id":"ca908453ca364769a3b803552da1d216","type":"GO_TERM","name":"maintenance of mitotic sister chromatid cohesion, arms","canonical_id":"go:GO:0071959","description":"\"The process in which the association between sister chromatids of a replicated chromosome along the length of the chromosome arms, is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate during a mitotic cell cycle.\" [GOC:mah, PMID:1708436]","metadata":null},{"id":"831aa6d3108540b89e87425156469f9c","type":"GO_TERM","name":"maintenance of mitotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:0071960","description":"\"The process in which the association between sister chromatids of a replicated chromosome along the length of the centromeric region is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate during a mitotic cell cycle.\" [GOC:mah, PMID:1708436]","metadata":null},{"id":"bcea631d02114ba6a39e85ce0b1c25f0","type":"GO_TERM","name":"maintenance of mitotic sister chromatid cohesion, telomeric","canonical_id":"go:GO:0099403","description":"\"The process in which the association between sister chromatids of a replicated chromosome along the length of the telomeric region is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate during a mitotic cell cycle.\" [GOC:BHF, GOC:BHF_telomere, GOC:dos, GOC:rph, PMID:26373281]","metadata":null},{"id":"9bcaa5d2defe417c836357af47a8ffb8","type":"GO_TERM","name":"maintenance of neuroblast polarity","canonical_id":"go:GO:0045201","description":"\"The maintenance of the apicobasal polarity of a neuroblast cell, a progenitor of the central nervous system.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"9b9b12ab317644ae92f0e42c86514790","type":"GO_TERM","name":"maintenance of nucleus location","canonical_id":"go:GO:0051658","description":"\"Any process in which the nucleus is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"75b5ec49353f44f9b295a195ce84ef82","type":"GO_TERM","name":"maintenance of organelle location","canonical_id":"go:GO:0051657","description":"\"Any process in which an organelle is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"ae950c4d52244ba18399d27c6ca25651","type":"GO_TERM","name":"maintenance of pigment granule location","canonical_id":"go:GO:0051906","description":"\"Any process in which a pigment granule is maintained in a location and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"4351194a9048447bbec6e83f81f800d5","type":"GO_TERM","name":"maintenance of plant organ identity","canonical_id":"go:GO:0090700","description":"\"The process in which the identity of a plant organ is maintained. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tb, PMID:9090883]","metadata":null},{"id":"3d73253c92b047d381a00d97fac7b6fa","type":"GO_TERM","name":"maintenance of plastid location","canonical_id":"go:GO:0051688","description":"\"Any process in which a plastid is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"6c43eb24fa224083b2571abe991fa31c","type":"GO_TERM","name":"maintenance of polarity of embryonic epithelium","canonical_id":"go:GO:0042250","description":"\"The maintenance of an established polarized embryonic epithelial sheet.\" [GOC:jl]","metadata":null},{"id":"36b4426db6c5447994dd40e0c95a3402","type":"GO_TERM","name":"maintenance of polarity of follicular epithelium","canonical_id":"go:GO:0042248","description":"\"The maintenance of an established polarized follicular epithelial sheet.\" [GOC:bf]","metadata":null},{"id":"1b5c6ec69afb4039b7ef0eb6b6a7ad43","type":"GO_TERM","name":"maintenance of polarity of larval imaginal disc epithelium","canonical_id":"go:GO:0042251","description":"\"The maintenance of an established polarized larval imaginal disc epithelium.\" [GOC:jl]","metadata":null},{"id":"8ffbf5bc11ec4d5cb6d857023ac2e8dd","type":"GO_TERM","name":"maintenance of postsynaptic density structure","canonical_id":"go:GO:0099562","description":"\"A process which maintains the organization and the arrangement of proteins in the presynaptic density.\" [GOC:dos]","metadata":null},{"id":"ba30328f91094c06aa0126a6df960135","type":"GO_TERM","name":"maintenance of postsynaptic specialization structure","canonical_id":"go:GO:0098880","description":"\"A process which maintains the organization and the arrangement of proteins in the presynaptic specialization.\" [GOC:dos]","metadata":null},{"id":"eef6848be9b2492db4b693fd0e6cbc67","type":"GO_TERM","name":"maintenance of presynaptic active zone structure","canonical_id":"go:GO:0048790","description":"\"A process which maintains the organization and the arrangement of proteins at the active zone to ensure the fusion and docking of vesicles and the release of neurotransmitters.\" [GOC:curators, GOC:dph, GOC:pr]","metadata":null},{"id":"a8858223dd9d400b854afaeaa47ebc81","type":"GO_TERM","name":"maintenance of protease location in T cell secretory granule","canonical_id":"go:GO:0033379","description":"\"A process in which a protease is maintained in a secretory granule in a T cell and prevented from moving elsewhere.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"8f9319ef895549c98cafd719019f5fba","type":"GO_TERM","name":"maintenance of protease location in mast cell secretory granule","canonical_id":"go:GO:0033373","description":"\"A process in which a protease is maintained in a secretory granule in a mast cell and prevented from moving elsewhere.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"1141657f87b546c8b6ff4d3dedf32496","type":"GO_TERM","name":"maintenance of protein complex location","canonical_id":"go:GO:0098544","description":"\"Any process in which a protein complex is maintained in a location and prevented from moving elsewhere. These include sequestration, stabilization to prevent transport elsewhere and the active retrieval of protein complexes that move away.\" [GOC:dos]","metadata":null},{"id":"15d2fbe37dda4a7f99325284d7be5ff9","type":"GO_TERM","name":"maintenance of protein complex location in cytoplasm","canonical_id":"go:GO:0098545","description":"\"Any process in which a protein complex is maintained in a specific location within the cytoplasm and is prevented from moving elsewhere.\" [GOC:dos]","metadata":null},{"id":"751f249db5d2432aa323e4f3f93bcb28","type":"GO_TERM","name":"maintenance of protein localization at cell tip","canonical_id":"go:GO:0099017","description":"\"Any process in which localization of a protein is maintained at the cell tip.\" [GOC:dos, GOC:vw, PMID:12894167]","metadata":null},{"id":"df1ce0799cb4433ca00867c66f523c89","type":"GO_TERM","name":"maintenance of protein localization at growing cell tip","canonical_id":"go:GO:0099019","description":"\"Any process in which localization of a protein is maintained at the growing cell tip.\" [GOC:dos, GOC:vw, PMID:24146635]","metadata":null},{"id":"da1ff415a4f9490b8a4bab11c4a4ce12","type":"GO_TERM","name":"maintenance of protein localization in endoplasmic reticulum","canonical_id":"go:GO:0035437","description":"\"Any process in which a protein is maintained in the endoplasmic reticulum and prevented from moving elsewhere. These include sequestration within the endoplasmic reticulum, protein stabilization to prevent transport elsewhere and the active retrieval of proteins that escape the endoplasmic reticulum.\" [GOC:bf, GOC:vw]","metadata":null},{"id":"12978a894bcb455b8f9bf372b91e5045","type":"GO_TERM","name":"maintenance of protein localization in organelle","canonical_id":"go:GO:0072595","description":"\"Any process in which a protein is maintained in a specific location a specific location on or in an organelle, and is prevented from moving elsewhere. Encompasses establishment of localization in the membrane or lumen of a membrane-bounded organelle.\" [GOC:mah]","metadata":null},{"id":"4314c69cfb164b2da812e396034a8e7b","type":"GO_TERM","name":"maintenance of protein localization to heterochromatin","canonical_id":"go:GO:1990153","description":"\"A process in which a protein is maintained in a location in telomeric heterochromatin.\" [PMID:21300781]","metadata":null},{"id":"ac76acd78194444686fc3a9cac880f3e","type":"GO_TERM","name":"maintenance of protein location","canonical_id":"go:GO:0045185","description":"\"Any process in which a protein is maintained in a location and prevented from moving elsewhere. These include sequestration, stabilization to prevent transport elsewhere and the active retrieval of proteins that do move away.\" [GOC:bf]","metadata":null},{"id":"ef2a59d5e1e74fdba6a4c752e8883c38","type":"GO_TERM","name":"maintenance of protein location in T cell secretory granule","canonical_id":"go:GO:0033377","description":"\"A process in which a protein is maintained in a secretory granule in a T cell and prevented from moving elsewhere.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"18501f1391044ee29455c0ec87244da5","type":"GO_TERM","name":"maintenance of protein location in cell","canonical_id":"go:GO:0032507","description":"\"Any process in which a protein is maintained in a specific location within, or in the membrane of, a cell, and is prevented from moving elsewhere.\" [GOC:isa_complete, GOC:mah]","metadata":null},{"id":"e52921e0fad946c290ce34c8f5aa3c23","type":"GO_TERM","name":"maintenance of protein location in cell cortex","canonical_id":"go:GO:0032065","description":"\"A process in which a protein or protein complex is maintained in a specific location in the cell cortex.\" [GOC:vw]","metadata":null},{"id":"0eaca81f10ba437c8f56ae36b58ff893","type":"GO_TERM","name":"maintenance of protein location in cell cortex of cell tip","canonical_id":"go:GO:0097248","description":"\"A process in which a protein or protein complex is maintained in a specific location in the cell cortex of a cell tip, and is prevented from moving elsewhere. The cell cortex of a cell tip is the region directly beneath the plasma membrane at either end of the longest axis of a cylindrical or elongated cell.\" [GOC:al, PMID:19646873]","metadata":null},{"id":"fcf2c71d0cee44c08876d287f8e9652a","type":"GO_TERM","name":"maintenance of protein location in chloroplast","canonical_id":"go:GO:0072597","description":"\"Any process in which a protein is maintained in a specific location in a chloroplast, and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"3c528d5f64244d61bc568d1bbe2020f5","type":"GO_TERM","name":"maintenance of protein location in extracellular region","canonical_id":"go:GO:0071694","description":"\"Any process in which a protein is maintained in a specific location within the extracellular region and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"a5a67d356b894cb79d93baf4ba587925","type":"GO_TERM","name":"maintenance of protein location in mast cell secretory granule","canonical_id":"go:GO:0033370","description":"\"A process in which a protein is maintained in a secretory granule in a mast cell and prevented from moving elsewhere.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"cd9fc90127394d5c99930022b00c3248","type":"GO_TERM","name":"maintenance of protein location in membrane","canonical_id":"go:GO:0072658","description":"\"Any process in which a protein is maintained in a specific location in a membrane, and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"840ba7fb1b7a4e60bd7e75e1c0558216","type":"GO_TERM","name":"maintenance of protein location in mitochondrion","canonical_id":"go:GO:0072656","description":"\"Any process in which a protein is maintained in a specific location in a mitochondrion, and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"eb0f0a13080e4cd1b9e261f14ac74870","type":"GO_TERM","name":"maintenance of protein location in nucleus","canonical_id":"go:GO:0051457","description":"\"Any process in which a protein is maintained in the nucleus and prevented from moving elsewhere. These include sequestration within the nucleus, protein stabilization to prevent transport elsewhere and the active retrieval of proteins that escape the nucleus.\" [GOC:ai]","metadata":null},{"id":"05f60b6706bc4304a178a80eb00b71fd","type":"GO_TERM","name":"maintenance of protein location in peroxisome","canonical_id":"go:GO:0072664","description":"\"Any process in which a protein is maintained in a specific location in a peroxisome, and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"94e9d02eb4f24bcaaed911f3e10c19d2","type":"GO_TERM","name":"maintenance of protein location in plasma membrane","canonical_id":"go:GO:0072660","description":"\"Any process in which a protein is maintained in a specific location in the plasma membrane, and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"6119fc1b86254cc882150b5aacbcc156","type":"GO_TERM","name":"maintenance of protein location in vacuole","canonical_id":"go:GO:0072667","description":"\"Any process in which a protein is maintained in a specific location in a vacuole, and is prevented from moving elsewhere.\" [GOC:mah]","metadata":null},{"id":"284e5245d94a497aadec3d8133aba2ff","type":"GO_TERM","name":"maintenance of protein location to spindle pole body","canonical_id":"go:GO:0071990","description":"\"Any process in which a protein is maintained in a specific location at the spindle pole body, and is prevented from moving elsewhere.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"d1ae9d7f819842e39b54817587922784","type":"GO_TERM","name":"maintenance of rDNA","canonical_id":"go:GO:0043007","description":"\"Any process involved in sustaining the fidelity and copy number of rDNA repeats.\" [GOC:vw, PMID:14528010]","metadata":null},{"id":"58c1914f83524503b8e013b7865cbbc4","type":"GO_TERM","name":"maintenance of reproductive diapause","canonical_id":"go:GO:0071984","description":"\"The dormancy process that results an organism remaining in reproductive diapause. Reproductive diapause is a form of diapause where the organism itself will remain fully active, including feeding and other routine activities, but the reproductive organs experience a tissue-specific reduction in metabolism, with characteristic triggering and releasing stimuli.\" [GOC:mah]","metadata":null},{"id":"dc547968b39248bca8a58f3c72034ffc","type":"GO_TERM","name":"maintenance of right sidedness","canonical_id":"go:GO:0061970","description":"\"The organization process that preserves the right sidedness in an organism's body plan or part of an organism with respect to the left and right halves.\" [GOC:BHF, PMID:18629866]","metadata":null},{"id":"c37e10ba0cbf4177b23ce5da8a0888a0","type":"GO_TERM","name":"maintenance of root meristem identity","canonical_id":"go:GO:0010078","description":"\"The process in which an organism retains a population of root meristem cells, preventing the commitment of all stem cell progeny to a differentiated cell fate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"edd4a917ce9c474f9e8e964aaff30aa8","type":"GO_TERM","name":"maintenance of secretory granule location","canonical_id":"go:GO:0032255","description":"\"Any process in which a secretory granule is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"bf35824a970e460bbbe36fa6c1b77675","type":"GO_TERM","name":"maintenance of seed dormancy","canonical_id":"go:GO:0010231","description":"\"Any process that maintains a seed in a dormant state.\" [ISBN:9781405139830, PMID:9580097]","metadata":null},{"id":"4f511d63caef481a9fb82da708a84b33","type":"GO_TERM","name":"maintenance of seed dormancy by absisic acid","canonical_id":"go:GO:0098755","description":"\"The process by which seed dormancy is maintained by the presence of absisic acid.\" [GOC:dos, PMID:9580097]","metadata":null},{"id":"1af23750878e43748fdb6d40525fd917","type":"GO_TERM","name":"maintenance of shoot apical meristem identity","canonical_id":"go:GO:0010492","description":"\"The process in which an organism retains a population of shoot apical meristem cells, preventing the commitment of all stem cell progeny to a differentiated cell fate.\" [GOC:dph, GOC:tb, PMID:17461786]","metadata":null},{"id":"96140e25461a49c297d01a354b582d2a","type":"GO_TERM","name":"maintenance of sister chromatid cohesion","canonical_id":"go:GO:0034086","description":"\"The process in which the association between sister chromatids of a replicated chromosome is maintained as chromosomes condense, attach to the spindle in a bipolar orientation, and congress to the metaphase plate.\" [GOC:mah, PMID:14623866]","metadata":null},{"id":"7e16490798364f0d82258ced041fb168","type":"GO_TERM","name":"maintenance of spindle location","canonical_id":"go:GO:0051687","description":"\"Any process in which the spindle is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"fc2fd9e35a384e3e8a6b186c35749941","type":"GO_TERM","name":"maintenance of synapse structure","canonical_id":"go:GO:0099558","description":"\"A process that preserves the structural organistation and orientation of a synaptic cellular component such as the synaptic cytoskeleton and molecular scaffolds.\" [GOC:dos, PMID:24449494, PMID:25611509]","metadata":null},{"id":"6ff3a441754243eb8a1340022500a380","type":"GO_TERM","name":"maintenance of transcriptional fidelity during transcription elongation","canonical_id":"go:GO:0001192","description":"\"Suppression of the occurrence of transcriptional errors, such as substitutions and/or insertions of nucleotides that do not correctly match the template base, during the process of transcription elongation on a DNA template.\" [GOC:txnOH]","metadata":null},{"id":"21ac47faed1d4e7693e4a6d611385dfd","type":"GO_TERM","name":"maintenance of transcriptional fidelity during transcription elongation by RNA polymerase II","canonical_id":"go:GO:0001193","description":"\"Suppression of the occurrence of transcriptional errors, such as substitutions and/or insertions of nucleotides that do not correctly match the template base, during the process of transcription elongation from an RNA polymerase II promoter.\" [GOC:txnOH, PMID:14531857, PMID:16492753, PMID:17535246]","metadata":null},{"id":"0e1ff5bb87fc4d5aa4082450d3f36ed4","type":"GO_TERM","name":"maintenance of transcriptional fidelity during transcription elongation by RNA polymerase III","canonical_id":"go:GO:0001195","description":"\"Suppression of the occurrence of transcriptional errors, such as substitutions and/or insertions of nucleotides that do not correctly match the template base, during the process of transcription elongation from a RNA polymerase III promoter.\" [GOC:txnOH]","metadata":null},{"id":"a47f16d25db946ddbd56a0b6af8d1fdf","type":"GO_TERM","name":"maintenance of translational fidelity","canonical_id":"go:GO:1990145","description":"\"Suppression of the occurrence of translational errors, such as codon-anticodon mis-paring, during the process of translation of a protein using an mRNA template.\" [GOC:hjd, ISBN:9781936113460, PMID:21841312]","metadata":null},{"id":"47a5b6718d5d4ce0806f333b54dedb5c","type":"GO_TERM","name":"maintenance of vegetative meristem identity","canonical_id":"go:GO:0010079","description":"\"The process in which an organism retains a population of vegetative meristem cells, preventing the commitment of all stem cell progeny to a differentiated cell fate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f9f5f7e6c4f14a2daa748e2dc9aaf338","type":"GO_TERM","name":"maintenance of vesicle location","canonical_id":"go:GO:0051655","description":"\"Any process in which a vesicle is maintained in a specific location within a cell and prevented from moving elsewhere.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"f2dc2fca275d465a8ad0c3a8e7fc0d5b","type":"GO_TERM","name":"maintenance of viral latency","canonical_id":"go:GO:0019044","description":"\"The perpetuation of a latent state, generally by repressing the viruses own lytic genes expression and ensuring expression of viral genes which function to keep the viral genome from being detected by the host defense mechanisms.\" [GOC:jl]","metadata":null},{"id":"f9a10f375e7f4df7b6533b3f66033d61","type":"DISEASE","name":"major depressive disorder","canonical_id":"mondo:0002009","description":null,"metadata":null},{"id":"77074d82823c4dceaef7ec4142deca68","type":"DISEASE","name":"major depressive disorder","canonical_id":"mesh:D003865","description":null,"metadata":null},{"id":"61510cf11c474a68a68cfe4d1e332425","type":"GO_TERM","name":"major mitochondrial derivative","canonical_id":"go:GO:0016008","description":"\"The larger of the two mitochondrial derivatives that arise by the unfolding of the Nebenkern during flagellum elongation; the major mitochondrial derivative is ovoid and darker than the minor derivative.\" [GOC:mah, PMID:17123504, PMID:24211517, PMID:30802236]","metadata":null},{"id":"20e7645e4a0047c2b6e222e9598426e3","type":"DISEASE","name":"malabsorption syndrome","canonical_id":"mondo:0020598","description":null,"metadata":null},{"id":"937fea042aa64e9ca56e5099a97c7ba3","type":"DISEASE","name":"malaria","canonical_id":"mondo:0005136","description":null,"metadata":null},{"id":"26e0326ad83e4059a201615fa69e76b8","type":"GO_TERM","name":"malate dehydrogenase (decarboxylating) (NAD+) activity","canonical_id":"go:GO:0004471","description":"\"Catalysis of the reaction: (S)-malate + NAD+ = pyruvate + CO2 + NADH.\" [RHEA:12653]","metadata":null},{"id":"6d70e75b79e5492d933bb0580ff7e2c5","type":"GO_TERM","name":"malate dehydrogenase (decarboxylating) (NADP+) activity","canonical_id":"go:GO:0004473","description":"\"Catalysis of the reaction: (S)-malate + NADP+ = pyruvate + CO2 + NADPH.\" [RHEA:18253]","metadata":null},{"id":"acdd708579e14ac0882b144026acedcd","type":"GO_TERM","name":"malate dehydrogenase activity","canonical_id":"go:GO:0016615","description":"\"Catalysis of the reversible conversion of pyruvate or oxaloacetate to malate.\" [GOC:mah, ISBN:0582227089]","metadata":null},{"id":"2aa2fc3808bb4df2aac77503b9e9eaf1","type":"GO_TERM","name":"malate import across plasma membrane","canonical_id":"go:GO:0098714","description":"\"The directed movement of malate from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"1ea55e1e5fc94e11aaa63356ff43f592","type":"GO_TERM","name":"malate metabolic process","canonical_id":"go:GO:0006108","description":"\"The chemical reactions and pathways involving malate, the anion of hydroxybutanedioic acid, a chiral hydroxydicarboxylic acid. The (+) enantiomer is an important intermediate in metabolism as a component of both the TCA cycle and the glyoxylate cycle.\" [ISBN:0198506732]","metadata":null},{"id":"4c71da21a7f54452a91ae12fcc973a24","type":"GO_TERM","name":"malate synthase activity","canonical_id":"go:GO:0004474","description":"\"Catalysis of the reaction: acetyl-CoA + glyoxylate + H2O = (S)-malate + CoA + H+.\" [RHEA:18181]","metadata":null},{"id":"6deea05e39c34889a7e007bc5608f0b2","type":"GO_TERM","name":"malate transmembrane transport","canonical_id":"go:GO:0071423","description":"\"A process in which a malate ion is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"7d87506f563b49a8951b00bbb65cbebb","type":"GO_TERM","name":"malate transmembrane transporter activity","canonical_id":"go:GO:0015140","description":"\"Enables the transfer of malate from one side of a membrane to the other. Malate is a chiral hydroxydicarboxylic acid, hydroxybutanedioic acid. The (+) enantiomer is an important intermediate in metabolism as a component of both the TCA cycle and the glyoxylate cycle.\" [GOC:ai]","metadata":null},{"id":"048a8a62197a4385ba5c73f2f1f90b1e","type":"GO_TERM","name":"malate transport","canonical_id":"go:GO:0015743","description":"\"The directed movement of malate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"e067a1699c844bd7aa91b6cc3d846327","type":"GO_TERM","name":"malate-CoA ligase activity","canonical_id":"go:GO:0050074","description":"\"Catalysis of the reaction: ATP + malate + CoA = ADP + phosphate + malyl-CoA.\" [EC:6.2.1.9, MetaCyc:MALATE--COA-LIGASE-RXN]","metadata":null},{"id":"31243d51d9834896bf1cd5b400c6c49e","type":"GO_TERM","name":"malate-aspartate shuttle","canonical_id":"go:GO:0043490","description":"\"The process of transferring reducing equivalents from NADH in the cytosol to the mitochondria via malate. Cytosolic aspartate aminotransferase converts aspartate to oxaloacetate, and cytosolic malate dehydrogenase uses NADH to convert oxaloacetate to malate in the cytosol; the malate-alpha-ketoglutarate carrier then transports the malate into the mitochondria where mitochondrial malate dehydrogenase uses NAD to convert malate back to oxaloacetate; the electrons on the reduced NADH are then available for use in the electron transport chain; mitochondrial aspartate aminotransferase converts oxaloacetate to aspartate, and the glutamate-aspartate carrier transports the aspartate back to the cytosol to complete the cycle.\" [GOC:sjm, PMID:16368075]","metadata":null},{"id":"59efba197bb44b029de86816143f1795","type":"GO_TERM","name":"malate:proton symporter activity","canonical_id":"go:GO:0015366","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: malate(out) + H+(out) = malate(in) + H+(in).\" [TC:2.A.16.2.1]","metadata":null},{"id":"3a6b5c770c8c4ae59307cad855b43d91","type":"GO_TERM","name":"malate:sodium symporter activity","canonical_id":"go:GO:0043882","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: malate(out) + Na+(out) = malate(in) + Na+(in).\" [GOC:jl, PMID:10903309]","metadata":null},{"id":"b3d44f892a3b40b2878ef5d5fea664cc","type":"GO_TERM","name":"male analia development","canonical_id":"go:GO:0045496","description":"\"The process whose specific outcome is the progression of the analia of the male over time, from formation to the mature structure. The analia is the posterior-most vertral appendage that develops from the genital disc. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11494318]","metadata":null},{"id":"484c65700518448187340d9a1efbcf77","type":"GO_TERM","name":"male analia morphogenesis","canonical_id":"go:GO:0048811","description":"\"The process in which the anatomical structures of the analia of the male are generated and organized. The analia is the posterior-most vertral appendage that develops from the genital disc.\" [GOC:mtg_sensu, PMID:11494318]","metadata":null},{"id":"314915b559d94c029b945a1d1a90110a","type":"GO_TERM","name":"male anatomical structure morphogenesis","canonical_id":"go:GO:0090598","description":"\"The processes by which anatomical structures that are only present in the male organism are generated and organized.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"81cba34793774c579cd1746551f6b9ea","type":"GO_TERM","name":"male courtship behavior","canonical_id":"go:GO:0008049","description":"\"The behavior of a male, for the purpose of attracting a sexual partner. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, GOC:pr]","metadata":null},{"id":"596e86352707455eb46ee7bd33418a76","type":"GO_TERM","name":"male courtship behavior, orientation prior to leg tapping and wing vibration","canonical_id":"go:GO:0016543","description":"\"The process during courtship, where the male orients towards a potential partner. An example of this is found in Drosophila melanogaster.\" [GOC:sensu, PMID:11092827]","metadata":null},{"id":"0bd903e34dc048008ab0ef41221d521f","type":"GO_TERM","name":"male courtship behavior, proboscis-mediated licking","canonical_id":"go:GO:0016546","description":"\"The process during courtship where the male fly licks the genitalia of a stationary female fly with his proboscis. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11092827]","metadata":null},{"id":"91197cab7f434223a469baaab422c779","type":"GO_TERM","name":"male courtship behavior, tapping to detect pheromone","canonical_id":"go:GO:0016544","description":"\"The process during courtship where the male insect taps the female with his frontal leg. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11092827]","metadata":null},{"id":"b751b66256c84b12b7579169ebd2aa3f","type":"GO_TERM","name":"male courtship behavior, veined wing extension","canonical_id":"go:GO:0048065","description":"\"The process during courtship where the male insect extends his wings. An example of this process is found in Drosophila melanogaster.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"e680b3b529e34885ac268f597a8be862","type":"GO_TERM","name":"male courtship behavior, veined wing generated song production","canonical_id":"go:GO:0045433","description":"\"The process during wing vibration where the male insect produces a species-specific acoustic signal called a love song.\" [GOC:mtg_sensu, PMID:11092827]","metadata":null},{"id":"f497fe43af884175abadb94d93b7848e","type":"GO_TERM","name":"male courtship behavior, veined wing vibration","canonical_id":"go:GO:0016545","description":"\"The process during courtship where the male insect vibrates his wings. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11092827]","metadata":null},{"id":"40765c53798740dd9431bc57ec442840","type":"GO_TERM","name":"male gamete generation","canonical_id":"go:GO:0048232","description":"\"Generation of the male gamete; specialised haploid cells produced by meiosis and along with a female gamete takes part in sexual reproduction.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"2c8d3b5ee2994720abf9755271222d49","type":"GO_TERM","name":"male genitalia development","canonical_id":"go:GO:0030539","description":"\"The process whose specific outcome is the progression of the male genitalia over time, from its formation to the mature structure.\" [GOC:ems, ISBN:0140512888]","metadata":null},{"id":"7d6741304b4142dfaa2e28ce6da99be6","type":"GO_TERM","name":"male genitalia morphogenesis","canonical_id":"go:GO:0048808","description":"\"The process in which the anatomical structures of male genitalia are generated and organized.\" [GOC:ems, ISBN:0140512888]","metadata":null},{"id":"1c29e30acab24682a4c3ab0fc03fa566","type":"GO_TERM","name":"male germ cell nucleus","canonical_id":"go:GO:0001673","description":"\"The nucleus of a male germ cell, a reproductive cell in males.\" [CL:0000015, GOC:hjd, GOC:mtg_sensu]","metadata":null},{"id":"ddb560305a504488bf3abdbe79d5faf2","type":"GO_TERM","name":"male germ cell proliferation","canonical_id":"go:GO:0002176","description":"\"The multiplication or reproduction of male germ cells, resulting in the expansion of a cell population.\" [GOC:hjd]","metadata":null},{"id":"34d765a1b99d4589a102d8a6d75533c8","type":"GO_TERM","name":"male germ-line cyst encapsulation","canonical_id":"go:GO:0048140","description":"\"Formation of a single follicular epithelium around the germ-line derived cells of a cyst formed in the male gonad.\" [GOC:jid, PMID:11591336]","metadata":null},{"id":"81cb96e48b164b3e8fda9e4f94a9a57f","type":"GO_TERM","name":"male germ-line cyst formation","canonical_id":"go:GO:0048136","description":"\"Formation of a group of interconnected cells derived from a single male gonial founder cell.\" [GOC:jid, PMID:10370240]","metadata":null},{"id":"316ed8c9cc5240f885de27cfef0fb1f3","type":"GO_TERM","name":"male germ-line sex determination","canonical_id":"go:GO:0019100","description":"\"The determination of sex and sexual phenotype in a male organism's germ line.\" [GOC:mah]","metadata":null},{"id":"b91773fd362b40f6a4f76ba6716349fc","type":"GO_TERM","name":"male germ-line stem cell asymmetric division","canonical_id":"go:GO:0048133","description":"\"The self-renewing division of a germline stem cell in the male gonad, to produce a daughter stem cell and a daughter germ cell, which will divide to form the male gametes.\" [GOC:jid]","metadata":null},{"id":"f68861542ddb40a3beb397e9b7725701","type":"GO_TERM","name":"male germ-line stem cell population maintenance","canonical_id":"go:GO:0036098","description":"\"The process by which an organism or tissue maintains a population of male germ-line stem cells.\" [GOC:sart, PMID:21752937]","metadata":null},{"id":"bef909649acc4d86af8e5893bee92f29","type":"GO_TERM","name":"male germline ring canal","canonical_id":"go:GO:0035323","description":"\"An intercellular bridge that connects the germline cells of a male cyst.\" [PMID:9635420]","metadata":null},{"id":"12180e99df004e60ba183e2ded57318e","type":"GO_TERM","name":"male germline ring canal formation","canonical_id":"go:GO:0030726","description":"\"Formation of the intercellular bridges that connect the germ-line cells of a male cyst.\" [ISBN:0879694238]","metadata":null},{"id":"89c921bc197d4089b484b4adfcd7905d","type":"GO_TERM","name":"male germline stem cell symmetric division","canonical_id":"go:GO:0098730","description":"\"The symmetric division of a male germline stem cell to produce two male germline stem cells. An example of this is found in mammalian spermatogonial stem cells, some proportion of which divide symmetrically, so amplifying the population. The choice between asymmetric and symmetric division in this case appears to be internal and stochastic.\" [GOC:dos, PMID:19948499]","metadata":null},{"id":"e3e5b898bf9540c09772a79899498b41","type":"GO_TERM","name":"male gonad development","canonical_id":"go:GO:0008584","description":"\"The process whose specific outcome is the progression of the male gonad over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"4358c878378a45a1b9acc19de4acdfa3","type":"DISEASE","name":"male infertility","canonical_id":"mondo:0005372","description":null,"metadata":null},{"id":"49fb5d6ca8a24fba96729a0a00dc0f0d","type":"GO_TERM","name":"male mating behavior","canonical_id":"go:GO:0060179","description":"\"The specific behavior of a male organism that is associated with reproduction.\" [GOC:dph, GOC:pr, GOC:tb]","metadata":null},{"id":"ea4f86dd0eba44639fe030d138553e24","type":"GO_TERM","name":"male meiosis I","canonical_id":"go:GO:0007141","description":"\"A cell cycle process comprising the steps by which a cell progresses through male meiosis I, the first meiotic division in the male germline.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"231063d27de04a92874cbad50a208cdc","type":"GO_TERM","name":"male meiosis II","canonical_id":"go:GO:0007142","description":"\"A cell cycle process comprising the steps by which a cell progresses through male meiosis II, the second meiotic division in the male germline.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"1ff3b8315ab54ebaae009d59411bc770","type":"GO_TERM","name":"male meiosis chromosome segregation","canonical_id":"go:GO:0007060","description":"\"The cell cycle process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets during the meiotic cell cycle in a male.\" [GOC:ai]","metadata":null},{"id":"0be2c81bd3a34619b11969a4aca5959f","type":"GO_TERM","name":"male meiosis chromosome separation","canonical_id":"go:GO:0051308","description":"\"The process in which paired chromosomes are physically detached from each other during male meiosis.\" [GOC:ai]","metadata":null},{"id":"2918bb8768f544d293415b80b151ce49","type":"GO_TERM","name":"male meiosis cytokinesis","canonical_id":"go:GO:0007112","description":"\"A cell cycle process that occurs as part of the male meiotic cell cycle and results in the division of the cytoplasm of a cell to produce two daughter cells.\" [GOC:ai]","metadata":null},{"id":"f3575450fbc24510a24ed27e3a7e448c","type":"GO_TERM","name":"male meiosis sister chromatid cohesion","canonical_id":"go:GO:0007065","description":"\"The joining of the sister chromatids of a replicated chromosome along the entire length of the chromosome that occurs during meiosis in a male.\" [GOC:ai]","metadata":null},{"id":"64d302f73e994570b53db3d430a0ce61","type":"GO_TERM","name":"male meiotic chromosome movement towards spindle pole","canonical_id":"go:GO:0016346","description":"\"The directed movement of chromosomes in the center of the spindle towards the spindle poles, mediated by the shortening of microtubules attached to the chromosomes, during male meiosis.\" [GOC:ai]","metadata":null},{"id":"8d42fda84af2475ab7b97158e15aa6dc","type":"GO_TERM","name":"male meiotic nuclear division","canonical_id":"go:GO:0007140","description":"\"A cell cycle process by which the cell nucleus divides as part of a meiotic cell cycle in the male germline.\" [GOC:dph, GOC:mah, GOC:vw]","metadata":null},{"id":"f6336b0e23134a88a06dd44adf391d50","type":"GO_TERM","name":"male pigmentation","canonical_id":"go:GO:0048094","description":"\"Establishment of a pattern of pigment in males.\" [GOC:jid]","metadata":null},{"id":"a7fad976d3b6400195ad92907de86017","type":"GO_TERM","name":"male pronuclear envelope synthesis","canonical_id":"go:GO:0035043","description":"\"Assembly of a nuclear envelope containing nuclear pores and a lamina around the male pronucleus, the final step in sperm pronuclear formation.\" [GOC:bf, PMID:11735001]","metadata":null},{"id":"2b98bcc9a03e4c83abe8aa90915cd12e","type":"GO_TERM","name":"male pronucleus","canonical_id":"go:GO:0001940","description":"\"The pronucleus originating from the spermatozoa that was involved in fertilization.\" [GOC:hjd, ISBN:0198506732]","metadata":null},{"id":"52cb8c35c128424e8805b51111c9a2c2","type":"GO_TERM","name":"male pronucleus assembly","canonical_id":"go:GO:0035039","description":"\"The conversion at fertilization of the inactive sperm nucleus into a male pronucleus with its chromosomes processed for the first zygotic division.\" [GOC:bf, PMID:11735001]","metadata":null},{"id":"5a8140d893bc4cb6b2ab2f1dc036548c","type":"GO_TERM","name":"male sex determination","canonical_id":"go:GO:0030238","description":"\"The specification of male sex of an individual organism.\" [GOC:mah]","metadata":null},{"id":"776c9c21d11845b4bece0f44875c1c86","type":"GO_TERM","name":"male sex differentiation","canonical_id":"go:GO:0046661","description":"\"The establishment of the sex of a male organism by physical differentiation.\" [GOC:bf]","metadata":null},{"id":"bfda56c42dee476fb8ff67f228f6d1c2","type":"GO_TERM","name":"male somatic sex determination","canonical_id":"go:GO:0019102","description":"\"The determination of sex and sexual phenotypes in a male organism's soma.\" [GOC:mah]","metadata":null},{"id":"c9bdde48fb994089bea75a62e50e3190","type":"GO_TERM","name":"male urethra development","canonical_id":"go:GO:0061069","description":"\"The progression of the male urethra over time from its initial formation to the mature structure. The male urethra is a renal system organ that carries urine from the bladder through the penis to outside the body.\" [GOC:dph]","metadata":null},{"id":"7d432ab0b553484db97cbd8833b5cb8f","type":"GO_TERM","name":"male-female gamete recognition during double fertilization forming a zygote and endosperm","canonical_id":"go:GO:0080173","description":"\"The initial contact step made between the male gamete and the female gamete during double fertilization forming a zygote and endosperm. An example can be found in Arabidopsis thaliana.\" [PMID:21123745]","metadata":null},{"id":"b467e4005bbf47f0a76c030393b9e59b","type":"GO_TERM","name":"male-specific antibacterial humoral response","canonical_id":"go:GO:0006962","description":"\"An immune response against bacteria, specific to males and mediated through a body fluid.\" [GOC:curators]","metadata":null},{"id":"29fb472d1f654ed4b20afa6b5f319ed2","type":"GO_TERM","name":"male-specific defense response to bacterium","canonical_id":"go:GO:0050831","description":"\"A set of reactions, specific to males, that are triggered in response to the presence of a bacterium that act to protect the cell or organism.\" [GOC:ai]","metadata":null},{"id":"b32356fd61454d4bb3e2faa83fb44432","type":"GO_TERM","name":"maleate hydratase activity","canonical_id":"go:GO:0050075","description":"\"Catalysis of the reaction: (R)-malate = H2O + maleate.\" [EC:4.2.1.31, RHEA:23692]","metadata":null},{"id":"b441a82d170244caa70a4ab9ca164568","type":"GO_TERM","name":"maleate isomerase activity","canonical_id":"go:GO:0050076","description":"\"Catalysis of the reaction: maleate = fumarate.\" [EC:5.2.1.1, RHEA:13169]","metadata":null},{"id":"fa2efe26f720450b84b7256a77830add","type":"GO_TERM","name":"maleimide hydrolase activity","canonical_id":"go:GO:0050539","description":"\"Catalysis of the reaction: H2O + maleimide = H+ + maleamate.\" [EC:3.5.2.16, RHEA:24476]","metadata":null},{"id":"af9f5c4a9b5041e7a32de23bbf63a99a","type":"GO_TERM","name":"maleylacetate reductase activity","canonical_id":"go:GO:0018506","description":"\"Catalysis of the reaction: 3-oxoadipate + NAD(P)+ = 2-maleylacetate + NAD(P)H + H+.\" [EC:1.3.1.32]","metadata":null},{"id":"e4ac8d11ff9840d9a86535fda8421786","type":"GO_TERM","name":"maleylacetoacetate isomerase activity","canonical_id":"go:GO:0016034","description":"\"Catalysis of the reaction: 4-maleylacetoacetate = 4-fumarylacetoacetate.\" [EC:5.2.1.2]","metadata":null},{"id":"d325e29df5a34c0fb48ee8c3d1d8e02d","type":"GO_TERM","name":"maleylpyruvate hydrolase activity","canonical_id":"go:GO:0102054","description":"\"Catalysis of the reaction: 3-maleylpyruvate(2-) + H2O = H+ + maleate(2-) + pyruvate.\" [GOC:pz, PMID:7400101, RHEA:47956]","metadata":null},{"id":"e397bda1d8f14eb6a32aba8bfc848a5b","type":"GO_TERM","name":"maleylpyruvate isomerase activity","canonical_id":"go:GO:0050077","description":"\"Catalysis of the reaction: 3-maleylpyruvate = 3-fumarylpyruvate.\" [EC:5.2.1.4, MetaCyc:MALEYLPYRUVATE-ISOMERASE-RXN]","metadata":null},{"id":"aa05265147f744edb97712e09a9c0fbc","type":"GO_TERM","name":"malic acid secretion","canonical_id":"go:GO:0046723","description":"\"The controlled release of malic acid, hydroxybutanedioic (hydroxysuccinic) acid, by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"db7a6966edef43ec82f9d1041261c523","type":"GO_TERM","name":"malic enzyme activity","canonical_id":"go:GO:0004470","description":"\"Catalysis of the oxidative decarboxylation of malate with the concomitant production of pyruvate.\" [ISBN:0198506732]","metadata":null},{"id":"631d0c4974564a1288fd4df3532c5697","type":"DISEASE","name":"malignant colon neoplasm","canonical_id":"mondo:0021063","description":null,"metadata":null},{"id":"d4bda8ec5a504629a9220e1d443157d7","type":"DISEASE","name":"malignant glioma","canonical_id":"mondo:0100342","description":null,"metadata":null},{"id":"0c7f1ed2076548869ba90ce95f84b39b","type":"DISEASE","name":"malignant hyperthermia of anesthesia","canonical_id":"mondo:0018493","description":null,"metadata":null},{"id":"a09033b3a59b4b6bbd872d6b65de25bf","type":"DISEASE","name":"malignant mesothelioma","canonical_id":"mondo:0006292","description":null,"metadata":null},{"id":"d2d60f84a02843b7b9a9ee74508beff4","type":"DISEASE","name":"malignant migrating partial seizures of infancy","canonical_id":"mondo:0017385","description":null,"metadata":null},{"id":"c5cf4f998cd94ff19eaf18d6d8e1fb75","type":"DISEASE","name":"malignant pancreatic neoplasm","canonical_id":"mondo:0009831","description":null,"metadata":null},{"id":"aea0a317e3124a5c9a226feadaa5987d","type":"DISEASE","name":"malignant pleural mesothelioma","canonical_id":"mondo:0005112","description":null,"metadata":null},{"id":"db8bd890ae6a45ec8ff12b800691b206","type":"DISEASE","name":"malignant tumor of neck","canonical_id":"mondo:0021310","description":null,"metadata":null},{"id":"9884c9e070894308b48a602350e0b63e","type":"DISEASE","name":"malnutrition","canonical_id":"efo:0008572","description":null,"metadata":null},{"id":"188331c040924c849bc01f19366b523e","type":"GO_TERM","name":"malolactic enzyme activity","canonical_id":"go:GO:0043883","description":"\"Catalysis of the reaction: (S)-malate + H+ = (S)-lactate + CO2.\" [PMID:3139053, RHEA:46276]","metadata":null},{"id":"b8b49298ca204a0bae86c05e1c2ed9f1","type":"GO_TERM","name":"malonate CoA-transferase activity","canonical_id":"go:GO:0050078","description":"\"Catalysis of the reaction: acetyl-CoA + malonate = acetate + malonyl-CoA.\" [RHEA:18817]","metadata":null},{"id":"499207faccca48479406f25215b05827","type":"GO_TERM","name":"malonate catabolic process","canonical_id":"go:GO:0090410","description":"\"The chemical reactions and pathways resulting in the breakdown of malonate, the propanedioate ion.\" [GOC:tb]","metadata":null},{"id":"2bf1139a55e04e87a33ecd8360151261","type":"GO_TERM","name":"malonate(1-) transmembrane transporter activity","canonical_id":"go:GO:1901239","description":"\"Enables the transfer of malonate(1-) from one side of a membrane to the other.\" [GOC:TermGenie, PMID:9128730, PMID:9573154]","metadata":null},{"id":"7165c0c6731f42dfb82a9d0fc3a8c2ef","type":"GO_TERM","name":"malonate-semialdehyde dehydrogenase (acetylating, [NAD(P)+]) activity","canonical_id":"go:GO:0018478","description":"\"Catalysis of the reaction: 3-oxopropanoate + CoA + NAD(P)+ = acetyl-CoA + CO2 + NAD(P)H.\" [EC:1.2.1.18]","metadata":null},{"id":"93eb0692c66c4e27ba20df5df7fafdb6","type":"GO_TERM","name":"malonate-semialdehyde dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0033722","description":"\"Catalysis of the reaction: 3-oxopropanoate + NAD(P)+ + H2O = malonate + NAD(P)H + H+.\" [EC:1.2.1.15]","metadata":null},{"id":"a151f81d81af453fb13c08f3a3e593b0","type":"GO_TERM","name":"malonic acid import across plasma membrane","canonical_id":"go:GO:0098715","description":"\"The directed movement of malonic acid from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"84d1fc6c9c6b48448dda588834f6c029","type":"GO_TERM","name":"malonic acid transmembrane transport","canonical_id":"go:GO:1901553","description":"\"The directed movement of malonic acid across a membrane.\" [GOC:al, GOC:TermGenie]","metadata":null},{"id":"0fd420b96956423ea0a5373fa35fdfa4","type":"GO_TERM","name":"malonic acid transport","canonical_id":"go:GO:1900752","description":"\"The directed movement of a malonic acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie, PMID:9128730, PMID:9573154]","metadata":null},{"id":"d4e8b6732fc041ed94b48691cde3ee0c","type":"GO_TERM","name":"malonyl-CoA biosynthetic process","canonical_id":"go:GO:2001295","description":"\"The chemical reactions and pathways resulting in the formation of malonyl-CoA, the S-malonyl derivative of coenzyme A.\" [GOC:yaf, UniPathway:UPA00655]","metadata":null},{"id":"89dd414f0569450c93e9898b8414f69e","type":"GO_TERM","name":"malonyl-CoA catabolic process","canonical_id":"go:GO:2001294","description":"\"The chemical reactions and pathways resulting in the breakdown of malonyl-CoA, the S-malonyl derivative of coenzyme A.\" [GOC:yaf]","metadata":null},{"id":"67ce0ff703924dbd996aade06d4705c5","type":"GO_TERM","name":"malonyl-CoA decarboxylase activity","canonical_id":"go:GO:0050080","description":"\"Catalysis of the reaction: malonyl-CoA = acetyl-CoA + CO2.\" [EC:4.1.1.9, MetaCyc:MALONYL-COA-DECARBOXYLASE-RXN]","metadata":null},{"id":"6acd0a89861c46628ef8af3d53c8c05e","type":"GO_TERM","name":"malonyl-CoA metabolic process","canonical_id":"go:GO:2001293","description":"\"The chemical reactions and pathways involving malonyl-CoA, the S-malonyl derivative of coenzyme A.\" [GOC:yaf, PMID:11902724, PMID:15726818, PMID:18981598]","metadata":null},{"id":"12b91911601a4bd8acc2cfa6497c41d9","type":"GO_TERM","name":"malonyl-CoA methyltransferase activity","canonical_id":"go:GO:0102130","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a malonyl-[acp] = S-adenosyl-L-homocysteine + a malonyl-[acp] methyl ester.\" [GOC:pz, RHEA:17105]","metadata":null},{"id":"8eddeeaf67b54b87a5a4a009cc1f140e","type":"GO_TERM","name":"malonyl-CoA synthetase activity","canonical_id":"go:GO:0090409","description":"\"Catalysis of the reaction: malonate + ATP + coenzyme A = malonyl-CoA + AMP + diphosphate.\" [RHEA:32139]","metadata":null},{"id":"79d6327c1f49456fa1431b3abcdc006f","type":"GO_TERM","name":"malonyltransferase activity","canonical_id":"go:GO:0016420","description":"\"Catalysis of the transfer of a malonyl (HOOC-CH2-CO-) group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"a812b1325a2f4643abbe979c131a860c","type":"GO_TERM","name":"maltodextrin phosphorylase activity","canonical_id":"go:GO:0031220","description":"\"Catalysis of the reaction: alpha-maltotetraose + phosphate = alpha-D-glucose 1-phosphate + alpha-maltotriose.\" [PMID:10348846, RHEA:29691]","metadata":null},{"id":"4d9a58468922476c8ce03ae9f70033bf","type":"GO_TERM","name":"maltodextrin transmembrane transport","canonical_id":"go:GO:0042956","description":"\"The directed movement of maltodextrin, any polysaccharide of glucose residues in beta-(1,4) linkage, across a membrane.\" [GOC:jl]","metadata":null},{"id":"4ef388cb4dde4e6c8655eaebae0fdd6e","type":"GO_TERM","name":"maltodextrin transmembrane transporter activity","canonical_id":"go:GO:0042958","description":"\"Enables the transfer of maltodextrin, any polysaccharide of glucose residues in beta-(1,4) linkage, from one side of a membrane to the other.\" [GOC:jl, PMID:15034926]","metadata":null},{"id":"afb25bcfbece4dce84fa501a9d74560a","type":"GO_TERM","name":"maltoheptaose binding","canonical_id":"go:GO:2001071","description":"\"Binding to maltoheptaose.\" [GOC:mengo_curators]","metadata":null},{"id":"2e828276a38c42d69af7cbf2ffe1e05e","type":"GO_TERM","name":"maltoheptaose catabolic process","canonical_id":"go:GO:2001123","description":"\"The chemical reactions and pathways resulting in the breakdown of a maltoheptaose.\" [GOC:mengo_curators]","metadata":null},{"id":"01b09f9e995440108958212b795ac5d3","type":"GO_TERM","name":"maltoheptaose transport","canonical_id":"go:GO:2001105","description":"\"The directed movement of a maltoheptaoseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"ed1dedbeec544438951695d5b54e1950","type":"GO_TERM","name":"maltohexaose transport","canonical_id":"go:GO:2001103","description":"\"The directed movement of a maltohexaoseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"e3c00bf718ad453e92d01f62495d4217","type":"GO_TERM","name":"maltopentaose transport","canonical_id":"go:GO:2001101","description":"\"The directed movement of a maltopentaoseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"3601df415f5c42bda8174f6f9dac7047","type":"GO_TERM","name":"maltose O-acetyltransferase activity","canonical_id":"go:GO:0008925","description":"\"Catalysis of the reaction: acetyl-CoA + maltose = CoA + acetyl-maltose.\" [EC:2.3.1.79]","metadata":null},{"id":"9c5124de0864427b9d623e27374d0445","type":"GO_TERM","name":"maltose alpha-D-glucosyltransferase activity","canonical_id":"go:GO:0047471","description":"\"Catalysis of the reaction: maltose = trehalose.\" [EC:5.4.99.16, MetaCyc:5.4.99.16-RXN]","metadata":null},{"id":"b618db8733eb4368ba9b623d4bae7d0a","type":"GO_TERM","name":"maltose binding","canonical_id":"go:GO:1901982","description":"\"Binding to maltose.\" [GOC:TermGenie, PMID:21566157]","metadata":null},{"id":"60fb356d43c64c239c396b11092dc999","type":"GO_TERM","name":"maltose biosynthetic process","canonical_id":"go:GO:0000024","description":"\"The chemical reactions and pathways resulting in the formation of the disaccharide maltose (4-O-alpha-D-glucopyranosyl-D-glucopyranose).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"5d38d54fd5e6410cb845a53ed5009742","type":"GO_TERM","name":"maltose catabolic process","canonical_id":"go:GO:0000025","description":"\"The chemical reactions and pathways resulting in the breakdown of the disaccharide maltose (4-O-alpha-D-glucopyranosyl-D-glucopyranose).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a1b93d895572410381b82333b5e81b4c","type":"GO_TERM","name":"maltose epimerase activity","canonical_id":"go:GO:0050558","description":"\"Catalysis of the reaction: alpha-maltose = beta-maltose.\" [EC:5.1.3.21, RHEA:21228]","metadata":null},{"id":"4a3d5cc47e8b45d5982e5ca0f1143168","type":"GO_TERM","name":"maltose import across plasma membrane","canonical_id":"go:GO:0106081","description":"\"The directed movement of maltose from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:11136464]","metadata":null},{"id":"cf8323ff31af4656aef2e142a8c9f4db","type":"GO_TERM","name":"maltose metabolic process","canonical_id":"go:GO:0000023","description":"\"The chemical reactions and pathways involving the disaccharide maltose (4-O-alpha-D-glucopyranosyl-D-glucopyranose), an intermediate in the catabolism of glycogen and starch.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"b4747ca9c83a4014a88e6296460420d5","type":"GO_TERM","name":"maltose phosphorylase activity","canonical_id":"go:GO:0050082","description":"\"Catalysis of the reaction: maltose + phosphate = D-glucose + beta-D-glucose 1-phosphate.\" [EC:2.4.1.8, MetaCyc:MALTOSE-PHOSPHORYLASE-RXN]","metadata":null},{"id":"bee5ab1a7d114171905ec3804567874e","type":"GO_TERM","name":"maltose synthase activity","canonical_id":"go:GO:0050420","description":"\"Catalysis of the reaction: 2 alpha-D-glucose 1-phosphate = maltose + 2 phosphate.\" [EC:2.4.1.139, MetaCyc:MALTOSE-SYNTHASE-RXN]","metadata":null},{"id":"8539ab044e7346599c6bd1328e9e7714","type":"GO_TERM","name":"maltose transmembrane transport","canonical_id":"go:GO:1904981","description":"\"The process in which maltose is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:11136464]","metadata":null},{"id":"8ce744c11dc94e699a21d19c30828057","type":"GO_TERM","name":"maltose transmembrane transporter activity","canonical_id":"go:GO:0005363","description":"\"Enables the transfer of maltose from one side of a membrane to the other. Maltose is the disaccharide 4-O-alpha-D-glucopyranosyl-D-glucopyranose, an intermediate in the enzymatic breakdown of glycogen and starch.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"9be7d5e4df164387b6ef97e175e14294","type":"GO_TERM","name":"maltose transport","canonical_id":"go:GO:0015768","description":"\"The directed movement of maltose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Maltose is the disaccharide 4-O-alpha-D-glucopyranosyl-D-glucopyranose, an intermediate in the catabolism of glycogen and starch.\" [GOC:ai]","metadata":null},{"id":"2173db617cb049c3a6129b5291be2dc5","type":"GO_TERM","name":"maltose transport complex","canonical_id":"go:GO:1990060","description":"\"Protein complex facilitating ATP-dependent maltose transport through inner cell membrane (periplasm to cytoplasm) in Gram-negative bacteria. In E. coli the system is composed of a periplasmic maltose-binding protein (MBP), two integral membrane proteins, MalF and MalG, and two copies of the cytoplasmic ATP-binding cassette MalK.\" [PMID:18033289]","metadata":null},{"id":"65762cb9189a4c8b89ee655a84bad374","type":"GO_TERM","name":"maltose transporting porin activity","canonical_id":"go:GO:0015481","description":"\"Enables the transfer of maltose from one side of a membrane to the other. Maltose is the disaccharide 4-O-alpha-D-glucopyranosyl-D-glucopyranose, an intermediate in the enzymatic breakdown of glycogen and starch. This transporter is a porin so enables the energy independent passage of substances, sized less than 1000 Da, across a membrane. The transmembrane portions of porins consist exclusively of beta-strands which form a beta-barrel. They are found in the outer membranes of Gram-negative bacteria, mitochondria, plastids and possibly acid-fast Gram-positive bacteria.\" [GOC:mtg_transport]","metadata":null},{"id":"8d1207d97cc94862a650bafb79ae9c8a","type":"GO_TERM","name":"maltose-6'-phosphate glucosidase activity","canonical_id":"go:GO:0050081","description":"\"Catalysis of the reaction: H2O + maltose 6'-phosphate = D-glucose + D-glucose 6-phosphate.\" [EC:3.2.1.122, MetaCyc:MALTOSE-6-PHOSPHATE-GLUCOSIDASE-RXN]","metadata":null},{"id":"04c00d66168e425390ebecaf4655b681","type":"GO_TERM","name":"maltose:proton symporter activity","canonical_id":"go:GO:0005364","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: maltose(out) + H+(out) = maltose(in) + H+(in).\" [TC:2.A.1.1.10]","metadata":null},{"id":"861d46ee590d46b8882cf4fb8f20a8f9","type":"GO_TERM","name":"maltotetraose transport","canonical_id":"go:GO:2001099","description":"\"The directed movement of a maltotetraoseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"e0d73e3231134ac6b9d6989119e2ffbf","type":"GO_TERM","name":"maltotriose transport","canonical_id":"go:GO:2001089","description":"\"The directed movement of a maltotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"6028916c2b3142f9ba66a6233e712893","type":"GO_TERM","name":"maltotriulose transport","canonical_id":"go:GO:2001090","description":"\"The directed movement of a maltotriuloseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"eabc30b312c0428998b633f2161ee4eb","type":"GO_TERM","name":"malyl-CoA lyase activity","canonical_id":"go:GO:0050083","description":"\"Catalysis of the reaction: (3S)-3-carboxy-3-hydroxypropanoyl-CoA = acetyl-CoA + glyoxylate.\" [EC:4.1.3.24, MetaCyc:MALYL-COA-LYASE-RXN]","metadata":null},{"id":"ec45b1bdabf1423eb5196287a3d2da54","type":"GO_TERM","name":"mammalian oogenesis stage","canonical_id":"go:GO:0022605","description":"\"A reproductive process that is a step in the formation and maturation of an ovum or female gamete from a primordial female germ cell.\" [GOC:isa_complete, GOC:mtg_sensu]","metadata":null},{"id":"bef732c178c341baa8c03bd6f9811c23","type":"GO_TERM","name":"mammary duct terminal end bud growth","canonical_id":"go:GO:0060763","description":"\"The morphogenetic growth of the large, club-shaped terminal end of a mammary gland duct during prepubertal growth and during puberty.\" [GOC:dph, PMID:10804170]","metadata":null},{"id":"75ea66a9ed8e4f759f026c4d29cd2f58","type":"GO_TERM","name":"mammary gland alveolus development","canonical_id":"go:GO:0060749","description":"\"The progression of the mammary gland alveolus over time, from its formation to its mature state. The mammary gland alveolus is a sac-like structure that is found in the mature gland.\" [GOC:dph]","metadata":null},{"id":"c0b1c2f5bddf4522b63c7ffce9ca65bc","type":"GO_TERM","name":"mammary gland branching involved in pregnancy","canonical_id":"go:GO:0060745","description":"\"The process in which the branching structure of the mammary gland duct is generated and organized as a part of pregnancy.\" [GOC:dph, PMID:19261859]","metadata":null},{"id":"5739e647328140f192a00024c391b2c6","type":"GO_TERM","name":"mammary gland branching involved in thelarche","canonical_id":"go:GO:0060744","description":"\"The process in which the branching structure of the mammary gland duct is generated and organized during the period of sexual maturity in mammals. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.\" [GOC:dph, PMID:19261859]","metadata":null},{"id":"8ba0e76a0c194286995c49c4ed49180a","type":"GO_TERM","name":"mammary gland bud elongation","canonical_id":"go:GO:0060649","description":"\"The process in which the mammary gland bud grows along its axis.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"1cb8433c1a7346c0a9e5c407a0b7d46d","type":"GO_TERM","name":"mammary gland bud formation","canonical_id":"go:GO:0060615","description":"\"The morphogenetic process in which a bud forms from the mammary placode. A mammary bud is bulb of epithelial cells that is distinct from the surrounding epidermis.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"5b155b6115df4e1bbfbad7c56c9a667a","type":"GO_TERM","name":"mammary gland bud morphogenesis","canonical_id":"go:GO:0060648","description":"\"The process in which anatomical structures of the mammary gland buds are generated and organized. Mammary gland buds form by an outpocketing of the mammary placodes and grow to invade the mammary fat, when they form the mammary cord.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"6fc5bc63b0c54e8eb720ce8685942148","type":"GO_TERM","name":"mammary gland cord elongation","canonical_id":"go:GO:0060654","description":"\"The process in which the mammary gland sprout grows along its axis.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"0b30f969c42348c4bf748a6dabb0799b","type":"GO_TERM","name":"mammary gland cord formation","canonical_id":"go:GO:0060616","description":"\"The process in which the mammary gland cord forms by elongation of the mammary bud. The cord is formed once the elongating bud breaks through the mesenchyme and reaches the fat pad.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"e0922a2600904ac2a3c2e82e2b3d8cc6","type":"GO_TERM","name":"mammary gland cord morphogenesis","canonical_id":"go:GO:0060652","description":"\"The process in which anatomical structures of the mammary gland cord are generated and organized. Mammary gland cords form when the mammary gland bud invades the mammary fat.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"a50fe7a24ab8441cab4c3ab6eb5a1adc","type":"GO_TERM","name":"mammary gland development","canonical_id":"go:GO:0030879","description":"\"The process whose specific outcome is the progression of the mammary gland over time, from its formation to the mature structure. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk. Its development starts with the formation of the mammary line and ends as the mature gland cycles between nursing and weaning stages.\" [PMID:9576833]","metadata":null},{"id":"fb01f9d46bb54a8493ebe37b4a242cdf","type":"GO_TERM","name":"mammary gland duct cavitation","canonical_id":"go:GO:0060604","description":"\"Creation of the central hole of the mammary gland duct by the hollowing out of a solid rod.\" [GOC:dph, PMID:17120154]","metadata":null},{"id":"382013313910473697d47ff12343cf7b","type":"GO_TERM","name":"mammary gland duct morphogenesis","canonical_id":"go:GO:0060603","description":"\"The process in which anatomical structures of the mammary ducts are generated and organized. Mammary ducts are epithelial tubes that transport milk.\" [GOC:dph, PMID:17120154]","metadata":null},{"id":"a06344086af048e392dd8663cfcd33a6","type":"GO_TERM","name":"mammary gland duct regression in males","canonical_id":"go:GO:0060641","description":"\"The process in which the epithelium of the mammary duct is destroyed in males.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"7c597e56efcd462eb1326ff0c8a8c944","type":"GO_TERM","name":"mammary gland epithelial cell differentiation","canonical_id":"go:GO:0060644","description":"\"The process in which a relatively unspecialized epithelial cell becomes a more specialized epithelial cell of the mammary gland.\" [GOC:dph]","metadata":null},{"id":"27cdc06773f14b048ccc49afdd9fa1af","type":"GO_TERM","name":"mammary gland epithelial cell proliferation","canonical_id":"go:GO:0033598","description":"\"The multiplication or reproduction of mammary gland epithelial cells, resulting in the expansion of a cell population. Mammary gland epithelial cells make up the covering of surfaces of the mammary gland. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"fb3b3b75bc674566b1f2846e9ce19084","type":"GO_TERM","name":"mammary gland epithelium development","canonical_id":"go:GO:0061180","description":"\"The process whose specific outcome is the progression of the mammary gland epithelium over time, from its formation to the mature structure. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"e63f448c28684346b4827ca7e0f053be","type":"GO_TERM","name":"mammary gland fat development","canonical_id":"go:GO:0060611","description":"\"The progression of the mammary gland fat over time, from its formation to the mature structure. The mammary fat is an adipose structure in the gland that is invaded by the mammary ducts.\" [GOC:dph]","metadata":null},{"id":"96c80be11701481a9bb5be641cc3664e","type":"GO_TERM","name":"mammary gland formation","canonical_id":"go:GO:0060592","description":"\"The process pertaining to the initial formation of the mammary gland from unspecified parts. The process begins with formation of the mammary line and ends when the solid mammary bud invades the primary mammary mesenchyme.\" [GOC:dph, PMID:16168142, PMID:17120154]","metadata":null},{"id":"ba46d1eb5a754ce7a8451b94e789c172","type":"GO_TERM","name":"mammary gland involution","canonical_id":"go:GO:0060056","description":"\"The tissue remodeling that removes differentiated mammary epithelia during weaning.\" [GOC:dph, PMID:15282149]","metadata":null},{"id":"ab80473a02754418b6822853f1ea1d73","type":"GO_TERM","name":"mammary gland lobule development","canonical_id":"go:GO:0061377","description":"\"The progression of the mammary gland lobule over time, from its formation to the mature structure. A mammary gland lobule is a small rounded projection of the mammary gland.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"5e0a32271e1a4f7bb8e41f0197063086","type":"GO_TERM","name":"mammary gland morphogenesis","canonical_id":"go:GO:0060443","description":"\"The process in which anatomical structures of the mammary gland are generated and organized. Morphogenesis refers to the creation of shape. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.\" [GOC:dph]","metadata":null},{"id":"2552db5af5d9445bbabeae8aa985bad1","type":"GO_TERM","name":"mammary gland specification","canonical_id":"go:GO:0060594","description":"\"The regionalization process in which the mammary line is specified. The mammary line is a ridge of epidermal cells that will form the mammary placodes.\" [GOC:dph]","metadata":null},{"id":"2236db0aa2934d49a6cc6b61b13b4d42","type":"GO_TERM","name":"mammary placode formation","canonical_id":"go:GO:0060596","description":"\"The developmental process in which the mammary placode forms. The mammary placode is a transient lens shaped structure that will give rise to the mammary bud proper.\" [GOC:dph, PMID:16168142]","metadata":null},{"id":"fe885f89d7f9497981df4ff2feabb654","type":"GO_TERM","name":"mammary stem cell proliferation","canonical_id":"go:GO:0002174","description":"\"The expansion of a mammary stem cell population by cell division. Mammary stem cells are a source of cells for growth of the mammary gland during puberty and gestation. These cells can give rise to both the luminal and myoepithelial cell types of the gland, and can regenerate the entire organ.\" [PMID:15987436]","metadata":null},{"id":"971a016c2f5d4a05ae271bbc9e032b08","type":"GO_TERM","name":"mammillary axonal complex development","canonical_id":"go:GO:0061373","description":"\"The progression of the mammillary axonal complex over time, from its formation to the mature structure. The mammillary axonal complex is formed by the axons from the lateral, medial mammillary and the dorsal premammillary nuclei which share a branching pattern. Every neuron gives off one axonal stem that bifurcates into 2 branches. One of the branches is directed dorsally to the thalamus and another caudally to the midbrain.\" [GOC:dph, GOC:yaf, PMID:10662642]","metadata":null},{"id":"4e0009c8fe7e42aeaae8c09c128d3af4","type":"GO_TERM","name":"mammillary body development","canonical_id":"go:GO:0021767","description":"\"The progression of the mammillary body over time from its initial formation until its mature state. The mammillary body is a protrusion at the posterior end of the hypothalamus that contains hypothalamic nuclei.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"8553d005c8294c71ae351a56696f028b","type":"GO_TERM","name":"mammillotectal axonal tract development","canonical_id":"go:GO:0061375","description":"\"The progression of the mammillotectal tract over time, from its formation to the mature structure. The mammillotectal tract is the collection of axons that connects the ventral diencephalon to the superior colliculus.\" [GOC:dph, GOC:yaf, PMID:10662642]","metadata":null},{"id":"0ee11a5fd71b4cc6b00331864bdb8f3a","type":"GO_TERM","name":"mammillotegmental axonal tract development","canonical_id":"go:GO:0061376","description":"\"The process in which the mammillotegmental tract progresses over time, from its formation to the mature structure. The mammillotegmental tract is the collection of axons that connects the ventral diencephalon to the tegmentum and pons.\" [GOC:dph, GOC:yaf, PMID:10662642]","metadata":null},{"id":"d9fa2d66d3b944d1a4535f651daf93c2","type":"GO_TERM","name":"mammillothalamic axonal tract development","canonical_id":"go:GO:0061374","description":"\"The progression of the mammillothalamic axonal tract, from its formation to the mature structure. The mammillothalamic tract is the collection of axons that connects the two major subdivisions of the diencephalon (hypothalamus and thalamus) and closes the diencephalic circuit.\" [GOC:dph, GOC:yaf, PMID:10662642]","metadata":null},{"id":"7bac52ba650e4af0904f96f148645aa4","type":"GO_TERM","name":"manchette","canonical_id":"go:GO:0002177","description":"\"A tubular array of microtubules that extends from the perinuclear ring surrounding the spermatid nucleus to the flagellar axoneme. The manchette may also contain F-actin filaments.\" [GOC:krc, PMID:15018141, PMID:22319670, PMID:24440897, PMID:26792866]","metadata":null},{"id":"e52af9c4c1d842fe841afc063c1a551a","type":"GO_TERM","name":"manchette assembly","canonical_id":"go:GO:1905198","description":"\"The aggregation, arrangement and bonding together of a set of components to form a manchette.\" [GO_REF:0000079, GOC:krc, GOC:TermGenie, PMID:22319670, PMID:24440897, PMID:26792866]","metadata":null},{"id":"3463716e2862441baaf2ae96b37cd4ed","type":"GO_TERM","name":"manchette disassembly","canonical_id":"go:GO:1905199","description":"\"The disaggregation of a manchette into its constituent components.\" [GO_REF:0000079, GOC:krc, GOC:TermGenie, PMID:22319670, PMID:24440897, PMID:26792866]","metadata":null},{"id":"b57ff382d531409793617a5fa9d84198","type":"GO_TERM","name":"mandelamide amidase activity","canonical_id":"go:GO:0050537","description":"\"Catalysis of the reaction: (R)-mandelamide + H2O = (R)-mandelate + NH4.\" [EC:3.5.1.86, RHEA:22876]","metadata":null},{"id":"c925c894ad9a4193baad7ae232700b62","type":"GO_TERM","name":"mandelate 4-monooxygenase activity","canonical_id":"go:GO:0050481","description":"\"Catalysis of the reaction: (S)-mandelate + 5,6,7,8-tetrahydrobiopterin + O2 = (S)-4-hydroxymandelate + 7,8-dihydrobiopterin + H2O. (S)-2-hydroxy-2-phenylacetate is also known as S-mandelate.\" [EC:1.14.16.6, RHEA:21716]","metadata":null},{"id":"7d3d12a720304359bda4a1369a1569ca","type":"GO_TERM","name":"mandelate biosynthetic process","canonical_id":"go:GO:0046236","description":"\"The chemical reactions and pathways resulting in the formation of mandelate, the anion of mandelic acid. Mandelic acid (alpha-hydroxybenzeneacetic acid) is an 8-carbon alpha-hydroxy acid (AHA) that is used in organic chemistry and as a urinary antiseptic.\" [GOC:ai]","metadata":null},{"id":"cfbfe0ade1d24886a15873267d99098e","type":"GO_TERM","name":"mandelate metabolic process","canonical_id":"go:GO:0018924","description":"\"The chemical reactions and pathways involving mandelate, the anion of mandelic acid. Mandelic acid (alpha-hydroxybenzeneacetic acid) is an 8-carbon alpha-hydroxy acid (AHA) that is used in organic chemistry and as a urinary antiseptic.\" [GOC:jl]","metadata":null},{"id":"d4640de4e2d04bac9f51b9a97c3c4b72","type":"GO_TERM","name":"mandelate racemase activity","canonical_id":"go:GO:0018838","description":"\"Catalysis of the reaction: (S)-mandelate = (R)-mandelate.\" [EC:5.1.2.2]","metadata":null},{"id":"7fc2593e8bbc414eaa6539930cb45f54","type":"GO_TERM","name":"mandelonitrile lyase activity","canonical_id":"go:GO:0046593","description":"\"Catalysis of the reaction: mandelonitrile = cyanide + benzaldehyde.\" [EC:4.1.2.10]","metadata":null},{"id":"86e4743d5ca7444bad3224c3248bb1c8","type":"GO_TERM","name":"mandibular condyle articular cartilage development","canonical_id":"go:GO:0061978","description":"\"The process whose specific outcome is the progression of mandibular joint condyle articular cartilage over time, from its formation to the mature structure.\" [PMID:20679519]","metadata":null},{"id":"e164f5407ded482c8e188fc14c7d83cd","type":"DISEASE","name":"mandibulofacial dysostosis with alopecia","canonical_id":"mondo:0014608","description":null,"metadata":null},{"id":"ded8a9f623b34dd6b12b655ecd961e7c","type":"GO_TERM","name":"manganese import into cell","canonical_id":"go:GO:0140967","description":"\"The directed movement of mangnanese ions from outside of a cell into a cell.\" [PMID:22773749]","metadata":null},{"id":"23916234a2c645cda1f6fc5d90525197","type":"GO_TERM","name":"manganese ion binding","canonical_id":"go:GO:0030145","description":"\"Binding to a manganese ion (Mn).\" [GOC:ai]","metadata":null},{"id":"8ad61455cf7946b983ee5da2c5795c23","type":"GO_TERM","name":"manganese ion export across plasma membrane","canonical_id":"go:GO:0140048","description":"\"The directed movement of manganese ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [PMID:25319704]","metadata":null},{"id":"4efd0b5dc0d946f6870fef38f1a21c1b","type":"GO_TERM","name":"manganese ion homeostasis","canonical_id":"go:GO:0055071","description":"\"Any process involved in the maintenance of an internal steady state of manganese ions within an organism or cell.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"077342441ef2484dbfc1bb56b76e0b9d","type":"GO_TERM","name":"manganese ion transmembrane transport","canonical_id":"go:GO:0071421","description":"\"A process in which a manganese ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"77dfce8c7f0d4defbf50879e96190678","type":"GO_TERM","name":"manganese ion transmembrane transporter activity","canonical_id":"go:GO:0005384","description":"\"Enables the transfer of manganese (Mn) ions from one side of a membrane to the other.\" [GOC:dgf]","metadata":null},{"id":"6611526053194410ae5d5c694d54e552","type":"GO_TERM","name":"manganese ion transport","canonical_id":"go:GO:0006828","description":"\"The directed movement of manganese (Mn) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"34046adb171a4c8392aa2c8bfbdd0d07","type":"GO_TERM","name":"manganese peroxidase activity","canonical_id":"go:GO:0016689","description":"\"Catalysis of the reaction: 2 Mn2+ + 2 H+ + H2O2 = 2 Mn3+ + 2 H2O.\" [EC:1.11.1.13]","metadata":null},{"id":"f0424e85f17e4c27937301596e5b87ed","type":"GO_TERM","name":"manganese:proton antiporter activity","canonical_id":"go:GO:0010486","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Mn2+(in) + H+(out) = Mn2+(out) + H+(in).\" [PMID:17559518]","metadata":null},{"id":"fc6a80fd316f4a6c9233d26cc5ef3815","type":"GO_TERM","name":"mannan 1,2-(1,3)-alpha-mannosidase activity","canonical_id":"go:GO:0033915","description":"\"Catalysis of the hydrolysis of (1->2) and (1->3) linkages in mannan, releasing mannose.\" [EC:3.2.1.77]","metadata":null},{"id":"99e477062e084932a1399a8382cf9057","type":"GO_TERM","name":"mannan 1,4-mannobiosidase activity","canonical_id":"go:GO:0033928","description":"\"Catalysis of the hydrolysis of (1->4)-beta-D-mannosidic linkages in (1->4)-beta-D-mannans, to remove successive mannobiose residues from the non-reducing chain ends.\" [EC:3.2.1.100]","metadata":null},{"id":"ee4c9925fd0d4c63b872f43d3a53362b","type":"GO_TERM","name":"mannan binding","canonical_id":"go:GO:2001065","description":"\"Binding to mannan.\" [GOC:mengo_curators]","metadata":null},{"id":"bc9bd1cabc3e402eb72b761b4f3b6ed8","type":"GO_TERM","name":"mannan biosynthetic process","canonical_id":"go:GO:0046354","description":"\"The chemical reactions and pathways resulting in the formation of mannan, the main hemicellulose of soft (coniferous) wood, made up of D-mannose, D-glucose and D-galactose.\" [ISBN:0198506732]","metadata":null},{"id":"8e0343afcc08487c94cbba05973f591f","type":"GO_TERM","name":"mannan catabolic process","canonical_id":"go:GO:0046355","description":"\"The chemical reactions and pathways resulting in the breakdown of mannan, the main hemicellulose of soft (coniferous) wood, made up of D-mannose, D-glucose and D-galactose.\" [ISBN:0198506732]","metadata":null},{"id":"c5332468679d43579fbbdbbe881a9d3b","type":"GO_TERM","name":"mannan endo-1,4-beta-mannosidase activity","canonical_id":"go:GO:0016985","description":"\"Catalysis of the random hydrolysis of (1->4)-beta-D-mannosidic linkages in mannans, galactomannans, glucomannans, and galactoglucomannans.\" [EC:3.2.1.78]","metadata":null},{"id":"0a1b5bc48e4e4b829a89d840c7d78904","type":"GO_TERM","name":"mannan endo-1,6-alpha-mannosidase activity","canonical_id":"go:GO:0008496","description":"\"Catalysis of the random hydrolysis of (1->6)-alpha-D-mannosidic linkages in unbranched (1->6)-mannans.\" [EC:3.2.1.101]","metadata":null},{"id":"b99e70b9514e4089b8282307f7be0564","type":"GO_TERM","name":"mannan exo-1,2-1,6-alpha-mannosidase activity","canonical_id":"go:GO:0033941","description":"\"Catalysis of the hydrolysis of (1->2)-alpha-D- and (1->6)-alpha-D- linkages in mannan, releasing D-mannose.\" [EC:3.2.1.137]","metadata":null},{"id":"a398cec709294bc689f2ba547a2cacad","type":"GO_TERM","name":"mannan metabolic process","canonical_id":"go:GO:0010412","description":"\"The chemical reactions and pathways involving mannan, a group of polysaccharides containing a backbone composed of a polymer of D-mannose units.\" [GOC:tair_curators]","metadata":null},{"id":"9a395d115b7345109c22d0318576203a","type":"GO_TERM","name":"mannan polymerase I complex","canonical_id":"go:GO:0140498","description":"\"A complex with alpha-(1->6)-mannosyltransferase activity, located in the cis Golgi membrane; adds mannan to N-linked glycans on proteins as part of the priming and elongation of alpha 1,6-linked Man backbone. In S. cerevisiae, contains Mnn9p and Van1p.\" [PMID:9430634]","metadata":null},{"id":"d49fd0301bd64069990e57056929c65b","type":"GO_TERM","name":"mannan polymerase II complex","canonical_id":"go:GO:0140497","description":"\"A complex with alpha-(1->6)-mannosyltransferase activity, located in the cis Golgi membrane; adds mannan to N-linked glycans on proteins as part of the elongation of alpha 1,6-linked Man backbone. In S. cerevisiae, contains Mnn9p, Anp1p, Mnn10p, Mnn11p, and Hoc1p.\" [PMID:9430634]","metadata":null},{"id":"16d34f9b7e514bf3bffa77ae1847f7a8","type":"GO_TERM","name":"mannan polymerase complex","canonical_id":"go:GO:0000136","description":"\"A protein complex with alpha-(1->6)-mannosyltransferase activity, located in the cis Golgi membrane; adds mannan to N-linked glycans on proteins.\" [GOC:mcc, PMID:10037752, PMID:11095735, PMID:18083825]","metadata":null},{"id":"eb0824b13d9f448787706f09f2eb4284","type":"GO_TERM","name":"mannan synthase activity","canonical_id":"go:GO:0051753","description":"\"Catalysis of the reaction: mannan(n) + GDP-mannose = mannan(n+1) + GDP. This reaction is the formation of the beta-(1->4)-linked mannan backbone in substrates such as galactomannan.\" [PMID:14726589]","metadata":null},{"id":"103c5dd68cdf4955a1e6040ead541343","type":"GO_TERM","name":"mannitol 2-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050085","description":"\"Catalysis of the reaction: D-mannitol + NADP+ = D-fructose + H+ + NADPH.\" [EC:1.1.1.138, RHEA:16765]","metadata":null},{"id":"9c7c17ecea8a47e4a03d7fde25bce784","type":"GO_TERM","name":"mannitol 2-dehydrogenase activity","canonical_id":"go:GO:0050086","description":"\"Catalysis of the reaction: D-mannitol + NAD+ = D-fructose + NADH.\" [EC:1.1.1.67, MetaCyc:MANNITOL-2-DEHYDROGENASE-RXN]","metadata":null},{"id":"1422964837094ab9bd548b07bcd55912","type":"GO_TERM","name":"mannitol biosynthetic process","canonical_id":"go:GO:0019593","description":"\"The chemical reactions and pathways resulting in the formation of mannitol, the alditol derived from D-mannose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"a88dde412c1147b1aad06ccc6ac1a1db","type":"GO_TERM","name":"mannitol catabolic process","canonical_id":"go:GO:0019592","description":"\"The chemical reactions and pathways resulting in the breakdown of mannitol, the alditol derived from D-mannose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"3baca4144f17432c825a66fb87283fcf","type":"GO_TERM","name":"mannitol dehydrogenase (cytochrome) activity","canonical_id":"go:GO:0050087","description":"\"Catalysis of the reaction: 2 [Fe(III)cytochrome c] + D-mannitol = 2 [Fe(II)cytochrome c] + D-fructose + 2 H+.\" [RHEA:17597]","metadata":null},{"id":"8c0603cb2d2545babbd7002d68b57e8e","type":"GO_TERM","name":"mannitol dehydrogenase activity","canonical_id":"go:GO:0046029","description":"\"Catalysis of the reaction: D-mannitol + NAD+ = D-mannose + H+ + NADH.\" [RHEA:15029]","metadata":null},{"id":"9c23fd2deca14d9d8bb6996aad6b3a6c","type":"GO_TERM","name":"mannitol metabolic process","canonical_id":"go:GO:0019594","description":"\"The chemical reactions and pathways involving mannitol, the alditol derived from D-mannose by reduction of the aldehyde group.\" [ISBN:0198506732]","metadata":null},{"id":"5cda9f6d85974d5fb4848a1e5802cdc4","type":"GO_TERM","name":"mannitol transmembrane transport","canonical_id":"go:GO:0015797","description":"\"The directed movement of mannitol across a membrane. Mannitol is the alditol derived from D-mannose by reduction of the aldehyde group.\" [GOC:ai]","metadata":null},{"id":"45bc0553a62b4de08098ed36618d1250","type":"GO_TERM","name":"mannitol transmembrane transporter activity","canonical_id":"go:GO:0015575","description":"\"Enables the transfer of mannitol from one side of a membrane to the other. Mannitol is the alditol derived from D-mannose by reduction of the aldehyde group.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"940d157244dc41e1b8f611fee5355eec","type":"GO_TERM","name":"mannitol-1-phosphatase activity","canonical_id":"go:GO:0050084","description":"\"Catalysis of the reaction: D-mannitol 1-phosphate + H2O = D-mannitol + 2 H+ + phosphate.\" [EC:3.1.3.22, RHEA:19537]","metadata":null},{"id":"ec3facf6119b40628cda2792921408a8","type":"GO_TERM","name":"mannitol-1-phosphate 5-dehydrogenase activity","canonical_id":"go:GO:0008926","description":"\"Catalysis of the reaction: D-mannitol 1-phosphate + NAD+ = D-fructose 6-phosphate + NADH + H+.\" [EC:1.1.1.17]","metadata":null},{"id":"65776dac93274f6ebf61648d0913c606","type":"GO_TERM","name":"mannogen biosynthetic process","canonical_id":"go:GO:0106304","description":"\"The chemical reactions and pathways resulting in the formation of mannogen, a mannose-containing polysaccharide that is a major energy reserve in Leishmania.\" [PMID:16766650, PMID:31513773, PMID:31662278]","metadata":null},{"id":"297768e97a974de8adfe7046283b5de2","type":"GO_TERM","name":"mannogen catabolic process","canonical_id":"go:GO:0106305","description":"\"The chemical reactions and pathways resulting in the breakdown of mannogen, a mannose-containing polysaccharide that is a major energy reserve in Leishmania.\" [PMID:12902334, PMID:31513773, PMID:31662278]","metadata":null},{"id":"464d06d193564d65bbe2ebddfc2135a8","type":"GO_TERM","name":"mannokinase activity","canonical_id":"go:GO:0019158","description":"\"Catalysis of the reaction: ATP + D-mannose = ADP + D-mannose 6-phosphate.\" [EC:2.7.1.7]","metadata":null},{"id":"1ab08ab66db14f979b6c79e7b54b3ea7","type":"GO_TERM","name":"mannonate dehydratase activity","canonical_id":"go:GO:0008927","description":"\"Catalysis of the reaction: D-mannonate = 2-dehydro-3-deoxy-D-gluconate + H2O.\" [EC:4.2.1.8, RHEA:20097]","metadata":null},{"id":"211c21b425924aca87557a2926289578","type":"GO_TERM","name":"mannosamine biosynthetic process","canonical_id":"go:GO:0046347","description":"\"The chemical reactions and pathways resulting in the formation of mannosomine, 2-amino-2-deoxymannose; the D-isomer is a constituent of neuraminic acids as well as mucolipids and mucoproteins.\" [GOC:curators]","metadata":null},{"id":"aa40a55c8b68463b960aa3886e753d0b","type":"GO_TERM","name":"mannosamine catabolic process","canonical_id":"go:GO:0046346","description":"\"The chemical reactions and pathways resulting in the breakdown of mannosomine, 2-amino-2-deoxymannose; the D-isomer is a constituent of neuraminic acids as well as mucolipids and mucoproteins.\" [GOC:curators]","metadata":null},{"id":"bd991d733f134f60bbfa8ac156c5a6d1","type":"GO_TERM","name":"mannose biosynthetic process","canonical_id":"go:GO:0019307","description":"\"The chemical reactions and pathways resulting in the formation of mannose, the aldohexose manno-hexose, the C-2 epimer of glucose.\" [GOC:ai]","metadata":null},{"id":"e2079982388c40988dd674efaf23f828","type":"GO_TERM","name":"mannose catabolic process","canonical_id":"go:GO:0019309","description":"\"The chemical reactions and pathways resulting in the breakdown of mannose, the aldohexose manno-hexose, the C-2 epimer of glucose.\" [GOC:ai]","metadata":null},{"id":"d1d4ccf585914f5ebf6d9143ec3a8b2a","type":"GO_TERM","name":"mannose isomerase activity","canonical_id":"go:GO:0050089","description":"\"Catalysis of the reaction: D-mannose = D-fructose.\" [RHEA:22604]","metadata":null},{"id":"6a5ccebd76444d7db53762221de8b7e4","type":"GO_TERM","name":"mannose metabolic process","canonical_id":"go:GO:0006013","description":"\"The chemical reactions and pathways involving mannose, the aldohexose manno-hexose, the C-2 epimer of glucose. The D-(+)-form is widely distributed in mannans and hemicelluloses and is of major importance in the core oligosaccharide of N-linked oligosaccharides of glycoproteins.\" [ISBN:0198506732]","metadata":null},{"id":"e953f9f5ca874a06a14414dff61f95fc","type":"GO_TERM","name":"mannose to fructose-6-phosphate catabolic process","canonical_id":"go:GO:0061611","description":"\"The chemical reactions and pathways in which mannose, the aldohexose manno-hexose, is converted to fructose-6-phosphate.\" [GOC:dph, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"af1e2b81e4034e6090dfc3cfecf22ea5","type":"GO_TERM","name":"mannose transmembrane transport","canonical_id":"go:GO:0015761","description":"\"The process in which mannose is transported across a lipid bilayer, from one side of a membrane to the other. Mannose is the aldohexose manno-hexose, the C-2 epimer of glucose. The D-(+)-form is widely distributed in mannans and hemicelluloses and is of major importance in the core oligosaccharide of N-linked oligosaccharides of glycoproteins.\" [GOC:ai]","metadata":null},{"id":"050867433c3d49d7ae054aba77a0ae4c","type":"GO_TERM","name":"mannose transmembrane transporter activity","canonical_id":"go:GO:0015578","description":"\"Enables the transfer of mannose from one side of a membrane to the other. Mannose is the aldohexose manno-hexose, the C-2 epimer of glucose. The D-(+)-form is widely distributed in mannans and hemicelluloses and is of major importance in the core oligosaccharide of N-linked oligosaccharides of glycoproteins.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"099c9de500414facb0e1177a52fa1f42","type":"GO_TERM","name":"mannose trimming involved in glycoprotein ERAD pathway","canonical_id":"go:GO:1904382","description":"\"The removal of one or more alpha 1,2-linked mannose residues from a mannosylated protein that occurs as part of glycoprotein ER-associated glycoprotein degradation (gpERAD).\" [GO_REF:0000060, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24519966]","metadata":null},{"id":"d136305649bb4cf095b80a3b88d165c1","type":"GO_TERM","name":"mannose-1-phosphate guanylyltransferase (GDP) activity","canonical_id":"go:GO:0008928","description":"\"Catalysis of the reaction: alpha-D-mannose 1-phosphate + GDP + H+ = GDP-alpha-D-mannose + phosphate.\" [RHEA:12905]","metadata":null},{"id":"4c9b2d614cf643c98b265a621f19a017","type":"GO_TERM","name":"mannose-1-phosphate guanylyltransferase (GTP) activity","canonical_id":"go:GO:0004475","description":"\"Catalysis of the reaction: alpha-D-mannose 1-phosphate + GTP = diphosphate + GDP-alpha-D-mannose.\" [RHEA:15229]","metadata":null},{"id":"7c4e0001447644c0902cc9d2a1fa61c2","type":"GO_TERM","name":"mannose-6-phosphate 6-reductase activity","canonical_id":"go:GO:0050088","description":"\"Catalysis of the reaction: D-mannitol 1-phosphate + NADP+ = D-mannose 6-phosphate + 3 H+ + NADPH.\" [EC:1.1.1.224, RHEA:14925]","metadata":null},{"id":"adef6da48e0d4763aae6e1fb9025d9c7","type":"GO_TERM","name":"mannose-6-phosphate isomerase activity","canonical_id":"go:GO:0004476","description":"\"Catalysis of the reaction: D-mannose 6-phosphate = D-fructose 6-phosphate.\" [RHEA:12356]","metadata":null},{"id":"4b912cce642a4523ab13e9219536b966","type":"GO_TERM","name":"mannose-ethanolamine phosphotransferase activity","canonical_id":"go:GO:0051377","description":"\"Catalysis of the transfer of ethanolamine phosphate to a mannose residue in the GPI lipid precursor.\" [PMID:15632136]","metadata":null},{"id":"6ba89274afa44f4fbc01c5d077598bf4","type":"GO_TERM","name":"mannose-specific flocculation","canonical_id":"go:GO:0036350","description":"\"The non-sexual aggregation of single-celled organisms mediated by the binding of cell wall proteins on one cell to mannose residues on the other.\" [GOC:vw, PMID:9851992]","metadata":null},{"id":"d9fbc35309be47ce9074803605328e0f","type":"GO_TERM","name":"mannose:proton symporter activity","canonical_id":"go:GO:0055053","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: mannose + H+ = mannose + H+.\" [GOC:ct]","metadata":null},{"id":"d83269f92f7f497393c1f0d181f8591a","type":"GO_TERM","name":"mannose:sodium symporter activity","canonical_id":"go:GO:0140929","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: D-mannose(out) + Na+(out) = D-mannose(in) + Na+(in).\" [PMID:22212718, PMID:23451068, PMID:24573086]","metadata":null},{"id":"6c4cd6ed0ada4b1c8c4b6b4114bba130","type":"GO_TERM","name":"mannosidase activity","canonical_id":"go:GO:0015923","description":"\"Catalysis of the hydrolysis of mannosyl compounds, substances containing a group derived from a cyclic form of mannose or a mannose derivative.\" [GOC:ai]","metadata":null},{"id":"79c686106b5b48a4b3053d1709c843f6","type":"GO_TERM","name":"mannoside alpha-1,4-mannosidase activity","canonical_id":"go:GO:0052766","description":"\"Catalysis of the hydrolysis of the alpha-(1->4) linkage of the terminal, non-reducing alpha-D-mannose residues in alpha-D-mannosides.\" [GOC:mengo_curators, PMID:20081828]","metadata":null},{"id":"efb0097c663f4ad68cb170a188b7523e","type":"GO_TERM","name":"mannosome","canonical_id":"go:GO:0042580","description":"\"A specialised tubular organelle, assembled in hexagonal bundles within an external membrane. Mannosomes are specific to molluscs and are thought to be involved in a general stress reaction.\" [GOC:jl, PMID:11912051, PMID:9799531]","metadata":null},{"id":"1fab527c7222497fab434cda9718d7a5","type":"GO_TERM","name":"mannosyl diphosphorylinositol ceramide metabolic process","canonical_id":"go:GO:0006676","description":"\"The chemical reactions and pathways involving mannosyl diphosphorylinositol ceramide, any lipid with a phosphodiester bridge between an inositol residue and the ceramide group which contains two phosphoryl (-P(O)=) groups and a mannose derivative.\" [GOC:ai]","metadata":null},{"id":"b30ec854d25d4ac5905692f52280ca0e","type":"GO_TERM","name":"mannosyl-3-phosphoglycerate phosphatase activity","canonical_id":"go:GO:0050531","description":"\"Catalysis of the reaction: 2-(alpha-D-mannosyl)-3-phosphoglycerate + H2O = 2-(alpha-D-mannosyl)-D-glycerate + phosphate.\" [EC:3.1.3.70, RHEA:19309]","metadata":null},{"id":"69ddb21dd528466c87d7b16119fff039","type":"GO_TERM","name":"mannosyl-3-phosphoglycerate synthase activity","canonical_id":"go:GO:0050504","description":"\"Catalysis of the reaction: 3-phospho-D-glycerate + GDP-alpha-D-mannose = 2-(alpha-D-mannosyl)-3-phosphoglycerate + GDP + H+.\" [EC:2.4.1.217, RHEA:13537]","metadata":null},{"id":"f9958c6b1b984702b59362800afd9db1","type":"GO_TERM","name":"mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activity","canonical_id":"go:GO:0033925","description":"\"Catalysis of the endohydrolysis of the N,N'-diacetylchitobiosyl unit in high-mannose glycopeptides and glycoproteins containing the -[Man(GlcNAc)2]Asn-structure. One N-acetyl-D-glucosamine residue remains attached to the protein; the rest of the oligosaccharide is released intact.\" [EC:3.2.1.96]","metadata":null},{"id":"71bd01c775804cc38e2eeae4a8ac9ddd","type":"GO_TERM","name":"mannosyl-inositol phosphorylceramide biosynthetic process","canonical_id":"go:GO:0051999","description":"\"The chemical reactions and pathways resulting in the formation of mannosyl-inositol phosphorylceramide, any lipid with a phosphodiester bridge between an inositol residue and the ceramide group which contains a phosphoryl (-P(O)=) groups and a mannose derivative.\" [PMID:20388730]","metadata":null},{"id":"12decbbbc24d449284b3cf2e200d10b1","type":"GO_TERM","name":"mannosyl-inositol phosphorylceramide metabolic process","canonical_id":"go:GO:0006675","description":"\"The chemical reactions and pathways involving mannosyl-inositol phosphorylceramide, any lipid with a phosphodiester bridge between an inositol residue and the ceramide group which contains a phosphoryl (-P(O)=) groups and a mannose derivative.\" [GOC:ai]","metadata":null},{"id":"e41380fe81aa46aca25ff0762a6dcd7c","type":"GO_TERM","name":"mannosyl-inositol phosphorylceramide phospholipase activity","canonical_id":"go:GO:0052714","description":"\"Catalysis of the reaction: mannosyl-inositol phosphorylceramide + H2O = C26-phytoceramide + mannosylphosphorylinositol.\" [GOC:ai]","metadata":null},{"id":"3e03c93136ad41328fe56ae998ced5db","type":"GO_TERM","name":"mannosyl-oligosaccharide 1,2-alpha-mannosidase activity","canonical_id":"go:GO:0004571","description":"\"Catalysis of the hydrolysis of the terminal (1->2)-linked alpha-D-mannose residues in an oligo-mannose oligosaccharide.\" [GOC:bf, PMID:25092655]","metadata":null},{"id":"af9565985e044c20a6204b1473deaf6f","type":"GO_TERM","name":"mannosyl-oligosaccharide 1,2-alpha-mannosidase complex","canonical_id":"go:GO:0106055","description":"\"A protein complex capable of catalysing the hydrolysis of the terminal (1->2)-linked alpha-D-mannose residues in an oligo-mannose oligosaccharide.\" [GOC:bhm, PMID:21700223]","metadata":null},{"id":"a0a19964058442ad91847b3ce9ae251e","type":"GO_TERM","name":"mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase activity","canonical_id":"go:GO:0004572","description":"\"Catalysis of the hydrolysis of the terminal (1->3)- and (1->6)-linked alpha-D-mannose residues in the mannosyl-oligosaccharide Man(5)(GlcNAc)(3).\" [EC:3.2.1.114]","metadata":null},{"id":"f718efadfa614886bf3478167954ce9c","type":"GO_TERM","name":"mannosyl-oligosaccharide 1,3-alpha-mannosidase activity","canonical_id":"go:GO:0052768","description":"\"Catalysis of the hydrolysis of the alpha-(1->3) bonds of alpha-D-mannose residues in mannosyl-oligosaccharide.\" [GOC:mengo_curators, PMID:1849817, PMID:2338081]","metadata":null},{"id":"fc2814fa2e4541fa95c1226d6801264c","type":"GO_TERM","name":"mannosyl-oligosaccharide 1,6-alpha-mannosidase activity","canonical_id":"go:GO:0052767","description":"\"Catalysis of the hydrolysis of the alpha-(1->6) bonds of alpha-D-mannose residues in mannosyl-oligosaccharide.\" [GOC:mengo_curators, PMID:1849817, PMID:2338081]","metadata":null},{"id":"3f675d32ff76448a8a06bb490dc8098d","type":"GO_TERM","name":"mannosyl-oligosaccharide mannosidase activity","canonical_id":"go:GO:0015924","description":"\"Catalysis of the hydrolysis of the terminal alpha-D-mannose residues in oligo-mannose oligosaccharides.\" [GOC:ai]","metadata":null},{"id":"79a43768629e4a4aa1b6bdb8a6723d98","type":"GO_TERM","name":"mannosylfructose-phosphate synthase activity","canonical_id":"go:GO:0103011","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose + beta-D-fructofuranose 6-phosphate = mannosylfructose-phosphate + GDP.\" [EC:2.4.1.246, GOC:pz]","metadata":null},{"id":"797f964d9656480abefdc43b7a1f88d2","type":"GO_TERM","name":"mannosylglycerate biosynthetic process","canonical_id":"go:GO:0051479","description":"\"The chemical reactions and pathways resulting in the formation of mannosylglycerate, a very common compatible solute in thermophilic and hyperthermophilic organisms.\" [GOC:ai]","metadata":null},{"id":"2e33efd1cf9b41319af624e54e06f5e6","type":"GO_TERM","name":"mannosylglycerate hydrolase activity","canonical_id":"go:GO:0102546","description":"\"Catalysis of the reaction: (2R)-2-O-(alpha-D-mannosyl)-glycerate + H2O = (R)-glycerate + D-mannose.\" [RHEA:58456]","metadata":null},{"id":"0287c7dfd2b744b8b648df31f7fd43a3","type":"GO_TERM","name":"mannosylglycerate metabolic process","canonical_id":"go:GO:0051478","description":"\"The chemical reactions and pathways involving mannosylglycerate, a very common compatible solute in thermophilic and hyperthermophilic organisms.\" [GOC:ai, PMID:11562374]","metadata":null},{"id":"4d73ab126f5f45a1b413f9474ee79ef6","type":"GO_TERM","name":"mannosylglycerate synthase activity","canonical_id":"go:GO:0102921","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose + D-glycerate = H+ + 2-(alpha-D-mannosyl)-D-glycerate + GDP.\" [EC:2.4.1.269, GOC:pz]","metadata":null},{"id":"3beea322a1524e5985d33fccb9ceb8b7","type":"GO_TERM","name":"mannosylglycerate transmembrane transporter activity","canonical_id":"go:GO:0051477","description":"\"Enables the transfer of a mannosylglycerate from one side of a membrane to the other.\" [GOC:ai, PMID:15034926]","metadata":null},{"id":"f72a0d2d770e40a88d72328d6e6d9928","type":"GO_TERM","name":"mannosylglycoprotein endo-beta-mannosidase activity","canonical_id":"go:GO:0033947","description":"\"Catalysis of the hydrolysis of the alpha-D-mannosyl-(1->6)-beta-D-mannosyl-(1->4)-beta-D-N-acetylglucosaminyl-(1->4)-beta-D-N-acetylglucosaminyl sequence of glycoprotein to alpha-D-mannosyl-(1->6)-D-mannose and beta-D-N-acetylglucosaminyl-(1->4)-beta-D-N-acetylglucosaminyl sequences.\" [EC:3.2.1.152]","metadata":null},{"id":"19636e12a0fe4200a0654dec3d281c4d","type":"GO_TERM","name":"mannosylphosphate transferase activity","canonical_id":"go:GO:0000031","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose + n {[alpha-D-Man-(1->2)-alpha-D-Man-(1->2)]-alpha-D-Man-(1->6)}60-(Man9GlcNAc2-[protein] = phosphorylated {[alpha-D-Man-(1->2)-alpha-D-Man-(1->2)]-alpha-D-Man-(1->6)}60-(Man9GlcNAc2-[protein] + n GMP + n H+ or GDP-alpha-D-mannose + alpha-D-Man-(1->3)-alpha-D-Man-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-3-O-(Ser/Thr)-[protein] = alpha-D-Man-(1->3)-alpha-D-Man-(1->3)-[alpha-D-Man-6P-]-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-3-O-(Ser/Thr)-[protein] + GMP + H+.\" [MetaCyc:RXN-22693, MetaCyc:RXN-22694]","metadata":null},{"id":"6c0eb1b14322470fa1c819516f1db52a","type":"GO_TERM","name":"mannosyltransferase activity","canonical_id":"go:GO:0000030","description":"\"Catalysis of the transfer of a mannosyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [GOC:ai, GOC:cjm]","metadata":null},{"id":"1d2139f98a23440ab84489dbb0ba3494","type":"GO_TERM","name":"mannosyltransferase complex","canonical_id":"go:GO:0031501","description":"\"A complex that possesses mannosyltransferase activity.\" [GOC:mah]","metadata":null},{"id":"40ab556c00f04593813aea7d500aa388","type":"GO_TERM","name":"mannotetraose 2-alpha-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047222","description":"\"Catalysis of the reaction: 1,3-alpha-D-mannosyl-1,2-alpha-D-mannosyl-1,2-alpha-D-mannosyl-D-mannose + UDP-N-acetyl-D-glucosamine = 1,3-alpha-D-mannosyl-1,2-(N-acetyl-alpha-D-glucosaminyl-alpha-D-mannosyl)-1,2-alpha-D-mannosyl-D-mannose + UDP.\" [EC:2.4.1.138, MetaCyc:2.4.1.138-RXN]","metadata":null},{"id":"b26805972e204eb59e1f68451fa8e54f","type":"GO_TERM","name":"mannotriose transport","canonical_id":"go:GO:2001095","description":"\"The directed movement of a mannotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"555d38a6c39d484f80525cfe1ecdeac9","type":"GO_TERM","name":"mannuronate reductase activity","canonical_id":"go:GO:0050090","description":"\"Catalysis of the reaction: D-mannonate + NAD(P)+ = D-mannuronate + NAD(P)H + H+.\" [EC:1.1.1.131, MetaCyc:MANNURONATE-REDUCTASE-RXN]","metadata":null},{"id":"01ee1fe420c84eeaaacce30e94451bb7","type":"GO_TERM","name":"manoyl oxide synthase activity","canonical_id":"go:GO:0062206","description":"\"Catalysis of the reaction: 8-hydroxycopalyl diphosphate = (13R)-manoyl oxide + diphosphate.\" [PMID:24990389, RHEA:54516]","metadata":null},{"id":"b9faae69f9a0475f8d5318bcaaa80df5","type":"DISEASE","name":"mantle cell lymphoma","canonical_id":"mondo:0018876","description":null,"metadata":null},{"id":"f437b7f2e0474f5fbd7205c52117688a","type":"DRUG","name":"maprotiline","canonical_id":"gtopdb:2402","description":null,"metadata":null},{"id":"364442fcb2e14126a0ea5c379e8016e0","type":"COMBINATION_TREATMENT","name":"maprotiline + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-e7d932edc3cb7ee1","description":null,"metadata":null},{"id":"9db253e6c33a4ccfb98874deee3de189","type":"DRUG","name":"maraviroc","canonical_id":"gtopdb:806","description":null,"metadata":null},{"id":"6f212e7472014987b7de925d8e4b8a22","type":"DRUG","name":"maraviroc","canonical_id":"chembl:CHEMBL256907","description":null,"metadata":null},{"id":"133163e50596420f964906781a759efe","type":"COMBINATION_TREATMENT","name":"maraviroc + plerixafor","canonical_id":"ctgov_combo:ctgov-combo-4b5e4811bea19171","description":null,"metadata":null},{"id":"fe72e1393fae48d28472b55166be482e","type":"COMBINATION_TREATMENT","name":"maraviroc + vorinostat","canonical_id":"ctgov_combo:ctgov-combo-ff012b9b74dfedec","description":null,"metadata":null},{"id":"0bd3b71b53a74d1ba51aea633a312ec8","type":"DRUG","name":"margetuximab","canonical_id":"gtopdb:8686","description":null,"metadata":null},{"id":"4082cece66074db28d1412cdddcea2d5","type":"DRUG","name":"margetuximab","canonical_id":"chembl:CHEMBL2364649","description":null,"metadata":null},{"id":"510d52e241b44ece83448f19af30e526","type":"COMBINATION_TREATMENT","name":"margetuximab + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-379d7f7ab8d00670","description":null,"metadata":null},{"id":"a7a8e5402b0f4448bef87dca426bf5ff","type":"GO_TERM","name":"marginal zone B cell differentiation","canonical_id":"go:GO:0002315","description":"\"The process in which a B cell in the spleen acquires the specialized features of a marginal zone B cell. Marginal zone B cells are localized in a distinct anatomical region of the spleen that represents the major antigen-filtering and scavenging area (by specialized macrophages resident there). It appears that they are preselected to express a BCR repertoire similar to B-1 B cells, biased toward bacterial cell wall constituents and senescent self-components (such as oxidized LDL).\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"dec02537721e40318aca36f98b1f4136","type":"DISEASE","name":"marginal zone lymphoma","canonical_id":"mondo:0017604","description":null,"metadata":null},{"id":"04e86942ba38466986a754e90d2d22fc","type":"GO_TERM","name":"marneral synthase activity","canonical_id":"go:GO:0034074","description":"\"Catalysis of the reaction: (S)-2,3-epoxysqualene = marneral.\" [PMID:16425307, PMID:18033581, RHEA:31875]","metadata":null},{"id":"b47824b1e44b41b48ae9ecdcf6baa572","type":"GO_TERM","name":"masculinization of hermaphrodite soma","canonical_id":"go:GO:0042003","description":"\"Promotion of male sex and sexual phenotypes in the hermaphroditic nematode soma. An example of this is found in Caenorhabditis elegans.\" [GOC:ems]","metadata":null},{"id":"7c70fee39cb44f1ab308a9bc417bde01","type":"GO_TERM","name":"masculinization of hermaphroditic germ-line","canonical_id":"go:GO:0042006","description":"\"The determination of male sex and sexual phenotype in the germ-line of the hermaphrodite. An example of this is found in Caenorhabditis elegans.\" [GOC:ems]","metadata":null},{"id":"5add3a5f1cee4d9cb0f8b122803474e7","type":"DRUG","name":"masoprocol","canonical_id":"mesh:D009637","description":null,"metadata":null},{"id":"83b0a83d6367415a80985f9418f535ff","type":"GO_TERM","name":"mast cell activation","canonical_id":"go:GO:0045576","description":"\"The change in morphology and behavior of a mast cell resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the mast cell has specifically bound via IgE bound to Fc-epsilonRI receptors.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"8192bc4eb36e4f1ba6f0724b5b92f8fb","type":"GO_TERM","name":"mast cell activation involved in immune response","canonical_id":"go:GO:0002279","description":"\"The change in morphology and behavior of a mast cell resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the mast cell has specifically bound via IgE bound to Fc-epsilonRI receptors, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d2fe17cda41a42838c677aae560d734a","type":"GO_TERM","name":"mast cell apoptotic process","canonical_id":"go:GO:0033024","description":"\"Any apoptotic process in a mast cell, a cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation.\" [CL:0000097, GOC:add, GOC:mtg_apoptosis, PMID:11292031, PMID:12360215, PMID:16605130]","metadata":null},{"id":"0562d23ae56c4773a66c09ee3fece3cb","type":"GO_TERM","name":"mast cell chemotaxis","canonical_id":"go:GO:0002551","description":"\"The movement of a mast cell in response to an external stimulus.\" [GOC:add, PMID:11292027, PMID:12789214, PMID:16448392]","metadata":null},{"id":"bcdc2a05b457484abefbfc40d618f16a","type":"GO_TERM","name":"mast cell cytokine production","canonical_id":"go:GO:0032762","description":"\"Any process that contributes to cytokine production by a mast cell.\" [GOC:mah]","metadata":null},{"id":"637f75d82cfd4c61b0b2da388c873443","type":"GO_TERM","name":"mast cell degranulation","canonical_id":"go:GO:0043303","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as histamine, serotonin, and neutral proteases by a mast cell.\" [ISBN:0781735149]","metadata":null},{"id":"ec60ba58a96543f6b4e13098538e42ab","type":"GO_TERM","name":"mast cell differentiation","canonical_id":"go:GO:0060374","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a mast cell. A mast cell is a cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"070d3f53377c46ac856ddc24e217121c","type":"GO_TERM","name":"mast cell granule","canonical_id":"go:GO:0042629","description":"\"Coarse, bluish-black staining cytoplasmic granules, bounded by a plasma membrane and found in mast cells and basophils. Contents include histamine, heparin, chondroitin sulfates, chymase and tryptase.\" [GOC:jl, PMID:12360215]","metadata":null},{"id":"5036548101054483b25e8ee358785d98","type":"GO_TERM","name":"mast cell homeostasis","canonical_id":"go:GO:0033023","description":"\"The process of regulating the proliferation and elimination of mast cells such that the total number of mast cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:add, PMID:11292031]","metadata":null},{"id":"d21139e0391b433fa32e557b724a0e35","type":"DISEASE","name":"mast cell leukemia","canonical_id":"mondo:0020334","description":null,"metadata":null},{"id":"6efcdee1ac3d4818a92f22b7aaefde7f","type":"GO_TERM","name":"mast cell mediated immunity","canonical_id":"go:GO:0002448","description":"\"Any process involved in the carrying out of an immune response by a mast cell.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"f8f09e1260574f89a4b8934bc86c1aa4","type":"GO_TERM","name":"mast cell migration","canonical_id":"go:GO:0097531","description":"\"The movement of a mast cell within or between different tissues and organs of the body.\" [GOC:cvs, PMID:24152847]","metadata":null},{"id":"3945837314264bf3bd5d258c5546859c","type":"GO_TERM","name":"mast cell proliferation","canonical_id":"go:GO:0070662","description":"\"The expansion of a mast cell population by cell division.\" [GOC:add]","metadata":null},{"id":"e62d2e7a5c9348fda499846aa90d56d9","type":"GO_TERM","name":"mast cell secretagogue receptor activity","canonical_id":"go:GO:1990595","description":"\"Combining with basic secretagogues to initiate pseudo-allergic reactions in mast cells.\" [GOC:sp, PMID:25517090]","metadata":null},{"id":"5eed7c6d863640799b262367fe97337b","type":"GO_TERM","name":"mast cell secretory granule organization","canonical_id":"go:GO:0033364","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a secretory granule in a mast cell. A secretory granule is a small subcellular vesicle, surrounded by a membrane, that is formed from the Golgi apparatus and contains a highly concentrated protein destined for secretion.\" [GOC:mah]","metadata":null},{"id":"2545b3ddd7f5478b90096c9537db7e90","type":"GO_TERM","name":"mastication","canonical_id":"go:GO:0071626","description":"\"The process of biting and mashing food with the teeth prior to swallowing.\" [GOC:gvg]","metadata":null},{"id":"f3b3c2469735467cac89c1a8d3d1e4c3","type":"GO_TERM","name":"mastigoneme","canonical_id":"go:GO:0097741","description":"\"A hair-like structure covering the flagella found in some algae (heterokonts and cryptophytes). It is approximately 15 nm in diameter, and usually consist of a tubular shaft that itself terminates in smaller hairs. It is composed of glycoproteins and, likely, carbohydrates. Mastigonemes may assist in locomotion by increasing the surface area of a flagellum.\" [GOC:cilia, PMID:943397, Wikipedia:Mastigoneme]","metadata":null},{"id":"c27a528a443c40af8d5da49172f4c3e0","type":"DISEASE","name":"mastocytosis","canonical_id":"mondo:0007950","description":null,"metadata":null},{"id":"df59cad703004f3398b4a999455f92cc","type":"GO_TERM","name":"maternal aggressive behavior","canonical_id":"go:GO:0002125","description":"\"Aggressive behavior of a female to protect her offspring from a threat.\" [GOC:hjd]","metadata":null},{"id":"be4f83f3db7841a9ad9ab0ef0816e614","type":"GO_TERM","name":"maternal behavior","canonical_id":"go:GO:0042711","description":"\"Female behaviors associated with the care and rearing of offspring.\" [GOC:curators]","metadata":null},{"id":"a84d76fd6af2421fb14010524a80dc37","type":"GO_TERM","name":"maternal determination of anterior/posterior axis, embryo","canonical_id":"go:GO:0008358","description":"\"The specification of the anterior/posterior axis of the embryo by gradients of maternally-transcribed gene products; exemplified in insects by the morphogens, bicoid and nanos.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"eee68db8f6224e25bf67d71b53274299","type":"GO_TERM","name":"maternal determination of dorsal/ventral axis, ovarian follicular epithelium, germ-line encoded","canonical_id":"go:GO:0008070","description":"\"Polarization of the ovarian follicle cells along the dorsal-ventral axis by a gene product encoded by cells of the germ line.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"a41597cc676846c3bc65d9a7fc16e753","type":"GO_TERM","name":"maternal determination of dorsal/ventral axis, ovarian follicular epithelium, soma encoded","canonical_id":"go:GO:0008071","description":"\"Polarization of the ovarian follicle cells along the dorsal-ventral axis by a gene product encoded by somatic cells. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"5c26af16ed2b4010bff4a393093dd872","type":"GO_TERM","name":"maternal mRNA clearance","canonical_id":"go:GO:0141065","description":"\"The chemical reactions and pathways resulting in the clearance of maternal mRNA transcripts from the zygote as part of the maternal-to-zygote transition in gene expression.\" [PMID:19204068, PMID:32558204]","metadata":null},{"id":"e95d3411aa98491cbcb1c94b727c9f7a","type":"GO_TERM","name":"maternal placenta development","canonical_id":"go:GO:0001893","description":"\"Maternally driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.\" [GOC:add, ISBN:068340007X]","metadata":null},{"id":"7b77f409a8b64a7ab52e5ce844e88d79","type":"GO_TERM","name":"maternal process involved in female pregnancy","canonical_id":"go:GO:0060135","description":"\"A reproductive process occurring in the mother that allows an embryo or fetus to develop within it.\" [GOC:dph]","metadata":null},{"id":"219ad2b600044d64aa4fbb07b6d1f5b9","type":"GO_TERM","name":"maternal process involved in parturition","canonical_id":"go:GO:0060137","description":"\"A reproductive process occurring in the mother that results in birth.\" [GOC:dph]","metadata":null},{"id":"8af3e88478094c41a8c03634d4cd50bc","type":"GO_TERM","name":"maternal specification of dorsal/ventral axis, oocyte, germ-line encoded","canonical_id":"go:GO:0007311","description":"\"Polarization of the oocyte along the dorsal-ventral axis, by a gene product encoded by cells of the germ line. An example of this is found in Drosophila melanogaster.\" [GOC:dph, GOC:mtg_sensu, GOC:tb, ISBN:0879694238]","metadata":null},{"id":"44059e7b7eeb486daa9aa090d6503c2c","type":"GO_TERM","name":"maternal specification of dorsal/ventral axis, oocyte, soma encoded","canonical_id":"go:GO:0007313","description":"\"Polarization of the oocyte along the dorsal-ventral axis, by a gene product encoded by somatic cells. An example of this is found in Drosophila melanogaster.\" [GOC:dph, GOC:mtg_sensu, GOC:tb, ISBN:0879694238]","metadata":null},{"id":"53e4efb6e38841d681a8a80687b0c5ed","type":"GO_TERM","name":"maternal-to-zygotic transition of gene expression","canonical_id":"go:GO:0160021","description":"\"Any process that modulates the frequency, rate or extent of gene expression by which developmental control passes from the maternal genome to the zygotic genome.\" [PMID:19204068, PMID:32558204]","metadata":null},{"id":"4447df65897c421d894d2136bb0edbf0","type":"DISEASE","name":"mathematical ability","canonical_id":"efo:0004875","description":null,"metadata":null},{"id":"ee270e26352842a2af441e40296cda7d","type":"GO_TERM","name":"mating","canonical_id":"go:GO:0007618","description":"\"The pairwise union of individuals for the purpose of sexual reproduction, ultimately resulting in the formation of zygotes.\" [GOC:jl, ISBN:0387520546]","metadata":null},{"id":"2cf1b0ea3d3c4fd9aed8d232cd19d510","type":"GO_TERM","name":"mating behavior","canonical_id":"go:GO:0007617","description":"\"The behavioral interactions between organisms for the purpose of mating, or sexual reproduction resulting in the formation of zygotes.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"7a6d92d4098f40b1b9b2d9c516fdb6a4","type":"GO_TERM","name":"mating behavior, sex discrimination","canonical_id":"go:GO:0048047","description":"\"The behavior of individuals for the purpose of discriminating between the sexes, for the purpose of finding a suitable mating partner.\" [GOC:jid, GOC:pr, PMID:12486700]","metadata":null},{"id":"992cec0bb62a44199883672061956d83","type":"GO_TERM","name":"mating pheromone activity","canonical_id":"go:GO:0000772","description":"\"The activity of binding to and activating specific cell surface receptors, thereby inducing a behavioral or physiological response(s) from a responding organism or cell that leads to the transfer or union of genetic material between organisms or cells. The mating pheromone can either be retained on the cell surface or secreted.\" [GOC:clt, GOC:elh]","metadata":null},{"id":"e7a1f2928d9849b3bb23f43be1825ae6","type":"GO_TERM","name":"mating pheromone secretion","canonical_id":"go:GO:0071834","description":"\"The regulated release of a mating pheromone, a peptide hormone that induces a behavioral or physiological response(s) from a responding organism or cell, that contributes to a process of sexual reproduction.\" [GOC:mah]","metadata":null},{"id":"e16d913f44224076909cad11f069e40d","type":"GO_TERM","name":"mating pheromone secretion involved in positive regulation of conjugation with cellular fusion","canonical_id":"go:GO:0071631","description":"\"The regulated release of a mating pheromone, a peptide hormone that induces a behavioral or physiological response(s) from a responding organism or cell, that positively regulates a conjugation process that results in the union of cellular and genetic information from compatible mating types.\" [GOC:elh, GOC:jh, GOC:mah]","metadata":null},{"id":"53ac1289faa34cba99a5008cb77992b1","type":"GO_TERM","name":"mating plug formation","canonical_id":"go:GO:0042628","description":"\"The deposition of a plug of sperm or other gelatinous material into the opening of the vulva by a male at the termination of copulation. Probably acts to prevent subsequent matings by other males.\" [GOC:jl, PMID:11267893]","metadata":null},{"id":"3202cf52f1594e029eef6e1d8426c2ec","type":"GO_TERM","name":"mating projection","canonical_id":"go:GO:0005937","description":"\"The projection formed by unicellular fungi in response to mating pheromone.\" [GOC:mcc]","metadata":null},{"id":"51f27d5f7c57487cadb75717498da614","type":"GO_TERM","name":"mating projection actin fusion focus","canonical_id":"go:GO:1990819","description":"\"A focus at the mating projection tip where the cell wall is degraded during cytogamy. Actin filaments form an aster-like structure from this location.\" [PMID:25825517]","metadata":null},{"id":"c71d4a246f3a46a0930b5601f000b56c","type":"GO_TERM","name":"mating projection actin fusion focus assembly","canonical_id":"go:GO:1904600","description":"\"The aggregation, arrangement and bonding together of a set of components to form an actin fusion focus.\" [GO_REF:0000079, GOC:TermGenie, PMID:25825517]","metadata":null},{"id":"664ebe4794744c5985459703a33034d5","type":"GO_TERM","name":"mating projection base","canonical_id":"go:GO:0001400","description":"\"The region where the mating projection meets the bulk of the cell, in unicellular fungi exposed to mating pheromone.\" [GOC:mcc]","metadata":null},{"id":"639446293fdf43fdaec281671cd4795a","type":"GO_TERM","name":"mating projection formation","canonical_id":"go:GO:0031382","description":"\"The aggregation, arrangement and bonding together of a set of components to form a cell projection in response to mating pheromone. This process is observed in unicellular fungi.\" [GOC:mah, PMID:14734532]","metadata":null},{"id":"75d5761df3e44d7c838b9b84fb261df9","type":"GO_TERM","name":"mating projection membrane","canonical_id":"go:GO:0070250","description":"\"The portion of the plasma membrane surrounding a mating projection, the projection formed by unicellular fungi in response to mating pheromone.\" [GOC:jp]","metadata":null},{"id":"4413fb768fea402eabe38c22b2e4b1e6","type":"GO_TERM","name":"mating projection septin band","canonical_id":"go:GO:0032162","description":"\"A septin band, i.e. a diffuse ring composed of a series of septin bars running parallel to the long axis of the cell, located at the neck of a shmoo (mating projection).\" [GOC:krc, GOC:mah, PMID:16151244]","metadata":null},{"id":"9cb0e08fcd6b4074810bb92b0aa0c1a0","type":"GO_TERM","name":"mating projection septin ring","canonical_id":"go:GO:0032175","description":"\"A septin ring, i.e. a ring-shaped structure composed of septins and septin-associated proteins, located at the neck of a shmoo (mating projection). The septin ring in the neck of a shmoo may act as a barrier to localize mating factors in the shmoo tip.\" [GOC:krc, GOC:mah, PMID:16151244]","metadata":null},{"id":"0b8d5bc80efb433f9ccd5cc94cedf63f","type":"GO_TERM","name":"mating projection tip","canonical_id":"go:GO:0043332","description":"\"The apex of the mating projection in unicellular fungi exposed to mating pheromone; site of polarized growth.\" [GOC:mcc]","metadata":null},{"id":"4c22012c274c4a40b34b6b5d2e4519b0","type":"GO_TERM","name":"mating projection tip cell wall disassembly","canonical_id":"go:GO:1904541","description":"\"Any fungal-type cell wall disassembly that is involved in conjugation with cellular fusion, where the cell wall is locally disassembled to enable conjugation with cellular fusion.\" [GO_REF:0000060, GOC:TermGenie, PMID:25825517]","metadata":null},{"id":"ae53875de67843edb7a6a782cee1fc9c","type":"GO_TERM","name":"mating projection tip membrane","canonical_id":"go:GO:0070867","description":"\"The portion of the plasma membrane surrounding a mating projection tip.\" [GOC:mah]","metadata":null},{"id":"ebfadc0fbc6648c8bd8cc6d167b48b35","type":"GO_TERM","name":"mating projection tip polarisome","canonical_id":"go:GO:0031563","description":"\"Protein complex that has a role in determining cell polarity, found at the tip of the mating projection in unicellular fungi exposed to mating pheromone.\" [PMID:14734532]","metadata":null},{"id":"bd24b3f09c824d4e85e776a3841c9676","type":"GO_TERM","name":"mating type determination","canonical_id":"go:GO:0007531","description":"\"Any process that establishes and transmits the specification of mating type upon an individual. Mating types are the equivalent in microorganisms of the sexes in higher organisms.\" [PMID:28916791, PMID:33313646, PMID:8274857, PMID:8785123]","metadata":null},{"id":"25f600de3f024059a1a97e62bf20ee23","type":"GO_TERM","name":"mating type switching","canonical_id":"go:GO:0007533","description":"\"The conversion of a single-cell organism from one mating type to another by the precise replacement of a DNA sequence at the expressed mating type locus with a copy of a sequence from a donor locus.\" [PMID:9928492]","metadata":null},{"id":"98d8300e82fa4a0885ea2489c7b5f874","type":"GO_TERM","name":"mating-type M-factor pheromone receptor activity","canonical_id":"go:GO:0036319","description":"\"Combining with the mating-type peptide pheromone M-factor and transmitting the signal across the membrane to initiate a change in cell activity. M-factor is a nine-membered oligopeptide that consists of tyrosyl, threonyl, prolyl, lysyl, valyl, prolyl, tyrosyl, methionyl and methyl S-farnesylcysteinate residues joined in sequence, and is a peptide pheromone released by Schizosaccharomyces pombe cells of the cellular mating type Minus.\" [GOC:al, PMID:7941744]","metadata":null},{"id":"d47850cb23aa49f5b00b9a0a299b30e0","type":"GO_TERM","name":"mating-type P-factor pheromone receptor activity","canonical_id":"go:GO:0036320","description":"\"Combining with the mating-type peptide pheromone P-factor and transmitting the signal across the membrane to initiate a change in cell activity. P-factor is a polypeptide of 23 residues, with the sequence Thr-Tyr-Ala-Asp-Phe-Leu-Arg-Ala-Tyr-Gln-Ser-Trp-Asn-Thr-Phe-Val-Asn-Pro-Asp-Arg-Pro-Asn-Leu, and is a peptide pheromone released by Schizosaccharomyces pombe cells of the cellular mating type Plus.\" [GOC:al, PMID:8314086]","metadata":null},{"id":"bf7d85db954e4d9c94f592d74a7041b5","type":"GO_TERM","name":"mating-type a-factor pheromone receptor activity","canonical_id":"go:GO:0004933","description":"\"Combining with the mating-type a-factor pheromone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"4647950df0514711911f6c0567b8773e","type":"GO_TERM","name":"mating-type alpha-factor pheromone receptor activity","canonical_id":"go:GO:0004934","description":"\"Combining with the mating-type alpha-factor pheromone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"341380bdf6c84a459bb7069127f1ead1","type":"GO_TERM","name":"mating-type factor pheromone receptor activity","canonical_id":"go:GO:0004932","description":"\"Combining with a mating-type factor pheromone to initiate a change in cell activity.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"48db7cb5c58147c7ab3406db57018955","type":"GO_TERM","name":"mating-type locus imprinting","canonical_id":"go:GO:0071515","description":"\"A genomic imprinting process in which a stable single-strand DNA lesion triggers programmed gene conversion at the mating-type locus, thereby restricting mating-type interconversion to one of the two sister chromatids during DNA replication.\" [GOC:mah, PMID:14765111, PMID:18723894]","metadata":null},{"id":"b7524903bbe3443a85d4213636559d2d","type":"GO_TERM","name":"mating-type region heterochromatin","canonical_id":"go:GO:0031934","description":"\"Heterochromatic regions of the chromosome found at silenced mating-type loci.\" [GOC:mah]","metadata":null},{"id":"32faf3ac5e3f4165a9e3cd918fcaf1c1","type":"GO_TERM","name":"matrilin complex","canonical_id":"go:GO:0120216","description":"\"A cartilage extracellular matrix complex that mediates interactions between major components of the extracellular matrix such as collagens and proteoglycans and contributes to their fibrillar network. Exists as an obligate homotrimer.\" [PMID:10367731, PMID:15075323, PMID:29310791, PMID:9699631]","metadata":null},{"id":"5e58b57d1fed4506a4607c2b26a879a0","type":"GO_TERM","name":"matrix metallopeptidase secretion","canonical_id":"go:GO:1990773","description":"\"The regulated release of matrix metallopeptidases, a family of zinc-dependent endopeptidases that can degrade extracellular matrix proteins and process other types of proteins.\" [PMID:8679543]","metadata":null},{"id":"fbe3669d53ab44ae9f9d7867ca38a745","type":"GO_TERM","name":"matrix side of mitochondrial inner membrane","canonical_id":"go:GO:0099617","description":"\"The leaflet of a mitochondrial inner membrane that faces the matrix, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"edbca3ae2f494b928f3c870bed338c47","type":"GO_TERM","name":"maturation of 2S rRNA","canonical_id":"go:GO:0000475","description":"\"Any process involved in the maturation of a precursor 2S ribosomal RNA (rRNA) molecule into a mature 2S rRNA molecule.\" [GOC:curators]","metadata":null},{"id":"d76b173f80a44e5f9f55c184ab43bc58","type":"GO_TERM","name":"maturation of 4.5S rRNA","canonical_id":"go:GO:0000476","description":"\"Any process involved in the maturation of a precursor 4.5S ribosomal RNA (rRNA) molecule into a mature 4.5S rRNA molecule.\" [GOC:curators]","metadata":null},{"id":"6f248217c303436094c8c0b1185b3057","type":"GO_TERM","name":"maturation of 5.8S rRNA","canonical_id":"go:GO:0000460","description":"\"Any process involved in the maturation of a precursor 5.8S ribosomal RNA (rRNA) molecule into a mature 5.8S rRNA molecule.\" [GOC:curators]","metadata":null},{"id":"81c8f52ed39842308e4b343510a7ebda","type":"GO_TERM","name":"maturation of 5.8S rRNA from tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000487","description":"\"Any process involved in the maturation of a precursor 5.8S ribosomal RNA (rRNA) molecule into a mature 5.8S rRNA molecule from the pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, the 8.8S rRNA, the 2S rRNA, and the Large Subunit (LSU) in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"418782b11be045f7837555e6dfcefce2","type":"GO_TERM","name":"maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000466","description":"\"Any process involved in the maturation of an rRNA molecule originally produced as part of a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.\" [GOC:curators, PMID:10690410]","metadata":null},{"id":"9afc466f81a74a6985c498894b1fbb84","type":"GO_TERM","name":"maturation of 5S rRNA","canonical_id":"go:GO:0000481","description":"\"Any process involved in the maturation of a precursor 5S ribosomal RNA (rRNA) molecule into a mature 5S rRNA molecule.\" [GOC:curators]","metadata":null},{"id":"944407d7c4244c2da47387fcbb1b0386","type":"GO_TERM","name":"maturation of 5S rRNA from tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000482","description":"\"Any process involved in the maturation of a precursor 5S ribosomal RNA (rRNA) molecule into a mature 5S rRNA molecule from the pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"f757064c32cd4c55a48e3bbbfece9c9a","type":"GO_TERM","name":"maturation of LSU-rRNA","canonical_id":"go:GO:0000470","description":"\"Any process involved in the maturation of a precursor Large SubUnit (LSU) ribosomal RNA (rRNA) molecule into a mature LSU-rRNA molecule.\" [GOC:curators]","metadata":null},{"id":"de6665582e7247e6ac6ea3f7abdd7df5","type":"GO_TERM","name":"maturation of LSU-rRNA from tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000473","description":"\"Any process involved in the maturation of a precursor Large SubUnit (LSU) ribosomal RNA (rRNA) molecule into a mature LSU-rRNA molecule from the pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, 5.8 S rRNA, 2S rRNA, and Large Subunit (LSU) in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"981df03acf8b43bb98dacf7f026ae38f","type":"GO_TERM","name":"maturation of LSU-rRNA from tetracistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 4.5S-rRNA, 5S-rRNA)","canonical_id":"go:GO:0000488","description":"\"Any process involved in the maturation of a precursor Large SubUnit (LSU) ribosomal RNA (rRNA) molecule into a mature LSU-rRNA molecule from the pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"c5147f94d5f540a2a0cbde40ae5209ed","type":"GO_TERM","name":"maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000463","description":"\"Any process involved in the maturation of a precursor Large SubUnit (LSU) ribosomal RNA (rRNA) molecule into a mature LSU-rRNA molecule from the pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, 5.8S rRNA, and Large Subunit (LSU) in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"dfa3c4b8746a48fda76e3b167680a781","type":"GO_TERM","name":"maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, LSU-rRNA,5S)","canonical_id":"go:GO:0002108","description":"\"Any process involved in the maturation of a precursor Large SubUnit (LSU) ribosomal RNA (rRNA) molecule into a mature LSU-rRNA molecule from the pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 5S rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"1dfbd227f00c43a486147cfee6943939","type":"GO_TERM","name":"maturation of SSU-rRNA","canonical_id":"go:GO:0030490","description":"\"Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule.\" [GOC:curators]","metadata":null},{"id":"33d9abf5510646b1998b4caaff6f80fa","type":"GO_TERM","name":"maturation of SSU-rRNA from tetracistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, 2S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000474","description":"\"Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule from the pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, 5.8 S rRNA, 2S rRNA, and Large Subunit (LSU) in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"00c119685402411b86e63a84c296e263","type":"GO_TERM","name":"maturation of SSU-rRNA from tetracistronic rRNA transcript (SSU-rRNA, LSU-rRNA, 4.5S-rRNA, 5S-rRNA)","canonical_id":"go:GO:0000489","description":"\"Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule from the pre-rRNA molecule originally produced as a tetracistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 4.5S rRNA, and the 5S rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"679c896542724408be7e107b9c006956","type":"GO_TERM","name":"maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)","canonical_id":"go:GO:0000462","description":"\"Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule from the pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, 5.8S rRNA, and the Large Subunit (LSU) in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"f8339e2b24264c5aaa643eba4537c2ac","type":"GO_TERM","name":"maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, LSU-rRNA,5S)","canonical_id":"go:GO:0002109","description":"\"Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule from the pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, Large Subunit (LSU) the 5S rRNA in that order from 5' to 3' along the primary transcript.\" [GOC:curators]","metadata":null},{"id":"e2f65e3c8ce14767bea530b71e212210","type":"GO_TERM","name":"mature B cell apoptotic process","canonical_id":"go:GO:0002901","description":"\"Any apoptotic process in a B cell that is mature, having left the bone marrow.\" [CL:0000785, GOC:add, GOC:mtg_apoptosis, ISBN:0781735149]","metadata":null},{"id":"b5f0abb0b92d4d04a1cdfd93521191da","type":"GO_TERM","name":"mature B cell differentiation","canonical_id":"go:GO:0002335","description":"\"The process in which transitional stage B cells acquire the specialized features of mature B cells in the spleen.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"7726135997be41e98b1f0a3a47c69d1a","type":"GO_TERM","name":"mature B cell differentiation involved in immune response","canonical_id":"go:GO:0002313","description":"\"The process in which a naive B cell acquires the specialized features of a mature or memory B cell during an immune response.\" [GOC:jal]","metadata":null},{"id":"bcbb3312283d4b6fad2c13df26da60a9","type":"DISEASE","name":"mature T-cell and NK-cell non-Hodgkin lymphoma","canonical_id":"mondo:0000430","description":null,"metadata":null},{"id":"87bb7f54b0ab4563a1d78f1a9256cda0","type":"GO_TERM","name":"mature chylomicron","canonical_id":"go:GO:0034359","description":"\"A chylomicron that contains apolipoprotein C2 (APOC2), a cofactor for lipoprotein lipase (LPL) activity, and has a mean diameter of 500 nm and density of 0.95g/ml. Mature chylomicron particles transport exogenous (dietary) lipids from the intestines to other body tissues, via the blood and lymph.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"136594b3eaef41ba9e3e41fcf668cf0d","type":"GO_TERM","name":"mature conventional dendritic cell differentiation","canonical_id":"go:GO:0097029","description":"\"The process in which antigen-activated dendritic cells acquire the specialized features of a mature conventional dendritic cell. Mature conventional dendritic cells upregulate the surface expression of MHC molecules, chemokine receptors and adhesion molecules, and increase the number of dendrites (cytoplasmic protrusions) in preparation for migration to lymphoid organs where they present antigen to T cells.\" [GOC:BHF, PMID:15845453]","metadata":null},{"id":"be228c70e8bd4abf835d54341637db59","type":"GO_TERM","name":"mature follicle stage","canonical_id":"go:GO:0048166","description":"\"The stage in oogenesis when the antrum is swollen with follicular fluid. The ovum is ready to erupt from the ovary and is arrested at metaphase of the second meiotic division.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"c7f393e20ca84835a4973ea2cd5b6b4d","type":"GO_TERM","name":"mature natural killer cell chemotaxis","canonical_id":"go:GO:0035782","description":"\"The directed movement of a mature natural killer cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis). A mature natural killer cell is a natural killer cell that is developmentally mature and expresses a variety of inhibitory and activating receptors that recognize MHC class and other stress related molecules.\" [CL:0000824, GOC:BHF]","metadata":null},{"id":"5d969ffd4956460ea688d39bc763d657","type":"DISEASE","name":"maturity-onset diabetes of the young","canonical_id":"mondo:0018911","description":null,"metadata":null},{"id":"fb7c7f7b8a254f639afdd122f2544629","type":"DISEASE","name":"maturity-onset diabetes of the young type 13","canonical_id":"mondo:0014589","description":null,"metadata":null},{"id":"3f10dc22ae264f1188c1a6a381dd5243","type":"DISEASE","name":"maturity-onset diabetes of the young, type 12","canonical_id":"mondo:0978299","description":null,"metadata":null},{"id":"faabfdafe01f4a1d92a274c564f58621","type":"DRUG","name":"mavorixafor","canonical_id":"gtopdb:8580","description":null,"metadata":null},{"id":"2d09ae3d169a476ba78f15fc174cc037","type":"DRUG","name":"mavorixafor","canonical_id":"chembl:CHEMBL518924","description":null,"metadata":null},{"id":"e01b2914ae0747cea84ef7ce31ef4ddc","type":"DRUG","name":"mazindol","canonical_id":"gtopdb:4797","description":null,"metadata":null},{"id":"b40cc79e6b7b452fb01b5f28332b78e8","type":"DRUG","name":"mazindol","canonical_id":"chembl:CHEMBL781","description":null,"metadata":null},{"id":"c9bb2b03e09448b4872dbedbc862270a","type":"DRUG","name":"mebanazine","canonical_id":"mesh:C004343","description":null,"metadata":null},{"id":"98c6b89360824847ad8fb7fd38900516","type":"DRUG","name":"mebeverine","canonical_id":"mesh:C005096","description":null,"metadata":null},{"id":"20ef2ce43dfb47a195a4767bc60751b8","type":"DRUG","name":"mecamylamine","canonical_id":"gtopdb:3990","description":null,"metadata":null},{"id":"ec13dba455f94ac5bca4540fe0141459","type":"DRUG","name":"mecamylamine","canonical_id":"mesh:D008464","description":null,"metadata":null},{"id":"154d521572d34f03ab1f9fd055c0006c","type":"COMBINATION_TREATMENT","name":"mecamylamine + varenicline","canonical_id":"ctgov_combo:ctgov-combo-2a8eac06097da04b","description":null,"metadata":null},{"id":"2870af9b2c0f4fb3af126e907d4b01ae","type":"DRUG","name":"mecasermin","canonical_id":"mesh:C000604197","description":null,"metadata":null},{"id":"8a905c51e624444fbbdfed6bc8a8f24f","type":"GO_TERM","name":"mechanoreceptor activity","canonical_id":"go:GO:0140897","description":"\"Combining with a mechanical force and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction.\" [PMID:23907979, PMID:34666001]","metadata":null},{"id":"8a03aac45d0f4b748a7cc3a8e69d39e2","type":"GO_TERM","name":"mechanoreceptor differentiation","canonical_id":"go:GO:0042490","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mechanoreceptor, a cell specialized to transduce mechanical stimuli and relay that information centrally in the nervous system.\" [CL:0000199, GOC:jl]","metadata":null},{"id":"c6aee6a84fd942a6bae86f2d6a5a3e29","type":"GO_TERM","name":"mechanoreceptor differentiation involved in mechanosensory epithelium regeneration","canonical_id":"go:GO:0070656","description":"\"Differentiation of new mechanoreceptors to replace those lost or destroyed by injury.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"779489e7181e48a38eeb3b4e90873c57","type":"GO_TERM","name":"mechanosensitive monoatomic cation channel activity","canonical_id":"go:GO:0140135","description":"\"Enables the transmembrane transfer of a monoatomic cation by a channel that opens in response to a mechanical stress.\" [GOC:ha, PMID:22343900]","metadata":null},{"id":"fe74acd9abd34eb2846b7e6e70653238","type":"GO_TERM","name":"mechanosensitive monoatomic ion channel activity","canonical_id":"go:GO:0008381","description":"\"Enables the transmembrane transfer of an monoatomic ion by a channel that opens in response to a mechanical stress.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"149f690d82ea4fd89662e1a59bb7e3c4","type":"GO_TERM","name":"mechanosensitive potassium channel activity","canonical_id":"go:GO:0098782","description":"\"Enables the transmembrane transfer of a potassium ion by a channel that opens in response to a mechanical stress.\" [PMID:22282805, PMID:25471887, PMID:25500157]","metadata":null},{"id":"c49ded89575c46219f2b7d9152aa7f9d","type":"GO_TERM","name":"mechanosensitive voltage-gated sodium channel activity","canonical_id":"go:GO:0101013","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel whose activity is modulated in response to mechanical stress. Response to mechanical stress and voltage gating together is different than the sum of individual responses. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [PMID:21041530, PMID:26838316]","metadata":null},{"id":"6124220e440242b8b61b9e66c3be3fcf","type":"GO_TERM","name":"mechanosensory behavior","canonical_id":"go:GO:0007638","description":"\"Behavior that is dependent upon the sensation of a mechanical stimulus.\" [GOC:curators]","metadata":null},{"id":"cdd0480ca68c4a56a73581e830f52ff0","type":"GO_TERM","name":"mechanosensory epithelium regeneration","canonical_id":"go:GO:0070655","description":"\"The regrowth of lost or destroyed mechanosensory epithelia.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"2dca0b442faa4f10b65f07a7f5c0f781","type":"GO_TERM","name":"mechanosensory lateral line system development","canonical_id":"go:GO:0048881","description":"\"The process whose specific outcome is the progression of the mechanosensory lateral line system over time, from its formation to the mature structure. The mechanosensory lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head and body of all fishes and most amphibians. The neuromasts are innervated by several lateral line nerves, which project primarily to the hindbrain. The mechanosensory lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance.\" [ISBN:0125296509]","metadata":null},{"id":"a4928a20cafc4802af149c62eb34322a","type":"DRUG","name":"meclocycline","canonical_id":"mesh:C100122","description":null,"metadata":null},{"id":"77d8380d5ae942f3ad2cb878d2acf1c4","type":"DRUG","name":"meclofenamic acid","canonical_id":"gtopdb:7219","description":null,"metadata":null},{"id":"e80cd3ff30014a8ba313114b38f7a16f","type":"DRUG","name":"meclozine","canonical_id":"mesh:D008468","description":null,"metadata":null},{"id":"1401890f95864a15a5cd56350c250edc","type":"GO_TERM","name":"medial cortex","canonical_id":"go:GO:0031097","description":"\"A medial cortical band overlaying the nucleus which acts as a landmark for contractile ring positioning and plays a role in cell cycle regulation.\" [GOC:vw, PMID:15572668, PMID:19474789]","metadata":null},{"id":"f52ae3879f8148faa5c5c1a2ca900aa2","type":"GO_TERM","name":"medial cortex septin ring","canonical_id":"go:GO:0036391","description":"\"A ring-shaped structure that forms at the medial cortex of a symmetrically dividing cell at the onset of cytokinesis; composed of members of the conserved family of filament forming proteins called septins as well as septin-associated proteins.\" [GOC:vw, PMID:16009555]","metadata":null},{"id":"e75634bf4b884ecd9318fda7283e0a16","type":"GO_TERM","name":"medial cortical node","canonical_id":"go:GO:0071341","description":"\"A component of the cell division site that contains the mid1, cdr2, wee1, klp8, and blt1 proteins, and is involved in contractile ring localization. Medial cortical node complexes appear as cortical dots in the middle of the cell during interphase, and function to recruit other ring components in early mitosis.\" [GOC:mah, GOC:vw, PMID:19474789, PMID:19959363]","metadata":null},{"id":"b26b851f9f014b71a2c6419800e0f8e0","type":"GO_TERM","name":"medial fin development","canonical_id":"go:GO:0033338","description":"\"The process whose specific outcome is the progression of a medial fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"3e114b3e984843b6bd9427bf3df05d42","type":"GO_TERM","name":"medial fin morphogenesis","canonical_id":"go:GO:0035141","description":"\"The process in which the anatomical structures of the medial fin are generated and organized. A medial fin is an unpaired fin of fish, usually located dorsomedially or ventromedially and primarily used for stability while swimming.\" [GOC:dgh]","metadata":null},{"id":"ee76ebb2cba443ab93d935247fcc2fae","type":"GO_TERM","name":"medial ganglionic eminence cell proliferation","canonical_id":"go:GO:0022020","description":"\"The multiplication or reproduction of medial ganglionic eminence cells, resulting in the expansion of a cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6205c0182438460aa7ed28e85ed51e9b","type":"GO_TERM","name":"medial layer of collagen and cuticulin-based cuticle extracellular matrix","canonical_id":"go:GO:0060109","description":"\"The fluid-filled cuticle layer that lies between the cortical and basal layers and is characterized by the presence of regularly spaced columnar struts that lie on either side of the annular furrows and link the two surrounding layers. In C. elegans, a defined medial layer is found only in adult animals.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"e3b97a9f31694b53a3cff09b3504741f","type":"GO_TERM","name":"medial membrane band","canonical_id":"go:GO:0032178","description":"\"A sterol-rich region of the plasma membrane which forms at the cell surface overlying the contractile ring and spreads into the invaginating plasma membrane surrounding the septum.\" [PMID:15517003]","metadata":null},{"id":"528497271e534869a2bc50f1dc31e226","type":"GO_TERM","name":"medial membrane band assembly","canonical_id":"go:GO:0032130","description":"\"The assembly of a sterol-rich region of the plasma membrane at the cell surface overlying the contractile ring.\" [PMID:15517003]","metadata":null},{"id":"4c59cec66e884013884445d525541ad0","type":"GO_TERM","name":"medial motor column neuron differentiation","canonical_id":"go:GO:0021526","description":"\"The process in which differentiating motor neurons in the neural tube acquire the specialized structural and/or functional features of medial motor column neurons. Medial motor column neurons are generated at all rostrocaudal levels and send axons to the axial muscles (medial group) and to the body wall muscles (lateral group). Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"d1dc28b6067b42a390292efb45f509df","type":"GO_TERM","name":"medial-Golgi-derived vesicle fusion with Golgi trans cisterna membrane","canonical_id":"go:GO:1990672","description":"\"The joining of the lipid bilayer membrane around a medial-Golgi-derived vesicle to the lipid bilayer membrane around the Golgi trans cisterna. Vesicles are involved in anterograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"883465644ea44875995be623fe940f4e","type":"GO_TERM","name":"median body","canonical_id":"go:GO:0097568","description":"\"A non-membrane bound, semi-organized microtubule array of unknown function found in Giardia species (trophozoite stage). It is located on the dorsal side of the trophozoite, slightly posterior to the ventral disc.\" [GOC:giardia, PMID:5961344]","metadata":null},{"id":"deb4f9830bf7420d82cef046789146bc","type":"GO_TERM","name":"mediator complex","canonical_id":"go:GO:0016592","description":"\"A protein complex that interacts with the carboxy-terminal domain of the largest subunit of RNA polymerase II and plays an active role in transducing the signal from a transcription factor to the transcriptional machinery. The mediator complex is required for activation of transcription of most protein-coding genes, but can also act as a transcriptional corepressor. The Saccharomyces complex contains several identifiable subcomplexes: a head domain comprising Srb2, -4, and -5, Med6, -8, and -11, and Rox3 proteins; a middle domain comprising Med1, -4, and -7, Nut1 and -2, Cse2, Rgr1, Soh1, and Srb7 proteins; a tail consisting of Gal11p, Med2p, Pgd1p, and Sin4p; and a regulatory subcomplex comprising Ssn2, -3, and -8, and Srb8 proteins. Metazoan mediator complexes have similar modular structures and include homologs of yeast Srb and Med proteins.\" [PMID:11454195, PMID:16168358, PMID:17870225]","metadata":null},{"id":"f55620fc96bf41139be1a40e5de5b6e1","type":"GO_TERM","name":"mediator complex assembly","canonical_id":"go:GO:0036034","description":"\"The aggregation, arrangement and bonding together of a set of components to form a mediator complex. The mediator complex is a protein complex that interacts with the carboxy-terminal domain of the largest subunit of RNA polymerase II and plays an active role in transducing the signal from a transcription factor to the transcriptional machinery. The Saccharomyces complex contains several identifiable subcomplexes: a head domain comprising Srb2, -4, and -5, Med6, -8, and -11, and Rox3 proteins; a middle domain comprising Med1, -4, and -7, Nut1 and -2, Cse2, Rgr1, Soh1, and Srb7 proteins; a tail consisting of Gal11p, Med2p, Pgd1p, and Sin4p; and a regulatory subcomplex comprising Ssn2, -3, and -8, and Srb8 proteins. Metazoan mediator complexes have similar modular structures and include homologs of yeast Srb and Med proteins.\" [GOC:yaf, PMID:17641689]","metadata":null},{"id":"6b5d460539c74960a6318595e3df1156","type":"GO_TERM","name":"mediator complex binding","canonical_id":"go:GO:0036033","description":"\"Binding to a mediator complex. The mediator complex is a protein complex that interacts with the carboxy-terminal domain of the largest subunit of RNA polymerase II and plays an active role in transducing the signal from a transcription factor to the transcriptional machinery. The Saccharomyces complex contains several identifiable subcomplexes: a head domain comprising Srb2, -4, and -5, Med6, -8, and -11, and Rox3 proteins; a middle domain comprising Med1, -4, and -7, Nut1 and -2, Cse2, Rgr1, Soh1, and Srb7 proteins; a tail consisting of Gal11p, Med2p, Pgd1p, and Sin4p; and a regulatory subcomplex comprising Ssn2, -3, and -8, and Srb8 proteins. Metazoan mediator complexes have similar modular structures and include homologs of yeast Srb and Med proteins.\" [GOC:yaf, PMID:18391015]","metadata":null},{"id":"e3230b8c4d984b1a833dfc7a1edd89ae","type":"GO_TERM","name":"mediolateral intercalation","canonical_id":"go:GO:0060031","description":"\"The interdigitation of cells along the mediolateral axis during gastrulation.\" [GOC:dgf, GOC:dph, PMID:12062082]","metadata":null},{"id":"7d5d6ddb57f74522a20eb423110b2862","type":"GO_TERM","name":"medium-chain fatty acid biosynthetic process","canonical_id":"go:GO:0051792","description":"\"The chemical reactions and pathways resulting in the formation of a medium-chain fatty acid. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [Wikipedia:Fatty_acid_metabolism]","metadata":null},{"id":"11529116cf35433c91418bd252f749ec","type":"GO_TERM","name":"medium-chain fatty acid catabolic process","canonical_id":"go:GO:0051793","description":"\"The chemical reactions and pathways resulting in the breakdown of a medium-chain fatty acid. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [Wikipedia:Fatty_acid_metabolism]","metadata":null},{"id":"7a791172356e4c69af826f622cc41eb1","type":"GO_TERM","name":"medium-chain fatty acid metabolic process","canonical_id":"go:GO:0051791","description":"\"The chemical reactions and pathways involving a medium-chain fatty acid. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [Wikipedia:Fatty_acid_metabolisms]","metadata":null},{"id":"fe99c1bbff2645de80c17bdfff73c822","type":"GO_TERM","name":"medium-chain fatty acid omega-1 hydroxylase activity","canonical_id":"go:GO:0120503","description":"\"Catalysis of the reaction: an (omega-1)-ethyl medium-chain fatty acid + O2 + reduced [NADPH-hemoprotein reductase] = an (omega-1)-hydroxy-medium-chain fatty acid + H+ + H2O + oxidized [NADPH-hemoprotein reductase. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [PMID:35934685]","metadata":null},{"id":"9f21279cfb1d4cf289c236490672a760","type":"GO_TERM","name":"medium-chain fatty acid omega-hydroxylase activity","canonical_id":"go:GO:0140981","description":"\"Catalysis of the reaction: an omega-methyl-medium-chain fatty acid + O2 + reduced [NADPH--hemoprotein reductase] = an omega-hydroxy-medium-chain fatty acid + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [RHEA:75279]","metadata":null},{"id":"4eb4a8ad96f54fa4ab303d2c1516bc32","type":"GO_TERM","name":"medium-chain fatty acid transport","canonical_id":"go:GO:0001579","description":"\"The directed movement of a medium-chain fatty acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [GOC:ai]","metadata":null},{"id":"a1ddf46000db4fafbad60cd752f993b5","type":"GO_TERM","name":"medium-chain fatty acid-CoA ligase activity","canonical_id":"go:GO:0031956","description":"\"Catalysis of the reaction: a medium-chain fatty acid + ATP + CoA = a medium-chain fatty acyl-CoA + AMP + diphosphate. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [RHEA:48340]","metadata":null},{"id":"be24a2dcccee420b950c1b8e759c8aff","type":"GO_TERM","name":"medium-chain fatty acyl-CoA dehydrogenase activity","canonical_id":"go:GO:0070991","description":"\"Catalysis of the reaction: a medium-chain 2,3-saturated fatty acyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = a medium-chain trans-(2E)-enoyl-CoA + reduced [electron-transfer flavoprotein]. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [RHEA:14477]","metadata":null},{"id":"b18bbd4ae6db407f9308c50cd643949c","type":"GO_TERM","name":"medium-chain fatty acyl-CoA hydrolase activity","canonical_id":"go:GO:0052815","description":"\"Catalysis of the reaction: a medium-chain fatty acyl-CoA + H2O = a medium-chain fatty acid + CoA + H+. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [RHEA:68184]","metadata":null},{"id":"83b24a1ea83f48c896ca7b9fb675979e","type":"GO_TERM","name":"medium-chain fatty acyl-CoA oxidase activity","canonical_id":"go:GO:0120523","description":"\"Catalysis of the reaction: a medium-chain 2,3-saturated fatty acyl-CoA + O2 = a medium-chain (2E)-enoyl-CoA + H2O2.\" [RHEA:78855]","metadata":null},{"id":"f4b6ecf33c834bcc935c92dd493a0901","type":"GO_TERM","name":"medium-chain fatty aldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0052814","description":"\"Catalysis of the reaction: a medium-chain fatty aldehyde + H2O + NAD+ = a medium chain fatty acid + 2 H+ + NADH.\" [RHEA:69763]","metadata":null},{"id":"70cc65b925464c21b57a7a28a26b6a12","type":"GO_TERM","name":"medium-chain fatty-acyl-CoA catabolic process","canonical_id":"go:GO:0036114","description":"\"The chemical reactions and pathways resulting in the breakdown of medium-chain fatty-acyl-CoAs, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a medium-chain fatty-acyl group. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [GOC:pm]","metadata":null},{"id":"3e7ce613410a4691bd5d8e0357b121eb","type":"GO_TERM","name":"medium-chain fatty-acyl-CoA metabolic process","canonical_id":"go:GO:0036112","description":"\"The chemical reactions and pathways involving medium-chain fatty-acyl-CoAs, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. A medium-chain fatty acid has an aliphatic tail containing 6 to 12 carbons.\" [GOC:pm]","metadata":null},{"id":"e9c9cebdbb134f6e9b1a7411c16f0042","type":"GO_TERM","name":"medium-term memory","canonical_id":"go:GO:0072375","description":"\"The memory process that deals with the storage, retrieval and modification of information received at a time ago that is intermediate between that of short and long term memory (30min - 7hrs in Drosophila melanogaster).\" [GOC:sart, PMID:14659098, PMID:7923375]","metadata":null},{"id":"86ab7481ca3147049b0b7b05577a54b0","type":"DRUG","name":"medroxyprogesterone","canonical_id":"gtopdb:2879","description":null,"metadata":null},{"id":"84eb231b52dd42869d883cbb35d501d7","type":"COMBINATION_TREATMENT","name":"medroxyprogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-7664ac4aa961ce6d","description":null,"metadata":null},{"id":"8062fce4db7c4959a92960cab58e33c0","type":"COMBINATION_TREATMENT","name":"medroxyprogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-d50408a112e483ff","description":null,"metadata":null},{"id":"9971b3b6c5c44f2d9d6bff6e47d07e3d","type":"COMBINATION_TREATMENT","name":"medroxyprogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-33f38ba84da402c6","description":null,"metadata":null},{"id":"c739171c7b4a4a3e9d72d4cc3e856665","type":"COMBINATION_TREATMENT","name":"medroxyprogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-76711b77fcbd76c6","description":null,"metadata":null},{"id":"899536054ee64bc9b530bf872af17099","type":"COMBINATION_TREATMENT","name":"medroxyprogesterone + progesterone","canonical_id":"ctgov_combo:ctgov-combo-3e7be5bbee788064","description":null,"metadata":null},{"id":"d4cf7fd32ff043d6bc271577e98e22d0","type":"DRUG","name":"medrysone","canonical_id":"mesh:C100283","description":null,"metadata":null},{"id":"a93984d0cbe542a9b2c3cfea6774d803","type":"GO_TERM","name":"medulla oblongata development","canonical_id":"go:GO:0021550","description":"\"The process whose specific outcome is the progression of the medulla oblongata over time, from its formation to the mature structure. The medulla oblongata lies directly above the spinal cord and controls vital autonomic functions such as digestion, breathing and the control of heart rate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"512ca5e8f0a14808a43f9c2bd38cbd39","type":"GO_TERM","name":"medulla oblongata formation","canonical_id":"go:GO:0021580","description":"\"The process that gives rise to the medulla oblongata. This process pertains to the initial formation of a structure from unspecified parts. The medulla oblongata lies directly above the spinal cord and controls vital autonomic functions such as digestion, breathing and the control of heart rate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"26bd98db49d143418f3f291893036735","type":"GO_TERM","name":"medulla oblongata maturation","canonical_id":"go:GO:0021582","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the medulla oblongata to attain its fully functional state. The medulla oblongata lies directly above the spinal cord and controls vital autonomic functions such as digestion, breathing and the control of heart rate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"de4f48c1d24949a384520bba747701c8","type":"GO_TERM","name":"medulla oblongata morphogenesis","canonical_id":"go:GO:0021579","description":"\"The process in which the anatomical structure of the medulla oblongata is generated and organized. The medulla oblongata lies directly above the spinal cord and controls vital autonomic functions such as digestion, breathing and the control of heart rate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"08f3b4a212a84c2a995699a4bd3f5cef","type":"GO_TERM","name":"medulla oblongata structural organization","canonical_id":"go:GO:0021581","description":"\"The process that contributes to the act of creating the structural organization of the medulla oblongata. This process pertains to the physical shaping of a rudimentary structure. The medulla oblongata lies directly above the spinal cord and controls vital autonomic functions such as digestion, breathing and the control of heart rate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"80f54699db964001a545abea98429d6d","type":"GO_TERM","name":"medulla reticulospinal tract morphogenesis","canonical_id":"go:GO:0021976","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the medulla towards target cells in the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5aec5871d58c4de8855c9fc7b6034fec","type":"GO_TERM","name":"medullary reticular formation development","canonical_id":"go:GO:0021723","description":"\"The process whose specific outcome is the progression of the medullary reticular formation over time, from its formation to the mature structure. The medullary reticular formation is a series of brain nuclei located in the medulla oblongata.\" [GO_REF:0000021, GOC:cjm, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid, https://www.ncbi.nlm.nih.gov/books/NBK556102/, Wikipedia:Rhombencephalon]","metadata":null},{"id":"95e5f56dba264beeae0b8234bf74e9a5","type":"DISEASE","name":"medullary thyroid gland carcinoma","canonical_id":"mondo:0015277","description":null,"metadata":null},{"id":"0ad6492ab6ae48c293f0fc243d2bb277","type":"DISEASE","name":"medulloblastoma","canonical_id":"mondo:0007959","description":null,"metadata":null},{"id":"f0225613ce54404eaf6106a3be894564","type":"DRUG","name":"mefenamic acid","canonical_id":"gtopdb:2593","description":null,"metadata":null},{"id":"43e2b3fec06348efbbb6b4455f61cdcd","type":"DRUG","name":"mefenamic acid","canonical_id":"chembl:CHEMBL686","description":null,"metadata":null},{"id":"9b1c0d722e6e4d56b1dd208c1552b9f5","type":"COMBINATION_TREATMENT","name":"mefenamic acid + sotagliflozin","canonical_id":"ctgov_combo:ctgov-combo-bbaeb5e9894b3038","description":null,"metadata":null},{"id":"ec8afc49d2f041c9b115ac4c2121dd97","type":"GO_TERM","name":"megagametogenesis","canonical_id":"go:GO:0009561","description":"\"The process whose specific outcome is the progression of the embryo sac over time, from its formation as the megaspore to the mature structure. The process begins when three of the four haploid megaspores disintegrate, and the fourth undergoes mitosis giving rise to a binucleate syncytial embryo sac. The two haploid nuclei migrate to the opposite poles of the embryo sac and then undergo two rounds of mitosis generating four haploid nuclei at each pole. One nucleus from each set of four migrates to the center of the cell. Cellularization occurs, resulting in an eight-nucleate seven-celled structure. This structure contains two synergid cells and an egg cell at the micropylar end, and three antipodal cells at the other end. A binucleate endosperm mother cell is formed at the center.\" [GOC:jl, GOC:mtg_plant]","metadata":null},{"id":"4e9b4eedd1294e62b8070f4be30dc8a6","type":"GO_TERM","name":"megagametophyte egg cell nucleus","canonical_id":"go:GO:0043082","description":"\"The nucleus of a plant egg cell. This nucleus is found at the micropylar end of the embryo.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"050fbdfa9b2849b8b7c4b450551b1217","type":"GO_TERM","name":"megakaryocyte development","canonical_id":"go:GO:0035855","description":"\"The process whose specific outcome is the progression of a megakaryocyte cell over time, from its formation to the mature structure. Megakaryocyte development does not include the steps involved in committing a cell to a megakaryocyte fate. A megakaryocyte is a giant cell 50 to 100 micron in diameter, with a greatly lobulated nucleus, found in the bone marrow.\" [CL:0000556, GOC:BHF, GOC:vk]","metadata":null},{"id":"006f060e7e7c4d018530ba6cb896ddff","type":"GO_TERM","name":"megakaryocyte differentiation","canonical_id":"go:GO:0030219","description":"\"The process in which a myeloid precursor cell acquires specializes features of a megakaryocyte.\" [GOC:mah]","metadata":null},{"id":"6cb14d181a494bc2990ac6ae97a9bd60","type":"DISEASE","name":"megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1","canonical_id":"mondo:0011313","description":null,"metadata":null},{"id":"e9c9e3b89eaa4fa6812a80a34b374432","type":"DISEASE","name":"megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2","canonical_id":"mondo:0014407","description":null,"metadata":null},{"id":"b5c59226ab9a4e3eb92f457c41f160a5","type":"DISEASE","name":"megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome","canonical_id":"mondo:0019375","description":null,"metadata":null},{"id":"477b99c5849947fdb511d29519e6128e","type":"GO_TERM","name":"megasome","canonical_id":"go:GO:0043246","description":"\"Large, cysteine proteinase rich lysosomes, often found in the amastigote (an intracytoplasmic, nonflagellated form of the parasite) stage of Leishmania species belonging to the mexicana complex.\" [PMID:11206117, PMID:1999020]","metadata":null},{"id":"fc7a1f32708941709c050d801e97dab6","type":"GO_TERM","name":"megasporocyte differentiation","canonical_id":"go:GO:1904159","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a megasporocyte.\" [GO_REF:0000086, GOC:tair_curators, GOC:TermGenie]","metadata":null},{"id":"d0c32ef3bf57404e9abde3e313f23219","type":"GO_TERM","name":"megasporocyte nucleus","canonical_id":"go:GO:0043076","description":"\"The nucleus of a megasporocyte, a diploid cell that undergoes meiosis to produce four megaspores, and its descendents.\" [GOC:jl, ISBN:0618254153]","metadata":null},{"id":"c641d342f0754b7eb77152102746625e","type":"GO_TERM","name":"megasporogenesis","canonical_id":"go:GO:0009554","description":"\"The process in which the megasporocyte undergoes meiosis, giving rise to four haploid megaspores in the nucellus.\" [GOC:mtg_plant, GOC:tb]","metadata":null},{"id":"e3e601696c2a4228b0bc7545de4d2694","type":"DRUG","name":"megestrol acetate","canonical_id":"mesh:D008535","description":null,"metadata":null},{"id":"72ca5b44a91e4f1c9fca3b61ac2aec43","type":"GO_TERM","name":"meiosis I","canonical_id":"go:GO:0007127","description":"\"The first meiotic nuclear division in which homologous chromosomes are paired and segregated from each other, producing two haploid daughter nuclei.\" [GOC:dph, GOC:jl, GOC:mtg_cell_cycle, PMID:9334324]","metadata":null},{"id":"e65733b10083473f98ae19f61296f45c","type":"GO_TERM","name":"meiosis I cell cycle phase","canonical_id":"go:GO:0098764","description":"\"A meiotic cell cycle phase prior to a during which some part of meiosis I nuclear division or the proceeding cytokinesis occurs.\" [GOC:dos]","metadata":null},{"id":"6c2adcbd46f742ff98494c12f735ef48","type":"GO_TERM","name":"meiosis I cell cycle process","canonical_id":"go:GO:0061982","description":"\"A process that contributes to the first meiotic division. The first meiotic division is the reductive division resulting in the separation of homologous chromosome pairs.\" [PMID:29385397]","metadata":null},{"id":"592214806fd048e98793b2a902eb5002","type":"GO_TERM","name":"meiosis I cytokinesis","canonical_id":"go:GO:0007110","description":"\"A cell cycle process that results in the division of the cytoplasm of a cell after meiosis I, resulting in the separation of the original cell into two daughter cells.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"f043cb93ea2d483c8af41a4c8bfa5c15","type":"GO_TERM","name":"meiosis I nuclear membrane disassembly","canonical_id":"go:GO:0051079","description":"\"The controlled breakdown of the nuclear membranes during the first division of meiosis.\" [GOC:bf]","metadata":null},{"id":"7f6801f4df2e427798266dcf9a84f386","type":"GO_TERM","name":"meiosis I nuclear membrane reassembly","canonical_id":"go:GO:0051334","description":"\"The reformation of the nuclear membranes during meiosis I.\" [GOC:ai]","metadata":null},{"id":"271a9b425d4240519cbe98184f41e54e","type":"GO_TERM","name":"meiosis I sister chromatid cohesion","canonical_id":"go:GO:0010789","description":"\"The cell cycle process in which sister chromatids of a replicated chromosome are joined along the entire length of the chromosome during meiosis I.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4ecfc9a260e8416c939f605fb2fb6af9","type":"GO_TERM","name":"meiosis I spindle assembly checkpoint signaling","canonical_id":"go:GO:1905318","description":"\"Any spindle assembly checkpoint that is involved in meiosis I.\" [GO_REF:0000060, GOC:TermGenie, PMID:26483559]","metadata":null},{"id":"b0167eca62c64aa29f36ed6f3904af8d","type":"GO_TERM","name":"meiosis I/meiosis II transition","canonical_id":"go:GO:1990946","description":"\"The cell cycle process in which a cell progresses from meiosis I to meiosis II.\" [PMID:21389117]","metadata":null},{"id":"202a250eb8dd433a8192152d4103dffa","type":"GO_TERM","name":"meiosis II","canonical_id":"go:GO:0007135","description":"\"The second nuclear division of meiosis, in which the two chromatids in each chromosome are separated, resulting in four daughter nuclei from the two nuclei produced in meiosis II.\" [GOC:dph, GOC:mah, ISBN:0198547684]","metadata":null},{"id":"3d82135c9cc44401b57f45f7cb3114d6","type":"GO_TERM","name":"meiosis II cell cycle phase","canonical_id":"go:GO:0098765","description":"\"A meiotic cell cycle phase that occurs after meiosis I (the first meiotic nuclear division).\" [GOC:dos]","metadata":null},{"id":"4aa22cd85a6b4c54a1c5116865580b86","type":"GO_TERM","name":"meiosis II cell cycle process","canonical_id":"go:GO:0061983","description":"\"A process that coontributes to the second meiotic division. The second meiotic division separates chromatids resulting in a haploid number of chromosomes.\" [PMID:29385397]","metadata":null},{"id":"03b394e66e2c4c1a9948b7f6c0561a9e","type":"GO_TERM","name":"meiosis II cytokinesis","canonical_id":"go:GO:0007111","description":"\"A cell cycle process that results in the division of the cytoplasm of a cell after meiosis II, resulting in the separation of the original cell into two daughter cells.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"8d7a3e879bc14f578348bd170583fd95","type":"GO_TERM","name":"meiosis II nuclear membrane disassembly","canonical_id":"go:GO:0051080","description":"\"The controlled breakdown of the nuclear membranes during the second division of meiosis.\" [GOC:bf]","metadata":null},{"id":"9b4473296ecb4308ba3b9a0c56d10549","type":"GO_TERM","name":"meiosis II nuclear membrane reassembly","canonical_id":"go:GO:0051335","description":"\"The reformation of the nuclear membrane during meiosis II.\" [GOC:ai]","metadata":null},{"id":"d1fa666b450c4db9bc36b08577dba477","type":"GO_TERM","name":"meiosis II sister chromatid cohesion","canonical_id":"go:GO:0010790","description":"\"The cell cycle process in which sister chromatids of a replicated chromosome are joined along the entire length of the chromosome during meiosis II.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8f9a289f45bb436a9d272091fee1bda5","type":"GO_TERM","name":"meiotic DNA double-strand break formation","canonical_id":"go:GO:0042138","description":"\"The cell cycle process in which double-strand breaks are generated at defined hotspots throughout the genome during meiosis I. This results in the initiation of meiotic recombination.\" [GOC:elh, GOC:jl, PMID:11529427]","metadata":null},{"id":"3f629dd312be4c448eabe097325ac859","type":"GO_TERM","name":"meiotic DNA double-strand break formation involved in reciprocal meiotic recombination","canonical_id":"go:GO:0010780","description":"\"The cell cycle process in which double-strand breaks are generated at defined hotspots throughout the genome during meiosis I resulting in meiotic recombination. Meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"5e7b6142b34146a3b3b816049d9d5de0","type":"GO_TERM","name":"meiotic DNA double-strand break processing","canonical_id":"go:GO:0000706","description":"\"The cell cycle process in which the 5' to 3' exonucleolytic resection of the DNA at the site of the break to form a 3' single-strand DNA overhang occurs. This takes place during meiosis.\" [GOC:elh, PMID:9334324]","metadata":null},{"id":"2c76478d55c945a792ee6e9c3bc59da3","type":"GO_TERM","name":"meiotic DNA double-strand break processing involved in reciprocal meiotic recombination","canonical_id":"go:GO:0010705","description":"\"The cell cycle process in which the 5' to 3' exonucleolytic resection of the DNA at the site of the break to form a 3' single-strand DNA overhang occurs resulting in double strand break formation and repair through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"42da86aabee648739b7e7444790d7129","type":"GO_TERM","name":"meiotic DNA integrity checkpoint signaling","canonical_id":"go:GO:0044778","description":"\"A signal transduction process that controls cell cycle progression in response to changes in DNA structure by monitoring the integrity of the DNA during meiosis. The DNA integrity checkpoint begins with detection of DNA damage, defects in DNA structure or DNA replication, and ends with signal transduction.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"b03e6ee8f0d34a25869bdb19c0c14a3a","type":"GO_TERM","name":"meiotic DNA recombinase assembly","canonical_id":"go:GO:0000707","description":"\"During meiosis, the aggregation, arrangement and bonding together of strand exchange proteins (recombinases) to form higher order oligomers on single-stranded DNA.\" [GOC:elh, PMID:11459983]","metadata":null},{"id":"17e96199d0624db58107f566cef3ac23","type":"GO_TERM","name":"meiotic DNA recombinase assembly involved in reciprocal meiotic recombination","canonical_id":"go:GO:0010772","description":"\"The aggregation, arrangement and bonding together of strand exchange proteins (recombinases) to form higher order oligomers on single-stranded DNA resulting in meiotic recombination. Meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e9be990e2d83448ca9ded258345f8300","type":"GO_TERM","name":"meiotic DNA repair synthesis","canonical_id":"go:GO:0000711","description":"\"During meiosis, the synthesis of DNA proceeding from the broken 3' single-strand DNA end that uses the homologous intact duplex as the template.\" [GOC:elh, PMID:9334324]","metadata":null},{"id":"422743ad1c644db58116590931bdf9cb","type":"GO_TERM","name":"meiotic DNA repair synthesis involved in reciprocal meiotic recombination","canonical_id":"go:GO:0010778","description":"\"The synthesis of DNA proceeding from the broken 3' single-strand DNA end that uses the homologous intact duplex as the template resulting in meiotic recombination. Meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"16d6de9d82b346c5b501782d60cef812","type":"GO_TERM","name":"meiotic DNA replication initiation","canonical_id":"go:GO:1902974","description":"\"Any DNA replication initiation involved in meiotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:TermGenie, PMID:10888871]","metadata":null},{"id":"e1179b10c0a84d81a90eab28fc1033f1","type":"GO_TERM","name":"meiotic G1 phase","canonical_id":"go:GO:0051330","description":"\"The cell cycle 'gap' phase which is the interval between the completion of DNA segregation by meiosis and the beginning of DNA synthesis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d12036bb844c4ca0a7608f2d8ca9a58b","type":"GO_TERM","name":"meiotic G2 phase","canonical_id":"go:GO:0051331","description":"\"The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation by meiosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"7543bbd16bff42a0bd2b0fd1ff126ea3","type":"GO_TERM","name":"meiotic G2/MI DNA replication checkpoint signaling","canonical_id":"go:GO:0033315","description":"\"A signal transduction process that controls the G2/M1 transition of the meiotic cell cycle and prevents the initiation of nuclear division until DNA replication is complete.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"a90dc7e6fa264670b88437aac285cdcd","type":"GO_TERM","name":"meiotic M phase","canonical_id":"go:GO:0051327","description":"\"A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase and occurs as part of a meiotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"edf993a85f4c4ed2bc9f0bcb2b4f9bf1","type":"GO_TERM","name":"meiotic S phase","canonical_id":"go:GO:0051332","description":"\"The cell cycle phase, following G1, during which DNA synthesis takes place as part of a meiotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"7a6529644c3943ab97330a958b4792d6","type":"GO_TERM","name":"meiotic actomyosin contractile ring","canonical_id":"go:GO:0110086","description":"\"A cytoskeletal structure composed of actin filaments, myosin, and myosin-associated proteins that forms beneath the plasma membrane of many cells, including animal cells and yeast cells, in a plane perpendicular to the axis of the meiotic spindle, i.e. the cell division plane. Ring contraction is associated with centripetal growth of the membrane that divides the cytoplasm of the two future daughter cells. In animal cells, the meiotic contractile ring is located inside the plasma membrane at the location of the cleavage furrow. In fungal cells, the meiotic contractile ring forms beneath the plasma membrane of the prospore envelope in preparation for completing cytokinesis.\" [GOC:vw, PMID:22526418]","metadata":null},{"id":"2f5b6bee2e35448090b02a3714f11062","type":"GO_TERM","name":"meiotic anaphase I","canonical_id":"go:GO:0007133","description":"\"The cell cycle phase during which chromosomes separate and migrate towards the poles of the spindle the as part of meiosis I.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"38b18ca5857047de9b7260a95eb0460f","type":"GO_TERM","name":"meiotic anaphase II","canonical_id":"go:GO:0007138","description":"\"The cell cycle phase during which chromosomes separate and migrate towards the poles of the spindle the as part of meiosis II.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"92fcc470c4f34373b305632c429fc60c","type":"GO_TERM","name":"meiotic attachment of telomere to nuclear envelope","canonical_id":"go:GO:0070197","description":"\"The meiotic cell cycle process in which physical connections are formed between telomeric heterochromatin and the nuclear envelope, facilitating bouquet formation.\" [GOC:jp, GOC:pr, GOC:vw, PMID:18818742]","metadata":null},{"id":"a6c98faefa034b64b9f14cb6dbd76734","type":"GO_TERM","name":"meiotic attachment of telomeric heterochromatin to spindle pole body","canonical_id":"go:GO:0032121","description":"\"The meiotic cell cycle process in which physical connections are formed between telomeric heterochromatin and the spindle pole body, facilitating bouquet formation.\" [GOC:pr, PMID:16615890]","metadata":null},{"id":"4d98fd53ad59488cbe4b80150bf5a818","type":"GO_TERM","name":"meiotic cell cycle","canonical_id":"go:GO:0051321","description":"\"Progression through the phases of the meiotic cell cycle, in which canonically a cell replicates to produce four offspring with half the chromosomal content of the progenitor cell via two nuclear divisions.\" [GOC:ai]","metadata":null},{"id":"183dfe8bcf254206929f8c1cef0734fe","type":"GO_TERM","name":"meiotic cell cycle checkpoint signaling","canonical_id":"go:GO:0033313","description":"\"A signaling process that contributes to a meiotic cell cycle checkpoint that ensures accurate chromosome replication and segregation by preventing progression through a meiotic cell cycle until conditions are suitable for the cell to proceed to the next stage.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"f338ad7157b84aa1933f0049ebbc4f95","type":"GO_TERM","name":"meiotic cell cycle phase","canonical_id":"go:GO:0098762","description":"\"One of the distinct periods or stages into which the meiotic cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events.\" [GOC:dos]","metadata":null},{"id":"1b2d4b82f50d4c07be12e6bde4dd1eb0","type":"GO_TERM","name":"meiotic cell cycle phase transition","canonical_id":"go:GO:0044771","description":"\"The cell cycle process by which a cell commits to entering the next meiotic cell cycle phase.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"54ce203fbc414ef3ba0c6cd9bbc1a7c7","type":"GO_TERM","name":"meiotic cell cycle process","canonical_id":"go:GO:1903046","description":"\"A process that is part of the meiotic cell cycle.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"0b65fcf23f1a4467ab82b5dc683a7158","type":"GO_TERM","name":"meiotic cell cycle process involved in oocyte maturation","canonical_id":"go:GO:1903537","description":"\"Any meiotic cell cycle process that is involved in oocyte maturation.\" [GO_REF:0000060, GOC:jz, GOC:TermGenie, PMID:25212395]","metadata":null},{"id":"c6809e323c9d4d9a92c6176fceaaa8fc","type":"GO_TERM","name":"meiotic centromere clustering","canonical_id":"go:GO:1990571","description":"\"The process by which centromeres/kinetochores attach to and migrate along microtubules to become localized to clusters at the spindle pole body during a meiotic prometaphase I.\" [PMID:10366596, PMID:9009280]","metadata":null},{"id":"36bb11c0cd8147e297005b7156d2f6b4","type":"GO_TERM","name":"meiotic centromeric cohesion protection in anaphase I","canonical_id":"go:GO:1990813","description":"\"The process in which the association between sister chromatids of a replicated chromosome centromeric region is maintained during homologous chromosome segregation at meiotic anaphase I after cohesin is cleaved by separase along the arm regions.\" [PMID:14730319, PMID:25533956]","metadata":null},{"id":"06b4f01ec0c04d18bcac4242083b1220","type":"GO_TERM","name":"meiotic chromosome condensation","canonical_id":"go:GO:0010032","description":"\"Compaction of chromatin structure prior to meiosis in eukaryotic cells.\" [PMID:10072401]","metadata":null},{"id":"f746e6b19080493a96cb8a467dd2f498","type":"GO_TERM","name":"meiotic chromosome movement towards spindle pole","canonical_id":"go:GO:0016344","description":"\"The cell cycle process in which the directed movement of chromosomes from the center of the spindle towards the spindle poles takes place, mediated by the shortening of microtubules attached to the chromosomes. This occurs during meiosis.\" [GOC:ai]","metadata":null},{"id":"f14b83872d354e98a11d5c824934ae74","type":"GO_TERM","name":"meiotic chromosome segregation","canonical_id":"go:GO:0045132","description":"\"The process in which genetic material, in the form of chromosomes, is organized into specific structures and then physically separated and apportioned to two or more sets during M phase of the meiotic cell cycle.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"98530d86b2c64a4e946fb665b35d264d","type":"GO_TERM","name":"meiotic chromosome separation","canonical_id":"go:GO:0051307","description":"\"The process in which chromosomes are physically detached from each other during meiosis.\" [GOC:ai]","metadata":null},{"id":"0951ce1599a84bb6ac68cb57b8d0872f","type":"GO_TERM","name":"meiotic cohesin complex","canonical_id":"go:GO:0030893","description":"\"A cohesin complex that mediates sister chromatid cohesion during meiosis; has a subunit composition distinct from that of the mitotic cohesin complex.\" [GOC:mah, PMID:12750522]","metadata":null},{"id":"d2d5411049d24963bce4f52df0b7efe2","type":"GO_TERM","name":"meiotic cytokinesis","canonical_id":"go:GO:0033206","description":"\"A cell cycle process that results in the division of the cytoplasm of a cell after meiosis, resulting in the separation of the original cell into two daughter cells.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"011b3cf7d1ed4289a257b09de14ef00f","type":"GO_TERM","name":"meiotic drive","canonical_id":"go:GO:0110134","description":"\"A biological process that results in the unequal transmission of alleles, haplotypes, or chromosomes from a parental genome to gametes. In the absence of meiotic drive, the two copies of each gene or chromosome in a diploid organism are transmitted to offspring with equal probability, whereas meiotic drive results in overrepresentation of the driving allele among the surviving products of meiosis.\" [GOC:mah, PMID:26920473, PMID:29322557, PMID:29499907]","metadata":null},{"id":"3274608c39574fe0bebada5f064152a3","type":"GO_TERM","name":"meiotic gene conversion","canonical_id":"go:GO:0006311","description":"\"The cell cycle process in which genetic information is transferred from one helix to another. It often occurs in association with general genetic recombination events, and is believed to be a straightforward consequence of the mechanisms of general recombination and DNA repair. For example, meiosis might yield three copies of the maternal version of an allele and only one copy of the paternal allele, indicating that one of the two copies of the paternal allele has been changed to a copy of the maternal allele.\" [ISBN:0815316194]","metadata":null},{"id":"c53951e2b1f24c4cb55e8503a6c5eda1","type":"GO_TERM","name":"meiotic heteroduplex formation","canonical_id":"go:GO:0000713","description":"\"During meiosis, the formation of a stable duplex DNA that contains one strand from each of the two recombining DNA molecules.\" [GOC:elh, PMID:9334324]","metadata":null},{"id":"bac2796f2a0246f3a17ba9990fb5db59","type":"GO_TERM","name":"meiotic interphase","canonical_id":"go:GO:0051328","description":"\"The cell cycle phase which begins after cytokinesis and ends when meiotic prophase begins. Meiotic cells have an interphase after each meiotic division, but only interphase I involves replication of the cell's DNA.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"c25a9b4a193c478ea6cf48bda84c6d19","type":"GO_TERM","name":"meiotic interphase II","canonical_id":"go:GO:0044844","description":"\"The cell cycle phase which begins at the end of meiosis I cytokinesis and ends when meiosis II prophase begins. During meiotic interphase II no DNA replication takes place, but the centrioles duplicate and spindle fibres emerge.\" [GOC:jl, GOC:mtg_cell_cycle]","metadata":null},{"id":"c4b824c0f5834c459f95ea573cb39df1","type":"GO_TERM","name":"meiotic joint molecule formation","canonical_id":"go:GO:0000709","description":"\"The conversion of the paired broken DNA and homologous duplex DNA into a four-stranded branched intermediate, known as a joint molecule, formed during meiotic recombination. These joint molecules contain Holliday junctions on either side of heteroduplex DNA.\" [GOC:elh, PMID:8521495]","metadata":null},{"id":"ccc2c83f0dbf4d09adbd9c36154411b1","type":"GO_TERM","name":"meiotic metaphase I","canonical_id":"go:GO:0007132","description":"\"The cell cycle phase, following prophase I, during which chromosomes become aligned on the equatorial plate of the cell as part of meiosis I.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d7dba2bb519a4e08b8ebbaf41d6321ec","type":"GO_TERM","name":"meiotic metaphase I homologous chromosome alignment","canonical_id":"go:GO:0043060","description":"\"A cell cycle process whereby homlogous chromosomes are positioned in a specific order and orientation at the metaphase plate (spindle equator) by the spindle machinery and centromere/kinetochore arrangement during meiosis I chromosome segregation. This alignment ensures that each daughter cell will receive the correct number of chromosomes during cell division.\" [PMID:10809666]","metadata":null},{"id":"369a8cb37aea49e1bf79ece58884cfc4","type":"GO_TERM","name":"meiotic metaphase II","canonical_id":"go:GO:0007137","description":"\"The cell cycle phase, following prophase II, during which chromosomes become aligned on the equatorial plate of the cell as part of meiosis II.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"2dc8f2569dd142a8987bd8d5f76cdc56","type":"GO_TERM","name":"meiotic metaphase II chromosome alignment","canonical_id":"go:GO:0043061","description":"\"A chromosome localization process whereby chromosomes are positioned in a specific order and orientation at the metaphase plate (spindle equator), during meiosis II chromosome segregation. This alignment ensures that each daughter cell will receive the correct number of chromosomes during cell division.\" [PMID:10809666]","metadata":null},{"id":"5b2d002f88ed46c9be8239435d29a183","type":"GO_TERM","name":"meiotic metaphase chromosome alignment","canonical_id":"go:GO:0051311","description":"\"A chromosome localization process whereby chromosomes are positioned in a specific order and orientation at the metaphase plate (spindle equator), during meiotic chromosome segregation. This alignment ensures that each daughter cell will receive the correct number of chromosomes during cell division.\" [GOC:vw]","metadata":null},{"id":"6c91804db436440eb48e3d5d550eda5e","type":"GO_TERM","name":"meiotic mismatch repair","canonical_id":"go:GO:0000710","description":"\"A system for the identification and correction of base-base mismatches, small insertion-deletion loops, and regions of heterology that are present in duplex DNA formed with strands from two recombining molecules. Correction of the mismatch can result in non-Mendelian segregation of alleles following meiosis.\" [GOC:elh, PMID:10357855]","metadata":null},{"id":"77debe6f00b94981b1956e14ef8da4f1","type":"GO_TERM","name":"meiotic mismatch repair involved in reciprocal meiotic recombination","canonical_id":"go:GO:0010777","description":"\"A system for the identification and correction of base-base mismatches, small insertion-deletion loops, and regions of heterology that are present in duplex DNA formed with strands from two recombining molecules resulting in meiotic recombination. Meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ffc38b347d914221a80a64cfe7c9062d","type":"GO_TERM","name":"meiotic nuclear division","canonical_id":"go:GO:0140013","description":"\"One of the two nuclear divisions that occur as part of the meiotic cell cycle.\" [PMID:9334324]","metadata":null},{"id":"eec93ef84d3141439fb425af603be6c0","type":"GO_TERM","name":"meiotic nuclear membrane disassembly","canonical_id":"go:GO:0051078","description":"\"The cell cycle process in which the controlled breakdown of the nuclear membranes during meiotic cell division occurs.\" [GOC:bf]","metadata":null},{"id":"b57c0e876efc4b7bbe5bc350836a4ade","type":"GO_TERM","name":"meiotic nuclear membrane microtubule tethering complex","canonical_id":"go:GO:0034993","description":"\"A nuclear membrane protein complex which connects the nuclear outer and inner membranes together, and links links the nuclear lumen to cytoplasmic microtubules during meiosis.\" [GOC:mah, PMID:18692466]","metadata":null},{"id":"85422b6478c84b619fde233aaf58a324","type":"GO_TERM","name":"meiotic nuclear membrane reassembly","canonical_id":"go:GO:0051333","description":"\"The cell cycle process in which the reformation of the nuclear membranes during meiosis occurs.\" [GOC:ai]","metadata":null},{"id":"e76227adbb3b4bbe91612a88e542f724","type":"GO_TERM","name":"meiotic prometaphase I","canonical_id":"go:GO:0098768","description":"\"The meiotic cell cycle phase in eukaryotes between meiotic prophase I and meiotic metaphase I. During meiotic prometaphase I, the nuclear envelope breaks down and one kinetochore forms per chromosome. Chromosomes attach to spindle microtubules and begin to move towards the metaphase plate.\" [PMID:16012859]","metadata":null},{"id":"f0e055f6e3e849189691bec885efaf58","type":"GO_TERM","name":"meiotic prophase I","canonical_id":"go:GO:0007128","description":"\"The cell cycle phase which is the first stage of meiosis I and during which chromosomes condense and the two daughter centrioles and their asters migrate toward the poles of the cell.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"b9e4a84b784946fba3ddc12df104c1f3","type":"GO_TERM","name":"meiotic prophase II","canonical_id":"go:GO:0007136","description":"\"The cell cycle phase which is the first stage of meiosis II and during which chromosomes condense and the two daughter centrioles and their asters migrate toward the poles of the cell.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"98d1ef28e79f49f49e21f93094081e47","type":"GO_TERM","name":"meiotic recombination checkpoint signaling","canonical_id":"go:GO:0051598","description":"\"A signaling process that contributes to a meiotic recombination checkpoint, that acts during late prophase I (pachytene) and prevents segregation of homologous chromosomes until recombination is completed, ensuring proper distribution of the genetic material to the gametes.\" [PMID:14718568]","metadata":null},{"id":"90934abc5f23441fa395930fc0ecbca0","type":"GO_TERM","name":"meiotic recombination initiation complex","canonical_id":"go:GO:0035808","description":"\"A protein complex that initiates the formation of double-strand breaks (DSBs) required for meiotic recombination. Consists of a protein that catalyses formation of the double-strand breaks (Spo11 in S. cerevisiae and Rec12 in S. pombe), and a number of accessory proteins.\" [GOC:vw, PMID:12897161, PMID:20364342, PMID:21429938]","metadata":null},{"id":"57c69023d243422dbc78438fc15fd4c0","type":"GO_TERM","name":"meiotic recombination nodule assembly","canonical_id":"go:GO:0007146","description":"\"During meiosis, the aggregation, arrangement and bonding together of strand exchange proteins (recombinases) to form small, electron dense structures in association with meiotic chromosomes.\" [GOC:jl, PMID:9334324]","metadata":null},{"id":"fe0b8b9672a14100800092a9873ffb5b","type":"GO_TERM","name":"meiotic septin complex","canonical_id":"go:GO:0032152","description":"\"A heterooligomeric septin complex that acts during meiotic cell division.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"c502338e625240baa001346628d21974","type":"GO_TERM","name":"meiotic sister chromatid arm separation","canonical_id":"go:GO:0051755","description":"\"The cell cycle process in which sister chromatid arms are physically detached from each other during meiosis.\" [GOC:ai]","metadata":null},{"id":"064a14c0b4724143942b2906b7f85d03","type":"GO_TERM","name":"meiotic sister chromatid centromere separation","canonical_id":"go:GO:0051756","description":"\"The cell cycle process in which the centromeres of sister chromatids are physically detached from each other during meiosis.\" [GOC:ai, PMID:14730319, PMID:16325576]","metadata":null},{"id":"9d76c1dcf07e430a9cb3e1d34eaebd96","type":"GO_TERM","name":"meiotic sister chromatid cohesion","canonical_id":"go:GO:0051177","description":"\"The cell cycle process in which sister chromatids of a replicated chromosome are joined along the entire length of the chromosome during meiosis.\" [GOC:ai]","metadata":null},{"id":"c9e8d68676c447f2b375cfd01d89a202","type":"GO_TERM","name":"meiotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:0051754","description":"\"The cell cycle process in which centromeres of sister chromatids are joined during meiosis.\" [PMID:14730319, PMID:16325576]","metadata":null},{"id":"8dcddd8deeba46e39130e2360cf9e0db","type":"GO_TERM","name":"meiotic sister chromatid segregation","canonical_id":"go:GO:0045144","description":"\"The cell cycle process in which sister chromatids are organized and then physically separated and randomly apportioned to two sets during the second division of the meiotic cell cycle.\" [GOC:ai, ISBN:0815316194]","metadata":null},{"id":"3210b734dae1426984dcce431972069c","type":"GO_TERM","name":"meiotic sister chromatid separation","canonical_id":"go:GO:0051757","description":"\"The process in which sister chromatids are physically detached from each other during meiosis.\" [GOC:ai, PMID:14730319, PMID:16325576]","metadata":null},{"id":"911eb2b292f443649ccb90dca4d7417b","type":"GO_TERM","name":"meiotic spindle","canonical_id":"go:GO:0072687","description":"\"A spindle that forms as part of meiosis. Several proteins, such as budding yeast Spo21p, fission yeast Spo2 and Spo13, and C. elegans mei-1, localize specifically to the meiotic spindle and are absent from the mitotic spindle.\" [GOC:mah, GOC:vw, PMID:11408572, PMID:18367542, PMID:8027178]","metadata":null},{"id":"7da46f97a7fe41cd82681a2cb3690d2e","type":"GO_TERM","name":"meiotic spindle assembly","canonical_id":"go:GO:0090306","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle that contributes to the process of meiosis.\" [GOC:tb, GOC:vw]","metadata":null},{"id":"88ba5c39a1f7479db61a4d1d4f380243","type":"GO_TERM","name":"meiotic spindle assembly checkpoint signaling","canonical_id":"go:GO:0033316","description":"\"A signal transduction process that contributes to a meiotic spindle assembly checkpoint, that delays the metaphase/anaphase transition of a meiotic cell cycle until the spindle is correctly assembled and chromosomes are attached to the spindle.\" [GOC:mah]","metadata":null},{"id":"a4c0c1f40dfc46e686f436272e506fd8","type":"GO_TERM","name":"meiotic spindle astral microtubule","canonical_id":"go:GO:1990574","description":"\"Any of the meiotic spindle microtubules that radiate in all directions from the spindle poles and are thought to contribute to the forces that separate the poles and position them in relation to the rest of the cell.\" [PMID:10366596]","metadata":null},{"id":"a463724462d442cf90e2900c24ad9e50","type":"GO_TERM","name":"meiotic spindle checkpoint signaling","canonical_id":"go:GO:0044779","description":"\"A signal transduction process that contributes to a cell cycle checkpoint that delays the metaphase/anaphase transition of a meiotic nuclear division until the spindle is correctly assembled and that the chromosomes are attached to the spindle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d37d3057b0aa4140a1345fe4b81f59fc","type":"GO_TERM","name":"meiotic spindle disassembly","canonical_id":"go:GO:0051229","description":"\"The controlled breakdown of the spindle during a meiotic cell cycle.\" [GOC:ai]","metadata":null},{"id":"bccf23be97564a21af5b9472e764a3ff","type":"GO_TERM","name":"meiotic spindle elongation","canonical_id":"go:GO:0051232","description":"\"The lengthening of the distance between poles of the spindle during a meiotic cell cycle.\" [GOC:ai]","metadata":null},{"id":"fab5729d4dfe4a1aa4b7870af467b602","type":"GO_TERM","name":"meiotic spindle formation (spindle phase two)","canonical_id":"go:GO:0140642","description":"\"The spindle organization process in which the spindle is maintained at a constant length during meiotic metaphase.\" [PMID:32723864]","metadata":null},{"id":"8a69ee0bf941407a88923988fed52a89","type":"GO_TERM","name":"meiotic spindle midzone","canonical_id":"go:GO:1990385","description":"\"The area in the center of the meiotic spindle where the spindle microtubules from opposite poles overlap.\" [GOC:kmv, PMID:12707312]","metadata":null},{"id":"74a0d32ec8454140bf2fb9b30424d431","type":"GO_TERM","name":"meiotic spindle midzone assembly","canonical_id":"go:GO:0051257","description":"\"The formation of the spindle midzone, the area in the center of the spindle where the spindle microtubules from opposite poles overlap, as a part of the process of meiosis.\" [GOC:ai, GOC:expert_rg, GOC:tb]","metadata":null},{"id":"9e5dd8c0c68348c9ac9b9371bb37a281","type":"GO_TERM","name":"meiotic spindle organization","canonical_id":"go:GO:0000212","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the microtubule spindle during a meiotic cell cycle.\" [GOC:curators, GOC:mah]","metadata":null},{"id":"9e222af2639b49749ceeb103e3d3fdcb","type":"GO_TERM","name":"meiotic spindle pole","canonical_id":"go:GO:0090619","description":"\"Either of the ends of a meiotic spindle, a spindle that forms as part of meiosis, where spindle microtubules are organized; usually contains a microtubule organizing center and accessory molecules, spindle microtubules and astral microtubules.\" [GOC:ha, PMID:18250200]","metadata":null},{"id":"6683f1ada50542bd8e46128c312b1c65","type":"GO_TERM","name":"meiotic spindle pole body","canonical_id":"go:GO:0035974","description":"\"The microtubule organizing center that forms as part of the meiotic cell cycle; functionally homologous to the animal cell centrosome.\" [GOC:vw, PMID:21775631]","metadata":null},{"id":"279ffd861d1b4df6b95d643bed675016","type":"GO_TERM","name":"meiotic spindle pole body organization","canonical_id":"go:GO:1990395","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the meiotic spindle pole body.\" [GOC:vw]","metadata":null},{"id":"729b7857c05f4f0082e609ef84358373","type":"GO_TERM","name":"meiotic strand displacement","canonical_id":"go:GO:0000714","description":"\"The cell cycle process in which the broken 3' single-strand DNA molecule that formed heteroduplex DNA with its complement in an intact duplex DNA is rejected. The Watson-Crick base pairing in the original duplex is restored. The rejected 3' single-strand DNA molecule reanneals with its original complement to reform two intact duplex molecules. This occurs during meiosis.\" [GOC:elh, PMID:10357855]","metadata":null},{"id":"807f3775b08c4f27966d06f506ef347f","type":"GO_TERM","name":"meiotic strand displacement involved in double-strand break repair via SDSA","canonical_id":"go:GO:1902346","description":"\"Any meiotic strand displacement that is involved in double-strand break repair via synthesis-dependent strand annealing (SDSA).\" [GOC:al, GOC:TermGenie, PMID:22723423]","metadata":null},{"id":"d8b99acde6f7448da67582ba0dc20dd5","type":"GO_TERM","name":"meiotic strand invasion","canonical_id":"go:GO:0000708","description":"\"The cell cycle process in which the nucleoprotein complex (composed of the broken single-strand DNA and the recombinase) searches and identifies a region of homology in intact duplex DNA. The broken single-strand DNA displaces the like strand and forms Watson-Crick base pairs with its complement, forming a duplex in which each strand is from one of the two recombining DNA molecules. This occurs during meiosis.\" [GOC:elh, PMID:10915877]","metadata":null},{"id":"49ea5dcb0d454db5a91327c5c7a28649","type":"GO_TERM","name":"meiotic strand invasion involved in reciprocal meiotic recombination","canonical_id":"go:GO:0010774","description":"\"The cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate resulting in meiotic recombination. Meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"67c743a38b7f44eba5cfb1b347d5eb9a","type":"GO_TERM","name":"meiotic telomere clustering","canonical_id":"go:GO:0045141","description":"\"The cell cycle process in which the dynamic reorganization of telomeres occurs in early meiotic prophase, during which meiotic chromosome ends are gathered in a bouquet arrangement at the inner surface of the nuclear envelope proximal to the spindle pole body. This plays an important role in progression through meiosis and precedes synapsis.\" [GOC:vw, PMID:10690419]","metadata":null},{"id":"2738c619a44644bca45714d0a85faab3","type":"GO_TERM","name":"meiotic telomere maintenance via semi-conservative replication","canonical_id":"go:GO:1902989","description":"\"Any telomere maintenance via semi-conservative replication that is involved in meiotic cell cycle.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"20903c93f8fe4a4da7538ef71c2ef8a1","type":"GO_TERM","name":"meiotic telomere tethering at nuclear periphery","canonical_id":"go:GO:0044821","description":"\"The process in which a telomere is maintained in a specific location at the nuclear periphery, as part of a meiotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"6adf988cf78f4e39a953884de47e0169","type":"GO_TERM","name":"meiotic telophase I","canonical_id":"go:GO:0007134","description":"\"The cell cycle phase which follows anaphase I of meiosis and during which the chromosomes arrive at the poles of the cell and the division of the cytoplasm starts.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"607fb8ecfa93449496069ae63e088718","type":"GO_TERM","name":"meiotic telophase II","canonical_id":"go:GO:0007139","description":"\"The cell cycle phase which follows anaphase II of meiosis and during which the chromosomes arrive at the poles of the cell and the division of the cytoplasm starts.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"5bab1190ea93433ba16d00cd81de4669","type":"GO_TERM","name":"meisosome","canonical_id":"go:GO:0160132","description":"\"A cell part that is composed of multifold plasma membrane of the epidermis where it is in direct contact with apical extracellular matrix. Meisosome, or multiple eisome is named because of its superficial similarity to yeast eisosome.\" [PMID:36913486]","metadata":null},{"id":"96ebb84e88dd456c9fa59fa51afba56d","type":"GO_TERM","name":"melanin biosynthetic process","canonical_id":"go:GO:0042438","description":"\"The chemical reactions and pathways resulting in the formation of melanins, pigments largely of animal origin. High molecular weight polymers of indole quinone, they are irregular polymeric structures and are divided into three groups: allomelanins in the plant kingdom and eumelanins and phaeomelanins in the animal kingdom.\" [GOC:curators]","metadata":null},{"id":"cf610832a67b49c291d4fbcc2b03eaf9","type":"GO_TERM","name":"melanin biosynthetic process from tyrosine","canonical_id":"go:GO:0006583","description":"\"The chemical reactions and pathways resulting in the formation of melanin from other compounds, including tyrosine.\" [GOC:go_curators]","metadata":null},{"id":"cb926b1cf13448ecb3eaf6f99f146f8d","type":"GO_TERM","name":"melanin catabolic process","canonical_id":"go:GO:0046150","description":"\"The chemical reactions and pathways resulting in the breakdown of melanins, pigments largely of animal origin. High molecular weight polymers of indole quinone, they are irregular polymeric structures and are divided into three groups: allomelanins in the plant kingdom and eumelanins and phaeomelanins in the animal kingdom.\" [ISBN:0198506732]","metadata":null},{"id":"0e96148017be4f12b47cb7212f788e1b","type":"GO_TERM","name":"melanin metabolic process","canonical_id":"go:GO:0006582","description":"\"The chemical reactions and pathways involving melanins, pigments largely of animal origin. High molecular weight polymers of indole quinone, they are irregular polymeric structures and are divided into three groups: allomelanins in the plant kingdom and eumelanins and phaeomelanins in the animal kingdom.\" [GOC:curators]","metadata":null},{"id":"be56ee672c4b4e37958e5f3e47680f71","type":"GO_TERM","name":"melanin-concentrating hormone activity","canonical_id":"go:GO:0030354","description":"\"The action characteristic of melanin-concentrating hormone, a cyclic peptide hormone that, upon receptor binding, induces melanin aggregation in melanocytes, and is also involved in regulating food intake and energy balance in mammals.\" [GOC:mah, PMID:11416225, PMID:9792536]","metadata":null},{"id":"6e94437f9e294b15b38196b13eca743f","type":"GO_TERM","name":"melanin-concentrating hormone receptor activity","canonical_id":"go:GO:0030273","description":"\"Combining with the cyclic peptide hormone melanin-concentrating hormone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"7b7cef26dfa940818b6f2f2c0fb19bbf","type":"GO_TERM","name":"melanin-concentrating hormone receptor binding","canonical_id":"go:GO:0031776","description":"\"Binding to a melanin-concentrating hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"458bb0190a1144d184f9294d5f5e1195","type":"GO_TERM","name":"melanization defense response","canonical_id":"go:GO:0035006","description":"\"The blackening of the wounded area of the cuticle or the surface of invading pathogens, parasites or parasitoids, resulting from a proteolytic cascade leading to the de novo synthesis and deposition of melanin.\" [GOC:bf, PMID:12408809]","metadata":null},{"id":"efc3aa6f3280420f98d02f44b08ea9d3","type":"GO_TERM","name":"melanization of appressorium wall","canonical_id":"go:GO:0075043","description":"\"The process in which melanin is produced in the appressorium of the symbiont. Melanization of the appressorium increases turgor pressure in the appressorium.\" [GOC:pamgo_curators, PMID:28165657, Wikipedia:Appressorium]","metadata":null},{"id":"214d8393903847abada4279e5bd9758c","type":"GO_TERM","name":"melanocortin receptor activity","canonical_id":"go:GO:0004977","description":"\"Combining with melanocortin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"3506ef63a1c84681a113e51666b5aeee","type":"GO_TERM","name":"melanocortin receptor binding","canonical_id":"go:GO:0031779","description":"\"Binding to a melanocortin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9cb7df3a98b545ec8b53307c712c9bf3","type":"GO_TERM","name":"melanocyte adhesion","canonical_id":"go:GO:0097326","description":"\"The attachment of a melanocyte to another cell via adhesion molecules.\" [CL:0000148, GOC:uh, PMID:22637532]","metadata":null},{"id":"e7adf1cd1e1043bf92ca870a94f93ce8","type":"GO_TERM","name":"melanocyte apoptotic process","canonical_id":"go:GO:1902362","description":"\"Any apoptotic process in a melanocyte, the main structural component of the epidermis.\" [GOC:ic, GOC:TermGenie, PMID:20530876]","metadata":null},{"id":"008eaed28059462babeee65b2b50fd0b","type":"GO_TERM","name":"melanocyte differentiation","canonical_id":"go:GO:0030318","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a melanocyte.\" [GOC:mah]","metadata":null},{"id":"29c6734a1f154efe8f57ea3fcc29a153","type":"GO_TERM","name":"melanocyte migration","canonical_id":"go:GO:0097324","description":"\"The orderly movement of melanocytes from one site to another, often during the development of a multicellular organism. A melanocyte is a pigment cell derived from the neural crest. It contains melanin-filled pigment granules, which give a brown to black appearance.\" [CL:0000148, GOC:uh, PMID:22637532]","metadata":null},{"id":"de14c7325949466c8b153060c0ae2acf","type":"GO_TERM","name":"melanocyte proliferation","canonical_id":"go:GO:0097325","description":"\"The multiplication or reproduction of melanocytes, resulting in the expansion of a cell population. A melanocyte is a pigment cell derived from the neural crest. It contains melanin-filled pigment granules, which give a brown to black appearance.\" [CL:0000148, GOC:uh, PMID:22637532]","metadata":null},{"id":"1fd54acaf46f4243a727f7755386810f","type":"GO_TERM","name":"melanocyte-stimulating hormone activity","canonical_id":"go:GO:0017044","description":"\"The action characteristic of melanocyte-stimulating hormone, any of three peptide hormones that are produced by the intermediate lobe of the pituitary gland and, upon receptor binding, cause dispersal of melanosomes in melanophores of poikilothermic vertebrates.\" [ISBN:0198506732]","metadata":null},{"id":"70b0505ec23e43b38aafb0819024b429","type":"GO_TERM","name":"melanocyte-stimulating hormone receptor activity","canonical_id":"go:GO:0004980","description":"\"Combining with melanocyte-stimulating hormone to initiate a change in cell activity.\" [GOC:jl, PMID:7581459]","metadata":null},{"id":"bf73b2fdf4c2441fac0db1951fe99508","type":"GO_TERM","name":"melanocyte-stimulating hormone secretion","canonical_id":"go:GO:0036160","description":"\"The regulated release of a melanocyte-stimulating hormone, any of a group of peptide hormones that are produced by cells in the intermediate lobe of the pituitary gland, and stimulate the production of melanin to increase pigmentation.\" [GOC:cjm, Wikipedia:Melanocyte-stimulating_hormone]","metadata":null},{"id":"73f53f537c7b49bfaeb25f54334e3c99","type":"DISEASE","name":"melanoma","canonical_id":"mondo:0005105","description":null,"metadata":null},{"id":"bf017762ca604c9dbddbf46d03e4feda","type":"DISEASE","name":"melanoma, cutaneous malignant, susceptibility to, 3","canonical_id":"mondo:0012183","description":null,"metadata":null},{"id":"bd49756bc3b640109186a2df08a28192","type":"GO_TERM","name":"melanosomal lumen acidification","canonical_id":"go:GO:7770038","description":"\"Any process that reduces the pH of the melanosomal lumen, corresponding to an increase in hydrogen ion concentration.\" [PMID:23205854, PMID:35469906]","metadata":null},{"id":"6a4ddc14b2a645c3bec177ca122e2971","type":"GO_TERM","name":"melanosomal lumen pH elevation","canonical_id":"go:GO:7770039","description":"\"Any process that increases the pH of the melanosomal lumen, corresponding to a decrease in hydrogen ion concentration.\" [PMID:11310796, PMID:27140606, PMID:32966160, PMID:35469906]","metadata":null},{"id":"577d3689f82246ddb6fe17b46f3cfccb","type":"GO_TERM","name":"melanosome","canonical_id":"go:GO:0042470","description":"\"A tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored. Melanosomes are synthesized in melanocyte cells.\" [GOC:jl, PMID:11584301]","metadata":null},{"id":"93f90e4759344d7eb1417db9922144f2","type":"GO_TERM","name":"melanosome assembly","canonical_id":"go:GO:1903232","description":"\"The aggregation, arrangement and bonding together of a set of components to form a melanosome, a tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22511774]","metadata":null},{"id":"77eaa21bf3174d26aeb0885404e25036","type":"GO_TERM","name":"melanosome localization","canonical_id":"go:GO:0032400","description":"\"Any process in which a melanosome is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ln]","metadata":null},{"id":"f80aa6816b1d4741bd3f5f99844e41be","type":"GO_TERM","name":"melanosome lumen","canonical_id":"go:GO:0034493","description":"\"The volume enclosed by the melanosome membrane.\" [GOC:rph]","metadata":null},{"id":"ca1459a0d3dd433b89726286f0744ce2","type":"GO_TERM","name":"melanosome membrane","canonical_id":"go:GO:0033162","description":"\"The lipid bilayer surrounding a melanosome.\" [GOC:mah]","metadata":null},{"id":"5c582556d43f46779f0cdcbd8834cb94","type":"GO_TERM","name":"melanosome organization","canonical_id":"go:GO:0032438","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a melanosome. A melanosome is a tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored.\" [GOC:vk]","metadata":null},{"id":"3b387416cefa475c810fc7fe3302e281","type":"GO_TERM","name":"melanosome transport","canonical_id":"go:GO:0032402","description":"\"The directed movement of melanosomes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ln]","metadata":null},{"id":"d0b921a4202a4f86a9c4ec1757a0c772","type":"GO_TERM","name":"melanotic encapsulation of foreign target","canonical_id":"go:GO:0035011","description":"\"Formation of a multilayered, melanized sheath of cells around a foreign invader.\" [GOC:bf]","metadata":null},{"id":"d25d3dbae71d4ec680c7e9c72eb20746","type":"DRUG","name":"melarsoprol","canonical_id":"mesh:D008549","description":null,"metadata":null},{"id":"fd71d241e8d741f88f8ddc6d5fe7f3ef","type":"DRUG","name":"melatonin","canonical_id":"gtopdb:224","description":null,"metadata":null},{"id":"01bdc64699504bc8b4304f4f63ccc36f","type":"DRUG","name":"melatonin","canonical_id":"mesh:D008550","description":null,"metadata":null},{"id":"e56563f0bc5e4885ae55395ccd0c22bf","type":"DRUG","name":"melatonin","canonical_id":"chembl:CHEMBL45","description":null,"metadata":null},{"id":"28ff488ad2b94f76b05179d06452b261","type":"GO_TERM","name":"melatonin binding","canonical_id":"go:GO:1904408","description":"\"Binding to melatonin.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10379923]","metadata":null},{"id":"b9f5404bd3ce49148ad78f3d506c5802","type":"GO_TERM","name":"melatonin biosynthetic process","canonical_id":"go:GO:0030187","description":"\"The chemical reactions and pathways resulting in the formation of melatonin (N-acetyl-5-methoxytryptamine).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"a0104b7aaae54cb18633d4dd2f461380","type":"GO_TERM","name":"melatonin catabolic process","canonical_id":"go:GO:0042442","description":"\"The chemical reactions and pathways resulting in the breakdown of melatonin (N-acetyl-5-methoxytryptamine).\" [GOC:jl]","metadata":null},{"id":"1d3be09bfc9d4576a9cc1eec43036af0","type":"GO_TERM","name":"melatonin metabolic process","canonical_id":"go:GO:0030186","description":"\"The chemical reactions and pathways involving melatonin (N-acetyl-5-methoxytryptamine).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"c4479cdbd87c4007b8fa32807ab2d34e","type":"GO_TERM","name":"melatonin receptor activity","canonical_id":"go:GO:0008502","description":"\"Combining with melatonin, N-acetyl-5-methoxytryptamine, to initiate a change in cell activity. Melatonin is a neuroendocrine substance that stimulates the aggregation of melanosomes in melanophores, thus lightening the skin.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"30fd31cb0a714a39883a089c5a57a33d","type":"GO_TERM","name":"melatonin receptor binding","canonical_id":"go:GO:0031784","description":"\"Binding to a melatonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6d61ec98e4c84c8c8c339f737d919151","type":"GO_TERM","name":"melibiose binding","canonical_id":"go:GO:1903777","description":"\"Binding to melibiose.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:11471732]","metadata":null},{"id":"95d39a33f0384ef1bf2727647069da0d","type":"GO_TERM","name":"melibiose biosynthetic process","canonical_id":"go:GO:0042544","description":"\"The chemical reactions and pathways resulting in the formation of melibiose, the disaccharide 6-O-alpha-D-galactopyranosyl-D-glucose.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"74b7c992c34b4a3c8f01116c2c327226","type":"GO_TERM","name":"melibiose catabolic process","canonical_id":"go:GO:0005995","description":"\"The chemical reactions and pathways resulting in the breakdown of melibiose, the disaccharide 6-O-alpha-D-galactopyranosyl-D-glucose.\" [ISBN:0198547684]","metadata":null},{"id":"986506860215447b80684b2ea5bf7766","type":"GO_TERM","name":"melibiose transmembrane transporter activity","canonical_id":"go:GO:0015156","description":"\"Enables the transfer of melibiose from one side of a membrane to the other. Melibiose is the disaccharide 6-O-alpha-D-galactopyranosyl-D-glucose and occurs as a constituent of the trisaccharide raffinose or in the exudates and nectaries of a number of plants.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"8635ce7987c44705bfa92cea621cc142","type":"GO_TERM","name":"melibiose transport","canonical_id":"go:GO:0015769","description":"\"The directed movement of melibiose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Melibiose is the disaccharide 6-O-alpha-D-galactopyranosyl-D-glucose.\" [GOC:ai]","metadata":null},{"id":"1f65297caeec4812a0f50a3e8cd4f6a7","type":"GO_TERM","name":"melibiose:monoatomic cation symporter activity","canonical_id":"go:GO:0015487","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: melibiose(out) + monovalent cation(out) = melibiose(in) + monovalent cation(in).\" [TC:2.A.2.1.1]","metadata":null},{"id":"df2b0a09a50b44f0b7165f702df9fa04","type":"GO_TERM","name":"melibiose:sodium symporter activity","canonical_id":"go:GO:0043887","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: melibiose(out) + Na+(out) = melibiose(in) + Na+(in).\" [PMID:1970646]","metadata":null},{"id":"b8c9314780ca48438c5b00dfcbd6a551","type":"GO_TERM","name":"melilotate 3-monooxygenase activity","canonical_id":"go:GO:0050091","description":"\"Catalysis of the reaction: 3-(2-hydroxyphenyl)propanoate + H+ + NADH + O2 = 3-(2,3-dihydroxyphenyl)propanoate + H2O + NAD+.\" [EC:1.14.13.4, RHEA:17669]","metadata":null},{"id":"8faeb314be81405ca16ca98451a4ab0c","type":"DISEASE","name":"melorheostosis","canonical_id":"mondo:0007970","description":null,"metadata":null},{"id":"ae9d395005424f2dad55d6ad78011f51","type":"DRUG","name":"meloxicam","canonical_id":"gtopdb:7220","description":null,"metadata":null},{"id":"5545287cc9514c6f8ad64b91ac6eb058","type":"DRUG","name":"meloxicam","canonical_id":"mesh:D000077239","description":null,"metadata":null},{"id":"74f3c037c2de469693e164d44348629b","type":"DRUG","name":"meloxicam","canonical_id":"chembl:CHEMBL599","description":null,"metadata":null},{"id":"81392dae904e4fa78868ddab3dfc00f0","type":"COMBINATION_TREATMENT","name":"meloxicam + naproxen","canonical_id":"ctgov_combo:ctgov-combo-1904f0d869cc66c2","description":null,"metadata":null},{"id":"415999e1d34241ecaf7f5cb56103b824","type":"COMBINATION_TREATMENT","name":"meloxicam + rizatriptan","canonical_id":"ctgov_combo:ctgov-combo-877067d1375ba557","description":null,"metadata":null},{"id":"e5cb2d56cb7c4c76acc6d603c36c1258","type":"COMBINATION_TREATMENT","name":"meloxicam + rizatriptan","canonical_id":"ctgov_combo:ctgov-combo-a243e12c9f20c127","description":null,"metadata":null},{"id":"aac1da6399da49609a97114e27ef7dbe","type":"GO_TERM","name":"membrane","canonical_id":"go:GO:0016020","description":"\"A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it.\" [GOC:dos, GOC:mah, ISBN:0815316194]","metadata":null},{"id":"4581264f68da46e580a66119b1493da6","type":"GO_TERM","name":"membrane addition at site of cytokinesis","canonical_id":"go:GO:0007107","description":"\"Any process involved in the net addition of membrane at the site of cytokinesis; includes vesicle recruitment and fusion, local lipid synthesis and insertion.\" [GOC:clt]","metadata":null},{"id":"0f2c206296cd4ee1843c77cf4782c7bf","type":"GO_TERM","name":"membrane addition at site of mitotic cytokinesis","canonical_id":"go:GO:0061796","description":"\"A mitotic cell cycle process involved in the net addition of membrane at the site of cytokinesis; includes vesicle recruitment and fusion, local lipid synthesis and insertion.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"b6ad94a44fa4466a8262c3510ac47766","type":"GO_TERM","name":"membrane assembly","canonical_id":"go:GO:0071709","description":"\"The aggregation, arrangement and bonding together of a set of components to form a membrane.\" [GOC:mah]","metadata":null},{"id":"f4ec47c78f4e45d1a76b34e204d7af0b","type":"GO_TERM","name":"membrane attack complex","canonical_id":"go:GO:0005579","description":"\"A protein complex produced by sequentially activated components of the complement cascade inserted into a target cell membrane and forming a pore leading to cell lysis via ion and water flow.\" [GOC:add, ISBN:0198547684, ISBN:068340007X, ISBN:0781735149]","metadata":null},{"id":"723388e9a4454ea89036661411a8251d","type":"GO_TERM","name":"membrane bending","canonical_id":"go:GO:0097753","description":"\"A membrane organization process resulting in the bending of a membrane.\" [GOC:krc, GOC:pr, GOC:vw, Wikipedia:Membrane_curvature]","metadata":null},{"id":"38a7d036b8d0440fa4a488e43d25b185","type":"GO_TERM","name":"membrane bending activity","canonical_id":"go:GO:0180020","description":"\"The activity of bending or deforming a membrane. This activity can occur by multiple mechanisms including the insertion amphipathic domains into one or both leaflets.\" [PMID:19780639]","metadata":null},{"id":"9e9afd930a514847be855ee38845b6eb","type":"GO_TERM","name":"membrane biogenesis","canonical_id":"go:GO:0044091","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a membrane.\" [GOC:jl]","metadata":null},{"id":"d4efabbc78e64f7c877d6226613f8873","type":"GO_TERM","name":"membrane bone morphogenesis","canonical_id":"go:GO:0061973","description":"\"The process in which bone which forms deep in the organism are generated and organized.\" [PMID:14579374]","metadata":null},{"id":"054f0639464c4e128d37336a2248480f","type":"GO_TERM","name":"membrane coat","canonical_id":"go:GO:0030117","description":"\"Any of several different proteinaceous coats that can associate with membranes. Membrane coats include those formed by clathrin plus an adaptor complex, the COPI and COPII complexes, and possibly others. They are found associated with membranes on many vesicles as well as other membrane features such as pits and perhaps tubules.\" [GOC:mah]","metadata":null},{"id":"7dbb1d331f584c04a4560d36d5099db7","type":"GO_TERM","name":"membrane curvature sensor activity","canonical_id":"go:GO:0140090","description":"\"Preferential binding of proteins on curved membranes. The binding to curved membranes by insertion (aka wedging) to curved membranes is mediated by both the hydrophobic and hydrophilic faces of the helix of membrane curvature sensing (MCS) proteins.\" [PMID:25898166]","metadata":null},{"id":"1db6f2c5bd3e4b9aa9416c240979a844","type":"GO_TERM","name":"membrane depolarization","canonical_id":"go:GO:0051899","description":"\"The process in which membrane potential decreases with respect to its steady-state potential, usually from negative potential to a more positive potential. For example, the initial depolarization during the rising phase of an action potential is in the direction from the negative steady-state resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:dh, Wikipedia:Depolarization]","metadata":null},{"id":"114818443fdf48bba8701924e5d1496b","type":"GO_TERM","name":"membrane depolarization during AV node cell action potential","canonical_id":"go:GO:0086045","description":"\"The process in which AV node cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"ca1a5845fdc84efc9a653966577b56c9","type":"GO_TERM","name":"membrane depolarization during Purkinje myocyte cell action potential","canonical_id":"go:GO:0086047","description":"\"The process in which Purkinje myocyte membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"945c7e20f03041aaacc8ee3b61665084","type":"GO_TERM","name":"membrane depolarization during SA node cell action potential","canonical_id":"go:GO:0086046","description":"\"The process in which SA node cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"96b11851ccbe41d0966e5420277c2405","type":"GO_TERM","name":"membrane depolarization during action potential","canonical_id":"go:GO:0086010","description":"\"The process in which membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"7ed8fb27a1d84993bdc53be0237f9b88","type":"GO_TERM","name":"membrane depolarization during atrial cardiac muscle cell action potential","canonical_id":"go:GO:0098912","description":"\"The process in which atrial cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb]","metadata":null},{"id":"ae21169104074c399380b6fd436b80c5","type":"GO_TERM","name":"membrane depolarization during bundle of His cell action potential","canonical_id":"go:GO:0086048","description":"\"The process in which bundle of His cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"dabbbd7c44c54e0e8287ecfe6c05520c","type":"GO_TERM","name":"membrane depolarization during cardiac muscle cell action potential","canonical_id":"go:GO:0086012","description":"\"The process in which cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"7518b7973c434d238a307190f5374830","type":"GO_TERM","name":"membrane depolarization during ventricular cardiac muscle cell action potential","canonical_id":"go:GO:0098913","description":"\"The process in which ventricular cardiac muscle cell membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.\" [GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb]","metadata":null},{"id":"8013d016f44246fd9c5b1118617b52d4","type":"GO_TERM","name":"membrane destabilizing activity","canonical_id":"go:GO:0140912","description":"\"Binding to a membrane and increasing its permeability. This may lead to cell membrane lysis and cell content release.\" [PMID:34496967]","metadata":null},{"id":"6fc67021eb4a47999d28c06ba8797295","type":"GO_TERM","name":"membrane disassembly","canonical_id":"go:GO:0030397","description":"\"The controlled breakdown of any cell membrane in the context of a normal process such as autophagy.\" [GOC:mah]","metadata":null},{"id":"be712b93ffe84fb1b554053716e11802","type":"GO_TERM","name":"membrane docking","canonical_id":"go:GO:0022406","description":"\"The initial attachment of a membrane or protein to a target membrane. Docking requires only that the proteins come close enough to interact and adhere.\" [GOC:isa_complete, PMID:27875684]","metadata":null},{"id":"be6ce4fe03004dc69cf4670450401283","type":"GO_TERM","name":"membrane fission","canonical_id":"go:GO:0090148","description":"\"A process that is carried out at the cellular level which results in the separation of a single continuous membrane into two membranes.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d489c9e8b0ab4cbca111b2db949562b1","type":"GO_TERM","name":"membrane fusion","canonical_id":"go:GO:0061025","description":"\"The membrane organization process that joins two lipid bilayers to form a single membrane.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"90f4cb23d2e543bd92411c099f03339f","type":"GO_TERM","name":"membrane fusion involved in acrosome reaction","canonical_id":"go:GO:0002078","description":"\"The fusion of the plasma membrane of the sperm with the outer acrosomal membrane.\" [GOC:dph, PMID:3886029]","metadata":null},{"id":"bb952fdeaf1541fda4f13c10d37a4606","type":"GO_TERM","name":"membrane fusion involved in viral entry into host cell","canonical_id":"go:GO:0039663","description":"\"Merging of the virion membrane and a host membrane (host plasma membrane or host organelle membrane) that is involved in the uptake of a virus into a host cell.\" [GOC:bf, GOC:jl, UniProtKB-KW:KW-1168]","metadata":null},{"id":"fd2a890915d1444faf88333c2ea00685","type":"GO_TERM","name":"membrane fusion priming complex","canonical_id":"go:GO:0120124","description":"\"A protein complex that primes vacuolar or vesicular membranes for fusion with other intracellular membranes, by promoting the dissociation of cis-SNARE complexes.\" [GOC:lnp, PMID:9015301]","metadata":null},{"id":"1b679a469c9d4037a7ceaa65bd220af6","type":"GO_TERM","name":"membrane grommet activity","canonical_id":"go:GO:0180024","description":"\"An activity in which a protein, or group of proteins, acts to restrict the size of a fenestration in a membrane or membrane system (i.e. restrict the diameter of a hole in a membrane). An example of this is the molecular function is performed by ESCRT-III proteins at the nuclear envelope of fission yeast during anaphase B.\" [PMID:37783794]","metadata":null},{"id":"8f9d80d7f52948619cabb9aad5c4fc1a","type":"GO_TERM","name":"membrane hyperpolarization","canonical_id":"go:GO:0060081","description":"\"The process in which membrane potential increases with respect to its steady-state potential, usually from negative potential to a more negative potential. For example, during the repolarization phase of an action potential the membrane potential often becomes more negative or hyperpolarized before returning to the steady-state resting potential.\" [GOC:dph]","metadata":null},{"id":"08b2e7a761504f0aa95fe73cda2d2a7a","type":"GO_TERM","name":"membrane insertase activity","canonical_id":"go:GO:0032977","description":"\"Binds transmembrane domain-containing proteins and mediates their integration into a membrane.\" [PMID:14739936, PMID:29809151, PMID:30415835, PMID:32459176]","metadata":null},{"id":"522b50cd2e8e42be8fa2c699b1b29021","type":"GO_TERM","name":"membrane invagination","canonical_id":"go:GO:0010324","description":"\"The infolding of a membrane.\" [GOC:tb]","metadata":null},{"id":"91dc3af1943345f79f90d24701448be0","type":"GO_TERM","name":"membrane macromolecule biosynthetic process","canonical_id":"go:GO:0071710","description":"\"The chemical reactions and pathways resulting in the formation of a macromolecule destined to form part of a membrane in a cell.\" [GOC:mah]","metadata":null},{"id":"20890b070729463ebf5d368a85b86256","type":"GO_TERM","name":"membrane microdomain","canonical_id":"go:GO:0098857","description":"\"A membrane region with a lipid composition that is distinct from that of the membrane regions that surround it.\" [PMID:20044567, PMID:26253820]","metadata":null},{"id":"374e1dff4b724df69548c310924efa4d","type":"GO_TERM","name":"membrane organization","canonical_id":"go:GO:0061024","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of a membrane. A membrane is a double layer of lipid molecules that encloses all cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c561507a9cb04ac58b361fe332d1a034","type":"GO_TERM","name":"membrane potential driven uniporter activity","canonical_id":"go:GO:0022810","description":"\"Enables the active transport of a solute across a membrane by a mechanism involving conformational change, where energy for active transport is derived from membrane potential if the solute is charged.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"d3fb34238e814e6d9882225b80484ef5","type":"GO_TERM","name":"membrane protein complex","canonical_id":"go:GO:0098796","description":"\"Any protein complex that is part of a membrane.\" [GOC:dos]","metadata":null},{"id":"d5d4b34d37854494a805eff0e509cbc0","type":"GO_TERM","name":"membrane protein dislocase activity","canonical_id":"go:GO:0140567","description":"\"The activity of removing a protein from a membrane, by binding to a transmembrane helical fragment of a tail-anchored protein and releasing it from the the hydrophobic region of one or both lipid bilayers. The reaction is driven by ATP hydrolysis.\" [PMID:24821790, PMID:28712723, PMID:32973005]","metadata":null},{"id":"53623a6c3623487e9228a8d2fd132b58","type":"GO_TERM","name":"membrane protein ectodomain proteolysis","canonical_id":"go:GO:0006509","description":"\"The proteolytic cleavage of transmembrane proteins and release of their ectodomain (extracellular domain).\" [GOC:jl, PMID:24227200]","metadata":null},{"id":"15dc11763a1e49cc88724aa07e4964d4","type":"GO_TERM","name":"membrane protein intracellular domain proteolysis","canonical_id":"go:GO:0031293","description":"\"The proteolytic cleavage of a transmembrane protein leading to the release of an intracellular domain.\" [PMID:12808018]","metadata":null},{"id":"cd76b10257594a6481949a830ba3afa9","type":"GO_TERM","name":"membrane protein proteolysis","canonical_id":"go:GO:0033619","description":"\"The proteolytic cleavage of a transmembrane protein leading to the release of its intracellular or ecto-domains.\" [GOC:pde]","metadata":null},{"id":"6210696577ae4f4ba1d597b56014f7f4","type":"GO_TERM","name":"membrane raft","canonical_id":"go:GO:0045121","description":"\"Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions.\" [PMID:16645198, PMID:20044567]","metadata":null},{"id":"5020c936fcfe47038ceceed1ee2d92bc","type":"GO_TERM","name":"membrane raft assembly","canonical_id":"go:GO:0001765","description":"\"The aggregation, arrangement and bonding together of a set of components to form a membrane raft, a small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalizes cellular processes.\" [PMID:12648772, PMID:12803918, PMID:16645198]","metadata":null},{"id":"a301fe4f32d74ed580d983791319addc","type":"GO_TERM","name":"membrane raft distribution","canonical_id":"go:GO:0031580","description":"\"The process that establishes the spatial arrangement of membrane rafts within a cellular membrane.\" [GOC:mah]","metadata":null},{"id":"8f67456fae804c07bf705b6ef493b7ab","type":"GO_TERM","name":"membrane raft localization","canonical_id":"go:GO:0051665","description":"\"Any process in which membrane rafts are transported to, or maintained in, a specific location. Membrane rafts are small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes.\" [GOC:ai, PMID:16645198]","metadata":null},{"id":"bfa1b931c5cf4d859f3a13b06845b003","type":"GO_TERM","name":"membrane raft organization","canonical_id":"go:GO:0031579","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of membrane rafts, small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"0e4a65fbf0b64981aba2ec62ac942d4d","type":"GO_TERM","name":"membrane raft polarization","canonical_id":"go:GO:0001766","description":"\"The clustering and aggregation of a membrane into domains. This serves as a mechanism to compartmentalize cellular activities and to establish cell polarity.\" [PMID:12615889]","metadata":null},{"id":"d6187f9bd083417290cf63ce94c501b2","type":"GO_TERM","name":"membrane reorganization involved in phagocytosis, engulfment","canonical_id":"go:GO:0060098","description":"\"The assembly and arrangement of the plasma membrane that is involved in the internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis.\" [GOC:dph]","metadata":null},{"id":"5c6f2bf8b10b456788be6045be71f4bd","type":"GO_TERM","name":"membrane repolarization","canonical_id":"go:GO:0086009","description":"\"The process in which ions are transported across a membrane such that the membrane potential changes in the repolarizing direction, toward the steady state potential. For example, the repolarization during an action potential is from a positive membrane potential towards a negative resting potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"6fb9b4358d6843279f648bcb330d40d6","type":"GO_TERM","name":"membrane repolarization during AV node cell action potential","canonical_id":"go:GO:0086049","description":"\"The process in which ions are transported across a membrane such that the AV node cardiac muscle cell membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"5faeddb02e1341beb76e59bb26be6eeb","type":"GO_TERM","name":"membrane repolarization during Purkinje myocyte action potential","canonical_id":"go:GO:0086051","description":"\"The process in which ions are transported across a membrane such that the Purkinje myocyte membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"fef2104bcfba4ca7b23dd400868ca659","type":"GO_TERM","name":"membrane repolarization during SA node cell action potential","canonical_id":"go:GO:0086052","description":"\"The process in which an SA node cardiac muscle cell membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"28a57cddd22f46dcbe77413826f34b7f","type":"GO_TERM","name":"membrane repolarization during action potential","canonical_id":"go:GO:0086011","description":"\"The process in which ions are transported across a membrane such that the membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"7aa76e82a7e04e37805a2976187985bc","type":"GO_TERM","name":"membrane repolarization during atrial cardiac muscle cell action potential","canonical_id":"go:GO:0098914","description":"\"The process in which ions are transported across a membrane such that the atrial cardiomyocyte membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb]","metadata":null},{"id":"c63f0b1ead1f44719dc76339b02a7cc9","type":"GO_TERM","name":"membrane repolarization during bundle of His cell action potential","canonical_id":"go:GO:0086050","description":"\"The process in which ions are transported across a membrane such that the bundle of His cardiac muscle cell membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"9b4ba3de82444b7eb54ccda512bd56da","type":"GO_TERM","name":"membrane repolarization during cardiac muscle cell action potential","canonical_id":"go:GO:0086013","description":"\"The process in which ions are transported across a membrane such that the cardiac muscle cell plasma membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"e3a567fa34eb414482bdc87779e03011","type":"GO_TERM","name":"membrane repolarization during ventricular cardiac muscle cell action potential","canonical_id":"go:GO:0098915","description":"\"The process in which ions are transported across a membrane such that the ventricular cardiomyocyte membrane potential changes in the direction from the positive membrane potential at the peak of the action potential towards the negative resting potential.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb]","metadata":null},{"id":"8b8015a5e25741b8a7e1aef8d303bdfa","type":"GO_TERM","name":"membrane scission GTPase motor activity","canonical_id":"go:GO:1990606","description":"\"Generation of a 'twisting' activity resulting in the scission of a membrane, driven by GTP hydrolysis.\" [PMID:11242086, PMID:23530241, PMID:24515348]","metadata":null},{"id":"9f099ff9b52249679ddbca9938607628","type":"GO_TERM","name":"membrane stack","canonical_id":"go:GO:1990007","description":"\"A configuration of endoplasmic reticulum (ER) found in Purkinje cells in the cerebellum and in axons in the lateral vestibular nucleus, consisting of parallel and interconnecting tubules whose outer surfaces are covered by particles or ringlike structures.\" [ISBN:9780195065718, NIF_Subcellular:sao2114874506]","metadata":null},{"id":"9d837a001e8e40e395619b14d4f074d4","type":"GO_TERM","name":"membrane tag activity","canonical_id":"go:GO:0141048","description":"\"A molecular function exhibited by a protein that is covalently attached (AKA tagged or conjugated) to a lipid, where it acts as a marker for a membrane, recognized by the cellular apparatus to target the tagged protein for some cellular process such as autophagy.\" [PMID:17632063]","metadata":null},{"id":"fe19a7740fc74cb4a9862329c68433ce","type":"GO_TERM","name":"membrane to membrane docking","canonical_id":"go:GO:0022614","description":"\"The initial attachment of a membrane to a target membrane, mediated by proteins protruding from the two membranes. Docking requires only that the membranes come close enough for the proteins to interact and adhere.\" [GOC:isa_complete]","metadata":null},{"id":"99d8f73098df4345920c65e9e30eacfa","type":"GO_TERM","name":"membrane tubulation","canonical_id":"go:GO:0097749","description":"\"A membrane organization process resulting in the formation of a tubular projection. This may face inwardly (as in tubular membrane invaginations) or outwardly (as in endosomal tubules).\" [GOC:pr]","metadata":null},{"id":"4de391b427034424a69ef4cf536606a5","type":"GO_TERM","name":"membrane-bounded organelle","canonical_id":"go:GO:0043227","description":"\"Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane.\" [GOC:curators]","metadata":null},{"id":"69f2a18c2ace48789b37cf24f378f747","type":"GO_TERM","name":"membrane-enclosed lumen","canonical_id":"go:GO:0031974","description":"\"The enclosed volume within a sealed membrane or between two sealed membranes. Encompasses the volume enclosed by the membranes of a particular organelle, e.g. endoplasmic reticulum lumen, or the space between the two lipid bilayers of a double membrane surrounding an organelle, e.g. nuclear envelope lumen.\" [GOC:add, GOC:mah]","metadata":null},{"id":"38e9e5960724427faebf684ff6aaf5c0","type":"GO_TERM","name":"membrane-membrane adaptor activity","canonical_id":"go:GO:0140177","description":"\"The binding activity of a molecule that brings together two membranes, either via membrane lipid binding or by interacting with a membrane protein, to establish or maintain the localization of the protein, protein complex, vesicle or organelle.\" [GOC:curators]","metadata":null},{"id":"a419781abb3d409bacca533dde6d9fb6","type":"GO_TERM","name":"membrane-oligosaccharide glycerophosphotransferase activity","canonical_id":"go:GO:0047495","description":"\"Catalysis of the transfer of a glycerophospho group from one membrane-derived oligosaccharide to another.\" [EC:2.7.8.21]","metadata":null},{"id":"73c0b81b6557423e961077ce1a837b31","type":"GO_TERM","name":"membraneless organelle","canonical_id":"go:GO:0043228","description":"\"Organized structure of distinctive morphology and function, not bounded by a lipid bilayer membrane. Includes ribosomes, the cytoskeleton and chromosomes.\" [GOC:curators]","metadata":null},{"id":"9242250a4fec4798bff9684fbb4fa9c7","type":"GO_TERM","name":"membraneless organelle assembly","canonical_id":"go:GO:0140694","description":"\"The aggregation, arrangement and bonding together of a set of components to form a non-membrane-bounded organelle.\" [PMID:28225081]","metadata":null},{"id":"3c0508c205164833ab997b38a6257b06","type":"GO_TERM","name":"membranous septum morphogenesis","canonical_id":"go:GO:0003149","description":"\"The process in which the membranous septum is generated and organized. The membranous septum is the upper part of ventricular septum.\" [GOC:mtg_heart]","metadata":null},{"id":"1c325338ec5b45ebbd94bc59809eb11f","type":"GO_TERM","name":"memory","canonical_id":"go:GO:0007613","description":"\"The activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. The main stages involved in the formation and retrieval of memory are encoding (processing of received information by acquisition), storage (building a permanent record of received information as a result of consolidation) and retrieval (calling back the stored information and use it in a suitable way to execute a given task).\" [GOC:curators, ISBN:0582227089]","metadata":null},{"id":"6e86b6402df446ca895b2ef9f7bd1ca5","type":"GO_TERM","name":"memory B cell differentiation","canonical_id":"go:GO:0002319","description":"\"The process in which a B cell acquires the specialized features of a memory B cell. Memory B cells are cells that can respond rapidly to antigen re-exposure by production of high-affinity antibody.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"e2aa560fe302425e8f1348d74d62283f","type":"GO_TERM","name":"memory T cell activation","canonical_id":"go:GO:0035709","description":"\"The change in morphology and behavior of a memory T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.\" [CL:0000813, GOC:BHF]","metadata":null},{"id":"ac153ceeb5af4e94bcd7300f291a37d9","type":"GO_TERM","name":"memory T cell differentiation","canonical_id":"go:GO:0043379","description":"\"The process in which a newly activated T cell acquires specialized features of a memory T cell.\" [ISBN:0781735149]","metadata":null},{"id":"91797e3745c942d283f44ce9cd7d73bc","type":"GO_TERM","name":"memory T cell extravasation","canonical_id":"go:GO:0035683","description":"\"The migration of a memory T cell from the blood vessels into the surrounding tissue. A memory T cell is a distinctly differentiated long-lived T cell that has the phenotype CD45RO-positive and CD127-positive.\" [CL:0000813, GOC:BHF]","metadata":null},{"id":"60f78451d3604a0fb9d1f6e1b45a67f4","type":"GO_TERM","name":"memory T cell proliferation","canonical_id":"go:GO:0061485","description":"\"The expansion of a memory T cell population by cell division.\" [GOC:dph, PMID:14647273]","metadata":null},{"id":"a953b099445142c1a0289169fba7e66f","type":"GO_TERM","name":"menadiol geranylgeranyltransferase activity","canonical_id":"go:GO:0120566","description":"\"Catalysis of the reaction: menadiol + (2E,6E,10E)-geranylgeranyl diphosphate = menaquinol-4 + diphosphate.\" [PMID:20953171, RHEA:74083]","metadata":null},{"id":"d9f4d715e1fa410691bb02f8abd296d7","type":"GO_TERM","name":"menaquinone biosynthetic process","canonical_id":"go:GO:0009234","description":"\"The chemical reactions and pathways resulting in the formation of any of the menaquinones. Structurally, menaquinones consist of a methylated naphthoquinone ring structure and side chains composed of a variable number of unsaturated isoprenoid residues. Menaquinones that have vitamin K activity and are known as vitamin K2.\" [GOC:jl, PMID:6127606]","metadata":null},{"id":"30b0db8d0e8a4235854cdf1ada3a0fa3","type":"GO_TERM","name":"menaquinone catabolic process","canonical_id":"go:GO:0042361","description":"\"The chemical reactions and pathways resulting in the breakdown of menaquinones, any of the quinone-derived compounds synthesized by intestinal bacteria. Structurally, menaquinones consist of a methylated naphthoquinone ring structure and side chains composed of a variable number of unsaturated isoprenoid residues. Menaquinones have vitamin K activity and are known as vitamin K2.\" [GOC:jl, PMID:37938463]","metadata":null},{"id":"c11f2b536cbb4535b80943bd5285a603","type":"GO_TERM","name":"menaquinone metabolic process","canonical_id":"go:GO:0009233","description":"\"The chemical reactions and pathways involving any of the menaquinones, quinone-derived compounds synthesized by intestinal bacteria. Structurally, menaquinones consist of a methylated naphthoquinone ring structure and side chains composed of a variable number of unsaturated isoprenoid residues. Menaquinones have vitamin K activity and are known as vitamin K2.\" [GOC:jl, PMID:6127606, PMID:8642453]","metadata":null},{"id":"417a09750c80480a98fec9247794ab87","type":"GO_TERM","name":"menarche","canonical_id":"go:GO:0042696","description":"\"The beginning of the menstrual cycle; the first menstrual cycle in an individual.\" [GOC:curators, PMID:16311040]","metadata":null},{"id":"c1aea82592e148d389d6d9e06bd0427e","type":"DISEASE","name":"meningeal tuberculosis","canonical_id":"mondo:0006042","description":null,"metadata":null},{"id":"7a8c05423ffd4a19904c7f6161359be9","type":"GO_TERM","name":"menopause","canonical_id":"go:GO:0042697","description":"\"Cessation of menstruation, occurring in (e.g.) the human female usually around the age of 50.\" [GOC:curators, PMID:18495681]","metadata":null},{"id":"34df1b734526401cb6ac87179c7ca15f","type":"DISEASE","name":"menopause","canonical_id":"go:0042697","description":null,"metadata":null},{"id":"4d04b6efddfb474aa77a3f35b81a5191","type":"GO_TERM","name":"menstrual cycle","canonical_id":"go:GO:0044850","description":"\"A type of ovulation cycle where the endometrium is shed if pregnancy does not occur.\" [GOC:jl]","metadata":null},{"id":"81b0c39be570442eb275555c5375b9ca","type":"GO_TERM","name":"menstrual cycle phase","canonical_id":"go:GO:0022601","description":"\"The progression of physiological phases, occurring in the endometrium during the menstrual cycle that recur at regular intervals during the reproductive years. The menstrual cycle is an ovulation cycle where the endometrium is shed if pregnancy does not occur.\" [GOC:dph, GOC:isa_complete, GOC:jid]","metadata":null},{"id":"645b7a5d3edd465488e166a36650c8d2","type":"DISEASE","name":"menstrual cycle-dependent periodic fever","canonical_id":"mondo:0044660","description":null,"metadata":null},{"id":"19efd8b0709448548953b03b03289f99","type":"GO_TERM","name":"menstruation","canonical_id":"go:GO:0042703","description":"\"The cyclic, physiologic discharge through the vagina of blood and endometrial tissues from the nonpregnant uterus.\" [GOC:curators, PMID:8693059]","metadata":null},{"id":"8962e4d811f444adbd39aa7ac82fe297","type":"DISEASE","name":"mental disorder","canonical_id":"mondo:0005084","description":null,"metadata":null},{"id":"55b74c73b64f478aa53f440dad4076f2","type":"GO_TERM","name":"menthol biosynthetic process","canonical_id":"go:GO:0031525","description":"\"The chemical reactions and pathways resulting in the formation of menthol, the monoterpene 2-isopropyl-5-methylcyclohexanol.\" [GOC:mah]","metadata":null},{"id":"6d873e37a8224650816e8173ecd7aeff","type":"DRUG","name":"mephenytoin","canonical_id":"mesh:D008617","description":null,"metadata":null},{"id":"ead7d7bddfcc42169ff6f2315a8b087f","type":"DRUG","name":"mepolizumab","canonical_id":"gtopdb:7685","description":null,"metadata":null},{"id":"6036a40c5f194045850a901f99a26ea6","type":"DRUG","name":"mepolizumab","canonical_id":"mesh:C434107","description":null,"metadata":null},{"id":"da6b77c499fa4084a47538d043664561","type":"DRUG","name":"mepolizumab","canonical_id":"chembl:CHEMBL2108429","description":null,"metadata":null},{"id":"a833793623f34fd08a8ca291421982b0","type":"GO_TERM","name":"meprin A complex","canonical_id":"go:GO:0017090","description":"\"A protein complex that is located in the cell membrane, and is involved in the metabolism of peptides, including neuropeptides. The complex has metalloendopeptidase activity that catalyzes the hydrolysis of protein and peptide substrates, preferentially on carboxyl side of hydrophobic residues.\" [GOC:mah, MEROPS_fam:M12]","metadata":null},{"id":"a27f8b8efd1542319b41368b2b2e4a69","type":"DRUG","name":"mepyramine","canonical_id":"gtopdb:1227","description":null,"metadata":null},{"id":"f185336411964ebe93f752525c7ca4ea","type":"DRUG","name":"mepyramine","canonical_id":"mesh:D011738","description":null,"metadata":null},{"id":"dbcabd58bfbc441397961e0abab3edd4","type":"COMBINATION_TREATMENT","name":"mepyramine + phenytoin","canonical_id":"ctgov_combo:ctgov-combo-59014b70d1023b25","description":null,"metadata":null},{"id":"6783672d209d4377862cb71a2c14de21","type":"DRUG","name":"mercaptamine","canonical_id":"mesh:D003543","description":null,"metadata":null},{"id":"00e059812b424700b0a2b5ea3507d876","type":"GO_TERM","name":"mercury (II) reductase (NADP+) activity","canonical_id":"go:GO:0016152","description":"\"Catalysis of the reaction: H+ + Hg + NADP+ = Hg2+ + NADPH.\" [RHEA:23856]","metadata":null},{"id":"0edb0869742d435a840c55804e692f4f","type":"GO_TERM","name":"mercury ion binding","canonical_id":"go:GO:0045340","description":"\"Binding to a mercury ion (Hg2+).\" [GOC:curators]","metadata":null},{"id":"47f72eb96a6b41a6b211f8ec2355af8e","type":"GO_TERM","name":"mercury ion transmembrane transporter activity","canonical_id":"go:GO:0015097","description":"\"Enables the transfer of mercury (Hg2+) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"032134636bb84e468879023987bd3997","type":"GO_TERM","name":"mercury ion transport","canonical_id":"go:GO:0015694","description":"\"The directed movement of mercury (Hg) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"578f78973ecd486c9780c242bbfb7ef5","type":"GO_TERM","name":"meristem determinacy","canonical_id":"go:GO:0010022","description":"\"The process in which a meristem becomes determinate (i.e. ceases to produce lateral organs and may or may not terminally differentiate).\" [GOC:lr]","metadata":null},{"id":"4a156396c2854ce2b9bbcbce780c6a94","type":"GO_TERM","name":"meristem development","canonical_id":"go:GO:0048507","description":"\"The process whose specific outcome is the progression of the meristem over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"254252123ef74d0faafbfc09310eecd5","type":"GO_TERM","name":"meristem growth","canonical_id":"go:GO:0035266","description":"\"The increase in size or mass of a meristem, a region of tissue in a plant that is composed of one or more undifferentiated cells capable of undergoing mitosis and differentiation.\" [GOC:bf, ISBN:0198547684]","metadata":null},{"id":"7867bad2b4724bb09ae95fc376c787c1","type":"GO_TERM","name":"meristem initiation","canonical_id":"go:GO:0010014","description":"\"Initiation of a region of tissue in a plant that is composed of one or more undifferentiated cells capable of undergoing mitosis and differentiation, thereby effecting growth and development of a plant by giving rise to more meristem or specialized tissue.\" [GOC:sm]","metadata":null},{"id":"fcde507d06fc48b7bf141dcde2aecbc0","type":"GO_TERM","name":"meristem maintenance","canonical_id":"go:GO:0010073","description":"\"Any process involved in maintaining the identity, size and shape of a meristem.\" [GOC:tb]","metadata":null},{"id":"9b8f6e97c1b34e9ca65d92e125135e75","type":"GO_TERM","name":"meristem structural organization","canonical_id":"go:GO:0009933","description":"\"Organization of a region of tissue in a plant that is composed of one or more undifferentiated cells capable of undergoing mitosis and differentiation, thereby effecting growth and development of a plant by giving rise to more meristem or specialized tissue.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"d16da644bfdf4ef2b8d47ba1125cd44a","type":"GO_TERM","name":"meristemoid mother cell division","canonical_id":"go:GO:0010443","description":"\"The asymmetric cell division by which a meristemoid mother cells (MMC) give rise to a meristemoid and another cell. The other cell may itself become a MMC or may generate an epidermal cell. Any cell that undergoes this type of division is a MMC.\" [GOC:expert_db, GOC:tb]","metadata":null},{"id":"5a816952553d4880ab57d80b1faee6b9","type":"DRUG","name":"meropenem","canonical_id":"mesh:C059500","description":null,"metadata":null},{"id":"5cc7e0cf589f451f9ed51b5c1ddddc0a","type":"GO_TERM","name":"mesaconyl-CoA hydratase activity","canonical_id":"go:GO:0043881","description":"\"Catalysis of the hydration of mesaconyl-CoA to beta-methylmalyl-CoA.\" [PMID:16856935, PMID:16856937]","metadata":null},{"id":"9190763ba6a2456da142ea70ca35b805","type":"DRUG","name":"mesalazine","canonical_id":"gtopdb:2700","description":null,"metadata":null},{"id":"4001cc292f104986afa21c9b3b77647f","type":"DRUG","name":"mesalazine","canonical_id":"chembl:CHEMBL704","description":null,"metadata":null},{"id":"5a2d8d5d18e64280ac2929a657d783fc","type":"GO_TERM","name":"mesangial cell development","canonical_id":"go:GO:0072143","description":"\"The process whose specific outcome is the progression of a mesangial cell in the kidney over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e4de2675f1854845b7f2f8a302a74dcb","type":"GO_TERM","name":"mesangial cell differentiation","canonical_id":"go:GO:0072007","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesangial cells of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"463271db4e0d417b89fa2da9b1d559be","type":"GO_TERM","name":"mesangial cell fate commitment","canonical_id":"go:GO:0072151","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesangial cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"579c57836d3e4d40bb7c7089f7a60506","type":"GO_TERM","name":"mesangial cell-matrix adhesion","canonical_id":"go:GO:0035759","description":"\"The binding of a mesangial cell to the extracellular matrix via adhesion molecules. A mesangial cell is a cell that encapsulates the capillaries and venules in the kidney.\" [CL:0000650, GOC:BHF, PMID:15569314]","metadata":null},{"id":"86b61deb03d04ace854d7726b515d5a2","type":"GO_TERM","name":"mesaxon","canonical_id":"go:GO:0097453","description":"\"Portion of the ensheathing process (either myelin or non-myelin) where the enveloping lips of the ensheathing cell come together so that their apposed plasma membranes run parallel to each other, separated by a cleft 12 nm wide.\" [ISBN:0195065719, NIF_Subcellular:sao2127666702]","metadata":null},{"id":"92e2d722cfe64296bd7834a0b1310ab7","type":"GO_TERM","name":"mesectoderm development","canonical_id":"go:GO:0048383","description":"\"The process whose specific outcome is the progression of the mesectoderm over time, from its formation to the mature structure. In animal embryos, mesectoderm development processes give rise to both mesoderm and ectoderm tissues.\" [GOC:jid]","metadata":null},{"id":"9d45d1d2d714414cb73799d7ef81c817","type":"GO_TERM","name":"mesencephalic trigeminal nucleus development","canonical_id":"go:GO:0021739","description":"\"The process whose specific outcome is the progression of the mesencephalic trigeminal nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9211539ce2734d2a9b5aad3988277bfd","type":"GO_TERM","name":"mesenchymal cell apoptotic process","canonical_id":"go:GO:0097152","description":"\"Any apoptotic process in a mesenchymal cell. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types.\" [CL:0000134, GOC:mtg_apoptosis, GOC:yaf, PMID:18231833]","metadata":null},{"id":"b3434103c11143488d5cffc1019dfe73","type":"GO_TERM","name":"mesenchymal cell apoptotic process involved in metanephros development","canonical_id":"go:GO:1900200","description":"\"Any mesenchymal cell apoptotic process that is involved in metanephros development.\" [GOC:mtg_apoptosis, GOC:mtg_kidney_jan10, GOC:TermGenie, GOC:yaf, PMID:17314325]","metadata":null},{"id":"18ba1bbaecc3480c8bc2fdc9f33d48ca","type":"GO_TERM","name":"mesenchymal cell apoptotic process involved in nephron morphogenesis","canonical_id":"go:GO:1901145","description":"\"Any mesenchymal cell apoptotic process that is involved in nephron morphogenesis.\" [GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"a612cffc4180479cb0ce8e85fdaa8999","type":"GO_TERM","name":"mesenchymal cell development","canonical_id":"go:GO:0014031","description":"\"The process aimed at the progression of a mesenchymal cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"06fa8f210c9a4cf3b78a63a5bec679cd","type":"GO_TERM","name":"mesenchymal cell differentiation","canonical_id":"go:GO:0048762","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"37b4140a310d45a0a453158cedb6fd2e","type":"GO_TERM","name":"mesenchymal cell differentiation involved in bone development","canonical_id":"go:GO:1901706","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesenchymal cells of bone as it progresses from its formation to the mature state.\" [GOC:hjd, GOC:TermGenie, PMID:21571217]","metadata":null},{"id":"f7d5a011531e4280b7dc0773d05583c8","type":"GO_TERM","name":"mesenchymal cell differentiation involved in kidney development","canonical_id":"go:GO:0072161","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesenchymal cells of the kidney as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2140631a765148209c3397ebd2def710","type":"GO_TERM","name":"mesenchymal cell differentiation involved in lung development","canonical_id":"go:GO:0060915","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell of the lung. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types.\" [GOC:dph]","metadata":null},{"id":"037f55da850c4870b2d7dd435ac2a8c3","type":"GO_TERM","name":"mesenchymal cell fate commitment","canonical_id":"go:GO:0014030","description":"\"The process in which a cell becomes committed to become a mesenchymal cell.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"b4a33b9b811d427fa227cfacbc08cf6d","type":"GO_TERM","name":"mesenchymal cell migration","canonical_id":"go:GO:0090497","description":"\"The orderly movement of a mesenchymal cell from one site to another, often during the development of a multicellular organism.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"217ff1e447e7492db5a034917b191257","type":"GO_TERM","name":"mesenchymal cell proliferation","canonical_id":"go:GO:0010463","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a5afa797df404d45aab9b06f9a514690","type":"GO_TERM","name":"mesenchymal cell proliferation involved in lung development","canonical_id":"go:GO:0060916","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population that contributes to the progression of the lung over time. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.\" [GOC:dph]","metadata":null},{"id":"f1b63c4cd20448a7bc65228ad24ac27c","type":"GO_TERM","name":"mesenchymal cell proliferation involved in ureter development","canonical_id":"go:GO:0072198","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population of the ureter, that contributes to ureter development.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c582556dd7ff48b78733e938165abfaf","type":"GO_TERM","name":"mesenchymal cell proliferation involved in ureteric bud development","canonical_id":"go:GO:0072138","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population of the ureteric bud, that contributes to ureteric bud development.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"dfcfc28663db4c0d8094059709fa44b2","type":"GO_TERM","name":"mesenchymal smoothened signaling pathway involved in prostate gland development","canonical_id":"go:GO:0060783","description":"\"The series of molecular signals generated as a consequence of activation of the transmembrane Smoothened-type protein in the mesenchymal cells of the prostate that contribute to the progression of the prostate over time. This process contributes to lung development.\" [PMID:12221011]","metadata":null},{"id":"d60bdf343aa7410998259b9a27b1067b","type":"GO_TERM","name":"mesenchymal stem cell differentiation","canonical_id":"go:GO:0072497","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal stem cell. A mesenchymal stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized mesenchymal cells.\" [CL:0002452, GOC:BHF]","metadata":null},{"id":"7f0f9b06167d4a0e996686fe042cb4ed","type":"GO_TERM","name":"mesenchymal stem cell maintenance involved in metanephric nephron morphogenesis","canonical_id":"go:GO:0072309","description":"\"The process in which an organism retains a population of mesenchymal stem cells that contributes to the shaping of a nephron in the metanephros. A mesenchymal stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"fda7ada6ee224a5abeaa8986e168a978","type":"GO_TERM","name":"mesenchymal stem cell maintenance involved in nephron morphogenesis","canonical_id":"go:GO:0072038","description":"\"The process in which an organism retains a population of mesenchymal stem cells that contributes to the shaping of a nephron. A mesenchymal stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b937c3b5bbd34ff88bef94685fb46dbd","type":"GO_TERM","name":"mesenchymal stem cell migration","canonical_id":"go:GO:1905319","description":"\"The orderly movement of a mesenchymal stem cell from one site to another.\" [GO_REF:0000091, GOC:TermGenie, PMID:24924806, PMID:25181476]","metadata":null},{"id":"131ae3bcd0ba42c1adca381e96020064","type":"GO_TERM","name":"mesenchymal stem cell proliferation","canonical_id":"go:GO:0097168","description":"\"The multiplication or reproduction of mesenchymal stem cells, resulting in the expansion of a stem cell population. A mesenchymal stem cell, or MSC, is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized mesenchymal cells.\" [CL:0000134, GOC:yaf, PMID:20626275]","metadata":null},{"id":"6d2f09b6b037431a8ea8c788806086e3","type":"GO_TERM","name":"mesenchymal to epithelial transition","canonical_id":"go:GO:0060231","description":"\"A transition where a mesenchymal cell establishes apical/basolateral polarity, forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"8e92cecfe4994c68a955d53560a90c83","type":"GO_TERM","name":"mesenchymal to epithelial transition involved in metanephric renal vesicle formation","canonical_id":"go:GO:0072285","description":"\"A transition where a mesenchymal cell establishes apical/basolateral polarity,forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell that will contribute to the shaping of the metanephric renal vesicle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9e1e25a547354b0f897bb23249673c3c","type":"GO_TERM","name":"mesenchymal to epithelial transition involved in metanephros morphogenesis","canonical_id":"go:GO:0003337","description":"\"A transition where a mesenchymal cell establishes apical/basolateral polarity,forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell that will contribute to the shaping of the metanephros.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"c21cacd2daf04e60b6d12c9e725c5851","type":"GO_TERM","name":"mesenchymal-endodermal cell signaling","canonical_id":"go:GO:0060497","description":"\"Any process that mediates the transfer of information between a mesenchymal cell and an endodermal cell.\" [GOC:dph]","metadata":null},{"id":"41a1c24f42c14f559a3090b6b30c9f1f","type":"GO_TERM","name":"mesenchymal-epithelial cell signaling","canonical_id":"go:GO:0060638","description":"\"Any process that mediates the transfer of information from a mesenchymal cell to an epithelial cell where it is received and interpreted.\" [GOC:dph]","metadata":null},{"id":"5e80abccc3e3440da68e4365391263bd","type":"GO_TERM","name":"mesenchymal-epithelial cell signaling involved in lung development","canonical_id":"go:GO:0060496","description":"\"Any process that mediates the transfer of information from a mesenchymal cell to an epithelial cell and contributes to the development of the lung.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"b8d12fab72134b27b676787aca657d24","type":"GO_TERM","name":"mesenchymal-epithelial cell signaling involved in prostate gland development","canonical_id":"go:GO:0060739","description":"\"Any process that mediates the transfer of information from a mesenchymal cell to an epithelial cell where it is received and interpreted contributing to the progression of the prostate gland over time.\" [GOC:dph]","metadata":null},{"id":"0239b5d35f614538b9e1aa08c8253325","type":"GO_TERM","name":"mesenchyme development","canonical_id":"go:GO:0060485","description":"\"The process whose specific outcome is the progression of a mesenchymal tissue over time, from its formation to the mature structure. A mesenchymal tissue is made up of loosely packed stellate cells.\" [GOC:dph]","metadata":null},{"id":"12dcc800d7a04957bcda7d016d5494fd","type":"GO_TERM","name":"mesenchyme migration","canonical_id":"go:GO:0090131","description":"\"The process in which the population of cells that make up a mesenchyme undergo directed movement.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"7aa485d055ba4823b0445ff521729252","type":"GO_TERM","name":"mesenchyme morphogenesis","canonical_id":"go:GO:0072132","description":"\"The process in which the anatomical structures of a mesenchymal tissue are generated and organized. A mesenchymal tissue is made up of loosely packed stellate cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9a3874acfeb74ce1a5df3db2b311d044","type":"GO_TERM","name":"mesendoderm development","canonical_id":"go:GO:0048382","description":"\"The process whose specific outcome is the progression of the mesendoderm over time, from its formation to the mature structure. In animal embryos, mesendoderm development gives rise to both mesoderm and endoderm tissues.\" [GOC:jid]","metadata":null},{"id":"9887f8ec61b74e5abafc93050c932161","type":"GO_TERM","name":"mesendoderm migration","canonical_id":"go:GO:0090133","description":"\"The process in which the population of cells that make up a mesendoderm undergo directed movement. The mesendoderm is the epithelial tissue that gives rise to both mesoderm and endoderm.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"535bedd7aab447209dbe4ad82f750d77","type":"GO_TERM","name":"meso-tartrate dehydrogenase activity","canonical_id":"go:GO:0050092","description":"\"Catalysis of the reaction: (2R,3S)-tartrate + NAD+ = dihydroxyfumarate + H+ + NADH.\" [EC:1.3.1.7, RHEA:18553]","metadata":null},{"id":"e1e524259ac546ec800341eb84c9d5c2","type":"GO_TERM","name":"mesoderm development","canonical_id":"go:GO:0007498","description":"\"The process whose specific outcome is the progression of the mesoderm over time, from its formation to the mature structure. The mesoderm is the middle germ layer that develops into muscle, bone, cartilage, blood and connective tissue.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"135d133f6eb44b2588a88910e25c4c75","type":"GO_TERM","name":"mesoderm formation","canonical_id":"go:GO:0001707","description":"\"The process that gives rise to the mesoderm. This process pertains to the initial formation of the structure from unspecified parts.\" [GOC:curators]","metadata":null},{"id":"3ac7e0e5ea5a410d98422e2e4430fc2f","type":"GO_TERM","name":"mesoderm migration involved in gastrulation","canonical_id":"go:GO:0007509","description":"\"The migration of mesodermal cells during gastrulation to help establish the multilayered body plan of the organism.\" [GOC:isa_complete, GOC:sat]","metadata":null},{"id":"291f60264fa248ba80de7d34fd8a8ff8","type":"GO_TERM","name":"mesoderm morphogenesis","canonical_id":"go:GO:0048332","description":"\"The process in which the anatomical structures of the mesoderm are generated and organized.\" [GOC:curators]","metadata":null},{"id":"a9985bedfa6c4e609a37f5e2f618610e","type":"GO_TERM","name":"mesoderm structural organization","canonical_id":"go:GO:0048338","description":"\"The process that contributes to the act of creating the structural organization of the mesoderm. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dgh]","metadata":null},{"id":"b055d2dc95fc4650a293c186b835728a","type":"GO_TERM","name":"mesodermal cell differentiation","canonical_id":"go:GO:0048333","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"4f92c9b8cacd44948084d5bbacccfeef","type":"GO_TERM","name":"mesodermal cell fate commitment","canonical_id":"go:GO:0001710","description":"\"The cell differentiation process that results in commitment of a cell to become part of the mesoderm.\" [GOC:curators, ISBN:0878932437]","metadata":null},{"id":"87461f81a6154c1e969d555052eab62e","type":"GO_TERM","name":"mesodermal cell fate determination","canonical_id":"go:GO:0007500","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a mesoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators, ISBN:0878932437]","metadata":null},{"id":"9f8a87e9b4044f2d8c96a56a362ab476","type":"GO_TERM","name":"mesodermal cell fate specification","canonical_id":"go:GO:0007501","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a mesoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:curators]","metadata":null},{"id":"e88f01c59d094bf98d59bb5738ffe2b4","type":"GO_TERM","name":"mesodermal cell migration","canonical_id":"go:GO:0008078","description":"\"The orderly movement of mesodermal cells from one site to another.\" [GOC:ascb_2009, GOC:dph, GOC:mah, GOC:sat, GOC:tb, PMID:25119047]","metadata":null},{"id":"ea66a014cad94995a169dbb168085b21","type":"GO_TERM","name":"mesodermal to mesenchymal transition involved in gastrulation","canonical_id":"go:GO:0060809","description":"\"The epithelial to mesenchymal transition process in which a mesodermal cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell as part of the process of gastrulation.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"a671f594a16b402b86e40df01316d2a9","type":"GO_TERM","name":"mesodermal-endodermal cell signaling","canonical_id":"go:GO:0003131","description":"\"Any process that mediates the transfer of information from mesodermal cells to endodermal cells.\" [GOC:mtg_heart]","metadata":null},{"id":"927a7f9307484d948309eb594ef7203d","type":"GO_TERM","name":"mesonephric S-shaped body morphogenesis","canonical_id":"go:GO:0061244","description":"\"The process in which the mesonephric S-shaped body is generated and organized. The mesonephric S-shaped body is the successor of the mesonephric comma-shaped body that contributes to the morphogenesis of a nephron in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"21fff56c463940e18e72556f9176a7d6","type":"GO_TERM","name":"mesonephric capsule development","canonical_id":"go:GO:0061285","description":"\"The progression of the mesonephric capsule over time, from its formation to the mature structure. The mesonephric capsule is the tough fibrous layer surrounding the mesonephros, covered in a thick layer of perinephric adipose tissue.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8d792858be964e70bcf082190e377fdd","type":"GO_TERM","name":"mesonephric capsule formation","canonical_id":"go:GO:0061287","description":"\"The developmental process pertaining to the initial formation of a mesonephric capsule from unspecified parts. The mesonephric capsule is the tough fibrous layer surrounding the mesonephros, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4a9c780c80b545cb822bcfccae8b3431","type":"GO_TERM","name":"mesonephric capsule morphogenesis","canonical_id":"go:GO:0061286","description":"\"The process in which the anatomical structures of the mesonephric capsule are generated and organized. The mesonephric capsule is the tough fibrous layer surrounding the mesonephros, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d5a5b70bb62a487ca0a6994410e4c3be","type":"GO_TERM","name":"mesonephric capsule specification","canonical_id":"go:GO:0061288","description":"\"The regionalization process in which the identity of the mesonephric capsule is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"432949c76c0f4b6dac1238de8b3255f0","type":"GO_TERM","name":"mesonephric collecting duct development","canonical_id":"go:GO:0061211","description":"\"The process whose specific outcome is the progression of a collecting duct in the mesonephros over time, from its formation to the mature structure. The collecting duct regulates water, electrolyte and acid-base balance. The collecting duct is the final common path through which urine flows before entering the ureter and then emptying into the bladder.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"202788890ade4485a4d4cbc90826dc45","type":"GO_TERM","name":"mesonephric comma-shaped body morphogenesis","canonical_id":"go:GO:0061236","description":"\"The process in which the mesonephric comma-shaped body is generated and organized. The mesonephric comma-shaped body is the precursor structure to the mesonephric S-shaped body that contributes to the morphogenesis of a nephron in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"431363ba1ac34a999070e39c5abb9110","type":"GO_TERM","name":"mesonephric connecting tubule development","canonical_id":"go:GO:0061272","description":"\"The process whose specific outcome is the progression of the mesonephric connecting tubule over time, from its formation to the mature structure. The mesonephric connecting tubule is a tubular segment of the mesonephric nephron; it connects the distal tubule to the collecting duct in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a75a320870a74f859aaa094f48fff201","type":"GO_TERM","name":"mesonephric distal tubule development","canonical_id":"go:GO:0061274","description":"\"The process whose specific outcome is the progression of the mesonephric distal tubule over time, from its formation to the mature structure. The mesonephric distal tubule is a mesonephric nephron tubule that begins at the terminal segment of the proximal tubule and ends at the mesonephric connecting tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"dc11a452770b49c88a003f8dbc19877a","type":"GO_TERM","name":"mesonephric distal tubule morphogenesis","canonical_id":"go:GO:0061273","description":"\"The process in which the anatomical structures of a mesonephric distal tubule are generated and organized. The mesonephric distal tubule is a mesonephric nephron tubule that begins at the macula densa and extends to the mesonephric connecting tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5dfe67b83fa94f7d8d8ab13c2c5e54e7","type":"GO_TERM","name":"mesonephric duct development","canonical_id":"go:GO:0072177","description":"\"The process whose specific outcome is the progression of a mesonephric duct over time, from its initial formation to a mature structure. A mesonephric duct is a tube drains the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"49318a90162644d681c1212d4e09b3be","type":"GO_TERM","name":"mesonephric duct formation","canonical_id":"go:GO:0072181","description":"\"The developmental process pertaining to the initial formation of a mesonephric duct. A mesonephric duct is a tube that drains the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f8e6d95612b34a2aad74aa7782ff193a","type":"GO_TERM","name":"mesonephric duct morphogenesis","canonical_id":"go:GO:0072180","description":"\"The process in which the anatomical structures of the mesonephric duct are generated and organized. A mesonephric duct is a tube drains the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3a44b273e67d4c7097b2f1fd73903ad2","type":"GO_TERM","name":"mesonephric epithelium development","canonical_id":"go:GO:0072163","description":"\"The process whose specific outcome is the progression of an epithelium in the mesonephros over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c2568d061d8d4a88808b3134e4ee1730","type":"GO_TERM","name":"mesonephric glomerular basement membrane development","canonical_id":"go:GO:0061233","description":"\"The process whose specific outcome is the progression of the mesonephric glomerular basement membrane over time, from its formation to the mature structure. The mesonephric glomerular basement membrane is the basal laminal portion of the mesonephric glomerulus which performs the actual filtration.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e289574006914ecc8e4983a49b5fc883","type":"GO_TERM","name":"mesonephric glomerular capillary formation","canonical_id":"go:GO:0061249","description":"\"The process that gives rise to a mesonephric glomerular capillary. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"10ea9adcfc514274b34939e2d37c0081","type":"GO_TERM","name":"mesonephric glomerular epithelial cell development","canonical_id":"go:GO:0061251","description":"\"The process whose specific outcome is the progression of a mesonephric glomerular epithelial cell over time, from its formation to the mature structure. Mesonephric glomerular epithelial cells are specialized epithelial cells that form part of the mesonephric glomerulus; there are two types, mesonephric glomerular parietal epithelial cells and mesonephric glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e3055c0f9a7d4263a8818f4c0c0207f2","type":"GO_TERM","name":"mesonephric glomerular epithelial cell differentiation","canonical_id":"go:GO:0061250","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mesonephric glomerular epithelial cell. Mesonephric glomerular epithelial cells are specialized epithelial cells that form part of the mesonephric glomerulus; there are two types, mesonephric glomerular parietal epithelial cells and mesonephric glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"20a0e27578054b2dbf5776aea4b584b2","type":"GO_TERM","name":"mesonephric glomerular epithelial cell fate commitment","canonical_id":"go:GO:0061252","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesonephric glomerular epithelial cell. Mesonephric glomerular epithelial cells are specialized epithelial cells that form part of the mesonephric glomerulus; there are two types, mesonephric glomerular parietal epithelial cells and mesonephric glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"fa1926f54608485291700b5f829dd337","type":"GO_TERM","name":"mesonephric glomerular epithelium development","canonical_id":"go:GO:0061232","description":"\"The process whose specific outcome is the progression of the mesonephric glomerular epithelium over time, from its formation to the mature structure. The mesonephric glomerular epithelium is an epithelial tissue that covers the outer surfaces of the glomerulus in the mesonephros. The mesonephric glomerular epithelium consists of both parietal and visceral epithelium. Mesonephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport. A mesonephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c91d558eb4b340978737902a3531fd47","type":"GO_TERM","name":"mesonephric glomerular mesangial cell development","canonical_id":"go:GO:0061263","description":"\"The process whose specific outcome is the progression of a glomerular mesangial cell in the mesonephros over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"19aa345d0397426e829fa1c335ee07f4","type":"GO_TERM","name":"mesonephric glomerular mesangial cell differentiation","canonical_id":"go:GO:0061259","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the glomerular mesangial cells of the mesonephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bcaccb1284ba4a60a58a2a16bd666c76","type":"GO_TERM","name":"mesonephric glomerular mesangial cell fate commitment","canonical_id":"go:GO:0061264","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesonephric glomerular mesangial cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"570714f799b54b9eaf422ad10e64f111","type":"GO_TERM","name":"mesonephric glomerular mesangium development","canonical_id":"go:GO:0061247","description":"\"The process whose specific outcome is the progression of the mesonephric glomerular mesangium over time, from its formation to the mature structure. The mesonephric glomerular mesangium is the thin membrane connective tissue composed of mesangial cells in the mesonephros, which helps to support the capillary loops in a renal glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ee8ebceb529944deac2e83e255eb30f6","type":"GO_TERM","name":"mesonephric glomerular parietal epithelial cell development","canonical_id":"go:GO:0061254","description":"\"The process whose specific outcome is the progression of a mesonephric glomerular parietal epithelial cell over time, from its formation to the mature structure. Mesonephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"271dccc3bb46408fbb9e11b9844f22cb","type":"GO_TERM","name":"mesonephric glomerular parietal epithelial cell differentiation","canonical_id":"go:GO:0061253","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mesonephric glomerular parietal epithelial cell. Mesonephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a9b54c06d60e4a1884d4f04ee5310bec","type":"GO_TERM","name":"mesonephric glomerular parietal epithelial cell fate commitment","canonical_id":"go:GO:0061255","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesonephric glomerular parietal epithelial cell. Mesonephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport. These cells may also give rise to podocytes.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6688e27d7edb43dabfa1a314bf16f701","type":"GO_TERM","name":"mesonephric glomerulus development","canonical_id":"go:GO:0061224","description":"\"The progression of the mesonephric glomerulus over time from its initial formation until its mature state. The mesonephric glomerulus is a capillary tuft which forms a close network with the visceral epithelium (podocytes) and the mesangium to form the filtration barrier and is surrounded by Bowman's capsule in nephrons of the mature vertebrate kidney, or mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e84c739f771c46838db8590983456609","type":"GO_TERM","name":"mesonephric glomerulus morphogenesis","canonical_id":"go:GO:0061234","description":"\"The process in which the anatomical structures of the mesonephric glomerulus are generated and organized. The mesonephric glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6ccd96f3baf5461782253c6332fe910a","type":"GO_TERM","name":"mesonephric glomerulus vasculature development","canonical_id":"go:GO:0061231","description":"\"The biological process whose specific outcome is the progression of a mesonephric glomerulus vasculature from an initial condition to its mature state. This process begins with the formation of the mesonephric glomerulus vasculature and ends with the mature structure. The mesonephric glomerulus vasculature is composed of the tubule structures that carry blood or lymph in the mesonephric glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ff8b7ebf485148f6b346dafc7002f0ac","type":"GO_TERM","name":"mesonephric glomerulus vasculature morphogenesis","canonical_id":"go:GO:0061248","description":"\"The process in which the anatomical structures of the mesonephric glomerulus vasculature are generated and organized. The mesonephric glomerulus vasculature is composed of the tubule structures that carry blood or lymph in the mesonephric glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3a1f51fcda8f4e3ea44bb76f4d25b2a9","type":"GO_TERM","name":"mesonephric interstitial fibroblast development","canonical_id":"go:GO:0061267","description":"\"The process whose specific outcome is the progression of a mesonephric interstitial fibroblast over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"58ed96a3b4944bc6aaff3008ee997d6e","type":"GO_TERM","name":"mesonephric interstitial fibroblast differentiation","canonical_id":"go:GO:0061266","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the interstitial fibroblasts of the mesonephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"46d9583bf63c4d5886168b0004737250","type":"GO_TERM","name":"mesonephric interstitial fibroblast fate commitment","canonical_id":"go:GO:0061268","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesonephric interstitial fibroblast.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c38715c7fe6148e6975eaf9bde3f9434","type":"GO_TERM","name":"mesonephric intraglomerular mesangial cell proliferation","canonical_id":"go:GO:0061270","description":"\"The multiplication or reproduction of intraglomerular glomerular mesangium cells in the mesonephros by cell division, resulting in the expansion of their population. Intraglomerular mesangial cells are specialized pericytes located among the glomerular capillaries within a renal corpuscle of a kidney. They are required for filtration, structural support and phagocytosis.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"43461f6147c6461ca168898c28bd5aa2","type":"GO_TERM","name":"mesonephric juxtaglomerular apparatus development","canonical_id":"go:GO:0061212","description":"\"The process whose specific outcome is the progression of the juxtaglomerular apparatus in the mesonephros over time, from its formation to the mature structure. The juxtaglomerular apparatus is an anatomical structure which consists of juxtaglomerular cells, extraglomerular mesangial cells and the macula densa. The juxtaglomerular apparatus lies adjacent to the glomerulus and regulates kidney function by maintaining the blood flow to the kidney and the filtration rate.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d434cd5cd785408b8c104850000c87b9","type":"GO_TERM","name":"mesonephric juxtaglomerulus cell development","canonical_id":"go:GO:0061229","description":"\"The process whose specific outcome is the progression of a mesonephric juxtaglomerulus cell over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0a16339e1c6341fa93397df5717a78a9","type":"GO_TERM","name":"mesonephric juxtaglomerulus cell differentiation","canonical_id":"go:GO:0061207","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells of the mesonephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c370bb521a0849beab48924f71f2c843","type":"GO_TERM","name":"mesonephric juxtaglomerulus cell fate commitment","canonical_id":"go:GO:0061230","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesonephric juxtaglomerulus cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6690129f05604773b0c5941302afab6c","type":"GO_TERM","name":"mesonephric macula densa development","canonical_id":"go:GO:0061220","description":"\"The process whose specific outcome is the progression of the mesonephric macula densa over time, from its formation to the mature structure. The mesonephric macula densa is an area of specialized cells in the distal tubule of the mesonephros that makes contact with the vascular pole of the glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"55438f2bdbb14152ab8e0889fe2619c7","type":"GO_TERM","name":"mesonephric mesangial cell differentiation","canonical_id":"go:GO:0061260","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesangial cells of the mesonephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"14d14ad9e6b1448fb113e70ff947fff0","type":"GO_TERM","name":"mesonephric mesenchymal cell differentiation","canonical_id":"go:GO:0061223","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesenchymal cells of the mesonephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2c17d26b30b047c2a3bed72e7549c0eb","type":"GO_TERM","name":"mesonephric mesenchyme development","canonical_id":"go:GO:0061219","description":"\"The biological process whose specific outcome is the progression of a mesonephric mesenchyme from an initial condition to its mature state. This process begins with the formation of mesonephric mesenchyme and ends with the mature structure. Mesonephric mesenchyme is the tissue made up of loosely connected mesenchymal cells in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"30153bd863ed415bb030c47ace9ce47f","type":"GO_TERM","name":"mesonephric mesenchyme morphogenesis","canonical_id":"go:GO:0061221","description":"\"The process in which the anatomical structures of a mesonephric mesenchymal tissue are generated and organized. Mesonephric mesenchyme is the tissue made up of loosely connected mesenchymal cells in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a41f01af00a049608f883c11e7e4f56e","type":"GO_TERM","name":"mesonephric nephron development","canonical_id":"go:GO:0061215","description":"\"The process whose specific outcome is the progression of a nephron in the mesonephros over time, from its formation to the mature structure. A nephron is the functional unit of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"68eced53fc3a472194597cd90276c56f","type":"GO_TERM","name":"mesonephric nephron epithelium development","canonical_id":"go:GO:0061241","description":"\"The process whose specific outcome is the progression of the mesonephric nephron epithelium over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure. The mesonephric nephron epithelium is a tissue that covers the surface of a nephron in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bad17817589249d5883bdeef6f5d565c","type":"GO_TERM","name":"mesonephric nephron morphogenesis","canonical_id":"go:GO:0061228","description":"\"The process in which the anatomical structures of the mesonephric nephron are generated and organized. A mesonephric nephron is the functional unit of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b9f774158a82458bb8b70c3e448ace45","type":"GO_TERM","name":"mesonephric nephron tubule development","canonical_id":"go:GO:0061242","description":"\"The progression of a mesonephric nephron tubule over time, from its initial formation to the mature structure. A mesonephric nephron tubule is an epithelial tube that is part of the mesonephric nephron, the functional part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6dcdbe344ef044969cae80cb2748f9ac","type":"GO_TERM","name":"mesonephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0061265","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the mesonephric nephron tubule as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e6564dc20add47148a207209f9605781","type":"GO_TERM","name":"mesonephric nephron tubule formation","canonical_id":"go:GO:0061277","description":"\"The developmental process pertaining to the initial formation of a mesonephric nephron tubule from unspecified parts. A mesonephric nephron tubule is an epithelial tube that is part of a nephron in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a5cd9715519d44788d279bb61196f16e","type":"GO_TERM","name":"mesonephric nephron tubule morphogenesis","canonical_id":"go:GO:0061240","description":"\"The process in which the anatomical structures of a mesonephric nephron tubule are generated and organized. A mesonephric nephron tubule is an epithelial tube that is part of the mesonephric nephron, the functional part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d722d7ea94d741cda5aa8a3508ab2bac","type":"GO_TERM","name":"mesonephric podocyte cell fate commitment","canonical_id":"go:GO:0061258","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a mesonephric glomerular visceral epithelial cell. A mesonephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"edba1a68f86649ccb489a692a9685cfe","type":"GO_TERM","name":"mesonephric podocyte development","canonical_id":"go:GO:0061257","description":"\"The process whose specific outcome is the progression of a mesonephric glomerular visceral epithelial cell over time, from its formation to the mature structure. A mesonephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"80364b2256f74fb095a4595140c2b0b6","type":"GO_TERM","name":"mesonephric podocyte differentiation","canonical_id":"go:GO:0061256","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a mesonephric glomerular visceral epithelial cell. A mesonephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"125527d69c444f99b1c4928835a7a92e","type":"GO_TERM","name":"mesonephric proximal tubule development","canonical_id":"go:GO:0061275","description":"\"The progression of the mesonephric proximal tubule over time, from its formation to the mature structure. The mesonephric proximal tubule extends from the capsule to the distal tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9c8c9705e3504969a8a031fb20496d89","type":"GO_TERM","name":"mesonephric proximal tubule morphogenesis","canonical_id":"go:GO:0061276","description":"\"The process in which the anatomical structures of a mesonephric proximal tubule are generated and organized. The mesonephric proximal tubule extends from the capsule to the distal tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2c47b6b5be334b2ba2c1914fc500b37f","type":"GO_TERM","name":"mesonephric renal vesicle formation","canonical_id":"go:GO:0061262","description":"\"The developmental process pertaining to the initial formation of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d6db3e2aca8c4929902ca3ea10093754","type":"GO_TERM","name":"mesonephric renal vesicle induction","canonical_id":"go:GO:0061294","description":"\"Signaling at short range between cells of the ureteric bud terminus and the kidney mesenchyme that positively regulates the formation of the mesonephric renal vesicle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"88ee36eb104d4f65b3054748b2267413","type":"GO_TERM","name":"mesonephric renal vesicle morphogenesis","canonical_id":"go:GO:0061243","description":"\"The process in which the anatomical structures of the mesonephric renal vesicle are generated and organized. The renal vesicle is the primordial structure of the mesonephric nephron epithelium, and is formed by the condensation of mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f9109e0a5bf542088e75cf3b477a39db","type":"GO_TERM","name":"mesonephric smooth muscle tissue development","canonical_id":"go:GO:0061214","description":"\"The process whose specific outcome is the progression of smooth muscle in the mesonephros over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b85d64803143420fb4c0f62f52e2aaf5","type":"GO_TERM","name":"mesonephric tubule development","canonical_id":"go:GO:0072164","description":"\"The progression of a mesonephric tubule over time, from its initial formation to the mature structure. A mesonephric tubule is an epithelial tube that is part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4d16bc49b5004340a93b67b9d4951505","type":"GO_TERM","name":"mesonephric tubule formation","canonical_id":"go:GO:0072172","description":"\"The developmental process pertaining to the initial formation of a mesonephric tubule from unspecified parts. A mesonephric tubule is an epithelial tube that is part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"093fa257ce0c488795b8d1c64b7aaf8c","type":"GO_TERM","name":"mesonephric tubule morphogenesis","canonical_id":"go:GO:0072171","description":"\"The process in which the anatomical structures of a mesonephric tubule are generated and organized. A mesonephric tubule is an epithelial tube that is part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cdda05e1ef0d46af8b552b3b728cf740","type":"GO_TERM","name":"mesonephros development","canonical_id":"go:GO:0001823","description":"\"The process whose specific outcome is the progression of the mesonephros over time, from its formation to the mature structure. In mammals, the mesonephros is the second of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the mesonephros will form the mature kidney.\" [GOC:dph, ISBN:0124020607, ISBN:0721662544, PMID:10535314]","metadata":null},{"id":"aa06a51c28c84c9ca602b8c36f767815","type":"GO_TERM","name":"mesonephros morphogenesis","canonical_id":"go:GO:0061206","description":"\"The process in which the anatomical structures of the mesonephros are generated and organized.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"79fda7bca7484aa789ee499f74527053","type":"GO_TERM","name":"mesosome","canonical_id":"go:GO:0046868","description":"\"An intracellular, often complex, membranous structure, sometimes with additional membranous lamellae inside, found in bacteria. They are associated with synthesis of DNA and secretion of proteins.\" [PMID:31921091, PMID:33327493]","metadata":null},{"id":"7c68cfc8287d41b3a28d17dfb28d35c0","type":"DISEASE","name":"mesothelioma","canonical_id":"mondo:0005065","description":null,"metadata":null},{"id":"aece47546c3b4b398c7a36997dd6d5db","type":"GO_TERM","name":"metabolic compound salvage","canonical_id":"go:GO:0043094","description":"\"Any process which produces a useful metabolic compound from derivatives of it without de novo synthesis, as carried out by individual cells.\" [GOC:mlg]","metadata":null},{"id":"ef2a0b533db54c9fb66c66cfd35e1906","type":"DISEASE","name":"metabolic disease","canonical_id":"mondo:0005066","description":null,"metadata":null},{"id":"44215518ca564f47835619b5f04d3380","type":"DISEASE","name":"metabolic dysfunction-associated steatohepatitis","canonical_id":"mondo:0007027","description":null,"metadata":null},{"id":"dda20e40297746f79dee9c5089fffb97","type":"GO_TERM","name":"metabolic process","canonical_id":"go:GO:0008152","description":"\"A cellular process consisting of the biochemical pathways by which a living organism transforms chemical substances. This includes including anabolism (biosynthetic process) and catabolism (catabolic process). Metabolic processes includes the transformation of small molecules, as well  macromolecular processes such as DNA repair and replication, protein synthesis and degradation.\" [GOC:curators, ISBN:0198547684]","metadata":null},{"id":"808a05c8fd1a480999daf8dede1a447a","type":"DISEASE","name":"metabolic syndrome","canonical_id":"efo:0000195","description":null,"metadata":null},{"id":"134ad9660c074e43a68e263ec8dd5388","type":"GO_TERM","name":"metabolite repair","canonical_id":"go:GO:0110051","description":"\"A cellular process that, through single- or multi-step enzymatic reactions, repairs useless or toxic endogenous compounds, formed as by-products of primary metabolism, by converting them into useful metabolites.\" [GOC:ka, PMID:23334546, PMID:28373563]","metadata":null},{"id":"05964c2a308d43758904d847756b298c","type":"GO_TERM","name":"metacyclogenesis","canonical_id":"go:GO:0140384","description":"\"The morphological, biochemical and genetic changes that induce the differentiation of non-pathogenic parasites into pathogenic metacyclic parasites in the Trypanosomatidae species. The pathogenic parasites are known as metacyclic trypomastigotes in Trypanosoma and metacyclic promastigotes in Leishmania.\" [PMID:12152483, PMID:21514274, PMID:2659372, PMID:29091711, PMID:29409544]","metadata":null},{"id":"312bccf4463f43a9a819ca0bebf60da0","type":"GO_TERM","name":"metal cation:monoatomic cation antiporter activity","canonical_id":"go:GO:0140828","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: solute(out) + Na+(in) = solute(in) + Na+(out).\" [GOC:pg]","metadata":null},{"id":"2a62fca5b348494db229dd0820119467","type":"GO_TERM","name":"metal cation:proton antiporter activity","canonical_id":"go:GO:0051139","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: metal ion(in) + H+(out) = metal ion(out) + H+(in).\" [GOC:mlg]","metadata":null},{"id":"05e82741357c498e8b741a47190b5fca","type":"GO_TERM","name":"metal chelating activity","canonical_id":"go:GO:0046911","description":"\"The formation of bonds from two or more atoms within the same ligand to a metal atom in complexes in which the metal is part of a ring.\" [ISBN:0198506732, ISBN:0716731363]","metadata":null},{"id":"81cee0f947fc488e9fc280d182810e68","type":"GO_TERM","name":"metal cluster binding","canonical_id":"go:GO:0051540","description":"\"Binding to a cluster of atoms including both metal ions and nonmetal atoms, usually sulfur and oxygen. Examples include iron-sulfur clusters and nickel-iron-sulfur clusters.\" [GOC:jsg]","metadata":null},{"id":"a1ea79d4e2db4a529735ab4bd0253353","type":"GO_TERM","name":"metal incorporation into metallo-molybdopterin complex","canonical_id":"go:GO:0042040","description":"\"The incorporation of a metal into a metallo-molybdopterin complex.\" [GOC:ai]","metadata":null},{"id":"f3905d85a6ea46acaa82646ce0a301ac","type":"GO_TERM","name":"metal incorporation into metallo-sulfur cluster","canonical_id":"go:GO:0018282","description":"\"The formation of a cluster of several metal atoms, including iron, nickel, molybdenum, vanadium, or copper, with one or more bridging (mu-bond) sulfur atoms; amino acids residues in proteins that may ligate the metal sulfur cluster are cysteine, histidine, aspartate, glutamate, serine and cysteine persulfide.\" [GOC:jsg]","metadata":null},{"id":"b6af1045e3924d2e8922207f81120b5b","type":"GO_TERM","name":"metal ion binding","canonical_id":"go:GO:0046872","description":"\"Binding to a metal ion.\" [GOC:ai]","metadata":null},{"id":"6c22f01f692943d0bfdc9e21f68588d7","type":"GO_TERM","name":"metal ion sensor activity","canonical_id":"go:GO:0140784","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of a metal ion.\" [GOC:pg]","metadata":null},{"id":"2b11904484ff454daae74ebbb2144633","type":"GO_TERM","name":"metal ion sequestering activity","canonical_id":"go:GO:0140487","description":"\"Binding to a metal ion to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:12050156]","metadata":null},{"id":"6c27dbf5e6f74681b0b628db7606d131","type":"GO_TERM","name":"metal ion transmembrane transporter activity","canonical_id":"go:GO:0046873","description":"\"Enables the transfer of metal ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"c4f14eeadd574d2592923d891b0e9521","type":"GO_TERM","name":"metal ion transport","canonical_id":"go:GO:0030001","description":"\"The directed movement of metal ions, any metal ion with an electric charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"fa80f3ed3bc240ef9a818925a7b7f002","type":"GO_TERM","name":"metal-dependent deNEDDylase activity","canonical_id":"go:GO:0140758","description":"\"An metal-dependent isopeptidase activity that cleaves NEDD8 from a target protein to which it is conjugated.\" [PMID:25628956]","metadata":null},{"id":"3f71a9845c9d493d94998ce175447e2b","type":"GO_TERM","name":"metal-dependent deubiquitinase activity","canonical_id":"go:GO:0140492","description":"\"An metal-dependent isopeptidase activity that cleaves ubiquitin from a target protein to which it is conjugated.\" [PMID:19489724]","metadata":null},{"id":"0fbe8918b3fb4ba696db4d1ad111cfac","type":"GO_TERM","name":"metallo-sulfur cluster assembly","canonical_id":"go:GO:0031163","description":"\"The incorporation of a metal and exogenous sulfur into a metallo-sulfur cluster.\" [GOC:jl, GOC:mah, GOC:pde, GOC:vw]","metadata":null},{"id":"c4236e6122374b96b9d189651cd22b70","type":"GO_TERM","name":"metalloaminopeptidase activity","canonical_id":"go:GO:0070006","description":"\"Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#AMINOPEPTIDASE]","metadata":null},{"id":"3777d9ffdc7943ddac17206843a9a039","type":"GO_TERM","name":"metallocarboxypeptidase activity","canonical_id":"go:GO:0004181","description":"\"Catalysis of the hydrolysis of a single C-terminal amino acid residue from a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#CARBOXYPEPTIDASE]","metadata":null},{"id":"e820b1d56b874be1bdf4a04bc02f6a1d","type":"GO_TERM","name":"metallochaperone activity","canonical_id":"go:GO:0016530","description":"\"Binding to and delivering metal ions to a target protein.\" [PMID:11739376]","metadata":null},{"id":"de00b6e923ad43b5a90d8cc605659cad","type":"GO_TERM","name":"metallochaperone complex","canonical_id":"go:GO:1902695","description":"\"A protein complex which is capable of metallochaperone activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:10426947]","metadata":null},{"id":"dbd0919b57c74e02917c3e5e5f12220d","type":"GO_TERM","name":"metallodipeptidase activity","canonical_id":"go:GO:0070573","description":"\"Catalysis of the hydrolysis of a dipeptide by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"a2f76f3c4aba47a3974da11d16b5428a","type":"GO_TERM","name":"metalloendopeptidase activity","canonical_id":"go:GO:0004222","description":"\"Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE]","metadata":null},{"id":"f600b9c0ddd34c0db2ff2160012d1077","type":"GO_TERM","name":"metalloendopeptidase activity involved in amyloid precursor protein catabolic process","canonical_id":"go:GO:1902945","description":"\"Any metalloendopeptidase activity that is involved in amyloid precursor protein catabolic process.\" [GO_REF:0000061, GOC:sjp, GOC:TermGenie, PMID:14598310, PMID:17855360]","metadata":null},{"id":"f40c079d6a3c4b8c9af0d8e8f4c45d83","type":"GO_TERM","name":"metalloendopeptidase inhibitor activity","canonical_id":"go:GO:0008191","description":"\"Binds to and stops, prevents or reduces the activity of metalloendopeptidases, enzymes that catalyze the hydrolysis of nonterminal peptide bonds in a polypeptide chain and contain a chelated metal ion at their active sites which is essential to their catalytic activity.\" [GOC:ai]","metadata":null},{"id":"5b046db79dbe4a9cb706cc3da6cb5d6c","type":"GO_TERM","name":"metalloexopeptidase activity","canonical_id":"go:GO:0008235","description":"\"Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml]","metadata":null},{"id":"61ff9b5ee0b24be6933e6ed7a11660e4","type":"GO_TERM","name":"metallopeptidase activity","canonical_id":"go:GO:0008237","description":"\"Catalysis of the hydrolysis of peptide bonds by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"8c75056186e9440a8917bca2ff496dc7","type":"GO_TERM","name":"metamorphosis","canonical_id":"go:GO:0007552","description":"\"A biological process in which an animal physically develops after birth or hatching, involving a conspicuous and relatively abrupt change in the animal's form or structure. Examples include the change from tadpole to frog, and the change from larva to adult. An example of this is found in Drosophila melanogaster.\" [GOC:sensu, ISBN:0198506732, ISBN:0721662544]","metadata":null},{"id":"19207f9d84f44468b68e33558fa456cc","type":"GO_TERM","name":"metanephric DCT cell development","canonical_id":"go:GO:0072241","description":"\"The process whose specific outcome is the progression of a metanephric distal convoluted tubule cell over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3d3bdf113499491d8fa19901ad4262b2","type":"GO_TERM","name":"metanephric DCT cell differentiation","canonical_id":"go:GO:0072240","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the distal convoluted tubule cells of the metanephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3f164c46fbf5481b8c40f5ff2d6fd99e","type":"GO_TERM","name":"metanephric DCT cell fate commitment","canonical_id":"go:GO:0072242","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric distal convoluted tubule cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"65cd035c020e4b2494bab638a9b1995f","type":"GO_TERM","name":"metanephric S-shaped body morphogenesis","canonical_id":"go:GO:0072284","description":"\"The process in which the metanephric S-shaped body is generated and organized. The metanephric S-shaped body is the successor of the metanephric comma-shaped body that contributes to the morphogenesis of a nephron in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"269706cff9e7429b96f2277cd3c90d7f","type":"GO_TERM","name":"metanephric ascending thin limb development","canonical_id":"go:GO:0072218","description":"\"The process whose specific outcome is the progression of a metanephric ascending thin limb over time, from its formation to the mature structure. The metanephric ascending thin limb is a segment of a nephron tubule in the metanephros lying in the inner medulla that is permeable to ions but not to water and has a simple epithelium; active transepithelial solute transport is absent.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"171da697a7724e40affddc93eca033bc","type":"GO_TERM","name":"metanephric cap development","canonical_id":"go:GO:0072185","description":"\"The biological process whose specific outcome is the progression of the metanephric cap from an initial condition to its mature state. The metanephric cap is formed by the condensation of metanephric mesenchymal cells surrounding the ureteric bud tip.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"703f810c0751474489db9f6ceb5fef65","type":"GO_TERM","name":"metanephric cap formation","canonical_id":"go:GO:0072187","description":"\"The developmental process pertaining to the initial formation of a metanephric cap from unspecified parts. The metanephric cap is formed by the condensation of metanephric mesenchymal cells surrounding the ureteric bud tip.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1d7cb50fbfce4cbf8e6fa79daa511dfd","type":"GO_TERM","name":"metanephric cap mesenchymal cell proliferation involved in metanephros development","canonical_id":"go:GO:0090094","description":"\"The multiplication or reproduction of metanephric cap mesenchymal cells, resulting in the expansion of the cell population. A metanephric cap mesenchymal cell is a mesenchymal cell that has condensed with other mesenchymal cells surrounding the ureteric bud tip.\" [GOC:dph, GOC:tb, GOC:yaf, PMID:19161241]","metadata":null},{"id":"cae3dd0e727d4836a1e5c956efc15b3d","type":"GO_TERM","name":"metanephric cap morphogenesis","canonical_id":"go:GO:0072186","description":"\"The process in which the anatomical structures of the metanephric cap are generated and organized. The metanephric cap is formed by the condensation of metanephric mesenchymal cells surrounding the ureteric bud tip.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d444da2b99e4404fa34e6689ec2b6476","type":"GO_TERM","name":"metanephric cap specification","canonical_id":"go:GO:0072188","description":"\"The process in which the metanephric cap acquires its identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cb9d79a974d241d58985163f11b664f9","type":"GO_TERM","name":"metanephric capsule development","canonical_id":"go:GO:0072213","description":"\"The process whose specific outcome is the progression of the metanephric capsule over time, from its formation to the mature structure. The metanephric capsule is the tough fibrous layer surrounding the metanephros, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cc0868dedaa544199024a95bd7d72c05","type":"GO_TERM","name":"metanephric capsule formation","canonical_id":"go:GO:0072266","description":"\"The developmental process pertaining to the initial formation of a metanephric capsule from unspecified parts. The metanephric capsule is the tough fibrous layer surrounding the metanephros, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d0b93a54d34049928911ae4924e068a8","type":"GO_TERM","name":"metanephric capsule morphogenesis","canonical_id":"go:GO:0072265","description":"\"The process in which the anatomical structures of the metanephric capsule are generated and organized. The metanephric capsule is the tough fibrous layer surrounding the metanephros, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"47c5d930a5a749ed9685bc62652e1bb9","type":"GO_TERM","name":"metanephric capsule specification","canonical_id":"go:GO:0072267","description":"\"The regionalization process in which the identity of the metanephric capsule is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"46cd51fa2245498da6bd5a3da6370d77","type":"GO_TERM","name":"metanephric collecting duct development","canonical_id":"go:GO:0072205","description":"\"The process whose specific outcome is the progression of a collecting duct in the metanephros over time, from its formation to the mature structure. The collecting duct responds to vasopressin and aldosterone to regulate water, electrolyte and acid-base balance. The collecting duct is the final common path through which urine flows before entering the ureter and then emptying into the bladder.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"03ae476766474865b40a3cd6fbe8ac61","type":"GO_TERM","name":"metanephric comma-shaped body morphogenesis","canonical_id":"go:GO:0072278","description":"\"The process in which the metanephric comma-shaped body is generated and organized. The metanephric comma-shaped body is the precursor structure to the metanephric S-shaped body that contributes to the morphogenesis of a nephron in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"81290aedf6d246318154d84b5214f8f8","type":"GO_TERM","name":"metanephric connecting tubule development","canonical_id":"go:GO:0072286","description":"\"The process whose specific outcome is the progression of the metanephric connecting tubule over time, from its formation to the mature structure. The metanephric connecting tubule is a tubular segment of the metanephric nephron; it connects the distal convoluted tubule to the collecting duct in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0e18f47dd9a2478180978ad46fb08d1b","type":"GO_TERM","name":"metanephric cortex development","canonical_id":"go:GO:0072214","description":"\"The process whose specific outcome is the progression of the metanephric cortex over time, from its formation to the mature structure. The metanephric cortex is the outer region of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4e3bde46851d42c5b47b92258f785792","type":"GO_TERM","name":"metanephric cortical collecting duct development","canonical_id":"go:GO:0072219","description":"\"The process whose specific outcome is the progression of the metanephric cortical collecting duct over time, from its formation to the mature structure. The metanephric cortical collecting duct is the portion of the metanephric collecting duct that resides in the renal cortex.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d85142391e8348e0a1c0a112e3ba05c2","type":"GO_TERM","name":"metanephric descending thin limb development","canonical_id":"go:GO:0072220","description":"\"The process whose specific outcome is the progression of the metanephric descending thin limb over time, from its formation to the mature structure. The metanephric descending thin limb is a part of the metanephric loop of Henle situated just after the proximal straight tubule (S3). It extends to the tip of the metanephric loop of Henle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8d90e019db5b412580dcdf349cee200f","type":"GO_TERM","name":"metanephric distal convoluted tubule development","canonical_id":"go:GO:0072221","description":"\"The process whose specific outcome is the progression of the metanephric distal convoluted tubule over time, from its formation to the mature structure. The metanephric distal convoluted tubule is the first segment of the metanephric nephron lying just downstream from the loop of Henle, immediately after the macula densa. Among other functions, in humans it is responsible for the reabsorption of about 5% of filtered sodium via the thiazide-sensitive Na-Cl symporter.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4dafe7f3e362448983813d4afd5bbf9a","type":"GO_TERM","name":"metanephric distal tubule development","canonical_id":"go:GO:0072235","description":"\"The process whose specific outcome is the progression of the metanephric distal tubule over time, from its formation to the mature structure. The metanephric distal tubule is a metanephric nephron tubule that begins at the metanephric macula densa and extends to the metanephric connecting tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9e963cc4cd85405a890ddfdc38a47c16","type":"GO_TERM","name":"metanephric distal tubule morphogenesis","canonical_id":"go:GO:0072287","description":"\"The process in which the anatomical structures of a metanephric distal tubule are generated and organized. The metanephric distal tubule is a metanephric nephron tubule that begins at the macula densa and extends to the metanephric connecting tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"55dd0b5057ea40c6a70265402e2807f6","type":"GO_TERM","name":"metanephric early distal convoluted tubule development","canonical_id":"go:GO:0072222","description":"\"The process whose specific outcome is the progression of the metanephric early distal convoluted tubule over time, from its formation to the mature structure. The metanephric early distal convoluted tubule contains metanephric DCT cells and is vasopressin-insensitive.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"06a4b53a64634461939ea70408fb9dbf","type":"GO_TERM","name":"metanephric epithelium development","canonical_id":"go:GO:0072207","description":"\"The process whose specific outcome is the progression of an epithelium in the metanephros over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cb9e3711f27b4be5968696c42012489c","type":"GO_TERM","name":"metanephric glomerular basement membrane development","canonical_id":"go:GO:0072274","description":"\"The process whose specific outcome is the progression of the metanephric glomerular basement membrane over time, from its formation to the mature structure. The metanephric glomerular basement membrane is the basal laminal portion of the metanephric glomerulus which performs the actual filtration.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5223e1f8a94d46759e76bc553d311df1","type":"GO_TERM","name":"metanephric glomerular capillary formation","canonical_id":"go:GO:0072277","description":"\"The process that gives rise to a metanephric glomerular capillary. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"66cd3d19b11f4afcb4631b8c01247d38","type":"GO_TERM","name":"metanephric glomerular endothelium development","canonical_id":"go:GO:0072264","description":"\"The process whose specific outcome is the progression of the metanephric glomerular endothelium over time, from its formation to the mature structure. The metanephric glomerular endothelium is an epithelial tissue that covers the internal surfaces of the glomerulus of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cb3be4b654e34357ae8801ddfd262308","type":"GO_TERM","name":"metanephric glomerular epithelial cell development","canonical_id":"go:GO:0072313","description":"\"The process whose specific outcome is the progression of a metanephric glomerular epithelial cell over time, from its formation to the mature structure. Metanephric glomerular epithelial cells are specialized epithelial cells that form part of the metanephric glomerulus; there are two types, metanephric glomerular parietal epithelial cells and metanephric glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d8556540c0fc45beba1941f304c8b6ed","type":"GO_TERM","name":"metanephric glomerular epithelial cell differentiation","canonical_id":"go:GO:0072312","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a metanephric glomerular epithelial cell. Metanephric glomerular epithelial cells are specialized epithelial cells that form part of the metanephric glomerulus; there are two types, metanephric glomerular parietal epithelial cells and metanephric glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"afdda96f055746e482d910bb9961d51e","type":"GO_TERM","name":"metanephric glomerular epithelial cell fate commitment","canonical_id":"go:GO:0072315","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric glomerular epithelial cell. Metanephric glomerular epithelial cells are specialized epithelial cells that form part of the metanephric glomerulus; there are two types, metanephric glomerular parietal epithelial cells and metanephric glomerular visceral epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ba6c791129a347acbde9ea834ecea27c","type":"GO_TERM","name":"metanephric glomerular epithelium development","canonical_id":"go:GO:0072244","description":"\"The process whose specific outcome is the progression of the metanephric glomerular epithelium over time, from its formation to the mature structure. The metanephric glomerular epithelium is an epithelial tissue that covers the outer surfaces of the glomerulus in the metanephros. The metanephric glomerular epithelium consists of both parietal and visceral epithelium. Metanephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport. A metanephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8b1f42ebc4f84261a491fc7f2f26aec7","type":"GO_TERM","name":"metanephric glomerular mesangial cell development","canonical_id":"go:GO:0072255","description":"\"The process whose specific outcome is the progression of a glomerular mesangial cell in the metanephros over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"90da14f96bd845d2a003b8b51ef28f89","type":"GO_TERM","name":"metanephric glomerular mesangial cell differentiation","canonical_id":"go:GO:0072254","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the glomerular mesangial cells of the metanephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5645726abaa6414a84134485266ca92e","type":"GO_TERM","name":"metanephric glomerular mesangial cell fate commitment","canonical_id":"go:GO:0072256","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric glomerular mesangial cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3a7f76f3ab124ef7ae2dd9c697ab0261","type":"GO_TERM","name":"metanephric glomerular mesangial cell proliferation involved in metanephros development","canonical_id":"go:GO:0072262","description":"\"The multiplication or reproduction of glomerular mesangial cells in the metanephros, resulting in the expansion of the population.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bca28fd964af45d78667d17232dbcbcb","type":"GO_TERM","name":"metanephric glomerular mesangium development","canonical_id":"go:GO:0072223","description":"\"The process whose specific outcome is the progression of the metanephric glomerular mesangium over time, from its formation to the mature structure. The metanephric glomerular mesangium is the thin membrane connective tissue composed of mesangial cells in the metanephros, which helps to support the capillary loops in a renal glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"26b2a9c153bb4129b90c4fab53b44f71","type":"GO_TERM","name":"metanephric glomerular parietal epithelial cell development","canonical_id":"go:GO:0072246","description":"\"The process whose specific outcome is the progression of a metanephric glomerular parietal epithelial cell over time, from its formation to the mature structure. Metanephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"7e5158696eee4b0b8d4f5440a71a99e7","type":"GO_TERM","name":"metanephric glomerular parietal epithelial cell differentiation","canonical_id":"go:GO:0072245","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a metanephric glomerular parietal epithelial cell. Metanephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"51f40386f62e459e9aabba5fdb912366","type":"GO_TERM","name":"metanephric glomerular parietal epithelial cell fate commitment","canonical_id":"go:GO:0072247","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric glomerular parietal epithelial cell. Metanephric glomerular parietal epithelial cells are specialized epithelial cells that form tight junctions as a barrier to protein transport. These cells may also give rise to podocytes.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"020d7435829149c5b03be7f806d14573","type":"GO_TERM","name":"metanephric glomerulus development","canonical_id":"go:GO:0072224","description":"\"The progression of the metanephric glomerulus over time from its initial formation until its mature state. The metanephric glomerulus is a capillary tuft which forms a close network with the visceral epithelium (podocytes) and the mesangium to form the filtration barrier and is surrounded by Bowman's capsule in nephrons of the mature vertebrate kidney, or metanephros.\" [GOC:mah]","metadata":null},{"id":"65dfccdd1af247779535d063e7791832","type":"GO_TERM","name":"metanephric glomerulus morphogenesis","canonical_id":"go:GO:0072275","description":"\"The process in which the anatomical structures of the metanephric glomerulus are generated and organized. The metanephric glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney, or metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9c59e5d956a6483582e40731683c9b34","type":"GO_TERM","name":"metanephric glomerulus vasculature development","canonical_id":"go:GO:0072239","description":"\"The biological process whose specific outcome is the progression of a metanephric glomerulus vasculature from an initial condition to its mature state. This process begins with the formation of the metanephric glomerulus vasculature and ends with the mature structure. The metanephric glomerulus vasculature is composed of the tubule structures that carry blood or lymph in the metanephric glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"750b6c39c8ee45e5b06b9a4a938580ee","type":"GO_TERM","name":"metanephric glomerulus vasculature morphogenesis","canonical_id":"go:GO:0072276","description":"\"The process in which the anatomical structures of the metanephric glomerulus vasculature are generated and organized. The metanephric glomerulus vasculature is composed of the tubule structures that carry blood or lymph in the metanephric glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"11c7a176e2684dd08559f2ff192156fd","type":"GO_TERM","name":"metanephric interstitial fibroblast development","canonical_id":"go:GO:0072259","description":"\"The process whose specific outcome is the progression of a metanephric interstitial fibroblast over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"28616b3690814fc3bd793f956af8e738","type":"GO_TERM","name":"metanephric interstitial fibroblast differentiation","canonical_id":"go:GO:0072258","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the interstitial fibroblasts of the metanephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f15a85bd106d485aafb8a3a633926ecb","type":"GO_TERM","name":"metanephric interstitial fibroblast fate commitment","canonical_id":"go:GO:0072260","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric interstitial fibroblast.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ac3150dd1f934dc79ff1435839cdbfb6","type":"GO_TERM","name":"metanephric intraglomerular mesangial cell proliferation","canonical_id":"go:GO:0072263","description":"\"The multiplication or reproduction of intraglomerular glomerular mesangium cells in the metanephros by cell division, resulting in the expansion of their population. Intraglomerular mesangial cells are specialized pericytes located among the glomerular capillaries within a renal corpuscle of a kidney. They are required for filtration, structural support and phagocytosis.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"56bd484981ef4fd4bdb4805398db9fbb","type":"GO_TERM","name":"metanephric juxtaglomerular apparatus development","canonical_id":"go:GO:0072206","description":"\"The process whose specific outcome is the progression of the juxtaglomerular apparatus in the metanephros over time, from its formation to the mature structure. The juxtaglomerular apparatus is an anatomical structure which consists of juxtaglomerular cells, extraglomerular mesangial cells and the macula densa. The juxtaglomerular apparatus lies adjacent to the glomerulus and regulates kidney function by maintaining the blood flow to the kidney and the filtration rate.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1ef0863bba794f27b7a1649543e45195","type":"GO_TERM","name":"metanephric juxtaglomerulus cell development","canonical_id":"go:GO:0072252","description":"\"The process whose specific outcome is the progression of a metanephric juxtaglomerulus cell over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"55f4c945a3c94be08982d75a93a25b33","type":"GO_TERM","name":"metanephric juxtaglomerulus cell differentiation","canonical_id":"go:GO:0072251","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the juxtaglomerulus cells of the metanephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c62b619459294383bc2765c0c94f53c6","type":"GO_TERM","name":"metanephric juxtaglomerulus cell fate commitment","canonical_id":"go:GO:0072253","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric juxtaglomerulus cell.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0ba123b71d184cea8d6445805260f2a0","type":"GO_TERM","name":"metanephric late distal convoluted tubule development","canonical_id":"go:GO:0072225","description":"\"The process whose specific outcome is the progression of the metanephric late distal convoluted tubule over time, from its formation to the mature structure. The metanephric late distal convoluted tubule contains metanephric DCT cells and intercalated (IC) alpha and beta cells and is vasopressin-sensitive.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bd9fbfa55db945aabd3e1119f3a1e144","type":"GO_TERM","name":"metanephric long descending thin limb bend development","canonical_id":"go:GO:0072226","description":"\"The process whose specific outcome is the progression of the metanephric long descending thin limb bend over time, from its formation to the mature structure. The metanephric long descending thin limb bend is a part of the descending thin limb of a long nephron that lies beyond the prebend segment in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6014dde0c4ad4c1e9f57b3c75ff53356","type":"GO_TERM","name":"metanephric long descending thin limb development","canonical_id":"go:GO:0072269","description":"\"The process whose specific outcome is the progression of the metanephric long descending thin limb over time, from its formation to the mature structure. The metanephric long descending thin limb is the descending thin limb of a long nephron in the metanephros that has a squamous epithelial morphology. The long descending limb starts in the inner stripe of the outer medulla and extends into the inner medulla.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f76c8457248a46b29e6cd926757ab641","type":"GO_TERM","name":"metanephric long nephron development","canonical_id":"go:GO:0072238","description":"\"The process whose specific outcome is the progression of a metanephric long nephron over time, from its formation to the mature structure. Long nephrons are associated with juxtamedullary glomeruli and extend into the inner medulla in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6fb00f99ad4a4e638ba28b90125da11c","type":"GO_TERM","name":"metanephric loop of Henle development","canonical_id":"go:GO:0072236","description":"\"The process whose specific outcome is the progression of the metanephric loop of Henle over time, from its formation to the mature structure. The metanephric loop of Henle is a metanephric nephron tubule that connects the proximal convoluted tubule to the distal convoluted tubule in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ed5dc01a4e3d4dfab100d8ee6fa93ded","type":"GO_TERM","name":"metanephric macula densa development","canonical_id":"go:GO:0072227","description":"\"The process whose specific outcome is the progression of the metanephric macula densa over time, from its formation to the mature structure. The metanephric macula densa is an area of specialized cells in the distal tubule of the metanephros that makes contact with the vascular pole of the glomerulus.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d4335c0ea463417492ad0133c32b1aec","type":"GO_TERM","name":"metanephric mesangial cell differentiation","canonical_id":"go:GO:0072209","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesangial cells of the metanephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a663d11d94ea4fc9985d085b6b3638a9","type":"GO_TERM","name":"metanephric mesenchymal cell differentiation","canonical_id":"go:GO:0072162","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mesenchymal cells of the metanephros as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"26297e2f07e94abfb323b7be3467a922","type":"GO_TERM","name":"metanephric mesenchymal cell migration","canonical_id":"go:GO:0035789","description":"\"The orderly movement of undifferentiated metanephric mesenchymal cells (precursors to metanephric mesangial cells) from the mesenchyme into the cleft of the developing glomerulus, during development of the metanephros.\" [GOC:bf, GOC:mtg_kidney_jan10, GOC:yaf, PMID:10734101, PMID:19019919]","metadata":null},{"id":"075bf7b449404e0180bc489cbfba8a14","type":"GO_TERM","name":"metanephric mesenchymal cell proliferation involved in metanephros development","canonical_id":"go:GO:0072136","description":"\"The multiplication or reproduction of cells, resulting in the expansion of a metanephric mesenchymal cell population.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f30fbc44ce5b4b47bcb819f5edc7b3f5","type":"GO_TERM","name":"metanephric mesenchyme development","canonical_id":"go:GO:0072075","description":"\"The biological process whose specific outcome is the progression of a metanephric mesenchyme from an initial condition to its mature state. This process begins with the formation of metanephric mesenchyme and ends with the mature structure. Metanephric mesenchyme is the tissue made up of loosely connected mesenchymal cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"304e38de8e1b47dda3b5fa9ca2f8c13a","type":"GO_TERM","name":"metanephric mesenchyme morphogenesis","canonical_id":"go:GO:0072133","description":"\"The process in which the anatomical structures of a metanephric mesenchymal tissue are generated and organized. Metanephric mesenchyme is the tissue made up of loosely connected mesenchymal cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b3b6a8395c514ee5a48bbfedb0722124","type":"GO_TERM","name":"metanephric nephron development","canonical_id":"go:GO:0072210","description":"\"The process whose specific outcome is the progression of a nephron in the metanephros over time, from its formation to the mature structure. A nephron is the functional unit of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b5251f88c0c24373a855040cae257c87","type":"GO_TERM","name":"metanephric nephron epithelium development","canonical_id":"go:GO:0072243","description":"\"The process whose specific outcome is the progression of the metanephric nephron epithelium over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure. The metanephric nephron epithelium is a tissue that covers the surface of a nephron in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"80fa291842ba4b5ca53967280dac14b2","type":"GO_TERM","name":"metanephric nephron morphogenesis","canonical_id":"go:GO:0072273","description":"\"The process in which the anatomical structures of the metanephric nephron are generated and organized. A metanephric nephron is the functional unit of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f32b5db7112d4f1d9ece8753da0cb846","type":"GO_TERM","name":"metanephric nephron tubule development","canonical_id":"go:GO:0072234","description":"\"The progression of a metanephric nephron tubule over time, from its initial formation to the mature structure. A metanephric nephron tubule is an epithelial tube that is part of the metanephric nephron, the functional part of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6bd77ac9774941148d1c9e653280478d","type":"GO_TERM","name":"metanephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0072257","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the metanephric nephron tubule as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3b70f69face944eebe39fe94efd6a368","type":"GO_TERM","name":"metanephric nephron tubule formation","canonical_id":"go:GO:0072289","description":"\"The developmental process pertaining to the initial formation of a metanephric nephron tubule from unspecified parts. A metanephric nephron tubule is an epithelial tube that is part of a nephron in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ac06f154150144fdb6bdc2c8d2c8e015","type":"GO_TERM","name":"metanephric nephron tubule morphogenesis","canonical_id":"go:GO:0072282","description":"\"The process in which the anatomical structures of a metanephric nephron tubule are generated and organized. A metanephric nephron tubule is an epithelial tube that is part of the metanephric nephron, the functional part of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f32b8ae64baf4556ae591b402999931e","type":"GO_TERM","name":"metanephric part of ureteric bud development","canonical_id":"go:GO:0035502","description":"\"The development of the portion of the ureteric bud tube that contributes to the morphogenesis of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a3154027e7f04509b36cbbd9b448e936","type":"GO_TERM","name":"metanephric podocyte cell fate commitment","canonical_id":"go:GO:0072250","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a metanephric glomerular visceral epithelial cell. A metanephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8b10939db8f54103a449458c42d93f54","type":"GO_TERM","name":"metanephric podocyte development","canonical_id":"go:GO:0072249","description":"\"The process whose specific outcome is the progression of a metanephric glomerular visceral epithelial cell over time, from its formation to the mature structure. A metanephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"af7b27eb59974cb886d1925177402145","type":"GO_TERM","name":"metanephric podocyte differentiation","canonical_id":"go:GO:0072248","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a metanephric glomerular visceral epithelial cell. A metanephric glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells in the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2db450b6b57841199aa9db25262b9c2f","type":"GO_TERM","name":"metanephric prebend segment development","canonical_id":"go:GO:0072228","description":"\"The process whose specific outcome is the progression of the metanephric prebend segment over time, from its formation to the mature structure. The metanephric prebend segment is a part of the metanephric descending thin limb that lies before the bend and exhibits permeabilities characteristic of the ascending limb, especially negligible water permeability.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ac9c7e5b1f924cf1a85bafc115643679","type":"GO_TERM","name":"metanephric proximal convoluted tubule development","canonical_id":"go:GO:0072229","description":"\"The process whose specific outcome is the progression of the metanephric proximal convoluted tubule over time, from its formation to the mature structure. The metanephric proximal convoluted tubule is the most proximal portion of the metanephric proximal tubule and extends from the metanephric glomerular capsule to the metanephric proximal straight tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4020e3c460714495bf42b8bf8428c8d9","type":"GO_TERM","name":"metanephric proximal convoluted tubule segment 1 development","canonical_id":"go:GO:0072231","description":"\"The process whose specific outcome is the progression of the S1 portion of the metanephric proximal convoluted tubule over time, from its formation to the mature structure. The S1 portion is the initial portion of the metanephric proximal convoluted tubule and is responsible for avid reabsorption of water and solutes.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"33049b701f624ffa8403c7287b6aa8f2","type":"GO_TERM","name":"metanephric proximal convoluted tubule segment 2 development","canonical_id":"go:GO:0072232","description":"\"The process whose specific outcome is the progression of the S2 portion of the metanephric proximal convoluted tubule over time, from its formation to the mature structure. The S2 portion of the metanephric proximal tubule is involved in reabsorption of water and sodium chloride.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"6085a65321144a18a27ce102a35d34eb","type":"GO_TERM","name":"metanephric proximal straight tubule development","canonical_id":"go:GO:0072230","description":"\"The process whose specific outcome is the progression of the metanephric proximal straight tubule over time, from its formation to the mature structure. The metanephric proximal straight tubule is the part of the metanephric descending limb that extends from the metanephric proximal convoluted tubule to the metanephric descending thin tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2eb876fe64804b1381a97cb3ab563ff2","type":"GO_TERM","name":"metanephric proximal tubule development","canonical_id":"go:GO:0072237","description":"\"The process whose specific outcome is the progression of the metanephric proximal tubule over time, from its formation to the mature structure. The metanephric proximal tubule is a metanephric nephron tubule that connects Bowman's capsule to the descending thin limb of the loop of Henle in the metanephros. It has a brush border epithelial morphology.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"79a9c0256f8843fd8badb9204c4a9b52","type":"GO_TERM","name":"metanephric proximal tubule morphogenesis","canonical_id":"go:GO:0072288","description":"\"The process in which the anatomical structures of a metanephric proximal tubule are generated and organized. The metanephric proximal tubule is a metanephric nephron tubule that connects Bowman's capsule to the descending thin limb of the loop of Henle in the metanephros. It has a brush border epithelial morphology.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5accf742545e4655b68daa23b196531a","type":"GO_TERM","name":"metanephric pyramids development","canonical_id":"go:GO:0072211","description":"\"The process whose specific outcome is the progression of the metanephric pyramids over time, from their formation to the mature structures. Metanephric pyramids are the conical masses that constitute the renal medulla in a metanephros; they contain the loops of Henle and the medullary collecting ducts.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d16b526c4f9744fcab4b666c2e26ec36","type":"GO_TERM","name":"metanephric renal vesicle formation","canonical_id":"go:GO:0072093","description":"\"The developmental process pertaining to the initial formation of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"084b5d53b8ac4972ac3ee8e852bba5fd","type":"GO_TERM","name":"metanephric renal vesicle induction","canonical_id":"go:GO:0072094","description":"\"Signaling at short range between cells of the ureteric bud terminus and the kidney mesenchyme that positively regulates the formation of the metanephric renal vesicle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"09a2e9cafdd245ed8ddaec1c548f99ad","type":"GO_TERM","name":"metanephric renal vesicle morphogenesis","canonical_id":"go:GO:0072283","description":"\"The process in which the anatomical structures of the metanephric renal vesicle are generated and organized. The renal vesicle is the primordial structure of the metanephric nephron epithelium, and is formed by the condensation of mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f2983ac4a6634aaa93be5f9c341f851b","type":"GO_TERM","name":"metanephric short descending thin limb development","canonical_id":"go:GO:0072271","description":"\"The process whose specific outcome is the progression of the metanephric short descending thin limb over time, from its formation to the mature structure. The metanephric short descending thin limb is the descending thin limb of a short nephron in the metanephros that has a squamous epithelial morphology.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0d6c0cbfe61d4e299778282367e1718e","type":"GO_TERM","name":"metanephric short nephron development","canonical_id":"go:GO:0072270","description":"\"The process whose specific outcome is the progression of a short nephron in the metanephros over time, from its formation to the mature structure. Short nephrons are associated with mid-cortical and superficial glomeruli, are situated entirely in the outer medulla, and have no thin ascending limb.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1a15c78271c6448eba74c122279b04a1","type":"GO_TERM","name":"metanephric smooth muscle tissue development","canonical_id":"go:GO:0072208","description":"\"The process whose specific outcome is the progression of smooth muscle in the metanephros over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2d0e55b008fd4348a569cd3a1b290e19","type":"GO_TERM","name":"metanephric thick ascending limb development","canonical_id":"go:GO:0072233","description":"\"The process whose specific outcome is the progression of the metanephric thick ascending limb over time, from its formation to the mature structure. The metanephric thick ascending limb is the last part of the metanephric loop of Henle. Its thick, mitochondria-rich epithelium characterizes the outer medulla, and is responsible for very avid active salt transport. At the macula densa, the thick ascending limb connects to the distal convoluted tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ed4a83759a3b4c95a514534ec3f973e3","type":"GO_TERM","name":"metanephric tubule development","canonical_id":"go:GO:0072170","description":"\"The progression of a metanephric tubule over time, from its initial formation to the mature structure. A metanephric tubule is an epithelial tube that is part of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9964cbf7063946d7bfef32c23652072a","type":"GO_TERM","name":"metanephric tubule formation","canonical_id":"go:GO:0072174","description":"\"The developmental process pertaining to the initial formation of a metanephric tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8db0e0679b324d96b5a448bb8ee7ca81","type":"GO_TERM","name":"metanephric tubule morphogenesis","canonical_id":"go:GO:0072173","description":"\"The process in which the anatomical structures of a metanephric tubule are generated and organized from an epithelium. A metanephric tubule is an epithelial tube that is part of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"29fcc050f4464a7b8d1259536ef10dae","type":"GO_TERM","name":"metanephros development","canonical_id":"go:GO:0001656","description":"\"The process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. In mammals, the metanephros is the excretory organ of the fetus, which develops into the mature kidney and is formed from the rear portion of the nephrogenic cord. The metanephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:bf, ISBN:0192800752]","metadata":null},{"id":"70defbfe258b47b09a75aa582b5f6922","type":"GO_TERM","name":"metanephros morphogenesis","canonical_id":"go:GO:0003338","description":"\"The process in which the anatomical structures of the metanephros are generated and organized.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"5a37931b062b4d3c925a2885504177ae","type":"GO_TERM","name":"metaphase","canonical_id":"go:GO:0051323","description":"\"The cell cycle phase, following prophase or prometaphase in higher eukaryotes, during which chromosomes become aligned on the equatorial plate of the cell.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"3ce661b91f6841c9ad38a1e13160d95d","type":"GO_TERM","name":"metaphase chromosome alignment","canonical_id":"go:GO:0051310","description":"\"A chromosome localization process whereby chromosomes are positioned in a specific order and orientation at the metaphase plate (spindle equator), during chromosome segregation. This alignment ensures that each daughter cell will receive the correct number of chromosomes during cell division.\" [GOC:vw]","metadata":null},{"id":"6dc55abf669a4996a32ea576cc0533f0","type":"GO_TERM","name":"metaphase plate","canonical_id":"go:GO:0070090","description":"\"The intracellular plane, located halfway between the poles of the spindle, where chromosomes align during metaphase of mitotic or meiotic nuclear division.\" [GOC:mah]","metadata":null},{"id":"684918423c88454b804225d1ef6f5855","type":"GO_TERM","name":"metaphase/anaphase transition of cell cycle","canonical_id":"go:GO:0044784","description":"\"The cell cycle process in which a cell progresses from metaphase to anaphase as part of the cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"20ffd2c591c94469bc0a534c2f71d67a","type":"GO_TERM","name":"metaphase/anaphase transition of meiosis I","canonical_id":"go:GO:1990949","description":"\"The cell cycle process in which a cell progresses from metaphase to anaphase as part of meiosis I.\" [ISBN:0815316194]","metadata":null},{"id":"3f16a2769c65439290d45877ee04ac70","type":"GO_TERM","name":"metaphase/anaphase transition of meiosis II","canonical_id":"go:GO:1990950","description":"\"The cell cycle process in which a cell progresses from metaphase to anaphase as part of meiosis II.\" [ISBN:0815316194]","metadata":null},{"id":"88b969dd6fc149c38d31b584532d9299","type":"GO_TERM","name":"metaphase/anaphase transition of meiotic cell cycle","canonical_id":"go:GO:0044785","description":"\"The cell cycle process in which a cell progresses from metaphase to anaphase as part of meiosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d756de7816c24807a4b134a121fb07fd","type":"GO_TERM","name":"metaphase/anaphase transition of mitotic cell cycle","canonical_id":"go:GO:0007091","description":"\"The cell cycle process in which a cell progresses from metaphase to anaphase during mitosis, triggered by the activation of the anaphase promoting complex by Cdc20/Sleepy homolog which results in the degradation of Securin.\" [GOC:mtg_cell_cycle, PMID:10465783]","metadata":null},{"id":"93f09f274bb946cfb0730eeaf33fe7e3","type":"DISEASE","name":"metaphyseal chondrodysplasia, Jansen type","canonical_id":"mondo:0007982","description":null,"metadata":null},{"id":"c4ccd8c67d254391bc1176b91798cc33","type":"DISEASE","name":"metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria","canonical_id":"mondo:0013941","description":null,"metadata":null},{"id":"1aa3c93c8228415bb86686638b37dbe1","type":"GO_TERM","name":"metaplastic ossification","canonical_id":"go:GO:0036074","description":"\"Direct ossification in which bone formation occurs as result of the direct transformation of non-bone cells into bone cells without cell division.\" [GO_REF:0000034]","metadata":null},{"id":"a0b913cc2f9f4b539c8eec24d749b6e1","type":"DRUG","name":"metaraminol","canonical_id":"mesh:D008680","description":null,"metadata":null},{"id":"b312867cfe8b48f6855d898c8649c6df","type":"DISEASE","name":"metastasis","canonical_id":"efo:0009708","description":null,"metadata":null},{"id":"c18b29fb68d043bab30ea603eee605ef","type":"DISEASE","name":"metastatic colorectal cancer","canonical_id":"efo:1001480","description":null,"metadata":null},{"id":"432b33eed451495c95d9a82602ae9c07","type":"DISEASE","name":"metastatic melanoma","canonical_id":"mondo:0005191","description":null,"metadata":null},{"id":"1392c9e15d22430c9568108888fa210e","type":"DISEASE","name":"metastatic prostate carcinoma","canonical_id":"mondo:0004956","description":null,"metadata":null},{"id":"935c359e1d854cf284245bd02d5cc8fe","type":"DRUG","name":"metaxalone","canonical_id":"mesh:C011301","description":null,"metadata":null},{"id":"9a4fb605e2ab479ca99370281ca77256","type":"GO_TERM","name":"metaxylem development","canonical_id":"go:GO:0090058","description":"\"The process whose specific outcome is the progression of the metaxylem over time, from its formation to the mature structure. The metaxylem is the part of the primary xylem that differentiates after the protoxylem and before the secondary xylem, if any of the latter is formed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"c8edbd90e237435bb68ded30328d243b","type":"GO_TERM","name":"metencephalon development","canonical_id":"go:GO:0022037","description":"\"The process whose specific outcome is the progression of the metencephalon over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"c4913a95b35b4ac9a98d26cfaf911caa","type":"GO_TERM","name":"metestrus","canonical_id":"go:GO:0060210","description":"\"The estrous cycle phase in which there is subsiding follicular function.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"6fe48157b49e49ebacadbd17f97bf4e3","type":"DRUG","name":"methadone","canonical_id":"gtopdb:5458","description":null,"metadata":null},{"id":"27a251fc8baf4cadab7825feff23b502","type":"COMBINATION_TREATMENT","name":"methadone + morphine","canonical_id":"ctgov_combo:ctgov-combo-3cac4b3744bf3c18","description":null,"metadata":null},{"id":"c7c6c04607984618960ec44a5252d0aa","type":"COMBINATION_TREATMENT","name":"methadone + morphine","canonical_id":"ctgov_combo:ctgov-combo-49826dc59733fdac","description":null,"metadata":null},{"id":"bc0ff05e1ebe4e648b54cd893224a8b0","type":"COMBINATION_TREATMENT","name":"methadone + sufentanil","canonical_id":"ctgov_combo:ctgov-combo-7272154df31d3eeb","description":null,"metadata":null},{"id":"7a274ede0ec54b0ab55dfca4aa3ed710","type":"GO_TERM","name":"methane catabolic process","canonical_id":"go:GO:0046188","description":"\"The chemical reactions and pathways resulting in the breakdown of methane, a colorless, odorless, flammable gas with the formula CH4. It is the simplest of the alkanes.\" [GOC:ai]","metadata":null},{"id":"f8af726c08cf48e090943433cbb8728f","type":"GO_TERM","name":"methane metabolic process","canonical_id":"go:GO:0015947","description":"\"The chemical reactions and pathways involving methane, a colorless, odorless, flammable gas with the formula CH4. It is the simplest of the alkanes.\" [ISBN:0198506732]","metadata":null},{"id":"0a9c23e1fcc8411abef8d76417aa65d7","type":"GO_TERM","name":"methane monooxygenase [NAD(P)H] activity","canonical_id":"go:GO:0015049","description":"\"Catalysis of the reaction: methane + NAD(P)H + H+ + O2 = methanol + NAD(P)+ + H2O.\" [EC:1.14.13.25, PMID:10896210]","metadata":null},{"id":"9d4c1f03bacc47728cf4c82253e0ffc8","type":"GO_TERM","name":"methane monooxygenase complex","canonical_id":"go:GO:0015050","description":"\"A protein complex that possesses methane monooxygenase activity; dimeric and trimeric complexes have been characterized.\" [GOC:mah, PMID:15544]","metadata":null},{"id":"5f9c71be90d44da5bd8e12a627e98642","type":"GO_TERM","name":"methane-oxidizing organelle","canonical_id":"go:GO:0044227","description":"\"A cytoplasmic, membrane-bounded compartment found within Methanotrophic bacteria that contains enzymes and electron transfer proteins for methane catabolism. This structure is analogous to the thylakoid of Cyanobacteria and the anammoxosome of anaerobic ammonium oxidation organisms.\" [GOC:dh]","metadata":null},{"id":"59501c4d4d77487d8ff378130af4bc8a","type":"GO_TERM","name":"methaneselenol methyltransferase activity","canonical_id":"go:GO:0098613","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + methaneselenol = S-adenosyl-L-homocysteine + dimethyl selenide.\" [PMID:14705, PMID:17988700, PMID:4380351]","metadata":null},{"id":"1e4ed8475e8b4264b14766174febfa0d","type":"GO_TERM","name":"methanesulfonate monooxygenase activity","canonical_id":"go:GO:0018648","description":"\"Catalysis of the reaction: methanesulfonate + NADH + H+ + O2 = formaldehyde + NAD+ + sulfite + H2O.\" [EC:1.14.13.111]","metadata":null},{"id":"baebe3c426a44b118bec9ffef42eb7d6","type":"GO_TERM","name":"methanethiol oxidase activity","canonical_id":"go:GO:0018549","description":"\"Catalysis of the reaction: methanethiol + O2 + H2O = hydrogen sulfide + formaldehyde + H2O2 + H+.\" [RHEA:11812]","metadata":null},{"id":"3e8a79684a99460896de3b63aec02d48","type":"GO_TERM","name":"methanofuran biosynthetic process","canonical_id":"go:GO:2001120","description":"\"The chemical reactions and pathways resulting in the formation of a methanofuran.\" [GOC:mengo_curators]","metadata":null},{"id":"f8dcf3f81996455cbf698b6e5b8362ef","type":"GO_TERM","name":"methanofuran metabolic process","canonical_id":"go:GO:2001119","description":"\"The chemical reactions and pathways involving a methanofuran.\" [GOC:mengo_curators]","metadata":null},{"id":"d69e1cd990464e03b0554d95b30ca4ce","type":"GO_TERM","name":"methanogenesis","canonical_id":"go:GO:0015948","description":"\"The chemical reactions and pathways resulting in the formation of methane, a colorless, odorless, flammable gas with the formula CH4. It is the simplest of the alkanes.\" [GOC:ai]","metadata":null},{"id":"738eef9c5f99437bbdf0eb5a0781d49b","type":"GO_TERM","name":"methanogenesis, from acetate","canonical_id":"go:GO:0019385","description":"\"The formation of methane, a colorless, odorless, flammable gas with the formula CH4, from other components, including acetate.\" [GOC:ai]","metadata":null},{"id":"52c2a53f9d594e1b99426419e0e73a67","type":"GO_TERM","name":"methanogenesis, from carbon dioxide","canonical_id":"go:GO:0019386","description":"\"The chemical reactions and pathways resulting in the formation of methane, a colorless, odorless, flammable gas with the formula CH4, from other compounds, including carbon dioxide (CO2).\" [GOC:ai]","metadata":null},{"id":"1bb8c69f37c846cd80e16e7200679d13","type":"GO_TERM","name":"methanogenesis, from methanol","canonical_id":"go:GO:0019387","description":"\"The formation of methane, a colorless, odorless, flammable gas with the formula CH4, from other components, including methanol.\" [GOC:ai]","metadata":null},{"id":"4db6d4a703484209ab0d4784d2a4177b","type":"GO_TERM","name":"methanol biosynthetic process","canonical_id":"go:GO:0046169","description":"\"The chemical reactions and pathways resulting in the formation of methanol, CH3-OH, a colorless, flammable, mobile, poisonous liquid, widely used as a solvent.\" [GOC:ai]","metadata":null},{"id":"9baf7d9fe7854ceba397795d8ae49d2e","type":"GO_TERM","name":"methanol catabolic process","canonical_id":"go:GO:0046170","description":"\"The chemical reactions and pathways resulting in the breakdown of methanol, CH3-OH, a colorless, flammable, mobile, poisonous liquid, widely used as a solvent.\" [GOC:ai]","metadata":null},{"id":"d10b2235b4c54f97a178bb3f0308ae45","type":"GO_TERM","name":"methanol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050093","description":"\"Catalysis of the reaction: methanol + NAD+ = formaldehyde + H+ + NADH.\" [EC:1.1.1.244, RHEA:19401]","metadata":null},{"id":"eec9632e36c744f08b6d2826f3a7e6de","type":"GO_TERM","name":"methanol metabolic process","canonical_id":"go:GO:0015945","description":"\"The chemical reactions and pathways involving methanol, CH3-OH, a colorless, flammable, mobile, poisonous liquid, widely used as a solvent.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b016e43aca634d1f90c2ae865c8efb74","type":"GO_TERM","name":"methanol oxidation","canonical_id":"go:GO:0015946","description":"\"The chemical reactions and pathways resulting in the conversion of methanol to methyl-Coenzyme M.\" [MetaCyc:CO2FORM-PWY]","metadata":null},{"id":"b64a2497a21a40b48de2ce6ae7fdbc10","type":"GO_TERM","name":"methanol-5-hydroxybenzimidazolylcobamide Co-methyltransferase activity","canonical_id":"go:GO:0047152","description":"\"Catalysis of the reaction: 5-hydroxybenzimidazolylcobamide + methanol = H2O + Co-methyl-Co-5-hydroxybenzimidazolylcob(I)amide.\" [PMID:6438059, RHEA:45204]","metadata":null},{"id":"47de11410dfb46aaadef8ca599fc92af","type":"GO_TERM","name":"methanol-CoM methyltransferase complex","canonical_id":"go:GO:0043853","description":"\"A heterotrimeric protein complex composed of a methanol methyltransferase subunit, a corrinoid protein and a methanol-specific corrinoid:coenzyme M methyltransferase subunit. Catalyzes the transfer of a methyl group from methanol to coenzyme M as part of the pathway of methanogenesis from methanol.\" [PMID:9363780]","metadata":null},{"id":"9b9b6e9871c1489f8022f06c5122138b","type":"GO_TERM","name":"methanophenazine biosynthetic process","canonical_id":"go:GO:1900630","description":"\"The chemical reactions and pathways resulting in the formation of methanophenazine.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9a00373e872645538d5f167a6b2add29","type":"GO_TERM","name":"methanophenazine reducing hydrogenase complex","canonical_id":"go:GO:0044679","description":"\"A protein complex which catalyzes the conversion of methanophenazine and hydrogen to form dihydromethanophenazine. This typically consists of three polypeptides.\" [GOC:mengo_curators, PMID:9555882]","metadata":null},{"id":"2188ec14d7054199b5978f7da40b6fd8","type":"GO_TERM","name":"methanopterin-containing compound biosynthetic process","canonical_id":"go:GO:2001116","description":"\"The chemical reactions and pathways resulting in the formation of a methanopterin.\" [GOC:mengo_curators]","metadata":null},{"id":"1c7800d0f0ab4ec29b18809b7fe72480","type":"DRUG","name":"methapyrilene","canonical_id":"mesh:D008701","description":null,"metadata":null},{"id":"b5d8b73f64364a8f9bb1da551104a7f8","type":"DRUG","name":"methazolamide","canonical_id":"gtopdb:6828","description":null,"metadata":null},{"id":"20df049ec213434fb9044430a7cf47dc","type":"DRUG","name":"methazolamide","canonical_id":"chembl:CHEMBL19","description":null,"metadata":null},{"id":"7b3b66b9bcdf4608bbe89fb490e6befa","type":"DRUG","name":"methdilazine","canonical_id":"mesh:C044642","description":null,"metadata":null},{"id":"18c806512e414adf8a1a6a844b512775","type":"GO_TERM","name":"methenyltetrahydrofolate cyclohydrolase activity","canonical_id":"go:GO:0004477","description":"\"Catalysis of the reaction: 5,10-methenyltetrahydrofolate + H2O = 10-formyltetrahydrofolate.\" [EC:3.5.4.9]","metadata":null},{"id":"ca7358d8c5f746dead50931eb89e6417","type":"GO_TERM","name":"methenyltetrahydromethanopterin cyclohydrolase activity","canonical_id":"go:GO:0018759","description":"\"Catalysis of the reaction: 5,10-methenyl-5,6,7,8-tetrahydromethanopterin + H2O = N(5)-formyl-5,6,7,8-tetrahydromethanopterin + H+.\" [EC:3.5.4.27, RHEA:19053]","metadata":null},{"id":"bf4a2465a097462bb72f4580c75687fd","type":"DRUG","name":"methimazole","canonical_id":"gtopdb:6649","description":null,"metadata":null},{"id":"9d5bdaddd40d40ac9adbc30c546188db","type":"DRUG","name":"methimazole","canonical_id":"mesh:D008713","description":null,"metadata":null},{"id":"4d6bb87f5b114a418df9b0574afce084","type":"DRUG","name":"methimazole","canonical_id":"chembl:CHEMBL1515","description":null,"metadata":null},{"id":"948de577cba14d328a47ec2ccabfa63f","type":"COMBINATION_TREATMENT","name":"methimazole + propylthiouracil","canonical_id":"ctgov_combo:ctgov-combo-1dc19be407ac4f9f","description":null,"metadata":null},{"id":"54c751318f124a6d997c3fd8d0c36080","type":"COMBINATION_TREATMENT","name":"methimazole + propylthiouracil","canonical_id":"ctgov_combo:ctgov-combo-7e9f7e8f75c6fb85","description":null,"metadata":null},{"id":"af7f50d1d1e0421b9a21009927517963","type":"COMBINATION_TREATMENT","name":"methimazole + propylthiouracil","canonical_id":"ctgov_combo:ctgov-combo-c7312e48add61016","description":null,"metadata":null},{"id":"41e88f1df643425fbf12ab0ed48bed7c","type":"GO_TERM","name":"methionine S-methyltransferase activity","canonical_id":"go:GO:0030732","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + L-methionine = S-adenosyl-L-homocysteine + S-methyl-L-methionine.\" [EC:2.1.1.12]","metadata":null},{"id":"6b2b6fdec2884d1e8790db570e406dcc","type":"GO_TERM","name":"methionine adenosyltransferase activity","canonical_id":"go:GO:0004478","description":"\"Catalysis of the reaction: ATP + L-methionine + H2O = phosphate + diphosphate + S-adenosyl-L-methionine.\" [EC:2.5.1.6]","metadata":null},{"id":"0e912e5936444c89bdb3d36629a1ad75","type":"GO_TERM","name":"methionine adenosyltransferase complex","canonical_id":"go:GO:0048269","description":"\"A multimeric enzyme complex composed of variable numbers of catalytic alpha subunits, and noncatalytic beta subunits. The beta subunits are believed to have a regulatory function. The enzyme complex catalyzes the synthesis of S-adenosylmethionine (AdoMet), which is the major methyl group donor, participating in the methylation of proteins, DNA, RNA, phospholipids, and other small molecules.\" [GOC:jid, PMID:10644686, PMID:25075345]","metadata":null},{"id":"d7c1925641cf4c04afc7c6c445ddb0e5","type":"GO_TERM","name":"methionine adenosyltransferase regulator activity","canonical_id":"go:GO:0048270","description":"\"Binds to and modulates the activity of methionine adenosyltransferase.\" [GOC:jid, PMID:10644686]","metadata":null},{"id":"99856ceb3741498a98638f8a78c2043d","type":"GO_TERM","name":"methionine decarboxylase activity","canonical_id":"go:GO:0050095","description":"\"Catalysis of the reaction: L-methionine + H+ = 3-methylthiopropanamine + CO2.\" [EC:4.1.1.57, RHEA:17757]","metadata":null},{"id":"8f3344923bd148fdba07abb3cce5d864","type":"GO_TERM","name":"methionine gamma-lyase activity","canonical_id":"go:GO:0018826","description":"\"Catalysis of the reaction: L-methionine + H2O = methanethiol + 2-oxobutanoate + NH4+.\" [RHEA:23800]","metadata":null},{"id":"dc00db22abd049b2937ceb075b3adb45","type":"GO_TERM","name":"methionine import across plasma membrane","canonical_id":"go:GO:1903692","description":"\"The directed movement of methionine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:17556368]","metadata":null},{"id":"7ae12b61089540bd9b8c46d4350f2f00","type":"GO_TERM","name":"methionine racemase activity","canonical_id":"go:GO:0018111","description":"\"Catalysis of the reaction: L-methionine = D-methionine.\" [EC:5.1.1.2, RHEA:12492]","metadata":null},{"id":"c68eeb3f092b47df90bfd799eef263a1","type":"GO_TERM","name":"methionine synthase activity","canonical_id":"go:GO:0008705","description":"\"Catalysis of the reaction: (6S)-5-methyl-5,6,7,8-tetrahydrofolate + L-homocysteine = (6S)-5,6,7,8-tetrahydrofolate + L-methionine.\" [EC:2.1.1.13, RHEA:11172]","metadata":null},{"id":"cfff2d01514241a3bc9ebd64e3d00465","type":"GO_TERM","name":"methionine transmembrane transporter activity","canonical_id":"go:GO:0043865","description":"\"Enables the transfer of methionine from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"4150c3989fb243d18f0998aaf0127182","type":"GO_TERM","name":"methionine transport","canonical_id":"go:GO:0015821","description":"\"The directed movement of methionine, 2-amino-4-(methylthio)butanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"41d55292d9ce46ddab78b81c1507b1ca","type":"GO_TERM","name":"methionine-importing ABC transporter complex","canonical_id":"go:GO:1990197","description":"\"An ATP-binding cassette (ABC) transporter complex that is capable of methionine-importing activity. An example is the bacterial MetNIQ methionine transporter, that consists of the dimeric ATPase subunit MetN located at the cytoplasmic side of the plasma membrane and the dimeric transmembrane subunit MetI. MetQ is regarded as the periplasmic methionine-binding chaperon subunit, and is capable of transporting methionine from the periplasm into the cytoplasm in an ATP-dependent manner.\" [GOC:bhm, PMID:22095702]","metadata":null},{"id":"70efbf7c8cb144a6ab427e3790129399","type":"GO_TERM","name":"methionine-importing complex","canonical_id":"go:GO:1902509","description":"\"A protein complex which is capable of methionine-importing activity.\" [GOC:pr, GOC:TermGenie, PMID:23748165]","metadata":null},{"id":"ba813e89965140c2ab1f7d753a8c130f","type":"GO_TERM","name":"methionine-tRNA ligase activity","canonical_id":"go:GO:0004825","description":"\"Catalysis of the reaction: ATP + L-methionine + tRNA(Met) = AMP + diphosphate + L-methionyl-tRNA(Met).\" [EC:6.1.1.10]","metadata":null},{"id":"92e535669de5462ba2fc10791fe29c88","type":"GO_TERM","name":"methionyl glutamyl tRNA synthetase complex","canonical_id":"go:GO:0017102","description":"\"A complex consisting of methionyl- and glutamyl-tRNA synthetases. The tRNA synthetases present in the complex bind to their cognate tRNAs more efficiently than they do as monomers.\" [GOC:mcc, PMID:11069915]","metadata":null},{"id":"386932c209e74853b660e4f7df3133da","type":"GO_TERM","name":"methionyl-initiator methionine tRNA binding","canonical_id":"go:GO:1990856","description":"\"Binding to methionine-initiator methionine tRNA.\" [GOC:hjd, ISBN:9781555810733]","metadata":null},{"id":"dc64d1bb66de40319ef73214bbbee5af","type":"GO_TERM","name":"methionyl-tRNA aminoacylation","canonical_id":"go:GO:0006431","description":"\"The process of coupling methionine to methionyl-tRNA, catalyzed by methionyl-tRNA synthetase. The methionyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a methionine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"1bb6c49e90f746c9b8c7944b4b9d736c","type":"GO_TERM","name":"methionyl-tRNA formyltransferase activity","canonical_id":"go:GO:0004479","description":"\"Catalysis of the reaction: 10-formyltetrahydrofolate + L-methionyl-tRNA + H2O = tetrahydrofolate + N-formylmethionyl-tRNA.\" [EC:2.1.2.9]","metadata":null},{"id":"5dbab4235e844cf398237c5c6d99085a","type":"DRUG","name":"methotrexate","canonical_id":"gtopdb:4815","description":null,"metadata":null},{"id":"0563ab34346c4edda9d96f688f535c97","type":"DRUG","name":"methotrexate","canonical_id":"mesh:D008727","description":null,"metadata":null},{"id":"aa09094e84b24cb5ba8964619738dc8e","type":"COMBINATION_TREATMENT","name":"methotrexate + methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-a3d30e7e3edceaf0","description":null,"metadata":null},{"id":"7ae6eb2e935048c99d782ec4f416da17","type":"COMBINATION_TREATMENT","name":"methotrexate + ofatumumab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-3aa0c96f9d9b8487","description":null,"metadata":null},{"id":"b4936295b4264d2ca07271a69eba5102","type":"COMBINATION_TREATMENT","name":"methotrexate + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-406f5d0a8d0d1317","description":null,"metadata":null},{"id":"6778ff65a8724dd6b85e6f7bbf4f5791","type":"COMBINATION_TREATMENT","name":"methotrexate + prednisolone + prednisone + thioguanine + vincristine","canonical_id":"ctgov_combo:ctgov-combo-6aca22fe7048e075","description":null,"metadata":null},{"id":"0364885aaaea41338624c9aa07161bbc","type":"COMBINATION_TREATMENT","name":"methotrexate + prednisone + thioguanine + vincristine","canonical_id":"ctgov_combo:ctgov-combo-96987193c7d5d487","description":null,"metadata":null},{"id":"d9bcbcb2c8364d9398b73b234ac13946","type":"COMBINATION_TREATMENT","name":"methotrexate + prednisone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-4eacb50ae37f8d3c","description":null,"metadata":null},{"id":"02a586343c4647c19d30c6917b234b32","type":"COMBINATION_TREATMENT","name":"methotrexate + sirolimus + temsirolimus + vincristine","canonical_id":"ctgov_combo:ctgov-combo-2a6dcf9ad2b0b55e","description":null,"metadata":null},{"id":"3a7212f6ddea472f890ebd1b2457b9f4","type":"COMBINATION_TREATMENT","name":"methotrexate + tamoxifen","canonical_id":"ctgov_combo:ctgov-combo-ee5cb47495b4e49f","description":null,"metadata":null},{"id":"065dae3853bd4557829cc28777d13f29","type":"COMBINATION_TREATMENT","name":"methotrexate + thioguanine","canonical_id":"ctgov_combo:ctgov-combo-d67809158f294c6b","description":null,"metadata":null},{"id":"0eef1844ab484eb4b813f0eb2f844b2c","type":"COMBINATION_TREATMENT","name":"methotrexate + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-91e20c49e01976e4","description":null,"metadata":null},{"id":"9c1ee951fc974a4996f4ffd0651bb9cf","type":"COMBINATION_TREATMENT","name":"methotrexate + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-008797c2181daa8e","description":null,"metadata":null},{"id":"dc8bed0620e9479083c17e0de2c07e9e","type":"COMBINATION_TREATMENT","name":"methotrexate + vincristine","canonical_id":"ctgov_combo:ctgov-combo-4dda2b1ff6585b78","description":null,"metadata":null},{"id":"07243a4f2ce743e1aa808383f2642110","type":"COMBINATION_TREATMENT","name":"methotrexate + vincristine","canonical_id":"ctgov_combo:ctgov-combo-344fd7dcdb408f3f","description":null,"metadata":null},{"id":"572c6ff78cb0462ea9657ef8a5db5bba","type":"GO_TERM","name":"methotrexate binding","canonical_id":"go:GO:0051870","description":"\"Binding to methotrexate, an antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate reductase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.\" [GOC:nln]","metadata":null},{"id":"da51f31585564d039fc756274a3e9afe","type":"GO_TERM","name":"methotrexate transmembrane transporter activity","canonical_id":"go:GO:0015350","description":"\"Enables the transfer of methotrexate, 4-amino-10-methylformic acid from one side of a membrane to the other. Methotrexate is a folic acid analogue and a potent competitive inhibitor of dihydrofolate reductase.\" [GOC:ai]","metadata":null},{"id":"83fa553888b2434d9b7450ea89d0de4a","type":"GO_TERM","name":"methotrexate transport","canonical_id":"go:GO:0051958","description":"\"The directed movement of methotrexate, 4-amino-10-methylformic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Methotrexate is a folic acid analogue and a potent competitive inhibitor of dihydrofolate reductase.\" [GOC:ai]","metadata":null},{"id":"273263c0381845c3b77b6f467b785caa","type":"DRUG","name":"methoxamine","canonical_id":"gtopdb:483","description":null,"metadata":null},{"id":"7cd6c6e681eb4c78b1cd32ce0fb91a15","type":"DRUG","name":"methsuximide","canonical_id":"mesh:C100286","description":null,"metadata":null},{"id":"7274ca9f56ea41f4a6c2421ff71d7b05","type":"GO_TERM","name":"methyl accepting chemotaxis protein complex","canonical_id":"go:GO:0098561","description":"\"A transmembrane protein complex that consists of multiple methyl-accepting chemoreceptor protein subunits, a histidine kinase and a connector protein and which functions in the regulation of flagellar rotary motor activity in response to an external chemical stimulus.\" [GOC:dos, PMID:1326408, PMID:15802240]","metadata":null},{"id":"aa9680ce314242f4b36cc01fdc574048","type":"GO_TERM","name":"methyl coenzyme M reductase complex","canonical_id":"go:GO:0044674","description":"\"A hexameric complex consisting of three polypeptides in an alpha2beta2gamma2 arrangement. Involved in the reduction of the coenzyme M-bound methyl group to methane, which is the final step in methanogenesis.\" [GOC:mengo_curators, PMID:9367957]","metadata":null},{"id":"bfe0b5ebedb344119d014de5df698230","type":"GO_TERM","name":"methyl ethyl ketone catabolic process","canonical_id":"go:GO:0046213","description":"\"The chemical reactions and pathways resulting in the breakdown of methyl ethyl ketone, a clear, colorless liquid with a fragrant, mint-like odor.\" [GOC:ai]","metadata":null},{"id":"cd4ba972001d4033a9f81c3e8a6cccef","type":"GO_TERM","name":"methyl farnesoate epoxidase activity","canonical_id":"go:GO:0120511","description":"\"Catalysis of the reaction: methyl (2E,6E)-farnesoate + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + juvenile hormone III + oxidized [NADPH--hemoprotein reductase].\" [PMID:23586995, PMID:38741075, RHEA:43728]","metadata":null},{"id":"bbd463a6f4484c55b74ba8a216856511","type":"GO_TERM","name":"methyl indole-3-acetate esterase activity","canonical_id":"go:GO:0080030","description":"\"Catalysis of the reaction: H2O + methyl (indol-3-yl)acetate = (indol-3-yl)acetate + H+ + methanol.\" [PMID:18467465, RHEA:32919]","metadata":null},{"id":"957c725350564291afd1423adca0cf55","type":"GO_TERM","name":"methyl jasmonate esterase activity","canonical_id":"go:GO:0080032","description":"\"Catalysis of the reaction: H2O + methyl (-)-jasmonate = H+ + jasmonate + methanol.\" [PMID:15233793, PMID:18467465, RHEA:55372]","metadata":null},{"id":"b61c592165f847bf8d07902772f00ae0","type":"GO_TERM","name":"methyl jasmonate methylesterase activity","canonical_id":"go:GO:0030795","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a jasmonate = S-adenosyl-L-homocysteine + a methyljasmonate.\" [RHEA:13349]","metadata":null},{"id":"ac798e13eac540958f22b75a4eb642f7","type":"DRUG","name":"methyl salicylate","canonical_id":"mesh:C033069","description":null,"metadata":null},{"id":"1132ffab1a7e4572a20421be0070b2d5","type":"GO_TERM","name":"methyl salicylate esterase activity","canonical_id":"go:GO:0080031","description":"\"Catalysis of the reaction: H2O + methyl salicylate = H+ + methanol + salicylate.\" [PMID:18467465, PMID:18643994, RHEA:33611]","metadata":null},{"id":"8fbbf519ce7a41e7a1f787f7e7d1caa8","type":"GO_TERM","name":"methyl transfer-driven active transmembrane transporter activity","canonical_id":"go:GO:0015452","description":"\"Primary active transport of a solute across a membrane driven by a methyl transfer reaction. Primary active transport is catalysis of the transport of a solute across a membrane, up the solute's concentration gradient, by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction and is driven by a primary energy source.\" [GOC:mtg_transport, ISBN:0815340729, TC:3.C.-.-.-]","metadata":null},{"id":"4974a094459c4d54a2d82b45c87a8ceb","type":"GO_TERM","name":"methyl-CpG binding","canonical_id":"go:GO:0008327","description":"\"Binding to a methylated cytosine/guanine dinucleotide.\" [GOC:jl, PMID:11746232]","metadata":null},{"id":"4db2ffeca6e24d6fbbc4a00e32614ea1","type":"GO_TERM","name":"methyl-CpNpG binding","canonical_id":"go:GO:0010428","description":"\"Binding to a methylated cytosine/unspecified/guanine trinucleotide.\" [PMID:17239600]","metadata":null},{"id":"f5a7a1e716014dfea5d6f46dc9560507","type":"GO_TERM","name":"methyl-CpNpN binding","canonical_id":"go:GO:0010429","description":"\"Binding to a methylated cytosine/unspecified/unspecified trinucleotide.\" [PMID:17239600]","metadata":null},{"id":"e4b6de77645543b292c33b5fcafcf6ae","type":"GO_TERM","name":"methyl-ONN-azoxymethanol beta-D-glucosyltransferase activity","canonical_id":"go:GO:0047236","description":"\"Catalysis of the reaction: methylazoxymethanol + UDP-D-glucose = H+ + cycasin + UDP.\" [EC:2.4.1.171, MetaCyc:2.4.1.171-RXN]","metadata":null},{"id":"ba40abddf3ce4f8882324e9a8e64863c","type":"GO_TERM","name":"methyl-branched fatty acid biosynthetic process","canonical_id":"go:GO:1902321","description":"\"The chemical reactions and pathways resulting in the formation of methyl-branched fatty acid.\" [GOC:kmv, GOC:TermGenie, PMID:15340492]","metadata":null},{"id":"77d886462c98409da0fd71dad60d5b65","type":"GO_TERM","name":"methyl-branched fatty acid metabolic process","canonical_id":"go:GO:0097089","description":"\"The chemical reactions and pathways involving methyl-branched fatty acids, aliphatic monocarboxylic acids with methyl branches on the main chain.\" [GOC:rs, PMID:19933331]","metadata":null},{"id":"26a5add61cd040a0919490a2d91ac18b","type":"GO_TERM","name":"methyl-tetrahydromethanopterin:coenzyme M methyltransferase complex","canonical_id":"go:GO:0044677","description":"\"A protein complex consisted of eight polypeptides. This complex catalyzes the formation of methyl-coenzyme M and H4MPT from N5-methyl-H4MPT and CoM during methanogenesis.\" [GOC:mengo_curators, PMID:8477726]","metadata":null},{"id":"6c369065e2844190beefae19d5ee4b00","type":"GO_TERM","name":"methyl/ethyl malonyl-CoA decarboxylase activity","canonical_id":"go:GO:0004492","description":"\"Catalysis of the reaction: (S)-methylmalonyl-CoA + H+ = CO2 + propanoyl-CoA or (2S)-ethylmalonyl-CoA + H+ = butanoyl-CoA + CO2.\" [PMID:22016388]","metadata":null},{"id":"36e1e209cc184f3dad5154dc041d155c","type":"GO_TERM","name":"methylamine dehydrogenase (amicyanin) activity","canonical_id":"go:GO:0052876","description":"\"Catalysis of the reaction: 2O + methylamine + 2 oxidized [amicyanin] = formaldehyde + 2 H+ + NH4+ + 2 reduced [amicyanin].\" [RHEA:30207]","metadata":null},{"id":"a3c5e39f301f4493963538ed4036db33","type":"GO_TERM","name":"methylamine metabolic process","canonical_id":"go:GO:0030416","description":"\"The chemical reactions and pathways involving methylamine (CH3NH2).\" [ISBN:0721662544]","metadata":null},{"id":"55f71ee195c34508910cba5ec77c0f27","type":"GO_TERM","name":"methylamine-glutamate N-methyltransferase activity","canonical_id":"go:GO:0047148","description":"\"Catalysis of the reaction: L-glutamate + methylammonium = N-methyl-L-glutamate + NH4.\" [EC:2.1.1.21, RHEA:15837]","metadata":null},{"id":"181efef8edfd4af6b58dd3047dc41511","type":"GO_TERM","name":"methylammonium channel activity","canonical_id":"go:GO:0015264","description":"\"Enables the energy-independent facilitated diffusion of methylammonium through a transmembrane aqueous pore or channel. Methylammonium is CH3NH2.\" [GOC:mtg_transport, GOC:pr]","metadata":null},{"id":"7f509904c0d148d9b53862a6a9b8e461","type":"GO_TERM","name":"methylammonium transmembrane transport","canonical_id":"go:GO:0072489","description":"\"The process in which methylammonium is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"af8229381e52421cb2852601f0e6b5ea","type":"GO_TERM","name":"methylammonium transmembrane transporter activity","canonical_id":"go:GO:0015200","description":"\"Enables directed movement of methylammonium, CH3NH2, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"ed4a267c540c4eddb1258ce5486bd5ec","type":"GO_TERM","name":"methylammonium transport","canonical_id":"go:GO:0015843","description":"\"The directed movement of methylammonium into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"4afecca7777146ba88248eb547cd0000","type":"GO_TERM","name":"methylarsonate reductase activity","canonical_id":"go:GO:0050610","description":"\"Catalysis of the reaction: 2 glutathione + H+ + methylarsonate = glutathione disulfide + H2O + methylarsonous acid.\" [EC:1.20.4.2, RHEA:15969]","metadata":null},{"id":"14ea2b0f36f54229a91b4db25e515e54","type":"GO_TERM","name":"methylaspartate ammonia-lyase activity","canonical_id":"go:GO:0050096","description":"\"Catalysis of the reaction: threo-3-methyl-L-aspartate = mesaconate + NH4.\" [EC:4.3.1.2, RHEA:12829]","metadata":null},{"id":"d85367be16624900825ef67db6924c6a","type":"GO_TERM","name":"methylaspartate mutase activity","canonical_id":"go:GO:0050097","description":"\"Catalysis of the reaction: threo-3-methyl-L-aspartate = L-glutamate.\" [EC:5.4.99.1, RHEA:12857]","metadata":null},{"id":"db4b3ad6139643dd8b1c198d5c334f73","type":"GO_TERM","name":"methylated-DNA-[protein]-cysteine S-methyltransferase activity","canonical_id":"go:GO:0003908","description":"\"Catalysis of the reaction: DNA (containing 6-O-methylguanine) + (protein)-L-cysteine = DNA (without 6-O-methylguanine) + protein S-methyl-L-cysteine.\" [EC:2.1.1.63]","metadata":null},{"id":"6a24b88543664969ae80ee9e1a439292","type":"GO_TERM","name":"methylation","canonical_id":"go:GO:0032259","description":"\"The process in which a methyl group is covalently attached to a molecule.\" [GOC:mah]","metadata":null},{"id":"bf727cdf5b394179935c0f3e61add84d","type":"GO_TERM","name":"methylation-dependent protein binding","canonical_id":"go:GO:0140034","description":"\"Binding to a protein upon methylation of the target protein.\" [PMID:26060076]","metadata":null},{"id":"5b26010c5d594b999436f70d28eac538","type":"GO_TERM","name":"methylcrotonoyl-CoA carboxylase activity","canonical_id":"go:GO:0004485","description":"\"Catalysis of the reaction: 3-methylbut-2-enoyl-CoA + ATP + bicarbonate = trans-3-methylglutaconyl-CoA + ADP + 2 H+ + phosphate.\" [EC:6.4.1.4, RHEA:13589]","metadata":null},{"id":"5bd17841d163407cb9e069b4c2a32d64","type":"GO_TERM","name":"methylcrotonoyl-CoA carboxylase complex","canonical_id":"go:GO:1905202","description":"\"A protein complex capable of methylcrotonoyl-CoA carboxylase activity. In mammals, it is a mitochondrial complex comprising a dodecamer of 6 alpha and 6 beta subunits: MCCC-alpha has a covalently bound biotin essential for the ATP-dependent carboxylation; MCCC-beta possesses carboxyltransferase activity which presumably is essential for binding to 3-methylcrotonyl-CoA.\" [GOC:bf, GOC:hjd, GOC:PARL, PMID:15868465, PMID:17360195, PMID:22158123, PMID:22869039]","metadata":null},{"id":"edcbfc8e96074745924ccbc9275bdd9f","type":"GO_TERM","name":"methylcytosine to 5-glyceryl-methylcytosine dioxygenase activity","canonical_id":"go:GO:0120204","description":"\"Catalysis of the reaction: methylcytosine + L-ascorbate + O2 = 5-glyceryl-methylcytosine + glyoxylate + CO2.\" [PMID:31043749]","metadata":null},{"id":"746e509f28a04f2b8e8822e0ee07206a","type":"DRUG","name":"methyldopa","canonical_id":"mesh:D008750","description":null,"metadata":null},{"id":"495bdbb9d53a41f2baca33b98d5c548a","type":"GO_TERM","name":"methylene-fatty-acyl-phospholipid synthase activity","canonical_id":"go:GO:0004481","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + phospholipid olefinic fatty acid = S-adenosyl-L-homocysteine + phospholipid methylene fatty acid.\" [EC:2.1.1.16]","metadata":null},{"id":"40d019f3ab4543aaa9df8b2be753bbf5","type":"GO_TERM","name":"methylenediurea deaminase activity","canonical_id":"go:GO:0047424","description":"\"Catalysis of the reaction: methylenediurea + 2 H2O + 2 H+ = N-(hydroxymethyl)urea + 2 NH4+ + CO2.\" [RHEA:15929]","metadata":null},{"id":"6d35dd219b25416baac95e7ddef3fe38","type":"GO_TERM","name":"methylenetetrahydrofolate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004487","description":"\"Catalysis of the reaction: (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NAD+ = (6R)-5,10-methenyltetrahydrofolate + NADH.\" [RHEA:22892]","metadata":null},{"id":"e91a6c51575742cf95c62a7e6d9c20bc","type":"GO_TERM","name":"methylenetetrahydrofolate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004488","description":"\"Catalysis of the reaction: (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NADP+ = (6R)-5,10-methenyltetrahydrofolate + NADPH.\" [RHEA:22812]","metadata":null},{"id":"94820992de25496082036c377cb136fc","type":"GO_TERM","name":"methylenetetrahydrofolate reductase (NADH) activity","canonical_id":"go:GO:0106312","description":"\"Catalysis of the reaction: (6S)-5-methyl-5,6,7,8-tetrahydrofolate + NAD+ = (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NADH + H+.\" [RHEA:19821]","metadata":null},{"id":"891c170015d743e1b79eacb56aac6f64","type":"GO_TERM","name":"methylenetetrahydrofolate reductase (NADPH) activity","canonical_id":"go:GO:0106313","description":"\"Catalysis of the reaction: (6S)-5-methyl-5,6,7,8-tetrahydrofolate + NADP+ = (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NADPH + H+.\" [RHEA:19817]","metadata":null},{"id":"277cd9182e744c9e9f3738fd04e90445","type":"GO_TERM","name":"methylenetetrahydrofolate reductase (ferredoxin) activity","canonical_id":"go:GO:0033738","description":"\"Catalysis of the reaction: 5-methyltetrahydrofolate + oxidized ferredoxin = 5,10-methylenetetrahydrofolate + reduced ferredoxin.\" [EC:1.5.7.1]","metadata":null},{"id":"a670c70e9c33461aa9688ba60bf62f64","type":"GO_TERM","name":"methylenetetrahydrofolate reductase [NAD(P)H] activity","canonical_id":"go:GO:0004489","description":"\"Catalysis of the reaction: (6S)-5-methyl-5,6,7,8-tetrahydrofolate + NAD(P)+ = (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NAD(P)H + H+.\" [EC:1.5.1.20, PMID:26872964]","metadata":null},{"id":"8181b737c4284f1eac4b4bef69e5fd09","type":"GO_TERM","name":"methylenetetrahydromethanopterin dehydrogenase activity","canonical_id":"go:GO:0030268","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydromethanopterin + coenzyme F420 + 2 H+ = 5,10-methenyl-5,6,7,8-tetrahydromethanopterin + reduced coenzyme F420.\" [EC:1.5.98.1, RHEA:16721]","metadata":null},{"id":"cf00ca71e51f40ac9f55ebf3ec956ad8","type":"GO_TERM","name":"methylgalactoside transmembrane transporter activity","canonical_id":"go:GO:0015592","description":"\"Enables the transfer of methylgalactoside from one side of a membrane to the other. Methylgalactoside is a compound in which the H of the OH group on carbon-1 of galactose is replaced by a methyl group.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"91683662008c4733b01df0ee26d024ea","type":"GO_TERM","name":"methylgalactoside transport","canonical_id":"go:GO:0015765","description":"\"The directed movement of methylgalactoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Methylgalactoside is a compound in which the H of the OH group on carbon-1 of galactose is replaced by a methyl group.\" [GOC:curators]","metadata":null},{"id":"8d9ad7dded5d414b9cbb50ea7d4f6caa","type":"GO_TERM","name":"methylgallate biosynthetic process","canonical_id":"go:GO:0046277","description":"\"The chemical reactions and pathways resulting in the formation of methylgallate, trihydroxymethylbenzoate, the anion of methylgallic acid.\" [GOC:ai]","metadata":null},{"id":"a6b8746cefc74766a1a7aaef21bd2f25","type":"GO_TERM","name":"methylgallate catabolic process","canonical_id":"go:GO:0046276","description":"\"The chemical reactions and pathways resulting in the breakdown of methylgallate, trihydroxymethylbenzoate, the anion of methylgallic acid.\" [GOC:ai]","metadata":null},{"id":"5adf3fd4bd0f41f499aba62dbf756123","type":"GO_TERM","name":"methylglutaconyl-CoA hydratase activity","canonical_id":"go:GO:0004490","description":"\"Catalysis of the reaction: (S)-3-hydroxy-3-methylglutaryl-CoA = trans-3-methylglutaconyl-CoA + H2O.\" [EC:4.2.1.18, RHEA:21536]","metadata":null},{"id":"3d201c6fafd445cd8339de928a6fee1b","type":"GO_TERM","name":"methylglutamate dehydrogenase activity","canonical_id":"go:GO:0050099","description":"\"Catalysis of the reaction: N-methyl-L-glutamate + A + H2O = L-glutamate + AH(2) + formaldehyde.\" [EC:1.5.99.5, RHEA:22572]","metadata":null},{"id":"71eba36730824d5fba0e63978116833a","type":"GO_TERM","name":"methylglyoxal biosynthetic process","canonical_id":"go:GO:0019242","description":"\"The chemical reactions and pathways resulting in the formation of methylglyoxal, CH3-CO-CHO, the aldehyde of pyruvic acid.\" [GOC:ai]","metadata":null},{"id":"577df443986f4a07a61eab69badd2d68","type":"GO_TERM","name":"methylglyoxal catabolic process","canonical_id":"go:GO:0051596","description":"\"The chemical reactions and pathways resulting in the breakdown of methylglyoxal, CH3-CO-CHO, the aldehyde of pyruvic acid.\" [GOC:ai]","metadata":null},{"id":"a1a9e31195944347a0483139c4582e04","type":"GO_TERM","name":"methylglyoxal metabolic process","canonical_id":"go:GO:0009438","description":"\"The chemical reactions and pathways involving methylglyoxal, CH3-CO-CHO, the aldehyde of pyruvic acid.\" [GOC:ai]","metadata":null},{"id":"129abb63d0d84f7aac09dc8e8c851ebf","type":"GO_TERM","name":"methylglyoxal reductase (NADH) activity","canonical_id":"go:GO:0019170","description":"\"Catalysis of the reaction: (R)-lactaldehyde + NAD+ = methylglyoxal + NADH + H+.\" [EC:1.1.1.78]","metadata":null},{"id":"df4de3ff4abc4987be0becf02fded437","type":"GO_TERM","name":"methylglyoxal reductase (NADPH) (acetol producing) activity","canonical_id":"go:GO:1990002","description":"\"Catalysis of the reaction: hydroxyacetone + NADP+ = H+ + methylglyoxal + NADPH.\" [PMID:16077126, RHEA:27986]","metadata":null},{"id":"f3bec5fd32d3477cb2f97cc3bc013b0f","type":"GO_TERM","name":"methylglyoxal reductase (NADPH) activity","canonical_id":"go:GO:0043892","description":"\"Catalysis of the reaction: lactaldehyde + NADP+ = methylglyoxal + NADPH + H+.\" [EC:1.1.1.283]","metadata":null},{"id":"c7ce74ac51474eddb69b1c9b5a897515","type":"GO_TERM","name":"methylglyoxal synthase activity","canonical_id":"go:GO:0008929","description":"\"Catalysis of the reaction: glycerone phosphate = methylglyoxal + phosphate.\" [EC:4.2.3.3, RHEA:17937]","metadata":null},{"id":"0d60b92b5347493c8a824c2d2a5c110b","type":"GO_TERM","name":"methylguanidinase activity","canonical_id":"go:GO:0050098","description":"\"Catalysis of the reaction: H2O + methylguanidine = methylammonium + urea.\" [EC:3.5.3.16, RHEA:11764]","metadata":null},{"id":"c745851cd2a4477b9eac8c75ea7994dc","type":"DRUG","name":"methylhomatropine","canonical_id":"mesh:C056244","description":null,"metadata":null},{"id":"63bba1a84d61444c9c39466411f0db17","type":"GO_TERM","name":"methylisocitrate lyase activity","canonical_id":"go:GO:0046421","description":"\"Catalysis of the reaction: (2S,3R)-3-hydroxybutane-1,2,3-tricarboxylate = pyruvate + succinate.\" [EC:4.1.3.30, RHEA:16809]","metadata":null},{"id":"0ddde5f021774d94862a99784820dbb4","type":"GO_TERM","name":"methylitaconate delta-isomerase activity","canonical_id":"go:GO:0050100","description":"\"Catalysis of the reaction: 2-methylene-3-methylsuccinate = dimethylmaleate.\" [RHEA:23480]","metadata":null},{"id":"c80342c56faa42b190335aee4c3b30d3","type":"GO_TERM","name":"methylmalonate-semialdehyde dehydrogenase (acylating, NAD+) activity","canonical_id":"go:GO:0004491","description":"\"Catalysis of the reaction: 2-methyl-3-oxopropanoate + CoA + NAD+ = propanoyl-CoA + hydrogencarbonate + NADH + H+. Can also use malonate (3-oxopropanoate) as a substrate. The reaction occurs in two steps with the decarboxylation process preceding CoA-binding. Bicarbonate rather than CO2 is released as a final product.\" [EC:1.2.1.27, PMID:2768248]","metadata":null},{"id":"561d2aa0cbf141949ef6e3ef2f3f1b0b","type":"GO_TERM","name":"methylmalonyl-CoA carboxytransferase activity","canonical_id":"go:GO:0047154","description":"\"Catalysis of the reaction: pyruvate + D-methylmalonyl-CoA = oxaloacetic acid + propionyl-CoA.\" [EC:2.1.3.1, MetaCyc:2.1.3.1-RXN]","metadata":null},{"id":"873aabe28bc54028a5b822fb19391acd","type":"GO_TERM","name":"methylmalonyl-CoA epimerase activity","canonical_id":"go:GO:0004493","description":"\"Catalysis of the reaction: (R)-methylmalonyl-CoA = (S)-methylmalonyl-CoA.\" [EC:5.1.99.1, RHEA:20553]","metadata":null},{"id":"30e1c43c303a4ceb88adaae965345222","type":"GO_TERM","name":"methylmalonyl-CoA mutase activity","canonical_id":"go:GO:0004494","description":"\"Catalysis of the reaction: (R)-methylmalonyl-CoA = succinyl-CoA.\" [EC:5.4.99.2, RHEA:22888]","metadata":null},{"id":"84bd4f97c5314dcc9e368a1cd72d959a","type":"GO_TERM","name":"methylmercury biosynthetic process","canonical_id":"go:GO:0042192","description":"\"The chemical reactions and pathways resulting in the formation of methylmercury (MeHg+), a highly toxic organometal.\" [GOC:ai, PMID:23393089, PMID:38407657]","metadata":null},{"id":"bf42f3d9d49e4835a7158f600167c12f","type":"GO_TERM","name":"methylmercury catabolic process","canonical_id":"go:GO:0042193","description":"\"The chemical reactions and pathways resulting in the breakdown of methylmercury (MeHg+), a highly toxic organometal.\" [GOC:ai]","metadata":null},{"id":"2d632c715a4a445ebb014770a351ec31","type":"DRUG","name":"methylnaltrexone","canonical_id":"gtopdb:7563","description":null,"metadata":null},{"id":"cbadc7f20e7a494083966ab2db0c5a8e","type":"COMBINATION_TREATMENT","name":"methylnaltrexone + naloxone","canonical_id":"ctgov_combo:ctgov-combo-89b217f3440f074d","description":null,"metadata":null},{"id":"926f787db86d4e81aa381351d999d41e","type":"GO_TERM","name":"methylnaphthalene catabolic process","canonical_id":"go:GO:0043635","description":"\"The chemical reactions and pathways resulting in the breakdown of methylnaphthalene, an organic compound, C10H7CH3, obtained from coal tar.\" [GOC:jl, PMID:16535687]","metadata":null},{"id":"171677170e234d00919ae0bbdfb3759f","type":"GO_TERM","name":"methylosome","canonical_id":"go:GO:0034709","description":"\"A large (20 S) protein complex that possesses protein arginine methyltransferase activity and modifies specific arginines to dimethylarginines in the arginine- and glycine-rich domains of several spliceosomal Sm proteins, thereby targeting these proteins to the survival of motor neurons (SMN) complex for assembly into small nuclear ribonucleoprotein (snRNP) core particles. Proteins found in the methylosome include the methyltransferase JBP1 (PRMT5), pICln (CLNS1A), MEP50 (WDR77), and unmethylated forms of SM proteins that have RG domains.\" [PMID:11713266, PMID:11756452]","metadata":null},{"id":"ab1cc2fcad534fe29aedebc4ce4b78bd","type":"DRUG","name":"methylphenidate","canonical_id":"gtopdb:7236","description":null,"metadata":null},{"id":"67c69aa5af8543448cd3230bac42b510","type":"DRUG","name":"methylphenidate","canonical_id":"mesh:D008774","description":null,"metadata":null},{"id":"a1203fc999884acfb75436a021e1be4a","type":"DRUG","name":"methylphenidate","canonical_id":"chembl:CHEMBL796","description":null,"metadata":null},{"id":"4bd3cc85426b464b9996da8aa2883c7c","type":"COMBINATION_TREATMENT","name":"methylphenidate + naltrexone","canonical_id":"ctgov_combo:ctgov-combo-f62fe78c16e8cc7d","description":null,"metadata":null},{"id":"fec8a6f016724f03b676ddc91071aa0f","type":"DRUG","name":"methylphenobarbital","canonical_id":"mesh:D008618","description":null,"metadata":null},{"id":"e765137969eb4f608bc58ccb5029b23d","type":"GO_TERM","name":"methylphosphothioglycerate phosphatase activity","canonical_id":"go:GO:0047382","description":"\"Catalysis of the reaction: S-methyl-3-phospho-1-thio-D-glycerate + H2O = S-methyl-1-thio-D-glycerate + phosphate.\" [EC:3.1.3.14, RHEA:16081]","metadata":null},{"id":"a55dadd00dbe447496e08558ccb88ff3","type":"DRUG","name":"methylprednisolone","canonical_id":"gtopdb:7088","description":null,"metadata":null},{"id":"d45d34f9e82b4b989865586c573686c9","type":"DRUG","name":"methylprednisolone","canonical_id":"mesh:D008775","description":null,"metadata":null},{"id":"e9f48b6129f44e16914af43802b8fd0c","type":"DRUG","name":"methylprednisolone","canonical_id":"chembl:CHEMBL650","description":null,"metadata":null},{"id":"beffaa6ea4d242ac8ce31405300e0fda","type":"COMBINATION_TREATMENT","name":"methylprednisolone + mycophenolate mofetil + prednisolone + prednisone + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-f1434d22aa5196d9","description":null,"metadata":null},{"id":"e4e8537bef474aec90124e465faf2349","type":"COMBINATION_TREATMENT","name":"methylprednisolone + mycophenolate mofetil + prednisolone + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-e89a253aca28edff","description":null,"metadata":null},{"id":"6321a703eae549a5b53e83be05913cae","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-639b975bfa7bbe12","description":null,"metadata":null},{"id":"770071542ff446559c9093031e4ab080","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-8e7bd492cc7bb9e6","description":null,"metadata":null},{"id":"a251b88adc5c40b8ada60b7e6bb36b12","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-cfdb9e7492e40934","description":null,"metadata":null},{"id":"343e7512b4ad490f840cb552849fae3d","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-8adb54feca4b5ece","description":null,"metadata":null},{"id":"ae5c81d448ec48a09b3760dc96a33415","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-71fad19d15197db4","description":null,"metadata":null},{"id":"059e08ca415949b6b75c81fc44822ad7","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-06a85abd3980ac4e","description":null,"metadata":null},{"id":"e0e2831848f4499fb9f859f68b380b55","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-ecc2028cbb1e1bf4","description":null,"metadata":null},{"id":"c8b9dff55dac4d6fa73ff66b3f9b26cf","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-3ecf372cc05a5a02","description":null,"metadata":null},{"id":"5baf30caf134425fbc1dc709e67b288f","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-9e98fe6f2f7b76ca","description":null,"metadata":null},{"id":"7703c30f73ac4953a8566b01b66e00a5","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-383bf0760cf3abd9","description":null,"metadata":null},{"id":"17429a27d4eb40aab2f04d7f76960596","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone + rituximab","canonical_id":"ctgov_combo:ctgov-combo-b92f06a539643bf9","description":null,"metadata":null},{"id":"7efd65b2e0ac48cabc9385ae71dec13a","type":"COMBINATION_TREATMENT","name":"methylprednisolone + prednisolone + rituximab","canonical_id":"ctgov_combo:ctgov-combo-2856920f35ce1bd0","description":null,"metadata":null},{"id":"24548b0c869c488eaf5f9e4805418327","type":"GO_TERM","name":"methylquercetagetin 6-O-methyltransferase activity","canonical_id":"go:GO:0030759","description":"\"Catalysis of the reaction: 3',4',5,6-tetrahydroxy-3,7-dimethoxyflavone + S-adenosyl-L-methionine(1+) = 3',4',5-trihydroxy-3,6,7-trimethoxyflavone + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.84, RHEA:18717]","metadata":null},{"id":"8ebb4f731c1b42ea9f3f36642b0a4fd6","type":"GO_TERM","name":"methylquinoline catabolic process","canonical_id":"go:GO:0019335","description":"\"The chemical reactions and pathways resulting in the breakdown of methylquinoline, an aromatic compound composed of a benzene ring and a heterocyclic N-containing ring.\" [GOC:ai, PMID:10746195]","metadata":null},{"id":"738731a0f32349c5b715c09c2750ad8f","type":"GO_TERM","name":"methylseleninic acid reductase activity","canonical_id":"go:GO:0098626","description":"\"Catalysis of the reaction: NADPH + H+ + CH3SeO2H = NADP+ + CH3SeOH + H2O.\" [PMID:11782468]","metadata":null},{"id":"1ccd0d76cc1e4fe9899f6825e23a0647","type":"GO_TERM","name":"methylselenol demethylase activity","canonical_id":"go:GO:0098608","description":"\"Catalysis of the reaction: methylselenol + H2O = H2Se + CH3OH.\" [PMID:17451884, PMID:17988700]","metadata":null},{"id":"c6ed7bc854284118b9f490e1d6be06e8","type":"GO_TERM","name":"methylselenol reductase activity","canonical_id":"go:GO:0098625","description":"\"Catalysis of the reaction: NADPH + H+ + CH3SeOH = NADP+ + CH3SeH + H2O.\" [PMID:11782468]","metadata":null},{"id":"ee10457ea7344960b5a9f9aaf846b96a","type":"DRUG","name":"methyltestosterone","canonical_id":"mesh:D008777","description":null,"metadata":null},{"id":"ba1a51f1e4a948fba63a015f7981d226","type":"GO_TERM","name":"methyltetrahydrofolate:corrinoid/iron-sulfur protein methyltransferase activity","canonical_id":"go:GO:0102036","description":"\"Catalysis of the reaction: a tetrahydrofolate + a [methyl-Co(III) corrinoid Fe-S protein] = an N5-methyl-tetrahydrofolate + a [Co(I) corrinoid Fe-S protein].\" [EC:2.1.1.258, GOC:pz, PMID:7928975]","metadata":null},{"id":"a9d4b80d62614d1db3542910004d0474","type":"GO_TERM","name":"methyltetrahydroprotoberberine 14-monooxygenase activity","canonical_id":"go:GO:0047084","description":"\"Catalysis of the reaction: O2 + NADPH + H+ + (S)-N-methylcanadine = H2O + NADP+ + allocryptopine.\" [EC:1.14.14.97, MetaCyc:1.14.13.37-RXN]","metadata":null},{"id":"54a187be2e4f433cba34e6f042a7beed","type":"GO_TERM","name":"methylthioadenosine nucleosidase activity","canonical_id":"go:GO:0008930","description":"\"Catalysis of the reaction: methylthioadenosine + H2O = adenine + 5-methylthio-D-ribose.\" [EC:3.2.2.16]","metadata":null},{"id":"273ebd452d064c2a9bc3a077497a4ca0","type":"GO_TERM","name":"methylthioalkylmalate synthase activity","canonical_id":"go:GO:0010177","description":"\"Catalysis of the reaction: acetyl-CoA + an omega-(methylsulfanyl)-2-oxoalkanoate + H2O = a 2-(omega-methylsulfanyl)alkylmalate + CoA + H+.\" [RHEA:50624]","metadata":null},{"id":"56715d698fb24d10a80c719a95914f1b","type":"GO_TERM","name":"methylthiol:coenzyme M methyltransferase activity","canonical_id":"go:GO:0044683","description":"\"Catalysis of the overall reaction: methyl-Co(III) methylated-thiol-specific corrinoid protein + coenzyme M = Co(I) methylated--thiol-specific corrinoid protein + methyl-CoM.\" [MetaCyc:RXN-8125, PMID:9371433]","metadata":null},{"id":"5736c3bc83d947db803479b0c1794bd5","type":"GO_TERM","name":"methylthiol:coenzyme M methyltransferase complex","canonical_id":"go:GO:0044680","description":"\"A protein complex of two polypeptides which catalyzes the transfer of methyl group from methylthiol to coenzyme M during methanogenesis.\" [GOC:mengo_curators, PMID:11073950, PMID:9371433]","metadata":null},{"id":"1641303aad5b4ee2b56b15111c3d4347","type":"GO_TERM","name":"methylthioribulose 1-phosphate dehydratase activity","canonical_id":"go:GO:0046570","description":"\"Catalysis of the reaction: S-methyl-5-thio-D-ribulose 1-phosphate = 5-(methylthio)-2,3-dioxopentyl phosphate + H2O.\" [EC:4.2.1.109, RHEA:15549]","metadata":null},{"id":"6451f68fa7aa4a3ebf428b7127cd6832","type":"GO_TERM","name":"methylthiotransferase activity","canonical_id":"go:GO:0035596","description":"\"Catalysis of the addition of a methylthioether group (-SCH3) to a nucleic acid or protein acceptor.\" [GOC:jh2, PMID:20472640]","metadata":null},{"id":"85431dc60a51486fa326fdb9d14d129b","type":"GO_TERM","name":"methyltransferase activity","canonical_id":"go:GO:0008168","description":"\"Catalysis of the transfer of a methyl group to an acceptor molecule.\" [ISBN:0198506732]","metadata":null},{"id":"91ffbe2ea9f64e31ae29670a579fabec","type":"GO_TERM","name":"methyltransferase cap1 activity","canonical_id":"go:GO:0004483","description":"\"Catalysis of the reaction: a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA or snRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-(2'-O-methyl-ribonucleoside) in mRNA or snRNA + S-adenosyl-L-homocysteine + H+. This activity catalyzes the methylation of the ribose on the first transcribed nucleotide of mRNAs and snRNAs.\" [EC:2.1.1.57]","metadata":null},{"id":"38260fffefda445a808aa556cec0dba2","type":"GO_TERM","name":"methyltransferase cap2 activity","canonical_id":"go:GO:0120550","description":"\"Catalysis of the reaction: a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-(2'-O-methyl-ribonucleoside)-(ribonucleotide) in mRNA or snRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-(2'-O-methyl-ribonucleoside)-(2'-O-methyl-ribonucleotide) in mRNA or snRNA + S-adenosyl-L-homocysteine + H+. This activity catalyzes the methylation of the ribose on the second transcribed nucleotide of mRNAs and snRNAs.\" [EC:2.1.1.296]","metadata":null},{"id":"1f937d3e8dce40f581e08f49164b4eef","type":"GO_TERM","name":"methyltransferase complex","canonical_id":"go:GO:0034708","description":"\"A protein complex that possesses methyltransferase activity.\" [GOC:mah]","metadata":null},{"id":"fb3aa24c991c42f58e52cebd6e633b1d","type":"GO_TERM","name":"methyltransferase regulator activity","canonical_id":"go:GO:0141107","description":"\"Binds to and modulates the activity of a methyltransferase.\" [PMID:15899842, PMID:34669960]","metadata":null},{"id":"c1abfa7e2dde48ed96acb4c043d1f8d6","type":"DRUG","name":"methyltyrosine","canonical_id":"gtopdb:5094","description":null,"metadata":null},{"id":"600612487bac4398acceb2ef945ed0d8","type":"GO_TERM","name":"methylumbelliferyl-acetate deacetylase activity","canonical_id":"go:GO:0047374","description":"\"Catalysis of the reaction: 4-methylumbelliferyl acetate + H2O = 4-methylumbelliferone + acetate + H+.\" [EC:3.1.1.56, RHEA:12208]","metadata":null},{"id":"9549621aed264ca6b2901e5153161881","type":"DRUG","name":"methysergide","canonical_id":"gtopdb:134","description":null,"metadata":null},{"id":"a6b363209812485da8eecd08d7dc8361","type":"DRUG","name":"meticillin","canonical_id":"mesh:D008712","description":null,"metadata":null},{"id":"6aa24897861c463a8318ece27db3824f","type":"DRUG","name":"metirosine","canonical_id":"mesh:D019805","description":null,"metadata":null},{"id":"a699d481f495467f8524bfaf1ff10883","type":"DRUG","name":"metoclopramide","canonical_id":"gtopdb:241","description":null,"metadata":null},{"id":"0644601be51d440d89c6b5009ff07740","type":"COMBINATION_TREATMENT","name":"metoclopramide + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-fd24db9a44b4260b","description":null,"metadata":null},{"id":"07263ee8c2c441f693244d66494e99fe","type":"DRUG","name":"metolazone","canonical_id":"gtopdb:4838","description":null,"metadata":null},{"id":"818f32c49f50453b9567565437cd8594","type":"DRUG","name":"metolazone","canonical_id":"mesh:D008788","description":null,"metadata":null},{"id":"33cce311ebcc4f49be84ae20a66c6c0e","type":"DRUG","name":"metolazone","canonical_id":"chembl:CHEMBL878","description":null,"metadata":null},{"id":"44a46c5af553452cbec641d9d81fcdf3","type":"COMBINATION_TREATMENT","name":"metolazone + tolvaptan","canonical_id":"ctgov_combo:ctgov-combo-523c7b6ccd6d57fe","description":null,"metadata":null},{"id":"f9432472b1a54bfba57a5d49ec625de5","type":"DRUG","name":"metoprolol","canonical_id":"gtopdb:553","description":null,"metadata":null},{"id":"9ac85f8a00884b7fb7df459a24d3b848","type":"COMBINATION_TREATMENT","name":"metoprolol + mirabegron","canonical_id":"ctgov_combo:ctgov-combo-73b769418748c00e","description":null,"metadata":null},{"id":"1103dda6ead84e86ae4312d196a6df46","type":"COMBINATION_TREATMENT","name":"metoprolol + nitisinone + tolbutamide","canonical_id":"ctgov_combo:ctgov-combo-8d62a92acecd45cc","description":null,"metadata":null},{"id":"462d0516b36a46ff8be0f7d1ce3cac17","type":"COMBINATION_TREATMENT","name":"metoprolol + ramipril","canonical_id":"ctgov_combo:ctgov-combo-58b8156d0ff7135b","description":null,"metadata":null},{"id":"a4535f71b7114672814bc7fee913f65b","type":"COMBINATION_TREATMENT","name":"metoprolol + sibutramine","canonical_id":"ctgov_combo:ctgov-combo-9c4b56737e5963ab","description":null,"metadata":null},{"id":"7131dc30526d413f895d05827645ead2","type":"COMBINATION_TREATMENT","name":"metoprolol + sotagliflozin","canonical_id":"ctgov_combo:ctgov-combo-68ddb37fae30de19","description":null,"metadata":null},{"id":"001248b0c0b9466da9d8c4e758030c55","type":"COMBINATION_TREATMENT","name":"metoprolol + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-5e62b2ab38491b59","description":null,"metadata":null},{"id":"0fa3b758f5ee43d9886a2ac7d2b174ec","type":"COMBINATION_TREATMENT","name":"metoprolol + tralokinumab","canonical_id":"ctgov_combo:ctgov-combo-4d07602b8cc9b568","description":null,"metadata":null},{"id":"e172c853b5834b82afc1d9ac0b183280","type":"DRUG","name":"metreleptin","canonical_id":"mesh:C415771","description":null,"metadata":null},{"id":"d2bf632d1c0f4cb5ba40f8cf1f58178a","type":"DRUG","name":"metronidazole","canonical_id":"mesh:D008795","description":null,"metadata":null},{"id":"d7be8c6ff6954936a9aad6573b7e08fb","type":"GO_TERM","name":"metula development","canonical_id":"go:GO:0070789","description":"\"The process whose specific outcome is the progression of metulae over time, from its formation to the mature structure. Metulae are elongated mononucleate cells that bud from the surface of the conidiophore tip.\" [PMID:9529886]","metadata":null},{"id":"bba33febcd2f434ab4d16881033ee5c0","type":"DRUG","name":"metyrapone","canonical_id":"gtopdb:5224","description":null,"metadata":null},{"id":"7c073ead22c1414a9c837a90a02b0b22","type":"DRUG","name":"metyrapone","canonical_id":"chembl:CHEMBL934","description":null,"metadata":null},{"id":"82896984d8d248c8a7df14547c8e3694","type":"GO_TERM","name":"mevalonate kinase activity","canonical_id":"go:GO:0004496","description":"\"Catalysis of the reaction: (R)-mevalonate + ATP = (R)-5-phosphomevalonate + ADP + 2 H+.\" [EC:2.7.1.36, RHEA:17065]","metadata":null},{"id":"63df6add2cb14385bea056c3dfb5a973","type":"DISEASE","name":"mevalonate kinase deficiency","canonical_id":"mondo:0017708","description":null,"metadata":null},{"id":"89d3a76975c148498f8ce83d50a2c297","type":"GO_TERM","name":"mevalonate transmembrane transporter activity","canonical_id":"go:GO:0015130","description":"\"Enables the transfer of mevalonate from one side of a membrane to the other. Mevalonate is the anion of mevalonic acid; its (R)-enantiomer is a strategic intermediate derived from hydroxymethylglutaryl-CoA in the biosynthesis of polyprenyl compounds.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"47c1960941214785b1e71e298620d455","type":"GO_TERM","name":"mevalonate transport","canonical_id":"go:GO:0015728","description":"\"The directed movement of mevalonate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"51037737feef43d086a4a54cdcd77263","type":"GO_TERM","name":"mevastatin biosynthetic process","canonical_id":"go:GO:0140877","description":"\"The chemical reactions and pathways resulting in the formation of mevastatin , also known as compactin or ML-236B, and which acts as a potent competitive inhibitor of HMG-CoA reductase.\" [PMID:12172803, PMID:12242508]","metadata":null},{"id":"bbb75c45745a4d2d9d2efa7608e448e4","type":"DRUG","name":"mexiletine","canonical_id":"gtopdb:2629","description":null,"metadata":null},{"id":"7ba26cdaf1144d50ba52e7c2fcb42f30","type":"COMBINATION_TREATMENT","name":"mexiletine + sotalol","canonical_id":"ctgov_combo:ctgov-combo-26db16f9b81ef412","description":null,"metadata":null},{"id":"57b901c4214b4edb9dc989ae0ee8a343","type":"DRUG","name":"mezlocillin","canonical_id":"mesh:D008802","description":null,"metadata":null},{"id":"05f6d71fa1994398ae665962938fb5d9","type":"GO_TERM","name":"miRNA binding","canonical_id":"go:GO:0035198","description":"\"Binding to a microRNA, a 21-23 nucleotide RNA that is processed from a stem-loop RNA precursor (pre-miRNA) that is encoded within plant and animal genomes.\" [PMID:15066283]","metadata":null},{"id":"9b231d6e44c44a349c3f91932f1108a2","type":"GO_TERM","name":"miRNA catabolic process","canonical_id":"go:GO:0010587","description":"\"The chemical reactions and pathways resulting in the breakdown of miRNA, microRNA, a class of single-stranded RNA molecules of about 21-23 nucleotides in length, which regulates gene expression.\" [PMID:17993620]","metadata":null},{"id":"a354f51e0c3b41218cf770f539be919d","type":"GO_TERM","name":"miRNA export from nucleus","canonical_id":"go:GO:0061716","description":"\"The directed movement of a processed miRNA from the nucleus to the cytoplasm.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:15738428, PMID:21554756]","metadata":null},{"id":"d0c6ee00ed5b479ba95f49ba06d1813b","type":"GO_TERM","name":"miRNA inhibitor activity via base-pairing","canonical_id":"go:GO:0140869","description":"\"Stops, prevents or reduces the activity of miRNA-mediated gene silencing activity by base-pairing with a target miRNA. An example of this activity is mediated by long non-coding RNAs (lncRNAs).\" [PMID:34454184]","metadata":null},{"id":"53a41a42f62944e49921ce9b0d969cbe","type":"GO_TERM","name":"miRNA metabolic process","canonical_id":"go:GO:0010586","description":"\"The chemical reactions and pathways involving miRNA, microRNA, a class of single-stranded RNA molecules of about 21-23 nucleotides in length, which regulates gene expression.\" [PMID:17993620]","metadata":null},{"id":"e1b1d3ffce58486697b08aa15f211276","type":"GO_TERM","name":"miRNA processing","canonical_id":"go:GO:0035196","description":"\"A process leading to the generation of a functional miRNA. Includes the cleavage of stem-loop RNA precursors into microRNAs (miRNAs). miRNAs are a class of small RNAs that primarily silence genes by blocking the translation of mRNA transcripts into protein, or by increasing the degradation of non-protein-coding RNA transcripts.\" [GOC:aruk, GOC:bc, GOC:dph, GOC:rl, GOC:tb, PMID:15066275, PMID:15066283, PMID:23985560, PMID:28379604]","metadata":null},{"id":"89043201103f448585d0b7bc89bb4d86","type":"GO_TERM","name":"miRNA transcription","canonical_id":"go:GO:0061614","description":"\"The cellular synthesis of microRNA (miRNA) transcripts. MicroRNA genes are synthesized as primary (pri) miRNA transcripts and subsequently processed to produce the ~22nt miRNAs that function in gene regulation.\" [GOC:dph, GOC:kmv, PMID:18778799]","metadata":null},{"id":"a33bd0a58c594e78ac7d13ce1ef1281d","type":"GO_TERM","name":"miRNA transport","canonical_id":"go:GO:1990428","description":"\"The directed movement of microRNA (miRNA) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore.\" [GO:jl, PMID:24356509]","metadata":null},{"id":"83cdbdbe8efa4844b4a39aab6363d07e","type":"GO_TERM","name":"miRNA-mediated gene silencing by inhibition of translation","canonical_id":"go:GO:0035278","description":"\"An RNA interference pathway in which microRNAs (miRNAs) block the translation of target mRNAs into proteins. Once incorporated into a RNA-induced silencing complex (RISC), a miRNA will typically mediate repression of translation if the miRNA imperfectly base-pairs with the 3' untranslated regions of target mRNAs.\" [PMID:14744438, PMID:15196554]","metadata":null},{"id":"a25f7047875b4769bfd8d5e7a7343fa9","type":"GO_TERM","name":"miRNA-mediated gene silencing by mRNA destabilization","canonical_id":"go:GO:0035279","description":"\"An RNA interference pathway in which microRNAs (miRNAs) direct the cleavage of target mRNAs. Once incorporated into a RNA-induced silencing complex (RISC), a miRNA base pairing with near-perfect complementarity to the target mRNA will typically direct targeted endonucleolytic cleavage of the mRNA. Many plant miRNAs downregulate gene expression through this mechanism.\" [GOC:dph, GOC:mtg_lung, PMID:14744438, PMID:15196554, PMID:21118121, PMID:23209154]","metadata":null},{"id":"74953084360f4e62aa65f53ae48895bb","type":"GO_TERM","name":"miRNA-mediated post-transcriptional gene silencing","canonical_id":"go:GO:0035195","description":"\"A post-transcriptional gene silencing pathway in which regulatory microRNAs (miRNAs) elicit silencing of specific target genes. miRNAs are endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate protein production by either of two posttranscriptional mechanisms: endonucleolytic cleavage of the RNA (often mRNA) or mRNA translational repression, usually accompanied by poly-A tail shortening and subsequent degradation of the mRNA. miRNAs are present in all the animals and in plants, whereas siRNAs are present in lower animals and in plants.\" [GOC:aruk, GOC:bc, GOC:rl, PMID:14744438, PMID:15066275, PMID:15066283, PMID:23209154, PMID:23985560, PMID:28379604]","metadata":null},{"id":"4b7625f8180f4c848ed3895237407d1c","type":"DRUG","name":"mianserin","canonical_id":"gtopdb:135","description":null,"metadata":null},{"id":"5c100ede80eb4f419d2daba14f713eb9","type":"DRUG","name":"mianserin","canonical_id":"mesh:D008803","description":null,"metadata":null},{"id":"e0c3ab9ae2c243fc8b718bd70815039a","type":"DRUG","name":"mibefradil","canonical_id":"mesh:D020748","description":null,"metadata":null},{"id":"8fd1814ec81b4cd584f0ef5030fe97c8","type":"DRUG","name":"micafungin","canonical_id":"mesh:C121905","description":null,"metadata":null},{"id":"bf017c75dd244c47bf7c1a6c467cfbd0","type":"DRUG","name":"miconazole","canonical_id":"mesh:D008825","description":null,"metadata":null},{"id":"d79f38c2df7b4d178443985d634c21c9","type":"GO_TERM","name":"microautophagy","canonical_id":"go:GO:0016237","description":"\"A type of autophagy where cytosolic components are ingested by late endosomes, lysosomes or yeast-type lytic vacuoles by direct invagination of the compartment membrane without prior sequestration into an autophagosome. The engulfing membranes fuse, resulting in the lysosomal delivery of the cargo wrapped in a single membrane derived from the invaginated lysosomal membrane.\" [PMID:14679207, PMID:15798367, PMID:16973210, PMID:9566964]","metadata":null},{"id":"3462bbef82084b27b0c8545d883781b2","type":"GO_TERM","name":"microbody","canonical_id":"go:GO:0042579","description":"\"Cytoplasmic organelles, spherical or oval in shape, that are bounded by a single membrane and contain oxidative enzymes, especially those utilizing hydrogen peroxide (H2O2).\" [ISBN:0198506732]","metadata":null},{"id":"dd82ce878194465fbe50659733c7c040","type":"GO_TERM","name":"microbody lumen","canonical_id":"go:GO:0031907","description":"\"The volume enclosed by the membranes of a microbody.\" [GOC:mah]","metadata":null},{"id":"9af22cf04a3f4894ae1b2519765037cc","type":"GO_TERM","name":"microbody membrane","canonical_id":"go:GO:0031903","description":"\"The lipid bilayer surrounding a microbody.\" [GOC:mah]","metadata":null},{"id":"812f452fe53f4e6e9c56b73fe52c93db","type":"GO_TERM","name":"microcin B17 transport","canonical_id":"go:GO:0042885","description":"\"The directed movement of microcin B17, a bactericidal peptide (antibiotic) produced by some enteric bacteria, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:11292337]","metadata":null},{"id":"d7a16b2010d446fe8f7498236efcf27f","type":"GO_TERM","name":"microcin transmembrane transporter activity","canonical_id":"go:GO:0015638","description":"\"Enables the transfer of a microcin from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"cf57582740ef4f068193b76b87ff703c","type":"GO_TERM","name":"microcin transport","canonical_id":"go:GO:0042884","description":"\"The directed movement of microcin, a class of glycine-rich, bactericidal peptides (antibiotics) produced by some enteric bacteria, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl, PMID:11292337]","metadata":null},{"id":"dff6f512b97f43f3aa68676bd857fe8c","type":"GO_TERM","name":"microcystin transport","canonical_id":"go:GO:1905431","description":"\"The directed movement of a microcystin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GO_REF:0000065, GOC:TermGenie, PMID:26055554]","metadata":null},{"id":"8c1ce2c1085b4aec98dc4c9b29f7bb75","type":"GO_TERM","name":"microfibril","canonical_id":"go:GO:0001527","description":"\"Extracellular matrix components occurring independently or along with elastin. Thought to have force-bearing functions in tendon. In addition to fibrillins, microfibrils may contain microfibrillar-Associated Proteins (MFAPs): MFAP1, MFAP2 (also known as MAGP-1), MFAP3, MFAP4, and MFAP5 (also known as MAGP-2).\" [PMID:27026396, PMID:31226403]","metadata":null},{"id":"ef0979b7b8934210adc6dacead58c8cb","type":"GO_TERM","name":"microfibril assembly","canonical_id":"go:GO:0160054","description":"\"The aggregation, arrangement and bonding together of microfibril.\" [PMID:32855533]","metadata":null},{"id":"730e5850aee245bb8a68cfcf7344511a","type":"GO_TERM","name":"microfibril binding","canonical_id":"go:GO:0050436","description":"\"Binding to a microfibril, any small fibril occurring in biological material.\" [GOC:ai]","metadata":null},{"id":"15f6afea34874536ae3194fa9c804e3a","type":"GO_TERM","name":"microfilament motor activity","canonical_id":"go:GO:0000146","description":"\"A motor activity that generates movement along a microfilament, driven by ATP hydrolysis.\" [PMID:29716949]","metadata":null},{"id":"f668a94f66d84e33bd723179a376eb76","type":"GO_TERM","name":"microgametogenesis","canonical_id":"go:GO:0055046","description":"\"The process whose specific outcome is the progression of the pollen grain over time, from its formation as the microspore to the mature structure.\" [GOC:mtg_plant]","metadata":null},{"id":"9bd15a5544a546a3bfc8ab01c05fcb28","type":"GO_TERM","name":"microgametophyte vegetative cell differentiation","canonical_id":"go:GO:0022620","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a microgametophyte. The microgametophyte vegetative cell gives rise to the pollen tube.\" [GOC:isa_complete]","metadata":null},{"id":"4a7b0487dd0d42258833dc01d31a2646","type":"GO_TERM","name":"microglia development","canonical_id":"go:GO:0014005","description":"\"The process aimed at the progression of a microglial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dgh, GOC:ef]","metadata":null},{"id":"7f5cbcfed7714ebb9df679137b9297e2","type":"GO_TERM","name":"microglia differentiation","canonical_id":"go:GO:0014004","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a microglial cell. Microglia are glial cells that act as the immune cells of the central nervous system. They form part of the supporting structure of this system.\" [GOC:ef]","metadata":null},{"id":"2849cfff927a40f1be18ca3e4289b2bb","type":"GO_TERM","name":"microglial cell activation","canonical_id":"go:GO:0001774","description":"\"The change in morphology and behavior of a microglial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, PMID:10626665, PMID:10695728, PMID:12580336, PMID:9893949]","metadata":null},{"id":"4d7d7ddd83df406aad812e678dee5778","type":"GO_TERM","name":"microglial cell activation involved in immune response","canonical_id":"go:GO:0002282","description":"\"The change in morphology and behavior of a microglial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a9975e25d571469888c3f6ff933e5aec","type":"GO_TERM","name":"microglial cell mediated cytotoxicity","canonical_id":"go:GO:0090634","description":"\"The directed killing of a target cell by a microglial cell.\" [GOC:BHF, GOC:nc, PMID:19100238]","metadata":null},{"id":"3a82b175d1e24fd98d4a671659702d68","type":"GO_TERM","name":"microglial cell migration","canonical_id":"go:GO:1904124","description":"\"The orderly movement of a microglial cell from one site to another.\" [GO_REF:0000091, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"5d3cfeb8de884ab8aafd0e0c57c2780b","type":"GO_TERM","name":"microglial cell proliferation","canonical_id":"go:GO:0061518","description":"\"The expansion of a microglial cell population by cell division.\" [GOC:dph, PMID:17344397]","metadata":null},{"id":"ce4d3f6cf4554cb185f101bd082fbf6b","type":"GO_TERM","name":"microlipophagy","canonical_id":"go:GO:0140504","description":"\"Degradation of a lipid droplet by microautophagy.\" [PMID:25070953, PMID:28394250, PMID:28838958, PMID:29293450, PMID:29601311]","metadata":null},{"id":"89e5ee0806d0472098d98fa21560ec29","type":"GO_TERM","name":"micromitophagy","canonical_id":"go:GO:0000424","description":"\"Degradation of a mitochondrion by microautophagy.\" [PMID:15798367, PMID:27003723]","metadata":null},{"id":"f23d794b0d404436b1c80456d5f6fdfd","type":"GO_TERM","name":"microneme","canonical_id":"go:GO:0020009","description":"\"A small, elongated secretory organelle that forms part of the apical complex, located along the main axis of an apicomplexan parasite cell within the extreme apical region and at the periphery under the inner membrane complex. Of the specialized secretory compartments identified in apicomplexans, micronemes discharge their contents first, during initial contact of the parasite's apical pole with the host cell surface. Micronemal proteins function during parasite attachment and penetration into the target cell.\" [ISBN:0521664470, PMID:11801218]","metadata":null},{"id":"69d719ff62ce4d8f85c434115e9b6058","type":"GO_TERM","name":"microneme lumen","canonical_id":"go:GO:0034494","description":"\"The volume enclosed by the microneme membrane.\" [GOC:rph]","metadata":null},{"id":"6e18cbb025d5494e9a4d2bea4a5b82ba","type":"GO_TERM","name":"microneme membrane","canonical_id":"go:GO:0033163","description":"\"The lipid bilayer surrounding a microneme.\" [GOC:mah]","metadata":null},{"id":"69910abac10a4479b8981d6f8d001b68","type":"GO_TERM","name":"micronucleus","canonical_id":"go:GO:0031040","description":"\"A membrane-bounded organelle of ciliated protozoan cells that contains a diploid copy of the cell's complete genome. Sections of contiguous sequence in the macronucleus are often interrupted by internal eliminated sequences (IES), and may be permuted, in micronuclei. Genic transcription is not found in micronuclei. Some ciliate species may contain multiple micronuclei per cell.\" [GOC:ns]","metadata":null},{"id":"67ff5d7ff02a4545a506510b14816e0e","type":"GO_TERM","name":"micronucleus organization","canonical_id":"go:GO:0032125","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the micronucleus.\" [GOC:dph, GOC:jl, GOC:mah, PMID:10503190]","metadata":null},{"id":"4ad5446c982b4d02a086867c12d60465","type":"GO_TERM","name":"micropexophagy","canonical_id":"go:GO:0000426","description":"\"Degradation of a peroxisome by microautophagy.\" [GOC:autophagy, GOC:pad, PMID:12914914, PMID:15350980, PMID:16973210]","metadata":null},{"id":"f2b40ff40fa0412cb15f936e4ef9e5b5","type":"GO_TERM","name":"micropexophagy-specific membrane apparatus","canonical_id":"go:GO:0032046","description":"\"A membrane-bounded flattened sac that is formed during micropexophagy between the membrane tips of an engulfing vacuole, completing the engulfment and sequestration of peroxisomes from the cytosol, and forming a micropexophagic body within the lumen of the vacuole.\" [PMID:15563611]","metadata":null},{"id":"18caf39b72c24fd686257b5afbcb239e","type":"DISEASE","name":"microphthalmia","canonical_id":"mondo:0021129","description":null,"metadata":null},{"id":"12dcbda7f2ce4372ae409af97431e689","type":"DISEASE","name":"microphthalmia, syndromic 12","canonical_id":"mondo:0014229","description":null,"metadata":null},{"id":"c12156f219414b3d9728ee57bed8a6df","type":"DISEASE","name":"microphthalmia, syndromic 9","canonical_id":"mondo:0011010","description":null,"metadata":null},{"id":"8ea2640c3f794cb3b11ba6fd0c586080","type":"GO_TERM","name":"micropinocytosis","canonical_id":"go:GO:0044350","description":"\"An endocytosis process that results in the uptake of liquid material by cells from their external environment by invagination of the plasma membrane to form uncoated micropinosomes, differentiated from macropinosomes by their smaller size, on average 95 nm.\" [PMID:14731589, PMID:14732047]","metadata":null},{"id":"551f2370e2ca4c2f8c71face6590751c","type":"GO_TERM","name":"micropinosome","canonical_id":"go:GO:0044353","description":"\"A membrane-bounded, uncoated intracellular vesicle formed by the process of micropinocytosis.\" [PMID:14731589, PMID:14732047]","metadata":null},{"id":"23df6c79df7c4973aef605f13d84d36f","type":"GO_TERM","name":"microprocessor complex","canonical_id":"go:GO:0070877","description":"\"A protein complex that binds to heme and to pri-miRNAs, and is required for the formation of a pre-microRNA (pre-miRNA), the initial step of microRNA (miRNA) biogenesis. The complex is composed of the double-stranded-RNA-specific RNase Drosha (also called RNASEN) and the RNA-binding protein DGCR8 (heme-free or heme-bound forms). Within the complex, DGCR8 function as a molecular anchor necessary for the recognition of pri-miRNA at dsRNA-ssRNA junction and directs RNASEN/Drosha to cleave the 3' and 5' strands of a stem-loop to release hairpin-shaped pre-miRNAs.\" [PMID:16963499, PMID:17159994]","metadata":null},{"id":"a35cb24bc02e42c997e7ae96b1e97d7c","type":"GO_TERM","name":"microsatellite binding","canonical_id":"go:GO:0035939","description":"\"Binding to a microsatellite, a repeat_region in DNA containing repeat units (2 to 4 base pairs) that is repeated multiple times in tandem.\" [GOC:yaf, PMID:21290414, SO:0000289]","metadata":null},{"id":"b1b762b123d84c28b7cdec5b680f442d","type":"DISEASE","name":"microscopic polyangiitis","canonical_id":"mondo:0019124","description":null,"metadata":null},{"id":"bd7f15783c794cf3bc4ce971a9b937c6","type":"PROTEIN","name":"microsomal long-chain fatty acyl-CoA synthetase","canonical_id":"uniprot:O14975","description":null,"metadata":null},{"id":"e9f62f5af4c04506a5ee30363e668466","type":"GO_TERM","name":"microspike","canonical_id":"go:GO:0044393","description":"\"A dynamic, actin-rich projection extending from the surface of a migrating animal cell.\" [PMID:11429692, PMID:12153987, PMID:19095735]","metadata":null},{"id":"e295959f5c1a48c48f2b0a335903b6a9","type":"GO_TERM","name":"microspike assembly","canonical_id":"go:GO:0030035","description":"\"Formation of a microspike, a dynamic, actin-rich projection extending from the surface of a migrating animal cell.\" [ISBN:0815316194, PMID:11429692, PMID:12153987, PMID:19095735]","metadata":null},{"id":"cd7ce865c9454262ba472b47eaa8b314","type":"GO_TERM","name":"microsporidian-type endospore","canonical_id":"go:GO:0090641","description":"\"The middle layer in a microsporidian spore wall that lies under the exospore and outside the plasma membrane, containing chitin and proteins.\" [PMID:19457051]","metadata":null},{"id":"b086b295902b442a8a90a5ed6d1ab360","type":"GO_TERM","name":"microsporidian-type exospore","canonical_id":"go:GO:0090642","description":"\"The dense, protein rich outermost layer of a microsporidian spore wall that lies above the endospore.\" [PMID:19457051, PMID:25363531]","metadata":null},{"id":"223d57faa99a47c3a7b38b2e731f5aef","type":"GO_TERM","name":"microsporocyte differentiation","canonical_id":"go:GO:0010480","description":"\"The process aimed at the progression of a microsporocyte cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. A microsporocyte is a diploid (2n) cell that undergoes meiosis and forms four haploid (1n) microspores; also called microspore mother cell and, in seed plants, pollen mother cell.\" [CL:0000248, PMID:16751349]","metadata":null},{"id":"367f4f2ac6b941aeae9968933b80c565","type":"GO_TERM","name":"microsporocyte nucleus","canonical_id":"go:GO:0048556","description":"\"The nucleus of the microsporocyte. The microsporocyte is a diploid cell in which meiosis will occur, resulting in four microspores. A microspore is a spore that, in vascular plants, gives rise to a male gametophyte.\" [GOC:tair_curators, ISBN:047186840X]","metadata":null},{"id":"37ee1ea684c1452283fa1188bb49737c","type":"GO_TERM","name":"microsporogenesis","canonical_id":"go:GO:0009556","description":"\"The process in which the microsporocyte undergoes meiosis, giving rise to four haploid microspores.\" [GOC:mtg_plant, GOC:tb]","metadata":null},{"id":"69d3c69b57ab4270b7cb31ca5b9071b1","type":"GO_TERM","name":"microtubule","canonical_id":"go:GO:0005874","description":"\"Any of the long, generally straight, hollow tubes of internal diameter 12-15 nm and external diameter 24 nm found in a wide variety of eukaryotic cells; each consists (usually) of 13 protofilaments of polymeric tubulin, staggered in such a manner that the tubulin monomers are arranged in a helical pattern on the microtubular surface, and with the alpha/beta axes of the tubulin subunits parallel to the long axis of the tubule; exist in equilibrium with pool of tubulin monomers and can be rapidly assembled or disassembled in response to physiological stimuli; concerned with force generation, e.g. in the spindle.\" [ISBN:0879693568]","metadata":null},{"id":"c098c76d68844da0a9432f4477d69a80","type":"GO_TERM","name":"microtubule anchoring","canonical_id":"go:GO:0034453","description":"\"Any process in which a microtubule is maintained in a specific location in a cell.\" [GOC:mah]","metadata":null},{"id":"bee34671ab624606b241edf00dbc5e6d","type":"GO_TERM","name":"microtubule anchoring at cell cortex of cell tip","canonical_id":"go:GO:0106007","description":"\"Any process in which a microtubule is maintained in a specific location at the cell tip by attachment to the cell cortex.\" [GOC:mah, PMID:25736293]","metadata":null},{"id":"edffa35ee89d4e2ba5c0e3e6a9909cd3","type":"GO_TERM","name":"microtubule anchoring at centrosome","canonical_id":"go:GO:0034454","description":"\"Any process in which a microtubule is maintained in a specific location in a cell by attachment to a centrosome.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"f9ad016a17ce4277852ca46eb43c0657","type":"GO_TERM","name":"microtubule anchoring at microtubule organizing center","canonical_id":"go:GO:0072393","description":"\"Any process in which a microtubule is maintained in a specific location in a cell by attachment to a microtubule organizing center.\" [GOC:BHF, PMID:19825938]","metadata":null},{"id":"5de4a125a3384dcdb0f1930854e94d9c","type":"GO_TERM","name":"microtubule anchoring at mitotic spindle pole body","canonical_id":"go:GO:1990810","description":"\"Any process in which a microtubule is maintained in a specific location in a cell by attachment to a mitotic spindle pole body. Microtubules attach to spindle pole bodies at the minus end.\" [PMID:17486116]","metadata":null},{"id":"be96245d0c834f4181d3e8703df8804a","type":"GO_TERM","name":"microtubule anchoring at spindle pole body","canonical_id":"go:GO:0034631","description":"\"Any process in which a microtubule is maintained in a specific location in a cell by attachment to a spindle pole body. Microtubules attach to spindle pole bodies at the minus end.\" [GOC:mah, PMID:17486116]","metadata":null},{"id":"b21e0d53a58f49a28f16009fa061ef54","type":"GO_TERM","name":"microtubule associated complex","canonical_id":"go:GO:0005875","description":"\"Any multimeric complex connected to a microtubule.\" [GOC:jl]","metadata":null},{"id":"6822d8b56d614b38a23a84a3ee0b403c","type":"GO_TERM","name":"microtubule binding","canonical_id":"go:GO:0008017","description":"\"Binding to a microtubule, a filament composed of tubulin monomers.\" [GOC:krc]","metadata":null},{"id":"b83f84e29b3c4cec83884d696733b69d","type":"GO_TERM","name":"microtubule bundle","canonical_id":"go:GO:0097427","description":"\"An arrangement of closely apposed microtubules running parallel to each other.\" [NIF_Subcellular:sao1872343973]","metadata":null},{"id":"080c201d73684ff29c31cc7633f34ef3","type":"GO_TERM","name":"microtubule bundle formation","canonical_id":"go:GO:0001578","description":"\"A process that results in a parallel arrangement of microtubules.\" [GOC:dph]","metadata":null},{"id":"0174372054be4d408b85ae6ce20da0aa","type":"GO_TERM","name":"microtubule bundle maintenance","canonical_id":"go:GO:0062195","description":"\"The organization process that preserves a microtubule bundle in a stable functional or structural state.\" [PMID:18061564]","metadata":null},{"id":"11088ff2fca44c01a108d72e55b3547f","type":"GO_TERM","name":"microtubule cytoskeleton","canonical_id":"go:GO:0015630","description":"\"The part of the cytoskeleton (the internal framework of a cell) composed of microtubules and associated proteins.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"dea8fe0147fc41faa3fcacffdf6e98fd","type":"GO_TERM","name":"microtubule cytoskeleton attachment to nuclear envelope","canonical_id":"go:GO:1990933","description":"\"A process in which the microtubule cytoskeleton is attached to the nuclear envelope.\" [PMID:14655046, PMID:20507227]","metadata":null},{"id":"63ab25bbe1424d308b42b59a4e110c64","type":"GO_TERM","name":"microtubule cytoskeleton organization","canonical_id":"go:GO:0000226","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising microtubules and their associated proteins.\" [GOC:mah]","metadata":null},{"id":"7e80c6835608454bbf3ea7c4b192d0b5","type":"GO_TERM","name":"microtubule cytoskeleton organization involved in establishment of planar polarity","canonical_id":"go:GO:0090176","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising microtubules and their associated proteins and contributes to the establishment of planar polarity.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"e4f0f68560904537a08eaf7a0f7bd844","type":"GO_TERM","name":"microtubule cytoskeleton organization involved in mitosis","canonical_id":"go:GO:1902850","description":"\"Any microtubule cytoskeleton organization that is involved in mitosis.\" [GO_REF:0000060, GOC:TermGenie, PMID:18799626]","metadata":null},{"id":"05a180c206c04b61b6a270606e9a041c","type":"GO_TERM","name":"microtubule depolymerization","canonical_id":"go:GO:0007019","description":"\"The removal of tubulin heterodimers from one or both ends of a microtubule.\" [ISBN:0815316194]","metadata":null},{"id":"418b11ec39aa4ce1be7ff0b5fbf77b09","type":"GO_TERM","name":"microtubule destabilizing activity","canonical_id":"go:GO:0170060","description":"\"A protein-containing complex destabilizing activity that promotes microtubule catastrophe (transition from microtubule growth to microtubule shrinkage).\" [PMID:29858272, PMID:36435910]","metadata":null},{"id":"fe69cd5a898649e9aac33c81a9ee0b37","type":"GO_TERM","name":"microtubule end","canonical_id":"go:GO:1990752","description":"\"Any end of a microtubule. Microtubule ends differ in that the so-called microtubule plus-end is the one that preferentially grows by polymerization, with respect to the minus-end.\" [GOC:pr]","metadata":null},{"id":"5bdd198a407441ebab3761cc3641a8fa","type":"GO_TERM","name":"microtubule lateral binding","canonical_id":"go:GO:0099609","description":"\"Binding to the side of a microtubule.\" [GOC:dos]","metadata":null},{"id":"a42ad84c096b47a7a24ef5696bde4ffe","type":"GO_TERM","name":"microtubule minus-end","canonical_id":"go:GO:0036449","description":"\"The end of a microtubule that does not preferentially grow (polymerize).\" [GOC:lb, PMID:23169647]","metadata":null},{"id":"4e651b39ad4146a0a0983f56f070c533","type":"GO_TERM","name":"microtubule minus-end binding","canonical_id":"go:GO:0051011","description":"\"Binding to the minus end of a microtubule.\" [GOC:ai, PMID:14557818, PMID:14614826]","metadata":null},{"id":"6c5313d5ab584a1bb0106daab6e86e3b","type":"GO_TERM","name":"microtubule motor activity","canonical_id":"go:GO:0003777","description":"\"A motor activity that generates movement along a microtubule, driven by ATP hydrolysis.\" [PMID:19686686, PMID:32684327, PMID:32842864]","metadata":null},{"id":"c528fbe65b0f43449e66f07ad6924802","type":"GO_TERM","name":"microtubule nucleation","canonical_id":"go:GO:0007020","description":"\"The process in which tubulin alpha-beta heterodimers begin aggregation to form an oligomeric tubulin structure (a microtubule seed). Microtubule nucleation is the initiating step in the formation of a microtubule in the absence of any existing microtubules ('de novo' microtubule formation).\" [GOC:curators, ISBN:0815316194, PMID:12517712]","metadata":null},{"id":"a019b3fd933547948afe6d36226e9b3a","type":"GO_TERM","name":"microtubule nucleation by interphase microtubule organizing center","canonical_id":"go:GO:0051415","description":"\"The 'de novo' formation of a microtubule by the interphase microtubule organizing center during interphase, the stage of cell cycle between successive rounds of chromosome segregation.\" [GOC:ai]","metadata":null},{"id":"932d68b85778452595b62ec5dfa4a748","type":"GO_TERM","name":"microtubule nucleation by microtubule organizing center","canonical_id":"go:GO:0051418","description":"\"The 'de novo' formation of a microtubule, mediated by the microtubule organizing center.\" [GOC:ai]","metadata":null},{"id":"0c1584399cea4392b33354b7cb6a7017","type":"GO_TERM","name":"microtubule nucleation by spindle pole body","canonical_id":"go:GO:0051417","description":"\"The 'de novo' formation of a microtubule, mediated by the spindle pole body.\" [GOC:ai]","metadata":null},{"id":"ef9156aa5654412ca1fd0b3158ce242a","type":"GO_TERM","name":"microtubule nucleator activity","canonical_id":"go:GO:0140490","description":"\"The action of a molecule that provides a shape mimicking the end of a microtubule to seed the formation of a new microtubule via self-assembly.\" [PMID:20631709, PMID:21993292]","metadata":null},{"id":"660b55351350432a9bf8d60a8f36dcbc","type":"GO_TERM","name":"microtubule organizing center","canonical_id":"go:GO:0005815","description":"\"An intracellular structure that can catalyze gamma-tubulin-dependent microtubule nucleation and that can anchor microtubules by interacting with their minus ends, plus ends or sides.\" [GOC:vw, ISBN:0815316194, PMID:17072892, PMID:17245416, Wikipedia:Microtubule_organizing_center]","metadata":null},{"id":"ffe13e4906ca423489338313d0ef5ead","type":"GO_TERM","name":"microtubule organizing center attachment site","canonical_id":"go:GO:0034992","description":"\"A region of the nuclear envelope to which a microtubule organizing center (MTOC) attaches; protein complexes embedded in the nuclear envelope mediate direct or indirect linkages between the microtubule cytoskeleton and the nuclear envelope.\" [GOC:mah, PMID:18692466]","metadata":null},{"id":"fe5975abdab840ae921ecde4863e0a57","type":"GO_TERM","name":"microtubule organizing center attachment site organization","canonical_id":"go:GO:0034994","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a microtubule organizing center attachment site. A microtubule organizing center attachment site is a region of the nuclear envelope to which a microtubule organizing center (MTOC) attaches.\" [GOC:mah, PMID:18692466]","metadata":null},{"id":"be7bd44d7cb040faa904153fdd8f8d09","type":"GO_TERM","name":"microtubule organizing center localization","canonical_id":"go:GO:0061842","description":"\"Any process in which the microtubule organizing center is transported to, and/or maintained in, a specific location within the cell.\" [PMID:21281821]","metadata":null},{"id":"c236b0ed5cd545c0b378ac935ad2a657","type":"GO_TERM","name":"microtubule organizing center organization","canonical_id":"go:GO:0031023","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a microtubule organizing center, a structure from which microtubules grow.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"664a1d49c3d246149c3d872b6b01cb7d","type":"GO_TERM","name":"microtubule plus end polymerase activity","canonical_id":"go:GO:0061863","description":"\"Catalysis of the transfer of tubulin dimers to the plus end of a microtubule. The reaction is reversible depending on the availability of dimers.\" [PMID:27872152]","metadata":null},{"id":"77ca46c6c116438692edaea66ccfe71d","type":"GO_TERM","name":"microtubule plus-end","canonical_id":"go:GO:0035371","description":"\"The growing (plus) end of a microtubule. In vitro, microtubules polymerize more quickly at the plus end than at the minus end. In vivo, microtubule growth occurs only at the plus end, and the plus end switches between periods of growth and shortening, a behavior known as dynamic instability.\" [GOC:bf, GOC:lb, PMID:12700769, PMID:16643273]","metadata":null},{"id":"5ddeba82a1844e9daf519750586a5e1c","type":"GO_TERM","name":"microtubule plus-end binding","canonical_id":"go:GO:0051010","description":"\"Binding to the plus end of a microtubule.\" [GOC:ai, PMID:14557818, PMID:14614826]","metadata":null},{"id":"d62d04687fb2426d8021a6624cbbad0c","type":"GO_TERM","name":"microtubule plus-end directed mitotic chromosome migration","canonical_id":"go:GO:0099606","description":"\"The cell cycle process in which chromosomes that are laterally attached to one or more mitotic spindle microtubules migrate towards the spindle equator via plus-end-directed movement along the microtubules. This process is part of mitotic metaphase plate congression.\" [GOC:dos, PMID:26258632, PMID:26705896]","metadata":null},{"id":"887851f635b74b3a8cd5438a7dbe8dbe","type":"GO_TERM","name":"microtubule polymerization","canonical_id":"go:GO:0046785","description":"\"The addition of tubulin heterodimers to one or both ends of a microtubule.\" [GOC:ai, GOC:curators]","metadata":null},{"id":"e2e273c4af5c4f2fbd19381b92805be8","type":"GO_TERM","name":"microtubule polymerization based movement","canonical_id":"go:GO:0099098","description":"\"The movement of a cellular component as a result of microtubule polymerization.\" [GOC:cjm, ISBN:0815316194]","metadata":null},{"id":"34b67fc0b1d34c1dbf78782981266fbe","type":"GO_TERM","name":"microtubule polymerization based protein transport","canonical_id":"go:GO:0099112","description":"\"The transport of a protein driven by polymerization of a microtubule to which it is attached.\" [GOC:dos, GOC:vw, PMID:11018050]","metadata":null},{"id":"344931f3b7b94861aa299fa37874c1cf","type":"GO_TERM","name":"microtubule polymerization based protein transport to cell tip cortex","canonical_id":"go:GO:0099110","description":"\"The transport of a protein to the cortex of the cell tip, driven by polymerization of a microtubule to which the protein is attached.\" [GOC:dos, GOC:vw, PMID:11018050]","metadata":null},{"id":"ac666d1948734bb09ac97a35341515f8","type":"GO_TERM","name":"microtubule polymerization or depolymerization","canonical_id":"go:GO:0031109","description":"\"Assembly or disassembly of microtubules by the addition or removal of tubulin heterodimers from a microtubule.\" [GOC:mah]","metadata":null},{"id":"36dc4995fa0c4701aaf90990e4c4f1a4","type":"GO_TERM","name":"microtubule severing","canonical_id":"go:GO:0051013","description":"\"The process in which a microtubule is broken down into smaller segments. Severing enzymes remove dimers from the middle of the filament to create new ends, unlike depolymerizing kinesins that use ATP to uncap microtubules at their ends.\" [GOC:ai, PMID:27037673]","metadata":null},{"id":"bc1f0161adbd43739519fd82777527cf","type":"GO_TERM","name":"microtubule severing ATPase activity","canonical_id":"go:GO:0008568","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate. Catalysis of the severing of a microtubule at a specific spot along its length, coupled to the hydrolysis of ATP.\" [PMID:10910766]","metadata":null},{"id":"d9e0feac3f3a48e887380a5967dc9556","type":"GO_TERM","name":"microtubule site clamp","canonical_id":"go:GO:1990644","description":"\"The binding activity of a molecule that attaches the spindle microtubules to the kinetochore.\" [PMID:20723757]","metadata":null},{"id":"d33ac427d3d04f7da621b9cb8c9ad799","type":"GO_TERM","name":"microtubule sliding","canonical_id":"go:GO:0051012","description":"\"The movement of one microtubule along another microtubule.\" [PMID:14557818, PMID:14614826]","metadata":null},{"id":"15a9570a95e34b578270b7a0aba14512","type":"GO_TERM","name":"microtubule stabilizing activity","canonical_id":"go:GO:0140778","description":"\"A protein-containing complex stabilizing activity that prevents dissociation of microtubules.\" [PMID:34970964]","metadata":null},{"id":"3cb986dcd35f4c448e824f62992c070d","type":"GO_TERM","name":"microtubule-based movement","canonical_id":"go:GO:0007018","description":"\"A microtubule-based process that results in the movement of organelles, other microtubules, or other cellular components. Examples include motor-driven movement along microtubules and movement driven by polymerization or depolymerization of microtubules.\" [GOC:cjm, ISBN:0815316194]","metadata":null},{"id":"bdfba5d13379486e806daca830aa7d93","type":"GO_TERM","name":"microtubule-based peroxisome localization","canonical_id":"go:GO:0060152","description":"\"The microtubule-based process in which a peroxisome is transported to, and/or maintained in, a specific location. A peroxisome is a small membrane-bounded organelle that uses dioxygen (O2) to oxidize organic molecules.\" [GOC:dph, PMID:16449325]","metadata":null},{"id":"abe9211ece15437a92cb9be3b367df52","type":"GO_TERM","name":"microtubule-based process","canonical_id":"go:GO:0007017","description":"\"Any cellular process that depends upon or alters the microtubule cytoskeleton, that part of the cytoskeleton comprising microtubules and their associated proteins.\" [GOC:mah]","metadata":null},{"id":"cf5a7f21bbee4b099d5463a40a2bf193","type":"GO_TERM","name":"microtubule-based protein transport","canonical_id":"go:GO:0099118","description":"\"A microtubule-based process that results in the transport of proteins.\" [GOC:vw]","metadata":null},{"id":"7fdaa8b4e5fd4010932af4efdc89c09d","type":"GO_TERM","name":"microtubule-based transport","canonical_id":"go:GO:0099111","description":"\"A microtubule-based process that results in the transport of organelles, other microtubules, or other cellular components. Examples include motor-driven movement along microtubules and movement driven by polymerization or depolymerization of microtubules.\" [GOC:cjm, ISBN:0815316194]","metadata":null},{"id":"c913b0e5f50243628c200a04ebb1a01a","type":"GO_TERM","name":"microtubule-dependent intracellular transport of viral material","canonical_id":"go:GO:0075519","description":"\"The directed movement of the viral genome or viral particle within the host cell cytoplasm along host microtubules. Microtubule-dependent transport involves motor proteins like dynein and kinesin and is mostly used by viruses that target their genomes to the nucleus.\" [VZ:983]","metadata":null},{"id":"6589cfff9e80437a9f6059c48542935d","type":"GO_TERM","name":"microtubule-dependent intracellular transport of viral material towards cell periphery","canonical_id":"go:GO:0039701","description":"\"The directed movement of the viral genome or a viral particle towards the cell periphery using host microtubules. Mostly used by viruses that replicate their genome near or in the nucleus to allows newly assembled viral progeny to reach the plasma membrane.\" [UniProtKB-KW:KW-1189, VZ:1816]","metadata":null},{"id":"2c31f150d31f476db275a887175bd73f","type":"GO_TERM","name":"microtubule-dependent intracellular transport of viral material towards nucleus","canonical_id":"go:GO:0075521","description":"\"The directed movement of a virus, or part of a virus, towards the host cell nucleus using host microtubules.\" [UniProtKB-KW:KW-1177, VZ:983]","metadata":null},{"id":"7e7ed221406c4c6b9c7f35406602c7f6","type":"GO_TERM","name":"microvesicle","canonical_id":"go:GO:1990742","description":"\"An extracellular vesicle released from the plasma membrane and ranging in size from about 100 nm to 1000 nm.\" [GOC:vesicles, PMID:22418571, PMID:24009894, Wikipedia:Microvesicles]","metadata":null},{"id":"748e70799c274397b908502aad1899d7","type":"GO_TERM","name":"microvillar actin bundle","canonical_id":"go:GO:0097516","description":"\"A parallel bundle of actin filaments at the core of a microvillus.\" [GOC:cjm, GOC:mah]","metadata":null},{"id":"da739c31256643708d941962a46403d8","type":"GO_TERM","name":"microvillar actin bundle assembly","canonical_id":"go:GO:0030034","description":"\"Assembly of the parallel bundle of actin filaments at the core of a microvillus.\" [GOC:mah]","metadata":null},{"id":"563c4a0a95674cd594c26004752b4115","type":"GO_TERM","name":"microvillus","canonical_id":"go:GO:0005902","description":"\"Thin cylindrical membrane-covered projections on the surface of an animal cell containing a core bundle of actin filaments. Present in especially large numbers on the absorptive surface of intestinal cells.\" [ISBN:0815316194]","metadata":null},{"id":"6fef1e808f1a42dd9fc057a834691684","type":"GO_TERM","name":"microvillus assembly","canonical_id":"go:GO:0030033","description":"\"Formation of a microvillus, a thin cylindrical membrane-covered projection on the surface of a cell.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"3eb1848c2f4c4769bc2f627040b95288","type":"GO_TERM","name":"microvillus membrane","canonical_id":"go:GO:0031528","description":"\"The portion of the plasma membrane surrounding a microvillus.\" [GOC:mah]","metadata":null},{"id":"fbd4c2aeab58469d84334caf1959d105","type":"GO_TERM","name":"microvillus organization","canonical_id":"go:GO:0032528","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a microvillus, a thin cylindrical membrane-covered projection on the surface of a cell.\" [GOC:mah]","metadata":null},{"id":"25a8543eb4844558830b1d997004d455","type":"GO_TERM","name":"micturition","canonical_id":"go:GO:0060073","description":"\"The regulation of body fluids process in which parasympathetic nerves stimulate the bladder wall muscle to contract and expel urine from the body.\" [GOC:dph]","metadata":null},{"id":"3863e9140f4f470792b44eeb3d08a28c","type":"DRUG","name":"midazolam","canonical_id":"mesh:D008874","description":null,"metadata":null},{"id":"581c496c213f4a2694e5922c1cdf5b64","type":"GO_TERM","name":"midbody","canonical_id":"go:GO:0030496","description":"\"A thin cytoplasmic bridge formed between daughter cells at the end of cytokinesis. The midbody forms where the contractile ring constricts, and may persist for some time before finally breaking to complete cytokinesis.\" [ISBN:0815316194]","metadata":null},{"id":"ad003704cebd4d21b4b3d750b7660630","type":"GO_TERM","name":"midbody abscission","canonical_id":"go:GO:0061952","description":"\"The process by which the midbody, the cytoplasmic bridge that connects the two prospective daughter cells, is severed at the end of mitotic cytokinesis, resulting in two separate daughter cells.\" [PMID:12737809, PMID:29903934]","metadata":null},{"id":"97c0ea87119e4bd5a383003ddc01e628","type":"GO_TERM","name":"midbrain development","canonical_id":"go:GO:0030901","description":"\"The process whose specific outcome is the progression of the midbrain over time, from its formation to the mature structure. The midbrain is the middle division of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes a ventral part containing the cerebral peduncles and a dorsal tectum containing the corpora quadrigemina and that surrounds the aqueduct of Sylvius connecting the third and fourth ventricles).\" [PMID:4975589, PMID:4992177]","metadata":null},{"id":"26fb4b028ed240daaeb9596250b8f369","type":"GO_TERM","name":"midbrain dopaminergic neuron differentiation","canonical_id":"go:GO:1904948","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a midbrain dopaminergic neuron.\" [GO_REF:0000086, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:17331494, PMID:19122665]","metadata":null},{"id":"c492d2bb0c22498482ef275fbca549e7","type":"GO_TERM","name":"midbrain morphogenesis","canonical_id":"go:GO:1904693","description":"\"The developmental process by which a midbrain is generated and organized.\" [GO_REF:0000083, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21347250]","metadata":null},{"id":"296972a4eaf346b6a30f25d4a5a9c3da","type":"GO_TERM","name":"midbrain-hindbrain boundary development","canonical_id":"go:GO:0030917","description":"\"The process whose specific outcome is the progression of the midbrain-hindbrain boundary over time, from its formation to the mature structure. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages.\" [GOC:dgh]","metadata":null},{"id":"78337d58a4854ebcb7910c733816d776","type":"GO_TERM","name":"midbrain-hindbrain boundary initiation","canonical_id":"go:GO:0021547","description":"\"The regionalization process that gives rise to the midbrain-hindbrain boundary. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages. An organizing center at the boundary patterns the midbrain and hindbrain primordia of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:isa_complete, GOC:jid, PMID:15541513]","metadata":null},{"id":"4d47b108fd234a47bbe44c1dc1f690e8","type":"GO_TERM","name":"midbrain-hindbrain boundary maturation","canonical_id":"go:GO:0021732","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the midbrain-hindbrain boundary to attain its fully functional state. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages. An organizing center at the boundary patterns the midbrain and hindbrain primordia of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15541513]","metadata":null},{"id":"deddfdaa59b94f2690977d166e8dff18","type":"GO_TERM","name":"midbrain-hindbrain boundary maturation during brain development","canonical_id":"go:GO:0022004","description":"\"A developmental process occurring after the brain has been specified along the neural axis that is required for the midbrain-hindbrain boundary to attain its fully functional state. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages. An organizing center at the boundary patterns the midbrain and hindbrain primordia of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15541513]","metadata":null},{"id":"640c6e5c350c4fbc9ce3f14f89317597","type":"GO_TERM","name":"midbrain-hindbrain boundary maturation during neural plate development","canonical_id":"go:GO:0022005","description":"\"A developmental process occurring before the brain has been specified along the neural axis that is required for the midbrain-hindbrain boundary to attain its fully functional state. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages. An organizing center at the boundary patterns the midbrain and hindbrain primordia of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15541513]","metadata":null},{"id":"7fd0dbd780ac405a9e13a4a4b996338b","type":"GO_TERM","name":"midbrain-hindbrain boundary morphogenesis","canonical_id":"go:GO:0021555","description":"\"The process in which the anatomical structure of the midbrain-hindbrain boundary is generated and organized. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages. An organizing center at the boundary patterns the midbrain and hindbrain primordia of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15541513]","metadata":null},{"id":"e4ab8d7dc8ed4277b87fb1e2e7a51045","type":"GO_TERM","name":"midbrain-hindbrain boundary structural organization","canonical_id":"go:GO:0021552","description":"\"The process that contributes to the act of creating the structural organization of the midbrain-hindbrain boundary structure. The midbrain-hindbrain domain of the embryonic brain is comprised of the mesencephalic vesicle and the first rhombencephalic vesicle at early somitogenesis stages. An organizing center at the boundary patterns the midbrain and hindbrain primordia of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15541513]","metadata":null},{"id":"f5b1e12458f749b38b92ed6c09bb7c84","type":"GO_TERM","name":"midchain alkane hydroxylase activity","canonical_id":"go:GO:0080133","description":"\"Catalysis of the conversion of an alkane to a secondary alcohol.\" [PMID:17905869]","metadata":null},{"id":"127f51a837244ac089a8656922cac921","type":"GO_TERM","name":"middle ear morphogenesis","canonical_id":"go:GO:0042474","description":"\"The process in which the anatomical structures of the middle ear are generated and organized. The middle ear is the air-filled cavity within the skull of vertebrates that lies between the outer ear and the inner ear. It is linked to the pharynx (and therefore to outside air) via the Eustachian tube and in mammals contains the three ear ossicles, which transmit auditory vibrations from the outer ear (via the tympanum) to the inner ear (via the oval window).\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"37b153e2870947d4bbee05c41bddd47e","type":"GO_TERM","name":"middle lamella","canonical_id":"go:GO:0009519","description":"\"Layer of intercellular material, chiefly pectic substances, cementing together the primary walls of contiguous cells.\" [ISBN:0471245208]","metadata":null},{"id":"29efa734dfad4f3c9693d7870be3126b","type":"GO_TERM","name":"middle viral transcription","canonical_id":"go:GO:0019084","description":"\"The viral transcription that takes place after early transcription in the viral life cycle, and which involves the transcription of genes required for replication.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"460519f4cb934f80a0ed655c94aad8cb","type":"GO_TERM","name":"midgut development","canonical_id":"go:GO:0007494","description":"\"The process whose specific outcome is the progression of the midgut over time, from its formation to the mature structure. The midgut is the middle part of the alimentary canal from the stomach, or entrance of the bile duct, to, or including, the large intestine.\" [GOC:jid, UBERON:0001045]","metadata":null},{"id":"2e2760cc4f8648ffafb06663d1d33550","type":"DRUG","name":"midostaurin","canonical_id":"gtopdb:5702","description":null,"metadata":null},{"id":"8046f280f5f247949afd8891c8c83294","type":"DRUG","name":"midostaurin","canonical_id":"mesh:C059539","description":null,"metadata":null},{"id":"0103dfdde5b940c58a614b8caff4cdfc","type":"DRUG","name":"midostaurin","canonical_id":"chembl:CHEMBL608533","description":null,"metadata":null},{"id":"4ade9a7d790141359cbcaa62a3ef9e64","type":"DRUG","name":"mifepristone","canonical_id":"gtopdb:2805","description":null,"metadata":null},{"id":"9ce1beeb5d4145fcaee82d93f2426cc7","type":"DRUG","name":"mifepristone","canonical_id":"chembl:CHEMBL1276308","description":null,"metadata":null},{"id":"f79d8f5fb07b4bef99590e0948e720c3","type":"DRUG","name":"migalastat","canonical_id":"mesh:C090092","description":null,"metadata":null},{"id":"8e75e634db0c4da28b3d9a5186321841","type":"DRUG","name":"miglitol","canonical_id":"gtopdb:4842","description":null,"metadata":null},{"id":"78ccb3a11bfe4e5cb0f375e81a8390ff","type":"DRUG","name":"miglitol","canonical_id":"chembl:CHEMBL1561","description":null,"metadata":null},{"id":"f268bc5d1f9c4bee98915f2264c6d0f3","type":"DRUG","name":"miglustat","canonical_id":"gtopdb:4841","description":null,"metadata":null},{"id":"313cde8fdf054edcb99c0946c123ecaa","type":"DRUG","name":"miglustat","canonical_id":"mesh:C059896","description":null,"metadata":null},{"id":"c1ddd4914e5346c8b3eec727423936eb","type":"DRUG","name":"miglustat","canonical_id":"chembl:CHEMBL1029","description":null,"metadata":null},{"id":"90759afe900742c3a6f76c7a20b40e28","type":"GO_TERM","name":"migracytosis","canonical_id":"go:GO:0140495","description":"\"A cell migration-dependent mechanism for releasing cellular contents.\" [PMID:25342562]","metadata":null},{"id":"21a6dc2be85d42ce919d77e92bb36b04","type":"DISEASE","name":"migraine disorder","canonical_id":"mondo:0005277","description":null,"metadata":null},{"id":"865566d311794c2ba1aebf1f8831b060","type":"GO_TERM","name":"migrasome","canonical_id":"go:GO:0140494","description":"\"A vesicular organelle that forms on retraction fibers behind migrating cells and mediates the release of cytoplasmic contents during cell migration.\" [PMID:25342562, PMID:31371827]","metadata":null},{"id":"ded1d712360640a3a7b5289a165a5470","type":"GO_TERM","name":"migration in host","canonical_id":"go:GO:0044001","description":"\"The directional movement of an organism from one place to another within its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"32a6b3ead61e4559a9b22fab3fe97bfe","type":"DISEASE","name":"mild hemophilia A","canonical_id":"mondo:0015721","description":null,"metadata":null},{"id":"0ac322dbb2ba4890861e9b166b866b54","type":"GO_TERM","name":"milk ejection reflex","canonical_id":"go:GO:0060156","description":"\"A reflex that occurs in response to suckling, beginning with a nerve impulse from a receptor in the mammary gland and ending with the ejection of milk from the gland. Signaling never reaches a level of consciousness.\" [GOC:cjm, GOC:dph, GOC:mr, GOC:st]","metadata":null},{"id":"d4d3c73844594a888a6a04686f57d8f8","type":"DRUG","name":"milnacipran","canonical_id":"gtopdb:7436","description":null,"metadata":null},{"id":"a54eb14db8d44ab9b4110bf119a1c27c","type":"DRUG","name":"milrinone","canonical_id":"gtopdb:5225","description":null,"metadata":null},{"id":"df6aa51d01d84ea597a3484afbacd44f","type":"COMBINATION_TREATMENT","name":"milrinone + nimodipine","canonical_id":"ctgov_combo:ctgov-combo-6504a87048c9374f","description":null,"metadata":null},{"id":"afe59da14f7a4036889c27d6e7c3735e","type":"DRUG","name":"miltefosine","canonical_id":"mesh:C039128","description":null,"metadata":null},{"id":"2ce4a046e3c84f6aab772592b6ef6456","type":"GO_TERM","name":"miltiradiene biosynthetic process","canonical_id":"go:GO:1901946","description":"\"The chemical reactions and pathways resulting in the formation of miltiradiene.\" [GOC:TermGenie, PMID:22027823]","metadata":null},{"id":"b09c79e8c2fa4efb998f3b603d974bc7","type":"GO_TERM","name":"miltiradiene catabolic process","canonical_id":"go:GO:1901945","description":"\"The chemical reactions and pathways resulting in the breakdown of miltiradiene.\" [GOC:TermGenie, PMID:22027823]","metadata":null},{"id":"3e37dd118f7a4089b1aea7003c6b6d8a","type":"GO_TERM","name":"miltiradiene synthase activity","canonical_id":"go:GO:0062205","description":"\"Catalysis of the reaction: (+)-copalyl diphosphate = diphosphate + miltiradiene.\" [PMID:24990389, RHEA:33983]","metadata":null},{"id":"fdeb28abba0a43b987a6186ddbd51ad0","type":"GO_TERM","name":"mimosinase activity","canonical_id":"go:GO:0050101","description":"\"Catalysis of the reaction: L-mimosine + H2O = 3-hydroxy-4H-pyrid-4-one + L-serine.\" [GOC:curators, RHEA:75355]","metadata":null},{"id":"362e1c8829fd4526a0f3ad84795bba93","type":"DISEASE","name":"mineral metabolism disease","canonical_id":"mondo:0000226","description":null,"metadata":null},{"id":"2e1c0a77bf8a4ea882846f15927b2968","type":"GO_TERM","name":"mineralocorticoid biosynthetic process","canonical_id":"go:GO:0006705","description":"\"The chemical reactions and pathways resulting in the formation of mineralocorticoids, hormonal C21 corticosteroids synthesized from cholesterol.\" [ISBN:0198506732]","metadata":null},{"id":"bfd29927e6a74521a81372d63b4a47ca","type":"GO_TERM","name":"mineralocorticoid catabolic process","canonical_id":"go:GO:0006712","description":"\"The chemical reactions and pathways resulting in the breakdown of mineralocorticoids, hormonal C21 corticosteroids synthesized from cholesterol.\" [ISBN:0198506732]","metadata":null},{"id":"2e167c6d4270438397b33f37039d238f","type":"GO_TERM","name":"mineralocorticoid metabolic process","canonical_id":"go:GO:0008212","description":"\"The chemical reactions and pathways involving mineralocorticoids, hormonal C21 corticosteroids synthesized from cholesterol. Mineralocorticoids act primarily on water and electrolyte balance.\" [ISBN:0198506732]","metadata":null},{"id":"cf521ac5d4c64f7194ceec6dc1f432f3","type":"GO_TERM","name":"mineralocorticoid secretion","canonical_id":"go:GO:0035931","description":"\"The regulated release of any mineralocorticoid into the circulatory system. Mineralocorticoids are a class of steroid hormones that regulate water and electrolyte metabolism.\" [GOC:sl]","metadata":null},{"id":"82355433aec1481ab9bfbbb4cc98280c","type":"GO_TERM","name":"mini excitatory postsynaptic potential","canonical_id":"go:GO:0098816","description":"\"A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell, induced by the spontaneous release of a single vesicle of an excitatory neurotransmitter into the synapse.\" [GOC:dos]","metadata":null},{"id":"8c5e0e942aae46d0af655555002a55c3","type":"DRUG","name":"minocycline","canonical_id":"mesh:D008911","description":null,"metadata":null},{"id":"f75acbd947c74b8eb260f83e6ec67ce2","type":"GO_TERM","name":"minor groove of adenine-thymine-rich DNA binding","canonical_id":"go:GO:0003680","description":"\"Binding to a DNA structure formed by the minor groove of adenine-thymine-rich DNA regions. Examples of proteins having this function are AT-rich interaction domain (ARID)-containing proteins.\" [GOC:jl, PMID:10545119, PMID:15802641, PMID:26223912, PMID:2670564]","metadata":null},{"id":"c09bdc1a914e44fc9c313f33248bbd67","type":"GO_TERM","name":"minor mitochondrial derivative","canonical_id":"go:GO:0016009","description":"\"The smaller of the two mitochondrial derivatives that arise by the unfolding of the Nebenkern during flagellum elongation.\" [GOC:mah, PMID:17123504, PMID:24211517, PMID:30802236]","metadata":null},{"id":"7d9343b5978c48baa679111a94c6c040","type":"DRUG","name":"minoxidil","canonical_id":"mesh:D008914","description":null,"metadata":null},{"id":"87c6a20035b54d7f965099dc77a99bf9","type":"GO_TERM","name":"minus-end directed microfilament motor activity","canonical_id":"go:GO:0060001","description":"\"A motor activity that generates movement along a microfilament towards the minus end, driven by ATP hydrolysis. The minus end of an actin filament is the end that does not preferentially add actin monomers.\" [GOC:dph, PMID:10519557]","metadata":null},{"id":"ebab23f48f5b44bda5a68328de89547a","type":"GO_TERM","name":"minus-end directed microtubule sliding","canonical_id":"go:GO:0031534","description":"\"The movement of one microtubule along another microtubule, where the motion is directed towards the minus ends of the microtubules.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"004e989c81164899a3b13f2955d5ef83","type":"GO_TERM","name":"minus-end kinesin complex","canonical_id":"go:GO:0005872","description":"\"Any complex that includes a dimer of molecules from the kinesin superfamily and any associated proteins, and moves towards the minus end of a microtubule.\" [GOC:mah]","metadata":null},{"id":"4c208ebddf5b44cfa5c41922975112c6","type":"GO_TERM","name":"minus-end specific microtubule depolymerization","canonical_id":"go:GO:0036078","description":"\"The removal of tubulin heterodimers from the minus end of a microtubule.\" [GOC:sart, PMID:17452528]","metadata":null},{"id":"fb883223f0bb42f0be8d32354acc7c41","type":"GO_TERM","name":"minus-end-directed microtubule motor activity","canonical_id":"go:GO:0008569","description":"\"A motor activity that generates movement along a microtubule toward the minus end, driven by ATP hydrolysis.\" [GOC:mah, GOC:vw, PMID:15659646, PMID:32842864]","metadata":null},{"id":"bbfadf8e23914d56bd0b26fdbca2dd5d","type":"GO_TERM","name":"minus-end-directed organelle transport along microtubule","canonical_id":"go:GO:0072385","description":"\"The directed movement of an organelle towards the minus end of a microtubule, mediated by motor proteins. This process begins with the attachment of an organelle to a microtubule, and ends when the organelle reaches its final destination.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"98cc8e5a08d64c32b4a809cec3b9bff1","type":"GO_TERM","name":"minus-end-directed vesicle transport along microtubule","canonical_id":"go:GO:0072382","description":"\"The directed movement of a vesicle towards the minus end of a microtubule, mediated by motor proteins. This process begins with the attachment of a vesicle to a microtubule, and ends when the vesicle reaches its final destination.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d0aa5d83c4494526b0378fee3d63170d","type":"DRUG","name":"mirabegron","canonical_id":"gtopdb:7445","description":null,"metadata":null},{"id":"e33455a4bb1c4f8eb405ae6c552e3b97","type":"DRUG","name":"mirabegron","canonical_id":"chembl:CHEMBL2095212","description":null,"metadata":null},{"id":"b11bf06f6e3a46099e50b7f7e6823526","type":"COMBINATION_TREATMENT","name":"mirabegron + oxybutynin + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-277fe7a98eed3b5b","description":null,"metadata":null},{"id":"05a5100b6ba945b69d166be1ecad8006","type":"COMBINATION_TREATMENT","name":"mirabegron + paroxetine","canonical_id":"ctgov_combo:ctgov-combo-1619fdb7a0084b27","description":null,"metadata":null},{"id":"ef9479f66aa7410a8a696198c059fb13","type":"COMBINATION_TREATMENT","name":"mirabegron + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-d735df09511a8070","description":null,"metadata":null},{"id":"7a341999dafa4aa19952f3a595cbf46a","type":"COMBINATION_TREATMENT","name":"mirabegron + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-1a53606a85cebe7e","description":null,"metadata":null},{"id":"476ae238e8b34b079781bd47ac3398a9","type":"COMBINATION_TREATMENT","name":"mirabegron + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-c6c0e44d11167498","description":null,"metadata":null},{"id":"22e9e2ab762d46b285ce887e2ea35d2f","type":"COMBINATION_TREATMENT","name":"mirabegron + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-cb19a64038169ba0","description":null,"metadata":null},{"id":"37045eb5cb4146a58ddb2ccf057df165","type":"COMBINATION_TREATMENT","name":"mirabegron + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-5ffc5f151be1f277","description":null,"metadata":null},{"id":"17a9802a863e4b1095e2ad22096fac4b","type":"COMBINATION_TREATMENT","name":"mirabegron + solifenacin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-c9bb83e9849e211c","description":null,"metadata":null},{"id":"83fdb1eb0d494965b2ccec9baf8abd86","type":"COMBINATION_TREATMENT","name":"mirabegron + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-37e465faedd4c3ee","description":null,"metadata":null},{"id":"9b2467a1666b4f09954d5291acc109f2","type":"COMBINATION_TREATMENT","name":"mirabegron + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-07d146aee9f8e23a","description":null,"metadata":null},{"id":"0418d7475c0f474989c25e32cfdaa89a","type":"COMBINATION_TREATMENT","name":"mirabegron + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-787a8c51911ae6d3","description":null,"metadata":null},{"id":"8c07f22902c24dfbb4df588297062025","type":"COMBINATION_TREATMENT","name":"mirabegron + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-5c9385fba3fe089d","description":null,"metadata":null},{"id":"351cc590319a493281e0a3d2104d4689","type":"DRUG","name":"mirdametinib","canonical_id":"gtopdb:7935","description":null,"metadata":null},{"id":"4de9d36bd382450c8ba8a80b9e02df21","type":"DRUG","name":"mirdametinib","canonical_id":"chembl:CHEMBL507361","description":null,"metadata":null},{"id":"db619e73e60d42fcb6ec7dd87027544d","type":"COMBINATION_TREATMENT","name":"mirdametinib + probenecid","canonical_id":"ctgov_combo:ctgov-combo-c1a6e3ab1adbf3af","description":null,"metadata":null},{"id":"9151c227a7564284a27a5ac2ef3f79d0","type":"DRUG","name":"mirikizumab","canonical_id":"gtopdb:9846","description":null,"metadata":null},{"id":"924ba7fe323a4bd3a59cfdbaaeed1b73","type":"DRUG","name":"mirikizumab","canonical_id":"chembl:CHEMBL3990014","description":null,"metadata":null},{"id":"622e85e8d09348ff83c2f5f2645712c1","type":"COMBINATION_TREATMENT","name":"mirikizumab + risankizumab + ustekinumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-1b3cc1e8a475f76f","description":null,"metadata":null},{"id":"0ea14c2eb2cd427fa620506526af3120","type":"COMBINATION_TREATMENT","name":"mirikizumab + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-f28ec901e9febb0d","description":null,"metadata":null},{"id":"5a405231c2fe48fb989883810eec1cc5","type":"DRUG","name":"mirodenafil","canonical_id":"mesh:C528396","description":null,"metadata":null},{"id":"342a9ad732e74d068aaf105ed2ca7f47","type":"DRUG","name":"mirtazapine","canonical_id":"gtopdb:7241","description":null,"metadata":null},{"id":"ffe621b0428f46df943058648e224e17","type":"DRUG","name":"mirtazapine","canonical_id":"chembl:CHEMBL654","description":null,"metadata":null},{"id":"48639fe86e7b4fad86e1407429340ad6","type":"COMBINATION_TREATMENT","name":"mirtazapine + sertraline","canonical_id":"ctgov_combo:ctgov-combo-85bd876b2a4d84cd","description":null,"metadata":null},{"id":"ae773e0e6dd94601900b55c3ef9118d6","type":"GO_TERM","name":"misfolded RNA binding","canonical_id":"go:GO:0034336","description":"\"Binding to an RNA molecule that has assumed an incorrect conformation.\" [GOC:mah, PMID:10393192]","metadata":null},{"id":"e8c4af0c31aa40f481038799ac499b88","type":"GO_TERM","name":"misfolded protein binding","canonical_id":"go:GO:0051787","description":"\"Binding to a misfolded protein.\" [GOC:ai]","metadata":null},{"id":"e0dc8d3f4f4c46a5b96dfc936ba7731b","type":"GO_TERM","name":"misfolded protein transport","canonical_id":"go:GO:0070843","description":"\"The directed movement of misfolded proteins in a cell, including the movement of proteins between specific compartments or structures within a cell.\" [GOC:BHF, GOC:mah, PMID:14675537]","metadata":null},{"id":"78454983bcd04786ba972da52dcb66cc","type":"GO_TERM","name":"mismatch base pair DNA N-glycosylase activity","canonical_id":"go:GO:0000700","description":"\"Catalysis of the removal of single bases present in mismatches by the cleavage the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site.\" [GOC:elh, PMID:9224623]","metadata":null},{"id":"59df1e6c9cf947dfa27143ca2c90cd72","type":"GO_TERM","name":"mismatch repair","canonical_id":"go:GO:0006298","description":"\"A system for the correction of errors in which an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. The mismatch repair system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops and heterologies generated during DNA replication and recombination.\" [ISBN:0198506732, PMID:11687886]","metadata":null},{"id":"5139e13d518f4366a4f0e192462edde5","type":"GO_TERM","name":"mismatch repair complex","canonical_id":"go:GO:0032300","description":"\"Any complex formed of proteins that act in mismatch repair.\" [GOC:mah]","metadata":null},{"id":"79f5d4686da746638baca9415d9f1c42","type":"GO_TERM","name":"mismatch repair complex binding","canonical_id":"go:GO:0032404","description":"\"Binding to a mismatch repair complex.\" [GOC:vk]","metadata":null},{"id":"a883569f96be47968b033b6f6f68c946","type":"GO_TERM","name":"mismatch repair involved in maintenance of fidelity involved in DNA-dependent DNA replication","canonical_id":"go:GO:0070716","description":"\"A mismatch repair process that corrects errors introduced that ensures the accuracy of DNA replication.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d74934ece99548348c2d04339f2e03b3","type":"GO_TERM","name":"mismatched DNA binding","canonical_id":"go:GO:0030983","description":"\"Binding to a double-stranded DNA region containing one or more mismatches.\" [GOC:mah]","metadata":null},{"id":"897bc3233b794eb1bde63879ef0bf81f","type":"DRUG","name":"misoprostol (methyl ester)","canonical_id":"gtopdb:1936","description":null,"metadata":null},{"id":"8e6c18f962994142b75206b743adeb41","type":"DRUG","name":"misoprostol (methyl ester)","canonical_id":"chembl:CHEMBL606","description":null,"metadata":null},{"id":"6377ffc2d8e942d192ebc2fc143b07d0","type":"GO_TERM","name":"mithramycin dehydrogenase (NADPH) activity","canonical_id":"go:GO:0102357","description":"\"Catalysis of the reaction: mithramycin DK + NADPH + H+ = iso-mithramycin + NADP+. Note that  iso-mithramycin (iso-MTM) is a C2-epimer of mithramycin.  This intermediate appears to be biologically important because it is non-toxic, then exported out of the cell and finally spontaneously epimerized into the toxic mithramycin. This could represent a self-resistance mechanism against MTM toxicity.\" [PMID:31702856]","metadata":null},{"id":"390b8ce5b7024b73bbecdbb18f680d41","type":"DRUG","name":"mitiglinide","canonical_id":"mesh:C087255","description":null,"metadata":null},{"id":"b38cdd5412ab4f85997611ed3e180f4e","type":"GO_TERM","name":"mitochondria-associated endoplasmic reticulum membrane contact site","canonical_id":"go:GO:0044233","description":"\"A zone of apposition between endoplasmic-reticulum and mitochondrial membranes, structured by bridging complexes. These contact sites are thought to facilitate inter-organelle calcium and phospholipid exchange.\" [GOC:jl, PMID:19556461, PMID:22078959, PMID:29626751, PMID:29684109]","metadata":null},{"id":"416e8e08f8c144d68eb72b9ae5ec81ff","type":"GO_TERM","name":"mitochondria-associated ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0072671","description":"\"The chemical reactions and pathways resulting in the breakdown of proteins transported from mitochondria and targeted to cytoplasmic proteasomes for degradation as a response to oxidative stress conditions.\" [GOC:mcc, PMID:21070972, PMID:21109188]","metadata":null},{"id":"e28c547ba26447c787958b8c0b935c01","type":"GO_TERM","name":"mitochondria-nucleus signaling pathway","canonical_id":"go:GO:0031930","description":"\"The series of molecular signals that forms a pathway of communication from the mitochondria to the nucleus and initiates cellular changes in response to changes in mitochondrial function.\" [GOC:jh, PMID:15068799]","metadata":null},{"id":"3e270b8a795040c18d62fb73cb97430a","type":"GO_TERM","name":"mitochondrial 2-oxoadipate transmembrane transport","canonical_id":"go:GO:1990551","description":"\"The process in which 2-oxoadipate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:11013234]","metadata":null},{"id":"feb0619501824279af2f1656d6343c69","type":"GO_TERM","name":"mitochondrial 3'-phospho-5'-adenylyl sulfate transmembrane transport","canonical_id":"go:GO:1990554","description":"\"The process in which 3'-phospho-5'-adenylyl sulfate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:24296033]","metadata":null},{"id":"fea492ba0f4a4d40a68d16ab9a8a2aec","type":"GO_TERM","name":"mitochondrial 5'-adenylyl sulfate transmembrane transport","canonical_id":"go:GO:1990553","description":"\"The process in which 5'-adenylyl sulfate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:24296033]","metadata":null},{"id":"513c7d98a1104e399c8c8ad6dec0f7fa","type":"GO_TERM","name":"mitochondrial ADP transmembrane transport","canonical_id":"go:GO:0140021","description":"\"The process in which ADP is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:2541251]","metadata":null},{"id":"32b16f6e6c00449498ed29f7e219d007","type":"GO_TERM","name":"mitochondrial ATP synthesis coupled electron transport","canonical_id":"go:GO:0042775","description":"\"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP, as it occurs in the mitochondrial inner membrane or chloroplast thylakoid membrane.\" [GOC:mtg_sensu, ISBN:0716731363]","metadata":null},{"id":"58f8f729e605411d952557f2203e8886","type":"GO_TERM","name":"mitochondrial ATP transmembrane transport","canonical_id":"go:GO:1990544","description":"\"The process in which ATP is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:18485069]","metadata":null},{"id":"90a3e2a84fd246c7ae9d7bffc7e7db2e","type":"GO_TERM","name":"mitochondrial ATP-gated potassium channel activity","canonical_id":"go:GO:0062156","description":"\"Enables the ATP-dependent diffusion of a potassium ion across the mitochondrial inner membrane.\" [PMID:31435016]","metadata":null},{"id":"58d696bd9b7c4b4493d62648f3cf7098","type":"GO_TERM","name":"mitochondrial ATP-gated potassium channel complex","canonical_id":"go:GO:0062157","description":"\"A protein-containing complex that is capable of the ATP-dependent diffusion of a potassium ion across the mitochondrial inner membrane.\" [PMID:31435016]","metadata":null},{"id":"376fb2b7de7640ffae3445e9f8845403","type":"GO_TERM","name":"mitochondrial DNA catabolic process","canonical_id":"go:GO:0032043","description":"\"The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA.\" [GOC:mah]","metadata":null},{"id":"33b1b715f7f04734a3222290e06a2ac3","type":"DISEASE","name":"mitochondrial DNA depletion syndrome","canonical_id":"mondo:0018158","description":null,"metadata":null},{"id":"dca9efe698274b56b9d9adfedac6168c","type":"GO_TERM","name":"mitochondrial DNA metabolic process","canonical_id":"go:GO:0032042","description":"\"The chemical reactions and pathways involving mitochondrial DNA.\" [GOC:mah]","metadata":null},{"id":"281a0cb4d6fa47ad8420893a8143d6f7","type":"GO_TERM","name":"mitochondrial DNA repair","canonical_id":"go:GO:0043504","description":"\"The process of restoring mitochondrial DNA after damage.\" [PMID:12565799, PMID:15189144, PMID:16050976]","metadata":null},{"id":"979a13aa99714a97b5ade6e0a3f1429d","type":"GO_TERM","name":"mitochondrial DNA replication","canonical_id":"go:GO:0006264","description":"\"The process in which new strands of DNA are synthesized in the mitochondrion.\" [GOC:ai]","metadata":null},{"id":"8fa67011dbb942d98572d0fc4ca400b8","type":"GO_TERM","name":"mitochondrial DNA-directed RNA polymerase complex","canonical_id":"go:GO:0034245","description":"\"A DNA-directed RNA polymerase complex located in the mitochondrion. Mitochondrial RNA polymerase is composed of two subunits, a catalytic core, which resembles the enzymes from bacteriophage T7 and T3, and a specificity factor required for promoter recognition, which is similar to members of the eubacterial sigma factor family. In S. cerevisiae, these are encoded by the nuclear genes RPO41 and MTF1 and the specificity factor, required for promoter recognition and initiation, is not present in the elongating form.\" [GOC:krc, GOC:mah, PMID:7929382]","metadata":null},{"id":"4798ee1ef45f493ca798f8992f835e34","type":"GO_TERM","name":"mitochondrial FAD transmembrane transport","canonical_id":"go:GO:1990548","description":"\"The process in which FAD is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:14555654]","metadata":null},{"id":"24e7ddc6d4184f4db7c127f9a5dc790f","type":"GO_TERM","name":"mitochondrial L-ornithine transmembrane transport","canonical_id":"go:GO:1990575","description":"\"The process in which L-ornithine is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:9237680]","metadata":null},{"id":"dfccdd86d9f44cdd966bfc276147ed68","type":"GO_TERM","name":"mitochondrial NAD transmembrane transport","canonical_id":"go:GO:1990549","description":"\"The process in which NAD is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:16291748]","metadata":null},{"id":"7b21917cd18745f48fa2ca0b20dae46a","type":"GO_TERM","name":"mitochondrial RNA 3'-end processing","canonical_id":"go:GO:0000965","description":"\"Any process involved in forming the mature 3' end of an RNA molecule transcribed from a mitochondrial genome; occurs in the mitochondrion.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"392162d399354d818353afad93ad64e8","type":"GO_TERM","name":"mitochondrial RNA 5'-end processing","canonical_id":"go:GO:0000964","description":"\"Any process involved in forming the mature 5' end of an RNA molecule transcribed from a mitochondrial genome; occurs in the mitochondrion.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"4bd87c4b46f5416ebd07986515acb295","type":"GO_TERM","name":"mitochondrial RNA catabolic process","canonical_id":"go:GO:0000957","description":"\"The chemical reactions and pathways resulting in the breakdown of RNA transcribed from the mitochondrial genome and occurring in the mitochondrion.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"026d5ec837be477f9af0c0ca1fbd732a","type":"GO_TERM","name":"mitochondrial RNA localization","canonical_id":"go:GO:0019093","description":"\"Any process in which mitochondrial RNA is transported to, or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"675cedd10f3a45d7978407a14d0cba84","type":"GO_TERM","name":"mitochondrial RNA metabolic process","canonical_id":"go:GO:0000959","description":"\"The chemical reactions and pathways involving RNA transcribed from the mitochondrial genome and occurring in the mitochondrion.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"ae1c041203674b418af4de66fe666bb2","type":"GO_TERM","name":"mitochondrial RNA modification","canonical_id":"go:GO:1900864","description":"\"Any RNA modification that takes place in mitochondrion.\" [GOC:TermGenie]","metadata":null},{"id":"8a49b99727e7465ea30d16c9f1a097b9","type":"GO_TERM","name":"mitochondrial RNA polymerase general transcription initiation factor activity","canonical_id":"go:GO:0180066","description":"\"A general transcription initiation factor activity that contributes to transcription start site selection and transcription initiation by the mitochondrial RNA polymerase.\" [PMID:29149603]","metadata":null},{"id":"4fd516d3d6754309bcf45304cdefc736","type":"GO_TERM","name":"mitochondrial RNA processing","canonical_id":"go:GO:0000963","description":"\"The conversion of a primary RNA molecule transcribed from a mitochondrial genome into one or more mature RNA molecules; occurs in the mitochondrion.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"a40e583429204441a54aacb489257f57","type":"GO_TERM","name":"mitochondrial RNA surveillance","canonical_id":"go:GO:2000827","description":"\"The set of processes involved in identifying and degrading defective or aberrant RNAs that takes place in the mitochondrion.\" [PMID:19864255]","metadata":null},{"id":"870541bfd6eb42be85e9e7f84543efb7","type":"GO_TERM","name":"mitochondrial S-adenosyl-L-methionine transmembrane transport","canonical_id":"go:GO:1990543","description":"\"The process in which S-adenosyl-L-methionine is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:14609944]","metadata":null},{"id":"bf46e1d100db4b908307c7601ef30d8f","type":"GO_TERM","name":"mitochondrial [2Fe-2S] assembly complex","canonical_id":"go:GO:0099128","description":"\"A protein complex capable of forming 2Fe-2S clusters in mitochondria. In humans it consists of ISCU, NFS1, LYRM4, NDUFAB1 and FXN.\" [PMID:31101807, PMID:34660592]","metadata":null},{"id":"06c90c70ed6246b2976ab857046b347d","type":"GO_TERM","name":"mitochondrial [4Fe-4S] assembly complex","canonical_id":"go:GO:0120510","description":"\"A protein complex capable of condensing two 2Fe-2S clusters into one 4Fe-4S center in mitochondria. In S. cerevisiae, it consists of Isa1 and Isa2. In humans it consists of ISCA1 and ISCA2. Additional proteins may be present.\" [PMID:25347204, PMID:29079644, PMID:33711344, PMID:34660592]","metadata":null},{"id":"e42e1fc06fd544a3a452aa71b08da8cd","type":"GO_TERM","name":"mitochondrial alanyl-tRNA aminoacylation","canonical_id":"go:GO:0070143","description":"\"The process of coupling alanine to alanyl-tRNA in a mitochondrion, catalyzed by alanyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"4aae5ac26d1d43ffa3ac3a2a4c0ab012","type":"GO_TERM","name":"mitochondrial alpha-ketoglutarate transmembrane transport","canonical_id":"go:GO:1990550","description":"\"The process in which alpha-ketoglutarate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:11013234, PMID:20371607]","metadata":null},{"id":"1f3951c9bd28429e8b2fa4baff7a897f","type":"GO_TERM","name":"mitochondrial arginyl-tRNA aminoacylation","canonical_id":"go:GO:0070144","description":"\"The process of coupling arginine to arginyl-tRNA in a mitochondrion, catalyzed by arginyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"f1136328a3fb4642b0f925fa4762f510","type":"GO_TERM","name":"mitochondrial asparaginyl-tRNA aminoacylation","canonical_id":"go:GO:0070145","description":"\"The process of coupling asparagine to asparaginyl-tRNA in a mitochondrion, catalyzed by asparaginyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"255b827609f34d6b8ca6b6781a315a5c","type":"GO_TERM","name":"mitochondrial aspartyl-tRNA aminoacylation","canonical_id":"go:GO:0070146","description":"\"The process of coupling aspartate to aspartyl-tRNA in a mitochondrion, catalyzed by aspartyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"eadd6ca3b2e04821b945e19d8409b39c","type":"GO_TERM","name":"mitochondrial calcium ion homeostasis","canonical_id":"go:GO:0051560","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions within the cytoplasm of a cell or between mitochondria and their surroundings.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"5315d954b42a4101a4538d2513f4698f","type":"GO_TERM","name":"mitochondrial calcium ion transmembrane transport","canonical_id":"go:GO:0006851","description":"\"The process in which a calcium ion (Ca2+) is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [GOC:ai]","metadata":null},{"id":"d24cb591274343f4a19eb23fabc020a6","type":"GO_TERM","name":"mitochondrial chromosome","canonical_id":"go:GO:0000262","description":"\"A chromosome found in the mitochondrion of a eukaryotic cell.\" [GOC:mah]","metadata":null},{"id":"58c7891308b646629789212c2dc4eb15","type":"GO_TERM","name":"mitochondrial chromosome packaging","canonical_id":"go:GO:0090139","description":"\"A process in which mitochondrial chromosomal DNA and associated proteins organize into a compact, orderly structure.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"7452bec650ce4c618db365be37cdfa13","type":"GO_TERM","name":"mitochondrial citrate transmembrane transport","canonical_id":"go:GO:0006843","description":"\"The directed movement of citrate, 2-hydroxy-1,2,3-propanetricarboxylate, into or out of a mitochondrial matrix.\" [GOC:ai, PMID:20371607]","metadata":null},{"id":"62a6ebc5ffc746cdb03fde102e2a1cc9","type":"GO_TERM","name":"mitochondrial cloud","canonical_id":"go:GO:0032019","description":"\"A prominent mass in the cytoplasm of previtellogenic oocytes. The cloud contains both mitochondria and electron-dense granulofibrillar material (GFM) and is the source of germinal granule material.\" [PMID:6541166]","metadata":null},{"id":"4974009398ea472787854d70d71674ac","type":"GO_TERM","name":"mitochondrial coenzyme A transmembrane transport","canonical_id":"go:GO:1990559","description":"\"The process in which coenzyme A is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:11158296]","metadata":null},{"id":"dba70610b6bb467bb2f88875f71c6152","type":"GO_TERM","name":"mitochondrial complex I intermediate assembly complex","canonical_id":"go:GO:0160295","description":"\"A protein complex involved in mitochondrial respiratory chain complex I (MCI) assembly. The mitochondrial complex I intermediate assembly (MCIA) complex is an inner mitochondrial membrane complex required for the aggregation, arrangement and bonding together of the subunits of the ND2-module of MCI. In humans, the MCIA complex is formed from NDUFAF1, ACAD9, ECSIT, TMEM126B, TMEM186 and COA1.\" [PMID:32320651]","metadata":null},{"id":"ac1010674990485e8a20e88f25ac2dbe","type":"GO_TERM","name":"mitochondrial creatine kinase complex","canonical_id":"go:GO:0002187","description":"\"An octomeric protein complex having creatine kinase activity.\" [PMID:16236486]","metadata":null},{"id":"6111ff569b644540b935e6da0a619652","type":"GO_TERM","name":"mitochondrial crista","canonical_id":"go:GO:0030061","description":"\"Any of the inward folds of the mitochondrial inner membrane. Their number, extent, and shape differ in mitochondria from different tissues and organisms. They appear to be devices for increasing the surface area of the mitochondrial inner membrane, where the enzymes of electron transport and oxidative phosphorylation are found. Their shape can vary with the respiratory state of the mitochondria.\" [ISBN:0198506732]","metadata":null},{"id":"166a9ccf2c4e4278aaa3bcbea876101a","type":"GO_TERM","name":"mitochondrial crista junction","canonical_id":"go:GO:0044284","description":"\"A tubular structure of relatively uniform size that connects a mitochondrial crista to the mitochondrial inner boundary membrane.\" [GOC:mcc, PMID:21944719, PMID:21987634, PMID:22009199]","metadata":null},{"id":"d60ab4f7744c4928b96c8d5a26389575","type":"GO_TERM","name":"mitochondrial cysteinyl-tRNA aminoacylation","canonical_id":"go:GO:0070147","description":"\"The process of coupling L-cysteine to cysteinyl-tRNA in a mitochondrion, catalyzed by cysteinyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"99d101cce77f439db095095d140854f2","type":"GO_TERM","name":"mitochondrial degradosome","canonical_id":"go:GO:0045025","description":"\"A mitochondrial protein complex with 3' to 5' exoribonuclease activity that participates in intron-independent turnover and processing of mitochondrial transcripts. In humans, the mitochondrial degradosome is a pentameric complex, and in yeast it exists as a heterodimer.\" [PMID:10397341, PMID:9829834]","metadata":null},{"id":"b3a31464abfe454283a6ba63618b6ad3","type":"GO_TERM","name":"mitochondrial depolarization","canonical_id":"go:GO:0051882","description":"\"The process in which the potential difference across the mitochondrial membrane is reduced from its steady state level.\" [Wikipedia:Depolarization, Wikipedia:Mitochondrion]","metadata":null},{"id":"7c9d4e27f852459c8db1741e8df66912","type":"GO_TERM","name":"mitochondrial derivative","canonical_id":"go:GO:0016007","description":"\"The major and minor mitochondrial derivatives are the mitochondria of the sperm tail and derive by the unfolding of the Nebenkern during flagellum elongation.\" [GOC:ma]","metadata":null},{"id":"db15753c69b7419cbb591104ccd4cf91","type":"GO_TERM","name":"mitochondrial double-strand break repair","canonical_id":"go:GO:0097551","description":"\"The repair of double-strand breaks in mitochondrial DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix.\" [GOC:di, PMID:22214610]","metadata":null},{"id":"72252ba253d04bff883d7cabdfb22ffd","type":"GO_TERM","name":"mitochondrial double-strand break repair via homologous recombination","canonical_id":"go:GO:0097552","description":"\"The repair of a double-strand break in mitochondrial DNA in which the broken DNA molecule is repaired using homologous sequences.\" [GOC:di, PMID:22214610]","metadata":null},{"id":"d345397be07d46a8b491941302576c2f","type":"GO_TERM","name":"mitochondrial electron transfer flavoprotein complex","canonical_id":"go:GO:0017133","description":"\"A protein complex located in the mitochondrion. It contains flavin adenine dinucleotide (FAD) that, together with an acyl-CoA dehydrogenase, forms a system that oxidizes an acyl-CoA molecule and reduces ubiquinone and other acceptors in the mitochondrial electron transport system.\" [GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"f8371e05ccb04d96a43d057008b851d2","type":"GO_TERM","name":"mitochondrial electron transport, NADH to ubiquinone","canonical_id":"go:GO:0006120","description":"\"The transfer of electrons from NADH to ubiquinone that occurs during oxidative phosphorylation.\" [ISBN:0716731363]","metadata":null},{"id":"26d64c0e0d4f4dabbb53543024a772d4","type":"GO_TERM","name":"mitochondrial electron transport, cytochrome c to oxygen","canonical_id":"go:GO:0006123","description":"\"The transfer of electrons from cytochrome c to oxygen that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex IV.\" [ISBN:0716731363]","metadata":null},{"id":"c2e5bccdb98f4c51b64d27ba8660cf92","type":"GO_TERM","name":"mitochondrial electron transport, succinate to ubiquinone","canonical_id":"go:GO:0006121","description":"\"The transfer of electrons from succinate to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex II.\" [ISBN:0716731363]","metadata":null},{"id":"cd529f9dead44f9cb05e03aea36e7572","type":"GO_TERM","name":"mitochondrial electron transport, ubiquinol to cytochrome c","canonical_id":"go:GO:0006122","description":"\"The transfer of electrons from ubiquinol to cytochrome c that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex III.\" [ISBN:0716731363]","metadata":null},{"id":"725234dca8ed4fde8004dd52a1866de1","type":"GO_TERM","name":"mitochondrial endopeptidase Clp complex","canonical_id":"go:GO:0009841","description":"\"A Clp endopeptidase complex located in the mitochondrion.\" [GOC:mah]","metadata":null},{"id":"4227659abe374e0a867bb47ecc51f2ce","type":"GO_TERM","name":"mitochondrial envelope","canonical_id":"go:GO:0005740","description":"\"The double lipid bilayer enclosing the mitochondrion and separating its contents from the cell cytoplasm; includes the intermembrane space.\" [GOC:ai, GOC:pz]","metadata":null},{"id":"7b6563f0fe954351add28a679ee6334d","type":"GO_TERM","name":"mitochondrial fatty acid beta-oxidation multienzyme complex","canonical_id":"go:GO:0016507","description":"\"A multienzyme complex possessing three activities in two subunits (alpha and beta) that catalyzes three steps of the fatty acid beta-oxidation cycle within the mitochondrial matrix. The alpha subunit comprises the enoyl-CoA hydratase (ECH) and 3-hydroxyacyl-CoA dehydrogenase (HACD) activities, and the beta subunit contains the acetyl-CoA C-acyltransferase (KACT)/thiolase activity.\" [GOC:sjm, PMID:29915090]","metadata":null},{"id":"d09ef534830d49bc8b7803d7883bf131","type":"GO_TERM","name":"mitochondrial fission","canonical_id":"go:GO:0000266","description":"\"The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.\" [PMID:11038192]","metadata":null},{"id":"30d4e7af4b96418ca371b6808256c821","type":"GO_TERM","name":"mitochondrial fragmentation involved in apoptotic process","canonical_id":"go:GO:0043653","description":"\"The change in the morphology of the mitochondria in an apoptotic cell from a highly branched network to a fragmented vesicular form.\" [GOC:mtg_apoptosis, GOC:rk, PMID:12867994]","metadata":null},{"id":"53be72bd30d5449485f50130fd84c4e5","type":"GO_TERM","name":"mitochondrial fusion","canonical_id":"go:GO:0008053","description":"\"Merging of two or more mitochondria within a cell to form a single compartment.\" [PMID:11038192, PMID:12052774]","metadata":null},{"id":"3c7af5839332475e834795d8dd42be89","type":"GO_TERM","name":"mitochondrial gene expression","canonical_id":"go:GO:0140053","description":"\"The process of transcribing and translating the mitochondrial genome (mtDNA) to produce at least a subset of oxidative phosphorylation (OXPHOS) proteins, 2 rRNAs, and mitochondrial tRNAs, which are critical for ATP production. Protein maturation is included when required to form an active form of a product from an inactive precursor form.\" [PMID:27058308, PMID:31861673, PMID:38117001]","metadata":null},{"id":"e3cb7b2027804c26944d6a507ebc2867","type":"GO_TERM","name":"mitochondrial glutamate synthase complex (NADH)","canonical_id":"go:GO:0043294","description":"\"A protein complex, found in the mitochondria, that in yeast consists of a large and a small subunit. Possesses glutamate synthase (NADH) activity.\" [GOC:jl, PMID:7047525]","metadata":null},{"id":"bf2bee9a9d564c2ba275484ddf21bc7a","type":"GO_TERM","name":"mitochondrial glutaminyl-tRNA aminoacylation","canonical_id":"go:GO:0070148","description":"\"The process of coupling glutamine to glutaminyl-tRNA in a mitochondrion, catalyzed by glutaminyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"6be5ec9bde37440fa37d3779cf56caab","type":"GO_TERM","name":"mitochondrial glutamyl-tRNA aminoacylation","canonical_id":"go:GO:0070149","description":"\"The process of coupling glutamate to glutamyl-tRNA in a mitochondrion, catalyzed by glutamyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"af01198e35694254ab0b2eacb5a3fc9d","type":"GO_TERM","name":"mitochondrial glycyl-tRNA aminoacylation","canonical_id":"go:GO:0070150","description":"\"The process of coupling glycine to glycyl-tRNA in a mitochondrion, catalyzed by glycyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"c57ce6107a174e029b48fbed4e451026","type":"GO_TERM","name":"mitochondrial guanine nucleotide transmembrane transport","canonical_id":"go:GO:0140140","description":"\"The process in which a guanine nucleotide is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [GOC:vw, PMID:14998997]","metadata":null},{"id":"fc204a1fabb349af95de561b1f9ea373","type":"GO_TERM","name":"mitochondrial histidyl-tRNA aminoacylation","canonical_id":"go:GO:0070151","description":"\"The process of coupling histidine to histidyl-tRNA in a mitochondrion, catalyzed by histidyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"0f12049491d94ba1b888d217ca82dd35","type":"GO_TERM","name":"mitochondrial inner boundary membrane","canonical_id":"go:GO:0097002","description":"\"The portion of the mitochondrial inner membrane that is not invaginated to form cristae. The inner boundary membrane lies parallel to the outer membrane.\" [GOC:mcc, PMID:16054341, PMID:19019989]","metadata":null},{"id":"cfcc80199d724569a773a87c3f648691","type":"GO_TERM","name":"mitochondrial inner membrane","canonical_id":"go:GO:0005743","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae.\" [GOC:ai]","metadata":null},{"id":"dbfecfe1705f4b2791c1fcca7ff06c8a","type":"GO_TERM","name":"mitochondrial inner membrane assembly complex","canonical_id":"go:GO:1990677","description":"\"A protein complex that promotes the biogenesis of mitochondrial F1Fo-ATP synthase by facilitating assembly of the peripheral stalk. Loss of INAC function causes dissociation of the F1-domain from the membrane-integral Fo-portion.\" [GOC:bhm, PMID:24942160]","metadata":null},{"id":"bf31473ad5374c588ff06bf9f54e7a99","type":"GO_TERM","name":"mitochondrial inner membrane fusion","canonical_id":"go:GO:1990627","description":"\"The membrane organization process that joins two mitochondrial inner membranes to form a single membrane.\" [GOC:vw, PMID:17055438]","metadata":null},{"id":"f667867beb654dfb8249e599c7263c11","type":"GO_TERM","name":"mitochondrial inner membrane peptidase complex","canonical_id":"go:GO:0042720","description":"\"Protease complex of the mitochondrial inner membrane, consisting of at least two subunits, involved in processing of both nuclear- and mitochondrially-encoded proteins targeted to the intermembrane space.\" [PMID:10821182, PMID:12191769]","metadata":null},{"id":"3caf3290251e425dad150ebe55023ae5","type":"GO_TERM","name":"mitochondrial inner-outer membrane contact site","canonical_id":"go:GO:0044289","description":"\"Sites of close apposition of the inner and outer mitochondrial membrane.\" [PMID:22009199]","metadata":null},{"id":"4b95e1fec01d452db0f115f9c26adc6f","type":"GO_TERM","name":"mitochondrial intermembrane space","canonical_id":"go:GO:0005758","description":"\"The region between the inner and outer lipid bilayers of the mitochondrial envelope.\" [GOC:mah]","metadata":null},{"id":"2ce987a359bb4cc4b2a82b42c84a39c3","type":"GO_TERM","name":"mitochondrial intermembrane space chaperone complex","canonical_id":"go:GO:0042719","description":"\"mitochondrial protein-containing complex localised in the mitochondrial inner membrane space that chaperones proteins to the TIM22 complex for insertion into the mitochondrial inner membrane.\" [GOC:vw]","metadata":null},{"id":"b8b75287fac04fe0b11db82fc5f6a194","type":"GO_TERM","name":"mitochondrial intracristal space","canonical_id":"go:GO:0044290","description":"\"The space bounded by the mitochondrial cristae membranes, continuous with the intermembrane space.\" [NIF_Subcellular:sao508958414]","metadata":null},{"id":"c16000ec0629435e9e13521e3db366f2","type":"GO_TERM","name":"mitochondrial isoleucyl-tRNA aminoacylation","canonical_id":"go:GO:0070152","description":"\"The process of coupling isoleucine to isoleucyl-tRNA in a mitochondrion, catalyzed by isoleucyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"43dcc55dc10940808fa82073722ab185","type":"GO_TERM","name":"mitochondrial isopropylmalate transmembrane transport","canonical_id":"go:GO:1990556","description":"\"The process in which 2-isopropylmalate(2-) is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:10428783]","metadata":null},{"id":"a6f2751e51f046d9891bf0ebceabc9c9","type":"GO_TERM","name":"mitochondrial large ribosomal subunit","canonical_id":"go:GO:0005762","description":"\"The larger of the two subunits of a mitochondrial ribosome. Two sites on the ribosomal large subunit are involved in translation: the aminoacyl site (A site) and peptidyl site (P site).\" [GOC:mcc]","metadata":null},{"id":"4af4f5f49a094deca9328a45f2e6a4fe","type":"GO_TERM","name":"mitochondrial large ribosomal subunit assembly","canonical_id":"go:GO:1902775","description":"\"The aggregation, arrangement and bonding together of a set of components to form a mitochondrial large ribosomal subunit.\" [GO_REF:0000079, GOC:TermGenie, PMID:24206665]","metadata":null},{"id":"f3b00f7dd4874cc79de19c069e2cd472","type":"GO_TERM","name":"mitochondrial large ribosomal subunit binding","canonical_id":"go:GO:0140978","description":"\"Binding to a mitochondrial large ribosomal subunit.\" [PMID:28892042]","metadata":null},{"id":"1f33d070a4c943348d9b5b4572568344","type":"GO_TERM","name":"mitochondrial leucyl-tRNA aminoacylation","canonical_id":"go:GO:0070153","description":"\"The process of coupling leucine to leucyl-tRNA in a mitochondrion, catalyzed by leucyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"711a8f003d024040bc5680d842ca609e","type":"GO_TERM","name":"mitochondrial lrRNA export from mitochondrion","canonical_id":"go:GO:0019091","description":"\"The process in which a lrRNA, large subunit ribosomal ribonucleic acid, is transported from the mitochondrial matrix into the cytosol.\" [GOC:ai]","metadata":null},{"id":"53dd9b34dfc04085a59eb098fb7ddc9e","type":"GO_TERM","name":"mitochondrial lysyl-tRNA aminoacylation","canonical_id":"go:GO:0070154","description":"\"The process of coupling lysine to lysyl-tRNA in a mitochondrion, catalyzed by lysyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"cdfe00bbb6f14adb9b8a5d397535a2c0","type":"GO_TERM","name":"mitochondrial mRNA 3'-end processing","canonical_id":"go:GO:0090616","description":"\"Any process involved in forming the mature 3' end of an mRNA molecule that derives from the mitochondrial genome.\" [GOC:tb, PMID:25181358]","metadata":null},{"id":"47153d25bb614bc8b271cbb29a249dd2","type":"GO_TERM","name":"mitochondrial mRNA 5'-end processing","canonical_id":"go:GO:0090617","description":"\"Any process involved in forming the mature 5' end of an mRNA molecule that derives from the mitochondrial genome.\" [GOC:tb, PMID:25181358]","metadata":null},{"id":"ba15aebcbfa14e38a6585ba2aa31dd33","type":"GO_TERM","name":"mitochondrial mRNA catabolic process","canonical_id":"go:GO:0000958","description":"\"The chemical reactions and pathways resulting in the breakdown of mRNA transcribed from the mitochondrial genome and occurring in the mitochondrion.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"a143d0f828094918878b77e8f6474e9f","type":"GO_TERM","name":"mitochondrial mRNA editing complex","canonical_id":"go:GO:0031019","description":"\"An mRNA editing complex found in the mitochondrion. The best characterized example is that of Trypanosoma brucei, which catalyzes the insertion and deletion of uridylates.\" [GOC:mah, PMID:12139607]","metadata":null},{"id":"0ef3170ac2284391a525f02d0e905cdc","type":"GO_TERM","name":"mitochondrial mRNA modification","canonical_id":"go:GO:0080156","description":"\"The covalent alteration within the mitochondrion of one or more nucleotides within an mRNA to produce an mRNA molecule with a sequence that differs from that coded genetically.\" [PMID:20566637]","metadata":null},{"id":"241b0f75d69a468d9f1583a75c3dfeb3","type":"GO_TERM","name":"mitochondrial mRNA polyadenylation","canonical_id":"go:GO:0097222","description":"\"The enzymatic addition of a sequence of 40-60 adenylyl residues at the 3' end of a eukaryotic mitochondrial mRNA primary transcript. Mitochondria contain both stabilizing and destabilizing poly(A) tails.\" [GOC:ans, PMID:18083837]","metadata":null},{"id":"ae023b52bf3b4fa7a5c89b4d3660c609","type":"GO_TERM","name":"mitochondrial mRNA processing","canonical_id":"go:GO:0090615","description":"\"Steps involved in processing precursor RNAs arising from transcription of operons in the mitochondrial genome into mature mRNAs.\" [GOC:tb, PMID:25181358]","metadata":null},{"id":"75652ec37e9f43e2abcaee7a5a9ca258","type":"GO_TERM","name":"mitochondrial mRNA surveillance","canonical_id":"go:GO:0035946","description":"\"The set of processes involved in identifying and degrading messenger RNA (mRNA) within the mitochondrion.\" [GOC:ans, PMID:19864255]","metadata":null},{"id":"58b258bcba7641469094a37d0cdd0b55","type":"GO_TERM","name":"mitochondrial magnesium ion transmembrane transport","canonical_id":"go:GO:0045016","description":"\"The process in which a magnesium ion (Mg2+) is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [GOC:ai, PMID:11254124]","metadata":null},{"id":"da4eef6c732749ffbe8f06a2d4de6d9b","type":"GO_TERM","name":"mitochondrial malonate(1-) transmembrane transport","canonical_id":"go:GO:1990558","description":"\"The process in which malonate(1-) is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:10428783]","metadata":null},{"id":"8ed2d3860e4c45e9a8b992e35f82f21b","type":"GO_TERM","name":"mitochondrial manganese ion transmembrane transport","canonical_id":"go:GO:1990540","description":"\"The process in which a manganese ion is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:12890866]","metadata":null},{"id":"9effdcd9888948319436d7de081c586a","type":"GO_TERM","name":"mitochondrial matrix","canonical_id":"go:GO:0005759","description":"\"The gel-like material, with considerable fine structure, that lies in the matrix space, or lumen, of a mitochondrion. It contains the enzymes of the tricarboxylic acid cycle and, in some organisms, the enzymes concerned with fatty acid oxidation.\" [GOC:as, ISBN:0198506732]","metadata":null},{"id":"6db360798369493abaf4d1cb408267bd","type":"GO_TERM","name":"mitochondrial membrane","canonical_id":"go:GO:0031966","description":"\"Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope.\" [GOC:mah, NIF_Subcellular:sao1045389829]","metadata":null},{"id":"5c741e14fe654429a9c79c82923c564c","type":"GO_TERM","name":"mitochondrial membrane fission","canonical_id":"go:GO:0090149","description":"\"A process that is carried out at the cellular level which results in the separation of a single continuous mitochondrial membrane into two membranes and contributes to mitochondrial fission.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"792bf1f3e6804afd8cb5d3f3e1a38357","type":"GO_TERM","name":"mitochondrial membrane organization","canonical_id":"go:GO:0007006","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrial membrane, either of the lipid bilayer surrounding a mitochondrion.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"ec0f5c8b3fbd4e0aa8eabf35518a6a38","type":"GO_TERM","name":"mitochondrial membrane scission site","canonical_id":"go:GO:0090692","description":"\"The site on the mitochondrial membrane where the separation of a single continuous mitochondrial membrane into two membranes occurs as a final step in mitochondrial fission.\" [GOC:bc, GOC:PARL, PMID:26618722]","metadata":null},{"id":"d870e0bc2d074372878dcf0e5e5ffcee","type":"GO_TERM","name":"mitochondrial methionyl-tRNA aminoacylation","canonical_id":"go:GO:0070155","description":"\"The process of coupling methionine to methionyl-tRNA in a mitochondrion, catalyzed by methionyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"05a34aa14aed41c88a93aa5bcfddfb0e","type":"GO_TERM","name":"mitochondrial ncRNA surveillance","canonical_id":"go:GO:0035945","description":"\"The set of processes involved in identifying and degrading defective or aberrant non-coding RNA transcripts (ncRNAs) within the mitochondrion.\" [GOC:ans, PMID:19864255]","metadata":null},{"id":"72ca7ad6e9ec40e7a1bf8347455103af","type":"GO_TERM","name":"mitochondrial nucleoid","canonical_id":"go:GO:0042645","description":"\"The region of a mitochondrion to which the DNA is confined.\" [GOC:jl]","metadata":null},{"id":"c4110a8c751848d3933b685329a404e3","type":"GO_TERM","name":"mitochondrial outer membrane","canonical_id":"go:GO:0005741","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the mitochondrial envelope.\" [GOC:ai]","metadata":null},{"id":"a0429262d029481d8ac7403510d8613a","type":"GO_TERM","name":"mitochondrial outer membrane fusion","canonical_id":"go:GO:1990626","description":"\"The membrane organization process that joins two mitochondrial outer membranes to form a single membrane.\" [GOC:vw, PMID:21385840]","metadata":null},{"id":"59cc311712a04b1dad351dbc98d76d4d","type":"GO_TERM","name":"mitochondrial outer membrane permeabilization","canonical_id":"go:GO:0097345","description":"\"The process by which the mitochondrial outer membrane becomes permeable to the passing of proteins and other molecules from the intermembrane space to the cytosol as part of the apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:pg, PMID:21041309]","metadata":null},{"id":"4554b2e6b1f34098ad8ddbe83b110b44","type":"GO_TERM","name":"mitochondrial outer membrane permeabilization involved in programmed cell death","canonical_id":"go:GO:1902686","description":"\"The process by which the mitochondrial outer membrane becomes permeable to the passing of proteins and other molecules from the intermembrane space to the cytosol as part of a programmed cell death process.\" [GO_REF:0000060, GOC:mtg_apoptosis, GOC:pg, GOC:TermGenie, PMID:20151314]","metadata":null},{"id":"b683dc67202748a6b6609fddf77b84a6","type":"GO_TERM","name":"mitochondrial outer membrane translocase complex","canonical_id":"go:GO:0005742","description":"\"A large complex of the mitochondrial outer membrane that mediates transport of proteins into all mitochondrial compartments.\" [PMID:12581629]","metadata":null},{"id":"63b45fbb35e1436aa16f89b2a07d0d63","type":"GO_TERM","name":"mitochondrial outer membrane translocase complex assembly","canonical_id":"go:GO:0070096","description":"\"The aggregation, arrangement and bonding together of a set of components to form a mitochondrial outer membrane translocase complex.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"2876e46e2d844c5fbeaaad795e4effbb","type":"GO_TERM","name":"mitochondrial oxaloacetate transmembrane transport","canonical_id":"go:GO:1990555","description":"\"The process in which oxaloacetate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:10428783]","metadata":null},{"id":"b376f51ef3dd4ad28dab42cbdf5c0e77","type":"GO_TERM","name":"mitochondrial permeability transition pore complex","canonical_id":"go:GO:0005757","description":"\"A protein complex that connects the inner and outer membranes of animal mitochondria and acts as a pore that can open transiently to allow free diffusion of solutes between the mitochondrial matrix and the cytosol. The pore complex is formed of the voltage-dependent anion channel (VDAC), the adenine nucleotide translocase (ANT) and cyclophilin-D (CyP-D).\" [PMID:10393078]","metadata":null},{"id":"12f9729213144b638aaa11b8f605113c","type":"GO_TERM","name":"mitochondrial phenylalanyl-tRNA aminoacylation","canonical_id":"go:GO:0070156","description":"\"The process of coupling phenylalanine to phenylalanyl-tRNA in a mitochondrion, catalyzed by phenylalanyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"fb08c457d24e4a789527a6d865c09254","type":"GO_TERM","name":"mitochondrial phosphate ion transmembrane transport","canonical_id":"go:GO:1990547","description":"\"The process in which a phosphate ion is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:9099701]","metadata":null},{"id":"3991cb783b53425bbc37eebeb2cace7b","type":"GO_TERM","name":"mitochondrial polycistronic RNA processing","canonical_id":"go:GO:0140040","description":"\"The conversion of polycistronic RNA transcribed from a mitochondrial genome into mono- or bi-cistronic RNAs.\" [PMID:20211597]","metadata":null},{"id":"9a5a7656040b4008a4e7111b726f3c0f","type":"GO_TERM","name":"mitochondrial potassium ion transmembrane transport","canonical_id":"go:GO:0140141","description":"\"The process in which a potassium ion is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [GOC:vw, PMID:20197279]","metadata":null},{"id":"c89097c3511b4b91ad62736cb30836d3","type":"GO_TERM","name":"mitochondrial processing peptidase complex","canonical_id":"go:GO:0017087","description":"\"A protein complex consisting of a regulatory subunit (alpha-MPP) and a catalytic subunit (beta-MPP) that catalyzes the release of N-terminal targeting peptides from precursor proteins imported into the mitochondrion.\" [GOC:mah]","metadata":null},{"id":"233daafba3384ba795c801b5a4dfeb90","type":"GO_TERM","name":"mitochondrial prohibitin complex","canonical_id":"go:GO:0035632","description":"\"A complex composed of two proteins, prohibitin 1 and prohibitin 2 (PHB1/PHB-1 and PHB2/PHB-2) that is highly conserved amongst eukaryotes and associated with the inner mitochondrial membrane. The mitochondrial prohibitin complex is a macromolecular supercomplex composed of repeating heterodimeric subunits of PHB1 and PHB2. The mitochondrial prohibitin complex plays a role in a number of biological processes, including mitochondrial biogenesis and function, development, replicative senescence, and cell death.\" [GOC:kmv, PMID:12237468, PMID:21164222]","metadata":null},{"id":"9962c5b6c71c47de868d5150375c770d","type":"GO_TERM","name":"mitochondrial prolyl-tRNA aminoacylation","canonical_id":"go:GO:0070157","description":"\"The process of coupling proline to prolyl-tRNA in a mitochondrion, catalyzed by prolyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"082e3d842c9c4ffcb2edc403d7111b4e","type":"GO_TERM","name":"mitochondrial promoter sequence-specific DNA binding","canonical_id":"go:GO:0001018","description":"\"Binding to a DNA region that controls the transcription of the mitochondrial DNA.\" [GOC:txnOH, GOC:vw, PMID:20056105]","metadata":null},{"id":"e528d0c9e9c047ea9acd6743a79fb608","type":"GO_TERM","name":"mitochondrial protein catabolic process","canonical_id":"go:GO:0035694","description":"\"The chemical reactions and pathways resulting in the breakdown of a mitochondrial protein. This process is necessary to maintain the healthy state of mitochondria and is thought to occur via the induction of an intramitochondrial lysosome-like organelle that acts to eliminate the damaged oxidised mitochondrial proteins without destroying the mitochondrial structure.\" [GOC:sp, PMID:21264221, PMID:21264228]","metadata":null},{"id":"a7f291c232cf4fd9821d45b05a1309b7","type":"GO_TERM","name":"mitochondrial protein import pathway","canonical_id":"go:GO:7770058","description":"\"The import of proteins from the cytosol to their final destination in the mitochondria.\" [PMID:36931257]","metadata":null},{"id":"c49e82ed431146ed8fb6ff973ee9c30d","type":"GO_TERM","name":"mitochondrial protein processing","canonical_id":"go:GO:0034982","description":"\"The peptide cleavage of mitochondrial proteins, including cleavage contributing to their import.\" [GOC:curators]","metadata":null},{"id":"d90affc6fc2b437a8d6b5c65feee40a9","type":"GO_TERM","name":"mitochondrial protein quality control","canonical_id":"go:GO:0141164","description":"\"The chemical reactions and pathways resulting in the breakdown of misfolded proteins in the mitochondrion, which are targeted for degradation.\" [PMID:38280230]","metadata":null},{"id":"716f7f34b14f4e049e84180738d87f4e","type":"GO_TERM","name":"mitochondrial protein-containing complex","canonical_id":"go:GO:0098798","description":"\"A protein complex that is part of a mitochondrion.\" [GOC:dos]","metadata":null},{"id":"6f01f44425be41c5a3668ea05edb41f7","type":"GO_TERM","name":"mitochondrial protein-transporting ATPase activity","canonical_id":"go:GO:0008566","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O = ADP + phosphate; drives the transport of proteins into the mitochondrion via the mitochondrial inner membrane translocase complex.\" [EC:7.4.2.3]","metadata":null},{"id":"ce9875ea45f645a3a18f06c063454ba8","type":"GO_TERM","name":"mitochondrial proton-transporting ATP synthase complex assembly","canonical_id":"go:GO:0033615","description":"\"The aggregation, arrangement and bonding together of a proton-transporting ATP synthase in the mitochondrial inner membrane.\" [GOC:mah]","metadata":null},{"id":"a438b224624843ffbed7d8e205c55b56","type":"GO_TERM","name":"mitochondrial proton-transporting ATP synthase complex binding","canonical_id":"go:GO:0140260","description":"\"Binding to a mitochondrial proton-transporting ATP synthase complex.\" [PMID:12110673]","metadata":null},{"id":"6707bca0c9974a5396457252e15b94f0","type":"GO_TERM","name":"mitochondrial pyruvate carrier complex","canonical_id":"go:GO:7770001","description":"\"An inner mitochondrial protein carrier capable of transporting pyruvate into the mitochondrion.\" [PMID:22628554, PMID:22628558]","metadata":null},{"id":"348bc4d8856d437686485fb04b57d6aa","type":"GO_TERM","name":"mitochondrial pyruvate dehydrogenase (lipoamide) phosphatase complex","canonical_id":"go:GO:0019910","description":"\"A mitochondrial complex of a regulatory and catalytic subunit that catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex. An example of this component is found in Mus musculus.\" [GOC:mtg_sensu, PMID:9395502]","metadata":null},{"id":"7e0ddc3e119a4acf86455f7a4edbb3e3","type":"GO_TERM","name":"mitochondrial rRNA export from mitochondrion","canonical_id":"go:GO:0019090","description":"\"The process in which a rRNA, ribosomal ribonucleic acid, is transported from the mitochondrial matrix into the cytosol.\" [GOC:ai, PMID:28115039]","metadata":null},{"id":"6b3f5202714c467f8d58311b0992c997","type":"GO_TERM","name":"mitochondrial respirasome assembly","canonical_id":"go:GO:0097250","description":"\"The aggregation, arrangement and bonding together of respiratory enzyme complexes I, III and IV of the mitochondrial inner membrane to form a large supercomplex.\" [PMID:30030361, PMID:32311046]","metadata":null},{"id":"e233e4bd712f45b291085531edd21a83","type":"GO_TERM","name":"mitochondrial respiratory chain complex I assembly","canonical_id":"go:GO:0032981","description":"\"The aggregation, arrangement and bonding together of a set of components to form mitochondrial respiratory chain complex I.\" [GOC:rph]","metadata":null},{"id":"600922cd554e425daca6df46344547ee","type":"GO_TERM","name":"mitochondrial respiratory chain complex II assembly","canonical_id":"go:GO:0034553","description":"\"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex II, in the mitochondrial inner membrane.\" [GOC:dgf]","metadata":null},{"id":"4d0c0255a9d748f4bb2a43c6b2f915ea","type":"GO_TERM","name":"mitochondrial respiratory chain complex III assembly","canonical_id":"go:GO:0034551","description":"\"The aggregation, arrangement and bonding together of a set of components to form the cytochrome bc(1) complex (also known as ubiquinol-cytochrome c reductase), in the mitochondrial inner membrane.\" [GOC:dgf, GOC:mcc]","metadata":null},{"id":"e64b2c09f01f4109ad5bde63a3d56eea","type":"GO_TERM","name":"mitochondrial respiratory chain complex IV assembly","canonical_id":"go:GO:0033617","description":"\"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase) in the mitochondrial inner membrane.\" [GOC:mah]","metadata":null},{"id":"85162a5d0ee2401b9df3b4458644b5dc","type":"GO_TERM","name":"mitochondrial respiratory chain complex IV pre-assembly complex","canonical_id":"go:GO:0062011","description":"\"A protein complex that contributes to and regulates mitochondrial respiratory chain complex IV (COX) formation. It acts by regulating mitochondrial COX1 translation and by promoting the assembly of COX components.\" [GOC:lnp, PMID:21068384]","metadata":null},{"id":"2d6766f285ba46248b3911f908fb6a1e","type":"GO_TERM","name":"mitochondrial respiratory chain complex assembly","canonical_id":"go:GO:0033108","description":"\"The aggregation, arrangement and bonding together of a set of components to form a mitochondrial respiratory chain complex or between respiratory chain complexes to form high-order structures.\" [GOC:mah]","metadata":null},{"id":"c66b28ce5bba456695b1b00fd8af2676","type":"GO_TERM","name":"mitochondrial ribonuclease P complex","canonical_id":"go:GO:0030678","description":"\"A ribonuclease P complex located in the mitochondrion of a eukaryotic cell, where it catalyzes the 5' endonucleolytic cleavage of precursor tRNAs to yield mature tRNAs. The subunit composition of mitochondrial ribonuclease P complexes varies between species. The complex contains a single RNA molecule and a single protein molecule in yeast (PMID:12045094), but comprises three proteins and lacks an RNA component in humans.\" [GOC:mah, PMID:12045094, PMID:27187488]","metadata":null},{"id":"d1de073b1a124cbda8d9d19273120c0b","type":"GO_TERM","name":"mitochondrial ribosomal large subunit rRNA binding","canonical_id":"go:GO:1990400","description":"\"Binding to a mitochondrial large ribosomal subunit RNA (LSU rRNA).\" [PMID:24206665]","metadata":null},{"id":"bc7a6d2af7be430486cfc03a32d1005d","type":"GO_TERM","name":"mitochondrial ribosome","canonical_id":"go:GO:0005761","description":"\"A ribosome found in the mitochondrion of a eukaryotic cell; contains a characteristic set of proteins distinct from those of cytosolic ribosomes.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"7ed9446b4e4047e79644d847e8406997","type":"GO_TERM","name":"mitochondrial ribosome assembly","canonical_id":"go:GO:0061668","description":"\"The aggregation, arrangement and bonding together of the mitochondrial ribosome and of its subunits.\" [GOC:dph]","metadata":null},{"id":"f35e7fe39fc648a1b50da38e441596ea","type":"GO_TERM","name":"mitochondrial ribosome binding","canonical_id":"go:GO:0097177","description":"\"Binding to a mitochondrial ribosome.\" [GOC:ans, PMID:20739282]","metadata":null},{"id":"a007053b2b88406e9acdad563aacabfd","type":"GO_TERM","name":"mitochondrial seryl-tRNA aminoacylation","canonical_id":"go:GO:0070158","description":"\"The process of coupling serine to seryl-tRNA in a mitochondrion, catalyzed by seryl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"77f6c94f77a3422f98c08e72bcbb7b5b","type":"GO_TERM","name":"mitochondrial signal sequence receptor activity","canonical_id":"go:GO:0140436","description":"\"Binding to a mitochondrial targeting sequence, a short stretch of amino acids found in a protein that acts as a signal to localize the protein to the mitochondrion.\" [PMID:20729931]","metadata":null},{"id":"644ac7aa7b8f4fdf8966a3e50d1613e2","type":"GO_TERM","name":"mitochondrial single-subunit type RNA polymerase binding","canonical_id":"go:GO:0001001","description":"\"Binding to a single subunit mitochondrial RNA polymerase enzyme, which is composed of a single catalytic subunit similar to the RNA polymerase enzymes from phages T3, T7, and SP6.\" [GOC:txnOH, PMID:20701995, PMID:2088182]","metadata":null},{"id":"6f34f1da71ac46c7a8c9004de442f0fc","type":"GO_TERM","name":"mitochondrial small ribosomal subunit","canonical_id":"go:GO:0005763","description":"\"The smaller of the two subunits of a mitochondrial ribosome.\" [GOC:mcc]","metadata":null},{"id":"4aa4a543ec81459c86cac2180a439f6b","type":"GO_TERM","name":"mitochondrial small ribosomal subunit assembly","canonical_id":"go:GO:0180026","description":"\"The aggregation, arrangement and bonding together of a set of components to form a mitochondrial small ribosomal subunit.\" [PMID:30467428]","metadata":null},{"id":"eef661b1b8cc43fb9d2657871577f3f6","type":"GO_TERM","name":"mitochondrial small ribosomal subunit binding","canonical_id":"go:GO:0180065","description":"\"Binding to a mitochondrial small ribosomal subunit.\" [PMID:40427588]","metadata":null},{"id":"91683a44cbf148afa76753a0390a6971","type":"GO_TERM","name":"mitochondrial srRNA export from mitochondrion","canonical_id":"go:GO:0019092","description":"\"The process in which a srRNA, small subunit ribosomal ribonucleic acid, is transported from the mitochondrial matrix into the cytosol.\" [GOC:ai]","metadata":null},{"id":"8ba779aac3b9429c85bfecc05d4e3c62","type":"GO_TERM","name":"mitochondrial sulfate transmembrane transport","canonical_id":"go:GO:1990557","description":"\"The process in which sulfate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:10428783]","metadata":null},{"id":"3ddc7c39ae524daa86ae789e51e1e2c0","type":"GO_TERM","name":"mitochondrial tRNA 3'-end processing","canonical_id":"go:GO:1990180","description":"\"The process in which the 3' end of a pre-tRNA molecule is converted to that of a mature tRNA in the mitochondrion.\" [GOC:mah, GOC:TermGenie, PMID:23928301]","metadata":null},{"id":"a63d3ce48dfa44aaa3b05edc13f535ab","type":"GO_TERM","name":"mitochondrial tRNA 5'-end processing","canonical_id":"go:GO:0097745","description":"\"The process in which the 5' end of a pre-tRNA molecule is converted to that of a mature tRNA in the mitochondrion.\" [GOC:pf, PMID:21307182, PMID:26143376, PMID:27484477]","metadata":null},{"id":"6a99d2cede044687b2e8a09edb636957","type":"GO_TERM","name":"mitochondrial tRNA methylation","canonical_id":"go:GO:0070901","description":"\"The posttranscriptional addition of methyl groups to specific residues in a mitochondrial tRNA molecule.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"41db4d712d164715913da78322946630","type":"GO_TERM","name":"mitochondrial tRNA modification","canonical_id":"go:GO:0070900","description":"\"The covalent alteration of one or more nucleotides within a mitochondrial tRNA molecule to produce a mitochondrial tRNA molecule with a sequence that differs from that coded genetically.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"3254f0db83ad4649ba27f97df244e794","type":"GO_TERM","name":"mitochondrial tRNA processing","canonical_id":"go:GO:0090646","description":"\"The process in which a pre-tRNA molecule is converted to a mature tRNA, ready for addition of an aminoacyl group, in the mitochondrion.\" [GOC:vw]","metadata":null},{"id":"d39bc326159a4fc4a80c0f5fc2c8630a","type":"GO_TERM","name":"mitochondrial tRNA pseudouridine synthesis","canonical_id":"go:GO:0070902","description":"\"The intramolecular conversion of uridine to pseudouridine in a mitochondrial tRNA molecule.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"9be6ea183b3642a9a078e4f479ac3cc4","type":"GO_TERM","name":"mitochondrial tRNA pseudouridine(27/28) synthase activity","canonical_id":"go:GO:0160153","description":"\"Catalysis of the reaction: uridine(27/28) in mitochondrial tRNA = pseudouridine(27/28) in mitochondrial tRNA.\" [EC:5.4.99.44]","metadata":null},{"id":"a28fe15c9e164ab1b0617b0442e8baa0","type":"GO_TERM","name":"mitochondrial tRNA thio-modification","canonical_id":"go:GO:0070903","description":"\"The addition a sulfur atom to a nucleotide in a mitochondrial tRNA molecule.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"4fa687a23f5444e08bcd56eabfd23fb3","type":"GO_TERM","name":"mitochondrial tRNA threonylcarbamoyladenosine modification","canonical_id":"go:GO:0072670","description":"\"The attachment of a carbonyl group and a threonine to the amino group of the adenine residue immediately 3' of the anticodon, in mitochondrial tRNAs that decode ANN codons (where N is any base).\" [GOC:mcc, PMID:21183954]","metadata":null},{"id":"136cc466f7024472bd1caf102ae0c1b5","type":"GO_TERM","name":"mitochondrial tRNA wobble position uridine thiolation","canonical_id":"go:GO:1990799","description":"\"The process in which a uridine residue at position 34 in the anticodon of a mitochondrial tRNA is post-transcriptionally thiolated at the C2 position. This process involves transfer of a sulfur from L-cysteine to position C2 by several steps.\" [PMID:15509579]","metadata":null},{"id":"4842048e48f2450e88d09691243ca1e8","type":"GO_TERM","name":"mitochondrial tRNA wobble uridine modification","canonical_id":"go:GO:0070899","description":"\"The process in which a uridine in position 34 of a mitochondrial tRNA is post-transcriptionally modified.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"8ae8f541ed3c4025aeb2a30d67420ad8","type":"GO_TERM","name":"mitochondrial thiamine pyrophosphate transmembrane transport","canonical_id":"go:GO:1990545","description":"\"The process in which thiamine pyrophosphate is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [PMID:12411483]","metadata":null},{"id":"f6caddfaf7874fd2920c2338e96991e6","type":"GO_TERM","name":"mitochondrial threonyl-tRNA aminoacylation","canonical_id":"go:GO:0070159","description":"\"The process of coupling threonine to threonyl-tRNA in a mitochondrion, catalyzed by threonyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"ab883f09d67640d08052a5fd534b69d3","type":"GO_TERM","name":"mitochondrial transcription","canonical_id":"go:GO:0006390","description":"\"The synthesis of RNA from a mitochondrial DNA template, usually by a specific mitochondrial RNA polymerase.\" [GOC:jl, PMID:23632312]","metadata":null},{"id":"af1e51d7118b4b0e8da20e39a0c17a66","type":"GO_TERM","name":"mitochondrial transcription factor activity","canonical_id":"go:GO:0034246","description":"\"Interacting with the mitochondrial promoter DNA to modulate transcription by the mitochondrial RNA polymerase.\" [GOC:txnOH-2018, PMID:18391175]","metadata":null},{"id":"e33c3bf8f42b4dc9a52fcce0d3f1a11a","type":"GO_TERM","name":"mitochondrial translation","canonical_id":"go:GO:0032543","description":"\"The chemical reactions and pathways resulting in the formation of a protein in a mitochondrion. This is a ribosome-mediated process in which the information in messenger RNA (mRNA) is used to specify the sequence of amino acids in the protein; the mitochondrion has its own ribosomes and transfer RNAs, and uses a genetic code that differs from the nuclear code.\" [GOC:curators]","metadata":null},{"id":"359ad6e0b07547cc9542100a3f587e2a","type":"GO_TERM","name":"mitochondrial translation initiation complex","canonical_id":"go:GO:0180052","description":"\"A ribonucleoprotein complex comprising the mRNA bound fully assembled 55S mitoribosome with the tRNA-met positioned in the P-site of the mitochondrial small subunit to recognize the mRNA start codon.\" [GOC:vw, PMID:32522994]","metadata":null},{"id":"ef6cf958a6dc4ac38ad10eeaca509794","type":"GO_TERM","name":"mitochondrial translation preinitiation complex","canonical_id":"go:GO:0180053","description":"\"A ribonucleoprotein complex comprising of the 28S small mitoribosomal subunit (mt-SSU) and mitochondrial initiation factors (e.g. mtIF3 and mtIF2-GTP) and the initiator tRNA-Met and an mRNA binding. The early steps of translation initiation, including the association of the 28S mitochondrial small subunit (mt-SSU) with initiation factors (mtIF3 and mtIF2), prevention of premature large subunit (39S) joining occur during the assembly of the mitochondrial pre-initiation complex (mtPIC).\" [GOC:vw, PMID:32522994]","metadata":null},{"id":"e86dfebf635148649b5a337060bc0f18","type":"GO_TERM","name":"mitochondrial translational elongation","canonical_id":"go:GO:0070125","description":"\"The successive addition of amino acid residues to a nascent polypeptide chain during protein biosynthesis in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"69ff3f7eb3394c1a894f28ca2cd9bea6","type":"GO_TERM","name":"mitochondrial translational initiation","canonical_id":"go:GO:0070124","description":"\"The process preceding formation of the peptide bond between the first two amino acids of a protein in a mitochondrion. This includes the formation of a complex of the ribosome, mRNA, and an initiation complex that contains the first aminoacyl-tRNA.\" [GOC:mah]","metadata":null},{"id":"d4548bcc9c8c4efea9f55e759cc078c2","type":"GO_TERM","name":"mitochondrial translational termination","canonical_id":"go:GO:0070126","description":"\"The process resulting in the release of a polypeptide chain from the ribosome in a mitochondrion, usually in response to a termination codon (note that mitochondria use variants of the universal genetic code that differ between different taxa).\" [GOC:mah, http://mitogenome.org/index.php/Genetic_Code_of_mitochondria]","metadata":null},{"id":"50ebbec66eef4e9395469e94726bf99f","type":"GO_TERM","name":"mitochondrial transmembrane transport","canonical_id":"go:GO:1990542","description":"\"The process in which a solute is transported from one side of a membrane to the other into, out of or within a mitochondrion.\" [PMID:20533899]","metadata":null},{"id":"222d2774fd16410c98974b4e094f7f35","type":"GO_TERM","name":"mitochondrial transport","canonical_id":"go:GO:0006839","description":"\"Transport of substances into, out of or within a mitochondrion.\" [GOC:ai]","metadata":null},{"id":"17417149ea634892a725ac7f1e7a548e","type":"GO_TERM","name":"mitochondrial tricarboxylic acid transmembrane transport","canonical_id":"go:GO:1990546","description":"\"The process in which a tricarboxylic acid is transported across a mitochondrial membrane, into or out of the mitochondrion.\" [GOC:vw]","metadata":null},{"id":"f6dd24697f6045479d0cdc03725dfaf9","type":"GO_TERM","name":"mitochondrial tryptophanyl-tRNA aminoacylation","canonical_id":"go:GO:0070183","description":"\"The process of coupling tryptophan to tryptophanyl-tRNA in a mitochondrion, catalyzed by tryptophanyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"7d59b73e834c4ebd9e865fee490ca03a","type":"GO_TERM","name":"mitochondrial tyrosyl-tRNA aminoacylation","canonical_id":"go:GO:0070184","description":"\"The process of coupling tyrosine to tyrosyl-tRNA in a mitochondrion, catalyzed by tyrosyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"1d4815f5cfd945b79611c9828ad51925","type":"GO_TERM","name":"mitochondrial unfolded protein response","canonical_id":"go:GO:0034514","description":"\"The series of molecular signals generated as a consequence of the presence of unfolded proteins in the mitochondrial matrix; results in transcriptional upregulation of nuclear genes encoding mitochondrial stress proteins.\" [GOC:mah, PMID:17849004]","metadata":null},{"id":"40eed608bb064542994705b4d47c1927","type":"GO_TERM","name":"mitochondrial valyl-tRNA aminoacylation","canonical_id":"go:GO:0070185","description":"\"The process of coupling valine to valyl-tRNA in a mitochondrion, catalyzed by valyl-tRNA synthetase. In tRNA aminoacylation, the amino acid is first activated by linkage to AMP and then transferred to either the 2'- or the 3'-hydroxyl group of the 3'-adenosine residue of the tRNA.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"078ed38666084862820b71610b4aefd9","type":"GO_TERM","name":"mitochondrial-lysosomal membrane contact site","canonical_id":"go:GO:7770051","description":"\"An organelle membrane contact site between the mitochondrial outer membrane and the lysosomal membrane.\" [PMID:29364868, PMID:30898429, PMID:32703809, PMID:33372681, PMID:33753743, PMID:35249745]","metadata":null},{"id":"7baece0dc0934ded94c2259d5d12f680","type":"GO_TERM","name":"mitochondrion","canonical_id":"go:GO:0005739","description":"\"A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.\" [GOC:giardia, ISBN:0198506732]","metadata":null},{"id":"636cc337c64046268ff777b71460e69f","type":"GO_TERM","name":"mitochondrion DNA recombination","canonical_id":"go:GO:1905951","description":"\"Any DNA recombination that takes place in mitochondrion.\" [GO_REF:0000062, GOC:TermGenie, PMID:8087883]","metadata":null},{"id":"f4927df474b947ec8d7396c4b0cf8585","type":"GO_TERM","name":"mitochondrion autophagosome adaptor activity","canonical_id":"go:GO:0140580","description":"\"The binding activity of a molecule that brings together a mitochondrial membrane and an autophagosome membrane during mitophagy.\" [PMID:33138913]","metadata":null},{"id":"d07f963b1ddd4fbcb6d7e8dbd504ac76","type":"GO_TERM","name":"mitochondrion distribution","canonical_id":"go:GO:0048311","description":"\"Any process that establishes the spatial arrangement of mitochondria between and within cells.\" [GOC:jid]","metadata":null},{"id":"ad9e65cfbeb546bca6d9c729fdcd6be1","type":"GO_TERM","name":"mitochondrion inheritance","canonical_id":"go:GO:0000001","description":"\"The distribution of mitochondria, including the mitochondrial genome, into daughter cells after mitosis or meiosis, mediated by interactions between mitochondria and the cytoskeleton.\" [GOC:mcc, PMID:10873824, PMID:11389764]","metadata":null},{"id":"7ef15f47e6d842319926bf23eb3eccdd","type":"GO_TERM","name":"mitochondrion localization","canonical_id":"go:GO:0051646","description":"\"Any process in which a mitochondrion or mitochondria are transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"47bb0d9482034150b2e60f5514110419","type":"GO_TERM","name":"mitochondrion migration along actin filament","canonical_id":"go:GO:0034642","description":"\"The directed movement of a mitochondrion along a microfilament, mediated by motor proteins.\" [GOC:mah, PMID:15979253, PMID:16306220]","metadata":null},{"id":"5a4780759f4740adabd6cfd3e2c081a7","type":"GO_TERM","name":"mitochondrion organization","canonical_id":"go:GO:0007005","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components.\" [GOC:dph, GOC:jl, GOC:mah, GOC:sgd_curators, PMID:9786946]","metadata":null},{"id":"afbaa314a44a41d992c84c97c08ff1b5","type":"GO_TERM","name":"mitochondrion to lysosome vesicle-mediated transport","canonical_id":"go:GO:0099074","description":"\"Vesicle-mediated transport of cargo from the mitochondrion to the lysosome, mediated by a mitochondrion-derived vesicle.\" [GOC:bc, GOC:pad, GOC:PARL-UCL, PMID:20619655]","metadata":null},{"id":"83f088d7d21a4ccb9262369ffbec338e","type":"GO_TERM","name":"mitochondrion to peroxisome vesicle-mediated transport","canonical_id":"go:GO:0099076","description":"\"Vesicle-mediated transport of cargo from the mitochondrion to the peroxisome, mediated by a mitochondrion-derived vesicle.\" [GOC:bc, GOC:pad, GOC:PARL-UCL, PMID:20619655]","metadata":null},{"id":"806a63603cfc48b5b52d50de76bcb3b1","type":"GO_TERM","name":"mitochondrion transport along microtubule","canonical_id":"go:GO:0047497","description":"\"The directed movement of a mitochondrion along a microtubule, mediated by motor proteins.\" [GOC:ecd]","metadata":null},{"id":"08b88ea023294ada8e123744684e28d3","type":"GO_TERM","name":"mitochondrion-associated adherens complex","canonical_id":"go:GO:0097423","description":"\"An organelle arrangement comprised of the following elements: a mitochondrion positioned near the presynaptic membrane; an electron-dense mitochondrial plaque adjacent to the outer mitochondrial membrane that faces the presynaptic membrane; filament-like elements appearing to link the mitochondrial plaque to a cell-cell junction region (sometimes termed punctum adherens); tubular or vesicular-appearing membrane (also called vesicular chain) interposed among the filaments. Mitochondrion-associated adherens complexes were initially described in the dorsal horn of the spinal cord. They are found in calyces and other large terminals of the auditory brainstem, and in a variety of mammalian species including humans.\" [NIF_Subcellular:sao1933817066, PMID:20089910]","metadata":null},{"id":"03afe0cb67654670a248b2599aabcba0","type":"GO_TERM","name":"mitochondrion-derived vesicle","canonical_id":"go:GO:0099073","description":"\"A vesicle derived via budding from a mitochondrion. These vesicles often contain inner membrane and, much more rarely, cristae.\" [GOC:bc, GOC:pad, GOC:PARL-UCL, PMID:18207745, PMID:20619655, PMID:22226745, PMID:23300790]","metadata":null},{"id":"18e63f4add72426486b3dcb613c38add","type":"GO_TERM","name":"mitochondrion-derived vesicle mediated transport","canonical_id":"go:GO:0099075","description":"\"Vesicle-mediated transport of cargo from the mitochondrion by a mitochondrion-derived vesicle.\" [GOC:bc, GOC:pad, GOC:PARL-UCL, PMID:20619655, PMID:37131163]","metadata":null},{"id":"0e6913722dd049e09992e9f9d638c8b9","type":"GO_TERM","name":"mitochondrion-endoplasmic reticulum membrane tether activity","canonical_id":"go:GO:0140474","description":"\"The binding activity of a molecule that brings together a mitochondrial outer membrane and an ER membrane either via membrane lipid binding or by interacting with a mitochondrial outer membrane protein, to establish or maintain the localization of the mitochondrion.\" [PMID:19556461, PMID:27875684]","metadata":null},{"id":"248579182522447fbe87c1c825b904ee","type":"GO_TERM","name":"mitochondrion-mitochondrion outer membrane tether activity","canonical_id":"go:GO:0160204","description":"\"The binding activity of a molecule that brings together two mitochondrion membranes via membrane lipid binding or by interacting with a mitochondrial outer membrane protein, to establish or maintain the localization of the mitochondrion.\" [PMID:38843396]","metadata":null},{"id":"feaca63e80c5441db02ca0991f8efc2a","type":"GO_TERM","name":"mitochondrion-plasma membrane adaptor activity","canonical_id":"go:GO:0140443","description":"\"The binding activity of a molecule that brings together a mitochondrial outer membrane and a plasma membrane either via membrane lipid binding or by interacting with a mitochondrial outer membrane protein, to establish or maintain the localization of the mitochondrion.\" [PMID:31582398]","metadata":null},{"id":"8c238396657641799492a04d421b91af","type":"GO_TERM","name":"mitocytosis","canonical_id":"go:GO:0160040","description":"\"A migrasome-mediated selective removal of damaged mitochondria process that maintains mitochondrion homeostasis in migrating cells.\" [PMID:34108688]","metadata":null},{"id":"2933cf0309114a808b48f69de78eabea","type":"GO_TERM","name":"mitogen-activated protein kinase binding","canonical_id":"go:GO:0051019","description":"\"Binding to a mitogen-activated protein kinase.\" [GOC:ai]","metadata":null},{"id":"a59d479f76194cb5b458e5477af2fb5a","type":"GO_TERM","name":"mitogen-activated protein kinase kinase binding","canonical_id":"go:GO:0031434","description":"\"Binding to a mitogen-activated protein kinase kinase, a protein that can phosphorylate a MAP kinase.\" [GOC:mah]","metadata":null},{"id":"70007e5729a54931aa24ec586917f26b","type":"GO_TERM","name":"mitogen-activated protein kinase kinase kinase binding","canonical_id":"go:GO:0031435","description":"\"Binding to a mitogen-activated protein kinase kinase kinase, a protein that can phosphorylate a MAP kinase kinase.\" [GOC:bf]","metadata":null},{"id":"bde3b348a15749259201237c3d4ffee7","type":"GO_TERM","name":"mitogen-activated protein kinase kinase kinase kinase binding","canonical_id":"go:GO:0033161","description":"\"Binding to a mitogen-activated protein kinase kinase kinase kinase, a protein that can phosphorylate a MAP kinase kinase kinase.\" [GOC:mah]","metadata":null},{"id":"f402e6a8ae1c473882557edb0c408161","type":"GO_TERM","name":"mitogen-activated protein kinase p38 binding","canonical_id":"go:GO:0048273","description":"\"Binding to mitogen-activated protein kinase p38, an enzyme that catalyzes the transfer of phosphate from ATP to hydroxyl side chains on proteins in response to mitogen activation.\" [GOC:curators, PMID:17827184]","metadata":null},{"id":"66f602fe818348668d2b1e6d06f85ab7","type":"GO_TERM","name":"mitomycin C biosynthetic process","canonical_id":"go:GO:1901777","description":"\"The chemical reactions and pathways resulting in the formation of mitomycin C.\" [GOC:TermGenie, GOC:yaf, PMID:10094699, PMID:10099135, UniPathway:UPA00851]","metadata":null},{"id":"5f773899a0ec4480b7e98dfcbb8e8655","type":"GO_TERM","name":"mitomycin C catabolic process","canonical_id":"go:GO:1901776","description":"\"The chemical reactions and pathways resulting in the breakdown of mitomycin C.\" [GOC:TermGenie, GOC:yaf, PMID:10094699, PMID:10099135]","metadata":null},{"id":"e1fe42f0b40e4315924598a08a451a3f","type":"GO_TERM","name":"mitophagy","canonical_id":"go:GO:0000423","description":"\"The selective autophagy process in which a mitochondrion is degraded by macroautophagy.\" [PMID:15798367]","metadata":null},{"id":"8b0114fa3e734fd1b5ca1c38dce75942","type":"GO_TERM","name":"mitophagy by internal vacuole formation","canonical_id":"go:GO:0035695","description":"\"The process in which cells degrade mitochondria by inducing a vacuole-like structure which directly engulfs and degrades the unhealthy mitochondria by accumulating lysosomes.\" [GOC:autophagy, GOC:bf, GOC:sp, PMID:21264228]","metadata":null},{"id":"aed4b2ea1ff7412e9af04a791bd68653","type":"GO_TERM","name":"mitosome","canonical_id":"go:GO:0032047","description":"\"A double-membrane-bounded organelle that functions in iron-sulfur protein maturation; evolutionarily derived from mitochondria. The mitosome has been detected only in anaerobic or microaerophilic organisms that do not have mitochondria, such as Entamoeba histolytica, Giardia intestinalis and several species of Microsporidia. These organisms are not capable of gaining energy from oxidative phosphorylation, which is normally performed by mitochondria.\" [GOC:giardia, PMID:10361303, PMID:14614504, PMID:24316280]","metadata":null},{"id":"a1ce88e0be9048f29647f4e1f12ed905","type":"GO_TERM","name":"mitotic DNA damage checkpoint signaling","canonical_id":"go:GO:0044773","description":"\"A signal transduction process involved in mitotic DNA damage checkpoint.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"c39cb0f1a23348eca466e664fc48eadb","type":"GO_TERM","name":"mitotic DNA integrity checkpoint signaling","canonical_id":"go:GO:0044774","description":"\"A signaling process that controls cell cycle progression in response to changes in DNA structure by monitoring the integrity of the DNA during mitosis. The DNA integrity checkpoint begins with detection of DNA damage, defects in DNA structure or DNA replication, and ends with signal transduction.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"a64f7d5e3568417c917c5d5575485f55","type":"GO_TERM","name":"mitotic DNA replication","canonical_id":"go:GO:1902969","description":"\"Any nuclear DNA replication that is involved in a mitotic cell cycle.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"e7a5c277b46b41c892072625279192f2","type":"GO_TERM","name":"mitotic DNA replication checkpoint signaling","canonical_id":"go:GO:0033314","description":"\"A signal transduction process that contributes to a mitotic DNA replication checkpoint.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"2d77ff5b40d14fdbb1ca2f21d45c4d39","type":"GO_TERM","name":"mitotic DNA replication initiation","canonical_id":"go:GO:1902975","description":"\"Any DNA replication initiation involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"d8dc3f57c24f4c1ba4b4114e9a8cbe5f","type":"GO_TERM","name":"mitotic DNA replication lagging strand elongation","canonical_id":"go:GO:1903459","description":"\"Any lagging strand elongation that is involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"86f17e529236444b906297c26d00bead","type":"GO_TERM","name":"mitotic DNA replication leading strand elongation","canonical_id":"go:GO:1903460","description":"\"Any leading strand elongation that is involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"29dcdbb36ddd4766b677bef7591cf470","type":"GO_TERM","name":"mitotic DNA replication maintenance of fidelity","canonical_id":"go:GO:1990505","description":"\"Any maintenance of fidelity that is involved in mitotic cell cycle DNA replication.\" [PMID:19185548]","metadata":null},{"id":"bb21a0957abd4e9987f074b33f381b97","type":"GO_TERM","name":"mitotic DNA replication preinitiation complex assembly","canonical_id":"go:GO:1902977","description":"\"Any DNA replication preinitiation complex assembly that is involved in mitotic cell cycle.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"400dba756a33477ca6a86b683090b469","type":"GO_TERM","name":"mitotic DNA replication termination","canonical_id":"go:GO:1902979","description":"\"Any DNA replication termination involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"7f21f0af7ed34f5bb09ce798c7301a83","type":"GO_TERM","name":"mitotic DNA-templated DNA replication","canonical_id":"go:GO:1990506","description":"\"A DNA replication process that uses parental DNA as a template for the DNA-dependent DNA polymerases that synthesize the new strands during the mitotic cell cycle.\" [PMID:16120966]","metadata":null},{"id":"5b396bd901f044029d917acfebc649e1","type":"GO_TERM","name":"mitotic G1 DNA damage checkpoint signaling","canonical_id":"go:GO:0031571","description":"\"A signal transduction process that contributes to a mitotic cell cycle G1/S transition DNA damage checkpoint.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"0e23eeefc17d4175a870eb52d78c15b9","type":"GO_TERM","name":"mitotic G1 cell size control checkpoint signaling","canonical_id":"go:GO:0031568","description":"\"A signal transduction process that contributes to a cell size control checkpoint during the G1/S transition of the cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"98a123df94b64a219e3c29b11f94871d","type":"GO_TERM","name":"mitotic G1 phase","canonical_id":"go:GO:0000080","description":"\"The cell cycle 'gap' phase which is the interval between the completion of DNA segregation by mitosis and the beginning of DNA synthesis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"29aee628b84d40b081d03a1299f12e5f","type":"GO_TERM","name":"mitotic G1/S transition checkpoint signaling","canonical_id":"go:GO:0044819","description":"\"A cell cycle checkpoint that detects and negatively regulates progression from G1 to S phase as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"3c7fcf924a744ea7bcc26c648f1cca4d","type":"GO_TERM","name":"mitotic G2 DNA damage checkpoint signaling","canonical_id":"go:GO:0007095","description":"\"A mitotic cell cycle checkpoint that detects and negatively regulates progression through the G2/M transition of the cell cycle in response to DNA damage.\" [GOC:mtg_cell_cycle, PMID:16299494]","metadata":null},{"id":"7330333d2656477296d3d56e60c3fb66","type":"GO_TERM","name":"mitotic G2 cell cycle arrest in response to glucose starvation","canonical_id":"go:GO:0036227","description":"\"The process in which the mitotic cell cycle is halted during G2 phase as a result of deprivation of glucose.\" [GOC:al, GOC:mah, GOC:mtg_cell_cycle, PMID:958201]","metadata":null},{"id":"0df32f02ca384baea64e1fb6aecb775e","type":"GO_TERM","name":"mitotic G2 cell size control checkpoint signaling","canonical_id":"go:GO:0031569","description":"\"A signal transduction process that contributes to a cell size control checkpoint prior to the G2/M transition of mitosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"17fc461a71164951a393927aa44fdc9b","type":"GO_TERM","name":"mitotic G2 phase","canonical_id":"go:GO:0000085","description":"\"The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation by mitosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"1c12d1fb196e47ce911f1cc2c2b36dbb","type":"GO_TERM","name":"mitotic G2/M transition checkpoint","canonical_id":"go:GO:0044818","description":"\"A cell cycle checkpoint that detects and negatively regulates progression from G2 to M phase as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"bbe1e676a5a94366b373f55b2ce0716b","type":"GO_TERM","name":"mitotic M phase","canonical_id":"go:GO:0000087","description":"\"A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase and occurs as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"27743714e02f43e8838bbabac8acc983","type":"GO_TERM","name":"mitotic S phase","canonical_id":"go:GO:0000084","description":"\"The cell cycle phase, following G1, during which DNA synthesis takes place as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"5070bb3c3fcd419da12420707aa9bef4","type":"GO_TERM","name":"mitotic actomyosin contractile ring","canonical_id":"go:GO:0110085","description":"\"A cytoskeletal structure composed of actin filaments, myosin, and myosin-associated proteins that forms beneath the plasma membrane of many cells, including animal cells and yeast cells, in a plane perpendicular to the axis of the mitotic spindle, i.e. the cell division plane. Ring contraction is associated with centripetal growth of the membrane that divides the cytoplasm of the two future daughter cells. In animal cells, the mitotic contractile ring is located inside the plasma membrane at the location of the cleavage furrow. In budding fungal cells, e.g. mitotic S. cerevisiae cells, the mitotic contractile ring forms beneath the plasma membrane at the mother-bud neck before mitosis.\" [GOC:vw, PMID:27505246]","metadata":null},{"id":"a6bb39e815b843589bd28d829b3912d0","type":"GO_TERM","name":"mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:1903475","description":"\"Any actomyosin contractile ring assembly that is involved in mitotic cytokinesis.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"f0373779bc7749dc9c1a1f95f9dca55e","type":"GO_TERM","name":"mitotic actomyosin contractile ring assembly actin filament organization","canonical_id":"go:GO:1903479","description":"\"Any actin filament organization that is involved in mitotic actomyosin contractile ring assembly.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"59d8181ecb624ab9b1a2494a8fb34270","type":"GO_TERM","name":"mitotic actomyosin contractile ring contraction","canonical_id":"go:GO:1902404","description":"\"Any actomyosin contractile ring contraction that is involved in mitotic cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"13b1912624e3465cac9cac42e62b3325","type":"GO_TERM","name":"mitotic actomyosin contractile ring maturation","canonical_id":"go:GO:1902406","description":"\"The cellular process in which the mitotic contractile ring cytokinetic ring attains its fully functional state.\" [PMID:25451933]","metadata":null},{"id":"f0895f7385f4499a9d84dbe005958d8a","type":"GO_TERM","name":"mitotic actomyosin contractile ring, distal actin filament layer","canonical_id":"go:GO:0120106","description":"\"The region of the mitotic actomyosin ring containing actin filaments and cross linkers, myosin motors, and connections to the plasma membrane through the intermediate layer. It is further from the plasma membrane than the intermediate layer which it is adjacent to.\" [GOC:krc, GOC:vw, PMID:28914606]","metadata":null},{"id":"67b970501ec84bb6b39d49cbc09d99bd","type":"GO_TERM","name":"mitotic actomyosin contractile ring, intermediate layer","canonical_id":"go:GO:0120105","description":"\"The region of the mitotic actomyosin ring in between the proximal layer and the actin filament layer. This region contains the accessory protein network, some actin filaments and connections between the proximal layer and the actin filament layer.\" [GOC:krc, GOC:vw, PMID:28914606]","metadata":null},{"id":"3144720359d74da8a9c9d2e7db7393ee","type":"GO_TERM","name":"mitotic actomyosin contractile ring, proximal layer","canonical_id":"go:GO:0120104","description":"\"The region of the mitotic actomyosin ring adjacent to the plasma membrane where membrane bound scaffolds are located.\" [GOC:krc, GOC:vw, PMID:28914606]","metadata":null},{"id":"e7e9d3f6025b41048435d06f854b48af","type":"GO_TERM","name":"mitotic anaphase","canonical_id":"go:GO:0000090","description":"\"The cell cycle phase during which chromosomes separate and migrate towards the poles of the spindle the as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"74e30708666c4915a1c5a02f579fd2ae","type":"GO_TERM","name":"mitotic anaphase A","canonical_id":"go:GO:0000091","description":"\"The cell cycle phase during which the kinetochore microtubules shorten as chromosomes move toward the spindle poles as part of mitosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"b2430dc65afb46c898de65db41b9cd42","type":"GO_TERM","name":"mitotic anaphase B","canonical_id":"go:GO:0000092","description":"\"The cell cycle phase during which the polar microtubules elongate and the two poles of the spindle move farther apart as part of mitosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"fb1d3b90de9f4d44b108b3a4e6bc39d8","type":"GO_TERM","name":"mitotic cell cycle","canonical_id":"go:GO:0000278","description":"\"Progression through the phases of the mitotic cell cycle, the most common eukaryotic cell cycle, which canonically comprises four successive phases called G1, S, G2, and M and includes replication of the genome and the subsequent segregation of chromosomes into daughter cells. In some variant cell cycles nuclear replication or nuclear division may not be followed by cell division, or G1 and G2 phases may be absent.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"f0fc3043ba754720bd03c9d148ed9f25","type":"GO_TERM","name":"mitotic cell cycle G1 arrest in response to pheromone","canonical_id":"go:GO:0000751","description":"\"The cell cycle regulatory process in which the mitotic cell cycle is halted during G1 as a result of a pheromone stimulus. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:clt, GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"6b4c01edf665485a8f4a3e21b5b42f98","type":"GO_TERM","name":"mitotic cell cycle checkpoint signaling","canonical_id":"go:GO:0007093","description":"\"A signaling process that ensures accurate chromosome replication and segregation by preventing progression through a mitotic cell cycle until conditions are suitable for the cell to proceed to the next stage.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"7c707cb32fe84d2fbccdf191a38f5dc6","type":"GO_TERM","name":"mitotic cell cycle phase","canonical_id":"go:GO:0098763","description":"\"One of the distinct periods or stages into which the mitotic cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events.\" [GOC:dos]","metadata":null},{"id":"33d5f586c88943d691ea174ea371248c","type":"GO_TERM","name":"mitotic cell cycle phase transition","canonical_id":"go:GO:0044772","description":"\"The cell cycle process by which a cell commits to entering the next mitotic cell cycle phase.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"f9f9f8537e364a4e97dd49e1122c032c","type":"GO_TERM","name":"mitotic cell cycle process","canonical_id":"go:GO:1903047","description":"\"A process that is part of the mitotic cell cycle.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"c91a856fcb1843ab89e5c2cbad9f9d6c","type":"GO_TERM","name":"mitotic cell cycle, embryonic","canonical_id":"go:GO:0045448","description":"\"The eukaryotic cell cycle in which a cell is duplicated without changing ploidy, occurring in the embryo.\" [GOC:curators]","metadata":null},{"id":"91cf5f9d92b4469f8862eeadf93a5a09","type":"GO_TERM","name":"mitotic cell size control checkpoint signaling","canonical_id":"go:GO:0031567","description":"\"A signal transduction process that contributes to a cell size control checkpoint during mitosis.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"324ec0de24b64a7cb20df1968df2562c","type":"GO_TERM","name":"mitotic centrosome separation","canonical_id":"go:GO:0007100","description":"\"Separation of duplicated centrosome components at the beginning of mitosis. The centriole pair within each centrosome becomes part of a separate microtubule organizing center that nucleates a radial array of microtubules called an aster. The two asters move to opposite sides of the nucleus to form the two poles of the mitotic spindle.\" [ISBN:0815316194]","metadata":null},{"id":"a5f1dbfdbd0e4cb69c09bd9869409809","type":"GO_TERM","name":"mitotic checkpoint complex","canonical_id":"go:GO:0033597","description":"\"A multiprotein complex that functions as a mitotic checkpoint inhibitor of the anaphase-promoting complex/cyclosome (APC/C). In budding yeast this complex consists of Mad2p, Mad3p, Bub3p and Cdc20p, and in mammalian cells it consists of MAD2, BUBR1, BUB3, and CDC20.\" [PMID:10704439, PMID:11535616, PMID:11726501, PMID:17650307]","metadata":null},{"id":"79fe54362bdc44d4b2935ebf7c70f793","type":"GO_TERM","name":"mitotic checkpoint complex assembly","canonical_id":"go:GO:1905660","description":"\"The aggregation, arrangement and bonding together of a set of components to form a mitotic checkpoint complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:26882497]","metadata":null},{"id":"202fb9c578524584915b4acedca6ff8e","type":"GO_TERM","name":"mitotic checkpoint complex, CDC20-MAD2 subcomplex","canonical_id":"go:GO:1990333","description":"\"A protein complex involved in the spindle checkpoint, preventing the activation of the anaphase-promoting complex until all chromosomes are correctly attached in a bipolar fashion to the mitotic spindle. In budding yeast this complex consists of Mad2p and Cdc20p, and in mammalian cells it consists of MAD2 and CDC20.\" [GOC:bhm, PMID:15879521]","metadata":null},{"id":"e0e615f782364f518bc032c81f2a5445","type":"GO_TERM","name":"mitotic chromosome arm condensation","canonical_id":"go:GO:1990892","description":"\"The cell cycle process in which chromosome arm chromatin structure is compacted prior to and during mitosis in eukaryotic cells.\" [PMID:21633354]","metadata":null},{"id":"e80248a598df4ea098e3d203dbc309df","type":"GO_TERM","name":"mitotic chromosome centromere condensation","canonical_id":"go:GO:1990893","description":"\"The cell cycle process in which centromere chromatin structure is compacted prior to and during mitosis.\" [PMID:21633354]","metadata":null},{"id":"3dfea126632b4c6eae7546ff01fbc9a5","type":"GO_TERM","name":"mitotic chromosome condensation","canonical_id":"go:GO:0007076","description":"\"The cell cycle process in which chromatin structure is compacted prior to and during mitosis in eukaryotic cells.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"3645bb2e08814f34a847b652c7dcee49","type":"GO_TERM","name":"mitotic chromosome movement towards spindle pole","canonical_id":"go:GO:0007079","description":"\"The cell cycle process in which the directed movement of chromosomes from the center of the spindle towards the spindle poles occurs. This mediates by the shortening of microtubules attached to the chromosomes, during mitosis.\" [GOC:ai]","metadata":null},{"id":"b344c8179eaf417d947236e54c2f2d0c","type":"GO_TERM","name":"mitotic cleavage furrow formation","canonical_id":"go:GO:1903673","description":"\"Any cleavage furrow formation that is involved in mitotic cell cycle.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"da8f8f9d25fa4d71b195ce5bf3725cbf","type":"GO_TERM","name":"mitotic cleavage furrow ingression","canonical_id":"go:GO:1990386","description":"\"Advancement of the mitotic cleavage furrow from the outside of the cell inward towards the center of the cell. The cleavage furrow acts as a 'purse string' which draws tight to separate daughter cells during mitotic cytokinesis and partition the cytoplasm between the two daughter cells. The furrow ingresses until a cytoplasmic bridge is formed.\" [GOC:kmv, PMID:12707312]","metadata":null},{"id":"7e7398c8975f44ecba1990c01d470944","type":"GO_TERM","name":"mitotic cohesin complex","canonical_id":"go:GO:0030892","description":"\"A cohesin complex that mediates sister chromatid cohesion during mitosis; has a subunit composition distinct from that of the meiotic cohesin complex.\" [GOC:mah, PMID:12750522]","metadata":null},{"id":"1bfb0e38bf01449a81e2710380a2f0bb","type":"GO_TERM","name":"mitotic contractile ring actin filament bundle assembly","canonical_id":"go:GO:1903477","description":"\"Any actin filament bundle assembly that is involved in mitotic actomyosin contractile ring assembly.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"9da9866662c44cb9beb29301d242756d","type":"GO_TERM","name":"mitotic cytokinesis","canonical_id":"go:GO:0000281","description":"\"A cell cycle process that results in the division of the cytoplasm of a cell after mitosis, resulting in the separation of the original cell into two daughter cells.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"9bc2f60d28f547be97152072b33786eb","type":"GO_TERM","name":"mitotic cytokinesis checkpoint signaling","canonical_id":"go:GO:0044878","description":"\"A signaling process that contributes to a mitotic cell cycle checkpoint that detects a defect in cytokinesis and prevents further rounds of nuclear division until cytokinesis is completed.\" [GOC:jl, GOC:mtg_cell_cycle, PMID:17538026]","metadata":null},{"id":"c743a12f61a246f6b9eeb3a2fe12d12c","type":"GO_TERM","name":"mitotic cytokinesis, division site positioning","canonical_id":"go:GO:1902408","description":"\"The process in which a contractile ring is positioned in a specific location during the mitotic cell cycle. This process is critical for both for both symmetric and asymmetric cell divisions.\" [PMID:26553932, PMID:28162898]","metadata":null},{"id":"816a1d99873b4412b7839d46f8f098c3","type":"GO_TERM","name":"mitotic cytokinetic process","canonical_id":"go:GO:1902410","description":"\"Any cytokinetic process that is involved in mitotic cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"0216be88210f4477a32ff230483c3c54","type":"GO_TERM","name":"mitotic division septum assembly","canonical_id":"go:GO:0140278","description":"\"The assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following mitotic cytokinesis. The progeny cells that form a division septum are not able to exchange intracellular material.\" [PMID:22786806]","metadata":null},{"id":"d3310041f64e481e9ef4ea8ead1b39ce","type":"GO_TERM","name":"mitotic interphase","canonical_id":"go:GO:0051329","description":"\"The cell cycle phase following cytokinesis which begins with G1 phase, proceeds through S phase and G2 phase and ends when mitotic prophase begins. During interphase the cell readies itself for mitosis and the replication of its DNA occurs.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"c4a300380b4e4251aadacdeac2fef8b5","type":"GO_TERM","name":"mitotic intra-S DNA damage checkpoint signaling","canonical_id":"go:GO:0031573","description":"\"A mitotic cell cycle checkpoint that slows DNA synthesis in response to DNA damage by the prevention of new origin firing and the stabilization of slow replication fork progression.\" [GOC:vw]","metadata":null},{"id":"a415192955c44b79b4ec1bd8ad65382a","type":"GO_TERM","name":"mitotic metaphase","canonical_id":"go:GO:0000089","description":"\"The cell cycle phase, following prophase, during which chromosomes become aligned on the equatorial plate of the cell as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"b8d0d817c0744eef91290caf157fe496","type":"GO_TERM","name":"mitotic metaphase chromosome alignment","canonical_id":"go:GO:0007080","description":"\"A chromosome localization process whereby chromosomes are positioned in a specific order and orientation at the metaphase plate (spindle equator), during mitotic chromosome segregation. This alignment ensures that each daughter cell will receive the correct number of chromosomes during cell division.\" [ISBN:0815316194]","metadata":null},{"id":"1575cff301ff49eda490ac70f9e9d08a","type":"GO_TERM","name":"mitotic metaphase chromosome recapture","canonical_id":"go:GO:1990942","description":"\"A mechanism to recapture 'lost' chromosomes (chromosomes which have become detached from the spindle) during metaphase of mitotic chromosome segregation. Chromosomes with unattached kinetochores are migrated along (non polar) spindle microtubules to the mitotic spindle pole body by a combination of microtubule depolymerisation and 'kinetochore sliding' (migration of the chromosome along the microtubule). The chromosome subsequently migrates along the polar spindle microtubule to the metaphase plate.\" [PMID:18256284]","metadata":null},{"id":"4a77738a639a417c979ea57514ad819f","type":"GO_TERM","name":"mitotic morphogenesis checkpoint signaling","canonical_id":"go:GO:0044879","description":"\"A signaling process that contributes to a mitotic cell cycle checkpoint which delays mitotic onset in response to perturbations that affect cell shape via the actin cytoskeleton, septin organization, small cell size, and/or the extent of membrane growth.\" [GOC:jl, GOC:mtg_cell_cycle]","metadata":null},{"id":"c408e5fc9b1d4593b1d078b0e1b17cfe","type":"GO_TERM","name":"mitotic nuclear bridge","canonical_id":"go:GO:0140510","description":"\"A narrow constricted region of the nucleus that forms around the anaphase spindle during closed mitosis, and connects the main portions of the newly forming daughter nuclei.\" [PMID:32848252]","metadata":null},{"id":"ee799945911b46da8fa945fb8adde65b","type":"GO_TERM","name":"mitotic nuclear bridge midzone","canonical_id":"go:GO:0140512","description":"\"The central region of a mitotic nuclear bridge, distal to the main portions of the daughter nuclei.\" [PMID:32848252]","metadata":null},{"id":"3e7c3323e86d43cd8bdc8fcfdc5c236c","type":"GO_TERM","name":"mitotic nuclear bridge midzone membrane domain","canonical_id":"go:GO:0140599","description":"\"A nuclear membrane part at the midzone of the mitotic nuclear bridge. The midzone forms a bulge that is enriched in nuclear pores that lack baskets.\" [PMID:25963819, PMID:32502403]","metadata":null},{"id":"7125cb13b2d84c8aa11f0fb2210347fe","type":"GO_TERM","name":"mitotic nuclear bridge organization","canonical_id":"go:GO:0140515","description":"\"A mitotic cell cycle process which results in the assembly, arrangement, or disassembly of the mitotic nuclear bridge during closed mitosis.\" [PMID:32848252]","metadata":null},{"id":"d2a23260881d4966ad1b867d2e8961db","type":"GO_TERM","name":"mitotic nuclear bridge stalk","canonical_id":"go:GO:0140511","description":"\"Either of the regions of a mitotic nuclear bridge proximal to the main portion of each daughter nucleus. The nuclear envelope in the stalk regions is depleted of nuclear pore complexes.\" [PMID:32848252]","metadata":null},{"id":"55311ba2bd234d81af7b706640c2d617","type":"GO_TERM","name":"mitotic nuclear division","canonical_id":"go:GO:0140014","description":"\"A mitotic cell cycle process comprising the steps by which the nucleus of a eukaryotic cell divides; the process involves condensation of chromosomal DNA into a highly compacted form. Canonically, mitosis produces two daughter nuclei whose chromosome complement is identical to that of the mother cell.\" [ISBN:0198547684]","metadata":null},{"id":"a042fd215c624bdaac15c595295d846e","type":"GO_TERM","name":"mitotic nuclear envelope segregation","canonical_id":"go:GO:0160052","description":"\"The mitotic cell cycle process in which the nuclear envelope, including nuclear pores, is equally distributed to the two daughter cells during the mitotic cell cycle.\" [GOC:vw, PMID:24184107]","metadata":null},{"id":"a3e398c804864b1bad13d4e8e2bab2e0","type":"GO_TERM","name":"mitotic nuclear membrane biogenesis","canonical_id":"go:GO:0101026","description":"\"A process in which the nuclear inner or outer membrane is synthesized, aggregates, and bonds together during mitotic nuclear division.\" [GOC:vw, PMID:26869222]","metadata":null},{"id":"d9da04549a2e442ab8203c435b147342","type":"GO_TERM","name":"mitotic nuclear membrane disassembly","canonical_id":"go:GO:0007077","description":"\"The mitotic cell cycle process in which the controlled partial or complete breakdown of the nuclear membranes during occurs during mitosis.\" [GOC:bf, PMID:32848252]","metadata":null},{"id":"0d7c6d2a31394cc4a921d3c1d981337b","type":"GO_TERM","name":"mitotic nuclear membrane microtubule tethering complex","canonical_id":"go:GO:0106084","description":"\"A protein complex capable of interacting with the spindle pole body and the nuclear envelope, in order to embed the spindle pole body in the nuclear envelope at fusion sites of the inner and outer nuclear membrane.\" [GOC:lnp, PMID:28356353]","metadata":null},{"id":"de0e39cab1be412ea361219aa5867b59","type":"GO_TERM","name":"mitotic nuclear membrane organization","canonical_id":"go:GO:0101024","description":"\"A mitotic cell cycle process which results in the assembly, arrangement, or disassembly of the nuclear inner or outer membrane during mitosis.\" [GOC:vw, PMID:15147872]","metadata":null},{"id":"78105fcd139a4ed5b97b57baa8977d61","type":"GO_TERM","name":"mitotic nuclear membrane reassembly","canonical_id":"go:GO:0007084","description":"\"The mitotic cell cycle process involving ESCRTIII that results in reformation of the nuclear envelope after mitotic nuclear division. In organisms undergoing closed mitosis this involves resealing or 'repair' of the nuclear envelope in the nuclear bridge.\" [PMID:26040712, PMID:28242692, PMID:32109380, PMID:32848252]","metadata":null},{"id":"2e209171bd634971acac11a8b718feb4","type":"GO_TERM","name":"mitotic nuclear pore complex disassembly","canonical_id":"go:GO:0140516","description":"\"The mitotic cell cycle process in which the controlled breakdown of the nuclear pores occurs during open or closed mitosis.\" [PMID:32848252]","metadata":null},{"id":"ea022bd706cc46d5881247098711e7d7","type":"GO_TERM","name":"mitotic nuclear pore complex reassembly","canonical_id":"go:GO:0007087","description":"\"The cell cycle process in which nuclear pore complexes reform during mitotic cell division.\" [GOC:ai]","metadata":null},{"id":"d0f92cdda91a4cb5981dc2dd659b10cb","type":"GO_TERM","name":"mitotic pre-replicative complex assembly","canonical_id":"go:GO:1902985","description":"\"Any pre-replicative complex assembly involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"f45d59166ef34893bd17cb2150ee3f2e","type":"GO_TERM","name":"mitotic prometaphase","canonical_id":"go:GO:0000236","description":"\"The cell cycle phase in higher eukaryotes which follows mitotic prophase and during which the nuclear envelope is disrupted and breaks into membrane vesicles, and the spindle microtubules enter the nuclear region. Kinetochores mature on each centromere and attach to some of the spindle microtubules. Kinetochore microtubules begin the process of aligning chromosomes in one plane halfway between the poles.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"faa61f11227942d7bb13835b3938c6a0","type":"GO_TERM","name":"mitotic prophase","canonical_id":"go:GO:0000088","description":"\"The cell cycle phase which is the first stage of M phase of mitosis and during which chromosomes condense and the two daughter centrioles and their asters migrate toward the poles of the cell.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"5192673feee0462c91f0a1c365e844da","type":"GO_TERM","name":"mitotic recombination","canonical_id":"go:GO:0006312","description":"\"The exchange, reciprocal or nonreciprocal, of genetic material between one DNA molecule and a homologous DNA region that occurs during mitotic cell cycles.\" [GOC:elh]","metadata":null},{"id":"8a3b8ffc682d4dab9f23135662176281","type":"GO_TERM","name":"mitotic recombination-dependent replication fork processing","canonical_id":"go:GO:1990426","description":"\"Replication fork processing that includes recombination between DNA near the arrested fork and homologous sequences. Proteins involved in homologous recombination are required for replication restart.\" [GOC:mah, PMID:23093942]","metadata":null},{"id":"5ffc4d8a9c114bf28e62acf9ed36dc16","type":"GO_TERM","name":"mitotic septin complex","canonical_id":"go:GO:0032151","description":"\"A heterooligomeric septin complex that acts during mitotic cell division.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"98aeb996230544478cc4870581528ac6","type":"GO_TERM","name":"mitotic sister chromatid arm separation","canonical_id":"go:GO:1990891","description":"\"The cell cycle process in which sister chromatid arms are physically detached from each other during mitosis.\" [PMID:21633354]","metadata":null},{"id":"878cf4edbc3f4be7b23155768988d439","type":"GO_TERM","name":"mitotic sister chromatid biorientation","canonical_id":"go:GO:1990758","description":"\"The mitotic cell cycle process in which sister chromatids establish stable, end-on attachments to the plus ends of microtubules emanating from opposite spindle poles, oriented such that separation can proceed. This is the final step in metaphase plate congression.\" [PMID:15309047, PMID:26258632, PMID:26705896]","metadata":null},{"id":"1c7ff8bf97534f4396926436021a87c1","type":"GO_TERM","name":"mitotic sister chromatid cohesion","canonical_id":"go:GO:0007064","description":"\"The cell cycle process in which the sister chromatids of a replicated chromosome are joined along the entire length of the chromosome, from their formation in S phase through metaphase during a mitotic cell cycle. This cohesion cycle is critical for high fidelity chromosome transmission.\" [GOC:ai, GOC:rn, PMID:10827941, PMID:11389843, PMID:14623866]","metadata":null},{"id":"28bc96c8aa6048e7afe4298712cc410c","type":"GO_TERM","name":"mitotic sister chromatid cohesion, arms","canonical_id":"go:GO:0071961","description":"\"The cell cycle process in which the sister chromatids of a replicated chromosome are joined along the length of the chromosome arms during mitosis.\" [GOC:mah]","metadata":null},{"id":"6a5bcd875466479d95302588a2d9d8d6","type":"GO_TERM","name":"mitotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:0071962","description":"\"The cell cycle process in which centromeres of sister chromatids are joined during mitosis.\" [GOC:mah]","metadata":null},{"id":"dabcce2d4b8e4a8ea0f5245b83bf4a89","type":"GO_TERM","name":"mitotic sister chromatid cohesion, telomeric","canonical_id":"go:GO:0099404","description":"\"The cell cycle process in which telomeres of sister chromatids are joined during mitosis.\" [GOC:BHF, GOC:BHF_telomere, GOC:mah, GOC:rph, PMID:26373281]","metadata":null},{"id":"9ef7ad02f67745c683de1b45e741647b","type":"GO_TERM","name":"mitotic sister chromatid segregation","canonical_id":"go:GO:0000070","description":"\"The cell cycle process in which replicated homologous chromosomes are organized and then physically separated and apportioned to two sets during the mitotic cell cycle. Each replicated chromosome, composed of two sister chromatids, aligns at the cell equator, paired with its homologous partner. One homolog of each morphologic type goes into each of the resulting chromosome sets.\" [GOC:ai, GOC:jl]","metadata":null},{"id":"ed3cda38d4444352b04b4bd8e5966a01","type":"GO_TERM","name":"mitotic sister chromatid separation","canonical_id":"go:GO:0051306","description":"\"The process in which sister chromatids are physically detached from each other during mitosis.\" [GOC:ai]","metadata":null},{"id":"59e24e5725154448a8d2bfa3d3f16f12","type":"GO_TERM","name":"mitotic spindle","canonical_id":"go:GO:0072686","description":"\"A spindle that forms as part of mitosis. Mitotic and meiotic spindles contain distinctive complements of proteins associated with microtubules.\" [GOC:mah, GOC:vw, PMID:11408572, PMID:18367542, PMID:8027178]","metadata":null},{"id":"bd04ca969c3541c780e8a33117bcc451","type":"GO_TERM","name":"mitotic spindle assembly","canonical_id":"go:GO:0090307","description":"\"Mitotic bipolar spindle assembly begins with spindle microtubule nucleation from the separated spindle pole body, includes spindle elongation during prometaphase, and is complete when all kinetochores are stably attached the spindle, and the spindle assembly checkpoint is satisfied.\" [GOC:tb, GOC:vw]","metadata":null},{"id":"73ca69a244ec4fe0ad12463c3624e740","type":"GO_TERM","name":"mitotic spindle assembly checkpoint MAD1-MAD2 complex","canonical_id":"go:GO:1990728","description":"\"A protein complex involved in the assembly of the mitotic checkpoint complex that in turn inhibits the anaphase promoting complex/cyclosome (APC/C). The MAD1 dimer recruits the open form of MAD2 (O-MAD2) turning it into the closed form (C-MAD2) upon binding. C-MAD2 inhibits CDC20, a member of the APC/C, upon release from the MAD1-MAD2 complex.\" [GOC:bhm, PMID:12006501, PMID:22898774]","metadata":null},{"id":"28274e0788f04e4cba3a13ebd59bb73e","type":"GO_TERM","name":"mitotic spindle assembly checkpoint signaling","canonical_id":"go:GO:0007094","description":"\"A mitotic cell cycle checkpoint that delays mitotic sister chromatid separation and consequently the mitotic metaphase/anaphase transition until the spindle is correctly assembled and chromosomes are attached to the spindle. Spindle assembly checkpoint signaling begins with the activated Mph family kinase, and results in the inhibition of the Anaphase Promoting Complex and its activator Sleepy/Cdc20 by the mitotic checkpoint complex (MCC).\" [GOC:mtg_cell_cycle, PMID:12360190]","metadata":null},{"id":"bca7a802396041f284359b37339ac3fb","type":"GO_TERM","name":"mitotic spindle astral microtubule","canonical_id":"go:GO:0061673","description":"\"Any of the mitotic spindle microtubules that radiate in all directions from the spindle poles and are thought to contribute to the forces that separate the poles and position them in relation to the rest of the cell.\" [GOC:dph]","metadata":null},{"id":"cf907771ac4f4dc48afd21742a9cb429","type":"GO_TERM","name":"mitotic spindle astral microtubule end","canonical_id":"go:GO:1905721","description":"\"Any microtubule end that is part of a mitotic spindle astral microtubule.\" [GO_REF:0000064, GOC:TermGenie, PMID:11007487]","metadata":null},{"id":"a021050567e544b78093d93f1e1e1030","type":"GO_TERM","name":"mitotic spindle checkpoint signaling","canonical_id":"go:GO:0071174","description":"\"A signaling process that contributes to a mitotic cell cycle checkpoint that originates from the spindle and delays the metaphase/anaphase transition of a mitotic nuclear division until the spindle is correctly assembled and oriented, the completion of anaphase until chromosomes are attached to the spindle, or mitotic exit and cytokinesis when the spindle does not form.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"704730e1787540b599c1e0e7c0e3ed66","type":"GO_TERM","name":"mitotic spindle disassembly","canonical_id":"go:GO:0051228","description":"\"The controlled breakdown of the spindle during a mitotic cell cycle.\" [GOC:ai]","metadata":null},{"id":"04d41e5ed6ab4eb39ae8d5f14aedf745","type":"GO_TERM","name":"mitotic spindle elongation","canonical_id":"go:GO:0000022","description":"\"The cell cycle process in which the distance is lengthened between poles of the mitotic spindle. Mitotic spindle elongation begins during mitotic prophase and ends during mitotic anaphase B.\" [GOC:mtg_cell_cycle, GOC:vw, PMID:19686686]","metadata":null},{"id":"c7752020ece94c24bb5ca39ee8b83607","type":"GO_TERM","name":"mitotic spindle elongation (spindle phase three)","canonical_id":"go:GO:0061805","description":"\"The cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic anaphase B.\" [GOC:dph, GOC:vw, PMID:21920317]","metadata":null},{"id":"cd64bbf3134540fc996688e9009729e0","type":"GO_TERM","name":"mitotic spindle formation (spindle phase one)","canonical_id":"go:GO:0061804","description":"\"The cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic prophase.\" [GOC:dph, GOC:vw, PMID:21920317]","metadata":null},{"id":"c3f3e3c770c741b6b0f9cfc25999f8ef","type":"GO_TERM","name":"mitotic spindle formation (spindle phase two)","canonical_id":"go:GO:0140641","description":"\"The spindle organization process in which the spindle is maintained at a constant length during mitotic metaphase.\" [PMID:32723864]","metadata":null},{"id":"30a57775e99f4922a86421189c06143e","type":"GO_TERM","name":"mitotic spindle kinetochore microtubule","canonical_id":"go:GO:1990941","description":"\"Any of the mitotic spindle microtubules that attach to the kinetochores of chromosomes by their plus ends, and maneuver the chromosomes during mitotic chromosome segregation.\" [PMID:18256284]","metadata":null},{"id":"87b13c3980d842d4828a16ed65f7f948","type":"GO_TERM","name":"mitotic spindle microtubule","canonical_id":"go:GO:1990498","description":"\"Any microtubule that is part of a mitotic spindle; anchored at one spindle pole.\" [GOC:vw]","metadata":null},{"id":"6d0909ec2ce84427886530d60be0229c","type":"GO_TERM","name":"mitotic spindle microtubule depolymerization","canonical_id":"go:GO:1990755","description":"\"The removal of tubulin heterodimers from one or both ends of a microtubule that is part of the mitotic spindle.\" [PMID:25253718]","metadata":null},{"id":"10e87bc947644d63be1742dc060f21c2","type":"GO_TERM","name":"mitotic spindle midzone","canonical_id":"go:GO:1990023","description":"\"The area in the center of the anaphase spindle consisting of microtubules, microtubule bundling factors and kinesin motors where the spindle microtubules from opposite poles overlap in an antiparallel manner.\" [GOC:mtg_cell_cycle, GOC:vw]","metadata":null},{"id":"525c01cd34db44d7a77ea36f0ebe3a81","type":"GO_TERM","name":"mitotic spindle midzone assembly","canonical_id":"go:GO:0051256","description":"\"The cell cycle process in which the aggregation, arrangement and bonding together of a set of components forms the spindle midzone.\" [GOC:mtg_cell_cycle, GOC:vw, PMID:24239120]","metadata":null},{"id":"3eb1df9c24ee49e7b43ec0b18d8bc5e7","type":"GO_TERM","name":"mitotic spindle organization","canonical_id":"go:GO:0007052","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the microtubule spindle during a mitotic cell cycle.\" [GOC:curators, GOC:mah]","metadata":null},{"id":"ce265a98fa414085873f5336e8318265","type":"GO_TERM","name":"mitotic spindle orientation checkpoint signaling","canonical_id":"go:GO:0031578","description":"\"A signaling process that monitors and signals errors in the placement or orientation of the spindle in the cell. This delays the completion of anaphase until errors are corrected.\" [GOC:mtg_cell_cycle, PMID:14616062]","metadata":null},{"id":"b72c4bee2a76416a8afcbaa8dd6ec53f","type":"GO_TERM","name":"mitotic spindle polar microtubule","canonical_id":"go:GO:1990537","description":"\"Any of the mitotic spindle microtubules that come from each pole and overlap at the spindle midzone.\" [PMID:16079915]","metadata":null},{"id":"0f6480b43ecb4ee787adb974585982a8","type":"GO_TERM","name":"mitotic spindle pole","canonical_id":"go:GO:0097431","description":"\"Either of the ends of a mitotic spindle, a spindle that forms as part of mitosis, where spindle microtubules are organized; usually contains a microtubule organizing center and accessory molecules, spindle microtubules and astral microtubules.\" [GOC:vw]","metadata":null},{"id":"6eb9d283c3884fdb99d966b251e3fb4b","type":"GO_TERM","name":"mitotic spindle pole body","canonical_id":"go:GO:0044732","description":"\"The microtubule organizing center that forms as part of the mitotic cell cycle; functionally homologous to the animal cell centrosome.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"26f47414453345b6900636e6f18b2298","type":"GO_TERM","name":"mitotic spindle pole body attachment site","canonical_id":"go:GO:0180028","description":"\"A region of the nuclear envelope to which a spindle pole body (SPB) attaches; protein complexes embedded in the nuclear envelope mediate direct or indirect linkages between the microtubule cytoskeleton and the nuclear envelope.\" [PMID:37783794]","metadata":null},{"id":"bcc50f8f9c384648b14ed78711453e1d","type":"GO_TERM","name":"mitotic spindle pole body duplication","canonical_id":"go:GO:1903087","description":"\"Any spindle pole body duplication that is involved in the mitotic cell cycle.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"ae51cc6cb3fa4111b03784318d308bd5","type":"GO_TERM","name":"mitotic spindle pole body insertion into the nuclear envelope","canonical_id":"go:GO:0140480","description":"\"A process in which the duplicated mitotic spindle pole body is inserted into a fenestra which opens in the nuclear envelope in early mitosis, and is subsequently tethered to the membrane.\" [PMID:19487457, PMID:24529240]","metadata":null},{"id":"c28b16b53eea45d3aa1c80981a8ce9ca","type":"GO_TERM","name":"mitotic spindle pole body localization","canonical_id":"go:GO:1990608","description":"\"A process in which a mitotic spindle pole body is transported to, or maintained in, a specific cellular location.\" [PMID:24963130]","metadata":null},{"id":"a4e28f60500b460a9bacd4f9fc330733","type":"GO_TERM","name":"mitotic spindle pole body organization","canonical_id":"go:GO:1905047","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitotic spindle pole body.\" [GOC:TermGenie, PMID:24963130]","metadata":null},{"id":"031806642aeb40be827b3b5915fd534e","type":"GO_TERM","name":"mitotic spindle-templated microtubule nucleation","canonical_id":"go:GO:0090221","description":"\"The 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates from within the mitotic spindle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"a593de30359e42ce8b0e30b9e2a2b744","type":"GO_TERM","name":"mitotic telomere clustering and tethering at nuclear periphery","canonical_id":"go:GO:0120109","description":"\"The process in which the telomeres are gathered together to a small number of foci per chromosome (usually one per chromosome or fewer), and moved to and tethered at the nuclear periphery, as part of a mitotic cell cycle.\" [PMID:25778919]","metadata":null},{"id":"719a4c6f825349b1b9b43a5f9a26eea0","type":"GO_TERM","name":"mitotic telomere maintenance via semi-conservative replication","canonical_id":"go:GO:1902990","description":"\"Any telomere maintenance via semi-conservative replication that is involved in mitotic cell cycle.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"fbe7cee7e9ac4978992898f82f58b567","type":"GO_TERM","name":"mitotic telomere tethering at nuclear periphery","canonical_id":"go:GO:0044820","description":"\"The process in which a telomere is maintained in a specific location at the nuclear periphery, as part of a mitotic cell cycle.\" [GOC:mtg_cell_cycle, PMID:25778919]","metadata":null},{"id":"0a052d65e8b94aee978bffa0ad9e0b58","type":"GO_TERM","name":"mitotic telophase","canonical_id":"go:GO:0000093","description":"\"The cell cycle phase which follows anaphase during M phase of mitosis and during which the chromosomes arrive at the poles of the cell and the division of the cytoplasm starts.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"05159e54c2664bc1974458139b9f259e","type":"GO_TERM","name":"mitral valve development","canonical_id":"go:GO:0003174","description":"\"The progression of the mitral valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"fad82109fe704cff8eaa20fc83b383d9","type":"GO_TERM","name":"mitral valve formation","canonical_id":"go:GO:0003192","description":"\"The developmental process pertaining to the initial formation of the mitral valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"412dbd3831534a3ea10c22a5d4dbff88","type":"GO_TERM","name":"mitral valve morphogenesis","canonical_id":"go:GO:0003183","description":"\"The process in which the structure of the mitral valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"1b7494e302e54164be1e48b2925e4db5","type":"GO_TERM","name":"mixed acid fermentation","canonical_id":"go:GO:0019664","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of phosphoenolpyruvate into ethanol, lactate, formate, succinate, and acetate.\" [ISBN:0716720094, MetaCyc:FERMENTATION-PWY]","metadata":null},{"id":"e5986e2eeec640d3a4ef94cc8c99f034","type":"DRUG","name":"mizolastine","canonical_id":"gtopdb:10102","description":null,"metadata":null},{"id":"7441d50e06214836a6d20f48436c4f6c","type":"DRUG","name":"mizolastine","canonical_id":"mesh:C076170","description":null,"metadata":null},{"id":"c65e3038843f42b0b31d62bf1b33d800","type":"DRUG","name":"mizolastine","canonical_id":"chembl:CHEMBL94454","description":null,"metadata":null},{"id":"8f7df75bd8894d8596c2f0a621994ca9","type":"GO_TERM","name":"mobile ion carrier activity","canonical_id":"go:GO:0022809","description":"\"Small molecule produced by bacteria that carries an ion across the membrane by enclosing the ion and travelling with the ion across the membrane. It does not form a fully open pore across the membrane.\" [GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"6727ee0432fe43fbb2aeb3ec06cee5fd","type":"DRUG","name":"moclobemide","canonical_id":"gtopdb:7428","description":null,"metadata":null},{"id":"e54b3edaab3a4e2dafd05328148a2c89","type":"DRUG","name":"moclobemide","canonical_id":"chembl:CHEMBL86304","description":null,"metadata":null},{"id":"95ef7c971117450d90721615dc20950b","type":"GO_TERM","name":"modification of dendritic spine","canonical_id":"go:GO:0098886","description":"\"Any process that modifies the structure of a dendritic spine.\" [GOC:dos]","metadata":null},{"id":"c6679c06d33442b090b8f2e2a564830f","type":"GO_TERM","name":"modification of postsynaptic actin cytoskeleton","canonical_id":"go:GO:0098885","description":"\"Any process that modifies the structure of a postsynaptic actin cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"28dfb4d962484baaa9d9483196290d84","type":"GO_TERM","name":"modification of postsynaptic structure","canonical_id":"go:GO:0099010","description":"\"Any process that modifies the structure of a postsynapse.\" [GOC:dos]","metadata":null},{"id":"b4ae598821714293a485ad0cc63a920e","type":"GO_TERM","name":"modification of synaptic structure","canonical_id":"go:GO:0099563","description":"\"Any process that modifies the structure/morphology of a synapse.\" [GOC:dos]","metadata":null},{"id":"08709717be3445b095c77b8816ebfc39","type":"GO_TERM","name":"modification of synaptic structure, modulating synaptic transmission","canonical_id":"go:GO:0099564","description":"\"Any process that modulates synaptic transmission via modification of the structure of the synapse.\" [GOC:dos]","metadata":null},{"id":"2bd9bc8610f14d5e858e4259f929cb64","type":"GO_TERM","name":"modification-dependent macromolecule catabolic process","canonical_id":"go:GO:0043632","description":"\"The chemical reactions and pathways resulting in the breakdown of a macromolecule, initiated by covalent modification of the target molecule.\" [GOC:jl]","metadata":null},{"id":"6b90e37c8b714fa495923abed6ac0766","type":"GO_TERM","name":"modification-dependent protein binding","canonical_id":"go:GO:0140030","description":"\"Binding to a protein upon post-translation modification of the target protein.\" [PMID:26060076]","metadata":null},{"id":"3dc48b909f0b4478a631383882a0b4a1","type":"GO_TERM","name":"modification-dependent protein catabolic process","canonical_id":"go:GO:0019941","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent modification of the target protein.\" [GOC:curators]","metadata":null},{"id":"d15b05c3279545e78c4feaff51ca49b5","type":"GO_TERM","name":"modified amino acid binding","canonical_id":"go:GO:0072341","description":"\"Binding to a modified amino acid.\" [GOC:mah]","metadata":null},{"id":"ac4eb2cb07fd45d2ac7985d5afff12b8","type":"GO_TERM","name":"modified amino acid biosynthetic process","canonical_id":"go:GO:0042398","description":"\"The chemical reactions and pathways resulting in the formation of compounds derived from amino acids, organic acids containing one or more amino substituents.\" [GOC:ai]","metadata":null},{"id":"ac9819037a184b70aa2287befdf08b50","type":"GO_TERM","name":"modified amino acid catabolic process","canonical_id":"go:GO:0042219","description":"\"The chemical reactions and pathways resulting in the breakdown of compounds derived from amino acids, organic acids containing one or more amino substituents.\" [GOC:ai]","metadata":null},{"id":"992cc805eefe4684968679fafd77a1da","type":"GO_TERM","name":"modified amino acid metabolic process","canonical_id":"go:GO:0006575","description":"\"The chemical reactions and pathways involving compounds derived from amino acids, organic acids containing one or more amino substituents.\" [GOC:ai]","metadata":null},{"id":"a834427aba6042ea96671ccac3ecf0f4","type":"GO_TERM","name":"modified amino acid transmembrane transporter activity","canonical_id":"go:GO:0072349","description":"\"Enables the transfer of modified amino acids from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"89f03118ee5b4b53ab1390ff9b3e050b","type":"GO_TERM","name":"modified amino acid transport","canonical_id":"go:GO:0072337","description":"\"The directed movement of modified amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"ce39d04d5a76424e87374edc12447c12","type":"GO_TERM","name":"modified histidine biosynthetic process","canonical_id":"go:GO:0052703","description":"\"The chemical reactions and pathways resulting in the formation of compounds derived from histidine, 2-amino-3-(1H-imidazol-4-yl)propanoic acid within a cell.\" [GOC:ai]","metadata":null},{"id":"e89cfe8488944e80aa21263829e2e730","type":"GO_TERM","name":"modified histidine catabolic process","canonical_id":"go:GO:0052702","description":"\"The chemical reactions and pathways resulting in the breakdown of compounds derived from histidine, 2-amino-3-(1H-imidazol-4-yl)propanoic acid.\" [GOC:ai]","metadata":null},{"id":"f0d769466c814652b8a67b6b33fbe482","type":"GO_TERM","name":"modulation by host of RNA binding by virus","canonical_id":"go:GO:1990968","description":"\"A process in which a host organism modulates the frequency, rate or extent of a viral gene product binding to RNA.\" [GOC:bf, GOC:PARL, PMID:25116364]","metadata":null},{"id":"8eb5bb1fee284eb2915c93607baefa13","type":"GO_TERM","name":"modulation by host of viral catalytic activity","canonical_id":"go:GO:0044867","description":"\"The process in which a host organism effects a change in the enzyme activity of a virus with which it is infected.\" [GOC:jl]","metadata":null},{"id":"c10691a6268a43b6a417f38d7b0306ca","type":"GO_TERM","name":"modulation by host of viral exo-alpha-sialidase activity","canonical_id":"go:GO:0044866","description":"\"The process in which a host organism effects a change in viral exo-alpha-sialidase activity, the catalysis of the hydrolysis of peptide bonds in a protein.\" [GOC:jl]","metadata":null},{"id":"c546815af5d244469cc635ba4c9d366b","type":"GO_TERM","name":"modulation by host of viral glycoprotein metabolic process","canonical_id":"go:GO:0044870","description":"\"A process in which a host organism modulates the frequency, rate or extent of viral glycoprotein metabolic process.\" [GOC:jl]","metadata":null},{"id":"406a90cd8a574c0caf2e62f705570a2e","type":"GO_TERM","name":"modulation by host of viral molecular function","canonical_id":"go:GO:0044868","description":"\"A process in which a host organism modulates the frequency, rate or extent of any molecular function being mediated by a virus with which it is infected.\" [GOC:jl]","metadata":null},{"id":"e3c1494a6e5047e38d3fe27fde623d6c","type":"GO_TERM","name":"modulation by symbiont of entry into host","canonical_id":"go:GO:0052372","description":"\"Any process in which an organism modulates the frequency, rate or extent to which it enters into the host organism, where the two organisms are in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"30addbb07c16451fb9dd1b61af6086c9","type":"GO_TERM","name":"modulation of chemical synaptic transmission","canonical_id":"go:GO:0050804","description":"\"Any process that modulates the frequency or amplitude of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. Amplitude, in this case, refers to the change in postsynaptic membrane potential due to a single instance of synaptic transmission.\" [GOC:ai]","metadata":null},{"id":"bac09a3487a94ed789f005c12afa3040","type":"GO_TERM","name":"modulation of excitatory postsynaptic potential","canonical_id":"go:GO:0098815","description":"\"Any process that modulates the frequency, rate or extent of excitatory postsynaptic potential (EPSP). EPSP is a process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential.\" [GOC:dos]","metadata":null},{"id":"344cd03ef6d349c9b72e13f2b8a6c7cb","type":"GO_TERM","name":"modulation of formation of structure involved in a symbiotic process","canonical_id":"go:GO:0044145","description":"\"Any process that modulates the frequency, rate or extent of the progression of an organism from an initial condition to a later condition, occurring in, on or near the exterior of its host organism.\" [GOC:jl, GOC:pamgo_curators]","metadata":null},{"id":"b69cfab0e7e94f7a8943ae145ffc126b","type":"GO_TERM","name":"modulation of formation of symbiont germ tube hook structure for appressorium development","canonical_id":"go:GO:0075030","description":"\"Any process that modulates the frequency, rate or extent of symbiont germ tube hook structure formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"93ae780669524d268c289e1c1931b375","type":"GO_TERM","name":"modulation of inhibitory postsynaptic potential","canonical_id":"go:GO:0098828","description":"\"Any process that modulates the frequency, rate or extent of inhibitory postsynaptic potential (IPSP). IPSP is a temporary decrease in postsynaptic membrane potential due to the flow of negatively charged ions into the postsynaptic cell. The flow of ions that causes an IPSP is an inhibitory postsynaptic current (IPSC) and makes it more difficult for the neuron to fire an action potential.\" [GOC:dos]","metadata":null},{"id":"e73653dd577b4666b696ac6e21ce4e03","type":"GO_TERM","name":"modulation of microtubule cytoskeleton involved in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021815","description":"\"Rearrangements of the microtubule cytoskeleton that contribute to the movement of cells along radial glial cells as a component of the process of cerebral cortex glial-mediated radial migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"87a0f88147d0413688efd391d159b569","type":"GO_TERM","name":"modulation of nutrient release by host","canonical_id":"go:GO:0052091","description":"\"Any process in which an organism modulates the frequency, rate or extent of the release of nutrients from its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"59a201e106aa44649e632876d480c52e","type":"GO_TERM","name":"modulation of nutrient release by symbiont","canonical_id":"go:GO:0052460","description":"\"Any process in which an organism modulates the frequency, rate or extent of the release of nutrients from a symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"d7ce8bd787ee44b8b769071804c0923a","type":"GO_TERM","name":"modulation of penetration peg formation","canonical_id":"go:GO:0075054","description":"\"Any process that modulates the frequency, rate or extent of symbiont penetration peg formation for entry into host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"9cd2da03cf004e1f83886b848f0a1f14","type":"GO_TERM","name":"modulation of process of another organism","canonical_id":"go:GO:0035821","description":"\"A process in which an organism effects a change in a biological process in another organism.\" [GOC:bf]","metadata":null},{"id":"8b87b7c500be450fb5f268856f8194d7","type":"GO_TERM","name":"modulation of spore encystment on host","canonical_id":"go:GO:0075215","description":"\"Any process that modulates the frequency, rate or extent of spore encystment on host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"52ae04ef61cb4575bb47065b2a95538a","type":"GO_TERM","name":"modulation of symbiont haustorium neck formation for entry into host","canonical_id":"go:GO:0075198","description":"\"Any process that modulates the frequency, rate or extent of symbiont haustorium neck formation for entry into host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"66ebbaf2ac1c46f99de9bdbcdb18a9df","type":"GO_TERM","name":"modulation of zoospore encystment on host","canonical_id":"go:GO:0075219","description":"\"Any process that modulates the frequency, rate or extent of zoospore encystment on host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"78a1b07c1ac44c7e876b3190e9023b8d","type":"DRUG","name":"moexipril","canonical_id":"gtopdb:6571","description":null,"metadata":null},{"id":"25ca58632afb49e4883f6770b1698627","type":"DRUG","name":"moexipril","canonical_id":"mesh:C058302","description":null,"metadata":null},{"id":"33f01423ac2f41978dee3211e4cfcd24","type":"DRUG","name":"mogamulizumab","canonical_id":"gtopdb:6477","description":null,"metadata":null},{"id":"aa4f77a8e6ca42a1a36457d4a5d0c23f","type":"DRUG","name":"mogamulizumab","canonical_id":"mesh:C549035","description":null,"metadata":null},{"id":"91c3049920ce44df9ac1b585cb000452","type":"DRUG","name":"mogamulizumab","canonical_id":"chembl:CHEMBL1743041","description":null,"metadata":null},{"id":"e566f159f849463b8618f9c2138f7e91","type":"COMBINATION_TREATMENT","name":"mogamulizumab + nivolumab","canonical_id":"ctgov_combo:ctgov-combo-f68eacab089af7a1","description":null,"metadata":null},{"id":"79efe6f804984e96b9e71185cb42b86e","type":"GO_TERM","name":"molecular adaptor activity","canonical_id":"go:GO:0060090","description":"\"The binding activity of a molecule that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way.\" [GOC:mtg_MIT_16mar07, GOC:vw]","metadata":null},{"id":"0cc9140a70f44603bfe34a5106ee5c31","type":"GO_TERM","name":"molecular carrier activity","canonical_id":"go:GO:0140104","description":"\"Directly binding to a specific ion or molecule and delivering it either to an acceptor molecule or to a specific location.\" [GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"e3e5617f642c4bdbbe2b59583a43f4ea","type":"GO_TERM","name":"molecular condensate scaffold activity","canonical_id":"go:GO:0140693","description":"\"Binding and bringing together two or more macromolecules in contact, permitting those molecules to organize as a molecular condensate.\" [PMID:28225081]","metadata":null},{"id":"1e525f1fc2d14828955b9013f2efc159","type":"GO_TERM","name":"molecular function activator activity","canonical_id":"go:GO:0140677","description":"\"A molecular function regulator that activates or increases the activity of its target via non-covalent binding that does not result in covalent modification to the target.\" [GOC:curators]","metadata":null},{"id":"ae8a5f74ab8f46b5b2e6587fd1f4970e","type":"GO_TERM","name":"molecular function inhibitor activity","canonical_id":"go:GO:0140678","description":"\"A molecular function regulator that inhibits or decreases the activity of its target via non-covalent binding that does not result in covalent modification to the target.\" [GOC:curators]","metadata":null},{"id":"93591abb45514e458885d3f1e367a348","type":"GO_TERM","name":"molecular function regulator activity","canonical_id":"go:GO:0098772","description":"\"A molecular function regulator regulates the activity of its target via non-covalent binding that does not result in covalent modification to the target. Examples of molecular function regulators include regulatory subunits of multimeric enzymes and channels. Mechanisms of regulation include allosteric changes in the target and competitive inhibition.\" [GOC:dos, GOC:pt]","metadata":null},{"id":"a1bcae1f23074eb7844dfca9be80798c","type":"GO_TERM","name":"molecular sensor activity","canonical_id":"go:GO:0140299","description":"\"Binding to a molecule and eliciting a change in the protein's activity in response to the intracellular level of that molecule.\" [PMID:26328879]","metadata":null},{"id":"b364da5c3c9c45f28ca11e7fc4833e84","type":"GO_TERM","name":"molecular sequestering activity","canonical_id":"go:GO:0140313","description":"\"Binding to a specific molecule to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:13130076]","metadata":null},{"id":"7cbf119db47c40f7ad6cf6386939e75c","type":"GO_TERM","name":"molecular tag activity","canonical_id":"go:GO:0141047","description":"\"A molecular function exhibited by a protein that is covalently attached (AKA tagged or conjugated) to another molecule (for example a protein or a lipid) where it acts as a marker, recognized by the cellular apparatus to target the tagged protein for some cellular process such as modification, sequestration, transport or degradation.\" [PMID:17632063]","metadata":null},{"id":"112a1f84e0cd4797a25f4bc7a5579f8d","type":"GO_TERM","name":"molecular template activity","canonical_id":"go:GO:0140489","description":"\"The action of a molecule that provides a shape or a sequence mimicking or complementary to the final product, providing template for copying the original molecule's shape or sequence.\" [GOC:pg]","metadata":null},{"id":"b1c41c98e1fa4475b3961946263bd3c8","type":"GO_TERM","name":"molecular transducer activity","canonical_id":"go:GO:0060089","description":"\"A compound molecular function in which an effector function is controlled by one or more regulatory components.\" [GOC:dos, GOC:pdt]","metadata":null},{"id":"7163f5861fbf4fd8be5f7479214c4bd5","type":"GO_TERM","name":"molecular_function","canonical_id":"go:GO:0003674","description":"\"A molecular process that can be carried out by the action of a single macromolecular machine, usually via direct physical interactions with other molecular entities. Function in this sense denotes an action, or activity, that a gene product (or a complex) performs.\" [GOC:pdt]","metadata":null},{"id":"a913861576854a3db79580800bb22b40","type":"DRUG","name":"molindone","canonical_id":"gtopdb:207","description":null,"metadata":null},{"id":"0cd1e007d8c74b0b8c8eef7e392f2102","type":"DRUG","name":"molsidomine","canonical_id":"mesh:D008981","description":null,"metadata":null},{"id":"6dd32fb7cd4443a9acefae13523a2545","type":"GO_TERM","name":"molting cycle","canonical_id":"go:GO:0042303","description":"\"The periodic casting off and regeneration of an outer covering of cuticle, feathers, hair, horns, skin, etc.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"e6b12b1e547846be89b98afdbe1f4f10","type":"GO_TERM","name":"molting cycle process","canonical_id":"go:GO:0022404","description":"\"A multicellular organismal process involved in the periodic casting off and regeneration of an outer covering of cuticle, feathers, hair, horns, skin.\" [GOC:isa_complete]","metadata":null},{"id":"49d3d9e463ee47d2b81dae68a26e6650","type":"GO_TERM","name":"molting cycle, chitin-based cuticle","canonical_id":"go:GO:0007591","description":"\"The periodic shedding of part or all of a chitin-based cuticle, which is then replaced by a new cuticle. An example of this is found in Drosophila melanogaster.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"17bd6641fc37430d96e77d932ff40baf","type":"GO_TERM","name":"molting cycle, collagen and cuticulin-based cuticle","canonical_id":"go:GO:0018996","description":"\"The periodic shedding of part or all of a collagen and cuticulin-based cuticle, which is then replaced by a new collagen and cuticulin-based cuticle. An example of this is found in the Nematode worm, Caenorhabditis elegans.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"5c82bb1dd0a443c7a66fabffaa701245","type":"GO_TERM","name":"molybdate ion binding","canonical_id":"go:GO:0030973","description":"\"Binding to a molybdate ion (MoO4 2-).\" [GOC:mlg]","metadata":null},{"id":"9790a1d8a7574319b43346a5216db570","type":"GO_TERM","name":"molybdate ion export from vacuole","canonical_id":"go:GO:0090414","description":"\"The directed movement of molybdate ions out of the vacuole.\" [GOC:tb]","metadata":null},{"id":"b10ec75ec00949288a2716fc57faf467","type":"GO_TERM","name":"molybdate ion transmembrane transporter activity","canonical_id":"go:GO:0015098","description":"\"Enables the transfer of molybdate (MoO4 2-) ions from one side of a membrane to the other. Molybdate is the bivalent anion derived from molybdic acid.\" [ISBN:0198506732]","metadata":null},{"id":"578eabadc2104ec8bd02e5b20c7a0539","type":"GO_TERM","name":"molybdate ion transport","canonical_id":"go:GO:0015689","description":"\"The directed movement of molybdate (MoO4 2-) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Molybdate is the bivalent anion derived from molybdic acid.\" [GOC:ai]","metadata":null},{"id":"4cbac425a9814782a4e5467ff9931c68","type":"GO_TERM","name":"molybdenum cofactor cytidylyltransferase activity","canonical_id":"go:GO:0061602","description":"\"Catalysis of the reaction: Mo-molybdopterin + CTP + H+ = Mo-molybdopterin cytosine dinucleotide + diphosphate.\" [RHEA:31335]","metadata":null},{"id":"aa70b56efc2d45b1b5b44a4d5c030dc9","type":"GO_TERM","name":"molybdenum cofactor guanylyltransferase activity","canonical_id":"go:GO:0061603","description":"\"Catalysis of the reaction GTP + molybdenum cofactor = diphosphate + guanylyl molybdenum cofactor.\" [EC:2.7.7.77, GOC:dph]","metadata":null},{"id":"502a5e5851d04013b229bbb813ed31f7","type":"GO_TERM","name":"molybdenum cofactor sulfurtransferase activity","canonical_id":"go:GO:0008265","description":"\"Catalysis of the reaction: AH2 + L-cysteine + Mo-molybdopterin = A + H2O + L-alanine + thio-Mo-molybdopterin.\" [PMID:11549764, RHEA:42636]","metadata":null},{"id":"fc9937b5b97549b09e8ceabeed9ceaea","type":"GO_TERM","name":"molybdenum incorporation into iron-sulfur cluster","canonical_id":"go:GO:0018291","description":"\"The incorporation of molybdenum into an iron-sulfur cluster.\" [GOC:ai]","metadata":null},{"id":"13d3dbdfb3024524b17a36b0054d4025","type":"GO_TERM","name":"molybdenum incorporation into metallo-sulfur cluster","canonical_id":"go:GO:0018289","description":"\"The incorporation of molybdenum into a metallo-sulfur cluster.\" [GOC:ai]","metadata":null},{"id":"a307a18cfaf2465d88d9d34d326a40d5","type":"GO_TERM","name":"molybdenum incorporation into molybdenum-molybdopterin complex","canonical_id":"go:GO:0018315","description":"\"The incorporation of molybdenum into a molybdenum-molybdopterin complex.\" [GOC:ai]","metadata":null},{"id":"413085af06ca4dd5ad24d1dd5fddf87d","type":"GO_TERM","name":"molybdenum ion binding","canonical_id":"go:GO:0030151","description":"\"Binding to a molybdenum ion (Mo).\" [GOC:ai]","metadata":null},{"id":"67e566c65088461f880db95354dc0f96","type":"GO_TERM","name":"molybdenum ion transmembrane transporter activity","canonical_id":"go:GO:0042888","description":"\"Enables the transfer of molybdenum (Mo) ions from one side of a membrane to the other.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a4cab61fd91d44e9be72f3284c15712b","type":"GO_TERM","name":"molybdenum-iron nitrogenase complex","canonical_id":"go:GO:0016612","description":"\"An enzyme complex containing a molybdenum-iron cluster found in many species. It is composed of two proteins, dinitrogenase and nitrogenase reductase; dinitrogenase, the molybdenum-iron protein, is tetrameric with an alpha2-beta2 structure, and nitrogenase reductase is a homodimer.\" [PMID:11566366]","metadata":null},{"id":"0d0e876a523947d98cb517ec7c929125","type":"GO_TERM","name":"molybdopterin adenylyltransferase activity","canonical_id":"go:GO:0061598","description":"\"Catalysis of the reaction ATP + molybdopterin = diphosphate + adenylyl-molybdopterin.\" [EC:2.7.7.75, GOC:dph]","metadata":null},{"id":"cd1d2a6112f84fc6843edba4d94d91db","type":"GO_TERM","name":"molybdopterin adenylyltransferase complex","canonical_id":"go:GO:1990133","description":"\"A heterotetrameric protein complex which adenylates two molecules of the sulfur carrier subunit of the molybdopterin cofactor synthase using ATP as part of molybdopterin cofactor (Moco) biosynthesis. In E. coli the subunits are MoeB and MoaD; in human the subunits are MOCS3 and MOCS2A. Moco biosynthesis and its constituent molecules are evolutionarily conserved.\" [GOC:bhm, PMID:11713534, PMID:16669776, PMID:18491921]","metadata":null},{"id":"4167bbb30ea1422c96293286498e1abe","type":"GO_TERM","name":"molybdopterin cofactor binding","canonical_id":"go:GO:0043546","description":"\"Binding to a molybdopterin cofactor (Moco), essential for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. The cofactor consists of a mononuclear molybdenum (Mo-molybdopterin) or tungsten ion (W-molybdopterin) coordinated by one or two molybdopterin ligands.\" [ISSN:09498257]","metadata":null},{"id":"67743f46fbee4d8f96012357de2d81ca","type":"GO_TERM","name":"molybdopterin cofactor biosynthetic process","canonical_id":"go:GO:0032324","description":"\"The chemical reactions and pathways resulting in the formation of the molybdopterin cofactor (Moco), essential for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. The cofactor consists of a mononuclear molybdenum (Mo-molybdopterin) or tungsten ion (W-molybdopterin) coordinated by one or two molybdopterin ligands.\" [GOC:mah]","metadata":null},{"id":"6ba94794cbda45a6a76aed830afd8db2","type":"GO_TERM","name":"molybdopterin cofactor catabolic process","canonical_id":"go:GO:0032325","description":"\"The chemical reactions and pathways resulting in the breakdown of the molybdopterin cofactor (Moco), essential for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. The cofactor consists of a mononuclear molybdenum (Mo-molybdopterin) or tungsten ion (W-molybdopterin) coordinated by one or two molybdopterin ligands.\" [GOC:mah]","metadata":null},{"id":"b07b3b85260e44a0858572410666baf7","type":"GO_TERM","name":"molybdopterin cofactor metabolic process","canonical_id":"go:GO:0043545","description":"\"The chemical reactions and pathways involving the molybdopterin cofactor (Moco), essential for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. The cofactor consists of a mononuclear molybdenum (Mo-molybdopterin) or tungsten ion (W-molybdopterin) coordinated by one or two molybdopterin ligands.\" [ISSN:09498257]","metadata":null},{"id":"a73ffe29125f4e9f8239c0e73869935a","type":"GO_TERM","name":"molybdopterin molybdotransferase activity","canonical_id":"go:GO:0061599","description":"\"Catalysis of the reaction adenylyl-molybdopterin + molybdate = molybdenum cofactor + AMP.\" [EC:2.10.1.1, GOC:dph]","metadata":null},{"id":"b3dbe74e642d4969a9c787a023ba8208","type":"GO_TERM","name":"molybdopterin synthase activity","canonical_id":"go:GO:0030366","description":"\"Catalysis of the conversion of precursor Z to molybdopterin, the final step in molybdopterin biosynthesis.\" [PMID:18154309, PMID:8514783]","metadata":null},{"id":"9620e5ac30fc45a6942a8bcdeb678c5d","type":"GO_TERM","name":"molybdopterin synthase complex","canonical_id":"go:GO:1990140","description":"\"A heterotetrameric protein complex that catalyses sulfur transfer from the sulfur carrier subunit of molybdopterin synthase to precursor Z to synthesize molybdopterin as part of molybdopterin cofactor (Moco) biosynthesis. In E. coli the subunits are MoaE and MoaD; in human, MOCS2B and MOCS2A. Moco biosynthesis and its constituent molecules are evolutionarily conserved.\" [GOC:bhm, PMID:11135669, PMID:16669776]","metadata":null},{"id":"d8e3f8cbee3e4fe0a9e9381515667d52","type":"GO_TERM","name":"molybdopterin-synthase adenylyltransferase activity","canonical_id":"go:GO:0061605","description":"\"Catalysis of the reaction: ATP [molybdopterin-synthase sulfur-carrier protein]-Gly-Gly = diphosphate [molybdopterin-synthase sulfur-carrier protein]-Gly-Gly-AMP.\" [EC:2.7.7.80, GOC:dph, PMID:18154309, PMID:22370186]","metadata":null},{"id":"10f433212f3a47948542cd62df12cce7","type":"GO_TERM","name":"molybdopterin-synthase sulfurtransferase activity","canonical_id":"go:GO:0061604","description":"\"Catalysis of the reaction: [Molybdopterin-synthase sulfur-carrier protein]-Gly-Gly-AMP + [cysteine desulfurase]-S-sulfanyl-L-cysteine = AMP [molybdopterin-synthase sulfur-carrier protein]-Gly-NH-CH(2)-C(O)SH + cysteine desulfurase.\" [EC:2.8.1.11, GOC:dph, PMID:18154309, PMID:22370186]","metadata":null},{"id":"11211544502e4737b3b5d0340b591c6b","type":"DRUG","name":"momelotinib","canonical_id":"gtopdb:7791","description":null,"metadata":null},{"id":"a894e504144145b3a3f9d8eddf55c42a","type":"DRUG","name":"momelotinib","canonical_id":"chembl:CHEMBL1078178","description":null,"metadata":null},{"id":"e4953335c6054a6788b00f9b14a9f75c","type":"COMBINATION_TREATMENT","name":"momelotinib + pacritinib","canonical_id":"ctgov_combo:ctgov-combo-d22ea01fa8d88390","description":null,"metadata":null},{"id":"a8d3412387774ab1a2be54c2ee1f3493","type":"COMBINATION_TREATMENT","name":"momelotinib + ruxolitinib","canonical_id":"ctgov_combo:ctgov-combo-7491642965babd39","description":null,"metadata":null},{"id":"21a226e94bef4de5be9c9aa11bb57303","type":"COMBINATION_TREATMENT","name":"momelotinib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-91d5da85de13562e","description":null,"metadata":null},{"id":"9063f2578766453eb38d75203b880bd0","type":"DRUG","name":"mometasone","canonical_id":"gtopdb:9029","description":null,"metadata":null},{"id":"bbc4a8b6f80242b1a9580919de358e28","type":"COMBINATION_TREATMENT","name":"mometasone + nortriptyline","canonical_id":"ctgov_combo:ctgov-combo-1421391bd500b5af","description":null,"metadata":null},{"id":"af09dc2ad80e479d871b52814dd1263e","type":"COMBINATION_TREATMENT","name":"mometasone + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-2ceb0778ba35be64","description":null,"metadata":null},{"id":"3c93f278af9d4209ad56bbbe9c1b04a7","type":"COMBINATION_TREATMENT","name":"mometasone + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-b72bb6721aa9052d","description":null,"metadata":null},{"id":"bccd844540f0435595aa92348ffc10db","type":"DRUG","name":"mometasone furoate","canonical_id":"mesh:D000068656","description":null,"metadata":null},{"id":"f360f75bb8724944a45bd611c6db034e","type":"GO_TERM","name":"momilactone-A synthase [NAD(P)H] activity","canonical_id":"go:GO:0102960","description":"\"Catalysis of the reaction: 3beta-hydroxy-9beta-pimara-7,15-diene-19,6beta-olide + NAD(P) = momilactone A + H+ + NAD(P)H.\" [EC:1.1.1.295]","metadata":null},{"id":"8ee490104701471b967e159f00970489","type":"GO_TERM","name":"monensin A biosynthetic process","canonical_id":"go:GO:1901730","description":"\"The chemical reactions and pathways resulting in the formation of monensin A.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00178]","metadata":null},{"id":"db23f76144e6469d88bce4d62f860e03","type":"GO_TERM","name":"monensin A catabolic process","canonical_id":"go:GO:1901729","description":"\"The chemical reactions and pathways resulting in the breakdown of monensin A.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00178]","metadata":null},{"id":"a2327bc2e15a430f927f5838401ab284","type":"GO_TERM","name":"mono-ADP-D-ribose binding","canonical_id":"go:GO:0072571","description":"\"Binding to monomeric ADP-D-ribose, an ADP-aldose having ribose as the aldose fragment.\" [GOC:mah, GOC:sart, PMID:20088964]","metadata":null},{"id":"4b8eed37f1c049d4a1d5dc297bb39066","type":"GO_TERM","name":"mono-ADP-D-ribose modification-dependent protein binding","canonical_id":"go:GO:0160003","description":"\"Binding to a protein upon mono-ADP-ribosylation of the target protein.\" [PMID:34023495]","metadata":null},{"id":"187ca57db2fa47af95835f3b4d85ef4b","type":"GO_TERM","name":"mono-olein transacylation activity","canonical_id":"go:GO:0051264","description":"\"Catalysis of the reaction: mono-olein + mono-olein = diolein + glycerol. Mono-olein, also known as mono-oleoylglycerol, is the monoglyceride formed from oleic acid, 9-octodecenoic acid; diolein is also known as dioleoylglycerol.\" [GOC:ai, PMID:15364929]","metadata":null},{"id":"2d90ea2c334844cc98fddc7e99d9c858","type":"GO_TERM","name":"monoacylglycerol biosynthetic process","canonical_id":"go:GO:0006640","description":"\"The chemical reactions and pathways resulting in the formation of monoacylglycerol, any ester of glycerol in which any one of its hydroxyl groups has been acylated with a fatty acid, the other being non-esterified.\" [ISBN:0198506732]","metadata":null},{"id":"b6adf015a8a0413593ba54e0bab1e24b","type":"GO_TERM","name":"monoacylglycerol catabolic process","canonical_id":"go:GO:0052651","description":"\"The chemical reactions and pathways resulting in the breakdown of monoacylglycerol, any ester of glycerol in which any one of its hydroxyl groups has been acylated with a fatty acid, the other being non-esterified.\" [PMID:25290914]","metadata":null},{"id":"06609ca107f8452a9396b456fade2e1e","type":"GO_TERM","name":"monoacylglycerol lipase activity","canonical_id":"go:GO:0047372","description":"\"Catalysis of the reaction: a monoacylglycerol + H2O = a fatty acid + glycerol + H+.\" [RHEA:15245]","metadata":null},{"id":"40177da15e2f43d68f331852bd6557e6","type":"GO_TERM","name":"monoacylglycerol metabolic process","canonical_id":"go:GO:0046462","description":"\"The chemical reactions and pathways involving monoacylglycerol, any ester of glycerol in which any one of its hydroxyl groups has been acylated with a fatty acid, the other being non-esterified.\" [ISBN:0198506732]","metadata":null},{"id":"79238f43e4794ebfaa3afcfe4a094bb8","type":"GO_TERM","name":"monoamine oxidase activity","canonical_id":"go:GO:0097621","description":"\"Catalysis of the reaction: RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2.\" [GOC:pr, PMID:15279562, PMID:16129825]","metadata":null},{"id":"f82df75f0a1f41928a496da84f876649","type":"GO_TERM","name":"monoamine transmembrane transporter activity","canonical_id":"go:GO:0008504","description":"\"Enables the transfer of monoamines, organic compounds that contain one amino group that is connected to an aromatic ring by an ethylene group (-CH2-CH2-), from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"3d66460b1bc446f9b952b023ae32bd67","type":"GO_TERM","name":"monoamine:proton antiporter activity","canonical_id":"go:GO:0015311","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + monoamine(in) = H+(in) + monoamine(out).\" [TC:2.A.1.2.11, TC:2.A.1.2.12]","metadata":null},{"id":"f2a7dfd2d0eb4ff5b7d869683507c8db","type":"GO_TERM","name":"monoatomic anion channel activity","canonical_id":"go:GO:0005253","description":"\"Enables the energy-independent facilitated diffusion of a monoatomic anion through a transmembrane aqueous pore or channel.\" [GOC:dph, GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"b241df6a3d6345f5a232c0fa96a383b0","type":"GO_TERM","name":"monoatomic anion homeostasis","canonical_id":"go:GO:0055081","description":"\"Any process involved in the maintenance of an internal steady state of monoatomic anions within an organism or cell. Monatomic anions (also called simple anions) are anions consisting of exactly one atom.\" [GOC:ceb, GOC:jid, GOC:mah]","metadata":null},{"id":"6857ae6f879742dfb8dfe921f62c19a8","type":"GO_TERM","name":"monoatomic anion transmembrane transport","canonical_id":"go:GO:0098656","description":"\"The process in which a monoatomic anion is transported across a membrane. Monatomic anions (also called simple anions) are negatively charged ions consisting of exactly one atom.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"544334c835ea4bb2a09412b58f1c17c5","type":"GO_TERM","name":"monoatomic anion transmembrane transporter activity","canonical_id":"go:GO:0008509","description":"\"Enables the transfer of a negatively charged ion from one side of a membrane to the other.\" [GOC:dgf, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ce2a6cf1cb13457984a1bf9337e1a342","type":"GO_TERM","name":"monoatomic anion transport","canonical_id":"go:GO:0006820","description":"\"The directed movement of a monoatomic anion, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Monatomic anions (also called simple anions) are negatively charged ions consisting of exactly one atom.\" [GOC:ai]","metadata":null},{"id":"60bd7ffc38cf49bab9567a7628f5c768","type":"GO_TERM","name":"monoatomic anion:monoatomic cation symporter activity","canonical_id":"go:GO:0015296","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: anion(out) + cation(out) = anion(in) + cation(in).\" [TC:2.A.1.14.-]","metadata":null},{"id":"194bfc6a63984dffb789c8e806c4aa3f","type":"GO_TERM","name":"monoatomic anion:sodium symporter activity","canonical_id":"go:GO:0015373","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: monoatomic anion(out) + Na+(out) = monoatomic anion(in) + Na+(in).\" [TC:2.A.21.5.-]","metadata":null},{"id":"2cd89ae4d4ac40da97f6be8e28714f1d","type":"GO_TERM","name":"monoatomic cation channel activity","canonical_id":"go:GO:0005261","description":"\"Enables the energy-independent facilitated diffusion of a monoatomic cation through a transmembrane aqueous pore or channel.\" [GOC:def, GOC:dph, GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"738261f39e9742f2ad3a2cf55bc3ce01","type":"GO_TERM","name":"monoatomic cation efflux transmembrane transporter activity","canonical_id":"go:GO:0046583","description":"\"Enables the transfer of a cation or cations from the inside of the cell to the outside of the cell across a membrane.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"47c780e9da0d4758b126f747be6a0d41","type":"GO_TERM","name":"monoatomic cation homeostasis","canonical_id":"go:GO:0055080","description":"\"Any process involved in the maintenance of an internal steady state of monoatomic cations within an organism or cell. Monatomic cations (also called simple cations) are cations consisting of exactly one atom.\" [GOC:ceb, GOC:jid, GOC:mah]","metadata":null},{"id":"1ccd8887bd7e4e75b8217c583f4d5de1","type":"GO_TERM","name":"monoatomic cation transmembrane transport","canonical_id":"go:GO:0098655","description":"\"The process in which a monoatomic cation is transported across a membrane. Monatomic cations (also called simple cations) are positively charged ions consisting of exactly one atom.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"0197db897ae44a88bb797170b1866cb0","type":"GO_TERM","name":"monoatomic cation transmembrane transporter activity","canonical_id":"go:GO:0008324","description":"\"Enables the transfer of cation from one side of a membrane to the other.\" [GOC:dgf, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"4bf0f21ef893418abb2eee88fc80f190","type":"GO_TERM","name":"monoatomic cation transport","canonical_id":"go:GO:0006812","description":"\"The directed movement of a monoatomic cation, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Monatomic cations (also called simple cations) are positively charged ions consisting of exactly one atom.\" [GOC:ai]","metadata":null},{"id":"cf17923d21cb418a98a4e548733eea1e","type":"GO_TERM","name":"monoatomic cation:bicarbonate symporter activity","canonical_id":"go:GO:0140410","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: monoatomic cation(out) + HCO3-(out) = monoatomic cation(in) + HCO3-(in).\" [PMID:27166256]","metadata":null},{"id":"9a9f28d5bc874a51bc09ed9284e76a89","type":"GO_TERM","name":"monoatomic ion channel activity","canonical_id":"go:GO:0005216","description":"\"Enables the facilitated diffusion of a monoatomic ion (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. May be either selective (it enables passage of a specific ion only) or non-selective (it enables passage of two or more ions of same charge but different size).\" [GOC:cy, GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"dafd24645c184bb2af19f37acf461394","type":"GO_TERM","name":"monoatomic ion channel complex","canonical_id":"go:GO:0034702","description":"\"A protein complex that spans a membrane and forms a water-filled channel across the phospholipid bilayer allowing selective monoatomic ion transport down its electrochemical gradient.\" [GOC:mah, ISBN:071673706X]","metadata":null},{"id":"0c6078f2ca6747f4bc07f315497e69f6","type":"GO_TERM","name":"monoatomic ion homeostasis","canonical_id":"go:GO:0050801","description":"\"Any process involved in the maintenance of an internal steady state of monoatomic ions within an organism or cell. Monatomic ions (also called simple ions) are ions consisting of exactly one atom.\" [GOC:ai]","metadata":null},{"id":"48ef24bdcfdb4bcbb157c99e4cbfe0ba","type":"GO_TERM","name":"monoatomic ion transmembrane transport","canonical_id":"go:GO:0034220","description":"\"A process in which a monoatomic ion is transported across a membrane. Monatomic ions (also called simple ions) are ions consisting of exactly one atom.\" [GOC:mah]","metadata":null},{"id":"627605f9296b4a9b88918dcd8d801d38","type":"GO_TERM","name":"monoatomic ion transmembrane transporter activity","canonical_id":"go:GO:0015075","description":"\"Enables the transfer of an ion from one side of a membrane to the other.\" [GOC:dgf, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ea062069315b497d846c408d298aec2a","type":"GO_TERM","name":"monoatomic ion transport","canonical_id":"go:GO:0006811","description":"\"The directed movement of a monoatomic ion into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Monatomic ions (also called simple ions) are ions consisting of exactly one atom.\" [GOC:ai]","metadata":null},{"id":"49084552dd434b9e9ccb6ec5b02c5551","type":"GO_TERM","name":"monoatomic ion-gated channel activity","canonical_id":"go:GO:0022839","description":"\"Enables the transmembrane transfer of a solute by a channel that opens in response to a specific ion stimulus.\" [GOC:mtg_transport]","metadata":null},{"id":"615cee66611e499dbe9b78798f01e1e5","type":"GO_TERM","name":"monocarboxylate:sodium symporter activity","canonical_id":"go:GO:0140161","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: monocarboxylate(out) + Na+(out) = monocarboxylate(in) + Na+(in).\" [GOC:ln, PMID:15322102]","metadata":null},{"id":"c0a198fe813e4d4b8db1e3cb0c231562","type":"GO_TERM","name":"monocarboxylic acid binding","canonical_id":"go:GO:0033293","description":"\"Binding to a monocarboxylic acid, any organic acid containing one carboxyl (COOH) group or anion (COO-).\" [GOC:mah]","metadata":null},{"id":"f2cd64f5f1b045f1a1fa8bd6aee84e27","type":"GO_TERM","name":"monocarboxylic acid biosynthetic process","canonical_id":"go:GO:0072330","description":"\"The chemical reactions and pathways resulting in the formation of monocarboxylic acids, any organic acid containing one carboxyl (-COOH) group.\" [GOC:mah]","metadata":null},{"id":"37f97f31c0134f91967f7f1dde4cecb1","type":"GO_TERM","name":"monocarboxylic acid catabolic process","canonical_id":"go:GO:0072329","description":"\"The chemical reactions and pathways resulting in the breakdown of monocarboxylic acids, any organic acid containing one carboxyl (-COOH) group.\" [GOC:mah]","metadata":null},{"id":"949011f50ae04e2e9747b786d3ae9d70","type":"GO_TERM","name":"monocarboxylic acid metabolic process","canonical_id":"go:GO:0032787","description":"\"The chemical reactions and pathways involving monocarboxylic acids, any organic acid containing one carboxyl (COOH) group or anion (COO-).\" [GOC:vk]","metadata":null},{"id":"debcbd4929294affa6c8b93074aa2fe3","type":"GO_TERM","name":"monocarboxylic acid transmembrane transporter activity","canonical_id":"go:GO:0008028","description":"\"Enables the transfer of monocarboxylic acids from one side of a membrane to the other. A monocarboxylic acid is an organic acid with one COOH group.\" [GOC:ai]","metadata":null},{"id":"64d6902ccfbc4431a6298704e64b97e0","type":"GO_TERM","name":"monocarboxylic acid transport","canonical_id":"go:GO:0015718","description":"\"The directed movement of monocarboxylic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"556a8022becf449d9465c2fa58beca0f","type":"GO_TERM","name":"monocoumaroyl dicaffeoyl spermidine meta-hydroxylase activity","canonical_id":"go:GO:0072549","description":"\"Catalysis of the reaction: monocoumaroyl dicaffeoyl spermidine + NADPH + O2 = tricaffeoyl spermidine + NADP+ + H2O.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"71af7249e011446bb70bc8079198ab5c","type":"GO_TERM","name":"monocyte activation","canonical_id":"go:GO:0042117","description":"\"The change in morphology and behavior of a monocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"043f683966504e9faca318bea60afaf9","type":"GO_TERM","name":"monocyte activation involved in immune response","canonical_id":"go:GO:0002280","description":"\"The change in morphology and behavior of a monocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149, PMID:16551245]","metadata":null},{"id":"cd0e3009832f40638a24a8795c79cadc","type":"GO_TERM","name":"monocyte aggregation","canonical_id":"go:GO:0070487","description":"\"The adhesion of one monocyte to one or more other monocytes via adhesion molecules.\" [GOC:sl, PMID:12972508]","metadata":null},{"id":"bae5e740905e4ba0b78c04a833a96d99","type":"GO_TERM","name":"monocyte antigen processing and presentation","canonical_id":"go:GO:0002471","description":"\"The process in which a monocyte expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, PMID:11200054]","metadata":null},{"id":"b61b9a396c0449daa279ce352d311c84","type":"GO_TERM","name":"monocyte chemotactic protein-1 production","canonical_id":"go:GO:0071605","description":"\"The appearance of monocyte chemotactic protein-1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:rv]","metadata":null},{"id":"02697eeb875a412c8dff524dc0a9584c","type":"GO_TERM","name":"monocyte chemotaxis","canonical_id":"go:GO:0002548","description":"\"The movement of a monocyte in response to an external stimulus.\" [GOC:add, PMID:11696603, PMID:15173832]","metadata":null},{"id":"597d6fd69dc249afa32bd2d501994142","type":"GO_TERM","name":"monocyte differentiation","canonical_id":"go:GO:0030224","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a monocyte.\" [GOC:mah]","metadata":null},{"id":"aa1b552b923648a98b4b04bd9bed7fd7","type":"GO_TERM","name":"monocyte extravasation","canonical_id":"go:GO:0035696","description":"\"The migration of a monocyte from the blood vessels into the surrounding tissue.\" [CL:0000576, GOC:BHF, PMID:10657654]","metadata":null},{"id":"64de12eb0566478c8339943e1fcf02fb","type":"GO_TERM","name":"monocyte homeostasis","canonical_id":"go:GO:0035702","description":"\"The process of regulating the proliferation and elimination of monocytes such that the total number of monocytes within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [CL:0000576, GOC:BHF, PMID:18832716]","metadata":null},{"id":"6f659e012b3f4241bcb6876f6da7d368","type":"GO_TERM","name":"monocyte migration into blood stream","canonical_id":"go:GO:0035703","description":"\"The movement of a monocyte from the bone marrow to the blood stream.\" [CL:0000576, GOC:BHF]","metadata":null},{"id":"629c92e5ce6a4c54b765c29a096cab1f","type":"GO_TERM","name":"monocyte proliferation","canonical_id":"go:GO:0061516","description":"\"The expansion of a monocyte population by cell division.\" [GOC:dph, PMID:18467591]","metadata":null},{"id":"1c5d71b28d7b40558cb54f039a741a3a","type":"GO_TERM","name":"monodehydroascorbate reductase (NADH) activity","canonical_id":"go:GO:0016656","description":"\"Catalysis of the reaction: 2 monodehydro-L-ascorbate radical + NADH + H+ = 2 L-ascorbate + NAD+.\" [RHEA:14581]","metadata":null},{"id":"3b35046c9eea4604bb119d048ba5e8dc","type":"GO_TERM","name":"monodictyphenone biosynthetic process","canonical_id":"go:GO:1900815","description":"\"The chemical reactions and pathways resulting in the formation of monodictyphenone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"99010bec8ca64594a15b3f1019d8f7d1","type":"GO_TERM","name":"monodictyphenone catabolic process","canonical_id":"go:GO:1900814","description":"\"The chemical reactions and pathways resulting in the breakdown of monodictyphenone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"66588e897abe4ecabc9ece90c2418572","type":"GO_TERM","name":"monodictyphenone metabolic process","canonical_id":"go:GO:1900813","description":"\"The chemical reactions and pathways involving monodictyphenone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a4101f53661d4297bbdcdb9aec7c9dad","type":"GO_TERM","name":"monoferuloyl di-(hydroxyferuloyl) spermidine meta-hydroxylase activity","canonical_id":"go:GO:0072552","description":"\"Catalysis of the reaction: monoferuloyl di-(hydroxyferuloyl) spermidine + NADPH + O2 = tri-(hydroxyferuloyl) spermidine + NADP+ + H2O.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"4c3dc47094554e708813baeb23a66b5c","type":"DISEASE","name":"monogenic diabetes","canonical_id":"mondo:0015967","description":null,"metadata":null},{"id":"92049eefd2dc411384b47fb9a5861c3f","type":"GO_TERM","name":"monolayer-surrounded lipid storage body","canonical_id":"go:GO:0012511","description":"\"A subcellular organelle of plant cells surrounded by 'half-unit' or a monolayer membrane instead of the more usual bilayer. The storage body has a droplet of triglyceride surrounded by a monolayer of phospholipids, interacting with the triglycerides and the hydrophilic head groups facing the cytosol, and containing major protein components called oleosins.\" [GOC:mtg_sensu, ISBN:0943088372]","metadata":null},{"id":"52b4bd24444c4bfb9275bad9a7fdb393","type":"GO_TERM","name":"monolayer-surrounded lipid storage body outer lipid monolayer","canonical_id":"go:GO:0034430","description":"\"The single layer of phopholipids surrounding a lipid storage body.\" [GOC:rph]","metadata":null},{"id":"dc26807a2f5c4743b27662931bea9255","type":"GO_TERM","name":"monomeric IgA immunoglobulin complex","canonical_id":"go:GO:0071748","description":"\"A protein complex composed of two identical immunoglobulin heavy chains of an IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"cbdeb7d501b64bc5ba485d6e17064ccb","type":"GO_TERM","name":"monomethyl-sulfatase activity","canonical_id":"go:GO:0050106","description":"\"Catalysis of the reaction: H2O + monomethyl sulfate = H+ + methanol + sulfate.\" [EC:3.1.6.16, RHEA:14221]","metadata":null},{"id":"2700408de81f4b62b272b0b23abbaff6","type":"GO_TERM","name":"monomethylamine methyltransferase activity","canonical_id":"go:GO:0043852","description":"\"Catalysis of the reaction: Co(I)-[methylamine-specific corrinoid protein] + methylamine + H+ = methyl-Co(III)-[methylamine-specific corrinoid protein] + NH4+.\" [PMID:9195968, RHEA:26059]","metadata":null},{"id":"60260504d1e74e49837aa594c1e92dcc","type":"GO_TERM","name":"mononeme","canonical_id":"go:GO:0070074","description":"\"A secretory organelle that forms part of the apical complex; a small, threadlike structure located is close proximity to the subpellicular microtubules. Its contents include a rhomboid protease (PfROM1 in Plasmodium falciparum) that moves from the lateral asymmetric localization to the merozoite apical pole and the posterior pole upon release of merozoites from schizonts.\" [GOC:BHF, PMID:18048320]","metadata":null},{"id":"0fe4acab1295429c9a636f50b9d69c3d","type":"GO_TERM","name":"mononuclear cell differentiation","canonical_id":"go:GO:1903131","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a mononuclear cell.\" [CL:0000842, GO_REF:0000086, GOC:TermGenie, PMID:24759906]","metadata":null},{"id":"2c2f5bd4b4654e7db4c3d6c300be6c8d","type":"GO_TERM","name":"mononuclear cell migration","canonical_id":"go:GO:0071674","description":"\"The movement of a mononuclear cell within or between different tissues and organs of the body.\" [GOC:mah]","metadata":null},{"id":"167d7f99810543a8b3ac0eaff8617a5c","type":"GO_TERM","name":"mononuclear cell proliferation","canonical_id":"go:GO:0032943","description":"\"The expansion of a mononuclear cell population by cell division. A mononuclear cell is a leukocyte with a single non-segmented nucleus in the mature form.\" [GOC:add]","metadata":null},{"id":"d0a9f3bc64f94fa0a4bd0149c0861898","type":"GO_TERM","name":"monooxygenase activity","canonical_id":"go:GO:0004497","description":"\"Catalysis of the incorporation of one atom of molecular oxygen (O2) into the substrate and the reduction of the other atom of O2 to water.\" [PMID:1444267]","metadata":null},{"id":"11d4350574d04300b0d809dcd51ba316","type":"GO_TERM","name":"monopolar cell growth","canonical_id":"go:GO:0042814","description":"\"Polarized growth from one end of a cell.\" [GOC:vw]","metadata":null},{"id":"b9559c9f1e5540e89776fd6acd6e8cda","type":"GO_TERM","name":"monopolin complex","canonical_id":"go:GO:0033551","description":"\"A protein complex required for clamping microtubule binding sites, ensuring orientation of sister kinetochores to the same pole (mono-orientation) during meiosis I. In the yeast S. cerevisiae this complex consists of Csm1p, Lrs4p, Hrr25p and Mam1p; in S. pombe Psc1 and Mde4 have been identified as subunits.\" [GOC:mah, GOC:rb, PMID:17627824]","metadata":null},{"id":"856c3b99a09c408cb112e9aaa4817559","type":"GO_TERM","name":"monosaccharide binding","canonical_id":"go:GO:0048029","description":"\"Binding to a monosaccharide. Monosaccharides are the simplest carbohydrates; they are polyhydroxy aldehydes H[CH(OH)]nC(=O)H or polyhydroxy ketones H[CHOH]nC(=O)[CHOH]mH with three or more carbon atoms. They form the constitutional repeating units of oligo- and polysaccharides.\" [GOC:jid]","metadata":null},{"id":"ea50511617b047b483522da92a3aef5e","type":"GO_TERM","name":"monosaccharide biosynthetic process","canonical_id":"go:GO:0046364","description":"\"The chemical reactions and pathways resulting in the formation of monosaccharides, polyhydric alcohols containing either an aldehyde or a keto group and between three to ten or more carbon atoms.\" [ISBN:0198506732]","metadata":null},{"id":"86c651b84da44aaeae8353a21f302651","type":"GO_TERM","name":"monosaccharide catabolic process","canonical_id":"go:GO:0046365","description":"\"The chemical reactions and pathways resulting in the breakdown of monosaccharides, polyhydric alcohols containing either an aldehyde or a keto group and between three to ten or more carbon atoms.\" [ISBN:0198506732]","metadata":null},{"id":"185efdcd83f7416190fe5a084744a60b","type":"GO_TERM","name":"monosaccharide metabolic process","canonical_id":"go:GO:0005996","description":"\"The chemical reactions and pathways involving monosaccharides, the simplest carbohydrates. They are polyhydric alcohols containing either an aldehyde or a keto group and between three to ten or more carbon atoms. They form the constitutional repeating units of oligo- and polysaccharides.\" [ISBN:0198506732]","metadata":null},{"id":"c40ca1ecbd9346f480adef1d5f003c72","type":"GO_TERM","name":"monosaccharide transmembrane transport","canonical_id":"go:GO:0015749","description":"\"The process in which a monosaccharide is transported across a lipid bilayer, from one side of a membrane to the other. Monosaccharides are the simplest carbohydrates; they are polyhydric alcohols containing either an aldehyde or a keto group and between three to ten or more carbon atoms. They form the constitutional repeating units of oligo- and polysaccharides.\" [GO_REF:0000069, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"f7382cead8124411b557b6949b8a7ce3","type":"GO_TERM","name":"monosaccharide transmembrane transporter activity","canonical_id":"go:GO:0015145","description":"\"Enables the transfer of a monosaccharide from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"bdb87e5791a04b7c8090c2a39d4c60c5","type":"GO_TERM","name":"monoterpene biosynthetic process","canonical_id":"go:GO:0043693","description":"\"The chemical reactions and pathways resulting in the formation of monoterpenes, terpenes with a C10 structure.\" [Wikipedia:Monoterpene]","metadata":null},{"id":"6ee0585a2a7f49e1af367f6d23a89930","type":"GO_TERM","name":"monoterpene catabolic process","canonical_id":"go:GO:0043694","description":"\"The chemical reactions and pathways resulting in the breakdown of monoterpenes, terpenes with a C10 structure.\" [PMID:25076942]","metadata":null},{"id":"b911fb07ef2846808c6b3871fb96d986","type":"GO_TERM","name":"monoterpene metabolic process","canonical_id":"go:GO:0043692","description":"\"The chemical reactions and pathways involving monoterpenes, terpenes with a C10 structure.\" [Wikipedia:Monoterpene]","metadata":null},{"id":"6220d7aecab44a0392e22ed6969bdcfd","type":"GO_TERM","name":"monoterpenoid biosynthetic process","canonical_id":"go:GO:0016099","description":"\"The chemical reactions and pathways resulting in the formation of monoterpenoid compounds, terpenoids having a C10 skeleton.\" [GOC:curators]","metadata":null},{"id":"ee88c5e5b3d74ef684c6f3f78cc4b79c","type":"GO_TERM","name":"monoterpenoid catabolic process","canonical_id":"go:GO:0016100","description":"\"The chemical reactions and pathways resulting in the breakdown of monoterpenoid compounds, terpenoids having a C10 skeleton.\" [GOC:curators]","metadata":null},{"id":"f71d40ea9d224a60bdd28885146697cc","type":"GO_TERM","name":"monoterpenoid metabolic process","canonical_id":"go:GO:0016098","description":"\"The chemical reactions and pathways involving monoterpenoid compounds, terpenoids having a C10 skeleton.\" [ISBN:0198547684]","metadata":null},{"id":"c40e75d6c5914f4c9f140eb749b0cb2d","type":"GO_TERM","name":"monoterpenol O-acetyltransferase activity","canonical_id":"go:GO:0050107","description":"\"Catalysis of the reaction: acetyl-CoA + a monoterpenol = CoA + a monoterpenol acetate ester.\" [EC:2.3.1.69, MetaCyc:MONOTERPENOL-O-ACETYLTRANSFERASE-RXN]","metadata":null},{"id":"54ac01cc21c74a77ab5ca014b220e0f0","type":"GO_TERM","name":"monoterpenol beta-glucosyltransferase activity","canonical_id":"go:GO:0047219","description":"\"Catalysis of the reaction: (-)-menthol + UDP-D-glucose = (-)-menthyl beta-D-glucoside + H+ + UDP.\" [EC:2.4.1.127, RHEA:11520]","metadata":null},{"id":"9bb910b1bca34a419fa69cda4f410e27","type":"GO_TERM","name":"monoterpenyl-diphosphatase activity","canonical_id":"go:GO:0050108","description":"\"Catalysis of the reaction: (2S,4R)-bornyl diphosphate + H2O = (1R,2S,4R)-borneol + diphosphate.\" [EC:3.1.7.3, PMID:42357]","metadata":null},{"id":"af980489d8dd4480948c9076ad628067","type":"GO_TERM","name":"monoubiquitinated protein deubiquitination","canonical_id":"go:GO:0035520","description":"\"The removal of the ubiquitin group from a monoubiquitinated protein.\" [GOC:bf]","metadata":null},{"id":"cc5196d9d4ad45d4bbe8868799f741e9","type":"GO_TERM","name":"monounsaturated fatty acid biosynthetic process","canonical_id":"go:GO:1903966","description":"\"The chemical reactions and pathways resulting in the formation of monounsaturated fatty acid.\" [GO_REF:0000068, GOC:hjd, GOC:TermGenie, PMID:16443825]","metadata":null},{"id":"e40f4307ff31499c92ef05740d583dcc","type":"GO_TERM","name":"monounsaturated fatty acid catabolic process","canonical_id":"go:GO:1903965","description":"\"The chemical reactions and pathways resulting in the breakdown of monounsaturated fatty acid.\" [GO_REF:0000068, GOC:hjd, GOC:TermGenie, PMID:16443825]","metadata":null},{"id":"10ff3a81446542b289d98c3dbe8a1dc6","type":"DRUG","name":"montelukast","canonical_id":"gtopdb:3340","description":null,"metadata":null},{"id":"e36bb800b33346e08a632db45e7c11dc","type":"COMBINATION_TREATMENT","name":"montelukast + prednisolone","canonical_id":"ctgov_combo:ctgov-combo-14e5babf0c8330fb","description":null,"metadata":null},{"id":"f63928d2b21b465a851bfccc91851f56","type":"COMBINATION_TREATMENT","name":"montelukast + roflumilast","canonical_id":"ctgov_combo:ctgov-combo-b73958bfe8a8eb0f","description":null,"metadata":null},{"id":"22c50eb224a54599992166d932af5f5a","type":"COMBINATION_TREATMENT","name":"montelukast + salmeterol","canonical_id":"ctgov_combo:ctgov-combo-0799f3db082ea593","description":null,"metadata":null},{"id":"02c7a3852f14498eb2889237f4634ac4","type":"DISEASE","name":"mood disorder","canonical_id":"mondo:0005371","description":null,"metadata":null},{"id":"1a60becbbe5941ed8124b4bbd663d595","type":"DISEASE","name":"morbid obesity","canonical_id":"mondo:0005139","description":null,"metadata":null},{"id":"0bcf6207b22744008db42736d887fd97","type":"DRUG","name":"morphine","canonical_id":"gtopdb:1627","description":null,"metadata":null},{"id":"814a695fdb144251a6f17295100bcb64","type":"DRUG","name":"morphine","canonical_id":"mesh:D009020","description":null,"metadata":null},{"id":"b7c791b23349473d87032a4952eb4525","type":"GO_TERM","name":"morphine 6-dehydrogenase activity","canonical_id":"go:GO:0050109","description":"\"Catalysis of the reaction: morphine + NAD(P)+ = morphinone + NAD(P)H + H+.\" [EC:1.1.1.218, MetaCyc:MORPHINE-6-DEHYDROGENASE-RXN]","metadata":null},{"id":"1acba74d6c0741b2826d3ca5de2a24a7","type":"GO_TERM","name":"morphine biosynthetic process","canonical_id":"go:GO:0097295","description":"\"The chemical reactions and pathways resulting in the formation of morphine, 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol. Morphine is a highly potent opiate analgesic psychoactive drug obtained form the opium poppy, Papaver somniferum.\" [GOC:yaf, PMID:19567876]","metadata":null},{"id":"2a6c10698c504c71a6f001d32d4ba5f4","type":"GO_TERM","name":"morphine catabolic process","canonical_id":"go:GO:0071273","description":"\"The chemical reactions and pathways resulting in the breakdown of morphine, 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol. Morphine is a highly potent opiate analgesic psychoactive drug obtained form the opium poppy, Papaver somniferum.\" [GOC:ecd, GOC:mah, PMID:22193538]","metadata":null},{"id":"026898cfa508432e8de6e09b7ab77c47","type":"GO_TERM","name":"morphine metabolic process","canonical_id":"go:GO:0071272","description":"\"The chemical reactions and pathways involving morphine, 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol. Morphine is a highly potent opiate analgesic psychoactive drug obtained form the opium poppy, Papaver somniferum.\" [GOC:mah]","metadata":null},{"id":"f71de1668c0a4878a9702423b99e1a0f","type":"GO_TERM","name":"morphine receptor activity","canonical_id":"go:GO:0038047","description":"\"Combining with morphine (17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol), and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:bf]","metadata":null},{"id":"f22500d7a28c451ebeca529e4a92dc12","type":"GO_TERM","name":"morphogen activity","canonical_id":"go:GO:0016015","description":"\"Acts as a trigger for a pattern specification process when present at a specific concentration within a gradient.\" [GOC:curators]","metadata":null},{"id":"d86dd4c4a5c54378a3d4e7077c0120e8","type":"GO_TERM","name":"morphogenesis of a branching epithelium","canonical_id":"go:GO:0061138","description":"\"The process in which the anatomical structures of a branched epithelium are generated and organized.\" [GOC:dph]","metadata":null},{"id":"3c9943770ed34e71b6eee3af0c7204b0","type":"GO_TERM","name":"morphogenesis of a branching structure","canonical_id":"go:GO:0001763","description":"\"The process in which the anatomical structures of branches are generated and organized. A branch is a division or offshoot from a main stem. Examples in animals would include blood vessels, nerves, lymphatics and other endothelial or epithelial tubes.\" [ISBN:0721662544]","metadata":null},{"id":"c7dd07b1dc024df5813aa3c669eaa130","type":"GO_TERM","name":"morphogenesis of a polarized epithelium","canonical_id":"go:GO:0001738","description":"\"The morphogenetic process in which the anatomical structures of a polarized epithelium are generated and organized. A polarized epithelium is an epithelium where the epithelial sheet is oriented with respect to the planar axis.\" [GOC:dph]","metadata":null},{"id":"b051fbd595434257b6d77242171c47be","type":"GO_TERM","name":"morphogenesis of an endothelium","canonical_id":"go:GO:0003159","description":"\"The process in which the anatomical structure of an endothelium is generated and organized. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells.\" [GOC:mtg_heart]","metadata":null},{"id":"de5aa379eab7454bb8badac3a00de2e3","type":"GO_TERM","name":"morphogenesis of an epithelial bud","canonical_id":"go:GO:0060572","description":"\"The morphogenetic process in which a bud forms from an epithelial sheet. A bud is a protrusion that forms form the sheet by localized folding.\" [GOC:dph]","metadata":null},{"id":"3977f5c56e5146cbbf81aa5e3e16b73e","type":"GO_TERM","name":"morphogenesis of an epithelial fold","canonical_id":"go:GO:0060571","description":"\"The morphogenetic process in which an epithelial sheet bends along a linear axis.\" [GOC:dph]","metadata":null},{"id":"26b06ce01f6a4d97956dcdd485e95613","type":"GO_TERM","name":"morphogenesis of an epithelial sheet","canonical_id":"go:GO:0002011","description":"\"The process in which the anatomical structures of an epithelial sheet are generated and organized. An epithelial sheet is a flat surface consisting of closely packed epithelial cells.\" [GOC:jl]","metadata":null},{"id":"c548d657a0d241df851903ba742748d3","type":"GO_TERM","name":"morphogenesis of an epithelium","canonical_id":"go:GO:0002009","description":"\"The process in which the anatomical structures of epithelia are generated and organized. An epithelium consists of closely packed cells arranged in one or more layers, that covers the outer surfaces of the body or lines any internal cavity or tube.\" [GOC:dph, GOC:jl, GOC:tb, ISBN:0198506732]","metadata":null},{"id":"4a8a5d0ca364424f9d8ce8f4e917e52e","type":"GO_TERM","name":"morphogenesis of embryonic epithelium","canonical_id":"go:GO:0016331","description":"\"The process in which the anatomical structures of embryonic epithelia are generated and organized.\" [GOC:jl]","metadata":null},{"id":"54b69d0551404a5fa33a407a3f2f20eb","type":"GO_TERM","name":"morphogenesis of follicular epithelium","canonical_id":"go:GO:0016333","description":"\"The process in which the anatomical structures of a follicular epithelium are generated and organized.\" [GOC:jl]","metadata":null},{"id":"adc7fe9a564549fba2de6ba42f42b34b","type":"GO_TERM","name":"morphogenesis of larval imaginal disc epithelium","canonical_id":"go:GO:0016335","description":"\"The process in which the anatomical structures of a larval imaginal disc epithelium are generated and organized.\" [GOC:jl]","metadata":null},{"id":"8dfb65ead1c64724a8c39cdba091c3e5","type":"GO_TERM","name":"morula development","canonical_id":"go:GO:0014000","description":"\"The process whose specific outcome is the progression of the morula over time. The morula is a spherical embryonic mass of blastomeres formed before the blastula and resulting from cleavage of the fertilized ovum.\" [PMID:37935903, PMID:38386558, PMID:39361745]","metadata":null},{"id":"357be87f8b7244d481f645f5f4da7769","type":"GO_TERM","name":"morula formation","canonical_id":"go:GO:0140001","description":"\"The initial formation of a spherical embryonic mass of blastomeres formed before the blastula and resulting from cleavage of the fertilized ovum.\" [PMID:37935903, PMID:38386558, PMID:39361745]","metadata":null},{"id":"9eb2af3dd1124f6db2456c9bae61cb71","type":"DRUG","name":"mosapramine","canonical_id":"mesh:C046384","description":null,"metadata":null},{"id":"44647978dd54441aa0ee2ba405a6211e","type":"GO_TERM","name":"mossy fiber rosette","canonical_id":"go:GO:0097471","description":"\"A synapse of a mossy fiber onto the dendrite of a granule cell; each mossy fiber can have up to 50 rosettes.\" [NIF_Subcellular:nlx_subcell_091021, Wikipedia:Mossy_fiber_(cerebellum)]","metadata":null},{"id":"9f2460a104e2442eb5ffcbf2af23a499","type":"GO_TERM","name":"motile cilium","canonical_id":"go:GO:0031514","description":"\"A cilium which may have a variable arrangement of axonemal microtubules and also contains molecular motors. It may beat with a whip-like pattern that promotes cell motility or transport of fluids and other cells across a cell surface, such as on epithelial cells that line the lumenal ducts of various tissues; or they may display a distinct twirling motion that directs fluid flow asymmetrically across the cellular surface to affect asymmetric body plan organization. Motile cilia can be found in single as well as multiple copies per cell.\" [GOC:cilia, GOC:dgh, GOC:kmv, PMID:17009929, PMID:20144998, PMID:22118931]","metadata":null},{"id":"0bb99f9a33944421a98294ed83e971ca","type":"GO_TERM","name":"motile cilium assembly","canonical_id":"go:GO:0044458","description":"\"The aggregation, arrangement and bonding together of a set of components to form a motile cilium.\" [GO_REF:0000079, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:19776033, PMID:21129373, ZFIN:dsf]","metadata":null},{"id":"d9032335e45d4ada99c8afae1f391725","type":"GO_TERM","name":"motilin receptor binding","canonical_id":"go:GO:0031788","description":"\"Binding to a motilin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"b5c6d30174a34425a48f9a13deb33426","type":"DISEASE","name":"motion sickness","canonical_id":"efo:0006928","description":null,"metadata":null},{"id":"32636c70a9644804acb5bed263cd98b1","type":"GO_TERM","name":"motogenic signaling initiating cell movement in cerebral cortex","canonical_id":"go:GO:0021807","description":"\"The interaction of soluble factors and receptors that result in the movement of cells in the primitive cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"d2d331bb00c540cf95895bfc71516a7b","type":"GO_TERM","name":"motor behavior","canonical_id":"go:GO:0061744","description":"\"The specific neuromuscular movement of a single organism in response to external or internal stimuli.\" [GOC:bf, GOC:PARL, PMID:25318560]","metadata":null},{"id":"8a6c422dd2244d618f4ec6a940af7400","type":"GO_TERM","name":"motor learning","canonical_id":"go:GO:0061743","description":"\"Any process in which an organism acquires a novel neuromuscular action or movement as the result of experience.\" [GOC:bf, GOC:PARL, Wikipedia:Motor_learning]","metadata":null},{"id":"85c226ce1c2145959637adf1f38b3030","type":"GO_TERM","name":"motor neuron apoptotic process","canonical_id":"go:GO:0097049","description":"\"Any apoptotic process in a motor neuron, an efferent neuron that passes from the central nervous system or a ganglion toward or to a muscle and conducts an impulse that causes movement.\" [CL:0000100, GOC:BHF, GOC:mtg_apoptosis, PMID:14523086]","metadata":null},{"id":"31230dd7730947d29a7a2503411ebd4e","type":"GO_TERM","name":"motor neuron axon guidance","canonical_id":"go:GO:0008045","description":"\"The process in which the migration of an axon growth cone of a motor neuron is directed to a specific target site in response to a combination of attractive and repulsive cues.\" [CL:0000100, GOC:pr, ISBN:0878932437]","metadata":null},{"id":"bebc52d4ce92422b9d0ec940c83f4da5","type":"DISEASE","name":"motor neuron disorder","canonical_id":"mondo:0020128","description":null,"metadata":null},{"id":"ef3dd8a6facd41fa89e6607ebd03999d","type":"GO_TERM","name":"motor neuron migration","canonical_id":"go:GO:0097475","description":"\"The orderly movement of a motor neuron from one site to another. A motor neuron is an efferent neuron that passes from the central nervous system or a ganglion toward or to a muscle and conducts an impulse that causes movement.\" [CL:0000100, GOC:yaf, PMID:20711475]","metadata":null},{"id":"167f1019a04446d1831c994d060ea504","type":"DISEASE","name":"movement disorder","canonical_id":"mondo:0005395","description":null,"metadata":null},{"id":"5745bf7d1b0244cab1743b8b1e7b4619","type":"GO_TERM","name":"movement of group I intron","canonical_id":"go:GO:0006316","description":"\"Lateral transfer of a group I intron to a homologous allele that lacks the intron, mediated by a site-specific endonuclease encoded within the mobile intron; group I introns are self-splicing introns that use guanosine as a cofactor in the splicing reaction.\" [GOC:mcc, ISBN:0716743663, PMID:10487208]","metadata":null},{"id":"296c7bc705d241ae82efc35e383fc418","type":"DRUG","name":"moxetumomab pasudotox","canonical_id":"gtopdb:7675","description":null,"metadata":null},{"id":"15e04d6ba22f49d6be566590f54d2892","type":"DRUG","name":"moxetumomab pasudotox","canonical_id":"chembl:CHEMBL1743043","description":null,"metadata":null},{"id":"4248b2af60674ec682a32fd2dd413d76","type":"DRUG","name":"moxifloxacin","canonical_id":"mesh:D000077266","description":null,"metadata":null},{"id":"0ac433095f114f488b0ba8bf967c0293","type":"DISEASE","name":"moyamoya disease 7","canonical_id":"mondo:0958202","description":null,"metadata":null},{"id":"135cad8a74704a84bcb42fd57de1af23","type":"GO_TERM","name":"mu-type opioid receptor binding","canonical_id":"go:GO:0031852","description":"\"Binding to a mu-type opioid receptor.\" [GOC:mah, GOC:nln, GOC:sl]","metadata":null},{"id":"f26c1f3a084f4894b9ac7d240eb85391","type":"GO_TERM","name":"mucilage biosynthetic process","canonical_id":"go:GO:0010192","description":"\"The chemical reactions and pathways resulting in the formation of mucilage, a gelatinous substance secreted by plants.\" [GOC:sm]","metadata":null},{"id":"c5b8f3f2774348119bcfc5d7c7709bd9","type":"GO_TERM","name":"mucilage biosynthetic process involved in seed coat development","canonical_id":"go:GO:0048354","description":"\"The chemical reactions and pathways resulting in the formation of mucilage that occur as part of seed coat development; mucilage is normally synthesized during seed coat development.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"836ee8e6e65a453784cba58fca64d9e7","type":"GO_TERM","name":"mucilage extrusion from seed coat","canonical_id":"go:GO:0080001","description":"\"The process in which seed mucilage expands through hydration and breaks the outer cell wall that encapsulates the whole seed upon imbibition. Mucilage, mainly composed of pectins, is formed during seed development and deposited into the apoplast underneath the outer wall of the seed coat.\" [PMID:18266922]","metadata":null},{"id":"b765cda477a34aa7bccf153632868502","type":"GO_TERM","name":"mucilage pectin biosynthetic process","canonical_id":"go:GO:0048358","description":"\"The chemical reactions and pathways resulting in the formation of the pectin component of mucilage.\" [GOC:jid]","metadata":null},{"id":"65ec626582f14084ae64fa0719bec629","type":"GO_TERM","name":"mucilage pectin metabolic process","canonical_id":"go:GO:0048363","description":"\"The chemical reactions and pathways involving the pectin component of mucilage.\" [GOC:jid]","metadata":null},{"id":"92640e5fe93249f886edec2d099eee87","type":"GO_TERM","name":"mucin granule","canonical_id":"go:GO:0098594","description":"\"A secretory granule that contains mucin.\" [PMID:16377632]","metadata":null},{"id":"1b5082d937e9468ab63494b713b126ae","type":"GO_TERM","name":"mucociliary clearance","canonical_id":"go:GO:0120197","description":"\"The respiratory system process driven by motile cilia on epithelial cells of the respiratory tract by which mucus and associated inhaled particles and pathogens trapped within it are moved out of the airways.\" [GOC:krc, PMID:24119105, PMID:27864314]","metadata":null},{"id":"1f07fed35929487fb9896aa6d82f31c5","type":"GO_TERM","name":"mucocyst","canonical_id":"go:GO:0036000","description":"\"A small subcellular vesicle, surrounded by a membrane, in the pellicle of ciliate protozoans that discharges a mucus-like secretion.\" [GOC:mag, PMID:10723937, PMID:4629881]","metadata":null},{"id":"69e5df40a06544be9728e554e2add948","type":"GO_TERM","name":"muconate cycloisomerase activity","canonical_id":"go:GO:0018849","description":"\"Catalysis of the reaction: 2,5-dihydro-5-oxofuran-2-acetate = cis,cis-hexadienedioate.\" [RHEA:30031]","metadata":null},{"id":"a72644ccd03e4c4c85c54dfa6783354a","type":"GO_TERM","name":"muconolactone delta-isomerase activity","canonical_id":"go:GO:0016159","description":"\"Catalysis of the reaction: (S)-muconolactone = (4,5-dihydro-5-oxofuran-2-yl)-acetate.\" [RHEA:12348]","metadata":null},{"id":"7d2868e59e3449ee82efaaf9f2844492","type":"GO_TERM","name":"mucosa-associated lymphoid tissue development","canonical_id":"go:GO:0048537","description":"\"The process whose specific outcome is the progression of mucosal-associated lymphoid tissue over time, from its formation to the mature structure. Mucosal-associated lymphoid tissue is typically found as nodules associated with mucosal epithelia with distinct internal structures including B- and T-zones for the activation of lymphocytes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7d4138ac2be541339fb5592cea643adf","type":"GO_TERM","name":"mucosal immune response","canonical_id":"go:GO:0002385","description":"\"An immune response taking place in mucosal tissues, including those of the intestinal tract, nasal and upper respiratory tract, and genital tract.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"3a62f9fe3350483abc4f548cac89d1a4","type":"GO_TERM","name":"mucosal lymphocyte homeostasis","canonical_id":"go:GO:0002261","description":"\"The process of regulating the proliferation and elimination of lymphocytes such that the total number of lymphocytes within the mucosal tissue of an organism is stable over time in the absence of an outside stimulus.\" [GOC:add, PMID:15609020]","metadata":null},{"id":"173e6d9ac2be4b739856f840b5d4d8ba","type":"GO_TERM","name":"mucosal tolerance induction","canonical_id":"go:GO:0002427","description":"\"Tolerance induction taking place in the mucosal tissues.\" [GOC:jal]","metadata":null},{"id":"f23ce1a48ea8446bb1150c08a5820b95","type":"DISEASE","name":"mucositis","canonical_id":"efo:1001898","description":null,"metadata":null},{"id":"d8417b45fb0741a1bc9eced59d992cb2","type":"GO_TERM","name":"mucus layer","canonical_id":"go:GO:0070701","description":"\"An extracellular region part that consists of a protective layer of mucus secreted by epithelial cells lining tubular organs of the body such as the colon or secreted into fluids such as saliva. Mucus is a viscous slimy secretion consisting of mucins (i.e. highly glycosylated mucin proteins) and various inorganic salts dissolved in water, with suspended epithelial cells and leukocytes.\" [GOC:krc, GOC:mah, GOC:mm2, PMID:18806221, PMID:19432394, Wikipedia:Mucin]","metadata":null},{"id":"2db2869920224b9e99bd8ab3cf8b1100","type":"GO_TERM","name":"mucus secretion","canonical_id":"go:GO:0070254","description":"\"The regulated release of mucus by the mucosa. Mucus is a viscous slimy secretion consisting of mucins and various inorganic salts dissolved in water, with suspended epithelial cells and leukocytes. The mucosa, or mucous membrane, is the membrane covered with epithelium that lines the tubular organs of the body. Mucins are carbohydrate-rich glycoproteins that have a lubricating and protective function.\" [GOC:add, ISBN:068340007X, ISBN:0721662544]","metadata":null},{"id":"6a02cbec83b44aea89e17005f0e4204d","type":"GO_TERM","name":"mugineic-acid 3-dioxygenase activity","canonical_id":"go:GO:0033761","description":"\"Catalysis of the reaction: mugineate + 2-oxoglutarate + O2 = 3-epihydroxymugineate + CO2 + H+ + succinate. Also converts 2'-deoxymugineate to 3-epihydroxy-2'-deoxymugineate.\" [EC:1.14.11.25]","metadata":null},{"id":"18229b7fc55e46a2b0c6e33e7ceb8d07","type":"TRIAL","name":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms","canonical_id":"clinicaltrials.gov:NCT04393246","description":"COVID-19","metadata":null},{"id":"ce8c82df992e44728a34183443aef2db","type":"TRIAL","name":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","canonical_id":"clinicaltrials.gov:NCT04390464","description":"COVID19","metadata":null},{"id":"3e128ff9a01d401d85f221c1e493d5f6","type":"GO_TERM","name":"multi-ciliated epithelial cell differentiation","canonical_id":"go:GO:1903251","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a multi-ciliated epithelial cell.\" [GO_REF:0000086, GOC:sp, GOC:TermGenie, PMID:22231168, PMID:24934224]","metadata":null},{"id":"44aeba3912244937b5998b6a785d3ce8","type":"GO_TERM","name":"multi-eIF complex","canonical_id":"go:GO:0043614","description":"\"A multifactor complex composed of multiple translation initiation factors and the initiatior tRNAiMet, which is ready to bind to the small (40S) ribosome to form the 43S preinitiation complex. In S. cerevisiae, this complex is composed of eIF1, eIF2, eIF3, and eIF5.\" [GOC:krc]","metadata":null},{"id":"ac3ff35ed3734104b7a9f228118ab23c","type":"GO_TERM","name":"multi-layer follicle stage","canonical_id":"go:GO:0048162","description":"\"The stage in oogenesis when many layers of follicle cells surround the oocyte. There is a yolk nucleus (Balbiani's Body) near the germinal vesicle.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"138508c74dd24b6fa7f09e51b6b49d5d","type":"GO_TERM","name":"multi-multicellular organism process","canonical_id":"go:GO:0044706","description":"\"A multicellular organism process which involves another multicellular organism of the same or different species.\" [GOC:jl]","metadata":null},{"id":"665df87c94aa4d41af1cdff0e832ba7f","type":"GO_TERM","name":"multi-organism reproductive process","canonical_id":"go:GO:0044703","description":"\"A biological process that directly contributes to the process of producing new individuals, involving another organism.\" [GOC:jl]","metadata":null},{"id":"5a775bc6a1a2475d88ca0978ae5bbf0e","type":"GO_TERM","name":"multi-pass translocon complex","canonical_id":"go:GO:0160064","description":"\"A protein complex that mediates the insertion of multi-pass transmembrane proteins into endoplasmic reticulum (ER) membrane. Substrates enter via the lateral gate of the Sec61 translocon. The complex comprises the GEL subcomplex (composed of RAB5IF/OPTI and TMCO1), the BOS subcomplex (composed of NCLN/Nicalin, NOMO and TMEM147) and the PAT subcomplex (composed of WDR83OS/Asterix and CCDC47).\" [PMID:36261522, PMID:36261528]","metadata":null},{"id":"c38f510931fc46bd896972f39a859bb1","type":"GO_TERM","name":"multi-pass transmembrane protein insertion into ER membrane","canonical_id":"go:GO:0160063","description":"\"A process of protein insertion of multi-pass membrane proteins into the endoplasmic reticulum (ER) membrane. Insertion of multi-pass membrane proteins is mediated by the multi-pass translocon complex and takes place following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex to promote insertion of subsequent transmembrane regions.\" [PMID:36261522, PMID:36261528]","metadata":null},{"id":"c1faea02468f42d084e4a53e3af7d576","type":"GO_TERM","name":"multi-species biofilm formation","canonical_id":"go:GO:0044399","description":"\"A process in which planktonically growing microorganisms of different species grow at a liquid-air interface or on a solid substrate under the flow of a liquid and produce extracellular polymers that facilitate matrix formation, resulting in a change in the organisms' growth rate and gene transcription.\" [GOC:cc, GOC:di, GOC:tb]","metadata":null},{"id":"e66f658c6f1245a8a2f94c3cbe7493ec","type":"GO_TERM","name":"multicellular organism adhesion","canonical_id":"go:GO:0022608","description":"\"The attachment of a multicellular organism to a substrate or other organism.\" [GOC:isa_complete]","metadata":null},{"id":"f459d409df55453181698b563cd29ce1","type":"GO_TERM","name":"multicellular organism adhesion to substrate","canonical_id":"go:GO:0022609","description":"\"The attachment of a multicellular organism to a surface or material.\" [GOC:isa_complete]","metadata":null},{"id":"22aae1de79964a2c8b1f4ffc06ac62dd","type":"GO_TERM","name":"multicellular organism development","canonical_id":"go:GO:0007275","description":"\"The biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).\" [GOC:dph, GOC:ems, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"1c5cfdbdd97044368942a50806d4bbbe","type":"GO_TERM","name":"multicellular organism growth","canonical_id":"go:GO:0035264","description":"\"The increase in size or mass of an entire multicellular organism, as opposed to cell growth.\" [GOC:bf, GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"b1cbee8948814cd98b5476b4f18ade33","type":"GO_TERM","name":"multicellular organismal locomotion","canonical_id":"go:GO:0071965","description":"\"Locomotion in a multicellular organism, i.e. self-propelled movement of a multicellular organism from one location to another.\" [GOC:mah]","metadata":null},{"id":"aae8fb4b82e8437c9fff8db63e02fddb","type":"GO_TERM","name":"multicellular organismal movement","canonical_id":"go:GO:0050879","description":"\"Any physiological process involved in changing the position of a multicellular organism or an anatomical part of a multicellular organism.\" [GOC:dph, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"1863c981053b4b5f84b47c4d8b1503ac","type":"GO_TERM","name":"multicellular organismal process","canonical_id":"go:GO:0032501","description":"\"Any biological process, occurring at the level of a multicellular organism, pertinent to its function.\" [GOC:curators, GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"26f3288d34574e47b126804fef515acf","type":"GO_TERM","name":"multicellular organismal reproductive process","canonical_id":"go:GO:0048609","description":"\"The process, occurring above the cellular level, that is pertinent to the reproductive function of a multicellular organism. This includes the integrated processes at the level of tissues and organs.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"b75ee0d1ce7849c4b90dbb5c9f93c5e8","type":"GO_TERM","name":"multicellular organismal response to stress","canonical_id":"go:GO:0033555","description":"\"Any process that results in a change in state or activity of a multicellular organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:mah]","metadata":null},{"id":"eb60e6a7504f480181501d053d523880","type":"GO_TERM","name":"multicellular organismal-level chemical homeostasis","canonical_id":"go:GO:0140962","description":"\"A homeostatic process involved in the maintenance of a steady state level of a chemical within extracellular body fluids, such as blood, xylem or phloem, of a multicellular organism. This is distinct from maintenance of cellular homeostasis, which occurs within a cell.\" [GOC:curators]","metadata":null},{"id":"39e02114aa004c29ba4247f4960f1706","type":"GO_TERM","name":"multicellular organismal-level extracellular fluid acidification","canonical_id":"go:GO:7770056","description":"\"Any process that reduces the pH of an extracellular fluid of a multicellular organism, corresponding to an increase in hydrogen ion concentration.\" [PMID:33326313, PMID:35666106]","metadata":null},{"id":"69952e164f2b4918959b2c7154ac44bf","type":"GO_TERM","name":"multicellular organismal-level homeostasis","canonical_id":"go:GO:0048871","description":"\"Any process involved in the maintenance of an internal steady state at the level of the multicellular organism.\" [GOC:isa_complete]","metadata":null},{"id":"5c7a422ba33944118c48b48cc775356b","type":"GO_TERM","name":"multicellular organismal-level iron ion homeostasis","canonical_id":"go:GO:0060586","description":"\"A chemical homeostatic process involved in the maintenance of a steady state level of iron within extracellular body fluids, such as blood, xylem or phloem, of a multicellular organism. This is distinct from maintenance of cellular homeostasis, which occurs within a cell.\" [PMID:31431773]","metadata":null},{"id":"beed58f2fa134c35bb2d4fd2951e7b37","type":"GO_TERM","name":"multicellular organismal-level water homeostasis","canonical_id":"go:GO:0050891","description":"\"A chemical homeostatic process involved in the maintenance of a steady state level of water within extracellular body fluids, such as blood, xylem or phloem, of a multicellular organism. This is distinct from maintenance of cellular homeostasis, which occurs within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2e394bbbb1194f37ac6af66e0ab46be3","type":"GO_TERM","name":"multidimensional cell growth","canonical_id":"go:GO:0009825","description":"\"The process in which a cell irreversibly increases in size in two or three [spatial] dimensions or along two or three axes.\" [ISBN:0943088399]","metadata":null},{"id":"af418209e1714e4681eb8f29211e5e62","type":"GO_TERM","name":"multimeric ribonuclease P complex","canonical_id":"go:GO:0030681","description":"\"A ribonuclease P complex that generally contains a single RNA molecule and several protein molecules. Examples of this complex are found in Archaeal species.\" [GOC:mah, PMID:11142368, PMID:12045094]","metadata":null},{"id":"665c5cd6c8974b1b9da37898739435e5","type":"GO_TERM","name":"multimerin complex","canonical_id":"go:GO:1990972","description":"\"Glycoprotein complex of the C1q/TNF superfamily involved in cell adhesion. A homotrimer that will combine to form supramolecular Multimerin structures.\" [PMID:18297547, PMID:22566882, PMID:9454761]","metadata":null},{"id":"1f0c610167be4b15b7d3523a36c85f94","type":"DISEASE","name":"multiminicore myopathy","canonical_id":"mondo:0018948","description":null,"metadata":null},{"id":"77bb9276a112464fa10f100b37e66dd9","type":"DISEASE","name":"multinodular goiter","canonical_id":"mondo:0000334","description":null,"metadata":null},{"id":"aaed0ae4bfba4a049ff72a99d4705e39","type":"GO_TERM","name":"multinuclear osteoclast differentiation","canonical_id":"go:GO:0072674","description":"\"The process in which a relatively unspecialized monocyte acquires the specialized features of a multinuclear osteoclast. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue.\" [CL:0000779, GOC:mah, PMID:12713016]","metadata":null},{"id":"dc0012bb2de54f1a85e7278c16aeee78","type":"DISEASE","name":"multiple benign circumferential skin creases on limbs 1","canonical_id":"mondo:0020738","description":null,"metadata":null},{"id":"6061361b880c486eaaeeedaf12880ddc","type":"DISEASE","name":"multiple endocrine neoplasia","canonical_id":"mondo:0017169","description":null,"metadata":null},{"id":"8eba421bc90a4bf7a1e4a28048bccedb","type":"DISEASE","name":"multiple endocrine neoplasia type 2","canonical_id":"mondo:0019003","description":null,"metadata":null},{"id":"81603942baa94b46994b3c465bd03fab","type":"DISEASE","name":"multiple endocrine neoplasia type 2A","canonical_id":"mondo:0008234","description":null,"metadata":null},{"id":"3e1105d0a9b844699a1e224c824eb699","type":"DISEASE","name":"multiple endocrine neoplasia type 2B","canonical_id":"mondo:0008082","description":null,"metadata":null},{"id":"1fe0283ee1684d8b8d0241e729a71133","type":"DISEASE","name":"multiple sclerosis symptom measurement","canonical_id":"efo:0803536","description":null,"metadata":null},{"id":"ab1977ca684643909eab2f48392e6dac","type":"GO_TERM","name":"multiple spine synapse organization","canonical_id":"go:GO:0150089","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synapse between a multiple synapse bouton and one or more dendritic spines.\" [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:11466428, PMID:18501438, PMID:22028887, PMID:29774619, PMID:7482800, PMID:8366344]","metadata":null},{"id":"154d5ecbad044932b1bf83f8c1b548c4","type":"GO_TERM","name":"multiple spine synapse organization, multiple dendrites","canonical_id":"go:GO:0150091","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synapse between a multiple synapse bouton and two or more dendritic spines protruding either from a single dendrite or from multiple dendrites.\" [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:22028887, PMID:24487234, PMID:7482800, PMID:8366344]","metadata":null},{"id":"e4d5e396a3c048d8a76a1582979a33fa","type":"GO_TERM","name":"multiple spine synapse organization, single dendrite","canonical_id":"go:GO:0150090","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synapse between a multiple synapse bouton and a single dendrite.\" [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:22028887, PMID:24487234]","metadata":null},{"id":"a5c457704a3f40efb8db2a882877d2d4","type":"GO_TERM","name":"multiple synapse bouton","canonical_id":"go:GO:0150086","description":"\"A single axon terminal bouton making contact onto two or more dendritic spines protruding either from a single dendrite or from multiple dendrites.\" [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:11466428, PMID:18501438, PMID:22028887, PMID:29774619, PMID:7482800, PMID:8366344]","metadata":null},{"id":"fafff337273345f181df0fbfd3fba4b3","type":"GO_TERM","name":"multiple synapse bouton, contacting multiple dendrites","canonical_id":"go:GO:0150088","description":"\"A single axon terminal bouton making contact onto two or more dendritic spines protruding from multiple dendrites.\" [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:22028887, PMID:24487234, PMID:7482800, PMID:8366344]","metadata":null},{"id":"cf2a6e8402aa4cd0810747a42b905afd","type":"GO_TERM","name":"multiple synapse bouton, contacting single dendrite","canonical_id":"go:GO:0150087","description":"\"A single axon terminal bouton making contact onto two or more dendritic spines protruding from the same dendrite.\" [GOC:aruk, GOC:bc, PMID:10586883, PMID:11248111, PMID:22028887, PMID:24487234]","metadata":null},{"id":"45b14257917f4ae2a4d5d1cfa8c058b0","type":"GO_TERM","name":"multiplexin collagen trimer","canonical_id":"go:GO:0140156","description":"\"Collagen that contains multiple triple-helix domains with interruptions.\" [PMID:21421911, PMID:27746220, PMID:31479735, PMID:33543021]","metadata":null},{"id":"5af572f3896941059cd5495a0e4f3620","type":"GO_TERM","name":"multivesicular body","canonical_id":"go:GO:0005771","description":"\"A type of endosome in which regions of the limiting endosomal membrane invaginate to form internal vesicles; membrane proteins that enter the internal vesicles are sequestered from the cytoplasm.\" [PMID:11566881, PMID:16533950]","metadata":null},{"id":"b34d12daa793476eb80e33e4517d4193","type":"GO_TERM","name":"multivesicular body HOPS complex","canonical_id":"go:GO:1902502","description":"\"Any HOPS complex that is part of a multivesicular body membrane.\" [GOC:TermGenie, PMID:23645161]","metadata":null},{"id":"726711d29e8c4a75a278722f40614275","type":"GO_TERM","name":"multivesicular body assembly","canonical_id":"go:GO:0036258","description":"\"The aggregation, arrangement and bonding together of a set of components to form a multivesicular body, a type of late endosome in which regions of the limiting endosomal membrane invaginate to form internal vesicles; membrane proteins that enter the internal vesicles are sequestered from the cytoplasm.\" [GOC:sart, PMID:11566881, PMID:19571114]","metadata":null},{"id":"a4c3db76183c4615aa73eaf206706f8f","type":"GO_TERM","name":"multivesicular body fusion to apical plasma membrane","canonical_id":"go:GO:0098866","description":"\"The fusion of the membrane of a multivesicular body with the apical plasma membrane, resulting in release of exosomes from the cell.\" [PMID:26459596]","metadata":null},{"id":"43c2fa943e374512a43bd462ed0633b6","type":"GO_TERM","name":"multivesicular body lumen","canonical_id":"go:GO:0097486","description":"\"The volume enclosed by the outermost membrane of a multivesicular body.\" [GOC:pde, PMID:21183070]","metadata":null},{"id":"35d470480391451e9b9f7a9223b124c9","type":"GO_TERM","name":"multivesicular body membrane","canonical_id":"go:GO:0032585","description":"\"The lipid bilayer surrounding a multivesicular body.\" [GOC:mah]","metadata":null},{"id":"dfd466dcf7b44072be69dfb5c98a291f","type":"GO_TERM","name":"multivesicular body membrane disassembly","canonical_id":"go:GO:0034496","description":"\"The controlled breakdown of the membranes of multivesicular bodies.\" [GOC:rb]","metadata":null},{"id":"7af59c2277284ba5a670baa1a4732cfd","type":"GO_TERM","name":"multivesicular body organization","canonical_id":"go:GO:0036257","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a multivesicular body. A multivesicular body is a type of late endosome in which regions of the limiting endosomal membrane invaginate to form internal vesicles; membrane proteins that enter the internal vesicles are sequestered from the cytoplasm.\" [GOC:sart, PMID:11566881]","metadata":null},{"id":"1c70e4015c2b415fb2022d876c091c90","type":"GO_TERM","name":"multivesicular body sorting pathway","canonical_id":"go:GO:0071985","description":"\"A vesicle-mediated transport process in which transmembrane proteins are ubiquitylated to facilitate their entry into luminal vesicles of multivesicular bodies (MVBs); upon subsequent fusion of MVBs with lysosomes or vacuoles, the cargo proteins are degraded.\" [GOC:mah, PMID:17603537]","metadata":null},{"id":"dceab3512432478a9b2e17d97c72597d","type":"GO_TERM","name":"multivesicular body, internal vesicle","canonical_id":"go:GO:0097487","description":"\"A membrane-bounded vesicle wholly contained within a multivesicular body.\" [GOC:pde, PMID:21183070]","metadata":null},{"id":"08e5ba51d91d4206b42de2d55b9c6b3c","type":"GO_TERM","name":"multivesicular body, internal vesicle lumen","canonical_id":"go:GO:0097489","description":"\"The volume enclosed by the membrane of the multivesicular body internal vesicle.\" [GOC:pde, PMID:21183070]","metadata":null},{"id":"4761479527d340fdba9b2794b74fdda7","type":"GO_TERM","name":"multivesicular body, internal vesicle membrane","canonical_id":"go:GO:0097488","description":"\"The lipid bilayer surrounding a multivesicular body internal vesicle.\" [GOC:pde, PMID:21183070]","metadata":null},{"id":"fc794cb9ec5e4ac39a64094883b53c43","type":"GO_TERM","name":"multivesicular body-lysosome fusion","canonical_id":"go:GO:0061763","description":"\"The organelle membrane fusion process in which the membrane of a multivesicular body fuses with a lysosome to create a hybrid organelle.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:21118109]","metadata":null},{"id":"2e4012ada8424f2fa348cd7eea49c955","type":"GO_TERM","name":"muramoyltetrapeptide carboxypeptidase activity","canonical_id":"go:GO:0106415","description":"\"GlcNAc-MurNAc-L-alanyl-gamma-D-glutamyl-meso-diaminopimelyl-D-alanine + H2O = GlcNAc-MurNAc-L-alanyl-gamma-D-glutamyl-meso-diaminopimelate + D-alanine.\" [PMID:10428950, PMID:15361936]","metadata":null},{"id":"8fbde64775d14c86a9637d7a9fc4b6fd","type":"GO_TERM","name":"muramyl dipeptide binding","canonical_id":"go:GO:0032500","description":"\"Interacting selectively and non-covalently, in a non-covalent manner, with muramyl dipeptide; muramyl dipeptide is derived from peptidoglycan.\" [GOC:rl]","metadata":null},{"id":"cee2b9239f1e4480ad2ceb9fc876101e","type":"GO_TERM","name":"muramyl dipeptide kinase activity","canonical_id":"go:GO:0160047","description":"\"Catalysis of the reaction: ATP + muramyl dipeptide = ADP + H+ + 6-O-phospho-muramyl dipeptide.\" [PMID:36002575]","metadata":null},{"id":"6af0a77855bd4751ba4bf5949cfa700e","type":"GO_TERM","name":"murein tripeptide carboxypeptidase activity","canonical_id":"go:GO:0061473","description":"\"Catalysis of the reaction: L-alanyl-gamma-D-glutamyl-meso-diaminoheptanedioate (murein tripeptide) + H2O = L-alanyl-D-glutamate + meso-2,6-diaminoheptanedioate.\" [PMID:22970852, RHEA:28398]","metadata":null},{"id":"5fddc1e54d98460b902acc37cb894d3b","type":"DRUG","name":"muromonab-CD3","canonical_id":"gtopdb:6889","description":null,"metadata":null},{"id":"b4ff2e8e29df4cbb8d595290e0eec26a","type":"DRUG","name":"muromonab-CD3","canonical_id":"chembl:CHEMBL1201608","description":null,"metadata":null},{"id":"9cf90990b79c49aeab931ac433f18e94","type":"GO_TERM","name":"muscle adaptation","canonical_id":"go:GO:0043500","description":"\"A process in which muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors. These adaptive events occur in both muscle fibers and associated structures (motoneurons and capillaries), and they involve alterations in regulatory mechanisms, contractile properties and metabolic capacities.\" [GOC:mtg_muscle, PMID:11181628, PMID:11449884, PMID:12605307]","metadata":null},{"id":"1c90d503595d43bc9322220d1c895821","type":"GO_TERM","name":"muscle alpha-actinin binding","canonical_id":"go:GO:0051371","description":"\"Binding to muscle isoforms of actinin. Muscle alpha-actinin isoforms are found in skeletal and cardiac muscle and are localized to the Z-disc.\" [PMID:10984498, PMID:11699871, PMID:15014165]","metadata":null},{"id":"46c38d772ffe416394750b4ed9c53c12","type":"GO_TERM","name":"muscle atrophy","canonical_id":"go:GO:0014889","description":"\"A process, occurring in the muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"b138b8fa53bd4c71989ff1bcb5f3326e","type":"GO_TERM","name":"muscle attachment","canonical_id":"go:GO:0016203","description":"\"The developmental process in which a skeletal muscle attaches to its target (such as bone or body wall).\" [GOC:isa_complete, GOC:sart]","metadata":null},{"id":"63d267e07fa74fc3ade3680029d2eaaf","type":"GO_TERM","name":"muscle cell apoptotic process","canonical_id":"go:GO:0010657","description":"\"A form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases, whose actions dismantle a muscle cell and result in its death. A muscle cell is a mature contractile cell, commonly known as a myocyte, that forms one of three kinds of muscle.\" [CL:0000187, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"155b237b7a3b409f986c0db517bc4936","type":"GO_TERM","name":"muscle cell cellular homeostasis","canonical_id":"go:GO:0046716","description":"\"The cellular homeostatic process that preserves a muscle cell in a stable functional or structural state.\" [GOC:mah, PMID:3091429, PMID:7781901]","metadata":null},{"id":"44931cc26f7a465dae350b0d5c775f64","type":"GO_TERM","name":"muscle cell chemotaxis toward tendon cell","canonical_id":"go:GO:0036061","description":"\"The directed movement of a muscle cell towards a tendon cell in response to an external stimulus. Tendon cells, for example, produce positive guidance cues that attract muscle cells.\" [GOC:sart, PMID:19793885]","metadata":null},{"id":"727175d0f9294614a1231a9013e09ec5","type":"GO_TERM","name":"muscle cell development","canonical_id":"go:GO:0055001","description":"\"The process whose specific outcome is the progression of a muscle cell over time, from its formation to the mature structure. Muscle cell development does not include the steps involved in committing an unspecified cell to the muscle cell fate.\" [CL:0000187, GOC:devbiol]","metadata":null},{"id":"2d8f04d0a18447978622016b2a825b8b","type":"GO_TERM","name":"muscle cell differentiation","canonical_id":"go:GO:0042692","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a muscle cell.\" [CL:0000187, GOC:curators]","metadata":null},{"id":"db765983d93f42268bb0948b3ffd8679","type":"GO_TERM","name":"muscle cell fate commitment","canonical_id":"go:GO:0042693","description":"\"The process in which the cellular identity of muscle cells is acquired and determined.\" [CL:0000187, GOC:curators]","metadata":null},{"id":"5644ec4be0d4496298ac9862078043da","type":"GO_TERM","name":"muscle cell fate determination","canonical_id":"go:GO:0007521","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a muscle cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [CL:0000187, GOC:curators]","metadata":null},{"id":"35a2475330b44ca99835b4684a738f44","type":"GO_TERM","name":"muscle cell fate specification","canonical_id":"go:GO:0042694","description":"\"The process in which a cell becomes capable of differentiating autonomously into a muscle cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [CL:0000187, GOC:curators]","metadata":null},{"id":"1eb719c2c3834e67a1869c344eba2422","type":"GO_TERM","name":"muscle cell migration","canonical_id":"go:GO:0014812","description":"\"The orderly movement of a muscle cell from one site to another, often during the development of a multicellular organism.\" [CL:0000187, GOC:mtg_muscle]","metadata":null},{"id":"e61c7b81fd2e4a9284c72be2ce020c55","type":"GO_TERM","name":"muscle cell postsynaptic specialization","canonical_id":"go:GO:0097482","description":"\"A postsynaptic specialization that is part of a neuromuscular junction.\" [GOC:pr]","metadata":null},{"id":"450248a8c4474ed480f5c546985a8f3a","type":"GO_TERM","name":"muscle cell projection","canonical_id":"go:GO:0036194","description":"\"A prolongation or process extending from a muscle cell. A muscle cell is a mature contractile cell, commonly known as a myocyte. This cell has as part of its cytoplasm myofibrils organized in various patterns.\" [CL:0000187, GOC:kmv, PMID:15930100, PMID:22464329]","metadata":null},{"id":"6499eb29fbaa4be7b4d3c48efddf328e","type":"GO_TERM","name":"muscle cell projection membrane","canonical_id":"go:GO:0036195","description":"\"The portion of the plasma membrane surrounding a muscle cell projection.\" [CL:0000187, GOC:kmv, PMID:15930100, PMID:22464329]","metadata":null},{"id":"93749f1e876e4f95a507d697601cd689","type":"GO_TERM","name":"muscle cell proliferation","canonical_id":"go:GO:0033002","description":"\"The expansion of a muscle cell population by cell division.\" [CL:0000187, GOC:mah]","metadata":null},{"id":"5fafaa67680a4abdb15b6e3dc87e3f20","type":"GO_TERM","name":"muscle contraction","canonical_id":"go:GO:0006936","description":"\"A process in which force is generated within muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis.\" [GOC:ef, GOC:mtg_muscle, ISBN:0198506732]","metadata":null},{"id":"2b0ee062e7924a7a8f8c67b5641d1982","type":"DISEASE","name":"muscle cramp","canonical_id":"efo:0009846","description":null,"metadata":null},{"id":"74fd7ce85e7641ed8768d28f424b3341","type":"GO_TERM","name":"muscle filament sliding","canonical_id":"go:GO:0030049","description":"\"The sliding of actin thin filaments and myosin thick filaments past each other in muscle contraction. This involves a process of interaction of myosin located on a thick filament with actin located on a thin filament. During this process ATP is split and forces are generated.\" [GOC:mah, GOC:mtg_muscle, ISBN:0815316194]","metadata":null},{"id":"568fd00f907c4919be5cfcd85b6e41a6","type":"GO_TERM","name":"muscle hyperplasia","canonical_id":"go:GO:0014900","description":"\"A muscle system process that results in an increase in cell number by cell division, often leading to an increase in the size of an organ.\" [GOC:mtg_muscle]","metadata":null},{"id":"cc1dc8c0187c46e0925b6c27a0ba68fe","type":"GO_TERM","name":"muscle hypertrophy","canonical_id":"go:GO:0014896","description":"\"The muscle system process that results in enlargement or overgrowth of all or part of a muscle organ due to an increase in the size of its muscle cells. Physiological hypertrophy is a normal process during development (it stops in cardiac muscle after adolescence) and can also be brought on in response to demand. In athletes cardiac and skeletal muscles undergo hypertrophy stimulated by increasing muscle activity on exercise. Smooth muscle cells in the uterus undergo hypertrophy during pregnancy.\" [GOC:mtg_muscle]","metadata":null},{"id":"7e0d3947018e4c39ac9ea987fe737500","type":"GO_TERM","name":"muscle hypertrophy in response to stress","canonical_id":"go:GO:0003299","description":"\"The enlargement or overgrowth of all or part of a muscle organ or tissue due to an increase in the size of its muscle cells as a result of a disturbance in organismal or cellular homeostasis.\" [GOC:mtg_heart]","metadata":null},{"id":"1802bd5d39604509b1111428f96aa981","type":"GO_TERM","name":"muscle myosin complex","canonical_id":"go:GO:0005859","description":"\"A filament of myosin found in a muscle cell of any type.\" [GOC:mah]","metadata":null},{"id":"4bb60546a1be46aa899627347faf0e46","type":"GO_TERM","name":"muscle organ development","canonical_id":"go:GO:0007517","description":"\"The process whose specific outcome is the progression of the muscle over time, from its formation to the mature structure. The muscle is an organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work.\" [GOC:jid, ISBN:0198506732]","metadata":null},{"id":"6e24eb4e09504b6493ac896245856074","type":"GO_TERM","name":"muscle organ morphogenesis","canonical_id":"go:GO:0048644","description":"\"The process in which the anatomical structures of muscle are generated and organized.\" [GOC:jid]","metadata":null},{"id":"4cb54f6ae76542a58cb43097a633911a","type":"GO_TERM","name":"muscle structure development","canonical_id":"go:GO:0061061","description":"\"The progression of a muscle structure over time, from its formation to its mature state. Muscle structures are contractile cells, tissues or organs that are found in multicellular organisms.\" [GOC:dph]","metadata":null},{"id":"6394a6a9b38345dc87b8db635a657149","type":"GO_TERM","name":"muscle system process","canonical_id":"go:GO:0003012","description":"\"An organ system process carried out at the level of a muscle. Muscle tissue is composed of contractile cells or fibers.\" [GOC:mtg_cardio]","metadata":null},{"id":"a76c9584173a4866af236baa5d4eef6e","type":"GO_TERM","name":"muscle tendon junction","canonical_id":"go:GO:0005927","description":"\"A cell-substrate junction found at the terminal anchorage site of skeletal muscle cells to tendons.\" [GOC:mtg_muscle, PMID:12842007]","metadata":null},{"id":"8e2d9f36fbb9489883df183b96ef76fe","type":"GO_TERM","name":"muscle thin filament assembly","canonical_id":"go:GO:0071689","description":"\"The aggregation, arrangement and bonding together of proteins to form the actin-based thin filaments of myofibrils in striated muscle.\" [GOC:mah]","metadata":null},{"id":"ac1e6029e96244f3a10a1f02ca643322","type":"GO_TERM","name":"muscle thin filament tropomyosin","canonical_id":"go:GO:0005862","description":"\"A form of the tropomyosin dimer found associated with actin and the troponin complex in muscle thin filaments.\" [ISBN:0815316194]","metadata":null},{"id":"64f032c14a2d4a87aae7a45ad72d9533","type":"GO_TERM","name":"muscle tissue development","canonical_id":"go:GO:0060537","description":"\"The progression of muscle tissue over time, from its initial formation to its mature state. Muscle tissue is a contractile tissue made up of actin and myosin fibers.\" [GOC:dph]","metadata":null},{"id":"72f9daa637284e609e1fc8023b6e9803","type":"GO_TERM","name":"muscle tissue morphogenesis","canonical_id":"go:GO:0060415","description":"\"The process in which the anatomical structures of muscle tissue are generated and organized. Muscle tissue consists of a set of cells that are part of an organ and carry out a contractive function.\" [GOC:dph]","metadata":null},{"id":"3bb7aabe0c304db298b5df4ebef9d680","type":"DISEASE","name":"muscular disease","canonical_id":"efo:0002970","description":null,"metadata":null},{"id":"00a1b30be922407b9615856968cbeea2","type":"GO_TERM","name":"muscular septum morphogenesis","canonical_id":"go:GO:0003150","description":"\"The process in which the muscular septum is generated and organized. The muscular septum is the lower part of the ventricular septum.\" [GOC:mtg_heart]","metadata":null},{"id":"6450c48465744950955d1feeb88ca4cf","type":"GO_TERM","name":"musculoskeletal movement","canonical_id":"go:GO:0050881","description":"\"The movement of an organism or part of an organism using mechanoreceptors, the nervous system, striated muscle and/or the skeletal system.\" [GOC:dph]","metadata":null},{"id":"485adb91583c45bc8315b418aaba72de","type":"GO_TERM","name":"musculoskeletal movement, spinal reflex action","canonical_id":"go:GO:0050883","description":"\"Involuntary movement caused by the application of a stimulus to an organism and a subsequent movement. The signal processing of this movement takes place in the spinal cord.\" [GOC:dph]","metadata":null},{"id":"9046374f974644908c7cb3f06f9eff62","type":"GO_TERM","name":"mushroom body development","canonical_id":"go:GO:0016319","description":"\"The process whose specific outcome is the progression of the mushroom body over time, from its formation to the mature structure. The mushroom body is composed of the prominent neuropil structures of the insect central brain, thought to be crucial for olfactory associated learning. These consist mainly of a bulbous calyx and tightly packaged arrays of thin parallel fibers of the Kenyon cells.\" [PMID:8790424]","metadata":null},{"id":"12c5a921988d4d1e966b65bc9054b2f7","type":"GO_TERM","name":"mutator focus","canonical_id":"go:GO:1990633","description":"\"A type of punctate focus localized to the perinuclear region of germline cytoplasm in C. elegans. Mutator foci are required for RNA interference (RNAi) and serve as sites of small inhibitory RNA (siRNA) amplification. As such, proteins that localize to mutator foci include RNA-directed RNA polymerases (RdRPs) and beta-nucleotidyltransferases. Mutator foci are distinct from, but adjacent to or partially overlap, P granules.\" [GOC:kmv, PMID:22713602, PMID:25635455]","metadata":null},{"id":"15067be027624b6fbd9676b9104e8cd1","type":"DISEASE","name":"myasthenia gravis","canonical_id":"mondo:0009688","description":null,"metadata":null},{"id":"ae7294258e47468a90ac9cdc8bdb371f","type":"GO_TERM","name":"mycinamicin VI 2''-O-methyltransferase activity","canonical_id":"go:GO:0102302","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + mycinamicin VI = S-adenosyl-L-homocysteine + mycinamicin III(1+) + H+.\" [EC:2.1.1.238, GOC:pz]","metadata":null},{"id":"49724c811b0348168fd9389fc3b83790","type":"GO_TERM","name":"mycocerosate synthase activity","canonical_id":"go:GO:0050111","description":"\"Catalysis of the reaction: acyl-CoA + 7n H+ + n methylmalonyl-CoA + 2n NADPH = n CO2 + n CoA + n H2O + multi-methyl-branched acyl-CoA + 2n NADP+.\" [EC:2.3.1.111, RHEA:10588]","metadata":null},{"id":"6708265a738b4eff92f29922ab3cdb6a","type":"GO_TERM","name":"mycodextranase activity","canonical_id":"go:GO:0033911","description":"\"Catalysis of the endohydrolysis of 1,4-alpha-D-glucosidic linkages in alpha-D-glucans containing both 1,3- and 1,4-bonds.\" [EC:3.2.1.61]","metadata":null},{"id":"0d39afe4bc204ec58b2c495c4a6c0f7e","type":"GO_TERM","name":"mycofactocin biosynthetic process","canonical_id":"go:GO:0140604","description":"\"The chemical reactions and pathways resulting in the formation of the coenzyme mycofactocin, a variably glycosylated small molecule electron pair carrier derived from the C-terminal valine-tyrosine dipeptide of the ribosomally translated precursor peptide MftA.\" [PMID:21223593, PMID:27312813, PMID:30183269, PMID:30778644, PMID:31381312, PMID:33014324]","metadata":null},{"id":"b83ccedcc79549eeaaad4280e20fe893","type":"GO_TERM","name":"mycolate cell wall layer assembly","canonical_id":"go:GO:0071769","description":"\"The aggregation, arrangement and bonding together of a set of components, including arabinogalactan mycolate and trehalose dimycolate, to form the mycolate layer of the Actinobacterium-type cell wall. The mycolate layer is physically attached to the peptidoglycan layer.\" [GOC:mah, MetaCyc:PWY-6397, PMID:15653820, PMID:3149973]","metadata":null},{"id":"81baf71694174ae0a2b43f9598c294a9","type":"GO_TERM","name":"mycolate outer membrane","canonical_id":"go:GO:0036407","description":"\"A mycolic acid-rich cell outer membrane containing a lipid bilayer and long-chain mycolic acids (hydroxylated branched-chain fatty acids) that are covalently linked to the cell wall peptidoglycan via an arabinogalactan network. Found in mycobacteria and related genera (e.g. corynebacteria).\" [GOC:bf, GOC:das, GOC:md, PMID:18316738, PMID:18567661]","metadata":null},{"id":"656524c1563a41ffb36993cd22d88431","type":"GO_TERM","name":"mycolic acid biosynthetic process","canonical_id":"go:GO:0071768","description":"\"The chemical reactions and pathways resulting in the formation of mycolic acids, beta-hydroxy fatty acids with a long alpha-alkyl side chain.\" [GOC:mah, MetaCyc:PWYG-321, PMID:15653820]","metadata":null},{"id":"4e4731989adc4c09a9b809754046e37c","type":"DRUG","name":"mycophenolate mofetil","canonical_id":"gtopdb:6831","description":null,"metadata":null},{"id":"2c4c849dc48c43b8bb80164a98297e7e","type":"DRUG","name":"mycophenolate mofetil","canonical_id":"chembl:CHEMBL1456","description":null,"metadata":null},{"id":"5610d7839f0f4692a7c34abd29d2b963","type":"COMBINATION_TREATMENT","name":"mycophenolate mofetil + rituximab","canonical_id":"ctgov_combo:ctgov-combo-836c4cca3c68266b","description":null,"metadata":null},{"id":"675bc6ab0425416bb08a53d315c25b02","type":"COMBINATION_TREATMENT","name":"mycophenolate mofetil + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-d14de87cf2aad2ad","description":null,"metadata":null},{"id":"493541a2d617473d9b77c9d07fd5d898","type":"COMBINATION_TREATMENT","name":"mycophenolate mofetil + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-081520933ea1dbbe","description":null,"metadata":null},{"id":"1fa437bb9813452f858fda9bc7be2c31","type":"COMBINATION_TREATMENT","name":"mycophenolate mofetil + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-d80413573d5f6547","description":null,"metadata":null},{"id":"1384a85370f748f9abae9dedbd316454","type":"COMBINATION_TREATMENT","name":"mycophenolate mofetil + tacrolimus","canonical_id":"ctgov_combo:ctgov-combo-3c21b0829ce27591","description":null,"metadata":null},{"id":"e2108ce79a1d4e11aab94b446b953b42","type":"DRUG","name":"mycophenolic acid","canonical_id":"gtopdb:6832","description":null,"metadata":null},{"id":"8b7ca0fc5b7342568e08cc8404f30917","type":"DRUG","name":"mycophenolic acid","canonical_id":"chembl:CHEMBL866","description":null,"metadata":null},{"id":"aeb607bbc4664e668dd1281f9bc9bfd8","type":"GO_TERM","name":"mycophenolic acid acyl-glucuronide esterase activity","canonical_id":"go:GO:0102390","description":"\"Catalysis of the reaction: mycophenolic acid O-acyl-glucuronide(1-) + H2O = mycophenolate + H+ + D-glucopyranuronate.\" [EC:3.1.1.93, GOC:pz]","metadata":null},{"id":"75c068bb312545f59f2bedd73bd6a7b4","type":"GO_TERM","name":"mycophenolic acid biosynthetic process","canonical_id":"go:GO:0140722","description":"\"The chemical reactions and pathways resulting in the formation of mycophenolic acid (MPA). MPA is the first isolated antibiotic natural product in the world obtained from a culture of Penicillium brevicompactum in 1893.\" [PMID:21398490, PMID:26751579, PMID:31209052]","metadata":null},{"id":"7753426db0cf444ba29a07d1fe4c5858","type":"DISEASE","name":"mycosis fungoides","canonical_id":"mondo:0009691","description":null,"metadata":null},{"id":"694560a7fe1e45e5b83fa1f0340853e1","type":"GO_TERM","name":"mycothiol biosynthetic process","canonical_id":"go:GO:0010125","description":"\"The chemical reactions and pathways resulting in the formation of mycothiol, which consists of N-acetyl-L-cysteine linked to a pseudodisaccharide, D-glucosamine and myo-inositol. Mycothiol is produced in actinomycetes like mycobacteria and serves similar functions to glutathione.\" [GOC:pz]","metadata":null},{"id":"5e180669db3b47eeb778064dcdfbb8da","type":"GO_TERM","name":"mycothiol metabolic process","canonical_id":"go:GO:0010126","description":"\"The chemical reactions and pathways involving mycothiol, which consists of N-acetyl-L-cysteine linked to a pseudodisaccharide, D-glucosamine and myo-inositol. Mycothiol is produced in actinomycetes like mycobacteria and serves similar functions to glutathione.\" [GOC:pz]","metadata":null},{"id":"9b625313888642cabc10594a61f48cce","type":"GO_TERM","name":"mycothiol synthase activity","canonical_id":"go:GO:0035447","description":"\"Catalysis of the reaction: 1D-myo-inositol-2-(L-cysteinylamido)-2-deoxy-alpha-D-glucopyranoside + acetyl-CoA = mycothiol + coA + H+. Mycothiol is also known as AcCys-GlcN-Ins and 1-D-myo-inosityl-2-L-cysteinylamido-2-deoxy-alpha-D-glucopyranoside as Cys-GlcN-Ins or desacetylmycothiol.\" [EC:2.3.1.189, PMID:12033919]","metadata":null},{"id":"e80b93a9455b4f6e844a46fe9ddc7076","type":"GO_TERM","name":"mycothiol-arsenate ligase activity","canonical_id":"go:GO:0102100","description":"\"Catalysis of the reaction: arsenate + mycothiol = mycothiol-arsenate conjugate + H2O.\" [EC:2.8.4.2, GOC:pz]","metadata":null},{"id":"5994b468e61a45ae8f0b25e202dce8d6","type":"GO_TERM","name":"mycothiol-dependent detoxification","canonical_id":"go:GO:0010127","description":"\"The chemical reactions using mycothiol to convert an alkylating agent to an S-conjugate of mycothiol. The latter is cleaved to release mercapturic acid which is excreted from the cell.\" [GOC:pz]","metadata":null},{"id":"a08421881e814c7da9791b8a7eaf8db8","type":"GO_TERM","name":"mycothione reductase [NAD(P)H] activity","canonical_id":"go:GO:0050627","description":"\"Catalysis of the reaction: NAD(P)+ + mycothiol = NAD(P)H + H+ + mycothione.\" [EC:1.8.1.15]","metadata":null},{"id":"cda992339e39402e815aea4d6bd7c347","type":"GO_TERM","name":"mycotoxin biosynthetic process","canonical_id":"go:GO:0043386","description":"\"The chemical reactions and pathways resulting in the formation of a mycotoxin, any poisonous substance produced by a fungus.\" [GOC:jl]","metadata":null},{"id":"798b7a04f6b349c0a6f34f41294660b0","type":"GO_TERM","name":"mycotoxin catabolic process","canonical_id":"go:GO:0043387","description":"\"The chemical reactions and pathways resulting in the breakdown of a mycotoxin, any poisonous substance produced by a fungus.\" [GOC:jl]","metadata":null},{"id":"223647330b24423a94d4c212ecfe2512","type":"GO_TERM","name":"mycotoxin metabolic process","canonical_id":"go:GO:0043385","description":"\"The chemical reactions and pathways involving a mycotoxin, any poisonous substance produced by a fungus.\" [GOC:jl]","metadata":null},{"id":"d9e9d13d708a4b0c8b579f2db553fcbd","type":"GO_TERM","name":"myelin assembly","canonical_id":"go:GO:0032288","description":"\"The process in which the wraps of cell membrane that constitute myelin are laid down around an axon in the central or peripheral nervous system.\" [GOC:dgh, GOC:dph, GOC:tb]","metadata":null},{"id":"16ed32bfc09a45dbbc4e62862f00a417","type":"GO_TERM","name":"myelin maintenance","canonical_id":"go:GO:0043217","description":"\"The process of preserving the structure and function of mature myelin. This includes maintaining the compact structure of myelin necessary for its electrical insulating characteristics as well as the structure of non-compact regions such as Schmidt-Lantermann clefts and paranodal loops. This does not include processes responsible for maintaining the nodes of Ranvier, which are not part of the myelin sheath.\" [GOC:dgh]","metadata":null},{"id":"486c8a889de744579e3e7a61ec79dcb1","type":"GO_TERM","name":"myelin sheath","canonical_id":"go:GO:0043209","description":"\"An electrically insulating fatty layer that surrounds the axons of many neurons. It is an outgrowth of glial cells: Schwann cells supply the myelin for peripheral neurons while oligodendrocytes supply it to those of the central nervous system.\" [GOC:cjm, GOC:jl, NIF_Subcellular:sao593830697, Wikipedia:Myelin]","metadata":null},{"id":"7d7be5fa6f554223b7afe792fafd8f5b","type":"GO_TERM","name":"myelin sheath abaxonal region","canonical_id":"go:GO:0035748","description":"\"The region of the myelin sheath furthest from the axon.\" [GOC:BHF, PMID:20237282]","metadata":null},{"id":"9fd302ea93c549aeaefef279d58f6b3f","type":"GO_TERM","name":"myelin sheath adaxonal region","canonical_id":"go:GO:0035749","description":"\"The region of the myelin sheath nearest to the axon.\" [GOC:BHF, PMID:20237282]","metadata":null},{"id":"3e7e637c9ccf4401849a803a3e2a5886","type":"GO_TERM","name":"myelin-proteolipid O-palmitoyltransferase activity","canonical_id":"go:GO:0047157","description":"\"Catalysis of the reaction: [myelin proteolipid] + palmityl-CoA = [myelin proteolipid] O-palmitoylprotein + CoA.\" [PMID:3818589]","metadata":null},{"id":"8695f9cec7cc45888b88c3e8aa06956a","type":"GO_TERM","name":"myelination","canonical_id":"go:GO:0042552","description":"\"The process in which myelin sheaths are formed and maintained around neurons. Oligodendrocytes in the brain and spinal cord and Schwann cells in the peripheral nervous system wrap axons with compact layers of their plasma membrane. Adjacent myelin segments are separated by a non-myelinated stretch of axon called a node of Ranvier.\" [GOC:dgh, GOC:mah]","metadata":null},{"id":"95d4b566f9334714a433f5bb4ce75cc8","type":"GO_TERM","name":"myelination in peripheral nervous system","canonical_id":"go:GO:0022011","description":"\"The process in which neuronal axons and dendrites become coated with a segmented lipid-rich sheath (myelin) to enable faster and more energetically efficient conduction of electrical impulses. The sheath is formed by the cell membranes of Schwann cells in the peripheral nervous system. Adjacent myelin segments are separated by a non-myelinated stretch of axon called a node of Ranvier.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7e2be0fba3d04885af7e809e81b066a8","type":"GO_TERM","name":"myelination of anterior lateral line nerve axons","canonical_id":"go:GO:0048914","description":"\"The formation of compact myelin sheaths around the axons of the anterior lateral line nerve.\" [PMID:12112375]","metadata":null},{"id":"ef36f9f8307343ac9f30186a3731218c","type":"GO_TERM","name":"myelination of lateral line nerve axons","canonical_id":"go:GO:0048897","description":"\"The formation of compact myelin sheaths around the axons of a lateral line nerve.\" [PMID:12112375]","metadata":null},{"id":"bd38e8d360b24991aae4815a67cd3ecc","type":"GO_TERM","name":"myelination of posterior lateral line nerve axons","canonical_id":"go:GO:0048932","description":"\"The formation of compact myelin sheaths around the axons of the posterior lateral line nerve.\" [PMID:12112375]","metadata":null},{"id":"51652d5f2a8f497abf6a41e30f1e4098","type":"DISEASE","name":"myelodysplastic syndrome","canonical_id":"mondo:0018881","description":null,"metadata":null},{"id":"a5177c2b296f41e8a2a085195f920642","type":"DISEASE","name":"myelodysplastic/myeloproliferative disease","canonical_id":"mondo:0020077","description":null,"metadata":null},{"id":"3a88ad5b34ea4f92b4933fb5c6e5f3ab","type":"DISEASE","name":"myelofibrosis","canonical_id":"mondo:0044903","description":null,"metadata":null},{"id":"a20cf420930a43109487ceaaaeea88a8","type":"DISEASE","name":"myelofibrosis with myeloid metaplasia","canonical_id":"mondo:0800305","description":null,"metadata":null},{"id":"c550564ecb0e4dc082c596fc4830d8a5","type":"GO_TERM","name":"myeloid cell activation involved in immune response","canonical_id":"go:GO:0002275","description":"\"A change in the morphology or behavior of a myeloid cell resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"2788806070b3475091e3b36766819752","type":"GO_TERM","name":"myeloid cell apoptotic process","canonical_id":"go:GO:0033028","description":"\"Any apoptotic process in a myeloid cell, a cell of the monocyte, granulocyte, mast cell, megakaryocyte, or erythroid lineage.\" [CL:0000763, GOC:add, GOC:mtg_apoptosis, PMID:11292031, PMID:15330259, PMID:17133093]","metadata":null},{"id":"48a7d304d6fe4e948a5c5939de34c3e8","type":"GO_TERM","name":"myeloid cell development","canonical_id":"go:GO:0061515","description":"\"The process whose specific outcome is the progression of a myeloid cell over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"a29179bdccca4680b39d11cb722f59f7","type":"GO_TERM","name":"myeloid cell differentiation","canonical_id":"go:GO:0030099","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of any cell of the myeloid leukocyte, megakaryocyte, thrombocyte, or erythrocyte lineages.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"61fbc6c022894529b66b9a9358a6c282","type":"GO_TERM","name":"myeloid cell homeostasis","canonical_id":"go:GO:0002262","description":"\"The process of regulating the proliferation and elimination of myeloid cells such that the total number of myeloid cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [CL:0000763, GOC:add]","metadata":null},{"id":"53c51deafc394ea286f50b621aa473cc","type":"GO_TERM","name":"myeloid dendritic cell activation","canonical_id":"go:GO:0001773","description":"\"The change in morphology and behavior of a dendritic cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"caa334c729994898beec221d636f15bc","type":"GO_TERM","name":"myeloid dendritic cell activation involved in immune response","canonical_id":"go:GO:0002277","description":"\"The change in morphology and behavior of a myeloid dendritic cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0cbf6a7404a94cd39e4b7fbdca1a889b","type":"GO_TERM","name":"myeloid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002469","description":"\"The process in which a myeloid dendritic cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"f8190f0d0d434087833b4dfac80b5878","type":"GO_TERM","name":"myeloid dendritic cell chemotaxis","canonical_id":"go:GO:0002408","description":"\"The movement of a myeloid dendritic cell in response to an external stimulus.\" [GOC:add, ISBN:0781735149, PMID:15814331, PMID:16056255]","metadata":null},{"id":"6ad0e473f7ec4736bc691bdc2e385c4d","type":"GO_TERM","name":"myeloid dendritic cell cytokine production","canonical_id":"go:GO:0002372","description":"\"Any process that contributes to cytokine production by a myeloid dendritic cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5379b6ed8fa745fa9971f6f364eca28a","type":"GO_TERM","name":"myeloid dendritic cell differentiation","canonical_id":"go:GO:0043011","description":"\"The process in which a monocyte acquires the specialized features of a dendritic cell, an immunocompetent cell of the lymphoid and hemopoietic systems and skin.\" [CL:0000782, GOC:jl]","metadata":null},{"id":"2c7b738e4e0c48a6916b29a55d402fec","type":"DISEASE","name":"myeloid leukemia","canonical_id":"mondo:0004643","description":null,"metadata":null},{"id":"68765f2169f54b89b1af23196be1be7c","type":"GO_TERM","name":"myeloid leukocyte activation","canonical_id":"go:GO:0002274","description":"\"A change in the morphology or behavior of a myeloid leukocyte resulting from exposure to an activating factor such as a cellular or soluble ligand.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"8baa560a207741aea670ef04808b2b45","type":"GO_TERM","name":"myeloid leukocyte cytokine production","canonical_id":"go:GO:0061082","description":"\"Any process that contributes to cytokine production by a myeloid cell.\" [GOC:dph]","metadata":null},{"id":"fda077022c514c949c77f28869a44649","type":"GO_TERM","name":"myeloid leukocyte differentiation","canonical_id":"go:GO:0002573","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of any cell of the myeloid leukocyte lineage.\" [GOC:add, PMID:16551251]","metadata":null},{"id":"c7048c88254c4973832c11e93ddede16","type":"GO_TERM","name":"myeloid leukocyte mediated immunity","canonical_id":"go:GO:0002444","description":"\"Any process involved in the carrying out of an immune response by a myeloid leukocyte.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"a5fd68bad8c7448e82014710bd2f4fef","type":"GO_TERM","name":"myeloid leukocyte migration","canonical_id":"go:GO:0097529","description":"\"The movement of a myeloid leukocyte within or between different tissues and organs of the body.\" [GOC:cvs, PMID:22342843, PMID:24157461]","metadata":null},{"id":"c4f74c8377fd491b87fdc59b7f786bd0","type":"GO_TERM","name":"myeloid progenitor cell differentiation","canonical_id":"go:GO:0002318","description":"\"The process in which a precursor cell type acquires the specialized features of a myeloid progenitor cell. Myeloid progenitor cells include progenitor cells for any of the myeloid lineages.\" [GOC:add, PMID:16551264]","metadata":null},{"id":"891b40c446ff43bbbf59e76f07342e44","type":"DISEASE","name":"myeloproliferative disorder","canonical_id":"efo:0004251","description":null,"metadata":null},{"id":"bdc09fb9fd7647e99d0558f4e8432eab","type":"GO_TERM","name":"myo-inositol hexakisphosphate biosynthetic process","canonical_id":"go:GO:0010264","description":"\"The chemical reactions and pathways resulting in the formation of phytic acid, myo-inositol hexakisphosphate, a regulator of intracellular signaling, a highly abundant animal anti-nutrient and a phosphate and mineral storage compound in plant seeds.\" [PMID:16107538]","metadata":null},{"id":"ef4c4c57a6d648e7a79637b2f288cde7","type":"GO_TERM","name":"myo-inositol hexakisphosphate transport","canonical_id":"go:GO:0033272","description":"\"The directed movement of myo-inositol hexakisphosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"a59e70170f7e4c7cb1b8b983059ab459","type":"GO_TERM","name":"myo-inositol import across plasma membrane","canonical_id":"go:GO:1904679","description":"\"The directed movement of myo-inositol from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:9560432]","metadata":null},{"id":"823232d96b0e4ec0843d342bb78ece15","type":"GO_TERM","name":"myo-inositol phosphate transport","canonical_id":"go:GO:0033271","description":"\"The directed movement of any phosphorylated myo-inositol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"93342d0ef0fd4ff39c23b75f5db7abfd","type":"GO_TERM","name":"myo-inositol transmembrane transporter activity","canonical_id":"go:GO:0005365","description":"\"Enables the transfer of myo-inositol from one side of a membrane to the other. Myo-inositol is 1,2,3,4,5/4,6-cyclohexanehexol, a growth factor for animals and microorganisms.\" [GOC:ai]","metadata":null},{"id":"20cfe0f2ef404ba1971330c0e1d9f619","type":"GO_TERM","name":"myo-inositol transport","canonical_id":"go:GO:0015798","description":"\"The directed movement of myo-inositol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Myo-inositol is 1,2,3,4,5/4,6-cyclohexanehexol, a growth factor for animals and microorganisms.\" [GOC:ai]","metadata":null},{"id":"a5f69e06a25348ff9429c144523ddab6","type":"GO_TERM","name":"myo-inositol:proton symporter activity","canonical_id":"go:GO:0005366","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: myo-inositol(out) + H+(out) = myo-inositol(in) + H+(in).\" [RHEA:60364]","metadata":null},{"id":"bd95f631d4ed405dbb2700c43d33174d","type":"GO_TERM","name":"myo-inositol:sodium symporter activity","canonical_id":"go:GO:0005367","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: myo-inositol(out) + Na+(out) = myo-inositol(in) + Na+(in).\" [RHEA:72987]","metadata":null},{"id":"0650efc123ea477090568342251fbfd5","type":"GO_TERM","name":"myo-inosose-2 dehydratase activity","canonical_id":"go:GO:0050114","description":"\"Catalysis of the reaction: 2,4,6/3,5-pentahydroxycyclohexanone = 3D-3,5/4-trihydroxycyclohexane-1,2-dione + H2O.\" [EC:4.2.1.44, RHEA:14065]","metadata":null},{"id":"fe4c67bb65a04bd6aeda2f266b4b0b18","type":"GO_TERM","name":"myoblast development","canonical_id":"go:GO:0048627","description":"\"The process whose specific outcome is the progression of the myoblast over time, from its formation to the mature structure. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:dph, GOC:mtg_muscle]","metadata":null},{"id":"a3956412cfe04925be8742bd75561145","type":"GO_TERM","name":"myoblast differentiation","canonical_id":"go:GO:0045445","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers.\" [CL:0000056, GOC:curators, GOC:mtg_muscle]","metadata":null},{"id":"3ff285ef5aa340789d71efb7eb4f53ce","type":"GO_TERM","name":"myoblast differentiation involved in skeletal muscle regeneration","canonical_id":"go:GO:0014835","description":"\"The process in which a relatively unspecialized satellite cell acquires specialized features of a myoblast. This occurs as part of skeletal muscle regeneration. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"dcaa8992325f4a339af28052fa7efdc7","type":"GO_TERM","name":"myoblast division","canonical_id":"go:GO:0014872","description":"\"The process resulting in the physical partitioning and separation of a myoblast into daughter cells. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"3cf13f685bca4b748eae404d07f5583b","type":"GO_TERM","name":"myoblast fate commitment","canonical_id":"go:GO:0048625","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:dph, GOC:mtg_muscle]","metadata":null},{"id":"626d86f6e45c4228be565ecfd958d2c9","type":"GO_TERM","name":"myoblast fate commitment in head","canonical_id":"go:GO:0014714","description":"\"The process, taking place in the head, whereby the developmental fate of a cell becomes restricted such that it will develop into a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:mtg_muscle]","metadata":null},{"id":"3565bfd620ee4b88852c4b39c1f4feec","type":"GO_TERM","name":"myoblast fate commitment in trunk","canonical_id":"go:GO:0014715","description":"\"The process taking place in the trunk whereby the developmental fate of a cell becomes restricted such that it will develop into a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:mtg_muscle]","metadata":null},{"id":"d2df16a110e84ec093fb2d1560f6abc1","type":"GO_TERM","name":"myoblast fate determination","canonical_id":"go:GO:0007518","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a myoblast regardless of its environment; upon determination, the cell fate cannot be reversed. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:curators]","metadata":null},{"id":"916f40b9eabc4fbfb75f512012c96153","type":"GO_TERM","name":"myoblast fate specification","canonical_id":"go:GO:0048626","description":"\"The process in which a cell becomes capable of differentiating autonomously into a myoblast in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:dph, GOC:mtg_muscle]","metadata":null},{"id":"e3280f9c86604ce78d709a948b839845","type":"GO_TERM","name":"myoblast fusion","canonical_id":"go:GO:0007520","description":"\"A process in which non-proliferating myoblasts fuse to existing fibers or to myotubes to form new fibers. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:mtg_muscle]","metadata":null},{"id":"64e638600c4b47b197fac49e775004b8","type":"GO_TERM","name":"myoblast fusion involved in skeletal muscle regeneration","canonical_id":"go:GO:0014905","description":"\"A process in which non-proliferating myoblasts, after migrating to the site of injury, fuse into existing damaged fibers or fuse to myotubes to form new fibers, as part of the process of skeletal muscle regeneration. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:mtg_muscle]","metadata":null},{"id":"b036497a616840cdb10abc91fa059eee","type":"GO_TERM","name":"myoblast maturation","canonical_id":"go:GO:0048628","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a myoblast to attain its fully functional state. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:dph, GOC:mtg_muscle]","metadata":null},{"id":"05c01bdccaae42faa9a49435eb2b2f50","type":"GO_TERM","name":"myoblast migration","canonical_id":"go:GO:0051451","description":"\"The orderly movement of a myoblast from one site to another, often during the development of a multicellular organism. A myoblast is a cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:ai, GOC:mtg_muscle]","metadata":null},{"id":"e60659c655354ee78a9a3ee8f6d3feae","type":"GO_TERM","name":"myoblast migration involved in skeletal muscle regeneration","canonical_id":"go:GO:0014839","description":"\"The process in which a myoblast migrates along an entire fiber to the site of injury. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"023a83e03d114a76a79d75c97bb9147b","type":"GO_TERM","name":"myoblast proliferation","canonical_id":"go:GO:0051450","description":"\"The multiplication or reproduction of myoblasts, resulting in the expansion of a myoblast cell population. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:ai, GOC:mtg_muscle]","metadata":null},{"id":"c2910aaf77d14d93af94331805cb3df3","type":"GO_TERM","name":"myoblast proliferation involved in skeletal muscle regeneration","canonical_id":"go:GO:0014844","description":"\"The multiplication or reproduction of myoblasts, resulting in the expansion of the cell population. This occurs as part of skeletal muscle regeneration. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"5c377e9d573545d69d8c8aedd792a897","type":"DISEASE","name":"myocardial infarction","canonical_id":"mondo:0005068","description":null,"metadata":null},{"id":"f8ae7ccca22c4bfe9d8115d165a00d27","type":"DISEASE","name":"myocardial ischemia","canonical_id":"mondo:0024644","description":null,"metadata":null},{"id":"b1a125c832934aeebc1e1bc879b2a075","type":"DISEASE","name":"myocarditis","canonical_id":"mondo:0004496","description":null,"metadata":null},{"id":"c7b5191fcb5645bb96ade1acc967fd13","type":"GO_TERM","name":"myofibril","canonical_id":"go:GO:0030016","description":"\"The contractile element of skeletal and cardiac muscle; a long, highly organized bundle of actin, myosin, and other proteins that contracts by a sliding filament mechanism.\" [ISBN:0815316194]","metadata":null},{"id":"644940e69a28407492aa1d3debdac2c3","type":"GO_TERM","name":"myofibril assembly","canonical_id":"go:GO:0030239","description":"\"Formation of myofibrils, the repeating units of striated muscle.\" [GOC:mah]","metadata":null},{"id":"b21f3f1481e44d6daf66a70b9d30eabf","type":"GO_TERM","name":"myofibroblast cell apoptotic process","canonical_id":"go:GO:1904516","description":"\"Any apoptotic process in a myofibroblast cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:23026405]","metadata":null},{"id":"1f3cd1d3abee4a5496bb6fb1d68f8f6a","type":"GO_TERM","name":"myofibroblast contraction","canonical_id":"go:GO:1990764","description":"\"The actin filament-based process in which cytoplasmic actin filaments slide past one another resulting in contraction of a myofibroblast.\" [PMID:19239477]","metadata":null},{"id":"11b78136a63e4d32ac5238b344a3e73c","type":"GO_TERM","name":"myofibroblast differentiation","canonical_id":"go:GO:0036446","description":"\"The process in which an undifferentiated cell acquires the features of a myofibroblast cell.\" [CL:0000186, GOC:nhn]","metadata":null},{"id":"1033aa137749416f804cb959cd3b54ac","type":"DISEASE","name":"myofibromatosis, infantile, 1","canonical_id":"mondo:0009227","description":null,"metadata":null},{"id":"92f869213dd045f8b2c6671c0c82ed0c","type":"GO_TERM","name":"myofilament","canonical_id":"go:GO:0036379","description":"\"Any of the smallest contractile units of a myofibril (striated muscle fiber).\" [Wikipedia:Myofilament]","metadata":null},{"id":"b95428215cdf4681ba4b5580cfde87fe","type":"GO_TERM","name":"myoinhibitory hormone activity","canonical_id":"go:GO:0016085","description":"\"The action characteristic of myostimulatory hormone, a peptide hormone that inhibits muscle contraction.\" [GOC:mah, PMID:8902848]","metadata":null},{"id":"770933858bf9451a9a263faa819a1241","type":"DISEASE","name":"myopathy","canonical_id":"mondo:0005336","description":null,"metadata":null},{"id":"1e6f6144bd604495a5d69e848d2fc73f","type":"DISEASE","name":"myopia","canonical_id":"mondo:0001384","description":null,"metadata":null},{"id":"3aab74818cc54210adf5dca5d1a72caa","type":"GO_TERM","name":"myosin I binding","canonical_id":"go:GO:0017024","description":"\"Binding to a class I myosin; myosin I heavy chains are single-headed, possess tails of various lengths, and do not self-associate into bipolar filaments.\" [GOC:bf, GOC:mah, PMID:18344022]","metadata":null},{"id":"146bbfd254bb4e58ac61bde7fa7cdd67","type":"GO_TERM","name":"myosin I complex","canonical_id":"go:GO:0045160","description":"\"A myosin complex containing a class I myosin heavy chain and associated light chains; myosin I heavy chains are single-headed, possess tails of various lengths, and do not self-associate into bipolar filaments; myosin I complexes are involved in diverse processes related to membrane traffic and cell movement.\" [GOC:mah, PMID:9438839]","metadata":null},{"id":"8c2ac3f5a0624f56920bba074c364c0e","type":"GO_TERM","name":"myosin I head/neck binding","canonical_id":"go:GO:0032031","description":"\"Binding to the head/neck region of a myosin I heavy chain.\" [GOC:mah]","metadata":null},{"id":"1e6ec36a93d746ffa16bdbe99fa424dc","type":"GO_TERM","name":"myosin I heavy chain binding","canonical_id":"go:GO:0032037","description":"\"Binding to a heavy chain of a myosin I complex.\" [GOC:mah]","metadata":null},{"id":"6d04a828a4e54064bfd094e55882d6d2","type":"GO_TERM","name":"myosin I light chain binding","canonical_id":"go:GO:0032030","description":"\"Binding to a light chain of a myosin I complex.\" [GOC:mah]","metadata":null},{"id":"feda799ae5584cafb6f0a6ce26f883b5","type":"GO_TERM","name":"myosin I tail binding","canonical_id":"go:GO:0032032","description":"\"Binding to the tail region of a myosin I heavy chain.\" [GOC:mah]","metadata":null},{"id":"45d01d564e27418cb72651ed2d500390","type":"GO_TERM","name":"myosin II binding","canonical_id":"go:GO:0045159","description":"\"Binding to a class II myosin, any member of the class of 'conventional' double-headed myosins that includes muscle myosin.\" [GOC:mah, PMID:27697842]","metadata":null},{"id":"e248cbbf62144d61b7a9c1efdbc19873","type":"GO_TERM","name":"myosin II complex","canonical_id":"go:GO:0016460","description":"\"A myosin complex containing two class II myosin heavy chains, two myosin essential light chains and two myosin regulatory light chains. Also known as classical myosin or conventional myosin, the myosin II class includes the major muscle myosin of vertebrate and invertebrate muscle, and is characterized by alpha-helical coiled coil tails that self assemble to form a variety of filament structures.\" [Wikipedia:Myosin]","metadata":null},{"id":"ddb4fb9e2c384ab592a5b60657eea002","type":"GO_TERM","name":"myosin II filament","canonical_id":"go:GO:0097513","description":"\"A bipolar filament composed of myosin II molecules.\" [GOC:cjm, GOC:mah]","metadata":null},{"id":"0a51d802407d455d9c4be57b4d5474cb","type":"GO_TERM","name":"myosin II filament assembly","canonical_id":"go:GO:0031036","description":"\"The formation of a bipolar filament composed of myosin II molecules.\" [GOC:mah]","metadata":null},{"id":"25ee707b16a34d7f93254dcd8c4bcc4b","type":"GO_TERM","name":"myosin II filament disassembly","canonical_id":"go:GO:0031037","description":"\"The disassembly of a bipolar filament composed of myosin II molecules.\" [GOC:mah]","metadata":null},{"id":"6ca8af0f16084ee8804a4eec73eed111","type":"GO_TERM","name":"myosin II filament organization","canonical_id":"go:GO:0031038","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a bipolar filament composed of myosin II molecules.\" [GOC:mah]","metadata":null},{"id":"d87e6d7fa3e94ec598c2c325a53fb4b8","type":"GO_TERM","name":"myosin II head/neck binding","canonical_id":"go:GO:0032034","description":"\"Binding to the head/neck region of a myosin II heavy chain.\" [GOC:mah]","metadata":null},{"id":"3a1512a4e21d484f902c0337678e8d38","type":"GO_TERM","name":"myosin II heavy chain binding","canonical_id":"go:GO:0032038","description":"\"Binding to a heavy chain of a myosin II complex.\" [GOC:mah]","metadata":null},{"id":"67c3e3f025014913bc870efbee90f0f0","type":"GO_TERM","name":"myosin II light chain binding","canonical_id":"go:GO:0032033","description":"\"Binding to a light chain of a myosin II complex.\" [GOC:mah]","metadata":null},{"id":"6e61a64d841e4152bd4cffdf298919ca","type":"GO_TERM","name":"myosin II tail binding","canonical_id":"go:GO:0032035","description":"\"Binding to the tail region of a myosin II heavy chain.\" [GOC:mah]","metadata":null},{"id":"9ca44cb77711420086ae1c2673df2208","type":"GO_TERM","name":"myosin III binding","canonical_id":"go:GO:0031473","description":"\"Binding to a class III myosin; myosin III is monomeric and has an N terminal kinase domain.\" [GOC:mah]","metadata":null},{"id":"ca4df44f9e75447c8b602d40d566e7f9","type":"GO_TERM","name":"myosin III complex","canonical_id":"go:GO:0042385","description":"\"A myosin complex containing a class III myosin heavy chain and associated light chains; myosin III is monomeric myosin that serves as a link between the cytoskeleton and the signaling complex involved in phototransduction, and differs from all other myosins in having an N-terminal kinase domain.\" [GOC:jl, PMID:33718386]","metadata":null},{"id":"9b16be8eb4454c33b62deeded47a90a2","type":"GO_TERM","name":"myosin IV complex","canonical_id":"go:GO:0031474","description":"\"A myosin complex containing one or more class IV myosin heavy chains and associated light chains; myosin IV is relatively uncharacterized, but is predicted to have a single motor domain, one IQ motif and a tail with a Myosin Tail Homology (myTH4) domain homologous to that in the tails of myosins VII and XV.\" [Wikipedia:Myosin]","metadata":null},{"id":"eff5a811b00b4c2d90e0c6dabff5089d","type":"GO_TERM","name":"myosin IX complex","canonical_id":"go:GO:0031479","description":"\"A myosin complex containing a class IX myosin heavy chain and associated light chains. Myosin IX is monomeric with a motor domain containing an N-terminal extension and an insert in the actin binding interface, followed by four to six IQ motifs and a tail region that contains a zinc binding motif and a domain with homology to GTPase activating proteins (GAPs) of the Rho family of G-proteins.\" [PMID:29679756]","metadata":null},{"id":"2e2755f6c06544e4bd724b1214c8eb4b","type":"GO_TERM","name":"myosin V binding","canonical_id":"go:GO:0031489","description":"\"Binding to a class V myosin; myosin V is a dimeric molecule involved in intracellular transport.\" [GOC:mah, PMID:11212351, PMID:33541831]","metadata":null},{"id":"83794554dd1b4bd4bec9c4bd964392d8","type":"GO_TERM","name":"myosin V complex","canonical_id":"go:GO:0031475","description":"\"A myosin complex containing a dimer of class V myosin heavy chains and associated light chains; involved in intracellular transport. Myosin V is a dimeric molecule consisting of conserved motor domains followed by 6 IQ motifs which bind specific light chains and calmodulin. The tail domain is important for cellular localization and cargo binding and can be divided into an alpha-helical coiled coil region and a C-terminal globular region.\" [Wikipedia:Myosin]","metadata":null},{"id":"46a6f3e58e7f42ea8db7df439a1d57e3","type":"GO_TERM","name":"myosin VI binding","canonical_id":"go:GO:0070853","description":"\"Binding to a class VI myosin. The myosin VI heavy chain has a single IQ motif in the neck and a tail region with a coiled coil domain followed by a unique globular domain, a unique insertion that enables myosin VI to move towards the pointed or minus end of actin filaments.\" [GOC:mah, PMID:15473855]","metadata":null},{"id":"b20fb66ea9904b438405a62667c865e7","type":"GO_TERM","name":"myosin VI complex","canonical_id":"go:GO:0031476","description":"\"A myosin complex containing one or more class VI myosin heavy chains and associated light chains. Myosin VI has a single IQ motif in the neck and a tail region with a coiled coil domain followed by a unique globular domain; a unique insertion that enables myosin VI to move towards the pointed or minus end of actin filaments.\" [PMID:15473855]","metadata":null},{"id":"7659719fe95a4b40a60fc5ab605c9c05","type":"GO_TERM","name":"myosin VI head/neck binding","canonical_id":"go:GO:0070855","description":"\"Binding to the head/neck region of a myosin VI heavy chain.\" [GOC:sart]","metadata":null},{"id":"7af003b8b841457396811eb4e24fa7f9","type":"GO_TERM","name":"myosin VI heavy chain binding","canonical_id":"go:GO:0070854","description":"\"Binding to a heavy chain of a myosin VI complex.\" [GOC:sart]","metadata":null},{"id":"ccb22dcb209e45af9c327c5a3d46131b","type":"GO_TERM","name":"myosin VI light chain binding","canonical_id":"go:GO:0070856","description":"\"Binding to a light chain of a myosin VI complex.\" [GOC:sart]","metadata":null},{"id":"41151c1a0c7f4a8a8ff75608dcbb0a35","type":"GO_TERM","name":"myosin VII complex","canonical_id":"go:GO:0031477","description":"\"A myosin complex containing a dimer of class VII myosin heavy chains and associated light chains. Myosin VII (240 kDa) is predicted to be a dimeric molecule with 5 IQ motifs and a tail region with a short stretch of coiled coil followed by two myosin-tail homology (MyTH4) domains, two talin-binding (FERM) domains and an SH3-domain.\" [PMID:28660889]","metadata":null},{"id":"d24371948e6745a7a7a5eabfa02640c9","type":"GO_TERM","name":"myosin VIII complex","canonical_id":"go:GO:0031478","description":"\"A myosin complex containing a dimer of class VIII myosin heavy chains and associated light chains. Myosin VIII is predicted to be dimeric, and contain an unusual 100-190 residue N-terminal extension prior to their motor domains, 3-4 IQ motifs, a short region (~70 residues) of predicted alpha-helical coiled coil and a C-terminal domain.\" [PMID:25247701]","metadata":null},{"id":"4a46c2d455534df6b54c4576da0d86b1","type":"GO_TERM","name":"myosin X complex","canonical_id":"go:GO:0031480","description":"\"A myosin complex containing one or more class X myosin heavy chains and associated light chains.\" [https://doi.org/10.9729/AM.2018.48.2.33, PMID:27580874]","metadata":null},{"id":"c78426976fec4e7ab17f5aa3f651e708","type":"GO_TERM","name":"myosin XI complex","canonical_id":"go:GO:0031481","description":"\"A myosin complex containing a dimer of class XI myosin heavy chains and associated light chains. Myosin XI heavy chain sizes are similar in molecular structure to the class V myosins with 5 to 6 IQ motifs and tail regions with predicted coiled coil domains (forming dimeric molecules) and large C-terminal regions.\" [PMID:22973289, PMID:29307817]","metadata":null},{"id":"157cff3f270841459b13a636d480bbd7","type":"GO_TERM","name":"myosin XI tail binding","canonical_id":"go:GO:0080115","description":"\"Binding to the tail region of a myosin XI heavy chain.\" [PMID:18703495]","metadata":null},{"id":"0eed3f47c9c34fc6b8eda3f7e3eafe60","type":"GO_TERM","name":"myosin XII complex","canonical_id":"go:GO:0031482","description":"\"A myosin complex containing one or more class XII myosin heavy chains and associated light chains; myosin XII contains a large tail region with two MyTH4 domains and a short region of coiled coil.\" [PMID:10722873]","metadata":null},{"id":"d98587fa315248a7bf9c558999d0a474","type":"GO_TERM","name":"myosin XIII complex","canonical_id":"go:GO:0031483","description":"\"A myosin complex containing one or more class XIII myosin heavy chains and associated light chains.\" [PMID:10722873]","metadata":null},{"id":"c385326ad0044232bb2ae5bc54443d55","type":"GO_TERM","name":"myosin XIV complex","canonical_id":"go:GO:0031484","description":"\"A myosin complex containing a class XIV myosin heavy chain and associated light chains; myosin XIV heavy chains are the simplest known, containing a motor domain, no classic IQ motif and variable length tails.\" [PMID:10722873]","metadata":null},{"id":"01ed024970c546f19233a117bf8473f1","type":"GO_TERM","name":"myosin XV complex","canonical_id":"go:GO:0031485","description":"\"A myosin complex containing a class XV myosin heavy chain and associated light chains. Myosin XV is single headed, and has a large extension (1200aa) at the N-terminus of the motor domain, two IQ motifs and a tail with a similar domain structure to that of the tail of myosin VII.\" [PMID:10722873]","metadata":null},{"id":"0e6dcc3564724e50b0d1125d29d262ea","type":"GO_TERM","name":"myosin XVI complex","canonical_id":"go:GO:0031486","description":"\"A myosin complex containing a class XVI myosin heavy chains and associated light chains; myosin XVI heavy chains contain ankyrin repeat.\" [PMID:11294886, PMID:32451869]","metadata":null},{"id":"70e4bf7a8173442094eafe8c9e9b731f","type":"GO_TERM","name":"myosin XVII complex","canonical_id":"go:GO:0031487","description":"\"A myosin complex containing one or more class XVII myosin heavy chains and associated light chains.\" [PMID:24443438]","metadata":null},{"id":"19f359952b5145a1a197392c72e4cebf","type":"GO_TERM","name":"myosin XVIII complex","canonical_id":"go:GO:0031488","description":"\"A myosin complex containing a class XVIII myosin heavy chain and associated light chains; myosin XVIII heavy chains contain an N-terminal PDZ domain.\" [PMID:11294886]","metadata":null},{"id":"8edc9c998d44494fa714a28883d553f8","type":"GO_TERM","name":"myosin binding","canonical_id":"go:GO:0017022","description":"\"Binding to a myosin; myosins are any of a superfamily of molecular motor proteins that bind to actin and use the energy of ATP hydrolysis to generate force and movement along actin filaments.\" [GOC:mah]","metadata":null},{"id":"728eba85f4fa4d94a4e29bb26052f6ed","type":"GO_TERM","name":"myosin complex","canonical_id":"go:GO:0016459","description":"\"A protein complex, formed of one or more myosin heavy chains plus associated light chains and other proteins, that functions as a molecular motor; uses the energy of ATP hydrolysis to move actin filaments or to move vesicles or other cargo on fixed actin filaments; has magnesium-ATPase activity and binds actin. Myosin classes are distinguished based on sequence features of the motor, or head, domain, but also have distinct tail regions that are believed to bind specific cargoes.\" [GOC:mah, Wikipedia:Myosin]","metadata":null},{"id":"8d0d1eaf08064d04ba924506fc18972d","type":"GO_TERM","name":"myosin filament","canonical_id":"go:GO:0032982","description":"\"A supramolecular fiber containing myosin heavy chains, plus associated light chains and other proteins, in which the myosin heavy chains are arranged into a filament.\" [GOC:mah]","metadata":null},{"id":"0660300f5d2442f5acc2d1c314aa4164","type":"GO_TERM","name":"myosin filament assembly","canonical_id":"go:GO:0031034","description":"\"The aggregation, arrangement and bonding together of a filament composed of myosin molecules.\" [GOC:mah]","metadata":null},{"id":"b906fbd72fc74cb59e2ecde9ad743394","type":"GO_TERM","name":"myosin filament disassembly","canonical_id":"go:GO:0031035","description":"\"The disassembly of a filament composed of myosin molecules.\" [GOC:mah]","metadata":null},{"id":"410b66c248e14bfe95bcef9cbaef1836","type":"GO_TERM","name":"myosin filament organization","canonical_id":"go:GO:0031033","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a filament composed of myosin molecules.\" [GOC:mah]","metadata":null},{"id":"0c891d5f0eae4baeb339217505faa667","type":"GO_TERM","name":"myosin head/neck binding","canonical_id":"go:GO:0032028","description":"\"Binding to the head/neck region of a myosin heavy chain.\" [GOC:mah]","metadata":null},{"id":"78bbf82f097643a89c28bd6063d6ce8d","type":"GO_TERM","name":"myosin heavy chain binding","canonical_id":"go:GO:0032036","description":"\"Binding to a heavy chain of a myosin complex.\" [GOC:mah]","metadata":null},{"id":"5a5a0b9b2bd44590ab92545fcee2be9d","type":"GO_TERM","name":"myosin heavy chain kinase activity","canonical_id":"go:GO:0016905","description":"\"Catalysis of the reaction: ATP + myosin-heavy-chain = ADP + myosin-heavy-chain phosphate.\" [EC:2.7.11.7]","metadata":null},{"id":"c53521f076614a15bca613f1228c9158","type":"GO_TERM","name":"myosin light chain binding","canonical_id":"go:GO:0032027","description":"\"Binding to a light chain of a myosin complex.\" [GOC:mah]","metadata":null},{"id":"3ca116ac37d3491d8fc373edfdd9d033","type":"GO_TERM","name":"myosin light chain kinase activity","canonical_id":"go:GO:0004687","description":"\"Catalysis of the reaction: ATP + myosin-light-chain = ADP + myosin-light-chain phosphate.\" [EC:2.7.11.18]","metadata":null},{"id":"62f12b0335e6473f995c4edf17eafcc2","type":"GO_TERM","name":"myosin phosphatase activity","canonical_id":"go:GO:0017018","description":"\"Catalysis of the reaction: phosphomyosin + H2O = myosin + phosphate.\" [EC:3.1.3.16]","metadata":null},{"id":"74e1765303e047369e6fb7c30fb00765","type":"GO_TERM","name":"myosin phosphatase complex","canonical_id":"go:GO:0017023","description":"\"An enzyme complex that catalyzes the removal of the phosphate group from phosphomyosin. Composed of a PP1 catalytic subunit (PP1c/PPP1CB) and a myosin phosphatase targeting subunit (MYPT1/PPP1R12A).\" [PMID:30076859]","metadata":null},{"id":"a3c09bddf62241a094d49aba9207d8d5","type":"GO_TERM","name":"myosin phosphatase regulator activity","canonical_id":"go:GO:0017020","description":"\"Binds to and modulates of the activity of myosin phosphatase.\" [GOC:ai, PMID:10491107]","metadata":null},{"id":"8d754d59d5f64ccdb0dd4a1d567a1e46","type":"GO_TERM","name":"myosin tail binding","canonical_id":"go:GO:0032029","description":"\"Binding to the tail region of a myosin heavy chain.\" [GOC:mah]","metadata":null},{"id":"a5b9c7b1b56a42798eb64fbc8d6ab322","type":"GO_TERM","name":"myosin-light-chain-phosphatase activity","canonical_id":"go:GO:0050115","description":"\"Catalysis of the reaction: myosin light-chain phosphate + H2O = myosin light chain + phosphate.\" [EC:3.1.3.53, MetaCyc:MYOSIN-LIGHT-CHAIN-PHOSPHATASE-RXN]","metadata":null},{"id":"64564df466404e3cb98929cedcfafc07","type":"GO_TERM","name":"myostimulatory hormone activity","canonical_id":"go:GO:0016084","description":"\"The action characteristic of myostimulatory hormone, a peptide hormone that stimulates muscle contraction.\" [GOC:mah, PMID:12204246]","metadata":null},{"id":"dc587357e7e14d4fbd8cb7df897d6ae2","type":"GO_TERM","name":"myosuppressin receptor activity","canonical_id":"go:GO:0035013","description":"\"Combining with the peptide myosuppressin to initiate a change in cell activity.\" [GOC:bf]","metadata":null},{"id":"2950359839c7432ba93660ea35eb9226","type":"GO_TERM","name":"myotome development","canonical_id":"go:GO:0061055","description":"\"The progression of the myotome over time, from its formation to the mature structure. The myotome is the portion of the somite that will give rise to muscle.\" [GOC:dph]","metadata":null},{"id":"4181c9aa9bc445b3a05b310b2febce80","type":"GO_TERM","name":"myotube cell development","canonical_id":"go:GO:0014904","description":"\"The process aimed at the progression of a myotube cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"c65081b79f444b3a8b5d30e45d61db36","type":"GO_TERM","name":"myotube cell development involved in skeletal muscle regeneration","canonical_id":"go:GO:0014906","description":"\"The process aimed at the progression of a myotube cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. This occurs as part of the process of skeletal muscle regeneration. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"814859b9e8854de0942ec539390d3a1d","type":"GO_TERM","name":"myotube cell migration","canonical_id":"go:GO:0110122","description":"\"The orderly movement of a myotube cell from one site to another, often during the development of a multicellular organism. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate, and fuse.\" [GOC:ha, PMID:29122742]","metadata":null},{"id":"8e0f5479c5d04da9870eebaeff3f13f8","type":"GO_TERM","name":"myotube differentiation","canonical_id":"go:GO:0014902","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotube differentiation starts with myoblast fusion and the appearance of specific cell markers (this is the cell development step). Then individual myotubes can fuse to form bigger myotubes and start to contract. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"64a872c200aa40fea48f1efa37b32975","type":"GO_TERM","name":"myotube differentiation involved in skeletal muscle regeneration","canonical_id":"go:GO:0014908","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotube differentiation starts with myoblast fusion and the appearance of specific cell markers (this is the cell development step). Then individual myotubes can fuse to form bigger myotubes and start to contract. This process occurs as part of the process of skeletal muscle regeneration. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"8a861c5fd48b4a939bd37611bf6a7208","type":"GO_TERM","name":"myrcene synthase activity","canonical_id":"go:GO:0050551","description":"\"Catalysis of the reaction: geranyl diphosphate = diphosphate + myrcene.\" [EC:4.2.3.15, RHEA:16965]","metadata":null},{"id":"7ed57e6a551348fda0589e0be356c283","type":"GO_TERM","name":"myricetin 3'-O-methyltransferase activity","canonical_id":"go:GO:0033799","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + myricetin = S-adenosyl-L-homocysteine + laricitrin.\" [RHEA:25629]","metadata":null},{"id":"752e5457146f49abbbf2b6a1215e7c3b","type":"GO_TERM","name":"myricetin 7-O-methyltransferase activity","canonical_id":"go:GO:0102435","description":"\"Catalysis of the reaction: myricetin + S-adenosyl-L-methionine = 7-O-methylmyricetin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74719]","metadata":null},{"id":"e723547fa33449bca07e54af2647a70f","type":"GO_TERM","name":"myristoyl-CoA ligase activity","canonical_id":"go:GO:0090432","description":"\"Catalysis of the reaction: ATP + myristic acid + CoA = AMP + diphosphate + myristoyl-CoA.\" [GOC:al, PMID:18071249]","metadata":null},{"id":"1e238ce988954fd4b4c85734fe87fb24","type":"GO_TERM","name":"myristoyltransferase activity","canonical_id":"go:GO:0019107","description":"\"Catalysis of the transfer of a myristoyl (CH3-[CH2]12-CO-) group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"12082a14c7b44bc7b566ab55a7b464fc","type":"GO_TERM","name":"mystery cell differentiation","canonical_id":"go:GO:0008583","description":"\"The process in which an undifferentiated cell acquires the features of a mystery cell. The mystery cells are a precluster of cells that emerge from the compound eye morphogenetic furrow, normally positioned between R3 and R4. They then disappear into the surrounding pool of undifferentiated cells and have no known fate in the mature ommatidium. An example of this process is found in Drosophila melanogaster.\" [ISBN:0632030488, PMID:1295747]","metadata":null},{"id":"235afd8dbde44434bd94093aaa525757","type":"DISEASE","name":"myxedema","canonical_id":"mondo:0009718","description":null,"metadata":null},{"id":"4456c9718d8f4b64bc1a8289ef7453cb","type":"GO_TERM","name":"myxococcal fruiting body development","canonical_id":"go:GO:0030583","description":"\"The process whose specific outcome is the progression of the myxococcal fruiting body over time, from its formation to the mature structure. The process begins when myxococci respond to a lack of nutrients in the environment and ends when the myxococcal fruiting body is a mature structure.\" [GOC:mtg_sensu, ISBN:0815316194, PMID:11121786]","metadata":null},{"id":"77db29418b3343f896b6c20dfcdbedd9","type":"GO_TERM","name":"myxospore formation","canonical_id":"go:GO:0034303","description":"\"The process in which differentiated, resting cells are formed, usually within a fruiting body by Myxobacteria. The myxospore is more resistant to high temperature, desiccation, and UV than vegetative myxobacteria.\" [GOC:ds, ISBN:0122268008]","metadata":null},{"id":"886c6dea804440a5992e70f929a25550","type":"GO_TERM","name":"n-octane oxidation","canonical_id":"go:GO:0019498","description":"\"The chemical reactions and pathways resulting in the conversion of n-octane to octanoyl-CoA.\" [MetaCyc:P221-PWY]","metadata":null},{"id":"79472296de50433a83e4eed991615f8e","type":"GO_TERM","name":"nBAF complex","canonical_id":"go:GO:0071565","description":"\"A SWI/SNF-type complex that is found in post-mitotic neurons, and in human contains actin and proteins encoded by the ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B genes. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth.\" [GOC:mah, GOC:ss, PMID:17640523]","metadata":null},{"id":"b78d815e38284a08a3560cf1cfcc6cd2","type":"DRUG","name":"nadifloxacin","canonical_id":"mesh:C062127","description":null,"metadata":null},{"id":"aa9dcef958ed4b4aaadda3362f09bcf5","type":"DRUG","name":"nadolol","canonical_id":"gtopdb:554","description":null,"metadata":null},{"id":"fba4b98b4aa2400b93becec770bb7e78","type":"DRUG","name":"nadolol","canonical_id":"chembl:CHEMBL521606","description":null,"metadata":null},{"id":"ecf5511f003f49009ea619e12e56c246","type":"COMBINATION_TREATMENT","name":"nadolol + propranolol","canonical_id":"ctgov_combo:ctgov-combo-b8936c1cdc29ca72","description":null,"metadata":null},{"id":"d19f0e5aac27467ea2ee95b2775b80eb","type":"DRUG","name":"nafamostat","canonical_id":"gtopdb:4262","description":null,"metadata":null},{"id":"dd6da4d7b9f94e09a1050f94dcb29000","type":"DRUG","name":"nafamostat","canonical_id":"mesh:C032855","description":null,"metadata":null},{"id":"e9e6984cfb804207886d220f53940da0","type":"DRUG","name":"nafarelin","canonical_id":"gtopdb:3902","description":null,"metadata":null},{"id":"65cb5a92f1ea408a905b2cee3c0e0284","type":"DRUG","name":"nafarelin","canonical_id":"mesh:D017274","description":null,"metadata":null},{"id":"3f21354349ef4e5caa4fcfb065899a8a","type":"DRUG","name":"nafcillin","canonical_id":"mesh:D009254","description":null,"metadata":null},{"id":"7912d55640b246a08998519fc1ca0db1","type":"DRUG","name":"naftopidil","canonical_id":"mesh:C064357","description":null,"metadata":null},{"id":"d7031b4f1daa439aa4cd25383a883e90","type":"GO_TERM","name":"nail development","canonical_id":"go:GO:0035878","description":"\"The process whose specific outcome is the progression of a nail over time, from its formation to the mature structure. A nail is a horn-like envelope covering the outer end of a finger or toe, and consists of the nail plate, the nail matrix and the nail bed below it, and the grooves surrounding it.\" [GOC:bf, ISBN:0323025781, UBERON:0001705, Wikipedia:Nail_(anatomy)]","metadata":null},{"id":"a6e7a8b74b5d49b5b537ef14195b5a2a","type":"DRUG","name":"nalbuphine","canonical_id":"gtopdb:1663","description":null,"metadata":null},{"id":"bc59352f449f41d782a6588297b7a357","type":"COMBINATION_TREATMENT","name":"nalbuphine + naloxone","canonical_id":"ctgov_combo:ctgov-combo-c4b102ca8cab1ce7","description":null,"metadata":null},{"id":"66be9af004254df081d8a64298bf75c1","type":"DRUG","name":"naldemedine","canonical_id":"gtopdb:9150","description":null,"metadata":null},{"id":"8059bf633cd04c6793c9a23e559d5a80","type":"DRUG","name":"naldemedine","canonical_id":"chembl:CHEMBL2105755","description":null,"metadata":null},{"id":"d24b9d44e34e48e097010b959c2c2272","type":"DRUG","name":"nalmefene","canonical_id":"gtopdb:1628","description":null,"metadata":null},{"id":"9d5a711a22034bf78bfa6b2cb71cf8fc","type":"DRUG","name":"nalorphine","canonical_id":"gtopdb:1629","description":null,"metadata":null},{"id":"9170c1efc8874513975c03d7e56c5cc2","type":"DRUG","name":"naloxone","canonical_id":"gtopdb:1638","description":null,"metadata":null},{"id":"84df0c3c5ce54392be595b51d134eb26","type":"DRUG","name":"naltrexone","canonical_id":"gtopdb:1639","description":null,"metadata":null},{"id":"890a5341e0a745d1ac62a0111113e0c7","type":"DRUG","name":"naltrexone","canonical_id":"chembl:CHEMBL19019","description":null,"metadata":null},{"id":"1b5a10931f5945d49472b1816f990fcc","type":"COMBINATION_TREATMENT","name":"naltrexone + propranolol","canonical_id":"ctgov_combo:ctgov-combo-f0a0fb0ec7bb975b","description":null,"metadata":null},{"id":"e0cc48c99cc74f11b57d02cecb5efd69","type":"DRUG","name":"nandrolone","canonical_id":"gtopdb:6949","description":null,"metadata":null},{"id":"093503fa9b744da89a7fae481a1c0beb","type":"GO_TERM","name":"naphthalene 1,2-dioxygenase activity","canonical_id":"go:GO:0018625","description":"\"Catalysis of the reaction: naphthalene + NADH + H+ + O2 = (1R,2S)-1,2-dihydronaphthalene-1,2-diol + NAD+.\" [EC:1.14.12.12]","metadata":null},{"id":"5e399596a2054d489972fbe255bb5b83","type":"GO_TERM","name":"naphthalene catabolic process","canonical_id":"go:GO:1901170","description":"\"The chemical reactions and pathways resulting in the breakdown of naphthalene.\" [GOC:TermGenie, GOC:yaf, PMID:11133965]","metadata":null},{"id":"1eb363d0996946cebba0ebb2b78945f1","type":"GO_TERM","name":"naphtho-gamma-pyrone biosynthetic process","canonical_id":"go:GO:1900787","description":"\"The chemical reactions and pathways resulting in the formation of naphtho-gamma-pyrone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8bba9fea5c8e40b79b78df06b5afff9c","type":"GO_TERM","name":"naphtho-gamma-pyrone catabolic process","canonical_id":"go:GO:1900786","description":"\"The chemical reactions and pathways resulting in the breakdown of naphtho-gamma-pyrone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c3ba5fe045b644cca8d5a2c2121c853d","type":"DRUG","name":"naproxen","canonical_id":"gtopdb:5230","description":null,"metadata":null},{"id":"23bca3d755e84990a99c15ad38cfda21","type":"DRUG","name":"naproxen","canonical_id":"mesh:D009288","description":null,"metadata":null},{"id":"6c808c61283b4262bb7cd8b6f70402be","type":"DRUG","name":"naproxen","canonical_id":"chembl:CHEMBL154","description":null,"metadata":null},{"id":"d0a7ff4a085347318403f9ce346594c0","type":"COMBINATION_TREATMENT","name":"naproxen + naratriptan","canonical_id":"ctgov_combo:ctgov-combo-e64b264da79cb5fa","description":null,"metadata":null},{"id":"9ccfb21419984c79ae7648fddbc1f48f","type":"COMBINATION_TREATMENT","name":"naproxen + naratriptan + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-2a9f805ccc871f10","description":null,"metadata":null},{"id":"8afdd1fe5dcb4657a7060f5e2589bcb9","type":"COMBINATION_TREATMENT","name":"naproxen + rofecoxib","canonical_id":"ctgov_combo:ctgov-combo-4992f5b14193eba4","description":null,"metadata":null},{"id":"7bd41a23cd4948b585c9aa3e3b3b9177","type":"COMBINATION_TREATMENT","name":"naproxen + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-763212191325eda4","description":null,"metadata":null},{"id":"4020bcfc496d4090a083378998aad128","type":"COMBINATION_TREATMENT","name":"naproxen + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-9dcf0e3efa319a48","description":null,"metadata":null},{"id":"64409fac37bc4891885ce8a670bbd901","type":"COMBINATION_TREATMENT","name":"naproxen + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-9a52f4da3dfa6cf1","description":null,"metadata":null},{"id":"731fac80d025452582cf70ea0c553471","type":"COMBINATION_TREATMENT","name":"naproxen + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-6e0d9b8750e109f6","description":null,"metadata":null},{"id":"4d7510a6a0a34e89a22af25f05ef2fcd","type":"COMBINATION_TREATMENT","name":"naproxen + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-6f152a3cdde44150","description":null,"metadata":null},{"id":"e2ecef6eac3a4416aa67eede42693807","type":"COMBINATION_TREATMENT","name":"naproxen + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-e7f8ec5c749e22f9","description":null,"metadata":null},{"id":"467516575cac464aa800d1e75a3cd9fe","type":"DRUG","name":"naratriptan","canonical_id":"gtopdb:45","description":null,"metadata":null},{"id":"d2af7bc5664c481fb35881630d806d41","type":"DISEASE","name":"narcolepsy","canonical_id":"mondo:0021107","description":null,"metadata":null},{"id":"8016f4da2c064aa2b9c344f618ac3091","type":"DISEASE","name":"narcolepsy-cataplexy syndrome","canonical_id":"mondo:0016158","description":null,"metadata":null},{"id":"a80a85bfd39d4bb6bcc3486686a34c40","type":"GO_TERM","name":"naringenin 2-hydroxylase activity","canonical_id":"go:GO:0102469","description":"\"Catalysis of the reaction:(2S)-naringenin + O2 + reduced [NADPH--hemoprotein reductase] = (2S)-2-hydroxynaringenin + H(+) + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:57588]","metadata":null},{"id":"8e99df0850614632bf1e0539d578bd3a","type":"GO_TERM","name":"naringenin 7-O-methyltransferase activity","canonical_id":"go:GO:0102766","description":"\"Catalysis of the reaction: (S)-naringenin(1-) + S-adenosyl-L-methionine = sakuranetin + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.232, GOC:pz]","metadata":null},{"id":"38b3ff5d7d6142b4bce6761185b8094d","type":"GO_TERM","name":"naringenin-chalcone synthase activity","canonical_id":"go:GO:0016210","description":"\"Catalysis of the reaction: 3 malonyl-CoA + 4-coumaroyl-CoA = 4 CoA + naringenin chalcone + 3 CO2.\" [EC:2.3.1.74]","metadata":null},{"id":"3bbb499a2cee44a5937ba6046f5de19f","type":"GO_TERM","name":"narrow pore channel activity","canonical_id":"go:GO:0022842","description":"\"Enables the transport of a solute across a membrane via a narrow pore channel that may be gated or ungated.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"fbf8815bd67a432d94467b7435b0ef17","type":"GO_TERM","name":"narrow pore, gated channel activity","canonical_id":"go:GO:0022831","description":"\"Enables the transport of a solute across a membrane via a narrow pore channel that opens in response to a particular stimulus.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"1b44e83dcfcc4e6faea6cbacdbabcc0d","type":"DRUG","name":"narsoplimab","canonical_id":"gtopdb:14317","description":null,"metadata":null},{"id":"7673d8fddb5146549e653972c5d33e5e","type":"DRUG","name":"narsoplimab","canonical_id":"chembl:CHEMBL4298195","description":null,"metadata":null},{"id":"1adf66b8b7ed4e3dacf0fa434063e868","type":"DISEASE","name":"nasal cavity polyp","canonical_id":"mondo:0006314","description":null,"metadata":null},{"id":"2f8cc3e1477f4dba89f254d40be7aa91","type":"GO_TERM","name":"nasal suture morphogenesis","canonical_id":"go:GO:0097097","description":"\"The process in which the nasal suture is generated and organized.\" [GOC:pr, GOC:sl, Wikipedia:Cranial_sutures, Wikipedia:Head_and_neck_anatomy#Musculoskeletal_system]","metadata":null},{"id":"79def7f2e72d4af2b28ad5d8a7bc5f2b","type":"GO_TERM","name":"nascent polypeptide-associated complex","canonical_id":"go:GO:0005854","description":"\"A heterodimeric protein complex that can reversibly bind to ribosomes, and is located in direct proximity to newly synthesized polypeptide chains as they emerge from the ribosome.\" [PMID:12475173, PMID:7568149]","metadata":null},{"id":"aa213d29d4084ca29923728826dd9a29","type":"GO_TERM","name":"nascent polypeptide-associated complex binding","canonical_id":"go:GO:1990593","description":"\"Binding to nascent polypeptide-associated complex, a heterodimeric protein complex that can reversibly bind to ribosomes and is located in direct proximity to newly synthesized polypeptide chains as they emerge from the ribosome.\" [PMID:25487825]","metadata":null},{"id":"46437695fadb4a568743a01be4a8d93f","type":"DISEASE","name":"nasopharyngeal carcinoma","canonical_id":"mondo:0015459","description":null,"metadata":null},{"id":"a68b2e3b97de488cbbb1d25243a24c5a","type":"DISEASE","name":"nasopharyngeal neoplasm","canonical_id":"mondo:0005375","description":null,"metadata":null},{"id":"3348f90586cf4d6195789e7c7d6cda91","type":"DRUG","name":"natalizumab","canonical_id":"gtopdb:6591","description":null,"metadata":null},{"id":"52d4051bf02844a1b3aa561485210760","type":"DRUG","name":"natalizumab","canonical_id":"chembl:CHEMBL1201607","description":null,"metadata":null},{"id":"97f8c4e001f94ffa9bfdc45ed165456a","type":"GO_TERM","name":"native siderophore export across plasma membrane","canonical_id":"go:GO:0180061","description":"\"The directed movement of siderophores, low molecular weight Fe(III)-chelating substances, from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:vw]","metadata":null},{"id":"c848a709db4d4fd984e71ed3a968a310","type":"GO_TERM","name":"natriuretic peptide receptor activity","canonical_id":"go:GO:0016941","description":"\"Combining with a natriuretic peptide and transmitting the signal to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"abdbee1a287540b387aa91bcf6e0b6a6","type":"GO_TERM","name":"natural killer cell activation","canonical_id":"go:GO:0030101","description":"\"The change in morphology and behavior of a natural killer cell in response to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"a82a395772a942f6b3917c644463eef0","type":"GO_TERM","name":"natural killer cell activation involved in immune response","canonical_id":"go:GO:0002323","description":"\"The change in morphology and behavior of a natural killer cell resulting from exposure a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, PMID:15032583]","metadata":null},{"id":"279ef976e8eb412288cd6ac60b8bc063","type":"GO_TERM","name":"natural killer cell apoptotic process","canonical_id":"go:GO:0070246","description":"\"Any apoptotic process in a natural killer cell, a lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation.\" [CL:0000623, GOC:add, GOC:mtg_apoptosis, PMID:15728472]","metadata":null},{"id":"680338322e3748c6a8dc5f4bfa8d779b","type":"GO_TERM","name":"natural killer cell chemotaxis","canonical_id":"go:GO:0035747","description":"\"The directed movement of a natural killer cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).\" [CL:0000623, GOC:BHF]","metadata":null},{"id":"73ac61871e3b4be19e7168dd7ca31360","type":"GO_TERM","name":"natural killer cell cytokine production","canonical_id":"go:GO:0002370","description":"\"Any process that contributes to cytokine production by a natural killer cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"9853abb61b5349c2a1c73063809554d8","type":"GO_TERM","name":"natural killer cell degranulation","canonical_id":"go:GO:0043320","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as perforin and granzymes by a natural killer cell.\" [ISBN:0781735149]","metadata":null},{"id":"2ebbc3b9ebe941c5840d22936f02120a","type":"GO_TERM","name":"natural killer cell differentiation","canonical_id":"go:GO:0001779","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a natural killer cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6053bbf2813342c1a23c0d393f8b2de8","type":"GO_TERM","name":"natural killer cell inhibitory signaling pathway","canonical_id":"go:GO:0002769","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of a natural killer cell capable of inhibiting an immune effector process contributing to an immune response.\" [GOC:add, ISBN:0781735149, PMID:15771571]","metadata":null},{"id":"7c68d5dee6a14fceab85f8f3d01abbfa","type":"GO_TERM","name":"natural killer cell lectin-like receptor binding","canonical_id":"go:GO:0046703","description":"\"Binding to a lectin-like natural killer cell receptor.\" [GOC:ai]","metadata":null},{"id":"88d1599e51fd4a1b8f26a1d1c4a35f74","type":"GO_TERM","name":"natural killer cell mediated cytotoxicity","canonical_id":"go:GO:0042267","description":"\"The directed killing of a target cell by a natural killer cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors.\" [GOC:add, GOC:pr]","metadata":null},{"id":"216d1b7b219e48a8b34872511d0df304","type":"GO_TERM","name":"natural killer cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002420","description":"\"The directed killing of a tumor cell by a natural killer cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"72449754d9a44cb7825cf6edc2bc2fed","type":"GO_TERM","name":"natural killer cell mediated immune response to tumor cell","canonical_id":"go:GO:0002423","description":"\"An immune response mediated by a natural killer cell triggered in response to the presence of a tumor cell.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"05eeb467207a4774b17e8f6010e0645c","type":"GO_TERM","name":"natural killer cell mediated immunity","canonical_id":"go:GO:0002228","description":"\"The promotion of an immune response by natural killer cells through direct recognition of target cells or through the release of cytokines.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"8474df252ae94064b0c6c862eef74013","type":"GO_TERM","name":"natural killer cell progenitor differentiation","canonical_id":"go:GO:0002321","description":"\"The process in which a precursor cell type acquires the specialized features of a natural killer cell progenitor.\" [GOC:add, PMID:16551251, PMID:16551264]","metadata":null},{"id":"101bf12900cd4ac485e5e0817bfe4f29","type":"GO_TERM","name":"natural killer cell proliferation","canonical_id":"go:GO:0001787","description":"\"The expansion of a natural killer cell population by cell division.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"76e354d291de49f1816a43c73cd9a3f4","type":"GO_TERM","name":"natural killer cell tolerance induction","canonical_id":"go:GO:0002519","description":"\"Tolerance induction of natural killer cells.\" [GOC:jal, PMID:16546094]","metadata":null},{"id":"9a48be8c51d348069028c2903a37292a","type":"DRUG","name":"navepegritide","canonical_id":"gtopdb:14293","description":null,"metadata":null},{"id":"ab8155e8c69a4679afa6042dbf04d09a","type":"DRUG","name":"naxitamab","canonical_id":"gtopdb:11341","description":null,"metadata":null},{"id":"8c50825caa674fe9b6f1ff4679379fb5","type":"DRUG","name":"necitumumab","canonical_id":"gtopdb:8090","description":null,"metadata":null},{"id":"dcd68d8b77c2499b9f60d1928cb35b49","type":"DRUG","name":"necitumumab","canonical_id":"chembl:CHEMBL1743047","description":null,"metadata":null},{"id":"0a74b32d9e0b418bb6e6fbfd95eef266","type":"GO_TERM","name":"neck portion of tanycyte","canonical_id":"go:GO:1990016","description":"\"Elongated portion of a tanycyte that sticks into the periventricular layer of neuropil where it appears to contact a blood vessel; characterized by numerous cytoplasmic extensions. A tanycyte is a specialized elongated ventricular ependymal cell that has processes that extend to the outer, or pial, surface of the CNS.\" [ISBN:0195065719, NIF_Subcellular:sao901230115]","metadata":null},{"id":"9eaa2e2954c44612ae31a487adc2e39a","type":"GO_TERM","name":"necroptotic process","canonical_id":"go:GO:0070266","description":"\"A programmed necrotic cell death process which begins when a cell receives a signal (e.g. a ligand binding to a death receptor or to a Toll-like receptor), and proceeds through a series of biochemical events (signaling pathways), characterized by activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 (RIPK1/3, also called RIP1/3) and by critical dependence on mixed lineage kinase domain-like (MLKL), and which typically lead to common morphological features of necrotic cell death. The process ends when the cell has died. The process is divided into a signaling phase, and an execution phase, which is triggered by the former.\" [GOC:BHF, GOC:dph, GOC:mah, GOC:mtg_apoptosis, GOC:tb, PMID:18846107, PMID:20823910, PMID:21737330, PMID:21760595, PMID:21876153]","metadata":null},{"id":"a5152c41235041fab63b7f49eec77d93","type":"GO_TERM","name":"necroptotic signaling pathway","canonical_id":"go:GO:0097527","description":"\"The series of molecular signals which triggers the necroptotic death of a cell. The pathway starts with reception of a signal, is characterized by activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 (RIPK1/3, also called RIP1/3), and ends when the execution phase of necroptosis is triggered.\" [GOC:mtg_apoptosis, PMID:20823910]","metadata":null},{"id":"7ef82fd7746e419380b303cc5f397ef7","type":"DISEASE","name":"necrosis","canonical_id":"efo:0009426","description":null,"metadata":null},{"id":"4d18d130507a407194c34c22bcf8b6ba","type":"GO_TERM","name":"nectar secretion","canonical_id":"go:GO:0071836","description":"\"The controlled release of a nectar by a cell or a tissue. Nectar is a fluid secreted by many angiosperms to promote pollination by providing a reward to pollinators. Nectar may also deter certain organisms from visiting or play other biological roles. Nectar is a complex solution that may include the following types of compounds: sugars, amino acids, organic acids, alkaloids, flavonoids, glycosides, vitamins, phenolics, metal ions, oils, free fatty acids, and proteins.\" [GOC:kad, PMID:19861655]","metadata":null},{"id":"befba15f0b5a4ff7ad00784813a466d1","type":"GO_TERM","name":"nectary development","canonical_id":"go:GO:0010254","description":"\"The process whose specific outcome is the progression of the floral nectaries over time, from its formation to the mature structure.\" [GOC:lr]","metadata":null},{"id":"a6582f1f407f43d381069b143d24a7a6","type":"DRUG","name":"nefazodone","canonical_id":"gtopdb:7247","description":null,"metadata":null},{"id":"acdb519e523a4b888dfed4e00291732b","type":"DRUG","name":"nefazodone","canonical_id":"mesh:C051752","description":null,"metadata":null},{"id":"20c2484f997d4f5fbc01b0576475cf6d","type":"GO_TERM","name":"negative T cell selection","canonical_id":"go:GO:0043383","description":"\"The process of elimination of immature T cells which react strongly with self-antigens.\" [ISBN:0781735149, PMID:12414722]","metadata":null},{"id":"bc851595019a4d4f9e618622483b39e5","type":"GO_TERM","name":"negative adaptation of signaling pathway","canonical_id":"go:GO:0022401","description":"\"The negative regulation of a signal transduction pathway in response to a stimulus upon prolonged exposure to that stimulus.\" [GOC:isa_complete]","metadata":null},{"id":"fe2ad62f6bff45bd945e913af1a5e929","type":"GO_TERM","name":"negative aerotaxis","canonical_id":"go:GO:0052130","description":"\"The directed movement of a motile cell or organism towards a lower concentration of environmental oxygen.\" [GOC:dph, GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"41900a27628d47cc8991dfebf6459c9d","type":"GO_TERM","name":"negative chemotaxis","canonical_id":"go:GO:0050919","description":"\"The directed movement of a motile cell or organism towards a lower concentration of a chemical.\" [GOC:ai, GOC:bf, GOC:isa_complete]","metadata":null},{"id":"6b353f7a53674d0da8d28ca1a1635e4d","type":"GO_TERM","name":"negative cofactor 2 complex","canonical_id":"go:GO:0017054","description":"\"A heterodimeric protein complex that can stably associate with TATA-binding protein on promoters, thereby preventing the assembly of transcription factors TFIIA and TFIIB and leading to repression of RNA polymerase II transcription. The two subunits, NC2alpha (Drap1) and NC2beta (Dr1), dimerize through histone fold domains of the H2A/H2B type present in the amino termini.\" [PMID:15574413]","metadata":null},{"id":"50e5afabf0f14d2f9d0ad7dcf3eb5ad5","type":"GO_TERM","name":"negative energy taxis","canonical_id":"go:GO:0052129","description":"\"The directed movement of a motile cell or organism towards a lower level of a physical stimulus involved in energy generation, such as light, oxygen, and oxidizable substrates.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"66918a3683b345db8c50c11d6ff06551","type":"GO_TERM","name":"negative extrathymic T cell selection","canonical_id":"go:GO:0045068","description":"\"The process of elimination of extrathymically maturing T cells which react strongly with self-antigens.\" [ISBN:0781735149, PMID:7880383]","metadata":null},{"id":"e8d73d97823a4f248d47d11c9d941062","type":"GO_TERM","name":"negative gravitaxis","canonical_id":"go:GO:0048060","description":"\"The directed movement of a motile cell or organism away from the source of gravity.\" [GOC:jid]","metadata":null},{"id":"8c2ab2f974ac4f868d5d6b2058997f1d","type":"GO_TERM","name":"negative gravitropism","canonical_id":"go:GO:0009959","description":"\"The orientation of plant parts away from gravity.\" [GOC:sm]","metadata":null},{"id":"4b4e9e813bc2488f82ef728f1149fdd7","type":"GO_TERM","name":"negative phototaxis","canonical_id":"go:GO:0046957","description":"\"The directed movement of a cell or organism away from a source of light.\" [GOC:ai]","metadata":null},{"id":"4d14ca67592e499296b543acd2f5e5a2","type":"GO_TERM","name":"negative regluation of nuclear-transribed mRNA catabolic process, no-go decay","canonical_id":"go:GO:0170075","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, no-go decay.\" [PMID:41607283]","metadata":null},{"id":"28d681d9ba7346a6bb549f633cc81dcc","type":"GO_TERM","name":"negative regulation by host of viral glycoprotein metabolic process","canonical_id":"go:GO:0044871","description":"\"A process in which a host organism stops, prevents or reduces the frequency, rate or extent of viral glycoprotein metabolic process.\" [GOC:jl]","metadata":null},{"id":"2b18a38b97a04ee2b08a083e1b9d9a08","type":"GO_TERM","name":"negative regulation by virus of viral protein levels in host cell","canonical_id":"go:GO:0046725","description":"\"Any process where the infecting virus reduces the levels of viral proteins in a cell.\" [GOC:ai]","metadata":null},{"id":"416a0509557e4496ac10efbf42966b30","type":"GO_TERM","name":"negative regulation melanotic encapsulation of foreign target","canonical_id":"go:GO:0140540","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of melanotic encapsulation of foreign target.\" [PMID:15749104, PMID:18457993]","metadata":null},{"id":"1d75f88d5cae42719d7ea2499fd52115","type":"GO_TERM","name":"negative regulation of 'de novo' NAD biosynthetic process from L-tryptophan","canonical_id":"go:GO:1905013","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of 'de novo' NAD biosynthetic process from L-tryptophan.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:12140278, PMID:19843166]","metadata":null},{"id":"89e42efab2fa45fabb778793240482ff","type":"GO_TERM","name":"negative regulation of (+)-kotanin biosynthetic process","canonical_id":"go:GO:1900693","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of (+)-kotanin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"64c02c40796b4fce885b8c2491304e10","type":"GO_TERM","name":"negative regulation of (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0060636","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"61f9686599a9490aa9c29acb6790be4b","type":"GO_TERM","name":"negative regulation of (R)-carnitine transmembrane transport","canonical_id":"go:GO:1902273","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of (R)-carnitine transmembrane transport.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"a072878ac0664bcb9af8980eb18a5e4b","type":"GO_TERM","name":"negative regulation of (R)-mevalonic acid biosynthetic process","canonical_id":"go:GO:0106108","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of (R)-mevalonic acid biosynthetic process.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:24296663]","metadata":null},{"id":"f9d8d8d3c048446a9251989e15f6b5c2","type":"GO_TERM","name":"negative regulation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process","canonical_id":"go:GO:1902647","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"51bcea102889414fab2be248259c8c9d","type":"GO_TERM","name":"negative regulation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process","canonical_id":"go:GO:1902642","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"73251b6908c54fddb3d8867f87796e25","type":"GO_TERM","name":"negative regulation of 3'-UTR-mediated mRNA stabilization","canonical_id":"go:GO:1905869","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of 3'-UTR-mediated mRNA stabilization.\" [GO_REF:0000058, GOC:TermGenie, PMID:19737525]","metadata":null},{"id":"4ff5ab0d4242408ca84e00bec702af2d","type":"GO_TERM","name":"negative regulation of AIM2 inflammasome complex assembly","canonical_id":"go:GO:0140972","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of AIM2 inflammasome complex assembly.\" [PMID:33467177]","metadata":null},{"id":"ee8d30e8853745db860e9a70cedffaf3","type":"GO_TERM","name":"negative regulation of AMPA glutamate receptor clustering","canonical_id":"go:GO:1904718","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of AMPA glutamate receptor clustering.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:21558424]","metadata":null},{"id":"c0b48eb712e049268c265c82db9ae7ec","type":"GO_TERM","name":"negative regulation of ARF protein signal transduction","canonical_id":"go:GO:0032013","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ARF protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"c9d02392249c4e3f815636fb26b4efa6","type":"GO_TERM","name":"negative regulation of ATF6-mediated unfolded protein response","canonical_id":"go:GO:1903892","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the ATF6-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"0fbd97e12be9465bb077d152f24762ba","type":"GO_TERM","name":"negative regulation of ATP biosynthetic process","canonical_id":"go:GO:2001170","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ATP biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"f77c186a16d74d4fb817ab9695b53bb1","type":"GO_TERM","name":"negative regulation of ATP metabolic process","canonical_id":"go:GO:1903579","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ATP metabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:20695849]","metadata":null},{"id":"f954f1b6268543c9ababfedee1a4a1ee","type":"GO_TERM","name":"negative regulation of ATP-dependent activity","canonical_id":"go:GO:0032780","description":"\"Any process that stops or reduces the rate of an ATP-dependent activity.\" [GOC:mah]","metadata":null},{"id":"f6d9463b0581492980a7ee82a02c0b9b","type":"GO_TERM","name":"negative regulation of ATPase-coupled calcium transmembrane transporter activity","canonical_id":"go:GO:1901895","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an ATPase-coupled calcium transmembrane transporter activity.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671]","metadata":null},{"id":"13e53cebb01a4c1eaf388ca2108fd4ff","type":"GO_TERM","name":"negative regulation of AV node cell action potential","canonical_id":"go:GO:1903950","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of AV node cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:25281747]","metadata":null},{"id":"5122c1471393469d97289510e378a18d","type":"GO_TERM","name":"negative regulation of Arp2/3 complex-mediated actin nucleation","canonical_id":"go:GO:0034316","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of actin nucleation mediated by the Arp2/3 complex and interacting proteins.\" [GOC:mah, PMID:16959963]","metadata":null},{"id":"ee7c542940944eeb8259cc525650f40c","type":"GO_TERM","name":"negative regulation of Atg1/ULK1 kinase complex assembly","canonical_id":"go:GO:1905865","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Atg1/ULK1 kinase complex assembly.\" [GO_REF:0000058, GOC:autophagy, GOC:mf, GOC:TermGenie, PMID:26567215]","metadata":null},{"id":"30ea07dcce8245b1ad692e799849b69c","type":"GO_TERM","name":"negative regulation of B cell activation","canonical_id":"go:GO:0050869","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of B cell activation.\" [GOC:ai]","metadata":null},{"id":"4d78b5b6e6f34bccb236ada1b5e5254e","type":"GO_TERM","name":"negative regulation of B cell anergy","canonical_id":"go:GO:0002671","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell anergy.\" [GOC:add]","metadata":null},{"id":"ee535aec70854a7cab1669da658e447c","type":"GO_TERM","name":"negative regulation of B cell antigen processing and presentation","canonical_id":"go:GO:0002623","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"66b2f518dd8c471cacb041c0e11d6b4f","type":"GO_TERM","name":"negative regulation of B cell apoptotic process","canonical_id":"go:GO:0002903","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"4eb126c66a88440e954b202cb1975595","type":"GO_TERM","name":"negative regulation of B cell chemotaxis","canonical_id":"go:GO:2000550","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of B cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"b9d3b062e67640f3ae0dcba20c6954aa","type":"GO_TERM","name":"negative regulation of B cell cytokine production","canonical_id":"go:GO:0002722","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell cytokine production.\" [GOC:add]","metadata":null},{"id":"fc4ad974836c4c6dae91575a9659ab18","type":"GO_TERM","name":"negative regulation of B cell deletion","canonical_id":"go:GO:0002868","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell deletion.\" [GOC:add]","metadata":null},{"id":"46363dc9db6b412987307abb0370acfa","type":"GO_TERM","name":"negative regulation of B cell differentiation","canonical_id":"go:GO:0045578","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of B cell differentiation.\" [GOC:curators]","metadata":null},{"id":"d8c3672f1c114419b3fe36de52d16d68","type":"GO_TERM","name":"negative regulation of B cell mediated immunity","canonical_id":"go:GO:0002713","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"ec8f108126184002883d4c0acb3a82e1","type":"GO_TERM","name":"negative regulation of B cell proliferation","canonical_id":"go:GO:0030889","description":"\"Any process that stops, prevents or reduces the rate or extent of B cell proliferation.\" [GOC:mah]","metadata":null},{"id":"c760d27dbeb349958569e7a78a59cb71","type":"GO_TERM","name":"negative regulation of B cell receptor signaling pathway","canonical_id":"go:GO:0050859","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell.\" [GOC:ai]","metadata":null},{"id":"74a954a1a0a241ceb0c98c2edc4c74d9","type":"GO_TERM","name":"negative regulation of B cell tolerance induction","canonical_id":"go:GO:0002662","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of B cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"bca64b55855941fe8242dceb48876000","type":"GO_TERM","name":"negative regulation of B-1 B cell differentiation","canonical_id":"go:GO:0001925","description":"\"Any process that stops, prevents, or reduces the rate of B-1 B cell differentiation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"9f0fa06cb4a3481d81cea2a9c063e0e2","type":"GO_TERM","name":"negative regulation of BMP secretion","canonical_id":"go:GO:2001285","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of BMP secretion.\" [GOC:sart]","metadata":null},{"id":"3aecb128504845108c49bc51be3c2adc","type":"GO_TERM","name":"negative regulation of BMP signaling pathway","canonical_id":"go:GO:0030514","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the BMP signaling pathway.\" [GOC:curators]","metadata":null},{"id":"72d227d876a24bbfb99a4a0c57fdedb7","type":"GO_TERM","name":"negative regulation of C-C chemokine receptor CCR7 signaling pathway","canonical_id":"go:GO:1903081","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of C-C chemokine receptor CCR7 signaling pathway.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11602640]","metadata":null},{"id":"01822d5f2a2c4f71be3f199c38322847","type":"GO_TERM","name":"negative regulation of CAMKK-AMPK signaling cascade","canonical_id":"go:GO:1905290","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CAMKK-AMPK signaling cascade.\" [GO_REF:0000058, GOC:TermGenie, PMID:22128786]","metadata":null},{"id":"cd046923241b459d87399d539de6be82","type":"GO_TERM","name":"negative regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation","canonical_id":"go:GO:0032830","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of differentiation of CD4-positive, CD25-positive, alpha-beta regulatory T cells.\" [GOC:mah]","metadata":null},{"id":"d51c2e7e9c374a10b17a755c1d8fcefc","type":"GO_TERM","name":"negative regulation of CD4-positive, alpha-beta T cell activation","canonical_id":"go:GO:2000515","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD4-positive, alpha-beta T cell activation.\" [GOC:obol]","metadata":null},{"id":"241df080972a477288c26c5e6bedbdda","type":"GO_TERM","name":"negative regulation of CD4-positive, alpha-beta T cell costimulation","canonical_id":"go:GO:1900280","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD4-positive, alpha-beta T cell costimulation.\" [GOC:BHF, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"8f5e1832c9b247b3b0aa6bd4522dc7b4","type":"GO_TERM","name":"negative regulation of CD4-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043371","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of CD4-positive, alpha-beta T cell differentiation.\" [GOC:add, GOC:pr, ISBN:0781735149]","metadata":null},{"id":"49589490c6f24a309f2a958ae19ea563","type":"GO_TERM","name":"negative regulation of CD4-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:2000562","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD4-positive, alpha-beta T cell proliferation.\" [GOC:obol]","metadata":null},{"id":"90228c7043fa4af48b2efa6624be91d9","type":"GO_TERM","name":"negative regulation of CD40 signaling pathway","canonical_id":"go:GO:2000349","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of signaling via the CD40 signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"6351cc80ab72480a9de6eee4213f2b1c","type":"GO_TERM","name":"negative regulation of CD8-positive, alpha-beta T cell activation","canonical_id":"go:GO:2001186","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD8-positive, alpha-beta T cell activation.\" [GOC:obol]","metadata":null},{"id":"6be8fbeec5c84434b1c43f39b8bbaa7c","type":"GO_TERM","name":"negative regulation of CD8-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043377","description":"\"Any process that stops, prevents, or reduces the rate of CD8-positive, alpha-beta T cell differentiation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f29ec4eda59644b186acc21ce091a922","type":"GO_TERM","name":"negative regulation of CD8-positive, alpha-beta T cell extravasation","canonical_id":"go:GO:2000450","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD8-positive, alpha-beta T cell extravasation.\" [GOC:obol]","metadata":null},{"id":"449daf7dbb25405b88f4cc8ed4fbeb53","type":"GO_TERM","name":"negative regulation of CD8-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:2000565","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD8-positive, alpha-beta T cell proliferation.\" [GOC:obol]","metadata":null},{"id":"5aefb9929e4e4a4a85a98ec8452832b1","type":"GO_TERM","name":"negative regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation","canonical_id":"go:GO:2000453","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of CD8-positive, alpha-beta cytotoxic T cell extravasation.\" [GOC:obol]","metadata":null},{"id":"eb1230cae3a94a54bc5d329a81ec550f","type":"GO_TERM","name":"negative regulation of D-aspartate import across plasma membrane","canonical_id":"go:GO:0140216","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the directed import of D-aspartate from the extracellular region across the plasma membrane and into the cytosol.\" [PMID:27663541]","metadata":null},{"id":"11391bb09a74482296427595e861edfa","type":"GO_TERM","name":"negative regulation of D-glucose import across plasma membrane","canonical_id":"go:GO:0046325","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell.\" [GOC:ai]","metadata":null},{"id":"4601708da6724797b662dc890eeec379","type":"GO_TERM","name":"negative regulation of D-glucose transmembrane transport","canonical_id":"go:GO:0010829","description":"\"Any process that decreases the frequency, rate or extent of glucose transport across a membrane. Glucose transport is the directed movement of the hexose monosaccharide glucose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"0186dc527bdc4cf2b70e3f410f41dfa5","type":"GO_TERM","name":"negative regulation of DNA amplification","canonical_id":"go:GO:1904524","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of DNA amplification.\" [GO_REF:0000058, GOC:TermGenie, PMID:26195783]","metadata":null},{"id":"a50665e71837418c83078eaed9fed0d3","type":"GO_TERM","name":"negative regulation of DNA binding","canonical_id":"go:GO:0043392","description":"\"Any process that stops or reduces the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid).\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"418da159b0064fb18afb67a4cea33d61","type":"GO_TERM","name":"negative regulation of DNA biosynthetic process","canonical_id":"go:GO:2000279","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of DNA biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"95175629cdba4a33ba37ae8cfb7935d1","type":"GO_TERM","name":"negative regulation of DNA catabolic process","canonical_id":"go:GO:1903625","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of DNA catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:2001740]","metadata":null},{"id":"4651b1182bef485b9980df5652dc191b","type":"GO_TERM","name":"negative regulation of DNA damage checkpoint","canonical_id":"go:GO:2000002","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a DNA damage checkpoint.\" [GOC:BHF, GOC:obol]","metadata":null},{"id":"2786f878aac94df891513eff94a0dc5b","type":"GO_TERM","name":"negative regulation of DNA damage response, signal transduction by p53 class mediator","canonical_id":"go:GO:0043518","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.\" [GOC:jl]","metadata":null},{"id":"bec4d379ced0468c91d9398b8e4b30f9","type":"GO_TERM","name":"negative regulation of DNA endoreduplication","canonical_id":"go:GO:0032876","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA endoreduplication.\" [GOC:mah]","metadata":null},{"id":"86230dfd24c644c0a88520177d57ca06","type":"GO_TERM","name":"negative regulation of DNA metabolic process","canonical_id":"go:GO:0051053","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving DNA.\" [GOC:ai]","metadata":null},{"id":"b83c11fe9e0c4dc79bfdad081b4b7bf8","type":"GO_TERM","name":"negative regulation of DNA methylation-dependent heterochromatin formation","canonical_id":"go:GO:0090310","description":"\"Any process that decreases the rate, frequency, or extent of DNA methylation-dependent heterochromatin formation.\" [GOC:BHF]","metadata":null},{"id":"3cafc407eade41b7a33c8713803706dd","type":"GO_TERM","name":"negative regulation of DNA recombinase disassembly","canonical_id":"go:GO:0062110","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA recombinase complex disassembly, the disaggregation of a DNA recombinase complex into its constituent components.\" [PMID:30297419]","metadata":null},{"id":"7891f4b1a99a4234900c9630c56bae2a","type":"GO_TERM","name":"negative regulation of DNA recombinase mediator complex assembly","canonical_id":"go:GO:1903873","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of DNA recombinase mediator complex assembly.\" [GO_REF:0000058, GOC:rb, GOC:TermGenie, PMID:18347097]","metadata":null},{"id":"8d24b1aa7e084923a7ce5749d1f1ea10","type":"GO_TERM","name":"negative regulation of DNA recombination","canonical_id":"go:GO:0045910","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA recombination.\" [GOC:curators]","metadata":null},{"id":"3203cb736da0479ab35212bb39bada20","type":"GO_TERM","name":"negative regulation of DNA recombination at centromere","canonical_id":"go:GO:0061808","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of genetic recombination at the centromere.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"4f5072fbd9e74ddd88b4e10ead214aa1","type":"GO_TERM","name":"negative regulation of DNA recombination at telomere","canonical_id":"go:GO:0048239","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of genetic recombination within the telomere.\" [GOC:jid, PMID:9635193]","metadata":null},{"id":"586a8e701c154b1888cd89ca51ce43bf","type":"GO_TERM","name":"negative regulation of DNA repair","canonical_id":"go:GO:0045738","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA repair.\" [GOC:curators]","metadata":null},{"id":"1e969994e02a436387fe01b14e9e54ce","type":"GO_TERM","name":"negative regulation of DNA replication","canonical_id":"go:GO:0008156","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA replication.\" [GOC:curators]","metadata":null},{"id":"ce51bc6ccca3439fba6a1dd75d994cf4","type":"GO_TERM","name":"negative regulation of DNA strand resection involved in replication fork processing","canonical_id":"go:GO:0110027","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA strand resection involved in replication fork processing.\" [GOC:mah, PMID:28475874]","metadata":null},{"id":"ef8ad6cc1ecc4c929092e6d19f1008f4","type":"GO_TERM","name":"negative regulation of DNA-templated DNA replication","canonical_id":"go:GO:2000104","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA-dependent DNA replication.\" [GOC:mah]","metadata":null},{"id":"bec038399499422b81e59eca56c826f6","type":"GO_TERM","name":"negative regulation of DNA-templated DNA replication initiation","canonical_id":"go:GO:0032297","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of initiation of DNA-dependent DNA replication.\" [GOC:mah]","metadata":null},{"id":"b97a99170acc462dbfd7369143525ece","type":"GO_TERM","name":"negative regulation of DNA-templated transcription","canonical_id":"go:GO:0045892","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"821ac677491344aa9c6640d67eeac33b","type":"GO_TERM","name":"negative regulation of DNA-templated transcription initiation","canonical_id":"go:GO:2000143","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA-templated transcription initiation.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"d7b74911ce0e4211a3f0196955102c6c","type":"GO_TERM","name":"negative regulation of DNA-templated transcription, elongation","canonical_id":"go:GO:0032785","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides catalyzed by a DNA-dependent RNA polymerase.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"805bfadae44f486d99600ee519f46ef2","type":"GO_TERM","name":"negative regulation of ER to Golgi vesicle-mediated transport","canonical_id":"go:GO:7770035","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ER to Golgi vesicle-mediated transport.\" [PMID:21693198]","metadata":null},{"id":"e4637f4ee6124c9794d27c5d8bd14b8d","type":"GO_TERM","name":"negative regulation of ERAD pathway","canonical_id":"go:GO:1904293","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ERAD pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22590560]","metadata":null},{"id":"a0b165d0a91d4c9d937206d46fef403d","type":"GO_TERM","name":"negative regulation of ERBB signaling pathway","canonical_id":"go:GO:1901185","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ERBB signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"19f0c2a927cf4ce7ad74f03cc954a3f6","type":"GO_TERM","name":"negative regulation of ERBB3 signaling pathway","canonical_id":"go:GO:1905579","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ERBB3 signaling pathway.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:27353365]","metadata":null},{"id":"c7fe56cfa5f648f3aab92ea21cc14046","type":"GO_TERM","name":"negative regulation of ERBB4 signaling pathway","canonical_id":"go:GO:0120154","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ERBB4 signaling pathway.\" [PMID:15219672]","metadata":null},{"id":"93ae7fd92dd8493f83c99f9e92d31cd2","type":"GO_TERM","name":"negative regulation of ERK1 and ERK2 cascade","canonical_id":"go:GO:0070373","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.\" [GOC:add, ISBN:0121245462, ISBN:0896039986]","metadata":null},{"id":"15a29c3e49c34335915a738818ed281d","type":"GO_TERM","name":"negative regulation of ERK5 cascade","canonical_id":"go:GO:0070377","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the ERK5 cascade.\" [GOC:add, ISBN:0121245462, ISBN:0896039986]","metadata":null},{"id":"1193e95408ee44ff9fa3f04a2a89ab4f","type":"GO_TERM","name":"negative regulation of F-9775A biosynthetic process","canonical_id":"go:GO:1900671","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of F-9775A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c037f39aae644a26b474e6e9904f405b","type":"GO_TERM","name":"negative regulation of F-9775B biosynthetic process","canonical_id":"go:GO:1900676","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of F-9775B biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8adc44db1b7d4230a1b9423de210a79e","type":"GO_TERM","name":"negative regulation of FACT complex assembly","canonical_id":"go:GO:1905645","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of FACT complex assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"22c32a97861a411a9849422b21c8eee3","type":"GO_TERM","name":"negative regulation of Fas signaling pathway","canonical_id":"go:GO:1902045","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Fas signaling pathway.\" [GOC:TermGenie, PMID:17245429]","metadata":null},{"id":"1d42b36e24144e56aac1802e15bbaf0f","type":"GO_TERM","name":"negative regulation of Fc-gamma receptor signaling pathway involved in phagocytosis","canonical_id":"go:GO:1905450","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Fc-gamma receptor signaling pathway involved in phagocytosis.\" [GO_REF:0000058, GOC:TermGenie, PMID:18832707]","metadata":null},{"id":"0d972e43ace446f9962f42b70720535e","type":"GO_TERM","name":"negative regulation of Frizzled Nuclear Import pathway","canonical_id":"go:GO:0140712","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a Frizzled Nuclear Import pathway.\" [PMID:22510459, PMID:22579286]","metadata":null},{"id":"9ffef3f75b784a02a9a0f939cc3eb0f7","type":"GO_TERM","name":"negative regulation of FtsZ-dependent cytokinesis","canonical_id":"go:GO:2000245","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Ftsz-dependent cytokinesis.\" [GOC:mah]","metadata":null},{"id":"56588bab4dd04cc2a546167d2d71794c","type":"GO_TERM","name":"negative regulation of G protein-coupled receptor internalization","canonical_id":"go:GO:1904021","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of G protein-coupled receptor internalization.\" [GO_REF:0000058, GOC:TermGenie, PMID:24732013]","metadata":null},{"id":"fd754ea36b874b9997745a42bc607630","type":"GO_TERM","name":"negative regulation of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0045744","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of G protein-coupled receptor signaling pathway.\" [GOC:curators]","metadata":null},{"id":"cb3b9fc8928a42dcaafb52f361578830","type":"GO_TERM","name":"negative regulation of G0 to G1 transition","canonical_id":"go:GO:0070317","description":"\"A cell cycle process that stops, prevents, or reduces the rate or extent of the transition from the G0 quiescent state to the G1 phase.\" [GOC:mah]","metadata":null},{"id":"f960f951ccdd4a728619daa247581d91","type":"GO_TERM","name":"negative regulation of G1 to G0 transition","canonical_id":"go:GO:1903451","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of G1 to G0 transition.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:24088570]","metadata":null},{"id":"ea187ae38e2a49f1ba1d62394e6863c5","type":"GO_TERM","name":"negative regulation of G1/S transition of mitotic cell cycle","canonical_id":"go:GO:2000134","description":"\"Any signaling pathway that decreases or inhibits the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"b6e13d14853f40be96dfdddbc25d8ac9","type":"GO_TERM","name":"negative regulation of G2/M transition of mitotic cell cycle","canonical_id":"go:GO:0010972","description":"\"Any signaling pathway that decreases or inhibits the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"e8e6bb6e9fee4022accfde21c1a60bad","type":"GO_TERM","name":"negative regulation of G2/MI transition of meiotic cell cycle","canonical_id":"go:GO:0110031","description":"\"Any signaling pathway that decreases or inhibits the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to MI phase of the meiotic cell cycle.\" [GOC:vw, PMID:25492408]","metadata":null},{"id":"8a64fa0a041146da920056eff7b2b7a8","type":"GO_TERM","name":"negative regulation of GABA catabolic process","canonical_id":"go:GO:1901716","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gamma-aminobutyric acid catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"a47a97d575f842b18677a64f0a003dee","type":"GO_TERM","name":"negative regulation of GCN2-mediated signaling","canonical_id":"go:GO:7770045","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of GCN2-mediated signaling.\" [PMID:23899355]","metadata":null},{"id":"b1db7d2cadf542c1819d29ec1e6434c9","type":"GO_TERM","name":"negative regulation of GDF15-GFRAL signaling pathway","canonical_id":"go:GO:0160145","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of GDF15-GFRAL signaling pathway.\" [PMID:35177851]","metadata":null},{"id":"54f9349e188c42d69eb2ffa2dd10ef10","type":"GO_TERM","name":"negative regulation of GTPase activity","canonical_id":"go:GO:0034260","description":"\"Any process that stops or reduces the rate of GTP hydrolysis by a GTPase.\" [GO_REF:0000058, GOC:mah, GOC:rb, GOC:TermGenie, PMID:16143306, PMID:24335649]","metadata":null},{"id":"841ebd0c2286424baffb908adead0f34","type":"GO_TERM","name":"negative regulation of Golgi to plasma membrane protein transport","canonical_id":"go:GO:0042997","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the transport of proteins from the Golgi to the plasma membrane.\" [GOC:jl]","metadata":null},{"id":"34676a5e16f74436bf4d5019623e68f3","type":"GO_TERM","name":"negative regulation of Golgi vesicle fusion to target membrane","canonical_id":"go:GO:0048216","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Golgi vesicle fusion to target membrane.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"30357a38fdee4c579099b773fa730973","type":"GO_TERM","name":"negative regulation of HRI-mediated signaling","canonical_id":"go:GO:0141191","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of HRI-mediated signaling.\" [PMID:38297121]","metadata":null},{"id":"f1ea7b180f8946c2a183c98d1ff3ca68","type":"GO_TERM","name":"negative regulation of Hulle cell development","canonical_id":"go:GO:0070809","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Hulle cell development, a process that leads to the formation of Hulle cells. Hulle cells are specialized multinucleate cells that originate from a nest-like aggregation of hyphae during sexual development and serve as nurse cells to the developing cleistothecium, or fruiting body.\" [GOC:mah]","metadata":null},{"id":"da09a1c59ace4c4db531cc74c4dd9466","type":"GO_TERM","name":"negative regulation of I-kappaB phosphorylation","canonical_id":"go:GO:1903720","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of I-kappaB phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23675531]","metadata":null},{"id":"3c9d51706dee4d588a73aa3faad30301","type":"GO_TERM","name":"negative regulation of IP-10 production","canonical_id":"go:GO:0071659","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of IP-10.\" [GOC:mah]","metadata":null},{"id":"2c559bcc679c442ebcabb52af0275d5d","type":"GO_TERM","name":"negative regulation of IRE1-mediated unfolded protein response","canonical_id":"go:GO:1903895","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the IRE1-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"27be2a24f62446faa0c901d607bec960","type":"GO_TERM","name":"negative regulation of JNK cascade","canonical_id":"go:GO:0046329","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the JNK cascade.\" [GOC:bf]","metadata":null},{"id":"18e099eb8060497f8f16343e3dbf155e","type":"GO_TERM","name":"negative regulation of JUN kinase activity","canonical_id":"go:GO:0043508","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of JUN kinase activity.\" [GOC:jl]","metadata":null},{"id":"78114239bf794df2897c3ad87b17c7dd","type":"GO_TERM","name":"negative regulation of Kit signaling pathway","canonical_id":"go:GO:1900235","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Kit signaling pathway.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"208a0aa095b34512a6e4c61d6720de6e","type":"GO_TERM","name":"negative regulation of L-arginine import across plasma membrane","canonical_id":"go:GO:1905542","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-arginine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:14718525]","metadata":null},{"id":"02371c024f7c4a608fccda71099cfb5a","type":"GO_TERM","name":"negative regulation of L-ascorbic acid biosynthetic process","canonical_id":"go:GO:2000083","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of L-ascorbic acid biosynthetic process.\" [PMID:19395407]","metadata":null},{"id":"1b4160dc20b04bdabaf841f838c7cd53","type":"GO_TERM","name":"negative regulation of L-glutamate biosynthetic process","canonical_id":"go:GO:0140387","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of L-glutamate biosynthetic process.\" [PMID:16899818, PMID:29649217]","metadata":null},{"id":"773cb5f920ce484bbd1fa59220fd4bf8","type":"GO_TERM","name":"negative regulation of L-glutamate import across plasma membrane","canonical_id":"go:GO:0002037","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-glutamate import into a cell.\" [GOC:TermGenie]","metadata":null},{"id":"100d64e1321848b18c02fb73770b1793","type":"GO_TERM","name":"negative regulation of L-glutamine biosynthetic process","canonical_id":"go:GO:0062133","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-glutamine biosynthesis.\" [GOC:ha, PMID:19755423]","metadata":null},{"id":"16cc12da5f5b44fe865b4312962cbcf5","type":"GO_TERM","name":"negative regulation of L-glutamine import across plasma membrane","canonical_id":"go:GO:1901035","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-glutamine import into a cell.\" [GOC:TermGenie]","metadata":null},{"id":"0e36c20d6d6142c89be57ed8ffc8a028","type":"GO_TERM","name":"negative regulation of L-leucine biosynthetic process","canonical_id":"go:GO:2001277","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-leucine biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"161e2a8702a0429991aaa2d0718232e9","type":"GO_TERM","name":"negative regulation of L-leucine import across plasma membrane","canonical_id":"go:GO:1905533","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-leucine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:10467003]","metadata":null},{"id":"b666522de6a0419b98f05858d78781e3","type":"GO_TERM","name":"negative regulation of L-lysine import across plasma membrane","canonical_id":"go:GO:1905009","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-lysine import into cell.\" [GO_REF:0000058, GOC:TermGenie, PMID:7499219]","metadata":null},{"id":"335b07ad23314ebfbb5f42424b386b9b","type":"GO_TERM","name":"negative regulation of L-methionine import across plasma membrane","canonical_id":"go:GO:1905625","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-methionine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:17556368]","metadata":null},{"id":"fff352764f524725b7ab64407c9b5ba8","type":"GO_TERM","name":"negative regulation of L-proline biosynthetic process","canonical_id":"go:GO:1902006","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-proline biosynthetic process.\" [GOC:TermGenie, PMID:23415322]","metadata":null},{"id":"06ef099949524961a130a0b890363a19","type":"GO_TERM","name":"negative regulation of L-proline catabolic process","canonical_id":"go:GO:2001157","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-proline catabolic process.\" [GOC:obol]","metadata":null},{"id":"96464e4312f442e0a406e9aefe2a2f2e","type":"GO_TERM","name":"negative regulation of L-proline import across plasma membrane","canonical_id":"go:GO:1905736","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-proline import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"a3374d19e9284636bfb2de997ad9311a","type":"GO_TERM","name":"negative regulation of L-threonine import across plasma membrane","canonical_id":"go:GO:1900927","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-threonine import into cell.\" [GOC:TermGenie]","metadata":null},{"id":"35593de806284d9186459930331579c5","type":"GO_TERM","name":"negative regulation of L-tyrosine import across plasma membrane","canonical_id":"go:GO:1900930","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of L-tyrosine import into the cell.\" [GOC:TermGenie]","metadata":null},{"id":"dd74a32271934d0ab8384a882f9a3c6f","type":"GO_TERM","name":"negative regulation of Lewy body formation","canonical_id":"go:GO:0140123","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Lewy body formation.\" [GOC:sl]","metadata":null},{"id":"6515f971e85444e5a48a8263e07cf320","type":"GO_TERM","name":"negative regulation of MAP kinase activity","canonical_id":"go:GO:0043407","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of MAP kinase activity.\" [GOC:curators, GOC:dph]","metadata":null},{"id":"d12e08f22c5541c2b22c83d47582e2a1","type":"GO_TERM","name":"negative regulation of MAPK cascade","canonical_id":"go:GO:0043409","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the MAPKKK cascade.\" [GOC:curators]","metadata":null},{"id":"413f2c89874b43eca666135e8ea62030","type":"GO_TERM","name":"negative regulation of MDA-5 signaling pathway","canonical_id":"go:GO:0039534","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the series of the MDA-5 signaling pathway.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"2069e3c3ab514bddad66e8e423147fdb","type":"GO_TERM","name":"negative regulation of MHC class I biosynthetic process","canonical_id":"go:GO:0045344","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class I.\" [GOC:curators]","metadata":null},{"id":"10566bfb3970443f9459f14239c40f22","type":"GO_TERM","name":"negative regulation of MHC class II biosynthetic process","canonical_id":"go:GO:0045347","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class II.\" [GOC:curators]","metadata":null},{"id":"c013f91e273e440eb8879b65597c1115","type":"GO_TERM","name":"negative regulation of MyD88-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0034125","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of MyD88-dependent toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"ca8c24b5c66c4cf09e3b8696c3efc304","type":"GO_TERM","name":"negative regulation of MyD88-independent toll-like receptor signaling pathway","canonical_id":"go:GO:0034128","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of MyD88-independent toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"7d612cb908b0473eaef2f5667499d90e","type":"GO_TERM","name":"negative regulation of N',N'',N'''-triacetylfusarinine C biosynthetic process","canonical_id":"go:GO:1900696","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of N',N'',N'''-triacetylfusarinine C biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2ccf792ea8f74d92bbab402ae557bbd7","type":"GO_TERM","name":"negative regulation of N-terminal peptidyl-lysine acetylation","canonical_id":"go:GO:2000760","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of N-terminal peptidyl-lysine acetylation.\" [GOC:obol]","metadata":null},{"id":"0f46ed9039514352abd48189f4b94eea","type":"GO_TERM","name":"negative regulation of N-terminal peptidyl-methionine acetylation","canonical_id":"go:GO:1904664","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of N-terminal peptidyl-methionine acetylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:20807799]","metadata":null},{"id":"756d80d7723246a199f36244be58b33f","type":"GO_TERM","name":"negative regulation of N-terminal protein palmitoylation","canonical_id":"go:GO:0060262","description":"\"Any process that decreases the rate frequency or extent of the covalent attachment of a palmitoyl group to the N-terminal amino acid residue of a protein.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"41f21c9b08104f4d8d6543f14e0ad6f2","type":"GO_TERM","name":"negative regulation of NAD metabolic process","canonical_id":"go:GO:1902689","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of NAD metabolic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:19846558]","metadata":null},{"id":"89e2b7b73292488e9d6857c3fd4fa19f","type":"GO_TERM","name":"negative regulation of NK T cell activation","canonical_id":"go:GO:0051134","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer T cell activation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"541ebcb7079d42d3a5d0efb2d519484e","type":"GO_TERM","name":"negative regulation of NK T cell differentiation","canonical_id":"go:GO:0051137","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer T cell differentiation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"f3ed27930180425dbf9eb470baf92fcf","type":"GO_TERM","name":"negative regulation of NK T cell proliferation","canonical_id":"go:GO:0051141","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer T cell proliferation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"6db981a3c0384a0ca730cd2aeb65d8f1","type":"GO_TERM","name":"negative regulation of NLRP3 inflammasome complex assembly","canonical_id":"go:GO:1900226","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of NLRP3 inflammasome complex assembly.\" [GOC:TermGenie]","metadata":null},{"id":"e5859de0c6ea417eb45b89b433b56987","type":"GO_TERM","name":"negative regulation of NMDA glutamate receptor activity","canonical_id":"go:GO:1904782","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of NMDA glutamate receptor activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:12857]","metadata":null},{"id":"84f1fde5ca824d75b27f34780fca28d5","type":"GO_TERM","name":"negative regulation of Notch signaling pathway","canonical_id":"go:GO:0045746","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the Notch signaling pathway.\" [GOC:curators]","metadata":null},{"id":"887b96217e7949f39831c55a95f6c236","type":"GO_TERM","name":"negative regulation of P-type sodium:potassium-exchanging transporter activity","canonical_id":"go:GO:1903407","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sodium:potassium-exchanging ATPase activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:8160880]","metadata":null},{"id":"23ba51de869c4c9db64567256c9830e0","type":"GO_TERM","name":"negative regulation of PERK-mediated unfolded protein response","canonical_id":"go:GO:1903898","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the PERK-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"13e63e094b9d40cb8e601f10dd69e946","type":"GO_TERM","name":"negative regulation of PKR/eIFalpha signaling","canonical_id":"go:GO:7770077","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of PKR/eIFalpha signaling.\" [PMID:19733181, PMID:29395325]","metadata":null},{"id":"174527acc2eb4680833272c6353233bf","type":"GO_TERM","name":"negative regulation of R7 cell differentiation","canonical_id":"go:GO:0045677","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of R7cell differentiation.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"343a9b7644614fe983d503c7f90f7196","type":"GO_TERM","name":"negative regulation of R7 cell fate commitment","canonical_id":"go:GO:0106398","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of R7 cell fate commitment.\" [GOC:ha, PMID:22878552]","metadata":null},{"id":"7cc379a130ca48fd944c7aa66bbc7817","type":"GO_TERM","name":"negative regulation of R8 cell differentiation","canonical_id":"go:GO:0045680","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of R8 cell differentiation.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"473d86d2ad2b4d7bb5f54041396c9ef1","type":"GO_TERM","name":"negative regulation of R8 cell spacing in compound eye","canonical_id":"go:GO:0045469","description":"\"Any process that stops or prevents the correct R8 cell spacing pattern in a compound eye.\" [GOC:dph, GOC:tb, PMID:11880339]","metadata":null},{"id":"56a25e3786964121a5863303dd3dc544","type":"GO_TERM","name":"negative regulation of RIG-I signaling pathway","canonical_id":"go:GO:0039536","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the RIG-I signaling pathway.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"73ba9c652ff6484485d404116c08046e","type":"GO_TERM","name":"negative regulation of RNA biosynthetic process","canonical_id":"go:GO:1902679","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of RNA biosynthetic process.\" [GO:jl, GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"9e80a2f7357142d9a01f3afbc6471e6f","type":"GO_TERM","name":"negative regulation of RNA catabolic process","canonical_id":"go:GO:1902369","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of RNA catabolic process.\" [GOC:bf, GOC:TermGenie, PMID:16640457]","metadata":null},{"id":"430e2f8cfc2a486b9aad27d727a3c1fd","type":"GO_TERM","name":"negative regulation of RNA export from nucleus","canonical_id":"go:GO:0046832","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of RNA from the nucleus into the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"dfed6d68319f473b89d04e3a567a1fa1","type":"GO_TERM","name":"negative regulation of RNA import into nucleus","canonical_id":"go:GO:0046829","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the movement of RNA from the cytoplasm into the nucleus.\" [GOC:bf]","metadata":null},{"id":"a5682e244c3c4cffade3aca0430704f2","type":"GO_TERM","name":"negative regulation of RNA metabolic process","canonical_id":"go:GO:0051253","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving RNA.\" [GOC:ai]","metadata":null},{"id":"939b8a8d7a9d45e8b4928bbb35093b9c","type":"GO_TERM","name":"negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding","canonical_id":"go:GO:1903026","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of RNA polymerase II regulatory region sequence-specific DNA binding.\" [GO_REF:0000059, GOC:dph, GOC:krc, GOC:TermGenie, PMID:20026326]","metadata":null},{"id":"0bbe763f41b64942ba97baa29ed6286a","type":"GO_TERM","name":"negative regulation of RNA polymerase II transcription preinitiation complex assembly","canonical_id":"go:GO:0017055","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of RNA polymerase II transcriptional preinitiation complex assembly.\" [GOC:curators]","metadata":null},{"id":"86fbf1a66ec64581a2760bb7bf639c6a","type":"GO_TERM","name":"negative regulation of RNA splicing","canonical_id":"go:GO:0033119","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of RNA splicing.\" [GOC:mah]","metadata":null},{"id":"e70c6cc0b36747ccb96156cff629b4a0","type":"GO_TERM","name":"negative regulation of RNA-dependent RNA polymerase activity","canonical_id":"go:GO:1900260","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of RNA-directed 5'-3' RNA polymerase activity.\" [GOC:pf, GOC:TermGenie]","metadata":null},{"id":"0c351b3e2905452c956819a1f1001d75","type":"GO_TERM","name":"negative regulation of Rac protein signal transduction","canonical_id":"go:GO:0035021","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Rac protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"fcecc9ae51644a5db85c24d8c660e70b","type":"GO_TERM","name":"negative regulation of Ras protein signal transduction","canonical_id":"go:GO:0046580","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Ras protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"b24bc725879247c28813f69f4ba6d1ea","type":"GO_TERM","name":"negative regulation of Rho guanyl-nucleotide exchange factor activity","canonical_id":"go:GO:2001107","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Rho guanyl-nucleotide exchange factor activity.\" [GOC:obol]","metadata":null},{"id":"214e2cab0e424fd6b223395c824bdee5","type":"GO_TERM","name":"negative regulation of Rho protein signal transduction","canonical_id":"go:GO:0035024","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Rho protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"da10e98a32cd46c5ae0a180f341ce4a8","type":"GO_TERM","name":"negative regulation of Roundabout signaling pathway","canonical_id":"go:GO:0035387","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the Roundabout signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"42b1f0f4c8c744eda0dd17c7924fb4ab","type":"GO_TERM","name":"negative regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process","canonical_id":"go:GO:0062026","description":"\"Any process that stops or decreases the rate, frequency or extent of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process, the chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by an SCF (Skp1/Cul1/F-box protein) complex, and mediated by the proteasome.\" [PMID:28007894]","metadata":null},{"id":"a5edfa821a8741828e8c52dfb80cadf3","type":"GO_TERM","name":"negative regulation of SMAD protein signal transduction","canonical_id":"go:GO:0060392","description":"\"Any process that decreases the rate, frequency or extent of the SMAD protein signaling pathway.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"88e70f80c7ab4868b7fef4bed12f5c8a","type":"GO_TERM","name":"negative regulation of SNARE complex assembly","canonical_id":"go:GO:0035544","description":"\"Any process that decreases the frequency, rate or extent of assembly of the SNARE complex. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb]","metadata":null},{"id":"959b3cad41454ce7bb5d6dbbdb98c937","type":"GO_TERM","name":"negative regulation of SNARE complex disassembly","canonical_id":"go:GO:0035541","description":"\"Any process that decreases the frequency, rate or extent of disassembly of the SNARE complex. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb]","metadata":null},{"id":"5673bc823de24a9683c9eee0cfe93965","type":"GO_TERM","name":"negative regulation of SREBP signaling pathway","canonical_id":"go:GO:2000639","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the SREBP signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"adf1d88380b54d598bc43164b5ae818a","type":"GO_TERM","name":"negative regulation of SREBP signaling pathway in response to increased oxygen levels","canonical_id":"go:GO:0038175","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the SREBP signaling pathway in response to an increase in oxygen levels.\" [GOC:al, PMID:22017871]","metadata":null},{"id":"2bdd108d32d24b7f9b2a3e296f173d90","type":"GO_TERM","name":"negative regulation of Schwann cell chemotaxis","canonical_id":"go:GO:1904267","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Schwann cell chemotaxis.\" [GO_REF:0000058, GOC:TermGenie, PMID:16203995]","metadata":null},{"id":"0de600a019df46f7b67dee47b1a87c9e","type":"GO_TERM","name":"negative regulation of Schwann cell differentiation","canonical_id":"go:GO:0014039","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of Schwann cell differentiation.\" [GOC:ef]","metadata":null},{"id":"2b831a73699f4820b56174020fe9f952","type":"GO_TERM","name":"negative regulation of Schwann cell migration","canonical_id":"go:GO:1900148","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Schwann cell migration.\" [GOC:sjw, GOC:TermGenie]","metadata":null},{"id":"d8ce90d402434301b1ac1fd07163fad5","type":"GO_TERM","name":"negative regulation of Schwann cell proliferation","canonical_id":"go:GO:0010626","description":"\"Any process that decreases the frequency or extent of the multiplication or reproduction of Schwann cells, resulting in the expansion of their population. Schwann cells are a type of glial cell in the peripheral nervous system.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"e43d2a4968164169b26bbecd2929f1a6","type":"GO_TERM","name":"negative regulation of T cell activation","canonical_id":"go:GO:0050868","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T cell activation.\" [GOC:ai]","metadata":null},{"id":"6d629df57f1642b198c1667999bfdb3d","type":"GO_TERM","name":"negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell","canonical_id":"go:GO:2001189","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell.\" [GOC:obol]","metadata":null},{"id":"3c7268fb48e1422daa2983f88e120932","type":"GO_TERM","name":"negative regulation of T cell anergy","canonical_id":"go:GO:0002668","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell anergy.\" [GOC:add]","metadata":null},{"id":"5904e821dc28432cbb953f7c11f95d7e","type":"GO_TERM","name":"negative regulation of T cell antigen processing and presentation","canonical_id":"go:GO:0002626","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"091cce4d015c4446981d707dd6721b4c","type":"GO_TERM","name":"negative regulation of T cell apoptotic process","canonical_id":"go:GO:0070233","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T cell death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"ab207512e20349b48cef100912950990","type":"GO_TERM","name":"negative regulation of T cell costimulation","canonical_id":"go:GO:2000524","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T cell costimulation.\" [GOC:obol]","metadata":null},{"id":"936ff600375a49949f17f5e94b56cd40","type":"GO_TERM","name":"negative regulation of T cell cytokine production","canonical_id":"go:GO:0002725","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell cytokine production.\" [GOC:add]","metadata":null},{"id":"13d760f0ec44442d9aa904a46db9305c","type":"GO_TERM","name":"negative regulation of T cell differentiation","canonical_id":"go:GO:0045581","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"2e3d0946e87a4926a42ac9bf8dde69f7","type":"GO_TERM","name":"negative regulation of T cell differentiation in thymus","canonical_id":"go:GO:0033085","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T cell differentiation in the thymus.\" [GOC:add, GOC:mah]","metadata":null},{"id":"3d215262d54e4a3aa168503d1e201212","type":"GO_TERM","name":"negative regulation of T cell extravasation","canonical_id":"go:GO:2000408","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T cell extravasation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"7e8ef3ffd201499687acd10b92683b22","type":"GO_TERM","name":"negative regulation of T cell homeostatic proliferation","canonical_id":"go:GO:0046014","description":"\"Any process that stops, prevents or reduces the rate or extent of resting T cell proliferation.\" [GOC:curators]","metadata":null},{"id":"95c4ec7a658c4ac089ccf853329b9514","type":"GO_TERM","name":"negative regulation of T cell mediated cytotoxicity","canonical_id":"go:GO:0001915","description":"\"Any process that stops, prevents, or reduces the rate of T cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d35e9d2f19cf490e9c18e03fc52a40e2","type":"GO_TERM","name":"negative regulation of T cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002853","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell mediated cytotoxicity directed against a tumor cell target.\" [GOC:add]","metadata":null},{"id":"77f1f061acd84d62ba004b8a2d78468e","type":"GO_TERM","name":"negative regulation of T cell mediated immune response to tumor cell","canonical_id":"go:GO:0002841","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a T cell mediated immune response to tumor cell.\" [GOC:add]","metadata":null},{"id":"d202a7969605477cb6fa26e2139aed33","type":"GO_TERM","name":"negative regulation of T cell mediated immunity","canonical_id":"go:GO:0002710","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"6320d23977e5433da04d0c10493cc1ec","type":"GO_TERM","name":"negative regulation of T cell migration","canonical_id":"go:GO:2000405","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T cell migration.\" [GOC:mah]","metadata":null},{"id":"7c4e4d461ef94e22a8b0bd3a0e8dd6d6","type":"GO_TERM","name":"negative regulation of T cell proliferation","canonical_id":"go:GO:0042130","description":"\"Any process that stops, prevents or reduces the rate or extent of T cell proliferation.\" [GOC:jl]","metadata":null},{"id":"0c1440fdf08741959949a0278e85e031","type":"GO_TERM","name":"negative regulation of T cell receptor signaling pathway","canonical_id":"go:GO:0050860","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.\" [GOC:ai]","metadata":null},{"id":"63b940efef06411aafb97ad8734b2ac5","type":"GO_TERM","name":"negative regulation of T cell tolerance induction","canonical_id":"go:GO:0002665","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"427ee691c4c64f5e9e680d429ae494cd","type":"GO_TERM","name":"negative regulation of T cell tolerance induction to tumor cell","canonical_id":"go:GO:0002847","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell tolerance induction to tumor cell.\" [GOC:add]","metadata":null},{"id":"46af0e2c467d4140899c42539a569f99","type":"GO_TERM","name":"negative regulation of T-helper 1 cell activation","canonical_id":"go:GO:2000518","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 1 cell activation.\" [GOC:obol]","metadata":null},{"id":"5707033921d144ec8d24129c2d841001","type":"GO_TERM","name":"negative regulation of T-helper 1 cell cytokine production","canonical_id":"go:GO:2000555","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 1 cell cytokine production.\" [GOC:obol]","metadata":null},{"id":"428ee47b72de483c9fbd51c1afd338fc","type":"GO_TERM","name":"negative regulation of T-helper 1 cell differentiation","canonical_id":"go:GO:0045626","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T-helper 1 cell differentiation.\" [GOC:curators]","metadata":null},{"id":"1eb9660526c84184916db90e348c5426","type":"GO_TERM","name":"negative regulation of T-helper 1 type immune response","canonical_id":"go:GO:0002826","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a T-helper 1 type immune response.\" [GOC:add]","metadata":null},{"id":"53cbc20257374c1886ce03c6aa0e0daf","type":"GO_TERM","name":"negative regulation of T-helper 17 cell differentiation","canonical_id":"go:GO:2000320","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 17 cell differentiation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ad33a4f2118045228d99454a4227791d","type":"GO_TERM","name":"negative regulation of T-helper 17 cell extravasation","canonical_id":"go:GO:2000456","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 17 cell extravasation.\" [GOC:obol]","metadata":null},{"id":"18779c24e3d34753b2de5f154d46c5bf","type":"GO_TERM","name":"negative regulation of T-helper 17 cell lineage commitment","canonical_id":"go:GO:2000329","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 17 cell lineage commitment.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"73baf88e7104472da9070233422ad18d","type":"GO_TERM","name":"negative regulation of T-helper 17 type immune response","canonical_id":"go:GO:2000317","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 17 type immune response.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"569401514d714c1bba8d0c389c456b3d","type":"GO_TERM","name":"negative regulation of T-helper 2 cell cytokine production","canonical_id":"go:GO:2000552","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of T-helper 2 cell cytokine production.\" [GOC:obol]","metadata":null},{"id":"89b249671ae0407a871591745836b6b1","type":"GO_TERM","name":"negative regulation of T-helper 2 cell differentiation","canonical_id":"go:GO:0045629","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T-helper 2 cell differentiation.\" [GOC:curators]","metadata":null},{"id":"73d760d9d89c452ca997ea58f71e4944","type":"GO_TERM","name":"negative regulation of T-helper cell differentiation","canonical_id":"go:GO:0045623","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of T-helper cell differentiation.\" [GOC:curators]","metadata":null},{"id":"12a62fa6f45c4543ac625cbf4ca6f999","type":"GO_TERM","name":"negative regulation of TOR signaling","canonical_id":"go:GO:0032007","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of TOR signaling.\" [GOC:mah]","metadata":null},{"id":"bd949b4fdca348ce8256932ec6e47c4f","type":"GO_TERM","name":"negative regulation of TORC1 signaling","canonical_id":"go:GO:1904262","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of TORC1 signaling.\" [GO_REF:0000058, GOC:TermGenie, PMID:25366275]","metadata":null},{"id":"78e3985826e947bd919114c41444066a","type":"GO_TERM","name":"negative regulation of TORC2 signaling","canonical_id":"go:GO:1903940","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of TORC2 signaling.\" [GO_REF:0000058, GOC:TermGenie, PMID:24247430]","metadata":null},{"id":"00e249ef8b8b4423bff749e5aa967844","type":"GO_TERM","name":"negative regulation of TRAIL production","canonical_id":"go:GO:0032719","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of TRAIL production.\" [GOC:mah]","metadata":null},{"id":"aa618ab2d8a44328b23fd576f3593c4e","type":"GO_TERM","name":"negative regulation of TRAIL-activated apoptotic signaling pathway","canonical_id":"go:GO:1903122","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of TRAIL-activated apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21785459]","metadata":null},{"id":"575530070fc849fd8a31b17df8acc75f","type":"GO_TERM","name":"negative regulation of Toll receptor ligand protein activation cascade","canonical_id":"go:GO:0160035","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Toll receptor ligand protein activation cascade.\" [PMID:23632253]","metadata":null},{"id":"ab271456fd344abb8f78fd6c09c44ec4","type":"GO_TERM","name":"negative regulation of Toll signaling pathway","canonical_id":"go:GO:0045751","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the Tl signaling pathway.\" [GOC:curators]","metadata":null},{"id":"86192c155729421784b2a5ffe7e2be65","type":"GO_TERM","name":"negative regulation of UDP-N-acetylglucosamine biosynthetic process","canonical_id":"go:GO:0106279","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the UDP-N-acetylglucosamine biosynthetic process.\" [PMID:32579556]","metadata":null},{"id":"df6d780dc9ab4f30b19eb9bf1add18f6","type":"GO_TERM","name":"negative regulation of VCP-NPL4-UFD1 AAA ATPase complex assembly","canonical_id":"go:GO:1904240","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of VCP-NPL4-UFD1 AAA ATPase complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:17000876]","metadata":null},{"id":"92d475ee125f4b57a1ee65a15a1a7d84","type":"GO_TERM","name":"negative regulation of Wnt protein secretion","canonical_id":"go:GO:0061358","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a Wnt protein from a cell.\" [GOC:bf, PMID:19223472]","metadata":null},{"id":"52a7559efd81485b98d88a2ff8e20c83","type":"GO_TERM","name":"negative regulation of Wnt signaling pathway","canonical_id":"go:GO:0030178","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the Wnt signaling pathway.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"c7119657d36d42f798ab4dadb9ef3367","type":"GO_TERM","name":"negative regulation of Wnt signaling pathway involved in heart development","canonical_id":"go:GO:0003308","description":"\"Any process that decreases the rate, frequency, or extent of the series of molecular signals initiated by binding of Wnt protein to a frizzled family receptor on the surface of the target cell, resulting a change in cell state that contributes to the progression of the heart over time.\" [GOC:mtg_heart]","metadata":null},{"id":"6fdf8cf162054f17ae3e0b3b5886de44","type":"GO_TERM","name":"negative regulation of Wnt signaling pathway, calcium modulating pathway","canonical_id":"go:GO:0045812","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the series of molecular signals initiated by binding of a Wnt protein to a receptor on the surface of the target cell where activated receptors leads to an increase in intracellular calcium and activation of protein kinase C (PKC).\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"ace8bd27d58549f5b330af91b5a4663e","type":"GO_TERM","name":"negative regulation of Wnt signaling pathway, planar cell polarity pathway","canonical_id":"go:GO:0141113","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the Wnt signaling pathway, planar cell polarity pathway.\" [PMID:19056682]","metadata":null},{"id":"abe6fb728994490a9432f89fc59f9b4c","type":"GO_TERM","name":"negative regulation of Wnt-Frizzled-LRP5/6 complex assembly","canonical_id":"go:GO:1904723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of Wnt-Frizzled-LRP5/6 complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11433302]","metadata":null},{"id":"ee32ee71fb7c42c2b6dfd07876309211","type":"GO_TERM","name":"negative regulation of [2Fe-2S] cluster assembly","canonical_id":"go:GO:1900488","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of [2Fe-2S] cluster assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"09e2e4c803a44b71a1f5e0340f267400","type":"GO_TERM","name":"negative regulation of [4Fe-4S] cluster assembly","canonical_id":"go:GO:1900492","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of [4Fe-4S] cluster assembly.\" [GOC:mengo_curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"7aa7982d9abc47a182699fe8d30a5f51","type":"GO_TERM","name":"negative regulation of abscisic acid biosynthetic process","canonical_id":"go:GO:0090359","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of abscisic acid.\" [GOC:tb]","metadata":null},{"id":"9b46b1fb3d054d5bb439d1d20902fb8d","type":"GO_TERM","name":"negative regulation of abscisic acid-activated signaling pathway","canonical_id":"go:GO:0009788","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of abscisic acid (ABA) signaling.\" [GOC:lr]","metadata":null},{"id":"029e9d2455f34617b39633ae5feca544","type":"GO_TERM","name":"negative regulation of acetate catabolic process","canonical_id":"go:GO:0045753","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of acetate.\" [GOC:curators]","metadata":null},{"id":"05e42f290d2a4740b3aba2fdcae3c809","type":"GO_TERM","name":"negative regulation of acetyl-CoA biosynthesis","canonical_id":"go:GO:0140391","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of acetyl-CoA biosynthetic process.\" [PMID:39019872]","metadata":null},{"id":"2d60bf268a584da89ff906460ecec689","type":"GO_TERM","name":"negative regulation of acetylcholine biosynthetic process","canonical_id":"go:GO:1905922","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of acetylcholine biosynthetic process.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:20164328]","metadata":null},{"id":"9c2f7759cbeb4eca95402aa1275e1b90","type":"GO_TERM","name":"negative regulation of acetylcholine secretion, neurotransmission","canonical_id":"go:GO:0014058","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of acetylcholine.\" [GOC:ef]","metadata":null},{"id":"4c2fbdbe139f4f5b8b96045545816325","type":"GO_TERM","name":"negative regulation of acetylcholine uptake","canonical_id":"go:GO:0051632","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of acetylcholine into a cell.\" [GOC:ai]","metadata":null},{"id":"4e732f8c7c7745c5b462e22cad209439","type":"GO_TERM","name":"negative regulation of acinar cell proliferation","canonical_id":"go:GO:1904698","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of acinar cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:9788538]","metadata":null},{"id":"fa08d40175714b559eeb2a07bf1ae946","type":"GO_TERM","name":"negative regulation of acrosome reaction","canonical_id":"go:GO:1902225","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of acrosome reaction.\" [GOC:TermGenie, PMID:23430248]","metadata":null},{"id":"0b040fd648164d97bdbeb7be87bcb5f8","type":"GO_TERM","name":"negative regulation of actin cortical patch assembly","canonical_id":"go:GO:0120133","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly of actin cortical patches.\" [PMID:19962315]","metadata":null},{"id":"16e8a5a09e56437da64c3f009f1b0c95","type":"GO_TERM","name":"negative regulation of actin filament annealing","canonical_id":"go:GO:0110055","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of actin filament annealing, i.e. the end-to-end joining of existing actin filaments.\" [GOC:mah, PMID:15743909]","metadata":null},{"id":"8d5037d22d544092ab7767e3e5f62768","type":"GO_TERM","name":"negative regulation of actin filament binding","canonical_id":"go:GO:1904530","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of actin filament binding.\" [GO_REF:0000059, GOC:als, GOC:TermGenie, PMID:24520051]","metadata":null},{"id":"12dd08bc3dcf4ea38b13a017727d8ba9","type":"GO_TERM","name":"negative regulation of actin filament bundle assembly","canonical_id":"go:GO:0032232","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly of actin filament bundles.\" [GOC:mah]","metadata":null},{"id":"a6c9823bfc494aaeba39146d526357a1","type":"GO_TERM","name":"negative regulation of actin filament depolymerization","canonical_id":"go:GO:0030835","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of actin depolymerization.\" [GOC:mah]","metadata":null},{"id":"665373eff9d74d119afb6cf97741ccf4","type":"GO_TERM","name":"negative regulation of actin filament polymerization","canonical_id":"go:GO:0030837","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of actin polymerization.\" [GOC:mah]","metadata":null},{"id":"fb216616e56f40ffbc31fbe4596ca8da","type":"GO_TERM","name":"negative regulation of actin filament severing","canonical_id":"go:GO:1903919","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of actin filament severing.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23325791]","metadata":null},{"id":"f497f73cbbea46c79e4fc30c28b829ef","type":"GO_TERM","name":"negative regulation of actin nucleation","canonical_id":"go:GO:0051126","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of actin nucleation, the initial step in the formation of an actin filament in which actin monomers combine to form a new filament.\" [GOC:ai]","metadata":null},{"id":"0115c45c5b804129938fcd37068804ce","type":"GO_TERM","name":"negative regulation of action potential","canonical_id":"go:GO:0045759","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:curators]","metadata":null},{"id":"c509ad6763664de6bde6d7fbbd558c83","type":"GO_TERM","name":"negative regulation of activated CD4-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905400","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of activated CD4-positive, alpha-beta T cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"a4d8fcb3c5574cdf9d3299d7fe4351a9","type":"GO_TERM","name":"negative regulation of activated CD8-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905403","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of activated CD8-positive, alpha-beta T cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"ac45d7509e96416d84251e1d8f37806f","type":"GO_TERM","name":"negative regulation of activated T cell autonomous cell death","canonical_id":"go:GO:0070240","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of activated T cell autonomous cell death.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"8477932c01914b42b816d37de714f748","type":"GO_TERM","name":"negative regulation of activated T cell proliferation","canonical_id":"go:GO:0046007","description":"\"Any process that stops, prevents or reduces the rate or extent of activated T cell proliferation.\" [GOC:curators]","metadata":null},{"id":"8a97bb88a29b4eb29d1920c17d91a7f9","type":"GO_TERM","name":"negative regulation of activation of membrane attack complex","canonical_id":"go:GO:0001971","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the activation of the membrane attack complex components of the complement cascade.\" [GOC:hjd]","metadata":null},{"id":"b43aff9881284354b1a8adc544f0a48b","type":"GO_TERM","name":"negative regulation of activation-induced cell death of T cells","canonical_id":"go:GO:0070236","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of activation-induced cell death of T cells.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"a1c4e957dd3942049b8cb2ed5ec9bc90","type":"GO_TERM","name":"negative regulation of activin receptor signaling pathway","canonical_id":"go:GO:0032926","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of any activin receptor signaling pathway.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"aa66aef64f6940d28af65a96e9d6c75f","type":"GO_TERM","name":"negative regulation of activin secretion","canonical_id":"go:GO:0032336","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of activin from a cell.\" [GOC:mah]","metadata":null},{"id":"62d7b449fa894af2969412dac5c0474c","type":"GO_TERM","name":"negative regulation of acute inflammatory response","canonical_id":"go:GO:0002674","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response.\" [GOC:add]","metadata":null},{"id":"7eaaeb6688154b9c98c07924b956f2dd","type":"GO_TERM","name":"negative regulation of acute inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002865","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"678358f687194957830deffe61583358","type":"GO_TERM","name":"negative regulation of acute inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002878","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response to a non-antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"6d38a7eaf6474339a333463650078e90","type":"GO_TERM","name":"negative regulation of acylglycerol transport","canonical_id":"go:GO:1901507","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of acylglycerol transport.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"c79e0515c6e04fd0b3af5499242a5366","type":"GO_TERM","name":"negative regulation of adaptive immune effector response","canonical_id":"go:GO:1905678","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of adaptive immune effector response.\" [GO_REF:0000058, GOC:TermGenie, ISBN:9781405196833]","metadata":null},{"id":"57976869be4e48e7a8ab56d48a075363","type":"GO_TERM","name":"negative regulation of adaptive immune memory response","canonical_id":"go:GO:1905675","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of adaptive immune memory response.\" [GO_REF:0000058, GOC:TermGenie, PMID:26831526]","metadata":null},{"id":"1b6e89fe23944fdaa203c8c2902c2c2c","type":"GO_TERM","name":"negative regulation of adaptive immune response","canonical_id":"go:GO:0002820","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response.\" [GOC:add]","metadata":null},{"id":"f1cf307f268447c8888fe4cf5e8f3b98","type":"GO_TERM","name":"negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains","canonical_id":"go:GO:0002823","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. An example of this process is found in the Gnathostomata.\" [GOC:add, GOC:mtg_sensu]","metadata":null},{"id":"fdd6247a64b9445cb2f65a3e2a1a7813","type":"GO_TERM","name":"negative regulation of adenosine receptor signaling pathway","canonical_id":"go:GO:0060169","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands.\" [GOC:dph]","metadata":null},{"id":"2ab62d5ddde5424391fc757f569cad3f","type":"GO_TERM","name":"negative regulation of adenosine transport","canonical_id":"go:GO:0032250","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of adenosine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"62ea879779194c4c870e357d5c5f20d8","type":"GO_TERM","name":"negative regulation of adenylate cyclase activity","canonical_id":"go:GO:0007194","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of adenylate cyclase activity.\" [GOC:curators]","metadata":null},{"id":"01941fabe3854e8081d85222511142a1","type":"GO_TERM","name":"negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0106072","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an adenylate cyclase-activating G protein-coupled receptor signaling pathway.\" [GOC:hjd, PMID:19246489]","metadata":null},{"id":"d1f458f1f09b410fbe42892516c9abd1","type":"GO_TERM","name":"negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway","canonical_id":"go:GO:0071878","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of an adenylate cyclase-activating adrenergic receptor protein signaling pathway activity. An adrenergic receptor signaling pathway is the series of molecular signals generated as a consequence of an adrenergic receptor binding to one of its physiological ligands.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"729211c0c01c45098010c3462433cba2","type":"GO_TERM","name":"negative regulation of adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0110034","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway.\" [GOC:al, PMID:24297439]","metadata":null},{"id":"5ff55337f0744e7189c858448f38132c","type":"GO_TERM","name":"negative regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway","canonical_id":"go:GO:1904991","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of adenylate cyclase-inhibiting dopamine receptor signaling pathway.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26554819]","metadata":null},{"id":"47a295aac20343f2a48858512e2db532","type":"GO_TERM","name":"negative regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway","canonical_id":"go:GO:1900730","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of adenylate cyclase-inhibiting opioid receptor signaling pathway.\" [GOC:sjw, GOC:TermGenie, PMID:17157995]","metadata":null},{"id":"c4f5a251ac8642d088a6786eb01f3042","type":"GO_TERM","name":"negative regulation of adherens junction organization","canonical_id":"go:GO:1903392","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of adherens junction organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:21724833]","metadata":null},{"id":"2925fe0606d04b57bb1c851a5ebe6c9d","type":"GO_TERM","name":"negative regulation of adiponectin secretion","canonical_id":"go:GO:0070164","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of adiponectin from a cell.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"540660ddfdff4b288c62bc2e7e82586d","type":"GO_TERM","name":"negative regulation of adipose tissue development","canonical_id":"go:GO:1904178","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of adipose tissue development.\" [GO_REF:0000058, GOC:TermGenie, PMID:23081848]","metadata":null},{"id":"c0fea57df3fa43f0abd6d67fe5ec75ac","type":"GO_TERM","name":"negative regulation of adult chitin-containing cuticle pigmentation","canonical_id":"go:GO:0048083","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of the adult pattern of pigmentation in the cuticle of an organism.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"a500d50b14094124a35f5f23922cedc1","type":"GO_TERM","name":"negative regulation of adult salivary gland boundary specification","canonical_id":"go:GO:0045709","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of salivary gland determination in an adult organism.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"f271738112f34fdc9b60f88d4df6fa77","type":"GO_TERM","name":"negative regulation of adult somatic muscle development","canonical_id":"go:GO:0062228","description":"\"Any process that decreases the rate, frequency or extent of adult somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"f4d78f58acf448c5b8f267bb725c5211","type":"GO_TERM","name":"negative regulation of aeciospore formation","canonical_id":"go:GO:0075250","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of aeciospore formation, a process in which a dikaryotic spore of typically a rust fungus is produced in an aecium.\" [GOC:pamgo_curators]","metadata":null},{"id":"8929630cef4d45bc9ec65405f0ce5171","type":"GO_TERM","name":"negative regulation of aecium development","canonical_id":"go:GO:0075270","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of aecium development, a process in which a cuplike structure containing chains of aeciospores is formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"c1f0d78023c44f74b5141dbfcd4a4a27","type":"GO_TERM","name":"negative regulation of aflatoxin biosynthetic process","canonical_id":"go:GO:1900178","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of aflatoxin biosynthetic process.\" [GOC:di]","metadata":null},{"id":"5fb70442e35345b9ac7c3811977a0eb4","type":"GO_TERM","name":"negative regulation of age-related resistance","canonical_id":"go:GO:1904249","description":"\"Any process that stops, prevents or reduces the extent of age-related resistance.\" [GO_REF:0000058, GOC:TermGenie, PMID:19694953]","metadata":null},{"id":"4844ca897af7490398a5996bbc15afbc","type":"GO_TERM","name":"negative regulation of aggregate size involved in sorocarp development","canonical_id":"go:GO:0031158","description":"\"Any process that decreases the size of the aggregate formed during sorocarp formation.\" [GOC:mah, GOC:mtg_sensu, GOC:pg, PMID:5002049]","metadata":null},{"id":"cd7e79505115497291adc3a8a459c4cc","type":"GO_TERM","name":"negative regulation of aggregation involved in sorocarp development","canonical_id":"go:GO:0110014","description":"\"Any process that decreases the frequency, rate or extent of aggregation involved in sorocarp development. Aggregation involved in sorocarp development is the process whose specific outcome is the progression of the aggregate over time, from its formation to the point when a slug is formed. Aggregate development begins in response to starvation and continues by the chemoattractant-mediated movement of cells toward each other. The aggregate is a multicellular structure that gives rise to the slug.\" [GOC:rjd, PMID:28257811]","metadata":null},{"id":"4aacc9019ae24648a9f72b97740c7f00","type":"GO_TERM","name":"negative regulation of aggrephagy","canonical_id":"go:GO:1905336","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of aggrephagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:25686248]","metadata":null},{"id":"19f060eaf99a4346b4cd7d7f5ce42d89","type":"GO_TERM","name":"negative regulation of alcohol biosynthetic process","canonical_id":"go:GO:1902931","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of alcohol biosynthetic process.\" [GO_REF:0000058, GOC:mengo_curators, GOC:TermGenie, PMID:23332010]","metadata":null},{"id":"1b3710a6c2b34262a934b930d59cd396","type":"GO_TERM","name":"negative regulation of alcohol catabolic process","canonical_id":"go:GO:1900420","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of  alcohol catabolic process within a cell.\" [GOC:TermGenie]","metadata":null},{"id":"81c26e43dc534022b29cc05344298c8d","type":"GO_TERM","name":"negative regulation of aldosterone biosynthetic process","canonical_id":"go:GO:0032348","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone.\" [GOC:mah]","metadata":null},{"id":"06d5d7f76f034c5badf0678abf3f76cc","type":"GO_TERM","name":"negative regulation of aldosterone secretion","canonical_id":"go:GO:2000859","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of aldosterone secretion.\" [GOC:sl]","metadata":null},{"id":"ce1fae4e39a7427988e3f3e6e32deea7","type":"GO_TERM","name":"negative regulation of alkane biosynthetic process","canonical_id":"go:GO:1901578","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of alkane biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"ab14bd402e2a48539500aa86966c6794","type":"GO_TERM","name":"negative regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity","canonical_id":"go:GO:0062003","description":"\"Any process that decreases the frequency or rate of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity.\" [PMID:23407971]","metadata":null},{"id":"c765cd54afef44d4a85981a1ec7c4d74","type":"GO_TERM","name":"negative regulation of alpha-beta T cell activation","canonical_id":"go:GO:0046636","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of alpha-beta T cell activation.\" [GOC:ai]","metadata":null},{"id":"9e65a9d782a945c3ae180078e565fd6c","type":"GO_TERM","name":"negative regulation of alpha-beta T cell differentiation","canonical_id":"go:GO:0046639","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of alpha-beta T cell differentiation.\" [GOC:ai]","metadata":null},{"id":"2c379dbb1bd14ede8c908b1026003d2d","type":"GO_TERM","name":"negative regulation of alpha-beta T cell proliferation","canonical_id":"go:GO:0046642","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of alpha-beta T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"6182b3508c8e4cecb60da675c1def6fe","type":"GO_TERM","name":"negative regulation of amacrine cell differentiation","canonical_id":"go:GO:1902870","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amacrine cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"b9809565e31142cd90fb8cf22972c705","type":"GO_TERM","name":"negative regulation of amine catabolic process","canonical_id":"go:GO:0033242","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of amines.\" [GOC:mah]","metadata":null},{"id":"250eb280f2a9468c94c13f84bb268837","type":"GO_TERM","name":"negative regulation of amine metabolic process","canonical_id":"go:GO:0033239","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving amines.\" [GOC:mah]","metadata":null},{"id":"32965febd32a4267bbdaa68c852395f4","type":"GO_TERM","name":"negative regulation of amine transport","canonical_id":"go:GO:0051953","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"37ec33a7ede84477a3aafa14dc4ff4fd","type":"GO_TERM","name":"negative regulation of amino acid biosynthetic process","canonical_id":"go:GO:2000283","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an amino acid biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"a0a2b0c15a434a1e847638a55775b1d9","type":"GO_TERM","name":"negative regulation of amino acid metabolic process","canonical_id":"go:GO:0045763","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving amino acid.\" [GOC:curators]","metadata":null},{"id":"35ac587b95a149ed9aa2725881b22865","type":"GO_TERM","name":"negative regulation of amino acid transport","canonical_id":"go:GO:0051956","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"4b095d0ef1e04999b9807287b0df58ea","type":"GO_TERM","name":"negative regulation of ammonia assimilation cycle","canonical_id":"go:GO:2001249","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ammonia assimilation cycle.\" [GOC:BHF]","metadata":null},{"id":"5c6687f0037a4201b98fe0f7b7a02eab","type":"GO_TERM","name":"negative regulation of amniotic stem cell differentiation","canonical_id":"go:GO:2000798","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amniotic stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"175718bd2d804afe8feab6988ac1eaf7","type":"GO_TERM","name":"negative regulation of amoeboid sperm motility","canonical_id":"go:GO:1905417","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amoeboid sperm motility.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie]","metadata":null},{"id":"6a0589eb75df46bcbd64bf3d5513fbcb","type":"GO_TERM","name":"negative regulation of amyloid fibril formation","canonical_id":"go:GO:1905907","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amyloid fibril formation.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:23106396]","metadata":null},{"id":"559c2992a3314091b43a385c3a5f2298","type":"GO_TERM","name":"negative regulation of amyloid precursor protein biosynthetic process","canonical_id":"go:GO:0042985","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of amyloid precursor protein (APP), the precursor of amyloid-beta.\" [GOC:curators]","metadata":null},{"id":"a13e11da5c4e41f28a0e1ca8725f476f","type":"GO_TERM","name":"negative regulation of amyloid precursor protein catabolic process","canonical_id":"go:GO:1902992","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amyloid precursor protein catabolic process.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:24499793]","metadata":null},{"id":"d2cbce4c64d246f6a2534840e1596987","type":"GO_TERM","name":"negative regulation of amyloid-beta clearance","canonical_id":"go:GO:1900222","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amyloid-beta clearance.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"90c21a688da7402ab24ec6b0346ea37b","type":"GO_TERM","name":"negative regulation of amyloid-beta formation","canonical_id":"go:GO:1902430","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amyloid-beta formation.\" [GOC:hjd, GOC:TermGenie, PMID:22992957]","metadata":null},{"id":"dd06d5ba079f4a548508e78b11cd22d0","type":"GO_TERM","name":"negative regulation of amylopectin catabolic process","canonical_id":"go:GO:2000946","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of amylopectin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"353d61bcac9b4bbdb718d38eb3764f96","type":"GO_TERM","name":"negative regulation of anaphase-promoting complex-dependent catabolic process","canonical_id":"go:GO:1905785","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anaphase-promoting complex-dependent catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:10921876]","metadata":null},{"id":"674a1bd85cba49e58ec4d766d033d9ae","type":"GO_TERM","name":"negative regulation of androgen biosynthetic process","canonical_id":"go:GO:2000180","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of androgen biosynthetic process.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"bca22ae2b32c4663b1c615dbdb50efcf","type":"GO_TERM","name":"negative regulation of androgen receptor signaling pathway","canonical_id":"go:GO:0060766","description":"\"Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway.\" [GOC:dph]","metadata":null},{"id":"fba7410a6f284431876991c525aa24b0","type":"GO_TERM","name":"negative regulation of androgen secretion","canonical_id":"go:GO:2000835","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of androgen secretion.\" [GOC:sl]","metadata":null},{"id":"d08bc9a42b7f4b9da29d5d663c2d4a89","type":"GO_TERM","name":"negative regulation of androst-4-ene-3,17-dione biosynthetic process","canonical_id":"go:GO:1903455","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of androst-4-ene-3,17-dione biosynthetic process.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:24399684]","metadata":null},{"id":"4f72e48765714233bb4dc2ef7b17dd33","type":"GO_TERM","name":"negative regulation of androstenedione secretion","canonical_id":"go:GO:2000838","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of androstenedione secretion.\" [GOC:sl]","metadata":null},{"id":"b6698207571940b2b7c2b9be63f5c6e7","type":"GO_TERM","name":"negative regulation of angiogenesis","canonical_id":"go:GO:0016525","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of angiogenesis.\" [GOC:curators]","metadata":null},{"id":"76ec6fdb7e3643b699316d4c04519b96","type":"GO_TERM","name":"negative regulation of angiotensin-activated signaling pathway","canonical_id":"go:GO:0110062","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the angiotensin-activated signaling pathway.\" [GOC:lf, PMID:28784619]","metadata":null},{"id":"02b4497d6f0c413c8995ee9b3702cdb7","type":"GO_TERM","name":"negative regulation of animal organ morphogenesis","canonical_id":"go:GO:0110111","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of animal organ morphogenesis.\" [GOC:kmv]","metadata":null},{"id":"908783d67fbe4e1a9afc848816b1d51a","type":"GO_TERM","name":"negative regulation of anion channel activity","canonical_id":"go:GO:0010360","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the anion channel activity.\" [PMID:17319842]","metadata":null},{"id":"4749fb65f7fb42c5b4168905449ae8ea","type":"GO_TERM","name":"negative regulation of anion transmembrane transport","canonical_id":"go:GO:1903960","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anion transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"5d18a16edc8742febec3faa364fb6578","type":"GO_TERM","name":"negative regulation of anoikis","canonical_id":"go:GO:2000811","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anoikis.\" [GOC:obol]","metadata":null},{"id":"26bfb4a011f548cc94b2842b0f3fd0fc","type":"GO_TERM","name":"negative regulation of anterior head development","canonical_id":"go:GO:2000743","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anterior head development.\" [GOC:obol]","metadata":null},{"id":"8eee9934a816459f8cf5aaae73c08aff","type":"GO_TERM","name":"negative regulation of anterior neural cell fate commitment of the neural plate","canonical_id":"go:GO:0022001","description":"\"Any process that stops, prevents or reduces the frequency or rate at which a cell adopts an anterior neural cell fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"50c076f969a94623a543c745535df73e","type":"GO_TERM","name":"negative regulation of anterior neural cell fate commitment of the neural plate by fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0022003","description":"\"The series of molecular signals that stops, prevents or reduces the frequency or rate at which cell adopts an anterior neural cell fate, generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"29baf2d64e6d4bb0b4b1b0adb2279770","type":"GO_TERM","name":"negative regulation of anterior/posterior axon guidance","canonical_id":"go:GO:1905487","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anterior/posterior axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"24d59930b6a5459ca7de976aa4562ccc","type":"GO_TERM","name":"negative regulation of anterograde axonal transport of mitochondrion","canonical_id":"go:GO:0061882","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of mitochondria along microtubules in axons away from the cell body and towards the presynapse.\" [PMID:24302729]","metadata":null},{"id":"87d5c66f27394341a740fa843c58183e","type":"GO_TERM","name":"negative regulation of anterograde dense core granule transport","canonical_id":"go:GO:1901952","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anterograde dense core granule transport.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"286c6bdf6a304420b36f754451d41de1","type":"GO_TERM","name":"negative regulation of anterograde synaptic vesicle transport","canonical_id":"go:GO:1903743","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anterograde synaptic vesicle transport.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25329901]","metadata":null},{"id":"0a4afeb7e1384930bd19422935e16cea","type":"GO_TERM","name":"negative regulation of anther dehiscence","canonical_id":"go:GO:0120196","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of anther dehiscence.\" [GOC:lr, PMID:30911018]","metadata":null},{"id":"7e1fa7924c8744149f069056742bdf64","type":"GO_TERM","name":"negative regulation of anthocyanin biosynthetic process","canonical_id":"go:GO:0031541","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of anthocyanins.\" [GOC:mah]","metadata":null},{"id":"0fdcee5022e74d86b294247e57bfa1ff","type":"GO_TERM","name":"negative regulation of anthocyanin catabolic process","canonical_id":"go:GO:1900001","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anthocyanin catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"7ca9cf3ba55a42e38465e9ed54af2f5c","type":"GO_TERM","name":"negative regulation of anthocyanin metabolic process","canonical_id":"go:GO:0031538","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of chemical reactions and pathways involving anthocyanins.\" [GOC:mah]","metadata":null},{"id":"572632fdeb434d949260255c1a0dd3ab","type":"GO_TERM","name":"negative regulation of anti-Mullerian hormone signaling pathway","canonical_id":"go:GO:1902613","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anti-Mullerian hormone signaling pathway.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:23624077]","metadata":null},{"id":"718d93ac50e44fceb53eba08e346141d","type":"GO_TERM","name":"negative regulation of antibacterial peptide biosynthetic process","canonical_id":"go:GO:0002809","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antibacterial peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"bf32c4d684e642a692d367153b3227da","type":"GO_TERM","name":"negative regulation of antibacterial peptide production","canonical_id":"go:GO:0002787","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antibacterial peptide production.\" [GOC:add]","metadata":null},{"id":"33192ad8f9344350803f9e5e8e94783d","type":"GO_TERM","name":"negative regulation of antibacterial peptide secretion","canonical_id":"go:GO:0002798","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antibacterial peptide secretion.\" [GOC:add]","metadata":null},{"id":"3c0e0b729de942f39c8d5e287277afc3","type":"GO_TERM","name":"negative regulation of antibody-dependent cellular cytotoxicity","canonical_id":"go:GO:0001814","description":"\"Any process that stops, prevents, or reduces the rate of antibody-dependent cellular cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f8df74c176814ca0a45c0c2a48d4c19f","type":"GO_TERM","name":"negative regulation of antifungal innate immune response","canonical_id":"go:GO:1905035","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an antifungal innate immune response.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:22470487]","metadata":null},{"id":"c4c3ea6987f64bb3a6aff1bf9ebfacad","type":"GO_TERM","name":"negative regulation of antifungal peptide biosynthetic process","canonical_id":"go:GO:0002811","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antifungal peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"52e817d00cad44d48b01261d7c1e5a1c","type":"GO_TERM","name":"negative regulation of antifungal peptide production","canonical_id":"go:GO:0002789","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antifungal peptide production.\" [GOC:add]","metadata":null},{"id":"2ba0feca23e0473ea0511f69a71a03c2","type":"GO_TERM","name":"negative regulation of antifungal peptide secretion","canonical_id":"go:GO:0002801","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antifungal peptide secretion.\" [GOC:add]","metadata":null},{"id":"68b31513c1874e2788c47c0d96cd68ec","type":"GO_TERM","name":"negative regulation of antigen processing and presentation","canonical_id":"go:GO:0002578","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"5cb86da22324464b903ca6b77f6a4045","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I","canonical_id":"go:GO:1904283","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of antigen processing and presentation of endogenous peptide antigen via MHC class I.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24643698]","metadata":null},{"id":"2716b001cfe741478543f653958a4382","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of lipid antigen via MHC class Ib","canonical_id":"go:GO:0002599","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of lipid antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"e7908d9647354a3c8e630fdb0a362adc","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of peptide antigen","canonical_id":"go:GO:0002584","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of peptide antigen.\" [GOC:add]","metadata":null},{"id":"2d6b1a68fba940f9a540cc633d66e449","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of peptide antigen via MHC class I","canonical_id":"go:GO:0002590","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class I.\" [GOC:add]","metadata":null},{"id":"d1e8931535a8437a99e79aef45cad157","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of peptide antigen via MHC class II","canonical_id":"go:GO:0002587","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class II.\" [GOC:add]","metadata":null},{"id":"baf8d2b165fa4beb9c28d5c0b51bfa78","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of peptide antigen via MHC class Ib","canonical_id":"go:GO:0002596","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"59ae9665be37419b9f78cce478f5a9c0","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002581","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of antigen (peptide or polysaccharide) via MHC class II.\" [GOC:add]","metadata":null},{"id":"5bb2d835c9714496944d0c78b70b6fde","type":"GO_TERM","name":"negative regulation of antigen processing and presentation of polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002602","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of polysaccharide antigen via MHC class II.\" [GOC:add]","metadata":null},{"id":"be81ea3b4a564113bee52b529b5247a6","type":"GO_TERM","name":"negative regulation of antigen processing and presentation via MHC class Ib","canonical_id":"go:GO:0002593","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"a229ef27ed47439f8aa95d5b5bb00b0c","type":"GO_TERM","name":"negative regulation of antigen receptor-mediated signaling pathway","canonical_id":"go:GO:0050858","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B- or T cell.\" [GOC:ai]","metadata":null},{"id":"71ebf10c6e694063b8de1421398eb0a3","type":"GO_TERM","name":"negative regulation of antimicrobial humoral response","canonical_id":"go:GO:0008348","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an antimicrobial humoral response.\" [GOC:curators]","metadata":null},{"id":"cee9374499684d9b89f309c475e2f2ba","type":"GO_TERM","name":"negative regulation of antimicrobial peptide biosynthetic process","canonical_id":"go:GO:0002806","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antimicrobial peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"77aad404e92e42c4851d3e71ba27b328","type":"GO_TERM","name":"negative regulation of antimicrobial peptide production","canonical_id":"go:GO:0002785","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antimicrobial peptide production.\" [GOC:add]","metadata":null},{"id":"2c8d3e346f694bffae254fd68a1bb065","type":"GO_TERM","name":"negative regulation of antimicrobial peptide secretion","canonical_id":"go:GO:0002795","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of antimicrobial peptide secretion.\" [GOC:add]","metadata":null},{"id":"7b6f5d5025514798aae56f69724f7550","type":"GO_TERM","name":"negative regulation of antipodal cell differentiation","canonical_id":"go:GO:0045689","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of antipodal cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"dc241c6c63f94d0193387d7959c40ce7","type":"GO_TERM","name":"negative regulation of antisense RNA transcription","canonical_id":"go:GO:0060195","description":"\"Any process that decreases the frequency, rate or extent of the synthesis of antisense RNA, an RNA molecule complementary in sequence to another RNA or DNA molecule, which, by binding the latter, acts to inhibit its function and/or completion of synthesis, on a template of DNA.\" [GOC:dph, GOC:tb, PMID:18075583]","metadata":null},{"id":"178c496984624e248919699288dd573e","type":"GO_TERM","name":"negative regulation of aorta morphogenesis","canonical_id":"go:GO:1903848","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of aorta morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"e3b91f67e7a449b2886208b42667730c","type":"GO_TERM","name":"negative regulation of aortic smooth muscle cell differentiation","canonical_id":"go:GO:1904830","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of aortic smooth muscle cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22034194]","metadata":null},{"id":"e99979d876234275b6cb1bee5ae3ed32","type":"GO_TERM","name":"negative regulation of apical ectodermal ridge formation","canonical_id":"go:GO:1905141","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apical ectodermal ridge formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:18359901]","metadata":null},{"id":"7451bdd1472b42508cadfc450713e917","type":"GO_TERM","name":"negative regulation of aplanospore formation","canonical_id":"go:GO:0075292","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of aplanospore formation, a process in which a nonmotile, asexual spore is formed within a cell in certain algae and fungi (commonly in the Phycomycetes), the wall of aplanospore is distinct from that of the parent cell.\" [GOC:pamgo_curators]","metadata":null},{"id":"75431e9346ba4c4dbbab120d788d2253","type":"GO_TERM","name":"negative regulation of apolipoprotein A-I-mediated signaling pathway","canonical_id":"go:GO:1905095","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apolipoprotein A-I-mediated signaling pathway.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25084135]","metadata":null},{"id":"58c397b68a4e42cb952297495e88f7b7","type":"GO_TERM","name":"negative regulation of apoptosome assembly","canonical_id":"go:GO:1905101","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptosome assembly.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:26265044]","metadata":null},{"id":"27c610a5ecdd4ed9bd528995f0349721","type":"GO_TERM","name":"negative regulation of apoptotic DNA fragmentation","canonical_id":"go:GO:1902511","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic DNA fragmentation.\" [GOC:hjd, GOC:TermGenie, PMID:15572351]","metadata":null},{"id":"864b15905405488d88b2e60bc1184668","type":"GO_TERM","name":"negative regulation of apoptotic cell clearance","canonical_id":"go:GO:2000426","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic cell clearance.\" [GOC:obol]","metadata":null},{"id":"d1dccc6cdb3e4602830aa1282f253ca8","type":"GO_TERM","name":"negative regulation of apoptotic process","canonical_id":"go:GO:0043066","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.\" [GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"c737751abfb54fa99c482b38b05a3aa5","type":"GO_TERM","name":"negative regulation of apoptotic process in bone marrow cell","canonical_id":"go:GO:0071866","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the occurrence or rate of cell death by apoptotic process in the bone marrow.\" [GOC:mah, GOC:mtg_apoptosis, GOC:yaf, PMID:17063141]","metadata":null},{"id":"216763576fb44361a7681415ca35b4be","type":"GO_TERM","name":"negative regulation of apoptotic process involved in development","canonical_id":"go:GO:1904746","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic process involved in development.\" [GO_REF:0000058, GOC:TermGenie, PMID:22801495]","metadata":null},{"id":"e2dea249af1344cab5b67a818e695b72","type":"GO_TERM","name":"negative regulation of apoptotic process involved in morphogenesis","canonical_id":"go:GO:1902338","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic process involved in morphogenesis.\" [GOC:sart, GOC:TermGenie, PMID:12202035]","metadata":null},{"id":"e16c9ab6cd724ae8b7d70392d33af9e0","type":"GO_TERM","name":"negative regulation of apoptotic process involved in outflow tract morphogenesis","canonical_id":"go:GO:1902257","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic process involved in outflow tract morphogenesis.\" [GOC:dph, GOC:mtg_apoptosis, GOC:TermGenie, PMID:16839542]","metadata":null},{"id":"fd87126c7a5a4ab1ba3571007cd414fc","type":"GO_TERM","name":"negative regulation of apoptotic signaling pathway","canonical_id":"go:GO:2001234","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"fef8b5a253b145eca9afea9aa3efb4c0","type":"GO_TERM","name":"negative regulation of appetite","canonical_id":"go:GO:0032099","description":"\"Any process that reduces appetite.\" [GOC:add]","metadata":null},{"id":"ab2e2c1abb4e471ab108baad3f44c3c2","type":"GO_TERM","name":"negative regulation of appetite by leptin-mediated signaling pathway","canonical_id":"go:GO:0038108","description":"\"The series of molecular signals initiated by leptin binding to its receptor on the surface of a cell, which reduces appetite, the desire or physical craving for food.\" [GOC:BHF, GOC:vk, PMID:19150989]","metadata":null},{"id":"5627638782fc4a3bbc6a5f7593eaa042","type":"GO_TERM","name":"negative regulation of appressorium formation","canonical_id":"go:GO:0075019","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of symbiont appressorium formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"422ff1b6f9e141dab61e1e109aaceb3e","type":"GO_TERM","name":"negative regulation of arabinoxylan-containing compound catabolic process","canonical_id":"go:GO:2000922","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of arabinoxylan-containing compound catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"4e191dd28ee84e12bcf331de5c865083","type":"GO_TERM","name":"negative regulation of arachidonate secretion","canonical_id":"go:GO:1900139","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of arachidonic acid secretion.\" [GOC:TermGenie]","metadata":null},{"id":"c67579a8c3c44635b1bd9fae12d644af","type":"GO_TERM","name":"negative regulation of arginine catabolic process","canonical_id":"go:GO:1900082","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of arginine catabolic process.\" [GOC:dgf, GOC:TermGenie]","metadata":null},{"id":"b1beb370461e4d80b5ca5acbb9c18ea0","type":"GO_TERM","name":"negative regulation of artery morphogenesis","canonical_id":"go:GO:1905652","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of artery morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:27389411]","metadata":null},{"id":"949569582d8b472fbf534e25c18c74a6","type":"GO_TERM","name":"negative regulation of artery smooth muscle contraction","canonical_id":"go:GO:1905655","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of artery smooth muscle contraction.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:27389411]","metadata":null},{"id":"a86e47c937df4ab1a5bbf7a920f997b2","type":"GO_TERM","name":"negative regulation of arugosin biosynthetic process","canonical_id":"go:GO:1900627","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of arugosin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"aa3ccf5d961246fdb7446c30727fffe7","type":"GO_TERM","name":"negative regulation of ascospore formation","canonical_id":"go:GO:0075297","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ascospore formation, a process in which a sexual spore, named ascospore, from Ascomycete fungi was produced inside an ascus.\" [GOC:pamgo_curators]","metadata":null},{"id":"00bb5c81ce834bcbba6afe2cb08ea82f","type":"GO_TERM","name":"negative regulation of ascus development","canonical_id":"go:GO:0075320","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ascus development, a saclike structure produced by fungi of the phylum Ascomycota (sac fungi) in which sexually produced spores (ascospores), usually four or eight in number, are formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"7eda85ef004744d0a8a85d4af1d605ee","type":"GO_TERM","name":"negative regulation of asexual reproduction","canonical_id":"go:GO:1903665","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of asexual reproduction.\" [GO_REF:0000058, GOC:TermGenie, PMID:24390142]","metadata":null},{"id":"c9624cd8cba14e13b259b0bf0fa3d73a","type":"GO_TERM","name":"negative regulation of asexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043944","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the formation of a cellular spore derived from the products of mitosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"4077738a0b5f49358f33dec0c287a0e5","type":"GO_TERM","name":"negative regulation of aspartate secretion","canonical_id":"go:GO:1904449","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of aspartate secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:2342602]","metadata":null},{"id":"0b9e467f9de14b4c8c891628c0b9a638","type":"GO_TERM","name":"negative regulation of asperfuranone biosynthetic process","canonical_id":"go:GO:1900638","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of asperfuranone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"18d4e210aa594ac4bf6437f4c753a0ac","type":"GO_TERM","name":"negative regulation of asperthecin biosynthetic process","canonical_id":"go:GO:1900380","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of asperthecin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6ce16078cf0341ea91407fabbf8b61b8","type":"GO_TERM","name":"negative regulation of astral microtubule depolymerization","canonical_id":"go:GO:0032932","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the depolymerization of astral microtubules.\" [GOC:mah]","metadata":null},{"id":"17a81e8487a14cc8a42d5d70cd888e0a","type":"GO_TERM","name":"negative regulation of astrocyte activation","canonical_id":"go:GO:0061889","description":"\"Any process that decreases the frequency, rate or extent of astrocyte activation.\" [GOC:aruk, GOC:bc, PMID:20005821]","metadata":null},{"id":"7b889a6529044ffea72de2d1eb67475a","type":"GO_TERM","name":"negative regulation of astrocyte chemotaxis","canonical_id":"go:GO:2000459","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of astrocyte chemotaxis.\" [GOC:obol]","metadata":null},{"id":"04a9f769d8304e4e9facf690f1681414","type":"GO_TERM","name":"negative regulation of astrocyte differentiation","canonical_id":"go:GO:0048712","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of astrocyte differentiation.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"6b04da372e174125bb77883420946b8b","type":"GO_TERM","name":"negative regulation of asymmetric cell division","canonical_id":"go:GO:0045769","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of asymmetric cell division.\" [GOC:curators]","metadata":null},{"id":"0cc4bc5a814b456e983ad0c93b4a9561","type":"GO_TERM","name":"negative regulation of atrial cardiac muscle cell action potential","canonical_id":"go:GO:1903948","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of atrial cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:25281747]","metadata":null},{"id":"be2c028a8f1044338d1decf8f7d53c6d","type":"GO_TERM","name":"negative regulation of atrichoblast fate specification","canonical_id":"go:GO:0010060","description":"\"Any process that suppresses atrichoblast fate specification.\" [GOC:tb]","metadata":null},{"id":"0b9cf9e3b960409b8e5ecb779cc258fa","type":"GO_TERM","name":"negative regulation of attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:1902424","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of attachment of spindle microtubules to kinetochore involved in mitotic sister chromatid segregation.\" [GOC:TermGenie, GOC:vw, PMID:22065639]","metadata":null},{"id":"f3b70ac4b49a437fa99d569bd9b49c14","type":"GO_TERM","name":"negative regulation of attachment of spindle microtubules to kinetochore","canonical_id":"go:GO:0051986","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the attachment of spindle microtubules to the kinetochore.\" [GOC:ai]","metadata":null},{"id":"a4c5db10473946188c993f64c3897e0c","type":"GO_TERM","name":"negative regulation of auditory receptor cell fate specification","canonical_id":"go:GO:0009999","description":"\"Any process that restricts, stops or prevents a cell from specifying into an auditory hair cell.\" [GOC:curators]","metadata":null},{"id":"eefbab5d21f047c2805679ae72ed0a64","type":"GO_TERM","name":"negative regulation of austinol biosynthetic process","canonical_id":"go:GO:1900641","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of austinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"51f21556c3204e2ca5c87bda7e8c11ec","type":"GO_TERM","name":"negative regulation of autophagic cell death","canonical_id":"go:GO:1904093","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of autophagic cell death.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25736836]","metadata":null},{"id":"1591498cbd67431b8bb33d1ad76a7b74","type":"GO_TERM","name":"negative regulation of autophagosome assembly","canonical_id":"go:GO:1902902","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of autophagosome assembly.\" [GO_REF:0000058, GOC:als, GOC:autophagy, GOC:TermGenie, PMID:21975012]","metadata":null},{"id":"e5cb83c379d742f59170eff72cb2e67d","type":"GO_TERM","name":"negative regulation of autophagosome maturation","canonical_id":"go:GO:1901097","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of autophagosome maturation.\" [GOC:autophagy, GOC:TermGenie, PMID:10436019, PMID:21383079]","metadata":null},{"id":"ce33b0ebe62f477aa393a86413d2e224","type":"GO_TERM","name":"negative regulation of autophagosome size","canonical_id":"go:GO:0045771","description":"\"Any process that reduces autophagosome size.\" [GOC:autophagy, GOC:curators]","metadata":null},{"id":"e9e1073f1aa34ac5a30aa10ac4dc59e9","type":"GO_TERM","name":"negative regulation of autophagy","canonical_id":"go:GO:0010507","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9eb4eb54cb13464ba7372145c50156d6","type":"GO_TERM","name":"negative regulation of autophagy of mitochondrion","canonical_id":"go:GO:1903147","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrion degradation by autophagy.\" [GO_REF:0000058, GOC:autophagy, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24600391]","metadata":null},{"id":"2fa6f2b0ee1c440bbb01d51acfccc75e","type":"GO_TERM","name":"negative regulation of auxin biosynthetic process","canonical_id":"go:GO:1901997","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of auxin biosynthetic process.\" [GOC:TermGenie, PMID:23377040]","metadata":null},{"id":"97477d86e79f4df6bb775c756e6e0fce","type":"GO_TERM","name":"negative regulation of auxin mediated signaling pathway","canonical_id":"go:GO:0010930","description":"\"Any process that decreases the rate, frequency or extent of auxin mediated signaling pathway. Auxin mediated signaling pathway is the series of molecular signals generated in response to detection of auxin.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"95f4de61f4864d4db71446c500bb6aca","type":"GO_TERM","name":"negative regulation of auxin metabolic process","canonical_id":"go:GO:0090356","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving auxins, plant hormones that regulate aspects of plant growth.\" [GOC:tb]","metadata":null},{"id":"664103233774428da7306a48c79b942c","type":"GO_TERM","name":"negative regulation of axial mesodermal cell fate determination","canonical_id":"go:GO:0048325","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axial mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"c59b1241a684485c95842a7d2fe63deb","type":"GO_TERM","name":"negative regulation of axial mesodermal cell fate specification","canonical_id":"go:GO:0048329","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axial mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"3ae83ed50a70465e85ebcd1d32719d29","type":"GO_TERM","name":"negative regulation of axo-dendritic protein transport","canonical_id":"go:GO:1905127","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of axo-dendritic protein transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20694152]","metadata":null},{"id":"132ef6b6c48f41398cd27cfef07c25a0","type":"GO_TERM","name":"negative regulation of axon extension","canonical_id":"go:GO:0030517","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axon outgrowth.\" [GOC:mah]","metadata":null},{"id":"74b4d2acb0f647ed91ed05387a23c8ff","type":"GO_TERM","name":"negative regulation of axon extension involved in axon guidance","canonical_id":"go:GO:0048843","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axon extension involved in axon guidance.\" [GOC:devbiol]","metadata":null},{"id":"a1cd1a8dc713405d8e0bd42e3bfa3c8c","type":"GO_TERM","name":"negative regulation of axon extension involved in regeneration","canonical_id":"go:GO:0048692","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axon extension involved in regeneration.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"c91493b86eb64a6385717133039532d7","type":"GO_TERM","name":"negative regulation of axon guidance","canonical_id":"go:GO:1902668","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of axon guidance.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:23006775]","metadata":null},{"id":"cdc9287bc8954514afcb46a46f6f0d3e","type":"GO_TERM","name":"negative regulation of axon regeneration","canonical_id":"go:GO:0048681","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axon regeneration.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"05c4b98c72844841a06663c32ea6b711","type":"GO_TERM","name":"negative regulation of axonemal microtubule depolymerization","canonical_id":"go:GO:0007027","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the depolymerization of the specialized microtubules of the axoneme.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"f95f8960a806480c9d476807fe864abf","type":"GO_TERM","name":"negative regulation of axonogenesis","canonical_id":"go:GO:0050771","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of axonogenesis.\" [GOC:ai]","metadata":null},{"id":"c9dec54b7ffc42d0b02fb4169360b3e3","type":"GO_TERM","name":"negative regulation of backward locomotion","canonical_id":"go:GO:1905851","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of backward locomotion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11717360]","metadata":null},{"id":"6ee878237e524bacb5f61de607628342","type":"GO_TERM","name":"negative regulation of bacterial-type flagellum assembly","canonical_id":"go:GO:1902209","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bacterial-type flagellum assembly.\" [GOC:jl, GOC:TermGenie]","metadata":null},{"id":"0d5be1819bc848afbcc87139cee550a5","type":"GO_TERM","name":"negative regulation of bacterial-type flagellum-dependent cell motility","canonical_id":"go:GO:1902201","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bacterial-type flagellum-dependent cell motility.\" [GOC:cilia, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"1524ad05b392440ca96109a336711282","type":"GO_TERM","name":"negative regulation of barbed-end actin filament capping","canonical_id":"go:GO:2000813","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of barbed-end actin filament capping.\" [GOC:BHF]","metadata":null},{"id":"83cafd9cd9ce4154bdc61a9c40892a2e","type":"GO_TERM","name":"negative regulation of base-excision repair","canonical_id":"go:GO:1905052","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of base-excision repair.\" [GO_REF:0000058, GOC:ah, GOC:TermGenie, PMID:18973764]","metadata":null},{"id":"cfa9c840a51a4701bbe185b5bdd387c6","type":"GO_TERM","name":"negative regulation of basidiospore formation","canonical_id":"go:GO:0075304","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of basidiospore formation, a process in which a sexually produced fungal spore is formed on a basidium in the fungi basidiomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"22d73198af5d42b682cb1eab8188a07a","type":"GO_TERM","name":"negative regulation of basidium development","canonical_id":"go:GO:0075316","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of basidium development, a process that leads to the formation of basidium, a small, specialized club-shaped structure typically bearing four basidiospores at the tips of minute projections. The basidium is unique to basidiomycetes and distinguishes them from other kinds of fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"a99f2cf7d9dc430a8fdd49e850983e54","type":"GO_TERM","name":"negative regulation of basophil degranulation","canonical_id":"go:GO:1903582","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of basophil degranulation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10880837]","metadata":null},{"id":"f6aa8b3acf16450db7f2d46a515b4cfb","type":"GO_TERM","name":"negative regulation of basophil differentiation","canonical_id":"go:GO:0045641","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of basophil differentiation.\" [GOC:curators]","metadata":null},{"id":"98852aed223b4bd487314c098c91ab32","type":"GO_TERM","name":"negative regulation of behavior","canonical_id":"go:GO:0048521","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of behavior, the internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or external stimuli.\" [GOC:jid, GOC:pr]","metadata":null},{"id":"0a2585e9b3de4891a2ad5d1e409d1c9f","type":"GO_TERM","name":"negative regulation of behavioral fear response","canonical_id":"go:GO:2000986","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of behavioral fear response.\" [GOC:obol]","metadata":null},{"id":"02bc5f00854b485497e36c95a842fc3b","type":"GO_TERM","name":"negative regulation of beige fat cell differentiation","canonical_id":"go:GO:0160276","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of beige fat cell differentiation.\" [PMID:35978186]","metadata":null},{"id":"7730d641bc654255ba3bacc11f089a79","type":"GO_TERM","name":"negative regulation of beta 2 integrin biosynthetic process","canonical_id":"go:GO:0045774","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of beta 2 integrins.\" [GOC:curators]","metadata":null},{"id":"39c7e13f5f984602bb5c28e5c9a11787","type":"GO_TERM","name":"negative regulation of beta-catenin-TCF complex assembly","canonical_id":"go:GO:1904864","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of beta-catenin-TCF complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18936100]","metadata":null},{"id":"2785ecde2a924556bc2269c8763e6918","type":"GO_TERM","name":"negative regulation of beta-galactosidase activity","canonical_id":"go:GO:1903770","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of beta-galactosidase activity.\" [GO_REF:0000059, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:11927518]","metadata":null},{"id":"075c2368ba454883a32b8b581baa25aa","type":"GO_TERM","name":"negative regulation of bicellular tight junction assembly","canonical_id":"go:GO:1903347","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tight junction assembly.\" [GO_REF:0000058, GOC:jz, GOC:TermGenie, PMID:25050009]","metadata":null},{"id":"b0e73dc3cb0e4010964d10a159afb389","type":"GO_TERM","name":"negative regulation of bicoid mRNA localization","canonical_id":"go:GO:0045853","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the process in which bicoid mRNA is transported to, or maintained in, a specific location.\" [GOC:curators]","metadata":null},{"id":"53f20935358842a99eb00be6e354eb84","type":"GO_TERM","name":"negative regulation of bile acid biosynthetic process","canonical_id":"go:GO:0070858","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ecc57711e74142c885df0d129e603bcb","type":"GO_TERM","name":"negative regulation of bile acid secretion","canonical_id":"go:GO:0120190","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:22767443]","metadata":null},{"id":"b6729ac2d32142db8f931af8c487fe05","type":"GO_TERM","name":"negative regulation of binding","canonical_id":"go:GO:0051100","description":"\"Any process that stops or reduces the rate or extent of binding, the selective interaction of a molecule with one or more specific sites on another molecule.\" [GOC:ai]","metadata":null},{"id":"cadfac25a6544bcb888ffa66357c4795","type":"GO_TERM","name":"negative regulation of binding of sperm to zona pellucida","canonical_id":"go:GO:2000360","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of binding of sperm to the zona pellucida.\" [GOC:obol]","metadata":null},{"id":"d8e0ea52602f4a9caaf69b32e715fa19","type":"GO_TERM","name":"negative regulation of biological process","canonical_id":"go:GO:0048519","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule.\" [GOC:jid]","metadata":null},{"id":"f4f57f88b4d24385ad432fe9f955833f","type":"GO_TERM","name":"negative regulation of bioluminescence","canonical_id":"go:GO:1905086","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bioluminescence.\" [GO_REF:0000058, GOC:BHF, GOC:rph, GOC:TermGenie, PMID:10913092]","metadata":null},{"id":"19a67248df6b448fb86d6aaac3da5a5b","type":"GO_TERM","name":"negative regulation of biomineral tissue development","canonical_id":"go:GO:0070168","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds.\" [GOC:mah]","metadata":null},{"id":"d252f4c384424739a4d622935d25dd6d","type":"GO_TERM","name":"negative regulation of biosynthetic process","canonical_id":"go:GO:0009890","description":"\"Any process that stops, prevents, or reduces the rate of the chemical reactions and pathways resulting in the formation of substances.\" [GOC:curators]","metadata":null},{"id":"0511bd635f14486285c323acfcffb068","type":"GO_TERM","name":"negative regulation of biosynthetic process of antibacterial peptides active against Gram-negative bacteria","canonical_id":"go:GO:0002814","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of biosynthesis of antibacterial peptides active against Gram-negative bacteria.\" [GOC:add]","metadata":null},{"id":"edcaf9774bb54795bf2d0d8faff10599","type":"GO_TERM","name":"negative regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria","canonical_id":"go:GO:0002817","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of biosynthesis of antibacterial peptides active against Gram-positive bacteria.\" [GOC:add]","metadata":null},{"id":"e368d379c3314a67801de7454b559008","type":"GO_TERM","name":"negative regulation of bipolar cell growth","canonical_id":"go:GO:0051517","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of bipolar cell growth, polarized growth from both ends of a cell.\" [GOC:ai]","metadata":null},{"id":"5898319c2b904b51a9c41a78b7c892f8","type":"GO_TERM","name":"negative regulation of bleb assembly","canonical_id":"go:GO:1904171","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bleb assembly.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:25651887]","metadata":null},{"id":"02996fe3d3094c7da3af32cd9b739989","type":"GO_TERM","name":"negative regulation of blood circulation","canonical_id":"go:GO:1903523","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood circulation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:10659969]","metadata":null},{"id":"83d81c7a00784e3aa46ef8299900c155","type":"GO_TERM","name":"negative regulation of blood coagulation","canonical_id":"go:GO:0030195","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of blood coagulation.\" [GOC:mah]","metadata":null},{"id":"7d40f05be64441ac8c5a8440f3d643c1","type":"GO_TERM","name":"negative regulation of blood coagulation, common pathway","canonical_id":"go:GO:2000261","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood coagulation, common pathway.\" [GOC:mah]","metadata":null},{"id":"ab7163771e1c46479b8ac3453928dfbc","type":"GO_TERM","name":"negative regulation of blood coagulation, extrinsic pathway","canonical_id":"go:GO:2000264","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood coagulation, extrinsic pathway.\" [GOC:mah]","metadata":null},{"id":"6b3b399284e14c59b9bbc7f33cac4a63","type":"GO_TERM","name":"negative regulation of blood coagulation, intrinsic pathway","canonical_id":"go:GO:2000267","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood coagulation, intrinsic pathway.\" [GOC:mah]","metadata":null},{"id":"10390f5f84b7481a94748e6801bc7a8a","type":"GO_TERM","name":"negative regulation of blood microparticle formation","canonical_id":"go:GO:2000333","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood microparticle formation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"419e6de2ec864680a696b9c487a79a4f","type":"GO_TERM","name":"negative regulation of blood pressure","canonical_id":"go:GO:0045776","description":"\"Any process in which the force of blood traveling through the circulatory system is decreased.\" [GOC:curators, GOC:mtg_cardio]","metadata":null},{"id":"0d0d809ed65f436db5602331e625b214","type":"GO_TERM","name":"negative regulation of blood vessel branching","canonical_id":"go:GO:1905554","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood vessel branching.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23201774]","metadata":null},{"id":"b49f11434a7e4bb08e7cb7dd55434a63","type":"GO_TERM","name":"negative regulation of blood vessel endothelial cell differentiation","canonical_id":"go:GO:0110059","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of blood vessel endothelial cell differentiation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:23072816]","metadata":null},{"id":"8fe9d1d1e0b0497c8bdf1423f7a97848","type":"GO_TERM","name":"negative regulation of blood vessel endothelial cell migration","canonical_id":"go:GO:0043537","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the migration of the endothelial cells of blood vessels.\" [GOC:curators]","metadata":null},{"id":"f48b3c4ab9cb4b21867a11fc36b86418","type":"GO_TERM","name":"negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis","canonical_id":"go:GO:1903588","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of blood vessel endothelial cell proliferation involved in sprouting angiogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:23388056]","metadata":null},{"id":"f73add7c57f44fbb878cd8a3ae6fc0d3","type":"GO_TERM","name":"negative regulation of blood vessel morphogenesis","canonical_id":"go:GO:2000181","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of blood vessel morphogenesis.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"d80c0064fe93423d97978b564b2d07fc","type":"GO_TERM","name":"negative regulation of blood vessel remodeling","canonical_id":"go:GO:0060313","description":"\"Any process that decreases the rate, frequency or extent of blood vessel remodeling, the reorganization or renovation of existing blood vessels.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"54d402fa231e449cb6fbf837d9e74411","type":"GO_TERM","name":"negative regulation of blood-brain barrier permeability","canonical_id":"go:GO:1905604","description":"\"Any process that decreases blood-brain barrier permeability, the quality of the blood-brain barrier that allows for a controlled passage of substances (e.g. macromolecules, small molecules, ions) into and out of the brain.\" [GO_REF:0000058, GOC:als, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:22524708, PMID:30280653]","metadata":null},{"id":"5c65dfb220f749b88a65e49945124e99","type":"GO_TERM","name":"negative regulation of bone development","canonical_id":"go:GO:1903011","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bone development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:22510437]","metadata":null},{"id":"91009d21c6e4471480af78a9f6ae3494","type":"GO_TERM","name":"negative regulation of bone mineralization","canonical_id":"go:GO:0030502","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of bone mineralization.\" [GOC:curators]","metadata":null},{"id":"a4cff042d3c048269d72c888e207227a","type":"GO_TERM","name":"negative regulation of bone mineralization involved in bone maturation","canonical_id":"go:GO:1900158","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bone mineralization involved in bone maturation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"b44316f573e94a00a866c6bbec9f5f44","type":"GO_TERM","name":"negative regulation of bone remodeling","canonical_id":"go:GO:0046851","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of bone remodeling.\" [GOC:ai]","metadata":null},{"id":"fbd5a19c6fe04b3683c9a4f3487cb7c0","type":"GO_TERM","name":"negative regulation of bone resorption","canonical_id":"go:GO:0045779","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of bone resorption.\" [GOC:curators]","metadata":null},{"id":"f61f986dbd004f51b057245457fda703","type":"GO_TERM","name":"negative regulation of bone trabecula formation","canonical_id":"go:GO:1900155","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of bone trabecula formation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"3882dc30a7934080a308ce19feaa789d","type":"GO_TERM","name":"negative regulation of border follicle cell delamination","canonical_id":"go:GO:0030712","description":"\"Any process that decreases the frequency, rate or extent of border cell delamination.\" [PMID:10822261]","metadata":null},{"id":"06ff8d4295f240f79db7609ee4ea79a8","type":"GO_TERM","name":"negative regulation of border follicle cell migration","canonical_id":"go:GO:1903687","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of border follicle cell migration.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18394891]","metadata":null},{"id":"bf1cc01049504723a3210e0670d67d2e","type":"GO_TERM","name":"negative regulation of brain-derived neurotrophic factor receptor signaling pathway","canonical_id":"go:GO:0031549","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signaling via the brain-derived neurotrophic factor receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"122e5e8184b6413d992bd4ed6fd85b60","type":"GO_TERM","name":"negative regulation of branching involved in lung morphogenesis","canonical_id":"go:GO:0061048","description":"\"Any process that decreases the rate, frequency, or extent of the process in which a highly ordered sequence of patterning events generates the branched structures of the lung, consisting of reiterated combinations of bud outgrowth, elongation, and dichotomous subdivision of terminal units.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"c14dbb4412554e85ac8148c663791301","type":"GO_TERM","name":"negative regulation of branching involved in ureteric bud morphogenesis","canonical_id":"go:GO:0090191","description":"\"Any process that decreases the rate, frequency or extent of branching involved in ureteric bud morphogenesis, the process in which the branching structure of the ureteric bud is generated and organized. The ureteric bud is an epithelial tube that grows out from the metanephric duct. The bud elongates and branches to give rise to the ureter and kidney collecting tubules.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"d9754ea6220249838d2f5c2058055bdd","type":"GO_TERM","name":"negative regulation of branching morphogenesis of a nerve","canonical_id":"go:GO:2000173","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of branching morphogenesis of a nerve.\" [GOC:BHF]","metadata":null},{"id":"b736f70141484de680b558f51aa6d8bf","type":"GO_TERM","name":"negative regulation of branchiomeric skeletal muscle development","canonical_id":"go:GO:0014713","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of branchiomeric skeletal muscle development. Branchiomeric skeletal muscle development is the process whose specific outcome is the progression of the branchiomeric skeletal muscle over time, from its formation to the mature structure.\" [GOC:mtg_muscle]","metadata":null},{"id":"c8dfb0f1b42e42c7b00f01d7d8c395b9","type":"GO_TERM","name":"negative regulation of brassinosteroid biosynthetic process","canonical_id":"go:GO:0010423","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of brassinosteroids.\" [PMID:16857903]","metadata":null},{"id":"03e57d5f2ff9452f92502217ae80936f","type":"GO_TERM","name":"negative regulation of brassinosteroid mediated signaling pathway","canonical_id":"go:GO:1900458","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of brassinosteroid mediated signaling pathway.\" [GOC:TermGenie, PMID:21855796]","metadata":null},{"id":"59eda21622e249599e750906b8e7a0d2","type":"GO_TERM","name":"negative regulation of brood size","canonical_id":"go:GO:0090728","description":"\"Any process that decreases brood size. Brood size is the number of progeny that survive embryogenesis and are cared for at one time.\" [GOC:rz]","metadata":null},{"id":"1fd50f0f57594bcb9a3c5bd198a51b39","type":"GO_TERM","name":"negative regulation of brown fat cell differentiation","canonical_id":"go:GO:1903444","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of brown fat cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23977283]","metadata":null},{"id":"791e49a4f59e490ba4b607e5101522e0","type":"GO_TERM","name":"negative regulation of brown fat cell proliferation","canonical_id":"go:GO:0070348","description":"\"Any process that stops or decreases the rate or extent of brown fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"de7d141cc88f4eb6a703ead64b566ccc","type":"GO_TERM","name":"negative regulation of c-di-GMP signaling","canonical_id":"go:GO:0061942","description":"\"Any process that decreases the rate, frequency or extent of c-di-GMP signaling.\" [PMID:22864416]","metadata":null},{"id":"e5af2245d9a54641a508627959eea0ec","type":"GO_TERM","name":"negative regulation of cAMP-dependent protein kinase activity","canonical_id":"go:GO:2000480","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cAMP-dependent protein kinase activity.\" [GOC:obol]","metadata":null},{"id":"c2b80fea34764053a324c542b9c923f2","type":"GO_TERM","name":"negative regulation of cAMP/PKA signal transduction","canonical_id":"go:GO:0141162","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cAMP/PKA signal transduction.\" [PMID:17376027]","metadata":null},{"id":"c84a5edb887e4c24963d08290f8a1e79","type":"GO_TERM","name":"negative regulation of cGAS/STING signaling pathway","canonical_id":"go:GO:0160049","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cGAS/STING signaling pathway.\" [PMID:29875158]","metadata":null},{"id":"034dcbeeb25b4e20a3aa40df8291cc89","type":"GO_TERM","name":"negative regulation of calcineurin-NFAT signaling cascade","canonical_id":"go:GO:0070885","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the calcineurin-NFAT signaling cascade.\" [GOC:mah]","metadata":null},{"id":"b623383239764bce9a6b3583f9ea2391","type":"GO_TERM","name":"negative regulation of calcineurin-mediated signaling","canonical_id":"go:GO:0106057","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcineurin-mediated signaling.\" [PMID:25081204]","metadata":null},{"id":"f79f98ee9f8145ae9b0636bdf613ccb5","type":"GO_TERM","name":"negative regulation of calcitonin secretion","canonical_id":"go:GO:1904363","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcitonin secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11278900]","metadata":null},{"id":"d1beeb801fd74aeeb6e0715350c8141b","type":"GO_TERM","name":"negative regulation of calcium import into the mitochondrion","canonical_id":"go:GO:0110099","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion import into the mitochondrion.\" [GOC:sl, PMID:24085037]","metadata":null},{"id":"23089c675258411ab264ef03de673f75","type":"GO_TERM","name":"negative regulation of calcium ion export across plasma membrane","canonical_id":"go:GO:1905913","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22362515]","metadata":null},{"id":"a58274fa3cb4443cb1a322285a75c06e","type":"GO_TERM","name":"negative regulation of calcium ion import","canonical_id":"go:GO:0090281","description":"\"Any process that decreases the rate, frequency, or extent of the directed movement of calcium ions into a cell or organelle.\" [GOC:BHF]","metadata":null},{"id":"1e7688a1c4fb4e8683ed0a618f3fcdd1","type":"GO_TERM","name":"negative regulation of calcium ion import across plasma membrane","canonical_id":"go:GO:1905949","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion import across plasma membrane.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:17640527]","metadata":null},{"id":"6a19ac87b054468fb0e1c1c8a83bdb7c","type":"GO_TERM","name":"negative regulation of calcium ion import into sarcoplasmic reticulum","canonical_id":"go:GO:1902081","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion import into sarcoplasmic reticulum.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:8349590]","metadata":null},{"id":"5a160e1cd24d4b998e82b2a661a0e217","type":"GO_TERM","name":"negative regulation of calcium ion transmembrane transport","canonical_id":"go:GO:1903170","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion transmembrane transport.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24125847]","metadata":null},{"id":"d29fa507bdca460b86046648256c96a8","type":"GO_TERM","name":"negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel","canonical_id":"go:GO:1904878","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion transmembrane transport via high voltage-gated calcium channel.\" [GO_REF:0000058, GOC:TermGenie, PMID:23071515]","metadata":null},{"id":"d41d878c380f48af9621b1790a94f87b","type":"GO_TERM","name":"negative regulation of calcium ion transmembrane transporter activity","canonical_id":"go:GO:1901020","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion transmembrane transporter activity.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"a5c89ce07f844fec99978147ac6ce5eb","type":"GO_TERM","name":"negative regulation of calcium ion transport","canonical_id":"go:GO:0051926","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"592281241f1c4ba4afd77f05d0293ae6","type":"GO_TERM","name":"negative regulation of calcium ion transport into cytosol","canonical_id":"go:GO:0010523","description":"\"Any process that decreases the rate of the directed movement of calcium ions into the cytosol of a cell. The cytosol is that part of the cytoplasm that does not contain membranous or particulate subcellular components.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"52b25b3f8dd44dcfb52b0f8c7e7090f0","type":"GO_TERM","name":"negative regulation of calcium ion-dependent exocytosis","canonical_id":"go:GO:0045955","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of calcium ion-dependent exocytosis.\" [GOC:curators]","metadata":null},{"id":"b7cfb9becee645658b09e039d947e9e2","type":"GO_TERM","name":"negative regulation of calcium ion-dependent exocytosis of neurotransmitter","canonical_id":"go:GO:1903234","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium ion-dependent exocytosis of neurotransmitter.\" [GO_REF:0000058, GOC:TermGenie, PMID:16782817]","metadata":null},{"id":"ce6722a409cd424a8f56779f1d3a4640","type":"GO_TERM","name":"negative regulation of calcium-dependent ATPase activity","canonical_id":"go:GO:1903611","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of calcium-dependent ATPase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:10861851]","metadata":null},{"id":"ebad4a16b7064e4283061d78f473e316","type":"GO_TERM","name":"negative regulation of calcium-dependent cell-cell adhesion","canonical_id":"go:GO:0046588","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of calcium-dependent cell-cell adhesion.\" [GOC:ai]","metadata":null},{"id":"b6fa2850c9fe4c94afc3288b30e15fd2","type":"GO_TERM","name":"negative regulation of calcium-independent cell-cell adhesion","canonical_id":"go:GO:0051042","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of calcium-independent cell-cell adhesion.\" [GOC:ai]","metadata":null},{"id":"bb99a32f72c04a71ad87d7113724fd20","type":"GO_TERM","name":"negative regulation of calcium-mediated signaling","canonical_id":"go:GO:0050849","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of calcium-mediated signaling.\" [GOC:ai, PMID:11696592]","metadata":null},{"id":"9d93f9a1ee4d43ad9d292e2a0da386b8","type":"GO_TERM","name":"negative regulation of canonical NF-kappaB signal transduction","canonical_id":"go:GO:0043124","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a canonical NF-kappaB signaling cascade.\" [GOC:jl]","metadata":null},{"id":"7039c7ba6d224e4ba3497bdb70e433f5","type":"GO_TERM","name":"negative regulation of canonical Wnt signaling pathway","canonical_id":"go:GO:0090090","description":"\"Any process that decreases the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"438ca583e34049a881d3670a94c65ed3","type":"GO_TERM","name":"negative regulation of cap-dependent translational initiation","canonical_id":"go:GO:1903675","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cap-dependent translational initiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"e7f29b2793b040788424b6f4eb7a2947","type":"GO_TERM","name":"negative regulation of cap-independent translational initiation","canonical_id":"go:GO:1903678","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cap-independent translational initiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"048163906726416fbf5de25db9d2604e","type":"GO_TERM","name":"negative regulation of capsule organization","canonical_id":"go:GO:1901914","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of capsule organization.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8e376e797f3349aea6eb13d8ec0881d8","type":"GO_TERM","name":"negative regulation of carbohydrate metabolic process","canonical_id":"go:GO:0045912","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving carbohydrate.\" [GOC:curators]","metadata":null},{"id":"3d5a4f1d0b234e488f5e188e3135146a","type":"GO_TERM","name":"negative regulation of carbohydrate utilization","canonical_id":"go:GO:0180068","description":"\"Any process that  that stops, prevents, or reduces the frequency, rate or extent of carbohydrate utilization.\" [GOC:vw]","metadata":null},{"id":"8fbfa28b40054c32a561790c2b827f4f","type":"GO_TERM","name":"negative regulation of cardiac cell fate specification","canonical_id":"go:GO:2000044","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac cell fate specification.\" [GOC:BHF]","metadata":null},{"id":"ca775361d65e4ae2abdff9761d5404ba","type":"GO_TERM","name":"negative regulation of cardiac chamber formation","canonical_id":"go:GO:1901211","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac chamber formation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"d76c1df147db4351a1f19baa547932e2","type":"GO_TERM","name":"negative regulation of cardiac chamber morphogenesis","canonical_id":"go:GO:1901220","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac chamber morphogenesis.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"35e41491f06840db8225d2f4d02553f9","type":"GO_TERM","name":"negative regulation of cardiac conduction","canonical_id":"go:GO:1903780","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac conduction.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:12967627]","metadata":null},{"id":"b16c72d947bd48eda3bf9abd3dcaa116","type":"GO_TERM","name":"negative regulation of cardiac endothelial to mesenchymal transition","canonical_id":"go:GO:0062001","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac endothelial to mesenchymal transition.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26857067]","metadata":null},{"id":"69f673db2f3341d5b1c7b85229e61f8c","type":"GO_TERM","name":"negative regulation of cardiac epithelial to mesenchymal transition","canonical_id":"go:GO:0062044","description":"\"Any process that stops or decreases the rate, frequency or extent of cardiac epithelial to mesenchymal transition, a transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BFH, GOC:rph, PMID:20951801]","metadata":null},{"id":"0193f372625142098b8788d23b15c796","type":"GO_TERM","name":"negative regulation of cardiac muscle adaptation","canonical_id":"go:GO:0010616","description":"\"Any process that decreases the rate, extent or frequency of the process in which cardiac muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"f6e09156fb704f139a49a24f288d9139","type":"GO_TERM","name":"negative regulation of cardiac muscle cell apoptotic process","canonical_id":"go:GO:0010667","description":"\"Any process that decreases the rate or extent of cardiac cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a cardiac muscle cell and result in its death.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:rl, GOC:tb]","metadata":null},{"id":"2ac3f3d3cdb64801855053b4a446b40f","type":"GO_TERM","name":"negative regulation of cardiac muscle cell contraction","canonical_id":"go:GO:0106135","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell contraction.\" [PMID:19525381]","metadata":null},{"id":"1fe0c6aaf5d24e3095d2c53b7e16ee62","type":"GO_TERM","name":"negative regulation of cardiac muscle cell differentiation","canonical_id":"go:GO:2000726","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac muscle cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"e7e99736bef34a3796e262b6e5fcc23f","type":"GO_TERM","name":"negative regulation of cardiac muscle cell myoblast differentiation","canonical_id":"go:GO:2000691","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac muscle cell myoblast differentiation.\" [GOC:obol]","metadata":null},{"id":"a9e657d5599042e6b4b5af12334813cd","type":"GO_TERM","name":"negative regulation of cardiac muscle cell proliferation","canonical_id":"go:GO:0060044","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell proliferation.\" [GOC:dph, GOC:rph]","metadata":null},{"id":"a60af3250abb40aabde601d196c0ea94","type":"GO_TERM","name":"negative regulation of cardiac muscle contraction","canonical_id":"go:GO:0055118","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle contraction.\" [GOC:ecd]","metadata":null},{"id":"d0383dfffcd54e4fb1a9e34202ded179","type":"GO_TERM","name":"negative regulation of cardiac muscle fiber development","canonical_id":"go:GO:0055019","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle fiber development.\" [GOC:vk]","metadata":null},{"id":"794361f448784908a6aa1dbebfb91e47","type":"GO_TERM","name":"negative regulation of cardiac muscle hypertrophy","canonical_id":"go:GO:0010614","description":"\"Any process that decreases the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"b2b1d5f4d02840289824902c14566bc6","type":"GO_TERM","name":"negative regulation of cardiac muscle hypertrophy in response to stress","canonical_id":"go:GO:1903243","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac muscle hypertrophy in response to stress.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19287093]","metadata":null},{"id":"ccd0dd937063470bba8c1fb48b402d6d","type":"GO_TERM","name":"negative regulation of cardiac muscle myoblast proliferation","canonical_id":"go:GO:0110023","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle myoblast proliferation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26512644]","metadata":null},{"id":"d2791326226b4cea9ed7267a070b35e8","type":"GO_TERM","name":"negative regulation of cardiac muscle tissue development","canonical_id":"go:GO:0055026","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle tissue development.\" [GOC:vk]","metadata":null},{"id":"2d72346ead294c8e9308dbdbe1bfe675","type":"GO_TERM","name":"negative regulation of cardiac muscle tissue growth","canonical_id":"go:GO:0055022","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle growth.\" [GOC:vk]","metadata":null},{"id":"7fd227afc1bb4b2098930da36cfc0f4f","type":"GO_TERM","name":"negative regulation of cardiac muscle tissue regeneration","canonical_id":"go:GO:1905179","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac muscle tissue regeneration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23222520]","metadata":null},{"id":"8df186f153fa40d8886220071c7ae100","type":"GO_TERM","name":"negative regulation of cardiac myofibril assembly","canonical_id":"go:GO:1905305","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac myofibril assembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16151019]","metadata":null},{"id":"9f8c7f99d05e4192b5ed0e8f44c98bff","type":"GO_TERM","name":"negative regulation of cardiac vascular smooth muscle cell differentiation","canonical_id":"go:GO:2000723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac vascular smooth muscle cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"3663c0218d4242deb22f2de43ef810a5","type":"GO_TERM","name":"negative regulation of cardiac ventricle development","canonical_id":"go:GO:1904413","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac ventricle development.\" [GO_REF:0000058, GOC:TermGenie, PMID:19590510]","metadata":null},{"id":"0695136f470e48d3b7283d5cdee9a237","type":"GO_TERM","name":"negative regulation of cardiac ventricle formation","canonical_id":"go:GO:1904943","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiac ventricle formation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23575307]","metadata":null},{"id":"e7211e23533c4f85980ea83829cf316c","type":"GO_TERM","name":"negative regulation of cardioblast cell fate specification","canonical_id":"go:GO:0009997","description":"\"Any process that restricts, stops or prevents a cell from specifying into a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:curators]","metadata":null},{"id":"465244464cd2433a825e6920e2ba354c","type":"GO_TERM","name":"negative regulation of cardioblast differentiation","canonical_id":"go:GO:0051892","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cardioblast differentiation, the process in which a relatively unspecialized mesodermal cell acquires the specialized structural and/or functional features of a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:ai]","metadata":null},{"id":"ed175251e6ce44909c1fdaf509d76086","type":"GO_TERM","name":"negative regulation of cardioblast proliferation","canonical_id":"go:GO:1905061","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardioblast proliferation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:24236097]","metadata":null},{"id":"9bc3437ab6a244afb67118a2a2045681","type":"GO_TERM","name":"negative regulation of cardiocyte differentiation","canonical_id":"go:GO:1905208","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiocyte differentiation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23069713]","metadata":null},{"id":"e6bebbe73e9a48f1ba4adc06c4da1c72","type":"GO_TERM","name":"negative regulation of cardiolipin metabolic process","canonical_id":"go:GO:1900209","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cardiolipin metabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"2fb118bb642a410ca3ea8746e408e1a0","type":"GO_TERM","name":"negative regulation of cargo loading into COPII-coated vesicle","canonical_id":"go:GO:1901303","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cargo loading into a COPII-coated vesicle.\" [GOC:lb, GOC:TermGenie, PMID:15899885]","metadata":null},{"id":"8299e908d54f4574bd26154d7f15318e","type":"GO_TERM","name":"negative regulation of carotenoid biosynthetic process","canonical_id":"go:GO:1904142","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of carotenoid biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:25675505]","metadata":null},{"id":"a289806627c14bffb3b4c57eeac2deb5","type":"GO_TERM","name":"negative regulation of cartilage condensation","canonical_id":"go:GO:1904932","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cartilage condensation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17604018]","metadata":null},{"id":"03ccaa35e28b4e64a68f8c4914ff5a97","type":"GO_TERM","name":"negative regulation of cartilage development","canonical_id":"go:GO:0061037","description":"\"Any process that decreases the rate, frequency, or extent of cartilage development, the process whose specific outcome is the progression of the cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.\" [GOC:dph]","metadata":null},{"id":"0b051474c0e240838f0f7dc70ed1a191","type":"GO_TERM","name":"negative regulation of catabolic process","canonical_id":"go:GO:0009895","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of substances.\" [GOC:curators]","metadata":null},{"id":"a3e7c247498c41d5992f9391f0c47ba1","type":"GO_TERM","name":"negative regulation of catalytic activity","canonical_id":"go:GO:0043086","description":"\"Any process that stops or reduces the activity of an enzyme.\" [GOC:ebc, GOC:jl, GOC:tb, GOC:vw]","metadata":null},{"id":"0adc928070bc4202aef9d0a28f1c7a77","type":"GO_TERM","name":"negative regulation of catecholamine secretion","canonical_id":"go:GO:0033604","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a catecholamine.\" [GOC:mah]","metadata":null},{"id":"5c09699b178a4bc3b037f2e0e46f7ebd","type":"GO_TERM","name":"negative regulation of cation transmembrane transport","canonical_id":"go:GO:1904063","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cation transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:15304482]","metadata":null},{"id":"08fc4e12b57d491aa0b76f19b510b048","type":"GO_TERM","name":"negative regulation of caveolin-mediated endocytosis","canonical_id":"go:GO:2001287","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of caveolin-mediated endocytosis.\" [GOC:obol]","metadata":null},{"id":"82192eee7b224bd68a4909cf31e8fd40","type":"GO_TERM","name":"negative regulation of cell activation","canonical_id":"go:GO:0050866","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell activation.\" [GOC:ai]","metadata":null},{"id":"bb5fa16cb9c84932bac96dabbec33e4f","type":"GO_TERM","name":"negative regulation of cell adhesion","canonical_id":"go:GO:0007162","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell adhesion.\" [GOC:curators]","metadata":null},{"id":"cc49dca0ca694915b3b0db079928b6c3","type":"GO_TERM","name":"negative regulation of cell adhesion in ventricular zone","canonical_id":"go:GO:0021804","description":"\"The process that results in the loss of attachments of a cell in the ventricular zone.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"08692c2bdd9a4a8d9f9364c5541930a2","type":"GO_TERM","name":"negative regulation of cell adhesion involved in single-species biofilm formation","canonical_id":"go:GO:1900188","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell adhesion involved in single-species biofilm formation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"851917c631174529b32ccd079eabf4c6","type":"GO_TERM","name":"negative regulation of cell adhesion involved in sprouting angiogenesis","canonical_id":"go:GO:0106089","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell adhesion involved in sprouting angiogenesis.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:24177325]","metadata":null},{"id":"664dd1e83589406894eb0f3c3d1ac0c2","type":"GO_TERM","name":"negative regulation of cell adhesion involved in substrate-bound cell migration","canonical_id":"go:GO:0006933","description":"\"The disassembly of adhesions at the front and rear of a migrating cell. At the leading edge, adhesion disassembly accompanies the formation of new protrusions; at the cell rear, it promotes tail retraction.\" [GOC:dph, GOC:tb, ISBN:0815316194, PMID:11944043, PMID:14657486]","metadata":null},{"id":"8f9be7c6ecde46a6b200194ee2a31b07","type":"GO_TERM","name":"negative regulation of cell adhesion mediated by integrin","canonical_id":"go:GO:0033629","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of cell adhesion mediated by integrin.\" [GOC:add]","metadata":null},{"id":"a1ceb49edd7f468cb4dd9c6a00587c99","type":"GO_TERM","name":"negative regulation of cell adhesion molecule production","canonical_id":"go:GO:0060354","description":"\"Any process that decreases the rate, frequency or extent of cell adhesion molecule production. Cell adhesion molecule production is the appearance of a cell adhesion molecule as a result of its biosynthesis or a decrease in its catabolism.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"9d3fb512b67343cfbe354127073a33b9","type":"GO_TERM","name":"negative regulation of cell budding","canonical_id":"go:GO:0045781","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell budding.\" [GOC:curators]","metadata":null},{"id":"fa3e750266bc4f39820afc5cc609c5e4","type":"GO_TERM","name":"negative regulation of cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:1904848","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell chemotaxis to fibroblast growth factor.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23233752]","metadata":null},{"id":"2ae4ab289ec34d43bcf610366efd4736","type":"GO_TERM","name":"negative regulation of cell communication","canonical_id":"go:GO:0010648","description":"\"Any process that decreases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"069234be5acd4d5287f4a603e7a3cb9a","type":"GO_TERM","name":"negative regulation of cell communication by chemical coupling","canonical_id":"go:GO:0010653","description":"\"Any process that decreases the frequency, rate or extent of cell communication via chemical coupling. Cell communication by chemical coupling is the process that mediates signaling interactions between one cell and another cell by the transfer of small, water-soluble molecules or metabolites between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"3f7fe6d2a74c45379d8df31c1795c02f","type":"GO_TERM","name":"negative regulation of cell communication by electrical coupling","canonical_id":"go:GO:0010651","description":"\"Any process that decreases the frequency, rate or extent of cell communication via electrical coupling. Cell communication via electrical coupling is the process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"32c389febe7548f6b10acf66bbdec1c8","type":"GO_TERM","name":"negative regulation of cell communication by electrical coupling involved in cardiac conduction","canonical_id":"go:GO:1901845","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell communication by electrical coupling involved in cardiac conduction.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17130302]","metadata":null},{"id":"4fc30659a1454296a08a3aa76dd7f046","type":"GO_TERM","name":"negative regulation of cell cycle","canonical_id":"go:GO:0045786","description":"\"Any process that stops, prevents or reduces the rate or extent of progression through the cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"c35035c1bb5d41c7a9710493cd8a6a03","type":"GO_TERM","name":"negative regulation of cell cycle G1/S phase transition","canonical_id":"go:GO:1902807","description":"\"Any signaling pathway that decreases or inhibits the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the cell cycle.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"b827960c323946dea5a6083d0206e9d1","type":"GO_TERM","name":"negative regulation of cell cycle G2/M phase transition","canonical_id":"go:GO:1902750","description":"\"Any signaling pathway that decreases or inhibits the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the cell cycle.\" [GO_REF:0000058, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"38daae4793f74f07874df3edf08bf299","type":"GO_TERM","name":"negative regulation of cell cycle checkpoint","canonical_id":"go:GO:1901977","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle checkpoint.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:23028116]","metadata":null},{"id":"1b4da83083eb4f2e90124c307bb5a51a","type":"GO_TERM","name":"negative regulation of cell cycle phase transition","canonical_id":"go:GO:1901988","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"49bb1d86f89542539e5a83f27a569cd7","type":"GO_TERM","name":"negative regulation of cell cycle process","canonical_id":"go:GO:0010948","description":"\"Any process that decreases the rate, frequency or extent of a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"783b3ce0bffb45e7831900146af0757f","type":"GO_TERM","name":"negative regulation of cell cycle switching, mitotic to meiotic cell cycle","canonical_id":"go:GO:0110045","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of mitotic to meiotic cell cycle switching, the process in which a cell switches cell cycle mode from mitotic to meiotic division.\" [GOC:al, PMID:17674143]","metadata":null},{"id":"83a1599d52af41a5b5cb141775fac507","type":"GO_TERM","name":"negative regulation of cell development","canonical_id":"go:GO:0010721","description":"\"Any process that decreases the rate, frequency or extent of the progression of the cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d7663cbaf1444f74a9e4a6d80c5554f4","type":"GO_TERM","name":"negative regulation of cell differentiation","canonical_id":"go:GO:0045596","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell differentiation.\" [GOC:curators]","metadata":null},{"id":"6ce228bc51cd46b0b2f975370f9ed6f9","type":"GO_TERM","name":"negative regulation of cell differentiation involved in embryonic placenta development","canonical_id":"go:GO:0060806","description":"\"Any process that decreases the rate, frequency or extent of cell differentiation that contributes to the progression of the placenta over time, from its initial condition to its mature state.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"0f73c15727744d3cb6cf22d7eca9f707","type":"GO_TERM","name":"negative regulation of cell division","canonical_id":"go:GO:0051782","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell division.\" [GOC:ai]","metadata":null},{"id":"fd3012aaf88348cca624ef9d43b84908","type":"GO_TERM","name":"negative regulation of cell fate commitment","canonical_id":"go:GO:0010454","description":"\"Any process that stops, prevents or reduces the frequency or rate of cell fate commitment. Cell fate commitment is the commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"29217ac3db7c43bb8a413266c3ad9a15","type":"GO_TERM","name":"negative regulation of cell fate determination","canonical_id":"go:GO:1905934","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell fate determination.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25793578]","metadata":null},{"id":"484ca379a67446efabe2913654dabb41","type":"GO_TERM","name":"negative regulation of cell fate specification","canonical_id":"go:GO:0009996","description":"\"Any process that restricts, stops or prevents a cell from adopting a specific cell fate.\" [GOC:curators]","metadata":null},{"id":"2daa7c0f8f044b27959eae5961dc0aa9","type":"GO_TERM","name":"negative regulation of cell growth","canonical_id":"go:GO:0030308","description":"\"Any process that stops, prevents, or reduces the frequency, rate, extent or direction of cell growth.\" [GOC:curators]","metadata":null},{"id":"5e1635a336db4b98b232d2624e36d925","type":"GO_TERM","name":"negative regulation of cell growth involved in cardiac muscle cell development","canonical_id":"go:GO:0061052","description":"\"Any process that decreases the rate, frequency, or extent of the growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"9ee580fd118b4adfaacc421a56e7dc75","type":"GO_TERM","name":"negative regulation of cell growth involved in contact inhibition","canonical_id":"go:GO:0060243","description":"\"The negative regulation of cell growth in response to increased cell density.\" [GOC:dph]","metadata":null},{"id":"7bc1bd5779fe4995a01ef3047b38aa13","type":"GO_TERM","name":"negative regulation of cell integrity MAPK cascade","canonical_id":"go:GO:1903138","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a cell integrity MAPK cascade.\" [GOC:vw]","metadata":null},{"id":"3a51541c334c489eb7c774d286e6bf1c","type":"GO_TERM","name":"negative regulation of cell junction assembly","canonical_id":"go:GO:1901889","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly.\" [GOC:TermGenie]","metadata":null},{"id":"4d2f7ab47192408891d3626c9c657568","type":"GO_TERM","name":"negative regulation of cell killing","canonical_id":"go:GO:0031342","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell killing.\" [GOC:mah]","metadata":null},{"id":"0633ca7847c248ff8eef8eb9fb2febbf","type":"GO_TERM","name":"negative regulation of cell maturation","canonical_id":"go:GO:1903430","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell maturation.\" [GO_REF:0000058, GOC:TermGenie, PMID:17459944]","metadata":null},{"id":"27ca26ad80674bbcab8dd316c01d6b81","type":"GO_TERM","name":"negative regulation of cell migration","canonical_id":"go:GO:0030336","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell migration.\" [GOC:curators]","metadata":null},{"id":"c1e5c96aecde4a898b6d44f3dd172f5d","type":"GO_TERM","name":"negative regulation of cell migration involved in sprouting angiogenesis","canonical_id":"go:GO:0090051","description":"\"Any process that decreases the frequency, rate or extent of cell migration involved in sprouting angiogenesis. Cell migration involved in sprouting angiogenesis is the orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels contributing to the process of sprouting angiogenesis.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"37b9675936d74e8baecc589804478692","type":"GO_TERM","name":"negative regulation of cell morphogenesis","canonical_id":"go:GO:0010771","description":"\"Any process that decreases the frequency, rate or extent of cell morphogenesis contributing to cell differentiation. Cell morphogenesis involved in differentiation is the change in form (cell shape and size) that occurs when relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6fd98a1fb3b34f2997c3aca96f33fccf","type":"GO_TERM","name":"negative regulation of cell motility","canonical_id":"go:GO:2000146","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell motility.\" [GOC:mah]","metadata":null},{"id":"4ba9b8aff0c14327a617764ff4fbcb60","type":"GO_TERM","name":"negative regulation of cell motility involved in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021822","description":"\"The intracellular signaling pathway that results in the cessation of cell movement involved in lamination of the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:tb, PMID:12626695]","metadata":null},{"id":"8db543dcb7c9495fbaa0737ac86a3e9b","type":"GO_TERM","name":"negative regulation of cell population proliferation","canonical_id":"go:GO:0008285","description":"\"Any process that stops, prevents or reduces the rate or extent of cell proliferation.\" [GOC:curators]","metadata":null},{"id":"51a26d645caa48d1b414849ffbe7db9d","type":"GO_TERM","name":"negative regulation of cell projection organization","canonical_id":"go:GO:0031345","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell projections.\" [GOC:mah]","metadata":null},{"id":"14fff9af9d1b4f24a023ff6b28a92915","type":"GO_TERM","name":"negative regulation of cell proliferation in bone marrow","canonical_id":"go:GO:1903769","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell proliferation in bone marrow.\" [GO_REF:0000058, GOC:TermGenie, PMID:9241534]","metadata":null},{"id":"08b6f44b98604b0bb9c54b0341fdcf35","type":"GO_TERM","name":"negative regulation of cell proliferation in dorsal spinal cord","canonical_id":"go:GO:1902832","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell proliferation in dorsal spinal cord.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:21730158]","metadata":null},{"id":"c6b0125fcd674f26bd158d80283f5aaf","type":"GO_TERM","name":"negative regulation of cell proliferation in midbrain","canonical_id":"go:GO:1904934","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell proliferation in midbrain.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18953410, PMID:24431302]","metadata":null},{"id":"b49434b5b71547ca81d982f5eb5b66de","type":"GO_TERM","name":"negative regulation of cell proliferation involved in contact inhibition","canonical_id":"go:GO:0060244","description":"\"Any process that stops, prevents or reduces the rate or extent of cell proliferation in response to cell density.\" [GOC:dph]","metadata":null},{"id":"7d9ddd84e53d4b01b48b8d063fa51ea1","type":"GO_TERM","name":"negative regulation of cell proliferation involved in heart morphogenesis","canonical_id":"go:GO:2000137","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell proliferation involved in heart morphogenesis.\" [GOC:dph]","metadata":null},{"id":"5e014df7598541a9afabb0db34c8c345","type":"GO_TERM","name":"negative regulation of cell proliferation involved in kidney development","canonical_id":"go:GO:1901723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell proliferation involved in kidney development.\" [GOC:TermGenie, PMID:18182616]","metadata":null},{"id":"fa6e710e49dd4cd4bd3792033c596e60","type":"GO_TERM","name":"negative regulation of cell septum assembly","canonical_id":"go:GO:1901892","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell septum assembly.\" [GOC:TermGenie]","metadata":null},{"id":"a41c3db571e74778af2e75bf92f5cf62","type":"GO_TERM","name":"negative regulation of cell size","canonical_id":"go:GO:0045792","description":"\"Any process that reduces cell size.\" [GOC:curators]","metadata":null},{"id":"1408a68b26044960a92bb73bb35d7e2d","type":"GO_TERM","name":"negative regulation of cell volume","canonical_id":"go:GO:0045794","description":"\"Any process that decreases cell volume.\" [GOC:curators]","metadata":null},{"id":"fb316015508e4878b8fdf74c382a035b","type":"GO_TERM","name":"negative regulation of cell wall organization or biogenesis","canonical_id":"go:GO:1903339","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell wall organization or biogenesis.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"b7864566746d41bcba87eecb9eeefe46","type":"GO_TERM","name":"negative regulation of cell wall polysaccharide catabolic process","canonical_id":"go:GO:2000967","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell wall polysaccharide catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"450b0b2b1774460c8a823120436f5d17","type":"GO_TERM","name":"negative regulation of cell-cell adhesion","canonical_id":"go:GO:0022408","description":"\"Any process that stops, prevents or reduces the rate or extent of cell adhesion to another cell.\" [GOC:isa_complete]","metadata":null},{"id":"33cdba899a0f496d860f80a5c6950ac9","type":"GO_TERM","name":"negative regulation of cell-cell adhesion mediated by cadherin","canonical_id":"go:GO:2000048","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell-cell adhesion mediated by cadherin.\" [GOC:obol]","metadata":null},{"id":"f03947975dba436db36a497827a98e84","type":"GO_TERM","name":"negative regulation of cell-cell adhesion mediated by integrin","canonical_id":"go:GO:0033633","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of cell-cell adhesion mediated by integrin.\" [GOC:add]","metadata":null},{"id":"2e6b62a7ed194594b94ff9b41eb8f5c3","type":"GO_TERM","name":"negative regulation of cell-matrix adhesion","canonical_id":"go:GO:0001953","description":"\"Any process that stops, prevents, or reduces the rate or extent of cell adhesion to the extracellular matrix.\" [GOC:hjd]","metadata":null},{"id":"a7a056aae05e4c0c85bf253b07bf7bbc","type":"GO_TERM","name":"negative regulation of cell-substrate adhesion","canonical_id":"go:GO:0010812","description":"\"Any process that decreases the frequency, rate or extent of cell-substrate adhesion. Cell-substrate adhesion is the attachment of a cell to the underlying substrate via adhesion molecules.\" [GOC:dph, GOC:pf, GOC:tb]","metadata":null},{"id":"00c5fab4b25742299d651f199c5c2ceb","type":"GO_TERM","name":"negative regulation of cell-substrate junction organization","canonical_id":"go:GO:0150118","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cell-substrate junction organization.\" [GOC:aruk]","metadata":null},{"id":"8208021e8bf7405086eb20fec08b2de2","type":"GO_TERM","name":"negative regulation of cellobiose catabolic process","canonical_id":"go:GO:1900283","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellobiose catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9c10ee7738c34bf1af460bcc88e3f283","type":"GO_TERM","name":"negative regulation of cellodextrin catabolic process","canonical_id":"go:GO:2000928","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellodextrin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"ba350bdca26145e8868e731695614949","type":"GO_TERM","name":"negative regulation of cellooligosaccharide catabolic process","canonical_id":"go:GO:2000964","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellooligosaccharide catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"9b7a089283e64eada6fa04adf27e96de","type":"GO_TERM","name":"negative regulation of cellotriose catabolic process","canonical_id":"go:GO:2000937","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellotriose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"976e9255cb7e4ec88f408b7fbd811729","type":"GO_TERM","name":"negative regulation of cellotriose transport","canonical_id":"go:GO:1900286","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"6555bcafc01a45b386c4db0db3eb3481","type":"GO_TERM","name":"negative regulation of cellular component organization","canonical_id":"go:GO:0051129","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell structures, including the plasma membrane and any external encapsulating structures such as the cell wall and cell envelope.\" [GOC:ai]","metadata":null},{"id":"c6b965b01b584381915b5eecf358e9ed","type":"GO_TERM","name":"negative regulation of cellular defense response","canonical_id":"go:GO:0051245","description":"\"Any process that stops, prevents, or reduces the rate of the cellular defense response.\" [GOC:ai]","metadata":null},{"id":"a7e2ef8b3ca84714920ffa73ad589335","type":"GO_TERM","name":"negative regulation of cellular extravasation","canonical_id":"go:GO:0002692","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of cellular extravasation.\" [GOC:add]","metadata":null},{"id":"342222f834184a94995c6c8761bbce5a","type":"GO_TERM","name":"negative regulation of cellular hyperosmotic salinity response","canonical_id":"go:GO:1900070","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular hyperosmotic salinity response.\" [GOC:dgf, GOC:TermGenie, PMID:16278455]","metadata":null},{"id":"9bdc5a7b30f0448f9ad46e16b750a104","type":"GO_TERM","name":"negative regulation of cellular process","canonical_id":"go:GO:0048523","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.\" [GOC:jid]","metadata":null},{"id":"f4135585dffa400489da4a48b0179805","type":"GO_TERM","name":"negative regulation of cellular respiration","canonical_id":"go:GO:1901856","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular respiration.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"f171295e49ec4d94a4681887b9b7aad3","type":"GO_TERM","name":"negative regulation of cellular response to X-ray","canonical_id":"go:GO:2000684","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to X-ray.\" [GOC:obol]","metadata":null},{"id":"0f3d3890f9404279839714e0e4b51396","type":"GO_TERM","name":"negative regulation of cellular response to alcohol","canonical_id":"go:GO:1905958","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to alcohol.\" [GO_REF:0000058, GOC:TermGenie, PMID:26434723]","metadata":null},{"id":"bbcb789a3e894225910777164bb43f6b","type":"GO_TERM","name":"negative regulation of cellular response to alkaline pH","canonical_id":"go:GO:1900068","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to alkalinity.\" [GOC:dgf, GOC:TermGenie, PMID:12509465, PMID:17023428]","metadata":null},{"id":"311388ca5a2447b2b8035f72cba0605d","type":"GO_TERM","name":"negative regulation of cellular response to amino acid starvation","canonical_id":"go:GO:1903574","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a cellular response to amino acid starvation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11381086]","metadata":null},{"id":"be0d3f8a81b5412cb91207af4d9ced72","type":"GO_TERM","name":"negative regulation of cellular response to caffeine","canonical_id":"go:GO:1901181","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to caffeine.\" [GOC:TermGenie]","metadata":null},{"id":"c6cd4301a8884fae9c77b92c9d782095","type":"GO_TERM","name":"negative regulation of cellular response to drug","canonical_id":"go:GO:2001039","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to drug.\" [GOC:obol]","metadata":null},{"id":"82a67581b5a64d7b95c758027b245916","type":"GO_TERM","name":"negative regulation of cellular response to gamma radiation","canonical_id":"go:GO:1905844","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to gamma radiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23505386]","metadata":null},{"id":"42089604b5e84704bfb6c18470f0883d","type":"GO_TERM","name":"negative regulation of cellular response to growth factor stimulus","canonical_id":"go:GO:0090288","description":"\"Any process that decreases the rate, frequency, or extent of a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.\" [GOC:BHF]","metadata":null},{"id":"f0adc57c424a44db885505ce4dcdb6bb","type":"GO_TERM","name":"negative regulation of cellular response to heat","canonical_id":"go:GO:1900035","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to heat.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"6733236dafeb46b58dccf39690178e6b","type":"GO_TERM","name":"negative regulation of cellular response to hepatocyte growth factor stimulus","canonical_id":"go:GO:2001113","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to hepatocyte growth factor stimulus.\" [GOC:obol]","metadata":null},{"id":"41c9fe8998fe47fd961e332934db7b94","type":"GO_TERM","name":"negative regulation of cellular response to hypoxia","canonical_id":"go:GO:1900038","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to hypoxia.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"fc96496069844bc19a555a034e724928","type":"GO_TERM","name":"negative regulation of cellular response to insulin stimulus","canonical_id":"go:GO:1900077","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to insulin stimulus.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"b6971b1c50284a91bc189b1d1351ef95","type":"GO_TERM","name":"negative regulation of cellular response to iron ion starvation","canonical_id":"go:GO:1901967","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to iron ion starvation.\" [GOC:TermGenie, PMID:23115244]","metadata":null},{"id":"7a2c1d1e424c4866960706f8d48a9f27","type":"GO_TERM","name":"negative regulation of cellular response to macrophage colony-stimulating factor stimulus","canonical_id":"go:GO:1903973","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to macrophage colony-stimulating factor stimulus.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"cf131914748640e0a7117b42089365a5","type":"GO_TERM","name":"negative regulation of cellular response to manganese ion","canonical_id":"go:GO:1905803","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to manganese ion.\" [GO_REF:0000058, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"679e315178e74bc6964846c1e089d5b4","type":"GO_TERM","name":"negative regulation of cellular response to nitrogen starvation","canonical_id":"go:GO:0010516","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a cellular response to nitrogen starvation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"907ed1f7c26140dd9725d7d8826b45ce","type":"GO_TERM","name":"negative regulation of cellular response to oxidative stress","canonical_id":"go:GO:1900408","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to oxidative stress.\" [GOC:mah, GOC:TermGenie]","metadata":null},{"id":"1c1fd647dfa044d9a99c6462ec8d919d","type":"GO_TERM","name":"negative regulation of cellular response to oxidopamine","canonical_id":"go:GO:1905847","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to oxidopamine.\" [GO_REF:0000058, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"ebd03a2d19714a29b75bb152b4b0de2b","type":"GO_TERM","name":"negative regulation of cellular response to phosphate starvation","canonical_id":"go:GO:0140256","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to phosphate starvation.\" [PMID:29414789]","metadata":null},{"id":"71e5402988124e46b32362de8f758f90","type":"GO_TERM","name":"negative regulation of cellular response to testosterone stimulus","canonical_id":"go:GO:2000655","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to testosterone stimulus.\" [GOC:BHF]","metadata":null},{"id":"0060989df7ae492cbab2fef377a882dd","type":"GO_TERM","name":"negative regulation of cellular response to transforming growth factor beta stimulus","canonical_id":"go:GO:1903845","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to transforming growth factor beta stimulus.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"d1b74bb1ea7e45d6821f2a4d3f7a4d9c","type":"GO_TERM","name":"negative regulation of cellular response to vascular endothelial growth factor stimulus","canonical_id":"go:GO:1902548","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to vascular endothelial growth factor stimulus.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17895370]","metadata":null},{"id":"bf1decfdd715495d99204ef1f7a8fdc3","type":"GO_TERM","name":"negative regulation of cellular response to very-low-density lipoprotein particle stimulus","canonical_id":"go:GO:1905888","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to very-low-density lipoprotein particle stimulus.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:7592957]","metadata":null},{"id":"d5d6f2c20b59482fad81625b71b012a8","type":"GO_TERM","name":"negative regulation of cellular senescence","canonical_id":"go:GO:2000773","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.\" [GOC:BHF]","metadata":null},{"id":"cba836f492f44b8284fd8d13046cd455","type":"GO_TERM","name":"negative regulation of cellulose biosynthetic process","canonical_id":"go:GO:2001007","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellulose biosynthetic process.\" [GOC:mengo_curators]","metadata":null},{"id":"22fa42bfe93745588d393fe3f587d7a2","type":"GO_TERM","name":"negative regulation of cellulose catabolic process","canonical_id":"go:GO:2000998","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"ef280f0dfc45457b8bf49749d918048e","type":"GO_TERM","name":"negative regulation of cellulosome assembly","canonical_id":"go:GO:1900504","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cellulosome assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"d697d62ec8a24c4a8fae492b91b94a71","type":"GO_TERM","name":"negative regulation of central B cell anergy","canonical_id":"go:GO:0002915","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of central B cell anergy.\" [GOC:add]","metadata":null},{"id":"83124ec8add24bf38cf42e7997cf15ad","type":"GO_TERM","name":"negative regulation of central B cell deletion","canonical_id":"go:GO:0002899","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of central B cell deletion.\" [GOC:add]","metadata":null},{"id":"c0a3ae8e74e445a3b2a1e07a15baff7a","type":"GO_TERM","name":"negative regulation of central B cell tolerance induction","canonical_id":"go:GO:0002896","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of central B cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"a1544d1062e8408696a1f327637fc43c","type":"GO_TERM","name":"negative regulation of central tolerance induction","canonical_id":"go:GO:0002647","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of central tolerance induction.\" [GOC:add]","metadata":null},{"id":"64307643535349b3bf541c1287469f70","type":"GO_TERM","name":"negative regulation of centriole elongation","canonical_id":"go:GO:1903723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of centriole elongation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:20616062]","metadata":null},{"id":"1db72d6ee24e4cf3b879f53cb96e0d6f","type":"GO_TERM","name":"negative regulation of centriole replication","canonical_id":"go:GO:0046600","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of centriole replication.\" [GOC:ai]","metadata":null},{"id":"24d83ea1e493408291e6a667905998be","type":"GO_TERM","name":"negative regulation of centriole-centriole cohesion","canonical_id":"go:GO:1903126","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of centriole-centriole cohesion.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24554434]","metadata":null},{"id":"b697196e41c64c6ca92a0da0ee43ff72","type":"GO_TERM","name":"negative regulation of centrosome cycle","canonical_id":"go:GO:0046606","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the centrosome cycle.\" [GOC:ai]","metadata":null},{"id":"257afe9e45b1461abe4f15e05d9139b6","type":"GO_TERM","name":"negative regulation of centrosome duplication","canonical_id":"go:GO:0010826","description":"\"Any process that decreases the frequency, rate or extent of centrosome duplication. Centrosome duplication is the replication of a centrosome, a structure comprised of a pair of centrioles and peri-centriolar material from which a microtubule spindle apparatus is organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b2c728de189a42588e045d8c5700ebdf","type":"GO_TERM","name":"negative regulation of ceramide biosynthetic process","canonical_id":"go:GO:1900060","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a ceramide biosynthetic process.\" [GOC:TermGenie, PMID:15302821]","metadata":null},{"id":"7930b64c352143a4ba2a717b38031271","type":"GO_TERM","name":"negative regulation of cerebellar granule cell precursor proliferation","canonical_id":"go:GO:0021941","description":"\"The process that stops, prevents or reduces the rate or extent of granule cell precursor proliferation.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"ff32dae85f024817b1aa9f295a278c19","type":"GO_TERM","name":"negative regulation of cerebellar neuron development","canonical_id":"go:GO:1905080","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cerebellar neuron development.\" [GO_REF:0000058, GOC:TermGenie, PMID:26609159]","metadata":null},{"id":"42df6c1c1a434797a26276351b561d4a","type":"GO_TERM","name":"negative regulation of cerebral blood circulation","canonical_id":"go:GO:0120278","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cerebral blood circulation.\" [GOC:krc, PMID:25397684]","metadata":null},{"id":"43990d3e972946e5ac0db96adc788441","type":"GO_TERM","name":"negative regulation of chanoclavine-I aldehyde biosynthetic process","canonical_id":"go:GO:1900647","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chanoclavine-I aldehyde biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4a240ba5888d4ccb8350a1651c27ce40","type":"GO_TERM","name":"negative regulation of chaperone-mediated autophagy","canonical_id":"go:GO:1904715","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chaperone-mediated autophagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20176123]","metadata":null},{"id":"e825cd2c6c514babb25beef01bb14dba","type":"GO_TERM","name":"negative regulation of chemokine (C-C motif) ligand 1 production","canonical_id":"go:GO:0071653","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of chemokine (C-C motif) ligand 1.\" [GOC:mah]","metadata":null},{"id":"8ce96dc65211422b8ae07b7e805a022f","type":"GO_TERM","name":"negative regulation of chemokine (C-C motif) ligand 20 production","canonical_id":"go:GO:1903885","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chemokine (C-C motif) ligand 20 production.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:20054338]","metadata":null},{"id":"5a5fd307292247f2b2994617fc798b6c","type":"GO_TERM","name":"negative regulation of chemokine (C-C motif) ligand 4 production","canonical_id":"go:GO:0071644","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of chemokine (C-C motif) ligand 4.\" [GOC:mah]","metadata":null},{"id":"90af1878baef4c94a9fa6d7b3bd415d9","type":"GO_TERM","name":"negative regulation of chemokine (C-C motif) ligand 5 production","canonical_id":"go:GO:0071650","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of chemokine (C-C motif) ligand 5.\" [GOC:mah]","metadata":null},{"id":"4333ef2b760548a1a545d114666607d6","type":"GO_TERM","name":"negative regulation of chemokine (C-C motif) ligand 6 production","canonical_id":"go:GO:0035532","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of chemokine (C-C motif) ligand 6 (CCL6).\" [GOC:add, GOC:bf]","metadata":null},{"id":"996b1795130b4b329b8a6aa3a3286c97","type":"GO_TERM","name":"negative regulation of chemokine (C-X-C motif) ligand 1 production","canonical_id":"go:GO:2000339","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chemokine (C-X-C motif) ligand 1 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"85e33ba7740c474caad56ee5d38ee3e0","type":"GO_TERM","name":"negative regulation of chemokine (C-X-C motif) ligand 2 production","canonical_id":"go:GO:2000342","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chemokine (C-X-C motif) ligand 2 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"81cba11a57ec4a9e94f661c00d55dd28","type":"GO_TERM","name":"negative regulation of chemokine (C-X-C motif) ligand 9 production","canonical_id":"go:GO:0035395","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of chemokine (C-X-C motif) ligand 9.\" [GOC:bf]","metadata":null},{"id":"14956d41b019498bbe6b2cfd71fba6e8","type":"GO_TERM","name":"negative regulation of chemokine activity","canonical_id":"go:GO:1900137","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chemokine activity.\" [GOC:TermGenie]","metadata":null},{"id":"8744b75ad0a3435d9222aca2c4cb93ee","type":"GO_TERM","name":"negative regulation of chemokine production","canonical_id":"go:GO:0032682","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of chemokine production.\" [GOC:mah]","metadata":null},{"id":"650c3abcbfda4e9f834efa3026f02e4e","type":"GO_TERM","name":"negative regulation of chemokine-mediated signaling pathway","canonical_id":"go:GO:0070100","description":"\"Any process that decreases the rate, frequency or extent of a chemokine-mediated signaling pathway.\" [GOC:mah]","metadata":null},{"id":"576936d0cda847159e25baec2b983768","type":"GO_TERM","name":"negative regulation of chemokinesis","canonical_id":"go:GO:1904366","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chemokinesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:8679543]","metadata":null},{"id":"d6b00abbb9ff4e6fb251d0ee334f8f8c","type":"GO_TERM","name":"negative regulation of chemotaxis","canonical_id":"go:GO:0050922","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism in response to a specific chemical concentration gradient.\" [GOC:ai]","metadata":null},{"id":"f354fd5604eb49428e3beeb5947ffb26","type":"GO_TERM","name":"negative regulation of chemotaxis to arachidonate","canonical_id":"go:GO:1904553","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chemotaxis to arachidonic acid.\" [GO_REF:0000058, GOC:TermGenie, PMID:16382163]","metadata":null},{"id":"5fcc6a4163614527af7316e6fe5ed81a","type":"GO_TERM","name":"negative regulation of chitin-based cuticle tanning","canonical_id":"go:GO:0045800","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of chitin-based cuticular tanning.\" [GOC:curators, GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"f5b14362d7c946309a5f4a8c370defd9","type":"GO_TERM","name":"negative regulation of chloride transport","canonical_id":"go:GO:2001226","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chloride transport.\" [GOC:dph]","metadata":null},{"id":"878b315c399b47cc851481e7004fa359","type":"GO_TERM","name":"negative regulation of chlorophyll biosynthetic process","canonical_id":"go:GO:1902325","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chlorophyll biosynthetic process.\" [GOC:TermGenie, PMID:23555952]","metadata":null},{"id":"18b0ecff02a34426b9b2ebfde9d5cfb0","type":"GO_TERM","name":"negative regulation of chlorophyll catabolic process","canonical_id":"go:GO:1903647","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chlorophyll catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24719469]","metadata":null},{"id":"1facdc4ad137426183036b931c01b208","type":"GO_TERM","name":"negative regulation of chloroplast fission","canonical_id":"go:GO:1905193","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chloroplast fission.\" [GO_REF:0000058, GOC:TermGenie, PMID:26862170]","metadata":null},{"id":"ccc6161a2af04e8db06428160e7e500a","type":"GO_TERM","name":"negative regulation of cholangiocyte apoptotic process","canonical_id":"go:GO:1904193","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cholangiocyte apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24498161]","metadata":null},{"id":"8959342ee961475a8f668a8ceb6d589d","type":"GO_TERM","name":"negative regulation of cholangiocyte proliferation","canonical_id":"go:GO:1904055","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cholangiocyte proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24434010]","metadata":null},{"id":"30d91dd36daf4aa5a9c6312f5af5a615","type":"GO_TERM","name":"negative regulation of cholesterol biosynthetic process","canonical_id":"go:GO:0045541","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of cholesterol.\" [GOC:curators]","metadata":null},{"id":"1c84aea5b18f4062b713aa94716add01","type":"GO_TERM","name":"negative regulation of cholesterol efflux","canonical_id":"go:GO:0090370","description":"\"Any process that decreases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"2e4f7b685d0b4f4985dec894966b84e7","type":"GO_TERM","name":"negative regulation of cholesterol import","canonical_id":"go:GO:0060621","description":"\"Any process that decreases the rate, frequency or extent of cholesterol import. Cholesterol import is the directed movement of cholesterol into a cell or organelle.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"9d142a8d28164a82b1b0679ac613b535","type":"GO_TERM","name":"negative regulation of cholesterol metabolic process","canonical_id":"go:GO:0090206","description":"\"Any process that decreases the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"d75fccf6fca8452b842027e2fdd4dc47","type":"GO_TERM","name":"negative regulation of cholesterol storage","canonical_id":"go:GO:0010887","description":"\"Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"c8afad43431f4bfb888b59226e4b1d37","type":"GO_TERM","name":"negative regulation of cholesterol transport","canonical_id":"go:GO:0032375","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of cholesterol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"447dba500f3749d18b0b3e1dd0dd61e4","type":"GO_TERM","name":"negative regulation of chondrocyte development","canonical_id":"go:GO:0061182","description":"\"Any process that decreases the rate, frequency, or extent of the process whose specific outcome is the progression of a chondrocyte over time, from its commitment to its mature state. Chondrocyte development does not include the steps involved in committing a chondroblast to a chondrocyte fate.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"bc04576bc72648c7a44d743e89e0eaf7","type":"GO_TERM","name":"negative regulation of chondrocyte differentiation","canonical_id":"go:GO:0032331","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of chondrocyte differentiation.\" [GOC:mah]","metadata":null},{"id":"9d695ce08fc14d0696f3fcb0377d9adc","type":"GO_TERM","name":"negative regulation of chondrocyte hypertrophy","canonical_id":"go:GO:1903042","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chondrocyte hypertrophy.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:23928032]","metadata":null},{"id":"01c5f9bfba5842a48c05ed3d88225036","type":"GO_TERM","name":"negative regulation of chondrocyte proliferation","canonical_id":"go:GO:1902731","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the multiplication or reproduction of chondrocytes by cell division, resulting in the expansion of their population. A chondrocyte is a polymorphic cell that forms cartilage.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"9154bfdc7876424a923147ce7e0c464e","type":"GO_TERM","name":"negative regulation of chorionic trophoblast cell proliferation","canonical_id":"go:GO:1901383","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chorionic trophoblast cell proliferation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"b32ee9a7f5bf41c8a10e5a8e45477b73","type":"GO_TERM","name":"negative regulation of chromatin binding","canonical_id":"go:GO:0035562","description":"\"Any process that stops or reduces the frequency, rate or extent of chromatin binding. Chromatin binding is the selective interaction with chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase.\" [GOC:bf, PMID:20404130]","metadata":null},{"id":"2397148077ff457ba7149f60bddaf540","type":"GO_TERM","name":"negative regulation of chromatin looping","canonical_id":"go:GO:0160164","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chromatin looping.\" [PMID:34856126]","metadata":null},{"id":"ed6c6123e9b74e5e897c6b2f69b5cf18","type":"GO_TERM","name":"negative regulation of chromatin organization","canonical_id":"go:GO:1905268","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chromatin organization.\" [GO_REF:0000058, GOC:pr, GOC:TermGenie, GOC:vw, PMID:654321]","metadata":null},{"id":"f4981e500a304b758832d9f24aa4c833","type":"GO_TERM","name":"negative regulation of chromosome attachment to the nuclear envelope","canonical_id":"go:GO:0120265","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chromosome attachment to the nuclear envelope.\" [GOC:krc]","metadata":null},{"id":"a708e0f9fcab45baae9034f479b5754e","type":"GO_TERM","name":"negative regulation of chromosome condensation","canonical_id":"go:GO:1902340","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chromosome condensation.\" [GOC:TermGenie, PMID:23219725]","metadata":null},{"id":"dd8310ea461940fbb782189ff68a30cf","type":"GO_TERM","name":"negative regulation of chromosome organization","canonical_id":"go:GO:2001251","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chromosome organization.\" [GOC:obol]","metadata":null},{"id":"2dae8d7452934926ac3451e6bc1ad410","type":"GO_TERM","name":"negative regulation of chromosome segregation","canonical_id":"go:GO:0051985","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of chromosome segregation, the process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets.\" [GOC:ai]","metadata":null},{"id":"adac6fa871a44be08871e5c9225b0721","type":"GO_TERM","name":"negative regulation of chromosome separation","canonical_id":"go:GO:1905819","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of chromosome separation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:21795393]","metadata":null},{"id":"1178d6198922411f868a5543d27e293f","type":"GO_TERM","name":"negative regulation of chronic inflammatory response","canonical_id":"go:GO:0002677","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a chronic inflammatory response.\" [GOC:add]","metadata":null},{"id":"06888aea38fe498abcc58b42c529fba3","type":"GO_TERM","name":"negative regulation of chronic inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002875","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a chronic inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"45a43bff66d3452b95203539e8c93485","type":"GO_TERM","name":"negative regulation of chronic inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002881","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a chronic inflammatory response to a non-antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"5afa30a9034d4fe0a018a56a6b28a733","type":"GO_TERM","name":"negative regulation of cilium assembly","canonical_id":"go:GO:1902018","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cilium assembly.\" [GOC:cilia, GOC:dph, GOC:TermGenie, PMID:17719545]","metadata":null},{"id":"8aa930b4e5734333a35df3b4749294b0","type":"GO_TERM","name":"negative regulation of cilium movement","canonical_id":"go:GO:0003354","description":"\"Any process that decreases the rate, frequency, or extent of cilium movement, the directed, self-propelled movement of a cilium.\" [GOC:dph]","metadata":null},{"id":"4464d7e0e2354328bf90186836a07e34","type":"GO_TERM","name":"negative regulation of cilium-dependent cell motility","canonical_id":"go:GO:1902020","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cilium-dependent cell motility.\" [GOC:cilia, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"6f094918bf884f2d83cceb9472a22d80","type":"GO_TERM","name":"negative regulation of circadian rhythm","canonical_id":"go:GO:0042754","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a circadian rhythm behavior.\" [GOC:curators]","metadata":null},{"id":"3da978406d634be1901b9727311a6a96","type":"GO_TERM","name":"negative regulation of circadian sleep/wake cycle, REM sleep","canonical_id":"go:GO:0042322","description":"\"Any process that stops, prevents or reduces the duration or quality of rapid eye movement (REM) sleep.\" [GOC:curators, GOC:jl]","metadata":null},{"id":"ced2c6c4127346c3a70a599f3a758900","type":"GO_TERM","name":"negative regulation of circadian sleep/wake cycle, non-REM sleep","canonical_id":"go:GO:0042323","description":"\"Any process that stops, prevents or reduces the duration or quality of non-rapid eye movement (NREM) sleep.\" [GOC:jl]","metadata":null},{"id":"a78f93abd60d4b29a44bcdb2d1c5c28a","type":"GO_TERM","name":"negative regulation of circadian sleep/wake cycle, sleep","canonical_id":"go:GO:0042321","description":"\"Any process that stops, prevents or reduces the duration or quality of sleep, a readily reversible state of reduced awareness and metabolic activity that occurs periodically in many animals.\" [GOC:curators, GOC:jl, ISBN:0192800981]","metadata":null},{"id":"d8d7c28395d6499ca483e823a001bce2","type":"GO_TERM","name":"negative regulation of circadian sleep/wake cycle, wakefulness","canonical_id":"go:GO:1904326","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of circadian sleep/wake cycle, wakefulness.\" [GO_REF:0000058, GOC:TermGenie, PMID:10923657]","metadata":null},{"id":"bb16df9857714bb884259f7a6d926b29","type":"GO_TERM","name":"negative regulation of circulating fibrinogen levels","canonical_id":"go:GO:0061754","description":"\"Any process that reduces the quantity of fibrinogen circulating in the bloodstream.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:20570858]","metadata":null},{"id":"c914d06075d0446b80d764f2e452f941","type":"GO_TERM","name":"negative regulation of citrulline biosynthetic process","canonical_id":"go:GO:1903249","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of citrulline biosynthetic process.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19278978]","metadata":null},{"id":"0cf72fda069041a59b3604fa4d71f960","type":"GO_TERM","name":"negative regulation of clathrin coat assembly","canonical_id":"go:GO:1905444","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of clathrin coat assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"c2c06c712f81458a8f2d35e7260d85e9","type":"GO_TERM","name":"negative regulation of clathrin-dependent endocytosis","canonical_id":"go:GO:1900186","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of clathrin-mediated endocytosis.\" [GOC:TermGenie]","metadata":null},{"id":"834e973050154f108e3ccddbfac281a3","type":"GO_TERM","name":"negative regulation of cleistothecium development","canonical_id":"go:GO:0070797","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cleistothecium development, a process that leads to the formation of a cleistothecium. The cleistothecium is a closed sexual fruiting body that contains ascospores in linear asci, characteristic of some filamentous Ascomycete fungi such as members of the genera Aspergillus and Emericella.\" [GOC:mah]","metadata":null},{"id":"0f638e5bd6fa42e2ad0f05817193f48f","type":"GO_TERM","name":"negative regulation of coagulation","canonical_id":"go:GO:0050819","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of coagulation.\" [GOC:ai]","metadata":null},{"id":"79f92755c14e4281b4936926a1bacef1","type":"GO_TERM","name":"negative regulation of cobalamin catabolic process","canonical_id":"go:GO:0106122","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a cobalamin (vitamin B12) catabolic process.\" [PMID:29056341]","metadata":null},{"id":"3a7574382a5f4468bc84d43d658c8001","type":"GO_TERM","name":"negative regulation of coenzyme F420-dependent bicyclic nitroimidazole catabolic process","canonical_id":"go:GO:1900289","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of coenzyme F420-dependent bicyclic nitroimidazole catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"7738c30de2264e1b8dfeed463b752d9f","type":"GO_TERM","name":"negative regulation of cold-induced thermogenesis","canonical_id":"go:GO:0120163","description":"\"Any process that stops, prevents, or reduces the rate of cold-induced thermogenesis.\" [PMID:27876809]","metadata":null},{"id":"5007f022a4f1435e91fe7b82111b6456","type":"GO_TERM","name":"negative regulation of collagen biosynthetic process","canonical_id":"go:GO:0032966","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.\" [GOC:mah]","metadata":null},{"id":"f3601d3f39104724af6fe4ed0fbb826c","type":"GO_TERM","name":"negative regulation of collagen catabolic process","canonical_id":"go:GO:0010711","description":"\"Any process that decreases the rate, frequency or extent of collagen catabolism. Collagen catabolism is the proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"19b7ade0104e48a2929bcbfd7eed3465","type":"GO_TERM","name":"negative regulation of collagen fibril organization","canonical_id":"go:GO:1904027","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of collagen fibril organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:25451920]","metadata":null},{"id":"162151dfe7e44349bf6ae0c86861726a","type":"GO_TERM","name":"negative regulation of collagen metabolic process","canonical_id":"go:GO:0010713","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the metabolism of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"db3c85d7abed4bb982643982ce84a67f","type":"GO_TERM","name":"negative regulation of collateral sprouting","canonical_id":"go:GO:0048671","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of collateral sprouting.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"f6274f384bd24cbaba646dc1a33570c4","type":"GO_TERM","name":"negative regulation of collateral sprouting in absence of injury","canonical_id":"go:GO:0048698","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of collateral sprouting in the absence of injury.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"7bc03225cd8745f6b01c5ff1ff114a8d","type":"GO_TERM","name":"negative regulation of collateral sprouting of injured axon","canonical_id":"go:GO:0048695","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of collateral sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"f43ec19d36d54a9cb8831dcb4536e8c4","type":"GO_TERM","name":"negative regulation of collateral sprouting of intact axon in response to injury","canonical_id":"go:GO:0048685","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of collateral sprouting of an intact axon as a result of injury to an axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"78ae495396fd49be8f67da5d16d68d72","type":"GO_TERM","name":"negative regulation of collecting lymphatic vessel constriction","canonical_id":"go:GO:1903815","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of collecting lymphatic vessel constriction.\" [GO_REF:0000058, GOC:TermGenie, PMID:23897233]","metadata":null},{"id":"f5123c449e71480caab03328c7fe24e2","type":"GO_TERM","name":"negative regulation of colon smooth muscle contraction","canonical_id":"go:GO:1904342","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of colon smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:24170253]","metadata":null},{"id":"5fbcf7bff8b34061826cfa9a33021e1b","type":"GO_TERM","name":"negative regulation of complement activation","canonical_id":"go:GO:0045916","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of complement activation.\" [GOC:curators]","metadata":null},{"id":"267396c14fb142d7898559904f54e83c","type":"GO_TERM","name":"negative regulation of complement activation, alternative pathway","canonical_id":"go:GO:0045957","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of complement activation by the alternative pathway.\" [GOC:curators]","metadata":null},{"id":"b35c000da76448a1a0b0baec2e102d4a","type":"GO_TERM","name":"negative regulation of complement activation, classical pathway","canonical_id":"go:GO:0045959","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of complement activation by the classical pathway.\" [GOC:curators]","metadata":null},{"id":"2a3f06c059604e568d1219890c3afd4b","type":"GO_TERM","name":"negative regulation of complement activation, lectin pathway","canonical_id":"go:GO:0001869","description":"\"Any process that stops, prevents, or reduces the rate of complement activation by the lectin pathway.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7f0d84635ac64195ace841952ebce430","type":"GO_TERM","name":"negative regulation of complement-dependent cytotoxicity","canonical_id":"go:GO:1903660","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of complement-dependent cytotoxicity.\" [GO_REF:0000058, GOC:TermGenie, PMID:24280217]","metadata":null},{"id":"698f0d796fbc48cba6f60dcaf010dc8f","type":"GO_TERM","name":"negative regulation of compound eye cone cell fate specification","canonical_id":"go:GO:0042683","description":"\"Any process that restricts, stops or prevents a cell from specifying into a compound eye cone cell.\" [GOC:mtg_sensu]","metadata":null},{"id":"ecb6a173ced448289fa4a1f03c4c2110","type":"GO_TERM","name":"negative regulation of compound eye photoreceptor cell differentiation","canonical_id":"go:GO:0110118","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of compound eye photoreceptor cell differentiation.\" [GOC:ha, PMID:16377567]","metadata":null},{"id":"19ddcec68f15415faac3bb286a1c3055","type":"GO_TERM","name":"negative regulation of compound eye photoreceptor development","canonical_id":"go:GO:0045316","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of compound eye photoreceptor development.\" [GOC:bf]","metadata":null},{"id":"2c4017523775428da9cf58f93798959b","type":"GO_TERM","name":"negative regulation of compound eye pigmentation","canonical_id":"go:GO:0048077","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of a pattern of pigment in the compound eye.\" [GOC:jid]","metadata":null},{"id":"07a74acaf5ea40e488bee450b1847e7f","type":"GO_TERM","name":"negative regulation of compound eye retinal cell apoptotic process","canonical_id":"go:GO:1901693","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of compound eye retinal cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:TermGenie, PMID:12021768]","metadata":null},{"id":"21b8eb6e7a5f4503b19c5a60e65e8cbd","type":"GO_TERM","name":"negative regulation of compound eye retinal cell programmed cell death","canonical_id":"go:GO:0046673","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of programmed cell death that occurs in the compound eye retina.\" [GOC:ai]","metadata":null},{"id":"79b87d2bedd0431a8df4636a1a7974cd","type":"GO_TERM","name":"negative regulation of conidiophore development","canonical_id":"go:GO:0070794","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of conidiophore development, a process that leads to the formation of a conidiophore. The conidiophore is a specialized hypha that extends aerially from the growth substrate and bears conidia, or asexual spores.\" [GOC:mah]","metadata":null},{"id":"267b52bb337c4aa3a3100d552d3aad60","type":"GO_TERM","name":"negative regulation of conidiophore stalk development","canonical_id":"go:GO:0070800","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of conidiophore stalk development, a process that leads to the formation of a conidiophore stalk. The conidiophore stalk is part of a specialized hypha that extends aerially from the growth substrate and supports structures from which conidia, or asexual spores, develop.\" [GOC:mah]","metadata":null},{"id":"42acfbf6bb6344f7b6b2edec3f662e85","type":"GO_TERM","name":"negative regulation of conidium formation","canonical_id":"go:GO:0075308","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of conidium formation, a process of producing non-motile spores, called conidia, via mitotic asexual reproduction in higher fungi. Conidia are haploid cells genetically identical to their haploid parent. They are produced by conversion of hyphal elements, or are borne on sporogenous cells on or within specialized structures termed conidiophores, and participate in dispersal of the fungus.\" [GOC:di, GOC:pamgo_curators]","metadata":null},{"id":"ecff34100adb4a8fbbb6a4a575aa383a","type":"GO_TERM","name":"negative regulation of conjugation with cellular fusion","canonical_id":"go:GO:0031138","description":"\"Any process that decreases the rate or frequency of conjugation with cellular fusion.\" [GOC:mah]","metadata":null},{"id":"ba87b8be790d415b9740a5dd0755a29a","type":"GO_TERM","name":"negative regulation of conjugation with zygote","canonical_id":"go:GO:0140538","description":"\"A process that prevents a zygote from fusing an additional cell.\" [PMID:30089908]","metadata":null},{"id":"9d5a1296aebb43d1942fb119914503d4","type":"GO_TERM","name":"negative regulation of connective tissue growth factor production","canonical_id":"go:GO:0032683","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of connective tissue growth factor production.\" [GOC:mah]","metadata":null},{"id":"f2c864fe85b14698a7dc4428a34a0676","type":"GO_TERM","name":"negative regulation of connective tissue replacement","canonical_id":"go:GO:1905204","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of connective tissue replacement.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25590961]","metadata":null},{"id":"68f29271c37140e9bb938ba669a553d9","type":"GO_TERM","name":"negative regulation of connective tissue replacement involved in inflammatory response wound healing","canonical_id":"go:GO:1904597","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of wound healing connective tissue replacement, which may be replaced with fibrotic material, that occurs as part of an inflammatory response.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:18245812]","metadata":null},{"id":"ecff7e869aa047619f121a4563b1fd6d","type":"GO_TERM","name":"negative regulation of constitutive secretory pathway","canonical_id":"go:GO:1903434","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of constitutive secretory pathway.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22899725]","metadata":null},{"id":"b812910b7d0e4656ba8522737f24f4a9","type":"GO_TERM","name":"negative regulation of copper ion transmembrane transport","canonical_id":"go:GO:1902312","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of copper ion transmembrane transport.\" [GOC:di, GOC:TermGenie, PMID:21489137]","metadata":null},{"id":"311b078e1c0d4e8ab7afa1a151ef88b9","type":"GO_TERM","name":"negative regulation of core promoter binding","canonical_id":"go:GO:1904797","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of core promoter binding.\" [GO_REF:0000059, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22723415]","metadata":null},{"id":"199c29c4aeb442b5a08f92c1c1035db8","type":"GO_TERM","name":"negative regulation of cornification","canonical_id":"go:GO:1905716","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cornification.\" [GO_REF:0000058, GOC:TermGenie, PMID:26014679]","metadata":null},{"id":"aba80c9c71c44efb8d53777da0f245f0","type":"GO_TERM","name":"negative regulation of corticosteroid hormone secretion","canonical_id":"go:GO:2000847","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of corticosteroid hormone secretion.\" [GOC:sl]","metadata":null},{"id":"133a58f6cd264848b79941a6a5429609","type":"GO_TERM","name":"negative regulation of corticosterone secretion","canonical_id":"go:GO:2000853","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of corticosterone secretion.\" [GOC:sl]","metadata":null},{"id":"afff3bcc5fec47449dabcb108a419847","type":"GO_TERM","name":"negative regulation of corticotropin secretion","canonical_id":"go:GO:0051460","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of corticotropic hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"41c33c07c3ad415fa0a880d1e8cb391d","type":"GO_TERM","name":"negative regulation of corticotropin-releasing hormone receptor activity","canonical_id":"go:GO:1900011","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of corticotropin-releasing hormone receptor activity.\" [GOC:TermGenie, GOC:yaf, PMID:18234674]","metadata":null},{"id":"1d821e70f5184f4b81ebaf2c96d26122","type":"GO_TERM","name":"negative regulation of corticotropin-releasing hormone secretion","canonical_id":"go:GO:0051465","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of corticotropin-releasing hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"c8f4c16f47ab47b48080c0f5ea3363c4","type":"GO_TERM","name":"negative regulation of cortisol biosynthetic process","canonical_id":"go:GO:2000065","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cortisol biosynthetic process.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"6ce7695a0ced4aaeb4fd55e5d1e360d0","type":"GO_TERM","name":"negative regulation of cortisol secretion","canonical_id":"go:GO:0051463","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of cortisol from a cell.\" [GOC:ai]","metadata":null},{"id":"1371cd1e8efc475ba53f7244e1f28151","type":"GO_TERM","name":"negative regulation of cristae formation","canonical_id":"go:GO:1903851","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cristae formation.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:19279012]","metadata":null},{"id":"1004310ac8ab427f8554a95c6825dcc9","type":"GO_TERM","name":"negative regulation of crystal cell differentiation","canonical_id":"go:GO:0042690","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of crystal cell differentiation.\" [GOC:curators]","metadata":null},{"id":"8305e7d4e4fc4e548ec64dd16517c6e0","type":"GO_TERM","name":"negative regulation of cumulus cell differentiation","canonical_id":"go:GO:0045593","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ovarian cumulus cell differentiation.\" [GOC:curators]","metadata":null},{"id":"8a9b18757481436ab45d1b2f35c4a6ba","type":"GO_TERM","name":"negative regulation of cuticle pigmentation","canonical_id":"go:GO:0048080","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of a pattern of pigment in the cuticle of an organism.\" [GOC:jid]","metadata":null},{"id":"9951e689191749839ec5fc28125f615b","type":"GO_TERM","name":"negative regulation of cutin biosynthetic process","canonical_id":"go:GO:1901958","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cutin biosynthetic process.\" [GOC:tb, GOC:TermGenie, PMID:23243127]","metadata":null},{"id":"dba2cd69cbad47cfa1439781809a30f6","type":"GO_TERM","name":"negative regulation of cyanophore differentiation","canonical_id":"go:GO:0048782","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cyanophore differentiation.\" [GOC:mh]","metadata":null},{"id":"84dfc69908014ffd8bae5bbbc45ef8b2","type":"GO_TERM","name":"negative regulation of cyclic-nucleotide phosphodiesterase activity","canonical_id":"go:GO:0051344","description":"\"Any process that stops or reduces the rate of cyclic nucleotide phosphodiesterase activity, the catalysis of the reaction: nucleotide 3',5'-cyclic phosphate + H2O = nucleotide 5'-phosphate.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"a9142a894b5841278218f00cf9f5e829","type":"GO_TERM","name":"negative regulation of cyclin-dependent protein kinase activity","canonical_id":"go:GO:1904030","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cyclin-dependent protein kinase activity.\" [GO_REF:0000059, GOC:als, GOC:TermGenie, PMID:22995177]","metadata":null},{"id":"dc59b4bd96c34c9cb575bab7076501d1","type":"GO_TERM","name":"negative regulation of cyclin-dependent protein serine/threonine kinase activity","canonical_id":"go:GO:0045736","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity.\" [GOC:curators, GOC:pr]","metadata":null},{"id":"1042c2ba8d5d4601b67e71b59c92beea","type":"GO_TERM","name":"negative regulation of cyclodextrin catabolic process","canonical_id":"go:GO:2000958","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cyclodextrin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"11bd46a1f3de4d219e9d3d83e7a49249","type":"GO_TERM","name":"negative regulation of cytokine activity","canonical_id":"go:GO:0060302","description":"\"Any process that decreases the rate, frequency or extent of the activity of a molecule that controls the survival, growth, differentiation and effector function of tissues and cells.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"bfcfd0b606104e3aa68d48fdd5ea7265","type":"GO_TERM","name":"negative regulation of cytokine production","canonical_id":"go:GO:0001818","description":"\"Any process that stops, prevents, or reduces the rate of production of a cytokine.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"197f047bb2ee4899a47e9198f9be6faf","type":"GO_TERM","name":"negative regulation of cytokine production involved in immune response","canonical_id":"go:GO:0002719","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production contributing to an immune response.\" [GOC:add]","metadata":null},{"id":"8cbeea14751443a49d7c4d358edfe6b5","type":"GO_TERM","name":"negative regulation of cytokine production involved in inflammatory response","canonical_id":"go:GO:1900016","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cytokine production involved in inflammatory response.\" [GOC:TermGenie]","metadata":null},{"id":"d103e6650c51469cbba0e89f899ea3cd","type":"GO_TERM","name":"negative regulation of cytokine-mediated signaling pathway","canonical_id":"go:GO:0001960","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the cytokine mediated signaling pathway.\" [GOC:hjd]","metadata":null},{"id":"17ce995785064a6eb2e6407faf4d1cb7","type":"GO_TERM","name":"negative regulation of cytokinesis","canonical_id":"go:GO:0032466","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the division of the cytoplasm of a cell, and its separation into two daughter cells.\" [GOC:mah]","metadata":null},{"id":"760c1940c7f9473788c451e35b2b5d6f","type":"GO_TERM","name":"negative regulation of cytokinesis, actomyosin contractile ring assembly","canonical_id":"go:GO:2000432","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cytokinesis, actomyosin contractile ring assembly.\" [GOC:obol]","metadata":null},{"id":"af35af84bee04e5584069d5d2169d12b","type":"GO_TERM","name":"negative regulation of cytokinesis, site selection","canonical_id":"go:GO:2000075","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of site selection that occurs as part of cytokinesis.\" [GOC:mtg_cell_cycle, GOC:obol]","metadata":null},{"id":"ca3e2c03bf344770a50e2a9b2023f5e1","type":"GO_TERM","name":"negative regulation of cytokinin-activated signaling pathway","canonical_id":"go:GO:0080037","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cytokinin signaling.\" [GOC:dhl, PMID:14973166]","metadata":null},{"id":"a87fca2355ec49e981c7392c04a68218","type":"GO_TERM","name":"negative regulation of cytolysis","canonical_id":"go:GO:0045918","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cytolysis.\" [GOC:curators]","metadata":null},{"id":"0daca196d42f482789df436f0f5fde15","type":"GO_TERM","name":"negative regulation of cytoplasmic mRNA processing body assembly","canonical_id":"go:GO:0010607","description":"\"Any process that decreases the rate, frequency, or extent of the aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic mRNA processing body.\" [GOC:dph, GOC:krc, GOC:tb]","metadata":null},{"id":"81bddf1d4f70473e908b463cc12f0865","type":"GO_TERM","name":"negative regulation of cytoplasmic pattern recognition receptor signaling pathway","canonical_id":"go:GO:0039532","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the series of a cytoplasmic pattern recognition receptor signaling pathway.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"99e2ef210392463c9fc38a5dd0ea11c5","type":"GO_TERM","name":"negative regulation of cytoplasmic stress granule assembly","canonical_id":"go:GO:0062030","description":"\"Any process that stops or decreases the rate, frequency or extent of cytoplasmic stress granule assembly, the aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic stress granule.\" [PMID:20180778]","metadata":null},{"id":"e92b3036990d4db8931b728af3c32e59","type":"GO_TERM","name":"negative regulation of cytoplasmic translation","canonical_id":"go:GO:2000766","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cytoplasmic translation.\" [GOC:obol]","metadata":null},{"id":"3b3da196c61f4f4c8ae0c59f3b90ef13","type":"GO_TERM","name":"negative regulation of cytoplasmic translational elongation","canonical_id":"go:GO:1900248","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cytoplasmic translational elongation.\" [GOC:TermGenie]","metadata":null},{"id":"b2ee44fd6ac54b5cb04b29dfd0f31411","type":"GO_TERM","name":"negative regulation of cytoplasmic translational elongation through polyproline stretches","canonical_id":"go:GO:1903271","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cytoplasmic translational elongation through polyproline stretches.\" [GO_REF:0000058, GOC:TermGenie, PMID:24923804]","metadata":null},{"id":"b3528c0075304efaa6decc0ff050500d","type":"GO_TERM","name":"negative regulation of cytoplasmic translational initiation","canonical_id":"go:GO:1904689","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of cytoplasmic translational initiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:12242291]","metadata":null},{"id":"0cdb8ae443d04590a0acf9049d1768fa","type":"GO_TERM","name":"negative regulation of cytoplasmic translational initiation in response to stress","canonical_id":"go:GO:1990625","description":"\"Any process that stops, prevents or reduces the rate of cytoplasmic translation initiation as a result of a stimulus indicating the organism is under stress.\" [GOC:vw, PMID:12242291]","metadata":null},{"id":"c086738ffa3048369e2b02ba68102c64","type":"GO_TERM","name":"negative regulation of cytoskeleton organization","canonical_id":"go:GO:0051494","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures.\" [GOC:ai]","metadata":null},{"id":"4da247e9c2d742cf92a1e3a0913f2243","type":"GO_TERM","name":"negative regulation of cytosolic calcium ion concentration","canonical_id":"go:GO:0051481","description":"\"Any process that decreases the concentration of calcium ions in the cytosol.\" [GOC:ai]","metadata":null},{"id":"cb9aff8846c9412c964058f94b63222f","type":"GO_TERM","name":"negative regulation of cytotoxic T cell degranulation","canonical_id":"go:GO:0043318","description":"\"Any process that stops, prevents, or reduces the rate of cytotoxic T cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"a0fc5fbd267849f189608b5810304df1","type":"GO_TERM","name":"negative regulation of cytotoxic T cell differentiation","canonical_id":"go:GO:0045584","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cytotoxic T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"6f420b6b006c440299c4d198f0186e5c","type":"GO_TERM","name":"negative regulation of dCDP biosynthetic process","canonical_id":"go:GO:1903529","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dCDP biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:16317005]","metadata":null},{"id":"701c479189a9475f83cc77ec19db32d5","type":"GO_TERM","name":"negative regulation of dauer entry","canonical_id":"go:GO:1905910","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dauer entry.\" [GO_REF:0000058, GOC:TermGenie, PMID:21531333]","metadata":null},{"id":"59d851873f8441b3a78c96ab189e2289","type":"GO_TERM","name":"negative regulation of dauer larval development","canonical_id":"go:GO:0061067","description":"\"Any process that decreases the rate, frequency, or extent of dauer larval development, the process whose specific outcome is the progression of the dauer larva over time, through the facultative diapause of the dauer (enduring) larval stage, with specialized traits adapted for dispersal and long-term survival, with elevated stress resistance and without feeding.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"8636338f8d044186be9f5f00cb674891","type":"GO_TERM","name":"negative regulation of deadenylation-dependent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:0106289","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of deadenylation-dependent decapping of nuclear-transcribed mRNA.\" [PMID:32354837]","metadata":null},{"id":"601a3349bb554dee95112d78e337da74","type":"GO_TERM","name":"negative regulation of death-inducing signaling complex assembly","canonical_id":"go:GO:1903073","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of death-inducing signaling complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21785459]","metadata":null},{"id":"5a7f25e4767946f39392889bc5b2cf04","type":"GO_TERM","name":"negative regulation of defecation","canonical_id":"go:GO:2000293","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of defecation.\" [GOC:obol]","metadata":null},{"id":"799ba1f733b94ba1bda3b04243a17692","type":"GO_TERM","name":"negative regulation of defecation rhythm","canonical_id":"go:GO:2000747","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of defecation rhythm.\" [GOC:kmv]","metadata":null},{"id":"def6316e342f418a965a541d4cfc9812","type":"GO_TERM","name":"negative regulation of defense response","canonical_id":"go:GO:0031348","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a defense response.\" [GOC:mah]","metadata":null},{"id":"48a92aab060e405cbcc4c3b9921822fb","type":"GO_TERM","name":"negative regulation of defense response to bacterium","canonical_id":"go:GO:1900425","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of defense response to bacterium.\" [GOC:TermGenie, PMID:22346749]","metadata":null},{"id":"8e1a7b1c6a0843b8968e75a4c1901daf","type":"GO_TERM","name":"negative regulation of defense response to insect","canonical_id":"go:GO:1900366","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of defense response to insect.\" [GOC:TermGenie, PMID:22474183]","metadata":null},{"id":"31823fe8fb314a2bb66cbe1d2b83da82","type":"GO_TERM","name":"negative regulation of defense response to oomycetes","canonical_id":"go:GO:1902289","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of defense response to oomycetes.\" [GOC:TermGenie, PMID:16040633]","metadata":null},{"id":"e64c522b0e56492f90a7be89858c7fb9","type":"GO_TERM","name":"negative regulation of defense response to virus","canonical_id":"go:GO:0050687","description":"\"Any process that stops, prevents or reduces the rate or extent of antiviral mechanisms, thereby facilitating viral replication.\" [GOC:ai]","metadata":null},{"id":"0966bcc5a2384615b6b2782d5f161731","type":"GO_TERM","name":"negative regulation of defense response to virus by host","canonical_id":"go:GO:0050689","description":"\"Any host process that results in the inhibition of antiviral immune response mechanisms, thereby facilitating viral replication. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"3adb429b48af45c387493a94c3d290d4","type":"GO_TERM","name":"negative regulation of dehydroaustinol biosynthetic process","canonical_id":"go:GO:1900650","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dehydroaustinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"235010aabbb449cd869636ae75d5e0cf","type":"GO_TERM","name":"negative regulation of dehydroepiandrosterone secretion","canonical_id":"go:GO:2000841","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dehydroepiandrosterone secretion.\" [GOC:sl]","metadata":null},{"id":"75d1804757e74d9a86b99748c5b8b9f4","type":"GO_TERM","name":"negative regulation of delayed rectifier potassium channel activity","canonical_id":"go:GO:1902260","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of delayed rectifier potassium channel activity.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:11299204]","metadata":null},{"id":"24d2d435dba545cbb2cece1286317cbc","type":"GO_TERM","name":"negative regulation of demethylkotanin biosynthetic process","canonical_id":"go:GO:1900653","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of demethylkotanin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"bbd05badf01a4d0f8642dd149e3080bf","type":"GO_TERM","name":"negative regulation of dendrite development","canonical_id":"go:GO:2000171","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of dendrite development.\" [GOC:obol]","metadata":null},{"id":"a01a0d3561dd4fea8d06953902682513","type":"GO_TERM","name":"negative regulation of dendrite extension","canonical_id":"go:GO:1903860","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dendrite extension.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24898855]","metadata":null},{"id":"6e1ca216f3f1446f9e40ac0f51e2b808","type":"GO_TERM","name":"negative regulation of dendrite morphogenesis","canonical_id":"go:GO:0050774","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of dendrite morphogenesis.\" [GOC:ai]","metadata":null},{"id":"21997db4bece44f185de192a2c5d7c9a","type":"GO_TERM","name":"negative regulation of dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002605","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"8b9f8924f79741bbb0c829e70b724f5c","type":"GO_TERM","name":"negative regulation of dendritic cell apoptotic process","canonical_id":"go:GO:2000669","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"93c7519606a84c39b8ef0c37715eef06","type":"GO_TERM","name":"negative regulation of dendritic cell chemotaxis","canonical_id":"go:GO:2000509","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"775bfba4138744cdba0181c9b7f4a3ac","type":"GO_TERM","name":"negative regulation of dendritic cell cytokine production","canonical_id":"go:GO:0002731","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"c43747ea663c4b68a99738faee22d02d","type":"GO_TERM","name":"negative regulation of dendritic cell dendrite assembly","canonical_id":"go:GO:2000548","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell dendrite assembly.\" [GOC:obol]","metadata":null},{"id":"562f5dbf3473457bace80049d7af2c57","type":"GO_TERM","name":"negative regulation of dendritic cell differentiation","canonical_id":"go:GO:2001199","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dendritic cell differentiation.\" [GOC:obol]","metadata":null},{"id":"ace00fedda1543a5a9b870371b83df9f","type":"GO_TERM","name":"negative regulation of dendritic spine development","canonical_id":"go:GO:0061000","description":"\"Any process that decreases the rate, frequency, or extent of dendritic spine development, the process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"e54b3802d4054047b3ee4db1b5ebb8f5","type":"GO_TERM","name":"negative regulation of dendritic spine maintenance","canonical_id":"go:GO:1902951","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dendritic spine maintenance.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24328732]","metadata":null},{"id":"2cfe451de9af44168b69bf28cb3e9747","type":"GO_TERM","name":"negative regulation of dendritic spine morphogenesis","canonical_id":"go:GO:0061002","description":"\"Any process that decreases the rate, frequency, or extent of dendritic spine morphogenesis, the process in which the anatomical structures of a dendritic spine are generated and organized. A dendritic spine is a protrusion from a dendrite and a specialized subcellular compartment involved in synaptic transmission.\" [GOC:dph]","metadata":null},{"id":"a5899e8f4b0e4fb0b5d0156214d7ca5d","type":"GO_TERM","name":"negative regulation of dense core granule biogenesis","canonical_id":"go:GO:2000706","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dense core granule biogenesis.\" [GOC:obol]","metadata":null},{"id":"fd319df34f404386a190618a65c580e0","type":"GO_TERM","name":"negative regulation of dense core granule exocytosis","canonical_id":"go:GO:1905414","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dense core granule exocytosis.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"6aa7c297f48c4f32a5f2f97bf712985b","type":"GO_TERM","name":"negative regulation of dense core granule transport","canonical_id":"go:GO:1904810","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dense core granule transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22699897]","metadata":null},{"id":"3d937ff60fe3414aa61dc8fa60d8d941","type":"GO_TERM","name":"negative regulation of dephosphorylation","canonical_id":"go:GO:0035305","description":"\"Any process the stops, prevents, or reduces the frequency, rate or extent of removal of phosphate groups from a molecule.\" [GOC:bf]","metadata":null},{"id":"10470b4fd7ab4f1b904a362fb17507de","type":"GO_TERM","name":"negative regulation of dermatome development","canonical_id":"go:GO:0061185","description":"\"Any process that decreases the rate, frequency, or extent of the progression of the dermatome over time, from its initial formation to the mature structure. The dermatome is the portion of a somite that will form skin.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"cd17d272d09e4363bc3a037312a78f28","type":"GO_TERM","name":"negative regulation of detection of glucose","canonical_id":"go:GO:2000971","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of detection of glucose.\" [GOC:BHF]","metadata":null},{"id":"cb6be09947854ecfad27afb5378e061f","type":"GO_TERM","name":"negative regulation of detection of mechanical stimulus involved in sensory perception of touch","canonical_id":"go:GO:1905788","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of detection of mechanical stimulus involved in sensory perception of touch.\" [GO_REF:0000058, GOC:TermGenie, PMID:8692859]","metadata":null},{"id":"2885a49f965c4083b528cc1448f31959","type":"GO_TERM","name":"negative regulation of determination of dorsal identity","canonical_id":"go:GO:2000016","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of determination of dorsal identity.\" [GOC:BHF, GOC:obol]","metadata":null},{"id":"eccd0be8cf174d3193c42ae512f3d004","type":"GO_TERM","name":"negative regulation of development, heterochronic","canonical_id":"go:GO:0045961","description":"\"Any process that modulates the consistent predetermined time point at which an integrated living unit or organism progresses from an initial condition to a later condition and decreases the rate at which this time point is reached.\" [GOC:curators]","metadata":null},{"id":"74f19285e4f54a87bdae72a6b07912fa","type":"GO_TERM","name":"negative regulation of developmental growth","canonical_id":"go:GO:0048640","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of developmental growth.\" [GOC:curators]","metadata":null},{"id":"67216457f4334cc9b3208dc4a19857f2","type":"GO_TERM","name":"negative regulation of developmental pigmentation","canonical_id":"go:GO:0048086","description":"\"Any process that decreases the frequency, rate or extent of the developmental process that results in the deposition of coloring matter in an organism.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"b59476c783bc4d1389b579cc00e9823c","type":"GO_TERM","name":"negative regulation of developmental process","canonical_id":"go:GO:0051093","description":"\"Any process that stops, prevents or reduces the rate or extent of development, the biological process whose specific outcome is the progression of an organism over time from an initial condition (e.g. a zygote, or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).\" [GOC:ai]","metadata":null},{"id":"279ede1cde86427cb37eab1aa5852a76","type":"GO_TERM","name":"negative regulation of developmental vegetative growth","canonical_id":"go:GO:1905614","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of developmental vegetative growth.\" [GO_REF:0000058, GOC:TermGenie, PMID:11606552]","metadata":null},{"id":"9457e348fd3b442a8d71199a94ca218a","type":"GO_TERM","name":"negative regulation of diacylglycerol biosynthetic process","canonical_id":"go:GO:1900481","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of diacylglycerol biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"9be06d6baa094e1f9e8e7f4189c72c55","type":"GO_TERM","name":"negative regulation of digestive system process","canonical_id":"go:GO:0060457","description":"\"Any process that decreases the frequency, rate or extent of a digestive system process, a physical, chemical, or biochemical process carried out by living organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4d13fae5c6bc432c89dbac688bfc4140","type":"GO_TERM","name":"negative regulation of dipeptide transmembrane transport","canonical_id":"go:GO:2001149","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dipeptide transmembrane transport.\" [GOC:obol]","metadata":null},{"id":"cc4160d131af4129b12eabe8fc756e99","type":"GO_TERM","name":"negative regulation of dipeptide transport","canonical_id":"go:GO:2000879","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dipeptide transport.\" [GOC:obol]","metadata":null},{"id":"dd7117fc4d18418aabe7333b64d7b88c","type":"GO_TERM","name":"negative regulation of direction of cell growth","canonical_id":"go:GO:0061391","description":"\"Any process that decreases the direction of cell growth.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"14698137afb8465984e7736c90f08b93","type":"GO_TERM","name":"negative regulation of distal tip cell migration","canonical_id":"go:GO:1903355","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of distal tip cell migration.\" [GO_REF:0000058, GOC:mm2, GOC:TermGenie, PMID:24968003]","metadata":null},{"id":"afebbc1895fe434b9895cf05208ef6b5","type":"GO_TERM","name":"negative regulation of division septum assembly","canonical_id":"go:GO:0010974","description":"\"Any process that decreases the frequency, rate or extent of division septum formation. division septum formation is he assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis.\" [GOC:mtg_cell_cycle, PMID:19959363, PMID:21246752, PMID:22786806]","metadata":null},{"id":"a4886c607c4f487d9bfca575cddf2d72","type":"GO_TERM","name":"negative regulation of dopamine biosynthetic process","canonical_id":"go:GO:1903180","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dopamine biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"73734dc34f6b43d6a6cf77c3e0009751","type":"GO_TERM","name":"negative regulation of dopamine metabolic process","canonical_id":"go:GO:0045963","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving dopamine.\" [GOC:curators]","metadata":null},{"id":"2e2afa2c5e5941388eaf8e269eaa38af","type":"GO_TERM","name":"negative regulation of dopamine receptor signaling pathway","canonical_id":"go:GO:0060160","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of dopamine receptor protein signaling pathway activity. A dopamine receptor signaling pathway is the series of molecular signals generated as a consequence of a dopamine receptor binding to one of its physiological ligands.\" [GOC:dph]","metadata":null},{"id":"7e85a2eee88c448fbb9917fd420441e4","type":"GO_TERM","name":"negative regulation of dopamine secretion","canonical_id":"go:GO:0033602","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of dopamine.\" [GOC:sl]","metadata":null},{"id":"6cc11566ee8842619c4a4dec107578c7","type":"GO_TERM","name":"negative regulation of dopamine uptake involved in synaptic transmission","canonical_id":"go:GO:0051585","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of dopamine into a presynaptic neuron or glial cell.\" [GOC:ai]","metadata":null},{"id":"7da5a93210e7402eadcc2bd94d0385b1","type":"GO_TERM","name":"negative regulation of dopaminergic neuron differentiation","canonical_id":"go:GO:1904339","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dopaminergic neuron differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15522889]","metadata":null},{"id":"1c1cc847bf2e424c85cbe64853fd3dc7","type":"GO_TERM","name":"negative regulation of dorsal/ventral axon guidance","canonical_id":"go:GO:1905816","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of dorsal/ventral axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:18434533]","metadata":null},{"id":"e48738634fd14849889f78aa4c8dd790","type":"GO_TERM","name":"negative regulation of double-strand break repair","canonical_id":"go:GO:2000780","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of double-strand break repair.\" [GOC:BHF]","metadata":null},{"id":"6516eb30ae7c434da04c911b87eb8228","type":"GO_TERM","name":"negative regulation of double-strand break repair via break-induced replication","canonical_id":"go:GO:1901592","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of double-strand break repair via break-induced replication.\" [GOC:TermGenie]","metadata":null},{"id":"e35f947de4c542dfa1f23b7391aab054","type":"GO_TERM","name":"negative regulation of double-strand break repair via homologous recombination","canonical_id":"go:GO:2000042","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of double-strand break repair via homologous recombination.\" [GOC:vw]","metadata":null},{"id":"ee1bada2ffa44081931018c953e9ce6c","type":"GO_TERM","name":"negative regulation of double-strand break repair via nonhomologous end joining","canonical_id":"go:GO:2001033","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of double-strand break repair via nonhomologous end joining.\" [GOC:obol]","metadata":null},{"id":"a251afa1de074f85b5cdf2a40c0f48c6","type":"GO_TERM","name":"negative regulation of double-strand break repair via single-strand annealing","canonical_id":"go:GO:1901291","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of double-strand break repair via single-strand annealing.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"d39640227b384c2399035c43f41fae9a","type":"GO_TERM","name":"negative regulation of ductus arteriosus closure","canonical_id":"go:GO:1904336","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ductus arteriosus closure.\" [GO_REF:0000058, GOC:TermGenie, PMID:16303610]","metadata":null},{"id":"1a1650da16c04d398500e3d0941baa61","type":"GO_TERM","name":"negative regulation of early endosome to late endosome transport","canonical_id":"go:GO:2000642","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of early endosome to late endosome transport.\" [GOC:BHF]","metadata":null},{"id":"91aaa6ae8c0a4d9bb2d2886d82587cf7","type":"GO_TERM","name":"negative regulation of early stripe melanocyte differentiation","canonical_id":"go:GO:0050947","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of early stripe melanocyte differentiation.\" [GOC:ai]","metadata":null},{"id":"b1b40d7081e744cf9ca199f255b564ae","type":"GO_TERM","name":"negative regulation of eating behavior","canonical_id":"go:GO:1903999","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of eating behavior.\" [GO_REF:0000058, GOC:TermGenie, PMID:11961051]","metadata":null},{"id":"d207de1152ac4a2fa3ed55916d695386","type":"GO_TERM","name":"negative regulation of ecdysone receptor signaling pathway","canonical_id":"go:GO:0120143","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of any ecdysone receptor signaling pathway.\" [GOC:ha, PMID:23072462]","metadata":null},{"id":"66e0d730db364e48a0f58b48c75dacff","type":"GO_TERM","name":"negative regulation of ecdysteroid biosynthetic process","canonical_id":"go:GO:0045997","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ecdysteroids.\" [GOC:curators]","metadata":null},{"id":"3f7fd54a9b8947ddb43c52fbba974c2e","type":"GO_TERM","name":"negative regulation of ecdysteroid secretion","canonical_id":"go:GO:0045999","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of ecdysteroid.\" [GOC:curators]","metadata":null},{"id":"9ec54d012e4641a2a7d303aa353b2291","type":"GO_TERM","name":"negative regulation of eclosion","canonical_id":"go:GO:0045804","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of eclosion.\" [GOC:curators]","metadata":null},{"id":"36a53041bd5441658053ecc00491dd4d","type":"GO_TERM","name":"negative regulation of ectoderm development","canonical_id":"go:GO:2000384","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ectoderm development.\" [GOC:BHF]","metadata":null},{"id":"3d991902c7344dff873d6aefe9c3a752","type":"GO_TERM","name":"negative regulation of ectodermal cell fate specification","canonical_id":"go:GO:0042666","description":"\"Any process that restricts, stops or prevents a cell from specifying into an ectoderm cell.\" [GOC:curators]","metadata":null},{"id":"2ab7e7853c694401a32465917be69b30","type":"GO_TERM","name":"negative regulation of egg-laying behavior","canonical_id":"go:GO:1901045","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of oviposition.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"7af5d0a9c65247cd86663035c0305b93","type":"GO_TERM","name":"negative regulation of elastin catabolic process","canonical_id":"go:GO:0060311","description":"\"Any process that decreases the rate, frequency or extent of elastin catabolism, the chemical reactions and pathways resulting in the breakdown of elastin.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5206f50ba2e84435b8f943bbd4765979","type":"GO_TERM","name":"negative regulation of embryo sac central cell differentiation","canonical_id":"go:GO:0045692","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of embryo sac central cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"dea10ecbf9044834bc8a1d8f1abaeb06","type":"GO_TERM","name":"negative regulation of embryo sac egg cell differentiation","canonical_id":"go:GO:0045695","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of embryo sac egg cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"5e0f4388d6b54d1aa1dc5ac71c10ef02","type":"GO_TERM","name":"negative regulation of embryonic camera-type eye development","canonical_id":"go:GO:1902864","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of embryonic camera-type eye development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"852de06820a24db897b657aa116500bc","type":"GO_TERM","name":"negative regulation of embryonic development","canonical_id":"go:GO:0045992","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of embryonic development.\" [GOC:curators]","metadata":null},{"id":"24ba3a043d7947f6909a6fbaf42713d3","type":"GO_TERM","name":"negative regulation of embryonic pattern specification","canonical_id":"go:GO:1902876","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of embryonic pattern specification.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"ad0f425486a441658dd8ef40237b7513","type":"GO_TERM","name":"negative regulation of embryonic skeletal joint development","canonical_id":"go:GO:1902763","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of embryonic skeletal joint development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16575901]","metadata":null},{"id":"2af6de3634204eaa926376e3b6dacda7","type":"GO_TERM","name":"negative regulation of emericellamide A biosynthetic process","canonical_id":"go:GO:1900662","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of emericellamide A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"df56285570b04b3486e1b236d62e9aaa","type":"GO_TERM","name":"negative regulation of emericellamide biosynthetic process","canonical_id":"go:GO:1900659","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of emericellamide biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e5fdfa92ece14368a94ecf737dd60a78","type":"GO_TERM","name":"negative regulation of emericellin biosynthetic process","canonical_id":"go:GO:1900835","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of emericellin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"36de48ba7bfe46aa90edbb9438938f09","type":"GO_TERM","name":"negative regulation of emodin biosynthetic process","canonical_id":"go:GO:1900665","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of emodin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"dc42da59de6f4054b3dd1235dce230ed","type":"GO_TERM","name":"negative regulation of enamel mineralization","canonical_id":"go:GO:0070174","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of enamel mineralization, the deposition of calcium salts in tooth enamel.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"49978d2806e1412dbad38e32ed392f41","type":"GO_TERM","name":"negative regulation of encysted zoospore germination","canonical_id":"go:GO:0075229","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of encysted zoospore germination.\" [GOC:pamgo_curators]","metadata":null},{"id":"9e9b651cb7614cebb60c3e934c93fb45","type":"GO_TERM","name":"negative regulation of endocardial cushion cell differentiation","canonical_id":"go:GO:0120076","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of endocardial cushion cell differentiation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"98ff8754a8a341559a53b67c3bb05ec4","type":"GO_TERM","name":"negative regulation of endocardial cushion to mesenchymal transition","canonical_id":"go:GO:0140050","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endocardial cushion to mesenchymal transition.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:21778427]","metadata":null},{"id":"8be5df60c6914c7e9210f3835308c67c","type":"GO_TERM","name":"negative regulation of endocrocin biosynthetic process","canonical_id":"go:GO:1900668","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endocrocin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3b1ac25a7bc946d7b95cf4810161e8c2","type":"GO_TERM","name":"negative regulation of endocytic recycling","canonical_id":"go:GO:2001136","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endocytic recycling.\" [GOC:obol]","metadata":null},{"id":"d03635129e004490b47ba524d70356aa","type":"GO_TERM","name":"negative regulation of endocytosis","canonical_id":"go:GO:0045806","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis.\" [GOC:curators]","metadata":null},{"id":"7379513d3ca04954a66d5c81244771c6","type":"GO_TERM","name":"negative regulation of endodermal cell differentiation","canonical_id":"go:GO:1903225","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endodermal cell differentiation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23154389]","metadata":null},{"id":"2ca8d60df425452182d0ef8a30fa0ae7","type":"GO_TERM","name":"negative regulation of endodermal cell fate specification","canonical_id":"go:GO:0042664","description":"\"Any process that restricts, stops or prevents a cell from specifying into an endoderm cell.\" [GOC:curators]","metadata":null},{"id":"4aaf59e3cdbf4806a04fe4a668283243","type":"GO_TERM","name":"negative regulation of endopeptidase activity","canonical_id":"go:GO:0010951","description":"\"Any process that decreases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"032a6c6254424d4fa83ecff01c336509","type":"GO_TERM","name":"negative regulation of endoplasmic reticulum calcium ion concentration","canonical_id":"go:GO:0032471","description":"\"Any process that decreases the concentration of calcium ions in the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"d32cccbe87ed49c0b977c0f3fc85c71e","type":"GO_TERM","name":"negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation","canonical_id":"go:GO:1903912","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endoplasmic reticulum stress-induced eiF2alpha phosphorylation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:16835242]","metadata":null},{"id":"9ff46b10d2724a13acf76d60995e909c","type":"GO_TERM","name":"negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1902236","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:20160352]","metadata":null},{"id":"d2bc4d93170b4a238026a0db6e3fd7b4","type":"GO_TERM","name":"negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903382","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23453807]","metadata":null},{"id":"61ff8e5787ee404facfecb34fce177c8","type":"GO_TERM","name":"negative regulation of endoplasmic reticulum tubular network organization","canonical_id":"go:GO:1903372","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endoplasmic reticulum tubular network organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24891604]","metadata":null},{"id":"603e0c1a50944de5b74da36f2635970f","type":"GO_TERM","name":"negative regulation of endoplasmic reticulum unfolded protein response","canonical_id":"go:GO:1900102","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endoplasmic reticulum unfolded protein response.\" [GOC:TermGenie]","metadata":null},{"id":"15d26f7865d742e8be38ccc59f8c6cdf","type":"GO_TERM","name":"negative regulation of endoribonuclease activity","canonical_id":"go:GO:0060702","description":"\"Any process that decreases the rate, frequency or extent of the catalysis of the hydrolysis of ester linkages within ribonucleic acid by creating internal breaks.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c957267dc4d4465b80c830b822509872","type":"GO_TERM","name":"negative regulation of endosomal vesicle fusion","canonical_id":"go:GO:1905362","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endosomal vesicle fusion.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"3c918e2143f8408baa97e12bcb77d34a","type":"GO_TERM","name":"negative regulation of endosome organization","canonical_id":"go:GO:1904979","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endosome organization.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22511594]","metadata":null},{"id":"c4d8a2751a0e4d2f952fcef88d763aff","type":"GO_TERM","name":"negative regulation of endosome to plasma membrane protein transport","canonical_id":"go:GO:1905750","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endosome to plasma membrane protein transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22869721]","metadata":null},{"id":"452c577a21444b1aafe2a3911dc4cebc","type":"GO_TERM","name":"negative regulation of endosperm development","canonical_id":"go:GO:1904095","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endosperm development.\" [GO_REF:0000058, GOC:TermGenie, PMID:25194028]","metadata":null},{"id":"adee2186a8eb4373b7b57d30d5391c2a","type":"GO_TERM","name":"negative regulation of endothelial cell activation","canonical_id":"go:GO:1904988","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell activation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:24255059]","metadata":null},{"id":"4de5976160cc416f95977a1dd5af4cbb","type":"GO_TERM","name":"negative regulation of endothelial cell apoptotic process","canonical_id":"go:GO:2000352","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell apoptotic process.\" [GOC:BHF, GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"3e368221e94b410da57289e4c050931b","type":"GO_TERM","name":"negative regulation of endothelial cell chemotaxis","canonical_id":"go:GO:2001027","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell chemotaxis.\" [GOC:BHF]","metadata":null},{"id":"c56bc36de7584dba9ebcf0ab2337fbca","type":"GO_TERM","name":"negative regulation of endothelial cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:2000545","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell chemotaxis to fibroblast growth factor.\" [GOC:obol]","metadata":null},{"id":"6c20e5ed7fe842859a4d235d65448671","type":"GO_TERM","name":"negative regulation of endothelial cell chemotaxis to vascular endothelial growth factor","canonical_id":"go:GO:1904858","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell chemotaxis to vascular endothelial growth factor.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:21885851]","metadata":null},{"id":"2641195f745d400e967e31acae633182","type":"GO_TERM","name":"negative regulation of endothelial cell development","canonical_id":"go:GO:1901551","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell development.\" [GOC:pr, GOC:TermGenie, PMID:19470579]","metadata":null},{"id":"8a5b82648a0d4abab29725f5a83f4531","type":"GO_TERM","name":"negative regulation of endothelial cell differentiation","canonical_id":"go:GO:0045602","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of endothelial cell differentiation.\" [GOC:curators]","metadata":null},{"id":"51fa85e012b848a5ba7220a057d61a16","type":"GO_TERM","name":"negative regulation of endothelial cell migration","canonical_id":"go:GO:0010596","description":"\"Any process that decreases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"4f3e41ea869c49fab4c999b8ff349b69","type":"GO_TERM","name":"negative regulation of endothelial cell proliferation","canonical_id":"go:GO:0001937","description":"\"Any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation.\" [GOC:add]","metadata":null},{"id":"c340e522c4ce4593a29d97bca3606188","type":"GO_TERM","name":"negative regulation of endothelial cell-matrix adhesion","canonical_id":"go:GO:1904905","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell-matrix adhesion.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:19460962]","metadata":null},{"id":"f3592f18e4aa4d809e45e1e4b77b65ab","type":"GO_TERM","name":"negative regulation of endothelial microparticle formation","canonical_id":"go:GO:2000336","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial microparticle formation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"78a47306089a4ea891dcafd424f5bb76","type":"GO_TERM","name":"negative regulation of endothelial tube morphogenesis","canonical_id":"go:GO:1905955","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelial tube morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:25961718]","metadata":null},{"id":"e97baf17b1ff45dda4a8422c51a8ac96","type":"GO_TERM","name":"negative regulation of endothelin production","canonical_id":"go:GO:1904471","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of endothelin production.\" [GO_REF:0000058, GOC:TermGenie, PMID:15560120]","metadata":null},{"id":"374095f6bd1140a7b42900471c8ab35f","type":"GO_TERM","name":"negative regulation of engulfment of apoptotic cell","canonical_id":"go:GO:1901075","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of engulfment of apoptotic cell.\" [GO:kmv, GOC:TermGenie, PMID:19402756]","metadata":null},{"id":"141de32c691e4672b4d3750616641584","type":"GO_TERM","name":"negative regulation of ent-pimara-8(14),15-diene biosynthetic process","canonical_id":"go:GO:1901543","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ent-pimara-8(14),15-diene biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ac5d7c51d37548a59f2b187331d83b9a","type":"GO_TERM","name":"negative regulation of enteroendocrine cell differentiation","canonical_id":"go:GO:7770019","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of enteroendocrine cell differentiation.\" [PMID:37883554]","metadata":null},{"id":"9efee7c5e2eb47028c1145838b46fb41","type":"GO_TERM","name":"negative regulation of entry into reproductive diapause","canonical_id":"go:GO:0061964","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the dormancy process that results in entry into reproductive diapause. Reproductive diapause is a form of diapause where the organism itself will remain fully active, including feeding and other routine activities, but the reproductive organs experience a tissue-specific reduction in metabolism, with characteristic triggering and releasing stimuli.\" [GOC:ha, PMID:27689881]","metadata":null},{"id":"51864ef3e1d54605915fa9311b6df034","type":"GO_TERM","name":"negative regulation of entry of bacterium into host cell","canonical_id":"go:GO:2000536","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of entry of bacterium into host cell.\" [GOC:obol]","metadata":null},{"id":"429afedce6f943aab0843b41be1edd08","type":"GO_TERM","name":"negative regulation of eosinophil activation","canonical_id":"go:GO:1902567","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of eosinophil activation.\" [GOC:TermGenie, PMID:16254138]","metadata":null},{"id":"07dfbbc849cd40d4be4d4e744d19d773","type":"GO_TERM","name":"negative regulation of eosinophil chemotaxis","canonical_id":"go:GO:2000423","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of eosinophil chemotaxis.\" [GOC:obol]","metadata":null},{"id":"5ba95b43682b4e3189c5b4e8128fee7b","type":"GO_TERM","name":"negative regulation of eosinophil degranulation","canonical_id":"go:GO:0043310","description":"\"Any process that stops, prevents, or reduces the rate of eosinophil degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"e7f07eeeb08548e0ba55ebd57382c789","type":"GO_TERM","name":"negative regulation of eosinophil differentiation","canonical_id":"go:GO:0045644","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of eosinophil differentiation.\" [GOC:curators]","metadata":null},{"id":"b8753c6a1db74d18bb74b0d1dcba5719","type":"GO_TERM","name":"negative regulation of eosinophil extravasation","canonical_id":"go:GO:2000420","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of eosinophil extravasation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b5979b3c36564c79bdb418658a172f29","type":"GO_TERM","name":"negative regulation of eosinophil migration","canonical_id":"go:GO:2000417","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of eosinophil migration.\" [GOC:mah]","metadata":null},{"id":"502a701b8667473db7e3febfb5ce3ac1","type":"GO_TERM","name":"negative regulation of ephrin receptor signaling pathway","canonical_id":"go:GO:1901188","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ephrin receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"917ced3ef2774a49966031668a31fe3b","type":"GO_TERM","name":"negative regulation of epiboly involved in gastrulation with mouth forming second","canonical_id":"go:GO:1904087","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epiboly involved in gastrulation with mouth forming second.\" [GO_REF:0000058, GOC:TermGenie, PMID:24892953]","metadata":null},{"id":"5ddfdf53a1fa4989a6c39cf9c8ed7a06","type":"GO_TERM","name":"negative regulation of epidermal cell differentiation","canonical_id":"go:GO:0045605","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal cell differentiation.\" [GOC:curators]","metadata":null},{"id":"52ffc6b69f8546d68559db76594f8717","type":"GO_TERM","name":"negative regulation of epidermal growth factor receptor signaling pathway","canonical_id":"go:GO:0042059","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"57367fce6eeb410b9095340d91cc4b7e","type":"GO_TERM","name":"negative regulation of epidermal growth factor-activated receptor activity","canonical_id":"go:GO:0007175","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of EGF-activated receptor activity.\" [GOC:curators]","metadata":null},{"id":"268121ac258d4ad5bff7f0fc6b9a6a2d","type":"GO_TERM","name":"negative regulation of epidermis development","canonical_id":"go:GO:0045683","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermis development.\" [GOC:curators]","metadata":null},{"id":"43db94b8b73f43eeb964b1231ac9970f","type":"GO_TERM","name":"negative regulation of epinephrine secretion","canonical_id":"go:GO:0032811","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of epinephrine.\" [GOC:vk]","metadata":null},{"id":"72d06ee85f30444ab098420c1e8a4023","type":"GO_TERM","name":"negative regulation of epinephrine uptake","canonical_id":"go:GO:0051627","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of epinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"6652dfff15d54898a4b0f26a6d6563ef","type":"GO_TERM","name":"negative regulation of epithelial cell apoptotic process","canonical_id":"go:GO:1904036","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epithelial cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:19137015]","metadata":null},{"id":"1efb4f858cae4676b5d0e0863e2109ff","type":"GO_TERM","name":"negative regulation of epithelial cell differentiation","canonical_id":"go:GO:0030857","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of epithelial cell differentiation.\" [GOC:mah]","metadata":null},{"id":"b89e4967a13c45cda21e16cb523fc4e0","type":"GO_TERM","name":"negative regulation of epithelial cell differentiation involved in kidney development","canonical_id":"go:GO:2000697","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epithelial cell differentiation involved in kidney development.\" [GOC:mtg_kidney_jan10, GOC:yaf]","metadata":null},{"id":"581a0eff7a104a5985560d88de6b67ed","type":"GO_TERM","name":"negative regulation of epithelial cell migration","canonical_id":"go:GO:0010633","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of epithelial cell migration.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"7a2f3cf0516544c489d83c61b32a1d00","type":"GO_TERM","name":"negative regulation of epithelial cell proliferation","canonical_id":"go:GO:0050680","description":"\"Any process that stops, prevents or reduces the rate or extent of epithelial cell proliferation.\" [GOC:ai]","metadata":null},{"id":"f66e7fc9be304f9297e2896f75529ccd","type":"GO_TERM","name":"negative regulation of epithelial cell proliferation involved in lung morphogenesis","canonical_id":"go:GO:2000795","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epithelial cell proliferation involved in lung morphogenesis.\" [PMID:21513708]","metadata":null},{"id":"21353249717140939e363516c852e75f","type":"GO_TERM","name":"negative regulation of epithelial cell proliferation involved in prostate gland development","canonical_id":"go:GO:0060770","description":"\"Any process that decreases the rate, frequency or extent of epithelial cell proliferation that contributes to the progression of the prostate gland over time.\" [GOC:dph]","metadata":null},{"id":"6968641cc8e84ade9280aa5e9fc406c4","type":"GO_TERM","name":"negative regulation of epithelial to mesenchymal transition","canonical_id":"go:GO:0010719","description":"\"Any process that decreases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"f8684b9c61a5441bbc4309c5d5184307","type":"GO_TERM","name":"negative regulation of epithelial to mesenchymal transition involved in endocardial cushion formation","canonical_id":"go:GO:1905006","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epithelial to mesenchymal transition involved in endocardial cushion formation.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"6d9a1e856e7f4da489d9356c7c031a57","type":"GO_TERM","name":"negative regulation of epithelial tube formation","canonical_id":"go:GO:1905277","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epithelial tube formation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25745997]","metadata":null},{"id":"e67426d5eabe463fb13b4cb8b8404bb1","type":"GO_TERM","name":"negative regulation of epithelium regeneration","canonical_id":"go:GO:1905042","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of epithelium regeneration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23221517]","metadata":null},{"id":"efba65a2b1394c6984687f65ffcddf86","type":"GO_TERM","name":"negative regulation of ergosterol biosynthetic process","canonical_id":"go:GO:0010895","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ergosterol.\" [GOC:tb]","metadata":null},{"id":"25ff41ead95e45ae83da390e8caa992d","type":"GO_TERM","name":"negative regulation of ergot alkaloid biosynthetic process","canonical_id":"go:GO:1900823","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ergot alkaloid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"d8eb37b8336d464bb90c87ca0c653391","type":"GO_TERM","name":"negative regulation of error-prone translesion synthesis","canonical_id":"go:GO:1904332","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of error-prone translesion synthesis.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22761594]","metadata":null},{"id":"8fcaaef9321c4f1eb20d8560af679d33","type":"GO_TERM","name":"negative regulation of erythrocyte aggregation","canonical_id":"go:GO:0034119","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of erythrocyte aggregation.\" [GOC:add]","metadata":null},{"id":"b584903a389e4a57b138c512ba38a03b","type":"GO_TERM","name":"negative regulation of erythrocyte apoptotic process","canonical_id":"go:GO:1902251","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of erythrocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"b7ae1135d1844e0ba8e2a8ef1e9b25f5","type":"GO_TERM","name":"negative regulation of erythrocyte clearance","canonical_id":"go:GO:0034107","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of erythrocyte clearance.\" [GOC:add, PMID:12905029, PMID:14754397]","metadata":null},{"id":"a420cf2f619e43c4b590da7c8a05a0bd","type":"GO_TERM","name":"negative regulation of erythrocyte differentiation","canonical_id":"go:GO:0045647","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of erythrocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"fc0a626dc495481c94f3de483a9dfb80","type":"GO_TERM","name":"negative regulation of erythrocyte enucleation","canonical_id":"go:GO:0061932","description":"\"Any process that decreases the frequency, rate or extent of erythrocyte enucleation.\" [PMID:25241935]","metadata":null},{"id":"5a8dabb6355e4593ac1ef005128e74ba","type":"GO_TERM","name":"negative regulation of erythrophore differentiation","canonical_id":"go:GO:0048779","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of erythrophore differentiation.\" [GOC:mh]","metadata":null},{"id":"8f51a8e0b45e45f5b1ba5a3ed97c7531","type":"GO_TERM","name":"negative regulation of establishment of RNA localization to telomere","canonical_id":"go:GO:1904911","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of RNA localization to telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"2c2a158ec5524adf9e5ab813fb14dcfa","type":"GO_TERM","name":"negative regulation of establishment of Sertoli cell barrier","canonical_id":"go:GO:1904445","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of Sertoli cell barrier.\" [GO_REF:0000058, GOC:TermGenie, PMID:18057314]","metadata":null},{"id":"0d343c686095457ab267a99e24ee7a23","type":"GO_TERM","name":"negative regulation of establishment of T cell polarity","canonical_id":"go:GO:1903904","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of T cell polarity.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"d38220d48a5d408f80f381424ff22a58","type":"GO_TERM","name":"negative regulation of establishment of bipolar cell polarity","canonical_id":"go:GO:1904846","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of bipolar cell polarity.\" [GO_REF:0000058, GOC:TermGenie, PMID:26525038]","metadata":null},{"id":"9ba40a21bd614d24ade219d27306bcdf","type":"GO_TERM","name":"negative regulation of establishment of blood-brain barrier","canonical_id":"go:GO:0090212","description":"\"Any process that decreases the rate, frequency or extent of the establishment of the blood-brain barrier, a selectively permeable structural and functional barrier that exists between the capillaries and the brain.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8d02b6e2885c4b0388cf1df7c5c177a2","type":"GO_TERM","name":"negative regulation of establishment of cell polarity regulating cell shape","canonical_id":"go:GO:2000783","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of cell polarity regulating cell shape.\" [GOC:Mah]","metadata":null},{"id":"a13f646165ad425b85fbe0c32d65b4b8","type":"GO_TERM","name":"negative regulation of establishment of competence for transformation","canonical_id":"go:GO:0045808","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of competence for transformation.\" [GOC:curators]","metadata":null},{"id":"982711a97ec64715bae6bd2bff7bae77","type":"GO_TERM","name":"negative regulation of establishment of endothelial barrier","canonical_id":"go:GO:1903141","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of endothelial barrier.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24851274]","metadata":null},{"id":"2be95c4bf87c4fd1908d92fa75b3cb8d","type":"GO_TERM","name":"negative regulation of establishment of protein localization","canonical_id":"go:GO:1904950","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of protein localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:22761445]","metadata":null},{"id":"a477e46657124de0931128a2fe78c90f","type":"GO_TERM","name":"negative regulation of establishment of protein localization to telomere","canonical_id":"go:GO:1904850","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of protein localization to telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"54322556a3414612b2a18f52cec59523","type":"GO_TERM","name":"negative regulation of establishment of protein-containing complex localization to telomere","canonical_id":"go:GO:1904914","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment of the localization of a protein-containing macromolecular complex to a telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"3c2f9a70df634acbae0d5eb1c6d325a6","type":"GO_TERM","name":"negative regulation of establishment or maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:2000750","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment or maintenance of bipolar cell polarity regulating cell shape.\" [GOC:mah]","metadata":null},{"id":"2d06a3840e1e4013a14a32bcb611670f","type":"GO_TERM","name":"negative regulation of establishment or maintenance of cell polarity regulating cell shape","canonical_id":"go:GO:2000770","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of establishment or maintenance of cell polarity regulating cell shape.\" [GOC:mah]","metadata":null},{"id":"63001f09ccf24203b6cca0054c37fb5f","type":"GO_TERM","name":"negative regulation of establishment or maintenance of neuroblast polarity","canonical_id":"go:GO:2000248","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment or maintenance of neuroblast polarity.\" [GOC:obol]","metadata":null},{"id":"90fe9046734b476993b9bc04e49781fa","type":"GO_TERM","name":"negative regulation of estradiol secretion","canonical_id":"go:GO:2000865","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of estradiol secretion.\" [GOC:sl]","metadata":null},{"id":"1d15369cbd1b4a2d85d403ea69965e2c","type":"GO_TERM","name":"negative regulation of estrogen biosynthetic process","canonical_id":"go:GO:1904077","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of estrogen biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24530842]","metadata":null},{"id":"50a4f64af7a04ba8ad001d6f98d05f7c","type":"GO_TERM","name":"negative regulation of estrogen secretion","canonical_id":"go:GO:2000862","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of estrogen secretion.\" [GOC:sl]","metadata":null},{"id":"df418319186e435f9449c4d721aa8af0","type":"GO_TERM","name":"negative regulation of estrone secretion","canonical_id":"go:GO:2000868","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of estrone secretion.\" [GOC:sl]","metadata":null},{"id":"91f554f2d7654177b1a256ec1c7f482d","type":"GO_TERM","name":"negative regulation of ethylene biosynthetic process","canonical_id":"go:GO:0010366","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of an ethylene biosynthetic process.\" [GOC:tair_curators]","metadata":null},{"id":"2672e01d6b5a4520a387e64c5afe3717","type":"GO_TERM","name":"negative regulation of ethylene-activated signaling pathway","canonical_id":"go:GO:0010105","description":"\"Any process that stops or prevents ethylene (ethene) signal transduction.\" [GOC:tb]","metadata":null},{"id":"8361c5fee7244b75bb6c6934f52c710c","type":"GO_TERM","name":"negative regulation of eukaryotic translation initiation factor 4F complex assembly","canonical_id":"go:GO:1905536","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of eukaryotic translation initiation factor 4F complex assembly.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:18426977]","metadata":null},{"id":"eb25f8c78854459e97f6092e16de6fef","type":"GO_TERM","name":"negative regulation of excitatory postsynaptic potential","canonical_id":"go:GO:0090394","description":"\"Any process that prevents the establishment or decreases the extent of the excitatory postsynaptic potential (EPSP) which is a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential.\" [GOC:BHF]","metadata":null},{"id":"8efb726d4efc4228ba9bfc6e48bf7b43","type":"GO_TERM","name":"negative regulation of excitatory synapse assembly","canonical_id":"go:GO:1904890","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of excitatory synapse assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"4c91bf25c1d4475a919caae8336b2ec2","type":"GO_TERM","name":"negative regulation of excitatory synapse pruning","canonical_id":"go:GO:1905811","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of excitatory synapse pruning.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"ff7eb1c6629b469f92f005c0f911be98","type":"GO_TERM","name":"negative regulation of execution phase of apoptosis","canonical_id":"go:GO:1900118","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of execution phase of apoptosis.\" [GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"e11edd3cdac54be5a5e32544c360c6a2","type":"GO_TERM","name":"negative regulation of exit from meiosis","canonical_id":"go:GO:0106061","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of exit from meiosis.\" [GOC:al, PMID:11493649]","metadata":null},{"id":"7245c7376e214c158a4e00c9176d3c4e","type":"GO_TERM","name":"negative regulation of exit from mitosis","canonical_id":"go:GO:0001100","description":"\"Any process involved in the inhibition of progression from anaphase/telophase (high mitotic CDK activity) to G1 (low mitotic CDK activity).\" [GOC:rn]","metadata":null},{"id":"166bed13c889458f950516b7df5cb806","type":"GO_TERM","name":"negative regulation of exocyst assembly","canonical_id":"go:GO:0001929","description":"\"Any process that stops, prevents, or reduces the rate or extent of exocyst assembly.\" [GOC:hjd]","metadata":null},{"id":"9630953082b74b9dbdb09ee22db5369e","type":"GO_TERM","name":"negative regulation of exocytosis","canonical_id":"go:GO:0045920","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of exocytosis.\" [GOC:curators]","metadata":null},{"id":"b5363e1185c540e89bae14e385168ff9","type":"GO_TERM","name":"negative regulation of exosomal secretion","canonical_id":"go:GO:1903542","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of exosomal secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:24105262]","metadata":null},{"id":"11851ab3538e437d94deef5950175ca2","type":"GO_TERM","name":"negative regulation of extracellular exosome assembly","canonical_id":"go:GO:1903552","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of extracellular vesicular exosome assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:24105262]","metadata":null},{"id":"fb8792c4461946f6ad35fe8c69af7a36","type":"GO_TERM","name":"negative regulation of extracellular matrix assembly","canonical_id":"go:GO:1901202","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of extracellular matrix assembly.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"521c1c64cb1345779b3bb1e98b36fdf1","type":"GO_TERM","name":"negative regulation of extracellular matrix constituent secretion","canonical_id":"go:GO:0003332","description":"\"Any process that decreases the rate, frequency, or extent the controlled release of molecules that form the extracellular matrix, including carbohydrates and glycoproteins by a cell or a group of cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3a30e9df89ce430692a328487b039a4a","type":"GO_TERM","name":"negative regulation of extracellular matrix disassembly","canonical_id":"go:GO:0010716","description":"\"Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"557c18e4f1df4adba9af912482614660","type":"GO_TERM","name":"negative regulation of extracellular matrix organization","canonical_id":"go:GO:1903054","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of extracellular matrix organization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22357537]","metadata":null},{"id":"5a460bf0f8654764a4e3602c14af1c80","type":"GO_TERM","name":"negative regulation of extraocular skeletal muscle development","canonical_id":"go:GO:0014726","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of extraocular skeletal muscle development. Extraocular skeletal muscle development is the process whose specific outcome is the progression of the extraocular skeletal muscle over time, from its formation to the mature structure. The extraocular muscle is derived from cranial mesoderm and controls eye movements. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle.\" [GOC:mtg_muscle]","metadata":null},{"id":"2535f30c959845f3a52198e4d76451cf","type":"GO_TERM","name":"negative regulation of extrathymic T cell differentiation","canonical_id":"go:GO:0033086","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of extrathymic T cell differentiation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"ac3678f81a2448d6b570b0a3c53584a2","type":"GO_TERM","name":"negative regulation of extrinsic apoptotic signaling pathway","canonical_id":"go:GO:2001237","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"95de69d256234f7a8416a7dd2582debe","type":"GO_TERM","name":"negative regulation of extrinsic apoptotic signaling pathway in absence of ligand","canonical_id":"go:GO:2001240","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway in absence of ligand.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"285bac870f5d4ae3a842ab8db23ae638","type":"GO_TERM","name":"negative regulation of extrinsic apoptotic signaling pathway via death domain receptors","canonical_id":"go:GO:1902042","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway via death domain receptors.\" [GOC:TermGenie, PMID:17245429]","metadata":null},{"id":"382cb42be0844fbe8b8070592ba32308","type":"GO_TERM","name":"negative regulation of eye photoreceptor cell development","canonical_id":"go:GO:0042480","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of eye photoreceptor development.\" [GOC:jl]","metadata":null},{"id":"7e47fd548dcd465a9b7592939b8f9d8e","type":"GO_TERM","name":"negative regulation of eye pigmentation","canonical_id":"go:GO:0048074","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of a pattern of pigment in the eye of an organism.\" [GOC:jid]","metadata":null},{"id":"2653afdb15d54a8fbfbe10ab1a5b7ea4","type":"GO_TERM","name":"negative regulation of fast-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031447","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of fast-twitch skeletal muscle contraction.\" [GOC:dph, GOC:ef, GOC:mah, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"4a1ce2486c864ead9e67e14198b1788c","type":"GO_TERM","name":"negative regulation of fat cell apoptotic process","canonical_id":"go:GO:1904650","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fat cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:17024416]","metadata":null},{"id":"93b3eafeb84c4f8b88cc3d25a71128c5","type":"GO_TERM","name":"negative regulation of fat cell differentiation","canonical_id":"go:GO:0045599","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of adipocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"7887fca97e8c418b9f093a009bac49bf","type":"GO_TERM","name":"negative regulation of fat cell proliferation","canonical_id":"go:GO:0070345","description":"\"Any process that stops or decreases the rate or extent of fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"2723f13b4fb741969c5ed8e11cfddc2f","type":"GO_TERM","name":"negative regulation of fatty acid beta-oxidation","canonical_id":"go:GO:0031999","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of fatty acid beta-oxidation.\" [GOC:mah]","metadata":null},{"id":"c51286d70a37480e9cab015c64799922","type":"GO_TERM","name":"negative regulation of fatty acid biosynthetic process","canonical_id":"go:GO:0045717","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids.\" [GOC:curators]","metadata":null},{"id":"a119197326ba4657a7aaac9aeb7269bd","type":"GO_TERM","name":"negative regulation of fatty acid metabolic process","canonical_id":"go:GO:0045922","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving fatty acids.\" [GOC:curators]","metadata":null},{"id":"6957b3129a7f4f028feda90f22ebdab2","type":"GO_TERM","name":"negative regulation of fatty acid oxidation","canonical_id":"go:GO:0046322","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of fatty acid oxidation.\" [GOC:ai]","metadata":null},{"id":"fa67ec46968f4df89d5404e46bb78f73","type":"GO_TERM","name":"negative regulation of fatty acid transport","canonical_id":"go:GO:2000192","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of fatty acid transport.\" [GOC:BHF]","metadata":null},{"id":"f1c05931a90a44d0a8ea5ca12bcf3901","type":"GO_TERM","name":"negative regulation of fear response","canonical_id":"go:GO:1903366","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fear response.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:8677262]","metadata":null},{"id":"96d602c3ef904540a47f47ee678658de","type":"GO_TERM","name":"negative regulation of feeding behavior","canonical_id":"go:GO:2000252","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of feeding behavior.\" [GOC:obol]","metadata":null},{"id":"5f1d57078bac4ead8adbdf690b6c1245","type":"GO_TERM","name":"negative regulation of female gonad development","canonical_id":"go:GO:2000195","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of female gonad development.\" [GOC:obol]","metadata":null},{"id":"e874904d8d6b4abaa79e56f7efa09cd8","type":"GO_TERM","name":"negative regulation of female pigmentation","canonical_id":"go:GO:0048090","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of a pattern of pigment in females.\" [GOC:jid]","metadata":null},{"id":"9afe63c882b54cc48586c741291d0117","type":"GO_TERM","name":"negative regulation of female receptivity","canonical_id":"go:GO:0007621","description":"\"Any process that stops, prevents or reduces the receptiveness of a female to male advances.\" [GOC:bf, PMID:11092827]","metadata":null},{"id":"2679ba9412854719bd54be67054ba8ae","type":"GO_TERM","name":"negative regulation of female receptivity, post-mating","canonical_id":"go:GO:0045434","description":"\"Any process that stops, prevents or reduces the receptiveness of a female to male advances subsequent to mating.\" [GOC:bf, PMID:11092827]","metadata":null},{"id":"476e027175194032b2625b906700221a","type":"GO_TERM","name":"negative regulation of fermentation","canonical_id":"go:GO:1901003","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fermentation.\" [GOC:TermGenie]","metadata":null},{"id":"b76071a1bc3b490ab02f64ff83e66588","type":"GO_TERM","name":"negative regulation of ferrichrome biosynthetic process","canonical_id":"go:GO:1905569","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ferrichrome biosynthetic process.\" [GO_REF:0000058, GOC:al, GOC:TermGenie, PMID:654321]","metadata":null},{"id":"06ca897f01de4e74842d996417dd2a7a","type":"GO_TERM","name":"negative regulation of ferrichrome biosynthetic process in response to iron","canonical_id":"go:GO:0097739","description":"\"Any process that stops, prevents or reduces the rate of ferrichrome biosynthetic process in response to an iron stimulus.\" [GOC:al]","metadata":null},{"id":"a26d422a25e843058e6c46fc4c987699","type":"GO_TERM","name":"negative regulation of ferricrocin biosynthetic process","canonical_id":"go:GO:1900679","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ferricrocin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"65dd62a1b7bf466886d875e016113677","type":"GO_TERM","name":"negative regulation of ferroptosis","canonical_id":"go:GO:0110076","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ferroptosis.\" [GOC:sp, PMID:24439385, PMID:25402683, PMID:29290465]","metadata":null},{"id":"a70c371575984cffbc31887d42be7ef1","type":"GO_TERM","name":"negative regulation of fertilization","canonical_id":"go:GO:0060467","description":"\"Any process that decreases the rate, frequency or extent of fertilization. Fertilization is the union of gametes of opposite sexes during the process of sexual reproduction to form a zygote. It involves the fusion of the gametic nuclei (karyogamy) and cytoplasm (plasmogamy).\" [GOC:dph]","metadata":null},{"id":"715afbe97c334cf2b74ed05aa6cb23a6","type":"GO_TERM","name":"negative regulation of ferulate catabolic process","canonical_id":"go:GO:1901467","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ferulate catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c8d58cbb323441568b06a3180c97741d","type":"GO_TERM","name":"negative regulation of fever generation","canonical_id":"go:GO:0031621","description":"\"Any process that stops, prevents, or reduces the rate or extent of fever generation.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"3da02bd8d1254edba8778e3c6be2c540","type":"GO_TERM","name":"negative regulation of fibrinolysis","canonical_id":"go:GO:0051918","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.\" [GOC:ai]","metadata":null},{"id":"b25c30d257514c42b0259b90f5c11658","type":"GO_TERM","name":"negative regulation of fibroblast apoptotic process","canonical_id":"go:GO:2000270","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fibroblast apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol, GOC:yaf]","metadata":null},{"id":"9e0b5a0de3194c61bfbe7e2c72b43c76","type":"GO_TERM","name":"negative regulation of fibroblast chemotaxis","canonical_id":"go:GO:1905211","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fibroblast chemotaxis.\" [GO_REF:0000058, GOC:TermGenie, PMID:8760137]","metadata":null},{"id":"f065c031e4ce4bac80a30a35fa1ffc4c","type":"GO_TERM","name":"negative regulation of fibroblast growth factor production","canonical_id":"go:GO:0090272","description":"\"Any process that decreases the rate, frequency or extent of the appearance of a fibroblast growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"34841afabe004be98184cf268d200707","type":"GO_TERM","name":"negative regulation of fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0040037","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"fad8f5415a554050a49c878c45574b6b","type":"GO_TERM","name":"negative regulation of fibroblast migration","canonical_id":"go:GO:0010764","description":"\"Any process that decreases the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"90ce98be930d471bb5769f2e5373424f","type":"GO_TERM","name":"negative regulation of fibroblast proliferation","canonical_id":"go:GO:0048147","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of multiplication or reproduction of fibroblast cells.\" [GOC:jid]","metadata":null},{"id":"f95ffd89a84945568ae479e202bfff3e","type":"GO_TERM","name":"negative regulation of fibronectin-dependent thymocyte migration","canonical_id":"go:GO:2000414","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fibronectin-dependent thymocyte migration.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"cea03c8f98c749c28a5919557c74d640","type":"GO_TERM","name":"negative regulation of filamentous growth","canonical_id":"go:GO:0060258","description":"\"Any process that decreases the frequency, rate or extent of the process in which a multicellular organism or a group of unicellular organisms grow in a threadlike, filamentous shape.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d6d576c5c35540a6915e1090894dd85f","type":"GO_TERM","name":"negative regulation of filamentous growth of a population of unicellular organisms","canonical_id":"go:GO:1900429","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of filamentous growth of a population of unicellular organisms.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"952be207f4b64ab49ab36142a1fc0345","type":"GO_TERM","name":"negative regulation of filamentous growth of a population of unicellular organisms in response to biotic stimulus","canonical_id":"go:GO:1900444","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to biotic stimulus.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f7d61477f94340fa9277c09abf4fd80e","type":"GO_TERM","name":"negative regulation of filamentous growth of a population of unicellular organisms in response to chemical stimulus","canonical_id":"go:GO:1900438","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to chemical stimulus.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"87355d663ccc453aaa17897945019a02","type":"GO_TERM","name":"negative regulation of filamentous growth of a population of unicellular organisms in response to heat","canonical_id":"go:GO:1900432","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to heat.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b395083923fc419cac2b699a95e7f69a","type":"GO_TERM","name":"negative regulation of filamentous growth of a population of unicellular organisms in response to neutral pH","canonical_id":"go:GO:1900441","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to neutral pH.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"76b5675d447d4949bffad519854aecb5","type":"GO_TERM","name":"negative regulation of filamentous growth of a population of unicellular organisms in response to pH","canonical_id":"go:GO:1900742","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to pH.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"215c40781d274204b6acb0f9c3ace4aa","type":"GO_TERM","name":"negative regulation of filopodium assembly","canonical_id":"go:GO:0051490","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone.\" [GOC:ai]","metadata":null},{"id":"8f2a153f62b54061ac77bc700123e3e6","type":"GO_TERM","name":"negative regulation of flagellated sperm motility","canonical_id":"go:GO:1901318","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of flagellated sperm motility.\" [GOC:cilia, GOC:krc, GOC:TermGenie]","metadata":null},{"id":"440205e1106a48a79602744066915c71","type":"GO_TERM","name":"negative regulation of flavonoid biosynthetic process","canonical_id":"go:GO:0009964","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of flavonoids.\" [GOC:tb]","metadata":null},{"id":"7a9aec64013e4597af4b0f972ecee87c","type":"GO_TERM","name":"negative regulation of flavonol biosynthetic process","canonical_id":"go:GO:1900385","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of flavonol biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"b59a79f3008e489aabd35c87f747e760","type":"GO_TERM","name":"negative regulation of flocculation","canonical_id":"go:GO:0060257","description":"\"Any process that decreases the rate, frequency or extent of the non-sexual aggregation of single-celled organisms.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1f6bfd2d961e48638fa5f0ee9ee487c9","type":"GO_TERM","name":"negative regulation of floral organ abscission","canonical_id":"go:GO:0060862","description":"\"Any process that decreases the rate, frequency, or extent of floral organ abscission, the controlled shedding of floral organs.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"54e6b2ccf6b942acaf121de91ac08574","type":"GO_TERM","name":"negative regulation of flower development","canonical_id":"go:GO:0009910","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of flower development.\" [GOC:curators]","metadata":null},{"id":"144d1ed54f8949b0b2d836fe65471410","type":"GO_TERM","name":"negative regulation of focal adhesion assembly","canonical_id":"go:GO:0051895","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of focal adhesion assembly, the establishment and maturation of focal adhesions.\" [GOC:ai]","metadata":null},{"id":"87e462063a6640cda9e80d3be85414eb","type":"GO_TERM","name":"negative regulation of focal adhesion disassembly","canonical_id":"go:GO:0120184","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a focal adhesion into its constituent components.\" [PMID:25490267]","metadata":null},{"id":"cc1d009ad2fe46df9562bb3aa22d5c58","type":"GO_TERM","name":"negative regulation of follicle-stimulating hormone secretion","canonical_id":"go:GO:0046882","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of follicle-stimulating hormone.\" [GOC:ai]","metadata":null},{"id":"6d4a88a99f66415b8533db2f4ed50938","type":"GO_TERM","name":"negative regulation of foraging behavior","canonical_id":"go:GO:1903369","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of foraging behavior.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:8677262]","metadata":null},{"id":"03b7e8782f42408588af0d768c9993a2","type":"GO_TERM","name":"negative regulation of forebrain neuron differentiation","canonical_id":"go:GO:2000978","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of forebrain neuron differentiation.\" [GOC:obol]","metadata":null},{"id":"6c2d2fc8ffef4ee6b25e2b937931b74f","type":"GO_TERM","name":"negative regulation of formation of growth cone in injured axon","canonical_id":"go:GO:1905943","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of formation of growth cone in injured axon.\" [GO_REF:0000058, GOC:TermGenie, PMID:19737525]","metadata":null},{"id":"81086dd7405a4e238a41a2cd16c4d281","type":"GO_TERM","name":"negative regulation of formation of radial glial scaffolds","canonical_id":"go:GO:0061925","description":"\"Any process that reduces the frequency, rate or extent of the formation of radial glial scaffolds. The scaffolds are used as a substrate for the radial migration of cells.\" [PMID:22076441]","metadata":null},{"id":"9b1e20588bb649369fc072dd32065de4","type":"GO_TERM","name":"negative regulation of formation of symbiont germ tube hook structure for appressorium development","canonical_id":"go:GO:0075032","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of symbiont germ tube hook structure formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"152f6df1bc824acb9dabe3a10bed6f2d","type":"GO_TERM","name":"negative regulation of formation of translation initiation ternary complex","canonical_id":"go:GO:1901191","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of formation of translation initiation ternary complex.\" [GOC:TermGenie]","metadata":null},{"id":"db9a137ed578404d80807a3b6924fbb6","type":"GO_TERM","name":"negative regulation of formation of translation preinitiation complex","canonical_id":"go:GO:1901194","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of formation of translation preinitiation complex.\" [GOC:TermGenie]","metadata":null},{"id":"d526cb0032e34bd59b275c41eda07635","type":"GO_TERM","name":"negative regulation of formin-nucleated actin cable assembly","canonical_id":"go:GO:0090339","description":"\"Any process that decreases the rate, frequency, or extent of formin-nucleated actin cable assembly. Formin-nucleated actin cable assembly is the aggregation, arrangement and bonding together of a set of components to form a formin-nucleated actin cable. A formin-nucleated actin cable is an actin filament bundle that consists of short filaments organized into bundles of uniform polarity, and is nucleated by formins.\" [GOC:jh, GOC:tb, PMID:12810699, PMID:15923184]","metadata":null},{"id":"8efca43744084e88ac88d0bd54ddd800","type":"GO_TERM","name":"negative regulation of forward locomotion","canonical_id":"go:GO:1905849","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of forward locomotion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11717360]","metadata":null},{"id":"8f4c23fc5f2f400f9d155a6accda09de","type":"GO_TERM","name":"negative regulation of fractalkine production","canonical_id":"go:GO:0032684","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of fractalkine production.\" [GOC:mah]","metadata":null},{"id":"8dd0c5443fb54ff49d6176f969c846c6","type":"GO_TERM","name":"negative regulation of free ubiquitin chain polymerization","canonical_id":"go:GO:1904543","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of free ubiquitin chain polymerization.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24660806]","metadata":null},{"id":"29b9ba34e32740489453157477dace0d","type":"GO_TERM","name":"negative regulation of fumagillin biosynthetic process","canonical_id":"go:GO:1902091","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fumagillin biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:23488861]","metadata":null},{"id":"32d9fe560b104747bbd115fec68a352f","type":"GO_TERM","name":"negative regulation of fumigaclavine C biosynthetic process","canonical_id":"go:GO:1900838","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fumigaclavine C biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"06c48d673e7447f8be0a4b2cbe8c2196","type":"GO_TERM","name":"negative regulation of fumonisin biosynthetic process","canonical_id":"go:GO:1900684","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fumonisin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3eecff721f834e219831cc875079d32b","type":"GO_TERM","name":"negative regulation of fusion cell fate specification","canonical_id":"go:GO:0035157","description":"\"Any process that restricts, stops or prevents a cell from adopting a fusion cell fate. Once the terminal and fusion fates have been correctly induced, inhibitory feedback loops prevent the remaining branch cells from assuming similar fates.\" [PMID:10684581]","metadata":null},{"id":"b4aef116df054c53983ece61883d634b","type":"GO_TERM","name":"negative regulation of fusion of sperm to egg plasma membrane","canonical_id":"go:GO:0043013","description":"\"Any process that stops or prevents the binding and fusion of a sperm to the oocyte plasma membrane.\" [GOC:jl, PMID:34459848]","metadata":null},{"id":"0207943de8df4bc6b8b1f7640fe32e58","type":"GO_TERM","name":"negative regulation of fusion of virus membrane with host plasma membrane","canonical_id":"go:GO:1903914","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fusion of virus membrane with host plasma membrane.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"5744febc4f3e4698a175c1c483af83c8","type":"GO_TERM","name":"negative regulation of galactoglucomannan catabolic process","canonical_id":"go:GO:2000913","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of galactoglucomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"68734737d92547d9886f3d0dbcd3bec0","type":"GO_TERM","name":"negative regulation of galactomannan catabolic process","canonical_id":"go:GO:2000992","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of galactomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"fd257d159ec24f68a33ceccecf546638","type":"GO_TERM","name":"negative regulation of galactotriose transport","canonical_id":"go:GO:1900292","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of galactotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2073f545594546c7befbb127d2a0906c","type":"GO_TERM","name":"negative regulation of gamma-aminobutyric acid secretion","canonical_id":"go:GO:0014053","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of gamma-aminobutyric acid.\" [GOC:ef]","metadata":null},{"id":"35950ece162c4c3496e88bff79262961","type":"GO_TERM","name":"negative regulation of gamma-delta T cell activation","canonical_id":"go:GO:0046644","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of gamma-delta T cell activation.\" [GOC:ai]","metadata":null},{"id":"535ea01d7eb849f79f8d2c8d74347b64","type":"GO_TERM","name":"negative regulation of gamma-delta T cell differentiation","canonical_id":"go:GO:0045587","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of gamma-delta T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"f51eb574066f4165a29412b423fe012b","type":"GO_TERM","name":"negative regulation of gamma-delta T cell proliferation","canonical_id":"go:GO:0046647","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of gamma-delta T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"c1955a92c05340f8afb314be5cfd9251","type":"GO_TERM","name":"negative regulation of gap junction assembly","canonical_id":"go:GO:1903597","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:25017399]","metadata":null},{"id":"2adb9d160fd14e269aa5520eb20db479","type":"GO_TERM","name":"negative regulation of gastric acid secretion","canonical_id":"go:GO:0060455","description":"\"Any process that decreases the rate frequency or extent of gastric secretion. Gastric secretion is the regulated release of gastric acid (hydrochloric acid) by parietal or oxyntic cells during digestion.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"567ade7d35584e0795d68f2e32cac51d","type":"GO_TERM","name":"negative regulation of gastric emptying","canonical_id":"go:GO:0120061","description":"\"Any process that decreases the frequency, rate or extent of any gastric emptying process, the process in which the liquid and liquid-suspended solid contents of the stomach exit through the pylorus into the duodenum.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"40bd5820fd74427aabdc6a43da9b3b56","type":"GO_TERM","name":"negative regulation of gastric mucosal blood circulation","canonical_id":"go:GO:1904345","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gastric mucosal blood circulation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10807413]","metadata":null},{"id":"f31bb549bbb945f998e1ae9e15bc48a2","type":"GO_TERM","name":"negative regulation of gastrin-induced gastric acid secretion","canonical_id":"go:GO:1903640","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gastrin-induced gastric acid secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11123201]","metadata":null},{"id":"18c41bbf20b84d35bb9fb3c632eabc60","type":"GO_TERM","name":"negative regulation of gastro-intestinal system smooth muscle contraction","canonical_id":"go:GO:1904305","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gastro-intestinal system smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:10821044]","metadata":null},{"id":"891d9cd3fd4a4aff9998ddbfcf894896","type":"GO_TERM","name":"negative regulation of gastrulation","canonical_id":"go:GO:2000542","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gastrulation.\" [GOC:obol]","metadata":null},{"id":"8b74bb6daa904f1ea377d8a300c165da","type":"GO_TERM","name":"negative regulation of gene expression","canonical_id":"go:GO:0010629","description":"\"Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).\" [GOC:txnOH-2018]","metadata":null},{"id":"a2616ad74d114cb89608acf0c061d222","type":"GO_TERM","name":"negative regulation of gene expression via chromosomal CpG island methylation","canonical_id":"go:GO:0044027","description":"\"An epigenetic gene regulation mechanism that negatively regulates gene expression by methylation of cytosine residues in chromosomal CpG islands. CpG islands are genomic regions that contain a high frequency of the CG dinucleotide associated with the transcription start site of genes.\" [PMID:11898023, Wikipedia:Cpg_island]","metadata":null},{"id":"e28f2d17ee054559913ed50ca7dbeafb","type":"GO_TERM","name":"negative regulation of gene expression, epigenetic","canonical_id":"go:GO:0045814","description":"\"An epigenetic process that silences gene expression at specific genomic regions through chromatin remodeling either by modifying higher order chromatin fiber structure, nucleosomal histones, or the cytosine DNA methylation.\" [PMID:22243696]","metadata":null},{"id":"9943859e7ff24955a6ba8983855249d7","type":"GO_TERM","name":"negative regulation of gene silencing by regulatory ncRNA","canonical_id":"go:GO:0060967","description":"\"Any process that decreases the rate, frequency, or extent of gene silencing by RNA. Gene silencing by RNA is the process in which RNA molecules inactivate expression of target genes.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"cf7f1e12e80c481d8963abd35e091c46","type":"GO_TERM","name":"negative regulation of gerfelin biosynthetic process","canonical_id":"go:GO:1900687","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gerfelin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2bf37abbba2a4481bc1f25c3ce37e337","type":"GO_TERM","name":"negative regulation of germ cell proliferation","canonical_id":"go:GO:1905937","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of germ cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15342467]","metadata":null},{"id":"4418970ac1564bf680ca02ae638c27d2","type":"GO_TERM","name":"negative regulation of germ plasm oskar mRNA localization","canonical_id":"go:GO:0045855","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a process in which oskar mRNA is transported to, or maintained in, the germ plasm.\" [GOC:curators]","metadata":null},{"id":"4154cfce0f6b4c459deee1411cdacc27","type":"GO_TERM","name":"negative regulation of germ tube formation","canonical_id":"go:GO:0075012","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of germ tube formation on or near host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"f0ba55ce1d514505852953acee7588c0","type":"GO_TERM","name":"negative regulation of germinal center formation","canonical_id":"go:GO:0002635","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of germinal center formation.\" [GOC:add]","metadata":null},{"id":"0a9b65e03e774fe2ba722974bdcf6675","type":"GO_TERM","name":"negative regulation of gibberellic acid mediated signaling pathway","canonical_id":"go:GO:0009938","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of gibberellic acid mediated signaling activity.\" [GOC:sm]","metadata":null},{"id":"b09d6973eacf404abb534c6f868a9a8c","type":"GO_TERM","name":"negative regulation of gibberellin biosynthetic process","canonical_id":"go:GO:0010373","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of gibberellins.\" [GOC:tair_curators]","metadata":null},{"id":"c990fd57087447ef8b16d04488d4cda0","type":"GO_TERM","name":"negative regulation of glial cell apoptotic process","canonical_id":"go:GO:0034351","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of glial cell apoptotic process.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"93f6d7445bba4d2a956aa7a7212b31f7","type":"GO_TERM","name":"negative regulation of glial cell differentiation","canonical_id":"go:GO:0045686","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of glia cell differentiation.\" [GOC:curators]","metadata":null},{"id":"20fd09adcbda4c0dbd24c8f5029c85f2","type":"GO_TERM","name":"negative regulation of glial cell migration","canonical_id":"go:GO:1903976","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glial cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"5da35780db3e4b09979bbde2897ea376","type":"GO_TERM","name":"negative regulation of glial cell proliferation","canonical_id":"go:GO:0060253","description":"\"Any process that stops or decreases the rate or extent of glial cell proliferation.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"3c0613e7e02d453f94b848a5e91f95c6","type":"GO_TERM","name":"negative regulation of glial cell-derived neurotrophic factor production","canonical_id":"go:GO:1900167","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glial cell-derived neurotrophic factor production.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"e3b20425929a440da0bd0cab9c7394ab","type":"GO_TERM","name":"negative regulation of gliogenesis","canonical_id":"go:GO:0014014","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of gliogenesis, the formation of mature glia.\" [GOC:ef]","metadata":null},{"id":"7651798bebff4128b359e387884d8df7","type":"GO_TERM","name":"negative regulation of gliotoxin biosynthetic process","canonical_id":"go:GO:1900690","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gliotoxin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"426640a648594606a184e47feffecb90","type":"GO_TERM","name":"negative regulation of glomerular filtration","canonical_id":"go:GO:0003105","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of glomerular filtration. Glomerular filtration is the process whereby blood is filtered by the glomerulus into the renal tubule.\" [GOC:mtg_cardio]","metadata":null},{"id":"672d8967f3ac48099f161f1f0740b31c","type":"GO_TERM","name":"negative regulation of glomerular filtration by angiotensin","canonical_id":"go:GO:0003106","description":"\"The process in which angiotensin directly decreases the rate of glomerular filtration in the kidney. Glomerular filtration is the process whereby blood is filtered by the glomerulus into the renal tubule.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"52313aeeb66a4e9c921b9df6fc068553","type":"GO_TERM","name":"negative regulation of glomerular mesangial cell proliferation","canonical_id":"go:GO:0072125","description":"\"Any process that decreases the frequency, rate or extent of glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0249718b1232491ab6c81e18704562d3","type":"GO_TERM","name":"negative regulation of glomerulus development","canonical_id":"go:GO:0090194","description":"\"Any process that decreases the rate, frequency or extent of glomerulus development, the progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"45a952d0bb644a45b8477345d8cb6f95","type":"GO_TERM","name":"negative regulation of glucagon secretion","canonical_id":"go:GO:0070093","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of glucagon.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"c08c3d063c884e248ef568a054f2926e","type":"GO_TERM","name":"negative regulation of glucocorticoid biosynthetic process","canonical_id":"go:GO:0031947","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"91589b3635dd40b1b661ed8c5a1a9c8d","type":"GO_TERM","name":"negative regulation of glucocorticoid catabolic process","canonical_id":"go:GO:0031950","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"c5444d5acd0e4772897a286c170dc614","type":"GO_TERM","name":"negative regulation of glucocorticoid secretion","canonical_id":"go:GO:2000850","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucocorticoid secretion.\" [GOC:sl]","metadata":null},{"id":"5a464eeb9f9d41c8aa397ef6c4009c58","type":"GO_TERM","name":"negative regulation of glucokinase activity","canonical_id":"go:GO:0033132","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of glucokinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a glucose molecule.\" [GOC:mah]","metadata":null},{"id":"6ba6408081994c428053a335dfa354d4","type":"GO_TERM","name":"negative regulation of glucomannan catabolic process","canonical_id":"go:GO:2000907","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"bd102464b84041ed96679a0e6bca94f3","type":"GO_TERM","name":"negative regulation of gluconate transmembrane transport","canonical_id":"go:GO:0035431","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of gluconate across a membrane by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"48702657a084466882e74b722004702d","type":"GO_TERM","name":"negative regulation of gluconeogenesis","canonical_id":"go:GO:0045721","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.\" [GOC:curators]","metadata":null},{"id":"972094bdb0354045ba3ef399e77daf6b","type":"GO_TERM","name":"negative regulation of glucose catabolic process to lactate via pyruvate","canonical_id":"go:GO:1904024","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucose catabolic process to lactate via pyruvate.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:20935145]","metadata":null},{"id":"afc2005f2a5249c9a257bd6add8e9772","type":"GO_TERM","name":"negative regulation of glucose mediated signaling pathway","canonical_id":"go:GO:1902660","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucose mediated signaling pathway.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:24277933]","metadata":null},{"id":"ea99eeb37112442c8578807b2d8f0562","type":"GO_TERM","name":"negative regulation of glucosylceramide biosynthetic process","canonical_id":"go:GO:0046318","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide.\" [GOC:ai, GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"4759fe4ad506448894c3cc1365ea1166","type":"GO_TERM","name":"negative regulation of glucuronoarabinoxylan catabolic process","canonical_id":"go:GO:2000919","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucuronoarabinoxylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"e1e74a159d16448ab9f41102eb7a26f7","type":"GO_TERM","name":"negative regulation of glucuronoxylan catabolic process","canonical_id":"go:GO:2000916","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucuronoxylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"beadef6bd72e45ab99809e12c616c0b0","type":"GO_TERM","name":"negative regulation of glutamate receptor signaling pathway","canonical_id":"go:GO:1900450","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glutamate receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"0feede40de034869aec681554500f44e","type":"GO_TERM","name":"negative regulation of glutamate secretion","canonical_id":"go:GO:0014050","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of glutamate.\" [GOC:ef]","metadata":null},{"id":"a6457f773da34900bf50b49baedb0754","type":"GO_TERM","name":"negative regulation of glutamate secretion, neurotransmission","canonical_id":"go:GO:1903295","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glutamate secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:16782817]","metadata":null},{"id":"d927b5463ebf4391a7dcbe28ed76fec8","type":"GO_TERM","name":"negative regulation of glutamatergic neuron differentiation","canonical_id":"go:GO:0120007","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glutamatergic neuron differentiation.\" [PMID:24030726]","metadata":null},{"id":"69822af531ef4614b783c89a9071bce8","type":"GO_TERM","name":"negative regulation of glutamine transport","canonical_id":"go:GO:2000486","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glutamine transport.\" [GOC:obol]","metadata":null},{"id":"1947a80f8ae94e4ba057f96a3044db1f","type":"GO_TERM","name":"negative regulation of glutathione biosynthetic process","canonical_id":"go:GO:1903787","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glutathione biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"146a0f49d42a4caf85906737e150a5c5","type":"GO_TERM","name":"negative regulation of glycerol transport","canonical_id":"go:GO:0090373","description":"\"Any process that decreases the rate, frequency, or extent of the directed movement of glycerol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:jh, GOC:tb]","metadata":null},{"id":"006632cfeba54517ace3613e03d7c5f8","type":"GO_TERM","name":"negative regulation of glycine import across plasma membrane","canonical_id":"go:GO:1900924","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glycine import into a cell.\" [GOC:TermGenie]","metadata":null},{"id":"7880002dec3e4219a169c533e3fc274e","type":"GO_TERM","name":"negative regulation of glycine secretion, neurotransmission","canonical_id":"go:GO:1904625","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glycine secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:22988142]","metadata":null},{"id":"3a06fb99215249c287459d493a7c0022","type":"GO_TERM","name":"negative regulation of glycogen (starch) synthase activity","canonical_id":"go:GO:2000466","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glycogen (starch) synthase activity.\" [GOC:obol]","metadata":null},{"id":"f967b5868a1f4b3cb8d2303a21f03252","type":"GO_TERM","name":"negative regulation of glycogen biosynthetic process","canonical_id":"go:GO:0045719","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen.\" [GOC:curators]","metadata":null},{"id":"1160c060dc144912804424eefc46edd4","type":"GO_TERM","name":"negative regulation of glycogen catabolic process","canonical_id":"go:GO:0045818","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen.\" [GOC:curators]","metadata":null},{"id":"37609b01dd5d40d3ba1cda86761db2cf","type":"GO_TERM","name":"negative regulation of glycogen metabolic process","canonical_id":"go:GO:0070874","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving glycogen.\" [GOC:mah]","metadata":null},{"id":"03b1b2618d1f4cfba9d08bc4aef9c0be","type":"GO_TERM","name":"negative regulation of glycolytic fermentation to ethanol","canonical_id":"go:GO:2001155","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glucose catabolic process to ethanol.\" [GOC:obol]","metadata":null},{"id":"c1bb177fd4224339befa9b4a16bcc921","type":"GO_TERM","name":"negative regulation of glycolytic process","canonical_id":"go:GO:0045820","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis.\" [GOC:curators]","metadata":null},{"id":"4b50f7376fb6469897818dad8c30b352","type":"GO_TERM","name":"negative regulation of glycolytic process through fructose-6-phosphate","canonical_id":"go:GO:1904539","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glycolytic process through fructose-6-phosphate.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"fd08e4c14ee4452d8df81082524450b8","type":"GO_TERM","name":"negative regulation of glycoprotein biosynthetic process","canonical_id":"go:GO:0010561","description":"\"Any process that decreases the rate, frequency, or extent of the chemical reactions and pathways resulting in the formation of a glycoprotein, a protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e77c75badc86433287c2ea20fc2ae262","type":"GO_TERM","name":"negative regulation of glycoprotein metabolic process","canonical_id":"go:GO:1903019","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glycoprotein metabolic process.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23544079]","metadata":null},{"id":"79dc0264513a4b19b8f2d64ebcbb10d7","type":"GO_TERM","name":"negative regulation of glyoxylate cycle","canonical_id":"go:GO:2000875","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glyoxylate cycle.\" [GOC:dgf]","metadata":null},{"id":"62819c6f2ded472fae3dc1c646f20579","type":"GO_TERM","name":"negative regulation of gonad development","canonical_id":"go:GO:1905940","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gonad development.\" [GO_REF:0000058, GOC:TermGenie, PMID:15342467]","metadata":null},{"id":"a67b2173f320444992966d1c6dcb01ff","type":"GO_TERM","name":"negative regulation of gonadotropin secretion","canonical_id":"go:GO:0032277","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a gonadotropin.\" [GOC:mah]","metadata":null},{"id":"94b3b25324f347b1bccb2f830e56c7eb","type":"GO_TERM","name":"negative regulation of granulocyte chemotaxis","canonical_id":"go:GO:0071623","description":"\"Any process that decreases the rate, frequency or extent of granulocyte chemotaxis. Granulocyte chemotaxis is the movement of a granulocyte in response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"43c3bec667394b7bb833868313520860","type":"GO_TERM","name":"negative regulation of granulocyte colony-stimulating factor production","canonical_id":"go:GO:0071656","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of granulocyte colony stimulating factor.\" [GOC:mah]","metadata":null},{"id":"cad2ee907d3643b48b9602358eb1732b","type":"GO_TERM","name":"negative regulation of granulocyte differentiation","canonical_id":"go:GO:0030853","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of granulocyte differentiation.\" [GOC:mah]","metadata":null},{"id":"d3cdba958a9a4cb2804da88747717ab7","type":"GO_TERM","name":"negative regulation of granulocyte macrophage colony-stimulating factor production","canonical_id":"go:GO:0032685","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of granulocyte macrophage colony-stimulating factor production.\" [GOC:mah]","metadata":null},{"id":"e014688a9a8a45deb9f5b79a35bbe152","type":"GO_TERM","name":"negative regulation of granuloma formation","canonical_id":"go:GO:0002632","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of granuloma formation.\" [GOC:add]","metadata":null},{"id":"cfa30a1560ee4271adbcea75b2ed2226","type":"GO_TERM","name":"negative regulation of granulosa cell apoptotic process","canonical_id":"go:GO:1904709","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of granulosa cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:19208546]","metadata":null},{"id":"d9178a694d3741b79cb5876fd8d08ef6","type":"GO_TERM","name":"negative regulation of granulosa cell proliferation","canonical_id":"go:GO:1904196","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of granulosa cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22383759]","metadata":null},{"id":"f8ff5db114db4b4996b41a719e1cabf0","type":"GO_TERM","name":"negative regulation of granzyme A production","canonical_id":"go:GO:2000512","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of granzyme A production.\" [GOC:obol]","metadata":null},{"id":"d554913d14814a8a92bb411b7c3982a9","type":"GO_TERM","name":"negative regulation of granzyme B production","canonical_id":"go:GO:0071662","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of granzyme B.\" [GOC:mah]","metadata":null},{"id":"54e2b9dffaca46478438a898e856e39c","type":"GO_TERM","name":"negative regulation of growth","canonical_id":"go:GO:0045926","description":"\"Any process that stops, prevents or reduces the rate or extent of growth, the increase in size or mass of all or part of an organism.\" [GOC:curators]","metadata":null},{"id":"bd73daf2ab6c4e908756fd4047cb0fa1","type":"GO_TERM","name":"negative regulation of growth factor dependent skeletal muscle satellite cell proliferation","canonical_id":"go:GO:1902727","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of satellite cell proliferation; dependent on specific growth factor activity such as fibroblast growth factors and transforming growth factor beta.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"af1b9b948c9f466b829808b7bb8a6164","type":"GO_TERM","name":"negative regulation of growth hormone receptor signaling pathway","canonical_id":"go:GO:0060400","description":"\"Any process that decreases the rate, frequency or extent of the growth hormone receptor signaling pathway. The growth hormone receptor signaling pathway is the series of molecular signals generated as a consequence of growth hormone receptor binding to its physiological ligand.\" [GOC:dph]","metadata":null},{"id":"645c3efc251f4225a6f983d1aea9603a","type":"GO_TERM","name":"negative regulation of growth hormone secretion","canonical_id":"go:GO:0060125","description":"\"Any process that decreases or stops the frequency, rate or extent of the regulated release of growth hormone from a cell.\" [GOC:dph]","metadata":null},{"id":"b2cf1e66e6674f49914d92e3151bb901","type":"GO_TERM","name":"negative regulation of growth of unicellular organism as a thread of attached cells","canonical_id":"go:GO:0070785","description":"\"Any process that decreases the frequency, rate or extent of the process in which cells remain attached after division and form thread-like filaments that may penetrate into a solid growth medium.\" [GOC:mah]","metadata":null},{"id":"530838d8e17f43dc9f11bfa34732d8c7","type":"GO_TERM","name":"negative regulation of growth plate cartilage chondrocyte proliferation","canonical_id":"go:GO:0061914","description":"\"Any process that decreases the rate, frequency, or extent of the multiplication or reproduction of chondrocytes in a growing endochondral bone, resulting in the expansion of a cell population.\" [PMID:19264869]","metadata":null},{"id":"6bb0dcc7afc04c71a35731c44f1a728a","type":"GO_TERM","name":"negative regulation of growth rate","canonical_id":"go:GO:0045967","description":"\"Any process that reduces the rate of growth of all or part of an organism.\" [GOC:mah]","metadata":null},{"id":"20670ad6b0ac42438051016ee0dc3684","type":"GO_TERM","name":"negative regulation of guanyl-nucleotide exchange factor activity","canonical_id":"go:GO:1905098","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of guanyl-nucleotide exchange factor activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:20484009]","metadata":null},{"id":"7bcb8944b5e940efbf00a09c4e9e8b88","type":"GO_TERM","name":"negative regulation of guanylate cyclase activity","canonical_id":"go:GO:0031283","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of guanylate cyclase activity.\" [GOC:mah]","metadata":null},{"id":"86334d1bbed8458889bbbf1ba1720ad0","type":"GO_TERM","name":"negative regulation of gut granule assembly","canonical_id":"go:GO:1904756","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of gut granule assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:17535251]","metadata":null},{"id":"3e601ff4578c4de2b9797f22ae2274cf","type":"GO_TERM","name":"negative regulation of hair cycle","canonical_id":"go:GO:0042636","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair.\" [GOC:curators, PMID:12230507]","metadata":null},{"id":"12a9b6ab7bf7405ea2a835ac0a547c3d","type":"GO_TERM","name":"negative regulation of hair follicle cell proliferation","canonical_id":"go:GO:0071337","description":"\"Any process that stops, prevents or reduces the rate or extent of hair follicle cell proliferation.\" [GOC:mah]","metadata":null},{"id":"7e5727e639c44190b48cde8cb71347e1","type":"GO_TERM","name":"negative regulation of hair follicle development","canonical_id":"go:GO:0051799","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of hair follicle development.\" [GOC:ai]","metadata":null},{"id":"46a486d311344598b6e8fe1c63706caf","type":"GO_TERM","name":"negative regulation of hair follicle maturation","canonical_id":"go:GO:0048817","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of hair follicle maturation.\" [GOC:devbiol]","metadata":null},{"id":"63be5faa0ffa43e5950fb257af7d461c","type":"GO_TERM","name":"negative regulation of hair follicle placode formation","canonical_id":"go:GO:0061170","description":"\"Any process that decreases the rate, frequency, or extent of hair follicle placode formation, the developmental process in which a hair placode forms. An hair follicle placode is a thickening of the ectoderm that will give rise to the hair follicle bud.\" [GOC:dph]","metadata":null},{"id":"6ac4f78193194cca823d4c21de975fe3","type":"GO_TERM","name":"negative regulation of haustorium mother cell formation","canonical_id":"go:GO:0075195","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of symbiont haustorium mother cell formation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"81ffbf5335644d688e94bce04138b758","type":"GO_TERM","name":"negative regulation of heart contraction","canonical_id":"go:GO:0045822","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of heart contraction.\" [GOC:curators]","metadata":null},{"id":"e8d31fba5b0642e59d6a16056420ace5","type":"GO_TERM","name":"negative regulation of heart growth","canonical_id":"go:GO:0061117","description":"\"Any process that decreases the rate or extent of heart growth. Heart growth is the increase in size or mass of the heart.\" [GOC:dph, GOC:hjd]","metadata":null},{"id":"1ea831ae7917460d945223783a93a0dd","type":"GO_TERM","name":"negative regulation of heart induction","canonical_id":"go:GO:1901320","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of heart induction.\" [GOC:TermGenie]","metadata":null},{"id":"9dcdc66e165a4acebfaad7a702afe4e0","type":"GO_TERM","name":"negative regulation of heart looping","canonical_id":"go:GO:1901208","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of heart looping.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"2aa33e7018d14272bafe1f23f1f15f38","type":"GO_TERM","name":"negative regulation of heart rate","canonical_id":"go:GO:0010459","description":"\"Any process that stops, prevents or reduces the frequency or rate of heart contraction.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ce476e5e5e56447a88ccd153b8c194fd","type":"GO_TERM","name":"negative regulation of heart rate by acetylcholine","canonical_id":"go:GO:0003063","description":"\"The process in which acetylcholine released from vagus nerve endings binds to muscarinic receptors on the pacemaker cells and decreases the rate of heart muscle contraction.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"49840aeba2564c1595f7776583ebf20d","type":"GO_TERM","name":"negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure","canonical_id":"go:GO:0001985","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of heart contraction as a result of the baroreceptor response to increased blood pressure.\" [ISBN:0721643949]","metadata":null},{"id":"65640b6731e447aeb842fcd824e99799","type":"GO_TERM","name":"negative regulation of heat dissipation","canonical_id":"go:GO:0031655","description":"\"Any process that stops, prevents, or reduces the rate or extent of heat dissipation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"ea13377dd81b4d6fba4f834373f07936","type":"GO_TERM","name":"negative regulation of heat generation","canonical_id":"go:GO:0031651","description":"\"Any process that stops, prevents, or reduces the rate or extent of heat generation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"b85ad54ab93441b38338cb757624cc09","type":"GO_TERM","name":"negative regulation of helicase activity","canonical_id":"go:GO:0051097","description":"\"Any process that stops or reduces the activity of a helicase.\" [GOC:ai]","metadata":null},{"id":"28143ffa5cf24d4badfb91fca9ea2590","type":"GO_TERM","name":"negative regulation of helvolic acid biosynthetic process","canonical_id":"go:GO:1900841","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of helvolic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c951f55b6d23446aa5912f561ba4df78","type":"GO_TERM","name":"negative regulation of hematopoietic progenitor cell differentiation","canonical_id":"go:GO:1901533","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hematopoietic progenitor cell differentiation.\" [GOC:BHF, GOC:rl, GOC:TermGenie]","metadata":null},{"id":"edff60e2b3a74aacae357b2c824cad7a","type":"GO_TERM","name":"negative regulation of hematopoietic stem cell differentiation","canonical_id":"go:GO:1902037","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hematopoietic stem cell differentiation.\" [GOC:TermGenie, PMID:23403623]","metadata":null},{"id":"249686a653e64768bee8570ad9123111","type":"GO_TERM","name":"negative regulation of hematopoietic stem cell migration","canonical_id":"go:GO:2000472","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hematopoietic stem cell migration.\" [GOC:obol]","metadata":null},{"id":"01bfe5e5a6624c1483cdc4cefd122319","type":"GO_TERM","name":"negative regulation of hematopoietic stem cell proliferation","canonical_id":"go:GO:1902034","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hematopoietic stem cell proliferation.\" [GOC:TermGenie, PMID:23403623]","metadata":null},{"id":"eb92b308660c4cc0a45cfd762560ac23","type":"GO_TERM","name":"negative regulation of heme biosynthetic process","canonical_id":"go:GO:0070454","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of heme.\" [GOC:mah]","metadata":null},{"id":"a2faab33c6214511a4ecfd82287679fd","type":"GO_TERM","name":"negative regulation of hemicellulose catabolic process","canonical_id":"go:GO:2000989","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hemicellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"01b804c50532408197244f9d988734e4","type":"GO_TERM","name":"negative regulation of hemocyte differentiation","canonical_id":"go:GO:0045611","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of hemocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"26db5c0626bb4658b8c1f2c27d714e37","type":"GO_TERM","name":"negative regulation of hemocyte proliferation","canonical_id":"go:GO:0035207","description":"\"Any process that stops, prevents or reduces the rate or extent of hemocyte proliferation. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"7d6ca02ce3704c70864e2802749e09f2","type":"GO_TERM","name":"negative regulation of hemoglobin biosynthetic process","canonical_id":"go:GO:0046986","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of hemoglobin, an oxygen carrying, conjugated protein containing four heme groups and globin.\" [GOC:ai]","metadata":null},{"id":"cdd78ec8bb5640f7938a23e2a499bbd3","type":"GO_TERM","name":"negative regulation of hemopoiesis","canonical_id":"go:GO:1903707","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hemopoiesis.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20080761]","metadata":null},{"id":"d126f68924fc437f9ed1d99cb3537f33","type":"GO_TERM","name":"negative regulation of hemostasis","canonical_id":"go:GO:1900047","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hemostasis.\" [GOC:TermGenie]","metadata":null},{"id":"1cdc1ae2475f45e6a985e70970bf9f74","type":"GO_TERM","name":"negative regulation of hepatic stellate cell activation","canonical_id":"go:GO:2000490","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hepatic stellate cell activation.\" [GOC:obol]","metadata":null},{"id":"cc396709cca54acb8ed3acc79e813d9a","type":"GO_TERM","name":"negative regulation of hepatic stellate cell contraction","canonical_id":"go:GO:0061875","description":"\"Any process that modulates stops, prevents, or reduces the frequency, rate or extent of hepatic stellate cell contraction.\" [PMID:24204762]","metadata":null},{"id":"20ea5c291192417a8e68c8bfaf1fe5ce","type":"GO_TERM","name":"negative regulation of hepatic stellate cell migration","canonical_id":"go:GO:0061871","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hepatic stellate cell migration.\" [PMID:24204762]","metadata":null},{"id":"22377f78328d408ebd8c8ae80102f167","type":"GO_TERM","name":"negative regulation of hepatic stellate cell proliferation","canonical_id":"go:GO:1904898","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hepatic stellate cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15358192]","metadata":null},{"id":"df0515a322264680b99a823de88672ea","type":"GO_TERM","name":"negative regulation of hepatocyte apoptotic process","canonical_id":"go:GO:1903944","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:8649852]","metadata":null},{"id":"d936b359496a47cd9fc7ada853b99538","type":"GO_TERM","name":"negative regulation of hepatocyte differentiation","canonical_id":"go:GO:0070367","description":"\"Any process that stops or decreases the rate or extent of hepatocyte differentiation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"234cf26148e547e986de2b49df0c4d2a","type":"GO_TERM","name":"negative regulation of hepatocyte growth factor production","canonical_id":"go:GO:0032686","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of hepatocyte growth factor production.\" [GOC:mah, PMID:1838014]","metadata":null},{"id":"2054990dd7754b9a87586be55d2ab45f","type":"GO_TERM","name":"negative regulation of hepatocyte growth factor receptor signaling pathway","canonical_id":"go:GO:1902203","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte growth factor receptor signaling pathway.\" [GOC:TermGenie, PMID:18819921]","metadata":null},{"id":"c97f4750e9044e5fba754caa9540ca5a","type":"GO_TERM","name":"negative regulation of hepatocyte proliferation","canonical_id":"go:GO:2000346","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte proliferation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"cf44f44bfba74c9f8381646e2fe14c82","type":"GO_TERM","name":"negative regulation of heptadecane biosynthetic process","canonical_id":"go:GO:1900897","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of heptadecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"fd2ac570c9f641e195c6dbe0c174fdf0","type":"GO_TERM","name":"negative regulation of heptasaccharide transport","canonical_id":"go:GO:1900295","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of heptasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"d6fbd41466e24fffb498552af5e38491","type":"GO_TERM","name":"negative regulation of heterochromatin formation","canonical_id":"go:GO:0031452","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of heterochromatin formation.\" [PMID:16855380]","metadata":null},{"id":"aaed52908c854234bb806b1d49658fa4","type":"GO_TERM","name":"negative regulation of heterochromatin organization","canonical_id":"go:GO:0120262","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of heterochromatin organization.\" [GOC:krc]","metadata":null},{"id":"2765b3777ac94d02a88077494c990fa0","type":"GO_TERM","name":"negative regulation of heterotypic cell-cell adhesion","canonical_id":"go:GO:0034115","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of heterotypic cell-cell adhesion.\" [GOC:add]","metadata":null},{"id":"b1f8ec9c88de499c98f1247ac5d51f9d","type":"GO_TERM","name":"negative regulation of hexadecanal biosynthetic process","canonical_id":"go:GO:1900903","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hexadecanal biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"84fb5ee0af3e4738aa6d0ddcdd7b72f8","type":"GO_TERM","name":"negative regulation of hexasaccharide transport","canonical_id":"go:GO:1900298","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hexasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f6af0e182ba242afaf00734fd90a30c3","type":"GO_TERM","name":"negative regulation of high voltage-gated calcium channel activity","canonical_id":"go:GO:1901842","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of high voltage-gated calcium channel activity.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12754254]","metadata":null},{"id":"258b06839cd64872ba11c79918db51af","type":"GO_TERM","name":"negative regulation of high-density lipoprotein particle clearance","canonical_id":"go:GO:0010987","description":"\"Any process that decreases the rate, frequency or extent of high-density lipoprotein particle clearance. High-density lipoprotein particle clearance is the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"4ae81dc550164bdd889c9c0a7f9d1080","type":"GO_TERM","name":"negative regulation of hindgut contraction","canonical_id":"go:GO:0060451","description":"\"Any process that decreases the frequency, rate or extent of muscle contraction of the hindgut, the posterior part of the alimentary canal, including the rectum, and the large intestine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7e2d0a5266c94289b1b4df0c01247bb3","type":"GO_TERM","name":"negative regulation of hippo signaling","canonical_id":"go:GO:0035331","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of hippo signaling.\" [GOC:bf]","metadata":null},{"id":"3a011c72320440428fa6ee32a63000c1","type":"GO_TERM","name":"negative regulation of hippocampal neuron apoptotic process","canonical_id":"go:GO:0110091","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process in hippocampal neurons.\" [GOC:sl, PMID:18940801]","metadata":null},{"id":"da819a2cae5448dea9aad1f2d522f996","type":"GO_TERM","name":"negative regulation of histamine secretion by mast cell","canonical_id":"go:GO:1903594","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of histamine secretion by mast cell.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18253931]","metadata":null},{"id":"9b23c0914320430dbef76da757cacbbb","type":"GO_TERM","name":"negative regulation of histamine uptake","canonical_id":"go:GO:0051617","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of histamine into a cell.\" [GOC:ai]","metadata":null},{"id":"13d9c8cdd57544a4817736363707e738","type":"GO_TERM","name":"negative regulation of histidine biosynthetic process","canonical_id":"go:GO:0120214","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of histidine biosynthetic process.\" [GOC:krc]","metadata":null},{"id":"f3d538ff92d04770ae98b2cdc5c0d10a","type":"GO_TERM","name":"negative regulation of homophilic cell adhesion","canonical_id":"go:GO:1903386","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of homophilic cell adhesion.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:21724833]","metadata":null},{"id":"ff940821c3884155a91e7391af3d561f","type":"GO_TERM","name":"negative regulation of homoserine biosynthetic process","canonical_id":"go:GO:1901711","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of homoserine biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"a067d96927d94e2e8aa4fc4e3fd1e0a7","type":"GO_TERM","name":"negative regulation of homotypic cell-cell adhesion","canonical_id":"go:GO:0034111","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of homotypic cell-cell adhesion.\" [GOC:add]","metadata":null},{"id":"d9b87e219f754e889980ac5243818703","type":"GO_TERM","name":"negative regulation of horizontal cell localization","canonical_id":"go:GO:1902873","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of horizontal cell localization.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"f2d3e0c08f1a407bb6bafea7607703c1","type":"GO_TERM","name":"negative regulation of hormone biosynthetic process","canonical_id":"go:GO:0032353","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of hormones.\" [GOC:ai]","metadata":null},{"id":"f344cc95dc044c449d6e8d0aec72e413","type":"GO_TERM","name":"negative regulation of hormone metabolic process","canonical_id":"go:GO:0032351","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving any hormone.\" [GOC:mah]","metadata":null},{"id":"24d9faeade1d4b32bc6ecb1962f7d248","type":"GO_TERM","name":"negative regulation of hormone secretion","canonical_id":"go:GO:0046888","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"493b3fa9cdbc4599852a23540541d770","type":"GO_TERM","name":"negative regulation of host-seeking behavior","canonical_id":"go:GO:0032539","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of any behavior associated with finding a host organism.\" [GOC:mah]","metadata":null},{"id":"9f7000e7487946ae9fb1cc70e22b2d89","type":"GO_TERM","name":"negative regulation of humoral immune response","canonical_id":"go:GO:0002921","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a humoral immune response.\" [GOC:add]","metadata":null},{"id":"2d185c0ee93b45abb667b22fe3b3e65a","type":"GO_TERM","name":"negative regulation of humoral immune response mediated by circulating immunoglobulin","canonical_id":"go:GO:0002924","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a humoral immune response mediated by circulating immunoglobulin.\" [GOC:add]","metadata":null},{"id":"3a8d45a2e03541159c2df0f567f27ddf","type":"GO_TERM","name":"negative regulation of hyaluranon cable assembly","canonical_id":"go:GO:1900105","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hyaluranon cable assembly.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"5f34eddcac5f4702a667d01f8d7873a1","type":"GO_TERM","name":"negative regulation of hyaluronan biosynthetic process","canonical_id":"go:GO:1900126","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hyaluronan biosynthetic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"c7dba2fd42864bd7a52034b9872bac97","type":"GO_TERM","name":"negative regulation of hydrogen peroxide biosynthetic process","canonical_id":"go:GO:0010730","description":"\"Any process that decreases the rate, frequency or extent of hydrogen peroxide biosynthesis. The chemical reactions and pathways resulting in the formation of hydrogen peroxide (H2O2), a potentially harmful byproduct of aerobic cellular respiration which can cause damage to DNA.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"2d9753c5af7846de9163ddfafbb7bb8d","type":"GO_TERM","name":"negative regulation of hydrogen peroxide catabolic process","canonical_id":"go:GO:2000296","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hydrogen peroxide catabolic process.\" [GOC:BHF]","metadata":null},{"id":"cac3f97228324c2aaf1b1f7de79a3119","type":"GO_TERM","name":"negative regulation of hydrogen peroxide metabolic process","canonical_id":"go:GO:0010727","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving hydrogen peroxide.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"fa38dcb3c93a4edfb0190dbfbc89387d","type":"GO_TERM","name":"negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903384","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23261939]","metadata":null},{"id":"5283073121fe420a9ead7aacdc729269","type":"GO_TERM","name":"negative regulation of hydrogen peroxide-mediated programmed cell death","canonical_id":"go:GO:1901299","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hydrogen peroxide-mediated programmed cell death.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"6c77b0b702fa487fba5f781e7500f30c","type":"GO_TERM","name":"negative regulation of hydrogen sulfide biosynthetic process","canonical_id":"go:GO:1904827","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hydrogen sulfide biosynthetic process.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22034194]","metadata":null},{"id":"a847f857531045c59b7c12b881b6f959","type":"GO_TERM","name":"negative regulation of hydrolase activity","canonical_id":"go:GO:0051346","description":"\"Any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds.\" [GOC:ai]","metadata":null},{"id":"3b203e93ea2d434eb1fef8764523c768","type":"GO_TERM","name":"negative regulation of hypersensitivity","canonical_id":"go:GO:0002884","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of hypersensitivity.\" [GOC:add]","metadata":null},{"id":"71bc1d23a73d4152815f5333d49dfe67","type":"GO_TERM","name":"negative regulation of hyphopodium formation","canonical_id":"go:GO:0075190","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of symbiont hyphopodium formation on or near its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"5af887d1b5474cd9bdae0871dcce9984","type":"GO_TERM","name":"negative regulation of hypoxanthine transport","canonical_id":"go:GO:0035347","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of hypoxanthine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"378aef184d27400d8427d7213af59c4d","type":"GO_TERM","name":"negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903298","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hypoxia-induced intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24553947]","metadata":null},{"id":"71e6668b8ad14d0a86fd071784df408e","type":"GO_TERM","name":"negative regulation of hypoxia-inducible factor-1alpha signaling pathway","canonical_id":"go:GO:1902072","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of hypoxia-inducible factor-1alpha signaling pathway.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"a222d9277c214f309f2c5c0acb7602d1","type":"GO_TERM","name":"negative regulation of icosanoid secretion","canonical_id":"go:GO:0032304","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of an icosanoid from a cell.\" [GOC:mah]","metadata":null},{"id":"bc88519e48464a68b7692f6d0057055c","type":"GO_TERM","name":"negative regulation of imaginal disc growth","canonical_id":"go:GO:0045571","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of imaginal disc growth.\" [GOC:curators]","metadata":null},{"id":"37f466871e0247cb8b49036816ae3b03","type":"GO_TERM","name":"negative regulation of imaginal disc-derived leg joint morphogenesis","canonical_id":"go:GO:0110139","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of imaginal disc-derived leg joint morphogenesis.\" [GOC:ha, PMID:25329825]","metadata":null},{"id":"4117701fd93a488f87f9db733d9720e1","type":"GO_TERM","name":"negative regulation of imaginal disc-derived wing size","canonical_id":"go:GO:0044720","description":"\"Any process that reduces the size of an imaginal disc-derived wing.\" [PMID:21393605]","metadata":null},{"id":"3fa72ea401174b96acf799b95ffe38ac","type":"GO_TERM","name":"negative regulation of imaginal disc-derived wing vein specification","canonical_id":"go:GO:0110109","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of imaginal disc-derived wing vein specification.\" [GOC:ha, PMID:11861482]","metadata":null},{"id":"bd00f215cfba40bd9dc04500ce4cefa7","type":"GO_TERM","name":"negative regulation of immature T cell proliferation","canonical_id":"go:GO:0033087","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of immature T cell proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"5b7fd2b38920404181801792414a5c63","type":"GO_TERM","name":"negative regulation of immature T cell proliferation in thymus","canonical_id":"go:GO:0033088","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of immature T cell proliferation in the thymus.\" [GOC:add, GOC:mah]","metadata":null},{"id":"b94571db72ee4d07ae5d2dbc294835f3","type":"GO_TERM","name":"negative regulation of immune effector process","canonical_id":"go:GO:0002698","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an immune effector process.\" [GOC:add]","metadata":null},{"id":"bef455989a974ff6a41c2a98d22e9c2d","type":"GO_TERM","name":"negative regulation of immune response","canonical_id":"go:GO:0050777","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.\" [GOC:ai]","metadata":null},{"id":"94a1db3ecd7d4a308c5d97e7a7f44ba1","type":"GO_TERM","name":"negative regulation of immune response to tumor cell","canonical_id":"go:GO:0002838","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an immune response to tumor cell.\" [GOC:add]","metadata":null},{"id":"b8cdf11b3d524203969fe9eb72230ffd","type":"GO_TERM","name":"negative regulation of immune system process","canonical_id":"go:GO:0002683","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an immune system process.\" [GOC:add]","metadata":null},{"id":"9304b847518b446e97e1555be1af4b81","type":"GO_TERM","name":"negative regulation of immunoglobulin mediated immune response","canonical_id":"go:GO:0002890","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an immunoglobulin mediated immune response.\" [GOC:add]","metadata":null},{"id":"f837f3fdfbe24a909116a6ad7d7eee2f","type":"GO_TERM","name":"negative regulation of immunoglobulin production","canonical_id":"go:GO:0002638","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of immunoglobulin production.\" [GOC:add]","metadata":null},{"id":"0927355bbb1f478fa1c547ed02a18f48","type":"GO_TERM","name":"negative regulation of immunological synapse formation","canonical_id":"go:GO:2000521","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of immunological synapse formation.\" [GOC:obol]","metadata":null},{"id":"1200c2b86e6043bd8d1221102071e500","type":"GO_TERM","name":"negative regulation of inclusion body assembly","canonical_id":"go:GO:0090084","description":"\"Any process that decreases the rate, frequency, or extent of inclusion body assembly. Inclusion body assembly is the aggregation, arrangement and bonding together of a set of components to form an inclusion body.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5a9af23ff5da4f19b767d02d4d5708c6","type":"GO_TERM","name":"negative regulation of infection cushion formation","canonical_id":"go:GO:0075186","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of symbiont infection cushion formation on or near its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"cd7d0db343264674b4d631355d616ec9","type":"GO_TERM","name":"negative regulation of inflammasome-mediated signaling pathway","canonical_id":"go:GO:0141086","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an inflammasome-mediated signaling pathway.\" [PMID:33467177]","metadata":null},{"id":"588e7c382f8d418ca8032f10480c0d97","type":"GO_TERM","name":"negative regulation of inflammatory response","canonical_id":"go:GO:0050728","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response.\" [GOC:ai]","metadata":null},{"id":"f7b18698e614498ea86be731ced1eb22","type":"GO_TERM","name":"negative regulation of inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002862","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"04026a5933f64e9989dcede4d202ddad","type":"GO_TERM","name":"negative regulation of inflammatory response to wounding","canonical_id":"go:GO:0106015","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response to wounding.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26022821]","metadata":null},{"id":"25d7a62f6eaf40cd8da34cb614cd5475","type":"GO_TERM","name":"negative regulation of inhibin secretion","canonical_id":"go:GO:0032339","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of inhibin from a cell.\" [GOC:mah]","metadata":null},{"id":"e812e9b10759447cb5d7ba77db2f41f0","type":"GO_TERM","name":"negative regulation of inhibitory G protein-coupled receptor phosphorylation","canonical_id":"go:GO:1904324","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of inhibitory G protein-coupled receptor phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15937517]","metadata":null},{"id":"1800eefe25354b57989d53a6e1fb27f5","type":"GO_TERM","name":"negative regulation of inhibitory synapse assembly","canonical_id":"go:GO:1905703","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of inhibitory synapse assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"3a0aefd1b6274ccaae99058cdd1b41a3","type":"GO_TERM","name":"negative regulation of initiation of premeiotic DNA replication","canonical_id":"go:GO:1904513","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of initiation of premeiotic DNA replication.\" [GO_REF:0000058, GOC:TermGenie, PMID:25891897]","metadata":null},{"id":"f3382935936a4f99ad556d8302ddb6b7","type":"GO_TERM","name":"negative regulation of innate immune response","canonical_id":"go:GO:0045824","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response.\" [GOC:curators]","metadata":null},{"id":"4d7c388d31fc411282ac58758779e302","type":"GO_TERM","name":"negative regulation of innate immunity memory response","canonical_id":"go:GO:1905681","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of innate immunity memory response.\" [GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"fc479d46689d46f2a6dcd9af7d32fe33","type":"GO_TERM","name":"negative regulation of inner ear auditory receptor cell differentiation","canonical_id":"go:GO:0045608","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of auditory hair cell differentiation.\" [GOC:curators]","metadata":null},{"id":"4a5615fcf21044a481671dff95f82b16","type":"GO_TERM","name":"negative regulation of inner ear receptor cell differentiation","canonical_id":"go:GO:2000981","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of inner ear receptor cell differentiation.\" [GOC:obol]","metadata":null},{"id":"792260d5c7d44420926281db57f8d71a","type":"GO_TERM","name":"negative regulation of inosine transport","canonical_id":"go:GO:0035343","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of inosine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"aef5fddc4c1b4064bea7ab76434d0d13","type":"GO_TERM","name":"negative regulation of inositol biosynthetic process","canonical_id":"go:GO:1900089","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of inositol biosynthetic process.\" [GOC:TermGenie, PMID:22307851]","metadata":null},{"id":"f0ece112147d461987a7b785ad797ab0","type":"GO_TERM","name":"negative regulation of inositol phosphate biosynthetic process","canonical_id":"go:GO:0010920","description":"\"Any process that decreases the rate, frequency or extent of inositol phosphate biosynthesis. Inositol phosphate biosynthetic processes are the chemical reactions and pathways resulting in the formation of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e21c329f391f4bab9f01ff49b75a8d33","type":"GO_TERM","name":"negative regulation of inositol trisphosphate biosynthetic process","canonical_id":"go:GO:0032961","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of inositol trisphosphate.\" [GOC:mah]","metadata":null},{"id":"dcdda2f6071949a6a66571a72476fae4","type":"GO_TERM","name":"negative regulation of insulin receptor signaling pathway","canonical_id":"go:GO:0046627","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of insulin receptor signaling.\" [GOC:bf]","metadata":null},{"id":"5a81cac99edb4becb4a689824fd4dd65","type":"GO_TERM","name":"negative regulation of insulin receptor signaling pathway by insulin receptor internalization","canonical_id":"go:GO:0038014","description":"\"Any process in which internalization of an insulin receptor stops, prevents, or reduces the frequency, rate or extent of insulin receptor signal transduction. Internalization of insulin in association with its receptor clears insulin from the circulation and is necessary for subsequent insulin dissociation from the receptor and insulin degradation.\" [GOC:bf, GOC:signaling, PMID:18492485, PMID:7821727, PMID:7978876, PMID:9609114]","metadata":null},{"id":"b58ceda14d2a45aa8c9c82330bd0065d","type":"GO_TERM","name":"negative regulation of insulin secretion","canonical_id":"go:GO:0046676","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of insulin.\" [GOC:ai]","metadata":null},{"id":"61b50c968d49455187f843dd8e71843a","type":"GO_TERM","name":"negative regulation of insulin secretion involved in cellular response to glucose stimulus","canonical_id":"go:GO:0061179","description":"\"Any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"cdabfcd762c249cd9b5be3a24d988ab4","type":"GO_TERM","name":"negative regulation of insulin-like growth factor receptor signaling pathway","canonical_id":"go:GO:0043569","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of insulin-like growth factor receptor signaling.\" [GOC:bf]","metadata":null},{"id":"dc531f3996184eef900dec9a6f4467c7","type":"GO_TERM","name":"negative regulation of integrin activation","canonical_id":"go:GO:0033624","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of integrin activation.\" [GOC:add]","metadata":null},{"id":"1a95700098bf471393c4e7209d90d06f","type":"GO_TERM","name":"negative regulation of integrin biosynthetic process","canonical_id":"go:GO:0045720","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of integrins.\" [GOC:curators]","metadata":null},{"id":"15eec18ffd144722be46cc721d0e618b","type":"GO_TERM","name":"negative regulation of integrin-mediated signaling pathway","canonical_id":"go:GO:2001045","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of integrin-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"5d972333c58f424ca32149c51165eec7","type":"GO_TERM","name":"negative regulation of interferon-alpha production","canonical_id":"go:GO:0032687","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-alpha production.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"1d52eeb57af24c7d89778713a8ceb0b2","type":"GO_TERM","name":"negative regulation of interferon-beta production","canonical_id":"go:GO:0032688","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-beta production.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"6cd294a704124acd967f9287f81fbe91","type":"GO_TERM","name":"negative regulation of interleukin-1 alpha production","canonical_id":"go:GO:0032690","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 alpha production.\" [GOC:mah]","metadata":null},{"id":"5fa5be8b7204425bbc9a59f83a75181a","type":"GO_TERM","name":"negative regulation of interleukin-1 beta production","canonical_id":"go:GO:0032691","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 beta production.\" [GOC:mah]","metadata":null},{"id":"22b9aab86a1140c2afba35b4455ec1f0","type":"GO_TERM","name":"negative regulation of interleukin-1 production","canonical_id":"go:GO:0032692","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 production.\" [GOC:mah]","metadata":null},{"id":"4c2c0a6003f246b093efa986d5e88332","type":"GO_TERM","name":"negative regulation of interleukin-1-mediated signaling pathway","canonical_id":"go:GO:2000660","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-1-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"950d98db895049b0a91e495a7a893091","type":"GO_TERM","name":"negative regulation of interleukin-10 production","canonical_id":"go:GO:0032693","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 production.\" [GOC:mah]","metadata":null},{"id":"6fdf3cad45074453a6931f49cf21ac0e","type":"GO_TERM","name":"negative regulation of interleukin-11 production","canonical_id":"go:GO:0032694","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-11 production.\" [GOC:mah, PMID:29286137]","metadata":null},{"id":"2c7c7df388764b548a3a0c0859b0661b","type":"GO_TERM","name":"negative regulation of interleukin-12 production","canonical_id":"go:GO:0032695","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-12 production.\" [GOC:mah]","metadata":null},{"id":"c0206253866345f3bcccf55f61099fd9","type":"GO_TERM","name":"negative regulation of interleukin-13 production","canonical_id":"go:GO:0032696","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-13 production.\" [GOC:mah]","metadata":null},{"id":"42815d4c85294f17b26081d1cc1c2f3a","type":"GO_TERM","name":"negative regulation of interleukin-15 production","canonical_id":"go:GO:0032698","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-15 production.\" [GOC:mah]","metadata":null},{"id":"1534c44e3cb94c43939b995ac17dec40","type":"GO_TERM","name":"negative regulation of interleukin-16 production","canonical_id":"go:GO:0032699","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-16 production.\" [GOC:mah]","metadata":null},{"id":"4f23db8866984dbeac75525ed6717ca3","type":"GO_TERM","name":"negative regulation of interleukin-17 production","canonical_id":"go:GO:0032700","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of any member of the interleukin-17 family of cytokines.\" [GOC:add, GOC:mah, PMID:16482511]","metadata":null},{"id":"41f01bf9b91748158ac69ad12465f4d4","type":"GO_TERM","name":"negative regulation of interleukin-17-mediated signaling pathway","canonical_id":"go:GO:1903882","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-17-mediated signaling pathway.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:20054338]","metadata":null},{"id":"ff6f8b880d814f9cabb49712d6a6e339","type":"GO_TERM","name":"negative regulation of interleukin-17A production","canonical_id":"go:GO:0150152","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-17A production.\" [GOC:aruk, PMID:27901018]","metadata":null},{"id":"7f2b9a21be8f45e1a8b8c004e2d15ec6","type":"GO_TERM","name":"negative regulation of interleukin-18 production","canonical_id":"go:GO:0032701","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-18 production.\" [GOC:mah, PMID:23710316]","metadata":null},{"id":"6a0f2d7e45454377862f93023ffa0f0f","type":"GO_TERM","name":"negative regulation of interleukin-18-mediated signaling pathway","canonical_id":"go:GO:2000493","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-18-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"42fa022d98e546deb9d8b8f417507261","type":"GO_TERM","name":"negative regulation of interleukin-19 production","canonical_id":"go:GO:0032702","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-19 production.\" [GOC:mah]","metadata":null},{"id":"47800641f13d403ba622af18cc4ea56b","type":"GO_TERM","name":"negative regulation of interleukin-2 production","canonical_id":"go:GO:0032703","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-2 production.\" [GOC:mah]","metadata":null},{"id":"229be9a8c0484a44a92053e27ee3a740","type":"GO_TERM","name":"negative regulation of interleukin-2-mediated signaling pathway","canonical_id":"go:GO:1902206","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-2-mediated signaling pathway.\" [GOC:TermGenie, PMID:11909529]","metadata":null},{"id":"040ba8155bf041f3b6d4592c44ac03f9","type":"GO_TERM","name":"negative regulation of interleukin-20 production","canonical_id":"go:GO:0032704","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-20 production.\" [GOC:mah]","metadata":null},{"id":"06e3a0e4e69c47a0ab0bc0c8fcbe579e","type":"GO_TERM","name":"negative regulation of interleukin-21 production","canonical_id":"go:GO:0032705","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-21 production.\" [GOC:mah]","metadata":null},{"id":"eff2fa226d45423b814fc93d117fb9ae","type":"GO_TERM","name":"negative regulation of interleukin-22 production","canonical_id":"go:GO:0032706","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-22 production.\" [GOC:mah]","metadata":null},{"id":"514b747a538d48de8fb8533fed3a049c","type":"GO_TERM","name":"negative regulation of interleukin-23 production","canonical_id":"go:GO:0032707","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-23 production.\" [GOC:mah]","metadata":null},{"id":"8dce5db2585a44518436ed6e7ee1486e","type":"GO_TERM","name":"negative regulation of interleukin-24 production","canonical_id":"go:GO:0032708","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-24 production.\" [GOC:mah]","metadata":null},{"id":"52cd50f4ca8a480da9b6dba706e02adc","type":"GO_TERM","name":"negative regulation of interleukin-25 production","canonical_id":"go:GO:0032709","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-25 production.\" [GOC:mah]","metadata":null},{"id":"dcff9d8a200d4e34ba0e58380c134826","type":"GO_TERM","name":"negative regulation of interleukin-26 production","canonical_id":"go:GO:0032710","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-26 production.\" [GOC:mah]","metadata":null},{"id":"2cdfa0b93f884db2a6f6671e8c2e57a1","type":"GO_TERM","name":"negative regulation of interleukin-27 production","canonical_id":"go:GO:0032711","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-27 production.\" [GOC:mah]","metadata":null},{"id":"8aec56b1b75f42d8a64a5c217ba6e444","type":"GO_TERM","name":"negative regulation of interleukin-27-mediated signaling pathway","canonical_id":"go:GO:0070108","description":"\"Any process that decreases the rate, frequency or extent of an interleukin-27-mediated signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d6551dcde5f74b80ba593ef334bb69ef","type":"GO_TERM","name":"negative regulation of interleukin-3 production","canonical_id":"go:GO:0032712","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-3 production.\" [GOC:mah]","metadata":null},{"id":"e046fb0ebc6744ebbfe7ea2dd4d1cbd9","type":"GO_TERM","name":"negative regulation of interleukin-32 production","canonical_id":"go:GO:0150190","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-32 production.\" [GOC:aruk, PMID:23729669]","metadata":null},{"id":"7b82cda727f448938dfaa5ac0bc5d4cb","type":"GO_TERM","name":"negative regulation of interleukin-33 production","canonical_id":"go:GO:0150128","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-33 production.\" [GOC:aruk, PMID:29778524]","metadata":null},{"id":"501db0e26d5e4583bb66028dfd60cf1b","type":"GO_TERM","name":"negative regulation of interleukin-34 production","canonical_id":"go:GO:0150159","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-34 production.\" [GOC:aruk, PMID:26754294]","metadata":null},{"id":"f5bd4608919c4f23b5b2885bbc94a7e8","type":"GO_TERM","name":"negative regulation of interleukin-35 production","canonical_id":"go:GO:0070755","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-35 production.\" [GOC:mah]","metadata":null},{"id":"94963eed47ff404cabcaeaafb5fb179a","type":"GO_TERM","name":"negative regulation of interleukin-35-mediated signaling pathway","canonical_id":"go:GO:0070759","description":"\"Any process that decreases the rate, frequency or extent of an interleukin-35-mediated signaling pathway.\" [GOC:mah]","metadata":null},{"id":"41aca0b5bd2044708b727846aa4c34aa","type":"GO_TERM","name":"negative regulation of interleukin-37 production","canonical_id":"go:GO:0150138","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-37 production.\" [GOC:aruk, PMID:30362558]","metadata":null},{"id":"9edbca696c194393a0c555643597ce4e","type":"GO_TERM","name":"negative regulation of interleukin-4 production","canonical_id":"go:GO:0032713","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-4 production.\" [GOC:mah, PMID:29778524]","metadata":null},{"id":"c58ea45559a94b6ba39afe19bffeb032","type":"GO_TERM","name":"negative regulation of interleukin-4-mediated signaling pathway","canonical_id":"go:GO:1902215","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-4-mediated signaling pathway.\" [GOC:TermGenie, PMID:17210636]","metadata":null},{"id":"a94e0d6d4aaf410bae3152a4317e2961","type":"GO_TERM","name":"negative regulation of interleukin-5 production","canonical_id":"go:GO:0032714","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-5 production.\" [GOC:mah]","metadata":null},{"id":"8cb0d0a5ce604cf7927de1acb0df3281","type":"GO_TERM","name":"negative regulation of interleukin-6 production","canonical_id":"go:GO:0032715","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-6 production.\" [GOC:mah]","metadata":null},{"id":"4cb9500f997b4b10947c2c6aa30ea4d1","type":"GO_TERM","name":"negative regulation of interleukin-6-mediated signaling pathway","canonical_id":"go:GO:0070104","description":"\"Any process that decreases the rate, frequency or extent of an interleukin-6-mediated signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"82d6387d14e1462ebd163a8cfb09c4a1","type":"GO_TERM","name":"negative regulation of interleukin-7 production","canonical_id":"go:GO:0032716","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-7 production.\" [GOC:mah, PMID:25962782]","metadata":null},{"id":"c41c59b1dbaf47b4b5662d8c316322ba","type":"GO_TERM","name":"negative regulation of interleukin-8 production","canonical_id":"go:GO:0032717","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-8 production.\" [GOC:mah]","metadata":null},{"id":"614a00d5613c4d3eaa9c97b09c03bb31","type":"GO_TERM","name":"negative regulation of interleukin-9 production","canonical_id":"go:GO:0032718","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-9 production.\" [GOC:mah]","metadata":null},{"id":"45022db165eb4c58889cac6706937b39","type":"GO_TERM","name":"negative regulation of intermediate filament depolymerization","canonical_id":"go:GO:0030843","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of intermediate filament depolymerization.\" [GOC:mah]","metadata":null},{"id":"1a76fc32dda2449fb72dc026c1c077fc","type":"GO_TERM","name":"negative regulation of intermediate filament polymerization","canonical_id":"go:GO:0030840","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of intermediate filament polymerization.\" [GOC:mah]","metadata":null},{"id":"9ae3cfdc71d3402b98ca142d458f21d2","type":"GO_TERM","name":"negative regulation of intermediate mesodermal cell fate determination","canonical_id":"go:GO:0048396","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of intermediate mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"8c38bed15a0c4578b71629a4c76255f4","type":"GO_TERM","name":"negative regulation of intermediate mesodermal cell fate specification","canonical_id":"go:GO:0048401","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of intermediate mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"fb033a3180e04564a919359dfc210502","type":"GO_TERM","name":"negative regulation of interphase mitotic telomere clustering","canonical_id":"go:GO:0110066","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mitotic telomere clustering during interphase.\" [GOC:vw, PMID:25778919]","metadata":null},{"id":"7ecb52db98b34ab2a721960a909c9add","type":"GO_TERM","name":"negative regulation of intestinal absorption","canonical_id":"go:GO:1904479","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intestinal absorption.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12469120]","metadata":null},{"id":"5de2ddf9744242baaf36edef5d57e311","type":"GO_TERM","name":"negative regulation of intestinal cholesterol absorption","canonical_id":"go:GO:0045796","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of uptake of cholesterol into the blood by absorption from the intestine.\" [GOC:curators]","metadata":null},{"id":"446cf681ee684a2fab0e296188535ef0","type":"GO_TERM","name":"negative regulation of intestinal epithelial cell development","canonical_id":"go:GO:1905299","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intestinal epithelial cell development.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23904268]","metadata":null},{"id":"9b4a68e5fc824aca8cd55988311ab513","type":"GO_TERM","name":"negative regulation of intestinal lipid absorption","canonical_id":"go:GO:1904730","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intestinal lipid absorption.\" [GO_REF:0000058, GOC:TermGenie, PMID:18768481]","metadata":null},{"id":"3127b5be5a7b4714b85e22f331b81432","type":"GO_TERM","name":"negative regulation of intestinal phytosterol absorption","canonical_id":"go:GO:0010949","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of phytosterols into the blood by absorption from the small intestine.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"cd6075f869bc41c7b98df15f8d906f4c","type":"GO_TERM","name":"negative regulation of intracellular cholesterol transport","canonical_id":"go:GO:0032384","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of cholesterol within cells.\" [GOC:mah]","metadata":null},{"id":"9f1daf9eab784c6fab5d582c078e1e00","type":"GO_TERM","name":"negative regulation of intracellular estrogen receptor signaling pathway","canonical_id":"go:GO:0033147","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of an intracellular estrogen receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"3a60c215110e4955b3673b9b68eb801d","type":"GO_TERM","name":"negative regulation of intracellular lipid transport","canonical_id":"go:GO:0032378","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids within cells.\" [GOC:mah]","metadata":null},{"id":"f037f4ed7d784d64bd3d5913fad592c5","type":"GO_TERM","name":"negative regulation of intracellular mRNA localization","canonical_id":"go:GO:1904581","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intracellular mRNA localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:21471000]","metadata":null},{"id":"9580908243cf4b41ab60625364e18b34","type":"GO_TERM","name":"negative regulation of intracellular protein transport","canonical_id":"go:GO:0090317","description":"\"Any process that decreases the frequency, rate or extent of the directed movement of proteins within cells.\" [GOC:tb]","metadata":null},{"id":"8a91e9727c5c4a878ad35d94bceb3e59","type":"GO_TERM","name":"negative regulation of intracellular signal transduction","canonical_id":"go:GO:1902532","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intracellular signal transduction.\" [GOC:dph, GOC:signaling, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"e05ce927f0e042dba8aac963c319900c","type":"GO_TERM","name":"negative regulation of intracellular steroid hormone receptor signaling pathway","canonical_id":"go:GO:0033144","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"c4d567fb5f324affb732a31ec7518add","type":"GO_TERM","name":"negative regulation of intracellular sterol transport","canonical_id":"go:GO:0032381","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of sterols within cells.\" [GOC:mah]","metadata":null},{"id":"c55a97e95a96497f82ab130635d503b2","type":"GO_TERM","name":"negative regulation of intracellular transport","canonical_id":"go:GO:0032387","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances within cells.\" [GOC:mah]","metadata":null},{"id":"184a3be0754f483fa2771035c0a97786","type":"GO_TERM","name":"negative regulation of intracellular transport of viral material","canonical_id":"go:GO:1901253","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intracellular transport of viral material.\" [GOC:bf, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"0242b3020fbf443282e2d6d606073713","type":"GO_TERM","name":"negative regulation of intraciliary anterograde transport","canonical_id":"go:GO:1905797","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intraciliary anterograde transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:27930654]","metadata":null},{"id":"7fa90c51693f4959a90cc19aceeca0d9","type":"GO_TERM","name":"negative regulation of intraciliary retrograde transport","canonical_id":"go:GO:1905800","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intraciliary retrograde transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:27930654]","metadata":null},{"id":"3d1d2521cc25426f8d461f82d2c5ddc8","type":"GO_TERM","name":"negative regulation of intralumenal vesicle formation","canonical_id":"go:GO:1905366","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intralumenal vesicle formation.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"a07614babe104562bbcbed463df3b515","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway","canonical_id":"go:GO:2001243","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"e2c1a3e2ef094585b95aa32bcd7e30a4","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator","canonical_id":"go:GO:1902254","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway by p53 class mediator.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15705871]","metadata":null},{"id":"5515e366fdb3487dab73335ae3469211","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage","canonical_id":"go:GO:1902230","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15314165]","metadata":null},{"id":"d4a936b05cd24cd18be6c1c879390939","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator","canonical_id":"go:GO:1902166","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator.\" [GOC:TermGenie, PMID:17719541]","metadata":null},{"id":"684b4eeab00543398c92657f75e33723","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide","canonical_id":"go:GO:1903751","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to hydrogen peroxide.\" [GO_REF:0000058, GOC:TermGenie, PMID:18681888]","metadata":null},{"id":"c79731257753418baf41ef8386f040e1","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress","canonical_id":"go:GO:1902219","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to osmotic stress.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"6e2b98f48abe418f8c687d43fa5f8c98","type":"GO_TERM","name":"negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator","canonical_id":"go:GO:1902239","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator.\" [GOC:krc, GOC:mtg_apoptosis, GOC:TermGenie, PMID:16571598]","metadata":null},{"id":"dfcb4862c385451e84589116241315b8","type":"GO_TERM","name":"negative regulation of invasive growth in response to glucose limitation","canonical_id":"go:GO:2000218","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of invasive growth in response to glucose limitation.\" [GOC:mah]","metadata":null},{"id":"9569702fec4d4f8790ae3681bbb77f61","type":"GO_TERM","name":"negative regulation of inward rectifier potassium channel activity","canonical_id":"go:GO:1903609","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of inward rectifier potassium channel activity.\" [GO_REF:0000059, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:18923542]","metadata":null},{"id":"bfc46f27226041fb9cc54e6a5f0a52d1","type":"GO_TERM","name":"negative regulation of iodide transmembrane transport","canonical_id":"go:GO:1904213","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of iodide transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"6df3fcba6fb543f683b3ea8fb2698474","type":"GO_TERM","name":"negative regulation of iodide transport","canonical_id":"go:GO:1904202","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of iodide transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"b0311bf1b3634a15a89c3c2d6507683c","type":"GO_TERM","name":"negative regulation of ion transmembrane transporter activity","canonical_id":"go:GO:0032413","description":"\"Any process that stops or reduces the activity of an ion transporter.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"da6fc306cd1b4863b87a6c32508e4819","type":"GO_TERM","name":"negative regulation of iridophore differentiation","canonical_id":"go:GO:0050943","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of iridophore differentiation.\" [GOC:ai]","metadata":null},{"id":"a0444912b195417a8664791d09908493","type":"GO_TERM","name":"negative regulation of iron export across plasma membrane","canonical_id":"go:GO:1904039","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of export of iron ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GO_REF:0000058, GOC:BHF, GOC:kom, GOC:TermGenie, PMID:15514116]","metadata":null},{"id":"5a28c54a2b214ac1ab2c915fa75ef8bd","type":"GO_TERM","name":"negative regulation of iron ion import across plasma membrane","canonical_id":"go:GO:1904439","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of iron ions import across plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:kom, GOC:TermGenie, PMID:18353247]","metadata":null},{"id":"122297410d064cff86e43f2fb7b6295c","type":"GO_TERM","name":"negative regulation of iron ion transmembrane transport","canonical_id":"go:GO:0034760","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of iron ions from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"2a5acd0935aa40dea4fb444d520f8bdc","type":"GO_TERM","name":"negative regulation of iron ion transport","canonical_id":"go:GO:0034757","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of iron ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"1f5b1d0b6d904acca516bad4b02ed16d","type":"GO_TERM","name":"negative regulation of iron-sulfur cluster assembly","canonical_id":"go:GO:1903330","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of iron-sulfur cluster assembly.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"5f59ea6aa8af4cbc9909c4ef5920920a","type":"GO_TERM","name":"negative regulation of iron-sulfur-molybdenum cofactor assembly","canonical_id":"go:GO:1900507","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of iron-sulfur-molybdenum cofactor assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"0dd1b4cbb485476c87aae7e3b26a03d8","type":"GO_TERM","name":"negative regulation of isopentenyl diphosphate biosynthetic process, methylerythritol phosphate pathway","canonical_id":"go:GO:0010323","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of isopentenyl diphosphate produced via the methylerythritol (MEP) pathway (mevalonate-independent).\" [PMID:16531478]","metadata":null},{"id":"768ad174fdb84bdab255bfa1fe321cbd","type":"GO_TERM","name":"negative regulation of isopentenyl diphosphate biosynthetic process, mevalonate pathway","canonical_id":"go:GO:2001211","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of isopentenyl diphosphate biosynthetic process, mevalonate pathway.\" [GOC:al]","metadata":null},{"id":"0b5df7f7445c4bfa8848ec396798b544","type":"GO_TERM","name":"negative regulation of isoprenoid metabolic process","canonical_id":"go:GO:0045827","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving isoprenoid.\" [GOC:curators]","metadata":null},{"id":"e35e4cd8f41145d5927c040b8884b188","type":"GO_TERM","name":"negative regulation of isotype switching","canonical_id":"go:GO:0045829","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of isotype switching.\" [GOC:curators]","metadata":null},{"id":"5ce9ef5608ad4f988cdb669539e0cdc7","type":"GO_TERM","name":"negative regulation of isotype switching to IgA isotypes","canonical_id":"go:GO:0048297","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of isotype switching to IgA isotypes.\" [GOC:jid]","metadata":null},{"id":"5c5419491dfb4058b8d165ea5d4ca744","type":"GO_TERM","name":"negative regulation of isotype switching to IgD isotypes","canonical_id":"go:GO:0048300","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of isotype switching to IgD isotypes.\" [GOC:jid]","metadata":null},{"id":"549f11b4b8104b76af67e4d1cf36bfb4","type":"GO_TERM","name":"negative regulation of isotype switching to IgE isotypes","canonical_id":"go:GO:0048294","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of isotype switching to IgE isotypes.\" [GOC:jid]","metadata":null},{"id":"45d094e03e324aafb1f62989aa24467d","type":"GO_TERM","name":"negative regulation of isotype switching to IgG isotypes","canonical_id":"go:GO:0048303","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of isotype switching to IgG isotypes.\" [GOC:jid]","metadata":null},{"id":"1a406a74885a47ab9423efd21e1e5ac0","type":"GO_TERM","name":"negative regulation of juvenile hormone biosynthetic process","canonical_id":"go:GO:0045968","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"cf4e963c4dec43c19ad42c08e345a232","type":"GO_TERM","name":"negative regulation of juvenile hormone catabolic process","canonical_id":"go:GO:0045970","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"12d8efcc24f5408cbdb8788ea09bb026","type":"GO_TERM","name":"negative regulation of juvenile hormone metabolic process","canonical_id":"go:GO:0045928","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"93e63e7ee11442e3b91337654be6c33f","type":"GO_TERM","name":"negative regulation of juvenile hormone secretion","canonical_id":"go:GO:0045972","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"2334a5c9249e48158b114a42d8075d70","type":"GO_TERM","name":"negative regulation of kainate selective glutamate receptor signaling pathway","canonical_id":"go:GO:0106427","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the kainate selective glutamate receptor signaling pathway.\" [PMID:12597860]","metadata":null},{"id":"f9e72446048f41a3843f8226927b43ee","type":"GO_TERM","name":"negative regulation of keratinocyte apoptotic process","canonical_id":"go:GO:1902173","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of keratinocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:18938133]","metadata":null},{"id":"9e7cb5a1471541de8c4e0740369a7419","type":"GO_TERM","name":"negative regulation of keratinocyte differentiation","canonical_id":"go:GO:0045617","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of keratinocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"518fa57bc59744928619a1124fb9e307","type":"GO_TERM","name":"negative regulation of keratinocyte migration","canonical_id":"go:GO:0051548","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of keratinocyte migration.\" [GOC:ai]","metadata":null},{"id":"7799bfecf8284f3e8e3bb71f85bac692","type":"GO_TERM","name":"negative regulation of keratinocyte proliferation","canonical_id":"go:GO:0010839","description":"\"Any process that decreases the rate, frequency or extent of keratinocyte proliferation. Keratinocyte proliferation is the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"151121a2e5c04def87e8a5431c43908a","type":"GO_TERM","name":"negative regulation of kidney development","canonical_id":"go:GO:0090185","description":"\"Any process that decreases the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"8daa5e2a1ae24d11bfc704a9b16bfed9","type":"GO_TERM","name":"negative regulation of kidney smooth muscle cell differentiation","canonical_id":"go:GO:2000357","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of kidney smooth muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"5ea3fabea758434697701a8b0de04477","type":"GO_TERM","name":"negative regulation of killing of cells of another organism","canonical_id":"go:GO:0051711","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the killing by an organism of cells in another organism.\" [GOC:ai]","metadata":null},{"id":"e9f983cc85cd4ccd969409be101e8f69","type":"GO_TERM","name":"negative regulation of kinase activity","canonical_id":"go:GO:0033673","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.\" [GOC:mah]","metadata":null},{"id":"b6e875e1e0114c84bd0e71c1448f7a2e","type":"GO_TERM","name":"negative regulation of kinetochore assembly","canonical_id":"go:GO:1905560","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of kinetochore assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"daaf70c974964c9eb04b388470f4b98a","type":"GO_TERM","name":"negative regulation of kinin cascade","canonical_id":"go:GO:0002257","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the kinin cascade.\" [GOC:jal]","metadata":null},{"id":"351604ec587f44778a43d8338917fe3f","type":"GO_TERM","name":"negative regulation of kojic acid biosynthetic process","canonical_id":"go:GO:1900395","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of kojic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"26ecd890d155464e8fc6adf18361878c","type":"GO_TERM","name":"negative regulation of lactation","canonical_id":"go:GO:1903488","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lactation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19563620]","metadata":null},{"id":"785ddaf7c7054b0dac0473d89f1191a6","type":"GO_TERM","name":"negative regulation of lactose biosynthetic process","canonical_id":"go:GO:1903535","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lactose biosynthetic process.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:12018418]","metadata":null},{"id":"94e6cd9f9d0245d08b7eb5039978c978","type":"GO_TERM","name":"negative regulation of lamellipodium assembly","canonical_id":"go:GO:0010593","description":"\"Any process that decreases the rate, frequency or extent of the formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8a913bb892854300b5ed7df5486c4661","type":"GO_TERM","name":"negative regulation of lamellipodium morphogenesis","canonical_id":"go:GO:2000393","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lamellipodium morphogenesis.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"9a7ea558b7ab4942b4b9e3b59f8b47db","type":"GO_TERM","name":"negative regulation of lamellipodium organization","canonical_id":"go:GO:1902744","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lamellipodium organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:16054028]","metadata":null},{"id":"2691c138cea34985beb2b3743209fca3","type":"GO_TERM","name":"negative regulation of lamellocyte differentiation","canonical_id":"go:GO:0035204","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lamellocyte differentiation. Lamellocytes differentiate massively in the lymph glands after parasitization and are large flat cells devoted to encapsulation of invaders too large to be phagocytosed by plasmatocytes.\" [PMID:14734104]","metadata":null},{"id":"01a66de01b5d496d8177d5e14fc05ca6","type":"GO_TERM","name":"negative regulation of laminaritriose transport","canonical_id":"go:GO:1900304","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of laminaritriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"e1612e2c6e514090b6814bdd54614351","type":"GO_TERM","name":"negative regulation of large conductance calcium-activated potassium channel activity","canonical_id":"go:GO:1902607","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of large conductance calcium-activated potassium channel activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:23407708]","metadata":null},{"id":"7ae6c12a210145d9a2f28ce1689338df","type":"GO_TERM","name":"negative regulation of larval salivary gland boundary specification","canonical_id":"go:GO:0045710","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of salivary gland determination in a larval organism.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"f4de071c4c5749c9a63af52bdeb7b0f6","type":"GO_TERM","name":"negative regulation of larval somatic muscle development","canonical_id":"go:GO:0062230","description":"\"Any process that decreases the rate, frequency or extent of larval somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"927f97d84eca4835adbe2d8c1aef0fe1","type":"GO_TERM","name":"negative regulation of late endosome to lysosome transport","canonical_id":"go:GO:1902823","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of late endosome to lysosome transport.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:23949442]","metadata":null},{"id":"82d449f6280a4e83bc8f6ef41d12d46c","type":"GO_TERM","name":"negative regulation of late stripe melanocyte differentiation","canonical_id":"go:GO:0050949","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of late stripe melanocyte differentiation.\" [GOC:ai]","metadata":null},{"id":"9ae922b476094240a860fe06b48cce3f","type":"GO_TERM","name":"negative regulation of lateral mesodermal cell fate determination","canonical_id":"go:GO:0048375","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lateral mesoderm cell fate determination.\" [GOC:jid]","metadata":null},{"id":"999a18fca3fc4aeb8d0695e8b9c8ef58","type":"GO_TERM","name":"negative regulation of lateral mesodermal cell fate specification","canonical_id":"go:GO:0048380","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lateral mesoderm cell fate specification.\" [GOC:jid]","metadata":null},{"id":"c0ece625ce12498283dca4b83ac58103","type":"GO_TERM","name":"negative regulation of lateral motor column neuron migration","canonical_id":"go:GO:1902077","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lateral motor column neuron migration.\" [GOC:TermGenie, GOC:yaf, PMID:20711475]","metadata":null},{"id":"8bfe7fb24d01417580a63c4ec324294e","type":"GO_TERM","name":"negative regulation of lateral root development","canonical_id":"go:GO:1901332","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lateral root development.\" [GOC:TermGenie]","metadata":null},{"id":"3cc6b13e42cc4c76a0ca7c9a0eb52c41","type":"GO_TERM","name":"negative regulation of leaf development","canonical_id":"go:GO:1905622","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leaf development.\" [GO_REF:0000058, GOC:TermGenie, PMID:11606552]","metadata":null},{"id":"cfc55475aa8b48aa8e83704f8d9dfec3","type":"GO_TERM","name":"negative regulation of leaf senescence","canonical_id":"go:GO:1900056","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leaf senescence.\" [GOC:TermGenie]","metadata":null},{"id":"567d900b89d144b0887cb5b737d4a61c","type":"GO_TERM","name":"negative regulation of lens epithelial cell proliferation","canonical_id":"go:GO:2001110","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lens epithelial cell proliferation.\" [GOC:obol]","metadata":null},{"id":"931a21ef4c944abebaae55295f21d27c","type":"GO_TERM","name":"negative regulation of lens fiber cell differentiation","canonical_id":"go:GO:1902747","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lens fiber cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17592637]","metadata":null},{"id":"c7d0b31a8d814e81943072b47a60bd9a","type":"GO_TERM","name":"negative regulation of leucine import in response to ammonium ion","canonical_id":"go:GO:0060360","description":"\"Any process that decreases the rate, frequency or extent of leucine import as a result of an ammonium ion stimulus. Leucine import is the directed movement of leucine into a cell or organelle.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"cc85f6dd47ed4a32aa0cb27283ce415c","type":"GO_TERM","name":"negative regulation of leucophore differentiation","canonical_id":"go:GO:0048776","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of leucophore differentiation.\" [GOC:mh]","metadata":null},{"id":"3b1b1c9e608b4dcfa78a9e239bfa6139","type":"GO_TERM","name":"negative regulation of leukocyte activation","canonical_id":"go:GO:0002695","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte activation.\" [GOC:add]","metadata":null},{"id":"b48020b5ae524735b646e1f8e98c3556","type":"GO_TERM","name":"negative regulation of leukocyte adhesion to arterial endothelial cell","canonical_id":"go:GO:1904998","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leukocyte adhesion to arterial endothelial cell.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22267480]","metadata":null},{"id":"09eb20a5e6824757b3e722d20c156e32","type":"GO_TERM","name":"negative regulation of leukocyte adhesion to vascular endothelial cell","canonical_id":"go:GO:1904995","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leukocyte adhesion to vascular endothelial cell.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23897866]","metadata":null},{"id":"6b80d8a0b73f4a14a26fad245a10660d","type":"GO_TERM","name":"negative regulation of leukocyte apoptotic process","canonical_id":"go:GO:2000107","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of leukocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis]","metadata":null},{"id":"b2eed54987ec405982fb5951b7a1ce61","type":"GO_TERM","name":"negative regulation of leukocyte cell-cell adhesion","canonical_id":"go:GO:1903038","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leukocyte cell-cell adhesion.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21106532]","metadata":null},{"id":"02ed161c571f488e9508df6e78cbfdaa","type":"GO_TERM","name":"negative regulation of leukocyte chemotaxis","canonical_id":"go:GO:0002689","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte chemotaxis.\" [GOC:add]","metadata":null},{"id":"fafcc1d10dd340abae9c58d4d6548492","type":"GO_TERM","name":"negative regulation of leukocyte degranulation","canonical_id":"go:GO:0043301","description":"\"Any process that stops, prevents, or reduces the rate of leukocyte degranulation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f332f424d29e4924ba27bd6293a10cdb","type":"GO_TERM","name":"negative regulation of leukocyte differentiation","canonical_id":"go:GO:1902106","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leukocyte differentiation.\" [GOC:add, GOC:TermGenie]","metadata":null},{"id":"ab2e6a14cba94d03953428bc52d01e35","type":"GO_TERM","name":"negative regulation of leukocyte mediated cytotoxicity","canonical_id":"go:GO:0001911","description":"\"Any process that stops, prevents, or reduces the rate of leukocyte mediated cytotoxicity.\" [GOC:add, ISBN:0781735149, PMID:11911826]","metadata":null},{"id":"11b84577e79d4d6dbcf83bf7b401f62a","type":"GO_TERM","name":"negative regulation of leukocyte mediated immunity","canonical_id":"go:GO:0002704","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"0bae6141e7cf49ecacb944029f9f936e","type":"GO_TERM","name":"negative regulation of leukocyte migration","canonical_id":"go:GO:0002686","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte migration.\" [GOC:add]","metadata":null},{"id":"9bf4a479560d49e29b6fe1ce5bf3fac3","type":"GO_TERM","name":"negative regulation of leukocyte proliferation","canonical_id":"go:GO:0070664","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of leukocyte proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"9437456a52c7435690b183b3626a09d5","type":"GO_TERM","name":"negative regulation of leukocyte tethering or rolling","canonical_id":"go:GO:1903237","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of leukocyte tethering or rolling.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18308860]","metadata":null},{"id":"c0f4fa01a94b4125b52de9219aef0645","type":"GO_TERM","name":"negative regulation of lipase activity","canonical_id":"go:GO:0060192","description":"\"Any process that decreases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"df336ba04edd4d75a0d607ae049b9ee7","type":"GO_TERM","name":"negative regulation of lipid binding","canonical_id":"go:GO:1900131","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lipid binding.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"2ca40cbc1ab04c3b8b487d66a03f9964","type":"GO_TERM","name":"negative regulation of lipid biosynthetic process","canonical_id":"go:GO:0051055","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.\" [GOC:ai]","metadata":null},{"id":"9a0069f1b84a42a89fbc62c9845d8a63","type":"GO_TERM","name":"negative regulation of lipid catabolic process","canonical_id":"go:GO:0050995","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.\" [GOC:ai]","metadata":null},{"id":"c2896795126645dda7bfb86bf53f6667","type":"GO_TERM","name":"negative regulation of lipid droplet fusion","canonical_id":"go:GO:0160078","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lipid droplet fusion.\" [PMID:36477540]","metadata":null},{"id":"4430581a3b29416e933125abf2edbec7","type":"GO_TERM","name":"negative regulation of lipid localization","canonical_id":"go:GO:1905953","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lipid localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:17564681]","metadata":null},{"id":"9d72b8d8c8484730ad0d79f36b27aac6","type":"GO_TERM","name":"negative regulation of lipid metabolic process","canonical_id":"go:GO:0045833","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipids.\" [GOC:curators]","metadata":null},{"id":"adb6b81df7db43cd8def021fbc7dab1d","type":"GO_TERM","name":"negative regulation of lipid storage","canonical_id":"go:GO:0010888","description":"\"Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1f3a0d754e604a8bade02855f2f9c97f","type":"GO_TERM","name":"negative regulation of lipid transport","canonical_id":"go:GO:0032369","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"63d32d5d3c1e4063b376bb3313763515","type":"GO_TERM","name":"negative regulation of lipid transport across blood-brain barrier","canonical_id":"go:GO:1903001","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lipid transport across blood-brain barrier.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24345162]","metadata":null},{"id":"cbc5a6da2167420592fabe62b3bf4712","type":"GO_TERM","name":"negative regulation of lipophagy","canonical_id":"go:GO:1904503","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lipophagy.\" [GO_REF:0000058, GOC:autophagy, GOC:dph, GOC:TermGenie, PMID:25383539]","metadata":null},{"id":"de06716c4edf41ac9ae83fc229b1c65b","type":"GO_TERM","name":"negative regulation of lipopolysaccharide-mediated signaling pathway","canonical_id":"go:GO:0031665","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signaling in response to detection of lipopolysaccharide.\" [GOC:mah]","metadata":null},{"id":"74415ef4d70049f98e68b365dde6b18b","type":"GO_TERM","name":"negative regulation of lipoprotein lipase activity","canonical_id":"go:GO:0051005","description":"\"Any process that stops or reduces the activity of the enzyme lipoprotein lipase.\" [GOC:ai]","metadata":null},{"id":"156b6a99efcc4c0d9b4f553e01aa3300","type":"GO_TERM","name":"negative regulation of lipoprotein lipid oxidation","canonical_id":"go:GO:0060588","description":"\"Any process that decreases the rate, frequency or extent of lipoprotein lipid oxidation. Lipoprotein lipid oxidation is the modification of a lipoprotein by oxidation of the lipid group.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"be3f4e07fc394ac78028435f34b4d0a0","type":"GO_TERM","name":"negative regulation of lipoprotein metabolic process","canonical_id":"go:GO:0050748","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipoproteins, any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.\" [GOC:ai]","metadata":null},{"id":"b991daccd49c462d8c0959dd8fcd0486","type":"GO_TERM","name":"negative regulation of lipoprotein oxidation","canonical_id":"go:GO:0034443","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lipoprotein oxidation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b1c40b21b7b1493ea3482d5912e020cf","type":"GO_TERM","name":"negative regulation of lipoprotein particle clearance","canonical_id":"go:GO:0010985","description":"\"Any process that decreases the rate, frequency, or extent of lipoprotein particle clearance. Lipoprotein particle clearance is the process in which a lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"98d0ea437b424f789814f9570a3b003f","type":"GO_TERM","name":"negative regulation of lipoprotein transport","canonical_id":"go:GO:0140076","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lipoprotein transport.\" [GOC:BHF, GOC:BHF_miRNA, GOC:RPH, PMID:26501192]","metadata":null},{"id":"aad1b3be41ad4ec3962bc86c1b7ba7c2","type":"GO_TERM","name":"negative regulation of lncRNA transcription","canonical_id":"go:GO:0140744","description":"\"Any process that decreases the frequency, rate or extent of the synthesis of a lncRNA.\" [PMID:33767452, PMID:33913806]","metadata":null},{"id":"6df0e029973b4974b1ad869d74e57e30","type":"GO_TERM","name":"negative regulation of locomotion","canonical_id":"go:GO:0040013","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of locomotion of a cell or organism.\" [GOC:curators]","metadata":null},{"id":"a34fd0d0c49f455ba41cd00fc76a5283","type":"GO_TERM","name":"negative regulation of locomotion involved in locomotory behavior","canonical_id":"go:GO:0090327","description":"\"Any process that decreases the frequency, rate, or extent of the self-propelled movement of a cell or organism from one location to another in a behavioral context; the aspect of locomotory behavior having to do with movement.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"07ea005010f348bc8ecdcd2e4144ac0e","type":"GO_TERM","name":"negative regulation of locomotor rhythm","canonical_id":"go:GO:1904060","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of locomotor rhythm.\" [GO_REF:0000058, GOC:TermGenie, PMID:16310969]","metadata":null},{"id":"c06aa797e8a54222855a2673fc77bdb4","type":"GO_TERM","name":"negative regulation of long-chain fatty acid import across plasma membrane","canonical_id":"go:GO:0010748","description":"\"Any process that decreases the rate, frequency or extent of plasma membrane long-chain fatty acid transport. Plasma membrane long-chain fatty acid transport is the directed movement of long-chain fatty acids across the plasma membrane.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"28402a2b523b4f9f9af01cbc1c7dc954","type":"GO_TERM","name":"negative regulation of long-chain fatty acid import into cell","canonical_id":"go:GO:0140213","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of long-chain fatty acid import into a cell.\" [PMID:28178239]","metadata":null},{"id":"01313aac2f0046378e306c25589bd768","type":"GO_TERM","name":"negative regulation of long-day photoperiodism, flowering","canonical_id":"go:GO:0048579","description":"\"Any process that stops, prevents or reduces long-day photoperiodism, where the response associated with the photoperiodism is flowering. Flowering is defined by the switch from the vegetative to the reproductive phase.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"af95c246b6b94ae3926b40817e4698e3","type":"GO_TERM","name":"negative regulation of long-term neuronal synaptic plasticity","canonical_id":"go:GO:0048171","description":"\"A process that decreases long-term neuronal synaptic plasticity, the ability of neuronal synapses to change long-term as circumstances require. Long-term neuronal synaptic plasticity generally involves increase or decrease in actual synapse numbers.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"27b639a8d84d441498b448eef494ed9a","type":"GO_TERM","name":"negative regulation of long-term synaptic depression","canonical_id":"go:GO:1900453","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of long term synaptic depression.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"08a9309fec1c4389b308c549d12645c8","type":"GO_TERM","name":"negative regulation of long-term synaptic potentiation","canonical_id":"go:GO:1900272","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of long-term synaptic potentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"94a13ed882564daca732b1092293d1fc","type":"GO_TERM","name":"negative regulation of low-density lipoprotein particle clearance","canonical_id":"go:GO:0010989","description":"\"Any process that decreases the rate, frequency or extent of low-density lipoprotein particle clearance. Low-density lipoprotein particle clearance is the process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"a73ea13db7354a02aa90c718621e10d4","type":"GO_TERM","name":"negative regulation of low-density lipoprotein particle receptor catabolic process","canonical_id":"go:GO:0032804","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of low-density lipoprotein receptors.\" [GOC:mah]","metadata":null},{"id":"1be87d1efd614ecb896a9670d0ccb875","type":"GO_TERM","name":"negative regulation of lung alveolus development","canonical_id":"go:GO:1904654","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lung alveolus development.\" [GO_REF:0000058, GOC:TermGenie, PMID:23962064]","metadata":null},{"id":"38df01a7d3f14743ab57bfc00da8aea7","type":"GO_TERM","name":"negative regulation of lung blood pressure","canonical_id":"go:GO:0061767","description":"\"The process that decreases the force with which blood travels through the lungs.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:dph, PMID:22161164]","metadata":null},{"id":"0e2ec50c589d406492aecebfd19d69d2","type":"GO_TERM","name":"negative regulation of lung ciliated cell differentiation","canonical_id":"go:GO:1901247","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lung ciliated cell differentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"fd57b5bc715d4609afa26fcebb6d7168","type":"GO_TERM","name":"negative regulation of lung goblet cell differentiation","canonical_id":"go:GO:1901250","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lung goblet cell differentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"c6f6b4b145f14bee8c7ff1502be99af3","type":"GO_TERM","name":"negative regulation of luteinizing hormone secretion","canonical_id":"go:GO:0033685","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of luteinizing hormone.\" [GOC:mah]","metadata":null},{"id":"7b382417918f494b81c52518c1d4b220","type":"GO_TERM","name":"negative regulation of lymphangiogenesis","canonical_id":"go:GO:1901491","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lymphangiogenesis.\" [GOC:dph, GOC:TermGenie, PMID:20133819]","metadata":null},{"id":"fc28089231204428bc407046f5a36878","type":"GO_TERM","name":"negative regulation of lymphocyte activation","canonical_id":"go:GO:0051250","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lymphocyte activation.\" [GOC:ai]","metadata":null},{"id":"9a56501b86b44d228678f6a5728b13ba","type":"GO_TERM","name":"negative regulation of lymphocyte anergy","canonical_id":"go:GO:0002912","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte anergy.\" [GOC:add]","metadata":null},{"id":"434baec2291a4643bbf5b5c40125972c","type":"GO_TERM","name":"negative regulation of lymphocyte apoptotic process","canonical_id":"go:GO:0070229","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lymphocyte death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"dbf184ede14d4d458bdd7f272ae38d40","type":"GO_TERM","name":"negative regulation of lymphocyte chemotaxis","canonical_id":"go:GO:1901624","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lymphocyte chemotaxis.\" [GOC:TermGenie]","metadata":null},{"id":"63b9340021a94997ba73908912424b66","type":"GO_TERM","name":"negative regulation of lymphocyte differentiation","canonical_id":"go:GO:0045620","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lymphocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"68a537fb2e7d4786b0e7a4736b9fafb7","type":"GO_TERM","name":"negative regulation of lymphocyte mediated immunity","canonical_id":"go:GO:0002707","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"ee0f62894c6648059734695edb6a7bad","type":"GO_TERM","name":"negative regulation of lymphocyte migration","canonical_id":"go:GO:2000402","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lymphocyte migration.\" [GOC:mah]","metadata":null},{"id":"78cd4448a5c9473c987cb1de0c606847","type":"GO_TERM","name":"negative regulation of lymphocyte proliferation","canonical_id":"go:GO:0050672","description":"\"Any process that stops, prevents or reduces the rate or extent of lymphocyte proliferation.\" [GOC:ai]","metadata":null},{"id":"193a306e336243d28ee6aa649c8eec1f","type":"GO_TERM","name":"negative regulation of lymphoid progenitor cell differentiation","canonical_id":"go:GO:1905457","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lymphoid progenitor cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27010503]","metadata":null},{"id":"d77936ad392b4351b2ca13a6ce831cbe","type":"GO_TERM","name":"negative regulation of lymphotoxin A production","canonical_id":"go:GO:0032721","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of lymphotoxin A production.\" [GOC:mah]","metadata":null},{"id":"f58d2767bcb645be936e099340423790","type":"GO_TERM","name":"negative regulation of lysosomal membrane permeability","canonical_id":"go:GO:0097215","description":"\"Any process that decreases the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane.\" [GOC:yaf, PMID:20544854]","metadata":null},{"id":"d64a11f785e843c7a55e270df7c01371","type":"GO_TERM","name":"negative regulation of lysosomal protein catabolic process","canonical_id":"go:GO:1905166","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lysosomal protein catabolic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"5ea62aaf1db14b47b90b3eacc321663b","type":"GO_TERM","name":"negative regulation of lysosome organization","canonical_id":"go:GO:1905672","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of lysosome organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:25561470]","metadata":null},{"id":"2620b57b16684d9cb0a21b4fd305e937","type":"GO_TERM","name":"negative regulation of mRNA 3'-end processing","canonical_id":"go:GO:0031441","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mRNA 3'-end processing.\" [GOC:mah]","metadata":null},{"id":"ca15a1f2c4f446efbc5ad74f2d3668bb","type":"GO_TERM","name":"negative regulation of mRNA catabolic process","canonical_id":"go:GO:1902373","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mRNA catabolic process.\" [GOC:bf, GOC:TermGenie, PMID:22626865]","metadata":null},{"id":"1aa6b8fc02d94466bdca2a150a248d9c","type":"GO_TERM","name":"negative regulation of mRNA cis splicing, via spliceosome","canonical_id":"go:GO:1905745","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mRNA cis splicing, via spliceosome.\" [GO_REF:0000058, GOC:TermGenie, PMID:2880558]","metadata":null},{"id":"aa16c30df0e042df960b4fb0143289e1","type":"GO_TERM","name":"negative regulation of mRNA metabolic process","canonical_id":"go:GO:1903312","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"174e668c0e1a497ebe72ec158c0cdabc","type":"GO_TERM","name":"negative regulation of mRNA modification","canonical_id":"go:GO:0090367","description":"\"Any process that decreases the rate, frequency, or extent of the covalent alteration of one or more nucleotides within an mRNA molecule to produce an mRNA molecule with a sequence that differs from that coded genetically.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"1ba323367d5843239c60868114797101","type":"GO_TERM","name":"negative regulation of mRNA processing","canonical_id":"go:GO:0050686","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mRNA processing.\" [GOC:ai]","metadata":null},{"id":"6a2d9baf182a4715a72bc133b7ab0813","type":"GO_TERM","name":"negative regulation of mRNA splicing, via spliceosome","canonical_id":"go:GO:0048025","description":"\"Any process that stops, prevents or reduces the rate or extent of mRNA splicing via a spliceosomal mechanism.\" [GOC:jid]","metadata":null},{"id":"bf7d20b985404183afc25c23067fe7dc","type":"GO_TERM","name":"negative regulation of macroautophagy","canonical_id":"go:GO:0016242","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of macroautophagy.\" [GOC:curators]","metadata":null},{"id":"39db7da56ba142d086013e27747b4530","type":"GO_TERM","name":"negative regulation of macromolecule biosynthetic process","canonical_id":"go:GO:0010558","description":"\"Any process that decreases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a2ae2303a60e4039b3d44e73735db29a","type":"GO_TERM","name":"negative regulation of macromolecule metabolic process","canonical_id":"go:GO:0010605","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4fce85aadbc542aebf2d42b9e190dfda","type":"GO_TERM","name":"negative regulation of macrophage activation","canonical_id":"go:GO:0043031","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage activation.\" [GOC:jl]","metadata":null},{"id":"d59d711a687142a697280213f4b9f736","type":"GO_TERM","name":"negative regulation of macrophage antigen processing and presentation","canonical_id":"go:GO:0002617","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of macrophage antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"641947024d0d41928d0d17ef554e82c8","type":"GO_TERM","name":"negative regulation of macrophage apoptotic process","canonical_id":"go:GO:2000110","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis]","metadata":null},{"id":"1e90e8cb7abd4eb7b0dae0379028b554","type":"GO_TERM","name":"negative regulation of macrophage chemotaxis","canonical_id":"go:GO:0010760","description":"\"Any process that decreases the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5f7b97dc645b4890a677295c982a50d2","type":"GO_TERM","name":"negative regulation of macrophage colony-stimulating factor production","canonical_id":"go:GO:1901257","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of macrophage colony-stimulating factor production.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"9a928941997148efa3711b5368e180c9","type":"GO_TERM","name":"negative regulation of macrophage colony-stimulating factor signaling pathway","canonical_id":"go:GO:1902227","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of macrophage colony-stimulating factor signaling pathway.\" [GOC:TermGenie, PMID:16705167]","metadata":null},{"id":"4c6de17d5f6443f6ac0d56150d2836ba","type":"GO_TERM","name":"negative regulation of macrophage cytokine production","canonical_id":"go:GO:0010936","description":"\"Any process that decreases the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"5730d74b4f0d4ad0a6ec054d648c49a8","type":"GO_TERM","name":"negative regulation of macrophage derived foam cell differentiation","canonical_id":"go:GO:0010745","description":"\"Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.\" [GOC:add, GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"e18f4e421fd34a14ac0af1e33f4559ac","type":"GO_TERM","name":"negative regulation of macrophage differentiation","canonical_id":"go:GO:0045650","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage differentiation.\" [GOC:curators]","metadata":null},{"id":"14953de4d439453e86437538604e919d","type":"GO_TERM","name":"negative regulation of macrophage fusion","canonical_id":"go:GO:0034240","description":"\"Any process that stops, prevents, or decreases the frequency, rate or extent of macrophage fusion.\" [GOC:mah]","metadata":null},{"id":"e7c94f23dd7240ef98f65fe36cf7aa73","type":"GO_TERM","name":"negative regulation of macrophage inflammatory protein 1 alpha production","canonical_id":"go:GO:0071641","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of macrophage inflammatory protein 1 alpha.\" [GOC:mah]","metadata":null},{"id":"54764b597aec4fbb9feb5d36ef8e3809","type":"GO_TERM","name":"negative regulation of macrophage inflammatory protein-1 gamma production","canonical_id":"go:GO:0071647","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of macrophage inflammatory protein-1 gamma.\" [GOC:mah]","metadata":null},{"id":"4a9c6a21e4684cba9d2cc1c363c09ef5","type":"GO_TERM","name":"negative regulation of macrophage migration","canonical_id":"go:GO:1905522","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of macrophage migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:25749876]","metadata":null},{"id":"260f3820017d4d4795c31df777c1c26d","type":"GO_TERM","name":"negative regulation of macrophage migration inhibitory factor signaling pathway","canonical_id":"go:GO:2000447","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of macrophage migration inhibitory factor signaling pathway.\" [GOC:obol]","metadata":null},{"id":"ea14fcda84654ee0aec43c5189c660e1","type":"GO_TERM","name":"negative regulation of macrophage proliferation","canonical_id":"go:GO:0120042","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage proliferation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"90a7dab65eef4870bd5c0641048d643c","type":"GO_TERM","name":"negative regulation of macropinocytosis","canonical_id":"go:GO:1905302","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of macropinocytosis.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:18691641]","metadata":null},{"id":"a89f4ae92e1c4c6aa5fbd4bfa0742c63","type":"GO_TERM","name":"negative regulation of maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:0061362","description":"\"Any process that decreases the frequency, rate or extent of maintenance of bipolar cell polarity regulating cell shape.\" [GOC:dph]","metadata":null},{"id":"8d5ec2144aae4b628214d734ceff4cb0","type":"GO_TERM","name":"negative regulation of maintenance of meiotic sister chromatid cohesion","canonical_id":"go:GO:0034095","description":"\"Any process that decreases the extent to which the association between sister chromatids of a replicated chromosome is maintained during a meiotic cell cycle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"ab254c4ba348447e90726347878abbea","type":"GO_TERM","name":"negative regulation of maintenance of meiotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:2000710","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maintenance of meiotic sister chromatid cohesion in the centromeric region.\" [GOC:mah]","metadata":null},{"id":"45d183e2da9d48cd8059120eafc3a16c","type":"GO_TERM","name":"negative regulation of maintenance of mitotic sister chromatid cohesion","canonical_id":"go:GO:0034183","description":"\"Any process that decreases the extent to which the association between sister chromatids of a replicated chromosome is maintained during a mitotic cell cycle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"6ee653a665a749d5928041dada39a740","type":"GO_TERM","name":"negative regulation of maintenance of mitotic sister chromatid cohesion, arms","canonical_id":"go:GO:2000716","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion along the chromosome arms.\" [GOC:mah]","metadata":null},{"id":"5106b9aec12a482e8195796fcd5c0b01","type":"GO_TERM","name":"negative regulation of maintenance of mitotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:2000719","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion in the centromeric region.\" [GOC:mah]","metadata":null},{"id":"98abd4dce77f4831b3f186f908214697","type":"GO_TERM","name":"negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric","canonical_id":"go:GO:1904908","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion, telomeric.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26373281]","metadata":null},{"id":"d7b4ef0e1f3b42bd873d64a9a8b880d9","type":"GO_TERM","name":"negative regulation of maintenance of sister chromatid cohesion","canonical_id":"go:GO:0034092","description":"\"Any process that decreases the extent to which the association between sister chromatids of a replicated chromosome is maintained.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"f4b79b03407a4ceaa912353aa2cda197","type":"GO_TERM","name":"negative regulation of male germ cell proliferation","canonical_id":"go:GO:2000255","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of male germ cell proliferation.\" [GOC:obol]","metadata":null},{"id":"1f0970faceee4c349e9f2e285f6787c2","type":"GO_TERM","name":"negative regulation of male germ-line stem cell asymmetric division","canonical_id":"go:GO:1904839","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of male germ-line stem cell asymmetric division.\" [GO_REF:0000058, GOC:TermGenie, PMID:19339709]","metadata":null},{"id":"9bed40b823bf45e081d8e28f34584413","type":"GO_TERM","name":"negative regulation of male gonad development","canonical_id":"go:GO:2000019","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of male gonad development.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"bf11f4c693c1465083d81b1d6ec485db","type":"GO_TERM","name":"negative regulation of male mating behavior","canonical_id":"go:GO:1902436","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of male mating behavior.\" [GOC:TermGenie, PMID:24089208]","metadata":null},{"id":"f707692498534c83a742e3f3a98b0474","type":"GO_TERM","name":"negative regulation of male pigmentation","canonical_id":"go:GO:0048092","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment of a pattern of pigment in males.\" [GOC:jid]","metadata":null},{"id":"c26d84b13a58448e9278910162756b68","type":"GO_TERM","name":"negative regulation of maltoheptaose transport","canonical_id":"go:GO:1900307","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maltoheptaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"44e99eb517f14af78012371bab350cc3","type":"GO_TERM","name":"negative regulation of maltohexaose transport","canonical_id":"go:GO:1900313","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maltohexaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"dbe29a9b06b749909e0d0453a5039df7","type":"GO_TERM","name":"negative regulation of maltopentaose transport","canonical_id":"go:GO:1900316","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maltopentaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"71046fd6633a46fead429de86f3a84a7","type":"GO_TERM","name":"negative regulation of maltose transport","canonical_id":"go:GO:1902344","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maltose transport.\" [GOC:dph, GOC:TermGenie, PMID:23770568]","metadata":null},{"id":"a1d987d1288a4c0489ec53fe5dce70c4","type":"GO_TERM","name":"negative regulation of maltotetraose transport","canonical_id":"go:GO:1900322","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maltotetraose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b5a670f813d04ddc90e28b527f3b35bb","type":"GO_TERM","name":"negative regulation of maltotriulose transport","canonical_id":"go:GO:1900325","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of maltotriulose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"3047a8942d3a4c83974d86f99542f27c","type":"GO_TERM","name":"negative regulation of mammary gland epithelial cell proliferation","canonical_id":"go:GO:0033600","description":"\"Any process that stops, prevents or reduces the rate or extent of mammary gland epithelial cell proliferation.\" [GOC:mah]","metadata":null},{"id":"3cfa4a64d7704842b6bd20d74c7e8a3b","type":"GO_TERM","name":"negative regulation of mammary gland involution","canonical_id":"go:GO:1903520","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mammary gland involution.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:23164222]","metadata":null},{"id":"2f4a6439d061437180bad5cf76f1a04a","type":"GO_TERM","name":"negative regulation of mammary stem cell proliferation","canonical_id":"go:GO:2000102","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mammary stem cell proliferation.\" [GOC:obol]","metadata":null},{"id":"7225191d91d94a28b8f88a0773a5e482","type":"GO_TERM","name":"negative regulation of mannan catabolic process","canonical_id":"go:GO:2000995","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"b006581cc77d4ea0afb4e9040ace01ab","type":"GO_TERM","name":"negative regulation of mannotriose transport","canonical_id":"go:GO:1900328","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mannotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b54f6dad8faa4093b5b1dabaa37a1e74","type":"GO_TERM","name":"negative regulation of mast cell activation","canonical_id":"go:GO:0033004","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell activation.\" [GOC:mah]","metadata":null},{"id":"0029f71cf62f4a4181487c58f3da2fa4","type":"GO_TERM","name":"negative regulation of mast cell activation involved in immune response","canonical_id":"go:GO:0033007","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell activation as part of an immune response.\" [GOC:mah]","metadata":null},{"id":"b74c555bdc2b41e18f2cff031d892c00","type":"GO_TERM","name":"negative regulation of mast cell apoptotic process","canonical_id":"go:GO:0033026","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"28b9e4f922c54051ab04b45a42549e2f","type":"GO_TERM","name":"negative regulation of mast cell chemotaxis","canonical_id":"go:GO:0060755","description":"\"Any process that decreases the rate, frequency or extent of mast cell chemotaxis. Mast cell chemotaxis is the movement of a mast cell in response to an external stimulus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"36204c0d0dc64885b3c04fcd158fb9a0","type":"GO_TERM","name":"negative regulation of mast cell cytokine production","canonical_id":"go:GO:0032764","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell cytokine production.\" [GOC:mah]","metadata":null},{"id":"c9e0a77c96414423af2973c11aed37ce","type":"GO_TERM","name":"negative regulation of mast cell degranulation","canonical_id":"go:GO:0043305","description":"\"Any process that stops, prevents, or reduces the rate of mast cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"ef29d53e57414a0395220fde3f6f6fa5","type":"GO_TERM","name":"negative regulation of mast cell differentiation","canonical_id":"go:GO:0060377","description":"\"Any process that decreases the rate, frequency or extent of mast cell differentiation, the process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a mast cell. A mast cell is a cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"960eeb07469849ae9ff66d63bf4e9c23","type":"GO_TERM","name":"negative regulation of mast cell proliferation","canonical_id":"go:GO:0070667","description":"\"Any process that stops, prevents or reduces the rate or extent of mast cell proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"5991b11fe3514fbf89f7f9f6c4040233","type":"GO_TERM","name":"negative regulation of mating type switching","canonical_id":"go:GO:0031495","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mating type switching.\" [GOC:mah]","metadata":null},{"id":"cd84be5f66aa440aa91ef32f7097e923","type":"GO_TERM","name":"negative regulation of mating-type specific transcription, DNA-templated","canonical_id":"go:GO:0045894","description":"\"Any mating-type specific process that stops, prevents or reduces the rate of cellular DNA-templated transcription.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"091dab864d534af3bddad07b869d7ef5","type":"GO_TERM","name":"negative regulation of matrix metallopeptidase secretion","canonical_id":"go:GO:1904465","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of matrix metallopeptidase secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:8679543]","metadata":null},{"id":"8adc04004b3942bc92e41b9023794072","type":"GO_TERM","name":"negative regulation of mature B cell apoptotic process","canonical_id":"go:GO:0002906","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of mature B cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"b923e66ec6d34f378f7d70be95327d8b","type":"GO_TERM","name":"negative regulation of mechanoreceptor differentiation","canonical_id":"go:GO:0045632","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mechanoreceptor differentiation.\" [GOC:curators]","metadata":null},{"id":"fa1866234ee04b67bb56463fdc9dffdf","type":"GO_TERM","name":"negative regulation of mechanosensory behavior","canonical_id":"go:GO:1905791","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mechanosensory behavior.\" [GO_REF:0000058, GOC:TermGenie, PMID:8692859]","metadata":null},{"id":"d29b76c53bec4e65b0edd1db06f22c95","type":"GO_TERM","name":"negative regulation of mediator complex assembly","canonical_id":"go:GO:2001177","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mediator complex assembly.\" [GOC:obol]","metadata":null},{"id":"afbb243640554f9e92987412d61a7acc","type":"GO_TERM","name":"negative regulation of megakaryocyte differentiation","canonical_id":"go:GO:0045653","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of megakaryocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"f3acffdcc9d34089b932f3fe1f864fcd","type":"GO_TERM","name":"negative regulation of meiosis I","canonical_id":"go:GO:0110029","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of meiosis I, a cell cycle process comprising the steps by which a cell progresses through the first phase of meiosis, in which cells divide and homologous chromosomes are paired and segregated from each other, producing two daughter cells.\" [GOC:vw]","metadata":null},{"id":"608f75f091414348b43b12651caefe1c","type":"GO_TERM","name":"negative regulation of meiotic DNA double-strand break formation","canonical_id":"go:GO:1903342","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of meiotic DNA double-strand break formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25103240]","metadata":null},{"id":"577b1217417c4f778bb9eaa61ea44125","type":"GO_TERM","name":"negative regulation of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination","canonical_id":"go:GO:1905262","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination.\" [GO_REF:0000058, GOC:TermGenie, PMID:26653857]","metadata":null},{"id":"83872eaac3484839bd5798e8502869f1","type":"GO_TERM","name":"negative regulation of meiotic cell cycle","canonical_id":"go:GO:0051447","description":"\"Any process that stops, prevents or reduces the rate or extent of progression through the meiotic cell cycle.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"8553129025ef453c83d736445ed9f8fa","type":"GO_TERM","name":"negative regulation of meiotic cell cycle phase transition","canonical_id":"go:GO:1901994","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of meiotic cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"a7660467c9854357b98d004c1c3d2963","type":"GO_TERM","name":"negative regulation of meiotic cell cycle process involved in oocyte maturation","canonical_id":"go:GO:1904145","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of meiotic cell cycle process involved in oocyte maturation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22674394]","metadata":null},{"id":"b0b9025f45494e489adf1b6a4b2dbcff","type":"GO_TERM","name":"negative regulation of meiotic chromosome separation","canonical_id":"go:GO:1905133","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of meiotic chromosome separation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw, PMID:15620645]","metadata":null},{"id":"d22c5b30a499420f884498b03de97679","type":"GO_TERM","name":"negative regulation of meiotic joint molecule formation","canonical_id":"go:GO:0010947","description":"\"Any process that decreases the frequency, rate or extent of meiotic joint molecule formation. Meiotic joint molecule formation is the conversion of the paired broken DNA and homologous duplex DNA into a four-stranded branched intermediate, known as a joint molecule, formed during meiotic recombination.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"30bfc7689fd14230a734da71b26f5101","type":"GO_TERM","name":"negative regulation of meiotic nuclear division","canonical_id":"go:GO:0045835","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of meiosis.\" [GOC:curators]","metadata":null},{"id":"0fa8f19c6a67465487ea24930319c13d","type":"GO_TERM","name":"negative regulation of meiotic spindle elongation","canonical_id":"go:GO:1902120","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of meiotic spindle elongation.\" [GOC:TermGenie, PMID:23370392]","metadata":null},{"id":"5fa816cfd66f403aa637daed25128e95","type":"GO_TERM","name":"negative regulation of melanin biosynthetic process","canonical_id":"go:GO:0048022","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of melanin.\" [GOC:jid]","metadata":null},{"id":"bb07bb95d3ae4b63b02906d5778e4b65","type":"GO_TERM","name":"negative regulation of melanization defense response","canonical_id":"go:GO:0035009","description":"\"Any process that reduces the rate or extent of the melanization defense response. This regulation is critical to limit melanization to the site of injury or infection.\" [GOC:bf, PMID:12408809]","metadata":null},{"id":"fc81fbdbe02e455d8cba00e94ec7dcd1","type":"GO_TERM","name":"negative regulation of melanocyte differentiation","canonical_id":"go:GO:0045635","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of melanocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"6c2fc348f8de4974b895d3bb0f0c7472","type":"GO_TERM","name":"negative regulation of melanosome organization","canonical_id":"go:GO:1903057","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of melanosome organization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24769727]","metadata":null},{"id":"e1e94f1acdcb4c7fa6e6a286ad750e49","type":"GO_TERM","name":"negative regulation of melanosome transport","canonical_id":"go:GO:1902909","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of melanosome transport.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23334344]","metadata":null},{"id":"701ba0f4ed8b441db424c3444924110e","type":"GO_TERM","name":"negative regulation of membrane depolarization","canonical_id":"go:GO:1904180","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane depolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:20826763]","metadata":null},{"id":"8a26a330418846ee848ebc2fcf7d5df1","type":"GO_TERM","name":"negative regulation of membrane depolarization during AV node cell action potential","canonical_id":"go:GO:1905028","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane depolarization during AV node cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:19726871]","metadata":null},{"id":"1a46ec518b764095bc23658f64e488d3","type":"GO_TERM","name":"negative regulation of membrane depolarization during cardiac muscle cell action potential","canonical_id":"go:GO:1900826","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane depolarization during a cardiac muscle cell action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:TermGenie]","metadata":null},{"id":"9792f798726e4234a488329ab5d65c22","type":"GO_TERM","name":"negative regulation of membrane hyperpolarization","canonical_id":"go:GO:1902631","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane hyperpolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:23223304]","metadata":null},{"id":"12529240034e480f9ac8fbd9d8f1ad2a","type":"GO_TERM","name":"negative regulation of membrane invagination","canonical_id":"go:GO:1905154","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane invagination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:26589353]","metadata":null},{"id":"f65bfc01d7fd4184a60acd82ea4274a6","type":"GO_TERM","name":"negative regulation of membrane permeability","canonical_id":"go:GO:1905709","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the passage or uptake of molecules by a membrane.\" [PMID:27482894]","metadata":null},{"id":"f805d52b7fc145309a60203c80734e80","type":"GO_TERM","name":"negative regulation of membrane potential","canonical_id":"go:GO:0045837","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:curators]","metadata":null},{"id":"e96c21f4760949c58b0e0fd4053fe589","type":"GO_TERM","name":"negative regulation of membrane protein ectodomain proteolysis","canonical_id":"go:GO:0051045","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of membrane protein ectodomain proteolysis.\" [GOC:ai]","metadata":null},{"id":"a7c4c3d546e74edc8bea50b8e32df14b","type":"GO_TERM","name":"negative regulation of membrane repolarization during atrial cardiac muscle cell action potential","canonical_id":"go:GO:1905001","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane repolarization during atrial cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:21098446]","metadata":null},{"id":"739e9a0a441b4f5b91bbc97ee4159492","type":"GO_TERM","name":"negative regulation of membrane repolarization during cardiac muscle cell action potential","canonical_id":"go:GO:1905032","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane repolarization during cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:23157812]","metadata":null},{"id":"b89e60050a3741858db38ccc3d9a20ae","type":"GO_TERM","name":"negative regulation of membrane repolarization during ventricular cardiac muscle cell action potential","canonical_id":"go:GO:1905025","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane repolarization during ventricular cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:19893015]","metadata":null},{"id":"e17b7ee9d500462486d57a06517bd4b2","type":"GO_TERM","name":"negative regulation of membrane tubulation","canonical_id":"go:GO:1903526","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of membrane tubulation.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:18388313]","metadata":null},{"id":"068e66a54f27416ea17162446ab529df","type":"GO_TERM","name":"negative regulation of memory T cell differentiation","canonical_id":"go:GO:0043381","description":"\"Any process that stops, prevents, or reduces the rate of memory T cell differentiation.\" [ISBN:0781735149]","metadata":null},{"id":"012a18ecd140408597b35d6141da9f7f","type":"GO_TERM","name":"negative regulation of mesenchymal cell apoptotic process","canonical_id":"go:GO:2001054","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"5fb2fc76423a4e16b330f981b2bc19d8","type":"GO_TERM","name":"negative regulation of mesenchymal cell apoptotic process involved in metanephros development","canonical_id":"go:GO:1900212","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal cell apoptotic process involved in metanephros development.\" [GOC:mtg_apoptosis, GOC:mtg_kidney_jan10, GOC:TermGenie, GOC:yaf, PMID:17314325]","metadata":null},{"id":"3cb53f467d964f3fac8859f820b84953","type":"GO_TERM","name":"negative regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis","canonical_id":"go:GO:0072040","description":"\"Any process that reduces the occurrence or rate of mesenchymal stem cell death by apoptotic process that contributes to the shaping of the nephron.\" [GOC:mtg_apoptosis, GOC:mtg_kidney_jan10]","metadata":null},{"id":"80cbda15eb7746fe965aabebea079069","type":"GO_TERM","name":"negative regulation of mesenchymal cell proliferation","canonical_id":"go:GO:0072201","description":"\"Any process that decreases the frequency, rate or extent of mesenchymal cell proliferation. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f0139d69121545ab89c328a802cf9c87","type":"GO_TERM","name":"negative regulation of mesenchymal cell proliferation involved in lung development","canonical_id":"go:GO:2000791","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal cell proliferation involved in lung development.\" [PMID:21513708]","metadata":null},{"id":"2bfc6f1d4cb349e480490b0af64553b2","type":"GO_TERM","name":"negative regulation of mesenchymal cell proliferation involved in ureter development","canonical_id":"go:GO:0072200","description":"\"Any process that decreases the frequency, rate or extent of mesenchymal cell proliferation that contributes to the progression of the ureter gland over time. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"250b621acb684c6e90406462db5868bc","type":"GO_TERM","name":"negative regulation of mesenchymal stem cell differentiation","canonical_id":"go:GO:2000740","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"557e1a4ee2eb45b2bbb33f0afd1b98bc","type":"GO_TERM","name":"negative regulation of mesenchymal stem cell migration","canonical_id":"go:GO:1905321","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal stem cell migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:26846297]","metadata":null},{"id":"86b42e885f3f42c792a75a95edc2824f","type":"GO_TERM","name":"negative regulation of mesenchymal stem cell proliferation","canonical_id":"go:GO:1902461","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal stem cell proliferation.\" [GOC:pm, GOC:TermGenie, PMID:18672106]","metadata":null},{"id":"01e4508632ed4056893fd9851253c14a","type":"GO_TERM","name":"negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis","canonical_id":"go:GO:0003340","description":"\"Any process that decreases the rate, frequency or extent of the transition where a mesenchymal cell establishes apical/basolateral polarity,forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell that will contribute to the shaping of the metanephros.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"431d2c955cad470380407aa408eb7962","type":"GO_TERM","name":"negative regulation of mesoderm development","canonical_id":"go:GO:2000381","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesoderm development.\" [GOC:BHF]","metadata":null},{"id":"1c02b48d46c24c758569b24f77d4803f","type":"GO_TERM","name":"negative regulation of mesoderm formation","canonical_id":"go:GO:1905903","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesoderm formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23939491]","metadata":null},{"id":"dccefcc956df4f689224caf7e00f3bf6","type":"GO_TERM","name":"negative regulation of mesodermal cell differentiation","canonical_id":"go:GO:1905771","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mesodermal cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23765923]","metadata":null},{"id":"ba07d99ce4e54077a52550b90fe11c3f","type":"GO_TERM","name":"negative regulation of mesodermal cell fate determination","canonical_id":"go:GO:0048335","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"8bd11ab0340e4431983abe75eb767563","type":"GO_TERM","name":"negative regulation of mesodermal cell fate specification","canonical_id":"go:GO:0042662","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mesoderm cell fate specification.\" [GOC:curators]","metadata":null},{"id":"ed180bfa3ec546dbbe7f02de8f42553f","type":"GO_TERM","name":"negative regulation of mesonephric glomerular mesangial cell proliferation","canonical_id":"go:GO:2000091","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mesonephric glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8be00bcbb0c7461584c9c3427f52609c","type":"GO_TERM","name":"negative regulation of mesonephric glomerulus development","canonical_id":"go:GO:2000088","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mesonephric glomerulus development.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c0c981c107574885bc9c06ede9c78503","type":"GO_TERM","name":"negative regulation of mesonephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:2000094","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mesonephric nephron tubule epithelial cell differentiation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ee536c0397c64845a788220f173160df","type":"GO_TERM","name":"negative regulation of mesonephros development","canonical_id":"go:GO:0061218","description":"\"Any process that decreases the rate, frequency or extent of mesonephros development. Mesonephros development is the process whose specific outcome is the progression of the mesonephros over time, from its formation to the mature structure. The mesonephros is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"2fbb0f3c66d44e7eba43c3f511cf7631","type":"GO_TERM","name":"negative regulation of metabolic process","canonical_id":"go:GO:0009892","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.\" [GOC:curators]","metadata":null},{"id":"5833488117d44732b10cb4e7dee3e544","type":"GO_TERM","name":"negative regulation of metallopeptidase activity","canonical_id":"go:GO:1905049","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metallopeptidase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:26473732]","metadata":null},{"id":"829edc9f909b459d8308c8af17004065","type":"GO_TERM","name":"negative regulation of metanephric DCT cell differentiation","canonical_id":"go:GO:2000593","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metanephric DCT cell differentiation.\" [GOC:obol]","metadata":null},{"id":"983444da569e482f96f343a2dbe514a9","type":"GO_TERM","name":"negative regulation of metanephric S-shaped body morphogenesis","canonical_id":"go:GO:2000005","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of metanephric S-shaped body morphogenesis.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"0e09ec11ace742dbb3fb839ef8c01756","type":"GO_TERM","name":"negative regulation of metanephric comma-shaped body morphogenesis","canonical_id":"go:GO:2000007","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of metanephric comma-shaped body morphogenesis.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"8dbf34d662304d35935faef5ca9d0ba8","type":"GO_TERM","name":"negative regulation of metanephric glomerular mesangial cell proliferation","canonical_id":"go:GO:0072302","description":"\"Any process that decreases the frequency, rate or extent of metanephric glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"06f3769198d34b91a8e4be5ca196ec38","type":"GO_TERM","name":"negative regulation of metanephric glomerulus development","canonical_id":"go:GO:0072299","description":"\"Any process that decreases the rate, frequency or extent of metanephric glomerulus development, the progression of the metanephric glomerulus over time from its initial formation until its mature state. The metanephric glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney, or metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a32060ff81254f16b5a5ce92c2adc951","type":"GO_TERM","name":"negative regulation of metanephric mesenchymal cell migration","canonical_id":"go:GO:2000590","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metanephric mesenchymal cell migration.\" [GOC:obol]","metadata":null},{"id":"f32579b892d84f25aa4368fd8972fe8f","type":"GO_TERM","name":"negative regulation of metanephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0072308","description":"\"Any process that decreases the frequency, rate or extent of metanephric nephron tubule epithelial cell differentiation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0ed513aa1a9d42e592c488cc53728875","type":"GO_TERM","name":"negative regulation of metanephric ureteric bud development","canonical_id":"go:GO:2001075","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metanephric ureteric bud development.\" [GOC:obol]","metadata":null},{"id":"5dd514d9dd714f7b9880cd20a47f05db","type":"GO_TERM","name":"negative regulation of metanephros development","canonical_id":"go:GO:0072217","description":"\"Any process that decreases the rate, frequency or extent of metanephros development. Metanephros development is the process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. The metanephros is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f1b853e6e55745a09d1371a77fa8b176","type":"GO_TERM","name":"negative regulation of metaphase/anaphase transition of cell cycle","canonical_id":"go:GO:1902100","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metaphase/anaphase transition of cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"2ff1dddfe79d443981de238a0ad97311","type":"GO_TERM","name":"negative regulation of metaphase/anaphase transition of meiosis I","canonical_id":"go:GO:1905187","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metaphase/anaphase transition of meiosis I.\" [GO_REF:0000058, GOC:TermGenie, PMID:21389117]","metadata":null},{"id":"b505d22ecb614441ad1386d7e97703ee","type":"GO_TERM","name":"negative regulation of metaphase/anaphase transition of meiosis II","canonical_id":"go:GO:1905190","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metaphase/anaphase transition of meiosis II.\" [GO_REF:0000058, GOC:TermGenie, PMID:21389117]","metadata":null},{"id":"7b7b1bf2e02e4df28ef83e28aaf83b09","type":"GO_TERM","name":"negative regulation of metaphase/anaphase transition of meiotic cell cycle","canonical_id":"go:GO:1902103","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of metaphase/anaphase transition of meiotic cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"c73b70cd7302451f997f63a25ec004b5","type":"GO_TERM","name":"negative regulation of methanofuran biosynthetic process","canonical_id":"go:GO:1900352","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of methanofuran biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"72cf3c3747ad43e1aa7b3f6a1202a320","type":"GO_TERM","name":"negative regulation of methanophenazine biosynthetic process","canonical_id":"go:GO:1900963","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of methanophenazine biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"0646ffbfccca4e159529eed9408c4574","type":"GO_TERM","name":"negative regulation of methyl-branched fatty acid biosynthetic process","canonical_id":"go:GO:1902323","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of methyl-branched fatty acid biosynthetic process.\" [GOC:kmv, GOC:TermGenie, PMID:15340492]","metadata":null},{"id":"864e99d55c1d430983799aabb050697b","type":"GO_TERM","name":"negative regulation of metula development","canonical_id":"go:GO:0070803","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of metula development, a process that leads to the formation of metulae. Metulae are elongated mononucleate cells that bud from the surface of the conidiophore tip.\" [GOC:mah]","metadata":null},{"id":"ad18af55026c4e9cbe5ef604bc4911e1","type":"GO_TERM","name":"negative regulation of miRNA catabolic process","canonical_id":"go:GO:2000626","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of miRNA catabolic process.\" [GOC:dph]","metadata":null},{"id":"cdc5acca5e2348a78995b5e8ce1749e6","type":"GO_TERM","name":"negative regulation of miRNA metabolic process","canonical_id":"go:GO:2000629","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of miRNA metabolic process.\" [GOC:dph]","metadata":null},{"id":"52aaf776ecbb40b98d1d921b3ff93b62","type":"GO_TERM","name":"negative regulation of miRNA processing","canonical_id":"go:GO:1903799","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microRNA processing.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"a2fcd5926f3e4c75ab20d84b4aa5431b","type":"GO_TERM","name":"negative regulation of miRNA transcription","canonical_id":"go:GO:1902894","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microRNA (miRNA) gene transcription.\" [GO_REF:0000058, GOC:dph, GOC:kmv, GOC:TermGenie, PMID:24699545]","metadata":null},{"id":"4ffb52b773a945ce96c3f630ab03707e","type":"GO_TERM","name":"negative regulation of miRNA-mediated gene silencing","canonical_id":"go:GO:0060965","description":"\"A process that decreases the rate, frequency, or extent of gene silencing by a microRNA (miRNA).\" [GOC:aruk, GOC:bc, GOC:dph, GOC:rl, GOC:tb, PMID:23985560, PMID:28379604]","metadata":null},{"id":"adacadc8a8994283b6b9a8323c1f0d08","type":"GO_TERM","name":"negative regulation of microglia differentiation","canonical_id":"go:GO:0014007","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of microglia differentiation, the process in which a relatively unspecialized cell acquires specialized features of a microglial cell.\" [GOC:ef]","metadata":null},{"id":"0ca431946ef74c4dbef58ffdde89c3e5","type":"GO_TERM","name":"negative regulation of microglial cell activation","canonical_id":"go:GO:1903979","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microglial cell activation.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"f7d3bd2f555544dc89876a681c5960e5","type":"GO_TERM","name":"negative regulation of microglial cell mediated cytotoxicity","canonical_id":"go:GO:1904150","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microglial cell mediated cytotoxicity.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"b5fe7a82a14c45ee89a2dc36e19fd9b7","type":"GO_TERM","name":"negative regulation of microglial cell migration","canonical_id":"go:GO:1904140","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microglial cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"063ec5b63ebc436494b52a0ced58b16a","type":"GO_TERM","name":"negative regulation of microtubule depolymerization","canonical_id":"go:GO:0007026","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of microtubule depolymerization; prevention of depolymerization of a microtubule can result from binding by 'capping' at the plus end (e.g. by interaction with another cellular protein of structure) or by exposing microtubules to a stabilizing drug such as taxol.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"672ed45a0ce94c288ca0a9d0073e3ec9","type":"GO_TERM","name":"negative regulation of microtubule nucleation","canonical_id":"go:GO:1905833","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microtubule nucleation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27689799]","metadata":null},{"id":"b0614d6eea624efca95b1c40fa2e2959","type":"GO_TERM","name":"negative regulation of microtubule polymerization","canonical_id":"go:GO:0031115","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of microtubule polymerization.\" [GOC:mah]","metadata":null},{"id":"c518e0ae6b1742f782de869dde952e4f","type":"GO_TERM","name":"negative regulation of microtubule polymerization or depolymerization","canonical_id":"go:GO:0031111","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of microtubule polymerization or depolymerization.\" [GOC:mah]","metadata":null},{"id":"a9d205dfcebc4edd9261ee2120f482b2","type":"GO_TERM","name":"negative regulation of microvillus assembly","canonical_id":"go:GO:1903697","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of microvillus assembly.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22797597]","metadata":null},{"id":"125e7f51ab9a47b68e248dd251582f8e","type":"GO_TERM","name":"negative regulation of microvillus length","canonical_id":"go:GO:1903982","description":"\"A process that decreases the length of a microvillus.\" [GOC:als, PMID:22114352]","metadata":null},{"id":"9b8d014b9f474459b1cc17269bbaa26c","type":"GO_TERM","name":"negative regulation of midbrain dopaminergic neuron differentiation","canonical_id":"go:GO:1904957","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of midbrain dopaminergic neuron differentiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"658e3912b291489d964bc801346c09ce","type":"GO_TERM","name":"negative regulation of mineralocorticoid secretion","canonical_id":"go:GO:2000856","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mineralocorticoid secretion.\" [GOC:sl]","metadata":null},{"id":"847fd2856a3c4abaa81af13797f47676","type":"GO_TERM","name":"negative regulation of mini excitatory postsynaptic potential","canonical_id":"go:GO:0061886","description":"\"Any process that decreases the frequency, rate or extent of mini excitatory postsynaptic potential. Mini excitatory postsynaptic potential is a process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell, induced by the spontaneous release of a single vesicle of an excitatory neurotransmitter into the synapse.\" [GOC:aruk, GOC:bc, PMID:20395454]","metadata":null},{"id":"65920adf900e488f85fe442844da9465","type":"GO_TERM","name":"negative regulation of mismatch repair","canonical_id":"go:GO:0032424","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mismatch repair.\" [GOC:vk]","metadata":null},{"id":"7aa72a407c1345e9a315efdbb97034cd","type":"GO_TERM","name":"negative regulation of mitochondrial ATP synthesis coupled electron transport","canonical_id":"go:GO:1905447","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial ATP synthesis coupled electron transport.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:23707074]","metadata":null},{"id":"f94c690cc2bb4b7587603af4517b71ab","type":"GO_TERM","name":"negative regulation of mitochondrial ATP synthesis coupled proton transport","canonical_id":"go:GO:1905707","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial ATP synthesis coupled proton transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:12809520, PMID:15294286]","metadata":null},{"id":"81fe722b06fa413ba6b78ff0532406ca","type":"GO_TERM","name":"negative regulation of mitochondrial DNA metabolic process","canonical_id":"go:GO:1901859","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial DNA metabolic process.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"c157444a84864588841e55de1458bdde","type":"GO_TERM","name":"negative regulation of mitochondrial DNA replication","canonical_id":"go:GO:0090298","description":"\"Any process that decreases the rate, frequency or extent of the process in which new strands of DNA are synthesized in the mitochondrion.\" [GOC:tb]","metadata":null},{"id":"86787d1546b64da1affd0db832663898","type":"GO_TERM","name":"negative regulation of mitochondrial RNA catabolic process","canonical_id":"go:GO:0000961","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving catabolism in the mitochondrion of RNA transcribed from the mitochondrial genome.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"de240afc700f4534bd2d99ce112ecc79","type":"GO_TERM","name":"negative regulation of mitochondrial calcium ion concentration","canonical_id":"go:GO:0051562","description":"\"Any process that decreases the concentration of calcium ions in mitochondria.\" [GOC:ai]","metadata":null},{"id":"a1ba865684184f41a25c2c4f5b8454c9","type":"GO_TERM","name":"negative regulation of mitochondrial depolarization","canonical_id":"go:GO:0051902","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the change in the membrane potential of the mitochondria from negative to positive.\" [GOC:ai]","metadata":null},{"id":"7ae50e6524b34f489d1c0ea7845dd918","type":"GO_TERM","name":"negative regulation of mitochondrial electron transport, NADH to ubiquinone","canonical_id":"go:GO:1902957","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:23530063]","metadata":null},{"id":"9d63d5c736a544f68d6ab81f16a60321","type":"GO_TERM","name":"negative regulation of mitochondrial fission","canonical_id":"go:GO:0090258","description":"\"Any process that decreases the rate, frequency or extent of mitochondrial fission. Mitochondrial fission is the division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.\" [GOC:sl, GOC:tb]","metadata":null},{"id":"4046e427e49840d2b94e11a3b8b60da4","type":"GO_TERM","name":"negative regulation of mitochondrial fusion","canonical_id":"go:GO:0010637","description":"\"Any process that decreases the frequency, rate or extent of merging of two or more mitochondria within a cell to form a single compartment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f3d31231d16f40daa4aea611345bb249","type":"GO_TERM","name":"negative regulation of mitochondrial mRNA catabolic process","canonical_id":"go:GO:1905638","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial mRNA catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:27122350]","metadata":null},{"id":"67f221df5ad24adba67f5d170b56d58f","type":"GO_TERM","name":"negative regulation of mitochondrial membrane permeability","canonical_id":"go:GO:0035795","description":"\"Any process that decreases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.\" [PMID:10781072]","metadata":null},{"id":"0d8c8a1b86d24effb0900cd90e72a922","type":"GO_TERM","name":"negative regulation of mitochondrial membrane permeability involved in apoptotic process","canonical_id":"go:GO:1902109","description":"\"Any negative regulation of mitochondrial membrane permeability that is involved in apoptotic process.\" [GOC:mtg_apoptosis, GOC:pm, GOC:TermGenie, PMID:19168129]","metadata":null},{"id":"9281032d161f4bb680c90c7af9698da9","type":"GO_TERM","name":"negative regulation of mitochondrial membrane potential","canonical_id":"go:GO:0010917","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of establishment or extent of a mitochondrial membrane potential, the electric potential existing across any mitochondrial membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"89c694734f8a4de684e5aec3752dd367","type":"GO_TERM","name":"negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway","canonical_id":"go:GO:1901029","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"83322cce05914eb196acaf3cd75ff9a4","type":"GO_TERM","name":"negative regulation of mitochondrial transcription","canonical_id":"go:GO:0170070","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transcription occurring in the mitochondrion.\" [PMID:23300484]","metadata":null},{"id":"c5e7d53d3c604cd29392fa2334e56928","type":"GO_TERM","name":"negative regulation of mitochondrial translation","canonical_id":"go:GO:0070130","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"489a61f13d2f4f158bb786fa68d1d2c1","type":"GO_TERM","name":"negative regulation of mitochondrial translational elongation","canonical_id":"go:GO:1905083","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial translational elongation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25738458]","metadata":null},{"id":"355d4fbf4b5c4989adcb99b4de9aefe5","type":"GO_TERM","name":"negative regulation of mitochondrial translational initiation","canonical_id":"go:GO:0070133","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the process preceding formation of the peptide bond between the first two amino acids of a protein in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"bfeeb5281372479690ed3db50a3db573","type":"GO_TERM","name":"negative regulation of mitophagy","canonical_id":"go:GO:1901525","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitophagy.\" [GOC:TermGenie]","metadata":null},{"id":"17e32cb94158488dba0c4a9175aa98d0","type":"GO_TERM","name":"negative regulation of mitotic DNA damage checkpoint","canonical_id":"go:GO:1904290","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic DNA damage checkpoint.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:16549501]","metadata":null},{"id":"09d32675b8de4db3afb3e44b808e84a2","type":"GO_TERM","name":"negative regulation of mitotic DNA replication initiation","canonical_id":"go:GO:1903467","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of DNA replication initiation involved in mitotic DNA replication.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"c6b0d660177442a0bce960641fcdc44e","type":"GO_TERM","name":"negative regulation of mitotic DNA replication initiation from late origin","canonical_id":"go:GO:0101018","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of firing from a late origin of replication involved in mitotic DNA replication.\" [PMID:26436827]","metadata":null},{"id":"ad306e4c196d4a8dbc1c993316cbdc17","type":"GO_TERM","name":"negative regulation of mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:1903500","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic actomyosin contractile ring assembly.\" [GO_REF:0000058, GOC:al, GOC:mtg_cell_cycle, GOC:TermGenie, GOC:vw, PMID:18256290]","metadata":null},{"id":"d176957a230640d6b805276c70ef8fd0","type":"GO_TERM","name":"negative regulation of mitotic actomyosin contractile ring contraction","canonical_id":"go:GO:1903472","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic actomyosin contractile ring contraction.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"84b7d7dd1b194b70b8b6f178a31a3c92","type":"GO_TERM","name":"negative regulation of mitotic cell cycle","canonical_id":"go:GO:0045930","description":"\"Any process that stops, prevents or reduces the rate or extent of progression through the mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"1104ea104e074ccca58fb0288485d3f1","type":"GO_TERM","name":"negative regulation of mitotic cell cycle DNA replication","canonical_id":"go:GO:1903464","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic cell cycle DNA replication.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"49003448160c4237bf1356ba403cb5c6","type":"GO_TERM","name":"negative regulation of mitotic cell cycle phase transition","canonical_id":"go:GO:1901991","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"45b123bd0acd415aa81b5914d3a7bf52","type":"GO_TERM","name":"negative regulation of mitotic cell cycle, embryonic","canonical_id":"go:GO:0045976","description":"\"Any process that stops, prevents or reduces the rate or extent of progression through the embryonic mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"28386be5efb7401d9bc67457d47c6f88","type":"GO_TERM","name":"negative regulation of mitotic centrosome separation","canonical_id":"go:GO:0046603","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of centrosome separation.\" [GOC:ai]","metadata":null},{"id":"f8ec8d82b5ea4c068d3a028ef6fc5f2f","type":"GO_TERM","name":"negative regulation of mitotic chromosome condensation","canonical_id":"go:GO:1905213","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic chromosome condensation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23219725]","metadata":null},{"id":"aaa758f32d384107bddf1c02b64ddb0b","type":"GO_TERM","name":"negative regulation of mitotic cytokinesis","canonical_id":"go:GO:1902413","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic cytokinesis.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"cebe2192c55a409f82eda688140fe1a5","type":"GO_TERM","name":"negative regulation of mitotic cytokinetic process","canonical_id":"go:GO:1903437","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic cytokinetic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"19009fda14554848877b4d1a15159ec5","type":"GO_TERM","name":"negative regulation of mitotic division septum assembly","canonical_id":"go:GO:0140280","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic division septum formation. Division septum formation is the assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis.\" [PMID:22786806]","metadata":null},{"id":"fb54d1f889b54d13b9ed340824f43abe","type":"GO_TERM","name":"negative regulation of mitotic metaphase/anaphase transition","canonical_id":"go:GO:0045841","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the cell cycle process in which a cell progresses from metaphase to anaphase during mitosis, triggered by the activation of the anaphase promoting complex by Cdc20/Sleepy homolog which results in the degradation of Securin.\" [GOC:curators]","metadata":null},{"id":"6cd7bf1287e745a4a8b2d2b7a5db8879","type":"GO_TERM","name":"negative regulation of mitotic nuclear division","canonical_id":"go:GO:0045839","description":"\"Any process that stops, prevents or reduces the rate or extent of mitosis. Mitosis is the division of the eukaryotic cell nucleus to produce two daughter nuclei that, usually, contain the identical chromosome complement to their mother.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"eaa4b9fb927c423a919ae643b4ab39c7","type":"GO_TERM","name":"negative regulation of mitotic nuclear envelope disassembly","canonical_id":"go:GO:1905558","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic nuclear envelope disassembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"9f3e8ca542f44ec4a2fe640e74eecb84","type":"GO_TERM","name":"negative regulation of mitotic recombination","canonical_id":"go:GO:0045950","description":"\"Any process that inhibits or decreases the rate of DNA recombination during mitosis.\" [GOC:curators, GOC:hjd]","metadata":null},{"id":"cd20598775d7446996a1ddc2d23e2981","type":"GO_TERM","name":"negative regulation of mitotic recombination-dependent replication fork processing","canonical_id":"go:GO:0120291","description":"\"Any process that inhibits or decreases the rate of mitotic recombination-dependent replication fork processing. Suppression of recombination at replication forks is necessary to prevent template switching.\" [GOC:krc, GOC:mah, PMID:28586299, PMID:30667359, PMID:31149897]","metadata":null},{"id":"09872aa800584b32b719a30d8c49d9e8","type":"GO_TERM","name":"negative regulation of mitotic sister chromatid arm separation","canonical_id":"go:GO:1905823","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic sister chromatid arm separation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"f5bbafe06409421daa997900d155d46e","type":"GO_TERM","name":"negative regulation of mitotic sister chromatid segregation","canonical_id":"go:GO:0033048","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sister chromatid segregation during mitosis.\" [GOC:mah]","metadata":null},{"id":"6f33761e8b2c4b0bbf1460e4ab60360d","type":"GO_TERM","name":"negative regulation of mitotic sister chromatid separation","canonical_id":"go:GO:2000816","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic sister chromatid separation.\" [GOC:obol]","metadata":null},{"id":"4a143e597ec346f78ec5c4d10378573f","type":"GO_TERM","name":"negative regulation of mitotic spindle assembly checkpoint signaling","canonical_id":"go:GO:0140499","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of negative regulation of mitotic spindle assembly checkpoint signaling.\" [PMID:28017606]","metadata":null},{"id":"dd571b2b4471454f84cf6770b2bc25cf","type":"GO_TERM","name":"negative regulation of mitotic spindle elongation","canonical_id":"go:GO:1902845","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic spindle elongation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"314c598741114efba261c603625b4acb","type":"GO_TERM","name":"negative regulation of mitotic spindle elongation (spindle phase three)","canonical_id":"go:GO:0110163","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic anaphase B (spindle phase three).\" [GOC:vw, PMID:27697865]","metadata":null},{"id":"c3203501c734430b9e9dbb265f40f8d8","type":"GO_TERM","name":"negative regulation of mitotic spindle formation (spindle phase one)","canonical_id":"go:GO:0110160","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic prophase (spindle phase one).\" [GOC:vw]","metadata":null},{"id":"500a481aafe1487abba17badf587410b","type":"GO_TERM","name":"negative regulation of mitotic spindle pole body separation","canonical_id":"go:GO:0010697","description":"\"Any process that decreases the rate, frequency or extent of the process involving the release of duplicated mitotic spindle pole bodies (SPBs) and their migration away from each other within the nuclear membrane.\" [GOC:dph, GOC:tb, PMID:16792804, PMID:18500339]","metadata":null},{"id":"b251321cd50e4abeb74bdec8024ba2e2","type":"GO_TERM","name":"negative regulation of mitotic telomere tethering at nuclear periphery","canonical_id":"go:GO:1904537","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of mitotic telomere tethering at nuclear periphery.\" [GO_REF:0000058, GOC:TermGenie, PMID:22959349]","metadata":null},{"id":"7a2ff65abe8b45248cb58d27f18c5055","type":"GO_TERM","name":"negative regulation of molecular function","canonical_id":"go:GO:0044092","description":"\"Any process that stops or reduces the rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding.\" [GO:jl]","metadata":null},{"id":"a4857aff6c8d4490a195fa22b718bc8f","type":"GO_TERM","name":"negative regulation of monoatomic anion transport","canonical_id":"go:GO:1903792","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of anion transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:11336802]","metadata":null},{"id":"008db5a0be91468c997b233a5d8464ac","type":"GO_TERM","name":"negative regulation of monoatomic ion transmembrane transport","canonical_id":"go:GO:0034766","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ions from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"febe2c9bfae9417ca5ddabeb0f058d6a","type":"GO_TERM","name":"negative regulation of monoatomic ion transport","canonical_id":"go:GO:0043271","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"5ea5da4b3b8e47e0a936a53f7594970e","type":"GO_TERM","name":"negative regulation of monocyte activation","canonical_id":"go:GO:0150102","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of monocyte activation.\" [GOC:aruk, PMID:15597323]","metadata":null},{"id":"dd368bab4e45406490779c50cc93e9d9","type":"GO_TERM","name":"negative regulation of monocyte aggregation","canonical_id":"go:GO:1900624","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of monocyte aggregation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"c91459ceec9044bab912e1b788e29bec","type":"GO_TERM","name":"negative regulation of monocyte antigen processing and presentation","canonical_id":"go:GO:0002614","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of monocyte antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"13538d855bf747fbb61b9b3f3e718858","type":"GO_TERM","name":"negative regulation of monocyte chemotactic protein-1 production","canonical_id":"go:GO:0071638","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of monocyte chemotactic protein-1.\" [GOC:mah]","metadata":null},{"id":"8228c9faf4744008957c23ba2646c401","type":"GO_TERM","name":"negative regulation of monocyte chemotaxis","canonical_id":"go:GO:0090027","description":"\"Any process that decreases the frequency, rate, or extent of monocyte chemotaxis.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3f6c191aedfe45939ce241d18d595dda","type":"GO_TERM","name":"negative regulation of monocyte differentiation","canonical_id":"go:GO:0045656","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of monocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"a71e55d85d82495486aa7dad0a05074b","type":"GO_TERM","name":"negative regulation of monocyte extravasation","canonical_id":"go:GO:2000438","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of monocyte extravasation.\" [GOC:obol]","metadata":null},{"id":"51694508e458413f8942227ef34fee94","type":"GO_TERM","name":"negative regulation of monodictyphenone biosynthetic process","canonical_id":"go:GO:1900844","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of monodictyphenone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"d27a91a464e14c598ee361987003c76e","type":"GO_TERM","name":"negative regulation of mononuclear cell migration","canonical_id":"go:GO:0071676","description":"\"Any process that decreases the rate, frequency or extent of mononuclear cell migration. Mononuclear cell migration is the movement of a mononuclear cell within or between different tissues and organs of the body.\" [GOC:mah]","metadata":null},{"id":"7e5c0cd499134b11b275a848628df931","type":"GO_TERM","name":"negative regulation of mononuclear cell proliferation","canonical_id":"go:GO:0032945","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of mononuclear cell proliferation.\" [GOC:add]","metadata":null},{"id":"f70a107caf8f49b3832ccb3c1b823382","type":"GO_TERM","name":"negative regulation of monopolar cell growth","canonical_id":"go:GO:0051514","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of monopolar cell growth, polarized growth from one end of a cell.\" [GOC:ai]","metadata":null},{"id":"a71be6d76dbe4da18adb2496c745ad7a","type":"GO_TERM","name":"negative regulation of morphogenesis of an epithelium","canonical_id":"go:GO:1905331","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of morphogenesis of an epithelium.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25745997]","metadata":null},{"id":"9fd642d2f3e64c54b91add43ec2be933","type":"GO_TERM","name":"negative regulation of motile cilium assembly","canonical_id":"go:GO:1905504","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of motile cilium assembly.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:25294941]","metadata":null},{"id":"9161c630cfaa4e00801b24c48cda8c3a","type":"GO_TERM","name":"negative regulation of motor neuron apoptotic process","canonical_id":"go:GO:2000672","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of motor neuron apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"444f5721dde5409392cedc79eab475fc","type":"GO_TERM","name":"negative regulation of motor neuron axon guidance","canonical_id":"go:GO:1905813","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of motor neuron axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:18434533]","metadata":null},{"id":"4357141c6be446b080c730d616c1ff1a","type":"GO_TERM","name":"negative regulation of motor neuron migration","canonical_id":"go:GO:1905484","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of motor neuron migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"b5e944504b1b4ac6af598cd64c357f5f","type":"GO_TERM","name":"negative regulation of mucus secretion","canonical_id":"go:GO:0070256","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of mucus from a cell or a tissue.\" [GOC:add]","metadata":null},{"id":"4bf57ad70398404b8e8e39b879404b59","type":"GO_TERM","name":"negative regulation of multicellular organism growth","canonical_id":"go:GO:0040015","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of growth of an organism to reach its usual body size.\" [GOC:dph, GOC:ems, GOC:tb]","metadata":null},{"id":"867adc070ac349a4b551c57ba62ffc31","type":"GO_TERM","name":"negative regulation of multicellular organismal process","canonical_id":"go:GO:0051241","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of an organismal process, the processes pertinent to the function of an organism above the cellular level; includes the integrated processes of tissues and organs.\" [GOC:ai]","metadata":null},{"id":"61040530a35744c7ac048757662d48de","type":"GO_TERM","name":"negative regulation of muscle adaptation","canonical_id":"go:GO:0014745","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of muscle adaptation.\" [GOC:mtg_muscle]","metadata":null},{"id":"1d404222ee594719a245afdc48272d66","type":"GO_TERM","name":"negative regulation of muscle atrophy","canonical_id":"go:GO:0014736","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of muscle atrophy.\" [GOC:mtg_muscle]","metadata":null},{"id":"2c030af545c243cb95cf56f153126612","type":"GO_TERM","name":"negative regulation of muscle cell apoptotic process","canonical_id":"go:GO:0010656","description":"\"Any process that decreases the rate or frequency of muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"a70ea6c6a6884942a33e54d40479450d","type":"GO_TERM","name":"negative regulation of muscle cell chemotaxis toward tendon cell","canonical_id":"go:GO:2001282","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the directed movement of a muscle cell towards a tendon cell in response to an external stimulus. For example, when the muscle cell arrives at the target tendon cell, migration is arrested so that attachments can be made between the cells.\" [GOC:sart, PMID:19793885, PMID:20404543]","metadata":null},{"id":"120932e1e5984005b7cf05c3bc8b0f7b","type":"GO_TERM","name":"negative regulation of muscle cell differentiation","canonical_id":"go:GO:0051148","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of muscle cell differentiation.\" [CL:0000187, GOC:ai]","metadata":null},{"id":"761b57b4ef344c1e9ff55f39a9665baf","type":"GO_TERM","name":"negative regulation of muscle contraction","canonical_id":"go:GO:0045932","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of muscle contraction.\" [GOC:curators]","metadata":null},{"id":"96ccc414f44f4b7d88a8fd8650ad1f75","type":"GO_TERM","name":"negative regulation of muscle filament sliding","canonical_id":"go:GO:1904113","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of muscle filament sliding.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25717181]","metadata":null},{"id":"6b31b73b6536440faff4f36141af3962","type":"GO_TERM","name":"negative regulation of muscle hyperplasia","canonical_id":"go:GO:0014740","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of muscle hyperplasia.\" [GOC:mtg_muscle]","metadata":null},{"id":"1c780544d5b24645916005f3e681eaf2","type":"GO_TERM","name":"negative regulation of muscle hypertrophy","canonical_id":"go:GO:0014741","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of muscle hypertrophy.\" [GOC:mtg_muscle]","metadata":null},{"id":"672fe5cdff4b418d9b2c85af4bf82bec","type":"GO_TERM","name":"negative regulation of muscle organ development","canonical_id":"go:GO:0048635","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of muscle development.\" [GOC:curators]","metadata":null},{"id":"6263834964484ae1b7d099c10a30c2a0","type":"GO_TERM","name":"negative regulation of muscle tissue development","canonical_id":"go:GO:1901862","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of muscle tissue development.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"da2a5d3adf2944b68bd54256be5aff03","type":"GO_TERM","name":"negative regulation of myelination","canonical_id":"go:GO:0031642","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the formation of a myelin sheath around nerve axons.\" [GOC:mah]","metadata":null},{"id":"8df20527f7d346e4b1e4cf8d659f3ef0","type":"GO_TERM","name":"negative regulation of myeloid cell apoptotic process","canonical_id":"go:GO:0033033","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a myeloid cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"9e97ed27d6ee4768824860521aeb75a6","type":"GO_TERM","name":"negative regulation of myeloid cell differentiation","canonical_id":"go:GO:0045638","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of myeloid cell differentiation.\" [GOC:curators]","metadata":null},{"id":"4637b545cfdc4c56a9bc942a69e4c0c2","type":"GO_TERM","name":"negative regulation of myeloid dendritic cell activation","canonical_id":"go:GO:0030886","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of myeloid dendritic cell activation.\" [GOC:mah]","metadata":null},{"id":"64047219a8774d7987848e0ee4f6a493","type":"GO_TERM","name":"negative regulation of myeloid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002608","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"8f057f67cfd74935ac8e6dd7196ae962","type":"GO_TERM","name":"negative regulation of myeloid dendritic cell chemotaxis","canonical_id":"go:GO:2000528","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myeloid dendritic cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"7aee00edc6a446498aaca42ff1c35a4d","type":"GO_TERM","name":"negative regulation of myeloid dendritic cell cytokine production","canonical_id":"go:GO:0002734","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"d5658d12e00f48868d52f216c0662aa2","type":"GO_TERM","name":"negative regulation of myeloid leukocyte differentiation","canonical_id":"go:GO:0002762","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid leukocyte differentiation.\" [GOC:add]","metadata":null},{"id":"5086400592544bf18c3796c88294a507","type":"GO_TERM","name":"negative regulation of myeloid leukocyte mediated immunity","canonical_id":"go:GO:0002887","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid leukocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"70f2644fb43b4c31ac9d2dbd53c952c1","type":"GO_TERM","name":"negative regulation of myeloid progenitor cell differentiation","canonical_id":"go:GO:1905454","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myeloid progenitor cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27010503]","metadata":null},{"id":"38a72477f43849c18891a2a5f6a0da16","type":"GO_TERM","name":"negative regulation of myoblast differentiation","canonical_id":"go:GO:0045662","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of myoblast differentiation. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:curators, GOC:mtg_muscle]","metadata":null},{"id":"bbce7dc63af643ffb9f034d91741c418","type":"GO_TERM","name":"negative regulation of myoblast fusion","canonical_id":"go:GO:1901740","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myoblast fusion.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21364645]","metadata":null},{"id":"3632de247ae64b7b99806c01401d4247","type":"GO_TERM","name":"negative regulation of myoblast proliferation","canonical_id":"go:GO:2000818","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myoblast proliferation.\" [GOC:obol]","metadata":null},{"id":"2f44513b267a4218a82cc83710678012","type":"GO_TERM","name":"negative regulation of myofibroblast cell apoptotic process","canonical_id":"go:GO:1904521","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myofibroblast cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:26119034]","metadata":null},{"id":"0ceb730c928246518212f7afce141018","type":"GO_TERM","name":"negative regulation of myofibroblast contraction","canonical_id":"go:GO:1904329","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myofibroblast contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:19239477]","metadata":null},{"id":"917be58363b649578a3bac87abd3517e","type":"GO_TERM","name":"negative regulation of myofibroblast differentiation","canonical_id":"go:GO:1904761","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myofibroblast differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20533548]","metadata":null},{"id":"d1101fc686f9423795253350ff3e701d","type":"GO_TERM","name":"negative regulation of myosin II filament assembly","canonical_id":"go:GO:1905510","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myosin II filament assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27237792, PMID:7691416]","metadata":null},{"id":"c2ed3eeef8b74419a49ef8728fd01735","type":"GO_TERM","name":"negative regulation of myosin II filament organization","canonical_id":"go:GO:1904900","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of myosin II filament organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:22761445]","metadata":null},{"id":"7e4fab1347094a9e8a75aa190077f085","type":"GO_TERM","name":"negative regulation of myotube cell migration","canonical_id":"go:GO:0110125","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of myotube cell migration.\" [GOC:ha, PMID:29122742]","metadata":null},{"id":"776c6282f14a4c50bfcef9074e6c14bc","type":"GO_TERM","name":"negative regulation of myotube differentiation","canonical_id":"go:GO:0010832","description":"\"Any process that decreases the frequency, rate or extent of myotube differentiation. Myotube differentiation is the process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"45d3c389b15548caaa9cd38213d32023","type":"GO_TERM","name":"negative regulation of naphtho-gamma-pyrone biosynthetic process","canonical_id":"go:GO:1900847","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of naphtho-gamma-pyrone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"927751669d8249e7a06997e8e2116476","type":"GO_TERM","name":"negative regulation of natural killer cell activation","canonical_id":"go:GO:0032815","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer cell activation.\" [GOC:mah]","metadata":null},{"id":"a329fb765ed14b678f69560c2c9673ae","type":"GO_TERM","name":"negative regulation of natural killer cell apoptotic process","canonical_id":"go:GO:0070248","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer cell death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"2b0a4d71497c4437a3e91c543b692531","type":"GO_TERM","name":"negative regulation of natural killer cell chemotaxis","canonical_id":"go:GO:2000502","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of natural killer cell chemotaxis.\" [GOC:BHF]","metadata":null},{"id":"f97d53fc5e694ff0bea8d8d78f2f5765","type":"GO_TERM","name":"negative regulation of natural killer cell cytokine production","canonical_id":"go:GO:0002728","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell cytokine production.\" [GOC:add]","metadata":null},{"id":"c38cc431be4d46109c8cdfda172d6d14","type":"GO_TERM","name":"negative regulation of natural killer cell degranulation","canonical_id":"go:GO:0043322","description":"\"Any process that stops, prevents, or reduces the rate of natural killer cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"66730ba8341a45728a53ebde453bde0b","type":"GO_TERM","name":"negative regulation of natural killer cell differentiation","canonical_id":"go:GO:0032824","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer cell differentiation.\" [GOC:mah]","metadata":null},{"id":"f27d963adc354edba6ede8ec347f091d","type":"GO_TERM","name":"negative regulation of natural killer cell mediated cytotoxicity","canonical_id":"go:GO:0045953","description":"\"Any process that stops, prevents, or reduces the rate of natural killer mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ed1615cbe8b34277819464a9e57f94c5","type":"GO_TERM","name":"negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002859","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell mediated cytotoxicity directed against tumor cell target.\" [GOC:add]","metadata":null},{"id":"79dd6088721743ce856186b7084f9e11","type":"GO_TERM","name":"negative regulation of natural killer cell mediated immune response to tumor cell","canonical_id":"go:GO:0002856","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell mediated immune response to a tumor cell.\" [GOC:add]","metadata":null},{"id":"bd286574627449169f8acddf6c135ccd","type":"GO_TERM","name":"negative regulation of natural killer cell mediated immunity","canonical_id":"go:GO:0002716","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"9e0a87bfadb743b6a8af75d36fcde4de","type":"GO_TERM","name":"negative regulation of natural killer cell proliferation","canonical_id":"go:GO:0032818","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of natural killer cell proliferation.\" [GOC:mah]","metadata":null},{"id":"c5e8b2d87e544508826067eba34681cc","type":"GO_TERM","name":"negative regulation of natural killer cell tolerance induction","canonical_id":"go:GO:0002872","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"aaea791943bf4d848b66ff1b3776ca2e","type":"GO_TERM","name":"negative regulation of necroptotic process","canonical_id":"go:GO:0060546","description":"\"Any process that decreases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"624784982c104f91ae2264ff9d0d7ac7","type":"GO_TERM","name":"negative regulation of negative chemotaxis","canonical_id":"go:GO:0050925","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"cc8f5703ae96419487c5e1d54f124b41","type":"GO_TERM","name":"negative regulation of nematode larval development","canonical_id":"go:GO:0061064","description":"\"Any process that decreases the rate, frequency, or extent of nematode larval development, the process whose specific outcome is the progression of the nematode larva over time, from its formation to the mature structure. Nematode larval development begins with the newly hatched first-stage larva (L1) and ends with the end of the last larval stage (for example the fourth larval stage (L4) in C. elegans). Each stage of nematode larval development is characterized by proliferation of specific cell lineages and an increase in body size without alteration of the basic body plan. Nematode larval stages are separated by molts in which each stage-specific exoskeleton, or cuticle, is shed and replaced anew.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"dbcc6b03498b413b8a06776c08576530","type":"GO_TERM","name":"negative regulation of nematode larval development, heterochronic","canonical_id":"go:GO:0090446","description":"\"Any process that modulates the consistent predetermined time point at which a nematode larva progresses from an initial condition to a later condition and decreases the rate at which this time point is reached.\" [PMID:17550772]","metadata":null},{"id":"9636a4029d19434db4e99156dd1321a5","type":"GO_TERM","name":"negative regulation of nematode male tail tip morphogenesis","canonical_id":"go:GO:0110038","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of nematode male tail tip morphogenesis.\" [GOC:rz, PMID:28068334]","metadata":null},{"id":"b0499736d7204bffadd79a168579ab65","type":"GO_TERM","name":"negative regulation of nematode pharyngeal pumping","canonical_id":"go:GO:1903745","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nematode pharyngeal pumping.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25329901]","metadata":null},{"id":"b959e53848964e3fa887447ca7ccf83d","type":"GO_TERM","name":"negative regulation of nematode pharynx morphogenesis","canonical_id":"go:GO:0110042","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of nematode pharynx morphogenesis.\" [GOC:rz, PMID:20805556]","metadata":null},{"id":"fd1afed20cf94af8bd3e7f7972585ed7","type":"GO_TERM","name":"negative regulation of neosartoricin biosynthetic process","canonical_id":"go:GO:1902054","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neosartoricin biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:23368997]","metadata":null},{"id":"14ce1a0e549c454ca83494dadbf22e20","type":"GO_TERM","name":"negative regulation of nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0072183","description":"\"Any process that decreases the frequency, rate or extent of nephron tubule epithelial cell differentiation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a0e26c3f223f4e0999c66cb102ac3ad3","type":"GO_TERM","name":"negative regulation of nerve growth factor production","canonical_id":"go:GO:0032904","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of nerve growth factor (NGF).\" [GOC:mah]","metadata":null},{"id":"8dfed690f3304487b0fea7c41448ec55","type":"GO_TERM","name":"negative regulation of nervous system development","canonical_id":"go:GO:0051961","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of nervous system development, the origin and formation of nervous tissue.\" [GOC:ai]","metadata":null},{"id":"4894b057578541369c31a927d9d28cc7","type":"GO_TERM","name":"negative regulation of nervous system process","canonical_id":"go:GO:0031645","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a neurophysiological process.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"3a425a58d21d47fba53227bd61973922","type":"GO_TERM","name":"negative regulation of netrin-activated signaling pathway","canonical_id":"go:GO:1902842","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of netrin-activated signaling pathway.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:24004945]","metadata":null},{"id":"c62250529f6b409495719998bec9658f","type":"GO_TERM","name":"negative regulation of neural crest cell differentiation","canonical_id":"go:GO:1905293","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neural crest cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15073157]","metadata":null},{"id":"16cf8f0c1a1d4573b56074f566c6b980","type":"GO_TERM","name":"negative regulation of neural crest cell fate specification","canonical_id":"go:GO:1905296","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neural crest cell fate specification.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15073157]","metadata":null},{"id":"736b8fd735004d788e47f242672c1d83","type":"GO_TERM","name":"negative regulation of neural crest formation","canonical_id":"go:GO:0090301","description":"\"Any process that decreases the rate, frequency, or extent of neural crest formation. Neural crest formation is the formation of the specialized region of ectoderm between the neural ectoderm (neural plate) and non-neural ectoderm. The neural crest gives rise to the neural crest cells that migrate away from this region as neural tube formation proceeds.\" [GOC:tb]","metadata":null},{"id":"d2fb8bb282c1481f986d4d1a5d9b4197","type":"GO_TERM","name":"negative regulation of neural precursor cell proliferation","canonical_id":"go:GO:2000178","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neural precursor cell proliferation.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"b3d50a63c3ea4ae1979f8ff0c4299f9d","type":"GO_TERM","name":"negative regulation of neural retina development","canonical_id":"go:GO:0061076","description":"\"Any process that decreases the rate, frequency, or extent of neural retina development, the progression of the neural retina over time from its initial formation to the mature structure. The neural retina is the part of the retina that contains neurons and photoreceptor cells.\" [GOC:dph]","metadata":null},{"id":"5f5a668c2d4e43cb874468f65b55f1c7","type":"GO_TERM","name":"negative regulation of neuroblast migration","canonical_id":"go:GO:0061855","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neuroblast migration.\" [PMID:23149556]","metadata":null},{"id":"e217e2aea9d1495c8c3a74c22e2e6118","type":"GO_TERM","name":"negative regulation of neuroblast proliferation","canonical_id":"go:GO:0007406","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the proliferation of neuroblasts.\" [GOC:ai]","metadata":null},{"id":"c1ef7daf787a413d96caae01780904d7","type":"GO_TERM","name":"negative regulation of neurofibrillary tangle assembly","canonical_id":"go:GO:1902997","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neurofibrillary tangle assembly.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:15897157]","metadata":null},{"id":"e4d74ed55bbc4161a28256c7f6eeb9a7","type":"GO_TERM","name":"negative regulation of neurogenesis","canonical_id":"go:GO:0050768","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neurogenesis, the generation of cells within the nervous system.\" [GOC:ai]","metadata":null},{"id":"dde1c69eb09f49be82d3e0c9e46d2bae","type":"GO_TERM","name":"negative regulation of neuroinflammatory response","canonical_id":"go:GO:0150079","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuroinflammatory response.\" [GOC:aruk, GOC:bc, PMID:11099416, PMID:18164423]","metadata":null},{"id":"519ff5cefda74bc9be478b6faa71eaa3","type":"GO_TERM","name":"negative regulation of neuromuscular junction development","canonical_id":"go:GO:1904397","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuromuscular junction development.\" [GO_REF:0000058, GOC:TermGenie, PMID:7722643]","metadata":null},{"id":"cd949938733d416da22ead8d0e30c7e4","type":"GO_TERM","name":"negative regulation of neuromuscular synaptic transmission","canonical_id":"go:GO:1900074","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuromuscular synaptic transmission.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"398bb7ac0b4244ebbe45a2156a3d8718","type":"GO_TERM","name":"negative regulation of neuron apoptotic process","canonical_id":"go:GO:0043524","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process in neurons.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"3d748d1b3ec5485d94650cc2e46d84b1","type":"GO_TERM","name":"negative regulation of neuron differentiation","canonical_id":"go:GO:0045665","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neuron differentiation.\" [GOC:curators]","metadata":null},{"id":"1a157158df27490d80f0cfac51ad993f","type":"GO_TERM","name":"negative regulation of neuron maturation","canonical_id":"go:GO:0014043","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neuron maturation.\" [GOC:ef]","metadata":null},{"id":"efb0ab2f98134934b698eb58e45d99e0","type":"GO_TERM","name":"negative regulation of neuron migration","canonical_id":"go:GO:2001223","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuron migration.\" [GOC:obol]","metadata":null},{"id":"f9701d3d08b4486eb1820025b3f6a604","type":"GO_TERM","name":"negative regulation of neuron projection arborization","canonical_id":"go:GO:0150013","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the process in which the anatomical structures of a neuron projection are generated and organized into branches.\" [GOC:aruk, GOC:bc, PMID:17114044]","metadata":null},{"id":"fb540c8dc42e4717bdc47742a41aea20","type":"GO_TERM","name":"negative regulation of neuron projection development","canonical_id":"go:GO:0010977","description":"\"Any process that decreases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d466d9eaf246445a874c29b131f035b7","type":"GO_TERM","name":"negative regulation of neuron projection regeneration","canonical_id":"go:GO:0070571","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neuron projection regeneration, the regrowth of neuronal processes such as axons or dendrites following their loss or damage.\" [GOC:mah]","metadata":null},{"id":"57f2f019c8c443d4aeebaf60f093d50c","type":"GO_TERM","name":"negative regulation of neuron remodeling","canonical_id":"go:GO:1904800","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuron remodeling.\" [GO_REF:0000058, GOC:TermGenie, PMID:21609829]","metadata":null},{"id":"f857f593cea444a7a591c0cb84a793cb","type":"GO_TERM","name":"negative regulation of neuronal action potential","canonical_id":"go:GO:1904456","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuronal action potential.\" [GO_REF:0000058, GOC:TermGenie, PMID:25126967]","metadata":null},{"id":"7b0a9fcbc38345849917d6d7c524095b","type":"GO_TERM","name":"negative regulation of neuronal signal transduction","canonical_id":"go:GO:1902848","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neuronal signal transduction.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie]","metadata":null},{"id":"c3e2af77bdde4e2fbbecd1e10613cf9a","type":"GO_TERM","name":"negative regulation of neurotransmitter secretion","canonical_id":"go:GO:0046929","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a neurotransmitter.\" [GOC:ai]","metadata":null},{"id":"9e9dc01446ae4eb9a23c1eefaad3664c","type":"GO_TERM","name":"negative regulation of neurotransmitter transport","canonical_id":"go:GO:0051589","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f03de8804fc340eca91f9ba120717f6d","type":"GO_TERM","name":"negative regulation of neurotransmitter uptake","canonical_id":"go:GO:0051581","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell.\" [GOC:ai]","metadata":null},{"id":"f99670b4f6794c7fbee4f6b5be816d37","type":"GO_TERM","name":"negative regulation of neurotrophin TRK receptor signaling pathway","canonical_id":"go:GO:0051387","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the neurotrophin TRK receptor signaling pathway.\" [GOC:ai]","metadata":null},{"id":"35c5f5e0060b4a0193e3ed57269b645f","type":"GO_TERM","name":"negative regulation of neurotrophin production","canonical_id":"go:GO:0032900","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of a neurotrophin.\" [GOC:mah]","metadata":null},{"id":"168e8c0507bd44cc8ba0af420bc9e3e5","type":"GO_TERM","name":"negative regulation of neutrophil activation","canonical_id":"go:GO:1902564","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neutrophil activation.\" [GOC:TermGenie, PMID:17588661]","metadata":null},{"id":"1284e6a17ddc49a29c731e6dde44ada2","type":"GO_TERM","name":"negative regulation of neutrophil aggregation","canonical_id":"go:GO:2000429","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neutrophil aggregation.\" [GOC:BHF]","metadata":null},{"id":"905ca23397bb453f861799b48036c778","type":"GO_TERM","name":"negative regulation of neutrophil apoptotic process","canonical_id":"go:GO:0033030","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of neutrophil apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"5eb51e5ac16e4645b2a59ea61d429103","type":"GO_TERM","name":"negative regulation of neutrophil chemotaxis","canonical_id":"go:GO:0090024","description":"\"Any process that decreases the frequency, rate, or extent of neutrophil chemotaxis. Neutrophil chemotaxis is the directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9fbe6973d42443d2969e497add946856","type":"GO_TERM","name":"negative regulation of neutrophil degranulation","canonical_id":"go:GO:0043314","description":"\"Any process that stops, prevents, or reduces the rate of neutrophil degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"6ed396427da649d78a967f0f1e5c6d51","type":"GO_TERM","name":"negative regulation of neutrophil differentiation","canonical_id":"go:GO:0045659","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of neutrophil differentiation.\" [GOC:curators]","metadata":null},{"id":"7371c2e76e924804896306b91e08f4fa","type":"GO_TERM","name":"negative regulation of neutrophil extravasation","canonical_id":"go:GO:2000390","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neutrophil extravasation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"0d8d1f0e31c74d16a9f83f394a6945b9","type":"GO_TERM","name":"negative regulation of neutrophil mediated cytotoxicity","canonical_id":"go:GO:0070954","description":"\"Any process that decreases the frequency, rate or extent of the directed killing of a target cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"9233fc00f2774c2bbaee5f1650eabe72","type":"GO_TERM","name":"negative regulation of neutrophil mediated killing of bacterium","canonical_id":"go:GO:0070956","description":"\"Any process that decreases the frequency, rate or extent of the directed killing of a bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"ceb128445c334e6092baa166731e0a3b","type":"GO_TERM","name":"negative regulation of neutrophil mediated killing of fungus","canonical_id":"go:GO:0070959","description":"\"Any process that decreases the frequency, rate or extent of the directed killing of a fungal cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"e4ece7d2f214454d91170b11c2caeabc","type":"GO_TERM","name":"negative regulation of neutrophil mediated killing of gram-negative bacterium","canonical_id":"go:GO:0070957","description":"\"Any process that decreases the frequency, rate or extent of the directed killing of a gram-negative bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"6fa049ab934b45a293640dd0ebb219e9","type":"GO_TERM","name":"negative regulation of neutrophil mediated killing of gram-positive bacterium","canonical_id":"go:GO:0070958","description":"\"Any process that decreases the frequency, rate or extent of the directed killing of a gram-positive bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"5ecc5bf8f2064c67acd01cf841bfc537","type":"GO_TERM","name":"negative regulation of neutrophil mediated killing of symbiont cell","canonical_id":"go:GO:0070955","description":"\"Any process that decreases the frequency, rate or extent of the directed killing of a symbiont target cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"dccd0f5fd3394000ba26711f8fd8a479","type":"GO_TERM","name":"negative regulation of neutrophil migration","canonical_id":"go:GO:1902623","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of neutrophil migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:1826836]","metadata":null},{"id":"94326e281c61491fb3e8715cb927a220","type":"GO_TERM","name":"negative regulation of nigerotriose transport","canonical_id":"go:GO:1900358","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nigerotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"6241a07394444918a16aca47eb136813","type":"GO_TERM","name":"negative regulation of nitric oxide biosynthetic process","canonical_id":"go:GO:0045019","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.\" [GOC:curators]","metadata":null},{"id":"29b98b64053d44d0bd4accfb585627c3","type":"GO_TERM","name":"negative regulation of nitric oxide-cGMP mediated signal transduction","canonical_id":"go:GO:0141151","description":"\"Any process that decreases the rate, frequency or extent of nitric oxide-cGMP mediated signal transduction.\" [PMID:35931019]","metadata":null},{"id":"7386c2a7699c4f65bb7d511e0fe816d4","type":"GO_TERM","name":"negative regulation of nitric-oxide synthase activity","canonical_id":"go:GO:0051001","description":"\"Any process that stops or reduces the activity of the enzyme nitric-oxide synthase.\" [GOC:ai]","metadata":null},{"id":"299228207f9d49ae88fd7e9c4be8be8f","type":"GO_TERM","name":"negative regulation of nitrogen utilization","canonical_id":"go:GO:0045847","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of nitrogen utilization.\" [GOC:curators]","metadata":null},{"id":"505e517d18214c868a637ada8b43c501","type":"GO_TERM","name":"negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1905259","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to nitrosative stress.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:14752510]","metadata":null},{"id":"95f26f3444a0474da4d5b0362601271d","type":"GO_TERM","name":"negative regulation of nodal receptor complex assembly","canonical_id":"go:GO:1900124","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nodal receptor complex assembly.\" [GOC:signaling, GOC:TermGenie, PMID:15062104]","metadata":null},{"id":"c849739908d6417f95b07faa1f8b5ef4","type":"GO_TERM","name":"negative regulation of nodal signaling pathway","canonical_id":"go:GO:1900108","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nodal signaling pathway.\" [GOC:BHF, GOC:TermGenie, GOC:vk]","metadata":null},{"id":"8079c24edd12408db3c93014d1fe11d5","type":"GO_TERM","name":"negative regulation of non-canonical NF-kappaB signal transduction","canonical_id":"go:GO:1901223","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of non-canonical NF-kappaB signaling cascade.\" [GOC:TermGenie]","metadata":null},{"id":"4181e1b99ac140f09f9d4ae6326f73b4","type":"GO_TERM","name":"negative regulation of non-canonical Wnt signaling pathway","canonical_id":"go:GO:2000051","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of non-canonical Wnt signaling pathway.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"fed9a6d7c591422e88cbdfd570c34137","type":"GO_TERM","name":"negative regulation of non-canonical inflammasome complex assembly","canonical_id":"go:GO:0160076","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of non-canonical inflammasome complex assembly.\" [PMID:22002608, PMID:26375259]","metadata":null},{"id":"4a606c26477b4ffba24cfafb812f1934","type":"GO_TERM","name":"negative regulation of non-motile cilium assembly","canonical_id":"go:GO:1902856","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of non-motile cilium assembly.\" [GO_REF:0000058, GOC:cilia, GOC:kmv, GOC:TermGenie, PMID:23807208]","metadata":null},{"id":"1e5b45d956024d03987604455dfdf9d0","type":"GO_TERM","name":"negative regulation of non-professional antigen presenting cell antigen processing and presentation","canonical_id":"go:GO:0002620","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of non-professional antigen presenting cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"28363cee9de8440cb6742faedc3cc245","type":"GO_TERM","name":"negative regulation of norepinephrine secretion","canonical_id":"go:GO:0010700","description":"\"Any process that decreases the frequency, rate or extent of the regulated release of norepinephrine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"573f0363bd53455f839ed7138a5925d4","type":"GO_TERM","name":"negative regulation of norepinephrine uptake","canonical_id":"go:GO:0051622","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of norepinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"8369a89a93b8438bab94673d9e68458b","type":"GO_TERM","name":"negative regulation of nuclear cell cycle DNA replication","canonical_id":"go:GO:1902576","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear cell cycle DNA replication.\" [GOC:TermGenie, PMID:19033384]","metadata":null},{"id":"300985b683554b6fb35fa02cb138f085","type":"GO_TERM","name":"negative regulation of nuclear division","canonical_id":"go:GO:0051784","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of nuclear division, the partitioning of the nucleus and its genetic information.\" [GOC:ai]","metadata":null},{"id":"b65e47d44e9e49c2b8e29aebcf3d419e","type":"GO_TERM","name":"negative regulation of nuclear mRNA surveillance of meiosis-specific transcripts","canonical_id":"go:GO:0120271","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of selective degradation of meiosis-specific nuclear transcribed transcripts during vegetative growth, by a mechanism that requires determinant of selective removal (DSR) sequences in the targeted mRNAs and involves a YTH family protein.\" [GOC:krc, PMID:24920274]","metadata":null},{"id":"3ae379ae998342f4a1cbc4ae8fbca4bf","type":"GO_TERM","name":"negative regulation of nuclear migration along microtubule","canonical_id":"go:GO:1902839","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear migration along microtubule.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"9d46a2fc23f74f958479d6e7a934f2c4","type":"GO_TERM","name":"negative regulation of nuclear migration during mitotic telophase","canonical_id":"go:GO:1902853","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear migration during mitotic telophase.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"41d50c5214dc413d84e3bc85622aaa58","type":"GO_TERM","name":"negative regulation of nuclear receptor-mediated glucocorticoid signaling pathway","canonical_id":"go:GO:2000323","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear receptor-mediated glucocorticoid signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"ad618e95540f4d56bbecb41d8468236e","type":"GO_TERM","name":"negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay","canonical_id":"go:GO:1900152","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay.\" [GOC:mcc, GOC:TermGenie]","metadata":null},{"id":"dd746baf60844534825267ee97f76c5b","type":"GO_TERM","name":"negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay","canonical_id":"go:GO:2000623","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay.\" [GOC:obol]","metadata":null},{"id":"6ee40b2e90e04c15892c28babcc6f5fd","type":"GO_TERM","name":"negative regulation of nuclear-transcribed mRNA poly(A) tail shortening","canonical_id":"go:GO:0060212","description":"\"Any process that decreases the frequency, rate or extent of poly(A) tail shortening of a nuclear-transcribed mRNA. Poly(A) tail shortening is the decrease in length of the poly(A) tail of an mRNA from full length to an oligo(A) length.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8978df8a1f5144c0a718d87c8cd4ae68","type":"GO_TERM","name":"negative regulation of nucleobase-containing compound metabolic process","canonical_id":"go:GO:0045934","description":"\"Any cellular process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids.\" [GOC:curators]","metadata":null},{"id":"62f631f764834fcb93f5220355c593e3","type":"GO_TERM","name":"negative regulation of nucleobase-containing compound transport","canonical_id":"go:GO:0032240","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of nucleobases, nucleosides, nucleotides and nucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"1f33e6c2fd714a9397f1197c800a0e61","type":"GO_TERM","name":"negative regulation of nucleocytoplasmic transport","canonical_id":"go:GO:0046823","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances between the cytoplasm and the nucleus.\" [GOC:bf]","metadata":null},{"id":"9f02fb359d00493b9d7cf158a77c8b44","type":"GO_TERM","name":"negative regulation of nucleoside metabolic process","canonical_id":"go:GO:0045978","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleosides.\" [GOC:curators]","metadata":null},{"id":"817d17fc956e4dd5b803bbe376a2394d","type":"GO_TERM","name":"negative regulation of nucleoside transport","canonical_id":"go:GO:0032243","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"486c33876a584694bd11acb2665d5802","type":"GO_TERM","name":"negative regulation of nucleotide biosynthetic process","canonical_id":"go:GO:0030809","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nucleotides.\" [GOC:mah]","metadata":null},{"id":"43f262756a4b4fb88e72bd8328c09387","type":"GO_TERM","name":"negative regulation of nucleotide catabolic process","canonical_id":"go:GO:0030812","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of nucleotides.\" [GOC:mah]","metadata":null},{"id":"02163955caec48aa8127f5338db08d31","type":"GO_TERM","name":"negative regulation of nucleotide metabolic process","canonical_id":"go:GO:0045980","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleotides.\" [GOC:curators]","metadata":null},{"id":"e20d4e3e87a546b4b5dac06c98e3c075","type":"GO_TERM","name":"negative regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway","canonical_id":"go:GO:0070425","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (NLR) pathway.\" [GOC:add]","metadata":null},{"id":"1af4c813c7624c0a9617552336b29d87","type":"GO_TERM","name":"negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway","canonical_id":"go:GO:0070429","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 1 (NOD1) pathway.\" [GOC:add]","metadata":null},{"id":"8a97d9caa9094d4294ded07cbfc42892","type":"GO_TERM","name":"negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway","canonical_id":"go:GO:0070433","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 2 (NOD2) pathway.\" [GOC:add]","metadata":null},{"id":"282366c4f34e4b52b267261a7d936d57","type":"GO_TERM","name":"negative regulation of nurse cell apoptotic process","canonical_id":"go:GO:0045849","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of nurse cell apoptotic process.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"67c0849dce7e4390abbf966e90495eb6","type":"GO_TERM","name":"negative regulation of o-orsellinic acid biosynthetic process","canonical_id":"go:GO:1900699","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of o-orsellinic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8031ae5c254f45b2a84e6da489d6be38","type":"GO_TERM","name":"negative regulation of octopamine or tyramine signaling pathway","canonical_id":"go:GO:2000126","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of octopamine or tyramine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"c8d31750520c4063b53db8dd6dc93b91","type":"GO_TERM","name":"negative regulation of octopamine signaling pathway","canonical_id":"go:GO:2000129","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of octopamine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"790cdaae143040ad96b1e11fd38dffb0","type":"GO_TERM","name":"negative regulation of odontoblast differentiation","canonical_id":"go:GO:1901330","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of odontoblast differentiation.\" [GOC:TermGenie]","metadata":null},{"id":"d4e3f4d148a24f40968f15f5b6172cc3","type":"GO_TERM","name":"negative regulation of odontogenesis","canonical_id":"go:GO:0042483","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the formation and development of a tooth or teeth.\" [GOC:jl]","metadata":null},{"id":"271a372f50b247eaa461726acaf3cd33","type":"GO_TERM","name":"negative regulation of odontogenesis of dentin-containing tooth","canonical_id":"go:GO:0042489","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the formation and development of teeth, the hard, bony appendages which are borne on the jaws, or on other bones in the walls of the mouth or pharynx.\" [GOC:jl, GOC:mtg_sensu, PMID:15355794]","metadata":null},{"id":"a6610fc6407f40aba09654ca67db554f","type":"GO_TERM","name":"negative regulation of olefin biosynthetic process","canonical_id":"go:GO:1900912","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of olefin biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"871cbcce7d49403bb04f69e28e27206d","type":"GO_TERM","name":"negative regulation of oligodendrocyte apoptotic process","canonical_id":"go:GO:1900142","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of oligodendrocyte apoptotic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"0070f7b21d0d4c98a80ea97f1516e056","type":"GO_TERM","name":"negative regulation of oligodendrocyte differentiation","canonical_id":"go:GO:0048715","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of oligodendrocyte differentiation.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"58ea267d4c98477a8fc7cf9a10616fa5","type":"GO_TERM","name":"negative regulation of oligodendrocyte progenitor proliferation","canonical_id":"go:GO:0070446","description":"\"Any process that stops or decreases the rate or extent of oligodendrocyte progenitor proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"147b779f74cc484c8f4737bc31b52dde","type":"GO_TERM","name":"negative regulation of oligopeptide transport","canonical_id":"go:GO:2000877","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of oligopeptide transport.\" [GOC:obol]","metadata":null},{"id":"c545302431584d119cabacc1fd6f5b56","type":"GO_TERM","name":"negative regulation of oocyte development","canonical_id":"go:GO:0060283","description":"\"Any process that decreases the rate or extent of the process whose specific outcome is the progression of an oocyte over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d55100fc995c460487f577371fae69d7","type":"GO_TERM","name":"negative regulation of oocyte karyosome formation","canonical_id":"go:GO:0120314","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of oocyte karyosome formation, the chromosome organization process in which meiotic chromosomes in the oocyte nucleus cluster together to form a compact spherical structure called the karyosome.\" [GOC:ha, GOC:krc, PMID:33382409]","metadata":null},{"id":"f57bed4d8a8a4ee9afa5eed78f194360","type":"GO_TERM","name":"negative regulation of oocyte maturation","canonical_id":"go:GO:1900194","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of oocyte maturation.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"030f4c9f345d405cb701d0eca14f37ad","type":"GO_TERM","name":"negative regulation of oogenesis","canonical_id":"go:GO:1905880","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of oogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:26434723]","metadata":null},{"id":"d89956d1b6de4ec7be0a92994be2465e","type":"GO_TERM","name":"negative regulation of oogonium development","canonical_id":"go:GO:0075266","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of oogonium development, a process that leads to the formation of a female gametangium of oomycetes, containing one or more gametes.\" [GOC:pamgo_curators]","metadata":null},{"id":"1ee8535897f54c6680360cb648dd0104","type":"GO_TERM","name":"negative regulation of oomycete sporangium development","canonical_id":"go:GO:0075324","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of oomycete sporangium development, a process that leads to the formation of oomycete sporangium, a single-celled or many-celled structure that germinates directly to form an infection hypha or differentiate, through specialized cleavage vesicles, into between 10 and 30 zoospores, which is laterally flagellated.\" [GOC:pamgo_curators]","metadata":null},{"id":"9b39f8a9f8d2494fb241ff12bbe6f015","type":"GO_TERM","name":"negative regulation of oospore formation","canonical_id":"go:GO:0075246","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of oospore formation, a process in which male and female gametangia develop and fuse to form a thick-walled resting spore of oomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"ec95f6b593f948ec80f7aca66c066273","type":"GO_TERM","name":"negative regulation of opioid receptor signaling pathway","canonical_id":"go:GO:2000475","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of opioid receptor signaling pathway.\" [GOC:obol]","metadata":null},{"id":"2e32a23d95de41d5972b7b8616e021e0","type":"GO_TERM","name":"negative regulation of opsin-mediated signaling pathway","canonical_id":"go:GO:0016059","description":"\"The process of restoring the photoreceptor cell to its unexcited state after termination of the stimulus (photon).\" [PMID:8316831]","metadata":null},{"id":"9b3f7cf576ed4a54bf33f2a7d2a1cdf6","type":"GO_TERM","name":"negative regulation of optic nerve formation","canonical_id":"go:GO:2000596","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of optic nerve formation.\" [GOC:obol]","metadata":null},{"id":"d5f8645611cc41109a4502de96f2c7b9","type":"GO_TERM","name":"negative regulation of optical nerve axon regeneration","canonical_id":"go:GO:1905592","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of optical nerve axon regeneration.\" [GO_REF:0000058, GOC:TermGenie, PMID:16699509]","metadata":null},{"id":"613bbfc3521c4a1c998ca453643dd56c","type":"GO_TERM","name":"negative regulation of orcinol biosynthetic process","canonical_id":"go:GO:1900702","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of orcinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7ca6c0e4baa54b148aaf2123868415fb","type":"GO_TERM","name":"negative regulation of organ growth","canonical_id":"go:GO:0046621","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of growth of an organ of an organism.\" [GOC:bf, GOC:tb]","metadata":null},{"id":"b6c09e1e39e345fcb77bbe8f6e48651d","type":"GO_TERM","name":"negative regulation of organelle assembly","canonical_id":"go:GO:1902116","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of organelle assembly.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"48752b6dfbf24c50b3244b8d5c7924d8","type":"GO_TERM","name":"negative regulation of organelle organization","canonical_id":"go:GO:0010639","description":"\"Any process that decreases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of an organelle.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7e3181e577eb4a5399a860967367ffc5","type":"GO_TERM","name":"negative regulation of organic acid transport","canonical_id":"go:GO:0032891","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of organic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"2a35469f16dd4ac8ae76748dd0203f2b","type":"GO_TERM","name":"negative regulation of organofluorine metabolic process","canonical_id":"go:GO:0090350","description":"\"Any process that decreases the rate, frequency or extent of the chemical reactions and pathways involving organofluorine compounds, as carried out by individual cells.\" [GOC:BHF]","metadata":null},{"id":"9c4d71ef3e054956a43790f30e69d0d9","type":"GO_TERM","name":"negative regulation of ornithine catabolic process","canonical_id":"go:GO:1903267","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ornithine catabolic process.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:12679340]","metadata":null},{"id":"83985d3291784fb9b71e2ccc63a1068a","type":"GO_TERM","name":"negative regulation of oskar mRNA translation","canonical_id":"go:GO:0007319","description":"\"Any process that stops, prevents or reduces the rate that oskar mRNAs are effectively translated into protein.\" [GOC:ems]","metadata":null},{"id":"4d07025cd1964aa7843b32990aca9df1","type":"GO_TERM","name":"negative regulation of ossification","canonical_id":"go:GO:0030279","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ossification, the formation of bone or of a bony substance or the conversion of fibrous tissue or of cartilage into bone or a bony substance.\" [GOC:curators]","metadata":null},{"id":"557fb56c2e2b42a39e62d7c31c67fea3","type":"GO_TERM","name":"negative regulation of osteoblast differentiation","canonical_id":"go:GO:0045668","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of osteoblast differentiation.\" [GOC:curators]","metadata":null},{"id":"ca618dbbb90b4a9d9c465a941606d266","type":"GO_TERM","name":"negative regulation of osteoblast proliferation","canonical_id":"go:GO:0033689","description":"\"Any process that stops, prevents or reduces the rate or extent of osteoblast proliferation.\" [GOC:mah]","metadata":null},{"id":"057b115dc22146e9990fc7cc35b7a45f","type":"GO_TERM","name":"negative regulation of osteoclast development","canonical_id":"go:GO:2001205","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of osteoclast development.\" [GOC:obol]","metadata":null},{"id":"a081aa342ad444dda5aa7fbfff21cde9","type":"GO_TERM","name":"negative regulation of osteoclast differentiation","canonical_id":"go:GO:0045671","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of osteoclast differentiation.\" [GOC:curators]","metadata":null},{"id":"d7b6a73cb4724779a263254ef352f6c6","type":"GO_TERM","name":"negative regulation of osteoclast proliferation","canonical_id":"go:GO:0090291","description":"\"Any process that decreases the rate, frequency, or extent of the multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population.\" [GOC:tb]","metadata":null},{"id":"32d9a0b2523f4318b48a57981225e8b6","type":"GO_TERM","name":"negative regulation of otic vesicle morphogenesis","canonical_id":"go:GO:1904119","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of otic vesicle morphogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:25677106]","metadata":null},{"id":"b0ef33c4df99424f8bb68252a15057ec","type":"GO_TERM","name":"negative regulation of outer hair cell apoptotic process","canonical_id":"go:GO:1905586","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of outer hair cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24472721]","metadata":null},{"id":"ebce75795e5e484392d8ab460ccf3d48","type":"GO_TERM","name":"negative regulation of ovarian follicle development","canonical_id":"go:GO:2000355","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ovarian follicle development.\" [GOC:obol]","metadata":null},{"id":"76142b7a30eb433690bf5f42a3b0aaa8","type":"GO_TERM","name":"negative regulation of ovulation","canonical_id":"go:GO:0060280","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ovulation, the release of a mature ovum/oocyte from an ovary.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"1ba47226b71c4bf2ab2a6acacec0e2ad","type":"GO_TERM","name":"negative regulation of oxidative phosphorylation","canonical_id":"go:GO:0090324","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.\" [GOC:BHF]","metadata":null},{"id":"c09ca5ed21fc44209b54c9637a01fb09","type":"GO_TERM","name":"negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1902176","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of an oxidative stress-induced intrinsic apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:TermGenie, PMID:11672522]","metadata":null},{"id":"551c16c78715406fbfa89a76675311dd","type":"GO_TERM","name":"negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903377","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of oxidative stress-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:15790595]","metadata":null},{"id":"b9574399d4cf4e2a8bb84c4a1fc4b42f","type":"GO_TERM","name":"negative regulation of oxidoreductase activity","canonical_id":"go:GO:0051354","description":"\"Any process that stops or reduces the rate of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered.\" [GOC:ai]","metadata":null},{"id":"7053ef6017d54758abf0904b7f3dd7ea","type":"GO_TERM","name":"negative regulation of oxytocin production","canonical_id":"go:GO:0140669","description":"\"Any process that stops, prevents, or reduces the rate of production of oxytocin.\" [PMID:25096581]","metadata":null},{"id":"35d83586bccf41aa97d2846688f9f9bb","type":"GO_TERM","name":"negative regulation of p38MAPK cascade","canonical_id":"go:GO:1903753","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of p38MAPK cascade.\" [GO_REF:0000058, GOC:TermGenie, PMID:18681888]","metadata":null},{"id":"cafbf36c8afd44788220098284632d2b","type":"GO_TERM","name":"negative regulation of pancreatic A cell differentiation","canonical_id":"go:GO:2000227","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic A cell differentiation.\" [GOC:mah]","metadata":null},{"id":"80fba685cfec4dd08e677af3f0b354a3","type":"GO_TERM","name":"negative regulation of pancreatic amylase secretion","canonical_id":"go:GO:1902277","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pancreatic amylase secretion.\" [GOC:jc, GOC:TermGenie]","metadata":null},{"id":"631bccf5c90c475fb1004759cc34ff27","type":"GO_TERM","name":"negative regulation of pancreatic juice secretion","canonical_id":"go:GO:0090188","description":"\"Any process that decreases the rate, frequency or extent of pancreatic juice secretion, the regulated release of pancreatic juice by the exocrine pancreas into the upper part of the intestine.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"f94726baad534d8eb19bbe869f115a7f","type":"GO_TERM","name":"negative regulation of pancreatic stellate cell proliferation","canonical_id":"go:GO:2000230","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic stellate cell proliferation.\" [GOC:mah]","metadata":null},{"id":"ddf5d5afce1146d1a976604dace3655b","type":"GO_TERM","name":"negative regulation of pancreatic trypsinogen secretion","canonical_id":"go:GO:1904243","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pancreatic trypsinogen secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:12771515]","metadata":null},{"id":"0c10f7e881e445c7a12818bc59b8221a","type":"GO_TERM","name":"negative regulation of parathyroid hormone secretion","canonical_id":"go:GO:2000829","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of parathyroid hormone secretion.\" [GOC:obol]","metadata":null},{"id":"ec417571e2af461189b90609eed950c3","type":"GO_TERM","name":"negative regulation of paraxial mesodermal cell fate determination","canonical_id":"go:GO:0048347","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of paraxial mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"5ef56b046e134d76908b401e640584c4","type":"GO_TERM","name":"negative regulation of paraxial mesodermal cell fate specification","canonical_id":"go:GO:0048351","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of paraxial mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"d17e7efd2d0b42d7b21f08d9d67fde69","type":"GO_TERM","name":"negative regulation of pectin catabolic process","canonical_id":"go:GO:2001004","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pectin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"f64181cd4b314ea1b86303dfec5615d6","type":"GO_TERM","name":"negative regulation of penicillin biosynthetic process","canonical_id":"go:GO:1900197","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of penicillin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"02167708ec0944bbb61491b97562571e","type":"GO_TERM","name":"negative regulation of penicillin catabolic process","canonical_id":"go:GO:0033248","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:mah]","metadata":null},{"id":"c07c0c201ea544519f7f39d06c94fa66","type":"GO_TERM","name":"negative regulation of penile erection","canonical_id":"go:GO:0060407","description":"\"Any process that stops, prevents, or reduces the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ff58eae432ed43baaf5ceae44156d655","type":"GO_TERM","name":"negative regulation of pentadecane biosynthetic process","canonical_id":"go:GO:1900888","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pentadecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"cc1c623f52d54efbbff8c081bedfa24f","type":"GO_TERM","name":"negative regulation of pentasaccharide transport","canonical_id":"go:GO:1900361","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pentasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"a7b15c78f4b64bd6a08c3bdbca0156b9","type":"GO_TERM","name":"negative regulation of pentose-phosphate shunt","canonical_id":"go:GO:1905856","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pentose-phosphate shunt.\" [GO_REF:0000058, GOC:TermGenie, PMID:19015259]","metadata":null},{"id":"203b566de5d3426c9b11f1b72d9a95de","type":"GO_TERM","name":"negative regulation of peptidase activity","canonical_id":"go:GO:0010466","description":"\"Any process that stops or reduces the rate of peptidase activity, the hydrolysis of peptide bonds within proteins.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e84d872902744826a05d2091bacec056","type":"GO_TERM","name":"negative regulation of peptide antigen transport","canonical_id":"go:GO:1901040","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of peptide antigen transport.\" [GOC:bf, GOC:TermGenie, PMID:16691491]","metadata":null},{"id":"ba40a3e8e9c24ecab40ca35eb1aae6aa","type":"GO_TERM","name":"negative regulation of peptide hormone processing","canonical_id":"go:GO:0060570","description":"\"Any process that decreases the rate, frequency or extent of peptide hormone processing. Peptide hormone processing is the generation of a mature peptide hormone by posttranslational processing of a prohormone.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bf2eb5a327d44a2583054ed1e32d0cbb","type":"GO_TERM","name":"negative regulation of peptide hormone secretion","canonical_id":"go:GO:0090278","description":"\"Any process that decreases the rate, frequency, or extent of the regulated release of a peptide hormone from secretory granules.\" [GOC:tb]","metadata":null},{"id":"f3a9ea1d15af437eb67f5b8a8d7295f7","type":"GO_TERM","name":"negative regulation of peptide secretion","canonical_id":"go:GO:0002792","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of peptide secretion.\" [GOC:add]","metadata":null},{"id":"d9c498d662f947eea730093cb138fa76","type":"GO_TERM","name":"negative regulation of peptidoglycan recognition protein signaling pathway","canonical_id":"go:GO:0061060","description":"\"Any process that decreases the rate, frequency, or extent of the peptidoglycan recognition protein signaling pathway.\" [GOC:dph]","metadata":null},{"id":"454a70aff573422f8bd9a6ad71c7520d","type":"GO_TERM","name":"negative regulation of peptidyl-L-cysteine S-palmitoylation","canonical_id":"go:GO:1902663","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of peptidyl-L-cysteine S-palmitoylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23444136]","metadata":null},{"id":"2b881e12c5b94487a04868d4087fef2a","type":"GO_TERM","name":"negative regulation of peptidyl-cysteine S-nitrosylation","canonical_id":"go:GO:1902083","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of peptidyl-cysteine S-nitrosylation.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19198614]","metadata":null},{"id":"41dc7dbc48ee4bbcada0ec8caacaee31","type":"GO_TERM","name":"negative regulation of peptidyl-lysine acetylation","canonical_id":"go:GO:2000757","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of peptidyl-lysine acetylation.\" [GOC:obol]","metadata":null},{"id":"6996314cfa4b4927a0ec9dc6e8ee6c98","type":"GO_TERM","name":"negative regulation of peptidyl-lysine crotonylation","canonical_id":"go:GO:0120094","description":"\"Any process that stops or reduces the rate of crotonylation of a lysine residue in a protein.\" [PMID:28803779]","metadata":null},{"id":"12bccb2f19874cbebd9300e7172c1215","type":"GO_TERM","name":"negative regulation of peptidyl-serine phosphorylation","canonical_id":"go:GO:0033137","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the phosphorylation of peptidyl-serine.\" [GOC:mah]","metadata":null},{"id":"a8522baff7e94dd6b9cd1db5fc53c515","type":"GO_TERM","name":"negative regulation of peptidyl-serine phosphorylation of STAT protein","canonical_id":"go:GO:0033140","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the phosphorylation of a serine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:mah]","metadata":null},{"id":"9c3d720da6b94dd28c7ec6f9eb5f49a2","type":"GO_TERM","name":"negative regulation of peptidyl-threonine phosphorylation","canonical_id":"go:GO:0010801","description":"\"Any process that decreases the frequency, rate or extent of peptidyl-threonine phosphorylation. Peptidyl-threonine phosphorylation is the phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"83909bd48e7a412295dda4995f7a7276","type":"GO_TERM","name":"negative regulation of peptidyl-tyrosine autophosphorylation","canonical_id":"go:GO:1900085","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of peptidyl-tyrosine autophosphorylation.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"281b9c3ac41745bcb3b54826045dc61e","type":"GO_TERM","name":"negative regulation of peptidyl-tyrosine phosphorylation","canonical_id":"go:GO:0050732","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.\" [GOC:ai]","metadata":null},{"id":"ee790491a469401ebe8ca59b9f2bbe4f","type":"GO_TERM","name":"negative regulation of peripheral B cell anergy","canonical_id":"go:GO:0002918","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of peripheral B cell anergy.\" [GOC:add]","metadata":null},{"id":"0a8bcd9840c54c5daf5caa638dd76050","type":"GO_TERM","name":"negative regulation of peripheral B cell deletion","canonical_id":"go:GO:0002909","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of peripheral B cell deletion.\" [GOC:add]","metadata":null},{"id":"8a845f77dc794e51b05fd022f2cc4077","type":"GO_TERM","name":"negative regulation of peripheral T cell tolerance induction","canonical_id":"go:GO:0002850","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of peripheral T cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"ca9235a9a318463d8f9bb2ae5cc2e74f","type":"GO_TERM","name":"negative regulation of peripheral tolerance induction","canonical_id":"go:GO:0002659","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of peripheral tolerance induction.\" [GOC:add]","metadata":null},{"id":"c09fb35475a84e528a0a1a25dc274c8f","type":"GO_TERM","name":"negative regulation of peroxisome proliferator activated receptor signaling pathway","canonical_id":"go:GO:0035359","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the peroxisome proliferator activated receptor signaling pathway.\" [GOC:bf]","metadata":null},{"id":"aebae66b4b0749d28045cd30c44f5d87","type":"GO_TERM","name":"negative regulation of phagocytosis","canonical_id":"go:GO:0050765","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of phagocytosis.\" [GOC:ai]","metadata":null},{"id":"92986a3f5505481f8eb9c9032c9c1e62","type":"GO_TERM","name":"negative regulation of phagocytosis, engulfment","canonical_id":"go:GO:0060101","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis.\" [GOC:dph]","metadata":null},{"id":"4d4a551674324f8db0f9081eb557c00a","type":"GO_TERM","name":"negative regulation of phagosome maturation","canonical_id":"go:GO:1905163","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phagosome maturation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"00be3c55c5c5462d994f0598273570bd","type":"GO_TERM","name":"negative regulation of phenazine biosynthetic process","canonical_id":"go:GO:1900981","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phenazine biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"56c9e1cd4df7454aa2ccfda13c0d82eb","type":"GO_TERM","name":"negative regulation of phenotypic switching","canonical_id":"go:GO:1900240","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phenotypic switching.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2cfa947d650242bebe522ccf92c04ca1","type":"GO_TERM","name":"negative regulation of pheromone response MAPK cascade","canonical_id":"go:GO:0180040","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a pheromone response MAPK cascade.\" [GOC:vw]","metadata":null},{"id":"9fc8b002d1f3436580b7f501ab042a54","type":"GO_TERM","name":"negative regulation of phialide development","canonical_id":"go:GO:0070806","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of phialide development, a process that leads to the formation of phialides. Phialides are specialized cells that bud from the ends of metulae on the conidiophore tip.\" [GOC:mah]","metadata":null},{"id":"966e7bebde0b4b28884a02870942e86a","type":"GO_TERM","name":"negative regulation of phosphatase activity","canonical_id":"go:GO:0010923","description":"\"Any process that decreases the rate or frequency of phosphatase activity. Phosphatases catalyze the hydrolysis of phosphoric monoesters, releasing inorganic phosphate.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d83f8f87e9a842a2976fa8501bc83904","type":"GO_TERM","name":"negative regulation of phosphate metabolic process","canonical_id":"go:GO:0045936","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving phosphates.\" [GOC:curators]","metadata":null},{"id":"bbafb637a3fc4a0ab25517deb849f69a","type":"GO_TERM","name":"negative regulation of phosphate transmembrane transport","canonical_id":"go:GO:2000186","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of phosphate transmembrane transport.\" [GOC:obol]","metadata":null},{"id":"e77d2242585b4084b86a0d8dd984184f","type":"GO_TERM","name":"negative regulation of phosphatidic acid biosynthetic process","canonical_id":"go:GO:1905694","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phosphatidic acid biosynthetic process.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:23767959]","metadata":null},{"id":"43571731e2f44a7189c88450294fdbec","type":"GO_TERM","name":"negative regulation of phosphatidylcholine biosynthetic process","canonical_id":"go:GO:2001246","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phosphatidylcholine biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"f1766dba133e4fec8bd513cb683bb99c","type":"GO_TERM","name":"negative regulation of phosphatidylcholine catabolic process","canonical_id":"go:GO:0010900","description":"\"Any process that decreases the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"21b69756180048e2a84f112a9a3cc0b8","type":"GO_TERM","name":"negative regulation of phosphatidylglycerol biosynthetic process","canonical_id":"go:GO:1901352","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phosphatidylglycerol biosynthetic process.\" [GOC:dgf, GOC:TermGenie, PMID:12869188]","metadata":null},{"id":"5ece9c4a56594eb4afe7feb5b3212e12","type":"GO_TERM","name":"negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction","canonical_id":"go:GO:0051898","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction.\" [GOC:ai]","metadata":null},{"id":"c58c664525194926ac54b7b020700296","type":"GO_TERM","name":"negative regulation of phosphatidylinositol biosynthetic process","canonical_id":"go:GO:0010512","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phosphatidylinositol.\" [GOC:dph, GOC:tb, GOC:vw]","metadata":null},{"id":"675470dda2b9422a8255c78659f87394","type":"GO_TERM","name":"negative regulation of phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity","canonical_id":"go:GO:2001145","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity.\" [GOC:obol]","metadata":null},{"id":"d8c0a573c2dd4a8fbd869f198a48d826","type":"GO_TERM","name":"negative regulation of phosphatidylserine biosynthetic process","canonical_id":"go:GO:1900469","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phosphatidylserine biosynthetic process.\" [GOC:dgf, GOC:TermGenie, PMID:8056324, PMID:8614637]","metadata":null},{"id":"24a88dec1e324bd49599762e69f4a898","type":"GO_TERM","name":"negative regulation of phosphatidylserine exposure on apoptotic cell surface","canonical_id":"go:GO:1905781","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phosphatidylserine exposure on apoptotic cell surface.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:17401362]","metadata":null},{"id":"dae771aa59cc448d86b095b375f9d11a","type":"GO_TERM","name":"negative regulation of phospholipase C-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:1900737","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phospholipase C-activating G protein-coupled receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"c5e6cc8a1a7d4a149d12c03f22900f8f","type":"GO_TERM","name":"negative regulation of phospholipase C-activating dopamine receptor signaling pathway","canonical_id":"go:GO:0060162","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the dopamine receptor, phospholipase C activating pathway.\" [GOC:dph, GOC:tb, PMID:15016423]","metadata":null},{"id":"f6e8ad85d74541bd9dd645e6628012b4","type":"GO_TERM","name":"negative regulation of phospholipase C-activating phototransduction signaling pathway","canonical_id":"go:GO:0016060","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phospholipase C-activating phototransduction signaling pathway. Activated rhodopsin (R*) is inactivated by a two-step process: first, R* is phosphorylated by rhodopsin kinase which lowers the activity of R*. Second, the protein arrestin binds to phosphorylated R* to de-activate it.\" [GOC:hb, PMID:8316831]","metadata":null},{"id":"af7faf7039024b2fba7bcdab0171c645","type":"GO_TERM","name":"negative regulation of phospholipase C/protein kinase C signal transduction","canonical_id":"go:GO:0160195","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phospholipase C/protein kinase C signal transduction.\" [PMID:32033984]","metadata":null},{"id":"68a365e07af64219bc703c9ddb446d06","type":"GO_TERM","name":"negative regulation of phospholipid biosynthetic process","canonical_id":"go:GO:0071072","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.\" [GOC:mah]","metadata":null},{"id":"c02d3b70bab34b738ef8fb21b6ad809e","type":"GO_TERM","name":"negative regulation of phospholipid efflux","canonical_id":"go:GO:1902999","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phospholipid efflux.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:12042316]","metadata":null},{"id":"373ea01d600b49e99a6c997964e3bbed","type":"GO_TERM","name":"negative regulation of phospholipid metabolic process","canonical_id":"go:GO:1903726","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phospholipid metabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:10657240]","metadata":null},{"id":"c4bf9c7853e846cebb5627fc0aaa6189","type":"GO_TERM","name":"negative regulation of phospholipid translocation","canonical_id":"go:GO:0061093","description":"\"Any process that decreases the frequency, rate or extent of the translocation, or flipping, of phospholipid molecules from one monolayer of a membrane bilayer to the opposite monolayer.\" [GOC:dph, GOC:jh, GOC:tb, PMID:19966303]","metadata":null},{"id":"d7dc4666a296434e9bdc7eb3d98e709d","type":"GO_TERM","name":"negative regulation of phospholipid transport","canonical_id":"go:GO:2001139","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of phospholipid transport.\" [GOC:obol]","metadata":null},{"id":"54dbd18ebd644107bb1b70e54e80b0a3","type":"GO_TERM","name":"negative regulation of phosphorelay signal transduction system","canonical_id":"go:GO:0070298","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction via a phosphorelay signal transduction system.\" [GOC:mah]","metadata":null},{"id":"73113c192a084f36bc03499035b5cd3b","type":"GO_TERM","name":"negative regulation of phosphorus metabolic process","canonical_id":"go:GO:0010563","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving phosphorus or compounds containing phosphorus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"860e1ae8c60c4400862b2cbbbfa7e6bd","type":"GO_TERM","name":"negative regulation of phosphorus utilization","canonical_id":"go:GO:0045942","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of phosphorus utilization.\" [GOC:curators]","metadata":null},{"id":"4bed0dcc076949bebc5008a910fb9a31","type":"GO_TERM","name":"negative regulation of phosphorylation","canonical_id":"go:GO:0042326","description":"\"Any process that stops, prevents or decreases the rate of addition of phosphate groups to a molecule.\" [GOC:jl]","metadata":null},{"id":"b78900d4db3749ec827a7f23b0a38d03","type":"GO_TERM","name":"negative regulation of photomorphogenesis","canonical_id":"go:GO:0010100","description":"\"Any process that stops, reduces or prevents photomorphogenesis.\" [GOC:tb]","metadata":null},{"id":"e654e23b019345968a390154f25d6525","type":"GO_TERM","name":"negative regulation of photoreceptor cell differentiation","canonical_id":"go:GO:0046533","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of photoreceptor cell differentiation. An example of this process is found in Drosophila melanogaster.\" [GOC:curators]","metadata":null},{"id":"608af78f50e248d58645b8e9ac043d50","type":"GO_TERM","name":"negative regulation of photosynthesis","canonical_id":"go:GO:1905156","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of photosynthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:7592491]","metadata":null},{"id":"fb2896c2fb724761a5232010ef131d0e","type":"GO_TERM","name":"negative regulation of photosynthesis, light reaction","canonical_id":"go:GO:0043155","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the light-dependent reaction of photosynthesis.\" [GOC:jl]","metadata":null},{"id":"5ae7b787764c48168eb96b4e4c42002e","type":"GO_TERM","name":"negative regulation of pigment cell differentiation","canonical_id":"go:GO:0050941","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pigment cell differentiation.\" [GOC:ai]","metadata":null},{"id":"408d1fc4e0544b418c0d80b78282e345","type":"GO_TERM","name":"negative regulation of pinocytosis","canonical_id":"go:GO:0048550","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes.\" [GOC:curators]","metadata":null},{"id":"e4539e1414c2470984daac87d4ef5598","type":"GO_TERM","name":"negative regulation of placenta blood vessel development","canonical_id":"go:GO:0110081","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of placenta blood vessel development.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:27748453]","metadata":null},{"id":"ce8e073d9c6841cda50666a6f9aaa7cd","type":"GO_TERM","name":"negative regulation of plant epidermal cell differentiation","canonical_id":"go:GO:1903889","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plant epidermal cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:123345]","metadata":null},{"id":"1c5670a4a83e474d920ca572bd4f49ec","type":"GO_TERM","name":"negative regulation of plant organ morphogenesis","canonical_id":"go:GO:1905422","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plant organ morphogenesis.\" [GO_REF:0000058, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"9ded848f675d44cbb49a4781a8bf92e6","type":"GO_TERM","name":"negative regulation of plant-type cell wall cellulose biosynthetic process","canonical_id":"go:GO:2001010","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plant-type cell wall cellulose biosynthetic process.\" [GOC:mengo_curators]","metadata":null},{"id":"00e999807c8c44bba8e21d6720d6129f","type":"GO_TERM","name":"negative regulation of plant-type cell wall cellulose catabolic process","canonical_id":"go:GO:2000940","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plant-type cell wall cellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"522b4502b7544da48eb7cc8267630c19","type":"GO_TERM","name":"negative regulation of plant-type hypersensitive response","canonical_id":"go:GO:0034051","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the hypersensitive response in a plant.\" [GOC:pamgo_curators]","metadata":null},{"id":"6842a7ba1091491197b6406054289ef4","type":"GO_TERM","name":"negative regulation of plasma cell differentiation","canonical_id":"go:GO:1900099","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plasma cell differentiation.\" [GOC:TermGenie]","metadata":null},{"id":"92837b7275ca43db95b62ce7edb35f01","type":"GO_TERM","name":"negative regulation of plasma kallikrein-kinin cascade","canonical_id":"go:GO:0002549","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the plasma kallikrein-kinin cascade.\" [GOC:add]","metadata":null},{"id":"833202d065a345198ed719ef3abc6d76","type":"GO_TERM","name":"negative regulation of plasma lipoprotein oxidation","canonical_id":"go:GO:0034445","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of lipoprotein particle oxidation, occurring in the blood plasma.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"4d17eef702b2464b8578cd5c6da4ad34","type":"GO_TERM","name":"negative regulation of plasma membrane bounded cell projection assembly","canonical_id":"go:GO:0120033","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plasma membrane bounded cell projection assembly.\" [GOC:krc]","metadata":null},{"id":"f7e3b5e86d8d497687c59f3c5b21cb57","type":"GO_TERM","name":"negative regulation of plasma membrane raft polarization","canonical_id":"go:GO:1903907","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plasma membrane raft polarization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"8b211ae2a3c140c79dcb1338b7bf072d","type":"GO_TERM","name":"negative regulation of plasma membrane repair","canonical_id":"go:GO:1905685","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of plasma membrane repair.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:22940583]","metadata":null},{"id":"88dc07c354004763bd552bec38992a1e","type":"GO_TERM","name":"negative regulation of plasmacytoid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002611","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of plasmacytoid dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"f8cf945b6d59454a9529173f58727812","type":"GO_TERM","name":"negative regulation of plasmacytoid dendritic cell cytokine production","canonical_id":"go:GO:0002737","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of plasmacytoid dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"91ce719e76b44c83808d74edf7242391","type":"GO_TERM","name":"negative regulation of plasmatocyte differentiation","canonical_id":"go:GO:0045614","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of plasmatocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"cb2d95d93a4646888ab438249a15b342","type":"GO_TERM","name":"negative regulation of plasminogen activation","canonical_id":"go:GO:0010757","description":"\"Any process that decreases the rate, frequency or extent of plasminogen activation. Plasminogen activation is the process in which plasminogen is processed to plasmin.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"29888b9d8aca4cd690ea845827260ebe","type":"GO_TERM","name":"negative regulation of platelet activation","canonical_id":"go:GO:0010544","description":"\"Any process that decreases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"3ef8d7a3f3b643e8b390b251b55375fe","type":"GO_TERM","name":"negative regulation of platelet aggregation","canonical_id":"go:GO:0090331","description":"\"Any process that decreases the rate, frequency or extent of platelet aggregation. Platelet aggregation is the adhesion of one platelet to one or more other platelets via adhesion molecules.\" [GOC:BHF]","metadata":null},{"id":"9282efd104764f6493cc77ad4b328b8d","type":"GO_TERM","name":"negative regulation of platelet formation","canonical_id":"go:GO:1905220","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of platelet formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10606160]","metadata":null},{"id":"6756cd90b2a3458b976fc2a56cddc4d7","type":"GO_TERM","name":"negative regulation of platelet rolling","canonical_id":"go:GO:0160019","description":"\"Any process that decreases the rate, frequency, or extent of platelet rolling.\" [GO_REF:0000058, GOC:sl, PMID:15738422]","metadata":null},{"id":"6aa8007721ab448d9002c64541650573","type":"GO_TERM","name":"negative regulation of platelet-derived growth factor receptor signaling pathway","canonical_id":"go:GO:0010642","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the platelet-derived growth factor receptor signaling pathway.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"21729bc68dd945d0872d66d99444ea90","type":"GO_TERM","name":"negative regulation of platelet-derived growth factor receptor-alpha signaling pathway","canonical_id":"go:GO:2000584","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of platelet-derived growth factor receptor-alpha signaling pathway.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"d4cf4e8d2ab34519b69c90fbda1d8b58","type":"GO_TERM","name":"negative regulation of platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:2000587","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of platelet-derived growth factor receptor-beta signaling pathway.\" [GOC:obol]","metadata":null},{"id":"43bf4b806d8249e1970909bcba833b0e","type":"GO_TERM","name":"negative regulation of plus-end directed microtubule sliding","canonical_id":"go:GO:0062168","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of plus-end directed microtubule sliding.\" [PMID:21892183]","metadata":null},{"id":"be23f8ad4e934b428bc6d4aa758af80d","type":"GO_TERM","name":"negative regulation of podocyte apoptotic process","canonical_id":"go:GO:1904634","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of glomerular visceral epithelial cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:23692924]","metadata":null},{"id":"eb68bfb7360743f1b0e1fe4957ddc724","type":"GO_TERM","name":"negative regulation of podosome assembly","canonical_id":"go:GO:0071802","description":"\"Any process that stops, prevents or reduces the rate or extent of podosome assembly.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"8c16378797be4f639e9710ddd806e616","type":"GO_TERM","name":"negative regulation of polarized epithelial cell differentiation","canonical_id":"go:GO:0030861","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of polarized epithelial cell differentiation.\" [GOC:mah]","metadata":null},{"id":"6fb2fe33a5bb4287b29f4441595d1265","type":"GO_TERM","name":"negative regulation of pollen tube guidance","canonical_id":"go:GO:0160068","description":"\"Any process that decreases the rate, frequency or extent of pollen tube guidance towards ovules. This is one mechanism to prevent polytuby, the simultaneous penetration of ovules by multiple pollen tubes.\" [PMID:33790463]","metadata":null},{"id":"cbe14a2847934efb84de553518d023ca","type":"GO_TERM","name":"negative regulation of polyamine biosynthetic process","canonical_id":"go:GO:0170066","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of polyamine biosynthesis. Polyamine biosynthesis is the chemical reactions and pathways resulting in the formation of polyamines, any organic compound containing two or more amino groups.\" [PMID:9769097]","metadata":null},{"id":"ca789f7d1ed84695a0f690db8c88a3eb","type":"GO_TERM","name":"negative regulation of polyamine transmembrane transport","canonical_id":"go:GO:1902268","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of polyamine transmembrane transport.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"9d5b0b4ba11b4ea0b63da90d3bcfa76f","type":"GO_TERM","name":"negative regulation of polyketide biosynthetic process","canonical_id":"go:GO:1900733","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of polyketide biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1d95ae36b54e4bbf9ec87364669bc437","type":"GO_TERM","name":"negative regulation of polynucleotide adenylyltransferase activity","canonical_id":"go:GO:1904246","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of polynucleotide adenylyltransferase activity.\" [GO_REF:0000059, GOC:kmv, GOC:TermGenie, PMID:19460348]","metadata":null},{"id":"922aa2e91434469d8f21b90043839d25","type":"GO_TERM","name":"negative regulation of positive chemotaxis","canonical_id":"go:GO:0050928","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"71a5470964e6442aba0fbbf8a9b623fd","type":"GO_TERM","name":"negative regulation of positive chemotaxis to cAMP","canonical_id":"go:GO:0061123","description":"\"Any process that decreases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP.\" [GOC:dph]","metadata":null},{"id":"eccf561174b745d0aadd789d669f90a8","type":"GO_TERM","name":"negative regulation of positive chemotaxis to cAMP by DIF-1","canonical_id":"go:GO:0061127","description":"\"Any process that decreases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of DIF-1. DIF-1 is a chlorinated alkylphenone.\" [GOC:dph]","metadata":null},{"id":"bfb644493a6543aa9e260be7b33d1bec","type":"GO_TERM","name":"negative regulation of positive chemotaxis to cAMP by DIF-2","canonical_id":"go:GO:0061129","description":"\"Any process that decreases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of DIF-2. DIF-2 is a chlorinated alkylphenone.\" [GOC:dph]","metadata":null},{"id":"a67350806767429cad2d69fe7d9341e6","type":"GO_TERM","name":"negative regulation of positive chemotaxis to cAMP by chlorinated alkylphenone","canonical_id":"go:GO:0061125","description":"\"Any process that decreases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of a chlorinated alkylphenone. An alkylphenone is an aromatic polyketide with methyl and chlorine substitutions.\" [GOC:dph]","metadata":null},{"id":"f97226a457e54ced836805d4120308ba","type":"GO_TERM","name":"negative regulation of positive thymic T cell selection","canonical_id":"go:GO:1902233","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of positive thymic T cell selection.\" [GOC:TermGenie, PMID:22080863]","metadata":null},{"id":"f71a95a53a8c43db9c4fdb1f51760225","type":"GO_TERM","name":"negative regulation of post-embryonic development","canonical_id":"go:GO:0048581","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of post-embryonic development. Post-embryonic development is defined as the process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure.\" [GOC:jid]","metadata":null},{"id":"f54672ee1d8c4b2b8c3aabf3811e18f2","type":"GO_TERM","name":"negative regulation of post-transcriptional gene silencing","canonical_id":"go:GO:0060149","description":"\"Any process that decreases the frequency, rate or extent of the inactivation of gene expression by a posttranscriptional mechanism.\" [GOC:dph]","metadata":null},{"id":"cb6c2790680146b8a1ef5464e7386bf9","type":"GO_TERM","name":"negative regulation of post-transcriptional gene silencing by regulatory ncRNA","canonical_id":"go:GO:1900369","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of post-transcriptional gene silencing by RNA.\" [GOC:kmv, GOC:TermGenie, PMID:22412382]","metadata":null},{"id":"d02ca97f98c140ac837df93db91442d5","type":"GO_TERM","name":"negative regulation of post-translational protein modification","canonical_id":"go:GO:1901874","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of post-translational protein modification.\" [GOC:TermGenie, GOC:yaf, PMID:21209915]","metadata":null},{"id":"f3ba0db5254c4893935dacb594ae4081","type":"GO_TERM","name":"negative regulation of post-translational protein targeting to membrane, translocation","canonical_id":"go:GO:0120236","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of posttranslational protein translocation through the ER membrane.\" [GOC:krc, GOC:rn, PMID:32513868]","metadata":null},{"id":"e428470ec6ed47bb88ca7a9b108c1e92","type":"GO_TERM","name":"negative regulation of postsynaptic density assembly","canonical_id":"go:GO:0160037","description":"\"Any process that decreases the rate, frequency, or extent of postsynaptic density assembly.\" [PMID:17626212]","metadata":null},{"id":"6894bdc89633430b92afc235d5d5639e","type":"GO_TERM","name":"negative regulation of postsynaptic density organization","canonical_id":"go:GO:1905875","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of postsynaptic density organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:21887379]","metadata":null},{"id":"61785119ebc341ffaccd87a119d08e70","type":"GO_TERM","name":"negative regulation of postsynaptic membrane organization","canonical_id":"go:GO:1901627","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of postsynaptic membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"238656f3e21e4d1eafe2782e042fa75f","type":"GO_TERM","name":"negative regulation of potassium ion export across plasma membrane","canonical_id":"go:GO:1903765","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of potassium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:19646991]","metadata":null},{"id":"a80555d0b3e84984ad55a170a09a099f","type":"GO_TERM","name":"negative regulation of potassium ion import across plasma membrane","canonical_id":"go:GO:1903287","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of potassium ion import across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:10636900]","metadata":null},{"id":"1676d8967b284228918895e7fe10b77d","type":"GO_TERM","name":"negative regulation of potassium ion transmembrane transport","canonical_id":"go:GO:1901380","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of potassium ion transmembrane transport.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"4d6068ff615a47f497a988f103bdbd25","type":"GO_TERM","name":"negative regulation of potassium ion transmembrane transporter activity","canonical_id":"go:GO:1901017","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of potassium ion transmembrane transporter activity.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"58788cce9cb646b58eb20943b1f8f5b3","type":"GO_TERM","name":"negative regulation of potassium ion transport","canonical_id":"go:GO:0043267","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"a720211c2f6c47eba0a7d71af9ce2ac6","type":"GO_TERM","name":"negative regulation of pre-B cell receptor expression","canonical_id":"go:GO:0140646","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the process leading up to expression of the pre-B cell receptor on the surface of pre-B cells.\" [PMID:22949502]","metadata":null},{"id":"81f4088bcf12464e812e0ecf4bf83577","type":"GO_TERM","name":"negative regulation of pre-miRNA processing","canonical_id":"go:GO:2000632","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pre-microRNA processing.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"af99103de3ea4718b0aa0fb93b2e9477","type":"GO_TERM","name":"negative regulation of preblastoderm mitotic cell cycle","canonical_id":"go:GO:0046001","description":"\"Any process that stops, prevents or reduces the rate or extent of progression through the preblastoderm mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"4e27a3593a98442e8ef79987f2d202ae","type":"GO_TERM","name":"negative regulation of premature acrosome loss","canonical_id":"go:GO:0061950","description":"\"Any process that stops, prevents or reduces the discharge, by sperm, of a single, anterior secretory granule before the sperm reaches to the zona pellucida of the oocyte. The process begins with the fusion of the outer acrosomal membrane with the sperm plasma membrane and ends with the exocytosis of the acrosomal contents.\" [PMID:22228629, PMID:23430248]","metadata":null},{"id":"fd1c26bc7ffd490487e12fcf00aca1b9","type":"GO_TERM","name":"negative regulation of presynapse assembly","canonical_id":"go:GO:1905607","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of presynapse assembly.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:25533483]","metadata":null},{"id":"4ec2b53894fd4b37914c4ca9562b8634","type":"GO_TERM","name":"negative regulation of presynaptic active zone assembly","canonical_id":"go:GO:1905519","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of presynaptic active zone assembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15797875]","metadata":null},{"id":"ca2dd75977e44f6babe5249b1c0961fb","type":"GO_TERM","name":"negative regulation of presynaptic cytosolic calcium concentration","canonical_id":"go:GO:0099113","description":"\"Any process that decreases the concentration of calcium ions in the presynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"781a57b95fff416f93058cd7428d8d57","type":"GO_TERM","name":"negative regulation of presynaptic membrane organization","canonical_id":"go:GO:1901630","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of presynaptic membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"14e3d2dcb6ad4bfda27fa0224fa0520c","type":"GO_TERM","name":"negative regulation of primary cell septum biogenesis","canonical_id":"go:GO:1905757","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of primary cell septum biogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:27898700]","metadata":null},{"id":"b17797dbd5f1419781dc90df4bdb38d2","type":"GO_TERM","name":"negative regulation of primary miRNA processing","canonical_id":"go:GO:2000635","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of primary microRNA processing.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"f2d3de0cd6ea4e4199c21e2a633690af","type":"GO_TERM","name":"negative regulation of pro-B cell differentiation","canonical_id":"go:GO:2000974","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pro-B cell differentiation.\" [GOC:obol]","metadata":null},{"id":"7a367f0025a94a4782ed1cf7d0b76728","type":"GO_TERM","name":"negative regulation of pro-T cell differentiation","canonical_id":"go:GO:2000175","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pro-T cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"ef06079a99d64d56909d65bf44310c2b","type":"GO_TERM","name":"negative regulation of production of molecular mediator of immune response","canonical_id":"go:GO:0002701","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the production of molecular mediator of immune response.\" [GOC:add]","metadata":null},{"id":"09f634223a704fc0a1bd472160d0c829","type":"GO_TERM","name":"negative regulation of progesterone biosynthetic process","canonical_id":"go:GO:2000183","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of progesterone biosynthetic process.\" [GOC:dph]","metadata":null},{"id":"acc449577683421796718ab5e10f6620","type":"GO_TERM","name":"negative regulation of progesterone secretion","canonical_id":"go:GO:2000871","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of progesterone secretion.\" [GOC:sl]","metadata":null},{"id":"cac33361dc654dd6a013491a97a0583f","type":"GO_TERM","name":"negative regulation of programmed cell death","canonical_id":"go:GO:0043069","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of programmed cell death, cell death resulting from activation of endogenous cellular processes.\" [GOC:jl]","metadata":null},{"id":"a48ae55362ce447997eb03d5582d9fff","type":"GO_TERM","name":"negative regulation of programmed necrotic cell death","canonical_id":"go:GO:0062099","description":"\"Any process that decreases the frequency, rate or extent of programmed necrotic cell death.\" [GOC:aruk, GOC:rph, PMID:27258785]","metadata":null},{"id":"8f83c0ea3dee47b98754e580fa3eefd9","type":"GO_TERM","name":"negative regulation of prolactin secretion","canonical_id":"go:GO:1902721","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of prolactin secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:16159377]","metadata":null},{"id":"8fc4ce5aba924bf8b542fc04f04e81bd","type":"GO_TERM","name":"negative regulation of prolactin signaling pathway","canonical_id":"go:GO:1902212","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of prolactin signaling pathway.\" [GOC:TermGenie, PMID:11773439]","metadata":null},{"id":"f4a0240d41d34e86a56d14d55e65cff7","type":"GO_TERM","name":"negative regulation of proline import across plasma membrane","canonical_id":"go:GO:1902835","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of proline import into cell.\" [GO_REF:0000058, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"3f5168fdc2b0438abfdba982ba589a7d","type":"GO_TERM","name":"negative regulation of promoter clearance from RNA polymerase II promoter","canonical_id":"go:GO:0140847","description":"\"A process that stops, prevents or reduces the transition from the initiation to the elongation phases of transcription by RNA polymerase II.\" [PMID:28248323]","metadata":null},{"id":"150365141fad456f9849a169dcc03f86","type":"GO_TERM","name":"negative regulation of pronephric nephron tubule development","canonical_id":"go:GO:1900207","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pronephric nephron tubule development.\" [GOC:bf, GOC:TermGenie, PMID:9758706]","metadata":null},{"id":"50a312bc665340dd99c6039512ba20a0","type":"GO_TERM","name":"negative regulation of prostaglandin biosynthetic process","canonical_id":"go:GO:0031393","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.\" [GOC:mah]","metadata":null},{"id":"e21326778d424ac48f10267e856247f5","type":"GO_TERM","name":"negative regulation of prostaglandin catabolic process","canonical_id":"go:GO:1905829","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of prostaglandin catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:12432938]","metadata":null},{"id":"ae72eeb76dad48c8905767b077460443","type":"GO_TERM","name":"negative regulation of prostaglandin secretion","canonical_id":"go:GO:0032307","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a prostaglandin from a cell.\" [GOC:mah]","metadata":null},{"id":"ab91da7769cb4a20a0501a9427bddb51","type":"GO_TERM","name":"negative regulation of prostatic bud formation","canonical_id":"go:GO:0060686","description":"\"Any process that decreases the rate, frequency, or extent of prostatic bud formation, the morphogenetic process in which a region of the fetal urogenital sinus epithelium is specified to become the prostate, resulting in prostate bud outgrowth.\" [GOC:dph]","metadata":null},{"id":"b52a04e4aa3143b9a5a28a4984799865","type":"GO_TERM","name":"negative regulation of proteasomal protein catabolic process","canonical_id":"go:GO:1901799","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21669198]","metadata":null},{"id":"5ec4f82796ec46a48667fa430f376db9","type":"GO_TERM","name":"negative regulation of proteasomal ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0032435","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.\" [GOC:mah]","metadata":null},{"id":"0959991192e7400c97052ee758135bbd","type":"GO_TERM","name":"negative regulation of protection from non-homologous end joining at telomere","canonical_id":"go:GO:1905765","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protection from non-homologous end joining at telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:14690602]","metadata":null},{"id":"5d7a9800f81d47a7b7c7646b36150d35","type":"GO_TERM","name":"negative regulation of protein ADP-ribosylation","canonical_id":"go:GO:0010836","description":"\"Any process that decreases the frequency, rate or extent of protein ADP-ribosylation. Protein ADP-ribosylation is the transfer, from NAD, of ADP-ribose to protein amino acids.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"cf674144f25f4808b10c349ef952a614","type":"GO_TERM","name":"negative regulation of protein K48-linked deubiquitination","canonical_id":"go:GO:1903094","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein K48-linked deubiquitination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21097510]","metadata":null},{"id":"15bdca35dee645fd82407a2a8e463c88","type":"GO_TERM","name":"negative regulation of protein K48-linked ubiquitination","canonical_id":"go:GO:0061944","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of K48-linked ubiquitination, a protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is added to a protein. K48-linked ubiquitination targets the substrate protein for degradation.\" [GOC:BHF, GOC:rph, PMID:23460740]","metadata":null},{"id":"33827ea2ffbf4252b160908853688cf7","type":"GO_TERM","name":"negative regulation of protein K63-linked deubiquitination","canonical_id":"go:GO:1903005","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein K63-linked deubiquitination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22970133]","metadata":null},{"id":"0bae8390b6f94d84bc5d65b91e623a1b","type":"GO_TERM","name":"negative regulation of protein K63-linked ubiquitination","canonical_id":"go:GO:1900045","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein K63-linked ubiquitination.\" [GOC:TermGenie]","metadata":null},{"id":"f0e6ea6112a84aeca02f9efe76d6854c","type":"GO_TERM","name":"negative regulation of protein O-linked glycosylation","canonical_id":"go:GO:1904099","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein O-linked glycosylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24509081]","metadata":null},{"id":"3365f245762e4f11a9571cfddc0df03b","type":"GO_TERM","name":"negative regulation of protein acetylation","canonical_id":"go:GO:1901984","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein acetylation.\" [GOC:TermGenie, PMID:22117195]","metadata":null},{"id":"3a10d07f4a654a2698d200baa35d04f4","type":"GO_TERM","name":"negative regulation of protein activation cascade","canonical_id":"go:GO:2000258","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein activation cascade.\" [GOC:mah]","metadata":null},{"id":"0e38e77986e84dd594a06a02e6f9629b","type":"GO_TERM","name":"negative regulation of protein adenylylation","canonical_id":"go:GO:1900723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein adenylylation.\" [GOC:TermGenie]","metadata":null},{"id":"0ca59fe025614a0886fa7236317c2aba","type":"GO_TERM","name":"negative regulation of protein autophosphorylation","canonical_id":"go:GO:0031953","description":"\"Any process that stops, prevents or decreases the rate of the phosphorylation by a protein of one or more of its own residues.\" [GOC:mah]","metadata":null},{"id":"776f565ef3464740a99f62b0aaed9478","type":"GO_TERM","name":"negative regulation of protein autoubiquitination","canonical_id":"go:GO:1905524","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein autoubiquitination.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:17237821]","metadata":null},{"id":"9b080088f6ef4e57ad093a778f4f3495","type":"GO_TERM","name":"negative regulation of protein binding","canonical_id":"go:GO:0032091","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein binding.\" [GOC:mah]","metadata":null},{"id":"9360defbadcb4ede8d86d87454a3dcbb","type":"GO_TERM","name":"negative regulation of protein catabolic process","canonical_id":"go:GO:0042177","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein catabolic process.\" [GO_REF:0000058, GOC:kmv, GOC:obol, GOC:TermGenie, PMID:24785082]","metadata":null},{"id":"3d783890727d4447a243e0088a551366","type":"GO_TERM","name":"negative regulation of protein catabolic process in the vacuole","canonical_id":"go:GO:1904351","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein catabolic process in the vacuole.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:25635054]","metadata":null},{"id":"6aaa756a105a4ee6a7d46bbd0c8a19cd","type":"GO_TERM","name":"negative regulation of protein depolymerization","canonical_id":"go:GO:1901880","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein depolymerization.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12032137]","metadata":null},{"id":"87ad669d1d9047eb8053da551fc63825","type":"GO_TERM","name":"negative regulation of protein desumoylation","canonical_id":"go:GO:0060190","description":"\"Any process that decreases the frequency, rate or extent of protein desumoylation. Protein desumoylation is the process in which a SUMO protein (small ubiquitin-related modifier) is cleaved from its target protein.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d881b2a94e1c42c6a471f40e0d2aa16f","type":"GO_TERM","name":"negative regulation of protein deubiquitination","canonical_id":"go:GO:0090086","description":"\"Any process that decreases the frequency, rate or extent of protein deubiquitination. Protein deubiquitination is the removal of one or more ubiquitin groups from a protein.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"20ff407a13064e7c9f289033b5aa5c46","type":"GO_TERM","name":"negative regulation of protein export from nucleus","canonical_id":"go:GO:0046826","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of proteins from the nucleus into the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"3415e177c4864664979d52c022c618b1","type":"GO_TERM","name":"negative regulation of protein folding","canonical_id":"go:GO:1903333","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein folding.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"7ae451b7f4f94e8c97ad8cecec5e0245","type":"GO_TERM","name":"negative regulation of protein geranylgeranylation","canonical_id":"go:GO:2000540","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein geranylgeranylation.\" [GOC:obol]","metadata":null},{"id":"c3701ea5bc1d48b09a990fbb40dc771f","type":"GO_TERM","name":"negative regulation of protein glutathionylation","canonical_id":"go:GO:0010734","description":"\"Any process that decreases the rate, frequency, or extent of protein glutathionylation. Protein glutathionylation is the protein modification process in which a glutathione molecule is added to a protein amino acid through a disulfide linkage.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"2f18681b06db481d988992402010d78f","type":"GO_TERM","name":"negative regulation of protein homooligomerization","canonical_id":"go:GO:0032463","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein homooligomerization.\" [GOC:mah]","metadata":null},{"id":"96a37dac124d46c2bb1ace6b91ba3cb4","type":"GO_TERM","name":"negative regulation of protein homotetramerization","canonical_id":"go:GO:1901094","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein homotetramerization.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"cf7ef25503f14b09bb72c3784dd7a69d","type":"GO_TERM","name":"negative regulation of protein import","canonical_id":"go:GO:1904590","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein import.\" [GO_REF:0000058, GOC:TermGenie, PMID:11406629]","metadata":null},{"id":"d0da595439824fafb18e6fe734397d05","type":"GO_TERM","name":"negative regulation of protein import into nucleus","canonical_id":"go:GO:0042308","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the movement of proteins from the cytoplasm into the nucleus.\" [GOC:jl]","metadata":null},{"id":"a24261bd11a74ab69ef15e3d32e05b58","type":"GO_TERM","name":"negative regulation of protein import into nucleus during spindle assembly checkpoint","canonical_id":"go:GO:1901925","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the movement of proteins from the cytoplasm into the nucleus, and that occurs as a response to the mitotic cell cycle spindle assembly checkpoint. In S. cerevisiae, this process involves inhibition of the karyopherin/importin Kap121p (also known as Pse1p), which acts as the specific nuclear import receptor for several proteins, including Glc7p. Glc7p functions in opposition to key spindle assembly checkpoint protein Aurora kinase (Ipl1p).\" [GOC:dgf, GOC:TermGenie, PMID:23177738]","metadata":null},{"id":"aab30289ddac451680b4c6a74538155f","type":"GO_TERM","name":"negative regulation of protein kinase C signaling","canonical_id":"go:GO:0090038","description":"\"Any process that decreases the frequency, rate, or extent of a series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7750116cbd784b34a7a36929ef926bf1","type":"GO_TERM","name":"negative regulation of protein kinase activity","canonical_id":"go:GO:0006469","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase activity.\" [GOC:curators]","metadata":null},{"id":"c4e7c45af728472a9f12844cdf8133ff","type":"GO_TERM","name":"negative regulation of protein kinase activity by regulation of protein phosphorylation","canonical_id":"go:GO:0044387","description":"\"The stopping, prevention, or reduction in frequency, rate or extent of protein kinase activity as a result of regulating the phosphorylation status of that protein kinase.\" [GOC:jl]","metadata":null},{"id":"82d61b5de277472890265aaf38eaaca7","type":"GO_TERM","name":"negative regulation of protein linear polyubiquitination","canonical_id":"go:GO:1902529","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein linear polyubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"158f2d615a7045c7aca7e1a965cdd40b","type":"GO_TERM","name":"negative regulation of protein lipidation","canonical_id":"go:GO:1903060","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein lipidation.\" [GO_REF:0000058, GOC:rph, GOC:TermGenie, PMID:21909394]","metadata":null},{"id":"1328dad33f1f41b6836800429dff279f","type":"GO_TERM","name":"negative regulation of protein localization","canonical_id":"go:GO:1903828","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a protein localization.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"17207947f7274a648e10837e0e496835","type":"GO_TERM","name":"negative regulation of protein localization to Cajal body","canonical_id":"go:GO:1904870","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to Cajal body.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"e1cb0af2285b417db6afb973554ab316","type":"GO_TERM","name":"negative regulation of protein localization to actin cortical patch","canonical_id":"go:GO:1904371","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to actin cortical patch.\" [GO_REF:0000058, GOC:TermGenie, PMID:18216290]","metadata":null},{"id":"8e1eff19dc374f20a5859294c979463c","type":"GO_TERM","name":"negative regulation of protein localization to adherens junction","canonical_id":"go:GO:1904703","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:kmv, GOC:TermGenie, PMID:26412237]","metadata":null},{"id":"5ee6e27ae3a1464486bbe0f6f98312d3","type":"GO_TERM","name":"negative regulation of protein localization to basolateral plasma membrane","canonical_id":"go:GO:1904509","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to basolateral plasma membrane.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26115433]","metadata":null},{"id":"49c369d7581940939f6dc096a7f06887","type":"GO_TERM","name":"negative regulation of protein localization to cell cortex","canonical_id":"go:GO:1904777","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell cortex.\" [GO_REF:0000058, GOC:TermGenie, PMID:17115027]","metadata":null},{"id":"523743bce5f549de8f59d9534e2455cd","type":"GO_TERM","name":"negative regulation of protein localization to cell cortex of cell tip","canonical_id":"go:GO:0106013","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to the cell cortex of the cell tip.\" [GOC:vw, PMID:19474792]","metadata":null},{"id":"568d6387c4e5491b992e756f82da4387","type":"GO_TERM","name":"negative regulation of protein localization to cell leading edge","canonical_id":"go:GO:1905872","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell leading edge.\" [GO_REF:0000058, GOC:TermGenie, PMID:26324884]","metadata":null},{"id":"1d0a96c4eac8463fb650d17c352c5c33","type":"GO_TERM","name":"negative regulation of protein localization to cell periphery","canonical_id":"go:GO:1904376","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell periphery.\" [GO_REF:0000058, GOC:TermGenie, PMID:18216290]","metadata":null},{"id":"91a5cb5e096c468680765e70e80b6acb","type":"GO_TERM","name":"negative regulation of protein localization to cell surface","canonical_id":"go:GO:2000009","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein localization to the cell surface.\" [GOC:obol]","metadata":null},{"id":"a1ddb062484d44cf9ba9b8d42ac93c64","type":"GO_TERM","name":"negative regulation of protein localization to cell tip","canonical_id":"go:GO:1903067","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell tip.\" [GO_REF:0000058, GOC:TermGenie, PMID:24554432]","metadata":null},{"id":"2437177fd3e545138d41176a8d927437","type":"GO_TERM","name":"negative regulation of protein localization to cell-cell junction","canonical_id":"go:GO:0150119","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cell-cell junction.\" [GOC:aruk, GOC:bc]","metadata":null},{"id":"a9c17359716e44d5b03ec7b6dfb9ec97","type":"GO_TERM","name":"negative regulation of protein localization to centrosome","canonical_id":"go:GO:1904780","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to centrosome.\" [GO_REF:0000058, GOC:TermGenie, PMID:17115027]","metadata":null},{"id":"dfb9fb55662c4380a5fe3c7c358ac6a2","type":"GO_TERM","name":"negative regulation of protein localization to chromatin","canonical_id":"go:GO:0120186","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein localization to chromatin.\" [PMID:20889714, PMID:29899453]","metadata":null},{"id":"54ee2fe626364cb29c52613bc2aba083","type":"GO_TERM","name":"negative regulation of protein localization to chromosome, telomeric region","canonical_id":"go:GO:1904815","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to chromosome, telomeric region.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:19487455]","metadata":null},{"id":"dad5e3b53aeb4de49f66762302349d57","type":"GO_TERM","name":"negative regulation of protein localization to ciliary membrane","canonical_id":"go:GO:1903568","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to ciliary membrane.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22072986]","metadata":null},{"id":"5e944a91f2b1440b8273d6df3cd6b628","type":"GO_TERM","name":"negative regulation of protein localization to cilium","canonical_id":"go:GO:1903565","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to cilium.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22072986]","metadata":null},{"id":"fa3cf48093b74eb7942e0c553bb15af7","type":"GO_TERM","name":"negative regulation of protein localization to endoplasmic reticulum","canonical_id":"go:GO:1905551","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to endoplasmic reticulum.\" [GO_REF:0000058, GOC:TermGenie, PMID:22768340]","metadata":null},{"id":"a0069a9c95b24e798feed2d33d4ad478","type":"GO_TERM","name":"negative regulation of protein localization to endosome","canonical_id":"go:GO:1905667","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to endosome.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:22732145]","metadata":null},{"id":"b90fa79f8f0a4155844e2734b14e69fd","type":"GO_TERM","name":"negative regulation of protein localization to kinetochore","canonical_id":"go:GO:1905341","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to kinetochore.\" [GO_REF:0000058, GOC:TermGenie, PMID:22581055]","metadata":null},{"id":"1ee2c404744c46658b56aa2688e29adc","type":"GO_TERM","name":"negative regulation of protein localization to lysosome","canonical_id":"go:GO:0150033","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to lysosome.\" [GOC:aruk, GOC:bc, PMID:24305806]","metadata":null},{"id":"180f363682ae4d32b9b7664e1955a7f3","type":"GO_TERM","name":"negative regulation of protein localization to medial cortex","canonical_id":"go:GO:0140325","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to the medial cortex.\" [PMID:30853434]","metadata":null},{"id":"1bd826a686904147938a5f00f9167006","type":"GO_TERM","name":"negative regulation of protein localization to meiotic spindle pole body","canonical_id":"go:GO:0140435","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to a meiotic spindle pole body.\" [PMID:22438582]","metadata":null},{"id":"51ac3d8ff4264bda97159ad960892639","type":"GO_TERM","name":"negative regulation of protein localization to membrane","canonical_id":"go:GO:1905476","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to membrane.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"00c7f30fde01401ea8b7cc171f8b513d","type":"GO_TERM","name":"negative regulation of protein localization to microtubule","canonical_id":"go:GO:1902817","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to microtubule.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw, PMID:23087209]","metadata":null},{"id":"740c490449ea4c818aba48525e322f01","type":"GO_TERM","name":"negative regulation of protein localization to mitochondrion","canonical_id":"go:GO:1903748","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to mitochondrion.\" [GO_REF:0000058, GOC:TermGenie, PMID:16857185]","metadata":null},{"id":"03e270772e734555be56f95b699c64dc","type":"GO_TERM","name":"negative regulation of protein localization to mitotic spindle pole body","canonical_id":"go:GO:1902543","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to mitotic spindle pole body.\" [GOC:TermGenie, PMID:22809626]","metadata":null},{"id":"f34a5305dd1348de993df0a801af05fe","type":"GO_TERM","name":"negative regulation of protein localization to non-growing cell tip","canonical_id":"go:GO:0062108","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to a non-growing cell tip.\" [PMID:18328707]","metadata":null},{"id":"51feedd24d7943f2a93f403685b95176","type":"GO_TERM","name":"negative regulation of protein localization to nucleolus","canonical_id":"go:GO:1904750","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to nucleolus.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24415760]","metadata":null},{"id":"3957249da20646d48915877e61b89f86","type":"GO_TERM","name":"negative regulation of protein localization to nucleus","canonical_id":"go:GO:1900181","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to nucleus.\" [GOC:TermGenie]","metadata":null},{"id":"22ee4eac01e7430c9fba9e6529f5758d","type":"GO_TERM","name":"negative regulation of protein localization to phagocytic vesicle","canonical_id":"go:GO:1905170","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to phagocytic vesicle.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"ac6b4476517b422c848dd03c2f142ae7","type":"GO_TERM","name":"negative regulation of protein localization to plasma membrane","canonical_id":"go:GO:1903077","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11602640]","metadata":null},{"id":"1f03433e86a74363a175128c55c694a0","type":"GO_TERM","name":"negative regulation of protein localization to presynapse","canonical_id":"go:GO:1905385","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to presynapse.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24449494]","metadata":null},{"id":"d4f20bbed83d486ab587ead59efeb800","type":"GO_TERM","name":"negative regulation of protein localization to spindle pole body","canonical_id":"go:GO:1902364","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein localization to spindle pole body.\" [GOC:TermGenie, PMID:21131906]","metadata":null},{"id":"b3cb0b5ceda343059f120647b843b163","type":"GO_TERM","name":"negative regulation of protein maturation","canonical_id":"go:GO:1903318","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein maturation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"21d2ce9452bd443abf825d2ebef617bc","type":"GO_TERM","name":"negative regulation of protein metabolic process","canonical_id":"go:GO:0051248","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of chemical reactions and pathways involving a protein.\" [GOC:ai]","metadata":null},{"id":"c905b48d56e743cfb881d27cd8e7adb2","type":"GO_TERM","name":"negative regulation of protein modification by small protein conjugation or removal","canonical_id":"go:GO:1903321","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein modification by small protein conjugation or removal.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"7999856963d14642aab93ef6658ef7d7","type":"GO_TERM","name":"negative regulation of protein modification process","canonical_id":"go:GO:0031400","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the covalent alteration of one or more amino acid residues within a protein.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"e444c3363d3445f19b9bb27f7522a6e9","type":"GO_TERM","name":"negative regulation of protein monoubiquitination","canonical_id":"go:GO:1902526","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein monoubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"401986312aba45fd957188db40c07334","type":"GO_TERM","name":"negative regulation of protein neddylation","canonical_id":"go:GO:2000435","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein neddylation.\" [GOC:obol]","metadata":null},{"id":"3efca94120d64a7fa801843c079b98c5","type":"GO_TERM","name":"negative regulation of protein oligomerization","canonical_id":"go:GO:0032460","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein oligomerization.\" [GOC:mah]","metadata":null},{"id":"778df71fb28a420893db3af8c1ab61ca","type":"GO_TERM","name":"negative regulation of protein oxidation","canonical_id":"go:GO:1904807","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein oxidation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22719267]","metadata":null},{"id":"3e34e56cd5fc44e8be342e5ba00ddc91","type":"GO_TERM","name":"negative regulation of protein phosphorylation","canonical_id":"go:GO:0001933","description":"\"Any process that stops, prevents or reduces the rate of addition of phosphate groups to amino acids within a protein.\" [GOC:hjd]","metadata":null},{"id":"4ee47dd243cd4cf0969740ac252eb49c","type":"GO_TERM","name":"negative regulation of protein polyglycylation","canonical_id":"go:GO:1903345","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein polyglycylation.\" [GO_REF:0000058, GOC:sart, GOC:TermGenie]","metadata":null},{"id":"d5c4797b9024454788ab1bb7ecc50320","type":"GO_TERM","name":"negative regulation of protein polymerization","canonical_id":"go:GO:0032272","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the process of creating protein polymers.\" [GOC:mah]","metadata":null},{"id":"d0a0377e7b7642a3ab19f2141e48ca0e","type":"GO_TERM","name":"negative regulation of protein polyubiquitination","canonical_id":"go:GO:1902915","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein polyubiquitination.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:23645667]","metadata":null},{"id":"d1ecad5a3c484ad798f6888a50b26202","type":"GO_TERM","name":"negative regulation of protein processing","canonical_id":"go:GO:0010955","description":"\"Any process that decreases the rate, frequency or extent of protein maturation by peptide bond cleavage.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"9e13b636b5594b3795b2b1a96f0bc4a4","type":"GO_TERM","name":"negative regulation of protein processing in phagocytic vesicle","canonical_id":"go:GO:1903922","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein processing in phagocytic vesicle.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23325791]","metadata":null},{"id":"d921e42a45ad45ab85a35361f3146c04","type":"GO_TERM","name":"negative regulation of protein refolding","canonical_id":"go:GO:0061084","description":"\"Any process that decreases the rate, frequency, or extent of protein refolding. Protein refolding is the process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"009d4aab496747d981105d3c1b6aae11","type":"GO_TERM","name":"negative regulation of protein secretion","canonical_id":"go:GO:0050709","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a protein from a cell.\" [GOC:ai]","metadata":null},{"id":"8e29269fa3844fe287d5fe8dcdf1f73d","type":"GO_TERM","name":"negative regulation of protein serine/threonine kinase activity","canonical_id":"go:GO:0071901","description":"\"Any process that decreases the rate, frequency, or extent of protein serine/threonine kinase activity.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"3d2eea6f0f85493a918a4a7709ed3cd5","type":"GO_TERM","name":"negative regulation of protein sumoylation","canonical_id":"go:GO:0033234","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of SUMO groups to a protein.\" [GOC:mah]","metadata":null},{"id":"48c0ad9eabae4bd69b7a0336d6886c3f","type":"GO_TERM","name":"negative regulation of protein targeting to membrane","canonical_id":"go:GO:0090315","description":"\"Any process that decreases the frequency, rate or extent of the process of directing proteins towards a membrane, usually using signals contained within the protein.\" [GOC:tb]","metadata":null},{"id":"2e8de5694b3e4e2ca0647bd8587dd534","type":"GO_TERM","name":"negative regulation of protein targeting to vacuolar membrane","canonical_id":"go:GO:1900484","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein targeting to vacuolar membrane.\" [GOC:TermGenie]","metadata":null},{"id":"027bf947a5cc4a4a97d8dc2453f0b64c","type":"GO_TERM","name":"negative regulation of protein tetramerization","canonical_id":"go:GO:1901091","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein tetramerization.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"a8fa82f2d330463ea29ec67d64eab1b6","type":"GO_TERM","name":"negative regulation of protein transport","canonical_id":"go:GO:0051224","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a protein into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"5ab02f02b0234aafadbf83c77a8d972e","type":"GO_TERM","name":"negative regulation of protein tyrosine kinase activity","canonical_id":"go:GO:0061099","description":"\"Any process that decreases the rate, frequency, or extent of protein tyrosine kinase activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"635f23301d824b158ab5268aa23c961b","type":"GO_TERM","name":"negative regulation of protein ubiquitination","canonical_id":"go:GO:0031397","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of ubiquitin groups to a protein.\" [GOC:mah]","metadata":null},{"id":"5cb28d60923e49389dbe9934eb1c248a","type":"GO_TERM","name":"negative regulation of protein-containing complex assembly","canonical_id":"go:GO:0031333","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly.\" [GOC:mah]","metadata":null},{"id":"9fe675f5530f47f9af914328ed2f9a16","type":"GO_TERM","name":"negative regulation of protein-containing complex disassembly","canonical_id":"go:GO:0043242","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex disassembly, the disaggregation of a protein complex into its constituent components.\" [GOC:jl]","metadata":null},{"id":"58302da592b749729c2d694aee292cd9","type":"GO_TERM","name":"negative regulation of protein-pyridoxal-5-phosphate linkage","canonical_id":"go:GO:1904286","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of protein-pyridoxal-5-phosphate linkage.\" [GO_REF:0000058, GOC:TermGenie, PMID:25957689]","metadata":null},{"id":"4224e658b26b47509908430690ecdd53","type":"GO_TERM","name":"negative regulation of proteoglycan biosynthetic process","canonical_id":"go:GO:1902729","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteoglycans, any glycoprotein in which the carbohydrate units are glycosaminoglycans.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"e5a84e897f0b41b9a5fe7ac2a9e29160","type":"GO_TERM","name":"negative regulation of proteolysis","canonical_id":"go:GO:0045861","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.\" [GOC:curators]","metadata":null},{"id":"b0ce8404556346188ffd12c4cbb66a67","type":"GO_TERM","name":"negative regulation of proteolysis associated with antigen processing and presentation","canonical_id":"go:GO:0002629","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of proteolysis associated with antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"63ada32adcf0410f99bfa05dd85e317f","type":"GO_TERM","name":"negative regulation of pseudohyphal growth","canonical_id":"go:GO:2000221","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pseudohyphal growth.\" [GOC:mah]","metadata":null},{"id":"4e85570f90ca43edb730a6b1b668f656","type":"GO_TERM","name":"negative regulation of pseudohyphal septin ring assembly","canonical_id":"go:GO:0062166","description":"\"Any process that decreases the rate, frequency or extent of pseudohyphal septin ring assembly.\" [PMID:29567712]","metadata":null},{"id":"9ebd947d5d98479db14d553ba790cb10","type":"GO_TERM","name":"negative regulation of pseudopodium assembly","canonical_id":"go:GO:0031273","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly of pseudopodia.\" [GOC:pg]","metadata":null},{"id":"4ab44388e2a04a8298d914c9b7d68544","type":"GO_TERM","name":"negative regulation of pseurotin A biosynthetic process","canonical_id":"go:GO:1900850","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pseurotin A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"55968b74e95d459c9d37c9e48bcc9615","type":"GO_TERM","name":"negative regulation of pulmonary blood vessel remodeling","canonical_id":"go:GO:1905110","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pulmonary blood vessel remodeling.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22161164]","metadata":null},{"id":"65aaafb34ce44498bf23a2d77003772c","type":"GO_TERM","name":"negative regulation of pupariation","canonical_id":"go:GO:0106024","description":"\"Any process that stops, prevents or reduces the rate of onset of pupariation.\" [PMID:26510564]","metadata":null},{"id":"fb22e86e96f74127b11539f0502739cf","type":"GO_TERM","name":"negative regulation of purine nucleobase metabolic process","canonical_id":"go:GO:0045982","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving purine nucleobases.\" [GOC:curators]","metadata":null},{"id":"5d7141d35f7242a39cb4e5c432a5a89e","type":"GO_TERM","name":"negative regulation of purine nucleoside transport","canonical_id":"go:GO:0032247","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a purine nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"a54d7d12e07f44538f178ea721ec2e41","type":"GO_TERM","name":"negative regulation of purine nucleotide biosynthetic process","canonical_id":"go:GO:1900372","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of purine nucleotide biosynthetic processes.\" [GOC:curators, GOC:TermGenie]","metadata":null},{"id":"cd26c017d976440388683105e10b1b77","type":"GO_TERM","name":"negative regulation of purine nucleotide catabolic process","canonical_id":"go:GO:0033122","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of purine nucleotides.\" [GOC:mah]","metadata":null},{"id":"ac712267f0154199972039bfb476217d","type":"GO_TERM","name":"negative regulation of purine nucleotide metabolic process","canonical_id":"go:GO:1900543","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of purine nucleotide metabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"0bec6bef8033467fb900e38d2f92ab57","type":"GO_TERM","name":"negative regulation of pyloric antrum smooth muscle contraction","canonical_id":"go:GO:0120073","description":"\"Any process that decreases the frequency, rate or extent of any pyloric antrum smooth muscle contraction.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"8ab5e8d5e8034956be48767d7528f766","type":"GO_TERM","name":"negative regulation of pyrimidine nucleobase metabolic process","canonical_id":"go:GO:0045984","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving pyrimidine nucleobases.\" [GOC:curators]","metadata":null},{"id":"3910a4f6a5d84a26992c4e5a2eaa9cc2","type":"GO_TERM","name":"negative regulation of pyrimidine nucleotide biosynthetic process","canonical_id":"go:GO:1900398","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of pyrimidine nucleotide biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"2e307d360175431ca587455da42a91d6","type":"GO_TERM","name":"negative regulation of pyroptotic inflammatory response","canonical_id":"go:GO:0160028","description":"\"Any process that decreases the frequency, rate or extent of a pyroptotic inflammatory response.\" [PMID:34637033]","metadata":null},{"id":"4c3d8d6f963d44adbeda54bc97c0401d","type":"GO_TERM","name":"negative regulation of pyruvate decarboxylation to acetyl-CoA","canonical_id":"go:GO:0160218","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acetyl-CoA from pyruvate. In most organisms, this pathway links glycolysis to the TCA cycle, by a series of three reactions carried out by a multisubunit complex called the 'pyruvate dehydrogenase complex', even though pyruvate dehydrogenase activity describes only one of those reactions.\" [PMID:26942675, PMID:36849569, PMID:37754565]","metadata":null},{"id":"04e867f0128c4e65ab6476bf290408ba","type":"GO_TERM","name":"negative regulation of quinolinate biosynthetic process","canonical_id":"go:GO:1904985","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of quinolinate biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:12140278, PMID:19843166]","metadata":null},{"id":"47755cb92e27416385d919ca36910605","type":"GO_TERM","name":"negative regulation of rDNA heterochromatin formation","canonical_id":"go:GO:0061188","description":"\"Any process that decreases the rate, frequency, or extent of ribosomal DNA heterochromatin formation.\" [GOC:dph, PMID:10388812]","metadata":null},{"id":"e33f5d58fc8c463ba6a8aaa4b7743b44","type":"GO_TERM","name":"negative regulation of rRNA processing","canonical_id":"go:GO:2000233","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of rRNA processing.\" [GOC:mah]","metadata":null},{"id":"1ba1e38360674c479b721a673e0e19ca","type":"GO_TERM","name":"negative regulation of raffinose biosynthetic process","canonical_id":"go:GO:1900092","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of raffinose biosynthetic process.\" [GOC:TermGenie, PMID:22307851]","metadata":null},{"id":"58134bbdb67a40c3a969f3996958f1e9","type":"GO_TERM","name":"negative regulation of reactive oxygen species biosynthetic process","canonical_id":"go:GO:1903427","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of reactive oxygen species biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24252804]","metadata":null},{"id":"8be837e6f0ff4b619f0d73fa8a1015fc","type":"GO_TERM","name":"negative regulation of reactive oxygen species metabolic process","canonical_id":"go:GO:2000378","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of reactive oxygen species metabolic process.\" [GOC:mah]","metadata":null},{"id":"19a2a9a16db6418dbfae9ec5c8378f92","type":"GO_TERM","name":"negative regulation of receptor binding","canonical_id":"go:GO:1900121","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a protein or other molecule binding to a receptor.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"d74557c988f24e0b8d1a441c7f8b6679","type":"GO_TERM","name":"negative regulation of receptor catabolic process","canonical_id":"go:GO:2000645","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of receptor catabolic process.\" [GOC:BHF]","metadata":null},{"id":"752cb7793153462da6642fd3ccda8065","type":"GO_TERM","name":"negative regulation of receptor clustering","canonical_id":"go:GO:1903910","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of receptor clustering.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"4d8e914f2c234b26bd228c95be37f764","type":"GO_TERM","name":"negative regulation of receptor guanylyl cyclase signaling pathway","canonical_id":"go:GO:0010754","description":"\"Any process that decreases the rate, frequency or extent of receptor guanylyl cyclase signaling pathway.\" [PMID:24015261]","metadata":null},{"id":"7de886cb1864400cbec41cf2310f6ccc","type":"GO_TERM","name":"negative regulation of receptor internalization","canonical_id":"go:GO:0002091","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of receptor internalization.\" [GOC:hjd]","metadata":null},{"id":"a429a413422f447bb7644e997f3313a3","type":"GO_TERM","name":"negative regulation of receptor localization to synapse","canonical_id":"go:GO:1902684","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of receptor localization to synapse.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22252129]","metadata":null},{"id":"9fe91128f48644a49ef32403489e00e9","type":"GO_TERM","name":"negative regulation of receptor recycling","canonical_id":"go:GO:0001920","description":"\"Any process that stops, prevents, or reduces the rate of receptor recycling.\" [GOC:add]","metadata":null},{"id":"a5fa8b76dc4a4ed3be3e6853a93e18d3","type":"GO_TERM","name":"negative regulation of receptor signaling pathway via JAK-STAT","canonical_id":"go:GO:0046426","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a receptor signaling pathway via JAK-STAT.\" [GOC:bf]","metadata":null},{"id":"4684830e0ea74cc3882edcf61232dffe","type":"GO_TERM","name":"negative regulation of receptor signaling pathway via STAT","canonical_id":"go:GO:1904893","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of receptor signaling via STAT.\" [GO_REF:0000058, GOC:rjd, GOC:TermGenie, PMID:24587195]","metadata":null},{"id":"a3e7d701bce54840a152b005ba2d9ae3","type":"GO_TERM","name":"negative regulation of receptor-mediated endocytosis","canonical_id":"go:GO:0048261","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.\" [GOC:curators]","metadata":null},{"id":"2eb9b9466d944bd3b1f9bc344788d62e","type":"GO_TERM","name":"negative regulation of receptor-mediated endocytosis involved in cholesterol transport","canonical_id":"go:GO:1905601","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of receptor-mediated endocytosis involved in cholesterol transport.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:22848640]","metadata":null},{"id":"5b880d7841714f5d823f06475ffcff7c","type":"GO_TERM","name":"negative regulation of receptor-mediated virion attachment to host cell","canonical_id":"go:GO:1902735","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of receptor-mediated virion attachment to host cell.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18385238]","metadata":null},{"id":"ee2ce3ceb38b40c3aedd9e945315cacc","type":"GO_TERM","name":"negative regulation of reciprocal meiotic recombination","canonical_id":"go:GO:0045128","description":"\"Any process that decreases the frequency, rate or extent of recombination during meiosis. Reciprocal meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"fd07c7d4e3ee499ba93b82aa8d0dc73f","type":"GO_TERM","name":"negative regulation of red or far-red light signaling pathway","canonical_id":"go:GO:0090229","description":"\"Any process that decreases the rate, frequency or extent of the red or far-red signaling pathway, the series of molecular signals initiated upon sensing by photoreceptor molecules of red light or far red light.\" [GOC:tb]","metadata":null},{"id":"e2e24f27dd9947d5807822c6405d11ff","type":"GO_TERM","name":"negative regulation of reductive pentose-phosphate cycle","canonical_id":"go:GO:0080153","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the reductive pentose-phosphate cycle.\" [PMID:17031544, PMID:20399532]","metadata":null},{"id":"210d1ff89f4347399201910d9cb08695","type":"GO_TERM","name":"negative regulation of regulated secretory pathway","canonical_id":"go:GO:1903306","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of regulated secretory pathway.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:12526776]","metadata":null},{"id":"be7c367b58104ebb86fb98994c9cef23","type":"GO_TERM","name":"negative regulation of regulation of vascular associated smooth muscle cell membrane depolarization","canonical_id":"go:GO:1904198","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of regulation of vascular smooth muscle cell membrane depolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:20826763]","metadata":null},{"id":"e3aa322d755e4a759eb6f4060fd75baa","type":"GO_TERM","name":"negative regulation of regulatory T cell differentiation","canonical_id":"go:GO:0045590","description":"\"Any process that stops, prevents, or reduces the rate of differentiation of regulatory T cells.\" [ISBN:0781735149]","metadata":null},{"id":"d1b7bb3026fd4407bbbf58e1f34c517b","type":"GO_TERM","name":"negative regulation of regulatory ncRNA-mediated heterochromatin formation","canonical_id":"go:GO:0060906","description":"\"Any process that decreases the frequency, rate or extent of non-coding RNA-mediated heterochromatin formation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"11aa545f619e4f8c896b56b188462c0f","type":"GO_TERM","name":"negative regulation of relaxation of cardiac muscle","canonical_id":"go:GO:1901898","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of relaxation of cardiac muscle.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671]","metadata":null},{"id":"91cb7bebc6c64b4d863443ddf5f24864","type":"GO_TERM","name":"negative regulation of relaxation of muscle","canonical_id":"go:GO:1901078","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of relaxation of muscle.\" [GOC:TermGenie]","metadata":null},{"id":"aefc642593a34928b4772a10c72ef27d","type":"GO_TERM","name":"negative regulation of relaxation of smooth muscle","canonical_id":"go:GO:1901081","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of relaxation of smooth muscle.\" [GOC:TermGenie]","metadata":null},{"id":"12a3c94e97924526a4eb758119b68fb1","type":"GO_TERM","name":"negative regulation of release of cytochrome c from mitochondria","canonical_id":"go:GO:0090201","description":"\"Any process that decreases the rate, frequency or extent of release of cytochrome c from mitochondria, the process in which cytochrome c is enabled to move from the mitochondrial intermembrane space into the cytosol, which is an early step in apoptosis and leads to caspase activation.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"fcf61fbb87224d4a9c3492fa7adb3aba","type":"GO_TERM","name":"negative regulation of release of sequestered calcium ion into cytosol","canonical_id":"go:GO:0051280","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.\" [GOC:ai]","metadata":null},{"id":"665aca6470684ed5b9749e0209d73891","type":"GO_TERM","name":"negative regulation of removal of superoxide radicals","canonical_id":"go:GO:1904832","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of removal of superoxide radicals.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22836756]","metadata":null},{"id":"0d922e1cc31948738f60dcb87064a5e0","type":"GO_TERM","name":"negative regulation of renal albumin absorption","canonical_id":"go:GO:2000533","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of renal albumin absorption.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"5e3ba709f1894f4fad635534e88a62ef","type":"GO_TERM","name":"negative regulation of renal amino acid absorption","canonical_id":"go:GO:1902753","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of renal amino acid absorption.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:1526373]","metadata":null},{"id":"9ca0d9f9d0374c5f948b915309a93aa5","type":"GO_TERM","name":"negative regulation of renal output by angiotensin","canonical_id":"go:GO:0003083","description":"\"The process in which angiotensin directly decreases the rate of natriuresis and diuresis in the kidney.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"89bec33766de464a8cc7ddb281a28e75","type":"GO_TERM","name":"negative regulation of renal phosphate excretion","canonical_id":"go:GO:1903403","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of renal phosphate excretion.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:8700837]","metadata":null},{"id":"5f52daa425f343ebba3c9af1f0c094ce","type":"GO_TERM","name":"negative regulation of renal sodium excretion","canonical_id":"go:GO:0035814","description":"\"Any process that decreases the amount of sodium excreted in urine over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"170c03379c524d048903b5f5dfd69cad","type":"GO_TERM","name":"negative regulation of renal sodium excretion by angiotensin","canonical_id":"go:GO:0035820","description":"\"The process in which angiotensin decreases the amount of sodium that is excreted in urine over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"f8613aec71ae4ee6a592b5c910542278","type":"GO_TERM","name":"negative regulation of renal water transport","canonical_id":"go:GO:2001152","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of renal water transport.\" [GOC:obol]","metadata":null},{"id":"74582c8916b64fd8b47441f877935d14","type":"GO_TERM","name":"negative regulation of renin secretion into blood stream","canonical_id":"go:GO:1900134","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of renin secretion into blood stream.\" [GOC:TermGenie]","metadata":null},{"id":"2d96f716491348d1b8fb16759c6e7adf","type":"GO_TERM","name":"negative regulation of replicative senescence","canonical_id":"go:GO:1904727","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of replicative senescence.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23496142]","metadata":null},{"id":"6d653f688a2a428d94d4ad5cf62ae4fa","type":"GO_TERM","name":"negative regulation of reproductive process","canonical_id":"go:GO:2000242","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of reproductive process.\" [GOC:mah]","metadata":null},{"id":"bda8e1579b7941bb8774732b6f4f7d31","type":"GO_TERM","name":"negative regulation of respiratory burst","canonical_id":"go:GO:0060268","description":"\"Any process that decreases the rate frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6155b39bba514a39a028aa8b2ba896c1","type":"GO_TERM","name":"negative regulation of respiratory burst involved in inflammatory response","canonical_id":"go:GO:0060266","description":"\"Any process that decreases the rate, frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases made as a defense response ; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"c420c1f00f4849d08c593389a388a3ce","type":"GO_TERM","name":"negative regulation of respiratory gaseous exchange","canonical_id":"go:GO:1903941","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of respiratory gaseous exchange.\" [GO_REF:0000058, GOC:TermGenie, PMID:22819705]","metadata":null},{"id":"383721946aff466d8a6765705f1c5010","type":"GO_TERM","name":"negative regulation of response to acetate","canonical_id":"go:GO:1901458","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to acetate.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"899d5908f05e48afaaac5520e905b035","type":"GO_TERM","name":"negative regulation of response to alcohol","canonical_id":"go:GO:1901420","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to alcohol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"ab06a5f7403246daa46d7436029b8423","type":"GO_TERM","name":"negative regulation of response to amylopectin","canonical_id":"go:GO:1900522","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to amylopectin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b3847bb0c589490d98cbdbfd4492a834","type":"GO_TERM","name":"negative regulation of response to benzene","canonical_id":"go:GO:1901452","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to benzene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"aa9100ee1901486682761a0ae82cc26b","type":"GO_TERM","name":"negative regulation of response to biotic stimulus","canonical_id":"go:GO:0002832","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a response to biotic stimulus.\" [GOC:add]","metadata":null},{"id":"6b4e4bcdf1ef405595633b2f4d6f99b9","type":"GO_TERM","name":"negative regulation of response to butan-1-ol","canonical_id":"go:GO:1901449","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to butan-1-ol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4cae11185feb4e13a2820bc4c0bc7204","type":"GO_TERM","name":"negative regulation of response to calcium ion","canonical_id":"go:GO:1905946","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to calcium ion.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:11404397]","metadata":null},{"id":"602251825d344b74a9c1642328f5a4d8","type":"GO_TERM","name":"negative regulation of response to cycloalkane","canonical_id":"go:GO:1901432","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to cycloalkane.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"121541751f30499e99cf779b0e63dd29","type":"GO_TERM","name":"negative regulation of response to cytokine stimulus","canonical_id":"go:GO:0060761","description":"\"Any process that decreases the rate, frequency, or extent of a response to cytokine stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"9e9f2e1bc6264fdeaede4f96daee8e43","type":"GO_TERM","name":"negative regulation of response to drug","canonical_id":"go:GO:2001024","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to drug.\" [GOC:obol]","metadata":null},{"id":"f259454530cd410e831eaea091639c00","type":"GO_TERM","name":"negative regulation of response to endoplasmic reticulum stress","canonical_id":"go:GO:1903573","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a response to endoplasmic reticulum stress.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11381086]","metadata":null},{"id":"de367c105f2247dd94fc22aca6510f38","type":"GO_TERM","name":"negative regulation of response to ethanol","canonical_id":"go:GO:1901417","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to ethanol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"1c4bfcb5541a489085561637fc520a75","type":"GO_TERM","name":"negative regulation of response to external stimulus","canonical_id":"go:GO:0032102","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"b06ae10ce1e04ef19ed67b76e9beaaf0","type":"GO_TERM","name":"negative regulation of response to food","canonical_id":"go:GO:0032096","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a response to a food stimulus.\" [GOC:add]","metadata":null},{"id":"8d23087bad444910bf66287b0d8d12f9","type":"GO_TERM","name":"negative regulation of response to formic acid","canonical_id":"go:GO:1901461","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to formic acid.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9b1aa0f782d14d8cbd46b48d0556ffcb","type":"GO_TERM","name":"negative regulation of response to furfural","canonical_id":"go:GO:1901443","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to furfural.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"046da84ba0b84b03934bd50670d8d6cb","type":"GO_TERM","name":"negative regulation of response to gamma radiation","canonical_id":"go:GO:2001229","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to gamma radiation.\" [GOC:obol]","metadata":null},{"id":"99b5df683913467aa8b705c3b83a34cf","type":"GO_TERM","name":"negative regulation of response to macrophage colony-stimulating factor","canonical_id":"go:GO:1903970","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to macrophage colony-stimulating factor.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"8fbb752898cb403c9a17abc225bbc116","type":"GO_TERM","name":"negative regulation of response to nutrient levels","canonical_id":"go:GO:0032108","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a response to nutrient levels.\" [GOC:mah]","metadata":null},{"id":"8e646050a01f41f0ae075f70a229e361","type":"GO_TERM","name":"negative regulation of response to oxidative stress","canonical_id":"go:GO:1902883","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to oxidative stress.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:16899554]","metadata":null},{"id":"de39cc91bba9450c87a5edcd5a7dd42d","type":"GO_TERM","name":"negative regulation of response to propan-1-ol","canonical_id":"go:GO:1901446","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to propan-1-ol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"1ecb26357f8e4ac4ba2f645212c8765b","type":"GO_TERM","name":"negative regulation of response to pullulan","canonical_id":"go:GO:1900519","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to pullulan.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2b576231fe674f149d88739fd19445cf","type":"GO_TERM","name":"negative regulation of response to reactive oxygen species","canonical_id":"go:GO:1901032","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to reactive oxygen species.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"f312704db2ab49f58d29d62fdbb94b26","type":"GO_TERM","name":"negative regulation of response to salt stress","canonical_id":"go:GO:1901001","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to salt stress.\" [GOC:TermGenie, PMID:22627139]","metadata":null},{"id":"d7c04043125d448abaca54ee41d56e0d","type":"GO_TERM","name":"negative regulation of response to stimulus","canonical_id":"go:GO:0048585","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.\" [GOC:jid]","metadata":null},{"id":"b851e66dab9041cea87401965acff94b","type":"GO_TERM","name":"negative regulation of response to toluene","canonical_id":"go:GO:1901455","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to toluene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2509f68b06dc480eb9442f6f2d40cd60","type":"GO_TERM","name":"negative regulation of response to tumor cell","canonical_id":"go:GO:0002835","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a response to tumor cell.\" [GOC:add]","metadata":null},{"id":"c2436aec1ea648e3a8bcbff8f185b01c","type":"GO_TERM","name":"negative regulation of response to type II interferon","canonical_id":"go:GO:0060331","description":"\"Any process that decreases the rate, frequency or extent of a response to type II interferon (interferon-gamma). Response to interferon gamma is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus.\" [GOC:dph]","metadata":null},{"id":"978323f4903649a4a1dc6bb70b895b0d","type":"GO_TERM","name":"negative regulation of response to water deprivation","canonical_id":"go:GO:0080148","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a response to water deprivation. Response to water deprivation is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a water deprivation stimulus, prolonged deprivation of water.\" [PMID:18835996]","metadata":null},{"id":"b27a252d5aa341f69a49f7fe3e5ac06d","type":"GO_TERM","name":"negative regulation of response to wounding","canonical_id":"go:GO:1903035","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of response to wounding.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:19164535]","metadata":null},{"id":"ae49dccba71d4ec380dc85e039a48ef9","type":"GO_TERM","name":"negative regulation of retina development in camera-type eye","canonical_id":"go:GO:1902867","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retina development in camera-type eye.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"9081c8d54dd34cdb8c0fc076456a8422","type":"GO_TERM","name":"negative regulation of retinal cell programmed cell death","canonical_id":"go:GO:0046671","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of programmed cell death that occurs in the retina.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"22f349e2f0a240f5bd3d3250eba7462b","type":"GO_TERM","name":"negative regulation of retinal cone cell fate commitment","canonical_id":"go:GO:0060226","description":"\"Any process that increases the process in which a cell becomes committed to a retinal cone cell fate. Retinal cone cell fate commitment is the process in which the developmental fate of a cell becomes restricted such that it will develop into a retinal cone cell.\" [GOC:dph]","metadata":null},{"id":"fe6ad602c08e403ebe745a68fc32a9a2","type":"GO_TERM","name":"negative regulation of retinal cone cell fate specification","canonical_id":"go:GO:0009998","description":"\"Any process that restricts, stops or prevents a cell from specifying into a retinal cone cell.\" [GOC:curators]","metadata":null},{"id":"9367d4f0e7fb402bbd3c0250648f845c","type":"GO_TERM","name":"negative regulation of retinal ganglion cell axon guidance","canonical_id":"go:GO:0090260","description":"\"Any process that decreases the frequency, rate, or extent of retinal ganglion cell axon guidance, the process in which the migration of an axon growth cone of a retinal ganglion cell (RGC) is directed to its target in the brain in response to a combination of attractive and repulsive cues.\" [GOC:tb, GOC:yaf]","metadata":null},{"id":"47b03c32f21f4c49baca81d93e914afa","type":"GO_TERM","name":"negative regulation of retinoic acid biosynthetic process","canonical_id":"go:GO:1900053","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retinoic acid biosynthetic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"63c367ded33e4a0387691fc740813140","type":"GO_TERM","name":"negative regulation of retinoic acid receptor signaling pathway","canonical_id":"go:GO:0048387","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of retinoic acid receptor signaling pathway activity.\" [GOC:dgh]","metadata":null},{"id":"2c51e64eb68a4ef585951d27004b6579","type":"GO_TERM","name":"negative regulation of retrograde axon cargo transport","canonical_id":"go:GO:2001018","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retrograde axon cargo transport.\" [GOC:obol]","metadata":null},{"id":"a8bd4f46acb3419899c15a7ee3f9156c","type":"GO_TERM","name":"negative regulation of retrograde dense core granule transport","canonical_id":"go:GO:1901955","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retrograde dense core granule transport.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"a5823feb559f461fa70c99cf114c6dfe","type":"GO_TERM","name":"negative regulation of retrograde protein transport, ER to cytosol","canonical_id":"go:GO:1904153","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retrograde protein transport, ER to cytosol.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18555783]","metadata":null},{"id":"1e472d19191541b38d4e7ac57fac146f","type":"GO_TERM","name":"negative regulation of retrograde trans-synaptic signaling by neuropeptide","canonical_id":"go:GO:1905433","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retrograde trans-synaptic signaling by neuropeptide.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:19448629]","metadata":null},{"id":"bbc5e4cdd5aa41afa225c706911736af","type":"GO_TERM","name":"negative regulation of retrograde transport, endosome to Golgi","canonical_id":"go:GO:1905280","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of retrograde transport, endosome to Golgi.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"ecd23032af8b406780e562c397dba8c9","type":"GO_TERM","name":"negative regulation of reverse cholesterol transport","canonical_id":"go:GO:1903063","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of reverse cholesterol transport.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23931754]","metadata":null},{"id":"6ef3533b8301424a89c8cf8edb704c62","type":"GO_TERM","name":"negative regulation of reverse transcription","canonical_id":"go:GO:1900269","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of reverse transcription.\" [GOC:TermGenie]","metadata":null},{"id":"bcf43769ba1b4427a14d34514794ed45","type":"GO_TERM","name":"negative regulation of ribonucleoprotein complex localization","canonical_id":"go:GO:2000198","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ribonucleoprotein complex localization.\" [GOC:mah]","metadata":null},{"id":"0a5f7491bfee40f3a1b2099a14261bd8","type":"GO_TERM","name":"negative regulation of ribosomal large subunit export from nucleus","canonical_id":"go:GO:2000204","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ribosomal large subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"d85242f2fc6a42b3a4ba7a8cdfe5c7a9","type":"GO_TERM","name":"negative regulation of ribosomal protein gene transcription by RNA polymerase II","canonical_id":"go:GO:0010688","description":"\"Any process that decreases the frequency, rate or extent of the synthesis of RNA from ribosomal protein genes mediated by RNA polymerase II.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"fe4a863a7bde49898f40f3efcc40fa3b","type":"GO_TERM","name":"negative regulation of ribosomal protein gene transcription from RNA polymerase II promoter in response to chemical stimulus","canonical_id":"go:GO:0010689","description":"\"Any process that decreases the frequency, rate or extent of the synthesis of RNA from ribosomal protein genes by RNA polymerase II, originating at an RNA polymerase II promoter, as a result of a chemical stimulus.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"88e05db242e34538bb184394890d9be8","type":"GO_TERM","name":"negative regulation of ribosomal protein gene transcription from RNA polymerase II promoter in response to nutrient levels","canonical_id":"go:GO:0010691","description":"\"Any process that decreases the frequency, rate or extent of the synthesis of RNA from ribosomal protein genes by RNA polymerase II, originating at an RNA polymerase II promoter, as a result of a stimulus reflecting the presence, absence, or concentration of nutrients.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"0ec97e1c9bef447dbe94067c60f679de","type":"GO_TERM","name":"negative regulation of ribosomal protein gene transcription from RNA polymerase II promoter in response to stress","canonical_id":"go:GO:0010690","description":"\"Any process that decreases the frequency, rate or extent of the synthesis of RNA from ribosomal protein genes by RNA polymerase II, originating at an RNA polymerase II promoter, as a result of a disturbance in organismal or cellular homeostasis.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"7b822e10765c43b0b68b900f0bcba687","type":"GO_TERM","name":"negative regulation of ribosomal small subunit export from nucleus","canonical_id":"go:GO:2000207","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ribosomal small subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"1793255c2b8f471086925ed9c8a7b8a7","type":"GO_TERM","name":"negative regulation of ribosomal subunit export from nucleus","canonical_id":"go:GO:2000201","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ribosomal subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"49409b5eea764df2b0f91d127aaa8fc1","type":"GO_TERM","name":"negative regulation of ribosome biogenesis","canonical_id":"go:GO:0090071","description":"\"Any process that decreases the rate, frequency or extent of ribosome biogenesis. Ribosome biogenesis is the cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of ribosome subunits.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a9cf41478c7a43859a18a840b3930984","type":"GO_TERM","name":"negative regulation of ripoptosome assembly involved in necroptotic process","canonical_id":"go:GO:1902443","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ripoptosome assembly involved in a necroptotic process.\" [GOC:dph, GOC:mtg_apoptosis, GOC:TermGenie, PMID:21052097]","metadata":null},{"id":"0614948bdfad4e74a070db370b2c2673","type":"GO_TERM","name":"negative regulation of root hair elongation","canonical_id":"go:GO:1902891","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of root hair elongation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22329353]","metadata":null},{"id":"a03951f68f2a4806a891d422f2ec2652","type":"GO_TERM","name":"negative regulation of ruffle assembly","canonical_id":"go:GO:1900028","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ruffle assembly.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"d16e58f5c85f44cfb3c39b1c960fe8f4","type":"GO_TERM","name":"negative regulation of ryanodine-sensitive calcium-release channel activity","canonical_id":"go:GO:0060315","description":"\"Any process that decreases the activity of a ryanodine-sensitive calcium-release channel. The ryanodine-sensitive calcium-release channel catalyzes the transmembrane transfer of a calcium ion by a channel that opens when a ryanodine class ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1218102482b04dcf83df4a7604986030","type":"GO_TERM","name":"negative regulation of saliva secretion","canonical_id":"go:GO:1905747","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of saliva secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:23419067]","metadata":null},{"id":"9e09ae4937f34201b63d75400f8a5456","type":"GO_TERM","name":"negative regulation of salivary gland boundary specification","canonical_id":"go:GO:0045705","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of salivary gland determination.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"66cb8ac81e97447f99ac71650e351193","type":"GO_TERM","name":"negative regulation of sarcinapterin biosynthetic process","canonical_id":"go:GO:1900972","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sarcinapterin biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"65baa6df466846adb0dc24ee14898ba6","type":"GO_TERM","name":"negative regulation of sarcomere organization","canonical_id":"go:GO:0060299","description":"\"Any process that decreases the rate, frequency or extent of myofibril assembly by organization of muscle actomyosin into sarcomeres. The sarcomere is the repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"e39f08dd25184a05bf08dca06d0cd1ef","type":"GO_TERM","name":"negative regulation of satellite cell differentiation","canonical_id":"go:GO:1902725","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of satellite cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"c16f371d9e99486d9f5816c1a07de996","type":"GO_TERM","name":"negative regulation of sclerotium development","canonical_id":"go:GO:1901923","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sclerotium development.\" [GOC:di, GOC:TermGenie, PMID:21148914]","metadata":null},{"id":"b63e046d2b8e4de582d03c985f46acfe","type":"GO_TERM","name":"negative regulation of sebum secreting cell proliferation","canonical_id":"go:GO:1904003","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sebum secreting cell proliferation.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:16901790]","metadata":null},{"id":"67b895fd095a4a9483db8ad592c5662f","type":"GO_TERM","name":"negative regulation of secondary cell septum biogenesis","canonical_id":"go:GO:1903396","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of secondary cell septum biogenesis.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:23878277]","metadata":null},{"id":"10f3aff7f8464b11b03572e3a4631ab6","type":"GO_TERM","name":"negative regulation of secondary cell wall biogenesis","canonical_id":"go:GO:1901347","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of secondary cell wall biogenesis.\" [GOC:TermGenie]","metadata":null},{"id":"85fe940fa71d4d21833074d3f0a63431","type":"GO_TERM","name":"negative regulation of secondary growth","canonical_id":"go:GO:2000604","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of secondary growth.\" [GOC:obol]","metadata":null},{"id":"ffe9e98f73f74facb637d0c75fe546d0","type":"GO_TERM","name":"negative regulation of secondary metabolite biosynthetic process","canonical_id":"go:GO:1900377","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of secondary metabolite biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"0b9bcf13f41e4ddf98cb9c3c83f1308a","type":"GO_TERM","name":"negative regulation of secretion","canonical_id":"go:GO:0051048","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a substance from a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"1ca382368d67435aa0bd2813397ca873","type":"GO_TERM","name":"negative regulation of secretion by cell","canonical_id":"go:GO:1903531","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of secretion by cell.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:12130530]","metadata":null},{"id":"7298166dec11482ab06fb51da9f83fb2","type":"GO_TERM","name":"negative regulation of secretion of lysosomal enzymes","canonical_id":"go:GO:0090341","description":"\"Any process that decreases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell.\" [GOC:BHF]","metadata":null},{"id":"2ef0881a0b8e4dd49c771d770bd83fda","type":"GO_TERM","name":"negative regulation of secretory granule organization","canonical_id":"go:GO:1904410","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of secretory granule organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:15039777]","metadata":null},{"id":"a45845ef7995443ea8b7e08e2dec31a1","type":"GO_TERM","name":"negative regulation of seed dormancy process","canonical_id":"go:GO:1902039","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of seed dormancy process.\" [GOC:TermGenie, PMID:23378449]","metadata":null},{"id":"c50d078bf5e8479aabdcab457ff188b6","type":"GO_TERM","name":"negative regulation of seed germination","canonical_id":"go:GO:0010187","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of seed germination.\" [GOC:tb]","metadata":null},{"id":"c928413a216a4a6bb5ebdadcce0855f2","type":"GO_TERM","name":"negative regulation of seed maturation","canonical_id":"go:GO:2000692","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of seed maturation.\" [GOC:obol]","metadata":null},{"id":"6b7e54e04f0a4645912e7bfd9ef26ade","type":"GO_TERM","name":"negative regulation of selenocysteine incorporation","canonical_id":"go:GO:1904570","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of selenocysteine incorporation.\" [GO_REF:0000058, GOC:TermGenie, PMID:21685449]","metadata":null},{"id":"f58f95f64d78485fb5e21eb7cc9ab783","type":"GO_TERM","name":"negative regulation of semaphorin-plexin signaling pathway","canonical_id":"go:GO:2001261","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of semaphorin-plexin signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"102055961875415695508eb24b0759cd","type":"GO_TERM","name":"negative regulation of sensory neuron axon guidance","canonical_id":"go:GO:1905490","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sensory neuron axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"a84bce0433084f1f9a40155b4c5d28dc","type":"GO_TERM","name":"negative regulation of sensory perception of bitter taste","canonical_id":"go:GO:1904661","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sensory perception of bitter taste.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:1716172]","metadata":null},{"id":"a8d873697b984ccabcdd3fc411247a21","type":"GO_TERM","name":"negative regulation of sensory perception of pain","canonical_id":"go:GO:1904057","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sensory perception of pain.\" [GO_REF:0000058, GOC:TermGenie, PMID:17167094]","metadata":null},{"id":"7b4980d6c1324cd3841c8f0c6ad1edbb","type":"GO_TERM","name":"negative regulation of sensory perception of sweet taste","canonical_id":"go:GO:1904657","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sensory perception of sweet taste.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:1716172]","metadata":null},{"id":"3b8a04516e0740ce92de6cd0ce46f97d","type":"GO_TERM","name":"negative regulation of septation initiation signaling","canonical_id":"go:GO:0031030","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of septation initiation signaling.\" [GOC:mah]","metadata":null},{"id":"9f32b767da2443c5aed4db9019e244a7","type":"GO_TERM","name":"negative regulation of septum digestion after cytokinesis","canonical_id":"go:GO:2001042","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of the process of physically separating the septal cell wall material by enzymatic digestion, that occurs after daughter cells are separated by cytokinesis.\" [GOC:mtg_cell_cycle, GOC:obol]","metadata":null},{"id":"e8c8c802b9ac44e4bacb9f4fc161961c","type":"GO_TERM","name":"negative regulation of serine-type endopeptidase activity","canonical_id":"go:GO:1900004","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of serine-type endopeptidase activity.\" [GOC:TermGenie]","metadata":null},{"id":"f12ef3c511004903a83900df2330ae08","type":"GO_TERM","name":"negative regulation of serine-type peptidase activity","canonical_id":"go:GO:1902572","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of serine-type peptidase activity.\" [GOC:krc, GOC:TermGenie, PMID:20179351]","metadata":null},{"id":"9aa9e980f8084598a6fba2c1a0f6fd3b","type":"GO_TERM","name":"negative regulation of serotonin biosynthetic process","canonical_id":"go:GO:1905628","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of serotonin biosynthetic process.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:25642596]","metadata":null},{"id":"d80da12f30424474b220b1102cfa086a","type":"GO_TERM","name":"negative regulation of serotonin secretion","canonical_id":"go:GO:0014063","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of serotonin.\" [GOC:ef]","metadata":null},{"id":"246989aea2144321a1661f8de205cd79","type":"GO_TERM","name":"negative regulation of serotonin uptake","canonical_id":"go:GO:0051612","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of serotonin into a cell.\" [GOC:ai]","metadata":null},{"id":"8d754d4f409f409dbeb6e7c57e3ac39c","type":"GO_TERM","name":"negative regulation of sevenless signaling pathway","canonical_id":"go:GO:0045873","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the sevenless signaling pathway.\" [GOC:curators]","metadata":null},{"id":"e57bbd3bec7548d7a15320e2769689de","type":"GO_TERM","name":"negative regulation of sexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043942","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the formation of cellular spores derived from the products of meiosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"484c2bc775424170b38778d16424b7f7","type":"GO_TERM","name":"negative regulation of shade avoidance","canonical_id":"go:GO:1902447","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of shade avoidance.\" [GOC:TermGenie, PMID:23763263]","metadata":null},{"id":"cbf4bcad16194baf8564287c5e7faf17","type":"GO_TERM","name":"negative regulation of shell calcification","canonical_id":"go:GO:1905649","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of shell calcification.\" [GO_REF:0000058, GOC:TermGenie, PMID:14648763]","metadata":null},{"id":"5040f477d7b34b75aa43234b6b9f2b96","type":"GO_TERM","name":"negative regulation of shelterin complex assembly","canonical_id":"go:GO:1904791","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of shelterin complex assembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24270157]","metadata":null},{"id":"2bfd9b545c514a54a8841428d16cfc7e","type":"GO_TERM","name":"negative regulation of shoot apical meristem development","canonical_id":"go:GO:1902184","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of shoot apical meristem development.\" [GOC:TermGenie, PMID:21496644]","metadata":null},{"id":"005c0d02188e4e26a2391b856ccd9964","type":"GO_TERM","name":"negative regulation of short-day photoperiodism, flowering","canonical_id":"go:GO:0048577","description":"\"Any process that stops, prevents or reduces short-day photoperiodism, where the response associated with the photoperiodism is flowering. Flowering is defined by the switch from the vegetative to the reproductive phase.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"5888fdf783c74ae3a35992ca6edc52f8","type":"GO_TERM","name":"negative regulation of short-term neuronal synaptic plasticity","canonical_id":"go:GO:0048174","description":"\"A process that decreases short-term neuronal synaptic plasticity, the ability of neuronal synapses to change in the short-term as circumstances require. Short-term neuronal synaptic plasticity generally involves increasing or decreasing synaptic sensitivity.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"bcfb7643ecf741498246f2e650ee65b7","type":"GO_TERM","name":"negative regulation of short-term synaptic potentiation","canonical_id":"go:GO:1905513","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of short-term synaptic potentiation.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:15470145]","metadata":null},{"id":"122fe50ab88b409395128ae8746e0597","type":"GO_TERM","name":"negative regulation of siRNA processing","canonical_id":"go:GO:1903704","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of siRNA processing.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19701182]","metadata":null},{"id":"a0976c355dbf4c299f110894e47636f3","type":"GO_TERM","name":"negative regulation of siderophore biosynthetic process","canonical_id":"go:GO:1900705","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of siderophore biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b3796b90efe74f4f9d663b26a4f03aea","type":"GO_TERM","name":"negative regulation of signal transduction","canonical_id":"go:GO:0009968","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction.\" [GOC:sm]","metadata":null},{"id":"37e14075067f4be687dceee17b2beceb","type":"GO_TERM","name":"negative regulation of signal transduction by p53 class mediator","canonical_id":"go:GO:1901797","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.\" [GOC:TermGenie]","metadata":null},{"id":"efba98911e434b6b95d85f2a38c953e4","type":"GO_TERM","name":"negative regulation of signal transduction by receptor internalization","canonical_id":"go:GO:0038011","description":"\"Any process in which internalization of a signaling receptor stops, prevents, or reduces the frequency, rate or extent of signal transduction. Receptor internalization can attenuate or reduce the strength of signaling by reducing the concentration of cell surface receptors available to ligands.\" [GOC:bf, GOC:signaling, PMID:17908284, PMID:19696798]","metadata":null},{"id":"dbae7008b46d4507bd4d4bffbf66a27e","type":"GO_TERM","name":"negative regulation of signal transduction in absence of ligand","canonical_id":"go:GO:1901099","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction in absence of ligand.\" [GOC:TermGenie]","metadata":null},{"id":"a8ff6dfba10f4fbe8a6ec4c7110ba6ad","type":"GO_TERM","name":"negative regulation of signaling","canonical_id":"go:GO:0023057","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process.\" [GOC:mtg_signal]","metadata":null},{"id":"a8233c66ae204528a8242f3c0b4a2421","type":"GO_TERM","name":"negative regulation of signaling receptor activity","canonical_id":"go:GO:2000272","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a signaling receptor activity.\" [GOC:obol]","metadata":null},{"id":"65edac68999f4fa1856e896a1e6c4012","type":"GO_TERM","name":"negative regulation of silent mating-type cassette heterochromatin formation","canonical_id":"go:GO:0061186","description":"\"Any process that decreases the frequency, rate, or extent of heterochromatin formation at silent mating-type cassette.\" [GOC:dph, PMID:10388812]","metadata":null},{"id":"267767456f0d46778940e28b6ad08690","type":"GO_TERM","name":"negative regulation of sinapate ester biosynthetic process","canonical_id":"go:GO:1903086","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sinapate ester biosynthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:11080161]","metadata":null},{"id":"38bbe6bb07574adfa48e5eb3abf08122","type":"GO_TERM","name":"negative regulation of single strand break repair","canonical_id":"go:GO:1903517","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of single strand break repair.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17395247]","metadata":null},{"id":"bb0a139c0b4a412a8d4cbe7253a7e515","type":"GO_TERM","name":"negative regulation of single stranded viral RNA replication via double stranded DNA intermediate","canonical_id":"go:GO:0045869","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of single stranded viral RNA replication via double stranded DNA intermediate.\" [GOC:curators]","metadata":null},{"id":"0505d3c640d44e39a9cf7e517bbe0d64","type":"GO_TERM","name":"negative regulation of single-species biofilm formation","canonical_id":"go:GO:1900191","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of single-species biofilm formation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1fd18191e72f48c9a886c02cf0fc9e78","type":"GO_TERM","name":"negative regulation of single-species biofilm formation in or on host organism","canonical_id":"go:GO:1900229","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of single-species biofilm formation in or on host organism.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1e7e560a3e3548ef95024409ed6d4083","type":"GO_TERM","name":"negative regulation of single-species biofilm formation on inanimate substrate","canonical_id":"go:GO:1900232","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of single-species biofilm formation on inanimate substrate.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"30ad358e5b084b6691ee773ee9f1dd42","type":"GO_TERM","name":"negative regulation of single-strand break repair via homologous recombination","canonical_id":"go:GO:1903111","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of single-strand break repair via homologous recombination.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:24339919]","metadata":null},{"id":"51dd942de35b49e9829579356b1b4736","type":"GO_TERM","name":"negative regulation of sister chromatid cohesion","canonical_id":"go:GO:0045875","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sister chromatid cohesion.\" [GOC:curators]","metadata":null},{"id":"d9ab37c260f14c5aad66bf3797171c06","type":"GO_TERM","name":"negative regulation of sister chromatid segregation","canonical_id":"go:GO:0033046","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sister chromatid segregation.\" [GOC:mah]","metadata":null},{"id":"84b3753f4ec340d380865146756a2bb6","type":"GO_TERM","name":"negative regulation of skeletal muscle acetylcholine-gated channel clustering","canonical_id":"go:GO:1904394","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of skeletal muscle acetylcholine-gated channel clustering.\" [GO_REF:0000058, GOC:TermGenie, PMID:7722643]","metadata":null},{"id":"dabb1cc22759456c84b27f6cbd7428c9","type":"GO_TERM","name":"negative regulation of skeletal muscle cell differentiation","canonical_id":"go:GO:2001015","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of skeletal muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"ce1363581c6846998fc762fb9233350c","type":"GO_TERM","name":"negative regulation of skeletal muscle cell proliferation","canonical_id":"go:GO:0014859","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle cell proliferation.\" [CL:0000188, GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"82c2cdffb5e44a16b41a00f84ebd3944","type":"GO_TERM","name":"negative regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion","canonical_id":"go:GO:0014811","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle contraction via the regulation of the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol. The sarcoplasmic reticulum is the endoplasmic reticulum of striated muscle, specialised for the sequestration of calcium ions that are released upon receipt of a signal relayed by the T tubules from the neuromuscular junction.\" [GOC:mtg_muscle]","metadata":null},{"id":"6158545497ca475fa980b77a6466f846","type":"GO_TERM","name":"negative regulation of skeletal muscle fiber development","canonical_id":"go:GO:0048744","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle fiber development. Muscle fibers are formed by the maturation of myotubes. They can be classed as slow, intermediate/fast or fast.\" [GOC:dph, GOC:jid, GOC:lm, GOC:mtg_muscle]","metadata":null},{"id":"7bf0093625994e6d81cf78482f56c1e9","type":"GO_TERM","name":"negative regulation of skeletal muscle fiber differentiation","canonical_id":"go:GO:1902810","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of skeletal muscle fiber differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17879321]","metadata":null},{"id":"e495f619660e457e8764b3bcf545cd06","type":"GO_TERM","name":"negative regulation of skeletal muscle hypertrophy","canonical_id":"go:GO:1904205","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of skeletal muscle hypertrophy.\" [GO_REF:0000058, GOC:TermGenie, PMID:23470307]","metadata":null},{"id":"c12e3a21781a43f597dc4e6ddc0b1703","type":"GO_TERM","name":"negative regulation of skeletal muscle satellite cell proliferation","canonical_id":"go:GO:1902723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of satellite cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"1d9f3efd423542da86c8618e8fc5bf2c","type":"GO_TERM","name":"negative regulation of skeletal muscle tissue development","canonical_id":"go:GO:0048642","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle tissue development.\" [GOC:curators]","metadata":null},{"id":"947e9ec3ed7d441faeffe79b6e3b4511","type":"GO_TERM","name":"negative regulation of skeletal muscle tissue growth","canonical_id":"go:GO:0048632","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle growth.\" [GOC:lm, PMID:15726494, PMID:15907921]","metadata":null},{"id":"f27c0d623a4b4994b2f100078c189197","type":"GO_TERM","name":"negative regulation of skeletal muscle tissue regeneration","canonical_id":"go:GO:0043417","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle regeneration.\" [GOC:jl]","metadata":null},{"id":"eb9e7c9557a04e219706d270defc1aec","type":"GO_TERM","name":"negative regulation of slow-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031450","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of slow-twitch skeletal muscle contraction.\" [GOC:dph, GOC:ef, GOC:mah, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"d1098c05933f4345be3f1e3a4f2348c7","type":"GO_TERM","name":"negative regulation of small GTPase mediated signal transduction","canonical_id":"go:GO:0051058","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of small GTPase mediated signal transduction.\" [GOC:ai]","metadata":null},{"id":"6d8d995240374941bea0044069c13834","type":"GO_TERM","name":"negative regulation of small intestinal transit","canonical_id":"go:GO:0120059","description":"\"Any process that decreases the frequency, rate or extent of any small intestinal transit process, the migration of ingested material along the length of the small intestine.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"419a19fdb0af4627866efd7a0b5f7cc7","type":"GO_TERM","name":"negative regulation of small intestine smooth muscle contraction","canonical_id":"go:GO:1904348","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of small intestine smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:11991626]","metadata":null},{"id":"789013d003ff4d3096e8853e00d5de32","type":"GO_TERM","name":"negative regulation of small molecule metabolic process","canonical_id":"go:GO:0062014","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a small molecule metabolic process.\" [GOC:vw]","metadata":null},{"id":"4d4e206c056c472a8b9986182fcee0c6","type":"GO_TERM","name":"negative regulation of smooth endoplasmic reticulum calcium ion concentration","canonical_id":"go:GO:0051565","description":"\"Any process that decreases the concentration of calcium ions in the smooth endoplasmic reticulum.\" [GOC:ai]","metadata":null},{"id":"569b4163ca1041b184980ec2f9d27b86","type":"GO_TERM","name":"negative regulation of smooth muscle cell apoptotic process","canonical_id":"go:GO:0034392","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of smooth muscle cell apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl]","metadata":null},{"id":"81aba78f81f14c989314bbc1dcf18b4f","type":"GO_TERM","name":"negative regulation of smooth muscle cell chemotaxis","canonical_id":"go:GO:0071672","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of smooth muscle cell chemotaxis.\" [GOC:mah]","metadata":null},{"id":"3217d983838b4e59bbca7b96cd7ace04","type":"GO_TERM","name":"negative regulation of smooth muscle cell differentiation","canonical_id":"go:GO:0051151","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle cell differentiation.\" [CL:0000192, GOC:ai]","metadata":null},{"id":"c8cada7462ca49db813f866521f08c66","type":"GO_TERM","name":"negative regulation of smooth muscle cell migration","canonical_id":"go:GO:0014912","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle cell migration.\" [CL:0000192, GOC:mtg_muscle]","metadata":null},{"id":"3b004e7fb98547e595a52e759b054393","type":"GO_TERM","name":"negative regulation of smooth muscle cell proliferation","canonical_id":"go:GO:0048662","description":"\"Any process that stops, prevents or reduces the rate or extent of smooth muscle cell proliferation.\" [CL:0000192, GOC:ebc]","metadata":null},{"id":"c905c85c4ff24ab689118c43107999fb","type":"GO_TERM","name":"negative regulation of smooth muscle cell-matrix adhesion","canonical_id":"go:GO:2000098","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle cell-matrix adhesion.\" [GOC:BHF]","metadata":null},{"id":"bca080ba4dd24dd2b97c3a876721ace9","type":"GO_TERM","name":"negative regulation of smooth muscle contraction","canonical_id":"go:GO:0045986","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle contraction.\" [GOC:curators]","metadata":null},{"id":"167eea90e4e241928f8daab4e08510c9","type":"GO_TERM","name":"negative regulation of smooth muscle hypertrophy","canonical_id":"go:GO:1905148","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of smooth muscle hypertrophy.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22161164]","metadata":null},{"id":"922dde5bb34f4ac583653a0fbacdacbb","type":"GO_TERM","name":"negative regulation of smooth muscle tissue development","canonical_id":"go:GO:1905900","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of smooth muscle tissue development.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:14709716]","metadata":null},{"id":"3bd5d1ad8b544e9f925f361093e4af01","type":"GO_TERM","name":"negative regulation of smoothened signaling pathway","canonical_id":"go:GO:0045879","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of smoothened signaling.\" [GOC:curators]","metadata":null},{"id":"f119281baa994bb39e74d7842441418d","type":"GO_TERM","name":"negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning","canonical_id":"go:GO:1901621","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of smoothened signaling pathway involved in dorsal/ventral neural tube patterning.\" [GOC:TermGenie]","metadata":null},{"id":"4a75631894984b0b913b49c8ef1ce040","type":"GO_TERM","name":"negative regulation of snRNA pseudouridine synthesis","canonical_id":"go:GO:1905357","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of snRNA pseudouridine synthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:27268497]","metadata":null},{"id":"c5f65c86865a438ab5a39d94c81f0352","type":"GO_TERM","name":"negative regulation of snRNA transcription by RNA polymerase II","canonical_id":"go:GO:1905381","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of snRNA transcription mediated by RNA polymerase II.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:10022900]","metadata":null},{"id":"a21647ce73fa4f60b998333feb216c42","type":"GO_TERM","name":"negative regulation of snoRNA metabolic process","canonical_id":"go:GO:1903324","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of snoRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"0666302e0ba94139beb2ba72bd0e01c3","type":"GO_TERM","name":"negative regulation of snoRNA processing","canonical_id":"go:GO:1902797","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of snoRNA processing.\" [GO_REF:0000058, GOC:TermGenie, PMID:24210919]","metadata":null},{"id":"20929e1c6f1d48838de926aaeaeb3f25","type":"GO_TERM","name":"negative regulation of sodium ion export across plasma membrane","canonical_id":"go:GO:1903277","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sodium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17095720]","metadata":null},{"id":"1a5281b1070347ed8681f0e8ff8cdeba","type":"GO_TERM","name":"negative regulation of sodium ion import across plasma membrane","canonical_id":"go:GO:1903783","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sodium ion import across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:19376779]","metadata":null},{"id":"ac537610826a456ab3a9fa3cec0965e8","type":"GO_TERM","name":"negative regulation of sodium ion transmembrane transport","canonical_id":"go:GO:1902306","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sodium ion transmembrane transport.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:18591664]","metadata":null},{"id":"729734049b374dc79d8a0654fedaef2f","type":"GO_TERM","name":"negative regulation of sodium ion transport","canonical_id":"go:GO:0010766","description":"\"Any process that decreases the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"940f351f9cfb463a855911f3ccf11dfd","type":"GO_TERM","name":"negative regulation of sodium-dependent phosphate transport","canonical_id":"go:GO:2000119","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sodium-dependent phosphate transport.\" [GOC:BHF]","metadata":null},{"id":"1818fc71550140f09da9622dfe4bae1d","type":"GO_TERM","name":"negative regulation of somatic muscle development","canonical_id":"go:GO:0062225","description":"\"Any process that decreases the rate, frequency or extent of somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"5de4edd7d75d4d3ca5e8d122e3010415","type":"GO_TERM","name":"negative regulation of somatic stem cell division","canonical_id":"go:GO:1904676","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of somatic stem cell division.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19409607]","metadata":null},{"id":"f1d294a5002c4ce79f1970edb30b455f","type":"GO_TERM","name":"negative regulation of somatic stem cell population maintenance","canonical_id":"go:GO:1904673","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of somatic stem cell population maintenance.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19409607]","metadata":null},{"id":"78e8f50ab41f4122b093be11ae91aa02","type":"GO_TERM","name":"negative regulation of somatostatin secretion","canonical_id":"go:GO:0090275","description":"\"Any process that decreases the rate, frequency, extent of the regulated release of somatostatin from secretory granules in the D cells of the pancreas.\" [GOC:BHF]","metadata":null},{"id":"407fee3d5f2248eba41c43f411e08982","type":"GO_TERM","name":"negative regulation of somitomeric trunk muscle development","canonical_id":"go:GO:0014710","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of somitomeric trunk muscle development. The somitomeric trunk muscle is derived from somitomeric mesoderm. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle.\" [GOC:mtg_muscle]","metadata":null},{"id":"af1ec00089344e26acc5038e4819fc14","type":"GO_TERM","name":"negative regulation of sorocarp spore cell differentiation","canonical_id":"go:GO:1901262","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sorocarp spore cell differentiation.\" [GOC:rjd, GOC:TermGenie]","metadata":null},{"id":"4dd1cae5ed61486fa039cb100b38736f","type":"GO_TERM","name":"negative regulation of sorocarp stalk cell differentiation","canonical_id":"go:GO:0031286","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sorocarp stalk cell differentiation. An example of this process is found in Dictyostelium discoideum.\" [GOC:kp, GOC:mtg_sensu, PMID:4338436]","metadata":null},{"id":"37ba24afc53c49199fb0c26d13e7ea10","type":"GO_TERM","name":"negative regulation of sperm capacitation","canonical_id":"go:GO:1902491","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sperm capacitation.\" [GOC:hjd, GOC:TermGenie, PMID:22539676]","metadata":null},{"id":"f1ab3d0c946442afa1686d76c30833e6","type":"GO_TERM","name":"negative regulation of spermatid nuclear differentiation","canonical_id":"go:GO:0045701","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of spermatid nuclear differentiation.\" [GOC:curators]","metadata":null},{"id":"f27e48ce01b1405a88579595b16e4c1e","type":"GO_TERM","name":"negative regulation of spermidine biosynthetic process","canonical_id":"go:GO:1901305","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of spermidine biosynthetic process.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"e259e1bdfca842acb3418839a952660a","type":"GO_TERM","name":"negative regulation of sphingolipid biosynthetic process","canonical_id":"go:GO:0090155","description":"\"Any process that decreases the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"7da61d7f11a44941a6e06d406a65ed3a","type":"GO_TERM","name":"negative regulation of sphingolipid mediated signaling pathway","canonical_id":"go:GO:1902069","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sphingolipid signaling.\" [GOC:TermGenie, PMID:20870412]","metadata":null},{"id":"b518fb2de67e4133977fa63ee6bfc9fb","type":"GO_TERM","name":"negative regulation of spinal cord association neuron differentiation","canonical_id":"go:GO:1902830","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of spinal cord association neuron differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:21730158]","metadata":null},{"id":"7245aeaefc3e48488cf23fb27caeccdc","type":"GO_TERM","name":"negative regulation of spindle assembly","canonical_id":"go:GO:1905831","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of spindle assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27689799]","metadata":null},{"id":"b123523570a44c998371fae7afda5fe7","type":"GO_TERM","name":"negative regulation of spindle checkpoint","canonical_id":"go:GO:0090233","description":"\"Any process that decreases the rate, frequency, or extent of the spindle checkpoint, a cell cycle checkpoint that delays the metaphase/anaphase transition until the spindle is correctly assembled and oriented, and chromosomes are attached to the spindle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"ffc339a121d3409891dad170f1b5ced5","type":"GO_TERM","name":"negative regulation of spontaneous neurotransmitter secretion","canonical_id":"go:GO:1904049","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of spontaneous neurotransmitter secretion.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22314364]","metadata":null},{"id":"4e4ea53b8f144c628b58ab5080e0e006","type":"GO_TERM","name":"negative regulation of sporangiospore formation","canonical_id":"go:GO:0075288","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sporangiospore formation, a process in which sporangiospores, a type of asexual spore found in fungi, are formed. Sporangiospores are formed within sac-like structure, the sporangium, following the division of the cytoplasm.\" [GOC:pamgo_curators]","metadata":null},{"id":"bf02573b00444fadae0ae67f10698843","type":"GO_TERM","name":"negative regulation of sporangium development","canonical_id":"go:GO:0075312","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sporangium development, a process that leads to the formation of sporangium, a single-celled or many-celled structure in which spores are produced, as in fungi, algae, mosses, and ferns, gymnosperms, angiosperms.\" [GOC:pamgo_curators]","metadata":null},{"id":"1ebd2e3751fe4c42a44984e3ca5690f2","type":"GO_TERM","name":"negative regulation of sporangium germination","canonical_id":"go:GO:0075225","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sporangium germination.\" [GOC:pamgo_curators]","metadata":null},{"id":"76fce99189d54d75b3c1169e97b4e46e","type":"GO_TERM","name":"negative regulation of spore encystment on host","canonical_id":"go:GO:0075217","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of spore encystment on host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"c6c3375c04e5464da27df8d8958b7a59","type":"GO_TERM","name":"negative regulation of spore germination","canonical_id":"go:GO:1904360","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of spore germination.\" [GO_REF:0000058, GOC:TermGenie, PMID:14718564, PMID:8798577]","metadata":null},{"id":"d4d3dfb823bc484aa39404a50e85c5a6","type":"GO_TERM","name":"negative regulation of spore-bearing organ development","canonical_id":"go:GO:0075262","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of spore-bearing organ development, a process in which hyphae grow into special aggregates called fruiting bodies that produce new spores.\" [GOC:pamgo_curators]","metadata":null},{"id":"0f4789d821034da88f38fa0109c5d23d","type":"GO_TERM","name":"negative regulation of sporocarp development involved in sexual reproduction","canonical_id":"go:GO:1902059","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sporocarp development involved in sexual reproduction.\" [GOC:di, GOC:TermGenie, PMID:23480775]","metadata":null},{"id":"2deda4bf410b4f218b2d8b06ee02ff4d","type":"GO_TERM","name":"negative regulation of sporulation","canonical_id":"go:GO:0043939","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sporulation, the process whose specific outcome is the progression of a spore over time, from its initiation to the mature structure.\" [GOC:pamgo_curators]","metadata":null},{"id":"a47b9e51e0d64d0b878f5eed826a2dcc","type":"GO_TERM","name":"negative regulation of sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0042174","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sporulation.\" [GOC:curators]","metadata":null},{"id":"f5ccab92d1514514a0e46819062b3026","type":"GO_TERM","name":"negative regulation of sprouting angiogenesis","canonical_id":"go:GO:1903671","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sprouting angiogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:16756958]","metadata":null},{"id":"38bf1816ff7f46d982373c2119d91d96","type":"GO_TERM","name":"negative regulation of sprouting of injured axon","canonical_id":"go:GO:0048688","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"d5baf8b5f152466a84fceefa9153c00b","type":"GO_TERM","name":"negative regulation of starch biosynthetic process","canonical_id":"go:GO:7770012","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of starch.\" [PMID:26554020]","metadata":null},{"id":"deeb07cd11e744c8a942dc342bca9b2a","type":"GO_TERM","name":"negative regulation of starch catabolic process","canonical_id":"go:GO:2000882","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of starch catabolic process.\" [GOC:obol]","metadata":null},{"id":"39957bf634274c99ba09143edf0dd707","type":"GO_TERM","name":"negative regulation of starch utilization system complex assembly","canonical_id":"go:GO:1900513","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of starch utilization system complex assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"cab908c904fe4a1d89d0ce32f2ea0efa","type":"GO_TERM","name":"negative regulation of stem cell differentiation","canonical_id":"go:GO:2000737","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"5b97af0908cd4e129fb5a7fa8a20f4ce","type":"GO_TERM","name":"negative regulation of stem cell population maintenance","canonical_id":"go:GO:1902455","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of stem cell population maintenance.\" [GOC:hjd, GOC:TermGenie, PMID:22969033]","metadata":null},{"id":"1926403135244e07b1a9765d582cb689","type":"GO_TERM","name":"negative regulation of stem cell proliferation","canonical_id":"go:GO:2000647","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of stem cell proliferation.\" [GOC:dph]","metadata":null},{"id":"42e654b4f3384f2584031a26e8009bd8","type":"GO_TERM","name":"negative regulation of sterigmatocystin biosynthetic process","canonical_id":"go:GO:1900760","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sterigmatocystin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a16aa0973fd940e8ad5ea9696f583514","type":"GO_TERM","name":"negative regulation of steroid biosynthetic process","canonical_id":"go:GO:0010894","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"7f581c8be3834e918b580d5db44854d0","type":"GO_TERM","name":"negative regulation of steroid hormone biosynthetic process","canonical_id":"go:GO:0090032","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroid hormones,compounds with a 1, 2, cyclopentanoperhydrophenanthrene nucleus that act as hormones.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0a32421e39234bb4901cdf99f0876332","type":"GO_TERM","name":"negative regulation of steroid hormone secretion","canonical_id":"go:GO:2000832","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of steroid hormone secretion.\" [GOC:sl]","metadata":null},{"id":"6dffb1ea17f74f40b268027668a9f0cb","type":"GO_TERM","name":"negative regulation of steroid metabolic process","canonical_id":"go:GO:0045939","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving steroids.\" [GOC:curators]","metadata":null},{"id":"0e1199c98cdc426d9f5b9b7ff1a0c5dd","type":"GO_TERM","name":"negative regulation of sterol biosynthetic process","canonical_id":"go:GO:0106119","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of a sterol biosynthetic process.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:16459310]","metadata":null},{"id":"77a4882e33d74c6dbaaf87b2556f5e2c","type":"GO_TERM","name":"negative regulation of sterol import","canonical_id":"go:GO:2000910","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of sterol import.\" [GOC:obol]","metadata":null},{"id":"2e47ad16d9e04b32b566b64e5848b44a","type":"GO_TERM","name":"negative regulation of sterol transport","canonical_id":"go:GO:0032372","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of sterols into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"5d50d6396c3447629d363a51e8581032","type":"GO_TERM","name":"negative regulation of stomach fundus smooth muscle contraction","canonical_id":"go:GO:0120070","description":"\"Any process that decreases the frequency, rate or extent of any stomach fundus smooth muscle contraction.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"e17fdc1b1ec1437897409c76fb6e84cd","type":"GO_TERM","name":"negative regulation of stomach neuroendocrine cell differentiation","canonical_id":"go:GO:0061106","description":"\"Any process that decreases the rate, frequency or extent of the differentiation of a neuroendocrine cell in the stomach.\" [GOC:dph]","metadata":null},{"id":"26c618fa4d22468d984a96b8d53ce803","type":"GO_TERM","name":"negative regulation of stomatal complex development","canonical_id":"go:GO:2000122","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of stomatal complex development.\" [GOC:obol]","metadata":null},{"id":"9dd53df6338248f68fb1959e85b6625f","type":"GO_TERM","name":"negative regulation of stomatal opening","canonical_id":"go:GO:1902457","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of stomatal opening.\" [GOC:TermGenie, PMID:23766366]","metadata":null},{"id":"5b513562a43b4130b3ad924079f16e09","type":"GO_TERM","name":"negative regulation of store-operated calcium channel activity","canonical_id":"go:GO:1901340","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of store-operated calcium channel activity.\" [GOC:TermGenie]","metadata":null},{"id":"fd8b98a7d7524f25baa110f7f43e8853","type":"GO_TERM","name":"negative regulation of store-operated calcium entry","canonical_id":"go:GO:0106128","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of store-operated calcium entry.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:23447642]","metadata":null},{"id":"4de83da260c54346b6c843051324f459","type":"GO_TERM","name":"negative regulation of strand invasion","canonical_id":"go:GO:0060543","description":"\"Any process that decreases the rate, frequency or extent of strand invasion. Strand invasion is the process in which the nucleoprotein complex (composed of the broken single-strand DNA and the recombinase) searches and identifies a region of homology in intact duplex DNA. The broken single-strand DNA displaces the like strand and forms Watson-Crick base pairs with its complement, forming a duplex in which each strand is from one of the two recombining DNA molecules.\" [GOC:dph, GOC:elh, GOC:tb]","metadata":null},{"id":"1bde9e208d27482c9de5856c392b1127","type":"GO_TERM","name":"negative regulation of stress fiber assembly","canonical_id":"go:GO:0051497","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly a stress fiber, a bundle of microfilaments and other proteins found in fibroblasts.\" [GOC:ai]","metadata":null},{"id":"3d0ae9e4d84348f890f1b25e6bf90100","type":"GO_TERM","name":"negative regulation of stress response to copper ion","canonical_id":"go:GO:1903854","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of stress response to copper ion.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:23437011]","metadata":null},{"id":"9f22fc67959c4ece9a8115e83cc64a70","type":"GO_TERM","name":"negative regulation of stress-activated MAPK cascade","canonical_id":"go:GO:0032873","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the stress-activated MAPK cascade.\" [GOC:mah]","metadata":null},{"id":"3c55c30fbd0b4423a9710bb0507fcff3","type":"GO_TERM","name":"negative regulation of stress-activated protein kinase signaling cascade","canonical_id":"go:GO:0070303","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of signaling via the stress-activated protein kinase signaling cascade.\" [GOC:mah]","metadata":null},{"id":"7ae0daa5593c481bbc08e161584d1b55","type":"GO_TERM","name":"negative regulation of striated muscle cell apoptotic process","canonical_id":"go:GO:0010664","description":"\"Any process that decreases the rate or extent of striated muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a striated muscle cell and result in its death.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:rl, GOC:tb]","metadata":null},{"id":"6daabc9f540c485f91c73cca05980d55","type":"GO_TERM","name":"negative regulation of striated muscle cell differentiation","canonical_id":"go:GO:0051154","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle cell differentiation.\" [CL:0000737, GOC:ai]","metadata":null},{"id":"847dcec3942b44b6a3a8692c35b19294","type":"GO_TERM","name":"negative regulation of striated muscle contraction","canonical_id":"go:GO:0045988","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle contraction.\" [GOC:curators]","metadata":null},{"id":"47c5c89bf95f4cc7884f9978eec597c2","type":"GO_TERM","name":"negative regulation of striated muscle tissue development","canonical_id":"go:GO:0045843","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle development.\" [GOC:curators]","metadata":null},{"id":"13698437e96b4f61b2fd5fca2adc95d7","type":"GO_TERM","name":"negative regulation of substance P secretion","canonical_id":"go:GO:1904459","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of substance P secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11278900]","metadata":null},{"id":"f11a5ea1657244f0879d598d73d20230","type":"GO_TERM","name":"negative regulation of substance P secretion, neurotransmission","canonical_id":"go:GO:1904495","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of substance P secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:15292051]","metadata":null},{"id":"9cf6982cdf834ee58d2e9c5da6d0095b","type":"GO_TERM","name":"negative regulation of substrate adhesion-dependent cell spreading","canonical_id":"go:GO:1900025","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of substrate adhesion-dependent cell spreading.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"cf7727b1c81f49d98979695c6d3be3f8","type":"GO_TERM","name":"negative regulation of substrate-dependent cell migration, cell attachment to substrate","canonical_id":"go:GO:1904236","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of substrate-dependent cell migration, cell attachment to substrate.\" [GO_REF:0000058, GOC:TermGenie, PMID:25834989]","metadata":null},{"id":"5294a7d703a049dd92166d56b56a91c8","type":"GO_TERM","name":"negative regulation of sulfur utilization","canonical_id":"go:GO:0045882","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of sulfur utilization.\" [GOC:curators]","metadata":null},{"id":"1ce1943bc31f42868d19c2a819ec5edc","type":"GO_TERM","name":"negative regulation of superoxide anion generation","canonical_id":"go:GO:0032929","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of enzymatic generation of superoxide by a cell.\" [GOC:mah]","metadata":null},{"id":"ed4a0d73b5244b20a66b6f6183d69697","type":"GO_TERM","name":"negative regulation of supramolecular fiber organization","canonical_id":"go:GO:1902904","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of fibril organization.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:23921388]","metadata":null},{"id":"cc202d2630674563826b49b944c04a83","type":"GO_TERM","name":"negative regulation of synapse assembly","canonical_id":"go:GO:0051964","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of synapse assembly, the aggregation, arrangement and bonding together of a set of components to form a synapse.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"12c46a7242974962b0aa5e28f0bf384e","type":"GO_TERM","name":"negative regulation of synapse maturation","canonical_id":"go:GO:2000297","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synapse maturation.\" [GOC:mah]","metadata":null},{"id":"08afc5cf75ee4a128a3fff58b419a14b","type":"GO_TERM","name":"negative regulation of synapse organization","canonical_id":"go:GO:1905809","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synapse organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"d7da80dc696b437c8f831fd77f9fbcdb","type":"GO_TERM","name":"negative regulation of synapse pruning","canonical_id":"go:GO:1905807","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synapse pruning.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"36b59a8ff1514a8a8cc5ad9bc1619540","type":"GO_TERM","name":"negative regulation of synapse structural plasticity","canonical_id":"go:GO:0051826","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of synapse structural plasticity.\" [GOC:ai]","metadata":null},{"id":"c064f4912f93480bafdc4e11cb6dc03d","type":"GO_TERM","name":"negative regulation of synaptic assembly at neuromuscular junction","canonical_id":"go:GO:0045886","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic assembly at neuromuscular junction.\" [GOC:curators]","metadata":null},{"id":"e117311c27f949be8b583702747e1825","type":"GO_TERM","name":"negative regulation of synaptic metaplasticity","canonical_id":"go:GO:0031917","description":"\"A process that decreases synaptic metaplasticity. Metaplasticity is a higher-order form of plasticity and is manifest as a change in the ability to induce subsequent synaptic plasticity that is the ability of synapses to change as circumstances require.\" [GOC:mah, PMID:8658594]","metadata":null},{"id":"d2d79584da8544738b09e12348fae321","type":"GO_TERM","name":"negative regulation of synaptic plasticity","canonical_id":"go:GO:0031914","description":"\"A process that decreases synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.\" [GOC:mah]","metadata":null},{"id":"9a990685fe594e339360641d6d12943e","type":"GO_TERM","name":"negative regulation of synaptic transmission","canonical_id":"go:GO:0050805","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.\" [GOC:ai]","metadata":null},{"id":"8767b3e660264e599dcc9b71a1a1d134","type":"GO_TERM","name":"negative regulation of synaptic transmission, GABAergic","canonical_id":"go:GO:0032229","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of GABAergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter gamma-aminobutyric acid (GABA).\" [GOC:mah]","metadata":null},{"id":"f00c600578da434eafd2f30e6200352b","type":"GO_TERM","name":"negative regulation of synaptic transmission, cholinergic","canonical_id":"go:GO:0032223","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of cholinergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter acetylcholine.\" [GOC:mah]","metadata":null},{"id":"9efdff56848d4b0c8ff3ed8edcc2e44a","type":"GO_TERM","name":"negative regulation of synaptic transmission, dopaminergic","canonical_id":"go:GO:0032227","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine.\" [GOC:mah]","metadata":null},{"id":"cae4826cb81b490c93f4c70a21bdc4e4","type":"GO_TERM","name":"negative regulation of synaptic transmission, glutamatergic","canonical_id":"go:GO:0051967","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate.\" [GOC:ai]","metadata":null},{"id":"8f81879eecb5473a8e8a8995c0ea8051","type":"GO_TERM","name":"negative regulation of synaptic transmission, glycinergic","canonical_id":"go:GO:0060093","description":"\"Any process that stops or decreases the frequency, rate or extent of glycinergic synaptic transmission. Glycinergic synaptic transmission is the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glycine.\" [GOC:dms, GOC:dph]","metadata":null},{"id":"bfe43de5ba174430a66f9091759f8447","type":"GO_TERM","name":"negative regulation of synaptic vesicle clustering","canonical_id":"go:GO:2000808","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle clustering.\" [PMID:21513708]","metadata":null},{"id":"42a2f1ebc5bb459998a5331be6fee4f2","type":"GO_TERM","name":"negative regulation of synaptic vesicle endocytosis","canonical_id":"go:GO:1900243","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle endocytosis.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"dd681e4f8eb54c9e878bf29e90abfce1","type":"GO_TERM","name":"negative regulation of synaptic vesicle exocytosis","canonical_id":"go:GO:2000301","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle exocytosis.\" [GOC:obol]","metadata":null},{"id":"ee9d200c49274eb5bdd3624cb156591e","type":"GO_TERM","name":"negative regulation of synaptic vesicle fusion to presynaptic active zone membrane","canonical_id":"go:GO:0031631","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic vesicle fusion to the presynaptic membrane.\" [GOC:mah]","metadata":null},{"id":"ca3134fb998d4554aa8f7d4c504e6ef0","type":"GO_TERM","name":"negative regulation of synaptic vesicle lumen acidification","canonical_id":"go:GO:1901547","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle lumen acidification.\" [GOC:TermGenie]","metadata":null},{"id":"eef41f233210436b9be7c8f6ff0908e2","type":"GO_TERM","name":"negative regulation of synaptic vesicle membrane organization","canonical_id":"go:GO:1901633","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"9db6720ef15243c0b9187961d13006ce","type":"GO_TERM","name":"negative regulation of synaptic vesicle priming","canonical_id":"go:GO:0010809","description":"\"Any process that decreases the frequency, rate or extent of synaptic vesicle priming. Synaptic vesicle priming is the formation of SNARE-containing complexes, bringing synaptic vesicle membrane and plasma membranes into close proximity and thereby facilitating membrane fusion.\" [GOC:dph, GOC:kmvs, GOC:tb, PMID:15489511]","metadata":null},{"id":"957577d186ac4286851b2b15d9f42a0b","type":"GO_TERM","name":"negative regulation of synaptic vesicle recycling","canonical_id":"go:GO:1903422","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle recycling.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22745285]","metadata":null},{"id":"0c97fcf754f746f08f9e554f6ddfbdfa","type":"GO_TERM","name":"negative regulation of synaptic vesicle transport","canonical_id":"go:GO:1902804","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle transport.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:23527112]","metadata":null},{"id":"43c06633f9914e6fa3681ac4011ecf16","type":"GO_TERM","name":"negative regulation of synaptic vesicle uncoating","canonical_id":"go:GO:1903389","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle uncoating.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21563316]","metadata":null},{"id":"2d5fec2c725e4f6aad63d34abe854966","type":"GO_TERM","name":"negative regulation of syncytial blastoderm mitotic cell cycle","canonical_id":"go:GO:0046003","description":"\"Any process that stops, prevents or reduces the rate or extent of progression through the syncytial blastoderm mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"11970c0013b94cd8980934ca6d5276e1","type":"GO_TERM","name":"negative regulation of syncytium formation by plasma membrane fusion","canonical_id":"go:GO:0034242","description":"\"Any process that decreases the frequency, rate or extent of the formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by the fusion of the plasma membranes of two or more individual cells.\" [GOC:mah]","metadata":null},{"id":"af322908f66946a9ab8bb0d23b433e72","type":"GO_TERM","name":"negative regulation of synergid differentiation","canonical_id":"go:GO:0045698","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of synergid cell differentiation.\" [GOC:curators]","metadata":null},{"id":"fb755524a2ff4966a0d797e62b6a14ed","type":"GO_TERM","name":"negative regulation of synoviocyte proliferation","canonical_id":"go:GO:1901646","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of synoviocyte proliferation.\" [GOC:TermGenie]","metadata":null},{"id":"809808b0d59c4df989ac6b38a0238e4f","type":"GO_TERM","name":"negative regulation of syringal lignin biosynthetic process","canonical_id":"go:GO:1901429","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of syringal lignin biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"67b76a58e3374be78970ca6cbc89d5fb","type":"GO_TERM","name":"negative regulation of syringal lignin catabolic process","canonical_id":"go:GO:1901470","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of syringal lignin catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"5c94f9dbd5b54c7d9ae9fbdcae054636","type":"GO_TERM","name":"negative regulation of systemic acquired resistance","canonical_id":"go:GO:0010113","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of systemic acquired resistance.\" [GOC:sm]","metadata":null},{"id":"ce9009b892134dc1a05317f8d41f5b76","type":"GO_TERM","name":"negative regulation of systemic arterial blood pressure","canonical_id":"go:GO:0003085","description":"\"The process that reduces the force with which blood travels through the systemic arterial circulatory system.\" [GOC:mtg_cardio]","metadata":null},{"id":"338170514d3e436588e6010cce12eeee","type":"GO_TERM","name":"negative regulation of t-SNARE clustering","canonical_id":"go:GO:1904033","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of t-SNARE clustering.\" [GO_REF:0000058, GOC:TermGenie, PMID:22528485]","metadata":null},{"id":"798d4daaf4074ea6b74c912c215c44ca","type":"GO_TERM","name":"negative regulation of t-circle formation","canonical_id":"go:GO:1904430","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of t-circle formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"661f7de4a5e64f1abec6d99b8c654b06","type":"GO_TERM","name":"negative regulation of tRNA catabolic process","canonical_id":"go:GO:1902371","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tRNA catabolic process.\" [GOC:bf, GOC:TermGenie, PMID:22919049]","metadata":null},{"id":"defbb76d5f05436eba91052c6a60552f","type":"GO_TERM","name":"negative regulation of tRNA export from nucleus","canonical_id":"go:GO:2000239","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of tRNA export from nucleus.\" [GOC:mah]","metadata":null},{"id":"1e1d7ebebdf04193881a663462f8ed3a","type":"GO_TERM","name":"negative regulation of tRNA metabolic process","canonical_id":"go:GO:1903327","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"e4eaa2294a1d43e2bbedd1aa1f4eb441","type":"GO_TERM","name":"negative regulation of tRNA processing","canonical_id":"go:GO:2000236","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of tRNA processing.\" [GOC:mah]","metadata":null},{"id":"1cba63451b6643a6b3334a527fa7d005","type":"GO_TERM","name":"negative regulation of teliospore formation","canonical_id":"go:GO:0075258","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of teliospore formation, which is the formation of a thick-walled resting or overwintering spore produced by the rust fungi (Uredinales) and smut fungi (Ustilaginales) in which karyogamy occurs.\" [GOC:pamgo_curators]","metadata":null},{"id":"ccf845d339a549168f5d996cb99bb665","type":"GO_TERM","name":"negative regulation of telium development","canonical_id":"go:GO:0075278","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of telium development, a process that leads to the formation of a teliospore-bearing sorus of the rust fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"bed4f282fd9d406cb7e98686f6021af4","type":"GO_TERM","name":"negative regulation of telomerase RNA localization to Cajal body","canonical_id":"go:GO:1904873","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomerase RNA localization to Cajal body.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"54faf05ec12d45ddb4841d3285e1ac6e","type":"GO_TERM","name":"negative regulation of telomerase catalytic core complex assembly","canonical_id":"go:GO:1904883","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomerase catalytic core complex assembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"ce9593d0b52f49aa85a04a45e0030147","type":"GO_TERM","name":"negative regulation of telomere capping","canonical_id":"go:GO:1904354","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomere capping.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23959892]","metadata":null},{"id":"320f98bed79f44b7aafee1dde5c10e50","type":"GO_TERM","name":"negative regulation of telomere maintenance","canonical_id":"go:GO:0032205","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a process that affects and monitors the activity of telomeric proteins and the length of telomeric DNA.\" [GOC:mah]","metadata":null},{"id":"b0d57f6e9e8d48d5a4f887fe87d6fddf","type":"GO_TERM","name":"negative regulation of telomere maintenance in response to DNA damage","canonical_id":"go:GO:1904506","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomere maintenance in response to DNA damage.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"3031451baa4e43bd93c37da5a35321bf","type":"GO_TERM","name":"negative regulation of telomere maintenance via recombination","canonical_id":"go:GO:0032208","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a recombinational process involved in the maintenance of proper telomeric length.\" [GOC:mah]","metadata":null},{"id":"2e97e532b650436cb84ef4707161139c","type":"GO_TERM","name":"negative regulation of telomere maintenance via semi-conservative replication","canonical_id":"go:GO:0032214","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the semi-conservative replication of telomeric DNA.\" [GOC:mah]","metadata":null},{"id":"05d3a0e3a16e4ce9a2d04dc950e38fdb","type":"GO_TERM","name":"negative regulation of telomere maintenance via telomerase","canonical_id":"go:GO:0032211","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of telomeric repeats by telomerase.\" [GOC:mah]","metadata":null},{"id":"40a4829567cd4d9eacfa7ea2a4ee4c99","type":"GO_TERM","name":"negative regulation of telomere maintenance via telomere lengthening","canonical_id":"go:GO:1904357","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomere maintenance via telomere lengthening.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23959892]","metadata":null},{"id":"07b75a9050fa4094affbbd22b7053d24","type":"GO_TERM","name":"negative regulation of telomere single strand break repair","canonical_id":"go:GO:1903824","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomere single strand break repair.\" [GO_REF:0000058, GOC:TermGenie, PMID:24374808]","metadata":null},{"id":"f2f72d7c38ef493490a099dda289e7e6","type":"GO_TERM","name":"negative regulation of telomeric D-loop disassembly","canonical_id":"go:GO:1905839","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomeric D-loop disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:15200954]","metadata":null},{"id":"23352fe539f6432ebc730bb03742aeb2","type":"GO_TERM","name":"negative regulation of telomeric loop disassembly","canonical_id":"go:GO:1904534","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomeric loop disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"bf5fbb0418f948ed85550a0421f298d4","type":"GO_TERM","name":"negative regulation of telomeric loop formation","canonical_id":"go:GO:1904419","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of telomeric loop formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"84fa5872dc094ffbba969e005f4bdac4","type":"GO_TERM","name":"negative regulation of tendon cell differentiation","canonical_id":"go:GO:2001050","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tendon cell differentiation.\" [GOC:obol]","metadata":null},{"id":"5425c948c1694c89b92d282e347caf39","type":"GO_TERM","name":"negative regulation of tensidol A biosynthetic process","canonical_id":"go:GO:1900708","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tensidol A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"702a370e2b0f42bdbdb6454b31fa7449","type":"GO_TERM","name":"negative regulation of tensidol B biosynthetic process","canonical_id":"go:GO:1900711","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tensidol B biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2c88d0a85ae54e288917cb866f93a904","type":"GO_TERM","name":"negative regulation of terminal button organization","canonical_id":"go:GO:1901613","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of terminal button organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"42a75884b34f4490a6da060153aa6c47","type":"GO_TERM","name":"negative regulation of terminal cell fate specification, open tracheal system","canonical_id":"go:GO:0035155","description":"\"Any process that restricts, stops or prevents a cell from adopting a terminal cell fate in an open tracheal system. Once the terminal and fusion fates have been correctly induced, inhibitory feedback loops prevent the remaining branch cells from assuming similar fates.\" [GOC:mtg_sensu, PMID:10684581]","metadata":null},{"id":"4467662a16b649b7a577eb37b6abccf9","type":"GO_TERM","name":"negative regulation of termination of DNA-templated transcription","canonical_id":"go:GO:0060567","description":"\"Any process that decreases the rate, frequency or extent of DNA-dependent transcription termination, the process in which transcription is completed; the formation of phosphodiester bonds ceases, the RNA-DNA hybrid dissociates, and RNA polymerase releases the DNA.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"5e1fc3faee014bc2886082c352791f2c","type":"GO_TERM","name":"negative regulation of termination of RNA polymerase I transcription","canonical_id":"go:GO:2000731","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of termination of RNA polymerase I transcription.\" [GOC:obol]","metadata":null},{"id":"8740670ce4464aa2baa983c0d1cbaf30","type":"GO_TERM","name":"negative regulation of termination of RNA polymerase II transcription","canonical_id":"go:GO:0120191","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of termination of RNA polymerase II transcription.\" [GOC:krc, GOC:vw, PMID:29899453]","metadata":null},{"id":"bfb137b17d2b487492127dcf2666a457","type":"GO_TERM","name":"negative regulation of termination of RNA polymerase II transcription, poly(A)-coupled","canonical_id":"go:GO:2000805","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of termination of RNA polymerase II transcription, poly(A)-coupled.\" [GOC:obol]","metadata":null},{"id":"bb20421736964d81ab81fb16ca494213","type":"GO_TERM","name":"negative regulation of testicular blood vessel morphogenesis","canonical_id":"go:GO:0061369","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of blood vessel morphogenesis in the testicle.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"822cd05cc3614bac863b737bc7de7010","type":"GO_TERM","name":"negative regulation of testosterone biosynthetic process","canonical_id":"go:GO:2000225","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of testosterone biosynthetic process.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"e629ac3f25cf435dbf4c2a491517d873","type":"GO_TERM","name":"negative regulation of testosterone secretion","canonical_id":"go:GO:2000844","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of testosterone secretion.\" [GOC:sl]","metadata":null},{"id":"f80cd20af3b0435aac5f0052755cf379","type":"GO_TERM","name":"negative regulation of tetrapyrrole biosynthetic process","canonical_id":"go:GO:1901464","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tetrapyrrole biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c5c81cc273a94e778f95ad0fd19dcd3a","type":"GO_TERM","name":"negative regulation of tetrapyrrole catabolic process","canonical_id":"go:GO:1901405","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tetrapyrrole catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"75b9a663c1434a4c9d5b28cf24dd3262","type":"GO_TERM","name":"negative regulation of the force of heart contraction","canonical_id":"go:GO:0098736","description":"\"Any process that decreases the force of heart muscle contraction.\" [GOC:BHF, GOC:dos, GOC:mtg_cardiac_conduct_nov11, GOC:rl, PMID:17242280]","metadata":null},{"id":"d656349725f145a199a0a8e6f9230837","type":"GO_TERM","name":"negative regulation of the force of heart contraction by acetylcholine","canonical_id":"go:GO:0003060","description":"\"The process in which acetylcholine released from vagus nerve endings binds to muscarinic receptors and decreases the force of heart muscle contraction.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"fb1c09c5158e4e79ae70fccd0852ff10","type":"GO_TERM","name":"negative regulation of the force of heart contraction by chemical signal","canonical_id":"go:GO:0003108","description":"\"Any process which decreases the force of heart muscle contraction mediated by chemical signaling, hormonal, autocrine or paracrine.\" [GOC:mtg_cardio]","metadata":null},{"id":"5a7b87d93e3b40028be16bb842910321","type":"GO_TERM","name":"negative regulation of the force of heart contraction involved in baroreceptor response to increased systemic arterial blood pressure","canonical_id":"go:GO:0001986","description":"\"Any process that decreases the force with which the cardiac muscles of the heart pump blood through the circulatory system as a result of the baroreceptor response to increased blood pressure.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"f4e578e8a19d4e74aac7a32f462f70d2","type":"GO_TERM","name":"negative regulation of thermomorphogenesis","canonical_id":"go:GO:0140921","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of thermomorphogenesis.\" [PMID:27250752]","metadata":null},{"id":"c297ca02a55840559bf9a78a73c4aee6","type":"GO_TERM","name":"negative regulation of thiamine biosynthetic process","canonical_id":"go:GO:0070624","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of thiamine.\" [GOC:mah]","metadata":null},{"id":"bbe5c843003f41df9b40534ea3c0701b","type":"GO_TERM","name":"negative regulation of thiamine diphosphate biosynthetic process","canonical_id":"go:GO:0070617","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of thiamine diphosphate.\" [GOC:mah]","metadata":null},{"id":"e08e2dcbbd2f40c6b0143b0e2dd1c497","type":"GO_TERM","name":"negative regulation of thrombin-activated receptor signaling pathway","canonical_id":"go:GO:0070495","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of thrombin-activated receptor protein signaling pathway activity. A thrombin receptor signaling pathway is the series of molecular signals generated as a consequence of a thrombin-activated receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"b02edfd60cce4b2f8ba8dd45baba4aa7","type":"GO_TERM","name":"negative regulation of thymine transport","canonical_id":"go:GO:0035366","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of thymine, 5-methyluracil, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf, GOC:sl]","metadata":null},{"id":"05fb4015ba434bcbae5e0f61769eafb5","type":"GO_TERM","name":"negative regulation of thymocyte aggregation","canonical_id":"go:GO:2000399","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of thymocyte aggregation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"45092c5f3f4a4527acbb0f43166ff227","type":"GO_TERM","name":"negative regulation of thymocyte apoptotic process","canonical_id":"go:GO:0070244","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of thymocyte death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"a63d461a842e42fdb05f7ce60ba04c9b","type":"GO_TERM","name":"negative regulation of thymocyte migration","canonical_id":"go:GO:2000411","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of thymocyte migration.\" [GOC:mah]","metadata":null},{"id":"201aba51771041059007ecb9456387f1","type":"GO_TERM","name":"negative regulation of thyroid gland epithelial cell proliferation","canonical_id":"go:GO:1904442","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of thyroid gland epithelial cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:17646383]","metadata":null},{"id":"bc7ab863c6af41259ddefab4d2b54195","type":"GO_TERM","name":"negative regulation of thyroid hormone generation","canonical_id":"go:GO:2000610","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of thyroid hormone generation.\" [GOC:obol]","metadata":null},{"id":"84b8ee39e8a34932b890fb5804c17b72","type":"GO_TERM","name":"negative regulation of thyroid hormone receptor signaling pathway","canonical_id":"go:GO:0002156","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of thyroid hormone mediated signaling pathway.\" [GOC:hjd]","metadata":null},{"id":"124794435c534e2c8bb18e0422c5829e","type":"GO_TERM","name":"negative regulation of thyroid-stimulating hormone secretion","canonical_id":"go:GO:2000613","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of thyroid-stimulating hormone secretion.\" [GOC:obol]","metadata":null},{"id":"2149855bb63a48bbbd0db21093db1a3b","type":"GO_TERM","name":"negative regulation of tight junction disassembly","canonical_id":"go:GO:1905074","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tight junction disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"5b5243db00584f698771f53bd5430d95","type":"GO_TERM","name":"negative regulation of timing of anagen","canonical_id":"go:GO:0051886","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of timing of anagen, the growth phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"741cf0e2badd45a4b27745c0cb197a7e","type":"GO_TERM","name":"negative regulation of timing of catagen","canonical_id":"go:GO:0051796","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of timing of catagen, the regression phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"2959458750f44ba6a329efcdd5e6a240","type":"GO_TERM","name":"negative regulation of timing of exogen","canonical_id":"go:GO:0051889","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of timing of exogen, the shedding phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"8b3e6ca907f64c52a58cd86e7f530378","type":"GO_TERM","name":"negative regulation of tissue kallikrein-kinin cascade","canonical_id":"go:GO:0002546","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of the tissue kallikrein-kinin cascade.\" [GOC:add]","metadata":null},{"id":"1d6e1c0ed6c24d32a8ddacf6d2e5b21e","type":"GO_TERM","name":"negative regulation of tissue remodeling","canonical_id":"go:GO:0034104","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tissue remodeling.\" [GOC:add]","metadata":null},{"id":"86d5f70b48bd43f988ceb412fb829296","type":"GO_TERM","name":"negative regulation of tolerance induction","canonical_id":"go:GO:0002644","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tolerance induction.\" [GOC:add]","metadata":null},{"id":"49797ce0b761485aacc9d914f4b462d6","type":"GO_TERM","name":"negative regulation of tolerance induction dependent upon immune response","canonical_id":"go:GO:0002653","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tolerance induction dependent upon immune response.\" [GOC:add]","metadata":null},{"id":"05723cde03a1441dade18fef8e658c35","type":"GO_TERM","name":"negative regulation of tolerance induction to nonself antigen","canonical_id":"go:GO:0002656","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tolerance induction to nonself antigen.\" [GOC:add]","metadata":null},{"id":"dc7c5aa26445467c9b4c1e55d63b3f13","type":"GO_TERM","name":"negative regulation of tolerance induction to self antigen","canonical_id":"go:GO:0002650","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tolerance induction to self antigen.\" [GOC:add]","metadata":null},{"id":"477d208f634f409f85081f1d56dad8f3","type":"GO_TERM","name":"negative regulation of tolerance induction to tumor cell","canonical_id":"go:GO:0002844","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tolerance induction to tumor cell.\" [GOC:add]","metadata":null},{"id":"7dc40aa05d9e46e08cfe0b4a945c843f","type":"GO_TERM","name":"negative regulation of toll-like receptor 1 signaling pathway","canonical_id":"go:GO:0034132","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 1 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"04906148a44743fb96eeec3194f5eba7","type":"GO_TERM","name":"negative regulation of toll-like receptor 10 signaling pathway","canonical_id":"go:GO:0034168","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 10 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"796fffc3226741aca2fb52cfe769d55f","type":"GO_TERM","name":"negative regulation of toll-like receptor 11 signaling pathway","canonical_id":"go:GO:0034172","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 11 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"13756cf987be474b9b0cd009e8d91dd9","type":"GO_TERM","name":"negative regulation of toll-like receptor 12 signaling pathway","canonical_id":"go:GO:0034176","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 12 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"89d273012661409ea29961b62dbd0385","type":"GO_TERM","name":"negative regulation of toll-like receptor 13 signaling pathway","canonical_id":"go:GO:0034180","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 13 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"7447ec78a1ba4481bc703f3e1420ea2c","type":"GO_TERM","name":"negative regulation of toll-like receptor 15 signaling pathway","canonical_id":"go:GO:2000441","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of toll-like receptor 15 signaling pathway.\" [GOC:obol]","metadata":null},{"id":"39e7d590eea74caba2aa8cbf1f3a87e7","type":"GO_TERM","name":"negative regulation of toll-like receptor 2 signaling pathway","canonical_id":"go:GO:0034136","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 2 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"813ee9e87fe54575ad17a71d09c62654","type":"GO_TERM","name":"negative regulation of toll-like receptor 21 signaling pathway","canonical_id":"go:GO:2000444","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of toll-like receptor 21 signaling pathway.\" [GOC:obol]","metadata":null},{"id":"69da1c0e69fc41f1a237cb2afcff2a42","type":"GO_TERM","name":"negative regulation of toll-like receptor 3 signaling pathway","canonical_id":"go:GO:0034140","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 3 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"8959c2291d90470d8e1ad83afb73e20c","type":"GO_TERM","name":"negative regulation of toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0034144","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 4 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"6836014534c840729bee9189a5351c9c","type":"GO_TERM","name":"negative regulation of toll-like receptor 5 signaling pathway","canonical_id":"go:GO:0034148","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 5 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"b8878489a4164586ade54ef5a6456886","type":"GO_TERM","name":"negative regulation of toll-like receptor 6 signaling pathway","canonical_id":"go:GO:0034152","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 6 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"d9343170926045efbce7a0d1d5ab57f7","type":"GO_TERM","name":"negative regulation of toll-like receptor 7 signaling pathway","canonical_id":"go:GO:0034156","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 7 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"ddd6d91ca6ae405296d03a87704d76ea","type":"GO_TERM","name":"negative regulation of toll-like receptor 8 signaling pathway","canonical_id":"go:GO:0034160","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 8 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"f8b05af9ee8744db89a1ef1153975300","type":"GO_TERM","name":"negative regulation of toll-like receptor 9 signaling pathway","canonical_id":"go:GO:0034164","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 9 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"5b460001177c41469b3983abe7fa6a9d","type":"GO_TERM","name":"negative regulation of toll-like receptor signaling pathway","canonical_id":"go:GO:0034122","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"3d11ed5ec8bc4983ab056b162adc0cce","type":"GO_TERM","name":"negative regulation of toluene catabolic process","canonical_id":"go:GO:1901435","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of toluene catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f4c311cd8bcd4a5a86f12b08918bbc5c","type":"GO_TERM","name":"negative regulation of tongue muscle cell differentiation","canonical_id":"go:GO:2001036","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tongue muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"aa5e8064678443f2a48f74774a02c972","type":"GO_TERM","name":"negative regulation of tonic skeletal muscle contraction","canonical_id":"go:GO:0014748","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of tonic skeletal muscle contraction.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"18229fcaf6ff45cdb8dc6cc9e634310e","type":"GO_TERM","name":"negative regulation of tooth mineralization","canonical_id":"go:GO:0070171","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of tooth mineralization, the deposition of calcium salts in tooth structures.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"90ed6aa33e484f49ac38e23430b80ff4","type":"GO_TERM","name":"negative regulation of torso signaling pathway","canonical_id":"go:GO:0120177","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the torso signaling pathway.\" [GOC:ha, PMID:23732470]","metadata":null},{"id":"22350e71e8ca4d5b994fc13f6e5f3d3c","type":"GO_TERM","name":"negative regulation of transcription by RNA polymerase I","canonical_id":"go:GO:0016479","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase I.\" [GOC:curators]","metadata":null},{"id":"ead84e624735475496bb7148c2a7ec14","type":"GO_TERM","name":"negative regulation of transcription by RNA polymerase II","canonical_id":"go:GO:0000122","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"1f8c8ff8ad004d2ab456a852f2d11265","type":"GO_TERM","name":"negative regulation of transcription by RNA polymerase III","canonical_id":"go:GO:0016480","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase III.\" [GOC:curators]","metadata":null},{"id":"df3b3de9a96048a28d11c13b37960310","type":"GO_TERM","name":"negative regulation of transcription by RNA polymerase V","canonical_id":"go:GO:1904280","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transcription mediated by RNA polymerase V.\" [GO_REF:0000058, GOC:TermGenie, PMID:24726328]","metadata":null},{"id":"9ea6fce786a044ccb37842dc12d0e6d3","type":"GO_TERM","name":"negative regulation of transcription by glucose","canonical_id":"go:GO:0061986","description":"\"Any process involving glucose that decreases the frequency, rate or extent or transcription.\" [PMID:11875061]","metadata":null},{"id":"d10cb449ba284398be7c60303fe54072","type":"GO_TERM","name":"negative regulation of transcription by transcription factor catabolism","canonical_id":"go:GO:0010620","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA-dependent transcription using a mechanism that involves the catabolism of a sequence-specific DNA-binding transcription factor by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.\" [GOC:bf, GOC:dph, GOC:tb]","metadata":null},{"id":"0386b152c8664819bacdf4357c00d4c2","type":"GO_TERM","name":"negative regulation of transcription elongation by RNA polymerase I","canonical_id":"go:GO:2001208","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transcription elongation mediated by RNA polymerase I.\" [PMID:20299458]","metadata":null},{"id":"dd69186648784e3f9551e6b3cedea0d7","type":"GO_TERM","name":"negative regulation of transcription elongation by RNA polymerase II","canonical_id":"go:GO:0034244","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"10f92fe344d447e58c2fa318f24db4af","type":"GO_TERM","name":"negative regulation of transcription from RNA polymerase II promoter by glucose","canonical_id":"go:GO:0061987","description":"\"Any process involving glucose that decreases the frequency, rate or extent or transcription from an RNA polymerase II promoter.\" [PMID:11875061]","metadata":null},{"id":"de66ff2e188d4fca8cc7fe017116bf2e","type":"GO_TERM","name":"negative regulation of transcription initiation by RNA polymerase II","canonical_id":"go:GO:0060633","description":"\"Any process that decreases the rate, frequency or extent of a process involved in starting transcription from an RNA polymerase II promoter.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"da76cb8300d4416a8f9ff7e637ef0864","type":"GO_TERM","name":"negative regulation of transcription initiation-coupled chromatin remodeling","canonical_id":"go:GO:0160217","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transcription initiation-coupled chromatin remodeling.\" [PMID:33980486]","metadata":null},{"id":"e1dd53955dbc4eca92e51ae3bca481e6","type":"GO_TERM","name":"negative regulation of transcription of nucleolar large rRNA by RNA polymerase I","canonical_id":"go:GO:1901837","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transcription of nuclear large rRNA transcript mediated by RNA polymerase I.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"9e461ceb2cc7414385681eb5baea3e59","type":"GO_TERM","name":"negative regulation of transcription regulatory region DNA binding","canonical_id":"go:GO:2000678","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transcription regulatory region DNA binding.\" [GOC:obol]","metadata":null},{"id":"3ffb28156fa04fe09b655c36f6f5951e","type":"GO_TERM","name":"negative regulation of transcytosis","canonical_id":"go:GO:1904299","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transcytosis.\" [GO_REF:0000058, GOC:TermGenie, PMID:9664076]","metadata":null},{"id":"29cee2ed72bc42c093a45726f93d0ed7","type":"GO_TERM","name":"negative regulation of transdifferentiation","canonical_id":"go:GO:1903619","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transdifferentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22118091]","metadata":null},{"id":"f3d016a00bcb44daa795b65111933f14","type":"GO_TERM","name":"negative regulation of transformation of host cell by virus","canonical_id":"go:GO:1904188","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transformation of host cell by virus.\" [GO_REF:0000058, GOC:TermGenie, PMID:12200142]","metadata":null},{"id":"d32d7811c77848cb9d7267dc9dc7227f","type":"GO_TERM","name":"negative regulation of transforming growth factor beta production","canonical_id":"go:GO:0071635","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta.\" [GOC:mah]","metadata":null},{"id":"3baac24a4d5f4feea322af9232bce77b","type":"GO_TERM","name":"negative regulation of transforming growth factor beta receptor signaling pathway","canonical_id":"go:GO:0030512","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of any TGF-beta receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"4b0f78e4a54245f9833f076d69996869","type":"GO_TERM","name":"negative regulation of transforming growth factor beta1 production","canonical_id":"go:GO:0032911","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta1.\" [GOC:mah]","metadata":null},{"id":"f5a1bfcd369d4b9d8e44bc5925a7e24c","type":"GO_TERM","name":"negative regulation of transforming growth factor beta2 production","canonical_id":"go:GO:0032912","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta2.\" [GOC:mah]","metadata":null},{"id":"d4b6e5e060164e72837f259fe5be3ffe","type":"GO_TERM","name":"negative regulation of transforming growth factor beta3 production","canonical_id":"go:GO:0032913","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta3.\" [GOC:mah]","metadata":null},{"id":"573e44e4911a4d408389dd039777aecd","type":"GO_TERM","name":"negative regulation of translation","canonical_id":"go:GO:0017148","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.\" [GOC:isa_complete]","metadata":null},{"id":"f54e803b79824f028af20a67d6e60e29","type":"GO_TERM","name":"negative regulation of translation in response to endoplasmic reticulum stress","canonical_id":"go:GO:1902010","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of translation as a result of endoplasmic reticulum stress.\" [GOC:dph, GOC:TermGenie, PMID:10882126]","metadata":null},{"id":"1419263df5854a1c8bb1c2198b120abb","type":"GO_TERM","name":"negative regulation of translation in response to osmotic stress","canonical_id":"go:GO:0032061","description":"\"Any process that stops, prevents or reduces the rate of translation as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:mah]","metadata":null},{"id":"9148697c313e4f4aac7fc132da92e4f4","type":"GO_TERM","name":"negative regulation of translation in response to oxidative stress","canonical_id":"go:GO:0032938","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of translation as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.\" [GOC:mah]","metadata":null},{"id":"ec8f9f4f6885457b82d97551de9b738e","type":"GO_TERM","name":"negative regulation of translation in response to stress","canonical_id":"go:GO:0032055","description":"\"Any process that stops, prevents or reduces the rate of translation as a result of a stimulus indicating the organism is under stress.\" [GOC:mah]","metadata":null},{"id":"e7e5067d94c4499ab154d9d0b8a4f8f3","type":"GO_TERM","name":"negative regulation of translation initiation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036495","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of translation initiation as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"0533af70546646268bbe11291b3714e8","type":"GO_TERM","name":"negative regulation of translational elongation","canonical_id":"go:GO:0045900","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of translational elongation.\" [GOC:curators]","metadata":null},{"id":"8385ca9e2437441a9746a5e91c54c9a9","type":"GO_TERM","name":"negative regulation of translational fidelity","canonical_id":"go:GO:0045902","description":"\"Any process that decreases the ability of the translational apparatus to interpret the genetic code.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9c4a319441ae4ae692ce331455e11647","type":"GO_TERM","name":"negative regulation of translational frameshifting","canonical_id":"go:GO:2001125","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of translational frameshifting.\" [GOC:obol]","metadata":null},{"id":"c956a98d2825439b966324f30fb37442","type":"GO_TERM","name":"negative regulation of translational initiation","canonical_id":"go:GO:0045947","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of translational initiation.\" [GOC:curators]","metadata":null},{"id":"d9ffa33b83e04fa78fea313903f7db74","type":"GO_TERM","name":"negative regulation of translational initiation by iron","canonical_id":"go:GO:0045993","description":"\"Any process involving iron that stops, prevents or reduces the rate of translational initiation.\" [GOC:curators]","metadata":null},{"id":"5f9cfdd6ca784ce9a77ef71ce3b678bc","type":"GO_TERM","name":"negative regulation of translational initiation in response to osmotic stress","canonical_id":"go:GO:0032063","description":"\"Any process that stops, prevents or reduces the rate of translation initiation, as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:mah]","metadata":null},{"id":"7d27625dc9f6474b92d240f3cee178db","type":"GO_TERM","name":"negative regulation of translational initiation in response to starvation","canonical_id":"go:GO:0071263","description":"\"Any process that stops, prevents or reduces the rate of translation initiation, as a result of deprivation of nourishment.\" [GOC:mah]","metadata":null},{"id":"15af3a1157344d46ba082a08eac856d9","type":"GO_TERM","name":"negative regulation of translational initiation in response to stress","canonical_id":"go:GO:0032057","description":"\"Any process that stops, prevents or reduces the rate of translation initiation as a result of a stimulus indicating the organism is under stress.\" [GOC:mah]","metadata":null},{"id":"cf872d891efb44598178155685734156","type":"GO_TERM","name":"negative regulation of translational termination","canonical_id":"go:GO:0045904","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of translational termination.\" [GOC:curators]","metadata":null},{"id":"9173ac64a28d4b889ef3f0ef492c71f7","type":"GO_TERM","name":"negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway","canonical_id":"go:GO:0090101","description":"\"Any process that decreases the rate, frequency, or extent of the series of molecular signals generated as a consequence of a transmembrane receptor serine/threonine kinase binding to its physiological ligand.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d92c0c1eb74f4df29660f587c8a53580","type":"GO_TERM","name":"negative regulation of transmembrane transport","canonical_id":"go:GO:0034763","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a solute from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"97a2d5bbb7234c538dda8957dac57753","type":"GO_TERM","name":"negative regulation of transmission of nerve impulse","canonical_id":"go:GO:0051970","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of transmission of a nerve impulse, the sequential electrochemical polarization and depolarization that travels across the membrane of a neuron in response to stimulation.\" [GOC:ai]","metadata":null},{"id":"3faf4df9533146b39648c37503297474","type":"GO_TERM","name":"negative regulation of transport","canonical_id":"go:GO:0051051","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"bfb5f9fdaf784383b379a97365588961","type":"GO_TERM","name":"negative regulation of transport across blood-brain barrier","canonical_id":"go:GO:0150202","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of transport across blood-brain barrier.\" [GOC:aruk, GOC:bc, PMID:29377008, PMID:30280653]","metadata":null},{"id":"83816d15d3754ec5afa26e5e1e4962e5","type":"GO_TERM","name":"negative regulation of transporter activity","canonical_id":"go:GO:0032410","description":"\"Any process that stops or reduces the activity of a transporter.\" [GOC:mah]","metadata":null},{"id":"e888056c271f4e8b9f997e5904e4151f","type":"GO_TERM","name":"negative regulation of trichoblast fate specification","canonical_id":"go:GO:0010062","description":"\"Any process that suppresses trichoblast fate specification.\" [GOC:tb]","metadata":null},{"id":"3dde54e462c34349bc2de76a8b672c3b","type":"GO_TERM","name":"negative regulation of trichome patterning","canonical_id":"go:GO:1900033","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of trichome patterning.\" [GOC:TermGenie]","metadata":null},{"id":"a5594609cfa747f0bd2c3403a55bd0c9","type":"GO_TERM","name":"negative regulation of tridecane biosynthetic process","canonical_id":"go:GO:1900885","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tridecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"422a614e26b04f9c971be238603a824d","type":"GO_TERM","name":"negative regulation of triglyceride biosynthetic process","canonical_id":"go:GO:0010868","description":"\"Any process that decreases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"58151d6e8078454093f4657262fb8942","type":"GO_TERM","name":"negative regulation of triglyceride catabolic process","canonical_id":"go:GO:0010897","description":"\"Any process that decreases the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride.\" [GOC:rn, GOC:tb]","metadata":null},{"id":"99db6220d55249469666f6978eb709a1","type":"GO_TERM","name":"negative regulation of triglyceride metabolic process","canonical_id":"go:GO:0090209","description":"\"Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving triglyceride, any triester of glycerol.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"9977d84433e048d283d83bf2317839db","type":"GO_TERM","name":"negative regulation of triglyceride storage","canonical_id":"go:GO:0010891","description":"\"Any process that decreases the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d27511e0e7384ec8826432c93b11edd4","type":"GO_TERM","name":"negative regulation of triglyceride transport","canonical_id":"go:GO:1905884","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of triglyceride transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:25849533]","metadata":null},{"id":"a1869de3ecad419d97105c9370c50572","type":"GO_TERM","name":"negative regulation of trophectodermal cell proliferation","canonical_id":"go:GO:1904074","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of trophectodermal cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24508636]","metadata":null},{"id":"4d09c94111594704bfdbda7febced67e","type":"GO_TERM","name":"negative regulation of trophoblast cell migration","canonical_id":"go:GO:1901164","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of trophoblast cell migration.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"d7b7f3c197ba4d7c8d6368ecfdf97b50","type":"GO_TERM","name":"negative regulation of trypanothione biosynthetic process","canonical_id":"go:GO:1905723","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of trypanothione biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:18949025]","metadata":null},{"id":"07cbeedd26f641f79f7a4b2594598b19","type":"GO_TERM","name":"negative regulation of tube lumen cavitation","canonical_id":"go:GO:1903133","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tube lumen cavitation.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:22898778]","metadata":null},{"id":"c4d06b6fe7924cb8ae454d36c0737431","type":"GO_TERM","name":"negative regulation of tubulin deacetylation","canonical_id":"go:GO:1904428","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tubulin deacetylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23886946]","metadata":null},{"id":"9bac8fc4c00f435fb146d60ad683f8a1","type":"GO_TERM","name":"negative regulation of tumor necrosis factor (ligand) superfamily member 11 production","canonical_id":"go:GO:2000308","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tumor necrosis factor (ligand) superfamily member 11 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"5e78f8e0521a4a04b34ecf43d1cd8b66","type":"GO_TERM","name":"negative regulation of tumor necrosis factor production","canonical_id":"go:GO:0032720","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of tumor necrosis factor production.\" [GOC:mah, PMID:10891884, PMID:15560120]","metadata":null},{"id":"b5d3e01f43934898a2810356f3fb982f","type":"GO_TERM","name":"negative regulation of tumor necrosis factor superfamily cytokine production","canonical_id":"go:GO:1903556","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of tumor necrosis factor superfamily cytokine production.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"48f80dd9107948d4960cd18047a6a244","type":"GO_TERM","name":"negative regulation of tumor necrosis factor-mediated signaling pathway","canonical_id":"go:GO:0010804","description":"\"Any process that decreases the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8def85e177a144e3a3a2e173bc1de9a7","type":"GO_TERM","name":"negative regulation of turning behavior involved in mating","canonical_id":"go:GO:0061096","description":"\"Any process that decreases the rate, frequency or extent of turning behavior involved in mating. Turning behavior is the sharp ventral turn performed by the male as he approaches either the hermaphrodite head or tail, whilst trying to locate his partner's vulva. Turning occurs via a sharp ventral coil of the male's tail.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"79b3aa317ffe4d6583c2b4e0407c9e58","type":"GO_TERM","name":"negative regulation of type 2 immune response","canonical_id":"go:GO:0002829","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of a type 2 immune response.\" [GOC:add]","metadata":null},{"id":"cd8b487f1282431ca6dba96220e627b2","type":"GO_TERM","name":"negative regulation of type 2 mitophagy","canonical_id":"go:GO:1905090","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of type 2 mitophagy.\" [GOC:vw, PMID:25009776, PMID:26942284]","metadata":null},{"id":"b65e014047be4355be1f29dbf81e7f6e","type":"GO_TERM","name":"negative regulation of type B pancreatic cell apoptotic process","canonical_id":"go:GO:2000675","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of type B pancreatic cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"17f8c00e945649eca0ba37577427f025","type":"GO_TERM","name":"negative regulation of type B pancreatic cell development","canonical_id":"go:GO:2000077","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic B cell development.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"c082c7dbee984461ba6b82d01f08c58a","type":"GO_TERM","name":"negative regulation of type B pancreatic cell proliferation","canonical_id":"go:GO:1904691","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of type B pancreatic cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24055447]","metadata":null},{"id":"2666178844d846f7adc5fa743fb106e3","type":"GO_TERM","name":"negative regulation of type I hypersensitivity","canonical_id":"go:GO:0001811","description":"\"Any process that stops, prevents, or reduces the rate of type I hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5393c4fa9fdc42078bdc1cfc9886cf3c","type":"GO_TERM","name":"negative regulation of type I interferon production","canonical_id":"go:GO:0032480","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, GOC:mah]","metadata":null},{"id":"fc36ed834014427d9b18fa0f8167fc6e","type":"GO_TERM","name":"negative regulation of type I interferon-mediated signaling pathway","canonical_id":"go:GO:0060339","description":"\"Any process that decreases the rate, frequency or extent of a type I interferon-mediated signaling pathway.\" [GOC:dph]","metadata":null},{"id":"087b3a34e2164fe4a7f02306fe4c0b78","type":"GO_TERM","name":"negative regulation of type II hypersensitivity","canonical_id":"go:GO:0002893","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of type II hypersensitivity.\" [GOC:add]","metadata":null},{"id":"ff5c18ef725f41f082cd00fefc3c53e4","type":"GO_TERM","name":"negative regulation of type II interferon production","canonical_id":"go:GO:0032689","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.\" [GOC:add, GOC:mah, PMID:15546383]","metadata":null},{"id":"aa502fcd3cc54a6599a3c6df761c4cd5","type":"GO_TERM","name":"negative regulation of type II interferon-mediated signaling pathway","canonical_id":"go:GO:0060336","description":"\"Any process that decreases the rate, frequency or extent of an interferon-gamma-mediated signaling pathway.\" [GOC:dph]","metadata":null},{"id":"013a0d7f11284dea8b9e4499cb2c4983","type":"GO_TERM","name":"negative regulation of type III hypersensitivity","canonical_id":"go:GO:0001804","description":"\"Any process that stops, prevents, or reduces the rate of type III hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b2c03214eaf043a28e3857e539a9b999","type":"GO_TERM","name":"negative regulation of type III interferon production","canonical_id":"go:GO:0034345","description":"\"Any process that stops, prevents, or reduces the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"72e9219a98ac4ea6b957553834907063","type":"GO_TERM","name":"negative regulation of type IIa hypersensitivity","canonical_id":"go:GO:0001797","description":"\"Any process that stops, prevents, or reduces the rate of type IIa hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"068fdc2d8b4f40b9b4a4b433b4678ab1","type":"GO_TERM","name":"negative regulation of type IIb hypersensitivity","canonical_id":"go:GO:0001800","description":"\"Any process that stops, prevents, or reduces the rate of type IIb hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"87a920dfa99c49df80ff8c3d94ab9a7d","type":"GO_TERM","name":"negative regulation of type IV hypersensitivity","canonical_id":"go:GO:0001808","description":"\"Any process that stops, prevents, or reduces the rate of type IV hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7a56d254f539444a80a6f0f596a463ea","type":"GO_TERM","name":"negative regulation of type IV pilus biogenesis","canonical_id":"go:GO:1903657","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of type IV pilus biogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:25049409]","metadata":null},{"id":"b16aaa62ec594457bc221ff0c62964ce","type":"GO_TERM","name":"negative regulation of tyramine signaling pathway","canonical_id":"go:GO:2000132","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of tyramine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"b80b15c8e5404278990bbd4e7d048e12","type":"GO_TERM","name":"negative regulation of tyrosine phosphorylation of STAT protein","canonical_id":"go:GO:0042532","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:jl, PMID:11426647]","metadata":null},{"id":"aa25d7ce6a5a4598b6b193714cc22aeb","type":"GO_TERM","name":"negative regulation of ubiquinone biosynthetic process","canonical_id":"go:GO:1904774","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ubiquinone biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:8125303]","metadata":null},{"id":"b1b8c92651c9477ab0a8b0f832e98c58","type":"GO_TERM","name":"negative regulation of ubiquitin protein ligase activity","canonical_id":"go:GO:1904667","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ubiquitin protein ligase activity.\" [GO_REF:0000059, GOC:dph, GOC:tb, GOC:TermGenie, PMID:26216882]","metadata":null},{"id":"dc73008062734ddfb81ba2f0a581c739","type":"GO_TERM","name":"negative regulation of ubiquitin-dependent endocytosis","canonical_id":"go:GO:2000396","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ubiquitin-dependent endocytosis.\" [GOC:mah]","metadata":null},{"id":"92e03227335e42d39c9c06faf78168e2","type":"GO_TERM","name":"negative regulation of ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:2000059","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ubiquitin-dependent protein catabolic process.\" [GOC:BHF]","metadata":null},{"id":"6a37cac961be457e8655003d149946cf","type":"GO_TERM","name":"negative regulation of ubiquitin-protein transferase activity","canonical_id":"go:GO:0051444","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ubiquitin transferase activity.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"8fa0b3f789e74a89a65d77f4b45232e0","type":"GO_TERM","name":"negative regulation of unidimensional cell growth","canonical_id":"go:GO:0051511","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of unidimensional cell growth, the process in which a cell irreversibly increases in size in one [spatial] dimension or along one axis.\" [GOC:ai]","metadata":null},{"id":"c22979ef771b4679827b9fb0b6ce95e2","type":"GO_TERM","name":"negative regulation of uracil import across plasma membrane","canonical_id":"go:GO:1905530","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of uracil import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:26536126]","metadata":null},{"id":"cac9204fe0084c28bb0ec18f645a536f","type":"GO_TERM","name":"negative regulation of urea catabolic process","canonical_id":"go:GO:1901713","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of urea catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"21354dbcdf774dfd9f108a35223d724b","type":"GO_TERM","name":"negative regulation of uredinium development","canonical_id":"go:GO:0075282","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of uredinium development, a process that leads to the formation of a reddish, pustule-like structure formed by a rust fungus and consisting of uredospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"6a7557da5def4c5a86fad98960a01752","type":"GO_TERM","name":"negative regulation of uredospore formation","canonical_id":"go:GO:0075254","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of uredospore formation, a process in which an asexual, dikaryotic, often rusty-colored spore, is formed in a structure called a uredinium.\" [GOC:pamgo_curators]","metadata":null},{"id":"bd21571c54cf45a8b7b497508cce8e84","type":"GO_TERM","name":"negative regulation of ureter smooth muscle cell differentiation","canonical_id":"go:GO:2000062","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of ureter smooth muscle cell differentiation.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"95b4f7bd3ebd426c8b14ccb68bfb698b","type":"GO_TERM","name":"negative regulation of urine volume","canonical_id":"go:GO:0035811","description":"\"Any process that decreases the amount of urine excreted from the body over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"9d59147289824add834114aa409a04fe","type":"GO_TERM","name":"negative regulation of urothelial cell proliferation","canonical_id":"go:GO:0050676","description":"\"Any process that stops, prevents or reduces the rate or extent of urothelial cell proliferation.\" [GOC:ai]","metadata":null},{"id":"c7def51ffe9b442496b1e8a7ecd0f93e","type":"GO_TERM","name":"negative regulation of uterine smooth muscle contraction","canonical_id":"go:GO:0070473","description":"\"Any process that decreases the frequency, rate or extent of uterine smooth muscle contraction.\" [GOC:curators]","metadata":null},{"id":"4bbc55cbd0db4b28be90cae9a91cd06d","type":"GO_TERM","name":"negative regulation of uterine smooth muscle relaxation","canonical_id":"go:GO:1900720","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of uterine smooth muscle relaxation.\" [GOC:TermGenie]","metadata":null},{"id":"3e220197d2d949b08d62c7ded037056e","type":"GO_TERM","name":"negative regulation of vacuolar transport","canonical_id":"go:GO:1903336","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vacuolar transport.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"a11e65ae986c4a1e98d6550a6aad5e99","type":"GO_TERM","name":"negative regulation of vacuole fusion, non-autophagic","canonical_id":"go:GO:0061192","description":"\"Any process that decreases the frequency, rate or extent of the fusion of two vacuole membranes to form a single vacuole.\" [GOC:dph]","metadata":null},{"id":"4b884d1d73884b708266c961df06e7df","type":"GO_TERM","name":"negative regulation of vascular associated smooth muscle cell apoptotic process","canonical_id":"go:GO:1905460","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular associated smooth muscle cell apoptotic process.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:26493107]","metadata":null},{"id":"cf03aed5a9084aff9bd6fa5814ad5e33","type":"GO_TERM","name":"negative regulation of vascular associated smooth muscle cell dedifferentiation","canonical_id":"go:GO:1905175","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular smooth muscle cell dedifferentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19088079]","metadata":null},{"id":"406e39542a0c497fb646039d6b938e6b","type":"GO_TERM","name":"negative regulation of vascular associated smooth muscle cell differentiation","canonical_id":"go:GO:1905064","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular smooth muscle cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19088079]","metadata":null},{"id":"b1e9af39e9f743ae87534c7420a6fa14","type":"GO_TERM","name":"negative regulation of vascular associated smooth muscle cell migration","canonical_id":"go:GO:1904753","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular associated smooth muscle cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20693317]","metadata":null},{"id":"13c7301028e24ab4aad72e0993e47845","type":"GO_TERM","name":"negative regulation of vascular associated smooth muscle cell proliferation","canonical_id":"go:GO:1904706","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular smooth muscle cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23246467]","metadata":null},{"id":"0404c662c60b435c97e869bc5a133936","type":"GO_TERM","name":"negative regulation of vascular associated smooth muscle contraction","canonical_id":"go:GO:1904694","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular smooth muscle contraction.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22158624]","metadata":null},{"id":"df0c4b10aec24c9d82e8191c10098ddf","type":"GO_TERM","name":"negative regulation of vascular endothelial cell proliferation","canonical_id":"go:GO:1905563","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular endothelial cell proliferation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23201774]","metadata":null},{"id":"df6d16f1d5fe4ed2b20357816de26ec6","type":"GO_TERM","name":"negative regulation of vascular endothelial growth factor production","canonical_id":"go:GO:1904046","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular endothelial growth factor production.\" [GO_REF:0000058, GOC:TermGenie, PMID:19404486]","metadata":null},{"id":"df0be5c665d14707803f990c6bba5495","type":"GO_TERM","name":"negative regulation of vascular endothelial growth factor receptor signaling pathway","canonical_id":"go:GO:0030948","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.\" [GOC:dgh]","metadata":null},{"id":"9ed9d665b213498297f675c962435d04","type":"GO_TERM","name":"negative regulation of vascular endothelial growth factor signaling pathway","canonical_id":"go:GO:1900747","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vascular endothelial growth factor signaling pathway.\" [GOC:TermGenie]","metadata":null},{"id":"d14d554906d943dc98bd8761988b9c10","type":"GO_TERM","name":"negative regulation of vascular permeability","canonical_id":"go:GO:0043116","description":"\"Any process that reduces the extent to which blood vessels can be pervaded by fluid.\" [GOC:jl]","metadata":null},{"id":"0372eb6c3cfc4777a7f7bc096bdabdd8","type":"GO_TERM","name":"negative regulation of vascular wound healing","canonical_id":"go:GO:0061044","description":"\"Any process that decreases the rate, frequency, or extent of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"5e053b6a7b9e4f3ea74eb2ce1f8badfa","type":"GO_TERM","name":"negative regulation of vasculature development","canonical_id":"go:GO:1901343","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vasculature development.\" [GOC:TermGenie]","metadata":null},{"id":"007f8c6d2db64edd9adeb576f0018843","type":"GO_TERM","name":"negative regulation of vasculature development involved in avascular cornea development in camera-type eye","canonical_id":"go:GO:1901346","description":"\"Any negative regulation of vasculature development that is involved in developing an avascular cornea of a camera-type eye.\" [GOC:TermGenie, GOC:uh, PMID:16849433, PMID:17051153]","metadata":null},{"id":"efc4be86f2234679999806f316785c88","type":"GO_TERM","name":"negative regulation of vasculogenesis","canonical_id":"go:GO:2001213","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vasculogenesis.\" [GOC:obol]","metadata":null},{"id":"bc5054ec12794d3288101dd50f81ce73","type":"GO_TERM","name":"negative regulation of vasoconstriction","canonical_id":"go:GO:0045906","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of vasoconstriction.\" [GOC:curators]","metadata":null},{"id":"7427753a432143a787babb96da65a4de","type":"GO_TERM","name":"negative regulation of vein smooth muscle contraction","canonical_id":"go:GO:0062088","description":"\"Any process that decreases the frequency, rate or extent of vein smooth muscle contraction.\" [PMID:8428203]","metadata":null},{"id":"465f44252f8d4e5aa5374da984a523e1","type":"GO_TERM","name":"negative regulation of venous endothelial cell fate commitment","canonical_id":"go:GO:2000788","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of venous endothelial cell fate commitment.\" [PMID:11585794]","metadata":null},{"id":"709136fde66b421da2573b9d6791957e","type":"GO_TERM","name":"negative regulation of ventricular cardiac muscle cell action potential","canonical_id":"go:GO:1903946","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of ventricular cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:25281747]","metadata":null},{"id":"c216d4893a3e4b6b9c98743f5e872f42","type":"GO_TERM","name":"negative regulation of vernalization response","canonical_id":"go:GO:0010221","description":"\"Any process that stops, prevents or reduces the vernalization response, by which induction of flowering is normally caused by extended exposure to cold temperatures.\" [GOC:sm]","metadata":null},{"id":"95ad32b7267f453ea831109d55db9d76","type":"GO_TERM","name":"negative regulation of very-low-density lipoprotein particle clearance","canonical_id":"go:GO:0010916","description":"\"Any process that decreases the rate, frequency or extent of very-low-density lipoprotein particle clearance. Very-low-density lipoprotein particle clearance is the process in which a very-low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"8d5c167041a643ff9dd94b036834fd4a","type":"GO_TERM","name":"negative regulation of very-low-density lipoprotein particle remodeling","canonical_id":"go:GO:0010903","description":"\"Any process that decreases the rate, frequency or extent of very-low-density lipoprotein particle remodeling. Very-low-density lipoprotein particle remodeling is the acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:tb]","metadata":null},{"id":"a6fe8965560b4d33a97f15892bd33212","type":"GO_TERM","name":"negative regulation of vesicle fusion","canonical_id":"go:GO:0031339","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of vesicle fusion.\" [GOC:mah]","metadata":null},{"id":"c422c1935eec4d949d86b961f85ca979","type":"GO_TERM","name":"negative regulation of vesicle fusion with Golgi apparatus","canonical_id":"go:GO:0106215","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vesicle fustion with Golgi apparatus.\" [GOC:se, PMID:26195667]","metadata":null},{"id":"a1c24b7a50434686b2a082048a4ccc2e","type":"GO_TERM","name":"negative regulation of vesicle transport along microtubule","canonical_id":"go:GO:1901609","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vesicle transport along microtubule.\" [GOC:TermGenie]","metadata":null},{"id":"1899ab0dc2684436b012c6feebb9761c","type":"GO_TERM","name":"negative regulation of violaceol I biosynthetic process","canonical_id":"go:GO:1900714","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of violaceol I biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7fff4b60a8bb4d7db12e003589cfed09","type":"GO_TERM","name":"negative regulation of violaceol II biosynthetic process","canonical_id":"go:GO:1900717","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of violaceol II biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"31f8641b522648f9b72813b00c0596ea","type":"GO_TERM","name":"negative regulation of viral budding via host ESCRT complex","canonical_id":"go:GO:1903773","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of viral budding via host ESCRT complex.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24878737]","metadata":null},{"id":"79ec50227e214531b1116c436eab25c8","type":"GO_TERM","name":"negative regulation of viral genome replication","canonical_id":"go:GO:0045071","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of viral genome replication.\" [GOC:curators]","metadata":null},{"id":"7835642a230e4f50bfde431c73e6fa25","type":"GO_TERM","name":"negative regulation of viral life cycle","canonical_id":"go:GO:1903901","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of viral life cycle.\" [GO_REF:0000058, GOC:TermGenie, PMID:18005716]","metadata":null},{"id":"cc6d70715e4c4da9896e9f4cfe2baba4","type":"GO_TERM","name":"negative regulation of viral process","canonical_id":"go:GO:0048525","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of a multi-organism process in which a virus is a participant.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"27862334c75f4069ae17567a96bc935f","type":"GO_TERM","name":"negative regulation of viral transcription","canonical_id":"go:GO:0032897","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of viral transcription.\" [GOC:mah]","metadata":null},{"id":"a126172ce31d420d96e91e50115e618e","type":"GO_TERM","name":"negative regulation of viral translation","canonical_id":"go:GO:1904972","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of viral translation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:19666601]","metadata":null},{"id":"e51e4ace1a944ee0af5d5088a17793af","type":"GO_TERM","name":"negative regulation of vitamin D biosynthetic process","canonical_id":"go:GO:0010957","description":"\"Any process that decreases the rate, frequency or extent of a vitamin D biosynthetic process. Vitamin D biosynthesis is the chemical reactions and pathways resulting in the formation of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"0ab374cc70e34329813df39a4cf679a3","type":"GO_TERM","name":"negative regulation of vitamin D receptor signaling pathway","canonical_id":"go:GO:0070563","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the vitamin D receptor signaling pathway activity.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"25b35b2047f441d298c1de37a4be0f9b","type":"GO_TERM","name":"negative regulation of vitamin metabolic process","canonical_id":"go:GO:0046137","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:ai]","metadata":null},{"id":"e8c06e6d3e6947af8b329b0be75391fa","type":"GO_TERM","name":"negative regulation of vitellogenesis","canonical_id":"go:GO:1903187","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of vitellogenesis.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19467235]","metadata":null},{"id":"c7d743d02f014c35bb2d424d38ad8cdf","type":"GO_TERM","name":"negative regulation of voltage-gated calcium channel activity","canonical_id":"go:GO:1901386","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of voltage-gated calcium channel activity.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"7d67e56de456459cad7e7059cb37ac6e","type":"GO_TERM","name":"negative regulation of voltage-gated potassium channel activity","canonical_id":"go:GO:1903817","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of voltage-gated potassium channel activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:19219384]","metadata":null},{"id":"dfa343e8e4974b93a58d900c7a45c0f6","type":"GO_TERM","name":"negative regulation of vulval development","canonical_id":"go:GO:0040027","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of development of the vulva. Vulval development is the process whose specific outcome is the progression of the egg-laying organ of female and hermaphrodite nematodes over time, from its formation to the mature structure. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed vulva in the adult.\" [GOC:ems, GOC:kmv]","metadata":null},{"id":"2def6bb7cbb94fa3aec49005c7a69703","type":"GO_TERM","name":"negative regulation of wax biosynthetic process","canonical_id":"go:GO:1904277","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of wax biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24692420]","metadata":null},{"id":"f3c48049ea7745cb87dd1b7b6c52dcff","type":"GO_TERM","name":"negative regulation of white fat cell differentiation","canonical_id":"go:GO:0160275","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of white fat cell differentiation.\" [PMID:24703692]","metadata":null},{"id":"d4a7ba7c66fb422688787fa949677470","type":"GO_TERM","name":"negative regulation of white fat cell proliferation","canonical_id":"go:GO:0070351","description":"\"Any process that stops or decreases the rate or extent of white fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"0d1d615838c64b9e991671487771a336","type":"GO_TERM","name":"negative regulation of wound healing","canonical_id":"go:GO:0061045","description":"\"Any process that decreases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.\" [GOC:dph]","metadata":null},{"id":"308e483e470641ddaf467e79a87b1d47","type":"GO_TERM","name":"negative regulation of wound healing, spreading of epidermal cells","canonical_id":"go:GO:1903690","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of wound healing, spreading of epidermal cells.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18394891]","metadata":null},{"id":"31abb205f47e4452bc3a673cb6ad842f","type":"GO_TERM","name":"negative regulation of xanthone-containing compound biosynthetic process","canonical_id":"go:GO:1900184","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of xanthone-containing compound biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f8a3857936ab43c6af29f0ded370ac49","type":"GO_TERM","name":"negative regulation of xanthophore differentiation","canonical_id":"go:GO:0050944","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of xanthophore differentiation.\" [GOC:ai]","metadata":null},{"id":"858778ea277a44688d99201c4a157d16","type":"GO_TERM","name":"negative regulation of xenobiotic detoxification by transmembrane export across the plasma membrane","canonical_id":"go:GO:1905700","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of xenobiotic transmembrane export. A xenobiotic is a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:15198509]","metadata":null},{"id":"de82cc5e2fed46fa933e39a196d429c6","type":"GO_TERM","name":"negative regulation of xenophagy","canonical_id":"go:GO:1904416","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of xenophagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21617041]","metadata":null},{"id":"432b51a66e0b43f18e1a25a0170e6d1c","type":"GO_TERM","name":"negative regulation of xylan catabolic process","canonical_id":"go:GO:2001001","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of xylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"ce9ebf50257544c7b68e13504cc308c2","type":"GO_TERM","name":"negative regulation of xyloglucan catabolic process","canonical_id":"go:GO:2000952","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of xyloglucan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"0206de1ea7d5483fba0df7b910a1a8f5","type":"GO_TERM","name":"negative regulation of xylose catabolic process to ethanol","canonical_id":"go:GO:1900516","description":"\"Any process that stops, prevents or reduces the frequency, rate or extent of xylose catabolic process to ethanol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"6be8d26328f14dab933f68241e2c3d8b","type":"GO_TERM","name":"negative regulation of zinc ion transmembrane import","canonical_id":"go:GO:0071584","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of zinc ion import.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"6688f0e1bb574a96a7824e9f31fefedb","type":"GO_TERM","name":"negative regulation of zinc ion transmembrane transport","canonical_id":"go:GO:0071583","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of zinc ions (Zn2+) from one side of a membrane to the other.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d8b3b9490bf143139dd68aa6ac27d789","type":"GO_TERM","name":"negative regulation of zinc ion transport","canonical_id":"go:GO:0071582","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of zinc ions (Zn2+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"6bf233b4e7a8495da1db7f747568227d","type":"GO_TERM","name":"negative regulation of zoospore encystment on host","canonical_id":"go:GO:0075221","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of zoospore encystment on host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"11387f2c40f84cf6b50e6457a8127099","type":"GO_TERM","name":"negative regulation of zoospore formation","canonical_id":"go:GO:0075242","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of zoospore formation, a process in which a diploid cell undergoes meiosis, and the meiotic products acquire specialized features of asexual motile mononucleate flagellated spores called zoospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"0534469bb4564e1abc6562ed20aa325d","type":"GO_TERM","name":"negative regulation of zygosporangium development","canonical_id":"go:GO:0075274","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of zygosporangium development, a process in which a fruiting body called zygosporangium is formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"91cd634548964a1c8b67a752a576bcd8","type":"GO_TERM","name":"negative regulation of zygospore formation","canonical_id":"go:GO:0075300","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of zygospore formation, a process in which a thick-walled spore of some algae and fungi is formed by union of two similar sexual cells, usually serves as a resting spore, and produces the sporophytic phase.\" [GOC:pamgo_curators]","metadata":null},{"id":"b28bca4c48124f428f89a114e0d302a2","type":"GO_TERM","name":"negative stranded viral RNA replication","canonical_id":"go:GO:0039689","description":"\"A viral genome replication process where the template genome is negative stranded, single stranded RNA ((-)ssRNA).\" [GOC:bf, GOC:jl, VZ:1096]","metadata":null},{"id":"28c5f1de22e4436abedddd5a8a2bbcab","type":"GO_TERM","name":"negative stranded viral RNA transcription","canonical_id":"go:GO:0039697","description":"\"A viral transcription process that uses negative stranded (-) single stranded (ss) RNA as a template.\" [VZ:1096]","metadata":null},{"id":"fb0d398927424c28a9b7979dce65bf20","type":"GO_TERM","name":"negative thymic T cell selection","canonical_id":"go:GO:0045060","description":"\"The process of elimination of immature T cells in the thymus which react strongly with self-antigens.\" [ISBN:0781735149, PMID:12414722]","metadata":null},{"id":"d70ec0e0575d4881803d4aee2e3ad65e","type":"DRUG","name":"nelarabine","canonical_id":"mesh:C104457","description":null,"metadata":null},{"id":"b493c499308c4d608aa46060e9bc736d","type":"GO_TERM","name":"nematocyst","canonical_id":"go:GO:0042151","description":"\"An organelle found in cnidoblast (nematoblast) cells. When matured, these stinging organelles store toxins and can deliver them when the cnidocil (a short extension of the cnidocyst) is stimulated by a prey or another stimulus.\" [DOI:10.1139/z02-135, GOC:jl]","metadata":null},{"id":"fef95fc95e1f4b63810ee8cfb5e8a7b8","type":"GO_TERM","name":"nematode larval development","canonical_id":"go:GO:0002119","description":"\"The process whose specific outcome is the progression of the nematode larva over time, from its formation to the mature structure. Nematode larval development begins with the newly hatched first-stage larva (L1) and ends with the end of the last larval stage (for example the fourth larval stage (L4) in C. elegans). Each stage of nematode larval development is characterized by proliferation of specific cell lineages and an increase in body size without alteration of the basic body plan. Nematode larval stages are separated by molts in which each stage-specific exoskeleton, or cuticle, is shed and replaced anew.\" [GOC:ems, GOC:kmv]","metadata":null},{"id":"c3264eca689f405997c33614ec585235","type":"GO_TERM","name":"nematode male tail mating organ morphogenesis","canonical_id":"go:GO:0090597","description":"\"The process in which the anatomical structures of the nematode male tail mating organ are generated and organized. The male tail is a sensory organ required for mating and, in C. elegans, consists of ray sensilla, an acellular cuticular fan, a sensory hook, and protracting, copulatory spicules.\" [GOC:kmv, PMID:1782863, PMID:18050419, PMID:7409314]","metadata":null},{"id":"7f54b12d67344e40bb3b5b49c836d5a0","type":"GO_TERM","name":"nematode male tail tip morphogenesis","canonical_id":"go:GO:0045138","description":"\"The process in which the anatomical structure of the adult male tail tip is generated and organized. In some species of rhabitid nematodes, the male tail tip undergoes a morphological change such that the most posterior hypodermal cells in the tail (hyp8-11 in C. elegans) fuse and retract anteriorly, changing the shape of the tail from a pointed, tapered cone, or spike, to a rounded, blunt dome.\" [GOC:kmv, PMID:16806150, PMID:18050419, PMID:21408209, PMID:7409314]","metadata":null},{"id":"78e2b83bac884dc0852dd5285f6fe6a5","type":"GO_TERM","name":"nematode pharyngeal gland morphogenesis","canonical_id":"go:GO:1905905","description":"\"The developmental process by which a nematode pharyngeal gland is generated and organized.\" [GO_REF:0000083, GOC:TermGenie, PMID:21868609]","metadata":null},{"id":"de53765a69194200a7a425e2e03ff5af","type":"GO_TERM","name":"nematode pharyngeal muscle development","canonical_id":"go:GO:0160096","description":"\"The process whose specific outcome is the progression of the nematode pharyngeal muscle over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"fc1c86f84f6c47a285521244d5ee1118","type":"GO_TERM","name":"nematode pharyngeal pumping","canonical_id":"go:GO:0043050","description":"\"The contraction and relaxation movements of the pharyngeal muscle that mediate feeding in nematodes.\" [GOC:cab1, PMID:2181052]","metadata":null},{"id":"79d2ddb67ce243e3a8e91f087638c8a0","type":"GO_TERM","name":"nematode pharynx development","canonical_id":"go:GO:0160094","description":"\"The process whose specific outcome is the progression of nematode pharynx over time, from its formation to the mature structure.\" [PMID:18050503]","metadata":null},{"id":"e7939c497b53450c9afd75236969b72a","type":"GO_TERM","name":"nematode pharynx morphogenesis","canonical_id":"go:GO:0110040","description":"\"The process in which the anatomical structures of the nematode pharynx are generated and organized.\" [GOC:rz, PMID:20805556]","metadata":null},{"id":"236656f71d864ee8b93dbc59906eb057","type":"GO_TERM","name":"nematosome","canonical_id":"go:GO:0097417","description":"\"Cytoplasmic, ball-like inclusion resembling a nucleolus and consisting of a convoluted network of electron-opaque strands embedded in a less dense matrix. It measures approximately 0.9 microns and lacks a limiting membrane. Its strands (diameter = 400-600 A) appear to be made of an entanglement of tightly packed filaments and particles approximately 25-50 A thick. Cytochemical studies suggest the presence of nonhistone proteins and some RNA. Usually only one such structure is present in a cell, and it appears to occur in most ganglion cells. Although they can be seen anywhere in the cell body, nematosomes are typically located in the perinuclear cytoplasm, where they are often associated with smooth-surfaced and coated vesicles.\" [NIF_Subcellular:sao138430598, PMID:5458990]","metadata":null},{"id":"cc516d22b1284293ad0aa3d4b07709da","type":"DRUG","name":"nemolizumab","canonical_id":"gtopdb:8720","description":null,"metadata":null},{"id":"554bd35911474ae2a37dfa7f00403d3e","type":"DRUG","name":"nemolizumab","canonical_id":"chembl:CHEMBL4297794","description":null,"metadata":null},{"id":"872bc55e07714f1f9102a95d32047620","type":"COMBINATION_TREATMENT","name":"nemolizumab + tralokinumab","canonical_id":"ctgov_combo:ctgov-combo-a7150147b43b043c","description":null,"metadata":null},{"id":"10bccc7c247d48baaac4a322c08cb3dc","type":"DRUG","name":"neomycin","canonical_id":"mesh:D009355","description":null,"metadata":null},{"id":"6d56ba6405664f2aa85578daa47d27ab","type":"GO_TERM","name":"neomycin biosynthetic process","canonical_id":"go:GO:1901158","description":"\"The chemical reactions and pathways resulting in the formation of neomycin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-7016, UniPathway:UPA00969]","metadata":null},{"id":"6bd6f712ac3f4be798df974bcb86da7a","type":"DISEASE","name":"neonatal diabetes mellitus","canonical_id":"mondo:0016391","description":null,"metadata":null},{"id":"4d0b8c88f01c43b389a63a9a9f1c8e6d","type":"DISEASE","name":"neonatal encephalopathy","canonical_id":"efo:0022985","description":null,"metadata":null},{"id":"bdb5e9189cc44e2fac940328bdf55bf0","type":"DISEASE","name":"neonatal severe primary hyperparathyroidism","canonical_id":"mondo:0009397","description":null,"metadata":null},{"id":"41d4ee8358da408aa133354d8fe99a3c","type":"DISEASE","name":"neoplasm","canonical_id":"mondo:0005070","description":null,"metadata":null},{"id":"4cc06dd0f8214eab8aa1f85f8f3626ef","type":"DISEASE","name":"neoplasm of esophagus","canonical_id":"mondo:0021355","description":null,"metadata":null},{"id":"3bed74e5edca4ca4911eef3909f36b9e","type":"DISEASE","name":"neoplasm of mature B-cells","canonical_id":"mondo:0004949","description":null,"metadata":null},{"id":"8e76069d37244ce9a397a3e16a300e3a","type":"DISEASE","name":"neoplasm with perivascular epithelioid cell differentiation","canonical_id":"mondo:0006359","description":null,"metadata":null},{"id":"e45b3d9338834242a96b9127c0e9a2b9","type":"GO_TERM","name":"neopullulanase activity","canonical_id":"go:GO:0031216","description":"\"Catalysis of the hydrolysis of pullulan to panose (6-alpha-D-glucosylmaltose).\" [EC:3.2.1.135, GOC:mlg]","metadata":null},{"id":"69f651228d8847c299b9107731a413d5","type":"GO_TERM","name":"neosartoricin biosynthetic process","canonical_id":"go:GO:1902050","description":"\"The chemical reactions and pathways resulting in the formation of neosartoricin.\" [GOC:di, GOC:TermGenie, PMID:23368997]","metadata":null},{"id":"4efe9e2ee0e34908aefc2641a1aca728","type":"GO_TERM","name":"neosartoricin catabolic process","canonical_id":"go:GO:1902049","description":"\"The chemical reactions and pathways resulting in the breakdown of neosartoricin.\" [GOC:di, GOC:TermGenie, PMID:23368997]","metadata":null},{"id":"37c099e4639643a89a6648a3276f74b9","type":"GO_TERM","name":"neoxanthin biosynthetic process","canonical_id":"go:GO:1901833","description":"\"The chemical reactions and pathways resulting in the formation of trans-neoxanthin and 9'-cis-neoxanthin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-6809, PMID:11029576, UniPathway:UPA00388]","metadata":null},{"id":"821e6dfb88c4425db5a3b53919972972","type":"GO_TERM","name":"neoxanthin synthase activity","canonical_id":"go:GO:0034020","description":"\"Catalysis of the reaction: all-trans-violaxanthin = all-trans-neoxanthin.\" [EC:5.3.99.9, RHEA:10128]","metadata":null},{"id":"af47090644dd463aac7fdea4e2c23bef","type":"GO_TERM","name":"nephric duct development","canonical_id":"go:GO:0072176","description":"\"The process whose specific outcome is the progression of a nephric duct over time, from its initial formation to a mature structure. A nephric duct is a tube that drains a primitive kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"edb04b6a656e49148cc6b74aff7f9a15","type":"GO_TERM","name":"nephric duct elongation","canonical_id":"go:GO:0035849","description":"\"The process in which the nephric duct grows along its axis. A nephric duct is a tube that drains a primitive kidney.\" [GOC:mtg_kidney_jan10, GOC:yaf, PMID:16216236]","metadata":null},{"id":"88f5df267d224927866b1deed0fa3784","type":"GO_TERM","name":"nephric duct formation","canonical_id":"go:GO:0072179","description":"\"The developmental process pertaining to the initial formation of a nephric duct. A nephric duct is a tube that drains a primitive kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"45a21693f83e41dd91b07b9d8b780843","type":"GO_TERM","name":"nephric duct morphogenesis","canonical_id":"go:GO:0072178","description":"\"The process in which the anatomical structures of the nephric duct are generated and organized. A nephric duct is a tube that drains a primitive kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1a13855fedca48de9bd804ef36559e01","type":"DISEASE","name":"nephrocalcinosis","canonical_id":"mondo:0001567","description":null,"metadata":null},{"id":"27401f336bb941a1b8c9fa83199902d8","type":"GO_TERM","name":"nephrocyte diaphragm","canonical_id":"go:GO:0005917","description":"\"A specialized cell-cell junction found between nephrocytes of the insect kidney, which is adapted for filtration of hemolymph. The insect nephrocyte is anatomically and functionally similar to the glomerular podocyte of vertebrates.\" [GOC:mtg_kidney_jan10, GOC:sart, PMID:18971929]","metadata":null},{"id":"4d238169e49649a1a3103329e6501951","type":"GO_TERM","name":"nephrocyte diaphragm assembly","canonical_id":"go:GO:0036059","description":"\"The aggregation, arrangement and bonding together of a set of components to form a nephrocyte diaphragm, a specialized cell-cell junction found between nephrocytes of the insect kidney.\" [GOC:mtg_kidney_jan10, GOC:sart, PMID:18971929]","metadata":null},{"id":"0fdd73238bd04794a2ac8a31a4b95b23","type":"GO_TERM","name":"nephrocyte differentiation","canonical_id":"go:GO:0061319","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a nephrocyte. A nephrocyte is an insect renal cell that filters hemolymph. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.\" [CL:0002520, GOC:dph, GOC:mtg_kidney_jan10, PMID:19783135]","metadata":null},{"id":"4c2ae722a6304c43bdd1ec8be199e319","type":"GO_TERM","name":"nephrocyte filtration","canonical_id":"go:GO:0097206","description":"\"The process by which hemolymph is filtered based on size and charge through a nephrocyte filtration barrier formed by the basement membrane and nephrocyte diaphragm.\" [GOC:sart, PMID:18971929]","metadata":null},{"id":"83ac37d4e6df4bad9370a108eb0172ab","type":"DISEASE","name":"nephrogenic diabetes insipidus","canonical_id":"mondo:0016383","description":null,"metadata":null},{"id":"da62ab81376e476e93baa414c42f975d","type":"GO_TERM","name":"nephrogenic mesenchyme development","canonical_id":"go:GO:0072076","description":"\"The biological process whose specific outcome is the progression of a nephrogenic mesenchyme from an initial condition to its mature state. This process begins with the formation of nephrogenic mesenchyme and ends with the mature structure. Nephrogenic mesenchyme is the tissue made up of loosely connected mesenchymal cells in the nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"eaf64144de3848d28c4980223840640a","type":"GO_TERM","name":"nephrogenic mesenchyme morphogenesis","canonical_id":"go:GO:0072134","description":"\"The process in which the anatomical structures of a nephrogenic mesenchymal tissue are generated and organized. Nephrogenic mesenchyme is the tissue made up of loosely connected mesenchymal cells in the nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ea8858fc0e27484daf5e0683623757f3","type":"DISEASE","name":"nephrogenic syndrome of inappropriate antidiuresis","canonical_id":"mondo:0010356","description":null,"metadata":null},{"id":"0f49994e180e496e8efd688e9a2a9d46","type":"DISEASE","name":"nephrolithiasis","canonical_id":"mondo:0008171","description":null,"metadata":null},{"id":"cc5291c588e94620ad51c7dc18afea4f","type":"GO_TERM","name":"nephron development","canonical_id":"go:GO:0072006","description":"\"The process whose specific outcome is the progression of the nephron over time, from its formation to the mature structure. A nephron is the functional unit of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ca2337535d7146b69b2a35d937d012f7","type":"GO_TERM","name":"nephron epithelium development","canonical_id":"go:GO:0072009","description":"\"The process whose specific outcome is the progression of the nephron epithelium over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure. The nephron epithelium is a tissue that covers the surface of a nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8bb7e7b0fcf8431b89f6d4e63b7ec87b","type":"GO_TERM","name":"nephron epithelium morphogenesis","canonical_id":"go:GO:0072088","description":"\"The process in which the anatomical structures of the nephron epithelium are generated and organized. The nephron epithelium is a tissue that covers the surface of a nephron.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c894b5c095244fe28d6eacf173ef611c","type":"GO_TERM","name":"nephron morphogenesis","canonical_id":"go:GO:0072028","description":"\"The process in which the anatomical structures of the nephron are generated and organized. A nephron is the functional unit of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"26d0cd57a01d4c06bfa905c034d4bd55","type":"GO_TERM","name":"nephron tubule development","canonical_id":"go:GO:0072080","description":"\"The progression of a nephron tubule over time, from its initial formation to the mature structure. A nephron tubule is an epithelial tube that is part of the nephron, the functional part of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c5b166f7880c4b31a28420032240b6cf","type":"GO_TERM","name":"nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0072160","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the nephron tubule as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"38b2772ee90c4cf6a148717dfe58a065","type":"GO_TERM","name":"nephron tubule formation","canonical_id":"go:GO:0072079","description":"\"The developmental process pertaining to the initial formation of a nephron tubule from unspecified parts. A nephron tubule is an epithelial tube that is part of the nephron, the functional part of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b71e940ca1724d618a01879d20ba668a","type":"GO_TERM","name":"nephron tubule morphogenesis","canonical_id":"go:GO:0072078","description":"\"The process in which the anatomical structures of a nephron tubule are generated and organized. A nephron tubule is an epithelial tube that is part of the nephron, the functional part of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"f0c9611f8bec42e6b90e0446be2949fc","type":"GO_TERM","name":"nephrostome development","canonical_id":"go:GO:0039018","description":"\"The process whose specific outcome is the progression of the nephrostome over time, from its formation to the mature structure. The nephrostome is the opening of the pronephros into the body cavity.\" [GOC:mtg_kidney_jan10, PMID:14686690, PMID:15647339, XAO:0000062]","metadata":null},{"id":"26facc5db7774472a53e910c310e2fac","type":"DISEASE","name":"nephrotic syndrome","canonical_id":"mondo:0005377","description":null,"metadata":null},{"id":"bf6135f72a7447e7b0dc55d9ca733d6a","type":"DRUG","name":"neratinib","canonical_id":"gtopdb:5686","description":null,"metadata":null},{"id":"09e2f57edca14fb195fa133a72817f24","type":"DRUG","name":"neratinib","canonical_id":"chembl:CHEMBL180022","description":null,"metadata":null},{"id":"dcba9c05bbd34019b7ee7677943ac237","type":"DRUG","name":"neridronic acid","canonical_id":"mesh:C053389","description":null,"metadata":null},{"id":"56bcccb4a40643b3b41aa47d4d021394","type":"GO_TERM","name":"nerve development","canonical_id":"go:GO:0021675","description":"\"The process whose specific outcome is the progression of a nerve over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"aef6f5dfacf84227abb3071d6e89ad6c","type":"GO_TERM","name":"nerve growth factor binding","canonical_id":"go:GO:0048406","description":"\"Binding to nerve growth factor (NGF).\" [GOC:dgh]","metadata":null},{"id":"ef34153f422a4311afd44c8a3820a26e","type":"GO_TERM","name":"nerve growth factor processing","canonical_id":"go:GO:0032455","description":"\"The generation of a mature nerve growth factor (NGF) by proteolysis of a precursor.\" [GOC:mah, PMID:8615794]","metadata":null},{"id":"57d1e434b94546aa94332bfdf53a5d28","type":"GO_TERM","name":"nerve growth factor production","canonical_id":"go:GO:0032902","description":"\"The appearance of nerve growth factor (NGF) due to biosynthesis or secretion by cells in a neuron's target field, resulting in an increase in its intracellular or extracellular levels.\" [GOC:ecd, GOC:mah]","metadata":null},{"id":"ac3e62aa89514d7390ce59872905e206","type":"GO_TERM","name":"nerve growth factor receptor activity","canonical_id":"go:GO:0010465","description":"\"Combining with nerve growth factor (NGF), to prevent apoptosis in neurons and promote nerve growth, or to initiate a change in cell activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b0b07b6bccf84c01b82ea9829270bc14","type":"GO_TERM","name":"nerve growth factor receptor binding","canonical_id":"go:GO:0005163","description":"\"Binding to a nerve growth factor receptor.\" [GOC:ai, PMID:15654015]","metadata":null},{"id":"d5ea92f366d24e78b7a8c5a49057ee2a","type":"GO_TERM","name":"nerve growth factor signaling pathway","canonical_id":"go:GO:0038180","description":"\"The series of molecular signals initiated by nerve growth factor (NGF) binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, PMID:11520933]","metadata":null},{"id":"5696b003c63f4cc0810a0b7ce9bbe7e8","type":"GO_TERM","name":"nerve maturation","canonical_id":"go:GO:0021682","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a nerve to attain its fully functional state.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"0ec3801a3e5b4a1f8eba1b87810b0f8d","type":"GO_TERM","name":"nervous system development","canonical_id":"go:GO:0007399","description":"\"The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state.\" [GOC:dgh]","metadata":null},{"id":"071683c4869940e286e9967532db0d4a","type":"GO_TERM","name":"nervous system process","canonical_id":"go:GO:0050877","description":"\"An organ system process carried out by any of the organs or tissues of the neurological system.\" [GOC:ai, GOC:mtg_cardio]","metadata":null},{"id":"74232f9d1ff541d9b5f485279f016111","type":"GO_TERM","name":"nervous system process involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0001976","description":"\"The regulation of blood pressure mediated by detection of stimuli and a neurological response.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"76a3b6421b1e47c3a8762aee323a9799","type":"GO_TERM","name":"netrin receptor activity","canonical_id":"go:GO:0005042","description":"\"Combining with a netrin signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:dph, GOC:signaling, PMID:15960985]","metadata":null},{"id":"c1a83c0fb69745158a6faa5f2b7902fc","type":"GO_TERM","name":"netrin receptor activity involved in chemoattraction","canonical_id":"go:GO:0038006","description":"\"Combining with a netrin signal and transmitting the signal from one side of the membrane to the other to contribute to the directed movement of a motile cell towards a higher concentration of netrin.\" [GOC:signaling]","metadata":null},{"id":"b344e679c92b441e9390c966776a2440","type":"GO_TERM","name":"netrin receptor activity involved in chemorepulsion","canonical_id":"go:GO:0005043","description":"\"Combining with a netrin signal and transmitting the signal from one side of the membrane to the other to contribute to the directed movement of a motile cell away from a higher concentration of netrin.\" [GOC:dph, GOC:signaling]","metadata":null},{"id":"14bd20afd27d435b9a7d76627928bad9","type":"GO_TERM","name":"netrin receptor binding","canonical_id":"go:GO:1990890","description":"\"Binding to a netrin receptor.\" [GOC:kmv, PMID:8861902, PMID:9126742]","metadata":null},{"id":"6331d669e90942538e4994f304cfeaa8","type":"GO_TERM","name":"netrin-activated signaling pathway","canonical_id":"go:GO:0038007","description":"\"The series of molecular signals initiated by the binding of a netrin protein to its receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Netrins can act as chemoattractant signals for some cells and chemorepellent signals for others. Netrins also have roles outside of cell and axon guidance.\" [GOC:signaling, PMID:10399919, PMID:15960985, PMID:19785719, PMID:20108323]","metadata":null},{"id":"42b7a62bbe124e13a9f5e86bf826e0e5","type":"GO_TERM","name":"network-forming collagen trimer","canonical_id":"go:GO:0098642","description":"\"A collagen trimer that forms networks.\" [PMID:21421911]","metadata":null},{"id":"c56a1e255ffc4682993efbb40e6e2f6f","type":"GO_TERM","name":"neural crest cell delamination","canonical_id":"go:GO:0036032","description":"\"The negative regulation of cell adhesion process in which a neural crest cell physically separates from the rest of the neural tube.\" [CL:0000333, PMID:17076275]","metadata":null},{"id":"f5d397120fb74a08811ddc15fe40d3a4","type":"GO_TERM","name":"neural crest cell development","canonical_id":"go:GO:0014032","description":"\"The process aimed at the progression of a neural crest cell over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"c5941e772e0c496f8d6a48d56aa078e7","type":"GO_TERM","name":"neural crest cell differentiation","canonical_id":"go:GO:0014033","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neural crest cell.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"82ef6ac8118142c48fa7931e0a642293","type":"GO_TERM","name":"neural crest cell fate commitment","canonical_id":"go:GO:0014034","description":"\"The process in which a cell becomes committed to become a neural crest cell.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"725de993e29246c1a7bdd4105e0523b7","type":"GO_TERM","name":"neural crest cell fate determination","canonical_id":"go:GO:0014035","description":"\"The process in which a cell becomes capable of differentiating autonomously into a neural crest cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"f3cda8f0e7314ee7988b1f597a88d206","type":"GO_TERM","name":"neural crest cell fate specification","canonical_id":"go:GO:0014036","description":"\"The process in which a cell becomes capable of differentiating autonomously into a neural crest cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"4ba5daca9b274d868a474614bab9a9fa","type":"GO_TERM","name":"neural crest cell migration","canonical_id":"go:GO:0001755","description":"\"The characteristic movement of cells from the dorsal ridge of the neural tube to a variety of locations in a vertebrate embryo.\" [GOC:ascb_2009, GOC:dph, GOC:tb, ISBN:0878932437]","metadata":null},{"id":"38bc73fe99e041d29f33268d92d402b7","type":"GO_TERM","name":"neural crest cell migration involved in autonomic nervous system development","canonical_id":"go:GO:1901166","description":"\"Any neural crest cell migration that is involved in autonomic nervous system development.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"e1671e3de2784dca8d64b0dd26ade581","type":"GO_TERM","name":"neural crest cell migration involved in heart formation","canonical_id":"go:GO:0003147","description":"\"The characteristic movement of a cell from the dorsal ridge of the neural tube towards the heart and that contributes to heart formation.\" [GOC:mtg_heart]","metadata":null},{"id":"2042301e312949d5bef22f34e66913a6","type":"GO_TERM","name":"neural crest cell migration involved in sympathetic nervous system development","canonical_id":"go:GO:1903045","description":"\"Any neural crest cell migration that is involved in sympathetic nervous system development.\" [GO_REF:0000060, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19325129]","metadata":null},{"id":"96baf52f4bbd40a9ae1a0b2fb82cb34a","type":"GO_TERM","name":"neural crest formation","canonical_id":"go:GO:0014029","description":"\"The formation of the specialized region of ectoderm between the neural ectoderm (neural plate) and non-neural ectoderm. The neural crest gives rise to the neural crest cells that migrate away from this region as neural tube formation proceeds.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"1d723d4f36144f16a910d0c607259ee5","type":"GO_TERM","name":"neural crest-derived cardiac fibroblast cell development","canonical_id":"go:GO:0060943","description":"\"The process whose specific outcome is the progression of a cardiac fibroblast over time, from its formation from a neural crest cell to the mature state. A cardiac fibroblast is a connective tissue cell of the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"5fc39ee996c445628b0c6d51fe29854c","type":"GO_TERM","name":"neural crest-derived cardiac fibroblast cell differentiation","canonical_id":"go:GO:0060942","description":"\"The process in which a neural crest cell acquires the specialized structural and/or functional features of a cardiac fibroblast. A cardiac fibroblast is a connective tissue cell in the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"e1a12be48a0f4235ad4aad48ddd102f4","type":"GO_TERM","name":"neural crest-derived cardiac fibroblast cell fate commitment","canonical_id":"go:GO:0060944","description":"\"The commitment of neural crest cells to a cardiac fibroblast fate and their capacity to differentiate into cardiac fibroblast cells. A cardiac fibroblast is a connective tissue cell in the heart which secretes an extracellular matrix rich in collagen and other macromolecules.\" [GOC:mtg_heart]","metadata":null},{"id":"43f6f7967fe04f368f433cea23f8a011","type":"GO_TERM","name":"neural crest-derived cardiac glial cell development","canonical_id":"go:GO:0060954","description":"\"The process aimed at the progression of a neural crest-derived cardiac glial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:mtg_heart]","metadata":null},{"id":"70e89afdc4ba4938a1944a378cd2a675","type":"GO_TERM","name":"neural crest-derived cardiac glial cell differentiation","canonical_id":"go:GO:0060951","description":"\"The process in which a neural crest cell acquires the specialized features of a glial cell of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"990f335c44c74651917a66063ff3e844","type":"GO_TERM","name":"neural crest-derived cardiac glial cell fate commitment","canonical_id":"go:GO:0060955","description":"\"The commitment of neural crest cells to cardiac glial cell fates and their capacity to differentiate into cardiac glial cells.\" [GOC:mtg_heart]","metadata":null},{"id":"90d96daa4256439cb22a4658ab8d443f","type":"GO_TERM","name":"neural fold bending","canonical_id":"go:GO:0021503","description":"\"The morphogenesis of the neural fold elevations that results in the movement of the tips of the elevations towards each other in order to fuse.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15806586]","metadata":null},{"id":"acd1309c889146da92687f9d69e0dc71","type":"GO_TERM","name":"neural fold elevation formation","canonical_id":"go:GO:0021502","description":"\"The process in which the lateral borders of the neural plate begin to migrate upwards to form the neural folds, caused by the proliferation of the underlying mesoderm.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15806586]","metadata":null},{"id":"ec8298944bd44c1290dec75463940995","type":"GO_TERM","name":"neural fold folding","canonical_id":"go:GO:0021505","description":"\"The process of folding the neuroepithelium around the medial hinge point to create the neural elevations, and around the lateral hinge points to produce convergence of the folds.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:13679871, PMID:15806586]","metadata":null},{"id":"2e9de67a4b6d457c955d665ba1c72613","type":"GO_TERM","name":"neural fold formation","canonical_id":"go:GO:0001842","description":"\"The process in which the neural fold is formed. The edges of the neural plate thicken and move up to form a U-shaped structure called the neural groove.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"123dc63c1dcc454fa425caf461bebe01","type":"GO_TERM","name":"neural fold hinge point formation","canonical_id":"go:GO:0021504","description":"\"The formation of the median and lateral hinge points in the neural folds. These are created by apical constriction and basal expansion of the underlying neural cells. The median hinge point extends for the entire length of the neural tube, and the lateral hinge points do not form in the spinal cord region of the neural tube.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:13679871, PMID:15806586]","metadata":null},{"id":"59613e10db9449faa3017d8a29fea90d","type":"GO_TERM","name":"neural keel formation","canonical_id":"go:GO:0014025","description":"\"The formation of a thickened region of the neurectoderm that is roughly triangular in cross section. The neural keel develops from the neural plate and develops into the neural rod. Neural keel formation occurs during primary neurulation in teleosts.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"53a6781e47754ac9bf99ba109b8b5a05","type":"GO_TERM","name":"neural nucleus development","canonical_id":"go:GO:0048857","description":"\"The biological process whose specific outcome is the progression of a neural nucleus from its initial condition to its mature state. A neural nucleus is an anatomical structure consisting of a discrete aggregate of neuronal soma.\" [GO_REF:0000021]","metadata":null},{"id":"913a6496c5f043678dd35aea59bab3d1","type":"GO_TERM","name":"neural plate anterior/posterior regionalization","canonical_id":"go:GO:0021999","description":"\"The process that regulates the coordinated growth and differentiation that establishes the non-random anterior-posterior spatial arrangement of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9accbb69a4ab4b1db235ace567095ac6","type":"GO_TERM","name":"neural plate axis specification","canonical_id":"go:GO:0021997","description":"\"The pattern specification process in which the axes of the nervous system are established.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"33f2347dcaa44b3791597ac02e5e071c","type":"GO_TERM","name":"neural plate development","canonical_id":"go:GO:0001840","description":"\"The process whose specific outcome is the progression of the neural plate over time, from its formation to the mature structure. The neural plate is a flat, thickened layer of ectodermal cells. The underlying dorsal mesoderm signals the ectodermal cells above it to elongate into columnar neural plate cells. The neural plate subsequently develops into the neural tube, which gives rise to the central nervous system.\" [GOC:dph, GOC:ef, ISBN:0878932437, ISBN:0878932585]","metadata":null},{"id":"ab742f249f604bb28a89c4d88f9d083e","type":"GO_TERM","name":"neural plate elongation","canonical_id":"go:GO:0014022","description":"\"The process in which the neural plate is shaped by the intrinsic movement of the epidermal and neural plate regions.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"2d7a7e7b0bde41ebb62f8a1eb3422b52","type":"GO_TERM","name":"neural plate formation","canonical_id":"go:GO:0021990","description":"\"The formation of the flat, thickened layer of ectodermal cells known as the neural plate. The underlying dorsal mesoderm signals the ectodermal cells above it to elongate into columnar neural plate cells. The neural plate subsequently develops into the neural tube, which gives rise to the central nervous system.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878932437, ISBN:0878932585, PMID:15806586]","metadata":null},{"id":"aa13ed88485141ee9c91a7d99d63563a","type":"GO_TERM","name":"neural plate mediolateral regionalization","canonical_id":"go:GO:0021998","description":"\"The process that regulates the coordinated growth and differentiation that establishes the non-random mediolateral spatial arrangement of the neural plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"483203b0c8434416a36e0c2f62fedaf7","type":"GO_TERM","name":"neural plate morphogenesis","canonical_id":"go:GO:0001839","description":"\"The process in which the anatomical structures of the neural plate are generated and organized. The neural plate is a specialized region of columnar epithelial cells in the dorsal ectoderm that will give rise to nervous system tissue.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"ec38fca7b8924150947b6ff395882b35","type":"GO_TERM","name":"neural plate pattern specification","canonical_id":"go:GO:0060896","description":"\"The developmental process that results in the creation of defined areas or spaces within the neural plate to which cells respond and eventually are instructed to differentiate.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"5b040cd944494e398cf46f929947b10d","type":"GO_TERM","name":"neural plate regionalization","canonical_id":"go:GO:0060897","description":"\"The pattern specification process that results in the subdivision of an axis or axes of the neural plate in space to define an area or volume in which specific patterns of cell differentiation will take place or in which cells interpret a specific environment.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3450968a8a994b6d9cdac357ca8020ea","type":"GO_TERM","name":"neural plate thickening","canonical_id":"go:GO:0021991","description":"\"The process of apical-basal elongation of individual ectodermal cells during the formation of the neural placode.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15806586]","metadata":null},{"id":"27b86309645143b2b10bfca7ebf9e58b","type":"GO_TERM","name":"neural precursor cell proliferation","canonical_id":"go:GO:0061351","description":"\"The multiplication or reproduction of neural precursor cells, resulting in the expansion of a cell population. A neural precursor cell is either a nervous system stem cell or a nervous system progenitor cell.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"f52367e6a2d7475080a2260ea970d966","type":"GO_TERM","name":"neural retina development","canonical_id":"go:GO:0003407","description":"\"The progression of the neural retina over time from its initial formation to the mature structure. The neural retina is the part of the retina that contains neurons and photoreceptor cells.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"f3db7cd719284e3d9fe0da93e8ec0e93","type":"GO_TERM","name":"neural rod formation","canonical_id":"go:GO:0014023","description":"\"The formation of a solid rod of neurectoderm derived from the neural keel. The neural rod is roughly circular in cross section. Neural rod formation occurs during primary neurulation in teleosts.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"d32df4baccc44bcd97071625060a7aff","type":"GO_TERM","name":"neural tissue regeneration","canonical_id":"go:GO:0097719","description":"\"The regrowth of neural tissue following its loss or destruction.\" [Wikipedia:Neuroregeneration]","metadata":null},{"id":"f6a0499c31884433924bfdd409d6d4eb","type":"GO_TERM","name":"neural tube closure","canonical_id":"go:GO:0001843","description":"\"The last step in the formation of the neural tube, where the paired neural folds are brought together and fuse at the dorsal midline.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"d5fe897427a84439a7b28c44d4f0ca0e","type":"GO_TERM","name":"neural tube development","canonical_id":"go:GO:0021915","description":"\"The process whose specific outcome is the progression of the neural tube over time, from its formation to the mature structure. The mature structure of the neural tube exists when the tube has been segmented into the forebrain, midbrain, hindbrain and spinal cord regions. In addition neural crest has budded away from the epithelium.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"4c09ea4d5c434efda3f900ecf73a9848","type":"GO_TERM","name":"neural tube formation","canonical_id":"go:GO:0001841","description":"\"The formation of a tube from the flat layer of ectodermal cells known as the neural plate. This will give rise to the central nervous system.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"9c21170d793f49c1a4a47b2231db88bd","type":"GO_TERM","name":"neural tube patterning","canonical_id":"go:GO:0021532","description":"\"The regionalization process that regulates the coordinated growth that establishes the non-random spatial arrangement of the neural tube.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"c531ae2a3a604aeabef173fd57e24ca0","type":"DISEASE","name":"neuralgia","canonical_id":"mondo:0021667","description":null,"metadata":null},{"id":"2a50c863e1d94805ad257b887c506fb9","type":"GO_TERM","name":"neuregulin binding","canonical_id":"go:GO:0038132","description":"\"Binding to a neuregulin, a member of the EGF family of growth factors.\" [GOC:bf, GOC:signaling]","metadata":null},{"id":"b80a92a12a334c7f9608bd3b3f96117c","type":"GO_TERM","name":"neuregulin receptor activity","canonical_id":"go:GO:0038131","description":"\"Combining with a neuregulin, a member of the EGF family of growth factors, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:signaling, PMID:16460914, PMID:20672328]","metadata":null},{"id":"d0006bef74d643c68e0535ebe4f7be30","type":"GO_TERM","name":"neurexin clustering involved in presynaptic membrane assembly","canonical_id":"go:GO:0097115","description":"\"The receptor clustering process involved in assembly of the presynaptic membrane in which neurexins are localized to distinct domains in the cell membrane. Neurexins are synaptic cell surface proteins which act as cell recognition molecules at nerve terminals.\" [GOC:BHF, GOC:sjp, PMID:12796785]","metadata":null},{"id":"7b28153277c04be98c98d5044e1d0803","type":"GO_TERM","name":"neurexin family protein binding","canonical_id":"go:GO:0042043","description":"\"Binding to a neurexin, a synaptic cell surface protein related to latrotoxin receptor, laminin and agrin. Neurexins act as cell recognition molecules at nerve terminals.\" [GOC:curators, GOC:pr, PMID:18923512]","metadata":null},{"id":"5d57481200a44a818eb463ce922837db","type":"GO_TERM","name":"neuroblast activation","canonical_id":"go:GO:0007407","description":"\"A change in the morphology or behavior of a neuroblast resulting from exposure to an activating factor such as a cellular or soluble ligand.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"7fa15d98a6d74a95b90d84e26c012b95","type":"GO_TERM","name":"neuroblast delamination","canonical_id":"go:GO:0060234","description":"\"The negative regulation of cell adhesion process in which a neuroblast splits off of a neurectodermal sheet.\" [GOC:dph]","metadata":null},{"id":"d9a4546349ad46ea8e782d5681beb3a7","type":"GO_TERM","name":"neuroblast development","canonical_id":"go:GO:0014019","description":"\"The process aimed at the progression of a neuroblast over time, from initial commitment of the cell to a specific state, to the mature neuroblast. It does not include processes where the neuroblast turns into a glial cell or a neuron.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"f0057506e74e49339961f66cc6cea4af","type":"GO_TERM","name":"neuroblast differentiation","canonical_id":"go:GO:0014016","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuroblast. There are at least four stages through which the pluripotent cells of epiblast or blastula become neuroblasts.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"4fd10e6795ef4b82adeb9ba2dbf73046","type":"GO_TERM","name":"neuroblast division","canonical_id":"go:GO:0055057","description":"\"The process resulting in the physical partitioning and separation of a neuroblast into daughter cells. A neuroblast is any cell that will divide and give rise to a neuron.\" [PMID:11163136, PMID:11250167]","metadata":null},{"id":"700823e514bd423aadc0ab789fff5bf1","type":"GO_TERM","name":"neuroblast division in dorsal lateral ganglionic eminence","canonical_id":"go:GO:0021851","description":"\"The division of neuroblasts in the dorsal region of the lateral ganglionic eminence. These cells give rise to embryonic interneuron precursors that will migrate tangentially to the olfactory bulb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"ef85a317635a41cb95a5a5351f2022f3","type":"GO_TERM","name":"neuroblast division in pallium","canonical_id":"go:GO:0022017","description":"\"The division of neuroblasts in the pallium. Neuroblasts are precursor cells that give rise to neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"096768960f8f48fc8389c6cdfdace09f","type":"GO_TERM","name":"neuroblast division in subpallium","canonical_id":"go:GO:0021848","description":"\"The division of neuroblasts in the subpallium area of the forebrain. The interneuron precursors that these cells give rise to include GABAergic interneurons and will migrate tangentially.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"dd29e9c8af63480e91c7470908bfb8af","type":"GO_TERM","name":"neuroblast division in subventricular zone","canonical_id":"go:GO:0021849","description":"\"The division of neuroblasts in the subventricular zone of the forebrain. The interneuron precursors that these cells give rise to include adult olfactory bulb interneurons and migrate tangentially.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"4b6503d74a86435f97999974d5729cc7","type":"GO_TERM","name":"neuroblast fate commitment","canonical_id":"go:GO:0014017","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will differentiate into a neuroblast.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"abbd68ee594745cd95ae914644aa325d","type":"GO_TERM","name":"neuroblast fate determination","canonical_id":"go:GO:0007400","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a neuroblast cell regardless of its environment; upon determination, the cell fate cannot be reversed. An example of this process is found in Mus musculus.\" [GOC:curators]","metadata":null},{"id":"89e4ab25d56d424085e6e73b2a7cc412","type":"GO_TERM","name":"neuroblast fate specification","canonical_id":"go:GO:0014018","description":"\"The process in which a cell becomes capable of differentiating autonomously into a neuroblast in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GOC:ef, ISBN:0878932585]","metadata":null},{"id":"031576d7749f41279430d0f30ca7b3e6","type":"GO_TERM","name":"neuroblast migration","canonical_id":"go:GO:0097402","description":"\"The orderly movement of a neuroblast from one site to another, often during the development of a multicellular organism or multicellular structure. A neuroblast is any cell that will divide and give rise to a neuron.\" [CL:0000031, GOC:jc, PMID:15543145]","metadata":null},{"id":"cbf3a0eec2a549a498bb313b15ede3c0","type":"GO_TERM","name":"neuroblast proliferation","canonical_id":"go:GO:0007405","description":"\"The expansion of a neuroblast population by cell division. A neuroblast is any cell that will divide and give rise to a neuron.\" [GOC:ai, GOC:mtg_sensu, GOC:sart]","metadata":null},{"id":"4dc36777ac7e4a85819487253c02beff","type":"DISEASE","name":"neuroblastoma","canonical_id":"mondo:0005072","description":null,"metadata":null},{"id":"b0d51f9f5b10409ea27030a49f398139","type":"DISEASE","name":"neuroblastoma, susceptibility to, 3","canonical_id":"mondo:0013083","description":null,"metadata":null},{"id":"1a19947516f347b3a795dc777056ef43","type":"DISEASE","name":"neurodegenerative disease","canonical_id":"mondo:0005559","description":null,"metadata":null},{"id":"d3aa28803fac4c38b91cf601008f1223","type":"DISEASE","name":"neurodevelopmental disorder","canonical_id":"mondo:0700092","description":null,"metadata":null},{"id":"0f15a4f29093443eb073a33e2dbfa6ed","type":"DISEASE","name":"neurodevelopmental disorder with alopecia and brain abnormalities","canonical_id":"mondo:0033642","description":null,"metadata":null},{"id":"8281adc9814e48ed8af547f38fb45df4","type":"DISEASE","name":"neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures","canonical_id":"mondo:0859286","description":null,"metadata":null},{"id":"d98a99ee199f472b8fc3eead404954f1","type":"DISEASE","name":"neuroendocrine carcinoma","canonical_id":"mondo:0002120","description":null,"metadata":null},{"id":"3fa05c0ede1a4bddbda3adf4e41a8054","type":"GO_TERM","name":"neuroendocrine cell differentiation","canonical_id":"go:GO:0061101","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a neuroendocrine cell. A neuroendocrine cell is a cell that receives input form a neuron which controls the secretion of an endocrine substance.\" [GOC:dph]","metadata":null},{"id":"2ed6de89b8e3497fa921c54c659c8ef9","type":"DISEASE","name":"neuroendocrine neoplasm","canonical_id":"mondo:0019496","description":null,"metadata":null},{"id":"2d467cda8b174a03b7052e8323d195e1","type":"GO_TERM","name":"neuroepithelial cell differentiation","canonical_id":"go:GO:0060563","description":"\"The process in which epiblast cells acquire specialized features of neuroepithelial cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3f01973430b6489fa336f4e610c1a61e","type":"GO_TERM","name":"neurofibrillary tangle","canonical_id":"go:GO:0097418","description":"\"Intracellular mass of paired, helically wound protein filaments (also called PHF) lying in the cytoplasm of neuronal cell bodies and neuritic cell processes. Neurofibrillary tangles contain an abnormally phosphorylated form of a microtubule-associated protein, tau. The shape of these inclusions may resemble a flame or a star.\" [NIF_Subcellular:nlx_subcell_20090201, NIF_Subcellular:nlx_subcell_20090202, NIF_Subcellular:sao2409833926]","metadata":null},{"id":"c428513971884f4ba9555e0653f28066","type":"GO_TERM","name":"neurofibrillary tangle assembly","canonical_id":"go:GO:1902988","description":"\"The aggregation, arrangement and bonding together of a set of components to form a neurofibrillary tangle.\" [GO_REF:0000079, GOC:sjp, GOC:TermGenie, PMID:15897157, PMID:22986780, PMID:24154541]","metadata":null},{"id":"857611c465284c68bace70437acd88d3","type":"DISEASE","name":"neurofibromatosis type 1","canonical_id":"mondo:0018975","description":null,"metadata":null},{"id":"3df5e9fab5794d50b364a361fe3aaea1","type":"GO_TERM","name":"neurofilament","canonical_id":"go:GO:0005883","description":"\"A type of intermediate filament found in the core of neuronal axons. Neurofilaments are heteropolymers composed of three type IV polypeptides: NF-L, NF-M, and NF-H (for low, middle, and high molecular weight). Neurofilaments are responsible for the radial growth of an axon and determine axonal diameter.\" [ISBN:0198506732, ISBN:0716731363, ISBN:0815316194]","metadata":null},{"id":"c07cd417bb28484783ad42f379890010","type":"GO_TERM","name":"neurofilament bundle assembly","canonical_id":"go:GO:0033693","description":"\"The assembly of neurofilaments into bundles, in which the filaments are longitudinally oriented, with numerous crossbridges between them. Neurofilament bundles may be cross-linked to each other, to membrane-bounded organelles or other cytoskeletal structures such as microtubules.\" [PMID:11034913, PMID:11264295]","metadata":null},{"id":"d208121fa2034b669bf1d6f02640db72","type":"GO_TERM","name":"neurofilament cytoskeleton","canonical_id":"go:GO:0060053","description":"\"Intermediate filament cytoskeletal structure that is made up of neurofilaments. Neurofilaments are specialized intermediate filaments found in neurons.\" [GOC:dph]","metadata":null},{"id":"f3de3d6eeaaf430c9d64c9f48dfeb1bb","type":"GO_TERM","name":"neurofilament cytoskeleton organization","canonical_id":"go:GO:0060052","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising neurofilaments and their associated proteins.\" [GOC:dph]","metadata":null},{"id":"5441484fbb844f4394fbc4327e897ef3","type":"GO_TERM","name":"neurogenesis","canonical_id":"go:GO:0022008","description":"\"Generation of cells within the nervous system.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"43b9aa1555434ef69744ec80314a7b1c","type":"DISEASE","name":"neurohypophyseal diabetes insipidus","canonical_id":"mondo:0007450","description":null,"metadata":null},{"id":"0d14eba38cb9438f8201a1e8d9c5d564","type":"GO_TERM","name":"neurohypophyseal hormone activity","canonical_id":"go:GO:0005185","description":"\"The action characteristic of a neurohypophyseal hormone, any of a family of structurally and functionally related nonapeptides that are synthesized as part of a larger precursor molecule comprising a signal peptide, the nonapeptide hormone, and a neurophysin.\" [GOC:mah, PMID:19243634]","metadata":null},{"id":"4b33dab3c9b642be82467c8cefe81d67","type":"GO_TERM","name":"neurohypophysis development","canonical_id":"go:GO:0021985","description":"\"The progression of the neurohypophysis over time from its initial formation until its mature state. The neurohypophysis is the part of the pituitary gland that secretes hormones involved in blood pressure regulation.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"aa80025d9cda492aa4420a51a36467cb","type":"GO_TERM","name":"neurohypophysis formation","canonical_id":"go:GO:0048849","description":"\"The process that gives rise to neurohypophysis. This process pertains to the initial formation of a structure from unspecified parts. The neurohypophysis is the part of the pituitary gland that secretes hormones involved in blood pressure regulation.\" [GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"efa16a9d086b4693a37e387d3de59856","type":"GO_TERM","name":"neurohypophysis morphogenesis","canonical_id":"go:GO:0048848","description":"\"The process in which the anatomical structures of the neurohypophysis are generated and organized. The neurohypophysis is the part of the pituitary gland that secretes hormones involved in blood pressure regulation.\" [GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6e17c0dc09d640e4b45777208ebe5fc3","type":"GO_TERM","name":"neuroinflammatory response","canonical_id":"go:GO:0150076","description":"\"The immediate defensive reaction by neural vertebrate tissue to infection or injury caused by chemical or physical agents.\" [GOC:aruk, GOC:bc, PMID:10981966, PMID:11099416, PMID:18164423]","metadata":null},{"id":"68fbea361cd642dabb85c798fca420cd","type":"GO_TERM","name":"neurokinin receptor binding","canonical_id":"go:GO:0031834","description":"\"Binding to a neurokinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"8028297029944ff5afbbf17bb6fc39c9","type":"GO_TERM","name":"neuroligin clustering involved in postsynaptic membrane assembly","canonical_id":"go:GO:0097118","description":"\"The receptor clustering process involved in assembly of the postsynaptic membrane in which neuroligins are localized to distinct domains in the cell membrane. Neuroligins are neuronal cell surface proteins on the postsynaptic membrane that mediate synapse formation between neurons.\" [GOC:BHF, GOC:sjp, PMID:12796785]","metadata":null},{"id":"000b959743be4982b5009113e63d667d","type":"GO_TERM","name":"neuroligin family protein binding","canonical_id":"go:GO:0097109","description":"\"Binding to a member of the neuroligin protein family, neuronal cell surface proteins that mediate synapse formation.\" [GOC:BHF, GOC:pr, GOC:sjp, PMID:21424692]","metadata":null},{"id":"b623e9216b584393ad858ec6c7d92e0a","type":"GO_TERM","name":"neuromast deposition","canonical_id":"go:GO:0048885","description":"\"The process in which a migrating neuromast primordium deposits clusters of undifferentiated cells (proneuromasts) along its migratory path in a developing lateral line.\" [PMID:15018940]","metadata":null},{"id":"759f394f8b7b4d5181e30e390ba3a72d","type":"GO_TERM","name":"neuromast development","canonical_id":"go:GO:0048884","description":"\"The process whose specific outcome is the progression of the neuromast over time, from its formation to the mature structure. The neuromast is the sensory organ of the lateral line and is composed of a population of sensory hair cells, and nonsensory supporting cells and mantle cells. Neuromasts are located superficially on the epithelium or in lateral line canals.\" [ISBN:0125296509]","metadata":null},{"id":"f12eaaeeecf34bffa9a296610e8ee83e","type":"GO_TERM","name":"neuromast hair cell development","canonical_id":"go:GO:0035675","description":"\"The process whose specific outcome is the progression of a neuromast hair cell over time, from its formation to the mature structure. A neuromast hair cell is a hair cell that acts as a sensory receptor of the neuromast; it is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface. Cell development does not include the steps involved in committing a cell to a specific fate.\" [CL:0000856]","metadata":null},{"id":"2083ec052b64454d8a5be29de535bbed","type":"GO_TERM","name":"neuromast hair cell differentiation","canonical_id":"go:GO:0048886","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuromast hair cell. Hair cells are the sensory receptors of the neuromast and are located in a portion of the neuromast called the sensory strip. Each hair cell of the neuromast is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface. There are approximately seven hair cells within each neuromast, with each hair cell innervated by afferent and efferent neurons.\" [CL:0000856, ISBN:0125296509]","metadata":null},{"id":"d4ab276685934addae7613d0790a30e9","type":"GO_TERM","name":"neuromast hair cell differentiation involved in neuromast regeneration","canonical_id":"go:GO:0070658","description":"\"Differentiation of new neuromast sensory hair cells to replace those lost or destroyed by injury.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"d53f5fbaea9a48fea36038fb7bf9c18f","type":"GO_TERM","name":"neuromast hair cell morphogenesis","canonical_id":"go:GO:0035678","description":"\"The change in form (cell shape and size) that occurs when a neuromast hair cell progresses from its initial formation to its mature state. A neuromast hair cell is a hair cell that acts as a sensory receptor of the neuromast; it is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface.\" [CL:0000856]","metadata":null},{"id":"b20c34e4050449029e36714f32550329","type":"GO_TERM","name":"neuromast mantle cell differentiation","canonical_id":"go:GO:0048888","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuromast mantle cell. Mantle cells are non-sensory cells that surround the sensory strip, separating the neuromast from the epidermis. Mantle cells secrete the cupula in which the ciliary bundles of all of the hair cells are embedded.\" [ISBN:0125296509]","metadata":null},{"id":"c69725f971c849a4a1e5e0969f9ffacc","type":"GO_TERM","name":"neuromast primordium migration","canonical_id":"go:GO:0048883","description":"\"The migration of a cluster of a relatively undifferentiated cell originating at specific cephalic placodes and depositing proneuromasts along a developing lateral line, from which the neuromasts will develop.\" [PMID:15018940, PMID:15832385]","metadata":null},{"id":"b0b97131aaff4a359116f518f627680e","type":"GO_TERM","name":"neuromast regeneration","canonical_id":"go:GO:0070657","description":"\"The regrowth of a neuromast following its loss or destruction.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"35a1054e8f744721972a9c51b174904a","type":"GO_TERM","name":"neuromast support cell differentiation","canonical_id":"go:GO:0048889","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuromast support cell. Support cells are non-sensory cells of the neuromast that extend between the sensory hair cells from the basement membrane to the apical surface; they are surrounded by mantle cells.\" [ISBN:0125296509]","metadata":null},{"id":"f2a0defff7e0417db0a8abe55b6f1821","type":"GO_TERM","name":"neuromedin B receptor binding","canonical_id":"go:GO:0031710","description":"\"Binding to a neuromedin B receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a30a08d5dce44586b9dc8e5059d8869e","type":"GO_TERM","name":"neuromedin K receptor activity","canonical_id":"go:GO:0016498","description":"\"Combining with neuromedin K, the peptide Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met to initiate a change in cell activity.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"9eb6def5d8694f109d698227396d475a","type":"GO_TERM","name":"neuromedin K receptor binding","canonical_id":"go:GO:0031836","description":"\"Binding to a neuromedin K receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"0c3290046ec0461eb54f64f62e22ccc4","type":"GO_TERM","name":"neuromedin U binding","canonical_id":"go:GO:0042924","description":"\"Interacting selectively and non-covalently and stoichiometrically with neuromedin U, a hypothalamic peptide involved in energy homeostasis and stress responses.\" [GOC:jl, PMID:12584108]","metadata":null},{"id":"0de55bdacdf642d19476d9016c59a285","type":"GO_TERM","name":"neuromedin U receptor activity","canonical_id":"go:GO:0001607","description":"\"Combining with neuromedin U to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"a0ffb1e124f7435d81d5535f2776e1ed","type":"GO_TERM","name":"neuromedin U receptor binding","canonical_id":"go:GO:0042922","description":"\"Binding to one or more specific sites on a neuromedin U receptor.\" [GOC:jl, PMID:10899166]","metadata":null},{"id":"de787d0a35994c28802ab76d97514e50","type":"GO_TERM","name":"neuromelanin biosynthetic process","canonical_id":"go:GO:0036489","description":"\"The chemical reactions and pathways resulting in the formation of neuromelanin. Neuromelanin is a polymer of 5,6-dihydroxyindole monomers.\" [GOC:bf, GOC:PARL, Wiki:Neuromelanin]","metadata":null},{"id":"381faa75a88644c8ab9e706554db01d9","type":"DISEASE","name":"neuromuscular disease","canonical_id":"mondo:0019056","description":null,"metadata":null},{"id":"e2414175c9d44391ae16f97a2ead9dbf","type":"DISEASE","name":"neuromuscular disease, congenital, with uniform type 1 fiber","canonical_id":"efo:0022975","description":null,"metadata":null},{"id":"769a4537e1364bf693d696e6087d5728","type":"GO_TERM","name":"neuromuscular junction","canonical_id":"go:GO:0031594","description":"\"The junction between the axon of a motor neuron and a muscle fiber. In response to the arrival of action potentials, the presynaptic button releases molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane of the muscle fiber, leading to a change in post-synaptic potential.\" [GOC:nln]","metadata":null},{"id":"ed6648e7bd1d40729bfd16deb238177c","type":"GO_TERM","name":"neuromuscular junction development","canonical_id":"go:GO:0007528","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a neuromuscular junction.\" [GOC:mtg_OBO2OWL_2013]","metadata":null},{"id":"1fc099bf94d54e9e97c5d68212e2c773","type":"GO_TERM","name":"neuromuscular junction development, skeletal muscle fiber","canonical_id":"go:GO:0098529","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a neuromuscular junction that targets a skeletal muscle fiber.\" [GOC:mtg_OBO2OWL_2013]","metadata":null},{"id":"7bd57b54f06548de8ba6932cc44a7c02","type":"GO_TERM","name":"neuromuscular junction of myotube","canonical_id":"go:GO:0098523","description":"\"A neuromuscular junction in which the target muscle cell is a myotube.\" [GOC:dos]","metadata":null},{"id":"2370fe6a8bb241d9a99fda68a57d7a06","type":"GO_TERM","name":"neuromuscular junction of skeletal muscle fiber","canonical_id":"go:GO:0098522","description":"\"A neuromuscular junction in which the target muscle cell is a skeletal muscle fiber.\" [GOC:dos]","metadata":null},{"id":"ddf67a4025034716814b630627ca745b","type":"GO_TERM","name":"neuromuscular junction of somatic muscle","canonical_id":"go:GO:0098527","description":"\"A neuromuscular junction in which the target muscle cell is a somatic muscle cell, such as those found in nematodes and arthropods.\" [GOC:dos]","metadata":null},{"id":"3150a3d9be07460c9df6dc746e5e0f73","type":"GO_TERM","name":"neuromuscular junction of somatic muscle myotube","canonical_id":"go:GO:0098524","description":"\"A neuromuscular junction in which the target muscle cell is a somatic muscle myotube, such as an arthropod somatic muscle cell.\" [GOC:dos]","metadata":null},{"id":"6d2bfa311a4a4bbea8ce37a3af29bfad","type":"GO_TERM","name":"neuromuscular process","canonical_id":"go:GO:0050905","description":"\"Any process pertaining to the functions of the nervous and muscular systems of an organism.\" [GOC:ai]","metadata":null},{"id":"249558b96243420fb91ca01aa53b5e28","type":"GO_TERM","name":"neuromuscular process controlling balance","canonical_id":"go:GO:0050885","description":"\"Any process that an organism uses to control its balance, the orientation of the organism (or the head of the organism) in relation to the source of gravity. In humans and animals, balance is perceived through visual cues, the labyrinth system of the inner ears and information from skin pressure receptors and muscle and joint receptors.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"989ebc14f0b64216ba21e6dfa69d11bd","type":"GO_TERM","name":"neuromuscular process controlling posture","canonical_id":"go:GO:0050884","description":"\"Any process in which an organism voluntarily modulates its posture, the alignment of its anatomical parts.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7dc594f644ba4cd48e12db630b75c969","type":"GO_TERM","name":"neuromuscular synaptic transmission","canonical_id":"go:GO:0007274","description":"\"The process of synaptic transmission from a neuron to a muscle, across a synapse.\" [GOC:dos, GOC:jl, MeSH:D009435]","metadata":null},{"id":"0068c1c981cf4a4baa3c2ed702dddcba","type":"DISEASE","name":"neuromyelitis optica","canonical_id":"mondo:0019100","description":null,"metadata":null},{"id":"2b3fc80cfeb94b8b83c8fafcbdb83b10","type":"GO_TERM","name":"neuron apoptotic process","canonical_id":"go:GO:0051402","description":"\"Any apoptotic process in a neuron, the basic cellular unit of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system.\" [CL:0000540, GOC:mtg_apoptosis]","metadata":null},{"id":"09287ab44dc84c768180c09f18289158","type":"GO_TERM","name":"neuron cell-cell adhesion","canonical_id":"go:GO:0007158","description":"\"The attachment of a neuron to another cell via adhesion molecules.\" [GOC:curators]","metadata":null},{"id":"b0871d7b96894fbbb4d0d5f7c5ea5433","type":"GO_TERM","name":"neuron cellular homeostasis","canonical_id":"go:GO:0070050","description":"\"The cellular homeostatic process that preserves a neuron in a stable, differentiated functional and structural state.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d393403d9812400195562a6a07b4ad6b","type":"GO_TERM","name":"neuron development","canonical_id":"go:GO:0048666","description":"\"The process whose specific outcome is the progression of a neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dph]","metadata":null},{"id":"b3e012e6d2524540806ea08b5de5888f","type":"GO_TERM","name":"neuron development involved in amphid sensory organ development","canonical_id":"go:GO:0003388","description":"\"The process whose specific outcome is the progression of a neuron over time, that contributes to the development of the amphid sensory organ.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"780e373e9046486287a53e4e31ee204e","type":"GO_TERM","name":"neuron differentiation","canonical_id":"go:GO:0030182","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron.\" [GOC:mah]","metadata":null},{"id":"3abfb45244ec402eb3573b6098e5f98b","type":"GO_TERM","name":"neuron differentiation involved in amphid sensory organ development","canonical_id":"go:GO:0003387","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron that contributes to the progression of the amphid sensory gland.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"77865c60b80742c4ae50799c8b650b09","type":"GO_TERM","name":"neuron fate commitment","canonical_id":"go:GO:0048663","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a neuron.\" [GOC:dph]","metadata":null},{"id":"4a4c66d89ea148dfa2e5e95734ff1253","type":"GO_TERM","name":"neuron fate determination","canonical_id":"go:GO:0048664","description":"\"The process in which a cell becomes capable of differentiating autonomously into a neuron regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:dph]","metadata":null},{"id":"1bdc4872fec14b2686970c12641e9f78","type":"GO_TERM","name":"neuron fate specification","canonical_id":"go:GO:0048665","description":"\"The process in which a cell becomes capable of differentiating autonomously into a neuron in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GOC:dph]","metadata":null},{"id":"b430605b4d824bb88e9bd03648414978","type":"GO_TERM","name":"neuron intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036483","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a neuron. The pathway is induced in response to a stimulus indicating endoplasmic reticulum (ER) stress, and ends when the execution phase of apoptosis is triggered. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.\" [GOC:bf, GOC:PARL, PMID:21113145]","metadata":null},{"id":"58b87b655d644926a7f84d45ef67cd56","type":"GO_TERM","name":"neuron intrinsic apoptotic signaling pathway in response to hydrogen peroxide","canonical_id":"go:GO:0036482","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a neuron in response to hydrogen peroxide.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"a1edeb05bab844399e9f01edefe9ca84","type":"GO_TERM","name":"neuron intrinsic apoptotic signaling pathway in response to oxidative stress","canonical_id":"go:GO:0036480","description":"\"The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a neuron. The pathway is induced in response to oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, and ends when the execution phase of apoptosis is triggered.\" [GOC:bf, GOC:PARL, PMID:23858059]","metadata":null},{"id":"bc4bd5b0188d45f18ff8d6ecfbd67db0","type":"GO_TERM","name":"neuron maturation","canonical_id":"go:GO:0042551","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a neuron to attain its fully functional state.\" [GOC:dph, GOC:jl]","metadata":null},{"id":"7dc80eae26fa44a3ba48ff443f6c680a","type":"GO_TERM","name":"neuron migration","canonical_id":"go:GO:0001764","description":"\"The characteristic movement of an immature neuron from germinal zones to specific positions where they will reside as they mature.\" [CL:0000540, GOC:curators]","metadata":null},{"id":"cfa070015d9a4d83a8f75faa02fc069b","type":"GO_TERM","name":"neuron projection","canonical_id":"go:GO:0043005","description":"\"A prolongation or process extending from a nerve cell, e.g. an axon or dendrite.\" [GOC:jl, PMID:3077060]","metadata":null},{"id":"edb5934f8ca241979e6a0a9daa2d21e6","type":"GO_TERM","name":"neuron projection arborization","canonical_id":"go:GO:0140058","description":"\"The process in which the anatomical structures of a neuron projection are generated and organized into branches. A neuron projection is any process extending from a neural cell, such as axons or dendrites.\" [GOC:aruk, GOC:bc, PMID:17114044, PMID:23270857, PMID:23764288]","metadata":null},{"id":"2817d885840141618cbfcf13449c0ed3","type":"GO_TERM","name":"neuron projection branch point","canonical_id":"go:GO:0061845","description":"\"The location where a secondary projection arises from a neuron projection.\" [PMID:25586189]","metadata":null},{"id":"1fc1a43ad6cd4acb8dc8195b0ccf8695","type":"GO_TERM","name":"neuron projection cytoplasm","canonical_id":"go:GO:0120111","description":"\"All of the contents of a plasma membrane bounded neuron projection, excluding the plasma membrane surrounding the projection.\" [GOC:ha]","metadata":null},{"id":"88099948bdda4d2ea6140df40b2138e9","type":"GO_TERM","name":"neuron projection development","canonical_id":"go:GO:0031175","description":"\"The process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).\" [GOC:mah]","metadata":null},{"id":"f0111bfc17cf4137ab1dfd095b33db03","type":"GO_TERM","name":"neuron projection extension","canonical_id":"go:GO:1990138","description":"\"Long distance growth of a single neuron projection involved in cellular development. A neuron projection is a prolongation or process extending from a nerve cell, e.g. an axon or dendrite.\" [GOC:BHF, GOC:rl, PMID:22790009]","metadata":null},{"id":"1551fccb26284a3f8d5e1973f612c79a","type":"GO_TERM","name":"neuron projection fasciculation","canonical_id":"go:GO:0106030","description":"\"The collection of neuronal projections into a bundle of rods, known as a fascicle.\" [GOC:aruk, GOC:bc., PMID:12761826]","metadata":null},{"id":"08aa99f7021a4520afc9f8c70e8ed02e","type":"GO_TERM","name":"neuron projection guidance","canonical_id":"go:GO:0097485","description":"\"The process in which the migration of a neuron projection is directed to a specific target site in response to a combination of attractive and repulsive cues.\" [GOC:BHF, GOC:rl, PMID:22790009]","metadata":null},{"id":"f933b8418f6b4473a5207bce2dbc344e","type":"GO_TERM","name":"neuron projection maintenance","canonical_id":"go:GO:1990535","description":"\"The organization process that preserves a neuron projection in a stable functional or structural state. A neuron projection is a prolongation or process extending from a nerve cell, e.g. an axon or dendrite.\" [GOC:kmv, PMID:25359212]","metadata":null},{"id":"072b170ca7884fbda197685710b2cd43","type":"GO_TERM","name":"neuron projection membrane","canonical_id":"go:GO:0032589","description":"\"The portion of the plasma membrane surrounding a neuron projection.\" [GOC:mah]","metadata":null},{"id":"c7344c86940147e1a756883ebef7eda9","type":"GO_TERM","name":"neuron projection morphogenesis","canonical_id":"go:GO:0048812","description":"\"The process in which the anatomical structures of a neuron projection are generated and organized. A neuron projection is any process extending from a neural cell, such as axons or dendrites.\" [GOC:mah]","metadata":null},{"id":"dee3d38456de442880659f84f528fe2f","type":"GO_TERM","name":"neuron projection organization","canonical_id":"go:GO:0106027","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a prolongation or process extending from a neuron, e.g. an axon, or a dendrite.\" [GOC:aruk, GOC:bc, PMID:11585923]","metadata":null},{"id":"028452fe98584038a6849cde0b524307","type":"GO_TERM","name":"neuron projection regeneration","canonical_id":"go:GO:0031102","description":"\"The regrowth of neuronal processes such as axons or dendrites in response to their loss or damage.\" [GOC:dgh, GOC:dph, GOC:tb]","metadata":null},{"id":"04bac13af5ce4e858bebad681820a374","type":"GO_TERM","name":"neuron projection retraction","canonical_id":"go:GO:0106028","description":"\"The organization process which results in the disassembly (either partial or complete) of constituent parts of a neuron projection. A neuron projection is a prolongation or process extending from a nerve cell, e.g. an axon or dendrite.\" [GOC:aruk, GOC:bc, PMID:11585923]","metadata":null},{"id":"9a7a27a2083a410f844689c7c72222da","type":"GO_TERM","name":"neuron projection terminus","canonical_id":"go:GO:0044306","description":"\"The specialized, terminal region of a neuron projection such as an axon or a dendrite.\" [GOC:jl]","metadata":null},{"id":"32cbadca171744cc9301831faa3328d7","type":"GO_TERM","name":"neuron recognition","canonical_id":"go:GO:0008038","description":"\"The process in which a neuronal cell in a multicellular organism interprets its surroundings.\" [GOC:curators]","metadata":null},{"id":"8afc32218a4c4e86bcaaf2f481ce30ba","type":"GO_TERM","name":"neuron remodeling","canonical_id":"go:GO:0016322","description":"\"The developmentally regulated remodeling of neuronal projections such as pruning to eliminate the extra dendrites and axons projections set up in early stages of nervous system development.\" [GOC:hb]","metadata":null},{"id":"5d1c9d0fbae14c4a9dddfbb5f7fd9ee7","type":"GO_TERM","name":"neuron spine","canonical_id":"go:GO:0044309","description":"\"A small membranous protrusion, often ending in a bulbous head and attached to the neuron by a narrow stalk or neck.\" [ISBN:0198504888, NIF_Subcellular:sao1145756102]","metadata":null},{"id":"f1c6edafdd944e5186c96fca3bbba75b","type":"GO_TERM","name":"neuron to neuron synapse","canonical_id":"go:GO:0098984","description":"\"A synapse in which pre and post-synaptic cells are neurons.\" [GOC:dos]","metadata":null},{"id":"0843a81079d4476b9e11490c741cf7c3","type":"GO_TERM","name":"neuron-glial cell signaling","canonical_id":"go:GO:0150099","description":"\"Cell-cell signaling that mediates the transfer of information from a neuron to a glial cell. This signaling has been shown to be mediated by various molecules released by different types of neurons, e.g. glutamate, gamma-amino butyric acid (GABA), noradrenaline, acetylcholine, dopamine and adenosine.\" [GOC:aruk, GOC:bc, PMID:10195197, PMID:10196584, PMID:10377338, PMID:10493741, PMID:11356870, PMID:11399439, PMID:15252819, PMID:27788368]","metadata":null},{"id":"b55858d4211f4d3ea32078d45a61e1d3","type":"GO_TERM","name":"neuron-neuron synaptic transmission","canonical_id":"go:GO:0007270","description":"\"The process of synaptic transmission from a neuron to another neuron across a synapse.\" [GOC:add, GOC:dos, GOC:jl, MeSH:D009435]","metadata":null},{"id":"bdd55727d2774602abb0ec11ad8bbc26","type":"GO_TERM","name":"neuronal action potential","canonical_id":"go:GO:0019228","description":"\"An action potential that occurs in a neuron.\" [GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"f4fae5fe27cf4f7597db2ea2fb99d96a","type":"GO_TERM","name":"neuronal action potential back-propagation","canonical_id":"go:GO:0098873","description":"\"Propagation of an action potential in a neuron, from its site of initiation (typically the axon hillock) towards the soma.\" [GOC:dos]","metadata":null},{"id":"7df03446f43444409bb87fecdd27fe40","type":"GO_TERM","name":"neuronal action potential propagation","canonical_id":"go:GO:0019227","description":"\"The propagation of an action potential along an axon, away from the soma.\" [GOC:isa_complete]","metadata":null},{"id":"b57d3c0e8596475586d8a3b2e51f0375","type":"GO_TERM","name":"neuronal cell body","canonical_id":"go:GO:0043025","description":"\"The portion of a neuron that includes the nucleus, but excludes cell projections such as axons and dendrites.\" [GOC:curators]","metadata":null},{"id":"b8b01b93a95d4f539fd62d7ae2588917","type":"GO_TERM","name":"neuronal cell body membrane","canonical_id":"go:GO:0032809","description":"\"The plasma membrane of a neuron cell body - excludes the plasma membrane of cell projections such as axons and dendrites.\" [GOC:jl]","metadata":null},{"id":"a1d6b0916dbe49cdbc2dc7d4d156128a","type":"GO_TERM","name":"neuronal dense core vesicle","canonical_id":"go:GO:0098992","description":"\"A dense core vesicle (granule) that is part of a neuron. These vesicles typically contain neuropeptides. They can be found in all parts of neurons, including the soma, dendrites, axonal swellings (varicosities) and synaptic terminals.\" [GOC:dos, ISBN:978-0-07-181001-2, Wikipedia:Neuropeptide&oldid=713905176]","metadata":null},{"id":"0b56670cf03e49c784cefc1e5b1b28e5","type":"GO_TERM","name":"neuronal dense core vesicle exocytosis","canonical_id":"go:GO:0099011","description":"\"The secretion of molecules (e.g. neuropeptides, insulin-related peptides or neuromodulators such as serotonin and dopamine) contained within a neuronal dense core vesicle by fusion of the granule with the plasma membrane of a neuron in response to increased cytosolic calcium levels.\" [GOC:kmv, PMID:17553987, PMID:24653208]","metadata":null},{"id":"1a30cda20b494bf5ada02d34f5eb41b5","type":"GO_TERM","name":"neuronal dense core vesicle lumen","canonical_id":"go:GO:0099013","description":"\"The volume enclosed by a neuronal dense core vesicle membrane.\" [GOC:dos]","metadata":null},{"id":"b05fc1a8ad924ad9ba5af52e1dd3c69c","type":"GO_TERM","name":"neuronal dense core vesicle membrane","canonical_id":"go:GO:0099012","description":"\"The lipid bilayer surrounding a neuronal dense core vesicle.\" [GOC:dos]","metadata":null},{"id":"14dc161fec194d29b115423b09c053f7","type":"GO_TERM","name":"neuronal dense core vesicle organization","canonical_id":"go:GO:0099014","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a neuronal dense core vesicle.\" [GOC:dos]","metadata":null},{"id":"cceeb57fd7dc45d68b110b25b85d0617","type":"GO_TERM","name":"neuronal ion channel clustering","canonical_id":"go:GO:0045161","description":"\"The process in which voltage-gated ion channels become localized to distinct subcellular domains in the neuron. Specific targeting, clustering, and maintenance of these channels in their respective domains are essential to achieve high conduction velocities of action potential propagation.\" [PMID:11456440]","metadata":null},{"id":"ab3874b933864ea3b2fe6a06799318f5","type":"GO_TERM","name":"neuronal pentraxin receptor activity","canonical_id":"go:GO:0008030","description":"\"Combining with a neuronal pentraxin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling, PMID:18840757]","metadata":null},{"id":"b92180e61f454724871970b934df3391","type":"GO_TERM","name":"neuronal ribonucleoprotein granule","canonical_id":"go:GO:0071598","description":"\"A ribonucleoprotein complex that is found in the cytoplasm of axons and dendrites, and transports translationally silenced mRNAs to dendritic synapses, where they are released and translated in response to specific exogenous stimuli.\" [GOC:BHF, GOC:curators, GOC:mah, PMID:19015237, PMID:20368989]","metadata":null},{"id":"a8aa3f6e93654af6b882209d2b2ff262","type":"GO_TERM","name":"neuronal signal transduction","canonical_id":"go:GO:0023041","description":"\"The process in which an activated neuronal cell receptor conveys information down a signaling pathway, resulting in a change in the function or state of a cell. This process may be intracellular or intercellular.\" [GOC:mtg_signal]","metadata":null},{"id":"16f84618f615462eb5b2a6e8d489eb65","type":"GO_TERM","name":"neuronal stem cell division","canonical_id":"go:GO:0036445","description":"\"The self-renewing division of a neuronal stem cell.\" [CL:0000047, GOC:nhn]","metadata":null},{"id":"ecca5eb230b9453881af021abf812acf","type":"GO_TERM","name":"neuronal stem cell population maintenance","canonical_id":"go:GO:0097150","description":"\"Any process in by an organism or tissue maintains a population of neuronal stem cells.\" [CL:0000047, GOC:dos, GOC:yaf, PMID:11399758]","metadata":null},{"id":"0f8b1315267449b88d2db12a6911f33d","type":"GO_TERM","name":"neuronal-glial interaction involved in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021812","description":"\"The changes in adhesion between neuronal cells and glial cells as a component of the process of cerebral cortex glial-mediated radial cell migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"4578813f429f49ec9fc22528436614d2","type":"GO_TERM","name":"neuronal-glial interaction involved in hindbrain glial-mediated radial cell migration","canonical_id":"go:GO:0021944","description":"\"The changes in adhesion between a neuronal cell and a glial cell as a component of the process of hindbrain glial-mediated radial cell migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"e82cf1a75d7c4d21bbed7f2c71946d04","type":"DISEASE","name":"neuropathic pain","canonical_id":"efo:0005762","description":null,"metadata":null},{"id":"042ac48ae43445d5bc38a0c1ea5f69e7","type":"GO_TERM","name":"neuropeptide F receptor activity","canonical_id":"go:GO:0042263","description":"\"Combining with neuropeptide F and transmitting the signal within the cell to initiate a change in cell activity. Neuropeptide F is an arthropod peptide of more than 28 residues (typically 28-45) with a consensus C-terminal RxRFamide (commonly RPRFa, but also RVRFa.\" [GOC:bf, GOC:ma, PMID:21440021]","metadata":null},{"id":"864c3643ad29475fab11dc6cbab6160d","type":"GO_TERM","name":"neuropeptide F receptor binding","canonical_id":"go:GO:0071859","description":"\"Binding to a neuropeptide F receptor.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"27d8da530d6e436180afa5434d4aa78e","type":"GO_TERM","name":"neuropeptide Y receptor activity","canonical_id":"go:GO:0004983","description":"\"Combining with neuropeptide Y to initiate a change in cell activity.\" [PMID:9315606]","metadata":null},{"id":"d9770c1aad1d45449c86e2b971df6070","type":"GO_TERM","name":"neuropeptide Y receptor binding","canonical_id":"go:GO:0031841","description":"\"Binding to a neuropeptide Y receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"46399779889047269b42d4685e117758","type":"GO_TERM","name":"neuropeptide activity","canonical_id":"go:GO:0160041","description":"\"The receptor ligand activity of any polypeptide expressed in, and secreted from a neuron.\" [PMID:18806786, PMID:21922398]","metadata":null},{"id":"85bf6be45c404c94a01a1b804f640e7a","type":"GO_TERM","name":"neuropeptide binding","canonical_id":"go:GO:0042923","description":"\"Interacting selectively and non-covalently and stoichiometrically with neuropeptides, peptides with direct synaptic effects (peptide neurotransmitters) or indirect modulatory effects on the nervous system (peptide neuromodulators).\" [PMID:10414961, PMID:38337033]","metadata":null},{"id":"ed99fe2812c94c6aac4bccb36af5293b","type":"GO_TERM","name":"neuropeptide catabolic process","canonical_id":"go:GO:0010813","description":"\"The chemical reactions and pathways resulting in the breakdown of neuropeptides. Neuropeptides are signaling peptides that travel across a synaptic junction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"391b10c0c3784b9fa043fa6b26c79a34","type":"GO_TERM","name":"neuropeptide hormone activity","canonical_id":"go:GO:0005184","description":"\"The action characteristic of a neuropeptide hormone, any peptide hormone that acts in the central nervous system. A neuropeptide is any of several types of molecules found in brain tissue, composed of short chains of amino acids; they include endorphins, enkephalins, vasopressin, and others. They are often localized in axon terminals at synapses and are classified as putative neurotransmitters, although some are also hormones.\" [GOC:mah]","metadata":null},{"id":"e2c290852d3640809aa1913324836425","type":"GO_TERM","name":"neuropeptide processing","canonical_id":"go:GO:0061837","description":"\"Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a neuropeptide precursor. Processing leads to the attainment of the full functional capacity of the neuropeptide.\" [PMID:12657671, PMID:17564681]","metadata":null},{"id":"2b6ef7606cb94259830098e8a02211bd","type":"GO_TERM","name":"neuropeptide receptor activity","canonical_id":"go:GO:0008188","description":"\"Combining with a neuropeptide to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"19abc508f35741ee88b14277d6de04b8","type":"GO_TERM","name":"neuropeptide receptor binding","canonical_id":"go:GO:0071855","description":"\"Binding to a neuropeptide receptor.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"75298e97df5747eebe10f175908cfe54","type":"GO_TERM","name":"neuropeptide secretion from presynapse","canonical_id":"go:GO:0099539","description":"\"The secretion of neuropeptides contained within a dense core vesicle by fusion of the granule with the presynaptic membrane, stimulated by a rise in cytosolic calcium ion concentration.\" [PMID:17553987, PMID:24653208]","metadata":null},{"id":"519082415ca448f9a328b20a838df3fa","type":"GO_TERM","name":"neuropeptide signaling pathway","canonical_id":"go:GO:0007218","description":"\"A G protein-coupled receptor signaling pathway initiated by a neuropeptide binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"ff4148463c344fbd8ecc66e9fb601b43","type":"GO_TERM","name":"neuropilin binding","canonical_id":"go:GO:0038191","description":"\"Binding to a member of the neuropilin family.\" [GOC:bf, PMID:23871893]","metadata":null},{"id":"a86386ff8c554ac6a7847684af899903","type":"GO_TERM","name":"neuropilin signaling pathway","canonical_id":"go:GO:0038189","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a neuropilin protein on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, PMID:12852851]","metadata":null},{"id":"545748c1754c4ecda419013ca816ab49","type":"GO_TERM","name":"neuropore closure","canonical_id":"go:GO:0021995","description":"\"The process of joining together the neural folds at either end of the neural tube.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d02088aaab8b47d2bafe6516c9044df1","type":"GO_TERM","name":"neurosecretory vesicle","canonical_id":"go:GO:1990008","description":"\"A large cytoplasmic membrane-bounded vesicle with an electron dense granular core, up to 150-200 nm in diameter, found in neurosecretory cells in the hypothalamus.\" [ISBN:0195065719, NIF_Subcellular:sao2031592629]","metadata":null},{"id":"c6fd8cfaddd84acdabf6c8204297ecfb","type":"GO_TERM","name":"neurotensin receptor activity, non-G protein-coupled","canonical_id":"go:GO:0030379","description":"\"Combining with neurotensin, a neuropeptide active in the central and peripheral nervous system in mammals, and transmitting the signal from one side of the membrane to the other by a mechanism independent of coupling to G proteins.\" [GOC:mah, GOC:signaling, PMID:9756851]","metadata":null},{"id":"159ecd78c8254c47b6c329ebaeda56e1","type":"GO_TERM","name":"neurotensin receptor binding","canonical_id":"go:GO:0031846","description":"\"Binding to a neurotensin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"eb97c2ad30464fe2972ca4f04429406b","type":"GO_TERM","name":"neurotransmitter loading into synaptic vesicle","canonical_id":"go:GO:0098700","description":"\"The active transport of neurotransmitters into a synaptic vesicle. This import is fuelled by an electrochemical gradient across the vesicle membrane, established by the action of proton pumps.\" [GOC:bf, GOC:pad, GOC:PARL, PMID:10099709, PMID:15217342]","metadata":null},{"id":"f693f2be254c4302a25f21dcec21c1ff","type":"GO_TERM","name":"neurotransmitter receptor activity","canonical_id":"go:GO:0030594","description":"\"Combining with a neurotransmitter and transmitting the signal to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"b85987233d2b46749f8dc55def673f21","type":"GO_TERM","name":"neurotransmitter receptor complex","canonical_id":"go:GO:0098878","description":"\"Any protein complex that is capable of functioning as a neurotransmitter receptor.\" [GOC:dos]","metadata":null},{"id":"097759b2cb8648af886867bb3d130bcb","type":"GO_TERM","name":"neurotransmitter receptor cycle","canonical_id":"go:GO:0099627","description":"\"The process during which neurotransmitter receptors, anchored in some region of the synaptic membrane, are recycled via the endosome. This cycle includes release from anchoring, diffusion in the synaptic membrane to an endocytic region, endocytosis, transport to the endosome, recycling in the endosome, transport back the synaptic membrane and subsequent anchoring (trapping).\" [GOC:dos]","metadata":null},{"id":"427433072d56419b9b06b4f772d8d5e0","type":"GO_TERM","name":"neurotransmitter receptor diffusion trapping","canonical_id":"go:GO:0099628","description":"\"The process by which diffusing neurotransmitter receptor becomes trapped in region of the plasma membrane.\" [PMID:18832033]","metadata":null},{"id":"c071bed042cc42dc85d24ec8bf9b48c6","type":"GO_TERM","name":"neurotransmitter receptor internalization","canonical_id":"go:GO:0099590","description":"\"A receptor-mediated endocytosis process that results in the internalization of a neurotransmitter receptor.\" [GOC:dos]","metadata":null},{"id":"474fc06cb19e48899520d5237d69d032","type":"GO_TERM","name":"neurotransmitter receptor localization to postsynaptic specialization membrane","canonical_id":"go:GO:0099645","description":"\"A process in which a neurotransmitter is transported to, or maintained in, a location within the membrane adjacent to a postsynaptic specialization (e.g. postsynaptic density).\" [GOC:dos]","metadata":null},{"id":"94f3e3d649a74a688944e6bbb44a0d36","type":"GO_TERM","name":"neurotransmitter receptor regulator activity","canonical_id":"go:GO:0099602","description":"\"A molecular function that directly (via physical interaction or direct modification) activates, inhibits or otherwise modulates the activity of a neurotransmitter receptor. Modulation of activity includes changes in desensitization rate, ligand affinity, ion selectivity and pore-opening/closing.\" [GOC:dos, PMID:12740117, PMID:18387948]","metadata":null},{"id":"84e0e3f904144c5eb6a417cd66464e36","type":"GO_TERM","name":"neurotransmitter receptor transport","canonical_id":"go:GO:0099637","description":"\"The directed movement of neurotransmitter receptors.\" [GOC:dos]","metadata":null},{"id":"e8b6d5db1f5748e3a38fc5cd8a5563e6","type":"GO_TERM","name":"neurotransmitter receptor transport postsynaptic membrane to endosome","canonical_id":"go:GO:0098968","description":"\"Vesicle-mediated transport of a neurotransmitter receptor complex from the postsynaptic membrane to the postsynaptic early endosome.\" [GOC:dos]","metadata":null},{"id":"765c751b63794041a06220b165c6fd18","type":"GO_TERM","name":"neurotransmitter receptor transport to plasma membrane","canonical_id":"go:GO:0098877","description":"\"The directed movement of neurotransmitter receptor to the plasma membrane in transport vesicles.\" [GOC:dos]","metadata":null},{"id":"6f441762fd2849cda80af351d2243b06","type":"GO_TERM","name":"neurotransmitter receptor transport to postsynaptic membrane","canonical_id":"go:GO:0098969","description":"\"The directed movement of neurotransmitter receptor to the postsynaptic membrane in transport vesicles.\" [GOC:dos]","metadata":null},{"id":"6ae6a063272148fd97eff8a721d5bb1f","type":"GO_TERM","name":"neurotransmitter receptor transport, endosome to plasma membrane","canonical_id":"go:GO:0099639","description":"\"The directed movement of neurotransmitter receptor from the endosome to the plasma membrane in transport vesicles.\" [GOC:dos]","metadata":null},{"id":"51fb447359174e38b5da1125cc040035","type":"GO_TERM","name":"neurotransmitter receptor transport, endosome to postsynaptic membrane","canonical_id":"go:GO:0098887","description":"\"The directed movement of neurotransmitter receptor from the postsynaptic endosome to the postsynaptic membrane in transport vesicles.\" [GOC:dos]","metadata":null},{"id":"f0e3a4fce0ec4c14ab46b0ce6a7716b8","type":"GO_TERM","name":"neurotransmitter receptor transport, plasma membrane to endosome","canonical_id":"go:GO:0099646","description":"\"Vesicle-mediated transport of a neurotransmitter receptor vesicle from the plasma membrane to the endosome.\" [GOC:dos]","metadata":null},{"id":"45b22502e79c4977961b6e4e82b74e3e","type":"GO_TERM","name":"neurotransmitter receptor transport, postsynaptic endosome to lysosome","canonical_id":"go:GO:0098943","description":"\"The directed movement of neurotransmitter receptor from the postsynaptic endosome in tranpsort vesicles to the lysosome for degradation.\" [GOC:dos]","metadata":null},{"id":"82a5c5b8cc2044f3bfe07982d6c496ba","type":"GO_TERM","name":"neurotransmitter reuptake","canonical_id":"go:GO:0098810","description":"\"The directed movement of neurotransmitter molecules from the extrasynaptic space into the presynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"4f0c98837c7f4ae7b42d7d1b32cc08c6","type":"GO_TERM","name":"neurotransmitter secretion","canonical_id":"go:GO:0007269","description":"\"The regulated release of neurotransmitter from the presynapse into the synaptic cleft via calcium-regulated exocytosis during synaptic transmission.\" [GOC:dph]","metadata":null},{"id":"fa6b7142c5d94cbe89010986ba5ca08d","type":"GO_TERM","name":"neurotransmitter secretion involved in regulation of skeletal muscle contraction","canonical_id":"go:GO:0014860","description":"\"The regulated release of neurotransmitter into the synaptic cleft involved in skeletal muscle contraction. A neurotransmitter is any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, noradrenaline, adrenaline, dopamine, glycine, gamma aminobutyrate, glutamic acid, substance P, enkephalins, endorphins and serotonin.\" [GOC:dph, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"59b307df0ce7447287e29cf39a744f74","type":"GO_TERM","name":"neurotransmitter transmembrane transporter activity","canonical_id":"go:GO:0005326","description":"\"Enables the directed movement of a neurotransmitter into, out of or within a cell, or between cells. Neurotransmitters are any chemical substance that is capable of transmitting (or inhibiting the transmission of) a nerve impulse from a neuron to another cell.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"f2a0e69298cc4a85816f73b7ff0816ed","type":"GO_TERM","name":"neurotransmitter transport","canonical_id":"go:GO:0006836","description":"\"The directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Neurotransmitters are any chemical substance that is capable of transmitting (or inhibiting the transmission of) a nerve impulse from a neuron to another cell.\" [GOC:ai]","metadata":null},{"id":"6e10610ca23e4d6d87a5ea47367a344b","type":"GO_TERM","name":"neurotransmitter uptake","canonical_id":"go:GO:0001504","description":"\"The directed movement of neurotransmitters into neurons or glial cells. This process leads to inactivation and recycling of neurotransmitters.\" [ISBN:0123668387]","metadata":null},{"id":"a6b749c5eac744cd932793d41b35a78e","type":"GO_TERM","name":"neurotransmitter-gated ion channel clustering","canonical_id":"go:GO:0072578","description":"\"The receptor clustering process in which neurotransmitter-gated ion channels are localized to distinct domains in the cell membrane.\" [GOC:dsf, PMID:20843816]","metadata":null},{"id":"6ab50f7880434f649ca8163f20e837b4","type":"GO_TERM","name":"neurotransmitter:sodium symporter activity","canonical_id":"go:GO:0005328","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: neurotransmitter(out) + Na+(out) = neurotransmitter(in) + Na+(in).\" [TC:2.A.22.-.-]","metadata":null},{"id":"01d108032c6c4653a0a8c91006855866","type":"GO_TERM","name":"neurotrophin TRK receptor binding","canonical_id":"go:GO:0005167","description":"\"Binding to a neurotrophin TRK receptor.\" [GOC:ai]","metadata":null},{"id":"0ffbc5fc0fc44eb0b329bf8f7462d745","type":"GO_TERM","name":"neurotrophin TRK receptor signaling pathway","canonical_id":"go:GO:0048011","description":"\"The series of molecular signals initiated by neurotrophin binding to its receptor on the surface of a target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:ceb, GOC:jc, GOC:signaling, PMID:12065629, Wikipedia:Trk_receptor]","metadata":null},{"id":"313ca94422414fff9bb7a3c35e760240","type":"GO_TERM","name":"neurotrophin TRKA receptor binding","canonical_id":"go:GO:0005168","description":"\"Binding to a neurotrophin TRKA receptor.\" [GOC:ai]","metadata":null},{"id":"807e4b9d094c43c6854edd6e650dd4bc","type":"GO_TERM","name":"neurotrophin TRKB receptor binding","canonical_id":"go:GO:0005169","description":"\"Binding to a neurotrophin TRKB receptor.\" [GOC:ai]","metadata":null},{"id":"3b5fdadc30dd42ca8800712b728b42e3","type":"GO_TERM","name":"neurotrophin TRKC receptor binding","canonical_id":"go:GO:0005170","description":"\"Binding to a neurotrophin TRKC receptor.\" [GOC:ai]","metadata":null},{"id":"b19c0c0beace4bd9907ce837bd80f8c7","type":"GO_TERM","name":"neurotrophin binding","canonical_id":"go:GO:0043121","description":"\"Binding to a neurotrophin, any of a family of growth factors that prevent apoptosis in neurons and promote nerve growth.\" [GOC:jl]","metadata":null},{"id":"b80a4e0e4242428da3d37ddca172ae7d","type":"GO_TERM","name":"neurotrophin p75 receptor binding","canonical_id":"go:GO:0005166","description":"\"Binding to a neurotrophin p75 receptor.\" [GOC:ai]","metadata":null},{"id":"b9fd105e61b741799f020b89fa793065","type":"GO_TERM","name":"neurotrophin production","canonical_id":"go:GO:0032898","description":"\"The appearance of a neurotrophin due to biosynthesis or secretion by cells in a neuron's target field, resulting in an increase in its intracellular or extracellular levels. A neurotrophin is any of a family of growth factors that prevent apoptosis in neurons and promote nerve growth.\" [GOC:ecd, GOC:mah, GOC:mtg_MIT_16mar07]","metadata":null},{"id":"f303120cca094910ba3fcda8ce98b4e3","type":"GO_TERM","name":"neurotrophin receptor activity","canonical_id":"go:GO:0005030","description":"\"Combining with a neurotrophin, any of a family of growth factors that prevent apoptosis in neurons and promote nerve growth, and transmitting the signal to initiate a change in cell activity.\" [GOC:jl, GOC:signaling]","metadata":null},{"id":"632306764cff40bc988b08114c712684","type":"GO_TERM","name":"neurotrophin receptor binding","canonical_id":"go:GO:0005165","description":"\"Binding to a neurotrophin receptor.\" [GOC:ai]","metadata":null},{"id":"68f3fd3cee1b4eed923e22f3b9d5f027","type":"GO_TERM","name":"neurotrophin signaling pathway","canonical_id":"go:GO:0038179","description":"\"The series of molecular signals initiated by neurotrophin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Neurotrophins are a family of secreted growth factors that induce the survival, development, and function of neurons.\" [GOC:bf, GOC:jc, GOC:signaling, PMID:17466268, Wikipedia:Neurotrophin]","metadata":null},{"id":"a253f80a811b4e2aa840f4d7921d98e3","type":"GO_TERM","name":"neutral L-amino acid secondary active transmembrane transporter activity","canonical_id":"go:GO:0005294","description":"\"Enables the transfer of a neutral L-amino acid from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport]","metadata":null},{"id":"181f21e7b7744a6bb0a1d0c4637658da","type":"GO_TERM","name":"neutral L-amino acid transmembrane transporter activity","canonical_id":"go:GO:0015175","description":"\"Enables the transfer of neutral L-amino acids from one side of a membrane to the other. Neutral amino acids have side chains with no charge at pH 7.3.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"8798658fb89b46e0aeb697e2f2751251","type":"GO_TERM","name":"neutral L-amino acid:sodium symporter activity","canonical_id":"go:GO:0005295","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: neutral L-amino acid(out) + Na+(out) = neutral L-amino acid(in) + Na+(in).\" [TC:2.A.23.3.1]","metadata":null},{"id":"548db1dca8ba47e7be7034216ccc6ef1","type":"GO_TERM","name":"neutral L-amino acid:sodium:chloride symporter activity","canonical_id":"go:GO:0140931","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: neutral L-amino acid(out) + Na+(out) + Cl-(out) = neutral L-amino acid(in) + Na+(in)+ Cl-(in).\" [PMID:19478081]","metadata":null},{"id":"beeb4b60ac1c4d9789b7ce514cd308be","type":"GO_TERM","name":"neutral amino acid transmembrane export from vacuole","canonical_id":"go:GO:0034489","description":"\"The directed movement of neutral amino acids out of the vacuole, across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"e7d1edd91f6142adb3becf4e168b44ee","type":"GO_TERM","name":"neutral amino acid transmembrane import into vacuole","canonical_id":"go:GO:0034491","description":"\"The directed movement of neutral amino acids into the vacuole across the vacuolar membrane.\" [GOC:mah]","metadata":null},{"id":"7f618e275c9f4dbcbe209ab57e89c2c1","type":"GO_TERM","name":"neutral amino acid transport","canonical_id":"go:GO:0015804","description":"\"The directed movement of neutral amino acids, amino acids with no net charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"07b8548e6bee4e3ebe01271f4ff545df","type":"GO_TERM","name":"neutral amino acid, sodium:proton antiporter activity","canonical_id":"go:GO:0140893","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(in) + amino acid(out) + Na+(out) = H+(out) + amino acid(in) + Na+(in).\" [PMID:11698233, PMID:34704597]","metadata":null},{"id":"41303b0d35df4d62999d5b54d500fd9c","type":"GO_TERM","name":"neutral lipid biosynthetic process","canonical_id":"go:GO:0046460","description":"\"The chemical reactions and pathways resulting in the formation of neutral lipids, lipids only soluble in solvents of very low polarity.\" [GOC:ai]","metadata":null},{"id":"f46fde56710a49f4a8701ce8143668b6","type":"GO_TERM","name":"neutral lipid catabolic process","canonical_id":"go:GO:0046461","description":"\"The chemical reactions and pathways resulting in the breakdown of neutral lipids, lipids only soluble in solvents of very low polarity.\" [GOC:ai]","metadata":null},{"id":"fc0e3cdd007e4677ac14a4855a9e2214","type":"GO_TERM","name":"neutral lipid metabolic process","canonical_id":"go:GO:0006638","description":"\"The chemical reactions and pathways involving neutral lipids, lipids only soluble in solvents of very low polarity.\" [ISBN:0198547684]","metadata":null},{"id":"7a5b416bad1d4d31926170a3e16f13fe","type":"GO_TERM","name":"neutral sphingomyelin phosphodiesterase activity","canonical_id":"go:GO:0061751","description":"\"Catalysis of the reaction: H2O + sphingomyelin = ceramide + choline phosphate + H+ in a neutral environment.\" [GOC:dph, PMID:26493087]","metadata":null},{"id":"63f09585a01e4482b926084539bf3301","type":"GO_TERM","name":"neutral, basic amino acid:sodium:chloride symporter activity","canonical_id":"go:GO:0015374","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: neutral/basic amino acid(out) + Na+(out) + Cl-(out) = neutral/basic amino acid(in) + Na+(in) + Cl-(in).\" [TC:2.A.22.2.3]","metadata":null},{"id":"0751db3292474347be2d417d414fca47","type":"DISEASE","name":"neutropenia","canonical_id":"mondo:0001475","description":null,"metadata":null},{"id":"3e10391a97dd4494aa93098e8d81940c","type":"DISEASE","name":"neutropenia, severe congenital, 1, autosomal dominant","canonical_id":"mondo:0042490","description":null,"metadata":null},{"id":"acacbc368ac74513a3577eeafc8fcbfe","type":"GO_TERM","name":"neutrophil activation","canonical_id":"go:GO:0042119","description":"\"The change in morphology and behavior of a neutrophil resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.\" [GOC:mgi_curators, ISBN:0781735149]","metadata":null},{"id":"dc16b848208240fa862695008c18bdd2","type":"GO_TERM","name":"neutrophil activation involved in immune response","canonical_id":"go:GO:0002283","description":"\"The change in morphology and behavior of a neutrophil resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"8f318ae52c724338982468800355f6c3","type":"GO_TERM","name":"neutrophil aggregation","canonical_id":"go:GO:0070488","description":"\"The adhesion of one neutrophil to one or more other neutrophils via adhesion molecules.\" [GOC:sl, PMID:12972508]","metadata":null},{"id":"87c0ef6e22c741129b4e6d4297fc0558","type":"GO_TERM","name":"neutrophil apoptotic process","canonical_id":"go:GO:0001781","description":"\"Any apoptotic process in a neutrophil, any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.\" [CL:0000775, GOC:add, GOC:mtg_apoptosis, PMID:12752675, PMID:12960266]","metadata":null},{"id":"fd6025f3aaa74229bcfbe8ef8366444d","type":"GO_TERM","name":"neutrophil chemotaxis","canonical_id":"go:GO:0030593","description":"\"The directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"404a1ed9a4e246b5b4c81363d354af78","type":"GO_TERM","name":"neutrophil clearance","canonical_id":"go:GO:0097350","description":"\"The selective elimination of senescent neutrophils from the body by autoregulatory mechanisms.\" [GOC:BHF, PMID:21957127]","metadata":null},{"id":"c481471ced034371a3724931941b994e","type":"GO_TERM","name":"neutrophil degranulation","canonical_id":"go:GO:0043312","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as proteases, lipases, and inflammatory mediators by a neutrophil.\" [ISBN:0781735149]","metadata":null},{"id":"2eadbda4814c47bf9958687c70c7ebe9","type":"GO_TERM","name":"neutrophil differentiation","canonical_id":"go:GO:0030223","description":"\"The process in which a myeloid precursor cell acquires the specialized features of a neutrophil.\" [GOC:mah]","metadata":null},{"id":"caffe26dc1bf4977834de35fb6a71511","type":"GO_TERM","name":"neutrophil dispersal","canonical_id":"go:GO:0140635","description":"\"The movement of a neutrophil away from the site of wound or infection following its initial migration to the site.\" [PMID:31727891]","metadata":null},{"id":"6576f59e90f84cdea7d508129c90073d","type":"GO_TERM","name":"neutrophil extracellular trap","canonical_id":"go:GO:0140644","description":"\"Extracellular microbicidal structure composed of nuclear chromatin, histones and granular antimicrobial proteins. Histones and several neutrophil granule proteins associated with the DNA framework damage entrapped microorganisms.\" [PMID:31172493]","metadata":null},{"id":"aef606095d3a40c792b2fa63a35cc2f2","type":"GO_TERM","name":"neutrophil extracellular trap formation","canonical_id":"go:GO:0140645","description":"\"The aggregation, arrangement and bonding together of a set of components to form a neutrophil extracellular trap, a network of extracellular fibers primarily composed of DNA from neutrophils, which bind and neutralizes pathogens.\" [PMID:28267716]","metadata":null},{"id":"a5eaf56a0051427b8a27089529da2a11","type":"GO_TERM","name":"neutrophil extravasation","canonical_id":"go:GO:0072672","description":"\"The migration of a neutrophil from the blood vessels into the surrounding tissue.\" [CL:0000775, GOC:BHF]","metadata":null},{"id":"a1e9c06b26924b9a8b815eee92d96753","type":"GO_TERM","name":"neutrophil homeostasis","canonical_id":"go:GO:0001780","description":"\"The process of regulating the proliferation and elimination of neutrophils such that the total number of neutrophils within a whole or part of an organism is stable over time in the absence of an outside stimulus.\" [GOC:add, GOC:pr, PMID:12752675, PMID:12960266]","metadata":null},{"id":"e3063eecfdfe4e3c9c55e763a2e73042","type":"GO_TERM","name":"neutrophil mediated cytotoxicity","canonical_id":"go:GO:0070942","description":"\"The directed killing of a target cell by a neutrophil.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"c570728d2d78487eaaa486ab5a9e88e6","type":"GO_TERM","name":"neutrophil mediated immunity","canonical_id":"go:GO:0002446","description":"\"Any process involved in the carrying out of an immune response by a neutrophil.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"8362c4e8f815493c83d63cd92f047a9b","type":"GO_TERM","name":"neutrophil migration","canonical_id":"go:GO:1990266","description":"\"The movement of a neutrophil within or between different tissues and organs of the body.\" [PMID:1826836]","metadata":null},{"id":"2a682cec3baa4b60bdecc7058b530b16","type":"GO_TERM","name":"neutrophil-mediated killing of bacterium","canonical_id":"go:GO:0070944","description":"\"The directed killing of a bacterium by a neutrophil.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"36388f0b57b84ac1a29b4bea18427164","type":"GO_TERM","name":"neutrophil-mediated killing of fungus","canonical_id":"go:GO:0070947","description":"\"The directed killing of a fungal cell by a neutrophil.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"ebc44903e0be45fb9ae59059b3ff40de","type":"GO_TERM","name":"neutrophil-mediated killing of gram-negative bacterium","canonical_id":"go:GO:0070945","description":"\"The directed killing of a gram-negative bacterium by a neutrophil.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"a6b7cac87c6d4470b7c591e28bdea833","type":"GO_TERM","name":"neutrophil-mediated killing of gram-positive bacterium","canonical_id":"go:GO:0070946","description":"\"The directed killing of a gram-positive bacterium by a neutrophil.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"9ea74380e41545bdabcfae72bf20016c","type":"GO_TERM","name":"neutrophil-mediated killing of symbiont cell","canonical_id":"go:GO:0070943","description":"\"The directed killing of a symbiont target cell by a neutrophil. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"e9431f3dfbb64d259bf386f127ad6a8f","type":"DRUG","name":"nevirapine","canonical_id":"mesh:D019829","description":null,"metadata":null},{"id":"90b2dbba70e84abeb5300a016be8ad66","type":"DISEASE","name":"nevus, epidermal","canonical_id":"mondo:0008093","description":null,"metadata":null},{"id":"75036e0691d44794b247356958eef514","type":"GO_TERM","name":"new cell pole","canonical_id":"go:GO:1990902","description":"\"The cell pole proximal to the most recent cell division.\" [GOC:jh2, PMID:10231492, PMID:8226658]","metadata":null},{"id":"3c477c15f122459f928d4ed276a59000","type":"GO_TERM","name":"new growing cell tip","canonical_id":"go:GO:0035841","description":"\"A cell tip that was newly formed at the last cell division, and that has started to grow after the cell has activated bipolar cell growth (i.e. in which new end take-off, NETO, has taken place). New end take-off is when monopolar cells initiate bipolar growth.\" [GOC:expert_jd, GOC:mah, PMID:19431238]","metadata":null},{"id":"f8d2042ff34b4e7dba2a9f4ca238b552","type":"GO_TERM","name":"new mitotic spindle pole body","canonical_id":"go:GO:0071958","description":"\"The spindle pole body that is formed by spindle pole body duplication, and to which proteins involved in mitotic exit signaling (for example, the septation initiation network in fission yeast) localize.\" [GOC:mah, GOC:vw, PMID:15132994]","metadata":null},{"id":"379f72bab38d4ea6b3b37261631b1674","type":"GO_TERM","name":"new spindle pole body SIN signaling complex","canonical_id":"go:GO:0160067","description":"\"A SIN signaling complex associated with the new mitotic spindle pole body during anaphase and characterized by the presence activated (GTP bound) GTPase (Spg1 in fission yeast) to activate SIN signaling.\" [PMID:21131906]","metadata":null},{"id":"64c95824b15f4f4bbf21dec4068288aa","type":"GO_TERM","name":"nexine","canonical_id":"go:GO:0043672","description":"\"The inner, non-sculptured part of the exine which lies below the sexine.\" [PMID:5722147]","metadata":null},{"id":"9435a99c1317404b998470ba65cb5c98","type":"GO_TERM","name":"nickel cation binding","canonical_id":"go:GO:0016151","description":"\"Binding to a nickel (Ni) cation.\" [GOC:ai]","metadata":null},{"id":"c8acecbb89434e60a62d7c616aa199e7","type":"GO_TERM","name":"nickel cation import across plasma membrane","canonical_id":"go:GO:0098716","description":"\"The directed movement of nickel cations from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"3a6bff4654b649eebb2ac2e2868d55a8","type":"GO_TERM","name":"nickel cation transmembrane transport","canonical_id":"go:GO:0035444","description":"\"The directed movement of nickel (Ni) cations across a membrane by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"586128b7c60d42aca78fcd8807b4d328","type":"GO_TERM","name":"nickel cation transmembrane transporter activity","canonical_id":"go:GO:0015099","description":"\"Enables the transfer of nickel (Ni) cations from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"35b502cbaf5e4f838f54f0b02e5bad65","type":"GO_TERM","name":"nickel cation transport","canonical_id":"go:GO:0015675","description":"\"The directed movement of nickel (Ni) cations into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"ea5643cfee5c4d59aaaafd2a2618ca4c","type":"GO_TERM","name":"nickel chaperone activity","canonical_id":"go:GO:0170061","description":"\"Directly binding to and delivering nickel ions to a target protein.\" [PMID:32133383, PMID:34530332]","metadata":null},{"id":"cb58967970d441b29a16682b0c46e1b8","type":"GO_TERM","name":"nickel incorporation into metallo-sulfur cluster","canonical_id":"go:GO:0018414","description":"\"The incorporation of nickel into a metallo-sulfur cluster.\" [GOC:ai]","metadata":null},{"id":"9bfd7b590d73430f99605e0d6e48e4ec","type":"GO_TERM","name":"nickel-pincer nucleotide cofactor biosynthetic process","canonical_id":"go:GO:7770034","description":"\"The chemical reactions and pathways resulting in the formation of nickel-pincer nucleotide (NPN) cofactor, also known as nickel pyridinium-3,5-bisthiocarboxylic acid mononucleotide.\" [PMID:24710389, PMID:27114550, PMID:33093595, PMID:39667499, PMID:39827451]","metadata":null},{"id":"f80f3ccfece94fbbaa590af53075ed0c","type":"DRUG","name":"nicorandil","canonical_id":"mesh:D020108","description":null,"metadata":null},{"id":"680d96e96ced4ce19c6be402aa120441","type":"GO_TERM","name":"nicotianamine biosynthetic process","canonical_id":"go:GO:0030418","description":"\"The chemical reactions and pathways resulting in the formation of nicotianamine.\" [GOC:curators, PMID:10069850]","metadata":null},{"id":"b15924d643684a67a9bbaa1ebade6300","type":"GO_TERM","name":"nicotianamine synthase activity","canonical_id":"go:GO:0030410","description":"\"Catalysis of the reaction: 3 S-adenosyl-L-methionine(1+) = 3 S-methyl-5'-thioadenosine + 3 H+ + nicotianamine.\" [EC:2.5.1.43, RHEA:16481]","metadata":null},{"id":"521e13993edc4b37934762b5babc1578","type":"GO_TERM","name":"nicotianamine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0033855","description":"\"Catalysis of the reaction: nicotianamine + 2-oxoglutarate = 3''-deamino-3''-oxonicotianamine + L-glutamate.\" [RHEA:22104]","metadata":null},{"id":"4942682a2a32402fb967f5471c26f188","type":"GO_TERM","name":"nicotinamidase activity","canonical_id":"go:GO:0008936","description":"\"Catalysis of the reaction: nicotinamide + H2O = nicotinate + NH4+.\" [RHEA:14545]","metadata":null},{"id":"260974ad31d349f9bd586794f0530365","type":"DRUG","name":"nicotinamide","canonical_id":"mesh:D009536","description":null,"metadata":null},{"id":"d1bbcdbdc63b4713840a07fef463c9b0","type":"GO_TERM","name":"nicotinamide N-methyltransferase activity","canonical_id":"go:GO:0008112","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + nicotinamide = 1-methylnicotinamide + S-adenosyl-L-homocysteine.\" [EC:2.1.1.1, RHEA:23884]","metadata":null},{"id":"de0ca7d4cee2465a9af1e3400b91f9c1","type":"GO_TERM","name":"nicotinamide metabolic process","canonical_id":"go:GO:0006769","description":"\"The chemical reactions and pathways involving nicotinamide, pyridine-3-carboxamide, the amide of nicotinic acid. It is a member of the B complex of vitamins and occurs widely in living organisms.\" [ISBN:0198506732]","metadata":null},{"id":"2fe5ce35b716447f88715c3e3ed214db","type":"GO_TERM","name":"nicotinamide mononucleotide transmembrane transport","canonical_id":"go:GO:0035353","description":"\"The process in which nicotinamide mononucleotide is transported across a membrane. Nicotinamide mononucleotide is a ribonucleotide in which the nitrogenous base, nicotinamide, is in beta-n-glycosidic linkage with the c-1 position of d-ribose. It is a constituent of NAD and NADP.\" [GOC:bf, ISBN:0721662544]","metadata":null},{"id":"8db092cb0de2432380c1efe491f1a58c","type":"GO_TERM","name":"nicotinamide mononucleotide transmembrane transporter activity","canonical_id":"go:GO:0015663","description":"\"Enables the directed movement of nicotinamide mononucleotide into, out of or within a cell, or between cells. Nicotinamide mononucleotide is a ribonucleotide in which the nitrogenous base, nicotinamide, is in beta-n-glycosidic linkage with the c-1 position of d-ribose. It is a constituent of NAD and NADP.\" [ISBN:0721662544]","metadata":null},{"id":"6c2066bf3c274d82ab4f638ad36cd40c","type":"GO_TERM","name":"nicotinamide mononucleotide transport","canonical_id":"go:GO:0015890","description":"\"The directed movement of nicotinamide mononucleotide into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Nicotinamide mononucleotide is a ribonucleotide in which the nitrogenous base, nicotinamide, is in beta-n-glycosidic linkage with the c-1 position of D-ribose. It is a constituent of NAD and NADP.\" [ISBN:0721662544]","metadata":null},{"id":"3f8473611f1d4ef7acfc922c2d4b7daf","type":"GO_TERM","name":"nicotinamide nucleotide biosynthetic process","canonical_id":"go:GO:0019359","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide nucleotides, any nucleotide that contains combined nicotinamide.\" [GOC:curators]","metadata":null},{"id":"be3e02b29b354bcdadaa1bddfc62e113","type":"GO_TERM","name":"nicotinamide nucleotide metabolic process","canonical_id":"go:GO:0046496","description":"\"The chemical reactions and pathways involving nicotinamide nucleotides, any nucleotide that contains combined nicotinamide.\" [ISBN:0198506732]","metadata":null},{"id":"83719d678c914542a3f58353d51515d0","type":"GO_TERM","name":"nicotinamide phosphoribosyltransferase activity","canonical_id":"go:GO:0047280","description":"\"Catalysis of the reaction: diphosphate + nicotinamide mononucleotide = 5-phospho-alpha-D-ribose 1-diphosphate + H+ + nicotinamide.\" [RHEA:16149]","metadata":null},{"id":"8130a459713d41b9ad3b4b9cbefce7a4","type":"GO_TERM","name":"nicotinamide riboside biosynthetic process","canonical_id":"go:GO:0071590","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide riboside, the product of the formation of a glycosidic bond between ribose and nicotinamide.\" [GOC:mah, PMID:19846558]","metadata":null},{"id":"fca3f04337c141069f64f3a153a8640e","type":"GO_TERM","name":"nicotinamide riboside catabolic process","canonical_id":"go:GO:0006738","description":"\"The chemical reactions and pathways resulting in the breakdown of nicotinamide riboside, the product of the formation of a glycosidic bond between ribose and nicotinamide.\" [ISBN:0198506732]","metadata":null},{"id":"0def9da2f358473687ae1c7f95abad2b","type":"GO_TERM","name":"nicotinamide riboside hydrolase activity","canonical_id":"go:GO:0070635","description":"\"Catalysis of the reaction: nicotinamide riboside + H2O = nicotinamide + D-ribose.\" [MetaCyc:RXN-8441, PMID:19001417]","metadata":null},{"id":"929cfd184cac4255b022c4e72827d509","type":"GO_TERM","name":"nicotinamide riboside metabolic process","canonical_id":"go:GO:0046495","description":"\"The chemical reactions and pathways involving nicotinamide riboside, the product of the formation of a glycosidic bond between ribose and nicotinamide.\" [ISBN:0198506732]","metadata":null},{"id":"d9b7cfe12f0d43b9b9f5d25da2600961","type":"GO_TERM","name":"nicotinamide riboside transmembrane transporter activity","canonical_id":"go:GO:0034257","description":"\"Enables the transfer of nicotinamide riboside, which is a pyridine-3-carboxamide covalently bonded to a ribose sugar, from one side of a membrane to the other.\" [GOC:se]","metadata":null},{"id":"13cf01b43c4a423788d87ccaa193b820","type":"GO_TERM","name":"nicotinamide riboside transport","canonical_id":"go:GO:0034258","description":"\"The directed movement of a nicotinamide riboside, which is a pyridine-3-carboxamide covalently bonded to a ribose sugar, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:se]","metadata":null},{"id":"91464513d42e49eb8d5d0e5874e4a136","type":"GO_TERM","name":"nicotinamide-nucleotide adenylyltransferase activity","canonical_id":"go:GO:0000309","description":"\"Catalysis of the reaction: beta-nicotinamide D-ribonucleotide + ATP + H+ = diphosphate + NAD+.\" [RHEA:21360]","metadata":null},{"id":"c67e1d2e25b34aad994b50de7eb63b83","type":"GO_TERM","name":"nicotinamide-nucleotide amidase activity","canonical_id":"go:GO:0019159","description":"\"Catalysis of the reaction: beta-nicotinamide D-ribonucleotide + H2O = nicotinate beta-D-ribonucleotide + NH4+.\" [RHEA:12400]","metadata":null},{"id":"b46e954d924246d99bb3ce639f35d275","type":"GO_TERM","name":"nicotinate N-methyltransferase activity","canonical_id":"go:GO:0008938","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + nicotinate = N-methylnicotinate + S-adenosyl-L-homocysteine.\" [EC:2.1.1.7, RHEA:20241]","metadata":null},{"id":"88d52e502d174687ad36287ad255c952","type":"GO_TERM","name":"nicotinate biosynthetic process","canonical_id":"go:GO:1901849","description":"\"The chemical reactions and pathways resulting in the formation of nicotinate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00830]","metadata":null},{"id":"2ab6c27e655443c3b44d2af81d4c3c0b","type":"GO_TERM","name":"nicotinate catabolic process","canonical_id":"go:GO:1901848","description":"\"The chemical reactions and pathways resulting in the breakdown of nicotinate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00830]","metadata":null},{"id":"fc3668d027514254b81c31473c3eca6e","type":"GO_TERM","name":"nicotinate dehydrogenase activity","canonical_id":"go:GO:0050138","description":"\"Catalysis of the reaction: H2O + NADP+ + nicotinate = 6-hydroxynicotinate + H+ + NADPH.\" [EC:1.17.1.5, RHEA:12236]","metadata":null},{"id":"53e8d66f98f14c5a8aafeb077d88f28f","type":"GO_TERM","name":"nicotinate metabolic process","canonical_id":"go:GO:1901847","description":"\"The chemical reactions and pathways involving nicotinate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00830]","metadata":null},{"id":"219d48f2352a48b5b1c1e0960a0cc03a","type":"GO_TERM","name":"nicotinate nucleotide biosynthetic process","canonical_id":"go:GO:0019357","description":"\"The chemical reactions and pathways resulting in the formation of nicotinamide nucleotides, any nucleotide that contains combined nicotinate (pyridine 3-carboxylic acid).\" [GOC:curators]","metadata":null},{"id":"5d1adff8169546149e5aae7dab42adac","type":"GO_TERM","name":"nicotinate nucleotide salvage","canonical_id":"go:GO:0019358","description":"\"The generation of nicotinate nucleotide without de novo synthesis.\" [GOC:curators]","metadata":null},{"id":"e2c3b83976d444358e725edd7bca9bbf","type":"GO_TERM","name":"nicotinate phosphoribosyltransferase activity","canonical_id":"go:GO:0004516","description":"\"Catalysis of the reaction: nicotinate + 5-phospho-alpha-D-ribose 1-diphosphate + ATP + H2O = nicotinate beta-D-ribonucleotide + ADP + phosphate + diphosphate.\" [PMID:7503993, RHEA:36163]","metadata":null},{"id":"96da9ad66f0b4b1a966a41053f1c4725","type":"GO_TERM","name":"nicotinate riboside kinase activity","canonical_id":"go:GO:0061769","description":"\"Catalysis of the reaction: N-ribosylnicotinate + ATP = ADP + 2 H+ + nicotinate mononucleotide.\" [PMID:17914902, RHEA:25568]","metadata":null},{"id":"7d2ead5020324bc98d8db2371dfbedb3","type":"GO_TERM","name":"nicotinate transmembrane transporter activity","canonical_id":"go:GO:0090416","description":"\"Enables the transfer of nicotinate from one side of a membrane to the other.\" [GOC:tb]","metadata":null},{"id":"6d9505508e924fd584f8709ac5fbe75b","type":"GO_TERM","name":"nicotinate transport","canonical_id":"go:GO:2001142","description":"\"The directed movement of a nicotinateacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:obol]","metadata":null},{"id":"61e2f373dcde4722953a87e0eea45722","type":"GO_TERM","name":"nicotinate-N-glucosyltransferase activity","canonical_id":"go:GO:0050139","description":"\"Catalysis of the reaction: nicotinate + UDP-D-glucose = N-(beta-D-glucosyl)nicotinate + UDP.\" [EC:2.4.1.196, RHEA:19437]","metadata":null},{"id":"caf44e4c583f4b988fcea57a57e7c112","type":"GO_TERM","name":"nicotinate-O-glucosyltransferase activity","canonical_id":"go:GO:0090704","description":"\"Catalysis of the reaction: nicotinate + UDP-D-glucose = O-D-glucosylnicotinate + UDP.\" [GOC:tb, PMID:26116607]","metadata":null},{"id":"3463ab040e0f4652b1759ad90f107ce6","type":"GO_TERM","name":"nicotinate-nucleotide adenylyltransferase activity","canonical_id":"go:GO:0004515","description":"\"Catalysis of the reaction: nicotinate beta-D-ribonucleotide + ATP + H+ = deamido-NAD+ + diphosphate.\" [RHEA:22860]","metadata":null},{"id":"617cd6c1579c46f3bc19f4c8cebcd654","type":"GO_TERM","name":"nicotinate-nucleotide diphosphorylase (carboxylating) activity","canonical_id":"go:GO:0004514","description":"\"Catalysis of the reaction: CO2 + diphosphate + nicotinate D-ribonucleotide = 5-phospho-alpha-D-ribose 1-diphosphate + 2 H+ + quinolinate.\" [EC:2.4.2.19, RHEA:12733]","metadata":null},{"id":"0b8965de7fc64fefb93d11727e20ecab","type":"GO_TERM","name":"nicotinate-nucleotide-dimethylbenzimidazole phosphoribosyltransferase activity","canonical_id":"go:GO:0008939","description":"\"Catalysis of the reaction: 5,6-dimethylbenzimidazole + nicotinate D-ribonucleotide = alpha-ribazole 5'-phosphate + H+ + nicotinate.\" [EC:2.4.2.21, RHEA:11196]","metadata":null},{"id":"8c0417de838847f28a542177c4d6989f","type":"DRUG","name":"nicotine","canonical_id":"mesh:D009538","description":null,"metadata":null},{"id":"d704aaf025084541a1e00b1cc29a2812","type":"GO_TERM","name":"nicotine biosynthetic process","canonical_id":"go:GO:0042179","description":"\"The chemical reactions and pathways resulting in the formation of nicotine, (S)(-)-3-(1-methyl-2-pyrrolidinyl)pyridine.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"a9add4f664e147309d5400509e871647","type":"GO_TERM","name":"nicotine catabolic process","canonical_id":"go:GO:0019608","description":"\"The chemical reactions and pathways resulting in the breakdown of nicotine, (S)(-)-3-(1-methyl-2-pyrrolidinyl)pyridine.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"f8c01bae4ce546fba03131989a55a987","type":"GO_TERM","name":"nicotine dehydrogenase activity","canonical_id":"go:GO:0018535","description":"\"Catalysis of the reaction: nicotine + acceptor + H2O = (S)-6-hydroxynicotine + reduced acceptor.\" [EC:1.5.99.4]","metadata":null},{"id":"10ade98bcb3b4a2d9e468324188b2c82","type":"DISEASE","name":"nicotine dependence","canonical_id":"mondo:0008575","description":null,"metadata":null},{"id":"1ba645872e444ecfa2416bedb0888f26","type":"GO_TERM","name":"nicotine metabolic process","canonical_id":"go:GO:0018933","description":"\"The chemical reactions and pathways involving nicotine, (S)(-)-3-(1-methyl-2-pyrrolidinyl)pyridine.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"dc53db9e2c40419c82cef419699f4d00","type":"GO_TERM","name":"nicotinic acid receptor activity","canonical_id":"go:GO:0070553","description":"\"Combining with nicotinic acid to initiate a change in cell activity.\" [GOC:mah, PMID:12522134]","metadata":null},{"id":"8ad3c258a4da49e18a5efdd50c961d47","type":"GO_TERM","name":"nicotinic acid riboside biosynthetic process","canonical_id":"go:GO:0071592","description":"\"The chemical reactions and pathways resulting in the formation of nicotinic acid riboside, the product of the formation of a glycosidic bond between ribose and nicotinic acid.\" [GOC:mah, PMID:19846558]","metadata":null},{"id":"c6f939eea1b84d83914788496fe7e273","type":"GO_TERM","name":"nicotinic acid riboside hydrolase activity","canonical_id":"go:GO:0070636","description":"\"Catalysis of the reaction: nicotinic acid riboside + H2O = nicotinic acid + D-ribose.\" [GOC:mah, PMID:19001417]","metadata":null},{"id":"d99bd528dcfd4ce3b66a1b2fdaa5089d","type":"DRUG","name":"nifurtimox","canonical_id":"mesh:D009547","description":null,"metadata":null},{"id":"856055e98d2e461e8931bf363e07d6d9","type":"GO_TERM","name":"nigerotriose transport","canonical_id":"go:GO:2001091","description":"\"The directed movement of a nigerotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"2fc234130e3d4a17b3a0b98840a6805c","type":"DRUG","name":"nilotinib","canonical_id":"gtopdb:5697","description":null,"metadata":null},{"id":"2a1d88017a374926b0ae5f87f4d4a834","type":"DRUG","name":"nilotinib","canonical_id":"mesh:C498826","description":null,"metadata":null},{"id":"79c00728ad48492ea930479204d42811","type":"COMBINATION_TREATMENT","name":"nilotinib + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-53ff71d9ed2e5553","description":null,"metadata":null},{"id":"06c55d4dfda0402a95aac7c4677cde53","type":"COMBINATION_TREATMENT","name":"nilotinib + sunitinib","canonical_id":"ctgov_combo:ctgov-combo-ce2bd3565587d823","description":null,"metadata":null},{"id":"42dfb8243828491e8dfef88f66aea708","type":"COMBINATION_TREATMENT","name":"nilotinib + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-b6dba7bcb38d04d6","description":null,"metadata":null},{"id":"b1e68deb81104f4b802f9bc045d90e5f","type":"COMBINATION_TREATMENT","name":"nilotinib + vinblastine","canonical_id":"ctgov_combo:ctgov-combo-3b48dc72b5411930","description":null,"metadata":null},{"id":"30067dd4b19741e29843b4b147a734f3","type":"DRUG","name":"nilutamide","canonical_id":"gtopdb:2864","description":null,"metadata":null},{"id":"aaeed42dbb3145669ebd71917848e3e3","type":"DRUG","name":"nilutamide","canonical_id":"chembl:CHEMBL1274","description":null,"metadata":null},{"id":"f922b5b3286b4c1f87f98bf7189ace89","type":"DRUG","name":"nimesulide","canonical_id":"gtopdb:7401","description":null,"metadata":null},{"id":"3ac8c54b416346aeb8ab01c9cfee8039","type":"DRUG","name":"nimodipine","canonical_id":"gtopdb:2523","description":null,"metadata":null},{"id":"83f1f45bd8364ef3be6b772e39fa564e","type":"DRUG","name":"nimodipine","canonical_id":"mesh:D009553","description":null,"metadata":null},{"id":"84745198431d4c87a034b023885ac574","type":"DRUG","name":"nimodipine","canonical_id":"chembl:CHEMBL1428","description":null,"metadata":null},{"id":"d0cde68c0ac44b228468999964e7c87c","type":"DRUG","name":"nintedanib","canonical_id":"gtopdb:5936","description":null,"metadata":null},{"id":"a2e1a3f150c0422b86e8d6219e3e6dbe","type":"DRUG","name":"nintedanib","canonical_id":"mesh:C530716","description":null,"metadata":null},{"id":"3d5718596691481ab6f1d01d1049d3ff","type":"COMBINATION_TREATMENT","name":"nintedanib + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-1fe14fea9bb9a3b7","description":null,"metadata":null},{"id":"d4d3424f65634c0781ae40e28dd0a306","type":"COMBINATION_TREATMENT","name":"nintedanib + sildenafil","canonical_id":"ctgov_combo:ctgov-combo-ccb8684be4297698","description":null,"metadata":null},{"id":"b026ff83d862429f91e3e9afe7245ca6","type":"DRUG","name":"nipocalimab","canonical_id":"gtopdb:13876","description":null,"metadata":null},{"id":"293e8f64c53744bfb8894c3a68de9953","type":"DRUG","name":"nipocalimab","canonical_id":"chembl:CHEMBL4594310","description":null,"metadata":null},{"id":"f3d44563e50541f5b78eb14ce3d8be8c","type":"GO_TERM","name":"nipple development","canonical_id":"go:GO:0060618","description":"\"The progression of the nipple over time, from its formation to the mature structure. The nipple is a part of the mammary gland that protrudes from the surface ectoderm.\" [GOC:dph]","metadata":null},{"id":"612bb0ff2c1e4fcfb1b7c03858b8c6b2","type":"GO_TERM","name":"nipple morphogenesis","canonical_id":"go:GO:0060658","description":"\"The process in which the nipple is generated and organized.\" [GOC:dph]","metadata":null},{"id":"6ed8af5947d44271a45f4f97b4a4f7fc","type":"GO_TERM","name":"nipple sheath formation","canonical_id":"go:GO:0060659","description":"\"The developmental process pertaining to the initial formation of the nipple sheath from the unspecified epidermis. This process begins with a circular ingrowth of the epidermis around the region of the mammary sprout. It ends before the region begins to elevate.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"746d7986dc964c62bfb61808fce283db","type":"DRUG","name":"niraparib","canonical_id":"gtopdb:8275","description":null,"metadata":null},{"id":"fa0a1397bff2448b8c9885f767cb8369","type":"DRUG","name":"niraparib","canonical_id":"chembl:CHEMBL1094636","description":null,"metadata":null},{"id":"66fdaf03fe62487ca3243f8d0e3c441b","type":"COMBINATION_TREATMENT","name":"niraparib + olaparib + rucaparib","canonical_id":"ctgov_combo:ctgov-combo-53d6e732a6fe395d","description":null,"metadata":null},{"id":"049cb22814f14f268e31cb8bfc176957","type":"COMBINATION_TREATMENT","name":"niraparib + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-ee8d842ff2d1fb15","description":null,"metadata":null},{"id":"6c5519fe822e4470a164decccad78bed","type":"DRUG","name":"nitisinone","canonical_id":"gtopdb:6834","description":null,"metadata":null},{"id":"f2bf75849b474ca8a91685e2ddd7e84d","type":"DRUG","name":"nitisinone","canonical_id":"chembl:CHEMBL1337","description":null,"metadata":null},{"id":"3b482633e665463aa3ee81cb7ce21565","type":"GO_TERM","name":"nitrate assimilation","canonical_id":"go:GO:0042128","description":"\"The nitrogen metabolic process that encompasses the uptake of nitrate from the environment and reduction to ammonia, and results in the incorporation of nitrogen derived from nitrate into cellular substances.\" [GOC:das, GOC:mah, PMID:10542156, PMID:8122899]","metadata":null},{"id":"fa098975c8df4e6aa1d2d6ff30ab0a70","type":"GO_TERM","name":"nitrate catabolic process","canonical_id":"go:GO:0043602","description":"\"The chemical reactions and pathways resulting in the breakdown of nitrates, inorganic or organic salts and esters of nitric acid.\" [GOC:jl]","metadata":null},{"id":"13f0fc89719c40b6a8bc6931f0024070","type":"GO_TERM","name":"nitrate efflux transmembrane transporter activity","canonical_id":"go:GO:0010542","description":"\"Enables the transfer of nitrate from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mah]","metadata":null},{"id":"1b9742ef8fe84c319b8b185ee33d09d1","type":"GO_TERM","name":"nitrate import","canonical_id":"go:GO:1902025","description":"\"The directed movement of nitrate into a cell or organelle.\" [GOC:TermGenie, PMID:22658680]","metadata":null},{"id":"61e0b69e5ccf4a90816767feabb1e335","type":"GO_TERM","name":"nitrate metabolic process","canonical_id":"go:GO:0042126","description":"\"The chemical reactions and pathways involving nitrates, inorganic or organic salts and esters of nitric acid.\" [GOC:jl]","metadata":null},{"id":"451b773c6c804a5a9c79532a947cb430","type":"GO_TERM","name":"nitrate reductase (NADH) activity","canonical_id":"go:GO:0009703","description":"\"Catalysis of the reaction: nitrite + NAD+ + H2O = nitrate + NADH + H+.\" [RHEA:17913]","metadata":null},{"id":"986ac9ec09a84e77821ee7e41473a9d8","type":"GO_TERM","name":"nitrate reductase (NADPH) activity","canonical_id":"go:GO:0050464","description":"\"Catalysis of the reaction: nitrite + NADP+ + H2O = nitrate + NADPH + H+.\" [RHEA:19061]","metadata":null},{"id":"28ec76dcd17f48eda08a313e99c87107","type":"GO_TERM","name":"nitrate reductase (cytochrome) activity","canonical_id":"go:GO:0050140","description":"\"Catalysis of the reaction: 2 Fe(II)-[cytochrome] + nitrate + 2 H+ = 2 Fe(III)-[cytochrome] + nitrite + H2O.\" [RHEA:12909]","metadata":null},{"id":"e06d5540e76d4c46ba4209ddc52500e5","type":"GO_TERM","name":"nitrate reductase (quinone) activity","canonical_id":"go:GO:0160182","description":"\"Catalysis of the reaction: a quinol + nitrate = a quinone + H2O + nitrite.\" [RHEA:56144]","metadata":null},{"id":"4ef9e27cd5bc4472b3b8c780d048d55f","type":"GO_TERM","name":"nitrate reductase [NAD(P)H] activity","canonical_id":"go:GO:0050463","description":"\"Catalysis of the reaction: nitrite + NAD(P)+ + H2O = nitrate + NAD(P)H + H+.\" [EC:1.7.1.2]","metadata":null},{"id":"e0b8562d46274f7e9c1bd4d2fe019665","type":"GO_TERM","name":"nitrate reductase activity","canonical_id":"go:GO:0008940","description":"\"Catalysis of the reaction: nitrite + acceptor = nitrate + reduced acceptor.\" [RHEA:21068]","metadata":null},{"id":"59dd8a0796b540a1a53fed5a3c94726d","type":"GO_TERM","name":"nitrate reductase complex","canonical_id":"go:GO:0009325","description":"\"An enzyme complex that catalyzes the formation of nitrate from nitrite with the concomitant reduction of an acceptor.\" [PMID:2139607]","metadata":null},{"id":"6556cacf0f844f1192ea6a06dd45315c","type":"GO_TERM","name":"nitrate transmembrane transport","canonical_id":"go:GO:0015706","description":"\"The directed movement of nitrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"768e64928d7d4e49a6d2dd1f526295f4","type":"GO_TERM","name":"nitrate transmembrane transporter activity","canonical_id":"go:GO:0015112","description":"\"Enables the transfer of nitrate ions (NO3-) from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"5caf1ca74c984376810698f03fa3cf53","type":"GO_TERM","name":"nitrate:proton symporter activity","canonical_id":"go:GO:0009671","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: nitrate(out) + H+(out) = nitrate(in) + H+(in).\" [GOC:mah, PMID:10066586, PMID:1990981]","metadata":null},{"id":"862ca0011c884a4ebacda92dc214dce5","type":"DRUG","name":"nitrazepam","canonical_id":"mesh:D009567","description":null,"metadata":null},{"id":"af7f9eb8a4db4aeab6ba31171fe5a433","type":"DRUG","name":"nitrendipine","canonical_id":"gtopdb:2334","description":null,"metadata":null},{"id":"6faf780b07454a0894152ad902c6b31f","type":"DRUG","name":"nitrendipine","canonical_id":"chembl:CHEMBL475534","description":null,"metadata":null},{"id":"9652216839fa4f7db7d0e59576d0dd65","type":"GO_TERM","name":"nitric oxide binding","canonical_id":"go:GO:0070026","description":"\"Binding to nitric oxide (NO).\" [GOC:ecd]","metadata":null},{"id":"4143f5727dc94a8f9502173537f1acf3","type":"GO_TERM","name":"nitric oxide biosynthetic process","canonical_id":"go:GO:0006809","description":"\"The chemical reactions and pathways resulting in the formation of nitric oxide, nitrogen monoxide (NO), a colorless gas only slightly soluble in water.\" [GOC:ai]","metadata":null},{"id":"9770defb5f33417297c48096a33a9126","type":"GO_TERM","name":"nitric oxide catabolic process","canonical_id":"go:GO:0046210","description":"\"The chemical reactions and pathways resulting in the breakdown of nitric oxide, nitrogen monoxide (NO), a colorless gas only slightly soluble in water.\" [GOC:ai]","metadata":null},{"id":"1b546767db0b4db79e6f63517d8e81fa","type":"GO_TERM","name":"nitric oxide dioxygenase [NAD(P)H] activity","canonical_id":"go:GO:0008941","description":"\"Catalysis of the reaction: 2 NO + 2 O2 + NAD(P)H + H+ = 2 nitrate + NAD(P)+.\" [EC:1.14.12.17]","metadata":null},{"id":"e26fb2a465284c0caf7eb099c5491ec7","type":"GO_TERM","name":"nitric oxide dioxygenase activity, heme protein as donor","canonical_id":"go:GO:0141118","description":"\"Catalysis of the reaction: Fe(II)-heme b-[protein] + nitric oxide + O2 = Fe(III)-heme b-[protein] + nitrate.\" [PMID:20511233]","metadata":null},{"id":"9a526b9e1eb64c058434fce3eb73b4a3","type":"GO_TERM","name":"nitric oxide metabolic process","canonical_id":"go:GO:0046209","description":"\"The chemical reactions and pathways involving nitric oxide, nitrogen monoxide (NO), a colorless gas only slightly soluble in water.\" [GOC:ai]","metadata":null},{"id":"5e05324083b3446db1fb25c6534c93ed","type":"GO_TERM","name":"nitric oxide production involved in inflammatory response","canonical_id":"go:GO:0002537","description":"\"The synthesis or release of nitric oxide following a stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ccc1311eb29446ee9faa1b15884a6b8c","type":"GO_TERM","name":"nitric oxide reductase [NAD(P)H] activity","canonical_id":"go:GO:0102199","description":"\"Catalysis of the reaction: H2O + NAD(P)+ + nitrous oxide = H+ + NAD(P)H + 2 nitric oxide.\" [EC:1.7.1.14]","metadata":null},{"id":"ef3cdd35167f4cbb941ec28743a9947b","type":"GO_TERM","name":"nitric oxide reductase activity","canonical_id":"go:GO:0016966","description":"\"Catalysis of the reaction: H2O + 2 ferricytochrome c + nitrous oxide = 2 H+ + 2 ferrocytochrome c + 2 nitric oxide.\" [EC:1.7.2.5]","metadata":null},{"id":"e5983b8645ee4b22bd19244b457d5bcf","type":"GO_TERM","name":"nitric oxide sensor activity","canonical_id":"go:GO:0035991","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of nitric oxide (NO).\" [GOC:kmv, PMID:21491957]","metadata":null},{"id":"68a7d07f47614aee91fcadce15fdd4e7","type":"GO_TERM","name":"nitric oxide storage","canonical_id":"go:GO:0035732","description":"\"The accumulation and maintenance in cells or tissues of nitric oxide (NO). Nitric oxide is stored in the form of dinitrosyl-iron complexes, which are stabilized, and possibly sequestered, by binding to glutathione S-transferase proteins.\" [GOC:BHF, PMID:12871945]","metadata":null},{"id":"da147c3b422b4a799e454b9570bcb652","type":"GO_TERM","name":"nitric oxide transmembrane transporter activity","canonical_id":"go:GO:0030184","description":"\"Enables the transfer of nitric oxide, nitrogen monoxide, from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"de581bf10d0e4e1383a72e9fe465cd4c","type":"GO_TERM","name":"nitric oxide transport","canonical_id":"go:GO:0030185","description":"\"The directed movement of nitric oxide, nitrogen monoxide, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"3f86335e52554198892249082568c231","type":"GO_TERM","name":"nitric oxide-cGMP-mediated signaling","canonical_id":"go:GO:0038060","description":"\"An intracellular signaling cassette in which the signal is passed on within the cell by nitric oxide (NO) activating soluble guanylyl cyclase (sGC). Includes synthesis of nitric oxide, guanylyl cyclase activity, and downstream effectors that further transmit the signal within the cell following activation by cGMP.\" [GOC:signaling, PMID:21549190, PMID:22019632]","metadata":null},{"id":"a60c78870fa242058631b33fc52c1bbd","type":"GO_TERM","name":"nitric-oxide synthase activity","canonical_id":"go:GO:0004517","description":"\"Catalysis of the reaction: L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+.\" [EC:1.14.13.39, RHEA:19897]","metadata":null},{"id":"71dd6679f2204ce5a1bee9a130d53352","type":"GO_TERM","name":"nitric-oxide synthase binding","canonical_id":"go:GO:0050998","description":"\"Binding to nitric-oxide synthase.\" [GOC:ai]","metadata":null},{"id":"aa17c4724c2a4992b9c71a7f1e00c523","type":"GO_TERM","name":"nitric-oxide synthase complex","canonical_id":"go:GO:1903958","description":"\"A protein complex which is capable of nitric-oxide synthase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:25417112]","metadata":null},{"id":"0930a7ed567045799b2d31c1555257a1","type":"GO_TERM","name":"nitric-oxide synthase inhibitor activity","canonical_id":"go:GO:0036487","description":"\"Binds to and stops, prevents or reduces the activity of nitric oxide synthase.\" [GOC:BHF, GOC:rl, PMID:17242280]","metadata":null},{"id":"c98cc5500e134e0ab1c5b4de2d3a0e56","type":"GO_TERM","name":"nitric-oxide synthase regulator activity","canonical_id":"go:GO:0030235","description":"\"Binds to and modulates the activity of nitric oxide synthase.\" [GOC:mah]","metadata":null},{"id":"dab109f2c09942aba97f6e1125b67a3c","type":"GO_TERM","name":"nitrilase activity","canonical_id":"go:GO:0000257","description":"\"Catalysis of the reaction: a nitrile + H2O = a carboxylate + NH4+. Acts on a wide range of aromatic nitriles including (indole-3-yl)-acetonitrile and some aliphatic nitriles, and on the corresponding acid amides.\" [RHEA:21724]","metadata":null},{"id":"20ba1cbe30a44b758ed985621a7116fb","type":"GO_TERM","name":"nitrile biosynthetic process","canonical_id":"go:GO:0080028","description":"\"The chemical reactions and pathways resulting in the formation of a nitrile, an organic compound containing trivalent nitrogen attached to one carbon atom.\" [PMID:18987211]","metadata":null},{"id":"373d3f0b0b2e4cbf8982e8f7da53cae3","type":"GO_TERM","name":"nitrile catabolic process","canonical_id":"go:GO:0050899","description":"\"The chemical reactions and pathways resulting in the breakdown of a nitrile, an organic compound containing trivalent nitrogen attached to one carbon atom.\" [ISBN:0721662544]","metadata":null},{"id":"ed4b448317b8437daacbb3d324b6710a","type":"GO_TERM","name":"nitrile hydratase activity","canonical_id":"go:GO:0018822","description":"\"Catalysis of the reaction: an aliphatic amide = a nitrile + H2O.\" [RHEA:12673]","metadata":null},{"id":"a16bd532f738457fa6ecd5c70c64f990","type":"GO_TERM","name":"nitrile metabolic process","canonical_id":"go:GO:0050898","description":"\"The chemical reactions and pathways involving nitriles, an organic compound containing trivalent nitrogen attached to one carbon atom. The nitriles are named with reference to the acids produced by their decomposition; for example, hydrocyanic acid is formic nitrile, and methyl cyanide is acetic nitrile.\" [PMID:18987211]","metadata":null},{"id":"18589c75c365466da56e5a8cc01740eb","type":"GO_TERM","name":"nitrilotriacetate monooxygenase activity","canonical_id":"go:GO:0018529","description":"\"Catalysis of the reaction: nitrilotriacetate + FMNH2 + O2 = aminodiacetate + FMN + glyoxylate + H2O.\" [RHEA:31359]","metadata":null},{"id":"a07e3e50f25947038fb8a4237744d910","type":"GO_TERM","name":"nitrite efflux transmembrane transporter activity","canonical_id":"go:GO:0015514","description":"\"Enables the transfer of nitrite from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ff6fce93014749ada2f3853da4000835","type":"GO_TERM","name":"nitrite reductase (NADH) activity","canonical_id":"go:GO:0106316","description":"\"Catalysis of the reaction: NH4+ + 3 NAD+ + 2 H2O = nitrite + 3 NADH + 5 H+.\" [RHEA:24628]","metadata":null},{"id":"69870c9025a9473f9455308bc10fcab2","type":"GO_TERM","name":"nitrite reductase (NADPH) activity","canonical_id":"go:GO:0106314","description":"\"Catalysis of the reaction: ammonium hydroxide + 3 NADP+ + H2O = nitrite + 3 NADPH + 3 H+.\" [RHEA:24632]","metadata":null},{"id":"812d27147a474f2d831c72d43b26373f","type":"GO_TERM","name":"nitrite reductase (NO-forming) activity","canonical_id":"go:GO:0050421","description":"\"Catalysis of the reaction: nitric oxide + Fe(III)-[cytochrome c] + H2O = Fe(II)-[cytochrome c] + nitrite + 2 H+.\" [RHEA:15233]","metadata":null},{"id":"fff5c6e2a75247e49e6f9ff5a6a1910f","type":"GO_TERM","name":"nitrite reductase (cytochrome, ammonia-forming) activity","canonical_id":"go:GO:0042279","description":"\"Catalysis of the reaction: 6 Fe(III)-[cytochrome c] + NH4+ + 2 H2O = 6 Fe(II)-[cytochrome c] + nitrite + 8 H+.\" [RHEA:13089]","metadata":null},{"id":"9fdb71b1c4b74475a22db8b026f3ca51","type":"GO_TERM","name":"nitrite reductase [NAD(P)H] activity","canonical_id":"go:GO:0008942","description":"\"Catalysis of the reaction: NH4+ + 3 NAD(P)+ + 2 H2O = nitrite + 3 NAD(P)H + 5 H+.\" [EC:1.7.1.4, PMID:31961593]","metadata":null},{"id":"7b8d8bf20a274a0d8885c9e6d0a4bb77","type":"GO_TERM","name":"nitrite reductase activity","canonical_id":"go:GO:0098809","description":"\"Catalysis of the reaction: nitrite + acceptor = product(s) of nitrate reduction + reduced acceptor.\" [GOC:dos, GOC:jh]","metadata":null},{"id":"356fbc63d4164167b19576e68336f5cb","type":"GO_TERM","name":"nitrite reductase complex [NAD(P)H]","canonical_id":"go:GO:0009344","description":"\"Complex that possesses nitrite reductase [NAD(P)H] activity.\" [GOC:mah]","metadata":null},{"id":"e5db945b746e4135ab23e6d9a2d710ea","type":"GO_TERM","name":"nitrite transmembrane transporter activity","canonical_id":"go:GO:0015113","description":"\"Enables the transfer of nitrite (NO2-) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"cc0489fd61654f099eea3d2053640ec1","type":"GO_TERM","name":"nitrite transport","canonical_id":"go:GO:0015707","description":"\"The directed movement of nitrite into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"c3d2e419bffe4751bc54dddd8fa0c164","type":"GO_TERM","name":"nitroalkane oxidase activity","canonical_id":"go:GO:0052664","description":"\"Catalysis of the reaction: a primary nitroalkane + H2O + O2 = an aldehyde + H+ + H2O2 + nitrite; also converts secondary nitroalkanes to a ketone.\" [EC:1.7.3.1]","metadata":null},{"id":"f2dadf1cf9b246b8983529f5fe01cb73","type":"GO_TERM","name":"nitrobenzene biosynthetic process","canonical_id":"go:GO:1900999","description":"\"The chemical reactions and pathways resulting in the formation of nitrobenzene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00923]","metadata":null},{"id":"ac949df62232434bb9e35ec725425e8d","type":"GO_TERM","name":"nitrobenzene catabolic process","canonical_id":"go:GO:1900998","description":"\"The chemical reactions and pathways resulting in the breakdown of nitrobenzene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00923]","metadata":null},{"id":"20d8575e869b49d49b1dff9623a99031","type":"GO_TERM","name":"nitrobenzene metabolic process","canonical_id":"go:GO:0018916","description":"\"The chemical reactions and pathways involving nitrobenzene (nitrobenzol), a derivative of benzene with an NO2 group attached to the ring. It is a yellow aromatic liquid used in perfumery and manufactured in large quantities in the preparation of aniline.\" [GOC:curators]","metadata":null},{"id":"a6d4e56551e94025b879bda93d67ae84","type":"GO_TERM","name":"nitrobenzene nitroreductase (NADPH) activity","canonical_id":"go:GO:0018546","description":"\"Catalysis of the reaction: H2O + N-phenylhydroxylamine + 2 NADP+ = 2 H+ + 2 NADPH + nitrobenzene.\" [PMID:16517619, RHEA:52884]","metadata":null},{"id":"25f2de2ad9404a0494eb0379ec49c739","type":"GO_TERM","name":"nitrogen catabolite activation of transcription","canonical_id":"go:GO:0090294","description":"\"A transcription regulation process in which the presence of one nitrogen source leads to an increase in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other nitrogen sources.\" [GOC:mah, GOC:rb, PMID:19104072]","metadata":null},{"id":"b8485ec6632842db944100a863bebb99","type":"GO_TERM","name":"nitrogen catabolite regulation of transcription","canonical_id":"go:GO:0090293","description":"\"A transcription regulation process in which the presence of one nitrogen source leads to the modulation of the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other nitrogen sources.\" [GOC:mah, GOC:rb, PMID:19104072]","metadata":null},{"id":"d9dc3b08773047949b096bfdbc06fd7a","type":"GO_TERM","name":"nitrogen catabolite repression of transcription","canonical_id":"go:GO:0090295","description":"\"A transcription regulation process in which the presence of one nitrogen source leads to a decrease in the frequency, rate, or extent of transcription of specific genes involved in the metabolism of other nitrogen sources.\" [GOC:mah, GOC:rb, PMID:19104072]","metadata":null},{"id":"512c3afd11cf423fb9a760caa4af98c2","type":"GO_TERM","name":"nitrogen compound transport","canonical_id":"go:GO:0071705","description":"\"The directed movement of nitrogen-containing compounds into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"b2bb84df07df4b5089d2e4096a7a7732","type":"GO_TERM","name":"nitrogen cycle metabolic process","canonical_id":"go:GO:0071941","description":"\"A nitrogen compound metabolic process that contributes to the nitrogen cycle. The nitrogen cycle is a series of metabolic pathways by which nitrogen is converted between various forms and redox states; it encompasses pathways in which nitrogen is acted upon directly, such as nitrification, denitrification, nitrogen fixation, and mineralization.\" [GOC:mah, PMID:16675690, Wikipedia:Nitrogen_cycle]","metadata":null},{"id":"1160feff3182404faab820c4c1b276be","type":"GO_TERM","name":"nitrogen fixation","canonical_id":"go:GO:0009399","description":"\"The process in which nitrogen is taken from its relatively inert molecular form (N2) in the atmosphere and converted into ammonium, which is more biologically available.\" [PMID:32796519, PMID:36344435]","metadata":null},{"id":"f9c10e768fd04be9ad605e78b8822812","type":"GO_TERM","name":"nitrogen utilization","canonical_id":"go:GO:0019740","description":"\"A series of processes that forms an integrated mechanism by which a cell or an organism detects the depletion of primary nitrogen source, usually ammonia, and then activates genes to scavenge the last traces of the primary nitrogen source and to transport and metabolize alternative nitrogen sources. The utilization process begins when the cell or organism detects nitrogen levels, includes the activation of genes whose products detect, transport or metabolize nitrogen-containing substances, and ends when nitrogen is incorporated into the cell or organism's metabolism.\" [GOC:mah, GOC:mlg]","metadata":null},{"id":"6435d5617e0940b5b27b2cfaa0e8c7df","type":"GO_TERM","name":"nitrogen-oxygen lyase activity","canonical_id":"go:GO:0141122","description":"\"Catalysis of the breakage of a nitrogen-oxygen bond by means other than hydrolysis and oxidation.\" [EC:4.8.1.-]","metadata":null},{"id":"5c77d786df014844a1c269265c88a4ae","type":"GO_TERM","name":"nitrogenase (flavodoxin) activity","canonical_id":"go:GO:0050142","description":"\"Catalysis of the reaction: N2 + 4 reduced [flavodoxin] + 16 ATP + 16 H2O = 4 oxidized [flavodoxin] + H2 + 2 NH4+ + 16 ADP + 16 phosphate + 18 H+.\" [RHEA:15645]","metadata":null},{"id":"d98e21fb876043c0b35c5e802fdce4e0","type":"GO_TERM","name":"nitrogenase P cluster assembly","canonical_id":"go:GO:0044573","description":"\"The biochemical reactions and pathways resulting in the formation of a P-cluster of a nitrogenase, a high-nuclearity, Fe/S-only cluster that can be viewed as two [4Fe-4S] sub-clusters sharing a gamma-6-sulfide.\" [PMID:17563349]","metadata":null},{"id":"0f234d531689409099de20f002a9f741","type":"GO_TERM","name":"nitrogenase activity","canonical_id":"go:GO:0016163","description":"\"Catalysis of the reaction: 16 ATP + 16 H2O + N2 + 8 reduced [2Fe-2S]-[ferredoxin] = 16 ADP + 6 H+ + H2 + 2 NH4+ + 8 oxidized [2Fe-2S]-[ferredoxin] + 16 phosphate.\" [PMID:15382920, RHEA:21448]","metadata":null},{"id":"a1ebe265384e4c0fac01c5e300cbd418","type":"GO_TERM","name":"nitrogenase complex","canonical_id":"go:GO:0016610","description":"\"An enzyme complex composed of two proteins, dinitrogenase and nitrogenase reductase; dinitrogenase is tetrameric with an alpha2-beta2 structure and nitrogenase reductase is a homodimer, and both are associated with metal ions, which differ between species. Both proteins are required for the enzyme activity of the complex, the formation of oxidized ferredoxin and ammonia from reduced ferredoxin and nitrogen.\" [PMID:10852721]","metadata":null},{"id":"ef266554f0394891bb6226f95f4e750e","type":"GO_TERM","name":"nitroglycerin metabolic process","canonical_id":"go:GO:0018937","description":"\"The chemical reactions and pathways involving nitroglycerin, a well-known nitrate ester and an important component of dynamite and other propellants. Toxic to algae, invertebrate, and vertebrates.\" [UM-BBD_pathwayID:ng]","metadata":null},{"id":"593162f7090b483faeba1d37297cc5e4","type":"GO_TERM","name":"nitroimidazole catabolic process","canonical_id":"go:GO:0052804","description":"\"The chemical reactions and pathways resulting in the breakdown of nitroimidazoles, imidazole derivatives with a nitro group attached to one ring.\" [PMID:16387854, PMID:19039139]","metadata":null},{"id":"235fbedeb4fe48ce80a4bc6406768e72","type":"GO_TERM","name":"nitronate monooxygenase (FMN-linked) activity","canonical_id":"go:GO:0036434","description":"\"Catalysis of the reaction: ethylnitronate + FMNH(2) + O2 = acetaldehyde + FMN + H2O + H+ + nitrite.\" [RHEA:26458]","metadata":null},{"id":"2f47c3822349493dbc0c2093e1f6747e","type":"GO_TERM","name":"nitronate monooxygenase activity","canonical_id":"go:GO:0018580","description":"\"Catalysis of the reaction: ethylnitronate + O2 = acetaldehyde + nitrite.\" [EC:1.13.12.16, RHEA:28767]","metadata":null},{"id":"c7a71363d46242579c7c547208ca43e3","type":"DRUG","name":"nitroprusside","canonical_id":"mesh:D009599","description":null,"metadata":null},{"id":"b2d91382e80349a39372ed6ed5f06d3c","type":"GO_TERM","name":"nitroquinoline-N-oxide reductase [NAD(P)H] activity","canonical_id":"go:GO:0050465","description":"\"Catalysis of the reaction: 4-(hydroxyamino)quinoline N-oxide + 2 NAD(P)+ + H2O = 4-nitroquinoline N-oxide + 2 NAD(P)H + 2 H+.\" [EC:1.7.1.9]","metadata":null},{"id":"8b82d4f6cd144882bf0848afb3eb606d","type":"GO_TERM","name":"nitrotoluene catabolic process","canonical_id":"go:GO:0046263","description":"\"The chemical reactions and pathways resulting in the breakdown of nitrotoluene, any methylbenzene molecule with NO2 group(s) attached.\" [GOC:ai]","metadata":null},{"id":"ad6da5ef11194f16ae03f198baa78a19","type":"GO_TERM","name":"nitrous-oxide reductase activity","canonical_id":"go:GO:0050304","description":"\"Catalysis of the reaction: H2O + 2 cytochrome c + nitrogen = 2 reduced cytochrome c + nitrous oxide.\" [EC:1.7.2.4, MetaCyc:RXN-12130]","metadata":null},{"id":"860e8759aa944c279fbad5de910494b6","type":"DRUG","name":"nivolumab","canonical_id":"gtopdb:7335","description":null,"metadata":null},{"id":"e563cde2082c42c383e8e16183768425","type":"DRUG","name":"nivolumab","canonical_id":"mesh:C581771","description":null,"metadata":null},{"id":"3528a73b47d544a8a50c10a3506e4ff8","type":"DRUG","name":"nivolumab","canonical_id":"chembl:CHEMBL2108738","description":null,"metadata":null},{"id":"ea413ec3dcd84306bbf05d3033ff3f6a","type":"COMBINATION_TREATMENT","name":"nivolumab + paclitaxel","canonical_id":"ctgov_combo:ctgov-combo-f8a964333199ec48","description":null,"metadata":null},{"id":"4253105ebbc0439195a032176c7e4254","type":"COMBINATION_TREATMENT","name":"nivolumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-b11d667f88b68ba9","description":null,"metadata":null},{"id":"1b94c7c5229b455eaac19ed6895f2b6d","type":"COMBINATION_TREATMENT","name":"nivolumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-38e221e6fbca49bb","description":null,"metadata":null},{"id":"60ba89612deb4d88aba07335ff9ebdc2","type":"COMBINATION_TREATMENT","name":"nivolumab + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-6b666c4a61299090","description":null,"metadata":null},{"id":"a728478a31c042ea9635200501974b8a","type":"COMBINATION_TREATMENT","name":"nivolumab + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-49d4b937b5486c33","description":null,"metadata":null},{"id":"d22841538a7d43b69a1baf29cf115bdc","type":"COMBINATION_TREATMENT","name":"nivolumab + relatlimab","canonical_id":"ctgov_combo:ctgov-combo-f766ec2e29070b4d","description":null,"metadata":null},{"id":"ea3415a7a1eb48b4b85e4248248ffbf4","type":"COMBINATION_TREATMENT","name":"nivolumab + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-3c31f89d199b9fa7","description":null,"metadata":null},{"id":"537ac7e5146042d69d023c96a09e10d4","type":"COMBINATION_TREATMENT","name":"nivolumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-8f6f3d3a6e9cc84a","description":null,"metadata":null},{"id":"374759804ff24feeaafec54500fadb1d","type":"DRUG","name":"nizatidine","canonical_id":"mesh:D016567","description":null,"metadata":null},{"id":"5606574f742d4771a30d2f5ea0bc9a66","type":"GO_TERM","name":"nocardicin-A epimerase activity","canonical_id":"go:GO:0050143","description":"\"Catalysis of the reaction: isonocardicin A = nocardicin A. May also catalyse the epimerisation of isonocardicin C, but the in vivo substrate appears to be isonocardicin A.\" [EC:5.1.1.14, RHEA:22792]","metadata":null},{"id":"02bce99e71a3438fbf5799f8b5f8399e","type":"GO_TERM","name":"nociceptin receptor activity","canonical_id":"go:GO:0001626","description":"\"Combining with the peptide nociceptin, and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:bf, GOC:mah, PMID:18670432]","metadata":null},{"id":"a8cc19c4ba9b4051bd05f6caed61cc02","type":"GO_TERM","name":"nociceptin receptor binding","canonical_id":"go:GO:0031853","description":"\"Binding to a nociceptin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7a9eed92f30a422fb34e0db89ff08b56","type":"GO_TERM","name":"nodal binding","canonical_id":"go:GO:0038100","description":"\"Binding to a nodal protein, a member of the transforming growth factor-beta superfamily.\" [GOC:bf, PMID:20629020]","metadata":null},{"id":"e69f68536f444f9481caa6a8eb725320","type":"GO_TERM","name":"nodal receptor complex","canonical_id":"go:GO:0038104","description":"\"A protein complex containing at least a type II activin receptor, a type I activin receptor, and a coreceptor (EGF-CFC protein) such as Cripto or Cryptic. Nodal receptor complexes are capable of binding a nodal protein and transducing the signal into the cell.\" [GOC:bf, GOC:signaling, PMID:11024047, PMID:15062104]","metadata":null},{"id":"b7d4bbbf38c84281afe53248eabd537a","type":"GO_TERM","name":"nodal receptor complex assembly","canonical_id":"go:GO:0038099","description":"\"The aggregation, arrangement and bonding together of a set of components to form a complex containing a type II activin receptor, a type I activin receptor, and a coreceptor of the EGF-CFC family (e.g. Cripto or Cryptic, in mammals).\" [GOC:bf, GOC:signaling, PMID:15062104]","metadata":null},{"id":"e406ce9da3b74df18fcc5c6dd28a5e88","type":"GO_TERM","name":"nodal signaling pathway","canonical_id":"go:GO:0038092","description":"\"The series of molecular signals initiated by nodal protein binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:vk, PMID:17287255]","metadata":null},{"id":"2999f01ce1024ccba2433bdfe55b4f47","type":"GO_TERM","name":"node of Ranvier","canonical_id":"go:GO:0033268","description":"\"An axon part that is a gap in the myelin where voltage-gated sodium channels cluster and saltatory conduction is executed.\" [GOC:mh]","metadata":null},{"id":"fe60bc1104cc421ba7cbc0f954446a4d","type":"DISEASE","name":"nodular goiter","canonical_id":"mondo:0006869","description":null,"metadata":null},{"id":"1486a27ab876465bb366b22b9043f175","type":"GO_TERM","name":"nodulation","canonical_id":"go:GO:0009877","description":"\"The formation of nitrogen-fixing root nodules on plant roots.\" [PMID:21856632, PMID:33317178]","metadata":null},{"id":"4db51497bb4542679c66c7ba65dc1b4f","type":"DRUG","name":"nomifensine","canonical_id":"gtopdb:4792","description":null,"metadata":null},{"id":"368336814e9446108d84c6312fd29a3c","type":"DISEASE","name":"non-Hodgkin lymphoma","canonical_id":"mondo:0018908","description":null,"metadata":null},{"id":"0f30bfad4b4d483ba7449b866a581234","type":"DISEASE","name":"non-alcoholic fatty liver","canonical_id":"efo:1001248","description":null,"metadata":null},{"id":"cdf97e1f3f6449c88c1f61857d9e2dc7","type":"DISEASE","name":"non-allergic rhinitis","canonical_id":"efo:0009364","description":null,"metadata":null},{"id":"12289ec875164e1595d00367e4a14fbc","type":"DISEASE","name":"non-autoimmune hemolytic anemia","canonical_id":"mondo:0021559","description":null,"metadata":null},{"id":"48128b36ff1c4fec97b4868bbb077dd5","type":"GO_TERM","name":"non-canonical NF-kappaB signal transduction","canonical_id":"go:GO:0038061","description":"\"An intracellular signaling cassette characterized by the NIK-dependent processing and activation of NF-kappaB. Begins with activation of the NF-kappaB-inducing kinase (NIK), which in turn phosphorylates and activates IkappaB kinase alpha (IKKalpha). IKKalpha phosphorylates the NF-kappa B2 protein (p100) leading to p100 processing and release of an active NF-kappaB (p52). The non-canonical NF-kappaB signaling pathway is generally activated by ligands of the TNF receptor superfamily, including lymphotoxin beta (LTB), CD40, OX40, RANK, TWEAK and B cell-activating factor (BAFF).\" [GOC:bf, GOC:mg2, GOC:signaling, GOC:vs, PMID:11239468, PMID:15140882, PMID:34659217]","metadata":null},{"id":"61d67bb1c719426aa6d5bf8d1e1b2855","type":"GO_TERM","name":"non-canonical Wnt signaling pathway","canonical_id":"go:GO:0035567","description":"\"A type of Wnt signaling pathway in which Wnt binding to its receptor on the surface of a target cell results in the by propagation of the molecular signals via effectors other than beta-catenin.\" [PMID:37804416]","metadata":null},{"id":"89678df57bff44d390536707e3218ae6","type":"GO_TERM","name":"non-canonical Wnt signaling pathway involved in heart development","canonical_id":"go:GO:0061341","description":"\"The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via effectors other than beta-catenin and contributing to the progression of the heart over time.\" [GOC:dph, GOC:mtg_heart, PMID:16860783]","metadata":null},{"id":"3ab3a0a5fba045e0a0727648d8e00e28","type":"GO_TERM","name":"non-canonical inflammasome complex","canonical_id":"go:GO:0160074","description":"\"An inflammasome complex containing CASP4, known as caspase-11 (Casp11) in mouse, which assembles upon cytosolic lipopolysaccharide-binding and directly activates Gasdermin-D (GSDMD).\" [PMID:33187725]","metadata":null},{"id":"d3d39dabf466451e8011fba5349e6cc3","type":"GO_TERM","name":"non-canonical inflammasome complex assembly","canonical_id":"go:GO:0160075","description":"\"The aggregation, arrangement and bonding together of a set of components to form a non-canonical inflammasome complex.\" [PMID:27291964]","metadata":null},{"id":"06515eae13d845f49d097ca10ce22d41","type":"GO_TERM","name":"non-classical arabinogalactan protein metabolic process","canonical_id":"go:GO:0010407","description":"\"The chemical reactions and pathways involving a cell wall arabinogalactan II glycoprotein where other amino acids besides Hyp, Ala, Ser, Thr and Gly can be present and grouped into regions, such as a Cys-rich or Asn-rich domains.\" [GOC:tair_curators]","metadata":null},{"id":"0a1ff385d0364439b9841d29b76f8cb5","type":"GO_TERM","name":"non-collagenous component of basement membrane","canonical_id":"go:GO:0140144","description":"\"The non-collagenous compartment of the solid phase in basement membrane ECM, including glycoproteins like laminins or nidogens.\" [PMID:21421915, PMID:28324731]","metadata":null},{"id":"1783402298264eb6b04f2d96e3ca02ae","type":"GO_TERM","name":"non-collagenous component of interstitial matrix","canonical_id":"go:GO:0140149","description":"\"The non-collagenous component of interstitial extracellular matrices, including glycoprotein like fibronectin and elastin.\" [PMID:21123617, PMID:25701227, PMID:33605520, PMID:39223427]","metadata":null},{"id":"a26fe9d229914eafb9b4cf3ab44bf5fa","type":"GO_TERM","name":"non-growing cell tip","canonical_id":"go:GO:0035839","description":"\"A cell tip at which no growth takes place. For example, in fission yeast the cell end newly formed by cell division does not grow immediately upon its formation, and lacks actin cytoskeletal structures.\" [GOC:expert_jd, GOC:mah]","metadata":null},{"id":"dc24b0feb7f24102bdb601c2d6e6e61b","type":"GO_TERM","name":"non-intein-mediated protein splicing","canonical_id":"go:GO:0030909","description":"\"The post-translational removal of peptide sequences from within a protein sequence, by a process not involving inteins.\" [GOC:mah]","metadata":null},{"id":"dfa8881be54146fc96add17775937f0f","type":"GO_TERM","name":"non-kinase phorbol ester receptor activity","canonical_id":"go:GO:0001566","description":"\"Combining with a phorbol ester and transmitting the signal by a mechanism independent of kinase activity.\" [PMID:10506570]","metadata":null},{"id":"2a281bd3a0404cfa96b7f079340a5563","type":"GO_TERM","name":"non-lytic viral release","canonical_id":"go:GO:0046753","description":"\"The exit of a viral particle from a host cell that does not involve cell lysis.\" [GOC:bf, GOC:jl, ISBN:0072370319]","metadata":null},{"id":"adb4aedf81684f4aa77e2ab0f43cc773","type":"GO_TERM","name":"non-membrane spanning protein tyrosine kinase activity","canonical_id":"go:GO:0004715","description":"\"Catalysis of the reaction: ATP + protein L-tyrosine = ADP + protein L-tyrosine phosphate by a non-membrane spanning protein.\" [EC:2.7.10.2]","metadata":null},{"id":"a8260a24de8a49bd9b51d43ad993ec12","type":"GO_TERM","name":"non-membrane spanning protein tyrosine phosphatase activity","canonical_id":"go:GO:0004726","description":"\"Catalysis of the reaction: non-membrane spanning protein tyrosine phosphate + H2O = non-membrane spanning protein tyrosine + phosphate.\" [PMID:34353440]","metadata":null},{"id":"d4263847c43547dbacc133a1141830ea","type":"GO_TERM","name":"non-motile cilium","canonical_id":"go:GO:0097730","description":"\"A cilium which may have a variable array of axonemal microtubules but does not contain molecular motors.\" [GOC:cilia, GOC:dgh, GOC:kmv, PMID:17009929, PMID:20144998, PMID:22118931]","metadata":null},{"id":"3bbf7e05e5174d2aa006f44d6222e0c7","type":"GO_TERM","name":"non-motile cilium assembly","canonical_id":"go:GO:1905515","description":"\"The aggregation, arrangement and bonding together of a set of components to form a non-motile cilium.\" [GO_REF:0000079, GOC:cilia, GOC:kmv, GOC:TermGenie, PMID:14521833, PMID:14521834]","metadata":null},{"id":"625b4d16056f4f2b838aa6038894040f","type":"GO_TERM","name":"non-motile cilium membrane","canonical_id":"go:GO:0098804","description":"\"The portion of the plasma membrane surrounding a non-motile cilium.\" [GOC:cilia, GOC:dos]","metadata":null},{"id":"bf7419fa9f4140e699a1737c20c2ce7e","type":"GO_TERM","name":"non-myelinated axon ensheathment","canonical_id":"go:GO:0032285","description":"\"The process in which a non-myelinating glial cell membrane closes around an axon.\" [GOC:dgh]","metadata":null},{"id":"82c0a3a14a774a58aaa2f6e83b25c723","type":"GO_TERM","name":"non-myelinated axon ensheathment in central nervous system","canonical_id":"go:GO:0032293","description":"\"The process in which a non-myelinating glial cell membrane encircles an axon in the central nervous system.\" [GOC:dgh]","metadata":null},{"id":"a695dc4c21b4433abe194067f63b8c53","type":"GO_TERM","name":"non-phosphorylated glucose catabolic process","canonical_id":"go:GO:0019595","description":"\"The chemical reactions and pathways resulting in the breakdown of non-phosphorylated forms of glucose.\" [GOC:ai]","metadata":null},{"id":"b4c57f9fa9a54b95b09ac58c6561e430","type":"GO_TERM","name":"non-photoreactive DNA repair","canonical_id":"go:GO:0010213","description":"\"A DNA repair process that is involved in repairing UV-induced DNA damage under non-photoreactivating conditions. The mechanism by which this repair process operates has not yet been completely elucidated.\" [GOC:syr]","metadata":null},{"id":"795d238cf2f34c47af4d804200ea1e68","type":"GO_TERM","name":"non-professional antigen presenting cell antigen processing and presentation","canonical_id":"go:GO:0002473","description":"\"The process in which a non-professional antigen presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex. Non-professional antigen presenting cells include all cell types but dendritic cells, B cells, T cells, monocytes, macrophages, and neutrophils.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"e9855070689e4bb690599b8947e65a93","type":"GO_TERM","name":"non-proteinogenic amino acid biosynthetic process","canonical_id":"go:GO:0170043","description":"\"The chemical reactions and pathways resulting in the formation of non-proteinogenic amino acids.\" [GOC:ew]","metadata":null},{"id":"ebea7dff44494040ac159e91bc76cec4","type":"GO_TERM","name":"non-proteinogenic amino acid catabolic process","canonical_id":"go:GO:0170044","description":"\"The chemical reactions and pathways resulting in the breakdown of non-proteinogenic amino acids.\" [GOC:ew]","metadata":null},{"id":"919f04c891694e67bd274a3d812602f4","type":"GO_TERM","name":"non-proteinogenic amino acid metabolic process","canonical_id":"go:GO:0170041","description":"\"The chemical reactions and pathways involving non-proteingenic amino acids.\" [GOC:ew]","metadata":null},{"id":"834cf63012e74b52b97b40cf0b5ed5aa","type":"GO_TERM","name":"non-recombinational interstrand cross-link repair","canonical_id":"go:GO:0036299","description":"\"Removal of a DNA interstrand crosslink (a covalent attachment of DNA bases on opposite strands of the DNA) and restoration of the DNA by a mechanism that does not involve homologous DNA recombination.\" [GOC:vw, PMID:11154259, PMID:22064477]","metadata":null},{"id":"43c08030960e4b838952801c310989a6","type":"GO_TERM","name":"non-replicative DNA transposition","canonical_id":"go:GO:0098038","description":"\"Process by which a transposable element is excised from the donor site and integrated at the target site without replication of the element. Also referred to as cut-and-paste transposition.\" [GOC:bm, PMID:2553270]","metadata":null},{"id":"e02ed05149a3483fa8c7698af3fde88a","type":"GO_TERM","name":"non-ribosomal peptide synthetase activity","canonical_id":"go:GO:1904091","description":"\"Catalysis of a multistep reaction that produce non-ribosomal peptides. The key chain-building reaction, a C-N bond-forming reaction, involves the generation of the characteristic peptide bond by nucleophilic attack of the amino group of an amino-acyl donor unit covalently bound to a downstream peptidyl carrier protein module (amino acyl-S-PCP) on the acyl group of an upstream electrophilic acyl- or peptidyl acyl-S-PCP chain, catalyzed by a condensation (C) domain. Supplementing these core chain-elongation domains are variable numbers of auxiliary domains that are responsible for modification of the growing polypeptide chain by a small set of iterated reactions including epimerization, N-methylation, and heterocyclization.\" [PMID:10631508, PMID:17502372]","metadata":null},{"id":"a1197c124b034adbbfb0c2e1a1cf7545","type":"GO_TERM","name":"non-sensory hair organization","canonical_id":"go:GO:0035316","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of non-sensory hairs. These hairs are polarized cellular extensions that cover much of the insect epidermis.\" [GOC:mtg_sensu, PMID:11064425]","metadata":null},{"id":"5d2cc4ff74be4415b98ef7e7f1311ad8","type":"GO_TERM","name":"non-sequence-specific DNA binding, bending","canonical_id":"go:GO:0044378","description":"\"The activity of binding selectively and non-covalently to DNA in a sequence-independent manner and distorting the original structure of DNA, typically a straight helix, into a bend, or increasing the bend if the original structure was intrinsically bent due to its sequence.\" [GOC:jl, GOC:vw, PMID:20123079]","metadata":null},{"id":"39c0e289fe4e4e2eb91ffd0a7ad2aefc","type":"DISEASE","name":"non-small cell lung carcinoma","canonical_id":"mondo:0005233","description":null,"metadata":null},{"id":"0d3845b412464fccb90add26950e05e6","type":"DISEASE","name":"non-small cell squamous lung carcinoma","canonical_id":"mondo:0056806","description":null,"metadata":null},{"id":"8259a518ff2d441a88a3b18dbf1d9f8a","type":"GO_TERM","name":"non-tyrosine kinase fibroblast growth factor receptor activity","canonical_id":"go:GO:0001571","description":"\"Combining with fibroblast growth factor (FGF) and transmitting the signal from one side of the membrane to the other by a mechanism independent of tyrosine kinase activity.\" [GOC:signaling, PMID:11418238]","metadata":null},{"id":"4f4e32ff62114e2eaf618b1f2789541c","type":"GO_TERM","name":"nonadec-1-ene biosynthetic process","canonical_id":"go:GO:1900877","description":"\"The chemical reactions and pathways resulting in the formation of nonadec-1-ene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"da4eed96d06047e6b945c441ac8a5b2c","type":"GO_TERM","name":"nonassociative learning","canonical_id":"go:GO:0046958","description":"\"A simple form of learning whereby the repeated presence of a stimulus leads to a change in the probability or strength of the response to that stimulus. There is no association of one type of stimulus with another, rather it is a generalized response to the environment.\" [ISBN:0582227089]","metadata":null},{"id":"c7ed9e7c1e1f475f8451529fc4557c47","type":"GO_TERM","name":"noncyclic photosynthetic phosphorylation","canonical_id":"go:GO:0009779","description":"\"A photosynthetic phosphorylation process in which ATP synthesis is linked to the transport of electrons from water to NADP+ with the production of NADPH and dioxygen (O2). Involves photosystem I and photosystem II.\" [ISBN:0198547684]","metadata":null},{"id":"ce765dfe59324efd8d1cfad132a2420b","type":"GO_TERM","name":"nonfunctional rRNA decay","canonical_id":"go:GO:0070651","description":"\"An rRNA catabolic process that results in the targeted detection and degradation of aberrant rRNAs contained within translationally defective ribosomes, thereby acting as a quality-control system.\" [GOC:mah, GOC:rn, PMID:17188037, PMID:19390089]","metadata":null},{"id":"0f937b051f3b42a69a4da83a010c098b","type":"GO_TERM","name":"nonhomologous end joining complex","canonical_id":"go:GO:0070419","description":"\"A protein complex that plays a role in DNA double-strand break repair via nonhomologous end joining. Such complexes typically contain a specialized DNA ligase (e.g. Lig4 in eukaryotes) and one or more proteins that bind to DNA ends.\" [GOC:mah, PMID:17072889, PMID:17938628]","metadata":null},{"id":"e28982291d144197a193579934cb0648","type":"GO_TERM","name":"nonphotochemical quenching","canonical_id":"go:GO:0010196","description":"\"The process by which excess light energy absorbed by chlorophyll and not used to drive photosynthesis is emitted as heat. This process helps maintain the balance between dissipation and utilization of light energy to minimize generation of oxidizing molecules, thereby protecting the plant against photo-oxidative damage.\" [PMID:10667783, PMID:10938857]","metadata":null},{"id":"136723a882ad4f6ebab20512f408ef44","type":"GO_TERM","name":"nonribosomal peptide biosynthetic process","canonical_id":"go:GO:0019184","description":"\"The biosynthetic process in which peptide bond formation occurs in the absence of the translational machinery. Examples include the synthesis of antibiotic peptides, and glutathione.\" [ISBN:0198506732]","metadata":null},{"id":"d4e16d755cef4782bfe6980436e97860","type":"GO_TERM","name":"nonsense-mediated decay complex","canonical_id":"go:GO:0170010","description":"\"A highly conserved protein complex that recognises and elicits the rapid degradation of mRNAs in which an amino-acid codon has changed to a nonsense codon; occurs when the 3' end is not protected by a 3'-poly(A) tail; degradation proceeds in the 3' to 5' direction.\" [GOC:lnp, PMID:1569946, PMID:29282598, PMID:9032286]","metadata":null},{"id":"ab51d0c407cb481ba1f85ca3947d3aa0","type":"DISEASE","name":"nonsyndromic genetic hearing loss","canonical_id":"mondo:0019497","description":null,"metadata":null},{"id":"f35f04cfdbcc4f9cb13eaa2230d0861b","type":"DISEASE","name":"nontoxic goiter","canonical_id":"mondo:0001658","description":null,"metadata":null},{"id":"9a7097306127425aaf5a533538a55845","type":"GO_TERM","name":"nor-spermidine biosynthetic process","canonical_id":"go:GO:0045312","description":"\"The chemical reactions and pathways resulting in the formation of nor-spermidine, a compound related to spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:curators]","metadata":null},{"id":"a2bcc7694f814b219c00f17513f4de1f","type":"GO_TERM","name":"nor-spermidine catabolic process","canonical_id":"go:GO:0046205","description":"\"The chemical reactions and pathways resulting in the breakdown of nor-spermidine, a compound related to spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:ai]","metadata":null},{"id":"8f1b7bd0bf184230aea160ba155892b6","type":"GO_TERM","name":"nor-spermidine metabolic process","canonical_id":"go:GO:0046204","description":"\"The chemical reactions and pathways involving nor-spermidine, a compound related to spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:ai]","metadata":null},{"id":"49836be95c9d433e955ebcaf817cac2d","type":"GO_TERM","name":"noradrenergic neuron development","canonical_id":"go:GO:0003358","description":"\"The process whose specific outcome is the progression of a noradrenergic neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dph]","metadata":null},{"id":"7e49fae321cb4e948365a38c14a6b0f0","type":"GO_TERM","name":"noradrenergic neuron differentiation","canonical_id":"go:GO:0003357","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an noradrenergic neuron, a neuron that secretes noradrenaline.\" [GOC:dph]","metadata":null},{"id":"58b0a0881bb34a7097be8dc31d604fe1","type":"GO_TERM","name":"noradrenergic neuron fate commitment","canonical_id":"go:GO:0003359","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a noradrenergic neuron.\" [GOC:dph]","metadata":null},{"id":"6335bf3016974c74a6bfb7c16134dd8e","type":"GO_TERM","name":"noradrenergic synapse","canonical_id":"go:GO:0098692","description":"\"A synapse that uses noradrenaline as a neurotransmitter.\" [GOC:dos]","metadata":null},{"id":"65c18b884f0a43d5b11c6dd1de214c59","type":"DRUG","name":"norepinephrine","canonical_id":"mesh:D009638","description":null,"metadata":null},{"id":"a31d04a46ada4294ba4c280e72bff3c4","type":"GO_TERM","name":"norepinephrine binding","canonical_id":"go:GO:0051380","description":"\"Binding to norepinephrine, (3,4-dihydroxyphenyl-2-aminoethanol), a hormone secreted by the adrenal medulla and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts of the CNS. It is also the biosynthetic precursor of epinephrine.\" [GOC:ai]","metadata":null},{"id":"1c50a1a342124c9e8380cdd13bf8e3e4","type":"GO_TERM","name":"norepinephrine biosynthetic process","canonical_id":"go:GO:0042421","description":"\"The chemical reactions and pathways resulting in the formation of norepinephrine, a hormone secreted by the adrenal medulla, and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts in the central nervous system. It is also the demethylated biosynthetic precursor of epinephrine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"5dce942075fc4e368d929b16c81d50c6","type":"GO_TERM","name":"norepinephrine catabolic process","canonical_id":"go:GO:0042422","description":"\"The chemical reactions and pathways resulting in the breakdown of norepinephrine, a hormone secreted by the adrenal medulla, and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts in the central nervous system. It is also the demethylated biosynthetic precursor of epinephrine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"56a557b70bf8429ea02fa08bca4aaa67","type":"GO_TERM","name":"norepinephrine metabolic process","canonical_id":"go:GO:0042415","description":"\"The chemical reactions and pathways involving norepinephrine, a hormone secreted by the adrenal medulla, and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts in the central nervous system. It is also the demethylated biosynthetic precursor of epinephrine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"33798d748fe6484f9a5bb024af4eaa5d","type":"GO_TERM","name":"norepinephrine secretion","canonical_id":"go:GO:0048243","description":"\"The regulated release of norepinephrine by a cell. Norepinephrine is a catecholamine and it acts as a hormone and as a neurotransmitter of most of the sympathetic nervous system.\" [GOC:ef, GOC:jid]","metadata":null},{"id":"ec14220f2ed74d9baa750752ff4ebb30","type":"GO_TERM","name":"norepinephrine secretion, neurotransmission","canonical_id":"go:GO:0061533","description":"\"The regulated release of norepinephrine by a cell, in which the norepinephrine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"8687dc029fc94926bc6ee3c8bd9d01fb","type":"GO_TERM","name":"norepinephrine uptake","canonical_id":"go:GO:0051620","description":"\"The directed movement of norepinephrine into a cell, typically presynaptic neurons or glial cells. Norepinephrine (3,4-dihydroxyphenyl-2-aminoethanol) is a hormone secreted by the adrenal medulla and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts of the CNS. It is also the biosynthetic precursor of epinephrine.\" [GOC:ai]","metadata":null},{"id":"c8cf5792fdbe4cf497023bb7d7ba4f7d","type":"GO_TERM","name":"norepinephrine-epinephrine catabolic process in blood stream","canonical_id":"go:GO:0001995","description":"\"The chemical reactions and pathways resulting in the breakdown of norepinephrine or epinephrine in the bloodstream.\" [GOC:hjd]","metadata":null},{"id":"9a8b67d8e6ce437dae726485a9069f8a","type":"GO_TERM","name":"norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0001994","description":"\"A process that results in a decrease in the diameter of an artery during the norepinephrine-epinephrine response to decreased blood pressure.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"4a41e92575bc4d98a5bccb327c38fcf1","type":"GO_TERM","name":"norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0002025","description":"\"A process that results in an increase in the diameter of an artery during the norepinephrine-epinephrine response to blood pressure change.\" [GOC:mtg_cardio, PMID:10358008]","metadata":null},{"id":"74f367d630e840c5b46bb74c3082f534","type":"GO_TERM","name":"norepinephrine-mediated vasodilation","canonical_id":"go:GO:0003122","description":"\"A vasodilation process resulting from secretion of norepinephrine into the bloodstream or released by nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"9167e09ad3284773abb64d13e1383762","type":"GO_TERM","name":"norepinephrine:sodium symporter activity","canonical_id":"go:GO:0005334","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: norepinephrine(out) + Na+(out) + Cl-(out) = norepinephrine(in) + Na+(in) + Cl-(in).\" [PMID:21752877, PMID:22519513, TC:2.A.22.1.2]","metadata":null},{"id":"e8277ec8f1664f1b92f547e5608945db","type":"DRUG","name":"norethisterone","canonical_id":"gtopdb:2880","description":null,"metadata":null},{"id":"a7e1918e17fa4099a24c3e093efbd8d7","type":"DRUG","name":"norethisterone","canonical_id":"mesh:D009640","description":null,"metadata":null},{"id":"cf61beb9f5314fc490240c1aa60454b3","type":"DRUG","name":"norfloxacin","canonical_id":"mesh:D009643","description":null,"metadata":null},{"id":"8dc537e645494e3db3338c2d5e253b6e","type":"GO_TERM","name":"norsolorinate anthrone synthase activity","canonical_id":"go:GO:0102973","description":"\"Catalysis of the reaction: 7 malonyl-CoA + 5 H+ + a hexanoyl-[acyl-carrier-protein] = norsolorinate anthrone + 7 coenzyme A + 7 carbon dioxide + 2 H2O + a holo-[acyl-carrier protein].\" [EC:2.3.1.221, GOC:pz]","metadata":null},{"id":"b437acda9a73426982eb801edfbca63d","type":"GO_TERM","name":"norsolorinic acid ketoreductase activity","canonical_id":"go:GO:0140393","description":"\"Catalysis of the reaction: (1'S)-averantin + NADP+ = norsolorinic acid + NADPH.\" [PMID:10584035, PMID:8368836, RHEA:35447]","metadata":null},{"id":"f1868ff74a9e46baae976854292296b0","type":"DRUG","name":"nortriptyline","canonical_id":"gtopdb:2404","description":null,"metadata":null},{"id":"902858fe6eff4ab686968cdb53cfe759","type":"DRUG","name":"nortriptyline","canonical_id":"mesh:D009661","description":null,"metadata":null},{"id":"7303fc4a47084d3486d60a8452bdcc38","type":"COMBINATION_TREATMENT","name":"nortriptyline + paroxetine + verapamil","canonical_id":"ctgov_combo:ctgov-combo-9105ecb8e094e12a","description":null,"metadata":null},{"id":"405f7f362c36496781018f8d28ad25c0","type":"COMBINATION_TREATMENT","name":"nortriptyline + paroxetine + verapamil","canonical_id":"ctgov_combo:ctgov-combo-49db9a1337e70d30","description":null,"metadata":null},{"id":"008ea057082e4cef9bd47641d3cd536c","type":"COMBINATION_TREATMENT","name":"nortriptyline + tranylcypromine","canonical_id":"ctgov_combo:ctgov-combo-a36363123c6f93ea","description":null,"metadata":null},{"id":"5a9736bb15ac4af8a96c330552e10e09","type":"GO_TERM","name":"nose development","canonical_id":"go:GO:0043584","description":"\"The process whose specific outcome is the progression of the nose over time, from its formation to the mature structure. The nose is the specialized structure of the face that serves as the organ of the sense of smell and as part of the respiratory system. Includes the nasi externus (external nose) and cavitas nasi (nasal cavity).\" [GOC:jl]","metadata":null},{"id":"f0ed396f4811457983d114955a9ccdea","type":"GO_TERM","name":"nose morphogenesis","canonical_id":"go:GO:0043585","description":"\"The process in which the anatomical structures of the nose are generated and organized. The nose is the specialized structure of the face that serves as the organ of the sense of smell and as part of the respiratory system. Includes the nasi externus (external nose) and cavitas nasi (nasal cavity).\" [GOC:jl]","metadata":null},{"id":"f9dfa64e530f41628446a6b791ceceab","type":"GO_TERM","name":"notochord cell development","canonical_id":"go:GO:0060035","description":"\"The process whose specific outcome is the progression of a notochord cell over time, from its formation to its mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:dph]","metadata":null},{"id":"3d7af0c0c3a84ab6978ee7f266d032ca","type":"GO_TERM","name":"notochord cell differentiation","canonical_id":"go:GO:0060034","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features cells that make up the notochord. Differentiation includes the processes involved in commitment of a cell to a notochord cell fate.\" [GOC:dph]","metadata":null},{"id":"976b5cdae56047a49995d098be3a02e8","type":"GO_TERM","name":"notochord cell vacuolation","canonical_id":"go:GO:0060036","description":"\"The assembly and arrangement of a vacuole within a cell of the notochord.\" [GOC:cb, GOC:dph, PMID:10964477]","metadata":null},{"id":"3cda03e2ff85456fb5e58437197296c4","type":"GO_TERM","name":"notochord development","canonical_id":"go:GO:0030903","description":"\"The process whose specific outcome is the progression of the notochord over time, from its formation to the mature structure. The notochord is a mesoderm-derived structure located ventral of the developing nerve cord. In vertebrates, the notochord serves as a core around which other mesodermal cells form the vertebrae. In the most primitive chordates, which lack vertebrae, the notochord persists as a substitute for a vertebral column.\" [GOC:dgh]","metadata":null},{"id":"067e4115d317484fac29e7d6cc88b563","type":"GO_TERM","name":"notochord formation","canonical_id":"go:GO:0014028","description":"\"The formation of the notochord from the chordamesoderm. The notochord is composed of large cells packed within a firm connective tissue sheath and is found in all chordates at the ventral surface of the neural tube. In vertebrates, the notochord contributes to the vertebral column.\" [GOC:dh, GOC:ef]","metadata":null},{"id":"4e8ae0924eda4d91b315fed7ace354e4","type":"GO_TERM","name":"notochord morphogenesis","canonical_id":"go:GO:0048570","description":"\"The process in which the anatomical structures of the notochord are generated and organized. The notochord is a mesoderm-derived structure located ventral of the developing nerve cord. In vertebrates, the notochord serves as a core around which other mesodermal cells form the vertebrae. In the most primitive chordates, which lack vertebrae, the notochord persists as a substitute for a vertebral column.\" [GOC:jid]","metadata":null},{"id":"73ef23f3154249fd9e5d5cebc58baefa","type":"GO_TERM","name":"notochord regression","canonical_id":"go:GO:0060032","description":"\"The developmental process in which the structure of the notochord is destroyed in an embryo.\" [GOC:dph]","metadata":null},{"id":"2e85e6465b724f3d84ed3a3c87ed12c9","type":"GO_TERM","name":"notum cell fate specification","canonical_id":"go:GO:0035310","description":"\"The process in which a cell in the larval wing imaginal disc becomes capable of differentiating autonomously into a notum cell, if left in its normal environment.\" [PMID:10860999]","metadata":null},{"id":"f34b39321e8f4e0bb546d68f9b3ed587","type":"GO_TERM","name":"notum development","canonical_id":"go:GO:0007477","description":"\"The process whose specific outcome is the progression of the dorsal part of the body over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"c89efd6ad9264012aab46540e37be65a","type":"GO_TERM","name":"notum morphogenesis","canonical_id":"go:GO:0048802","description":"\"The process in which the anatomical structures of the dorsal part of the body are generated and organized.\" [GOC:jid]","metadata":null},{"id":"dae0bc9240f048af86ac635cfd0f774e","type":"GO_TERM","name":"novobiocin biosynthetic process","canonical_id":"go:GO:0043642","description":"\"The chemical reactions and pathways resulting in the formation of novobiocin, a coumarin antibiotic produced by the bacterium Gyrasestreptomyces spheroides, that acts by inhibiting DNA gyrase.\" [GOC:jl]","metadata":null},{"id":"da5fec4869f546a1957ae77d2de751c0","type":"GO_TERM","name":"novofumigatonin biosynthetic process","canonical_id":"go:GO:0140782","description":"\"The chemical reactions and pathways resulting in the formation of novofumigatonin, a heavily oxygenated meroterpenoid containing a unique orthoester moiety.\" [PMID:29968715]","metadata":null},{"id":"d95870bc03954b91afa874d226ec35cf","type":"GO_TERM","name":"npBAF complex","canonical_id":"go:GO:0071564","description":"\"A SWI/SNF-type complex that is found in neural stem or progenitor cells, and in human contains actin and proteins encoded by the ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A genes. The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells.\" [GOC:mah, GOC:ss, PMID:17640523]","metadata":null},{"id":"7ff1da6f89f346ecae9235e4835e82bd","type":"GO_TERM","name":"nuatigenin 3-beta-glucosyltransferase activity","canonical_id":"go:GO:0047248","description":"\"Catalysis of the reaction: nuatigenin + UDP-D-glucose = H+ + nuatigenin 3-beta-D-glucopyranoside + UDP.\" [EC:2.4.1.192, RHEA:19329]","metadata":null},{"id":"fa36feb7c70d4ab99b5a6066ecaab3cc","type":"GO_TERM","name":"nuclear DNA replication","canonical_id":"go:GO:0033260","description":"\"The DNA-dependent DNA replication that occurs in the nucleus of eukaryotic organisms as part of the cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"9da19e2847664c92973aeb98812bd29b","type":"GO_TERM","name":"nuclear DNA replication factor C complex","canonical_id":"go:GO:0043599","description":"\"A nuclear complex of five polypeptides that loads the DNA polymerase processivity factor proliferating cell nuclear antigen (PCNA) onto DNA, thereby permitting processive DNA synthesis catalyzed by DNA polymerase delta or epsilon. In Saccharomyces and several other species, the subunits are known as Rfc1p-Rfc5p, although subunit names do not necessarily correspond between different species.\" [GOC:mtg_sensu, PMID:14614842]","metadata":null},{"id":"37643e01dc274b2494db50b9b1e606f0","type":"GO_TERM","name":"nuclear DNA replication termination","canonical_id":"go:GO:1902317","description":"\"Any DNA replication termination that is involved in nuclear cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"6af4cdff9e614be89a42d03e67432362","type":"GO_TERM","name":"nuclear DNA-directed RNA polymerase complex","canonical_id":"go:GO:0055029","description":"\"A protein complex, located in the nucleus, that possesses DNA-directed RNA polymerase activity.\" [GOC:mtg_sensu]","metadata":null},{"id":"3c9a9f6373b14f2eb4a13f5438de0a74","type":"GO_TERM","name":"nuclear RNA export factor complex","canonical_id":"go:GO:0042272","description":"\"A protein complex that contains two proteins (know in several organisms, including Drosophila, as NXF1 and NXF2) and is required for the export of the majority of mRNAs from the nucleus to the cytoplasm; localized in the nucleoplasm and at both the nucleoplasmic and cytoplasmic faces of the nuclear pore complex; shuttles between the nucleus and the cytoplasm.\" [PMID:11780633]","metadata":null},{"id":"4a5e5ab7dd3f412f9a5317a056a41a97","type":"GO_TERM","name":"nuclear RNA surveillance","canonical_id":"go:GO:0071027","description":"\"A process that identifies and degrades defective or aberrant RNAs within the nucleus.\" [GOC:dgf, GOC:krc, PMID:18644474]","metadata":null},{"id":"78f80553dc8e45088e1e7358a2e6cb37","type":"GO_TERM","name":"nuclear RNA-directed RNA polymerase complex","canonical_id":"go:GO:0031380","description":"\"A complex required for RNAi mediated heterochromatin assembly. In S. pombe this contains RNA-directed RNA polymerase, a putative helicase and a protein containing a pap25 associated domain.\" [GOC:vw, PMID:15607976]","metadata":null},{"id":"5ba211b53d3f436d8d6602d10e7bcc3f","type":"GO_TERM","name":"nuclear SCF ubiquitin ligase complex","canonical_id":"go:GO:0043224","description":"\"A ubiquitin ligase complex, located in the nucleus, in which a cullin from the Cul1 subfamily and a RING domain protein form the catalytic core; substrate specificity is conferred by a Skp1 adaptor and an F-box protein. SCF complexes are involved in targeting proteins for degradation by the proteasome. The best characterized complexes are those from yeast and mammals (with core subunits named Cdc53/Cul1, Rbx1/Hrt1/Roc1).\" [PMID:15571813, PMID:15688063]","metadata":null},{"id":"03099ed0577c4d0bb194f07c754b62e2","type":"GO_TERM","name":"nuclear androgen receptor binding","canonical_id":"go:GO:0050681","description":"\"Binding to a nuclear androgen receptor.\" [GOC:ai]","metadata":null},{"id":"fbf385498a1f4eb9a4d8369a099cfbfc","type":"GO_TERM","name":"nuclear aryl hydrocarbon receptor complex","canonical_id":"go:GO:0034753","description":"\"An aryl hydrocarbon receptor (AhR) complex found in the nucleus; ; consists of ligand-bound AhR and the aryl hydrocarbon receptor nuclear translocator (ARNT).\" [PMID:7598497]","metadata":null},{"id":"4355e3088fc0407c96ba905575e9ee51","type":"GO_TERM","name":"nuclear axial expansion","canonical_id":"go:GO:0035191","description":"\"The stepwise asymmetric spreading out of nuclei internally along the anterior-posterior axis of the developing insect embryo during mitotic cycles 4 to 6. This movement leads to the distribution of nuclei in a hollow ellipsoid underlying the cortex.\" [PMID:8314839]","metadata":null},{"id":"c6ecc6dfb87543cbaa254530988ec85a","type":"GO_TERM","name":"nuclear body","canonical_id":"go:GO:0016604","description":"\"Membraneless organelle present in the nucleoplasm and usually visible by confocal microscopy.\" [PMID:28577509]","metadata":null},{"id":"b7655f240c2a40ee875c0d0363b48215","type":"GO_TERM","name":"nuclear body organization","canonical_id":"go:GO:0030575","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of any of the extra-nucleolar nuclear domains usually visualized by confocal microscopy and fluorescent antibodies to specific proteins.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"0bb948f8a1c64612870d540ee14edb3a","type":"GO_TERM","name":"nuclear cap binding complex","canonical_id":"go:GO:0005846","description":"\"A conserved heterodimeric protein complex that binds to the 5' terminal cap structure m7G(5')ppp(5')N of nascent eukaryotic RNA polymerase II transcripts such as pre-mRNA and U snRNA. The consists of proteins known as CBP20 and CBP80, binds to cap structures in the nucleus, and is involved in pre-mRNA splicing, 3'-end formation, and RNA nuclear export.\" [PMID:16043498]","metadata":null},{"id":"18f8252197054f3ab67ccfd8fc2bd0f4","type":"GO_TERM","name":"nuclear capsid assembly","canonical_id":"go:GO:0039708","description":"\"The assembly of a virus capsid that occurs in the nucleus. The assembly of large icosahedral shells for herpesviridae and adenoviridae requires structural proteins that act as chaperones for assembly.\" [VZ:1516]","metadata":null},{"id":"3f24a2b1da504854bfb551237c84444f","type":"GO_TERM","name":"nuclear cell cycle DNA replication initiation","canonical_id":"go:GO:1902315","description":"\"Any DNA replication initiation that is involved in nuclear cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"e2260c82c48c481aa2e6f19c29699208","type":"GO_TERM","name":"nuclear chromosome","canonical_id":"go:GO:0000228","description":"\"A chromosome that encodes the nuclear genome and is found in the nucleus of a eukaryotic cell during the cell cycle phases when the nucleus is intact.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"419e31a6880c40e7b17e421843007e71","type":"GO_TERM","name":"nuclear chromosome segregation","canonical_id":"go:GO:0098813","description":"\"The process in which genetic material, in the form of nuclear chromosomes, is organized into specific structures and then physically separated and apportioned to two or more sets. Nuclear chromosome segregation begins with the condensation of chromosomes, includes chromosome separation, and ends when chromosomes have completed movement to the spindle poles.\" [GOC:dos]","metadata":null},{"id":"8f4337b1d80f466c8cbfaecbfdef7477","type":"GO_TERM","name":"nuclear cortical migration","canonical_id":"go:GO:0035192","description":"\"The symmetric outward movement of the syncytial nuclei from their positions in the ellipsoid toward the periphery of the embryo, during mitotic cycles 8 and 9. This movement results in the placement of nuclei in a uniform monolayer at the cortex of the developing embryo.\" [PMID:8314839]","metadata":null},{"id":"539b4dde8f33408d83b7fc926c0002ae","type":"GO_TERM","name":"nuclear cortisol receptor activity","canonical_id":"go:GO:0031963","description":"\"A nuclear receptor activity regulated by cortisol binding and modulating the transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:mah, PMID:12511169]","metadata":null},{"id":"5b09dae4843943468ef162f5630e1b2f","type":"GO_TERM","name":"nuclear cortisol receptor binding","canonical_id":"go:GO:0031961","description":"\"Binding to a nuclear cortisol receptor.\" [GOC:mah, PMID:12511169]","metadata":null},{"id":"c2143da0e53541c0943b6015df6cf52f","type":"GO_TERM","name":"nuclear cyclin-dependent protein kinase holoenzyme complex","canonical_id":"go:GO:0019908","description":"\"Cyclin-dependent protein kinase (CDK) complex found in the nucleus.\" [GOC:krc]","metadata":null},{"id":"93904ee2fd7f4033a2054c31ac7bc2dd","type":"GO_TERM","name":"nuclear dicing body","canonical_id":"go:GO:0010445","description":"\"A small round nuclear body, measuring 0.2-0.8 microns in diameter that is diffusely distributed throughout the nucleoplasm. Several proteins known to be involved in miRNA processing have been localized to these structures. D-bodies are thought to be involved in primary-miRNA processing and/or storage/assembly of miRNA processing complexes.\" [PMID:17442570]","metadata":null},{"id":"7cd994a0879c486db290e62431f7f4fd","type":"GO_TERM","name":"nuclear dicing body assembly","canonical_id":"go:GO:1904258","description":"\"The aggregation, arrangement and bonding together of a set of components to form a nuclear dicing body.\" [GO_REF:0000079, GOC:TermGenie, PMID:25902521]","metadata":null},{"id":"9cc591fcbbc0440d891fbd84d957827f","type":"GO_TERM","name":"nuclear division","canonical_id":"go:GO:0000280","description":"\"The division of a cell nucleus into two nuclei, with DNA and other nuclear contents distributed between the daughter nuclei.\" [GOC:mah]","metadata":null},{"id":"6a5c4a00a6104d3cb5346ad46cad1af2","type":"GO_TERM","name":"nuclear envelope","canonical_id":"go:GO:0005635","description":"\"The double lipid bilayer that encloses the nucleus, separating its contents from the cytoplasm. It consists of an inner and outer nuclear membrane, with an intermembrane space (20-40 nm wide, also called the perinuclear space) between them. The envelope is supported by the nuclear lamina and contains nuclear pore complexes, which regulate molecular transport.\" [ISBN:0198547684, PMID:16164970]","metadata":null},{"id":"f33a8a28e3dc4e3586bcb99f18b43afe","type":"GO_TERM","name":"nuclear envelope adjacent to nuclear pore complex","canonical_id":"go:GO:0120321","description":"\"The region of the nuclear envelope situated in close proximity to a nuclear pore complex.\" [GOC:mah, PMID:21802294, PMID:24184107]","metadata":null},{"id":"bb8a670466754bf8b667dfa6f7021495","type":"GO_TERM","name":"nuclear envelope budding","canonical_id":"go:GO:0140591","description":"\"The process by which large macromolecular complexes are budded through the inner nuclear membrane, into the perinuclear space, thus acquiring a membrane envelope. The enveloped particle fuses with the outer nuclear membrane and is released into the cytoplasm.\" [PMID:27236823, PMID:32503943]","metadata":null},{"id":"30d3f6c6c1e34e53a985c2af76f3ff27","type":"GO_TERM","name":"nuclear envelope lumen","canonical_id":"go:GO:0005641","description":"\"The region between the two lipid bilayers of the nuclear envelope; 20-40 nm wide.\" [GOC:ai]","metadata":null},{"id":"2ac4a7cfba2743f083dd1092599f567a","type":"GO_TERM","name":"nuclear envelope organization","canonical_id":"go:GO:0006998","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear envelope.\" [GOC:dph, GOC:ems, GOC:jl, GOC:mah]","metadata":null},{"id":"c6602f8802bb4f148a65bee47322a58b","type":"GO_TERM","name":"nuclear estrogen receptor activity","canonical_id":"go:GO:0030284","description":"\"A nuclear receptor activity regulated by estrogen binding and modulating the transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:signaling, PMID:17615392]","metadata":null},{"id":"a10c07f55bfc4757ad068514a030d96b","type":"GO_TERM","name":"nuclear estrogen receptor binding","canonical_id":"go:GO:0030331","description":"\"Binding to a nuclear estrogen receptor.\" [GOC:ai]","metadata":null},{"id":"1fcb74b73f454788b53ee057f702e69b","type":"GO_TERM","name":"nuclear exosome (RNase complex)","canonical_id":"go:GO:0000176","description":"\"A ribonuclease complex that has 3-prime to 5-prime processive and distributive hydrolytic exoribonuclease activity and endoribonuclease activity, producing 5-prime-phosphomonoesters. Participates in a multitude of cellular RNA processing and degradation events preventing nuclear export and/or translation of aberrant RNAs. Restricted to processing linear and circular single-stranded RNAs (ssRNA) only. RNAs with complex secondary structures may have to be unwound or pre-processed by co-factors prior to entering the complex, esp if the 3-prime end is structured.\" [PMID:17174896, PMID:20531386, PMID:26726035]","metadata":null},{"id":"b3cdd2f462ea42c59fec87e625c35329","type":"GO_TERM","name":"nuclear exosome focus","canonical_id":"go:GO:1990251","description":"\"An nuclear body involved in nuclear mRNA surveilllance. Contains at least Mmi1, or an ortholog of it, and the nuclear exosome.\" [GOC:al, GOC:vw, PMID:16823445, PMID:23980030, PMID:32012158]","metadata":null},{"id":"0831f71d2b98444598951cd233e4cbc5","type":"GO_TERM","name":"nuclear exosome targeting complex","canonical_id":"go:GO:0062141","description":"\"A protein-containing complex that functions with the RNA exosome and contributes to the degradation of abberant transcripts.\" [PMID:21855801, PMID:29844170]","metadata":null},{"id":"558ea539ce6d45a0a36eae6c0fb764e0","type":"GO_TERM","name":"nuclear export","canonical_id":"go:GO:0051168","description":"\"The directed movement of substances out of the nucleus.\" [GOC:ai]","metadata":null},{"id":"90cdf052bbbd47f5bb60553c5a28c041","type":"GO_TERM","name":"nuclear export signal receptor activity","canonical_id":"go:GO:0005049","description":"\"Combining with a nuclear export signal (NES) on a cargo to be transported, to mediate transport of a the cargo through the nuclear pore, from the nuclear lumen to the cytoplasm. The cargo can be either a RNA or a protein.\" [GOC:bf, GOC:mah, GOC:pg, GOC:vw, PMID:11743003, PMID:25802992, PMID:28713609, Wikipedia:Nuclear_transport]","metadata":null},{"id":"5d014741692d459eb6640873cbac02af","type":"GO_TERM","name":"nuclear fragmentation involved in apoptotic nuclear change","canonical_id":"go:GO:0030264","description":"\"The breakdown of the nucleus into small membrane-bounded compartments, or blebs, each of which contain compacted DNA.\" [GOC:dph, GOC:mah, GOC:mtg_apoptosis, GOC:tb, ISBN:0721639976]","metadata":null},{"id":"72f58b21617d408893e5e550de8b14f2","type":"GO_TERM","name":"nuclear glucocorticoid receptor activity","canonical_id":"go:GO:0004883","description":"\"A nuclear receptor activity regulated by glucocorticoid binding and modulating the transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:signaling, PMID:17689856, PMID:20920967]","metadata":null},{"id":"856d2cb567af40a892acd950c1969bcf","type":"GO_TERM","name":"nuclear glucocorticoid receptor binding","canonical_id":"go:GO:0035259","description":"\"Binding to a nuclear glucocorticoid receptor.\" [GOC:bf]","metadata":null},{"id":"c197094f39ab464389a915d125743c64","type":"GO_TERM","name":"nuclear histone mRNA catabolic process","canonical_id":"go:GO:0071045","description":"\"The chemical reactions and pathways resulting in the breakdown of histone messenger RNA (mRNA) within the nucleus.\" [GOC:dgf, GOC:krc, PMID:17179095, PMID:17855393]","metadata":null},{"id":"372a90775a00450ba106640f04f2f45a","type":"GO_TERM","name":"nuclear import signal receptor activity","canonical_id":"go:GO:0061608","description":"\"Combining with a nuclear import signal (NIS) on a cargo to be transported, to mediate transport of the cargo through the nuclear pore, from the cytoplasm to the nuclear lumen. The cargo can be either a RNA or a protein.\" [GOC:dph, GOC:pg, GOC:vw, PMID:28713609, Wikipedia:Nuclear_transport]","metadata":null},{"id":"0f34429cd3564c989754c097893a1a97","type":"GO_TERM","name":"nuclear inclusion body","canonical_id":"go:GO:0042405","description":"\"An intranuclear focus at which aggregated proteins have been sequestered.\" [GOC:jl]","metadata":null},{"id":"68fcda2efa734d879c00272c6ae9efec","type":"GO_TERM","name":"nuclear inner membrane","canonical_id":"go:GO:0005637","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the nuclear envelope.\" [GOC:ma]","metadata":null},{"id":"76f2fd7efeaf468fb6ab532dac01a262","type":"GO_TERM","name":"nuclear inner membrane organization","canonical_id":"go:GO:0071765","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear inner membrane.\" [GOC:mah]","metadata":null},{"id":"c54677a3889a46ff84e7463f9cb18f3f","type":"GO_TERM","name":"nuclear lamina","canonical_id":"go:GO:0005652","description":"\"The fibrous, electron-dense layer lying on the nucleoplasmic side of the inner membrane of a cell nucleus, composed of lamin filaments. The polypeptides of the lamina are thought to be concerned in the dissolution of the nuclear envelope and its re-formation during mitosis. The lamina is composed of lamin A and lamin C filaments cross-linked into an orthogonal lattice, which is attached via lamin B to the inner nuclear membrane through interactions with a lamin B receptor, an IFAP, in the membrane.\" [ISBN:0198506732, ISBN:0716731363]","metadata":null},{"id":"d2d60437bd394d568cadb99da43fc377","type":"GO_TERM","name":"nuclear lncRNA surveillance","canonical_id":"go:GO:0180036","description":"\"A process that identifies and degrades defective or aberrant lncRNAs within the nucleus.\" [GOC:vw]","metadata":null},{"id":"14abc2cafda54a54b7cc4d5d8dd33473","type":"GO_TERM","name":"nuclear lumen","canonical_id":"go:GO:0031981","description":"\"The volume enclosed by the nuclear inner membrane.\" [GOC:mah, GOC:pz]","metadata":null},{"id":"5c039f23175e4b8bb8a3fba4d49f3cc5","type":"GO_TERM","name":"nuclear mRNA surveillance","canonical_id":"go:GO:0071028","description":"\"A process that identifies and degrades defective or aberrant mRNAs within the nucleus.\" [GOC:dgf, GOC:krc, PMID:11586364, PMID:12417728, PMID:14718167, PMID:18644474]","metadata":null},{"id":"4c838c4422f44c1d897e421e0a17e83b","type":"GO_TERM","name":"nuclear mRNA surveillance of mRNA 3'-end processing","canonical_id":"go:GO:0071031","description":"\"The set of processes involved in identifying and degrading mRNAs with incorrectly formed 3'-ends within the nucleus.\" [GOC:dgf, GOC:krc, PMID:18644474]","metadata":null},{"id":"a0660df70f184516acc8902405f2c342","type":"GO_TERM","name":"nuclear mRNA surveillance of mRNP export","canonical_id":"go:GO:0071032","description":"\"The set of processes involved in identifying and degrading incorrectly formed or aberrant nuclear mRNPs docked at the nuclear pore complex prior to export to the cytoplasm.\" [GOC:dgf, GOC:krc, PMID:18644474]","metadata":null},{"id":"1874716aa3a24680988050bd51d15347","type":"GO_TERM","name":"nuclear mRNA surveillance of meiosis-specific transcripts","canonical_id":"go:GO:0033621","description":"\"The chemical reactions and pathways resulting in the selective degradation of meiosis-specific transcripts during vegetative growth, by a mechanism that requires determinant of selective removal (DSR) sequences in the targeted mRNAs and involves a YTH family protein.\" [PMID:16823445]","metadata":null},{"id":"49aeeef41310470c876de9c64064d7b1","type":"GO_TERM","name":"nuclear mRNA surveillance of spliceosomal pre-mRNA splicing","canonical_id":"go:GO:0071030","description":"\"The set of processes involved in identifying and degrading incorrectly spliced pre-mRNAs within the nucleus.\" [GOC:dgf, GOC:krc, PMID:18644474]","metadata":null},{"id":"b1eb9c2f17a94cf2b313dbd554072afe","type":"GO_TERM","name":"nuclear matrix","canonical_id":"go:GO:0016363","description":"\"A dynamic, proteinaceous framework within the nucleus of eukaryotic cells, composed of proteins and RNA, that provides structural support for chromatin organization, gene regulation, and nuclear processes.\" [PMID:15608168, PMID:3058729, PMID:39789220]","metadata":null},{"id":"a797cedbb9d6422a8be1f0e699e37aa7","type":"GO_TERM","name":"nuclear matrix anchoring at nuclear membrane","canonical_id":"go:GO:0090292","description":"\"The process in which the nuclear matrix, the dense fibrillar network lying on the inner side of the nuclear membrane, is directly or indirectly linked to the nuclear membrane.\" [GOC:tb]","metadata":null},{"id":"4f1419608ce34d9296b39578bd72127e","type":"GO_TERM","name":"nuclear matrix organization","canonical_id":"go:GO:0043578","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear matrix, the dense fibrillar network lying on the inner side of the nuclear membrane.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"c1099f7143c3401f9cd9d44c51a1af62","type":"GO_TERM","name":"nuclear membrane","canonical_id":"go:GO:0031965","description":"\"Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space.\" [GOC:mah, GOC:pz]","metadata":null},{"id":"9a52d9714f2241ef9329d86aa51a1f77","type":"GO_TERM","name":"nuclear membrane biogenesis","canonical_id":"go:GO:0101025","description":"\"The process in which a nuclear membrane is synthesized, aggregates, and bonds together.\" [GOC:vw]","metadata":null},{"id":"ca23425429cf467c8db315caa6daa26d","type":"GO_TERM","name":"nuclear membrane complex Bqt3-Bqt4","canonical_id":"go:GO:1990862","description":"\"A protein complex that resides in the inner nuclear membrane and anchors telomeres to the nuclear envelope. In fission yeast, it is composed of Bqt3 and Bqt4.\" [PMID:19948484]","metadata":null},{"id":"d2635ef3db6a42d29b14084a1062418b","type":"GO_TERM","name":"nuclear membrane disassembly","canonical_id":"go:GO:0051081","description":"\"The controlled breakdown of the nuclear membranes, for example during cellular division.\" [GOC:ai]","metadata":null},{"id":"5946616ae9084de69bae125e187b1850","type":"GO_TERM","name":"nuclear membrane fusion","canonical_id":"go:GO:0000740","description":"\"The joining of 2 or more lipid bilayer membranes that surround the nucleus.\" [GOC:elh]","metadata":null},{"id":"343c43e1088543059d8c4ec6079116c3","type":"GO_TERM","name":"nuclear membrane fusion involved in karyogamy","canonical_id":"go:GO:0048288","description":"\"The joining of 2 or more lipid bilayer membranes that surround the nucleus during the creation of a single nucleus from multiple nuclei.\" [GOC:jid]","metadata":null},{"id":"8f44837080e64e409f5e88c30f4a66f9","type":"GO_TERM","name":"nuclear membrane microtubule tethering complex","canonical_id":"go:GO:0106094","description":"\"A nuclear membrane protein complex which connects the nuclear outer and inner membranes together, and links thereby links the nuclear lumen to cytoplasmic microtubules.\" [GOC:vw, PMID:19225124]","metadata":null},{"id":"26cee36122f6494a834c5c724d220327","type":"GO_TERM","name":"nuclear membrane organization","canonical_id":"go:GO:0071763","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear inner or outer membrane.\" [GOC:mah]","metadata":null},{"id":"6a4ab06a52f243759d51b2b9158edaf7","type":"GO_TERM","name":"nuclear membrane protein complex","canonical_id":"go:GO:0106083","description":"\"Any protein complex that is part of the nuclear membrane.\" [GOC:lnp, PMID:28356353]","metadata":null},{"id":"a6af76b5f47e47a68ce99be379db5052","type":"GO_TERM","name":"nuclear membrane reassembly","canonical_id":"go:GO:0031468","description":"\"The reformation of the nuclear membranes following their breakdown in the context of a normal process.\" [GOC:mah]","metadata":null},{"id":"c365898be04d4c57aaf5d6a197f57d5d","type":"GO_TERM","name":"nuclear microtubule","canonical_id":"go:GO:0005880","description":"\"Any microtubule in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"8d958b1178d845a8a7e8f7bc93e4effd","type":"GO_TERM","name":"nuclear migration","canonical_id":"go:GO:0007097","description":"\"The directed movement of the nucleus to a specific location within a cell.\" [GOC:ai]","metadata":null},{"id":"2fc298105d574d608b946bdc6f334332","type":"GO_TERM","name":"nuclear migration along microfilament","canonical_id":"go:GO:0031022","description":"\"The directed movement of the nucleus along microfilaments within the cell, mediated by motor proteins.\" [GOC:mah]","metadata":null},{"id":"97e33bbdee6048a3af40a603659abf11","type":"GO_TERM","name":"nuclear migration along microtubule","canonical_id":"go:GO:0030473","description":"\"The directed movement of the nucleus along microtubules within the cell, mediated by motor proteins.\" [GOC:mah, GOC:sgd_curators]","metadata":null},{"id":"24e17f723385441fa877fb0b6beb5168","type":"GO_TERM","name":"nuclear migration by microtubule mediated pushing forces","canonical_id":"go:GO:0098863","description":"\"The directed movement of the nucleus by pushing forces exerted by polymerization of backward-extending microtubules.\" [GOC:vw, PMID:11309419, PMID:16611238]","metadata":null},{"id":"4e0e6e4fda5e4dd1bfbb638790a0b7fc","type":"GO_TERM","name":"nuclear migration during mitotic telophase","canonical_id":"go:GO:0090561","description":"\"The dynein-driven microtubule based nuclear migration, whereby daughter nuclei are positioned away from the cell division site prior to cytokinesis.\" [GOC:vw, PMID:23087209]","metadata":null},{"id":"1ee0abd3d3904e6e964080053fd0053e","type":"GO_TERM","name":"nuclear migration involved in conjugation with cellular fusion","canonical_id":"go:GO:0000743","description":"\"The microtubule-based movement of nuclei towards one another as a prelude to karyogamy in organisms undergoing conjugation with cellular fusion.\" [GOC:clt, GOC:vw, PMID:16380440]","metadata":null},{"id":"5d9d2cde1c364a8595cca7450f9b13d5","type":"GO_TERM","name":"nuclear migration to embryo sac poles","canonical_id":"go:GO:0023002","description":"\"Migration of the nuclei of the two-nucleate embryo sac to opposite poles of the cell.\" [GOC:jid, GOC:mtg_plant, ISBN:047186840X]","metadata":null},{"id":"0b4842b2125f48ed8a4d434cd1a923e1","type":"GO_TERM","name":"nuclear migration to the embryo sac center","canonical_id":"go:GO:0023003","description":"\"Migration of one of the four nuclei at each pole of the eight-nucleate embryo sac, to the center of the cell.\" [GOC:jid, GOC:mtg_plant, ISBN:047186840X]","metadata":null},{"id":"4da019a0800a4b14b2753e3e5786eccf","type":"GO_TERM","name":"nuclear mineralocorticoid receptor binding","canonical_id":"go:GO:0031962","description":"\"Binding to a nuclear mineralocorticoid receptor.\" [GOC:mah, PMID:12511169]","metadata":null},{"id":"3b5486bc18c8489fa5deb10c51258471","type":"GO_TERM","name":"nuclear origin of replication recognition complex","canonical_id":"go:GO:0005664","description":"\"A multisubunit complex that is located at the replication origins of a chromosome in the nucleus.\" [GOC:elh]","metadata":null},{"id":"8d57944b468743d9b82931f142e40c82","type":"GO_TERM","name":"nuclear outer membrane","canonical_id":"go:GO:0005640","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the nuclear envelope; continuous with the endoplasmic reticulum of the cell and sometimes studded with ribosomes.\" [ISBN:0198547684]","metadata":null},{"id":"73b2d48ec8314f8caf437737b701baea","type":"GO_TERM","name":"nuclear outer membrane organization","canonical_id":"go:GO:0071764","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear outer membrane.\" [GOC:mah]","metadata":null},{"id":"4424d14ac527483aa6218fde848cb5df","type":"GO_TERM","name":"nuclear outer membrane-endoplasmic reticulum membrane network","canonical_id":"go:GO:0042175","description":"\"The continuous network of membranes encompassing the nuclear outer membrane and the endoplasmic reticulum membrane.\" [GOC:bf, GOC:jl, GOC:mah, GOC:mcc, GOC:pr, GOC:vw]","metadata":null},{"id":"f3c1e44afc3f49ebb6ff04891c407307","type":"GO_TERM","name":"nuclear periphery","canonical_id":"go:GO:0034399","description":"\"The portion of the nuclear lumen proximal to the inner nuclear membrane.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"dbb9353955734ef298d64817ade1fb09","type":"GO_TERM","name":"nuclear polyadenylation-dependent CUT catabolic process","canonical_id":"go:GO:0071039","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of a cryptic unstable transcript (CUT), initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target CUT.\" [GOC:dgf, GOC:krc, PMID:15935759, PMID:16973436, PMID:16973437, PMID:18007593, PMID:18591258]","metadata":null},{"id":"622b47105e174b3f9f6a15d05fcb5cea","type":"GO_TERM","name":"nuclear polyadenylation-dependent antisense transcript catabolic process","canonical_id":"go:GO:0071040","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of an antisense transcript, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target antisense transcript.\" [GOC:dgf, GOC:krc, PMID:18022365]","metadata":null},{"id":"68e3865a97ca45a78eb289b473e14f62","type":"GO_TERM","name":"nuclear polyadenylation-dependent mRNA catabolic process","canonical_id":"go:GO:0071042","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of a messenger RNA (mRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target mRNA.\" [GOC:dgf, GOC:krc, PMID:15145828, PMID:15828860, PMID:16431988, PMID:17643380, PMID:18000032, PMID:18644474]","metadata":null},{"id":"79d6741fa8f74902bdd8b63e7ea126e2","type":"GO_TERM","name":"nuclear polyadenylation-dependent ncRNA catabolic process","canonical_id":"go:GO:0071046","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of a noncoding RNA (ncRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target ncRNA.\" [GOC:dgf, GOC:jl, GOC:krc, PMID:17410208]","metadata":null},{"id":"6658fed06c244dc7bd10c11af406f979","type":"GO_TERM","name":"nuclear polyadenylation-dependent rRNA catabolic process","canonical_id":"go:GO:0071035","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of a ribosomal RNA (rRNA) molecule, including RNA fragments released as part of processing the primary transcript into multiple mature rRNA species, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target rRNA.\" [GOC:dgf, GOC:krc, PMID:15173578, PMID:15572680, PMID:15935758, PMID:17652137, PMID:18591258]","metadata":null},{"id":"1235002d22c14477aa284e81522a7970","type":"GO_TERM","name":"nuclear polyadenylation-dependent snRNA catabolic process","canonical_id":"go:GO:0071037","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of a small nuclear RNA (snRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target snRNA.\" [GOC:dgf, GOC:krc]","metadata":null},{"id":"3b4f5a2284974cc99faeddcf3aab5e7b","type":"GO_TERM","name":"nuclear polyadenylation-dependent snoRNA catabolic process","canonical_id":"go:GO:0071036","description":"\"The chemical reactions and pathways occurring in the nucleus and resulting in the breakdown of a small nucleolar RNA (snoRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target snoRNA.\" [GOC:dgf, GOC:krc, PMID:15935758]","metadata":null},{"id":"0e126f2958354968bb61548f1ac0e0c7","type":"GO_TERM","name":"nuclear pore","canonical_id":"go:GO:0005643","description":"\"A protein complex providing a discrete opening in the nuclear envelope of a eukaryotic cell, where the inner and outer nuclear membranes are joined.\" [ISBN:0198547684]","metadata":null},{"id":"0f8a427590bf433bb83ef0ac65e3d4cd","type":"GO_TERM","name":"nuclear pore central transport channel","canonical_id":"go:GO:0044613","description":"\"The central substructure of the nuclear pore complex (NPC), through which nucleocytoplasmic transport of RNAs, proteins and small molecules occurs. The central transport channel is filled with FG-nucleoporins, which form a selective barrier and provide a series of binding sites for transporter proteins. Characterized S. cerevisiae FG-nucleoporins include Nup159p, Nup145Np, Nup116p, Nup100p, Nsp1p, Nup57p, Nup49p, Nup42p, Nup53p, Nup59p/Asm4p, Nup60p and Nup1. Characterized vertebrate FG-nucleoporins include Nup214, Nup98, Nup62, Nup54, Nup58/45, NLP1, and Nup153.\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"60801f847aa54dceb5de24bb938b2b03","type":"GO_TERM","name":"nuclear pore complex assembly","canonical_id":"go:GO:0051292","description":"\"The aggregation, arrangement and bonding together of a set of components to form a nuclear pore complex.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"809b45f03cf64820aac136f00a0bff5a","type":"GO_TERM","name":"nuclear pore cytoplasmic filaments","canonical_id":"go:GO:0044614","description":"\"Filamentous extensions on cytoplasmic face of the nuclear pore complex (NPC). In S. cerevisiae, Nup159p, Nup82p, and Nup42p contribute to the cytoplasmic filaments. In vertebrates, Nup358 is a major component.\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"c2c9958f6ed34d0e8506a14b8f6a8d13","type":"GO_TERM","name":"nuclear pore inner ring","canonical_id":"go:GO:0044611","description":"\"A subcomplex of the nuclear pore complex (NPC) that forms the inner rings of the core scaffold, a lattice-like structure that gives the NPC its shape and strength. In S. cerevisiae, the two inner rings are each composed of Nup192p, Nup188p, Nup170p and Nup157p. In vertebrates, the two inner rings are each composed of Nup205, Nup188 and Nup155. Components are arranged in 8-fold symmetrical 'spokes' around the central transport channel. A single 'spoke', can be isolated and is sometimes referred to as the Nup170 complex.\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"660e29353d3e40158830e04ed6da351c","type":"GO_TERM","name":"nuclear pore linkers","canonical_id":"go:GO:0044612","description":"\"A substructure of the nuclear pore complex (NPC) that serves to connect members of the central transport channel (composed of FG-nucleoporins) to the core scaffold (composed of the inner and outer NPC rings). In S. cerevisiae, the linkers are Nic96p and Nup82p. In vertebrates, they are Nup93 and Nup88. Components are arranged in 8-fold symmetrical 'spokes' around the central transport channel. Both linkers can be isolated in association with specific FG-nucleoporins, complexes that are sometimes referred to as the Nic96 complex (Nic96p-Nsp1p-Nup49p-Nup57p) and the Nup82 complex (Nup82p-Nup116p-Nup159p-Gle2p).\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"3a75f8dc38e54411b36e7671c1a28458","type":"GO_TERM","name":"nuclear pore localization","canonical_id":"go:GO:0051664","description":"\"Any process in which nuclear pores are transported to, or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"74c282dadddc4d93affab1a351c6ca1d","type":"GO_TERM","name":"nuclear pore nuclear basket","canonical_id":"go:GO:0044615","description":"\"A filamentous, cage-like assembly on the nuclear face of the nuclear pore complex (NPC). In S. cerevisiae, Mlp1p and Mlp2p are two major components of the NPC nuclear basket. In vertebrates, Tpr is a major component.\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"bd5e7fdc85ca46a0907d00cd26f9493b","type":"GO_TERM","name":"nuclear pore organization","canonical_id":"go:GO:0006999","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear pore.\" [GOC:dph, GOC:jid, GOC:jl, GOC:mah]","metadata":null},{"id":"d3014a0956db4c3ea347d47ff81a5b7a","type":"GO_TERM","name":"nuclear pore outer ring","canonical_id":"go:GO:0031080","description":"\"A subcomplex of the nuclear pore complex (NPC) that forms the outer rings of the core scaffold, a lattice-like structure that gives the NPC its shape and strength. In S. cerevisiae, the two outer rings each contain multiple copies of the following proteins: Nup133p, Nup120p, Nup145Cp, Nup85p, Nup84p, Seh1p, and Sec13p. In vertebrates, the two outer rings each contain multiple copies of the following proteins: Nup133, Nup160, Nup96, Nup75, Nup107, Seh1, Sec13, Nup43, Nup37, and ALADIN. Components are arranged in 8-fold symmetrical 'spokes' around the central transport channel. A single 'spoke', can be isolated and is sometimes referred to as the Nup84 complex (S. cerevisiae) or the Nup107-160 complex (vertebrates).\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"64e11fb432b64f7caf87c2f807bca905","type":"GO_TERM","name":"nuclear pore transmembrane ring","canonical_id":"go:GO:0070762","description":"\"A subcomplex of the nuclear pore complex (NPC) that spans the nuclear membrane and anchors the NPC to the nuclear envelope. In S. cerevisiae, the transmembrane ring is composed of Pom152p, Pom34p, and Ndc1p. In vertebrates, it is composed of Gp210, Ndc1, and Pom121. Components are arranged in 8-fold symmetrical 'spokes' around the central transport channel. A single 'spoke', can be isolated and is sometime referred to as the Ndc1 complex.\" [GOC:dgf, PMID:18046406, PMID:19524430, PMID:20947011, PMID:22419078]","metadata":null},{"id":"6c8a5851e5694cc1824122f70fc7a19a","type":"GO_TERM","name":"nuclear pre-replicative complex","canonical_id":"go:GO:0005656","description":"\"A protein-DNA complex assembled at eukaryotic DNA replication origins during late mitosis and G1, allowing the origin to become competent, or 'licensed', for replication. The complex normally includes the origin recognition complex (ORC), Cdc6, Cdt1 and the MiniChromosome Maintenance (Mcm2-7) proteins.\" [PMID:15222894]","metadata":null},{"id":"bec91402a8fa4bcaaa2116d09b65bba1","type":"GO_TERM","name":"nuclear progesterone receptor binding","canonical_id":"go:GO:0033142","description":"\"Binding to a nuclear progesterone receptor.\" [GOC:mah]","metadata":null},{"id":"8799b9284e124583969482312d0dc08b","type":"GO_TERM","name":"nuclear proteasome complex","canonical_id":"go:GO:0031595","description":"\"A proteasome found in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"6f5cbf86301b447d9e82722b6506f598","type":"GO_TERM","name":"nuclear proteasome core complex","canonical_id":"go:GO:0031601","description":"\"The core complex of a proteasome located in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"80da090ba2de41558ec5fbf465222e4a","type":"GO_TERM","name":"nuclear proteasome core complex, alpha-subunit complex","canonical_id":"go:GO:0031604","description":"\"The subunits forming the outer ring of the core complex of a proteasome located in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"e9ad9252153447e18d542905f77fd6b1","type":"GO_TERM","name":"nuclear proteasome core complex, beta-subunit complex","canonical_id":"go:GO:0031607","description":"\"The subunits forming the inner ring of the core complex of a proteasome located in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"4d7efa6867844e59b69ef3c617a2cef0","type":"GO_TERM","name":"nuclear proteasome regulatory particle","canonical_id":"go:GO:0031598","description":"\"The regulatory subcomplex of a proteasome located in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"582411d173b9440ba9f1d6eaf8737364","type":"GO_TERM","name":"nuclear proteasome regulatory particle, base subcomplex","canonical_id":"go:GO:0031610","description":"\"The subunits of the regulatory particle that directly associate with the core complex of a proteasome located in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"850598540eb14b4cab8826ed8b8dcc25","type":"GO_TERM","name":"nuclear proteasome regulatory particle, lid subcomplex","canonical_id":"go:GO:0031613","description":"\"The subunits that form the peripheral lid of the regulatory particle of a proteasome located in the nucleus of a cell.\" [GOC:mah]","metadata":null},{"id":"ffa81e1271564ec989bb5b676ecab757","type":"GO_TERM","name":"nuclear protein quality control by the ubiquitin-proteasome system","canonical_id":"go:GO:0071630","description":"\"A protein quality control pathway that results in the breakdown of misfolded, damaged or unassembled proteins via a mechanism in which the proteins are ubiquitinated, and then targeted to nuclear proteasomes for degradation.\" [PMID:20080635, PMID:21211726]","metadata":null},{"id":"fc3f4e1a99924ac28a53e9aabca826df","type":"GO_TERM","name":"nuclear protein-containing complex","canonical_id":"go:GO:0140513","description":"\"A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together in the nucleus.\" [GOC:pg]","metadata":null},{"id":"328595d17f0745c1959f11e4cfa412bc","type":"GO_TERM","name":"nuclear receptor activity","canonical_id":"go:GO:0004879","description":"\"A DNA-binding transcription factor activity regulated by binding to a ligand that modulates the transcription of specific gene sets transcribed by RNA polymerase II. Nuclear receptor ligands are usually lipid-based (such as a steroid hormone) and the binding of the ligand to its receptor often occurs in the cytosol, which leads to its translocation to the nucleus.\" [GOC:txnOH-2018, PMID:23457262]","metadata":null},{"id":"e643b77c66ee494f8f46e712191801dc","type":"GO_TERM","name":"nuclear receptor binding","canonical_id":"go:GO:0016922","description":"\"Binding to a nuclear receptor protein. Nuclear receptor proteins are DNA-binding transcription factors which are regulated by binding to a ligand.\" [PMID:7776974]","metadata":null},{"id":"eeb2654b57ff4c6aadf5fd843866180b","type":"GO_TERM","name":"nuclear receptor-mediated bile acid signaling pathway","canonical_id":"go:GO:0038185","description":"\"A nuclear receptor-mediated signaling pathway initiated by a bile acid binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:10334992, PMID:36409000]","metadata":null},{"id":"e316c9c69ec24c92aa9127c7f733f523","type":"GO_TERM","name":"nuclear receptor-mediated corticosteroid signaling pathway","canonical_id":"go:GO:0031958","description":"\"A nuclear receptor-mediated signaling pathway initiated by a corticosteroid binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:11027914, PMID:12606724]","metadata":null},{"id":"66012baa35a149d9912519bef8221c61","type":"GO_TERM","name":"nuclear receptor-mediated glucocorticoid signaling pathway","canonical_id":"go:GO:0042921","description":"\"A nuclear receptor-mediated signaling pathway initiated by a glucocorticoid binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:15240347]","metadata":null},{"id":"5b43ee1c5105464f9389f5683a44e5ef","type":"GO_TERM","name":"nuclear receptor-mediated mineralocorticoid signaling pathway","canonical_id":"go:GO:0031959","description":"\"A nuclear receptor-mediated signaling pathway initiated by a mineralocorticoid binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:11027914, PMID:12606724, PMID:15240347]","metadata":null},{"id":"71b6694b929742e38bd64e2e526c937a","type":"GO_TERM","name":"nuclear receptor-mediated signaling pathway","canonical_id":"go:GO:0141193","description":"\"The series of molecular signals initiated by a signaling molecule binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:25614732]","metadata":null},{"id":"50bd2bdf5833442c8dd25824f969a32f","type":"GO_TERM","name":"nuclear receptor-mediated steroid hormone signaling pathway","canonical_id":"go:GO:0030518","description":"\"A nuclear receptor-mediated signaling pathway initiated by a steroid binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"c1036f0158e54e099bd64812933dba0c","type":"GO_TERM","name":"nuclear replication fork","canonical_id":"go:GO:0043596","description":"\"The Y-shaped region of a nuclear replicating DNA molecule, resulting from the separation of the DNA strands and in which the synthesis of new strands takes place. Also includes associated protein complexes.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"fb53fe8714a84c65a60cf63d04f71b82","type":"GO_TERM","name":"nuclear replisome","canonical_id":"go:GO:0043601","description":"\"A multi-component enzymatic machine at the nuclear replication fork, which mediates DNA replication. Includes DNA primase, one or more DNA polymerases, DNA helicases, and other proteins.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"7a718a79d94341eabc9f78e42351ce31","type":"GO_TERM","name":"nuclear retinoic acid receptor binding","canonical_id":"go:GO:0042974","description":"\"Binding to a nuclear retinoic acid receptor, a ligand-regulated transcription factor belonging to the nuclear receptor superfamily.\" [GOC:jl, PMID:12476796]","metadata":null},{"id":"a8009ca0a8b3461eaa6de4ac2da778b5","type":"GO_TERM","name":"nuclear retinoid X receptor binding","canonical_id":"go:GO:0046965","description":"\"Binding to a nuclear retinoid X receptor.\" [GOC:ai]","metadata":null},{"id":"b3755e5649604ad08701473f6feda57d","type":"GO_TERM","name":"nuclear ribonucleoprotein granule","canonical_id":"go:GO:0140168","description":"\"A ribonucleoprotein granule located in the nucleus.\" [PMID:32475683, PMID:35355287, PMID:37890457]","metadata":null},{"id":"b3da19b6e7124c3794bce431f5a1de93","type":"GO_TERM","name":"nuclear speck","canonical_id":"go:GO:0016607","description":"\"A discrete extra-nucleolar subnuclear domain, 20-50 in number, in which splicing factors are seen to be localized by immunofluorescence microscopy.\" [PMID:28977640]","metadata":null},{"id":"df4b6a4cbaab4399b28c7276204a9214","type":"GO_TERM","name":"nuclear speck organization","canonical_id":"go:GO:0035063","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of nuclear specks, a class of nuclear body in which splicing factors are localized.\" [GOC:bf, GOC:curators]","metadata":null},{"id":"3d33075d19514c80b74fe26571fbbb30","type":"GO_TERM","name":"nuclear steroid receptor activity","canonical_id":"go:GO:0003707","description":"\"A nuclear receptor activity regulated by steroid binding and modulating the transcription of specific gene sets transcribed by RNA polymerase II.\" [GOC:signaling, PMID:14708019]","metadata":null},{"id":"44a3817441f74d469933f0cfd4a1f930","type":"GO_TERM","name":"nuclear stress granule","canonical_id":"go:GO:0097165","description":"\"A dense aggregation in the nucleus composed of proteins and RNAs that appear when the cell is under stress.\" [GOC:ans, PMID:10359787, PMID:12865437]","metadata":null},{"id":"1ba298647c544e06bdf46607a49bfc79","type":"GO_TERM","name":"nuclear telomere cap complex","canonical_id":"go:GO:0000783","description":"\"A complex of DNA and protein located at the end of a linear chromosome in the nucleus that protects and stabilizes a linear chromosome.\" [GOC:elh]","metadata":null},{"id":"8ed24f4d111b44b39a6b4ed79b6d83d1","type":"GO_TERM","name":"nuclear thyroid hormone receptor binding","canonical_id":"go:GO:0046966","description":"\"Binding to a nuclear thyroid hormone receptor.\" [GOC:ai]","metadata":null},{"id":"c9033a8fb3f6410dabeb3115d18c5df1","type":"GO_TERM","name":"nuclear transport","canonical_id":"go:GO:0051169","description":"\"The directed movement of substances into, out of, or within the nucleus.\" [GOC:ai]","metadata":null},{"id":"f2086d02f9bb45f8b922e15d65439442","type":"GO_TERM","name":"nuclear ubiquitin ligase complex","canonical_id":"go:GO:0000152","description":"\"A ubiquitin ligase complex found in the nucleus.\" [GOC:mah]","metadata":null},{"id":"a711e74a292840e9a3e0e58ab98446de","type":"GO_TERM","name":"nuclear viral factory","canonical_id":"go:GO:0039715","description":"\"A viral factory located in the nucleus of a host cell.\" [VZ:1951]","metadata":null},{"id":"e9867d96e5ef4fd2b93a49b11d97978c","type":"GO_TERM","name":"nuclear vitamin D receptor binding","canonical_id":"go:GO:0042809","description":"\"Binding to a nuclear vitamin D receptor, a nuclear receptor that mediates the action of vitamin D by binding DNA and controlling the transcription of hormone-sensitive genes.\" [GOC:jl, PMID:12637589]","metadata":null},{"id":"9d93e41d594c4cb6a28779c6c6e0e17b","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process","canonical_id":"go:GO:0000956","description":"\"The chemical reactions and pathways resulting in the breakdown of nuclear-transcribed mRNAs in eukaryotic cells.\" [GOC:krc]","metadata":null},{"id":"e4109539999b424fbe0ddcabc4215b4f","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, 3'-5' exonucleolytic nonsense-mediated decay","canonical_id":"go:GO:0070478","description":"\"The chemical reactions and pathways resulting in the breakdown of the nuclear-transcribed mRNA transcript body of an mRNA in which an amino-acid codon has changed to a nonsense codon; occurs when the 3' end is not protected by a 3'-poly(A) tail; degradation proceeds in the 3' to 5' direction.\" [PMID:12769863]","metadata":null},{"id":"2f1288d3bd924c3694aa977ecf86fea6","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, 5'-3' exonucleolytic nonsense-mediated decay","canonical_id":"go:GO:0070479","description":"\"The chemical reactions and pathways resulting in the breakdown of the nuclear-transcribed mRNA transcript body of an mRNA in which an amino-acid codon has changed to a nonsense codon; occurs when the 5' end is not protected by a 5'-cap; degradation proceeds in the 5' to 3' direction.\" [PMID:18554525]","metadata":null},{"id":"01fa01d3bb84412aafe4baf41e5b6414","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, RNase MRP-dependent","canonical_id":"go:GO:0000294","description":"\"A minor MRP-dependent nuclear-transcribed mRNA degradation pathway that begins with an endonucleolytic cleavage to generate unprotected ends.\" [PMID:14729943]","metadata":null},{"id":"7390a2d98f9a47448bea05ef94dbdbbc","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay","canonical_id":"go:GO:0000288","description":"\"A major pathway of degradation of nuclear-transcribed mRNAs that proceeds through a series of ordered steps that includes poly(A) tail shortening and that can regulate mRNA stability.\" [GOC:jp, GOC:krc]","metadata":null},{"id":"a2f6c3cc48de437e9489ff96b3b738c1","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, deadenylation-independent decay","canonical_id":"go:GO:0031086","description":"\"A pathway of degradation of nuclear-transcribed mRNAs that proceeds through a series of steps that is independent of deadenylation, but requires decapping followed by transcript decay, and that can regulate mRNA stability.\" [GOC:krc, PMID:15225542, PMID:15225544]","metadata":null},{"id":"1f3470f930804e4abb2e8cb7761751f0","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, no-go decay","canonical_id":"go:GO:0070966","description":"\"The chemical reactions and pathways resulting in the breakdown of the transcript body of a nuclear-transcribed mRNA with stalls in translation elongation.\" [GOC:jp, PMID:16554824]","metadata":null},{"id":"a623534408e24425a64ee2964b7a0b5a","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, non-stop decay","canonical_id":"go:GO:0070481","description":"\"The chemical reactions and pathways resulting in the breakdown of the transcript body of a nuclear-transcribed mRNA that is lacking a stop codon.\" [PMID:11910110]","metadata":null},{"id":"226f3b3e03b54fbca98854de6bcf5587","type":"GO_TERM","name":"nuclear-transcribed mRNA catabolic process, nonsense-mediated decay","canonical_id":"go:GO:0000184","description":"\"The nonsense-mediated decay pathway for nuclear-transcribed mRNAs degrades mRNAs in which an amino-acid codon has changed to a nonsense codon; this prevents the translation of such mRNAs into truncated, and potentially harmful, proteins.\" [GOC:krc, GOC:ma, PMID:10025395]","metadata":null},{"id":"d2890ca500734db9b6501e3fce25e592","type":"GO_TERM","name":"nuclear-transcribed mRNA poly(A) tail shortening","canonical_id":"go:GO:0000289","description":"\"Shortening of the poly(A) tail of a nuclear-transcribed mRNA from full length to an oligo(A) length.\" [GOC:krc]","metadata":null},{"id":"7e7e720a7d724dbe8a275994c6ee969c","type":"GO_TERM","name":"nuclease activator activity","canonical_id":"go:GO:0170053","description":"\"Binds to and increases the activity of a nuclease.\" [PMID:24736845]","metadata":null},{"id":"6002fe5b0d9646d093589c56bf1e8c38","type":"GO_TERM","name":"nuclease activity","canonical_id":"go:GO:0004518","description":"\"Catalysis of the cleavage of ester linkages within nucleic acids.\" [ISBN:0198547684]","metadata":null},{"id":"9fe0fcd3c406404ea0057a72fbf62609","type":"GO_TERM","name":"nuclease inhibitor activity","canonical_id":"go:GO:0140721","description":"\"Binds to and modulates the activity of a nuclease.\" [PMID:28785032, PMID:29554913, PMID:30046034]","metadata":null},{"id":"6ae33aaf454f477db0ea02b749d8cb35","type":"GO_TERM","name":"nucleate erythrocyte development","canonical_id":"go:GO:0048823","description":"\"The process aimed at the progression of a nucleate erythrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:devbiol]","metadata":null},{"id":"667c83c993914e28b3004658ccd864fe","type":"GO_TERM","name":"nucleate erythrocyte differentiation","canonical_id":"go:GO:0043363","description":"\"The process in which a myeloid precursor cell acquires specializes features of an erythrocyte with a nucleus, as found in non-mammalian vertebrates such as birds.\" [GOC:jl]","metadata":null},{"id":"5176425ef1f04233a98f412cbb26a8b7","type":"GO_TERM","name":"nucleate erythrocyte maturation","canonical_id":"go:GO:0043362","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a nucleate erythrocyte to attain its fully functional state. A nucleate erythrocyte is an erythrocyte with a nucleus.\" [GOC:devbiol, GOC:jl]","metadata":null},{"id":"ef892e4b725443078f823dc0c6a6149e","type":"GO_TERM","name":"nucleic acid binding","canonical_id":"go:GO:0003676","description":"\"Binding to a nucleic acid.\" [GOC:jl]","metadata":null},{"id":"d72daf699e1f42138ae325986917a878","type":"GO_TERM","name":"nucleic acid biosynthetic process","canonical_id":"go:GO:0141187","description":"\"The biosynthetic process resulting in the formation of a nucleic acid.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3d5881e33ecb4418a8ef25b9c649b9f7","type":"GO_TERM","name":"nucleic acid catabolic process","canonical_id":"go:GO:0141188","description":"\"The cellular DNA metabolic process resulting in the breakdown of a nucleic acid.\" [GOC:curators]","metadata":null},{"id":"8fb7c6a8028740e2b39f53fe50306e16","type":"GO_TERM","name":"nucleic acid conformation isomerase activity","canonical_id":"go:GO:0120545","description":"\"Catalysis of a reaction that alters the conformation of a nucleic acid.\" [EC:5.6.2.-]","metadata":null},{"id":"75a1ec964f364bafbf7ff09fec6817ad","type":"GO_TERM","name":"nucleic acid metabolic process","canonical_id":"go:GO:0090304","description":"\"Any cellular metabolic process involving nucleic acids.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"36ace9feac12457a9242572524007c89","type":"GO_TERM","name":"nucleic acid transmembrane transporter activity","canonical_id":"go:GO:0051032","description":"\"Enables the transfer of nucleic acids from one side of a membrane to the other. Nucleic acids are single or double-stranded polynucleotides involved in the storage, transmission and transfer of genetic information.\" [GOC:ai]","metadata":null},{"id":"930cf7bbc7ef4203a9b3f34d8fac0960","type":"GO_TERM","name":"nucleic acid transport","canonical_id":"go:GO:0050657","description":"\"The directed movement of nucleic acids, single or double-stranded polynucleotides involved in the storage, transmission and transfer of genetic information, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"b8260ec9c1d041628283af623dab6c15","type":"GO_TERM","name":"nucleic acid-protein covalent cross-linking","canonical_id":"go:GO:0018143","description":"\"The formation of a covalent cross-link between a nucleic acid and a protein.\" [GOC:ma]","metadata":null},{"id":"38f24f66a1294583b20e4f50238ac1c9","type":"GO_TERM","name":"nucleobase binding","canonical_id":"go:GO:0002054","description":"\"Binding to a nucleobase, any of a class of pyrmidines or purines, organic nitrogenous bases.\" [GOC:hjd]","metadata":null},{"id":"ce27ba704532459cbaad4738e8b5d5d0","type":"GO_TERM","name":"nucleobase biosynthetic process","canonical_id":"go:GO:0046112","description":"\"The chemical reactions and pathways resulting in the formation of a nucleobase, a nitrogenous base that is a constituent of a nucleic acid.\" [GOC:ai]","metadata":null},{"id":"f8fc834c93cd424c8f5536076d205805","type":"GO_TERM","name":"nucleobase catabolic process","canonical_id":"go:GO:0046113","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleobase, a nitrogenous base that is a constituent of a nucleic acid.\" [GOC:ai]","metadata":null},{"id":"bbe71592b3e0476dbf38c99c38ea9c78","type":"GO_TERM","name":"nucleobase metabolic process","canonical_id":"go:GO:0009112","description":"\"The chemical reactions and pathways involving a nucleobase, a nitrogenous base that is a constituent of a nucleic acid, e.g. the purines: adenine, guanine, hypoxanthine, xanthine and the pyrimidines: cytosine, uracil, thymine.\" [GOC:ma]","metadata":null},{"id":"a63c4148570f4a1089e79b95b36df478","type":"GO_TERM","name":"nucleobase transmembrane transporter activity","canonical_id":"go:GO:0015205","description":"\"Enables the transfer of a nucleobase, any nitrogenous base that is a constituent of a nucleoside, nucleotide, or nucleic acidfrom one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"5e8d5f11ed8248a0840ed3e88913b04c","type":"GO_TERM","name":"nucleobase transport","canonical_id":"go:GO:0015851","description":"\"The directed movement of a nucleobase, any nitrogenous base that is a constituent of a nucleoside, nucleotide, or nucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [ISBN:0198506732]","metadata":null},{"id":"25a130ea545e42e09f8ca9c4c90df2cd","type":"GO_TERM","name":"nucleobase-containing compound biosynthetic process","canonical_id":"go:GO:0034654","description":"\"The chemical reactions and pathways resulting in the formation of nucleobases, nucleosides, nucleotides and nucleic acids.\" [GOC:mah]","metadata":null},{"id":"00a1778f2aa54d34866d115bec891439","type":"GO_TERM","name":"nucleobase-containing compound catabolic process","canonical_id":"go:GO:0034655","description":"\"The chemical reactions and pathways resulting in the breakdown of nucleobases, nucleosides, nucleotides and nucleic acids.\" [GOC:mah]","metadata":null},{"id":"ec6c61945bd9467aa28f19910382734c","type":"GO_TERM","name":"nucleobase-containing compound kinase activity","canonical_id":"go:GO:0019205","description":"\"Catalysis of the transfer of a phosphate group, usually from ATP or GTP, to a nucleobase, nucleoside, nucleotide or polynucleotide substrate.\" [GOC:jl]","metadata":null},{"id":"141a58bd13754118b78585029ddd7183","type":"GO_TERM","name":"nucleobase-containing compound metabolic process","canonical_id":"go:GO:0006139","description":"\"Any cellular metabolic process involving nucleobases, nucleosides, nucleotides and nucleic acids.\" [GOC:ai]","metadata":null},{"id":"67ee67fbc66e436db506a4bdb23a6105","type":"GO_TERM","name":"nucleobase-containing compound transmembrane transporter activity","canonical_id":"go:GO:0015932","description":"\"Enables the transfer of nucleobases, nucleosides, nucleotides and nucleic acids from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"81ca6831e12248d8a62a5c230057340e","type":"GO_TERM","name":"nucleobase-containing compound transport","canonical_id":"go:GO:0015931","description":"\"The directed movement of nucleobases, nucleosides, nucleotides and nucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f2f1c9a8275a4601970c3988a96ca91f","type":"GO_TERM","name":"nucleobase-containing small molecule biosynthetic process","canonical_id":"go:GO:0034404","description":"\"The chemical reactions and pathways resulting in the formation of a nucleobase-containing small molecule: a nucleobase, a nucleoside, or a nucleotide.\" [GOC:mah]","metadata":null},{"id":"618804d7a2f0412085dd563ed3e59caf","type":"GO_TERM","name":"nucleobase-containing small molecule catabolic process","canonical_id":"go:GO:0034656","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleobase-containing small molecule: a nucleobase, a nucleoside, or a nucleotide.\" [GOC:mah]","metadata":null},{"id":"44a673320c9048d7a542c206b26af57a","type":"GO_TERM","name":"nucleobase-containing small molecule interconversion","canonical_id":"go:GO:0015949","description":"\"The chemical reactions and pathways by which a nucleobase, nucleoside or nucleotide small molecule is synthesized from another nucleobase, nucleoside or nucleotide small molecule.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"b9c4220a630e4501a765bad114a291ab","type":"GO_TERM","name":"nucleobase-containing small molecule metabolic process","canonical_id":"go:GO:0055086","description":"\"The cellular chemical reactions and pathways involving a nucleobase-containing small molecule: a nucleobase, a nucleoside, or a nucleotide.\" [GOC:vw]","metadata":null},{"id":"8a593883716f4d3ea5c8110099a02132","type":"GO_TERM","name":"nucleobase:monoatomic cation symporter activity","canonical_id":"go:GO:0015391","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: nucleobase(out) + cation(out) = nucleobase(in) + cation(in).\" [GOC:ai]","metadata":null},{"id":"a5e32926dfa14f28afa0f2b582c580c0","type":"GO_TERM","name":"nucleocytoplasmic carrier activity","canonical_id":"go:GO:0140142","description":"\"Binding to and carrying a cargo between the nucleus and the cytoplasm by moving along with the cargo. The cargo can be either a RNA or a protein.\" [GOC:pg]","metadata":null},{"id":"d888a408694c45f29b9cfa18412e7c5c","type":"GO_TERM","name":"nucleocytoplasmic transport","canonical_id":"go:GO:0006913","description":"\"The directed movement of molecules between the nucleus and the cytoplasm.\" [GOC:curators]","metadata":null},{"id":"76e79a0ad34541a2af18427d1fac2e3d","type":"GO_TERM","name":"nucleocytoplasmic transport complex","canonical_id":"go:GO:0031074","description":"\"Any complex that acts to move proteins or RNAs into or out of the nucleus through nuclear pores.\" [GOC:mah]","metadata":null},{"id":"e1511ae63160470b9263cc347acca0d1","type":"GO_TERM","name":"nucleoid","canonical_id":"go:GO:0009295","description":"\"The region of a virus, bacterial cell, mitochondrion or chloroplast to which the nucleic acid is confined.\" [GOC:bm, GOC:ma, ISBN:3540076689]","metadata":null},{"id":"0d8cf62595054a9ba0b297d6458d72da","type":"GO_TERM","name":"nucleokinesis involved in cell motility in cerebral cortex radial glia guided migration","canonical_id":"go:GO:0021817","description":"\"The microtubule-mediated movement of the nucleus that is required for the movement of cells along radial glial fibers as a component of the process of cerebral cortex glial-mediated radial cell migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:tb, PMID:12626695]","metadata":null},{"id":"9686f289237840e2a53fe322596b9f1f","type":"GO_TERM","name":"nucleolar chromatin","canonical_id":"go:GO:0030874","description":"\"The portion of nuclear chromatin associated with the nucleolus; includes the DNA encoding the ribosomal RNA.\" [GOC:mah]","metadata":null},{"id":"e97427d2d1f8471e8c3d6563d7b5b5e3","type":"GO_TERM","name":"nucleolar chromatin organization","canonical_id":"go:GO:1990700","description":"\"Any process that results in the specification, formation or maintenance of the physical structure of nucleolar chromatin.\" [PMID:18362178]","metadata":null},{"id":"a662bf3b3be24193b5bbef0117c1b6d2","type":"GO_TERM","name":"nucleolar exosome (RNase complex)","canonical_id":"go:GO:0101019","description":"\"A ribonuclease complex that has 3-prime to 5-prime distributive hydrolytic exoribonuclease activity and in some taxa (e.g. yeast) endoribonuclease activity, producing 5-prime-phosphomonoesters. Participates in a multitude of cellular RNA processing and degradation events preventing nuclear export and/or translation of aberrant RNAs. Restricted to processing linear and circular single-stranded RNAs (ssRNA) only. RNAs with complex secondary structures may have to be unwound or pre-processed by co-factors prior to entering the complex, esp if the 3-prime end is structured.\" [PMID:17174896, PMID:20531386, PMID:26726035]","metadata":null},{"id":"bbc659c21f9447b6a1339e61b052976a","type":"GO_TERM","name":"nucleolar large rRNA transcription by RNA polymerase I","canonical_id":"go:GO:0042790","description":"\"The synthesis of the large ribosomal RNA (rRNA) transcript which encodes several rRNAs, e.g. in mammals 28S, 18S and 5.8S, from a nuclear DNA template transcribed by RNA polymerase I.\" [GOC:jl, GOC:txnOH, ISBN:0321000382]","metadata":null},{"id":"44ea9dabd99d4a47a61541eaad1f3ecc","type":"GO_TERM","name":"nucleolar peripheral inclusion body","canonical_id":"go:GO:0140602","description":"\"Inclusion bodies located at the nucleolar periphery where several nuclear factors are reversibly aggregated and sequestered during acute heat stress or starvation.\" [PMID:33176152, PMID:37128864]","metadata":null},{"id":"a2a6ddf148d34bf29f8aab9891ee5c67","type":"GO_TERM","name":"nucleolar ribonuclease P complex","canonical_id":"go:GO:0005655","description":"\"A ribonuclease P complex located in the nucleolus of a eukaryotic cell, where it catalyzes the 5' endonucleolytic cleavage of precursor tRNAs to yield mature tRNAs. Eukaryotic nucleolar ribonuclease P complexes generally contain a single RNA molecule that is necessary but not sufficient for catalysis, and several protein molecules.\" [GOC:mah, PMID:12045094]","metadata":null},{"id":"11dfb702e5de489bba3521c785c53d11","type":"GO_TERM","name":"nucleologenesis","canonical_id":"go:GO:0017126","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a nucleolus, a small, dense body one or more of which are present in the nucleus of eukaryotic cells.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f1e9e7aa739949f3a49a70a9d327ce6e","type":"GO_TERM","name":"nucleolus","canonical_id":"go:GO:0005730","description":"\"A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome.\" [ISBN:0198506732]","metadata":null},{"id":"63bdcfee7c28471082e7877b2696af27","type":"GO_TERM","name":"nucleolus organization","canonical_id":"go:GO:0007000","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nucleolus.\" [GOC:dph, GOC:jid, GOC:jl, GOC:mah]","metadata":null},{"id":"0cfdb1464fee441e90adf0ff3855cd08","type":"GO_TERM","name":"nucleolus organizer region","canonical_id":"go:GO:0005731","description":"\"A region of a chromosome where nucleoli form during interphase, and where genes encoding the largest rRNA precursor transcript are tandemly arrayed.\" [PMID:14504406]","metadata":null},{"id":"5635145c986a4b6a91be62d1bddd43b2","type":"GO_TERM","name":"nucleolus-associated heterochromatin","canonical_id":"go:GO:0097424","description":"\"Dense particles of heterochromatin, consisting of a loosely twisted strand about 600 Angstrom thick, found associated with the nucleolus.\" [NIF_Subcellular:sao1210952635]","metadata":null},{"id":"b2fc76b78cf848728c4146e0bd9003d1","type":"GO_TERM","name":"nucleolus-like body","canonical_id":"go:GO:1990934","description":"\"A nuclear compartment containing significant amounts of non-nucleolar, spliceosomal components. It is commonly found in germinal vesicle (GV) stage oocytes, and is similar to both nucleoli and sphere organelles.\" [PMID:26226217, PMID:9021878]","metadata":null},{"id":"9bfeed5295894571af469efc841c6046","type":"GO_TERM","name":"nucleomorph","canonical_id":"go:GO:0033009","description":"\"A small, vestigial nucleus found in some plastids that derive from a eukaryotic endosymbiont. Observed in chlorarachniophytes and cryptomonads, which acquired their plastids from a green and red alga respectively.\" [PMID:16760254]","metadata":null},{"id":"a52c0ad38ce24f1d81795d3fc3592b26","type":"GO_TERM","name":"nucleophagy","canonical_id":"go:GO:0044804","description":"\"A form of autophagy, by which damaged or non-essential parts of the nucleus, or even an entire nucleus is degraded.\" [GOC:autophagy, GOC:jl, PMID:24013549]","metadata":null},{"id":"cb9348a6d4c04e0bbdbee8b6ca109b3d","type":"GO_TERM","name":"nucleoplasm","canonical_id":"go:GO:0005654","description":"\"That part of the nuclear content other than the chromosomes or the nucleolus.\" [GOC:ma, ISBN:0124325653]","metadata":null},{"id":"ca54018a2b134facab7cb3b127519669","type":"GO_TERM","name":"nucleoplasmic THO complex","canonical_id":"go:GO:0000446","description":"\"The THO complex when it is acting as a nuclear complex that is required for transcription elongation through genes containing tandemly repeated DNA sequences. In S. cerevisiae, it is composed of four subunits: Hpr1, Tho2, Thp2, and Mft1, while the human complex is composed of 7 subunits.\" [GOC:krc, GOC:se, PMID:11060033, PMID:11979277, PMID:16983072]","metadata":null},{"id":"1670c283bb364d7b94199313ed5a433f","type":"GO_TERM","name":"nucleoplasmic periphery of the nuclear pore complex","canonical_id":"go:GO:1990826","description":"\"Nucleoplasm situated in close proximity and peripheral to a nuclear pore complex.\" [PMID:10633080]","metadata":null},{"id":"57ee318d35ed4249a9224dd86d408ab5","type":"GO_TERM","name":"nucleoplasmic reticulum","canonical_id":"go:GO:0044195","description":"\"Long, dynamic tubular channels, formed by invagination of the nuclear envelope, that extend deep into the nucleoplasm. The channels have an underlying lamina and are implicated in functioning in signaling and transport.\" [GOC:jl, PMID:17959832, PMID:9024685]","metadata":null},{"id":"f8412d0cbe2f4a35aba5ab49fafaee1d","type":"GO_TERM","name":"nucleoplasmic side of nuclear pore","canonical_id":"go:GO:1990875","description":"\"The side of the nuclear pore complex (NPC) that faces the nucleoplasm.\" [PMID:8422679]","metadata":null},{"id":"4b0bd01911a847ea9c9265aae07bcae6","type":"GO_TERM","name":"nucleoside binding","canonical_id":"go:GO:0001882","description":"\"Binding to a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose.\" [GOC:hjd]","metadata":null},{"id":"ac536f229d424a979b3db507c2daf571","type":"GO_TERM","name":"nucleoside biosynthetic process","canonical_id":"go:GO:0009163","description":"\"The chemical reactions and pathways resulting in the formation of any one of a family of organic molecules consisting of a purine or pyrimidine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:jl, ISBN:0140512713]","metadata":null},{"id":"0595b6fc022f45db95ca25e183a17324","type":"GO_TERM","name":"nucleoside bisphosphate biosynthetic process","canonical_id":"go:GO:0033866","description":"\"The chemical reactions and pathways resulting in the formation of a nucleoside bisphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"b2ff0fe9e2774150989af7735f5f219e","type":"GO_TERM","name":"nucleoside bisphosphate catabolic process","canonical_id":"go:GO:0033869","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleoside bisphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"b6ee3c206f8e4c97b29db88185ee3c8c","type":"GO_TERM","name":"nucleoside bisphosphate metabolic process","canonical_id":"go:GO:0033865","description":"\"The chemical reactions and pathways involving a nucleoside bisphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"cff8cbf0ddbb4da3acf85c62b101f910","type":"GO_TERM","name":"nucleoside catabolic process","canonical_id":"go:GO:0009164","description":"\"The chemical reactions and pathways resulting in the breakdown of any one of a family of organic molecules consisting of a purine or pyrimidine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:jl]","metadata":null},{"id":"e57e9081750941cba0410e67f72e1a84","type":"GO_TERM","name":"nucleoside deoxyribosyltransferase activity","canonical_id":"go:GO:0050144","description":"\"Catalysis of the reaction: 2-deoxy-D-ribosyl-base1 + base2 = 2-deoxy-D-ribosyl-base2 + base1.\" [EC:2.4.2.6, MetaCyc:NUCLEOSIDE-DEOXYRIBOSYLTRANSFERASE-RXN]","metadata":null},{"id":"2c2d8cc1c1364117a678f76b3a717a3c","type":"GO_TERM","name":"nucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009133","description":"\"The chemical reactions and pathways resulting in the formation of a nucleoside diphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"e3bbaf7f9a7444a0882f6b8a74a7bbe7","type":"GO_TERM","name":"nucleoside diphosphate catabolic process","canonical_id":"go:GO:0009134","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleoside diphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"40dd5f1ba7374ad7a39f292d3daf14a7","type":"GO_TERM","name":"nucleoside diphosphate kinase activity","canonical_id":"go:GO:0004550","description":"\"Catalysis of the reaction: ATP + nucleoside diphosphate = ADP + nucleoside triphosphate.\" [EC:2.7.4.6]","metadata":null},{"id":"2ac49dcc743b4dceb37099e7e9f66f53","type":"GO_TERM","name":"nucleoside diphosphate metabolic process","canonical_id":"go:GO:0009132","description":"\"The chemical reactions and pathways involving a nucleoside diphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"e02b41fd78cd462cbe21ed2a6ed3ac82","type":"GO_TERM","name":"nucleoside diphosphate phosphatase activity","canonical_id":"go:GO:0017110","description":"\"Catalysis of the reaction: a nucleoside diphosphate + H2O = a nucleoside monophosphate + phosphate.\" [EC:3.6.1.6]","metadata":null},{"id":"bd313e11bd864fdda14ff8ae89b26036","type":"GO_TERM","name":"nucleoside import across plasma membrane","canonical_id":"go:GO:0180015","description":"\"The directed movement of nucleoside from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:21998139, PMID:30658162]","metadata":null},{"id":"92e1df046faa4c32b270253485bbc55c","type":"GO_TERM","name":"nucleoside kinase activity","canonical_id":"go:GO:0019206","description":"\"Catalysis of the reaction: ATP + nucleoside = ADP + nucleoside monophosphate.\" [GOC:ai]","metadata":null},{"id":"3c2eb827bb994f9e9224b61b7685c2ab","type":"GO_TERM","name":"nucleoside metabolic process","canonical_id":"go:GO:0009116","description":"\"The chemical reactions and pathways involving a nucleoside, a nucleobase linked to either beta-D-ribofuranose (a ribonucleoside) or 2-deoxy-beta-D-ribofuranose, (a deoxyribonucleoside), e.g. adenosine, guanosine, inosine, cytidine, uridine and deoxyadenosine, deoxyguanosine, deoxycytidine and thymidine (= deoxythymidine).\" [GOC:ma]","metadata":null},{"id":"653aa41eab5e4385a873c0bbf3057fb1","type":"GO_TERM","name":"nucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009124","description":"\"The chemical reactions and pathways resulting in the formation of a nucleoside monophosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0d10790cd7254a45bb34b87af0dac12e","type":"GO_TERM","name":"nucleoside monophosphate catabolic process","canonical_id":"go:GO:0009125","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleoside monophosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"4b01b9b6c1684cd58ddaceca5fa30dc2","type":"GO_TERM","name":"nucleoside monophosphate kinase activity","canonical_id":"go:GO:0050145","description":"\"Catalysis of the reaction: a ribonucleoside 5'-phosphate + ATP = a ribonucleoside 5'-diphosphate + ADP.\" [RHEA:24036]","metadata":null},{"id":"b28b90a3c3f34b0089f451da0a406c7d","type":"GO_TERM","name":"nucleoside monophosphate metabolic process","canonical_id":"go:GO:0009123","description":"\"The chemical reactions and pathways involving a nucleoside monophosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d3314cb175d94f7baf5df62bcf6debc4","type":"GO_TERM","name":"nucleoside monophosphate phosphorylation","canonical_id":"go:GO:0046940","description":"\"The process of introducing one or more phosphate groups into a nucleoside monophosphate to produce a polyphosphorylated nucleoside.\" [GOC:ai]","metadata":null},{"id":"f1c25db9878d418c9a0c90be763bbd4e","type":"GO_TERM","name":"nucleoside oxidase (hydrogen peroxide-forming) activity","canonical_id":"go:GO:0033716","description":"\"Catalysis of the reaction: adenosine + 2 O2 + H2O = 9-riburonosyladenine + 2 H2O2 + H+.\" [RHEA:15489]","metadata":null},{"id":"89ba56d73ccb4df298d18c194ee6d4fb","type":"GO_TERM","name":"nucleoside oxidase activity","canonical_id":"go:GO:0033715","description":"\"Catalysis of the reactions: inosine + O2 = 9-riburonosylhypoxanthine + 2 H2O; (1a) 2 inosine + O2 = 2 5'-dehydroinosine + 2 H2O, and (1b) 2 5'-dehydroinosine + O2 = 2 9-riburonosylhypoxanthine + 2 H2O.\" [EC:1.1.3.28, RHEA:28651]","metadata":null},{"id":"1a195b5c7f324ecf95c4ff41aeda4006","type":"GO_TERM","name":"nucleoside phosphate binding","canonical_id":"go:GO:1901265","description":"\"Binding to nucleoside phosphate.\" [GOC:TermGenie]","metadata":null},{"id":"f6855b59654f46ecaf619ddeb973ad02","type":"GO_TERM","name":"nucleoside phosphate biosynthetic process","canonical_id":"go:GO:1901293","description":"\"The chemical reactions and pathways resulting in the formation of a nucleoside phosphate.\" [GOC:TermGenie]","metadata":null},{"id":"c4126ec61bee4988b71629eb75968a5a","type":"GO_TERM","name":"nucleoside phosphate catabolic process","canonical_id":"go:GO:1901292","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleoside phosphate.\" [GOC:TermGenie]","metadata":null},{"id":"b1a471598d764aeeba4fa82607ff6711","type":"GO_TERM","name":"nucleoside phosphate metabolic process","canonical_id":"go:GO:0006753","description":"\"The chemical reactions and pathways involving any phosphorylated nucleoside.\" [GOC:mah]","metadata":null},{"id":"b9e57306dd304a5480106ab3d42fd305","type":"GO_TERM","name":"nucleoside phosphoacylhydrolase activity","canonical_id":"go:GO:0033974","description":"\"Catalysis of the hydrolysis of mixed phospho-anhydride bonds.\" [EC:3.6.1.24]","metadata":null},{"id":"33d78e8622cc4ca5953ec3e0fde4fbc7","type":"GO_TERM","name":"nucleoside phosphotransferase activity","canonical_id":"go:GO:0050146","description":"\"Catalysis of the reaction: a nucleotide + a 2'-deoxynucleoside = a nucleoside + a 2'-deoxynucleoside 5'-monophosphate.\" [EC:2.7.1.77, MetaCyc:NUCLEOSIDE-PHOSPHOTRANSFERASE-RXN]","metadata":null},{"id":"fdcc4a9d4f7e464e91795b5fcb248b70","type":"GO_TERM","name":"nucleoside ribosyltransferase activity","canonical_id":"go:GO:0050147","description":"\"Catalysis of the reaction: D-ribosyl-base1 + base2 = D-ribosyl-base2 + base1.\" [EC:2.4.2.5, MetaCyc:NUCLEOSIDE-RIBOSYLTRANSFERASE-RXN]","metadata":null},{"id":"6930b1c55a0f446ea61453929a312c7b","type":"GO_TERM","name":"nucleoside salvage","canonical_id":"go:GO:0043174","description":"\"Any process which produces a nucleotide, a nucleobase linked to either beta-D-ribofuranose (ribonucleoside) or 2-deoxy-beta-D-ribofuranose (a deoxyribonucleotide), from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"da7f9b97816d4ea9bf77ca2ba315985e","type":"GO_TERM","name":"nucleoside transmembrane transport","canonical_id":"go:GO:1901642","description":"\"The directed movement of nucleoside across a membrane.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"9bda03952b0c439bb8688d7100775f04","type":"GO_TERM","name":"nucleoside transmembrane transporter activity","canonical_id":"go:GO:0005337","description":"\"Enables the transfer of a nucleoside, a nucleobase linked to either beta-D-ribofuranose (ribonucleoside) or 2-deoxy-beta-D-ribofuranose, (a deoxyribonucleotide) from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"de2bfb62a51e452ba87e94372d862e82","type":"GO_TERM","name":"nucleoside transmembrane transporter activity, against a concentration gradient","canonical_id":"go:GO:0010174","description":"\"Enables the transfer of a nucleoside, from one side of a membrane to the other, up a concentration gradient.\" [GOC:tb]","metadata":null},{"id":"d2a05673f8eb466aabd24cc645248cf0","type":"GO_TERM","name":"nucleoside transmembrane transporter activity, down a concentration gradient","canonical_id":"go:GO:0015395","description":"\"Enables the transfer of a nucleoside, from one side of a membrane to the other, down the concentration gradient.\" [PMID:10353709, PMID:11749958, PMID:12446811]","metadata":null},{"id":"8c919cce681940aeb1d36045d90ac7fe","type":"GO_TERM","name":"nucleoside transport","canonical_id":"go:GO:0015858","description":"\"The directed movement of a nucleoside, a nucleobase linked to either beta-D-ribofuranose (ribonucleoside) or 2-deoxy-beta-D-ribofuranose, (a deoxyribonucleotide), into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"98a78d602f514085a69a74ad19de65a6","type":"GO_TERM","name":"nucleoside triphosphate adenylate kinase activity","canonical_id":"go:GO:0046899","description":"\"Catalysis of the reaction: nucleoside triphosphate + AMP = nucleoside diphosphate + ADP.\" [EC:2.7.4.10]","metadata":null},{"id":"f1f71218eb5c4495b6e916db4cbbd3a2","type":"GO_TERM","name":"nucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009142","description":"\"The chemical reactions and pathways resulting in the formation of a nucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"6c8925766d354590a05a7500d2ab8c7a","type":"GO_TERM","name":"nucleoside triphosphate catabolic process","canonical_id":"go:GO:0009143","description":"\"The chemical reactions and pathways resulting in the breakdown of a nucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"8072e188f68149deabeec55ae5e44ed8","type":"GO_TERM","name":"nucleoside triphosphate diphosphatase activity","canonical_id":"go:GO:0047429","description":"\"Catalysis of the reaction: a nucleoside triphosphate + H2O = a nucleotide + H+ + diphosphate.\" [EC:3.6.1.9]","metadata":null},{"id":"abc738d594054d8fa411d8b98ccec0fd","type":"GO_TERM","name":"nucleoside triphosphate metabolic process","canonical_id":"go:GO:0009141","description":"\"The chemical reactions and pathways involving a nucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"707dab23c2fd4ebdb68455ea45749ab0","type":"GO_TERM","name":"nucleoside-specific channel forming porin activity","canonical_id":"go:GO:0015471","description":"\"Enables the energy independent passage of nucleoside, sized less than 1000 Da, across a membrane. The transmembrane portions of porins consist exclusively of beta-strands which form a beta-barrel. They are found in the outer membranes of Gram-negative bacteria, mitochondria, plastids and possibly acid-fast Gram-positive bacteria.\" [GOC:mtg_transport]","metadata":null},{"id":"7c8316f7c8884709a16b0c020f5aed19","type":"GO_TERM","name":"nucleoside-triphosphatase regulator activity","canonical_id":"go:GO:0060589","description":"\"Binds to and modulates the activity of an NTPase.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ba0fd017a1544c6a99a43d3bf0da9ea9","type":"GO_TERM","name":"nucleoside-triphosphate-hexose-1-phosphate nucleotidyltransferase activity","canonical_id":"go:GO:0047339","description":"\"Catalysis of the reaction: hexose 1-phosphate + nucleoside triphosphate = NDP-hexose + diphosphate.\" [EC:2.7.7.28, MetaCyc:2.7.7.28-RXN]","metadata":null},{"id":"96bcabc3cbd64b498e598da3dc16e2b5","type":"GO_TERM","name":"nucleoside:proton symporter activity","canonical_id":"go:GO:0015506","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: nucleoside(out) + H+(out) = nucleoside(in) + H+(in).\" [TC:2.A.1.10.1, TC:2.A.41.1.1]","metadata":null},{"id":"8e64a4cebd1a4445bb18fff674a48faf","type":"GO_TERM","name":"nucleoside:sodium symporter activity","canonical_id":"go:GO:0005415","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: nucleoside(out) + Na+(out) = nucleoside(in) + Na+(in).\" [GOC:ai]","metadata":null},{"id":"fe536547613844f2a21600a44a4dcba7","type":"GO_TERM","name":"nucleosomal DNA binding","canonical_id":"go:GO:0031492","description":"\"Binding to the DNA portion of a nucleosome.\" [GOC:mah]","metadata":null},{"id":"617825c4ccab464a8d72d0111ebf6ade","type":"GO_TERM","name":"nucleosomal methylation activator complex","canonical_id":"go:GO:0070311","description":"\"A protein complex that contains eight subunits in common with the SWI/SNF complex, plus the ATPase BRG1 (SMARCA4) and the histone methyltransferase CARM1; the complex is involved in regulating nuclear receptor-dependent transcription.\" [GOC:mah, PMID:14729568]","metadata":null},{"id":"2c2c33aa4ba7453da32df0bf7c53970b","type":"GO_TERM","name":"nucleosome","canonical_id":"go:GO:0000786","description":"\"A complex comprised of DNA wound around a multisubunit core and associated proteins, which forms the primary packing unit of DNA into higher order structures.\" [GOC:elh]","metadata":null},{"id":"67226d32eb3143629c0ab04f90b6492b","type":"GO_TERM","name":"nucleosome array spacer activity","canonical_id":"go:GO:0140750","description":"\"A histone octamer slider activity that spaces nucleosomes along chromosomal DNA. This activity is involved in assembling chromatin in uniform nucleosome arrays to regulate transcription by RNA polymerases I, II, and III, as well as DNA replication, recombination and repair.\" [PMID:11683384, PMID:16468993]","metadata":null},{"id":"9f60dfb7bd754a81bb043b1af1fadffa","type":"GO_TERM","name":"nucleosome assembly","canonical_id":"go:GO:0006334","description":"\"The aggregation, arrangement and bonding together of a nucleosome, the beadlike structural units of eukaryotic chromatin composed of histones and DNA.\" [GOC:mah]","metadata":null},{"id":"c8edad4effd44fa1ba42c37f84aaed30","type":"GO_TERM","name":"nucleosome binding","canonical_id":"go:GO:0031491","description":"\"Binding to a nucleosome, a complex comprised of DNA wound around a multisubunit core and associated proteins, which forms the primary packing unit of DNA into higher order structures.\" [GOC:mah]","metadata":null},{"id":"99d23017814c462e9bfe3f60c85aa796","type":"GO_TERM","name":"nucleosome disassembly","canonical_id":"go:GO:0006337","description":"\"The controlled breakdown of nucleosomes, the beadlike structural units of eukaryotic chromatin composed of histones and DNA.\" [GOC:mah]","metadata":null},{"id":"eb24eb3b4288413ead2a26b0d752ea2d","type":"GO_TERM","name":"nucleosome organization","canonical_id":"go:GO:0034728","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of one or more nucleosomes.\" [GOC:mah]","metadata":null},{"id":"d715872a2dd64b3b9b776ea8db0a0a40","type":"GO_TERM","name":"nucleotidase activity","canonical_id":"go:GO:0008252","description":"\"Catalysis of the reaction: a nucleotide + H2O = a nucleoside + phosphate.\" [PMID:12947102, PMID:22555564]","metadata":null},{"id":"fd80d431d9e74f7eb2a573983fdd699d","type":"GO_TERM","name":"nucleotide binding","canonical_id":"go:GO:0000166","description":"\"Binding to a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"b6294be68e7e42eea291b26900e8e9c1","type":"GO_TERM","name":"nucleotide biosynthetic process","canonical_id":"go:GO:0009165","description":"\"The chemical reactions and pathways resulting in the formation of nucleotides, any nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic-nucleotides (nucleoside cyclic phosphates).\" [GOC:curators]","metadata":null},{"id":"614f5a16d9b24c5e930a4b716649efb4","type":"GO_TERM","name":"nucleotide catabolic process","canonical_id":"go:GO:0009166","description":"\"The chemical reactions and pathways resulting in the breakdown of nucleotides, any nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic-nucleotides (nucleoside cyclic phosphates).\" [GOC:curators]","metadata":null},{"id":"7448aa8e4b8143bd8cd48e58afde8685","type":"GO_TERM","name":"nucleotide diphosphokinase activity","canonical_id":"go:GO:0050148","description":"\"Catalysis of the reaction: ATP + nucleoside 5'-phosphate = AMP + 5'-phosphonucleoside 3'-diphosphate.\" [RHEA:12713]","metadata":null},{"id":"b3bf6d89be854e50a26ff6e28c2e38f6","type":"GO_TERM","name":"nucleotide metabolic process","canonical_id":"go:GO:0009117","description":"\"The chemical reactions and pathways involving a nucleotide, a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic nucleotides (nucleoside cyclic phosphates).\" [GOC:ma]","metadata":null},{"id":"6acb7b9e0f6142b9bb23f036ea569553","type":"GO_TERM","name":"nucleotide receptor activity","canonical_id":"go:GO:0016502","description":"\"Combining with a nucleotide and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. A nucleotide is a compound that consists of a nucleoside esterified with a phosphate molecule.\" [GOC:signaling, ISBN:0198506732]","metadata":null},{"id":"220b09963f8e4b94b7dc2d64404a5335","type":"GO_TERM","name":"nucleotide salvage","canonical_id":"go:GO:0043173","description":"\"Any process which produces a nucleotide, a compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"22b1f467e14946bf80062bd50faa8967","type":"GO_TERM","name":"nucleotide transmembrane transport","canonical_id":"go:GO:1901679","description":"\"The directed movement of nucleotide across a membrane.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"6780f2475e22466fbdc3f316e6a84439","type":"GO_TERM","name":"nucleotide transmembrane transporter activity","canonical_id":"go:GO:0015215","description":"\"Enables the transfer of a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate, from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"cebc4baa723844d0a23729794ed122e2","type":"GO_TERM","name":"nucleotide transport","canonical_id":"go:GO:0006862","description":"\"The directed movement of a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate, into, out of or within a cell.\" [ISBN:0198506732]","metadata":null},{"id":"9311b580556d40ce8748afd32c281e86","type":"GO_TERM","name":"nucleotide-activated protein kinase complex","canonical_id":"go:GO:0031588","description":"\"A protein complex that possesses nucleotide-dependent protein kinase activity. The nucleotide can be AMP (in S. pombe and human) or ADP (in S. cerevisiae).\" [GOC:bhm, GOC:mah, GOC:vw]","metadata":null},{"id":"962a2d2d1ead4759a521751ee797ba08","type":"GO_TERM","name":"nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway","canonical_id":"go:GO:0035872","description":"\"The series of molecular signals initiated by a ligand binding to a nucleotide-binding domain, leucine rich repeat containing receptor (NLR), and ending with the regulation of a downstream cellular process. NLRs are cytoplasmic receptors defined by their tripartite domain architecture that contains: a variable C-terminus, a middle nucleotide-binding domain, and a LRR domain that is variable in the repeats composition and number.\" [GOC:sj, PMID:18280719, PMID:32838963, PMID:36973360]","metadata":null},{"id":"7c72d7285bf34681a0a0bcc5120bb2ad","type":"GO_TERM","name":"nucleotide-binding leucine-rich repeat receptor complex","canonical_id":"go:GO:7770053","description":"\"A protein complex that contains one or more nucleotide-binding leucine-rich repeat (NLR) proteins and functions as an intracellular innate immune receptor. Upon activation by pathogen effectors or danger signals, the complex oligomerizes with adaptor and effector proteins to trigger downstream immune responses including programmed cell death.\" [PMID:26355215, PMID:30948526, PMID:30948527]","metadata":null},{"id":"5c6df86be0ad4006917ca9aa12e0db92","type":"GO_TERM","name":"nucleotide-binding oligomerization domain containing 1 signaling pathway","canonical_id":"go:GO:0070427","description":"\"The series of molecular signals initiated by the binding of a ligand (such as a bacterial peptidoglycan) to a cytoplasmic nucleotide-binding oligomerization domain containing 1 (NOD1) protein receptor, and ending with regulation of a downstream cellular process.\" [GOC:add, PMID:17944960, PMID:18585455]","metadata":null},{"id":"e680578dce8a45e09b6007501b5fba9e","type":"GO_TERM","name":"nucleotide-binding oligomerization domain containing 2 signaling pathway","canonical_id":"go:GO:0070431","description":"\"The series of molecular signals initiated by the binding of a ligand (such as a bacterial peptidoglycan) to a cytoplasmic nucleotide-binding oligomerization domain containing 2 (NOD2) protein receptor, and ending with regulation of a downstream cellular process.\" [GOC:add, PMID:17944960, PMID:18585455]","metadata":null},{"id":"e4f9156d9c214b8a82b59ddc1b77e889","type":"GO_TERM","name":"nucleotide-excision repair","canonical_id":"go:GO:0006289","description":"\"A DNA repair process in which a small region of the strand surrounding the damage is removed from the DNA helix as an oligonucleotide. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase. Nucleotide excision repair recognizes a wide range of substrates, including damage caused by UV irradiation (pyrimidine dimers and 6-4 photoproducts) and chemicals (intrastrand cross-links and bulky adducts).\" [PMID:10197977]","metadata":null},{"id":"4794138459bb4b779f7c3ed2b037246d","type":"GO_TERM","name":"nucleotide-excision repair complex","canonical_id":"go:GO:0000109","description":"\"Any complex formed of proteins that act in nucleotide-excision repair.\" [PMID:10915862]","metadata":null},{"id":"522f41844a30488c885a3309fae9721d","type":"GO_TERM","name":"nucleotide-excision repair factor 1 complex","canonical_id":"go:GO:0000110","description":"\"One of several protein complexes involved in nucleotide-excision repair; possesses DNA damage recognition and endodeoxynuclease activities. In S. cerevisiae, it is composed of Rad1p, Rad10p, and Rad14p; in human the subunits are ERCC4/XPF, ERCC1 and XPA, respectively.\" [PMID:10915862]","metadata":null},{"id":"9fda846ca7004ea5b25de94b87ed0551","type":"GO_TERM","name":"nucleotide-excision repair factor 2 complex","canonical_id":"go:GO:0000111","description":"\"One of several protein complexes involved in nucleotide-excision repair; possesses damaged DNA binding activity. In S. cerevisiae, it is composed of Rad4p and Rad23p.\" [PMID:10915862]","metadata":null},{"id":"a80363bed1ae4662b1f1d1f2571e30dc","type":"GO_TERM","name":"nucleotide-excision repair factor 3 complex","canonical_id":"go:GO:0000112","description":"\"One of several protein complexes involved in nucleotide-excision repair; possesses endodeoxynuclease and DNA helicase activities. In S. cerevisiae, it is composed of Rad2p and the core TFIIH-Ssl2p complex (core TFIIH is composed of Rad3p, Tfb1p, Tfb2p, Ssl1p, Tfb4p and Tfb5p. Note that Ssl2p is also called Rad25p).\" [GOC:ew, PMID:10915862, PMID:14500720, PMID:7813015]","metadata":null},{"id":"a459792195d24f27b4c629fa2d438a81","type":"GO_TERM","name":"nucleotide-excision repair factor 4 complex","canonical_id":"go:GO:0000113","description":"\"One of several protein complexes involved in nucleotide-excision repair; possesses DNA damage recognition and DNA-dependent ATPase activities. In S. cerevisiae, it is composed of Rad7p and Rad16p.\" [PMID:10915862]","metadata":null},{"id":"0cbd38dff7a1402b9a4087f8a53fc98c","type":"GO_TERM","name":"nucleotide-excision repair involved in interstrand cross-link repair","canonical_id":"go:GO:1901255","description":"\"Any nucleotide-excision repair that is involved in interstrand cross-link repair.\" [GOC:TermGenie, PMID:22064477]","metadata":null},{"id":"86e171487f6d4c82adc77cc4eec5d0b4","type":"GO_TERM","name":"nucleotide-excision repair, DNA damage recognition","canonical_id":"go:GO:0000715","description":"\"The identification of lesions in DNA, such as pyrimidine-dimers, intrastrand cross-links, and bulky adducts. The wide range of substrate specificity suggests the repair complex recognizes distortions in the DNA helix.\" [GOC:elh, PMID:10197977]","metadata":null},{"id":"778f82da964d4950adae5f84b8ff7ae0","type":"GO_TERM","name":"nucleotide-excision repair, DNA damage recognition complex","canonical_id":"go:GO:1990249","description":"\"A protein complex that is capable of identifying lesions in DNA, such as pyrimidine-dimers, intrastrand cross-links, and bulky adducts. The wide range of substrate specificity suggests that the repair complex recognizes distortions in the DNA helix. It subsequently recruits a nucleotide-excision repair, preincision complex.\" [GOC:bhm, PMID:22331906]","metadata":null},{"id":"139b64e88ca64c4d9c352dee5162d08f","type":"GO_TERM","name":"nucleotide-excision repair, DNA gap filling","canonical_id":"go:GO:0006297","description":"\"Repair of the gap in the DNA helix by DNA polymerase and DNA ligase after the portion of the strand containing the lesion has been removed by pyrimidine-dimer repair enzymes.\" [ISBN:0815316194]","metadata":null},{"id":"6df93e4933874a29ba72a73ded1965ad","type":"GO_TERM","name":"nucleotide-excision repair, preincision complex","canonical_id":"go:GO:0097520","description":"\"A multiprotein complex involved in damage recognition, DNA helix unwinding, and endonucleolytic cleavage at the site of DNA damage.\" [GOC:cjm, GOC:elh, PMID:10197977]","metadata":null},{"id":"41a5659c40154874af9f424980ff148e","type":"GO_TERM","name":"nucleotide-excision repair, preincision complex assembly","canonical_id":"go:GO:0006294","description":"\"The aggregation, arrangement and bonding together of proteins on DNA to form the multiprotein complex involved in damage recognition, DNA helix unwinding, and endonucleolytic cleavage at the site of DNA damage. This assembly occurs before the phosphodiester backbone of the damaged strand is cleaved 3' and 5' of the site of DNA damage.\" [GOC:elh, PMID:10197977]","metadata":null},{"id":"5f20bd397e8d40d0b3133a70f65bdc3d","type":"GO_TERM","name":"nucleotide-excision repair, preincision complex stabilization","canonical_id":"go:GO:0006293","description":"\"The stabilization of the multiprotein complex involved in damage recognition, DNA helix unwinding, and endonucleolytic cleavage at the site of DNA damage as well as the unwound DNA. The stabilization of the protein-DNA complex ensures proper positioning of the preincision complex before the phosphodiester backbone of the damaged strand is cleaved 3' and 5' of the site of DNA damage.\" [GOC:elh, PMID:10197977]","metadata":null},{"id":"9e41d02c4f884496831386540cd08c5d","type":"GO_TERM","name":"nucleotide-sugar biosynthetic process","canonical_id":"go:GO:0009226","description":"\"The chemical reactions and pathways resulting in the formation of nucleotide-sugars, any nucleotide-carbohydrate in which the distal phosphoric residue of a nucleoside 5'-diphosphate is in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [ISBN:0198506732]","metadata":null},{"id":"465a31bb419c42fcbe133d54ce7a8938","type":"GO_TERM","name":"nucleotide-sugar metabolic process","canonical_id":"go:GO:0009225","description":"\"The cellular chemical reactions and pathways involving nucleotide-sugars, any nucleotide-carbohydrate in which the distal phosphoric residue of a nucleoside 5'-diphosphate is in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [ISBN:0198506732]","metadata":null},{"id":"fda678595ce1471b8c7ba3bff0d8e988","type":"GO_TERM","name":"nucleotide-sugar transmembrane transport","canonical_id":"go:GO:0015780","description":"\"The directed movement of nucleotide-sugars into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Nucleotide-sugars are any nucleotide in which the distal phosphoric residue of a nucleoside 5'-diphosphate is in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [ISBN:0198506732]","metadata":null},{"id":"56f58ad4c7684739954ed5d570ef7a00","type":"GO_TERM","name":"nucleotide-sugar transmembrane transporter activity","canonical_id":"go:GO:0005338","description":"\"Enables the transfer of a nucleotide-sugar from one side of a membrane to the other. A nucleotide-sugar is any nucleotide in which the distal phosphoric residue of a nucleoside 5'-diphosphate is in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729, PMID:15034926]","metadata":null},{"id":"769e5cbec0c447a5aec0655217b5cb04","type":"GO_TERM","name":"nucleotide-sulfate transmembrane transporter activity","canonical_id":"go:GO:0005340","description":"\"Enables the transfer of nucleotide-sulfate from one side of a membrane to the other.\" [GOC:mtg_transport]","metadata":null},{"id":"8a54696215ec4a42ade38c18987771f3","type":"GO_TERM","name":"nucleotide-sulfate transport","canonical_id":"go:GO:0015715","description":"\"The directed movement of nucleotide sulfate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"5f8adff4be8a47f5bc78fd87cb8c8281","type":"GO_TERM","name":"nucleotidyltransferase activity","canonical_id":"go:GO:0016779","description":"\"Catalysis of the transfer of a nucleotidyl group from one compound (donor) to another (acceptor).\" [EC:2.7.7.-]","metadata":null},{"id":"8593e9ddc39041cb9c7cebd7060d1921","type":"GO_TERM","name":"nucleus","canonical_id":"go:GO:0005634","description":"\"A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.\" [GOC:curators]","metadata":null},{"id":"71285e65cee642f7b2a1db4f326a9c42","type":"GO_TERM","name":"nucleus accumbens development","canonical_id":"go:GO:0021768","description":"\"The progression of the nucleus accumbens over time from its initial formation until its mature state. The nucleus accumbens is a collection of pleomorphic cells in the caudal part of the anterior horn of the lateral ventricle, in the region of the olfactory tubercle, lying between the head of the caudate nucleus and the anterior perforated substance. It is part of the ventral striatum, a composite structure considered part of the basal ganglia.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"05867beffc44497f936f4a7cf177663f","type":"GO_TERM","name":"nucleus ambiguus development","canonical_id":"go:GO:0021745","description":"\"The process whose specific outcome is the progression of the nucleus ambiguus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"8931377ef5cf49b7be03a283674f8be7","type":"GO_TERM","name":"nucleus disassembly","canonical_id":"go:GO:1905690","description":"\"The disaggregation of a nucleus into its constituent components.\" [GO_REF:0000079, GOC:autophagy, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"9138eebd4491452183c60b33fbe277c9","type":"GO_TERM","name":"nucleus lagging edge","canonical_id":"go:GO:0110093","description":"\"The area of a motile nucleus furthest from the direction of movement.\" [GOC:kmv, PMID:24335254]","metadata":null},{"id":"a6b1e59c7dbf4d5da892e75004342f0e","type":"GO_TERM","name":"nucleus leading edge","canonical_id":"go:GO:0110092","description":"\"The area of a motile nucleus closest to the direction of movement.\" [GOC:al, GOC:mah, GOC:vw, PMID:15030757, PMID:24335254]","metadata":null},{"id":"51bc7a538bff44c09383de63ecb07ee4","type":"GO_TERM","name":"nucleus localization","canonical_id":"go:GO:0051647","description":"\"Any process in which the nucleus is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"9e56adf9b5a142fa99ad98b8607b2091","type":"GO_TERM","name":"nucleus organization","canonical_id":"go:GO:0006997","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nucleus.\" [GOC:dph, GOC:ems, GOC:jl, GOC:mah]","metadata":null},{"id":"d3a1127adf9f45e8a70458e0bb57deeb","type":"GO_TERM","name":"nucleus-vacuole junction","canonical_id":"go:GO:0071561","description":"\"An organelle membrane contact site formed between the vacuole membrane and the outer nuclear membrane. In S. cerevisiae these contacts are mediated through direct physical interaction between Vac8p and Nvj1p.\" [GOC:jp, PMID:16709156, PMID:16806880]","metadata":null},{"id":"b789b423be9249bd9facb831f01e000b","type":"GO_TERM","name":"nucleus-vacuole junction assembly","canonical_id":"go:GO:0071562","description":"\"The aggregation, arrangement and bonding together of a set of components to form a nucleus-vacuole junction (NVJ), membrane contact sites formed between the vacuole membrane and the outer nuclear membrane. In S. cerevisiae these contacts are mediated through direct physical interaction between Vac8p and Nvj1p. The NVJ plays roles in piecemeal microautophagy of the nucleus and in the cytoplasm-to-vacuole targeting pathway.\" [GOC:jp, PMID:16709156, PMID:28533415]","metadata":null},{"id":"2c432141357a4a35aa13e927bbd73e6c","type":"GO_TERM","name":"nurse cell apoptotic process","canonical_id":"go:GO:0045476","description":"\"Any apoptotic process in a nurse cell. During late oogenesis, following the transfer of substances from the nurse cells to the oocyte, nurse cell remnants are cleared from the egg chamber by apoptotic process.\" [CL:0000026, GOC:mtg_apoptosis, PMID:11973306]","metadata":null},{"id":"8643984486d642328bff518ea704dad3","type":"GO_TERM","name":"nurse cell nucleus anchoring","canonical_id":"go:GO:0007302","description":"\"Attachment of the nurse cell nucleus to the plasma membrane.\" [ISBN:0879694238]","metadata":null},{"id":"658ff881a5e54d08b9a4330716201e75","type":"GO_TERM","name":"nutrient reservoir activity","canonical_id":"go:GO:0045735","description":"\"Functions in the storage of nutritious substrates.\" [GOC:ai]","metadata":null},{"id":"dc6f5c2090d64f1c8b58c6d535750d9c","type":"GO_TERM","name":"nutrient storage","canonical_id":"go:GO:0170062","description":"\"The accumulation and maintenance in cells or tissues of a nutrient, a substance that is used by an organism to survive, to grow, and to reproduce; such as proteins, vitamins, and minerals. Nutrient reserves can be accumulated for mobilization and utilization when needed.\" [GOC:ew]","metadata":null},{"id":"6c231a075b214c83ae4bd46ff6c885b3","type":"DISEASE","name":"nutritional or metabolic disease","canonical_id":"otar:0000020","description":null,"metadata":null},{"id":"d5a6353cb23941e6a12d0220ab5ca353","type":"GO_TERM","name":"nylon catabolic process","canonical_id":"go:GO:0019876","description":"\"The chemical reactions and pathways resulting in the breakdown of nylon, a polymer where the main polymer chain comprises recurring amide groups; these compounds are generally formed from combinations of diamines, diacids and amino acids.\" [UniProtKB-KW:KW-0549]","metadata":null},{"id":"54f07aa3ec5d4b9ea6db9d5cf5f4a62c","type":"DRUG","name":"nystatin","canonical_id":"mesh:D009761","description":null,"metadata":null},{"id":"603b7aeb0dca4db38b51a4de00518e4c","type":"GO_TERM","name":"o-aminophenol oxidase activity","canonical_id":"go:GO:0050149","description":"\"Catalysis of the reaction: 2 2-aminophenol + 3 O2 = 2 isophenoxazine + 6 H2O.\" [EC:1.10.3.4, MetaCyc:O-AMINOPHENOL-OXIDASE-RXN]","metadata":null},{"id":"a44154d233024148a2c8fd37625487ac","type":"GO_TERM","name":"o-dihydroxycoumarin 7-O-glucosyltransferase activity","canonical_id":"go:GO:0047208","description":"\"Catalysis of the reaction: 7,8-dihydroxycoumarin + UDP-D-glucose = daphnin + H+ + UDP.\" [EC:2.4.1.104, RHEA:14325]","metadata":null},{"id":"b7b40988592e4103bf7e2f7c74ad4139","type":"GO_TERM","name":"o-orsellinic acid biosynthetic process","canonical_id":"go:GO:1900584","description":"\"The chemical reactions and pathways resulting in the formation of o-orsellinic acid.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"80461c375ce74278a57cbcb020744d6e","type":"GO_TERM","name":"o-orsellinic acid catabolic process","canonical_id":"go:GO:1900583","description":"\"The chemical reactions and pathways resulting in the breakdown of o-orsellinic acid.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"885fb6fe482a4b3f8c10f4c1242c38cb","type":"GO_TERM","name":"o-pyrocatechuate decarboxylase activity","canonical_id":"go:GO:0050150","description":"\"Catalysis of the reaction: 2,3-dihydroxybenzoate + H+ = catechol + CO2.\" [EC:4.1.1.46, RHEA:21492]","metadata":null},{"id":"1edf8f65eda244c68256284fd7e85577","type":"GO_TERM","name":"o-succinylbenzoate-CoA ligase activity","canonical_id":"go:GO:0008756","description":"\"Catalysis of the reaction: 2-succinylbenzoate + ATP + CoA = 2-succinylbenzoyl-CoA + AMP + diphosphate.\" [EC:6.2.1.26]","metadata":null},{"id":"3c36925ade9c4681a6fbbffb5ea1a35d","type":"GO_TERM","name":"o-xylene catabolic process","canonical_id":"go:GO:0042186","description":"\"The chemical reactions and pathways resulting in the breakdown of o-xylene, (1,2-dimethylbenzene) a colorless, liquid aromatic hydrocarbon.\" [GOC:jl]","metadata":null},{"id":"897a8f0ef8e740ac980a837e9b361e28","type":"DISEASE","name":"obesity disorder","canonical_id":"mondo:0011122","description":null,"metadata":null},{"id":"9aca11018d884747abf808b2cf0830dd","type":"DRUG","name":"obeticholic acid","canonical_id":"gtopdb:3435","description":null,"metadata":null},{"id":"043024ba0d1741a7a65244beb43ddd7b","type":"DRUG","name":"obeticholic acid","canonical_id":"chembl:CHEMBL566315","description":null,"metadata":null},{"id":"05f0b1505d2e41af98605579f0f7d5cb","type":"DRUG","name":"obiltoxaximab","canonical_id":"mesh:C000611266","description":null,"metadata":null},{"id":"a9fe48f0863e4a12ab497dd63fd3a92b","type":"DRUG","name":"obinutuzumab","canonical_id":"gtopdb:6941","description":null,"metadata":null},{"id":"e6a235e5d4644b7bb393377fb3a25db3","type":"DRUG","name":"obinutuzumab","canonical_id":"chembl:CHEMBL1743048","description":null,"metadata":null},{"id":"db982ebf59be4d83a66ba6d16bf32c68","type":"COMBINATION_TREATMENT","name":"obinutuzumab + polatuzumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-5404f943ae477e28","description":null,"metadata":null},{"id":"150ec9d712114edfa5b7f0ad8ac4b801","type":"COMBINATION_TREATMENT","name":"obinutuzumab + polatuzumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-e7576d68afd28a3a","description":null,"metadata":null},{"id":"2379ca851106499384a21fbd4f9d46ad","type":"COMBINATION_TREATMENT","name":"obinutuzumab + polatuzumab vedotin + prednisone + rituximab + tocilizumab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-48ae16a9b068a2aa","description":null,"metadata":null},{"id":"c4bcbb3b6daa4999a454ed3957e213cf","type":"COMBINATION_TREATMENT","name":"obinutuzumab + polatuzumab vedotin + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-fdb37adea45475c4","description":null,"metadata":null},{"id":"c80c711221de46eb8bc5cc48960764e6","type":"COMBINATION_TREATMENT","name":"obinutuzumab + rituximab","canonical_id":"ctgov_combo:ctgov-combo-4818c325c2422471","description":null,"metadata":null},{"id":"d175e76f9f834ab1939be035f31eedb3","type":"COMBINATION_TREATMENT","name":"obinutuzumab + romidepsin","canonical_id":"ctgov_combo:ctgov-combo-7b02e5f4cec6ae3d","description":null,"metadata":null},{"id":"75f9a47f4df944d686c6365fd5f110cd","type":"COMBINATION_TREATMENT","name":"obinutuzumab + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-3859a6258e2e29a3","description":null,"metadata":null},{"id":"6224e9efa9854fb88c34d7eafea44bd4","type":"COMBINATION_TREATMENT","name":"obinutuzumab + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-2592116d0de15be2","description":null,"metadata":null},{"id":"956a796966de439fa72040297a173ecb","type":"COMBINATION_TREATMENT","name":"obinutuzumab + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-c67b11b19ad43e34","description":null,"metadata":null},{"id":"625a8907da4c4dc789b1c889eebb98dc","type":"COMBINATION_TREATMENT","name":"obinutuzumab + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-eb88054574b72b3a","description":null,"metadata":null},{"id":"b4b3ab383fad4d65827d21e7d3bcb1ac","type":"COMBINATION_TREATMENT","name":"obinutuzumab + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-8a8f84feb8189eda","description":null,"metadata":null},{"id":"68757c481ea14bb6ae27dc02e96c2f35","type":"GO_TERM","name":"observational learning","canonical_id":"go:GO:0098597","description":"\"Learning that occurs through observing the behavior of others.\" [GOC:dos, Wikipedia:Observational_learning&oldid=603524137]","metadata":null},{"id":"cc30f610129c42499bd1966088f526e8","type":"DISEASE","name":"obsessive-compulsive disorder","canonical_id":"mondo:0008114","description":null,"metadata":null},{"id":"8370dc090239444eb6dda0aea84ff99a","type":"DISEASE","name":"obstructive sleep apnea syndrome","canonical_id":"mondo:0007147","description":null,"metadata":null},{"id":"8c414e7e6c5d4b1e9e9b6abc703016f2","type":"GO_TERM","name":"ocelloid","canonical_id":"go:GO:0097693","description":"\"Eye-like subcellular structure found in dinoflagellates (a large group of single-celled eukaryotes). Consists of subcellular analogues to a cornea, lens, iris, and retina. Ocelloids are built from pre-existing organelles, including a cornea-like layer made of mitochondria and a retinal body made of anastomosing plastids.\" [GOC:ar, PMID:26131935]","metadata":null},{"id":"5d14e9edab384a488f36d5af23045ecf","type":"GO_TERM","name":"ocellus development","canonical_id":"go:GO:0008056","description":"\"The process whose specific outcome is the progression of the ocellus over time, from its formation to the mature structure. The ocellus is a simple visual organ of insects.\" [http://fly.ebi.ac.uk/.bin/cvreport2?id=FBcv0004540]","metadata":null},{"id":"ad2043e578ab4e43ae233a9aba95cfea","type":"GO_TERM","name":"ocellus morphogenesis","canonical_id":"go:GO:0048816","description":"\"The process in which the anatomical structures of the ocellus are generated and organized. The ocellus is a simple visual organ of insects.\" [http://fly.ebi.ac.uk/.bin/cvreport2?id=FBcv0004540]","metadata":null},{"id":"4a34b028713841e88618e7fc280771af","type":"GO_TERM","name":"ocellus photoreceptor cell development","canonical_id":"go:GO:0042463","description":"\"Development of photoreceptors, sensory cells that react to the presence of light, found in the ocellus.\" [GOC:jl, ISBN:0192800981, PMID:11542766]","metadata":null},{"id":"e7030585769942cbb71202e3e718001a","type":"GO_TERM","name":"ocellus photoreceptor cell differentiation","canonical_id":"go:GO:0042705","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a photoreceptor cell found in the ocellus.\" [GOC:curators]","metadata":null},{"id":"c7cfc78b56de420db70922ede0ae551f","type":"GO_TERM","name":"ocellus photoreceptor cell fate commitment","canonical_id":"go:GO:0042707","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into photoreceptor cell in the ocellus. A photoreceptor cell is a cell that responds to incident electromagnetic radiation. Different classes of photoreceptor have different spectral sensitivities and express different photosensitive pigments.\" [GOC:mtg_sensu]","metadata":null},{"id":"e76bb91fe9ee4f07a6b5ebbc3165ff8d","type":"GO_TERM","name":"ocellus pigment biosynthetic process","canonical_id":"go:GO:0008055","description":"\"The chemical reactions and pathways resulting in the formation of ocellus pigments, general or particular coloring matter in living organisms, found or utilized in the ocellus, a minute simple eye found in many invertebrates.\" [GOC:ai, PMID:15176085, PMID:18421706]","metadata":null},{"id":"77b7eee2246348d681365699b2745f41","type":"GO_TERM","name":"ocellus pigment catabolic process","canonical_id":"go:GO:0046159","description":"\"The chemical reactions and pathways resulting in the breakdown of ocellus pigments, any general or particular coloring matter in living organisms, found or utilized in the ocellus, a minute simple eye found in many invertebrates.\" [GOC:ai, PMID:15176085, PMID:18421706]","metadata":null},{"id":"27a67c307c924fa19bf5179510868b52","type":"GO_TERM","name":"ocellus pigment granule organization","canonical_id":"go:GO:0008058","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of intracellular pigment storage granules in the ocellus.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm]","metadata":null},{"id":"5adb8776293c48c8a1f971443b174993","type":"GO_TERM","name":"ocellus pigment metabolic process","canonical_id":"go:GO:0046158","description":"\"The chemical reactions and pathways involving ocellus pigments, any general or particular coloring matter in living organisms, found or utilized in the ocellus, a minute simple eye found in many invertebrates.\" [GOC:ai, PMID:15176085, PMID:18421706]","metadata":null},{"id":"eec4a15e564f4c328b4f67bac246e871","type":"GO_TERM","name":"ocellus pigmentation","canonical_id":"go:GO:0033060","description":"\"The deposition or aggregation of coloring matter in an ocellus, a minute simple eye found in many invertebrates.\" [GOC:mtg_MIT_16mar07]","metadata":null},{"id":"eb6ce432996b4affb94a837eb3657324","type":"GO_TERM","name":"ochratoxin A biosynthetic process","canonical_id":"go:GO:1900818","description":"\"The chemical reactions and pathways resulting in the formation of ochratoxin A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3519e087d13544bea20b1b77228220e3","type":"GO_TERM","name":"ochratoxin A catabolic process","canonical_id":"go:GO:1900817","description":"\"The chemical reactions and pathways resulting in the breakdown of ochratoxin A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f6fe6faeb3e045348736287d05bce9f5","type":"DRUG","name":"ocrelizumab","canonical_id":"gtopdb:7580","description":null,"metadata":null},{"id":"68fc3af82b63411ba9ba13927ab16708","type":"DRUG","name":"ocrelizumab","canonical_id":"chembl:CHEMBL2108041","description":null,"metadata":null},{"id":"29cd7762b98a47769063c04f3657314c","type":"COMBINATION_TREATMENT","name":"ocrelizumab + ofatumumab","canonical_id":"ctgov_combo:ctgov-combo-1abdd4d02a13cc5d","description":null,"metadata":null},{"id":"b2a0f580a3a14c9cbb2c53492b1e733c","type":"COMBINATION_TREATMENT","name":"ocrelizumab + ofatumumab + teriflunomide","canonical_id":"ctgov_combo:ctgov-combo-1ea3ad1c52e8af37","description":null,"metadata":null},{"id":"cd334caf4ae144469ef02fd6602bf658","type":"COMBINATION_TREATMENT","name":"ocrelizumab + ublituximab","canonical_id":"ctgov_combo:ctgov-combo-25482237fd8b34ce","description":null,"metadata":null},{"id":"0372476836584be8953e6c0afa8bfbbe","type":"GO_TERM","name":"octamethylcyclotetrasiloxane catabolic process","canonical_id":"go:GO:0046517","description":"\"The chemical reactions and pathways resulting in the breakdown of octamethylcyclotetrasiloxane, a cyclic silicone-oxygen ring compound with two methyl groups attached to each silicone atom.\" [GOC:ai, PMID:10224038]","metadata":null},{"id":"b4b7a2202148442b84c2a1d50d868928","type":"GO_TERM","name":"octanoic acid binding","canonical_id":"go:GO:1904767","description":"\"Binding to octanoic acid.\" [GO_REF:0000067, GOC:kmv, GOC:TermGenie, PMID:19828452]","metadata":null},{"id":"1073c480e79c4b1fa439ca3f75523df1","type":"GO_TERM","name":"octanol biosynthetic process","canonical_id":"go:GO:0046171","description":"\"The chemical reactions and pathways resulting in the formation of octanol, the 8-carbon alcohol with the formula C8H17OH.\" [GOC:ai]","metadata":null},{"id":"56c8a163500f4cda9749932e343ec6d9","type":"GO_TERM","name":"octanol catabolic process","canonical_id":"go:GO:0046172","description":"\"The chemical reactions and pathways resulting in the breakdown of octanol, the 8-carbon alcohol with the formula C8H17OH.\" [GOC:ai]","metadata":null},{"id":"9a671077c91b498b8947ecbed6464173","type":"GO_TERM","name":"octanol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004552","description":"\"Catalysis of the reaction: 1-octanol + NAD+ = 1-octanal + H+ + NADH.\" [EC:1.1.1.73, RHEA:24620]","metadata":null},{"id":"58c807c9d4114f0a9f95ea8939e1084d","type":"GO_TERM","name":"octanol metabolic process","canonical_id":"go:GO:0006070","description":"\"The chemical reactions and pathways involving octanol, the 8-carbon alcohol with the formula C8H17OH.\" [GOC:curators]","metadata":null},{"id":"54580313b840487ba2d5ccd6bd46ddd7","type":"DRUG","name":"octatropine methylbromide","canonical_id":"mesh:C100237","description":null,"metadata":null},{"id":"66f40be0818244e8bb48124804c2416f","type":"DRUG","name":"octinoxate","canonical_id":"mesh:C516303","description":null,"metadata":null},{"id":"f97c66bf650e4b899eab18abbf31d880","type":"GO_TERM","name":"octopamine biosynthetic process","canonical_id":"go:GO:0006589","description":"\"The chemical reactions and pathways resulting in the formation of octopamine, 1-(p-hydroxyphenyl)-2-aminoethanol. The D enantiomer is about one-tenth as active as norepinephrine and is found in the salivary glands of Octopus and Eledone species.\" [ISBN:0198506732]","metadata":null},{"id":"ce5ed66997634eae813de5d1a4666222","type":"GO_TERM","name":"octopamine catabolic process","canonical_id":"go:GO:0046334","description":"\"The chemical reactions and pathways resulting in the breakdown of octopamine, 1-(p-hydroxyphenyl)-2-aminoethanol. The D enantiomer is about one-tenth as active as norepinephrine and is found in the salivary glands of Octopus and Eledone species.\" [ISBN:0198506732]","metadata":null},{"id":"b59dde7f4f0b42efb71383ac5ae53c58","type":"GO_TERM","name":"octopamine dehydratase activity","canonical_id":"go:GO:0050202","description":"\"Catalysis of the reaction: 1-(4-hydroxyphenyl)-2-aminoethanol = (4-hydroxyphenyl)acetaldehyde + NH4.\" [EC:4.2.1.87, RHEA:18173]","metadata":null},{"id":"b1365b1018244263bfda17ffd35b1941","type":"GO_TERM","name":"octopamine loading into synaptic vesicle","canonical_id":"go:GO:0160312","description":"\"The active transport of octopamine neurotransmitters into a synaptic vesicle.\" [PMID:15849736, PMID:9870940]","metadata":null},{"id":"4e28950aede24aafb2d2de1b947ee737","type":"GO_TERM","name":"octopamine metabolic process","canonical_id":"go:GO:0046333","description":"\"The chemical reactions and pathways involving octopamine, 1-(p-hydroxyphenyl)-2-aminoethanol. The D enantiomer is about one-tenth as active as norepinephrine and is found in the salivary glands of Octopus and Eledone species.\" [ISBN:0198506732]","metadata":null},{"id":"29677387cd414e139d1a7a630468685b","type":"GO_TERM","name":"octopamine or tyramine signaling pathway","canonical_id":"go:GO:0007211","description":"\"A G protein-coupled receptor signaling pathway initiated by octopamine or tyramine binding to their receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription, and ending with the regulation of a downstream cellular process. Octopamine and tyramine are decarboxylation products of tyrosine, and are the invertebrate counterparts of the vertebrate adrenergic transmitters.\" [GOC:mah, PMID:15355245]","metadata":null},{"id":"1954428d234d43ff80d736ddbc0e25a9","type":"GO_TERM","name":"octopamine receptor activity","canonical_id":"go:GO:0004989","description":"\"Combining with the biogenic amine octopamine to initiate a change in cell activity. Octopamine is found in both vertebrates and invertebrates and can have properties both of a hormone and a neurotransmitter and acts as an adrenergic agonist.\" [GOC:ai]","metadata":null},{"id":"c9d751d5c558484da2f401d2e01e3dbf","type":"GO_TERM","name":"octopamine secretion","canonical_id":"go:GO:0061539","description":"\"The controlled release of octopamine by a cell.\" [GOC:dph]","metadata":null},{"id":"da91961577354484be2d89f8d5d761ac","type":"GO_TERM","name":"octopamine secretion, neurotransmission","canonical_id":"go:GO:0061540","description":"\"The controlled release of octopamine by a cell, in which the octopamine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"289f1aacba5c4c048cd1fbb4d1c7bcfc","type":"GO_TERM","name":"octopamine signaling pathway","canonical_id":"go:GO:0071927","description":"\"The series of molecular signals generated as a consequence of octopamine binding to a cell surface receptor.\" [GOC:mah, PMID:15355245]","metadata":null},{"id":"36f6f6d3bacd47b48d291acce2f313bd","type":"GO_TERM","name":"octopamine transport","canonical_id":"go:GO:7770033","description":"\"The directed movement of octopamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Octopamine is a monoamine neurotransmitter occurring predominantly in invertebrates.\" [PMID:15849736, PMID:32305263, PMID:9870940]","metadata":null},{"id":"5047e58c71774b4ca9089d44bb9bba72","type":"DISEASE","name":"ocular hypertension","canonical_id":"mondo:0006875","description":null,"metadata":null},{"id":"1850cd2b67eb4ccb810ae9941ac05a8d","type":"DISEASE","name":"ocular vascular disorder","canonical_id":"mondo:0005552","description":null,"metadata":null},{"id":"484e37a6a8ab40a19739bc085d16b7c6","type":"GO_TERM","name":"oculomotor nerve development","canonical_id":"go:GO:0021557","description":"\"The process whose specific outcome is the progression of the oculomotor nerve over time, from its formation to the mature structure. This motor nerve innervates all extraocular muscles except the superior oblique and the lateral rectus muscles. The superior division supplies the levator palpebrae superioris and superior rectus muscles. The inferior division supplies the medial rectus, inferior rectus and inferior oblique muscles. This nerve also innervates the striated muscles of the eyelid. Pupillary constriction and lens movement are mediated by this nerve for near vision. In the orbit the inferior division sends branches that enter the ciliary ganglion where they form functional contacts (synapses) with the ganglion cells. The ganglion cells send nerve fibers into the back of the eye where they travel to ultimately innervate the ciliary muscle and the constrictor pupillae muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"5902e63d85c54aebae8fdd8111c9245f","type":"GO_TERM","name":"oculomotor nerve formation","canonical_id":"go:GO:0021623","description":"\"The process that gives rise to the oculomotor nerve. This process pertains to the initial formation of a structure from unspecified parts. This motor nerve innervates all extraocular muscles except the superior oblique and the lateral rectus muscles. The superior division supplies the levator palpebrae superioris and superior rectus muscles. The inferior division supplies the medial rectus, inferior rectus and inferior oblique muscles. This nerve also innervates the striated muscles of the eyelid. Pupillary constriction and lens movement are mediated by this nerve for near vision. In the orbit the inferior division sends branches that enter the ciliary ganglion where they form functional contacts (synapses) with the ganglion cells. The ganglion cells send nerve fibers into the back of the eye where they travel to ultimately innervate the ciliary muscle and the constrictor pupillae muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"eb38c07583d349b8bd7785de3d3babd4","type":"GO_TERM","name":"oculomotor nerve maturation","canonical_id":"go:GO:0021625","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the oculomotor nerve to attain its fully functional state. This motor nerve innervates all extraocular muscles except the superior oblique and the lateral rectus muscles. The superior division supplies the levator palpebrae superioris and superior rectus muscles. The inferior division supplies the medial rectus, inferior rectus and inferior oblique muscles. This nerve also innervates the striated muscles of the eyelid. Pupillary constriction and lens movement are mediated by this nerve for near vision. In the orbit the inferior division sends branches that enter the ciliary ganglion where they form functional contacts (synapses) with the ganglion cells. The ganglion cells send nerve fibers into the back of the eye where they travel to ultimately innervate the ciliary muscle and the constrictor pupillae muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"2e679e84c84e4d4493d416953c987aac","type":"GO_TERM","name":"oculomotor nerve morphogenesis","canonical_id":"go:GO:0021622","description":"\"The process in which the anatomical structure of the oculomotor nerve is generated and organized. This motor nerve innervates all extraocular muscles except the superior oblique and the lateral rectus muscles. The superior division supplies the levator palpebrae superioris and superior rectus muscles. The inferior division supplies the medial rectus, inferior rectus and inferior oblique muscles. This nerve also innervates the striated muscles of the eyelid. Pupillary constriction and lens movement are mediated by this nerve for near vision. In the orbit the inferior division sends branches that enter the ciliary ganglion where they form functional contacts (synapses) with the ganglion cells. The ganglion cells send nerve fibers into the back of the eye where they travel to ultimately innervate the ciliary muscle and the constrictor pupillae muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"3f205ee14aa547539e6069d7ae23739f","type":"GO_TERM","name":"oculomotor nerve structural organization","canonical_id":"go:GO:0021624","description":"\"The process that contributes to the act of creating the structural organization of the oculomotor nerve. This process pertains to the physical shaping of a rudimentary structure. This motor nerve innervates all extraocular muscles except the superior oblique and the lateral rectus muscles. The superior division supplies the levator palpebrae superioris and superior rectus muscles. The inferior division supplies the medial rectus, inferior rectus and inferior oblique muscles. This nerve also innervates the striated muscles of the eyelid. Pupillary constriction and lens movement are mediated by this nerve for near vision. In the orbit the inferior division sends branches that enter the ciliary ganglion where they form functional contacts (synapses) with the ganglion cells. The ganglion cells send nerve fibers into the back of the eye where they travel to ultimately innervate the ciliary muscle and the constrictor pupillae muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"902f76fc1d974d33883f7b3a80c0b6fa","type":"GO_TERM","name":"odontoblast differentiation","canonical_id":"go:GO:0071895","description":"\"The process in which a relatively unspecialized cell of neural crest origin acquires the specialized features of an odontoblast, a cell on the outer surface of the dental pulp whose biological function is the creation of dentin.\" [GOC:sl, PMID:20425127]","metadata":null},{"id":"7cdc71cc335c44ec8d0e0343086c9733","type":"GO_TERM","name":"odontogenesis","canonical_id":"go:GO:0042476","description":"\"The process whose specific outcome is the progression of a tooth or teeth over time, from formation to the mature structure(s). A tooth is any hard bony, calcareous, or chitinous organ found in the mouth or pharynx of an animal and used in procuring or masticating food.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"3633346db418498b9ed7649a119a6d21","type":"GO_TERM","name":"odontogenesis of dentin-containing tooth","canonical_id":"go:GO:0042475","description":"\"The process whose specific outcome is the progression of a dentin-containing tooth over time, from its formation to the mature structure. A dentin-containing tooth is a hard, bony organ borne on the jaw or other bone of a vertebrate, and is composed mainly of dentin, a dense calcified substance, covered by a layer of enamel.\" [GOC:cjm, GOC:mah, GOC:mtg_sensu, PMID:10333884, PMID:15355794]","metadata":null},{"id":"f7ed897aa88f4a72972fc8aa38181ea6","type":"GO_TERM","name":"odorant binding","canonical_id":"go:GO:0005549","description":"\"Binding to an odorant, any substance capable of stimulating the sense of smell.\" [GOC:jl, ISBN:0721662544]","metadata":null},{"id":"f8a3be2b60bd4afc8849849d37d72eb8","type":"GO_TERM","name":"oenocyte delamination","canonical_id":"go:GO:0060233","description":"\"The negative regulation of cell adhesion process in which an oenocyte splits off of an existing epithelial sheet.\" [GOC:dph]","metadata":null},{"id":"e3a24598f6f848e0a6f1d71799dbc646","type":"GO_TERM","name":"oenocyte development","canonical_id":"go:GO:0007438","description":"\"The process whose specific outcome is the progression of the oenocyte over time, from its formation to the mature structure. The oenocytes are large secretory cells found in clusters underlying the epidermis of larval abdominal segments.\" [GOC:bf, PMID:11171397]","metadata":null},{"id":"da655b3f56cb4aa1b4167f7b12761bb6","type":"GO_TERM","name":"oenocyte differentiation","canonical_id":"go:GO:0001742","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an oenocyte. Oenocytes are large secretory cells found in clusters underlying the epidermis of larval abdominal segments.\" [GOC:curators]","metadata":null},{"id":"4103465bb1f441f791785726926ed797","type":"DRUG","name":"ofatumumab","canonical_id":"gtopdb:6778","description":null,"metadata":null},{"id":"7fa7af969b934de6a26fe140d3461fbe","type":"DRUG","name":"ofatumumab","canonical_id":"chembl:CHEMBL1201836","description":null,"metadata":null},{"id":"71606b9e4d8249beb33d4b91a714bf66","type":"COMBINATION_TREATMENT","name":"ofatumumab + pentostatin","canonical_id":"ctgov_combo:ctgov-combo-56ad799a2f417053","description":null,"metadata":null},{"id":"ec02fad5f5fd47288f980834bf561631","type":"COMBINATION_TREATMENT","name":"ofatumumab + thioguanine","canonical_id":"ctgov_combo:ctgov-combo-16a3c9e06fee0f5f","description":null,"metadata":null},{"id":"5db5d8b6d1c2449f966a801226ca8172","type":"DRUG","name":"ofloxacin","canonical_id":"mesh:D015242","description":null,"metadata":null},{"id":"d2e533fc9a91452b9f45bbcbda1d667b","type":"GO_TERM","name":"oidium formation","canonical_id":"go:GO:0034297","description":"\"The process in which oidia, a type of asexual spore found in fungi, are formed. Oidia are borne a few at a time on very simple hyphae that protrude a short distance into the substrate, and are usually presumed not to constitute the main reproductive strategy of the fungus.\" [GOC:mah, https://doi.org/10.1007/BF02464287]","metadata":null},{"id":"e4752a1495024b9d9d29ea820befeca5","type":"DRUG","name":"olanzapine","canonical_id":"gtopdb:47","description":null,"metadata":null},{"id":"18a850b760b64c2ab48ca1d082a34d78","type":"DRUG","name":"olanzapine","canonical_id":"chembl:CHEMBL715","description":null,"metadata":null},{"id":"8750e1187df646a0bed95bdc9efdea4f","type":"COMBINATION_TREATMENT","name":"olanzapine + palonosetron","canonical_id":"ctgov_combo:ctgov-combo-d246041b95cf3420","description":null,"metadata":null},{"id":"8ce2c338f8804c19a31c65cd27dcc2dd","type":"COMBINATION_TREATMENT","name":"olanzapine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-c8fd007ad9b73934","description":null,"metadata":null},{"id":"a9655863658445bb87d29da314cfe9ce","type":"COMBINATION_TREATMENT","name":"olanzapine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-20c23f23f2ea1eec","description":null,"metadata":null},{"id":"a0147095e00a4cb28feb20ab16a21e85","type":"COMBINATION_TREATMENT","name":"olanzapine + risperidone","canonical_id":"ctgov_combo:ctgov-combo-726619c27f38df8a","description":null,"metadata":null},{"id":"84182fdd33db454a96233b824880e7b4","type":"COMBINATION_TREATMENT","name":"olanzapine + risperidone + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-249e75a64feb5cec","description":null,"metadata":null},{"id":"3aa3ac091fb846bcb7f0ed2b4f7a6f00","type":"COMBINATION_TREATMENT","name":"olanzapine + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-48f82935d3191a26","description":null,"metadata":null},{"id":"7a1fbbf7f6d148e2abc96ea2fe0f78dc","type":"COMBINATION_TREATMENT","name":"olanzapine + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-4e74c4c18381c172","description":null,"metadata":null},{"id":"f898ba081525416c9c55bc848ecfb756","type":"COMBINATION_TREATMENT","name":"olanzapine + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-7556b04469b0d9bf","description":null,"metadata":null},{"id":"239c956183a942c394350aabaecab702","type":"DRUG","name":"olaparib","canonical_id":"gtopdb:7519","description":null,"metadata":null},{"id":"549496ee280c4e4981b7285a234e0e48","type":"DRUG","name":"olaparib","canonical_id":"chembl:CHEMBL521686","description":null,"metadata":null},{"id":"6b5661b147744ac2976441f93d43d627","type":"COMBINATION_TREATMENT","name":"olaparib + prednisolone + prednisone","canonical_id":"ctgov_combo:ctgov-combo-49ff721a402b4122","description":null,"metadata":null},{"id":"fcc795ab57814009a577877488c8f7ea","type":"DRUG","name":"olaratumab","canonical_id":"gtopdb:9172","description":null,"metadata":null},{"id":"734276ae5e2a47809c0ebb639627ac09","type":"DRUG","name":"olaratumab","canonical_id":"mesh:C000589393","description":null,"metadata":null},{"id":"871dff13c6c9431990a755293a0f2883","type":"DRUG","name":"olaratumab","canonical_id":"chembl:CHEMBL1743049","description":null,"metadata":null},{"id":"8a60990c201544ddae855b7745d7c4f2","type":"GO_TERM","name":"old cell pole","canonical_id":"go:GO:1990901","description":"\"The cell pole distal from the most recent cell division.\" [GOC:jh2, PMID:10231492, PMID:8226658]","metadata":null},{"id":"e78b5c9aa526486697ce13e5c6289bc1","type":"GO_TERM","name":"old growing cell tip","canonical_id":"go:GO:0035840","description":"\"A cell tip which has existed for at least one complete cell cycle, and at which polarized growth occurs. For example, in fission yeast the cell end that existed prior to cell division grows immediately after division, and contains a distinctive complement of proteins including actin cytoskeletal structures.\" [GOC:expert_jd, GOC:mah]","metadata":null},{"id":"2df013b948f841b084b9e32f4ffeb231","type":"GO_TERM","name":"old mitotic spindle pole body","canonical_id":"go:GO:0071957","description":"\"The spindle pole body that exists in a cell prior to spindle pole body duplication. An old spindle pole body segregates to the daughter cell upon mitosis, and lacks active proteins involved in signaling exit from mitosis.\" [GOC:mah, GOC:vw, PMID:15132994]","metadata":null},{"id":"c2ed4e6187a842808e93cbca685a1f70","type":"GO_TERM","name":"oleate 12-hydroxylase activity","canonical_id":"go:GO:0102517","description":"\"Catalysis of the reaction: (9Z)-octadecenoate + AH2 + O2 = (12R)-hydroxy-(9Z)-octadecenoate + acceptor + H2O.\" [RHEA:55956]","metadata":null},{"id":"1823d53c532647778f1f628738db7fc1","type":"GO_TERM","name":"oleate hydratase activity","canonical_id":"go:GO:0050151","description":"\"Catalysis of the reaction: (R)-10-hydroxystearate = H2O + oleate.\" [EC:4.2.1.53, RHEA:21852]","metadata":null},{"id":"74f143c1f0f74a32aaa1b165d3600470","type":"GO_TERM","name":"oleate transmembrane transporter activity","canonical_id":"go:GO:1901480","description":"\"Enables the transfer of oleate from one side of a membrane to the other.\" [GOC:TermGenie, PMID:19493158]","metadata":null},{"id":"2346ed6d27bd481ca57fb4ca9ca6cdbc","type":"GO_TERM","name":"olefin biosynthetic process","canonical_id":"go:GO:1900674","description":"\"The chemical reactions and pathways resulting in the formation of olefin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"46e630caee9a41eeac9902d2b6628f0a","type":"GO_TERM","name":"olefin metabolic process","canonical_id":"go:GO:1900673","description":"\"The chemical reactions and pathways involving olefin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"6209b8e09b964fe3ba5e0c6b891e29e1","type":"GO_TERM","name":"olefinic compound biosynthetic process","canonical_id":"go:GO:0120255","description":"\"The chemical reactions and pathways resulting in the formation of an olefinic compound, any compound which contains a carbon-carbon double bond (aka C=C).\" [GOC:krc]","metadata":null},{"id":"55def63f8700448ea68c8c3956da7aed","type":"GO_TERM","name":"olefinic compound catabolic process","canonical_id":"go:GO:0120256","description":"\"The chemical reactions and pathways resulting in the breakdown of an olefinic compound, any compound which contains a carbon-carbon double bond (aka C=C).\" [GOC:krc]","metadata":null},{"id":"07c7301ad3e447bb9c3e217c723bb85f","type":"GO_TERM","name":"olefinic compound metabolic process","canonical_id":"go:GO:0120254","description":"\"The chemical reactions and pathways involving an olefinic compound, any compound which contains a carbon-carbon double bond (aka C=C).\" [GOC:krc]","metadata":null},{"id":"5c8e252b139f4f95824ca0a2f036c886","type":"GO_TERM","name":"oleic acid binding","canonical_id":"go:GO:0070538","description":"\"Binding to oleic acid, the 18-carbon monounsaturated fatty acid (9Z)-octadec-9-enoic acid.\" [GOC:lp, GOC:mah]","metadata":null},{"id":"04d32bd41f7f4ee2b74003ffe430a6f7","type":"GO_TERM","name":"oleoyl-CoA ligase activity","canonical_id":"go:GO:0090434","description":"\"Catalysis of the reaction: ATP + oleic acid + CoA = AMP + diphosphate + oleoyl-CoA.\" [GOC:al, PMID:18071249]","metadata":null},{"id":"4a44a9fd2890433bb789140bdfa4d51b","type":"GO_TERM","name":"olfactory behavior","canonical_id":"go:GO:0042048","description":"\"The behavior of an organism in response to an odor.\" [GOC:jid, GOC:pr]","metadata":null},{"id":"e0e8e2876ac04cac9d0a08ae60eda6bc","type":"GO_TERM","name":"olfactory bulb axon guidance","canonical_id":"go:GO:0071678","description":"\"The process in which the migration of an axon growth cone of a neuron in the olfactory bulb is directed to its target in the brain in response to a combination of attractive and repulsive cues.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"222c5a4afa6b40dea2f4f3d48ce3192a","type":"GO_TERM","name":"olfactory bulb development","canonical_id":"go:GO:0021772","description":"\"The progression of the olfactory bulb over time from its initial formation until its mature state. The olfactory bulb coordinates neuronal signaling involved in the perception of smell. It receives input from the sensory neurons and outputs to the olfactory cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"600a6f1b461841a6bf38642197f977fd","type":"GO_TERM","name":"olfactory bulb interneuron development","canonical_id":"go:GO:0021891","description":"\"The process whose specific outcome is the progression of an interneuron residing in the olfactory bulb, from its initial commitment, to the fully functional differentiated cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"26a40c4bbc6442a7893d77035a14b910","type":"GO_TERM","name":"olfactory bulb interneuron differentiation","canonical_id":"go:GO:0021889","description":"\"The process in which a neuroblast acquires specialized features of an interneuron residing in the olfactory bulb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"d2f099fb97c84fc18847a8494004da67","type":"GO_TERM","name":"olfactory bulb interneuron fate commitment","canonical_id":"go:GO:0021890","description":"\"The process in which the developmental fate of a neuroblast becomes restricted such that it will develop into an interneuron residing in the olfactory bulb.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"c599abcbb34e4374a15ff47d4041b560","type":"GO_TERM","name":"olfactory bulb mitral cell layer development","canonical_id":"go:GO:0061034","description":"\"The progression of the olfactory bulb mitral cell layer over time from its initial formation until its mature state. The mitral cell layer is composed of pyramidal neurons whose cell bodies are located between the granule cell layer and the plexiform layer.\" [GOC:dph]","metadata":null},{"id":"dc50f9464f4f482eaaef0ecec5d3b316","type":"GO_TERM","name":"olfactory bulb tufted cell development","canonical_id":"go:GO:0061449","description":"\"The process whose specific outcome is the progression of an olfactory bulb tufted cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dph]","metadata":null},{"id":"3079c90a9236415b82bc2d0a3697beb1","type":"GO_TERM","name":"olfactory cortex development","canonical_id":"go:GO:0021989","description":"\"The progression of the olfactory cortex over time from its initial formation until its mature state. The olfactory cortex is involved in the perception of smell. It receives input from the olfactory bulb and is responsible for the identification of odors.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"0922aab37c55480987bba4c095a6010f","type":"GO_TERM","name":"olfactory learning","canonical_id":"go:GO:0008355","description":"\"Any process in an organism in which a relatively long-lasting adaptive behavioral change occurs in response to (repeated) exposure to an olfactory cue.\" [ISBN:0582227089]","metadata":null},{"id":"6d68904b17fd44e893a863557126de80","type":"GO_TERM","name":"olfactory lobe development","canonical_id":"go:GO:0021988","description":"\"The progression of the olfactory lobe over time from its initial formation until its mature state. The olfactory lobe is the area of the brain that process the neural inputs for the sense of smell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"ca8ffe4a6b874ba0988ed5fa24abaa2b","type":"GO_TERM","name":"olfactory nerve development","canonical_id":"go:GO:0021553","description":"\"The process whose specific outcome is the progression of the olfactory nerve over time, from its formation to the mature structure. The olfactory nerve is a collection of sensory nerve rootlets that extend down from the olfactory bulb to the olfactory mucosa of the upper parts of the nasal cavity. This nerve conducts odor information to the brainstem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"98ccfafc00414bda92f2d514ed27ce99","type":"GO_TERM","name":"olfactory nerve formation","canonical_id":"go:GO:0021628","description":"\"The process that gives rise to the olfactory nerve. This process pertains to the initial formation of a structure from unspecified parts. The olfactory nerve is a collection of sensory nerve rootlets that extend down from the olfactory bulb to the olfactory mucosa of the upper parts of the nasal cavity. This nerve conducts odor information to the brainstem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8d30e7168d004c9fad8c8f1b0891a435","type":"GO_TERM","name":"olfactory nerve maturation","canonical_id":"go:GO:0021630","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the olfactory nerve to attain its fully functional state. The olfactory nerve is a collection of sensory nerve rootlets that extend down from the olfactory bulb to the olfactory mucosa of the upper parts of the nasal cavity. This nerve conducts odor information to the brainstem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a1d444d4538c4bfdb39ae9f282722b1a","type":"GO_TERM","name":"olfactory nerve morphogenesis","canonical_id":"go:GO:0021627","description":"\"The process in which the anatomical structure of the olfactory nerve is generated and organized. The olfactory nerve is a collection of sensory nerve rootlets that extend down from the olfactory bulb to the olfactory mucosa of the upper parts of the nasal cavity. This nerve conducts odor information to the brainstem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8b9965c809be4d69b828584177ef26c1","type":"GO_TERM","name":"olfactory nerve structural organization","canonical_id":"go:GO:0021629","description":"\"The process that contributes to the act of creating the structural organization of the oculomotor nerve. This process pertains to the physical shaping of a rudimentary structure. The olfactory nerve is a collection of sensory nerve rootlets that extend down from the olfactory bulb to the olfactory mucosa of the upper parts of the nasal cavity. This nerve conducts odor information to the brainstem.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"fbb162bb54f74648aa3f0a8f137cd7f6","type":"GO_TERM","name":"olfactory pit development","canonical_id":"go:GO:0060166","description":"\"The biological process whose specific outcome is the progression of the olfactory pit from an initial condition to its mature state. This process begins with the formation of the olfactory pit, which is an indentation of the olfactory placode, and ends when the pits hollows out to form the nasopharynx.\" [GOC:dph, ISBN:0124020607]","metadata":null},{"id":"3e8d4e29f72f4dd3860329054df85f5d","type":"GO_TERM","name":"olfactory placode development","canonical_id":"go:GO:0071698","description":"\"The progression of the olfactory placode over time from its initial formation until its mature state. The olfactory placode is a thickening of the neural ectoderm in the head region of the vertebrate embryo which develops into the olfactory region of the nasal cavity.\" [GOC:mah]","metadata":null},{"id":"e570d84038264ceb92ba382fc34725ba","type":"GO_TERM","name":"olfactory placode formation","canonical_id":"go:GO:0030910","description":"\"The formation of a thickening of the neural ectoderm in the head region of the vertebrate embryo which develops into the olfactory region of the nasal cavity.\" [GOC:dgh]","metadata":null},{"id":"868ec16ba693403ca3009078d637c194","type":"GO_TERM","name":"olfactory placode maturation","canonical_id":"go:GO:0071700","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the olfactory placode to attain its fully functional state. The olfactory placode is a thickening of the neural ectoderm in the head region of the vertebrate embryo which develops into the olfactory region of the nasal cavity.\" [GOC:mah]","metadata":null},{"id":"795e81b294ad4112bd587aa87813dd2a","type":"GO_TERM","name":"olfactory placode morphogenesis","canonical_id":"go:GO:0071699","description":"\"The process in which the anatomical structures of the olfactory placode are generated and organized. The olfactory placode is a thickening of the neural ectoderm in the head region of the vertebrate embryo which develops into the olfactory region of the nasal cavity.\" [GOC:mah]","metadata":null},{"id":"283954250983403d8c3e38ffeb1c735f","type":"GO_TERM","name":"olfactory receptor activity","canonical_id":"go:GO:0004984","description":"\"Combining with an odorant and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity in response to detection of smell.\" [GOC:bf, GOC:dph, GOC:sart, PMID:19135896, PMID:21041441]","metadata":null},{"id":"00ce695387e048beaddb53deeddfe457","type":"GO_TERM","name":"olfactory receptor binding","canonical_id":"go:GO:0031849","description":"\"Binding to an olfactory receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cd0e65b4faa144e391c3d6462970cf8b","type":"GO_TERM","name":"olfactory sociosexual communication","canonical_id":"go:GO:0120318","description":"\"The use of external chemical cues called pheromones to send social and sexual information between members of the same species, leading to specific behavioral responses. Pheromones may be detected by two olfactory sensory circuits, the main olfactory pathway and the vomeronasal system.\" [GOC:krc, PMID:17935991]","metadata":null},{"id":"5f426540e4d1483b8a62b699cb51b3be","type":"GO_TERM","name":"oligo-1,6-glucosidase activity","canonical_id":"go:GO:0004574","description":"\"Catalysis of the hydrolysis of (1->6)-alpha-D-glucosidic linkages in some oligosaccharides produced from starch and glycogen by alpha-amylase, and in isomaltose. Releases a free alpha-D-glucose.\" [EC:3.2.1.10]","metadata":null},{"id":"5a0c20b877784dffb0b945a19aa51dd4","type":"GO_TERM","name":"oligodendrocyte apoptotic process","canonical_id":"go:GO:0097252","description":"\"Any apoptotic process in an oligodendrocyte. Oligodendrocytes belong to a class of large neuroglial (macroglial) cells in the central nervous system, where they form the insulating myelin sheath of axons.\" [CL:0000128, GOC:mtg_apoptosis, GOC:yaf, PMID:16723520]","metadata":null},{"id":"350962907d0a4262a457987ced49a128","type":"GO_TERM","name":"oligodendrocyte cell fate commitment","canonical_id":"go:GO:0021779","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an oligodendrocyte.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"609a9ca36bc24c1d9fdf5b01e9310d4a","type":"GO_TERM","name":"oligodendrocyte cell fate specification","canonical_id":"go:GO:0021778","description":"\"The process in which a cell becomes capable of differentiating autonomously into an oligodendrocyte in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2fca8752ede24839823ceae273c7f081","type":"GO_TERM","name":"oligodendrocyte cell migration from the subpallium to the cortex","canonical_id":"go:GO:0021829","description":"\"The directed movement of oligodendrocytes from the subpallium to the cerebral cortex during forebrain development.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"45e0aebfab0146e2885a98f0f51c238c","type":"GO_TERM","name":"oligodendrocyte development","canonical_id":"go:GO:0014003","description":"\"The process aimed at the progression of an oligodendrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. An oligodendrocyte is a type of glial cell involved in myelinating the axons in the central nervous system.\" [GOC:dgh, GOC:ef]","metadata":null},{"id":"bc07187b631348468d01f7c7927079d8","type":"GO_TERM","name":"oligodendrocyte differentiation","canonical_id":"go:GO:0048709","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of an oligodendrocyte. An oligodendrocyte is a type of glial cell involved in myelinating the axons of neurons in the central nervous system.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"e756281f87c44050b2b247e259d2f62c","type":"GO_TERM","name":"oligodendrocyte progenitor proliferation","canonical_id":"go:GO:0070444","description":"\"The multiplication or reproduction of oligodendrocyte progenitor cells by cell division, resulting in the expansion of their population. Oligodendrocyte progenitors give rise to oligodendrocytes, which form the insulating myelin sheath of axons in the central nervous system.\" [GOC:mah, GOC:sl, PMID:15504915]","metadata":null},{"id":"a8e5266850d84ceabe6837492e861957","type":"DISEASE","name":"oligodendroglioma","canonical_id":"mondo:0016695","description":null,"metadata":null},{"id":"a9e31ffdc2494ae1a0cbd730b1938669","type":"GO_TERM","name":"oligogalacturonide lyase activity","canonical_id":"go:GO:0047487","description":"\"Catalysis of the reaction: 4-(4-deoxy-alpha-D-gluc-4-enuronosyl)-D-galacturonate = 2 5-dehydro-4-deoxy-D-glucuronate.\" [EC:4.2.2.6, MetaCyc:OLIGOGALACTURONIDE-LYASE-RXN]","metadata":null},{"id":"b94301cf7a114e9a800f11caa5c2f6a8","type":"GO_TERM","name":"oligogalacturonide transport","canonical_id":"go:GO:0033156","description":"\"The directed movement of oligogalacturonides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mlg]","metadata":null},{"id":"fd921b748abf4d04aeaa52d1281a1856","type":"GO_TERM","name":"oligopeptidase activity","canonical_id":"go:GO:0070012","description":"\"Catalysis of the hydrolysis of a peptide bond in an oligopeptide, i.e. a molecule containing a small number (2 to 20) of amino acid residues connected by peptide bonds.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"afed2d73d64143a3a3096540cd86985c","type":"GO_TERM","name":"oligopeptide binding","canonical_id":"go:GO:1900750","description":"\"Binding to an oligopeptide.\" [GOC:TermGenie, PMID:21854595]","metadata":null},{"id":"021f07cafc88490198f242d5e34c045d","type":"GO_TERM","name":"oligopeptide export from mitochondrion","canonical_id":"go:GO:0090374","description":"\"The process in which an oligopeptide is transported out of the mitochondrial matrix. Oligopeptides are molecules that contain a small number (2 to 20) of amino-acid residues connected by peptide linkages.\" [PMID:11251115]","metadata":null},{"id":"2d73a06955da4b80a1a31becdb8050d2","type":"GO_TERM","name":"oligopeptide import across plasma membrane","canonical_id":"go:GO:0140205","description":"\"The directed movement of an oligopeptide from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:22226946]","metadata":null},{"id":"687caab2dbc84a63b7675e39fd8fca6f","type":"GO_TERM","name":"oligopeptide transmembrane transport","canonical_id":"go:GO:0035672","description":"\"The process in which an oligopeptide is transported across a membrane. Oligopeptides are molecules that contain a small number (2 to 20) of amino-acid residues connected by peptide linkages.\" [GOC:vw, ISBN:0198506732]","metadata":null},{"id":"eb346bc5771348b5a33c5e5d3c7c0f1a","type":"GO_TERM","name":"oligopeptide transmembrane transporter activity","canonical_id":"go:GO:0035673","description":"\"Enables the transfer of oligopeptides from one side of a membrane to the other. Oligopeptides are molecules that contain a small number (2 to 20) of amino-acid residues connected by peptide linkages.\" [GOC:vw, ISBN:0198506732]","metadata":null},{"id":"5a65df480bba4de1bb2eaa7adc84d2b2","type":"GO_TERM","name":"oligopeptide transport","canonical_id":"go:GO:0006857","description":"\"The directed movement of oligopeptides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Oligopeptides are molecules that contain a small number (2 to 20) of amino-acid residues connected by peptide linkages.\" [ISBN:0198506732]","metadata":null},{"id":"c103d89b89ea41d89a3014f44082b191","type":"GO_TERM","name":"oligosaccharide 4-alpha-D-glucosyltransferase activity","canonical_id":"go:GO:0033825","description":"\"Catalysis of the transfer of the non-reducing terminal alpha-D-glucose residue from a 1,4-alpha-D-glucan to the 4-position of an alpha-D-glucan, thus bringing about the hydrolysis of oligosaccharides.\" [EC:2.4.1.161]","metadata":null},{"id":"0248353dcfb648e088499a2826869718","type":"GO_TERM","name":"oligosaccharide binding","canonical_id":"go:GO:0070492","description":"\"Binding to an oligosaccharide, a molecule with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.\" [GOC:mah]","metadata":null},{"id":"f8a0a50d241841fd92ab0e9efce997ee","type":"GO_TERM","name":"oligosaccharide biosynthetic process","canonical_id":"go:GO:0009312","description":"\"The chemical reactions and pathways resulting in the formation of oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.\" [ISBN:0198506732]","metadata":null},{"id":"c96a559006da4f5f818c4c5685051e33","type":"GO_TERM","name":"oligosaccharide catabolic process","canonical_id":"go:GO:0009313","description":"\"The chemical reactions and pathways resulting in the breakdown of oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.\" [ISBN:0198506732]","metadata":null},{"id":"e9f6dd51e8294851a6b8dc63285cbd2e","type":"GO_TERM","name":"oligosaccharide metabolic process","canonical_id":"go:GO:0009311","description":"\"The chemical reactions and pathways involving oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.\" [ISBN:0198506732]","metadata":null},{"id":"50d1a78975b841bbb413e27aef71f8ac","type":"GO_TERM","name":"oligosaccharide reducing-end xylanase activity","canonical_id":"go:GO:0033951","description":"\"Catalysis of the hydrolysis of 1,4-beta-D-xylose residues from the reducing end of oligosaccharides.\" [EC:3.2.1.156]","metadata":null},{"id":"44c4d2d0804a413e80f4a81ef86438f7","type":"GO_TERM","name":"oligosaccharide transmembrane transporter activity","canonical_id":"go:GO:0015157","description":"\"Enables the transfer of oligosaccharide from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"6487f06984784ea7a3fc7fd56b27b8b2","type":"GO_TERM","name":"oligosaccharide transport","canonical_id":"go:GO:0015772","description":"\"The directed movement of oligosaccharides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Oligosaccharides are molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.\" [GOC:ai]","metadata":null},{"id":"44c87555244a4374bad0afc1d920881e","type":"GO_TERM","name":"oligosaccharide transporting porin activity","canonical_id":"go:GO:0015478","description":"\"Enables the transfer of oligosaccharide, sized less than 1000 Da, from one side of a membrane to the other. The transmembrane portions of porins consist exclusively of beta-strands which form a beta-barrel. They are found in the outer membranes of Gram-negative bacteria, mitochondria, plastids and possibly acid-fast Gram-positive bacteria.\" [GOC:mtg_transport]","metadata":null},{"id":"6d3018e5ee5b45e1b831ce43cc307a6b","type":"GO_TERM","name":"oligosaccharide-diphosphodolichol diphosphatase activity","canonical_id":"go:GO:0047430","description":"\"Catalysis of the reaction: H2O + oligosaccharide-diphosphodolichol = dolichol-phosphate + oligosaccharide phosphate.\" [EC:3.6.1.44, MetaCyc:3.6.1.44-RXN]","metadata":null},{"id":"611444d375ed44c4bb34ae6b00280254","type":"GO_TERM","name":"oligosaccharyl transferase activity","canonical_id":"go:GO:0004576","description":"\"Catalysis of the transfer of a oligosaccharyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [GOC:ai]","metadata":null},{"id":"9a0ca488ff9c4d158666a86b66cd3968","type":"GO_TERM","name":"oligosaccharyltransferase complex","canonical_id":"go:GO:0008250","description":"\"A protein complex that is found in the endoplasmic reticulum membrane of eukaryotes and transfers lipid-linked oligosaccharide precursor to asparagine residues on nascent proteins. The complex includes at least eight non-identical subunits. Different forms of the complex containing distinct subunits have been detected in mammals.\" [PMID:15835887, PMID:31810196, PMID:32316603]","metadata":null},{"id":"6037138a733746f9869aa7acfc1b3e07","type":"GO_TERM","name":"oligosaccharyltransferase complex A","canonical_id":"go:GO:0160226","description":"\"An oligosaccharyltransferase complex that contains STT3A as the catalytic subunit.\" [PMID:31831667, PMID:39509507]","metadata":null},{"id":"a4f20f1e6cf849c295654a4542e5ebd3","type":"GO_TERM","name":"oligosaccharyltransferase complex B","canonical_id":"go:GO:0160227","description":"\"An oligosaccharyltransferase complex that contains STT3B as the catalytic subunit.\" [PMID:31831667, PMID:39509507]","metadata":null},{"id":"71bb315e7801447aa2a9114ae26f4b3a","type":"GO_TERM","name":"oligosaccharyltransferase complex binding","canonical_id":"go:GO:0062062","description":"\"Binding to an oligosaccharyltransferase complex.\" [PMID:12887896]","metadata":null},{"id":"6931feb6d9c141c09610e158d75efaf8","type":"GO_TERM","name":"oligoxyloglucan beta-glycosidase activity","canonical_id":"go:GO:0033935","description":"\"Catalysis of the hydrolysis of (1->4)-beta-D-glucosidic links in oligoxyloglucans so as to remove successive isoprimeverose (i.e. alpha-xylo-1,6-beta-D-glucosyl-) residues from the non-reducing chain ends.\" [EC:3.2.1.120]","metadata":null},{"id":"024f6346e9cf4a2db5a8103c77616343","type":"GO_TERM","name":"oligoxyloglucan reducing-end-specific cellobiohydrolase activity","canonical_id":"go:GO:0033945","description":"\"Catalysis of the hydrolysis of cellobiose from the reducing end of xyloglucans consisting of a beta-(1->4) linked glucan carrying alpha-D-xylosyl groups on O-6 of the glucose residues. To be a substrate, the first residue must be unsubstituted, the second residue may bear a xylosyl group, whether further glycosylated or not, and the third residue, which becomes the new terminus by the action of the enzyme, is preferably xylosylated, but this xylose residue must not be further substituted.\" [EC:3.2.1.150]","metadata":null},{"id":"b1e5cd8563394be3be65f966605136a7","type":"GO_TERM","name":"olivetolic acid biosynthetic process","canonical_id":"go:GO:1901697","description":"\"The chemical reactions and pathways resulting in the formation of olivetolic acid.\" [GOC:TermGenie]","metadata":null},{"id":"783a195808fa40a5944486ceec8d7fae","type":"DRUG","name":"olmesartan","canonical_id":"gtopdb:591","description":null,"metadata":null},{"id":"c68134d20fc247e1b9fd204e473b224f","type":"DRUG","name":"olmesartan","canonical_id":"chembl:CHEMBL1516","description":null,"metadata":null},{"id":"6ec3c95b142646d7a235054aff3d7d01","type":"COMBINATION_TREATMENT","name":"olmesartan + perindopril","canonical_id":"ctgov_combo:ctgov-combo-8b818b7e6fca6d6c","description":null,"metadata":null},{"id":"cecdbe1350c94df3a04798b3a7817912","type":"COMBINATION_TREATMENT","name":"olmesartan + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-667ad264afd27156","description":null,"metadata":null},{"id":"71ec4ad42eab4ef0b6d9dc8eb5b8f61e","type":"DRUG","name":"olmutinib","canonical_id":"mesh:C000617753","description":null,"metadata":null},{"id":"767c5a5fd40844b5b46eadd9e00c5440","type":"DRUG","name":"olodaterol","canonical_id":"gtopdb:7543","description":null,"metadata":null},{"id":"d1457af95bbe427f97b9ad07cdb64dd0","type":"DRUG","name":"olodaterol","canonical_id":"mesh:C549647","description":null,"metadata":null},{"id":"cd3beec7103c4ae0bbbfad3e4de669c3","type":"COMBINATION_TREATMENT","name":"olodaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-a57a0f79a25be412","description":null,"metadata":null},{"id":"57977ceb80074e2782944ac645ef63f5","type":"COMBINATION_TREATMENT","name":"olodaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-f47634bf8109208d","description":null,"metadata":null},{"id":"a9ab70ec79724011b6de7f44dbe8a37c","type":"COMBINATION_TREATMENT","name":"olodaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-954dd42190610d39","description":null,"metadata":null},{"id":"a887a471aaef4db2be2285b3bccc8423","type":"COMBINATION_TREATMENT","name":"olodaterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-2e8c2b459684e74d","description":null,"metadata":null},{"id":"9b87df50bc394c2aa058c45e42afcc69","type":"COMBINATION_TREATMENT","name":"olodaterol + tiotropium + vilanterol","canonical_id":"ctgov_combo:ctgov-combo-edae2fa2ad7d29f5","description":null,"metadata":null},{"id":"8c44014dd6d24a98b9e2662a9959ca02","type":"DRUG","name":"omacetaxine mepesuccinate","canonical_id":"mesh:C001652","description":null,"metadata":null},{"id":"807d02e4d1ce42be83fe17dfd4a9b479","type":"DRUG","name":"omalizumab","canonical_id":"gtopdb:6890","description":null,"metadata":null},{"id":"4318bad189d34704a409dffdbff3e6f6","type":"DRUG","name":"omalizumab","canonical_id":"mesh:D000069444","description":null,"metadata":null},{"id":"e59a1ff359144585b5aaf1ce9a9f82a2","type":"DRUG","name":"omalizumab","canonical_id":"chembl:CHEMBL1201589","description":null,"metadata":null},{"id":"4a92ecc6c255408ba75dcbff6a915919","type":"GO_TERM","name":"omega peptidase activity","canonical_id":"go:GO:0008242","description":"\"Catalysis of the cleavage of non-standard peptide bonds releasing substituted amino acids such as pyroglutamate or cleave isopeptide bonds, such as many deubiquitinating enzymes.\" [EC:3.4.19.-, PMID:20157488, PMID:9920379]","metadata":null},{"id":"337f7244c5e34ccf922f09762c740b1e","type":"GO_TERM","name":"omega speckle","canonical_id":"go:GO:0035062","description":"\"A nucleoplasmic speckle distributed in the interchromatin space of cells in close proximity to chromatin. Omega speckles are distinct from interchromatin granules and contain heterogeneous nuclear RNA-binding proteins (hnRNPs).\" [GOC:bf, PMID:10984439]","metadata":null},{"id":"14811cfcaded49d4bf626b911db2dd13","type":"GO_TERM","name":"omega-3 fatty acid desaturase activity","canonical_id":"go:GO:0042389","description":"\"Catalysis of the introduction of an omega-3 double bond into the fatty acid hydrocarbon chain.\" [GOC:jl, PMID:9037020]","metadata":null},{"id":"f0018008e219485393a57a88840e6b8d","type":"GO_TERM","name":"omega-6 fatty acid desaturase activity","canonical_id":"go:GO:0045485","description":"\"Catalysis of the introduction of an omega-6 double bond into the fatty acid hydrocarbon chain.\" [PMID:7846158]","metadata":null},{"id":"415fb93e9abe405592383735d5dcce72","type":"GO_TERM","name":"omega-amidase activity","canonical_id":"go:GO:0050152","description":"\"Catalysis of the reaction: a monoamide of a dicarboxylic acid + H2O = a dicarboxylate + NH4+. Substrates include 2-oxosuccinamate and 2-oxoglutaramate, which get converted to oxaloacetate and 2-oxoglutarate, respectively.\" [RHEA:11716]","metadata":null},{"id":"8efc8c54e56640b7b07aea85f70e3ed6","type":"GO_TERM","name":"omega-hydroxyceramide biosynthetic process","canonical_id":"go:GO:0106342","description":"\"The chemical reactions and pathways resulting in the formation of omega-hydroxyceramide/acylceramide.\" [PMID:28248318]","metadata":null},{"id":"52de946c2e2a40fd8eed93a3ec3d8190","type":"GO_TERM","name":"omega-hydroxyceramide transacylase activity","canonical_id":"go:GO:0106341","description":"\"Catalysis of the reaction: an N-(omega-hydroxy-ultra-long chain fatty acyl)-sphingoid base + a (9Z,12Z)-octadecadienoyl-containing triacyl-sn-glycerol = an N-[omega-(9Z,12Z-octadecadienoyloxy)-O-ultra-long chain fatty acyl]-sphingoid base + a diacylglycerol.\" [PMID:28248318, RHEA:61528]","metadata":null},{"id":"8fe1026ce5984f589f41b1debc788d74","type":"GO_TERM","name":"omega-hydroxydecanoate dehydrogenase activity","canonical_id":"go:GO:0050153","description":"\"Catalysis of the reaction: 10-hydroxydecanoate + NAD+ = 10-oxodecanoate + H+ + NADH.\" [EC:1.1.1.66, RHEA:20880]","metadata":null},{"id":"1ff401a17529453f98bf816164d81544","type":"GO_TERM","name":"omega-hydroxylase P450 pathway","canonical_id":"go:GO:0097267","description":"\"The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation.\" [GOC:mw, PMID:10681399]","metadata":null},{"id":"ca438e54f06041a9b79dd19be34f59ba","type":"GO_TERM","name":"omega-hydroxypalmitate O-sinapoyl transferase activity","canonical_id":"go:GO:0102406","description":"\"Catalysis of the reaction: sinapoyl-CoA + 16-hydroxypalmitate = coenzyme A + 16-sinapoyloxypalmitate.\" [EC:2.3.1.188, GOC:pz]","metadata":null},{"id":"a2ee50d64ec84f0b992fa5282dc34490","type":"GO_TERM","name":"omegasome","canonical_id":"go:GO:1990462","description":"\"Omega-shaped (as in the Greek capital letter) intracellular membrane-bounded organelle enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. Omegasomes are the first step of the formation of autophagosomes via the phagophore assembly sites.\" [GOC:autophagy, GOC:mf, PMID:18725538, PMID:24591649]","metadata":null},{"id":"373b9a32ef9b44e697789bf31af5cd9b","type":"GO_TERM","name":"omegasome membrane","canonical_id":"go:GO:1903349","description":"\"Any membrane that is part of an omegasome.\" [GO_REF:0000064, GOC:mf, GOC:TermGenie, PMID:18725538, PMID:24591649]","metadata":null},{"id":"3236b5e59ab24ffdb9a0f853d069e8e8","type":"DRUG","name":"omeprazole","canonical_id":"gtopdb:4279","description":null,"metadata":null},{"id":"043f8bb305c7490c87257de3001085d9","type":"DRUG","name":"omeprazole","canonical_id":"chembl:CHEMBL1503","description":null,"metadata":null},{"id":"16f38109aa044c44a11b66376a587537","type":"COMBINATION_TREATMENT","name":"omeprazole + rosuvastatin","canonical_id":"ctgov_combo:ctgov-combo-698ac1cfd2cc753c","description":null,"metadata":null},{"id":"f5485511f6a745aba1cb361a73d8d00c","type":"COMBINATION_TREATMENT","name":"omeprazole + warfarin","canonical_id":"ctgov_combo:ctgov-combo-5dea22038b37fb1f","description":null,"metadata":null},{"id":"e1d245e6272d451aaaf3bbe9ad285394","type":"GO_TERM","name":"ommatidial rotation","canonical_id":"go:GO:0016318","description":"\"The process in which photoreceptors are arranged in ommatidia in the dorsal and ventral fields to be mirror images. The polarity is established in the imaginal discs concurrently with cell fate specification.\" [PMID:10725247]","metadata":null},{"id":"6dd8fde7dfe14934847b3c1cf65c1dd8","type":"GO_TERM","name":"ommochrome biosynthetic process","canonical_id":"go:GO:0006727","description":"\"The chemical reactions and pathways resulting in the formation of ommochromes, any of a large group of natural polycyclic pigments commonly found in the Arthropoda, particularly in the ommatidia of the compound eye.\" [ISBN:0198506732]","metadata":null},{"id":"f70f220dd44445ac9a575b1ebb1353d6","type":"GO_TERM","name":"ommochrome catabolic process","canonical_id":"go:GO:0046153","description":"\"The chemical reactions and pathways resulting in the breakdown of ommochromes, any of a large group of natural polycyclic pigments commonly found in the Arthropoda, particularly in the ommatidia of the compound eye.\" [ISBN:0198506732]","metadata":null},{"id":"cd2bc06f251a4655be0e55ef5d8e9a96","type":"GO_TERM","name":"ommochrome metabolic process","canonical_id":"go:GO:0046152","description":"\"The chemical reactions and pathways involving ommochromes, any of a large group of natural polycyclic pigments commonly found in the Arthropoda, particularly in the ommatidia of the compound eye.\" [ISBN:0198506732]","metadata":null},{"id":"b2e27e69795a453b8115afd11109c2ea","type":"GO_TERM","name":"oncogene-induced cell senescence","canonical_id":"go:GO:0090402","description":"\"A cellular senescence process associated with the dismantling of a cell as a response to oncogenic stress, such as the activation of the Ras oncogenic family.\" [GOC:BHF]","metadata":null},{"id":"4c1495003b1f4df8a1e8fdb54070289c","type":"GO_TERM","name":"oncostatin M production","canonical_id":"go:GO:0044808","description":"\"The appearance of oncostatin M due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"eddd0d23d105450c90a325ef04f40218","type":"GO_TERM","name":"oncostatin-M receptor activity","canonical_id":"go:GO:0004924","description":"\"Combining with oncostatin-M and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"10d5e74096a442029c1c31c799567efc","type":"GO_TERM","name":"oncostatin-M receptor binding","canonical_id":"go:GO:0005147","description":"\"Binding to an oncostatin-M receptor.\" [GOC:ai]","metadata":null},{"id":"c4a9770880d844f28a6b36749242eac7","type":"GO_TERM","name":"oncostatin-M-mediated signaling pathway","canonical_id":"go:GO:0038165","description":"\"The series of molecular signals initiated by oncostatin-M (OSM) binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. OSM can signal via at least two different receptors (a specific receptor and a LIF receptor) to activate different downstream signal transduction pathways.\" [GOC:nhn, GOC:signaling, PMID:10579456, PMID:12811586]","metadata":null},{"id":"cff2bde6f45846e589f4b2546da0fd23","type":"DRUG","name":"ondansetron","canonical_id":"gtopdb:2290","description":null,"metadata":null},{"id":"8a9d66ae6e9a4cd59b4c8d9722c5750a","type":"DRUG","name":"ondansetron","canonical_id":"chembl:CHEMBL46","description":null,"metadata":null},{"id":"43963623e5304701b2fd9dcb3cc610f3","type":"COMBINATION_TREATMENT","name":"ondansetron + prochlorperazine","canonical_id":"ctgov_combo:ctgov-combo-ad9f6ed177d5a78d","description":null,"metadata":null},{"id":"3b33324722a5460f96e9d1c2bba98434","type":"COMBINATION_TREATMENT","name":"ondansetron + prochlorperazine","canonical_id":"ctgov_combo:ctgov-combo-77df18eb5c580aa1","description":null,"metadata":null},{"id":"375fbaf883f242ceab8201b93077d73a","type":"COMBINATION_TREATMENT","name":"ondansetron + rucaparib","canonical_id":"ctgov_combo:ctgov-combo-9bc9a1c89d4e9d19","description":null,"metadata":null},{"id":"c0ec834162374f17b34a8a3a23688638","type":"GO_TERM","name":"one-carbon compound transport","canonical_id":"go:GO:0019755","description":"\"The directed movement of one-carbon compounds into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"e24759efe2d947278c8d5424fb85b3cb","type":"GO_TERM","name":"one-carbon metabolic process","canonical_id":"go:GO:0006730","description":"\"The chemical reactions and pathways involving the transfer of one-carbon units in various oxidation states.\" [GOC:hjd, GOC:mah, GOC:pde]","metadata":null},{"id":"23c0a06f881d4853b4364a9e10d32e8e","type":"DRUG","name":"ongericimab","canonical_id":"gtopdb:13787","description":null,"metadata":null},{"id":"53bfc87ae09c46cf9cfc6769878e7e47","type":"DRUG","name":"ongericimab","canonical_id":"chembl:CHEMBL4594566","description":null,"metadata":null},{"id":"cfd964c59a094b00a542772329fea832","type":"GO_TERM","name":"oocyte animal/vegetal axis specification","canonical_id":"go:GO:0060832","description":"\"The establishment, maintenance and elaboration of the animal/vegetal axis in the oocyte. The animal/vegetal axis of an oocyte is defined by the placement of the nucleus in the oocyte and can sometimes be identified by the asymmetric placement of other substances such as yolk in the oocyte. The pole of the egg that is closest to the nucleus defines the animal end, with the axis passing through the nucleus.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"dab39f2c4a8b480e85371828ba4b08fa","type":"GO_TERM","name":"oocyte anterior/posterior axis specification","canonical_id":"go:GO:0007314","description":"\"Polarization of the oocyte along its anterior-posterior axis. An example of this is found in Drosophila melanogaster.\" [GOC:dph, GOC:mtg_sensu, GOC:tb, ISBN:0879694238]","metadata":null},{"id":"c12c6ad4d52c41b6b8947feec99bd602","type":"GO_TERM","name":"oocyte axis specification","canonical_id":"go:GO:0007309","description":"\"The establishment, maintenance and elaboration of an axis in the oocyte. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"4ebdf9fe546648af9c4e1cd4102c4479","type":"GO_TERM","name":"oocyte construction","canonical_id":"go:GO:0007308","description":"\"The synthesis, deposition, and organization of the materials in a cell of an ovary; where the cell can then undergo meiosis and form an ovum. An example of this is found in Drosophila melanogaster.\" [GOC:dph, GOC:ems, GOC:mtg_sensu, GOC:tb, ISBN:0198506732]","metadata":null},{"id":"52fc97595b0944acb1349b1eef43df9a","type":"GO_TERM","name":"oocyte development","canonical_id":"go:GO:0048599","description":"\"The process whose specific outcome is the progression of an oocyte over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell.\" [GOC:curators]","metadata":null},{"id":"7cdbbf7e5cb84e66a027ddcc41aa703b","type":"GO_TERM","name":"oocyte differentiation","canonical_id":"go:GO:0009994","description":"\"The process in which a relatively unspecialized immature germ cell acquires the specialized features of a mature female gamete.\" [GOC:curators, GOC:mtg_sensu]","metadata":null},{"id":"9422d5c99e974fc8b206949bb775d25e","type":"GO_TERM","name":"oocyte dorsal/ventral axis specification","canonical_id":"go:GO:0007310","description":"\"The establishment, maintenance and elaboration of the dorsal/ventral axis of the oocyte. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"421457274bb0468bbd35c3eb00674b29","type":"GO_TERM","name":"oocyte fate commitment","canonical_id":"go:GO:0048600","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an oocyte.\" [GOC:curators]","metadata":null},{"id":"dbe0285fe0444a71b8777ee12feb8930","type":"GO_TERM","name":"oocyte fate determination","canonical_id":"go:GO:0030716","description":"\"The process in which a cell becomes capable of differentiating autonomously into an oocyte cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators]","metadata":null},{"id":"0af58a9c605d4f0c9bf8a35abc019463","type":"GO_TERM","name":"oocyte growth","canonical_id":"go:GO:0001555","description":"\"The developmental growth process in which an oocyte irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"40fe307ea8764e7d8ac992b02e3004fc","type":"GO_TERM","name":"oocyte growth in germarium-derived egg chamber","canonical_id":"go:GO:0030715","description":"\"The increase in volume of an oocyte during the growth phase of the egg chamber, once the egg chamber has left the germarium. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"2416aa5215064e539c60932e31e2523b","type":"GO_TERM","name":"oocyte karyosome formation","canonical_id":"go:GO:0030717","description":"\"The chromosome organization process in which meiotic chromosomes in the oocyte nucleus cluster together to form a compact spherical structure called the karyosome.\" [PMID:11700288, PMID:18039935]","metadata":null},{"id":"8f3d972bdd564d5b8be94c1bd36f0a2f","type":"GO_TERM","name":"oocyte localization involved in germarium-derived egg chamber formation","canonical_id":"go:GO:0030720","description":"\"Directed movement of the oocyte, following its specification, from its original central position in the cyst to a posterior position relative to the nurse cells of the egg chamber, and its maintenance in this posterior location. This is the first sign of anterior-posterior asymmetry in the developing egg chamber.\" [GOC:mtg_sensu, PMID:10449356]","metadata":null},{"id":"f8f646c652bc468a912fc290208fbc19","type":"GO_TERM","name":"oocyte maturation","canonical_id":"go:GO:0001556","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an oocyte to attain its fully functional state. Oocyte maturation commences after reinitiation of meiosis commonly starting with germinal vesicle breakdown, and continues up to the second meiotic arrest prior to fertilization.\" [GOC:devbiol, https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"5afa655a8eb04481a4b83e5c82df8b4a","type":"GO_TERM","name":"oocyte microtubule cytoskeleton organization","canonical_id":"go:GO:0016325","description":"\"Formation and maintenance of a polarized microtubule array originating from a microtubule-organizing center (MTOC) in the oocyte. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11231123]","metadata":null},{"id":"8309cef6ff3444dd8918123ff2b65dae","type":"GO_TERM","name":"oocyte microtubule cytoskeleton polarization","canonical_id":"go:GO:0008103","description":"\"Establishment and maintenance of a specific axis of polarity of the oocyte microtubule network. The axis is set so that the minus and plus ends of the microtubules of the mid stage oocyte are positioned along the anterior cortex and at the posterior pole, respectively. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11807042]","metadata":null},{"id":"f52d6449e29240db83a536689aa37b0e","type":"GO_TERM","name":"oocyte morphogenesis","canonical_id":"go:GO:0048601","description":"\"The process in which the structures of an oocyte are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of an oocyte.\" [GOC:curators]","metadata":null},{"id":"74a19bb2b23b45f79f6ed63ddf2d9037","type":"GO_TERM","name":"oocyte nucleus localization involved in oocyte dorsal/ventral axis specification","canonical_id":"go:GO:0051663","description":"\"The directed movement of the nucleus to a specific location within a cell during the establishment and maintenance of the dorsal/ventral axis of the oocyte.\" [GOC:ai, GOC:dph, GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"c0d65d3231764535bb06b0e65cd1fd05","type":"GO_TERM","name":"oocyte nucleus migration involved in oocyte dorsal/ventral axis specification","canonical_id":"go:GO:0007312","description":"\"The directed movement of the oocyte nucleus within the cell as part of the establishment and maintenance of the dorsal/ventral axis of the oocyte. An example of this is found in Drosophila melanogaster.\" [GOC:dph, GOC:mah, GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"c92fa891e3fd42958dadb06c6245854d","type":"GO_TERM","name":"oogenesis","canonical_id":"go:GO:0048477","description":"\"The complete process of formation and maturation of an ovum or female gamete from a primordial female germ cell. Examples of this process are found in Mus musculus and Drosophila melanogaster.\" [GOC:kmv, GOC:mtg_sensu, GOC:pr]","metadata":null},{"id":"dbe018d9c379464c9c390ce05bf01bef","type":"GO_TERM","name":"oogonium development","canonical_id":"go:GO:0075263","description":"\"The process that leads to the development of an oogonium, a female gametangium of Oomycetes, containing one or more gametes.\" [GOC:pamgo_curators]","metadata":null},{"id":"8dce7098b68648e2b1e81bd523a5a34d","type":"GO_TERM","name":"oogonium stage","canonical_id":"go:GO:0048158","description":"\"The stage in mammalian oogenesis when the primordial germ cell is hardly distinguishable from other cortical cells of the ovary.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"a0254012f7004fd28cca6343f130be1e","type":"GO_TERM","name":"oomycete sporangium development","canonical_id":"go:GO:0075321","description":"\"The process that leads to the development of an oomycete sporangium, a single-celled or many-celled structure that germinates directly to form an infection hypha or differentiates, through specialized cleavage vesicles, into between 10 and 30 zoospores, which are laterally flagellated.\" [GOC:pamgo_curators]","metadata":null},{"id":"10bd5ec68aa94dcd84d731401df8856c","type":"GO_TERM","name":"ooplasm","canonical_id":"go:GO:1990917","description":"\"The cytoplasm of an ovum.\" [PMID:19022436]","metadata":null},{"id":"c22344ed994740a9b1088913826e7518","type":"GO_TERM","name":"oospore formation","canonical_id":"go:GO:0075243","description":"\"The process in which male and female gametangia develop and fuse to form an oospore, a thick-walled resting spore of Oomycetes and certain algae and fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"12acf5287127447f9baf5a9057e9d1b6","type":"GO_TERM","name":"open form four-way junction DNA binding","canonical_id":"go:GO:0000401","description":"\"Binding to a DNA segment containing the open form of a four-way junction, also known as a Holliday junction, a structure where two DNA double strands are held together by reciprocal exchange of two of the four strands, one strand each from the two original helices. The open form of a four-way junction can be diagrammed without any of the strands crossing over.\" [GOC:krc, ISBN:0815332181, PMID:15563464]","metadata":null},{"id":"615422c742aa44a28bea6ba715bdc378","type":"GO_TERM","name":"open rectifier potassium channel activity","canonical_id":"go:GO:0005252","description":"\"Enables the transmembrane transfer of a potassium ion by an open rectifier voltage-gated channel. An open rectifier current-voltage relationship is one in which the direction of rectification depends on the external potassium ion concentration.\" [GOC:mah, PMID:8917578]","metadata":null},{"id":"2669b8f4796b41b1837694efb8365365","type":"GO_TERM","name":"open tracheal system development","canonical_id":"go:GO:0007424","description":"\"The process whose specific outcome is the progression of an open tracheal system over time, from its formation to the mature structure. An open tracheal system is a respiratory system, a branched network of epithelial tubes that supplies oxygen to target tissues via spiracles. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:8625828]","metadata":null},{"id":"e1c66ef6b6da46ad9c2e40ccf3817df1","type":"DISEASE","name":"open-angle glaucoma","canonical_id":"mondo:0005338","description":null,"metadata":null},{"id":"3645928a00ed4b44a8bc2eff1b53bc80","type":"GO_TERM","name":"operant conditioning","canonical_id":"go:GO:0035106","description":"\"Learning to anticipate future events on the basis of past experience with the consequences of one's own behavior.\" [PMID:14662373]","metadata":null},{"id":"5fba8511cfce43ebb0404ec02b5c3ee0","type":"GO_TERM","name":"opheline kinase activity","canonical_id":"go:GO:0050154","description":"\"Catalysis of the reaction: ATP + guanidinoethyl methyl phosphate = N'-phosphoguanidinoethyl methylphosphate + ADP + 2 H+.\" [EC:2.7.3.7, RHEA:17553]","metadata":null},{"id":"cdd7abf766be45cd9959aec924f64be1","type":"DISEASE","name":"ophthalmic herpes zoster","canonical_id":"mondo:0005883","description":null,"metadata":null},{"id":"c0205a4a4da84281bcdafac557ebfef1","type":"DISEASE","name":"opiate dependence","canonical_id":"mondo:0005530","description":null,"metadata":null},{"id":"ce83250fe01c46499d05ed3e34df48f3","type":"DRUG","name":"opicapone","canonical_id":"gtopdb:8988","description":null,"metadata":null},{"id":"f9c483cb8fa14be78f17d1b0bb4747f8","type":"DRUG","name":"opicapone","canonical_id":"chembl:CHEMBL1089318","description":null,"metadata":null},{"id":"7025dcd5ab294b5a9929150c53677559","type":"GO_TERM","name":"opine dehydrogenase activity","canonical_id":"go:GO:0047129","description":"\"Catalysis of the reaction: (2S)-2-[(R)-1-carboxyethylamino]pentanoate + H2O + NAD+ = L-2-aminopentanoate + H+ + NADH + pyruvate.\" [EC:1.5.1.28, RHEA:21592]","metadata":null},{"id":"20229359620f42efbfc81ad45316e1dd","type":"GO_TERM","name":"opioid growth factor receptor activity","canonical_id":"go:GO:0140625","description":"\"Combining with the opioid growth factor (OGF, met-enkephalin) and transmitting the signal across the nuclear membrane. Met-enkephalin is an endogenous opioid peptide that binds to opioid and opioid growth factor receptors, regulating tissue growth in a variety of cellular processes.\" [PMID:11890982]","metadata":null},{"id":"f7744fed520f43f8b3d49318f8b5bb54","type":"GO_TERM","name":"opioid growth factor receptor signaling pathway","canonical_id":"go:GO:0140626","description":"\"The series of molecular signals generated as a consequence of an opioid growth factor receptor binding to its physiological ligand, opioid growth factor (OGF, met-enkephalin). The OGF-OGFr complex leads to the increase in the synthesis of the selective cyclin-dependent kinase (CDK) inhibitor proteins, p12 (POLD4) and p16 (CDKN2A).\" [PMID:19675283, PMID:19923357]","metadata":null},{"id":"ec168197ab56473483ec09b7851b6644","type":"GO_TERM","name":"opioid peptide activity","canonical_id":"go:GO:0001515","description":"\"Naturally occurring peptide that is an opioid (any non-alkaloid having an opiate-like effect that can be reversed by naloxone or other recognized morphine antagonist). These include Leu- and Met-enkephalin, dynorphin and neoendorphin, alpha, beta, gamma and delta endorphins formed from beta-lipotropin, various pronase-resistant peptides such as beta casamorphin, and other peptides whose opiate-like action seems to be indirect.\" [ISBN:0198506732]","metadata":null},{"id":"87b55654fad24e95a1bd887ca97438bd","type":"GO_TERM","name":"opioid receptor binding","canonical_id":"go:GO:0031628","description":"\"Binding to an opioid receptor.\" [GOC:nln]","metadata":null},{"id":"d6c9263dafa84122a3b4893384f3cf3e","type":"DISEASE","name":"opioid use disorder","canonical_id":"efo:0010702","description":null,"metadata":null},{"id":"6e82dab89b80457894941e3c5a65662c","type":"DRUG","name":"oprelvekin","canonical_id":"gtopdb:6971","description":null,"metadata":null},{"id":"1284546b58bd467cad43f087fe991d02","type":"DRUG","name":"oprelvekin","canonical_id":"mesh:C105308","description":null,"metadata":null},{"id":"c733d58827d04a5ab7568e429deacc80","type":"DRUG","name":"oprelvekin","canonical_id":"chembl:CHEMBL1201573","description":null,"metadata":null},{"id":"d129023601f14f5ea3770078175211d9","type":"GO_TERM","name":"opsin binding","canonical_id":"go:GO:0002046","description":"\"Binding to an opsin, any of a group of hydrophobic, integral membrane glycoproteins located primarily in the disc membrane of rods or cones, involved in photoreception.\" [GOC:hjd]","metadata":null},{"id":"39568002d6804e2ea5b0598a8802a59d","type":"GO_TERM","name":"opsin transport","canonical_id":"go:GO:0036372","description":"\"The directed movement of an opsin (a G protein-coupled receptor of photoreceptor cells) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore.\" [GOC:atm, PMID:20238016, PMID:22855808]","metadata":null},{"id":"7b0f344ec39b48de9c4c90bd897907c4","type":"GO_TERM","name":"opsonin binding","canonical_id":"go:GO:0001846","description":"\"Binding to an opsonin, such as a complement component or antibody, deposited on the surface of a bacteria, virus, immune complex, or other particulate material.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"460de670c6a744068696a8adf2bd5f47","type":"GO_TERM","name":"opsonin receptor activity","canonical_id":"go:GO:0001847","description":"\"Combining with an opsonin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"01172570ea194c4c9fb416786d75a47b","type":"GO_TERM","name":"opsonization","canonical_id":"go:GO:0008228","description":"\"The process in which a microorganism (or other particulate material) is rendered more susceptible to phagocytosis by coating with an opsonin, a blood serum protein such as a complement component or antibody.\" [GOC:add, GOC:mah, ISBN:0198506732, ISBN:068340007X, ISBN:0781735149]","metadata":null},{"id":"605736c35e2a4240b8da00d82a69f4e6","type":"GO_TERM","name":"optic chiasma development","canonical_id":"go:GO:0061360","description":"\"The developmental process pertaining to the progression of the optic chiasm from its initial formation to the mature structure. The process begins when the pathfinding of the axons of the developing optic nerve cause some axons to cross at the midline of the brain and ends when the axons are mature.\" [GOC:dph]","metadata":null},{"id":"c1412727c66a41698dc17cfcb1099623","type":"GO_TERM","name":"optic cup formation involved in camera-type eye development","canonical_id":"go:GO:0003408","description":"\"The developmental process pertaining to the initial formation of the optic cup, a two-walled vesicle formed from the optic vesicle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"aa8167ff709e4bbcbbfb14b52217ecc4","type":"GO_TERM","name":"optic cup morphogenesis involved in camera-type eye development","canonical_id":"go:GO:0002072","description":"\"The invagination of the optic vesicle to form two-walled indentations, the optic cups, that will go on to form the retina. This process begins with the optic vesicle becoming a two-walled structure and its subsequent shape changes. It does not include the fate commitment of cells to become the pigmented retina and the neural retina. An example of this process is found in Mus musculus.\" [GOC:dph, GOC:mtg_sensu, GOC:sdb_2009, GOC:tb, ISBN:0878932437]","metadata":null},{"id":"622c868cb74c4191a6cf037f6cf981c0","type":"GO_TERM","name":"optic cup structural organization","canonical_id":"go:GO:0003409","description":"\"The process that contributes to creating the structural organization of the optic cup. This process pertains to the physical shaping of the rudimentary structure.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0d0bf345ee8b406793fbf69d2743b62a","type":"GO_TERM","name":"optic nerve development","canonical_id":"go:GO:0021554","description":"\"The process whose specific outcome is the progression of the optic nerve over time, from its formation to the mature structure. The sensory optic nerve originates from the bipolar cells of the retina and conducts visual information to the brainstem. The optic nerve exits the back of the eye in the orbit, enters the optic canal, and enters the central nervous system at the optic chiasm (crossing) where the nerve fibers become the optic tract just prior to entering the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"f6f6b4642cb54da393eaf8598623400d","type":"GO_TERM","name":"optic nerve formation","canonical_id":"go:GO:0021634","description":"\"The process that gives rise to the optic nerve. This process pertains to the initial formation of a structure from unspecified parts. The sensory optic nerve originates from the bipolar cells of the retina and conducts visual information to the brainstem. The optic nerve exits the back of the eye in the orbit, enters the optic canal, and enters the central nervous system at the optic chiasm (crossing) where the nerve fibers become the optic tract just prior to entering the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"9935f47c4f174faea82e37190d26c66e","type":"GO_TERM","name":"optic nerve maturation","canonical_id":"go:GO:0021632","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the optic nerve to attain its fully functional state. The sensory optic nerve originates from the bipolar cells of the retina and conducts visual information to the brainstem. The optic nerve exits the back of the eye in the orbit, enters the optic canal, and enters the central nervous system at the optic chiasm (crossing) where the nerve fibers become the optic tract just prior to entering the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"32d6ad4c6c6c4b20ab920c73ce647ba4","type":"GO_TERM","name":"optic nerve morphogenesis","canonical_id":"go:GO:0021631","description":"\"The process in which the anatomical structure of the optic nerve is generated and organized. The sensory optic nerve originates from the bipolar cells of the retina and conducts visual information to the brainstem. The optic nerve exits the back of the eye in the orbit, enters the optic canal, and enters the central nervous system at the optic chiasm (crossing) where the nerve fibers become the optic tract just prior to entering the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"86752eb07c0849739189537d2cdfab90","type":"GO_TERM","name":"optic nerve structural organization","canonical_id":"go:GO:0021633","description":"\"The process that contributes to the act of creating the structural organization of the optic nerve. This process pertains to the physical shaping of a rudimentary structure. The sensory optic nerve originates from the bipolar cells of the retina and conducts visual information to the brainstem. The optic nerve exits the back of the eye in the orbit, enters the optic canal, and enters the central nervous system at the optic chiasm (crossing) where the nerve fibers become the optic tract just prior to entering the hindbrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"42b413ebdf504b40bb894386d3f1676d","type":"DISEASE","name":"optic neuritis","canonical_id":"mondo:0005885","description":null,"metadata":null},{"id":"6db7f8c0941a4b029621d065812d6c55","type":"GO_TERM","name":"optic vesicle elongation","canonical_id":"go:GO:0003405","description":"\"The developmental growth that results in the lengthening of the optic vesicle in the posterior direction.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"a454b5d298b941c1b5f00ed1dc17e7a5","type":"GO_TERM","name":"optic vesicle formation","canonical_id":"go:GO:0003403","description":"\"The developmental process pertaining to the initial formation of the optic vesicle from the lateral wall of the forebrain. This process begins with the specific processes that contribute to the appearance of the vesicle and ends when the vesicle has evaginated. The optic vesicle is the evagination of neurectoderm that precedes formation of the optic cup.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0ae92e3a0c1e4891a3f30cc054437690","type":"GO_TERM","name":"optic vesicle morphogenesis","canonical_id":"go:GO:0003404","description":"\"The developmental process pertaining to the formation and shaping of the optic vesicle. This process begins with the specific processes that contribute to the appearance of the vesicle and ends when the vesicle has evaginated. The optic vesicle is the evagination of neurectoderm that precedes formation of the optic cup.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"b2e5cb336954409b8c0e1f38538b7e79","type":"GO_TERM","name":"optical nerve axon regeneration","canonical_id":"go:GO:0101027","description":"\"The regrowth of axons of the optical nerve following their loss or damage.\" [GOC:pga, PMID:16699509]","metadata":null},{"id":"5ec544feb43246ce9da396cb40eb175d","type":"GO_TERM","name":"optokinetic behavior","canonical_id":"go:GO:0007634","description":"\"The behavior of an organism pertaining to movement of the eyes and of objects in the visual field, as in nystagmus.\" [GOC:jid, GOC:pr]","metadata":null},{"id":"5bb36fe6dcfd4b9a9e78488bcd043b3e","type":"GO_TERM","name":"optomotor response","canonical_id":"go:GO:0071632","description":"\"Eye, head or whole body movements that help to compensate movements of the environment in order to stabilize its image on the retina. In the case of whole body movements, these motor actions may also stabilize a locomotor course in response to some disturbance. Examples include: the optokinetic reflex, which allows human eyes to follow objects in motion while the head remains stationary reflex; the optomotor responses of flying insects and swimming fish.\" [GOC:dos, PMID:12726833, PMID:2469195]","metadata":null},{"id":"4d5e6543192c4b5bb87af1d2a2a23abe","type":"GO_TERM","name":"oral apparatus","canonical_id":"go:GO:0031912","description":"\"Complex basket- or funnel-like structure used by the cell to collect food and channel it to the cytostome; includes specialized sub-structures made up of closely-spaced cilia and underlying basal bodies and fibrillar systems.\" [PMID:10503189]","metadata":null},{"id":"2ae56de1cf5142018fcd8665b0b45d87","type":"GO_TERM","name":"oral apparatus organization","canonical_id":"go:GO:0032122","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the oral apparatus. The oral apparatus is a funnel-like structure used by the cell to collect food and channel it to the cytostome, characteristic of ciliate protozoans.\" [PMID:10503189, PMID:6414830]","metadata":null},{"id":"4206dd71e1f74248ae2cddc0a2c874aa","type":"GO_TERM","name":"oral incubation","canonical_id":"go:GO:0060747","description":"\"A parental behavior in which fertilized eggs are taken into the mouth and held until hatching.\" [GOC:dph]","metadata":null},{"id":"9b219c21217940a996ff5969cc4e08c9","type":"DISEASE","name":"oral mucositis","canonical_id":"efo:1001904","description":null,"metadata":null},{"id":"f34e4ac0bb2346d1b5e9b0b7c0e2c3a1","type":"GO_TERM","name":"oral/aboral axis specification","canonical_id":"go:GO:0060834","description":"\"The establishment, maintenance and elaboration of a line that delineates the mouth and the anus of an embryo.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"2b9d78d9d5f7455ebf4b04f5553e2f55","type":"GO_TERM","name":"orbitofrontal cortex development","canonical_id":"go:GO:0021769","description":"\"The progression of the orbitofrontal cortex over time from its initial formation until its mature state. The orbitofrontal cortex is a cerebral cortex region located in the frontal lobe.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"0af15e04a2074bd0aeea5530cd53ab84","type":"DISEASE","name":"orchitis","canonical_id":"mondo:0006882","description":null,"metadata":null},{"id":"1715f6f2511348a1bcc49e17d27d6b65","type":"GO_TERM","name":"orcinol 2-monooxygenase activity","canonical_id":"go:GO:0018661","description":"\"Catalysis of the reaction: H+ + NADH + O2 + orcinol = 2,3,5-trihydroxytoluene + H2O + NAD+.\" [EC:1.14.13.6, RHEA:19601]","metadata":null},{"id":"d2986cc6fcc448d89f34b47acf7b96d0","type":"GO_TERM","name":"orcinol biosynthetic process","canonical_id":"go:GO:0046197","description":"\"The chemical reactions and pathways resulting in the formation of orcinol (5-methyl-1,3-benzenediol), an aromatic compound derived from the fermentation of lichen and synthesized by some higher plants.\" [GOC:ai]","metadata":null},{"id":"5ef0b6f4685b44298e31840bd7601912","type":"GO_TERM","name":"orcinol catabolic process","canonical_id":"go:GO:0042209","description":"\"The chemical reactions and pathways resulting in the breakdown of orcinol (5-methyl-1,3-benzenediol), an aromatic compound derived from the fermentation of lichen and synthesized by some higher plants.\" [GOC:jl]","metadata":null},{"id":"0040d3838b554757a9a1b754530acc51","type":"GO_TERM","name":"orexigenic neuropeptide QRFP receptor binding","canonical_id":"go:GO:0031854","description":"\"Binding to an orexigenic neuropeptide QRFP receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a6688faff04446eb842373bfc25a6d01","type":"GO_TERM","name":"orexin receptor activity","canonical_id":"go:GO:0016499","description":"\"Combining with orexin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"4ab998e447c7416daa0c68a63a0bd3dc","type":"GO_TERM","name":"orexin receptor binding","canonical_id":"go:GO:0042324","description":"\"Binding to an orexin receptor.\" [GOC:ceb, PMID:11988773]","metadata":null},{"id":"3c65d1bc15e743409814bfbdeccda3f5","type":"GO_TERM","name":"orexin secretion","canonical_id":"go:GO:0061584","description":"\"The controlled release of orexin from a cell or a tissue.\" [GOC:dph]","metadata":null},{"id":"6d6453ca45984a68b2664b0fee5fa780","type":"GO_TERM","name":"orexin secretion, neurotransmission","canonical_id":"go:GO:0061585","description":"\"The controlled release of orexin from a cell in which orexin acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"a08d668298ab41b9813f42f6b69bf43e","type":"GO_TERM","name":"organ boundary specification between lateral organs and the meristem","canonical_id":"go:GO:0010199","description":"\"The process in which boundaries between lateral organs and the meristem is established and maintained.\" [PMID:12068116]","metadata":null},{"id":"023dc8d27b1745c38cdfff52373219f0","type":"GO_TERM","name":"organ growth","canonical_id":"go:GO:0035265","description":"\"The increase in size or mass of an organ. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that function together as to perform a specific function.\" [GOC:bf, ISBN:0471245208, ISBN:0721662544]","metadata":null},{"id":"5582850a68b249fca830289e4a1b3227","type":"GO_TERM","name":"organ induction","canonical_id":"go:GO:0001759","description":"\"The interaction of two or more cells or tissues that causes them to change their fates and specify the development of an organ.\" [ISBN:0878932437]","metadata":null},{"id":"8843d71d74d44cd1a6ac298bc15d7557","type":"GO_TERM","name":"organ or tissue specific immune response","canonical_id":"go:GO:0002251","description":"\"An immune response taking place in an organ or tissues such as the liver, brain, mucosa, or nervous system tissues.\" [GO_REF:0000022, GOC:jal]","metadata":null},{"id":"e125bf02ca164733a47f3fc5717b84fb","type":"GO_TERM","name":"organellar chromatophore","canonical_id":"go:GO:0070111","description":"\"A bacteroid-containing symbiosome in which the bacterial component is a genetically highly reduced cyanobacterium that is photosynthetically active and incapable of an independent existence outside its host. The chromatophore functions as a photosynthetic organelle, and has been found and characterized in the amoeba Paulinella chromatophora.\" [GOC:expert_mm, PMID:18356055]","metadata":null},{"id":"02cddca1036d4bfa9651c71bc1be6bae","type":"GO_TERM","name":"organellar chromatophore inner membrane","canonical_id":"go:GO:0070113","description":"\"The inner, i.e. lumen-facing, of the two lipid bilayers surrounding an organellar chromatophore.\" [GOC:mah]","metadata":null},{"id":"57f83e35fd7a44488bfb2c49a8121bc7","type":"GO_TERM","name":"organellar chromatophore intermembrane space","canonical_id":"go:GO:0070115","description":"\"The region between the inner and outer lipid bilayers that surround an organellar chromatophore.\" [GOC:mah]","metadata":null},{"id":"34752d49c2f3480ba349438f979393a6","type":"GO_TERM","name":"organellar chromatophore membrane","canonical_id":"go:GO:0070112","description":"\"Either of the lipid bilayers that surround an organellar chromatophore.\" [GOC:mah]","metadata":null},{"id":"24829771d47647a0beb1017af85763e0","type":"GO_TERM","name":"organellar chromatophore outer membrane","canonical_id":"go:GO:0070114","description":"\"The outer, i.e. cytoplasm-facing, of the two lipid bilayers surrounding an organellar chromatophore.\" [GOC:mah]","metadata":null},{"id":"50c565281f144ce1a7f80b8e2e0c1e97","type":"GO_TERM","name":"organellar chromatophore thylakoid","canonical_id":"go:GO:0070116","description":"\"A thylakoid located in an organellar chromatophore.\" [GOC:mah]","metadata":null},{"id":"e257199d6c454760b23f77692d5452f8","type":"GO_TERM","name":"organellar chromatophore thylakoid lumen","canonical_id":"go:GO:0070117","description":"\"The volume enclosed by an organellar chromatophore thylakoid membrane.\" [GOC:mah]","metadata":null},{"id":"471bea182d0146b1a650dbf62eb8a7cc","type":"GO_TERM","name":"organellar chromatophore thylakoid membrane","canonical_id":"go:GO:0070118","description":"\"The lipid bilayer membrane of any thylakoid within an organellar chromatophore.\" [GOC:mah]","metadata":null},{"id":"00107663d074412a903961f1127af2ed","type":"GO_TERM","name":"organellar large ribosomal subunit","canonical_id":"go:GO:0000315","description":"\"The larger of the two subunits of an organellar ribosome. Two sites on the ribosomal large subunit are involved in translation: the aminoacyl site (A site) and peptidyl site (P site).\" [GOC:mcc]","metadata":null},{"id":"20961ee00f0d48b8b61b6018998a3d8d","type":"GO_TERM","name":"organellar ribosome","canonical_id":"go:GO:0000313","description":"\"A ribosome contained within a subcellular membrane-bounded organelle.\" [GOC:mah, GOC:mcc]","metadata":null},{"id":"fe3a71269b9e4171b697ad40ec556078","type":"GO_TERM","name":"organellar small ribosomal subunit","canonical_id":"go:GO:0000314","description":"\"The smaller of the two subunits of an organellar ribosome.\" [GOC:mcc]","metadata":null},{"id":"a850445f38cd4862836fa3b911b27c32","type":"GO_TERM","name":"organellar voltage-gated chloride channel activity","canonical_id":"go:GO:0015274","description":"\"Enables the transmembrane transfer of a chloride ion by a voltage-gated channel. The membrane is an organellar membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"15e23403d9944ab9b93128b31c0edb1c","type":"GO_TERM","name":"organelle","canonical_id":"go:GO:0043226","description":"\"Organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton, and prokaryotic structures such as anammoxosomes and pirellulosomes. Excludes the plasma membrane.\" [GOC:curators]","metadata":null},{"id":"19313215ec0d4f3ea880e24380d5bfd2","type":"GO_TERM","name":"organelle assembly","canonical_id":"go:GO:0070925","description":"\"The aggregation, arrangement and bonding together of a set of components to form an organelle. An organelle is an organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. Excludes the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"abcd81505141420f82d2aba97bdf8351","type":"GO_TERM","name":"organelle disassembly","canonical_id":"go:GO:1903008","description":"\"The disaggregation of an organelle into its constituent components.\" [GO_REF:0000079, GOC:TermGenie]","metadata":null},{"id":"11821737d10a426f8af1461061ba2a17","type":"GO_TERM","name":"organelle envelope","canonical_id":"go:GO:0031967","description":"\"A double membrane structure enclosing an organelle, including two lipid bilayers and the region between them. In some cases, an organelle envelope may have more than two membranes.\" [GOC:mah, GOC:pz]","metadata":null},{"id":"cf69d9f5395942d49573e840521dc93f","type":"GO_TERM","name":"organelle envelope lumen","canonical_id":"go:GO:0031970","description":"\"The region between the inner and outer lipid bilayers of an organelle envelope.\" [GOC:mah]","metadata":null},{"id":"95607f53da754fe280dceb8907edd6b0","type":"GO_TERM","name":"organelle fission","canonical_id":"go:GO:0048285","description":"\"The creation of two or more organelles by division of one organelle.\" [GOC:jid]","metadata":null},{"id":"4e10829b3a52426290e1f37ec0e1e711","type":"GO_TERM","name":"organelle fusion","canonical_id":"go:GO:0048284","description":"\"The creation of a single organelle from two or more organelles.\" [GOC:jid]","metadata":null},{"id":"0fd3eb4828e84a7a94b877fad72cd24a","type":"GO_TERM","name":"organelle inheritance","canonical_id":"go:GO:0048308","description":"\"The partitioning of organelles between daughter cells at cell division.\" [GOC:jid]","metadata":null},{"id":"2b2547cacbf24835b1aace3d9f9b6008","type":"GO_TERM","name":"organelle inner membrane","canonical_id":"go:GO:0019866","description":"\"The inner, i.e. lumen-facing, lipid bilayer of an organelle envelope; usually highly selective to most ions and metabolites.\" [GOC:mah]","metadata":null},{"id":"9f1476fb826c4afaaa6d97bb177d260d","type":"GO_TERM","name":"organelle localization","canonical_id":"go:GO:0051640","description":"\"Any process in which an organelle is transported to, and/or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"a47a4eb0002a4782ba464fcfa074647e","type":"GO_TERM","name":"organelle localization by membrane tethering","canonical_id":"go:GO:0140056","description":"\"The process by which an organelle membrane interacts with another membrane via molecular tethers that physically bridge the two membranes and attach them to each other.\" [PMID:27875684]","metadata":null},{"id":"4f3a25703adf4d29ac7e66c75813b21a","type":"GO_TERM","name":"organelle lumen","canonical_id":"go:GO:0043233","description":"\"The internal volume enclosed by the membranes of a particular organelle; includes the volume enclosed by a single organelle membrane, e.g. endoplasmic reticulum lumen, or the volume enclosed by the innermost of the two lipid bilayers of an organelle envelope, e.g. nuclear lumen.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"c94f326de3214628af7166a7186ceee5","type":"GO_TERM","name":"organelle membrane","canonical_id":"go:GO:0031090","description":"\"A membrane that is one of the two lipid bilayers of an organelle envelope or the outermost membrane of single membrane bound organelle.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"78c509af29784201999134145f1a2a6f","type":"GO_TERM","name":"organelle membrane contact site","canonical_id":"go:GO:0044232","description":"\"A zone of apposition between the membranes of an organelle with another membrane, either another membrane of the same organelle, a membrane of another organelle, or the plasma membrane. Membrane contact sites (MCSs) are structured by bridging complexes. They are specialized for communication, including the efficient traffic of small molecules such as Ca2+ ions and lipids, as well as enzyme-substrate interactions.\" [GOC:jl, PMID:16806880]","metadata":null},{"id":"f788010abdb845989d6d4b0f3696c6d1","type":"GO_TERM","name":"organelle membrane fusion","canonical_id":"go:GO:0090174","description":"\"The joining of two lipid bilayers to form a single organelle membrane.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"78153e057318417db951de93380706b9","type":"GO_TERM","name":"organelle organization","canonical_id":"go:GO:0006996","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an organelle within a cell. An organelle is an organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. Excludes the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"4abfc67070124c9caebd2a24ffa5cb69","type":"GO_TERM","name":"organelle outer membrane","canonical_id":"go:GO:0031968","description":"\"The outer, i.e. cytoplasm-facing in a cellular organelle, lipid bilayer of an organelle envelope.\" [GOC:mah]","metadata":null},{"id":"b3c89a43979745ce8a03a5f2d93f1914","type":"GO_TERM","name":"organelle subcompartment","canonical_id":"go:GO:0031984","description":"\"A compartment that consists of a lumen and an enclosing membrane, and is part of an organelle.\" [GOC:mah, GOC:pz]","metadata":null},{"id":"d035a4d7b7c74d7ba094eb7db092a173","type":"GO_TERM","name":"organelle transport along microtubule","canonical_id":"go:GO:0072384","description":"\"The directed movement of an organelle along a microtubule, mediated by motor proteins. This process begins with the attachment of an organelle to a microtubule, and ends when the organelle reaches its final destination.\" [GOC:mah]","metadata":null},{"id":"580ba25c8c9b4da1a45fd63ef6080ee5","type":"GO_TERM","name":"organelle-enclosing lipid monolayer","canonical_id":"go:GO:0034646","description":"\"A lipid monolayer that surrounds and encloses an organelle.\" [GOC:mah]","metadata":null},{"id":"a5b0bc9d687b464684993076bc1e49b3","type":"GO_TERM","name":"organic acid binding","canonical_id":"go:GO:0043177","description":"\"Binding to an organic acid, any acidic compound containing carbon in covalent linkage.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"4623a4d8c05047e097cc558ecc6ed208","type":"GO_TERM","name":"organic acid transport","canonical_id":"go:GO:0015849","description":"\"The directed movement of organic acids, any acidic compound containing carbon in covalent linkage, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [ISBN:0198506732]","metadata":null},{"id":"95221d51adcc4545b171c16b03836861","type":"GO_TERM","name":"organic acid:sodium symporter activity","canonical_id":"go:GO:0005343","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: organic acid(out) + Na+(out) = organic acid(in) + Na+(in).\" [TC:2.A.28.1.1]","metadata":null},{"id":"8115e8c5e9f54b63a260561f1951f9df","type":"GO_TERM","name":"organic hydroxy compound transport","canonical_id":"go:GO:0015850","description":"\"The directed movement of an organic hydroxy compound (organic alcohol) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. An organic hydroxy compound is an organic compound having at least one hydroxy group attached to a carbon atom.\" [GOC:ai]","metadata":null},{"id":"9c91a8362ff54fe385465ea2a3a6d7b1","type":"GO_TERM","name":"organic phosphonate biosynthetic process","canonical_id":"go:GO:0032923","description":"\"The chemical reactions and pathways resulting in the formation of phosphonates, any organic compound containing one or more C-PO(OH)2 or C-PO(OR)2 (with R=alkyl, aryl) groups. Synthesis of phosphonic acid itself, an inorganic compound without the biochemically relevant C-P bond, is not included.\" [GOC:js]","metadata":null},{"id":"aa3705a77cb54b34b41b904554913e80","type":"GO_TERM","name":"organic phosphonate catabolic process","canonical_id":"go:GO:0019700","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphonates, any organic compound containing one or more C-PO(OH)2 or C-PO(OR)2 (with R=alkyl, aryl) groups. Catabolism of phosphonic acid itself, an inorganic compound without the biochemically relevant C-P bond, is not included.\" [GOC:js]","metadata":null},{"id":"712355e5f9d24225a6e3aa579089afbc","type":"GO_TERM","name":"organic phosphonate metabolic process","canonical_id":"go:GO:0019634","description":"\"The chemical reactions and pathways involving phosphonates, any organic compounds containing one or more C-PO(OH)2 or C-PO(OR)2 (with R=alkyl, aryl) groups. Metabolism of phosphonic acid itself, an inorganic compound without the biochemically relevant C-P bond, is not included.\" [GOC:js, ISBN:0721662544]","metadata":null},{"id":"bd25911f06e64dceaba958004dd2039d","type":"GO_TERM","name":"organic phosphonate transport","canonical_id":"go:GO:0015716","description":"\"The directed movement of phosphonates into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A phosphonate is any salt, anion, or ester of phosphonic acid (HPO(OH)2).\" [GOC:krc]","metadata":null},{"id":"bde8e4a9d2194ec9b51ae914b887ca3e","type":"GO_TERM","name":"organism emergence from protective structure","canonical_id":"go:GO:0071684","description":"\"The developmental process in which an organism emerges from a surrounding protective structure such as an egg or pupa case.\" [GOC:mah]","metadata":null},{"id":"f8ef3272471b45da88c3e8c2264f566a","type":"GO_TERM","name":"organofluorine metabolic process","canonical_id":"go:GO:0090346","description":"\"The chemical reactions and pathways involving organofluorine compounds, as carried out by individual cells.\" [GOC:BHF]","metadata":null},{"id":"05517057b30442dd88c8e36abdccc291","type":"GO_TERM","name":"organohalogen metabolic process","canonical_id":"go:GO:0090345","description":"\"The chemical reactions and pathways involving organohalogen compounds, as carried out by individual cells.\" [GOC:BHF]","metadata":null},{"id":"cdca0cedc630496094babf46e61c5e37","type":"GO_TERM","name":"organometal metabolic process","canonical_id":"go:GO:0018942","description":"\"The chemical reactions and pathways involving organometals, any metal-containing organic compound, especially one in which the metal atom is linked directly to one of more carbon atoms.\" [ISBN:0198506732, PMID:36598231]","metadata":null},{"id":"6dd5ffb0b118414fa743647c851c0c71","type":"GO_TERM","name":"organomineral extracellular matrix","canonical_id":"go:GO:1990377","description":"\"An extracellular matrix consisting of a densely packed organomineral assembly in which the mineral phase represents the majority of the material by weight.\" [GOC:jh2, PMID:15994301]","metadata":null},{"id":"c2e4042dd70e4a158f310c2d336ddd66","type":"GO_TERM","name":"organophosphate biosynthetic process","canonical_id":"go:GO:0090407","description":"\"The chemical reactions and pathways resulting in the biosynthesis of deoxyribose phosphate, the phosphorylated sugar 2-deoxy-erythro-pentose.\" [GOC:chem_mtg]","metadata":null},{"id":"0126153c00d04baaabe244543ec7e5ef","type":"GO_TERM","name":"organophosphate catabolic process","canonical_id":"go:GO:0046434","description":"\"The chemical reactions and pathways resulting in the breakdown of organophosphates, any phosphate-containing organic compound.\" [GOC:ai]","metadata":null},{"id":"40b89523c9764d8e9e39e5430e2f267d","type":"GO_TERM","name":"organophosphate ester transmembrane transporter activity","canonical_id":"go:GO:0015605","description":"\"Enables the transfer of organophosphate esters from one side of a membrane to the other. Organophosphate esters are small organic molecules containing phosphate ester bonds.\" [GOC:mcc]","metadata":null},{"id":"d7f271cac23d402da89db8a6f8154b36","type":"GO_TERM","name":"organophosphate ester transport","canonical_id":"go:GO:0015748","description":"\"The directed movement of organophosphate esters into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Organophosphate esters are small organic molecules containing phosphate ester bonds.\" [GOC:mcc]","metadata":null},{"id":"42004ebebb60445e97f4463e227bed80","type":"GO_TERM","name":"organophosphate metabolic process","canonical_id":"go:GO:0019637","description":"\"The chemical reactions and pathways involving organophosphates, any phosphate-containing organic compound.\" [ISBN:0198506732]","metadata":null},{"id":"dae0fa2ddd0c4414ab862467ef36dc72","type":"DISEASE","name":"organophosphate poisoning","canonical_id":"efo:0010581","description":null,"metadata":null},{"id":"835b71f51b5d43c29b81397350249780","type":"GO_TERM","name":"organophosphate:phosphate antiporter activity","canonical_id":"go:GO:0015315","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: organophosphate(out) + phosphate(in) = organophosphate(in) +  phosphate(out).\" [TC:2.A.1.4.-]","metadata":null},{"id":"3b4848e16b0a40c9a3680acb0d4e8d77","type":"GO_TERM","name":"organosilicon catabolic process","canonical_id":"go:GO:0046455","description":"\"The chemical reactions and pathways resulting in the breakdown of organosilicons, any organic compound that contains silicon.\" [GOC:ai]","metadata":null},{"id":"49e005aee0d54ee5940e57b653adf5b1","type":"GO_TERM","name":"origin recognition complex","canonical_id":"go:GO:0000808","description":"\"A multisubunit complex that is located at the replication origins of a chromosome.\" [GOC:elh]","metadata":null},{"id":"949fad66462e425091821e896153cacd","type":"GO_TERM","name":"origin recognition complex assembly","canonical_id":"go:GO:1902561","description":"\"The aggregation, arrangement and bonding together of a set of components to form an origin recognition complex.\" [GOC:TermGenie, PMID:11717425]","metadata":null},{"id":"46a779fb966744649149700445beacfd","type":"DRUG","name":"oritavancin","canonical_id":"mesh:C100708","description":null,"metadata":null},{"id":"ee13fffd8df748afbbd15b2128ee99db","type":"GO_TERM","name":"orlandin biosynthetic process","canonical_id":"go:GO:1900821","description":"\"The chemical reactions and pathways resulting in the formation of orlandin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"436c0fe64b174368925c3a79b17ff722","type":"GO_TERM","name":"orlandin catabolic process","canonical_id":"go:GO:1900820","description":"\"The chemical reactions and pathways resulting in the breakdown of orlandin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6c3bd878a20d45b288eab8191e70c528","type":"GO_TERM","name":"orlandin metabolic process","canonical_id":"go:GO:1900819","description":"\"The chemical reactions and pathways involving orlandin.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"239b484b48784d2ab7414eeaa92259ff","type":"DRUG","name":"orlistat","canonical_id":"gtopdb:5277","description":null,"metadata":null},{"id":"a0ba2354285b4402981503066e2f94a9","type":"DRUG","name":"orlistat","canonical_id":"mesh:C055122","description":null,"metadata":null},{"id":"51a6e97444064b7db19c0dd74ff6b010","type":"DRUG","name":"orlistat","canonical_id":"chembl:CHEMBL175247","description":null,"metadata":null},{"id":"ec7d44752a3d49818ec47f1ea26aa598","type":"COMBINATION_TREATMENT","name":"orlistat + sibutramine","canonical_id":"ctgov_combo:ctgov-combo-08f949751b40fc9a","description":null,"metadata":null},{"id":"edd6f7a07d304228bbb306eee832d0d8","type":"COMBINATION_TREATMENT","name":"orlistat + sibutramine","canonical_id":"ctgov_combo:ctgov-combo-ad1f8b39d280288c","description":null,"metadata":null},{"id":"60a0ca95099e4215bb9211119ba35562","type":"COMBINATION_TREATMENT","name":"orlistat + sibutramine","canonical_id":"ctgov_combo:ctgov-combo-1db301d717bdab11","description":null,"metadata":null},{"id":"b52994c6f341409ca079d0e538f6c76a","type":"COMBINATION_TREATMENT","name":"orlistat + sibutramine","canonical_id":"ctgov_combo:ctgov-combo-0556ada3e8e4c419","description":null,"metadata":null},{"id":"256c1392ef1a493d82235bf02fce1be3","type":"COMBINATION_TREATMENT","name":"orlistat + sibutramine","canonical_id":"ctgov_combo:ctgov-combo-a9a4ae587b53f045","description":null,"metadata":null},{"id":"18413aa15edb44cb817264d10da2cae2","type":"GO_TERM","name":"ornithine N-benzoyltransferase activity","canonical_id":"go:GO:0050156","description":"\"Catalysis of the reaction: L-ornithine + 2 benzoyl-CoA = N(2),N(5)-dibenzoyl-L-ornithine + 2 CoA + 2 H+.\" [EC:2.3.1.127, RHEA:16929]","metadata":null},{"id":"a8bd5e31140c489b9e9b139abbe6ad03","type":"GO_TERM","name":"ornithine N5-monooxygenase activity","canonical_id":"go:GO:0031172","description":"\"Catalysis of the reaction: L-ornithine + O2 + H+ = N5-hydroxy-L-ornithine + H2O.\" [MetaCyc:RXN-11128, PMID:12828635]","metadata":null},{"id":"4f1d9159b3f14bd6b4248d03fa7d3b50","type":"GO_TERM","name":"ornithine carbamoyltransferase activity","canonical_id":"go:GO:0004585","description":"\"Catalysis of the reaction: carbamoyl phosphate + L-ornithine = phosphate + L-citrulline.\" [EC:2.1.3.3]","metadata":null},{"id":"240f9dbb429343a9a9c33a72c7a4d84b","type":"GO_TERM","name":"ornithine carbamoyltransferase inhibitor activity","canonical_id":"go:GO:0090369","description":"\"Binds to and stops, prevents, or reduces the activity of ornithine carbamoyltransferase.\" [GOC:dph, GOC:jp, GOC:tb]","metadata":null},{"id":"ce8a14701957451ca7b81d459d5e8ce5","type":"GO_TERM","name":"ornithine carbamoyltransferase inhibitor complex","canonical_id":"go:GO:1903269","description":"\"A protein complex which is capable of ornithine carbamoyltransferase inhibitor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:12679340]","metadata":null},{"id":"745a301ee6d7469c85e8ca94f3b41036","type":"GO_TERM","name":"ornithine cyclodeaminase activity","canonical_id":"go:GO:0008473","description":"\"Catalysis of the reaction: L-ornithine = L-proline + NH4.\" [EC:4.3.1.12, RHEA:24368]","metadata":null},{"id":"990362cf0f5a4513b825cb6ecc964a08","type":"GO_TERM","name":"ornithine decarboxylase activator activity","canonical_id":"go:GO:0042978","description":"\"Binds to and increases ornithine decarboxylase activity.\" [GOC:jl]","metadata":null},{"id":"b77efd2644eb45409c96e1a338bbda64","type":"GO_TERM","name":"ornithine decarboxylase activity","canonical_id":"go:GO:0004586","description":"\"Catalysis of the reaction: L-ornithine + H+ = CO2 + putrescine.\" [EC:4.1.1.17, RHEA:22964]","metadata":null},{"id":"8498e05d730c413d8b8b60d128bcb473","type":"GO_TERM","name":"ornithine decarboxylase inhibitor activity","canonical_id":"go:GO:0008073","description":"\"Binds to and stops, prevents or reduces the activity of ornithine decarboxylase.\" [GOC:jl]","metadata":null},{"id":"d32e8ef4d4e84d43b5896a2ddbec3a92","type":"GO_TERM","name":"ornithine decarboxylase regulator activity","canonical_id":"go:GO:0042979","description":"\"Binds to and modulates the activity of the enzyme ornithine decarboxylase.\" [GOC:jl]","metadata":null},{"id":"afe58558466041e0b8ebe4facad80dc6","type":"GO_TERM","name":"ornithine lipid biosynthetic process","canonical_id":"go:GO:0140371","description":"\"The chemical reactions and pathways resulting in the formation of ornithine lipids, any of a class of phosphorus-free bacterial membrane lipids with an L-ornithine-derived head group.\" [PMID:22724388]","metadata":null},{"id":"8bd91dc5696041af8b116f06f51ab081","type":"GO_TERM","name":"ornithine metabolic process","canonical_id":"go:GO:0006591","description":"\"The chemical reactions and pathways involving ornithine, an amino acid only rarely found in proteins, but which is important in living organisms as an intermediate in the reactions of the urea cycle and in arginine biosynthesis.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"ec09bdcf90874b2e903e4c57bb5338db","type":"GO_TERM","name":"ornithine racemase activity","canonical_id":"go:GO:0050157","description":"\"Catalysis of the reaction: L-ornithine = D-ornithine.\" [EC:5.1.1.12]","metadata":null},{"id":"397d79d84f4845efabb6010055bc4a5a","type":"GO_TERM","name":"ornithine transmembrane import into vacuole","canonical_id":"go:GO:0090455","description":"\"The directed movement of ornithine into the vacuole across the vacuolar membrane.\" [GOC:tb]","metadata":null},{"id":"611a8362cd994369b3c4b574f6d78a66","type":"GO_TERM","name":"ornithine transport","canonical_id":"go:GO:0015822","description":"\"The directed movement of ornithine, 2,5-diaminopentanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"4714fc27417a40d9ae5891ec052baacd","type":"GO_TERM","name":"ornithine-acyl [acyl carrier protein] N-acyltransferase activity","canonical_id":"go:GO:0043810","description":"\"Catalysis of the reaction: (3R)-3-hydroxyacyl-[acyl-carrier protein] + L-ornithine = lyso-ornithine lipid + [acyl-carrier protein]. The enzyme, found in bacteria, catalyzes the first step in the biosynthesis of ornithine lipids.\" [PMID:15341653, RHEA:20633]","metadata":null},{"id":"e09b10eb4fa94b918e4dd84ba117d083","type":"DISEASE","name":"ornithosis","canonical_id":"mondo:0005888","description":null,"metadata":null},{"id":"96673ae986d84164bef1fb5c5a955af3","type":"GO_TERM","name":"orotate phosphoribosyltransferase activity","canonical_id":"go:GO:0004588","description":"\"Catalysis of the reaction: orotidine 5'-phosphate + diphosphate = orotate + 5-phospho-alpha-D-ribose 1-diphosphate.\" [EC:2.4.2.10]","metadata":null},{"id":"6aebd98c71c8494d90806f510ef27e9a","type":"GO_TERM","name":"orotate:monoatomic anion antiporter activity","canonical_id":"go:GO:0140812","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: orotate(out) + anion (in) = orotate (in) + anion (out).\" [PMID:21350910, PMID:35144162]","metadata":null},{"id":"6867f2c5eb3f4eb4a9c82dcb1339df42","type":"GO_TERM","name":"orotidine-5'-phosphate decarboxylase activity","canonical_id":"go:GO:0004590","description":"\"Catalysis of the reaction: H+ + orotidine 5'-phosphate = CO2 + UMP.\" [EC:4.1.1.23, RHEA:11596]","metadata":null},{"id":"a32b45911c7f4d66bb8ef26a0a47998d","type":"GO_TERM","name":"orsellinate decarboxylase activity","canonical_id":"go:GO:0050159","description":"\"Catalysis of the reaction: o-orsellinate + H+ = CO2 + orcinol.\" [EC:4.1.1.58, RHEA:16733]","metadata":null},{"id":"bbbd1b9ab44c415f95335e9b9f49a4fd","type":"GO_TERM","name":"orsellinate-depside hydrolase activity","canonical_id":"go:GO:0050160","description":"\"Catalysis of the reaction: H2O + orsellinate depside = 2 o-orsellinate + H+.\" [EC:3.1.1.40, RHEA:19549]","metadata":null},{"id":"1f7f7365d7f74e74b9d3281c74ac4c11","type":"GO_TERM","name":"ortho-trichlorophenol reductive dehalogenase activity","canonical_id":"go:GO:0050781","description":"\"Catalysis of the reaction: 2,4,6-trichlorophenol + 2 H+ + 2 e- = 2,4-dichlorophenol + HCl.\" [GOC:ai, PMID:12697029]","metadata":null},{"id":"0db1dcf7b5974ebdb7b57e2cf305bdf0","type":"GO_TERM","name":"orthodenticle mRNA localization","canonical_id":"go:GO:0060812","description":"\"Any process in which orthodenticle mRNA is transported to and maintained in the oocyte and/or syncytial embryo as part of the process that will specify the anterior/posterior axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3621e4ea5a3b4ba6987a9bff954494cb","type":"GO_TERM","name":"orthogonal array","canonical_id":"go:GO:1990014","description":"\"Square array of closely spaced intramembrane particles, 4-6 nm in size, that form supramolecular aggregates found in the plasma membrane of astrocytes, skeletal muscle and epithelial cells. They have been shown to contain aquaporins (water channels).\" [NIF_Subcellular:sao1747012216, PMID:22718347]","metadata":null},{"id":"9df3d782149846e69d1bbaf18ff3bd03","type":"GO_TERM","name":"orthogonal dichotomous subdivision of terminal units involved in lung branching morphogenesis","canonical_id":"go:GO:0060488","description":"\"The process in which a lung bud bifurcates perpendicular to the plane of the previous bud.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"689d1729fce3472390ad88a259c7074a","type":"GO_TERM","name":"orthokinesis","canonical_id":"go:GO:0042467","description":"\"The movement of a cell or organism in response to a stimulus in which the speed or frequency of movement is increased or decreased.\" [GOC:jl, PMID:8207088]","metadata":null},{"id":"3a69057ad52840acb4c2cebca15292c9","type":"DISEASE","name":"orthostatic hypotension","canonical_id":"mondo:0005469","description":null,"metadata":null},{"id":"be12620626464997928e8d6abc5846d2","type":"GO_TERM","name":"oscillatory cAMP signaling","canonical_id":"go:GO:0140676","description":"\"Fluctuation in the extracellular cAMP levels due to the alternate activation of adenylate cyclase, which produces cAMP, and phosphodiesterase, which degrades it. Occurs in Dictyostelium during early sorocarp development. Oscillation in signaling result is directional chemotaxis of cells towards the center of the aggregate.\" [PMID:18657484]","metadata":null},{"id":"8cbf6634bfd34bc7a34bc3969d412e65","type":"GO_TERM","name":"oscillatory muscle contraction","canonical_id":"go:GO:0014703","description":"\"A process in which force is generated within oscillatory skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Oscillatory muscle contraction occurs in insect wing muscles and is characterized by asynchrony between action potential and contraction and by stretch activation.\" [GOC:mtg_muscle]","metadata":null},{"id":"231268b0f1eb484c974c50753ae85bf2","type":"GO_TERM","name":"osmiophilic body","canonical_id":"go:GO:0044310","description":"\"A membrane-bounded vesicle found predominantly in Plasmodium female gametocytes, that becomes progressively more abundant as the gametocyte reaches full maturity. These vesicles lie beneath the subpellicular membrane of the gametocyte, and the release of their contents into the parasitophorous vacuole has been postulated to aid in the escape of gametocytes from the erythrocyte after ingestion by the mosquito.\" [GOC:jl, PMID:18086189]","metadata":null},{"id":"170bb1db8e7942e49df6b005d7e724b6","type":"GO_TERM","name":"osmolarity-sensing monoatomic cation channel activity","canonical_id":"go:GO:1990760","description":"\"Enables the transmembrane transfer of a monoatomic cation by a channel that opens when a change in the osmolarity occurs in the extracellular space of the cell in which the cation channel resides.\" [PMID:18279313]","metadata":null},{"id":"dd84dbecd5f84333a5b8463009ba00ff","type":"GO_TERM","name":"osmoregulated periplasmic glucan biosynthetic process","canonical_id":"go:GO:1900727","description":"\"The chemical reactions and pathways resulting in the formation of osmoregulated periplasmic glucan.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"08f607e84f874782980e32b537bb1d4c","type":"GO_TERM","name":"osmoregulated periplasmic glucan catabolic process","canonical_id":"go:GO:1900726","description":"\"The chemical reactions and pathways resulting in the breakdown of osmoregulated periplasmic glucan.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"b1163f3cea394946bea75cab2436bf0b","type":"GO_TERM","name":"osmosensor activity","canonical_id":"go:GO:0005034","description":"\"Sensing extracellular osmolarity to initiate a change in cell activity, and spanning the membrane of the cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"dfa6bdbced7c4b21be2ffb56c939f998","type":"GO_TERM","name":"osmosensory signaling pathway","canonical_id":"go:GO:0007231","description":"\"The series of molecular signals initiated in response to osmotic change.\" [GOC:jl]","metadata":null},{"id":"2fba87c0da3d446f9964a8ce72c99ef3","type":"GO_TERM","name":"osmosensory signaling pathway via Sho1 osmosensor","canonical_id":"go:GO:0007232","description":"\"The series of molecular signals generated in response to osmotic change, as mediated through a Sho1 osmosensor system.\" [GOC:jl, PMID:26787842]","metadata":null},{"id":"b984036e73064e7eb65e0cfe5bccb749","type":"GO_TERM","name":"osmosensory signaling via phosphorelay pathway","canonical_id":"go:GO:0007234","description":"\"The series of molecular signals generated in response to osmotic change, as mediated through a phosphorelay system. In S.cerevisiae, the osmosensor is the histidine kinase Sln1.\" [PMID:26787842, PMID:9843501]","metadata":null},{"id":"e048d5175b854a85af6fbfed93e9f60f","type":"DRUG","name":"ospemifene","canonical_id":"gtopdb:7349","description":null,"metadata":null},{"id":"496b35fbee174e1a81f45ac6ce81adca","type":"DRUG","name":"ospemifene","canonical_id":"mesh:C119141","description":null,"metadata":null},{"id":"f669b46126da44b7a630a2a11916481b","type":"DRUG","name":"ospemifene","canonical_id":"chembl:CHEMBL2105395","description":null,"metadata":null},{"id":"4157ef69e2bd4f45bafc278ffa69383a","type":"GO_TERM","name":"ossification","canonical_id":"go:GO:0001503","description":"\"The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance.\" [GOC:mtg_mpo, PMID:17572649]","metadata":null},{"id":"64f119b30b3a4d6188eaa7d266dc628e","type":"GO_TERM","name":"ossification involved in bone maturation","canonical_id":"go:GO:0043931","description":"\"The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone, involved in the progression of the skeleton from its formation to its mature state.\" [GOC:dph, GOC:mah, GOC:mtg_mpo]","metadata":null},{"id":"857c947a2203413897b1582b65485eab","type":"GO_TERM","name":"ossification involved in bone remodeling","canonical_id":"go:GO:0043932","description":"\"The formation or growth of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone, involved in response to injury or other physical, physiological or environmental stress stimuli.\" [GO_REF:0000034, GOC:mtg_mpo]","metadata":null},{"id":"7811d40fc3bc4cb9a32e7bbd2a395f50","type":"DISEASE","name":"osteoarthritis","canonical_id":"mondo:0005178","description":null,"metadata":null},{"id":"a1cef0112e64404d8de011b453c2fbf1","type":"DISEASE","name":"osteoarthritis, hip","canonical_id":"mondo:0006629","description":null,"metadata":null},{"id":"84cdd31801594eaf86d02fe072a2e202","type":"DISEASE","name":"osteoarthritis, knee","canonical_id":"mondo:0005416","description":null,"metadata":null},{"id":"916cd29f8d7e4545b839863306fd9958","type":"GO_TERM","name":"osteoblast development","canonical_id":"go:GO:0002076","description":"\"The process whose specific outcome is the progression of an osteoblast over time, from its formation to the mature structure. Osteoblast development does not include the steps involved in committing a cranial neural crest cell or an osteoprogenitor cell to an osteoblast fate. An osteoblast is a cell that gives rise to bone.\" [GOC:dph]","metadata":null},{"id":"bceb0d19357e455382ba79c690b77af9","type":"GO_TERM","name":"osteoblast differentiation","canonical_id":"go:GO:0001649","description":"\"The process whereby a relatively unspecialized cell acquires the specialized features of an osteoblast, a mesodermal or neural crest cell that gives rise to bone.\" [CL:0000062, GO_REF:0000034, GOC:jid]","metadata":null},{"id":"2b9824aabc8945cf90914c9e8a8f5c5e","type":"GO_TERM","name":"osteoblast fate commitment","canonical_id":"go:GO:0002051","description":"\"The commitment of mesenchymal cells to the specific cell fate of an osteoblast. An osteoblast is a bone-forming cell which secretes an extracellular matrix. Hydroxyapatite crystals are then deposited into the matrix to form bone.\" [GOC:dph]","metadata":null},{"id":"bbdb9877f9c04294b067703ac48aac79","type":"GO_TERM","name":"osteoblast proliferation","canonical_id":"go:GO:0033687","description":"\"The multiplication or reproduction of osteoblasts, resulting in the expansion of an osteoblast cell population. An osteoblast is a bone-forming cell which secretes an extracellular matrix. Hydroxyapatite crystals are then deposited into the matrix to form bone.\" [GOC:mah]","metadata":null},{"id":"f53ab8e41a9644cabf9f8e9d6c877ec0","type":"GO_TERM","name":"osteoclast development","canonical_id":"go:GO:0036035","description":"\"The process whose specific outcome is the progression of a osteoclast from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue.\" [CL:0000092, GOC:bf, GOC:yaf]","metadata":null},{"id":"f103d2ad16554f8f9c6b365c1657362e","type":"GO_TERM","name":"osteoclast differentiation","canonical_id":"go:GO:0030316","description":"\"The process in which a relatively unspecialized monocyte acquires the specialized features of an osteoclast. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue.\" [CL:0000092, GOC:add, ISBN:0781735149, PMID:12161749]","metadata":null},{"id":"ecb2f30e55b849bcb4cfbc4208743991","type":"GO_TERM","name":"osteoclast fusion","canonical_id":"go:GO:0072675","description":"\"The plasma membrane fusion process that results in fusion of mononuclear osteoclasts to form a multinuclear osteoclast.\" [CL:0000092, CL:0000779, GOC:BHF, GOC:mah, PMID:12713016]","metadata":null},{"id":"83a7c994c2c149828cfb9fa59e42811f","type":"GO_TERM","name":"osteoclast maturation","canonical_id":"go:GO:0036179","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for an osteoclast cell to attain its fully functional state. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue, and which typically differentiates from monocytes.\" [CL:0000092, GOC:pg]","metadata":null},{"id":"662608f3486142ffa636d40c1f62c522","type":"GO_TERM","name":"osteoclast proliferation","canonical_id":"go:GO:0002158","description":"\"The multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue, which typically differentiates from monocytes.\" [CL:0000092, GOC:hjd]","metadata":null},{"id":"a0b058982a944205baece9baf7df78c6","type":"DISEASE","name":"osteogenesis imperfecta","canonical_id":"mondo:0019019","description":null,"metadata":null},{"id":"64fb7e91985f44848d9194ba5079dd7d","type":"DISEASE","name":"osteoglophonic dysplasia","canonical_id":"mondo:0008150","description":null,"metadata":null},{"id":"fdf92ffa5bd14dff9bed24a123331877","type":"DISEASE","name":"osteomalacia","canonical_id":"efo:1002027","description":null,"metadata":null},{"id":"d7bc4039a48f4e94bece14d3dd92c04c","type":"DISEASE","name":"osteopetrosis","canonical_id":"mondo:0017198","description":null,"metadata":null},{"id":"a50a914c89d2449dbe5e742ef8b40141","type":"DISEASE","name":"osteoporosis","canonical_id":"mondo:0005298","description":null,"metadata":null},{"id":"1f0a6c0a3fcb4be78151628c3b150b8f","type":"DISEASE","name":"osteoporosis","canonical_id":"mesh:D010024","description":null,"metadata":null},{"id":"49a513b8bead4cddbfcf98f18aafbfe7","type":"DISEASE","name":"osteosarcoma","canonical_id":"mondo:0009807","description":null,"metadata":null},{"id":"6a6d258db2084a9591261b3e537c0687","type":"GO_TERM","name":"other organism cell membrane","canonical_id":"go:GO:0044218","description":"\"The cell membrane of a secondary organism with which the first organism is interacting.\" [GOC:jl]","metadata":null},{"id":"0a0db19196d84674a0cac392891fc639","type":"GO_TERM","name":"other organism part","canonical_id":"go:GO:0044217","description":"\"Any constituent part of a secondary organism with which the first organism is interacting.\" [GOC:jl]","metadata":null},{"id":"8e44ec14f3ca432d899675090f69e4e4","type":"GO_TERM","name":"otic placode development","canonical_id":"go:GO:1905040","description":"\"The process whose specific outcome is the progression of an otic placode over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:bf, GOC:mat, GOC:PARL, GOC:TermGenie, PMID:18356247]","metadata":null},{"id":"42cedb849ac141f19813552c93b2e6b6","type":"GO_TERM","name":"otic placode formation","canonical_id":"go:GO:0043049","description":"\"The initial developmental process that will lead to the formation of the vertebrate inner ear. The otic placode forms as a thickening of the head ectoderm adjacent to the developing hindbrain.\" [GOC:curators, PMID:12668634]","metadata":null},{"id":"292f32b2eb874453a82f7cffe9c624c0","type":"GO_TERM","name":"otic vesicle development","canonical_id":"go:GO:0071599","description":"\"The process whose specific outcome is the progression of the otic vesicle over time, from its formation to the mature structure. The otic vesicle is a transient embryonic structure formed during development of the vertebrate inner ear.\" [GOC:mah]","metadata":null},{"id":"36c67e34fa7642d18bf5c1d2a0f514a4","type":"GO_TERM","name":"otic vesicle formation","canonical_id":"go:GO:0030916","description":"\"The process resulting in the transition of the otic placode into the otic vesicle, a transient embryonic structure formed during development of the vertebrate inner ear.\" [GOC:dgh]","metadata":null},{"id":"e62b3e3c3a514484acc2478f00a6a77b","type":"GO_TERM","name":"otic vesicle morphogenesis","canonical_id":"go:GO:0071600","description":"\"The process in which the anatomical structures of the otic vesicle are generated and organized. The otic vesicle is a transient embryonic structure formed during development of the vertebrate inner ear.\" [GOC:mah]","metadata":null},{"id":"34fdb6b69e36495490860188488e62a9","type":"DISEASE","name":"otitis externa","canonical_id":"mondo:0004795","description":null,"metadata":null},{"id":"4fbe8b3ad3d64f1480e50f85b03fbda8","type":"GO_TERM","name":"otolith development","canonical_id":"go:GO:0048840","description":"\"The process whose specific outcome is the progression of the otolith over time, from its formation to the mature structure.\" [GOC:sr]","metadata":null},{"id":"a5d141bf4c274a72b373a8f4c2964c75","type":"GO_TERM","name":"otolith formation","canonical_id":"go:GO:0032475","description":"\"The process that gives rise to an otolith. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:dgh]","metadata":null},{"id":"255904bb3d8f4111a78845fb35737d7b","type":"GO_TERM","name":"otolith mineralization","canonical_id":"go:GO:0045299","description":"\"The precipitation of specific crystal forms of calcium carbonate with extracellular matrix proteins in the otolith organs of the vertebrate inner ear.\" [GOC:dsf, PMID:15581873]","metadata":null},{"id":"8dfd176a038f408789f0ae42f48b3e50","type":"GO_TERM","name":"otolith mineralization completed early in development","canonical_id":"go:GO:0031173","description":"\"The formation of otoliths during embryogenesis with completion in early postembryonic development. Formation occurs by precipitation of specific crystal forms of calcium carbonate around an organic core of extracellular matrix proteins. Otoconia (otoliths) are small (~10 micron) dense extracellular particles present in the otolith end organs of the vertebrate inner ear.\" [GOC:dsf, PMID:15581873]","metadata":null},{"id":"dfd5ffb1a1d044588befb7aa775c1208","type":"GO_TERM","name":"otolith morphogenesis","canonical_id":"go:GO:0032474","description":"\"The process in which the anatomical structures of an otolith are generated and organized.\" [GOC:dgh]","metadata":null},{"id":"26ceeabbfabe4d7c9c4c5f3fa6736397","type":"GO_TERM","name":"otolith tethering","canonical_id":"go:GO:0035889","description":"\"The attachment of a developing otolith to the kinocilia of tether cells in the inner ear.\" [GOC:dgh, PMID:14499652]","metadata":null},{"id":"d5be5c66284142708af2f9edb7e81b0b","type":"GO_TERM","name":"outer acrosomal membrane","canonical_id":"go:GO:0002081","description":"\"The acrosomal membrane region that underlies the plasma membrane of the sperm. This membrane fuses with the sperm plasma membrane as part of the acrosome reaction.\" [GOC:dph, PMID:8936405]","metadata":null},{"id":"ad0ac3a3fef5443493ec7b90e19f07f4","type":"GO_TERM","name":"outer dense fiber","canonical_id":"go:GO:0001520","description":"\"A supramolecular fiber found in the flagella of mammalian sperm that surrounds the nine microtubule doublets. These dense fibers are stiff and noncontractile. In human, they consist of about 10 major and at least 15 minor proteins, where all major proteins are ODF1, ODF2 or ODF2-related proteins.\" [GOC:cilia, GOC:krc, ISBN:0824072820, PMID:10381817, PMID:21586547, PMID:25361759]","metadata":null},{"id":"146a9da2278c424a877f6ef3e60494f5","type":"GO_TERM","name":"outer dense plaque of desmosome","canonical_id":"go:GO:0090636","description":"\"The desmosomal part containing plakoglobins, plakophilins, the N-termini of desmoplakins, as well as the cytoplasmic tails of the desmosomal cadherins, which together attach the plaque to the plasma membrane.\" [PMID:20066089]","metadata":null},{"id":"9712dfc42e6a4032bb89b37d88996c92","type":"GO_TERM","name":"outer dynein arm","canonical_id":"go:GO:0036157","description":"\"Outer arm structure present on the outer doublet microtubules of ciliary and flagellar axonemes. Outer dynein arms contain 2-3 heavy chains, two or more intermediate chains and a cluster of 4-8 light chains. Inner and outer dynein arms have different functions in the generation of microtubule-based motility.\" [GOC:BHF, GOC:vk, PMID:2557057, PMID:6218174]","metadata":null},{"id":"515eea00911a4daaaa3988b6538643db","type":"GO_TERM","name":"outer dynein arm assembly","canonical_id":"go:GO:0036158","description":"\"The aggregation, arrangement and bonding together of a set of components to form an axonemal dynein outer arm, an outer arm structure present on the outer doublet microtubules of ciliary and flagellar axonemes.\" [GOC:BHF, GOC:vk, PMID:19944400]","metadata":null},{"id":"14b8a5cc75b540559b5fb18a18f404c1","type":"GO_TERM","name":"outer dynein arm docking complex","canonical_id":"go:GO:0120228","description":"\"A complex which stabilizes the binding of and correctly positions the outer dynein arm complex along an A-tubule of the flagellar axoneme outer doublet microtubules.\" [GOC:krc, PMID:15064350, PMID:24067530, PMID:25192045, PMID:27486780, PMID:8045937]","metadata":null},{"id":"0f99295a3eb6438ea2e135c541c8af47","type":"GO_TERM","name":"outer ear emergence","canonical_id":"go:GO:0060186","description":"\"The growth of the outer ear.\" [GOC:dph]","metadata":null},{"id":"b8f1bde6cecc4bf0be04f6f962b35f4f","type":"GO_TERM","name":"outer ear morphogenesis","canonical_id":"go:GO:0042473","description":"\"The process in which the anatomical structures of the outer ear are generated and organized. The outer ear is the part of the ear external to the tympanum (eardrum). It consists of a tube (the external auditory meatus) that directs sound waves on to the tympanum, and may also include the external pinna, which extends beyond the skull.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"fc631533cbca425eb0b007e2e6b30b1c","type":"GO_TERM","name":"outer ear unfolding","canonical_id":"go:GO:0060185","description":"\"The opening and spreading out of the outer ear.\" [GOC:dph]","metadata":null},{"id":"324b3cc36bcf44e8934bfd3a8205fe57","type":"GO_TERM","name":"outer endospore membrane","canonical_id":"go:GO:0043594","description":"\"The outer membrane around a bacterial endospore, located between the endospore cortex and endospore coat.\" [GOC:mlg]","metadata":null},{"id":"018a50b3309048de9a512cd87ba0998e","type":"GO_TERM","name":"outer hair cell apoptotic process","canonical_id":"go:GO:1905584","description":"\"Any apoptotic process in an outer hair cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:12062759, PMID:24472721]","metadata":null},{"id":"04f5cd40cbd9477098af8d2a15cc1d8e","type":"GO_TERM","name":"outer kinetochore","canonical_id":"go:GO:0000940","description":"\"The region of a kinetochore most external to centromeric DNA; this outer region mediates kinetochore-microtubule interactions.\" [GOC:clt, PMID:11483983]","metadata":null},{"id":"8386817964834988af009facc5d00e05","type":"GO_TERM","name":"outer medullary collecting duct development","canonical_id":"go:GO:0072060","description":"\"The process whose specific outcome is the progression of the outer medullary collecting duct over time, from its formation to the mature structure. The outer medullary collecting duct is the portion of the collecting duct that lies in the renal outer medulla.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a7c442518eea4c83aa5a25a044dd26b4","type":"GO_TERM","name":"outer membrane","canonical_id":"go:GO:0019867","description":"\"The external membrane of Gram-negative bacteria or certain organelles such as mitochondria and chloroplasts; freely permeable to most ions and metabolites.\" [GOC:curators]","metadata":null},{"id":"0c41549ea19343acaaaf17a7deb63298","type":"GO_TERM","name":"outer membrane protein complex","canonical_id":"go:GO:0106234","description":"\"Any protein complex that is part of the bacterial outer membrane. An example In E.coli, is RcsF associated with any one of several outer membrane beta-barrel proteins (OMPs), such as OmpA, OmpF, or OmpcC.\" [GOC:am, PMID:25267629, PMID:27282389]","metadata":null},{"id":"19722d1767924758ac0476806f88f1f0","type":"GO_TERM","name":"outer membrane-bounded periplasmic space","canonical_id":"go:GO:0030288","description":"\"The region between the inner (cytoplasmic or plasma) membrane and outer membrane of organisms with two membranes such as Gram negative bacteria. These periplasmic spaces are relatively thick and contain a thin peptidoglycan layer (PGL), also referred to as a thin cell wall.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"a23e372bf4da4d34a2202ec654c298e6","type":"GO_TERM","name":"outer mitochondrial membrane organization","canonical_id":"go:GO:0007008","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the mitochondrial outer membrane.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"117ac73387d24367a04ec103bfdb7668","type":"GO_TERM","name":"outer mitochondrial membrane protein complex","canonical_id":"go:GO:0098799","description":"\"Any protein complex that is part of the outer mitochondrial membrane.\" [GOC:dos]","metadata":null},{"id":"64c4d1a72c6e4082b8317909bd139b65","type":"GO_TERM","name":"outer mucus layer","canonical_id":"go:GO:0070703","description":"\"The outer of two mucus layers secreted by epithelial cells in the colon; the outer mucus layer is loosely packed and can be colonized by bacteria.\" [GOC:mah, GOC:mm2, PMID:18806221, PMID:19432394]","metadata":null},{"id":"373a72982880483e8069c91ffe3323fc","type":"GO_TERM","name":"outer plaque of mitotic spindle pole body","canonical_id":"go:GO:0061499","description":"\"One of three laminate structures that form the mitotic spindle pole body; the outer plaque is in the cytoplasm.\" [GOC:dph]","metadata":null},{"id":"2cedce00a6d24bfd9330898d2ba31687","type":"GO_TERM","name":"outer plaque of spindle pole body","canonical_id":"go:GO:0005824","description":"\"One of three laminate structures that form the spindle pole body; the outer plaque is in the cytoplasm.\" [ISBN:0879693568]","metadata":null},{"id":"9dce2bea72274519af799a3cda305422","type":"GO_TERM","name":"outer stripe development","canonical_id":"go:GO:0072058","description":"\"The process whose specific outcome is the progression of the outer stripe over time, from its formation to the mature structure. The outer stripe is the region of the kidney outer medulla that lies just below the cortex. The proximal straight tubules (S3) characterize this region.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"473e5d17601d40ba835d82209a8cced5","type":"GO_TERM","name":"outflow tract morphogenesis","canonical_id":"go:GO:0003151","description":"\"The process in which the anatomical structures of the outflow tract are generated and organized. The outflow tract is the portion of the heart through which blood flows into the arteries.\" [GOC:mtg_heart, UBERON:0004145]","metadata":null},{"id":"de9b535dd32d4ff69717350d1f3c1568","type":"GO_TERM","name":"outflow tract septum morphogenesis","canonical_id":"go:GO:0003148","description":"\"The process in which the anatomical structures of the outflow tract septum are generated and organized. The outflow tract septum is a partition in the outflow tract.\" [GOC:mtg_heart]","metadata":null},{"id":"31f20abc976e492c9047b948d4e44723","type":"GO_TERM","name":"outward migration of deep nuclear neurons","canonical_id":"go:GO:0021947","description":"\"The directed movement of a deep nuclear neuron from their ventrolateral origin to a rostrodorsal region of the cerebellar plate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"f918420324264c6e91d402e798ed9eeb","type":"GO_TERM","name":"outward rectifier potassium channel activity","canonical_id":"go:GO:0015271","description":"\"Enables the transmembrane transfer of a potassium ion by an outwardly-rectifying voltage-gated channel. An outwardly rectifying current-voltage relation is one where at any given driving force the outward flow of K+ ions exceeds the inward flow for the opposite driving force.\" [GOC:mah]","metadata":null},{"id":"f65f86e2100f4b97ad2752efb5b0f9cc","type":"GO_TERM","name":"outward rectifier potassium channel inhibitor activity","canonical_id":"go:GO:0140628","description":"\"Binds to and stops, prevents, or reduces the activity of an outwardly rectifying potassium channel.\" [PMID:28108814]","metadata":null},{"id":"cd789aba93b74f23ba1ff9552f0946de","type":"DISEASE","name":"ovarian cancer","canonical_id":"mondo:0008170","description":null,"metadata":null},{"id":"07994353ae2447ab8e3221ef2d2de975","type":"DISEASE","name":"ovarian carcinoma","canonical_id":"mondo:0005140","description":null,"metadata":null},{"id":"ba80afc303fd4a648033d52baa9b1934","type":"GO_TERM","name":"ovarian cumulus expansion","canonical_id":"go:GO:0001550","description":"\"Increase in size of the cumulus surrounding the oocyte including change in morphology due to proliferation and dispersion of cumulus cells.\" [PMID:30010832]","metadata":null},{"id":"3955d89cbe754cefb6144fbecc02e2da","type":"GO_TERM","name":"ovarian follicle atresia","canonical_id":"go:GO:0001552","description":"\"A periodic process in which immature ovarian follicles degenerate and are subsequently re-absorbed.\" [GOC:mtg_apoptosis, PMID:18638134]","metadata":null},{"id":"4cb82e2a4cad4c0b9120598e171f597b","type":"GO_TERM","name":"ovarian follicle development","canonical_id":"go:GO:0001541","description":"\"The process whose specific outcome is the progression of the ovarian follicle over time, from its formation to the mature structure.\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"cb835fb8fb8e47b59c9a9675400c0144","type":"GO_TERM","name":"ovarian follicle endowment","canonical_id":"go:GO:0001551","description":"\"Association of oocytes with supporting epithelial granulosa cells to form primordial follicles.\" [PMID:30010832]","metadata":null},{"id":"0f4731ea708e4cb3a527794037db5d71","type":"GO_TERM","name":"ovarian follicle rupture","canonical_id":"go:GO:0001543","description":"\"Disruption of theca cell layer releasing follicular fluid and/or the oocyte.\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"a86d9c66e74f4f3c9667c58ae4117251","type":"GO_TERM","name":"ovarian fusome organization","canonical_id":"go:GO:0030723","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the fusome of ovarian cells, an organelle derived from the spectrosome. It anchors the mitotic spindle pole to provide orientation during cystoblast cell divisions.\" [GOC:dph, GOC:jl, GOC:mah, ISBN:0879694238]","metadata":null},{"id":"be04d56a83544649923316026f8c089a","type":"DISEASE","name":"ovarian hyperstimulation syndrome","canonical_id":"mondo:0011972","description":null,"metadata":null},{"id":"73d1eb507b2346879b2a65353bdd8384","type":"DISEASE","name":"ovarian neoplasm","canonical_id":"mondo:0021068","description":null,"metadata":null},{"id":"9e4daaf78ca040e7998352a8c3cb92cd","type":"GO_TERM","name":"ovarian nurse cell to oocyte transport","canonical_id":"go:GO:0007300","description":"\"Transfer of constituents synthesized in the ovarian nurse cells to the oocyte, through the ring canals, as the egg chamber is growing. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"bb970679f02d4314ae6d8e469306ee42","type":"GO_TERM","name":"ovary septum development","canonical_id":"go:GO:0080126","description":"\"The process whose specific outcome is the progression of the ovary septum over time, from its formation to the mature structure. The ovary septum is the thin partition that divides the ovary, the basal portion of a carpel or group of fused carpels, that encloses the ovule(s).\" [PMID:17855426]","metadata":null},{"id":"3f19c9d31d5c4cce856b36d3cb161d44","type":"DISEASE","name":"overactive bladder","canonical_id":"mondo:0006624","description":null,"metadata":null},{"id":"623b20950a0c4581b3bd9f517d48bfbe","type":"DISEASE","name":"overdose","canonical_id":"efo:0020911","description":null,"metadata":null},{"id":"e3d141644f7f48de9229abe9f9de695b","type":"DISEASE","name":"overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes","canonical_id":"mondo:0100283","description":null,"metadata":null},{"id":"94527fe8d04a41c29bd607ea037cdf4e","type":"GO_TERM","name":"oviduct development","canonical_id":"go:GO:0060066","description":"\"The reproductive developmental process whose specific outcome is the progression of an oviduct over time, from its formation to the mature structure. An oviduct is a tube through which an ova passes from the ovary to the uterus, or from the ovary to the outside of the organism.\" [GOC:dph, GOC:ebc, PMID:22918811, PMID:27875265]","metadata":null},{"id":"7d48e27a6f484fa8b18a5a974f556d2b","type":"GO_TERM","name":"oviduct epithelium development","canonical_id":"go:GO:0035846","description":"\"The progression of the oviduct epithelium over time from its initial formation to the mature structure. An oviduct is a tube through which an ova passes from the ovary to the uterus, or from the ovary to the outside of the organism. The oviduct epithelium is the specialized epithelium that lines the oviduct.\" [GOC:yaf, PMID:34496237]","metadata":null},{"id":"3bb8cb0bb89c41a3a08b573673c2e423","type":"GO_TERM","name":"oviduct morphogenesis","canonical_id":"go:GO:0035848","description":"\"The process in which anatomical structures of the oviduct are generated and organized. An oviduct is a tube through which an ova passes from the ovary to the uterus, or from the ovary to the outside of the organism.\" [GOC:yaf, PMID:22918811]","metadata":null},{"id":"53bd512fb18a4ab4bcf9444799a6fb82","type":"GO_TERM","name":"ovulation","canonical_id":"go:GO:0030728","description":"\"The release of a mature ovum/oocyte from an ovary.\" [GOC:bf, ISBN:0878932437]","metadata":null},{"id":"90f358905c644c90b188ab26d57ee0ca","type":"DISEASE","name":"ovulation","canonical_id":"go:0030728","description":null,"metadata":null},{"id":"6c7eec2914b84afe9f5ecea8b699c1b4","type":"GO_TERM","name":"ovulation cycle","canonical_id":"go:GO:0042698","description":"\"The type of sexual cycle seen in females, often with physiologic changes in the endometrium that recur at regular intervals during the reproductive years.\" [ISBN:0721662544]","metadata":null},{"id":"6bdcc62ac8854486a716b21469b0f7f3","type":"GO_TERM","name":"ovulation cycle process","canonical_id":"go:GO:0022602","description":"\"A process involved in the sexual cycle seen in females, often with physiologic changes in the endometrium that recur at regular intervals during the reproductive years.\" [GOC:isa_complete]","metadata":null},{"id":"6197e82130b24424979f8784051083aa","type":"GO_TERM","name":"ovulation from ovarian follicle","canonical_id":"go:GO:0001542","description":"\"The process leading to the rupture of the follicle, releasing the centrally located oocyte into the oviduct. An example of this is found in Mus musculus.\" [GOC:mtg_sensu, https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"0e2cf334ea134522b9cc5cf12204ec49","type":"GO_TERM","name":"oxalate biosynthetic process","canonical_id":"go:GO:0033610","description":"\"The chemical reactions and pathways resulting in the formation of oxalate, the organic acid ethanedioate.\" [GOC:mlg]","metadata":null},{"id":"08bb9ab806c2461c8a642db8602b3570","type":"GO_TERM","name":"oxalate catabolic process","canonical_id":"go:GO:0033611","description":"\"The chemical reactions and pathways resulting in the breakdown of oxalate, the organic acid ethanedioate.\" [GOC:mlg]","metadata":null},{"id":"eb509cdb58874a59bbbbbe14dae26a18","type":"GO_TERM","name":"oxalate decarboxylase activity","canonical_id":"go:GO:0046564","description":"\"Catalysis of the reaction: H+ + oxalate = CO2 + formate.\" [EC:4.1.1.2, RHEA:16509]","metadata":null},{"id":"a4df8bec02c642ea9f38b6dd013c1cda","type":"GO_TERM","name":"oxalate metabolic process","canonical_id":"go:GO:0033609","description":"\"The chemical reactions and pathways involving oxalate, the organic acid ethanedioate.\" [GOC:mlg]","metadata":null},{"id":"0f55939bc057406faa363218e63c235f","type":"GO_TERM","name":"oxalate oxidase activity","canonical_id":"go:GO:0050162","description":"\"Catalysis of the reaction: 2 H+ + O2 + oxalate = 2 CO2 + H2O2.\" [RHEA:21880]","metadata":null},{"id":"687f8b10616b4c5090af4d2ab9eb02eb","type":"GO_TERM","name":"oxalate transmembrane transporter activity","canonical_id":"go:GO:0019531","description":"\"Enables the transfer of oxalate from one side of a membrane to the other. Oxalate, or ethanedioic acid, occurs in many plants and is highly toxic to animals.\" [ISBN:0198506732]","metadata":null},{"id":"b6f446f27daa4bc3993d743ed94fbdeb","type":"GO_TERM","name":"oxalate transport","canonical_id":"go:GO:0019532","description":"\"The directed movement of oxalate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Oxalate, or ethanedioic acid, occurs in many plants and is highly toxic to animals.\" [ISBN:0198506732]","metadata":null},{"id":"9e79006224274bc49f4c47d344abbeae","type":"GO_TERM","name":"oxalate-CoA ligase activity","canonical_id":"go:GO:0050203","description":"\"Catalysis of the reaction: ATP + CoA + oxalate = AMP + diphosphate + H+ + oxalyl-CoA.\" [RHEA:18293]","metadata":null},{"id":"0544807369c7460dba6af50cce3c6723","type":"GO_TERM","name":"oxalate:chloride antiporter activity","canonical_id":"go:GO:0160046","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: chloride(out) + oxalate(in) = chloride(in) + oxalate(out).\" [PMID:17442754]","metadata":null},{"id":"4e453b92615048b38c6a07668be5ace3","type":"GO_TERM","name":"oxalic acid secretion","canonical_id":"go:GO:0046724","description":"\"The controlled release of oxalic acid, ethanedioic acid, by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"5c192e56aedd4354a7f6d1e44045cf6d","type":"GO_TERM","name":"oxaloacetase activity","canonical_id":"go:GO:0030603","description":"\"Catalysis of the reaction: H2O + oxaloacetate = acetate + H+ + oxalate.\" [EC:3.7.1.1, RHEA:24432]","metadata":null},{"id":"9b32e21781004c69967bd0739145309f","type":"GO_TERM","name":"oxaloacetate decarboxylase activity","canonical_id":"go:GO:0008948","description":"\"Catalysis of the reaction: H+ + oxaloacetate = CO2 + pyruvate.\" [RHEA:15641]","metadata":null},{"id":"878dc57e035f4a0ba9f5decbf8490236","type":"GO_TERM","name":"oxaloacetate metabolic process","canonical_id":"go:GO:0006107","description":"\"The chemical reactions and pathways involving oxaloacetate, the anion of oxobutanedioic acid, an important intermediate in metabolism, especially as a component of the TCA cycle.\" [ISBN:0198506732]","metadata":null},{"id":"6e38f6db2ea74a5990e3b0694fb9d687","type":"GO_TERM","name":"oxaloacetate tautomerase activity","canonical_id":"go:GO:0050163","description":"\"Catalysis of the reaction: oxaloacetate = <stereo>enol</stereo>-oxaloacetate.\" [EC:5.3.2.2, RHEA:16021]","metadata":null},{"id":"d3e77d52e0bc46f48981e55e100818a3","type":"GO_TERM","name":"oxaloacetate transmembrane transporter activity","canonical_id":"go:GO:0015131","description":"\"Enables the transfer of oxaloacetate, the anion of oxobutanedioic acid, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"fcf030ea650448ebab353dbd3c72cf74","type":"GO_TERM","name":"oxaloacetate transport","canonical_id":"go:GO:0015729","description":"\"The directed movement of oxaloacetate, the anion of oxobutanedioic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"2e841e10d75e4ab7951fabe86087cd4a","type":"GO_TERM","name":"oxaloacetate(2-) transmembrane transport","canonical_id":"go:GO:1902356","description":"\"The directed movement of oxaloacetate(2-) across a membrane.\" [GOC:dph, GOC:TermGenie, PMID:18682385]","metadata":null},{"id":"e361e0edfd5646ac885c61e5c766f2a7","type":"GO_TERM","name":"oxaloglycolate reductase (decarboxylating) activity","canonical_id":"go:GO:0047047","description":"\"Catalysis of the reaction: glycerate + CO2 + NAD(P)+ = NAD(P)H + H+ + 2-hydroxy-3-oxosuccinate.\" [EC:1.1.1.92, MetaCyc:1.1.1.92-RXN]","metadata":null},{"id":"4a4cddb1092d44c8aa56c67dd4eca489","type":"GO_TERM","name":"oxalomalate lyase activity","canonical_id":"go:GO:0050204","description":"\"Catalysis of the reaction: 3-oxalomalate = glyoxylate + oxaloacetate.\" [EC:4.1.3.13, RHEA:22032]","metadata":null},{"id":"8ce455504b7047b2b12ea1a1564b241e","type":"GO_TERM","name":"oxalyl-CoA decarboxylase activity","canonical_id":"go:GO:0008949","description":"\"Catalysis of the reaction: H+ + oxalyl-CoA = CO2 + formyl-CoA.\" [EC:4.1.1.8, RHEA:19333]","metadata":null},{"id":"2d1f4231058e4acca26731ba01adc1b3","type":"GO_TERM","name":"oxamate carbamoyltransferase activity","canonical_id":"go:GO:0050205","description":"\"Catalysis of the reaction: carbamoyl phosphate + oxamate = oxalurate + phosphate.\" [EC:2.1.3.5, RHEA:22984]","metadata":null},{"id":"13f77f9502384f2389e648bca47766ec","type":"DRUG","name":"oxamniquine","canonical_id":"mesh:D010073","description":null,"metadata":null},{"id":"57aa501cd2d148a28ba0c3de6f1b58e5","type":"GO_TERM","name":"oxanine DNA N-glycosylase activity","canonical_id":"go:GO:0097509","description":"\"DNA N-glycosylase activity acting on deaminated guanine where the resulting base (oxanine) is generated by NO- or HNO2-induced nitrosative deamination.\" [GOC:al, PMID:18789404]","metadata":null},{"id":"9a216948ed2b443798651e2af42c50d8","type":"DRUG","name":"oxaprozin","canonical_id":"gtopdb:7252","description":null,"metadata":null},{"id":"ec97e823900f41b7b0e6a636376bd447","type":"DRUG","name":"oxaprozin","canonical_id":"mesh:C008729","description":null,"metadata":null},{"id":"29617da0ddb1499aabc1a5494ce6b8e6","type":"DRUG","name":"oxaprozin","canonical_id":"chembl:CHEMBL1071","description":null,"metadata":null},{"id":"34b2e5189f1642e2a2e8bc584ed7d95f","type":"DRUG","name":"oxcarbazepine","canonical_id":"mesh:C036006","description":null,"metadata":null},{"id":"a6b25ffc117c4e138fc4519765a93917","type":"DRUG","name":"oxiconazole","canonical_id":"mesh:C022155","description":null,"metadata":null},{"id":"d2bebb4d922d40a0aa3bf3e30fb787f7","type":"GO_TERM","name":"oxidation-dependent protein catabolic process","canonical_id":"go:GO:0070407","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the oxidation of one or more amino acid residues in the protein.\" [GOC:mah]","metadata":null},{"id":"26a16efb3b6c4148b920cfacf9628000","type":"GO_TERM","name":"oxidative RNA demethylase activity","canonical_id":"go:GO:0035515","description":"\"Catalysis of the removal of a methyl group from one or more nucleosides within a RNA molecule involving the oxidation (i.e. electron loss) of one or more atoms.\" [PMID:12594517, PMID:16482161, PMID:18775698]","metadata":null},{"id":"50cbc501982743d0a958e8af88f1b2a0","type":"GO_TERM","name":"oxidative RNA demethylation","canonical_id":"go:GO:0035513","description":"\"The removal of the methyl group from one or more nucleotides within an RNA molecule involving oxidation (i.e. electron loss) of one or more atoms.\" [PMID:12594517, PMID:16482161, PMID:18775698]","metadata":null},{"id":"61858d19108248c0919b3e0d9d13b206","type":"GO_TERM","name":"oxidative demethylation","canonical_id":"go:GO:0070989","description":"\"The process of removing one or more methyl groups from a molecule, involving the oxidation (i.e. electron loss) of one or more atoms in the substrate.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"a2be0f784877497fae25d7d3c667fe39","type":"GO_TERM","name":"oxidative phosphorylation","canonical_id":"go:GO:0006119","description":"\"The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.\" [ISBN:0198506732, ISBN:0471331309]","metadata":null},{"id":"a3179dadbc36443e9f87da363ddb3822","type":"GO_TERM","name":"oxidative phosphorylation uncoupler activity","canonical_id":"go:GO:0017077","description":"\"Enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.\" [PMID:15738989, PMID:16179945]","metadata":null},{"id":"609f766935774cd684e5f12203d90a1b","type":"GO_TERM","name":"oxidative photosynthetic carbon pathway","canonical_id":"go:GO:0009854","description":"\"The reactions of the C2 pathway bring about the metabolic conversion of two molecules of 2-phosphoglycolate to one molecule of 3-phosphoglycerate, which can be used by the C3 cycle, and one molecule of carbon dioxide (CO2).\" [ISBN:0943088399]","metadata":null},{"id":"7f1977fa2bee49a68d78a7a32ff9e6b3","type":"GO_TERM","name":"oxidative stress-induced premature senescence","canonical_id":"go:GO:0090403","description":"\"A cellular senescence process associated with the dismantling of a cell as a response to oxidative stress, e.g. high levels of reactive oxygen species, such as superoxide anions, hydrogen peroxide, and hydroxyl radicals.\" [GOC:BHF]","metadata":null},{"id":"bbf358ceb007493b989ba50a4ce2b89e","type":"GO_TERM","name":"oxidised low-density lipoprotein particle clearance","canonical_id":"go:GO:0150024","description":"\"The process in which an oxidised low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:aruk, GOC:bc, PMID:27607416]","metadata":null},{"id":"e915612fe2df4533b797b15a94d1a2f4","type":"GO_TERM","name":"oxidised low-density lipoprotein particle receptor activity","canonical_id":"go:GO:0150025","description":"\"Combining with an oxidised low-density lipoprotein particle and delivering the oxidised low-density lipoprotein particle into the cell via endocytosis.\" [GOC:aruk, GOC:bc, PMID:27607416]","metadata":null},{"id":"a8718c80d08b498db210ad95cb5b66bc","type":"GO_TERM","name":"oxidized DNA binding","canonical_id":"go:GO:0032356","description":"\"Binding to a DNA region containing an oxidized residue.\" [GOC:vk]","metadata":null},{"id":"0d9f76fa536941129dd79357358b0ec3","type":"GO_TERM","name":"oxidized base lesion DNA N-glycosylase activity","canonical_id":"go:GO:0000702","description":"\"Catalysis of the removal of oxidized bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site.\" [GOC:elh, PMID:11554296]","metadata":null},{"id":"fd14604fff3941caac0d6844c84f6327","type":"GO_TERM","name":"oxidized purine DNA binding","canonical_id":"go:GO:0032357","description":"\"Binding to a DNA region containing an oxidized purine residue.\" [GOC:vk]","metadata":null},{"id":"718cd630ce33476dbf5b290e2cd32935","type":"GO_TERM","name":"oxidized purine nucleobase lesion DNA N-glycosylase activity","canonical_id":"go:GO:0008534","description":"\"Catalysis of the removal of oxidized purine bases by cleaving the N-C1' glycosidic bond between the oxidized purine and the deoxyribose sugar. The reaction involves the formation of a covalent enzyme-substrate intermediate. Release of the enzyme and free base by a beta-elimination or a beta, gamma-elimination mechanism results in the cleavage of the DNA backbone 3' of the apurinic (AP) site.\" [GOC:elh, PMID:11554296]","metadata":null},{"id":"408ed1b2e42e437199f794b9733c98e9","type":"GO_TERM","name":"oxidized pyrimidine DNA binding","canonical_id":"go:GO:0032358","description":"\"Binding to a DNA region containing an oxidized pyrimidine residue.\" [GOC:vk]","metadata":null},{"id":"49e0a350259649d2bf4c13de97424568","type":"GO_TERM","name":"oxidized pyrimidine nucleobase lesion DNA N-glycosylase activity","canonical_id":"go:GO:0000703","description":"\"Catalysis of the removal oxidized pyrimidine bases by cleaving the N-C1' glycosidic bond between the oxidized pyrimidine and the deoxyribose sugar. The reaction involves formation of a covalent enzyme-pyrimidine base intermediate. Release of the enzyme and free base by a beta-elimination or a beta, gamma-elimination mechanism results in the cleavage of the DNA backbone 3' of the apyrimidinic (AP) site.\" [GOC:elh, PMID:11554296]","metadata":null},{"id":"554f110790cb44818c453e740d2acc2d","type":"GO_TERM","name":"oxidoreductase activity","canonical_id":"go:GO:0016491","description":"\"Catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.\" [EC:1.-.-.-]","metadata":null},{"id":"601ae7ef89e847b7b0c87f14f0a877a2","type":"GO_TERM","name":"oxidoreductase activity, acting on CH or CH2 groups","canonical_id":"go:GO:0016725","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH2 group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"46ec2a6f9a1343d492c361cd5b2d52a8","type":"GO_TERM","name":"oxidoreductase activity, acting on CH or CH2 groups, NAD or NADP as acceptor","canonical_id":"go:GO:0016726","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH2 group acts as a hydrogen or electron donor and reduces NAD+ or NADP.\" [GOC:ai]","metadata":null},{"id":"98135c488b584462b8be4ac9baa76654","type":"GO_TERM","name":"oxidoreductase activity, acting on CH or CH2 groups, disulfide as acceptor","canonical_id":"go:GO:0016728","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH2 group acts as a hydrogen or electron donor and reduces a disulfide group.\" [GOC:ai]","metadata":null},{"id":"9d96e536bf09417db5f974634ee98505","type":"GO_TERM","name":"oxidoreductase activity, acting on CH or CH2 groups, oxygen as acceptor","canonical_id":"go:GO:0016727","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH2 group acts as a hydrogen or electron donor and reduces an oxygen molecule.\" [GOC:ai]","metadata":null},{"id":"a136dec0ba37469599a316db054fc534","type":"GO_TERM","name":"oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor","canonical_id":"go:GO:0033695","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH2 group acts as a hydrogen or electron donor and reduces a quinone or similar acceptor molecule.\" [EC:1.17.5.-, GOC:mah]","metadata":null},{"id":"0a5e9632057f4da1bedc86f33072bac7","type":"GO_TERM","name":"oxidoreductase activity, acting on CH or CH2 groups, with an iron-sulfur protein as acceptor","canonical_id":"go:GO:0052592","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH2 group acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [GOC:ai]","metadata":null},{"id":"5f6ff5c41c3746c99798b9b84605dc63","type":"GO_TERM","name":"oxidoreductase activity, acting on CH-OH group of donors","canonical_id":"go:GO:0016614","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-OH group act as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"97fd210acf904c1d9117f5e380c0799b","type":"GO_TERM","name":"oxidoreductase activity, acting on NAD(P)H","canonical_id":"go:GO:0016651","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which NADH or NADPH acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"831136b706ec49d7b016387bdb056200","type":"GO_TERM","name":"oxidoreductase activity, acting on NAD(P)H as acceptor","canonical_id":"go:GO:0016652","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which NADH or NADPH acts as a hydrogen or electron donor and reduces NAD+ or NADP.\" [EC:1.6.1.-]","metadata":null},{"id":"e25a1ad8e2b6439cb9d54d9a2bdcf204","type":"GO_TERM","name":"oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor","canonical_id":"go:GO:0016653","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which NADH or NADPH acts as a hydrogen or electron donor and reduces a heme protein.\" [GOC:ai]","metadata":null},{"id":"da11ff5280ee43cc98ae0f1f59f02bf7","type":"GO_TERM","name":"oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor","canonical_id":"go:GO:0050664","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which NADH or NADPH acts as a hydrogen or electron donor and reduces an oxygen molecule.\" [EC:1.6.3.-]","metadata":null},{"id":"eed6d9eb5cdd4ccdb0d80997c7372e65","type":"GO_TERM","name":"oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor","canonical_id":"go:GO:0016655","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which NADH or NADPH acts as a hydrogen or electron donor and reduces a quinone or a similar acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"deb890fe811c49f8959e48bf4c98bca2","type":"GO_TERM","name":"oxidoreductase activity, acting on X-H and Y-H to form an X-Y bond","canonical_id":"go:GO:0046992","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which X-H and Y-H form X-Y.\" [GOC:ai]","metadata":null},{"id":"a8bffa8111964bc0883fc1fbcaa1086e","type":"GO_TERM","name":"oxidoreductase activity, acting on X-H and Y-H to form an X-Y bond, with a disulfide as acceptor","canonical_id":"go:GO:0050485","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which X-H and Y-H form X-Y and the acceptor is disulfide.\" [EC:1.21.4.-]","metadata":null},{"id":"47ec831c005b4732bc438badd09db897","type":"GO_TERM","name":"oxidoreductase activity, acting on X-H and Y-H to form an X-Y bond, with oxygen as acceptor","canonical_id":"go:GO:0046993","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which X-H and Y-H form X-Y and the acceptor is oxygen.\" [GOC:ai]","metadata":null},{"id":"4427240e1a544315948b8abb2bc8f8cc","type":"GO_TERM","name":"oxidoreductase activity, acting on a heme group of donors","canonical_id":"go:GO:0016675","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a heme group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"07e8cf4213bc4bc6ba7ce147b63a66b0","type":"GO_TERM","name":"oxidoreductase activity, acting on a heme group of donors, nitrogenous group as acceptor","canonical_id":"go:GO:0016677","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a heme group acts as a hydrogen or electron donor and reduces a nitrogenous group.\" [GOC:jl]","metadata":null},{"id":"251859634f4946f3b041e7ce4e309be4","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors","canonical_id":"go:GO:0016667","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [EC:1.8.-.-, GOC:ai]","metadata":null},{"id":"5db9645d40bb41d39fee874ab8095a64","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor","canonical_id":"go:GO:0016668","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces NAD or NADP.\" [GOC:jl]","metadata":null},{"id":"3a245240ed28454aadbaa04ad0f28ac0","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors, cytochrome as acceptor","canonical_id":"go:GO:0016669","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces a cytochrome.\" [GOC:jl]","metadata":null},{"id":"ba06c6c001c54d389ec3017790817ff8","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor","canonical_id":"go:GO:0016671","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces disulfide.\" [GOC:jl]","metadata":null},{"id":"dc52456463d24d7abce0147a9e0f459b","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors, iron-sulfur protein as acceptor","canonical_id":"go:GO:0016673","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [GOC:jl]","metadata":null},{"id":"431b7b2bd6c34de199f848d45119568b","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors, oxygen as acceptor","canonical_id":"go:GO:0016670","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces oxygen.\" [GOC:jl]","metadata":null},{"id":"3c8f5d4a5c7040779f1bf1e3441b1f44","type":"GO_TERM","name":"oxidoreductase activity, acting on a sulfur group of donors, quinone or similar compound as acceptor","canonical_id":"go:GO:0016672","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a sulfur-containing group acts as a hydrogen or electron donor and reduces quinone or a related compound.\" [GOC:jl]","metadata":null},{"id":"1362a7450014489ca7892f6a88aef81c","type":"GO_TERM","name":"oxidoreductase activity, acting on diphenols and related substances as donors","canonical_id":"go:GO:0016679","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a diphenol or related substance acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"11e20e6b58b549629a95086c6a5268dc","type":"GO_TERM","name":"oxidoreductase activity, acting on diphenols and related substances as donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016680","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a diphenol, or related compound, acts as a hydrogen or electron donor and reduces NAD or NADP.\" [GOC:jl]","metadata":null},{"id":"28c0870ddb344df3ba6c1134cd8b14ae","type":"GO_TERM","name":"oxidoreductase activity, acting on diphenols and related substances as donors, oxygen as acceptor","canonical_id":"go:GO:0016682","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a diphenol, or related compound, acts as a hydrogen or electron donor and reduces oxygen.\" [GOC:jl]","metadata":null},{"id":"3595a18890c64483a17004a6d6b05e78","type":"GO_TERM","name":"oxidoreductase activity, acting on diphenols and related substances as donors, with copper protein as acceptor","canonical_id":"go:GO:0052880","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a diphenol, or related compound, acts as a hydrogen or electron donor and reduces a copper protein.\" [GOC:jl]","metadata":null},{"id":"80e629e7870642e091ccd3187ce48cf4","type":"GO_TERM","name":"oxidoreductase activity, acting on hydrogen as donor","canonical_id":"go:GO:0016695","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen acts as an electron donor.\" [GOC:jl]","metadata":null},{"id":"8fa560a17cf54316be85c34031f3335f","type":"GO_TERM","name":"oxidoreductase activity, acting on hydrogen as donor, NAD or NADP as acceptor","canonical_id":"go:GO:0016696","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen acts as an electron donor and reduces NAD or NADP.\" [GOC:jl]","metadata":null},{"id":"cb868774f7be41359a108e1c7d00e5ac","type":"GO_TERM","name":"oxidoreductase activity, acting on hydrogen as donor, cytochrome as acceptor","canonical_id":"go:GO:0016697","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen acts as an electron donor and reduces a cytochrome.\" [GOC:jl]","metadata":null},{"id":"36061b60d6b54d6da11ade2ac4642df3","type":"GO_TERM","name":"oxidoreductase activity, acting on hydrogen as donor, iron-sulfur protein as acceptor","canonical_id":"go:GO:0016699","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen acts as an electron donor and reduces an iron-sulfur protein.\" [GOC:jl]","metadata":null},{"id":"ee3a407730124df481d87e0e1c8de283","type":"GO_TERM","name":"oxidoreductase activity, acting on hydrogen as donor, with a quinone or similar compound as acceptor","canonical_id":"go:GO:0046994","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen acts as an electron donor and reduces quinone or similar compound.\" [GOC:jl]","metadata":null},{"id":"593db8b0252c411691edcbefa9cc469f","type":"GO_TERM","name":"oxidoreductase activity, acting on hydrogen as donor, with other known acceptors","canonical_id":"go:GO:0046995","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen reduces a known acceptor other than a cytochrome, an iron-sulfur protein, NAD, NADP, or a quinone or similar compound.\" [GOC:ai]","metadata":null},{"id":"201b51e40bb34adfa93790b650c488c1","type":"GO_TERM","name":"oxidoreductase activity, acting on iron-sulfur proteins as donors","canonical_id":"go:GO:0016730","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an iron-sulfur protein acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"55df465f53bb47149cabc322d9d547c3","type":"GO_TERM","name":"oxidoreductase activity, acting on iron-sulfur proteins as donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016731","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an iron-sulfur protein acts as a hydrogen or electron donor and reduces NAD or NADP.\" [GOC:jl]","metadata":null},{"id":"b1ac7501d9e746779843f2fcb46a1fe1","type":"GO_TERM","name":"oxidoreductase activity, acting on iron-sulfur proteins as donors, dinitrogen as acceptor","canonical_id":"go:GO:0016732","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an iron-sulfur protein acts as a hydrogen or electron donor and reduces dinitrogen.\" [GOC:jl]","metadata":null},{"id":"4f44d799f06646de924032a81b9be287","type":"GO_TERM","name":"oxidoreductase activity, acting on metal ions","canonical_id":"go:GO:0016722","description":"\"Catalysis of an oxidation-reduction in which the oxidation state of metal ion is altered.\" [GOC:mah]","metadata":null},{"id":"e684e1e0801b4382b9b1bef81f9c137e","type":"GO_TERM","name":"oxidoreductase activity, acting on metal ions, NAD or NADP as acceptor","canonical_id":"go:GO:0016723","description":"\"Catalysis of an oxidation-reduction in which the metal ion is reduced and NAD+ or NADP+ acts as an electron acceptor.\" [GOC:mah]","metadata":null},{"id":"027d9d4d092c44209407a4a059cee468","type":"GO_TERM","name":"oxidoreductase activity, acting on metal ions, oxygen as acceptor","canonical_id":"go:GO:0016724","description":"\"Catalysis of an oxidation-reduction in which the oxidation state of metal ion is altered and oxygen acts as an electron acceptor.\" [GOC:mah]","metadata":null},{"id":"ab1e7fa92f054300b6c2fd25c0ae7693","type":"GO_TERM","name":"oxidoreductase activity, acting on other nitrogenous compounds as donors","canonical_id":"go:GO:0016661","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a nitrogenous group, excluding NH and NH2 groups, acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [EC:1.7.-.-]","metadata":null},{"id":"bc541a48d8a445888e248ba55e604801","type":"GO_TERM","name":"oxidoreductase activity, acting on other nitrogenous compounds as donors, cytochrome as acceptor","canonical_id":"go:GO:0016662","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a nitrogenous group, excluding NH and NH2 groups, acts as a hydrogen or electron donor and reduces a cytochrome.\" [EC:1.7.2.-]","metadata":null},{"id":"9449f23bc20648269051b7956312a367","type":"GO_TERM","name":"oxidoreductase activity, acting on other nitrogenous compounds as donors, iron-sulfur protein as acceptor","canonical_id":"go:GO:0016664","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a nitrogenous group, excluding NH and NH2 groups, acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [EC:1.7.7.-]","metadata":null},{"id":"536c231fb0e34854b182e7e3337b3dd0","type":"GO_TERM","name":"oxidoreductase activity, acting on other nitrogenous compounds as donors, oxygen as acceptor","canonical_id":"go:GO:0016663","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a nitrogenous group, excluding NH and NH2 groups, acts as a hydrogen or electron donor and reduces oxygen.\" [EC:1.7.3.-, GOC:jl]","metadata":null},{"id":"db7a1f930ff244dbbf063f0cc4ba0bb3","type":"GO_TERM","name":"oxidoreductase activity, acting on other nitrogenous compounds as donors, with NAD or NADP as acceptor","canonical_id":"go:GO:0046857","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a nitrogenous group, excluding NH and NH2 groups, acts as a hydrogen or electron donor and reduces NAD or NADP.\" [EC:1.7.1.-, GOC:jl]","metadata":null},{"id":"d603111258364d6e95cf78114ff4d4d7","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen","canonical_id":"go:GO:0016705","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from each of two donors, and molecular oxygen is reduced or incorporated into a donor.\" [EC:1.14.-.-]","metadata":null},{"id":"69e2c4db7a39475eaae2a78fa9839425","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen","canonical_id":"go:GO:0016709","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from NADH or NADPH and one other donor, and one atom of oxygen is incorporated into one donor.\" [EC:1.14.13.-]","metadata":null},{"id":"16578ade55fb40ea9e70bd3cf8e54a42","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of two atoms of oxygen into one donor","canonical_id":"go:GO:0016708","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from NADH or NADPH and one other donor, and two atoms of oxygen are incorporated into one donor.\" [EC:1.14.12.-]","metadata":null},{"id":"5fee56af469842448cd8640535ee89fb","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, another compound as one donor, and incorporation of one atom of oxygen","canonical_id":"go:GO:0016716","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from each of two donors, and one atom of oxygen is incorporated into one donor.\" [EC:1.14.18.-]","metadata":null},{"id":"9fd01b37b65c4177b0e68531327cede3","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced ascorbate as one donor, and incorporation of one atom of oxygen","canonical_id":"go:GO:0016715","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced ascorbate and one other donor, and one atom of oxygen is incorporated into one donor.\" [EC:1.14.17.-]","metadata":null},{"id":"f58774deb83e4b5dbf1bb141ad8bacaf","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen","canonical_id":"go:GO:0016712","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced flavin or flavoprotein and one other donor, and one atom of oxygen is incorporated into one donor.\" [EC:1.14.14.-]","metadata":null},{"id":"4b0a8af962484020a19f54de9c10888c","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen","canonical_id":"go:GO:0016713","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced iron-sulfur protein and one other donor, and one atom of oxygen is incorporated into one donor.\" [EC:1.14.15.-]","metadata":null},{"id":"24b9c5b961104c6cbd9a4b9a6bf0d827","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen","canonical_id":"go:GO:0016714","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced pteridine and one other donor, and one atom of oxygen is incorporated into one donor.\" [EC:1.14.16.-]","metadata":null},{"id":"a5f36fa0daca410dbada90b50d977f21","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, with 2-oxoglutarate as one donor, and the other dehydrogenated","canonical_id":"go:GO:0050498","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from 2-oxoglutarate and one other donor, and the latter donor is dehydrogenated.\" [EC:1.14.20.-]","metadata":null},{"id":"02840dfaa8d142ec827102070e478a53","type":"GO_TERM","name":"oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water","canonical_id":"go:GO:0016717","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from each of two donors, and molecular oxygen is reduced to two molecules of water.\" [EC:1.14.19.-]","metadata":null},{"id":"0d9b7ad04e164fa68aeb9134412fb845","type":"GO_TERM","name":"oxidoreductase activity, acting on peroxide as acceptor","canonical_id":"go:GO:0016684","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which the peroxide group acts as a hydrogen or electron acceptor.\" [EC:1.11.-.-]","metadata":null},{"id":"bf03492d89d14161976310ad7cf4364d","type":"GO_TERM","name":"oxidoreductase activity, acting on phosphorus or arsenic in donors","canonical_id":"go:GO:0030613","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a phosphorus- or arsenic-containing group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [EC:1.20.-.-]","metadata":null},{"id":"3e884693ef3743a9b23f5795f65b0e47","type":"GO_TERM","name":"oxidoreductase activity, acting on phosphorus or arsenic in donors, disulfide as acceptor","canonical_id":"go:GO:0030614","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a phosphorus- or arsenic-containing group acts as a hydrogen or electron donor and reduces a disulfide.\" [GOC:mah]","metadata":null},{"id":"6c8e5c6d6b0d4a4694fcbbeff6030ab2","type":"GO_TERM","name":"oxidoreductase activity, acting on phosphorus or arsenic in donors, with NAD(P)+ as acceptor","canonical_id":"go:GO:0050499","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a phosphorus- or arsenic-containing group acts as a hydrogen or electron donor and reduces a NAD(P)+ to NAD(P)H.\" [GOC:mah]","metadata":null},{"id":"8fb34ad4dea4423a85e181296a4fb828","type":"GO_TERM","name":"oxidoreductase activity, acting on phosphorus or arsenic in donors, with a copper protein as acceptor","canonical_id":"go:GO:0052882","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a phosphorus- or arsenic-containing group acts as a hydrogen or electron donor and reduces a copper protein.\" [GOC:jl]","metadata":null},{"id":"c3c80824cf1346d795c4fe2f301e8664","type":"GO_TERM","name":"oxidoreductase activity, acting on reduced flavodoxin as donor","canonical_id":"go:GO:0016737","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which reduced flavodoxin acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [EC:1.19.-.-]","metadata":null},{"id":"f9e7ac61daf04277bfc4e35edf56e69a","type":"GO_TERM","name":"oxidoreductase activity, acting on reduced flavodoxin as donor, dinitrogen as acceptor","canonical_id":"go:GO:0016738","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which reduced flavodoxin acts as a hydrogen or electron donor and reduces dinitrogen.\" [GOC:jl]","metadata":null},{"id":"b88473d1099b4b7ba5a2c20457cbe8a4","type":"GO_TERM","name":"oxidoreductase activity, acting on single donors with incorporation of molecular oxygen","canonical_id":"go:GO:0016701","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from one donor, and molecular oxygen is incorporated into a donor.\" [EC:1.13.-.-]","metadata":null},{"id":"cced22d61b0742a1823713c47e0f6830","type":"GO_TERM","name":"oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)","canonical_id":"go:GO:0016703","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from one donor, and one oxygen atom is incorporated into a donor.\" [EC:1.13.12.-, GOC:mah]","metadata":null},{"id":"fa00bc1c77e8469eb649c5cfb8a71c64","type":"GO_TERM","name":"oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen","canonical_id":"go:GO:0016702","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from one donor, and two oxygen atoms is incorporated into a donor.\" [GOC:mah]","metadata":null},{"id":"d63b8495d93e434788a6a5e60bbb3fd4","type":"GO_TERM","name":"oxidoreductase activity, acting on superoxide radicals as acceptor","canonical_id":"go:GO:0016721","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a superoxide radical (O2- or O2.-) acts as a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"6420e5b8e2de4068920d82ef53a67c3e","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors","canonical_id":"go:GO:0016627","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [EC:1.3.-.-]","metadata":null},{"id":"5b625a75a1934552b726cb0c26fc8dec","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016628","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces NAD or NADP.\" [EC:1.3.1.-]","metadata":null},{"id":"c96c43b855fd40988c7f85bd3eaf682c","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors, cytochrome as acceptor","canonical_id":"go:GO:0016632","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces a cytochrome.\" [EC:1.3.2.-]","metadata":null},{"id":"d70c2e3c4c164cf49fc962f30d006e5e","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors, iron-sulfur protein as acceptor","canonical_id":"go:GO:0016636","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [EC:1.3.7.-]","metadata":null},{"id":"d65ddb66ba004242acc0ae7649b40825","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors, oxygen as acceptor","canonical_id":"go:GO:0016634","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces oxygen.\" [EC:1.3.3.-]","metadata":null},{"id":"4ef119d9a91d46caa197e328acea151c","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors, quinone or related compound as acceptor","canonical_id":"go:GO:0016635","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces a quinone or related compound.\" [EC:1.3.5.-]","metadata":null},{"id":"fbc9ef6708514d0a80e4281b10c265e2","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor","canonical_id":"go:GO:0052890","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces a flavin.\" [EC:1.3.8.-]","metadata":null},{"id":"d530000f9e9f430ca9cd447f141083dc","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors","canonical_id":"go:GO:0016645","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"e657209a4e6a413189b0ff3df7dd51df","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016646","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces NAD or NADP.\" [GOC:jl]","metadata":null},{"id":"4122d0548ded44579becce43bd540f8d","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors, disulfide as acceptor","canonical_id":"go:GO:0016648","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces disulfide.\" [GOC:jl]","metadata":null},{"id":"760f90811aa1456891e5c8d971713000","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors, flavin as acceptor","canonical_id":"go:GO:0046997","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces a flavin.\" [GOC:jl]","metadata":null},{"id":"04ab8ca719d44b8a883582b3ef863989","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors, iron-sulfur protein as acceptor","canonical_id":"go:GO:0033694","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [GOC:jl]","metadata":null},{"id":"e30042a3a197499b8a5aa8332b4a613f","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors, oxygen as acceptor","canonical_id":"go:GO:0016647","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces oxygen.\" [GOC:jl]","metadata":null},{"id":"e5ead5ddec7045b3bd81291b3ac00d97","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH group of donors, quinone or similar compound as acceptor","canonical_id":"go:GO:0016649","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH group acts as a hydrogen or electron donor and reduces quinone or similar compound.\" [GOC:jl]","metadata":null},{"id":"ffe44e85547e47e9bbca5e18a27c51f2","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors","canonical_id":"go:GO:0016638","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [EC:1.4.-.-, GOC:ai]","metadata":null},{"id":"135c80feb9a24353b6a9ba3895fdd04a","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016639","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and reduces NAD+ or NADP.\" [GOC:ai]","metadata":null},{"id":"866b2a4fd78743838a06bddfd82fd481","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors, cytochrome as acceptor","canonical_id":"go:GO:0016640","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and reduces a cytochrome molecule.\" [GOC:ai]","metadata":null},{"id":"3a534e08f876489f865b0be7b33052ef","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors, disulfide as acceptor","canonical_id":"go:GO:0016642","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and reduces a disulfide group.\" [GOC:ai]","metadata":null},{"id":"e3621e7720664d11b4c91635a0c0d17f","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors, iron-sulfur protein as acceptor","canonical_id":"go:GO:0016643","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [GOC:ai]","metadata":null},{"id":"62a45b184ff34ae19ff6c38350faf324","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor","canonical_id":"go:GO:0016641","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and reduces an oxygen molecule.\" [GOC:ai]","metadata":null},{"id":"e5368ef891f04d8fb8ff7fe3002e85ad","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-NH2 group of donors, with a copper protein as acceptor","canonical_id":"go:GO:0052877","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-NH2 group acts as a hydrogen or electron donor and a copper protein is the acceptor.\" [GOC:ai]","metadata":null},{"id":"2ae9b69dde13467eb0874318e01b0b07","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016616","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-OH group acts as a hydrogen or electron donor and reduces NAD+ or NADP.\" [EC:1.1.1.-]","metadata":null},{"id":"c34e7aa7308e40bb8ab47a53d081f61c","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-OH group of donors, cytochrome as acceptor","canonical_id":"go:GO:0016898","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-OH group acts as a hydrogen or electron donor and reduces a cytochrome molecule.\" [GOC:ai]","metadata":null},{"id":"80ad1ff641734b9f874e8dcc94e830e3","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-OH group of donors, oxygen as acceptor","canonical_id":"go:GO:0016899","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-OH group acts as a hydrogen or electron donor and reduces an oxygen molecule.\" [GOC:ai]","metadata":null},{"id":"4006735c44fb47558886d4128512a1fb","type":"GO_TERM","name":"oxidoreductase activity, acting on the CH-OH group of donors, quinone or similar compound as acceptor","canonical_id":"go:GO:0016901","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-OH group acts as a hydrogen or electron donor and reduces a quinone or a similar acceptor molecule.\" [EC:1.1.5.-, GOC:ai]","metadata":null},{"id":"d79236d188784b34a57a9d0e60c36307","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors","canonical_id":"go:GO:0016903","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor.\" [GOC:ai]","metadata":null},{"id":"d804052e378c4f43badbd5cf4a5217aa","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor","canonical_id":"go:GO:0016620","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces NAD or NADP.\" [GOC:jl]","metadata":null},{"id":"7d837b2d2ca640fc8c74ce65dfef35a3","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors, cytochrome as acceptor","canonical_id":"go:GO:0016622","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces a cytochrome.\" [GOC:jl]","metadata":null},{"id":"678516e53de548b885778172d8b5b88e","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor","canonical_id":"go:GO:0016624","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces a disulfide.\" [GOC:jl]","metadata":null},{"id":"2ee0d46fbc7c43d5b352c726ce0d20ee","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors, iron-sulfur protein as acceptor","canonical_id":"go:GO:0016625","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces an iron-sulfur protein.\" [GOC:jl]","metadata":null},{"id":"b6cc7fe847c043eab8db9fba95c206d4","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors, oxygen as acceptor","canonical_id":"go:GO:0016623","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces oxygen.\" [EC:1.2.3.-]","metadata":null},{"id":"271d7d8c67bb4c8685bb607e49159801","type":"GO_TERM","name":"oxidoreductase activity, acting on the aldehyde or oxo group of donors, with a quinone or similar compound as acceptor","canonical_id":"go:GO:0052738","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which an aldehyde or ketone (oxo) group acts as a hydrogen or electron donor and reduces a quinone or similar compound.\" [EC:1.2.5.-]","metadata":null},{"id":"12abee066e47459aae7dd5437a9e0709","type":"GO_TERM","name":"oxidoreductase activity, reducing C-O-C group as acceptor","canonical_id":"go:GO:0120546","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a reducing C-O-C group acts as acceptor.\" [EC:1.23.-.-]","metadata":null},{"id":"9f50525df9854eaa9ba03631dd4feae0","type":"GO_TERM","name":"oxidoreductase complex","canonical_id":"go:GO:1990204","description":"\"Any protein complex that possesses oxidoreductase activity.\" [GOC:bhm, PMID:18982432]","metadata":null},{"id":"d705aa43d06f4761b90db8b452989f72","type":"GO_TERM","name":"oxidoreduction-driven active transmembrane transporter activity","canonical_id":"go:GO:0015453","description":"\"Primary active transport of a solute across a membrane, driven by exothermic flow of electrons from a reduced substrate to an oxidized substrate. Primary active transport is catalysis of the transport of a solute across a membrane, up the solute's concentration gradient, by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction and is driven by a primary energy source.\" [GOC:mtg_transport, ISBN:0815340729, TC:3.D.-.-.-]","metadata":null},{"id":"441085dcc2254946b32fe75a29cdeaf0","type":"GO_TERM","name":"oxidosqualene cyclase activity","canonical_id":"go:GO:0031559","description":"\"Catalysis of the cyclization of (S)-2,3-epoxysqualene to form a triterpene.\" [GOC:ct]","metadata":null},{"id":"25414a005393453eb32a43db72799ae4","type":"DRUG","name":"oxiglutatione","canonical_id":"gtopdb:6835","description":null,"metadata":null},{"id":"23291d6c79a84831a5595f1e2542bb57","type":"DRUG","name":"oxiglutatione","canonical_id":"chembl:CHEMBL1372","description":null,"metadata":null},{"id":"e2a11bff0231497e82273decbf4f54c1","type":"GO_TERM","name":"oximinotransferase activity","canonical_id":"go:GO:0050206","description":"\"Catalysis of the reaction: 2-(hydroxyimino)propanoate + acetone = acetone oxime + pyruvate.\" [RHEA:11624]","metadata":null},{"id":"60b93a582d6c4f01b4bd1b5fff651579","type":"GO_TERM","name":"oxo-acid-lyase activity","canonical_id":"go:GO:0016833","description":"\"Catalysis of the cleavage of a C-C bond by other means than by hydrolysis or oxidation, of a 3-hydroxy acid.\" [EC:4.1.3.-, GOC:jl]","metadata":null},{"id":"439463dedc434f8593bb049111de7bd9","type":"GO_TERM","name":"oxoacid metabolic process","canonical_id":"go:GO:0043436","description":"\"The chemical reactions and pathways involving any oxoacid; an oxoacid is a compound which contains oxygen, at least one other element, and at least one hydrogen bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons).\" [Wikipedia:Oxyacid]","metadata":null},{"id":"b92b24ac22d14cb39a1cfb65c6916b44","type":"GO_TERM","name":"oxoadipate dehydrogenase complex","canonical_id":"go:GO:0160167","description":"\"A multi-enzyme complex that catalyzes the oxidative decarboxylation of 2-oxoadipate to glutaryl-CoA, thereby acting in the final step of lysine and tryptophan catabolism in mitochondria. The complex comprises multiple copies of three enzymes referred to as E1, E2 and E3: 2-oxoadipate dehydrogenase (E1), dihydrolipoamide S-glutaryltransferase (E2) and dihydrolipoamide dehydrogenase (E3).\" [PMID:29191460, PMID:32695416]","metadata":null},{"id":"0a94c754da2448cf99503d715b90ff30","type":"GO_TERM","name":"oxoglutarate dehydrogenase (succinyl-transferring) activity","canonical_id":"go:GO:0004591","description":"\"Catalysis of the reaction: N(6)-[(R)-lipoyl]-L-lysyl-[dihydrolipoyllysine-residue succinyltransferase] + 2-oxoglutarate + H+ = N(6)-[(R)-S(8)-succinyldihydrolipoyl]-L-lysyl-[dihydrolipoyllysine-residue succinyltransferase] + CO2.\" [RHEA:12188]","metadata":null},{"id":"94cea50560e045e19a2f5954fad32524","type":"GO_TERM","name":"oxoglutarate dehydrogenase complex","canonical_id":"go:GO:0045252","description":"\"A multi-enzyme complex that catalyzes the oxidative decarboxylation of alpha-ketoglutarate (also known as 2-oxoglutarate) to form succinyl-CoA. The complex comprises multiple copies of three enzymes referred to as E1, E2 and E3: oxoglutarate dehydrogenase (lipoamide) (E1), dihydrolipoamide S-succinyltransferase (E2) and dihydrolipoamide dehydrogenase (E3). Additional proteins may also be present.\" [PMID:10672230]","metadata":null},{"id":"c17285bd972f41d8bf74e9f6edf2bbda","type":"GO_TERM","name":"oxoglutarate:malate antiporter activity","canonical_id":"go:GO:0015367","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: oxoglutarate(out) + malate(in) = oxoglutarate(in) + malate(out).\" [TC:2.A.29.2.1]","metadata":null},{"id":"eea68de82e5c4955bea94350068d329d","type":"DRUG","name":"oxybutynin","canonical_id":"gtopdb:359","description":null,"metadata":null},{"id":"c41149d6a9a54ddcb737fb4f46e41d15","type":"DRUG","name":"oxybutynin","canonical_id":"chembl:CHEMBL1231","description":null,"metadata":null},{"id":"18c436a5135a425a8005972db6c51ded","type":"COMBINATION_TREATMENT","name":"oxybutynin + solifenacin","canonical_id":"ctgov_combo:ctgov-combo-5f6c884b34dbd06b","description":null,"metadata":null},{"id":"7243fa8fe3a2439388599c18058536ca","type":"COMBINATION_TREATMENT","name":"oxybutynin + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-8222c476e9a0e44e","description":null,"metadata":null},{"id":"1faf8d871fe44dcca5ce00a9f9f7ffbb","type":"GO_TERM","name":"oxygen binding","canonical_id":"go:GO:0019825","description":"\"Binding to oxygen (O2).\" [GOC:jl]","metadata":null},{"id":"5befe1b7e9b04b25b9c533884fcc3e2e","type":"GO_TERM","name":"oxygen carrier activity","canonical_id":"go:GO:0005344","description":"\"Binding to oxygen and delivering it to an acceptor molecule or a specific location.\" [GOC:ai]","metadata":null},{"id":"aefce0c5441a4aec835f6885dfc5d426","type":"GO_TERM","name":"oxygen evolving activity","canonical_id":"go:GO:0010242","description":"\"Catalysis of the reaction: 2 a plastoquinone + 4 hnu + 2 H2O = 2 a plastoquinol + O2. The evolution of oxygen from oxidizing water is carried out by the oxygen evolving complex in photosystem II of plants.\" [PMID:17091926, PMID:7948862, RHEA:36359]","metadata":null},{"id":"0a7ec5b86f4348acb34619fbb71ae72e","type":"GO_TERM","name":"oxygen metabolic process","canonical_id":"go:GO:0072592","description":"\"The chemical reactions and pathways involving diatomic oxygen (O2).\" [GOC:mah]","metadata":null},{"id":"5062c67bcf9c461aaad8e6ef723698bf","type":"GO_TERM","name":"oxygen sensor activity","canonical_id":"go:GO:0019826","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of oxygen (O2).\" [GOC:mah]","metadata":null},{"id":"e0c333adc700401f87b06ef94122c871","type":"GO_TERM","name":"oxygen transport","canonical_id":"go:GO:0015671","description":"\"The directed movement of oxygen (O2) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"3f888833ff374074a12e696e93a8e459","type":"GO_TERM","name":"oxylipin biosynthetic process","canonical_id":"go:GO:0031408","description":"\"The chemical reactions and pathways resulting in the formation of any oxylipin, any of a group of biologically active compounds formed by oxidative metabolism of polyunsaturated fatty acids.\" [GOC:mah, PMID:11960741]","metadata":null},{"id":"797fc658e3b04860bf8a9418e6209758","type":"GO_TERM","name":"oxylipin metabolic process","canonical_id":"go:GO:0031407","description":"\"The chemical reactions and pathways involving any oxylipin, any of a group of biologically active compounds formed by oxidative metabolism of polyunsaturated fatty acids.\" [GOC:mah, PMID:11960741]","metadata":null},{"id":"dad12305070f4c7d84aa3c2ac364cbc5","type":"DRUG","name":"oxymetazoline","canonical_id":"gtopdb:124","description":null,"metadata":null},{"id":"ed6a77f7e3f24808b46edeaf85b4e48e","type":"DRUG","name":"oxymetazoline","canonical_id":"mesh:D010109","description":null,"metadata":null},{"id":"04c28b4076f64ab6bf8be6d59c9bbd37","type":"DRUG","name":"oxymetholone","canonical_id":"mesh:D010110","description":null,"metadata":null},{"id":"73dcd6d5648647f98c02519275d28f7f","type":"DRUG","name":"oxymorphone","canonical_id":"mesh:D010111","description":null,"metadata":null},{"id":"06976a70ce614afeb0916ac6fe072302","type":"DRUG","name":"oxyphencyclimine","canonical_id":"mesh:C100201","description":null,"metadata":null},{"id":"c8c6fbbb790a430e971c0874a2817d7d","type":"GO_TERM","name":"oxysterol 7-alpha-hydroxylase activity","canonical_id":"go:GO:0008396","description":"\"Catalysis of the reaction: 7-oxocholesterol + H+ + NADPH = 7alpha-hydroxycholesterol + NADP+.\" [RHEA:68740]","metadata":null},{"id":"42b504dd2c884f66a396b4a735486dd2","type":"GO_TERM","name":"oxysterol binding","canonical_id":"go:GO:0008142","description":"\"Binding to oxysterol, an oxidized form of cholesterol.\" [GOC:curators]","metadata":null},{"id":"c12d346a08004568933f22b32890a2a1","type":"GO_TERM","name":"oxysterol receptor signaling pathway","canonical_id":"go:GO:0141209","description":"\"A nuclear receptor-mediated signaling pathway initiated by an oxysterol binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:37541371, PMID:9794827]","metadata":null},{"id":"c43d3b4625df4b76b034ea6fbc6e3bfc","type":"GO_TERM","name":"oxysterol transfer activity","canonical_id":"go:GO:0120021","description":"\"Removes oxysterol from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"f61ae04632324ee7a3292001c2e0f7e4","type":"DRUG","name":"oxytetracycline","canonical_id":"mesh:D010118","description":null,"metadata":null},{"id":"4a47ef74109e4c048a02ce0296538b71","type":"GO_TERM","name":"oxytetracycline biosynthetic process","canonical_id":"go:GO:1901763","description":"\"The chemical reactions and pathways resulting in the formation of oxytetracycline.\" [GOC:TermGenie, GOC:yaf, PMID:8163168, UniPathway:UPA00926]","metadata":null},{"id":"2eb4198643d84acba503080277bcbcba","type":"GO_TERM","name":"oxytetracycline catabolic process","canonical_id":"go:GO:1901762","description":"\"The chemical reactions and pathways resulting in the breakdown of oxytetracycline.\" [GOC:TermGenie, GOC:yaf, PMID:8163168]","metadata":null},{"id":"dbe3149b257b44e89c044c815f560f0d","type":"DRUG","name":"oxytocin","canonical_id":"gtopdb:2174","description":null,"metadata":null},{"id":"8e48f91ba567437781ff8fcb69dad972","type":"DRUG","name":"oxytocin","canonical_id":"mesh:D010121","description":null,"metadata":null},{"id":"f9b8f89315ab40228cf8267fe77bcce6","type":"COMBINATION_TREATMENT","name":"oxytocin + propranolol","canonical_id":"ctgov_combo:ctgov-combo-dc6f630d1e007e96","description":null,"metadata":null},{"id":"894599f919614c9eb59f17ca9759e8a2","type":"COMBINATION_TREATMENT","name":"oxytocin + tranexamic acid","canonical_id":"ctgov_combo:ctgov-combo-c498bf9058939b5e","description":null,"metadata":null},{"id":"16688130cfaf489abd9640eb7cf1295c","type":"COMBINATION_TREATMENT","name":"oxytocin + vasopressin","canonical_id":"ctgov_combo:ctgov-combo-8ca3f0bcb0450d72","description":null,"metadata":null},{"id":"936ed4acfd3e4130a1692c13788a376b","type":"GO_TERM","name":"oxytocin production","canonical_id":"go:GO:0036162","description":"\"The appearance of oxytocin, a cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG, due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Oxytocin is the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary, and together with the neuropeptide vasopressin, is believed to influence social cognition and behavior. It also acts as a neurotransmitter in the brain.\" [GOC:cjm, Wikipedia:Oxytocin]","metadata":null},{"id":"909852f9583a466cb94cc10403de314c","type":"GO_TERM","name":"oxytocin receptor activity","canonical_id":"go:GO:0004990","description":"\"Combining with oxytocin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"604fff88f81a428399d7a57d7e5b9996","type":"GO_TERM","name":"oxytocin receptor binding","canonical_id":"go:GO:0031855","description":"\"Binding to an oxytocin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"2d0e7806c3374aa881cfc99502e96c68","type":"PROTEIN","name":"oxytocin receptors","canonical_id":"uniprot:P30559","description":null,"metadata":null},{"id":"75854dee7f4b444b91a847969a932774","type":"DRUG","name":"ozagrel","canonical_id":"mesh:C034364","description":null,"metadata":null},{"id":"2af0dd65686c4ff7a13b419c78837e4d","type":"DRUG","name":"ozanimod","canonical_id":"gtopdb:8709","description":null,"metadata":null},{"id":"567e43e1cf394c398ff81e342d9b5d9d","type":"DRUG","name":"ozanimod","canonical_id":"chembl:CHEMBL3707247","description":null,"metadata":null},{"id":"372da8b5774549ffb726a9b6cd2ea93b","type":"COMBINATION_TREATMENT","name":"ozanimod + phenelzine","canonical_id":"ctgov_combo:ctgov-combo-9f5c18a54561181c","description":null,"metadata":null},{"id":"66926f7da9184c38941bdc339f796589","type":"COMBINATION_TREATMENT","name":"ozanimod + ponesimod + siponimod","canonical_id":"ctgov_combo:ctgov-combo-3eac5a0915bc8bc2","description":null,"metadata":null},{"id":"0b5a8a40ce764396b6a273b331c41655","type":"COMBINATION_TREATMENT","name":"ozanimod + ustekinumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-31459668581addf9","description":null,"metadata":null},{"id":"60b4330bcda54a209b2c419b7cff3673","type":"GO_TERM","name":"p-aminobenzoyl-glutamate transmembrane transport","canonical_id":"go:GO:1902604","description":"\"The directed movement of N-(4-aminobenzoyl)-L-glutamate across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"0d9fd42dc6bd442c8d4f22d14092515e","type":"GO_TERM","name":"p-aminobenzoyl-glutamate transport","canonical_id":"go:GO:0015814","description":"\"The directed movement of p-aminobenzoyl-glutamate, the anion of p-aminobenzoyl-glutamic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"1a1e3b8938bf446db327db4c39eb65c1","type":"GO_TERM","name":"p-benzoquinone reductase (NADPH) activity","canonical_id":"go:GO:0018541","description":"\"Catalysis of the reaction: 1,4-benzoquinone + H+ + NADPH = hydroquinone + NADP+.\" [RHEA:23488]","metadata":null},{"id":"06027f3ee1c742a69594d7fa4f286842","type":"GO_TERM","name":"p-coumarate 3-hydroxylase activity","canonical_id":"go:GO:0046409","description":"\"Catalysis of the reaction: shikimate or quinate ester of p-coumaric acid + NADPH + H+ + O2 = caffeic acid conjugate (caffeoyl shikimic acid or chlorogenic acid) + H2O + NADP+.\" [PMID:11429408, PMID:11891223]","metadata":null},{"id":"77779a3a468c4ef2a3288441da6c4e7b","type":"GO_TERM","name":"p-coumaryl alcohol transport","canonical_id":"go:GO:1901140","description":"\"The directed movement of a p-coumaryl alcohol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie]","metadata":null},{"id":"e9bbfb71c77247d086310f33de6b64ae","type":"GO_TERM","name":"p-cresol biosynthetic process","canonical_id":"go:GO:1901786","description":"\"The chemical reactions and pathways resulting in the formation of p-cresol.\" [GOC:TermGenie, GOC:yaf, PMID:10623531]","metadata":null},{"id":"cf80e18e3f1042728efc426ff2b83bb9","type":"GO_TERM","name":"p-cresol catabolic process","canonical_id":"go:GO:1901785","description":"\"The chemical reactions and pathways resulting in the breakdown of p-cresol.\" [GOC:TermGenie, GOC:yaf, PMID:10623531, UniPathway:UPA00708]","metadata":null},{"id":"a5caff1167524927aa748e7119a426c9","type":"GO_TERM","name":"p-cumate 2,3-dioxygenase activity","canonical_id":"go:GO:0018570","description":"\"Catalysis of the reaction: p-cumate + NADH + H+ + O2 = NAD+ + cis-2,3-dihydroxy-2,3-dihydro-p-cumate.\" [RHEA:42344]","metadata":null},{"id":"e812cac84a48475fbf1390aaa84e1a8e","type":"GO_TERM","name":"p-cumate biosynthetic process","canonical_id":"go:GO:1901783","description":"\"The chemical reactions and pathways resulting in the formation of p-cumate.\" [GOC:TermGenie, GOC:yaf, PMID:8631713]","metadata":null},{"id":"79b3015681d64af485703c89345121bd","type":"GO_TERM","name":"p-cumate catabolic process","canonical_id":"go:GO:1901782","description":"\"The chemical reactions and pathways resulting in the breakdown of p-cumate.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5273, PMID:8631713, UniPathway:UPA00937]","metadata":null},{"id":"c8a72de860d9433aba25ae01114c4cfe","type":"GO_TERM","name":"p-cymene catabolic process","canonical_id":"go:GO:0019334","description":"\"The chemical reactions and pathways resulting in the breakdown of p-cymene, 1-methyl-4-isopropylbenzene, one of the alkyl-substituted aromatic hydrocarbons found in volatile oils from over 100 plants.\" [GOC:ai]","metadata":null},{"id":"d26ce8e477554410b486607028988ff3","type":"GO_TERM","name":"p-cymene methyl hydroxylase activity","canonical_id":"go:GO:0018694","description":"\"Catalysis of the reaction: 2 H+ + O2 + p-cymene + 2 reduced [2Fe-2S]-[ferredoxin] = 4-isopropylbenzyl alcohol + H2O + 2 oxidized [2Fe-2S]-[ferredoxin].\" [RHEA:51604]","metadata":null},{"id":"4849e59841bb4458a7635323c63776c5","type":"GO_TERM","name":"p-hydroxyphenyl lignin biosynthetic process","canonical_id":"go:GO:1901060","description":"\"The chemical reactions and pathways resulting in the formation of p-hydroxyphenyl lignin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"d13fec99e209400791940c2b1c554842","type":"GO_TERM","name":"p-hydroxyphenyl lignin catabolic process","canonical_id":"go:GO:1901059","description":"\"The chemical reactions and pathways resulting in the breakdown of p-hydroxyphenyl lignin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"90fd88d7c30a4391ba29cc3cb9a826ac","type":"GO_TERM","name":"p-xylene catabolic process","canonical_id":"go:GO:0042187","description":"\"The chemical reactions and pathways resulting in the breakdown of p-xylene (1,4-dimethylbenzene), a colorless, liquid aromatic hydrocarbon.\" [GOC:jl]","metadata":null},{"id":"85e7d6b5b89b4221a1fc15d3f5f95883","type":"GO_TERM","name":"p24 cargo receptor complex","canonical_id":"go:GO:7770070","description":"\"A conserved, hetero-oligomeric (often tetrameric) cycling ER-Golgi protein complex that selectively recruits secretory cargo, especially GPI-anchored proteins, into COPII vesicles and helps maintain early secretory pathway organization. A functional p24 complex typically contains one member of each subfamily of p24 proteins, alpha, beta, gamma and delta.\" [PMID:19566487, PMID:26224213, PMID:27569046, PMID:32456004, PMID:34647572]","metadata":null},{"id":"7ff9935ea4dc4934a15bc18ac3277e9f","type":"GO_TERM","name":"p38MAPK cascade","canonical_id":"go:GO:0038066","description":"\"A MAPK cascade containing at least the p38MAPK (MAPK14) MAP kinase, or Hog1 in yeast. It starts with the activation of a MAP3K, and the consecutive activation of a MPK2K and of p38MAPK. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinases in the downstream tier. The p38MAPK cascade is activated by stress signals, including hyperosmolarity, as well as by G protein-coupled receptors, growth factors, and cytokines, and results in cellular responses such as cell proliferation, cell differentiation, apoptosis and inflammation.\" [PMID:20811974, PMID:23125017, PMID:32794416]","metadata":null},{"id":"6c3c890140cb4065bcd4c6c7e9cd1fa9","type":"GO_TERM","name":"p53 binding","canonical_id":"go:GO:0002039","description":"\"Binding to one of the p53 family of proteins.\" [GOC:hjd]","metadata":null},{"id":"a181cacae9424cfaa66ea0dae3b5e519","type":"GO_TERM","name":"pH elevation","canonical_id":"go:GO:0045852","description":"\"Any process that increases the internal pH of an organism, part of an organism or a cell, corresponding to a decrease in hydrogen ion concentration.\" [GOC:curators]","metadata":null},{"id":"b62cbc17d6db4079a451983eb2f3fcd5","type":"GO_TERM","name":"pH reduction","canonical_id":"go:GO:0045851","description":"\"Any process that reduces the internal pH of an organism, part of an organism or a cell, corresponding to an increase in hydrogen ion concentration.\" [GOC:curators]","metadata":null},{"id":"c0d2ce0ecf634ce8ac4a790a620796d8","type":"GO_TERM","name":"pH-gated calcium channel activity","canonical_id":"go:GO:0160126","description":"\"A gated channel activity that enables the transmembrane transfer of a calcium ion by a channel that opens in response to a change in pH.\" [PMID:30930064, PMID:34767445]","metadata":null},{"id":"e8fd87f3c3c24ce585144115a18a22ec","type":"GO_TERM","name":"pH-gated chloride channel activity","canonical_id":"go:GO:0061797","description":"\"A gated channel activity that enables the transmembrane transfer of a chloride ion by a channel that opens in response to a change in pH.\" [GOC:dph, PMID:27358471]","metadata":null},{"id":"5bacc718863840d4b8711d28b22585ee","type":"GO_TERM","name":"pH-gated monoatomic ion channel activity","canonical_id":"go:GO:0160128","description":"\"Enables the transmembrane transfer of an inorganic ion by a channel that opens in response to a change in proton concentration (pH).\" [PMID:17167423, PMID:29513651]","metadata":null},{"id":"17208bce1cc348648fe32ec5fb507390","type":"GO_TERM","name":"pH-gated sodium channel activity","canonical_id":"go:GO:0160125","description":"\"A gated channel activity that enables the transmembrane transfer of a sodium ion by a channel that opens in response to a change in pH.\" [PMID:34767445]","metadata":null},{"id":"ae5fa3b3ccf64c948a332ebafdf5e099","type":"GO_TERM","name":"pICln-Sm protein complex","canonical_id":"go:GO:0034715","description":"\"A protein complex that contains pICln (CLNS1A) and several Sm proteins, including SmD1, SmD2, SmE, SmF, and SmG.\" [GOC:mah, PMID:11713266]","metadata":null},{"id":"857d334816394c0f9477ef62b9413656","type":"TRIAL","name":"pRospective Evaluation of Clinical Outcomes in Patients With metAsTatI\u0441 melanOma Treated With dabrafeNib and trAmetinib in reaL practicE","canonical_id":"clinicaltrials.gov:NCT05171374","description":"Melanoma Stage III; Melanoma Stage IV; Melanoma","metadata":null},{"id":"a860f9d0bc014325b7fac2667a891ac1","type":"GO_TERM","name":"pachytene","canonical_id":"go:GO:0000239","description":"\"The cell cycle phase which follows zygotene during prophase I of meiosis, and during which crossing over occurs between a chromatid in one partner and another chromatid in the homologous chromosome.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"6dd8ce73fec14f0e88acbdfd48daacd2","type":"DRUG","name":"paclitaxel","canonical_id":"gtopdb:2770","description":null,"metadata":null},{"id":"40e63dbe6cbf4c9cb03ee6c0a342ef54","type":"DRUG","name":"paclitaxel","canonical_id":"chembl:CHEMBL428647","description":null,"metadata":null},{"id":"dc6db5dada254e39a75e9c928643db33","type":"COMBINATION_TREATMENT","name":"paclitaxel + pembrolizumab","canonical_id":"ctgov_combo:ctgov-combo-7954d0671adc0fef","description":null,"metadata":null},{"id":"fb162d3801c749f0b6565e3b59c199bd","type":"COMBINATION_TREATMENT","name":"paclitaxel + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-abba81ae33568dfc","description":null,"metadata":null},{"id":"a17d48c96f5f43b6b017f16cb100cde0","type":"COMBINATION_TREATMENT","name":"paclitaxel + serplulimab","canonical_id":"ctgov_combo:ctgov-combo-f204063988946537","description":null,"metadata":null},{"id":"77e18a32c0e24d56be8d61d7bcab6488","type":"COMBINATION_TREATMENT","name":"paclitaxel + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-3c4ab7efa93fb128","description":null,"metadata":null},{"id":"09908ec2a47d4f59be5ca0e464bb3a4b","type":"COMBINATION_TREATMENT","name":"paclitaxel + sirolimus","canonical_id":"ctgov_combo:ctgov-combo-c7668b39f637d8cb","description":null,"metadata":null},{"id":"3cdeb99b37954e798487450a4d696e2a","type":"COMBINATION_TREATMENT","name":"paclitaxel + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-f5fd5e927cff1b2c","description":null,"metadata":null},{"id":"d21ab671cce9440ea5daaaff06c535f5","type":"GO_TERM","name":"paclitaxel biosynthetic process","canonical_id":"go:GO:0042617","description":"\"The chemical reactions and pathways resulting in the formation of paclitaxel, a tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia.\" [GOC:jl, GOC:krc]","metadata":null},{"id":"eaa850e398f040639ed008f9a58a19a1","type":"DRUG","name":"pacritinib","canonical_id":"gtopdb:7793","description":null,"metadata":null},{"id":"2084e110a4e34769b779c82d45bebf09","type":"DRUG","name":"pacritinib","canonical_id":"chembl:CHEMBL2035187","description":null,"metadata":null},{"id":"a83a5a4f2b5545749380360a1d022da6","type":"DISEASE","name":"pain agnosia","canonical_id":"mondo:0000675","description":null,"metadata":null},{"id":"aa7dce055652453fb6a8986572ee7d01","type":"GO_TERM","name":"pairing center","canonical_id":"go:GO:0036224","description":"\"A special chromosome region located towards one end of a chromosome that contains dispersed copies of short, repetitive DNA sequences and functions as a cis-acting element essential for presynaptic homologous chromosome pairing and chromosome-nuclear envelope attachment.\" [GOC:kmv, PMID:18597662]","metadata":null},{"id":"75333551a51d49e5bc802e6071aebb5b","type":"DRUG","name":"palbociclib","canonical_id":"gtopdb:7380","description":null,"metadata":null},{"id":"1c7232e91f72435897749ba3cc0ce8da","type":"DRUG","name":"palbociclib","canonical_id":"chembl:CHEMBL189963","description":null,"metadata":null},{"id":"4e2a1a20b5e24978916d617e113e263b","type":"COMBINATION_TREATMENT","name":"palbociclib + pazopanib","canonical_id":"ctgov_combo:ctgov-combo-9b6568f67f9e22e8","description":null,"metadata":null},{"id":"34a4b9ced2754f3d9a9438a3a63b8af8","type":"COMBINATION_TREATMENT","name":"palbociclib + pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-e0a662eee17a126c","description":null,"metadata":null},{"id":"d51784a50e87444aacc96609d974e973","type":"COMBINATION_TREATMENT","name":"palbociclib + pioglitazone","canonical_id":"ctgov_combo:ctgov-combo-2209e6d4222451e6","description":null,"metadata":null},{"id":"bf7dadf2181a414e939690e2c2f280c9","type":"COMBINATION_TREATMENT","name":"palbociclib + ribociclib","canonical_id":"ctgov_combo:ctgov-combo-1756c1f9b100401a","description":null,"metadata":null},{"id":"1dff72d873f948beb1e22928db6b299b","type":"DRUG","name":"palifermin","canonical_id":"gtopdb:6954","description":null,"metadata":null},{"id":"3c53735d6e3d4a8cba3776924b850339","type":"DRUG","name":"palifermin","canonical_id":"chembl:CHEMBL1201821","description":null,"metadata":null},{"id":"df808e6b702c4f50bde3c014cec47159","type":"COMBINATION_TREATMENT","name":"palifermin + plerixafor","canonical_id":"ctgov_combo:ctgov-combo-97592f66ce9b48b1","description":null,"metadata":null},{"id":"fee419e8069c4c59bfc732a09660398d","type":"GO_TERM","name":"palisade mesophyll development","canonical_id":"go:GO:1903866","description":"\"The process whose specific outcome is the progression of a palisade mesophyll over time, from its formation to the mature structure.\" [GO_REF:0000080, GOC:TermGenie, PMID:24663344]","metadata":null},{"id":"f0ebafa5654b45658f2a809177a71864","type":"DRUG","name":"palivizumab","canonical_id":"mesh:D000069455","description":null,"metadata":null},{"id":"5e8b7fcc96d449caafa11bf23635c008","type":"GO_TERM","name":"pallium cell proliferation in forebrain","canonical_id":"go:GO:0022013","description":"\"The multiplication or reproduction of pallium cells in the forebrain, resulting in the expansion of the cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"8a45bedfe866456080494432b4a247cf","type":"GO_TERM","name":"pallium development","canonical_id":"go:GO:0021543","description":"\"The process whose specific outcome is the progression of the pallium over time, from its formation to the mature structure. The pallium is the roof region of the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"3b4103fad6194625bd57823991a9400a","type":"GO_TERM","name":"pallium glioblast division","canonical_id":"go:GO:0022016","description":"\"The division of a glioblast in the pallium. A glioblast is a dividing precursor cell that gives rise to glial cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"1a37fa900539435e9180c581000dfeb7","type":"GO_TERM","name":"palmatine biosynthetic process","canonical_id":"go:GO:0035831","description":"\"The chemical reactions and pathways resulting in the formation of palmatine, a berberine alkaloid found in many plants.\" [GOC:yaf, PMID:21327819]","metadata":null},{"id":"7618b1e2f112417dbeaaec3089ca59d8","type":"GO_TERM","name":"palmitic acid biosynthetic process","canonical_id":"go:GO:1900535","description":"\"The chemical reactions and pathways resulting in the formation of palmitic acid.\" [GOC:TermGenie]","metadata":null},{"id":"71a96b279fe1458783b71133596527f8","type":"GO_TERM","name":"palmitoleoyl [acyl-carrier-protein]-dependent acyltransferase activity","canonical_id":"go:GO:0008951","description":"\"Catalysis of the reaction: a palmitoleoyl-[acyl-carrier protein] + alpha-KDO-(2->4)-alpha-KDO-(2->6)-lipid IVA = KDO2-(palmitoleoyl)-lipid IVA + a holo-[acyl-carrier protein].\" [MetaCyc:PALMITOTRANS-RXN]","metadata":null},{"id":"843546f773aa4603a1e65ba2b4082620","type":"GO_TERM","name":"palmitoleoyltransferase activity","canonical_id":"go:GO:1990698","description":"\"Catalysis of the transfer of a palmitoleoyl group, a 16-carbon monounsaturated fatty acid (C16:1), to an acceptor molecule.\" [PMID:17141155, PMID:25731175]","metadata":null},{"id":"8d4b8468f2f84c459cfa0bfff7276a2a","type":"GO_TERM","name":"palmitoleyl hydrolase activity","canonical_id":"go:GO:1990699","description":"\"Catalysis of a hydrolase reaction that removes a palmitoleyl moiety, a 16-carbon monounsaturated fatty acid (C16:1), from some substrate.\" [PMID:25731175]","metadata":null},{"id":"b314655c96fd4ba8a12c5a321bddbc51","type":"GO_TERM","name":"palmitoyl hydrolase activity","canonical_id":"go:GO:0098599","description":"\"Catalysis of a hydrolase reaction that removes a palmitoyl moiety from some substrate.\" [GOC:dos, GOC:pg]","metadata":null},{"id":"c1c4e91aed3a45e7983dfb88902d1583","type":"GO_TERM","name":"palmitoyl-(protein) hydrolase activity","canonical_id":"go:GO:0008474","description":"\"Catalysis of the reaction: palmitoyl-protein + H2O = palmitate + protein.\" [EC:3.1.2.22]","metadata":null},{"id":"afb89a9cea8a4aef8fac1c92a0f97f43","type":"GO_TERM","name":"palmitoyl-CoA 9-desaturase activity","canonical_id":"go:GO:0032896","description":"\"Catalysis of the reaction: hexadecanoyl-CoA + 2 Fe(II)-[cytochrome b5] + O2 + 2 H(+) = (9Z)-hexadecenoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [PMID:16443825, RHEA:36931]","metadata":null},{"id":"8732d8c7625e4b03b7eeef728fd1c395","type":"GO_TERM","name":"palmitoyl-CoA ligase activity","canonical_id":"go:GO:0090433","description":"\"Catalysis of the reaction: ATP + palmitic acid + CoA = AMP + diphosphate + palmitoyl-CoA.\" [GOC:al, PMID:18071249]","metadata":null},{"id":"a57a0c053e3b4181bf1f2f8c8fb45ab7","type":"GO_TERM","name":"palmitoyl-[glycerolipid] 3-(E)-desaturase activity","canonical_id":"go:GO:0102654","description":"\"Catalysis of the reaction: a 1-acyl-2-hexadecanoyl-glycerolipid + 2 H+ + O2 + 2 reduced [2Fe-2S]-[ferredoxin] = a 1-acyl-2-[(3E)-hexadec-3-enoyl]-glycerolipid + 2 H2O + 2 oxidized [2Fe-2S]-[ferredoxin]. The this activity introduces an unusual trans double bond at carbon 3 of a palmitoyl group attached to the sn-2 position of glycerolipids.\" [RHEA:46764]","metadata":null},{"id":"c1c9a7a11dfa476f9f640a3992d4bb3a","type":"GO_TERM","name":"palmitoyl-[glycerolipid] 7-desaturase activity","canonical_id":"go:GO:0102843","description":"\"Catalysis of the reaction: a 1-acyl-2-hexadecanoyl-glycerolipid + 2 H+ + O2 + 2 reduced [2Fe-2S]-[ferredoxin] = a 1-acyl-2-[(7Z)-hexadecenoyl]-glycerolipid + 2 H2O + 2 oxidized [2Fe-2S]-[ferredoxin].\" [RHEA:46756]","metadata":null},{"id":"9f7536b834db4212b34b2e092060b397","type":"GO_TERM","name":"palmitoyltransferase activity","canonical_id":"go:GO:0016409","description":"\"Catalysis of the transfer of a palmitoyl (CH3-[CH2]14-CO-) group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"3f4dd0ec0d2c4c6aae75f3231275fa8a","type":"GO_TERM","name":"palmitoyltransferase complex","canonical_id":"go:GO:0002178","description":"\"A protein complex with palmitoyltransferase activity.\" [GOC:hjd]","metadata":null},{"id":"fc246b7aa2f149feaeb203d81d24dc4a","type":"DRUG","name":"palonosetron","canonical_id":"gtopdb:7486","description":null,"metadata":null},{"id":"e6a3aec931bb48c296504c61c168f25c","type":"COMBINATION_TREATMENT","name":"palonosetron + prochlorperazine","canonical_id":"ctgov_combo:ctgov-combo-95550dc0b4dab946","description":null,"metadata":null},{"id":"086e0603f4c145e0bb5be58ec06fcf7c","type":"DRUG","name":"palovarotene","canonical_id":"gtopdb:8276","description":null,"metadata":null},{"id":"7d9c833e04334682bdfc770eef05ffe8","type":"DRUG","name":"palovarotene","canonical_id":"chembl:CHEMBL2105648","description":null,"metadata":null},{"id":"071749e907794426afa3d183f0844538","type":"DRUG","name":"pamidronic acid","canonical_id":"gtopdb:7259","description":null,"metadata":null},{"id":"fae7d9404be84f52a65ba13322dae6e6","type":"GO_TERM","name":"pancreas development","canonical_id":"go:GO:0031016","description":"\"The process whose specific outcome is the progression of the pancreas over time, from its formation to the mature structure. The pancreas is an endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating hormones.\" [GOC:cvs]","metadata":null},{"id":"a14e404c408f4af29a0fa9ffdcaba9e8","type":"GO_TERM","name":"pancreas field specification","canonical_id":"go:GO:0061131","description":"\"The process in which a specific region of the gut is delineated into the area in which the pancreas will develop.\" [GOC:dph]","metadata":null},{"id":"bde1b44aedbc46288b0e9aa3252bad3e","type":"GO_TERM","name":"pancreas induction","canonical_id":"go:GO:0061132","description":"\"The close range interaction of two or more cells or tissues that causes the cells of the gut to change their fates and specify the development of the pancreas.\" [GOC:dph]","metadata":null},{"id":"5321777663cf4215be1e95aaedfdb008","type":"GO_TERM","name":"pancreas morphogenesis","canonical_id":"go:GO:0061113","description":"\"Morphogenesis of the pancreas. Morphogenesis is the process in which anatomical structures are generated and organized.\" [GOC:dph]","metadata":null},{"id":"735e91f1146f40e6954b26932aa3f2ea","type":"GO_TERM","name":"pancreas regeneration","canonical_id":"go:GO:1990798","description":"\"The regrowth of a destroyed pancreas.\" [PMID:1985964]","metadata":null},{"id":"938adad8f91746d295bb1191d1286407","type":"GO_TERM","name":"pancreatic A cell development","canonical_id":"go:GO:0003322","description":"\"The process whose specific outcome is the progression of a pancreatic A cell over time, from its formation to the mature structure. A pancreatic A cell is a cell in the pancreas that secretes glucagon.\" [GOC:dph]","metadata":null},{"id":"d2427ec751174e94bd2e06a40832b53f","type":"GO_TERM","name":"pancreatic A cell differentiation","canonical_id":"go:GO:0003310","description":"\"The process in which relatively unspecialized cells acquire specialized structural and functional features of a pancreatic A cell. A pancreatic A cell is a cell in the pancreas that secretes glucagon.\" [GOC:dph, PMID:11076772]","metadata":null},{"id":"47d95c99891d4d6c984c99ecff80c8d3","type":"GO_TERM","name":"pancreatic A cell fate commitment","canonical_id":"go:GO:0003326","description":"\"The commitment of a cell to a pancreatic A cell and its capacity to differentiate into a pancreatic A cell. A pancreatic A cell is a cell in the pancreas that secretes glucagon.\" [GOC:dph]","metadata":null},{"id":"19dad46c9c1f409da53194d55eee1513","type":"GO_TERM","name":"pancreatic D cell development","canonical_id":"go:GO:0003324","description":"\"The process whose specific outcome is the progression of a pancreatic delta cell over time, from its formation to the mature structure. A delta cell is a cell of the pancreas that produces somatostatin.\" [GOC:dph]","metadata":null},{"id":"0badb4fd90a9457e8786832be261bc12","type":"GO_TERM","name":"pancreatic D cell differentiation","canonical_id":"go:GO:0003311","description":"\"The process in which relatively unspecialized cells acquire specialized structural and functional features that characterize a pancreatic delta cell. A delta cell is a cell of the pancreas that produces somatostatin.\" [GOC:dph, PMID:11076772]","metadata":null},{"id":"5c57dd7908df4a539698b790e5a340b9","type":"GO_TERM","name":"pancreatic D cell fate commitment","canonical_id":"go:GO:0003328","description":"\"The commitment of a cell to a pancreatic D cell fate and its capacity to differentiate into a pancreatic D cell. A delta cell is a cell of the pancreas that produces somatostatin.\" [GOC:dph]","metadata":null},{"id":"69a5ec81cacf486e9660dc7af0d88859","type":"GO_TERM","name":"pancreatic E cell development","canonical_id":"go:GO:0090105","description":"\"The process whose specific outcome is the progression of a pancreatic E cell over time, from its formation to the mature structure.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bea76f9261624f068ec3d3964b2e1f61","type":"GO_TERM","name":"pancreatic E cell fate commitment","canonical_id":"go:GO:0090106","description":"\"The commitment of a cell to a pancreatic E cell fate and its capacity to differentiate into a pancreatic E cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f4fde030ce774db283f87136c8fe24cb","type":"GO_TERM","name":"pancreatic PP cell development","canonical_id":"go:GO:0003325","description":"\"The process whose specific outcome is the progression of a pancreatic PP cell over time, from its formation to the mature structure. A pancreatic polypeptide-producing cell is a cell in the pancreas that produces pancreatic polypeptide.\" [GOC:dph]","metadata":null},{"id":"4631e3600a4c465b8af0af358dd1c210","type":"GO_TERM","name":"pancreatic PP cell differentiation","canonical_id":"go:GO:0003312","description":"\"The process in which relatively unspecialized cells acquire specialized structural and functional features of a pancreatic polypeptide-producing cell. A pancreatic polypeptide-producing cell is a cell in the pancreas that produces pancreatic polypeptide.\" [GOC:dph, PMID:11076772]","metadata":null},{"id":"89704403ad3c41e0a65662c595132c71","type":"GO_TERM","name":"pancreatic PP cell fate commitment","canonical_id":"go:GO:0003329","description":"\"The commitment of a cell to a pancreatic PP cell fate and its capacity to differentiate into a pancreatic PP cell. A pancreatic polypeptide-producing cell is a cell in the pancreas that produces pancreatic polypeptide.\" [GOC:dph]","metadata":null},{"id":"0869b5ba7d7842919c2d0f2fde924cdd","type":"DISEASE","name":"pancreatic adenocarcinoma","canonical_id":"mondo:0006047","description":null,"metadata":null},{"id":"2ba999d1410f4a43af5a1225eeeb7bbd","type":"GO_TERM","name":"pancreatic amylase secretion","canonical_id":"go:GO:0036395","description":"\"The controlled release of amylase from a cell of the pancreas.\" [GOC:jc, PMID:19028687]","metadata":null},{"id":"4aed4c7dc5fe49e7ad87126a438dfac1","type":"GO_TERM","name":"pancreatic bud formation","canonical_id":"go:GO:0061130","description":"\"The morphogenetic process in which the foregut region specified to become the pancreas forms a bud.\" [GOC:dph]","metadata":null},{"id":"1ba3c69cc58a47b193815e2db7dc5407","type":"DISEASE","name":"pancreatic ductal adenocarcinoma","canonical_id":"mondo:0005184","description":null,"metadata":null},{"id":"162f51d58c53410e8d13ce22ea1629a0","type":"GO_TERM","name":"pancreatic epsilon cell differentiation","canonical_id":"go:GO:0090104","description":"\"The process in which relatively unspecialized cells acquire specialized structural and functional features of a pancreatic epsilon cell. A pancreatic epsilon cell is a cell in the pancreas that secretes ghrelin.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"13bb2dc0822e4db1a73f23ae1c52f61e","type":"GO_TERM","name":"pancreatic juice secretion","canonical_id":"go:GO:0030157","description":"\"The regulated release of pancreatic juice by the exocrine pancreas into the upper part of the intestine. Pancreatic juice is slightly alkaline and contains numerous enzymes and inactive enzyme precursors including alpha-amylase, chymotrypsinogen, lipase, procarboxypeptidase, proelastase, prophospholipase A2, ribonuclease, and trypsinogen. Its high concentration of bicarbonate ions helps to neutralize the acid from the stomach.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"1ce70172f0684805b20160f76a89e6fd","type":"DISEASE","name":"pancreatic neoplasm","canonical_id":"mondo:0021040","description":null,"metadata":null},{"id":"600771609eeb40e8b39f83857f925a7f","type":"GO_TERM","name":"pancreatic polypeptide receptor activity","canonical_id":"go:GO:0001602","description":"\"Combining with pancreatic polypeptide PP to initiate a change in cell activity.\" [PMID:9315606]","metadata":null},{"id":"f19e4196c3514327b68931a4d28e3f2b","type":"GO_TERM","name":"pancreatic polypeptide secretion","canonical_id":"go:GO:0036322","description":"\"The regulated release of pancreatic polypeptide (PP) from a cell. Pancreatic polypeptide is a 36 amino acid polypeptide secreted by islets of Langerhans cells in the pancreas.\" [GOC:cjm, PMID:12730894, Wikipedia:Pancreatic_polypeptide]","metadata":null},{"id":"7e34ffabb9164ea89f0afa4af73dc4ee","type":"GO_TERM","name":"pancreatic stellate cell proliferation","canonical_id":"go:GO:0072343","description":"\"The multiplication or reproduction of pancreatic stellate cells, resulting in the expansion of a pancreatic stellate cell population. Pancreatic stellate cells are found in the periacinar space of the exocrine pancreas and in perivascular and periductal regions of the pancreas, and have long cytoplasmic processes that encircle the base of the acinus.\" [CL:0002410, GOC:mah, PMID:17200706]","metadata":null},{"id":"6ca8efb887b846f2b4619f5d556e2c5d","type":"DISEASE","name":"pancreatic triacylglycerol lipase deficiency","canonical_id":"mondo:0013700","description":null,"metadata":null},{"id":"3317dc6f263947f5bfeb1690edc95d0e","type":"GO_TERM","name":"pancreatic trypsinogen secretion","canonical_id":"go:GO:1990747","description":"\"The regulated release of trypsinogen from the cells of the exocrine pancreas.\" [PMID:12771515]","metadata":null},{"id":"2b192ac15b254c0c96c0888c2a0bc979","type":"DISEASE","name":"pancreatitis","canonical_id":"mondo:0004982","description":null,"metadata":null},{"id":"9063c931e63e4b21a022480de407bdae","type":"DRUG","name":"pancuronium","canonical_id":"gtopdb:4001","description":null,"metadata":null},{"id":"20c9c97e9a934f71aedb94966249e9af","type":"DISEASE","name":"panic disorder","canonical_id":"mondo:0005383","description":null,"metadata":null},{"id":"019a99a9af4340a8b2de29b2b04c48ea","type":"DRUG","name":"panitumumab","canonical_id":"gtopdb:6883","description":null,"metadata":null},{"id":"06cc2fc7fd15403a8f9daf0e45511b80","type":"DRUG","name":"panitumumab","canonical_id":"chembl:CHEMBL1201827","description":null,"metadata":null},{"id":"e21406b925844cd69bbd74856143b50c","type":"COMBINATION_TREATMENT","name":"panitumumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-4b72420ed7977477","description":null,"metadata":null},{"id":"b79c8035934c480d956b4deffdce8e80","type":"COMBINATION_TREATMENT","name":"panitumumab + trametinib","canonical_id":"ctgov_combo:ctgov-combo-8e20b54a74e4b482","description":null,"metadata":null},{"id":"eab246ce26d84721a0d10fd807065513","type":"GO_TERM","name":"pantetheine hydrolase activity","canonical_id":"go:GO:0017159","description":"\"Catalysis of the reaction: (R)-pantetheine + H2O = (R)-pantothenate + cysteamine.\" [EC:3.5.1.92, RHEA:13445]","metadata":null},{"id":"3b8191dd26a94e33b53fa14575fcbbd9","type":"GO_TERM","name":"pantetheine kinase activity","canonical_id":"go:GO:0050165","description":"\"Catalysis of the reaction: ATP + pantetheine = ADP + pantetheine 4'-phosphate.\" [EC:2.7.1.34, MetaCyc:PANTETHEINE-KINASE-RXN]","metadata":null},{"id":"ed5248f8abd041e389b81df88ad59f26","type":"GO_TERM","name":"pantetheine-phosphate adenylyltransferase activity","canonical_id":"go:GO:0004595","description":"\"Catalysis of the reaction: ATP + pantetheine 4'-phosphate = 3'-dephospho-CoA + diphosphate.\" [EC:2.7.7.3, RHEA:19801]","metadata":null},{"id":"538058c5f7fa4e00bb134a3d2d1d6459","type":"GO_TERM","name":"pantoate 4-dehydrogenase activity","canonical_id":"go:GO:0050166","description":"\"Catalysis of the reaction: (R)-pantoate + NAD+ = (R)-4-dehydropantoate + H+ + NADH.\" [EC:1.1.1.106, RHEA:23000]","metadata":null},{"id":"b0de05826d3e4ded8f5e4390f52491b0","type":"GO_TERM","name":"pantoate-beta-alanine ligase activity","canonical_id":"go:GO:0004592","description":"\"Catalysis of the reaction: ATP + (R)-pantoate + beta-alanine = AMP + diphosphate + (R)-pantothenate.\" [EC:6.3.2.1]","metadata":null},{"id":"da42936b257b458ebc422ad13c7c3ea6","type":"GO_TERM","name":"pantothenase activity","canonical_id":"go:GO:0004593","description":"\"Catalysis of the reaction: (R)-pantothenate + H2O = (R)-pantoate + beta-alanine.\" [EC:3.5.1.22, RHEA:12448]","metadata":null},{"id":"e051ad6a7bdf4dbe82840d576600e620","type":"GO_TERM","name":"pantothenate biosynthetic process","canonical_id":"go:GO:0015940","description":"\"The chemical reactions and pathways resulting in the formation of pantothenate, the anion of pantothenic acid. It is a B complex vitamin that is a constituent of coenzyme A and is distributed ubiquitously in foods.\" [GOC:ai, ISBN:0721662544]","metadata":null},{"id":"965879170687442087fb8d0aed8df4a7","type":"GO_TERM","name":"pantothenate catabolic process","canonical_id":"go:GO:0015941","description":"\"The chemical reactions and pathways resulting in the breakdown of pantothenate, the anion of pantothenic acid. It is a B complex vitamin that is a constituent of coenzyme A and is distributed ubiquitously in foods.\" [GOC:ai, ISBN:0721662544]","metadata":null},{"id":"ec3f0d41579d42b095ab26714a6dccfe","type":"GO_TERM","name":"pantothenate import across plasma membrane","canonical_id":"go:GO:0098717","description":"\"The directed movement of pantothenate from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"f87119c9f69946a2a05b3486aba432c4","type":"GO_TERM","name":"pantothenate kinase activity","canonical_id":"go:GO:0004594","description":"\"Catalysis of the reaction: ATP + pantothenate = ADP + D-4'-phosphopantothenate.\" [EC:2.7.1.33]","metadata":null},{"id":"c8cb07836b6f4fb18dffa38a51dc1593","type":"GO_TERM","name":"pantothenate metabolic process","canonical_id":"go:GO:0015939","description":"\"The chemical reactions and pathways involving pantothenate, the anion of pantothenic acid, the amide of beta-alanine and pantoic acid. It is a B complex vitamin that is a constituent of coenzyme A and is distributed ubiquitously in foods.\" [GOC:ai, ISBN:0721662544]","metadata":null},{"id":"b08f155315d248a9ba43f3bd216c0945","type":"GO_TERM","name":"pantothenate transmembrane transport","canonical_id":"go:GO:0015887","description":"\"The process in which pantothenate is transported across a membrane. Pantothenate is the anion of pantothenic acid, the amide of beta-alanine and pantoic acid; it is a B complex vitamin that is a constituent of coenzyme A and is distributed ubiquitously in foods.\" [GOC:ai, ISBN:0721662544]","metadata":null},{"id":"df73fa34b8944db58e1989806b3a7eec","type":"GO_TERM","name":"pantothenate transmembrane transporter activity","canonical_id":"go:GO:0015233","description":"\"Enables the directed movement of pantothenate across a membrane. Pantothenate is the anion of pantothenic acid, the amide of beta-alanine and pantoic acid; it is a B complex vitamin that is a constituent of coenzyme A and is distributed ubiquitously in foods.\" [GOC:ai, ISBN:0721662544]","metadata":null},{"id":"23c6545398594fb5a63a8957b923f822","type":"GO_TERM","name":"pantothenate:sodium symporter activity","canonical_id":"go:GO:0015498","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: pantothenate(out) + Na+(out) = pantothenate(in) + Na+(in).\" [TC:2.A.21.1.1]","metadata":null},{"id":"96db58d502df481c8da75dad0ba5b3c5","type":"GO_TERM","name":"pantothenoylcysteine decarboxylase activity","canonical_id":"go:GO:0050167","description":"\"Catalysis of the reaction: N-[(R)-pantothenoyl]-L-cysteine + H+ = (R)-pantetheine + CO2.\" [EC:4.1.1.30, RHEA:15077]","metadata":null},{"id":"6130d489da5d4cf9b62625066f2c5303","type":"DISEASE","name":"panuveitis","canonical_id":"mondo:0017255","description":null,"metadata":null},{"id":"5b58317dd33e4c6797047e6428840dca","type":"DISEASE","name":"papillary renal cell carcinoma","canonical_id":"mondo:0017884","description":null,"metadata":null},{"id":"39f8ab622071408b84b9c2a3872df802","type":"GO_TERM","name":"para-aminobenzoyl-glutamate hydrolase activity","canonical_id":"go:GO:0071713","description":"\"Catalysis of the reaction: para-aminobenzoyl-glutamate + H2O = para-aminobenzoate + L-glutamate.\" [GOC:imk, PMID:20190044]","metadata":null},{"id":"8222925e55df45aab10f49b0340e345f","type":"GO_TERM","name":"paracellular tight junction channel activity","canonical_id":"go:GO:0160187","description":"\"Enables size- and charge-selective transport of solutes through a tight junction barrier paracellularly, across the epithelium.\" [PMID:30665499]","metadata":null},{"id":"760b34d4e1824407a27f84e4c5730df3","type":"GO_TERM","name":"paracellular transport","canonical_id":"go:GO:0160184","description":"\"The directed movement of substance through the space in between adjacent cells, rather than through the cells themselves.\" [PMID:28452575, WIki:Paracellular_transport]","metadata":null},{"id":"7a382fd479c94297be2a5662af62c584","type":"GO_TERM","name":"paracrine signaling","canonical_id":"go:GO:0038001","description":"\"The transfer of information from one cell to another, where the signal travels from the signal-producing cell to the receiving cell by passive diffusion or bulk flow in intercellular fluid. The signaling cell and the receiving cell are usually in the vicinity of each other.\" [GOC:mtg_signaling_feb11, ISBN:3527303782]","metadata":null},{"id":"c4fab0e072f944d18fec7f181409e346","type":"GO_TERM","name":"paraferritin complex","canonical_id":"go:GO:0070826","description":"\"A cytoplasmic protein complex that contains integrin, mobilferrin and a flavin monooxygenase, is capable of reducing Fe(III) to Fe(II) utilizing NADPH, and is involved in iron transport. Fe(II) is required in the cell as the substrate for ferrochelatase in the synthesis of heme.\" [GOC:mah, GOC:rph, PMID:11842004, PMID:8639593]","metadata":null},{"id":"75fdcd8e78c043428153e539d0b1c1ff","type":"GO_TERM","name":"paraflagellar rod","canonical_id":"go:GO:0097740","description":"\"A large lattice-like axial structure found in some flagellated protists which extends alongside the axoneme. Protein components of the paraflagellar rod are likely implicated, among other, in adenine nucleotide signaling and metabolism, and in calcium signaling.\" [GOC:cilia, PMID:19879876, PMID:26199333, PMID:26688619]","metadata":null},{"id":"a21af4039b5e46b49017c4126fe5258a","type":"GO_TERM","name":"paraflagellar rod assembly","canonical_id":"go:GO:0120268","description":"\"The aggregation, arrangement and bonding together of a set of components to form a paraflagellar rod, a large lattice-like axial structure found in some flagellated protists which extends alongside the axoneme.\" [GOC:ach, GOC:krc, PMID:23787017, PMID:32295845]","metadata":null},{"id":"09405c758e46443bb67f62013689be3e","type":"GO_TERM","name":"paraherquonin biosynthetic process","canonical_id":"go:GO:0140874","description":"\"The chemical reactions and pathways resulting in the formation of paraherquonin, a meroterpenoid with a unique, highly congested hexacyclic molecular architecture.\" [PMID:27602587]","metadata":null},{"id":"7c81c1d16b8f4c568e0f065d7e69ad5a","type":"GO_TERM","name":"parahippocampal gyrus development","canonical_id":"go:GO:0021770","description":"\"The progression of the parahippocampal gyrus over time from its initial formation until its mature state. The parahippocampal gyrus is a ridge in the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"9fdb806985104835b5a3b598e72d99af","type":"GO_TERM","name":"parallel actin filament bundle","canonical_id":"go:GO:0097518","description":"\"An actin filament bundle in which the filaments are tightly packed (approximately 10-20 nm apart) and oriented with the same polarity.\" [GOC:cjm, GOC:mah, ISBN:0815316194]","metadata":null},{"id":"c9b7b8292f3d4fe59c2d2e52ad111e82","type":"GO_TERM","name":"parallel actin filament bundle assembly","canonical_id":"go:GO:0030046","description":"\"Assembly of actin filament bundles in which the filaments are tightly packed (approximately 10-20 nm apart) and oriented with the same polarity.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"2a51a9ba4d5e4520a7cf53838f29d084","type":"GO_TERM","name":"parallel fiber","canonical_id":"go:GO:1990032","description":"\"A parallel fiber results from the bifurcation of a cerebellar granule cell axon in the molecular layer into two diametrically opposed branches, that are oriented parallel to the long axis of the folium.\" [ISBN:0195159551, NIF_Subcellular:nlx_330]","metadata":null},{"id":"3aeb0a893e1543b98cc4c4e9296ddfe1","type":"GO_TERM","name":"parallel fiber to Purkinje cell synapse","canonical_id":"go:GO:0098688","description":"\"An excitatory synapse formed by the parallel fibers of granule cells synapsing onto the dendrites of Purkinje cells.\" [PMID:16623829, PMID:3209740]","metadata":null},{"id":"0ccfdcd4f70a4c519fbd1ae5f6035775","type":"GO_TERM","name":"paramesonephric duct development","canonical_id":"go:GO:0061205","description":"\"The process whose specific outcome is the progression of the paramesonephric duct over time, from its formation to the mature structure. Mullerian ducts (or paramesonephric ducts) are paired ducts of the embryo that run down the lateral sides of the urogenital ridge and terminate at the mullerian eminence in the primitive urogenital sinus. In the female, they will develop to form the fallopian tubes, uterus, cervix, and the upper portion of the vagina; in the male, they are lost. These ducts are made of tissue of mesodermal origin.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"97635b44c75d4ed4abf9686a631fe40a","type":"GO_TERM","name":"paramyosin filament assembly or disassembly","canonical_id":"go:GO:0061204","description":"\"The formation or disassembly of a filament composed of paramyosin molecules.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"d3b348ca8484433fa25e0b4e76c5bf80","type":"DISEASE","name":"paramyotonia congenita of Von Eulenburg","canonical_id":"mondo:0008195","description":null,"metadata":null},{"id":"55bb71872aa6493ebbfad181db412b0b","type":"GO_TERM","name":"paranodal junction","canonical_id":"go:GO:0033010","description":"\"A highly specialized cell-cell junction found in vertebrates, which forms between a neuron and a glial cell, and has structural similarity to Drosophila septate junctions. It flanks the node of Ranvier in myelinated nerve and electrically isolates the myelinated from unmyelinated nerve segments and physically separates the voltage-gated sodium channels at the node from the cluster of potassium channels underneath the myelin sheath.\" [PMID:11395001, PMID:14630217]","metadata":null},{"id":"25d8cfcb918642c99fa5982f7ca289f6","type":"GO_TERM","name":"paranodal junction assembly","canonical_id":"go:GO:0030913","description":"\"Formation of the junction between an axon and the glial cell that forms the myelin sheath. Paranodal junctions form at each paranode, i.e. at the ends of the unmyelinated nodes of Ranvier.\" [PMID:14715942]","metadata":null},{"id":"93661f5bd40540cf87300cb7101de1e5","type":"GO_TERM","name":"paranodal junction maintenance","canonical_id":"go:GO:1990227","description":"\"The maintenance of a paranodal junction, a highly specialized cell-cell junction found in vertebrates, which forms between a neuron and a glial cell, and has structural similarity to Drosophila septate junctions. A paranodal junction flanks the node of Ranvier in myelinated nerve, electrically isolates the myelinated from unmyelinated nerve segments, and physically separates the voltage-gated sodium channels at the node from the cluster of potassium channels underneath the myelin sheath.\" [GOC:pr, PMID:24011083]","metadata":null},{"id":"8e27a456cf984cec9c6c52de893b2627","type":"GO_TERM","name":"paranode region of axon","canonical_id":"go:GO:0033270","description":"\"An axon part that is located adjacent to the nodes of Ranvier and surrounded by lateral loop portions of myelin sheath.\" [GOC:mah, GOC:mh, NIF_Subcellular:sao936144858]","metadata":null},{"id":"f69782f2346b4fce97846e71ec8adb7a","type":"DISEASE","name":"parapsoriasis","canonical_id":"mondo:0006592","description":null,"metadata":null},{"id":"24f87bc70199411cab429c5c9bc14e03","type":"GO_TERM","name":"parasexual reproduction with cellular fusion","canonical_id":"go:GO:1990277","description":"\"A type of reproduction in which new individuals are produced from two individuals, with the fusion of two somatic cells.\" [GOC:di, PMID:26210747]","metadata":null},{"id":"743f10fa2d454d0889a2d5dc53fbe97b","type":"GO_TERM","name":"paraspeckles","canonical_id":"go:GO:0042382","description":"\"Discrete subnuclear bodies in the interchromatin nucleoplasmic space, often located adjacent to nuclear specks. 10-20 paraspeckles are typically found in human cell nuclei.\" [GOC:jl, PMID:11790299]","metadata":null},{"id":"737b8fec0c544901ae66b05ab0363c43","type":"GO_TERM","name":"parasympathetic nervous system development","canonical_id":"go:GO:0048486","description":"\"The process whose specific outcome is the progression of the parasympathetic nervous system over time, from its formation to the mature structure. The parasympathetic nervous system is one of the two divisions of the vertebrate autonomic nervous system. Parasympathetic nerves emerge cranially as pre ganglionic fibers from oculomotor, facial, glossopharyngeal and vagus and from the sacral region of the spinal cord. Most neurons are cholinergic and responses are mediated by muscarinic receptors. The parasympathetic system innervates, for example: salivary glands, thoracic and abdominal viscera, bladder and genitalia.\" [FMA:9907, GOC:jid, GOC:sr]","metadata":null},{"id":"ea871685470e4d86b9078bbf0256c073","type":"GO_TERM","name":"parathion catabolic process","canonical_id":"go:GO:0019339","description":"\"The chemical reactions and pathways resulting in the breakdown of parathion, a highly toxic organophosphate compound. Degradation of parathion by sunlight or liver enzymes can result in the formation of the active compound paraoxon which interferes with the nervous system through cholinesterase inhibition.\" [MetaCyc:PARATHION-DEGRADATION-PWY]","metadata":null},{"id":"7e9ea4e3bfa24d7daf20681f9720dfc1","type":"DISEASE","name":"parathyroid gland carcinoma","canonical_id":"mondo:0012004","description":null,"metadata":null},{"id":"fd808d9481524dd49f7b22d9cbab0728","type":"GO_TERM","name":"parathyroid gland development","canonical_id":"go:GO:0060017","description":"\"The process whose specific outcome is the progression of the parathyroid gland over time, from its formation to the mature structure. The parathyroid gland is an organ specialised for secretion of parathyroid hormone.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"140e91ef1d6c4cadb4bbaf20ea12ea1b","type":"DISEASE","name":"parathyroid gland disorder","canonical_id":"mondo:0001223","description":null,"metadata":null},{"id":"6dac93e8f04340438a577becaf0dad3c","type":"DRUG","name":"parathyroid hormone","canonical_id":"mesh:D010281","description":null,"metadata":null},{"id":"9c62710d036f44f185f129c0eb987bfa","type":"GO_TERM","name":"parathyroid hormone receptor activity","canonical_id":"go:GO:0004991","description":"\"Combining with parathyroid hormone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"1e024d0ccf69419f9155bf1438f85ced","type":"GO_TERM","name":"parathyroid hormone receptor binding","canonical_id":"go:GO:0031856","description":"\"Binding to a parathyroid hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"80fff25167874f3086ddf5227f2cbad2","type":"GO_TERM","name":"parathyroid hormone secretion","canonical_id":"go:GO:0035898","description":"\"The regulated release of parathyroid hormone into the circulatory system.\" [GOC:cjm, PMID:12171519, PMID:21164021]","metadata":null},{"id":"434f4bbbeead4215ba20b55e0b604bcb","type":"GO_TERM","name":"paraxial mesoderm development","canonical_id":"go:GO:0048339","description":"\"The process whose specific outcome is the progression of the paraxial mesoderm over time, from its formation to the mature structure. The paraxial mesoderm is the mesoderm located bilaterally adjacent to the notochord and neural tube.\" [GOC:dgh]","metadata":null},{"id":"7a6a1d1482c3486b97a22b54209c68c2","type":"GO_TERM","name":"paraxial mesoderm formation","canonical_id":"go:GO:0048341","description":"\"The process that gives rise to the paraxial mesoderm. This process pertains to the initial formation of the structure from unspecified parts.\" [GOC:dgh]","metadata":null},{"id":"29045f7a9b9240bcb7e9ce44fc4ba438","type":"GO_TERM","name":"paraxial mesoderm morphogenesis","canonical_id":"go:GO:0048340","description":"\"The process in which the anatomical structures of the paraxial mesoderm are generated and organized.\" [GOC:curators]","metadata":null},{"id":"79d85c9c4f1b46fd9cf227d611ad09a6","type":"GO_TERM","name":"paraxial mesoderm structural organization","canonical_id":"go:GO:0048352","description":"\"The process that contributes to the act of creating the structural organization of the paraxial mesoderm. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dgh]","metadata":null},{"id":"29165e0e67394d8c98b251006e9e6d02","type":"GO_TERM","name":"paraxial mesodermal cell differentiation","canonical_id":"go:GO:0048342","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a paraxial mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"5d46f768fa07478f8639e949d483e3e9","type":"GO_TERM","name":"paraxial mesodermal cell fate commitment","canonical_id":"go:GO:0048343","description":"\"The process in which a cell becomes committed to become a paraxial mesoderm cell.\" [GOC:dgh]","metadata":null},{"id":"bf57f20d02424085851430995214b60c","type":"GO_TERM","name":"paraxial mesodermal cell fate determination","canonical_id":"go:GO:0048344","description":"\"The process in which a cell becomes capable of differentiating autonomously into a paraxial mesoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:dgh]","metadata":null},{"id":"36af124fb05345fa87fcab743e6243c1","type":"GO_TERM","name":"paraxial mesodermal cell fate specification","canonical_id":"go:GO:0048348","description":"\"The process in which a cell becomes capable of differentiating autonomously into a paraxial mesoderm cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:dgh]","metadata":null},{"id":"fa6d2ed66ce0444fb388bf023cdaf96e","type":"GO_TERM","name":"parental behavior","canonical_id":"go:GO:0060746","description":"\"A reproductive behavior in which a parent cares for and rears offspring.\" [GOC:dph]","metadata":null},{"id":"2799d01d40c542fcad77b7808e1db48b","type":"DRUG","name":"pargyline","canonical_id":"mesh:D010293","description":null,"metadata":null},{"id":"0016113dcd1f4c3d9e29d55444488906","type":"DRUG","name":"paricalcitol","canonical_id":"gtopdb:2791","description":null,"metadata":null},{"id":"8f8e1d4949dd44f9b83ac58c9487e3d3","type":"DRUG","name":"paricalcitol","canonical_id":"chembl:CHEMBL1200622","description":null,"metadata":null},{"id":"3c59f562e3da48859846210bebd734bd","type":"GO_TERM","name":"parietal peritoneum development","canonical_id":"go:GO:1904819","description":"\"The process whose specific outcome is the progression of a parietal peritoneum over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:dph, GOC:TermGenie, PMID:15840053]","metadata":null},{"id":"4a8a98b9381f45d58fb64ba6de16902d","type":"DISEASE","name":"parkinsonism-dystonia, infantile","canonical_id":"mondo:0013150","description":null,"metadata":null},{"id":"aa12062aba78460b94cec67fee5efd31","type":"GO_TERM","name":"paromomycin biosynthetic process","canonical_id":"go:GO:1901155","description":"\"The chemical reactions and pathways resulting in the formation of paromomycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00970]","metadata":null},{"id":"99a4fd2a48044729973ef763cfcdea62","type":"GO_TERM","name":"paromomycin catabolic process","canonical_id":"go:GO:1901154","description":"\"The chemical reactions and pathways resulting in the breakdown of paromomycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00970]","metadata":null},{"id":"dfa0c7f5807c4886af50263a3ab27b69","type":"DRUG","name":"paroxetine","canonical_id":"gtopdb:4790","description":null,"metadata":null},{"id":"a30db063ef964da7b474378600d5c071","type":"COMBINATION_TREATMENT","name":"paroxetine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-aef6bc323551a49e","description":null,"metadata":null},{"id":"f104ae8f325a46998a2579789ba9913f","type":"COMBINATION_TREATMENT","name":"paroxetine + venlafaxine","canonical_id":"ctgov_combo:ctgov-combo-8e724b1a3becd674","description":null,"metadata":null},{"id":"40c361b51b2646a495a01947a50ee380","type":"COMBINATION_TREATMENT","name":"paroxetine + vilazodone","canonical_id":"ctgov_combo:ctgov-combo-e430c88241f1a880","description":null,"metadata":null},{"id":"9c9ceccb02154c1f8bc061c892c0033f","type":"DISEASE","name":"paroxysmal extreme pain disorder","canonical_id":"mondo:0008179","description":null,"metadata":null},{"id":"a84406d075704340a9a1adaa18dac6ab","type":"DISEASE","name":"paroxysmal nocturnal hemoglobinuria","canonical_id":"mondo:0100244","description":null,"metadata":null},{"id":"b77d5f4affad45b2a882cb772a992965","type":"DISEASE","name":"paroxysmal tachycardia","canonical_id":"efo:0009493","description":null,"metadata":null},{"id":"ec3838cb6cf44525ae9e9945c37c109c","type":"GO_TERM","name":"parthenolide 3beta-hydroxylase activity","canonical_id":"go:GO:0102627","description":"\"Catalysis of the reaction: O2 + parthenolide + reduced [NADPH--hemoprotein reductase] = 3beta-hydroxyparthenolide + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:61328]","metadata":null},{"id":"350267426b5d422c941c93f33ade9c9d","type":"GO_TERM","name":"parthenolide synthase activity","canonical_id":"go:GO:0102626","description":"\"Catalysis of the reaction: (+)-costunolide + O2 + reduced [NADPH--hemoprotein reductase] = H+ + H2O + oxidized [NADPH--hemoprotein reductase] + parthenolide.\" [RHEA:61320]","metadata":null},{"id":"eeae864ef2bf4453b06b1dc81e6ad170","type":"DISEASE","name":"partial adenosine deaminase deficiency","canonical_id":"efo:0009147","description":null,"metadata":null},{"id":"0f7bc2e172f240ab9b23639863f71c2b","type":"DISEASE","name":"partial androgen insensitivity syndrome","canonical_id":"mondo:0010720","description":null,"metadata":null},{"id":"34a9cd92865c4fa4b98985c79cd6623f","type":"DISEASE","name":"partial chromosome Y deletion","canonical_id":"mondo:0015607","description":null,"metadata":null},{"id":"2ff252fab1594ad3a81735f0fac827f2","type":"GO_TERM","name":"parturition","canonical_id":"go:GO:0007567","description":"\"The reproductive process in which the parent is separated from its offspring either by giving birth to live young or by laying eggs.\" [ISBN:0198506732]","metadata":null},{"id":"e3cf61bc1b96466f95e48f3bfd2951a9","type":"DRUG","name":"pasireotide","canonical_id":"gtopdb:2018","description":null,"metadata":null},{"id":"946701c9566249f09f89a9a482f422c1","type":"DRUG","name":"pasireotide","canonical_id":"mesh:C517782","description":null,"metadata":null},{"id":"c135a36af8e542dcba55b47d74c81d94","type":"COMBINATION_TREATMENT","name":"pasireotide + pegvisomant","canonical_id":"ctgov_combo:ctgov-combo-2ed7622d2ae3539d","description":null,"metadata":null},{"id":"17bcfab7a7694675a9e3401772b39d40","type":"COMBINATION_TREATMENT","name":"pasireotide + verapamil","canonical_id":"ctgov_combo:ctgov-combo-1155cf93e89e3e2f","description":null,"metadata":null},{"id":"97df3a58c86e485a9b9fb4057eaae0aa","type":"GO_TERM","name":"passive transmembrane transporter activity","canonical_id":"go:GO:0022803","description":"\"Enables the transfer of a single solute from one side of a membrane to the other by a mechanism involving conformational change, either by facilitated diffusion or in a membrane potential dependent process if the solute is charged.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"94070291623a42d7947ae3c23d989710","type":"GO_TERM","name":"patched binding","canonical_id":"go:GO:0005113","description":"\"Binding to a patched (ptc) protein, a receptor for hedgehog proteins.\" [GOC:ceb, PMID:11731473]","metadata":null},{"id":"3bdc4a58fd0f44979f66a2491a571351","type":"GO_TERM","name":"patched ligand maturation","canonical_id":"go:GO:0007225","description":"\"The posttranslational modification of members of the Hedgehog family of signaling proteins in order for Hedgehog to exert its biological activity. These modifications include cleavage of its signal sequence, autocatalytic protein cleavage and the attachment of sterol groups.\" [PMID:15057936]","metadata":null},{"id":"9a3c1ed8129c49cd942d158bc4c4a7ec","type":"GO_TERM","name":"paternal behavior","canonical_id":"go:GO:0042712","description":"\"Male behaviors associated with the care and rearing offspring.\" [GOC:curators]","metadata":null},{"id":"320a0bea327d4273b0b3c2c3cd158b2c","type":"GO_TERM","name":"pathogen-associated molecular pattern receptor signaling pathway","canonical_id":"go:GO:0140426","description":"\"The series of molecular signals initiated by a ligand binding of a pattern recognition receptor (PRR) to activate a plant innate immune response. PAMP-triggered immunity PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species.\" [PMID:25744358]","metadata":null},{"id":"3a06c16b67a54e0888e0c7a56351555b","type":"GO_TERM","name":"pathogen-containing vacuole","canonical_id":"go:GO:0140220","description":"\"A membrane-bound intracellular compartment that is formed upon internalization of a pathogen into a host cell, and in which the pathogen resides.\" [PMID:10560000, PMID:26842840]","metadata":null},{"id":"b6379f182f494042a04f18ed211a3577","type":"GO_TERM","name":"pathogen-containing vacuole lumen","canonical_id":"go:GO:0140222","description":"\"The enclosed volume within the sealed membrane of a pathogen-containing vacuole.\" [PMID:10560000, PMID:26842840]","metadata":null},{"id":"91b935883ea441cdbf28029e97f42eff","type":"GO_TERM","name":"pathogen-containing vacuole membrane","canonical_id":"go:GO:0140221","description":"\"Host-derived membrane of a pathogen-containing vacuole.\" [PMID:10560000, PMID:26842840]","metadata":null},{"id":"094defb15af940a482817d9a6cd0f67a","type":"GO_TERM","name":"pathogen-derived receptor ligand activity","canonical_id":"go:GO:0140295","description":"\"The activity of a pathogen-derived entity that interacts with a host receptor to activate effector-triggered immunity.\" [PMID:20601497]","metadata":null},{"id":"7b31436acefa49a8ab49a454b61f2188","type":"DISEASE","name":"pathological myopia","canonical_id":"efo:0004207","description":null,"metadata":null},{"id":"59f83220ad0e4cd08f06687792831130","type":"GO_TERM","name":"pattern orientation","canonical_id":"go:GO:0007633","description":"\"The actions or reactions of an individual in response to the orientation of a visual pattern. This is exemplified by some classes of insects which are able to detect and learn the orientation of a set of stripes and subsequently behaviorally discriminate between horizontal, vertical or 45 degree stripes.\" [GOC:jid, PMID:9933535]","metadata":null},{"id":"d89028a8be494a54bc57c0b4262690c2","type":"GO_TERM","name":"pattern recognition receptor activity","canonical_id":"go:GO:0038187","description":"\"Combining with a pathogen-associated molecular pattern (PAMP), a structure conserved among microbial species to initiate an innate immune response.\" [GOC:ar, GOC:bf]","metadata":null},{"id":"07ec1f89e65c42f0a691374172007ccd","type":"GO_TERM","name":"pattern recognition receptor complex","canonical_id":"go:GO:0140389","description":"\"A signaling receptor complex that combines with a pathogen-associated molecular pattern (PAMP), a structure conserved among pathogenic organisms, to initiate an innate immune response.\" [PMID:22654057, PMID:28302675, PMID:41719893]","metadata":null},{"id":"ad0f09aa95d4413f966dd4dc166ea1b8","type":"GO_TERM","name":"pattern recognition receptor signaling pathway","canonical_id":"go:GO:0002221","description":"\"The series of molecular signals initiated by a ligand binding to a pattern recognition receptor (PRR), and ending with the regulation of a downstream cellular process, e.g. transcription. PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species, or damage-associated molecular pattern (DAMPs), endogenous molecules released from damaged cells.\" [GOC:add, GOC:ar, ISBN:0781735149, PMID:15199967]","metadata":null},{"id":"4d00c73800b54e4ab1604f255e92153f","type":"GO_TERM","name":"pattern specification involved in metanephros development","canonical_id":"go:GO:0072268","description":"\"Any developmental process that results in the creation of defined areas or spaces within the metanephros to which cells respond and eventually are instructed to differentiate.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"24cb1ade1e204d408f4cf1816de1dfe5","type":"GO_TERM","name":"pattern specification process","canonical_id":"go:GO:0007389","description":"\"Any developmental process that results in the creation of defined areas or spaces within an organism to which cells respond and eventually are instructed to differentiate.\" [GOC:curators, GOC:isa_complete, ISBN:0521436125]","metadata":null},{"id":"f314f7fc830241f481086c8b6ce90010","type":"GO_TERM","name":"patulin biosynthetic process","canonical_id":"go:GO:0140723","description":"\"The chemical reactions and pathways resulting in the formation of patulin, an acetate-derived tetraketide mycotoxin produced by several fungal species that shows antimicrobial properties against several bacteria.\" [PMID:25120234, PMID:30680886]","metadata":null},{"id":"d42251a7815a48539fc9743bba544c26","type":"GO_TERM","name":"paxilline biosynthetic process","canonical_id":"go:GO:0140873","description":"\"The chemical reactions and pathways resulting in the formation of paxilline, a mycotoxin that acts as an inhibitor of mammalian maxi-K channels.\" [PMID:23949005]","metadata":null},{"id":"9f15a2cfd3c74b6aa57d0a1daa77d0d3","type":"DRUG","name":"pazopanib","canonical_id":"gtopdb:5698","description":null,"metadata":null},{"id":"f5bdd56f788444d7908d3f58d9c32ebd","type":"DRUG","name":"pazopanib","canonical_id":"mesh:C516667","description":null,"metadata":null},{"id":"0e79654d5b8f44788bd4a721917a590f","type":"COMBINATION_TREATMENT","name":"pazopanib + ranibizumab","canonical_id":"ctgov_combo:ctgov-combo-1484dd45a0c2859f","description":null,"metadata":null},{"id":"b3e8d4d85ab942d9abfe24eeb49a75be","type":"COMBINATION_TREATMENT","name":"pazopanib + sunitinib","canonical_id":"ctgov_combo:ctgov-combo-310e62a755ae0d34","description":null,"metadata":null},{"id":"6da3c94cd1d643f4955d52e3bd16787d","type":"GO_TERM","name":"pectate disaccharide-lyase activity","canonical_id":"go:GO:0047489","description":"\"Catalysis of the reaction: a pectate = a pectate + 4-(4-deoxy-alpha-D-galact-4-enuronosyl)-D-galacturonate. This reaction is the eliminative cleavage of 4-(4-deoxy-alpha-D-galact-4-enuronosyl)-D-galacturonate from the reducing end of pectate, i.e. de-esterified pectin.\" [EC:4.2.2.9]","metadata":null},{"id":"58c652ebf9634e1a9254529396fe4d83","type":"GO_TERM","name":"pectate lyase activity","canonical_id":"go:GO:0030570","description":"\"Catalysis of the reaction: a pectate = a pectate + a pectate oligosaccharide with 4-(4-deoxy-alpha-D-galact-4-enuronosyl)-D-galacturonate end. This reaction is the eliminative cleavage of pectate to give oligosaccharides with 4-deoxy-alpha-D-gluc-4-enuronosyl groups at their non-reducing ends.\" [EC:4.2.2.2]","metadata":null},{"id":"b3ba3775b02b4ff48831bb541ce79711","type":"GO_TERM","name":"pectic galactan metabolic process","canonical_id":"go:GO:0010401","description":"\"The chemical reactions and pathways involving galactan, a polymer of D-galactosyl units that can be found as a side chain of the pectin rhamnogalacturonan I.\" [GOC:tair_curators]","metadata":null},{"id":"c25e7bca5feb41e5a96ce1c2691394ed","type":"GO_TERM","name":"pectic matrix","canonical_id":"go:GO:0048217","description":"\"The gel-like pectin matrix consists of the interlinked acidic and neutral pectin networks that are further cross-linked by calcium bridges. Pectins consist largely of long chains of mostly galacturonic acid units (typically 1,4 linkages and sometimes methyl esters). Three major pectic polysaccharides (homogalacturonan, rhamnogalacturonan I and rhamnogalacturonan II) are thought to occur in all primary cell walls.\" [GOC:jid, PMID:11554482]","metadata":null},{"id":"a5c6efaa26484c268204dcfe2e995bb6","type":"GO_TERM","name":"pectin acetylesterase activity","canonical_id":"go:GO:0052793","description":"\"Catalysis of the reaction: pectin + H2O = pectate + acetate. This reaction is the hydrolysis of acetyl esters of pectin, producing pectate, partially esterified pectin.\" [GOC:mengo_curators, PMID:9218776]","metadata":null},{"id":"b003b308c00e4485b12009dc66b1cdb4","type":"GO_TERM","name":"pectin binding","canonical_id":"go:GO:0044589","description":"\"Binding to pectin.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"791f62f9479f4163a7e975b56b08d804","type":"GO_TERM","name":"pectin biosynthetic process","canonical_id":"go:GO:0045489","description":"\"The chemical reactions and pathways resulting in the formation of pectin, a polymer containing a backbone of alpha-1,4-linked D-galacturonic acid residues.\" [GOC:curators, PMID:11931668]","metadata":null},{"id":"666975edf9ff43b9a17503dcfaaa555f","type":"GO_TERM","name":"pectin catabolic process","canonical_id":"go:GO:0045490","description":"\"The chemical reactions and pathways resulting in the breakdown of pectin, a polymer containing a backbone of alpha-1,4-linked D-galacturonic acid residues.\" [PMID:11931668, PMID:23079077]","metadata":null},{"id":"b43b09541bed4c8aae9cff54406dd443","type":"GO_TERM","name":"pectin lyase activity","canonical_id":"go:GO:0047490","description":"\"Catalysis of the reaction: a pectin = an oligosaccharide with 4-deoxy-6-O-methyl-alpha-D-galact-4-enuronate end + a pectin. This reaction is the eliminative cleavage of (1->4)-alpha-D-galacturonan methyl ester to give oligosaccharides with 4-deoxy-6-O-methyl-alpha-D-galact-4-enuronosyl groups at their nonreducing ends.\" [EC:4.2.2.10]","metadata":null},{"id":"ad83e85358664ff195ee09f6b08b2056","type":"GO_TERM","name":"pectin metabolic process","canonical_id":"go:GO:0045488","description":"\"The chemical reactions and pathways involving pectin, a group of galacturonic acid-containing, water-soluble colloidal carbohydrates of high molecular weight and of net negative charge.\" [GOC:tair_curators]","metadata":null},{"id":"b4f0c320013e44eaaf6410bcf281987f","type":"GO_TERM","name":"pectinesterase activity","canonical_id":"go:GO:0030599","description":"\"Catalysis of the reaction: pectin + n H2O = n methanol + pectate.\" [EC:3.1.1.11]","metadata":null},{"id":"50e7f389ab8e4ef09bfa6b40f6a8ec30","type":"GO_TERM","name":"pectinesterase inhibitor activity","canonical_id":"go:GO:0046910","description":"\"Binds to and stops, prevents or reduces the activity of pectinesterase.\" [GOC:ai, PMID:10880981]","metadata":null},{"id":"68375caf70574cd0b269e7f5ad7102da","type":"GO_TERM","name":"pectoral fin development","canonical_id":"go:GO:0033339","description":"\"The process whose specific outcome is the progression of the pectoral fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"4108cfc7c789470c8d5fdc8afcb3a05c","type":"GO_TERM","name":"pectoral fin morphogenesis","canonical_id":"go:GO:0035138","description":"\"The process in which the anatomical structures of the pectoral fin are generated and organized. Pectoral fins are bilaterally paired fins mounted laterally and located behind the gill covers of fish. These fins are used for lateral mobility and propulsion.\" [GOC:dgh]","metadata":null},{"id":"991aaca75fbe444fa76e4fd947336e0b","type":"GO_TERM","name":"pedicel mucilage biosynthetic process","canonical_id":"go:GO:0048357","description":"\"The chemical reactions and pathways resulting in the formation of mucilage that occur in the flower stem.\" [GOC:jid]","metadata":null},{"id":"3f8c30d336594e6dac4c9732939333a4","type":"GO_TERM","name":"peg and socket contact","canonical_id":"go:GO:0044286","description":"\"A cell-cell contact zone that consists of membrane invaginations extending from either cell, which contain tight-, gap-, and adherens junctions. Peg and socket contacts form between endothelial cells and pericytes, and between lens fiber cells.\" [GOC:tfm, NIF_Subcellular:sao1943947957, PMID:12883993, PMID:16166562, PMID:17591898]","metadata":null},{"id":"5ea31beda3344f0da3af72fd8f6e6cb3","type":"DRUG","name":"pegaptanib","canonical_id":"gtopdb:6836","description":null,"metadata":null},{"id":"2092fb8f61374bf283bc492de80760b0","type":"DRUG","name":"pegaptanib","canonical_id":"chembl:CHEMBL1201421","description":null,"metadata":null},{"id":"b3375573fdaf4c07bc97827d4e621551","type":"DRUG","name":"pegaspargase","canonical_id":"mesh:C042705","description":null,"metadata":null},{"id":"a7527b1150c14791a8584babf21c1faa","type":"DRUG","name":"pegfilgrastim","canonical_id":"gtopdb:6969","description":null,"metadata":null},{"id":"7d6d326822db420b85fe50b7f56fde5a","type":"DRUG","name":"pegfilgrastim","canonical_id":"chembl:CHEMBL1201568","description":null,"metadata":null},{"id":"02d092f74f7b44c396aa6634eb8fa858","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + polatuzumab vedotin","canonical_id":"ctgov_combo:ctgov-combo-4cd2293bd114bfd9","description":null,"metadata":null},{"id":"f94ec3b46b74425381988f9a8ff5ddcc","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + ponatinib","canonical_id":"ctgov_combo:ctgov-combo-2004c9c108f4ef77","description":null,"metadata":null},{"id":"d49a8e9b73c24bee8a3ad57faa22de69","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + rituximab","canonical_id":"ctgov_combo:ctgov-combo-d4b85e4cb33c3ecc","description":null,"metadata":null},{"id":"968d3cadf7a3433fa7821ebcddbb2a20","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-249358c66f514090","description":null,"metadata":null},{"id":"c980b1a19bfb4f91ae72a3472e021deb","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-0cc6290e190e7a28","description":null,"metadata":null},{"id":"e83a450cf78943aaab7d1ab6056732c8","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + vincristine","canonical_id":"ctgov_combo:ctgov-combo-14594f1754dadaf1","description":null,"metadata":null},{"id":"d882539cdaf84c15abb8cd213ec416ec","type":"COMBINATION_TREATMENT","name":"pegfilgrastim + vincristine","canonical_id":"ctgov_combo:ctgov-combo-d0deff3a093bb1c9","description":null,"metadata":null},{"id":"b35daa695d2e4f59895717b5ec5208f3","type":"DRUG","name":"peginesatide","canonical_id":"gtopdb:7447","description":null,"metadata":null},{"id":"934a0075fc7744d2927f2606702223f3","type":"DRUG","name":"peginesatide","canonical_id":"chembl:CHEMBL2107866","description":null,"metadata":null},{"id":"07ca3e5b893940d48f73b819798c4c82","type":"DRUG","name":"peginterferon alfa-2a","canonical_id":"mesh:C100416","description":null,"metadata":null},{"id":"6108c9c4a6c4477ba47d1b00d4384b4c","type":"DRUG","name":"peginterferon alfa-2b","canonical_id":"gtopdb:7462","description":null,"metadata":null},{"id":"e83468ce80c54340ad6704b22ff63e5f","type":"DRUG","name":"peginterferon alfa-2b","canonical_id":"mesh:C417083","description":null,"metadata":null},{"id":"12cda14e62af42b992387f5220acc408","type":"DRUG","name":"peginterferon alfa-2b","canonical_id":"chembl:CHEMBL1201561","description":null,"metadata":null},{"id":"5424c969c94e4d38bf1cf68c5fb53b9e","type":"COMBINATION_TREATMENT","name":"peginterferon alfa-2b + ribavirin","canonical_id":"ctgov_combo:ctgov-combo-ff2dbafb4021ff15","description":null,"metadata":null},{"id":"37330850bbd14b5fae178f22e9c0bc31","type":"COMBINATION_TREATMENT","name":"peginterferon alfa-2b + ribavirin","canonical_id":"ctgov_combo:ctgov-combo-22627f8d3acc60c1","description":null,"metadata":null},{"id":"1e49d5f2351848f499435ee2e9ffe666","type":"COMBINATION_TREATMENT","name":"peginterferon alfa-2b + ribavirin","canonical_id":"ctgov_combo:ctgov-combo-b1783571c1c57550","description":null,"metadata":null},{"id":"062cb67a9bf045a29e813046c4ea823a","type":"COMBINATION_TREATMENT","name":"peginterferon alfa-2b + ribavirin","canonical_id":"ctgov_combo:ctgov-combo-66925170f22dc176","description":null,"metadata":null},{"id":"225c4e508549403fa5c5cb16fbf26b53","type":"DRUG","name":"pegloticase","canonical_id":"mesh:C031545","description":null,"metadata":null},{"id":"db8688a3772e4eedbf87b4fc30d67f75","type":"DRUG","name":"pegvisomant","canonical_id":"gtopdb:7485","description":null,"metadata":null},{"id":"78cea6caf42447ba817dc28e1b2e975a","type":"DRUG","name":"pegvisomant","canonical_id":"chembl:CHEMBL1201515","description":null,"metadata":null},{"id":"8ac4a749c24342f5b9a8dbf39e506c72","type":"COMBINATION_TREATMENT","name":"pegvisomant + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-d4636994643066cf","description":null,"metadata":null},{"id":"c0e963a225054788b49c4780ace648cd","type":"GO_TERM","name":"pelargonidin 3-O-glucoside biosynthetic process","canonical_id":"go:GO:0033487","description":"\"The chemical reactions and pathways resulting in the formation of pelargonidin 3-O-glucoside, a basic anthocyanin responsible for red to magenta coloration of flowers and fruits.\" [GOC:mah, MetaCyc:PWY-5125]","metadata":null},{"id":"2923fdbcdd534df788db2a5c60f48288","type":"GO_TERM","name":"pellicle","canonical_id":"go:GO:0020039","description":"\"The structure enclosing certain parasite cells such as certain apicomplexa and Euglenozoa; consists of the cell membrane with its associated infrastructure of microtubules, microfilaments and other organelles.\" [GOC:mah, GOC:mb]","metadata":null},{"id":"326ae45569c1403f81b857998433dfe6","type":"GO_TERM","name":"pellicular membrane","canonical_id":"go:GO:0120267","description":"\"The portion of the plasma membrane surrounding the pellicle, a structure enclosing some parasite cells such as certain apicomplexa and Euglenozoa. These membranes are associated with an infrastructure of microtubules, microfilaments, and other organelles.\" [GOC:ach, GOC:krc, PMID:18095354, PMID:30550896, PMID:6993644, PMID:7175771]","metadata":null},{"id":"f09519c4465d42e69074bf3d3681aa41","type":"GO_TERM","name":"pelvic fin development","canonical_id":"go:GO:0033340","description":"\"The process whose specific outcome is the progression of the pelvic fin over time, from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"2c074f9e58434077a580c601c533625a","type":"GO_TERM","name":"pelvic fin morphogenesis","canonical_id":"go:GO:0035139","description":"\"The process in which the anatomical structures of the pelvic fin are generated and organized. Pelvic fins are bilaterally paired fins mounted in a ventral-lateral position on most fish. These fins are used primarily for lateral mobility and propulsion.\" [GOC:dgh]","metadata":null},{"id":"b80a9d76506d4135b0879d68346deacd","type":"DRUG","name":"pembrolizumab","canonical_id":"gtopdb:7499","description":null,"metadata":null},{"id":"a142339f5e5c4042b51ae13d8eca814a","type":"DRUG","name":"pembrolizumab","canonical_id":"chembl:CHEMBL3137343","description":null,"metadata":null},{"id":"c75e1b9b095945b5a4a3765cd546991e","type":"COMBINATION_TREATMENT","name":"pembrolizumab + pemetrexed","canonical_id":"ctgov_combo:ctgov-combo-69d2314801eaca40","description":null,"metadata":null},{"id":"8e58654f4c294b6babfaadda1cb9deeb","type":"COMBINATION_TREATMENT","name":"pembrolizumab + pemetrexed + pralsetinib","canonical_id":"ctgov_combo:ctgov-combo-9a21c7a1a857e5c8","description":null,"metadata":null},{"id":"193ba486320248958fce070a258050cb","type":"COMBINATION_TREATMENT","name":"pembrolizumab + regorafenib","canonical_id":"ctgov_combo:ctgov-combo-7ef798d526b10b6a","description":null,"metadata":null},{"id":"14999de8bd984ce88963eefd84f81dba","type":"DRUG","name":"pemetrexed","canonical_id":"gtopdb:6837","description":null,"metadata":null},{"id":"542e138167bf42589b7b1810dc5d1138","type":"DRUG","name":"pemetrexed","canonical_id":"chembl:CHEMBL225072","description":null,"metadata":null},{"id":"c74e8523ac1d47a592a8d236a742849c","type":"COMBINATION_TREATMENT","name":"pemetrexed + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-9e4c7677fb0fee4f","description":null,"metadata":null},{"id":"e11888240e50427c877387b8af410c10","type":"COMBINATION_TREATMENT","name":"pemetrexed + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-dd129c35fe4ebd9e","description":null,"metadata":null},{"id":"e0ff19063d244cb3bdfffaa5e84506ab","type":"COMBINATION_TREATMENT","name":"pemetrexed + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-96543e6dcd7fdb60","description":null,"metadata":null},{"id":"59ca00d888164ee58c9d54c33f2c5274","type":"DISEASE","name":"pemphigus","canonical_id":"mondo:0006594","description":null,"metadata":null},{"id":"e564bb65e4aa474f82349118966bb6d5","type":"DISEASE","name":"pemphigus vulgaris","canonical_id":"mondo:0008219","description":null,"metadata":null},{"id":"e511379d69c3472c81c25f38d43099ce","type":"DRUG","name":"penbutolol","canonical_id":"mesh:D010394","description":null,"metadata":null},{"id":"e5e8220e8f8a454381094d0c0955f6b1","type":"DRUG","name":"penciclovir","canonical_id":"mesh:C053539","description":null,"metadata":null},{"id":"e10f868154234309841827ac96e05cf1","type":"GO_TERM","name":"penetration hypha formation","canonical_id":"go:GO:0075201","description":"\"The assembly by the symbiont of a threadlike, tubular structure, which may contain multiple nuclei and may or may not be divided internally by septa or cross-walls, for the purpose of penetration into its host organism. In the case of an appressorium existing, this term is defined in further details as the process in which the symbiont penetration peg expands to form a hypha which traverses the epidermal cell and emerges into the intercellular space of the mesophyll tissue. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators, PMID:26441323]","metadata":null},{"id":"9d49156ece6445c4aacb4ee82c1f1867","type":"GO_TERM","name":"penetration of cumulus oophorus","canonical_id":"go:GO:0061956","description":"\"The infiltration by sperm of the cumulus oophorus to reach the oocyte. The process involves digestive enzymes from a modified lysosome called the acrosome, situated at the head of the sperm.\" [PMID:21380641]","metadata":null},{"id":"ea62b13501c64f268c99201c0c367235","type":"GO_TERM","name":"penetration of zona pellucida","canonical_id":"go:GO:0007341","description":"\"The infiltration by sperm of the zona pellucida to reach the oocyte. The process involves digestive enzymes from a modified lysosome called the acrosome, situated at the head of the sperm.\" [GOC:jl, PMID:21755679]","metadata":null},{"id":"c66af1ebe52f44479b1645ec6fdd7108","type":"GO_TERM","name":"penetration peg formation","canonical_id":"go:GO:0075053","description":"\"The assembly by the symbiont of a peg-like structure for the purpose of penetration into its host organism, which penetrates through the host cuticle and epidermal cell wall. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators, PMID:26441323]","metadata":null},{"id":"091f3abd4bb94f6c8f0dc98daa1d01de","type":"DRUG","name":"penicillamine","canonical_id":"mesh:D010396","description":null,"metadata":null},{"id":"63f8f326da694cbeafe0bfadf6d04565","type":"GO_TERM","name":"penicillin amidase activity","canonical_id":"go:GO:0008953","description":"\"Catalysis of the reaction: penicillin + H2O = a carboxylate + 6-aminopenicillanate.\" [EC:3.5.1.11]","metadata":null},{"id":"dac4f0fdf5c94b0ea1da0407dbe4da81","type":"GO_TERM","name":"penicillin binding","canonical_id":"go:GO:0008658","description":"\"Binding to penicillin, an antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:ai]","metadata":null},{"id":"ad7df67b8c1640cba64bad2e6183e0ab","type":"GO_TERM","name":"penicillin biosynthetic process","canonical_id":"go:GO:0042318","description":"\"The chemical reactions and pathways resulting in the formation of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"7b26a25a6a164a5a9f584d2cbf92ecef","type":"GO_TERM","name":"penicillin catabolic process","canonical_id":"go:GO:0042317","description":"\"The chemical reactions and pathways resulting in the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"d5435fa9aefe4ebb87e7c10b8f763294","type":"GO_TERM","name":"penicillin metabolic process","canonical_id":"go:GO:0042316","description":"\"The chemical reactions and pathways involving any antibiotic that contains the condensed beta-lactamthiazolidine ring system. Penicillins are produced naturally during the growth of various microfungi of the genera Penicillium and Aspergillus.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"477d37fd87bb41eca3edb0b2c156c18e","type":"GO_TERM","name":"penile erection","canonical_id":"go:GO:0043084","description":"\"The hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow.\" [GOC:jl, Wikipedia:Penile_erection]","metadata":null},{"id":"b6e5eb8963f24de184f2eb65442b0bdb","type":"GO_TERM","name":"penta-snRNP complex","canonical_id":"go:GO:0071003","description":"\"A ribonucleoprotein complex that is formed by the association of the U1, U2, U4/U6 and U5 small nuclear ribonucleoproteins.\" [GOC:krc, GOC:mah, PMID:11804584, PMID:12724403]","metadata":null},{"id":"77da655544c24e0cad0ce838106b9535","type":"GO_TERM","name":"pentachlorophenol catabolic process","canonical_id":"go:GO:0019338","description":"\"The chemical reactions and pathways resulting in the breakdown of pentachlorophenol, a chlorinated insecticide and fungicide used primarily to protect timber from fungal rot and wood boring insects. Pentachlorophenol is significantly toxic to mammals, plants, and many microorganisms.\" [GOC:curators]","metadata":null},{"id":"28b3171e5d024ac790c1e96f8d480b09","type":"GO_TERM","name":"pentachlorophenol monooxygenase activity","canonical_id":"go:GO:0018677","description":"\"Catalysis of the reaction: pentachlorophenol + NADPH + H+ + O2 = tetrachlorohydroquinone + NADP+ + chloride.\" [EC:1.14.13.50]","metadata":null},{"id":"e71d9294e9d047578ab5f786cf6cc890","type":"GO_TERM","name":"pentacyclic triterpenoid biosynthetic process","canonical_id":"go:GO:0019745","description":"\"The chemical reactions and pathways resulting in the formation of pentacyclic triterpenoid compounds, terpenoids with six isoprene units and 5 carbon rings.\" [ISBN:0198506732]","metadata":null},{"id":"7e400f520a1d4f02a1f9750763eb7068","type":"GO_TERM","name":"pentacyclic triterpenoid catabolic process","canonical_id":"go:GO:0019741","description":"\"The chemical reactions and pathways resulting in the breakdown of pentacyclic triterpenoid compounds, terpenoids with six isoprene units and 5 carbon rings.\" [ISBN:0198506732]","metadata":null},{"id":"15f228bd8c974fb0b9392fba035a62cb","type":"GO_TERM","name":"pentacyclic triterpenoid metabolic process","canonical_id":"go:GO:0019742","description":"\"The chemical reactions and pathways involving pentacyclic triterpenoid compounds, terpenoids with six isoprene units and 5 carbon rings.\" [ISBN:0198506732]","metadata":null},{"id":"f5f9dded0239415e870e31e1a5ef3cda","type":"GO_TERM","name":"pentadec-1-ene biosynthetic process","canonical_id":"go:GO:1900873","description":"\"The chemical reactions and pathways resulting in the formation of pentadec-1-ene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4b3a022b05fb4c3a82b4bb59f3769eae","type":"GO_TERM","name":"pentadecane biosynthetic process","canonical_id":"go:GO:1900634","description":"\"The chemical reactions and pathways resulting in the formation of pentadecane.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"a4552c41d91b4063956c8a65bab5f780","type":"GO_TERM","name":"pentalenene synthase activity","canonical_id":"go:GO:0050467","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = diphosphate + pentalenene.\" [EC:4.2.3.7, RHEA:18081]","metadata":null},{"id":"7ee268196daa4731ad9fe729b46b8a92","type":"GO_TERM","name":"pentalenolactone biosynthetic process","canonical_id":"go:GO:1901780","description":"\"The chemical reactions and pathways resulting in the formation of pentalenolactone.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-6915, PMID:17178094, UniPathway:UPA00974]","metadata":null},{"id":"660bdcc733f242c49eeea863af753351","type":"GO_TERM","name":"pentalenolactone catabolic process","canonical_id":"go:GO:1901779","description":"\"The chemical reactions and pathways resulting in the breakdown of pentalenolactone.\" [GOC:TermGenie, GOC:yaf, PMID:17178094]","metadata":null},{"id":"6ffb2f4bcf624139b863010058325af7","type":"GO_TERM","name":"pentameric IgM immunoglobulin complex","canonical_id":"go:GO:0071756","description":"\"A circulating form of IgM consisting of a pentamer of IgM core units with a single J chain polypeptide.\" [GOC:add, ISBN:0781765196, PMID:20176268]","metadata":null},{"id":"cadd7cbeb1e64a8f9f4633b4d1224999","type":"GO_TERM","name":"pentanamidase activity","canonical_id":"go:GO:0050168","description":"\"Catalysis of the reaction: H2O + pentanamide = NH4 + valerate.\" [EC:3.5.1.50, RHEA:10000]","metadata":null},{"id":"06ce52b3c6dc4a03a9060bfeeed5a50a","type":"GO_TERM","name":"pentasaccharide transport","canonical_id":"go:GO:2001100","description":"\"The directed movement of a pentasaccharideacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"4ec41c085cac411b9d6daf7ce7cef401","type":"GO_TERM","name":"pentitol biosynthetic process","canonical_id":"go:GO:0019526","description":"\"The chemical reactions and pathways resulting in the formation of pentitols, any alditol with a chain of five carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"cb0aebe337f248718857b27e8c99801f","type":"GO_TERM","name":"pentitol catabolic process","canonical_id":"go:GO:0019527","description":"\"The chemical reactions and pathways resulting in the breakdown of pentitols, any alditol with a chain of five carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"8a6b9031894c4bb99623cf5944af451d","type":"GO_TERM","name":"pentitol metabolic process","canonical_id":"go:GO:0019519","description":"\"The chemical reactions and pathways involving pentitols, any alditol with a chain of five carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"c44ffdea9ced487d93bb6cfdf2f38a28","type":"DRUG","name":"pentobarbital","canonical_id":"mesh:D010424","description":null,"metadata":null},{"id":"f65959bc062b4935bbe841371013155f","type":"GO_TERM","name":"pentose biosynthetic process","canonical_id":"go:GO:0019322","description":"\"The chemical reactions and pathways resulting in the formation of a pentose, any monosaccharide with a chain of five carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"f05e708529c34d2cadd5964c29b89e8a","type":"GO_TERM","name":"pentose catabolic process","canonical_id":"go:GO:0019323","description":"\"The chemical reactions and pathways resulting in the breakdown of a pentose, any monosaccharide with a chain of five carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"f4b41d6f8dd04a4fba5a67d0da83a0fb","type":"GO_TERM","name":"pentose metabolic process","canonical_id":"go:GO:0019321","description":"\"The chemical reactions and pathways involving a pentose, any monosaccharide with a chain of five carbon atoms in the molecule.\" [ISBN:0198506732]","metadata":null},{"id":"d01f415fe6d343b18f6d6c6ed47ac030","type":"GO_TERM","name":"pentose transmembrane transport","canonical_id":"go:GO:0015750","description":"\"The process in which pentose is transported across a lipid bilayer, from one side of a membrane to the other. A pentose is any aldose with a chain of five carbon atoms in the molecule.\" [GOC:ai]","metadata":null},{"id":"82abd8f504444aea8bc28f124e1b0ba7","type":"GO_TERM","name":"pentose transmembrane transporter activity","canonical_id":"go:GO:0015146","description":"\"Enables the transfer of a pentose sugar from one side of a membrane to the other. Pentose is a monosaccharide with 5 carbon atoms.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"024cc6a0beed44b7999467a62b5b78c8","type":"GO_TERM","name":"pentose-phosphate shunt","canonical_id":"go:GO:0006098","description":"\"The metabolic process in which glucose-6-phosphate is oxidized to form carbon dioxide (CO2) and ribulose 5-phosphate, coupled to reduction of NADP+ to NADPH; ribulose 5-P then enters a series of reactions that can yield biosynthetic precursors (ribose-5-phosphate and erythrose-4-phosphate) and glycolytic intermediates (fructose-6-phosphate and glyceraldehyde-3-phosphate).\" [GOC:pde, ISBN:0198506732, MetaCyc:PENTOSE-P-PWY]","metadata":null},{"id":"c3e9a9476cb649d7aac34da0544909c0","type":"GO_TERM","name":"pentose-phosphate shunt, non-oxidative branch","canonical_id":"go:GO:0009052","description":"\"The branch of the pentose-phosphate shunt which does not involve oxidation reactions. It comprises a series of sugar phosphate interconversions, starting with ribulose 5-P and producing fructose 6-P and glyceraldehyde 3-P.\" [ISBN:0198506732, MetaCyc:NONOXIPENT-PWY]","metadata":null},{"id":"c82237d5401b4e36be06241df48770b6","type":"GO_TERM","name":"pentose-phosphate shunt, oxidative branch","canonical_id":"go:GO:0009051","description":"\"The branch of the pentose-phosphate shunt which involves the oxidation of glucose 6-P and produces ribulose 5-P, reduced NADP+ and carbon dioxide (CO2).\" [ISBN:0198506732, MetaCyc:OXIDATIVEPENT-PWY]","metadata":null},{"id":"6c616342313347d88d45b283efda7f9f","type":"DRUG","name":"pentostatin","canonical_id":"gtopdb:4805","description":null,"metadata":null},{"id":"1722781f64df452cb0102c8b6b3e774c","type":"DRUG","name":"pentostatin","canonical_id":"mesh:D015649","description":null,"metadata":null},{"id":"0c930c8779f243138375378cbaabf4d8","type":"DRUG","name":"pentostatin","canonical_id":"chembl:CHEMBL1580","description":null,"metadata":null},{"id":"076161eec01744cba0435bdff1a83bdd","type":"GO_TERM","name":"pentosyltransferase activity","canonical_id":"go:GO:0016763","description":"\"Catalysis of the transfer of a pentosyl group from one compound (donor) to another (acceptor).\" [GOC:jl]","metadata":null},{"id":"93a2d83414634e09a003f015b6c428b3","type":"GO_TERM","name":"pentraxin binding","canonical_id":"go:GO:0001864","description":"\"Binding to a pentraxin, a member of a family of inflammatory proteins with a radially symmetric arrangement of five identical, noncovalently linked chains in a pentagonal array.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"15351d4a3458420aa1d9c0278acbb565","type":"GO_TERM","name":"pentraxin receptor activity","canonical_id":"go:GO:0008029","description":"\"Combining with a pentraxin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"588e9fe0b1f5492397a31c75998272f8","type":"DISEASE","name":"peptic esophagitis","canonical_id":"mondo:0006896","description":null,"metadata":null},{"id":"c45c89892eb343a593bcd926a4572906","type":"DISEASE","name":"peptic ulcer disease","canonical_id":"mondo:0004247","description":null,"metadata":null},{"id":"21d680d9e31e40c6b92016a6d502bb7c","type":"GO_TERM","name":"peptidase activator activity","canonical_id":"go:GO:0016504","description":"\"Binds to and increases the activity of a peptidase.\" [GOC:ai]","metadata":null},{"id":"2a51357ff15f46d593edf97f36241b4a","type":"GO_TERM","name":"peptidase activator activity involved in apoptotic process","canonical_id":"go:GO:0016505","description":"\"Binds to and increases the activity of a peptidase that is involved in the apoptotic process.\" [GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]","metadata":null},{"id":"5b4ed290b9394e818adfaca56ed3e5f3","type":"GO_TERM","name":"peptidase activity","canonical_id":"go:GO:0008233","description":"\"Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.\" [EC:3.4.-.-, GOC:jl]","metadata":null},{"id":"80e3cc8f395b48df97b94cb83251423a","type":"GO_TERM","name":"peptidase complex","canonical_id":"go:GO:1905368","description":"\"A protein complex which is capable of peptidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:1689240]","metadata":null},{"id":"0253557a808d494cab52b328f4e0f088","type":"GO_TERM","name":"peptidase inhibitor activity","canonical_id":"go:GO:0030414","description":"\"Binds to and stops, prevents or reduces the activity of a peptidase, any enzyme that catalyzes the hydrolysis peptide bonds.\" [GOC:jl]","metadata":null},{"id":"ef73ed2e00c840eeb6ba18c939b643cd","type":"GO_TERM","name":"peptidase inhibitor complex","canonical_id":"go:GO:1904090","description":"\"A protein complex which is capable of peptidase inhibitor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:20860624]","metadata":null},{"id":"a57588319ec147bf92c696ae21546eab","type":"GO_TERM","name":"peptidase regulator activity","canonical_id":"go:GO:0061134","description":"\"Binds to and modulates the activity of a peptidase, any enzyme that catalyzes the hydrolysis peptide bonds.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"421df04a2dbb462798946f7de4c25308","type":"GO_TERM","name":"peptide 2-hydroxyisobutyryltransferase activity","canonical_id":"go:GO:0106226","description":"\"Catalysis of the reaction: 2-hydroxyisobutyryl-CoA + lysine in peptide = CoA + N-2-hydroxyisobutyryl-lysine-peptide.\" [GOC:sp, PMID:29775581]","metadata":null},{"id":"1dcfc157362b484393b1c5db38cb51d1","type":"GO_TERM","name":"peptide N-succinyltransferase activity","canonical_id":"go:GO:0106075","description":"\"Catalysis of the acetylation of an amino acid residue of a peptide or protein, according to the reaction: succinyl-CoA + peptide = CoA + N-succinylpeptide.\" [PMID:29211711]","metadata":null},{"id":"e0dcd9a6f41149dea2535505bc7fa904","type":"GO_TERM","name":"peptide YY receptor activity","canonical_id":"go:GO:0001601","description":"\"Combining with gut peptide YY to initiate a change in cell activity.\" [PMID:9315606]","metadata":null},{"id":"fe8dc056e3d1479c9a6ffc14b92de69e","type":"GO_TERM","name":"peptide alpha-N-propionyltransferase activity","canonical_id":"go:GO:0061607","description":"\"Catalysis of the reaction: propionyl-CoA + peptide = CoA + N-alpha-propionylpeptide. This reaction is the propionylation of the N-terminal amino acid residue of a peptide or protein.\" [GOC:dph, PMID:23043182]","metadata":null},{"id":"1db9774bf6ae424cb59c00bb7ae6ca4d","type":"GO_TERM","name":"peptide amidation","canonical_id":"go:GO:0001519","description":"\"The posttranslational conversion of C-terminal glycine-extended peptides to C-terminal alpha-amidated peptides. Occurs to over half of all peptide hormones to give bioactive peptides. This is a two step process catalyzed by a peptidyl-glycine alpha-hydroxylating monooxygenase and a peptidyl-alpha-hydroxyglycine alpha-amidating lyase. In some organisms, this process is catalyzed by two separate enzymes, whereas in higher organisms, one polypeptide catalyzes both reactions.\" [PMID:11028916]","metadata":null},{"id":"4dc235b0200f48b08bf159989f7d5a7d","type":"GO_TERM","name":"peptide antibiotic biosynthetic process","canonical_id":"go:GO:0030651","description":"\"The chemical reactions and pathways resulting in the formation of peptides with antibiotic activity.\" [GOC:mah]","metadata":null},{"id":"dea4ea14fe1c443a8fb68a86716e07a6","type":"GO_TERM","name":"peptide antibiotic catabolic process","canonical_id":"go:GO:0030652","description":"\"The chemical reactions and pathways resulting in the breakdown of peptides with antibiotic activity.\" [GOC:mah]","metadata":null},{"id":"4ac9ff9d20334a829d60c4ce4408efff","type":"GO_TERM","name":"peptide antigen assembly with MHC class I protein complex","canonical_id":"go:GO:0002502","description":"\"The binding of a peptide to the antigen binding groove of an MHC class I protein complex. Class I here refers to classical class I molecules.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"60dd31e3b1a649249a188f89e137a5b4","type":"GO_TERM","name":"peptide antigen assembly with MHC class II protein complex","canonical_id":"go:GO:0002503","description":"\"The binding of a peptide to the antigen binding groove of an MHC class II protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"8b141cb705c24a31a39854ad345a0a5f","type":"GO_TERM","name":"peptide antigen assembly with MHC class Ib protein complex","canonical_id":"go:GO:0002492","description":"\"The binding of a peptide antigen to the antigen binding groove of an MHC class Ib protein complex. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.\" [GOC:add, PMID:15928678]","metadata":null},{"id":"57ac6611533240fc815b12fe43684fb3","type":"GO_TERM","name":"peptide antigen assembly with MHC protein complex","canonical_id":"go:GO:0002501","description":"\"The binding of a peptide to the antigen binding groove of an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"bf78b1b36e444bdea10a4d4da5c7989b","type":"GO_TERM","name":"peptide antigen binding","canonical_id":"go:GO:0042605","description":"\"Binding to an antigen peptide.\" [GOC:add, GOC:jl, GOC:rv]","metadata":null},{"id":"bea938e48e7c472d83a247b113a58768","type":"GO_TERM","name":"peptide antigen stabilization","canonical_id":"go:GO:0050823","description":"\"Any process involved in maintaining the structure and integrity of a peptide antigen and preventing it from being degraded.\" [GOC:ai]","metadata":null},{"id":"801a9e4a435d4a19b06f11c142979605","type":"GO_TERM","name":"peptide antigen transport","canonical_id":"go:GO:0046968","description":"\"The directed movement of a peptide antigen into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. The peptide antigen is typically, but not always, processed from an endogenous or exogenous protein.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"30056864c411436cab3943c260cd9568","type":"GO_TERM","name":"peptide binding","canonical_id":"go:GO:0042277","description":"\"Binding to a peptide, an organic compound comprising two or more amino acids linked by peptide bonds.\" [GOC:jl]","metadata":null},{"id":"4c0c9786fea54e339bf8850557307714","type":"GO_TERM","name":"peptide biosynthetic process","canonical_id":"go:GO:0043043","description":"\"The chemical reactions and pathways resulting in the formation of peptides, compounds of 2 or more (but usually less than 100) amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another. This may include the translation of a precursor protein and its subsequent processing into a functional peptide.\" [GOC:dph, GOC:jl]","metadata":null},{"id":"c40aa48941b44d498f456a4cc5ba6ba0","type":"GO_TERM","name":"peptide butyryltransferase activity","canonical_id":"go:GO:0140065","description":"\"Catalysis of the reaction: butyryl-CoA + lysine in peptide = CoA + N-butyryl-lysine-peptide.\" [PMID:27105113]","metadata":null},{"id":"9c2c377a5b534e82a5c8f1e7781cce19","type":"GO_TERM","name":"peptide catabolic process","canonical_id":"go:GO:0043171","description":"\"The chemical reactions and pathways resulting in the breakdown of peptides, compounds of 2 or more (but usually less than 100) amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another.\" [GOC:jl]","metadata":null},{"id":"77e2d59d52f444cea494eddc952d9895","type":"GO_TERM","name":"peptide chain release factor N(5)-glutamine methyltransferase activity","canonical_id":"go:GO:0102559","description":"\"Catalysis of the reaction: L-glutaminyl-[peptide chain release factor] + S-adenosyl-L-methionine = N(5)-methyl-L-glutaminyl-[peptide chain release factor] + S-adenosyl-L-homocysteine + H+.\" [RHEA:42896]","metadata":null},{"id":"5cf119ac92004f05a774e3455a5f0785","type":"GO_TERM","name":"peptide cross-linking","canonical_id":"go:GO:0018149","description":"\"The formation of a covalent cross-link between or within protein chains.\" [GOC:jsg]","metadata":null},{"id":"89ba6bed4b9b4b2dbe9d462620c58c40","type":"GO_TERM","name":"peptide cross-linking via L-cystine","canonical_id":"go:GO:0018316","description":"\"The oxidation of two peptidyl-cysteine residues to form a peptidyl-L-cystine (dicysteine) in which segments of peptide chain are linked by a disulfide bond; the cross-link may be between different or the same peptide chain.\" [RESID:AA0025]","metadata":null},{"id":"df71d420f1d647be9ebf73b3ec197bfc","type":"GO_TERM","name":"peptide crotonyltransferase activity","canonical_id":"go:GO:0140064","description":"\"Catalysis of the reaction: crotonyl-CoA + lysine in peptide = CoA + N-crotonyl-lysine-peptide.\" [PMID:25818647]","metadata":null},{"id":"889587cdcc2a46ee8b12f014f65dac41","type":"GO_TERM","name":"peptide deformylase activity","canonical_id":"go:GO:0042586","description":"\"Catalysis of the reaction: formyl-L-methionyl peptide + H2O = formate + methionyl peptide.\" [EC:3.5.1.88, GOC:jl]","metadata":null},{"id":"5ebd84f27caa4f989dacb94882956395","type":"GO_TERM","name":"peptide dopaminyltransferase activity","canonical_id":"go:GO:0120296","description":"\"Catalysis of the reaction: dopamine + L-glutaminyl-[protein] = 5-dopaminyl-L-glutamyl-[protein] + NH4+.\" [GOC:sp, PMID:22858378, PMID:32273471]","metadata":null},{"id":"4c0928c7e3a546968f84be0a38c4268f","type":"GO_TERM","name":"peptide glutaryltransferase activity","canonical_id":"go:GO:0106228","description":"\"Catalysis of the reaction: glutaryl-CoA + L-lysyl-[protein] = CoA + H+ + N6-glutaryl-L-lysyl-[protein].\" [GOC:sp, PMID:31542297]","metadata":null},{"id":"f4f440fc72554f3d906fbc9c5a89f480","type":"GO_TERM","name":"peptide histaminyltransferase activity","canonical_id":"go:GO:0120299","description":"\"Catalysis of the reaction: histamine + L-glutaminyl-[protein] = 5-histaminyl-L-glutamyl-[protein].\" [GOC:sp, PMID:23022564, PMID:23797785]","metadata":null},{"id":"82fc072e5b08464c8221e5abdb9d7eb7","type":"GO_TERM","name":"peptide hormone binding","canonical_id":"go:GO:0017046","description":"\"Binding to a peptide with hormonal activity in animals.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"6918e6584acb4c4f96393b95187426a2","type":"GO_TERM","name":"peptide hormone processing","canonical_id":"go:GO:0016486","description":"\"The generation of a mature peptide hormone by posttranslational processing of a prohormone.\" [GOC:mah]","metadata":null},{"id":"057923aa974d4364bda4bbfad06cde18","type":"GO_TERM","name":"peptide hormone receptor binding","canonical_id":"go:GO:0051428","description":"\"Binding to a receptor for a peptide hormone.\" [GOC:ai]","metadata":null},{"id":"606d90790dbb42479b4709f0b3063652","type":"GO_TERM","name":"peptide hormone secretion","canonical_id":"go:GO:0030072","description":"\"The regulated release of a peptide hormone from a cell.\" [GOC:mah]","metadata":null},{"id":"04e010d5b1f3410d8186ccd66f616451","type":"GO_TERM","name":"peptide lactyltransferase (ATP-dependent) activity","canonical_id":"go:GO:0141207","description":"\"Catalysis of the reaction: lactate + ATP + L-lysyl-[protein] = N(6)-lactoyl-L-lysyl-[protein]+ AMP + diphosphate. Can also act on free lactate.\" [PMID:38512451, PMID:38653238, RHEA:80271]","metadata":null},{"id":"ebb71fff5457459c9012d41a9fa70779","type":"GO_TERM","name":"peptide lactyltransferase (CoA-dependent) activity","canonical_id":"go:GO:0120300","description":"\"Catalysis of the reaction: (L-lysyl-[protein] + lactoyl-CoA = CoA + H+ + N(6)-lactoyl-L-lysyl-[protein].\" [GOC:sp, PMID:31645732, RHEA:61996]","metadata":null},{"id":"30ac139563784f06b951e968340a068e","type":"GO_TERM","name":"peptide metabolic process","canonical_id":"go:GO:0006518","description":"\"The chemical reactions and pathways involving peptides, compounds of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another.\" [GOC:curators]","metadata":null},{"id":"c62e98ab61ce4f699cfdd28c5d262200","type":"GO_TERM","name":"peptide modification","canonical_id":"go:GO:0031179","description":"\"The covalent alteration of one or more amino acid residues within a peptide, resulting in a change in the properties of that peptide.\" [GOC:mah]","metadata":null},{"id":"de1c509dd46f43d08abd54c1750cc550","type":"GO_TERM","name":"peptide noradrenalinyltransferase activity","canonical_id":"go:GO:0120298","description":"\"Catalysis of the reaction: (R)-noradrenaline + L-glutaminyl-[protein] = 5-(R)-noradrenalinyl-L-glutamyl-[protein] + NH4+.\" [GOC:sp, PMID:22858378]","metadata":null},{"id":"0f63ce18b2ad43618a4740ebdd5b7122","type":"GO_TERM","name":"peptide pheromone export","canonical_id":"go:GO:0000770","description":"\"The directed movement of a peptide pheromone out of a cell by a secretion or export pathway used solely for the export of peptide pheromones.\" [GOC:elh]","metadata":null},{"id":"4ed0c28003b64707be963cc0ccd30f14","type":"GO_TERM","name":"peptide pheromone export by transmembrane transport","canonical_id":"go:GO:0090539","description":"\"The directed movement of a peptide pheromone across a membrane and out of a cell.\" [GOC:al, GOC:tb, GOC:vw]","metadata":null},{"id":"f18fed5bd2f143c99552353532d094d9","type":"GO_TERM","name":"peptide pheromone maturation","canonical_id":"go:GO:0007323","description":"\"The generation of a mature, active peptide pheromone via processes unique to its processing and modification. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:elh]","metadata":null},{"id":"41a8c52c088643bc8ffb0e23d1cb8519","type":"GO_TERM","name":"peptide pheromone receptor activity","canonical_id":"go:GO:0036318","description":"\"Combining with a peptide pheromone, and transmitting the signal across the membrane to initiate a change in cell activity.\" [GOC:al]","metadata":null},{"id":"7b65382a722b415e9b9c55504669e3a9","type":"GO_TERM","name":"peptide pheromone secretion","canonical_id":"go:GO:0090538","description":"\"The regulated release of a peptide pheromone from a cell.\" [GOC:al, GOC:tb, GOC:vw]","metadata":null},{"id":"c8d85c9dc37d44b3b2bd37c3f44a97bb","type":"GO_TERM","name":"peptide receptor activity","canonical_id":"go:GO:0001653","description":"\"Combining with an extracellular or intracellular peptide to initiate a change in cell activity.\" [GOC:jl]","metadata":null},{"id":"6835b236faf04af592e15d61de403114","type":"GO_TERM","name":"peptide secretion","canonical_id":"go:GO:0002790","description":"\"The controlled release of a peptide from a cell or a tissue.\" [GOC:add]","metadata":null},{"id":"607be6227b1d4a2fa8e9fcef51e37c4e","type":"GO_TERM","name":"peptide secretion, neurotransmission","canonical_id":"go:GO:0061544","description":"\"The controlled release of a peptide from a cell in which the peptide acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"a84c1214a58b4dd6a3f7ea04848e676c","type":"GO_TERM","name":"peptide serotonyltransferase activity","canonical_id":"go:GO:0120294","description":"\"Catalysis of the reaction: L-glutaminyl-[protein] + serotonin = 5-serotonyl-L-glutamyl-[protein] + NH4+.\" [GOC:sp, PMID:14697203]","metadata":null},{"id":"5a08fdc9593f4f9c9a1b7a06512681d5","type":"GO_TERM","name":"peptide stabilization","canonical_id":"go:GO:0050822","description":"\"Any process involved in maintaining the structure and integrity of a peptide and preventing it from being degraded.\" [GOC:ai]","metadata":null},{"id":"063e10de798d4ae08d44269d235ccc7a","type":"GO_TERM","name":"peptide transmembrane transporter activity","canonical_id":"go:GO:1904680","description":"\"Enables the transfer of a peptide from one side of a membrane to the other.\" [GO_REF:0000070, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"500df1a5cc244c4db6ea628ea724db02","type":"GO_TERM","name":"peptide transport","canonical_id":"go:GO:0015833","description":"\"The directed movement of peptides, compounds of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"dfaa83aa2a5b4445a95a8d63673027f9","type":"GO_TERM","name":"peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity","canonical_id":"go:GO:0000224","description":"\"Catalysis of the reaction: 4-N-(N-acetyl-D-glucosaminyl)-protein + H2O = N-acetyl-beta-D-glucosaminylamine + peptide L-aspartate. This reaction is the hydrolysis of an N4-(acetyl-beta-D-glucosaminyl)asparagine residue in which the N-acetyl-D-glucosamine residue may be further glycosylated, to yield a (substituted) N-acetyl-beta-D-glucosaminylamine and the peptide containing an aspartic residue.\" [EC:3.5.1.52]","metadata":null},{"id":"efb2073f11c04546b6a75e0c84c76fd2","type":"GO_TERM","name":"peptide-O-fucosyltransferase activity","canonical_id":"go:GO:0046922","description":"\"Catalysis of the transfer of an alpha-L-fucosyl residue from GDP-beta-L-fucose to the serine hydroxy group of a protein acceptor.\" [EC:2.4.1.221]","metadata":null},{"id":"707eab771e9347a8af1eb7de293864ea","type":"GO_TERM","name":"peptide-lysine-N-succinyltransferase activity","canonical_id":"go:GO:0106076","description":"\"Catalysis of the reaction: succinyl-CoA + lysine in peptide = CoA + N-succinyl-lysine-peptide.\" [PMID:29211711]","metadata":null},{"id":"5b83716728a7442583c8a2416a8739f9","type":"GO_TERM","name":"peptide-methionine (R)-S-oxide reductase activity","canonical_id":"go:GO:0033743","description":"\"Catalysis of the reaction: L-methionyl-[protein] + [thioredoxin]-disulfide + H2O = L-methionyl-(R)-S-oxide-[protein] + [thioredoxin]-dithiol.\" [RHEA:24164]","metadata":null},{"id":"25e9a74170a340a08d707a503aa1064c","type":"GO_TERM","name":"peptide-methionine (S)-S-oxide reductase activity","canonical_id":"go:GO:0008113","description":"\"Catalysis of the reaction: L-methionyl-[protein] + [thioredoxin]-disulfide + H2O = L-methionyl-(S)-S-oxide-[protein] + [thioredoxin]-dithiol.\" [RHEA:14217]","metadata":null},{"id":"fe72a15929c847449963af31bc482032","type":"GO_TERM","name":"peptide:proton symporter activity","canonical_id":"go:GO:0015333","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: peptide(out) + H+(out) = peptide(in) + H+(in), up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by hydrogen ion movement.\" [GOC:mtg_transport, TC:2.A.17.-.-]","metadata":null},{"id":"5e033dc6c4dd4291a6c944889a8013fa","type":"GO_TERM","name":"peptidoglycan L,D-transpeptidase activity","canonical_id":"go:GO:0071972","description":"\"Catalysis of the reaction: 2 a peptidoglycan dimer (tetrapeptide) + 3 H2O = a peptidoglycan tetramer with L,D cross-links (L-Lys-D-Asn-L-Lys) + di-trans,poly-cis-undecaprenyl diphosphate + 4 D-alanine.\" [MetaCyc:RXN-11349]","metadata":null},{"id":"cbd6c2307fc7483c8a34550730c05107","type":"GO_TERM","name":"peptidoglycan N-acetylglucosaminidase activity","canonical_id":"go:GO:0061784","description":"\"Catalysis of the hydrolysis of (1->4)-beta linkages of N-acetyl-D-glucosamine (GlcNAc) from peptidoglycan.\" [GOC:dph, GOC:jh, PMID:22748813]","metadata":null},{"id":"d5956dc4a92446b59b6d2df2d93b21bb","type":"GO_TERM","name":"peptidoglycan beta-N-acetylmuramidase activity","canonical_id":"go:GO:0033922","description":"\"Catalysis of the hydrolysis of terminal, non-reducing N-acetylmuramic residues.\" [EC:3.2.1.92]","metadata":null},{"id":"9d29d76785884870af3f79c8088bb9b9","type":"GO_TERM","name":"peptidoglycan binding","canonical_id":"go:GO:0042834","description":"\"Interacting selectively and non-covalently, in a non-covalent manner, with peptidoglycan, any of a class of glycoconjugates found in bacterial cell walls.\" [GOC:curators, PMID:14698226]","metadata":null},{"id":"9565804c0701474ca0132f94ca52c9b4","type":"GO_TERM","name":"peptidoglycan biosynthetic process","canonical_id":"go:GO:0009252","description":"\"The chemical reactions and pathways resulting in the formation of peptidoglycans, any of a class of glycoconjugates found in bacterial cell walls and consisting of long glycan strands of alternating residues of beta-(1,4) linked N-acetylglucosamine and N-acetylmuramic acid, cross-linked by short peptides.\" [PMID:18266853]","metadata":null},{"id":"65b1ffa046294898bbbd15f6a5c48cdb","type":"GO_TERM","name":"peptidoglycan catabolic process","canonical_id":"go:GO:0009253","description":"\"The chemical reactions and pathways resulting in the breakdown of peptidoglycans, any of a class of glycoconjugates found in bacterial cell walls and consisting of long glycan strands of alternating residues of beta-(1,4) linked N-acetylglucosamine and N-acetylmuramic acid, cross-linked by short peptides.\" [PMID:9158729]","metadata":null},{"id":"c29164d87f8b44ef81900bf0e9d5e4c6","type":"GO_TERM","name":"peptidoglycan cross-bridge peptide endopeptidase activity","canonical_id":"go:GO:0061787","description":"\"A peptidoglycan endopeptidase activity that acts on a peptidoglycan cross-bridge.\" [GOC:dph, GOC:jh, PMID:22748813]","metadata":null},{"id":"db269fa0a44142479b0b11d47a08b64f","type":"GO_TERM","name":"peptidoglycan endopeptidase activity","canonical_id":"go:GO:0061785","description":"\"An endopeptidase activity that uses peptidoglycan as a substrate.\" [GOC:dph, GOC:jh, PMID:22748813]","metadata":null},{"id":"c825620d13e542488b2a36b2f459220b","type":"GO_TERM","name":"peptidoglycan glycosyltransferase activity","canonical_id":"go:GO:0008955","description":"\"Catalysis of the reaction: [GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)](n)-di-trans,octa-cis-undecaprenyl diphosphate + beta-D-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl diphosphate = [GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)](n+1)-di-trans-octa-cis-undecaprenyl diphosphate + di-trans,octa-cis-undecaprenyl diphosphate + H+.\" [RHEA:23708]","metadata":null},{"id":"d1e18289530f4d43b0a83853c3d13267","type":"GO_TERM","name":"peptidoglycan immune receptor activity","canonical_id":"go:GO:0016019","description":"\"Combining with a peptidoglycan and transmitting the signal to initiate an innate immune response.\" [PMID:14698226]","metadata":null},{"id":"206d27a078764f6289d50441e8c1614e","type":"GO_TERM","name":"peptidoglycan lytic transglycosylase activity","canonical_id":"go:GO:0008933","description":"\"Catalysis of the cleavage of a peptidoglycan chain into a peptidoglycan chain with N-acetyl-1,6-anhydromuramyl-[peptide] at the reducing end + a peptidoglycan chain with N-acetylglucosamine at the non-reducing end. Includes endolytic transglycosylase activity that fragments the glycan chain internally and exolytic transgylcosylase activity that cleaves a terminal disaccharide from the end of the glycan strand.\" [EC:4.2.2.29, PMID:10964424, PMID:22748813]","metadata":null},{"id":"0ebc39852d4f46c18e0b71af9a133877","type":"GO_TERM","name":"peptidoglycan metabolic process","canonical_id":"go:GO:0000270","description":"\"The chemical reactions and pathways involving peptidoglycans, any of a class of glycoconjugates found only in bacterial cell walls and consisting of long glycan strands of alternating residues of beta-(1,4) linked N-acetylglucosamine and N-acetylmuramic acid, cross-linked by short peptides.\" [PMID:33139480]","metadata":null},{"id":"f61846aa43ae43e988ed66bc2cd19442","type":"GO_TERM","name":"peptidoglycan muralytic activity","canonical_id":"go:GO:0061783","description":"\"A catalytic activity that contributes to the degradation of peptidoglycan.\" [GOC:dph, GOC:jh, PMID:22748813]","metadata":null},{"id":"dbf85aed47954deb933254745e853a9f","type":"GO_TERM","name":"peptidoglycan peptide transmembrane transporter activity","canonical_id":"go:GO:0015640","description":"\"Enables the transfer of peptidoglycan peptides from one side of a membrane to the other. Peptidoglycan peptides are the oligopeptides found in peptidoglycan networks which cross-link the polysaccharide chains.\" [ISBN:0198506732]","metadata":null},{"id":"a43d0eb98a08477bb28163bb5e15ec68","type":"GO_TERM","name":"peptidoglycan recognition protein signaling pathway","canonical_id":"go:GO:0061057","description":"\"The series of molecular signals initiated by binding of peptidoglycan to a receptor and ending with regulation of a downstream cellular process. The main outcome of the Imd signaling is the production of antimicrobial peptides.\" [GOC:dph, PMID:18688280, PMID:24706930]","metadata":null},{"id":"ae748b6bc33f4b8497a5f286d036597e","type":"GO_TERM","name":"peptidoglycan stem peptide endopeptidase activity","canonical_id":"go:GO:0061786","description":"\"A peptidoglycan endopeptidase activity that acts on a stem peptide of peptidoglycan.\" [GOC:dph, GOC:jh, PMID:22748813]","metadata":null},{"id":"7c0873ed9d0340278be7b1d7159c3264","type":"GO_TERM","name":"peptidoglycan transmembrane transporter activity","canonical_id":"go:GO:0015647","description":"\"Enables the transfer of peptidoglycans, a class of glycoconjugates found in bacterial cell walls, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"ce830548a86648f88967501c43392c8f","type":"GO_TERM","name":"peptidoglycan transport","canonical_id":"go:GO:0015835","description":"\"The directed movement of peptidoglycans, a class of glycoconjugates found in bacterial cell walls, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"e16c49c747c04eed9cb346170a3ca751","type":"GO_TERM","name":"peptidoglycan turnover","canonical_id":"go:GO:0009254","description":"\"The continual breakdown and regeneration of peptidoglycan required to maintain the bacterial cell wall. Peptidoglycans consist of long glycan strands of alternating residues of beta-(1,4) linked N-acetylglucosamine and N-acetylmuramic acid, cross-linked by short peptides.\" [PMID:31296364]","metadata":null},{"id":"1f6711c2b1454ee4acc91e42e9022655","type":"GO_TERM","name":"peptidoglycan-associated peptide transport","canonical_id":"go:GO:0015834","description":"\"The directed movement of peptidoglycan peptides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Peptidoglycan peptides are the oligopeptides found in peptidoglycan networks which cross-link the polysaccharide chains.\" [ISBN:0198506732]","metadata":null},{"id":"1e4474d3648641ca85b8b7bd1469acb2","type":"GO_TERM","name":"peptidoglycan-based cell wall","canonical_id":"go:GO:0009274","description":"\"A protective structure outside the cytoplasmic membrane composed of peptidoglycan (also known as murein), a molecule made up of a glycan (sugar) backbone of repetitively alternating N-acetylglucosamine and N-acetylmuramic acid with short, attached, cross-linked peptide chains containing unusual amino acids. An example of this component is found in Escherichia coli.\" [GOC:mlg, ISBN:0815108893]","metadata":null},{"id":"d28eb686352c4e108ab7ce98591fc7a3","type":"GO_TERM","name":"peptidoglycan-based cell wall biogenesis","canonical_id":"go:GO:0009273","description":"\"The chemical reactions and pathways resulting in the formation of the peptidoglycan-based cell wall. An example of this process is found in Escherichia coli.\" [GOC:curators]","metadata":null},{"id":"42b9996290f3496989da2823d56bf320","type":"GO_TERM","name":"peptidoglycan-based cell wall organization","canonical_id":"go:GO:0031504","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the peptidoglycan-based cell wall.\" [GOC:dph, GOC:jl, GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"1ceb662814174bf18e671632789d5826","type":"GO_TERM","name":"peptidoglycan-protein cross-linking","canonical_id":"go:GO:0018104","description":"\"The process of covalently linking peptidoglycan (murein) to proteins.\" [GOC:jsg]","metadata":null},{"id":"85bd129200bf47c38d807432f45fbd9c","type":"GO_TERM","name":"peptidyl-L-cysteine S-palmitoylation","canonical_id":"go:GO:0018230","description":"\"The covalent attachment of a palmitoyl group to a sulfur (S) atom within a cysteine residue to form peptidyl-S-palmitoyl-L-cysteine.\" [RESID:AA0106]","metadata":null},{"id":"bb7d278830ff493abfc9c712e5e45207","type":"GO_TERM","name":"peptidyl-N-phospho-arginine dephosphorylation","canonical_id":"go:GO:0098628","description":"\"The removal of phosphate residues from peptidyl-N-phospho-arginine to form peptidyl-arginine.\" [PMID:23770242]","metadata":null},{"id":"ca7f2bea4b57457ba13b1b2d81c59e2a","type":"GO_TERM","name":"peptidyl-arginine 3-dioxygenase activity","canonical_id":"go:GO:0106157","description":"\"Catalyzes the reaction: 2-oxoglutarate + [protein]-L-arginine + O2 = [protein]-(3R)-3-hydroxy-L-arginine + CO2 + succinate.\" [PMID:29563586]","metadata":null},{"id":"1d16dcc6ba9544469ae92a1461a0a5e6","type":"GO_TERM","name":"peptidyl-arginine N-methylation","canonical_id":"go:GO:0035246","description":"\"The addition of a methyl group onto a nitrogen atom of an arginine residue in a protein.\" [GOC:bf]","metadata":null},{"id":"b4eea52740f84e79a9e0435b52126c0b","type":"GO_TERM","name":"peptidyl-arginine hydroxylation","canonical_id":"go:GO:0030961","description":"\"The hydroxylation of peptidyl-arginine to form peptidyl-hydroxyarginine.\" [GOC:mah]","metadata":null},{"id":"4fd923b178f74523b788d8403bfccf6c","type":"GO_TERM","name":"peptidyl-arginine methylation","canonical_id":"go:GO:0018216","description":"\"The addition of a methyl group to an arginine residue in a protein.\" [GOC:mah]","metadata":null},{"id":"d238bb3541f74c2092a3bcf4ab20b8c4","type":"GO_TERM","name":"peptidyl-arginine methylation, to asymmetrical-dimethyl arginine","canonical_id":"go:GO:0019919","description":"\"The process of methylation of peptidyl-arginine to form peptidyl-N(omega),N(omega)-dimethyl-L-arginine.\" [RESID:AA0068, RESID:AA0069]","metadata":null},{"id":"0f705d479dc44469a4182ddabb995599","type":"GO_TERM","name":"peptidyl-arginine methylation, to symmetrical-dimethyl arginine","canonical_id":"go:GO:0019918","description":"\"The process of methylation of peptidyl-arginine to form peptidyl-N(omega),N'(omega)-dimethyl-L-arginine.\" [RESID:AA0067, RESID:AA0069]","metadata":null},{"id":"ae9218fde5a64c92a27455274b304db6","type":"GO_TERM","name":"peptidyl-arginine modification","canonical_id":"go:GO:0018195","description":"\"The modification of peptidyl-arginine.\" [GOC:curators]","metadata":null},{"id":"b735a68e02d74abb99de448897c69f3a","type":"GO_TERM","name":"peptidyl-arginine omega-N-methylation","canonical_id":"go:GO:0035247","description":"\"The addition of a methyl group onto a terminal nitrogen (omega nitrogen) atom of an arginine residue in a protein.\" [PMID:14705965, RESID:AA0067, RESID:AA0068, RESID:AA0069]","metadata":null},{"id":"40397322b40f49cd950a49e750effac2","type":"GO_TERM","name":"peptidyl-arginine phosphorylation","canonical_id":"go:GO:0018109","description":"\"The phosphorylation of peptidyl-arginine to form omega-N-phospho-L-arginine.\" [RESID:AA0222]","metadata":null},{"id":"77d1240b9a174c32aae5fddbe0bffeb4","type":"GO_TERM","name":"peptidyl-aspartic acid 3-dioxygenase activity","canonical_id":"go:GO:0062101","description":"\"Catalysis of the reaction: protein L-aspartate + 2-oxoglutarate + O2 = protein 3-hydroxy-L-aspartate + succinate + CO2.\" [PMID:1378441, PMID:1856229, RHEA:11508]","metadata":null},{"id":"01b4037829364cc399aaea8b3be627df","type":"GO_TERM","name":"peptidyl-aspartic acid hydroxylation","canonical_id":"go:GO:0042264","description":"\"The hydroxylation of peptidyl-aspartic acid to form peptidyl-hydroxyaspartic acid.\" [GOC:mah]","metadata":null},{"id":"9ba2afeba1af414f8b6accfda013571f","type":"GO_TERM","name":"peptidyl-aspartic acid phosphorylation","canonical_id":"go:GO:0018217","description":"\"The phosphorylation of peptidyl-aspartic acid.\" [GOC:jl]","metadata":null},{"id":"e290d88885c3416f820968a759974663","type":"GO_TERM","name":"peptidyl-cysteine S-nitrosylase activity","canonical_id":"go:GO:0035605","description":"\"Catalysis of the transfer of a nitric oxide (NO) group to a sulphur atom within a cysteine residue of a protein.\" [GOC:sp, PMID:20972425, PMID:20972426]","metadata":null},{"id":"9d4a0a082a454d8a876d128706ce22be","type":"GO_TERM","name":"peptidyl-cysteine S-nitrosylation","canonical_id":"go:GO:0018119","description":"\"The covalent addition of a nitric oxide (NO) group to the sulphur (S) atom of a cysteine residue in a protein, to form peptidyl-S-nitrosyl-L-cysteine.\" [RESID:AA0230]","metadata":null},{"id":"807d0adafbcb4825a0dd1faa14b4a087","type":"GO_TERM","name":"peptidyl-cysteine S-trans-nitrosylation","canonical_id":"go:GO:0035606","description":"\"Transfer of a nitric oxide (NO) group from one cysteine residue to another.\" [PMID:19854201, PMID:20972425, PMID:20972426]","metadata":null},{"id":"3501c165dae04376845b64d3d257c9c0","type":"GO_TERM","name":"peptidyl-cysteine methylation","canonical_id":"go:GO:0018125","description":"\"The methylation of peptidyl-cysteine to form peptidyl-S-methyl-L-cysteine.\" [RESID:AA0234]","metadata":null},{"id":"8761089a9d664df4b5900e16dcd29928","type":"GO_TERM","name":"peptidyl-cysteine oxidation","canonical_id":"go:GO:0018171","description":"\"The oxidation of peptidyl-cysteine to peptidyl-L-cysteine sulfinic acid or peptidyl-L-cysteine sulfenic acid.\" [PMID:9586994, RESID:AA0205, RESID:AA0262]","metadata":null},{"id":"a9969a08715145c0bb99d862aafd7b46","type":"GO_TERM","name":"peptidyl-cystine sulfhydration","canonical_id":"go:GO:0044525","description":"\"The modification of a peptidyl-cystine residue in a protein by the addition of sulfur, to form peptidyl-cysteine persulfide.\" [GOC:jl, GOC:jsg]","metadata":null},{"id":"d127a974d69d40d1919fe8c94e9cbd4c","type":"GO_TERM","name":"peptidyl-dipeptidase activity","canonical_id":"go:GO:0008241","description":"\"Catalysis of the release of C-terminal dipeptides from a polypeptide chain.\" [EC:3.4.15.-, GOC:mb]","metadata":null},{"id":"042c0c5911f84223beacaf50b774c157","type":"GO_TERM","name":"peptidyl-dipeptidase inhibitor activity","canonical_id":"go:GO:0060422","description":"\"Binds to and stops, prevents or reduces the activity of a peptidyl-dipeptidase. Peptidyl-dipeptidase activity catalyzes the release of C-terminal dipeptides from a polypeptide chain.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"00030b867b0f4466a05f9ac3815481d5","type":"GO_TERM","name":"peptidyl-glutamate ADP-deribosylation","canonical_id":"go:GO:0140291","description":"\"The removal of ADP-ribose from ADP-ribosylglutamate.\" [PMID:23481255]","metadata":null},{"id":"73c7ac16eba444afba9c1dbbeffe3fcf","type":"GO_TERM","name":"peptidyl-glutamic acid carboxylation","canonical_id":"go:GO:0017187","description":"\"The gamma-carboxylation of peptidyl-glutamic acid; catalyzed by the vitamin K dependent gamma-glutamyl carboxylase.\" [RESID:AA0032]","metadata":null},{"id":"d0f2355ca2a8424eaab179c6128057d7","type":"GO_TERM","name":"peptidyl-glutamic acid modification","canonical_id":"go:GO:0018200","description":"\"The modification of peptidyl-glutamic acid.\" [GOC:curators]","metadata":null},{"id":"1aac29ee4b9a4ae88699080331748654","type":"GO_TERM","name":"peptidyl-glutamine methylation","canonical_id":"go:GO:0018364","description":"\"The addition of a methyl group to a glutamine residue in a protein.\" [GOC:mah]","metadata":null},{"id":"cf5946c8038d449bb6781805ca5b9f15","type":"GO_TERM","name":"peptidyl-glycine modification","canonical_id":"go:GO:0018201","description":"\"The modification of peptidyl-glycine.\" [GOC:curators]","metadata":null},{"id":"a7cbfcec21524a80b1d845c5aaeda41b","type":"GO_TERM","name":"peptidyl-histidine dephosphorylation","canonical_id":"go:GO:0035971","description":"\"The removal of phosphoric residues from peptidyl-O-phospho-L-histidine to form peptidyl-histidine.\" [GOC:BHF, GOC:vk, PMID:12383260]","metadata":null},{"id":"77e706f22c934decacc678550c302f34","type":"GO_TERM","name":"peptidyl-histidine dioxygenase activity","canonical_id":"go:GO:0036139","description":"\"Catalysis of the reaction: L-histidyl-[protein] + 2-oxoglutarate + O2 = (3S)-3-hydroxy-L-histidyl-[protein] + succinate + CO2.\" [PMID:21251231, RHEA:54256]","metadata":null},{"id":"6e641923189a4b1e83b478a198915abc","type":"GO_TERM","name":"peptidyl-histidine methylation","canonical_id":"go:GO:0018021","description":"\"The methylation of peptidyl-L-histidine to form peptidyl-L-1'-methyl-L-histidine (otherwise known as tau-methylhistidine, tele-methylhistidine) or peptidyl-L-3'-methyl-L-histidine (otherwise known as pi-methylhistidine, pros-methylhistidine).\" [RESID:AA0073, RESID:AA0317]","metadata":null},{"id":"ff20e9bc09db4af0bf29aefc57ef906c","type":"GO_TERM","name":"peptidyl-histidine methylation, to form tele-methylhistidine","canonical_id":"go:GO:0042038","description":"\"The methylation of peptidyl-L-histidine to form peptidyl-L-1'-methyl-L-histidine (otherwise known as tau-methylhistidine, tele-methylhistidine).\" [RESID:AA0317]","metadata":null},{"id":"4f5f2f2ea0624668993593f1c0990bd5","type":"GO_TERM","name":"peptidyl-histidine phosphorylation","canonical_id":"go:GO:0018106","description":"\"The phosphorylation of peptidyl-histidine to form peptidyl-1'-phospho-L-histidine (otherwise known as tau-phosphohistidine, tele-phosphohistidine) or peptidyl-3'-phospho-L-histidine (otherwise known as pi-phosphohistidine, pros-phosphohistidine).\" [RESID:AA0035, RESID:AA0036]","metadata":null},{"id":"3e8a649ce38b48cb9e5d294a552feff9","type":"GO_TERM","name":"peptidyl-hypusine biosynthetic process","canonical_id":"go:GO:0008612","description":"\"The modification of peptidyl-lysine to form hypusine, peptidyl-N6-(4-amino-2-hydroxybutyl)-L-lysine, an unusual amino acid synthesized post-translationally.\" [PMID:19880510, PMID:22438895]","metadata":null},{"id":"035b7429693f437c88ae76505c6633f8","type":"GO_TERM","name":"peptidyl-lysine 3-dioxygenase activity","canonical_id":"go:GO:0106155","description":"\"Catalysis of the reaction: protein L-lysine + 2-oxoglutarate + O2 = protein 3-hydroxy-L-lysine + succinate + CO2.\" [GOC:al, PMID:29915238, RHEA:57152]","metadata":null},{"id":"ad562b614e6448c9a7568f9384321578","type":"GO_TERM","name":"peptidyl-lysine 4-dioxygenase activity","canonical_id":"go:GO:0106156","description":"\"Catalysis of the reaction: protein L-lysine + 2-oxoglutarate + O2 = protein 4-hydroxy-L-lysine + succinate + CO2.\" [GOC:pde, PMID:24486019, RHEA:57156]","metadata":null},{"id":"e288854dd2fe495b856de41de3ec238e","type":"GO_TERM","name":"peptidyl-lysine 5-dioxygenase activity","canonical_id":"go:GO:0070815","description":"\"Catalysis of the reaction: L-lysyl-[protein] + 2-oxoglutarate + O2 = (5S)-5-hydroxy-L-lysyl-[protein] + succinate + CO2.\" [PMID:19574390, RHEA:58360]","metadata":null},{"id":"95d4400e2f3544afbf4bdffad2d77a30","type":"GO_TERM","name":"peptidyl-lysine N6-acetylation","canonical_id":"go:GO:0018003","description":"\"The acetylation of the peptidyl-lysine of proteins to form the derivative peptidyl-N6-acetyl-L-lysine.\" [RESID:AA0055]","metadata":null},{"id":"95d5621c1c55478782a87cbdafaec25d","type":"GO_TERM","name":"peptidyl-lysine N6-myristoyltransferase activity","canonical_id":"go:GO:0018030","description":"\"Catalysis of the transfer of a myristoyl group to the N6 nitrogen atom on a lysine residue of a peptide or protein molecule.\" [GOC:mah, PMID:1402651]","metadata":null},{"id":"4c13ee4f66db413ab4ce2ed55e0aa245","type":"GO_TERM","name":"peptidyl-lysine N6-palmitoyltransferase activity","canonical_id":"go:GO:0018031","description":"\"Catalysis of the transfer of a palmitoyl group to the N6 nitrogen atom on a lysine residue of a peptide or protein molecule.\" [GOC:mah, PMID:29074776]","metadata":null},{"id":"1f9e3b0eb498422c8fdba74623d0e2aa","type":"GO_TERM","name":"peptidyl-lysine acetylation","canonical_id":"go:GO:0018394","description":"\"The acetylation of peptidyl-lysine.\" [GOC:mah]","metadata":null},{"id":"dc76f897b57d4abf89a9b2fd1d876f8e","type":"GO_TERM","name":"peptidyl-lysine butyrylation","canonical_id":"go:GO:0140067","description":"\"The butyrylation of a lysine residue in a protein. Butyryl is the univalent radical C3H7COO- derived from butyric acid.\" [PMID:27105113, Wikipedia:butyryl]","metadata":null},{"id":"22923c62e47548188b527e2f57253a8d","type":"GO_TERM","name":"peptidyl-lysine crotonylation","canonical_id":"go:GO:0140066","description":"\"The crotonylation of a lysine residue in a protein. Crotonyl is the univalent radical CH3-CH=CH-CO- derived from crotonic acid.\" [PMID:25818647, Wikipedia:crotonyl]","metadata":null},{"id":"40e757c2a06941a0a6475c65f79de6d7","type":"GO_TERM","name":"peptidyl-lysine deacetylation","canonical_id":"go:GO:0034983","description":"\"The removal of an acetyl group from an acetylated lysine residue in a peptide or protein.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"be8d091a070148f2a221caf31e6efaf4","type":"GO_TERM","name":"peptidyl-lysine deglycation","canonical_id":"go:GO:0036528","description":"\"The removal of a sugar or dicarbonyl from a lysine residue of a glycated protein.\" [GOC:bf, GOC:PARL, PMID:14568004, PMID:25416785]","metadata":null},{"id":"4f86c276178d4e0095f408c6a39bc5e1","type":"GO_TERM","name":"peptidyl-lysine demalonylation","canonical_id":"go:GO:0036047","description":"\"The process of removing a malonyl group (CO-CH2-CO) from an malonylated lysine residue in a peptide or protein.\" [GOC:sp, PMID:22076378]","metadata":null},{"id":"f13767bd6336410884f4ff0f6c810fdb","type":"GO_TERM","name":"peptidyl-lysine desuccinylation","canonical_id":"go:GO:0036049","description":"\"The removal of a succinyl group (CO-CH2-CH2-CO) from a succinylated lysine residue in a peptide or protein.\" [GOC:sp, PMID:22076378]","metadata":null},{"id":"d716c28b4dac41479ed50873c12c16f2","type":"GO_TERM","name":"peptidyl-lysine dimethylation","canonical_id":"go:GO:0018027","description":"\"The methylation of peptidyl-lysine to form peptidyl-N6,N6-dimethyl-L-lysine.\" [RESID:AA0075]","metadata":null},{"id":"97f9816c101b4407aad339fa51474eba","type":"GO_TERM","name":"peptidyl-lysine glutarylation","canonical_id":"go:GO:0106227","description":"\"The glutarylation of a lysine residue in a protein.\" [GOC:sp, PMID:31542297]","metadata":null},{"id":"9cc4af9179cc4080ba2cd98adc9adc7b","type":"GO_TERM","name":"peptidyl-lysine hydroxylation","canonical_id":"go:GO:0017185","description":"\"The hydroxylation of peptidyl-lysine to form peptidyl-hydroxylysine.\" [GOC:ai]","metadata":null},{"id":"b4492156273e49af97b80bd3ba4b56e7","type":"GO_TERM","name":"peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine","canonical_id":"go:GO:0018395","description":"\"The hydroxylation of peptidyl-lysine to peptidyl-5-hydroxy-L-lysine.\" [RESID:AA0028]","metadata":null},{"id":"ac677b1e05b84d6d91d2db2e010b4a81","type":"GO_TERM","name":"peptidyl-lysine methylation","canonical_id":"go:GO:0018022","description":"\"The methylation of peptidyl-lysine to form either the mono-, di- or trimethylated derivative.\" [GOC:ai]","metadata":null},{"id":"965f85db0ec54d1c9451fd061ffadd81","type":"GO_TERM","name":"peptidyl-lysine modification","canonical_id":"go:GO:0018205","description":"\"The modification of peptidyl-lysine.\" [GOC:curators]","metadata":null},{"id":"db6ad63e6db147d4bdf6bd1a7592ffbf","type":"GO_TERM","name":"peptidyl-lysine monomethylation","canonical_id":"go:GO:0018026","description":"\"The methylation of peptidyl-lysine to form peptidyl-N6-methyl-L-lysine.\" [RESID:AA0076]","metadata":null},{"id":"bc70209b6d4b44a9b73b4156ccb4e616","type":"GO_TERM","name":"peptidyl-lysine oxidation","canonical_id":"go:GO:0018057","description":"\"The oxidation of the terminal amino-methylene groups of peptidyl-L-lysine or peptidyl-5-hydroxy-L-lysine to aldehyde groups to form allysine or hydroxyallysine residues, respectively; these are intermediates in the formation of covalent cross-links between adjacent polypeptide chains in proteins such as collagens.\" [ISBN:0198547684, RESID:AA0121]","metadata":null},{"id":"8aa6adf5c0e445d8a86afd91e8a3cb1a","type":"GO_TERM","name":"peptidyl-lysine propionylation","canonical_id":"go:GO:0061921","description":"\"The propionylation of peptidyl-lysine.\" [PMID:17267393]","metadata":null},{"id":"792a9467a7384ba8a21710ac12d2cadb","type":"GO_TERM","name":"peptidyl-lysine trimethylation","canonical_id":"go:GO:0018023","description":"\"The methylation of peptidyl-lysine to form peptidyl-N6,N6,N6-trimethyl-L-lysine.\" [RESID:AA0074]","metadata":null},{"id":"4928f9b78ed942a4b91c775c6eee2388","type":"GO_TERM","name":"peptidyl-methionine modification","canonical_id":"go:GO:0018206","description":"\"The modification of peptidyl-methionine.\" [GOC:curators]","metadata":null},{"id":"5c9c88e9fd9d4ec2a74cde78289fd647","type":"GO_TERM","name":"peptidyl-phenylalanine modification","canonical_id":"go:GO:0018207","description":"\"The modification of peptidyl-phenylalanine.\" [GOC:curators]","metadata":null},{"id":"c6ba23507672450cb7013dfd80146296","type":"GO_TERM","name":"peptidyl-proline 3-dioxygenase activity","canonical_id":"go:GO:0031544","description":"\"Catalysis of the reaction: peptidyl L-proline + 2-oxoglutarate + O2 = peptidyl trans-3-hydroxy-L-proline + succinate + CO2.\" [GOC:mah]","metadata":null},{"id":"38836ff7749246f796fed1fce359a740","type":"GO_TERM","name":"peptidyl-proline 4-dioxygenase activity","canonical_id":"go:GO:0031545","description":"\"Catalysis of the reaction: peptidyl L-proline + 2-oxoglutarate + O2 = peptidyl trans-4-hydroxy-L-proline + succinate + CO2.\" [GOC:mah]","metadata":null},{"id":"46b07288478c491db84aff71f11b2722","type":"GO_TERM","name":"peptidyl-proline 4-dioxygenase binding","canonical_id":"go:GO:0098650","description":"\"Binding to a peptidyl-proline 4-dioxygenase.\" [GOC:dos, GOC:kvm]","metadata":null},{"id":"c1dd553cafa64f3da91ff48778fa7d6c","type":"GO_TERM","name":"peptidyl-proline di-hydroxylation","canonical_id":"go:GO:0018188","description":"\"The modification of peptidyl-proline to form trans-2,3-cis-3,4-dihydroxy-L-proline.\" [RESID:AA0282]","metadata":null},{"id":"c39e2f1745534224aa9300d7dbfcf98a","type":"GO_TERM","name":"peptidyl-proline dioxygenase activity","canonical_id":"go:GO:0031543","description":"\"Catalysis of the reaction: peptidyl L-proline + 2-oxoglutarate + O2 = peptidyl hydroxy-L-proline + succinate + CO2.\" [GOC:mah, GOC:vw, PMID:24550447, PMID:24550462]","metadata":null},{"id":"11aeb84f419e4bd3b4162bc5f50facc3","type":"GO_TERM","name":"peptidyl-proline hydroxylation","canonical_id":"go:GO:0019511","description":"\"The hydroxylation of peptidyl-proline to form peptidyl-hydroxyproline.\" [GOC:mah]","metadata":null},{"id":"ae1de917beef41d381239a81e89a9ee8","type":"GO_TERM","name":"peptidyl-proline hydroxylation to 3-hydroxy-L-proline","canonical_id":"go:GO:0018400","description":"\"The modification of peptidyl-proline to form 3-hydroxy-L-proline; catalyzed by procollagen-proline 3-dioxygenase.\" [RESID:AA0029]","metadata":null},{"id":"e8dffce40dfa40ee911bb67d21c6fbe9","type":"GO_TERM","name":"peptidyl-proline hydroxylation to 4-hydroxy-L-proline","canonical_id":"go:GO:0018401","description":"\"The modification of peptidyl-proline to form 4-hydroxy-L-proline; catalyzed by procollagen-proline,2-oxoglutarate-4-dioxygenase.\" [RESID:AA0030]","metadata":null},{"id":"5d2f55a9fac54614ad6661295bfd8ecd","type":"GO_TERM","name":"peptidyl-proline modification","canonical_id":"go:GO:0018208","description":"\"The modification of peptidyl-proline.\" [GOC:curators]","metadata":null},{"id":"9e57be22e3174c4b863e23a816a42bce","type":"GO_TERM","name":"peptidyl-prolyl cis-trans isomerase activity","canonical_id":"go:GO:0003755","description":"\"Catalysis of the reaction: peptidyl-proline (omega=180) = peptidyl-proline (omega=0).\" [EC:5.2.1.8]","metadata":null},{"id":"c88e9cdee1164f939c2be030ff87fa6f","type":"GO_TERM","name":"peptidyl-serine ADP-deribosylation","canonical_id":"go:GO:0140290","description":"\"The removal of ADP-ribose from ADP-ribosylserine.\" [PMID:28650317, PMID:29234005]","metadata":null},{"id":"e7c5410837a342c8b42d8a71c260207a","type":"GO_TERM","name":"peptidyl-serine acetylation","canonical_id":"go:GO:0030920","description":"\"The acetylation of peptidyl-serine.\" [GOC:mah]","metadata":null},{"id":"b927dcca9b9d49339d7b4a28c3ad3b4e","type":"GO_TERM","name":"peptidyl-serine autophosphorylation","canonical_id":"go:GO:0036289","description":"\"The phosphorylation by a protein of one or more of its own serine amino acid residues, or a serine residue on an identical protein.\" [GOC:pm]","metadata":null},{"id":"f4156a2c3b024541b9503ed0ef3ce5ed","type":"GO_TERM","name":"peptidyl-serine dephosphorylation","canonical_id":"go:GO:0070262","description":"\"The removal of phosphoric residues from peptidyl-O-phospho-L-serine to form peptidyl-serine.\" [GOC:bf]","metadata":null},{"id":"dc186b2e429e48b3bc284d739e53fb38","type":"GO_TERM","name":"peptidyl-serine octanoylation","canonical_id":"go:GO:0018191","description":"\"The octanoylation of peptidyl-serine to form peptidyl-O3-octanoyl-L-serine, typical of the protein ghrelin.\" [PMID:10604470, RESID:AA0290]","metadata":null},{"id":"735a48c3d4604e8596e012de74eb2d10","type":"GO_TERM","name":"peptidyl-serine phosphopantetheinylation","canonical_id":"go:GO:0018070","description":"\"The phosphopantetheinylation of peptidyl-serine to form peptidyl-O-phosphopantetheine-L-serine.\" [RESID:AA0150]","metadata":null},{"id":"75d1072304464beab244dbe40346777f","type":"GO_TERM","name":"peptidyl-serine phosphorylation","canonical_id":"go:GO:0018105","description":"\"The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine.\" [RESID:AA0037]","metadata":null},{"id":"c4aed7dd54ac4714ab4f951965809ef1","type":"GO_TERM","name":"peptidyl-tRNA hydrolase activity","canonical_id":"go:GO:0004045","description":"\"Catalysis of the reaction: an N-acyl-L-alpha-aminoacyl-tRNA + H2O = an N-acyl-L-amino acid + a tRNA + H+.\" [RHEA:54448]","metadata":null},{"id":"1da0b309b6774463ab35ee64af4abf68","type":"GO_TERM","name":"peptidyl-threonine acetylation","canonical_id":"go:GO:0120257","description":"\"The acetylation of peptidyl-threonine.\" [GOC:krc, PMID:16728640, PMID:22802624]","metadata":null},{"id":"0d289e90d19944489ba4fef437ab3fdd","type":"GO_TERM","name":"peptidyl-threonine autophosphorylation","canonical_id":"go:GO:1990443","description":"\"The phosphorylation by a protein of one or more of its own threonine amino acid residues, or a threonine residue on an identical protein.\" [PMID:7803855]","metadata":null},{"id":"ec86f5a9936a44ee9afac7ec93270019","type":"GO_TERM","name":"peptidyl-threonine dephosphorylation","canonical_id":"go:GO:0035970","description":"\"The removal of phosphoric residues from peptidyl-O-phospho-L-threonine to form peptidyl-threonine.\" [GOC:bf]","metadata":null},{"id":"b50bcea37fb240518c9d02c8589a4147","type":"GO_TERM","name":"peptidyl-threonine phosphorylation","canonical_id":"go:GO:0018107","description":"\"The phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine.\" [RESID:AA0038]","metadata":null},{"id":"cf13e64beeeb4117a3e36395a5862be9","type":"GO_TERM","name":"peptidyl-tyrosine autophosphorylation","canonical_id":"go:GO:0038083","description":"\"The phosphorylation by a protein of one or more of its own tyrosine amino acid residues, or a tyrosine residue on an identical protein.\" [PMID:10037737, PMID:10068444, PMID:10940390]","metadata":null},{"id":"c9641a8a9e914267ab3c1f2ca03ed6be","type":"GO_TERM","name":"peptidyl-tyrosine dephosphorylation","canonical_id":"go:GO:0035335","description":"\"The removal of phosphoric residues from peptidyl-O-phospho-tyrosine to form peptidyl-tyrosine.\" [GOC:bf]","metadata":null},{"id":"6880aeb6e351424e98978d2707f49492","type":"GO_TERM","name":"peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity","canonical_id":"go:GO:1990264","description":"\"Any peptidyl-tyrosine dephosphorylation that is involved in inactivation of protein kinase activity.\" [PMID:7501024]","metadata":null},{"id":"7db5d901f9dd416e908c4ddfd7a15f88","type":"GO_TERM","name":"peptidyl-tyrosine hydroxylation","canonical_id":"go:GO:0018336","description":"\"The hydroxylation of peptidyl-tyrosine to form peptidyl-dihydroxyphenylalanine.\" [GOC:ai]","metadata":null},{"id":"1c056c24d7c84fc8b4cdbc70e66619ff","type":"GO_TERM","name":"peptidyl-tyrosine phosphorylation","canonical_id":"go:GO:0018108","description":"\"The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine.\" [RESID:AA0039]","metadata":null},{"id":"be004e42ef5e477d83b299ad9d2ea3b0","type":"GO_TERM","name":"peptidyl-tyrosine sulfation","canonical_id":"go:GO:0006478","description":"\"The sulfation of peptidyl-tyrosine residues to form peptidyl-O4'-sulfo-L-tyrosine.\" [RESID:AA0172]","metadata":null},{"id":"42a18da0232a4bce9e7519bbf991d189","type":"GO_TERM","name":"peptidylamidoglycolate lyase activity","canonical_id":"go:GO:0004598","description":"\"Catalysis of the reaction: peptidylamidoglycolate = peptidyl amide + glyoxylate.\" [EC:4.3.2.5]","metadata":null},{"id":"485ba0e2e85e4a4dbde153121c28deb2","type":"GO_TERM","name":"peptidylglycine monooxygenase activity","canonical_id":"go:GO:0004504","description":"\"Catalysis of the reaction: peptidyl-glycine + ascorbate + O2 = peptidyl(2-hydroxyglycine) + dehydroascorbate + H2O.\" [EC:1.14.17.3]","metadata":null},{"id":"172aab2bbaf54d28b75cb9e8c84f14fe","type":"GO_TERM","name":"peptidyltransferase activity","canonical_id":"go:GO:0000048","description":"\"Catalysis of the reaction: peptidyl-tRNA(1) + aminoacyl-tRNA(2) = tRNA(1) + peptidylaminoacyl-tRNA(2). This reaction is catalyzed by a ribozyme.\" [EC:2.3.2.12, PMID:11433365, PMID:9242921]","metadata":null},{"id":"ae99eaf68534440894b7bcd80384f9dc","type":"DRUG","name":"peramivir","canonical_id":"mesh:C414210","description":null,"metadata":null},{"id":"2f5ab01aa6754046bd7e912d7fda1ab2","type":"DRUG","name":"perampanel","canonical_id":"mesh:C551441","description":null,"metadata":null},{"id":"04333da17ca948cea492c67e6148826d","type":"GO_TERM","name":"perception of rate of movement","canonical_id":"go:GO:0019232","description":"\"The series of events by which an organism senses the speed and direction of movement of the body and its parts.\" [GOC:mah]","metadata":null},{"id":"13ffed82685e438bbc6247b1b280b573","type":"GO_TERM","name":"perception of static position","canonical_id":"go:GO:0019231","description":"\"The perception of the orientation of different parts of the body with respect to one another.\" [ISBN:072168677X]","metadata":null},{"id":"0b2c47fb313a4b4093109cac00f9151a","type":"GO_TERM","name":"peregrinol diphosphate synthase activity","canonical_id":"go:GO:0106238","description":"\"Catalysis of the reaction:peregrinol diphosphate = all-trans-geranylgeranyl diphosphate + H2O.\" [GOC:emb, PMID:24990389, PMID:29315936, RHEA:54652]","metadata":null},{"id":"96f6789d1d5947ed9becedfc0f710ebb","type":"DISEASE","name":"perennial allergic rhinitis","canonical_id":"mondo:0024332","description":null,"metadata":null},{"id":"767ad2341b9e4efd87c603173354f514","type":"GO_TERM","name":"perforant pathway to dendrate granule cell synapse","canonical_id":"go:GO:0140240","description":"\"A neuron to neuron synapse of a pyramidal neuron in the entorhinal cortex onto a granule cell in the dentate gyrus of the hippocampus.\" [PMID:22727665, PMID:29199135]","metadata":null},{"id":"9a53c74ce3dc47e89affda62bc43d493","type":"GO_TERM","name":"perforation plate","canonical_id":"go:GO:1990073","description":"\"A cell wall part that is the part of a wall of a vessel member and bears one or more openings (perforations).\" [GOC:PO_curators, ISBN:0471245194]","metadata":null},{"id":"95aa84d164b348c1934c6acc006db7df","type":"GO_TERM","name":"perforin production","canonical_id":"go:GO:0035944","description":"\"The appearance of a perforin protein due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rv]","metadata":null},{"id":"b03504f5d2f741c29abe2f524eb699d8","type":"DRUG","name":"pergolide","canonical_id":"mesh:D010479","description":null,"metadata":null},{"id":"40d0772bc4364bb7b8ca385cd52376ed","type":"GO_TERM","name":"peri-centrosomal recycling endosome","canonical_id":"go:GO:0098832","description":"\"A recycling endosome that is organized around the microtubule organizing center, close to the nucleus. This is the main recycling endosome of most cells. It receives input from the Golgi as well as recycled molecules from early endosomes.\" [PMID:19696797, PMID:20820847]","metadata":null},{"id":"e4259a24659d465c99189e945c0b3a3c","type":"GO_TERM","name":"perianth development","canonical_id":"go:GO:0090428","description":"\"The process whose specific outcome is the progression of the perianth over time, from its formation to the mature structure. The perianth is a collective phyllome structure composed of two or more petals, sepals, or tepals.\" [GOC:tb, PO:0009058]","metadata":null},{"id":"56cb1c8fe04c4142974b3bc8df94e0d4","type":"GO_TERM","name":"periarbuscular membrane","canonical_id":"go:GO:0085042","description":"\"A host-derived membrane surrounding the symbiont arbuscule during symbiosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"adc627f80fe74454ad6d77e2c0a59fc2","type":"GO_TERM","name":"peribacteroid fluid","canonical_id":"go:GO:0043662","description":"\"The soluble material inside the peribacteroid membrane, but outside of the bacteroid, within a bacteroid-containing symbiosome.\" [GOC:cc]","metadata":null},{"id":"0437bc4ef06a436a8c55119deac4a165","type":"GO_TERM","name":"peribacteroid membrane","canonical_id":"go:GO:0043661","description":"\"A membrane that surrounds one or more bacteroids (such as nitrogen-fixing bacteroids within legume root nodule cells).\" [GOC:cc]","metadata":null},{"id":"99a048e1a4134c019df13d4f49bf1a39","type":"GO_TERM","name":"pericanalicular vesicle","canonical_id":"go:GO:0033675","description":"\"A membrane-bounded vesicle found near the apical, or pericanalicular, membrane of a hepatocyte; contains proteins involved in bile salt transport and other fluid and solute transport processes.\" [PMID:15763347, PMID:9790571]","metadata":null},{"id":"1988d7ea20774038bb2f3fdc7ccc9110","type":"GO_TERM","name":"pericardial nephrocyte differentiation","canonical_id":"go:GO:0061320","description":"\"The process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of a pericardial nephrocyte. A pericardial nephrocyte is an insect renal cell that filters hemolymph and is found with other pericardial nephrocytes in two rows flanking the dorsal vessel. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.\" [CL:0000474, GOC:dph, GOC:mtg_kidney_jan10, GOC:sart, PMID:19783135]","metadata":null},{"id":"f9b1fc0fcb004b4e91e0e77fecd56f27","type":"DISEASE","name":"pericarditis","canonical_id":"mondo:0005904","description":null,"metadata":null},{"id":"63aa3591bd7a4399bf8076b101082587","type":"GO_TERM","name":"pericardium development","canonical_id":"go:GO:0060039","description":"\"The process whose specific outcome is the progression of the pericardium over time, from its formation to the mature structure. The pericardium is a double-walled sac that contains the heart and the roots of the aorta, vena cava and the pulmonary artery.\" [GOC:dph, GOC:rph, PMID:15138308, PMID:16376438]","metadata":null},{"id":"b775d06ae8d64b97bcd21c7a2569189e","type":"GO_TERM","name":"pericardium morphogenesis","canonical_id":"go:GO:0003344","description":"\"The process in which the anatomical structure of the pericardium is generated and organized.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"63a674fc4dd545639485db8e7c591933","type":"GO_TERM","name":"pericellular basket","canonical_id":"go:GO:1990030","description":"\"Ramification of basket cell axon surrounding cell bodies, forming the characteristic pericellular baskets from which the cell class derives its name.\" [NIF_Subcellular:sao413722576]","metadata":null},{"id":"2b3cea159e61417697d2bc878ec4feca","type":"GO_TERM","name":"pericentric heterochromatin","canonical_id":"go:GO:0005721","description":"\"Heterochromatin that is located adjacent to the CENP-A rich centromere 'central core' and characterized by methylated H3 histone at lysine 9 (H3K9me2/H3K9me3).\" [PMID:12019236, PMID:20206496, PMID:21437270, PMID:22729156, PMID:9413993]","metadata":null},{"id":"b9e4d29c3c06428aa4165840b51645bc","type":"GO_TERM","name":"pericentric heterochromatin formation","canonical_id":"go:GO:0031508","description":"\"The compaction of chromatin located adjacent to the CENP-A rich centromere 'central core' and characterized by methylation of histone H3K9, into heterochromatin, resulting in the repression of transcription at pericentric DNA.\" [GOC:mah, PMID:14612388, PMID:20206496, PMID:22729156]","metadata":null},{"id":"28ab1841a3734ec3ba239cd8a2d6ef95","type":"GO_TERM","name":"pericentriolar material","canonical_id":"go:GO:0000242","description":"\"A network of small fibers that surrounds the centrioles in cells; contains the microtubule nucleating activity of the centrosome.\" [GOC:clt, ISBN:0815316194]","metadata":null},{"id":"16f3d8f086664f55b1b02635c020efe6","type":"GO_TERM","name":"perichondral bone morphogenesis","canonical_id":"go:GO:0061974","description":"\"The process in which bones are generated and organized as a result of the conversion of initial connective tissue surrounding cartilage into bone.\" [PMID:21901110]","metadata":null},{"id":"f483925012aa47d3a3760841fd975226","type":"GO_TERM","name":"perichondral ossification","canonical_id":"go:GO:0036073","description":"\"Intramembranous ossification from the surface of a cartilage element as the perichondrium becomes a periosteum, without replacement of cartilage.\" [GO_REF:0000034]","metadata":null},{"id":"481a2bb7e34e411fb832b0a600167c3b","type":"GO_TERM","name":"perichromatin fibrils","canonical_id":"go:GO:0005726","description":"\"Structures of variable diameter visible in the nucleoplasm by electron microscopy, mainly observed near the border of condensed chromatin. The fibrils are enriched in RNA, and are believed to be sites of pre-mRNA splicing and polyadenylylation representing the in situ form of nascent transcripts.\" [PMID:14731598]","metadata":null},{"id":"5b5a5461482543c6b81a7941a9fd65bf","type":"GO_TERM","name":"periciliary membrane compartment","canonical_id":"go:GO:1990075","description":"\"A plasma membrane region adjacent to the base of eukaryotic cilia and flagella that is enriched in endocytosis-associated proteins and vesicles and that appears to regulate ciliary membrane homeostasis.\" [GOC:cilia, GOC:dr, GOC:krc, PMID:22342749]","metadata":null},{"id":"ec0c07a52da54794bd233f15742e05ae","type":"GO_TERM","name":"periclinal cell division","canonical_id":"go:GO:0090511","description":"\"A cell division process where the division plane is parallel to the surface of the organ. It creates a new cell layer or cell file.\" [GOC:tair_curators, PMID:21391814]","metadata":null},{"id":"7f67b004afa94b51a3f73fc04d648ac5","type":"GO_TERM","name":"pericyte cell differentiation","canonical_id":"go:GO:1904238","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a pericyte cell.\" [GO_REF:0000086, GOC:dph, GOC:TermGenie, PMID:23868830]","metadata":null},{"id":"600cd0c197eb45bd895ee67b67331d4e","type":"GO_TERM","name":"pericyte cell migration","canonical_id":"go:GO:1905351","description":"\"The orderly movement of a pericyte cell from one site to another.\" [GO_REF:0000091, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:26268439]","metadata":null},{"id":"fb5b64516c9f4a02824d6679df494a70","type":"GO_TERM","name":"perikaryon","canonical_id":"go:GO:0043204","description":"\"The portion of the cell soma (neuronal cell body) that excludes the nucleus.\" [GOC:jl]","metadata":null},{"id":"6cb4496b56174079b024ea7dae87f69d","type":"GO_TERM","name":"perillic acid-CoA ligase (AMP-forming) activity","canonical_id":"go:GO:0052686","description":"\"Catalysis of the reaction: perillic acid + CoA-SH + ATP = H2O + AMP + diphosphate + perillyl-CoA.\" [KEGG_REACTION:R06368, PMID:24952578]","metadata":null},{"id":"e92a54ad18284074a5ba91495bbc7521","type":"GO_TERM","name":"perillyl-alcohol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018457","description":"\"Catalysis of the reaction: NAD+ + perillyl alcohol = H+ + NADH + perillyl aldehyde.\" [EC:1.1.1.144, RHEA:10664]","metadata":null},{"id":"4e90030ebb4f40d59905fb2b3f1319aa","type":"DRUG","name":"perindopril","canonical_id":"gtopdb:6367","description":null,"metadata":null},{"id":"475a94aa0a5b493f834f5657d6738d33","type":"COMBINATION_TREATMENT","name":"perindopril + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-f803fd5620977b2e","description":null,"metadata":null},{"id":"e7fad9631e0046199fc074669196c993","type":"COMBINATION_TREATMENT","name":"perindopril + zofenopril","canonical_id":"ctgov_combo:ctgov-combo-0369acc5fc6effb5","description":null,"metadata":null},{"id":"e6c723d69c5d4b61ac484a35bb54d011","type":"DRUG","name":"perindoprilat","canonical_id":"gtopdb:6373","description":null,"metadata":null},{"id":"8514a023819b49a09cfd6758c1b57e12","type":"GO_TERM","name":"perineurial glial growth","canonical_id":"go:GO:0042066","description":"\"Glial cell growth that occurs in the perineurium, a cell layer that ensheaths projections of peripheral nerves, such as motor axons.\" [GOC:mah, PMID:11517334, PMID:18176560]","metadata":null},{"id":"667d36c9253f4d05a0236ed6b5c522a1","type":"GO_TERM","name":"perineuronal net","canonical_id":"go:GO:0072534","description":"\"A dense extracellular matrix (ECM) that forms around many neuronal cell bodies and dendrites late in development and is responsible for synaptic stabilization in the adult brain.\" [GOC:sl, PMID:18364019]","metadata":null},{"id":"b2ef602f6471459583bc69679bc12477","type":"GO_TERM","name":"perinuclear endoplasmic reticulum","canonical_id":"go:GO:0097038","description":"\"The portion of endoplasmic reticulum, the intracellular network of tubules and cisternae, that occurs near the nucleus. The lumen of the perinuclear endoplasmic reticulum is contiguous with the nuclear envelope lumen (also called perinuclear space), the region between the inner and outer nuclear membranes.\" [GOC:bf, GOC:mah, GOC:mcc, GOC:pr, GOC:vw]","metadata":null},{"id":"d1d30b5c57b040a790388f159a514e73","type":"GO_TERM","name":"perinuclear endoplasmic reticulum lumen","canonical_id":"go:GO:0099020","description":"\"The volume enclosed by the membranes of the perinuclear endoplasmic reticulum.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"fb7d315286e24e6994ecef6d73b916d5","type":"GO_TERM","name":"perinuclear endoplasmic reticulum membrane","canonical_id":"go:GO:1990578","description":"\"The membrane of the perinuclear endoplasmic reticulum, which is the portion of endoplasmic reticulum, the intracellular network of tubules and cisternae, that occurs near the nucleus.\" [PMID:25454947]","metadata":null},{"id":"ddbf0de67b3e4dd9a1e4afa1bd3690e2","type":"GO_TERM","name":"perinuclear region of cytoplasm","canonical_id":"go:GO:0048471","description":"\"Cytoplasm situated near, or occurring around, the nucleus.\" [GOC:jid]","metadata":null},{"id":"d9a12ba8e7de471a81e7d1f54c7e60a0","type":"GO_TERM","name":"perinuclear theca","canonical_id":"go:GO:0033011","description":"\"A condensed cytoplasmic structure that covers the nucleus of mammalian spermatozoa except for a narrow zone around the insertion of the tail. It shows two distinct regions, a subacrosomal layer and, continuing caudally beyond the acrosomic system, the postacrosomal sheath. The perinuclear theca has been considered a cytoskeletal scaffold responsible for maintaining the overall architecture of the mature sperm head; however, recent studies indicate that the bulk of its constituent proteins are not traditional cytoskeletal proteins but rather a variety of cytosolic proteins.\" [PMID:17289678, PMID:8025156]","metadata":null},{"id":"dae047fe13144b02baad681ddb7b6a49","type":"GO_TERM","name":"perinucleolar chromocenter","canonical_id":"go:GO:0010370","description":"\"A chromocenter adjacent to the nucleolus.\" [PMID:15805479]","metadata":null},{"id":"da885c0ab1d644cd8e491dd45b8c2be4","type":"GO_TERM","name":"perinucleolar compartment","canonical_id":"go:GO:0097356","description":"\"The perinucleolar compartment (PNC) is a subnuclear structure associated with, but structurally distinct from, the nucleolus. The PNC contains large amounts of the heterogeneous nuclear ribonucleoprotein complex (hnRNP) called hnRNP 1 (PTB). Many RNA binding proteins as well as RNA polymerase III transcripts are highly enriched in this compartment. PTB and pol III transcripts are required for the integrity of the PNC.\" [GOC:vw, PMID:21385875, Wikipedia:Perinucleolar_compartment]","metadata":null},{"id":"4d588a079887466db0d3044810db5f9f","type":"GO_TERM","name":"periodic partitioning","canonical_id":"go:GO:0007365","description":"\"The regionalization process that divides the spatial regions of an embryo into serially repeated regions.\" [GOC:dph, GOC:isa_complete, GOC:ma]","metadata":null},{"id":"3b76c7e6edd54c1298d7b3a925811cfc","type":"GO_TERM","name":"periodic partitioning by pair rule gene","canonical_id":"go:GO:0007366","description":"\"Allocation of cells to parasegments in the embryo, through the action of overlapping series of pair rule gene activities.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0632030488, ISBN:0879694238]","metadata":null},{"id":"2576b7f77651476ea5782b20524abd8d","type":"DISEASE","name":"periodontitis","canonical_id":"mondo:0005076","description":null,"metadata":null},{"id":"9fcb51c8814b44afb76c5ee5f7d71ad1","type":"DISEASE","name":"periodontitis","canonical_id":"mesh:D010518","description":null,"metadata":null},{"id":"41ba99db0afc402ea43a94f5814edcfa","type":"DISEASE","name":"periodontitis, aggressive","canonical_id":"mondo:0980757","description":null,"metadata":null},{"id":"87282f22801545f4adf836a9d8159c61","type":"DISEASE","name":"periodontitis, aggressive 1","canonical_id":"mondo:0008226","description":null,"metadata":null},{"id":"82244c2c06554899a9908795619b94ca","type":"GO_TERM","name":"periphagosomal region of cytoplasm","canonical_id":"go:GO:1990783","description":"\"Cytoplasm situated near, or occurring around, a phagosome.\" [PMID:18250451]","metadata":null},{"id":"66c4e49a913e455c832561aa1c462efb","type":"GO_TERM","name":"peripheral B cell anergy","canonical_id":"go:GO:0002453","description":"\"Any process contributing to anergy, a state of functional inactivation that occurs as part of tolerance induction, in peripheral B cells.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"413f65d3a6784691af7b0a2c04efee71","type":"GO_TERM","name":"peripheral B cell deletion","canonical_id":"go:GO:0002454","description":"\"The deletion of B cells by apoptotic process occurring as part of peripheral tolerance induction and B cell selection.\" [GOC:add, GOC:jal, GOC:mtg_apoptosis, ISBN:0781735149]","metadata":null},{"id":"1a018eef32d740de87e103cea472fc7c","type":"GO_TERM","name":"peripheral B cell negative selection","canonical_id":"go:GO:0002356","description":"\"Any process leading to negative selection of B cells in the periphery.\" [GOC:jal]","metadata":null},{"id":"5beb7f698cb6417589d9be1c753227b0","type":"GO_TERM","name":"peripheral B cell positive selection","canonical_id":"go:GO:0002350","description":"\"Any process leading to positive selection of B cells in the periphery. Positive selection is the process in which B or T cells are selected to survive based on signaling through their antigen receptors.\" [GOC:jal]","metadata":null},{"id":"f1236f1d15cb4052a840ee3cb4f81b82","type":"GO_TERM","name":"peripheral B cell receptor editing","canonical_id":"go:GO:0002345","description":"\"The process that takes place mainly in germinal center B cells in which a large number of mutations are generated in the heavy chain and light chain V-region genes and their immediately surrounding introns in order to increase antibody diversity and contribute to affinity maturation.\" [GOC:jal]","metadata":null},{"id":"bc08291bc99a4f598f864adc7d795363","type":"GO_TERM","name":"peripheral B cell selection","canonical_id":"go:GO:0002343","description":"\"Any B cell selection process that occurs in the periphery.\" [GOC:jal]","metadata":null},{"id":"147cfffc915a4d86a5d2f4798cfdf415","type":"GO_TERM","name":"peripheral B cell tolerance induction","canonical_id":"go:GO:0002451","description":"\"Tolerance induction of mature B cells in the peripheral lymphoid tissues: the blood, lymph nodes, spleen, and mucosal-associated lymphoid tissue.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"33bbd02178c347ca86bc3ad2f55189fd","type":"GO_TERM","name":"peripheral T cell tolerance induction","canonical_id":"go:GO:0002458","description":"\"Tolerance induction of T cells in the periphery, in this case, any location in the body other than the thymus.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"3470f871be94431989ac0f4158786280","type":"DISEASE","name":"peripheral T-cell lymphoma, not otherwise specified","canonical_id":"mondo:0004964","description":null,"metadata":null},{"id":"b49a5a6b151b4f8e80905da2aea1f08d","type":"DISEASE","name":"peripheral arterial disease","canonical_id":"mondo:0005386","description":null,"metadata":null},{"id":"2130021215484dbfba9747141ea3e605","type":"GO_TERM","name":"peripheral mammary gland bud epithelial cell differentiation","canonical_id":"go:GO:0060645","description":"\"The process in which a relatively unspecialized epithelial cell of the mammary placode becomes an epithelial cell at the periphery of the mammary gland bud. Cells at the periphery of the bud are larger that those of the surrounding epithelium and are arranged concentrically.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"7539e4112f8e472ebce50e7eb48cb174","type":"GO_TERM","name":"peripheral nervous system axon ensheathment","canonical_id":"go:GO:0032292","description":"\"The process in which a Schwann cell membrane closes around an axon in the peripheral nervous system. This can be a myelinating or a non-myelinating neuron-glial interaction.\" [GOC:dgh]","metadata":null},{"id":"86147c70daa04a68b3b6393f9bfd9676","type":"GO_TERM","name":"peripheral nervous system axon regeneration","canonical_id":"go:GO:0014012","description":"\"The regrowth of axons outside the central nervous system (outside the brain and spinal cord) following an axonal injury.\" [GOC:ef]","metadata":null},{"id":"34e8db9ca8064e05b180b5da0b20c281","type":"GO_TERM","name":"peripheral nervous system development","canonical_id":"go:GO:0007422","description":"\"The process whose specific outcome is the progression of the peripheral nervous system over time, from its formation to the mature structure. The peripheral nervous system is one of the two major divisions of the nervous system. Nerves in the PNS connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands.\" [GOC:curators, UBERON:0000010]","metadata":null},{"id":"84829218f8d3445fbbff608cf95ecb73","type":"GO_TERM","name":"peripheral nervous system myelin formation","canonical_id":"go:GO:0032290","description":"\"The process in which the wraps of cell membrane that constitute myelin are laid down around an axon by Schwann cells in the peripheral nervous system.\" [GOC:dgh]","metadata":null},{"id":"c8a021c161994878bb7884a69189c714","type":"GO_TERM","name":"peripheral nervous system myelin maintenance","canonical_id":"go:GO:0032287","description":"\"The process in which the structure and material content of mature peripheral nervous system myelin is kept in a functional state.\" [GOC:dgh]","metadata":null},{"id":"ebd3c8d64d0c46bb9d47a63d1fd5e2c5","type":"GO_TERM","name":"peripheral nervous system neuron axonogenesis","canonical_id":"go:GO:0048936","description":"\"Generation of a long process from a neuron whose cell body resides in the peripheral nervous system. The axon carries action potential from the cell body towards target cells.\" [GOC:dgh]","metadata":null},{"id":"e7c1cbe1581c4b32984e4c36c7eee4ea","type":"GO_TERM","name":"peripheral nervous system neuron development","canonical_id":"go:GO:0048935","description":"\"The process whose specific outcome is the progression of a neuron whose cell body is located in the peripheral nervous system, from initial commitment of the cell to a neuronal fate, to the fully functional differentiated neuron.\" [GOC:dgh]","metadata":null},{"id":"ae5b19f4924945d690ccc4700adc16c5","type":"GO_TERM","name":"peripheral nervous system neuron differentiation","canonical_id":"go:GO:0048934","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron whose cell body resides in the peripheral nervous system.\" [GOC:dgh]","metadata":null},{"id":"1b269947da4448a49318bda392ad7327","type":"GO_TERM","name":"peripheral nervous system non-myelinated axon ensheathment","canonical_id":"go:GO:0032294","description":"\"The process in which a non-myelinating Schwann cell membrane encircles an axon in the peripheral nervous system. A single non-myelinating Schwann cell will typically associate with multiple axons.\" [GOC:dgh]","metadata":null},{"id":"b87d6bd63e864125870ceaf926f40831","type":"DISEASE","name":"peripheral precocious puberty","canonical_id":"mondo:0015791","description":null,"metadata":null},{"id":"684b9487ebd9403295262a6e9bf3df37","type":"GO_TERM","name":"peripheral region of growth cone","canonical_id":"go:GO:0090725","description":"\"The non-central region or periphery of the migrating motile tip of a growing nerve cell axon or dendrite.\" [GOC:sl, PMID:16260607]","metadata":null},{"id":"2ae71ffa5afb4417b93fbe1144ce4cbe","type":"DISEASE","name":"peripheral resistance to thyroid hormones","canonical_id":"mondo:0019995","description":null,"metadata":null},{"id":"9d1c44c176d54ea9bb9a12a7200b5a8e","type":"GO_TERM","name":"peripheral tolerance induction","canonical_id":"go:GO:0002465","description":"\"Tolerance induction in the peripheral lymphoid tissues: blood, lymph nodes, spleen, and mucosal-associated lymphoid tissues.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"f720d51f1cb44693a9057e06b3ad00ee","type":"GO_TERM","name":"peripheral tolerance induction to nonself antigen","canonical_id":"go:GO:0002464","description":"\"Tolerance induction to nonself antigens in the periphery.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"e553ea47e4e24bf9b18ef4bbd33704c4","type":"GO_TERM","name":"peripheral tolerance induction to self antigen","canonical_id":"go:GO:0002466","description":"\"Tolerance induction to self antigens in the peripheral lymphoid tissues: blood, lymph nodes, spleen, and mucosal-associated lymphoid tissues.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"ecf561d2953442a5b6417669cdac53f0","type":"DISEASE","name":"peripheral vascular disease","canonical_id":"mondo:0005294","description":null,"metadata":null},{"id":"c14c9488955341e2bf2f6e5f9515c394","type":"GO_TERM","name":"periplasmic flagellum","canonical_id":"go:GO:0055040","description":"\"Flagellar filaments located in the periplasmic space; characterized in spirochetes, in which they are essential for shape and motility. Composed of a core surrounded by two sheath layers, the flagella rotate to allow migration of the cell through viscous media, which would not be possible using external flagella.\" [GOC:jid, GOC:rph, PMID:15175283, PMID:1624463]","metadata":null},{"id":"da425bf95f0c4170975b39f0f631dab2","type":"GO_TERM","name":"periplasmic side of cell outer membrane","canonical_id":"go:GO:0031241","description":"\"The leaflet of a outer cell membrane that faces the periplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"b130a26e3e5f416c8ca31dc3a8d4b250","type":"GO_TERM","name":"periplasmic side of plasma membrane","canonical_id":"go:GO:0098567","description":"\"The leaflet of the plasma membrane that faces the periplasm, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"996bf145c785495dad244c865adce861","type":"GO_TERM","name":"periplasmic space","canonical_id":"go:GO:0042597","description":"\"The region between the inner (cytoplasmic) and outer membrane (Gram-negative Bacteria) or cytoplasmic membrane and cell wall (Fungi and Gram-positive Bacteria).\" [GOC:curators, GOC:md]","metadata":null},{"id":"3911b4c4e92345abb5f751d4c8860ef6","type":"GO_TERM","name":"periplasmic space organization","canonical_id":"go:GO:0043580","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the periplasmic space, the region between the inner (cytoplasmic) and outer membrane in Gram-negative bacteria, or the inner membrane and cell wall in fungi.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"d2cc1f65298a44bab834766399bd1cd4","type":"GO_TERM","name":"periplastidial membrane","canonical_id":"go:GO:7770041","description":"\"The lipid bilayer that forms the second outermost membrane of complex plastids in organisms that acquired their plastids through secondary endosymbiosis. The periplastidial membrane is evolutionarily derived from the plasma membrane of the engulfed algal endosymbiont and together with the outer envelope membrane of the plastid defines the periplastidial compartment.\" [PMID:15937721, PMID:27179349, PMID:39383259]","metadata":null},{"id":"76705d3b61e24afaa1c17a998adc579b","type":"GO_TERM","name":"peristalsis","canonical_id":"go:GO:0030432","description":"\"A wavelike sequence of involuntary muscular contraction and relaxation that passes along a tubelike structure, such as the intestine, impelling the contents onwards.\" [ISBN:0198506732]","metadata":null},{"id":"e3778f3476fe4b188e2560640164277b","type":"GO_TERM","name":"peristromal region viral factory","canonical_id":"go:GO:0039721","description":"\"A nuclear viral factory formed at the periphery of the host cell nucleus by Baculoviruses.\" [PMID:18434402, VZ:1951]","metadata":null},{"id":"f6bd493c396e46cc99e468e8011924fd","type":"GO_TERM","name":"perisynaptic extracellular matrix","canonical_id":"go:GO:0098966","description":"\"The portion of the extracellular matrix that lies within the perisynaptic space.\" [GOC:dos]","metadata":null},{"id":"595b658356b84f32a6fba605af322261","type":"GO_TERM","name":"perisynaptic space","canonical_id":"go:GO:0099544","description":"\"The extracellular region immediately adjacent to to a synapse.\" [GOC:dos]","metadata":null},{"id":"a87bf73bcf8141faa24382769adc9406","type":"GO_TERM","name":"perithecium development","canonical_id":"go:GO:0120165","description":"\"The process whose specific outcome is the progression of a perithecium over time, from its formation to the mature structure. Peritheicum is a flask-shaped fruiting body of certain molds and ascomycetous fungi having a pore for the escape of spores. In the ascomycetous fungi such as Neurospora crassa and Sordaria macrospora, these perithecia are formed in the sexual phase and they discharge ascospores through the ostiolum at the tip of the perithecial neck.\" [DOI:10.1007/978-3-642-00286-1_2, PMID:125266, PMID:19547974, PMID:20739093, PMID:25311923]","metadata":null},{"id":"092a4e30727346e289279ef47b66ef85","type":"GO_TERM","name":"perithecium formation","canonical_id":"go:GO:0106154","description":"\"The process of producing flask-shaped fruiting bodies, called perithecia. In the ascomycetous fungi such as Neurospora crassa and Sordaria macrospora, these perithecia are formed in the sexual phase and they discharge ascospores through the ostiolum at the tip of the perithecial neck.\" [DOI:10.1007/978-3-642-00286-1_2, GOC:ach, PMID:19547974, PMID:21134480, PMID:25311923]","metadata":null},{"id":"9e47d94beadb4bde95bbea2f71066986","type":"DISEASE","name":"peritoneal neoplasm","canonical_id":"mondo:0006901","description":null,"metadata":null},{"id":"dbaee584d0d8472f9761c95655f13075","type":"DISEASE","name":"peritoneum cancer","canonical_id":"mondo:0002087","description":null,"metadata":null},{"id":"8bdadf151bf944c59c9d49987a134d0a","type":"GO_TERM","name":"peritoneum development","canonical_id":"go:GO:1904820","description":"\"The process whose specific outcome is the progression of a peritoneum over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:dph, GOC:TermGenie, PMID:15840053]","metadata":null},{"id":"86e71503271e4bed90893d00236a97f6","type":"GO_TERM","name":"perivitelline space","canonical_id":"go:GO:0098595","description":"\"The space between the membrane of an oocyte and a surrounding membranous structure (zona pellucida or perivitelline membrane).\" [GOC:dos]","metadata":null},{"id":"5d10144b4c5642489efde77c83b43454","type":"DISEASE","name":"permanent neonatal diabetes mellitus","canonical_id":"mondo:0100164","description":null,"metadata":null},{"id":"c1dd790ffce7434eae768d0eb00cd887","type":"DISEASE","name":"permanent neonatal diabetes mellitus 1","canonical_id":"mondo:0100165","description":null,"metadata":null},{"id":"a4d5fc94d45248469a57d961564e76e7","type":"GO_TERM","name":"permeabilization of host organelle membrane involved in viral entry into host cell","canonical_id":"go:GO:0039665","description":"\"Induction of organellar membrane permeabilization triggered by an interaction between the host membrane and a membrane-penetration protein associated with a viral capsid. Results in release of the virus contents from an organelle into the host cell cytoplasm.\" [GOC:bf, GOC:jl, UniProtKB-KW:KW-1173, VZ:985]","metadata":null},{"id":"f386f2b29bd64d50a20732a44c337846","type":"DRUG","name":"permethrin","canonical_id":"mesh:D026023","description":null,"metadata":null},{"id":"2382b975d05a4f47bd376d93086b1baa","type":"DRUG","name":"perospirone","canonical_id":"gtopdb:7556","description":null,"metadata":null},{"id":"be593eac464844e9bf9652683ce85b73","type":"DRUG","name":"perospirone","canonical_id":"mesh:C065533","description":null,"metadata":null},{"id":"a57e3eb7af6a4f808c130e580fdf6816","type":"GO_TERM","name":"peroxidase activity","canonical_id":"go:GO:0004601","description":"\"Catalysis of the reaction: a reduced substrate + ROOH = an oxidized substrate + ROH + H2O.\" [PMID:33992367]","metadata":null},{"id":"3adbf05aadc14a35b7ecc683b0aa0ee9","type":"GO_TERM","name":"peroxidase inhibitor activity","canonical_id":"go:GO:0036479","description":"\"Binds to and stops, prevents or reduces the activity of peroxidase.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"47005c90bcdb41a4b115613282e3aaa2","type":"GO_TERM","name":"peroxidase-heme linkage","canonical_id":"go:GO:0018186","description":"\"The covalent linkage of heme to peroxidase.\" [RESID:AA0279, RESID:AA0280]","metadata":null},{"id":"c7b4d5ca44ff4557a074802b3b0d2e4c","type":"GO_TERM","name":"peroxide sensor activity","canonical_id":"go:GO:0140442","description":"\"Binding to hydrogen peroxide (H2O2) and eliciting a change in the protein's activity in response to the intracellular level of that small molecule.\" [PMID:20919928]","metadata":null},{"id":"fdbede6529cf4e7a85622a895c326830","type":"GO_TERM","name":"peroxiredoxin activity","canonical_id":"go:GO:0051920","description":"\"Catalysis of the reaction: [protein]-dithol + ROOH = [protein]-disulfide + H2O + ROH.\" [RHEA:10008]","metadata":null},{"id":"f1d3d830a2d14d9c81710cda92876e66","type":"GO_TERM","name":"peroxisomal importomer complex","canonical_id":"go:GO:1990429","description":"\"A protein complex responsible for transporting proteins into the peroxisomal matrix. An example of this complex is Pex14 found in S. cerevisae which has 9 core components and 12 transient interaction partners.\" [PMID:12667447, PMID:20154681, PMID:22375831]","metadata":null},{"id":"e31c5497dca64e3c95ba017e620daebd","type":"GO_TERM","name":"peroxisomal matrix","canonical_id":"go:GO:0005782","description":"\"The volume contained within the membranes of a peroxisome; in many cells the matrix contains a crystalloid core largely composed of urate oxidase.\" [GOC:curators, ISBN:0815316194]","metadata":null},{"id":"5b491916706f4f3c8f03bd38eca1d3b0","type":"GO_TERM","name":"peroxisomal membrane","canonical_id":"go:GO:0005778","description":"\"The lipid bilayer surrounding a peroxisome.\" [GOC:mah]","metadata":null},{"id":"77b102ac6124450a8f06a13df03564e1","type":"GO_TERM","name":"peroxisomal membrane transport","canonical_id":"go:GO:0015919","description":"\"The directed movement of substances to, from or across the peroxisomal membrane.\" [GOC:ai]","metadata":null},{"id":"62d1f0bc5d6e42178b9ee869baab9bf8","type":"GO_TERM","name":"peroxisomal transport","canonical_id":"go:GO:0043574","description":"\"Transport of substances into, out of or within a peroxisome, a small, membrane-bounded organelle that uses dioxygen (O2) to oxidize organic molecules.\" [GOC:jl]","metadata":null},{"id":"5ee84aff41b34ac6864f38b3d3571c4e","type":"GO_TERM","name":"peroxisomal-mitochondrial contact site","canonical_id":"go:GO:0160189","description":"\"An organelle membrane contact site between peroxisomal membrane and mitochondrial outer membrane.\" [PMID:29684109, PMID:38669296]","metadata":null},{"id":"a67979be2b6f4cffb1185b8416a2a520","type":"GO_TERM","name":"peroxisome","canonical_id":"go:GO:0005777","description":"\"A small organelle enclosed by a single membrane, and found in most eukaryotic cells. Contains peroxidases and other enzymes involved in a variety of metabolic processes including free radical detoxification, lipid catabolism and biosynthesis, and hydrogen peroxide metabolism.\" [GOC:pm, PMID:9302272, UniProtKB-KW:KW-0576]","metadata":null},{"id":"a7099e6b4f49459583b431730d0709b8","type":"GO_TERM","name":"peroxisome fission","canonical_id":"go:GO:0016559","description":"\"The division of a mature peroxisome within a cell to form two or more separate peroxisome compartments.\" [GOC:mah, PMID:11687502, PMID:14754507]","metadata":null},{"id":"7a4fb4dbd7c4423bb7edf0fb6066311a","type":"GO_TERM","name":"peroxisome inheritance","canonical_id":"go:GO:0045033","description":"\"The acquisition of peroxisomes by daughter cells from the mother cell after replication. In Saccharomyces cerevisiae, the number of peroxisomes cells is fairly constant; a subset of the organelles are targeted and segregated to the bud in a highly ordered, vectorial process. Efficient segregation of peroxisomes from mother to bud is dependent on the actin cytoskeleton, and active movement of peroxisomes along actin filaments is driven by the class V myosin motor protein, Myo2p.\" [PMID:11733545]","metadata":null},{"id":"f1d11784a9d04ade83ca6286ac75e498","type":"GO_TERM","name":"peroxisome localization","canonical_id":"go:GO:0060151","description":"\"Any process in which a peroxisome is transported to, and/or maintained in, a specific location. A peroxisome is a small membrane-bounded organelle that uses dioxygen (O2) to oxidize organic molecules.\" [GOC:dph, PMID:16449325]","metadata":null},{"id":"8f6e92be993d4837a4efd1e111b2d675","type":"GO_TERM","name":"peroxisome membrane biogenesis","canonical_id":"go:GO:0016557","description":"\"The process in which a peroxisome membrane is synthesized, aggregates, and bonds together.\" [GOC:mah]","metadata":null},{"id":"f95cf613cdd24be19328f31bedd16c79","type":"GO_TERM","name":"peroxisome organization","canonical_id":"go:GO:0007031","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a peroxisome. A peroxisome is a small, membrane-bounded organelle that uses dioxygen (O2) to oxidize organic molecules.\" [GOC:mah]","metadata":null},{"id":"fb2aab3977894c6dbb171424ef270ce8","type":"GO_TERM","name":"peroxisome proliferator activated receptor binding","canonical_id":"go:GO:0042975","description":"\"Binding to a peroxisome proliferator activated receptor, alpha, beta or gamma.\" [GOC:jl, PMID:12769781]","metadata":null},{"id":"848e6360c11e48f8a8c17437cbe6cd5b","type":"GO_TERM","name":"peroxisome proliferator activated receptor signaling pathway","canonical_id":"go:GO:0035357","description":"\"A nuclear receptor-mediated signaling pathway initiated by a ligand binding to an intracellular peroxisome proliferator activated receptor (alpha, beta or gamma) of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:18221086]","metadata":null},{"id":"194a32066e2a4fdcb3a1158075d4ee9c","type":"GO_TERM","name":"peroxisome signal sequence receptor activity","canonical_id":"go:GO:0000268","description":"\"Binding to a peroxisomal targeting sequence, a short stretch of amino acids found in a protein that acts as a signal to localize the protein to the peroxisome.\" [PMID:20659419]","metadata":null},{"id":"4c8c2f11edeb4d5980965a65d43c60fd","type":"GO_TERM","name":"peroxisome transport along microtubule","canonical_id":"go:GO:0036250","description":"\"The directed movement of a peroxisome along a microtubule, mediated by motor proteins.\" [GOC:pm, PMID:21525035]","metadata":null},{"id":"bb5a633b99bd4986b09e63d56e9c799e","type":"GO_TERM","name":"peroxisome-chloroplast membrane tether activity","canonical_id":"go:GO:7770065","description":"\"The binding activity of a molecule that brings together the peroxisome membrane and the chloroplast membrane, establishing the localization of the peroxisome close to the chloroplast.\" [PMID:17215364]","metadata":null},{"id":"f977cf689b534529846ce406a79f7f92","type":"GO_TERM","name":"peroxisome-endoplasmic reticulum membrane tether activity","canonical_id":"go:GO:0160229","description":"\"The binding activity of a molecule that brings together a peroxisome membrane and an ER membrane, either via membrane lipid binding or by interacting with a membrane protein.\" [PMID:39271061]","metadata":null},{"id":"ab6c4be3c9cf47ada6df716bb1369bfd","type":"GO_TERM","name":"peroxisome-mitochondrion membrane tether activity","canonical_id":"go:GO:0160190","description":"\"The binding activity of a molecule that brings together the peroxisome membrane and the mitochondrial outer membrane, establishing the localization of the peroxisome close to the mitochondrion.\" [PMID:29720625, PMID:38669296]","metadata":null},{"id":"b5b84ca5b94e477d9c65f76d6dd2f666","type":"GO_TERM","name":"peroxynitrite isomerase activity","canonical_id":"go:GO:0062213","description":"\"Catalysis of the reaction: peroxynitrite = nitrate.\" [PMID:30524950, RHEA:63116]","metadata":null},{"id":"ee054adbd66f47a5aec3c2752b14fca6","type":"GO_TERM","name":"peroxynitrite reductase activity","canonical_id":"go:GO:0072541","description":"\"Catalysis of the reaction: [protein]-dithiol + ONOO- = [protein]-disulfide + NO2- + H2O.\" [GOC:rs, PMID:11001062]","metadata":null},{"id":"91ec82b0ba6b45fcbd1311f98f446886","type":"DRUG","name":"perphenazine","canonical_id":"gtopdb:209","description":null,"metadata":null},{"id":"0fb6b009131445828d5c3170a0eaa276","type":"DRUG","name":"perphenazine","canonical_id":"mesh:D010546","description":null,"metadata":null},{"id":"89d3fbb8b030461c91aa20d54a664155","type":"DRUG","name":"perphenazine","canonical_id":"chembl:CHEMBL567","description":null,"metadata":null},{"id":"b6aa63d0b1c74ac8b917dfa31eafebfb","type":"COMBINATION_TREATMENT","name":"perphenazine + propylthiouracil","canonical_id":"ctgov_combo:ctgov-combo-ee7747b15a085acb","description":null,"metadata":null},{"id":"615e63420c374f90a4337a1b7312b394","type":"COMBINATION_TREATMENT","name":"perphenazine + propylthiouracil","canonical_id":"ctgov_combo:ctgov-combo-8e687ac386ee3670","description":null,"metadata":null},{"id":"f3e0e398ab2e4c4da82246833905efad","type":"DRUG","name":"pertuzumab","canonical_id":"gtopdb:5046","description":null,"metadata":null},{"id":"8beafc69d17247d28759c47f0a488ac2","type":"DRUG","name":"pertuzumab","canonical_id":"chembl:CHEMBL2007641","description":null,"metadata":null},{"id":"0ed49155bb4d408cb44a282dcc25d1f3","type":"COMBINATION_TREATMENT","name":"pertuzumab + ramucirumab","canonical_id":"ctgov_combo:ctgov-combo-ec9e975352c65683","description":null,"metadata":null},{"id":"159903a2810d4236b61037545cda5010","type":"COMBINATION_TREATMENT","name":"pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-441f6f1fa9d5286a","description":null,"metadata":null},{"id":"dd9a75b95813404aa1d6e0a7a3ec488b","type":"COMBINATION_TREATMENT","name":"pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-5607345cd128a3dc","description":null,"metadata":null},{"id":"6423391a076342bf882c820e2030b151","type":"COMBINATION_TREATMENT","name":"pertuzumab + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-d145e12178dc65c4","description":null,"metadata":null},{"id":"e0b2e0fd29c74ef6bdfc0691c5f9598a","type":"GO_TERM","name":"petal development","canonical_id":"go:GO:0048441","description":"\"The process whose specific outcome is the progression of the petal over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"a8a246cf802e4c1a89f0064207891c19","type":"GO_TERM","name":"petal epidermis patterning","canonical_id":"go:GO:0080172","description":"\"The regionalization process that regulates the coordinated growth and establishes the non-random spatial arrangement of the cells in the petal epidermis.\" [GOC:tb]","metadata":null},{"id":"92a3d461396f4fcd9f16c3c7c6264900","type":"GO_TERM","name":"petal formation","canonical_id":"go:GO:0048451","description":"\"The process that gives rise to the petal. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid]","metadata":null},{"id":"47a1cd2c3a074e38a6c64ec09985f9aa","type":"GO_TERM","name":"petal morphogenesis","canonical_id":"go:GO:0048446","description":"\"The process in which the anatomical structures of the petal are generated and organized.\" [GOC:curators]","metadata":null},{"id":"8067a2350639457dbbd39d25f1e39a76","type":"GO_TERM","name":"petal structural organization","canonical_id":"go:GO:0048452","description":"\"The process that contributes to the act of creating the structural organization of the petal. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid]","metadata":null},{"id":"a09ec5286c694b31b3c7a6c5fbfb6d10","type":"GO_TERM","name":"petal vascular tissue pattern formation","canonical_id":"go:GO:0080056","description":"\"Vascular tissue pattern formation as it occurs in the petal of vascular plants.\" [PMID:17369435]","metadata":null},{"id":"0514387bca364e029455acef7118ffdd","type":"DRUG","name":"pethidine","canonical_id":"gtopdb:7221","description":null,"metadata":null},{"id":"85185242e92b4e0a825f9e9660d4a0e3","type":"DRUG","name":"pethidine","canonical_id":"mesh:D008614","description":null,"metadata":null},{"id":"32bfcb4457b24865a61823e9f1407867","type":"GO_TERM","name":"petromyzonol sulfotransferase activity","canonical_id":"go:GO:0033873","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + 5alpha-cholane-3alpha,7alpha,12alpha,24-tetrol = 3alpha,7alpha,12alpha-trihydroxy-5alpha-cholan-24-yl sulfate + adenosine 3',5'-diphosphate + H+.\" [EC:2.8.2.31, RHEA:16997]","metadata":null},{"id":"dfca2e4634e54f4abae1205ba7cf727e","type":"DRUG","name":"pexidartinib","canonical_id":"gtopdb:8710","description":null,"metadata":null},{"id":"4c3efa9da6f64b0586cbc1c3a5409ceb","type":"DRUG","name":"pexidartinib","canonical_id":"chembl:CHEMBL3813873","description":null,"metadata":null},{"id":"81dad22216bd4927af7ae4f294bf817c","type":"COMBINATION_TREATMENT","name":"pexidartinib + probenecid","canonical_id":"ctgov_combo:ctgov-combo-6495ca794e72141a","description":null,"metadata":null},{"id":"f2899ca581bf4cc387e0a7b153c706e5","type":"COMBINATION_TREATMENT","name":"pexidartinib + tolbutamide","canonical_id":"ctgov_combo:ctgov-combo-f6fa1da219e6bf16","description":null,"metadata":null},{"id":"97e831950eb4402aa982f97d2ac5a43b","type":"GO_TERM","name":"pexophagosome","canonical_id":"go:GO:1990457","description":"\"A membrane-bounded intracellular vesicle involved in the degradation of peroxisome by macropexophagy.\" [PMID:22536249]","metadata":null},{"id":"ddd3d706da9743e6a715c85241581db6","type":"GO_TERM","name":"pexophagy","canonical_id":"go:GO:0000425","description":"\"The selective autophagy process in which a peroxisome is degraded by macroautophagy.\" [GOC:autophagy, PMID:12914914, PMID:16973210]","metadata":null},{"id":"b7a95b5661cd4ad5a15a3057aab8f355","type":"GO_TERM","name":"phage shock","canonical_id":"go:GO:0009271","description":"\"A response by bacterial cells to a variety of stresses including filamentous phage infection, mislocalization of envelope proteins, extremes of temperature, osmolarity or ethanol concentration, and the presence of proton ionophores such as carbonylcyanide m-chlorophenylhydrazone (CCCP), that involves expression of the phage shock protein operon, and acts to protect the bacterial cells from damage.\" [GOC:add, GOC:jl, PMID:15485810, PMID:16045608]","metadata":null},{"id":"85dc2094cfb048c3a00b1f2162747276","type":"GO_TERM","name":"phagocytic cup","canonical_id":"go:GO:0001891","description":"\"An invagination of the cell membrane formed by an actin dependent process during phagocytosis. Following internalization it is converted into a phagosome.\" [PMID:10358769]","metadata":null},{"id":"9a1514b731f1444cbadc41a6f4d93c3e","type":"GO_TERM","name":"phagocytic cup base","canonical_id":"go:GO:0097204","description":"\"The older part of the phagocytic cup where the actin cytoskeleton disassembles, allowing early incoming and outgoing vesicular trafficking.\" [GOC:pf, PMID:20200225]","metadata":null},{"id":"ef2a6690d3c443ae8e3732902fdc9680","type":"GO_TERM","name":"phagocytic cup lip","canonical_id":"go:GO:0097203","description":"\"The tip or margin of the progressing circular lamella that engulfs a particle during phagocytosis. When the two lips of the cup fuse it is converted into a phagosome.\" [GOC:pf, PMID:20200225]","metadata":null},{"id":"1fa9994f2ab34d678268f8a7f5d33172","type":"GO_TERM","name":"phagocytic vesicle","canonical_id":"go:GO:0045335","description":"\"A membrane-bounded intracellular vesicle that arises from the ingestion of particulate material by phagocytosis.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"23688af899ba4e7eada62b28508db046","type":"GO_TERM","name":"phagocytic vesicle lumen","canonical_id":"go:GO:0097013","description":"\"The volume enclosed by the membrane of a phagocytic vesicle.\" [GOC:rs]","metadata":null},{"id":"a12291af794a4a3e90b7bdb312f82441","type":"GO_TERM","name":"phagocytic vesicle membrane","canonical_id":"go:GO:0030670","description":"\"The lipid bilayer surrounding a phagocytic vesicle.\" [GOC:mah]","metadata":null},{"id":"98ead97e4dd84f66bb99c8bdb7b05a16","type":"GO_TERM","name":"phagocytosis","canonical_id":"go:GO:0006909","description":"\"A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles.\" [ISBN:0198506732]","metadata":null},{"id":"91aeafe1f8fd4de58bd15d4105330b39","type":"GO_TERM","name":"phagocytosis, engulfment","canonical_id":"go:GO:0006911","description":"\"The internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis, including the membrane and cytoskeletal processes required, which involves one of three mechanisms: zippering of pseudopods around a target via repeated receptor-ligand interactions, sinking of the target directly into plasma membrane of the phagocytosing cell, or induced uptake via an enhanced membrane ruffling of the phagocytosing cell similar to macropinocytosis.\" [GOC:curators, ISBN:0781735149]","metadata":null},{"id":"f28408e8cb8f46899a1062c33ac0a25d","type":"GO_TERM","name":"phagocytosis, recognition","canonical_id":"go:GO:0006910","description":"\"The initial step in phagocytosis involving adhesion to bacteria, immune complexes and other particulate matter, or an apoptotic cell and based on recognition of factors such as bacterial cell wall components, opsonins like complement and antibody or protein receptors and lipids like phosphatidyl serine, and leading to intracellular signaling in the phagocytosing cell.\" [GOC:curators, ISBN:0781735149]","metadata":null},{"id":"248a7376c5ae4d7383e76cace5d96488","type":"GO_TERM","name":"phagolysosome","canonical_id":"go:GO:0032010","description":"\"A membrane-bounded intracellular vesicle formed by maturation of an early phagosome following the ingestion of particulate material by phagocytosis; during maturation, phagosomes acquire markers of late endosomes and lysosomes.\" [GOC:mah, PMID:12388753, PMID:14733906]","metadata":null},{"id":"b1a4f96757374a6eaad03481ca045873","type":"GO_TERM","name":"phagolysosome assembly","canonical_id":"go:GO:0001845","description":"\"The process that results in the fusion of a phagosome, a vesicle formed by phagocytosis, with a lysosome.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"797e862d71444f55805af344ce6ac71e","type":"GO_TERM","name":"phagolysosome assembly involved in apoptotic cell clearance","canonical_id":"go:GO:0090387","description":"\"The process in which a phagosome, a vesicle formed by phagocytosis, fuses with a lysosome as a part of apoptotic cell clearance.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"908356d1514b43f088088ce2908c7bfa","type":"GO_TERM","name":"phagolysosome membrane","canonical_id":"go:GO:0061474","description":"\"The lipid bilayer surrounding a phagolysosome.\" [GOC:dph, PMID:22073313]","metadata":null},{"id":"273c803afea64b1a9b6fa1cf58f69af9","type":"GO_TERM","name":"phagolysosome vesicle lumen","canonical_id":"go:GO:0106174","description":"\"The volume enclosed by the membrane of a phagolysosome.\" [GOC:pde, PMID:29471269]","metadata":null},{"id":"d0cf1f806e5345e9b3c27c0180abe26d","type":"GO_TERM","name":"phagolysosome vesicle membrane","canonical_id":"go:GO:0106175","description":"\"The lipid bylayer surrounding a phagolysosome.\" [GOC:pde, PMID:29471269]","metadata":null},{"id":"a0756e786d6f42bc9841a165c037ac52","type":"GO_TERM","name":"phagophore","canonical_id":"go:GO:0061908","description":"\"A disk-like structure that expands, rounds up into a cup-shaped structure, and eventually closes around its cargo (for example cytoplasmic components) to become an autophagosome or Cvt vesicle.\" [PMID:22664348, PMID:24201109]","metadata":null},{"id":"6408abb3d47341cf99177405a01528e8","type":"GO_TERM","name":"phagophore assembly site","canonical_id":"go:GO:0000407","description":"\"Punctate structures proximal to the endoplasmic reticulum which are the sites where the Atg machinery assembles upon autophagy induction.\" [GOC:elh, PMID:11689437, PMID:12048214, PMID:12554655]","metadata":null},{"id":"7b456eeb95494f1d82a2624b10c9fd1d","type":"GO_TERM","name":"phagophore assembly site membrane","canonical_id":"go:GO:0034045","description":"\"A cellular membrane associated with the phagophore assembly site.\" [GOC:mah, GOC:rph, PMID:16874040, PMID:17382324]","metadata":null},{"id":"2b1e841d5fca4dceb1a564a5ed7bdd16","type":"GO_TERM","name":"phagosome acidification","canonical_id":"go:GO:0090383","description":"\"Any process that reduces the pH of the phagosome, corresponding to an increase in hydrogen ion concentration.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"45a2f904ca034550a01495f23a946c29","type":"GO_TERM","name":"phagosome acidification involved in apoptotic cell clearance","canonical_id":"go:GO:0090390","description":"\"Any process that reduces the pH of the phagosome, corresponding to an increase in hydrogen ion concentration, and occurs as a part of apoptotic cell clearance.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"409312b7bd7b4088a7aa07f6c307aa6d","type":"GO_TERM","name":"phagosome maturation","canonical_id":"go:GO:0090382","description":"\"A process that is carried out at the cellular level which results in the arrangement of constituent parts of a phagosome within a cell. Phagosome maturation begins with endocytosis and formation of the early phagosome and ends with the formation of the hybrid organelle, the phagolysosome.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"ac9d8eec16bb4b1abbbad0c351bb08cb","type":"GO_TERM","name":"phagosome maturation involved in apoptotic cell clearance","canonical_id":"go:GO:0090386","description":"\"A process that is carried out at the cellular level which results in the arrangement of constituent parts of a phagosome within a cell and contributes to apoptotic cell clearance. Phagosome maturation begins with endocytosis and formation of the early phagosome and ends with the formation of the hybrid organelle, the phagolysosome.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"69541e7e3c174d01b45340cc5fc0d27d","type":"GO_TERM","name":"phagosome reneutralization","canonical_id":"go:GO:0044655","description":"\"Any process that increases the pH of the phagosome, corresponding to a decrease in hydrogen ion concentration, as part of the process of phagosome maturation.\" [GOC:rjd, PMID:22008230]","metadata":null},{"id":"b349a6a704fe44dcbc455eb6b5d4467e","type":"GO_TERM","name":"phagosome-lysosome fusion","canonical_id":"go:GO:0090385","description":"\"The creation of a phagolysosome from a phagosome and a lysosome.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"eb6d5ea2e3ce4eb28a81ae1170f2faa1","type":"GO_TERM","name":"phagosome-lysosome fusion involved in apoptotic cell clearance","canonical_id":"go:GO:0090389","description":"\"The creation of a phagolysosome from a phagosome and a lysosome as a part of apoptotic cell clearance.\" [GOC:kmv, GOC:tb]","metadata":null},{"id":"d49ce7fe86f34869a50d4b6206d5efaa","type":"GO_TERM","name":"pharyngeal arch artery morphogenesis","canonical_id":"go:GO:0061626","description":"\"The process in which the anatomical structures of a pharyngeal arch artery is generated and organized. The pharyngeal arch arteries are a series of six paired embryological vascular structures, the development of which give rise to several major arteries, such as the stapedial artery, the middle meningeal artery, the internal carotid artery and the pulmonary artery.\" [GOC:BHF, GOC:dph, PMID:20122914]","metadata":null},{"id":"964a84b7819146158ad9eeba284fb070","type":"GO_TERM","name":"pharyngeal system development","canonical_id":"go:GO:0060037","description":"\"The process whose specific outcome is the progression of the pharyngeal system over time, from its formation to the mature structure. The pharyngeal system is a transient embryonic complex that is specific to vertebrates. It comprises the pharyngeal arches, bulges of tissues of mesoderm and neural crest derivation through which pass nerves and pharyngeal arch arteries. The arches are separated internally by pharyngeal pouches, evaginations of foregut endoderm, and externally by pharyngeal clefts, invaginations of surface ectoderm. The development of the system ends when the structure it contributes to are forming: the thymus, thyroid, parathyroids, maxilla, mandible, aortic arch, cardiac outflow tract, external and middle ear.\" [GOC:dph]","metadata":null},{"id":"d8709357b814422290d339b19bb0b073","type":"DISEASE","name":"pharyngitis","canonical_id":"mondo:0002258","description":null,"metadata":null},{"id":"cd36bd82fdc7432c8615d35c446bc369","type":"GO_TERM","name":"pharynx development","canonical_id":"go:GO:0060465","description":"\"The biological process whose specific outcome is the progression of a pharynx from an initial condition to its mature state. The pharynx is the part of the digestive system immediately posterior to the mouth.\" [GOC:dph, GOC:rk]","metadata":null},{"id":"6716667e18304dc8bd3bb464a8a34cd9","type":"GO_TERM","name":"phaseic acid biosynthetic process","canonical_id":"go:GO:0010379","description":"\"The chemical reactions and pathways resulting in the formation of phaseic acid (PA), a catabolite of the plant hormone abscisic acid (ABA).\" [MetaCyc:PWY-5271]","metadata":null},{"id":"b14b39b31df8444fb896695d7ff001a0","type":"GO_TERM","name":"phaseollidin hydratase activity","canonical_id":"go:GO:0047454","description":"\"Catalysis of the reaction: phaseollidin hydrate = H2O + phaseollidin.\" [EC:4.2.1.97, RHEA:19769]","metadata":null},{"id":"a0dc2e7907e04840a9713b16a2c7ce32","type":"GO_TERM","name":"phasic smooth muscle contraction","canonical_id":"go:GO:0014821","description":"\"A process in which force is generated within phasic smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. In the phasic smooth muscle, the muscle contraction occurs without an ordered sarcomeric structure. Phasic smooth muscle contraction occurs in a series of discrete contractions and relaxations.\" [GOC:mtg_muscle]","metadata":null},{"id":"a2b034cd94f54b009cc04086d383b16a","type":"GO_TERM","name":"phenanthrene catabolic process","canonical_id":"go:GO:0042216","description":"\"The chemical reactions and pathways resulting in the breakdown of phenanthrene, a tricyclic aromatic hydrocarbon.\" [GOC:jl]","metadata":null},{"id":"b77f1c4922b448bc868129d6c4c295bd","type":"GO_TERM","name":"phenanthrene-9,10-epoxide hydrolase activity","canonical_id":"go:GO:0019119","description":"\"Catalysis of the reaction: phenanthrene-9,10-oxide + H2O = trans-9,10-dihydrodiolphenanthrene.\" [GOC:mah, UM-BBD_reactionID:r0496, UM-BBD_reactionID:r0560]","metadata":null},{"id":"4f3e60e3ccda46898198a4e6f253025c","type":"GO_TERM","name":"phenanthrene-epoxide hydrolase activity","canonical_id":"go:GO:0019118","description":"\"Catalysis of the reaction: a phenanthrene dioxide + H2O = a dihydrodiolphenanthrene.\" [GOC:mah, UM-BBD_reactionID:r0535, UM-BBD_reactionID:r0536]","metadata":null},{"id":"31fad0e27e2849deb031b75261ecf830","type":"GO_TERM","name":"phenazine biosynthetic process","canonical_id":"go:GO:0002047","description":"\"The chemical reactions and pathways resulting in the formation of a phenazine antibiotic, a polycyclic pyrazine with two nitrogen atoms in the ring.\" [GOC:dph]","metadata":null},{"id":"cec10c52304343f6819c2a2b0e59beeb","type":"DRUG","name":"phendimetrazine","canonical_id":"mesh:C100294","description":null,"metadata":null},{"id":"10d67a85df6f4288a14a2e4283b5d103","type":"DRUG","name":"phenelzine","canonical_id":"gtopdb:7266","description":null,"metadata":null},{"id":"92d41ac774c84496be3af58205143f31","type":"DRUG","name":"phenindione","canonical_id":"gtopdb:6838","description":null,"metadata":null},{"id":"6ed164854d27426c85f110baeba4db75","type":"DRUG","name":"phenindione","canonical_id":"chembl:CHEMBL711","description":null,"metadata":null},{"id":"c2201c06e29e4d65b042340e7f0ef6a8","type":"DRUG","name":"pheniramine","canonical_id":"mesh:D010632","description":null,"metadata":null},{"id":"d849bf584805454e86a0486b6959dfe1","type":"DRUG","name":"phenmetrazine","canonical_id":"mesh:D010633","description":null,"metadata":null},{"id":"9a3ac4cc271f4cabaa1f1fec20bfbe95","type":"DRUG","name":"phenobarbital","canonical_id":"mesh:D010634","description":null,"metadata":null},{"id":"9336e9adde4a47fda27ae470989e45e6","type":"DRUG","name":"phenol","canonical_id":"mesh:D019800","description":null,"metadata":null},{"id":"61cf2b6b0c8e47d290f9eb53d8cb0a35","type":"GO_TERM","name":"phenol 2-monooxygenase activity","canonical_id":"go:GO:0018662","description":"\"Catalysis of the reaction: phenol + NADPH + H+ + O2 = catechol + NADP+ + H2O.\" [EC:1.14.13.7]","metadata":null},{"id":"5d7050d6af764aaf9fdf5be98538b4d3","type":"GO_TERM","name":"phenol O-methyltransferase activity","canonical_id":"go:GO:0030736","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + phenol = S-adenosyl-L-homocysteine + anisole + H+.\" [EC:2.1.1.25, RHEA:14809]","metadata":null},{"id":"955d541ce71b40e58b990c59741a58f2","type":"GO_TERM","name":"phenol kinase activity","canonical_id":"go:GO:0018720","description":"\"Catalysis of the reaction: phenol + X-phosphate = XH + phenylphosphate.\" [PMID:16980461, UM-BBD_reactionID:r0155]","metadata":null},{"id":"760aa28d40be421d8626994c31c4a488","type":"GO_TERM","name":"phenol-containing compound biosynthetic process","canonical_id":"go:GO:0046189","description":"\"The chemical reactions and pathways resulting in the formation of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring.\" [GOC:ai]","metadata":null},{"id":"a5759304ee0d40bb9c5077ee0be0cb55","type":"GO_TERM","name":"phenol-containing compound catabolic process","canonical_id":"go:GO:0019336","description":"\"The chemical reactions and pathways resulting in the breakdown of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring.\" [ISBN:0198506732]","metadata":null},{"id":"8a8774e24efe4ec983cc193baa02d2ae","type":"GO_TERM","name":"phenol-containing compound metabolic process","canonical_id":"go:GO:0018958","description":"\"The chemical reactions and pathways involving a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring.\" [ISBN:0198506732]","metadata":null},{"id":"da37cdc7b2b844b89b9e565832a6ba08","type":"GO_TERM","name":"phenolic phthiocerol biosynthetic process","canonical_id":"go:GO:0097041","description":"\"The chemical reactions and pathways resulting in the formation of phenolic phthiocerol, a phthiocerol derivative having a 4-hydroxyphenyl substituent at the 29-position.\" [GOC:dph, GOC:ecd, PMID:9201977]","metadata":null},{"id":"32a62b15f6494894a79a2b106c0d3709","type":"GO_TERM","name":"phenotypic switching","canonical_id":"go:GO:0036166","description":"\"A reversible switch of a cell from one cell type or form to another, at a frequency above the expected frequency for somatic mutations. Phenotypic switching involves changes in cell morphology and altered gene expression patterns. For example, Candida albicans switches from white cells to opaque cells for sexual mating. Phenotypic switching also occurs in multicellular organisms; smooth muscle cells (SMCs) exhibit phenotypic transitions to allow rapid adaption to fluctuating environmental cues.\" [GOC:bf, GOC:di, PMID:12443899, PMID:22406749, PMID:8456504, Wikipedia:Phenotypic_switching]","metadata":null},{"id":"63b817ad796646f1857f80189b8e614e","type":"DRUG","name":"phenoxybenzamine","canonical_id":"gtopdb:7268","description":null,"metadata":null},{"id":"bf967a916d7d4ff1bed567432cb7ee9f","type":"DRUG","name":"phenoxybenzamine","canonical_id":"mesh:D010643","description":null,"metadata":null},{"id":"e59cbf830fbf425e8b9a02759116dcee","type":"DRUG","name":"phenoxymethylpenicillin","canonical_id":"mesh:D010404","description":null,"metadata":null},{"id":"ec9783c868574ed18560a21757564c68","type":"DRUG","name":"phenprocoumon","canonical_id":"gtopdb:6839","description":null,"metadata":null},{"id":"41074fa4cc5d442d9ba7404cc33b4219","type":"DRUG","name":"phenprocoumon","canonical_id":"mesh:D010644","description":null,"metadata":null},{"id":"557a58aaffca45779f2e9f544a2caaf6","type":"DRUG","name":"phenprocoumon","canonical_id":"chembl:CHEMBL1465","description":null,"metadata":null},{"id":"3660df5783f041a29650219ebbc1c916","type":"COMBINATION_TREATMENT","name":"phenprocoumon + vemurafenib","canonical_id":"ctgov_combo:ctgov-combo-e85c7dfa84ddb78a","description":null,"metadata":null},{"id":"c038792f76324939bfabcf26e2b85c07","type":"DRUG","name":"phentolamine","canonical_id":"gtopdb:502","description":null,"metadata":null},{"id":"93168c255a5545e7ac49ace22c789c9e","type":"COMBINATION_TREATMENT","name":"phentolamine + pilocarpine","canonical_id":"ctgov_combo:ctgov-combo-b2cb88b3d77a0c74","description":null,"metadata":null},{"id":"5daec2a62f464d4197b019f3140fa42d","type":"COMBINATION_TREATMENT","name":"phentolamine + pilocarpine","canonical_id":"ctgov_combo:ctgov-combo-6f19fda2968ca5e9","description":null,"metadata":null},{"id":"2a692c8a4de24889a90dbc6e8d7e60c3","type":"COMBINATION_TREATMENT","name":"phentolamine + pilocarpine","canonical_id":"ctgov_combo:ctgov-combo-b1b18a00fe6f39d7","description":null,"metadata":null},{"id":"f235fd798f084af7beb749cff4e35c00","type":"COMBINATION_TREATMENT","name":"phentolamine + propranolol","canonical_id":"ctgov_combo:ctgov-combo-bdb24276ea05a641","description":null,"metadata":null},{"id":"0d8763146e334b32893785d565870772","type":"COMBINATION_TREATMENT","name":"phentolamine + sildenafil","canonical_id":"ctgov_combo:ctgov-combo-859cb2628f5fa863","description":null,"metadata":null},{"id":"957e624436894ca3b6aa2f9f407e3068","type":"GO_TERM","name":"phenyl propionate uniporter activity","canonical_id":"go:GO:0015544","description":"\"Enables the transfer of phenyl propionate from one side of a membrane to the other.\" [GOC:mtg_transport, TC:2.A.1.27.1]","metadata":null},{"id":"8f8d4b9fdef541e3b82b6996aeaa83e1","type":"GO_TERM","name":"phenyl-phosphate phosphatase/carboxylase activity","canonical_id":"go:GO:0018862","description":"\"Catalysis of the reaction: 4-hydroxybenzoate + H+ + phosphate = CO2 + H2O + phenyl phosphate.\" [RHEA:74015]","metadata":null},{"id":"66a165f8120c4c8db4e19bcda8d0a3e6","type":"GO_TERM","name":"phenylacetaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008957","description":"\"Catalysis of the reaction: 2-phenylacetaldehyde + H2O + NAD+ = 2-phenylacetate + 2 H+ + NADH.\" [RHEA:21392]","metadata":null},{"id":"ccd68cd9205d44b4a488ec3e31035e87","type":"GO_TERM","name":"phenylacetaldehyde reductase activity","canonical_id":"go:GO:0102386","description":"\"Catalysis of the reaction: 2-phenylacetaldehyde + NADPH + H+ = 2-phenylethanol + NADP+.\" [PMID:17644147, RHEA:63736]","metadata":null},{"id":"949018fbf8d84c0ba1958a5366b31989","type":"GO_TERM","name":"phenylacetaldehyde synthase activity","canonical_id":"go:GO:1990055","description":"\"Catalyzes the reaction: L-phenylalanine + O2 + H2O + H+ = 2-phenylacetaldehyde + H2O2 + NH4+ + CO2.\" [PMID:16766535, PMID:23204519, RHEA:55532]","metadata":null},{"id":"d46311175f7c47baa236f34748b1f984","type":"GO_TERM","name":"phenylacetaldoxime dehydratase activity","canonical_id":"go:GO:0018814","description":"\"Catalysis of the reaction: (trans)-phenylacetaldoxime = H2O + phenylacetonitrile.\" [PMID:25015725, RHEA:20069]","metadata":null},{"id":"ea9db43f0cc74582857717744e87e25a","type":"GO_TERM","name":"phenylacetate 2-hydroxylase activity","canonical_id":"go:GO:0018631","description":"\"Catalysis of the reaction: 2-phenylacetate + O2 + reduced [NADPH--hemoprotein reductase] = (2-hydroxyphenyl)acetate + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:53392]","metadata":null},{"id":"c90599c8c3e744979daead43432757ad","type":"GO_TERM","name":"phenylacetate catabolic process","canonical_id":"go:GO:0010124","description":"\"The chemical reactions and pathways resulting in the breakdown of phenylacetate.\" [GOC:pz]","metadata":null},{"id":"5fa36230ced54ae1be76aa1d384dae7a","type":"GO_TERM","name":"phenylacetate-CoA ligase activity","canonical_id":"go:GO:0047475","description":"\"Catalysis of the reaction: ATP + CoA + phenylacetate = AMP + diphosphate + H+ + phenylacetyl-CoA.\" [RHEA:20956]","metadata":null},{"id":"323e5518f19e4a1098413b1d25d1273e","type":"DRUG","name":"phenylacetic acid","canonical_id":"mesh:C025136","description":null,"metadata":null},{"id":"b1ad1de9bb494c8487b19cd74b83de88","type":"GO_TERM","name":"phenylacetone monooxygenase activity","canonical_id":"go:GO:0033776","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + phenylacetone = benzyl acetate + H2O + NADP+.\" [EC:1.14.13.92, RHEA:10124]","metadata":null},{"id":"81e3ac98fdd44a3dbc32dac2163e0b40","type":"GO_TERM","name":"phenylacetyl-CoA 1,2-epoxidase activity","canonical_id":"go:GO:0097266","description":"\"Catalysis of the reaction: phenylacetyl-CoA + H+ + NADPH + O2 = 2-(1,2-epoxy-1,2-dihydrophenyl)acetyl-CoA + H2O + NADP+.\" [EC:1.14.13.149, GOC:bf, GOC:gk, PMID:20660314, PMID:21247899]","metadata":null},{"id":"a8646a6a44db4ff497116ae8357b8045","type":"GO_TERM","name":"phenylacetyl-CoA 1,2-epoxidase complex","canonical_id":"go:GO:0062077","description":"\"A protein complex capable of catalysing the reaction: phenylacetyl-CoA + H+ + NADPH + O2 = 2-(1,2-epoxy-1,2-dihydrophenyl)acetyl-CoA + H2O + NADP+.\" [GOC:bhm, PMID:21247899]","metadata":null},{"id":"0088234eaee6409abd691428fc8c26ab","type":"GO_TERM","name":"phenylacetyl-CoA dehydrogenase activity","canonical_id":"go:GO:0033789","description":"\"Catalysis of the reaction: 2 1,4-benzoquinone + H2O + phenylacetyl-CoA = 2 hydroquinone + phenylglyoxylyl-CoA.\" [RHEA:15705]","metadata":null},{"id":"0687b3559985497ea5d80a95bc005f39","type":"GO_TERM","name":"phenylacetyl-CoA hydrolase activity","canonical_id":"go:GO:0033880","description":"\"Catalysis of the reaction: H2O + phenylglyoxylyl-CoA = CoA + H+ + phenylglyoxylate.\" [EC:3.1.2.25, RHEA:15337]","metadata":null},{"id":"fc0099b5cbe24f1a8f32cf4a773bde36","type":"GO_TERM","name":"phenylacetyl-coenzyme A:glycine N-acyltransferase activity","canonical_id":"go:GO:0102080","description":"\"Catalysis of the reaction: phenylacetyl-CoA + glycine = H+ + phenylacetylglycine + coenzyme A.\" [EC:2.3.1.192, GOC:pz]","metadata":null},{"id":"751bf975c18247c9bb98e4f757269a48","type":"GO_TERM","name":"phenylalanine 2-monooxygenase activity","canonical_id":"go:GO:0050172","description":"\"Catalysis of the reaction: L-phenylalanine + O2 = 2-phenylacetamide + CO2 + H2O.\" [EC:1.13.12.9, RHEA:10712]","metadata":null},{"id":"9dc342a026144708b2161610f54dbac7","type":"GO_TERM","name":"phenylalanine 4-monooxygenase activity","canonical_id":"go:GO:0004505","description":"\"Catalysis of the reaction: L-phenylalanine + tetrahydrobiopterin + O2 = L-tyrosine + 4-alpha-hydroxytetrahydrobiopterin.\" [PMID:4004813, RHEA:20273]","metadata":null},{"id":"08d5d3bd428b44b4b934800138ef82c1","type":"GO_TERM","name":"phenylalanine ammonia-lyase activity","canonical_id":"go:GO:0045548","description":"\"Catalysis of the reaction: L-phenylalanine = NH4 + trans-cinnamate.\" [RHEA:21384]","metadata":null},{"id":"e1c03373e7ff4f208e4248aa81cc4dbd","type":"GO_TERM","name":"phenylalanine decarboxylase activity","canonical_id":"go:GO:0050174","description":"\"Catalysis of the reaction: L-phenylalanine = phenylethylamine + CO2.\" [EC:4.1.1.53, MetaCyc:PHENYLALANINE-DECARBOXYLASE-RXN]","metadata":null},{"id":"a1276c16421844aeafe62d9fe1b0e73a","type":"GO_TERM","name":"phenylalanine racemase (ATP-hydrolyzing) activity","canonical_id":"go:GO:0047462","description":"\"Catalysis of the reaction: L-phenylalanine + ATP + H2O = D-phenylalanine + AMP + diphosphate + 2 H+.\" [EC:5.1.1.11, RHEA:20201]","metadata":null},{"id":"86070e769c6a438b80cd43375cf4141f","type":"GO_TERM","name":"phenylalanine transport","canonical_id":"go:GO:0015823","description":"\"The directed movement of phenylalanine, 2-amino-3-phenylpropanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"13f5b45fe6384d70bba8074bc686bea9","type":"GO_TERM","name":"phenylalanine-tRNA ligase activity","canonical_id":"go:GO:0004826","description":"\"Catalysis of the reaction: ATP + L-phenylalanine + tRNA(Phe) = AMP + diphosphate + L-phenylalanyl-tRNA(Phe).\" [EC:6.1.1.20]","metadata":null},{"id":"e8c09902041d457db9df3351d25eadae","type":"GO_TERM","name":"phenylalanine-tRNA ligase complex","canonical_id":"go:GO:0009328","description":"\"An enzyme complex that catalyzes the ligation of phenylalanine to tRNA(Phe), forming L-phenylalanyl-tRNA(Phe).\" [PMID:20223217]","metadata":null},{"id":"f0d788692f6d4bfa89fbb8b2653b052c","type":"GO_TERM","name":"phenylalanine:proton symporter activity","canonical_id":"go:GO:0015492","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: phenylalanine(out) + H+(out) = phenylalanine(in) + H+(in).\" [TC:2.A.3.1.1]","metadata":null},{"id":"60d45af471f14edf82f2ad9bcc029ca0","type":"GO_TERM","name":"phenylalanyl-tRNA aminoacylation","canonical_id":"go:GO:0006432","description":"\"The process of coupling phenylalanine to phenylalanyl-tRNA, catalyzed by phenylalanyl-tRNA synthetase. The phenylalanyl-tRNA synthetase is a class-II synthetase. However, unlike other class II enzymes, The activated amino acid is transferred to the 2'-OH group of a phenylalanine-accepting tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"f802e705781947c2986a604dacb526db","type":"GO_TERM","name":"phenylalkylamine binding","canonical_id":"go:GO:0008145","description":"\"Binding to phenylalkylamine or one of its derivatives.\" [GOC:jl]","metadata":null},{"id":"717d65986941408786c299c465226c04","type":"DRUG","name":"phenylbutazone","canonical_id":"gtopdb:7270","description":null,"metadata":null},{"id":"7706f14a4c8c4526bc1ad823004b34cb","type":"DRUG","name":"phenylbutazone","canonical_id":"chembl:CHEMBL101","description":null,"metadata":null},{"id":"21195097af204daba73576316d6ad353","type":"GO_TERM","name":"phenylcoumaran benzylic ether reductase activity","canonical_id":"go:GO:0032442","description":"\"Catalysis of the NADPH-dependent 7-O-4' reduction of phenylcoumaran lignans to the corresponding diphenols; for example, catalysis of the reaction: dehydrodiconiferyl alcohol + NADPH + H+ = isodihydrodehydrodiconiferyl alcohol + NADP+.\" [PMID:11030549, PMID:13129921]","metadata":null},{"id":"bcd78b6b2724498a88e568ac8bf37720","type":"DRUG","name":"phenylephrine","canonical_id":"gtopdb:485","description":null,"metadata":null},{"id":"e6d8fc7f51d74a1aa2679e5e11040155","type":"DRUG","name":"phenylephrine","canonical_id":"mesh:D010656","description":null,"metadata":null},{"id":"f2db7d849103468f8d9daff930294234","type":"GO_TERM","name":"phenylethanolamine N-methyltransferase activity","canonical_id":"go:GO:0004603","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + phenylethanolamine = S-adenosyl-L-homocysteine + N-methylphenylethanolamine.\" [EC:2.1.1.28]","metadata":null},{"id":"616966d6daa848e9b6ef702a4b507546","type":"GO_TERM","name":"phenylethylamine biosynthetic process","canonical_id":"go:GO:0042444","description":"\"The chemical reactions and pathways resulting in the formation of phenylethylamine, an amine with pharmacological properties similar to those of amphetamine, occurs naturally as a neurotransmitter in the brain, and is present in chocolate and oil of bitter almonds.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"746c3af7ab5143228bde582300e71aab","type":"GO_TERM","name":"phenylethylamine catabolic process","canonical_id":"go:GO:0019607","description":"\"The chemical reactions and pathways resulting in the breakdown of phenylethylamine, an amine with pharmacological properties similar to those of amphetamine, occurs naturally as a neurotransmitter in the brain, and is present in chocolate and oil of bitter almonds.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"ce9bc734c8004f5dbc38dadeaf4dfa41","type":"GO_TERM","name":"phenylethylamine metabolic process","canonical_id":"go:GO:0042443","description":"\"The chemical reactions and pathways involving phenylethylamine, an amine with pharmacological properties similar to those of amphetamine, occurs naturally as a neurotransmitter in the brain, and is present in chocolate and oil of bitter almonds.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"0fb87b0327af4771a8f9853a97785b38","type":"GO_TERM","name":"phenylglyoxylate dehydrogenase (acylating, NAD+) activity","canonical_id":"go:GO:0047110","description":"\"Catalysis of the reaction: CoA + NAD+ + phenylglyoxylate = benzoyl-CoA + CO2 + NADH.\" [RHEA:10372]","metadata":null},{"id":"9977e8b4d2684109a680d279ea667720","type":"DISEASE","name":"phenylketonuria","canonical_id":"mondo:0009861","description":null,"metadata":null},{"id":"cc3682d2035548f28b5bd0993346d7e8","type":"GO_TERM","name":"phenyllactate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0097256","description":"\"Catalysis of the reaction: (R)-3-phenyllactate + NAD+ = 3-phenylpyruvate + H+ + NADH.\" [GOC:pde, PMID:10849007, RHEA:38351]","metadata":null},{"id":"c1eedac934a3400993914afcbb7e10e7","type":"GO_TERM","name":"phenylmercury acetate catabolic process","canonical_id":"go:GO:0019506","description":"\"The chemical reactions and pathways resulting in the breakdown of phenylmercury acetate, an organomercurial compound composed of a mercury atom attached to a benzene ring and an acetate group.\" [GOC:ai]","metadata":null},{"id":"ae391f596ffd4287a31994138574a909","type":"GO_TERM","name":"phenyloplast","canonical_id":"go:GO:0062116","description":"\"A chloroplast-derived plastid in which the solid form of phenol is stored.\" [PMID:24683183]","metadata":null},{"id":"7dc9080d747d4d26b8fef6a9c1999c0f","type":"GO_TERM","name":"phenylpropanoid biosynthetic process","canonical_id":"go:GO:0009699","description":"\"The chemical reactions and pathways resulting in the formation of aromatic derivatives of trans-cinnamic acid.\" [GOC:jl]","metadata":null},{"id":"6746b65127834abfa314d2a73bbd5186","type":"GO_TERM","name":"phenylpropanoid catabolic process","canonical_id":"go:GO:0046271","description":"\"The chemical reactions and pathways resulting in the breakdown of aromatic derivatives of trans-cinnamic acid.\" [GOC:ai]","metadata":null},{"id":"c21f65c181934a33af7ff401b78de659","type":"GO_TERM","name":"phenylpropanoid metabolic process","canonical_id":"go:GO:0009698","description":"\"The chemical reactions and pathways involving aromatic derivatives of trans-cinnamic acid.\" [GOC:jl]","metadata":null},{"id":"83c0c7bc1eef41fbb58073a6b58539ff","type":"GO_TERM","name":"phenylpropanoyltransferase activity","canonical_id":"go:GO:0102922","description":"\"Catalysis of the reaction: (3R)-3-amino-3-phenylpropanoyl-CoA + baccatin III = 3'-N-debenzoyl-2'-deoxytaxol + CoA.\" [RHEA:42488]","metadata":null},{"id":"9bf1eb90457545b5b30ed06cfdfb8e20","type":"GO_TERM","name":"phenylpyruvate decarboxylase activity","canonical_id":"go:GO:0050177","description":"\"Catalysis of the reaction: phenylpyruvate = phenylacetaldehyde + CO2.\" [EC:4.1.1.43, MetaCyc:PHENYLPYRUVATE-DECARBOXYLASE-RXN]","metadata":null},{"id":"d9b8c5a8a7ad4441931663141a64b41c","type":"GO_TERM","name":"phenylpyruvate tautomerase activity","canonical_id":"go:GO:0050178","description":"\"Catalysis of the reaction: keto-phenylpyruvate = enol-phenylpyruvate.\" [RHEA:17097]","metadata":null},{"id":"8bd3efaee2e84e55aa5c8402e6b25bfe","type":"GO_TERM","name":"phenylserine aldolase activity","canonical_id":"go:GO:0050179","description":"\"Catalysis of the reaction: L-threo-3-phenylserine = benzaldehyde + glycine.\" [EC:4.1.2.26, RHEA:21712]","metadata":null},{"id":"a2078cda5a2141a8927b5ad61926e43f","type":"DRUG","name":"phenytoin","canonical_id":"gtopdb:2624","description":null,"metadata":null},{"id":"b851b90acaf74922925ab0aed01ac4be","type":"DRUG","name":"phenytoin","canonical_id":"chembl:CHEMBL16","description":null,"metadata":null},{"id":"d9a57b452a614ab79d48c6ab327059c3","type":"COMBINATION_TREATMENT","name":"phenytoin + probenecid","canonical_id":"ctgov_combo:ctgov-combo-212b91b3f77110fd","description":null,"metadata":null},{"id":"a529133eb04441129c95aa9ac9889631","type":"COMBINATION_TREATMENT","name":"phenytoin + simvastatin + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-db7c9b26196bda9a","description":null,"metadata":null},{"id":"ecd7ca2a565549fead8206d25f7b7846","type":"DISEASE","name":"pheochromocytoma","canonical_id":"mondo:0008233","description":null,"metadata":null},{"id":"3b32479d0ca74e4ca316d8e9a69b2191","type":"GO_TERM","name":"pheophorbidase activity","canonical_id":"go:GO:0035560","description":"\"Catalysis of the reaction: pheophorbide a + H2O = pyropheophorbide a + methanol + CO2. The reaction occurs in two steps; pheophoridase catalyzes the conversion of pheophorbide a to a precursor of pyropheophorbide a, C-13(2)-carboxylpyropheophorbide a, by demethylation, and then the precursor is decarboxylated non-enzymatically to yield pyropheophorbide a.\" [PMID:16228561, RHEA:32483]","metadata":null},{"id":"301528b31c9a49058386854d60c24ba8","type":"GO_TERM","name":"pheophorbide a oxygenase activity","canonical_id":"go:GO:0032441","description":"\"Catalysis of the reaction: pheophorbide a + 2 reduced [2Fe-2S]-[ferredoxin] + O2 + 2 H(+) = red chlorophyll catabolite + 2 oxidized [2Fe-2S]-[ferredoxin].\" [PMID:14657372, RHEA:48140]","metadata":null},{"id":"f695e75e4a43434098265c78561b8e29","type":"GO_TERM","name":"pheophytinase activity","canonical_id":"go:GO:0080124","description":"\"Catalysis of the reaction: pheophytin + H2O = phytol + pheophorbide.\" [PMID:19304936]","metadata":null},{"id":"50a3e46f18484872953d0db006ccd3e3","type":"GO_TERM","name":"pheromone activity","canonical_id":"go:GO:0005186","description":"\"The activity of binding to and activating specific cell surface receptors, thereby inducing behavioral, developmental, or physiological response(s) from a responding organism or cell. The substance may be released or retained on the cell surface. Pheromones may serve as a specific attractant, social communicator, or sexual stimulant.\" [GOC:sgd_curators, ISBN:0198506732]","metadata":null},{"id":"e20ba75debd44793b3a6cd9ab1a2d143","type":"GO_TERM","name":"pheromone binding","canonical_id":"go:GO:0005550","description":"\"Binding to a pheromone, a substance, or characteristic mixture of substances, that is secreted and released by an organism and detected by a second organism of the same or a closely related species, in which it causes a specific reaction, such as a definite behavioral reaction or a developmental process.\" [GOC:ai]","metadata":null},{"id":"ce9cae5ed6894b0aafa1b86d0bce54dc","type":"GO_TERM","name":"pheromone biosynthetic process","canonical_id":"go:GO:0042811","description":"\"The chemical reactions and pathways resulting in the formation of pheromones, a substance that is secreted and released by an organism and detected by a second organism of the same or a closely related species, in which it causes a specific reaction, such as a definite behavioral reaction or a developmental process.\" [ISBN:0198506732]","metadata":null},{"id":"1651a7c46d964c8197f3cac1d5bf82d3","type":"GO_TERM","name":"pheromone catabolic process","canonical_id":"go:GO:0042812","description":"\"The chemical reactions and pathways resulting in the breakdown of pheromones, a substance that is secreted and released by an organism and detected by a second organism of the same or a closely related species, in which it causes a specific reaction, such as a definite behavioral reaction or a developmental process.\" [ISBN:0198506732]","metadata":null},{"id":"7f8e52bf29ee46fdac68227d579452f1","type":"GO_TERM","name":"pheromone metabolic process","canonical_id":"go:GO:0042810","description":"\"The chemical reactions and pathways involving pheromones, a substance that is secreted and released by an organism and detected by a second organism of the same or a closely related species, in which it causes a specific reaction, such as a definite behavioral reaction or a developmental process.\" [ISBN:0198506732]","metadata":null},{"id":"87c420b7637d473eb220869f95637e2f","type":"GO_TERM","name":"pheromone receptor activity","canonical_id":"go:GO:0016503","description":"\"Combining with a pheromone to initiate a change in cell activity. A pheromone is a substance used in olfactory communication between organisms of the same species eliciting a change in sexual or social behavior.\" [GOC:hjd, ISBN:0198506732]","metadata":null},{"id":"4b049891d8f44a509d3b18547aecadfc","type":"GO_TERM","name":"pheromone response MAPK cascade","canonical_id":"go:GO:0071507","description":"\"A MAPK cascade containing at least the Fus3 MAP kinase. It starts with the activation of Ste20, a MAP4K, which activates Ste11, a MAP3K, which in turn activate Ste7, a MAP2K, which activates Fus3. The kinases in each tier phosphorylate and activate the kinases in the downstream tier. This MAPK cascade is triggered by a pheromone activating its G protein-coupled receptor, and results in cellular responses that lead to conjugation with cellular fusion.\" [GOC:mah, GOC:vw, PMID:17604854]","metadata":null},{"id":"dc4c62a77daa4a6d8ee2f649aeeaa27b","type":"GO_TERM","name":"pheromone-induced unidirectional conjugation","canonical_id":"go:GO:0000762","description":"\"Unidirectional transfer of genetic information triggered by to a pheromone signal.\" [GOC:elh, PMID:17360276, PMID:27021562, PMID:31191478]","metadata":null},{"id":"94e5a419b435443797e7e869c393f797","type":"GO_TERM","name":"phialide development","canonical_id":"go:GO:0070790","description":"\"The process whose specific outcome is the progression of phialides over time, from its formation to the mature structure. Phialides are specialized cells that bud from the ends of metulae on the conidiophore tip. Chains of conidia, or asexual spores, develop from the phialide tips.\" [PMID:9529886]","metadata":null},{"id":"41bd0af8bce5429995b26651597f6184","type":"DISEASE","name":"phlebitis","canonical_id":"mondo:0004625","description":null,"metadata":null},{"id":"2cc2186008a0488186f62f5af749a81f","type":"GO_TERM","name":"phlobaphene biosynthetic process","canonical_id":"go:GO:0051559","description":"\"The chemical reactions and pathways resulting in the formation of phlobaphenes, red pigments with oligomeric or polymeric structure derived from the flavonoid intermediate flavan-4-ols.\" [PMID:11402179]","metadata":null},{"id":"d3fb96c7e50c4f618a67400b8a767e71","type":"GO_TERM","name":"phloem development","canonical_id":"go:GO:0010088","description":"\"The formation of the principal food-conducting tissue of a vascular plant.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"33ab221fcc9d4cdfa0c520c1bc9d55d8","type":"GO_TERM","name":"phloem glucosinolate loading","canonical_id":"go:GO:0090449","description":"\"The process of loading glucosinolates into the sieve tube or companion cell of the phloem for long distance transport from source to sink.\" [PMID:22864417]","metadata":null},{"id":"c776c188ef7a49c6b1509b6296895014","type":"GO_TERM","name":"phloem loading","canonical_id":"go:GO:0110126","description":"\"The process of loading solutes into the sieve tube or companion cell of the phloem for long distance transport from source to sink.\" [GOC:lr, PMID:19025382]","metadata":null},{"id":"459ce26cb6684cbdbdad12b3c7db928d","type":"GO_TERM","name":"phloem nitrate loading","canonical_id":"go:GO:0090408","description":"\"The process of loading nitrate into the sieve tube or companion cell of the phloem for long distance transport from source to sink.\" [GOC:tb]","metadata":null},{"id":"8908985778674f528e4a98759934c043","type":"GO_TERM","name":"phloem or xylem histogenesis","canonical_id":"go:GO:0010087","description":"\"The process whose specific outcome is the progression of phloem and/or xylem over time, from formation to the mature structure. An example of this process is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"25320d5a121440569e71f49cb3458096","type":"GO_TERM","name":"phloem sucrose loading","canonical_id":"go:GO:0009915","description":"\"The process of loading sucrose into the sieve tube or companion cell of the phloem for long distance transport from source to sink.\" [GOC:sm]","metadata":null},{"id":"a1ebe450abaa416eaf815c7e14db6b70","type":"GO_TERM","name":"phloem sucrose unloading","canonical_id":"go:GO:0110128","description":"\"The process of unloading sucrose that is produced in the source tissues, from the sieve tube or companion cell of the phloem into the sink tissues.\" [GOC:lr, PMID:30018170]","metadata":null},{"id":"64ba50ff2ce74b379b2b29ed5a54df2a","type":"GO_TERM","name":"phloem transport","canonical_id":"go:GO:0010233","description":"\"The directed movement of substances, into, out of or within the phloem during long distance transport between source and sink tissues.\" [GOC:sm, PMID:19025382]","metadata":null},{"id":"283290330fea4d24889691dd778f264f","type":"GO_TERM","name":"phloem unloading","canonical_id":"go:GO:0110127","description":"\"The process of unloading solutes that are produced in the source tissues, from the sieve tube or companion cell of the phloem into the sink tissues.\" [GOC:lr, PMID:19025382]","metadata":null},{"id":"82661bae0bfb454ebbb8941e5be39e0e","type":"GO_TERM","name":"phloretin hydrolase activity","canonical_id":"go:GO:0050180","description":"\"Catalysis of the reaction: H2O + phloretin = H+ + phloretate + phloroglucinol.\" [EC:3.7.1.4, RHEA:23396]","metadata":null},{"id":"61e1cebf94c5437886641d8c13fdeafe","type":"GO_TERM","name":"phlorizin hydrolase activity","canonical_id":"go:GO:0140749","description":"\"Catalysis of the reaction: phlorizin + H2O = beta-D-glucose + phloretin.\" [PMID:9762914, RHEA:69639]","metadata":null},{"id":"25ddf58a1d2d461daf8f949a03d5e685","type":"GO_TERM","name":"phloroglucinol reductase activity","canonical_id":"go:GO:0018510","description":"\"Catalysis of the reaction: dihydrophloroglucinol + NADP+ = H+ + NADPH + phloroglucinol.\" [EC:1.3.1.57, RHEA:10080]","metadata":null},{"id":"7d9eece940ea406799f8b6e9920396b1","type":"GO_TERM","name":"phloroisovalerophenone synthase activity","canonical_id":"go:GO:0050634","description":"\"Catalysis of the reaction: isovaleryl-CoA + 3 malonyl-CoA = 4 CoASH + 3 CO2 + 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one.\" [EC:2.3.1.156, MetaCyc:2.3.1.156-RXN]","metadata":null},{"id":"d84f914bdfe84b4588565cb4aee74116","type":"GO_TERM","name":"phorbol ester receptor activity","canonical_id":"go:GO:0001565","description":"\"Combining with a phorbol ester and transmitting the signal to initiate a change in cell activity.\" [GOC:ai, GOC:signaling, PMID:10506570]","metadata":null},{"id":"36f8e92bcf414fb3ae13f1be08211c3c","type":"GO_TERM","name":"phorbol-diester hydrolase activity","canonical_id":"go:GO:0050181","description":"\"Catalysis of the reaction: H2O + phorbol 12,13-dibutanoate = butanoate + H+ + phorbol 13-butanoate.\" [EC:3.1.1.51, RHEA:21316]","metadata":null},{"id":"42c2d33cd59449c9b8b87b0f873cfefd","type":"GO_TERM","name":"phosphagen biosynthetic process","canonical_id":"go:GO:0042396","description":"\"The chemical reactions and pathways resulting in the formation of phosphagen, any of a group of guanidine phosphates that occur in muscle and can be used to regenerate ATP from ADP during muscular contraction.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"d9f79959662e4a2cb0e9f6c746628f65","type":"GO_TERM","name":"phosphagen catabolic process","canonical_id":"go:GO:0042397","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphagen, any of a group of guanidine phosphates that occur in muscle and can be used to regenerate ATP from ADP during muscular contraction.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"492122d17bee44428ea1e246bf893a1b","type":"GO_TERM","name":"phosphatase activator activity","canonical_id":"go:GO:0019211","description":"\"Binds to and increases the activity of a phosphatase.\" [GOC:ai]","metadata":null},{"id":"3f9c70ca95b241f48749c06bcdf941d5","type":"GO_TERM","name":"phosphatase activity","canonical_id":"go:GO:0016791","description":"\"Catalysis of the hydrolysis of a phosphoric monoester, releasing a phosphate.\" [GOC:curators]","metadata":null},{"id":"b43613452e8d4cf1bea21b07cc1cf5b1","type":"GO_TERM","name":"phosphatase binding","canonical_id":"go:GO:0019902","description":"\"Binding to a phosphatase.\" [GOC:jl]","metadata":null},{"id":"2348969362424bfa96d644609f1ea80f","type":"GO_TERM","name":"phosphatase complex","canonical_id":"go:GO:1903293","description":"\"A protein complex which is capable of phosphatase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:24766807]","metadata":null},{"id":"f07eadac97e84b94857d8b24ccb07605","type":"GO_TERM","name":"phosphatase inhibitor activity","canonical_id":"go:GO:0019212","description":"\"Binds to and stops, prevents or reduces the activity of a phosphatase.\" [GOC:ai]","metadata":null},{"id":"92b5bc6ad86c4842a1923be0a6c990df","type":"GO_TERM","name":"phosphatase regulator activity","canonical_id":"go:GO:0019208","description":"\"Binds to and modulates the activity of a phosphatase, an enzyme which catalyzes of the removal of a phosphate group from a substrate molecule.\" [GOC:ai]","metadata":null},{"id":"68cdd8e588b0468fb644c2745a901fa6","type":"GO_TERM","name":"phosphate acetyltransferase activity","canonical_id":"go:GO:0008959","description":"\"Catalysis of the reaction: acetyl-CoA + phosphate = CoA + acetyl phosphate.\" [EC:2.3.1.8]","metadata":null},{"id":"748643da1ba2445595d2b5783fe78faf","type":"GO_TERM","name":"phosphate butyryltransferase activity","canonical_id":"go:GO:0050182","description":"\"Catalysis of the reaction: butanoyl-CoA + phosphate = butanoyl phosphate + CoA.\" [EC:2.3.1.19, RHEA:20892]","metadata":null},{"id":"dbd1a5f7a6b94ac79e7fb39227176629","type":"GO_TERM","name":"phosphate ion binding","canonical_id":"go:GO:0042301","description":"\"Binding to a phosphate ion.\" [GOC:jl]","metadata":null},{"id":"51a4fc90a39c4edf95fa04c2fa532692","type":"GO_TERM","name":"phosphate ion export across plasma membrane","canonical_id":"go:GO:0180029","description":"\"The directed movement of phosphate ions (Pi) from inside of a cell, across the plasma membrane and into the extracellular region.\" [PMID:37949217]","metadata":null},{"id":"dd45c196c21c42719700dac94aa7986e","type":"GO_TERM","name":"phosphate ion homeostasis","canonical_id":"go:GO:0055062","description":"\"Any process involved in the maintenance of an internal steady state of phosphate ions within an organism or cell.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"a514eb3718aa44618afa049d218ba3aa","type":"GO_TERM","name":"phosphate ion transmembrane transport","canonical_id":"go:GO:0035435","description":"\"The process in which a phosphate is transported across a membrane.\" [GOC:vw]","metadata":null},{"id":"4ca71d88ad8c43a68bfa70114f6429eb","type":"GO_TERM","name":"phosphate ion transport","canonical_id":"go:GO:0006817","description":"\"The directed movement of phosphate ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"e5b651278d8d49b3b5af5a058455c13f","type":"GO_TERM","name":"phosphate ion uniporter activity","canonical_id":"go:GO:0140787","description":"\"Catalysis of the active transport of a phosphate ion across a membrane by a mechanism involving conformational change, where energy for active transport is derived from membrane potential if the solute is charged.\" [PMID:29642010]","metadata":null},{"id":"c7408f3ba53f4605bbc4d340268114b6","type":"GO_TERM","name":"phosphate transmembrane transporter activity","canonical_id":"go:GO:0005315","description":"\"Enables the transfer of phosphate ions from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport]","metadata":null},{"id":"804e3c6a56cc4307a1dc1db6d43674be","type":"GO_TERM","name":"phosphate-containing compound metabolic process","canonical_id":"go:GO:0006796","description":"\"The chemical reactions and pathways involving the phosphate group, the anion or salt of any phosphoric acid.\" [GOC:ai]","metadata":null},{"id":"289e8de34383468a81434a384aa05ea1","type":"GO_TERM","name":"phosphate:acyl-[acyl carrier protein] acyltransferase activity","canonical_id":"go:GO:0043811","description":"\"Catalysis of the reaction: a fatty acyl-[acyl-carrier protein] + orthophosphate = acyl phosphate + [acyl-carrier protein].\" [RHEA:42292]","metadata":null},{"id":"db79c4a9dee24924b5e48e493e7ef49c","type":"GO_TERM","name":"phosphate:proton symporter activity","canonical_id":"go:GO:0015317","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: phosphate(out) + H+(out) = phosphate(in) + H+(in).\" [TC:2.A.1.9.-]","metadata":null},{"id":"d532aa1a657b479b8a43b4a630d3ed6c","type":"GO_TERM","name":"phosphatidate cytidylyltransferase activity","canonical_id":"go:GO:0004605","description":"\"Catalysis of the reaction: CTP + phosphatidate = diphosphate + CDP-diacylglycerol.\" [EC:2.7.7.41]","metadata":null},{"id":"9645211452a542719c139784476990ee","type":"GO_TERM","name":"phosphatidate phosphatase activity","canonical_id":"go:GO:0008195","description":"\"Catalysis of the reaction: a 1,2-diacylglycerol 3-phosphate + H2O = a 1,2-diacyl-sn-glycerol + phosphate.\" [GOC:pr, PMID:25814022, RHEA:27429]","metadata":null},{"id":"cede50433aa24e2b918d775a7af1b8a9","type":"GO_TERM","name":"phosphatidate-sterol O-acyltransferase activity","canonical_id":"go:GO:0080096","description":"\"Catalysis of the reaction: a phosphatidate + a sterol = a sterol ester + a lysophosphatidate.\" [PMID:16020547]","metadata":null},{"id":"3674f9db5bc44b9293572276ae58c7da","type":"GO_TERM","name":"phosphatidic acid binding","canonical_id":"go:GO:0070300","description":"\"Binding to phosphatidic acid, any of a class of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.\" [CHEBI:16337, GOC:jp, ISBN:0198506732]","metadata":null},{"id":"f4431d7a378a47059e1dc442ff86701d","type":"GO_TERM","name":"phosphatidic acid biosynthetic process","canonical_id":"go:GO:0006654","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.\" [ISBN:0198506732]","metadata":null},{"id":"0bbb024783e94696a981cf9e0f0dae57","type":"GO_TERM","name":"phosphatidic acid metabolic process","canonical_id":"go:GO:0046473","description":"\"The chemical reactions and pathways involving phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.\" [ISBN:0198506732]","metadata":null},{"id":"0b7b9043e7444e9ab5f1c8980ca4682e","type":"GO_TERM","name":"phosphatidic acid transfer activity","canonical_id":"go:GO:1990050","description":"\"Removes a phosphatidic acid from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle. Phosphatidic acid refers to a glycophospholipids with, in general, a saturated fatty acid bonded to carbon-1, an unsaturated fatty acid bonded to carbon-2, and a phosphate group bonded to carbon-3.\" [PMID:23042293]","metadata":null},{"id":"7ceb27d7f1e64225b516933e9e6328bf","type":"GO_TERM","name":"phosphatidyl-N-methylethanolamine N-methyltransferase activity","canonical_id":"go:GO:0000773","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + phosphatidyl-N-methylethanolamine = S-adenosyl-L-homocysteine + phosphatidyl-N-dimethylethanolamine. Also catalyzes the transfer of a further methylgroup, producing phosphatidylcholine.\" [EC:2.1.1.71, PMID:19366698]","metadata":null},{"id":"baff3b9857ba4b75a7e0bc2e1bd15994","type":"GO_TERM","name":"phosphatidyl-N-monomethylethanolamine biosynthetic process","canonical_id":"go:GO:0006647","description":"\"The chemical reactions and pathways involving phosphatidyl-N-monomethylethanolamine (PMME), a derivative of phosphatidylethanolamine with a methylated amine group.\" [PMID:35071223]","metadata":null},{"id":"50c6ee013f2a4ab3ae011719f678bd2c","type":"GO_TERM","name":"phosphatidylcholine 12-monooxygenase activity","canonical_id":"go:GO:0050183","description":"\"Catalysis of the reaction: 1-acyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphocholine + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = 1-acyl-2-[(R)-12-hydroxyoleoyl]-sn-glycero-3-phosphocholine + 2 Fe(III)-[cytochrome b5] + H2O.\" [RHEA:46360]","metadata":null},{"id":"f6bff5832fa24862b1950853b0027d9e","type":"GO_TERM","name":"phosphatidylcholine acyl-chain remodeling","canonical_id":"go:GO:0036151","description":"\"Remodeling the acyl chains of phosphatidylcholine, through sequential deacylation and re-acylation reactions, to generate phosphatidylcholine containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:18195019, PMID:18458083]","metadata":null},{"id":"61244a996c35410bb9cb83c1a69f0c57","type":"GO_TERM","name":"phosphatidylcholine binding","canonical_id":"go:GO:0031210","description":"\"Binding to a phosphatidylcholine, a glycophospholipid in which a phosphatidyl group is esterified to the hydroxyl group of choline.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"f2cc3d8d085d495eb54ca9a1156e85be","type":"GO_TERM","name":"phosphatidylcholine biosynthetic process","canonical_id":"go:GO:0006656","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.\" [ISBN:0198506732]","metadata":null},{"id":"0f5b99af938844de9aeb9ab81adfcdbc","type":"GO_TERM","name":"phosphatidylcholine catabolic process","canonical_id":"go:GO:0034638","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.\" [GOC:jp]","metadata":null},{"id":"85dd7e7e810f4d80b918a6dd4f98cbb0","type":"GO_TERM","name":"phosphatidylcholine flippase activity","canonical_id":"go:GO:0140345","description":"\"Catalysis of the movement of phosphatidylcholine from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:11870854]","metadata":null},{"id":"02ffdf228c6249b6ad2d4e07acbd2fce","type":"GO_TERM","name":"phosphatidylcholine floppase activity","canonical_id":"go:GO:0090554","description":"\"Catalysis of the movement of phosphatidylcholine from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [GOC:ab, PMID:16452632, RHEA:38583]","metadata":null},{"id":"a7f2f9532ece47cd951d8f154e60373e","type":"GO_TERM","name":"phosphatidylcholine intramembrane carrier activity","canonical_id":"go:GO:0008525","description":"\"Enables the transport of phosphatidylcholine from a region of a membrane to a different region on the same membrane.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"fb66f7eb45504438aae3cdb2b36a5dc2","type":"GO_TERM","name":"phosphatidylcholine lysophospholipase A1 activity","canonical_id":"go:GO:0004622","description":"\"Catalysis of the reaction: a 1-acyl-sn-glycero-3-phosphocholine + H2O = a fatty acid + H+ + sn-glycerol 3-phosphocholine.\" [RHEA:15177]","metadata":null},{"id":"5edac3011bee4edf926d8f1dc3b5eac4","type":"GO_TERM","name":"phosphatidylcholine metabolic process","canonical_id":"go:GO:0046470","description":"\"The chemical reactions and pathways involving phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. They are important constituents of cell membranes.\" [ISBN:0198506732]","metadata":null},{"id":"c94c0497d1ff46cbb38f399650df0a07","type":"GO_TERM","name":"phosphatidylcholine phospholipase C activity","canonical_id":"go:GO:0034480","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1,2-diacyl-sn-glycerol + H+ + phosphocholine.\" [RHEA:10604]","metadata":null},{"id":"a90b760fedf24dd8a7764a741ae165a5","type":"GO_TERM","name":"phosphatidylcholine synthase activity","canonical_id":"go:GO:0050520","description":"\"Catalysis of the reaction: CDP-diacylglycerol + choline = 1,2-diacyl-sn-glycero-3-phosphocholine + CMP + H+.\" [EC:2.7.8.24, RHEA:14597]","metadata":null},{"id":"de5ba74862b24420a527ab2cd328ce43","type":"GO_TERM","name":"phosphatidylcholine transfer activity","canonical_id":"go:GO:0120019","description":"\"Removes phosphatidylcholine from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"11c56df2bebc4b98b1f351c291c9d8d9","type":"GO_TERM","name":"phosphatidylcholine-dolichol O-acyltransferase activity","canonical_id":"go:GO:0047199","description":"\"Catalysis of the reaction: 1,2-diacyl-sn-glycero-3-phosphocholine + dolichol = 1-acyl-sn-glycero-3-phosphocholine + acyldolichol.\" [EC:2.3.1.83, RHEA:19285]","metadata":null},{"id":"f5d4ddf540c742d49a5ffc1a0942d7a7","type":"GO_TERM","name":"phosphatidylcholine-retinol O-acyltransferase activity","canonical_id":"go:GO:0047173","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phosphocholine + all-trans-retinol--[retinol-binding protein] = a 2-acyl-sn-glycero-3-phosphocholine + an all-trans-retinyl ester + apo--[retinol-binding protein]. Recognizes the substrate both in free form and when bound to cellular-retinol-binding-protein, but has higher affinity for the bound form.\" [RHEA:17469]","metadata":null},{"id":"7d6fd24f4ea64f6b93b3cf7aefe2ba68","type":"GO_TERM","name":"phosphatidylcholine-sterol O-acyltransferase activator activity","canonical_id":"go:GO:0060228","description":"\"Binds to and increases the activity of phosphatidylcholine-sterol O-acyltransferase.\" [GOC:BHF, GOC:dph, GOC:tb, PMID:4335615]","metadata":null},{"id":"10be65af921f4adab755242fa3605878","type":"GO_TERM","name":"phosphatidylcholine-sterol O-acyltransferase activity","canonical_id":"go:GO:0004607","description":"\"Catalysis of the reaction: phosphatidylcholine + a sterol = a sterol ester + 1-acylglycerophosphocholine.\" [EC:2.3.1.43]","metadata":null},{"id":"ce86d64173f145cd8289d219efe63dc6","type":"GO_TERM","name":"phosphatidylcholine:cardiolipin O-linoleoyltransferase activity","canonical_id":"go:GO:0032577","description":"\"Catalysis of the transfer of a linoleoyl ((9Z,12Z)-octadeca-9,12-dienoyl) group from phosphatidylcholine to an oxygen atom on a cardiolipin molecule.\" [GOC:cb, GOC:mah]","metadata":null},{"id":"84e3cbdfefc448c8ba37446aae32f57f","type":"GO_TERM","name":"phosphatidylethanolamine N-methyltransferase activity","canonical_id":"go:GO:0004608","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + phosphatidylethanolamine = S-adenosyl-L-homocysteine + H+ + phosphatidyl-N-methylethanolamine.\" [EC:2.1.1.17, RHEA:11164]","metadata":null},{"id":"80353b4eedfc44249f039f5aaac2e2f4","type":"GO_TERM","name":"phosphatidylethanolamine acyl-chain remodeling","canonical_id":"go:GO:0036152","description":"\"Remodeling the acyl chains of phosphatidylethanolamine, through sequential deacylation and re-acylation reactions, to generate phosphatidylethanolamine containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:18287005, PMID:18458083]","metadata":null},{"id":"2745873a4c44409a8b476f0f8b0a4453","type":"GO_TERM","name":"phosphatidylethanolamine binding","canonical_id":"go:GO:0008429","description":"\"Binding to a phosphatidylethanolamine, a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.\" [ISBN:0198506732]","metadata":null},{"id":"d41b231b79744efda591cde7092be04c","type":"GO_TERM","name":"phosphatidylethanolamine biosynthetic process","canonical_id":"go:GO:0006646","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.\" [ISBN:0198506732]","metadata":null},{"id":"74bd76ab63004ea9bf8aa572b5386e36","type":"GO_TERM","name":"phosphatidylethanolamine catabolic process","canonical_id":"go:GO:0046338","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.\" [ISBN:0198506732]","metadata":null},{"id":"375b9feb12d9454fa1d2970aa39cfa67","type":"GO_TERM","name":"phosphatidylethanolamine flippase activity","canonical_id":"go:GO:0090555","description":"\"Catalysis of the movement of phosphatidylethanolamine from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [GOC:ab, PMID:16452632, PMID:20043909]","metadata":null},{"id":"3fa54508c00f4548b17a9c7c19911a33","type":"GO_TERM","name":"phosphatidylethanolamine floppase activity","canonical_id":"go:GO:0140341","description":"\"Catalysis of the movement of phosphatidylethanolamine from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:10029989]","metadata":null},{"id":"066af315a7284bad8de3049cc68bcb02","type":"GO_TERM","name":"phosphatidylethanolamine lysophospholipase A1 activity","canonical_id":"go:GO:0120559","description":"\"Catalysis of the reaction: a 1-acyl-sn-glycero-3-phosphoethanolamine + H2O = sn-glycero-3-phosphoethanolamine + a fatty acid + H+.\" [RHEA:32967]","metadata":null},{"id":"f777507f1c8f4afa816f756d2d45d2e2","type":"GO_TERM","name":"phosphatidylethanolamine metabolic process","canonical_id":"go:GO:0046337","description":"\"The chemical reactions and pathways involving phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine. It is a major structural phospholipid in mammalian systems. It tends to be more abundant than phosphatidylcholine in the internal membranes of the cell and is an abundant component of prokaryotic membranes.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"db414109009e4d2ab2976064eff68a25","type":"GO_TERM","name":"phosphatidylethanolamine transfer activity","canonical_id":"go:GO:1904121","description":"\"Removes phosphatidylethanolamine from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GO_REF:0000066, GOC:TermGenie, PMID:8606365]","metadata":null},{"id":"75bc433aa0e44973bab5650560573a83","type":"GO_TERM","name":"phosphatidylethanolamine-sterol O-acyltransferase activity","canonical_id":"go:GO:0080095","description":"\"Catalysis of the reaction: a phosphatidylethanolamine + a sterol = a sterol ester + a lysophosphatidylethanolamine.\" [PMID:16020547]","metadata":null},{"id":"e2950d2a18a44099aedaa1af3d253ce1","type":"GO_TERM","name":"phosphatidylethanolamine:Kdo2-lipid A phosphoethanolamine transferase activity","canonical_id":"go:GO:0043838","description":"\"Catalysis of the reaction: Kdo2-lipid A + phosphatidylethanolamine = phosphoethanolamine-Kdo2-lipid A + diacylglycerol.\" [PMID:15795227]","metadata":null},{"id":"c57002cf81084bbd944962a65141bea9","type":"GO_TERM","name":"phosphatidylglycerol acyl-chain remodeling","canonical_id":"go:GO:0036148","description":"\"Remodeling the acyl chains of phosphatidylglycerol, through sequential deacylation and re-acylation reactions, to generate phosphatidylglycerol containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:15485873, PMID:18458083]","metadata":null},{"id":"35520092a1464071ba2421469a8ce3d5","type":"GO_TERM","name":"phosphatidylglycerol alanyltransferase activity","canonical_id":"go:GO:0047637","description":"\"Catalysis of the reaction: 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + L-alanyl-tRNA(Ala) = 1,2-diacyl-sn-glycero-3-phospho-1'-(3'-O-L-alanyl)-sn-glycerol + tRNA(Ala).\" [EC:2.3.2.11]","metadata":null},{"id":"fc8f2a4c7b5745d3b6c200334fcaed6a","type":"GO_TERM","name":"phosphatidylglycerol binding","canonical_id":"go:GO:1901611","description":"\"Binding to phosphatidylglycerol.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"38b1c1669b264d708df7dfb3c9e9a2de","type":"GO_TERM","name":"phosphatidylglycerol biosynthetic process","canonical_id":"go:GO:0006655","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol.\" [ISBN:0198506732]","metadata":null},{"id":"d75c8a0e0dd0437f8e9d7d0dacb148bb","type":"GO_TERM","name":"phosphatidylglycerol catabolic process","canonical_id":"go:GO:0034478","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphatidylglycerols, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol.\" [GOC:mah]","metadata":null},{"id":"e112676c538d4de2af9d0da72dbf45ad","type":"GO_TERM","name":"phosphatidylglycerol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0160242","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + NAD+ = a 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerone) + NADH + H+.\" [PMID:26338420, RHEA:81099]","metadata":null},{"id":"a5ef1acb1f354c7f883a528bd97c2736","type":"GO_TERM","name":"phosphatidylglycerol lysyltransferase activity","canonical_id":"go:GO:0050071","description":"\"Catalysis of the reaction: 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + L-lysyl-tRNA(Lys) = 1,2-diacyl-sn-glycero-3-phospho-1'-(3'-O-L-lysyl)-sn-glycerol + tRNA(Lys).\" [EC:2.3.2.3]","metadata":null},{"id":"e61cb6ed99364dd185bd817eea865edf","type":"GO_TERM","name":"phosphatidylglycerol metabolic process","canonical_id":"go:GO:0046471","description":"\"The chemical reactions and pathways involving phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. They are important constituents of cell membranes.\" [ISBN:0198506732]","metadata":null},{"id":"1eaf06a0c7c2486fb7c5581e62f94e6d","type":"GO_TERM","name":"phosphatidylglycerol phospholipase C activity","canonical_id":"go:GO:0034479","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) + H2O = sn-glycerol 3-phosphate + a 1,2-diacyl-sn-glycerol + H+.\" [PMID:18434318, RHEA:32927]","metadata":null},{"id":"2e6e403993ff44dd828043e9cde98d5a","type":"GO_TERM","name":"phosphatidylglycerol transfer activity","canonical_id":"go:GO:0140339","description":"\"Directly binding to phosphatidylglycerol and delivering it either to an acceptor molecule or to a specific location.\" [PMID:9132017]","metadata":null},{"id":"b8d5100c7fa746fabe5477bb772d7378","type":"GO_TERM","name":"phosphatidylglycerol-membrane-oligosaccharide glycerophosphotransferase activity","canonical_id":"go:GO:0008960","description":"\"Catalysis of the reaction: phosphatidylglycerol + membrane-derived-oligosaccharide D-glucose = 1,2-diacyl-sn-glycerol + membrane-derived-oligosaccharide 6-(glycerophospho)-D-glucose.\" [EC:2.7.8.20]","metadata":null},{"id":"82a12ff6aabe477ca42c2872f6d15b8e","type":"GO_TERM","name":"phosphatidylglycerol-phosphatidylethanolamine phosphatidyltransferase activity","canonical_id":"go:GO:0090483","description":"\"Catalysis of the reaction: phosphatidylglycerol + phosphatidylethanolamine = cardiolipin + ethanolamine.\" [PMID:22988102]","metadata":null},{"id":"21367790afbe4c77a215a73fc6daee55","type":"GO_TERM","name":"phosphatidylglycerol-prolipoprotein diacylglyceryl transferase activity","canonical_id":"go:GO:0008961","description":"\"Catalysis of the transfer of the diacylglyceryl group from phosphatidylglycerol to the sulfhydryl group of the prospective N-terminal cysteine residue in an unmodified prolipoprotein.\" [PMID:8051048, RHEA:56712]","metadata":null},{"id":"cfc89ca5ac484c5f85a82b04eb4c7312","type":"GO_TERM","name":"phosphatidylglycerophosphatase activity","canonical_id":"go:GO:0008962","description":"\"Catalysis of the reaction: phosphatidylglycerophosphate + H2O = phosphatidylglycerol + phosphate.\" [PMID:4292860]","metadata":null},{"id":"5e623b8219be4db1b137a2e32b961785","type":"GO_TERM","name":"phosphatidylinositol 3-kinase activator activity","canonical_id":"go:GO:0141038","description":"\"Binds to and increases the activity of a phosphatidylinositol 3-kinase (PI3K).\" [PMID:31686003]","metadata":null},{"id":"06dd631e6177426a99da023ecfded53e","type":"GO_TERM","name":"phosphatidylinositol 3-kinase binding","canonical_id":"go:GO:0043548","description":"\"Binding to a phosphatidylinositol 3-kinase, any enzyme that catalyzes the addition of a phosphate group to an inositol lipid at the 3' position of the inositol ring.\" [PMID:10209156, PMID:9255069]","metadata":null},{"id":"c6550cf0c12e4f7a8cd7ffe6425253ed","type":"GO_TERM","name":"phosphatidylinositol 3-kinase catalytic subunit binding","canonical_id":"go:GO:0036313","description":"\"Binding to the catalytic subunit of a phosphatidylinositol 3-kinase. The catalytic subunit catalyzes the addition of a phosphate group to an inositol lipid at the 3' position of the inositol ring.\" [GOC:bf, PMID:17475214]","metadata":null},{"id":"63e0292e92ff4019ad4e20da646dd6b1","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex","canonical_id":"go:GO:0005942","description":"\"A protein complex capable of phosphatidylinositol 3-kinase activity and containing subunits of any phosphatidylinositol 3-kinase (PI3K) enzyme. These complexes are divided in three classes (called I, II and III) that differ for their presence across taxonomic groups and for the type of their constituents. Catalytic subunits of phosphatidylinositol 3-kinase enzymes are present in all 3 classes; regulatory subunits of phosphatidylinositol 3-kinase enzymes are present in classes I and III; adaptor proteins have been observed in class II complexes and may be present in other classes too.\" [GOC:bf, PMID:24587488]","metadata":null},{"id":"3a3eda2f20a341d5a77271c34b3e1d1c","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class I","canonical_id":"go:GO:0097651","description":"\"A phosphatidylinositol 3-kinase complex that contains a catalytic and a regulatory subunit of a phosphatidylinositol 3-kinase (PI3K) enzyme, plus one or more adaptor proteins. Class I PI3Ks phosphorylate phosphatidylinositol [PI], phosphatidylinositol-4-phosphate [PI(4)P] and phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2], and are divided into subclasses A and B according to the type of adaptor subunit with which they associate. The class I PI3K subfamily of genes comprises members in vertebrates, worm and fly, but none in yeast.\" [GOC:ha, PMID:24587488]","metadata":null},{"id":"dd9fa3a2ef5c48aa8a29243af9b3f080","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class IA","canonical_id":"go:GO:0005943","description":"\"A class I phosphatidylinositol 3-kinase complex that possesses 1-phosphatidylinositol-4-phosphate 3-kinase activity; comprises a catalytic class IA phosphoinositide 3-kinase (PI3K) subunit and an associated SH2 domain-containing regulatory subunit that is a member of a family of related proteins often called p85 proteins. Through the interaction with the SH2-containing adaptor subunits, Class IA PI3K catalytic subunits are linked to tyrosine kinase signaling pathways.\" [PMID:9255069, PMID:9759495]","metadata":null},{"id":"63ad2385b9fc48ab97ed5bea59fb2ccd","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class IB","canonical_id":"go:GO:0005944","description":"\"A class I phosphatidylinositol 3-kinase complex that possesses 1-phosphatidylinositol-4-phosphate 3-kinase activity; comprises a catalytic class IB phosphoinositide 3-kinase (PI3K) subunit and an associated regulatory subunit that is larger than, and unrelated to, the p85 proteins present in class IA complexes. Class IB PI3Ks are stimulated by G-proteins and do not interact with the SH2-domain containing adaptors that bind to Class IA PI3Ks.\" [PMID:9255069, PMID:9759495]","metadata":null},{"id":"ad29ddae6fca434fa54cd462ec4bfa03","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class II","canonical_id":"go:GO:0097652","description":"\"A phosphatidylinositol 3-kinase complex that contains a catalytic subunit of a phosphatidylinositol 3-kinase (PI3K) enzyme and one or more adaptor proteins. There is no known obligatory regulatory subunit. The class II PI3K (PI3KC2) subfamily of genes has members in vertebrates, worm and fly, but none in yeast.\" [GOC:ha, PMID:24587488]","metadata":null},{"id":"f288477f6f1d4b7c80a1fe19ddf1964b","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class III","canonical_id":"go:GO:0035032","description":"\"A phosphatidylinositol 3-kinase complex that contains a catalytic class III phosphoinositide 3-kinase (PI3K) subunit bound to a regulatory (adaptor) subunit. Additional adaptor proteins may be present. Class III PI3Ks have a substrate specificity restricted to phosphatidylinositol (PI).\" [GOC:bf, PMID:9255069]","metadata":null},{"id":"76aedfc6302e475ca5229165713a4efd","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class III, type I","canonical_id":"go:GO:0034271","description":"\"A class III phosphatidylinositol 3-kinase complex that is involved in autophagy. In budding yeast, this complex consists of Vps30p, Vps34p, Apg14p and Vps15p.\" [GOC:ha, GOC:rb, PMID:11157979, PMID:16421251]","metadata":null},{"id":"53526d3e39154a76a29ebc17fea0166c","type":"GO_TERM","name":"phosphatidylinositol 3-kinase complex, class III, type II","canonical_id":"go:GO:0034272","description":"\"A class III phosphatidylinositol 3-kinase complex that is involved in vacuolar protein sorting (VPS) via endosomes. In budding yeast, this complex consists of Vps30p, Vps34p, Vps38 and Vps15p.\" [GOC:ha, GOC:rb, PMID:11157979, PMID:16421251]","metadata":null},{"id":"234c65f4153a4546867bd18a90dd2178","type":"GO_TERM","name":"phosphatidylinositol 3-kinase inhibitor activity","canonical_id":"go:GO:0141039","description":"\"Binds to and decreases the activity of a phosphatidylinositol 3-kinase (PI3K).\" [PMID:31686003]","metadata":null},{"id":"65601668a11a4595938750c111fe4240","type":"GO_TERM","name":"phosphatidylinositol 3-kinase regulator activity","canonical_id":"go:GO:0035014","description":"\"Modulates the activity of a phosphatidylinositol 3-kinase (PI3K). Regulatory subunits can link a PI3K catalytic subunit to upstream signaling events and help position the catalytic subunits close to their lipid substrates.\" [GOC:bf, PMID:9255069]","metadata":null},{"id":"80ee6fa1b5f14d45ae188e08242fb76f","type":"GO_TERM","name":"phosphatidylinositol 3-kinase regulatory subunit binding","canonical_id":"go:GO:0036312","description":"\"Binding to a regulatory subunit of phosphatidylinositol 3-kinase. The regulatory subunit associates with the catalytic subunit to regulate both its activity and subcellular location.\" [GOC:bf, PMID:20505341]","metadata":null},{"id":"eb288e49b35e4804a5a570bdc08b6cac","type":"GO_TERM","name":"phosphatidylinositol 3-kinase/protein kinase B signal transduction","canonical_id":"go:GO:0043491","description":"\"An intracellular signaling cassette that starts with phosphatidylinositol 3-kinase (PI3K) activation, production of phosphatidylinositol 3-phosphate (PI3P), activation of PDK1, which recruits and ending with the activation of protein kinase B (PKB, also known as Akt). PI3K is activated by cell surface receptors. Note that PTEN is an inhibitor of the pathway.\" [PMID:20517722, PMID:22952397]","metadata":null},{"id":"a451baf1cd2143248574b5ac29af600b","type":"GO_TERM","name":"phosphatidylinositol 4-phosphate biosynthetic process","canonical_id":"go:GO:0180048","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylinositol 4-phosphate.\" [PMID:39239853]","metadata":null},{"id":"5296b52de632443caed7ae5f3af02f56","type":"GO_TERM","name":"phosphatidylinositol 5-phosphate biosynthetic process","canonical_id":"go:GO:1904563","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylinositol 5-phosphate.\" [GO_REF:0000068, GOC:autophagy, GOC:dph, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:23916588]","metadata":null},{"id":"bbcb053879bb4050a6644a3df369249c","type":"GO_TERM","name":"phosphatidylinositol 5-phosphate metabolic process","canonical_id":"go:GO:1904562","description":"\"The chemical reactions and pathways involving phosphatidylinositol 5-phosphate.\" [GO_REF:0000068, GOC:autophagy, GOC:dph, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:23916588]","metadata":null},{"id":"2e68ee27239747a7b60c2b5ea6c384cf","type":"GO_TERM","name":"phosphatidylinositol N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0017176","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + phosphatidylinositol = UDP + N-acetyl-D-glucosaminylphosphatidylinositol.\" [EC:2.4.1.198]","metadata":null},{"id":"3f682590691046f8850b9cd67e6f037c","type":"GO_TERM","name":"phosphatidylinositol acyl-chain remodeling","canonical_id":"go:GO:0036149","description":"\"Remodeling the acyl chains of phosphatidylinositol, through sequential deacylation and re-acylation reactions, to generate phosphatidylinositol containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:18094042, PMID:18772128]","metadata":null},{"id":"8c02e07a5e134e81876d4d277b11f894","type":"GO_TERM","name":"phosphatidylinositol alpha-mannosyltransferase activity","canonical_id":"go:GO:0043750","description":"\"Catalysis of the transfer of one or more alpha-D-mannose residues from GDP-mannose to positions 2,6 and others in 1-phosphatidyl-myo-inositol.\" [EC:2.4.1.345]","metadata":null},{"id":"987cfa1edd49450b9c0720a1d930598e","type":"GO_TERM","name":"phosphatidylinositol binding","canonical_id":"go:GO:0035091","description":"\"Binding to an inositol-containing glycerophospholipid, i.e. phosphatidylinositol (PtdIns) and its phosphorylated derivatives.\" [PMID:11395417]","metadata":null},{"id":"2d19b26a1b77422a911b36dc003fa503","type":"GO_TERM","name":"phosphatidylinositol biosynthetic process","canonical_id":"go:GO:0006661","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylinositol, any glycophospholipid in which the sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.\" [ISBN:0198506732]","metadata":null},{"id":"6e2cf643165b4e0b91c1e47801758312","type":"GO_TERM","name":"phosphatidylinositol bisphosphate binding","canonical_id":"go:GO:1902936","description":"\"Binding to phosphatidylinositol bisphosphate.\" [GO_REF:0000067, GOC:bhm, GOC:TermGenie, PMID:18690034]","metadata":null},{"id":"06d6111db02048aeb170d83c25809d18","type":"GO_TERM","name":"phosphatidylinositol bisphosphate phosphatase activity","canonical_id":"go:GO:0034593","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol bisphosphate + H2O = phosphatidylinositol phosphate + phosphate.\" [GOC:mah]","metadata":null},{"id":"90580ad34cb24d3f8b0df3405d1ade70","type":"GO_TERM","name":"phosphatidylinositol catabolic process","canonical_id":"go:GO:0031161","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphatidylinositol, any glycophospholipid with its sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.\" [GOC:mah]","metadata":null},{"id":"83d221772aeb4934b1b88c9e753d5a52","type":"GO_TERM","name":"phosphatidylinositol deacylase activity","canonical_id":"go:GO:0050185","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol + H2O = 1-acyl-sn-glycero-3-phospho-D-myo-inositol + a carboxylate + H+.\" [EC:3.1.1.52, RHEA:18001]","metadata":null},{"id":"52b7927ad8fe412d8d7b9b233b55d41a","type":"GO_TERM","name":"phosphatidylinositol dephosphorylation","canonical_id":"go:GO:0046856","description":"\"The process of removing one or more phosphate groups from a phosphatidylinositol.\" [ISBN:0198506732]","metadata":null},{"id":"51a0cf3c613b4155b37ddca9545bc7bd","type":"GO_TERM","name":"phosphatidylinositol diacylglycerol-lyase activity","canonical_id":"go:GO:0004436","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol = D-myo-inositol 1,2-cyclic phosphate + diacylglycerol.\" [EC:4.6.1.13]","metadata":null},{"id":"ae38b64f860c4cbeb39c12b59fa1b718","type":"GO_TERM","name":"phosphatidylinositol kinase activity","canonical_id":"go:GO:0052742","description":"\"Catalysis of the reaction: ATP + a phosphatidylinositol = ADP + a phosphatidylinositol phosphate.\" [GOC:ai]","metadata":null},{"id":"facea325f8d140898915a415a095ad71","type":"GO_TERM","name":"phosphatidylinositol lysophospholipase A1 activity","canonical_id":"go:GO:0120561","description":"\"Catalysis of the reaction: a 1-acyl-sn-glycero-3-phospho-(1D-myo-inositol) + H2O = sn-glycero-3-phospho-1D-myo-inositol + a fatty acid + H+.\" [RHEA:32987]","metadata":null},{"id":"fc9485bb77214c37932d6e5e7bbc536a","type":"GO_TERM","name":"phosphatidylinositol metabolic process","canonical_id":"go:GO:0046488","description":"\"The chemical reactions and pathways involving phosphatidylinositol, any glycophospholipid in which a sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.\" [ISBN:0198506732]","metadata":null},{"id":"48b64cdf8f0a4a058f3ee603ab4c2a3f","type":"GO_TERM","name":"phosphatidylinositol monophosphate phosphatase activity","canonical_id":"go:GO:0052744","description":"\"Catalysis of the reaction: phosphatidyl-1D-myo-inositol monophosphate + H2O = phosphatidylinositol + phosphate.\" [GOC:ai]","metadata":null},{"id":"7a907b53209d4270bde3fb09734f5d48","type":"GO_TERM","name":"phosphatidylinositol phosphate 4-phosphatase activity","canonical_id":"go:GO:0034596","description":"\"Catalysis of the removal of the 4-phosphate group of a phosphatidylinositol phosphate.\" [GOC:mah]","metadata":null},{"id":"10c53629494e412db8f7bde6fc1bda63","type":"GO_TERM","name":"phosphatidylinositol phosphate 5-phosphatase activity","canonical_id":"go:GO:0034595","description":"\"Catalysis of the removal of the 5-phosphate group of a phosphatidylinositol phosphate.\" [GOC:elh]","metadata":null},{"id":"22ee3c337c4f4b84bea21c7ef785fac2","type":"GO_TERM","name":"phosphatidylinositol phosphate binding","canonical_id":"go:GO:1901981","description":"\"Binding to phosphatidylinositol phosphate.\" [GOC:TermGenie, PMID:23445487]","metadata":null},{"id":"aea5574911334efda47c0ebd2f1f87ab","type":"GO_TERM","name":"phosphatidylinositol phosphate biosynthetic process","canonical_id":"go:GO:0046854","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylinositol phosphate.\" [ISBN:0198506732]","metadata":null},{"id":"8ba5f7ba220a4acd8974ec9b3abfc317","type":"GO_TERM","name":"phosphatidylinositol phosphate phosphatase activity","canonical_id":"go:GO:0052866","description":"\"Catalysis of the reaction: phosphatidylinositol phosphate(n) + H2O = phosphatidylinositol phosphate(n-1) + phosphate. This reaction is the removal of a phosphate group from a phosphatidylinositol phosphate.\" [GOC:ai]","metadata":null},{"id":"9aae8eeb8d5d4f2593167640c00d6768","type":"GO_TERM","name":"phosphatidylinositol phosphate phosphatase complex","canonical_id":"go:GO:1904144","description":"\"A protein complex which is capable of phosphatidylinositol phosphate phosphatase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:12525165]","metadata":null},{"id":"818bb6f1b4514993b70e917b3b088c52","type":"GO_TERM","name":"phosphatidylinositol phospholipase C activity","canonical_id":"go:GO:0120548","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + H2O = 1D-myo-inositol 1-phosphate + a 1,2-diacyl-sn-glycerol + H+.\" [RHEA:43484]","metadata":null},{"id":"067328155e4141479080de8b76413d78","type":"GO_TERM","name":"phosphatidylinositol transfer activity","canonical_id":"go:GO:0008526","description":"\"Removes phosphatidylinositol from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"64f85d94b8a946d0b501fa637a948911","type":"GO_TERM","name":"phosphatidylinositol transporter complex","canonical_id":"go:GO:1902556","description":"\"A protein complex which is capable of phosphatidylinositol transporter activity.\" [GOC:bhm, GOC:TermGenie, PMID:9890948]","metadata":null},{"id":"6b533fda691647c8a89e7b5688e162d9","type":"GO_TERM","name":"phosphatidylinositol trisphosphate phosphatase activity","canonical_id":"go:GO:0034594","description":"\"Catalysis of the reaction: phosphatidylinositol trisphosphate + H2O = phosphatidylinositol bisphosphate + phosphate.\" [GOC:mah]","metadata":null},{"id":"a681923da80e4edaa368011a8683e470","type":"GO_TERM","name":"phosphatidylinositol-1,4,5-trisphosphate 5-phosphatase activity","canonical_id":"go:GO:0052867","description":"\"Catalysis of the reaction: phosphatidyl-1D-myo-inositol 1,4,5-trisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 1,4-bisphosphate + phosphate.\" [GOC:curators]","metadata":null},{"id":"9d796c1d0a344d97974065e6467c9d4f","type":"GO_TERM","name":"phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity","canonical_id":"go:GO:0016314","description":"\"Catalysis of the reaction: phosphatidylinositol-3,4,5-trisphosphate + H2O = phosphatidylinositol-4,5-bisphosphate + phosphate.\" [EC:3.1.3.67]","metadata":null},{"id":"ff58ae3cfbee4fe998f90ad00a2c6c19","type":"GO_TERM","name":"phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity","canonical_id":"go:GO:0034485","description":"\"1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate.\" [EC:3.1.3.86, GOC:pf]","metadata":null},{"id":"b491e8b921634243a50eef473cd645c2","type":"GO_TERM","name":"phosphatidylinositol-3,4,5-trisphosphate binding","canonical_id":"go:GO:0005547","description":"\"Binding to phosphatidylinositol-3,4,5-trisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3', 4' and 5' positions.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"2f8bc80c56f44d949cdf341c0968d0d9","type":"GO_TERM","name":"phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity","canonical_id":"go:GO:0051800","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 4-phosphate + phosphate.\" [GOC:bf, PMID:9811831]","metadata":null},{"id":"355d140dbc4c43298a217b22fd8113b1","type":"GO_TERM","name":"phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity","canonical_id":"go:GO:0016316","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 3-phosphate + phosphate.\" [GOC:hb, RHEA:17193]","metadata":null},{"id":"fa0348dcafee4259a4698f40b146634b","type":"GO_TERM","name":"phosphatidylinositol-3,4-bisphosphate binding","canonical_id":"go:GO:0043325","description":"\"Binding to phosphatidylinositol-3,4-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' and 4' positions.\" [GOC:bf, GOC:curators]","metadata":null},{"id":"3f47dcb79d874928bd1f31f1c6c6548f","type":"GO_TERM","name":"phosphatidylinositol-3,4-bisphosphate phosphatase activity","canonical_id":"go:GO:0106017","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol phosphate + phosphate.\" [GOC:hjd]","metadata":null},{"id":"bf536b62a8214ec38d2f796a803002c9","type":"GO_TERM","name":"phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity","canonical_id":"go:GO:0052629","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 5-phosphate + phosphate + 2 H+.\" [PMID:19901554, RHEA:39019]","metadata":null},{"id":"f66cac3299544a49ab8633d49ba7ea87","type":"GO_TERM","name":"phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity","canonical_id":"go:GO:0043813","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,5-bisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + phosphate.\" [PMID:10806194, PMID:16607019, RHEA:32955]","metadata":null},{"id":"dc97d547ae524e47a6e3d2b3ee040de8","type":"GO_TERM","name":"phosphatidylinositol-3,5-bisphosphate binding","canonical_id":"go:GO:0080025","description":"\"Binding to phosphatidylinositol-3,5-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' and 5' positions.\" [GOC:bf, PMID:18397324]","metadata":null},{"id":"8c3a0370868746ab923542bb601cd25a","type":"GO_TERM","name":"phosphatidylinositol-3,5-bisphosphate phosphatase activity","canonical_id":"go:GO:0106018","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol phosphate + phosphate.\" [GOC:hjd]","metadata":null},{"id":"a558284139f44d1cacde701fd22a275a","type":"GO_TERM","name":"phosphatidylinositol-3-phosphate binding","canonical_id":"go:GO:0032266","description":"\"Binding to phosphatidylinositol-3-phosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 3' position.\" [GOC:bf, PMID:10209156, PMID:11395417, PMID:11557775]","metadata":null},{"id":"de855b63034944778a24329f3b1c8f13","type":"GO_TERM","name":"phosphatidylinositol-3-phosphate biosynthetic process","canonical_id":"go:GO:0036092","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylinositol-3-phosphate, a phosphatidylinositol monophosphate carrying the phosphate group at the 3-position.\" [GOC:al, GOC:vw]","metadata":null},{"id":"47dcb29bf6ff4ce6af549ab3345d7f52","type":"GO_TERM","name":"phosphatidylinositol-3-phosphate phosphatase activity","canonical_id":"go:GO:0004438","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 3-phosphate + H2O = 1-phosphatidyl-1D-myo-inositol + phosphate.\" [EC:3.1.3.64]","metadata":null},{"id":"cab4230ba5484c029068b250c299a6e4","type":"GO_TERM","name":"phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity","canonical_id":"go:GO:0034597","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 3-phosphate + phosphate.\" [GOC:mah, RHEA:25674]","metadata":null},{"id":"436c8c173e7f4dd1bdfc329a4786d118","type":"GO_TERM","name":"phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity","canonical_id":"go:GO:0004439","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 4-phosphate + phosphate.\" [RHEA:22764]","metadata":null},{"id":"cb3433d931874673bca2375768a1f3c1","type":"GO_TERM","name":"phosphatidylinositol-4,5-bisphosphate binding","canonical_id":"go:GO:0005546","description":"\"Binding to phosphatidylinositol-4,5-bisphosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 4' and 5' positions.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"953263fa51334d22be4a0909833f7c99","type":"GO_TERM","name":"phosphatidylinositol-4,5-bisphosphate phosphatase activity","canonical_id":"go:GO:0106019","description":"\"Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H2O = 1-phosphatidyl-1D-myo-inositol phosphate + phosphate.\" [GOC:hjd]","metadata":null},{"id":"b2ab719284b948ff908f6c6554fb2ea4","type":"GO_TERM","name":"phosphatidylinositol-4,5-bisphosphate phospholipase C activity","canonical_id":"go:GO:0004435","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2-diacyl-sn-glycerol + H+.\" [RHEA:33179]","metadata":null},{"id":"d87109d0e52642588760ebdbd290755f","type":"GO_TERM","name":"phosphatidylinositol-4,5-bisphosphate sensor activity","canonical_id":"go:GO:0140550","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of phosphatidylinositol-4,5-bisphosphate.\" [PMID:33172987]","metadata":null},{"id":"3687e8a7edd649c6be168cc6e61d8ddc","type":"GO_TERM","name":"phosphatidylinositol-4-phosphate binding","canonical_id":"go:GO:0070273","description":"\"Binding to phosphatidylinositol-4-phosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 4' position.\" [GOC:bf, GOC:mah]","metadata":null},{"id":"a7c0c2cbc9354e69aa5b365fc43b71d0","type":"GO_TERM","name":"phosphatidylinositol-4-phosphate phosphatase activity","canonical_id":"go:GO:0043812","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate.\" [PMID:10224048, RHEA:55652]","metadata":null},{"id":"b35476c2e06a4d2bb619a7586267dd54","type":"GO_TERM","name":"phosphatidylinositol-4-phosphate-cholesterol exchange activity","canonical_id":"go:GO:0160291","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate)(out) + cholesterol(in) = 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate)(in) + cholesterol(out). This reaction results in the exchange of cholesterol for phosphatidylinositol-4-phosphate (PI(4)P) between membranes.\" [PMID:24209621, PMID:29596003, RHEA:84179]","metadata":null},{"id":"feff975c4ef04b9b902a62fc9fade975","type":"GO_TERM","name":"phosphatidylinositol-5-phosphate binding","canonical_id":"go:GO:0010314","description":"\"Binding to phosphatidylinositol-5-phosphate, a derivative of phosphatidylinositol in which the inositol ring is phosphorylated at the 5' position.\" [GOC:bf, GOC:tair_curators]","metadata":null},{"id":"403c6d409c3140c4b5c15b06fca34905","type":"GO_TERM","name":"phosphatidylinositol-5-phosphate phosphatase activity","canonical_id":"go:GO:0102091","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + phosphate.\" [PMID:12878591, RHEA:41147]","metadata":null},{"id":"33ed0063bd8c4f21a3c142c223d0bb58","type":"GO_TERM","name":"phosphatidylinositol-mediated signaling","canonical_id":"go:GO:0048015","description":"\"The series of molecular signals in which a cell uses a phosphatidylinositol-mediated signaling to convert a signal into a response. Phosphatidylinositols include phosphatidylinositol (PtdIns) and its phosphorylated derivatives.\" [GOC:bf, GOC:ceb, ISBN:0198506732]","metadata":null},{"id":"f346029c72924fbeb6be96451fa2a975","type":"GO_TERM","name":"phosphatidylserine acyl-chain remodeling","canonical_id":"go:GO:0036150","description":"\"Remodeling the acyl chains of phosphatidylserine, through sequential deacylation and re-acylation reactions, to generate phosphatidylserine containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:18287005, PMID:18458083]","metadata":null},{"id":"4ba0dd61eae64bc18f478bae52a71032","type":"GO_TERM","name":"phosphatidylserine binding","canonical_id":"go:GO:0001786","description":"\"Binding to phosphatidylserine, a class of glycophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of L-serine.\" [ISBN:0198506732, PMID:12000961]","metadata":null},{"id":"a880f490a1d2462e81a462607d5298b7","type":"GO_TERM","name":"phosphatidylserine biosynthetic process","canonical_id":"go:GO:0006659","description":"\"The chemical reactions and pathways resulting in the formation of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine.\" [ISBN:0198506732]","metadata":null},{"id":"b6be7412cfdb4a27b5da4c4c22febe7a","type":"GO_TERM","name":"phosphatidylserine catabolic process","canonical_id":"go:GO:0006660","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine.\" [ISBN:0198506732]","metadata":null},{"id":"8f4fb44c761f443aa3a2b2a57c921c90","type":"GO_TERM","name":"phosphatidylserine decarboxylase activity","canonical_id":"go:GO:0004609","description":"\"Catalysis of the reaction: H+ + phosphatidyl-L-serine = CO2 + phosphatidylethanolamine.\" [EC:4.1.1.65, RHEA:20828]","metadata":null},{"id":"579b3b99087d4746b818087f2614b101","type":"GO_TERM","name":"phosphatidylserine exposure on apoptotic cell surface","canonical_id":"go:GO:0070782","description":"\"A phospholipid scrambling process that results in the appearance of phosphatidylserine on the outer leaflet of the plasma membrane of an apoptotic cell, which acts as an 'eat-me' signal for engulfing cells. Phosphatidylserine is exposed on the apoptotic cell surface by a phospholipid scramblase activity.\" [GOC:mah, GOC:mtg_apoptosis, GOC:rk, PMID:11536005]","metadata":null},{"id":"26629e4215344966a66df9dc0b03d168","type":"GO_TERM","name":"phosphatidylserine exposure on blood platelet","canonical_id":"go:GO:0097045","description":"\"A phospholipid scrambling process that results in the appearance of phosphatidylserine on the surface of activated blood platelets, and triggers the clotting system.\" [GOC:bf, GOC:lf, GOC:pr, PMID:21107324]","metadata":null},{"id":"427ce323bb05424387d31ec69881e4c7","type":"GO_TERM","name":"phosphatidylserine flippase activity","canonical_id":"go:GO:0140346","description":"\"Catalysis of the movement of phosphatidylserine from the exoplasmic to the cytosolic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [PMID:11870854]","metadata":null},{"id":"063bf429f10540b0b53159c64cb0c7df","type":"GO_TERM","name":"phosphatidylserine floppase activity","canonical_id":"go:GO:0090556","description":"\"Catalysis of the movement of phosphatidylserine from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [GOC:ab, PMID:16452632, PMID:20224745, RHEA:38567]","metadata":null},{"id":"a9e05bc846c841f9a976f375ca11567d","type":"GO_TERM","name":"phosphatidylserine lysophospholipase A1 activity","canonical_id":"go:GO:0120560","description":"\"Catalysis of the reaction: a 1-acyl-sn-glycero-3-phospho-L-serine + H2O = sn-glycero-3-phospho-L-serine + a fatty acid + H+.\" [RHEA:32979]","metadata":null},{"id":"09636d15ea3e44adb3aac05e6fc6afef","type":"GO_TERM","name":"phosphatidylserine metabolic process","canonical_id":"go:GO:0006658","description":"\"The chemical reactions and pathways involving phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine. They are important constituents of cell membranes.\" [ISBN:0198506732]","metadata":null},{"id":"6a4aa4d9ebdc46e2842e45e76e6664f1","type":"GO_TERM","name":"phosphatidylserine receptor activity","canonical_id":"go:GO:7770029","description":"\"Combining with phosphatidylserine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [PMID:17960135, PMID:18082433]","metadata":null},{"id":"a0e77d105a574a0f93cec3e59d3475d6","type":"GO_TERM","name":"phosphatidylserine transfer activity","canonical_id":"go:GO:0140343","description":"\"Removes phosphatidylserine from the outer leaflet of a donor membrane, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to the outer leaflet of an acceptor membrane.\" [PMID:26206935]","metadata":null},{"id":"4555b34289f54e8fb5fe68e78398f5c3","type":"GO_TERM","name":"phosphatidylserine-phosphatidylinositol-4-phosphate exchange activity","canonical_id":"go:GO:0160270","description":"\"Catalysis of the reaction: a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate)(out) + a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate)(in) + a 1,2-diacyl-sn-glycero-3-phospho-L-serine(out). This reaction results in the exchange of phosphatidylserine (PS) for phosphatidylinositol-4-phosphate (PI(4)P) between membranes.\" [PMID:34249917, PMID:39106189, RHEA:81667]","metadata":null},{"id":"9c703ffdb85646c6b943fcd7a2e9f8da","type":"GO_TERM","name":"phosphatidyltransferase activity","canonical_id":"go:GO:0030572","description":"\"Catalysis of the reaction involving the transfer of a phosphatidate (otherwise known as diacylglycerol 3-phosphosphate) group.\" [GOC:mb]","metadata":null},{"id":"d9ff23dcbb5046538c2cbeddf311c09a","type":"GO_TERM","name":"phosphinothricin N-acetyltransferase activity","canonical_id":"go:GO:0102971","description":"\"Catalysis of the reaction: acetyl-CoA + phosphinothricin = H+ + coenzyme A(4-) + N-acetylphosphinatothricinate.\" [EC:2.3.1.183, GOC:pz]","metadata":null},{"id":"ada30bc4314240a78d6da1b4c4b2c634","type":"GO_TERM","name":"phospho-N-acetylmuramoyl-pentapeptide-transferase activity","canonical_id":"go:GO:0008963","description":"\"Catalysis of the reaction: di-trans,octa-cis-undecaprenyl phosphate + UDP-N-acetyl-alpha-D-muramoyl-L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanyl-D-alanine = Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl diphosphate + UMP.\" [RHEA:21920]","metadata":null},{"id":"bf724ec47ff14375acc6a359f7c1f74e","type":"GO_TERM","name":"phosphoacetylglucosamine mutase activity","canonical_id":"go:GO:0004610","description":"\"Catalysis of the reaction: N-acetyl-alpha-D-glucosamine 1-phosphate = N-acetyl-D-glucosamine 6-phosphate.\" [EC:5.4.2.3, RHEA:23804]","metadata":null},{"id":"54d118e3b1614fb4a9c73b2869065ff6","type":"GO_TERM","name":"phosphoadenylyl-sulfate reductase (thioredoxin) activity","canonical_id":"go:GO:0004604","description":"\"Catalysis of the reaction: adenosine 3',5'-diphosphate + H+ + sulfite + thioredoxin disulfide = 3'-phospho-5'-adenylyl sulfate + thioredoxin. Thioredoxin disulfide is the oxidized form of thioredoxin; 3'-phosphoadenosine 5'-phosphosulfate is also known as PAPS.\" [EC:1.8.4.8, RHEA:11724]","metadata":null},{"id":"acec9e3e0a8944b8846519b3006c65f6","type":"GO_TERM","name":"phosphoadenylylsulfatase activity","canonical_id":"go:GO:0050186","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + H2O = adenosine 3',5'-bisphosphate + sulfate.\" [EC:3.6.2.2]","metadata":null},{"id":"6a6f3a4ebb36487e83c87934304367d8","type":"GO_TERM","name":"phosphoamidase activity","canonical_id":"go:GO:0050187","description":"\"Catalysis of the reaction: N-phosphocreatine + H2O = creatine + phosphate.\" [RHEA:12977]","metadata":null},{"id":"41172b8f44f440fc93f3d6b4518b2d39","type":"GO_TERM","name":"phosphoanandamide dephosphorylation","canonical_id":"go:GO:0035644","description":"\"The process of removing one or more phosphate groups from a phosphorylated anandamide.\" [GOC:BHF, PMID:16938887]","metadata":null},{"id":"2420cf76c1654d078467fa8b0eb2d44b","type":"GO_TERM","name":"phosphocholine hydrolase activity","canonical_id":"go:GO:0044606","description":"\"Catalysis of the reaction: protein-serine-choline phosphate + H2O = protein-serine + choline phosphate.\" [GOC:sp, PMID:22158903]","metadata":null},{"id":"0100d91fa279486b9760ab84d39681c3","type":"GO_TERM","name":"phosphocholine phosphatase activity","canonical_id":"go:GO:0052731","description":"\"Catalysis of the reaction: phosphocholine + H2O = choline + phosphate.\" [RHEA:10492]","metadata":null},{"id":"1665cb844322456cbf615f5840218bcc","type":"GO_TERM","name":"phosphocholine transferase activity","canonical_id":"go:GO:0044605","description":"\"Catalysis of the reaction: CDP-choline + protein-serine = CMP + protein-serine-choline phosphate.\" [GOC:sp, PMID:21822290]","metadata":null},{"id":"b43fc32f28074fdea2a6d006edc57b7f","type":"GO_TERM","name":"phosphocreatine biosynthetic process","canonical_id":"go:GO:0046314","description":"\"The chemical reactions and pathways resulting in the formation of phosphocreatine, a phosphagen of creatine which is synthesized and broken down by creatine phosphokinase.\" [GOC:ai]","metadata":null},{"id":"e957124e300949b19183561dfd45e6d6","type":"GO_TERM","name":"phosphocreatine catabolic process","canonical_id":"go:GO:0046315","description":"\"The chemical reactions and pathways resulting in the breakdown of phosphocreatine, a phosphagen of creatine which is synthesized and broken down by creatine phosphokinase.\" [GOC:ai]","metadata":null},{"id":"bd03074904b54764bd04785757c04acb","type":"GO_TERM","name":"phosphocreatine metabolic process","canonical_id":"go:GO:0006603","description":"\"The chemical reactions and pathways involving phosphocreatine, a phosphagen of creatine present in high concentration in striated muscle which is synthesized and broken down by creatine phosphokinase to buffer ATP concentration. It acts as an immediate energy reserve for muscle.\" [PMID:16371597]","metadata":null},{"id":"31daa6fe46594b0dab34f572abbc052e","type":"GO_TERM","name":"phosphodiesterase I activity","canonical_id":"go:GO:0004528","description":"\"Catalysis of the sequential hydrolytic removal of 5'-nucleotides from the 3'-hydroxy termini of 3'-hydroxy-terminated oligonucleotides.\" [EC:3.1.4.1]","metadata":null},{"id":"cbcaf4a668b242f8b3cb17e535ebc5eb","type":"GO_TERM","name":"phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strands","canonical_id":"go:GO:0090580","description":"\"Catalysis of the hydrolytic removal of phosphoglycolate from the 3'-terminus of a 3'-phosphoglycolate-terminated DNA strand.\" [GOC:pde, GOC:rb, PMID:11238902]","metadata":null},{"id":"5cd21f59694f41faa51195f7dae67505","type":"GO_TERM","name":"phosphodiesterase decapping endonuclease activity","canonical_id":"go:GO:1990174","description":"\"Catalysis of the removal of the cap from an unmethylated 5'-end capped RNA resulting in the release of the entire cap structure (GpppN) and a 5' monophosphorylated RNA.\" [GOC:dgf, PMID:20802481]","metadata":null},{"id":"4e019a9f08dd486196ac468ebf5e47a7","type":"GO_TERM","name":"phosphoenolpyruvate carboxykinase (ATP) activity","canonical_id":"go:GO:0004612","description":"\"Catalysis of the reaction: ATP + oxaloacetate = ADP + CO2 + H+ + phosphoenolpyruvate.\" [EC:4.1.1.49, RHEA:18617]","metadata":null},{"id":"c5e5dc30d94343a9b4f7bf4dad6db29f","type":"GO_TERM","name":"phosphoenolpyruvate carboxykinase (GTP) activity","canonical_id":"go:GO:0004613","description":"\"Catalysis of the reaction: GTP + oxaloacetate = GDP + phosphoenolpyruvate + CO2.\" [EC:4.1.1.32]","metadata":null},{"id":"491bdec9269d4066ac26e2b6bd29a12d","type":"GO_TERM","name":"phosphoenolpyruvate carboxykinase (diphosphate) activity","canonical_id":"go:GO:0030585","description":"\"Catalysis of the reaction: diphosphate + oxaloacetate = CO2 + phosphate + phosphoenolpyruvate.\" [EC:4.1.1.38, RHEA:22356]","metadata":null},{"id":"1bfeba9e0b984a2db605deecd7e6ec40","type":"GO_TERM","name":"phosphoenolpyruvate carboxykinase activity","canonical_id":"go:GO:0004611","description":"\"Catalysis of the reaction: phosphate + oxaloacetate = phosphoenolpyruvate + CO2 + other reaction products.\" [GOC:curators]","metadata":null},{"id":"2b12404af8e04216b0aa6a2b43f26069","type":"GO_TERM","name":"phosphoenolpyruvate carboxylase activity","canonical_id":"go:GO:0008964","description":"\"Catalysis of the reaction: phosphate + oxaloacetate = phosphoenolpyruvate + HCO3-.\" [EC:4.1.1.31]","metadata":null},{"id":"41af83d8017e4a0e8c9fdd084249d980","type":"GO_TERM","name":"phosphoenolpyruvate mutase activity","canonical_id":"go:GO:0050188","description":"\"Catalysis of the reaction: phosphoenolpyruvate = 3-phosphonopyruvate.\" [EC:5.4.2.9, RHEA:17013]","metadata":null},{"id":"4d5299423cde49e690f9b6970aafd8d2","type":"GO_TERM","name":"phosphoenolpyruvate phosphatase activity","canonical_id":"go:GO:0050189","description":"\"Catalysis of the reaction: H2O + phosphoenolpyruvate = phosphate + pyruvate.\" [EC:3.1.3.60, RHEA:19997]","metadata":null},{"id":"91bae0054847419296a0b32d69bb7634","type":"GO_TERM","name":"phosphoenolpyruvate transmembrane import into Golgi lumen","canonical_id":"go:GO:1990536","description":"\"The directed movement of phosphoenolpyruvate into the Golgi lumen across the Golgi membrane.\" [PMID:25195688]","metadata":null},{"id":"598aa4dba5644a07b8bcd7ba695d61a5","type":"GO_TERM","name":"phosphoenolpyruvate transmembrane transport","canonical_id":"go:GO:0089722","description":"\"The directed movement of phosphoenolpytuvate across a membrane.\" [GOC:dos]","metadata":null},{"id":"f4fa5ae6a117438f82e16f60ab3c511a","type":"GO_TERM","name":"phosphoenolpyruvate transmembrane transporter activity","canonical_id":"go:GO:0089721","description":"\"Enables the transfer of a phosphoenolpyruvate from one side of a membrane to the other.\" [GOC:dos]","metadata":null},{"id":"378937582b67472893b45f03737c24e9","type":"GO_TERM","name":"phosphoenolpyruvate transport","canonical_id":"go:GO:0015714","description":"\"The directed movement of phosphoenolpyruvate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"b402eb3f27ff4b96a47fbf733ac00962","type":"GO_TERM","name":"phosphoenolpyruvate-dependent mannosylglycerate phosphotransferase system","canonical_id":"go:GO:0051476","description":"\"A phosphoenolpyruvate-dependent sugar phosphotransferase transport specific for mammosylglycerate.\" [PMID:368051]","metadata":null},{"id":"e9a888441f8a43e894080ddc1e1fa48c","type":"GO_TERM","name":"phosphoenolpyruvate-dependent sugar phosphotransferase complex","canonical_id":"go:GO:0019197","description":"\"Includes phosphoenolpyruvate-protein phosphatase (enzyme I of the phosphotransferase system) and protein-N(PI)-phosphohistidine-sugar phosphotransferase (enzyme II of the phosphotransferase system).\" [GOC:ma]","metadata":null},{"id":"9af36cea30384610bc006bbf50eab06b","type":"GO_TERM","name":"phosphoenolpyruvate-dependent sugar phosphotransferase system","canonical_id":"go:GO:0009401","description":"\"The uptake and phosphorylation of specific carbohydrates from the extracellular environment; uptake and phosphorylation are coupled, making the PTS a link between the uptake and metabolism of sugars; phosphoenolpyruvate is the original phosphate donor; phosphoenolpyruvate passes the phosphate via a signal transduction pathway, to enzyme 1 (E1), which in turn passes it on to the histidine protein, HPr; the next step in the system involves sugar-specific membrane-bound complex, enzyme 2 (EII), which transports the sugar into the cell; it includes the sugar permease, which catalyzes the transport reactions; EII is usually divided into three different domains, EIIA, EIIB, and EIIC.\" [PMID:31209249, PMID:33820910]","metadata":null},{"id":"bbaee8abf78349948d466dae225d6800","type":"GO_TERM","name":"phosphoenolpyruvate-glycerone phosphotransferase activity","canonical_id":"go:GO:0047324","description":"\"Catalysis of the reaction: glycerone + phosphoenolpyruvate = glycerone phosphate + pyruvate.\" [EC:2.7.1.121, RHEA:18381]","metadata":null},{"id":"375f0a419c2a49959f76e2e2a277e770","type":"GO_TERM","name":"phosphoenolpyruvate-protein phosphotransferase activity","canonical_id":"go:GO:0008965","description":"\"Catalysis of the reaction: phosphoenolpyruvate + protein L-histidine = pyruvate + protein N(pi)-phospho-L-histidine.\" [EC:2.7.3.9]","metadata":null},{"id":"f56dda8503ff4acda4e31e0088862f2e","type":"GO_TERM","name":"phosphoenolpyruvate:phosphate antiporter activity","canonical_id":"go:GO:0015121","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: phosphoenolpyruvate(out) + phosphate(in) = phosphoenolpyruvate(in) + phosphate(out).\" [GOC:bf, GOC:jl]","metadata":null},{"id":"43562279898a4f34a602151ebaec89d2","type":"GO_TERM","name":"phosphoethanolamine N-methyltransferase activity","canonical_id":"go:GO:0000234","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + ethanolamine phosphate = S-adenosyl-L-homocysteine + N-methylethanolamine phosphate.\" [EC:2.1.1.103]","metadata":null},{"id":"6a07aab4153a4b9bbe74a14d136fd15a","type":"GO_TERM","name":"phosphoethanolamine phosphatase activity","canonical_id":"go:GO:0052732","description":"\"Catalysis of the reaction: phosphoethanolamine + H2O = ethanolamine + phosphate.\" [RHEA:16089]","metadata":null},{"id":"621871c54abd46269e5b3dbb10057f98","type":"GO_TERM","name":"phosphofructokinase activity","canonical_id":"go:GO:0008443","description":"\"Catalysis of the transfer of a phosphate group, usually from ATP, to a phosphofructose substrate molecule.\" [GOC:jl]","metadata":null},{"id":"a97fe9cf7d5348818d523343af3a1e4b","type":"GO_TERM","name":"phosphoglucan, water dikinase activity","canonical_id":"go:GO:0051752","description":"\"Catalysis of the reaction: [(1->4)-6-phospho-alpha-D-glucosyl](n) + n ATP + n H2O = [(1->4)-3,6-bisphospho-alpha-alpha-glucosyl](n) + n AMP + 2n H+ + n phosphate.\" [PMID:15618411, RHEA:10256]","metadata":null},{"id":"5e18e3e8e3174e9eba7f05cb1a3b9244","type":"GO_TERM","name":"phosphoglucokinase activity","canonical_id":"go:GO:0050190","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + ATP = alpha-D-glucose 1,6-bisphosphate + ADP + 2 H+.\" [EC:2.7.1.10, RHEA:13377]","metadata":null},{"id":"9731d6dccc6247a5913ba078658bf95f","type":"GO_TERM","name":"phosphoglucomutase activity","canonical_id":"go:GO:0004614","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate = alpha-D-glucose 6-phosphate.\" [EC:5.4.2.2]","metadata":null},{"id":"9da804aa93894a23aceafe344c04b7ad","type":"GO_TERM","name":"phosphogluconate 2-dehydrogenase activity","canonical_id":"go:GO:0008114","description":"\"Catalysis of the reaction: 6-phospho-D-gluconate + NADP+ = 6-phospho-2-dehydro-D-gluconate + NADPH.\" [EC:1.1.1.43]","metadata":null},{"id":"fc12418936c64d5689c6556c8f9a29c3","type":"GO_TERM","name":"phosphogluconate dehydratase activity","canonical_id":"go:GO:0004456","description":"\"Catalysis of the reaction: 6-phospho-D-gluconate = 2-dehydro-3-deoxy-6-phospho-D-gluconate + H2O.\" [EC:4.2.1.12, RHEA:17277]","metadata":null},{"id":"f6191a51ee4f423a889d93486969fbae","type":"GO_TERM","name":"phosphogluconate dehydrogenase (decarboxylating) activity","canonical_id":"go:GO:0004616","description":"\"Catalysis of the reaction: 6-phospho-D-gluconate + NADP+ = D-ribulose 5-phosphate + CO2 + NADPH + H+.\" [EC:1.1.1.44]","metadata":null},{"id":"bbdec2e458e74945ac14f0f6eb0a4f63","type":"GO_TERM","name":"phosphoglucosamine mutase activity","canonical_id":"go:GO:0008966","description":"\"Catalysis of the reaction: alpha-D-glucosamine 1-phosphate = D-glucosamine 6-phosphate.\" [EC:5.4.2.10, RHEA:23424]","metadata":null},{"id":"8a576d2ffa4a48ce9b24304f846052ec","type":"GO_TERM","name":"phosphoglycerate dehydrogenase activity","canonical_id":"go:GO:0004617","description":"\"Catalysis of the reaction: 3-phosphoglycerate + NAD+ = 3-phosphohydroxypyruvate + NADH + H+.\" [EC:1.1.1.95]","metadata":null},{"id":"e7260db9e11d4656a3fba0d2c59bf45f","type":"GO_TERM","name":"phosphoglycerate kinase (GTP) activity","canonical_id":"go:GO:0050191","description":"\"Catalysis of the reaction: 3-phospho-D-glycerate + GTP = 3-phospho-D-glyceroyl phosphate + GDP + H+.\" [EC:2.7.2.10, RHEA:23332]","metadata":null},{"id":"38b72811788b4ae8837016facc325ed4","type":"GO_TERM","name":"phosphoglycerate kinase activity","canonical_id":"go:GO:0004618","description":"\"Catalysis of the reaction: 3-phospho-D-glycerate + ATP = 3-phospho-D-glyceroyl phosphate + ADP + H+.\" [EC:2.7.2.3, RHEA:14801]","metadata":null},{"id":"bb0d14d391954286869aa08bd6771c31","type":"GO_TERM","name":"phosphoglycerate mutase activity","canonical_id":"go:GO:0004619","description":"\"Catalysis of the reaction: (2R)-2-phosphoglycerate = (2R)-3-phosphoglycerate.\" [RHEA:15901]","metadata":null},{"id":"c0e123ac3970462288444446d158960e","type":"GO_TERM","name":"phosphoglycerate phosphatase activity","canonical_id":"go:GO:0050192","description":"\"Catalysis of the reaction: 2-phospho-D-glycerate + H2O = D-glycerate + phosphate.\" [EC:3.1.3.20, RHEA:21156]","metadata":null},{"id":"61f293892bfd4c54a39dce88b5b639d5","type":"GO_TERM","name":"phosphoglycerate transmembrane transport","canonical_id":"go:GO:0015713","description":"\"The process in which phosphoglycerate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"fc292a5b1f2f466da3e6cce11ed4aa69","type":"GO_TERM","name":"phosphoglycerate transmembrane transporter activity","canonical_id":"go:GO:0015120","description":"\"Enables the transfer of phosphoglycerates from one side of a membrane to the other. Phosphoglycerates are important intermediates in glycolysis and 3-phosphoglycerate is a precursor in serine biosynthesis.\" [GOC:ai]","metadata":null},{"id":"b87cdb0fa4644ed9b894c34030c5265b","type":"GO_TERM","name":"phosphoglycerol geranylgeranyltransferase activity","canonical_id":"go:GO:0047294","description":"\"Catalysis of the reaction: (2E,6E,10E)-geranylgeranyl diphosphate + sn-glycerol 1-phosphate = diphosphate + sn-3-O-(geranylgeranyl)glycerol 1-phosphate.\" [PMID:12801917, PMID:17253090, PMID:8408023, RHEA:23404]","metadata":null},{"id":"65f88510d44945f69376c3e28021061d","type":"GO_TERM","name":"phosphoglycolate phosphatase activity","canonical_id":"go:GO:0008967","description":"\"Catalysis of the reaction: 2-phosphoglycolate + H2O = glycolate + phosphate.\" [EC:3.1.3.18, RHEA:14369]","metadata":null},{"id":"20681af2dc1e4dca91383024cec8898e","type":"GO_TERM","name":"phosphoketolase activity","canonical_id":"go:GO:0050193","description":"\"Catalysis of the reaction: D-xylulose 5-phosphate + phosphate = acetyl phosphate + D-glyceraldehyde 3-phosphate + H2O.\" [EC:4.1.2.9, MetaCyc:PHOSPHOKETOLASE-RXN]","metadata":null},{"id":"e34ad2a5b85243e09a6707637d847f88","type":"GO_TERM","name":"phospholactate guanylyltransferase activity","canonical_id":"go:GO:0043814","description":"\"Catalysis of the reaction: 2-phospho-(S)-lactate + GTP = lactyl-2-diphospho-5'-guanosine + diphosphate.\" [PMID:18260642, RHEA:63424]","metadata":null},{"id":"3c96e364f0514d489816c53469be430f","type":"GO_TERM","name":"phospholamban complex","canonical_id":"go:GO:1990629","description":"\"A protein complex found as a homopentamer of the phospholamban (PLN) protein in the sarcoplasmic reticulum (SR) membrane of cardiomyocytes. Cardiac PLN is a main determinant of muscle contraction and relaxation, by regulating intracellular calcium levels.\" [GOC:ame, PMID:16043693]","metadata":null},{"id":"e165b80f9e37454ea8b9b153beca8eef","type":"GO_TERM","name":"phospholipase A2 activator activity","canonical_id":"go:GO:0016005","description":"\"Binds to and increases the activity of the enzyme phospholipase A2.\" [GOC:ai]","metadata":null},{"id":"07e90f3fe7704105854d14ae01028e55","type":"GO_TERM","name":"phospholipase A2 inhibitor activity","canonical_id":"go:GO:0019834","description":"\"Binds to and stops, prevents or reduces the activity of phospholipase A2.\" [GOC:ai]","metadata":null},{"id":"901a8a4ac0db4a148d87722843d49d08","type":"GO_TERM","name":"phospholipase C activator activity","canonical_id":"go:GO:0160185","description":"\"Binds to and increases the activity of the enzyme phospholipase C.\" [PMID:28130414]","metadata":null},{"id":"4cb2b33f34694a34b9923d2af73a1b45","type":"GO_TERM","name":"phospholipase C inhibitor activity","canonical_id":"go:GO:0160186","description":"\"Binds to and stops, prevents or reduces the activity of the enzyme phospholipase C.\" [PMID:28130414]","metadata":null},{"id":"a751e036d4464a70b41699ff79275476","type":"GO_TERM","name":"phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway","canonical_id":"go:GO:0007207","description":"\"A phospholipase C-activating G protein-coupled receptor signaling pathway initiated by acetylcholine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"cb0aa98a6ee14e7c862e87b3997bc01f","type":"GO_TERM","name":"phospholipase C-activating G protein-coupled glutamate receptor signaling pathway","canonical_id":"go:GO:0007206","description":"\"A phospholipase C-activating G protein-coupled receptor signaling pathway initiated by glutamate binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"5b3456b812fb4053a0a14a0386cbb8b2","type":"GO_TERM","name":"phospholipase C-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0007200","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 regulates the opening of calcium channels in intracellular calcium store, leading to the release of calcium into the cytosol. Calcium and DAG activate protein kinase C (PKC), which in turn activates downstream effectors.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194]","metadata":null},{"id":"91a7b6eba9304bc2948c050900f254c8","type":"GO_TERM","name":"phospholipase C-activating N-formyl peptide-activated signaling pathway","canonical_id":"go:GO:0140307","description":"\"A phospholipase C-activating G protein-coupled receptor signaling pathway initiated by an N-formyl peptide binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. chemotaxis. N-formyl peptides include N-formylmethionyl-leucyl-phenylalanine (fMLF, fMLP or N-formyl-met-leu-phe), an N-formylated tripeptide sometimes simply referred to as chemotactic peptide. fMLF is a potent polymorphonuclear leukocyte (PMN) chemotactic factor and is also a macrophage activator.\" [PMID:10466071, PMID:22728827, PMID:23994464]","metadata":null},{"id":"4f4dbd7d1dc84368b0feae27dea59dd5","type":"GO_TERM","name":"phospholipase C-activating adrenergic receptor signaling pathway","canonical_id":"go:GO:0071882","description":"\"A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"32962e645a4b47809e94e763d0c24758","type":"GO_TERM","name":"phospholipase C-activating angiotensin-activated signaling pathway","canonical_id":"go:GO:0086097","description":"\"A phospholipase C-activating G protein-coupled receptor signaling pathway initiated by angiotensin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"57edcf46a0fb4295adf14f21c2bfdbfd","type":"GO_TERM","name":"phospholipase C-activating dopamine receptor signaling pathway","canonical_id":"go:GO:0060158","description":"\"A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dph, GOC:signaling, GOC:tb, PMID:12675914]","metadata":null},{"id":"c53bb60a2caa4b57bb6fd58f67342aaa","type":"GO_TERM","name":"phospholipase C-activating endothelin receptor signaling pathway","canonical_id":"go:GO:0160135","description":"\"A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by endothelin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:35284927]","metadata":null},{"id":"f7d410e4c0c5497aa74e6345bc5f8e86","type":"GO_TERM","name":"phospholipase C-activating opsin-mediated signaling pathway","canonical_id":"go:GO:0030265","description":"\"A phospholipase C-activating receptor G protein-coupled receptor signaling pathway that starts with an opsin being activated by a photon, and transmitting the signal through the Gq-mediated activation of phospholipase C (PLC). PLC hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into the second messengers inositol-1,4,5,-triphosphate (IP3) and diacylglycerol (DAG). The second messengers, including cGMP, activate channels that result in transmission of the light signal  through the synapses. Typical examples are rhabdomeric photoreceptors in the eyes of protostomes.\" [PMID:19720651, PMID:22498302, PMID:8823931]","metadata":null},{"id":"9503cdfe1ea8457a99322a755d0eda2c","type":"GO_TERM","name":"phospholipase C-activating serotonin receptor signaling pathway","canonical_id":"go:GO:0007208","description":"\"A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by serotonin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"3407caa5956f43549c827730477796a6","type":"GO_TERM","name":"phospholipase C-activating tachykinin receptor signaling pathway","canonical_id":"go:GO:0007209","description":"\"A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by tachykinin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]","metadata":null},{"id":"3672e311a5f44e19a39dffa3cb98a8b1","type":"GO_TERM","name":"phospholipase C-inhibiting G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0030845","description":"\"A G protein-coupled receptor signaling pathway which proceeds with inhibition of phospholipase C (PLC) activity and a subsequent decrease in the levels of cellular inositol trisphosphate (IP3) and diacylglycerol (DAG).\" [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, PMID:8280098]","metadata":null},{"id":"81adfb4e6e044f2091692a8cd26abe18","type":"GO_TERM","name":"phospholipase C/protein kinase C signal transduction","canonical_id":"go:GO:0141212","description":"\"An intracellular signaling cassette that starts with activation of phospholipase C (PLC) activity and ends with the activation of protein kinase C (PKC). PLC produces inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 regulates the opening of calcium channels in intracellular calcium store, leading to the release of calcium into the cytosol. Calcium and DAG activate protein kinase C (PKC), which in turn activates downstream effectors. This cassette is often part of the phospholipase C-activating G protein-coupled receptor signaling pathway.\" [PMID:26605346]","metadata":null},{"id":"3baac1a9280e4e799b3a8817e808dfb8","type":"GO_TERM","name":"phospholipase D activator activity","canonical_id":"go:GO:1990583","description":"\"Binds to and increases the activity of the enzyme phospholipase D.\" [PMID:7972129]","metadata":null},{"id":"8faea740beea4f81ac15f1642f96a2e0","type":"GO_TERM","name":"phospholipase D inhibitor activity","canonical_id":"go:GO:0060961","description":"\"Binds to and stops, prevents or reduces the activity of phospholipase D.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"864730c183b84cc48c0d01aa3e6bd732","type":"GO_TERM","name":"phospholipase D-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0031583","description":"\"A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase D (PLD) and a subsequent increase in the intracellular concentration of phosphatidic acid (PA).\" [GOC:mah, GOC:signaling, PMID:11812783, PMID:15924269]","metadata":null},{"id":"4040756c7eae421f955d41371464d96f","type":"GO_TERM","name":"phospholipase activator activity","canonical_id":"go:GO:0016004","description":"\"Binds to and increases the activity of a phospholipase, an enzyme that catalyzes of the hydrolysis of a glycerophospholipid.\" [GOC:ai]","metadata":null},{"id":"e2a6b587e395498eb4ebf4c05b37462f","type":"GO_TERM","name":"phospholipase activity","canonical_id":"go:GO:0120569","description":"\"Catalysis of the hydrolysis of a phospholipid.\" [PMID:30109646]","metadata":null},{"id":"67a30854cb7a4617b07a2e51fcf64a4e","type":"GO_TERM","name":"phospholipase binding","canonical_id":"go:GO:0043274","description":"\"Binding to a phospholipase.\" [GOC:jl]","metadata":null},{"id":"21408cc99abf479290ca444e03f73c74","type":"GO_TERM","name":"phospholipase inhibitor activity","canonical_id":"go:GO:0004859","description":"\"Binds to and stops, prevents or reduces the activity of a phospholipase, an enzyme that catalyzes of the hydrolysis of a phospholipid.\" [GOC:ai, GOC:rl]","metadata":null},{"id":"8fb760970dce404e87e6bf2773af3550","type":"GO_TERM","name":"phospholipid binding","canonical_id":"go:GO:0005543","description":"\"Binding to a phospholipid, a class of lipids containing phosphoric acid as a mono- or diester.\" [ISBN:0198506732]","metadata":null},{"id":"795c9f83bb214baa8a00bb05cdab076a","type":"GO_TERM","name":"phospholipid biosynthetic process","canonical_id":"go:GO:0008654","description":"\"The chemical reactions and pathways resulting in the formation of a phospholipid, a lipid containing phosphoric acid as a mono- or diester.\" [ISBN:0198506732]","metadata":null},{"id":"9feabd8e8be44e3687545c1d8fbf2b67","type":"GO_TERM","name":"phospholipid catabolic process","canonical_id":"go:GO:0009395","description":"\"The chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.\" [ISBN:0198506732]","metadata":null},{"id":"325f3cccbb3748eeb3ece506a0feed11","type":"GO_TERM","name":"phospholipid dephosphorylation","canonical_id":"go:GO:0046839","description":"\"The process of removing one or more phosphate groups from a phosphorylated lipid, any member of a group of substances soluble in lipid solvents but only sparingly soluble in aqueous solvents.\" [ISBN:0198506732]","metadata":null},{"id":"7a659a92eee440dd86be50b0946eb603","type":"GO_TERM","name":"phospholipid efflux","canonical_id":"go:GO:0033700","description":"\"The directed movement of a phospholipid out of a cell or organelle.\" [GOC:mah]","metadata":null},{"id":"990d389542bd48b8bfa741a4416c234a","type":"GO_TERM","name":"phospholipid homeostasis","canonical_id":"go:GO:0055091","description":"\"Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"9657d04a0d1e4ab2a6cbdf5402e5a8ad","type":"GO_TERM","name":"phospholipid metabolic process","canonical_id":"go:GO:0006644","description":"\"The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester.\" [ISBN:0198506732]","metadata":null},{"id":"0739c4df527c49f6af16e9ad3cedefb4","type":"GO_TERM","name":"phospholipid scramblase activity","canonical_id":"go:GO:0017128","description":"\"Catalysis of the movement of phospholipids from one membrane bilayer leaflet to the other, by an ATP-independent mechanism.\" [GOC:cjm, PMID:20043909, PMID:20302864]","metadata":null},{"id":"23586370dcac403798664bbcaf2ea516","type":"GO_TERM","name":"phospholipid transfer activity","canonical_id":"go:GO:0120014","description":"\"Removes a phospholipid from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"c12f4e4eeb094637bfefd3df9729c32c","type":"GO_TERM","name":"phospholipid transfer to membrane","canonical_id":"go:GO:0006649","description":"\"The transfer of a phospholipid from its site of synthesis to the plasma membrane.\" [GOC:curators]","metadata":null},{"id":"e82fd4177a65484581d1d2e59da1e1a2","type":"GO_TERM","name":"phospholipid translocation","canonical_id":"go:GO:0045332","description":"\"The movement of a phospholipid molecule from one leaflet of a membrane bilayer to the opposite leaflet.\" [ISBN:0815316194, PMID:16452632, PMID:20043909, PMID:20302864]","metadata":null},{"id":"acd18a824bc34d08ad17343a9124ac5f","type":"GO_TERM","name":"phospholipid transport","canonical_id":"go:GO:0015914","description":"\"The directed movement of phospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Phospholipids are any lipids containing phosphoric acid as a mono- or diester.\" [GOC:ai]","metadata":null},{"id":"d40eb27d51e84353b3e10ab39fe82d70","type":"GO_TERM","name":"phospholipid-hydroperoxide glutathione peroxidase activity","canonical_id":"go:GO:0047066","description":"\"Catalysis of the reaction: a hydroperoxy polyunsaturated fatty acid + 2 glutathione = a hydroxy polyunsaturated fatty acid + glutathione disulfide + H2O.\" [PMID:3978121, PMID:8617728, RHEA:19057]","metadata":null},{"id":"ac38f7bfbb394a08bdb30a65c8266c95","type":"GO_TERM","name":"phospholipid-translocating ATPase complex","canonical_id":"go:GO:1990531","description":"\"A protein complex that functions as a phospholipid-translocating P-Type ATPase.\" [GOC:dph, GOC:rb, PMID:15090616]","metadata":null},{"id":"660793f2aa214780b77929bd70724cba","type":"GO_TERM","name":"phospholipid:diacylglycerol acyltransferase activity","canonical_id":"go:GO:0046027","description":"\"Catalysis of the reaction: a glycerophospholipid + a 1,2-diacyl-sn-glycerol = a monoacylglycerophospholipid + a triacyl-sn-glycerol.\" [RHEA:14057]","metadata":null},{"id":"de784fbb160e4fd0b959c8fa610ca562","type":"GO_TERM","name":"phosphomannan mannosephosphotransferase activity","canonical_id":"go:GO:0047361","description":"\"Catalysis of the reaction: phosphomannan(n) + GDP-mannose = phosphomannan(n+1) + GMP.\" [EC:2.7.8.9, MetaCyc:2.7.8.9-RXN]","metadata":null},{"id":"3613bf7802bb4a3f93d027a34e2fdfed","type":"GO_TERM","name":"phosphomannomutase activity","canonical_id":"go:GO:0004615","description":"\"Catalysis of the reaction: alpha-D-mannose 1-phosphate = D-mannose 6-phosphate.\" [EC:5.4.2.8, RHEA:11140]","metadata":null},{"id":"46fee004b4cb4135b588f6002e9b3466","type":"GO_TERM","name":"phosphomannomutase complex","canonical_id":"go:GO:1990232","description":"\"A protein complex capable of phosphomannomutase activity.\" [GOC:bhm, PMID:16540464]","metadata":null},{"id":"a2bf0c14a47e4bf4bc70b29ae65c743a","type":"GO_TERM","name":"phosphomethylpyrimidine kinase activity","canonical_id":"go:GO:0008972","description":"\"Catalysis of the reaction: ATP + 4-amino-2-methyl-5-phosphomethylpyrimidine = ADP + 4-amino-2-methyl-5-diphosphomethylpyrimidine.\" [EC:2.7.4.7]","metadata":null},{"id":"ef70530a79b048f2b80b9642341e1889","type":"GO_TERM","name":"phosphomethylpyrimidine synthase activity","canonical_id":"go:GO:0070284","description":"\"Catalysis of the reaction: 5-amino-1-(5-phospho-beta-D-ribosyl)imidazole + S-adenosyl-L-methionine = 4-amino-2-methyl-5-(phosphooxymethyl)pyrimidine + CO + 5'-deoxyadenosine + formate + L-methionine + 3 H+.\" [PMID:18953358, RHEA:24840]","metadata":null},{"id":"317aaefa5e2246f993f6c0dececbe513","type":"GO_TERM","name":"phosphomevalonate decarboxylase activity","canonical_id":"go:GO:0090710","description":"\"Catalysis of the reaction: (R)-5-phosphomevalonate + ATP = ADP + CO2 + isopentenyl phosphate + phosphate.\" [PMID:24375100, RHEA:40955]","metadata":null},{"id":"25c6929a758147f1ad717675d19e7283","type":"GO_TERM","name":"phosphomevalonate kinase activity","canonical_id":"go:GO:0004631","description":"\"Catalysis of the reaction: (R)-5-phosphomevalonate + ATP = (R)-5-diphosphomevalonate + ADP + H+.\" [EC:2.7.4.2, RHEA:16341]","metadata":null},{"id":"5062137e24b547ce93bb34f7778ba5c3","type":"GO_TERM","name":"phosphonate dehydrogenase activity","canonical_id":"go:GO:0050609","description":"\"Catalysis of the reaction: H2O + NAD+ + phosphonate = 2 H+ + NADH + phosphate.\" [EC:1.20.1.1, RHEA:13173]","metadata":null},{"id":"3cbd331b73a74663b1634f1bd277bfe7","type":"GO_TERM","name":"phosphonoacetaldehyde hydrolase activity","canonical_id":"go:GO:0050194","description":"\"Catalysis of the reaction: H2O + phosphonoacetaldehyde = acetaldehyde + H+ + phosphate.\" [RHEA:18905]","metadata":null},{"id":"429bed90102d4517975f69e33918ca73","type":"GO_TERM","name":"phosphonoacetate hydrolase activity","canonical_id":"go:GO:0047400","description":"\"Catalysis of the reaction: H2O + phosphonoacetate = acetate + H+ + phosphate.\" [RHEA:16749]","metadata":null},{"id":"6e8ad89b03b9411a91797ef19565d673","type":"GO_TERM","name":"phosphonoacetate metabolic process","canonical_id":"go:GO:0019636","description":"\"The chemical reactions and pathways involving phosphonoacetate, C2H4PO5, a substance composed of an acetate and a phosphonic acid residue.\" [MetaCyc:P483-PWY]","metadata":null},{"id":"4bf8b409d1ea4057a5a08948c09251cc","type":"GO_TERM","name":"phosphonopyruvate decarboxylase activity","canonical_id":"go:GO:0033980","description":"\"Catalysis of the reaction: 3-phosphonopyruvate + 2 H+ = CO2 + phosphonoacetaldehyde.\" [EC:4.1.1.82, RHEA:20768]","metadata":null},{"id":"585d4aac838c46adbec681e459576565","type":"GO_TERM","name":"phosphonopyruvate hydrolase activity","canonical_id":"go:GO:0033978","description":"\"Catalysis of the reaction: 3-phosphonopyruvate + H2O = H+ + phosphate + pyruvate.\" [RHEA:16673]","metadata":null},{"id":"c2d23be40d04442399e11dbe14d6a2be","type":"GO_TERM","name":"phosphopantetheine binding","canonical_id":"go:GO:0031177","description":"\"Binding to phosphopantetheine, the vitamin pantetheine 4'-(dihydrogen phosphate).\" [GOC:mah, GOC:vw]","metadata":null},{"id":"fd995c8638aa48aeb349b6f0da7f8b90","type":"GO_TERM","name":"phosphopantetheine-dependent carrier activity","canonical_id":"go:GO:0140414","description":"\"Binding a substrate via a thioester at the terminal thiol of a covalentely linked phosphopantetheine prosthetic group and mediating protein-protein interactions with cognate enzymes for processing or offloading of the thiol-bound substrate.\" [PMID:17502372]","metadata":null},{"id":"fcc88b337f4e40d6b4dacbe56b3a3cc8","type":"GO_TERM","name":"phosphopantothenate--cysteine ligase activity","canonical_id":"go:GO:0004632","description":"\"Catalysis of the reaction: CTP + (R)-4'-phosphopantothenate + L-cysteine = CMP + diphosphate + (R)-4'-phosphopantothenoyl-L-cysteine. Cysteine can be replaced by some of its derivatives.\" [EC:6.3.2.5]","metadata":null},{"id":"8bff48ba55874293adc2c750e455780e","type":"GO_TERM","name":"phosphopantothenoylcysteine decarboxylase activity","canonical_id":"go:GO:0004633","description":"\"Catalysis of the reaction: N-[(R)-4-phosphonatopantothenoyl]-L-cysteinate + H+ = CO2 + pantetheine 4'-phosphate.\" [EC:4.1.1.36, RHEA:16793]","metadata":null},{"id":"3514e85413814797b5fca95bbfaf3d60","type":"GO_TERM","name":"phosphopantothenoylcysteine decarboxylase complex","canonical_id":"go:GO:0071513","description":"\"A protein complex that catalyzes decarboxylation of 4'-phosphopantothenoylcysteine to yield 4'-phosphopantetheine; this is the third step in the biosynthesis of Coenzyme A. The complex is homotrimeric in many eukaryotes, but is a heterotrimer in Saccharomyces.\" [GOC:jh, PMID:19915539]","metadata":null},{"id":"b976a54dba3c432791b9df2c5c0b2463","type":"GO_TERM","name":"phosphopentomutase activity","canonical_id":"go:GO:0008973","description":"\"Catalysis of the reaction: D-ribose 1-phosphate = D-ribose 5-phosphate. Also converts 2-deoxy-alpha-D-ribose 1-phosphate into 2-deoxy-D-ribose 5-phosphate.\" [EC:5.4.2.7]","metadata":null},{"id":"66bcf0d8ac35486f95afdda56948d10c","type":"GO_TERM","name":"phosphopolyprenol glucosyltransferase activity","canonical_id":"go:GO:0047272","description":"\"Catalysis of the reaction: polyprenyl phosphate + UDP-D-glucose = polyprenylphosphate-glucose + UDP.\" [EC:2.4.1.78, MetaCyc:2.4.1.78-RXN]","metadata":null},{"id":"86a2dbc23eb843a185f5ec63e5bb209a","type":"GO_TERM","name":"phosphoprotein binding","canonical_id":"go:GO:0051219","description":"\"Binding to a phosphorylated protein.\" [GOC:ai]","metadata":null},{"id":"f2314f0b1d6546fb8ae145889bf767ad","type":"GO_TERM","name":"phosphoprotein phosphatase activity","canonical_id":"go:GO:0004721","description":"\"Catalysis of the reaction: a phosphoprotein + H2O = a protein + phosphate. Together with protein kinases, these enzymes control the state of phosphorylation of cellular proteins and thereby provide an important mechanism for regulating cellular activity.\" [ISBN:0198547684]","metadata":null},{"id":"9b065146f9af460888216a777c16ec81","type":"GO_TERM","name":"phosphopyruvate hydratase activity","canonical_id":"go:GO:0004634","description":"\"Catalysis of the reaction: 2-phospho-D-glycerate = phosphoenolpyruvate + H2O.\" [EC:4.2.1.11, ISBN:0198506732]","metadata":null},{"id":"876fe219fb744bd1aa525d979624543c","type":"GO_TERM","name":"phosphopyruvate hydratase complex","canonical_id":"go:GO:0000015","description":"\"A multimeric enzyme complex, usually a dimer or an octamer, that catalyzes the conversion of 2-phospho-D-glycerate to phosphoenolpyruvate and water.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"d67849be1b0144539a4d9639c488e86f","type":"GO_TERM","name":"phosphoramidate-hexose phosphotransferase activity","canonical_id":"go:GO:0047329","description":"\"Catalysis of the reaction: phosphoramidate + a D-hexose + H+ = alpha-D-hexose 1-phosphate + NH4+.\" [RHEA:10972]","metadata":null},{"id":"bed91b4d48464062a9a1b471bd5dce5a","type":"GO_TERM","name":"phosphorelay response regulator activity","canonical_id":"go:GO:0000156","description":"\"Responds to a phosphorelay sensor to initiate a change in cell state or activity. The activity of the response regulator is regulated by transfer of a phosphate from a histidine residue in the sensor, to an aspartate residue in the response regulator. Many but not all response regulators act as transcriptional regulators to elicit a response.\" [GOC:bf, PMID:10966457, PMID:11842140]","metadata":null},{"id":"253505c94aae42f7960efc85dd1018ed","type":"GO_TERM","name":"phosphorelay sensor kinase activity","canonical_id":"go:GO:0000155","description":"\"Catalysis of the phosphorylation of a histidine residue in response to detection of an extracellular signal such as a chemical ligand or change in environment, to initiate a change in cell state or activity. The two-component sensor is a histidine kinase that autophosphorylates a histidine residue in its active site. The phosphate is then transferred to an aspartate residue in a downstream response regulator, to trigger a response.\" [GOC:bf, GOC:mcc, PMID:10966457, PMID:20223701, PMID:31386843, PMID:9191038]","metadata":null},{"id":"849cb91fac3948b19842346371b9bec4","type":"GO_TERM","name":"phosphorelay signal transduction system","canonical_id":"go:GO:0000160","description":"\"A conserved series of molecular signals found in prokaryotes and eukaryotes; involves autophosphorylation of a histidine kinase and the transfer of the phosphate group to an aspartate that then acts as a phospho-donor to response regulator proteins.\" [PMID:9191038]","metadata":null},{"id":"2cb181631198496ba25da8518140f25d","type":"GO_TERM","name":"phosphoribokinase activity","canonical_id":"go:GO:0050195","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + ATP = D-ribose 1,5-diphosphate + ADP + 2 H+.\" [EC:2.7.1.18, RHEA:21216]","metadata":null},{"id":"649e4aa3e3ab43a2b119fca6278209c9","type":"GO_TERM","name":"phosphoribosyl 1,2-cyclic phosphate 1,2-diphosphodiesterase activity","canonical_id":"go:GO:0102561","description":"\"Catalysis of the reaction: alpha-D-ribose 1,2-cyclic phosphate 5-phosphate + H2O = D-ribose 2,5-bisphosphate + H+.\" [EC:3.1.4.57]","metadata":null},{"id":"7a642c9bedf349beb2216a7e11229235","type":"GO_TERM","name":"phosphoribosyl 1,2-cyclic phosphate phosphodiesterase activity","canonical_id":"go:GO:0103043","description":"\"Catalysis of the reaction: alpha-D-ribose 1,2-cyclic phosphate 5-phosphate + H2O = alpha-D-ribose 1,5-bisphosphate + H+.\" [EC:3.1.4.55]","metadata":null},{"id":"c50e035d64834e38b7504f116212712c","type":"GO_TERM","name":"phosphoribosyl-AMP cyclohydrolase activity","canonical_id":"go:GO:0004635","description":"\"Catalysis of the reaction: 1-(5-phosphonatoribosyl)-5'-AMP + H2O = 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino]imidazole-4-carboxamide.\" [EC:3.5.4.19, RHEA:20049]","metadata":null},{"id":"ded6fe731b304584ba56f0986269156c","type":"GO_TERM","name":"phosphoribosyl-ATP diphosphatase activity","canonical_id":"go:GO:0004636","description":"\"Catalysis of the reaction: 1-(5-phospho-D-ribosyl)-ATP + H2O = 1-(5-phosphonatoribosyl)-5'-AMP + diphosphate + H+.\" [EC:3.6.1.31, RHEA:22828]","metadata":null},{"id":"517c2dbc712f45ad8ca74aba77fa71d0","type":"GO_TERM","name":"phosphoribosylamine-glycine ligase activity","canonical_id":"go:GO:0004637","description":"\"Catalysis of the reaction: 5-phospho-D-ribosylamine + ATP + glycine = N(1)-(5-phospho-D-ribosyl)glycinamide + ADP + 2 H+ + phosphate.\" [EC:6.3.4.13, RHEA:17453]","metadata":null},{"id":"21eb1fb2facb4ccb92dcf88e6fe8f34c","type":"GO_TERM","name":"phosphoribosylaminoimidazole carboxylase activity","canonical_id":"go:GO:0004638","description":"\"Catalysis of the reaction: 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate + 2 H+ = 5-amino-1-(5-phospho-D-ribosyl)imidazole + CO2.\" [EC:4.1.1.21, RHEA:10792]","metadata":null},{"id":"8845dc8c742b443c84d9d93fca10398f","type":"GO_TERM","name":"phosphoribosylaminoimidazole carboxylase complex","canonical_id":"go:GO:0009320","description":"\"A protein complex that possesses phosphoribosylaminoimidazole carboxylase activity.\" [GOC:mah]","metadata":null},{"id":"b3084faff5c14b66904362e75bbf6078","type":"GO_TERM","name":"phosphoribosylaminoimidazolecarboxamide formyltransferase activity","canonical_id":"go:GO:0004643","description":"\"Catalysis of the reaction: 10-formyltetrahydrofolate + 5'-phosphoribosyl-5-amino-4-imidazolecarboxamide = tetrahydrofolate + 5'-phosphoribosyl-5-formamido-4-imidazolecarboxamide.\" [EC:2.1.2.3]","metadata":null},{"id":"8e376582474e4f9eb31fc4ab3e19c766","type":"GO_TERM","name":"phosphoribosylaminoimidazolesuccinocarboxamide synthase activity","canonical_id":"go:GO:0004639","description":"\"Catalysis of the reaction: 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate + L-aspartate + ATP = (2S)-2-[5-amino-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamido]succinate + ADP + 2 H+ + phosphate.\" [EC:6.3.2.6, RHEA:22628]","metadata":null},{"id":"b4dc3df059d14a06914eb16b52339cea","type":"GO_TERM","name":"phosphoribosylanthranilate isomerase activity","canonical_id":"go:GO:0004640","description":"\"Catalysis of the reaction: N-(5-phospho-beta-D-ribosyl)anthranilate = 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate.\" [RHEA:21540]","metadata":null},{"id":"71b9927bedad42cab07d395c59da5428","type":"GO_TERM","name":"phosphoribosylformylglycinamidine cyclo-ligase activity","canonical_id":"go:GO:0004641","description":"\"Catalysis of the reaction: 2-(formamido)-N(1)-(5-phospho-D-ribosyl)acetamidine + ATP = 5-amino-1-(5-phospho-D-ribosyl)imidazole + ADP + 2 H+ + phosphate.\" [EC:6.3.3.1, RHEA:23032]","metadata":null},{"id":"c930b15f0c0c49d3a16f3dfc90f8b84a","type":"GO_TERM","name":"phosphoribosylformylglycinamidine synthase activity","canonical_id":"go:GO:0004642","description":"\"Catalysis of the reaction: N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide + L-glutamine + ATP + H2O = 2-(formamido)-N(1)-(5-phospho-D-ribosyl)acetamidine + L-glutamate + ADP + 2 H+ + phosphate.\" [EC:6.3.5.3, RHEA:17129]","metadata":null},{"id":"50ebc4a9fd8343afb67157aa7508eb15","type":"GO_TERM","name":"phosphoribosylglycinamide formyltransferase 2 activity","canonical_id":"go:GO:0043815","description":"\"Catalysis of the reaction: ATP + formate + N1-(5-phospho-beta-D-ribosyl)glycinamide = ADP + H+ + N2-formyl-N1-(5-phospho-beta-D-ribosyl)glycinamide + phosphate.\" [PMID:8117714, RHEA:24829]","metadata":null},{"id":"88a919528c8544adbfb75b0480fdb86d","type":"GO_TERM","name":"phosphoribosylglycinamide formyltransferase activity","canonical_id":"go:GO:0004644","description":"\"Catalysis of the reaction: 10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide = tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide.\" [EC:2.1.2.2]","metadata":null},{"id":"0ba5ea2b7bd64779a54a5fa66ac28b87","type":"GO_TERM","name":"phosphoribulokinase activity","canonical_id":"go:GO:0008974","description":"\"Catalysis of the reaction: D-ribulose 5-phosphate + ATP = D-ribulose 1,5-bisphosphate + ADP + 2 H+.\" [EC:2.7.1.19, RHEA:19365]","metadata":null},{"id":"5c085396f53f4ddf8fc8f3dee93c3e9d","type":"GO_TERM","name":"phosphoric diester hydrolase activity","canonical_id":"go:GO:0008081","description":"\"Catalysis of the hydrolysis of a phosphodiester to give a phosphomonoester and a free hydroxyl group.\" [EC:3.1.4.-]","metadata":null},{"id":"6e0ab9ed233c403aa2e9f499be748e8d","type":"GO_TERM","name":"phosphoric ester hydrolase activity","canonical_id":"go:GO:0042578","description":"\"Catalysis of the reaction: RPO-R' + H2O = RPOOH + R'H. This reaction is the hydrolysis of any phosphoric ester bond, any ester formed from orthophosphoric acid, O=P(OH)3.\" [GOC:jl]","metadata":null},{"id":"2649023df0574881a60a6fc9b8cdc10a","type":"GO_TERM","name":"phosphoric triester hydrolase activity","canonical_id":"go:GO:0016795","description":"\"Catalysis of the hydrolysis of a phosphoric triester.\" [EC:3.1.8.-, GOC:curators]","metadata":null},{"id":"bfb3591d356244db827a7f6f3c8b0445","type":"GO_TERM","name":"phosphorus metabolic process","canonical_id":"go:GO:0006793","description":"\"The chemical reactions and pathways involving the nonmetallic element phosphorus or compounds that contain phosphorus.\" [GOC:ai]","metadata":null},{"id":"9d7837f18e98484eadedf4add3b002c5","type":"GO_TERM","name":"phosphorus utilization","canonical_id":"go:GO:0006794","description":"\"A series of processes that forms an integrated mechanism by which a cell or an organism detects the depletion of primary phosphorus source and then activates genes to scavenge the last traces of the primary phosphorus source and to transport and metabolize alternative phosphorus sources. The utilization process begins when the cell or organism detects phosphorus levels, includes the phosphorus-containing substances, and ends when phosphorus is incorporated into the cell or organism's metabolism.\" [GOC:mah, GOC:mlg]","metadata":null},{"id":"0d27ae78feed434b9178618228b7d7c5","type":"GO_TERM","name":"phosphorus-oxygen lyase activity","canonical_id":"go:GO:0016849","description":"\"Catalysis of the cleavage of a phosphorus-oxygen bond by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond.\" [GOC:jl]","metadata":null},{"id":"098f9dcd2d66402baafdc71c273e5c57","type":"GO_TERM","name":"phosphorylase kinase activity","canonical_id":"go:GO:0004689","description":"\"Catalysis of the reaction: 4 ATP + 2 phosphorylase b = 4 ADP + phosphorylase a.\" [EC:2.7.11.19]","metadata":null},{"id":"8dda5bcd8ecb4c559475890c183fd54b","type":"GO_TERM","name":"phosphorylase kinase complex","canonical_id":"go:GO:0005964","description":"\"An enzyme complex that catalyzes the phosphorylation of phosphorylase b to form phosphorylase a.\" [PMID:1370475]","metadata":null},{"id":"4cc8e76d8b8344089c6a3580d4bdb7fc","type":"GO_TERM","name":"phosphorylase kinase regulator activity","canonical_id":"go:GO:0008607","description":"\"Modulation of the activity of the enzyme phosphorylase kinase.\" [GOC:curators]","metadata":null},{"id":"d833d40e929948b68c84f7bfb391767f","type":"GO_TERM","name":"phosphorylation","canonical_id":"go:GO:0016310","description":"\"The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide.\" [ISBN:0198506732]","metadata":null},{"id":"cae1cddb4cd34f76bf3795cc14e6d695","type":"GO_TERM","name":"phosphorylation-dependent protein binding","canonical_id":"go:GO:0140031","description":"\"Binding to a protein upon phosphorylation of the target protein.\" [PMID:26060076]","metadata":null},{"id":"fff640efb9fb48b38ab81640212ea3f3","type":"GO_TERM","name":"phosphoserine residue binding","canonical_id":"go:GO:0050815","description":"\"Binding to a phosphorylated serine residue within a protein.\" [GOC:ai]","metadata":null},{"id":"37b415b070fb4547b426a875b7813cb2","type":"GO_TERM","name":"phosphoserine-tRNA(Cys) ligase activity","canonical_id":"go:GO:0043816","description":"\"Catalysis of the reaction: tRNA(Cys) + O-phospho-L-serine + ATP = AMP + diphosphate + phosphoseryl-tRNA(Cys).\" [PMID:17110438, RHEA:25678]","metadata":null},{"id":"349d56f7466840c1b2964426b6b9e505","type":"GO_TERM","name":"phosphoserine:homoserine phosphotransferase activity","canonical_id":"go:GO:0043899","description":"\"Catalysis of the transfer of a phosphoryl group from phosphoserine to homoserine to form phosphohomoserine.\" [GOC:jl, PMID:14699121]","metadata":null},{"id":"3c4ae86f36ba447c8921756c4b4266cd","type":"GO_TERM","name":"phosphosulfolactate synthase activity","canonical_id":"go:GO:0043817","description":"\"Catalysis of the reaction: (2R)-O-phospho-3-sulfolactate = phosphoenolpyruvate + sulfite.\" [EC:4.4.1.19, RHEA:22784]","metadata":null},{"id":"76e4565ff437414eb43416e903ebcdb4","type":"GO_TERM","name":"phosphothreonine lyase activity","canonical_id":"go:GO:0034598","description":"\"Catalysis of the removal of the phosphate group from phosphothreonine by cleavage of the C-OP bond with the concomitant abstraction of the alpha proton, generating a double bond-containing product.\" [PMID:17303758, PMID:18084305]","metadata":null},{"id":"e55c68a9cb314c7ea46ac650ca00755a","type":"GO_TERM","name":"phosphothreonine residue binding","canonical_id":"go:GO:0050816","description":"\"Binding to a phosphorylated threonine residue within a protein.\" [GOC:ai]","metadata":null},{"id":"dd6e7d4a6f784f40946aaa44192ef104","type":"GO_TERM","name":"phosphotransferase activity, alcohol group as acceptor","canonical_id":"go:GO:0016773","description":"\"Catalysis of the transfer of a phosphorus-containing group from one compound (donor) to an alcohol group (acceptor).\" [EC:2.7.1.-]","metadata":null},{"id":"693ff53fd011412ba217b19b547191dd","type":"GO_TERM","name":"phosphotransferase activity, carboxyl group as acceptor","canonical_id":"go:GO:0016774","description":"\"Catalysis of the transfer of a phosphorus-containing group from one compound (donor) to a carboxyl group (acceptor).\" [EC:2.7.2.-]","metadata":null},{"id":"ff9f06bedb4d4a61aa6d62d7ccda9a13","type":"GO_TERM","name":"phosphotransferase activity, for other substituted phosphate groups","canonical_id":"go:GO:0016780","description":"\"Catalysis of the transfer of a substituted phosphate group, other than diphosphate or nucleotidyl residues, from one compound (donor) to a another (acceptor).\" [EC:2.7.8.-]","metadata":null},{"id":"d5e45742bee848fe800b573a20479475","type":"GO_TERM","name":"phosphotransferase activity, nitrogenous group as acceptor","canonical_id":"go:GO:0016775","description":"\"Catalysis of the transfer of a phosphorus-containing group from one compound (donor) to a nitrogenous group (acceptor).\" [EC:2.7.3.-]","metadata":null},{"id":"3e0140e66f7540b1b78b0f17f3aabd03","type":"GO_TERM","name":"phosphotransferase activity, paired acceptors","canonical_id":"go:GO:0016781","description":"\"Catalysis of the transfer of two phosphate groups from a donor, such as ATP, to two different acceptors.\" [EC:2.7.9.-]","metadata":null},{"id":"80c7f828cdbe43f282c3619835284200","type":"GO_TERM","name":"phosphotransferase activity, phosphate group as acceptor","canonical_id":"go:GO:0016776","description":"\"Catalysis of the transfer of a phosphorus-containing group from one compound (donor) to a phosphate group (acceptor).\" [EC:2.7.4.-]","metadata":null},{"id":"45b31ce8b88a4214bd29638955db66d2","type":"GO_TERM","name":"phosphotyrosine residue binding","canonical_id":"go:GO:0001784","description":"\"Binding to a phosphorylated tyrosine residue within a protein.\" [PMID:14636584]","metadata":null},{"id":"218a134bfa8247ec8bfb24f6db000879","type":"GO_TERM","name":"photoinhibition","canonical_id":"go:GO:0010205","description":"\"The mechanism by which high light intensity inhibits photosynthesis through inactivation of the D1 protein of photosystem II.\" [GOC:mtg_electron_transport, PMID:12068126]","metadata":null},{"id":"8a74dff51e50429e957f6425ca8da669","type":"GO_TERM","name":"photomorphogenesis","canonical_id":"go:GO:0009640","description":"\"The control of plant growth, development, and differentiation by the duration and nature of light, independent of photosynthesis.\" [GOC:lr]","metadata":null},{"id":"0f98ff75b3df40569d4e269d2be3d531","type":"GO_TERM","name":"photoperiodism","canonical_id":"go:GO:0009648","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a period of light or dark of a given length, measured relative to a particular duration known as the 'critical day length'. The critical day length varies between species.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"1e707c2262834bcbb811017d94f57c84","type":"GO_TERM","name":"photoperiodism, flowering","canonical_id":"go:GO:0048573","description":"\"A change from the vegetative to the reproductive phase as a result of detection of, or exposure to, a period of light or dark of a given length. The length of the period of light or dark required to initiate the change is set relative to a particular duration known as the 'critical day length'. The critical day length varies between species.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"feff9bfacac84fb0a8a5f27d356be67e","type":"GO_TERM","name":"photoprotection","canonical_id":"go:GO:0010117","description":"\"Protection mechanism used by plants and cyanobacteria under conditions of excess energy absorption as a consequence of the light reactions of photosynthesis.\" [PMID:30765616]","metadata":null},{"id":"8326ed81563b4d5bb07c2f3613cf0b95","type":"GO_TERM","name":"photoreactive repair","canonical_id":"go:GO:0000719","description":"\"The repair of UV-induced T-T, C-T and C-C dimers by directly reversing the damage to restore the original pyrimidines.\" [GOC:elh, PMID:10915863]","metadata":null},{"id":"912e38c884e34081a2cbfe699b5dd0d6","type":"GO_TERM","name":"photoreceptor activity","canonical_id":"go:GO:0009881","description":"\"The function of absorbing and responding to incidental electromagnetic radiation, particularly visible light. The response may involve a change in conformation.\" [GOC:ai, GOC:curators]","metadata":null},{"id":"a2e1f844f8e2428387c072f62d31f549","type":"GO_TERM","name":"photoreceptor cell axon guidance","canonical_id":"go:GO:0072499","description":"\"The chemotaxis process that directs the migration of a photoreceptor cell axon growth cone to its target in the optic lobe in response to a combination of attractive and repulsive cues.\" [GOC:sart, PMID:20826677]","metadata":null},{"id":"f5ce4211ffb3440082a002220d106983","type":"GO_TERM","name":"photoreceptor cell cilium","canonical_id":"go:GO:0097733","description":"\"A specialised 9+0 non-motile cilium found in photoreceptor cells. A ciliary transition zone called 'photoreceptor connecting cilium' links the photoreceptor outer segment to the inner segment.\" [GOC:cilia, Wikipedia:Photoreceptor_cell#Histology]","metadata":null},{"id":"0244cd150133474f97bb997713079990","type":"GO_TERM","name":"photoreceptor cell development","canonical_id":"go:GO:0042461","description":"\"Development of a photoreceptor, a cell that responds to incident electromagnetic radiation, particularly visible light.\" [GOC:curators]","metadata":null},{"id":"6d9f3f343a3c4bb482aff3b6a0095cdc","type":"GO_TERM","name":"photoreceptor cell differentiation","canonical_id":"go:GO:0046530","description":"\"The specialization of organization of a photoreceptor, a cell that responds to incident electromagnetic radiation, particularly visible light. An example of this process is found in Drosophila melanogaster.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"b1a5679e71974004ad47fd314c330781","type":"GO_TERM","name":"photoreceptor cell fate commitment","canonical_id":"go:GO:0046552","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a photoreceptor cell. A photoreceptor cell is a cell that responds to incident electromagnetic radiation. Different classes of photoreceptor have different spectral sensitivities and express different photosensitive pigments.\" [GOC:mtg_sensu]","metadata":null},{"id":"33a96b8c145c483c953700651a395ba7","type":"GO_TERM","name":"photoreceptor cell fate determination","canonical_id":"go:GO:0043703","description":"\"The process in which a cell becomes capable of differentiating autonomously into a photoreceptor cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:mtg_sensu]","metadata":null},{"id":"ee35c25997bd4c2e986190b0b83418ea","type":"GO_TERM","name":"photoreceptor cell fate specification","canonical_id":"go:GO:0043704","description":"\"The process in which a cell becomes capable of differentiating autonomously into a photoreceptor cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GOC:mtg_sensu]","metadata":null},{"id":"15cb6b193c654fa1b617f72cfca5f3ed","type":"GO_TERM","name":"photoreceptor cell maintenance","canonical_id":"go:GO:0045494","description":"\"Any process preventing the degeneration of the photoreceptor, a specialized cell type that is sensitive to light.\" [CL:0000210, GOC:bf, GOC:rl]","metadata":null},{"id":"9b5e054cf746490db0c565c1091ea70c","type":"GO_TERM","name":"photoreceptor cell morphogenesis","canonical_id":"go:GO:0008594","description":"\"The process in which the structures of a photoreceptor cell are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of a photoreceptor cell, a sensory cell that reacts to the presence of light. An example of this is found in Drosophila melanogaster.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"0210d0eae95d40a1a5bb5cd465dad085","type":"GO_TERM","name":"photoreceptor cell outer segment organization","canonical_id":"go:GO:0035845","description":"\"A process that is carried out at the cellular level and results in the assembly, arrangement of constituent parts, or disassembly of the outer segment of a photoreceptor cell, a sensory cell that reacts to the presence of light. The outer segment of the photoreceptor cell contains the light-absorbing materials.\" [ISBN:0824072820, PMID:14507858]","metadata":null},{"id":"5ef90e7f7a0040a0b7ca72b9b3a2cfcf","type":"GO_TERM","name":"photoreceptor cell terminal bouton","canonical_id":"go:GO:1990796","description":"\"A specialized region of the axon terminus portion of a photoreceptor cell axon. A photoreceptor cell is a neuron specialized to detect and transduce light.\" [PMID:19883736]","metadata":null},{"id":"aca45a2628744c75a62100fd5ae23402","type":"GO_TERM","name":"photoreceptor connecting cilium","canonical_id":"go:GO:0032391","description":"\"The portion of the photoreceptor cell cilium linking the photoreceptor inner and outer segments. It's considered to be equivalent to the ciliary transition zone.\" [GOC:cilia, PMID:15917207, PMID:22653444, PMID:8718680]","metadata":null},{"id":"a99dfc350adf418da0026ec9fda7d8ac","type":"GO_TERM","name":"photoreceptor disc membrane","canonical_id":"go:GO:0097381","description":"\"Stack of disc membranes located inside a photoreceptor outer segment, and containing densely packed molecules of photoreceptor proteins that traverse the lipid bilayer. Disc membranes arise as evaginations of the ciliary membrane during the development of the outer segment and may or may not remain contiguous with the ciliary membrane.\" [GOC:bj, GOC:krc, GOC:pde, PMID:11826267, PMID:19501669, PMID:2537204, PMID:26574505, PMID:6771304, PMID:7507907]","metadata":null},{"id":"72a5c5df5cb54565970600c205632c40","type":"GO_TERM","name":"photoreceptor distal connecting cilium","canonical_id":"go:GO:0120206","description":"\"The distal region of the photoreceptor connecting cilium is structurally unique to the photoreceptor and is maintained by retina-specific protein, SPATA7, and its interacting partners RPGR and RPGRIP1. It is essential for photoreceptor sensory cilium stability.\" [GOC:krc, PMID:29899041]","metadata":null},{"id":"d5150a9406704f89a85eba124be46744","type":"GO_TERM","name":"photoreceptor inner segment","canonical_id":"go:GO:0001917","description":"\"The inner segment of a vertebrate photoreceptor containing mitochondria, ribosomes and membranes where opsin molecules are assembled and passed to be part of the outer segment discs.\" [GOC:add, PMID:12019563]","metadata":null},{"id":"69c0626fc38f4693acf6425d5491d617","type":"GO_TERM","name":"photoreceptor inner segment membrane","canonical_id":"go:GO:0060342","description":"\"The membrane surrounding the inner segment of a vertebrate photoreceptor. The photoreceptor inner segment contains mitochondria, ribosomes and membranes where opsin molecules are assembled and passed to be part of the outer segment discs.\" [GOC:dph]","metadata":null},{"id":"83572cb6aaa1457f8c9a5413c63f10ff","type":"GO_TERM","name":"photoreceptor outer segment","canonical_id":"go:GO:0001750","description":"\"The outer segment of a vertebrate photoreceptor that contains a stack of membrane discs embedded with photoreceptor proteins.\" [GOC:cilia, GOC:krc, GOC:pde, ISBN:0824072820, PMID:19501669, PMID:26574505, PMID:6771304]","metadata":null},{"id":"cf9bc5e095a54b519cd38d30338520fd","type":"GO_TERM","name":"photoreceptor outer segment membrane","canonical_id":"go:GO:0042622","description":"\"The membrane surrounding the outer segment of a vertebrate photoreceptor.\" [GOC:jl]","metadata":null},{"id":"8a5a95ed4d2040998562d1c44461adcc","type":"GO_TERM","name":"photoreceptor proximal connecting cilium","canonical_id":"go:GO:0120205","description":"\"The proximal region of the photoreceptor connecting cilium is similar to the transition zone of unspecialized primary cilia and houses several major transition zone complexes, including NPHP, MKS, and RPGR.\" [GOC:krc, PMID:29899041]","metadata":null},{"id":"72069da23c0248269f13e646c6e2df03","type":"GO_TERM","name":"photoreceptor ribbon synapse","canonical_id":"go:GO:0098684","description":"\"A ribbon synapse between a retinal photoreceptor cell (rod or cone) and a retinal bipolar cell. These contain a plate-like synaptic ribbon.\" [PMID:15626493]","metadata":null},{"id":"ea88364dc46442d09cb497534d885146","type":"GO_TERM","name":"photorespiration","canonical_id":"go:GO:0009853","description":"\"A light-dependent catabolic process occurring concomitantly with photosynthesis in plants (especially C3 plants) whereby dioxygen (O2) is consumed and carbon dioxide (CO2) is evolved. The substrate is glycolate formed in large quantities in chloroplasts from 2-phosphoglycolate generated from ribulose 1,5-bisphosphate by the action of ribulose-bisphosphate carboxylase; the glycolate enters the peroxisomes where it is converted by glycolate oxidase to glyoxylate which undergoes transamination to glycine. This then passes into the mitochondria where it is decarboxylated forming one molecule of serine for every two molecules of glycine. This pathway also exists in photosynthetic bacteria.\" [ISBN:0198506732]","metadata":null},{"id":"eecbf10a23d647ec8db4420b67b4d55e","type":"GO_TERM","name":"photoresponse recovery","canonical_id":"go:GO:0036368","description":"\"The processes required for a photoreceptor to recover, following light activation, so that it can respond to a subsequent light stimulus. Photoreceptor recovery requires the shutoff of active participants in the phototransduction cascade, including the visual pigment and downstream signal transducers.\" [PMID:16039565, PMID:22802362]","metadata":null},{"id":"3a5be53c0f7649b78ae32ac7809b402a","type":"GO_TERM","name":"photosynthesis","canonical_id":"go:GO:0015979","description":"\"The synthesis by organisms of organic chemical compounds, especially carbohydrates, from carbon dioxide (CO2) using energy obtained from light rather than from the oxidation of chemical compounds.\" [ISBN:0198547684]","metadata":null},{"id":"f73f95398d4e4bfba93c33b3e2e36124","type":"GO_TERM","name":"photosynthesis, dark reaction","canonical_id":"go:GO:0019685","description":"\"A complex cycle of enzyme-mediated reactions which catalyzes the reduction of carbon dioxide to sugar. As well as carbon dioxide the cycle requires reducing power in the form of reduced nicotinamide adenine dinucleotide phosphate (NADP) and chemical energy in the form of adenosine triphosphate (ATP). The reduced NADP (NADPH) and ATP are produced by the 'light' reactions.\" [ISBN:0582015952]","metadata":null},{"id":"033f0c3c6a6f4ebdb265419cab965962","type":"GO_TERM","name":"photosynthesis, light harvesting","canonical_id":"go:GO:0009765","description":"\"Absorption and transfer of the energy absorbed from light photons between photosystem reaction centers.\" [GOC:sm]","metadata":null},{"id":"1373536c893b4da8bcf5ab0dc100a5bd","type":"GO_TERM","name":"photosynthesis, light harvesting in photosystem I","canonical_id":"go:GO:0009768","description":"\"After a photon of light is absorbed by one of the many chlorophyll molecules, in one of the light-harvesting complexes of an antenna on photosystem I, some of the absorbed energy is transferred to the pair of chlorophyll molecules in the reaction center.\" [GOC:jid, ISBN:0716731363, ISBN:0816017360]","metadata":null},{"id":"6e12c21b38694df6abbc2fd4e6174786","type":"GO_TERM","name":"photosynthesis, light harvesting in photosystem II","canonical_id":"go:GO:0009769","description":"\"After a photon of light is absorbed by one of the many chlorophyll molecules, in one of the light-harvesting complexes of an antenna on photosystem II, some of the absorbed energy is transferred to the pair of chlorophyll molecules in the reaction center.\" [GOC:jid, ISBN:0716731363, ISBN:0816017360]","metadata":null},{"id":"41daf8d0738f4644b8ae8a00c18946e1","type":"GO_TERM","name":"photosynthesis, light reaction","canonical_id":"go:GO:0019684","description":"\"The light reactions of photosynthesis, which take place in photosystems II and I. Light energy is harvested and used to power the transfer of electrons among a series of electron donors and acceptors. The final electron acceptor is NADP+, which is reduced to NADPH. NADPH generated from light reactions is used in sugar synthesis in dark reactions. Light reactions also generate a proton motive force across the thylakoid membrane, and the proton gradient is used to synthesize ATP. There are two chemical reactions involved in the light reactions: water oxidation in photosystem II, and NADP reduction in photosystem I.\" [PMID:15746074]","metadata":null},{"id":"0a47d5b8ae7e4ea8ba985261d9ed226a","type":"GO_TERM","name":"photosynthetic acclimation","canonical_id":"go:GO:0009643","description":"\"A response to light intensity in which exposure to medium-intensity light results in increased tolerance to high-intensity light.\" [GOC:mah, PMID:11069694]","metadata":null},{"id":"6596a8315d434a4c9b2b19220813c38c","type":"GO_TERM","name":"photosynthetic electron transport chain","canonical_id":"go:GO:0009767","description":"\"A process, occurring as part of photosynthesis, in which light provides the energy for a series of electron carriers to operate together to transfer electrons and generate a transmembrane electrochemical gradient.\" [GOC:mtg_electron_transport, ISBN:0198547684]","metadata":null},{"id":"6ed383dd560c47e7b1f9c2a24123a24c","type":"GO_TERM","name":"photosynthetic electron transport in photosystem I","canonical_id":"go:GO:0009773","description":"\"A photosynthetic electron transport chain in which electrons move from the primary electron acceptor (Quinone, X) through a chain of electron transport molecules in the thylakoid membrane until they reach ferredoxin which passes the electron to the ultimate electron acceptor; NADP.\" [GOC:jid, ISBN:0716731363, ISBN:0816017360]","metadata":null},{"id":"b5dbd3d147cf4f6989dbec19aa77d555","type":"GO_TERM","name":"photosynthetic electron transport in photosystem II","canonical_id":"go:GO:0009772","description":"\"A photosynthetic electron transport chain in which electrons move from the primary electron acceptor (Quinone, Q) through a chain of electron transport molecules in the thylakoid membrane until they reach the ultimate electron acceptor of Photosystem II, which is plastocyanin (PC). The electron is then passed to the P700 chlorophyll a molecules of the reaction centre of photosystem I.\" [GOC:jid, ISBN:0716731363, ISBN:0816017360]","metadata":null},{"id":"27f18cc9213449e2b1c6394b5fe75153","type":"GO_TERM","name":"photosynthetic membrane","canonical_id":"go:GO:0034357","description":"\"A membrane enriched in complexes formed of reaction centers, accessory pigments and electron carriers, in which photosynthetic reactions take place.\" [GOC:ds, GOC:mah]","metadata":null},{"id":"33962c98b7ca434e95a19ac3065c4098","type":"GO_TERM","name":"photosynthetic phosphorylation","canonical_id":"go:GO:0009777","description":"\"Any metabolic process in which photosynthetic organisms use light energy to convert ADP to ATP without the concomitant reduction of dioxygen (O2) to water that occurs in phosphorylation.\" [ISBN:0198547684]","metadata":null},{"id":"5884ff09bb164b349776e62720b7bf93","type":"GO_TERM","name":"photosynthetic state transition","canonical_id":"go:GO:0062055","description":"\"A regulation of the phtosynthetic light reaction in which the light harvesting antenna complexes transition between photosystems.\" [PMID:29967049]","metadata":null},{"id":"2480014ebf9c4778a100fcaffa0efd5a","type":"GO_TERM","name":"photosystem","canonical_id":"go:GO:0009521","description":"\"A complex located in a photosynthetic membrane that consists of a photoreaction center associated with accessory pigments and electron carriers. Examples of this component are found in Arabidopsis thaliana and in photosynthetic bacterial and archaeal species.\" [GOC:ds, GOC:mah, ISBN:0140514031, PMID:9821949]","metadata":null},{"id":"1001abd095f94d65a8c1576a4a374947","type":"GO_TERM","name":"photosystem I","canonical_id":"go:GO:0009522","description":"\"A photosystem that contains an iron-sulfur reaction center associated with accessory pigments and electron carriers. In cyanobacteria and chloroplasts, photosystem I functions as a light-dependent plastocyanin-ferredoxin oxidoreductase, transferring electrons from plastocyanin to ferredoxin; in photosynthetic bacteria that have only a single type I photosystem, such as the green sulfur bacteria, electrons can go either to ferredoxin (Fd) -> NAD+ or to menaquinone (MK) -> Cytb/FeS -> Cytc555 -> photosystem I (cyclic photophosphorylation).\" [GOC:ds, GOC:mah, ISBN:0140514031, PMID:9821949]","metadata":null},{"id":"c7b9cd70a59549cd8f9a249577a6e885","type":"GO_TERM","name":"photosystem I antenna complex","canonical_id":"go:GO:0009782","description":"\"The antenna complex of photosystem I. A photosystem has two closely linked components, an antenna containing light-absorbing pigments and a reaction center. Each antenna contains one or more light-harvesting complexes (LHCs).\" [GOC:jid, ISBN:0716731363]","metadata":null},{"id":"7357c65618af45de95907ad81642bc59","type":"GO_TERM","name":"photosystem I assembly","canonical_id":"go:GO:0048564","description":"\"The aggregation, arrangement and bonding together of a set of components to form a photosystem I complex on the thylakoid membrane.\" [GOC:curators]","metadata":null},{"id":"20d1121898104e08bc02ea43577f41b9","type":"GO_TERM","name":"photosystem I reaction center","canonical_id":"go:GO:0009538","description":"\"A photochemical system containing P700, the chlorophyll a dimer that functions as a primary electron donor. Functioning as a light-dependent plastocyanin-ferredoxin oxidoreductase, it transfers electrons from plastocyanin to ferredoxin.\" [GOC:kd, ISBN:0943088399]","metadata":null},{"id":"4b774bf8fff2489fbc2e9301a57e918e","type":"GO_TERM","name":"photosystem I stabilization","canonical_id":"go:GO:0042550","description":"\"The stabilization of the photosystem I protein complex, resulting from the phosphorylation of its structural protein subunits, in a cell actively involved in photosynthesis.\" [GOC:curators]","metadata":null},{"id":"16f7d5070fd54980b6d884b6f36d4686","type":"GO_TERM","name":"photosystem II","canonical_id":"go:GO:0009523","description":"\"A photosystem that contains a pheophytin-quinone reaction center with associated accessory pigments and electron carriers. In cyanobacteria and chloroplasts, in the presence of light, PSII functions as a water-plastoquinone oxidoreductase, transferring electrons from water to plastoquinone, whereas other photosynthetic bacteria carry out anoxygenic photosynthesis and oxidize other compounds to re-reduce the photoreaction center.\" [GOC:ds, GOC:mah, ISBN:0943088399, PMID:9821949]","metadata":null},{"id":"2e0bdaefeda74722a308a2352f6cb5d1","type":"GO_TERM","name":"photosystem II antenna complex","canonical_id":"go:GO:0009783","description":"\"The antenna complex of photosystem II. A photosystem has two closely linked components, an antenna containing light-absorbing pigments and a reaction center. Each antenna contains one or more light-harvesting complexes (LHCs).\" [GOC:jid, ISBN:0716731363]","metadata":null},{"id":"cd7b7ca391974fe0b2ee9e7f38f3f27d","type":"GO_TERM","name":"photosystem II assembly","canonical_id":"go:GO:0010207","description":"\"The aggregation, arrangement and bonding together of a set of components to form a photosystem II complex on the thylakoid membrane. The photosystem II complex consists of at least 20 polypeptides and around 80 cofactors in most organisms.\" [GOC:aa, GOC:pz]","metadata":null},{"id":"f74078eb08f84e67b6a9950f188f508b","type":"GO_TERM","name":"photosystem II oxygen evolving complex","canonical_id":"go:GO:0009654","description":"\"A complex, composed of a cluster of manganese, calcium and chloride ions bound to extrinsic proteins, that catalyzes the splitting of water to O2 and 4 H+. In cyanobacteria there are five extrinsic proteins in OEC (PsbO, PsbP-like, PsbQ-like, PsbU and PsbV), while in plants there are only three (PsbO, PsbP and PsbQ).\" [GOC:cjm, InterPro:IPR002683]","metadata":null},{"id":"335e7a8ce8c146e8927f776890a67df2","type":"GO_TERM","name":"photosystem II oxygen evolving complex assembly","canonical_id":"go:GO:0010270","description":"\"The aggregation, arrangement and bonding together of a set of components to form the oxygen evolving complex (OEC) of photosystem II on a thylakoid membrane. The OEC protects the calcium-4 manganese-5 oxide cluster which is bound to the D1 and CP43 proteins. The exact protein composition of the OEC varies between cyanobacteria and plants, and in plants consists of three extrinsic nuclear-encoded polypeptides: PsbO, PsbP and PsbQ.\" [GOC:aa, PMID:16282331]","metadata":null},{"id":"67ccf10f2e9b4eee8fbc3ae2ac0514cd","type":"GO_TERM","name":"photosystem II reaction center","canonical_id":"go:GO:0009539","description":"\"An integral membrane complex containing P680, the chlorophyll a molecule that functions as a primary electron donor. In the light, functioning as a water-plastoquinone oxidoreductase, it transfers electrons from water to plastoquinone.\" [GOC:kd, ISBN:0943088399]","metadata":null},{"id":"6c24a01662e94b9686f99adb43721361","type":"GO_TERM","name":"photosystem II repair","canonical_id":"go:GO:0010206","description":"\"Proteolysis of the damaged D1 protein and re-assembly of a new D1 subunit in the photosystem II following photoinhibition.\" [GOC:sm]","metadata":null},{"id":"a8163afd132e48ef9fff7d39fce8898e","type":"GO_TERM","name":"photosystem II stabilization","canonical_id":"go:GO:0042549","description":"\"The stabilization of the photosystem II protein complex, resulting from the phosphorylation of its structural protein subunits, in a cell actively involved in photosynthesis.\" [GOC:curators]","metadata":null},{"id":"571c462fde444854afbbd3df49e5687b","type":"GO_TERM","name":"photosystem stoichiometry adjustment","canonical_id":"go:GO:0080005","description":"\"Adjustment of Photosystem I/Photosystem II ratio in response to light conditions. The function of photosystem stoichiometry adjustment is to compensate for any deficiency in energy conversion at either photosystem I or photosystem II by increasing the quantity the photosystem that will otherwise become the rate-limiting to overall photosynthesis.\" [PMID:11607105]","metadata":null},{"id":"f24b32f951c74278841b9eb38b34bd3a","type":"GO_TERM","name":"phototaxis","canonical_id":"go:GO:0042331","description":"\"The directed movement of a motile cell or organism in response to light.\" [GOC:jl, ISBN:0192800981]","metadata":null},{"id":"0f61a4ccd6e74ed1a9da4ea89c7f062e","type":"GO_TERM","name":"phototransduction","canonical_id":"go:GO:0007602","description":"\"The sequence of reactions within a cell required to convert absorbed photons into a molecular signal.\" [GOC:curators]","metadata":null},{"id":"42662ecbe027496d8fe19356b2f04a2f","type":"GO_TERM","name":"phototransduction, UV","canonical_id":"go:GO:0007604","description":"\"The sequence of reactions within a cell required to convert absorbed photons from UV light into a molecular signal; ultraviolet radiation is electromagnetic radiation with a wavelength in the range of 10 to 400 nanometers.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"be8646cab62c42e289371696f373f6c7","type":"GO_TERM","name":"phototransduction, visible light","canonical_id":"go:GO:0007603","description":"\"The sequence of reactions within a cell required to convert absorbed photons from visible light into a molecular signal. A visible light stimulus is electromagnetic radiation that can be perceived visually by an organism; for organisms lacking a visual system, this can be defined as light with a wavelength within the range 380 to 780 nm.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"be36c58275454a2a9aa7ae5c64ef997d","type":"GO_TERM","name":"phototropism","canonical_id":"go:GO:0009638","description":"\"The movement of an organism, or part of an organism, in response to a light stimulus, usually toward or away from it.\" [GOC:jl, GOC:mtg_far_red, PMID:16870491]","metadata":null},{"id":"50e56687915741e7b56699e0dfe1c265","type":"GO_TERM","name":"phragmoplast","canonical_id":"go:GO:0009524","description":"\"The phragmoplast is a plant cell specific cytoplasmic structure composed of cytoskeletal polymers, membranes, and associated cytosolic proteins that functions as the focused secretory module for assembling the cell plate.\" [PMID:28943203]","metadata":null},{"id":"94473108ee90478997286f7365bfddd9","type":"GO_TERM","name":"phragmoplast assembly","canonical_id":"go:GO:0000914","description":"\"The formation of a structure composed of actin, myosin, and associated proteins that will function in cytokinesis in cells that perform cytokinesis by cell plate formation. The structure usually contains antiparallel microtubules and membrane (often visible as vesicles).\" [GOC:clt]","metadata":null},{"id":"85d808cf7c934c02b1a658a6b594d300","type":"GO_TERM","name":"phragmoplast microtubule organization","canonical_id":"go:GO:0080175","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures formed of microtubules and associated proteins in phragmoplast, a plant cell specific structure that forms during late cytokinesis. Phragmoplast serves as a scaffold for cell plate assembly and subsequent formation of a new cell wall separating the two daughter cells.\" [PMID:19383896]","metadata":null},{"id":"0a2e41c834464d2a8f2cd85d48e329c3","type":"GO_TERM","name":"phragmosome","canonical_id":"go:GO:0009525","description":"\"A flattened membranous vesicle containing cell wall components.\" [ISBN:0943088399]","metadata":null},{"id":"95de531008f7457db4516a8ab1bd19d6","type":"GO_TERM","name":"phthalate 4,5-cis-dihydrodiol dehydrogenase activity","canonical_id":"go:GO:0018517","description":"\"Catalysis of the reaction: cis-4,5-dihydroxycyclohexa-2,6-diene-1,2-dicarboxylate + NAD+ = 4,5-dihydroxyphthalate + H+ + NADH.\" [EC:1.3.1.64, RHEA:13837]","metadata":null},{"id":"eb9dd0f75d6348c7b7366fa2740b25db","type":"GO_TERM","name":"phthalate 4,5-dioxygenase activity","canonical_id":"go:GO:0018620","description":"\"Catalysis of the reaction: phthalate + NADH + O2 + H+ = cis-4,5-dihydroxycyclohexa-2,6-diene-1,2-dicarboxylate + NAD+.\" [RHEA:17489]","metadata":null},{"id":"5c48fe04be22432b899bf9c0cefbabb5","type":"GO_TERM","name":"phthalate binding","canonical_id":"go:GO:0035273","description":"\"Binding to a phthalate, any ester or salt of phthalic acid.\" [PMID:31116073]","metadata":null},{"id":"206e4ac67ce4450892773ff2b815b2a9","type":"GO_TERM","name":"phthalate catabolic process","canonical_id":"go:GO:0046239","description":"\"The chemical reactions and pathways resulting in the breakdown of phthalate, the anion of phthalic acid.\" [GOC:ai]","metadata":null},{"id":"2216a947a7e943d19cbde230f41bcb16","type":"GO_TERM","name":"phthalate metabolic process","canonical_id":"go:GO:0018963","description":"\"The chemical reactions and pathways involving phthalate, the anion of phthalic acid. Phthalic acid diesters are used industrially in the production of a variety of household and consumer goods including plastic polymers, lubricating oils, and carriers for perfumes in cosmetics, while phthalic acid itself is used industrially as a plasticizer. Terephthalate is used in the synthesis of polyethylene terephthalate (polyethene terephthlate, abbreviated PET or PETE), a plastic polymer with many commercial uses.\" [UM-BBD_pathwayID:pth]","metadata":null},{"id":"40f52ad6f451410097f4c03da016fa4e","type":"GO_TERM","name":"phthalyl amidase activity","canonical_id":"go:GO:0047418","description":"\"Catalysis of the reaction: H2O + a phthalylamide = phthalate + substituted amine.\" [EC:3.5.1.79, MetaCyc:3.5.1.79-RXN]","metadata":null},{"id":"eb8f1b8bf566424fbc619bafd1dae5b3","type":"GO_TERM","name":"phthiocerol biosynthetic process","canonical_id":"go:GO:0097040","description":"\"The chemical reactions and pathways resulting in the formation of phthiocerol, a lipid-based 1,3-glycol consisting of (3S,4R)-3-methoxy-4-methylnonacosane having (9R)- and (11S)-hydroxy substituents.\" [GOC:dph, GOC:ecd, PMID:9201977]","metadata":null},{"id":"46ead78e33444aa8803a62e124aea357","type":"GO_TERM","name":"phycobilisome","canonical_id":"go:GO:0030089","description":"\"Any of the granules, approximately 32 nm x 48 nm and consisting of highly aggregated phycobiliproteins, that are attached in arrays to the external face of a thylakoid membrane in algae of the phyla Cyanophyta and Rhodophyta, where they function as light-harvesting devices in photosynthesis. Excitation energy in the phycobilisome flows in the sequence: phycoerythrin, phycocyanin, allophycocyanin before passing to the antenna chlorophyll of photosystem II.\" [GOC:jl, PMID:11734882, Wikipedia:Phycobilisome]","metadata":null},{"id":"bdb985c2313e4c76b518b7ea4d285fa5","type":"GO_TERM","name":"phycocyanobilin biosynthetic process","canonical_id":"go:GO:0140609","description":"\"The chemical reactions or pathway resulting in the formation of phycocyanobilin, which involves the oxidative cleavage of heme by a heme oxygenase (HO) to form biliverdin IX alpha. Biliverdin IX alpha is subsequently converted to phycocyanobilin by a ferredoxin-dependent oxidoreductase (PCYA).\" [PMID:23345435]","metadata":null},{"id":"a7541fa5cbc7498cad1acb0abe25bf49","type":"GO_TERM","name":"phycocyanobilin:ferredoxin oxidoreductase activity","canonical_id":"go:GO:0050620","description":"\"Catalysis of the reaction: (3Z)-phycocyanobilin + oxidized ferredoxin = biliverdin IXa + reduced ferredoxin.\" [EC:1.3.7.5, MetaCyc:1.3.7.5-RXN]","metadata":null},{"id":"d3910d0e203e463a8afc363fd2036414","type":"GO_TERM","name":"phycoerythrobilin synthase activity","canonical_id":"go:GO:7770044","description":"\"Catalysis of the reaction: biliverdin IXalpha + 2 reduced ferredoxin + 4 H+ = (3Z)-phycoerythrobilin + 2 oxidized ferredoxin.\" [PMID:18662988, RHEA:25359]","metadata":null},{"id":"312d045ea1e64558a102b209e9ff829c","type":"GO_TERM","name":"phycoerythrobilin:ferredoxin oxidoreductase activity","canonical_id":"go:GO:0050618","description":"\"Catalysis of the reaction: (3Z)-phycoerythrobilin + oxidized ferredoxin = 15,16-dihydrobiliverdin + reduced ferredoxin.\" [EC:1.3.7.3, MetaCyc:1.3.7.3-RXN]","metadata":null},{"id":"7683df71b9c14f79a62881fbbc89da7f","type":"GO_TERM","name":"phyllome development","canonical_id":"go:GO:0048827","description":"\"The process whose specific outcome is the progression of a phyllome over time, from its formation to the mature structure. A phyllome is a collective term for all the different types of leaves appearing on plants.\" [GOC:devbiol, GOC:tb, PO:0006001]","metadata":null},{"id":"985d20efaa024ae7958081e7997e132c","type":"GO_TERM","name":"phylloquinone biosynthetic process","canonical_id":"go:GO:0042372","description":"\"The chemical reactions and pathways resulting in the formation of phylloquinone, vitamin K1, a quinone-derived compound synthesized by green plants.\" [GOC:jl, https://doi.org/10.1016/B978-0-12-385853-5.00001-5, PMID:23821151, PMID:27337968]","metadata":null},{"id":"0d6e365b27eb4a399ecc772b089d71cc","type":"GO_TERM","name":"phylloquinone catabolic process","canonical_id":"go:GO:0042376","description":"\"The chemical reactions and pathways resulting in the breakdown of phylloquinone, vitamin K1, a quinone-derived compound synthesized by green plants.\" [GOC:jl, https://doi.org/10.1016/B978-0-12-385853-5.00001-5, PMID:27337968]","metadata":null},{"id":"cb1e04daee8f4e6a8dd47ea526e349d8","type":"GO_TERM","name":"phylloquinone monooxygenase (2,3-epoxidizing) activity","canonical_id":"go:GO:0047097","description":"\"Catalysis of the reaction: AH2 + O2 + phylloquinone = 2,3-epoxyphylloquinone + A + H2O.\" [RHEA:16745]","metadata":null},{"id":"2a01e0e22a814c19b0de7b7308b55889","type":"GO_TERM","name":"phyllotactic patterning","canonical_id":"go:GO:0060771","description":"\"The radial pattern formation process that results in the formation of plant organs (leaves or leaf-like structures) or flower primordia around a central axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"a2a5ae6d2d5b4af8ae0863a0165382ba","type":"GO_TERM","name":"physiological cardiac muscle hypertrophy","canonical_id":"go:GO:0003301","description":"\"The enlargement or overgrowth of all or part of the heart muscle due to an increase in size of cardiac muscle cells without cell division. This process contributes to the developmental growth of the heart.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:mtg_heart]","metadata":null},{"id":"6da015e18e1143c98c9a7135aebaaab2","type":"GO_TERM","name":"physiological muscle hypertrophy","canonical_id":"go:GO:0003298","description":"\"The enlargement or overgrowth of all or part of a muscle organ or tissue due to an increase in the size of its muscle cells. Physiological hypertrophy is a normal process during development.\" [GOC:mtg_heart]","metadata":null},{"id":"dd59b68cc6794fa186c723ff121d52b0","type":"DISEASE","name":"physiological sexual disorder","canonical_id":"mondo:0002134","description":null,"metadata":null},{"id":"2ac416f2ed61482a9290bc4def815314","type":"DRUG","name":"physostigmine","canonical_id":"gtopdb:6598","description":null,"metadata":null},{"id":"1781dbfc39b24f46ad53d8b3e935f4cf","type":"GO_TERM","name":"phytanate-CoA ligase activity","canonical_id":"go:GO:0050197","description":"\"Catalysis of the reaction: ATP + CoA + phytanate = AMP + diphosphate + H+ + phytanoyl-CoA.\" [EC:6.2.1.24, RHEA:21380]","metadata":null},{"id":"a93b8ab0db334cc88f79a1e0fc12754f","type":"GO_TERM","name":"phytanic acid metabolic process","canonical_id":"go:GO:1903512","description":"\"The chemical reactions and pathways involving phytanic acid.\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:16799769]","metadata":null},{"id":"0552bda7109c4af4bbfc3f7cf989f172","type":"GO_TERM","name":"phytanoyl-CoA dioxygenase activity","canonical_id":"go:GO:0048244","description":"\"Catalysis of the reaction: 2-oxoglutarate + O2 + phytanoyl-CoA = 2-hydroxyphytanoyl-CoA + CO2 + succinate.\" [EC:1.14.11.18, RHEA:16065]","metadata":null},{"id":"5bdbe3e1733a4802958cb7af0632d2c3","type":"GO_TERM","name":"phytoalexin biosynthetic process","canonical_id":"go:GO:0052315","description":"\"The chemical reactions and pathways resulting in the formation of phytoalexins, any of a range of substances produced by plants as part of their defense response.\" [PMID:22209038, PMID:3882051, Wikipedia:Phytoalexin]","metadata":null},{"id":"2d8167710ad4442195162f32f57eb7b5","type":"GO_TERM","name":"phytoalexin catabolic process","canonical_id":"go:GO:0052316","description":"\"The chemical reactions and pathways resulting in the breakdown of phytoalexins, any of a range of substances produced by plants as part of their defense response.\" [GOC:ai]","metadata":null},{"id":"b00e466820254897b8069e0b5544df87","type":"GO_TERM","name":"phytoalexin metabolic process","canonical_id":"go:GO:0052314","description":"\"The chemical reactions and pathways involving phytoalexins, any of a range of substances produced by plants as part of their defense response.\" [Wikipedia:Phytoalexin]","metadata":null},{"id":"023e86eafdbc4d20bf4a56be07e17c65","type":"GO_TERM","name":"phytochelatin 2 import into vacuole","canonical_id":"go:GO:0036246","description":"\"The directed movement of phytochelatin 2 (PC2) into the vacuole. Phytochelatin 2 is a glutathione-related peptide composed of (gamma-Glu-Cys)n-Gly where n=2, and where the Glu and Cys residues are linked through a gamma-carboxylamide bond.\" [GOC:al, PMID:19001374]","metadata":null},{"id":"f359ceddfe6048d0a83ba4272c26639b","type":"GO_TERM","name":"phytochelatin 3 import into vacuole","canonical_id":"go:GO:0036247","description":"\"The directed movement of phytochelatin 3 (PC3) into the vacuole. Phytochelatin 3 is a glutathione-related peptide composed of (gamma-Glu-Cys)n-Gly where n=3, and where the Glu and Cys residues are linked through a gamma-carboxylamide bond.\" [GOC:al, PMID:19001374]","metadata":null},{"id":"0dfcba11a8d74e77b48e1b8aa62a09e2","type":"GO_TERM","name":"phytochelatin 4 import into vacuole","canonical_id":"go:GO:0036248","description":"\"The directed movement of phytochelatin 4 (PC4) into the vacuole. Phytochelatin 4 is a glutathione-related peptide composed of (gamma-Glu-Cys)n-Gly where n=4, and where the Glu and Cys residues are linked through a gamma-carboxylamide bond.\" [GOC:al, PMID:19001374]","metadata":null},{"id":"a84c389ae57b4c7dba33bcd8d9e6b590","type":"GO_TERM","name":"phytochelatin biosynthetic process","canonical_id":"go:GO:0046938","description":"\"The chemical reactions and pathways resulting in the formation of phytochelatins, any of a group of peptides that bind metals (Cd, Zn, Cu, Pb, Hg) in thiolate coordination complexes. The structure is of the type (gamma-glutamyl-cysteinyl)n-glycine, where n is 2 to 11.\" [ISBN:0198506732]","metadata":null},{"id":"965e797ecbff4f15beafab636d453401","type":"GO_TERM","name":"phytochelatin import into vacuole","canonical_id":"go:GO:0071995","description":"\"The directed movement of phytochelatins into the vacuole. Phytochelatins are a group of peptides that bind metals (Cd, Zn, Cu, Pb, Hg) in thiolate coordination complexes.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"f664eeb64c254e049651927d7609fc5f","type":"GO_TERM","name":"phytochelatin metabolic process","canonical_id":"go:GO:0046937","description":"\"The chemical reactions and pathways involving phytochelatins, any of a group of peptides that bind metals (Cd, Zn, Cu, Pb, Hg) in thiolate coordination complexes. The structure is of the type (gamma-glutamyl-cysteinyl)n-glycine, where n is 2 to 11.\" [ISBN:0198506732]","metadata":null},{"id":"c4708261944e42fa8a0c8619b982a343","type":"GO_TERM","name":"phytochelatin transmembrane transport","canonical_id":"go:GO:0071994","description":"\"The process in which a phytochelatin is transported across a membrane. Phytochelatins are a group of peptides that bind metals (Cd, Zn, Cu, Pb, Hg) in thiolate coordination complexes.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"9c17c549468d4301abcae98ffd912c0c","type":"GO_TERM","name":"phytochelatin transport","canonical_id":"go:GO:0071993","description":"\"The directed movement of a phytochelatin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Phytochelatins are a group of peptides that bind metals (Cd, Zn, Cu, Pb, Hg) in thiolate coordination complexes.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"fd5e8fc949624587998e8de59e9dc643","type":"GO_TERM","name":"phytochelatin-metal complex formation","canonical_id":"go:GO:0090423","description":"\"A phytochelatin metabolic process in which a metal is incorporated with phytochelatin to form a complex.\" [GOC:tb]","metadata":null},{"id":"6127040fdd264df0b9f8875e5a5853aa","type":"GO_TERM","name":"phytochelatin-metal-sulfur complex formation","canonical_id":"go:GO:0090424","description":"\"A phytochelatin metabolic process in which a metal and exogenous sulfur are incorporated with phytochelatin to form a complex.\" [GOC:tb]","metadata":null},{"id":"74e8b28fc6014be4bdde1d55c78d9541","type":"GO_TERM","name":"phytochrome binding","canonical_id":"go:GO:0010313","description":"\"Binding to a phytochrome.\" [PMID:15486102]","metadata":null},{"id":"e7a4fb2641ba474f8336b6e9e25985ca","type":"GO_TERM","name":"phytochrome chromophore biosynthetic process","canonical_id":"go:GO:0048543","description":"\"The chemical reactions and pathways resulting in the formation of the phytochrome chromophore. The phytochrome chromophore is a linear tetrapyrrolic prosthetic group covalently attached to the large soluble protein phytochrome. Light absorption by the phytochrome chromophore triggers photoconversion between two spectrally distinct forms of the photoreceptor: Pr, the red light absorbing form, and Pfr, the far red light absorbing form.\" [GOC:pj, PMID:2909515]","metadata":null},{"id":"3aa2140f2b57462e881d28ef557a247e","type":"GO_TERM","name":"phytochromobilin biosynthetic process","canonical_id":"go:GO:0010024","description":"\"The chemical reactions and pathways resulting in the formation of phytochromobilin, which involves the oxidative cleavage of heme by a heme oxygenase(HO) to form biliverdin IX alpha.\" [PMID:11402195]","metadata":null},{"id":"de0e76817fa5485683185d17f1ffe907","type":"GO_TERM","name":"phytochromobilin:ferredoxin oxidoreductase activity","canonical_id":"go:GO:0050619","description":"\"Catalysis of the reaction: (3Z)-phytochromobilin + oxidized ferredoxin = biliverdin IXa + reduced ferredoxin.\" [EC:1.3.7.4, MetaCyc:1.3.7.4-RXN]","metadata":null},{"id":"c6fe99a70218448fbe7d7abd88b505c4","type":"GO_TERM","name":"phytoene biosynthetic process","canonical_id":"go:GO:1901174","description":"\"The chemical reactions and pathways resulting in the formation of phytoene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00799]","metadata":null},{"id":"c150c8a9f15c4a49be9e5cd0681ce19c","type":"GO_TERM","name":"phytoene catabolic process","canonical_id":"go:GO:1901173","description":"\"The chemical reactions and pathways resulting in the breakdown of phytoene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00799]","metadata":null},{"id":"7faec492737f463b92d42c377e596625","type":"GO_TERM","name":"phytoene dehydrogenase activity","canonical_id":"go:GO:0016166","description":"\"Catalysis of the dehydrogenation of phytoene to produce a carotenoid intermediate such as phytofluene.\" [PMID:29176862]","metadata":null},{"id":"3bb40335f2ae45ecb56c98e5e9d01768","type":"GO_TERM","name":"phytol biosynthetic process","canonical_id":"go:GO:0033520","description":"\"The chemical reactions and pathways resulting in the formation of phytol, (2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol.\" [GOC:mah]","metadata":null},{"id":"75a6bc13bd904df0b27331f7aaa20f75","type":"GO_TERM","name":"phytol kinase activity","canonical_id":"go:GO:0010276","description":"\"Catalysis of the reaction: phytol + CTP = phytyl monophosphate + CDP + H+.\" [RHEA:38055]","metadata":null},{"id":"c2b6cfaaae7341ae90a048ce24625b40","type":"GO_TERM","name":"phytol metabolic process","canonical_id":"go:GO:0033306","description":"\"The chemical reactions and pathways involving phytol, (2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol.\" [GOC:mah]","metadata":null},{"id":"385eb6fec4eb4151b43daea62e9b00b4","type":"GO_TERM","name":"phytol salvage","canonical_id":"go:GO:0033307","description":"\"A process that generates phytol, (2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol, from derivatives of it without de novo synthesis.\" [GOC:mah, MetaCyc:PWY-5107]","metadata":null},{"id":"3e4a59bb89b1433c910d8a03810a2842","type":"GO_TERM","name":"phytosphingosine biosynthetic process","canonical_id":"go:GO:0071602","description":"\"The chemical reactions and pathways resulting in the formation of phytosphingosine, (2S,3S,4R)-2-aminooctadecane-1,3,4-triol.\" [GOC:mah]","metadata":null},{"id":"63a373dfe65144a78d1d160f00eac30f","type":"GO_TERM","name":"phytosphingosine metabolic process","canonical_id":"go:GO:0006671","description":"\"The chemical reactions and pathways involving phytosphingosine, (2S,3S,4R)-2-aminooctadecane-1,3,4-triol, a constituent of many plant sphingolipids.\" [ISBN:0198506732]","metadata":null},{"id":"4f6ba47337af4e61b47893f00512dcd4","type":"GO_TERM","name":"phytosteroid biosynthetic process","canonical_id":"go:GO:0016129","description":"\"The chemical reactions and pathways resulting in the formation of phytosteroids, steroids that differ from animal steroids in having substitutions at C24 and/or a double bond at C22. Phytosteroids are so named because they occur in higher plants; some, notably ergosterol, are also found in fungi.\" [GOC:curators, GOC:mah, ISBN:0471331309]","metadata":null},{"id":"7d460f3371ae4fef9a0f5a4ce89ac523","type":"GO_TERM","name":"phytosteroid catabolic process","canonical_id":"go:GO:0016130","description":"\"The chemical reactions and pathways resulting in the breakdown of phytosteroids, steroids that differ from animal steroids in having substitutions at C24 and/or a double bond at C22. Phytosteroids are so named because they occur in higher plants; some, notably ergosterol, are also found in fungi.\" [GOC:curators, GOC:mah]","metadata":null},{"id":"f7c0fb22486f4b02ad6554a3a1f77807","type":"GO_TERM","name":"phytyl diphosphate biosynthetic process","canonical_id":"go:GO:0033521","description":"\"The chemical reactions and pathways resulting in the formation of phytyl diphosphate, (2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl trihydrogen diphosphate.\" [GOC:mah]","metadata":null},{"id":"9dcf32c121044f71946f347fbb88748e","type":"GO_TERM","name":"phytyl-P kinase activity","canonical_id":"go:GO:0102763","description":"\"Catalysis of the reaction: a ribonucleoside 5'-triphosphate + phytyl phosphate = a ribonucleoside 5'-diphosphate + phytyl diphosphate.\" [RHEA:38099]","metadata":null},{"id":"9f87fdfc4d9d46ad8f584ede7a82075d","type":"GO_TERM","name":"pi-body","canonical_id":"go:GO:0071546","description":"\"A P granule that contains the PIWIL2-TDRD1 module, a set of proteins that act in the primary piRNA pathway. The pi-body corresponds to the cementing material between mitochondria found in gonocytes.\" [GOC:sp, PMID:20011505]","metadata":null},{"id":"e2adf97fd6d74d1da1b3c067ab4b598c","type":"GO_TERM","name":"piP-body","canonical_id":"go:GO:0071547","description":"\"A P granule that contains the PIWIL4-TDRD9 module, a set of proteins that act in the secondary piRNA pathway.\" [GOC:sp, PMID:20011505]","metadata":null},{"id":"8cb21cbd0a4848c3b5c7fa6bf4e0ab8f","type":"GO_TERM","name":"piRNA binding","canonical_id":"go:GO:0034584","description":"\"Binding to a piRNA, a Piwi-associated RNA, a 24- to 30-nucleotide RNA derived from repeat or complex DNA sequence elements and processed by a Dicer-independent mechanism.\" [GOC:kmv]","metadata":null},{"id":"b632ae1e62b34f319d1327c49f8677dd","type":"GO_TERM","name":"piRNA cluster binding","canonical_id":"go:GO:1990470","description":"\"Binding to piRNA clusters, double-stranded DNA regions that give rise to PIWI-interacting RNAs (piRNAs).\" [GOC:bhm, PMID:24906153]","metadata":null},{"id":"960ec83039914e09be17621db1a5cafc","type":"GO_TERM","name":"piRNA dual-strand cluster binding","canonical_id":"go:GO:1990472","description":"\"Binding to dual-strand piRNA clusters, double-stranded DNA regions that give rise to PIWI-interacting RNAs (piRNAs) where piRNAs originate from both DNA strands via noncanonical transcription.\" [GOC:bhm, PMID:24906153]","metadata":null},{"id":"b9b389f8223b46a7bb44b37582c74d58","type":"GO_TERM","name":"piRNA processing","canonical_id":"go:GO:0034587","description":"\"A process leading to the generation of a functional piRNA. piRNAs (Piwi-associated RNAs) are a class of 24- to 30-nucleotide RNAs derived from repeat or complex DNA sequence elements and processed by a Dicer-independent mechanism.\" [GOC:kmv, PMID:23329111, PMID:24696457, PMID:34724117]","metadata":null},{"id":"a9213b614e56423882b2a7cbe5dfff30","type":"GO_TERM","name":"piRNA transcription","canonical_id":"go:GO:0140541","description":"\"The cellular synthesis of Piwi-interacting RNA piRNAs, a class of 24- to 30-nucleotide RNA derived from repeat or complex DNA sequence elements and processed by a Dicer-independent mechanism.\" [PMID:28847004]","metadata":null},{"id":"ca8a3707d38246159047a1d8d0269165","type":"GO_TERM","name":"piRNA uni-strand cluster binding","canonical_id":"go:GO:1990471","description":"\"Binding to uni-strand piRNA clusters, double-stranded DNA regions that give rise to PIWI-interacting RNAs (piRNAs) that map predominantly to only one strand and exhibit hallmarks of canonical Pol II transcription. Uni-strand piRNA clusters are found in many taxa.\" [GOC:bhm, PMID:24906153]","metadata":null},{"id":"20b8e0ee7e834cb5be946f1d139816b1","type":"GO_TERM","name":"piRNA-mediated gene silencing by mRNA destabilization","canonical_id":"go:GO:0140991","description":"\"A cytoplasmic post-transcriptional gene silencing pathway in which piRNAs direct the cleavage of target mRNAs. The target mRNA, often transcribed from a transposable element, is destabilized by the activity of a PIWI class endonuclease within the piRNA-induced silencing complex. This may also be accompanied by mRNA deadenylation and decapping.\" [PMID:29281264, PMID:33419460]","metadata":null},{"id":"c1e53f1c92034d4287a8d0ca8b891cdd","type":"GO_TERM","name":"piRNA-mediated heterochromatin formation","canonical_id":"go:GO:0140966","description":"\"The formation of heterochromatin into a heterochromatin domain, enriched in histone H3 methylated on lysine 9 (H3K9me), by a process mediated by a Piwi-associated RNA (piRNA).\" [PMID:23329111]","metadata":null},{"id":"b0d78531ac1c4def9b7cb0d49c57738b","type":"GO_TERM","name":"piccolo histone acetyltransferase complex","canonical_id":"go:GO:0032777","description":"\"A heterotrimeric H4/H2A histone acetyltransferase complex with a substrate preference of chromatin over free histones. It contains a subset of the proteins found in the larger NuA4 histone acetyltransferase complex; for example, the S. cerevisiae complex contains Esa1p, Yng2p, and Epl1p.\" [GOC:rb, PMID:12782659, PMID:15964809]","metadata":null},{"id":"c258633bcd85450d8c46e8b8980d25aa","type":"GO_TERM","name":"piccolo-bassoon transport vesicle","canonical_id":"go:GO:1990257","description":"\"A cytoplasmic dense-core vesicle that transports a range of proteins including piccolo, bassoon, N-cadherin and syntaxin. The transported proteins may be associated with the external side of the vesicle, rather than being contained within the vesicle, therefore forming an aggregate of vesicle and proteins. Piccolo-bassoon transport vesicles (or PTVs) range in size from approximately 80 nm in diameter for dense core vesicles to 130 nm by 220 nm in area for aggregates. They are packaged via the trans-Golgi network before being transported through the axon.\" [GOC:dr, PMID:21569270]","metadata":null},{"id":"ac1efa5293be4b8e8d594baa815278ec","type":"GO_TERM","name":"picolinic acid biosynthetic process","canonical_id":"go:GO:1905004","description":"\"The chemical reactions and pathways resulting in the formation of picolinic acid.\" [GO_REF:0000068, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:19843166]","metadata":null},{"id":"886f67dae2154249bb149cef864d9eb3","type":"DISEASE","name":"piebaldism","canonical_id":"mondo:0008244","description":null,"metadata":null},{"id":"ee23ec8862f84ef38bfa45127912349d","type":"GO_TERM","name":"piecemeal microautophagy of the nucleus","canonical_id":"go:GO:0034727","description":"\"Degradation of a cell nucleus by microautophagy.\" [GOC:autophagy, GOC:jp, PMID:18701704]","metadata":null},{"id":"6f3f91676a5d468bbe3e96813bc3df5b","type":"GO_TERM","name":"pigment accumulation","canonical_id":"go:GO:0043476","description":"\"The aggregation of coloring matter in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.\" [GOC:jl]","metadata":null},{"id":"283cd39915594bbf94eb8bac3c5b913e","type":"GO_TERM","name":"pigment accumulation in response to UV light","canonical_id":"go:GO:0043478","description":"\"The aggregation of coloring matter in a particular location in an organism, tissue or cell, occurring in response to a UV light stimulus.\" [GOC:jl]","metadata":null},{"id":"f062bf3249c949839e04ff5a9da1a9ec","type":"GO_TERM","name":"pigment accumulation in tissues","canonical_id":"go:GO:0043480","description":"\"The aggregation of coloring matter in a particular location in a tissue, occurring in response to an external stimulus.\" [GOC:jl]","metadata":null},{"id":"58ba1a7a70ac4e39b6ff6c93149664f0","type":"GO_TERM","name":"pigment accumulation in tissues in response to UV light","canonical_id":"go:GO:0043479","description":"\"The aggregation of coloring matter in a particular location in a tissue, occurring in response to a UV light stimulus.\" [GOC:jl]","metadata":null},{"id":"cfdca77cd4594656b6f3bb3bc3745af3","type":"GO_TERM","name":"pigment binding","canonical_id":"go:GO:0031409","description":"\"Binding to a pigment, a general or particular coloring matter in living organisms, e.g. melanin.\" [GOC:mah]","metadata":null},{"id":"8909ad3a4b5144f8b90a90ec446fc2cb","type":"GO_TERM","name":"pigment biosynthetic process","canonical_id":"go:GO:0046148","description":"\"The chemical reactions and pathways resulting in the formation of a pigment, any general or particular coloring matter in living organisms, e.g. melanin.\" [ISBN:0198506732]","metadata":null},{"id":"1f47b2369def48ea8fb3a8b622c5af80","type":"GO_TERM","name":"pigment biosynthetic process involved in pigment accumulation","canonical_id":"go:GO:0043477","description":"\"The chemical reactions and pathways resulting in the formation of a pigment, any general or particular coloring matter in living organisms, resulting in pigment accumulation.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"c28b50e04b914f3bba40d4f5ed093290","type":"GO_TERM","name":"pigment catabolic process","canonical_id":"go:GO:0046149","description":"\"The chemical reactions and pathways resulting in the breakdown of a pigment, any general or particular coloring matter in living organisms, e.g. melanin.\" [ISBN:0198506732]","metadata":null},{"id":"639c153724aa414794a70940f832c67c","type":"GO_TERM","name":"pigment cell development","canonical_id":"go:GO:0070285","description":"\"The process whose specific outcome is the progression of a pigment cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a pigment cell fate.\" [GOC:cvs]","metadata":null},{"id":"9b2ea57685424f97bac364ba0d083fd4","type":"GO_TERM","name":"pigment cell differentiation","canonical_id":"go:GO:0050931","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a pigmented cell, such as a melanocyte.\" [GOC:dgh]","metadata":null},{"id":"fdec6a88745c4bfb9c1e412894f34261","type":"GO_TERM","name":"pigment cell precursor differentiation","canonical_id":"go:GO:0048824","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a pigment cell precursor.\" [GOC:dgh, PMID:16499899]","metadata":null},{"id":"fffeadcbc5e34d4a98f93dd99046ac5e","type":"GO_TERM","name":"pigment granule","canonical_id":"go:GO:0048770","description":"\"A small, subcellular membrane-bounded vesicle containing pigment and/or pigment precursor molecules. Pigment granule biogenesis is poorly understood, as pigment granules are derived from multiple sources including the endoplasmic reticulum, coated vesicles, lysosomes, and endosomes.\" [GOC:jid, GOC:mh]","metadata":null},{"id":"75f0238ce92d419a80349f1ccadbc047","type":"GO_TERM","name":"pigment granule aggregation in cell center","canonical_id":"go:GO:0051877","description":"\"The directed movement of dispersed pigment granules towards the center of the cell.\" [GOC:mh]","metadata":null},{"id":"f891b066b5a143e0824f3ed1b0e46b3a","type":"GO_TERM","name":"pigment granule dispersal","canonical_id":"go:GO:0051876","description":"\"The directed movement of pigment granules within a cell towards the cell periphery.\" [GOC:mh]","metadata":null},{"id":"08b35feb6d7141749b7579dcb5b17103","type":"GO_TERM","name":"pigment granule localization","canonical_id":"go:GO:0051875","description":"\"Any process in which a pigment granule is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"6b4aab1b04374ad78c9c2470484bc07c","type":"GO_TERM","name":"pigment granule maturation","canonical_id":"go:GO:0048757","description":"\"Steps required to form a membrane-bounded organelle into a pigment granule containing pigment. Maturation is a developmental process, independent of morphogenetic (shape) change, that is required for a cell or structure to attain its fully functional state.\" [GOC:dgh, GOC:jid, GOC:mh]","metadata":null},{"id":"0312484f83194461836199aea4f9343d","type":"GO_TERM","name":"pigment granule membrane","canonical_id":"go:GO:0090741","description":"\"Any membrane that is part of a pigment granule.\" [PMID:11294610]","metadata":null},{"id":"25ce0f23203b46f18a38d3b199e1ac7d","type":"GO_TERM","name":"pigment granule organization","canonical_id":"go:GO:0048753","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a pigment granule.\" [GOC:rc]","metadata":null},{"id":"fe7c746ccb7d4fe7b2e6bb52a9f104cf","type":"GO_TERM","name":"pigment granule transport","canonical_id":"go:GO:0051904","description":"\"The directed movement of pigment granules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"6636600133e447ab968f0b7f603762df","type":"GO_TERM","name":"pigment metabolic process","canonical_id":"go:GO:0042440","description":"\"The chemical reactions and pathways involving pigment, any general or particular coloring matter in living organisms, e.g. melanin.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"dead1c4f20ed45ba8b58929bc9a5b098","type":"GO_TERM","name":"pigment metabolic process involved in developmental pigmentation","canonical_id":"go:GO:0043324","description":"\"The chemical reactions and pathways involving biological pigments e.g. melanin, occurring as part of the development of an organ or organism.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a46175fd10ae4ba4a41346aaa022a27e","type":"GO_TERM","name":"pigment metabolic process involved in pigmentation","canonical_id":"go:GO:0043474","description":"\"The chemical reactions and pathways involving a pigment, any general or particular coloring matter in living organisms, resulting in the deposition or aggregation of pigment in an organism, tissue or cell.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"ec68aa62d027449eb473050e9a3f89b7","type":"GO_TERM","name":"pigmentation","canonical_id":"go:GO:0043473","description":"\"The accumulation of pigment in an organism, tissue or cell, either by increased deposition or by increased number of cells.\" [GOC:jl]","metadata":null},{"id":"f5108c0937ea4120b8c47a2be39c3259","type":"DISEASE","name":"pigmented villonodular synovitis","canonical_id":"efo:1001106","description":null,"metadata":null},{"id":"2d6909d8ffb748419f4d7ef8e76104e8","type":"DRUG","name":"pilocarpine","canonical_id":"gtopdb:305","description":null,"metadata":null},{"id":"5f2d9391f9944544b8f43468aaeff131","type":"DRUG","name":"pilocarpine","canonical_id":"mesh:D010862","description":null,"metadata":null},{"id":"759be7e00eba4664b127241621cd5194","type":"DRUG","name":"pilocarpine","canonical_id":"chembl:CHEMBL550","description":null,"metadata":null},{"id":"dc22a033fa054fa2af441d736f5c074d","type":"COMBINATION_TREATMENT","name":"pilocarpine + tropicamide","canonical_id":"ctgov_combo:ctgov-combo-0ff426f49a8d83f8","description":null,"metadata":null},{"id":"8883a24d22cd4c5f9dde16dc179366b6","type":"DISEASE","name":"pilocytic astrocytoma","canonical_id":"mondo:0016691","description":null,"metadata":null},{"id":"5d02f368dfb64652b3f068b9949f00fe","type":"GO_TERM","name":"pilomotor reflex","canonical_id":"go:GO:0097195","description":"\"The reflex process in which the arrectores pilorum (hair follicle) muscles contract and cause the hair to stand erect.\" [GOC:BHF, PMID:21335239, Wikipedia:Pilomotor_reflex]","metadata":null},{"id":"07d2a0ddd81048a3a1d58a40970f9842","type":"GO_TERM","name":"pilus","canonical_id":"go:GO:0009289","description":"\"A proteinaceous hair-like appendage on the surface of bacteria ranging from 2-8 nm in diameter.\" [GOC:pamgo_curators, PMID:28496159]","metadata":null},{"id":"bd653e23588a46d2893386b84f0830bf","type":"GO_TERM","name":"pilus assembly","canonical_id":"go:GO:0009297","description":"\"The assembly from its constituent parts of a pilus, a short filamentous structure of bacterial cell, flagella-like in structure and generally present in many copies. Pili are variously involved in transfer of nucleic acids, adherence to surfaces, and formation of pellicles. Is required for bacterial conjugation, or can play a role in adherence to surfaces (when it is called a fimbrium), and in the formation of pellicles.\" [GOC:dgh, GOC:mcc2, GOC:tb]","metadata":null},{"id":"89cb9ddf0cb94d95af3473d46bea8986","type":"GO_TERM","name":"pilus organization","canonical_id":"go:GO:0043711","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a pilus, a short filamentous structure on a bacterial cell, flagella-like in structure and generally present in many copies.\" [GOC:jl]","metadata":null},{"id":"5e8c91aa5f0645ea8f9a4919e4079319","type":"GO_TERM","name":"pilus retraction","canonical_id":"go:GO:0043108","description":"\"The process of withdrawing a pilus back into a cell.\" [GOC:curators, PMID:17355871]","metadata":null},{"id":"42644b2a5339495ba7cfa831b5e5f543","type":"GO_TERM","name":"pilus shaft","canonical_id":"go:GO:0009418","description":"\"The long, slender, mid section of a pilus.\" [GOC:jl]","metadata":null},{"id":"06c287f3960744e4b77400e6412294bf","type":"GO_TERM","name":"pilus tip","canonical_id":"go:GO:0009419","description":"\"The pointed extremity furthest from the cell of a pilus.\" [GOC:jl]","metadata":null},{"id":"7e17c8cc231c416ab42aeeb9747f55fa","type":"DRUG","name":"pimavanserin","canonical_id":"gtopdb:8423","description":null,"metadata":null},{"id":"ae5ebd7e7c6f4f7c875589fb5fdb3b32","type":"DRUG","name":"pimecrolimus","canonical_id":"gtopdb:6783","description":null,"metadata":null},{"id":"3bc50f1ef0484ef68df6fa44c736da99","type":"DRUG","name":"pimecrolimus","canonical_id":"chembl:CHEMBL1200686","description":null,"metadata":null},{"id":"75079b1d258d48efb19182f6cb5c1a2f","type":"GO_TERM","name":"pimeloyl-CoA dehydrogenase activity","canonical_id":"go:GO:0018515","description":"\"Catalysis of the reaction: NAD+ + pimelyl-CoA = 2,3-didehydropimeloyl-CoA + H+ + NADH.\" [EC:1.3.1.62, RHEA:19665]","metadata":null},{"id":"6f233325176042a0abe98dd15f354d0c","type":"GO_TERM","name":"pimelyl-[acyl-carrier protein] methyl ester esterase activity","canonical_id":"go:GO:0090499","description":"\"Catalysis of the reaction: 6-carboxyhexanoyl-[ACP] methyl ester + H2O = 6-carboxyhexanoyl-[ACP] + H+ + methanol.\" [PMID:23045647, RHEA:42700]","metadata":null},{"id":"fe7a838a5e3045188a6db483531322fa","type":"DRUG","name":"pimozide","canonical_id":"gtopdb:90","description":null,"metadata":null},{"id":"7bcda0968d72422684a8c6853011854c","type":"DRUG","name":"pimozide","canonical_id":"mesh:D010868","description":null,"metadata":null},{"id":"2742900ce2274bec92420a7f2024fb09","type":"DRUG","name":"pimozide","canonical_id":"chembl:CHEMBL1423","description":null,"metadata":null},{"id":"c067037cfee84960ada3b1cb2c4736ef","type":"DRUG","name":"pinacidil","canonical_id":"mesh:D020110","description":null,"metadata":null},{"id":"c471c44855f34cca970df316c0722424","type":"GO_TERM","name":"pinceau fiber","canonical_id":"go:GO:1990031","description":"\"Dense plexus formed by the descending collaterals of cerebellar basket cells that wrap around a Purkinje cell axonal initial segment.\" [NIF_Subcellular:sao109906988]","metadata":null},{"id":"076e8ace35d6401a81e95efdec17d27d","type":"DRUG","name":"pindolol","canonical_id":"gtopdb:91","description":null,"metadata":null},{"id":"3d81efe18b9a4faeb50c5d346eed2f34","type":"DRUG","name":"pindolol","canonical_id":"chembl:CHEMBL500","description":null,"metadata":null},{"id":"7729c0a357044c05be9620e160268d55","type":"COMBINATION_TREATMENT","name":"pindolol + trazodone","canonical_id":"ctgov_combo:ctgov-combo-288a4aa650ca58b3","description":null,"metadata":null},{"id":"a5b44fb6434c4c5d932de25292c6f3c4","type":"GO_TERM","name":"pineal gland development","canonical_id":"go:GO:0021982","description":"\"The progression of the pineal gland over time from its initial formation until its mature state. The pineal gland is an endocrine gland that secretes melatonin and is involved in circadian rhythms.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"ab6184fe3fcc44288f952b557444079d","type":"GO_TERM","name":"pinene catabolic process","canonical_id":"go:GO:0033074","description":"\"The chemical reactions and pathways leading to the breakdown of the monoterpenoid pinene; alpha-pinene is (1S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-2-ene, and beta-pinene is (1S,5S)-6,6-dimethyl-2-methylenebicyclo[3.1.1]heptane.\" [GOC:mah, PMID:11452597]","metadata":null},{"id":"cecca40804df412da1843ca780d83997","type":"GO_TERM","name":"pinene metabolic process","canonical_id":"go:GO:0033073","description":"\"The chemical reactions and pathways involving the monoterpenoid pinene; alpha-pinene is (1S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-2-ene, and beta-pinene is (1S,5S)-6,6-dimethyl-2-methylenebicyclo[3.1.1]heptane.\" [GOC:mah, PMID:12623076]","metadata":null},{"id":"4b153edf10db483eb1319984cc29e792","type":"GO_TERM","name":"pinene synthase activity","canonical_id":"go:GO:0050550","description":"\"Catalysis of the reaction: geranyl diphosphate = pinene + diphosphate. This reaction can produce (1R,5R)-alpha-pinene, (1S,5S)-alpha-pinene, (1R,5R)-beta-pinene and (1S,5S)-beta-pinene.\" [PMID:21385377, PMID:23679205]","metadata":null},{"id":"3e51104ef0564e89b1e214f7315f0f0c","type":"GO_TERM","name":"pinocytosis","canonical_id":"go:GO:0006907","description":"\"An endocytosis process that results in the uptake of liquid material by cells from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, called pinosomes, formed by invagination of the plasma membrane.\" [ISBN:0198506732]","metadata":null},{"id":"9b3c329dd5ca47e8a4b0bde71e6b5d38","type":"GO_TERM","name":"pinoresinol reductase activity","canonical_id":"go:GO:0010283","description":"\"Catalysis of the reaction: pinoresinol + NADPH + H+ = lariciresinol + NADP+.\" [PMID:10066819, PMID:7592828]","metadata":null},{"id":"620409bfc2d54f5d968109af701d4e08","type":"GO_TERM","name":"pinosome","canonical_id":"go:GO:0044352","description":"\"A membrane-bounded, uncoated intracellular vesicle formed by the process of pinocytosis.\" [PMID:14731589, PMID:14732047]","metadata":null},{"id":"05c74a01e7dc4bb99ebaa2e455685203","type":"GO_TERM","name":"pinosylvin synthase activity","canonical_id":"go:GO:0050198","description":"\"Catalysis of the reaction: trans-cinnamoyl-CoA + 3 H+ + 3 malonyl-CoA = 4 CO2 + 4 CoA + pinosylvin.\" [EC:2.3.1.146, RHEA:12552]","metadata":null},{"id":"9f6d7df62d2a48c8bd046543efa4733a","type":"DRUG","name":"pioglitazone","canonical_id":"gtopdb:2694","description":null,"metadata":null},{"id":"8d267a84a11140fd88a5b381c0cf9729","type":"COMBINATION_TREATMENT","name":"pioglitazone + prednisone","canonical_id":"ctgov_combo:ctgov-combo-d515408144d0ee65","description":null,"metadata":null},{"id":"577ebaf66f794b4bb6c0b01b42ab6afe","type":"COMBINATION_TREATMENT","name":"pioglitazone + saxagliptin","canonical_id":"ctgov_combo:ctgov-combo-b375c9ce2e02d902","description":null,"metadata":null},{"id":"5aa029da1bc8494aa03cc0adeb3253d4","type":"COMBINATION_TREATMENT","name":"pioglitazone + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-33d44d8c4c41781a","description":null,"metadata":null},{"id":"5cad038bdfee47bb9410a258bf0f137a","type":"COMBINATION_TREATMENT","name":"pioglitazone + teneligliptin","canonical_id":"ctgov_combo:ctgov-combo-d8a42fccf2d055aa","description":null,"metadata":null},{"id":"8ff78343058c409aa6bf7ff079599c91","type":"GO_TERM","name":"pipecolic acid N-hydroxylase activity","canonical_id":"go:GO:0062047","description":"\"Catalysis of the reaction: L-pipecolic acid + NAD(P)H + O2 + H+ = N-hydroxypipecolic acid + NAD(P)+ + H2O.\" [PMID:27758894, PMID:28330936]","metadata":null},{"id":"2b9a5d9ac10b418d9f33357e1cc63696","type":"DRUG","name":"piperacillin","canonical_id":"mesh:D010878","description":null,"metadata":null},{"id":"6ceee9c9114b4bc5b6093b1c8b7e5d45","type":"GO_TERM","name":"piperidine N-piperoyltransferase activity","canonical_id":"go:GO:0050199","description":"\"Catalysis of the reaction: (E,E)-piperoyl-CoA + piperidine = N-[(E,E)-piperoyl]piperidine + CoA + H+.\" [EC:2.3.1.145, RHEA:14561]","metadata":null},{"id":"31d58f48c4f3445f94149746f90f16c3","type":"GO_TERM","name":"piperine biosynthetic process","canonical_id":"go:GO:0160181","description":"\"The chemical reactions and pathways resulting in the formation of piperine.\" [PMID:33435446, PMID:33833371]","metadata":null},{"id":"1984823ed3224207bf85c14f2abec284","type":"GO_TERM","name":"piperitol synthase activity","canonical_id":"go:GO:0102915","description":"\"Catalysis of the reaction: (+)-pinoresinol + reduced [NADPH--hemoprotein reductase] + O2 = (+)-piperitol + oxidized [NADPH--hemoprotein reductase] + 2 H2O + H+. Also catalyzes the synthesis of (+)-sesamin from (+)-piperitol.\" [EC:1.14.19.74, PMID:16785429]","metadata":null},{"id":"a8c261a02b4444aba220d2dff48429be","type":"DRUG","name":"pipotiazine","canonical_id":"gtopdb:7557","description":null,"metadata":null},{"id":"f4773ce6784c40559cd60463d23fe5c5","type":"GO_TERM","name":"pirellulosome","canonical_id":"go:GO:0044223","description":"\"A cytoplasmic structure found in bacterial phyla Planctomycetes and Verrucomicrobia containing a condensed nucleoid and ribosomes and surrounded by an intracytoplasmic membrane. It is surrounded by ribosome-free cytoplasm, in a compartment called the paryphoplasm.\" [GOC:dh, PMID:19133117]","metadata":null},{"id":"c9c1de5cae2642c39d308ddfb6477aaf","type":"DRUG","name":"pirenzepine","canonical_id":"gtopdb:328","description":null,"metadata":null},{"id":"b377e7b0206b4b24972f124e654010f6","type":"DRUG","name":"pirenzepine","canonical_id":"mesh:D010890","description":null,"metadata":null},{"id":"6bd5d500080549eca07ed0be1f530b54","type":"DRUG","name":"pirenzepine","canonical_id":"chembl:CHEMBL9967","description":null,"metadata":null},{"id":"41567ade37054b278b235d2c1e69b84e","type":"DRUG","name":"piroxicam","canonical_id":"gtopdb:7273","description":null,"metadata":null},{"id":"a1b4a39c721241db88f42e55ff5704ce","type":"DRUG","name":"piroxicam","canonical_id":"mesh:D010894","description":null,"metadata":null},{"id":"5dbbdd7927b54d36b2e8e6ac5412f695","type":"DRUG","name":"piroxicam","canonical_id":"chembl:CHEMBL527","description":null,"metadata":null},{"id":"b16bc3511a1e4ba7a30baa68298dc67d","type":"COMBINATION_TREATMENT","name":"piroxicam + valdecoxib","canonical_id":"ctgov_combo:ctgov-combo-5addc56b42dbff91","description":null,"metadata":null},{"id":"d4726d5dab9a443b9f6fd8bccaec154d","type":"DRUG","name":"pitolisant","canonical_id":"gtopdb:8924","description":null,"metadata":null},{"id":"e04e3190386d4c9b9bfd50d10635b4ad","type":"DRUG","name":"pitolisant","canonical_id":"chembl:CHEMBL462605","description":null,"metadata":null},{"id":"7466d8da9e4f4dd297fa0125e6728812","type":"GO_TERM","name":"pituitary adenylate cyclase activating polypeptide activity","canonical_id":"go:GO:0016521","description":"\"The action characteristic of pituitary adenylate cyclase activating polypeptide, a peptide produced in the hypothalamus that binds to receptors to exert pleiotropic effects including control of neurotransmitter release, vasodilation, bronchodilation, activation of intestinal motility, increase in insulin and histamine secretion, immune modulation, and stimulation of cell proliferation and differentiation.\" [GOC:mah, PMID:19805477]","metadata":null},{"id":"67f0aa27c6f44659bc39b5e632f8b0f7","type":"GO_TERM","name":"pituitary adenylate cyclase-activating polypeptide receptor activity","canonical_id":"go:GO:0001634","description":"\"A G protein-coupled receptor that interacts with pituitary adenylate cyclase-activating polypeptide.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"487f4bc710b1414a9e6500e1f566cea0","type":"GO_TERM","name":"pituitary adenylate cyclase-activating polypeptide receptor binding","canonical_id":"go:GO:0031858","description":"\"Binding to a pituitary adenylate cyclase-activating polypeptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9ba658ac668644be93eeb815bebbc041","type":"DISEASE","name":"pituitary dwarfism","canonical_id":"mondo:0006909","description":null,"metadata":null},{"id":"7777c147b0bb445794e7137c429160b4","type":"GO_TERM","name":"pituitary gland development","canonical_id":"go:GO:0021983","description":"\"The progression of the pituitary gland over time from its initial formation until its mature state. The pituitary gland is an endocrine gland that secretes hormones that regulate many other glands.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"1ddade33ef8b427980c64e6397d174b6","type":"DISEASE","name":"pituitary gland disorder","canonical_id":"mondo:0003381","description":null,"metadata":null},{"id":"2ac62dedf6fb4e3488340eccae6962e9","type":"GO_TERM","name":"pituitary gonadotropin complex","canonical_id":"go:GO:0061696","description":"\"A protein complex that is a protein hormone secreted by gonadotrope cells of the anterior pituitary of vertebrates. capable of regulating normal growth, sexual development, and reproductive function.\" [GOC:dph, PMID:11420129]","metadata":null},{"id":"d1cbd9c6a6624047920a05d9b3810b09","type":"GO_TERM","name":"pivalyl-CoA mutase activity","canonical_id":"go:GO:0034784","description":"\"Catalysis of the reaction: 3-methylbutanoyl-CoA = 2,2-dimethylpropanoyl-CoA.\" [RHEA:52620]","metadata":null},{"id":"fd747cd87d1e4f38ad0b0eb94bc920cb","type":"GO_TERM","name":"placenta blood vessel development","canonical_id":"go:GO:0060674","description":"\"The process whose specific outcome is the progression of a blood vessel of the placenta over time, from its formation to the mature structure.\" [GOC:dph, PMID:16916377]","metadata":null},{"id":"8b17ba63441749d4be7fa98822d2d694","type":"GO_TERM","name":"placenta development","canonical_id":"go:GO:0001890","description":"\"The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.\" [GOC:add, ISBN:068340007X]","metadata":null},{"id":"ef33b41a9bb24f0bbe17462de3951c22","type":"GO_TERM","name":"placental growth factor receptor activity","canonical_id":"go:GO:0036332","description":"\"Combining with placental growth factor (PlGF) receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:uh, PMID:12871269, PMID:7929268, Wikipedia:Placental_growth_factor]","metadata":null},{"id":"d818c02c618541c1b2751d1c38b69ea7","type":"GO_TERM","name":"planar dichotomous subdivision of terminal units involved in lung branching morphogenesis","canonical_id":"go:GO:0060489","description":"\"The process in which a lung bud bifurcates parallel to the plane of the previous bud.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"f480243804c844a9b6ae2f04f4f703f6","type":"GO_TERM","name":"plant cell papilla","canonical_id":"go:GO:0090395","description":"\"A cell projection that is a short, rounded projection from a plant epidermal cell.\" [GOC:tb]","metadata":null},{"id":"e597378d33034b92b21195cf5fc5cc49","type":"GO_TERM","name":"plant endodermal cell differentiation","canonical_id":"go:GO:0160058","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a plant endodermal cell.\" [PMID:21735349]","metadata":null},{"id":"72564bdc2f4b46c3a8cb5fa1cef97c14","type":"GO_TERM","name":"plant endodermal cell fate specification","canonical_id":"go:GO:0160057","description":"\"The process in which a cell becomes capable of differentiating autonomously into a plant endodermal cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [PMID:26415082]","metadata":null},{"id":"ca7e1985a8664317b3d5ef3ae84fbbf4","type":"GO_TERM","name":"plant epidermal cell differentiation","canonical_id":"go:GO:0090627","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a plant epidermal cell.\" [GOC:tb]","metadata":null},{"id":"f35a622810324413b0bf59e5838784f4","type":"GO_TERM","name":"plant epidermal cell fate specification","canonical_id":"go:GO:0090628","description":"\"The process in which a cell becomes capable of differentiating autonomously into a plant epidermal cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GOC:tb]","metadata":null},{"id":"d80598b1c5f24c1482cd431b6eba0fe8","type":"GO_TERM","name":"plant epidermis development","canonical_id":"go:GO:0090558","description":"\"The process whose specific outcome is the progression of the plant epidermis over time, from its formation to the mature structure.\" [GOC:tb]","metadata":null},{"id":"b2cfab42ca0e4ea99570304757bf5323","type":"GO_TERM","name":"plant epidermis morphogenesis","canonical_id":"go:GO:0090626","description":"\"The process in which the anatomical structures of the plant epidermis are generated and organized.\" [GOC:tb]","metadata":null},{"id":"0e24d82a91ba40b4910501548c161664","type":"GO_TERM","name":"plant gross anatomical part developmental process","canonical_id":"go:GO:0160109","description":"\"A developmental process whose specific outcome is the progression of a gross anatomical part of a plant over time from an initial condition to a later condition.\" [GOC:pg]","metadata":null},{"id":"7778892a7a1243778a84f9aa2b3e334f","type":"GO_TERM","name":"plant organ development","canonical_id":"go:GO:0099402","description":"\"Development of a plant organ, a multi-tissue plant structure that forms a functional unit.\" [GOC:dos]","metadata":null},{"id":"90600d29778948e78bfd69d656003da6","type":"GO_TERM","name":"plant organ formation","canonical_id":"go:GO:1905393","description":"\"The process that gives rise to the plant organ. This process pertains to the initial formation of a structure from unspecified parts.\" [GO_REF:0000081, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"9e401f9b31ef4e6cb40fc438c3cb2368","type":"GO_TERM","name":"plant organ morphogenesis","canonical_id":"go:GO:1905392","description":"\"The developmental process by which a plant organ is generated and organized.\" [GO_REF:0000083, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"b33d942c83c24acd8ad8d214cb30d61c","type":"GO_TERM","name":"plant organ senescence","canonical_id":"go:GO:0090693","description":"\"A plant organ developmental process during which a plant dismantles cellular components to reclaim the cellular building blocks and nutrients that have been deposited in the plant organs during growth.\" [GOC:tb, PMID:17177638, PMID:34938309]","metadata":null},{"id":"5e6489722e184412bb92a29631cc0be3","type":"GO_TERM","name":"plant ovule development","canonical_id":"go:GO:0048481","description":"\"The process whose specific outcome is the progression of the ovule over time, from its formation to the mature structure. The ovule is the structure in seed plants enclosing the female gametophyte, and is composed of the nucellus, one or two integuments, and the funiculus; it develops into the seed.\" [GOC:tb]","metadata":null},{"id":"9cefb50d44bb4b16b532bd5ce2973414","type":"GO_TERM","name":"plant ovule morphogenesis","canonical_id":"go:GO:0048482","description":"\"The process in which the anatomical structures of the ovule are generated and organized. The ovule is the structure in seed plants enclosing the female gametophyte, and is composed of the nucellus, one or two integuments, and the funiculus; it develops into the seed.\" [GOC:tb]","metadata":null},{"id":"9c7dbea4f0b948268922265668903b8c","type":"GO_TERM","name":"plant parenchymal cell differentiation","canonical_id":"go:GO:0048760","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a parenchymal cell. Parenchymal cells are the most abundant and versatile cells in plants. They have very few distinguishing characteristics and botanists classify them as any cell type that cannot be assigned to any other structural or functional class. They can redifferentiate and dedifferentiate and are involved in storage, basic metabolism and other processes. The cells are polyhedral, typically with thin, non-lignified cellulose cell walls and nucleate living protoplasm. They vary in size, form, and wall structure.\" [CL:0000668, GOC:jid, ISBN:069716957X, PO:0005421]","metadata":null},{"id":"5b5e18b34cc54d4a8da13a16a2af1957","type":"GO_TERM","name":"plant seed peroxygenase activity","canonical_id":"go:GO:1990137","description":"\"Catalysis of the reaction: RH + ROOH = ROH + ROH.\" [EC:1.11.2.3, PMID:19467604]","metadata":null},{"id":"eeeed864bc0e4fd6b6ed4e4e778d3e53","type":"GO_TERM","name":"plant septum development","canonical_id":"go:GO:1905328","description":"\"The process whose specific outcome is the progression of a septum over time, from its formation to the mature structure.\" [GO_REF:0000080, GOC:tb, GOC:TermGenie, PMID:4562349]","metadata":null},{"id":"4b5fc9bd0703400c86e942cb0c3067a8","type":"GO_TERM","name":"plant-type cell wall","canonical_id":"go:GO:0009505","description":"\"A more or less rigid structure lying outside the cell membrane of a cell and composed of cellulose and pectin and other organic and inorganic substances.\" [ISBN:0471245208, PMID:39878232]","metadata":null},{"id":"89844cdb7a4748cc8a80c05d53a20d16","type":"GO_TERM","name":"plant-type cell wall assembly","canonical_id":"go:GO:0071668","description":"\"The aggregation, arrangement and bonding together of a set of components to form a cellulose- and pectin-containing cell wall.\" [GOC:mah]","metadata":null},{"id":"e81fd23da14b4e609c522b68e1b6ec54","type":"GO_TERM","name":"plant-type cell wall biogenesis","canonical_id":"go:GO:0009832","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cellulose and pectin-containing cell wall. An example of this is found in Arabidopsis thaliana.\" [GOC:curators, GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"e9c6e667de8e43d3a6ab5cc7441b0a3a","type":"GO_TERM","name":"plant-type cell wall cellulose biosynthetic process","canonical_id":"go:GO:0052324","description":"\"The chemical reactions and pathways resulting in the formation of cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation, as part of the organization and biogenesis of the cell wall.\" [GOC:ai]","metadata":null},{"id":"361937e5259841ac9a24799c230e0dc2","type":"GO_TERM","name":"plant-type cell wall cellulose catabolic process","canonical_id":"go:GO:0044348","description":"\"The chemical reactions and pathways resulting in the breakdown of cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation, which forms part of the cell wall.\" [GOC:mengo_curators]","metadata":null},{"id":"8bfa9c4e17bb41a5b0df5bd2f943c727","type":"GO_TERM","name":"plant-type cell wall cellulose metabolic process","canonical_id":"go:GO:0052541","description":"\"The chemical reactions and pathways involving cellulose, a linear beta1-4 glucan of molecular mass 50-400 kDa with the pyranose units in the -4C1 conformation, as part of the organization and biogenesis of the cell wall.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"a674ad8e81ea464fb584763ee903a5c3","type":"GO_TERM","name":"plant-type cell wall loosening","canonical_id":"go:GO:0009828","description":"\"The series of events causing chemical and structural alterations of an existing cellulose and pectin-containing cell wall that results in greater extensibility of the wall. An example of this is found in Arabidopsis thaliana.\" [GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"ee8d31b5dfc64727bccacedeb8d6f596","type":"GO_TERM","name":"plant-type cell wall modification","canonical_id":"go:GO:0009827","description":"\"The series of events leading to chemical and structural alterations of an existing cellulose and pectin-containing cell wall that can result in loosening, increased extensibility or disassembly. An example of this is found in Arabidopsis thaliana.\" [GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"096ff9c6bd6b4ae297b9a4400e6aad03","type":"GO_TERM","name":"plant-type cell wall modification involved in multidimensional cell growth","canonical_id":"go:GO:0009831","description":"\"The series of events that occur during cell growth that result in chemical or structural changes to existing cell walls of the type composed chiefly of cellulose and pectin. An example of this is found in Arabidopsis thaliana.\" [GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"bb0d4cd3fcf64188aa589300d3520ae0","type":"GO_TERM","name":"plant-type cell wall organization","canonical_id":"go:GO:0009664","description":"\"A process that results in the assembly and arrangement of constituent parts of the cellulose and pectin-containing cell wall, or in the disassembly of the cellulose and pectin-containing cell wall. This process is carried out at the cellular level. An example of this process is found in Arabidopsis thaliana.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"82ddc013e4f0402ab078e1c735afdf07","type":"GO_TERM","name":"plant-type cell wall organization or biogenesis","canonical_id":"go:GO:0071669","description":"\"A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cellulose- and pectin-containing cell wall.\" [GOC:ecd, GOC:mah]","metadata":null},{"id":"c7e703aa080345f8a4a4770acb46ada2","type":"GO_TERM","name":"plant-type hypersensitive response","canonical_id":"go:GO:0009626","description":"\"The rapid, localized death of plant cells in response to invasion by a pathogen.\" [ISBN:0582227089]","metadata":null},{"id":"6765aebb36a540658692206ec67860f1","type":"GO_TERM","name":"plant-type ovary development","canonical_id":"go:GO:0035670","description":"\"The process whose specific outcome is the progression of an ovary that produces an ovule over time, from its formation to the mature structure. The ovary is the enlarged basal portion of a carpel and matures into a fruit. An ovule is the multicellular structure that gives rise to and contains the female reproductive cells, and develops into a seed.\" [GOC:bf, GOC:tb, ISBN:0879015322]","metadata":null},{"id":"d79166c14fd3467a9ead6d47c633280e","type":"GO_TERM","name":"plant-type primary cell wall biogenesis","canonical_id":"go:GO:0009833","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of cellulose and pectin-containing cell walls that form adjacent to the middle lamella following cell division and during cell expansion. An example of this is found in Arabidopsis thaliana.\" [GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"10c1610ea7e34935bc55c0b43ccb75b6","type":"GO_TERM","name":"plant-type secondary cell wall biogenesis","canonical_id":"go:GO:0009834","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of inextensible cellulose- and pectin-containing cell walls that are formed between the plasma membrane and primary cell wall after cell expansion is complete. An example of this is found in Arabidopsis thaliana.\" [GOC:lr, GOC:mtg_sensu]","metadata":null},{"id":"8e29ac4a211046ad884412bda45d4826","type":"GO_TERM","name":"plant-type sporogenesis","canonical_id":"go:GO:0048236","description":"\"The formation of plant spores derived from the products of meiosis. The spore gives rise to gametophytes.\" [GOC:tb]","metadata":null},{"id":"80d1dba1c36646c68ef61d2bccfa40ae","type":"GO_TERM","name":"plant-type vacuole","canonical_id":"go:GO:0000325","description":"\"A closed structure that is completely surrounded by a unit membrane, contains liquid, and retains the same shape regardless of cell cycle phase. An example of this structure is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, ISBN:0815316208]","metadata":null},{"id":"5e96cb83d47245fbb2c36febfe0aecab","type":"GO_TERM","name":"plant-type vacuole lumen","canonical_id":"go:GO:0000330","description":"\"The volume enclosed within the vacuolar membrane of a vacuole that retains the same shape regardless of cell cycle phase. An example of this is found in Arabidopsis thaliana.\" [GOC:krc, GOC:mtg_sensu]","metadata":null},{"id":"9f68ca2a96be42389a05af69a552fa9d","type":"GO_TERM","name":"plant-type vacuole membrane","canonical_id":"go:GO:0009705","description":"\"The lipid bilayer surrounding a vacuole that retains the same shape regardless of cell cycle phase. The membrane separates its contents from the cytoplasm of the cell. An example of this component is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, ISBN:0471245208]","metadata":null},{"id":"f34d580e48694163b6c580b39d3b3b66","type":"GO_TERM","name":"plantlet formation on parent plant","canonical_id":"go:GO:0048624","description":"\"The process in which a new plantlet develops from a meristem on the plant body. As part of this process, when the plantlet is large enough to live independently, the physical connection between the new plantlet and the main plant is severed.\" [GOC:curators]","metadata":null},{"id":"7c9ee5a094ef4f5cb9d311f5c92340e5","type":"GO_TERM","name":"plasma cell differentiation","canonical_id":"go:GO:0002317","description":"\"The process in which a B cell acquires the specialized features of a plasma cell. A plasma cell is a lymphocyte which develops from a B cell and produces high amounts of antibody.\" [GOC:jal]","metadata":null},{"id":"35d2c153d9514b34a1d62007e5c34db3","type":"DISEASE","name":"plasma cell myeloma","canonical_id":"mondo:0009693","description":null,"metadata":null},{"id":"4c2dfd8d60114dc3923bc60e670b5c95","type":"GO_TERM","name":"plasma kallikrein-kinin cascade","canonical_id":"go:GO:0002353","description":"\"A series of reactions that takes place outside the cell occurring in response to tissue damage and initiated within blood plasma by the action of activated Factor XII (Hageman Factor) on prekallikrein to convert it to plasma kallikrein, and the subsequent reaction of plasma kallikrein with high molecular weight kininogen. The ultimate product of the plasma kallikrein-kinin cascade is bradykinin, an agent known to induce smooth muscle contraction, vasoconstriction, and increased vascular permeability.\" [GOC:add, ISBN:0721601871, PMID:11842287, PMID:14501145]","metadata":null},{"id":"950f0f9fe57949bfa3eb8c5f838b4b07","type":"GO_TERM","name":"plasma lipoprotein particle","canonical_id":"go:GO:0034358","description":"\"A spherical particle with a hydrophobic core of triglycerides and/or cholesterol esters, surrounded by an amphipathic monolayer of phospholipids, cholesterol and apolipoproteins. Plasma lipoprotein particles transport lipids, which are non-covalently associated with the particles, in the blood or lymph.\" [GOC:BHF, GOC:expert_pt, GOC:rl]","metadata":null},{"id":"1f6e12af2ae24cef96874820b88dc995","type":"GO_TERM","name":"plasma lipoprotein particle assembly","canonical_id":"go:GO:0034377","description":"\"The non-covalent aggregation and arrangement of proteins and lipids to form a plasma lipoprotein particle.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"c329f16d6bd64ae98c88b6cdcfa1a845","type":"GO_TERM","name":"plasma lipoprotein particle clearance","canonical_id":"go:GO:0034381","description":"\"The process in which a lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:ascb_2009, GOC:BHF, GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"ae34a4b49ac34cc0bc1d4a920cbfbe75","type":"GO_TERM","name":"plasma lipoprotein particle disassembly","canonical_id":"go:GO:0071829","description":"\"The disaggregation of a plasma lipoprotein particle into its constituent components.\" [GOC:mah]","metadata":null},{"id":"14d9c0c53d5f4177acfe723549f43c94","type":"GO_TERM","name":"plasma lipoprotein particle organization","canonical_id":"go:GO:0071827","description":"\"A protein-lipid complex subunit organization process that results in the formation, disassembly, or alteration of a plasma lipoprotein particle. A plasma lipoprotein particle is a spherical particle with a hydrophobic core of triglycerides and/or cholesterol esters, surrounded by an amphipathic monolayer of phospholipids, cholesterol and apolipoproteins.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a5f5e775abb24a738583e0ec0ec1a3ed","type":"GO_TERM","name":"plasma lipoprotein particle oxidation","canonical_id":"go:GO:0034441","description":"\"The modification of a lipid or protein within a plasma lipoprotein particle by oxidation of the lipid or one or more amino acids.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1ae2764a9659419cae4cb6bce861c10c","type":"GO_TERM","name":"plasma lipoprotein particle remodeling","canonical_id":"go:GO:0034369","description":"\"The acquisition, loss or modification of a protein or lipid within a plasma lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase, with the subsequent loss of free fatty acid, and the esterification of cholesterol by phosphatidylcholine-sterol O-acyltransferase (lecithin cholesterol acyltransferase; LCAT).\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"16c0ad1413434bbc8dea7517f54b9bee","type":"GO_TERM","name":"plasma membrane","canonical_id":"go:GO:0005886","description":"\"The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.\" [ISBN:0716731363]","metadata":null},{"id":"1483ad314ac648d99d57790bea9a5151","type":"GO_TERM","name":"plasma membrane ATP synthesis coupled electron transport","canonical_id":"go:GO:0042774","description":"\"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP in the plasma membrane.\" [GOC:mtg_sensu, ISBN:0716731363]","metadata":null},{"id":"93a1ff0b10384c1986e89935ce2c66a2","type":"GO_TERM","name":"plasma membrane acetate transport","canonical_id":"go:GO:0006847","description":"\"The directed movement of acetate across a plasma membrane.\" [GOC:ai]","metadata":null},{"id":"a253b79137b243b091aeede443d0e419","type":"GO_TERM","name":"plasma membrane bounded cell projection","canonical_id":"go:GO:0120025","description":"\"A prolongation or process extending from a cell and that is bounded by plasma membrane, e.g. a cilium, lamellipodium, or axon.\" [GOC:krc]","metadata":null},{"id":"3303e89627974acaaea0e1513397eb6a","type":"GO_TERM","name":"plasma membrane bounded cell projection assembly","canonical_id":"go:GO:0120031","description":"\"Formation of a prolongation or process extending and that is bounded by plasma membrane, e.g. a cilium, lamellipodium, or axon.\" [GOC:krc]","metadata":null},{"id":"a7e7ce8c08314b3ba0d3cefa070bd898","type":"GO_TERM","name":"plasma membrane bounded cell projection cytoplasm","canonical_id":"go:GO:0032838","description":"\"All of the contents of a plasma membrane bounded cell projection, excluding the plasma membrane surrounding the projection.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"7ce05544afbd4e69a184b1f6e9b8ef4d","type":"GO_TERM","name":"plasma membrane bounded cell projection morphogenesis","canonical_id":"go:GO:0120039","description":"\"The process in which the anatomical structures of a plasma membrane bounded cell projection are generated and organized.\" [GOC:krc]","metadata":null},{"id":"5d52aa037e814923b5176e55ed3c39e8","type":"GO_TERM","name":"plasma membrane bounded cell projection organization","canonical_id":"go:GO:0120036","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a plasma membrane bounded prolongation or process extending from a cell, e.g. a cilium or axon.\" [GOC:krc]","metadata":null},{"id":"fdd4045442324b6887ed019ebc0657b4","type":"GO_TERM","name":"plasma membrane copper ion transport","canonical_id":"go:GO:0015679","description":"\"The directed movement of copper ions across the plasma membrane.\" [GOC:ai]","metadata":null},{"id":"ee4c1fca2d5b4ca98bc02f0e54186bd2","type":"GO_TERM","name":"plasma membrane electron transport, NADH to quinone","canonical_id":"go:GO:0030965","description":"\"The transfer of electrons from NADH to the quinone pool that occurs during oxidative phosphorylation and results in the generation of a proton gradient, mediated by the enzyme known as NADH-quinone oxidoreductase.\" [GOC:mah, GOC:sd]","metadata":null},{"id":"7ae2f9b2debc46829647dead764ce231","type":"GO_TERM","name":"plasma membrane expansion","canonical_id":"go:GO:7770017","description":"\"A cellular process which results in an increase in the size (surface area) of the plasma membrane during cell growth or osmotic stress. This can occur by lipid transfer, membrane trafficking, or eisosome disassembly.\" [PMID:40629316]","metadata":null},{"id":"59e0673bf14c4771a7001819286bb68d","type":"GO_TERM","name":"plasma membrane invagination","canonical_id":"go:GO:0099024","description":"\"An infolding of the plasma membrane.\" [GOC:dos, GOC:vw]","metadata":null},{"id":"2c36da11568c474ebad4f1194f8c1a14","type":"GO_TERM","name":"plasma membrane lactate transport","canonical_id":"go:GO:0035879","description":"\"The directed movement of lactate across a plasma membrane.\" [GOC:mcc]","metadata":null},{"id":"b9f818524af4495fbb2fddc2423c6037","type":"GO_TERM","name":"plasma membrane light-harvesting complex","canonical_id":"go:GO:0030077","description":"\"A plasma membrane protein-pigment complex that may be closely or peripherally associated to photosynthetic reaction centers that participate in harvesting and transferring radiant energy to the reaction center. Examples of this complex are found in bacterial species.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"844e2a77af334d7b8218a1624ecd7023","type":"GO_TERM","name":"plasma membrane of cell tip","canonical_id":"go:GO:0031520","description":"\"The portion of the plasma membrane surrounding the cell tip.\" [GOC:mah]","metadata":null},{"id":"d61c5d95303f4e25868cf1821f2351f7","type":"GO_TERM","name":"plasma membrane of growing cell tip","canonical_id":"go:GO:1902929","description":"\"Any plasma membrane part that is part of a growing cell tip.\" [GO_REF:0000064, GOC:TermGenie, PMID:17085965]","metadata":null},{"id":"ed06b34015b3428b87bcf62a696e1683","type":"GO_TERM","name":"plasma membrane organization","canonical_id":"go:GO:0007009","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the plasma membrane.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"3f4b6d3cd198494dbd02921a1c1c13eb","type":"GO_TERM","name":"plasma membrane phospholipid scrambling","canonical_id":"go:GO:0017121","description":"\"The movement of a population of phospholipid molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet, resulting in loss of lipid asymmetry and surface exposure of phosphatidylserine (PS) and phosphatidylethanolamine (PE).\" [GOC:cjm, PMID:20043909, PMID:20302864]","metadata":null},{"id":"480db4e2434641b39bbcd9910f17ec00","type":"GO_TERM","name":"plasma membrane protein complex","canonical_id":"go:GO:0098797","description":"\"Any protein complex that is part of the plasma membrane.\" [GOC:dos]","metadata":null},{"id":"9eefd03da0a74f0abe0cdf7de5a526c0","type":"GO_TERM","name":"plasma membrane proton-transporting ATP synthase complex assembly","canonical_id":"go:GO:0033616","description":"\"The aggregation, arrangement and bonding together of a proton-transporting ATP synthase in the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"c440709c5ad7407b8d2ec93842c0450f","type":"GO_TERM","name":"plasma membrane proton-transporting V-type ATPase complex","canonical_id":"go:GO:0033181","description":"\"A proton-transporting two-sector ATPase complex found in the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"d423c00638c9456587b6407e76f2de76","type":"GO_TERM","name":"plasma membrane proton-transporting V-type ATPase, V0 domain","canonical_id":"go:GO:0000222","description":"\"The V0 domain of a proton-transporting V-type ATPase found in the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"39458610d4b346a6b9ba63fcedf33f5b","type":"GO_TERM","name":"plasma membrane proton-transporting V-type ATPase, V1 domain","canonical_id":"go:GO:0000223","description":"\"The V1 domain of a proton-transporting V-type ATPase found in the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"ebbd606ecb8045978a6c44cd34121e7f","type":"GO_TERM","name":"plasma membrane pyruvate transport","canonical_id":"go:GO:0006849","description":"\"The directed movement of pyruvate, 2-oxopropanoate, across a plasma membrane.\" [GOC:ai]","metadata":null},{"id":"7b03dc7dc0f044d68ea4c557f73d8773","type":"GO_TERM","name":"plasma membrane raft","canonical_id":"go:GO:0044853","description":"\"A membrane raft that is part of the plasma membrane.\" [GOC:jl]","metadata":null},{"id":"3d7a66f385844a31bcc090572d69a319","type":"GO_TERM","name":"plasma membrane raft assembly","canonical_id":"go:GO:0044854","description":"\"The aggregation, arrangement and bonding together of a set of components to form a plasma membrane raft.\" [GOC:jl]","metadata":null},{"id":"7722554d12034f6e9fa2edc5dc8074a3","type":"GO_TERM","name":"plasma membrane raft distribution","canonical_id":"go:GO:0044855","description":"\"The process that establishes the spatial arrangement of membrane rafts within a plasma membrane.\" [GOC:jl]","metadata":null},{"id":"cc9872675d0b40bb861d6a6cacd02153","type":"GO_TERM","name":"plasma membrane raft localization","canonical_id":"go:GO:0044856","description":"\"Any process in which plasma membrane rafts are transported to, or maintained in, a specific location.\" [GOC:jl]","metadata":null},{"id":"03392ec7cbc443019aa885e760556a32","type":"GO_TERM","name":"plasma membrane raft organization","canonical_id":"go:GO:0044857","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of plasma membrane rafts.\" [GOC:jl]","metadata":null},{"id":"6cbf2fb1d17d4a11b65dcb06a6688297","type":"GO_TERM","name":"plasma membrane raft polarization","canonical_id":"go:GO:0044858","description":"\"The clustering and aggregation of a plasma membrane into domains. This serves as a mechanism to compartmentalize cellular activities and to establish cell polarity.\" [GOC:jl]","metadata":null},{"id":"fd0fa8dc7d3c4cb783ca6c44df096f3c","type":"GO_TERM","name":"plasma membrane region","canonical_id":"go:GO:0098590","description":"\"A membrane that is a (regional) part of the plasma membrane.\" [GOC:dos]","metadata":null},{"id":"ee3bb2c6d62b436e91e9f519746aa165","type":"GO_TERM","name":"plasma membrane repair","canonical_id":"go:GO:0001778","description":"\"The resealing of a cell plasma membrane after cellular wounding due to, for instance, mechanical stress.\" [GOC:add, PMID:12925704]","metadata":null},{"id":"15f4d49895654422a46f798228c4d69f","type":"GO_TERM","name":"plasma membrane respiratory chain complex IV assembly","canonical_id":"go:GO:0033618","description":"\"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase) in the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"84b1180c077a4774920d06d7bcb95e99","type":"GO_TERM","name":"plasma membrane selenite transport","canonical_id":"go:GO:0097080","description":"\"The directed movement of inorganic selenite (HSeO3-1 at physiological pH) across a plasma membrane.\" [GOC:mcc, PMID:20861301]","metadata":null},{"id":"d352e6a40f9d40ef9c11ae1462e6d784","type":"GO_TERM","name":"plasma membrane signaling receptor complex","canonical_id":"go:GO:0098802","description":"\"Any protein complex that is part of the plasma membrane and which functions as a signaling receptor.\" [GOC:dos]","metadata":null},{"id":"e12bcbc5c15247e2834ba321ffc1955b","type":"GO_TERM","name":"plasma membrane to endosome transport","canonical_id":"go:GO:0048227","description":"\"Transport of a vesicle from the plasma membrane to the endosome.\" [GOC:jid]","metadata":null},{"id":"ed0d4a376c6546529b310ed4998f3870","type":"GO_TERM","name":"plasma membrane tubulation","canonical_id":"go:GO:0097320","description":"\"A membrane tubulation process occurring in a plasma membrane.\" [GOC:BHF, GOC:pr, PMID:15252009, PMID:20730103]","metadata":null},{"id":"7fd19cb72bb049d5a8dd4240b3b4239e","type":"GO_TERM","name":"plasma membrane-derived chromatophore","canonical_id":"go:GO:0042716","description":"\"A pigment-bearing structure that is derived from the cytoplasmic membrane, sometimes consisting of simple invaginations and sometimes a complete vesicle. This component is found in certain photosynthetic bacteria and cyanobacteria.\" [GOC:jl, ISBN:0395825172, PMID:11867431]","metadata":null},{"id":"01e66df09d51471c83749fff9e899f65","type":"GO_TERM","name":"plasma membrane-derived chromatophore membrane","canonical_id":"go:GO:0042717","description":"\"The lipid bilayer associated with a plasma membrane-derived chromatophore; surrounds chromatophores that form complete vesicles.\" [GOC:jl, GOC:mah, ISBN:0395825172, PMID:11867431]","metadata":null},{"id":"b2704d664319420dac9ac308d21970a9","type":"GO_TERM","name":"plasma membrane-derived photosystem I","canonical_id":"go:GO:0030094","description":"\"A protein complex located in the plasma membrane-derived thylakoid. The photosystem functions as a light-dependent plastocyanin-ferredoxin oxidoreductase, transferring electrons from plastocyanin to ferredoxin. Examples of this complex are found in bacterial species.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"a16c23da5a6b4d4498aa1edf3f75da75","type":"GO_TERM","name":"plasma membrane-derived thylakoid lumen","canonical_id":"go:GO:0031979","description":"\"The volume enclosed by a plasma membrane-derived thylakoid.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"8af0d15e64704e889a47fd5193b52b0b","type":"GO_TERM","name":"plasma membrane-derived thylakoid membrane","canonical_id":"go:GO:0031676","description":"\"The pigmented membrane of a plasma membrane-derived thylakoid.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"9339a4e9813043d3a26dcd47669be5c7","type":"GO_TERM","name":"plasma membrane-derived thylakoid photosystem II","canonical_id":"go:GO:0030096","description":"\"A protein complex, located in the membrane-derived thylakoid, containing the P680 reaction center. In the light, PSII functions as a water-plastoquinone oxidoreductase, transferring electrons from water to plastoquinone.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"33c42aad973d40f19faacc8229053af6","type":"GO_TERM","name":"plasma membrane-derived thylakoid ribulose bisphosphate carboxylase complex","canonical_id":"go:GO:0048493","description":"\"A complex, located in the plasma membrane-derived thylakoid, containing either both large and small subunits or just small subunits. It carries out the activity of producing 3-phosphoglycerate from carbon dioxide and ribulose-1,5-bisphosphate.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"3805b8a364124d33ab0babc7b0bb522a","type":"GO_TERM","name":"plasmacytoid dendritic cell activation","canonical_id":"go:GO:0002270","description":"\"A change in the morphology or behavior of a plasmacytoid dendritic cell resulting from exposure to an activating factor such as a cellular or soluble ligand.\" [GOC:add, PMID:15990333, PMID:16174109]","metadata":null},{"id":"c469e0f300ca4e3dad2cee6ce444f359","type":"GO_TERM","name":"plasmacytoid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002470","description":"\"The process in which a plasmacytoid dendritic cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"34a1afcac1284d6787cb59d599b1857c","type":"GO_TERM","name":"plasmacytoid dendritic cell chemotaxis","canonical_id":"go:GO:0002410","description":"\"The movement of a plasmacytoid dendritic cell in response to an external stimulus.\" [GOC:add, PMID:15159375, PMID:15814331]","metadata":null},{"id":"e6e9ca0fec464fc8877fb8706d78e2f5","type":"GO_TERM","name":"plasmacytoid dendritic cell cytokine production","canonical_id":"go:GO:0002373","description":"\"Any process that contributes to cytokine production by a plasmacytoid dendritic cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f6a538bb3db44b15ba631fcad1758a95","type":"GO_TERM","name":"plasmacytoid dendritic cell differentiation","canonical_id":"go:GO:0002273","description":"\"The process in which a relatively unspecialized hemopoietic precursor cell acquires the specialized features of a plasmacytoid dendritic cell.\" [GOC:add, PMID:15990333, PMID:16174108]","metadata":null},{"id":"0f89b0ad9282432998de7d8081b28705","type":"GO_TERM","name":"plasmalogen synthase activity","canonical_id":"go:GO:0047159","description":"\"Catalysis of the reaction: 1-O-(1Z-alkenyl)-sn-glycero-3-phosphocholine + an acyl-CoA = 1-O-(1Z-alkenyl)-2-acyl-sn-glycero-3-phosphocholine + CoA.\" [RHEA:10344]","metadata":null},{"id":"6433c717e86a4b7c956dcdd82877e160","type":"GO_TERM","name":"plasmanylethanolamine desaturase activity","canonical_id":"go:GO:0050207","description":"\"Catalysis of the reaction:1-(1,2-saturated alkyl)-2-acyl-sn-glycero-3-phosphoethanolamine + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = 1-O-(1Z-alkenyl)-2-acyl-sn-glycero-3-phosphoethanolamine + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:22956]","metadata":null},{"id":"8960620478ea4eb6a4ba237a3408aa5f","type":"GO_TERM","name":"plasmatocyte differentiation","canonical_id":"go:GO:0042387","description":"\"The process in which a hemocyte precursor cell acquires the characteristics of the phagocytic blood-cell type, the plasmatocyte. Plasmatocytes are a class of arthropod hemocytes important in the cellular defense response.\" [PMID:11921077, PMID:8174791]","metadata":null},{"id":"2351c51eae5f4be49d4fc208e3c82f25","type":"GO_TERM","name":"plasmid copy number maintenance","canonical_id":"go:GO:0060908","description":"\"The maintenance of the number of copies of extrachromosomal plasmid DNA.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9946ec104d6e437698e0064e76c50d1b","type":"GO_TERM","name":"plasmid maintenance","canonical_id":"go:GO:0006276","description":"\"The maintenance of the integrity of extrachromosomal plasmid DNA; includes processes that ensure plasmids are retained in the daughter cells after cell division.\" [GOC:ai]","metadata":null},{"id":"e50c581ff44b4d4fb1aad85da002db95","type":"GO_TERM","name":"plasmid partitioning","canonical_id":"go:GO:0030541","description":"\"Any process in which plasmids are segregated or distributed into daughter cells upon cell division.\" [GOC:mah]","metadata":null},{"id":"378de76f42064e9d93a8011b197ec2ec","type":"GO_TERM","name":"plasmid recombination","canonical_id":"go:GO:0042150","description":"\"A process of DNA recombination occurring within a plasmid or between plasmids and other plasmids or DNA molecules.\" [GOC:mlg]","metadata":null},{"id":"cc541ae4b5444d48ac8f36499c5c05b4","type":"GO_TERM","name":"plasminogen activation","canonical_id":"go:GO:0031639","description":"\"The process in which inactive plasminogen is processed to active plasmin. This process includes cleavage at an internal Arg-Val site to form an N-terminal A-chain and C-terminal B-chain held together by a disulfide bond, and can include further proteolytic cleavage events to remove the preactivation peptide.\" [PMID:9548733]","metadata":null},{"id":"09a04eb6f07341d5b197910a82970b6a","type":"GO_TERM","name":"plasmodesma","canonical_id":"go:GO:0009506","description":"\"A fine cytoplasmic channel, found in all higher plants, that connects the cytoplasm of one cell to that of an adjacent cell.\" [PMID:29880547]","metadata":null},{"id":"8322b4afaca445229d991e25d8e4bfda","type":"GO_TERM","name":"plasmodesma organization","canonical_id":"go:GO:0009663","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a plasmodesma, a fine cytoplasmic channel, found in all higher plants, that connects the cytoplasm of one cell to that of an adjacent cell.\" [GOC:mah, PMID:29880547]","metadata":null},{"id":"801cafef001d4806b9359c1eba1c418c","type":"GO_TERM","name":"plasmodesmata-mediated intercellular transport","canonical_id":"go:GO:0010497","description":"\"The movement of substances between cells via plasmodesmata. Plasmodesmata is a fine cytoplasmic channel, found in all higher plants, that connects the cytoplasm of one cell to that of an adjacent cell.\" [PMID:17601829]","metadata":null},{"id":"d82174040a7344b9b97f6996ef9412c4","type":"GO_TERM","name":"plasmodesmatal cytoplasmic sleeve","canonical_id":"go:GO:0009546","description":"\"The space between the plasma membrane and the desmotubule of a plasmodesma.\" [PMID:29880547]","metadata":null},{"id":"9c1d00a95cf1431790eae879693b83ba","type":"GO_TERM","name":"plasmodesmatal desmotubule","canonical_id":"go:GO:0009510","description":"\"A tightly wound cylinder of membrane that is located within the plasmodesmal pore and runs the length of the plasmodesma. The desmotubule likely provides a rigid stability to plasmodesmata and confers a fixed diameter and pore size to the plasmodesmal canal, and is linked to the endoplasmic reticulum in each of the adjacent cell.\" [PMID:29880547]","metadata":null},{"id":"e702bc6da9e1463b999520b6b5fb6164","type":"GO_TERM","name":"plasmodesmatal endoplasmic reticulum","canonical_id":"go:GO:0009511","description":"\"Endoplasmic reticulum found in plasmodesmata, junctions connecting the cytoplasm of adjacent plant cells.\" [GOC:ai, PMID:29880547]","metadata":null},{"id":"7180b95014804dd5ac42274897906530","type":"GO_TERM","name":"plasmodesmatal plasma membrane","canonical_id":"go:GO:0009548","description":"\"The portion of the plasma membrane surrounding a plasmodesma.\" [GOC:mah]","metadata":null},{"id":"4a112982ee104a2e94f91d3dcfd66a51","type":"GO_TERM","name":"plastid","canonical_id":"go:GO:0009536","description":"\"Any member of a family of organelles found in the cytoplasm of plants and some protists, which are membrane-bounded and contain DNA. Plant plastids develop from a common type, the proplastid.\" [GOC:jl, ISBN:0198547684]","metadata":null},{"id":"171471c1fc664f1689f55fee30d0765e","type":"GO_TERM","name":"plastid ADPG pyrophosphorylase complex","canonical_id":"go:GO:0031009","description":"\"An ADPG pyrophosphorylase complex found in a plastid.\" [GOC:mah]","metadata":null},{"id":"aa580fa15589428797812be64f51cef6","type":"GO_TERM","name":"plastid DNA metabolic process","canonical_id":"go:GO:0033258","description":"\"The chemical reactions and pathways involving plastid DNA.\" [GOC:mah]","metadata":null},{"id":"0b9cd616937a418fae4496d7167037cc","type":"GO_TERM","name":"plastid DNA replication","canonical_id":"go:GO:0033259","description":"\"The process in which new strands of DNA are synthesized in a plastid.\" [GOC:mah]","metadata":null},{"id":"0a42d03c6ff7482f8c54f2ae634cef91","type":"GO_TERM","name":"plastid PEP RNA polymerase core enzyme binding","canonical_id":"go:GO:0001052","description":"\"Binding to a bacterial-type plastid PEP RNA polymerase core enzyme, typically consisting of two alpha, one beta, one beta prime, and one double prime subunit.\" [GOC:txnOH, PMID:20701995]","metadata":null},{"id":"3b08eabcb38844d7a48d9e3fe44a084c","type":"GO_TERM","name":"plastid acetate CoA-transferase complex","canonical_id":"go:GO:0032283","description":"\"An acetate CoA-transferase complex located in the stroma of a plastid.\" [GOC:mah]","metadata":null},{"id":"3145a5fb8a6e44e1be12253d88a8352d","type":"GO_TERM","name":"plastid acetyl-CoA carboxylase complex","canonical_id":"go:GO:0032282","description":"\"An acetyl-CoA carboxylase complex located in the stroma of a plastid.\" [GOC:mah]","metadata":null},{"id":"e046ea8a14d940249151814009883877","type":"GO_TERM","name":"plastid chromosome","canonical_id":"go:GO:0009508","description":"\"A circular DNA molecule containing plastid encoded genes.\" [ISBN:0943088399]","metadata":null},{"id":"b92dbc3a89a94f1cba5aa0e7172b1ddc","type":"GO_TERM","name":"plastid chromosome packaging","canonical_id":"go:GO:1900160","description":"\"A process in which plastidial DNA and associated proteins organize into a compact, orderly structure.\" [GOC:emb, GOC:TermGenie, PMID:12081370]","metadata":null},{"id":"2010aa2413cf4de58c0cc03577b430d2","type":"GO_TERM","name":"plastid envelope","canonical_id":"go:GO:0009526","description":"\"The double lipid bilayer enclosing a plastid and separating its contents from the rest of the cytoplasm; includes the intermembrane space.\" [GOC:jy]","metadata":null},{"id":"6f0958445ddf44f2bf79b9190e4222d3","type":"GO_TERM","name":"plastid fission","canonical_id":"go:GO:0043572","description":"\"The creation of two or more plastids by division of one plastid. A plastid is any member of a family of organelles found in the cytoplasm of plants and some protists, which are membrane-bounded and contain DNA.\" [GOC:jl]","metadata":null},{"id":"64cad2509cd14a58a33f20aa35912eb5","type":"GO_TERM","name":"plastid gene expression","canonical_id":"go:GO:0140899","description":"\"The process in which a plastid gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.\" [PMID:28377785]","metadata":null},{"id":"e5ee7a7f2b2e4a81ac8b1f6b61cec15b","type":"GO_TERM","name":"plastid inheritance","canonical_id":"go:GO:0009665","description":"\"The partitioning of plastids between daughter cells at cell division.\" [GOC:mah]","metadata":null},{"id":"303cc601d8d046099ea1b7d03e7e35e2","type":"GO_TERM","name":"plastid inner membrane","canonical_id":"go:GO:0009528","description":"\"The inner, i.e. lumen-facing, lipid bilayer of the plastid envelope; also faces the plastid stroma.\" [GOC:lr]","metadata":null},{"id":"b37ee44b73dc48128cf970b3ee31fc5e","type":"GO_TERM","name":"plastid inner membrane organization","canonical_id":"go:GO:0009667","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the inner membrane of a plastid.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"2969945e532740fca66c1c5fed4acfea","type":"GO_TERM","name":"plastid intermembrane space","canonical_id":"go:GO:0009529","description":"\"The region between the inner and outer lipid bilayers of the plastid envelope.\" [GOC:lr]","metadata":null},{"id":"a14ed8b9b5714ee6ae51d1690bec2f00","type":"GO_TERM","name":"plastid large ribosomal subunit","canonical_id":"go:GO:0000311","description":"\"The larger of the two subunits of a plastid ribosome. Two sites on the ribosomal large subunit are involved in translation: the aminoacyl site (A site) and peptidyl site (P site).\" [GOC:mcc]","metadata":null},{"id":"9463f77c30f94975b78b4d29c81b5c68","type":"GO_TERM","name":"plastid localization","canonical_id":"go:GO:0051644","description":"\"Any process in which a plastid is transported to, and/or maintained in, a specific location within the cell.\" [GOC:ai]","metadata":null},{"id":"82d0cc5244a44730aff9efd911ed16fe","type":"GO_TERM","name":"plastid mRNA editing complex","canonical_id":"go:GO:0031020","description":"\"An mRNA editing complex found in a plastid.\" [GOC:mah]","metadata":null},{"id":"1035f55af3e244d9bb636258af73ad84","type":"GO_TERM","name":"plastid membrane","canonical_id":"go:GO:0042170","description":"\"Any lipid bilayer that surrounds a plastid or is part of the plastid envelope. Primary plastids (in plants, green algae, red algae, and glaucophytes) are surrounded by two membranes; complex plastids derived from secondary endosymbiosis are surrounded by three or four membranes.\" [GOC:mah, PMID:20124341]","metadata":null},{"id":"8f8cb81d68904476b3e9d4fd77fc4af7","type":"GO_TERM","name":"plastid membrane organization","canonical_id":"go:GO:0009668","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of either of the lipid bilayers surrounding a plastid.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"fbb416087a3e40619800f3f89cca0056","type":"GO_TERM","name":"plastid nucleoid","canonical_id":"go:GO:0042646","description":"\"The region of a plastid to which the DNA is confined.\" [GOC:jl]","metadata":null},{"id":"cdbe4231946144ac8d6c626be5ac8632","type":"GO_TERM","name":"plastid organization","canonical_id":"go:GO:0009657","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a plastid.\" [GOC:mah]","metadata":null},{"id":"76417541200a4900a2ea136cd348f917","type":"GO_TERM","name":"plastid outer membrane","canonical_id":"go:GO:0009527","description":"\"The outer, i.e. cytoplasm-facing, lipid bilayer of the plastid envelope.\" [GOC:lr]","metadata":null},{"id":"50cb73a06e6b4f908e67a8e94f9b770a","type":"GO_TERM","name":"plastid outer membrane organization","canonical_id":"go:GO:0009666","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the outer membrane of a plastid.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"04d765545cc24cd4b3150ef3bd6da3fe","type":"GO_TERM","name":"plastid promoter transcription regulatory region sequence-specific DNA binding","canonical_id":"go:GO:0001019","description":"\"Binding to a DNA region that controls transcription by a plastid RNA polymerase. Binding may occur as a sequence specific interaction or as an interaction observed only once a factor has been recruited to the DNA by other factors.\" [GOC:txnOH, GOC:vw]","metadata":null},{"id":"c61baec45f4a4b2590f49bb2010a7e28","type":"GO_TERM","name":"plastid rRNA transcription","canonical_id":"go:GO:0042794","description":"\"The synthesis of ribosomal RNA (rRNA) from a plastid DNA template, usually by a specific plastid RNA polymerase.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"aa7cc1c3a5a248e985dc4c1f97e99308","type":"GO_TERM","name":"plastid ribosome","canonical_id":"go:GO:0009547","description":"\"A ribosome contained within a plastid.\" [GOC:tair_curators]","metadata":null},{"id":"97bdf47b6e234579824c4910d84d7a83","type":"GO_TERM","name":"plastid single-subunit type RNA polymerase binding","canonical_id":"go:GO:0001051","description":"\"Binding to a single subunit plastid RNA polymerase enzyme, which is composed of a single catalytic subunit similar to the RNA polymerase enzymes from phages T3, T7, and SP6.\" [GOC:txnOH, PMID:20701995]","metadata":null},{"id":"45fead2c5a7a4207b18e735039142a21","type":"GO_TERM","name":"plastid small ribosomal subunit","canonical_id":"go:GO:0000312","description":"\"The smaller of the two subunits of a plastid ribosome.\" [GOC:mcc]","metadata":null},{"id":"0e4ac2c086214884a2bbac0b6d136a28","type":"GO_TERM","name":"plastid stroma","canonical_id":"go:GO:0009532","description":"\"The proteinaceous ground substance of plastids.\" [ISBN:0943088399]","metadata":null},{"id":"b032d5df555949e688992aa3e4e54f09","type":"GO_TERM","name":"plastid thylakoid","canonical_id":"go:GO:0031976","description":"\"Any thylakoid within a plastid.\" [GOC:pz]","metadata":null},{"id":"d8d899f936d84539824ed28b6cf3df99","type":"GO_TERM","name":"plastid thylakoid lumen","canonical_id":"go:GO:0031978","description":"\"The volume enclosed by a plastid thylakoid membrane.\" [GOC:mah]","metadata":null},{"id":"2f783966ec5f4935a7acb96b32ea5248","type":"GO_TERM","name":"plastid thylakoid membrane","canonical_id":"go:GO:0055035","description":"\"The lipid bilayer membrane of any thylakoid within a plastid.\" [GOC:jid, GOC:rph]","metadata":null},{"id":"3b2b20dae7274a74bbb7da9c83905a4d","type":"GO_TERM","name":"plastid to vacuole vesicle-mediated transport","canonical_id":"go:GO:1904962","description":"\"The vesicle-mediated and directed movement of substances from plastid to vacuole.\" [GO_REF:0000076, GOC:TermGenie, PMID:25281689]","metadata":null},{"id":"983283ba5cb84a25bdcdeb5e3b2f7ecf","type":"GO_TERM","name":"plastid transcription","canonical_id":"go:GO:0042793","description":"\"The synthesis of RNA from a plastid DNA template, usually by a specific plastid RNA polymerase.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"d71f4f30439248fc80ee40024ccd0acb","type":"GO_TERM","name":"plastid translation","canonical_id":"go:GO:0032544","description":"\"The chemical reactions and pathways resulting in the formation of a protein in a plastid. This is a ribosome-mediated process in which the information in messenger RNA (mRNA) is used to specify the sequence of amino acids in the protein; the plastid has its own ribosomes and transfer RNAs, and uses a genetic code that differs from the nuclear code.\" [GOC:curators]","metadata":null},{"id":"b071f72068174dfcada602eac649153c","type":"GO_TERM","name":"plastid-encoded plastid RNA polymerase complex","canonical_id":"go:GO:0000427","description":"\"An RNA polymerase complex containing polypeptides encoded by the plastid genome. Plastid-encoded DNA-directed RNA polymerases resemble eubacterial multisubunit RNA polymerases, with a core composed of alpha, beta, and beta-prime subunits. Some forms contain multiple additional subunits. An additional sigma factor subunit is required for promoter recognition.\" [GOC:krc, GOC:mah, GOC:pj]","metadata":null},{"id":"eeea39621dfd48ae9f99b351081d2960","type":"GO_TERM","name":"plastid-encoded plastid RNA polymerase complex A","canonical_id":"go:GO:0000343","description":"\"A plastid-encoded DNA-directed RNA polymerase complex that resembles eubacterial multisubunit RNA polymerases, with a core composed of alpha, beta, and beta-prime subunits. An additional subunit, a sigma factor, is required for promoter recognition. PEP-A is generated from the PEP-B form during chloroplast maturation to generate a complex composed of at least thirteen polypeptides that is not sensitive to the antibiotic rifampicin, like its precursor form the PEP-B complex.\" [PMID:10946105]","metadata":null},{"id":"7e980dbc2f374feb9272ca1d7b4e99d5","type":"GO_TERM","name":"plastid-encoded plastid RNA polymerase complex B","canonical_id":"go:GO:0000344","description":"\"A plastid-encoded DNA-directed RNA polymerase complex that resembles eubacterial multisubunit RNA polymerases with a core composed of alpha, beta, and beta-prime subunits. An additional subunit, a sigma factor, is required for promoter recognition. PEP-B is distinguished from PEP-A by its sensitivity to the antibiotic rifampicin. PEP-B is found in both etioplasts and chloroplasts, but is the predominate form in etioplasts. It forms the core of the PEP-A form; the conversion from PEP-B to PEP-A occurs during chloroplast maturation.\" [PMID:10946105]","metadata":null},{"id":"bf653972c332427a881bbbafa598a86b","type":"GO_TERM","name":"plastoglobule","canonical_id":"go:GO:0010287","description":"\"A lipoprotein particle present in chloroplasts. They are rich in non-polar lipids (triglycerides, esters) as well as in prenylquinones, plastoquinone and tocopherols. Plastoglobules are often associated with thylakoid membranes, suggesting an exchange of lipids with thylakoids.\" [GOC:tair_curators, PMID:16461379]","metadata":null},{"id":"261db0348ecb4a4c908dbcf498034d0c","type":"GO_TERM","name":"plastoglobule organization","canonical_id":"go:GO:0080177","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the plastoglobule. Plastoglobule is a lipoprotein particle present in chloroplasts. They are rich in non-polar lipids (triglycerides, esters) as well as in prenylquinones, plastoquinone and tocopherols. Plastoglobules are often associated with thylakoid membranes, suggesting an exchange of lipids with thylakoids.\" [PMID:20813909]","metadata":null},{"id":"f0e16ec15aff43bfa542f9c586a7c71d","type":"GO_TERM","name":"plastoquinol--plastocyanin reductase activity","canonical_id":"go:GO:0009496","description":"\"Catalysis of the reaction: 2 H+[side 1] + 2 oxidized plastocyanin + plastoquinol-1 = 2 H+[side 2] + 2 reduced plastocyanin + plastoquinone. This reaction involves the concomitant transfer of 2 H+ ions across a membrane.\" [RHEA:22148]","metadata":null},{"id":"37ec122541054c159f9e8c6eb1137133","type":"GO_TERM","name":"plastoquinone biosynthetic process","canonical_id":"go:GO:0010236","description":"\"The chemical reactions and pathways resulting in the formation of plastoquinone, a lipid-soluble electron-transporting coenzyme present in the chloroplast.\" [GOC:sm]","metadata":null},{"id":"a953cf549b664c849b1eef1a6c081713","type":"GO_TERM","name":"platelet SNARE complex","canonical_id":"go:GO:0097654","description":"\"A SNARE complex that is capable of fusing intracellular vesicles to the plasma membrane of platelets for exocytosis of alpha-granules or dense granules. Contains isoforms of VAMP, SNAP and syntaxin proteins. Ternary SNARE complexes interact in a circular array to form ring complexes or channels around the membrane fusion. A common composition in human is VAMP-8, SNAP-23 and syntaxin-2 or -4.\" [GOC:bhm, PMID:12130530, PMID:19450911]","metadata":null},{"id":"8fd54d3d30b642af93612b8d85010ddd","type":"GO_TERM","name":"platelet activating factor biosynthetic process","canonical_id":"go:GO:0006663","description":"\"The chemical reactions and pathways resulting in the formation of platelet activating factor, 1-O-alkyl-2-acetyl-sn-glycerol 3-phosphocholine, where alkyl = hexadecyl or octadecyl. Platelet activating factor is an inflammatory mediator released from a variety of cells in response to various stimuli.\" [ISBN:0198547684]","metadata":null},{"id":"9d82fa62c4aa4a34ba0ff85c44380b3d","type":"GO_TERM","name":"platelet activating factor catabolic process","canonical_id":"go:GO:0062234","description":"\"The chemical reactions and pathways resulting in the breakdown of platelet activating factor, 2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine.\" [PMID:16371369]","metadata":null},{"id":"bf4628e23ba741348c438480e11278f2","type":"GO_TERM","name":"platelet activating factor metabolic process","canonical_id":"go:GO:0046469","description":"\"The chemical reactions and pathways involving platelet activating factor, 1-O-alkyl-2-acetyl-sn-glycerol 3-phosphocholine, where alkyl = hexadecyl or octadecyl. Platelet activating factor is an inflammatory mediator released from a variety of cells in response to various stimuli.\" [ISBN:0198547684]","metadata":null},{"id":"5b2c8a64fd0c4d94adbfe83aebffb090","type":"GO_TERM","name":"platelet activating factor receptor activity","canonical_id":"go:GO:0004992","description":"\"Combining with platelet activating factor to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"9355d61fd48445498fd0082c8d62459b","type":"GO_TERM","name":"platelet activating factor receptor binding","canonical_id":"go:GO:0031859","description":"\"Binding to a platelet activating factor receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"2070660545f8405bbc20adfe1c1ebaa6","type":"GO_TERM","name":"platelet activation","canonical_id":"go:GO:0030168","description":"\"A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.\" [PMID:27403440]","metadata":null},{"id":"2d87c2f6586740db8ad0c38139c0e228","type":"GO_TERM","name":"platelet aggregation","canonical_id":"go:GO:0070527","description":"\"The adhesion of one platelet to one or more other platelets via adhesion molecules.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"53df518df1014e098a4b14460aa63339","type":"GO_TERM","name":"platelet alpha granule","canonical_id":"go:GO:0031091","description":"\"A secretory organelle found in blood platelets, which is unique in that it exhibits further compartmentalization and acquires its protein content via two distinct mechanisms: (1) biosynthesis predominantly at the megakaryocyte (MK) level (with some vestigial platelet synthesis) (e.g. platelet factor 4) and (2) endocytosis and pinocytosis at both the MK and circulating platelet levels (e.g. fibrinogen (Fg) and IgG).\" [PMID:8467233]","metadata":null},{"id":"ebeeeda5a4ec4e1caa049ad79582eb36","type":"GO_TERM","name":"platelet alpha granule lumen","canonical_id":"go:GO:0031093","description":"\"The volume enclosed by the membrane of the platelet alpha granule.\" [GOC:mah, PMID:8467233]","metadata":null},{"id":"ed85fc7c45a54402b17d2ca627ceb94a","type":"GO_TERM","name":"platelet alpha granule membrane","canonical_id":"go:GO:0031092","description":"\"The lipid bilayer surrounding the platelet alpha granule.\" [GOC:mah, PMID:8467233]","metadata":null},{"id":"08032b59c65d4065a23df3ddb2a47cc8","type":"GO_TERM","name":"platelet alpha granule organization","canonical_id":"go:GO:0070889","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a platelet alpha granule. A platelet alpha granule is a secretory organelle found in blood platelets.\" [GOC:rph, PMID:16123220]","metadata":null},{"id":"18e4d293eb58446899a99155c134abed","type":"GO_TERM","name":"platelet degranulation","canonical_id":"go:GO:0002576","description":"\"The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.\" [GOC:add]","metadata":null},{"id":"4712afec55574cce8bdc2a0be7ab625d","type":"GO_TERM","name":"platelet dense granule","canonical_id":"go:GO:0042827","description":"\"Electron-dense granule occurring in blood platelets that stores and secretes adenosine nucleotides and serotonin. They contain a highly condensed core consisting of serotonin, histamine, calcium, magnesium, ATP, ADP, pyrophosphate and membrane lysosomal proteins.\" [GOC:jl, PMID:10403682, PMID:11487378]","metadata":null},{"id":"8471a5d1b79f4f64bc53064e5e18f1af","type":"GO_TERM","name":"platelet dense granule lumen","canonical_id":"go:GO:0031089","description":"\"The volume enclosed by the membrane of the platelet dense granule.\" [GOC:mah]","metadata":null},{"id":"8c9330f4d83640de98970f4897b84f5f","type":"GO_TERM","name":"platelet dense granule membrane","canonical_id":"go:GO:0031088","description":"\"The lipid bilayer surrounding the platelet dense granule.\" [GOC:mah]","metadata":null},{"id":"a299e1739d47477d94a1dd11db6d13f0","type":"GO_TERM","name":"platelet dense granule organization","canonical_id":"go:GO:0060155","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a platelet dense granule. A platelet dense granule is an electron-dense granule occurring in blood platelets that stores and secretes adenosine nucleotides and serotonin. They contain a highly condensed core consisting of serotonin, histamine, calcium, magnesium, ATP, ADP, pyrophosphate and membrane lysosomal proteins.\" [GOC:dph, PMID:11487378]","metadata":null},{"id":"718ccb5b53de4181aa08cbeed4425fe9","type":"GO_TERM","name":"platelet dense tubular network","canonical_id":"go:GO:0031094","description":"\"A network of membrane-bounded compartments found in blood platelets, where they regulate platelet activation by sequestering or releasing calcium. The dense tubular network exists as thin elongated membranes in resting platelets, and undergoes a major ultrastructural change, to a rounded vesicular form, upon addition of thrombin.\" [PMID:1322202]","metadata":null},{"id":"4ad0447882474b428169ebcdf3f76e87","type":"GO_TERM","name":"platelet dense tubular network lumen","canonical_id":"go:GO:0031096","description":"\"The volume enclosed by the membranes of the platelet dense tubular network.\" [GOC:mah, PMID:1322202]","metadata":null},{"id":"cf2740c38afe48eeb236b2b131b8aa94","type":"GO_TERM","name":"platelet dense tubular network membrane","canonical_id":"go:GO:0031095","description":"\"The lipid bilayer surrounding the platelet dense tubular network.\" [GOC:mah, PMID:1322202]","metadata":null},{"id":"b20a93d66d604de0b873337a5f57a256","type":"GO_TERM","name":"platelet formation","canonical_id":"go:GO:0030220","description":"\"The process in which platelets bud from long processes extended by megakaryocytes.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"bb37514b12274fbcb394962e9dffdd65","type":"GO_TERM","name":"platelet glycocalyx","canonical_id":"go:GO:0120240","description":"\"The carbohydrate rich layer at the outermost periphery of a platelet.\" [GOC:krc, PMID:24967889]","metadata":null},{"id":"8ebd4e0d9fe7499b974f0a42fb476722","type":"GO_TERM","name":"platelet maturation","canonical_id":"go:GO:0036345","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a platelet to attain its fully functional state. A platelet is a non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.\" [CL:0000233, GOC:BHF, GOC:vk]","metadata":null},{"id":"cc9e13f27e49420194dae1698ed4d0a8","type":"GO_TERM","name":"platelet morphogenesis","canonical_id":"go:GO:0036344","description":"\"Generation and organization of a platelet, a non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.\" [CL:0000233, GOC:BHF, GOC:vk]","metadata":null},{"id":"4379ea5fc57a4c12bf4919db05c4052d","type":"GO_TERM","name":"platelet rolling","canonical_id":"go:GO:0160015","description":"\"Transient adhesive interactions between platelets and endothelial cells lining blood vessels. Carbohydrates on circulating platelets bind selectins or other molecules on the vessel wall causing the platelets to slow down and roll along the inner surface of the vessel wall. During this rolling motion, transitory bonds are formed and broken between surface molecules of platelets and endothelium.\" [GOC:sl, PMID:29018081]","metadata":null},{"id":"2fc307e5e05a4e1c8a07c641c25eaeef","type":"GO_TERM","name":"platelet-activating factor acetyltransferase activity","canonical_id":"go:GO:0047179","description":"\"Catalysis of the reaction: 1-radyl-2-acyl-sn-glycero-3-phospholipid + 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine = 1-alkyl-2-lyso-sn-glycero-3-phosphocholine + 1-radyl-2-acetyl-sn-glycero-3-phospholipid.\" [EC:2.3.1.149, MetaCyc:2.3.1.149-RXN]","metadata":null},{"id":"00d54a020c26417f983153ef10cb791c","type":"GO_TERM","name":"platelet-derived growth factor alpha-receptor activity","canonical_id":"go:GO:0005018","description":"\"Combining with platelet-derived growth factor isoform PDGF-AA, PDGF-BB or PDGF-AB to initiate a change in cell activity.\" [PMID:1657917]","metadata":null},{"id":"2485bd0d329b4cad8cc04579adee0ba8","type":"GO_TERM","name":"platelet-derived growth factor beta-receptor activity","canonical_id":"go:GO:0005019","description":"\"Combining with platelet-derived growth factor isoform PDGF-BB or PDGF-AB to initiate a change in cell activity.\" [PMID:1657917]","metadata":null},{"id":"b75fc36d2b9948cdbb3f1b5931c4f454","type":"GO_TERM","name":"platelet-derived growth factor binding","canonical_id":"go:GO:0048407","description":"\"Binding to platelet-derived growth factor.\" [GOC:dgh]","metadata":null},{"id":"ee67019cadca4ffd8847f9658d1822b5","type":"GO_TERM","name":"platelet-derived growth factor complex","canonical_id":"go:GO:1990265","description":"\"A protein complex consisting of two chains of platelet-derived growth factor (PDGF) subunits. PDGF dimers bind to PDGF receptors in the plasma membrane and induce receptor dimerization and activation. PDGFs are involved in a wide variety of signaling processes. PDGFs are found in all vertebrates where at least 2 different chains (A and B) exist. In human (and other mammals), four types of PDGF chains (A, B, C, and D) are known which form five different dimers (AA, AB, BB, CC and DD).\" [GOC:bhm, PMID:11331882]","metadata":null},{"id":"69777e77d474443cb6cacbb23a8ba1fc","type":"GO_TERM","name":"platelet-derived growth factor production","canonical_id":"go:GO:0090360","description":"\"The appearance of any platelet-derived growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"e08167dc1b714f84b683d066cb6fd45b","type":"GO_TERM","name":"platelet-derived growth factor receptor activity","canonical_id":"go:GO:0005017","description":"\"Combining with platelet-derived growth factor receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"89648e28c2c8462bab56c4ff645f40ac","type":"GO_TERM","name":"platelet-derived growth factor receptor binding","canonical_id":"go:GO:0005161","description":"\"Binding to a platelet-derived growth factor receptor.\" [GOC:ai]","metadata":null},{"id":"b285d7b5dcf24a9ea791bd629e8fc5de","type":"GO_TERM","name":"platelet-derived growth factor receptor signaling pathway","canonical_id":"go:GO:0048008","description":"\"The series of molecular signals initiated by a ligand binding to a platelet-derived growth factor receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb]","metadata":null},{"id":"1fedeacce5f84ba9a6c8e6378da186aa","type":"GO_TERM","name":"platelet-derived growth factor receptor-alpha signaling pathway","canonical_id":"go:GO:0035790","description":"\"The series of molecular signals initiated a ligand binding to an alpha-type platelet-derived growth factor receptor (PDGFalpha) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:yaf, PMID:10372961]","metadata":null},{"id":"4d8a9b7bebea40519d6beecc5fe32be8","type":"GO_TERM","name":"platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:0035791","description":"\"The series of molecular signals initiated by the binding of a ligand to a beta-type platelet-derived growth factor receptor (PDGFbeta) on the surface of a signal-receiving cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:signaling, GOC:yaf, PMID:10372961]","metadata":null},{"id":"dadd5cc93b4b44f287d22fcbff7b0f61","type":"GO_TERM","name":"platelet-derived growth factor receptor-ligand complex","canonical_id":"go:GO:1990270","description":"\"A tetrameric protein complex consisting of two platelet-derived growth factor (PDGF) receptor subunits and two PDGF ligand subunits. Binding of the PDGF ligand dimer to the PDGF receptor in the plasma membrane induces receptor dimerization and activation. PDGFs are involved in a wide variety of signaling processes and are found in all vertebrates. At least two different receptor chains (A and B) and four types of ligand chains (A, B, C, and D) are known forming a wide variety of combinations of receptor-ligand complexes.\" [GOC:bhm, PMID:11331882]","metadata":null},{"id":"8c7796c3822e4c12b45f169638cb5521","type":"DISEASE","name":"platelet-type bleeding disorder 8","canonical_id":"mondo:0012354","description":null,"metadata":null},{"id":"2e68a2145e664cec91c3264a761e5b7f","type":"GO_TERM","name":"pleated septate junction","canonical_id":"go:GO:0005919","description":"\"A septate junction in which regular arrays of electron-dense septae span the intermembrane space.\" [PMID:11700298]","metadata":null},{"id":"6200b2566ec34c639c0fca366930e673","type":"DRUG","name":"plerixafor","canonical_id":"gtopdb:844","description":null,"metadata":null},{"id":"656d20d96df2475dac558bbd0dbc8dcf","type":"DRUG","name":"plerixafor","canonical_id":"chembl:CHEMBL18442","description":null,"metadata":null},{"id":"c9f9ae4f7277459b846026f9b0fc2816","type":"DISEASE","name":"pleural mesothelioma","canonical_id":"mondo:0003308","description":null,"metadata":null},{"id":"1949f7c09cd74728bdf4203c069c13fa","type":"DISEASE","name":"plexiform neurofibroma","canonical_id":"efo:0000658","description":null,"metadata":null},{"id":"26435e512d5f4ba89ba6e868d7928f55","type":"DRUG","name":"plicamycin","canonical_id":"mesh:D008926","description":null,"metadata":null},{"id":"159ad2cb912d4d69997cd718cfc283b8","type":"GO_TERM","name":"plus-end directed microfilament motor activity","canonical_id":"go:GO:0060002","description":"\"A motor activity that generates movement along a microfilament towards the plus end, driven by ATP hydrolysis. The minus end of an actin filament is the end that does not preferentially add actin monomers.\" [GOC:dph, PMID:10519557]","metadata":null},{"id":"24e6a357d54043c4be744c9199250641","type":"GO_TERM","name":"plus-end directed microtubule sliding","canonical_id":"go:GO:0031535","description":"\"The movement of one microtubule along another microtubule, where the motion is directed towards the plus ends of the microtubules.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"bbee1fd213b64c42ae080e9b15b29e54","type":"GO_TERM","name":"plus-end kinesin complex","canonical_id":"go:GO:0005873","description":"\"Any complex that includes a dimer of molecules from the kinesin superfamily and any associated proteins, and moves towards the plus end of a microtubule.\" [GOC:mah]","metadata":null},{"id":"bab32f7157504182bff2216e8a309e8c","type":"GO_TERM","name":"plus-end specific microtubule depolymerization","canonical_id":"go:GO:0070462","description":"\"The removal of tubulin heterodimers from the plus end of a microtubule.\" [GOC:krc, PMID:16906145, PMID:16906148]","metadata":null},{"id":"e619819e720e4de5bc485779a4adf692","type":"GO_TERM","name":"plus-end-directed endosome transport along mitotic spindle midzone microtubule","canonical_id":"go:GO:0140024","description":"\"The directed movement of an endosome towards the plus end of a microtubule, mediated by motor proteins. This process begins with the attachment of an endosome to a microtubule, and ends when the endosome reaches its final destination.\" [PMID:24803650, PMID:25706234]","metadata":null},{"id":"8f71f25628b64ccd91f363b9924b2946","type":"GO_TERM","name":"plus-end-directed microtubule motor activity","canonical_id":"go:GO:0008574","description":"\"A motor activity that generates movement along a microtubule toward the plus end, driven by ATP hydrolysis.\" [GOC:vw, PMID:32842864]","metadata":null},{"id":"853e328e7ecc4d40aeba8db0cf8c6dc8","type":"GO_TERM","name":"plus-end-directed organelle transport along microtubule","canonical_id":"go:GO:0072386","description":"\"The directed movement of an organelle towards the plus end of a microtubule, mediated by motor proteins. This process begins with the attachment of an organelle to a microtubule, and ends when the organelle reaches its final destination.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"58ac088655f54f2dbe71a9087b30c167","type":"GO_TERM","name":"plus-end-directed vesicle transport along microtubule","canonical_id":"go:GO:0072383","description":"\"The directed movement of a vesicle towards the plus end of a microtubule, mediated by motor proteins. This process begins with the attachment of a vesicle to a microtubule, and ends when the vesicle reaches its final destination.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a2aecbfff8e04822b65fc6cefd9be0c7","type":"DISEASE","name":"pneumonia","canonical_id":"mondo:0005249","description":null,"metadata":null},{"id":"21c08332f0ee4a808987ea3c2f11252b","type":"GO_TERM","name":"podocyte apoptotic process","canonical_id":"go:GO:1903210","description":"\"Any apoptotic process in a glomerular visceral epithelial cell.\" [GO_REF:0000085, GOC:TermGenie, PMID:23515840]","metadata":null},{"id":"cef14072425d4f119ee8a508eea977e4","type":"GO_TERM","name":"podocyte cell fate commitment","canonical_id":"go:GO:0072149","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a glomerular visceral epithelial cell. A glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"dd3ea451dd6842a2b99e150abd4ede20","type":"GO_TERM","name":"podocyte cell migration","canonical_id":"go:GO:0090521","description":"\"The orderly movement of a podocyte from one site to another, often during the development of a multicellular organism or multicellular structure. A podocyte is a specialized kidney epithelial cell.\" [GOC:pm, PMID:21402783]","metadata":null},{"id":"fd667c9b24d648bf91dd729101520952","type":"GO_TERM","name":"podocyte development","canonical_id":"go:GO:0072015","description":"\"The process whose specific outcome is the progression of a glomerular visceral epithelial cell over time, from its formation to the mature structure. A glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"19db64bd72814a0c98b989a4bc644a31","type":"GO_TERM","name":"podocyte differentiation","canonical_id":"go:GO:0072112","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glomerular visceral epithelial cell. A glomerular visceral epithelial cell is a specialized epithelial cell that contains 'feet' that interdigitate with the 'feet' of other glomerular epithelial cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1c83b7c6b71b47df814afc898e92c6d9","type":"GO_TERM","name":"podocyte foot","canonical_id":"go:GO:0098846","description":"\"A cell projection of a podocyte (glomerular visceral epithelial cell) forming a foot-like structure projecting from a podocyte primary projection, that wraps around capillaries of a renal glomerulus. Adjacent feet (pedicels) interdigitate, leaving thin filtration slits between them, which are covered by slit diaphragms.\" [PMID:25324828]","metadata":null},{"id":"10be28bc52b84dd688eae2fb9e350c9b","type":"GO_TERM","name":"podocyte primary projection","canonical_id":"go:GO:0098854","description":"\"A cell projection originating from a renal glomerular podocyte and extending to the renal glomerular podocyte foot.\" [PMID:24309184, PMID:25324828]","metadata":null},{"id":"99d3fc15c60a4350a3510f77d1ac34f1","type":"DRUG","name":"podophyllotoxin","canonical_id":"mesh:D011034","description":null,"metadata":null},{"id":"52054a261b2d44fa80b0ed27abbc3a1e","type":"GO_TERM","name":"podosome","canonical_id":"go:GO:0002102","description":"\"An actin-rich adhesion structure characterized by formation upon cell substrate contact and localization at the substrate-attached part of the cell, contain an F-actin-rich core surrounded by a ring structure containing proteins such as vinculin and talin, and have a diameter of 0.5 mm.\" [PMID:12837608, PMID:15890982]","metadata":null},{"id":"f83f72f423fc4556aae4f738f9fded79","type":"GO_TERM","name":"podosome assembly","canonical_id":"go:GO:0071800","description":"\"The aggregation, arrangement and bonding together of a set of components to form a podosome, an actin-rich adhesion structure characterized by formation upon cell substrate contact and localization at the substrate-attached part of the cell.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"c5837aa66b6e4f41a44ccea8133eac3d","type":"GO_TERM","name":"podosome core","canonical_id":"go:GO:0061825","description":"\"The F-actin-rich core of an adhesion structure characterized by formation upon cell substrate contact and localization at the substrate-attached part of the cell.\" [PMID:23158496]","metadata":null},{"id":"955c2576cc8e444c8672eced1aea510c","type":"GO_TERM","name":"podosome ring","canonical_id":"go:GO:0061826","description":"\"The ring structure surrounding the podosome core, containing proteins such as vinculin and talin.\" [PMID:23158496]","metadata":null},{"id":"26661d3a656644f4889a536e99602ef0","type":"GO_TERM","name":"pointed-end actin filament capping","canonical_id":"go:GO:0051694","description":"\"The binding of a protein or protein complex to the pointed (or minus) end of an actin filament, thus preventing the addition, exchange or removal of further actin subunits.\" [ISBN:071673706X]","metadata":null},{"id":"965be3c300104c8082d7ec7c42870191","type":"GO_TERM","name":"pointed-end actin filament uncapping","canonical_id":"go:GO:0051696","description":"\"The removal of capping protein from the pointed (or minus) end of actin filaments to free the ends for addition, exchange or removal of further actin subunits.\" [GOC:pf]","metadata":null},{"id":"e4a638e9ee5d4f188d45cf5ef9456405","type":"DISEASE","name":"poisoning","canonical_id":"mondo:0029000","description":null,"metadata":null},{"id":"925bab4aa83f4f97b466aef8836f309b","type":"DRUG","name":"polaprezinc","canonical_id":"mesh:C061957","description":null,"metadata":null},{"id":"7b5aeaa1193b4655a241d5994a16a9a6","type":"GO_TERM","name":"polar body extrusion after meiotic divisions","canonical_id":"go:GO:0040038","description":"\"The cell cycle process in which two small cells are generated, as byproducts destined to degenerate, as a result of the first and second meiotic divisions of a primary oocyte during its development to a mature ovum. One polar body is formed in the first division of meiosis and the other in the second division; at each division, the cytoplasm divides unequally, so that the polar body is of much smaller size than the developing oocyte. At the second division in which a polar body is formed, the polar body and the developing oocyte each contain a haploid set of chromosomes.\" [GOC:ems, ISBN:0198506732]","metadata":null},{"id":"5332ac45a94e46b8830308a2b6a5e433","type":"GO_TERM","name":"polar microtubule","canonical_id":"go:GO:0005827","description":"\"Any of the spindle microtubules that come from each pole and overlap at the spindle midzone. This interdigitating structure consisting of antiparallel microtubules is responsible for pushing the poles of the spindle apart.\" [ISBN:0815316194]","metadata":null},{"id":"b66324e114574d8c8f6d1b64813248a9","type":"GO_TERM","name":"polar nucleus","canonical_id":"go:GO:0043078","description":"\"Either of two nuclei located centrally in a flowering plant embryo sac that eventually fuse to form the endosperm nucleus.\" [ISBN:0618254153]","metadata":null},{"id":"ec4ba808ec7642d09fede9ac7d00233f","type":"GO_TERM","name":"polar nucleus fusion","canonical_id":"go:GO:0010197","description":"\"The merging of the polar nuclei, the two nuclei contained within the same cell that are created from the mitotic division of the megaspore during angiosperm reproduction. Polar nuclear fusion takes place in the ovule, forming in the fusion nucleus and giving rise to the endosperm when fertilized.\" [GOC:mtg_plant, GOC:sm]","metadata":null},{"id":"5af9a4137f834695b6625388f465be4c","type":"GO_TERM","name":"polar ring of apical complex","canonical_id":"go:GO:0020031","description":"\"An electron dense ring at the most anterior position of the apical complex, from which the conoid fibers originate; formed during an invasive life cycle stage of an apicomplexan parasite.\" [GOC:mb, PMID:16518471]","metadata":null},{"id":"e00da9aa6d0f47fcb62c4e6025756028","type":"GO_TERM","name":"polar tube","canonical_id":"go:GO:0044099","description":"\"A highly specialized structure unique to microsporidia that is required for host cell invasion. In the spore, the polar tube is connected at the anterior end, and then coils around the sporoplasm. Upon appropriate environmental stimulation, the polar tube rapidly discharges out of the spore, pierces a cell membrane and serves as a conduit for sporoplasm passage into the new host cell.\" [GOC:mf, PMID:12076771, PMID:9723921]","metadata":null},{"id":"6abdc9d2ddbe476989298b9950e7c5b8","type":"GO_TERM","name":"polar tube anchoring disc","canonical_id":"go:GO:0160202","description":"\"A structural component of the microsporidian spore's invasion apparatus that is located at the anterior end of the spore and serves to attach the polar tube to the inside of the spore wall.\" [PMID:16005007, PMID:19673893]","metadata":null},{"id":"adbbe1765b094e028c184208c99c0925","type":"GO_TERM","name":"polarisome","canonical_id":"go:GO:0000133","description":"\"Protein complex that plays a role in determining cell polarity by directing the localized assembly of actin filaments at polarization sites; in Saccharomyces the polarisome includes Bni1p, Spa2p, Pea2p, and Bud6p.\" [PMID:14734532, PMID:14998522, PMID:9632790]","metadata":null},{"id":"b4920680c4e94099a24decc47c9f9a3f","type":"GO_TERM","name":"polarity specification of adaxial/abaxial axis","canonical_id":"go:GO:0009944","description":"\"The process resulting in the establishment of polarity along the adaxial/abaxial axis. Adaxial refers to being situated toward an axis of an anatomical structure. Abaxial refers to being situated away from an axis of an anatomical structure.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d0eaab8788d74f54bbf71e3baa12f5d0","type":"GO_TERM","name":"polarity specification of anterior/posterior axis","canonical_id":"go:GO:0009949","description":"\"Any process resulting in the establishment of polarity along the anterior/posterior axis.\" [GOC:curators]","metadata":null},{"id":"c431e1f2b0ef486ba0cbecc49b36cde8","type":"GO_TERM","name":"polarity specification of dorsal/ventral axis","canonical_id":"go:GO:0009951","description":"\"Any process resulting in the establishment of polarity along the dorsal/ventral axis.\" [GOC:curators]","metadata":null},{"id":"7bb5cfa33e39480d91f8d16d0ef09fce","type":"GO_TERM","name":"polarity specification of proximal/distal axis","canonical_id":"go:GO:0010085","description":"\"Any process resulting in the establishment of polarity along the proximal/distal axis.\" [GOC:tb]","metadata":null},{"id":"686482799ba6445cad8dc2bab4c7affa","type":"GO_TERM","name":"polarized epithelial cell differentiation","canonical_id":"go:GO:0030859","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a polarized epithelial cell. The polarized epithelial cell can be any of the cells within an epithelium where the epithelial sheet is oriented with respect to the planar axis.\" [GOC:mah]","metadata":null},{"id":"2c339ff1e21548809bfbf9b6b978f098","type":"GO_TERM","name":"polarized secretion of basement membrane proteins in epithelium","canonical_id":"go:GO:0061865","description":"\"The basement membrane constituent secretion in which there is a restriction or targeting of basement membrane proteins for controlled release on the basal side of polarized epithelium.\" [PMID:26610918, PMID:28228250]","metadata":null},{"id":"007330973646414eabe5976bd5c83555","type":"GO_TERM","name":"polaroplast","canonical_id":"go:GO:0160201","description":"\"A membrane-bounded organelle found in a microsporidian spore,  that swells with water, and exerts pressure to rupture the polar cap and evert the polar tube through which the sporoplasm escapes to infect the host.\" [PMID:16005007, PMID:19673893, Wikipedia:polaroplast]","metadata":null},{"id":"d1b5be431a4441a89d75ae676282800c","type":"DRUG","name":"polatuzumab vedotin","canonical_id":"gtopdb:8404","description":null,"metadata":null},{"id":"20b0b6f867444cdc9fbef6138d736c25","type":"DRUG","name":"polatuzumab vedotin","canonical_id":"chembl:CHEMBL3301582","description":null,"metadata":null},{"id":"5d6bed25e7c24bd294b5f7204b2a4047","type":"COMBINATION_TREATMENT","name":"polatuzumab vedotin + tafasitamab","canonical_id":"ctgov_combo:ctgov-combo-dd46d35e9843a019","description":null,"metadata":null},{"id":"7d38a0ea5d7642ddb1c6e94bdba263d6","type":"COMBINATION_TREATMENT","name":"polatuzumab vedotin + tocilizumab","canonical_id":"ctgov_combo:ctgov-combo-f799a53651bc10f3","description":null,"metadata":null},{"id":"b96bbc31f6de4c26a2ec60bb6e91a91c","type":"GO_TERM","name":"pole cell development","canonical_id":"go:GO:0007277","description":"\"The process whose specific outcome is the progression of the pole cell over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"587520f95c854dcbadb87cd46bbd3ac7","type":"GO_TERM","name":"pole cell fate determination","canonical_id":"go:GO:0007278","description":"\"The cell fate determination process in which a cell becomes capable of differentiating autonomously into a pole cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators]","metadata":null},{"id":"7e01f099d0e549a5a8e42ec3aceb48bd","type":"GO_TERM","name":"pole cell formation","canonical_id":"go:GO:0007279","description":"\"Formation of a small group of cells (pole cells) at the posterior pole of the insect blastula. They are the first cells to cellularize after the arrival of nuclei at the end of the syncytial blastula stage and are the precursors to the insect germ cells.\" [GOC:bf, PMID:9988212]","metadata":null},{"id":"e49e3a38d5814fb0a7d8e67a83bfc697","type":"DRUG","name":"polidocanol","canonical_id":"mesh:C008976","description":null,"metadata":null},{"id":"55fc60a9adf44f7abf48d9386a1ffe66","type":"GO_TERM","name":"polkadots","canonical_id":"go:GO:0002096","description":"\"A punctate, filamentous structure composed of Bcl10 that appears in the cytoplasm of T-cells shortly after T-cell receptor stimulation. Polkadots stands for Punctate Oligomeric Killing and Activating DOmains Transducing Signals.\" [PMID:14724296, PMID:16495340]","metadata":null},{"id":"e33eaa6adf9f480894145d47d7f97ad0","type":"GO_TERM","name":"pollen adhesion","canonical_id":"go:GO:0009876","description":"\"The process in which pollen deposited on the stigma adheres to cells of the stigma.\" [GOC:tair_curators]","metadata":null},{"id":"afcf02e0069f4594a5513e194d07e002","type":"GO_TERM","name":"pollen aperture","canonical_id":"go:GO:0062074","description":"\"An area where exine is reduced or absent, in the pollen wall.\" [PMID:30150313]","metadata":null},{"id":"4f581638719f40508abd0171bed57aa2","type":"GO_TERM","name":"pollen aperture formation","canonical_id":"go:GO:0062075","description":"\"The cellular component assembly process of forming pollen apertures, areas where exine is reduced or absent, in the pollen cell wall.\" [PMID:30150313]","metadata":null},{"id":"76fea11c38ef4e8184a4eb9605b53cb2","type":"GO_TERM","name":"pollen coat","canonical_id":"go:GO:0070505","description":"\"A layer of extracellular matrix deposited onto the surface of the pollen wall upon disintegration of the tapetal layer of the anther wall in the late stages of pollen development. The composition of this material is highly heterogeneous and includes waxes, lipid droplets, small aromatic molecules, and proteins. The pollen coat is proposed to have many functions, such as holding pollen in the anther until dispersal, facilitation of pollen dispersal, protection of pollen from water loss and UV radiation, and facilitation of adhesion of pollen to the stigma.\" [GOC:mah, GOC:rph, PMID:12930826, PMID:15012271, PMID:28955324]","metadata":null},{"id":"fc4ae966f9c6483c9ef80d5b3f422a2d","type":"GO_TERM","name":"pollen development","canonical_id":"go:GO:0009555","description":"\"The process whose specific outcome is the progression of the pollen grain over time, from its formation to the mature structure. The process begins with the meiosis of the microsporocyte to form four haploid microspores. The nucleus of each microspore then divides by mitosis to form a two-celled organism, the pollen grain, that contains a tube cell as well as a smaller generative cell. The pollen grain is surrounded by an elaborate cell wall. In some species, the generative cell immediately divides again to give a pair of sperm cells. In most flowering plants, however this division takes place later, in the tube that develops when a pollen grain germinates.\" [GOC:mtg_plant, GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"f2546b2c454b4f90b08eb2e386c2ebf1","type":"GO_TERM","name":"pollen exine formation","canonical_id":"go:GO:0010584","description":"\"The formation of the pollen exine. The reticulate pollen wall pattern consists of two layers, exine and intine.\" [GOC:dhl]","metadata":null},{"id":"78eff10336bd4647a2efeb280ae0c69a","type":"GO_TERM","name":"pollen germination","canonical_id":"go:GO:0009846","description":"\"The physiological and developmental changes that occur in a heterosporous plant pollen grain, beginning with hydration and terminating with the emergence of the pollen tube through the aperture.\" [GOC:lr, ISBN:0943088399, PMID:30669423]","metadata":null},{"id":"2cdc37d369a9475aa056aa851aae9044","type":"GO_TERM","name":"pollen hydration","canonical_id":"go:GO:0009859","description":"\"The process in which water is taken up by pollen.\" [GOC:lr]","metadata":null},{"id":"0e00c5928f5d4d47bae568afda3aaba9","type":"GO_TERM","name":"pollen intine formation","canonical_id":"go:GO:0160030","description":"\"Formation of pollen intine, the inner layer of the pollen wall. The reticulate pollen wall pattern consists of two layers, exine and intine.\" [PMID:35498668]","metadata":null},{"id":"35375d9de19a4035aa1851ae25140265","type":"GO_TERM","name":"pollen maturation","canonical_id":"go:GO:0010152","description":"\"The final stages of microgametogenesis after the trinucleate stage has been reached resulting in viable pollen grains.\" [PMID:11595796]","metadata":null},{"id":"31e48703c35c4b768d690dc10cf7890d","type":"GO_TERM","name":"pollen sperm cell differentiation","canonical_id":"go:GO:0048235","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a haploid sperm cell within the plant gametophyte.\" [CL:0000366, GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"49fdb85a72e84467bf678b41835cb9ff","type":"GO_TERM","name":"pollen tube","canonical_id":"go:GO:0090406","description":"\"A tubular cell projection that is part of a pollen tube cell and extends from a pollen grain.\" [GOC:tb, PO:0025195, PO:0025281]","metadata":null},{"id":"baface4da30d432b9a9f4108af277941","type":"GO_TERM","name":"pollen tube adhesion","canonical_id":"go:GO:0009865","description":"\"The process in which the pollen tube adheres to cells of the stigma and style.\" [GOC:tair_curators, PMID:12602877]","metadata":null},{"id":"fe1ead1880dd4318bb6c8b6c4ccbd3d5","type":"GO_TERM","name":"pollen tube development","canonical_id":"go:GO:0048868","description":"\"The process whose specific outcome is the progression of a pollen tube over time, from its initial formation to a mature structure.\" [GOC:isa_complete]","metadata":null},{"id":"ac34e11e3ff848f58e10bca4af6dbd6b","type":"GO_TERM","name":"pollen tube growth","canonical_id":"go:GO:0009860","description":"\"Growth of pollen via tip extension of the intine wall.\" [ISBN:0943088399]","metadata":null},{"id":"587ac16d39a24abba445df8776d6c80e","type":"GO_TERM","name":"pollen tube guidance","canonical_id":"go:GO:0010183","description":"\"The process in which the growth of pollen tube is directed towards the female gametophyte.\" [GOC:lr]","metadata":null},{"id":"93488266826e42768a7bd8dd20497863","type":"GO_TERM","name":"pollen tube reception","canonical_id":"go:GO:0010483","description":"\"An interaction between the pollen tube, part of the male gametophyte, and the female gametophyte (typically the synergid cells), that results in the arrest of pollen tube growth, rupture of the pollen tube and the release of the sperm cells.\" [PMID:37640641]","metadata":null},{"id":"9fdb2c5034014cca9b24e7dcbe8042e3","type":"GO_TERM","name":"pollen tube tip","canonical_id":"go:GO:0090404","description":"\"The region at growing end of the pollen tube cell, where polarized growth occurs.\" [GOC:tb, PO:0025195, PO:0025281]","metadata":null},{"id":"f8d8291cf4ee4c0db7017619d5a0a1f8","type":"GO_TERM","name":"pollen wall","canonical_id":"go:GO:0043667","description":"\"The wall surrounding a mature pollen grain; a multilayered structure consisting of a pectocellulosic intine surrounded by a sporopollenin-based exine, which itself contains two layers, the inner nexine and the outer sexine.\" [GOC:fz, PMID:15131249]","metadata":null},{"id":"2720b633dd9143839880245007c1a240","type":"GO_TERM","name":"pollen wall assembly","canonical_id":"go:GO:0010208","description":"\"The formation of reticulate pollen wall pattern consisting of two layers, exine and intine.\" [PMID:11743117]","metadata":null},{"id":"78bfef88d21943d983c0f177c31e21cb","type":"GO_TERM","name":"pollen-pistil interaction","canonical_id":"go:GO:0009875","description":"\"The interaction between a pollen grain and pistil.\" [PMID:27899537]","metadata":null},{"id":"07cc96b275a44b519e84fef2952b787a","type":"GO_TERM","name":"pollen-stigma interaction","canonical_id":"go:GO:0140301","description":"\"The interactions (or cell to cell communication) that occur between the pollen grain (male gametophyte) and the stigmatic tissues of the female sporophyte after the pollen reaches the stigmatic papillae.\" [PMID:27899537]","metadata":null},{"id":"185655510aed416daf9d9347fb74f4c0","type":"GO_TERM","name":"pollen-style interaction","canonical_id":"go:GO:0140302","description":"\"The interactions (or cell to cell communication) that occur between the male gametophyte (pollen/pollen tube) and the stylar tissues of the female sporophyte.\" [PMID:27899537]","metadata":null},{"id":"60ce218f6ec24d81815f058696b77b1e","type":"GO_TERM","name":"pollination","canonical_id":"go:GO:0009856","description":"\"The cascade of biological processes occurring in plants beginning when the pollen lands on the female reproductive organs of a plant and continuing up to, but not including, fertilization, as defined by sperm-egg cell fusion.\" [GOC:tb, PMID:10973091]","metadata":null},{"id":"69655958eae44ff0a94f0ec7a51a8d82","type":"DRUG","name":"polmacoxib","canonical_id":"mesh:C000599293","description":null,"metadata":null},{"id":"4237aab6acbc4737a4323334e63e3d3f","type":"GO_TERM","name":"polo box domain specific binding","canonical_id":"go:GO:0090488","description":"\"Binding to a polo box domain of a protein. The polo box domain is involved in binding substrates of polo kinases.\" [GOC:al, GOC:tb, Pfam:PF00659, PMID:12352953]","metadata":null},{"id":"7d074d5102de4e7f9ecb3a2c84682a45","type":"GO_TERM","name":"poly(3-hydroxyalkanoate) binding","canonical_id":"go:GO:0043287","description":"\"Binding to a poly(3-hydroxyalkanoate), a polyester of 3-hydroxyacids produced as intracellular granules by a large variety of bacteria.\" [GOC:jl]","metadata":null},{"id":"845bd879e02f4b1397967dad4eb69d23","type":"GO_TERM","name":"poly(3-hydroxyalkanoate) biosynthetic process","canonical_id":"go:GO:0042621","description":"\"The chemical reactions and pathways resulting in the formation of poly(3-hydroxyalkanoates), polyesters of 3-hydroxyacids produced as intracellular granules by a large variety of bacteria.\" [GOC:jl, PMID:9925580]","metadata":null},{"id":"15672df93af54388947a2c9d53a398a6","type":"GO_TERM","name":"poly(3-hydroxyalkanoate) metabolic process","canonical_id":"go:GO:0042620","description":"\"The chemical reactions and pathways involving poly(3-hydroxyalkanoates), polyesters of 3-hydroxyacids produced as intracellular granules by a large variety of bacteria.\" [GOC:jl, PMID:9925580]","metadata":null},{"id":"5118e85d678146c2a39322d0c8d55b06","type":"GO_TERM","name":"poly(3-hydroxybutyrate) depolymerase activity","canonical_id":"go:GO:0050526","description":"\"Catalysis of the reaction: H2O + poly[(R)-3-hydroxybutanoate](n) = poly[(R)-3-hydroxybutanoate](x) + poly[(R)-3-hydroxybutanoate](n-x); x is 1-5.\" [EC:3.1.1.75, MetaCyc:3.1.1.75-RXN]","metadata":null},{"id":"6643b2d35aa04996bac6174675314783","type":"GO_TERM","name":"poly(3-hydroxyoctanoate) depolymerase activity","canonical_id":"go:GO:0050527","description":"\"Catalysis of the reaction: H2O + poly[(R)-3-hydroxyoctanoate](n) = poly[(R)-3-hydroxyoctanoate](x) + poly[(R)-3-hydroxyoctanoate](n-x); x is 1-5.\" [EC:3.1.1.76, MetaCyc:3.1.1.76-RXN]","metadata":null},{"id":"ea51f863c3da4165b19023ff69ad623f","type":"GO_TERM","name":"poly(3-hydroxyvalerate) biosynthetic process","canonical_id":"go:GO:1902923","description":"\"The chemical reactions and pathways resulting in the formation of poly(3-hydroxyvalerate).\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:21705209]","metadata":null},{"id":"c177907a9b75440e970da109a3d6dd36","type":"GO_TERM","name":"poly(5-hydroxyvalerate) biosynthetic process","canonical_id":"go:GO:1902919","description":"\"The chemical reactions and pathways resulting in the formation of poly(5-hydroxyvalerate).\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:21705209]","metadata":null},{"id":"d2e9d313e1704a4f972c7059941002c8","type":"GO_TERM","name":"poly(A) RNA polymerase activity","canonical_id":"go:GO:1990817","description":"\"Catalysis of the reaction: ATP + RNA(n) = diphosphate + RNA(n)-3'-adenine ribonucleotide. The primer may be an RNA or DNA fragment, or oligo(A) bearing a 3'-OH terminal group.\" [PMID:13965521, RHEA:11332]","metadata":null},{"id":"9e2e16257c454ed39c760ef4b4470b1c","type":"GO_TERM","name":"poly(A) binding","canonical_id":"go:GO:0008143","description":"\"Binding to a sequence of adenylyl residues in an RNA molecule, such as the poly(A) tail, a sequence of adenylyl residues at the 3' end of eukaryotic mRNA.\" [GOC:jl]","metadata":null},{"id":"12349854efcb42c3bf941f58c2418360","type":"GO_TERM","name":"poly(A)+ mRNA export from nucleus","canonical_id":"go:GO:0016973","description":"\"The directed movement of poly(A)+ mRNA out of the nucleus into the cytoplasm.\" [GOC:ai]","metadata":null},{"id":"6627812ad3af4c729a1d6ac255019ccb","type":"GO_TERM","name":"poly(A)-dependent snoRNA 3'-end processing","canonical_id":"go:GO:0071051","description":"\"Any process involved in forming the mature 3' end of a snoRNA molecule linked to prior polyadenylation of the 3'-end of the precursor snoRNA.\" [GOC:dgf, GOC:krc, PMID:18951092]","metadata":null},{"id":"37348dfd13c9455c8067c1ac40326985","type":"GO_TERM","name":"poly(A)-specific ribonuclease activity","canonical_id":"go:GO:0004535","description":"\"Catalysis of the exonucleolytic cleavage of poly(A) to 5'-AMP.\" [EC:3.1.13.4, ISBN:0198547684]","metadata":null},{"id":"8c2a667e404f4da0820d6c13ec125e8d","type":"GO_TERM","name":"poly(ADP-ribose) glycohydrolase activity","canonical_id":"go:GO:0004649","description":"\"Catalysis of the hydrolysis of poly(ADP-ribose) at glycosidic (1''-2') linkage of ribose-ribose bond to produce free ADP-ribose.\" [EC:3.2.1.143]","metadata":null},{"id":"7229561219a4437abf5ca0241eab4dff","type":"GO_TERM","name":"poly(C) RNA binding","canonical_id":"go:GO:0017130","description":"\"Binding to a sequence of cytosine residues in an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"afbd900b390a42c1a154e71c31f049ca","type":"GO_TERM","name":"poly(G) binding","canonical_id":"go:GO:0034046","description":"\"Binding to a sequence of guanine residues in an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"1a659f1bdbc84a1c8c73dda5859ffbf7","type":"GO_TERM","name":"poly(U) RNA binding","canonical_id":"go:GO:0008266","description":"\"Binding to a sequence of uracil residues in an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"b3aee6ed27e3415c87d33e022336f5c9","type":"GO_TERM","name":"poly(U)-specific exoribonuclease activity, producing 3' uridine cyclic phosphate ends","canonical_id":"go:GO:1990838","description":"\"Catalysis of the reaction: a 3'-end uridylyl-uridine-RNA = a 3'-end 2',3'-cyclophospho-uridine-RNA + uridine.\" [PMID:23022480, RHEA:46052]","metadata":null},{"id":"80b3fb80d2284db8bb7f0a601bf2cac9","type":"GO_TERM","name":"poly(alpha-L-guluronate) lyase activity","canonical_id":"go:GO:0047491","description":"\"Catalysis of the reaction: polysaccharides containing a terminal alpha-L-guluronate group = oligosaccharides with 4-deoxy-alpha-L-erythro-hex-4-enuronosyl end. This reaction is the eliminative cleavage of polysaccharides containing a terminal a-L-guluronate group, to give oligopolysaccharides with 4-deoxy-a-L-erythro-hex-4-enuronosyl groups at their nonreducing ends.\" [EC:4.2.2.11]","metadata":null},{"id":"6b664315bb9043bebaee73a0c4a95b11","type":"GO_TERM","name":"poly(beta-D-mannuronate) lyase activity","canonical_id":"go:GO:0045135","description":"\"Catalysis of the reaction: polysaccharides containing beta-D-mannuronate residues = oligosaccharides with 4-deoxy-alpha-L-erythro-hex-4-enopyranuronosyl end. This reaction is the eliminative cleavage of polysaccharides containing beta-D-mannuronate residues to give oligosaccharides with 4-deoxy-alpha-L-erythro-hex-4-enopyranuronosyl groups at their ends.\" [EC:4.2.2.3]","metadata":null},{"id":"0d46cf5f00914170a77c919f4214610e","type":"GO_TERM","name":"poly(glucopyranosyl N-acetylgalactosamine 1-phosphate) teichoic acid biosynthetic process","canonical_id":"go:GO:1902016","description":"\"The chemical reactions and pathways resulting in the formation of poly(glucopyranosyl N-acetylgalactosamine 1-phosphate) teichoic acid.\" [GOC:TermGenie, PMID:16735734, UniPathway:UPA00789, UniPathway:UPA00828]","metadata":null},{"id":"3cd8660ccee74e43a4d151513119d7c0","type":"GO_TERM","name":"poly(glycerol phosphate) teichoic acid biosynthetic process","canonical_id":"go:GO:1902014","description":"\"The chemical reactions and pathways resulting in the formation of poly(glycerol phosphate) teichoic acid.\" [GOC:TermGenie, PMID:11882717, UniPathway:UPA00827]","metadata":null},{"id":"786bd09063fa465ea5a9a8eb2f27a2cb","type":"GO_TERM","name":"poly(glycerol-phosphate) alpha-glucosyltransferase activity","canonical_id":"go:GO:0047265","description":"\"Catalysis of the reaction: poly(glycerol phosphate) + UDP-D-glucose = alpha-D-glucosylpoly(glycerol phosphate) + UDP.\" [EC:2.4.1.52]","metadata":null},{"id":"806079dd3c7649899e604a4f0ac13eaa","type":"GO_TERM","name":"poly(hydroxyalkanoate) biosynthetic process","canonical_id":"go:GO:1901441","description":"\"The chemical reactions and pathways resulting in the formation of poly(hydroxyalkanoate).\" [GOC:mengo_curators, GOC:TermGenie, MetaCyc:PWY-6657]","metadata":null},{"id":"2871143b292041c99a58fc6c4cc1b21b","type":"GO_TERM","name":"poly(hydroxyvalerate) biosynthetic process","canonical_id":"go:GO:1902921","description":"\"The chemical reactions and pathways resulting in the formation of poly(hydroxyvalerate).\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:21705209]","metadata":null},{"id":"fb31985846194b47a3e06aa11c02bc2f","type":"GO_TERM","name":"poly(ribitol phosphate) teichoic acid biosynthetic process","canonical_id":"go:GO:1902012","description":"\"The chemical reactions and pathways resulting in the formation of poly(ribitol phosphate) teichoic acid.\" [GOC:TermGenie, PMID:11882717, UniPathway:UPA00790]","metadata":null},{"id":"9fae3403fe324e3b9e0ee311dd9dd4bc","type":"GO_TERM","name":"poly(ribitol-phosphate) N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047269","description":"\"Catalysis of the reaction: poly(ribitol phosphate) + UDP-N-acetyl-D-glucosamine = N-acetyl-D-glucosaminyl-poly(ribitol phosphate) + UDP.\" [EC:2.4.1.70]","metadata":null},{"id":"842eae8ae6f9439f84015cdfbfca32c1","type":"GO_TERM","name":"poly(ribitol-phosphate) beta-glucosyltransferase activity","canonical_id":"go:GO:0047266","description":"\"Catalysis of the reaction: poly(ribitol phosphate) + UDP-D-glucose = beta-D-glucosylpoly(ribitol phosphate) + UDP.\" [EC:2.4.1.53]","metadata":null},{"id":"7e066597adec4d9fa7bc20c5a5d8754e","type":"GO_TERM","name":"poly-ADP-D-ribose binding","canonical_id":"go:GO:0072572","description":"\"Binding to polymeric ADP-D-ribose, a polymer that is composed of poly-ADP-D-ribose units linked through 1,2-glycosidic bonds at the ribose ring.\" [GOC:mah, GOC:sart, PMID:20088964]","metadata":null},{"id":"4a37744bc0a84afcb59b27462a63876e","type":"GO_TERM","name":"poly-ADP-D-ribose modification-dependent protein binding","canonical_id":"go:GO:0160004","description":"\"Binding to a protein upon poly-ADP-ribosylation of the target protein.\" [PMID:26673700]","metadata":null},{"id":"b0d756e6a89245d7b63ae41f0172edf2","type":"GO_TERM","name":"poly-N-acetyllactosamine biosynthetic process","canonical_id":"go:GO:0030311","description":"\"The chemical reactions and pathways resulting in the formation of poly-N-acetyllactosamine, a carbohydrate composed of N-acetyllactosamine repeats (Gal-beta-1,4-GlcNAc-beta-1,3)n.\" [GOC:mah, PMID:9405606]","metadata":null},{"id":"6fd008233c52452c91fda97cd4e9f32d","type":"GO_TERM","name":"poly-N-acetyllactosamine catabolic process","canonical_id":"go:GO:0030310","description":"\"The chemical reactions and pathways resulting in the breakdown of poly-N-acetyllactosamine, a carbohydrate composed of N-acetyllactosamine repeats (Gal-beta-1,4-GlcNAc-beta-1,3)n.\" [GOC:mah, PMID:9405606]","metadata":null},{"id":"47e4f72eb6ed455ab708ca03f024f541","type":"GO_TERM","name":"poly-N-acetyllactosamine metabolic process","canonical_id":"go:GO:0030309","description":"\"The chemical reactions and pathways involving poly-N-acetyllactosamine, a carbohydrate composed of N-acetyllactosamine repeats (Gal-beta-1,4-GlcNAc-beta-1,3)n.\" [GOC:mah, PMID:9405606]","metadata":null},{"id":"6d532ae5f282470a9a93778bda754f3b","type":"GO_TERM","name":"poly-beta-1,6-N-acetyl-D-glucosamine transmembrane transporter activity","canonical_id":"go:GO:1901515","description":"\"Enables the transfer of poly-beta-1,6-N-acetyl-D-glucosamine from one side of a membrane to the other.\" [GOC:TermGenie, PMID:15090514, PMID:18359807]","metadata":null},{"id":"af9fa7556caa444fb468803616f77b44","type":"GO_TERM","name":"poly-gamma-glutamate biosynthetic process","canonical_id":"go:GO:0070501","description":"\"The chemical reactions and pathways resulting in the formation of poly-gamma-glutamate, a polymer of D- and/or L-glutamic acid residues linked by gamma-peptidyl bonds.\" [GOC:mah, PMID:16689787]","metadata":null},{"id":"10d55b6b1f3c49a08097559f6ee289cf","type":"GO_TERM","name":"poly-glutamine tract binding","canonical_id":"go:GO:0008267","description":"\"Binding to a polyglutamine tract, i.e. a series of consecutive glutamine residues, in a protein.\" [GOC:mah]","metadata":null},{"id":"e4587c863b8440d682304dc099407a4d","type":"GO_TERM","name":"poly-hydroxybutyrate biosynthetic process","canonical_id":"go:GO:0042619","description":"\"The chemical reactions and pathways resulting in the formation of poly-hydroxybutyrate (PHB), a polymer of beta-hydroxybutyrate and a common storage material of prokaryotic cells.\" [GOC:jl, PMID:18640095]","metadata":null},{"id":"7fb7e82918844da19d3e6d2ae4c7beda","type":"GO_TERM","name":"poly-hydroxybutyrate metabolic process","canonical_id":"go:GO:0042618","description":"\"The chemical reactions and pathways involving poly-hydroxybutyrate (PHB), a polymer of beta-hydroxybutyrate and a common storage material of prokaryotic cells.\" [GOC:jl, PMID:18640095]","metadata":null},{"id":"d061e8f1ba12480a8e94e84780af05a9","type":"GO_TERM","name":"poly-purine tract binding","canonical_id":"go:GO:0070717","description":"\"Binding to a stretch of purines (adenine or guanine) in an RNA molecule.\" [GOC:mah]","metadata":null},{"id":"31c9e315c70347afbfb5f357e9a6d9c0","type":"GO_TERM","name":"poly-pyrimidine tract binding","canonical_id":"go:GO:0008187","description":"\"Binding to a stretch of pyrimidines (cytosine or uracil) in an RNA molecule.\" [GOC:jl]","metadata":null},{"id":"518950dc6fd34139b372660e332ff42a","type":"GO_TERM","name":"polyacyltrehalose biosynthetic process","canonical_id":"go:GO:0097093","description":"\"The chemical reactions and pathways resulting in the formation of polyacyltrehalose, a pentaacylated, trehalose-based glycolipid.\" [GOC:rs, PMID:19729090]","metadata":null},{"id":"aa1a617353904c608682e080d768de7b","type":"GO_TERM","name":"polyadenylation of viral mRNA by polymerase stuttering","canonical_id":"go:GO:0039698","description":"\"Polyadenylation of viral mRNA through a polymerase stuttering mechanism. The stop signal present at the end of each gene comprises a stretch of uridine on which the viral polymerase acquires a stuttering behavior: after each adenine inserted, the polymerase moves back one nucleotide along with the mRNA. It resumes transcription adding a new adenine, then again moves back, thereby producing a polyA tail.\" [VZ:1916]","metadata":null},{"id":"5cbb755f592849409dc70251e00767dd","type":"GO_TERM","name":"polyadenylation-dependent RNA catabolic process","canonical_id":"go:GO:0043633","description":"\"The chemical reactions and pathways resulting in the breakdown of an RNA molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3'-end of the target RNA.\" [GOC:dgf, GOC:jl, GOC:krc]","metadata":null},{"id":"f11847da73f04d8ead31cdea19387927","type":"GO_TERM","name":"polyadenylation-dependent mRNA catabolic process","canonical_id":"go:GO:0071047","description":"\"The chemical reactions and pathways resulting in the breakdown of a messenger RNA (mRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target mRNA.\" [GOC:dgf, GOC:krc]","metadata":null},{"id":"db60298b40ef4f9482e62e49beb8896b","type":"GO_TERM","name":"polyadenylation-dependent ncRNA catabolic process","canonical_id":"go:GO:0043634","description":"\"The chemical reactions and pathways resulting in the breakdown of a noncoding RNA (ncRNA) molecule, initiated by the enzymatic addition of a sequence of adenylyl residues (polyadenylation) at the 3' end the target ncRNA.\" [GOC:dgf, GOC:jl, GOC:krc]","metadata":null},{"id":"bfde0c11b1d54794b6e64560faae1013","type":"GO_TERM","name":"polyadic synapse","canonical_id":"go:GO:0098979","description":"\"A synapse consisting of a single presynapse and multiple postsynapses. These postsynapses may come from the same cell of from different cells. Polyadic synapses are common in arthropod and nematode central nervous systems.\" [PMID:26780543]","metadata":null},{"id":"dfb205abca8640b19232d8ed3d97defc","type":"GO_TERM","name":"polyamine binding","canonical_id":"go:GO:0019808","description":"\"Binding to a polyamine, an organic compound containing two or more amino groups.\" [GOC:ai]","metadata":null},{"id":"b182d49880dc443fb2e3b447d95d9eb3","type":"GO_TERM","name":"polyamine biosynthetic process","canonical_id":"go:GO:0006596","description":"\"The chemical reactions and pathways resulting in the formation of polyamines, any organic compound containing two or more amino groups.\" [ISBN:0198506732]","metadata":null},{"id":"f5be55e7b48a4ca4a5652ba6a0f4fce5","type":"GO_TERM","name":"polyamine catabolic process","canonical_id":"go:GO:0006598","description":"\"The chemical reactions and pathways resulting in the breakdown of polyamines, any organic compound containing two or more amino groups.\" [ISBN:0198506732]","metadata":null},{"id":"be8c67c5e6f3429aa4b956ec32322b8d","type":"GO_TERM","name":"polyamine import across plasma membrane","canonical_id":"go:GO:0140202","description":"\"The directed movement of a polyamine from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:17218313]","metadata":null},{"id":"5caf72d7d1bd4246a331a3350a8ad77a","type":"GO_TERM","name":"polyamine metabolic process","canonical_id":"go:GO:0006595","description":"\"The chemical reactions and pathways involving polyamines, any organic compound containing two or more amino groups.\" [ISBN:0198506732]","metadata":null},{"id":"fd1d18ee3ea644eba410267867c4b4a2","type":"GO_TERM","name":"polyamine oxidase (propane-1,3-diamine-forming) activity","canonical_id":"go:GO:0052900","description":"\"Catalysis of the reaction: spermidine + O2 + H2O = 4-aminobutanal + propane-1,3-diamine + H2O2. Weak activity on N(1)-acetylspermine and spermine.\" [EC:1.5.3.14]","metadata":null},{"id":"717f7121090b4f99a78796b2c8b63772","type":"GO_TERM","name":"polyamine oxidase activity","canonical_id":"go:GO:0046592","description":"\"Catalysis of the oxidative degradation or interconversion of polyamines.\" [PMID:1567380]","metadata":null},{"id":"d1e7062a5484425bb67129db0e5ce717","type":"GO_TERM","name":"polyamine transmembrane transport","canonical_id":"go:GO:1902047","description":"\"The process in which a polyamine macromolecule is transported across a membrane.\" [GOC:TermGenie, GOC:vw]","metadata":null},{"id":"576c0f066b34479691713cc1701e6fb3","type":"GO_TERM","name":"polyamine transmembrane transporter activity","canonical_id":"go:GO:0015203","description":"\"Enables the transfer of polyamines, organic compounds containing two or more amino groups, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"8a8ed91a3c264354a1c60c4c90ee0ad6","type":"GO_TERM","name":"polyamine transport","canonical_id":"go:GO:0015846","description":"\"The directed movement of polyamines, organic compounds containing two or more amino groups, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc, ISBN:0198506732]","metadata":null},{"id":"99017ae5dc624e91a69c36772a9b728c","type":"GO_TERM","name":"polyamine:proton antiporter activity","canonical_id":"go:GO:0015312","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + polyamine(in) = H+(in) + polyamine(out).\" [TC:2.A.1.2.16]","metadata":null},{"id":"58e524ab96e9417eb7826fd329caa7c9","type":"GO_TERM","name":"polychlorinated biphenyl binding","canonical_id":"go:GO:0097160","description":"\"Binding to a polychlorinated biphenyl (PCB), a biphenyl compound containing between 2 and 10 chlorine atoms attached to the two benzene rings.\" [GOC:sjw, PMID:7583672]","metadata":null},{"id":"f56a1ecb3bbd410f9032d0a163d3ca78","type":"GO_TERM","name":"polycistronic mRNA processing","canonical_id":"go:GO:0031426","description":"\"The conversion of a primary mRNA transcript containing more than one complete protein-coding region into individual mature mRNA molecules.\" [GOC:mah]","metadata":null},{"id":"5747da594bf1459bbc6ba101bdcaaa8f","type":"DISEASE","name":"polycystic kidney disease","canonical_id":"mondo:0020642","description":null,"metadata":null},{"id":"ca901e416c9a4dbc819227e885ae0f7a","type":"DISEASE","name":"polycystic ovary syndrome","canonical_id":"mondo:0008487","description":null,"metadata":null},{"id":"6138c272711740c08790854f9ca2626a","type":"GO_TERM","name":"polycystin complex","canonical_id":"go:GO:0002133","description":"\"A stable heterodimeric complex composed of polycystin-1 and polycystin-2.\" [GOC:hjd, PMID:11901144]","metadata":null},{"id":"65481ba904244a67afc88f29b5ad1925","type":"DISEASE","name":"polycythemia","canonical_id":"mondo:0005571","description":null,"metadata":null},{"id":"4f2f51dd56bb4218a2fae0696503b42c","type":"GO_TERM","name":"polyenoic fatty acid isomerase activity","canonical_id":"go:GO:0034016","description":"\"Catalysis of the reaction: all-cis-icosa-5,8,11,14,17-pentaenoate = (5Z,7E,9E,14Z,17Z)-icosapentaenoate.\" [RHEA:14889]","metadata":null},{"id":"72267e391d7e4aac8949f223f9daf106","type":"GO_TERM","name":"polygalacturonase activity","canonical_id":"go:GO:0004650","description":"\"Catalysis of the random hydrolysis of (1->4)-alpha-D-galactosiduronic linkages in pectate and other galacturonans.\" [EC:3.2.1.15]","metadata":null},{"id":"4f0dcbcbe8584acc8f38c258e2686421","type":"GO_TERM","name":"polygalacturonase inhibitor activity","canonical_id":"go:GO:0090353","description":"\"Binds to and stops, prevents or reduces the activity of polygalacturonase.\" [GOC:tb]","metadata":null},{"id":"9d7ebedd2b0f4fbaafdfdcb81312cf00","type":"GO_TERM","name":"polygalacturonate 4-alpha-galacturonosyltransferase activity","canonical_id":"go:GO:0047262","description":"\"Catalysis of the reaction: UDP-D-galacturonate + 1,4-alpha-D-galacturonosyl(n) = 1,4-alpha-D-galacturonosyl(n+1) + UDP.\" [EC:2.4.1.43, MetaCyc:2.4.1.43-RXN]","metadata":null},{"id":"00523384ddf54531b70539110214c9db","type":"GO_TERM","name":"polyhydroxyalkanoate granule","canonical_id":"go:GO:0070088","description":"\"An inclusion body located in the cytoplasm of prokaryotes that consists of polyhydroxyalkanoate (PHA) molecules and associated proteins, surrounded by a phospholipid monolayer; the proteins include PHA synthase, PHA depolymerase and 3HB-oligomer hydroxylase, phasins (PhaPs), which are thought to be the major structural proteins of the membrane surrounding the inclusion, and the regulator of phasin expression PhaR.\" [GOC:mah, PMID:15762612]","metadata":null},{"id":"25a3036cc0cf48038278e97e16cfe794","type":"GO_TERM","name":"polyketide biosynthetic process","canonical_id":"go:GO:0030639","description":"\"The chemical reactions and pathways resulting in the formation of polyketides, any of a diverse group of natural products synthesized via linear poly-beta-ketones, which are themselves formed by repetitive head-to-tail addition of acetyl (or substituted acetyl) units indirectly derived from acetate (or a substituted acetate) by a mechanism similar to that for fatty acid biosynthesis but without the intermediate reductive steps.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"ebe7825873264f1a954b755888f89513","type":"GO_TERM","name":"polyketide catabolic process","canonical_id":"go:GO:0030640","description":"\"The chemical reactions and pathways resulting in the breakdown of polyketides, any of a diverse group of natural products synthesized via linear poly-beta-ketones, which are themselves formed by repetitive head-to-tail addition of acetyl (or substituted acetyl) units indirectly derived from acetate (or a substituted acetate) by a mechanism similar to that for fatty acid biosynthesis but without the intermediate reductive steps.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"c562c0b6cf9442ee87f37db3ac2358d8","type":"GO_TERM","name":"polyketide metabolic process","canonical_id":"go:GO:0030638","description":"\"The chemical reactions and pathways involving polyketides, any of a diverse group of natural products synthesized via linear poly-beta-ketones, which are themselves formed by repetitive head-to-tail addition of acetyl (or substituted acetyl) units indirectly derived from acetate (or a substituted acetate) by a mechanism similar to that for fatty acid biosynthesis but without the intermediate reductive steps.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"15516215010c4e8bae50d42cea533a90","type":"GO_TERM","name":"polyketide synthase activity","canonical_id":"go:GO:0016218","description":"\"Catalysis of a multistep reaction that produce polyketides through decarboxylative condensation of carboxylic acids. The key chain-building reaction, a C-N bond-forming reaction, involves the generation of the characteristic peptide bond by nucleophilic attack of the amino group of an amino-acyl donor unit covalently bound to a downstream peptidyl carrier protein module (amino acyl-S-PCP) on the acyl group of an upstream electrophilic acyl- or peptidyl acyl-S-PCP chain, catalyzed by a condensation (C) domain. Supplementing these core chain-elongation domains are variable numbers of auxiliary domains that are responsible for modification of the growing polypeptide chain by a small set of iterated reactions including epimerization, N-methylation, and heterocyclization.\" [PMID:10631508]","metadata":null},{"id":"34b029b471da4bd3ade237a3e23aa197","type":"GO_TERM","name":"polyketide synthase complex","canonical_id":"go:GO:0034081","description":"\"A protein complex that carries out enzymatic reactions involved in the biosynthesis of polyketides, any of a diverse group of natural products synthesized via linear poly-beta-ketones.\" [GOC:mah, PMID:12636085]","metadata":null},{"id":"77a6cc1c5b70419e8d5653fd1fb64527","type":"GO_TERM","name":"polymannuronate hydrolase activity","canonical_id":"go:GO:0033936","description":"\"Catalysis of the endohydrolysis of the D-mannuronide linkages of polymannuronate.\" [EC:3.2.1.121]","metadata":null},{"id":"77a2e3498d874b5299d2a5db2274c1b1","type":"GO_TERM","name":"polymeric IgA immunoglobulin complex","canonical_id":"go:GO:0071749","description":"\"A protein complex composed of two, three, or four monomeric IgA immunoglobulin complexes linked through both direct disulfide bonds and through disulfide binded monomers of J chain acting as a bridge. Each IgA monomer consists of two identical immunoglobulin heavy chains of an IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds. Dimeric IgA is sometimes complexed additionally with secretory component, and present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"e10c919f4de342caa74a1c769de4ea86","type":"GO_TERM","name":"polymeric cytoskeletal fiber","canonical_id":"go:GO:0099513","description":"\"A component of the cytoskeleton consisting of a homo or heteropolymeric fiber constructed from an indeterminate number of protein subunits.\" [GOC:dos]","metadata":null},{"id":"1db89ba3f89c4f61add3d8e9ee83baad","type":"GO_TERM","name":"polymeric immunoglobulin binding","canonical_id":"go:GO:0001790","description":"\"Binding to a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7f0e6fc6ddb84b36a260392904fe9bce","type":"GO_TERM","name":"polymeric immunoglobulin receptor activity","canonical_id":"go:GO:0001792","description":"\"Combining with a J-chain-containing polymeric immunoglobulin of the IgA or IgM isotypes via the Fc region, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:signaling, ISBN:0781735149]","metadata":null},{"id":"46e6addda931412485b99468ae2bd678","type":"DISEASE","name":"polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis","canonical_id":"mondo:0014679","description":null,"metadata":null},{"id":"3a7ba8399d824c9b80dba6cf8221c833","type":"DISEASE","name":"polymyositis","canonical_id":"mondo:0019127","description":null,"metadata":null},{"id":"0c02c5bc2c934385be8da054c3b604fc","type":"GO_TERM","name":"polymyxin transmembrane transporter activity","canonical_id":"go:GO:0042897","description":"\"Enables the transfer of polymyxin, any of a group of related antibiotics produced by Bacillus polymyxa and active against most Gram-negative bacteria, from one side of a membrane to the other.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a7662d9f2bf3484a82ffedf0ca0893c3","type":"GO_TERM","name":"polymyxin transport","canonical_id":"go:GO:0042893","description":"\"The directed movement of polymyxin, any of a group of related antibiotics produced by Bacillus polymyxa and active against most Gram-negative bacteria, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"c59b66fd9bf64e57b3cbfb337fc86083","type":"GO_TERM","name":"polyneuridine-aldehyde esterase activity","canonical_id":"go:GO:0050529","description":"\"Catalysis of the reaction: H2O + polyneuridine aldehyde = 16-epivellosimine + CO2 + methanol.\" [EC:3.1.1.78, RHEA:17501]","metadata":null},{"id":"9150ba23155e4a42bbc8c3b1db719ed6","type":"GO_TERM","name":"polynucleotide 3' dephosphorylation","canonical_id":"go:GO:0098506","description":"\"The process of removing one or more phosphate groups from the 3' end of a polynucleotide.\" [GOC:dos]","metadata":null},{"id":"656c538dc9ad4948a4b8f905ea556ad0","type":"GO_TERM","name":"polynucleotide 3'-phosphatase activity","canonical_id":"go:GO:0046403","description":"\"Catalysis of the reaction: a 3'end (2'-deoxyribonucleotide 3'-phosphate)-DNA + H2O = a 3'-end 2'-deoxyribonucleotide-DNA + phosphate.\" [RHEA:14113]","metadata":null},{"id":"c3f01cc163f046d39220e2af4c0d110d","type":"GO_TERM","name":"polynucleotide 5' dephosphorylation","canonical_id":"go:GO:0098507","description":"\"The process of removing one or more phosphate groups from the 5' end of a polynucleotide.\" [GOC:dos]","metadata":null},{"id":"9b302e878413430594973b41a32b971f","type":"GO_TERM","name":"polynucleotide 5'-hydroxyl-kinase activity","canonical_id":"go:GO:0051731","description":"\"Catalysis of the reaction: NTP + 5'-dephosphopolynucleotide = NDP + 5'-phosphopolynucleotide. The polynucleotide may be DNA or RNA.\" [GOC:curators]","metadata":null},{"id":"3a2e0106186441ae9edcce77a5b1ec90","type":"GO_TERM","name":"polynucleotide 5'-phosphatase activity","canonical_id":"go:GO:0004651","description":"\"Catalysis of the reaction: a 5'-phosphopolynucleotide + H2O = a polynucleotide + phosphate.\" [EC:3.1.3.33]","metadata":null},{"id":"7bbd3a1f461b473cabf00d3ddc192104","type":"GO_TERM","name":"polynucleotide adenylyltransferase activator activity","canonical_id":"go:GO:1990749","description":"\"Increases the activity of the enzyme polynucleotide adenylyltransferase.\" [GOC:kmv, PMID:19460348]","metadata":null},{"id":"8053af3979c94c5da597286aec9c601b","type":"GO_TERM","name":"polyol biosynthetic process","canonical_id":"go:GO:0046173","description":"\"The chemical reactions and pathways resulting in the formation of a polyol, any alcohol containing three or more hydroxyl groups attached to saturated carbon atoms.\" [GOC:curators]","metadata":null},{"id":"ec34d1362b52422f9f584aa6a9759bdf","type":"GO_TERM","name":"polyol catabolic process","canonical_id":"go:GO:0046174","description":"\"The chemical reactions and pathways resulting in the breakdown of a polyol, any alcohol containing three or more hydroxyl groups attached to saturated carbon atoms.\" [GOC:curators]","metadata":null},{"id":"9ee58a01ad044e37b4f37ca00217c98c","type":"GO_TERM","name":"polyol metabolic process","canonical_id":"go:GO:0019751","description":"\"The chemical reactions and pathways involving a polyol, any alcohol containing three or more hydroxyl groups attached to saturated carbon atoms.\" [PMID:30240188]","metadata":null},{"id":"66f017af7bc14b1da0395725c536572c","type":"GO_TERM","name":"polyol transmembrane transport","canonical_id":"go:GO:0015791","description":"\"The directed movement of polyols, any polyhydric alcohol, across a membrane.\" [GOC:ai]","metadata":null},{"id":"255e5932e71d4cc3aca8eaa171625a65","type":"GO_TERM","name":"polyol transmembrane transporter activity","canonical_id":"go:GO:0015166","description":"\"Enables the transfer of a polyol from one side of a membrane to the other. A polyol is any polyhydric alcohol.\" [ISBN:0198506732]","metadata":null},{"id":"f6c2869af01d4ac08b24abca0c258c0c","type":"GO_TERM","name":"polypeptide N-acetylgalactosaminyltransferase activity","canonical_id":"go:GO:0004653","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-galactosamine + polypeptide = UDP + N-acetyl-D-galactosaminyl-polypeptide. This reaction is the modification of serine or threonine residues in polypeptide chains by the transfer of a N-acetylgalactose from UDP-N-acetylgalactose to the hydroxyl group of the amino acid; it is the first step in O-glycan biosynthesis.\" [EC:2.4.1.41, ISBN:0879695595]","metadata":null},{"id":"3396408767db4e829ea16448b0d4a440","type":"GO_TERM","name":"polypeptide conformation or assembly isomerase activity","canonical_id":"go:GO:0120544","description":"\"Catalysis of a reaction that alters the conformation or assembly of a polypeptide.\" [EC:5.6.1.-]","metadata":null},{"id":"7e75f4293c04452088878547e361517e","type":"GO_TERM","name":"polyphenic determination","canonical_id":"go:GO:0048647","description":"\"The process in which individuals that have the potential to develop any of several possible distinct developmental paths have their individual developmental fates determined in response to environmental and/or genetic cues.\" [GOC:jid]","metadata":null},{"id":"63e595bec0c5412494c6b8085fca8fb7","type":"GO_TERM","name":"polyphenic determination, influence by environmental factors","canonical_id":"go:GO:0048651","description":"\"The process in which individuals that have the potential to develop any of several possible distinct developmental paths have their individual developmental fates determined in response to environmental cues.\" [GOC:jid]","metadata":null},{"id":"2c9dd50d6a614798aa540ec3ac1a9b50","type":"GO_TERM","name":"polyphenic determination, influence by genetic factors","canonical_id":"go:GO:0048652","description":"\"The process in which individuals that have the potential to develop any of several possible distinct developmental paths have their individual developmental fates determined in response to genetic cues.\" [GOC:jid]","metadata":null},{"id":"4e9e812dc30243368b20a0c6344a4719","type":"GO_TERM","name":"polyphosphate biosynthetic process","canonical_id":"go:GO:0006799","description":"\"The chemical reactions and pathways resulting in the formation of a polyphosphate, the anion or salt of polyphosphoric acid.\" [ISBN:0198506732]","metadata":null},{"id":"72f2fe709f204742b52290a9160c1a3a","type":"GO_TERM","name":"polyphosphate catabolic process","canonical_id":"go:GO:0006798","description":"\"The chemical reactions and pathways resulting in the breakdown of a polyphosphate, the anion or salt of polyphosphoric acid.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"8de2ac5799c7489bbb8719fdfc18444d","type":"GO_TERM","name":"polyphosphate import into vacuole","canonical_id":"go:GO:0180042","description":"\"The directed movement of polyphosphate into the vacuole across the vacuolar membrane.\" [PMID:37066886]","metadata":null},{"id":"a46c9cfd969a49598364124fbd046fd7","type":"GO_TERM","name":"polyphosphate kinase activity","canonical_id":"go:GO:0008976","description":"\"Catalysis of the reaction: ATP + phosphate(n) = ADP + phosphate(n+1).\" [EC:2.7.4.1]","metadata":null},{"id":"9a43a0b4452247939c53b3f4b0d2287f","type":"GO_TERM","name":"polyphosphate kinase complex","canonical_id":"go:GO:0009358","description":"\"A protein complex that possesses polyphosphate kinase activity.\" [GOC:mah]","metadata":null},{"id":"25b232208c2f43168d97b9bbce7f2edc","type":"GO_TERM","name":"polyphosphate metabolic process","canonical_id":"go:GO:0006797","description":"\"The chemical reactions and pathways involving a polyphosphate, the anion or salt of polyphosphoric acid.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"8888e68a288a489e9e51ea57ead661b1","type":"GO_TERM","name":"polyphosphate-glucose phosphotransferase activity","canonical_id":"go:GO:0047330","description":"\"Catalysis of the reaction: beta-D-glucose + long chain polyphosphate = glucose-6-phosphate + long chain polyphosphate.\" [EC:2.7.1.63, MetaCyc:2.7.1.63-RXN]","metadata":null},{"id":"462c2f508cfe41eba10a80c1c17713de","type":"GO_TERM","name":"polyphosphate-mediated signaling","canonical_id":"go:GO:0110094","description":"\"Any process that mediates the transfer of information from one cell to another using polyphosphate as the signal.\" [GOC:rjd, PMID:27519410, PMID:28584190]","metadata":null},{"id":"7f42d09ab3dc400aa9d25d9a7421e42e","type":"GO_TERM","name":"polyphosphate:AMP phosphotransferase activity","canonical_id":"go:GO:0043751","description":"\"Catalysis of the reaction: (polyphosphate)n + AMP = (polyphosphate)n-1 + ADP.\" [PMID:11237733]","metadata":null},{"id":"3cf401e5e676448bbf8b31591169d528","type":"GO_TERM","name":"polyprenal reductase activity","canonical_id":"go:GO:0160198","description":"\"Catalysis of the reaction: ditrans,polycis-polyprenal+ H+ + NADPH = ditrans,polycis-dolichal+ NADP.\" [PMID:38821050, RHEA:80727]","metadata":null},{"id":"6e8b89df9aee40c1833490dd7d7a17c9","type":"GO_TERM","name":"polyprenol biosynthetic process","canonical_id":"go:GO:0016094","description":"\"The chemical reactions and pathways resulting in the formation of polyprenols, prenols with more than 4 isoprenoid residues, which may be all-trans, or a mixture of cis and trans.\" [GOC:curators, PMID:11108713]","metadata":null},{"id":"9f6cc7ab55f44bca920d4380f04bb609","type":"GO_TERM","name":"polyprenol catabolic process","canonical_id":"go:GO:0016095","description":"\"The chemical reactions and pathways resulting in the breakdown of polyprenols, prenols with more than 4 isoprenoid residues, which may be all-trans, or a mixture of cis and trans.\" [GOC:curators, Wikipedia:Polyprenol]","metadata":null},{"id":"a561240de6df487f9a3713310f3322b4","type":"GO_TERM","name":"polyprenol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0160196","description":"\"Catalysis of the reaction: a di-trans,poly-cis-polyprenol + NAD+ = a di-trans,poly-cis-polyprenal + NADH + H+.\" [PMID:38821050, RHEA:80719]","metadata":null},{"id":"3d208c232a96417fa875d7d861045130","type":"GO_TERM","name":"polyprenol metabolic process","canonical_id":"go:GO:0016093","description":"\"The chemical reactions and pathways involving polyprenols, prenols with more than 4 isoprenoid residues, which may be all-trans, or a mixture of cis and trans.\" [PMID:11108713]","metadata":null},{"id":"db930009f2f54d058468e1e494858f71","type":"GO_TERM","name":"polyprenol reductase activity","canonical_id":"go:GO:0102389","description":"\"Catalysis of the reaction: NADP + a ditrans,polycis-dolichol = NADPH + H+ + a di-trans, poly-cis-polyprenol.\" [GOC:pz, RHEA:34279]","metadata":null},{"id":"515fea344675400482203002bc4bf9be","type":"GO_TERM","name":"polyprenyl diphosphate phosphatase activity","canonical_id":"go:GO:0120556","description":"\"Catalysis of the dephosphorylation of polyprenyl diphosphates.\" [GOC:curators]","metadata":null},{"id":"f06e568fef8946dfa3295f98e0ecf253","type":"GO_TERM","name":"polyprenyl diphosphate synthase complex","canonical_id":"go:GO:0032476","description":"\"A complex that possesses polyprenyl diphosphate synthase activity involved in the synthesis of the isoprenoid chain of ubiquinone whose length varies between organisms.\" [GOC:mah, PMID:14519123, PMID:16262699]","metadata":null},{"id":"4f1602df0cc24feb910177df9ffd2d69","type":"GO_TERM","name":"polyprenyldihydroxybenzoate methyltransferase activity","canonical_id":"go:GO:0010420","description":"\"Catalysis of the reaction: a 3,4-dihydroxy-5-all-trans-polyprenylbenzoate + S-adenosyl-L-methionine = a 3-methoxy,4-hydroxy-5-all-trans-polyprenylbenzoate + S-adenosyl-L-homocysteine + H+.\" [PMID:10419476, PMID:23190198, PMID:9628017, RHEA:44452]","metadata":null},{"id":"f40e2dbe65594159898d6acc6709d222","type":"GO_TERM","name":"polyribonucleotide nucleotidyltransferase activity","canonical_id":"go:GO:0004654","description":"\"Catalysis of the reaction: RNA(n+1) + phosphate = RNA(n) + a nucleoside diphosphate.\" [EC:2.7.7.8]","metadata":null},{"id":"8b2cfff6de584a2aae202ce1e17b5208","type":"GO_TERM","name":"polysaccharide O-methyltransferase activity","canonical_id":"go:GO:0030734","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 1,4-N1-D-glucooligosaccharide = S-adenosyl-L-homocysteine + oligosaccharide containing 6-methyl-D-glucose units.\" [EC:2.1.1.18]","metadata":null},{"id":"aa113c48b7c8457ba9d9eb5a95932b40","type":"GO_TERM","name":"polysaccharide binding","canonical_id":"go:GO:0030247","description":"\"Binding to a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [GOC:mah]","metadata":null},{"id":"2b704746e5ea49c9805fe96d4241321f","type":"GO_TERM","name":"polysaccharide biosynthetic process","canonical_id":"go:GO:0000271","description":"\"The chemical reactions and pathways resulting in the formation of a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [GOC:curators]","metadata":null},{"id":"f9a13087639546e3a985734f77cb2123","type":"GO_TERM","name":"polysaccharide catabolic process","canonical_id":"go:GO:0000272","description":"\"The chemical reactions and pathways resulting in the breakdown of a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [PMID:33139480]","metadata":null},{"id":"c37ceea7af734d5da6814f6840cb3751","type":"GO_TERM","name":"polysaccharide digestion","canonical_id":"go:GO:0044245","description":"\"The whole of the physical, chemical, and biochemical processes carried out by living organisms to break down ingested polysaccharides into components that may be easily absorbed and directed into metabolism.\" [GOC:curators]","metadata":null},{"id":"9106bea62bb645dc84260041a03c5764","type":"GO_TERM","name":"polysaccharide immune receptor activity","canonical_id":"go:GO:0001873","description":"\"Combining with a polysaccharide and transmitting the signal to initiate an innate immune response. A polysaccharide is a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [PMID:14707091]","metadata":null},{"id":"242aace29d7a4f0cbab8c220a157b954","type":"GO_TERM","name":"polysaccharide localization","canonical_id":"go:GO:0033037","description":"\"Any process in which a polysaccharide is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"7c69d2ee11c549559e8bd6114e9779ab","type":"GO_TERM","name":"polysaccharide metabolic process","canonical_id":"go:GO:0005976","description":"\"The chemical reactions and pathways involving a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [ISBN:0198547684]","metadata":null},{"id":"c3e828f2812649769647e3843660ea19","type":"GO_TERM","name":"polysaccharide transmembrane transporter activity","canonical_id":"go:GO:0015159","description":"\"Enables the transfer of polysaccharides from one side of a membrane to the other. A polysaccharide is a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"0cf5a0b91c4141e795d2d706ee5d3b3a","type":"GO_TERM","name":"polysaccharide transport","canonical_id":"go:GO:0015774","description":"\"The directed movement of polysaccharides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A polysaccharide is a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.\" [GOC:ai]","metadata":null},{"id":"e9b9f12279b54727810ea1beefa3c978","type":"GO_TERM","name":"polysialic-acid O-acetyltransferase activity","canonical_id":"go:GO:0050208","description":"\"Catalysis of the reaction: acetyl-CoA + an alpha-2,8-linked polymer of sialic acid = CoA + polysialic acid acetylated at O-7 or O-9.\" [EC:2.3.1.136, MetaCyc:POLYSIALIC-ACID-O-ACETYLTRANSFERASE-RXN]","metadata":null},{"id":"51479f66a9dc4a5aaf07398ba0028b70","type":"GO_TERM","name":"polyspecific organic cation:proton antiporter activity","canonical_id":"go:GO:0140968","description":"\"Enables the transfer of various organic cations in exchange for a proton, according to the reaction: H+(out) + organic cation(in) = H+(in) + organic cation(out). The transported substrates are usually toxic molecules, drugs and xenobiotics.\" [PMID:17047166, PMID:17509534]","metadata":null},{"id":"434f83f8992b425fa4a831096b8e74c7","type":"GO_TERM","name":"polytene chromosome","canonical_id":"go:GO:0005700","description":"\"A type of chromosome in a polyploid cell, formed when multiple copies of homologous chromosomes are aligned side by side to give a giant chromosome in which distinct chromosome bands are readily visible.\" [ISBN:0198506732]","metadata":null},{"id":"1c39f7e822cc44199caf93bd0205e007","type":"GO_TERM","name":"polytene chromosome band","canonical_id":"go:GO:0005704","description":"\"A stretch of densely packed chromatin along the polytene chromosome, visible as a morphologically distinct band.\" [GOC:bf, PMID:11361342]","metadata":null},{"id":"6097db7c518f4bf5beb53ddfb994385a","type":"GO_TERM","name":"polytene chromosome chromocenter","canonical_id":"go:GO:0005701","description":"\"A region at which the centric regions of polytene chromosomes are joined together.\" [GOC:bf, ISBN:0120649012]","metadata":null},{"id":"430c5c6f4b574ec9a8a2a174a4924b33","type":"GO_TERM","name":"polytene chromosome ectopic fiber","canonical_id":"go:GO:0005706","description":"\"A thread-like connection joining two regions of ectopically paired polytene chromosomes.\" [GOC:bf, ISBN:0120649012]","metadata":null},{"id":"d990f79e987442bc9c0cf5e6a1b2597a","type":"GO_TERM","name":"polytene chromosome interband","canonical_id":"go:GO:0005705","description":"\"A stretch of less tightly packed chromatin along the polytene chromosome, found between bands.\" [GOC:bf, PMID:11361342]","metadata":null},{"id":"cbccb0e045e34407b88cf77ddbf53612","type":"GO_TERM","name":"polytene chromosome puff","canonical_id":"go:GO:0005703","description":"\"A swelling at a site along the length of a polytene chromosome, thought to be the site of active transcription.\" [GOC:bf, ISBN:0120649012]","metadata":null},{"id":"e5904680a5a748b6aed3b6b23e8071ed","type":"GO_TERM","name":"polytene chromosome puffing","canonical_id":"go:GO:0035079","description":"\"The decondensing (loosening) and swelling of the chromosomal sites of target genes on polytene chromosomes following response to a stimulus, to facilitate sudden bursts of transcriptional activity in response to transient environmental signals.\" [GOC:bf, PMID:12543962]","metadata":null},{"id":"8d3c6b71124545c5a0108a63903d6970","type":"GO_TERM","name":"polytene chromosome weak point","canonical_id":"go:GO:0005702","description":"\"A region of the polytene chromosome where the diameter is considerably decreased, probably resulting from local differences in chromosome organization.\" [GOC:bf, ISBN:0120649012]","metadata":null},{"id":"f65c90cb2d434dfdab20813cbde4e500","type":"GO_TERM","name":"polyterpenoid biosynthetic process","canonical_id":"go:GO:0016112","description":"\"The chemical reactions and pathways resulting in the formation of polyterpenoid compounds, terpenoids with more than eight isoprene units.\" [GOC:curators]","metadata":null},{"id":"c0677f4f16f1410c9f60b009acb83d6d","type":"GO_TERM","name":"polyterpenoid catabolic process","canonical_id":"go:GO:0016113","description":"\"The chemical reactions and pathways resulting in the breakdown of polyterpenoid compounds, terpenoids with more than eight isoprene units.\" [GOC:curators]","metadata":null},{"id":"d35b0dd97e5d4fe5b6b5e4372ef7fb84","type":"DRUG","name":"polythiazide","canonical_id":"mesh:D011139","description":null,"metadata":null},{"id":"a201d8cc3afb47acb854850370e6476c","type":"GO_TERM","name":"polyubiquitin modification-dependent protein binding","canonical_id":"go:GO:0031593","description":"\"Binding to a protein upon poly-ubiquitination of the target protein.\" [GOC:pg]","metadata":null},{"id":"7629e4f88b0141afb07c1d405912d1ae","type":"GO_TERM","name":"polyubiquitinated misfolded protein transport","canonical_id":"go:GO:0070845","description":"\"The directed movement of misfolded polyubiquitinated proteins in a cell, including the movement of proteins between specific compartments or structures within a cell.\" [GOC:BHF, GOC:mah, PMID:14675537]","metadata":null},{"id":"10cda82ad6e54ca59a717d21e1db17af","type":"GO_TERM","name":"polyubiquitinated protein transport","canonical_id":"go:GO:0070844","description":"\"The directed movement of polyubiquitinated proteins in a cell, including the movement of proteins between specific compartments or structures within a cell.\" [GOC:BHF, GOC:mah, PMID:14675537]","metadata":null},{"id":"9a994d21379349ce9b37ed90844a321c","type":"GO_TERM","name":"polyuridylation-dependent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:0036450","description":"\"Cleavage of the 5'-cap of a nuclear-transcribed mRNA that has been modified by the enzymatic addition of a sequence of uridylyl residues (polyuridylation) at the 3' end.\" [GOC:vw, PMID:19430462]","metadata":null},{"id":"567715ba582446efab95d519fab0f51b","type":"GO_TERM","name":"polyuridylation-dependent mRNA catabolic process","canonical_id":"go:GO:1990074","description":"\"The chemical reactions and pathways resulting in the breakdown of a messenger RNA (mRNA) molecule, initiated by the enzymatic addition of a sequence of uridylyl residues (polyuridylation) at the 3' end of the target mRNA.\" [GOC:vw, PMID:23503588]","metadata":null},{"id":"8794b50e53f1415c9108b858b6f1b1ed","type":"GO_TERM","name":"polyvinyl alcohol dehydrogenase (cytochrome) activity","canonical_id":"go:GO:0047059","description":"\"Catalysis of the reaction: polyvinyl alcohol + ferricytochrome c = oxidized polyvinyl alcohol + ferrocytochrome c + H+.\" [EC:1.1.2.6]","metadata":null},{"id":"9bba2a93a5154be68573cd2927bfdcda","type":"GO_TERM","name":"polyvinyl-alcohol oxidase activity","canonical_id":"go:GO:0050209","description":"\"Catalysis of the reaction: polyvinyl alcohol + O2 = oxidized polyvinyl alcohol + H2O2.\" [EC:1.1.3.30, MetaCyc:POLYVINYL-ALCOHOL-OXIDASE-RXN]","metadata":null},{"id":"5e528e96715d4033ad734086e7b3b464","type":"DRUG","name":"ponatinib","canonical_id":"gtopdb:5890","description":null,"metadata":null},{"id":"a99e6400964645be9d65dc5ea9ed216d","type":"DRUG","name":"ponatinib","canonical_id":"mesh:D004103","description":null,"metadata":null},{"id":"9a7fe97b94854a069b95928343bf37d7","type":"COMBINATION_TREATMENT","name":"ponatinib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-10d673ce096bd33a","description":null,"metadata":null},{"id":"706a8bbc6c744e36bdee99e8c97bcc62","type":"DRUG","name":"ponesimod","canonical_id":"gtopdb:9320","description":null,"metadata":null},{"id":"4cb550ec489942cfb73c908170fb1e89","type":"DRUG","name":"ponesimod","canonical_id":"chembl:CHEMBL1096146","description":null,"metadata":null},{"id":"8061c5efb02847ff84db1dc411226663","type":"COMBINATION_TREATMENT","name":"ponesimod + teriflunomide","canonical_id":"ctgov_combo:ctgov-combo-d280da7a213c45ff","description":null,"metadata":null},{"id":"54b6f0498010452d879e72bded2cbc7b","type":"GO_TERM","name":"pons development","canonical_id":"go:GO:0021548","description":"\"The process whose specific outcome is the progression of the pons over time, from its formation to the mature structure. The pons lies above the medulla and next to the cerebellum. The pons conveys information about movement from the cerebral hemisphere to the cerebellum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"aa3e6ff7c2024a84b35525b58663327d","type":"GO_TERM","name":"pons formation","canonical_id":"go:GO:0021584","description":"\"The process that gives rise to the pons. This process pertains to the initial formation of a structure from unspecified parts. The pons lies above the medulla and next to the cerebellum. The pons conveys information about movement from the cerebral hemisphere to the cerebellum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"a8a82c2bb38d49f7a402f1fb8299ec86","type":"GO_TERM","name":"pons maturation","canonical_id":"go:GO:0021586","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the pons to attain its fully functional state. The pons lies above the medulla and next to the cerebellum. The pons conveys information about movement from the cerebral hemisphere to the cerebellum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"cef0735b05f84466b44b5c55c6260eb1","type":"GO_TERM","name":"pons morphogenesis","canonical_id":"go:GO:0021583","description":"\"The process in which the anatomical structure of the pons is generated and organized. The pons lies above the medulla and next to the cerebellum. The pons conveys information about movement from the cerebral hemisphere to the cerebellum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"52ad47e1b671418781568b9152be8334","type":"GO_TERM","name":"pons reticulospinal tract morphogenesis","canonical_id":"go:GO:0021975","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the pons towards target cells in the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"8c980a3626104ad9beeed533233e9bed","type":"GO_TERM","name":"pons structural organization","canonical_id":"go:GO:0021585","description":"\"The process that contributes to the act of creating the structural organization of the pons. This process pertains to the physical shaping of a rudimentary structure. The pons lies above the medulla and next to the cerebellum. The pons conveys information about movement from the cerebral hemisphere to the cerebellum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"a4f1d49122a84843b0fdd2dabd14fc8a","type":"GO_TERM","name":"pore complex","canonical_id":"go:GO:0046930","description":"\"A protein complex providing a discrete opening in a membrane that allows the passage of gases and/or liquids.\" [ISBN:0198506732]","metadata":null},{"id":"db0da0a02e144e55a5762c81e992bf57","type":"GO_TERM","name":"pore complex assembly","canonical_id":"go:GO:0046931","description":"\"The aggregation, arrangement and bonding together of a set of components to form a pore complex. A pore complex is a small opening in a membrane that allows the passage of liquids and/or gases.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"395223b9b33648beb67146621a5df269","type":"GO_TERM","name":"pore formation during contractile vacuole discharge","canonical_id":"go:GO:0140028","description":"\"The formation of a transient pore in the plasma membrane and the attached contractile vacuolar membrane, to release water from the cell. This process does not involve fusion of the two membranes.\" [PMID:22323285, Wikipedia:Exocytosis]","metadata":null},{"id":"49ae53e5cb704de0ba87a976bd229690","type":"GO_TERM","name":"pore formation in membrane of another organism","canonical_id":"go:GO:0035915","description":"\"The aggregation, arrangement and bonding together of a set of components by an organism to form a pore complex in a membrane of another organism.\" [GOC:bf, GOC:fj, PMID:21549739]","metadata":null},{"id":"4f4fe52f7248467295511743e233cab1","type":"GO_TERM","name":"pore-forming activity","canonical_id":"go:GO:0140911","description":"\"An activity in which a protein is inserted into the membrane of another cell where it forms transmembrane pores. Pores disrupts the integrity of the cell membrane, resulting in deregulated ion homeostasis, cellular dysfunction, and can result in cell death.\" [PMID:1406491, PMID:25157079, PMID:34387717]","metadata":null},{"id":"77580b54694f4d8da65ef575a3d20015","type":"GO_TERM","name":"porin activity","canonical_id":"go:GO:0015288","description":"\"Enables the transfer of substances, sized less than 1000 Da, from one side of a membrane to the other. The transmembrane portions of porins consist exclusively of beta-strands which form a beta-barrel. They are found in the outer membranes of Gram-negative bacteria, mitochondria, plastids and possibly acid-fast Gram-positive bacteria.\" [GOC:mtg_transport, ISBN:0815340729, PMID:10839820, TC:1.B.1.-.-]","metadata":null},{"id":"fe404ab1a85e48b8a4648c8d139e1d48","type":"GO_TERM","name":"porosome","canonical_id":"go:GO:0033012","description":"\"A permanent cup-shaped structure at the cell plasma membrane in secretory cells. Following a secretory stimulus, secretory vesicles transiently dock and fuse at the base of porosomes and release intravesicular contents dictated by the turgor pressure generated from the swelling of secretory vesicles.\" [PMID:15090256, PMID:16563225]","metadata":null},{"id":"bdcc4504df944393ad194ad153458e91","type":"GO_TERM","name":"porous cell septum","canonical_id":"go:GO:0000934","description":"\"A septum or cross wall which does not entirely span the space between two portions of cell wall and may contain a specialized central pore structure. A porous septum allows the movement of organelles and/or cytoplasm between compartments.\" [GOC:clt]","metadata":null},{"id":"02772180d6bf4761bf9bd642d5f244cf","type":"GO_TERM","name":"porphobilinogen synthase activity","canonical_id":"go:GO:0004655","description":"\"Catalysis of the reaction: 2 5-aminolevulinate = 2 H2O + H+ + porphobilinogen.\" [EC:4.2.1.24, RHEA:24064]","metadata":null},{"id":"e8089abbdc67480f8451a478d3a4b2b8","type":"DISEASE","name":"porphyria","canonical_id":"mondo:0037939","description":null,"metadata":null},{"id":"48b2013148f9407eaa472bc7d9d67461","type":"GO_TERM","name":"porphyrin-containing compound biosynthetic process","canonical_id":"go:GO:0006779","description":"\"The chemical reactions and pathways resulting in the formation of any member of a large group of derivatives or analogs of porphyrin. Porphyrin consists of a ring of four pyrrole nuclei linked each to the next at their alpha positions through a methine group.\" [GOC:jl, ISBN:0198506732, Wikipedia:Porphyrin#Natural_formation]","metadata":null},{"id":"92ac9a55313a45f6a722ad32afa4f326","type":"GO_TERM","name":"porphyrin-containing compound catabolic process","canonical_id":"go:GO:0006787","description":"\"The chemical reactions and pathways resulting in the breakdown of any member of a large group of derivatives or analogs of porphyrin. Porphyrin consists of a ring of four pyrrole nuclei linked each to the next at their alpha positions through a methine group.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f0593ddb17ca4a159ba32c7578408531","type":"GO_TERM","name":"porphyrin-containing compound metabolic process","canonical_id":"go:GO:0006778","description":"\"The chemical reactions and pathways involving any member of a large group of derivatives or analogs of porphyrin. Porphyrins consists of a ring of four pyrrole nuclei linked each to the next at their alpha positions through a methine group.\" [GOC:jl, ISBN:0198506732, Wikipedia:Porphyrin#Natural_formation]","metadata":null},{"id":"b2eb4ff3293f418989f995076e11a294","type":"DRUG","name":"posaconazole","canonical_id":"mesh:C101425","description":null,"metadata":null},{"id":"f9de3aecc5a64d10bee35f8541279cdf","type":"GO_TERM","name":"positive T cell selection","canonical_id":"go:GO:0043368","description":"\"The process of sparing immature T cells which react with self-MHC protein complexes with low affinity levels from apoptotic death.\" [ISBN:0781735149, PMID:12414722]","metadata":null},{"id":"b5d011e7ed194822ad2d62d1c85ff747","type":"GO_TERM","name":"positive adaptation of signaling pathway","canonical_id":"go:GO:0023059","description":"\"The positive regulation of a signal transduction pathway in response to a stimulus upon prolonged exposure to that stimulus.\" [GOC:mtg_signal]","metadata":null},{"id":"695c8a727bf344bba5ec403ebb617ff3","type":"GO_TERM","name":"positive aerotaxis","canonical_id":"go:GO:0052131","description":"\"The directed movement of a motile cell or organism towards a higher concentration of environmental oxygen.\" [GOC:dph, GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"ed1ff17900ef466780a71d989e307e54","type":"GO_TERM","name":"positive chemotaxis","canonical_id":"go:GO:0050918","description":"\"The directed movement of a motile cell or organism towards a higher concentration of a chemical.\" [GOC:ai, GOC:bf, GOC:isa_complete]","metadata":null},{"id":"30f3f3e103864b15b5bfc1f3789f8dcc","type":"GO_TERM","name":"positive energy taxis","canonical_id":"go:GO:0052128","description":"\"The directed movement of a motile cell or organism towards a higher level of a physical stimulus involved in energy generation, such as light, oxygen, and oxidizable substrates.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"a15148e14146456698041fb54eafe6bb","type":"GO_TERM","name":"positive extrathymic T cell selection","canonical_id":"go:GO:0045067","description":"\"The process of sparing extrathymically maturing T cells which react with self-MHC protein complexes with low affinity levels from apoptotic death.\" [ISBN:0781735149, PMID:7880383]","metadata":null},{"id":"20c130e003864ebdb3f5dc0e027c6269","type":"GO_TERM","name":"positive gravitaxis","canonical_id":"go:GO:0048061","description":"\"The directed movement of a motile cell or organism towards the source of gravity.\" [GOC:jid]","metadata":null},{"id":"4f52039ccb1749b782179dfffa9947b3","type":"GO_TERM","name":"positive gravitropism","canonical_id":"go:GO:0009958","description":"\"The orientation of plant parts towards gravity.\" [GOC:sm]","metadata":null},{"id":"8a9267bb4a6742f9a92dad5f4ca7ea76","type":"GO_TERM","name":"positive phototaxis","canonical_id":"go:GO:0046956","description":"\"The directed movement of a cell or organism towards a source of light.\" [GOC:ai]","metadata":null},{"id":"a4dc449c9d7b4d6f8ff90059dcbe20b3","type":"GO_TERM","name":"positive regulation by symbiont of entry into host","canonical_id":"go:GO:0075294","description":"\"Any process that activates or increases the frequency, rate or extent to which it enters into the host organism, where the two organisms are in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"1ef797b430e946aa88cc1748082a3a62","type":"GO_TERM","name":"positive regulation by virus of viral protein levels in host cell","canonical_id":"go:GO:0046726","description":"\"Any process where the infecting virus increases the levels of viral proteins in a cell.\" [GOC:ai]","metadata":null},{"id":"7b6ff1bebd4b428a9119f86a1ad73fcc","type":"GO_TERM","name":"positive regulation of 'de novo' NAD biosynthetic process from L-tryptophan","canonical_id":"go:GO:1905014","description":"\"Any process that activates or increases the frequency, rate or extent of 'de novo' NAD biosynthetic process from L-tryptophan.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"dd3579237dd6440880b548c66bb33456","type":"GO_TERM","name":"positive regulation of (+)-kotanin biosynthetic process","canonical_id":"go:GO:1900694","description":"\"Any process that activates or increases the frequency, rate or extent of (+)-kotanin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"17f84421ef4c47968772b3ddabe3e4ad","type":"GO_TERM","name":"positive regulation of (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0060635","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2aa22f04aefc459489d11d6611bd417e","type":"GO_TERM","name":"positive regulation of (R)-carnitine transmembrane transport","canonical_id":"go:GO:1902274","description":"\"Any process that activates or increases the frequency, rate or extent of (R)-carnitine transmembrane transport.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"826d9dee730e4475a909059c2548cab8","type":"GO_TERM","name":"positive regulation of (R)-mevalonic acid biosynthetic process","canonical_id":"go:GO:0106109","description":"\"Any process that activates or increases the frequency, rate or extent of (R)-mevalonic acid biosynthetic process.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:24296663]","metadata":null},{"id":"bf2e91264074467581f82213de76409a","type":"GO_TERM","name":"positive regulation of 1,2-propanediol catabolic process","canonical_id":"go:GO:0160161","description":"\"Any process that activates or increases the frequency, rate or extent of 1,2-propanediol catabolic process.\" [PMID:7559322, PMID:9023178]","metadata":null},{"id":"b13999b6d5a3422580cacedfa4316a14","type":"GO_TERM","name":"positive regulation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process","canonical_id":"go:GO:1902648","description":"\"Any process that activates or increases the frequency, rate or extent of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"28f5845002b444b29b7e099eeb6aee6b","type":"GO_TERM","name":"positive regulation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process","canonical_id":"go:GO:1902643","description":"\"Any process that activates or increases the frequency, rate or extent of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"d5274be5d7104f0096794b575f224039","type":"GO_TERM","name":"positive regulation of 3'-UTR-mediated mRNA stabilization","canonical_id":"go:GO:1905870","description":"\"Any process that activates or increases the frequency, rate or extent of 3'-UTR-mediated mRNA stabilization.\" [GO_REF:0000058, GOC:TermGenie, PMID:19737525]","metadata":null},{"id":"f0f15a7df7a44a9a8285eeb8360068e1","type":"GO_TERM","name":"positive regulation of 5-methylcytosine DNA demethylation, direct 5-methylcytosine excision pathway","canonical_id":"go:GO:0141170","description":"\"Any process that activates or increases the frequency, rate or extent of positive regulation of 5-methylcytosine DNA demethylation, direct 5-methylcytosine excision pathway.\" [PMID:36478523]","metadata":null},{"id":"dc1455f4c8f744b0b897797bff05b347","type":"GO_TERM","name":"positive regulation of 7-methylguanosine mRNA capping","canonical_id":"go:GO:0160199","description":"\"Any process that activates or increases the frequency, rate or extent of 7-methylguanosine mRNA capping.\" [PMID:19328067]","metadata":null},{"id":"d4d3f9ab01fb4b89a98fea30a2a08ced","type":"GO_TERM","name":"positive regulation of AIM2 inflammasome complex assembly","canonical_id":"go:GO:0140973","description":"\"Any process that activates or increases the frequency, rate or extent of AIM2 inflammasome complex assembly.\" [PMID:33467177]","metadata":null},{"id":"e4eaa3ca5a8844c2b51194b0200a5127","type":"GO_TERM","name":"positive regulation of AMPA glutamate receptor clustering","canonical_id":"go:GO:1904719","description":"\"Any process that activates or increases the frequency, rate or extent of AMPA glutamate receptor clustering.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:21558424]","metadata":null},{"id":"80f359fc92fb4decb002aa0ad58898b4","type":"GO_TERM","name":"positive regulation of AMPA receptor activity","canonical_id":"go:GO:2000969","description":"\"Any process that activates or increases the frequency, rate or extent of AMPA selective glutamate receptor activity.\" [PMID:21423165]","metadata":null},{"id":"89bf92d89b574fbe81e02f354f83e3d9","type":"GO_TERM","name":"positive regulation of ARF protein signal transduction","canonical_id":"go:GO:0032014","description":"\"Any process that activates or increases the frequency, rate or extent of ARF protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"980614ed43894477b884a0e2e163e9d1","type":"GO_TERM","name":"positive regulation of ATF6-mediated unfolded protein response","canonical_id":"go:GO:1903893","description":"\"Any process that activates or increases the frequency, rate or extent of the ATF6-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"2b37bf23240b441698a5b91bc29d5565","type":"GO_TERM","name":"positive regulation of ATP biosynthetic process","canonical_id":"go:GO:2001171","description":"\"Any process that activates or increases the frequency, rate or extent of ATP biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"5603ea7536fc4ec2b9b31e00dba610da","type":"GO_TERM","name":"positive regulation of ATP metabolic process","canonical_id":"go:GO:1903580","description":"\"Any process that activates or increases the frequency, rate or extent of ATP metabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:20695849]","metadata":null},{"id":"48995f3f94b842f2a93a97aa1fd0b884","type":"GO_TERM","name":"positive regulation of ATP-dependent activity","canonical_id":"go:GO:0032781","description":"\"Any process that activates or increases the rate of an ATP-dependent activity.\" [GOC:mah]","metadata":null},{"id":"f67714ed048a496bb1d0210ef5231fd0","type":"GO_TERM","name":"positive regulation of ATPase-coupled calcium transmembrane transporter activity","canonical_id":"go:GO:1901896","description":"\"Any process that activates or increases the frequency, rate or extent of an ATPase-coupled calcium transmembrane transporter activity.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671]","metadata":null},{"id":"c7d39822949745889c12162f2fb6cdb5","type":"GO_TERM","name":"positive regulation of AV node cell action potential","canonical_id":"go:GO:1903951","description":"\"Any process that activates or increases the frequency, rate or extent of AV node cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:25281747]","metadata":null},{"id":"2073a46a857d4e6dad57ff21ef3920a4","type":"GO_TERM","name":"positive regulation of Arp2/3 complex-mediated actin nucleation","canonical_id":"go:GO:2000601","description":"\"Any process that activates or increases the frequency, rate or extent of Arp2/3 complex-mediated actin nucleation.\" [PMID:21454476]","metadata":null},{"id":"3c16edf6d0204726808fb5e46d53e0a7","type":"GO_TERM","name":"positive regulation of Atg1/ULK1 kinase complex assembly","canonical_id":"go:GO:1905866","description":"\"Any process that activates or increases the frequency, rate or extent of Atg1/ULK1 kinase complex assembly.\" [GO_REF:0000058, GOC:autophagy, GOC:mf, GOC:TermGenie, PMID:26567215]","metadata":null},{"id":"0b9ea2826ba24dd8ae712d8109b12432","type":"GO_TERM","name":"positive regulation of B cell activation","canonical_id":"go:GO:0050871","description":"\"Any process that activates or increases the frequency, rate or extent of B cell activation.\" [GOC:ai]","metadata":null},{"id":"17905436dfdb46879516a5ab1c04a0e8","type":"GO_TERM","name":"positive regulation of B cell anergy","canonical_id":"go:GO:0002672","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell anergy.\" [GOC:add]","metadata":null},{"id":"ac716af47c8d4fca8cfc7d34c2c3aac3","type":"GO_TERM","name":"positive regulation of B cell antigen processing and presentation","canonical_id":"go:GO:0002624","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"c7b1cdbe4fbe4adc9a2817c5d7556d81","type":"GO_TERM","name":"positive regulation of B cell apoptotic process","canonical_id":"go:GO:0002904","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"0f59f790c98f433cb14809208c07713e","type":"GO_TERM","name":"positive regulation of B cell chemotaxis","canonical_id":"go:GO:2000538","description":"\"Any process that activates or increases the frequency, rate or extent of B cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"65f3318b591442c1a6cbd5b1392fbfb6","type":"GO_TERM","name":"positive regulation of B cell cytokine production","canonical_id":"go:GO:0002723","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell cytokine production.\" [GOC:add]","metadata":null},{"id":"277b89c57e544f23ae90a4b5fb210686","type":"GO_TERM","name":"positive regulation of B cell deletion","canonical_id":"go:GO:0002869","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell deletion.\" [GOC:add]","metadata":null},{"id":"e22eeaf86f55413fb98af6889b289991","type":"GO_TERM","name":"positive regulation of B cell differentiation","canonical_id":"go:GO:0045579","description":"\"Any process that activates or increases the frequency, rate or extent of B cell differentiation.\" [GOC:curators]","metadata":null},{"id":"7f27933c2a65475897daa46e169f360b","type":"GO_TERM","name":"positive regulation of B cell mediated immunity","canonical_id":"go:GO:0002714","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"840e83e5d1c14d528fbe1d8f9cc58b0e","type":"GO_TERM","name":"positive regulation of B cell proliferation","canonical_id":"go:GO:0030890","description":"\"Any process that activates or increases the rate or extent of B cell proliferation.\" [GOC:mah]","metadata":null},{"id":"b546c3f693c744bfa2c7977020abea3f","type":"GO_TERM","name":"positive regulation of B cell receptor signaling pathway","canonical_id":"go:GO:0050861","description":"\"Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell.\" [GOC:ai]","metadata":null},{"id":"6deb06531b94460da883e832885a37ed","type":"GO_TERM","name":"positive regulation of B cell tolerance induction","canonical_id":"go:GO:0002663","description":"\"Any process that activates or increases the frequency, rate, or extent of B cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"280cfab827e34a1f8e398b32d9f960be","type":"GO_TERM","name":"positive regulation of B-1 B cell differentiation","canonical_id":"go:GO:0001926","description":"\"Any process that activates or increases the frequency, rate or extent of B-1 B cell differentiation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1a9a9dab54d24c08be9161a0ace80784","type":"GO_TERM","name":"positive regulation of BMP secretion","canonical_id":"go:GO:1900144","description":"\"Any process that activates or increases the frequency, rate or extent of BMP secretion.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"4325e1c10233470295e85a310fc58071","type":"GO_TERM","name":"positive regulation of BMP signaling pathway","canonical_id":"go:GO:0030513","description":"\"Any process that activates or increases the frequency, rate or extent of BMP signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"0c95bbe7070949ada5549f433b21dee8","type":"GO_TERM","name":"positive regulation of C-C chemokine receptor CCR7 signaling pathway","canonical_id":"go:GO:1903082","description":"\"Any process that activates or increases the frequency, rate or extent of C-C chemokine receptor CCR7 signaling pathway.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11602640]","metadata":null},{"id":"8b95f5aa2b1d4f09952e4b1ca9862d7f","type":"GO_TERM","name":"positive regulation of CAMKK-AMPK signaling cascade","canonical_id":"go:GO:1905291","description":"\"Any process that activates or increases the frequency, rate or extent of CAMKK-AMPK signaling cascade.\" [GO_REF:0000058, GOC:TermGenie, PMID:22128786]","metadata":null},{"id":"f01c0a2db4584ae59eadd8a613eb419d","type":"GO_TERM","name":"positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation","canonical_id":"go:GO:0032831","description":"\"Any process that activates or increases the frequency, rate or extent of differentiation of CD4-positive, CD25-positive, alpha-beta regulatory T cells.\" [GOC:mah]","metadata":null},{"id":"7034a755551b45a9b7ac943cb5872f28","type":"GO_TERM","name":"positive regulation of CD4-positive, alpha-beta T cell activation","canonical_id":"go:GO:2000516","description":"\"Any process that activates or increases the frequency, rate or extent of CD4-positive, alpha-beta T cell activation.\" [GOC:obol]","metadata":null},{"id":"a08df7df9de1471f8ffbdfa825f76932","type":"GO_TERM","name":"positive regulation of CD4-positive, alpha-beta T cell costimulation","canonical_id":"go:GO:1900281","description":"\"Any process that activates or increases the frequency, rate or extent of CD4-positive, alpha-beta T cell costimulation.\" [GOC:BHF, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"5a71753e0a9b44919cb05534480b07e4","type":"GO_TERM","name":"positive regulation of CD4-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043372","description":"\"Any process that activates or increases the frequency, rate or extent of CD4-positive, alpha-beta T cell differentiation.\" [GOC:add, GOC:pr, ISBN:0781735149]","metadata":null},{"id":"7e13510cbd2540e0a07e6f8d409d740b","type":"GO_TERM","name":"positive regulation of CD4-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:2000563","description":"\"Any process that activates or increases the frequency, rate or extent of CD4-positive, alpha-beta T cell proliferation.\" [GOC:obol]","metadata":null},{"id":"b0abedb8238643f6a089aec5987b0f6e","type":"GO_TERM","name":"positive regulation of CD40 signaling pathway","canonical_id":"go:GO:2000350","description":"\"Any process that activates or increases the frequency, rate or extent of signaling via the CD40 signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"92bf8a4580424baabf1e433219f1a4e4","type":"GO_TERM","name":"positive regulation of CD8-positive, alpha-beta T cell activation","canonical_id":"go:GO:2001187","description":"\"Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell activation.\" [GOC:obol]","metadata":null},{"id":"0ad87bb77c184dcc8a01c0e577cbf440","type":"GO_TERM","name":"positive regulation of CD8-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043378","description":"\"Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell differentiation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7d99c662c2a14c98b1c04a500d033638","type":"GO_TERM","name":"positive regulation of CD8-positive, alpha-beta T cell extravasation","canonical_id":"go:GO:2000451","description":"\"Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell extravasation.\" [GOC:obol]","metadata":null},{"id":"9f98d7672a0945f7ba005a9bd84234e4","type":"GO_TERM","name":"positive regulation of CD8-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:2000566","description":"\"Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell proliferation.\" [GOC:obol]","metadata":null},{"id":"74e198f9c48543ebb44ea672c07d8109","type":"GO_TERM","name":"positive regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation","canonical_id":"go:GO:2000454","description":"\"Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta cytotoxic T cell extravasation.\" [GOC:obol]","metadata":null},{"id":"14c66ba79bdc4e03bb52710d9b998bb3","type":"GO_TERM","name":"positive regulation of D-aspartate import across plasma membrane","canonical_id":"go:GO:0140217","description":"\"Any process that activates or increases the frequency, rate or extent of the directed import of D-aspartate from the extracellular region across the plasma membrane and into the cytosol.\" [PMID:27663541]","metadata":null},{"id":"b62151078b2f4a6a943326a6efd3c72b","type":"GO_TERM","name":"positive regulation of D-glucose import across plasma membrane","canonical_id":"go:GO:0046326","description":"\"Any process that activates or increases the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"370da19d1be94b6f9e4f129011bce1b1","type":"GO_TERM","name":"positive regulation of D-glucose transmembrane transport","canonical_id":"go:GO:0010828","description":"\"Any process that increases the frequency, rate or extent of glucose transport across a membrane. Glucose transport is the directed movement of the hexose monosaccharide glucose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"02c58c261f724156914ae74e2a8666be","type":"GO_TERM","name":"positive regulation of DNA amplification","canonical_id":"go:GO:1904525","description":"\"Any process that activates or increases the frequency, rate or extent of DNA amplification.\" [GO_REF:0000058, GOC:TermGenie, PMID:26195783]","metadata":null},{"id":"2295428a5f574d46b315fdeadc9aceef","type":"GO_TERM","name":"positive regulation of DNA binding","canonical_id":"go:GO:0043388","description":"\"Any process that increases the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid).\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"4a65484981ac462fb6afbb72131b4e6f","type":"GO_TERM","name":"positive regulation of DNA biosynthetic process","canonical_id":"go:GO:2000573","description":"\"Any process that activates or increases the frequency, rate or extent of DNA biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"d34774e817a74917b80f5d61e97c38a5","type":"GO_TERM","name":"positive regulation of DNA catabolic process","canonical_id":"go:GO:1903626","description":"\"Any process that activates or increases the frequency, rate or extent of DNA catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:2001740]","metadata":null},{"id":"264255c47850475eb57aed3d6730ced0","type":"GO_TERM","name":"positive regulation of DNA damage checkpoint","canonical_id":"go:GO:2000003","description":"\"Any process that activates or increases the frequency, rate or extent of a DNA damage checkpoint.\" [GOC:obol]","metadata":null},{"id":"ef1c43c4ff604ec6a93e25a553821183","type":"GO_TERM","name":"positive regulation of DNA damage response, signal transduction by p53 class mediator","canonical_id":"go:GO:0043517","description":"\"Any process that activates, maintains or increases the rate of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.\" [GOC:jl]","metadata":null},{"id":"c32f378bd079417cbfd3030cc142f261","type":"GO_TERM","name":"positive regulation of DNA endoreduplication","canonical_id":"go:GO:0032877","description":"\"Any process that activates or increases the frequency, rate or extent of DNA endoreduplication.\" [GOC:mah]","metadata":null},{"id":"870cec956c534fb4a20253db0e034efe","type":"GO_TERM","name":"positive regulation of DNA metabolic process","canonical_id":"go:GO:0051054","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving DNA.\" [GOC:ai]","metadata":null},{"id":"1e9a1fd87e6845529828126d203f36f0","type":"GO_TERM","name":"positive regulation of DNA recombination","canonical_id":"go:GO:0045911","description":"\"Any process that activates or increases the frequency, rate or extent of DNA recombination.\" [GOC:curators]","metadata":null},{"id":"200fac0021164d4981ac201a25fc015c","type":"GO_TERM","name":"positive regulation of DNA recombination at centromere","canonical_id":"go:GO:0061807","description":"\"Any process that activates or increases the frequency, rate or extent of DNA recombination at the centromere.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"26e9a0676158461ca9df7626def074eb","type":"GO_TERM","name":"positive regulation of DNA recombination at telomere","canonical_id":"go:GO:0072696","description":"\"Any process that activates or increases the frequency, rate or extent of DNA recombination within the telomere.\" [GOC:mah]","metadata":null},{"id":"7f97c0b48a714e789c2ad642fcb74810","type":"GO_TERM","name":"positive regulation of DNA repair","canonical_id":"go:GO:0045739","description":"\"Any process that activates or increases the frequency, rate or extent of DNA repair.\" [GOC:curators]","metadata":null},{"id":"b884bacc97b146d996e4f5e8c3c22076","type":"GO_TERM","name":"positive regulation of DNA replication","canonical_id":"go:GO:0045740","description":"\"Any process that activates or increases the frequency, rate or extent of DNA replication.\" [GOC:curators]","metadata":null},{"id":"7ba83b6ab17141e7825b42327aadc0c4","type":"GO_TERM","name":"positive regulation of DNA replication initiation","canonical_id":"go:GO:1903468","description":"\"Any process that activates or increases the frequency, rate or extent of DNA replication initiation involved in mitotic DNA replication.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"3671c54a1da843af893298c79c70522e","type":"GO_TERM","name":"positive regulation of DNA strand elongation","canonical_id":"go:GO:0060383","description":"\"Any process that increases the rate, frequency or extent of DNA strand elongation. DNA strand elongation is the DNA metabolic process in which an existing DNA strand is extended by activities including the addition of nucleotides to the 3' end of the strand.\" [GOC:mah]","metadata":null},{"id":"9c9bdb3b3e2e43fa8e07c03e8c9cab16","type":"GO_TERM","name":"positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity","canonical_id":"go:GO:2000373","description":"\"Any process that activates or increases the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity.\" [GOC:mah]","metadata":null},{"id":"efa7e174674542b2a55c812bb8f3d713","type":"GO_TERM","name":"positive regulation of DNA-directed DNA polymerase activity","canonical_id":"go:GO:1900264","description":"\"Any process that activates or increases the frequency, rate or extent of DNA-directed DNA polymerase activity.\" [GOC:TermGenie]","metadata":null},{"id":"19fcb6b577aa4e57a596c0c455aec082","type":"GO_TERM","name":"positive regulation of DNA-templated DNA replication","canonical_id":"go:GO:2000105","description":"\"Any process that activates or increases the frequency, rate or extent of DNA-templated DNA replication.\" [GOC:mah]","metadata":null},{"id":"fccd179c6b0f481b8130b7040b91d583","type":"GO_TERM","name":"positive regulation of DNA-templated DNA replication initiation","canonical_id":"go:GO:0032298","description":"\"Any process that activates or increases the frequency, rate or extent of initiation of DNA-dependent DNA replication.\" [GOC:mah]","metadata":null},{"id":"58c84a6ace10426489a93eacb0b2348e","type":"GO_TERM","name":"positive regulation of DNA-templated transcription","canonical_id":"go:GO:0045893","description":"\"Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"c0de52a5dd164cad89e362b8c3ecc4fd","type":"GO_TERM","name":"positive regulation of DNA-templated transcription initiation","canonical_id":"go:GO:2000144","description":"\"Any process that activates or increases the frequency, rate or extent of DNA-templated transcription initiation.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"c2056159b17c4d53a9dcbaffc1a5f1f8","type":"GO_TERM","name":"positive regulation of DNA-templated transcription, elongation","canonical_id":"go:GO:0032786","description":"\"Any process that activates or increases the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides catalyzed by a DNA-dependent RNA polymerase.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"202ec2e1a14b431fa8894d78b9ba0492","type":"GO_TERM","name":"positive regulation of ER to Golgi vesicle-mediated transport","canonical_id":"go:GO:1902953","description":"\"Any process that activates or increases the frequency, rate or extent of ER to Golgi vesicle-mediated transport.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:17855360]","metadata":null},{"id":"ca014754d93c43879acf5881de63b98e","type":"GO_TERM","name":"positive regulation of ERAD pathway","canonical_id":"go:GO:1904294","description":"\"Any process that activates or increases the frequency, rate or extent of ERAD pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"9a1749e0298345db89ad80eaab07e395","type":"GO_TERM","name":"positive regulation of ERBB signaling pathway","canonical_id":"go:GO:1901186","description":"\"Any process that activates or increases the frequency, rate or extent of ERBB signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"027dfe7bee6344048e55a4849c4170e1","type":"GO_TERM","name":"positive regulation of ERBB3 signaling pathway","canonical_id":"go:GO:1905580","description":"\"Any process that activates or increases the frequency, rate or extent of ERBB3 signaling pathway.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:27353365]","metadata":null},{"id":"89cad0a023484342bd47e60dc18867eb","type":"GO_TERM","name":"positive regulation of ERK1 and ERK2 cascade","canonical_id":"go:GO:0070374","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.\" [GOC:mah]","metadata":null},{"id":"e929869d6e7645b494618d73d6c98a8c","type":"GO_TERM","name":"positive regulation of ERK5 cascade","canonical_id":"go:GO:0070378","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK5 cascade.\" [GOC:mah]","metadata":null},{"id":"2f2be5f327394d54bc864346698568a9","type":"GO_TERM","name":"positive regulation of F-9775A biosynthetic process","canonical_id":"go:GO:1900672","description":"\"Any process that activates or increases the frequency, rate or extent of F-9775A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"34ee05d6e22a47648f9b276e84185576","type":"GO_TERM","name":"positive regulation of F-9775B biosynthetic process","canonical_id":"go:GO:1900677","description":"\"Any process that activates or increases the frequency, rate or extent of F-9775B biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5f4ab9f23f304b7dbfc4bd7ca768c14d","type":"GO_TERM","name":"positive regulation of FACT complex assembly","canonical_id":"go:GO:1905646","description":"\"Any process that activates or increases the frequency, rate or extent of FACT complex assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"80c62f68208c4aa3a6a394456676d12e","type":"GO_TERM","name":"positive regulation of Fas signaling pathway","canonical_id":"go:GO:1902046","description":"\"Any process that activates or increases the frequency, rate or extent of Fas signaling pathway.\" [GOC:TermGenie, PMID:17245429]","metadata":null},{"id":"22d26e97e9864afdba4b1e49349dc2d8","type":"GO_TERM","name":"positive regulation of Fc receptor mediated stimulatory signaling pathway","canonical_id":"go:GO:0060369","description":"\"Any process that increases the rate, frequency or extent of the Fc receptor mediated stimulatory signaling pathway.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"fb76e8c8de704a5c873752488e083ed8","type":"GO_TERM","name":"positive regulation of Fc-gamma receptor signaling pathway involved in phagocytosis","canonical_id":"go:GO:1905451","description":"\"Any process that activates or increases the frequency, rate or extent of Fc-gamma receptor signaling pathway involved in phagocytosis.\" [GO_REF:0000058, GOC:TermGenie, PMID:18832707]","metadata":null},{"id":"907572ac9cf544afb7a4be55759c43ab","type":"GO_TERM","name":"positive regulation of Frizzled Nuclear Import pathway","canonical_id":"go:GO:0140711","description":"\"Any process that activates or increases the frequency, rate or extent of a Frizzled Nuclear Import pathway.\" [PMID:22510459, PMID:22579286]","metadata":null},{"id":"ac5f8158ad02496fba32fd9fdebc09fa","type":"GO_TERM","name":"positive regulation of FtsZ-dependent cytokinesis","canonical_id":"go:GO:2000246","description":"\"Any process that activates or increases the frequency, rate or extent of Ftsz-dependent cytokinesis.\" [GOC:mah]","metadata":null},{"id":"02a69f77112c4a9293f1eb8f45d70669","type":"GO_TERM","name":"positive regulation of G protein-coupled receptor internalization","canonical_id":"go:GO:1904022","description":"\"Any process that activates or increases the frequency, rate or extent of G protein-coupled receptor internalization.\" [GO_REF:0000058, GOC:TermGenie, PMID:24732013]","metadata":null},{"id":"d4c9724a4eb848f79c89b40d9b93efb4","type":"GO_TERM","name":"positive regulation of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0045745","description":"\"Any process that activates or increases the frequency, rate or extent of G protein-coupled receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"e0d5aad635644a29b9224321a09f0002","type":"GO_TERM","name":"positive regulation of G0 to G1 transition","canonical_id":"go:GO:0070318","description":"\"A cell cycle process that activates or increases the rate or extent of the transition from the G0 quiescent state to the G1 phase.\" [GOC:mah]","metadata":null},{"id":"e3714897c1e54903b804bc1fcce2a613","type":"GO_TERM","name":"positive regulation of G1 to G0 transition","canonical_id":"go:GO:1903452","description":"\"Any process that activates or increases the frequency, rate or extent of G1 to G0 transition.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:24088570]","metadata":null},{"id":"e8ea5cef037640148461a5d41cfb49ab","type":"GO_TERM","name":"positive regulation of G1/S transition of mitotic cell cycle","canonical_id":"go:GO:1900087","description":"\"Any signaling pathway that increases or activates a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"ff79a1f7059e4cbf957ba861c1845ac2","type":"GO_TERM","name":"positive regulation of G2/M transition of mitotic cell cycle","canonical_id":"go:GO:0010971","description":"\"Any signaling pathway that activates or increases the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the mitotic cell cycle.\" [GOC:dph, GOC:mtg_cell_cycle, GOC:tb]","metadata":null},{"id":"5e95f81f90c3422784d47829762eedc7","type":"GO_TERM","name":"positive regulation of G2/M transition of mitotic cell cycle involved in cellular response to nitrogen starvation","canonical_id":"go:GO:1905287","description":"\"Any positive regulation of G2/M transition of mitotic cell cycle that is involved in cellular response to nitrogen starvation.\" [GO_REF:0000060, GOC:TermGenie, PMID:26776736]","metadata":null},{"id":"09a023d64eed403693a5b514022c13c5","type":"GO_TERM","name":"positive regulation of G2/MI transition of meiotic cell cycle","canonical_id":"go:GO:0110032","description":"\"Any signaling pathway that activates or increases the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to MI phase of the meiotic cell cycle.\" [GOC:vw, PMID:25492408]","metadata":null},{"id":"2d26aee825dd4bc985a60c3f7754da82","type":"GO_TERM","name":"positive regulation of GABA catabolic process","canonical_id":"go:GO:1901717","description":"\"Any process that activates or increases the frequency, rate or extent of gamma-aminobutyric acid catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"45f75765e5fb422789591d54cd0ddb38","type":"GO_TERM","name":"positive regulation of GTP binding","canonical_id":"go:GO:1904426","description":"\"Any process that activates or increases the frequency, rate or extent of GTP binding.\" [GO_REF:0000059, GOC:TermGenie, PMID:19066305, PMID:21454546]","metadata":null},{"id":"dadcdc2bc9884e2eb261dc8d952f3677","type":"GO_TERM","name":"positive regulation of GTPase activity","canonical_id":"go:GO:0043547","description":"\"Any process that activates or increases the activity of a GTPase.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"d49ab3c12f7a40558fa02b7c594a1abc","type":"GO_TERM","name":"positive regulation of Golgi to plasma membrane protein transport","canonical_id":"go:GO:0042998","description":"\"Any process that activates or increases the frequency, rate or extent of the transport of proteins from the Golgi to the plasma membrane.\" [GOC:jl]","metadata":null},{"id":"2ff3d1aa3ed9436cbec2e80a222da835","type":"GO_TERM","name":"positive regulation of Golgi vesicle fusion to target membrane","canonical_id":"go:GO:0048215","description":"\"Any process that activates or increases the frequency, rate or extent of Golgi vesicle fusion to target membrane.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"8f0a08ba597a4a7bbe8998ee5f880ac7","type":"GO_TERM","name":"positive regulation of Hulle cell development","canonical_id":"go:GO:0070810","description":"\"Any process that activates or increases the frequency, rate or extent of Hulle cell development, a process that leads to the formation of Hulle cells. Hulle cells are specialized multinucleate cells that originate from a nest-like aggregation of hyphae during sexual development and serve as nurse cells to the developing cleistothecium, or fruiting body.\" [GOC:mah]","metadata":null},{"id":"8516f6c59efe491382d11653639f9469","type":"GO_TERM","name":"positive regulation of I-kappaB phosphorylation","canonical_id":"go:GO:1903721","description":"\"Any process that activates or increases the frequency, rate or extent of I-kappaB phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23675531]","metadata":null},{"id":"905f9fe092714af3bbbe654053e638fa","type":"GO_TERM","name":"positive regulation of IP-10 production","canonical_id":"go:GO:0071660","description":"\"Any process that activates or increases the frequency, rate, or extent of production of IP-10.\" [GOC:mah]","metadata":null},{"id":"0192a62da5234ae2a5e79c14d1c2469f","type":"GO_TERM","name":"positive regulation of IRE1-mediated unfolded protein response","canonical_id":"go:GO:1903896","description":"\"Any process that activates or increases the frequency, rate or extent of the IRE1-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"9eda975bcf75433e9723e43a3e35b819","type":"GO_TERM","name":"positive regulation of JNK cascade","canonical_id":"go:GO:0046330","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade.\" [GOC:bf]","metadata":null},{"id":"3173790f60be4006804fde378cb61bce","type":"GO_TERM","name":"positive regulation of JUN kinase activity","canonical_id":"go:GO:0043507","description":"\"Any process that activates or increases the frequency, rate or extent of JUN kinase activity.\" [GOC:jl]","metadata":null},{"id":"8ec7b063e4d9420d955f03658a1a7135","type":"GO_TERM","name":"positive regulation of Kit signaling pathway","canonical_id":"go:GO:1900236","description":"\"Any process that activates or increases the frequency, rate or extent of Kit signaling pathway.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"92e5f475e81a4f9483c360e22159c15d","type":"GO_TERM","name":"positive regulation of L-arginine import across plasma membrane","canonical_id":"go:GO:1905589","description":"\"Any process that activates or increases the frequency, rate or extent of L-arginine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:14718525]","metadata":null},{"id":"7c4c1445205446138817b13d72462035","type":"GO_TERM","name":"positive regulation of L-glutamate import across plasma membrane","canonical_id":"go:GO:0002038","description":"\"Any process that activates or increases the frequency, rate or extent of L-glutamate import into a cell.\" [GOC:TermGenie]","metadata":null},{"id":"70127a434cc34f0288e5e95afe5f76b9","type":"GO_TERM","name":"positive regulation of L-glutamine biosynthetic process","canonical_id":"go:GO:0062134","description":"\"Any process that starts, increases the frequency, rate or extent of L-glutamine biosynthesis.\" [GOC:ha, PMID:19755423]","metadata":null},{"id":"2c0fe2916b84488888d96ace1bab687e","type":"GO_TERM","name":"positive regulation of L-glutamine import across plasma membrane","canonical_id":"go:GO:1901036","description":"\"Any process that activates or increases the frequency, rate or extent of L-glutamine import into cell.\" [GOC:TermGenie]","metadata":null},{"id":"652371a2bb0c42f7bfebc96d3403f0b4","type":"GO_TERM","name":"positive regulation of L-leucine biosynthetic process","canonical_id":"go:GO:2001278","description":"\"Any process that activates or increases the frequency, rate or extent of L-leucine biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"4bd758be98da4cfe8ede5fa557e060ab","type":"GO_TERM","name":"positive regulation of L-leucine import across plasma membrane","canonical_id":"go:GO:1905534","description":"\"Any process that activates or increases the frequency, rate or extent of L-leucine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:10467003]","metadata":null},{"id":"33033099872f44918f20442ff1b17ec3","type":"GO_TERM","name":"positive regulation of L-lysine import across plasma membrane","canonical_id":"go:GO:1905010","description":"\"Any process that activates or increases the frequency, rate or extent of L-lysine import into cell.\" [GO_REF:0000058, GOC:TermGenie, PMID:7499219]","metadata":null},{"id":"b3e6d46285594b2da9b96ccc90bf8dec","type":"GO_TERM","name":"positive regulation of L-methionine import across plasma membrane","canonical_id":"go:GO:1905626","description":"\"Any process that activates or increases the frequency, rate or extent of L-methionine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:17556368]","metadata":null},{"id":"5cff711c7c7b4b278548ea8a3a3179d7","type":"GO_TERM","name":"positive regulation of L-proline catabolic process","canonical_id":"go:GO:2001158","description":"\"Any process that activates or increases the frequency, rate or extent of L-proline catabolic process.\" [GOC:obol]","metadata":null},{"id":"d25b73c30a3d4157afd1cee9b3c3aedc","type":"GO_TERM","name":"positive regulation of L-proline import across plasma membrane","canonical_id":"go:GO:1905737","description":"\"Any process that activates or increases the frequency, rate or extent of L-proline import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"894c850add1e44139b072e8cd932bacc","type":"GO_TERM","name":"positive regulation of L-threonine import across plasma membrane","canonical_id":"go:GO:1900928","description":"\"Any process that activates or increases the frequency, rate or extent of L-threonine import into cell.\" [GOC:TermGenie]","metadata":null},{"id":"67b178cd28ea4be6841aa75066fb7840","type":"GO_TERM","name":"positive regulation of L-tyrosine import across plasma membrane","canonical_id":"go:GO:1900931","description":"\"Any process that activates or increases the frequency, rate or extent of L-tyrosine import into the cell.\" [GOC:TermGenie]","metadata":null},{"id":"c0857039c2514163945749039ab86579","type":"GO_TERM","name":"positive regulation of Lewy body formation","canonical_id":"go:GO:0140124","description":"\"Any process that activates or increases the frequency, rate or extent of Lewy body formation.\" [GOC:sl]","metadata":null},{"id":"143df071058e4b5793fde3cb914e86fb","type":"GO_TERM","name":"positive regulation of MAP kinase activity","canonical_id":"go:GO:0043406","description":"\"Any process that activates or increases the frequency, rate or extent of MAP kinase activity.\" [GOC:curators, GOC:dph]","metadata":null},{"id":"092482c43caf4fe3b39eeb00e867e40f","type":"GO_TERM","name":"positive regulation of MAPK cascade","canonical_id":"go:GO:0043410","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.\" [GOC:curators]","metadata":null},{"id":"4b35eddd9ae34783ac13dd9677d46538","type":"GO_TERM","name":"positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0090080","description":"\"The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands resulting in an increase in the rate or frequency of a MAPKKK cascade.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2285f77650384edeb26299e8dedd426f","type":"GO_TERM","name":"positive regulation of MDA-5 signaling pathway","canonical_id":"go:GO:1900245","description":"\"Any process that activates or increases the frequency, rate or extent of MDA-5 signaling pathway.\" [GOC:TermGenie]","metadata":null},{"id":"a8694cb23b2a4433afdff037270f90b0","type":"GO_TERM","name":"positive regulation of MHC class I biosynthetic process","canonical_id":"go:GO:0045345","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class I.\" [GOC:curators]","metadata":null},{"id":"40a9b136dc6440c89bce135528b61f88","type":"GO_TERM","name":"positive regulation of MHC class II biosynthetic process","canonical_id":"go:GO:0045348","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class II.\" [GOC:curators]","metadata":null},{"id":"90e0d5251ca9487282eb9a7388e1010c","type":"GO_TERM","name":"positive regulation of MyD88-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0034126","description":"\"Any process that activates or increases the frequency, rate, or extent of MyD88-dependent toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"58c963699ae94526ae46c12ea317c7ab","type":"GO_TERM","name":"positive regulation of MyD88-independent toll-like receptor signaling pathway","canonical_id":"go:GO:0034129","description":"\"Any process that activates or increases the frequency, rate, or extent of MyD88-independent toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"b4b782ca6dcc472d929ab3064587eb2c","type":"GO_TERM","name":"positive regulation of N',N'',N'''-triacetylfusarinine C biosynthetic process","canonical_id":"go:GO:1900697","description":"\"Any process that activates or increases the frequency, rate or extent of N',N'',N'''-triacetylfusarinine C biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e55b3f6311d14df8959c7ce4bd0999fe","type":"GO_TERM","name":"positive regulation of N-acetylmuramic acid catabolic process","canonical_id":"go:GO:0160159","description":"\"Any process that activates or increases the frequency, rate or extent of N-acetylmuramic acid catabolic process.\" [PMID:18723630]","metadata":null},{"id":"d0de9aa3be5d4f4482d03c8e6047cac2","type":"GO_TERM","name":"positive regulation of N-terminal peptidyl-lysine acetylation","canonical_id":"go:GO:2000761","description":"\"Any process that activates or increases the frequency, rate or extent of N-terminal peptidyl-lysine acetylation.\" [GOC:obol]","metadata":null},{"id":"276634f5ef7f4227a82d8fff071002ac","type":"GO_TERM","name":"positive regulation of N-terminal peptidyl-methionine acetylation","canonical_id":"go:GO:1904665","description":"\"Any process that activates or increases the frequency, rate or extent of N-terminal peptidyl-methionine acetylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:20807799]","metadata":null},{"id":"61ce95387caf4c27b156bce78072ad70","type":"GO_TERM","name":"positive regulation of NAD metabolic process","canonical_id":"go:GO:1902690","description":"\"Any process that activates or increases the frequency, rate or extent of NAD metabolic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:19846558]","metadata":null},{"id":"a1180873d0604219817b0286a6076d90","type":"GO_TERM","name":"positive regulation of NAD(P)H oxidase activity","canonical_id":"go:GO:0033864","description":"\"Any process that activates or increases the activity of the enzyme NAD(P)H oxidase.\" [GOC:mah]","metadata":null},{"id":"f25b743be4de46f69d67033a2d2d4028","type":"GO_TERM","name":"positive regulation of NK T cell activation","canonical_id":"go:GO:0051135","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer T cell activation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"fbd33c5ec9c54dfa9e60eccd07d77477","type":"GO_TERM","name":"positive regulation of NK T cell differentiation","canonical_id":"go:GO:0051138","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer T cell differentiation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"d225f174f244465987693219cd6f5b29","type":"GO_TERM","name":"positive regulation of NK T cell proliferation","canonical_id":"go:GO:0051142","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer T cell proliferation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"37e92b1f42954b15a410ff78fdc751b7","type":"GO_TERM","name":"positive regulation of NLRP3 inflammasome complex assembly","canonical_id":"go:GO:1900227","description":"\"Any process that activates or increases the frequency, rate or extent of NLRP3 inflammasome complex assembly.\" [GOC:TermGenie]","metadata":null},{"id":"6dfe11a70536457f87032324da5af467","type":"GO_TERM","name":"positive regulation of Notch signaling pathway","canonical_id":"go:GO:0045747","description":"\"Any process that activates or increases the frequency, rate or extent of the Notch signaling pathway.\" [GOC:curators]","metadata":null},{"id":"c47cab58c64b4667a2ed044098e73323","type":"GO_TERM","name":"positive regulation of P-type sodium:potassium-exchanging transporter activity","canonical_id":"go:GO:1903408","description":"\"Any process that activates or increases the frequency, rate or extent of sodium:potassium-exchanging ATPase activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:8160880]","metadata":null},{"id":"ef531fef27884ac794af346ac92cc865","type":"GO_TERM","name":"positive regulation of PERK-mediated unfolded protein response","canonical_id":"go:GO:1903899","description":"\"Any process that activates or increases the frequency, rate or extent of the PERK-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"b1640207ba6d48e2892aea43d9af217d","type":"GO_TERM","name":"positive regulation of R7 cell differentiation","canonical_id":"go:GO:0045678","description":"\"Any process that activates or increases the frequency, rate or extent of R7 cell differentiation.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"bf5d6d57f59043f4b36b57c370aaeb5e","type":"GO_TERM","name":"positive regulation of R7 cell fate commitment","canonical_id":"go:GO:0106397","description":"\"Any process that activates or increases the frequency, rate or extent of R7 cell fate commitment.\" [GOC:ha, PMID:22878552]","metadata":null},{"id":"c862b40f07b643efabcc4d7d21cf293c","type":"GO_TERM","name":"positive regulation of R8 cell differentiation","canonical_id":"go:GO:0045681","description":"\"Any process that activates or increases the frequency, rate or extent of R8 cell differentiation.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"4194a41c813e469d943d969adf3757af","type":"GO_TERM","name":"positive regulation of R8 cell spacing in compound eye","canonical_id":"go:GO:0045748","description":"\"Any process that activates or enforces the correct R8 cell spacing in a compound eye.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"7b9bc213fcdc48d896d28a54c9ce1a4f","type":"GO_TERM","name":"positive regulation of RIG-I signaling pathway","canonical_id":"go:GO:1900246","description":"\"Any process that activates or increases the frequency, rate or extent of RIG-I signaling pathway.\" [GOC:TermGenie]","metadata":null},{"id":"419a5e8333ad41a1a5532e998b154664","type":"GO_TERM","name":"positive regulation of RNA binding","canonical_id":"go:GO:1905216","description":"\"Any process that activates or increases the frequency, rate or extent of RNA binding.\" [GO_REF:0000059, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:25116364]","metadata":null},{"id":"bad7b7cec7f047a1b28e1840f4bb853d","type":"GO_TERM","name":"positive regulation of RNA biosynthetic process","canonical_id":"go:GO:1902680","description":"\"Any process that activates or increases the frequency, rate or extent of RNA biosynthetic process.\" [GO:jl, GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"11bb97ee76c14093b64212946763319d","type":"GO_TERM","name":"positive regulation of RNA export from nucleus","canonical_id":"go:GO:0046833","description":"\"Any process that activates or increases the frequency, rate or extent of directed movement of RNA from the nucleus into the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"ef53242df2f3471f83eb8356add81225","type":"GO_TERM","name":"positive regulation of RNA import into nucleus","canonical_id":"go:GO:0046830","description":"\"Any process that activates or increases the frequency, rate or extent of movement of RNA from the cytoplasm into the nucleus.\" [GOC:bf]","metadata":null},{"id":"b56a52710d304b7c97499e622dcf81ef","type":"GO_TERM","name":"positive regulation of RNA metabolic process","canonical_id":"go:GO:0051254","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving RNA.\" [GOC:ai]","metadata":null},{"id":"bdd015ba03be401bb350a88b1afb4028","type":"GO_TERM","name":"positive regulation of RNA polymerase II transcription preinitiation complex assembly","canonical_id":"go:GO:0045899","description":"\"Any process that activates or increases the frequency, rate or extent of RNA polymerase II transcriptional preinitiation complex assembly.\" [GOC:curators]","metadata":null},{"id":"4d27e1f02d6c467180de3d317a9e3ace","type":"GO_TERM","name":"positive regulation of RNA splicing","canonical_id":"go:GO:0033120","description":"\"Any process that activates or increases the frequency, rate or extent of RNA splicing.\" [GOC:mah]","metadata":null},{"id":"52ca708dc6784f529d1e4e8ef28a001f","type":"GO_TERM","name":"positive regulation of Rac protein signal transduction","canonical_id":"go:GO:0035022","description":"\"Any process that activates or increases the frequency, rate or extent of Rac protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"abc6fca3f9bb43d0b93063e09b30de42","type":"GO_TERM","name":"positive regulation of Ras protein signal transduction","canonical_id":"go:GO:0046579","description":"\"Any process that activates or increases the frequency, rate or extent of Ras protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"e41b84f0ffd94bf889c6d926725f135d","type":"GO_TERM","name":"positive regulation of Rho protein signal transduction","canonical_id":"go:GO:0035025","description":"\"Any process that activates or increases the frequency, rate or extent of Rho protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"1167f5e3f29740919f9e2b8893ed1f5a","type":"GO_TERM","name":"positive regulation of Roundabout signaling pathway","canonical_id":"go:GO:0035388","description":"\"Any process that activates or increases the frequency, rate or extent of the Roundabout signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"836ec96b44a94767bdb60a30d6a0b0c1","type":"GO_TERM","name":"positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process","canonical_id":"go:GO:0062027","description":"\"Any process that starts or increases the rate, frequency or extent of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process, the chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by an SCF (Skp1/Cul1/F-box protein) complex, and mediated by the proteasome.\" [PMID:28007894]","metadata":null},{"id":"c39ad226bcbe46039bc00b4dec157a06","type":"GO_TERM","name":"positive regulation of SMAD protein signal transduction","canonical_id":"go:GO:0060391","description":"\"Any process that increases the rate, frequency or extent of SMAD protein signal transduction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"6b4aeae47453403e81081e8fcfff0a91","type":"GO_TERM","name":"positive regulation of SNARE complex assembly","canonical_id":"go:GO:0035543","description":"\"Any process that increases the frequency, rate or extent of assembly of the SNARE complex. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb]","metadata":null},{"id":"5bc72af5e8d144449c4dda64d09a08c4","type":"GO_TERM","name":"positive regulation of SNARE complex disassembly","canonical_id":"go:GO:0035540","description":"\"Any process that increases the frequency, rate or extent of disassembly of the SNARE complex. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb]","metadata":null},{"id":"0c0eddbbc84844c4b3ea57e515c5bf12","type":"GO_TERM","name":"positive regulation of SREBP signaling pathway","canonical_id":"go:GO:2000640","description":"\"Any process that activates or increases the frequency, rate or extent of the SREBP signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"b936e5385e38430d948744dd7cb01c82","type":"GO_TERM","name":"positive regulation of SREBP signaling pathway in response to decreased oxygen levels","canonical_id":"go:GO:0038176","description":"\"Any process that activates or increases the frequency, rate or extent of the SREBP signaling pathway in response to a decrease in oxygen levels.\" [GOC:al, PMID:22017871]","metadata":null},{"id":"fc676e622b52407cb337b7891905cea3","type":"GO_TERM","name":"positive regulation of Schwann cell chemotaxis","canonical_id":"go:GO:1904268","description":"\"Any process that activates or increases the frequency, rate or extent of Schwann cell chemotaxis.\" [GO_REF:0000058, GOC:TermGenie, PMID:16203995]","metadata":null},{"id":"ada1820e4b654c2b8a6ff8d9bab10d77","type":"GO_TERM","name":"positive regulation of Schwann cell differentiation","canonical_id":"go:GO:0014040","description":"\"Any process that activates or increases the frequency, rate or extent of Schwann cell differentiation.\" [GOC:ef]","metadata":null},{"id":"46d598e59d3a4b68808f99ef5be06b26","type":"GO_TERM","name":"positive regulation of Schwann cell migration","canonical_id":"go:GO:1900149","description":"\"Any process that activates or increases the frequency, rate or extent of Schwann cell migration.\" [GOC:sjw, GOC:TermGenie]","metadata":null},{"id":"7a2c49bfd49b449481851a8aa2c11fa6","type":"GO_TERM","name":"positive regulation of Schwann cell proliferation","canonical_id":"go:GO:0010625","description":"\"Any process that increases the frequency or rate of the multiplication or reproduction of Schwann cells, resulting in the expansion of their population. Schwann cells are a type of glial cell in the peripheral nervous system.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"e4261603fe544977aa64ae988722206f","type":"GO_TERM","name":"positive regulation of T cell activation","canonical_id":"go:GO:0050870","description":"\"Any process that activates or increases the frequency, rate or extent of T cell activation.\" [GOC:ai]","metadata":null},{"id":"1d9c6f3d04364eada406a0cfab0a3b0c","type":"GO_TERM","name":"positive regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell","canonical_id":"go:GO:2001190","description":"\"Any process that activates or increases the frequency, rate or extent of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell.\" [GOC:obol]","metadata":null},{"id":"3ca02b520a7a436fa6ea196aeeff0dbe","type":"GO_TERM","name":"positive regulation of T cell anergy","canonical_id":"go:GO:0002669","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell anergy.\" [GOC:add]","metadata":null},{"id":"f2c846fa91534ef79d5600d175000c12","type":"GO_TERM","name":"positive regulation of T cell antigen processing and presentation","canonical_id":"go:GO:0002627","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"ca0e4bd89d5f48a384bc4c31620b5653","type":"GO_TERM","name":"positive regulation of T cell apoptotic process","canonical_id":"go:GO:0070234","description":"\"Any process that activates or increases the frequency, rate or extent of T cell death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"ac4b88dd6f964e4a850334ec5bb7d670","type":"GO_TERM","name":"positive regulation of T cell chemotaxis","canonical_id":"go:GO:0010820","description":"\"Any process that increases the rate, frequency or extent of T cell chemotaxis. T cell chemotaxis is the directed movement of a T cell in response to an external stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"154287faf4b04c819cfd77eca0a08d67","type":"GO_TERM","name":"positive regulation of T cell costimulation","canonical_id":"go:GO:2000525","description":"\"Any process that activates or increases the frequency, rate or extent of T cell costimulation.\" [GOC:obol]","metadata":null},{"id":"1e7ed932af564f5089ea63ee9a4d8848","type":"GO_TERM","name":"positive regulation of T cell cytokine production","canonical_id":"go:GO:0002726","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell cytokine production.\" [GOC:add]","metadata":null},{"id":"19f4d53ef17f468cb059df60ef113976","type":"GO_TERM","name":"positive regulation of T cell differentiation","canonical_id":"go:GO:0045582","description":"\"Any process that activates or increases the frequency, rate or extent of T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"543fe52105cb43a6a113896546894a5e","type":"GO_TERM","name":"positive regulation of T cell differentiation in thymus","canonical_id":"go:GO:0033089","description":"\"Any process that activates or increases the frequency, rate or extent of T cell differentiation in the thymus.\" [GOC:add, GOC:mah]","metadata":null},{"id":"08a39ec114c44d41896c1b5b6d0f9a21","type":"GO_TERM","name":"positive regulation of T cell extravasation","canonical_id":"go:GO:2000409","description":"\"Any process that activates or increases the frequency, rate or extent of T cell extravasation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"6fa827248a3842d5896164507565167b","type":"GO_TERM","name":"positive regulation of T cell homeostatic proliferation","canonical_id":"go:GO:0042103","description":"\"Any process that activates or increases the rate or extent of resting T cell proliferation.\" [GOC:jl]","metadata":null},{"id":"ec666a0f2d6a48c78fb177a05cb83c98","type":"GO_TERM","name":"positive regulation of T cell mediated cytotoxicity","canonical_id":"go:GO:0001916","description":"\"Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"8fae715f03604522a7cb490bd763f7f6","type":"GO_TERM","name":"positive regulation of T cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002854","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell mediated cytotoxicity directed against a tumor cell target.\" [GOC:add]","metadata":null},{"id":"9c75098ff656412a8e622ba49c93ae74","type":"GO_TERM","name":"positive regulation of T cell mediated immune response to tumor cell","canonical_id":"go:GO:0002842","description":"\"Any process that activates or increases the frequency, rate, or extent of a T cell mediated immune response to tumor cell.\" [GOC:add]","metadata":null},{"id":"6b432a4be2244ffda6c475ac4c85b02a","type":"GO_TERM","name":"positive regulation of T cell mediated immunity","canonical_id":"go:GO:0002711","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"e24059e808a64b03bf7779fc3576cf68","type":"GO_TERM","name":"positive regulation of T cell migration","canonical_id":"go:GO:2000406","description":"\"Any process that activates or increases the frequency, rate or extent of T cell migration.\" [GOC:mah]","metadata":null},{"id":"058ff33a664843b4a02459dd5e340fd0","type":"GO_TERM","name":"positive regulation of T cell proliferation","canonical_id":"go:GO:0042102","description":"\"Any process that activates or increases the rate or extent of T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"88112be4487349a1b4a604b5f329fdb9","type":"GO_TERM","name":"positive regulation of T cell receptor signaling pathway","canonical_id":"go:GO:0050862","description":"\"Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.\" [GOC:ai]","metadata":null},{"id":"17adcf0f2379404698d5988625a29351","type":"GO_TERM","name":"positive regulation of T cell tolerance induction","canonical_id":"go:GO:0002666","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"ebcce18ede2842358af9875ae71775d9","type":"GO_TERM","name":"positive regulation of T cell tolerance induction to tumor cell","canonical_id":"go:GO:0002848","description":"\"Any process that activates or increases the frequency, rate, or extent of T cell tolerance induction to tumor cell.\" [GOC:add]","metadata":null},{"id":"12fa3643abfc4a6bb05b2cf411eff570","type":"GO_TERM","name":"positive regulation of T-helper 1 cell activation","canonical_id":"go:GO:2000519","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 1 cell activation.\" [GOC:obol]","metadata":null},{"id":"58126e4f96b04491ba36f3eb67ec8aa6","type":"GO_TERM","name":"positive regulation of T-helper 1 cell cytokine production","canonical_id":"go:GO:2000556","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 1 cell cytokine production.\" [GOC:obol]","metadata":null},{"id":"9eac2d3a449d4fcbacfcf1b2d2ebeb8c","type":"GO_TERM","name":"positive regulation of T-helper 1 cell differentiation","canonical_id":"go:GO:0045627","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 1 cell differentiation.\" [GOC:curators]","metadata":null},{"id":"bcbe3e57dc8f437289f6e4cc966505e9","type":"GO_TERM","name":"positive regulation of T-helper 1 type immune response","canonical_id":"go:GO:0002827","description":"\"Any process that activates or increases the frequency, rate, or extent of a T-helper 1 type immune response.\" [GOC:add]","metadata":null},{"id":"58bacb8991644b0282224275d6a7299d","type":"GO_TERM","name":"positive regulation of T-helper 17 cell differentiation","canonical_id":"go:GO:2000321","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 17 cell differentiation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a334bc4a9cc645a78dac0cd1875643df","type":"GO_TERM","name":"positive regulation of T-helper 17 cell extravasation","canonical_id":"go:GO:2000457","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 17 cell extravasation.\" [GOC:obol]","metadata":null},{"id":"ab7f14dd690846c0844218324d94e0e6","type":"GO_TERM","name":"positive regulation of T-helper 17 cell lineage commitment","canonical_id":"go:GO:2000330","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 17 cell lineage commitment.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b3c2b888a3034ff6850c6dd5418e3e3a","type":"GO_TERM","name":"positive regulation of T-helper 17 type immune response","canonical_id":"go:GO:2000318","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 17 type immune response.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"557a89fcb0af428eb0bac06121efade5","type":"GO_TERM","name":"positive regulation of T-helper 2 cell activation","canonical_id":"go:GO:2000570","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 2 cell activation.\" [GOC:obol]","metadata":null},{"id":"3b46d1b6e08b445cae574f5bd39431a2","type":"GO_TERM","name":"positive regulation of T-helper 2 cell cytokine production","canonical_id":"go:GO:2000553","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 2 cell cytokine production.\" [GOC:obol]","metadata":null},{"id":"e41bf8588e5c404187a195a2e9f718cd","type":"GO_TERM","name":"positive regulation of T-helper 2 cell differentiation","canonical_id":"go:GO:0045630","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper 2 cell differentiation.\" [GOC:curators]","metadata":null},{"id":"d45868a364274408b34963c65d77eed1","type":"GO_TERM","name":"positive regulation of T-helper cell differentiation","canonical_id":"go:GO:0045624","description":"\"Any process that activates or increases the frequency, rate or extent of T-helper cell differentiation.\" [GOC:curators]","metadata":null},{"id":"94690de46d614589ad8f398b2c26e3dd","type":"GO_TERM","name":"positive regulation of TOR signaling","canonical_id":"go:GO:0032008","description":"\"Any process that activates or increases the frequency, rate or extent of TOR signaling.\" [GOC:mah]","metadata":null},{"id":"cee0664b64614e6db6899c024d81e2f6","type":"GO_TERM","name":"positive regulation of TORC1 signaling","canonical_id":"go:GO:1904263","description":"\"Any process that activates or increases the frequency, rate or extent of TORC1 signaling.\" [GO_REF:0000058, GOC:TermGenie, PMID:25366275]","metadata":null},{"id":"75249bbac1634a25ab1b8592d62acc35","type":"GO_TERM","name":"positive regulation of TORC2 signaling","canonical_id":"go:GO:1904515","description":"\"Any process that activates or increases the frequency, rate or extent of TORC2 signaling.\" [GO_REF:0000058, GOC:TermGenie, PMID:25590601]","metadata":null},{"id":"023826c8b8524c5d916bd8e86a360e64","type":"GO_TERM","name":"positive regulation of TRAIL production","canonical_id":"go:GO:0032759","description":"\"Any process that activates or increases the frequency, rate, or extent of TRAIL production.\" [GOC:mah]","metadata":null},{"id":"879665c9c6c94d089ae40fae7072d671","type":"GO_TERM","name":"positive regulation of TRAIL-activated apoptotic signaling pathway","canonical_id":"go:GO:1903984","description":"\"Any process that activates or increases the frequency, rate or extent of TRAIL-activated apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24939851]","metadata":null},{"id":"caecd8b593b44d1cbd0e168411bbda80","type":"GO_TERM","name":"positive regulation of Toll receptor ligand protein activation cascade","canonical_id":"go:GO:0160034","description":"\"Any process that activates or increases the frequency, rate or extent of Toll receptor ligand protein activation cascade.\" [PMID:23632253]","metadata":null},{"id":"4d16f044f4e94413b1dfc28cf51e7a5b","type":"GO_TERM","name":"positive regulation of Toll signaling pathway","canonical_id":"go:GO:0045752","description":"\"Any process that activates or increases the frequency, rate or extent of the Tl signaling pathway.\" [GOC:curators]","metadata":null},{"id":"b94761433bb043c69ff4ac42f955b995","type":"GO_TERM","name":"positive regulation of UDP-N-acetylglucosamine biosynthetic process","canonical_id":"go:GO:0106280","description":"\"Any process that activates or increases the frequency, rate or extent of the UDP-N-acetylglucosamine biosynthetic process.\" [PMID:32579556]","metadata":null},{"id":"be34b8be37da4639aac556f89b9786c6","type":"GO_TERM","name":"positive regulation of VCP-NPL4-UFD1 AAA ATPase complex assembly","canonical_id":"go:GO:1904241","description":"\"Any process that activates or increases the frequency, rate or extent of VCP-NPL4-UFD1 AAA ATPase complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"6f2d96b2a3874f66a5a98af219729f53","type":"GO_TERM","name":"positive regulation of Wnt protein secretion","canonical_id":"go:GO:0061357","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled release of a Wnt protein from a cell.\" [GOC:bf, PMID:19223472]","metadata":null},{"id":"0115461528c6459ba8f9f7726d0e2b9a","type":"GO_TERM","name":"positive regulation of Wnt signaling pathway","canonical_id":"go:GO:0030177","description":"\"Any process that activates or increases the frequency, rate or extent of Wnt signal transduction.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"44e9af1f4c47412cbeda5992d67fccb8","type":"GO_TERM","name":"positive regulation of Wnt signaling pathway, calcium modulating pathway","canonical_id":"go:GO:0045813","description":"\"Any process that activates or increases the frequency, rate or extent of the series of molecular signals initiated by binding of a Wnt protein to a receptor on the surface of the target cell where activated receptors leads to an increase in intracellular calcium and activation of protein kinase C (PKC).\" [GOC:curators]","metadata":null},{"id":"e93adf10de434ec48f3c314407c534eb","type":"GO_TERM","name":"positive regulation of Wnt signaling pathway, planar cell polarity pathway","canonical_id":"go:GO:2000096","description":"\"Any process that activates or increases the frequency, rate or extent of Wnt signaling pathway, planar cell polarity pathway.\" [GOC:BHF]","metadata":null},{"id":"d0280c91a78548779d217a0a354aeeab","type":"GO_TERM","name":"positive regulation of Wnt-Frizzled-LRP5/6 complex assembly","canonical_id":"go:GO:1904712","description":"\"Any process that activates or increases the frequency, rate or extent of Wnt-Frizzled-LRP5/6 complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"578c552064f849a0b8b2affd9dd6949a","type":"GO_TERM","name":"positive regulation of [2Fe-2S] cluster assembly","canonical_id":"go:GO:1900489","description":"\"Any process that activates or increases the frequency, rate or extent of [2Fe-2S] cluster assembly.\" [GOC:mengo_curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"0f275d163aef4293b169c01e15e07053","type":"GO_TERM","name":"positive regulation of [4Fe-4S] cluster assembly","canonical_id":"go:GO:1900493","description":"\"Any process that activates or increases the frequency, rate or extent of [4Fe-4S] cluster assembly.\" [GOC:mengo_curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"deadee1048d841c9a1729e6fd2d82cc1","type":"GO_TERM","name":"positive regulation of abscisic acid biosynthetic process","canonical_id":"go:GO:0010116","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of abscisic acid.\" [GOC:sm]","metadata":null},{"id":"328fdde4471a4f79b8ad5acf9a2b6aa0","type":"GO_TERM","name":"positive regulation of abscisic acid-activated signaling pathway","canonical_id":"go:GO:0009789","description":"\"Any process that activates or increases the frequency, rate or extent of abscisic acid (ABA) signaling.\" [GOC:lr]","metadata":null},{"id":"113b4a0d445c4a74bd90bfe5af44ff0c","type":"GO_TERM","name":"positive regulation of acetate catabolic process","canonical_id":"go:GO:0045754","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of acetate.\" [GOC:curators]","metadata":null},{"id":"25e9585d917d41f9a0a0544d73e3daa7","type":"GO_TERM","name":"positive regulation of acetyl-CoA biosynthesis","canonical_id":"go:GO:0140390","description":"\"Any process that increases the rate, frequency, or extent of acetyl-CoA biosynthetic process.\" [PMID:41730913]","metadata":null},{"id":"17d51fcb2d9f423ab792bec7e0c488b5","type":"GO_TERM","name":"positive regulation of acetylcholine biosynthetic process","canonical_id":"go:GO:1905923","description":"\"Any process that activates or increases the frequency, rate or extent of acetylcholine biosynthetic process.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:20164328]","metadata":null},{"id":"a86f428025954bd084be181863abe994","type":"GO_TERM","name":"positive regulation of acetylcholine metabolic process","canonical_id":"go:GO:0060409","description":"\"Any process that increases the rate, frequency or extent of the chemical reactions and pathways involving acetylcholine, the acetic acid ester of the organic base choline. Acetylcholine is a major neurotransmitter and neuromodulator both in the central and peripheral nervous systems. It also acts as a paracrine signal in various non-neural tissues.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"485bf118a938406c82bb92331a09c8d2","type":"GO_TERM","name":"positive regulation of acetylcholine secretion, neurotransmission","canonical_id":"go:GO:0014057","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of acetylcholine.\" [GOC:ef]","metadata":null},{"id":"5c7cc0e790dd489cad32fdcee8d54ebb","type":"GO_TERM","name":"positive regulation of acetylcholine uptake","canonical_id":"go:GO:0051633","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of acetylcholine into a cell.\" [GOC:ai]","metadata":null},{"id":"d566346696304aa5a3dc2b7993d5f68e","type":"GO_TERM","name":"positive regulation of acinar cell proliferation","canonical_id":"go:GO:1904699","description":"\"Any process that activates or increases the frequency, rate or extent of acinar cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:9788538]","metadata":null},{"id":"497c6e52d1254e9c87617e4cc152aa22","type":"GO_TERM","name":"positive regulation of acrosomal vesicle exocytosis","canonical_id":"go:GO:2000368","description":"\"Any process that activates or increases the frequency, rate or extent of acrosomal vesicle exocytosis.\" [GOC:obol]","metadata":null},{"id":"a38540a9d8e3490d9e65c893124ac7a4","type":"GO_TERM","name":"positive regulation of acrosome reaction","canonical_id":"go:GO:2000344","description":"\"Any process that activates or increases the frequency, rate or extent of the acrosome reaction.\" [GOC:obol]","metadata":null},{"id":"902fb7c6530148a188d77bbe1cb76e9d","type":"GO_TERM","name":"positive regulation of actin filament annealing","canonical_id":"go:GO:0110056","description":"\"Any process that activates or increases the frequency, rate or extent of actin filament annealing, i.e. the end-to-end joining of existing actin filaments.\" [GOC:mah, PMID:10585915, PMID:11575927, PMID:19244341]","metadata":null},{"id":"315bce98d18d423598d62aa95c3d8130","type":"GO_TERM","name":"positive regulation of actin filament binding","canonical_id":"go:GO:1904531","description":"\"Any process that activates or increases the frequency, rate or extent of actin filament binding.\" [GO_REF:0000059, GOC:als, GOC:TermGenie, PMID:24520051]","metadata":null},{"id":"25a82153895c40b58953e881a06d46bb","type":"GO_TERM","name":"positive regulation of actin filament bundle assembly","canonical_id":"go:GO:0032233","description":"\"Any process that activates or increases the frequency, rate or extent of the assembly of actin filament bundles.\" [GOC:mah]","metadata":null},{"id":"f87cdc75632e41768aca03e4ae0f5f01","type":"GO_TERM","name":"positive regulation of actin filament depolymerization","canonical_id":"go:GO:0030836","description":"\"Any process that activates or increases the frequency, rate or extent of actin depolymerization.\" [GOC:mah]","metadata":null},{"id":"ed608836907941f48262dc4cccc311a3","type":"GO_TERM","name":"positive regulation of actin filament polymerization","canonical_id":"go:GO:0030838","description":"\"Any process that activates or increases the frequency, rate or extent of actin polymerization.\" [GOC:mah]","metadata":null},{"id":"3aaf84db88e34cf292d6ec809aa48c8d","type":"GO_TERM","name":"positive regulation of actin filament severing","canonical_id":"go:GO:1903920","description":"\"Any process that activates or increases the frequency, rate or extent of actin filament severing.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23325791]","metadata":null},{"id":"bda6fdba6879402d888c37b514ac5bf1","type":"GO_TERM","name":"positive regulation of actin filament-based movement","canonical_id":"go:GO:1903116","description":"\"Any process that activates or increases the frequency, rate or extent of actin filament-based movement.\" [GO_REF:0000058, GOC:TermGenie, PMID:24798735]","metadata":null},{"id":"9ae2af7f012140d7b99e0c0bbd79676d","type":"GO_TERM","name":"positive regulation of actin nucleation","canonical_id":"go:GO:0051127","description":"\"Any process that activates or increases the frequency, rate or extent of actin nucleation, the initial step in the formation of an actin filament in which actin monomers combine to form a new filament.\" [GOC:ai]","metadata":null},{"id":"3bcf46a222ee430fbd8dc834f66b4318","type":"GO_TERM","name":"positive regulation of action potential","canonical_id":"go:GO:0045760","description":"\"Any process that activates or increases the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:curators]","metadata":null},{"id":"03aa3084bfb84905a2a6a305ba48027e","type":"GO_TERM","name":"positive regulation of activated CD4-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905401","description":"\"Any process that activates or increases the frequency, rate or extent of activated CD4-positive, alpha-beta T cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"0141af508fa9466db90a44d050af3ac3","type":"GO_TERM","name":"positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905404","description":"\"Any process that activates or increases the frequency, rate or extent of activated CD8-positive, alpha-beta T cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"86ab73be22944fca85f254054487320b","type":"GO_TERM","name":"positive regulation of activated T cell autonomous cell death","canonical_id":"go:GO:0070241","description":"\"Any process that activates or increases the frequency, rate or extent of activated T cell autonomous cell death.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"38281da380814e5b8fe3d05b23bf9f7d","type":"GO_TERM","name":"positive regulation of activated T cell proliferation","canonical_id":"go:GO:0042104","description":"\"Any process that activates or increases the rate or extent of activated T cell proliferation.\" [GOC:jl]","metadata":null},{"id":"13576dd42c4246edb50053b01c7cfbbd","type":"GO_TERM","name":"positive regulation of activation of membrane attack complex","canonical_id":"go:GO:0001970","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the activation of the membrane attack complex components of the complement cascade.\" [GOC:hjd]","metadata":null},{"id":"cc13df036ebf4e71ba6783ca53c8f061","type":"GO_TERM","name":"positive regulation of activation-induced cell death of T cells","canonical_id":"go:GO:0070237","description":"\"Any process that activates or increases the frequency, rate or extent of activation-induced cell death of T cells.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"3ec4ab02fba34113ad9f20341d41e5bc","type":"GO_TERM","name":"positive regulation of activin receptor signaling pathway","canonical_id":"go:GO:0032927","description":"\"Any process that activates or increases the frequency, rate or extent of the activity of any activin receptor signaling pathway.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"d11f7c458fff4f479f521439d69f0094","type":"GO_TERM","name":"positive regulation of activin secretion","canonical_id":"go:GO:0032337","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of activin from a cell.\" [GOC:mah]","metadata":null},{"id":"49f9188c656f4c10bb1824959ea78a11","type":"GO_TERM","name":"positive regulation of acute inflammatory response","canonical_id":"go:GO:0002675","description":"\"Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response.\" [GOC:add]","metadata":null},{"id":"8c03f2e3822c4f34a86b6facefe10f61","type":"GO_TERM","name":"positive regulation of acute inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002866","description":"\"Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"c434b36a4325485a987879aa5a5e94b3","type":"GO_TERM","name":"positive regulation of acute inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002879","description":"\"Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response to a non-antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"aea1fb34ee194f04b5f887b92cfb9c15","type":"GO_TERM","name":"positive regulation of acylglycerol transport","canonical_id":"go:GO:1901508","description":"\"Any process that activates or increases the frequency, rate or extent of acylglycerol transport.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"605ca72e189143bc86b21f8df3b82dbb","type":"GO_TERM","name":"positive regulation of adaptive immune effector response","canonical_id":"go:GO:1905679","description":"\"Any process that activates or increases the frequency, rate or extent of adaptive immune effector response.\" [GO_REF:0000058, GOC:TermGenie, ISBN:9781405196833]","metadata":null},{"id":"b17e92c4298149d992572e8153214f21","type":"GO_TERM","name":"positive regulation of adaptive immune memory response","canonical_id":"go:GO:1905676","description":"\"Any process that activates or increases the frequency, rate or extent of adaptive immune memory response.\" [GO_REF:0000058, GOC:TermGenie, PMID:26831526]","metadata":null},{"id":"87535a4a8f3b465db8bdbb5c116b2ff2","type":"GO_TERM","name":"positive regulation of adaptive immune response","canonical_id":"go:GO:0002821","description":"\"Any process that activates or increases the frequency, rate, or extent of an adaptive immune response.\" [GOC:add]","metadata":null},{"id":"9e764a02aedb47dfa5441305b428767e","type":"GO_TERM","name":"positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains","canonical_id":"go:GO:0002824","description":"\"Any process that activates or increases the frequency, rate, or extent of an adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. An example of this process is found in the Gnathostomata.\" [GOC:add, GOC:mtg_sensu]","metadata":null},{"id":"a0303206b7664cf0895b8838f6cfacb5","type":"GO_TERM","name":"positive regulation of adenosine receptor signaling pathway","canonical_id":"go:GO:0060168","description":"\"Any process that activates or increases the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands.\" [GOC:dph]","metadata":null},{"id":"101c8a30d77f45978a16caf58b66dffe","type":"GO_TERM","name":"positive regulation of adenosine transport","canonical_id":"go:GO:0032251","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of adenosine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"7312038f65764ea586cf11665e919b55","type":"GO_TERM","name":"positive regulation of adenylate cyclase activity","canonical_id":"go:GO:0045762","description":"\"Any process that activates or increases the frequency, rate or extent of adenylate cyclase activity.\" [GOC:curators]","metadata":null},{"id":"a14ef5327bc44d51920fd83ffb46889f","type":"GO_TERM","name":"positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0106071","description":"\"Any process that activates or increases the frequency, rate or extent of an adenylate cyclase-activating G protein-coupled receptor signaling pathway.\" [GOC:hjd, PMID:19246489]","metadata":null},{"id":"cd139951a22147cba4933b8a67f20256","type":"GO_TERM","name":"positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway","canonical_id":"go:GO:0071879","description":"\"Any process that activates or increases the frequency, rate or extent of the adenylate cyclase-activating adrenergic receptor protein signaling pathway. An adrenergic receptor signaling pathway is the series of molecular signals generated as a consequence of an adrenergic receptor binding to one of its physiological ligands.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"debaf9d052fb4eeeb8f86cc4475e94ad","type":"GO_TERM","name":"positive regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway","canonical_id":"go:GO:1904992","description":"\"Any process that activates or increases the frequency, rate or extent of adenylate cyclase-inhibiting dopamine receptor signaling pathway.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26554819]","metadata":null},{"id":"468fa636c1e04237a4a95fc35ab7dbfe","type":"GO_TERM","name":"positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway","canonical_id":"go:GO:1900731","description":"\"Any process that activates or increases the frequency, rate or extent of adenylate cyclase-inhibiting opioid receptor signaling pathway.\" [GOC:sjw, GOC:TermGenie, PMID:17157995]","metadata":null},{"id":"b3039cc1b4b3489bb27d0911bc2bbeb4","type":"GO_TERM","name":"positive regulation of adherens junction organization","canonical_id":"go:GO:1903393","description":"\"Any process that activates or increases the frequency, rate or extent of adherens junction organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:21724833]","metadata":null},{"id":"d47cce0f7a984bccbff288a25ffb6d9b","type":"GO_TERM","name":"positive regulation of adiponectin secretion","canonical_id":"go:GO:0070165","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of adiponectin from a cell.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a52f44df1e6c44ea974adbc3e24767ba","type":"GO_TERM","name":"positive regulation of adipose tissue development","canonical_id":"go:GO:1904179","description":"\"Any process that activates or increases the frequency, rate or extent of adipose tissue development.\" [GO_REF:0000058, GOC:TermGenie, PMID:23081848]","metadata":null},{"id":"b32de10966da43c889e2bf6b019d554b","type":"GO_TERM","name":"positive regulation of adult chitin-containing cuticle pigmentation","canonical_id":"go:GO:0048084","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of the adult pattern of pigmentation in the cuticle of an organism.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"fbc6f22b4b3145e58f84ed1f606affa2","type":"GO_TERM","name":"positive regulation of adult salivary gland boundary specification","canonical_id":"go:GO:0045711","description":"\"Any process that activates or increases the frequency, rate or extent of salivary gland determination in an adult organism.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"d27211fa9e7a4fa387beed954f406435","type":"GO_TERM","name":"positive regulation of adult somatic muscle development","canonical_id":"go:GO:0062227","description":"\"Any process that increases the rate, frequency or extent of adult somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"b519f9cb87484154862fc3d19356f973","type":"GO_TERM","name":"positive regulation of aeciospore formation","canonical_id":"go:GO:0075249","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of aeciospore formation, a process in which a dikaryotic spore of typically a rust fungus is produced in an aecium.\" [GOC:pamgo_curators]","metadata":null},{"id":"d4550121cef94db9802a36032b1b5c89","type":"GO_TERM","name":"positive regulation of aecium development","canonical_id":"go:GO:0075269","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of aecium development, a process in which a cuplike structure containing chains of aeciospores is formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"a4bd77b3bd0744cdb03e160b22d2663f","type":"GO_TERM","name":"positive regulation of aflatoxin biosynthetic process","canonical_id":"go:GO:1900179","description":"\"Any process that activates or increases the frequency, rate or extent of aflatoxin biosynthetic process.\" [GOC:di]","metadata":null},{"id":"885758917a3d4919a0b0dd91a2583a2b","type":"GO_TERM","name":"positive regulation of age-related resistance","canonical_id":"go:GO:1904250","description":"\"Any process that activates or increases the extent of age-related resistance.\" [GO_REF:0000058, GOC:TermGenie, PMID:19694953]","metadata":null},{"id":"8740b088de4f439e802c4558654136b4","type":"GO_TERM","name":"positive regulation of aggregate size involved in sorocarp development","canonical_id":"go:GO:0031159","description":"\"Any process that increases the size of the aggregate formed during sorocarp formation.\" [GOC:mah, GOC:pg, PMID:5002049]","metadata":null},{"id":"1568a315a86e4e1a92de30599374a1fb","type":"GO_TERM","name":"positive regulation of aggregation involved in sorocarp development","canonical_id":"go:GO:0110013","description":"\"Any process that increases the frequency, rate or extent of aggregation involved in sorocarp development. Aggregation involved in sorocarp development is the process whose specific outcome is the progression of the aggregate over time, from its formation to the point when a slug is formed. Aggregate development begins in response to starvation and continues by the chemoattractant-mediated movement of cells toward each other. The aggregate is a multicellular structure that gives rise to the slug.\" [GOC:rjd, PMID:28257811]","metadata":null},{"id":"654f428115be40e0943c02ec61c4169d","type":"GO_TERM","name":"positive regulation of aggrephagy","canonical_id":"go:GO:1905337","description":"\"Any process that activates or increases the frequency, rate or extent of aggrephagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:25686248]","metadata":null},{"id":"e0897075674547909ebf1b6950834f55","type":"GO_TERM","name":"positive regulation of alcohol biosynthetic process","canonical_id":"go:GO:1902932","description":"\"Any process that activates or increases the frequency, rate or extent of alcohol biosynthetic process.\" [GO_REF:0000058, GOC:mengo_curators, GOC:TermGenie, PMID:23332010]","metadata":null},{"id":"c47ddd3ba7ab4e3fb8e60ebec4569b5a","type":"GO_TERM","name":"positive regulation of alcohol catabolic process","canonical_id":"go:GO:1900421","description":"\"Any process that activates or increases the frequency, rate or extent of alcohol catabolic process within a cell.\" [GOC:TermGenie]","metadata":null},{"id":"8f67d403a9a244e0987f4e866f0ef9a4","type":"GO_TERM","name":"positive regulation of aldosterone biosynthetic process","canonical_id":"go:GO:0032349","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone.\" [GOC:mah]","metadata":null},{"id":"5b36f0d722d446afbe36da2fcbe683c4","type":"GO_TERM","name":"positive regulation of aldosterone secretion","canonical_id":"go:GO:2000860","description":"\"Any process that activates or increases the frequency, rate or extent of aldosterone secretion.\" [GOC:sl]","metadata":null},{"id":"4a1d966c627a4ad38d0fd38382231894","type":"GO_TERM","name":"positive regulation of alkaline phosphatase activity","canonical_id":"go:GO:0010694","description":"\"Any process that increases the frequency, rate or extent of alkaline phosphatase activity, the catalysis of the reaction: an orthophosphoric monoester + H2O = an alcohol + phosphate, with an alkaline pH optimum.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e86de04ee61b46348c614a05d79570d2","type":"GO_TERM","name":"positive regulation of alkane biosynthetic process","canonical_id":"go:GO:1901579","description":"\"Any process that activates or increases the frequency, rate or extent of alkane biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"fe8fe27a60d341ff80d527339175ba91","type":"GO_TERM","name":"positive regulation of alpha-beta T cell activation","canonical_id":"go:GO:0046635","description":"\"Any process that activates or increases the frequency, rate or extent of alpha-beta T cell activation.\" [GOC:ai]","metadata":null},{"id":"fbae1c47bde34e1c9d4c9b2f563add02","type":"GO_TERM","name":"positive regulation of alpha-beta T cell differentiation","canonical_id":"go:GO:0046638","description":"\"Any process that activates or increases the frequency, rate or extent of alpha-beta T cell differentiation.\" [GOC:ai]","metadata":null},{"id":"b0067c839bdc4e88944d94618bdfe81b","type":"GO_TERM","name":"positive regulation of alpha-beta T cell proliferation","canonical_id":"go:GO:0046641","description":"\"Any process that activates or increases the frequency, rate or extent of alpha-beta T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"4065f6e42ded4e0fa99229aefcf8300e","type":"GO_TERM","name":"positive regulation of amacrine cell differentiation","canonical_id":"go:GO:1902871","description":"\"Any process that activates or increases the frequency, rate or extent of amacrine cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"5467526a443e4a65b82a3a50d951141e","type":"GO_TERM","name":"positive regulation of amine catabolic process","canonical_id":"go:GO:0033243","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of amines.\" [GOC:mah]","metadata":null},{"id":"f12c2cfbe0fe4501a9041868c7c0748b","type":"GO_TERM","name":"positive regulation of amine metabolic process","canonical_id":"go:GO:0033240","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving amines.\" [GOC:mah]","metadata":null},{"id":"9c7f7eb99562496fb9d9ab0a84305bc5","type":"GO_TERM","name":"positive regulation of amine transport","canonical_id":"go:GO:0051954","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"780261f32a014ff4960baaf22d81c3aa","type":"GO_TERM","name":"positive regulation of amino acid biosynthetic process","canonical_id":"go:GO:2000284","description":"\"Any process that activates or increases the frequency, rate or extent of cellular amino acid biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"07673fc8891c4a0586e806bd11649c82","type":"GO_TERM","name":"positive regulation of amino acid metabolic process","canonical_id":"go:GO:0045764","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving amino acid.\" [GOC:curators]","metadata":null},{"id":"41fe5af1932f462a941c2cfab0d46aee","type":"GO_TERM","name":"positive regulation of amino acid transport","canonical_id":"go:GO:0051957","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the directed movement of amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"7ccb2a7f47c941e38857d3cfa4637d06","type":"GO_TERM","name":"positive regulation of ammonia assimilation cycle","canonical_id":"go:GO:2001250","description":"\"Any process that activates or increases the frequency, rate or extent of ammonia assimilation cycle.\" [GOC:BHF]","metadata":null},{"id":"bc7baa0fd13d4c48b1ebd95231404eca","type":"GO_TERM","name":"positive regulation of amniotic stem cell differentiation","canonical_id":"go:GO:2000799","description":"\"Any process that activates or increases the frequency, rate or extent of amniotic stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"c7a1659bac124c6b91257c4dead57008","type":"GO_TERM","name":"positive regulation of amoeboid sperm motility","canonical_id":"go:GO:1905418","description":"\"Any process that activates or increases the frequency, rate or extent of amoeboid sperm motility.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie]","metadata":null},{"id":"83e476907e7c4ec18194b5a360a93e5c","type":"GO_TERM","name":"positive regulation of amphiregulin production","canonical_id":"go:GO:0140732","description":"\"Any process that activates or increases the frequency, rate or extent of production of amphiregulin.\" [PMID:24463227]","metadata":null},{"id":"d5b13a8fe72545258e9850779e9f6b90","type":"GO_TERM","name":"positive regulation of amyloid fibril formation","canonical_id":"go:GO:1905908","description":"\"Any process that activates or increases the frequency, rate or extent of amyloid fibril formation.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:23106396]","metadata":null},{"id":"5a45e26772af47bca0f3021ca8fe109a","type":"GO_TERM","name":"positive regulation of amyloid precursor protein biosynthetic process","canonical_id":"go:GO:0042986","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of amyloid precursor protein (APP), the precursor of amyloid-beta.\" [GOC:curators]","metadata":null},{"id":"6c81f28dfb124af9aab725bdc3f3edf9","type":"GO_TERM","name":"positive regulation of amyloid precursor protein catabolic process","canonical_id":"go:GO:1902993","description":"\"Any process that activates or increases the frequency, rate or extent of amyloid precursor protein catabolic process.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:24499793]","metadata":null},{"id":"ca9d29610cf0486eb6ff26e3e3b3407a","type":"GO_TERM","name":"positive regulation of amyloid-beta clearance","canonical_id":"go:GO:1900223","description":"\"Any process that activates or increases the frequency, rate or extent of amyloid-beta clearance.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"3b2f0153534f498aa8f6565cdd5c9dbd","type":"GO_TERM","name":"positive regulation of amyloid-beta formation","canonical_id":"go:GO:1902004","description":"\"Any process that activates or increases the frequency, rate or extent of amyloid-beta formation.\" [GOC:dph, GOC:TermGenie, PMID:17098871]","metadata":null},{"id":"efdb37d01f524450a4a3911d60136a36","type":"GO_TERM","name":"positive regulation of amylopectin catabolic process","canonical_id":"go:GO:2000947","description":"\"Any process that activates or increases the frequency, rate or extent of amylopectin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"0fe24282ccca4275a14cd61fdf1f0566","type":"GO_TERM","name":"positive regulation of anaphase-promoting complex-dependent catabolic process","canonical_id":"go:GO:1905786","description":"\"Any process that activates or increases the frequency, rate or extent of anaphase-promoting complex-dependent catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:10921876]","metadata":null},{"id":"71ac2f0be26b4b4288f57371287da00a","type":"GO_TERM","name":"positive regulation of androgen receptor signaling pathway","canonical_id":"go:GO:0160207","description":"\"Any process that activates or increases the frequency, rate or extent of androgen receptor signaling.\" [PMID:29057879]","metadata":null},{"id":"e69b20b49cab431cb8ccf6ac0fe7d28d","type":"GO_TERM","name":"positive regulation of androgen secretion","canonical_id":"go:GO:2000836","description":"\"Any process that activates or increases the frequency, rate or extent of androgen secretion.\" [GOC:sl]","metadata":null},{"id":"f5a6f633a88c428cb50039315cb0c250","type":"GO_TERM","name":"positive regulation of androst-4-ene-3,17-dione biosynthetic process","canonical_id":"go:GO:1903456","description":"\"Any process that activates or increases the frequency, rate or extent of androst-4-ene-3,17-dione biosynthetic process.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:24399684]","metadata":null},{"id":"288d9eb3b9e840ae834c3c6f84037bf0","type":"GO_TERM","name":"positive regulation of androstenedione secretion","canonical_id":"go:GO:2000839","description":"\"Any process that activates or increases the frequency, rate or extent of androstenedione secretion.\" [GOC:sl]","metadata":null},{"id":"731f0b314a43445595a4ff65bd029e7b","type":"GO_TERM","name":"positive regulation of angiogenesis","canonical_id":"go:GO:0045766","description":"\"Any process that activates or increases angiogenesis.\" [GOC:curators]","metadata":null},{"id":"20e277c6cbc942e2bb5f45d7c17d5024","type":"GO_TERM","name":"positive regulation of angiotensin-activated signaling pathway","canonical_id":"go:GO:0110063","description":"\"Any process that activates or increases the frequency, rate or extent of the angiotensin-activated signaling pathway.\" [GOC:lf, PMID:28784619]","metadata":null},{"id":"dcb064a351364d36b4322ce3dca39026","type":"GO_TERM","name":"positive regulation of animal organ morphogenesis","canonical_id":"go:GO:0110110","description":"\"Any process that activates or increases the frequency, rate or extent of animal organ morphogenesis.\" [GOC:kmv]","metadata":null},{"id":"2dcef0a3c817452a8681b678ca005a9b","type":"GO_TERM","name":"positive regulation of anion channel activity","canonical_id":"go:GO:1901529","description":"\"Any process that activates or increases the frequency, rate or extent of anion channel activity.\" [GOC:TermGenie]","metadata":null},{"id":"049e25d9a9ba4af9b491a8e172465f83","type":"GO_TERM","name":"positive regulation of anion transmembrane transport","canonical_id":"go:GO:1903961","description":"\"Any process that activates or increases the frequency, rate or extent of anion transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"e71b3e5059014880b5176a5516d68bba","type":"GO_TERM","name":"positive regulation of anoikis","canonical_id":"go:GO:2000210","description":"\"Any process that activates or increases the frequency, rate or extent of anoikis.\" [GOC:mah]","metadata":null},{"id":"10cd8e2347bf49ef91642ecd0a011d6f","type":"GO_TERM","name":"positive regulation of anterior head development","canonical_id":"go:GO:2000744","description":"\"Any process that activates or increases the frequency, rate or extent of anterior head development.\" [GOC:obol]","metadata":null},{"id":"2581104f04b7426e931701c4c9565cf6","type":"GO_TERM","name":"positive regulation of anterior/posterior axon guidance","canonical_id":"go:GO:1905488","description":"\"Any process that activates or increases the frequency, rate or extent of anterior/posterior axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"3ce322327ac34a04bf9ade5bdd631e1e","type":"GO_TERM","name":"positive regulation of anterograde axonal transport of mitochondrion","canonical_id":"go:GO:0061881","description":"\"Any process that activates or increasesthe frequency, rate or extent of the directed movement of mitochondria along microtubules in axons away from the cell body and towards the presynapse.\" [PMID:24302729]","metadata":null},{"id":"d94b6458f7e843b3b9cacf0ee162fe30","type":"GO_TERM","name":"positive regulation of anterograde dense core granule transport","canonical_id":"go:GO:1901953","description":"\"Any process that activates or increases the frequency, rate or extent of anterograde dense core granule transport.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"3c24e8ea33f647f29c00264a3807f05f","type":"GO_TERM","name":"positive regulation of anterograde synaptic vesicle transport","canonical_id":"go:GO:1903744","description":"\"Any process that activates or increases the frequency, rate or extent of anterograde synaptic vesicle transport.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25329901]","metadata":null},{"id":"dd11b7297a974011a99fc761e991cebf","type":"GO_TERM","name":"positive regulation of anther dehiscence","canonical_id":"go:GO:0120195","description":"\"Any process that activates or increases the frequency, rate or extent of anther dehiscence.\" [GOC:lr, PMID:30911018]","metadata":null},{"id":"19b5cc43b1e043daa0d555e43fad4461","type":"GO_TERM","name":"positive regulation of anthocyanin biosynthetic process","canonical_id":"go:GO:0031542","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of anthocyanins.\" [GOC:mah]","metadata":null},{"id":"7c91331853214befb0d9290f03be1452","type":"GO_TERM","name":"positive regulation of anthocyanin catabolic process","canonical_id":"go:GO:1900002","description":"\"Any process that activates or increases the frequency, rate or extent of anthocyanin catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"182f8957dc9f40c6b0d7801201502a11","type":"GO_TERM","name":"positive regulation of anthocyanin metabolic process","canonical_id":"go:GO:0031539","description":"\"Any process that activates or increases the frequency, rate or extent of chemical reactions and pathways involving anthocyanins.\" [GOC:mah]","metadata":null},{"id":"2452785583bc4b97bc74386091c52b28","type":"GO_TERM","name":"positive regulation of anti-Mullerian hormone signaling pathway","canonical_id":"go:GO:1902614","description":"\"Any process that activates or increases the frequency, rate or extent of anti-Mullerian hormone signaling pathway.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:23624077]","metadata":null},{"id":"789ca6b3adfe4b2c8a87407209a2aa21","type":"GO_TERM","name":"positive regulation of antibacterial peptide biosynthetic process","canonical_id":"go:GO:0006963","description":"\"Any process that activates or increases the frequency, rate, or extent of antibacterial peptide biosynthesis.\" [GOC:mah, PMID:10973475]","metadata":null},{"id":"c08081ba854c494998e019d026a5c4bf","type":"GO_TERM","name":"positive regulation of antibacterial peptide production","canonical_id":"go:GO:0002803","description":"\"Any process that activates or increases the frequency, rate, or extent of antibacterial peptide production.\" [GOC:add]","metadata":null},{"id":"26bf0e89f35a4a3598387ae84c307c76","type":"GO_TERM","name":"positive regulation of antibacterial peptide secretion","canonical_id":"go:GO:0002799","description":"\"Any process that activates or increases the frequency, rate, or extent of antibacterial peptide secretion.\" [GOC:add]","metadata":null},{"id":"1fbd5fec4d814c7784235ada3796a6ba","type":"GO_TERM","name":"positive regulation of antibody-dependent cellular cytotoxicity","canonical_id":"go:GO:0001815","description":"\"Any process that activates or increases the frequency, rate or extent of antibody-dependent cellular cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"628f38e0f4014401b6f0accc9c800d73","type":"GO_TERM","name":"positive regulation of antifungal innate immune response","canonical_id":"go:GO:1905036","description":"\"Any process that activates or increases the frequency, rate or extent of an antifungal innate immune response.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:22470487]","metadata":null},{"id":"29a0d2209523481fa033748b4d6e7daa","type":"GO_TERM","name":"positive regulation of antifungal peptide biosynthetic process","canonical_id":"go:GO:0006967","description":"\"Any process that activates or increases the frequency, rate, or extent of antifungal peptide biosynthesis.\" [GOC:mah]","metadata":null},{"id":"9f68ce928985499199b14315d312bb35","type":"GO_TERM","name":"positive regulation of antifungal peptide production","canonical_id":"go:GO:0002804","description":"\"Any process that activates or increases the frequency, rate, or extent of antifungal peptide production.\" [GOC:add]","metadata":null},{"id":"61e59949cf7c4ddc88c0ff1e33e350b5","type":"GO_TERM","name":"positive regulation of antifungal peptide secretion","canonical_id":"go:GO:0002802","description":"\"Any process that activates or increases the frequency, rate, or extent of antifungal peptide secretion.\" [GOC:add]","metadata":null},{"id":"0fbcd544f3d94787b5435a379c0503fe","type":"GO_TERM","name":"positive regulation of antigen processing and presentation","canonical_id":"go:GO:0002579","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"61b840c716f04f169ebb860273850f7f","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I","canonical_id":"go:GO:1904284","description":"\"Any process that activates or increases the frequency, rate or extent of antigen processing and presentation of endogenous peptide antigen via MHC class I.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24643698]","metadata":null},{"id":"45ea5b01e8094cee9f8df7d03f097f52","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of lipid antigen via MHC class Ib","canonical_id":"go:GO:0002600","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of lipid antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"d7db478b88294f0790644fdf2d586664","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of peptide antigen","canonical_id":"go:GO:0002585","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of peptide antigen.\" [GOC:add]","metadata":null},{"id":"c239a39b2c224dde93991b6dc391805c","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of peptide antigen via MHC class I","canonical_id":"go:GO:0002591","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class I.\" [GOC:add]","metadata":null},{"id":"e152f9ce50ae4062abb8116ee78dcfa2","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of peptide antigen via MHC class II","canonical_id":"go:GO:0002588","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class II.\" [GOC:add]","metadata":null},{"id":"069f69677b084d338589894e39a0a8af","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of peptide antigen via MHC class Ib","canonical_id":"go:GO:0002597","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"5dcbcb2c09724991b545fb189ef7123e","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002582","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of antigen (peptide or polysaccharide) via MHC class II.\" [GOC:add]","metadata":null},{"id":"bd80d7ea67db4605bd1f0c3a59468306","type":"GO_TERM","name":"positive regulation of antigen processing and presentation of polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002603","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of polysaccharide antigen via MHC class II.\" [GOC:add]","metadata":null},{"id":"0ae8e7209e264d27be1415a3a83270e2","type":"GO_TERM","name":"positive regulation of antigen processing and presentation via MHC class Ib","canonical_id":"go:GO:0002594","description":"\"Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation of antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"7186c9b5956641feb650e8e66bff0698","type":"GO_TERM","name":"positive regulation of antigen receptor-mediated signaling pathway","canonical_id":"go:GO:0050857","description":"\"Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B- or T cell.\" [GOC:ai]","metadata":null},{"id":"32602a234d6340ef9b1d08ab46b4fa35","type":"GO_TERM","name":"positive regulation of antimicrobial humoral response","canonical_id":"go:GO:0002760","description":"\"Any process that activates or increases the frequency, rate, or extent of an antimicrobial humoral response.\" [GOC:add]","metadata":null},{"id":"531e355ff65f4c17905919b2036082cb","type":"GO_TERM","name":"positive regulation of antimicrobial peptide biosynthetic process","canonical_id":"go:GO:0002807","description":"\"Any process that activates or increases the frequency, rate, or extent of antimicrobial peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"adbfa29868a74c42bad044468b0899a5","type":"GO_TERM","name":"positive regulation of antimicrobial peptide production","canonical_id":"go:GO:0002225","description":"\"Any process that activates or increases the frequency, rate, or extent of antimicrobial peptide production.\" [GOC:add, PMID:11807545]","metadata":null},{"id":"5e67b6932b294dc19627193ced7e7ab3","type":"GO_TERM","name":"positive regulation of antimicrobial peptide secretion","canonical_id":"go:GO:0002796","description":"\"Any process that activates or increases the frequency, rate, or extent of antimicrobial peptide secretion.\" [GOC:add]","metadata":null},{"id":"2f449e46a0374ff483267a453c3fa661","type":"GO_TERM","name":"positive regulation of antipodal cell differentiation","canonical_id":"go:GO:0045690","description":"\"Any process that activates or increases the frequency, rate or extent of antipodal cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"b0c35a0dc6b540d7884271b946b6594a","type":"GO_TERM","name":"positive regulation of antisense RNA transcription","canonical_id":"go:GO:0060196","description":"\"Any process that increases the frequency, rate or extent of the synthesis of antisense RNA, an RNA molecule complementary in sequence to another RNA or DNA molecule, which, by binding the latter, acts to inhibit its function and/or completion of synthesis, on a template of DNA.\" [GOC:dph, GOC:tb, PMID:18075583]","metadata":null},{"id":"0b2058c4c37b40a78d40880ac44f137a","type":"GO_TERM","name":"positive regulation of antral ovarian follicle growth","canonical_id":"go:GO:2000388","description":"\"Any process that activates or increases the frequency, rate or extent of antral ovarian follicle growth.\" [GOC:obol]","metadata":null},{"id":"d980fc99c41a4e5e848b0feecc359479","type":"GO_TERM","name":"positive regulation of aorta morphogenesis","canonical_id":"go:GO:1903849","description":"\"Any process that activates or increases the frequency, rate or extent of aorta morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"cad2f0c7defa4df29ce697f87666e30f","type":"GO_TERM","name":"positive regulation of aortic smooth muscle cell differentiation","canonical_id":"go:GO:1904831","description":"\"Any process that activates or increases the frequency, rate or extent of aortic smooth muscle cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22034194]","metadata":null},{"id":"02c116d6353e46a79346f334555e0437","type":"GO_TERM","name":"positive regulation of apical constriction involved in ventral furrow formation","canonical_id":"go:GO:0110074","description":"\"Any process that activates or increases the frequency, rate or extent of apical constriction involved in ventral furrow formation.\" [GOC:ha, PMID:28495958]","metadata":null},{"id":"db2def2067694c1e9e51bb6d3e0070c0","type":"GO_TERM","name":"positive regulation of apical ectodermal ridge formation","canonical_id":"go:GO:1905142","description":"\"Any process that activates or increases the frequency, rate or extent of apical ectodermal ridge formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:18359901]","metadata":null},{"id":"7bab69399b9b40fba7a7141c848a162c","type":"GO_TERM","name":"positive regulation of aplanospore formation","canonical_id":"go:GO:0075291","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of aplanospore formation, a process in which a nonmotile, asexual spore is formed within a cell in certain algae and fungi (commonly in the Phycomycetes), the wall of aplanospore is distinct from that of the parent cell.\" [GOC:pamgo_curators]","metadata":null},{"id":"30bb0c680b3b4ac9961669b79b7e22d5","type":"GO_TERM","name":"positive regulation of apolipoprotein A-I-mediated signaling pathway","canonical_id":"go:GO:1905096","description":"\"Any process that activates or increases the frequency, rate or extent of apolipoprotein A-I-mediated signaling pathway.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25084135]","metadata":null},{"id":"0986cfdcfde24af883e3d5ec736079b3","type":"GO_TERM","name":"positive regulation of apoptosome assembly","canonical_id":"go:GO:1905102","description":"\"Any process that activates or increases the frequency, rate or extent of apoptosome assembly.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:26265044]","metadata":null},{"id":"9f67d60deb1f41c7a69152604e746f71","type":"GO_TERM","name":"positive regulation of apoptotic DNA fragmentation","canonical_id":"go:GO:1902512","description":"\"Any process that activates or increases the frequency, rate or extent of apoptotic DNA fragmentation.\" [GOC:hjd, GOC:TermGenie, PMID:15572351]","metadata":null},{"id":"16d1aedd3eff4733abbd88f3a6355d77","type":"GO_TERM","name":"positive regulation of apoptotic cell clearance","canonical_id":"go:GO:2000427","description":"\"Any process that activates or increases the frequency, rate or extent of apoptotic cell clearance.\" [GOC:obol]","metadata":null},{"id":"668ccf2d67da4f1895e89380b3b6f4a4","type":"GO_TERM","name":"positive regulation of apoptotic process","canonical_id":"go:GO:0043065","description":"\"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.\" [GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"04cf5e49d515472f9ce77e7df189c0bd","type":"GO_TERM","name":"positive regulation of apoptotic process in bone marrow cell","canonical_id":"go:GO:0120132","description":"\"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process in the bone marrow.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:27908889]","metadata":null},{"id":"b854ed0ad4934fdeb90c00ed605d85dc","type":"GO_TERM","name":"positive regulation of apoptotic process involved in development","canonical_id":"go:GO:1904747","description":"\"Any process that activates or increases the frequency, rate or extent of apoptotic process involved in development.\" [GO_REF:0000058, GOC:TermGenie, PMID:22801495]","metadata":null},{"id":"62d09c42d52a4fb1a466ac136f971a39","type":"GO_TERM","name":"positive regulation of apoptotic process involved in mammary gland involution","canonical_id":"go:GO:0060058","description":"\"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process of mammary epithelial cells during mammary gland involution.\" [GOC:dph, GOC:mtg_apoptosis, PMID:15282149]","metadata":null},{"id":"4151b19e6f0e49f6a061b9fa3ec3ee56","type":"GO_TERM","name":"positive regulation of apoptotic process involved in morphogenesis","canonical_id":"go:GO:1902339","description":"\"Any process that activates or increases the frequency, rate or extent of apoptotic process involved in morphogenesis.\" [GOC:sart, GOC:TermGenie, PMID:12202035]","metadata":null},{"id":"eaf2e9c694084edb881f8f169885c013","type":"GO_TERM","name":"positive regulation of apoptotic signaling pathway","canonical_id":"go:GO:2001235","description":"\"Any process that activates or increases the frequency, rate or extent of apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"646744496a22476aacced876dd225f30","type":"GO_TERM","name":"positive regulation of appetite","canonical_id":"go:GO:0032100","description":"\"Any process that increases appetite.\" [GOC:add]","metadata":null},{"id":"4d12d9027f114bec8f500bb103a47d91","type":"GO_TERM","name":"positive regulation of appressorium formation","canonical_id":"go:GO:0075018","description":"\"Any process that activates or increases the frequency, rate or extent of symbiont appressorium formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"b074bcd3d11e4cf69c4e648fa6f5bfdd","type":"GO_TERM","name":"positive regulation of arabinoxylan-containing compound catabolic process","canonical_id":"go:GO:2000923","description":"\"Any process that activates or increases the frequency, rate or extent of arabinoxylan-containing compound catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"aa1f495a6f894208be9c2e66ae7d7664","type":"GO_TERM","name":"positive regulation of arachidonate secretion","canonical_id":"go:GO:0090238","description":"\"Any process that increases the rate, frequency, or extent of arachidonic acid secretion, the controlled release of arachidonic acid from a cell or a tissue.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"61420beb50f74d358688a87e9bf88ce7","type":"GO_TERM","name":"positive regulation of arbuscule formation for nutrient acquisition from host","canonical_id":"go:GO:0075330","description":"\"Any process that activates or increases the frequency, rate or extent of symbiont arbuscule formation for nutrient acquisition from host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"7d48d706159a47e7985b074598ad5ff3","type":"GO_TERM","name":"positive regulation of arginine biosynthetic process","canonical_id":"go:GO:1900080","description":"\"Any process that activates or increases the frequency, rate or extent of arginine biosynthetic process.\" [GOC:dgf, GOC:TermGenie]","metadata":null},{"id":"94915c4d0af149d592cd42f83a5edd91","type":"GO_TERM","name":"positive regulation of artery morphogenesis","canonical_id":"go:GO:1905653","description":"\"Any process that activates or increases the frequency, rate or extent of artery morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:27389411]","metadata":null},{"id":"8ca59c10f67844e5a665e8c6b7cce1ad","type":"GO_TERM","name":"positive regulation of artery smooth muscle contraction","canonical_id":"go:GO:1905656","description":"\"Any process that activates or increases the frequency, rate or extent of artery smooth muscle contraction.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:27389411]","metadata":null},{"id":"225c63ae070b4aaa9664b9754767b139","type":"GO_TERM","name":"positive regulation of arugosin biosynthetic process","canonical_id":"go:GO:1900628","description":"\"Any process that activates or increases the frequency, rate or extent of arugosin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"244d26f5319041e19e9316c6d28b414d","type":"GO_TERM","name":"positive regulation of ascospore formation","canonical_id":"go:GO:0075296","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of ascospore formation, a process in which a sexual spore, named ascospore, from Ascomycete fungi was produced inside an ascus.\" [GOC:pamgo_curators]","metadata":null},{"id":"4fb08a75b5ce40129e66949a9a7617c0","type":"GO_TERM","name":"positive regulation of ascospore-type prospore membrane formation","canonical_id":"go:GO:1903024","description":"\"Any process that activates or increases the frequency, rate or extent of formation of an ascospore-type prospore membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:11405625]","metadata":null},{"id":"8d8f4c62021e4468950e1449ef7966c1","type":"GO_TERM","name":"positive regulation of ascus development","canonical_id":"go:GO:0075319","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of ascus development, a saclike structure produced by fungi of the phylum Ascomycota (sac fungi) in which sexually produced spores (ascospores), usually four or eight in number, are formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"80b28b9ef88c4f03be451267fe109ba7","type":"GO_TERM","name":"positive regulation of asexual reproduction","canonical_id":"go:GO:1903666","description":"\"Any process that activates or increases the frequency, rate or extent of asexual reproduction.\" [GO_REF:0000058, GOC:TermGenie, PMID:24390142]","metadata":null},{"id":"99ecabf523f94137959b7e6ee867a569","type":"GO_TERM","name":"positive regulation of asexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043945","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the formation of a cellular spore derived from the products of mitosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"ef10dc3c345145df90a59880e000a4c3","type":"GO_TERM","name":"positive regulation of aspartate secretion","canonical_id":"go:GO:1904450","description":"\"Any process that activates or increases the frequency, rate or extent of aspartate secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:2342602]","metadata":null},{"id":"8481333680f54437b3d0767863fd1a28","type":"GO_TERM","name":"positive regulation of aspartic-type peptidase activity","canonical_id":"go:GO:1905247","description":"\"Any process that activates or increases the frequency, rate or extent of aspartic-type peptidase activity.\" [GO_REF:0000059, GOC:jl, GOC:TermGenie, PMID:21745575]","metadata":null},{"id":"c5f86f27e89242459456a5abd5b164dd","type":"GO_TERM","name":"positive regulation of asperfuranone biosynthetic process","canonical_id":"go:GO:1900639","description":"\"Any process that activates or increases the frequency, rate or extent of asperfuranone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"411c2360bdde42e0ace2b211febb60d3","type":"GO_TERM","name":"positive regulation of asperthecin biosynthetic process","canonical_id":"go:GO:1900381","description":"\"Any process that activates or increases the frequency, rate or extent of asperthecin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c8f8972427f5438fb27395172b5c47fa","type":"GO_TERM","name":"positive regulation of assembly of large subunit precursor of preribosome","canonical_id":"go:GO:1902628","description":"\"Any process that activates or increases the frequency, rate or extent of assembly of a large subunit precursor of preribosome.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22735702]","metadata":null},{"id":"5f55099eaff446918effb38724dbaae9","type":"GO_TERM","name":"positive regulation of astrocyte activation","canonical_id":"go:GO:0061890","description":"\"Any process that increases the frequency, rate or extent of astrocyte activation.\" [GOC:aruk, GOC:bc, PMID:20005821]","metadata":null},{"id":"70b2ee0ebcdc410dbc0108f298fca46e","type":"GO_TERM","name":"positive regulation of astrocyte chemotaxis","canonical_id":"go:GO:2000464","description":"\"Any process that activates or increases the frequency, rate or extent of astrocyte chemotaxis.\" [GOC:obol]","metadata":null},{"id":"213fb50b662947969740b9b51c3e80d0","type":"GO_TERM","name":"positive regulation of astrocyte differentiation","canonical_id":"go:GO:0048711","description":"\"Any process that activates or increases the frequency, rate or extent of astrocyte differentiation.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"576ccbfcf2e844feb671d30fa4d56088","type":"GO_TERM","name":"positive regulation of asymmetric cell division","canonical_id":"go:GO:0045770","description":"\"Any process that activates or increases the frequency, rate or extent of asymmetric cell division.\" [GOC:curators]","metadata":null},{"id":"62683b42094843078757936888d930d3","type":"GO_TERM","name":"positive regulation of asymmetric protein localization involved in cell fate determination","canonical_id":"go:GO:1904787","description":"\"Any process that activates or increases the frequency, rate or extent of asymmetric protein localization involved in cell fate determination.\" [GO_REF:0000058, GOC:TermGenie, PMID:17476329]","metadata":null},{"id":"1d7a77effe184493b7885d369020969b","type":"GO_TERM","name":"positive regulation of atrial cardiac muscle cell action potential","canonical_id":"go:GO:1903949","description":"\"Any process that activates or increases the frequency, rate or extent of atrial cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:25281747]","metadata":null},{"id":"80246d62dd6f47ffa7765f01b054748b","type":"GO_TERM","name":"positive regulation of atrichoblast fate specification","canonical_id":"go:GO:0010059","description":"\"Any process that induces or promotes atrichoblast fate specification.\" [GOC:tb]","metadata":null},{"id":"e91af5a2c3654b689350f000b1c5ec22","type":"GO_TERM","name":"positive regulation of attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:1902425","description":"\"Any process that activates or increases the frequency, rate or extent of attachment of spindle microtubules to kinetochore involved in mitotic sister chromatid segregation.\" [GOC:TermGenie, PMID:22065639]","metadata":null},{"id":"fcabdeef7a25449bbecd1e09fac9e468","type":"GO_TERM","name":"positive regulation of attachment of spindle microtubules to kinetochore","canonical_id":"go:GO:0051987","description":"\"Any process that activates or increases the frequency, rate or extent of the attachment of spindle microtubules to the kinetochore.\" [GOC:ai]","metadata":null},{"id":"4b7072b7eddc434991e31dc5f0b5ad79","type":"GO_TERM","name":"positive regulation of austinol biosynthetic process","canonical_id":"go:GO:1900642","description":"\"Any process that activates or increases the frequency, rate or extent of austinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"829c257dfb154a0ba07d4481e597ffb7","type":"GO_TERM","name":"positive regulation of autophagic cell death","canonical_id":"go:GO:1904094","description":"\"Any process that activates or increases the frequency, rate or extent of autophagic cell death.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25736836]","metadata":null},{"id":"f26b737fc1ee40bc97acf6e454966c88","type":"GO_TERM","name":"positive regulation of autophagosome assembly","canonical_id":"go:GO:2000786","description":"\"Any process that activates or increases the frequency, rate or extent of autophagic vacuole assembly.\" [GOC:autophagy, GOC:BHF]","metadata":null},{"id":"1d076daffad64c53b3fb3268a4625909","type":"GO_TERM","name":"positive regulation of autophagosome maturation","canonical_id":"go:GO:1901098","description":"\"Any process that activates or increases the frequency, rate or extent of autophagosome maturation.\" [GOC:autophagy, GOC:TermGenie, PMID:10436019, PMID:21383079]","metadata":null},{"id":"8534b5556d43462cb63670a07cb56f74","type":"GO_TERM","name":"positive regulation of autophagosome size","canonical_id":"go:GO:0045772","description":"\"Any process that increases autophagosome size.\" [GOC:autophagy, GOC:curators]","metadata":null},{"id":"9aa315e0e56b4cd399e3aa38798966f6","type":"GO_TERM","name":"positive regulation of autophagosome-lysosome fusion","canonical_id":"go:GO:0160177","description":"\"Any process that activates or increases the rate which autophagosomes fuse with a vacuole (yeast) or lysosome (e.g. mammals and insects).\" [PMID:38360932]","metadata":null},{"id":"f76b9a9589ec43adb39f1b0c3639d9c7","type":"GO_TERM","name":"positive regulation of autophagy","canonical_id":"go:GO:0010508","description":"\"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6057216dd21d4475b9f33d82f9af9317","type":"GO_TERM","name":"positive regulation of autophagy in response to ER overload","canonical_id":"go:GO:0034263","description":"\"The process in which the accumulation of misfolded proteins in the endoplasmic reticulum triggers a response that positively regulates autophagy.\" [GOC:mah]","metadata":null},{"id":"99fe6a1839ad42caa211a009ac1a028f","type":"GO_TERM","name":"positive regulation of autophagy of mitochondrion","canonical_id":"go:GO:1903599","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrion degradation by autophagy.\" [GO_REF:0000058, GOC:autophagy, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21753002]","metadata":null},{"id":"51f913c05be6434b88ce69d04d6a12e5","type":"GO_TERM","name":"positive regulation of auxin biosynthetic process","canonical_id":"go:GO:0010601","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of auxins, plant hormones that regulate aspects of plant growth.\" [PMID:18287041]","metadata":null},{"id":"4aa106d4b8ac4527862198354ee2f649","type":"GO_TERM","name":"positive regulation of auxin mediated signaling pathway","canonical_id":"go:GO:0010929","description":"\"Any process that increases the rate, frequency or extent of auxin mediated signaling pathway. Auxin mediated signaling pathway is the series of molecular signals generated in response to detection of auxin.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8ec73427e45541d29bf6dca966d7b40d","type":"GO_TERM","name":"positive regulation of auxin metabolic process","canonical_id":"go:GO:0090355","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways involving auxins, plant hormones that regulate aspects of plant growth.\" [GOC:tb]","metadata":null},{"id":"ab5703bdba6248c3b4cf70d3e61d62c5","type":"GO_TERM","name":"positive regulation of axial mesodermal cell fate determination","canonical_id":"go:GO:0048326","description":"\"Any process that activates or increases the frequency, rate or extent of axial mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"03b158b94f6f42b78fda1975e07a9cf1","type":"GO_TERM","name":"positive regulation of axial mesodermal cell fate specification","canonical_id":"go:GO:0048330","description":"\"Any process that activates or increases the frequency, rate or extent of axial mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"c2aac9455ac945488fcd5d29908d49e8","type":"GO_TERM","name":"positive regulation of axo-dendritic protein transport","canonical_id":"go:GO:1905128","description":"\"Any process that activates or increases the frequency, rate or extent of axo-dendritic protein transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20694152]","metadata":null},{"id":"8ed09775839d4d839779e875f057d13d","type":"GO_TERM","name":"positive regulation of axon extension","canonical_id":"go:GO:0045773","description":"\"Any process that activates or increases the frequency, rate or extent of axon extension.\" [GOC:curators]","metadata":null},{"id":"95b72b116156487eba653f66658b2e6c","type":"GO_TERM","name":"positive regulation of axon extension involved in axon guidance","canonical_id":"go:GO:0048842","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of axon extension involved in axon guidance.\" [GOC:devbiol]","metadata":null},{"id":"8c1b9f69cf1e4a82adcc214fdc356b98","type":"GO_TERM","name":"positive regulation of axon extension involved in regeneration","canonical_id":"go:GO:0048691","description":"\"Any process that activates, maintains or increases the rate of axon extension involved in regeneration.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"84c9281fe7ac4898a614ac54600cadad","type":"GO_TERM","name":"positive regulation of axon guidance","canonical_id":"go:GO:1902669","description":"\"Any process that activates or increases the frequency, rate or extent of axon guidance.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:23006775]","metadata":null},{"id":"02e248cf4e6f42f4a581292c1651ab8c","type":"GO_TERM","name":"positive regulation of axon regeneration","canonical_id":"go:GO:0048680","description":"\"Any process that activates, maintains or increases the rate of axon regeneration.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"976b4b3b1985482eb968b82e563a074a","type":"GO_TERM","name":"positive regulation of axonogenesis","canonical_id":"go:GO:0050772","description":"\"Any process that activates or increases the frequency, rate or extent of axonogenesis.\" [GOC:ai]","metadata":null},{"id":"0dbc49757eb446df87b8ed9ad7f7c9cd","type":"GO_TERM","name":"positive regulation of backward locomotion","canonical_id":"go:GO:1905852","description":"\"Any process that activates or increases the frequency, rate or extent of backward locomotion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11717360]","metadata":null},{"id":"a5e2749598ec4097a52c83caa893f8fb","type":"GO_TERM","name":"positive regulation of bacterial-type flagellum assembly","canonical_id":"go:GO:1902210","description":"\"Any process that activates or increases the frequency, rate or extent of bacterial-type flagellum assembly.\" [GOC:jl, GOC:TermGenie]","metadata":null},{"id":"30f06aedb5f04e67a0d74a0310065b17","type":"GO_TERM","name":"positive regulation of barbed-end actin filament capping","canonical_id":"go:GO:2000814","description":"\"Any process that activates or increases the frequency, rate or extent of barbed-end actin filament capping.\" [GOC:BHF]","metadata":null},{"id":"f26917fe724c4e8188e642cc3a93cbc6","type":"GO_TERM","name":"positive regulation of base-excision repair","canonical_id":"go:GO:1905053","description":"\"Any process that activates or increases the frequency, rate or extent of base-excision repair.\" [GO_REF:0000058, GOC:ah, GOC:TermGenie, PMID:18973764]","metadata":null},{"id":"7d7a3f4d4b89439ab13292ff395674e4","type":"GO_TERM","name":"positive regulation of basidiospore formation","canonical_id":"go:GO:0075303","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of frequency, rate or extent of basidiospore formation, a process in which a sexually produced fungal spore is formed on a basidium in the fungi basidiomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"bdffa21b94ca45fb9827ffc041ed5c3d","type":"GO_TERM","name":"positive regulation of basidium development","canonical_id":"go:GO:0075315","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of basidium development, a process that leads to the formation of basidium, a small, specialized club-shaped structure typically bearing four basidiospores at the tips of minute projections. The basidium is unique to basidiomycetes and distinguishes them from other kinds of fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"f6cee6c6afb042f9b73a27b27fcfff80","type":"GO_TERM","name":"positive regulation of basophil degranulation","canonical_id":"go:GO:1903583","description":"\"Any process that activates or increases the frequency, rate or extent of basophil degranulation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10880837]","metadata":null},{"id":"7ec16844da244675ba77877b5ae3fb65","type":"GO_TERM","name":"positive regulation of basophil differentiation","canonical_id":"go:GO:0045642","description":"\"Any process that activates or increases the frequency, rate or extent of basophil differentiation.\" [GOC:curators]","metadata":null},{"id":"a9764f3e72eb48b99cbaa5f6efa19553","type":"GO_TERM","name":"positive regulation of behavior","canonical_id":"go:GO:0048520","description":"\"Any process that activates or increases the frequency, rate or extent of behavior, the internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or external stimuli.\" [GOC:jid, GOC:pr]","metadata":null},{"id":"4319854aada94732943f758f0f8e54ab","type":"GO_TERM","name":"positive regulation of behavioral fear response","canonical_id":"go:GO:2000987","description":"\"Any process that activates or increases the frequency, rate or extent of behavioral fear response.\" [GOC:obol]","metadata":null},{"id":"c270dfa1bc604c9494c273ea39b3cb7d","type":"GO_TERM","name":"positive regulation of beta 2 integrin biosynthetic process","canonical_id":"go:GO:0045775","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of beta 2 integrins.\" [GOC:curators]","metadata":null},{"id":"8ef324053be24b20bab2d85375b3fd0a","type":"GO_TERM","name":"positive regulation of beta-catenin-TCF complex assembly","canonical_id":"go:GO:1904865","description":"\"Any process that activates or increases the frequency, rate or extent of beta-catenin-TCF complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"f19a6824ab944e4c93bfa8cd7609e823","type":"GO_TERM","name":"positive regulation of beta-galactosidase activity","canonical_id":"go:GO:1903771","description":"\"Any process that activates or increases the frequency, rate or extent of beta-galactosidase activity.\" [GO_REF:0000059, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:11927518]","metadata":null},{"id":"5acbd5ae26464d5d9a289d2986a70721","type":"GO_TERM","name":"positive regulation of bicellular tight junction assembly","canonical_id":"go:GO:1903348","description":"\"Any process that activates or increases the frequency, rate or extent of tight junction assembly.\" [GO_REF:0000058, GOC:jz, GOC:TermGenie, PMID:25050009]","metadata":null},{"id":"17e20f9cb24a4b0e8b73df100bd73337","type":"GO_TERM","name":"positive regulation of bicoid mRNA localization","canonical_id":"go:GO:0045854","description":"\"Any process that activates or increases the frequency, rate or extent of the process in which bicoid mRNA is transported to, or maintained in, a specific location.\" [GOC:curators]","metadata":null},{"id":"a8a0d4d41c464736836a9e17fb60f80c","type":"GO_TERM","name":"positive regulation of bile acid biosynthetic process","canonical_id":"go:GO:0070859","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b7600cabc3a545d18438a2988b9ae056","type":"GO_TERM","name":"positive regulation of bile acid secretion","canonical_id":"go:GO:0120189","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:22767443]","metadata":null},{"id":"dbe9bb0e32f74178a29889b3303f162f","type":"GO_TERM","name":"positive regulation of binding","canonical_id":"go:GO:0051099","description":"\"Any process that activates or increases the rate or extent of binding, the selective interaction of a molecule with one or more specific sites on another molecule.\" [GOC:ai]","metadata":null},{"id":"8f40241ce61345cab85e181c60de5a97","type":"GO_TERM","name":"positive regulation of biological process","canonical_id":"go:GO:0048518","description":"\"Any process that activates or increases the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule.\" [GOC:jid]","metadata":null},{"id":"446e5fb15e0840c990cfbef7fd538619","type":"GO_TERM","name":"positive regulation of bioluminescence","canonical_id":"go:GO:1905087","description":"\"Any process that activates or increases the frequency, rate or extent of bioluminescence.\" [GO_REF:0000058, GOC:BHF, GOC:rph, GOC:TermGenie, PMID:10913092]","metadata":null},{"id":"ad063e90826f4eaeab0c4a875eb14fce","type":"GO_TERM","name":"positive regulation of biomineral tissue development","canonical_id":"go:GO:0070169","description":"\"Any process that activates or increases the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds.\" [GOC:mah]","metadata":null},{"id":"cb8b7b6ce2764583875f40723334402d","type":"GO_TERM","name":"positive regulation of biosynthetic process","canonical_id":"go:GO:0009891","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances.\" [GOC:curators]","metadata":null},{"id":"02cb5386734d4c1e91fa51b86cd081c8","type":"GO_TERM","name":"positive regulation of biosynthetic process of antibacterial peptides active against Gram-negative bacteria","canonical_id":"go:GO:0006964","description":"\"Any process that activates or increases the frequency, rate, or extent of biosynthesis of antibacterial peptides active against Gram-negative bacteria.\" [GOC:mah, PMID:10973475]","metadata":null},{"id":"507451662e484425b70ce5973d8aa10b","type":"GO_TERM","name":"positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria","canonical_id":"go:GO:0006965","description":"\"Any process that activates or increases the frequency, rate, or extent of biosynthesis of antibacterial peptides active against Gram-positive bacteria.\" [GOC:mah, PMID:10973475]","metadata":null},{"id":"d83bd3e72cb24706b8093bfe645b8b71","type":"GO_TERM","name":"positive regulation of bipolar cell growth","canonical_id":"go:GO:0051518","description":"\"Any process that activates or increases the frequency, rate or extent of bipolar cell growth, polarized growth from both ends of a cell.\" [GOC:ai]","metadata":null},{"id":"1f37e665bd4945c6b158dbd2aacaa62b","type":"GO_TERM","name":"positive regulation of bleb assembly","canonical_id":"go:GO:1904172","description":"\"Any process that activates or increases the frequency, rate or extent of bleb assembly.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:25651887]","metadata":null},{"id":"e5c5536e69e44ccfb6232951af2975a4","type":"GO_TERM","name":"positive regulation of blood circulation","canonical_id":"go:GO:1903524","description":"\"Any process that activates or increases the frequency, rate or extent of blood circulation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:10659969]","metadata":null},{"id":"061ad8ce2c2849ed964c63c3f0a6896b","type":"GO_TERM","name":"positive regulation of blood coagulation","canonical_id":"go:GO:0030194","description":"\"Any process that activates or increases the frequency, rate or extent of blood coagulation.\" [GOC:mah]","metadata":null},{"id":"918295866d2f4314b42a7708b68f723e","type":"GO_TERM","name":"positive regulation of blood coagulation, common pathway","canonical_id":"go:GO:2000262","description":"\"Any process that activates or increases the frequency, rate or extent of blood coagulation, common pathway.\" [GOC:mah]","metadata":null},{"id":"8dafa647028945b69e96d53d6e38099a","type":"GO_TERM","name":"positive regulation of blood coagulation, extrinsic pathway","canonical_id":"go:GO:2000265","description":"\"Any process that activates or increases the frequency, rate or extent of blood coagulation, extrinsic pathway.\" [GOC:mah]","metadata":null},{"id":"ff032beaf20e4f74929ae1713ef14fbd","type":"GO_TERM","name":"positive regulation of blood coagulation, intrinsic pathway","canonical_id":"go:GO:2000268","description":"\"Any process that activates or increases the frequency, rate or extent of blood coagulation, intrinsic pathway.\" [GOC:mah]","metadata":null},{"id":"fa23be55541846d18b4500bcc1117612","type":"GO_TERM","name":"positive regulation of blood microparticle formation","canonical_id":"go:GO:2000334","description":"\"Any process that activates or increases the frequency, rate or extent of blood microparticle formation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ce1449d3d26544ddb808ba6df6913e1a","type":"GO_TERM","name":"positive regulation of blood pressure","canonical_id":"go:GO:0045777","description":"\"Any process in which the force of blood traveling through the circulatory system is increased.\" [GOC:curators, GOC:mtg_cardio]","metadata":null},{"id":"563552ad63ad4730a817f1ac2348bec2","type":"GO_TERM","name":"positive regulation of blood pressure by epinephrine-norepinephrine","canonical_id":"go:GO:0003321","description":"\"Any process in which the force of blood traveling through the circulatory system is increased by the chemicals epinephrine and norepinephrine.\" [GOC:dph]","metadata":null},{"id":"7093970828fe427b91474fa737f74d59","type":"GO_TERM","name":"positive regulation of blood vessel branching","canonical_id":"go:GO:1905555","description":"\"Any process that activates or increases the frequency, rate or extent of blood vessel branching.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23201774]","metadata":null},{"id":"aff94c09ddd24186892d5863b236e260","type":"GO_TERM","name":"positive regulation of blood vessel endothelial cell differentiation","canonical_id":"go:GO:0110058","description":"\"Any process that activates or increases the frequency, rate or extent of blood vessel endothelial cell differentiation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:23072816]","metadata":null},{"id":"2ce2be139ff1449da547b08d7eb291c8","type":"GO_TERM","name":"positive regulation of blood vessel endothelial cell migration","canonical_id":"go:GO:0043536","description":"\"Any process that activates or increases the frequency, rate or extent of the migration of the endothelial cells of blood vessels.\" [GOC:curators]","metadata":null},{"id":"236815e0f674424cb2722a94e2c3aafd","type":"GO_TERM","name":"positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis","canonical_id":"go:GO:1903589","description":"\"Any process that activates or increases the frequency, rate or extent of blood vessel endothelial cell proliferation involved in sprouting angiogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:23388056]","metadata":null},{"id":"20bf163a8b084b7db6094113e36cdc97","type":"GO_TERM","name":"positive regulation of blood vessel remodeling","canonical_id":"go:GO:2000504","description":"\"Any process that activates or increases the frequency, rate or extent of blood vessel remodeling.\" [GOC:obol]","metadata":null},{"id":"63f8ccf79d734c2382bf3d85ed269d97","type":"GO_TERM","name":"positive regulation of blood-brain barrier permeability","canonical_id":"go:GO:1905605","description":"\"Any process that increases blood-brain barrier permeability, the quality of the blood-brain barrier that allows for a controlled passage of substances (e.g. macromolecules, small molecules, ions) into and out of the brain.\" [GO_REF:0000058, GOC:als, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:22524708, PMID:30280653]","metadata":null},{"id":"4aeb7c94159444db9c3c3e74f4b27265","type":"GO_TERM","name":"positive regulation of bone development","canonical_id":"go:GO:1903012","description":"\"Any process that activates or increases the frequency, rate or extent of bone development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:22510437]","metadata":null},{"id":"5bcfdc88884548219e413699065421cd","type":"GO_TERM","name":"positive regulation of bone mineralization","canonical_id":"go:GO:0030501","description":"\"Any process that activates or increases the frequency, rate or extent of bone mineralization.\" [GOC:curators]","metadata":null},{"id":"8329e8bfd7794a91866037d2e4d2dce7","type":"GO_TERM","name":"positive regulation of bone mineralization involved in bone maturation","canonical_id":"go:GO:1900159","description":"\"Any process that activates or increases the frequency, rate or extent of bone mineralization involved in bone maturation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"95d5f4ffad4e4f47a05dd7b6fbd1f045","type":"GO_TERM","name":"positive regulation of bone remodeling","canonical_id":"go:GO:0046852","description":"\"Any process that activates or increases the frequency, rate or extent of bone remodeling.\" [GOC:ai]","metadata":null},{"id":"c76139d63df7420e904c8313386a1d21","type":"GO_TERM","name":"positive regulation of bone resorption","canonical_id":"go:GO:0045780","description":"\"Any process that activates or increases the frequency, rate or extent of bone resorption.\" [GOC:curators]","metadata":null},{"id":"4dbc02085c1d4f83951426642b7f1df1","type":"GO_TERM","name":"positive regulation of bone trabecula formation","canonical_id":"go:GO:1900156","description":"\"Any process that activates or increases the frequency, rate or extent of bone trabecula formation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"8e19925a230b419a95b98414962a8092","type":"GO_TERM","name":"positive regulation of border follicle cell delamination","canonical_id":"go:GO:0030711","description":"\"Any process that increases the frequency, rate or extent of border cell delamination.\" [PMID:10822261]","metadata":null},{"id":"d9b7d30bfd2144a6bcd938087f21cc01","type":"GO_TERM","name":"positive regulation of border follicle cell migration","canonical_id":"go:GO:1903688","description":"\"Any process that activates or increases the frequency, rate or extent of border follicle cell migration.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18394891]","metadata":null},{"id":"aec189f48ae5433ab58873c4ddf605ec","type":"GO_TERM","name":"positive regulation of brain-derived neurotrophic factor receptor signaling pathway","canonical_id":"go:GO:0031550","description":"\"Any process that activates or increases the frequency, rate or extent of signaling via the brain-derived neurotrophic factor receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"96c924b839e545b98eeca11bf6bd02e1","type":"GO_TERM","name":"positive regulation of branching involved in lung morphogenesis","canonical_id":"go:GO:0061047","description":"\"Any process that increases the rate, frequency, or extent of the process in which a highly ordered sequence of patterning events generates the branched structures of the lung, consisting of reiterated combinations of bud outgrowth, elongation, and dichotomous subdivision of terminal units.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"f3dfc45131ce4fcd9cfa19daa4319bcc","type":"GO_TERM","name":"positive regulation of branching involved in ureteric bud morphogenesis","canonical_id":"go:GO:0090190","description":"\"Any process that increases the rate, frequency or extent of branching involved in ureteric bud morphogenesis, the process in which the branching structure of the ureteric bud is generated and organized. The ureteric bud is an epithelial tube that grows out from the metanephric duct. The bud elongates and branches to give rise to the ureter and kidney collecting tubules.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"facadb2f15ad474dbc7e82f3ab2f6ba6","type":"GO_TERM","name":"positive regulation of branching morphogenesis of a nerve","canonical_id":"go:GO:1905492","description":"\"Any process that activates or increases the frequency, rate or extent of branching morphogenesis of a nerve.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"2c3324ee84324eb2be8591430868fa6e","type":"GO_TERM","name":"positive regulation of branchiomeric skeletal muscle development","canonical_id":"go:GO:0014712","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of branchiomeric skeletal muscle development. Branchiomeric skeletal muscle development is the process whose specific outcome is the progression of the branchiomeric skeletal muscle over time, from its formation to the mature structure.\" [GOC:mtg_muscle]","metadata":null},{"id":"ae591dd1f84c402780a793ce4239eff0","type":"GO_TERM","name":"positive regulation of brassinosteroid biosynthetic process","canonical_id":"go:GO:2000488","description":"\"Any process that activates or increases the frequency, rate or extent of brassinosteroid biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"b37a8f03d8184643bbd8ceefbe3f4e88","type":"GO_TERM","name":"positive regulation of brassinosteroid mediated signaling pathway","canonical_id":"go:GO:1900459","description":"\"Any process that activates or increases the frequency, rate or extent of brassinosteroid mediated signaling pathway.\" [GOC:TermGenie, PMID:21855796]","metadata":null},{"id":"7df4ecea1cad443ea9075cf9e680b2cb","type":"GO_TERM","name":"positive regulation of brood size","canonical_id":"go:GO:0090727","description":"\"Any process that increases brood size. Brood size is the number of progeny that survive embryogenesis and are cared for at one time.\" [GOC:rz]","metadata":null},{"id":"0e8b13d732fe4bd88abc443ff2b2fcdb","type":"GO_TERM","name":"positive regulation of brown fat cell differentiation","canonical_id":"go:GO:0090336","description":"\"Any process that increases the rate, frequency, or extent of brown fat cell differentiation. Brown fat cell differentiation is the process in which a relatively unspecialized cell acquires specialized features of a brown adipocyte, an animal connective tissue cell involved in adaptive thermogenesis. Brown adipocytes contain multiple small droplets of triglycerides and a high number of mitochondria.\" [GOC:BHF]","metadata":null},{"id":"832ba053c7f944eb9a08b7d0f369a15b","type":"GO_TERM","name":"positive regulation of brown fat cell proliferation","canonical_id":"go:GO:0070349","description":"\"Any process that activates or increases the rate or extent of brown fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"1b4e3ea852b448c88a853536982b8242","type":"GO_TERM","name":"positive regulation of c-di-GMP signaling","canonical_id":"go:GO:0061941","description":"\"Any process that increases the rate, frequency or extent of c-di-GMP signaling.\" [PMID:22864416]","metadata":null},{"id":"6a06fe82e1a64b4dba9d17a0494df1f9","type":"GO_TERM","name":"positive regulation of cAMP-dependent protein kinase activity","canonical_id":"go:GO:2000481","description":"\"Any process that activates or increases the frequency, rate or extent of cAMP-dependent protein kinase activity.\" [GOC:obol]","metadata":null},{"id":"64529a335d074411bc42365fbd9f7dab","type":"GO_TERM","name":"positive regulation of cAMP/PKA signal transduction","canonical_id":"go:GO:0141163","description":"\"Any process that activates or increases the frequency, rate or extent of cAMP/PKA signal transduction.\" [PMID:21585352]","metadata":null},{"id":"aee82bf3c29a414f925261ca55eb8a10","type":"GO_TERM","name":"positive regulation of cGAS/STING signaling pathway","canonical_id":"go:GO:0141111","description":"\"Any process that activates or increases the frequency, rate or extent of of cGAS/STING signaling pathway.\" [PMID:37802025]","metadata":null},{"id":"242631081c4444d5b085ca709b49ad38","type":"GO_TERM","name":"positive regulation of calcineurin-NFAT signaling cascade","canonical_id":"go:GO:0070886","description":"\"Any process that activates or increases the frequency, rate or extent of signaling via the calcineurin-NFAT signaling cascade.\" [GOC:mah]","metadata":null},{"id":"f77b76d9372a4180944f8482b745cf01","type":"GO_TERM","name":"positive regulation of calcineurin-mediated signaling","canonical_id":"go:GO:0106058","description":"\"Any process that activates or increases the frequency, rate or extent of calcineurin-mediated signaling.\" [PMID:25081204]","metadata":null},{"id":"7e397ec411fd45668324fe78dc0fcce9","type":"GO_TERM","name":"positive regulation of calcitonin secretion","canonical_id":"go:GO:1904364","description":"\"Any process that activates or increases the frequency, rate or extent of calcitonin secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11278900]","metadata":null},{"id":"2a578989c7014933a00d9823c683846b","type":"GO_TERM","name":"positive regulation of calcium import into the mitochondrion","canonical_id":"go:GO:0110098","description":"\"Any process that activates or increases the frequency, rate or extent of calcium import into the mitochondrion.\" [GOC:sl, PMID:24085037]","metadata":null},{"id":"b0fce449eeb049caac3aa6d5b1310dd7","type":"GO_TERM","name":"positive regulation of calcium ion export across plasma membrane","canonical_id":"go:GO:1905914","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22362515]","metadata":null},{"id":"a89c9f37d2274a199f7a810a1e56392a","type":"GO_TERM","name":"positive regulation of calcium ion import","canonical_id":"go:GO:0090280","description":"\"Any process that increases the rate, frequency, or extent of the directed movement of calcium ions into a cell or organelle.\" [GOC:BHF]","metadata":null},{"id":"4d1a010453c049aa9211e11d442f7248","type":"GO_TERM","name":"positive regulation of calcium ion import across plasma membrane","canonical_id":"go:GO:1905665","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion import across plasma membrane.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:17640527]","metadata":null},{"id":"f515891e8c834bc2a58e741349736a2d","type":"GO_TERM","name":"positive regulation of calcium ion import into sarcoplasmic reticulum","canonical_id":"go:GO:1902082","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion import into sarcoplasmic reticulum.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:8349590]","metadata":null},{"id":"ae8aa9c8d7aa40a7b060689a1bae58b6","type":"GO_TERM","name":"positive regulation of calcium ion transmembrane transport","canonical_id":"go:GO:1904427","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22910094]","metadata":null},{"id":"78c09a0195954c3ea9ca8ecfe55cddf1","type":"GO_TERM","name":"positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel","canonical_id":"go:GO:1904879","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion transmembrane transport via high voltage-gated calcium channel.\" [GO_REF:0000058, GOC:TermGenie, PMID:23071515]","metadata":null},{"id":"f2ec2d9c341346b49a1e7653d0be8bb0","type":"GO_TERM","name":"positive regulation of calcium ion transport","canonical_id":"go:GO:0051928","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"88d6bb7fd2ac4b9b81e54478ed6844a3","type":"GO_TERM","name":"positive regulation of calcium ion transport into cytosol","canonical_id":"go:GO:0010524","description":"\"Any process that increases the rate of the directed movement of calcium ions into the cytosol of a cell. The cytosol is that part of the cytoplasm that does not contain membranous or particulate subcellular components.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0101f21458c5417bb88fb3659687f59a","type":"GO_TERM","name":"positive regulation of calcium ion-dependent exocytosis","canonical_id":"go:GO:0045956","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion-dependent exocytosis.\" [GOC:curators]","metadata":null},{"id":"9770474dfb1a4417a488fea953a207a9","type":"GO_TERM","name":"positive regulation of calcium ion-dependent exocytosis of neurotransmitter","canonical_id":"go:GO:1903235","description":"\"Any process that activates or increases the frequency, rate or extent of calcium ion-dependent exocytosis of neurotransmitter.\" [GO_REF:0000058, GOC:TermGenie, PMID:16782817]","metadata":null},{"id":"42bd192ca17a404c8f364c29c32cb556","type":"GO_TERM","name":"positive regulation of calcium-dependent ATPase activity","canonical_id":"go:GO:1903612","description":"\"Any process that activates or increases the frequency, rate or extent of calcium-dependent ATPase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:10861851]","metadata":null},{"id":"7e19d6c4f6a74a0880c9b8f525d9e7d8","type":"GO_TERM","name":"positive regulation of calcium-dependent cell-cell adhesion","canonical_id":"go:GO:0046587","description":"\"Any process that activates or increases the frequency, rate or extent of calcium-dependent cell-cell adhesion.\" [GOC:ai]","metadata":null},{"id":"57b75990c02248d4834ef3661937b4ca","type":"GO_TERM","name":"positive regulation of calcium-independent cell-cell adhesion","canonical_id":"go:GO:0051041","description":"\"Any process that activates or increases the frequency, rate or extent of calcium-independent cell-cell adhesion.\" [GOC:ai]","metadata":null},{"id":"fcbdc4efedba413b8ba504410b09ca7d","type":"GO_TERM","name":"positive regulation of calcium-mediated signaling","canonical_id":"go:GO:0050850","description":"\"Any process that activates or increases the frequency, rate or extent of calcium-mediated signaling.\" [GOC:ai]","metadata":null},{"id":"65a33801e5c842a58bb2c5e2efdb9f88","type":"GO_TERM","name":"positive regulation of camalexin biosynthetic process","canonical_id":"go:GO:1901183","description":"\"Any process that activates or increases the frequency, rate or extent of camalexin biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"3ed25cc2bce0489699a0da0709de3538","type":"GO_TERM","name":"positive regulation of canonical NF-kappaB signal transduction","canonical_id":"go:GO:0043123","description":"\"Any process that activates or increases the frequency, rate or extent of a canonical NF-kappaB signaling cascade.\" [GOC:jl]","metadata":null},{"id":"a4fb29e413f14bd4b270e27319f73aa4","type":"GO_TERM","name":"positive regulation of canonical Wnt signaling pathway","canonical_id":"go:GO:0090263","description":"\"Any process that increases the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.\" [GOC:tb]","metadata":null},{"id":"ab373e597109408a943128d92464a136","type":"GO_TERM","name":"positive regulation of cap-dependent translational initiation","canonical_id":"go:GO:1903676","description":"\"Any process that activates or increases the frequency, rate or extent of cap-dependent translational initiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11959995]","metadata":null},{"id":"40f1336aa8fc4a59bcfb1afff74b7623","type":"GO_TERM","name":"positive regulation of cap-independent translational initiation","canonical_id":"go:GO:1903679","description":"\"Any process that activates or increases the frequency, rate or extent of cap-independent translational initiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:11959995]","metadata":null},{"id":"33fa5a0ae53d43db96c59229fcf46468","type":"GO_TERM","name":"positive regulation of capsule organization","canonical_id":"go:GO:1901915","description":"\"Any process that activates or increases the frequency, rate or extent of capsule organization.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f1dedd6cc1504f9db876b72318b5b9ed","type":"GO_TERM","name":"positive regulation of capsule polysaccharide biosynthetic process","canonical_id":"go:GO:0062085","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of polysaccharides that make up the capsule, a protective structure surrounding some species of bacteria and fungi.\" [PMID:21917918]","metadata":null},{"id":"d549fcc9003d464aa61a22765ad9d83e","type":"GO_TERM","name":"positive regulation of carbohydrate metabolic process","canonical_id":"go:GO:0045913","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving carbohydrate.\" [GOC:curators]","metadata":null},{"id":"acd6a83b537446b0992b1a53bbd154ec","type":"GO_TERM","name":"positive regulation of cardiac chamber formation","canonical_id":"go:GO:1901212","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac chamber formation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"baec52a30ea0408a8fe39caae252a3b0","type":"GO_TERM","name":"positive regulation of cardiac chamber morphogenesis","canonical_id":"go:GO:1901221","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac chamber morphogenesis.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"5085bfedb31346f5b6eebbce86d17904","type":"GO_TERM","name":"positive regulation of cardiac conduction","canonical_id":"go:GO:1903781","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac conduction.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:12967627]","metadata":null},{"id":"8821d66a060f41f79180f09c74bafc4d","type":"GO_TERM","name":"positive regulation of cardiac endothelial to mesenchymal transition","canonical_id":"go:GO:0062000","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac endothelial to mesenchymal trnasition.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26857067]","metadata":null},{"id":"120b385a129a4aba9b3fe1e4d4c01b20","type":"GO_TERM","name":"positive regulation of cardiac epithelial to mesenchymal transition","canonical_id":"go:GO:0062043","description":"\"Any process that starts or increases the rate, frequency or extent of cardiac epithelial to mesenchymal transition, a transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BHF, GOC:rph, PMID:20951801]","metadata":null},{"id":"af3d5c178eeb4e8f97f0482b468d0a17","type":"GO_TERM","name":"positive regulation of cardiac muscle adaptation","canonical_id":"go:GO:0010615","description":"\"Any process that increases the rate, extent or frequency of the process in which cardiac muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"b395c3936a054543be59700cce3d22ee","type":"GO_TERM","name":"positive regulation of cardiac muscle cell apoptotic process","canonical_id":"go:GO:0010666","description":"\"Any process that increases the rate or extent of cardiac cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a cardiac muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"62e03d2636e04f7f85784acfd156d689","type":"GO_TERM","name":"positive regulation of cardiac muscle cell contraction","canonical_id":"go:GO:0106134","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle cell contraction.\" [PMID:19525381]","metadata":null},{"id":"ded93e012c994b0cbd580cf3c9cb6b84","type":"GO_TERM","name":"positive regulation of cardiac muscle cell differentiation","canonical_id":"go:GO:2000727","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"b6a3cccdd39b45478233e47aa00ed0cc","type":"GO_TERM","name":"positive regulation of cardiac muscle cell myoblast differentiation","canonical_id":"go:GO:2000700","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle cell myoblast differentiation.\" [GOC:obol]","metadata":null},{"id":"9b143b589797483688b741b91a13c763","type":"GO_TERM","name":"positive regulation of cardiac muscle cell proliferation","canonical_id":"go:GO:0060045","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle cell proliferation.\" [GOC:dph, GOC:rph]","metadata":null},{"id":"78bc7522876348bc89174f740f6c7752","type":"GO_TERM","name":"positive regulation of cardiac muscle contraction","canonical_id":"go:GO:0060452","description":"\"Any process that increases the frequency, rate or extent of cardiac muscle contraction.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"62af7a032397497daed5564cfba3ec7a","type":"GO_TERM","name":"positive regulation of cardiac muscle fiber development","canonical_id":"go:GO:0055020","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of cardiac muscle fiber development.\" [GOC:vk]","metadata":null},{"id":"4773c380e38845299762a671f2311708","type":"GO_TERM","name":"positive regulation of cardiac muscle hypertrophy","canonical_id":"go:GO:0010613","description":"\"Any process that increases the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"649f98a2528c49d6a5778eb90b512585","type":"GO_TERM","name":"positive regulation of cardiac muscle hypertrophy in response to stress","canonical_id":"go:GO:1903244","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle hypertrophy in response to stress.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19287093]","metadata":null},{"id":"ece66bc647054975a49377f8964e81be","type":"GO_TERM","name":"positive regulation of cardiac muscle myoblast proliferation","canonical_id":"go:GO:0110024","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle myoblast proliferation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26512644]","metadata":null},{"id":"e629a1412fde4f7a9ac40086429ae132","type":"GO_TERM","name":"positive regulation of cardiac muscle tissue development","canonical_id":"go:GO:0055025","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of cardiac muscle tissue development.\" [GOC:vk]","metadata":null},{"id":"e6f7d2cd66f143419d6d3da93dc8d025","type":"GO_TERM","name":"positive regulation of cardiac muscle tissue growth","canonical_id":"go:GO:0055023","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of cardiac muscle growth.\" [GOC:vk]","metadata":null},{"id":"96d229f8546d443685a83be2fe70aa5c","type":"GO_TERM","name":"positive regulation of cardiac muscle tissue regeneration","canonical_id":"go:GO:1905180","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac muscle tissue regeneration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23222520]","metadata":null},{"id":"0a6968e28712490892c6efe0c31f6896","type":"GO_TERM","name":"positive regulation of cardiac myofibril assembly","canonical_id":"go:GO:1905306","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac myofibril assembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16151019]","metadata":null},{"id":"a6df714506ff4afd87ba7f4899649675","type":"GO_TERM","name":"positive regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis","canonical_id":"go:GO:1905312","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac neural crest cell migration involved in outflow tract morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17628518]","metadata":null},{"id":"4cb417d18efe4dadb6bdd568dbe94dd2","type":"GO_TERM","name":"positive regulation of cardiac vascular smooth muscle cell differentiation","canonical_id":"go:GO:2000724","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac vascular smooth muscle cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"cc72e8c5df1148d9a1fbc90dce63f8c0","type":"GO_TERM","name":"positive regulation of cardiac ventricle development","canonical_id":"go:GO:1904414","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac ventricle development.\" [GO_REF:0000058, GOC:TermGenie, PMID:19590510]","metadata":null},{"id":"5ed91736b28e4aa782d7a64648b2bd38","type":"GO_TERM","name":"positive regulation of cardiac ventricle formation","canonical_id":"go:GO:1904944","description":"\"Any process that activates or increases the frequency, rate or extent of cardiac ventricle formation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23575307]","metadata":null},{"id":"cae60e0652e74f6fbdfd70ae9c23e859","type":"GO_TERM","name":"positive regulation of cardioblast differentiation","canonical_id":"go:GO:0051891","description":"\"Any process that activates or increases the frequency, rate or extent of cardioblast differentiation, the process in which a relatively unspecialized mesodermal cell acquires the specialized structural and/or functional features of a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:ai]","metadata":null},{"id":"cc035c3f1a0b4c42b33f9b90be5e4f24","type":"GO_TERM","name":"positive regulation of cardioblast proliferation","canonical_id":"go:GO:1905062","description":"\"Any process that activates or increases the frequency, rate or extent of cardioblast proliferation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:24236097]","metadata":null},{"id":"30482155bb504dbab15a9956946bb3ee","type":"GO_TERM","name":"positive regulation of cardiocyte differentiation","canonical_id":"go:GO:1905209","description":"\"Any process that activates or increases the frequency, rate or extent of cardiocyte differentiation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23069713]","metadata":null},{"id":"d2443c80480c4fc09adb8b3674144f34","type":"GO_TERM","name":"positive regulation of cardiolipin metabolic process","canonical_id":"go:GO:1900210","description":"\"Any process that activates or increases the frequency, rate or extent of cardiolipin metabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"e1a95374dbf14eeda49041e52fa2ac56","type":"GO_TERM","name":"positive regulation of carotenoid biosynthetic process","canonical_id":"go:GO:1904143","description":"\"Any process that activates or increases the frequency, rate or extent of carotenoid biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:25675505]","metadata":null},{"id":"0f494aa8ee404992a130e0ec9ee202dc","type":"GO_TERM","name":"positive regulation of cartilage condensation","canonical_id":"go:GO:1902027","description":"\"Any process that activates or increases the frequency, rate or extent of cartilage condensation.\" [GOC:TermGenie, PMID:17202865]","metadata":null},{"id":"9c8dcf6826164fc3a8f095e3efd43459","type":"GO_TERM","name":"positive regulation of cartilage development","canonical_id":"go:GO:0061036","description":"\"Any process that increases the rate, frequency, or extent of cartilage development, the process whose specific outcome is the progression of the cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.\" [GOC:dph]","metadata":null},{"id":"290451e1c6374302b6f7c7c8a5431458","type":"GO_TERM","name":"positive regulation of catabolic process","canonical_id":"go:GO:0009896","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of substances.\" [GOC:curators]","metadata":null},{"id":"8b5b6e8fcd0649818700c3c67d5bb637","type":"GO_TERM","name":"positive regulation of catalase activity","canonical_id":"go:GO:1902553","description":"\"Any process that activates or increases the frequency, rate or extent of catalase activity.\" [GOC:TermGenie, PMID:24285797]","metadata":null},{"id":"fbdffdc1b55544f3b40d3423aedfeeea","type":"GO_TERM","name":"positive regulation of catalytic activity","canonical_id":"go:GO:0043085","description":"\"Any process that activates or increases the activity of an enzyme.\" [GOC:ebc, GOC:jl, GOC:tb, GOC:vw]","metadata":null},{"id":"b735fe8dd8554131a3558c42f1ad5512","type":"GO_TERM","name":"positive regulation of catecholamine secretion","canonical_id":"go:GO:0033605","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of a catecholamine.\" [GOC:mah]","metadata":null},{"id":"ce20cda2d0844a2981ca8c0d959fcf4c","type":"GO_TERM","name":"positive regulation of catecholamine uptake involved in synaptic transmission","canonical_id":"go:GO:0051944","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"91d3d394f1d94a47967656df7dd3b2d2","type":"GO_TERM","name":"positive regulation of cation channel activity","canonical_id":"go:GO:2001259","description":"\"Any process that activates or increases the frequency, rate or extent of cation channel activity.\" [GOC:BHF]","metadata":null},{"id":"4eefd6e5330745ca93e1fda430418336","type":"GO_TERM","name":"positive regulation of cation transmembrane transport","canonical_id":"go:GO:1904064","description":"\"Any process that activates or increases the frequency, rate or extent of cation transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:15304482]","metadata":null},{"id":"c61ee6361ec44742b14c3846c6773ece","type":"GO_TERM","name":"positive regulation of caveolin-mediated endocytosis","canonical_id":"go:GO:2001288","description":"\"Any process that activates or increases the frequency, rate or extent of caveolin-mediated endocytosis.\" [GOC:obol]","metadata":null},{"id":"5783891ef4d6492c9d24370183eeab89","type":"GO_TERM","name":"positive regulation of cell activation","canonical_id":"go:GO:0050867","description":"\"Any process that activates or increases the frequency, rate or extent of activation.\" [GOC:ai]","metadata":null},{"id":"82264eaf78bc47ed8c8f3bfc8243ed5f","type":"GO_TERM","name":"positive regulation of cell adhesion","canonical_id":"go:GO:0045785","description":"\"Any process that activates or increases the frequency, rate or extent of cell adhesion.\" [GOC:curators]","metadata":null},{"id":"2f6dc8af08b648c993ae51d5619ee71d","type":"GO_TERM","name":"positive regulation of cell adhesion involved in single-species biofilm formation","canonical_id":"go:GO:1900189","description":"\"Any process that activates or increases the frequency, rate or extent of cell adhesion involved in single-species biofilm formation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6450930c6a0f4a03ac02f14ba0c716b3","type":"GO_TERM","name":"positive regulation of cell adhesion involved in sprouting angiogenesis","canonical_id":"go:GO:0106090","description":"\"Any process that activates or increases the frequency, rate or extent of cell adhesion involved in sprouting angiogenesis.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:24177325]","metadata":null},{"id":"7a5c5db1b6f244d689b9856e88255603","type":"GO_TERM","name":"positive regulation of cell adhesion mediated by integrin","canonical_id":"go:GO:0033630","description":"\"Any process that activates or increases the frequency, rate, or extent of cell adhesion mediated by integrin.\" [GOC:add]","metadata":null},{"id":"50bb1d7a8f2d4d4a8472f52ad3b19ff4","type":"GO_TERM","name":"positive regulation of cell adhesion molecule production","canonical_id":"go:GO:0060355","description":"\"Any process that increases the rate, frequency or extent of cell adhesion molecule production. Cell adhesion molecule production is the appearance of a cell adhesion molecule as a result of its biosynthesis or a decrease in its catabolism.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"2ba8d7f315ae4dd6a59132de7edf71c4","type":"GO_TERM","name":"positive regulation of cell budding","canonical_id":"go:GO:0045782","description":"\"Any process that activates or increases the frequency, rate or extent of cell budding.\" [GOC:curators]","metadata":null},{"id":"98f784835ce044ee8aac4b44ecf38dcb","type":"GO_TERM","name":"positive regulation of cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:1904849","description":"\"Any process that activates or increases the frequency, rate or extent of cell chemotaxis to fibroblast growth factor.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23233752]","metadata":null},{"id":"8a468b03c32045b292e229126551cc67","type":"GO_TERM","name":"positive regulation of cell communication","canonical_id":"go:GO:0010647","description":"\"Any process that increases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"878928231f8244cf952aeffaf4a8fe16","type":"GO_TERM","name":"positive regulation of cell communication by chemical coupling","canonical_id":"go:GO:0010652","description":"\"Any process that increases the frequency, rate or extent of cell communication via chemical coupling. Cell communication by chemical coupling is the process that mediates signaling interactions between one cell and another cell by the transfer of small, water-soluble molecules or metabolites between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"c7926c0d37ec4b28aefaee1eaa213b17","type":"GO_TERM","name":"positive regulation of cell communication by electrical coupling","canonical_id":"go:GO:0010650","description":"\"Any process that increases the frequency, rate or extent of cell communication via electrical coupling. Cell communication via electrical coupling is the process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"4ab2df1a8e1a4673a525eece5118c26a","type":"GO_TERM","name":"positive regulation of cell communication by electrical coupling involved in cardiac conduction","canonical_id":"go:GO:1901846","description":"\"Any process that activates or increases the frequency, rate or extent of cell communication by electrical coupling involved in cardiac conduction.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17130302]","metadata":null},{"id":"0c92111a57474410981ace75f016b836","type":"GO_TERM","name":"positive regulation of cell cycle","canonical_id":"go:GO:0045787","description":"\"Any process that activates or increases the rate or extent of progression through the cell cycle.\" [GOC:curators]","metadata":null},{"id":"983cd2ceec484c74a744fa9e70d6ca01","type":"GO_TERM","name":"positive regulation of cell cycle G1/S phase transition","canonical_id":"go:GO:1902808","description":"\"Any signaling pathway that activates or increases the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the cell cycle.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"55f801cdb6234b459816c1181dfdf291","type":"GO_TERM","name":"positive regulation of cell cycle G2/M phase transition","canonical_id":"go:GO:1902751","description":"\"Any signaling pathway that activates or increases the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the cell cycle.\" [GO_REF:0000058, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"05159599c80446929c53ea0f2d85c17c","type":"GO_TERM","name":"positive regulation of cell cycle checkpoint","canonical_id":"go:GO:1901978","description":"\"Any process that activates or increases the frequency, rate or extent of cell cycle checkpoint.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:23028116]","metadata":null},{"id":"96fb9bc2a39241fdbfdedc074d2da8fb","type":"GO_TERM","name":"positive regulation of cell cycle phase transition","canonical_id":"go:GO:1901989","description":"\"Any process that activates or increases the frequency, rate or extent of cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"1b73a7419709453da5afc803e8c11683","type":"GO_TERM","name":"positive regulation of cell cycle process","canonical_id":"go:GO:0090068","description":"\"Any process that increases the rate, frequency or extent of a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"5499091cf8ac4f838cb533d80f2637e6","type":"GO_TERM","name":"positive regulation of cell cycle switching, mitotic to meiotic cell cycle","canonical_id":"go:GO:0140648","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic to meiotic cell cycle switching, the process in which a cell switches cell cycle mode from mitotic to meiotic division.\" [PMID:22375066]","metadata":null},{"id":"46e424e9e07648e2bad160decb4ebd6b","type":"GO_TERM","name":"positive regulation of cell development","canonical_id":"go:GO:0010720","description":"\"Any process that increases the rate, frequency or extent of the progression of the cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"a2b1469e790e476493b73250e83386bf","type":"GO_TERM","name":"positive regulation of cell differentiation","canonical_id":"go:GO:0045597","description":"\"Any process that activates or increases the frequency, rate or extent of cell differentiation.\" [GOC:curators]","metadata":null},{"id":"d4b548c9210644b2a4abfa4491d24321","type":"GO_TERM","name":"positive regulation of cell division","canonical_id":"go:GO:0051781","description":"\"Any process that activates or increases the frequency, rate or extent of cell division.\" [GOC:ai]","metadata":null},{"id":"00f472b02fd34554ba9c926f671e054e","type":"GO_TERM","name":"positive regulation of cell fate commitment","canonical_id":"go:GO:0010455","description":"\"Any process that activates, maintains or increases the frequency or rate of cell fate commitment. Cell fate commitment is the commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"329b5c8518894d5bb92b0cdf0ae9a7c8","type":"GO_TERM","name":"positive regulation of cell fate determination","canonical_id":"go:GO:1905935","description":"\"Any process that activates or increases the frequency, rate or extent of cell fate determination.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25793578]","metadata":null},{"id":"86ffc31454b24eaabaa6931d55892f90","type":"GO_TERM","name":"positive regulation of cell fate specification","canonical_id":"go:GO:0042660","description":"\"Any process that activates or enables a cell to adopt a specific fate.\" [GOC:curators]","metadata":null},{"id":"f736a3d2e50f45ad9e260823c12d11ad","type":"GO_TERM","name":"positive regulation of cell growth","canonical_id":"go:GO:0030307","description":"\"Any process that activates or increases the frequency, rate, extent or direction of cell growth.\" [GOC:curators]","metadata":null},{"id":"e296a9e807d64bf48835ee50353d95be","type":"GO_TERM","name":"positive regulation of cell growth involved in cardiac muscle cell development","canonical_id":"go:GO:0061051","description":"\"Any process that increases the rate, frequency, or extent of the growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"00266bb3b19447348fe99daa619a0c41","type":"GO_TERM","name":"positive regulation of cell integrity MAPK cascade","canonical_id":"go:GO:1903139","description":"\"Any process that activates or increases the frequency, rate or extent of a cell integrity MAPK cascade.\" [GOC:vw]","metadata":null},{"id":"b131ddcf6fd040de9e641d018c81f263","type":"GO_TERM","name":"positive regulation of cell junction assembly","canonical_id":"go:GO:1901890","description":"\"Any process that activates or increases the frequency, rate or extent of cell junction assembly.\" [GOC:TermGenie]","metadata":null},{"id":"3ec398e1921645d5ba5bdc2f8a6b3731","type":"GO_TERM","name":"positive regulation of cell killing","canonical_id":"go:GO:0031343","description":"\"Any process that activates or increases the frequency, rate or extent of cell killing.\" [GOC:mah]","metadata":null},{"id":"d0c506b2a4324274afc219ac74c3fa46","type":"GO_TERM","name":"positive regulation of cell maturation","canonical_id":"go:GO:1903431","description":"\"Any process that activates or increases the frequency, rate or extent of cell maturation.\" [GO_REF:0000058, GOC:TermGenie, PMID:17459944]","metadata":null},{"id":"32964f8f762241a28d6a8b3a9b3b6735","type":"GO_TERM","name":"positive regulation of cell migration","canonical_id":"go:GO:0030335","description":"\"Any process that activates or increases the frequency, rate or extent of cell migration.\" [GOC:curators]","metadata":null},{"id":"a6f31287ff1e45c493845d4a75de7da5","type":"GO_TERM","name":"positive regulation of cell migration by VEGF-activated platelet derived growth factor receptor signaling pathway","canonical_id":"go:GO:0038090","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to a platelet-derived growth factor receptor (PDGFR) on the surface of a cell, which activates or increases the frequency, rate or extent of the orderly movement of a cell from one site to another.\" [GOC:bf, GOC:signaling, PMID:17470632]","metadata":null},{"id":"dca7923c2d34486f824bb5d19d84d286","type":"GO_TERM","name":"positive regulation of cell migration by vascular endothelial growth factor signaling pathway","canonical_id":"go:GO:0038089","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to its receptor on the surface of a cell, which activates or increases the frequency, rate or extent of the orderly movement of a cell from one site to another.\" [GOC:bf, GOC:signaling]","metadata":null},{"id":"f44465b1d1e3471a940a25c9b5e480f3","type":"GO_TERM","name":"positive regulation of cell migration involved in sprouting angiogenesis","canonical_id":"go:GO:0090050","description":"\"Any process that increases the frequency, rate or extent of cell migration involved in sprouting angiogenesis. Cell migration involved in sprouting angiogenesis is the orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels contributing to the process of sprouting angiogenesis.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"36c1b29033ee49bab58be83e4585d11d","type":"GO_TERM","name":"positive regulation of cell morphogenesis","canonical_id":"go:GO:0010770","description":"\"Any process that increases the frequency, rate or extent of cell morphogenesis contributing to cell differentiation. Cell morphogenesis involved in differentiation is the change in form (cell shape and size) that occurs when relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0df67dee6bb74e999f116ed356cc4ff0","type":"GO_TERM","name":"positive regulation of cell motility","canonical_id":"go:GO:2000147","description":"\"Any process that activates or increases the frequency, rate or extent of cell motility.\" [GOC:mah]","metadata":null},{"id":"037f5f6a8d9e4e98bb8c973514b28368","type":"GO_TERM","name":"positive regulation of cell population proliferation","canonical_id":"go:GO:0008284","description":"\"Any process that activates or increases the rate or extent of cell proliferation.\" [GOC:curators]","metadata":null},{"id":"60399927b240411a9effd873fa6b8beb","type":"GO_TERM","name":"positive regulation of cell projection organization","canonical_id":"go:GO:0031346","description":"\"Any process that activates or increases the frequency, rate or extent of the process involved in the formation, arrangement of constituent parts, or disassembly of cell projections.\" [GOC:mah]","metadata":null},{"id":"a0910b9df9f9401eac653aefc537eef6","type":"GO_TERM","name":"positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway","canonical_id":"go:GO:0038091","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding to a platelet-derived growth factor receptor (PDGFR) on the surface of a cell, which activates or increases the frequency, rate or extent of cell proliferation.\" [GOC:signaling, PMID:17470632]","metadata":null},{"id":"5ade5f6c2ee64974a00096c135f77db8","type":"GO_TERM","name":"positive regulation of cell proliferation in bone marrow","canonical_id":"go:GO:0071864","description":"\"A process that activates or increases the frequency, rate or extent of cell proliferation in the bone marrow.\" [GOC:mah, GOC:yaf, PMID:17063141]","metadata":null},{"id":"b07861bbb1e5438197628349187e8fb4","type":"GO_TERM","name":"positive regulation of cell proliferation in dorsal spinal cord","canonical_id":"go:GO:1902833","description":"\"Any process that activates or increases the frequency, rate or extent of cell proliferation in dorsal spinal cord.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:21730158]","metadata":null},{"id":"aaa0cffdab6e41d583765fc93eef093c","type":"GO_TERM","name":"positive regulation of cell proliferation in midbrain","canonical_id":"go:GO:1904935","description":"\"Any process that activates or increases the frequency, rate or extent of cell proliferation in midbrain.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24431302]","metadata":null},{"id":"f30e8da9a7f0484bb88f985f1d9e8254","type":"GO_TERM","name":"positive regulation of cell proliferation involved in compound eye morphogenesis","canonical_id":"go:GO:2000497","description":"\"Any process that activates or increases the frequency, rate or extent of cell proliferation involved in compound eye morphogenesis.\" [GOC:obol]","metadata":null},{"id":"6909af62e31e4988b64dfe3393149186","type":"GO_TERM","name":"positive regulation of cell proliferation involved in heart morphogenesis","canonical_id":"go:GO:2000138","description":"\"Any process that activates or increases the frequency, rate or extent of cell proliferation involved in heart morphogenesis.\" [GOC:dph]","metadata":null},{"id":"cb54bd9a7dbc4223885da7d50cd2e11a","type":"GO_TERM","name":"positive regulation of cell proliferation involved in kidney development","canonical_id":"go:GO:1901724","description":"\"Any process that activates or increases the frequency, rate or extent of cell proliferation involved in kidney development.\" [GOC:TermGenie, PMID:18182616]","metadata":null},{"id":"87c88f64c2f345c0892cd777364d7abf","type":"GO_TERM","name":"positive regulation of cell septum assembly","canonical_id":"go:GO:1901893","description":"\"Any process that activates or increases the frequency, rate or extent of cell septum assembly.\" [GOC:TermGenie]","metadata":null},{"id":"efe872dc1ad54e908fa977bf1b885747","type":"GO_TERM","name":"positive regulation of cell size","canonical_id":"go:GO:0045793","description":"\"Any process that increases cell size.\" [GOC:curators]","metadata":null},{"id":"266ec341e28948eaaa33c2a562f35c1a","type":"GO_TERM","name":"positive regulation of cell volume","canonical_id":"go:GO:0045795","description":"\"Any process that increases cell volume.\" [GOC:curators]","metadata":null},{"id":"c03c99082b674a93b700c3a05ae43883","type":"GO_TERM","name":"positive regulation of cell wall organization or biogenesis","canonical_id":"go:GO:1903340","description":"\"Any process that activates or increases the frequency, rate or extent of cell wall organization or biogenesis.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"6a31abb2924d4abab770c15d61957286","type":"GO_TERM","name":"positive regulation of cell wall polysaccharide catabolic process","canonical_id":"go:GO:2000968","description":"\"Any process that activates or increases the frequency, rate or extent of cell wall polysaccharide catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"de9c626539bf4a1f8b7a55b072bad37e","type":"GO_TERM","name":"positive regulation of cell-cell adhesion","canonical_id":"go:GO:0022409","description":"\"Any process that activates or increases the rate or extent of cell adhesion to another cell.\" [GOC:isa_complete]","metadata":null},{"id":"75caaec3a7ad4bf99e31b45a4fe01968","type":"GO_TERM","name":"positive regulation of cell-cell adhesion mediated by cadherin","canonical_id":"go:GO:2000049","description":"\"Any process that activates or increases the frequency, rate or extent of cell-cell adhesion mediated by cadherin.\" [GOC:obol]","metadata":null},{"id":"66f9333225134d5fb8cea4bd8907d8c2","type":"GO_TERM","name":"positive regulation of cell-cell adhesion mediated by integrin","canonical_id":"go:GO:0033634","description":"\"Any process that activates or increases the frequency, rate, or extent of cell-cell adhesion mediated by integrin.\" [GOC:add]","metadata":null},{"id":"85b8820bce9047afa36f17955ce998a4","type":"GO_TERM","name":"positive regulation of cell-matrix adhesion","canonical_id":"go:GO:0001954","description":"\"Any process that activates or increases the rate or extent of cell adhesion to an extracellular matrix.\" [GOC:hjd]","metadata":null},{"id":"27d9a4f17e0e4b898abfe143eee6ae22","type":"GO_TERM","name":"positive regulation of cell-substrate adhesion","canonical_id":"go:GO:0010811","description":"\"Any process that increases the frequency, rate or extent of cell-substrate adhesion. Cell-substrate adhesion is the attachment of a cell to the underlying substrate via adhesion molecules.\" [GOC:dph, GOC:pf, GOC:tb]","metadata":null},{"id":"f5ab353e5eec45faa2fd24f85fae433d","type":"GO_TERM","name":"positive regulation of cell-substrate junction organization","canonical_id":"go:GO:0150117","description":"\"Any process that activates or increases the frequency, rate or extent of cell-substrate junction organization.\" [GOC:aruk]","metadata":null},{"id":"453e0ed54aec4942b5aec58fe91ba123","type":"GO_TERM","name":"positive regulation of cellobiose catabolic process","canonical_id":"go:GO:1900284","description":"\"Any process that activates or increases the frequency, rate or extent of cellobiose catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"ac27373c1f1b4820bf04744940464a3f","type":"GO_TERM","name":"positive regulation of cellodextrin catabolic process","canonical_id":"go:GO:2000929","description":"\"Any process that activates or increases the frequency, rate or extent of cellodextrin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"c3848f08496a4c1ba2644f37532db9b5","type":"GO_TERM","name":"positive regulation of cellooligosaccharide catabolic process","canonical_id":"go:GO:2000965","description":"\"Any process that activates or increases the frequency, rate or extent of cellooligosaccharide catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"47c9510fbb964c53ad89afd818eeb844","type":"GO_TERM","name":"positive regulation of cellotriose catabolic process","canonical_id":"go:GO:2000938","description":"\"Any process that activates or increases the frequency, rate or extent of cellotriose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"26ce5453e6ef4b13bd08fcef158226d3","type":"GO_TERM","name":"positive regulation of cellotriose transport","canonical_id":"go:GO:1900287","description":"\"Any process that activates or increases the frequency, rate or extent of cellotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"5e33c2ee0f1f468c8b6c221bccef5bf3","type":"GO_TERM","name":"positive regulation of cellular component biogenesis","canonical_id":"go:GO:0044089","description":"\"Any process that activates or increases the frequency, rate or extent of cellular component biogenesis, a process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cellular component.\" [GOC:jl]","metadata":null},{"id":"ea08073249694536930f32cbcf31341a","type":"GO_TERM","name":"positive regulation of cellular component organization","canonical_id":"go:GO:0051130","description":"\"Any process that activates or increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell structures, including the plasma membrane and any external encapsulating structures such as the cell wall and cell envelope.\" [GOC:ai]","metadata":null},{"id":"f8f46afdca9345a3afde0100e678e28e","type":"GO_TERM","name":"positive regulation of cellular defense response","canonical_id":"go:GO:0010186","description":"\"Any process that activates or increases the frequency, rate or extent of cellular defense response.\" [GOC:sm]","metadata":null},{"id":"525ded14826d4227b85af4908805aac3","type":"GO_TERM","name":"positive regulation of cellular extravasation","canonical_id":"go:GO:0002693","description":"\"Any process that activates or increases the frequency, rate, or extent of cellular extravasation.\" [GOC:add]","metadata":null},{"id":"339e9603d3e543e4af07f5ac818103ae","type":"GO_TERM","name":"positive regulation of cellular process","canonical_id":"go:GO:0048522","description":"\"Any process that activates or increases the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.\" [GOC:jid]","metadata":null},{"id":"bb791e8a617e4ed4b3892b8178c11555","type":"GO_TERM","name":"positive regulation of cellular respiration","canonical_id":"go:GO:1901857","description":"\"Any process that activates or increases the frequency, rate or extent of cellular respiration.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"2d6926b0a024441981f37d500f22f63f","type":"GO_TERM","name":"positive regulation of cellular response to X-ray","canonical_id":"go:GO:2000685","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to X-ray.\" [GOC:obol]","metadata":null},{"id":"104b266be16a411c96dac411cfbbd616","type":"GO_TERM","name":"positive regulation of cellular response to alcohol","canonical_id":"go:GO:1905959","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to alcohol.\" [GO_REF:0000058, GOC:TermGenie, PMID:26434723]","metadata":null},{"id":"baffb8db322244358dcc1f3536170513","type":"GO_TERM","name":"positive regulation of cellular response to amino acid starvation","canonical_id":"go:GO:1903833","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to amino acid starvation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25002487, PMID:7623840]","metadata":null},{"id":"4b0a9864d7794d2da4edacc14e0f5865","type":"GO_TERM","name":"positive regulation of cellular response to drug","canonical_id":"go:GO:2001040","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to drug.\" [GOC:obol]","metadata":null},{"id":"97d634153d934dd183eeca125065832b","type":"GO_TERM","name":"positive regulation of cellular response to gamma radiation","canonical_id":"go:GO:1905845","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to gamma radiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23505386]","metadata":null},{"id":"a9a0dd8dbb284f379e0aee88bb675353","type":"GO_TERM","name":"positive regulation of cellular response to heat","canonical_id":"go:GO:1900036","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to heat.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"eac54bdad9184eea97bbad78194cb8cb","type":"GO_TERM","name":"positive regulation of cellular response to hepatocyte growth factor stimulus","canonical_id":"go:GO:2001114","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to hepatocyte growth factor stimulus.\" [GOC:obol]","metadata":null},{"id":"b469fc48ec8d46eba4921388b14cfc30","type":"GO_TERM","name":"positive regulation of cellular response to hypoxia","canonical_id":"go:GO:1900039","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to hypoxia.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"4ef368e388e544d2bb0f11cce31b315a","type":"GO_TERM","name":"positive regulation of cellular response to insulin stimulus","canonical_id":"go:GO:1900078","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to insulin stimulus.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"d091cefe37bc496da15ee3ee2b1aeaa3","type":"GO_TERM","name":"positive regulation of cellular response to macrophage colony-stimulating factor stimulus","canonical_id":"go:GO:1903974","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to macrophage colony-stimulating factor stimulus.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"898c12a0a3254ceaba13dce3166ac7ed","type":"GO_TERM","name":"positive regulation of cellular response to manganese ion","canonical_id":"go:GO:1905804","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to manganese ion.\" [GO_REF:0000058, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"fd3b2896adfa4736bf032ea9a62af3d9","type":"GO_TERM","name":"positive regulation of cellular response to oxidative stress","canonical_id":"go:GO:1900409","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress.\" [GOC:mah, GOC:TermGenie]","metadata":null},{"id":"099796cad748421493af691b52bcb47d","type":"GO_TERM","name":"positive regulation of cellular response to oxidopamine","canonical_id":"go:GO:1905848","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to oxidopamine.\" [GO_REF:0000058, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"d5c70c7cb32a40638638d6802842d2c0","type":"GO_TERM","name":"positive regulation of cellular response to phosphate starvation","canonical_id":"go:GO:0080040","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to phosphate starvation.\" [PMID:18315545]","metadata":null},{"id":"4e2d9aadcbfc4f05a892d6a53846db50","type":"GO_TERM","name":"positive regulation of cellular response to transforming growth factor beta stimulus","canonical_id":"go:GO:1903846","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to transforming growth factor beta stimulus.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"5aab8b90fdd84b29b967cda990859ad7","type":"GO_TERM","name":"positive regulation of cellular response to very-low-density lipoprotein particle stimulus","canonical_id":"go:GO:1905889","description":"\"Any process that activates or increases the frequency, rate or extent of cellular response to very-low-density lipoprotein particle stimulus.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:7592957]","metadata":null},{"id":"756f490fdd414f9ea0d1363369ebd638","type":"GO_TERM","name":"positive regulation of cellular senescence","canonical_id":"go:GO:2000774","description":"\"Any process that activates or increases the frequency, rate or extent of cellular senescence.\" [GOC:BHF]","metadata":null},{"id":"084f04532a5f4b95bfd753521897b13e","type":"GO_TERM","name":"positive regulation of cellulose biosynthetic process","canonical_id":"go:GO:2001008","description":"\"Any process that activates or increases the frequency, rate or extent of cellulose biosynthetic process.\" [GOC:mengo_curators]","metadata":null},{"id":"6219c4ab4cd24efa940c46f414e31c7a","type":"GO_TERM","name":"positive regulation of cellulose catabolic process","canonical_id":"go:GO:2000999","description":"\"Any process that activates or increases the frequency, rate or extent of cellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"eda76ae587f64132adbde9a76bdf98a9","type":"GO_TERM","name":"positive regulation of cellulosome assembly","canonical_id":"go:GO:1900505","description":"\"Any process that activates or increases the frequency, rate or extent of cellulosome assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"0bdc9ca14c894c0891fc9a0106532e06","type":"GO_TERM","name":"positive regulation of central B cell anergy","canonical_id":"go:GO:0002916","description":"\"Any process that activates or increases the frequency, rate, or extent of central B cell anergy.\" [GOC:add]","metadata":null},{"id":"5260a6ecface4ed384a65a17a41ef592","type":"GO_TERM","name":"positive regulation of central B cell deletion","canonical_id":"go:GO:0002900","description":"\"Any process that activates or increases the frequency, rate, or extent of central B cell deletion.\" [GOC:add]","metadata":null},{"id":"2685adfbcd504165b328bedb20a3dc31","type":"GO_TERM","name":"positive regulation of central B cell tolerance induction","canonical_id":"go:GO:0002897","description":"\"Any process that activates or increases the frequency, rate, or extent of central B cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"a18f21a20a1c442f9b92d0ac2e7ab7ad","type":"GO_TERM","name":"positive regulation of central tolerance induction","canonical_id":"go:GO:0002648","description":"\"Any process that activates or increases the frequency, rate, or extent of central tolerance induction.\" [GOC:add]","metadata":null},{"id":"8b2dfe753fd94e58815404c84ecfe19e","type":"GO_TERM","name":"positive regulation of centriole elongation","canonical_id":"go:GO:1903724","description":"\"Any process that activates or increases the frequency, rate or extent of centriole elongation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:20616062]","metadata":null},{"id":"633bbf1d05c548cba826e0e07084ccb5","type":"GO_TERM","name":"positive regulation of centriole replication","canonical_id":"go:GO:0046601","description":"\"Any process that activates or increases the frequency, rate or extent of centriole replication.\" [GOC:ai]","metadata":null},{"id":"7a37a9ff4c094f5ca773107fb8e6dcfe","type":"GO_TERM","name":"positive regulation of centriole-centriole cohesion","canonical_id":"go:GO:1903127","description":"\"Any process that activates or increases the frequency, rate or extent of centriole-centriole cohesion.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24554434]","metadata":null},{"id":"c769bdef21934624a31654e28d241766","type":"GO_TERM","name":"positive regulation of centrosome cycle","canonical_id":"go:GO:0046607","description":"\"Any process that activates or increases the frequency, rate or extent of the centrosome cycle.\" [GOC:ai]","metadata":null},{"id":"5d112ebde9bd498fb37d9004271f5b1f","type":"GO_TERM","name":"positive regulation of centrosome duplication","canonical_id":"go:GO:0010825","description":"\"Any process that increases the frequency, rate or extent of centrosome duplication. Centrosome duplication is the replication of a centrosome, a structure comprised of a pair of centrioles and peri-centriolar material from which a microtubule spindle apparatus is organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"079d7959628f4fc2a37498e58b705f63","type":"GO_TERM","name":"positive regulation of ceramide biosynthetic process","canonical_id":"go:GO:2000304","description":"\"Any process that activates or increases the frequency, rate or extent of ceramide biosynthetic process.\" [GOC:dph]","metadata":null},{"id":"fa36eb170dbd411a99ade0e5e6e6f259","type":"GO_TERM","name":"positive regulation of cerebellar granule cell precursor proliferation","canonical_id":"go:GO:0021940","description":"\"The process that activates or increases the rate or extent of granule cell precursor proliferation.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"c47fd86f7f4a4b2ab44c0a98a02c79eb","type":"GO_TERM","name":"positive regulation of cerebellar neuron development","canonical_id":"go:GO:1905081","description":"\"Any process that activates or increases the frequency, rate or extent of cerebellar neuron development.\" [GO_REF:0000058, GOC:TermGenie, PMID:26609159]","metadata":null},{"id":"08a3252808fe4475b1e821c961b0248a","type":"GO_TERM","name":"positive regulation of cerebral blood circulation","canonical_id":"go:GO:0120277","description":"\"Any process that activates or increases the frequency, rate or extent of cerebral blood circulation.\" [GOC:krc, PMID:25397684]","metadata":null},{"id":"642bac0ede704ac690ce0c8dd3d0868f","type":"GO_TERM","name":"positive regulation of chanoclavine-I aldehyde biosynthetic process","canonical_id":"go:GO:1900648","description":"\"Any process that activates or increases the frequency, rate or extent of chanoclavine-I aldehyde biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5673b5f68ff841c099d6b889a49222a1","type":"GO_TERM","name":"positive regulation of chaperone-mediated autophagy","canonical_id":"go:GO:1904716","description":"\"Any process that activates or increases the frequency, rate or extent of chaperone-mediated protein folding.\" [PMID:24375412]","metadata":null},{"id":"8f2e92ebd54843a18a7be610a4e131eb","type":"GO_TERM","name":"positive regulation of chaperone-mediated protein complex assembly","canonical_id":"go:GO:0090035","description":"\"Any process that increases the frequency, rate, or extent of chaperone-mediated protein complex assembly. Chaperone-mediated protein complex assembly is the aggregation, arrangement and bonding together of a set of components to form a protein complex, mediated by chaperone molecules that do not form part of the finished complex.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1a3815b9b69b4b42b849af6e30a8d8ed","type":"GO_TERM","name":"positive regulation of chemokine (C-C motif) ligand 1 production","canonical_id":"go:GO:0071654","description":"\"Any process that activates or increases the frequency, rate, or extent of production of chemokine (C-C motif) ligand 1.\" [GOC:mah]","metadata":null},{"id":"7674ba9b21994da5a782b1b1c3dfeb68","type":"GO_TERM","name":"positive regulation of chemokine (C-C motif) ligand 20 production","canonical_id":"go:GO:1903886","description":"\"Any process that activates or increases the frequency, rate or extent of chemokine (C-C motif) ligand 20 production.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:20054338]","metadata":null},{"id":"dfe5ab05ba5144bfbecf037bcb60b3a3","type":"GO_TERM","name":"positive regulation of chemokine (C-C motif) ligand 4 production","canonical_id":"go:GO:0071645","description":"\"Any process that activates or increases the frequency, rate, or extent of production of chemokine (C-C motif) ligand 4.\" [GOC:mah]","metadata":null},{"id":"d0a165e99f004b4284d9069a991c0d38","type":"GO_TERM","name":"positive regulation of chemokine (C-C motif) ligand 5 production","canonical_id":"go:GO:0071651","description":"\"Any process that activates or increases the frequency, rate, or extent of production of chemokine (C-C motif) ligand 5.\" [GOC:mah]","metadata":null},{"id":"7fd2390523b84120bac1d77bdbe1f6c4","type":"GO_TERM","name":"positive regulation of chemokine (C-C motif) ligand 6 production","canonical_id":"go:GO:0035533","description":"\"Any process that activates or increases the frequency, rate, or extent of production of chemokine (C-C motif) ligand 6 (CCL6).\" [GOC:add, GOC:bf]","metadata":null},{"id":"1b9fae169e954d21a4f4a0fe006f690d","type":"GO_TERM","name":"positive regulation of chemokine (C-X-C motif) ligand 1 production","canonical_id":"go:GO:2000340","description":"\"Any process that activates or increases the frequency, rate or extent of chemokine (C-X-C motif) ligand 1 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"5c420ff4985b4e9b9e4d7f9e62548f7f","type":"GO_TERM","name":"positive regulation of chemokine (C-X-C motif) ligand 2 production","canonical_id":"go:GO:2000343","description":"\"Any process that activates or increases the frequency, rate or extent of chemokine (C-X-C motif) ligand 2 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1f012ca06d5d4e2db15a334997846d06","type":"GO_TERM","name":"positive regulation of chemokine (C-X-C motif) ligand 9 production","canonical_id":"go:GO:0035396","description":"\"Any process that activates or increases the frequency, rate, or extent of production of chemokine (C-X-C motif) ligand 9.\" [GOC:bf]","metadata":null},{"id":"e24a7958164342e086d6d5bb508ef3ff","type":"GO_TERM","name":"positive regulation of chemokine production","canonical_id":"go:GO:0032722","description":"\"Any process that activates or increases the frequency, rate, or extent of chemokine production.\" [GOC:mah]","metadata":null},{"id":"4614fe96e7274c419a2493d04e0ad324","type":"GO_TERM","name":"positive regulation of chemokine-mediated signaling pathway","canonical_id":"go:GO:0070101","description":"\"Any process that increases the rate, frequency or extent of a chemokine-mediated signaling pathway.\" [GOC:mah]","metadata":null},{"id":"f58e1f458a1b45d8b9555c679dff96e7","type":"GO_TERM","name":"positive regulation of chemokinesis","canonical_id":"go:GO:1904367","description":"\"Any process that activates or increases the frequency, rate or extent of chemokinesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:8679543]","metadata":null},{"id":"386eceb4a9564999af7e8f31db27d8bb","type":"GO_TERM","name":"positive regulation of chemotaxis","canonical_id":"go:GO:0050921","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a motile cell or organism in response to a specific chemical concentration gradient.\" [GOC:ai]","metadata":null},{"id":"5f44123c388e488893598c0d00dc3288","type":"GO_TERM","name":"positive regulation of chemotaxis to arachidonate","canonical_id":"go:GO:1904554","description":"\"Any process that activates or increases the frequency, rate or extent of chemotaxis to arachidonic acid.\" [GO_REF:0000058, GOC:TermGenie, PMID:16382163]","metadata":null},{"id":"1897994e7cad4b4498da88d1e0e4ed6c","type":"GO_TERM","name":"positive regulation of chemotaxis to cAMP by DIF-2","canonical_id":"go:GO:0061128","description":"\"Any process that increases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of DIF-2. DIF-2 is a chlorinated alkylphenone.\" [GOC:dph]","metadata":null},{"id":"2a5613c9e5f34c5eb377bbd237597cee","type":"GO_TERM","name":"positive regulation of chitin-based cuticle tanning","canonical_id":"go:GO:0045801","description":"\"Any process that activates or increases the frequency, rate or extent of chitin-based cuticular tanning.\" [GOC:curators, GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"8b7b07d8d69e454cb8ca75d65b7a0855","type":"GO_TERM","name":"positive regulation of chlorophyll biosynthetic process","canonical_id":"go:GO:1902326","description":"\"Any process that activates or increases the frequency, rate or extent of chlorophyll biosynthetic process.\" [GOC:TermGenie, PMID:23555952]","metadata":null},{"id":"a8526ca6a2a44a7e99c7eb736c1b2c4a","type":"GO_TERM","name":"positive regulation of chlorophyll catabolic process","canonical_id":"go:GO:1903648","description":"\"Any process that activates or increases the frequency, rate or extent of chlorophyll catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24719469]","metadata":null},{"id":"20999ed76f4145a38beec444561d3719","type":"GO_TERM","name":"positive regulation of chloroplast fission","canonical_id":"go:GO:1905194","description":"\"Any process that activates or increases the frequency, rate or extent of chloroplast fission.\" [GO_REF:0000058, GOC:TermGenie, PMID:26862170]","metadata":null},{"id":"67c0045e7eda4126af2440ea912769e0","type":"GO_TERM","name":"positive regulation of cholangiocyte apoptotic process","canonical_id":"go:GO:1904194","description":"\"Any process that activates or increases the frequency, rate or extent of cholangiocyte apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24498161]","metadata":null},{"id":"cf9897aed5444a9fb3fbba2a5a585e0b","type":"GO_TERM","name":"positive regulation of cholangiocyte proliferation","canonical_id":"go:GO:1904056","description":"\"Any process that activates or increases the frequency, rate or extent of cholangiocyte proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24434010]","metadata":null},{"id":"92bd66d107424bf8b9f0b736dc7f9c35","type":"GO_TERM","name":"positive regulation of cholesterol biosynthetic process","canonical_id":"go:GO:0045542","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of cholesterol.\" [GOC:curators]","metadata":null},{"id":"88d71b8323fe452894b07a6b1938129d","type":"GO_TERM","name":"positive regulation of cholesterol efflux","canonical_id":"go:GO:0010875","description":"\"Any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"7ce2b7ada5044e209688fe0cb9d451fd","type":"GO_TERM","name":"positive regulation of cholesterol import","canonical_id":"go:GO:1904109","description":"\"Any process that activates or increases the frequency, rate or extent of cholesterol import.\" [GO_REF:0000058, GOC:TermGenie, PMID:16772292]","metadata":null},{"id":"b0407cce4ea54cf0b8f3ec1db3d8cd93","type":"GO_TERM","name":"positive regulation of cholesterol metabolic process","canonical_id":"go:GO:0090205","description":"\"Any process that increases the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"0c83bd69dd0c468b856a8ea0f31978dc","type":"GO_TERM","name":"positive regulation of cholesterol storage","canonical_id":"go:GO:0010886","description":"\"Any process that increases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1f79674ffc2043edba19a04d1dad8589","type":"GO_TERM","name":"positive regulation of cholesterol transport","canonical_id":"go:GO:0032376","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of cholesterol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"3d74e3c5172f423ba84231c3f2a9b871","type":"GO_TERM","name":"positive regulation of chondrocyte development","canonical_id":"go:GO:1902761","description":"\"Any process that activates or increases the frequency, rate or extent of chondrocyte development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16575901]","metadata":null},{"id":"5d10fd1213bc4e558e086df2a49a1930","type":"GO_TERM","name":"positive regulation of chondrocyte differentiation","canonical_id":"go:GO:0032332","description":"\"Any process that activates or increases the frequency, rate or extent of chondrocyte differentiation.\" [GOC:mah]","metadata":null},{"id":"d048f4fa211c4a9bbe5775023191e733","type":"GO_TERM","name":"positive regulation of chondrocyte hypertrophy","canonical_id":"go:GO:1903043","description":"\"Any process that activates or increases the frequency, rate or extent of chondrocyte hypertrophy.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:23928032]","metadata":null},{"id":"52c090248de5481680aa4c70f442e2a2","type":"GO_TERM","name":"positive regulation of chondrocyte proliferation","canonical_id":"go:GO:1902732","description":"\"Any process that increases the frequency, rate or extent of the multiplication or reproduction of chondrocytes by cell division, resulting in the expansion of their population. A chondrocyte is a polymorphic cell that forms cartilage.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"76ee2dee86ab40738992d0569327828f","type":"GO_TERM","name":"positive regulation of chorionic trophoblast cell proliferation","canonical_id":"go:GO:1901384","description":"\"Any process that activates or increases the frequency, rate or extent of chorionic trophoblast cell proliferation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"a5191d6dc93d494d8d00ce09ed4a6b21","type":"GO_TERM","name":"positive regulation of chromatin binding","canonical_id":"go:GO:0035563","description":"\"Any process that increases the frequency, rate or extent of chromatin binding. Chromatin binding is the selective interaction with chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase.\" [GOC:bf, PMID:20404130]","metadata":null},{"id":"628776b2f080403d87e2f66a2f877415","type":"GO_TERM","name":"positive regulation of chromatin organization","canonical_id":"go:GO:1905269","description":"\"Any process that activates or increases the frequency, rate or extent of chromatin organization.\" [GO_REF:0000058, GOC:pr, GOC:TermGenie, GOC:vw, PMID:654321]","metadata":null},{"id":"6c8f57ade3e94158bb11609150dacd68","type":"GO_TERM","name":"positive regulation of chromosome attachment to the nuclear envelope","canonical_id":"go:GO:0120266","description":"\"Any process that activates or increases the frequency, rate or extent of the chromosome attachment to the nuclear envelope.\" [GOC:krc]","metadata":null},{"id":"1d7e50d5e524444992d1fc3d2052b6e6","type":"GO_TERM","name":"positive regulation of chromosome condensation","canonical_id":"go:GO:1905821","description":"\"Any process that activates or increases the frequency, rate or extent of chromosome condensation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:17268547]","metadata":null},{"id":"7f9642426278409b97fb8c8e1d0b1609","type":"GO_TERM","name":"positive regulation of chromosome organization","canonical_id":"go:GO:2001252","description":"\"Any process that activates or increases the frequency, rate or extent of chromosome organization.\" [GOC:obol]","metadata":null},{"id":"315078026f51451898c95f8d2e5d10a4","type":"GO_TERM","name":"positive regulation of chromosome passenger complex localization to kinetochore","canonical_id":"go:GO:0140430","description":"\"Any process that activates or increases the frequency, rate or extent of a chromosome passenger complex localization to kinetochore.\" [PMID:20739936]","metadata":null},{"id":"980eb16b9be0494bbbabd13c5b9e3a00","type":"GO_TERM","name":"positive regulation of chromosome segregation","canonical_id":"go:GO:0051984","description":"\"Any process that activates or increases the frequency, rate or extent of chromosome segregation, the process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets.\" [GOC:ai]","metadata":null},{"id":"e634e7a8a89d43bdbd2b565433fc677f","type":"GO_TERM","name":"positive regulation of chromosome separation","canonical_id":"go:GO:1905820","description":"\"Any process that activates or increases the frequency, rate or extent of chromosome separation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:21795393]","metadata":null},{"id":"727df2c104384b8599c8ab107c772a29","type":"GO_TERM","name":"positive regulation of chronic inflammatory response","canonical_id":"go:GO:0002678","description":"\"Any process that activates or increases the frequency, rate, or extent of a chronic inflammatory response.\" [GOC:add]","metadata":null},{"id":"52bb6fbcdbda4eada9d50b155083e715","type":"GO_TERM","name":"positive regulation of chronic inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002876","description":"\"Any process that activates or increases the frequency, rate, or extent of a chronic inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"b467e5aaa34a4c968311f1bff5b50335","type":"GO_TERM","name":"positive regulation of chronic inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002882","description":"\"Any process that activates or increases the frequency, rate, or extent of a chronic inflammatory response to a non-antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"8a08c633d2354d3d82752bf5e598e6ab","type":"GO_TERM","name":"positive regulation of chylomicron remnant clearance","canonical_id":"go:GO:0090321","description":"\"Any process that increases the rate, frequency or extent of chylomicron remnant clearance. Chylomicron clearance is the process in which a chylomicron remnant is removed from the blood via receptor-mediated endocytosis into liver cells and its constituent parts degraded.\" [GOC:BHF]","metadata":null},{"id":"14ce52bedf234f009713036d09ff54a4","type":"GO_TERM","name":"positive regulation of chylomicron remodeling","canonical_id":"go:GO:0090319","description":"\"Any process that increases the rate, frequency, or extent of chylomicron remodeling. Chylomicron remodeling is the acquisition, loss or modification of a protein or lipid within a chylomicron, including the hydrolysis of triglyceride by lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:BHF]","metadata":null},{"id":"fcc51bf5921547969abc6ff0fedfe21a","type":"GO_TERM","name":"positive regulation of cilium assembly","canonical_id":"go:GO:0045724","description":"\"Any process that activates or increases the frequency, rate or extent of the formation of a cilium.\" [GOC:cilia, GOC:curators]","metadata":null},{"id":"8e9ad8e5b647460180eaacb7f82bd326","type":"GO_TERM","name":"positive regulation of cilium beat frequency involved in ciliary motility","canonical_id":"go:GO:0120030","description":"\"Any process that activates or increases the frequency of cilium beating involved in ciliary motility.\" [PMID:28035044]","metadata":null},{"id":"01daa0c0cafb46b28f6a60958a1fa6b4","type":"GO_TERM","name":"positive regulation of cilium movement","canonical_id":"go:GO:0003353","description":"\"Any process that increases the rate, frequency, or extent of cilium movement, the directed, self-propelled movement of a cilium.\" [GOC:dph]","metadata":null},{"id":"8a70bb9a41eb497ca30f56c077ea3e92","type":"GO_TERM","name":"positive regulation of cilium-dependent cell motility","canonical_id":"go:GO:2000155","description":"\"Any process that activates or increases the frequency, rate or extent of cilium-dependent cell motility.\" [GOC:cilia, GOC:jl]","metadata":null},{"id":"6909fd30823a488e99526b5a16f2f193","type":"GO_TERM","name":"positive regulation of circadian rhythm","canonical_id":"go:GO:0042753","description":"\"Any process that activates or increases the frequency, rate or extent of a circadian rhythm behavior.\" [GOC:curators]","metadata":null},{"id":"424798ab3c744616911a4ccb05a5dfda","type":"GO_TERM","name":"positive regulation of circadian sleep/wake cycle, REM sleep","canonical_id":"go:GO:0046005","description":"\"Any process that activates or increases the duration or quality of rapid eye movement (REM) sleep.\" [GOC:curators]","metadata":null},{"id":"8d6e3e41586d4c67b1c1c97f8c3a0b1e","type":"GO_TERM","name":"positive regulation of circadian sleep/wake cycle, non-REM sleep","canonical_id":"go:GO:0046010","description":"\"Any process that activates or increases the duration or quality of non-rapid eye movement (NREM) sleep.\" [GOC:curators]","metadata":null},{"id":"2e93efc566b9453483f053343a012412","type":"GO_TERM","name":"positive regulation of circadian sleep/wake cycle, sleep","canonical_id":"go:GO:0045938","description":"\"Any process that activates or increases the duration or quality of sleep, a readily reversible state of reduced awareness and metabolic activity that occurs periodically in many animals.\" [GOC:curators]","metadata":null},{"id":"3a55d607a757457a98c88fb2db35850a","type":"GO_TERM","name":"positive regulation of circadian sleep/wake cycle, wakefulness","canonical_id":"go:GO:0010841","description":"\"Any process that increases the frequency, or extent of the wakeful phase of the circadian sleep/wake cycle. The wakeful phase is the part of the circadian sleep/wake cycle where the organism is not asleep.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"22e4a12004824f5fbf998c9548b25073","type":"GO_TERM","name":"positive regulation of circulating fibrinogen levels","canonical_id":"go:GO:0061755","description":"\"Any process that increases the quantity of fibrinogen circulating in the bloodstream.\" [GOC:bf, GOC:BHF, GOC:BHF_miRNA, PMID:20570858]","metadata":null},{"id":"af0ddcef6c27446ebdc93c604e3628b0","type":"GO_TERM","name":"positive regulation of citrulline biosynthetic process","canonical_id":"go:GO:1903250","description":"\"Any process that activates or increases the frequency, rate or extent of citrulline biosynthetic process.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19278978]","metadata":null},{"id":"f867b37f142a452ebb98f36bde10d818","type":"GO_TERM","name":"positive regulation of clathrin coat assembly","canonical_id":"go:GO:1905445","description":"\"Any process that activates or increases the frequency, rate or extent of clathrin coat assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:15533940]","metadata":null},{"id":"aee3a382ba4c456fbb36d00da5751aa4","type":"GO_TERM","name":"positive regulation of clathrin-dependent endocytosis","canonical_id":"go:GO:2000370","description":"\"Any process that activates or increases the frequency, rate or extent of clathrin-mediated endocytosis.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"671cacc176254edfa5158628617127ec","type":"GO_TERM","name":"positive regulation of cleistothecium development","canonical_id":"go:GO:0070798","description":"\"Any process that activates or increases the frequency, rate or extent of cleistothecium development, a process that leads to the formation of a cleistothecium. The cleistothecium is a closed sexual fruiting body that contains ascospores in linear asci, characteristic of some filamentous Ascomycete fungi such as members of the genera Aspergillus and Emericella.\" [GOC:mah]","metadata":null},{"id":"d1d3a9784f8a4c15a227ea622cb8bbf5","type":"GO_TERM","name":"positive regulation of coagulation","canonical_id":"go:GO:0050820","description":"\"Any process that activates or increases the frequency, rate or extent of coagulation.\" [GOC:ai]","metadata":null},{"id":"7a7d650d8f0c47a7ab9d9ee9d735c9f5","type":"GO_TERM","name":"positive regulation of cobalamin catabolic process","canonical_id":"go:GO:0106121","description":"\"Any process that activates or increases the frequency, rate or extent of a cobalamin (vitamin B12) catabolic process.\" [PMID:29056341]","metadata":null},{"id":"40ba1eefa90f4e4d99c5e30b45166aaa","type":"GO_TERM","name":"positive regulation of coenzyme F420-dependent bicyclic nitroimidazole catabolic process","canonical_id":"go:GO:1900290","description":"\"Any process that activates or increases the frequency, rate or extent of coenzyme F420-dependent bicyclic nitroimidazole catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"191361c42def4c9b938d43a20fa8ed27","type":"GO_TERM","name":"positive regulation of cold-induced thermogenesis","canonical_id":"go:GO:0120162","description":"\"Any process that activates or increases the frequency, rate or extent of cold-induced thermogenesis.\" [PMID:27876809]","metadata":null},{"id":"f0a5cd0b7d3e4d5f9ebd07a153c5cfb7","type":"GO_TERM","name":"positive regulation of collagen biosynthetic process","canonical_id":"go:GO:0032967","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.\" [GOC:mah]","metadata":null},{"id":"30e1565fe6534d47b63feb85fce63077","type":"GO_TERM","name":"positive regulation of collagen catabolic process","canonical_id":"go:GO:0120158","description":"\"Any process that activates or increases the frequency, rate or extent of collagen catabolism. Collagen catabolism is the proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"dfd879498e8a48d2873b6b07d62fc9c1","type":"GO_TERM","name":"positive regulation of collagen fibril organization","canonical_id":"go:GO:1904028","description":"\"Any process that activates or increases the frequency, rate or extent of collagen fibril organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:25451920]","metadata":null},{"id":"328bd7a9205146d680cd4773f6e0b7e5","type":"GO_TERM","name":"positive regulation of collagen metabolic process","canonical_id":"go:GO:0010714","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the metabolism of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"21b65f7979bf4c3c9446b51631778d28","type":"GO_TERM","name":"positive regulation of collateral sprouting","canonical_id":"go:GO:0048672","description":"\"Any process that activates or increases the frequency, rate or extent of collateral sprouting.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"be92f0ebd3e64222985236cd74fceab2","type":"GO_TERM","name":"positive regulation of collateral sprouting in absence of injury","canonical_id":"go:GO:0048697","description":"\"Any process that activates or increases the frequency, rate or extent of collateral sprouting in the absence of injury.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"50ffcafc91024595b15bb0776dc03777","type":"GO_TERM","name":"positive regulation of collateral sprouting of injured axon","canonical_id":"go:GO:0048694","description":"\"Any process that activates, maintains or increases the rate of collateral sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"1648ed6b7f4e466283c7ce18f3c549b4","type":"GO_TERM","name":"positive regulation of collateral sprouting of intact axon in response to injury","canonical_id":"go:GO:0048684","description":"\"Any process that activates, maintains or increases the rate of collateral sprouting of an intact axon as a result of injury to an axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"cc7531d49536442488923b8516c12baf","type":"GO_TERM","name":"positive regulation of collecting lymphatic vessel constriction","canonical_id":"go:GO:1903816","description":"\"Any process that activates or increases the frequency, rate or extent of collecting lymphatic vessel constriction.\" [GO_REF:0000058, GOC:TermGenie, PMID:23897233]","metadata":null},{"id":"399d5f64b1684a77a010d8ba7e0287f3","type":"GO_TERM","name":"positive regulation of colon smooth muscle contraction","canonical_id":"go:GO:1904343","description":"\"Any process that activates or increases the frequency, rate or extent of colon smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:24170253]","metadata":null},{"id":"2f21cc17d0e5485cb8c5a89becaf0004","type":"GO_TERM","name":"positive regulation of complement activation","canonical_id":"go:GO:0045917","description":"\"Any process that activates or increases the frequency, rate or extent of complement activation.\" [GOC:curators]","metadata":null},{"id":"db889b1535e34af68b50a7fe7d5dd116","type":"GO_TERM","name":"positive regulation of complement activation, alternative pathway","canonical_id":"go:GO:0045958","description":"\"Any process that activates or increases the frequency, rate or extent of complement activation by the alternative pathway.\" [GOC:curators]","metadata":null},{"id":"8e0a9c127389438ab21487b03cf2c57b","type":"GO_TERM","name":"positive regulation of complement activation, classical pathway","canonical_id":"go:GO:0045960","description":"\"Any process that activates or increases the frequency, rate or extent of complement activation by the classical pathway.\" [GOC:curators]","metadata":null},{"id":"3a982872420340da9aa4afbad1e52355","type":"GO_TERM","name":"positive regulation of complement activation, lectin pathway","canonical_id":"go:GO:0001870","description":"\"Any process that activates or increases the frequency, rate or extent of complement activation by the lectin pathway.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1a59fcf60ac541acbc544c9c6409bac3","type":"GO_TERM","name":"positive regulation of complement-dependent cytotoxicity","canonical_id":"go:GO:1903661","description":"\"Any process that activates or increases the frequency, rate or extent of complement-dependent cytotoxicity.\" [GO_REF:0000058, GOC:TermGenie, PMID:24280217]","metadata":null},{"id":"079cb09deb9e4a41ae63b4b7f136ddcc","type":"GO_TERM","name":"positive regulation of compound eye photoreceptor cell differentiation","canonical_id":"go:GO:0110117","description":"\"Any process that activates or increases the frequency, rate or extent of compound eye photoreceptor cell differentiation.\" [GOC:ha, PMID:16377567]","metadata":null},{"id":"02608374efab4f99b60dfcd7a12996e1","type":"GO_TERM","name":"positive regulation of compound eye photoreceptor development","canonical_id":"go:GO:0045315","description":"\"Any process that activates or increases the frequency, rate or extent of compound eye photoreceptor development.\" [GOC:bf]","metadata":null},{"id":"68cac340d4834380b5737c120142d76a","type":"GO_TERM","name":"positive regulation of compound eye pigmentation","canonical_id":"go:GO:0048078","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of a pattern of pigment in the compound eye.\" [GOC:jid]","metadata":null},{"id":"e64bebb337e24e3ba8b6a024f999bbc5","type":"GO_TERM","name":"positive regulation of compound eye retinal cell apoptotic process","canonical_id":"go:GO:1901694","description":"\"Any process that activates or increases the frequency, rate or extent of compound eye retinal cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:TermGenie, PMID:12021768]","metadata":null},{"id":"4251931e176a40d0b5e1e407544df26a","type":"GO_TERM","name":"positive regulation of compound eye retinal cell programmed cell death","canonical_id":"go:GO:0046672","description":"\"Any process that activates or increases the frequency, rate or extent of programmed cell death that occurs in the compound eye retina.\" [GOC:ai]","metadata":null},{"id":"e5f61d6f7583423093876f1b535d3575","type":"GO_TERM","name":"positive regulation of conidiophore development","canonical_id":"go:GO:0070795","description":"\"Any process that activates or increases the frequency, rate or extent of conidiophore development, a process that leads to the formation of a conidiophore. The conidiophore is a specialized hypha that extends aerially from the growth substrate and bears conidia, or asexual spores.\" [GOC:mah]","metadata":null},{"id":"c610725b84574a63b5d62e09f700407b","type":"GO_TERM","name":"positive regulation of conidiophore stalk development","canonical_id":"go:GO:0070801","description":"\"Any process that activates or increases the frequency, rate or extent of conidiophore stalk development, a process that leads to the formation of a conidiophore stalk. The conidiophore stalk is part of a specialized hypha that extends aerially from the growth substrate and supports structures from which conidia, or asexual spores, develop.\" [GOC:mah]","metadata":null},{"id":"f279e197b41e43ddb0571ecd8d6f7b06","type":"GO_TERM","name":"positive regulation of conidium formation","canonical_id":"go:GO:0075307","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of conidium formation, a process of producing non-motile spores, called conidia, via mitotic asexual reproduction in higher fungi. Conidia are haploid cells genetically identical to their haploid parent. They are produced by conversion of hyphal elements, or are borne on sporogenous cells on or within specialized structures termed conidiophores, and participate in dispersal of the fungus.\" [GOC:di, GOC:pamgo_curators]","metadata":null},{"id":"8b7fcfeea36349a398d07029c8d93f86","type":"GO_TERM","name":"positive regulation of conjugation with cellular fusion","canonical_id":"go:GO:0031139","description":"\"Any process that increases the rate or frequency of conjugation with cellular fusion.\" [GOC:mah]","metadata":null},{"id":"2be78fca145d43809aaed83c515d382f","type":"GO_TERM","name":"positive regulation of connective tissue growth factor production","canonical_id":"go:GO:0032723","description":"\"Any process that activates or increases the frequency, rate, or extent of connective tissue growth factor production.\" [GOC:mah]","metadata":null},{"id":"d1bf909568bb4ebb94e7f41eb27fe0a9","type":"GO_TERM","name":"positive regulation of connective tissue replacement","canonical_id":"go:GO:1905205","description":"\"Any process that activates or increases the frequency, rate or extent of connective tissue replacement.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25590961]","metadata":null},{"id":"27f9777f422f4c2f9181cfd8cfc45c2d","type":"GO_TERM","name":"positive regulation of connective tissue replacement involved in inflammatory response wound healing","canonical_id":"go:GO:1904598","description":"\"Any process that activates or increases the frequency, rate or extent of wound healing connective tissue replacement, which may be replaced with fibrotic material, that occurs as part of an inflammatory response.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:18245812]","metadata":null},{"id":"acc476a4c234439a89382fc74f42766b","type":"GO_TERM","name":"positive regulation of constitutive secretory pathway","canonical_id":"go:GO:1903435","description":"\"Any process that activates or increases the frequency, rate or extent of constitutive secretory pathway.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22899725]","metadata":null},{"id":"62103e97fbd74903ba987218734e94b2","type":"GO_TERM","name":"positive regulation of convergent extension involved in gastrulation","canonical_id":"go:GO:1904105","description":"\"Any process that activates or increases the frequency, rate or extent of convergent extension involved in gastrulation.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:24892953]","metadata":null},{"id":"33ec5f04d72f4ba9a394030278308c41","type":"GO_TERM","name":"positive regulation of copper ion transmembrane transport","canonical_id":"go:GO:1902313","description":"\"Any process that activates or increases the frequency, rate or extent of copper ion transmembrane transport.\" [GOC:di, GOC:TermGenie, PMID:21489137]","metadata":null},{"id":"cf0d8fcdc49441aa834f80931fd561ec","type":"GO_TERM","name":"positive regulation of core promoter binding","canonical_id":"go:GO:1904798","description":"\"Any process that activates or increases the frequency, rate or extent of core promoter binding.\" [GO_REF:0000059, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22723415]","metadata":null},{"id":"a7022d72d72b4753859d4f9024fe7938","type":"GO_TERM","name":"positive regulation of cornification","canonical_id":"go:GO:1905717","description":"\"Any process that activates or increases the frequency, rate or extent of cornification.\" [GO_REF:0000058, GOC:TermGenie, PMID:26014679]","metadata":null},{"id":"d4cc992099544db29600a9d27c78dc0e","type":"GO_TERM","name":"positive regulation of cortical granule exocytosis by positive regulation of cytosolic calcium ion concentration","canonical_id":"go:GO:0060472","description":"\"Any process that activates or increases the frequency, rate or extent of cortical granule exocytosis by directing movement of calcium ions (Ca2+) into the cytosol.\" [GOC:dph]","metadata":null},{"id":"bd28cda3d88441c5a670987bf7543da6","type":"GO_TERM","name":"positive regulation of corticosteroid hormone secretion","canonical_id":"go:GO:2000848","description":"\"Any process that activates or increases the frequency, rate or extent of corticosteroid hormone secretion.\" [GOC:sl]","metadata":null},{"id":"a19ea464549b4d0683679634283800f6","type":"GO_TERM","name":"positive regulation of corticosterone secretion","canonical_id":"go:GO:2000854","description":"\"Any process that activates or increases the frequency, rate or extent of corticosterone secretion.\" [GOC:sl]","metadata":null},{"id":"e8fbbd6a3f994f938c734190f101e0d9","type":"GO_TERM","name":"positive regulation of corticotropin secretion","canonical_id":"go:GO:0051461","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of corticotropin hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"5e734ab355f34c7184721d0b7643a8e9","type":"GO_TERM","name":"positive regulation of corticotropin-releasing hormone secretion","canonical_id":"go:GO:0051466","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of corticotropin-releasing hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"3e0b2f559fe344a984d84272e292340f","type":"GO_TERM","name":"positive regulation of cortisol biosynthetic process","canonical_id":"go:GO:2000066","description":"\"Any process that activates or increases the frequency, rate or extent of cortisol biosynthetic process.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"d6a1654350e5410bbd159b6d1d5a9943","type":"GO_TERM","name":"positive regulation of cortisol secretion","canonical_id":"go:GO:0051464","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of cortisol from a cell.\" [GOC:ai]","metadata":null},{"id":"574aaff96420420490c63a655a589786","type":"GO_TERM","name":"positive regulation of cristae formation","canonical_id":"go:GO:1903852","description":"\"Any process that activates or increases the frequency, rate or extent of cristae formation.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:19279012]","metadata":null},{"id":"86d9ec3cbb334758829d7b1bd8934114","type":"GO_TERM","name":"positive regulation of crystal cell differentiation","canonical_id":"go:GO:0042691","description":"\"Any process that activates or increases the frequency, rate or extent of crystal cell differentiation.\" [GOC:curators]","metadata":null},{"id":"2e8c2432745b4e869b999d311eb83789","type":"GO_TERM","name":"positive regulation of cumulus cell differentiation","canonical_id":"go:GO:0045594","description":"\"Any process that activates or increases the frequency, rate or extent of ovarian cumulus cell differentiation.\" [GOC:curators]","metadata":null},{"id":"76a4c8ef956e4bfeab2aefa7badddcc7","type":"GO_TERM","name":"positive regulation of cuticle pigmentation","canonical_id":"go:GO:0048081","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of a pattern of pigment in the cuticle of an organism.\" [GOC:jid]","metadata":null},{"id":"33d54f6a10cc4bb680b34217bb8dc7d5","type":"GO_TERM","name":"positive regulation of cutin biosynthetic process","canonical_id":"go:GO:1901959","description":"\"Any process that activates or increases the frequency, rate or extent of cutin biosynthetic process.\" [GOC:tb, GOC:TermGenie, PMID:23243127]","metadata":null},{"id":"0439af5881a248a3ab66cc34b436b7af","type":"GO_TERM","name":"positive regulation of cyanophore differentiation","canonical_id":"go:GO:0048783","description":"\"Any process that activates or increases the frequency, rate or extent of cyanophore differentiation.\" [GOC:mh]","metadata":null},{"id":"7ab313a9309d45388fc2a6735d4f0ad6","type":"GO_TERM","name":"positive regulation of cyclase activity","canonical_id":"go:GO:0031281","description":"\"Any process that activates or increases the activity of a cyclase.\" [GOC:mah]","metadata":null},{"id":"90234ed8eb6245139a3435517814cbac","type":"GO_TERM","name":"positive regulation of cyclin-dependent protein kinase activity","canonical_id":"go:GO:1904031","description":"\"Any process that activates or increases the frequency, rate or extent of cyclin-dependent protein kinase activity.\" [GO_REF:0000059, GOC:als, GOC:TermGenie, PMID:22995177]","metadata":null},{"id":"009eb57f10e64b8e9bc4f8c1cafe01ac","type":"GO_TERM","name":"positive regulation of cyclin-dependent protein serine/threonine kinase activity","canonical_id":"go:GO:0045737","description":"\"Any process that activates or increases the frequency, rate or extent of CDK activity.\" [GOC:curators, GOC:pr]","metadata":null},{"id":"fc0da6f075f04e92ba196fc19f8e61be","type":"GO_TERM","name":"positive regulation of cyclodextrin catabolic process","canonical_id":"go:GO:2000959","description":"\"Any process that activates or increases the frequency, rate or extent of cyclodextrin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"61696486d73f48bf9e824bf22e84c5a8","type":"GO_TERM","name":"positive regulation of cytochrome-c oxidase activity","canonical_id":"go:GO:1904960","description":"\"Any process that activates or increases the frequency, rate or extent of cytochrome-c oxidase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:26734017]","metadata":null},{"id":"1939b5940c1748499a7e5128b0429e40","type":"GO_TERM","name":"positive regulation of cytogamy","canonical_id":"go:GO:7770079","description":"\"Any process that activates or increases the frequency, rate or extent of cytogamy.\" [PMID:27798845]","metadata":null},{"id":"c5e495cdf40d4d43badce4b66cc13cad","type":"GO_TERM","name":"positive regulation of cytokine production","canonical_id":"go:GO:0001819","description":"\"Any process that activates or increases the frequency, rate or extent of production of a cytokine.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ae630977e0f44b5e84122a73312e4d3e","type":"GO_TERM","name":"positive regulation of cytokine production involved in immune response","canonical_id":"go:GO:0002720","description":"\"Any process that activates or increases the frequency, rate, or extent of cytokine production that contributes to an immune response.\" [GOC:add]","metadata":null},{"id":"826fc566cb344afb899b38d7b44897ea","type":"GO_TERM","name":"positive regulation of cytokine production involved in inflammatory response","canonical_id":"go:GO:1900017","description":"\"Any process that activates or increases the frequency, rate or extent of cytokine production involved in inflammatory response.\" [GOC:TermGenie]","metadata":null},{"id":"b0c8299fd65846ba93862ce8ed3a488b","type":"GO_TERM","name":"positive regulation of cytokine-mediated signaling pathway","canonical_id":"go:GO:0001961","description":"\"Any process that activates or increases the frequency, rate or extent of a cytokine mediated signaling pathway.\" [GOC:hjd]","metadata":null},{"id":"8213c63a9c5243fc8c2db5752d4ed27f","type":"GO_TERM","name":"positive regulation of cytokinesis","canonical_id":"go:GO:0032467","description":"\"Any process that activates or increases the frequency, rate or extent of the division of the cytoplasm of a cell, and its separation into two daughter cells.\" [GOC:mah]","metadata":null},{"id":"cd7a0082426e411aba7dc0ed055633f2","type":"GO_TERM","name":"positive regulation of cytokinesis, actomyosin contractile ring assembly","canonical_id":"go:GO:2000433","description":"\"Any process that activates or increases the frequency, rate or extent of cytokinesis, actomyosin contractile ring assembly.\" [GOC:obol]","metadata":null},{"id":"76650ca9e8e64c72ab4617ee807b733b","type":"GO_TERM","name":"positive regulation of cytokinesis, site selection","canonical_id":"go:GO:2000076","description":"\"Any process that activates or increases the frequency, rate or extent of site selection that occurs as part of cytokinesis.\" [GOC:mtg_cell_cycle, GOC:obol]","metadata":null},{"id":"071a36826241494081328f45fbacf7db","type":"GO_TERM","name":"positive regulation of cytokinin-activated signaling pathway","canonical_id":"go:GO:0080038","description":"\"Any process that activates or increases the frequency, rate or extent of cytokinin signaling.\" [GOC:dhl]","metadata":null},{"id":"6c0743cafe51494d8e7d1f5a0515bb41","type":"GO_TERM","name":"positive regulation of cytolysis","canonical_id":"go:GO:0045919","description":"\"Any process that activates or increases the frequency, rate or extent of cytolysis.\" [GOC:curators]","metadata":null},{"id":"b7f570c44b5c41879dfa9f6c2adf9656","type":"GO_TERM","name":"positive regulation of cytoplasmic mRNA processing body assembly","canonical_id":"go:GO:0010606","description":"\"Any process that increases the rate, frequency, or extent of the aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic mRNA processing body.\" [GOC:dph, GOC:krc, GOC:tb]","metadata":null},{"id":"a4c8245918134468a85c427bac84b1d9","type":"GO_TERM","name":"positive regulation of cytoplasmic stress granule assembly","canonical_id":"go:GO:0062029","description":"\"Any process that starts or increases the rate, frequency or extent of cytoplasmic stress granule assembly, the aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic stress granule.\" [PMID:20180778]","metadata":null},{"id":"cf6b7b41c79a4a298acb5e2a5912b14e","type":"GO_TERM","name":"positive regulation of cytoplasmic translation","canonical_id":"go:GO:2000767","description":"\"Any process that activates or increases the frequency, rate or extent of cytoplasmic translation.\" [GOC:obol]","metadata":null},{"id":"f904cf6e27cb470ea8ecf60b7036b574","type":"GO_TERM","name":"positive regulation of cytoplasmic translational elongation","canonical_id":"go:GO:1900249","description":"\"Any process that activates or increases the frequency, rate or extent of cytoplasmic translational elongation.\" [GOC:TermGenie]","metadata":null},{"id":"672ed9d8fd1248139b5ec0ee2582da84","type":"GO_TERM","name":"positive regulation of cytoplasmic translational elongation through polyproline stretches","canonical_id":"go:GO:1903272","description":"\"Any process that activates or increases the frequency, rate or extent of cytoplasmic translational elongation through polyproline stretches.\" [GO_REF:0000058, GOC:TermGenie, PMID:24923804]","metadata":null},{"id":"86d71952d9e34e29b349be87f4b4a8e7","type":"GO_TERM","name":"positive regulation of cytoplasmic translational initiation","canonical_id":"go:GO:1904690","description":"\"Any process that activates or increases the frequency, rate or extent of cytoplasmic translational initiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:12242291]","metadata":null},{"id":"37bbd5cc4d324e529ac2ebde3eb3cb91","type":"GO_TERM","name":"positive regulation of cytoskeleton organization","canonical_id":"go:GO:0051495","description":"\"Any process that activates or increases the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures.\" [GOC:ai]","metadata":null},{"id":"896fe24f11de4a139d56d82ecec6c18c","type":"GO_TERM","name":"positive regulation of cytosolic calcium ion concentration","canonical_id":"go:GO:0007204","description":"\"Any process that increases the concentration of calcium ions in the cytosol.\" [GOC:ai]","metadata":null},{"id":"58c44d41826441c6b3e7907e51021df2","type":"GO_TERM","name":"positive regulation of cytosolic calcium ion concentration involved in egg activation","canonical_id":"go:GO:0060470","description":"\"The process that increases the concentration of calcium ions in the cytosol after fertilization or the physiological activation of an egg.\" [GOC:dph]","metadata":null},{"id":"6c46b6415f4d415c9250cf89489aa6a4","type":"GO_TERM","name":"positive regulation of cytotoxic T cell degranulation","canonical_id":"go:GO:0043319","description":"\"Any process that activates or increases the frequency, rate or extent of cytotoxic T cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"e3956d9ae5db470c99949aa8493eae8b","type":"GO_TERM","name":"positive regulation of cytotoxic T cell differentiation","canonical_id":"go:GO:0045585","description":"\"Any process that activates or increases the frequency, rate or extent of cytotoxic T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"7af08dc79b094b8b8e8f705f8346bff3","type":"GO_TERM","name":"positive regulation of dauer entry","canonical_id":"go:GO:1905911","description":"\"Any process that activates or increases the frequency, rate or extent of dauer entry.\" [GO_REF:0000058, GOC:TermGenie, PMID:21531333]","metadata":null},{"id":"88f81d325a2a4c28ab84867107255582","type":"GO_TERM","name":"positive regulation of dauer larval development","canonical_id":"go:GO:0061066","description":"\"Any process that increases the rate, frequency, or extent of dauer larval development, the process whose specific outcome is the progression of the dauer larva over time, through the facultative diapause of the dauer (enduring) larval stage, with specialized traits adapted for dispersal and long-term survival, with elevated stress resistance and without feeding.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"76f919471c1946db9a0d8082142e3219","type":"GO_TERM","name":"positive regulation of deacetylase activity","canonical_id":"go:GO:0090045","description":"\"Any process that activates or increases the frequency, rate or extent of deacetylase activity, the catalysis of the hydrolysis of an acetyl group or groups from a substrate molecule.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"7a5e77265c404bba8d3da76ccc53737a","type":"GO_TERM","name":"positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:1901835","description":"\"Any process that activates or increases the frequency, rate or extent of deadenylation-independent decapping of nuclear-transcribed mRNA.\" [GOC:TermGenie]","metadata":null},{"id":"39741dbb61d54477a855c39ed0a39f34","type":"GO_TERM","name":"positive regulation of defecation","canonical_id":"go:GO:2000294","description":"\"Any process that activates or increases the frequency, rate or extent of defecation.\" [GOC:obol]","metadata":null},{"id":"0654ea75eb0a4947a46a83b5374e6211","type":"GO_TERM","name":"positive regulation of defecation rhythm","canonical_id":"go:GO:2000748","description":"\"Any process that activates or increases the frequency, rate or extent of defecation rhythm.\" [GOC:kmv]","metadata":null},{"id":"3db631c45998460a8725537de48ed253","type":"GO_TERM","name":"positive regulation of defense response","canonical_id":"go:GO:0031349","description":"\"Any process that activates or increases the frequency, rate or extent of a defense response.\" [GOC:mah]","metadata":null},{"id":"98a2ad338e1b4e42917579734f95b709","type":"GO_TERM","name":"positive regulation of defense response to bacterium","canonical_id":"go:GO:1900426","description":"\"Any process that activates or increases the frequency, rate or extent of defense response to bacterium.\" [GOC:TermGenie, PMID:22346749]","metadata":null},{"id":"a4184d49478e4e7bb8a1a582d5bc2aa2","type":"GO_TERM","name":"positive regulation of defense response to insect","canonical_id":"go:GO:1900367","description":"\"Any process that activates or increases the frequency, rate or extent of defense response to insect.\" [GOC:TermGenie, PMID:22474183]","metadata":null},{"id":"7b3e2232e3784d2491471006a0b18ed1","type":"GO_TERM","name":"positive regulation of defense response to oomycetes","canonical_id":"go:GO:1902290","description":"\"Any process that activates or increases the frequency, rate or extent of defense response to oomycetes.\" [GOC:TermGenie, PMID:16040633]","metadata":null},{"id":"871996abd52443c18c49aa723b8ada81","type":"GO_TERM","name":"positive regulation of defense response to virus by host","canonical_id":"go:GO:0002230","description":"\"Any host process that results in the promotion of antiviral immune response mechanisms, thereby limiting viral replication.\" [GOC:add, GOC:dph, GOC:tb, ISBN:0781735149]","metadata":null},{"id":"be63249b342243c18a097d850323fe1c","type":"GO_TERM","name":"positive regulation of dehydroaustinol biosynthetic process","canonical_id":"go:GO:1900651","description":"\"Any process that activates or increases the frequency, rate or extent of dehydroaustinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6d4ad8f32b664544bc9322a93fc55a81","type":"GO_TERM","name":"positive regulation of dehydroepiandrosterone secretion","canonical_id":"go:GO:2000842","description":"\"Any process that activates or increases the frequency, rate or extent of dehydroepiandrosterone secretion.\" [GOC:sl]","metadata":null},{"id":"c410e8db61b34e549e93cb47a2eb8e76","type":"GO_TERM","name":"positive regulation of demethylkotanin biosynthetic process","canonical_id":"go:GO:1900654","description":"\"Any process that activates or increases the frequency, rate or extent of demethylkotanin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"81a6d5b4a028466ba383d97524dd9478","type":"GO_TERM","name":"positive regulation of dendrite development","canonical_id":"go:GO:1900006","description":"\"Any process that activates or increases the frequency, rate or extent of dendrite development.\" [GOC:TermGenie]","metadata":null},{"id":"67bde8bbd8ea4cab856a9028b8bf82b1","type":"GO_TERM","name":"positive regulation of dendrite extension","canonical_id":"go:GO:1903861","description":"\"Any process that activates or increases the frequency, rate or extent of dendrite extension.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24898855]","metadata":null},{"id":"add8402fe2c94c3ea50bff2b40850d8b","type":"GO_TERM","name":"positive regulation of dendrite morphogenesis","canonical_id":"go:GO:0050775","description":"\"Any process that activates or increases the frequency, rate or extent of dendrite morphogenesis.\" [GOC:ai]","metadata":null},{"id":"61b2a4cf283b43d8938751e787114d7f","type":"GO_TERM","name":"positive regulation of dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002606","description":"\"Any process that activates or increases the frequency, rate, or extent of dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"c2f06462c0054b299475f25e044a7e09","type":"GO_TERM","name":"positive regulation of dendritic cell apoptotic process","canonical_id":"go:GO:2000670","description":"\"Any process that activates or increases the frequency, rate or extent of dendritic cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"6ed381f7af084e97ade3773415bcfb5a","type":"GO_TERM","name":"positive regulation of dendritic cell chemotaxis","canonical_id":"go:GO:2000510","description":"\"Any process that activates or increases the frequency, rate or extent of dendritic cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"f53cd9f60b594b12b0d572aaf54f4dd2","type":"GO_TERM","name":"positive regulation of dendritic cell cytokine production","canonical_id":"go:GO:0002732","description":"\"Any process that activates or increases the frequency, rate, or extent of dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"6bc7f433c53e45a3bc2ed93ed2d81a49","type":"GO_TERM","name":"positive regulation of dendritic cell dendrite assembly","canonical_id":"go:GO:2000549","description":"\"Any process that activates or increases the frequency, rate or extent of dendritic cell dendrite assembly.\" [GOC:obol]","metadata":null},{"id":"be73289db46d43769ea5b5fd0e2cf776","type":"GO_TERM","name":"positive regulation of dendritic cell differentiation","canonical_id":"go:GO:2001200","description":"\"Any process that activates or increases the frequency, rate or extent of dendritic cell differentiation.\" [GOC:obol]","metadata":null},{"id":"e649375dd5cc47d39ddd492ab8c491fd","type":"GO_TERM","name":"positive regulation of dendritic spine development","canonical_id":"go:GO:0060999","description":"\"Any process that increases the rate, frequency, or extent of dendritic spine development, the process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"fd8d7429bdfb4ffcb606a280f90cfd72","type":"GO_TERM","name":"positive regulation of dendritic spine maintenance","canonical_id":"go:GO:1902952","description":"\"Any process that activates or increases the frequency, rate or extent of dendritic spine maintenance.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24328732]","metadata":null},{"id":"ce93be187c414b489343c10a4dedee5c","type":"GO_TERM","name":"positive regulation of dendritic spine morphogenesis","canonical_id":"go:GO:0061003","description":"\"Any process that increases the rate, frequency, or extent of dendritic spine morphogenesis, the process in which the anatomical structures of a dendritic spine are generated and organized. A dendritic spine is a protrusion from a dendrite and a specialized subcellular compartment involved in synaptic transmission.\" [GOC:dph]","metadata":null},{"id":"f165231537f4415f890ec3f61bd444bd","type":"GO_TERM","name":"positive regulation of dense core granule biogenesis","canonical_id":"go:GO:2000707","description":"\"Any process that activates or increases the frequency, rate or extent of dense core granule biogenesis.\" [GOC:obol]","metadata":null},{"id":"41bf12b16779464bb78c386f378a72ef","type":"GO_TERM","name":"positive regulation of dense core granule exocytosis","canonical_id":"go:GO:1905415","description":"\"Any process that activates or increases the frequency, rate or extent of dense core granule exocytosis.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18468511]","metadata":null},{"id":"c9a57e40f8e54a4cacd4515147720f42","type":"GO_TERM","name":"positive regulation of dense core granule transport","canonical_id":"go:GO:1904811","description":"\"Any process that activates or increases the frequency, rate or extent of dense core granule transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22699897]","metadata":null},{"id":"af9e85fb95884322a3ad0d0db73f4dad","type":"GO_TERM","name":"positive regulation of dentin-containing tooth bud formation by mesenchymal-epithelial signaling","canonical_id":"go:GO:0060640","description":"\"Any process that initiates the formation of a tooth bud by the secretion of a signal from a mesenchymal cell and its reception and subsequent change in the identity of an epithelial cell of the tooth bud.\" [GOC:dph]","metadata":null},{"id":"1b3e73d6ffb144ae9949c1921e4f5e9e","type":"GO_TERM","name":"positive regulation of deoxyribonuclease activity","canonical_id":"go:GO:0032077","description":"\"Any process that activates or increases the frequency, rate or extent of deoxyribonuclease activity, the hydrolysis of ester linkages within deoxyribonucleic acid.\" [GOC:mah]","metadata":null},{"id":"cc1644a861ad4acf95b76262130ea276","type":"GO_TERM","name":"positive regulation of dephosphorylation","canonical_id":"go:GO:0035306","description":"\"Any process that activates or increases the frequency, rate or extent of removal of phosphate groups from a molecule.\" [GOC:bf]","metadata":null},{"id":"2c53895f70d8476f83bd65b83396a87b","type":"GO_TERM","name":"positive regulation of dermatome development","canonical_id":"go:GO:0061184","description":"\"Any process that increases the rate, frequency, or extent of the progression of the dermatome over time, from its initial formation to the mature structure. The dermatome is the portion of a somite that will form skin.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"f25c32a3132e48d299afdb222234f68d","type":"GO_TERM","name":"positive regulation of detection of glucose","canonical_id":"go:GO:2000972","description":"\"Any process that activates or increases the frequency, rate or extent of detection of glucose.\" [GOC:BHF]","metadata":null},{"id":"47579088511f4e2bb59526f3c12b459c","type":"GO_TERM","name":"positive regulation of detection of mechanical stimulus involved in sensory perception of touch","canonical_id":"go:GO:1905789","description":"\"Any process that activates or increases the frequency, rate or extent of detection of mechanical stimulus involved in sensory perception of touch.\" [GO_REF:0000058, GOC:TermGenie, PMID:8692859]","metadata":null},{"id":"78b1bfe915fa4e03b1bdb5579773b98c","type":"GO_TERM","name":"positive regulation of determination of dorsal identity","canonical_id":"go:GO:2000017","description":"\"Any process that activates or increases the frequency, rate or extent of determination of dorsal identity.\" [GOC:obol]","metadata":null},{"id":"b5f7a0900f834969a26f7e419bcb2648","type":"GO_TERM","name":"positive regulation of development of symbiont in host","canonical_id":"go:GO:0044129","description":"\"Any process in which the symbiont activates or maintains its progression from an initial condition to a later condition, within the cells or tissues of the host organism. The host is defined as the larger of the organisms involved in the symbiotic interaction.\" [GOC:jl, GOC:pamgo_curators]","metadata":null},{"id":"0f2bc4a792bf48989f083e713cb446d7","type":"GO_TERM","name":"positive regulation of development, heterochronic","canonical_id":"go:GO:0045962","description":"\"Any process that modulates the consistent predetermined time point at which an integrated living unit or organism progresses from an initial condition to a later condition and increases the rate at which this time point is reached.\" [GOC:curators]","metadata":null},{"id":"05182d7607194defb33d182792336876","type":"GO_TERM","name":"positive regulation of developmental growth","canonical_id":"go:GO:0048639","description":"\"Any process that activates, maintains or increases the rate of developmental growth.\" [GOC:curators]","metadata":null},{"id":"ec4bc56ac38e4e5e9339949534f2b40e","type":"GO_TERM","name":"positive regulation of developmental pigmentation","canonical_id":"go:GO:0048087","description":"\"Any process that increases the frequency, rate or extent of the developmental process that results in the deposition of coloring matter in an organism.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"e293e65d343f4f9691fd80e87882d309","type":"GO_TERM","name":"positive regulation of developmental process","canonical_id":"go:GO:0051094","description":"\"Any process that activates or increases the rate or extent of development, the biological process whose specific outcome is the progression of an organism over time from an initial condition (e.g. a zygote, or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).\" [GOC:ai]","metadata":null},{"id":"45d4a2ed54164179ab5c3aee6a5f48e5","type":"GO_TERM","name":"positive regulation of developmental vegetative growth","canonical_id":"go:GO:1905615","description":"\"Any process that activates or increases the frequency, rate or extent of developmental vegetative growth.\" [GO_REF:0000058, GOC:TermGenie, PMID:11606552]","metadata":null},{"id":"1cbaa3d53e054bcfb3f04520394eb3bb","type":"GO_TERM","name":"positive regulation of diacylglycerol biosynthetic process","canonical_id":"go:GO:1900482","description":"\"Any process that activates or increases the frequency, rate or extent of diacylglycerol biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"bd9389bec1e34d858514a52ae27ace03","type":"GO_TERM","name":"positive regulation of digestive system process","canonical_id":"go:GO:0060456","description":"\"Any process that increases the frequency, rate or extent of a digestive system process, a physical, chemical, or biochemical process carried out by living organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"67486c2a58c047f981969c9e1eea5733","type":"GO_TERM","name":"positive regulation of dipeptide transmembrane transport","canonical_id":"go:GO:2001150","description":"\"Any process that activates or increases the frequency, rate or extent of dipeptide transmembrane transport.\" [GOC:obol]","metadata":null},{"id":"b74134a3a76d40b9883ec05405f15f5c","type":"GO_TERM","name":"positive regulation of dipeptide transport","canonical_id":"go:GO:2000880","description":"\"Any process that activates or increases the frequency, rate or extent of dipeptide transport.\" [GOC:obol]","metadata":null},{"id":"738c87defc6447c196ef8331795811b6","type":"GO_TERM","name":"positive regulation of direction of cell growth","canonical_id":"go:GO:0061390","description":"\"Any process that increases the direction of cell growth.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"9f318509651b4d87a0a33a98fd1af078","type":"GO_TERM","name":"positive regulation of distal tip cell migration","canonical_id":"go:GO:1903356","description":"\"Any process that activates or increases the frequency, rate or extent of distal tip cell migration.\" [GO_REF:0000058, GOC:mm2, GOC:TermGenie, PMID:24968003]","metadata":null},{"id":"e61711c3d0884259abece5804d71ff2d","type":"GO_TERM","name":"positive regulation of division septum assembly","canonical_id":"go:GO:0010973","description":"\"Any process that increases the frequency, rate or extent of division septum formation. division septum formation is the assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis.\" [GOC:mtg_cell_cycle, PMID:19959363, PMID:21246752, PMID:22786806]","metadata":null},{"id":"6277e537231f45ba84c63f9aea52944a","type":"GO_TERM","name":"positive regulation of dopamine biosynthetic process","canonical_id":"go:GO:1903181","description":"\"Any process that activates or increases the frequency, rate or extent of dopamine biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:19703902]","metadata":null},{"id":"b282225e8fd04104a8f3d20ee8c3d031","type":"GO_TERM","name":"positive regulation of dopamine metabolic process","canonical_id":"go:GO:0045964","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving dopamine.\" [GOC:curators]","metadata":null},{"id":"f093681129f24c55a681bbba27903fce","type":"GO_TERM","name":"positive regulation of dopamine receptor signaling pathway","canonical_id":"go:GO:0060161","description":"\"Any process that activates or increases the frequency, rate or extent of the dopamine receptor protein signaling pathway. A dopamine receptor signaling pathway is the series of molecular signals generated as a consequence of a dopamine receptor binding to one of its physiological ligands.\" [GOC:dph]","metadata":null},{"id":"5f916d0dd31f400991dd44eca94bf2f9","type":"GO_TERM","name":"positive regulation of dopamine secretion","canonical_id":"go:GO:0033603","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of dopamine.\" [GOC:sl]","metadata":null},{"id":"aab727c45d7247dcaf50a6bfc63a554d","type":"GO_TERM","name":"positive regulation of dopamine uptake involved in synaptic transmission","canonical_id":"go:GO:0051586","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of dopamine into a cell.\" [GOC:ai]","metadata":null},{"id":"73bd41dfd4c6475d85238acba33b3962","type":"GO_TERM","name":"positive regulation of dopaminergic neuron differentiation","canonical_id":"go:GO:1904340","description":"\"Any process that activates or increases the frequency, rate or extent of dopaminergic neuron differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15522889]","metadata":null},{"id":"c0d4daec7540421aa663fb163fe9608a","type":"GO_TERM","name":"positive regulation of dorsal/ventral axon guidance","canonical_id":"go:GO:1905817","description":"\"Any process that activates or increases the frequency, rate or extent of dorsal/ventral axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:18434533]","metadata":null},{"id":"07861dc49acf4f158c783b9147bbf741","type":"GO_TERM","name":"positive regulation of double-strand break repair","canonical_id":"go:GO:2000781","description":"\"Any process that activates or increases the frequency, rate or extent of double-strand break repair.\" [GOC:BHF]","metadata":null},{"id":"61929e270f71473d8f7bf0f6402ea036","type":"GO_TERM","name":"positive regulation of double-strand break repair via homologous recombination","canonical_id":"go:GO:1905168","description":"\"Any process that activates or increases the frequency, rate or extent of double-strand break repair via homologous recombination.\" [GO_REF:0000058, GOC:TermGenie, PMID:12023299]","metadata":null},{"id":"9518cef164a840508f8dbe7668889f05","type":"GO_TERM","name":"positive regulation of double-strand break repair via nonhomologous end joining","canonical_id":"go:GO:2001034","description":"\"Any process that activates or increases the frequency, rate or extent of double-strand break repair via nonhomologous end joining.\" [GOC:obol]","metadata":null},{"id":"2110408e440d4dba881e1596e93eb03b","type":"GO_TERM","name":"positive regulation of ductus arteriosus closure","canonical_id":"go:GO:1904337","description":"\"Any process that activates or increases the frequency, rate or extent of ductus arteriosus closure.\" [GO_REF:0000058, GOC:TermGenie, PMID:16303610]","metadata":null},{"id":"f54f0b6131724b28b310f18bd9489e8a","type":"GO_TERM","name":"positive regulation of early endosome to late endosome transport","canonical_id":"go:GO:2000643","description":"\"Any process that activates or increases the frequency, rate or extent of early endosome to late endosome transport.\" [GOC:BHF]","metadata":null},{"id":"131421e1e6f0422393ec023140771af6","type":"GO_TERM","name":"positive regulation of early stripe melanocyte differentiation","canonical_id":"go:GO:0050948","description":"\"Any process that activates or increases the frequency, rate or extent of early stripe melanocyte differentiation.\" [GOC:ai]","metadata":null},{"id":"aafcdce0f8344cb59b771a0eaa17b316","type":"GO_TERM","name":"positive regulation of eating behavior","canonical_id":"go:GO:1904000","description":"\"Any process that activates or increases the frequency, rate or extent of eating behavior.\" [GO_REF:0000058, GOC:TermGenie, PMID:11961051]","metadata":null},{"id":"2c6700ec265844b0bc5c72446ea5bc3a","type":"GO_TERM","name":"positive regulation of ecdysone receptor signaling pathway","canonical_id":"go:GO:0120142","description":"\"Any process that activates or increases the frequency, rate or extent of any ecdysone receptor signaling pathway.\" [GOC:ha, PMID:23072462]","metadata":null},{"id":"cd8f428be77647eab0bc60a7ba4910c0","type":"GO_TERM","name":"positive regulation of ecdysteroid biosynthetic process","canonical_id":"go:GO:0045998","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ecdysteroids.\" [GOC:curators]","metadata":null},{"id":"ceeaa9f4c09841d8a98a84724b2234d9","type":"GO_TERM","name":"positive regulation of ecdysteroid secretion","canonical_id":"go:GO:0046000","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of ecdysteroid.\" [GOC:curators]","metadata":null},{"id":"4cf76964582449d2826b5e7958a64f2f","type":"GO_TERM","name":"positive regulation of eclosion","canonical_id":"go:GO:0045805","description":"\"Any process that activates or increases the frequency, rate or extent of eclosion.\" [GOC:curators]","metadata":null},{"id":"82a453c9ff9e4f9ba53d3926db5b9559","type":"GO_TERM","name":"positive regulation of ectoderm development","canonical_id":"go:GO:2000385","description":"\"Any process that activates or increases the frequency, rate or extent of ectoderm development.\" [GOC:BHF]","metadata":null},{"id":"02ffc94f71d64404863879848963c91a","type":"GO_TERM","name":"positive regulation of egg-laying behavior","canonical_id":"go:GO:1901046","description":"\"Any process that activates or increases the frequency, rate or extent of oviposition.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"33eb109604b24c2a9a6f93aac4067ecf","type":"GO_TERM","name":"positive regulation of elastin catabolic process","canonical_id":"go:GO:0110015","description":"\"Any process that activates or increases the frequency, rate or extent of elastin catabolism, the chemical reactions and pathways resulting in the breakdown of elastin.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"1bee72547d0a48879cf91645b19e2b80","type":"GO_TERM","name":"positive regulation of embryo sac central cell differentiation","canonical_id":"go:GO:0045693","description":"\"Any process that activates or increases the frequency, rate or extent of embryo sac central cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"a12fa588017442f79e40e02380989b11","type":"GO_TERM","name":"positive regulation of embryo sac egg cell differentiation","canonical_id":"go:GO:0045696","description":"\"Any process that activates or increases the frequency, rate or extent of embryo sac egg cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"9c6d246e405849799a36a67962c73be7","type":"GO_TERM","name":"positive regulation of embryonic camera-type eye development","canonical_id":"go:GO:1902865","description":"\"Any process that activates or increases the frequency, rate or extent of embryonic camera-type eye development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"92b63888c61443c5974361d12f2ff3f2","type":"GO_TERM","name":"positive regulation of embryonic development","canonical_id":"go:GO:0040019","description":"\"Any process that activates or increases the frequency, rate or extent of embryonic development.\" [GOC:curators]","metadata":null},{"id":"56f7ff706d63419eb027856aba8580e3","type":"GO_TERM","name":"positive regulation of embryonic pattern specification","canonical_id":"go:GO:1902877","description":"\"Any process that activates or increases the frequency, rate or extent of embryonic pattern specification.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"5754e37bf554431f8e282449ba6351c7","type":"GO_TERM","name":"positive regulation of embryonic skeletal joint development","canonical_id":"go:GO:1902764","description":"\"Any process that activates or increases the frequency, rate or extent of embryonic skeletal joint development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16575901]","metadata":null},{"id":"eff8d28963ef45138ce7156df5e831be","type":"GO_TERM","name":"positive regulation of emericellamide A biosynthetic process","canonical_id":"go:GO:1900663","description":"\"Any process that activates or increases the frequency, rate or extent of emericellamide A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"32d7d78b31d84a90b9ed2043856d29c5","type":"GO_TERM","name":"positive regulation of emericellamide biosynthetic process","canonical_id":"go:GO:1900660","description":"\"Any process that activates or increases the frequency, rate or extent of emericellamide biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"9859cb38920c4c5b9ad5f1c5bb15de34","type":"GO_TERM","name":"positive regulation of emericellin biosynthetic process","canonical_id":"go:GO:1900836","description":"\"Any process that activates or increases the frequency, rate or extent of emericellin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f03177cf08f046f5bcabd0e155dea004","type":"GO_TERM","name":"positive regulation of emodin biosynthetic process","canonical_id":"go:GO:1900666","description":"\"Any process that activates or increases the frequency, rate or extent of emodin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"0568d91510a94d5baa42e0bd157cd984","type":"GO_TERM","name":"positive regulation of enamel mineralization","canonical_id":"go:GO:0070175","description":"\"Any process that activates or increases the frequency, rate or extent of enamel mineralization, the deposition of calcium salts in tooth enamel.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"f22956eb36c54aaeb0543f074d77a354","type":"GO_TERM","name":"positive regulation of encysted zoospore germination","canonical_id":"go:GO:0075228","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of encysted zoospore germination.\" [GOC:pamgo_curators]","metadata":null},{"id":"ab97c2f3469e415d8274ae2776117c7b","type":"GO_TERM","name":"positive regulation of endocardial cushion cell differentiation","canonical_id":"go:GO:0120075","description":"\"Any process that activates or increases the frequency, rate or extent of endocardial cushion cell differentiation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"4c82bdd51e3041768dbff9b8d1c2a355","type":"GO_TERM","name":"positive regulation of endocardial cushion to mesenchymal transition","canonical_id":"go:GO:0140051","description":"\"Any process that activates or increases the frequency, rate or extent of endocardial cushion to mesenchymal transition.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:21778427]","metadata":null},{"id":"75a5d9b6b86d4d1c917074ff14680ef6","type":"GO_TERM","name":"positive regulation of endocardial cushion to mesenchymal transition involved in heart valve formation","canonical_id":"go:GO:2000802","description":"\"Any process that activates or increases the frequency, rate or extent of endocardial cushion to mesenchymal transition involved in heart valve formation.\" [GOC:BHF]","metadata":null},{"id":"97dd4a4f337345efb34dabdf9883bfe5","type":"GO_TERM","name":"positive regulation of endocrocin biosynthetic process","canonical_id":"go:GO:1900669","description":"\"Any process that activates or increases the frequency, rate or extent of endocrocin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6d0412949f7347aebf2999c2d27def76","type":"GO_TERM","name":"positive regulation of endocytic recycling","canonical_id":"go:GO:2001137","description":"\"Any process that activates or increases the frequency, rate or extent of endocytic recycling.\" [GOC:obol]","metadata":null},{"id":"a99defbfea324ea1b333c8a29a5b2e44","type":"GO_TERM","name":"positive regulation of endocytosis","canonical_id":"go:GO:0045807","description":"\"Any process that activates or increases the frequency, rate or extent of endocytosis.\" [GOC:curators]","metadata":null},{"id":"4f2a7578914843749b523df21aaf42a7","type":"GO_TERM","name":"positive regulation of endodeoxyribonuclease activity","canonical_id":"go:GO:0032079","description":"\"Any process that activates or increases the frequency, rate or extent of endodeoxyribonuclease activity, the hydrolysis of ester linkages within deoxyribonucleic acid by creating internal breaks.\" [GOC:mah]","metadata":null},{"id":"4da376c08f2045de82207caa3708bd68","type":"GO_TERM","name":"positive regulation of endodermal cell differentiation","canonical_id":"go:GO:1903226","description":"\"Any process that activates or increases the frequency, rate or extent of endodermal cell differentiation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23154389]","metadata":null},{"id":"8ff4654553e14972a8d2f414f79d87ac","type":"GO_TERM","name":"positive regulation of endopeptidase activity","canonical_id":"go:GO:0010950","description":"\"Any process that increases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1b4ed15b005d42d6b96f2f552ad0ca91","type":"GO_TERM","name":"positive regulation of endoplasmic reticulum calcium ion concentration","canonical_id":"go:GO:0032470","description":"\"Any process that increases the concentration of calcium ions in the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"27a4ec56dbb543f283f9760778242071","type":"GO_TERM","name":"positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1902237","description":"\"Any process that activates or increases the frequency, rate or extent of an endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:20160352]","metadata":null},{"id":"0f33255e94a74f4198decec933fea4d5","type":"GO_TERM","name":"positive regulation of endoplasmic reticulum tubular network organization","canonical_id":"go:GO:1903373","description":"\"Any process that activates or increases the frequency, rate or extent of endoplasmic reticulum tubular network organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24891604]","metadata":null},{"id":"9a18fc7c64ba43dfacb8bcbe3cf37d3c","type":"GO_TERM","name":"positive regulation of endoplasmic reticulum unfolded protein response","canonical_id":"go:GO:1900103","description":"\"Any process that activates or increases the frequency, rate or extent of endoplasmic reticulum unfolded protein response.\" [GOC:TermGenie]","metadata":null},{"id":"4ebc300351064f54afc88525bfa247ad","type":"GO_TERM","name":"positive regulation of endosomal vesicle fusion","canonical_id":"go:GO:1905363","description":"\"Any process that activates or increases the frequency, rate or extent of endosomal vesicle fusion.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"1374da57bbe04f63b50e7d08bc9ca1a9","type":"GO_TERM","name":"positive regulation of endosome organization","canonical_id":"go:GO:1904980","description":"\"Any process that activates or increases the frequency, rate or extent of endosome organization.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22511594]","metadata":null},{"id":"0c441d3dad7645df8d6b54d93d77fd05","type":"GO_TERM","name":"positive regulation of endosome to plasma membrane protein transport","canonical_id":"go:GO:1905751","description":"\"Any process that activates or increases the frequency, rate or extent of endosome to plasma membrane protein transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22869721]","metadata":null},{"id":"e2b03553f7a442f2b2eb536e4729f8d1","type":"GO_TERM","name":"positive regulation of endothelial cell activation","canonical_id":"go:GO:1904989","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell activation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:24255059]","metadata":null},{"id":"99e87e824f7949438195b3b1cf938e06","type":"GO_TERM","name":"positive regulation of endothelial cell apoptotic process","canonical_id":"go:GO:2000353","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell apoptotic process.\" [GOC:BHF, GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"beaafb35db1a4a1aa2038b59e8ae8633","type":"GO_TERM","name":"positive regulation of endothelial cell chemotaxis","canonical_id":"go:GO:2001028","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell chemotaxis.\" [GOC:BHF]","metadata":null},{"id":"e15ffcccbea74e13b67d9889057682d6","type":"GO_TERM","name":"positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway","canonical_id":"go:GO:0038033","description":"\"The series of molecular signals initiated by the binding of a vascular endothelial growth factor (VEGF) to its receptor on the surface of a cell, which activates or increases the frequency, rate or extent of endothelial cell chemotaxis.\" [GOC:bf, GOC:BHF, GOC:rl, PMID:21245381]","metadata":null},{"id":"c3d81d3ab4ac4bd1897796c19833047b","type":"GO_TERM","name":"positive regulation of endothelial cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:2000546","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell chemotaxis to fibroblast growth factor.\" [GOC:obol]","metadata":null},{"id":"9369fb14a6bf434d8ca546a2f9aacfda","type":"GO_TERM","name":"positive regulation of endothelial cell chemotaxis to vascular endothelial growth factor","canonical_id":"go:GO:1904859","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell chemotaxis to vascular endothelial growth factor.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:21885851]","metadata":null},{"id":"af6683fee6534612a1184dda9d8cd8ee","type":"GO_TERM","name":"positive regulation of endothelial cell development","canonical_id":"go:GO:1901552","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell development.\" [GOC:pr, GOC:TermGenie, PMID:19470579]","metadata":null},{"id":"4322856432b542499ac3af86afeb11fe","type":"GO_TERM","name":"positive regulation of endothelial cell differentiation","canonical_id":"go:GO:0045603","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell differentiation.\" [GOC:curators]","metadata":null},{"id":"64c7f5e2323e46c49f344047e5f4ae6d","type":"GO_TERM","name":"positive regulation of endothelial cell migration","canonical_id":"go:GO:0010595","description":"\"Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"09e67dbbf8614ae8b1a98c7477f67f75","type":"GO_TERM","name":"positive regulation of endothelial cell proliferation","canonical_id":"go:GO:0001938","description":"\"Any process that activates or increases the rate or extent of endothelial cell proliferation.\" [GOC:add]","metadata":null},{"id":"612565531612478c86e054a9c28d37f1","type":"GO_TERM","name":"positive regulation of endothelial cell-matrix adhesion","canonical_id":"go:GO:1904906","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial cell-matrix adhesion.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:19460962]","metadata":null},{"id":"7b3905d829f74664baf1fab43f664f95","type":"GO_TERM","name":"positive regulation of endothelial microparticle formation","canonical_id":"go:GO:2000337","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial microparticle formation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"4dd6e4f1e0624979839408d3c09920c8","type":"GO_TERM","name":"positive regulation of endothelial tube morphogenesis","canonical_id":"go:GO:1905956","description":"\"Any process that activates or increases the frequency, rate or extent of endothelial tube morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:25961718]","metadata":null},{"id":"ebf3248bb6e04e4686e38df47cd702b2","type":"GO_TERM","name":"positive regulation of endothelin production","canonical_id":"go:GO:1904472","description":"\"Any process that activates or increases the frequency, rate or extent of endothelin production.\" [GO_REF:0000058, GOC:TermGenie, PMID:15560120]","metadata":null},{"id":"0d3fa048cb9f4645a2b826ccf91bb7fb","type":"GO_TERM","name":"positive regulation of engulfment of apoptotic cell","canonical_id":"go:GO:1901076","description":"\"Any process that activates or increases the frequency, rate or extent of engulfment of apoptotic cell.\" [GO:kmv, GOC:TermGenie, PMID:19402756]","metadata":null},{"id":"85d9858e9951424a88338fe64123be81","type":"GO_TERM","name":"positive regulation of ent-pimara-8(14),15-diene biosynthetic process","canonical_id":"go:GO:1901544","description":"\"Any process that activates or increases the frequency, rate or extent of ent-pimara-8(14),15-diene biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"649dae50d2644b8384379d286b963746","type":"GO_TERM","name":"positive regulation of entry into reproductive diapause","canonical_id":"go:GO:0061965","description":"\"Any process that activates or increases the rate or extent of the dormancy process that results in entry into reproductive diapause. Reproductive diapause is a form of diapause where the organism itself will remain fully active, including feeding and other routine activities, but the reproductive organs experience a tissue-specific reduction in metabolism, with characteristic triggering and releasing stimuli.\" [GOC:ha, PMID:27689881]","metadata":null},{"id":"319e52e64127476bb75faf5e5f497a78","type":"GO_TERM","name":"positive regulation of eosinophil activation","canonical_id":"go:GO:1902568","description":"\"Any process that activates or increases the frequency, rate or extent of eosinophil activation.\" [GOC:TermGenie, PMID:16254138]","metadata":null},{"id":"17001b0665b84d5681fcba9f29507a16","type":"GO_TERM","name":"positive regulation of eosinophil chemotaxis","canonical_id":"go:GO:2000424","description":"\"Any process that activates or increases the frequency, rate or extent of eosinophil chemotaxis.\" [GOC:obol]","metadata":null},{"id":"2bafc5bf4d9a42f28a8c240bca66ff48","type":"GO_TERM","name":"positive regulation of eosinophil degranulation","canonical_id":"go:GO:0043311","description":"\"Any process that activates or increases the frequency, rate or extent of eosinophil degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"c2b4acb616d04042848ca8e204b162a7","type":"GO_TERM","name":"positive regulation of eosinophil differentiation","canonical_id":"go:GO:0045645","description":"\"Any process that activates or increases the frequency, rate or extent of eosinophil differentiation.\" [GOC:curators]","metadata":null},{"id":"19530d3207c048468f3a8d6ec25955ac","type":"GO_TERM","name":"positive regulation of eosinophil extravasation","canonical_id":"go:GO:2000421","description":"\"Any process that activates or increases the frequency, rate or extent of eosinophil extravasation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"4f6fa34d542f438b8b66b55ef820fe3d","type":"GO_TERM","name":"positive regulation of eosinophil migration","canonical_id":"go:GO:2000418","description":"\"Any process that activates or increases the frequency, rate or extent of eosinophil migration.\" [GOC:mah]","metadata":null},{"id":"37b5285d12c940959884c229e5a48bb0","type":"GO_TERM","name":"positive regulation of ephrin receptor signaling pathway","canonical_id":"go:GO:1901189","description":"\"Any process that activates or increases the frequency, rate or extent of ephrin receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"20ef7257b615419aa03a5bc974f4bf8a","type":"GO_TERM","name":"positive regulation of epiboly involved in gastrulation with mouth forming second","canonical_id":"go:GO:1904088","description":"\"Any process that activates or increases the frequency, rate or extent of epiboly involved in gastrulation with mouth forming second.\" [GO_REF:0000058, GOC:TermGenie, PMID:24892953]","metadata":null},{"id":"1276dfcce3714b5196156e84543d3174","type":"GO_TERM","name":"positive regulation of epidermal cell differentiation","canonical_id":"go:GO:0045606","description":"\"Any process that activates or increases the frequency, rate or extent of epidermal cell differentiation.\" [GOC:curators]","metadata":null},{"id":"6615811e5b4f403eb2b19610f7ef21fe","type":"GO_TERM","name":"positive regulation of epidermal growth factor receptor signaling pathway","canonical_id":"go:GO:0045742","description":"\"Any process that activates or increases the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"00e7e855e1ad426c81c98339487abbcb","type":"GO_TERM","name":"positive regulation of epidermis development","canonical_id":"go:GO:0045684","description":"\"Any process that activates or increases the frequency, rate or extent of epidermis development.\" [GOC:curators]","metadata":null},{"id":"027623f30b044aa88dc3f666b85720dd","type":"GO_TERM","name":"positive regulation of epinephrine secretion","canonical_id":"go:GO:0032812","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of epinephrine.\" [GOC:vk]","metadata":null},{"id":"bbe7b98920084866a2bd8a9bae96103b","type":"GO_TERM","name":"positive regulation of epinephrine uptake","canonical_id":"go:GO:0051628","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of epinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"d76b7abec6e04f9c98800c599678ad21","type":"GO_TERM","name":"positive regulation of epithelial cell apoptotic process","canonical_id":"go:GO:1904037","description":"\"Any process that activates or increases the frequency, rate or extent of epithelial cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:19137015]","metadata":null},{"id":"9b28bfbb6b934eb7a3a0a7ec4d7cca10","type":"GO_TERM","name":"positive regulation of epithelial cell differentiation","canonical_id":"go:GO:0030858","description":"\"Any process that activates or increases the frequency, rate or extent of epithelial cell differentiation.\" [GOC:mah]","metadata":null},{"id":"8e59054f0daa47ba94941d7451552e4d","type":"GO_TERM","name":"positive regulation of epithelial cell migration","canonical_id":"go:GO:0010634","description":"\"Any process that activates or increases the frequency, rate or extent of epithelial cell migration.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"50613bf0eb70432585cc22ae0509659b","type":"GO_TERM","name":"positive regulation of epithelial cell proliferation","canonical_id":"go:GO:0050679","description":"\"Any process that activates or increases the rate or extent of epithelial cell proliferation.\" [GOC:ai]","metadata":null},{"id":"2ad6d4eb662f46dcae93271a8f012c40","type":"GO_TERM","name":"positive regulation of epithelial cell proliferation involved in lung morphogenesis","canonical_id":"go:GO:0060501","description":"\"Any process that increases the rate or frequency of epithelial cell proliferation that results in the lung attaining its shape.\" [GOC:dph]","metadata":null},{"id":"50b46b41a2bb48d08fdead6ca2f66eae","type":"GO_TERM","name":"positive regulation of epithelial cell proliferation involved in prostate gland development","canonical_id":"go:GO:0060769","description":"\"Any process that increases the rate, frequency or extent of epithelial cell proliferation that contributes to the progression of the prostate gland over time.\" [GOC:dph]","metadata":null},{"id":"f96cecd4ce0f4d35a72f1dbef2da19c9","type":"GO_TERM","name":"positive regulation of epithelial cell proliferation involved in wound healing","canonical_id":"go:GO:0060054","description":"\"Any process that activates or increases the rate or extent of epithelial cell proliferation, contributing to the restoration of integrity to a damaged tissue following an injury.\" [GOC:dph]","metadata":null},{"id":"4637421ec9a74d03827ffff7c19b52f5","type":"GO_TERM","name":"positive regulation of epithelial to mesenchymal transition","canonical_id":"go:GO:0010718","description":"\"Any process that increases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition is where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"65f6cbe655a24cc38bcea137253e313a","type":"GO_TERM","name":"positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation","canonical_id":"go:GO:1905007","description":"\"Any process that activates or increases the frequency, rate or extent of epithelial to mesenchymal transition involved in endocardial cushion formation.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"c928b2ea5b5f457bb62e56a4aaabcb69","type":"GO_TERM","name":"positive regulation of epithelial tube formation","canonical_id":"go:GO:1905278","description":"\"Any process that activates or increases the frequency, rate or extent of epithelial tube formation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25745997]","metadata":null},{"id":"84d0c6e962f44561aff90006db84893b","type":"GO_TERM","name":"positive regulation of epithelium regeneration","canonical_id":"go:GO:1905043","description":"\"Any process that activates or increases the frequency, rate or extent of epithelium regeneration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23221517]","metadata":null},{"id":"85b9277403874c5f8244c928cf7bdb79","type":"GO_TERM","name":"positive regulation of ergosterol biosynthetic process","canonical_id":"go:GO:0070452","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ergosterol.\" [GOC:mah]","metadata":null},{"id":"0a831a8fd88d4afd9b2819b1ee411dfa","type":"GO_TERM","name":"positive regulation of ergot alkaloid biosynthetic process","canonical_id":"go:GO:1900824","description":"\"Any process that activates or increases the frequency, rate or extent of ergot alkaloid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"212cff72dce6403eae7ff9901a6241e1","type":"GO_TERM","name":"positive regulation of error-prone translesion synthesis","canonical_id":"go:GO:1904333","description":"\"Any process that activates or increases the frequency, rate or extent of error-prone translesion synthesis.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22761594]","metadata":null},{"id":"a5046e6c2f694f1580133f5c21f7012b","type":"GO_TERM","name":"positive regulation of erythrocyte aggregation","canonical_id":"go:GO:0034120","description":"\"Any process that activates or increases the frequency, rate, or extent of erythrocyte aggregation.\" [GOC:add]","metadata":null},{"id":"8eca40b4cbdd4e0c9a869582dbbf603b","type":"GO_TERM","name":"positive regulation of erythrocyte apoptotic process","canonical_id":"go:GO:1902252","description":"\"Any process that activates or increases the frequency, rate or extent of erythrocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"660720ec433243bd931eea6da4b04278","type":"GO_TERM","name":"positive regulation of erythrocyte clearance","canonical_id":"go:GO:0034108","description":"\"Any process that activates or increases the frequency, rate, or extent of erythrocyte clearance.\" [GOC:add, PMID:12905029, PMID:14754397]","metadata":null},{"id":"a182226801a7400e811809707c689e5f","type":"GO_TERM","name":"positive regulation of erythrocyte differentiation","canonical_id":"go:GO:0045648","description":"\"Any process that activates or increases the frequency, rate or extent of erythrocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"2da57b1307f14585a7bc06ef6a67ef6e","type":"GO_TERM","name":"positive regulation of erythrocyte enucleation","canonical_id":"go:GO:0061931","description":"\"Any process that increases the frequency, rate or extent of erythrocyte enucleation.\" [PMID:25241935]","metadata":null},{"id":"cd0b74d51fe043b4a3fe775a1fa2cc09","type":"GO_TERM","name":"positive regulation of erythrophore differentiation","canonical_id":"go:GO:0048780","description":"\"Any process that activates or increases the frequency, rate or extent of erythrophore differentiation.\" [GOC:mh]","metadata":null},{"id":"4d69a087d36d4db89613ca4db33d39f1","type":"GO_TERM","name":"positive regulation of establishment of RNA localization to telomere","canonical_id":"go:GO:1904912","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of RNA localization to telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"8c6f3768d6784f83a06ed842a7c07291","type":"GO_TERM","name":"positive regulation of establishment of Sertoli cell barrier","canonical_id":"go:GO:1904446","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of Sertoli cell barrier.\" [GO_REF:0000058, GOC:TermGenie, PMID:18057314]","metadata":null},{"id":"f0a62c30776c41f4854ced214ea62880","type":"GO_TERM","name":"positive regulation of establishment of T cell polarity","canonical_id":"go:GO:1903905","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of T cell polarity.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"4a3d480f32a6485592630f3ed89469c5","type":"GO_TERM","name":"positive regulation of establishment of bipolar cell polarity","canonical_id":"go:GO:0061173","description":"\"Any process that increases the rate, frequency or extent of the establishment of bipolar cell polarity.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"b87d7ce9bd01492aa20fc64800ede3d4","type":"GO_TERM","name":"positive regulation of establishment of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:0061161","description":"\"Any process that increases the rate, frequency or extent of the establishment of bipolar cell polarity that regulates the shape of a cell.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"921525752fde457f827e9abaa4820939","type":"GO_TERM","name":"positive regulation of establishment of blood-brain barrier","canonical_id":"go:GO:0090211","description":"\"Any process that increases the rate, frequency or extent of the establishment of the blood-brain barrier, a selectively permeable structural and functional barrier that exists between the capillaries and the brain.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"0718a44401ae47b384882353764ccce6","type":"GO_TERM","name":"positive regulation of establishment of cell polarity regulating cell shape","canonical_id":"go:GO:2000784","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of cell polarity regulating cell shape.\" [GOC:Mah]","metadata":null},{"id":"c176dd91146c44aab395f605e4de1ee8","type":"GO_TERM","name":"positive regulation of establishment of competence for transformation","canonical_id":"go:GO:0045809","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of competence for transformation.\" [GOC:curators]","metadata":null},{"id":"559c587797194b3ab433086ff4bb0c48","type":"GO_TERM","name":"positive regulation of establishment of endothelial barrier","canonical_id":"go:GO:1903142","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of endothelial barrier.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24851274]","metadata":null},{"id":"ba72aae44b6c4310ad741e512ee02c05","type":"GO_TERM","name":"positive regulation of establishment of protein localization","canonical_id":"go:GO:1904951","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of protein localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:22761445]","metadata":null},{"id":"bc071854cbd64b8bbef82b155f46d154","type":"GO_TERM","name":"positive regulation of establishment of protein localization to telomere","canonical_id":"go:GO:1904851","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of protein localization to telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"78d3f693da08405f821caf046a86715f","type":"GO_TERM","name":"positive regulation of establishment of protein-containing complex localization to telomere","canonical_id":"go:GO:1904915","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of the localization of a protein-containing macromolecular complex to a telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"97faa0ac0aef400a8a81e310ae2f911e","type":"GO_TERM","name":"positive regulation of establishment or maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:2000247","description":"\"Any process that activates or increases the frequency, rate or extent of establishment or maintenance of bipolar cell polarity regulating cell shape.\" [GOC:obol]","metadata":null},{"id":"6e1a989692384c9792bcc104c7ec9a1b","type":"GO_TERM","name":"positive regulation of establishment or maintenance of cell polarity regulating cell shape","canonical_id":"go:GO:2000771","description":"\"Any process that activates or increases the frequency, rate or extent of establishment or maintenance of cell polarity regulating cell shape.\" [GOC:mah]","metadata":null},{"id":"95d60509e6f3433da7a6bb3cfe243f9b","type":"GO_TERM","name":"positive regulation of estradiol secretion","canonical_id":"go:GO:2000866","description":"\"Any process that activates or increases the frequency, rate or extent of estradiol secretion.\" [GOC:sl]","metadata":null},{"id":"243bd5e0ce6540ac88f67a493fb3c090","type":"GO_TERM","name":"positive regulation of estrogen biosynthetic process","canonical_id":"go:GO:1904078","description":"\"Any process that activates or increases the frequency, rate or extent of estrogen biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24530842]","metadata":null},{"id":"1d6a7e67de1341aabac07e064958143c","type":"GO_TERM","name":"positive regulation of estrogen secretion","canonical_id":"go:GO:2000863","description":"\"Any process that activates or increases the frequency, rate or extent of estrogen secretion.\" [GOC:sl]","metadata":null},{"id":"f795e035ff7a48448aeb182d99839a73","type":"GO_TERM","name":"positive regulation of estrone secretion","canonical_id":"go:GO:2000869","description":"\"Any process that activates or increases the frequency, rate or extent of estrone secretion.\" [GOC:sl]","metadata":null},{"id":"6ade671514044ada939385a01a0b7186","type":"GO_TERM","name":"positive regulation of ethanol catabolic process","canonical_id":"go:GO:1900066","description":"\"Any process that activates or increases the frequency, rate or extent of ethanol catabolic process.\" [GOC:TermGenie, PMID:10608811, PMID:7760841]","metadata":null},{"id":"76f12a2a23c6476b88a91ec82149d2cc","type":"GO_TERM","name":"positive regulation of ethylene biosynthetic process","canonical_id":"go:GO:0010365","description":"\"Any process that activates or increases the frequency, rate or extent of an ethylene biosynthetic process.\" [GOC:tair_curators]","metadata":null},{"id":"a2440624ff9c4cc79c068182c71622d1","type":"GO_TERM","name":"positive regulation of eukaryotic translation initiation factor 4F complex assembly","canonical_id":"go:GO:1905537","description":"\"Any process that activates or increases the frequency, rate or extent of eukaryotic translation initiation factor 4F complex assembly.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:18426977]","metadata":null},{"id":"d7c17104b64a4cf48e490107236e5d89","type":"GO_TERM","name":"positive regulation of excitatory postsynaptic potential","canonical_id":"go:GO:2000463","description":"\"Any process that enhances the establishment or increases the extent of the excitatory postsynaptic potential (EPSP) which is a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential.\" [GOC:bf, GOC:BHF]","metadata":null},{"id":"e7833b7cd9e1477c9cae4f72859c86a1","type":"GO_TERM","name":"positive regulation of excitatory synapse assembly","canonical_id":"go:GO:1904891","description":"\"Any process that activates or increases the frequency, rate or extent of excitatory synapse assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21670302]","metadata":null},{"id":"24f5d498063b48bcbc33d147fb8f8f8c","type":"GO_TERM","name":"positive regulation of execution phase of apoptosis","canonical_id":"go:GO:1900119","description":"\"Any process that activates or increases the frequency, rate or extent of execution phase of apoptosis.\" [GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"1914d1a4d9c643c59cd0fb9bed47e6e8","type":"GO_TERM","name":"positive regulation of exit from meiosis","canonical_id":"go:GO:0106062","description":"\"Any process that activates or increases the frequency, rate or extent of exit from meiosis.\" [GOC:al, PMID:11493649]","metadata":null},{"id":"c888ea569c674e888ba1829519dc3d90","type":"GO_TERM","name":"positive regulation of exit from mitosis","canonical_id":"go:GO:0031536","description":"\"Any process that activates or increases the rate of progression from anaphase/telophase (high mitotic CDK activity) to G1 (low mitotic CDK activity).\" [GOC:mah]","metadata":null},{"id":"bd3c58944be44de4aa1913a0ea066daa","type":"GO_TERM","name":"positive regulation of exo-alpha-sialidase activity","canonical_id":"go:GO:1903017","description":"\"Any process that activates or increases the frequency, rate or extent of exo-alpha-sialidase activity.\" [GO_REF:0000059, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23544079]","metadata":null},{"id":"e70bf92b6b1f41fab1db50ceba6d5a7b","type":"GO_TERM","name":"positive regulation of exocyst assembly","canonical_id":"go:GO:0001930","description":"\"Any process that increases the rate or extent of exocyst assembly.\" [GOC:hjd]","metadata":null},{"id":"258348906a0443a6bb315fd8601df15e","type":"GO_TERM","name":"positive regulation of exocytosis","canonical_id":"go:GO:0045921","description":"\"Any process that activates or increases the frequency, rate or extent of exocytosis.\" [GOC:curators]","metadata":null},{"id":"9ab276c75ad944ec80e53f4f1789d5e5","type":"GO_TERM","name":"positive regulation of exosomal secretion","canonical_id":"go:GO:1903543","description":"\"Any process that activates or increases the frequency, rate or extent of exosomal secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:24105262]","metadata":null},{"id":"a997f51933314b8cbe1d748166ad93d1","type":"GO_TERM","name":"positive regulation of extracellular exosome assembly","canonical_id":"go:GO:1903553","description":"\"Any process that activates or increases the frequency, rate or extent of extracellular vesicular exosome assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:24105262]","metadata":null},{"id":"190c15e1ca194670aa2a5d8616ed0804","type":"GO_TERM","name":"positive regulation of extracellular matrix assembly","canonical_id":"go:GO:1901203","description":"\"Any process that activates or increases the frequency, rate or extent of extracellular matrix assembly.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"f8cfaacb928446ee92ef39af1d01a2fa","type":"GO_TERM","name":"positive regulation of extracellular matrix constituent secretion","canonical_id":"go:GO:0003331","description":"\"Any process that increases the rate, frequency, or extent of the controlled release of molecules that form the extracellular matrix, including carbohydrates and glycoproteins by a cell or a group of cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2abd63f5a6384a479b111bec4f573491","type":"GO_TERM","name":"positive regulation of extracellular matrix disassembly","canonical_id":"go:GO:0090091","description":"\"Any process that increases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ba43cad2f00b43ea992229ab98b4b47f","type":"GO_TERM","name":"positive regulation of extracellular matrix organization","canonical_id":"go:GO:1903055","description":"\"Any process that activates or increases the frequency, rate or extent of extracellular matrix organization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22357537]","metadata":null},{"id":"429713d8610b4c58b12b052d175bdd33","type":"GO_TERM","name":"positive regulation of extraocular skeletal muscle development","canonical_id":"go:GO:0014727","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of extraocular skeletal muscle development. Extraocular skeletal muscle development is the process whose specific outcome is the progression of the extraocular skeletal muscle over time, from its formation to the mature structure. The extraocular muscle is derived from cranial mesoderm and controls eye movements. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle.\" [GOC:mtg_muscle]","metadata":null},{"id":"f53565e5408c4338b7cb735263c80687","type":"GO_TERM","name":"positive regulation of extrathymic T cell differentiation","canonical_id":"go:GO:0033090","description":"\"Any process that activates or increases the frequency, rate or extent of extrathymic T cell differentiation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"53a3a94172014da28b2f1e33ae6b34de","type":"GO_TERM","name":"positive regulation of extrinsic apoptotic signaling pathway","canonical_id":"go:GO:2001238","description":"\"Any process that activates or increases the frequency, rate or extent of extrinsic apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"baa4ada7f44b454483f9fce1bbd4d07a","type":"GO_TERM","name":"positive regulation of extrinsic apoptotic signaling pathway in absence of ligand","canonical_id":"go:GO:2001241","description":"\"Any process that activates or increases the frequency, rate or extent of extrinsic apoptotic signaling pathway in absence of ligand.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"62483b1b79054b2aba83dac99691dc9b","type":"GO_TERM","name":"positive regulation of extrinsic apoptotic signaling pathway via death domain receptors","canonical_id":"go:GO:1902043","description":"\"Any process that activates or increases the frequency, rate or extent of extrinsic apoptotic signaling pathway via death domain receptors.\" [GOC:TermGenie, PMID:17245429]","metadata":null},{"id":"773c09dc767946128b856d381c7e85a6","type":"GO_TERM","name":"positive regulation of eye photoreceptor cell development","canonical_id":"go:GO:0042479","description":"\"Any process that activates or increases the frequency, rate or extent of eye photoreceptor development.\" [GOC:jl]","metadata":null},{"id":"f4a19c01425e4f4c8db497de3601dd08","type":"GO_TERM","name":"positive regulation of eye pigmentation","canonical_id":"go:GO:0048075","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of a pattern of pigment in the eye of an organism.\" [GOC:jid]","metadata":null},{"id":"12470bcd0c1d4c72992c35c5e8c546d5","type":"GO_TERM","name":"positive regulation of fast-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031448","description":"\"Any process that activates or increases the frequency, rate or extent of fast-twitch skeletal muscle contraction.\" [GOC:dph, GOC:ef, GOC:mah, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"e4b97de2cd3143cb8cfe51291f8bb19a","type":"GO_TERM","name":"positive regulation of fat cell apoptotic process","canonical_id":"go:GO:1904651","description":"\"Any process that activates or increases the frequency, rate or extent of fat cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:17024416]","metadata":null},{"id":"46fc182765f44299833b8fa814c8c4f4","type":"GO_TERM","name":"positive regulation of fat cell differentiation","canonical_id":"go:GO:0045600","description":"\"Any process that activates or increases the frequency, rate or extent of adipocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"2e827118d4a948bbb07c77b95e077f93","type":"GO_TERM","name":"positive regulation of fat cell proliferation","canonical_id":"go:GO:0070346","description":"\"Any process that activates or increases the rate or extent of fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"1ac1551d92924585b0100d7ecc0e933a","type":"GO_TERM","name":"positive regulation of fatty acid beta-oxidation","canonical_id":"go:GO:0032000","description":"\"Any process that activates or increases the frequency, rate or extent of fatty acid beta-oxidation.\" [GOC:mah]","metadata":null},{"id":"303028af21d54770a65ab27857e96e3d","type":"GO_TERM","name":"positive regulation of fatty acid biosynthetic process","canonical_id":"go:GO:0045723","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids.\" [GOC:curators]","metadata":null},{"id":"9205fbbe2e9a48fab8023d3b07000d73","type":"GO_TERM","name":"positive regulation of fatty acid metabolic process","canonical_id":"go:GO:0045923","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving fatty acids.\" [GOC:curators]","metadata":null},{"id":"acc49ecbbb604713998c2dff986f501c","type":"GO_TERM","name":"positive regulation of fatty acid oxidation","canonical_id":"go:GO:0046321","description":"\"Any process that activates or increases the frequency, rate or extent of fatty acid oxidation.\" [GOC:ai]","metadata":null},{"id":"b3bec65c39e246d5a74268cc69e69fcc","type":"GO_TERM","name":"positive regulation of fatty acid transport","canonical_id":"go:GO:2000193","description":"\"Any process that activates or increases the frequency, rate or extent of fatty acid transport.\" [GOC:BHF]","metadata":null},{"id":"c0fa555bc7a64e9eabd18b4a1e9ad12e","type":"GO_TERM","name":"positive regulation of fear response","canonical_id":"go:GO:1903367","description":"\"Any process that activates or increases the frequency, rate or extent of fear response.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:8677262]","metadata":null},{"id":"6b4525d14b914e27a1758f796a1762c5","type":"GO_TERM","name":"positive regulation of feeding behavior","canonical_id":"go:GO:2000253","description":"\"Any process that activates or increases the frequency, rate or extent of feeding behavior.\" [GOC:obol]","metadata":null},{"id":"fa7a2e23ff004af99d9885223f6826c4","type":"GO_TERM","name":"positive regulation of female gonad development","canonical_id":"go:GO:2000196","description":"\"Any process that activates or increases the frequency, rate or extent of female gonad development.\" [GOC:obol]","metadata":null},{"id":"81f9c4abeda2430484f461e2f6085036","type":"GO_TERM","name":"positive regulation of female pigmentation","canonical_id":"go:GO:0048091","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of a pattern of pigment in females.\" [GOC:jid]","metadata":null},{"id":"7f8c644c92634acfacaaa00762c0c931","type":"GO_TERM","name":"positive regulation of female receptivity","canonical_id":"go:GO:0045925","description":"\"Any process that activates or increases the receptiveness of a female to male advances.\" [GOC:curators]","metadata":null},{"id":"07847b17538846bdadb168620b2afb33","type":"GO_TERM","name":"positive regulation of female receptivity, post-mating","canonical_id":"go:GO:0046009","description":"\"Any process that increases the receptiveness of a female to male advances subsequent to mating.\" [GOC:curators]","metadata":null},{"id":"85c995e992ec4c0f8616dadbbc2ef03e","type":"GO_TERM","name":"positive regulation of ferrichrome biosynthetic process","canonical_id":"go:GO:1905570","description":"\"Any process that activates or increases the frequency, rate or extent of ferrichrome biosynthetic process.\" [GO_REF:0000058, GOC:al, GOC:TermGenie, PMID:654321]","metadata":null},{"id":"c18d04be8abd4c6fb6731c428f04f612","type":"GO_TERM","name":"positive regulation of ferricrocin biosynthetic process","canonical_id":"go:GO:1900680","description":"\"Any process that activates or increases the frequency, rate or extent of ferricrocin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b88a6405c27941b894a6223f54861d39","type":"GO_TERM","name":"positive regulation of ferroptosis","canonical_id":"go:GO:0160020","description":"\"Any process that activates or increases the frequency, rate or extent of ferroptosis.\" [PMID:32015325]","metadata":null},{"id":"f47ab49cecb24aa98e4d61f5fb247c0a","type":"GO_TERM","name":"positive regulation of fertilization","canonical_id":"go:GO:1905516","description":"\"Any process that activates or increases the frequency, rate or extent of fertilization.\" [GO_REF:0000058, GOC:hbye, GOC:TermGenie, PMID:27564576]","metadata":null},{"id":"d57e6caaf4734a749402f3a0cf2efc97","type":"GO_TERM","name":"positive regulation of ferulate catabolic process","canonical_id":"go:GO:1901468","description":"\"Any process that activates or increases the frequency, rate or extent of ferulate catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f298ec3008904c0795d1eebf5416d87c","type":"GO_TERM","name":"positive regulation of fever generation","canonical_id":"go:GO:0031622","description":"\"Any process that activates or increases the frequency, rate, or extent of fever generation.\" [GOC:add]","metadata":null},{"id":"3a0c2e3475c446b0801e2556bc43947e","type":"GO_TERM","name":"positive regulation of fever generation by positive regulation of prostaglandin biosynthesis","canonical_id":"go:GO:0071811","description":"\"Any process that increases the rate or extent of fever generation via positive regulation of the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.\" [GOC:BHF, GOC:dph, GOC:mah]","metadata":null},{"id":"22774b347245466e8acb04a6ef73d728","type":"GO_TERM","name":"positive regulation of fever generation by positive regulation of prostaglandin secretion","canonical_id":"go:GO:0071812","description":"\"Any process that increases the rate or extent of fever generation via positive regulation of the frequency, rate or extent of the regulated release of a prostaglandin from a cell.\" [GOC:BHF, GOC:dph, GOC:mah]","metadata":null},{"id":"b3f564a2e1074ec5b8ed66b12a36c44d","type":"GO_TERM","name":"positive regulation of fever generation by prostaglandin biosynthetic process","canonical_id":"go:GO:0100010","description":"\"Any prostaglandin biosynthetic process process that positively_regulates fever generation.\" [GOC:cjm, GOC:obol]","metadata":null},{"id":"b9fc7e26f5d04b1c8db69b432c2aceea","type":"GO_TERM","name":"positive regulation of fever generation by prostaglandin secretion","canonical_id":"go:GO:0100011","description":"\"Any prostaglandin secretion process that positively_regulates fever generation.\" [GOC:cjm, GOC:obol]","metadata":null},{"id":"5828c9b53e304752ad672dece3720079","type":"GO_TERM","name":"positive regulation of fibrinolysis","canonical_id":"go:GO:0051919","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.\" [GOC:ai]","metadata":null},{"id":"2c815179f9b146c3b206cdbfa5a7b614","type":"GO_TERM","name":"positive regulation of fibroblast apoptotic process","canonical_id":"go:GO:2000271","description":"\"Any process that activates or increases the frequency, rate or extent of fibroblast apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol, GOC:yaf]","metadata":null},{"id":"b6afb64def9f46c6b1efc33bd34b4489","type":"GO_TERM","name":"positive regulation of fibroblast chemotaxis","canonical_id":"go:GO:1905212","description":"\"Any process that activates or increases the frequency, rate or extent of fibroblast chemotaxis.\" [GO_REF:0000058, GOC:TermGenie, PMID:8760137]","metadata":null},{"id":"d11a023e1c19468a81cd76930e240322","type":"GO_TERM","name":"positive regulation of fibroblast growth factor production","canonical_id":"go:GO:0090271","description":"\"Any process that increases the rate, frequency or extent of the appearance of a fibroblast growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"2ddf03f9763c4f64a4ffb4287814721a","type":"GO_TERM","name":"positive regulation of fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0045743","description":"\"Any process that activates or increases the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"436273abf78d4d8b8e0ecd87ec4ad04a","type":"GO_TERM","name":"positive regulation of fibroblast migration","canonical_id":"go:GO:0010763","description":"\"Any process that increases the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"9a66e5e5b158440090156a425e6bffdb","type":"GO_TERM","name":"positive regulation of fibroblast proliferation","canonical_id":"go:GO:0048146","description":"\"Any process that activates or increases the frequency, rate or extent of multiplication or reproduction of fibroblast cells.\" [GOC:jid]","metadata":null},{"id":"b55b4d1f78014ac9bcdeb1b49f79e048","type":"GO_TERM","name":"positive regulation of fibronectin-dependent thymocyte migration","canonical_id":"go:GO:2000415","description":"\"Any process that activates or increases the frequency, rate or extent of fibronectin-dependent thymocyte migration.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"93a1e028a64b4dfca8c277ee014e903f","type":"GO_TERM","name":"positive regulation of filamentous growth","canonical_id":"go:GO:0090033","description":"\"Any process that increases the frequency, rate or extent of the process in which a multicellular organism or a group of unicellular organisms grow in a threadlike, filamentous shape.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"400ff679ff4f422295032ed16efd78ac","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms","canonical_id":"go:GO:1900430","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"d6caf64e8f3045aba6345f2bd3f78f15","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms in response to biotic stimulus","canonical_id":"go:GO:1900445","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to biotic stimulus.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"659dffbd33b84bd295b6e2036d11fb70","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms in response to chemical stimulus","canonical_id":"go:GO:1900439","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to chemical stimulus.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"93b4537ebd9d4aa187f1a582e5abe9cc","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms in response to heat","canonical_id":"go:GO:1900433","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to heat.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"94568b737ebf4267815f68bf15d82cbf","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms in response to neutral pH","canonical_id":"go:GO:1900442","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to neutral pH.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ef7ebfb8fb2140ddb2eee054d33b8c47","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms in response to pH","canonical_id":"go:GO:1900743","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to pH.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b1aa9df2d6a44d1a912d037eff890477","type":"GO_TERM","name":"positive regulation of filamentous growth of a population of unicellular organisms in response to starvation","canonical_id":"go:GO:1900436","description":"\"Any process that activates or increases the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to starvation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f1a5ea229c88479ebc2fb4e86b3ea0b6","type":"GO_TERM","name":"positive regulation of filopodium assembly","canonical_id":"go:GO:0051491","description":"\"Any process that activates or increases the frequency, rate or extent of the assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"c4761552aa6b46488d813abeccded283","type":"GO_TERM","name":"positive regulation of flagellated sperm motility","canonical_id":"go:GO:1902093","description":"\"Any process that activates or increases the frequency, rate or extent of flagellated sperm motility.\" [GOC:cilia, GOC:jh2, GOC:krc, GOC:TermGenie, PMID:7513657]","metadata":null},{"id":"f32ccb5c2db74fa5820294017f0299fb","type":"GO_TERM","name":"positive regulation of flagellated sperm motility involved in capacitation","canonical_id":"go:GO:0060474","description":"\"The process in which the controlled movement of a flagellated sperm cell is initiated as part of the process required for flagellated sperm to reach fertilization competence.\" [GOC:cilia, GOC:dph, GOC:krc]","metadata":null},{"id":"cabe340148be4e23bd5ad2c51221ce2a","type":"GO_TERM","name":"positive regulation of flavonoid biosynthetic process","canonical_id":"go:GO:0009963","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of flavonoids.\" [GOC:tb]","metadata":null},{"id":"40ef8081b78748f4894cfdcbfac52b51","type":"GO_TERM","name":"positive regulation of flavonol biosynthetic process","canonical_id":"go:GO:1900386","description":"\"Any process that activates or increases the frequency, rate or extent of flavonol biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"410ca760be794b02816a2245634ba013","type":"GO_TERM","name":"positive regulation of flocculation","canonical_id":"go:GO:1900735","description":"\"Any process that activates or increases the frequency, rate or extent of flocculation.\" [GOC:dgf, GOC:TermGenie, PMID:10591965, PMID:15466424, PMID:16568252]","metadata":null},{"id":"3ed19b7cb19940678973bcdb90b2b0a6","type":"GO_TERM","name":"positive regulation of floral organ abscission","canonical_id":"go:GO:0060861","description":"\"Any process that increases the rate, frequency, or extent of floral organ shedding, the controlled shedding of floral organs.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"06d75a64487a445799dc5aebcad46ae4","type":"GO_TERM","name":"positive regulation of flower development","canonical_id":"go:GO:0009911","description":"\"Any process that activates or increases the frequency, rate or extent of flower development.\" [GOC:curators]","metadata":null},{"id":"370894a81f24415fa4de6933800c5cfc","type":"GO_TERM","name":"positive regulation of focal adhesion assembly","canonical_id":"go:GO:0051894","description":"\"Any process that activates or increases the frequency, rate or extent of focal adhesion assembly, the establishment and maturation of focal adhesions.\" [GOC:ai]","metadata":null},{"id":"d1b25d4e63f24af5b56ac67d215eec68","type":"GO_TERM","name":"positive regulation of focal adhesion disassembly","canonical_id":"go:GO:0120183","description":"\"Any process that activates or increases the frequency, rate or extent of disaggregation of a focal adhesion into its constituent components.\" [PMID:25490267]","metadata":null},{"id":"ef6124065046411ba95030efa7fcce21","type":"GO_TERM","name":"positive regulation of follicle-stimulating hormone secretion","canonical_id":"go:GO:0046881","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of follicle-stimulating hormone.\" [GOC:ai]","metadata":null},{"id":"8f0cc3fa47884ad8a36e1f96b522c14a","type":"GO_TERM","name":"positive regulation of foraging behavior","canonical_id":"go:GO:1903370","description":"\"Any process that activates or increases the frequency, rate or extent of foraging behavior.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:8677262]","metadata":null},{"id":"a6804c9833f34f9a9136048f8ff8b635","type":"GO_TERM","name":"positive regulation of forebrain neuron differentiation","canonical_id":"go:GO:2000979","description":"\"Any process that activates or increases the frequency, rate or extent of forebrain neuron differentiation.\" [GOC:obol]","metadata":null},{"id":"8ec8d2b26fe64c94a7f053b544b0e803","type":"GO_TERM","name":"positive regulation of formation by symbiont of haustorium for nutrient acquisition from host","canonical_id":"go:GO:0075046","description":"\"Any process that activates or increases the frequency, rate or extent of symbiont haustorium formation for nutrient acquisition from host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"f5aadcdbf669446ca17534547a51169a","type":"GO_TERM","name":"positive regulation of formation of growth cone in injured axon","canonical_id":"go:GO:1905944","description":"\"Any process that activates or increases the frequency, rate or extent of formation of growth cone in injured axon.\" [GO_REF:0000058, GOC:TermGenie, PMID:19737525]","metadata":null},{"id":"917ea4f4d6194b63b872f7e19533c512","type":"GO_TERM","name":"positive regulation of formation of radial glial scaffolds","canonical_id":"go:GO:0061926","description":"\"Any process that increases the frequency, rate or extent of the formation of radial glial cell scaffolds.\" [PMID:22076441]","metadata":null},{"id":"7a7fc9e0995f43b68043ff36ced51ba9","type":"GO_TERM","name":"positive regulation of formation of symbiont germ tube hook structure for appressorium development","canonical_id":"go:GO:0075031","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of symbiont germ tube hook structure formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"dd4a27b1b6144666a9909ff1c78a9326","type":"GO_TERM","name":"positive regulation of formation of translation initiation ternary complex","canonical_id":"go:GO:1901192","description":"\"Any process that activates or increases the frequency, rate or extent of formation of translation initiation ternary complex.\" [GOC:TermGenie]","metadata":null},{"id":"cfe19c0b12074d67818b5cd951cdfd25","type":"GO_TERM","name":"positive regulation of formation of translation preinitiation complex","canonical_id":"go:GO:1901195","description":"\"Any process that activates or increases the frequency, rate or extent of formation of translation preinitiation complex.\" [GOC:TermGenie]","metadata":null},{"id":"1fbe7e2aa45a418e9e74b5c755a89998","type":"GO_TERM","name":"positive regulation of formin-nucleated actin cable assembly","canonical_id":"go:GO:0090338","description":"\"Any process that increases the rate, frequency, or extent of formin-nucleated actin cable assembly. Formin-nucleated actin cable assembly is the aggregation, arrangement and bonding together of a set of components to form a formin-nucleated actin cable. A formin-nucleated actin cable is an actin filament bundle that consists of short filaments organized into bundles of uniform polarity, and is nucleated by formins.\" [GOC:jh, GOC:tb, PMID:12810699, PMID:15923184]","metadata":null},{"id":"59a041183d5c4d768f58453501970796","type":"GO_TERM","name":"positive regulation of forward locomotion","canonical_id":"go:GO:1905850","description":"\"Any process that activates or increases the frequency, rate or extent of forward locomotion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11717360]","metadata":null},{"id":"69b2d3ec1c7640659aeda980c455af6e","type":"GO_TERM","name":"positive regulation of fractalkine production","canonical_id":"go:GO:0032724","description":"\"Any process that activates or increases the frequency, rate, or extent of fractalkine production.\" [GOC:mah]","metadata":null},{"id":"092001305c644fc9b38b865213e4e2e7","type":"GO_TERM","name":"positive regulation of free ubiquitin chain polymerization","canonical_id":"go:GO:1904544","description":"\"Any process that activates or increases the frequency, rate or extent of free ubiquitin chain polymerization.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24660806]","metadata":null},{"id":"376e32a138db45f3aa245de70c7bb2cf","type":"GO_TERM","name":"positive regulation of fructose 1,6-bisphosphate metabolic process","canonical_id":"go:GO:0060552","description":"\"Any process that increases the rate, frequency or extent of fructose 1,6-bisphosphate metabolism. Fructose 1,6-bisphosphate metabolism is the chemical reactions and pathways involving fructose 1,6-bisphosphate, also known as FBP. The D enantiomer is a metabolic intermediate in glycolysis and gluconeogenesis.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"3f1a662989104b5db1a0a17683fd54d6","type":"GO_TERM","name":"positive regulation of fumagillin biosynthetic process","canonical_id":"go:GO:1902092","description":"\"Any process that activates or increases the frequency, rate or extent of fumagillin biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:23488861]","metadata":null},{"id":"7a904a18e8d94332a722cfba8b301835","type":"GO_TERM","name":"positive regulation of fumigaclavine C biosynthetic process","canonical_id":"go:GO:1900839","description":"\"Any process that activates or increases the frequency, rate or extent of fumigaclavine C biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"68f7ee185eab4379b5932b84c656e154","type":"GO_TERM","name":"positive regulation of fumonisin biosynthetic process","canonical_id":"go:GO:1900685","description":"\"Any process that activates or increases the frequency, rate or extent of fumonisin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3780c9f621ed4e22ad6da7be3d081a91","type":"GO_TERM","name":"positive regulation of fusion of virus membrane with host plasma membrane","canonical_id":"go:GO:1903915","description":"\"Any process that activates or increases the frequency, rate or extent of fusion of virus membrane with host plasma membrane.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"f22a6b020f1049158eee17c6dfe04147","type":"GO_TERM","name":"positive regulation of galactoglucomannan catabolic process","canonical_id":"go:GO:2000914","description":"\"Any process that activates or increases the frequency, rate or extent of galactoglucomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"a0bf0acb009d4a408accc7e426dfae00","type":"GO_TERM","name":"positive regulation of galactomannan catabolic process","canonical_id":"go:GO:2000993","description":"\"Any process that activates or increases the frequency, rate or extent of galactomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"20f2e55d02b74be88c90eccffeaa3b07","type":"GO_TERM","name":"positive regulation of galactotriose transport","canonical_id":"go:GO:1900293","description":"\"Any process that activates or increases the frequency, rate or extent of galactotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"78cd253f93ac4cafb717aa5177fa6f15","type":"GO_TERM","name":"positive regulation of gamma-aminobutyric acid secretion","canonical_id":"go:GO:0014054","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of gamma-aminobutyric acid.\" [GOC:ef]","metadata":null},{"id":"8d9aacaa8b024b68b26101eae59e3db0","type":"GO_TERM","name":"positive regulation of gamma-delta T cell activation","canonical_id":"go:GO:0046645","description":"\"Any process that activates or increases the frequency, rate or extent of gamma-delta T cell activation.\" [GOC:ai]","metadata":null},{"id":"f56452be69bc41eab0c35ef62dece8a0","type":"GO_TERM","name":"positive regulation of gamma-delta T cell differentiation","canonical_id":"go:GO:0045588","description":"\"Any process that activates or increases the frequency, rate or extent of gamma-delta T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"592d3c637e99492e941a4f7b3ab89dfd","type":"GO_TERM","name":"positive regulation of gamma-delta T cell proliferation","canonical_id":"go:GO:0046648","description":"\"Any process that activates or increases the frequency, rate or extent of gamma-delta T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"48d486f65ca64b72a537058adfc579bf","type":"GO_TERM","name":"positive regulation of gap junction assembly","canonical_id":"go:GO:1903598","description":"\"Any process that activates or increases the frequency, rate or extent of gap junction assembly.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:25017399]","metadata":null},{"id":"d383dd99c5c5491d8514367cdc39d946","type":"GO_TERM","name":"positive regulation of gastric acid secretion","canonical_id":"go:GO:0060454","description":"\"Any process that increases the rate frequency or extent of gastric secretion. Gastric secretion is the regulated release of gastric acid (hydrochloric acid) by parietal or oxyntic cells during digestion.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"aecdca718ab94ce989c4ab4787e1df03","type":"GO_TERM","name":"positive regulation of gastric emptying","canonical_id":"go:GO:0120062","description":"\"Any process that increases the frequency, rate or extent of any gastric emptying process, the process in which the liquid and liquid-suspended solid contents of the stomach exit through the pylorus into the duodenum.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"6234cf3f01c643c496bc8d2586571751","type":"GO_TERM","name":"positive regulation of gastric mucosal blood circulation","canonical_id":"go:GO:1904346","description":"\"Any process that activates or increases the frequency, rate or extent of gastric mucosal blood circulation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10807413]","metadata":null},{"id":"3cced69ba03146df9991d9551a8bf4e8","type":"GO_TERM","name":"positive regulation of gastrin-induced gastric acid secretion","canonical_id":"go:GO:1903641","description":"\"Any process that activates or increases the frequency, rate or extent of gastrin-induced gastric acid secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11123201]","metadata":null},{"id":"f402e23914094216aedee0445b5d1244","type":"GO_TERM","name":"positive regulation of gastro-intestinal system smooth muscle contraction","canonical_id":"go:GO:1904306","description":"\"Any process that activates or increases the frequency, rate or extent of gastro-intestinal system smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:10821044]","metadata":null},{"id":"7cbd680cba694fe99b7be5af0fdcd76b","type":"GO_TERM","name":"positive regulation of gastrulation","canonical_id":"go:GO:2000543","description":"\"Any process that activates or increases the frequency, rate or extent of gastrulation.\" [GOC:obol]","metadata":null},{"id":"288a9204c65b471eb9d28dd8ae87f675","type":"GO_TERM","name":"positive regulation of gene expression","canonical_id":"go:GO:0010628","description":"\"Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).\" [GOC:txnOH-2018]","metadata":null},{"id":"68f18e3cfe4847d6b26a2d3a8fc7ee9c","type":"GO_TERM","name":"positive regulation of gene expression via chromosomal CpG island demethylation","canonical_id":"go:GO:0044029","description":"\"An epigenetic gene regulation mechanism that positively regulates gene expression by demethylation of cytosine residues in chromosomal CpG islands. CpG islands are genomic regions that contain a high frequency of the CG dinucleotide and are often associated with the transcription start site of genes.\" [PMID:36150101, Wikipedia:Cpg_island]","metadata":null},{"id":"ddb16dcabdb34a30817a8b0a1efb4515","type":"GO_TERM","name":"positive regulation of gene expression, epigenetic","canonical_id":"go:GO:0141137","description":"\"An epigenetic process that increases gene expression at specific genomic regions through chromatin remodeling either by modifying higher order chromatin fiber structure, nucleosomal histones, or the cytosine DNA demethylation.\" [PMID:36618446]","metadata":null},{"id":"d539935792fc42b29d1964a7b3f00acb","type":"GO_TERM","name":"positive regulation of gerfelin biosynthetic process","canonical_id":"go:GO:1900688","description":"\"Any process that activates or increases the frequency, rate or extent of gerfelin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6f8f8a1b218144fa953984871ecb6a07","type":"GO_TERM","name":"positive regulation of germ cell proliferation","canonical_id":"go:GO:1905938","description":"\"Any process that activates or increases the frequency, rate or extent of germ cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15342467]","metadata":null},{"id":"4c5ca8f24670497ebf5601edf5c71419","type":"GO_TERM","name":"positive regulation of germ plasm oskar mRNA localization","canonical_id":"go:GO:0045856","description":"\"Any process that activates or increases the frequency, rate or extent of the process in which oskar mRNA is transported to, or maintained in, the germ plasm.\" [GOC:curators]","metadata":null},{"id":"570606604c3c4c9b81ff11f49fbf8050","type":"GO_TERM","name":"positive regulation of germ tube formation","canonical_id":"go:GO:0075011","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of germ tube formation on or near host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"7b632ff989e84787a2021c25fc183ae7","type":"GO_TERM","name":"positive regulation of germinal center formation","canonical_id":"go:GO:0002636","description":"\"Any process that activates or increases the frequency, rate, or extent of germinal center formation.\" [GOC:add]","metadata":null},{"id":"439fcecd9ce644478516078f778b2e1e","type":"GO_TERM","name":"positive regulation of gibberellic acid mediated signaling pathway","canonical_id":"go:GO:0009939","description":"\"Any process that activates or increases the frequency, rate or extent of gibberellic acid mediated signaling activity.\" [GOC:sm]","metadata":null},{"id":"8cba36ea51814cf088a8b1a0fb0a6508","type":"GO_TERM","name":"positive regulation of gibberellin biosynthetic process","canonical_id":"go:GO:0010372","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of gibberellins.\" [GOC:tair_curators]","metadata":null},{"id":"b75a5a8e0ef8479fb68acd00a64e197b","type":"GO_TERM","name":"positive regulation of glial cell apoptotic process","canonical_id":"go:GO:0034352","description":"\"Any process that activates or increases the frequency, rate, or extent of glial cell apoptotic process.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"f8959e4e8e374636837a068fa8bb342d","type":"GO_TERM","name":"positive regulation of glial cell differentiation","canonical_id":"go:GO:0045687","description":"\"Any process that activates or increases the frequency, rate or extent of glia cell differentiation.\" [GOC:curators]","metadata":null},{"id":"95e24b88c28449589fb469f309892f85","type":"GO_TERM","name":"positive regulation of glial cell migration","canonical_id":"go:GO:1903977","description":"\"Any process that activates or increases the frequency, rate or extent of glial cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"33c377e6f3ec46b6b9626480bc87a506","type":"GO_TERM","name":"positive regulation of glial cell proliferation","canonical_id":"go:GO:0060252","description":"\"Any process that activates or increases the rate or extent of glial cell proliferation.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"4e4434bb38184facb55312c7b32248ff","type":"GO_TERM","name":"positive regulation of glial cell-derived neurotrophic factor production","canonical_id":"go:GO:1900168","description":"\"Any process that activates or increases the frequency, rate or extent of glial cell-derived neurotrophic factor production.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"caf6821bbd174aef89bba2a988ef89ae","type":"GO_TERM","name":"positive regulation of gliogenesis","canonical_id":"go:GO:0014015","description":"\"Any process that activates or increases the frequency, rate or extent of gliogenesis, the formation of mature glia.\" [GOC:ef]","metadata":null},{"id":"0307e684728a4b1194ba451bb3d484ed","type":"GO_TERM","name":"positive regulation of gliotoxin biosynthetic process","canonical_id":"go:GO:1900691","description":"\"Any process that activates or increases the frequency, rate or extent of gliotoxin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8d3397e591804d2da9ecfd66ee0f5422","type":"GO_TERM","name":"positive regulation of glomerular filtration","canonical_id":"go:GO:0003104","description":"\"Any process that activates or increases the frequency, rate or extent of glomerular filtration. Glomerular filtration is the process whereby blood is filtered by the glomerulus into the renal tubule.\" [GOC:mtg_cardio]","metadata":null},{"id":"bff3c7120bca4f408f9247c1bd8cdec6","type":"GO_TERM","name":"positive regulation of glomerular mesangial cell proliferation","canonical_id":"go:GO:0072126","description":"\"Any process that increases the frequency, rate or extent of glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"eea894f21df54707a5d8c3e36b537bd2","type":"GO_TERM","name":"positive regulation of glomerular metanephric mesangial cell proliferation","canonical_id":"go:GO:0072303","description":"\"Any process that increases the frequency, rate or extent of metanephric glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d88fae48650848fbbfe885ad9613b510","type":"GO_TERM","name":"positive regulation of glomerulus development","canonical_id":"go:GO:0090193","description":"\"Any process that increases the rate, frequency or extent of glomerulus development, the progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"1e83cc459272478f8417c40ae5ff00ad","type":"GO_TERM","name":"positive regulation of glucagon secretion","canonical_id":"go:GO:0070094","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of glucagon.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"30b30a766fd74b6c91acc0c86ae75a22","type":"GO_TERM","name":"positive regulation of glucocorticoid biosynthetic process","canonical_id":"go:GO:0031948","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"33c99e3d48df43af8ccac9c4a984a476","type":"GO_TERM","name":"positive regulation of glucocorticoid catabolic process","canonical_id":"go:GO:0031951","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"65f76c4d0b7d4e5aa49cc96e02e1f886","type":"GO_TERM","name":"positive regulation of glucocorticoid secretion","canonical_id":"go:GO:2000851","description":"\"Any process that activates or increases the frequency, rate or extent of glucocorticoid secretion.\" [GOC:sl]","metadata":null},{"id":"3de978f44a0a4e95a0cca2c6b3bd8d97","type":"GO_TERM","name":"positive regulation of glucomannan catabolic process","canonical_id":"go:GO:2000908","description":"\"Any process that activates or increases the frequency, rate or extent of glucomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"43bf2cc16ed8408baec7c18939182908","type":"GO_TERM","name":"positive regulation of gluconate transmembrane transport","canonical_id":"go:GO:0035432","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of gluconate across a membrane by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"407d276a2c4d4c4aa351e6c8c68be393","type":"GO_TERM","name":"positive regulation of gluconeogenesis","canonical_id":"go:GO:0045722","description":"\"Any process that activates or increases the frequency, rate or extent of gluconeogenesis.\" [GOC:curators]","metadata":null},{"id":"6ae9133804d34769a5c6feb0148360b3","type":"GO_TERM","name":"positive regulation of glucose catabolic process to lactate via pyruvate","canonical_id":"go:GO:1904025","description":"\"Any process that activates or increases the frequency, rate or extent of glucose catabolic process to lactate via pyruvate.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:20935145]","metadata":null},{"id":"d54cc6ae99a64c709e09661057e39039","type":"GO_TERM","name":"positive regulation of glucose mediated signaling pathway","canonical_id":"go:GO:1902661","description":"\"Any process that activates or increases the frequency, rate or extent of glucose mediated signaling pathway.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:24277933]","metadata":null},{"id":"c0adf0dfecc74a9fa3bb41a16b0be253","type":"GO_TERM","name":"positive regulation of glucose metabolic process","canonical_id":"go:GO:0010907","description":"\"Any process that increases the rate, frequency or extent of glucose metabolism. Glucose metabolic processes are the chemical reactions and pathways involving glucose, the aldohexose gluco-hexose.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"ca9c4232e7344c179398f818b04ecff1","type":"GO_TERM","name":"positive regulation of glucosylceramide biosynthetic process","canonical_id":"go:GO:0046319","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide.\" [GOC:ai]","metadata":null},{"id":"9a294996e82d4cc0b158712ae8293a9e","type":"GO_TERM","name":"positive regulation of glucosylceramide catabolic process","canonical_id":"go:GO:2000753","description":"\"Any process that activates or increases the frequency, rate or extent of glucosylceramide catabolic process.\" [GOC:BHF]","metadata":null},{"id":"01d71098b5b94fd7a8c7df9cef120cc5","type":"GO_TERM","name":"positive regulation of glucuronoarabinoxylan catabolic process","canonical_id":"go:GO:2000920","description":"\"Any process that activates or increases the frequency, rate or extent of glucuronoarabinoxylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"cfff0a7607374c97a72f90dba6588c12","type":"GO_TERM","name":"positive regulation of glucuronoxylan catabolic process","canonical_id":"go:GO:2000917","description":"\"Any process that activates or increases the frequency, rate or extent of glucuronoxylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"b09ea40622d6463d95372295fd990a07","type":"GO_TERM","name":"positive regulation of glutamate neurotransmitter secretion in response to membrane depolarization","canonical_id":"go:GO:0061646","description":"\"Any process that activates or increases the frequency, rate or extent of glutamate secretion in response to membrane depolarization, where glutamate acts as a neurotransmitter.\" [GOC:pad, GOC:PARL]","metadata":null},{"id":"27e8acf2b87a47a3a04775e67d8390d3","type":"GO_TERM","name":"positive regulation of glutamate receptor signaling pathway","canonical_id":"go:GO:1900451","description":"\"Any process that activates or increases the frequency, rate or extent of glutamate receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"c8dfd0395ec342deb9356232a352ddfc","type":"GO_TERM","name":"positive regulation of glutamate secretion","canonical_id":"go:GO:0014049","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled release of glutamate.\" [GOC:ef]","metadata":null},{"id":"55a4710eac8442799329e124c6b68b03","type":"GO_TERM","name":"positive regulation of glutamate secretion, neurotransmission","canonical_id":"go:GO:1903296","description":"\"Any process that activates or increases the frequency, rate or extent of glutamate secretion, where glutamate acts as a neurotransmitter.\" [GO_REF:0000058, GOC:TermGenie, PMID:16782817]","metadata":null},{"id":"d7ee6c8b97e14be0b8dfb50d56c69fd1","type":"GO_TERM","name":"positive regulation of glutamate uptake involved in transmission of nerve impulse","canonical_id":"go:GO:0051951","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the directed movement of L-glutamate into a neuron or glial cell.\" [GOC:ai]","metadata":null},{"id":"c72556dfb92445f2bf55ddcdd423f3c0","type":"GO_TERM","name":"positive regulation of glutamatergic neuron differentiation","canonical_id":"go:GO:0120008","description":"\"Any process that activates or increases the frequency, rate or extent of glutamatergic neuron differentiation.\" [PMID:24030726]","metadata":null},{"id":"a1c2a42ebdea4c11968e3e0683c144d0","type":"GO_TERM","name":"positive regulation of glutamine transport","canonical_id":"go:GO:2000487","description":"\"Any process that activates or increases the frequency, rate or extent of glutamine transport.\" [GOC:obol]","metadata":null},{"id":"21d8bca6301c445b96af010de07bc925","type":"GO_TERM","name":"positive regulation of glutathione biosynthetic process","canonical_id":"go:GO:1903788","description":"\"Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"73edda4e0f1b4360936778563d9d22ff","type":"GO_TERM","name":"positive regulation of glycerol transport","canonical_id":"go:GO:0090372","description":"\"Any process that increases the rate, frequency, or extent of the directed movement of glycerol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:jh, GOC:tb]","metadata":null},{"id":"30046bfcc8c145808fe183523bc3a4a1","type":"GO_TERM","name":"positive regulation of glycine import across plasma membrane","canonical_id":"go:GO:1900925","description":"\"Any process that activates or increases the frequency, rate or extent of glycine import.\" [GOC:TermGenie]","metadata":null},{"id":"a028d1e4708049dcaf9be41ccbac673d","type":"GO_TERM","name":"positive regulation of glycine secretion, neurotransmission","canonical_id":"go:GO:1904626","description":"\"Any process that activates or increases the frequency, rate or extent of glycine secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:22988142]","metadata":null},{"id":"5d23e79b325b4a528b1d1a0ad14a62ca","type":"GO_TERM","name":"positive regulation of glycogen (starch) synthase activity","canonical_id":"go:GO:2000467","description":"\"Any process that activates or increases the frequency, rate or extent of glycogen (starch) synthase activity.\" [GOC:obol]","metadata":null},{"id":"32ba984acd2d4a519be27accf639aaa5","type":"GO_TERM","name":"positive regulation of glycogen biosynthetic process","canonical_id":"go:GO:0045725","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen.\" [GOC:curators]","metadata":null},{"id":"c9d352c2a77941d1b2eda8fec9cd6a5e","type":"GO_TERM","name":"positive regulation of glycogen catabolic process","canonical_id":"go:GO:0045819","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen.\" [GOC:curators]","metadata":null},{"id":"e05dbfddd8af421a8add940b3ebe708f","type":"GO_TERM","name":"positive regulation of glycogen metabolic process","canonical_id":"go:GO:0070875","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving glycogen.\" [GOC:mah]","metadata":null},{"id":"c103b13efb7e46caa42c417ba442f51a","type":"GO_TERM","name":"positive regulation of glycolytic fermentation to ethanol","canonical_id":"go:GO:2001172","description":"\"Any process that activates or increases the frequency, rate or extent of glucose catabolic process to ethanol.\" [GOC:obol]","metadata":null},{"id":"10565b39460e48e58885b9d2933a3600","type":"GO_TERM","name":"positive regulation of glycolytic process","canonical_id":"go:GO:0045821","description":"\"Any process that activates or increases the frequency, rate or extent of glycolysis.\" [GOC:curators]","metadata":null},{"id":"581e543b2b5c4675a4b3be98e9a2046f","type":"GO_TERM","name":"positive regulation of glycolytic process through fructose-6-phosphate","canonical_id":"go:GO:1904540","description":"\"Any process that activates or increases the frequency, rate or extent of glycolytic process through fructose-6-phosphate.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, ISBN:0201090910, ISBN:0879010479]","metadata":null},{"id":"b9001b7cf57c4385952a6ade9ffc422a","type":"GO_TERM","name":"positive regulation of glycoprotein biosynthetic process","canonical_id":"go:GO:0010560","description":"\"Any process that increases the rate, frequency, or extent of the chemical reactions and pathways resulting in the formation of a glycoprotein, a protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"29f389729d9042929b662ed39f3d25a8","type":"GO_TERM","name":"positive regulation of glycoprotein metabolic process","canonical_id":"go:GO:1903020","description":"\"Any process that activates or increases the frequency, rate or extent of glycoprotein metabolic process.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23544079]","metadata":null},{"id":"07cccc4d0c1f42d2ac776eb7f7cf9a6d","type":"GO_TERM","name":"positive regulation of glyoxylate cycle","canonical_id":"go:GO:2000876","description":"\"Any process that activates or increases the frequency, rate or extent of glyoxylate cycle.\" [GOC:dgf]","metadata":null},{"id":"eeb600b2685245a893b35e2807708f98","type":"GO_TERM","name":"positive regulation of gonad development","canonical_id":"go:GO:1905941","description":"\"Any process that activates or increases the frequency, rate or extent of gonad development.\" [GO_REF:0000058, GOC:TermGenie, PMID:15342467]","metadata":null},{"id":"934b143bc60e4216aa9cf8b3d5486998","type":"GO_TERM","name":"positive regulation of gonadotropin secretion","canonical_id":"go:GO:0032278","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of a gonadotropin.\" [GOC:mah]","metadata":null},{"id":"9b6b90a1cb0f4b4a867c1265e6ec4d10","type":"GO_TERM","name":"positive regulation of granulocyte chemotaxis","canonical_id":"go:GO:0071624","description":"\"Any process that increases the rate, frequency or extent of granulocyte chemotaxis. Granulocyte chemotaxis is the movement of a granulocyte in response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"a2e9cfe000d548228d68a457b27e3f59","type":"GO_TERM","name":"positive regulation of granulocyte colony-stimulating factor production","canonical_id":"go:GO:0071657","description":"\"Any process that activates or increases the frequency, rate, or extent of production of granulocyte colony-stimulating factor.\" [GOC:mah]","metadata":null},{"id":"e099a5c70e324d87aef8dc50e1cfb0b5","type":"GO_TERM","name":"positive regulation of granulocyte differentiation","canonical_id":"go:GO:0030854","description":"\"Any process that activates or increases the frequency, rate or extent of granulocyte differentiation.\" [GOC:mah]","metadata":null},{"id":"509c1268fefa4276b65723c539969aaa","type":"GO_TERM","name":"positive regulation of granulocyte macrophage colony-stimulating factor production","canonical_id":"go:GO:0032725","description":"\"Any process that activates or increases the frequency, rate, or extent of granulocyte macrophage colony-stimulating factor production.\" [GOC:mah]","metadata":null},{"id":"5417ef31a5494e4bb841e329032a8536","type":"GO_TERM","name":"positive regulation of granuloma formation","canonical_id":"go:GO:0002633","description":"\"Any process that activates or increases the frequency, rate, or extent of granuloma formation.\" [GOC:add]","metadata":null},{"id":"16dd4a1ae050473cbd783a1a7dfb05cf","type":"GO_TERM","name":"positive regulation of granulosa cell apoptotic process","canonical_id":"go:GO:1904710","description":"\"Any process that activates or increases the frequency, rate or extent of granulosa cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:19208546]","metadata":null},{"id":"1e7dced4cacf4dd2800a2c588984dd8f","type":"GO_TERM","name":"positive regulation of granulosa cell proliferation","canonical_id":"go:GO:1904197","description":"\"Any process that activates or increases the frequency, rate or extent of granulosa cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22383759]","metadata":null},{"id":"0f1d599ddbb34222813d628de84b566e","type":"GO_TERM","name":"positive regulation of granzyme A production","canonical_id":"go:GO:2000513","description":"\"Any process that activates or increases the frequency, rate or extent of granzyme A production.\" [GOC:obol]","metadata":null},{"id":"6fd5b69de1a848499d69697f75738d5b","type":"GO_TERM","name":"positive regulation of granzyme B production","canonical_id":"go:GO:0071663","description":"\"Any process that activates or increases the frequency, rate, or extent of production of granzyme B.\" [GOC:mah]","metadata":null},{"id":"48ca498294cc4b24830e8d8751c5ce27","type":"GO_TERM","name":"positive regulation of growth","canonical_id":"go:GO:0045927","description":"\"Any process that activates or increases the rate or extent of growth, the increase in size or mass of all or part of an organism.\" [GOC:curators]","metadata":null},{"id":"28e1f40daa7a405b9bc5cea7f975881f","type":"GO_TERM","name":"positive regulation of growth factor dependent skeletal muscle satellite cell proliferation","canonical_id":"go:GO:1902728","description":"\"Any process that activates or increases the frequency, rate or extent of satellite cell proliferation; dependent on specific growth factor activity such as fibroblast growth factors and transforming growth factor beta.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"cb84a3fe485f4fef8fc077c65588e1db","type":"GO_TERM","name":"positive regulation of growth hormone receptor signaling pathway","canonical_id":"go:GO:0060399","description":"\"Any process that increases the rate, frequency or extent of the growth hormone receptor signaling pathway. The growth hormone receptor signaling pathway is the series of molecular signals generated as a consequence of growth hormone receptor binding to its physiological ligand.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"ac7dd1acb0b642d68d0ee2185f515ea5","type":"GO_TERM","name":"positive regulation of growth hormone secretion","canonical_id":"go:GO:0060124","description":"\"Any process that increases the frequency, rate or extent of the regulated release of growth hormone from a cell.\" [GOC:dph]","metadata":null},{"id":"6a110dda44604bcbb17fe101e24af7c1","type":"GO_TERM","name":"positive regulation of growth of unicellular organism as a thread of attached cells","canonical_id":"go:GO:0070786","description":"\"Any process that activates or increases the frequency, rate or extent of the process in which cells remain attached after division and form thread-like filaments that may penetrate into a solid growth medium.\" [GOC:mah]","metadata":null},{"id":"afd7c77f12754d3098801423391d8f08","type":"GO_TERM","name":"positive regulation of growth plate cartilage chondrocyte proliferation","canonical_id":"go:GO:0061913","description":"\"Any process that increases the rate, frequency, or extent of the multiplication or reproduction of chondrocytes in a growing endochondral bone, resulting in the expansion of a cell population.\" [PMID:19264869]","metadata":null},{"id":"0e0b357a34e044c48f7ec224cdc73e99","type":"GO_TERM","name":"positive regulation of growth rate","canonical_id":"go:GO:0040010","description":"\"Any process that increases the rate of growth of all or part of an organism.\" [GOC:mah]","metadata":null},{"id":"a3de4ef4060e4926a630926fba4345e7","type":"GO_TERM","name":"positive regulation of guanylate cyclase activity","canonical_id":"go:GO:0031284","description":"\"Any process that activates or increases the frequency, rate or extent of guanylate cyclase activity.\" [GOC:mah]","metadata":null},{"id":"8af554318ea84002a8085ca7d6ab0197","type":"GO_TERM","name":"positive regulation of gut granule assembly","canonical_id":"go:GO:1904757","description":"\"Any process that activates or increases the frequency, rate or extent of gut granule assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:17535251]","metadata":null},{"id":"2f3f7ac2f6404fe79a2e7824a16e3693","type":"GO_TERM","name":"positive regulation of hair cycle","canonical_id":"go:GO:0042635","description":"\"Any process that activates or increases the frequency, rate or extent of the cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair.\" [GOC:curators, PMID:12230507]","metadata":null},{"id":"d71be615a72b40098583831df874bced","type":"GO_TERM","name":"positive regulation of hair follicle cell proliferation","canonical_id":"go:GO:0071338","description":"\"Any process that activates or increases the rate or extent of hair follicle cell proliferation.\" [GOC:mah]","metadata":null},{"id":"5e6cf307251d4b16b79e0c8d6de5fcf4","type":"GO_TERM","name":"positive regulation of hair follicle development","canonical_id":"go:GO:0051798","description":"\"Any process that activates or increases the frequency, rate or extent of hair follicle development.\" [GOC:ai]","metadata":null},{"id":"a66b1caf3dd34412bc6eed634a2e7122","type":"GO_TERM","name":"positive regulation of hair follicle maturation","canonical_id":"go:GO:0048818","description":"\"Any process that activates or increases the frequency, rate or extent of hair follicle maturation.\" [GOC:devbiol]","metadata":null},{"id":"ee7197f706a14f0fab8a6c48bd53c60d","type":"GO_TERM","name":"positive regulation of hair placode formation","canonical_id":"go:GO:0061169","description":"\"Any process that increases the rate, frequency, or extent of hair follicle placode formation, the developmental process in which a hair placode forms. An hair follicle placode is a thickening of the ectoderm that will give rise to the hair follicle bud.\" [GOC:dph]","metadata":null},{"id":"25dc8e87ebb3403c9082645a86f34a45","type":"GO_TERM","name":"positive regulation of haustorium mother cell formation","canonical_id":"go:GO:0075194","description":"\"Any process that activates or increases the frequency, rate or extent of symbiont haustorium mother cell formation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"fe6d7b6fdf9c4b5bb038407d4fcf8f50","type":"GO_TERM","name":"positive regulation of heart contraction","canonical_id":"go:GO:0045823","description":"\"Any process that activates or increases the frequency, rate or extent of heart contraction.\" [GOC:curators]","metadata":null},{"id":"e459dd26e66946a9a6ddcba099c7a839","type":"GO_TERM","name":"positive regulation of heart growth","canonical_id":"go:GO:0060421","description":"\"Any process that increases the rate or extent of heart growth. Heart growth is the increase in size or mass of the heart.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"fdba275e5aad4635afafed31bd889137","type":"GO_TERM","name":"positive regulation of heart induction","canonical_id":"go:GO:1901321","description":"\"Any process that activates or increases the frequency, rate or extent of heart induction.\" [GOC:TermGenie]","metadata":null},{"id":"771c70feedf84ad68e983880ad18d72e","type":"GO_TERM","name":"positive regulation of heart looping","canonical_id":"go:GO:1901209","description":"\"Any process that activates or increases the frequency, rate or extent of heart looping.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"2d976329226f4b3c970035c3a0d6ea27","type":"GO_TERM","name":"positive regulation of heart rate","canonical_id":"go:GO:0010460","description":"\"Any process that activates or increases the frequency or rate of heart contraction.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ab9e52aade2b47f0b81b6b8e847b3132","type":"GO_TERM","name":"positive regulation of heart rate by circulating epinephrine","canonical_id":"go:GO:0003111","description":"\"The process in which the secretion of epinephrine into the bloodstream increases the rate of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"f26a7d7cb52c4519a50370d3eedd5327","type":"GO_TERM","name":"positive regulation of heart rate by circulating norepinephrine","canonical_id":"go:GO:0003114","description":"\"The process in which the secretion of norepinephrine into the bloodstream increases the rate of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"f54cb986c5ab47a5ac3d921345a66cf3","type":"GO_TERM","name":"positive regulation of heart rate by epinephrine","canonical_id":"go:GO:0003065","description":"\"The process in which the secretion of epinephrine into the bloodstream or released from nerve endings increases the rate of heart muscle contraction.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"986f1e3aa420491fbd6a1a4501ee474c","type":"GO_TERM","name":"positive regulation of heart rate by epinephrine-norepinephrine","canonical_id":"go:GO:0001996","description":"\"The process in which the presence of epinephrine or norepinephrine in the bloodstream activates, maintains or increases the rate of heart contraction.\" [GOC:dph]","metadata":null},{"id":"df084546de23445c93d332b6bc1197fc","type":"GO_TERM","name":"positive regulation of heart rate by neuronal epinephrine","canonical_id":"go:GO:0003112","description":"\"The process in which the secretion of epinephrine from nerve endings increases the rate of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"f7be4e2dd81842c786c1c8a5d741d0cc","type":"GO_TERM","name":"positive regulation of heart rate by neuronal norepinephrine","canonical_id":"go:GO:0003113","description":"\"The process in which the secretion of norepinephrine released from nerve endings increases the rate of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"7125152edb714890af2648e68b67d76f","type":"GO_TERM","name":"positive regulation of heart rate by norepinephrine","canonical_id":"go:GO:0003066","description":"\"The process in which the secretion of norepinephrine into the bloodstream or released from nerve endings increases the rate of heart muscle contraction.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"c80e836743a24a2da9a3f7cf41e3a54b","type":"GO_TERM","name":"positive regulation of heart rate involved in baroreceptor response to decreased systemic arterial blood pressure","canonical_id":"go:GO:0001988","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of heart contraction as a result of the baroreceptor response to decreased blood pressure.\" [ISBN:0721643949]","metadata":null},{"id":"565d42deb0b44ca5a7cdc10ea57ed22a","type":"GO_TERM","name":"positive regulation of heat dissipation","canonical_id":"go:GO:0031656","description":"\"Any process that activates or increases the rate or extent of heat dissipation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"42da7248b68c42c5aa9add669f0d1f7f","type":"GO_TERM","name":"positive regulation of heat generation","canonical_id":"go:GO:0031652","description":"\"Any process that activates or increases the rate or extent of heat generation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"ca4096039ad3444fa6ef84ddeb83865e","type":"GO_TERM","name":"positive regulation of helicase activity","canonical_id":"go:GO:0051096","description":"\"Any process that activates or increases the activity of a helicase.\" [GOC:ai]","metadata":null},{"id":"ea23cc27dc2745e19d37f3030b64bfce","type":"GO_TERM","name":"positive regulation of helvolic acid biosynthetic process","canonical_id":"go:GO:1900842","description":"\"Any process that activates or increases the frequency, rate or extent of helvolic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2205642f230a4a13ae17bf9e27ed8975","type":"GO_TERM","name":"positive regulation of hematopoietic progenitor cell differentiation","canonical_id":"go:GO:1901534","description":"\"Any process that activates or increases the frequency, rate or extent of hematopoietic progenitor cell differentiation.\" [GOC:BHF, GOC:rl, GOC:TermGenie]","metadata":null},{"id":"06da51076e144be7bfb938b55e551585","type":"GO_TERM","name":"positive regulation of hematopoietic stem cell differentiation","canonical_id":"go:GO:1902038","description":"\"Any process that activates or increases the frequency, rate or extent of hematopoietic stem cell differentiation.\" [GOC:TermGenie, PMID:23403623]","metadata":null},{"id":"cbd132d3145e4faa8c9c6c6b473cc977","type":"GO_TERM","name":"positive regulation of hematopoietic stem cell migration","canonical_id":"go:GO:2000473","description":"\"Any process that activates or increases the frequency, rate or extent of hematopoietic stem cell migration.\" [GOC:obol]","metadata":null},{"id":"600a1f2c5c6e4709ac335eb8bc8416aa","type":"GO_TERM","name":"positive regulation of hematopoietic stem cell proliferation","canonical_id":"go:GO:1902035","description":"\"Any process that activates or increases the frequency, rate or extent of hematopoietic stem cell proliferation.\" [GOC:TermGenie, PMID:23403623]","metadata":null},{"id":"5fd8c0f1741d4536aa88cff638987a6e","type":"GO_TERM","name":"positive regulation of heme biosynthetic process","canonical_id":"go:GO:0070455","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of heme.\" [GOC:mah]","metadata":null},{"id":"e9a3e90c5ddf46aebc85940c1e2dcba3","type":"GO_TERM","name":"positive regulation of hemicellulose catabolic process","canonical_id":"go:GO:2000990","description":"\"Any process that activates or increases the frequency, rate or extent of hemicellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"c0bc2db4493640618b086c68d5c4e669","type":"GO_TERM","name":"positive regulation of hemocyte differentiation","canonical_id":"go:GO:0045612","description":"\"Any process that activates or increases the frequency, rate or extent of hemocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"cbf804338faa44efa4b931be6cffcf05","type":"GO_TERM","name":"positive regulation of hemocyte proliferation","canonical_id":"go:GO:0035208","description":"\"Any process that activates or increases the rate or extent of hemocyte proliferation. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) that are involved in defense and clotting of hemolymph, but not involved in transport of oxygen. An example of this process is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"8b599d99ecca44e786b31bf1ad1b8bbd","type":"GO_TERM","name":"positive regulation of hemoglobin biosynthetic process","canonical_id":"go:GO:0046985","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of hemoglobin, an oxygen carrying, conjugated protein containing four heme groups and globin.\" [GOC:ai]","metadata":null},{"id":"69d667c118314c3f8b7ff25977cef6a1","type":"GO_TERM","name":"positive regulation of hemopoiesis","canonical_id":"go:GO:1903708","description":"\"Any process that activates or increases the frequency, rate or extent of hemopoiesis.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20080761]","metadata":null},{"id":"3adad53412194733bb8a2deb7023e01f","type":"GO_TERM","name":"positive regulation of hemostasis","canonical_id":"go:GO:1900048","description":"\"Any process that activates or increases the frequency, rate or extent of hemostasis.\" [GOC:TermGenie]","metadata":null},{"id":"24e2ed46186843919bb99f238e95b907","type":"GO_TERM","name":"positive regulation of heparan sulfate proteoglycan biosynthetic process","canonical_id":"go:GO:0010909","description":"\"Any process that increases the rate, frequency or extent of heparan sulfate proteoglycan biosynthesis. Heparan sulfate proteoglycan biosynthetic processes are the chemical reactions and pathways resulting in the formation of the heparan sulfate proteoglycan, which consists of a core protein linked to a heparan sulfate glycosaminoglycan. The heparan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid.\" [GOC:curators]","metadata":null},{"id":"48dc5d729dfb4d8689d49529c222e5a6","type":"GO_TERM","name":"positive regulation of hepatic stellate cell activation","canonical_id":"go:GO:2000491","description":"\"Any process that activates or increases the frequency, rate or extent of hepatic stellate cell activation.\" [GOC:obol]","metadata":null},{"id":"0b360aaa020a4a61b6eec8c65f10700e","type":"GO_TERM","name":"positive regulation of hepatic stellate cell contraction","canonical_id":"go:GO:0061874","description":"\"Any process that activates or increases the frequency, rate or extent of hepatic stellate cell contraction.\" [PMID:24204762]","metadata":null},{"id":"71183727128b44c6913518700ed109f9","type":"GO_TERM","name":"positive regulation of hepatic stellate cell migration","canonical_id":"go:GO:0061870","description":"\"Any process that increases the frequency, rate or extent of hepatic stellate cell migration.\" [PMID:24204762]","metadata":null},{"id":"ede56154d7654492a000e7282b95077f","type":"GO_TERM","name":"positive regulation of hepatic stellate cell proliferation","canonical_id":"go:GO:1904899","description":"\"Any process that activates or increases the frequency, rate or extent of hepatic stellate cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15358192]","metadata":null},{"id":"542480e91f384e849d482a4f94f18d30","type":"GO_TERM","name":"positive regulation of hepatocyte apoptotic process","canonical_id":"go:GO:1903945","description":"\"Any process that activates or increases the frequency, rate or extent of hepatocyte apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:8649852]","metadata":null},{"id":"4f15fad270f5458ea1dff781249cd477","type":"GO_TERM","name":"positive regulation of hepatocyte differentiation","canonical_id":"go:GO:0070368","description":"\"Any process that activates or increases the rate or extent of hepatocyte differentiation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"10038c4b4c2d419db5317b332bf3ac0c","type":"GO_TERM","name":"positive regulation of hepatocyte growth factor production","canonical_id":"go:GO:0032726","description":"\"Any process that activates or increases the frequency, rate, or extent of hepatocyte growth factor production.\" [GOC:mah, PMID:1838014]","metadata":null},{"id":"0b2e83c5188441cb93b5c78f13ea677f","type":"GO_TERM","name":"positive regulation of hepatocyte growth factor receptor signaling pathway","canonical_id":"go:GO:1902204","description":"\"Any process that activates or increases the frequency, rate or extent of hepatocyte growth factor receptor signaling pathway.\" [GOC:TermGenie, PMID:18819921]","metadata":null},{"id":"b431f4bdad734863abe47db36c8be21e","type":"GO_TERM","name":"positive regulation of hepatocyte proliferation","canonical_id":"go:GO:2000347","description":"\"Any process that activates or increases the frequency, rate or extent of hepatocyte proliferation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"89bf783888534a69a0eee187e047ca15","type":"GO_TERM","name":"positive regulation of heptadecane biosynthetic process","canonical_id":"go:GO:1900898","description":"\"Any process that activates or increases the frequency, rate or extent of heptadecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2da833109b5f4baa8b545c0f79476085","type":"GO_TERM","name":"positive regulation of heptasaccharide transport","canonical_id":"go:GO:1900296","description":"\"Any process that activates or increases the frequency, rate or extent of heptasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2e723ad0cd38413089f9fd63648968d6","type":"GO_TERM","name":"positive regulation of heterochromatin formation","canonical_id":"go:GO:0031453","description":"\"Any process that activates or increases the frequency, rate or extent of heterochromatin formation.\" [GOC:mah]","metadata":null},{"id":"42fa5764fbbb44a3a073ad564a7045f8","type":"GO_TERM","name":"positive regulation of heterochromatin organization","canonical_id":"go:GO:0120263","description":"\"Any process that activates or increases the frequency, rate or extent of heterochromatin organization.\" [GOC:krc]","metadata":null},{"id":"77c45fa1611a4b9bb62836727be11704","type":"GO_TERM","name":"positive regulation of heterotypic cell-cell adhesion","canonical_id":"go:GO:0034116","description":"\"Any process that activates or increases the frequency, rate, or extent of heterotypic cell-cell adhesion.\" [GOC:add]","metadata":null},{"id":"f04366cf6a0f4531a365b0cab5677f72","type":"GO_TERM","name":"positive regulation of hexadecanal biosynthetic process","canonical_id":"go:GO:1900904","description":"\"Any process that activates or increases the frequency, rate or extent of hexadecanal biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"e45d16920c524b3ea6ba4b31a6847bd9","type":"GO_TERM","name":"positive regulation of hexasaccharide transport","canonical_id":"go:GO:1900299","description":"\"Any process that activates or increases the frequency, rate or extent of hexasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c02b641d365342caac00bd5f197fef9e","type":"GO_TERM","name":"positive regulation of hexokinase activity","canonical_id":"go:GO:1903301","description":"\"Any process that activates or increases the frequency, rate or extent of hexokinase activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:15804508]","metadata":null},{"id":"cfc0b4495de647f5829b722c5d3d1cc0","type":"GO_TERM","name":"positive regulation of high voltage-gated calcium channel activity","canonical_id":"go:GO:1901843","description":"\"Any process that activates or increases the frequency, rate or extent of high voltage-gated calcium channel activity.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12754254]","metadata":null},{"id":"329d8b74880345c19dc19211c9206f9a","type":"GO_TERM","name":"positive regulation of high-density lipoprotein particle assembly","canonical_id":"go:GO:0090108","description":"\"Any process that increases the frequency, rate, or extent of high-density lipoprotein particle assembly. High-density lipoprotein particle assembly is the aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"105317e05b0046318a60898124d48ac0","type":"GO_TERM","name":"positive regulation of high-density lipoprotein particle clearance","canonical_id":"go:GO:0010983","description":"\"Any process that increases the rate, frequency or extent of high-density lipoprotein particle clearance. High-density lipoprotein particle clearance is the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"db052b14f57a4ca9b9b29441e5e7cecf","type":"GO_TERM","name":"positive regulation of hindgut contraction","canonical_id":"go:GO:0060450","description":"\"Any process that increases the frequency, rate or extent of muscle contraction of the hindgut, the posterior part of the alimentary canal, including the rectum, and the large intestine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2c43919a3a0c40dfacc054d60b1ffde4","type":"GO_TERM","name":"positive regulation of hippo signaling","canonical_id":"go:GO:0035332","description":"\"Any process that activates or increases the frequency, rate or extent of hippo signaling.\" [GOC:bf]","metadata":null},{"id":"3daa226a413643ebb66b725d060ef279","type":"GO_TERM","name":"positive regulation of hippocampal neuron apoptotic process","canonical_id":"go:GO:0110090","description":"\"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process in hippocampal neurons.\" [GOC:sl, PMID:18940801]","metadata":null},{"id":"11ba132846ce48f58158fe2c8215a525","type":"GO_TERM","name":"positive regulation of histamine secretion by mast cell","canonical_id":"go:GO:1903595","description":"\"Any process that activates or increases the frequency, rate or extent of histamine secretion by mast cell.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18253931]","metadata":null},{"id":"ba2738a6994e410b9a0fc306a05c76d4","type":"GO_TERM","name":"positive regulation of histamine uptake","canonical_id":"go:GO:0051618","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of histamine into a cell.\" [GOC:ai]","metadata":null},{"id":"cf64021a8b4f4c4891c917e34b14e3ae","type":"GO_TERM","name":"positive regulation of histidine biosynthetic process","canonical_id":"go:GO:0120215","description":"\"Any process that activates or increases the frequency, rate or extent of histidine biosynthetic process.\" [GOC:krc]","metadata":null},{"id":"2b7a4fa1b7c84ed6bdb3767810e01fd1","type":"GO_TERM","name":"positive regulation of homophilic cell adhesion","canonical_id":"go:GO:1903387","description":"\"Any process that activates or increases the frequency, rate or extent of homophilic cell adhesion.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:21724833]","metadata":null},{"id":"7c6cd0bec14a4543987730e3731a9661","type":"GO_TERM","name":"positive regulation of homoserine biosynthetic process","canonical_id":"go:GO:1901712","description":"\"Any process that activates or increases the frequency, rate or extent of homoserine biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"3479e82970a746e29f33d3189b251adf","type":"GO_TERM","name":"positive regulation of homotypic cell-cell adhesion","canonical_id":"go:GO:0034112","description":"\"Any process that activates or increases the frequency, rate, or extent of homotypic cell-cell adhesion.\" [GOC:add]","metadata":null},{"id":"4ca8ff7b5dbb4ebdb40985986e906998","type":"GO_TERM","name":"positive regulation of horizontal cell localization","canonical_id":"go:GO:1902874","description":"\"Any process that activates or increases the frequency, rate or extent of horizontal cell localization.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"40da10ab859c402a9902552f39f08ed8","type":"GO_TERM","name":"positive regulation of hormone biosynthetic process","canonical_id":"go:GO:0046886","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of hormones.\" [GOC:ai]","metadata":null},{"id":"21e256ea237d4716b7c1c6dd6905cc84","type":"GO_TERM","name":"positive regulation of hormone metabolic process","canonical_id":"go:GO:0032352","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving any hormone.\" [GOC:mah]","metadata":null},{"id":"e0b23b7e989a45dcb180c4694ef1d09e","type":"GO_TERM","name":"positive regulation of hormone secretion","canonical_id":"go:GO:0046887","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of a hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"83a6ef22052845cb9a5f317ab688e05c","type":"GO_TERM","name":"positive regulation of host-seeking behavior","canonical_id":"go:GO:0032540","description":"\"Any process that activates or increases the frequency, rate or extent of any behavior associated with finding a host organism.\" [GOC:mah]","metadata":null},{"id":"1156fbc84ee24e9eaaa040c06b664c0c","type":"GO_TERM","name":"positive regulation of humoral immune response","canonical_id":"go:GO:0002922","description":"\"Any process that activates or increases the frequency, rate, or extent of a humoral immune response.\" [GOC:add]","metadata":null},{"id":"546599944fb14cdd80cf62bfba70d8ad","type":"GO_TERM","name":"positive regulation of humoral immune response mediated by circulating immunoglobulin","canonical_id":"go:GO:0002925","description":"\"Any process that activates or increases the frequency, rate, or extent of a humoral immune response mediated by circulating immunoglobulin.\" [GOC:add]","metadata":null},{"id":"d1fc2222f95340858b568389ec1cae84","type":"GO_TERM","name":"positive regulation of hyaluranon cable assembly","canonical_id":"go:GO:1900106","description":"\"Any process that activates or increases the frequency, rate or extent of hyaluranon cable assembly.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"8213edfa6ee949a4bee743180cc91491","type":"GO_TERM","name":"positive regulation of hyaluronan biosynthetic process","canonical_id":"go:GO:1900127","description":"\"Any process that activates or increases the frequency, rate or extent of hyaluronan biosynthetic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"29954783cc4e4399bb2b3ec35ae899cb","type":"GO_TERM","name":"positive regulation of hydrogen peroxide biosynthetic process","canonical_id":"go:GO:0010729","description":"\"Any process that increases the rate, frequency or extent of hydrogen peroxide biosynthesis. The chemical reactions and pathways resulting in the formation of hydrogen peroxide (H2O2), a potentially harmful byproduct of aerobic cellular respiration which can cause damage to DNA.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"e5f2fc48d5bd4b4cb3df331b1036c7b6","type":"GO_TERM","name":"positive regulation of hydrogen peroxide catabolic process","canonical_id":"go:GO:1903285","description":"\"Any process that activates or increases the frequency, rate or extent of hydrogen peroxide catabolic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23507046]","metadata":null},{"id":"c6a13dfa76cd41e3811c0ec7ab038727","type":"GO_TERM","name":"positive regulation of hydrogen peroxide-mediated programmed cell death","canonical_id":"go:GO:1901300","description":"\"Any process that activates or increases the frequency, rate or extent of hydrogen peroxide-mediated programmed cell death.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"d60a9fd420b546e2be097edbe36f0deb","type":"GO_TERM","name":"positive regulation of hydrogen sulfide biosynthetic process","canonical_id":"go:GO:1904828","description":"\"Any process that activates or increases the frequency, rate or extent of hydrogen sulfide biosynthetic process.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22034194]","metadata":null},{"id":"408705ce6af54087ab7d44c43755b730","type":"GO_TERM","name":"positive regulation of hydrolase activity","canonical_id":"go:GO:0051345","description":"\"Any process that activates or increases the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds.\" [GOC:ai]","metadata":null},{"id":"897a7a9efe28487fae95c2a19192178e","type":"GO_TERM","name":"positive regulation of hypersensitivity","canonical_id":"go:GO:0002885","description":"\"Any process that activates or increases the frequency, rate, or extent of hypersensitivity.\" [GOC:add]","metadata":null},{"id":"051e24c6130248ed8e6c6c5564fbfabd","type":"GO_TERM","name":"positive regulation of hyphopodium formation","canonical_id":"go:GO:0075189","description":"\"Any process that activates or increases the frequency, rate or extent of symbiont hyphopodium formation on or near its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"291522afced842cca5d6ade1b3617831","type":"GO_TERM","name":"positive regulation of hypoxanthine transport","canonical_id":"go:GO:0035346","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of hypoxanthine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"80dd2f374d0c45dcb02752050215f2c9","type":"GO_TERM","name":"positive regulation of hypoxia-inducible factor-1alpha signaling pathway","canonical_id":"go:GO:1902073","description":"\"Any process that activates or increases the frequency, rate or extent of hypoxia-inducible factor-1alpha signaling pathway.\" [GOC:bf, GOC:TermGenie, PMID:21685248]","metadata":null},{"id":"d872be44db584ede9068bb5318131da3","type":"GO_TERM","name":"positive regulation of icosanoid secretion","canonical_id":"go:GO:0032305","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled release of an icosanoid from a cell.\" [GOC:mah]","metadata":null},{"id":"af8121e830304d5c9d5a2a3b15169fb3","type":"GO_TERM","name":"positive regulation of imaginal disc growth","canonical_id":"go:GO:0045572","description":"\"Any process that activates or increases the frequency, rate or extent of imaginal disc growth.\" [GOC:curators]","metadata":null},{"id":"68784072ca3a45af8a035ee50c9bb62d","type":"GO_TERM","name":"positive regulation of imaginal disc-derived leg joint morphogenesis","canonical_id":"go:GO:0110138","description":"\"Any process that activates or increases the frequency, rate or extent of imaginal disc-derived leg joint morphogenesis.\" [GOC:ha, PMID:25329825]","metadata":null},{"id":"913ab40840a14654ac3040a404f816b6","type":"GO_TERM","name":"positive regulation of imaginal disc-derived wing size","canonical_id":"go:GO:0120198","description":"\"Any process that increases the size of an imaginal disc-derived wing.\" [GOC:ha, PIMD:23485686]","metadata":null},{"id":"60572647b56d4d61ae0cfbebc2448dcb","type":"GO_TERM","name":"positive regulation of imaginal disc-derived wing vein specification","canonical_id":"go:GO:0110108","description":"\"Any process that activates or increases the frequency, rate or extent of imaginal disc-derived wing vein specification.\" [GOC:ha, PMID:11861482]","metadata":null},{"id":"fda557e5a04b435e9243e78a20803d34","type":"GO_TERM","name":"positive regulation of immature T cell proliferation","canonical_id":"go:GO:0033091","description":"\"Any process that activates or increases the frequency, rate or extent of immature T cell proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"ef6e57b71ea3439ab81bb8c849838cfe","type":"GO_TERM","name":"positive regulation of immature T cell proliferation in thymus","canonical_id":"go:GO:0033092","description":"\"Any process that activates or increases the frequency, rate or extent of immature T cell proliferation in the thymus.\" [GOC:add, GOC:mah]","metadata":null},{"id":"d1d2f8c25a0c41e2a0c5cbae685e678b","type":"GO_TERM","name":"positive regulation of immune complex clearance by monocytes and macrophages","canonical_id":"go:GO:0090265","description":"\"Any process that increases the rate, frequency, or extent of the process of immune complex clearance by monocytes or macrophages.\" [GOC:BHF]","metadata":null},{"id":"208af82104844143a6f313f92fe995a8","type":"GO_TERM","name":"positive regulation of immune effector process","canonical_id":"go:GO:0002699","description":"\"Any process that activates or increases the frequency, rate, or extent of an immune effector process.\" [GOC:add]","metadata":null},{"id":"d8c9e708a65945d0beefadc64ac552c4","type":"GO_TERM","name":"positive regulation of immune response","canonical_id":"go:GO:0050778","description":"\"Any process that activates or increases the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.\" [GOC:ai]","metadata":null},{"id":"763d480dc70447458d9e9c3c358bd2d3","type":"GO_TERM","name":"positive regulation of immune response to tumor cell","canonical_id":"go:GO:0002839","description":"\"Any process that activates or increases the frequency, rate, or extent of an immune response to tumor cell.\" [GOC:add]","metadata":null},{"id":"b465bb549926477f81ba9a1ced2a0c8f","type":"GO_TERM","name":"positive regulation of immune system process","canonical_id":"go:GO:0002684","description":"\"Any process that activates or increases the frequency, rate, or extent of an immune system process.\" [GOC:add]","metadata":null},{"id":"e0c51170b14a4f44b5955bd8f04e97de","type":"GO_TERM","name":"positive regulation of immunoglobulin mediated immune response","canonical_id":"go:GO:0002891","description":"\"Any process that activates or increases the frequency, rate, or extent of an immunoglobulin mediated immune response.\" [GOC:add]","metadata":null},{"id":"eb9dd9c3ac5b47ba9e3261d41425fc11","type":"GO_TERM","name":"positive regulation of immunoglobulin production","canonical_id":"go:GO:0002639","description":"\"Any process that activates or increases the frequency, rate, or extent of immunoglobulin production.\" [GOC:add]","metadata":null},{"id":"35aaf6c8c64343e7941c5d84f937998a","type":"GO_TERM","name":"positive regulation of immunoglobulin production in mucosal tissue","canonical_id":"go:GO:2000558","description":"\"Any process that activates or increases the frequency, rate or extent of immunoglobulin production in mucosal tissue.\" [GOC:obol]","metadata":null},{"id":"0b71693677534f299a6903db7197288f","type":"GO_TERM","name":"positive regulation of immunological synapse formation","canonical_id":"go:GO:2000522","description":"\"Any process that activates or increases the frequency, rate or extent of immunological synapse formation.\" [GOC:obol]","metadata":null},{"id":"82115c6de41c4796918e63fc1503f063","type":"GO_TERM","name":"positive regulation of inclusion body assembly","canonical_id":"go:GO:0090261","description":"\"Any process that increases the rate, frequency, or extent of inclusion body assembly. Inclusion body assembly is the aggregation, arrangement and bonding together of a set of components to form an inclusion body.\" [GOC:tb]","metadata":null},{"id":"0d26c239a897426ba836f3b1578d525c","type":"GO_TERM","name":"positive regulation of infection cushion formation","canonical_id":"go:GO:0075185","description":"\"Any process that activates or increases the frequency, rate or extent of symbiont infection cushion formation on or near its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"732944f14c9140f7b081841c7cbb5a44","type":"GO_TERM","name":"positive regulation of inflammasome-mediated signaling pathway","canonical_id":"go:GO:0141087","description":"\"Any process that activates or increases the frequency, rate or extent of an inflammasome-mediated signaling pathway.\" [PMID:33467177]","metadata":null},{"id":"dea88d9cfacc40d0a6dacb7908eca61d","type":"GO_TERM","name":"positive regulation of inflammatory response","canonical_id":"go:GO:0050729","description":"\"Any process that activates or increases the frequency, rate or extent of the inflammatory response.\" [GOC:ai]","metadata":null},{"id":"864ff8330f2843dca834c2d1fb1261c9","type":"GO_TERM","name":"positive regulation of inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002863","description":"\"Any process that activates or increases the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"ecd7f9aa9f43413bb30792c161eac0d8","type":"GO_TERM","name":"positive regulation of inflammatory response to wounding","canonical_id":"go:GO:0106016","description":"\"Any process that activates or increases the frequency, rate or extent of the inflammatory response to wounding.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26022821]","metadata":null},{"id":"0a5b13dc64aa471d9e4ea79f950924e2","type":"GO_TERM","name":"positive regulation of inhibin secretion","canonical_id":"go:GO:0032340","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of inhibin from a cell.\" [GOC:mah]","metadata":null},{"id":"dd2a49c6ccf44be39b56a5d712c3b89a","type":"GO_TERM","name":"positive regulation of inhibitory G protein-coupled receptor phosphorylation","canonical_id":"go:GO:1904325","description":"\"Any process that activates or increases the frequency, rate or extent of inhibitory G protein-coupled receptor phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15937517]","metadata":null},{"id":"8747a49e80d64315bf68030067cbaabc","type":"GO_TERM","name":"positive regulation of inhibitory postsynaptic potential","canonical_id":"go:GO:0097151","description":"\"Any process that activates or increases the frequency, rate or extent of inhibitory postsynaptic potential (IPSP). IPSP is a temporary decrease in postsynaptic membrane potential due to the flow of negatively charged ions into the postsynaptic cell. The flow of ions that causes an IPSP is an inhibitory postsynaptic current (IPSC) and makes it more difficult for the neuron to fire an action potential.\" [GOC:BHF, GOC:sjp, PMID:18550748]","metadata":null},{"id":"5639049b20974520b9cd8af4433e07d9","type":"GO_TERM","name":"positive regulation of inhibitory synapse assembly","canonical_id":"go:GO:1905704","description":"\"Any process that activates or increases the frequency, rate or extent of inhibitory synapse assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"1ce52c575ee34d0dbe88a2f5d1fe4060","type":"GO_TERM","name":"positive regulation of initiation of premeiotic DNA replication","canonical_id":"go:GO:1904514","description":"\"Any process that activates or increases the frequency, rate or extent of initiation of premeiotic DNA replication.\" [GO_REF:0000058, GOC:TermGenie, PMID:25891897]","metadata":null},{"id":"5f3b46c533f4469da3ea8ebb979aba89","type":"GO_TERM","name":"positive regulation of innate immune response","canonical_id":"go:GO:0045089","description":"\"Any process that activates or increases the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.\" [GOC:ebc]","metadata":null},{"id":"6760ad79270248b1aa0fde4353907e8e","type":"GO_TERM","name":"positive regulation of innate immunity memory response","canonical_id":"go:GO:1905682","description":"\"Any process that activates or increases the frequency, rate or extent of innate immunity memory response.\" [GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"3200d972cdf643b7b48deaa893ac7506","type":"GO_TERM","name":"positive regulation of inner ear auditory receptor cell differentiation","canonical_id":"go:GO:0045609","description":"\"Any process that activates or increases the frequency, rate or extent of auditory hair cell differentiation.\" [GOC:curators]","metadata":null},{"id":"c084b7dbad124f8c910840481c105f39","type":"GO_TERM","name":"positive regulation of inner ear receptor cell differentiation","canonical_id":"go:GO:2000982","description":"\"Any process that activates or increases the frequency, rate or extent of inner ear receptor cell differentiation.\" [GOC:obol]","metadata":null},{"id":"e95d72e8d05d4314bbbfa25841fa58ec","type":"GO_TERM","name":"positive regulation of inosine transport","canonical_id":"go:GO:0035342","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of inosine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"65487e9046604715ac218df6a5effe2b","type":"GO_TERM","name":"positive regulation of inositol biosynthetic process","canonical_id":"go:GO:1900090","description":"\"Any process that activates or increases the frequency, rate or extent of inositol biosynthetic process.\" [GOC:TermGenie, PMID:22307851]","metadata":null},{"id":"33c50ed3a2f1440b9cc34148a4c4a1da","type":"GO_TERM","name":"positive regulation of inositol phosphate biosynthetic process","canonical_id":"go:GO:0060732","description":"\"Any process that increases the rate, frequency or extent of inositol phosphate biosynthesis. Inositol phosphate biosynthetic processes are the chemical reactions and pathways resulting in the formation of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"17bb4b0d77ca448da4acba7450ea4d1d","type":"GO_TERM","name":"positive regulation of inositol trisphosphate biosynthetic process","canonical_id":"go:GO:0032962","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of inositol trisphosphate.\" [GOC:mah]","metadata":null},{"id":"62a8e0aecba84c7bab81e5a357939ebd","type":"GO_TERM","name":"positive regulation of insulin receptor signaling pathway","canonical_id":"go:GO:0046628","description":"\"Any process that increases the frequency, rate or extent of insulin receptor signaling.\" [GOC:bf]","metadata":null},{"id":"b5cd4a54cc804835bb09560a325ea298","type":"GO_TERM","name":"positive regulation of insulin receptor signaling pathway by insulin receptor internalization","canonical_id":"go:GO:0038015","description":"\"Any process in which internalization of an insulin receptor activates or increases the frequency, rate or extent of the insulin receptor signaling pathway. Endocytosis of activated receptors can concentrate receptors within endosomes and allow the insulin receptor to phosphorylate substrates that are spatially distinct from those accessible at the plasma membrane.\" [GOC:bf, GOC:signaling, PMID:9609114]","metadata":null},{"id":"b0680e91ee1f4f178a7cbaf9043787a0","type":"GO_TERM","name":"positive regulation of insulin secretion","canonical_id":"go:GO:0032024","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of insulin.\" [GOC:mah]","metadata":null},{"id":"caaa00bb1dbf408bbc1c5aebb0690408","type":"GO_TERM","name":"positive regulation of insulin secretion involved in cellular response to glucose stimulus","canonical_id":"go:GO:0035774","description":"\"Any process that increases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose.\" [GOC:bf, GOC:yaf]","metadata":null},{"id":"37c0a6b827b3480caa070bd58a3351de","type":"GO_TERM","name":"positive regulation of insulin-like growth factor receptor signaling pathway","canonical_id":"go:GO:0043568","description":"\"Any process that increases the frequency, rate or extent of insulin-like growth factor receptor signaling.\" [GOC:bf]","metadata":null},{"id":"42a2c82b4d44422a99fb66cc8e0da45e","type":"GO_TERM","name":"positive regulation of integrin activation","canonical_id":"go:GO:0033625","description":"\"Any process that activates or increases the frequency, rate, or extent of integrin activation.\" [GOC:add]","metadata":null},{"id":"ea5b23ea39f14a80b3877c4e01d6ffac","type":"GO_TERM","name":"positive regulation of integrin activation by cell surface receptor linked signal transduction","canonical_id":"go:GO:0033626","description":"\"Any process that activates or increases the frequency, rate, or extent of integrin activation by cell surface receptor linked signal transduction. This can occur by increased affinity of an integrin for its extracellular ligands.\" [GOC:add, PMID:12213832, PMID:14754902]","metadata":null},{"id":"11394ef5baae464d87cee8088bf0d88e","type":"GO_TERM","name":"positive regulation of integrin biosynthetic process","canonical_id":"go:GO:0045726","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of integrins.\" [GOC:curators]","metadata":null},{"id":"8c2e9f9bffd64c2284feb05073b5f990","type":"GO_TERM","name":"positive regulation of integrin-mediated signaling pathway","canonical_id":"go:GO:2001046","description":"\"Any process that activates or increases the frequency, rate or extent of integrin-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"ee7ff505a0c7415285736b865a20dec2","type":"GO_TERM","name":"positive regulation of interferon-alpha production","canonical_id":"go:GO:0032727","description":"\"Any process that activates or increases the frequency, rate, or extent of interferon-alpha production.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"1a531fe3d21a4c1099dffb31588089a7","type":"GO_TERM","name":"positive regulation of interferon-beta production","canonical_id":"go:GO:0032728","description":"\"Any process that activates or increases the frequency, rate, or extent of interferon-beta production.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"44a7a11c75d443d6a0490edc2f097d54","type":"GO_TERM","name":"positive regulation of interleukin-1 alpha production","canonical_id":"go:GO:0032730","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-1 alpha production.\" [GOC:mah]","metadata":null},{"id":"52869a73e7c143b380e31c11a7468d22","type":"GO_TERM","name":"positive regulation of interleukin-1 beta production","canonical_id":"go:GO:0032731","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-1 beta production.\" [GOC:mah]","metadata":null},{"id":"58c3ba3fe4284e01b740fd4fdbebc0b4","type":"GO_TERM","name":"positive regulation of interleukin-1 production","canonical_id":"go:GO:0032732","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-1 production.\" [GOC:mah]","metadata":null},{"id":"ac477f668f864e82be0b6b9dc0f49311","type":"GO_TERM","name":"positive regulation of interleukin-1-mediated signaling pathway","canonical_id":"go:GO:2000661","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-1-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"ca2bc2e8b01b42c8b32aa95683b85e58","type":"GO_TERM","name":"positive regulation of interleukin-10 production","canonical_id":"go:GO:0032733","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-10 production.\" [GOC:mah]","metadata":null},{"id":"470a387f6abb4404bd3e502a8873a3d6","type":"GO_TERM","name":"positive regulation of interleukin-11 production","canonical_id":"go:GO:0032734","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-11 production.\" [GOC:mah]","metadata":null},{"id":"88234b69513f4de5865a424992f75f5c","type":"GO_TERM","name":"positive regulation of interleukin-12 production","canonical_id":"go:GO:0032735","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-12 production.\" [GOC:mah]","metadata":null},{"id":"6d495a1df7d2488c9741ec9cfbd58533","type":"GO_TERM","name":"positive regulation of interleukin-13 production","canonical_id":"go:GO:0032736","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-13 production.\" [GOC:mah]","metadata":null},{"id":"80860d76d5ff4e9cb5b1327ff34c8fe8","type":"GO_TERM","name":"positive regulation of interleukin-15 production","canonical_id":"go:GO:0032738","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-15 production.\" [GOC:mah]","metadata":null},{"id":"753fcc70bf5b47a28515271fb7d382a7","type":"GO_TERM","name":"positive regulation of interleukin-16 production","canonical_id":"go:GO:0032739","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-16 production.\" [GOC:mah]","metadata":null},{"id":"87e95d1faf594f1b89b3738a618d5e6b","type":"GO_TERM","name":"positive regulation of interleukin-17 production","canonical_id":"go:GO:0032740","description":"\"Any process that activates or increases the frequency, rate, or extent of production of any member of the interleukin-17 family of cytokines.\" [GOC:add, GOC:mah, PMID:16482511]","metadata":null},{"id":"00d75b53b5b146e998375ff31e11fce5","type":"GO_TERM","name":"positive regulation of interleukin-17-mediated signaling pathway","canonical_id":"go:GO:1903883","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-17-mediated signaling pathway.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:20054338]","metadata":null},{"id":"d57e798d447a40d58d7fbf04eda4c805","type":"GO_TERM","name":"positive regulation of interleukin-17A production","canonical_id":"go:GO:0150153","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-17A production.\" [GOC:aruk]","metadata":null},{"id":"776bccd8707c44419d4670634f58558d","type":"GO_TERM","name":"positive regulation of interleukin-18 production","canonical_id":"go:GO:0032741","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-18 production.\" [GOC:mah]","metadata":null},{"id":"d5df26a54d5c40188dd9b2c1d934d09f","type":"GO_TERM","name":"positive regulation of interleukin-18-mediated signaling pathway","canonical_id":"go:GO:2000494","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-18-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"7793f7577aad42d4a3726263f60d996b","type":"GO_TERM","name":"positive regulation of interleukin-19 production","canonical_id":"go:GO:0032742","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-19 production.\" [GOC:mah]","metadata":null},{"id":"c9a97b8b89fb429daabe0932474fd223","type":"GO_TERM","name":"positive regulation of interleukin-2 production","canonical_id":"go:GO:0032743","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-2 production.\" [GOC:mah]","metadata":null},{"id":"d61011efe85149f38d10e8c39adf493b","type":"GO_TERM","name":"positive regulation of interleukin-2-mediated signaling pathway","canonical_id":"go:GO:1902207","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-2-mediated signaling pathway.\" [GOC:TermGenie, PMID:11909529]","metadata":null},{"id":"b279d87031de4c9d8c8fa3910b01e205","type":"GO_TERM","name":"positive regulation of interleukin-20 production","canonical_id":"go:GO:0032744","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-20 production.\" [GOC:mah]","metadata":null},{"id":"edbae7a02c514de08237d103d54376bf","type":"GO_TERM","name":"positive regulation of interleukin-21 production","canonical_id":"go:GO:0032745","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-21 production.\" [GOC:mah]","metadata":null},{"id":"af5d250567bd4fe3ad5bf25b5767e28c","type":"GO_TERM","name":"positive regulation of interleukin-22 production","canonical_id":"go:GO:0032746","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-22 production.\" [GOC:mah]","metadata":null},{"id":"ae86bfdb9d5341179fa97cc4811cc0d1","type":"GO_TERM","name":"positive regulation of interleukin-23 production","canonical_id":"go:GO:0032747","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-23 production.\" [GOC:mah]","metadata":null},{"id":"53196cb9768945c8aea41ef3584a0e98","type":"GO_TERM","name":"positive regulation of interleukin-24 production","canonical_id":"go:GO:0032748","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-24 production.\" [GOC:mah]","metadata":null},{"id":"4c41fd5dd99c4d69994cdf950257a21a","type":"GO_TERM","name":"positive regulation of interleukin-25 production","canonical_id":"go:GO:0032749","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-25 production.\" [GOC:mah]","metadata":null},{"id":"cb9bf62a88454926b798d708cf8bdbfd","type":"GO_TERM","name":"positive regulation of interleukin-26 production","canonical_id":"go:GO:0032750","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-26 production.\" [GOC:mah]","metadata":null},{"id":"80429dec644146718ad240b11ad2ae31","type":"GO_TERM","name":"positive regulation of interleukin-27 production","canonical_id":"go:GO:0032751","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-27 production.\" [GOC:mah]","metadata":null},{"id":"402ad5764f0246f8a7f973bd6219be83","type":"GO_TERM","name":"positive regulation of interleukin-27-mediated signaling pathway","canonical_id":"go:GO:0070109","description":"\"Any process that increases the rate, frequency or extent of an interleukin-27-mediated signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1d3a25c1e7194ccab521d8a5717dfa38","type":"GO_TERM","name":"positive regulation of interleukin-3 production","canonical_id":"go:GO:0032752","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-3 production.\" [GOC:mah]","metadata":null},{"id":"dd8c1f248a41422e89ed38889ca70bd2","type":"GO_TERM","name":"positive regulation of interleukin-32 production","canonical_id":"go:GO:0150191","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-32 production.\" [GOC:aruk]","metadata":null},{"id":"2175292e013b4af586cc8619787bb59d","type":"GO_TERM","name":"positive regulation of interleukin-33 production","canonical_id":"go:GO:0150129","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-33 production.\" [GOC:aruk]","metadata":null},{"id":"7d7bbed9fe124fe6a8680078528606c9","type":"GO_TERM","name":"positive regulation of interleukin-34 production","canonical_id":"go:GO:0150158","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-34 production.\" [GOC:aruk]","metadata":null},{"id":"b1d8dd1de19647d1a8b69820d7ab2324","type":"GO_TERM","name":"positive regulation of interleukin-35 production","canonical_id":"go:GO:0070756","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-35 production.\" [GOC:mah]","metadata":null},{"id":"ca4f0bda8694478eb88b3029767fc1b1","type":"GO_TERM","name":"positive regulation of interleukin-35-mediated signaling pathway","canonical_id":"go:GO:0070760","description":"\"Any process that increases the rate, frequency or extent of an interleukin-35-mediated signaling pathway.\" [GOC:mah]","metadata":null},{"id":"ac1d5cb7dd6941ce95e62928142b7dde","type":"GO_TERM","name":"positive regulation of interleukin-37 production","canonical_id":"go:GO:0150139","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-37 production.\" [GOC:aruk]","metadata":null},{"id":"d8a02965ad8941f39902a4f66b411673","type":"GO_TERM","name":"positive regulation of interleukin-4 production","canonical_id":"go:GO:0032753","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-4 production.\" [GOC:mah]","metadata":null},{"id":"3d0603097f4b48c09cd7a30d8272224b","type":"GO_TERM","name":"positive regulation of interleukin-4-dependent isotype switching to IgE isotypes","canonical_id":"go:GO:2000572","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-4-dependent isotype switching to IgE isotypes.\" [GOC:obol]","metadata":null},{"id":"b95b6fb4c5ce4230a58913c01958fc02","type":"GO_TERM","name":"positive regulation of interleukin-4-mediated signaling pathway","canonical_id":"go:GO:1902216","description":"\"Any process that activates or increases the frequency, rate or extent of interleukin-4-mediated signaling pathway.\" [GOC:TermGenie, PMID:17210636]","metadata":null},{"id":"31f8ca2f1d0c41b3b433e1c1b53e5111","type":"GO_TERM","name":"positive regulation of interleukin-5 production","canonical_id":"go:GO:0032754","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-5 production.\" [GOC:mah]","metadata":null},{"id":"676bc94f768d4696b8a60bdb0bff8225","type":"GO_TERM","name":"positive regulation of interleukin-6 production","canonical_id":"go:GO:0032755","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-6 production.\" [GOC:mah]","metadata":null},{"id":"d16034a38b0f47bd8a9b1130137c5483","type":"GO_TERM","name":"positive regulation of interleukin-6-mediated signaling pathway","canonical_id":"go:GO:0070105","description":"\"Any process that increases the rate, frequency or extent of an interleukin-6-mediated signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ac95ea8ed348418cbe926a813ea9b063","type":"GO_TERM","name":"positive regulation of interleukin-7 production","canonical_id":"go:GO:0032756","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-7 production.\" [GOC:mah]","metadata":null},{"id":"039f421aa2d6438bb06d5f9aba833587","type":"GO_TERM","name":"positive regulation of interleukin-8 production","canonical_id":"go:GO:0032757","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-8 production.\" [GOC:mah]","metadata":null},{"id":"e5076c990ece47fa86af427b2438ff13","type":"GO_TERM","name":"positive regulation of interleukin-9 production","canonical_id":"go:GO:0032758","description":"\"Any process that activates or increases the frequency, rate, or extent of interleukin-9 production.\" [GOC:mah]","metadata":null},{"id":"9703f347319f45d7ba8c3a1f863fa916","type":"GO_TERM","name":"positive regulation of intermediate filament depolymerization","canonical_id":"go:GO:0030844","description":"\"Any process that activates or increases the frequency, rate or extent of intermediate filament depolymerization.\" [GOC:mah]","metadata":null},{"id":"f67a0377fb1647c39d3359d698ff8e81","type":"GO_TERM","name":"positive regulation of intermediate filament polymerization","canonical_id":"go:GO:0030841","description":"\"Any process that activates or increases the frequency, rate or extent of intermediate filament polymerization.\" [GOC:mah]","metadata":null},{"id":"ac5db28421c14c30a1f2139ad949a83c","type":"GO_TERM","name":"positive regulation of intermediate mesodermal cell fate determination","canonical_id":"go:GO:0048397","description":"\"Any process that activates or increases the frequency, rate or extent of intermediate mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"229f4ee9464242d1beae152b3af60621","type":"GO_TERM","name":"positive regulation of intermediate mesodermal cell fate specification","canonical_id":"go:GO:0048400","description":"\"Any process that activates or increases the frequency, rate or extent of intermediate mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"76f443d4733f4dd3aad97f10fa57fcdd","type":"GO_TERM","name":"positive regulation of intestinal absorption","canonical_id":"go:GO:1904480","description":"\"Any process that activates or increases the frequency, rate or extent of intestinal absorption.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12469120]","metadata":null},{"id":"df8c999f84764f3fbf148a3b84a3133d","type":"GO_TERM","name":"positive regulation of intestinal cholesterol absorption","canonical_id":"go:GO:0045797","description":"\"Any process that activates or increases the frequency, rate or extent of uptake of cholesterol into the blood by absorption from the intestine.\" [GOC:curators]","metadata":null},{"id":"d621d518a77c4e14ae4cee56791cf0e6","type":"GO_TERM","name":"positive regulation of intestinal epithelial cell development","canonical_id":"go:GO:1905300","description":"\"Any process that activates or increases the frequency, rate or extent of intestinal epithelial cell development.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23904268]","metadata":null},{"id":"f5611eaeafe24ccfbf30ebb7a153d621","type":"GO_TERM","name":"positive regulation of intestinal epithelial structure maintenance","canonical_id":"go:GO:0060731","description":"\"Any process the increases the rate, frequency or extent of intestinal epithelial structure maintenance, a tissue homeostatic process required for the maintenance of the structure of the intestinal epithelium.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a1adf758bb964db98850a31a3b029335","type":"GO_TERM","name":"positive regulation of intestinal lipid absorption","canonical_id":"go:GO:1904731","description":"\"Any process that activates or increases the frequency, rate or extent of intestinal lipid absorption.\" [GO_REF:0000058, GOC:TermGenie, PMID:18768481]","metadata":null},{"id":"44e0eb5226664ce2b0b38024b18fb6d3","type":"GO_TERM","name":"positive regulation of intracellular cholesterol transport","canonical_id":"go:GO:0032385","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of cholesterol within cells.\" [GOC:mah]","metadata":null},{"id":"00150e81a5314005b771564b6e5bfb29","type":"GO_TERM","name":"positive regulation of intracellular estrogen receptor signaling pathway","canonical_id":"go:GO:0033148","description":"\"Any process that activates or increases the frequency, rate or extent of the activity of an intracellular estrogen receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"a4ff93ef2d8b4e4ba77c0f3022e5e793","type":"GO_TERM","name":"positive regulation of intracellular lipid transport","canonical_id":"go:GO:0032379","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of lipids within cells.\" [GOC:mah]","metadata":null},{"id":"028d675f29d942a1a97e2942d1e3dec0","type":"GO_TERM","name":"positive regulation of intracellular mRNA localization","canonical_id":"go:GO:1904582","description":"\"Any process that activates or increases the frequency, rate or extent of intracellular mRNA localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:21471000]","metadata":null},{"id":"038c04583614419a8166e4aeba52f814","type":"GO_TERM","name":"positive regulation of intracellular protein transport","canonical_id":"go:GO:0090316","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of proteins within cells.\" [GOC:tb]","metadata":null},{"id":"b18ad6aea8824650ac5007a15f9ac265","type":"GO_TERM","name":"positive regulation of intracellular signal transduction","canonical_id":"go:GO:1902533","description":"\"Any process that activates or increases the frequency, rate or extent of intracellular signal transduction.\" [GOC:BHF, GOC:dph, GOC:signaling, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"12024a8a4a3f4241924feb9b2154c77c","type":"GO_TERM","name":"positive regulation of intracellular steroid hormone receptor signaling pathway","canonical_id":"go:GO:0033145","description":"\"Any process that activates or increases the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"7f7ae071e0e4431095d10cd401147a6d","type":"GO_TERM","name":"positive regulation of intracellular sterol transport","canonical_id":"go:GO:0032382","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of sterols within cells.\" [GOC:mah]","metadata":null},{"id":"3469560dd7974b89bea4961a1fd3cb7b","type":"GO_TERM","name":"positive regulation of intracellular transport","canonical_id":"go:GO:0032388","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of substances within cells.\" [GOC:mah]","metadata":null},{"id":"cc14b674a51d4a23a65945022416cd30","type":"GO_TERM","name":"positive regulation of intracellular transport of viral material","canonical_id":"go:GO:1901254","description":"\"Any process that activates or increases the frequency, rate or extent of intracellular transport of viral material.\" [GOC:bf, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"55617f66bb824376a2dfc85d03f24e73","type":"GO_TERM","name":"positive regulation of intraciliary anterograde transport","canonical_id":"go:GO:1905798","description":"\"Any process that activates or increases the frequency, rate or extent of intraciliary anterograde transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:27930654]","metadata":null},{"id":"aef7a69cf0094bce801baccba8e2d424","type":"GO_TERM","name":"positive regulation of intraciliary retrograde transport","canonical_id":"go:GO:1905801","description":"\"Any process that activates or increases the frequency, rate or extent of intraciliary retrograde transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:27930654]","metadata":null},{"id":"1c68fd01fab3401184b43eae1b21bd05","type":"GO_TERM","name":"positive regulation of intralumenal vesicle formation","canonical_id":"go:GO:1905367","description":"\"Any process that activates or increases the frequency, rate or extent of intralumenal vesicle formation.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"efc2c915d83741e7a2a6f245b50ff17c","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway","canonical_id":"go:GO:2001244","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"9f8744023a4640c0a187e2ac8b0b4d09","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator","canonical_id":"go:GO:1902255","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway by p53 class mediator.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15705871]","metadata":null},{"id":"2d16c53715414e71931df68d9d35bfbe","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage","canonical_id":"go:GO:1902231","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15314165]","metadata":null},{"id":"725779601cb34e06a173cd7b0d149a22","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator","canonical_id":"go:GO:1902167","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator.\" [GOC:TermGenie, PMID:17719541]","metadata":null},{"id":"92f17e202c394eb0bf46aa77ee1da8a9","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide","canonical_id":"go:GO:1903752","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to hydrogen peroxide.\" [GO_REF:0000058, GOC:TermGenie, PMID:18681888]","metadata":null},{"id":"9f12f1dd57ea4983b91bffeaccf098a3","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway in response to osmotic stress","canonical_id":"go:GO:1902220","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to osmotic stress.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"8cf30ffa35bf41d294add1b2c6311096","type":"GO_TERM","name":"positive regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator","canonical_id":"go:GO:1902240","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator.\" [GOC:krc, GOC:mtg_apoptosis, GOC:TermGenie, PMID:16571598]","metadata":null},{"id":"aa21ca7e35734893b8d05fda695639a3","type":"GO_TERM","name":"positive regulation of invasive growth in response to glucose limitation","canonical_id":"go:GO:2000219","description":"\"Any process that activates or increases the frequency, rate or extent of invasive growth in response to glucose limitation.\" [GOC:mah]","metadata":null},{"id":"5f7c90dd11c344fe9d0fc64b8e3dca0c","type":"GO_TERM","name":"positive regulation of iodide transmembrane transport","canonical_id":"go:GO:1904214","description":"\"Any process that activates or increases the frequency, rate or extent of iodide transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"66b081bf29ab44ae99294a300e35fd3e","type":"GO_TERM","name":"positive regulation of iodide transport","canonical_id":"go:GO:1904203","description":"\"Any process that activates or increases the frequency, rate or extent of iodide transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"f1a5f9650d0d4b19b2e7a199ee49f953","type":"GO_TERM","name":"positive regulation of ion transmembrane transporter activity","canonical_id":"go:GO:0032414","description":"\"Any process that activates or increases the activity of an ion transporter.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"e97e7537939a4d3ebac81ed97ec9ef01","type":"GO_TERM","name":"positive regulation of iridophore differentiation","canonical_id":"go:GO:0050945","description":"\"Any process that activates or increases the frequency, rate or extent of iridophore differentiation.\" [GOC:ai]","metadata":null},{"id":"c7f45d2dd8204cfe982f0a56e2b9ffdb","type":"GO_TERM","name":"positive regulation of iron export across plasma membrane","canonical_id":"go:GO:1904040","description":"\"Any process that activates or increases the frequency, rate or extent of export of iron ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GO_REF:0000058, GOC:BHF, GOC:kom, GOC:TermGenie, PMID:15514116]","metadata":null},{"id":"f50ed47ded614fa7a40259be8b93ceb1","type":"GO_TERM","name":"positive regulation of iron ion import across plasma membrane","canonical_id":"go:GO:1904440","description":"\"Any process that activates or increases the frequency, rate or extent of iron ions import across plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:kom, GOC:TermGenie, PMID:18353247]","metadata":null},{"id":"6fea56abee764be89d896231ce597f18","type":"GO_TERM","name":"positive regulation of iron ion transmembrane transport","canonical_id":"go:GO:0034761","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of iron ions from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"cd1727338db946b3a7b92ea68acfdf11","type":"GO_TERM","name":"positive regulation of iron ion transport","canonical_id":"go:GO:0034758","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of iron ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"1c12942b6bce44fb85b01666abef0ea0","type":"GO_TERM","name":"positive regulation of iron-sulfur cluster assembly","canonical_id":"go:GO:1903331","description":"\"Any process that activates or increases the frequency, rate or extent of iron-sulfur cluster assembly.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"a2b6ce17bc62418a8451191fe8b0d024","type":"GO_TERM","name":"positive regulation of iron-sulfur-molybdenum cofactor assembly","canonical_id":"go:GO:1900508","description":"\"Any process that activates or increases the frequency, rate or extent of iron-sulfur-molybdenum cofactor assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"420a412a0bbc419bbbd341f8315a45cd","type":"GO_TERM","name":"positive regulation of isopentenyl diphosphate biosynthetic process, methylerythritol phosphate pathway","canonical_id":"go:GO:1900949","description":"\"Any process that activates or increases the frequency, rate or extent of isoprene biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"3cc2600e028d4cb090790c9a040f26a7","type":"GO_TERM","name":"positive regulation of isopentenyl diphosphate biosynthetic process, mevalonate pathway","canonical_id":"go:GO:1900486","description":"\"Any process that activates or increases the frequency, rate or extent of isopentenyl diphosphate biosynthetic process, mevalonate pathway.\" [GOC:TermGenie]","metadata":null},{"id":"1f92acb2549c40c0a2839fb9b8dc1273","type":"GO_TERM","name":"positive regulation of isotype switching","canonical_id":"go:GO:0045830","description":"\"Any process that activates or increases the frequency, rate or extent of isotype switching.\" [GOC:curators]","metadata":null},{"id":"76a44e8bbd4249189da77b37e6248643","type":"GO_TERM","name":"positive regulation of isotype switching to IgA isotypes","canonical_id":"go:GO:0048298","description":"\"Any process that activates or increases the frequency, rate or extent of isotype switching to IgA isotypes.\" [GOC:jid]","metadata":null},{"id":"6e62d935dbca40a2a7f1d2f5966e1a01","type":"GO_TERM","name":"positive regulation of isotype switching to IgD isotypes","canonical_id":"go:GO:0048301","description":"\"Any process that activates or increases the frequency, rate or extent of isotype switching to IgD isotypes.\" [GOC:jid]","metadata":null},{"id":"6ea3c7f590d846628f28a06442502310","type":"GO_TERM","name":"positive regulation of isotype switching to IgE isotypes","canonical_id":"go:GO:0048295","description":"\"Any process that activates or increases the frequency, rate or extent of isotype switching to IgE isotypes.\" [GOC:jid]","metadata":null},{"id":"1c1c7af5146445c580e1b7905e14a43a","type":"GO_TERM","name":"positive regulation of isotype switching to IgG isotypes","canonical_id":"go:GO:0048304","description":"\"Any process that activates or increases the frequency, rate or extent of isotype switching to IgG isotypes.\" [GOC:jid]","metadata":null},{"id":"93f3b73511c14026b5992a61f65b3e66","type":"GO_TERM","name":"positive regulation of juvenile hormone biosynthetic process","canonical_id":"go:GO:0045969","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"cf27a7d516ca4c30a5a6416329f26b0a","type":"GO_TERM","name":"positive regulation of juvenile hormone catabolic process","canonical_id":"go:GO:0045971","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"ed9fa639162e49afafaa329a7df4460e","type":"GO_TERM","name":"positive regulation of juvenile hormone secretion","canonical_id":"go:GO:0045973","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"b80f94f541724c91a2d9cb8132a63923","type":"GO_TERM","name":"positive regulation of kainate selective glutamate receptor signaling pathway","canonical_id":"go:GO:0106428","description":"\"Any process that activates or increases the frequency, rate or extent of the kainate selective glutamate receptor signaling pathway.\" [PMID:12597860]","metadata":null},{"id":"4c356766479f4fdcb71537e99b5b239f","type":"GO_TERM","name":"positive regulation of keratinocyte apoptotic process","canonical_id":"go:GO:1902174","description":"\"Any process that activates or increases the frequency, rate or extent of keratinocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:18938133]","metadata":null},{"id":"c749b8e5cea64c688127343cf06148b7","type":"GO_TERM","name":"positive regulation of keratinocyte differentiation","canonical_id":"go:GO:0045618","description":"\"Any process that activates or increases the frequency, rate or extent of keratinocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"c752d627440c4121bc3656db2bd05fc2","type":"GO_TERM","name":"positive regulation of keratinocyte migration","canonical_id":"go:GO:0051549","description":"\"Any process that activates or increases the frequency, rate or extent of keratinocyte migration.\" [GOC:ai]","metadata":null},{"id":"66650c97320b4fd8907238305afd7ca9","type":"GO_TERM","name":"positive regulation of keratinocyte proliferation","canonical_id":"go:GO:0010838","description":"\"Any process that increases the rate, frequency or extent of keratinocyte proliferation. Keratinocyte proliferation is the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1e3cddf55b994b87a92927682209f647","type":"GO_TERM","name":"positive regulation of kidney development","canonical_id":"go:GO:0090184","description":"\"Any process that increases the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"245f9df617044689ad7dc315b514df48","type":"GO_TERM","name":"positive regulation of kidney smooth muscle cell differentiation","canonical_id":"go:GO:2000358","description":"\"Any process that activates or increases the frequency, rate or extent of kidney smooth muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"5990cfc4169241e6b81d1c1662fa048f","type":"GO_TERM","name":"positive regulation of killing of cells of another organism","canonical_id":"go:GO:0051712","description":"\"Any process that activates or increases the frequency, rate or extent of the killing by an organism of cells in another organism.\" [GOC:ai]","metadata":null},{"id":"12f09ce4e1c948fea84f386b0e898ff4","type":"GO_TERM","name":"positive regulation of kinase activity","canonical_id":"go:GO:0033674","description":"\"Any process that activates or increases the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.\" [GOC:mah]","metadata":null},{"id":"22a1ea2502f14edcb6e2a6f54d05cd37","type":"GO_TERM","name":"positive regulation of kinetochore assembly","canonical_id":"go:GO:1905561","description":"\"Any process that activates or increases the frequency, rate or extent of kinetochore assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"1a7f227fb3a34d49a2176e0dc0156b73","type":"GO_TERM","name":"positive regulation of kinin cascade","canonical_id":"go:GO:0002258","description":"\"Any process that activates or increases the frequency, rate, or extent of the kinin cascade.\" [GOC:jal]","metadata":null},{"id":"4e82a2575f4c47c1929ee76841829bcf","type":"GO_TERM","name":"positive regulation of kojic acid biosynthetic process","canonical_id":"go:GO:1900396","description":"\"Any process that activates or increases the frequency, rate or extent of kojic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a32c40fc6f954faaa9a927e8ba3764b5","type":"GO_TERM","name":"positive regulation of lactation","canonical_id":"go:GO:1903489","description":"\"Any process that activates or increases the frequency, rate or extent of lactation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19563620]","metadata":null},{"id":"016ba903b60d4c4392a5a14d644ad8ab","type":"GO_TERM","name":"positive regulation of lactation by mesenchymal-epithelial cell signaling","canonical_id":"go:GO:0060637","description":"\"The process that increases the rate, frequency, or extent of lactation as a result of the secretion of a signal from the mammary fat and its reception by a mammary epithelial cell.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"ab643dded15e45bbbe3af47f8d67efdc","type":"GO_TERM","name":"positive regulation of lactose biosynthetic process","canonical_id":"go:GO:1903536","description":"\"Any process that activates or increases the frequency, rate or extent of lactose biosynthetic process.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:12018418]","metadata":null},{"id":"892d83c8ce2f4791a37dc98d71967350","type":"GO_TERM","name":"positive regulation of lamellipodium assembly","canonical_id":"go:GO:0010592","description":"\"Any process that increases the rate, frequency or extent of the formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e1d0a415cce64c39a39f978acb69d084","type":"GO_TERM","name":"positive regulation of lamellipodium morphogenesis","canonical_id":"go:GO:2000394","description":"\"Any process that activates or increases the frequency, rate or extent of lamellipodium morphogenesis.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"75695e7fa49e4730b6f30136a03ca39c","type":"GO_TERM","name":"positive regulation of lamellipodium organization","canonical_id":"go:GO:1902745","description":"\"Any process that activates or increases the frequency, rate or extent of lamellipodium organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:16054028]","metadata":null},{"id":"243047b3cb9a4f6f9b871329138e5268","type":"GO_TERM","name":"positive regulation of lamellocyte differentiation","canonical_id":"go:GO:0035205","description":"\"Any process that activates or increases the frequency, rate or extent of lamellocyte differentiation. Lamellocytes differentiate massively in the lymph glands after parasitization and are large flat cells devoted to encapsulation of invaders too large to be phagocytosed by plasmatocytes.\" [PMID:14734104]","metadata":null},{"id":"9f05b70f430d40da9b3635fc1560d654","type":"GO_TERM","name":"positive regulation of laminaritriose transport","canonical_id":"go:GO:1900305","description":"\"Any process that activates or increases the frequency, rate or extent of laminaritriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"44e118ef85224a55add7ce0b6125e839","type":"GO_TERM","name":"positive regulation of large conductance calcium-activated potassium channel activity","canonical_id":"go:GO:1902608","description":"\"Any process that activates or increases the frequency, rate or extent of large conductance calcium-activated potassium channel activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:23407708]","metadata":null},{"id":"340ae632646c46018a571ba83dd5669e","type":"GO_TERM","name":"positive regulation of larval salivary gland boundary specification","canonical_id":"go:GO:0045712","description":"\"Any process that activates or increases the frequency, rate or extent of salivary gland determination in a larval organism.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"b99e5be0984b42f294d36bcff074e058","type":"GO_TERM","name":"positive regulation of larval somatic muscle development","canonical_id":"go:GO:0062231","description":"\"Any process that increases the rate, frequency or extent of larval somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"d1bd38ca87e346448ef9a72cac4fb626","type":"GO_TERM","name":"positive regulation of late endosome to lysosome transport","canonical_id":"go:GO:1902824","description":"\"Any process that activates or increases the frequency, rate or extent of late endosome to lysosome transport.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:23949442]","metadata":null},{"id":"702c4794ea11437499fd5c0ae3fa78a8","type":"GO_TERM","name":"positive regulation of late stripe melanocyte differentiation","canonical_id":"go:GO:0050950","description":"\"Any process that activates or increases the frequency, rate or extent of late stripe melanocyte differentiation.\" [GOC:ai]","metadata":null},{"id":"96e873a3f03541d682c86bed641ae8e5","type":"GO_TERM","name":"positive regulation of lateral attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:1905116","description":"\"Any process that activates or increases the frequency, rate or extent of lateral attachment of mitotic spindle microtubules to kinetochore.\" [GO_REF:0000058, GOC:TermGenie, PMID:22375062]","metadata":null},{"id":"77203933884443b9ae468e07c1efda67","type":"GO_TERM","name":"positive regulation of lateral mesodermal cell fate determination","canonical_id":"go:GO:0048376","description":"\"Any process that activates or increases the frequency, rate or extent of lateral mesoderm cell fate determination.\" [GOC:jid]","metadata":null},{"id":"6940960e94e74909b1b7cd16e9d687f7","type":"GO_TERM","name":"positive regulation of lateral mesodermal cell fate specification","canonical_id":"go:GO:0048379","description":"\"Any process that activates or increases the frequency, rate or extent of lateral mesoderm cell fate specification.\" [GOC:jid]","metadata":null},{"id":"155bd474a56f477abd5b79e16d7bacad","type":"GO_TERM","name":"positive regulation of lateral motor column neuron migration","canonical_id":"go:GO:1902078","description":"\"Any process that activates or increases the frequency, rate or extent of lateral motor column neuron migration.\" [GOC:TermGenie, GOC:yaf, PMID:20711475]","metadata":null},{"id":"27eb269c2bde42c3a70843fce093adc4","type":"GO_TERM","name":"positive regulation of lateral root development","canonical_id":"go:GO:1901333","description":"\"Any process that activates or increases the frequency, rate or extent of lateral root development.\" [GOC:TermGenie]","metadata":null},{"id":"0254f7e5585543febd43fe7ad6a6d786","type":"GO_TERM","name":"positive regulation of leaf development","canonical_id":"go:GO:1905623","description":"\"Any process that activates or increases the frequency, rate or extent of leaf development.\" [GO_REF:0000058, GOC:TermGenie, PMID:11606552]","metadata":null},{"id":"5f0367c0e71f4d79974f70148130d553","type":"GO_TERM","name":"positive regulation of leaf senescence","canonical_id":"go:GO:1900057","description":"\"Any process that activates or increases the frequency, rate or extent of leaf senescence.\" [GOC:TermGenie]","metadata":null},{"id":"bc49d91fdf3e41ba82749604b1d14477","type":"GO_TERM","name":"positive regulation of leaflet formation by auxin mediated signaling pathway","canonical_id":"go:GO:0090015","description":"\"Any process that increases the frequency, rate or extent of leaflet formation as a result of the series of molecular signals generated in response to detection of auxin.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"d6b8d0aacee54f64a8ecb053ca78f708","type":"GO_TERM","name":"positive regulation of lens epithelial cell proliferation","canonical_id":"go:GO:2001111","description":"\"Any process that activates or increases the frequency, rate or extent of lens epithelial cell proliferation.\" [GOC:obol]","metadata":null},{"id":"2747a8134f6a487680c829a1a29d3dc4","type":"GO_TERM","name":"positive regulation of lens fiber cell differentiation","canonical_id":"go:GO:1902748","description":"\"Any process that activates or increases the frequency, rate or extent of lens fiber cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17592637]","metadata":null},{"id":"446fc1a15e284ee996a330e04b13d1e8","type":"GO_TERM","name":"positive regulation of leucophore differentiation","canonical_id":"go:GO:0048777","description":"\"Any process that activates or increases the frequency, rate or extent of leucophore differentiation.\" [GOC:mh]","metadata":null},{"id":"db11ddfb479b41f989f2e783384836be","type":"GO_TERM","name":"positive regulation of leukocyte activation","canonical_id":"go:GO:0002696","description":"\"Any process that activates or increases the frequency, rate, or extent of leukocyte activation.\" [GOC:add]","metadata":null},{"id":"ad0c0679bc77462b99b15e5807994047","type":"GO_TERM","name":"positive regulation of leukocyte adhesion to arterial endothelial cell","canonical_id":"go:GO:1904999","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte adhesion to arterial endothelial cell.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22267480]","metadata":null},{"id":"ba88c8fcc90a4c21b2be34e580177420","type":"GO_TERM","name":"positive regulation of leukocyte adhesion to vascular endothelial cell","canonical_id":"go:GO:1904996","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte adhesion to vascular endothelial cell.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23897866]","metadata":null},{"id":"f94fd40fd7e14777ad85c3120aafc09f","type":"GO_TERM","name":"positive regulation of leukocyte apoptotic process","canonical_id":"go:GO:2000108","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis]","metadata":null},{"id":"04f31beefffc4474b4a4186f7a38e9ad","type":"GO_TERM","name":"positive regulation of leukocyte cell-cell adhesion","canonical_id":"go:GO:1903039","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte cell-cell adhesion.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21106532]","metadata":null},{"id":"adaba1a427004bffb831d1a35b2a08d7","type":"GO_TERM","name":"positive regulation of leukocyte chemotaxis","canonical_id":"go:GO:0002690","description":"\"Any process that activates or increases the frequency, rate, or extent of leukocyte chemotaxis.\" [GOC:add]","metadata":null},{"id":"b9a7dfd395ac488c9acff2b0b9840d42","type":"GO_TERM","name":"positive regulation of leukocyte degranulation","canonical_id":"go:GO:0043302","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte degranulation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"cae2a2a272954698a39ab67cb9b8b689","type":"GO_TERM","name":"positive regulation of leukocyte differentiation","canonical_id":"go:GO:1902107","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte differentiation.\" [GOC:add, GOC:TermGenie]","metadata":null},{"id":"00bbe5019fd34e66b5c020d9161c8cd5","type":"GO_TERM","name":"positive regulation of leukocyte mediated cytotoxicity","canonical_id":"go:GO:0001912","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte mediated cytotoxicity.\" [GOC:add, ISBN:0781735149, PMID:11911826]","metadata":null},{"id":"e078208b15c646539334bb77b89a2512","type":"GO_TERM","name":"positive regulation of leukocyte mediated immunity","canonical_id":"go:GO:0002705","description":"\"Any process that activates or increases the frequency, rate, or extent of leukocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"4b3b9a2d460c4be4bbdb66a2adaba9e9","type":"GO_TERM","name":"positive regulation of leukocyte migration","canonical_id":"go:GO:0002687","description":"\"Any process that activates or increases the frequency, rate, or extent of leukocyte migration.\" [GOC:add]","metadata":null},{"id":"7071d7c338bf4a7aa47ad29c93eb3bb6","type":"GO_TERM","name":"positive regulation of leukocyte proliferation","canonical_id":"go:GO:0070665","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"d4d37b57de5e41ce8277e04ac039f73d","type":"GO_TERM","name":"positive regulation of leukocyte tethering or rolling","canonical_id":"go:GO:1903238","description":"\"Any process that activates or increases the frequency, rate or extent of leukocyte tethering or rolling.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18308860]","metadata":null},{"id":"f23799d257bc44a4978081aceeb9a37c","type":"GO_TERM","name":"positive regulation of leukotriene production involved in inflammatory response","canonical_id":"go:GO:0035491","description":"\"Any process that increases the rate, frequency or extent of the synthesis or release of any leukotriene following a stimulus as part of an inflammatory response.\" [GOC:bf]","metadata":null},{"id":"d719b9702c99453aa278c9b8cc2504b9","type":"GO_TERM","name":"positive regulation of ligase activity","canonical_id":"go:GO:0051351","description":"\"Any process that activates or increases the frequency, rate or extent of ligase activity, the catalysis of the ligation of two substances with concomitant breaking of a diphosphate linkage, usually in a nucleoside triphosphate.\" [GOC:ai]","metadata":null},{"id":"47718d79bf174943bfdc213eae5c1435","type":"GO_TERM","name":"positive regulation of lipase activity","canonical_id":"go:GO:0060193","description":"\"Any process that increases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"533fe8e5cfb545e8932a3a4feff7778b","type":"GO_TERM","name":"positive regulation of lipid biosynthetic process","canonical_id":"go:GO:0046889","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.\" [GOC:ai]","metadata":null},{"id":"f9e07f66cb7c484489708ce8b3b9339e","type":"GO_TERM","name":"positive regulation of lipid catabolic process","canonical_id":"go:GO:0050996","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.\" [GOC:ai]","metadata":null},{"id":"0aa36096f2d745658573262ba381297c","type":"GO_TERM","name":"positive regulation of lipid kinase activity","canonical_id":"go:GO:0090218","description":"\"Any process that increases the frequency, rate or extent of lipid kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a simple or complex lipid.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2213e765c1824691a9f6176c7ee5ec9d","type":"GO_TERM","name":"positive regulation of lipid localization","canonical_id":"go:GO:1905954","description":"\"Any process that activates or increases the frequency, rate or extent of lipid localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:17564681]","metadata":null},{"id":"84d7c21a7bb749ca80e44f512554b743","type":"GO_TERM","name":"positive regulation of lipid metabolic process","canonical_id":"go:GO:0045834","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving lipids.\" [GOC:curators]","metadata":null},{"id":"8c94dce2da1d4a6ca857ec75e4749f43","type":"GO_TERM","name":"positive regulation of lipid storage","canonical_id":"go:GO:0010884","description":"\"Any process that increases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"87d4672f4dd1485989723d76f45365a1","type":"GO_TERM","name":"positive regulation of lipid transport","canonical_id":"go:GO:0032370","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"824af6a7a57146a9938a73280d0bbd41","type":"GO_TERM","name":"positive regulation of lipid transport across blood-brain barrier","canonical_id":"go:GO:1903002","description":"\"Any process that activates or increases the frequency, rate or extent of lipid transport across blood-brain barrier.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24345162]","metadata":null},{"id":"32a926d4f93f4ca7aef4dfada91231c7","type":"GO_TERM","name":"positive regulation of lipophagy","canonical_id":"go:GO:1904504","description":"\"Any process that activates or increases the frequency, rate or extent of lipophagy.\" [GO_REF:0000058, GOC:autophagy, GOC:dph, GOC:TermGenie, PMID:25383539]","metadata":null},{"id":"409a16dacbd04443a0839d1438d6527a","type":"GO_TERM","name":"positive regulation of lipopolysaccharide-mediated signaling pathway","canonical_id":"go:GO:0031666","description":"\"Any process that activates or increases the frequency, rate or extent of signaling in response to detection of lipopolysaccharide.\" [GOC:mah]","metadata":null},{"id":"93cc5c785265423ba9e8b8dc333b081d","type":"GO_TERM","name":"positive regulation of lipoprotein lipase activity","canonical_id":"go:GO:0051006","description":"\"Any process that activates or increases the activity of the enzyme lipoprotein lipase.\" [GOC:ai]","metadata":null},{"id":"7501cb9a7af04c4587778180ac7ee92e","type":"GO_TERM","name":"positive regulation of lipoprotein metabolic process","canonical_id":"go:GO:0050747","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving lipoproteins, any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.\" [GOC:ai]","metadata":null},{"id":"24dfca243d7e4ca2a82f701bcd427cf9","type":"GO_TERM","name":"positive regulation of lipoprotein particle clearance","canonical_id":"go:GO:0010986","description":"\"Any process that increases the rate, frequency, or extent of lipoprotein particle clearance. Lipoprotein particle clearance is the process in which a lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"ccb6abefe2e147fbbb394c8ca5e50da3","type":"GO_TERM","name":"positive regulation of lipoprotein transport","canonical_id":"go:GO:0140077","description":"\"Any process that activates or increases the rate or extent of lipoprotein transport.\" [GOC:BHF, GOC:BHF_miRNA, GOC:RPH, PMID:26501192]","metadata":null},{"id":"e26297d7c55d4d85a91a7635bce25a0f","type":"GO_TERM","name":"positive regulation of locomotion","canonical_id":"go:GO:0040017","description":"\"Any process that activates or increases the frequency, rate or extent of locomotion of a cell or organism.\" [GOC:curators]","metadata":null},{"id":"356880cc913847eb8db3ba113a5cb162","type":"GO_TERM","name":"positive regulation of locomotion involved in locomotory behavior","canonical_id":"go:GO:0090326","description":"\"Any process that increases the frequency, rate, or extent of the self-propelled movement of a cell or organism from one location to another in a behavioral context; the aspect of locomotory behavior having to do with movement.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"4ae91b6a08d54564a0e01389c3e66bf7","type":"GO_TERM","name":"positive regulation of locomotor rhythm","canonical_id":"go:GO:1904061","description":"\"Any process that activates or increases the frequency, rate or extent of locomotor rhythm.\" [GO_REF:0000058, GOC:TermGenie, PMID:16310969]","metadata":null},{"id":"857d256a6f3c4a90ae49606201cbd799","type":"GO_TERM","name":"positive regulation of long-chain fatty acid import across plasma membrane","canonical_id":"go:GO:0010747","description":"\"Any process that increases the rate, frequency or extent of plasma membrane long-chain fatty acid transport. Plasma membrane long-chain fatty acid transport is the directed movement of long-chain fatty acids across the plasma membrane. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"eff24f38478b4a93aaf84ea141cd36c9","type":"GO_TERM","name":"positive regulation of long-chain fatty acid import into cell","canonical_id":"go:GO:0140214","description":"\"Any process that activates or increases the frequency, rate or extent of long-chain fatty acid import into a cell.\" [PMID:28178239]","metadata":null},{"id":"b9a900a605cd4130b3e41a4cfca7623d","type":"GO_TERM","name":"positive regulation of long-day photoperiodism, flowering","canonical_id":"go:GO:0048578","description":"\"Any process that activates, maintains or increases long-day photoperiodism, where the response associated with the photoperiodism is flowering. Flowering is defined by the switch from the vegetative to the reproductive phase.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"dffd7e3c8ffe48c89e05b74196e5d019","type":"GO_TERM","name":"positive regulation of long-term neuronal synaptic plasticity","canonical_id":"go:GO:0048170","description":"\"A process that increases long-term neuronal synaptic plasticity, the ability of neuronal synapses to change long-term as circumstances require. Long-term neuronal synaptic plasticity generally involves increase or decrease in actual synapse numbers.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"43bba27022fc44b385408fd71de73c03","type":"GO_TERM","name":"positive regulation of long-term synaptic depression","canonical_id":"go:GO:1900454","description":"\"Any process that activates or increases the frequency, rate or extent of long term synaptic depression.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"eeb651ea82ea42a4900cb95e7757d3e8","type":"GO_TERM","name":"positive regulation of long-term synaptic potentiation","canonical_id":"go:GO:1900273","description":"\"Any process that activates or increases the frequency, rate or extent of long-term synaptic potentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"19fccb9b67044043922e97e188c46508","type":"GO_TERM","name":"positive regulation of lovastatin biosynthetic process","canonical_id":"go:GO:0140736","description":"\"Any process that increases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of lovastin.\" [PMID:10334994, PMID:19781329]","metadata":null},{"id":"b0c047048ad1499e89cf5792b5cf4b58","type":"GO_TERM","name":"positive regulation of low-density lipoprotein particle clearance","canonical_id":"go:GO:1905581","description":"\"Any process that activates or increases the frequency, rate or extent of low-density lipoprotein particle clearance.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:22848640]","metadata":null},{"id":"71d3d6df69834b418465dd808e80eb11","type":"GO_TERM","name":"positive regulation of low-density lipoprotein particle receptor catabolic process","canonical_id":"go:GO:0032805","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of low-density lipoprotein particle receptors.\" [GOC:mah]","metadata":null},{"id":"13f5398f1fd54d808966effaafb8d2ae","type":"GO_TERM","name":"positive regulation of lung alveolus development","canonical_id":"go:GO:1904655","description":"\"Any process that activates or increases the frequency, rate or extent of lung alveolus development.\" [GO_REF:0000058, GOC:TermGenie, PMID:23962064]","metadata":null},{"id":"07a87138221347f1b57c0a042bab1807","type":"GO_TERM","name":"positive regulation of lung blood pressure","canonical_id":"go:GO:0061766","description":"\"The process that increases the force with which blood travels through the lungs.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:22161164]","metadata":null},{"id":"68b6fa73e08e4ed4b7a13bd44ad06ce4","type":"GO_TERM","name":"positive regulation of lung ciliated cell differentiation","canonical_id":"go:GO:1901248","description":"\"Any process that activates or increases the frequency, rate or extent of lung ciliated cell differentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"f04838dfe66b41a68d7603b06fc45920","type":"GO_TERM","name":"positive regulation of lung goblet cell differentiation","canonical_id":"go:GO:1901251","description":"\"Any process that activates or increases the frequency, rate or extent of lung goblet cell differentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"afb5bd7aaed947b181427262ed365710","type":"GO_TERM","name":"positive regulation of luteinizing hormone secretion","canonical_id":"go:GO:0033686","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of luteinizing hormone.\" [GOC:mah]","metadata":null},{"id":"c25ec0d1641a4cd4b03248d0c006fe18","type":"GO_TERM","name":"positive regulation of lyase activity","canonical_id":"go:GO:0051349","description":"\"Any process that activates or increases the frequency, rate or extent of lyase activity, the catalysis of the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond.\" [GOC:ai]","metadata":null},{"id":"dc6d7983104d4af98f7862bab37d0d42","type":"GO_TERM","name":"positive regulation of lymphangiogenesis","canonical_id":"go:GO:1901492","description":"\"Any process that activates or increases the frequency, rate or extent of lymphangiogenesis.\" [GOC:dph, GOC:TermGenie, PMID:20133819]","metadata":null},{"id":"4d0d8c4a27164b54a69dd10100f47fa1","type":"GO_TERM","name":"positive regulation of lymphocyte activation","canonical_id":"go:GO:0051251","description":"\"Any process that activates or increases the frequency, rate or extent of lymphocyte activation.\" [GOC:ai]","metadata":null},{"id":"789ab163c6fd43589b02e5b2c1e39287","type":"GO_TERM","name":"positive regulation of lymphocyte anergy","canonical_id":"go:GO:0002913","description":"\"Any process that activates or increases the frequency, rate, or extent of lymphocyte anergy.\" [GOC:add]","metadata":null},{"id":"e9cc490348b945d68a229c0796f2d29e","type":"GO_TERM","name":"positive regulation of lymphocyte apoptotic process","canonical_id":"go:GO:0070230","description":"\"Any process that activates or increases the frequency, rate or extent of lymphocyte death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"1257015e3c43411483492d18c9836bd3","type":"GO_TERM","name":"positive regulation of lymphocyte chemotaxis","canonical_id":"go:GO:0140131","description":"\"Any process that activates or increases the frequency, rate or extent of lymphocyte chemotaxis.\" [PMID:19255442]","metadata":null},{"id":"872ae0f847c145beb200cf2196162420","type":"GO_TERM","name":"positive regulation of lymphocyte differentiation","canonical_id":"go:GO:0045621","description":"\"Any process that activates or increases the frequency, rate or extent of lymphocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"01f7624cb794411f91b3d8758b71e73f","type":"GO_TERM","name":"positive regulation of lymphocyte mediated immunity","canonical_id":"go:GO:0002708","description":"\"Any process that activates or increases the frequency, rate, or extent of lymphocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"1c8cdccd8d7c4ae6b859a34db1b7178f","type":"GO_TERM","name":"positive regulation of lymphocyte migration","canonical_id":"go:GO:2000403","description":"\"Any process that activates or increases the frequency, rate or extent of lymphocyte migration.\" [GOC:mah]","metadata":null},{"id":"24c3666027634bb49615237a5c0db5c1","type":"GO_TERM","name":"positive regulation of lymphocyte proliferation","canonical_id":"go:GO:0050671","description":"\"Any process that activates or increases the rate or extent of lymphocyte proliferation.\" [GOC:ai]","metadata":null},{"id":"56fe90c8fbd74b97897e1db8dda4b4f5","type":"GO_TERM","name":"positive regulation of lymphoid progenitor cell differentiation","canonical_id":"go:GO:1905458","description":"\"Any process that activates or increases the frequency, rate or extent of lymphoid progenitor cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27010503]","metadata":null},{"id":"106b28eb24364797be496eaacfa012de","type":"GO_TERM","name":"positive regulation of lymphotoxin A production","canonical_id":"go:GO:0032761","description":"\"Any process that activates or increases the frequency, rate, or extent of lymphotoxin A production.\" [GOC:mah]","metadata":null},{"id":"e4e40df63c744ff29c423e56aca6069e","type":"GO_TERM","name":"positive regulation of lysine biosynthetic process via alpha-aminoadipate and saccharopine","canonical_id":"go:GO:2001196","description":"\"Any process that activates or increases the frequency, rate or extent of lysine biosynthetic process via alpha-aminoadipate and saccharopine.\" [GOC:obol]","metadata":null},{"id":"34cb43a3c49241aa87e424504d627f29","type":"GO_TERM","name":"positive regulation of lysosomal membrane permeability","canonical_id":"go:GO:0097214","description":"\"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane.\" [GOC:yaf, PMID:20544854]","metadata":null},{"id":"ae157b94138c415b8a2f7ccd9b92aa48","type":"GO_TERM","name":"positive regulation of lysosomal protein catabolic process","canonical_id":"go:GO:1905167","description":"\"Any process that activates or increases the frequency, rate or extent of lysosomal protein catabolic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"5f20f3e2f4964bbcb00296bab8143d49","type":"GO_TERM","name":"positive regulation of lysosome organization","canonical_id":"go:GO:1905673","description":"\"Any process that activates or increases the frequency, rate or extent of lysosome organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:25561470]","metadata":null},{"id":"d6da54cebcee48d397a33f921a6ced25","type":"GO_TERM","name":"positive regulation of lysozyme activity","canonical_id":"go:GO:1903592","description":"\"Any process that activates or increases the frequency, rate or extent of lysozyme activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:23954697]","metadata":null},{"id":"b7278806ea3a490b8e01aa7cb5619b6e","type":"GO_TERM","name":"positive regulation of mRNA 3'-end processing","canonical_id":"go:GO:0031442","description":"\"Any process that activates or increases the frequency, rate or extent of mRNA 3'-end processing.\" [GOC:mah]","metadata":null},{"id":"178eb3f88fd347649673a5c8f185882b","type":"GO_TERM","name":"positive regulation of mRNA alternative polyadenylation","canonical_id":"go:GO:0140409","description":"\"Any process that activates or increases the frequency, rate or extent of mRNA alternative polyadenylation.\" [PMID:29507755]","metadata":null},{"id":"c5f0e60516e54622b5f1ea4009e8fe62","type":"GO_TERM","name":"positive regulation of mRNA binding","canonical_id":"go:GO:1902416","description":"\"Any process that activates or increases the frequency, rate or extent of mRNA binding.\" [GOC:rb, GOC:TermGenie, PMID:22890846]","metadata":null},{"id":"97c8eafdd8694c698674a49fcc2300c8","type":"GO_TERM","name":"positive regulation of mRNA catabolic process","canonical_id":"go:GO:0061014","description":"\"Any process that increases the rate, frequency, or extent of a mRNA catabolic process, the chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"6e4f1b7e9ed54d11bc793ca3d20b2521","type":"GO_TERM","name":"positive regulation of mRNA cis splicing, via spliceosome","canonical_id":"go:GO:1905746","description":"\"Any process that activates or increases the frequency, rate or extent of mRNA cis splicing, via spliceosome.\" [GO_REF:0000058, GOC:TermGenie, PMID:2880558]","metadata":null},{"id":"d02f831c81d84c6da646df4fbe0ad446","type":"GO_TERM","name":"positive regulation of mRNA metabolic process","canonical_id":"go:GO:1903313","description":"\"Any process that activates or increases the frequency, rate or extent of mRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"a039700beeb948c58ad8cd9083ee14a2","type":"GO_TERM","name":"positive regulation of mRNA modification","canonical_id":"go:GO:0090366","description":"\"Any process that increases the rate, frequency, or extent of the covalent alteration of one or more nucleotides within an mRNA molecule to produce an mRNA molecule with a sequence that differs from that coded genetically.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"457b4cbc99104ff693509426d762e56d","type":"GO_TERM","name":"positive regulation of mRNA processing","canonical_id":"go:GO:0050685","description":"\"Any process that activates or increases the frequency, rate or extent of mRNA processing.\" [GOC:ai]","metadata":null},{"id":"9728d0593ac746918e5a050005011b9e","type":"GO_TERM","name":"positive regulation of mRNA splicing, via spliceosome","canonical_id":"go:GO:0048026","description":"\"Any process that activates or increases the rate or extent of mRNA splicing via a spliceosomal mechanism.\" [GOC:jid]","metadata":null},{"id":"b66473fa98ee4014baf9b9341b83301b","type":"GO_TERM","name":"positive regulation of macroautophagy","canonical_id":"go:GO:0016239","description":"\"Any process, such as recognition of nutrient depletion, that activates or increases the rate of macroautophagy to bring cytosolic macromolecules to the vacuole/lysosome for degradation.\" [GOC:curators, PMID:9412464]","metadata":null},{"id":"badf50cc10e24dd7845dde01a36d7e39","type":"GO_TERM","name":"positive regulation of macromolecule biosynthetic process","canonical_id":"go:GO:0010557","description":"\"Any process that increases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"611d1b09c7a0430f96f2365f266f740c","type":"GO_TERM","name":"positive regulation of macromolecule metabolic process","canonical_id":"go:GO:0010604","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"06c1b8ac5f0a4f58be75b40ed521f46c","type":"GO_TERM","name":"positive regulation of macrophage activation","canonical_id":"go:GO:0043032","description":"\"Any process that stimulates, induces or increases the rate of macrophage activation.\" [GOC:jl]","metadata":null},{"id":"c1a7189a865540a8800494a1fe264c5f","type":"GO_TERM","name":"positive regulation of macrophage antigen processing and presentation","canonical_id":"go:GO:0002618","description":"\"Any process that activates or increases the frequency, rate, or extent of macrophage antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"100b33749fdd47729877e50509745ab5","type":"GO_TERM","name":"positive regulation of macrophage apoptotic process","canonical_id":"go:GO:2000111","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis]","metadata":null},{"id":"0605d2b2a43e4ff79549fd6fc8cb7125","type":"GO_TERM","name":"positive regulation of macrophage chemotaxis","canonical_id":"go:GO:0010759","description":"\"Any process that increases the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d8e9310c32b645d282e07cc3d072575d","type":"GO_TERM","name":"positive regulation of macrophage colony-stimulating factor production","canonical_id":"go:GO:1901258","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage colony-stimulating factor production.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"e186599e6cdf4745b8c376b6799e9357","type":"GO_TERM","name":"positive regulation of macrophage colony-stimulating factor signaling pathway","canonical_id":"go:GO:1902228","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage colony-stimulating factor signaling pathway.\" [GOC:TermGenie, PMID:16705167]","metadata":null},{"id":"60e008a577e74a99a86bb2dcb8b9ff82","type":"GO_TERM","name":"positive regulation of macrophage cytokine production","canonical_id":"go:GO:0060907","description":"\"Any process that increases the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"443b9ac840f84bd3bfc7d0cd890ac83f","type":"GO_TERM","name":"positive regulation of macrophage derived foam cell differentiation","canonical_id":"go:GO:0010744","description":"\"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"e03e498dad5c4764a2291f7dc50ec640","type":"GO_TERM","name":"positive regulation of macrophage differentiation","canonical_id":"go:GO:0045651","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage differentiation.\" [GOC:curators]","metadata":null},{"id":"c1eb38c227294329a0da02c22c1f12ee","type":"GO_TERM","name":"positive regulation of macrophage fusion","canonical_id":"go:GO:0034241","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage fusion.\" [GOC:mah]","metadata":null},{"id":"40918c8b6a14461f8870b54e9d8c3ba5","type":"GO_TERM","name":"positive regulation of macrophage inflammatory protein 1 alpha production","canonical_id":"go:GO:0071642","description":"\"Any process that activates or increases the frequency, rate, or extent of production of macrophage inflammatory protein 1 alpha.\" [GOC:mah]","metadata":null},{"id":"41f2977b73f8404fbbd0af7c11733c1f","type":"GO_TERM","name":"positive regulation of macrophage inflammatory protein-1 gamma production","canonical_id":"go:GO:0071648","description":"\"Any process that activates or increases the frequency, rate, or extent of production of macrophage inflammatory protein-1 gamma.\" [GOC:mah]","metadata":null},{"id":"2e889c082c9e43929c84cdf362444ce2","type":"GO_TERM","name":"positive regulation of macrophage migration","canonical_id":"go:GO:1905523","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:25749876]","metadata":null},{"id":"4396f6e78de64ec283a929df7ddfd3cb","type":"GO_TERM","name":"positive regulation of macrophage migration inhibitory factor signaling pathway","canonical_id":"go:GO:2000448","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage migration inhibitory factor signaling pathway.\" [GOC:obol]","metadata":null},{"id":"613443debf5a45519e516227e5fc9e56","type":"GO_TERM","name":"positive regulation of macrophage proliferation","canonical_id":"go:GO:0120041","description":"\"Any process that activates or increases the frequency, rate or extent of macrophage proliferation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"c7bf0f321195405d81cfd1516b468b63","type":"GO_TERM","name":"positive regulation of macrophage tolerance induction","canonical_id":"go:GO:0010933","description":"\"Any process that increases the frequency, rate, or extent of B cell tolerance induction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1085e7c9c3a349fa8fd26598c3090a0f","type":"GO_TERM","name":"positive regulation of macropinocytosis","canonical_id":"go:GO:1905303","description":"\"Any process that activates or increases the frequency, rate or extent of macropinocytosis.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:18691641]","metadata":null},{"id":"5f0df04c33534b08b5ccbf49104161de","type":"GO_TERM","name":"positive regulation of maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:0061361","description":"\"Any process that increases the frequency, rate or extent of maintenance of bipolar cell polarity regulating cell shape.\" [GOC:dph]","metadata":null},{"id":"bb41b0ef7a48422991be296c96ce6d6d","type":"GO_TERM","name":"positive regulation of maintenance of meiotic sister chromatid cohesion","canonical_id":"go:GO:0034096","description":"\"Any process that increases the extent to which the association between sister chromatids of a replicated chromosome is maintained during a meiotic cell cycle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"93701532848e4b8990c15108d82a88a1","type":"GO_TERM","name":"positive regulation of maintenance of meiotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:2000711","description":"\"Any process that activates or increases the frequency, rate or extent of maintenance of meiotic sister chromatid cohesion in the centromeric region.\" [GOC:mah]","metadata":null},{"id":"a8bf08dda0b0484783cac3e62088e4d8","type":"GO_TERM","name":"positive regulation of maintenance of mitotic sister chromatid cohesion","canonical_id":"go:GO:0034184","description":"\"Any process that increases the extent to which the association between sister chromatids of a replicated chromosome is maintained during a mitotic cell cycle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"20cffaa9cd884d6e941dac971231a202","type":"GO_TERM","name":"positive regulation of maintenance of mitotic sister chromatid cohesion, arms","canonical_id":"go:GO:2000717","description":"\"Any process that activates or increases the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion along the chromosome arms.\" [GOC:mah]","metadata":null},{"id":"62259530ae234996b96ab0124660b908","type":"GO_TERM","name":"positive regulation of maintenance of mitotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:2000720","description":"\"Any process that activates or increases the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion in the centromeric region.\" [GOC:mah]","metadata":null},{"id":"3610bf6e79514742a89ff0a89c10f95d","type":"GO_TERM","name":"positive regulation of maintenance of mitotic sister chromatid cohesion, telomeric","canonical_id":"go:GO:1904909","description":"\"Any process that activates or increases the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion, telomeric.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26373281]","metadata":null},{"id":"afcf8065e14244b595398cdb7d5964e7","type":"GO_TERM","name":"positive regulation of maintenance of sister chromatid cohesion","canonical_id":"go:GO:0034093","description":"\"Any process that increases the extent to which the association between sister chromatids of a replicated chromosome is maintained.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"337890f9139f45dfa6caafe5ddedb97d","type":"GO_TERM","name":"positive regulation of male germ cell proliferation","canonical_id":"go:GO:2000256","description":"\"Any process that activates or increases the frequency, rate or extent of male germ cell proliferation.\" [GOC:obol]","metadata":null},{"id":"110bf8315bf645e5aba7256bc7ebda59","type":"GO_TERM","name":"positive regulation of male germ-line stem cell asymmetric division","canonical_id":"go:GO:1904840","description":"\"Any process that activates or increases the frequency, rate or extent of male germ-line stem cell asymmetric division.\" [GO_REF:0000058, GOC:TermGenie, PMID:19339709]","metadata":null},{"id":"9e909a1dbabb4c64bbae4ed00704435f","type":"GO_TERM","name":"positive regulation of male gonad development","canonical_id":"go:GO:2000020","description":"\"Any process that activates or increases the frequency, rate or extent of male gonad development.\" [GOC:obol]","metadata":null},{"id":"4bf147a409ec42a18b007c2735866375","type":"GO_TERM","name":"positive regulation of male mating behavior","canonical_id":"go:GO:1902437","description":"\"Any process that activates or increases the frequency, rate or extent of male mating behavior.\" [GOC:TermGenie, PMID:24089208]","metadata":null},{"id":"cca11d6176644166ab427af66669d024","type":"GO_TERM","name":"positive regulation of male pigmentation","canonical_id":"go:GO:0048093","description":"\"Any process that activates or increases the frequency, rate or extent of establishment of a pattern of pigment in males.\" [GOC:jid]","metadata":null},{"id":"fd42ab3705bd4f2f8db59ac152637bed","type":"GO_TERM","name":"positive regulation of maltoheptaose transport","canonical_id":"go:GO:1900308","description":"\"Any process that activates or increases the frequency, rate or extent of maltoheptaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b295e5acd9f3480e852e53f07726da43","type":"GO_TERM","name":"positive regulation of maltohexaose transport","canonical_id":"go:GO:1900314","description":"\"Any process that activates or increases the frequency, rate or extent of maltohexaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"651db77fe43b451aa6dd1ea31c33fb0c","type":"GO_TERM","name":"positive regulation of maltopentaose transport","canonical_id":"go:GO:1900317","description":"\"Any process that activates or increases the frequency, rate or extent of maltopentaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c044bb47c5c040a4a9a069e101bdecf3","type":"GO_TERM","name":"positive regulation of maltose transport","canonical_id":"go:GO:1902345","description":"\"Any process that activates or increases the frequency, rate or extent of maltose transport.\" [GOC:dph, GOC:TermGenie, PMID:23770568]","metadata":null},{"id":"fca0a5086b0f4ba3b30718309b085977","type":"GO_TERM","name":"positive regulation of maltotetraose transport","canonical_id":"go:GO:1900323","description":"\"Any process that activates or increases the frequency, rate or extent of maltotetraose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"476905deb1754088b518838152b2b81b","type":"GO_TERM","name":"positive regulation of maltotriulose transport","canonical_id":"go:GO:1900326","description":"\"Any process that activates or increases the frequency, rate or extent of maltotriulose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"dee3d929ebaa474fa4052fdc782684d3","type":"GO_TERM","name":"positive regulation of mammary gland epithelial cell proliferation","canonical_id":"go:GO:0033601","description":"\"Any process that activates or increases the rate or extent of mammary gland epithelial cell proliferation.\" [GOC:mah]","metadata":null},{"id":"72473397f134431398b6f3548ed39c81","type":"GO_TERM","name":"positive regulation of mammary gland involution","canonical_id":"go:GO:1903521","description":"\"Any process that activates or increases the frequency, rate or extent of mammary gland involution.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:23164222]","metadata":null},{"id":"553d0d8fdaac42af8f42d7348dd3216c","type":"GO_TERM","name":"positive regulation of mammary placode formation by mesenchymal-epithelial signaling","canonical_id":"go:GO:0060617","description":"\"Any process that initiates the formation of a mammary placode through a mechanism that mediates the transfer of information from a mesenchymal cell to an epithelial cell resulting in the epithelial cell adopting the identity of a cell of the mammary placode.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"73d0987cb956461e9014e0c813ccd79c","type":"GO_TERM","name":"positive regulation of mammary stem cell proliferation","canonical_id":"go:GO:2000103","description":"\"Any process that activates or increases the frequency, rate or extent of mammary stem cell proliferation.\" [GOC:obol]","metadata":null},{"id":"726467a9a6ba48a6b721025bdac9cdb8","type":"GO_TERM","name":"positive regulation of mannan catabolic process","canonical_id":"go:GO:2000996","description":"\"Any process that activates or increases the frequency, rate or extent of mannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"8cb2b8a10f4b47c6bad7ee2b3685efcb","type":"GO_TERM","name":"positive regulation of mannotriose transport","canonical_id":"go:GO:1900329","description":"\"Any process that activates or increases the frequency, rate or extent of mannotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"768761f9002948fc81e73cea07d9e153","type":"GO_TERM","name":"positive regulation of mast cell activation","canonical_id":"go:GO:0033005","description":"\"Any process that activates or increases the frequency, rate, or extent of mast cell activation.\" [GOC:mah]","metadata":null},{"id":"9c35ae6b9b864320960e48fd9853ae27","type":"GO_TERM","name":"positive regulation of mast cell activation by Fc-epsilon receptor signaling pathway","canonical_id":"go:GO:0038097","description":"\"An Fc-epsilon receptor signaling pathway that results in the change in morphology and behavior of a mast cell resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the mast cell has specifically bound via IgE bound to Fc-epsilonRI receptors.\" [GOC:phg, PMID:12413516]","metadata":null},{"id":"058f1e3fcdf44d7a9cbe1dad7b15cc84","type":"GO_TERM","name":"positive regulation of mast cell activation involved in immune response","canonical_id":"go:GO:0033008","description":"\"Any process that activates or increases the frequency, rate, or extent of mast cell activation as part of an immune response.\" [GOC:mah]","metadata":null},{"id":"85c5d96bf94744b1b4df5463f68c39e0","type":"GO_TERM","name":"positive regulation of mast cell apoptotic process","canonical_id":"go:GO:0033027","description":"\"Any process that activates or increases the frequency, rate, or extent of mast cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"9eb097300d47442296efced766e5f927","type":"GO_TERM","name":"positive regulation of mast cell chemotaxis","canonical_id":"go:GO:0060754","description":"\"Any process that increases the rate, frequency or extent of mast cell chemotaxis. Mast cell chemotaxis is the movement of a mast cell in response to an external stimulus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"36d2de43801f462db9532a046b9b4ee4","type":"GO_TERM","name":"positive regulation of mast cell cytokine production","canonical_id":"go:GO:0032765","description":"\"Any process that activates or increases the frequency, rate, or extent of mast cell cytokine production.\" [GOC:mah]","metadata":null},{"id":"55b6eee08c794f60ad82c004028bf2ae","type":"GO_TERM","name":"positive regulation of mast cell degranulation","canonical_id":"go:GO:0043306","description":"\"Any process that activates or increases the frequency, rate or extent of mast cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"3e78dbed81b346fc8ab8af79b13a25fe","type":"GO_TERM","name":"positive regulation of mast cell differentiation","canonical_id":"go:GO:0060376","description":"\"Any process that increases the rate, frequency or extent of mast cell differentiation, the process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a mast cell. A mast cell is a cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b84b5f83be26450783ca5c2d2be1d364","type":"GO_TERM","name":"positive regulation of mast cell proliferation","canonical_id":"go:GO:0070668","description":"\"Any process that activates or increases the rate or extent of mast cell proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"8d113141fdc141beb662503c59d0e6ef","type":"GO_TERM","name":"positive regulation of mating projection assembly","canonical_id":"go:GO:1902917","description":"\"Any process that activates or increases the frequency, rate or extent of mating projection assembly.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:12455985]","metadata":null},{"id":"48cc6763387646989bec7bf20faf4810","type":"GO_TERM","name":"positive regulation of mating type switching","canonical_id":"go:GO:0031496","description":"\"Any process that activates or increases the frequency, rate or extent of mating type switching.\" [GOC:mah]","metadata":null},{"id":"df045ba195a349b2aac767ad6e67cedf","type":"GO_TERM","name":"positive regulation of mating-type specific transcription, DNA-templated","canonical_id":"go:GO:0045895","description":"\"Any mating-type specific process that activates or increases the rate of cellular DNA-templated transcription.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"b38444a94cc64f08970ec4721eee9a64","type":"GO_TERM","name":"positive regulation of matrix metallopeptidase secretion","canonical_id":"go:GO:1904466","description":"\"Any process that activates or increases the frequency, rate or extent of matrix metallopeptidase secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:8679543]","metadata":null},{"id":"a7d7799eb3e64be1965aa4210087e5d6","type":"GO_TERM","name":"positive regulation of mature B cell apoptotic process","canonical_id":"go:GO:0002907","description":"\"Any process that activates or increases the frequency, rate, or extent of mature B cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"f8360f6281874071a411c8d41e8c6b3b","type":"GO_TERM","name":"positive regulation of mechanoreceptor differentiation","canonical_id":"go:GO:0045633","description":"\"Any process that activates or increases the frequency, rate or extent of mechanoreceptor differentiation.\" [GOC:curators]","metadata":null},{"id":"10d8ec2bdb7d4c8c87af382c849450ec","type":"GO_TERM","name":"positive regulation of mechanosensory behavior","canonical_id":"go:GO:1905792","description":"\"Any process that activates or increases the frequency, rate or extent of mechanosensory behavior.\" [GO_REF:0000058, GOC:TermGenie, PMID:8692859]","metadata":null},{"id":"dfc84de5697c4777b0fa7679357c3339","type":"GO_TERM","name":"positive regulation of mediator complex assembly","canonical_id":"go:GO:2001178","description":"\"Any process that activates or increases the frequency, rate or extent of mediator complex assembly.\" [GOC:obol]","metadata":null},{"id":"fe5f503c2d6743caa78c77d6df6ed39b","type":"GO_TERM","name":"positive regulation of megakaryocyte differentiation","canonical_id":"go:GO:0045654","description":"\"Any process that activates or increases the frequency, rate or extent of megakaryocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"9ad9c02942ac4b80826deb271e49a2c9","type":"GO_TERM","name":"positive regulation of meiosis I","canonical_id":"go:GO:0060903","description":"\"Any process that increases the rate, frequency, or extent of meiosis I, a cell cycle process comprising the steps by which a cell progresses through the first phase of meiosis, in which cells divide and homologous chromosomes are paired and segregated from each other, producing two daughter cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8b6e2cc9f4b149f9b4e00f192f08e5fb","type":"GO_TERM","name":"positive regulation of meiosis I spindle assembly checkpoint","canonical_id":"go:GO:1905326","description":"\"Any process that activates or increases the frequency, rate or extent of the meiosis I spindle assembly checkpoint.\" [GO_REF:0000058, GOC:TermGenie, PMID:26483559]","metadata":null},{"id":"1d0f3e0ccaf346e2891c924b8a8d581f","type":"GO_TERM","name":"positive regulation of meiotic DNA double-strand break formation","canonical_id":"go:GO:1903343","description":"\"Any process that activates or increases the frequency, rate or extent of meiotic DNA double-strand break formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25103240]","metadata":null},{"id":"7dde476f147c477f8857249e8c54efeb","type":"GO_TERM","name":"positive regulation of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination","canonical_id":"go:GO:1905263","description":"\"Any process that activates or increases the frequency, rate or extent of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination.\" [GO_REF:0000058, GOC:TermGenie, PMID:26653857]","metadata":null},{"id":"37f332f4f7624f8e9aac14357b1b4310","type":"GO_TERM","name":"positive regulation of meiotic cell cycle","canonical_id":"go:GO:0051446","description":"\"Any process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"8f291ba6507b419d8f1e62f402f98799","type":"GO_TERM","name":"positive regulation of meiotic cell cycle phase transition","canonical_id":"go:GO:1901995","description":"\"Any process that activates or increases the frequency, rate or extent of meiotic cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"4c0644fdd35d415cbf21ab3ffc930b31","type":"GO_TERM","name":"positive regulation of meiotic cell cycle process involved in oocyte maturation","canonical_id":"go:GO:1904146","description":"\"Any process that activates or increases the frequency, rate or extent of meiotic cell cycle process involved in oocyte maturation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22674394]","metadata":null},{"id":"65ebc212416f491c9ca62647a0637c91","type":"GO_TERM","name":"positive regulation of meiotic chromosome separation","canonical_id":"go:GO:1905134","description":"\"Any process that activates or increases the frequency, rate or extent of meiotic chromosome separation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw, PMID:15620645]","metadata":null},{"id":"43922a94685e4c6ea8953d0243826cc9","type":"GO_TERM","name":"positive regulation of meiotic nuclear division","canonical_id":"go:GO:0045836","description":"\"Any process that activates or increases the frequency, rate or extent of meiosis.\" [GOC:curators]","metadata":null},{"id":"bd7954de25ad4d6f9551a57c32cee4bb","type":"GO_TERM","name":"positive regulation of meiotic sister chromatid arm separation","canonical_id":"go:GO:0062041","description":"\"Any process that increases the rate or extent of meiotic sister chromatid arm separation, the cell cycle process in which sister chromatid arms are physically detached from each other during meiosis.\" [PMID:20383139]","metadata":null},{"id":"c1f45657cb6940ca8ca892ecadb4c40e","type":"GO_TERM","name":"positive regulation of melanin biosynthetic process","canonical_id":"go:GO:0048023","description":"\"Any process that activates or increases the rate or extent of the chemical reactions and pathways resulting in the formation of melanin.\" [GOC:jid]","metadata":null},{"id":"7e5d3e3f22dd4751b4843e29e626bb26","type":"GO_TERM","name":"positive regulation of melanization defense response","canonical_id":"go:GO:0035008","description":"\"Any process that increases the rate or extent of the melanization defense response during injury or invasion.\" [GOC:bf]","metadata":null},{"id":"ca05ad527d144d999cf0991f303fd22a","type":"GO_TERM","name":"positive regulation of melanocyte differentiation","canonical_id":"go:GO:0045636","description":"\"Any process that activates or increases the frequency, rate or extent of melanocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"c47bf8c7637a44eb90a90948578c931d","type":"GO_TERM","name":"positive regulation of melanosome organization","canonical_id":"go:GO:1903058","description":"\"Any process that activates or increases the frequency, rate or extent of melanosome organization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24769727]","metadata":null},{"id":"eea354e2cf0a43dda5f93d88962104d9","type":"GO_TERM","name":"positive regulation of melanosome transport","canonical_id":"go:GO:1902910","description":"\"Any process that activates or increases the frequency, rate or extent of melanosome transport.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23334344]","metadata":null},{"id":"9f1f4e380411451289aec5029bea0acb","type":"GO_TERM","name":"positive regulation of membrane depolarization","canonical_id":"go:GO:1904181","description":"\"Any process that activates or increases the frequency, rate or extent of membrane depolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:20826763]","metadata":null},{"id":"5ca487b8c12c46deb118c7bae6088ada","type":"GO_TERM","name":"positive regulation of membrane depolarization during AV node cell action potential","canonical_id":"go:GO:1905029","description":"\"Any process that activates or increases the frequency, rate or extent of membrane depolarization during AV node cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:19726871]","metadata":null},{"id":"c7dfc83b6b804ad385279b5b0a5d9a91","type":"GO_TERM","name":"positive regulation of membrane depolarization during cardiac muscle cell action potential","canonical_id":"go:GO:1900827","description":"\"Any process that activates or increases the frequency, rate or extent of membrane depolarization during a cardiac muscle cell action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:TermGenie]","metadata":null},{"id":"91f05f968f4441388b2e07e72a52a13a","type":"GO_TERM","name":"positive regulation of membrane hyperpolarization","canonical_id":"go:GO:1902632","description":"\"Any process that activates or increases the frequency, rate or extent of membrane hyperpolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:23223304]","metadata":null},{"id":"da4a79f98f354135bf75b2610536f948","type":"GO_TERM","name":"positive regulation of membrane invagination","canonical_id":"go:GO:1905155","description":"\"Any process that activates or increases the frequency, rate or extent of membrane invagination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"f8d09991804d4fe9af45603627b6e046","type":"GO_TERM","name":"positive regulation of membrane permeability","canonical_id":"go:GO:1905710","description":"\"Any process that activates or increases the frequency, rate or extent of the passage or uptake of molecules by a membrane.\" [PMID:27482894]","metadata":null},{"id":"53e9900679c649df9039518c7e9d7062","type":"GO_TERM","name":"positive regulation of membrane potential","canonical_id":"go:GO:0045838","description":"\"Any process that activates or increases the frequency, rate or extent of establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:curators]","metadata":null},{"id":"33c1e9da7bef4ae1aca772d9d43eb687","type":"GO_TERM","name":"positive regulation of membrane protein ectodomain proteolysis","canonical_id":"go:GO:0051044","description":"\"Any process that activates or increases the frequency, rate or extent of membrane protein ectodomain peptidolysis.\" [GOC:ai]","metadata":null},{"id":"c880be79c3ae44978fab3cebba8b5857","type":"GO_TERM","name":"positive regulation of membrane repolarization during atrial cardiac muscle cell action potential","canonical_id":"go:GO:1905002","description":"\"Any process that activates or increases the frequency, rate or extent of membrane repolarization during atrial cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:21098446]","metadata":null},{"id":"3259266e4e214d85b77c675cfe54bb2b","type":"GO_TERM","name":"positive regulation of membrane repolarization during cardiac muscle cell action potential","canonical_id":"go:GO:1905033","description":"\"Any process that activates or increases the frequency, rate or extent of membrane repolarization during cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:23157812]","metadata":null},{"id":"ced01401c4bc423cab5b4c17aba04c72","type":"GO_TERM","name":"positive regulation of membrane repolarization during ventricular cardiac muscle cell action potential","canonical_id":"go:GO:1905026","description":"\"Any process that activates or increases the frequency, rate or extent of membrane repolarization during ventricular cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:19893015]","metadata":null},{"id":"79a346b0e258440ab259b68add51ae0d","type":"GO_TERM","name":"positive regulation of membrane tubulation","canonical_id":"go:GO:1903527","description":"\"Any process that activates or increases the frequency, rate or extent of membrane tubulation.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:18388313]","metadata":null},{"id":"c3a15471ebf649cd89215cf2220409d3","type":"GO_TERM","name":"positive regulation of memory T cell activation","canonical_id":"go:GO:2000568","description":"\"Any process that activates or increases the frequency, rate or extent of memory T cell activation.\" [GOC:obol]","metadata":null},{"id":"60b08364fa9f4b27b549144bb1bfd0ce","type":"GO_TERM","name":"positive regulation of memory T cell differentiation","canonical_id":"go:GO:0043382","description":"\"Any process that activates or increases the frequency, rate or extent of memory T cell differentiation.\" [ISBN:0781735149]","metadata":null},{"id":"f67da9fb79c9461a92f259644ffce562","type":"GO_TERM","name":"positive regulation of mesenchymal cell apoptotic process","canonical_id":"go:GO:2001055","description":"\"Any process that activates or increases the frequency, rate or extent of mesenchymal cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"60f1082ff3594990abf34d3efceb2d09","type":"GO_TERM","name":"positive regulation of mesenchymal cell proliferation","canonical_id":"go:GO:0002053","description":"\"The process of activating or increasing the rate or extent of mesenchymal cell proliferation. Mesenchymal cells are loosely organized embryonic cells.\" [GOC:dph]","metadata":null},{"id":"5e536d24c14346fd95e3a7334a963e9a","type":"GO_TERM","name":"positive regulation of mesenchymal cell proliferation involved in ureter development","canonical_id":"go:GO:2000729","description":"\"Any process that activates or increases the frequency, rate or extent of mesenchymal cell proliferation involved in ureter development.\" [GOC:obol]","metadata":null},{"id":"1e3ddcd7b59043a39a43f97e88c8485c","type":"GO_TERM","name":"positive regulation of mesenchymal stem cell differentiation","canonical_id":"go:GO:2000741","description":"\"Any process that activates or increases the frequency, rate or extent of mesenchymal stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"c131bd8687434bfaaf7d1896ed36fd32","type":"GO_TERM","name":"positive regulation of mesenchymal stem cell migration","canonical_id":"go:GO:1905322","description":"\"Any process that activates or increases the frequency, rate or extent of mesenchymal stem cell migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:26846297]","metadata":null},{"id":"5817be5909844ed4ab0e6c4a51a03e75","type":"GO_TERM","name":"positive regulation of mesenchymal stem cell proliferation","canonical_id":"go:GO:1902462","description":"\"Any process that activates or increases the frequency, rate or extent of mesenchymal stem cell proliferation.\" [GOC:pm, GOC:TermGenie, PMID:18672106]","metadata":null},{"id":"a84d3574b897434894298794414d0507","type":"GO_TERM","name":"positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis","canonical_id":"go:GO:0072108","description":"\"Any process that increases the rate, frequency or extent of the transition where a mesenchymal cell establishes apical/basolateral polarity, forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell that will contribute to the shaping of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1ff0ccd69cc045b79584249ed6d03bd6","type":"GO_TERM","name":"positive regulation of mesoderm development","canonical_id":"go:GO:2000382","description":"\"Any process that activates or increases the frequency, rate or extent of mesoderm development.\" [GOC:BHF]","metadata":null},{"id":"0e087e2c5b6d413cbf1c05c9e7cbdf5d","type":"GO_TERM","name":"positive regulation of mesoderm formation","canonical_id":"go:GO:1905904","description":"\"Any process that activates or increases the frequency, rate or extent of mesoderm formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23939491]","metadata":null},{"id":"6b86d51c05fc45d1b4a303f3f3dca4f0","type":"GO_TERM","name":"positive regulation of mesodermal cell differentiation","canonical_id":"go:GO:1905772","description":"\"Any process that activates or increases the frequency, rate or extent of mesodermal cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23765923]","metadata":null},{"id":"f582eb0fb6bf4be1afbd86b1a3b15409","type":"GO_TERM","name":"positive regulation of mesodermal cell fate determination","canonical_id":"go:GO:0048336","description":"\"Any process that activates or increases the frequency, rate or extent of mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"b8b7094167c443ddb28aa113a42dc2a0","type":"GO_TERM","name":"positive regulation of mesodermal cell fate specification","canonical_id":"go:GO:0048337","description":"\"Any process that activates or increases the frequency, rate or extent of mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"98ae6454b164423cacec6151ef6decc3","type":"GO_TERM","name":"positive regulation of mesonephric glomerular mesangial cell proliferation","canonical_id":"go:GO:2000092","description":"\"Any process that activates or increases the frequency, rate or extent of mesonephric glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8f0209f3fbe140c8bcb29d18705d393b","type":"GO_TERM","name":"positive regulation of mesonephric glomerulus development","canonical_id":"go:GO:2000089","description":"\"Any process that activates or increases the frequency, rate or extent of mesonephric glomerulus development.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"25761cd09a3f4f358034b9531291190a","type":"GO_TERM","name":"positive regulation of mesonephros development","canonical_id":"go:GO:0061213","description":"\"Any process that increases the rate, frequency or extent of mesonephros development. Mesonephros development is the process whose specific outcome is the progression of the mesonephros over time, from its formation to the mature structure. The mesonephros is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"7fb90bd2ac7c4a8c9693e0ec4339e99a","type":"GO_TERM","name":"positive regulation of metabolic process","canonical_id":"go:GO:0009893","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.\" [GOC:curators]","metadata":null},{"id":"948e7cf503be44cfbf15ba5f432730e3","type":"GO_TERM","name":"positive regulation of metalloendopeptidase activity","canonical_id":"go:GO:1904685","description":"\"Any process that activates or increases the frequency, rate or extent of metalloendopeptidase activity.\" [GO_REF:0000059, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:18591254]","metadata":null},{"id":"f1f4e18912e54e3b8af71137a5962f69","type":"GO_TERM","name":"positive regulation of metallopeptidase activity","canonical_id":"go:GO:1905050","description":"\"Any process that activates or increases the frequency, rate or extent of metallopeptidase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:26473732]","metadata":null},{"id":"107f9450568a47a8a6fa64fbec2ea23e","type":"GO_TERM","name":"positive regulation of metanephric DCT cell differentiation","canonical_id":"go:GO:2000594","description":"\"Any process that activates or increases the frequency, rate or extent of metanephric DCT cell differentiation.\" [GOC:obol]","metadata":null},{"id":"5bb39401c41748ab8585bfb1373f9b8e","type":"GO_TERM","name":"positive regulation of metanephric cap mesenchymal cell proliferation","canonical_id":"go:GO:0090096","description":"\"Any process that increases the frequency, rate, or extent of metanephric cap mesenchymal cell proliferation. Metanephric cap mesenchymal cell proliferation is the multiplication or reproduction of metanephric cap mesenchymal cells, resulting in the expansion of the cell population. A metanephric cap mesenchymal cell is a mesenchymal cell that has condensed with other mesenchymal cells surrounding the ureteric bud tip.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"b8971efc26314dbda63c6a84a1d2ec20","type":"GO_TERM","name":"positive regulation of metanephric glomerulus development","canonical_id":"go:GO:0072300","description":"\"Any process that increases the rate, frequency or extent of metanephric glomerulus development, the progression of the metanephric glomerulus over time from its initial formation until its mature state. The metanephric glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney, or metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5b674bf6f7bf42bb88bd8b76d0988dfd","type":"GO_TERM","name":"positive regulation of metanephric mesenchymal cell migration","canonical_id":"go:GO:2000591","description":"\"Any process that activates or increases the frequency, rate or extent of metanephric mesenchymal cell migration.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"43061f35d33140ee9b0dc7566f9f4c59","type":"GO_TERM","name":"positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:0035793","description":"\"Any process that increases the frequency, rate or extent of metanephric mesenchymal cell migration resulting from the platelet-derived growth factor receptor-beta signaling pathway.\" [GOC:bf, GOC:mtg_kidney_jan10, GOC:yaf, PMID:10734101]","metadata":null},{"id":"c6e5106c80234ef29f18dbf37fbf3f3a","type":"GO_TERM","name":"positive regulation of metanephric podocyte development","canonical_id":"go:GO:2000478","description":"\"Any process that activates or increases the frequency, rate or extent of metanephric glomerular visceral epithelial cell development.\" [GOC:obol]","metadata":null},{"id":"2703759a1dd141228154e4f9bed51a6d","type":"GO_TERM","name":"positive regulation of metanephric ureteric bud development","canonical_id":"go:GO:2001076","description":"\"Any process that activates or increases the frequency, rate or extent of metanephric ureteric bud development.\" [GOC:obol]","metadata":null},{"id":"590dd6c2680e46b1ac9f10122ecc2ad4","type":"GO_TERM","name":"positive regulation of metanephros development","canonical_id":"go:GO:0072216","description":"\"Any process that increases the rate, frequency or extent of metanephros development. Metanephros development is the process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. The metanephros is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"61903a2631774302b377cbe8abde1b5f","type":"GO_TERM","name":"positive regulation of metaphase/anaphase transition of cell cycle","canonical_id":"go:GO:1902101","description":"\"Any process that activates or increases the frequency, rate or extent of metaphase/anaphase transition of cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"24b126e9125049ce94880c1ab3f71e1e","type":"GO_TERM","name":"positive regulation of metaphase/anaphase transition of meiosis I","canonical_id":"go:GO:1905188","description":"\"Any process that activates or increases the frequency, rate or extent of metaphase/anaphase transition of meiosis I.\" [GO_REF:0000058, GOC:TermGenie, PMID:21389117]","metadata":null},{"id":"ac7a867fe92a4990a207d977412ca845","type":"GO_TERM","name":"positive regulation of metaphase/anaphase transition of meiosis II","canonical_id":"go:GO:1905191","description":"\"Any process that activates or increases the frequency, rate or extent of metaphase/anaphase transition of meiosis II.\" [GO_REF:0000058, GOC:TermGenie, PMID:21389117]","metadata":null},{"id":"99792344ae094ce6876fb18d6662231c","type":"GO_TERM","name":"positive regulation of metaphase/anaphase transition of meiotic cell cycle","canonical_id":"go:GO:1902104","description":"\"Any process that activates or increases the frequency, rate or extent of metaphase/anaphase transition of meiotic cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"ba505d5f95bc4c99bd4b37c4a0d86f3a","type":"GO_TERM","name":"positive regulation of methanofuran biosynthetic process","canonical_id":"go:GO:1900353","description":"\"Any process that activates or increases the frequency, rate or extent of methanofuran biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"ac0ab61cc246410bb9a6fe868bb37238","type":"GO_TERM","name":"positive regulation of methanophenazine biosynthetic process","canonical_id":"go:GO:1900964","description":"\"Any process that activates or increases the frequency, rate or extent of methanophenazine biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"81e3e9a0dc634056929b99816fba94a5","type":"GO_TERM","name":"positive regulation of methyl-branched fatty acid biosynthetic process","canonical_id":"go:GO:1902324","description":"\"Any process that activates or increases the frequency, rate or extent of methyl-branched fatty acid biosynthetic process.\" [GOC:kmv, GOC:TermGenie, PMID:15340492]","metadata":null},{"id":"caa1b210d2e147c7a00572e26b53139a","type":"GO_TERM","name":"positive regulation of metula development","canonical_id":"go:GO:0070804","description":"\"Any process that activates or increases the frequency, rate or extent of metula development, a process that leads to the formation of metulae. Metulae are elongated mononucleate cells that bud from the surface of the conidiophore tip.\" [GOC:mah]","metadata":null},{"id":"e53a5e0220494f2baa9f03933a98e4c3","type":"GO_TERM","name":"positive regulation of miRNA catabolic process","canonical_id":"go:GO:2000627","description":"\"Any process that activates or increases the frequency, rate or extent of miRNA catabolic process.\" [GOC:dph]","metadata":null},{"id":"67bf3bea32db4fb2a68b30b490483bea","type":"GO_TERM","name":"positive regulation of miRNA metabolic process","canonical_id":"go:GO:2000630","description":"\"Any process that activates or increases the frequency, rate or extent of miRNA metabolic process.\" [GOC:dph]","metadata":null},{"id":"acba891c95aa4e6caf41d7de28163e09","type":"GO_TERM","name":"positive regulation of miRNA processing","canonical_id":"go:GO:1903800","description":"\"Any process that activates or increases the frequency, rate or extent of microRNA processing.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"2bfd0e90bc6f42299b1c174aaf35ec0f","type":"GO_TERM","name":"positive regulation of miRNA transcription","canonical_id":"go:GO:1902895","description":"\"Any process that activates or increases the frequency, rate or extent of microRNA (miRNA) gene transcription.\" [GO_REF:0000058, GOC:dph, GOC:kmv, GOC:TermGenie, PMID:24699545]","metadata":null},{"id":"14d8e73f8b514fba86f9629a112e772d","type":"GO_TERM","name":"positive regulation of miRNA-mediated gene silencing","canonical_id":"go:GO:2000637","description":"\"A process that activates or increases the frequency, rate or extent of gene silencing by a microRNA (miRNA).\" [GOC:dph]","metadata":null},{"id":"1c7ee5cfdc574199866a407fb5f7dca0","type":"GO_TERM","name":"positive regulation of microglia differentiation","canonical_id":"go:GO:0014008","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of microglia differentiation, the process in which a relatively unspecialized cell acquires specialized features of a microglial cell.\" [GOC:ef]","metadata":null},{"id":"0f19cfa9d0554ed39936e4a2c4c3cd40","type":"GO_TERM","name":"positive regulation of microglial cell activation","canonical_id":"go:GO:1903980","description":"\"Any process that activates or increases the frequency, rate or extent of microglial cell activation.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"f7fd55cc9ac04c3c9a28d564ece2028f","type":"GO_TERM","name":"positive regulation of microglial cell mediated cytotoxicity","canonical_id":"go:GO:1904151","description":"\"Any process that activates or increases the frequency, rate or extent of microglial cell mediated cytotoxicity.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"2b7066fc0b594b648e96d7e057365acd","type":"GO_TERM","name":"positive regulation of microglial cell migration","canonical_id":"go:GO:1904141","description":"\"Any process that activates or increases the frequency, rate or extent of microglial cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"1241c935cf2b4bf4aaa6a60fc0a56ca5","type":"GO_TERM","name":"positive regulation of microtubule depolymerization","canonical_id":"go:GO:0031117","description":"\"Any process that activates or increases the frequency, rate or extent of microtubule depolymerization.\" [GOC:mah]","metadata":null},{"id":"f6604f0df8ba448caeb86f8cf5e3494c","type":"GO_TERM","name":"positive regulation of microtubule nucleation","canonical_id":"go:GO:0090063","description":"\"Any process that increases the rate, frequency or extent of microtubule nucleation. Microtubule nucleation is the 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates, some of which go on to support formation of a complete microtubule. Microtubule nucleation usually occurs from a specific site within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d3462eae5ed7481e906cec5a3c161c3a","type":"GO_TERM","name":"positive regulation of microtubule polymerization","canonical_id":"go:GO:0031116","description":"\"Any process that activates or increases the frequency, rate or extent of microtubule polymerization.\" [GOC:mah]","metadata":null},{"id":"cb272632e5d444f796e8e9671686dfaf","type":"GO_TERM","name":"positive regulation of microtubule polymerization or depolymerization","canonical_id":"go:GO:0031112","description":"\"Any process that activates or increases the frequency, rate or extent of microtubule polymerization or depolymerization.\" [GOC:mah]","metadata":null},{"id":"2976224e8c544567a880cc096f8d668a","type":"GO_TERM","name":"positive regulation of microvillus assembly","canonical_id":"go:GO:1903698","description":"\"Any process that activates or increases the frequency, rate or extent of microvillus assembly.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22797597]","metadata":null},{"id":"dc411bf85a234c88872e63af22d32867","type":"GO_TERM","name":"positive regulation of microvillus length","canonical_id":"go:GO:1903983","description":"\"A process that increases the length of a microvillus.\" [GOC:als, PMID:22114352]","metadata":null},{"id":"e5f7554449bf4fca82060080c1e040b0","type":"GO_TERM","name":"positive regulation of midbrain dopaminergic neuron differentiation","canonical_id":"go:GO:1904958","description":"\"Any process that activates or increases the frequency, rate or extent of midbrain dopaminergic neuron differentiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21347250]","metadata":null},{"id":"7f7c5ed0adb9422cb0e5cf59b7e7227e","type":"GO_TERM","name":"positive regulation of mineralocorticoid secretion","canonical_id":"go:GO:2000857","description":"\"Any process that activates or increases the frequency, rate or extent of mineralocorticoid secretion.\" [GOC:sl]","metadata":null},{"id":"2da22fcab683413bab2bf466635123bd","type":"GO_TERM","name":"positive regulation of mini excitatory postsynaptic potential","canonical_id":"go:GO:0061885","description":"\"Any process that increases the frequency, rate or extent of mini excitatory postsynaptic potential. Mini excitatory postsynaptic potential is a process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell, induced by the spontaneous release of a single vesicle of an excitatory neurotransmitter into the synapse.\" [GOC:aruk, GOC:bc, PMID:20395454]","metadata":null},{"id":"d1eee3bb2682440f9e6839684b982a2d","type":"GO_TERM","name":"positive regulation of mismatch repair","canonical_id":"go:GO:0032425","description":"\"Any process that activates or increases the frequency, rate or extent of mismatch repair.\" [GOC:vk]","metadata":null},{"id":"a7c0d8f86f6147d28f65dade84f6d02f","type":"GO_TERM","name":"positive regulation of mitochondrial ATP synthesis coupled electron transport","canonical_id":"go:GO:1905448","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial ATP synthesis coupled electron transport.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:23707074]","metadata":null},{"id":"95f489747f8844479a60fb5ceb7e20f7","type":"GO_TERM","name":"positive regulation of mitochondrial DNA metabolic process","canonical_id":"go:GO:1901860","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial DNA metabolic process.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"65f79ce30fd04239b7b0937ce78fc29d","type":"GO_TERM","name":"positive regulation of mitochondrial DNA replication","canonical_id":"go:GO:0090297","description":"\"Any process that increases the rate, frequency or extent of the process in which new strands of DNA are synthesized in the mitochondrion.\" [GOC:tb]","metadata":null},{"id":"918ce82e57c446918301a95543585740","type":"GO_TERM","name":"positive regulation of mitochondrial RNA catabolic process","canonical_id":"go:GO:0000962","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving catabolism in the mitochondrion of RNA transcribed from the mitochondrial genome.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"2a3305f40276497a931ba7510484193c","type":"GO_TERM","name":"positive regulation of mitochondrial calcium ion concentration","canonical_id":"go:GO:0051561","description":"\"Any process that increases the concentration of calcium ions in mitochondria.\" [GOC:ai]","metadata":null},{"id":"170352c055b946dea07d16ebf0346d40","type":"GO_TERM","name":"positive regulation of mitochondrial depolarization","canonical_id":"go:GO:0051901","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the change in the membrane potential of the mitochondria from negative to positive.\" [GOC:ai]","metadata":null},{"id":"df5c0c2d04f6455bbf60863e5ae75562","type":"GO_TERM","name":"positive regulation of mitochondrial electron transport, NADH to ubiquinone","canonical_id":"go:GO:1902958","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:23530063]","metadata":null},{"id":"e54bab8eff1b45679e8c87631923fccd","type":"GO_TERM","name":"positive regulation of mitochondrial fission","canonical_id":"go:GO:0090141","description":"\"Any process that increases the rate, frequency or extent of mitochondrial fission. Mitochondrial fission is the division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"9087eb14e9ba48bdb97a10f183687c99","type":"GO_TERM","name":"positive regulation of mitochondrial fusion","canonical_id":"go:GO:0010636","description":"\"Any process that increases the frequency, rate or extent of merging of two or more mitochondria within a cell to form a single compartment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a92335e2464c4ffb9eabf23ae6e78f64","type":"GO_TERM","name":"positive regulation of mitochondrial mRNA catabolic process","canonical_id":"go:GO:1905639","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial mRNA catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:27122350]","metadata":null},{"id":"8faa15edc1064e1eb2566a40c55d46ce","type":"GO_TERM","name":"positive regulation of mitochondrial membrane permeability","canonical_id":"go:GO:0035794","description":"\"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.\" [GOC:bf, PMID:12546810]","metadata":null},{"id":"7673134db1814aa2812c343814c1e96c","type":"GO_TERM","name":"positive regulation of mitochondrial membrane permeability involved in apoptotic process","canonical_id":"go:GO:1902110","description":"\"Any positive regulation of mitochondrial membrane permeability that is involved in apoptotic process.\" [GOC:mtg_apoptosis, GOC:pm, GOC:TermGenie, PMID:19168129]","metadata":null},{"id":"d398f008e8c040959377bb814ea465b8","type":"GO_TERM","name":"positive regulation of mitochondrial membrane potential","canonical_id":"go:GO:0010918","description":"\"Any process that activates or increases the frequency, rate or extent of establishment or extent of a mitochondrial membrane potential, the electric potential existing across any mitochondrial membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"92809043634c49cebef8a208a7a78ef4","type":"GO_TERM","name":"positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway","canonical_id":"go:GO:1901030","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"fcce3c7cdbe544dca456dd6d2a9b7699","type":"GO_TERM","name":"positive regulation of mitochondrial transcription","canonical_id":"go:GO:1903109","description":"\"Any process that activates or increases the frequency, rate or extent of transcription occurring in the mitochondrion.\" [GO_REF:0000058, GOC:TermGenie, PMID:21357609]","metadata":null},{"id":"1cdfd1b800684be6b5be75e56b7311c2","type":"GO_TERM","name":"positive regulation of mitochondrial translation","canonical_id":"go:GO:0070131","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"36659fd31fce4fc69c9d2f2d82c66b6d","type":"GO_TERM","name":"positive regulation of mitochondrial translation in response to stress","canonical_id":"go:GO:0010892","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial translation as a result of a stimulus indicating the organism is under stress.\" [GOC:dph, GOC:jp, GOC:tb, PMID:8830768]","metadata":null},{"id":"cfe8995118bd4ea4b433ba3ed16d7f39","type":"GO_TERM","name":"positive regulation of mitochondrial translational elongation","canonical_id":"go:GO:1905084","description":"\"Any process that activates or increases the frequency, rate or extent of mitochondrial translational elongation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25738458]","metadata":null},{"id":"dbf51568cd2a48e2b3cef23bf49b450e","type":"GO_TERM","name":"positive regulation of mitochondrial translational initiation","canonical_id":"go:GO:0070134","description":"\"Any process that activates or increases the frequency, rate or extent of the process preceding formation of the peptide bond between the first two amino acids of a protein in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"48122c1b12ad430aa88737e412d80150","type":"GO_TERM","name":"positive regulation of mitophagy","canonical_id":"go:GO:1901526","description":"\"Any process that activates or increases the frequency, rate or extent of mitophagy.\" [GOC:TermGenie]","metadata":null},{"id":"29898873975041768b5c9aae93c22c01","type":"GO_TERM","name":"positive regulation of mitotic DNA damage checkpoint","canonical_id":"go:GO:1904291","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic DNA damage checkpoint.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:16549501]","metadata":null},{"id":"5c88bbb3be8a45f98f4ed5f96ea2e5fa","type":"GO_TERM","name":"positive regulation of mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:1903501","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic actomyosin contractile ring assembly.\" [GO_REF:0000058, GOC:al, GOC:mtg_cell_cycle, GOC:TermGenie, GOC:vw, PMID:18256290]","metadata":null},{"id":"fc29b6c5274344a293f45e5562f17d1f","type":"GO_TERM","name":"positive regulation of mitotic actomyosin contractile ring contraction","canonical_id":"go:GO:1903473","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic actomyosin contractile ring contraction.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"0ab75b0d9cb24701a954897268bb560d","type":"GO_TERM","name":"positive regulation of mitotic cell cycle","canonical_id":"go:GO:0045931","description":"\"Any process that activates or increases the rate or extent of progression through the mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"d8291eab90d7461c8ad6fb6d49208440","type":"GO_TERM","name":"positive regulation of mitotic cell cycle DNA replication","canonical_id":"go:GO:1903465","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic cell cycle DNA replication.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"5da84e3cca9f4528803364aeef2d4149","type":"GO_TERM","name":"positive regulation of mitotic cell cycle phase transition","canonical_id":"go:GO:1901992","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"932c53113a074e45aa444fe596f63788","type":"GO_TERM","name":"positive regulation of mitotic cell cycle spindle assembly checkpoint","canonical_id":"go:GO:0090267","description":"\"Any process that increases the rate, frequency, or extent of the mitotic cell cycle spindle assembly checkpoint, a cell cycle checkpoint that delays the metaphase/anaphase transition of a mitotic nuclear division until the spindle is correctly assembled and chromosomes are attached to the spindle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"1263aa4ca9aa4e2b8f20611149d68f28","type":"GO_TERM","name":"positive regulation of mitotic cell cycle, embryonic","canonical_id":"go:GO:0045977","description":"\"Any process that activates or increases the frequency, rate or extent of progression through the embryonic mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"57b5441ed1a1443b87193d7d302a6d64","type":"GO_TERM","name":"positive regulation of mitotic centrosome separation","canonical_id":"go:GO:0046604","description":"\"Any process that activates or increases the frequency, rate or extent of centrosome separation.\" [GOC:ai]","metadata":null},{"id":"6bd1cfa7ef4e499197cf620f67d2bc0f","type":"GO_TERM","name":"positive regulation of mitotic chromosome condensation","canonical_id":"go:GO:1903380","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic chromosome condensation.\" [GO_REF:0000058, GOC:TermGenie, PMID:9490640]","metadata":null},{"id":"6741debc7dd34371b02b47a1d917a2b1","type":"GO_TERM","name":"positive regulation of mitotic cytokinesis","canonical_id":"go:GO:1903490","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic cytokinesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:24920823]","metadata":null},{"id":"4e370db79f304aec82c87edbadde6584","type":"GO_TERM","name":"positive regulation of mitotic cytokinesis, division site positioning","canonical_id":"go:GO:1903617","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic cytokinesis, division site positioning.\" [PMID:21246752, PMID:9852154]","metadata":null},{"id":"9630b99b258b4e74b63abca9379b1edb","type":"GO_TERM","name":"positive regulation of mitotic cytokinetic process","canonical_id":"go:GO:1903438","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic cytokinetic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"c6d99b6175c8438c9989cd464a47b3a3","type":"GO_TERM","name":"positive regulation of mitotic division septum assembly","canonical_id":"go:GO:0140281","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic division septum formation. Division septum formation is the assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis.\" [PMID:22786806]","metadata":null},{"id":"bcd680630b0947ebbaacc2b5b0acb07c","type":"GO_TERM","name":"positive regulation of mitotic metaphase/anaphase transition","canonical_id":"go:GO:0045842","description":"\"Any process that activates or increases the frequency, rate or extent of the cell cycle process in which a cell progresses from metaphase to anaphase during mitosis, triggered by the activation of the anaphase promoting complex by Cdc20/Sleepy homolog which results in the degradation of Securin.\" [GOC:curators]","metadata":null},{"id":"087b9c570e8d4d09bccef6de68f56d4d","type":"GO_TERM","name":"positive regulation of mitotic nuclear division","canonical_id":"go:GO:0045840","description":"\"Any process that activates or increases the frequency, rate or extent of mitosis.\" [GOC:curators]","metadata":null},{"id":"dd3cd1e9e550433291a480c846f6a1c6","type":"GO_TERM","name":"positive regulation of mitotic nuclear envelope disassembly","canonical_id":"go:GO:1905559","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic nuclear envelope disassembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"51e6d00c4a8b4e5fbf11d37c9d03086b","type":"GO_TERM","name":"positive regulation of mitotic recombination","canonical_id":"go:GO:0045951","description":"\"Any process that activates or increases the frequency, rate or extent of DNA recombination during mitosis.\" [GOC:curators]","metadata":null},{"id":"42c7e387adc04011a5793e0dd86681fb","type":"GO_TERM","name":"positive regulation of mitotic recombination-dependent replication fork processing","canonical_id":"go:GO:0120292","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic recombination-dependent replication fork processing. Regulation of mitotic recombination prevents recombination between inappropriate homologous sequences. Proteins involved in homologous recombination are required for replication restart.\" [GOC:krc, GOC:mah, PMID:23093942, PMID:28586299, PMID:31149897]","metadata":null},{"id":"2ff2ca3d43c64fc8a20f84ed43164d8d","type":"GO_TERM","name":"positive regulation of mitotic sister chromatid arm separation","canonical_id":"go:GO:1905824","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic sister chromatid arm separation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"e6bd2c37f4ef46289a0df9c92208d5ca","type":"GO_TERM","name":"positive regulation of mitotic sister chromatid biorientation","canonical_id":"go:GO:0140429","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic sister chromatid biorientation, the mitotic cell cycle process in which sister chromatids establish stable, end-on attachments to the plus ends of microtubules emanating from opposite spindle poles, oriented such that separation can proceed.\" [GOC:mtg_cell_cycle, GOC:vw, PMID:15525536, PMID:20739936, PMID:21306900]","metadata":null},{"id":"bc65de13caf44642bf9d014e41054310","type":"GO_TERM","name":"positive regulation of mitotic sister chromatid segregation","canonical_id":"go:GO:0062033","description":"\"Any process that starts or increases the frequency, rate or extent of sister chromatid segregation during mitosis.\" [PMID:12773390]","metadata":null},{"id":"a551f0da5ed84bf4b6cd1013d14dfa1f","type":"GO_TERM","name":"positive regulation of mitotic sister chromatid separation","canonical_id":"go:GO:1901970","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic sister chromatid separation.\" [GOC:TermGenie, PMID:1846086]","metadata":null},{"id":"c7148886ac2049ddba2aa749e03758c8","type":"GO_TERM","name":"positive regulation of mitotic spindle disassembly","canonical_id":"go:GO:1904687","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic spindle disassembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:25963819]","metadata":null},{"id":"bf6f845cc01c47ce9c27ea3235b34ff4","type":"GO_TERM","name":"positive regulation of mitotic spindle elongation","canonical_id":"go:GO:1902846","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic spindle elongation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"248aff460d44494ab3ff67863344da1e","type":"GO_TERM","name":"positive regulation of mitotic spindle elongation (spindle phase three)","canonical_id":"go:GO:0110164","description":"\"Any process that activates or increases the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic anaphase B (spindle phase three).\" [GOC:vw, PMID:27697865]","metadata":null},{"id":"9fa0fac12d9f43df8746c1ff0d2a3bf0","type":"GO_TERM","name":"positive regulation of mitotic spindle formation (spindle phase one)","canonical_id":"go:GO:0110161","description":"\"Any process that activates or increases the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic prophase (spindle phase one).\" [GOC:vw]","metadata":null},{"id":"c7386a0c329e4024906d8d9388ea1c51","type":"GO_TERM","name":"positive regulation of mitotic spindle organization","canonical_id":"go:GO:0110028","description":"\"Any process that activates or increases the frequency, rate or extent of mitotic spindle organization.\" [GOC:bhm, PMID:17576815]","metadata":null},{"id":"4257a4d6ea1842a5b14e9f2fa327c054","type":"GO_TERM","name":"positive regulation of mitotic spindle pole body separation","canonical_id":"go:GO:0010696","description":"\"Any process that increases the rate, frequency or extent of the process involving the release of duplicated mitotic spindle pole bodies (SPBs) and their migration away from each other within the nuclear membrane.\" [GOC:dph, GOC:tb, PMID:16792804, PMID:18500339]","metadata":null},{"id":"f450be6610ff4265a9f218604e5af939","type":"GO_TERM","name":"positive regulation of molecular function","canonical_id":"go:GO:0044093","description":"\"Any process that activates or increases the rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding.\" [GO:jl]","metadata":null},{"id":"b5dd6549276f4324be509488ef4004b1","type":"GO_TERM","name":"positive regulation of monoatomic anion transport","canonical_id":"go:GO:1903793","description":"\"Any process that activates or increases the frequency, rate or extent of anion transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:11336802]","metadata":null},{"id":"9f14e2bb1db74919abd0fee3d72f5a07","type":"GO_TERM","name":"positive regulation of monoatomic ion transmembrane transport","canonical_id":"go:GO:0034767","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of ions from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"1d8a93a03c9646589176529595b0030b","type":"GO_TERM","name":"positive regulation of monoatomic ion transport","canonical_id":"go:GO:0043270","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"f6e5bf33862c48528f3fa1679deda6c0","type":"GO_TERM","name":"positive regulation of monocyte aggregation","canonical_id":"go:GO:1900625","description":"\"Any process that activates or increases the frequency, rate or extent of monocyte aggregation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"ed3f673c515844be85b49729c86adab2","type":"GO_TERM","name":"positive regulation of monocyte antigen processing and presentation","canonical_id":"go:GO:0002615","description":"\"Any process that activates or increases the frequency, rate, or extent of monocyte antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"49df609cd2a24670b70786b5a60cb538","type":"GO_TERM","name":"positive regulation of monocyte chemotactic protein-1 production","canonical_id":"go:GO:0071639","description":"\"Any process that activates or increases the frequency, rate, or extent of production of monocyte chemotactic protein-1.\" [GOC:mah]","metadata":null},{"id":"ddb94eb51cc748bcbf8a377f4c4a58ee","type":"GO_TERM","name":"positive regulation of monocyte chemotaxis","canonical_id":"go:GO:0090026","description":"\"Any process that increases the frequency, rate, or extent of monocyte chemotaxis.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9b00830ad8514662941eaed763549ec1","type":"GO_TERM","name":"positive regulation of monocyte differentiation","canonical_id":"go:GO:0045657","description":"\"Any process that activates or increases the frequency, rate or extent of monocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"6a21adb3e1854157b6ac31010b681660","type":"GO_TERM","name":"positive regulation of monocyte extravasation","canonical_id":"go:GO:2000439","description":"\"Any process that activates or increases the frequency, rate or extent of monocyte extravasation.\" [GOC:obol]","metadata":null},{"id":"e05c593251a146a9a6334ccbcdfc385e","type":"GO_TERM","name":"positive regulation of monodictyphenone biosynthetic process","canonical_id":"go:GO:1900845","description":"\"Any process that activates or increases the frequency, rate or extent of monodictyphenone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"19cae019770d4af29836fe056c7f6edd","type":"GO_TERM","name":"positive regulation of mononuclear cell migration","canonical_id":"go:GO:0071677","description":"\"Any process that increases the rate, frequency or extent of mononuclear cell migration. Mononuclear cell migration is the movement of a mononuclear cell within or between different tissues and organs of the body.\" [GOC:mah]","metadata":null},{"id":"db878e055ea84f6cb099028fbb5a812e","type":"GO_TERM","name":"positive regulation of mononuclear cell proliferation","canonical_id":"go:GO:0032946","description":"\"Any process that activates or increases the frequency, rate or extent of mononuclear cell proliferation.\" [GOC:add]","metadata":null},{"id":"b16711afcf57402180c1eb3ac473034e","type":"GO_TERM","name":"positive regulation of monopolar cell growth","canonical_id":"go:GO:0051515","description":"\"Any process that activates or increases the frequency, rate or extent of monopolar cell growth, polarized growth from one end of a cell.\" [GOC:ai]","metadata":null},{"id":"e6d8a8a90c6d4f7d90b5ad6b5ee7bf1d","type":"GO_TERM","name":"positive regulation of morphogenesis of an epithelium","canonical_id":"go:GO:1905332","description":"\"Any process that activates or increases the frequency, rate or extent of morphogenesis of an epithelium.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25745997]","metadata":null},{"id":"42a6dc7e1af548bf98fdfc0ced4d9a44","type":"GO_TERM","name":"positive regulation of motile cilium assembly","canonical_id":"go:GO:1905505","description":"\"Any process that activates or increases the frequency, rate or extent of motile cilium assembly.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:25294941]","metadata":null},{"id":"c4433b0c0ddd4f6ca26c45c6f5410b76","type":"GO_TERM","name":"positive regulation of motor neuron apoptotic process","canonical_id":"go:GO:2000673","description":"\"Any process that activates or increases the frequency, rate or extent of motor neuron apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"e8a07136e5254f22a1b72a0e029d11cb","type":"GO_TERM","name":"positive regulation of motor neuron axon guidance","canonical_id":"go:GO:1905814","description":"\"Any process that activates or increases the frequency, rate or extent of motor neuron axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:18434533]","metadata":null},{"id":"67551663ab0542dc9299bd2276f65f1e","type":"GO_TERM","name":"positive regulation of motor neuron migration","canonical_id":"go:GO:1905485","description":"\"Any process that activates or increases the frequency, rate or extent of motor neuron migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"a447b83a0e87421293ba9c7151c613f5","type":"GO_TERM","name":"positive regulation of mucus secretion","canonical_id":"go:GO:0070257","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of mucus from a cell or a tissue.\" [GOC:add]","metadata":null},{"id":"8fbe63e9744041e4a0e549d2b517e2f8","type":"GO_TERM","name":"positive regulation of multicellular organism growth","canonical_id":"go:GO:0040018","description":"\"Any process that activates or increases the frequency, rate or extent of growth of an organism to reach its usual body size.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"0d6c676261a944c597df6fb6d6c0a017","type":"GO_TERM","name":"positive regulation of multicellular organismal process","canonical_id":"go:GO:0051240","description":"\"Any process that activates or increases the frequency, rate or extent of an organismal process, any of the processes pertinent to the function of an organism above the cellular level; includes the integrated processes of tissues and organs.\" [GOC:ai]","metadata":null},{"id":"4b810d86f15348a09e0b1b41cc084958","type":"GO_TERM","name":"positive regulation of muscle adaptation","canonical_id":"go:GO:0014744","description":"\"Any process that activates or increases the frequency, rate or extent of muscle adaptation.\" [GOC:mtg_muscle]","metadata":null},{"id":"a08088da773b412da3c3232d890024f7","type":"GO_TERM","name":"positive regulation of muscle atrophy","canonical_id":"go:GO:0014737","description":"\"Any process that activates or increases the frequency, rate or extent of muscle atrophy.\" [GOC:mtg_muscle]","metadata":null},{"id":"5a992661ae4b40d4a8a8807b16d11bdc","type":"GO_TERM","name":"positive regulation of muscle cell apoptotic process","canonical_id":"go:GO:0010661","description":"\"Any process that increases the rate or frequency of muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"117762329c0a43c288d189e206da5f87","type":"GO_TERM","name":"positive regulation of muscle cell differentiation","canonical_id":"go:GO:0051149","description":"\"Any process that activates or increases the frequency, rate or extent of muscle cell differentiation.\" [CL:0000187, GOC:ai]","metadata":null},{"id":"e80421d6dada44ac9d7ee99efb66be0d","type":"GO_TERM","name":"positive regulation of muscle contraction","canonical_id":"go:GO:0045933","description":"\"Any process that activates or increases the frequency, rate or extent of muscle contraction.\" [GOC:curators]","metadata":null},{"id":"a7e12014b305428a90ec0ec825b2448d","type":"GO_TERM","name":"positive regulation of muscle filament sliding","canonical_id":"go:GO:1904114","description":"\"Any process that activates or increases the frequency, rate or extent of muscle filament sliding.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25717181]","metadata":null},{"id":"287d5544b4c240acabc988902b936a25","type":"GO_TERM","name":"positive regulation of muscle hyperplasia","canonical_id":"go:GO:0014739","description":"\"Any process that activates or increases the frequency, rate or extent of muscle hyperplasia.\" [GOC:mtg_muscle]","metadata":null},{"id":"60bba34fa5f34512810f2c2c83bf263a","type":"GO_TERM","name":"positive regulation of muscle hypertrophy","canonical_id":"go:GO:0014742","description":"\"Any process that activates or increases the frequency, rate or extent of muscle hypertrophy.\" [GOC:mtg_muscle]","metadata":null},{"id":"fea668c5dfea49768c66da22b5174ec4","type":"GO_TERM","name":"positive regulation of muscle organ development","canonical_id":"go:GO:0048636","description":"\"Any process that activates, maintains or increases the rate of muscle development.\" [GOC:curators]","metadata":null},{"id":"c66fc97a02ab40fc9fdecd69934ae10b","type":"GO_TERM","name":"positive regulation of muscle tissue development","canonical_id":"go:GO:1901863","description":"\"Any process that activates or increases the frequency, rate or extent of muscle tissue development.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"843b4582012146ffaeb12812fa4448a3","type":"GO_TERM","name":"positive regulation of myelination","canonical_id":"go:GO:0031643","description":"\"Any process that activates or increases the frequency, rate or extent of the formation of a myelin sheath around nerve axons.\" [GOC:mah]","metadata":null},{"id":"0b4ca4c870054efaa2f2851414612c8a","type":"GO_TERM","name":"positive regulation of myeloid cell apoptotic process","canonical_id":"go:GO:0033034","description":"\"Any process that activates or increases the frequency, rate, or extent of myeloid cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"e1613efd25b5479c8a6ee7bf4037d037","type":"GO_TERM","name":"positive regulation of myeloid cell differentiation","canonical_id":"go:GO:0045639","description":"\"Any process that activates or increases the frequency, rate or extent of myeloid cell differentiation.\" [GOC:curators]","metadata":null},{"id":"d24dd84982bf47ce865523542574ebd1","type":"GO_TERM","name":"positive regulation of myeloid dendritic cell activation","canonical_id":"go:GO:0030887","description":"\"Any process that stimulates, induces or increases the rate of myeloid dendritic cell activation.\" [GOC:mah]","metadata":null},{"id":"bb51844e035d4e0088c5662fc94c2d8a","type":"GO_TERM","name":"positive regulation of myeloid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002609","description":"\"Any process that activates or increases the frequency, rate, or extent of myeloid dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"c8261931cacf4dba9a16954eb316c1f7","type":"GO_TERM","name":"positive regulation of myeloid dendritic cell chemotaxis","canonical_id":"go:GO:2000529","description":"\"Any process that activates or increases the frequency, rate or extent of myeloid dendritic cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"c66adbfe43e94f5f888860192cea2cc0","type":"GO_TERM","name":"positive regulation of myeloid dendritic cell cytokine production","canonical_id":"go:GO:0002735","description":"\"Any process that activates or increases the frequency, rate, or extent of myeloid dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"8239bb8fe22d4c28a3482760c020002e","type":"GO_TERM","name":"positive regulation of myeloid leukocyte cytokine production involved in immune response","canonical_id":"go:GO:0061081","description":"\"Any process that modulates the rate, frequency, or extent of the production of a cytokine that contributes to the immune response.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"32f7aa3a2e4741369841bc1359b6a94d","type":"GO_TERM","name":"positive regulation of myeloid leukocyte differentiation","canonical_id":"go:GO:0002763","description":"\"Any process that activates or increases the frequency, rate, or extent of myeloid leukocyte differentiation.\" [GOC:add]","metadata":null},{"id":"5070bf0031334eb5a4ea3b20f083dddf","type":"GO_TERM","name":"positive regulation of myeloid leukocyte mediated immunity","canonical_id":"go:GO:0002888","description":"\"Any process that activates or increases the frequency, rate, or extent of myeloid leukocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"e597297ae41a4800bc0833ca686251b8","type":"GO_TERM","name":"positive regulation of myeloid progenitor cell differentiation","canonical_id":"go:GO:1905455","description":"\"Any process that activates or increases the frequency, rate or extent of myeloid progenitor cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27010503]","metadata":null},{"id":"fc2a2285d0474a55833b811617e56f43","type":"GO_TERM","name":"positive regulation of myoblast differentiation","canonical_id":"go:GO:0045663","description":"\"Any process that activates or increases the frequency, rate or extent of myoblast differentiation. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:curators, GOC:mtg_muscle]","metadata":null},{"id":"221027c81f8241b19b630afae5a528b8","type":"GO_TERM","name":"positive regulation of myoblast fusion","canonical_id":"go:GO:1901741","description":"\"Any process that activates or increases the frequency, rate or extent of myoblast fusion.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21364645]","metadata":null},{"id":"a60630f117684ebc8dad7dcbe5a6615a","type":"GO_TERM","name":"positive regulation of myoblast proliferation","canonical_id":"go:GO:2000288","description":"\"Any process that activates or increases the frequency, rate or extent of myoblast proliferation.\" [GOC:BHF]","metadata":null},{"id":"25e05b637a1049ffa8318c0899239359","type":"GO_TERM","name":"positive regulation of myofibroblast cell apoptotic process","canonical_id":"go:GO:1904522","description":"\"Any process that activates or increases the frequency, rate or extent of myofibroblast cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:26119034]","metadata":null},{"id":"c03ccb6642ae40548614c7917202850e","type":"GO_TERM","name":"positive regulation of myofibroblast contraction","canonical_id":"go:GO:1904330","description":"\"Any process that activates or increases the frequency, rate or extent of myofibroblast contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:19239477]","metadata":null},{"id":"8993b5dc5e404b90a19dbe8f0b2eae8c","type":"GO_TERM","name":"positive regulation of myofibroblast differentiation","canonical_id":"go:GO:1904762","description":"\"Any process that activates or increases the frequency, rate or extent of myofibroblast differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20533548]","metadata":null},{"id":"1433a2f725c34628b6bd4d938af8efc0","type":"GO_TERM","name":"positive regulation of myosin II filament assembly","canonical_id":"go:GO:1905511","description":"\"Any process that activates or increases the frequency, rate or extent of myosin II filament assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27237792, PMID:7691416]","metadata":null},{"id":"044dea27914548a9b6f1644212ebcbb0","type":"GO_TERM","name":"positive regulation of myosin II filament organization","canonical_id":"go:GO:1904901","description":"\"Any process that activates or increases the frequency, rate or extent of myosin II filament organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:22761445]","metadata":null},{"id":"34ce40d1db42467abba0aa4642e0313b","type":"GO_TERM","name":"positive regulation of myotome development","canonical_id":"go:GO:2000287","description":"\"Any process that activates or increases the frequency, rate or extent of myotome development.\" [GOC:BHF]","metadata":null},{"id":"c6fb8585fc3c451a934f740dcfd159bf","type":"GO_TERM","name":"positive regulation of myotube cell migration","canonical_id":"go:GO:0110124","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of myotube cell migration.\" [GOC:ha, PMID:29122742]","metadata":null},{"id":"b3bb2ea42662469cbba22b13e8c9dde7","type":"GO_TERM","name":"positive regulation of myotube differentiation","canonical_id":"go:GO:0010831","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of myotube differentiation. Myotube differentiation is the process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e40a95fc4d8c437d9ad74ff5c547bcda","type":"GO_TERM","name":"positive regulation of naphtho-gamma-pyrone biosynthetic process","canonical_id":"go:GO:1900848","description":"\"Any process that activates or increases the frequency, rate or extent of naphtho-gamma-pyrone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b5fe85a7df4c47a28899a4d7e5d0a6a2","type":"GO_TERM","name":"positive regulation of natural killer cell activation","canonical_id":"go:GO:0032816","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell activation.\" [GOC:mah]","metadata":null},{"id":"1a0d755f2cd248318a668eb528d9c895","type":"GO_TERM","name":"positive regulation of natural killer cell apoptotic process","canonical_id":"go:GO:0070249","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"6239669af94a4eda947059977579f531","type":"GO_TERM","name":"positive regulation of natural killer cell chemotaxis","canonical_id":"go:GO:2000503","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell chemotaxis.\" [GOC:BHF]","metadata":null},{"id":"280d10db661644a6b63a5e0154de4031","type":"GO_TERM","name":"positive regulation of natural killer cell cytokine production","canonical_id":"go:GO:0002729","description":"\"Any process that activates or increases the frequency, rate, or extent of natural killer cell cytokine production.\" [GOC:add]","metadata":null},{"id":"ec985ec12d3c41088e487aafac318c75","type":"GO_TERM","name":"positive regulation of natural killer cell degranulation","canonical_id":"go:GO:0043323","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"71eadbf5763e4f0ab61a97dfcca8b13c","type":"GO_TERM","name":"positive regulation of natural killer cell differentiation","canonical_id":"go:GO:0032825","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell differentiation.\" [GOC:mah]","metadata":null},{"id":"3b25e6879c154f238262f21226b146cb","type":"GO_TERM","name":"positive regulation of natural killer cell mediated cytotoxicity","canonical_id":"go:GO:0045954","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5a066d70bda24838a3fca3392e0a5aa3","type":"GO_TERM","name":"positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002860","description":"\"Any process that activates or increases the frequency, rate, or extent of natural killer cell mediated cytotoxicity directed against tumor cell target.\" [GOC:add]","metadata":null},{"id":"4a96abeb83cd4075a44ac70afff2661d","type":"GO_TERM","name":"positive regulation of natural killer cell mediated immune response to tumor cell","canonical_id":"go:GO:0002857","description":"\"Any process that activates or increases the frequency, rate, or extent of natural killer cell mediated immune response to a tumor cell.\" [GOC:add]","metadata":null},{"id":"eeaf86ca67994f5da16d432f55dd44bd","type":"GO_TERM","name":"positive regulation of natural killer cell mediated immunity","canonical_id":"go:GO:0002717","description":"\"Any process that activates or increases the frequency, rate, or extent of natural killer cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"811bbfd785ee490ab2d28cad484bcb2d","type":"GO_TERM","name":"positive regulation of natural killer cell proliferation","canonical_id":"go:GO:0032819","description":"\"Any process that activates or increases the frequency, rate or extent of natural killer cell proliferation.\" [GOC:mah]","metadata":null},{"id":"fd7b12b4fa0f47e793bb42bad3aafd0b","type":"GO_TERM","name":"positive regulation of natural killer cell tolerance induction","canonical_id":"go:GO:0002873","description":"\"Any process that activates or increases the frequency, rate, or extent of natural killer cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"0a2e929023834fac97d81619983a3f43","type":"GO_TERM","name":"positive regulation of necroptotic process","canonical_id":"go:GO:0060545","description":"\"Any process that increases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"18b07acdd2fd44719cfd984fe9b2c45a","type":"GO_TERM","name":"positive regulation of negative chemotaxis","canonical_id":"go:GO:0050924","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"df1e28bb9b4b43a79d53390a870e785e","type":"GO_TERM","name":"positive regulation of nematode larval development","canonical_id":"go:GO:0061063","description":"\"Any process that increases the rate, frequency, or extent of nematode larval development, the process whose specific outcome is the progression of the nematode larva over time, from its formation to the mature structure. Nematode larval development begins with the newly hatched first-stage larva (L1) and ends with the end of the last larval stage (for example the fourth larval stage (L4) in C. elegans). Each stage of nematode larval development is characterized by proliferation of specific cell lineages and an increase in body size without alteration of the basic body plan. Nematode larval stages are separated by molts in which each stage-specific exoskeleton, or cuticle, is shed and replaced anew.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"87a2bc7d4c3a41d6a7afbf474c469d46","type":"GO_TERM","name":"positive regulation of nematode larval development, heterochronic","canonical_id":"go:GO:0090445","description":"\"Any process that modulates the consistent predetermined time point at which a nematode larva progresses from an initial condition to a later condition and increases the rate at which this time point is reached.\" [PMID:17550772]","metadata":null},{"id":"4fe2a07b579644b685c87579f99d6901","type":"GO_TERM","name":"positive regulation of nematode male tail tip morphogenesis","canonical_id":"go:GO:0110039","description":"\"Any process that activates or increases the frequency, rate or extent of nematode male tail tip morphogenesis.\" [GOC:rz, PMID:28068334]","metadata":null},{"id":"44da65bfc05c4469ba164e06e4b08a4a","type":"GO_TERM","name":"positive regulation of nematode pharyngeal pumping","canonical_id":"go:GO:1903746","description":"\"Any process that activates or increases the frequency, rate or extent of nematode pharyngeal pumping.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25329901]","metadata":null},{"id":"4939f8e1bd094ec691f28cafd50d6b86","type":"GO_TERM","name":"positive regulation of nematode pharynx morphogenesis","canonical_id":"go:GO:0110043","description":"\"Any process that activates or increases the frequency, rate or extent of nematode pharynx morphogenesis.\" [GOC:rz, PMID:20805556]","metadata":null},{"id":"733e7d9e41d54c9996a19d20f7e8248c","type":"GO_TERM","name":"positive regulation of neosartoricin biosynthetic process","canonical_id":"go:GO:1902055","description":"\"Any process that activates or increases the frequency, rate or extent of neosartoricin biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:23368997]","metadata":null},{"id":"456edc54745141ac8d69c533f3342916","type":"GO_TERM","name":"positive regulation of nephron tubule epithelial cell differentiation","canonical_id":"go:GO:2000768","description":"\"Any process that activates or increases the frequency, rate or extent of nephron tubule epithelial cell differentiation.\" [GOC:obol]","metadata":null},{"id":"495eb1548c994e77a9f68b160df9112b","type":"GO_TERM","name":"positive regulation of nervous system development","canonical_id":"go:GO:0051962","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of nervous system development, the origin and formation of nervous tissue.\" [GOC:ai]","metadata":null},{"id":"3ec6ff0b522c47768101cd5fd25615b7","type":"GO_TERM","name":"positive regulation of nervous system process","canonical_id":"go:GO:0031646","description":"\"Any process that activates or increases the frequency, rate or extent of a neurophysiological process.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"2072d616c689402db7c6f9942b652ff0","type":"GO_TERM","name":"positive regulation of netrin-activated signaling pathway","canonical_id":"go:GO:1902843","description":"\"Any process that activates or increases the frequency, rate or extent of netrin-activated signaling pathway.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:24004945]","metadata":null},{"id":"8fed5042291d489b80beeb26fc502a73","type":"GO_TERM","name":"positive regulation of neural crest cell differentiation","canonical_id":"go:GO:1905294","description":"\"Any process that activates or increases the frequency, rate or extent of neural crest cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15073157]","metadata":null},{"id":"8b5beacb16b340a8a9a0a261958ebe19","type":"GO_TERM","name":"positive regulation of neural crest cell fate specification","canonical_id":"go:GO:1905297","description":"\"Any process that activates or increases the frequency, rate or extent of neural crest cell fate specification.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15073157]","metadata":null},{"id":"ee044544add34b3b87bd4f83983ad54d","type":"GO_TERM","name":"positive regulation of neural crest formation","canonical_id":"go:GO:0090300","description":"\"Any process that increases the rate, frequency, or extent of neural crest formation. Neural crest formation is the formation of the specialized region of ectoderm between the neural ectoderm (neural plate) and non-neural ectoderm. The neural crest gives rise to the neural crest cells that migrate away from this region as neural tube formation proceeds.\" [GOC:tb]","metadata":null},{"id":"f38347b6c5de487ea8eb7e8330c15015","type":"GO_TERM","name":"positive regulation of neural precursor cell proliferation","canonical_id":"go:GO:2000179","description":"\"Any process that activates or increases the frequency, rate or extent of neural precursor cell proliferation.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"5cc4b0c8735d4cfa994c2aad1bbab7bf","type":"GO_TERM","name":"positive regulation of neural retina development","canonical_id":"go:GO:0061075","description":"\"Any process that increases the rate, frequency, or extent of neural retina development, the progression of the neural retina over time from its initial formation to the mature structure. The neural retina is the part of the retina that contains neurons and photoreceptor cells.\" [GOC:dph]","metadata":null},{"id":"719639558a954d238ef18d6b51335fb4","type":"GO_TERM","name":"positive regulation of neuroblast migration","canonical_id":"go:GO:0061854","description":"\"Any process that activates or increases the frequency, rate or extent of neuroblast migration.\" [PMID:23149556]","metadata":null},{"id":"3c5f97ceba974932b39f7ab4cb34a9a2","type":"GO_TERM","name":"positive regulation of neuroblast proliferation","canonical_id":"go:GO:0002052","description":"\"Any process that activates or increases the rate of neuroblast proliferation.\" [GOC:dph]","metadata":null},{"id":"b111e4ea266e427596fc09311f1f5b3c","type":"GO_TERM","name":"positive regulation of neuroepithelial cell differentiation","canonical_id":"go:GO:1902913","description":"\"Any process that activates or increases the frequency, rate or extent of neuroepithelial cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16916506]","metadata":null},{"id":"15eeca30b8454d829a880c9e4e0a1578","type":"GO_TERM","name":"positive regulation of neurofibrillary tangle assembly","canonical_id":"go:GO:1902998","description":"\"Any process that activates or increases the frequency, rate or extent of neurofibrillary tangle assembly.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:15897157]","metadata":null},{"id":"12a94074b7e445b1855c4e2034ff8a96","type":"GO_TERM","name":"positive regulation of neurogenesis","canonical_id":"go:GO:0050769","description":"\"Any process that activates or increases the frequency, rate or extent of neurogenesis, the generation of cells within the nervous system.\" [GOC:ai]","metadata":null},{"id":"1d2600a8b7e343fe81b9c458ab3e2c0d","type":"GO_TERM","name":"positive regulation of neuroinflammatory response","canonical_id":"go:GO:0150078","description":"\"Any process that activates or increases the frequency, rate or extent of neuroinflammatory response.\" [GOC:aruk, GOC:bc]","metadata":null},{"id":"13c6e6cbcf344ad69a5ce5d54218e3e7","type":"GO_TERM","name":"positive regulation of neuromuscular junction development","canonical_id":"go:GO:1904398","description":"\"Any process that activates or increases the frequency, rate or extent of neuromuscular junction development.\" [GO_REF:0000058, GOC:TermGenie, PMID:7722643]","metadata":null},{"id":"41de78ee70b045498e0aaecd9a6d5f72","type":"GO_TERM","name":"positive regulation of neuromuscular synaptic transmission","canonical_id":"go:GO:1900075","description":"\"Any process that activates or increases the frequency, rate or extent of neuromuscular synaptic transmission.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"b5875cbb2f614a1488c65b75f5d4d5fa","type":"GO_TERM","name":"positive regulation of neuron apoptotic process","canonical_id":"go:GO:0043525","description":"\"Any process that activates or increases the frequency, rate or extent of cell death of neurons by apoptotic process.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"5cf5029b9c3543c9b5184d8069484e1a","type":"GO_TERM","name":"positive regulation of neuron differentiation","canonical_id":"go:GO:0045666","description":"\"Any process that activates or increases the frequency, rate or extent of neuron differentiation.\" [GOC:curators]","metadata":null},{"id":"bac26aeb7ff54041b8a08c2e7ac0ae61","type":"GO_TERM","name":"positive regulation of neuron maturation","canonical_id":"go:GO:0014042","description":"\"Any process that activates or increases the frequency, rate or extent of neuron maturation.\" [GOC:ef]","metadata":null},{"id":"c500454892184aee961e5a13659ba8f7","type":"GO_TERM","name":"positive regulation of neuron migration","canonical_id":"go:GO:2001224","description":"\"Any process that activates or increases the frequency, rate or extent of neuron migration.\" [GOC:obol]","metadata":null},{"id":"cbcabf2ea0a743a7b2144d39309676ac","type":"GO_TERM","name":"positive regulation of neuron projection arborization","canonical_id":"go:GO:0150012","description":"\"Any process that activates or increases the frequency, rate or extent of the process in which the anatomical structures of a neuron projection are generated and organized into branches.\" [GOC:aruk, GOC:bc, PMID:17114044]","metadata":null},{"id":"b8c6fef3f53d4ba68a27d59ce27e9436","type":"GO_TERM","name":"positive regulation of neuron projection development","canonical_id":"go:GO:0010976","description":"\"Any process that increases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1303531bc69843648b8e7e7072f4e57d","type":"GO_TERM","name":"positive regulation of neuron projection regeneration","canonical_id":"go:GO:0070572","description":"\"Any process that activates or increases the frequency, rate or extent of neuron projection regeneration, the regrowth of neuronal processes such as axons or dendrites following their loss or damage.\" [GOC:mah]","metadata":null},{"id":"04744f3dcb0b49d0a231993a55af66c4","type":"GO_TERM","name":"positive regulation of neuron remodeling","canonical_id":"go:GO:1904801","description":"\"Any process that activates or increases the frequency, rate or extent of neuron remodeling.\" [GO_REF:0000058, GOC:TermGenie, PMID:21609829]","metadata":null},{"id":"0491fcbce22647eeacf32e2c21a1255e","type":"GO_TERM","name":"positive regulation of neuronal action potential","canonical_id":"go:GO:1904457","description":"\"Any process that activates or increases the frequency, rate or extent of neuronal action potential.\" [GO_REF:0000058, GOC:TermGenie, PMID:25126967]","metadata":null},{"id":"d43030cb510342799da6f5b4fc571786","type":"GO_TERM","name":"positive regulation of neuronal signal transduction","canonical_id":"go:GO:1902849","description":"\"Any process that activates or increases the frequency, rate or extent of neuronal signal transduction.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie]","metadata":null},{"id":"38d8e3119ee946e58f0d9632d6b48073","type":"GO_TERM","name":"positive regulation of neurotransmitter secretion","canonical_id":"go:GO:0001956","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of a neurotransmitter.\" [GOC:hjd]","metadata":null},{"id":"4e4e56bb0caf4c76b6b9667fd67f6d7b","type":"GO_TERM","name":"positive regulation of neurotransmitter transport","canonical_id":"go:GO:0051590","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"54575db74a204e1bb796474c9a4fb5b8","type":"GO_TERM","name":"positive regulation of neurotransmitter uptake","canonical_id":"go:GO:0051582","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell.\" [GOC:ai]","metadata":null},{"id":"0650e6f63e8f412498a4e0659287dbe1","type":"GO_TERM","name":"positive regulation of neurotrophin TRK receptor signaling pathway","canonical_id":"go:GO:0051388","description":"\"Any process that activates or increases the frequency, rate or extent of the neurotrophin TRK receptor signaling pathway.\" [GOC:ai]","metadata":null},{"id":"0c9fee265fd04749874fc1aebab1c205","type":"GO_TERM","name":"positive regulation of neurotrophin production","canonical_id":"go:GO:0032901","description":"\"Any process that activates or increases the frequency, rate, or extent of production of a neurotrophin.\" [GOC:mah]","metadata":null},{"id":"d2612d5811734ac9b3ded3d1fb6aa661","type":"GO_TERM","name":"positive regulation of neutrophil activation","canonical_id":"go:GO:1902565","description":"\"Any process that activates or increases the frequency, rate or extent of neutrophil activation.\" [GOC:TermGenie, PMID:17588661]","metadata":null},{"id":"161c3bf287694d4e9582484b00530b97","type":"GO_TERM","name":"positive regulation of neutrophil aggregation","canonical_id":"go:GO:2000430","description":"\"Any process that activates or increases the frequency, rate or extent of neutrophil aggregation.\" [GOC:BHF]","metadata":null},{"id":"cb77d3b214ab4842a4157a771bbc2966","type":"GO_TERM","name":"positive regulation of neutrophil apoptotic process","canonical_id":"go:GO:0033031","description":"\"Any process that activates or increases the frequency, rate, or extent of neutrophil apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"b6a7e7ac6c204d10ae3c01540259d244","type":"GO_TERM","name":"positive regulation of neutrophil chemotaxis","canonical_id":"go:GO:0090023","description":"\"Any process that increases the frequency, rate, or extent of neutrophil chemotaxis. Neutrophil chemotaxis is the directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"faf9b12d7e084b15afe8021cb923999f","type":"GO_TERM","name":"positive regulation of neutrophil degranulation","canonical_id":"go:GO:0043315","description":"\"Any process that activates or increases the frequency, rate or extent of neutrophil degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"ede7a3ee1edb4318be95e6f765eb4f19","type":"GO_TERM","name":"positive regulation of neutrophil differentiation","canonical_id":"go:GO:0045660","description":"\"Any process that activates or increases the frequency, rate or extent of neutrophil differentiation.\" [GOC:curators]","metadata":null},{"id":"b8debd9ab2d1425297f61cd5624c0d47","type":"GO_TERM","name":"positive regulation of neutrophil extravasation","canonical_id":"go:GO:2000391","description":"\"Any process that activates or increases the frequency, rate or extent of neutrophil extravasation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"f285ab1711fc445b90c37437ca199c33","type":"GO_TERM","name":"positive regulation of neutrophil mediated cytotoxicity","canonical_id":"go:GO:0070960","description":"\"Any process that increases the frequency, rate or extent of the directed killing of a target cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"84c9e888dc63493e98df42cfa5810d09","type":"GO_TERM","name":"positive regulation of neutrophil mediated killing of bacterium","canonical_id":"go:GO:0070962","description":"\"Any process that increases the frequency, rate or extent of the directed killing of a bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"9089c739b243442b91defbe24f9bc3ab","type":"GO_TERM","name":"positive regulation of neutrophil mediated killing of fungus","canonical_id":"go:GO:0070965","description":"\"Any process that increases the frequency, rate or extent of the directed killing of a fungal cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"e4a49285f77d4eb78cc1b29a7970752a","type":"GO_TERM","name":"positive regulation of neutrophil mediated killing of gram-negative bacterium","canonical_id":"go:GO:0070963","description":"\"Any process that increases the frequency, rate or extent of the directed killing of a gram-negative bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"8789b658446246f3971b4260c07abfdb","type":"GO_TERM","name":"positive regulation of neutrophil mediated killing of gram-positive bacterium","canonical_id":"go:GO:0070964","description":"\"Any process that increases the frequency, rate or extent of the directed killing of a gram-positive bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"c0b90cad9ab6495abf21a9d0cf040146","type":"GO_TERM","name":"positive regulation of neutrophil mediated killing of symbiont cell","canonical_id":"go:GO:0070961","description":"\"Any process that increases the frequency, rate or extent of the directed killing of a symbiont target cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"d77d95339d38475ca7030266d9d1578f","type":"GO_TERM","name":"positive regulation of neutrophil migration","canonical_id":"go:GO:1902624","description":"\"Any process that activates or increases the frequency, rate or extent of neutrophil migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:1826836]","metadata":null},{"id":"c60b220c44df4c6caed8e6519ae7a23b","type":"GO_TERM","name":"positive regulation of nicotine catabolic process","canonical_id":"go:GO:0160160","description":"\"Any process that activates or increases the frequency, rate or extent of nicotine catabolic process.\" [PMID:15838033]","metadata":null},{"id":"2550b23f01fb440b9aa51ed8ca10f8f6","type":"GO_TERM","name":"positive regulation of nigerotriose transport","canonical_id":"go:GO:1900359","description":"\"Any process that activates or increases the frequency, rate or extent of nigerotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"87a44f3bd1054c6f8af517f06fd111eb","type":"GO_TERM","name":"positive regulation of nitric oxide biosynthetic process","canonical_id":"go:GO:0045429","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.\" [GOC:curators]","metadata":null},{"id":"daa5f9c0b6c2455582aba1944f9c3486","type":"GO_TERM","name":"positive regulation of nitric oxide-cGMP mediated signal transduction","canonical_id":"go:GO:0141150","description":"\"Any process that increases the rate, frequency or extent of nitric oxide-cGMP mediated signal transduction.\" [PMID:14615391]","metadata":null},{"id":"5ddc119389ef4f7180ce01c4b0fbd7fc","type":"GO_TERM","name":"positive regulation of nitric-oxide synthase activity","canonical_id":"go:GO:0051000","description":"\"Any process that activates or increases the activity of the enzyme nitric-oxide synthase.\" [GOC:ai]","metadata":null},{"id":"77b178f192454d94a64c2bda7b1d8d85","type":"GO_TERM","name":"positive regulation of nitrogen utilization","canonical_id":"go:GO:0045848","description":"\"Any process that activates or increases the frequency, rate or extent of nitrogen utilization.\" [GOC:curators]","metadata":null},{"id":"310ecc422fa042e682bac22d52c9a901","type":"GO_TERM","name":"positive regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1905260","description":"\"Any process that activates or increases the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to nitrosative stress.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"16e63adea6f24b48961daf4db96774e2","type":"GO_TERM","name":"positive regulation of nodal signaling pathway","canonical_id":"go:GO:0141092","description":"\"Any process that increases the rate, frequency or extent of nodal signaling pathway.\" [PMID:17239842]","metadata":null},{"id":"d4a33ea6df404eb9b148c8b420bc2e21","type":"GO_TERM","name":"positive regulation of non-canonical NF-kappaB signal transduction","canonical_id":"go:GO:1901224","description":"\"Any process that activates or increases the frequency, rate or extent of the non-canonical NF-kappaB cascade.\" [GOC:TermGenie]","metadata":null},{"id":"3bea3636ef2b4cfe9a575585f05f40fe","type":"GO_TERM","name":"positive regulation of non-canonical Wnt signaling pathway","canonical_id":"go:GO:2000052","description":"\"Any process that activates or increases the frequency, rate or extent of non-canonical Wnt-activated signaling pathway.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"20c26d964fb941deb804bfbb63e5083e","type":"GO_TERM","name":"positive regulation of non-motile cilium assembly","canonical_id":"go:GO:1902857","description":"\"Any process that activates or increases the frequency, rate or extent of non-motile cilium assembly.\" [GO_REF:0000058, GOC:cilia, GOC:kmv, GOC:TermGenie, PMID:23807208]","metadata":null},{"id":"741fa35523d8418c90a5bec6f4c79521","type":"GO_TERM","name":"positive regulation of non-professional antigen presenting cell antigen processing and presentation","canonical_id":"go:GO:0002621","description":"\"Any process that activates or increases the frequency, rate, or extent of non-professional antigen presenting cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"8679282e87664717b427d4a8bbead823","type":"GO_TERM","name":"positive regulation of norepinephrine secretion","canonical_id":"go:GO:0010701","description":"\"Any process that increases the frequency, rate or extent of the regulated release of norepinephrine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"340c195e7daa407991423fb0fcafd29c","type":"GO_TERM","name":"positive regulation of norepinephrine uptake","canonical_id":"go:GO:0051623","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of norepinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"f06e3b020212468f9c29df911dd39f63","type":"GO_TERM","name":"positive regulation of nuclear cell cycle DNA replication","canonical_id":"go:GO:0010571","description":"\"Any process that activates or increases the frequency, rate or extent of the DNA-dependent DNA replication that occurs in the nucleus of eukaryotic organisms as part of the cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"41da87bb657a4c2ca347a9549de40d28","type":"GO_TERM","name":"positive regulation of nuclear division","canonical_id":"go:GO:0051785","description":"\"Any process that activates or increases the frequency, rate or extent of nuclear division, the partitioning of the nucleus and its genetic information.\" [GOC:ai]","metadata":null},{"id":"f668d1594d3f46fbb1781f46306220ab","type":"GO_TERM","name":"positive regulation of nuclear mRNA surveillance of meiosis-specific transcripts","canonical_id":"go:GO:0120272","description":"\"Any process that activates or increases the frequency, rate or extent of degradation of meiosis-specific nuclear transcribed transcripts during vegetative growth, by a mechanism that requires determinant of selective removal (DSR) sequences in the targeted mRNAs and involves a YTH family protein.\" [GOC:krc, PMID:24920274]","metadata":null},{"id":"360c78a6321444e0a497e9f340685f68","type":"GO_TERM","name":"positive regulation of nuclear migration along microtubule","canonical_id":"go:GO:1902840","description":"\"Any process that activates or increases the frequency, rate or extent of nuclear migration along microtubule.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"3398b1fd15cc4a679d6dde780bc69d83","type":"GO_TERM","name":"positive regulation of nuclear migration during mitotic telophase","canonical_id":"go:GO:1902854","description":"\"Any process that activates or increases the frequency, rate or extent of nuclear migration during mitotic telophase.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"7a9d149d9f1742c78280560af5798a41","type":"GO_TERM","name":"positive regulation of nuclear receptor-mediated glucocorticoid signaling pathway","canonical_id":"go:GO:2000324","description":"\"Any process that activates or increases the frequency, rate or extent of nuclear receptor-mediated glucocorticoid signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"5c7d4c81a15c4bdba9cfa72a7b6bf702","type":"GO_TERM","name":"positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay","canonical_id":"go:GO:1900153","description":"\"Any process that activates or increases the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay.\" [GOC:mcc, GOC:TermGenie]","metadata":null},{"id":"c0f81e3fab22458ebb552b0535beedf6","type":"GO_TERM","name":"positive regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay","canonical_id":"go:GO:2000624","description":"\"Any process that activates or increases the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay.\" [GOC:obol]","metadata":null},{"id":"2b4caf75936f433baa3bebed0c099abc","type":"GO_TERM","name":"positive regulation of nuclear-transcribed mRNA poly(A) tail shortening","canonical_id":"go:GO:0060213","description":"\"Any process that increases the frequency, rate or extent of poly(A) tail shortening of a nuclear-transcribed mRNA. Poly(A) tail shortening is the decrease in length of the poly(A) tail of an mRNA from full length to an oligo(A) length.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"506c1073d6514fe29a787fb5f1a1a786","type":"GO_TERM","name":"positive regulation of nucleobase-containing compound transport","canonical_id":"go:GO:0032241","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of nucleobases, nucleosides, nucleotides and nucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"165f522a442d44889c2eb3bac212d984","type":"GO_TERM","name":"positive regulation of nucleocytoplasmic transport","canonical_id":"go:GO:0046824","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of substances between the nucleus and the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"a2480a6ffc4040f290dd8e6b67d378a1","type":"GO_TERM","name":"positive regulation of nucleoside metabolic process","canonical_id":"go:GO:0045979","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving nucleosides.\" [GOC:curators]","metadata":null},{"id":"b41162bc3f9c46fa9971ecbb9749a97c","type":"GO_TERM","name":"positive regulation of nucleoside transport","canonical_id":"go:GO:0032244","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"7d3a93a32747482bb78b2ff50d5e50ba","type":"GO_TERM","name":"positive regulation of nucleosome disassembly","canonical_id":"go:GO:0140887","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled breakdown of nucleosomes, the beadlike structural units of eukaryotic chromatin composed of histones and DNA.\" [PMID:34471130, PMID:35308047]","metadata":null},{"id":"3b97310ff81d4bbd88035c156dcafd06","type":"GO_TERM","name":"positive regulation of nucleotide biosynthetic process","canonical_id":"go:GO:0030810","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nucleotides.\" [GOC:mah]","metadata":null},{"id":"7ba0a5e3b95b454b9a1da5536e9fc39b","type":"GO_TERM","name":"positive regulation of nucleotide catabolic process","canonical_id":"go:GO:0030813","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of nucleotides.\" [GOC:mah]","metadata":null},{"id":"6e6c7d37ab7445fcb4e8639771551400","type":"GO_TERM","name":"positive regulation of nucleotide metabolic process","canonical_id":"go:GO:0045981","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving nucleotides.\" [GOC:curators]","metadata":null},{"id":"ac54aeb81e41458795f3590833dd9901","type":"GO_TERM","name":"positive regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway","canonical_id":"go:GO:0070426","description":"\"Any process that activates or increases the frequency, rate, or extent of a nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (NLR) pathway.\" [GOC:add]","metadata":null},{"id":"63676885a7df488487b270309bc8ef66","type":"GO_TERM","name":"positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway","canonical_id":"go:GO:0070430","description":"\"Any process that activates or increases the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 1 (NOD1) pathway.\" [GOC:add]","metadata":null},{"id":"3ece3365db41414780c8e7bd24efec83","type":"GO_TERM","name":"positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway","canonical_id":"go:GO:0070434","description":"\"Any process that activates or increases the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 2 (NOD2) pathway.\" [GOC:add]","metadata":null},{"id":"fd86c6f097104a1c8909aea706a0ef74","type":"GO_TERM","name":"positive regulation of nurse cell apoptotic process","canonical_id":"go:GO:0045850","description":"\"Any process that activates or increases the frequency, rate or extent of nurse cell apoptotic process.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"7a643a8befa746b199b1d668aea9fb49","type":"GO_TERM","name":"positive regulation of nutrient release by host","canonical_id":"go:GO:0052092","description":"\"Any process in which an organism activates, maintains or increases the frequency, rate or extent of the release of nutrients from its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"812c50eba9824d34949c1dafc538689f","type":"GO_TERM","name":"positive regulation of nutrient release by symbiont","canonical_id":"go:GO:0052519","description":"\"Any process in which an organism activates, maintains or increases the frequency, rate or extent of the release of nutrients from a symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"4eac9700590a4d8aa6bc847d1b57b5ad","type":"GO_TERM","name":"positive regulation of o-orsellinic acid biosynthetic process","canonical_id":"go:GO:1900700","description":"\"Any process that activates or increases the frequency, rate or extent of o-orsellinic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2d7630323d1647eea89cba7308a93639","type":"GO_TERM","name":"positive regulation of octopamine or tyramine signaling pathway","canonical_id":"go:GO:2000127","description":"\"Any process that activates or increases the frequency, rate or extent of octopamine or tyramine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"47f93d6aa43c425897b6cc1ae4983e10","type":"GO_TERM","name":"positive regulation of octopamine signaling pathway","canonical_id":"go:GO:2000130","description":"\"Any process that activates or increases the frequency, rate or extent of octopamine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"994d652382fc486fb26ab80e47e39c22","type":"GO_TERM","name":"positive regulation of odontoblast differentiation","canonical_id":"go:GO:1901331","description":"\"Any process that activates or increases the frequency, rate or extent of odontoblast differentiation.\" [GOC:TermGenie]","metadata":null},{"id":"c7a0adff8ad34dfa831fe6a7555ad132","type":"GO_TERM","name":"positive regulation of odontogenesis","canonical_id":"go:GO:0042482","description":"\"Any process that activates or increases the frequency, rate or extent of the formation and development of a tooth or teeth.\" [GOC:jl]","metadata":null},{"id":"987413e2769f485ea2b911a4523e65a9","type":"GO_TERM","name":"positive regulation of odontogenesis of dentin-containing tooth","canonical_id":"go:GO:0042488","description":"\"Any process that activates or increases the frequency, rate or extent of the formation and development of teeth, the hard, bony appendages that are borne on the jaws, or on other bones in the walls of the mouth or pharynx of most vertebrates.\" [GOC:jl, PMID:15355794]","metadata":null},{"id":"1f82cb6895e24db3a92460c6a3033f27","type":"GO_TERM","name":"positive regulation of olefin biosynthetic process","canonical_id":"go:GO:1900913","description":"\"Any process that activates or increases the frequency, rate or extent of olefin biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"fd989b297d9349b081de512cd7a60184","type":"GO_TERM","name":"positive regulation of oligodendrocyte apoptotic process","canonical_id":"go:GO:1900143","description":"\"Any process that activates or increases the frequency, rate or extent of oligodendrocyte apoptotic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"1f73e2ae20684df4945997467c3e7168","type":"GO_TERM","name":"positive regulation of oligodendrocyte differentiation","canonical_id":"go:GO:0048714","description":"\"Any process that activates or increases the frequency, rate or extent of oligodendrocyte differentiation.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"e6cba5670db1425a8a2c6780957d104a","type":"GO_TERM","name":"positive regulation of oligodendrocyte progenitor proliferation","canonical_id":"go:GO:0070447","description":"\"Any process that activates or increases the rate or extent of oligodendrocyte progenitor proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"0c7133989d9c42009c471760a85293bf","type":"GO_TERM","name":"positive regulation of oligopeptide transport","canonical_id":"go:GO:2000878","description":"\"Any process that activates or increases the frequency, rate or extent of oligopeptide transport.\" [GOC:obol]","metadata":null},{"id":"688166711ced4dbf87c10e936ee24774","type":"GO_TERM","name":"positive regulation of oocyte development","canonical_id":"go:GO:0060282","description":"\"Any process that increases the rate or extent of the process whose specific outcome is the progression of an oocyte over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d88e1f06ba8b4668a43764c6d9b0bf4e","type":"GO_TERM","name":"positive regulation of oocyte karyosome formation","canonical_id":"go:GO:0120315","description":"\"Any process that activates or increases the frequency, rate or extent of oocyte karyosome formation, the chromosome organization process in which meiotic chromosomes in the oocyte nucleus cluster together to form a compact spherical structure called the karyosome.\" [GOC:ha, GOC:krc, PMID:33382409]","metadata":null},{"id":"9b7b527aeb444451b3c895bd366064b1","type":"GO_TERM","name":"positive regulation of oocyte maturation","canonical_id":"go:GO:1900195","description":"\"Any process that activates or increases the frequency, rate or extent of oocyte maturation.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"b605bd41f9a848379d8b07af688d804b","type":"GO_TERM","name":"positive regulation of oogenesis","canonical_id":"go:GO:1905881","description":"\"Any process that activates or increases the frequency, rate or extent of oogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:26434723]","metadata":null},{"id":"daa173a9806c44b2be856bc5b2ee7d82","type":"GO_TERM","name":"positive regulation of oogonium development","canonical_id":"go:GO:0075265","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of oogonium development, a process that leads to the formation of a female gametangium of oomycetes, containing one or more gametes.\" [GOC:pamgo_curators]","metadata":null},{"id":"0bef85f7f5a142cfb6235069ac761703","type":"GO_TERM","name":"positive regulation of oomycete sporangium development","canonical_id":"go:GO:0075323","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of oomycete sporangium development, a process that leads to the formation of oomycete sporangium, a single-celled or many-celled structure that germinates directly to form an infection hypha or differentiate, through specialized cleavage vesicles, into between 10 and 30 zoospores, which is laterally flagellated.\" [GOC:pamgo_curators]","metadata":null},{"id":"ba099147f97448f9993863fd747e068a","type":"GO_TERM","name":"positive regulation of oospore formation","canonical_id":"go:GO:0075245","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of oospore formation, a process in which male and female gametangia develop and fuse to form a thick-walled resting spore of oomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"b7c885aa17a544c2ac0b9183dc054c58","type":"GO_TERM","name":"positive regulation of opioid receptor signaling pathway","canonical_id":"go:GO:2000476","description":"\"Any process that activates or increases the frequency, rate or extent of opioid receptor signaling pathway.\" [GOC:obol]","metadata":null},{"id":"fa17381705f144d68b7a7f3b50d3706c","type":"GO_TERM","name":"positive regulation of opsonization","canonical_id":"go:GO:1903028","description":"\"Any process that activates or increases the frequency, rate or extent of opsonization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22333221]","metadata":null},{"id":"cee2194079914deaba6ffa90a5b90f52","type":"GO_TERM","name":"positive regulation of optic nerve formation","canonical_id":"go:GO:2000597","description":"\"Any process that activates or increases the frequency, rate or extent of optic nerve formation.\" [GOC:obol]","metadata":null},{"id":"111ae931ae274a738bdea57119c5eb10","type":"GO_TERM","name":"positive regulation of optical nerve axon regeneration","canonical_id":"go:GO:1905593","description":"\"Any process that activates or increases the frequency, rate or extent of optical nerve axon regeneration.\" [GO_REF:0000058, GOC:TermGenie, PMID:16699509]","metadata":null},{"id":"e86c8cfb6a334cb98cc6896188e2ed8a","type":"GO_TERM","name":"positive regulation of orcinol biosynthetic process","canonical_id":"go:GO:1900703","description":"\"Any process that activates or increases the frequency, rate or extent of orcinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f8ec1e633d0f4b93a9efb2df496cff3e","type":"GO_TERM","name":"positive regulation of organ growth","canonical_id":"go:GO:0046622","description":"\"Any process that activates or increases the frequency, rate or extent of growth of an organ of an organism.\" [GOC:bf, GOC:tb]","metadata":null},{"id":"2469fdf41c9c4fd581ed61b2189aa05b","type":"GO_TERM","name":"positive regulation of organelle assembly","canonical_id":"go:GO:1902117","description":"\"Any process that activates or increases the frequency, rate or extent of organelle assembly.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"c892f82703774805bf571dececcb14d3","type":"GO_TERM","name":"positive regulation of organelle organization","canonical_id":"go:GO:0010638","description":"\"Any process that increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of an organelle.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"44c90cbcc7454bcba4f74f00ce47a017","type":"GO_TERM","name":"positive regulation of organic acid transport","canonical_id":"go:GO:0032892","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of organic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"1d4633bdb5244579818ae99ce2a7be8d","type":"GO_TERM","name":"positive regulation of ornithine catabolic process","canonical_id":"go:GO:1903268","description":"\"Any process that activates or increases the frequency, rate or extent of ornithine catabolic process.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:12679340]","metadata":null},{"id":"6fefab49a7374fa88e0dca8ad89e8644","type":"GO_TERM","name":"positive regulation of oskar mRNA translation","canonical_id":"go:GO:0046012","description":"\"Any process that activates or increases the frequency, rate or extent of oskar mRNA translation.\" [GOC:curators]","metadata":null},{"id":"5cf40eb01a994bc4999c33c13ebcd98c","type":"GO_TERM","name":"positive regulation of ossification","canonical_id":"go:GO:0045778","description":"\"Any process that activates or increases the frequency, rate or extent of ossification, the formation of bone or of a bony substance or the conversion of fibrous tissue or of cartilage into bone or a bony substance.\" [GOC:curators]","metadata":null},{"id":"f9dda6f80b0540379411047e3e196d9f","type":"GO_TERM","name":"positive regulation of osteoblast differentiation","canonical_id":"go:GO:0045669","description":"\"Any process that activates or increases the frequency, rate or extent of osteoblast differentiation.\" [GOC:curators]","metadata":null},{"id":"f7f01e15d71448b8b21e7cdeb4b3f04b","type":"GO_TERM","name":"positive regulation of osteoblast proliferation","canonical_id":"go:GO:0033690","description":"\"Any process that activates or increases the rate or extent of osteoblast proliferation.\" [GOC:mah]","metadata":null},{"id":"014d2ed00a8544fa9da54c4ac4b6efc4","type":"GO_TERM","name":"positive regulation of osteoclast development","canonical_id":"go:GO:2001206","description":"\"Any process that activates or increases the frequency, rate or extent of osteoclast development.\" [GOC:obol]","metadata":null},{"id":"8e988084b2604e2ea64211b7951e9890","type":"GO_TERM","name":"positive regulation of osteoclast differentiation","canonical_id":"go:GO:0045672","description":"\"Any process that activates or increases the frequency, rate or extent of osteoclast differentiation.\" [GOC:curators]","metadata":null},{"id":"6e5cba4d2aba44698378052c135f6b6a","type":"GO_TERM","name":"positive regulation of osteoclast proliferation","canonical_id":"go:GO:0090290","description":"\"Any process that increases the rate, frequency, or extent of the multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population.\" [GOC:tb]","metadata":null},{"id":"8c602b77278349c2921da42d400a6b03","type":"GO_TERM","name":"positive regulation of otic vesicle morphogenesis","canonical_id":"go:GO:1904120","description":"\"Any process that activates or increases the frequency, rate or extent of otic vesicle morphogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:25677106]","metadata":null},{"id":"d5b5bcfbef67430496f093f6b5724b4f","type":"GO_TERM","name":"positive regulation of outer hair cell apoptotic process","canonical_id":"go:GO:1905587","description":"\"Any process that activates or increases the frequency, rate or extent of outer hair cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24472721]","metadata":null},{"id":"bd7d851d03f14b9ba01e084542d9c75a","type":"GO_TERM","name":"positive regulation of ovarian follicle development","canonical_id":"go:GO:2000386","description":"\"Any process that activates or increases the frequency, rate or extent of ovarian follicle development.\" [GOC:obol]","metadata":null},{"id":"3db066fd9301423b93ba35dc3912e9f8","type":"GO_TERM","name":"positive regulation of ovulation","canonical_id":"go:GO:0060279","description":"\"Any process that activates or increases the frequency, rate or extent of ovulation, the release of a mature ovum/oocyte from an ovary.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"b725dca529f04b369d2bebfb04f53b2f","type":"GO_TERM","name":"positive regulation of oxidative phosphorylation","canonical_id":"go:GO:1903862","description":"\"Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10225962]","metadata":null},{"id":"3db28a964bd545ad93c093838b358fc9","type":"GO_TERM","name":"positive regulation of oxidative phosphorylation uncoupler activity","canonical_id":"go:GO:2000277","description":"\"Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupler activity.\" [GOC:mah]","metadata":null},{"id":"2294b6285d3548b2bc2f5b81f7d305e1","type":"GO_TERM","name":"positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1902177","description":"\"Any process that activates or increases the frequency, rate or extent of an oxidative stress-induced intrinsic apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:TermGenie, PMID:11672522]","metadata":null},{"id":"05ee779aea2d49ff95219bcdcee6ff8d","type":"GO_TERM","name":"positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903378","description":"\"Any process that activates or increases the frequency, rate or extent of oxidative stress-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"c30b0d8ebf4e4277bb89c9b2898ed445","type":"GO_TERM","name":"positive regulation of oxidoreductase activity","canonical_id":"go:GO:0051353","description":"\"Any process that activates or increases the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered.\" [GOC:ai]","metadata":null},{"id":"053bd53f2bff4973a6c118d0287468e3","type":"GO_TERM","name":"positive regulation of oxytocin production","canonical_id":"go:GO:0140668","description":"\"Any process that activates or increases the frequency, rate or extent of production of oxytocin.\" [PMID:25096581]","metadata":null},{"id":"599a644a77184e3da240f6b44564b889","type":"GO_TERM","name":"positive regulation of p38MAPK cascade","canonical_id":"go:GO:1900745","description":"\"Any process that activates or increases the frequency, rate or extent of p38MAPK cascade.\" [GOC:TermGenie]","metadata":null},{"id":"8dc0dc2231394118aa6e35b158559599","type":"GO_TERM","name":"positive regulation of pancreatic A cell differentiation","canonical_id":"go:GO:2000228","description":"\"Any process that activates or increases the frequency, rate or extent of pancreatic A cell differentiation.\" [GOC:mah]","metadata":null},{"id":"5e3b667d732f42f8a4120653470cb42a","type":"GO_TERM","name":"positive regulation of pancreatic amylase secretion","canonical_id":"go:GO:1902278","description":"\"Any process that activates or increases the frequency, rate or extent of pancreatic amylase secretion.\" [GOC:jc, GOC:TermGenie, PMID:19028687]","metadata":null},{"id":"7d2dff5ac34f43579a148f7c8c0d7e39","type":"GO_TERM","name":"positive regulation of pancreatic amylase secretion by cholecystokinin signaling pathway","canonical_id":"go:GO:1902279","description":"\"A cholecystokinin signaling pathway that results in positive regulation of pancreatic amylase secretion.\" [GOC:jc, GOC:TermGenie, PMID:19028687]","metadata":null},{"id":"25febde120c4466b9e6f3e583053cde7","type":"GO_TERM","name":"positive regulation of pancreatic juice secretion","canonical_id":"go:GO:0090187","description":"\"Any process that increases the rate, frequency or extent of pancreatic juice secretion, the regulated release of pancreatic juice by the exocrine pancreas into the upper part of the intestine.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"04ce59e01cf04efd8d8a8d394c623f17","type":"GO_TERM","name":"positive regulation of pancreatic stellate cell proliferation","canonical_id":"go:GO:2000231","description":"\"Any process that activates or increases the frequency, rate or extent of pancreatic stellate cell proliferation.\" [GOC:mah]","metadata":null},{"id":"57f4547bed834345b20c2c21cbf01169","type":"GO_TERM","name":"positive regulation of pancreatic trypsinogen secretion","canonical_id":"go:GO:1904244","description":"\"Any process that activates or increases the frequency, rate or extent of pancreatic trypsinogen secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:12771515]","metadata":null},{"id":"7ae0dff2bd234dd6983395b1551937f3","type":"GO_TERM","name":"positive regulation of parathyroid hormone secretion","canonical_id":"go:GO:2000830","description":"\"Any process that activates or increases the frequency, rate or extent of parathyroid hormone secretion.\" [GOC:obol]","metadata":null},{"id":"ec09dd39c50944c5ad56845bcb4bcdfd","type":"GO_TERM","name":"positive regulation of paraxial mesodermal cell fate determination","canonical_id":"go:GO:0048346","description":"\"Any process that activates or increases the frequency, rate or extent of paraxial mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"e57da776216f40d4970f6c5f09b543cf","type":"GO_TERM","name":"positive regulation of paraxial mesodermal cell fate specification","canonical_id":"go:GO:0048350","description":"\"Any process that activates or increases the frequency, rate or extent of paraxial mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"86055e8cb6f24a6688b1c94a201645b7","type":"GO_TERM","name":"positive regulation of pattern recognition receptor signaling pathway","canonical_id":"go:GO:0062208","description":"\"Any process that decreases the rate, frequency or extent of a pattern recognition receptor signaling pathway.\" [PMID:30610168]","metadata":null},{"id":"1dfbcea429e446058512213c6884e8f6","type":"GO_TERM","name":"positive regulation of patulin biosynthetic process","canonical_id":"go:GO:0140724","description":"\"Any process that increases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of patulin.\" [PMID:25625822]","metadata":null},{"id":"6af6ff56a5794701b7e22798aea0b28c","type":"GO_TERM","name":"positive regulation of pectin catabolic process","canonical_id":"go:GO:2001005","description":"\"Any process that activates or increases the frequency, rate or extent of pectin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"7933abb3b90345f9923d20837482e83a","type":"GO_TERM","name":"positive regulation of penetration hypha formation","canonical_id":"go:GO:0075203","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of symbiont penetration hypha formation for entry into host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"2c497a3f7345422895d4e998e303f75d","type":"GO_TERM","name":"positive regulation of penetration peg formation","canonical_id":"go:GO:0075055","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of symbiont penetration peg formation for entry into host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"1cff03701c2f405d8867e35ee230b76d","type":"GO_TERM","name":"positive regulation of penicillin biosynthetic process","canonical_id":"go:GO:1900198","description":"\"Any process that activates or increases the frequency, rate or extent of penicillin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a1c72ba638754fa88637765e0d319460","type":"GO_TERM","name":"positive regulation of penicillin catabolic process","canonical_id":"go:GO:0033249","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:mah]","metadata":null},{"id":"7ac4c0efb5064eea9ed864b1058addeb","type":"GO_TERM","name":"positive regulation of penicillin metabolic process","canonical_id":"go:GO:0033246","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving any antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:mah]","metadata":null},{"id":"604dbcb53f1f40fa88fb1bada744977f","type":"GO_TERM","name":"positive regulation of penile erection","canonical_id":"go:GO:0060406","description":"\"Any process that increases the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0e0ddb808d1c4b1fb41ebdf2379df4d9","type":"GO_TERM","name":"positive regulation of pentadecane biosynthetic process","canonical_id":"go:GO:1900889","description":"\"Any process that activates or increases the frequency, rate or extent of pentadecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"834772969a8b4e9191f4979421541a02","type":"GO_TERM","name":"positive regulation of pentasaccharide transport","canonical_id":"go:GO:1900362","description":"\"Any process that activates or increases the frequency, rate or extent of pentasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"38b7c7fe98d346079627719a5f3ca102","type":"GO_TERM","name":"positive regulation of pentose-phosphate shunt","canonical_id":"go:GO:1905857","description":"\"Any process that activates or increases the frequency, rate or extent of pentose-phosphate shunt.\" [GO_REF:0000058, GOC:TermGenie, PMID:19015259]","metadata":null},{"id":"7b3d122d00c048f6b8d403f65e3f82d4","type":"GO_TERM","name":"positive regulation of peptidase activity","canonical_id":"go:GO:0010952","description":"\"Any process that increases the frequency, rate or extent of peptidase activity, the hydrolysis of peptide bonds within proteins.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"1328b4b4f1c240b49e96d2f5fe25707a","type":"GO_TERM","name":"positive regulation of peptide antigen transport","canonical_id":"go:GO:1901041","description":"\"Any process that activates or increases the frequency, rate or extent of peptide antigen transport.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"0e1cc721be03457c9b50af1af9cd39e6","type":"GO_TERM","name":"positive regulation of peptide hormone processing","canonical_id":"go:GO:0060569","description":"\"Any process that increases the rate, frequency or extent of peptide hormone processing. Peptide hormone processing is the generation of a mature peptide hormone by posttranslational processing of a prohormone.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"69f67bbd0a0745c18abe6ed0c7233e6a","type":"GO_TERM","name":"positive regulation of peptide hormone secretion","canonical_id":"go:GO:0090277","description":"\"Any process that increases the rate, frequency, or extent of the regulated release of a peptide hormone from secretory granules.\" [GOC:tb]","metadata":null},{"id":"26abf2daa69c4c1b9ab4a91a65140835","type":"GO_TERM","name":"positive regulation of peptide secretion","canonical_id":"go:GO:0002793","description":"\"Any process that activates or increases the frequency, rate, or extent of peptide secretion.\" [GOC:add]","metadata":null},{"id":"a2652ad0405d43d7a70859a00c5b5492","type":"GO_TERM","name":"positive regulation of peptidoglycan biosynthetic process","canonical_id":"go:GO:0140310","description":"\"Any process that increases the rate, frequency, or extent of peptidoglycan biosynthetic process.\" [PMID:37688380]","metadata":null},{"id":"013e4b0f8b3f489c94535952453fd14d","type":"GO_TERM","name":"positive regulation of peptidoglycan recognition protein signaling pathway","canonical_id":"go:GO:0061059","description":"\"Any process that increases the rate, frequency, or extent of the peptidoglycan recognition protein signaling pathway.\" [GOC:dph]","metadata":null},{"id":"4b5f8050b2f24c27abb641595bdd61ee","type":"GO_TERM","name":"positive regulation of peptidyl-L-cysteine S-palmitoylation","canonical_id":"go:GO:1902664","description":"\"Any process that activates or increases the frequency, rate or extent of peptidyl-L-cysteine S-palmitoylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23444136]","metadata":null},{"id":"2865a62f206c4cac8deec9342e238718","type":"GO_TERM","name":"positive regulation of peptidyl-cysteine S-nitrosylation","canonical_id":"go:GO:2000170","description":"\"Any process that activates or increases the frequency, rate or extent of peptidyl-cysteine S-nitrosylation.\" [GOC:obol]","metadata":null},{"id":"1ba1c03e357b4c8791701f4d9e7d43c9","type":"GO_TERM","name":"positive regulation of peptidyl-lysine acetylation","canonical_id":"go:GO:2000758","description":"\"Any process that activates or increases the frequency, rate or extent of peptidyl-lysine acetylation.\" [GOC:obol]","metadata":null},{"id":"25a706eaff084df2abb44b6758757eb5","type":"GO_TERM","name":"positive regulation of peptidyl-serine phosphorylation","canonical_id":"go:GO:0033138","description":"\"Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-serine.\" [GOC:mah]","metadata":null},{"id":"fddd2d4d409f4ed99355cd63ee884f04","type":"GO_TERM","name":"positive regulation of peptidyl-serine phosphorylation of STAT protein","canonical_id":"go:GO:0033141","description":"\"Any process that activates or increases the frequency, rate or extent of the phosphorylation of a serine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:mah]","metadata":null},{"id":"b23bddc8d9cf423a819969c2985bb951","type":"GO_TERM","name":"positive regulation of peptidyl-threonine phosphorylation","canonical_id":"go:GO:0010800","description":"\"Any process that increases the frequency, rate or extent of peptidyl-threonine phosphorylation. Peptidyl-threonine phosphorylation is the phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8d300203a4a643a7ab64d7f963b85483","type":"GO_TERM","name":"positive regulation of peptidyl-tyrosine autophosphorylation","canonical_id":"go:GO:1900086","description":"\"Any process that activates or increases the frequency, rate or extent of peptidyl-tyrosine autophosphorylation.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"b383d72127a740f08c89ac1ddb1fb703","type":"GO_TERM","name":"positive regulation of peptidyl-tyrosine phosphorylation","canonical_id":"go:GO:0050731","description":"\"Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.\" [GOC:ai]","metadata":null},{"id":"17c55b74f8aa4a77a00f25f4eb434e03","type":"GO_TERM","name":"positive regulation of pericentric heterochromatin formation","canonical_id":"go:GO:0090053","description":"\"Any process that increases the frequency, rate or extent of pericentric heterochromatin formation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c8738ad019a0459a93fb34fd37cbecbe","type":"GO_TERM","name":"positive regulation of peripheral B cell anergy","canonical_id":"go:GO:0002919","description":"\"Any process that activates or increases the frequency, rate, or extent of peripheral B cell anergy.\" [GOC:add]","metadata":null},{"id":"c2a32f14840e4fce80a1a19b99238c97","type":"GO_TERM","name":"positive regulation of peripheral B cell deletion","canonical_id":"go:GO:0002910","description":"\"Any process that activates or increases the frequency, rate, or extent of peripheral B cell deletion.\" [GOC:add]","metadata":null},{"id":"76162452833c4d4cb85651d1aa582493","type":"GO_TERM","name":"positive regulation of peripheral T cell tolerance induction","canonical_id":"go:GO:0002851","description":"\"Any process that activates or increases the frequency, rate, or extent of peripheral T cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"9d1f709e8d734c3c9f61992ba07905e3","type":"GO_TERM","name":"positive regulation of peripheral tolerance induction","canonical_id":"go:GO:0002660","description":"\"Any process that activates or increases the frequency, rate, or extent of peripheral tolerance induction.\" [GOC:add]","metadata":null},{"id":"cc7f9bd03ddf4c4795e9ed73cc747652","type":"GO_TERM","name":"positive regulation of peroxisome organization","canonical_id":"go:GO:1900064","description":"\"Any process that activates or increases the frequency, rate or extent of peroxisome organization.\" [GOC:TermGenie, PMID:7500953]","metadata":null},{"id":"03382d2e84604b429cb6cf87172e71d6","type":"GO_TERM","name":"positive regulation of peroxisome proliferator activated receptor signaling pathway","canonical_id":"go:GO:0035360","description":"\"Any process that activates or increases the frequency, rate or extent of the peroxisome proliferator activated receptor signaling pathway.\" [GOC:bf]","metadata":null},{"id":"53be259bd1d24cb990ce59644e9b66ff","type":"GO_TERM","name":"positive regulation of phagocytosis","canonical_id":"go:GO:0050766","description":"\"Any process that activates or increases the frequency, rate or extent of phagocytosis.\" [GOC:ai]","metadata":null},{"id":"af4f42e3851449ab8e5e466fd1c862b2","type":"GO_TERM","name":"positive regulation of phagocytosis, engulfment","canonical_id":"go:GO:0060100","description":"\"Any process that activates or increases the frequency, rate or extent of the internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis.\" [GOC:dph]","metadata":null},{"id":"580fa9b30e3641b2a1f28034521bb8b4","type":"GO_TERM","name":"positive regulation of phagosome maturation","canonical_id":"go:GO:1905164","description":"\"Any process that activates or increases the frequency, rate or extent of phagosome maturation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"5f93beb0112d45628bb8fe2e4b5fbc17","type":"GO_TERM","name":"positive regulation of phenazine biosynthetic process","canonical_id":"go:GO:1900982","description":"\"Any process that activates or increases the frequency, rate or extent of phenazine biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"aa71890b12af40bdb4e0c7e9b261dd0b","type":"GO_TERM","name":"positive regulation of phenotypic switching","canonical_id":"go:GO:1900241","description":"\"Any process that activates or increases the frequency, rate or extent of phenotypic switching.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5f9200d2e27a4bd299beaedb12fb4048","type":"GO_TERM","name":"positive regulation of pheromone response MAPK cascade","canonical_id":"go:GO:0062038","description":"\"Any process that activates or increases the frequency, rate or extent of a pheromone response MAPK cascade.\" [PMID:9315645]","metadata":null},{"id":"2228dd1f21bb4fb6ac43b94f9e4c3b8d","type":"GO_TERM","name":"positive regulation of phialide development","canonical_id":"go:GO:0070807","description":"\"Any process that activates or increases the frequency, rate or extent of phialide development, a process that leads to the formation of phialides. Phialides are specialized cells that bud from the ends of metulae on the conidiophore tip.\" [GOC:mah]","metadata":null},{"id":"7d7fe72d714741b88d48cdbb171e199d","type":"GO_TERM","name":"positive regulation of phosphatase activity","canonical_id":"go:GO:0010922","description":"\"Any process that increases the rate or frequency of phosphatase activity. Phosphatases catalyze the hydrolysis of phosphoric monoesters, releasing inorganic phosphate.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"03904a8ac12c4bcc8f1ba2041169880b","type":"GO_TERM","name":"positive regulation of phosphate metabolic process","canonical_id":"go:GO:0045937","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving phosphates.\" [GOC:curators]","metadata":null},{"id":"c9fb2605b122425d9ea5a15ae838e22e","type":"GO_TERM","name":"positive regulation of phosphate transmembrane transport","canonical_id":"go:GO:2000187","description":"\"Any process that activates or increases the frequency, rate or extent of phosphate transmembrane transport.\" [GOC:obol]","metadata":null},{"id":"9f73a49346054d4ab38c6b6dc6d23485","type":"GO_TERM","name":"positive regulation of phosphatidic acid biosynthetic process","canonical_id":"go:GO:1905695","description":"\"Any process that activates or increases the frequency, rate or extent of phosphatidic acid biosynthetic process.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:23767959]","metadata":null},{"id":"fd97af00eeca44a8a1403a4ee80abdd5","type":"GO_TERM","name":"positive regulation of phosphatidylcholine biosynthetic process","canonical_id":"go:GO:2001247","description":"\"Any process that activates or increases the frequency, rate or extent of phosphatidylcholine biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"52a42930f6f5478c81588691da6f71de","type":"GO_TERM","name":"positive regulation of phosphatidylglycerol biosynthetic process","canonical_id":"go:GO:1901353","description":"\"Any process that activates or increases the frequency, rate or extent of phosphatidylglycerol biosynthetic process.\" [GOC:dgf, GOC:TermGenie, PMID:12869188]","metadata":null},{"id":"c91051007bb64d4c9836696cdc6286b4","type":"GO_TERM","name":"positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction","canonical_id":"go:GO:0051897","description":"\"Any process that activates or increases the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction.\" [GOC:ai]","metadata":null},{"id":"49fbd84a20724d1e8cfb097c41ce48d9","type":"GO_TERM","name":"positive regulation of phosphatidylinositol biosynthetic process","canonical_id":"go:GO:0010513","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phosphatidylinositol.\" [GOC:dph, GOC:tb, GOC:vw]","metadata":null},{"id":"5fae0459f7cd49eb98ffdb167af0cd76","type":"GO_TERM","name":"positive regulation of phosphatidylserine biosynthetic process","canonical_id":"go:GO:1900470","description":"\"Any process that activates or increases the frequency, rate or extent of phosphatidylserine biosynthetic process.\" [GOC:dgf, GOC:TermGenie, PMID:8056324, PMID:8614637]","metadata":null},{"id":"f8697415661f4c4d811b71dfe610d7f3","type":"GO_TERM","name":"positive regulation of phosphatidylserine exposure on apoptotic cell surface","canonical_id":"go:GO:1905782","description":"\"Any process that activates or increases the frequency, rate or extent of phosphatidylserine exposure on apoptotic cell surface.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:17401362]","metadata":null},{"id":"80fdd1d90b5448adb04ade7fb98cb417","type":"GO_TERM","name":"positive regulation of phosphodiesterase I activity","canonical_id":"go:GO:1902800","description":"\"Any process that activates or increases the frequency, rate or extent of phosphodiesterase I activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:24559510]","metadata":null},{"id":"f20dc85916724287be2d03040dfb3fc6","type":"GO_TERM","name":"positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:1900738","description":"\"Any process that activates or increases the frequency, rate or extent of phospholipase C-activating G protein-coupled receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"b20fcda6a77d487ca19e3b9c80448bb1","type":"GO_TERM","name":"positive regulation of phospholipase C/protein kinase C signal transduction","canonical_id":"go:GO:0141214","description":"\"Any process that activates or increases the frequency, rate or extent of phospholipase C/protein kinase C signal transduction.\" [PMID:24008408, PMID:32255775]","metadata":null},{"id":"ce62b7e36dcf45e683a287d95ebaf39e","type":"GO_TERM","name":"positive regulation of phospholipase activity","canonical_id":"go:GO:0010518","description":"\"Any process that increases the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"247a01b3063b4ce88349e70f54b07382","type":"GO_TERM","name":"positive regulation of phospholipid biosynthetic process","canonical_id":"go:GO:0071073","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.\" [GOC:mah]","metadata":null},{"id":"261628513d914a7ebdc1dc5c62793330","type":"GO_TERM","name":"positive regulation of phospholipid catabolic process","canonical_id":"go:GO:0060697","description":"\"Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"b4660f55c1b7427aadfde3eddca2c6ae","type":"GO_TERM","name":"positive regulation of phospholipid efflux","canonical_id":"go:GO:1902995","description":"\"Any process that activates or increases the frequency, rate or extent of phospholipid efflux.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:12042316]","metadata":null},{"id":"bc16d4f012a14883859d0eb5e300f333","type":"GO_TERM","name":"positive regulation of phospholipid metabolic process","canonical_id":"go:GO:1903727","description":"\"Any process that activates or increases the frequency, rate or extent of phospholipid metabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:10657240]","metadata":null},{"id":"7eb93787e0d748d6aa5a05df48884aff","type":"GO_TERM","name":"positive regulation of phospholipid scramblase activity","canonical_id":"go:GO:1900163","description":"\"Any process that activates or increases the frequency, rate or extent of phospholipid scramblase activity.\" [GOC:TermGenie]","metadata":null},{"id":"800ac452ac7e4206a0c5d4e56039c384","type":"GO_TERM","name":"positive regulation of phospholipid translocation","canonical_id":"go:GO:0061092","description":"\"Any process that increases the frequency, rate or extent of the translocation, or flipping, of phospholipid molecules from one monolayer of a membrane bilayer to the opposite monolayer.\" [GOC:dph, GOC:jh, GOC:tb, PMID:19966303]","metadata":null},{"id":"9296c1e500b64779a69ebd0bfe24fe9c","type":"GO_TERM","name":"positive regulation of phospholipid transport","canonical_id":"go:GO:2001140","description":"\"Any process that activates or increases the frequency, rate or extent of phospholipid transport.\" [GOC:obol]","metadata":null},{"id":"c04fa653d9c14414a0ea4bfe75347140","type":"GO_TERM","name":"positive regulation of phosphorelay signal transduction system","canonical_id":"go:GO:0070299","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction via a phosphorelay signal transduction system.\" [GOC:mah]","metadata":null},{"id":"f9d2e8e1b6144327b739fffa939ad4ed","type":"GO_TERM","name":"positive regulation of phosphorus metabolic process","canonical_id":"go:GO:0010562","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways involving phosphorus or compounds containing phosphorus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c638c41ed659433bb790ee6aa0af0595","type":"GO_TERM","name":"positive regulation of phosphorus utilization","canonical_id":"go:GO:0045949","description":"\"Any process that activates or increases the frequency, rate or extent of phosphorus utilization.\" [GOC:curators]","metadata":null},{"id":"b8fc2749c4f64612a2308879381dfeaa","type":"GO_TERM","name":"positive regulation of phosphorylation","canonical_id":"go:GO:0042327","description":"\"Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to a molecule.\" [GOC:jl]","metadata":null},{"id":"9acec4a45bf54e7abf3331efc05bc73e","type":"GO_TERM","name":"positive regulation of photomorphogenesis","canonical_id":"go:GO:2000306","description":"\"Any process that activates or increases the frequency, rate or extent of photomorphogenesis.\" [GOC:obol]","metadata":null},{"id":"29124d14380841da8a464b7a02cb6e87","type":"GO_TERM","name":"positive regulation of photoreceptor cell differentiation","canonical_id":"go:GO:0046534","description":"\"Any process that activates or increases the frequency, rate or extent of photoreceptor cell differentiation. An example of this process is found in Drosophila melanogaster.\" [GOC:curators]","metadata":null},{"id":"e4d8d21ca3e345b48c9bac848d783a06","type":"GO_TERM","name":"positive regulation of photosynthesis","canonical_id":"go:GO:1905157","description":"\"Any process that activates or increases the frequency, rate or extent of photosynthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:7592491]","metadata":null},{"id":"dcdec40d66324402a1e0bfe7f49a2471","type":"GO_TERM","name":"positive regulation of phytoalexin biosynthetic process","canonical_id":"go:GO:0052322","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of phytoalexin biosynthesis, the chemical reactions and pathways resulting in the formation of phytoalexins.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"1cc0c7b30dc4467f9ce3e3358a616879","type":"GO_TERM","name":"positive regulation of phytol biosynthetic process","canonical_id":"go:GO:1904964","description":"\"Any process that activates or increases the frequency, rate or extent of phytol biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24275650]","metadata":null},{"id":"642fa264c0e7437aa94aafbb2c848c79","type":"GO_TERM","name":"positive regulation of piRNA transcription","canonical_id":"go:GO:0140543","description":"\"Any process that increases the frequency, rate or extent of the synthesis of piRNA.\" [PMID:28847004]","metadata":null},{"id":"7d48bb4783da4f6cb383fdf84c18ad49","type":"GO_TERM","name":"positive regulation of pigment cell differentiation","canonical_id":"go:GO:0050942","description":"\"Any process that activates or increases the frequency, rate or extent of pigment cell differentiation.\" [GOC:ai]","metadata":null},{"id":"d6a2f987835448b3950492a425e24524","type":"GO_TERM","name":"positive regulation of pinocytosis","canonical_id":"go:GO:0048549","description":"\"Any process that activates, maintains or increases the rate of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes.\" [GOC:curators]","metadata":null},{"id":"e1ebdeae8aae44b2b1cd3549ef2bae53","type":"GO_TERM","name":"positive regulation of placenta blood vessel development","canonical_id":"go:GO:0110080","description":"\"Any process that activates or increases the frequency, rate or extent of placenta blood vessel development.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:27748453]","metadata":null},{"id":"012e8337820049b0818a0228c8e6037b","type":"GO_TERM","name":"positive regulation of plant epidermal cell differentiation","canonical_id":"go:GO:1903890","description":"\"Any process that activates or increases the frequency, rate or extent of plant epidermal cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:123345]","metadata":null},{"id":"9c99b2bcd4b84bfcb6e53f669a4bf2a7","type":"GO_TERM","name":"positive regulation of plant organ morphogenesis","canonical_id":"go:GO:1905423","description":"\"Any process that activates or increases the frequency, rate or extent of plant organ morphogenesis.\" [GO_REF:0000058, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"a325bfe7e03745e3a2ee4d291c4e30a4","type":"GO_TERM","name":"positive regulation of plant-type cell wall cellulose biosynthetic process","canonical_id":"go:GO:2001011","description":"\"Any process that activates or increases the frequency, rate or extent of plant-type cell wall cellulose biosynthetic process.\" [GOC:mengo_curators]","metadata":null},{"id":"2afb1b1497f44fe8aa716aa876dc8c62","type":"GO_TERM","name":"positive regulation of plant-type cell wall cellulose catabolic process","canonical_id":"go:GO:2000941","description":"\"Any process that activates or increases the frequency, rate or extent of plant-type cell wall cellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"5ef2e517b19e4fd5833c1a3aec470498","type":"GO_TERM","name":"positive regulation of plant-type hypersensitive response","canonical_id":"go:GO:0034052","description":"\"Any process that activates or increases the frequency, rate or extent of the hypersensitive response in a plant.\" [GOC:pamgo_curators]","metadata":null},{"id":"4148e347705c40328d4539ebf698da59","type":"GO_TERM","name":"positive regulation of plasma cell differentiation","canonical_id":"go:GO:1900100","description":"\"Any process that activates or increases the frequency, rate or extent of plasma cell differentiation.\" [GOC:TermGenie]","metadata":null},{"id":"07f4c70990314575a2231004f0fac891","type":"GO_TERM","name":"positive regulation of plasma kallikrein-kinin cascade","canonical_id":"go:GO:0002550","description":"\"Any process that activates or increases the frequency, rate, or extent of the plasma kallikrein-kinin cascade.\" [GOC:add]","metadata":null},{"id":"278dcbce7df647cfb1cba57c8efdb209","type":"GO_TERM","name":"positive regulation of plasma membrane bounded cell projection assembly","canonical_id":"go:GO:0120034","description":"\"Any process that activates or increases the frequency, rate or extent of plasma membrane bounded cell projection assembly.\" [GOC:krc]","metadata":null},{"id":"05ced0a1ec75424d939107a26f58b091","type":"GO_TERM","name":"positive regulation of plasma membrane expansion","canonical_id":"go:GO:7770018","description":"\"Any process that activates or increases the frequency, rate or extent of plasma membrane expansion.\" [PMID:40629316]","metadata":null},{"id":"70ea559e00aa4073a309df8da544b745","type":"GO_TERM","name":"positive regulation of plasma membrane raft polarization","canonical_id":"go:GO:1903908","description":"\"Any process that activates or increases the frequency, rate or extent of plasma membrane raft polarization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"3fd6dd10186e4e94b86b9bbaf1ba9d58","type":"GO_TERM","name":"positive regulation of plasma membrane repair","canonical_id":"go:GO:1905686","description":"\"Any process that activates or increases the frequency, rate or extent of plasma membrane repair.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:22940583]","metadata":null},{"id":"47f4fe8cb194441f8d99aa885e5e0794","type":"GO_TERM","name":"positive regulation of plasmacytoid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002612","description":"\"Any process that activates or increases the frequency, rate, or extent of plasmacytoid dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"0e85cc9ebc3442e6b03d844210d64fcb","type":"GO_TERM","name":"positive regulation of plasmacytoid dendritic cell cytokine production","canonical_id":"go:GO:0002738","description":"\"Any process that activates or increases the frequency, rate, or extent of plasmacytoid dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"f68c35812db744e28a228d253e631728","type":"GO_TERM","name":"positive regulation of plasmatocyte differentiation","canonical_id":"go:GO:0045615","description":"\"Any process that activates or increases the frequency, rate or extent of plasmatocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"7ca7ae62f2144733ac684a69491e5fda","type":"GO_TERM","name":"positive regulation of plasminogen activation","canonical_id":"go:GO:0010756","description":"\"Any process that increases the rate, frequency or extent of plasminogen activation. Plasminogen activation is the process in which plasminogen is processed to plasmin.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"41cc9016597341aba49dfa0c0aaa6f3d","type":"GO_TERM","name":"positive regulation of platelet activation","canonical_id":"go:GO:0010572","description":"\"Any process that increases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"e0d24454bbb04be483c9e4c93937c3ca","type":"GO_TERM","name":"positive regulation of platelet aggregation","canonical_id":"go:GO:1901731","description":"\"Any process that activates or increases the frequency, rate or extent of platelet aggregation. Platelet aggregation is the adhesion of one platelet to one or more other platelets via adhesion molecules.\" [GOC:fj, GOC:TermGenie]","metadata":null},{"id":"65e998078da344278689e88e3509bf82","type":"GO_TERM","name":"positive regulation of platelet formation","canonical_id":"go:GO:1905221","description":"\"Any process that activates or increases the frequency, rate or extent of platelet formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10606160]","metadata":null},{"id":"54f98d1a5be94790878c36a98406652d","type":"GO_TERM","name":"positive regulation of platelet rolling","canonical_id":"go:GO:0160018","description":"\"Any process that increases the rate, frequency, or extent of platelet rolling.\" [GO_REF:0000058, GOC:sl]","metadata":null},{"id":"9d7033ad795c4e8aa354fbce9e83783b","type":"GO_TERM","name":"positive regulation of platelet-derived growth factor production","canonical_id":"go:GO:0090362","description":"\"Any process that increases the rate, frequency, or extent of the appearance of any platelet-derived growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"eea17d1bb6914f4c839b812d08349a77","type":"GO_TERM","name":"positive regulation of platelet-derived growth factor receptor signaling pathway","canonical_id":"go:GO:0010641","description":"\"Any process that increases the frequency, rate or extent of the platelet-derived growth factor receptor signaling pathway.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"c997e2eeb0364906bc2eb5e747547f11","type":"GO_TERM","name":"positive regulation of platelet-derived growth factor receptor-alpha signaling pathway","canonical_id":"go:GO:2000585","description":"\"Any process that activates or increases the frequency, rate or extent of platelet-derived growth factor receptor-alpha signaling pathway.\" [GOC:obol]","metadata":null},{"id":"25a19c7f29074edab903c1f45d743349","type":"GO_TERM","name":"positive regulation of platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:2000588","description":"\"Any process that activates or increases the frequency, rate or extent of platelet-derived growth factor receptor-beta signaling pathway.\" [GOC:obol]","metadata":null},{"id":"87a988a9baee48c8a9e3526f3e405cfc","type":"GO_TERM","name":"positive regulation of podocyte apoptotic process","canonical_id":"go:GO:1904635","description":"\"Any process that activates or increases the frequency, rate or extent of glomerular visceral epithelial cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:23692924]","metadata":null},{"id":"391b7082495644ea9ccf83bc4b3a5da0","type":"GO_TERM","name":"positive regulation of podosome assembly","canonical_id":"go:GO:0071803","description":"\"Any process that activates or increases the rate or extent of podosome assembly.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"6b49568a0a0745589ce838bcf7467095","type":"GO_TERM","name":"positive regulation of polarized epithelial cell differentiation","canonical_id":"go:GO:0030862","description":"\"Any process that activates or increases the rate or extent of polarized epithelial cell differentiation.\" [GOC:mah]","metadata":null},{"id":"bef6e8832bbe480493ccf7574c3d6a4d","type":"GO_TERM","name":"positive regulation of polyamine transmembrane transport","canonical_id":"go:GO:1902269","description":"\"Any process that activates or increases the frequency, rate or extent of polyamine transmembrane transport.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"92a0e68e308b49298c842b97134854da","type":"GO_TERM","name":"positive regulation of polyketide biosynthetic process","canonical_id":"go:GO:1900734","description":"\"Any process that activates or increases the frequency, rate or extent of polyketide biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"38f878e4df1046bf808173174c810571","type":"GO_TERM","name":"positive regulation of polynucleotide adenylyltransferase activity","canonical_id":"go:GO:1904247","description":"\"Any process that activates or increases the frequency, rate or extent of polynucleotide adenylyltransferase activity.\" [GO_REF:0000059, GOC:kmv, GOC:TermGenie, PMID:19460348]","metadata":null},{"id":"8a159763c9034615aec2638aad409ef6","type":"GO_TERM","name":"positive regulation of positive chemotaxis","canonical_id":"go:GO:0050927","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"7139ae6ccda24969a16edc1a8597fbfb","type":"GO_TERM","name":"positive regulation of positive chemotaxis to cAMP","canonical_id":"go:GO:0061122","description":"\"Any process that increases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP.\" [GOC:dph]","metadata":null},{"id":"7daa20b0b7ea45c6b7c86328066eec73","type":"GO_TERM","name":"positive regulation of positive chemotaxis to cAMP by DIF-1","canonical_id":"go:GO:0061126","description":"\"Any process that increases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of DIF-1. DIF-1 is a chlorinated alkylphenone.\" [GOC:dph]","metadata":null},{"id":"e4bc1d4ff2a14d7999b3bafbcd4d4146","type":"GO_TERM","name":"positive regulation of positive chemotaxis to cAMP by chlorinated alkylphenone","canonical_id":"go:GO:0061124","description":"\"Any process that increases the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of a chlorinated alkylphenone. An alkylphenone is an aromatic polyketide with methyl and chlorine substitutions.\" [GOC:dph]","metadata":null},{"id":"7ab56acbea0c4e35aa1027fada0fc26d","type":"GO_TERM","name":"positive regulation of positive thymic T cell selection","canonical_id":"go:GO:1902234","description":"\"Any process that activates or increases the frequency, rate or extent of positive thymic T cell selection.\" [GOC:TermGenie, PMID:22080863]","metadata":null},{"id":"15ca7cce90604ca9a8bced4bcddb1820","type":"GO_TERM","name":"positive regulation of post-embryonic development","canonical_id":"go:GO:0048582","description":"\"Any process that activates or increases the frequency, rate or extent of post-embryonic development. Post-embryonic development is defined as the process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure.\" [GOC:jid]","metadata":null},{"id":"957448f532a64b2381c57f33a3d98ab5","type":"GO_TERM","name":"positive regulation of post-transcriptional gene silencing","canonical_id":"go:GO:0060148","description":"\"Any process that increases the frequency, rate or extent of the inactivation of gene expression by a posttranscriptional mechanism.\" [GOC:dph]","metadata":null},{"id":"8b80c6ce576a4ec0902987ffd2350ec9","type":"GO_TERM","name":"positive regulation of post-transcriptional gene silencing by RNA","canonical_id":"go:GO:1900370","description":"\"Any process that activates or increases the frequency, rate or extent of post-transcriptional gene silencing by RNA.\" [GOC:kmv, GOC:TermGenie, PMID:22412382]","metadata":null},{"id":"4c4714e3e60849639ec48a9fdbd23260","type":"GO_TERM","name":"positive regulation of post-translational protein modification","canonical_id":"go:GO:1901875","description":"\"Any process that activates or increases the frequency, rate or extent of post-translational protein modification.\" [GOC:TermGenie, GOC:yaf, PMID:21209915]","metadata":null},{"id":"a90f9af2cfbe49fcba675c6bbfda62bf","type":"GO_TERM","name":"positive regulation of posterior neural plate formation by fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0060787","description":"\"Any process that increases the rate or extent of the formation of the posterior neural plate, the posterior end of the flat, thickened layer of ectodermal cells known as the neural plate.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"a313c65f8bba4c7eba0551cdcd9a3bf9","type":"GO_TERM","name":"positive regulation of postsynaptic cytosolic calcium concentration","canonical_id":"go:GO:0099588","description":"\"Any process that increases the concentration of calcium ions in the postsynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"facc50b950084c41ad6440a94753ed04","type":"GO_TERM","name":"positive regulation of postsynaptic density assembly","canonical_id":"go:GO:0160036","description":"\"Any process that activates or increases the frequency, rate or extent of postsynaptic density assembly.\" [PMID:17626212]","metadata":null},{"id":"1642c2d4c19940ec81ba583c019fbbb6","type":"GO_TERM","name":"positive regulation of postsynaptic density organization","canonical_id":"go:GO:1905876","description":"\"Any process that activates or increases the frequency, rate or extent of postsynaptic density organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:21887379]","metadata":null},{"id":"8056d10aaf5745ca8b2bf2dbf7d65ae4","type":"GO_TERM","name":"positive regulation of postsynaptic membrane organization","canonical_id":"go:GO:1901628","description":"\"Any process that activates or increases the frequency, rate or extent of postsynaptic membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"0e53590c85b84ef1a77c8b7a19ccc574","type":"GO_TERM","name":"positive regulation of potassium ion export across plasma membrane","canonical_id":"go:GO:1903766","description":"\"Any process that activates or increases the frequency, rate or extent of potassium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:19646991]","metadata":null},{"id":"19dacdb4fb7443169b9470041fd0ac3c","type":"GO_TERM","name":"positive regulation of potassium ion import across plasma membrane","canonical_id":"go:GO:1903288","description":"\"Any process that activates or increases the frequency, rate or extent of potassium ion import across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:10636900]","metadata":null},{"id":"be440214393647d9ba9be6ae0112fa28","type":"GO_TERM","name":"positive regulation of potassium ion transmembrane transport","canonical_id":"go:GO:1901381","description":"\"Any process that activates or increases the frequency, rate or extent of potassium ion transmembrane transport.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"ade1cd09e348485c8c542d2f527cc7ed","type":"GO_TERM","name":"positive regulation of potassium ion transport","canonical_id":"go:GO:0043268","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"e33b01f69290479cb08efb91dfab4e08","type":"GO_TERM","name":"positive regulation of pre-miRNA processing","canonical_id":"go:GO:2000633","description":"\"Any process that activates or increases the frequency, rate or extent of pre-microRNA processing.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"b82ec1dd66d84e21bb4104f8f1f6295a","type":"GO_TERM","name":"positive regulation of preblastoderm mitotic cell cycle","canonical_id":"go:GO:0046002","description":"\"Any process that activates or increases the rate or extent of progression through the preblastoderm mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"4e2d7b6552724b2c87d5454e68b26ceb","type":"GO_TERM","name":"positive regulation of presynapse assembly","canonical_id":"go:GO:1905608","description":"\"Any process that activates or increases the frequency, rate or extent of presynapse assembly.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:25533483]","metadata":null},{"id":"826ca2915d7c46eaa3b04f495dc39310","type":"GO_TERM","name":"positive regulation of presynaptic active zone assembly","canonical_id":"go:GO:1905520","description":"\"Any process that activates or increases the frequency, rate or extent of presynaptic active zone assembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15797875]","metadata":null},{"id":"d7c02f8c28a94955a2857cdb6719b3f9","type":"GO_TERM","name":"positive regulation of presynaptic cytosolic calcium concentration","canonical_id":"go:GO:0099533","description":"\"Any process that increases the concentration of calcium ions in the presynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"5ca67af168df46da91bd3413eec2164e","type":"GO_TERM","name":"positive regulation of presynaptic membrane organization","canonical_id":"go:GO:1901631","description":"\"Any process that activates or increases the frequency, rate or extent of presynaptic membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"9da418d46ff64781bf08cc03c26bee77","type":"GO_TERM","name":"positive regulation of primary cell septum biogenesis","canonical_id":"go:GO:1905758","description":"\"Any process that activates or increases the frequency, rate or extent of primary cell septum biogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:27898700]","metadata":null},{"id":"444396aca81b42c19ec8731d848ddd23","type":"GO_TERM","name":"positive regulation of primary miRNA processing","canonical_id":"go:GO:2000636","description":"\"Any process that activates or increases the frequency, rate or extent of primary microRNA processing.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"5b8d80d11cf84cca9e2b7f4a22e27a9c","type":"GO_TERM","name":"positive regulation of pro-B cell differentiation","canonical_id":"go:GO:2000975","description":"\"Any process that activates or increases the frequency, rate or extent of pro-B cell differentiation.\" [GOC:obol]","metadata":null},{"id":"5bd1e4376a744075a65f6aa70e2d3d6b","type":"GO_TERM","name":"positive regulation of pro-T cell differentiation","canonical_id":"go:GO:2000176","description":"\"Any process that activates or increases the frequency, rate or extent of pro-T cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"441789bcf6e34d4eb023e1d62e8709e3","type":"GO_TERM","name":"positive regulation of production of molecular mediator of immune response","canonical_id":"go:GO:0002702","description":"\"Any process that activates or increases the frequency, rate, or extent of the production of molecular mediator of immune response.\" [GOC:add]","metadata":null},{"id":"aa4b46819ea449d38c0c69a4d765ca75","type":"GO_TERM","name":"positive regulation of progesterone biosynthetic process","canonical_id":"go:GO:2000184","description":"\"Any process that activates or increases the frequency, rate or extent of progesterone biosynthetic process.\" [GOC:dph]","metadata":null},{"id":"a11ff81b603e477ab6eb0ec496602338","type":"GO_TERM","name":"positive regulation of progesterone secretion","canonical_id":"go:GO:2000872","description":"\"Any process that activates or increases the frequency, rate or extent of progesterone secretion.\" [GOC:sl]","metadata":null},{"id":"c70e46f56e0f4c549d96eccbd4d4c362","type":"GO_TERM","name":"positive regulation of programmed cell death","canonical_id":"go:GO:0043068","description":"\"Any process that activates or increases the frequency, rate or extent of programmed cell death, cell death resulting from activation of endogenous cellular processes.\" [GOC:jl]","metadata":null},{"id":"6e1f185b7e484a3390aeb4852bf28998","type":"GO_TERM","name":"positive regulation of programmed necrotic cell death","canonical_id":"go:GO:0062100","description":"\"Any process that increases the frequency, rate or extent of programmed necrotic cell death.\" [GOC:aruk, GOC:rph, PMID:27258785]","metadata":null},{"id":"e4787fd6e6c041fc8b4f769f6e3a6176","type":"GO_TERM","name":"positive regulation of prolactin secretion","canonical_id":"go:GO:1902722","description":"\"Any process that activates or increases the frequency, rate or extent of prolactin secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:16159377]","metadata":null},{"id":"df269d8f48694c288906e4b91df4916a","type":"GO_TERM","name":"positive regulation of prolactin signaling pathway","canonical_id":"go:GO:1902213","description":"\"Any process that activates or increases the frequency, rate or extent of prolactin signaling pathway.\" [GOC:TermGenie, PMID:11773439]","metadata":null},{"id":"8b9d260972f6491db0c526c565b359cd","type":"GO_TERM","name":"positive regulation of proline import across plasma membrane","canonical_id":"go:GO:1902836","description":"\"Any process that activates or increases the frequency, rate or extent of proline import into cell.\" [GO_REF:0000058, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"4a248516d1e143cfa6247ff4438addf9","type":"GO_TERM","name":"positive regulation of promoter clearance from RNA polymerase II promoter","canonical_id":"go:GO:0140846","description":"\"A process that activates or increases the frequency, rate or extent of the transition from the initiation to the elongation phases of transcription by RNA polymerase II.\" [PMID:28248323]","metadata":null},{"id":"28086ae6fb724534a74d8da7e323c030","type":"GO_TERM","name":"positive regulation of prostaglandin biosynthetic process","canonical_id":"go:GO:0031394","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.\" [GOC:mah]","metadata":null},{"id":"0ffddb337e2c4a1996f3f0ca4c1c700f","type":"GO_TERM","name":"positive regulation of prostaglandin catabolic process","canonical_id":"go:GO:1905830","description":"\"Any process that activates or increases the frequency, rate or extent of prostaglandin catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:12432938]","metadata":null},{"id":"f55e924a4571496090938a3a9e6c9fa0","type":"GO_TERM","name":"positive regulation of prostaglandin secretion","canonical_id":"go:GO:0032308","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of a prostaglandin from a cell.\" [GOC:mah]","metadata":null},{"id":"f8c2063788654cb3a0b287d1b4dea737","type":"GO_TERM","name":"positive regulation of proteasomal protein catabolic process","canonical_id":"go:GO:1901800","description":"\"Any process that activates or increases the frequency, rate or extent of proteasomal protein catabolic process.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21669198]","metadata":null},{"id":"50cc60d2f3524346964636e03de5108a","type":"GO_TERM","name":"positive regulation of proteasomal ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0032436","description":"\"Any process that activates or increases the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.\" [GOC:mah]","metadata":null},{"id":"b11b7f3e21204e2baa872eefc894f08f","type":"GO_TERM","name":"positive regulation of protection from non-homologous end joining at telomere","canonical_id":"go:GO:1905766","description":"\"Any process that activates or increases the frequency, rate or extent of protection from non-homologous end joining at telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:14690602]","metadata":null},{"id":"92e47a5e28a248c5b12bc492ee4432f0","type":"GO_TERM","name":"positive regulation of protein K48-linked ubiquitination","canonical_id":"go:GO:1902524","description":"\"Any process that activates or increases the frequency, rate or extent of protein K48-linked ubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"576c4d22449e4f0d83eb0bf4f25d10af","type":"GO_TERM","name":"positive regulation of protein K63-linked deubiquitination","canonical_id":"go:GO:1903006","description":"\"Any process that activates or increases the frequency, rate or extent of protein K63-linked deubiquitination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22970133]","metadata":null},{"id":"a5a1a3452ec6468a89f94d41b48460fa","type":"GO_TERM","name":"positive regulation of protein K63-linked ubiquitination","canonical_id":"go:GO:1902523","description":"\"Any process that activates or increases the frequency, rate or extent of protein K63-linked ubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"5f6ec7c679ea4a2aab3f0870453ef251","type":"GO_TERM","name":"positive regulation of protein O-linked glycosylation","canonical_id":"go:GO:1904100","description":"\"Any process that activates or increases the frequency, rate or extent of protein O-linked glycosylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24509081]","metadata":null},{"id":"7b064a5d8bab4e35831d5a1a20be8d77","type":"GO_TERM","name":"positive regulation of protein acetylation","canonical_id":"go:GO:1901985","description":"\"Any process that activates or increases the frequency, rate or extent of protein acetylation.\" [GOC:TermGenie, PMID:22117195]","metadata":null},{"id":"107411f7681d4e94a97226c4f73a05f6","type":"GO_TERM","name":"positive regulation of protein activation cascade","canonical_id":"go:GO:2000259","description":"\"Any process that activates or increases the frequency, rate or extent of protein activation cascade.\" [GOC:mah]","metadata":null},{"id":"3d41d89027224b3da1d0236e85848993","type":"GO_TERM","name":"positive regulation of protein adenylylation","canonical_id":"go:GO:1900724","description":"\"Any process that activates or increases the frequency, rate or extent of protein adenylylation.\" [GOC:TermGenie]","metadata":null},{"id":"ae2f2153e93242c3902b76a9092ea179","type":"GO_TERM","name":"positive regulation of protein autophosphorylation","canonical_id":"go:GO:0031954","description":"\"Any process that activates or increases the frequency, rate or extent of the phosphorylation by a protein of one or more of its own residues.\" [GOC:mah]","metadata":null},{"id":"22a57ffcabd749d48787915d67e1f7b0","type":"GO_TERM","name":"positive regulation of protein autoubiquitination","canonical_id":"go:GO:1902499","description":"\"Any process that activates or increases the frequency, rate or extent of protein autoubiquitination.\" [GOC:rb, GOC:TermGenie, PMID:24069405]","metadata":null},{"id":"bd6ea10bbeb44463a31ab68c46818d7d","type":"GO_TERM","name":"positive regulation of protein binding","canonical_id":"go:GO:0032092","description":"\"Any process that activates or increases the frequency, rate or extent of protein binding.\" [GOC:mah]","metadata":null},{"id":"ffbecf143a5640b9bbc3aec289bda464","type":"GO_TERM","name":"positive regulation of protein catabolic process","canonical_id":"go:GO:0045732","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.\" [GOC:curators]","metadata":null},{"id":"9005701596f74906b27921815198ba7f","type":"GO_TERM","name":"positive regulation of protein catabolic process in the vacuole","canonical_id":"go:GO:1904352","description":"\"Any process that activates or increases the frequency, rate or extent of protein catabolic process in the vacuole.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:25635054]","metadata":null},{"id":"27dd223322b744de9066c60691297a06","type":"GO_TERM","name":"positive regulation of protein deacetylation","canonical_id":"go:GO:0090312","description":"\"Any process that increases the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [GOC:ecd, PMID:20027304]","metadata":null},{"id":"655569ea94724144bd63ce6edf9cfa35","type":"GO_TERM","name":"positive regulation of protein depolymerization","canonical_id":"go:GO:1901881","description":"\"Any process that activates or increases the frequency, rate or extent of protein depolymerization.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12032137]","metadata":null},{"id":"f88d31f1f8c64ba0b722bcab36a305e9","type":"GO_TERM","name":"positive regulation of protein desumoylation","canonical_id":"go:GO:0060189","description":"\"Any process that increases the frequency, rate or extent of protein desumoylation. Protein desumoylation is the process in which a SUMO protein (small ubiquitin-related modifier) is cleaved from its target protein.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bf195dd765614245b8310cee23f95733","type":"GO_TERM","name":"positive regulation of protein deubiquitination","canonical_id":"go:GO:1903003","description":"\"Any process that activates or increases the frequency, rate or extent of protein deubiquitination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22970133]","metadata":null},{"id":"87b111b510da4e7d8ada4d13c6d4a77e","type":"GO_TERM","name":"positive regulation of protein export from nucleus","canonical_id":"go:GO:0046827","description":"\"Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"06a5ba3264014647901716414bd2729a","type":"GO_TERM","name":"positive regulation of protein export from nucleus during meiotic anaphase II","canonical_id":"go:GO:1900199","description":"\"Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm, during anaphase occurring as part of meiosis II.\" [GOC:al, GOC:TermGenie, PMID:20970342]","metadata":null},{"id":"b73ee1502a354561b231042e8ab4d7c2","type":"GO_TERM","name":"positive regulation of protein export from nucleus in response to glucose starvation","canonical_id":"go:GO:0036279","description":"\"Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm in response to deprivation of glucose.\" [GOC:al, PMID:3541942]","metadata":null},{"id":"67b51e50ef514efabec8ddc1d2f1b387","type":"GO_TERM","name":"positive regulation of protein folding","canonical_id":"go:GO:1903334","description":"\"Any process that activates or increases the frequency, rate or extent of protein folding.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"0780aa74a21e46d69fe9a9952cbcf704","type":"GO_TERM","name":"positive regulation of protein geranylgeranylation","canonical_id":"go:GO:2000541","description":"\"Any process that activates or increases the frequency, rate or extent of protein geranylgeranylation.\" [GOC:obol]","metadata":null},{"id":"01d395ef267649799d33f381a77f2920","type":"GO_TERM","name":"positive regulation of protein glutathionylation","canonical_id":"go:GO:0010733","description":"\"Any process that increases the rate, frequency, or extent of protein glutathionylation. Protein glutathionylation is the protein modification process in which a glutathione molecule is added to a protein amino acid through a disulfide linkage.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"1bc88e39b4a447ef8cee2be05bc4eecd","type":"GO_TERM","name":"positive regulation of protein homooligomerization","canonical_id":"go:GO:0032464","description":"\"Any process that activates or increases the frequency, rate or extent of protein homooligomerization.\" [GOC:mah]","metadata":null},{"id":"b646734a91b34921ba619a9a9abb3e2b","type":"GO_TERM","name":"positive regulation of protein homotetramerization","canonical_id":"go:GO:1901095","description":"\"Any process that activates or increases the frequency, rate or extent of protein homotetramerization.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"8b87306f49a74faa81066ce658eaee1e","type":"GO_TERM","name":"positive regulation of protein import","canonical_id":"go:GO:1904591","description":"\"Any process that activates or increases the frequency, rate or extent of protein import.\" [GO_REF:0000058, GOC:TermGenie, PMID:11406629]","metadata":null},{"id":"4d5a7a3744d24483b88cd9e2f5f02f9c","type":"GO_TERM","name":"positive regulation of protein import into chloroplast stroma","canonical_id":"go:GO:1904216","description":"\"Any process that activates or increases the frequency, rate or extent of protein import into chloroplast stroma.\" [GO_REF:0000058, GOC:TermGenie, PMID:25901327]","metadata":null},{"id":"67e9c90e17354d15a0764536ebce92f8","type":"GO_TERM","name":"positive regulation of protein import into nucleus","canonical_id":"go:GO:0042307","description":"\"Any process that activates or increases the frequency, rate or extent of movement of proteins from the cytoplasm into the nucleus.\" [GOC:jl]","metadata":null},{"id":"a5fbacfe22f647388c2432052ef22cb6","type":"GO_TERM","name":"positive regulation of protein kinase C activity","canonical_id":"go:GO:1900020","description":"\"Any process that activates or increases the frequency, rate or extent of protein kinase C activity.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"3681a06416844fd8b4f01fabac815eaa","type":"GO_TERM","name":"positive regulation of protein kinase C signaling","canonical_id":"go:GO:0090037","description":"\"Any process that increases the frequency, rate, or extent of a series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f2566cbc52834b579ca331d567ea93ce","type":"GO_TERM","name":"positive regulation of protein kinase activity","canonical_id":"go:GO:0045860","description":"\"Any process that activates or increases the frequency, rate or extent of protein kinase activity.\" [GOC:curators]","metadata":null},{"id":"2ef9de96f7414f42913f03311ab1aaad","type":"GO_TERM","name":"positive regulation of protein linear polyubiquitination","canonical_id":"go:GO:1902530","description":"\"Any process that activates or increases the frequency, rate or extent of protein linear polyubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"294915d263de419aa63f08b1c334f2f6","type":"GO_TERM","name":"positive regulation of protein lipidation","canonical_id":"go:GO:1903061","description":"\"Any process that activates or increases the frequency, rate or extent of protein lipidation.\" [GO_REF:0000058, GOC:rph, GOC:TermGenie, PMID:21909394]","metadata":null},{"id":"8e12f42f94b6463bb818420a09f1ea18","type":"GO_TERM","name":"positive regulation of protein localization","canonical_id":"go:GO:1903829","description":"\"Any process that activates or increases the frequency, rate or extent of a protein localization.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"0df0d5552edc44189a13da396b1623fd","type":"GO_TERM","name":"positive regulation of protein localization to Cajal body","canonical_id":"go:GO:1904871","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to Cajal body.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"c408d530f7e54cf39bf42fee9646938b","type":"GO_TERM","name":"positive regulation of protein localization to actin cortical patch","canonical_id":"go:GO:1904372","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to actin cortical patch.\" [GO_REF:0000058, GOC:TermGenie, PMID:18216290]","metadata":null},{"id":"b46e512546914264b17c79bca7d462e4","type":"GO_TERM","name":"positive regulation of protein localization to adherens junction","canonical_id":"go:GO:1904704","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:kmv, GOC:TermGenie, PMID:26412237]","metadata":null},{"id":"8f59186d68b04cd4afc44e64d0966ea4","type":"GO_TERM","name":"positive regulation of protein localization to basolateral plasma membrane","canonical_id":"go:GO:1904510","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to basolateral plasma membrane.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26115433]","metadata":null},{"id":"24e8095a5fb742dda4a38d51dfb31f94","type":"GO_TERM","name":"positive regulation of protein localization to cell cortex","canonical_id":"go:GO:1904778","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cell cortex.\" [GO_REF:0000058, GOC:TermGenie, PMID:17115027]","metadata":null},{"id":"b8653f1121c1429faae00c7558866142","type":"GO_TERM","name":"positive regulation of protein localization to cell division site involved in mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:0110083","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cell division site involved in mitotic actomyosin contractile ring assembly.\" [GOC:vw, PMID:29343550]","metadata":null},{"id":"c0abf5ef46ce4f6ab9376f2c27e7f6c6","type":"GO_TERM","name":"positive regulation of protein localization to cell leading edge","canonical_id":"go:GO:1905873","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cell leading edge.\" [GO_REF:0000058, GOC:TermGenie, PMID:26324884]","metadata":null},{"id":"a2a155f20ac24e8b868a1e0c0731982a","type":"GO_TERM","name":"positive regulation of protein localization to cell periphery","canonical_id":"go:GO:1904377","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cell periphery.\" [GO_REF:0000058, GOC:TermGenie, PMID:18216290]","metadata":null},{"id":"10033d11e87f4c048bad2911215ff958","type":"GO_TERM","name":"positive regulation of protein localization to cell surface","canonical_id":"go:GO:2000010","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to the cell surface.\" [GOC:obol]","metadata":null},{"id":"48f4f0ac70214c37a09d9148aece7fc5","type":"GO_TERM","name":"positive regulation of protein localization to cell tip","canonical_id":"go:GO:1903068","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cell tip.\" [GO_REF:0000058, GOC:TermGenie, PMID:24554432]","metadata":null},{"id":"e888c778295a414a8da524f777ff0eb3","type":"GO_TERM","name":"positive regulation of protein localization to cell-cell junction","canonical_id":"go:GO:0150107","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cell-cell junction.\" [GOC:aruk, GOC:bc, PMID:26706435]","metadata":null},{"id":"0c85e507592d4576a99a947acc0eafaa","type":"GO_TERM","name":"positive regulation of protein localization to centrosome","canonical_id":"go:GO:1904781","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to centrosome.\" [GO_REF:0000058, GOC:TermGenie, PMID:17115027]","metadata":null},{"id":"e635850225d147b786bbe8dbb126b325","type":"GO_TERM","name":"positive regulation of protein localization to chromatin","canonical_id":"go:GO:0120187","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to chromatin.\" [PMID:20889714, PMID:29899453]","metadata":null},{"id":"119068ba572f48a0a66225c842da952b","type":"GO_TERM","name":"positive regulation of protein localization to chromosome, telomeric region","canonical_id":"go:GO:1904816","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to chromosome, telomeric region.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:19487455]","metadata":null},{"id":"2b10d3b247954120a97b313b23fea42e","type":"GO_TERM","name":"positive regulation of protein localization to ciliary membrane","canonical_id":"go:GO:1903569","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to ciliary membrane.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22072986]","metadata":null},{"id":"6223f06850644671be107a0f2997ca20","type":"GO_TERM","name":"positive regulation of protein localization to cilium","canonical_id":"go:GO:1903566","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to cilium.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22072986]","metadata":null},{"id":"728f2cafe31441daa3a5350b5f9ab9c4","type":"GO_TERM","name":"positive regulation of protein localization to early endosome","canonical_id":"go:GO:1902966","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to early endosome.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:22621900]","metadata":null},{"id":"6af96ca3f8184d1c92478abcbec35045","type":"GO_TERM","name":"positive regulation of protein localization to endoplasmic reticulum","canonical_id":"go:GO:1905552","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to endoplasmic reticulum.\" [GO_REF:0000058, GOC:TermGenie, PMID:22768340]","metadata":null},{"id":"4cb28f3c4bb24eaea8e1ad7e2f470518","type":"GO_TERM","name":"positive regulation of protein localization to endosome","canonical_id":"go:GO:1905668","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to endosome.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:22732145]","metadata":null},{"id":"6aefc90998e745c0bb7709412838ab37","type":"GO_TERM","name":"positive regulation of protein localization to kinetochore","canonical_id":"go:GO:1905342","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to kinetochore.\" [GO_REF:0000058, GOC:TermGenie, PMID:22581055]","metadata":null},{"id":"f140422099134b80a87d81a6cc74cb46","type":"GO_TERM","name":"positive regulation of protein localization to lysosome","canonical_id":"go:GO:0150032","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to lysosome.\" [GOC:aruk, GOC:bc]","metadata":null},{"id":"50edf737a3144517adc6be210a65bd3e","type":"GO_TERM","name":"positive regulation of protein localization to medial cortex","canonical_id":"go:GO:0106012","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to the medial cortex.\" [GOC:hjd, PMID:19474789]","metadata":null},{"id":"248e5fccffcb4113a1b5110c26f30a1a","type":"GO_TERM","name":"positive regulation of protein localization to medial cortical node","canonical_id":"go:GO:0120047","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to a medial cortical node.\" [PMID:19474789]","metadata":null},{"id":"79026d0eda5842748e88f8b3f9d1cd20","type":"GO_TERM","name":"positive regulation of protein localization to meiotic spindle pole body","canonical_id":"go:GO:0140434","description":"\"Any process that increases the frequency, rate or extent of protein localization to a meiotic spindle pole body.\" [PMID:22438582]","metadata":null},{"id":"82e4c4f201fe41678d3550f2725a2dc7","type":"GO_TERM","name":"positive regulation of protein localization to membrane","canonical_id":"go:GO:1905477","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to membrane.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"a7b00b8c49fc4bedbab945e64fc1fe4c","type":"GO_TERM","name":"positive regulation of protein localization to mitochondrion","canonical_id":"go:GO:1903749","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to mitochondrion.\" [GO_REF:0000058, GOC:TermGenie, PMID:16857185]","metadata":null},{"id":"843fdfa3ef884d5c92350fb0e89a2247","type":"GO_TERM","name":"positive regulation of protein localization to nucleolus","canonical_id":"go:GO:1904751","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to nucleolus.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24415760]","metadata":null},{"id":"9d9ecf22839f49c3bce3843fa43d532b","type":"GO_TERM","name":"positive regulation of protein localization to nucleus","canonical_id":"go:GO:1900182","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to nucleus.\" [GOC:TermGenie]","metadata":null},{"id":"59da57d00f7340258371da3de591205b","type":"GO_TERM","name":"positive regulation of protein localization to phagocytic vesicle","canonical_id":"go:GO:1905171","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to phagocytic vesicle.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23303671]","metadata":null},{"id":"2c0bbaabdee94c4c80943287c73a0bb3","type":"GO_TERM","name":"positive regulation of protein localization to plasma membrane","canonical_id":"go:GO:1903078","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11602640]","metadata":null},{"id":"dc71194b05ac41f1927c4762cf7cba93","type":"GO_TERM","name":"positive regulation of protein localization to presynapse","canonical_id":"go:GO:1905386","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to presynapse.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24449494]","metadata":null},{"id":"8fb798f81807448aafe4ab876e18379c","type":"GO_TERM","name":"positive regulation of protein localization to prospore membrane","canonical_id":"go:GO:2001232","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to prospore membrane.\" [GOC:mah]","metadata":null},{"id":"fb97643b5ad145759a069bb94a0a1c7f","type":"GO_TERM","name":"positive regulation of protein localization to spindle pole body","canonical_id":"go:GO:1902365","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to spindle pole body.\" [GOC:TermGenie, PMID:21131906]","metadata":null},{"id":"154ddea6080545a0be025ecfcf2455a9","type":"GO_TERM","name":"positive regulation of protein localization to synapse","canonical_id":"go:GO:1902474","description":"\"Any process that activates or increases the frequency, rate or extent of protein localization to synapse.\" [GOC:kmv, GOC:TermGenie, PMID:22588719]","metadata":null},{"id":"3718e780aa2a4b638d22f5b92f488810","type":"GO_TERM","name":"positive regulation of protein maturation","canonical_id":"go:GO:1903319","description":"\"Any process that activates or increases the frequency, rate or extent of protein maturation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"bc71d403a0324ebd90066e0cafa9dce0","type":"GO_TERM","name":"positive regulation of protein metabolic process","canonical_id":"go:GO:0051247","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a protein.\" [GOC:ai]","metadata":null},{"id":"282499b950a6454bb9c10afb22629396","type":"GO_TERM","name":"positive regulation of protein modification by small protein conjugation or removal","canonical_id":"go:GO:1903322","description":"\"Any process that activates or increases the frequency, rate or extent of protein modification by small protein conjugation or removal.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"3d7ebaf736e0452499608cf894569bfe","type":"GO_TERM","name":"positive regulation of protein modification process","canonical_id":"go:GO:0031401","description":"\"Any process that activates or increases the frequency, rate or extent of the covalent alteration of one or more amino acid residues within a protein.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"d8a10e8f084f4623845a6dea062d50e6","type":"GO_TERM","name":"positive regulation of protein monoubiquitination","canonical_id":"go:GO:1902527","description":"\"Any process that activates or increases the frequency, rate or extent of protein monoubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"4d06566c135a45b098f6f79b369e7edb","type":"GO_TERM","name":"positive regulation of protein neddylation","canonical_id":"go:GO:2000436","description":"\"Any process that activates or increases the frequency, rate or extent of protein neddylation.\" [GOC:obol]","metadata":null},{"id":"dda9089028424c44b941aeee39eb58be","type":"GO_TERM","name":"positive regulation of protein oligomerization","canonical_id":"go:GO:0032461","description":"\"Any process that activates or increases the frequency, rate or extent of protein oligomerization.\" [GOC:mah]","metadata":null},{"id":"41e98288c25f4a7db42baa2f36f1c582","type":"GO_TERM","name":"positive regulation of protein oxidation","canonical_id":"go:GO:1904808","description":"\"Any process that activates or increases the frequency, rate or extent of protein oxidation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22719267]","metadata":null},{"id":"3952cc0097de4e55b90906ce84e3844a","type":"GO_TERM","name":"positive regulation of protein phosphorylation","canonical_id":"go:GO:0001934","description":"\"Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.\" [GOC:hjd]","metadata":null},{"id":"4abba2f208d54cce91d106c0ea15424b","type":"GO_TERM","name":"positive regulation of protein polyglycylation","canonical_id":"go:GO:1903346","description":"\"Any process that activates or increases the frequency, rate or extent of protein polyglycylation.\" [GO_REF:0000058, GOC:sart, GOC:TermGenie, PMID:21298005]","metadata":null},{"id":"541de1d8a7a34bf49dc33c84a942adbd","type":"GO_TERM","name":"positive regulation of protein polymerization","canonical_id":"go:GO:0032273","description":"\"Any process that activates or increases the frequency, rate or extent of the process of creating protein polymers.\" [GOC:mah]","metadata":null},{"id":"fb7b6407c9d5462fb065dbcd3458dd46","type":"GO_TERM","name":"positive regulation of protein polyubiquitination","canonical_id":"go:GO:1902916","description":"\"Any process that activates or increases the frequency, rate or extent of protein polyubiquitination.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:23645667]","metadata":null},{"id":"5a958639989b4f4d958be125ec176369","type":"GO_TERM","name":"positive regulation of protein processing","canonical_id":"go:GO:0010954","description":"\"Any process that increases the rate, frequency or extent of protein maturation by peptide bond cleavage.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"885244371afb41a89a793965a2111305","type":"GO_TERM","name":"positive regulation of protein processing in phagocytic vesicle","canonical_id":"go:GO:1903923","description":"\"Any process that activates or increases the frequency, rate or extent of protein processing in phagocytic vesicle.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23325791]","metadata":null},{"id":"afe3a27d817c4a6380fd9d140c758797","type":"GO_TERM","name":"positive regulation of protein refolding","canonical_id":"go:GO:1904592","description":"\"Any process that activates or increases the frequency, rate or extent of protein refolding.\" [GO_REF:0000058, GOC:TermGenie, PMID:11360998]","metadata":null},{"id":"3bbcc56ef9ed4f40a6ec9f0da7ec4e35","type":"GO_TERM","name":"positive regulation of protein secretion","canonical_id":"go:GO:0050714","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled release of a protein from a cell.\" [GOC:ai]","metadata":null},{"id":"7260102043284fd3a5ebf6129c6117ef","type":"GO_TERM","name":"positive regulation of protein serine/threonine kinase activity","canonical_id":"go:GO:0071902","description":"\"Any process that increases the rate, frequency, or extent of protein serine/threonine kinase activity.\" [GOC:mah]","metadata":null},{"id":"15ed9dc7a4b84a7d8d8c7afb0f506a30","type":"GO_TERM","name":"positive regulation of protein sumoylation","canonical_id":"go:GO:0033235","description":"\"Any process that activates or increases the frequency, rate or extent of the addition of SUMO groups to a protein.\" [GOC:mah]","metadata":null},{"id":"fcd14a6099ae443b99cd2092ee1537a2","type":"GO_TERM","name":"positive regulation of protein targeting to membrane","canonical_id":"go:GO:0090314","description":"\"Any process that increases the frequency, rate or extent of the process of directing proteins towards a membrane, usually using signals contained within the protein.\" [GOC:tb]","metadata":null},{"id":"ce18d60a7dc84971b55e650773053a24","type":"GO_TERM","name":"positive regulation of protein targeting to vacuolar membrane","canonical_id":"go:GO:1900485","description":"\"Any process that activates or increases the frequency, rate or extent of protein targeting to vacuolar membrane.\" [GOC:TermGenie]","metadata":null},{"id":"dfceffade02642a3a1603103ef25559f","type":"GO_TERM","name":"positive regulation of protein tetramerization","canonical_id":"go:GO:1901092","description":"\"Any process that activates or increases the frequency, rate or extent of protein tetramerization.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"fd9b962bf2b44964807969e562366db4","type":"GO_TERM","name":"positive regulation of protein transport","canonical_id":"go:GO:0051222","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a protein into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"d1d2d2a8c2ac49b4b82f7de79c53db7d","type":"GO_TERM","name":"positive regulation of protein tyrosine kinase activity","canonical_id":"go:GO:0061098","description":"\"Any process that increases the rate, frequency, or extent of protein tyrosine kinase activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ae5cb10cef1b4d0bab7de0f2f07f83aa","type":"GO_TERM","name":"positive regulation of protein ubiquitination","canonical_id":"go:GO:0031398","description":"\"Any process that activates or increases the frequency, rate or extent of the addition of ubiquitin groups to a protein.\" [GOC:mah]","metadata":null},{"id":"a598d6601fd04212a81188bb7ba88ca0","type":"GO_TERM","name":"positive regulation of protein-containing complex assembly","canonical_id":"go:GO:0031334","description":"\"Any process that activates or increases the frequency, rate or extent of protein complex assembly.\" [GOC:mah]","metadata":null},{"id":"200f1a5201d04eadac164455e5380af1","type":"GO_TERM","name":"positive regulation of protein-containing complex disassembly","canonical_id":"go:GO:0043243","description":"\"Any process that activates or increases the frequency, rate or extent of protein complex disassembly, the disaggregation of a protein complex into its constituent components.\" [GOC:jl]","metadata":null},{"id":"a0cedf83d7e74883aa24344781f42f5c","type":"GO_TERM","name":"positive regulation of protein-glutamine gamma-glutamyltransferase activity","canonical_id":"go:GO:0150074","description":"\"Any process that activates or increases the frequency, rate or extent of protein-glutamine gamma-glutamyltransferase activity.\" [GOC:aruk, GOC:bc, PMID:26670206]","metadata":null},{"id":"a0f7f0d97cbd4201aec8a88cfa1aa279","type":"GO_TERM","name":"positive regulation of protein-pyridoxal-5-phosphate linkage","canonical_id":"go:GO:1904287","description":"\"Any process that activates or increases the frequency, rate or extent of protein-pyridoxal-5-phosphate linkage.\" [GO_REF:0000058, GOC:TermGenie, PMID:25957689]","metadata":null},{"id":"ee60de11afa542e781b168d067ed64ae","type":"GO_TERM","name":"positive regulation of proteoglycan biosynthetic process","canonical_id":"go:GO:1902730","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteoglycans, any glycoprotein in which the carbohydrate units are glycosaminoglycans.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"999859b35c94491daf70024d02a8fd49","type":"GO_TERM","name":"positive regulation of proteolysis","canonical_id":"go:GO:0045862","description":"\"Any process that activates or increases the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.\" [GOC:curators]","metadata":null},{"id":"794eedf0fbdf46e2aa7d4471ef465d41","type":"GO_TERM","name":"positive regulation of proteolysis associated with antigen processing and presentation","canonical_id":"go:GO:0002630","description":"\"Any process that activates or increases the frequency, rate, or extent of proteolysis associated with antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"44608270eb7043c4abad5d499b09befa","type":"GO_TERM","name":"positive regulation of proton-transporting ATP synthase activity, rotational mechanism","canonical_id":"go:GO:1905273","description":"\"Any process that activates or increases the frequency, rate or extent of proton-transporting ATP synthase activity, rotational mechanism.\" [GO_REF:0000059, GOC:als, GOC:TermGenie, PMID:21106936]","metadata":null},{"id":"18b2323a5efd47ce9c0643393eda0943","type":"GO_TERM","name":"positive regulation of pseudohyphal growth","canonical_id":"go:GO:2000222","description":"\"Any process that activates or increases the frequency, rate or extent of pseudohyphal growth.\" [GOC:mah]","metadata":null},{"id":"99aac0985eeb47fca184dd95183ab210","type":"GO_TERM","name":"positive regulation of pseudohyphal growth by positive regulation of transcription from RNA polymerase II promoter","canonical_id":"go:GO:1900461","description":"\"Any process that activates or increases the frequency, rate or extent of pseudohyphal growth by activating or increasing the frequency, rate or extent of transcription from an RNA polymerase II promoter.\" [GOC:dgf, GOC:TermGenie, PMID:11046133, PMID:8710886, PMID:9987114]","metadata":null},{"id":"3d7c36453b28410e9f13b86caae93f4a","type":"GO_TERM","name":"positive regulation of pseudohyphal septin ring assembly","canonical_id":"go:GO:0062165","description":"\"Any process that increases the rate, frequency or extent of pseudohyphal septin ring formation.\" [PMID:29567712]","metadata":null},{"id":"7ca8c47a773c43ad8b437786eaa735ab","type":"GO_TERM","name":"positive regulation of pseudopodium assembly","canonical_id":"go:GO:0031274","description":"\"Any process that activates or increases the frequency, rate or extent of the assembly of pseudopodia.\" [GOC:pg]","metadata":null},{"id":"76a91b400ed54de498850308f974fcc9","type":"GO_TERM","name":"positive regulation of pseurotin A biosynthetic process","canonical_id":"go:GO:1900851","description":"\"Any process that activates or increases the frequency, rate or extent of pseurotin A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4406545752f44a698bf3336ae9f04ce4","type":"GO_TERM","name":"positive regulation of pulmonary blood vessel remodeling","canonical_id":"go:GO:1905111","description":"\"Any process that activates or increases the frequency, rate or extent of pulmonary blood vessel remodeling.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22161164]","metadata":null},{"id":"32529b7ddfd244e58897216132f33c52","type":"GO_TERM","name":"positive regulation of pupariation","canonical_id":"go:GO:0106025","description":"\"Any process that activates or increases the frequency, rate or extent of onset of pupariation.\" [GOC:hjd]","metadata":null},{"id":"91023c15ce6640209b192ad8906d86d2","type":"GO_TERM","name":"positive regulation of purine nucleobase metabolic process","canonical_id":"go:GO:0045983","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving purine bases.\" [GOC:curators]","metadata":null},{"id":"e7ca2abd54b8480eab3d7b3a3676d658","type":"GO_TERM","name":"positive regulation of purine nucleoside transport","canonical_id":"go:GO:0032248","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a purine nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"de2223aa741a42c8a18a2e094b6743e9","type":"GO_TERM","name":"positive regulation of purine nucleotide biosynthetic process","canonical_id":"go:GO:1900373","description":"\"Any process that activates or increases the frequency, rate or extent of purine nucleotide biosynthetic processes.\" [GOC:curators, GOC:TermGenie]","metadata":null},{"id":"8655f08d7ac7416f919a853e85b4d28d","type":"GO_TERM","name":"positive regulation of purine nucleotide catabolic process","canonical_id":"go:GO:0033123","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of purine nucleotides.\" [GOC:mah]","metadata":null},{"id":"bb23e6a2c7b247cfa55a5419ab1c9673","type":"GO_TERM","name":"positive regulation of purine nucleotide metabolic process","canonical_id":"go:GO:1900544","description":"\"Any process that activates or increases the frequency, rate or extent of purine nucleotide metabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"a7a48deb4fd34236b9fd3276339f3a92","type":"GO_TERM","name":"positive regulation of pyloric antrum smooth muscle contraction","canonical_id":"go:GO:0120072","description":"\"Any process that increases the frequency, rate or extent of any pyloric antrum smooth muscle contraction.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"f05086cf378b4d05b003f24b5c8a468b","type":"GO_TERM","name":"positive regulation of pyocyanine biosynthetic process","canonical_id":"go:GO:0062162","description":"\"Any process that increases the frequency, rate or extent of a pyocyanine biosynthetic process.\" [PMID:28715477]","metadata":null},{"id":"0d596c32cafd415a90bf854128b3f6f3","type":"GO_TERM","name":"positive regulation of pyrimidine nucleobase metabolic process","canonical_id":"go:GO:0045985","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving pyrimidine nucleobases.\" [GOC:curators]","metadata":null},{"id":"d56b93c89f8841129af30d9e4ef1a92c","type":"GO_TERM","name":"positive regulation of pyrimidine nucleotide biosynthetic process","canonical_id":"go:GO:1900399","description":"\"Any process that activates or increases the frequency, rate or extent of pyrimidine nucleotide biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"c829f825a2034938ab918cd234bd3d56","type":"GO_TERM","name":"positive regulation of pyrimidine-containing compound salvage","canonical_id":"go:GO:1903931","description":"\"Any process that activates or increases the frequency, rate or extent of pyrimidine-containing compound salvage.\" [GO_REF:0000058, GOC:TermGenie, PMID:23695302]","metadata":null},{"id":"b936c0579bf64c46889d7cb1f28b0fb1","type":"GO_TERM","name":"positive regulation of pyroptotic inflammatory response","canonical_id":"go:GO:0140639","description":"\"Any process that increases the frequency, rate or extent of a pyroptotic inflammatory response.\" [PMID:24626226]","metadata":null},{"id":"0f1cc763938441a1bb430b337dfaa8dd","type":"GO_TERM","name":"positive regulation of pyruvate decarboxylation to acetyl-CoA","canonical_id":"go:GO:0140176","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acetyl-CoA from pyruvate. In most organisms, this pathway links glycolysis to the TCA cycle, by a series of three reactions carried out by a multisubunit complex called the 'pyruvate dehydrogenase complex', even though pyruvate dehydrogenase activity describes only one of those reactions.\" [PMID:15855260]","metadata":null},{"id":"0601aa390d4444efb43827ce27b393e2","type":"GO_TERM","name":"positive regulation of quinolinate biosynthetic process","canonical_id":"go:GO:1904986","description":"\"Any process that activates or increases the frequency, rate or extent of quinolinate biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"9b2312c91f24416d941ca342f1af5fae","type":"GO_TERM","name":"positive regulation of rDNA heterochromatin formation","canonical_id":"go:GO:2000749","description":"\"Any process that activates or increases the frequency, rate or extent of rDNA heterochromatin formation.\" [PMID:10899127]","metadata":null},{"id":"199193ac9b0e4afcb262a98e7b13e3a0","type":"GO_TERM","name":"positive regulation of rRNA processing","canonical_id":"go:GO:2000234","description":"\"Any process that activates or increases the frequency, rate or extent of rRNA processing.\" [GOC:mah]","metadata":null},{"id":"1598044fed3e4bd2a207b94b7bf8b15d","type":"GO_TERM","name":"positive regulation of raffinose biosynthetic process","canonical_id":"go:GO:1900093","description":"\"Any process that activates or increases the frequency, rate or extent of raffinose biosynthetic process.\" [GOC:TermGenie, PMID:22307851]","metadata":null},{"id":"601d8c1eec0846389f850beeb178b747","type":"GO_TERM","name":"positive regulation of reactive oxygen species biosynthetic process","canonical_id":"go:GO:1903428","description":"\"Any process that activates or increases the frequency, rate or extent of reactive oxygen species biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24252804]","metadata":null},{"id":"8aaf4c218de54829badcd0f045e1aef3","type":"GO_TERM","name":"positive regulation of reactive oxygen species metabolic process","canonical_id":"go:GO:2000379","description":"\"Any process that activates or increases the frequency, rate or extent of reactive oxygen species metabolic process.\" [GOC:mah]","metadata":null},{"id":"f2226b4c13034c5ebb00e476ceea18dd","type":"GO_TERM","name":"positive regulation of receptor catabolic process","canonical_id":"go:GO:2000646","description":"\"Any process that activates or increases the frequency, rate or extent of receptor catabolic process.\" [GOC:BHF]","metadata":null},{"id":"8eca233a539a465e9ea12bce5f28bf2b","type":"GO_TERM","name":"positive regulation of receptor clustering","canonical_id":"go:GO:1903911","description":"\"Any process that activates or increases the frequency, rate or extent of receptor clustering.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"eaf4702db5db4fc4b5144a1b70dd2345","type":"GO_TERM","name":"positive regulation of receptor internalization","canonical_id":"go:GO:0002092","description":"\"Any process that activates or increases the frequency, rate or extent of receptor internalization.\" [GOC:hjd]","metadata":null},{"id":"401b850b9acc4456aa6dcd97ef6af2a7","type":"GO_TERM","name":"positive regulation of receptor localization to synapse","canonical_id":"go:GO:1902685","description":"\"Any process that activates or increases the frequency, rate or extent of receptor localization to synapse.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22252129]","metadata":null},{"id":"e7d37a37abb8471a8d64d9bb0bff5f79","type":"GO_TERM","name":"positive regulation of receptor recycling","canonical_id":"go:GO:0001921","description":"\"Any process that activates or increases the frequency, rate or extent of receptor recycling.\" [GOC:add]","metadata":null},{"id":"744c9d340de1459e8ac20ff4da4c0bca","type":"GO_TERM","name":"positive regulation of receptor signaling pathway via JAK-STAT","canonical_id":"go:GO:0046427","description":"\"Any process that activates or increases the frequency, rate or extent of the JAK-STAT signaling pathway activity.\" [GOC:bf]","metadata":null},{"id":"f8bdb5681d97465c9914a5ad15525de2","type":"GO_TERM","name":"positive regulation of receptor signaling pathway via STAT","canonical_id":"go:GO:1904894","description":"\"Any process that activates or increases the frequency, rate or extent of receptor signaling pathway via STAT.\" [GO_REF:0000058, GOC:rjd, GOC:TermGenie, PMID:24587195]","metadata":null},{"id":"778fab9a68964f898ccbc2df4c4f4d42","type":"GO_TERM","name":"positive regulation of receptor-mediated endocytosis","canonical_id":"go:GO:0048260","description":"\"Any process that activates or increases the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"2c97e7a9944348e898f49e6ccc700235","type":"GO_TERM","name":"positive regulation of receptor-mediated endocytosis involved in cholesterol transport","canonical_id":"go:GO:1905602","description":"\"Any process that activates or increases the frequency, rate or extent of receptor-mediated endocytosis involved in cholesterol transport.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:22848640]","metadata":null},{"id":"9c847cdacd0946b4b6fbee0372a7b09f","type":"GO_TERM","name":"positive regulation of receptor-mediated virion attachment to host cell","canonical_id":"go:GO:1902736","description":"\"Any process that activates or increases the frequency, rate or extent of receptor-mediated virion attachment to host cell.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18385238]","metadata":null},{"id":"9340bbdddb7e4f938392aa0732073e8c","type":"GO_TERM","name":"positive regulation of reciprocal meiotic recombination","canonical_id":"go:GO:0010845","description":"\"Any process that increases the frequency, rate or extent of recombination during meiosis. Reciprocal meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"fb15fafe7c8640fab072703dcd325e61","type":"GO_TERM","name":"positive regulation of red or far-red light signaling pathway","canonical_id":"go:GO:0090228","description":"\"Any process that increases the rate, frequency or extent of the red or far-red signaling pathway, the series of molecular signals initiated upon sensing by photoreceptor molecules of red light or far red light.\" [GOC:tb]","metadata":null},{"id":"5caa17cd13794903b1c4feb815c6d0a0","type":"GO_TERM","name":"positive regulation of regulated secretory pathway","canonical_id":"go:GO:1903307","description":"\"Any process that activates or increases the frequency, rate or extent of regulated secretory pathway.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:12526776]","metadata":null},{"id":"e9c870311ae1457eb0d2a05480809806","type":"GO_TERM","name":"positive regulation of regulation of ascospore wall (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0140748","description":"\"Any process that activates or increases the frequency, rate or extent of ascospore wall (1->3)-beta-D-glucan biosynthetic process.\" [PMID:19189958]","metadata":null},{"id":"f868df56d9a44f64b2bbdce7d9d53051","type":"GO_TERM","name":"positive regulation of regulation of vascular associated smooth muscle cell membrane depolarization","canonical_id":"go:GO:1904199","description":"\"Any process that activates or increases the frequency, rate or extent of regulation of vascular smooth muscle cell membrane depolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:20826763]","metadata":null},{"id":"e66fc052d5614909a10068c323f8d3ab","type":"GO_TERM","name":"positive regulation of regulatory T cell differentiation","canonical_id":"go:GO:0045591","description":"\"Any process that activates or increases the frequency, rate or extent of differentiation of regulatory T cells.\" [ISBN:0781735149]","metadata":null},{"id":"52a17f517250454ab828321a1e18b77c","type":"GO_TERM","name":"positive regulation of relaxation of cardiac muscle","canonical_id":"go:GO:1901899","description":"\"Any process that activates or increases the frequency, rate or extent of relaxation of cardiac muscle.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671]","metadata":null},{"id":"65183c8dc96144ffbd3d21a015faf575","type":"GO_TERM","name":"positive regulation of relaxation of muscle","canonical_id":"go:GO:1901079","description":"\"Any process that activates or increases the frequency, rate or extent of relaxation of muscle.\" [GOC:TermGenie]","metadata":null},{"id":"d89d5ad937f544c4bb118bb641a25430","type":"GO_TERM","name":"positive regulation of relaxation of smooth muscle","canonical_id":"go:GO:1901082","description":"\"Any process that activates or increases the frequency, rate or extent of relaxation of smooth muscle.\" [GOC:TermGenie]","metadata":null},{"id":"dc1c5be8476b4dafbd90ea91a75cc2ff","type":"GO_TERM","name":"positive regulation of release of cytochrome c from mitochondria","canonical_id":"go:GO:0090200","description":"\"Any process that increases the rate, frequency or extent of release of cytochrome c from mitochondria, the process in which cytochrome c is enabled to move from the mitochondrial intermembrane space into the cytosol, which is an early step in apoptosis and leads to caspase activation.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"1d0b9818e27446f69ea6706d14023d7d","type":"GO_TERM","name":"positive regulation of release of sequestered calcium ion into cytosol","canonical_id":"go:GO:0051281","description":"\"Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.\" [GOC:ai]","metadata":null},{"id":"ceb644c9c8da41a1b59aea202a93fd00","type":"GO_TERM","name":"positive regulation of removal of superoxide radicals","canonical_id":"go:GO:1904833","description":"\"Any process that activates or increases the frequency, rate or extent of removal of superoxide radicals.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22836756]","metadata":null},{"id":"655b0ee223234d67a1aedcd21b182c03","type":"GO_TERM","name":"positive regulation of renal albumin absorption","canonical_id":"go:GO:2000534","description":"\"Any process that activates or increases the frequency, rate or extent of renal albumin absorption.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"2b33e2870c4f45ef82d21aaa58eb1cc1","type":"GO_TERM","name":"positive regulation of renal amino acid absorption","canonical_id":"go:GO:1902754","description":"\"Any process that activates or increases the frequency, rate or extent of renal amino acid absorption.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:1526373]","metadata":null},{"id":"e24d337ffedd49d599c32948cd1f4f64","type":"GO_TERM","name":"positive regulation of renal phosphate excretion","canonical_id":"go:GO:1903404","description":"\"Any process that activates or increases the frequency, rate or extent of renal phosphate excretion.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:8700837]","metadata":null},{"id":"41b2f5681f6c4ef483f525994e7f9f27","type":"GO_TERM","name":"positive regulation of renal sodium excretion","canonical_id":"go:GO:0035815","description":"\"Any process that increases the amount of sodium excreted in urine over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"593d245434894d829b17ea95fc496b05","type":"GO_TERM","name":"positive regulation of renal sodium excretion by pressure natriuresis","canonical_id":"go:GO:0035819","description":"\"An increase in the amount of sodium excreted in urine over a unit of time, as a result of pressure natriuresis.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"2ce11850e09941dd89ada5e710ccfe41","type":"GO_TERM","name":"positive regulation of renal water transport","canonical_id":"go:GO:2001153","description":"\"Any process that activates or increases the frequency, rate or extent of renal water transport.\" [GOC:obol]","metadata":null},{"id":"f5facbd8cc6e497e8585e2762c8120d8","type":"GO_TERM","name":"positive regulation of renin secretion into blood stream","canonical_id":"go:GO:1900135","description":"\"Any process that activates or increases the frequency, rate or extent of renin secretion into blood stream.\" [GOC:TermGenie]","metadata":null},{"id":"1202fbea7ecc4881899afb2d737323f9","type":"GO_TERM","name":"positive regulation of replicative senescence","canonical_id":"go:GO:1904728","description":"\"Any process that activates or increases the frequency, rate or extent of replicative senescence.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23496142]","metadata":null},{"id":"b4c85b5d7b234ea08a21c75f16f410bf","type":"GO_TERM","name":"positive regulation of reproductive process","canonical_id":"go:GO:2000243","description":"\"Any process that activates or increases the frequency, rate or extent of reproductive process.\" [GOC:mah]","metadata":null},{"id":"1a29c7ee50d14337a70d0f9c8ac3c32d","type":"GO_TERM","name":"positive regulation of respiratory burst","canonical_id":"go:GO:0060267","description":"\"Any process that increases the rate frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8022502e20e54fd1983547ebc7217dc0","type":"GO_TERM","name":"positive regulation of respiratory burst involved in inflammatory response","canonical_id":"go:GO:0060265","description":"\"Any process that increases the rate, frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases made as a defense response ; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"fef1f484df374583b30c8a148f03158f","type":"GO_TERM","name":"positive regulation of respiratory gaseous exchange","canonical_id":"go:GO:1903942","description":"\"Any process that activates or increases the frequency, rate or extent of respiratory gaseous exchange.\" [GO_REF:0000058, GOC:TermGenie, PMID:22819705]","metadata":null},{"id":"4a309f73de354c4fb496381c22ea88a7","type":"GO_TERM","name":"positive regulation of response to DNA damage checkpoint signaling","canonical_id":"go:GO:1902154","description":"\"Any process that activates or increases the frequency, rate or extent of response to DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"6c806eb1f4c4465fa5e77e9529da091f","type":"GO_TERM","name":"positive regulation of response to DNA integrity checkpoint signaling","canonical_id":"go:GO:1902152","description":"\"Any process that activates or increases the frequency, rate or extent of response to DNA integrity checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"78201f549e4247df868f5118138e807b","type":"GO_TERM","name":"positive regulation of response to G1 DNA damage checkpoint signaling","canonical_id":"go:GO:1902156","description":"\"Any process that activates or increases the frequency, rate or extent of response to G1 DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"1b1c8c5796834f2a8e4897f0f4d7b0dc","type":"GO_TERM","name":"positive regulation of response to G2 DNA damage checkpoint signaling","canonical_id":"go:GO:1902158","description":"\"Any process that activates or increases the frequency, rate or extent of response to G2 DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"fd911888666248d9ace5955f51a906a4","type":"GO_TERM","name":"positive regulation of response to acetate","canonical_id":"go:GO:1901459","description":"\"Any process that activates or increases the frequency, rate or extent of response to acetate.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b03ec6a1f5394e4e8712ec61004447b0","type":"GO_TERM","name":"positive regulation of response to alcohol","canonical_id":"go:GO:1901421","description":"\"Any process that activates or increases the frequency, rate or extent of response to alcohol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b53e8ff079384f2996d87d294e0485e2","type":"GO_TERM","name":"positive regulation of response to amylopectin","canonical_id":"go:GO:1900523","description":"\"Any process that activates or increases the frequency, rate or extent of response to amylopectin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"1208c0574089405e86e2a8ce2ba5b720","type":"GO_TERM","name":"positive regulation of response to benzene","canonical_id":"go:GO:1901453","description":"\"Any process that activates or increases the frequency, rate or extent of response to benzene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"00c32f9e2b6e4177a8d822d363bb3888","type":"GO_TERM","name":"positive regulation of response to biotic stimulus","canonical_id":"go:GO:0002833","description":"\"Any process that activates or increases the frequency, rate, or extent of a response to biotic stimulus.\" [GOC:add]","metadata":null},{"id":"891403cec854402080c3f96b979f7bca","type":"GO_TERM","name":"positive regulation of response to butan-1-ol","canonical_id":"go:GO:1901450","description":"\"Any process that activates or increases the frequency, rate or extent of response to butan-1-ol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"647d2d1a96f54e1780f817b8b18d7892","type":"GO_TERM","name":"positive regulation of response to calcium ion","canonical_id":"go:GO:1905947","description":"\"Any process that activates or increases the frequency, rate or extent of response to calcium ion.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:11404397]","metadata":null},{"id":"8ce5701af0ea4489b12385640fd81112","type":"GO_TERM","name":"positive regulation of response to cell cycle checkpoint signaling","canonical_id":"go:GO:1902146","description":"\"Any process that activates or increases the frequency, rate or extent of response to cell cycle checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"67c4938c13f74e048d369b7b0d9abf70","type":"GO_TERM","name":"positive regulation of response to cycloalkane","canonical_id":"go:GO:1901433","description":"\"Any process that activates or increases the frequency, rate or extent of response to cycloalkane.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"01058e0379b64f3ab8fbd8c168b0a866","type":"GO_TERM","name":"positive regulation of response to cytokine stimulus","canonical_id":"go:GO:0060760","description":"\"Any process that increases the rate, frequency, or extent of a response to cytokine stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"247466c678444b19a93ea6d74c1f183f","type":"GO_TERM","name":"positive regulation of response to cytokinesis checkpoint signaling","canonical_id":"go:GO:1902148","description":"\"Any process that activates or increases the frequency, rate or extent of response to cytokinesis checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"0855dafa82174aa9bf69755337cbe6e6","type":"GO_TERM","name":"positive regulation of response to drug","canonical_id":"go:GO:2001025","description":"\"Any process that activates or increases the frequency, rate or extent of response to drug.\" [GOC:obol]","metadata":null},{"id":"9d86cae66fa14e4b91004b0dcf3a8205","type":"GO_TERM","name":"positive regulation of response to endoplasmic reticulum stress","canonical_id":"go:GO:1905898","description":"\"Any process that activates or increases the frequency, rate or extent of response to endoplasmic reticulum stress.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:21803450]","metadata":null},{"id":"50cfac77c18642499edcc43f9fae300f","type":"GO_TERM","name":"positive regulation of response to ethanol","canonical_id":"go:GO:1901418","description":"\"Any process that activates or increases the frequency, rate or extent of response to ethanol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"94251694b4384e2fb5a5bb068d5913f1","type":"GO_TERM","name":"positive regulation of response to external stimulus","canonical_id":"go:GO:0032103","description":"\"Any process that activates, maintains or increases the rate of a response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"7bb45f8dced04562bc858d26c62b3117","type":"GO_TERM","name":"positive regulation of response to food","canonical_id":"go:GO:0032097","description":"\"Any process that activates, maintains, or increases the rate of a response to a food stimulus.\" [GOC:add]","metadata":null},{"id":"171be7123772470b969ce4453b0cd3ac","type":"GO_TERM","name":"positive regulation of response to formic acid","canonical_id":"go:GO:1901462","description":"\"Any process that activates or increases the frequency, rate or extent of response to formic acid.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9f558ca1a22f49e0acbc8dec5e38554f","type":"GO_TERM","name":"positive regulation of response to furfural","canonical_id":"go:GO:1901444","description":"\"Any process that activates or increases the frequency, rate or extent of response to furfural.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"8ae53ef996804afe8bdd319109f5738d","type":"GO_TERM","name":"positive regulation of response to gamma radiation","canonical_id":"go:GO:2001230","description":"\"Any process that activates or increases the frequency, rate or extent of response to gamma radiation.\" [GOC:obol]","metadata":null},{"id":"317a6e14f3614920a46f96c872e42d2c","type":"GO_TERM","name":"positive regulation of response to macrophage colony-stimulating factor","canonical_id":"go:GO:1903971","description":"\"Any process that activates or increases the frequency, rate or extent of response to macrophage colony-stimulating factor.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"f4e750b3d9834c3f9eef3acf4a9d4e3d","type":"GO_TERM","name":"positive regulation of response to nutrient levels","canonical_id":"go:GO:0032109","description":"\"Any process that activates or increases the frequency, rate or extent of a response to nutrient levels.\" [GOC:mah]","metadata":null},{"id":"e100f680302a4041abcb9cef3959f414","type":"GO_TERM","name":"positive regulation of response to oxidative stress","canonical_id":"go:GO:1902884","description":"\"Any process that activates or increases the frequency, rate or extent of response to oxidative stress.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:16899554]","metadata":null},{"id":"6a5303dc7f2d4806bb72eb3c0070941c","type":"GO_TERM","name":"positive regulation of response to propan-1-ol","canonical_id":"go:GO:1901447","description":"\"Any process that activates or increases the frequency, rate or extent of response to propan-1-ol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"1c7fe8258c2c4e599b38f2de6b91193d","type":"GO_TERM","name":"positive regulation of response to pullulan","canonical_id":"go:GO:1900520","description":"\"Any process that activates or increases the frequency, rate or extent of response to pullulan.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2e1eef287a354770882253ad983b8539","type":"GO_TERM","name":"positive regulation of response to reactive oxygen species","canonical_id":"go:GO:1901033","description":"\"Any process that activates or increases the frequency, rate or extent of response to reactive oxygen species.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"b545c7e5e7b5469fbeeb22785b0bd739","type":"GO_TERM","name":"positive regulation of response to salt stress","canonical_id":"go:GO:1901002","description":"\"Any process that activates or increases the frequency, rate or extent of response to salt stress.\" [GOC:TermGenie, PMID:22627139]","metadata":null},{"id":"4537960e1dbb48dbb9b62de7fb5b1b90","type":"GO_TERM","name":"positive regulation of response to stimulus","canonical_id":"go:GO:0048584","description":"\"Any process that activates, maintains or increases the rate of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.\" [GOC:jid]","metadata":null},{"id":"ccfd06c49fc84076bd21ebd0d5c1bf5f","type":"GO_TERM","name":"positive regulation of response to toluene","canonical_id":"go:GO:1901456","description":"\"Any process that activates or increases the frequency, rate or extent of response to toluene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4ee035b8150c4b2394d881989d489418","type":"GO_TERM","name":"positive regulation of response to tumor cell","canonical_id":"go:GO:0002836","description":"\"Any process that activates or increases the frequency, rate, or extent of a response to tumor cell.\" [GOC:add]","metadata":null},{"id":"0d59c90bb7fb427794f705433a8a278b","type":"GO_TERM","name":"positive regulation of response to type II interferon","canonical_id":"go:GO:0060332","description":"\"Any process that increases the rate, frequency or extent of a response to type II interferon (interferon-gamma). Response to interferon gamma is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus.\" [GOC:dph]","metadata":null},{"id":"a943ab0da8854b78b6393eaf8bac2fbb","type":"GO_TERM","name":"positive regulation of response to water deprivation","canonical_id":"go:GO:1902584","description":"\"Any process that activates or increases the frequency, rate or extent of response to water deprivation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24198318]","metadata":null},{"id":"6f20b2dcd395497d99d0fe7246a796f3","type":"GO_TERM","name":"positive regulation of response to wounding","canonical_id":"go:GO:1903036","description":"\"Any process that activates or increases the frequency, rate or extent of response to wounding.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:19164535]","metadata":null},{"id":"7dee4fc5ea0c44dfa8cf36ffc4ef2108","type":"GO_TERM","name":"positive regulation of reticulophagy","canonical_id":"go:GO:0140501","description":"\"Any process that increases the frequency, rate or extent of reticulophagy.\" [PMID:32735772]","metadata":null},{"id":"52ab63d7a49d4bea9fec458eb5e63b9a","type":"GO_TERM","name":"positive regulation of retina development in camera-type eye","canonical_id":"go:GO:1902868","description":"\"Any process that activates or increases the frequency, rate or extent of retina development in camera-type eye.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"24e3ce8f6ae644eeb26e4a002b02adbb","type":"GO_TERM","name":"positive regulation of retinal cell programmed cell death","canonical_id":"go:GO:0046670","description":"\"Any process that activates or increases the frequency, rate or extent of programmed cell death that occurs in the retina.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"16bf3eeb3ac44f05b79e3def15fba1bd","type":"GO_TERM","name":"positive regulation of retinal ganglion cell axon guidance","canonical_id":"go:GO:1902336","description":"\"Any process that activates or increases the frequency, rate or extent of retinal ganglion cell axon guidance.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21658587]","metadata":null},{"id":"12510e212fce47e2a7a7f79f73f6e487","type":"GO_TERM","name":"positive regulation of retinal rod cell fate commitment","canonical_id":"go:GO:0060225","description":"\"Any process that increases the process in which the developmental fate of a cell becomes restricted such that it will develop into a retinal rod cell. A retinal rod cell is one of the two photoreceptor subtypes in a camera-type eye.\" [GOC:dph]","metadata":null},{"id":"e4f7c56a20474800ac16d3434f524846","type":"GO_TERM","name":"positive regulation of retinoic acid biosynthetic process","canonical_id":"go:GO:1900054","description":"\"Any process that activates or increases the frequency, rate or extent of retinoic acid biosynthetic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"4a00231fa3964335ba700547a2e162e5","type":"GO_TERM","name":"positive regulation of retinoic acid receptor signaling pathway","canonical_id":"go:GO:0048386","description":"\"Any process that activates or increases the frequency, rate or extent of retinoic acid receptor signaling pathway activity.\" [GOC:dgh]","metadata":null},{"id":"47a6b00dd8e645c18c1044ddee6a25b9","type":"GO_TERM","name":"positive regulation of retrograde axon cargo transport","canonical_id":"go:GO:2001019","description":"\"Any process that activates or increases the frequency, rate or extent of retrograde axon cargo transport.\" [GOC:obol]","metadata":null},{"id":"32fac4afb5894010b4f9609deeb7aaff","type":"GO_TERM","name":"positive regulation of retrograde dense core granule transport","canonical_id":"go:GO:1901956","description":"\"Any process that activates or increases the frequency, rate or extent of retrograde dense core granule transport.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"445b56bd23394d28a8f45d50f6361e32","type":"GO_TERM","name":"positive regulation of retrograde protein transport, ER to cytosol","canonical_id":"go:GO:1904154","description":"\"Any process that activates or increases the frequency, rate or extent of retrograde protein transport, ER to cytosol.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18555783]","metadata":null},{"id":"c4bc4863e1e74becba560e1030133613","type":"GO_TERM","name":"positive regulation of retrograde trans-synaptic signaling by neuropeptide","canonical_id":"go:GO:1905434","description":"\"Any process that activates or increases the frequency, rate or extent of retrograde trans-synaptic signaling by neuropeptide.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:19448629]","metadata":null},{"id":"525f5ecb0b874a6cacb98d17d6ff9ea7","type":"GO_TERM","name":"positive regulation of retrograde transport, endosome to Golgi","canonical_id":"go:GO:1905281","description":"\"Any process that activates or increases the frequency, rate or extent of retrograde transport, endosome to Golgi.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"48730c1141a74fb89eee600c5122b84c","type":"GO_TERM","name":"positive regulation of reverse cholesterol transport","canonical_id":"go:GO:1903064","description":"\"Any process that activates or increases the frequency, rate or extent of reverse cholesterol transport.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23931754]","metadata":null},{"id":"4536dd4bbc5c463aa3e86fc7a87d60a9","type":"GO_TERM","name":"positive regulation of reverse transcription","canonical_id":"go:GO:1900270","description":"\"Any process that activates or increases the frequency, rate or extent of reverse transcription.\" [GOC:TermGenie]","metadata":null},{"id":"7bb3610110974350a51ff7e68b3533eb","type":"GO_TERM","name":"positive regulation of ribonucleoprotein complex localization","canonical_id":"go:GO:2000199","description":"\"Any process that activates or increases the frequency, rate or extent of ribonucleoprotein complex localization.\" [GOC:mah]","metadata":null},{"id":"948ba7aeba404f029037041d8da3eb84","type":"GO_TERM","name":"positive regulation of ribosomal large subunit export from nucleus","canonical_id":"go:GO:2000205","description":"\"Any process that activates or increases the frequency, rate or extent of ribosomal large subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"6b8b30018b67431c883b0a99fd93233d","type":"GO_TERM","name":"positive regulation of ribosomal protein gene transcription by RNA polymerase II","canonical_id":"go:GO:0060963","description":"\"Any process that increases the frequency, rate or extent of the synthesis of RNA from ribosomal protein genes mediated by RNA polymerase II.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"aaa1c44854cb4e028af4124bf1c3a06b","type":"GO_TERM","name":"positive regulation of ribosomal small subunit export from nucleus","canonical_id":"go:GO:2000208","description":"\"Any process that activates or increases the frequency, rate or extent of ribosomal small subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"c933a62bffe44cf480933b8f2a9b8a41","type":"GO_TERM","name":"positive regulation of ribosomal subunit export from nucleus","canonical_id":"go:GO:2000202","description":"\"Any process that activates or increases the frequency, rate or extent of ribosomal subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"5e64de2554d8441e9fc4eb3c0efa972b","type":"GO_TERM","name":"positive regulation of ribosome biogenesis","canonical_id":"go:GO:0090070","description":"\"Any process that increases the rate, frequency or extent of ribosome biogenesis. Ribosome biogenesis is the cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of ribosome subunits.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"38795ad2bf8443298df3a42c2cbc41aa","type":"GO_TERM","name":"positive regulation of root hair elongation","canonical_id":"go:GO:1902892","description":"\"Any process that activates or increases the frequency, rate or extent of root hair elongation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22329353]","metadata":null},{"id":"11b16c7661304feaa7b80aac679bf42b","type":"GO_TERM","name":"positive regulation of ruffle assembly","canonical_id":"go:GO:1900029","description":"\"Any process that activates or increases the frequency, rate or extent of ruffle assembly.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"f372b191c8f04553b67cf71e60fac185","type":"GO_TERM","name":"positive regulation of salicylic acid mediated signaling pathway","canonical_id":"go:GO:0080151","description":"\"Any process that activates or increases the frequency, rate or extent of salicylic acid mediated signal transduction.\" [PMID:20181750]","metadata":null},{"id":"38a446ceefe54721b6cee6e163468402","type":"GO_TERM","name":"positive regulation of saliva secretion","canonical_id":"go:GO:0046878","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of saliva.\" [GOC:ai]","metadata":null},{"id":"f9e54b3a606442e1b8524183910b532b","type":"GO_TERM","name":"positive regulation of salivary gland boundary specification","canonical_id":"go:GO:0045706","description":"\"Any process that activates or increases the frequency, rate or extent of salivary gland determination.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"24b8aa9e81894e7abdbb93a2db94fa8f","type":"GO_TERM","name":"positive regulation of salivary gland formation by mesenchymal-epithelial signaling","canonical_id":"go:GO:0060639","description":"\"Any process that induces the formation of the salivary gland field by means of the secretion of a signal by a mesenchymal cell and its reception and interpretation by an epithelial cell resulting in it adopting the identity of a salivary gland bud cell.\" [GOC:dph]","metadata":null},{"id":"3d9cfa4a0bec47529c6311732517a1f7","type":"GO_TERM","name":"positive regulation of sarcinapterin biosynthetic process","canonical_id":"go:GO:1900973","description":"\"Any process that activates or increases the frequency, rate or extent of sarcinapterin biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"7d598ba3c468444ba226f3462b3491b7","type":"GO_TERM","name":"positive regulation of sarcomere organization","canonical_id":"go:GO:0060298","description":"\"Any process that increases the rate, frequency or extent of myofibril assembly by organization of muscle actomyosin into sarcomeres. The sarcomere is the repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"2b4dd989dd934934a5c999d81fab1eba","type":"GO_TERM","name":"positive regulation of satellite cell activation involved in skeletal muscle regeneration","canonical_id":"go:GO:0014718","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of activation of satellite cell involved in skeletal muscle regeneration. The activation of satellite cell is the process that initiates satellite cell division by causing it to move from quiescence to the G1 stage of the cell cycle. The cell swells and there are a number of other small changes. The cells then start to divide. Following cell division the cells will differentiate.\" [GOC:mtg_muscle]","metadata":null},{"id":"d184440b2b1d4d8abca97f68b1cd19d0","type":"GO_TERM","name":"positive regulation of sclerenchyma cell differentiation","canonical_id":"go:GO:1904369","description":"\"Any process that activates or increases the frequency, rate or extent of sclerenchyma cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:26025534]","metadata":null},{"id":"7cebe549b2cd43af8aeb12f6e6297fa7","type":"GO_TERM","name":"positive regulation of sclerotium development","canonical_id":"go:GO:1901924","description":"\"Any process that activates or increases the frequency, rate or extent of sclerotium development.\" [GOC:di, GOC:TermGenie, PMID:21148914]","metadata":null},{"id":"9867d2aea5144c1cbc622f60d4fcc762","type":"GO_TERM","name":"positive regulation of sclerotome development","canonical_id":"go:GO:0061189","description":"\"Any process that increases the rate, frequency, or extent of the progression of the sclerotome over time, from its initial formation to the mature structure. The sclerotome is the portion of the somite that will give rise to a vertebra.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"296fb702da3e42a1a61273d0a34da0dd","type":"GO_TERM","name":"positive regulation of sebum secreting cell proliferation","canonical_id":"go:GO:1904004","description":"\"Any process that activates or increases the frequency, rate or extent of sebum secreting cell proliferation.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:16901790]","metadata":null},{"id":"bbc991709cd94f83b7bd9bd1c4dec696","type":"GO_TERM","name":"positive regulation of secondary cell septum biogenesis","canonical_id":"go:GO:1903397","description":"\"Any process that activates or increases the frequency, rate or extent of secondary cell septum biogenesis.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:23878277]","metadata":null},{"id":"bdeb02deac82405298da500998051b5c","type":"GO_TERM","name":"positive regulation of secondary cell wall biogenesis","canonical_id":"go:GO:1901348","description":"\"Any process that activates or increases the frequency, rate or extent of secondary cell wall biogenesis.\" [GOC:TermGenie]","metadata":null},{"id":"8b68b33a435a4442be5cbca6a8efe0ec","type":"GO_TERM","name":"positive regulation of secondary growth","canonical_id":"go:GO:2000605","description":"\"Any process that activates or increases the frequency, rate or extent of secondary growth.\" [GOC:obol]","metadata":null},{"id":"cfbb511db5e7404ab7e3817328c635c5","type":"GO_TERM","name":"positive regulation of secondary heart field cardioblast proliferation","canonical_id":"go:GO:0072513","description":"\"Any process that activates or increases the frequency, rate or extent of cardioblast proliferation in the second heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating. The secondary heart field is the region of the heart that will form the majority of the mesodermal component of the right ventricle, the arterial pole (outflow tract) and the venous pole (inflow tract).\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"d09f0ca21d39476499fc851abce1e104","type":"GO_TERM","name":"positive regulation of secondary metabolite biosynthetic process","canonical_id":"go:GO:1900378","description":"\"Any process that activates or increases the frequency, rate or extent of secondary metabolite biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"a523b3b2a274447aa3724d0a1ec68829","type":"GO_TERM","name":"positive regulation of secretion","canonical_id":"go:GO:0051047","description":"\"Any process that activates or increases the frequency, rate or extent of the controlled release of a substance from a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"77ac847fa8c644269f112ffb00de179c","type":"GO_TERM","name":"positive regulation of secretion by cell","canonical_id":"go:GO:1903532","description":"\"Any process that activates or increases the frequency, rate or extent of secretion by cell.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:12130530]","metadata":null},{"id":"b923395cecdb4e018d8eff6c956e7a8a","type":"GO_TERM","name":"positive regulation of secretion of lysosomal enzymes","canonical_id":"go:GO:0090340","description":"\"Any process that increases the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell.\" [GOC:BHF]","metadata":null},{"id":"e6365af6a86b4dc5a7d459a21a153dd8","type":"GO_TERM","name":"positive regulation of secretory granule organization","canonical_id":"go:GO:1904411","description":"\"Any process that activates or increases the frequency, rate or extent of secretory granule organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:15039777]","metadata":null},{"id":"6835ed7bc6c7471fa1a4b088ef5568da","type":"GO_TERM","name":"positive regulation of seed dormancy process","canonical_id":"go:GO:1902040","description":"\"Any process that activates or increases the frequency, rate or extent of seed dormancy process.\" [GOC:TermGenie, PMID:23378449]","metadata":null},{"id":"95e99ce3021d4d12b7b0431b29c9737d","type":"GO_TERM","name":"positive regulation of seed germination","canonical_id":"go:GO:0010030","description":"\"Any process that activates or increase the rate of seed germination.\" [GOC:sm]","metadata":null},{"id":"de903f154f974ccf9059d7c1a9a79758","type":"GO_TERM","name":"positive regulation of seed maturation","canonical_id":"go:GO:2000693","description":"\"Any process that activates or increases the frequency, rate or extent of seed maturation.\" [GOC:obol]","metadata":null},{"id":"09b680a3c9e643f596f0083562929889","type":"GO_TERM","name":"positive regulation of selenocysteine incorporation","canonical_id":"go:GO:1904571","description":"\"Any process that activates or increases the frequency, rate or extent of selenocysteine incorporation.\" [GO_REF:0000058, GOC:TermGenie, PMID:21685449]","metadata":null},{"id":"e034b6e82bea4172a5695258ab4c63c0","type":"GO_TERM","name":"positive regulation of semaphorin-plexin signaling pathway","canonical_id":"go:GO:2001262","description":"\"Any process that activates or increases the frequency, rate or extent of semaphorin-plexin signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"8b6b6e19a09b49bca2549d20b28da099","type":"GO_TERM","name":"positive regulation of sensory neuron axon guidance","canonical_id":"go:GO:1905491","description":"\"Any process that activates or increases the frequency, rate or extent of sensory neuron axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"096bdbf478ec4ab9a6c222e69011dac5","type":"GO_TERM","name":"positive regulation of sensory perception of bitter taste","canonical_id":"go:GO:1904662","description":"\"Any process that activates or increases the frequency, rate or extent of sensory perception of bitter taste.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:1716172]","metadata":null},{"id":"a5c12071b7da4f18b7e52e7b88834379","type":"GO_TERM","name":"positive regulation of sensory perception of pain","canonical_id":"go:GO:1904058","description":"\"Any process that activates or increases the frequency, rate or extent of sensory perception of pain.\" [GO_REF:0000058, GOC:TermGenie, PMID:17167094]","metadata":null},{"id":"5f4beadf2f1547e4aaf3583385be8e0c","type":"GO_TERM","name":"positive regulation of sensory perception of sweet taste","canonical_id":"go:GO:1904658","description":"\"Any process that activates or increases the frequency, rate or extent of sensory perception of sweet taste.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:1716172]","metadata":null},{"id":"b859b4a3733c4652b82aa75df003ffbd","type":"GO_TERM","name":"positive regulation of septation initiation signaling","canonical_id":"go:GO:0031031","description":"\"Any process that activates or increases the frequency, rate or extent of septation initiation signaling.\" [GOC:mah]","metadata":null},{"id":"17a7ccbfe7a548198df2801181f7a916","type":"GO_TERM","name":"positive regulation of septum digestion after cytokinesis","canonical_id":"go:GO:2001043","description":"\"Any process that activates or increases the frequency, rate or extent of the process of physically separating the septal cell wall material by enzymatic digestion, that occurs after daughter cells are separated by cytokinesis.\" [GOC:mtg_cell_cycle, GOC:obol]","metadata":null},{"id":"57892d435c7a43e8b70b2aea369a0932","type":"GO_TERM","name":"positive regulation of serine C-palmitoyltransferase activity","canonical_id":"go:GO:1904222","description":"\"Any process that activates or increases the frequency, rate or extent of serine C-palmitoyltransferase activity.\" [GO_REF:0000059, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16120614]","metadata":null},{"id":"8c4dede1bc93456080e7cf55c63e76e7","type":"GO_TERM","name":"positive regulation of serine-type endopeptidase activity","canonical_id":"go:GO:1900005","description":"\"Any process that activates or increases the frequency, rate or extent of serine-type endopeptidase activity.\" [GOC:TermGenie]","metadata":null},{"id":"514dd55cc3c34a8c9f125ea436261fae","type":"GO_TERM","name":"positive regulation of serotonin biosynthetic process","canonical_id":"go:GO:1905629","description":"\"Any process that activates or increases the frequency, rate or extent of serotonin biosynthetic process.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:25642596]","metadata":null},{"id":"b4bf526ae3604120b26dfb9928af199c","type":"GO_TERM","name":"positive regulation of serotonin secretion","canonical_id":"go:GO:0014064","description":"\"Any process that activates or increases the frequency, rate or extent of the regulated release of serotonin.\" [GOC:ef]","metadata":null},{"id":"2c906ae4009248cf83ead7d1ce3e85c4","type":"GO_TERM","name":"positive regulation of serotonin uptake","canonical_id":"go:GO:0051613","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of serotonin into a cell.\" [GOC:ai]","metadata":null},{"id":"a1974479c8a74f53954cd3db3822ffc6","type":"GO_TERM","name":"positive regulation of sevenless signaling pathway","canonical_id":"go:GO:0045874","description":"\"Any process that activates or increases the frequency, rate or extent of the sevenless signaling pathway.\" [GOC:curators]","metadata":null},{"id":"2e12135ce3e7432cb2c1c1629610785b","type":"GO_TERM","name":"positive regulation of sexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043941","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of the formation of cellular spores derived from the products of meiosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"1fa7633fcdeb484a89a5b6ff6ff0fd53","type":"GO_TERM","name":"positive regulation of shade avoidance","canonical_id":"go:GO:1902448","description":"\"Any process that activates or increases the frequency, rate or extent of shade avoidance.\" [GOC:TermGenie, PMID:23763263]","metadata":null},{"id":"827640a0b6254607b7ff072843d13e38","type":"GO_TERM","name":"positive regulation of shell calcification","canonical_id":"go:GO:1905650","description":"\"Any process that activates or increases the frequency, rate or extent of shell calcification.\" [GO_REF:0000058, GOC:TermGenie, PMID:14648763]","metadata":null},{"id":"4aa2c7b11d714647a062a6b7befd4e3e","type":"GO_TERM","name":"positive regulation of shelterin complex assembly","canonical_id":"go:GO:1904792","description":"\"Any process that activates or increases the frequency, rate or extent of shelterin complex assembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24270157]","metadata":null},{"id":"2b46cc30c9b2496e80662252e082aa43","type":"GO_TERM","name":"positive regulation of shoot apical meristem development","canonical_id":"go:GO:1902185","description":"\"Any process that activates or increases the frequency, rate or extent of shoot apical meristem development.\" [GOC:TermGenie, PMID:21496644]","metadata":null},{"id":"a38e60338203488da0f4f29cd441f7f1","type":"GO_TERM","name":"positive regulation of short-day photoperiodism, flowering","canonical_id":"go:GO:0048576","description":"\"Any process that activates, maintains or increases short-day photoperiodism, where the response associated with the photoperiodism is flowering. Flowering is defined by the switch from the vegetative to the reproductive phase.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"540cad92f52d496aa0aad48cac30ed34","type":"GO_TERM","name":"positive regulation of short-term neuronal synaptic plasticity","canonical_id":"go:GO:0048173","description":"\"A process that increases short-term neuronal synaptic plasticity, the ability of neuronal synapses to change in the short-term as circumstances require. Short-term neuronal synaptic plasticity generally involves increasing or decreasing synaptic sensitivity.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"701c22136170445fbc323e5a40145b2d","type":"GO_TERM","name":"positive regulation of short-term synaptic potentiation","canonical_id":"go:GO:1905514","description":"\"Any process that activates or increases the frequency, rate or extent of short-term synaptic potentiation.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:15470145]","metadata":null},{"id":"c0e8df0508634259aa1d886200b92ddd","type":"GO_TERM","name":"positive regulation of siRNA processing","canonical_id":"go:GO:1903705","description":"\"Any process that activates or increases the frequency, rate or extent of siRNA processing.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19701182]","metadata":null},{"id":"56450b220233428c9241294d20cdb21b","type":"GO_TERM","name":"positive regulation of siderophore biosynthetic process","canonical_id":"go:GO:1900706","description":"\"Any process that activates or increases the frequency, rate or extent of siderophore biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"454fa73c324c4608ba215e65f46656d7","type":"GO_TERM","name":"positive regulation of signal transduction","canonical_id":"go:GO:0009967","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction.\" [GOC:sm]","metadata":null},{"id":"e5daede28f8440a5827485d4d440fbad","type":"GO_TERM","name":"positive regulation of signal transduction by p53 class mediator","canonical_id":"go:GO:1901798","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction by p53 class mediator.\" [GOC:TermGenie]","metadata":null},{"id":"4bce5c02753143a28177d44a3384fbe2","type":"GO_TERM","name":"positive regulation of signal transduction by receptor internalization","canonical_id":"go:GO:0038010","description":"\"Any process in which the internalization of a signaling receptor activates or increases the frequency, rate or extent of signal transduction. Receptor internalization can enhance signaling by concentrating signaling molecules in one location, or by moving a ligand-activated receptor to the location of downstream signaling proteins. Endosomes for example can serve as important intracellular signaling platforms.\" [GOC:bf, GOC:signaling, PMID:17908284, PMID:19696798]","metadata":null},{"id":"1c02af3cb9284979a10830e888088bbe","type":"GO_TERM","name":"positive regulation of signaling","canonical_id":"go:GO:0023056","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of a signaling process.\" [GOC:mtg_signal]","metadata":null},{"id":"ff52411b62974f6a9edf731a86a214dc","type":"GO_TERM","name":"positive regulation of silent mating-type cassette heterochromatin formation","canonical_id":"go:GO:0090055","description":"\"Any process that increases the frequency, rate, or extent of heterochromatin formation at silent mating-type cassette.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0e86c2c1cc17422ea5c2acf1652dc985","type":"GO_TERM","name":"positive regulation of single strand break repair","canonical_id":"go:GO:1903518","description":"\"Any process that activates or increases the frequency, rate or extent of single strand break repair.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17395247]","metadata":null},{"id":"cd66313e83cb4473a7ed50a6de1d3995","type":"GO_TERM","name":"positive regulation of single stranded viral RNA replication via double stranded DNA intermediate","canonical_id":"go:GO:0045870","description":"\"Any process that activates or increases the frequency, rate or extent of retroviral genome replication.\" [GOC:curators]","metadata":null},{"id":"71bedb96a63f4a5eb560aae565a362ac","type":"GO_TERM","name":"positive regulation of single-species biofilm formation","canonical_id":"go:GO:1900192","description":"\"Any process that activates or increases the frequency, rate or extent of single-species biofilm formation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"0994738d25b34ccf9e1f2fed02b24cde","type":"GO_TERM","name":"positive regulation of single-species biofilm formation in or on host organism","canonical_id":"go:GO:1900230","description":"\"Any process that activates or increases the frequency, rate or extent of single-species biofilm formation in or on host organism.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"cf2b9660131f436eb80c274d2ef1da5a","type":"GO_TERM","name":"positive regulation of single-species biofilm formation on inanimate substrate","canonical_id":"go:GO:1900233","description":"\"Any process that activates or increases the frequency, rate or extent of single-species biofilm formation on inanimate substrate.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f387818dae434d83b1d51cae1eb2d245","type":"GO_TERM","name":"positive regulation of single-strand break repair via homologous recombination","canonical_id":"go:GO:1903112","description":"\"Any process that activates or increases the frequency, rate or extent of single-strand break repair via homologous recombination.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:24339919]","metadata":null},{"id":"900b4261e2544f9db6215a55132ecb8e","type":"GO_TERM","name":"positive regulation of sister chromatid cohesion","canonical_id":"go:GO:0045876","description":"\"Any process that activates or increases the frequency, rate or extent of sister chromatid cohesion.\" [GOC:curators]","metadata":null},{"id":"d8d12a5130ea4b73bac4970cc7fb8ac4","type":"GO_TERM","name":"positive regulation of skeletal muscle acetylcholine-gated channel clustering","canonical_id":"go:GO:1904395","description":"\"Any process that activates or increases the frequency, rate or extent of skeletal muscle acetylcholine-gated channel clustering.\" [GO_REF:0000058, GOC:TermGenie, PMID:7722643]","metadata":null},{"id":"39c407acfa4d4c58bf14bcc8c177683e","type":"GO_TERM","name":"positive regulation of skeletal muscle cell differentiation","canonical_id":"go:GO:2001016","description":"\"Any process that activates or increases the frequency, rate or extent of skeletal muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"4a07f53c18624b5382438e136bb7639b","type":"GO_TERM","name":"positive regulation of skeletal muscle cell proliferation","canonical_id":"go:GO:0014858","description":"\"Any process that activates or increases the frequency, rate or extent of skeletal muscle cell proliferation.\" [CL:0000188, GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"68f00fa4f3a34c1f98ab62063a180c3a","type":"GO_TERM","name":"positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion","canonical_id":"go:GO:0014810","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of skeletal muscle contraction via the regulation of the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol. The sarcoplasmic reticulum is the endoplasmic reticulum of striated muscle, specialised for the sequestration of calcium ions that are released upon receipt of a signal relayed by the T tubules from the neuromuscular junction.\" [GOC:mtg_muscle]","metadata":null},{"id":"61b469e7042c405084aec9a1c90c608a","type":"GO_TERM","name":"positive regulation of skeletal muscle fiber development","canonical_id":"go:GO:0048743","description":"\"Any process that activates, maintains or increases the rate of skeletal muscle fiber development. Muscle fibers are formed by the maturation of myotubes. They can be classed as slow, intermediate/fast or fast.\" [GOC:dph, GOC:jid, GOC:lm, GOC:mtg_muscle]","metadata":null},{"id":"a55eca1004ba4da5af4e2fba0a90a8d1","type":"GO_TERM","name":"positive regulation of skeletal muscle fiber differentiation","canonical_id":"go:GO:1902811","description":"\"Any process that activates or increases the frequency, rate or extent of skeletal muscle fiber differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17879321]","metadata":null},{"id":"3f2d15d15bd7484894ffe485f889758d","type":"GO_TERM","name":"positive regulation of skeletal muscle hypertrophy","canonical_id":"go:GO:1904206","description":"\"Any process that activates or increases the frequency, rate or extent of skeletal muscle hypertrophy.\" [GO_REF:0000058, GOC:TermGenie, PMID:23470307]","metadata":null},{"id":"a0e6daf2dfde4e9d95c4803691971cf2","type":"GO_TERM","name":"positive regulation of skeletal muscle satellite cell differentiation","canonical_id":"go:GO:1902726","description":"\"Any process that activates or increases the frequency, rate or extent of satellite cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"8ec8d2d5ee1c4d0dbc0eea14d26b269f","type":"GO_TERM","name":"positive regulation of skeletal muscle satellite cell proliferation","canonical_id":"go:GO:1902724","description":"\"Any process that activates or increases the frequency, rate or extent of skeletal muscle satellite cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"7b7a710f6dd94fa0b991314bf6669054","type":"GO_TERM","name":"positive regulation of skeletal muscle tissue development","canonical_id":"go:GO:0048643","description":"\"Any process that activates, maintains or increases the rate of skeletal muscle tissue development.\" [GOC:curators]","metadata":null},{"id":"ec3b2379780b47439b81b259a2dc9528","type":"GO_TERM","name":"positive regulation of skeletal muscle tissue growth","canonical_id":"go:GO:0048633","description":"\"Any process that activates, maintains or increases the rate of skeletal muscle growth.\" [GOC:lm, PMID:15726494, PMID:15907921]","metadata":null},{"id":"909284811a6442a683418bfccff500cd","type":"GO_TERM","name":"positive regulation of skeletal muscle tissue regeneration","canonical_id":"go:GO:0043415","description":"\"Any process that activates or increase the rate of skeletal muscle regeneration.\" [GOC:jl]","metadata":null},{"id":"fb48986d7ecc478a922b860a7929d329","type":"GO_TERM","name":"positive regulation of slow-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031451","description":"\"Any process that activates or increases the frequency, rate or extent of slow-twitch skeletal muscle contraction.\" [GOC:dph, GOC:ef, GOC:mah, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"a0e2310829fa4911ac6c8e503520852f","type":"GO_TERM","name":"positive regulation of small GTPase mediated signal transduction","canonical_id":"go:GO:0051057","description":"\"Any process that activates or increases the frequency, rate or extent of small GTPase mediated signal transduction.\" [GOC:ai]","metadata":null},{"id":"c8607cab817448c4ad1b265b4fe742e2","type":"GO_TERM","name":"positive regulation of small intestinal transit","canonical_id":"go:GO:0120058","description":"\"Any process that increases the frequency, rate or extent of any small intestinal transit process, the migration of ingested material along the length of the small intestine.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"e672ceb8c2b4457dae3e13a3c54a5a50","type":"GO_TERM","name":"positive regulation of small intestine smooth muscle contraction","canonical_id":"go:GO:1904349","description":"\"Any process that activates or increases the frequency, rate or extent of small intestine smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:11991626]","metadata":null},{"id":"c303d2c9c04241358d613a13b0ebf609","type":"GO_TERM","name":"positive regulation of small molecule metabolic process","canonical_id":"go:GO:0062013","description":"\"Any process that activates or increases the frequency, rate or extent of a small molecule metabolic process.\" [GOC:vw]","metadata":null},{"id":"462cdf72c30641d6b94528452b076290","type":"GO_TERM","name":"positive regulation of smooth endoplasmic reticulum calcium ion concentration","canonical_id":"go:GO:0051564","description":"\"Any process that increases the concentration of calcium ions in the smooth endoplasmic reticulum.\" [GOC:ai]","metadata":null},{"id":"f89caef9aa6c4c81b6c6e5225c01f795","type":"GO_TERM","name":"positive regulation of smooth muscle cell apoptotic process","canonical_id":"go:GO:0034393","description":"\"Any process that activates or increases the frequency, rate, or extent of smooth muscle cell apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl]","metadata":null},{"id":"2d7e3d61b02d4822b6030aefdb8d9628","type":"GO_TERM","name":"positive regulation of smooth muscle cell chemotaxis","canonical_id":"go:GO:0071673","description":"\"Any process that activates or increases the frequency, rate, or extent of smooth muscle cell chemotaxis.\" [GOC:mah]","metadata":null},{"id":"5121df2a136f46918693764f7d3c9d20","type":"GO_TERM","name":"positive regulation of smooth muscle cell differentiation","canonical_id":"go:GO:0051152","description":"\"Any process that activates or increases the frequency, rate or extent of smooth muscle cell differentiation.\" [CL:0000192, GOC:ai]","metadata":null},{"id":"ae0f7e4eb28847b09dcd9bc17e2bbb7b","type":"GO_TERM","name":"positive regulation of smooth muscle cell migration","canonical_id":"go:GO:0014911","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of smooth muscle cell migration.\" [CL:0000192, GOC:mtg_muscle]","metadata":null},{"id":"177358d6e8e14395b4126fe24a842e15","type":"GO_TERM","name":"positive regulation of smooth muscle cell proliferation","canonical_id":"go:GO:0048661","description":"\"Any process that activates or increases the rate or extent of smooth muscle cell proliferation.\" [CL:0000192, GOC:ebc]","metadata":null},{"id":"9d845f3da8324c528a444318650806f8","type":"GO_TERM","name":"positive regulation of smooth muscle cell-matrix adhesion","canonical_id":"go:GO:1905609","description":"\"Any process that activates or increases the frequency, rate or extent of smooth muscle cell-matrix adhesion.\" [GO_REF:0000058, GOC:TermGenie, PMID:14970114]","metadata":null},{"id":"a49f2e40c06a443782c9199a878bb88c","type":"GO_TERM","name":"positive regulation of smooth muscle contraction","canonical_id":"go:GO:0045987","description":"\"Any process that activates or increases the frequency, rate or extent of smooth muscle contraction.\" [GOC:curators]","metadata":null},{"id":"ff0b323dfd364c42896caddbbc6648fc","type":"GO_TERM","name":"positive regulation of smooth muscle hypertrophy","canonical_id":"go:GO:1905149","description":"\"Any process that activates or increases the frequency, rate or extent of smooth muscle hypertrophy.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22161164]","metadata":null},{"id":"8ae48d11a4af4603b0fdc46c3a9c173f","type":"GO_TERM","name":"positive regulation of smooth muscle tissue development","canonical_id":"go:GO:1905901","description":"\"Any process that activates or increases the frequency, rate or extent of smooth muscle tissue development.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:14709716]","metadata":null},{"id":"e6ed06c9a152467e94b3a4ac6bc774f0","type":"GO_TERM","name":"positive regulation of smoothened signaling pathway","canonical_id":"go:GO:0045880","description":"\"Any process that activates or increases the frequency, rate or extent of smoothened signaling.\" [GOC:curators]","metadata":null},{"id":"a757b8bfb78c4d6bb02d15082d08911a","type":"GO_TERM","name":"positive regulation of snRNA pseudouridine synthesis","canonical_id":"go:GO:1905358","description":"\"Any process that activates or increases the frequency, rate or extent of snRNA pseudouridine synthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:27268497]","metadata":null},{"id":"2c6874579143488682d970d783871777","type":"GO_TERM","name":"positive regulation of snRNA transcription by RNA polymerase II","canonical_id":"go:GO:1905382","description":"\"Any process that activates or increases the frequency, rate or extent of snRNA transcription mediated by RNA polymerase II.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:10022900]","metadata":null},{"id":"94581b20e5ce4126a8243480a3cb5556","type":"GO_TERM","name":"positive regulation of snoRNA metabolic process","canonical_id":"go:GO:1903325","description":"\"Any process that activates or increases the frequency, rate or extent of snoRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"591873b488e44f68b28c8c06b1c7c653","type":"GO_TERM","name":"positive regulation of snoRNA processing","canonical_id":"go:GO:1902798","description":"\"Any process that activates or increases the frequency, rate or extent of snoRNA processing.\" [GO_REF:0000058, GOC:TermGenie, PMID:24210919]","metadata":null},{"id":"64ba9a3c6653433bb8a8dfec6793d632","type":"GO_TERM","name":"positive regulation of sodium ion export across plasma membrane","canonical_id":"go:GO:1903278","description":"\"Any process that activates or increases the frequency, rate or extent of sodium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17095720]","metadata":null},{"id":"31020676c8ef495d99f2b2cdf84b6122","type":"GO_TERM","name":"positive regulation of sodium ion import across plasma membrane","canonical_id":"go:GO:1903784","description":"\"Any process that activates or increases the frequency, rate or extent of sodium ion import across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:19376779]","metadata":null},{"id":"1d1da02455814698a2ac9a9b2f855057","type":"GO_TERM","name":"positive regulation of sodium ion transmembrane transport","canonical_id":"go:GO:1902307","description":"\"Any process that activates or increases the frequency, rate or extent of sodium ion transmembrane transport.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:18591664]","metadata":null},{"id":"88766152e8ff4c74b5624d2e5087e66b","type":"GO_TERM","name":"positive regulation of sodium ion transmembrane transporter activity","canonical_id":"go:GO:2000651","description":"\"Any process that activates or increases the frequency, rate or extent of sodium ion transmembrane transporter activity.\" [GOC:obol]","metadata":null},{"id":"36c5194458264a15abde3e8661c1989c","type":"GO_TERM","name":"positive regulation of sodium ion transport","canonical_id":"go:GO:0010765","description":"\"Any process that increases the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"22d2365469de465babd581244ce0a163","type":"GO_TERM","name":"positive regulation of sodium-dependent phosphate transport","canonical_id":"go:GO:2000120","description":"\"Any process that activates or increases the frequency, rate or extent of sodium-dependent phosphate transport.\" [GOC:BHF]","metadata":null},{"id":"2c6cb3a3c65543b1b1c730bfc063cb50","type":"GO_TERM","name":"positive regulation of sodium:proton antiporter activity","canonical_id":"go:GO:0032417","description":"\"Any process that activates or increases the activity of a sodium:hydrogen antiporter, which catalyzes the reaction: Na+(out) + H+(in) = Na+(in) + H+(out).\" [GOC:mah]","metadata":null},{"id":"8a59a22ea0614d198a6bf6578937b6c8","type":"GO_TERM","name":"positive regulation of somatic muscle development","canonical_id":"go:GO:0062224","description":"\"Any process that increases the rate, frequency or extent of somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"6a4a5af693e849938ffb930abe8cf2fb","type":"GO_TERM","name":"positive regulation of somatic stem cell division","canonical_id":"go:GO:1904677","description":"\"Any process that activates or increases the frequency, rate or extent of somatic stem cell division.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19409607]","metadata":null},{"id":"fb749e12fe844c948f5ef6b52a922c07","type":"GO_TERM","name":"positive regulation of somatic stem cell population maintenance","canonical_id":"go:GO:1904674","description":"\"Any process that activates or increases the frequency, rate or extent of somatic stem cell population maintenance.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19409607]","metadata":null},{"id":"6ece85d5701c4461a3a88c0a93950916","type":"GO_TERM","name":"positive regulation of somatostatin secretion","canonical_id":"go:GO:0090274","description":"\"Any process that increases the rate, frequency, extent of the regulated release of somatostatin from secretory granules in the D cells of the pancreas.\" [GOC:BHF]","metadata":null},{"id":"454838597ae34a668e78546127c9a442","type":"GO_TERM","name":"positive regulation of somitomeric trunk muscle development","canonical_id":"go:GO:0014709","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of somitomeric trunk muscle development. The somitomeric trunk muscle is derived from somitomeric mesoderm. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle.\" [GOC:mtg_muscle]","metadata":null},{"id":"426077c51a3b4db7bb444837625e5e35","type":"GO_TERM","name":"positive regulation of sorocarp spore cell differentiation","canonical_id":"go:GO:1901263","description":"\"Any process that activates or increases the frequency, rate or extent of sorocarp spore cell differentiation.\" [GOC:rjd, GOC:TermGenie]","metadata":null},{"id":"01e4baef07fc4da4b19b3c3ce282c4ef","type":"GO_TERM","name":"positive regulation of sorocarp stalk cell differentiation","canonical_id":"go:GO:0031287","description":"\"Any process that activates or increases the frequency, rate or extent of sorocarp stalk cell differentiation. An example of this process is found in Dictyostelium discoideum.\" [GOC:kp, GOC:mtg_sensu, PMID:4338436]","metadata":null},{"id":"ffa91573c89b49e380548e75f0937335","type":"GO_TERM","name":"positive regulation of sperm capacitation","canonical_id":"go:GO:1902492","description":"\"Any process that activates or increases the frequency, rate or extent of sperm capacitation.\" [GOC:hjd, GOC:TermGenie, PMID:22539676]","metadata":null},{"id":"2a16835e380242cfa79c840ba55d5e5f","type":"GO_TERM","name":"positive regulation of spermatid nuclear differentiation","canonical_id":"go:GO:0045702","description":"\"Any process that activates or increases the frequency, rate or extent of spermatid nuclear differentiation.\" [GOC:curators]","metadata":null},{"id":"ab39993024134e1eadcae3ed7f542629","type":"GO_TERM","name":"positive regulation of spermidine biosynthetic process","canonical_id":"go:GO:1901307","description":"\"Any process that activates or increases the frequency, rate or extent of spermidine biosynthetic process.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"67d2226457b4418a8af8ee52e868e56a","type":"GO_TERM","name":"positive regulation of sphingolipid biosynthetic process","canonical_id":"go:GO:0090154","description":"\"Any process that increases the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"58482354f0514ab194aac2493a79c3e1","type":"GO_TERM","name":"positive regulation of sphingolipid mediated signaling pathway","canonical_id":"go:GO:1902070","description":"\"Any process that activates or increases the frequency, rate or extent of sphingolipid signaling.\" [GOC:TermGenie, PMID:20870412]","metadata":null},{"id":"b7e3b80d30484712bb45da65c9744c40","type":"GO_TERM","name":"positive regulation of sphingomyelin catabolic process","canonical_id":"go:GO:2000755","description":"\"Any process that activates or increases the frequency, rate or extent of sphingomyelin catabolic process.\" [GOC:BHF]","metadata":null},{"id":"7392add2a92b4eac8dd7e9ffd886f460","type":"GO_TERM","name":"positive regulation of spinal cord association neuron differentiation","canonical_id":"go:GO:1902831","description":"\"Any process that activates or increases the frequency, rate or extent of spinal cord association neuron differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:21730158]","metadata":null},{"id":"d425f93c363b4ad992a6e2693ae472cf","type":"GO_TERM","name":"positive regulation of spindle assembly","canonical_id":"go:GO:1905832","description":"\"Any process that activates or increases the frequency, rate or extent of spindle assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27689799]","metadata":null},{"id":"d473fe3d62144fa58eb4c183f84fb72b","type":"GO_TERM","name":"positive regulation of spindle attachment to meiosis I kinetochore","canonical_id":"go:GO:1904968","description":"\"Any process that activates or increases the frequency, rate or extent of attachment of spindle microtubules to kinetochore involved in homologous chromosome segregation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23770679]","metadata":null},{"id":"f7005c51755e452e9ef976f73b7a582e","type":"GO_TERM","name":"positive regulation of spindle checkpoint","canonical_id":"go:GO:0090232","description":"\"Any process that increases the rate, frequency, or extent of the spindle checkpoint, a cell cycle checkpoint that delays the metaphase/anaphase transition until the spindle is correctly assembled and oriented, and chromosomes are attached to the spindle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"da3fb25397374b98b61875c60474d4b0","type":"GO_TERM","name":"positive regulation of spontaneous neurotransmitter secretion","canonical_id":"go:GO:1904050","description":"\"Any process that activates or increases the frequency, rate or extent of spontaneous neurotransmitter secretion.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22314364]","metadata":null},{"id":"877a23db01ff470589cfbb296886f913","type":"GO_TERM","name":"positive regulation of sporangiospore formation","canonical_id":"go:GO:0075287","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of sporangiospore formation, a process in which sporangiospores, a type of asexual spore found in fungi, are formed. Sporangiospores are formed within sac-like structure, the sporangium, following the division of the cytoplasm.\" [GOC:pamgo_curators]","metadata":null},{"id":"e93cefcb6d7945038b451b3610b848e6","type":"GO_TERM","name":"positive regulation of sporangium development","canonical_id":"go:GO:0075311","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of sporangium development, a process that leads to the formation of sporangium, a single-celled or many-celled structure in which spores are produced, as in fungi, algae, mosses, and ferns, gymnosperms, angiosperms.\" [GOC:pamgo_curators]","metadata":null},{"id":"54702535505b48e3aaa281030a9f9397","type":"GO_TERM","name":"positive regulation of sporangium germination","canonical_id":"go:GO:0075224","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of sporangium germination.\" [GOC:pamgo_curators]","metadata":null},{"id":"4ecc3822ec8645dda9162e1f6cb67525","type":"GO_TERM","name":"positive regulation of spore encystment on host","canonical_id":"go:GO:0075216","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of spore encystment on host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"18a92b0e1d2d4a90af4547ee31a8aa1e","type":"GO_TERM","name":"positive regulation of spore germination","canonical_id":"go:GO:1904361","description":"\"Any process that activates or increases the frequency, rate or extent of spore germination.\" [GO_REF:0000058, GOC:TermGenie, PMID:14718564, PMID:8798577]","metadata":null},{"id":"0cb372a4175a4262a938318a31f6b324","type":"GO_TERM","name":"positive regulation of spore-bearing organ development","canonical_id":"go:GO:0075261","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of spore-bearing organ development, a process in which hyphae grow into special aggregates called fruiting bodies that produce new spores.\" [GOC:pamgo_curators]","metadata":null},{"id":"d4c63b7d8f23493a9665d0713ff4fbb8","type":"GO_TERM","name":"positive regulation of sporocarp development involved in sexual reproduction","canonical_id":"go:GO:1902060","description":"\"Any process that activates or increases the frequency, rate or extent of sporocarp development involved in sexual reproduction.\" [GOC:di, GOC:TermGenie, PMID:23480775]","metadata":null},{"id":"eca5458e037a4c3bafe9d332a6401d53","type":"GO_TERM","name":"positive regulation of sporulation","canonical_id":"go:GO:0043938","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of sporulation, the process whose specific outcome is the progression of a spore over time, from its initiation to the mature structure.\" [GOC:pamgo_curators]","metadata":null},{"id":"14b81674cc7b4540b59718a55b3468e4","type":"GO_TERM","name":"positive regulation of sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0045881","description":"\"Any process that activates or increases the frequency, rate or extent of sporulation.\" [GOC:curators]","metadata":null},{"id":"85d78c357f6c4549991c6c936fb07569","type":"GO_TERM","name":"positive regulation of sprouting angiogenesis","canonical_id":"go:GO:1903672","description":"\"Any process that activates or increases the frequency, rate or extent of sprouting angiogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:16756958]","metadata":null},{"id":"963e8475786842e5ba96f01c62eed5d7","type":"GO_TERM","name":"positive regulation of sprouting of injured axon","canonical_id":"go:GO:0048687","description":"\"Any process that activates, maintains or increases the rate of sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"4631fa4b18b04ee09f2fde936c315464","type":"GO_TERM","name":"positive regulation of starch catabolic process","canonical_id":"go:GO:2000883","description":"\"Any process that activates or increases the frequency, rate or extent of starch catabolic process.\" [GOC:obol]","metadata":null},{"id":"df3a9cd24b5c40599e82986783e3c849","type":"GO_TERM","name":"positive regulation of starch utilization system complex assembly","canonical_id":"go:GO:1900514","description":"\"Any process that activates or increases the frequency, rate or extent of starch utilization system complex assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"8dff31aff221435db0dc42bcfe11aeec","type":"GO_TERM","name":"positive regulation of stem cell differentiation","canonical_id":"go:GO:2000738","description":"\"Any process that activates or increases the frequency, rate or extent of stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"675fb13351e84e6ab7dbc60f88306f3d","type":"GO_TERM","name":"positive regulation of stem cell population maintenance","canonical_id":"go:GO:1902459","description":"\"Any process that activates or increases the frequency, rate or extent of stem cell population maintenance.\" [GOC:hjd, GOC:TermGenie, PMID:22969033]","metadata":null},{"id":"49e5eaa8959e457ea488db298d1b597a","type":"GO_TERM","name":"positive regulation of stem cell proliferation","canonical_id":"go:GO:2000648","description":"\"Any process that activates or increases the frequency, rate or extent of stem cell proliferation.\" [GOC:dph]","metadata":null},{"id":"fef562a76ca14e6f81c96f127f49d2e1","type":"GO_TERM","name":"positive regulation of sterigmatocystin biosynthetic process","canonical_id":"go:GO:0010914","description":"\"Any process that increases the rate, frequency, or extent of sterigmatocystin biosynthesis. Sterigmatocystin biosynthetic processes are the chemical reactions and pathways resulting in the formation of sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"fe3ad84500fa4d2eb160f3446eaea0bd","type":"GO_TERM","name":"positive regulation of steroid biosynthetic process","canonical_id":"go:GO:0010893","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.\" [GOC:tb]","metadata":null},{"id":"a963d0bcf71f4eae870a8b33f2af016c","type":"GO_TERM","name":"positive regulation of steroid hormone biosynthetic process","canonical_id":"go:GO:0090031","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroid hormones,compounds with a 1, 2, cyclopentanoperhydrophenanthrene nucleus that act as hormones.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"073c1a513d324b64b75bc0522e3c5162","type":"GO_TERM","name":"positive regulation of steroid hormone secretion","canonical_id":"go:GO:2000833","description":"\"Any process that activates or increases the frequency, rate or extent of steroid hormone secretion.\" [GOC:sl]","metadata":null},{"id":"29c897fb67b44d3e930df82825a8c6b6","type":"GO_TERM","name":"positive regulation of steroid metabolic process","canonical_id":"go:GO:0045940","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving steroids.\" [GOC:curators]","metadata":null},{"id":"250d67563c6f40ea8e75e8ba0f360386","type":"GO_TERM","name":"positive regulation of sterol biosynthetic process","canonical_id":"go:GO:0106120","description":"\"Any process that activates or increases the frequency, rate or extent of a sterol biosynthetic process.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:16459310]","metadata":null},{"id":"b64dc30847bf4d529b6207fa3244c4f6","type":"GO_TERM","name":"positive regulation of sterol import","canonical_id":"go:GO:2000911","description":"\"Any process that activates or increases the frequency, rate or extent of sterol import.\" [GOC:obol]","metadata":null},{"id":"17d206c71aa24ee3a1c06f6d9ca05885","type":"GO_TERM","name":"positive regulation of sterol transport","canonical_id":"go:GO:0032373","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of sterols into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"dc72e237569b4027ace20d72e9f03c34","type":"GO_TERM","name":"positive regulation of stomach fundus smooth muscle contraction","canonical_id":"go:GO:0120069","description":"\"Any process that increases the frequency, rate or extent of any stomach fundus smooth muscle contraction.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"4c28ec6f5e074e1dab69e7bcd0d0a889","type":"GO_TERM","name":"positive regulation of stomatal complex development","canonical_id":"go:GO:2000123","description":"\"Any process that activates or increases the frequency, rate or extent of stomatal complex development.\" [GOC:obol]","metadata":null},{"id":"d562e9ff615a405eb20d87ac636340cf","type":"GO_TERM","name":"positive regulation of stomatal opening","canonical_id":"go:GO:1902458","description":"\"Any process that activates or increases the frequency, rate or extent of stomatal opening.\" [GOC:TermGenie, PMID:23766366]","metadata":null},{"id":"cbcf54af0ed840a3921e6f3b1c9f3837","type":"GO_TERM","name":"positive regulation of store-operated calcium channel activity","canonical_id":"go:GO:1901341","description":"\"Any process that activates or increases the frequency, rate or extent of store-operated calcium channel activity.\" [GOC:TermGenie]","metadata":null},{"id":"d083d7f90ccb4654b8a00209c6c8c8bd","type":"GO_TERM","name":"positive regulation of store-operated calcium entry","canonical_id":"go:GO:0106129","description":"\"Any process that activates or increases the frequency, rate or extent of store-operated calcium entry.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:23447642]","metadata":null},{"id":"b2ab676db478429e8354aec42513b9ce","type":"GO_TERM","name":"positive regulation of strand invasion","canonical_id":"go:GO:0098530","description":"\"Any process that increases the rate, frequency or extent of strand invasion. Strand invasion is the process in which the nucleoprotein complex (composed of the broken single-strand DNA and the recombinase) searches and identifies a region of homology in intact duplex DNA. The broken single-strand DNA displaces the like strand and forms Watson-Crick base pairs with its complement, forming a duplex in which each strand is from one of the two recombining DNA molecules.\" [GOC:dos, GOC:dph, GOC:elh, GOC:tb]","metadata":null},{"id":"6cd50e07518c4255b563406ebf3605f9","type":"GO_TERM","name":"positive regulation of stress fiber assembly","canonical_id":"go:GO:0051496","description":"\"Any process that activates or increases the frequency, rate or extent of the assembly of a stress fiber, a bundle of microfilaments and other proteins found in fibroblasts.\" [GOC:ai]","metadata":null},{"id":"eacc7d28f33741218f2db0d868030aa4","type":"GO_TERM","name":"positive regulation of stress response to copper ion","canonical_id":"go:GO:1903855","description":"\"Any process that activates or increases the frequency, rate or extent of stress response to copper ion.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:23437011]","metadata":null},{"id":"92676b4e2aae4ed188e39631d9eb6c6c","type":"GO_TERM","name":"positive regulation of stress-activated MAPK cascade","canonical_id":"go:GO:0032874","description":"\"Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the stress-activated MAPK cascade.\" [GOC:mah]","metadata":null},{"id":"79d1f2e4d04546b0965dec6967e86f42","type":"GO_TERM","name":"positive regulation of stress-activated protein kinase signaling cascade","canonical_id":"go:GO:0070304","description":"\"Any process that activates or increases the frequency, rate or extent of signaling via the stress-activated protein kinase signaling cascade.\" [GOC:mah]","metadata":null},{"id":"cb34fa7e2f0a4441ae3770c556e8de25","type":"GO_TERM","name":"positive regulation of striated muscle cell apoptotic process","canonical_id":"go:GO:0010663","description":"\"Any process that increases the rate or extent of striated muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a striated muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"960b9f00904f4dea8555ea2fdb2bae18","type":"GO_TERM","name":"positive regulation of striated muscle cell differentiation","canonical_id":"go:GO:0051155","description":"\"Any process that activates or increases the frequency, rate or extent of striated muscle cell differentiation.\" [CL:0000737, GOC:ai]","metadata":null},{"id":"5a3ecdbefa66462dae9f300ebcf2ee5f","type":"GO_TERM","name":"positive regulation of striated muscle contraction","canonical_id":"go:GO:0045989","description":"\"Any process that activates or increases the frequency, rate or extent of striated muscle contraction.\" [GOC:curators]","metadata":null},{"id":"891a466572d54db9803ba599ba24a5b2","type":"GO_TERM","name":"positive regulation of striated muscle tissue development","canonical_id":"go:GO:0045844","description":"\"Any process that activates or increases the frequency, rate or extent of striated muscle development.\" [GOC:curators]","metadata":null},{"id":"ad6f9595f55649b38d1a61e7672f6d4e","type":"GO_TERM","name":"positive regulation of substance P secretion","canonical_id":"go:GO:1904460","description":"\"Any process that activates or increases the frequency, rate or extent of substance P secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11278900]","metadata":null},{"id":"b2c7c9970565406a9562a13314acd19b","type":"GO_TERM","name":"positive regulation of substance P secretion, neurotransmission","canonical_id":"go:GO:1904496","description":"\"Any process that activates or increases the frequency, rate or extent of substance P secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:15292051]","metadata":null},{"id":"ebf1c9fba8c340f68036aa0898f14f50","type":"GO_TERM","name":"positive regulation of substrate adhesion-dependent cell spreading","canonical_id":"go:GO:1900026","description":"\"Any process that activates or increases the frequency, rate or extent of substrate adhesion-dependent cell spreading.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"25ade199dd114ba88427fb8c3e766a2e","type":"GO_TERM","name":"positive regulation of substrate-dependent cell migration, cell attachment to substrate","canonical_id":"go:GO:1904237","description":"\"Any process that activates or increases the frequency, rate or extent of substrate-dependent cell migration, cell attachment to substrate.\" [GO_REF:0000058, GOC:TermGenie, PMID:25834989]","metadata":null},{"id":"6a9d45bed63e49aeb7c6abecae5cbe16","type":"GO_TERM","name":"positive regulation of succinate dehydrogenase activity","canonical_id":"go:GO:1904231","description":"\"Any process that activates or increases the frequency, rate or extent of succinate dehydrogenase activity.\" [GO_REF:0000059, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18160053]","metadata":null},{"id":"0e0ace3e64cb47d984eea156f42b4dfc","type":"GO_TERM","name":"positive regulation of sulfate assimilation","canonical_id":"go:GO:1900059","description":"\"Any process that activates or increases the frequency, rate or extent of sulfate assimilation.\" [GOC:TermGenie, PMID:7601277, PMID:7891681]","metadata":null},{"id":"2b9f2d937c0c4ec6a02850ad0ebd3134","type":"GO_TERM","name":"positive regulation of sulfite transmembrane transport","canonical_id":"go:GO:1900072","description":"\"Any process that activates or increases the frequency, rate or extent of sulfite transmembrane transport.\" [GOC:TermGenie, PMID:10234785, PMID:10870099]","metadata":null},{"id":"2f6c028a3f344a05a6fc70f604a2f4d1","type":"GO_TERM","name":"positive regulation of sulfur utilization","canonical_id":"go:GO:0045883","description":"\"Any process that activates or increases the frequency, rate or extent of sulfur utilization.\" [GOC:curators]","metadata":null},{"id":"d7c09fb617104c4fa7bfb6a473906953","type":"GO_TERM","name":"positive regulation of superoxide anion generation","canonical_id":"go:GO:0032930","description":"\"Any process that activates or increases the frequency, rate or extent of enzymatic generation of superoxide by a cell.\" [GOC:mah]","metadata":null},{"id":"93903cecb64747b08cf52fa50082c014","type":"GO_TERM","name":"positive regulation of superoxide dismutase activity","canonical_id":"go:GO:1901671","description":"\"Any process that activates or increases the frequency, rate or extent of superoxide dismutase activity.\" [GOC:TermGenie]","metadata":null},{"id":"539b37e6d1ef4fe9b187e505d51a9340","type":"GO_TERM","name":"positive regulation of supramolecular fiber organization","canonical_id":"go:GO:1902905","description":"\"Any process that activates or increases the frequency, rate or extent of supramolecular fiber organization.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:23921388]","metadata":null},{"id":"82ebb3449aeb45f39858b6bcacd6711a","type":"GO_TERM","name":"positive regulation of symbiont haustorium neck formation for entry into host","canonical_id":"go:GO:0075199","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of symbiont haustorium neck formation for entry into host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"944c5ca563d34e5d8de8610ea0dca052","type":"GO_TERM","name":"positive regulation of synapse assembly","canonical_id":"go:GO:0051965","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of synapse assembly, the aggregation, arrangement and bonding together of a set of components to form a synapse.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"bad57eccdb94446881fdc54a0190c3ec","type":"GO_TERM","name":"positive regulation of synapse maturation","canonical_id":"go:GO:0090129","description":"\"Any process that increases the extent of synapse maturation, the process that organizes a synapse so that it attains its fully functional state.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d58f10f7f32c4c0dad39c3b1f3efea30","type":"GO_TERM","name":"positive regulation of synapse maturation by synaptic transmission","canonical_id":"go:GO:0090127","description":"\"Any process that increases the extent of synaptic maturation as a result of the communication from a pre-synaptic cell to a post-synaptic cell across a synapse.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0abc439bbb7a4d7e8129d155d8ce8984","type":"GO_TERM","name":"positive regulation of synapse pruning","canonical_id":"go:GO:1905808","description":"\"Any process that activates or increases the frequency, rate or extent of synapse pruning.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"45bd923c73d24d8fb35eef6179b2843a","type":"GO_TERM","name":"positive regulation of synapse structural plasticity","canonical_id":"go:GO:0051835","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of synaptic structural plasticity.\" [GOC:ai]","metadata":null},{"id":"a2bb315b60474ff49388d1d54d461c04","type":"GO_TERM","name":"positive regulation of synaptic assembly at neuromuscular junction","canonical_id":"go:GO:0045887","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic assembly at neuromuscular junction.\" [GOC:curators]","metadata":null},{"id":"ac87926af7d64aa9b1778d4191c26bee","type":"GO_TERM","name":"positive regulation of synaptic metaplasticity","canonical_id":"go:GO:0031918","description":"\"A process that increases synaptic metaplasticity. Metaplasticity is a higher-order form of plasticity and is manifest as a change in the ability to induce subsequent synaptic plasticity that is the ability of synapses to change as circumstances require.\" [GOC:mah, PMID:8658594]","metadata":null},{"id":"e4b3183e9b734feba6923ca42c789164","type":"GO_TERM","name":"positive regulation of synaptic plasticity","canonical_id":"go:GO:0031915","description":"\"A process that increases synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.\" [GOC:mah]","metadata":null},{"id":"93fe3d984e424f759ee6ab8da152f6eb","type":"GO_TERM","name":"positive regulation of synaptic plasticity by chemical substance","canonical_id":"go:GO:0051914","description":"\"The process in which a chemical substance increases synaptic plasticity, the ability of synapses to change as circumstances require.\" [GOC:ai]","metadata":null},{"id":"4a21ff064ac34636ae7b52a2c413bb3b","type":"GO_TERM","name":"positive regulation of synaptic transmission","canonical_id":"go:GO:0050806","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.\" [GOC:ai]","metadata":null},{"id":"70ab1c2938e34cf49bd98cb0fa283b7a","type":"GO_TERM","name":"positive regulation of synaptic transmission, GABAergic","canonical_id":"go:GO:0032230","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of GABAergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter gamma-aminobutyric acid (GABA).\" [GOC:mah]","metadata":null},{"id":"c0e1f43253c94cbeb154473e2af8572d","type":"GO_TERM","name":"positive regulation of synaptic transmission, cholinergic","canonical_id":"go:GO:0032224","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of cholinergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter acetylcholine.\" [GOC:mah]","metadata":null},{"id":"338cf15454824ab4a3a4f7357706b9b4","type":"GO_TERM","name":"positive regulation of synaptic transmission, dopaminergic","canonical_id":"go:GO:0032226","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine.\" [GOC:mah]","metadata":null},{"id":"627f2ac01a884731a89a6921c800dea8","type":"GO_TERM","name":"positive regulation of synaptic transmission, glutamatergic","canonical_id":"go:GO:0051968","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate.\" [GOC:ai]","metadata":null},{"id":"2e85d2ffe9d147fc83fb8ba6dbfc8045","type":"GO_TERM","name":"positive regulation of synaptic transmission, glycinergic","canonical_id":"go:GO:0060094","description":"\"Any process that activates or increases the frequency, rate or extent of glycinergic synaptic transmission. Glycinergic synaptic transmission is the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glycine.\" [GOC:dms, GOC:dph]","metadata":null},{"id":"da56aa016cd1469eb3770f542fa0c0d3","type":"GO_TERM","name":"positive regulation of synaptic vesicle clustering","canonical_id":"go:GO:2000809","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle clustering.\" [PMID:21513708]","metadata":null},{"id":"e0836e3cfc5e4133bad1dd26d31fd7ef","type":"GO_TERM","name":"positive regulation of synaptic vesicle endocytosis","canonical_id":"go:GO:1900244","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle endocytosis.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"7a9b376439744c139eefbe9a535e81b3","type":"GO_TERM","name":"positive regulation of synaptic vesicle exocytosis","canonical_id":"go:GO:2000302","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle exocytosis.\" [GOC:obol]","metadata":null},{"id":"20f18d0e48af450181d419a0d6e762cd","type":"GO_TERM","name":"positive regulation of synaptic vesicle fusion to presynaptic active zone membrane","canonical_id":"go:GO:0031632","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle fusion to the presynaptic membrane.\" [GOC:mah]","metadata":null},{"id":"c63049be5f204daf8fdd3ea688033408","type":"GO_TERM","name":"positive regulation of synaptic vesicle lumen acidification","canonical_id":"go:GO:1901548","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle lumen acidification.\" [GOC:TermGenie]","metadata":null},{"id":"9bd7a043bb454b0ba9dec37ec1422f86","type":"GO_TERM","name":"positive regulation of synaptic vesicle membrane organization","canonical_id":"go:GO:1901634","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"9b8ed48037324195b1cd37a2c16f9b36","type":"GO_TERM","name":"positive regulation of synaptic vesicle priming","canonical_id":"go:GO:0010808","description":"\"Any process that increases the frequency, rate or extent of synaptic vesicle priming. Synaptic vesicle priming is the formation of SNARE-containing complexes, bringing synaptic vesicle membrane and plasma membranes into close proximity and thereby facilitating membrane fusion.\" [GOC:dph, GOC:kmv, GOC:tb, PMID:15489511]","metadata":null},{"id":"b04242739caa4ada8ede1212ec09be26","type":"GO_TERM","name":"positive regulation of synaptic vesicle recycling","canonical_id":"go:GO:1903423","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle recycling.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22745285]","metadata":null},{"id":"d07a303172e34c90802c622aa9514d0f","type":"GO_TERM","name":"positive regulation of synaptic vesicle transport","canonical_id":"go:GO:1902805","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle transport.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:23527112]","metadata":null},{"id":"e5c26791faa245bb8c3536e875702240","type":"GO_TERM","name":"positive regulation of synaptic vesicle uncoating","canonical_id":"go:GO:1903390","description":"\"Any process that activates or increases the frequency, rate or extent of synaptic vesicle uncoating.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21563316]","metadata":null},{"id":"0cf26f9f5cad47d1abf539e4f49a6d49","type":"GO_TERM","name":"positive regulation of synaptonemal complex assembly","canonical_id":"go:GO:1905088","description":"\"Any process that activates or increases the frequency, rate or extent of synaptonemal complex assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:24797370]","metadata":null},{"id":"dafcef7652e840bea06e25bb90bdbf1c","type":"GO_TERM","name":"positive regulation of syncytial blastoderm mitotic cell cycle","canonical_id":"go:GO:0046004","description":"\"Any process that activates or increases the rate or extent of progression through the syncytial blastoderm mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"a95030f3bbeb448197669b4fa1104e81","type":"GO_TERM","name":"positive regulation of syncytium formation by plasma membrane fusion","canonical_id":"go:GO:0060143","description":"\"Any process that increases the frequency, rate or extent of the formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by the fusion of the plasma membranes of two or more individual cells.\" [GOC:dph]","metadata":null},{"id":"564732d7c1ae4561bd4010c550de5f4e","type":"GO_TERM","name":"positive regulation of synergid differentiation","canonical_id":"go:GO:0045699","description":"\"Any process that activates or increases the frequency, rate or extent of synergid cell differentiation.\" [GOC:curators]","metadata":null},{"id":"9f1193ded78b405d944bc0a6285b47be","type":"GO_TERM","name":"positive regulation of synoviocyte proliferation","canonical_id":"go:GO:1901647","description":"\"Any process that activates or increases the frequency, rate or extent of synoviocyte proliferation.\" [GOC:TermGenie]","metadata":null},{"id":"50fbe9a70b1440e39950a39c8f33defe","type":"GO_TERM","name":"positive regulation of syringal lignin biosynthetic process","canonical_id":"go:GO:1901430","description":"\"Any process that activates or increases the frequency, rate or extent of syringal lignin biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"756c7b53b5c642d0ac57abe5d2cec40f","type":"GO_TERM","name":"positive regulation of syringal lignin catabolic process","canonical_id":"go:GO:1901471","description":"\"Any process that activates or increases the frequency, rate or extent of syringal lignin catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"e7592644dab8414d90e271e9c0137b3e","type":"GO_TERM","name":"positive regulation of systemic acquired resistance","canonical_id":"go:GO:1901672","description":"\"Any process that activates or increases the frequency, rate or extent of systemic acquired resistance.\" [GOC:TermGenie]","metadata":null},{"id":"fa227a1efbcd43e596336cb9a051bd94","type":"GO_TERM","name":"positive regulation of systemic arterial blood pressure","canonical_id":"go:GO:0003084","description":"\"The process that increases the force with which blood travels through the systemic arterial circulatory system.\" [GOC:mtg_cardio]","metadata":null},{"id":"5ee9d11dd0ed496f823f229c204fcf0f","type":"GO_TERM","name":"positive regulation of t-SNARE clustering","canonical_id":"go:GO:1904034","description":"\"Any process that activates or increases the frequency, rate or extent of t-SNARE clustering.\" [GO_REF:0000058, GOC:TermGenie, PMID:22528485]","metadata":null},{"id":"506473cb5fc94d1d8b48f7c46374b8eb","type":"GO_TERM","name":"positive regulation of t-circle formation","canonical_id":"go:GO:1904431","description":"\"Any process that activates or increases the frequency, rate or extent of t-circle formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"ffb47f90bad646c7a12a4ea4c344c0eb","type":"GO_TERM","name":"positive regulation of tRNA C5-cytosine methylation","canonical_id":"go:GO:0110005","description":"\"Any process that activates or increases the frequency, rate or extent of tRNA C5-cytosine methylation.\" [GOC:vw, PMID:23074192]","metadata":null},{"id":"443f344f4046436b9803e83ecc4243f4","type":"GO_TERM","name":"positive regulation of tRNA catabolic process","canonical_id":"go:GO:1902372","description":"\"Any process that activates or increases the frequency, rate or extent of tRNA catabolic process.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"a796be8fceae4b28993574da717703b7","type":"GO_TERM","name":"positive regulation of tRNA export from nucleus","canonical_id":"go:GO:2000240","description":"\"Any process that activates or increases the frequency, rate or extent of tRNA export from nucleus.\" [GOC:mah]","metadata":null},{"id":"20cc705fd4ae4dbe87c1ea33c7b9fec4","type":"GO_TERM","name":"positive regulation of tRNA metabolic process","canonical_id":"go:GO:1903328","description":"\"Any process that activates or increases the frequency, rate or extent of tRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"58f82f8e039040e286324a429d0865eb","type":"GO_TERM","name":"positive regulation of tRNA methylation","canonical_id":"go:GO:0110004","description":"\"Any process that activates or increases the frequency, rate or extent of tRNA methylation.\" [GOC:vw, PMID:23074192]","metadata":null},{"id":"7fbb7f360385488fa097f8784b0f31bb","type":"GO_TERM","name":"positive regulation of tRNA processing","canonical_id":"go:GO:2000237","description":"\"Any process that activates or increases the frequency, rate or extent of tRNA processing.\" [GOC:mah]","metadata":null},{"id":"28f974be08c646ff8633de178619fe7e","type":"GO_TERM","name":"positive regulation of taurine biosynthetic process","canonical_id":"go:GO:0062090","description":"\"Any process that activates or increases the frequency, rate or extent of taurine biosynthesis.\" [GOC:BHF, PMID:18648510, PMID:24911144]","metadata":null},{"id":"1ef9bc7909d44b45a576388bc7cf62b7","type":"GO_TERM","name":"positive regulation of teliospore formation","canonical_id":"go:GO:0075257","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of teliospore formation, which is the formation of a thick-walled resting or overwintering spore produced by the rust fungi (Uredinales) and smut fungi (Ustilaginales) in which karyogamy occurs.\" [GOC:pamgo_curators]","metadata":null},{"id":"ab89ff90dbee40e08a50ab3b3c8bbd0a","type":"GO_TERM","name":"positive regulation of telium development","canonical_id":"go:GO:0075277","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of telium development, a process that leads to the formation of a teliospore-bearing sorus of the rust fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"e44d7c3963e74a4da42f00fdc71df84e","type":"GO_TERM","name":"positive regulation of telomerase RNA localization to Cajal body","canonical_id":"go:GO:1904874","description":"\"Any process that activates or increases the frequency, rate or extent of telomerase RNA localization to Cajal body.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"e9ecadf04e5748a48302218bf0f9a6da","type":"GO_TERM","name":"positive regulation of telomerase catalytic core complex assembly","canonical_id":"go:GO:1904884","description":"\"Any process that activates or increases the frequency, rate or extent of telomerase catalytic core complex assembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"2eff28fca9fe4e0286edccab5b1f43a3","type":"GO_TERM","name":"positive regulation of telomere capping","canonical_id":"go:GO:1904355","description":"\"Any process that activates or increases the frequency, rate or extent of telomere capping.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23959892]","metadata":null},{"id":"d0b3c6066f4146a9b93856357dee6f93","type":"GO_TERM","name":"positive regulation of telomere maintenance","canonical_id":"go:GO:0032206","description":"\"Any process that activates or increases the frequency, rate or extent of a process that affects and monitors the activity of telomeric proteins and the length of telomeric DNA.\" [GOC:mah]","metadata":null},{"id":"01a583a1875840d4a967b5c082d0e176","type":"GO_TERM","name":"positive regulation of telomere maintenance in response to DNA damage","canonical_id":"go:GO:1904507","description":"\"Any process that activates or increases the frequency, rate or extent of telomere maintenance in response to DNA damage.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"5ff7a66b658343baaf635620db3b8ce1","type":"GO_TERM","name":"positive regulation of telomere maintenance via recombination","canonical_id":"go:GO:0032209","description":"\"Any process that activates or increases the frequency, rate or extent of a recombinational process involved in the maintenance of proper telomeric length.\" [GOC:mah]","metadata":null},{"id":"cd8beb653c48445780d32af62f8cb030","type":"GO_TERM","name":"positive regulation of telomere maintenance via semi-conservative replication","canonical_id":"go:GO:0032215","description":"\"Any process that activates or increases the frequency, rate or extent of the semi-conservative replication of telomeric DNA.\" [GOC:mah]","metadata":null},{"id":"9b0a07f437c245b08c37985fbbc3dc9a","type":"GO_TERM","name":"positive regulation of telomere maintenance via telomerase","canonical_id":"go:GO:0032212","description":"\"Any process that activates or increases the frequency, rate or extent of the addition of telomeric repeats by telomerase.\" [GOC:mah]","metadata":null},{"id":"5192c20ff4344aad91707e8c29a9888e","type":"GO_TERM","name":"positive regulation of telomere maintenance via telomere lengthening","canonical_id":"go:GO:1904358","description":"\"Any process that activates or increases the frequency, rate or extent of telomere maintenance via telomere lengthening.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23959892]","metadata":null},{"id":"bf992b988ac14a57a70dcdea81e954f0","type":"GO_TERM","name":"positive regulation of telomeric D-loop disassembly","canonical_id":"go:GO:1905840","description":"\"Any process that activates or increases the frequency, rate or extent of telomeric D-loop disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:15200954]","metadata":null},{"id":"bbdb80e3d14b4f12a5a4551a118240b0","type":"GO_TERM","name":"positive regulation of telomeric loop disassembly","canonical_id":"go:GO:1904535","description":"\"Any process that activates or increases the frequency, rate or extent of telomeric loop disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"097a0f71bcce4453a600957b45e3583d","type":"GO_TERM","name":"positive regulation of telomeric loop formation","canonical_id":"go:GO:1904420","description":"\"Any process that activates or increases the frequency, rate or extent of telomeric loop formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"8f077b788f184a75aeb6dff20e8e9b0a","type":"GO_TERM","name":"positive regulation of tendon cell differentiation","canonical_id":"go:GO:2001051","description":"\"Any process that activates or increases the frequency, rate or extent of tendon cell differentiation.\" [GOC:obol]","metadata":null},{"id":"afa93a570f484150a90ce0263a151e22","type":"GO_TERM","name":"positive regulation of tensidol A biosynthetic process","canonical_id":"go:GO:1900709","description":"\"Any process that activates or increases the frequency, rate or extent of tensidol A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5f6b570217424a4483466af5f751ab03","type":"GO_TERM","name":"positive regulation of tensidol B biosynthetic process","canonical_id":"go:GO:1900712","description":"\"Any process that activates or increases the frequency, rate or extent of tensidol B biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5ba85085fa1c444dae1a939cf2d948af","type":"GO_TERM","name":"positive regulation of terminal button organization","canonical_id":"go:GO:1901614","description":"\"Any process that activates or increases the frequency, rate or extent of terminal button organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"9fb16234212446d4ae5728ba4ec649f0","type":"GO_TERM","name":"positive regulation of termination of DNA-templated transcription","canonical_id":"go:GO:0060566","description":"\"Any process that increases the rate, frequency or extent of DNA-templated transcription termination, the process in which transcription is completed; the formation of phosphodiester bonds ceases, the RNA-DNA hybrid dissociates, and RNA polymerase releases the DNA.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"034c2ffaae5e4bfc965edd8c150583cf","type":"GO_TERM","name":"positive regulation of termination of RNA polymerase I transcription","canonical_id":"go:GO:2000732","description":"\"Any process that activates or increases the frequency, rate or extent of termination of RNA polymerase I transcription.\" [GOC:obol]","metadata":null},{"id":"b5d67bcf96cd49b89bb3fc5ad979abdc","type":"GO_TERM","name":"positive regulation of termination of RNA polymerase II transcription","canonical_id":"go:GO:1904595","description":"\"Any process that activates or increases the frequency, rate or extent of termination of RNA polymerase II transcription.\" [GO_REF:0000058, GOC:TermGenie, PMID:25417108]","metadata":null},{"id":"6eb9d2345fe2402a8c05523549fbbadf","type":"GO_TERM","name":"positive regulation of termination of RNA polymerase II transcription, poly(A)-coupled","canonical_id":"go:GO:2000806","description":"\"Any process that activates or increases the frequency, rate or extent of termination of RNA polymerase II transcription, poly(A)-coupled.\" [GOC:obol]","metadata":null},{"id":"f18f98b3ae8b49c2a54c2717ab4938a3","type":"GO_TERM","name":"positive regulation of terreate biosynthetic process","canonical_id":"go:GO:0180069","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of terreate.\" [PMID:25265334]","metadata":null},{"id":"962012a5d7eb42daa580ac5c89fd9ca7","type":"GO_TERM","name":"positive regulation of terrequinone A biosynthetic process","canonical_id":"go:GO:1900854","description":"\"Any process that activates or increases the frequency, rate or extent of terrequinone A biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:24066102]","metadata":null},{"id":"cac25dafa763443f98874113ba58d79e","type":"GO_TERM","name":"positive regulation of testosterone secretion","canonical_id":"go:GO:2000845","description":"\"Any process that activates or increases the frequency, rate or extent of testosterone secretion.\" [GOC:sl]","metadata":null},{"id":"efe36613303b4fa9b05484217d272861","type":"GO_TERM","name":"positive regulation of tetrapyrrole biosynthetic process","canonical_id":"go:GO:1901465","description":"\"Any process that activates or increases the frequency, rate or extent of tetrapyrrole biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"79a7a383d9d54af2a481efb6e520e2a1","type":"GO_TERM","name":"positive regulation of tetrapyrrole catabolic process","canonical_id":"go:GO:1901406","description":"\"Any process that activates or increases the frequency, rate or extent of tetrapyrrole catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4a5a0f4aba0845d683bcb6bc5843cf11","type":"GO_TERM","name":"positive regulation of the force of heart contraction","canonical_id":"go:GO:0098735","description":"\"Any process that increases the force of heart muscle contraction.\" [GOC:BHF, GOC:dos, GOC:mtg_cardiac_conduct_nov11, GOC:rl, PMID:17242280]","metadata":null},{"id":"ecb30449ea63480f8f6a69af818a4e3d","type":"GO_TERM","name":"positive regulation of the force of heart contraction by chemical signal","canonical_id":"go:GO:0003099","description":"\"Any process which increases the force of heart muscle contraction mediated by chemical signaling, hormonal, autocrine or paracrine.\" [GOC:mtg_cardio]","metadata":null},{"id":"d9ae5d3296714b66b5fb81dd9d4b426a","type":"GO_TERM","name":"positive regulation of the force of heart contraction by circulating epinephrine","canonical_id":"go:GO:0003088","description":"\"The process in which the secretion of epinephrine into the bloodstream modulates the force of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"151a1c58262a4a40a2f6e53c078c45b7","type":"GO_TERM","name":"positive regulation of the force of heart contraction by circulating epinephrine-norepinephrine","canonical_id":"go:GO:0003089","description":"\"Any process that increases the force with which the cardiac muscles of the heart pump blood through the circulatory system as a result of the presence of epinephrine or norepinephrine in the bloodstream.\" [GOC:mtg_cardio]","metadata":null},{"id":"53271be9920e4faeacfc78e1c6a6edd7","type":"GO_TERM","name":"positive regulation of the force of heart contraction by circulating norepinephrine","canonical_id":"go:GO:0003109","description":"\"The process in which the secretion of norepinephrine into the bloodstream modulates the force of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"68932afe7cf649bab206ef46bd107799","type":"GO_TERM","name":"positive regulation of the force of heart contraction by epinephrine","canonical_id":"go:GO:0003059","description":"\"The process in which the secretion of epinephrine into the bloodstream or released from nerve endings modulates the force of heart muscle contraction.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"acfef971e27f47d1ae476b559421d0ef","type":"GO_TERM","name":"positive regulation of the force of heart contraction by epinephrine-norepinephrine","canonical_id":"go:GO:0001997","description":"\"Any process that increases the force with which the cardiac muscles of the heart pump blood through the circulatory system as a result of the presence of epinephrine or norepinephrine in the bloodstream or released from the nerve endings.\" [GOC:dph, GOC:mtg_cardio]","metadata":null},{"id":"c9c82f2eef004ce89ecb307ada6c0422","type":"GO_TERM","name":"positive regulation of the force of heart contraction by neuronal epinephrine","canonical_id":"go:GO:0003087","description":"\"The process in which the release of epinephrine from nerve endings modulates the force of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"94b022cb166744bcbc0a5e599a584c40","type":"GO_TERM","name":"positive regulation of the force of heart contraction by neuronal epinephrine-norepinephrine","canonical_id":"go:GO:0003090","description":"\"Any process that increases the force with which the cardiac muscles of the heart pump blood through the circulatory system as a result of the presence of epinephrine or norepinephrine released from the nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"05bd0aabcab9492e80865a801e4545e7","type":"GO_TERM","name":"positive regulation of the force of heart contraction by neuronal norepinephrine","canonical_id":"go:GO:0003110","description":"\"The process in which the release of norepinephrine from nerve endings modulates the force of heart muscle contraction.\" [GOC:mtg_cardio]","metadata":null},{"id":"c71e7cd3a94745cb9ad0e2fbc53186a3","type":"GO_TERM","name":"positive regulation of the force of heart contraction by norepinephrine","canonical_id":"go:GO:0003061","description":"\"The process in which the secretion of norepinephrine into the bloodstream or released from nerve endings modulates the force of heart musclecontraction.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"9e24271ceae04bc8a7e75c4b4360fb45","type":"GO_TERM","name":"positive regulation of thermomorphogenesis","canonical_id":"go:GO:0140922","description":"\"Any process that increases the rate, frequency or extent of thermomorphogenesis.\" [PMID:27250752]","metadata":null},{"id":"63389b92490a48eabff0a5b422c11cde","type":"GO_TERM","name":"positive regulation of thiamine biosynthetic process","canonical_id":"go:GO:0090180","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of thiamine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4ce55dde84ec4d149b0c87c12a225044","type":"GO_TERM","name":"positive regulation of thrombin-activated receptor signaling pathway","canonical_id":"go:GO:0070496","description":"\"Any process that activates or increases the frequency, rate or extent of thrombin-activated receptor protein signaling pathway activity. A thrombin receptor signaling pathway is the series of molecular signals generated as a consequence of a thrombin-activated receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"07ec3be25f5449299c0410d23f723908","type":"GO_TERM","name":"positive regulation of thymine transport","canonical_id":"go:GO:0035367","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of thymine, 5-methyluracil, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf, GOC:sl]","metadata":null},{"id":"dc27f69d5945496b9342a952290d9aa0","type":"GO_TERM","name":"positive regulation of thymocyte aggregation","canonical_id":"go:GO:2000400","description":"\"Any process that activates or increases the frequency, rate or extent of thymocyte aggregation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"2221d7ee15ce4647bd9e3fe67f564d3d","type":"GO_TERM","name":"positive regulation of thymocyte apoptotic process","canonical_id":"go:GO:0070245","description":"\"Any process that activates or increases the frequency, rate or extent of thymocyte death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"2283e1824699456aa2bfb3cd6c94148c","type":"GO_TERM","name":"positive regulation of thymocyte migration","canonical_id":"go:GO:2000412","description":"\"Any process that activates or increases the frequency, rate or extent of thymocyte migration.\" [GOC:mah]","metadata":null},{"id":"763982be277148d2b295941e61b0ad58","type":"GO_TERM","name":"positive regulation of thyroid gland epithelial cell proliferation","canonical_id":"go:GO:1904443","description":"\"Any process that activates or increases the frequency, rate or extent of thyroid gland epithelial cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:17646383]","metadata":null},{"id":"9ad7725a09374c82845280ba320fd2a1","type":"GO_TERM","name":"positive regulation of thyroid hormone generation","canonical_id":"go:GO:2000611","description":"\"Any process that activates or increases the frequency, rate or extent of thyroid hormone generation.\" [GOC:obol]","metadata":null},{"id":"df0b2bf6c2404235bdc5f8f164ab0103","type":"GO_TERM","name":"positive regulation of thyroid hormone receptor signaling pathway","canonical_id":"go:GO:0002157","description":"\"Any process that increases the frequency, rate or extent of thyroid hormone mediated signaling pathway.\" [GOC:hjd]","metadata":null},{"id":"46b1c013ea9942f08053747293d15e93","type":"GO_TERM","name":"positive regulation of thyroid-stimulating hormone secretion","canonical_id":"go:GO:2000614","description":"\"Any process that activates or increases the frequency, rate or extent of thyroid-stimulating hormone secretion.\" [GOC:obol]","metadata":null},{"id":"046aeb923f1348fcab62f40230bcf82d","type":"GO_TERM","name":"positive regulation of tight junction disassembly","canonical_id":"go:GO:1905075","description":"\"Any process that activates or increases the frequency, rate or extent of tight junction disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"7c49db48a7084789af02a4c3d0c098b9","type":"GO_TERM","name":"positive regulation of timing of anagen","canonical_id":"go:GO:0051885","description":"\"Any process that activates or increases the frequency, rate or extent of timing of anagen, the growth phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"665c6f4316624d16af3de75ba278e17e","type":"GO_TERM","name":"positive regulation of timing of catagen","canonical_id":"go:GO:0051795","description":"\"Any process that activates or increases the frequency, rate or extent of timing of catagen, the regression phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"4aa9d718659a4a678f9815260c8fc1a4","type":"GO_TERM","name":"positive regulation of timing of exogen","canonical_id":"go:GO:0051888","description":"\"Any process that activates or increases the frequency, rate or extent of timing of exogen, the shedding phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"e766a9b5947646e89dc168a4ef5e94a7","type":"GO_TERM","name":"positive regulation of tissue kallikrein-kinin cascade","canonical_id":"go:GO:0002547","description":"\"Any process that activates or increases the frequency, rate, or extent of the tissue kallikrein-kinin cascade.\" [GOC:add]","metadata":null},{"id":"0fae01c6b2c04a348bfc6e839129fe5b","type":"GO_TERM","name":"positive regulation of tissue remodeling","canonical_id":"go:GO:0034105","description":"\"Any process that activates or increases the frequency, rate, or extent of tissue remodeling.\" [GOC:add]","metadata":null},{"id":"0d03bf542d6c4da497933fde43c5c8f8","type":"GO_TERM","name":"positive regulation of tolerance induction","canonical_id":"go:GO:0002645","description":"\"Any process that activates or increases the frequency, rate, or extent of tolerance induction.\" [GOC:add]","metadata":null},{"id":"2d9b31b2bbd34e1bb9dbdd54e63c7661","type":"GO_TERM","name":"positive regulation of tolerance induction dependent upon immune response","canonical_id":"go:GO:0002654","description":"\"Any process that activates or increases the frequency, rate, or extent of tolerance induction dependent upon immune response.\" [GOC:add]","metadata":null},{"id":"a2b1b14e71c14b1faa9eee810f37f56f","type":"GO_TERM","name":"positive regulation of tolerance induction to nonself antigen","canonical_id":"go:GO:0002657","description":"\"Any process that activates or increases the frequency, rate, or extent of tolerance induction to nonself antigen.\" [GOC:add]","metadata":null},{"id":"cf08f410da014cb8b7ea0dcfc971cfc9","type":"GO_TERM","name":"positive regulation of tolerance induction to self antigen","canonical_id":"go:GO:0002651","description":"\"Any process that activates or increases the frequency, rate, or extent of tolerance induction to self antigen.\" [GOC:add]","metadata":null},{"id":"5ed3e2d9d6144c778888a9f853aecc1d","type":"GO_TERM","name":"positive regulation of tolerance induction to tumor cell","canonical_id":"go:GO:0002845","description":"\"Any process that activates or increases the frequency, rate, or extent of tolerance induction to tumor cell.\" [GOC:add]","metadata":null},{"id":"c46c8943ad554d89a1d5102cf73c3220","type":"GO_TERM","name":"positive regulation of toll-like receptor 1 signaling pathway","canonical_id":"go:GO:0034133","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 1 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"d93030cf07c14b02bb606ed8b8a7ad4c","type":"GO_TERM","name":"positive regulation of toll-like receptor 10 signaling pathway","canonical_id":"go:GO:0034169","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 10 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"bd092eda30c94dd48227aab28eb71cab","type":"GO_TERM","name":"positive regulation of toll-like receptor 11 signaling pathway","canonical_id":"go:GO:0034173","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 11 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"36bf4601bb634e9e961ac17619b5bb45","type":"GO_TERM","name":"positive regulation of toll-like receptor 12 signaling pathway","canonical_id":"go:GO:0034177","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 12 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"ee046e9b19aa4b038115cec78c445451","type":"GO_TERM","name":"positive regulation of toll-like receptor 13 signaling pathway","canonical_id":"go:GO:0034181","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 13 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"0b6f0fd3b72942178103deb2228b8b90","type":"GO_TERM","name":"positive regulation of toll-like receptor 15 signaling pathway","canonical_id":"go:GO:2000442","description":"\"Any process that activates or increases the frequency, rate or extent of toll-like receptor 15 signaling pathway.\" [GOC:obol]","metadata":null},{"id":"4651b5e8deac4241bcc440e2f4a95e8e","type":"GO_TERM","name":"positive regulation of toll-like receptor 2 signaling pathway","canonical_id":"go:GO:0034137","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 2 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"ebfc5eacbee94b4bb4e7bce7970bb23a","type":"GO_TERM","name":"positive regulation of toll-like receptor 21 signaling pathway","canonical_id":"go:GO:2000445","description":"\"Any process that activates or increases the frequency, rate or extent of toll-like receptor 21 signaling pathway.\" [GOC:obol]","metadata":null},{"id":"6acb9ce45d7d4e2aa1f4f08b3103bc27","type":"GO_TERM","name":"positive regulation of toll-like receptor 3 signaling pathway","canonical_id":"go:GO:0034141","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 3 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"fedad0b6496a4dcf80e916bcc1fbead2","type":"GO_TERM","name":"positive regulation of toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0034145","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 4 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"5deab03c05694c0a88a60b62da88ab10","type":"GO_TERM","name":"positive regulation of toll-like receptor 5 signaling pathway","canonical_id":"go:GO:0034149","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 5 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"66ff53f79b4a42d4b4aa4fb0841f04d4","type":"GO_TERM","name":"positive regulation of toll-like receptor 6 signaling pathway","canonical_id":"go:GO:0034153","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 6 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"8b12f8972c1f4b87a0cd4f85e0b267fd","type":"GO_TERM","name":"positive regulation of toll-like receptor 7 signaling pathway","canonical_id":"go:GO:0034157","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 7 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"22f733e344d049638041a59277304577","type":"GO_TERM","name":"positive regulation of toll-like receptor 8 signaling pathway","canonical_id":"go:GO:0034161","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 8 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"04ea992d518d4552baae6a1cee7f1ba4","type":"GO_TERM","name":"positive regulation of toll-like receptor 9 signaling pathway","canonical_id":"go:GO:0034165","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor 9 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"4da08df4cf484561af0971fb71604b3a","type":"GO_TERM","name":"positive regulation of toll-like receptor 9 signaling pathway by B cell receptor internalization","canonical_id":"go:GO:1901245","description":"\"The movement of a B cell receptor (BCR) from the plasma membrane to the inside of the cell, which results in positive regulation of toll-like receptor 9 (TLR9) signaling. For example, internalized BCR signals to recruit TLR9 from multiple small endosomes to large autophagosome-like compartments to enhance TLR9 signaling.\" [GOC:amm, GOC:bf, GOC:TermGenie, PMID:18513998]","metadata":null},{"id":"9c6b0846285e4055bd02280475bad434","type":"GO_TERM","name":"positive regulation of toll-like receptor signaling pathway","canonical_id":"go:GO:0034123","description":"\"Any process that activates or increases the frequency, rate, or extent of toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"beb1e2eb9e5e432b993f57cd9700dc01","type":"GO_TERM","name":"positive regulation of toluene catabolic process","canonical_id":"go:GO:1901436","description":"\"Any process that activates or increases the frequency, rate or extent of toluene catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"8b62d3e89dcc46d888e38e5d2f29dfaa","type":"GO_TERM","name":"positive regulation of tongue muscle cell differentiation","canonical_id":"go:GO:2001037","description":"\"Any process that activates or increases the frequency, rate or extent of tongue muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"6eede8f9f010436f99d96ca1f4ff4a5d","type":"GO_TERM","name":"positive regulation of tonic skeletal muscle contraction","canonical_id":"go:GO:0014747","description":"\"Any process that activates or increases the frequency, rate or extent of tonic skeletal muscle contraction.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"c34ca985e4df4a5f8b2a80f7ba2c3304","type":"GO_TERM","name":"positive regulation of tooth mineralization","canonical_id":"go:GO:0070172","description":"\"Any process that activates or increases the frequency, rate or extent of tooth mineralization, the deposition of calcium salts in tooth structures.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"76335e65e4b14b5e8eac5c1edd07fa94","type":"GO_TERM","name":"positive regulation of torso signaling pathway","canonical_id":"go:GO:0120176","description":"\"Any process that activates or increases the frequency, rate or extent of the torso signaling pathway.\" [GOC:ha, PMID:23732470]","metadata":null},{"id":"67877ee384d44bec8e07ee4d66dd0693","type":"GO_TERM","name":"positive regulation of transcription by RNA polymerase I","canonical_id":"go:GO:0045943","description":"\"Any process that activates or increases the frequency, rate or extent of transcription mediated by RNA polymerase I.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"7ba7976d6432454486649883365cf05a","type":"GO_TERM","name":"positive regulation of transcription by RNA polymerase II","canonical_id":"go:GO:0045944","description":"\"Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"3ca9c6e47bc849a8a081b14bfa5d7746","type":"GO_TERM","name":"positive regulation of transcription by RNA polymerase III","canonical_id":"go:GO:0045945","description":"\"Any process that activates or increases the frequency, rate or extent of transcription mediated by RNA polymerase III.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"0acdeaae625d4e96b9222d8226538f95","type":"GO_TERM","name":"positive regulation of transcription by RNA polymerase V","canonical_id":"go:GO:1904281","description":"\"Any process that activates or increases the frequency, rate or extent of transcription mediated by RNA polymerase V.\" [GO_REF:0000058, GOC:TermGenie, PMID:24726328]","metadata":null},{"id":"e26ef08e46f04e3da47dcca7501d86ce","type":"GO_TERM","name":"positive regulation of transcription by galactose","canonical_id":"go:GO:0000411","description":"\"Any process involving galactose that activates or increases the rate of transcription.\" [GOC:curators]","metadata":null},{"id":"e8872f0f7a274b738a258b3be779a3c3","type":"GO_TERM","name":"positive regulation of transcription by glucose","canonical_id":"go:GO:0046016","description":"\"Any process involving glucose that activates or increases the rate of transcription.\" [GOC:curators]","metadata":null},{"id":"cbdf8ecde654473b86ab08e9ad930bf7","type":"GO_TERM","name":"positive regulation of transcription by transcription factor localization","canonical_id":"go:GO:0061586","description":"\"Any process that activates or increases the frequency, rate or extent of DNA-dependent transcription using a mechanism that involves the localization of a transcription factor.\" [GOC:dph]","metadata":null},{"id":"75e3af4b7e7c4d56b6877dc798c77fb2","type":"GO_TERM","name":"positive regulation of transcription elongation by RNA polymerase I","canonical_id":"go:GO:2001209","description":"\"Any process that activates or increases the frequency, rate or extent of transcription elongation from RNA polymerase I promoter.\" [PMID:20299458]","metadata":null},{"id":"9ac53657af0245a782eaccf276117040","type":"GO_TERM","name":"positive regulation of transcription elongation by RNA polymerase II","canonical_id":"go:GO:0032968","description":"\"Any process that activates or increases the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"7307a8a29cb04d4181433cfaf3e69dea","type":"GO_TERM","name":"positive regulation of transcription from RNA polymerase II promoter by galactose","canonical_id":"go:GO:0000435","description":"\"Any process involving galactose that activates or increases the rate of transcription from an RNA polymerase II promoter.\" [GOC:krc]","metadata":null},{"id":"19a036c28c6946328040f1ae62451894","type":"GO_TERM","name":"positive regulation of transcription from RNA polymerase II promoter by glucose","canonical_id":"go:GO:0000432","description":"\"Any process involving glucose that activates or increases the rate of transcription from an RNA polymerase II promoter.\" [GOC:krc]","metadata":null},{"id":"9f2e07b07def482da8f5ae17f6e63eb4","type":"GO_TERM","name":"positive regulation of transcription from RNA polymerase II promoter by oleic acid","canonical_id":"go:GO:0061429","description":"\"Any process involving oleic acid that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.\" [GOC:dph, PMID:20395639]","metadata":null},{"id":"9c2592969b83465eafde2fd73f23d975","type":"GO_TERM","name":"positive regulation of transcription from a mobile element promoter","canonical_id":"go:GO:0061435","description":"\"Any process that activates or increases the frequency, rate or extent of transcription from a mobile element promoter.\" [GOC:dph, PMID:12230120, PMID:9271107]","metadata":null},{"id":"53f7d92b5aca407eb14e7d5295181eab","type":"GO_TERM","name":"positive regulation of transcription initiation by RNA polymerase II","canonical_id":"go:GO:0060261","description":"\"Any process that increases the rate, frequency or extent of a process involved in starting transcription from an RNA polymerase II promoter.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"8f50b06287fa4cd29a094fbf79624e7d","type":"GO_TERM","name":"positive regulation of transcription of Notch receptor target","canonical_id":"go:GO:0007221","description":"\"The activation of transcription of specific genes as a result of Notch signaling, mediated by the Notch intracellular domain.\" [PMID:12651094]","metadata":null},{"id":"14f48b257f4e4789ac273f7d43968ffb","type":"GO_TERM","name":"positive regulation of transcription of nucleolar large rRNA by RNA polymerase I","canonical_id":"go:GO:1901838","description":"\"Any process that activates or increases the frequency, rate or extent of transcription of nuclear large rRNA mediated by RNA polymerase I.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"98f4628ec64649e5b639d86bc14a97a8","type":"GO_TERM","name":"positive regulation of transcription regulatory region DNA binding","canonical_id":"go:GO:2000679","description":"\"Any process that activates or increases the frequency, rate or extent of transcription regulatory region DNA binding.\" [GOC:obol]","metadata":null},{"id":"6b5478eebdc0452dba46a237dd34102d","type":"GO_TERM","name":"positive regulation of transcytosis","canonical_id":"go:GO:1904300","description":"\"Any process that activates or increases the frequency, rate or extent of transcytosis.\" [GO_REF:0000058, GOC:TermGenie, PMID:9664076]","metadata":null},{"id":"3a1021e0c43640419cf6bb78ad47b872","type":"GO_TERM","name":"positive regulation of transdifferentiation","canonical_id":"go:GO:1903620","description":"\"Any process that activates or increases the frequency, rate or extent of transdifferentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22118091]","metadata":null},{"id":"f177e11d215740388890eb534b156d19","type":"GO_TERM","name":"positive regulation of transepithelial migration of symbiont in host","canonical_id":"go:GO:0140471","description":"\"Any process that activates or increases the frequency, rate or extent of transepithelial migration of symbiont in host.\" [PMID:29113016]","metadata":null},{"id":"7ac72060d0534dfbacfcbf87826dca95","type":"GO_TERM","name":"positive regulation of transformation of host cell by virus","canonical_id":"go:GO:1904189","description":"\"Any process that activates or increases the frequency, rate or extent of transformation of host cell by virus.\" [GO_REF:0000058, GOC:TermGenie, PMID:12200142]","metadata":null},{"id":"affc46afda80448aac410201ef9397e6","type":"GO_TERM","name":"positive regulation of transforming growth factor beta production","canonical_id":"go:GO:0071636","description":"\"Any process that activates or increases the frequency, rate, or extent of production of transforming growth factor-beta.\" [GOC:mah]","metadata":null},{"id":"dcd4191693cb43139da09d1b64f05034","type":"GO_TERM","name":"positive regulation of transforming growth factor beta receptor signaling pathway","canonical_id":"go:GO:0030511","description":"\"Any process that activates or increases the frequency, rate or extent of TGF-beta receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"56f96a40a70f4f0bb9c260b1585bf6ff","type":"GO_TERM","name":"positive regulation of transforming growth factor beta1 production","canonical_id":"go:GO:0032914","description":"\"Any process that activates or increases the frequency, rate, or extent of production of transforming growth factor-beta1.\" [GOC:mah]","metadata":null},{"id":"081ed787ae7c426fbf408d98613d2ffb","type":"GO_TERM","name":"positive regulation of transforming growth factor beta2 production","canonical_id":"go:GO:0032915","description":"\"Any process that activates or increases the frequency, rate, or extent of production of transforming growth factor-beta2.\" [GOC:mah]","metadata":null},{"id":"77604488be6d4a9199b3bccaa2308482","type":"GO_TERM","name":"positive regulation of transforming growth factor beta3 production","canonical_id":"go:GO:0032916","description":"\"Any process that activates or increases the frequency, rate, or extent of production of transforming growth factor-beta3.\" [GOC:mah]","metadata":null},{"id":"159c1c5a5d6e483ea1fa2a8d136199ea","type":"GO_TERM","name":"positive regulation of translation","canonical_id":"go:GO:0045727","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"dfbbe0dd6c5f48f5b0f3a8cc52a613fb","type":"GO_TERM","name":"positive regulation of translation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036493","description":"\"Any process that activates, or increases the frequency, rate or extent of translation as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"b0b0a3178955434aaaa5566faa5f9298","type":"GO_TERM","name":"positive regulation of translation in response to osmotic stress","canonical_id":"go:GO:0032062","description":"\"Any process that activates or increases the frequency, rate or extent of translation as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:mah]","metadata":null},{"id":"20e5f3c7d8de4bc8a49204564fdb8e57","type":"GO_TERM","name":"positive regulation of translation in response to oxidative stress","canonical_id":"go:GO:0032939","description":"\"Any process that activates or increases the frequency, rate or extent of translation as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.\" [GOC:mah]","metadata":null},{"id":"d8d4cb615a604915976f6d3ff84d3027","type":"GO_TERM","name":"positive regulation of translation in response to stress","canonical_id":"go:GO:0032056","description":"\"Any process that activates or increases the frequency, rate or extent of translation as a result of a stimulus indicating the organism is under stress.\" [GOC:mah]","metadata":null},{"id":"bee32dbfce324a6d859cc04e1e76d32a","type":"GO_TERM","name":"positive regulation of translation initiation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036494","description":"\"Any process that activates, or increases the frequency, rate or extent of translation initiation as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"705a7888c0914d1c968d019037d95e6a","type":"GO_TERM","name":"positive regulation of translation, ncRNA-mediated","canonical_id":"go:GO:0045975","description":"\"Any process, mediated by small non-coding RNAs, that activates or increases the rate that mRNAs are effectively translated into protein.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"845fc4df9b654df5b1d3b0a60836f934","type":"GO_TERM","name":"positive regulation of translational elongation","canonical_id":"go:GO:0045901","description":"\"Any process that activates or increases the frequency, rate or extent of translational elongation.\" [GOC:curators]","metadata":null},{"id":"b3b8cffc467547c8b9647ca6f9ee0019","type":"GO_TERM","name":"positive regulation of translational fidelity","canonical_id":"go:GO:0045903","description":"\"Any process that increases the ability of the translational apparatus to interpret the genetic code.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"83972a8a0b094906852c8ca1424a55d5","type":"GO_TERM","name":"positive regulation of translational frameshifting","canonical_id":"go:GO:2001126","description":"\"Any process that activates or increases the frequency, rate or extent of translational frameshifting.\" [GOC:obol]","metadata":null},{"id":"20cb261930474d9a95ef104fe2441314","type":"GO_TERM","name":"positive regulation of translational initiation","canonical_id":"go:GO:0045948","description":"\"Any process that activates or increases the frequency, rate or extent of translational initiation.\" [GOC:curators]","metadata":null},{"id":"14977f086cde426183fdf542eb616b0f","type":"GO_TERM","name":"positive regulation of translational initiation by iron","canonical_id":"go:GO:0045994","description":"\"Any process involving iron that activates or increases the rate of translational initiation.\" [GOC:curators]","metadata":null},{"id":"c85c9e3f504a499bb306796648499c25","type":"GO_TERM","name":"positive regulation of translational initiation in response to osmotic stress","canonical_id":"go:GO:0032064","description":"\"Any process that activates or increases the frequency, rate or extent of translation initiation, as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:mah]","metadata":null},{"id":"ae12471d6e794dfc9a180a8abd5e344c","type":"GO_TERM","name":"positive regulation of translational initiation in response to starvation","canonical_id":"go:GO:0071264","description":"\"Any process that activates or increases the frequency, rate or extent of translation initiation, as a result of deprivation of nourishment.\" [GOC:mah]","metadata":null},{"id":"6c57ae3eeba6435dba33558209af7a9c","type":"GO_TERM","name":"positive regulation of translational initiation in response to stress","canonical_id":"go:GO:0032058","description":"\"Any process that activates or increases the frequency, rate or extent of translation initiation as a result of a stimulus indicating the organism is under stress.\" [GOC:mah]","metadata":null},{"id":"1b45840c4fe546ffb1c181a9a46796f1","type":"GO_TERM","name":"positive regulation of translational termination","canonical_id":"go:GO:0045905","description":"\"Any process that activates or increases the frequency, rate or extent of translational termination.\" [GOC:curators]","metadata":null},{"id":"82c831a57f024240bd6959141fc96e0a","type":"GO_TERM","name":"positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway","canonical_id":"go:GO:0090100","description":"\"Any process that increases the rate, frequency, or extent of the series of molecular signals generated as a consequence of a transmembrane receptor serine/threonine kinase binding to its physiological ligand.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d2cd787a1ce648f298cc9b6788bc8ed2","type":"GO_TERM","name":"positive regulation of transmembrane transport","canonical_id":"go:GO:0034764","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of a solute from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"309e8c3444bf4c34ab267d493b50fa21","type":"GO_TERM","name":"positive regulation of transmission of nerve impulse","canonical_id":"go:GO:0051971","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of transmission of a nerve impulse, the sequential electrochemical polarization and depolarization that travels across the membrane of a neuron in response to stimulation.\" [GOC:ai]","metadata":null},{"id":"67f4b92f7ec54213b6f3de751280b3d9","type":"GO_TERM","name":"positive regulation of transport","canonical_id":"go:GO:0051050","description":"\"Any process that activates or increases the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"1d574ebf228c45c78d85712b9030ca82","type":"GO_TERM","name":"positive regulation of transport across blood-brain barrier","canonical_id":"go:GO:0150201","description":"\"Any process that activates or increases the frequency, rate or extent of transport across blood-brain barrier.\" [GOC:aruk, GOC:bc, PMID:29377008, PMID:30280653]","metadata":null},{"id":"911da3be94aa4b0faf98e5d985b34cfd","type":"GO_TERM","name":"positive regulation of transporter activity","canonical_id":"go:GO:0032411","description":"\"Any process that activates or increases the activity of a transporter.\" [GOC:mah]","metadata":null},{"id":"95da71c782d5418eba3341e90617a879","type":"GO_TERM","name":"positive regulation of trehalose catabolic process","canonical_id":"go:GO:1901319","description":"\"Any process that activates or increases the frequency, rate or extent of trehalose catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"781dc02036fa4deea970087190699f51","type":"GO_TERM","name":"positive regulation of trichoblast fate specification","canonical_id":"go:GO:0010063","description":"\"Any process that induces or promotes trichoblast fate specification.\" [GOC:tb]","metadata":null},{"id":"a15f7eb2557f452e8f333570e60dc790","type":"GO_TERM","name":"positive regulation of tridecane biosynthetic process","canonical_id":"go:GO:1900886","description":"\"Any process that activates or increases the frequency, rate or extent of tridecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c5680e94f014463a98815fe687b4dd40","type":"GO_TERM","name":"positive regulation of triglyceride biosynthetic process","canonical_id":"go:GO:0010867","description":"\"Any process that increases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"29076562b3d445208961afdedb69700f","type":"GO_TERM","name":"positive regulation of triglyceride catabolic process","canonical_id":"go:GO:0010898","description":"\"Any process that increases the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride.\" [GOC:rn, GOC:tb]","metadata":null},{"id":"c1b838c37f4544ac9c2320077d8438bc","type":"GO_TERM","name":"positive regulation of triglyceride lipase activity","canonical_id":"go:GO:0061365","description":"\"Any process that increases the activity of triglyceride lipase.\" [GOC:dph]","metadata":null},{"id":"de4a291950d44b8e995301d75dfeb126","type":"GO_TERM","name":"positive regulation of triglyceride metabolic process","canonical_id":"go:GO:0090208","description":"\"Any process that increases the frequency, rate or extent of the chemical reactions and pathways involving triglyceride, any triester of glycerol.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"9b41f4e6f43748f198ee70676bc5dbe4","type":"GO_TERM","name":"positive regulation of triglyceride storage","canonical_id":"go:GO:0010890","description":"\"Any process that increases the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5d90684facc3465590835f0fc2a0ab7b","type":"GO_TERM","name":"positive regulation of triglyceride transport","canonical_id":"go:GO:1905885","description":"\"Any process that activates or increases the frequency, rate or extent of triglyceride transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:25849533]","metadata":null},{"id":"06bde6c9e01748a4b7c5d4a9ad28c058","type":"GO_TERM","name":"positive regulation of trophectodermal cell proliferation","canonical_id":"go:GO:1904075","description":"\"Any process that activates or increases the frequency, rate or extent of trophectodermal cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24508636]","metadata":null},{"id":"31641471958a4ff38a131b4768756e0d","type":"GO_TERM","name":"positive regulation of trophoblast cell migration","canonical_id":"go:GO:1901165","description":"\"Any process that activates or increases the frequency, rate or extent of trophoblast cell migration.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"7a2ca3ad3c734aa9b535e2d9cdb345f6","type":"GO_TERM","name":"positive regulation of trypanothione biosynthetic process","canonical_id":"go:GO:1905724","description":"\"Any process that activates or increases the frequency, rate or extent of trypanothione biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:18949025]","metadata":null},{"id":"03ace4886f09452d923d70c85741d84c","type":"GO_TERM","name":"positive regulation of tubulin deacetylation","canonical_id":"go:GO:0090044","description":"\"Any process that increases the frequency, rate or extent of tubulin deacetylation. Tubulin deacetylation is the removal of an acetyl group from a protein amino acid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"3160b857baeb491296bec0373ec63e08","type":"GO_TERM","name":"positive regulation of tumor necrosis factor (ligand) superfamily member 11 production","canonical_id":"go:GO:2000309","description":"\"Any process that activates or increases the frequency, rate or extent of tumor necrosis factor (ligand) superfamily member 11 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"739983c8e79848709fbe746bb6f7afb4","type":"GO_TERM","name":"positive regulation of tumor necrosis factor production","canonical_id":"go:GO:0032760","description":"\"Any process that activates or increases the frequency, rate or extent of tumor necrosis factor production.\" [GO_REF:0000058, GOC:TermGenie, PMID:10891884, PMID:15560120]","metadata":null},{"id":"e25e93a71d5947748d6ffcf54d00c8ca","type":"GO_TERM","name":"positive regulation of tumor necrosis factor superfamily cytokine production","canonical_id":"go:GO:1903557","description":"\"Any process that activates or increases the frequency, rate or extent of tumor necrosis factor superfamily cytokine production.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"ded2a77f74b34fcf86466a01c925d25e","type":"GO_TERM","name":"positive regulation of tumor necrosis factor-mediated signaling pathway","canonical_id":"go:GO:1903265","description":"\"Any process that activates or increases the frequency, rate or extent of tumor necrosis factor-mediated signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23453807]","metadata":null},{"id":"d96ce4c4624a4d8a8c4378d728f16d5b","type":"GO_TERM","name":"positive regulation of type 2 immune response","canonical_id":"go:GO:0002830","description":"\"Any process that activates or increases the frequency, rate, or extent of a type 2 immune response.\" [GOC:add]","metadata":null},{"id":"a63ece6542db4f8aabe3cb6f0b9ec5a2","type":"GO_TERM","name":"positive regulation of type 2 mitophagy","canonical_id":"go:GO:1905091","description":"\"Any process that activates or increases the frequency, rate or extent of type 2 mitophagy.\" [GOC:vw, PMID:25009776, PMID:26942284]","metadata":null},{"id":"9160e2edd9b246fba8ad7272203738fa","type":"GO_TERM","name":"positive regulation of type B pancreatic cell apoptotic process","canonical_id":"go:GO:2000676","description":"\"Any process that activates or increases the frequency, rate or extent of type B pancreatic cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"de14b8be02814d18b031e61f6a40fe06","type":"GO_TERM","name":"positive regulation of type B pancreatic cell development","canonical_id":"go:GO:2000078","description":"\"Any process that activates or increases the frequency, rate or extent of pancreatic B cell development.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"6fd20a8d06324c49b9eb6e0403d267dd","type":"GO_TERM","name":"positive regulation of type B pancreatic cell proliferation","canonical_id":"go:GO:1904692","description":"\"Any process that activates or increases the frequency, rate or extent of type B pancreatic cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24055447]","metadata":null},{"id":"b5e40eead315442c95efb169d01d959a","type":"GO_TERM","name":"positive regulation of type I hypersensitivity","canonical_id":"go:GO:0001812","description":"\"Any process that activates or increases the frequency, rate or extent of type I hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"4903d707b94844e990bd62d22669a023","type":"GO_TERM","name":"positive regulation of type I interferon production","canonical_id":"go:GO:0032481","description":"\"Any process that activates or increases the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, GOC:mah]","metadata":null},{"id":"18579e4d8c464fa28b6ac46dd566ca36","type":"GO_TERM","name":"positive regulation of type I interferon-mediated signaling pathway","canonical_id":"go:GO:0060340","description":"\"Any process that increases the rate, frequency or extent of a type I interferon-mediated signaling pathway.\" [GOC:dph]","metadata":null},{"id":"7050511c6cac4af5a626015df864625d","type":"GO_TERM","name":"positive regulation of type II hypersensitivity","canonical_id":"go:GO:0002894","description":"\"Any process that activates or increases the frequency, rate, or extent of type II hypersensitivity.\" [GOC:add]","metadata":null},{"id":"1942f24869c5404fa87b675c81dbe40a","type":"GO_TERM","name":"positive regulation of type II interferon production","canonical_id":"go:GO:0032729","description":"\"Any process that activates or increases the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.\" [GOC:add, GOC:mah, PMID:15546383]","metadata":null},{"id":"c82583aad3654ee98032ace80993bd18","type":"GO_TERM","name":"positive regulation of type II interferon-mediated signaling pathway","canonical_id":"go:GO:0060335","description":"\"Any process that increases the rate, frequency or extent of an interferon-gamma-mediated signaling pathway.\" [GOC:dph]","metadata":null},{"id":"3c00462b188441c1af664007ee17f7e7","type":"GO_TERM","name":"positive regulation of type III hypersensitivity","canonical_id":"go:GO:0001805","description":"\"Any process that activates or increases the frequency, rate or extent of type III hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6cfd303c551143b2b1daeb3f4924a67a","type":"GO_TERM","name":"positive regulation of type III interferon production","canonical_id":"go:GO:0034346","description":"\"Any process that activates or increases the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"5909b5c47e8d4b9d8cf1d03cd96d52ef","type":"GO_TERM","name":"positive regulation of type IIa hypersensitivity","canonical_id":"go:GO:0001798","description":"\"Any process that activates or increases the frequency, rate or extent of type IIa hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"66abda3c3b7e471fb31267c08c75d085","type":"GO_TERM","name":"positive regulation of type IIb hypersensitivity","canonical_id":"go:GO:0001801","description":"\"Any process that activates or increases the frequency, rate or extent of type IIb hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ddfeaeb47775406d927702940abb1d39","type":"GO_TERM","name":"positive regulation of type IV hypersensitivity","canonical_id":"go:GO:0001809","description":"\"Any process that activates or increases the frequency, rate or extent of type IV hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c9de4fa745384deaacf841209fadf3a8","type":"GO_TERM","name":"positive regulation of type IV pilus biogenesis","canonical_id":"go:GO:1903658","description":"\"Any process that activates or increases the frequency, rate or extent of type IV pilus biogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:25049409]","metadata":null},{"id":"23b562ae013040c8a1672e34b0fd6e6b","type":"GO_TERM","name":"positive regulation of tyramine signaling pathway","canonical_id":"go:GO:2000133","description":"\"Any process that activates or increases the frequency, rate or extent of tyramine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"15af047cf92c4b26ac4b625215162fad","type":"GO_TERM","name":"positive regulation of tyrosine phosphorylation of STAT protein","canonical_id":"go:GO:0042531","description":"\"Any process that activates or increases the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:jl, PMID:11426647]","metadata":null},{"id":"cf80e72ad4dc4f8bb5ebdd30229a90e2","type":"GO_TERM","name":"positive regulation of ubiquinone biosynthetic process","canonical_id":"go:GO:1904775","description":"\"Any process that activates or increases the frequency, rate or extent of ubiquinone biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:8125303]","metadata":null},{"id":"5fa39a35374c4d65898af423328f0aea","type":"GO_TERM","name":"positive regulation of ubiquitin protein ligase activity","canonical_id":"go:GO:1904668","description":"\"Any process that activates or increases the frequency, rate or extent of ubiquitin protein ligase activity.\" [GO_REF:0000059, GOC:dph, GOC:TermGenie, GOC:vw, PMID:10921876, PMID:26216882]","metadata":null},{"id":"4c6bddac4a3c4a08af7caba2b9bf6aff","type":"GO_TERM","name":"positive regulation of ubiquitin-dependent endocytosis","canonical_id":"go:GO:2000397","description":"\"Any process that activates or increases the frequency, rate or extent of ubiquitin-dependent endocytosis.\" [GOC:mah]","metadata":null},{"id":"40de8e4e6d5e40dca8761e76102fd18b","type":"GO_TERM","name":"positive regulation of ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:2000060","description":"\"Any process that activates or increases the frequency, rate or extent of ubiquitin-dependent protein catabolic process.\" [GOC:BHF]","metadata":null},{"id":"2291bdc9ee9249f1a8b1f4a31336b983","type":"GO_TERM","name":"positive regulation of ubiquitin-protein transferase activity","canonical_id":"go:GO:0051443","description":"\"Any process that activates, maintains or increases the rate of ubiquitin transferase activity.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"59007982ad1e443eb32e7d1b23553557","type":"GO_TERM","name":"positive regulation of ubiquitin-specific protease activity","canonical_id":"go:GO:2000158","description":"\"Any process that activates or increases the frequency, rate or extent of ubiquitin-specific protease (deubiquitinase) activity.\" [GOC:obol]","metadata":null},{"id":"3439a46a6e86403ca5938d4352090a30","type":"GO_TERM","name":"positive regulation of unidimensional cell growth","canonical_id":"go:GO:0051512","description":"\"Any process that activates or increases the frequency, rate or extent of unidimensional cell growth, the process in which a cell irreversibly increases in size in one [spatial] dimension or along one axis.\" [GOC:ai]","metadata":null},{"id":"eb553d989a064e409de55ff9dae17cd6","type":"GO_TERM","name":"positive regulation of unsaturated fatty acid biosynthetic process","canonical_id":"go:GO:2001280","description":"\"Any process that activates or increases the frequency, rate or extent of unsaturated fatty acid biosynthetic process.\" [GO:0006636]","metadata":null},{"id":"afd87a04a65b4cc7a3964dad1d258941","type":"GO_TERM","name":"positive regulation of uracil import across plasma membrane","canonical_id":"go:GO:1905531","description":"\"Any process that activates or increases the frequency, rate or extent of uracil import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:26536126]","metadata":null},{"id":"981ce9ccc1d145a38129e95d36564b52","type":"GO_TERM","name":"positive regulation of urea catabolic process","canonical_id":"go:GO:1901714","description":"\"Any process that activates or increases the frequency, rate or extent of urea catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"56d728c8571147b1ab6412e50dff703b","type":"GO_TERM","name":"positive regulation of uredinium development","canonical_id":"go:GO:0075281","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of uredinium development, a process that leads to the formation of a reddish, pustule-like structure formed by a rust fungus and consisting of uredospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"37a5f2879813412da4daec91388d4e45","type":"GO_TERM","name":"positive regulation of uredospore formation","canonical_id":"go:GO:0075253","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of uredospore formation, a process in which an asexual, dikaryotic, often rusty-colored spore, is formed in a structure called a uredinium.\" [GOC:pamgo_curators]","metadata":null},{"id":"b58648e07d974e1c8259df9a93874940","type":"GO_TERM","name":"positive regulation of ureter smooth muscle cell differentiation","canonical_id":"go:GO:2000063","description":"\"Any process that activates or increases the frequency, rate or extent of ureter smooth muscle cell differentiation.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"8a2ac91f297645e9bc4b2e378e934bc3","type":"GO_TERM","name":"positive regulation of ureteric bud formation","canonical_id":"go:GO:0072107","description":"\"Any process that increases the rate or extent of the developmental process pertaining to the initial formation of the ureteric bud from the Wolffian duct.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"4bc2b1e7ee754bbe9fe09a51306cb433","type":"GO_TERM","name":"positive regulation of urine volume","canonical_id":"go:GO:0035810","description":"\"Any process that increases the amount of urine excreted from the body over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"5a1abc0990b04cfbb6678655eafbdb9b","type":"GO_TERM","name":"positive regulation of urine volume by pressure natriuresis","canonical_id":"go:GO:0035818","description":"\"An increase in the amount of urine excreted over a unit of time, as a result of pressure natriuresis.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"ae5090cc3cb74e10947293f9d43ccc3a","type":"GO_TERM","name":"positive regulation of urothelial cell proliferation","canonical_id":"go:GO:0050677","description":"\"Any process that activates or increases the rate or extent of urothelial cell proliferation.\" [GOC:ai]","metadata":null},{"id":"0db23a84b95d4f29b128dfd01d054fac","type":"GO_TERM","name":"positive regulation of uterine smooth muscle contraction","canonical_id":"go:GO:0070474","description":"\"Any process that increases the frequency, rate or extent of uterine smooth muscle contraction.\" [GOC:curators]","metadata":null},{"id":"ae57a168555f423d8b2f7e91998509b0","type":"GO_TERM","name":"positive regulation of uterine smooth muscle relaxation","canonical_id":"go:GO:1900721","description":"\"Any process that activates or increases the frequency, rate or extent of uterine smooth muscle relaxation.\" [GOC:TermGenie]","metadata":null},{"id":"4b09df718f3e4625b9c76fc06313c057","type":"GO_TERM","name":"positive regulation of vacuolar transport","canonical_id":"go:GO:1903337","description":"\"Any process that activates or increases the frequency, rate or extent of vacuolar transport.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"74a31bde22424cfeb175dfd1810f0b7f","type":"GO_TERM","name":"positive regulation of vacuole fusion, non-autophagic","canonical_id":"go:GO:0061191","description":"\"Any process that increases the frequency, rate or extent of the fusion of two vacuole membranes to form a single vacuole.\" [GOC:dph]","metadata":null},{"id":"12d79ee13d70406ca62f929cc5c8c66d","type":"GO_TERM","name":"positive regulation of vacuole organization","canonical_id":"go:GO:0044090","description":"\"Any process that activates or increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a vacuole.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"7d9f3cf0c7e1496388184e06c2378d80","type":"GO_TERM","name":"positive regulation of vascular associated smooth muscle cell apoptotic process","canonical_id":"go:GO:1905461","description":"\"Any process that activates or increases the frequency, rate or extent of vascular associated smooth muscle cell apoptotic process.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:26493107]","metadata":null},{"id":"8edfe44abcce49ce9d444386630232a6","type":"GO_TERM","name":"positive regulation of vascular associated smooth muscle cell dedifferentiation","canonical_id":"go:GO:1905176","description":"\"Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell dedifferentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19088079]","metadata":null},{"id":"21dd31ed96654cf899d0299a4332551e","type":"GO_TERM","name":"positive regulation of vascular associated smooth muscle cell differentiation","canonical_id":"go:GO:1905065","description":"\"Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19088079]","metadata":null},{"id":"4ee4fa7962694193a7d867b1d9ebc4a0","type":"GO_TERM","name":"positive regulation of vascular associated smooth muscle cell migration","canonical_id":"go:GO:1904754","description":"\"Any process that activates or increases the frequency, rate or extent of vascular associated smooth muscle cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20693317]","metadata":null},{"id":"d8945fa334ed4f56a6656b84c76015d1","type":"GO_TERM","name":"positive regulation of vascular associated smooth muscle cell proliferation","canonical_id":"go:GO:1904707","description":"\"Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23246467]","metadata":null},{"id":"004be8952e4c46d799d3037bc6095ddb","type":"GO_TERM","name":"positive regulation of vascular associated smooth muscle contraction","canonical_id":"go:GO:1904695","description":"\"Any process that activates or increases the frequency, rate or extent of vascular smooth muscle contraction.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22158624]","metadata":null},{"id":"c1d15815b93b4a77a35f6d5bdcb92730","type":"GO_TERM","name":"positive regulation of vascular endothelial cell proliferation","canonical_id":"go:GO:1905564","description":"\"Any process that activates or increases the frequency, rate or extent of vascular endothelial cell proliferation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23201774]","metadata":null},{"id":"f91c1f5e4f834716817ba0cf1de6a31b","type":"GO_TERM","name":"positive regulation of vascular endothelial growth factor production","canonical_id":"go:GO:0010575","description":"\"Any process that increases or activates the frequency, rate, or extent of production of vascular endothelial growth factor.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"95e3671cf1fe494cb4833f5ab2e9e0f2","type":"GO_TERM","name":"positive regulation of vascular endothelial growth factor receptor signaling pathway","canonical_id":"go:GO:0030949","description":"\"Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.\" [GOC:dgh]","metadata":null},{"id":"4f3e3283f742427395554db11e1f86be","type":"GO_TERM","name":"positive regulation of vascular endothelial growth factor signaling pathway","canonical_id":"go:GO:1900748","description":"\"Any process that activates or increases the frequency, rate or extent of vascular endothelial growth factor signaling pathway.\" [GOC:TermGenie]","metadata":null},{"id":"0108c8e787db429db5eb8f5eb3a264c6","type":"GO_TERM","name":"positive regulation of vascular permeability","canonical_id":"go:GO:0043117","description":"\"Any process that increases the extent to which blood vessels can be pervaded by fluid.\" [GOC:jl]","metadata":null},{"id":"fedc7ea6ec1449efba19f28f251135cb","type":"GO_TERM","name":"positive regulation of vascular wound healing","canonical_id":"go:GO:0035470","description":"\"Any process that increases the rate, frequency, or extent of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature.\" [GOC:rph]","metadata":null},{"id":"fa38287195be40cd9aadf0ee70ad5121","type":"GO_TERM","name":"positive regulation of vasculature development","canonical_id":"go:GO:1904018","description":"\"Any process that activates or increases the frequency, rate or extent of vasculature development.\" [GO_REF:0000058, GOC:TermGenie, PMID:21472453]","metadata":null},{"id":"752f79d1cc9b4d749dfa29347d6f0124","type":"GO_TERM","name":"positive regulation of vasculogenesis","canonical_id":"go:GO:2001214","description":"\"Any process that activates or increases the frequency, rate or extent of vasculogenesis.\" [GOC:obol]","metadata":null},{"id":"83f92ef2284447e399947d0abcd4a991","type":"GO_TERM","name":"positive regulation of vasoconstriction","canonical_id":"go:GO:0045907","description":"\"Any process that activates or increases the frequency, rate or extent of vasoconstriction.\" [GOC:curators]","metadata":null},{"id":"a927a487ed1b46be966b7a1ef5cf2594","type":"GO_TERM","name":"positive regulation of vein smooth muscle contraction","canonical_id":"go:GO:0062087","description":"\"Any process that increases the frequency, rate or extent of vein smooth muscle contraction.\" [PMID:8428203]","metadata":null},{"id":"7b15dcb722da4f2ba25fce331a16fe50","type":"GO_TERM","name":"positive regulation of venous endothelial cell fate commitment","canonical_id":"go:GO:2000789","description":"\"Any process that activates or increases the frequency, rate or extent of venous endothelial cell fate commitment.\" [PMID:11585794]","metadata":null},{"id":"2f5ec79f58a24d38bc7184fd37c3c786","type":"GO_TERM","name":"positive regulation of ventricular cardiac muscle cell action potential","canonical_id":"go:GO:1903947","description":"\"Any process that activates or increases the frequency, rate or extent of ventricular cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:25281747]","metadata":null},{"id":"6b16f764fb564d15b19226fd6fcb3220","type":"GO_TERM","name":"positive regulation of vernalization response","canonical_id":"go:GO:0010220","description":"\"Any process that activates or induces the rate of the vernalization response, by which induction of flowering is normally caused by extended exposure to cold temperatures.\" [GOC:sm]","metadata":null},{"id":"13b784396bf24482a165834d4f38fe22","type":"GO_TERM","name":"positive regulation of very-low-density lipoprotein particle clearance","canonical_id":"go:GO:0110119","description":"\"Any process that increases the frequency, rate or extent of very-low-density lipoprotein particle clearance.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:25510864]","metadata":null},{"id":"14e3a7871d0b414fa37c7cd049d48767","type":"GO_TERM","name":"positive regulation of very-low-density lipoprotein particle remodeling","canonical_id":"go:GO:0010902","description":"\"Any process that increases the rate, frequency or extent of very-low-density lipoprotein particle remodeling. Very-low-density lipoprotein particle remodeling is the acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:tb]","metadata":null},{"id":"51e291e4e39d4f11a5b1fc4aab0d963d","type":"GO_TERM","name":"positive regulation of vesicle fusion","canonical_id":"go:GO:0031340","description":"\"Any process that activates or increases the frequency, rate or extent of vesicle fusion.\" [GOC:mah]","metadata":null},{"id":"8c709beeb468441d914ab4380d78843c","type":"GO_TERM","name":"positive regulation of vesicle fusion with Golgi apparatus","canonical_id":"go:GO:0106216","description":"\"Any process that activates or increases the frequency, rate or extent of vesicle fusion with Golgi apparatus.\" [GOC:se, PMID:26195667]","metadata":null},{"id":"4b2be15cd74e49409e81910eb8da4c93","type":"GO_TERM","name":"positive regulation of vesicle transport along microtubule","canonical_id":"go:GO:1901610","description":"\"Any process that activates or increases the frequency, rate or extent of vesicle transport along microtubule.\" [GOC:TermGenie]","metadata":null},{"id":"a797c52489e640c7841843de0742236c","type":"GO_TERM","name":"positive regulation of violaceol I biosynthetic process","canonical_id":"go:GO:1900715","description":"\"Any process that activates or increases the frequency, rate or extent of violaceol I biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"9fdc1996717f4559935dfcebdfa4db97","type":"GO_TERM","name":"positive regulation of violaceol II biosynthetic process","canonical_id":"go:GO:1900718","description":"\"Any process that activates or increases the frequency, rate or extent of violaceol II biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"02860ec4ba58487e88f230fc165f90d2","type":"GO_TERM","name":"positive regulation of viral DNA genome packaging via site-specific sequence recognition","canonical_id":"go:GO:1905138","description":"\"Any process that activates or increases the frequency, rate or extent of viral DNA genome packaging via site-specific sequence recognition.\" [GO_REF:0000058, GOC:TermGenie, PMID:24711378]","metadata":null},{"id":"eec9f2df13f041ee9994d0001920782a","type":"GO_TERM","name":"positive regulation of viral budding via host ESCRT complex","canonical_id":"go:GO:1903774","description":"\"Any process that activates or increases the frequency, rate or extent of viral budding via host ESCRT complex.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24878737]","metadata":null},{"id":"5c2cc430efbf4e3cb687acfa60b0173a","type":"GO_TERM","name":"positive regulation of viral entry into host cell","canonical_id":"go:GO:0046598","description":"\"Any process that activates or increases the frequency, rate or extent of the introduction of viral entry into the host cell.\" [GOC:jl]","metadata":null},{"id":"29c41cb4aac34f42b204f3b1eaf578bf","type":"GO_TERM","name":"positive regulation of viral genome replication","canonical_id":"go:GO:0045070","description":"\"Any process that activates or increases the frequency, rate or extent of viral genome replication.\" [GOC:ai]","metadata":null},{"id":"64d3fe48c90a43238f36509d14a54f90","type":"GO_TERM","name":"positive regulation of viral life cycle","canonical_id":"go:GO:1903902","description":"\"Any process that activates or increases the frequency, rate or extent of viral life cycle.\" [GO_REF:0000058, GOC:TermGenie, PMID:18005716]","metadata":null},{"id":"2d30acb90ce34b6a9e9bd71cb69dce79","type":"GO_TERM","name":"positive regulation of viral process","canonical_id":"go:GO:0048524","description":"\"Any process that activates or increases the frequency, rate or extent of a multi-organism process in which a virus is a participant.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"e043dc75c115448e909cef34d1e8b40d","type":"GO_TERM","name":"positive regulation of viral transcription","canonical_id":"go:GO:0050434","description":"\"Any process that activates or increases the frequency, rate or extent of viral transcription.\" [GOC:ai]","metadata":null},{"id":"1299ce90425f4f47a4f4f26be0c87cf1","type":"GO_TERM","name":"positive regulation of viral translation","canonical_id":"go:GO:1904973","description":"\"Any process that activates or increases the frequency, rate or extent of viral translation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:19666601]","metadata":null},{"id":"c26a2b07f2a44c6f8dc4fe515b593395","type":"GO_TERM","name":"positive regulation of vitamin D biosynthetic process","canonical_id":"go:GO:0060557","description":"\"Any process that increases the rate, frequency or extent of a vitamin D biosynthetic process. Vitamin D biosynthesis is the chemical reactions and pathways resulting in the formation of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [CHEBI:27300, GOC:BHF, GOC:mah, ISBN:0471331309]","metadata":null},{"id":"29a241b8507b45debf6cdd4da6e0a428","type":"GO_TERM","name":"positive regulation of vitamin D receptor signaling pathway","canonical_id":"go:GO:0070564","description":"\"Any process that activates or increases the frequency, rate or extent of vitamin D receptor signaling pathway activity.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"9a69b6854130411989945dce2ab47d7a","type":"GO_TERM","name":"positive regulation of vitamin E biosynthetic process","canonical_id":"go:GO:1904966","description":"\"Any process that activates or increases the frequency, rate or extent of vitamin E biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:20823244]","metadata":null},{"id":"c15ad76f198445caa94a0971d240724e","type":"GO_TERM","name":"positive regulation of vitamin metabolic process","canonical_id":"go:GO:0046136","description":"\"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:ai]","metadata":null},{"id":"3cc459e85a5c459d8894893039c0984c","type":"GO_TERM","name":"positive regulation of vitellogenesis","canonical_id":"go:GO:1903188","description":"\"Any process that activates or increases the frequency, rate or extent of vitellogenesis.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19467235]","metadata":null},{"id":"894fce2fd7b444c48163a300bed86fa5","type":"GO_TERM","name":"positive regulation of voltage-gated calcium channel activity","canonical_id":"go:GO:1901387","description":"\"Any process that activates or increases the frequency, rate or extent of voltage-gated calcium channel activity.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"a5cfa431d1c44a42b94d4d686897bf8f","type":"GO_TERM","name":"positive regulation of voltage-gated chloride channel activity","canonical_id":"go:GO:1902943","description":"\"Any process that activates or increases the frequency, rate or extent of voltage-gated chloride channel activity.\" [GO_REF:0000059, GOC:als, GOC:TermGenie, PMID:22006324]","metadata":null},{"id":"2796562ecc98405abdbcacd864ba2337","type":"GO_TERM","name":"positive regulation of voltage-gated potassium channel activity","canonical_id":"go:GO:1903818","description":"\"Any process that activates or increases the frequency, rate or extent of voltage-gated potassium channel activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:19219384]","metadata":null},{"id":"a57571af7c6541e6b8e6bea7a80a7bb0","type":"GO_TERM","name":"positive regulation of voltage-gated sodium channel activity","canonical_id":"go:GO:1905152","description":"\"Any process that activates or increases the frequency, rate or extent of voltage-gated sodium channel activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:24198377]","metadata":null},{"id":"14bb61b716d6429d941ba11da3439569","type":"GO_TERM","name":"positive regulation of vulval development","canonical_id":"go:GO:0040026","description":"\"Any process that activates or increases the frequency, rate or extent of development of the vulva. Vulval development is the process whose specific outcome is the progression of the egg-laying organ of female and hermaphrodite nematodes over time, from its formation to the mature structure. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed vulva in the adult.\" [GOC:ems, GOC:kmv]","metadata":null},{"id":"acda0c91d1cc48ebbeab3fcadcc6f6bd","type":"GO_TERM","name":"positive regulation of wax biosynthetic process","canonical_id":"go:GO:1904278","description":"\"Any process that activates or increases the frequency, rate or extent of wax biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24692420]","metadata":null},{"id":"a2489b02ee354d51a4b9bd62e5bf1460","type":"GO_TERM","name":"positive regulation of white fat cell proliferation","canonical_id":"go:GO:0070352","description":"\"Any process that activates or increases the rate or extent of white fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"3103631b7cf04aa793850cc5246971f8","type":"GO_TERM","name":"positive regulation of wound healing","canonical_id":"go:GO:0090303","description":"\"Any process that increases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.\" [GOC:BHF]","metadata":null},{"id":"104a0cc80224453fbb4b4b56e9be0556","type":"GO_TERM","name":"positive regulation of wound healing, spreading of epidermal cells","canonical_id":"go:GO:1903691","description":"\"Any process that activates or increases the frequency, rate or extent of wound healing, spreading of epidermal cells.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18394891]","metadata":null},{"id":"d0a5ec8c9b4a4ec980758833c034165d","type":"GO_TERM","name":"positive regulation of xanthone-containing compound biosynthetic process","canonical_id":"go:GO:1900185","description":"\"Any process that activates or increases the frequency, rate or extent of xanthone-containing compound biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e103f245b0954bc08dbe0a1c8144514f","type":"GO_TERM","name":"positive regulation of xanthophore differentiation","canonical_id":"go:GO:0050946","description":"\"Any process that activates or increases the frequency, rate or extent of xanthophore differentiation.\" [GOC:ai]","metadata":null},{"id":"4ccce36ea4384e458941fb34cb1da8f0","type":"GO_TERM","name":"positive regulation of xenobiotic detoxification by transmembrane export across the plasma membrane","canonical_id":"go:GO:1905701","description":"\"Any process that activates or increases the frequency, rate or extent of xenobiotic transmembrane export. A xenobiotic is a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:15198509]","metadata":null},{"id":"dbfd61a3b7fa408f92715db9f0a506e7","type":"GO_TERM","name":"positive regulation of xenophagy","canonical_id":"go:GO:1904417","description":"\"Any process that activates or increases the frequency, rate or extent of xenophagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21617041]","metadata":null},{"id":"95215c43045a4820881e0ae9d76524ae","type":"GO_TERM","name":"positive regulation of xylan catabolic process","canonical_id":"go:GO:2001002","description":"\"Any process that activates or increases the frequency, rate or extent of xylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"f88f8ab37bda4f908f7d0212ddb3cd42","type":"GO_TERM","name":"positive regulation of xyloglucan catabolic process","canonical_id":"go:GO:2000953","description":"\"Any process that activates or increases the frequency, rate or extent of xyloglucan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"c0cbddf2797e4f0b8d08440e69133432","type":"GO_TERM","name":"positive regulation of xylose catabolic process to ethanol","canonical_id":"go:GO:1900517","description":"\"Any process that activates or increases the frequency, rate or extent of xylose catabolic process to ethanol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"545aa5f221b6408dbba18b5b92822534","type":"GO_TERM","name":"positive regulation of zoospore encystment on host","canonical_id":"go:GO:0075220","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of zoospore encystment on host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"ef4d1e98fb1f4dab8cf8bd2569c813f8","type":"GO_TERM","name":"positive regulation of zoospore formation","canonical_id":"go:GO:0075241","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of zoospore formation, a process in which a diploid cell undergoes meiosis, and the meiotic products acquire specialized features of asexual motile mononucleate flagellated spores called zoospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"05373f4bd0d348168a67b3ca97268db5","type":"GO_TERM","name":"positive regulation of zygosporangium development","canonical_id":"go:GO:0075273","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of zygosporangium development, a process in which a fruiting body called zygosporangium is formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"e8999070f3b344bf8f7471b889153e35","type":"GO_TERM","name":"positive regulation of zygospore formation","canonical_id":"go:GO:0075299","description":"\"Any process that activates, maintains or increases the frequency, rate or extent of frequency, rate or extent of zygospore formation, a process in which a thick-walled spore of some algae and fungi is formed by union of two similar sexual cells, usually serves as a resting spore, and produces the sporophytic phase.\" [GOC:pamgo_curators]","metadata":null},{"id":"c6717ee1870941368698c27c787086ba","type":"GO_TERM","name":"positive regulation terrein biosynthetic process","canonical_id":"go:GO:0140881","description":"\"Any process that increases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of the fungal metabolite terrein.\" [PMID:24816227, PMID:25852654]","metadata":null},{"id":"dabdce188e9d42ff9c926b564f0c18d1","type":"GO_TERM","name":"positive stranded viral RNA replication","canonical_id":"go:GO:0039690","description":"\"A viral genome replication process where the template genome is positive stranded, single stranded RNA ((+)ssRNA). Replication of the positive strand leads to dsRNA formation, which in turn is transcribed into positive single stranded RNA.\" [GOC:bf, GOC:jl, VZ:1116]","metadata":null},{"id":"75e40726de40454c9c2b1bf7d654807a","type":"GO_TERM","name":"positive thymic T cell selection","canonical_id":"go:GO:0045059","description":"\"The process of sparing immature T cells in the thymus which react with self-MHC protein complexes with low affinity levels from apoptotic death.\" [ISBN:0781735149, PMID:12414722]","metadata":null},{"id":"ed2e6ffdef7b415cb8a58a811cdcdb8a","type":"DISEASE","name":"post operative nausea and vomiting","canonical_id":"efo:0004888","description":null,"metadata":null},{"id":"aad46cb683604ae3890db7f78d262217","type":"GO_TERM","name":"post-Golgi vesicle-mediated transport","canonical_id":"go:GO:0006892","description":"\"The directed movement of substances from the Golgi to other parts of the cell, including organelles and the plasma membrane, mediated by small transport vesicles.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"5e4260e29b24407f915f60cc67e5f5f4","type":"GO_TERM","name":"post-anal tail morphogenesis","canonical_id":"go:GO:0036342","description":"\"The process in which a post-anal tail is generated and organized. A post-anal tail is a muscular region of the body that extends posterior to the anus. The post-anal tail may aid locomotion and balance.\" [GOC:bf, GOC:kmv, Wikipedia:Chordate]","metadata":null},{"id":"ac60e915a1424b13a019905b51176548","type":"GO_TERM","name":"post-anaphase array microtubule","canonical_id":"go:GO:1905759","description":"\"Any microtubule that is part of a post-anaphase microtubule array.\" [GO_REF:0000064, GOC:TermGenie, PMID:11007487]","metadata":null},{"id":"b5b007a3ff854ad4a68b4b9a26eee594","type":"GO_TERM","name":"post-anaphase array microtubule end","canonical_id":"go:GO:1905760","description":"\"Any microtubule end that is part of a post-anaphase array microtubule.\" [GO_REF:0000064, GOC:TermGenie, PMID:11007487]","metadata":null},{"id":"1863b666cc544fe9a7d586e261f6c0f2","type":"GO_TERM","name":"post-anaphase microtubule array","canonical_id":"go:GO:1990295","description":"\"A cytoskeletal part that consists of an array of microtubules and associated molecules that forms at the end of anaphase, and in which microtubules are nucleated from an equatorial microtubule organizing center.\" [PMID:11792817, PMID:17072892, PMID:9601091]","metadata":null},{"id":"f69c8cc7b17c432d9e24590d18f68e15","type":"GO_TERM","name":"post-anaphase microtubule array organization","canonical_id":"go:GO:1904186","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly ofa post-anaphase microtubule array.\" [GOC:TermGenie, PMID:15004232]","metadata":null},{"id":"d0c38a918f294ea0bfc10959a2848d27","type":"GO_TERM","name":"post-chaperonin tubulin folding pathway","canonical_id":"go:GO:0007023","description":"\"Completion of folding of alpha- and beta-tubulin; takes place subsequent to chaperonin-mediated partial folding; mediated by a complex of folding cofactors.\" [PMID:10542094]","metadata":null},{"id":"cfb434283be445d7b397368abf9c4470","type":"GO_TERM","name":"post-embryonic anal fin morphogenesis","canonical_id":"go:GO:0035135","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the anal fin are generated and organized. An anal fin is an unpaired medial fin on the ventral aspect near the caudal end of a fish, which provides lateral stability while swimming.\" [GOC:dgh]","metadata":null},{"id":"f0bf3842193f4b2c9ec527c6ec818cb2","type":"GO_TERM","name":"post-embryonic animal morphogenesis","canonical_id":"go:GO:0009886","description":"\"The process, occurring after animal embryonic development, by which anatomical structures are generated and organized.\" [GOC:curators]","metadata":null},{"id":"a9ebe1f252ba4df29872775e75f1be38","type":"GO_TERM","name":"post-embryonic anterior midgut (ectodermal) morphogenesis","canonical_id":"go:GO:0048616","description":"\"The process in which the anatomical structures of the anterior midgut (ectodermal) are generated and organized, during the post-embryonic phase.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"c374752961e74046a90716c6109236ff","type":"GO_TERM","name":"post-embryonic appendage morphogenesis","canonical_id":"go:GO:0035120","description":"\"The process, occurring after embryonic development, by which the anatomical structures of an appendage are generated and organized. An appendage is an organ or part that is attached to the trunk of an organism, such as a limb or a branch.\" [ISBN:0582227089]","metadata":null},{"id":"0e3690bcfaad4f1487391d4068562c87","type":"GO_TERM","name":"post-embryonic body morphogenesis","canonical_id":"go:GO:0040032","description":"\"The process in which the anatomical structures of the post-embryonic soma are generated and organized.\" [GOC:ems, ISBN:0140512888]","metadata":null},{"id":"010cb55c13c24e87a9b60cf83e894e7c","type":"GO_TERM","name":"post-embryonic camera-type eye development","canonical_id":"go:GO:0031077","description":"\"The process occurring during the post-embryonic phase whose specific outcome is the progression of the camera-type eye over time, from its formation to the mature structure.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"76d15d82421c47e2a05bc6050bd73735","type":"GO_TERM","name":"post-embryonic camera-type eye morphogenesis","canonical_id":"go:GO:0048597","description":"\"The process in which the anatomical structures of the eye are generated and organized during post-embryonic development.\" [GOC:jid, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"cd42f54a9c384925b0e0b9f5d90ed13f","type":"GO_TERM","name":"post-embryonic cardiac muscle cell growth involved in heart morphogenesis","canonical_id":"go:GO:0003247","description":"\"The growth of a cardiac muscle cell during the postembryonic period that contributes to the shaping of the heart.\" [GOC:mtg_heart]","metadata":null},{"id":"8ddb5283507940e6a9936e892e15e6e2","type":"GO_TERM","name":"post-embryonic caudal fin morphogenesis","canonical_id":"go:GO:0035133","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the caudal fin are generated and organized. The caudal fin is an unpaired medial fin mounted at the caudal end of the fish and is the main fin used for propulsion.\" [GOC:dgh]","metadata":null},{"id":"eebc7c78a2fa403eb8ec92fdb5aee26b","type":"GO_TERM","name":"post-embryonic development","canonical_id":"go:GO:0009791","description":"\"The process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure. See embryonic development.\" [GOC:curators]","metadata":null},{"id":"2d74fa709de646cb88d32a6055e35732","type":"GO_TERM","name":"post-embryonic digestive tract morphogenesis","canonical_id":"go:GO:0048621","description":"\"The process, occurring during the post-embryonic phase, by which the anatomical structures of the digestive tract are generated and organized. The digestive tract is the anatomical structure through which food passes and is processed.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"e670c49e90f246d7a4797a9e8852cf0e","type":"GO_TERM","name":"post-embryonic dorsal fin morphogenesis","canonical_id":"go:GO:0035134","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the dorsal fin are generated and organized. A dorsal fin is an unpaired medial fin on the dorsal aspect of a fish that provides lateral stability while swimming. Generally fish have one or two dorsal fins.\" [GOC:dgh]","metadata":null},{"id":"f0b167960fa04054a7fbb21f4557a5f6","type":"GO_TERM","name":"post-embryonic ectodermal digestive tract development","canonical_id":"go:GO:0048612","description":"\"The process, occurring during the post-embryonic phase, whose specific outcome is the progression of the ectodermal gut over time, from its formation to the mature structure.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"dd96f6a65a9e4275bd1aee13a850e188","type":"GO_TERM","name":"post-embryonic ectodermal digestive tract morphogenesis","canonical_id":"go:GO:0048614","description":"\"The process, occurring during the post-embryonic phase, by which the anatomical structures of the ectodermal gut are generated and organized.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"cba34e39c13a4d06b99919301587d70b","type":"GO_TERM","name":"post-embryonic eye morphogenesis","canonical_id":"go:GO:0048050","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the eye are generated and organized. The eye is the organ of sight.\" [GOC:jid, GOC:sensu]","metadata":null},{"id":"d6b8e54d7b724c7c8fd4b7763886bccf","type":"GO_TERM","name":"post-embryonic foregut morphogenesis","canonical_id":"go:GO:0048618","description":"\"The process in which the anatomical structures of the foregut are generated and organized, during the post-embryonic phase.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"58e657e69aa0402f82b79904892b830f","type":"GO_TERM","name":"post-embryonic forelimb morphogenesis","canonical_id":"go:GO:0035128","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the forelimb are generated and organized. The forelimbs are the front limbs of an organism.\" [GOC:bf]","metadata":null},{"id":"efc691e5190d42e98a729984213af7d1","type":"GO_TERM","name":"post-embryonic genitalia morphogenesis","canonical_id":"go:GO:0035126","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the genitalia are generated and organized.\" [GOC:bf]","metadata":null},{"id":"73435bd8168140ce9e8d3f23cb682626","type":"GO_TERM","name":"post-embryonic hemopoiesis","canonical_id":"go:GO:0035166","description":"\"The stages of blood cell formation that take place after completion of embryonic development.\" [GOC:bf]","metadata":null},{"id":"55d4c894ca374abd8d650426a0fdb167","type":"GO_TERM","name":"post-embryonic hindgut morphogenesis","canonical_id":"go:GO:0048620","description":"\"The process in which the anatomical structures of the hindgut are generated and organized, during the post-embryonic phase.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"79558a9f71234eb2a57b0318343b5c3d","type":"GO_TERM","name":"post-embryonic hindlimb morphogenesis","canonical_id":"go:GO:0035129","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the hindlimb are generated and organized.\" [GOC:bf]","metadata":null},{"id":"7bbce66f138c4f1486b2d92c3db5333f","type":"GO_TERM","name":"post-embryonic limb morphogenesis","canonical_id":"go:GO:0035127","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the limb are generated and organized. A limb is an appendage of an animal used for locomotion or grasping.\" [ISBN:0395825172]","metadata":null},{"id":"dc7a0a267ffd4b0da19405f3cd03067e","type":"GO_TERM","name":"post-embryonic medial fin morphogenesis","canonical_id":"go:GO:0035132","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the medial fin are generated and organized. Medial fins are unpaired fins of fish, usually located dorsomedially or ventromedially and primarily used for stability while swimming.\" [GOC:dgh]","metadata":null},{"id":"44f50c6965db4a10ad55633915695498","type":"GO_TERM","name":"post-embryonic pectoral fin morphogenesis","canonical_id":"go:GO:0035130","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the pectoral fin are generated and organized. Pectoral fins are bilaterally paired fins mounted laterally and located behind the gill covers of fish. These fins are used for lateral mobility and propulsion.\" [GOC:dgh]","metadata":null},{"id":"b3e8e38438ef4912be2371937466d7c6","type":"GO_TERM","name":"post-embryonic pelvic fin morphogenesis","canonical_id":"go:GO:0035131","description":"\"The process, occurring after embryonic development, by which the anatomical structures of the pelvic fin are generated and organized. The pelvic fins are bilaterally paired fins mounted in a ventral-lateral position on most fish. These fins are used primarily for lateral mobility and propulsion.\" [GOC:dgh]","metadata":null},{"id":"96e00d67b5b94a1c9e31500e6d0406d1","type":"GO_TERM","name":"post-embryonic plant morphogenesis","canonical_id":"go:GO:0090698","description":"\"The process, occurring after plant embryonic development, by which anatomical structures are generated and organized.\" [GOC:tb]","metadata":null},{"id":"ecab43d893de45738e4f68f033b4b928","type":"GO_TERM","name":"post-embryonic plant organ development","canonical_id":"go:GO:0090696","description":"\"Development, taking place during the post-embryonic phase of a plant tissue or tissues that work together to perform a specific function or functions. Development pertains to the process whose specific outcome is the progression of a structure over time, from its formation to the mature structure. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:tb]","metadata":null},{"id":"ae17cc79b50f46ec846449f713d9d09c","type":"GO_TERM","name":"post-embryonic plant organ morphogenesis","canonical_id":"go:GO:0090697","description":"\"Morphogenesis, during the post-embryonic phase, of a plant tissue or tissues that work together to perform a specific function or functions. Morphogenesis pertains to process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:tb]","metadata":null},{"id":"85fc7ff4df0544a88aebd344265d1381","type":"GO_TERM","name":"post-embryonic retina morphogenesis in camera-type eye","canonical_id":"go:GO:0060060","description":"\"The process in which the anatomical structure of the retina is generated and organized in a camera-type eye during the post-embryonic life stage.\" [GOC:dgh, GOC:dph]","metadata":null},{"id":"545d6fa204bb4c468f2e8966b817345e","type":"GO_TERM","name":"post-embryonic root development","canonical_id":"go:GO:0048528","description":"\"The process whose specific outcome is the progression of the post-embryonic root over time, from its formation to the mature structure.\" [GOC:tb]","metadata":null},{"id":"ba36cbb8a75545aa92d79389ec0a3975","type":"GO_TERM","name":"post-embryonic root morphogenesis","canonical_id":"go:GO:0010101","description":"\"The process in which the anatomical structures of the post-embryonic root are generated and organized. The post-embryonic root is the root formed after the embryonic phase has been completed.\" [GOC:tb]","metadata":null},{"id":"50a39a7e2c894043babde29aa0cd8f63","type":"GO_TERM","name":"post-lysosomal vacuole","canonical_id":"go:GO:0032195","description":"\"A membrane-bounded intracellular vesicle formed late in the endocytic pathway when the pH in the vacuole becomes neutral prior to exocytosis.\" [GOC:pf, PMID:23494323, PMID:9276759, PMID:9394012]","metadata":null},{"id":"4c9883dece6546948a8aa7750bf6ac8b","type":"GO_TERM","name":"post-mRNA release spliceosomal complex","canonical_id":"go:GO:0071014","description":"\"A spliceosomal complex that is formed following the release of the spliced product from the post-spliceosomal complex and contains the excised intron and three snRNPs, either U2 or U12, U5, and either U6 or U6atac.\" [GOC:ab, GOC:krc, GOC:mah, ISBN:0879695897, PMID:19239890, PMID:20149226]","metadata":null},{"id":"fc053804756d425685e6665c2d690622","type":"GO_TERM","name":"post-spliceosomal complex","canonical_id":"go:GO:0071020","description":"\"A spliceosomal complex that is formed following the second splicing event and contains the spliced product, the excised intron, and three snRNPs, including U5.\" [GOC:krc, GOC:mah, ISBN:0879695897, ISBN:0879697393]","metadata":null},{"id":"ec6cb216a64a4463b2480d60ef3292ad","type":"GO_TERM","name":"post-transcriptional gene silencing","canonical_id":"go:GO:0016441","description":"\"The inactivation of gene expression that occurs after transcription.\" [GOC:mah, PMID:15020054]","metadata":null},{"id":"4e6e053ca4374884b91948074768450c","type":"GO_TERM","name":"post-transcriptional regulation of gene expression","canonical_id":"go:GO:0010608","description":"\"Any process that modulates the frequency, rate or extent of gene expression after the production of an RNA transcript.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"93506dc216fe4b7c98799a4507c2c2ba","type":"GO_TERM","name":"post-transcriptional tethering of RNA polymerase II gene DNA at nuclear periphery","canonical_id":"go:GO:0000973","description":"\"The chromosome organization process in which the DNA sequence containing a gene transcribed by RNA polymerase II is maintained in a specific location at the nuclear periphery even after transcription has been repressed.\" [GOC:krc, PMID:17373856, PMID:18614049]","metadata":null},{"id":"aebb3ee908c142f3a8636239d474e2f6","type":"GO_TERM","name":"post-translational protein acetylation","canonical_id":"go:GO:0034421","description":"\"The addition of an acetyl group to one or more amino acids in a protein, occurring after the protein has been completely translated and released from the ribosome.\" [GOC:mah]","metadata":null},{"id":"007d77f2956042cb97a517b3fd11fff6","type":"GO_TERM","name":"post-translational protein modification","canonical_id":"go:GO:0043687","description":"\"The process of covalently altering one or more amino acids in a protein after the protein has been completely translated and released from the ribosome.\" [GOC:jsg]","metadata":null},{"id":"b5fb40b9406c49e2a5ed9ab8b5828afb","type":"GO_TERM","name":"post-translational protein targeting to endoplasmic reticulum membrane","canonical_id":"go:GO:0006620","description":"\"The targeting of proteins to a membrane that occurs after their translation. Some secretory proteins exhibit posttranslational transport into the endoplasmic reticulum (ER) lumen: they are synthesized in their entirety on free cytosolic ribosomes and then released into the cytosol, where they are bound by chaperones which keep them in an unfolded state, and subsequently are translocated across the ER membrane.\" [ISBN:0716731363]","metadata":null},{"id":"189eac8c1ba3473a899c0bd8381f7e02","type":"GO_TERM","name":"post-translational protein targeting to membrane, docking","canonical_id":"go:GO:0031203","description":"\"The process in which the signal sequence of a translated protein binds to and forms a complex with the Sec complex.\" [PMID:12518217, PMID:8707814]","metadata":null},{"id":"43aa989889404d1b85dddb04841c6c4d","type":"GO_TERM","name":"post-translational protein targeting to membrane, translocation","canonical_id":"go:GO:0031204","description":"\"The process in which a protein translocates through the ER membrane posttranslationally.\" [PMID:12518317, PMID:8707814]","metadata":null},{"id":"88ada5a54e4b4b66bd18054e979feb0d","type":"DISEASE","name":"postaxial acrofacial dysostosis","canonical_id":"mondo:0009903","description":null,"metadata":null},{"id":"20674ee43bcb433abbbdab78b68ca7ba","type":"DISEASE","name":"postencephalitic Parkinson disease","canonical_id":"mondo:0001945","description":null,"metadata":null},{"id":"22673571f0034d93b9692c2841ea5cea","type":"GO_TERM","name":"posterior Malpighian tubule development","canonical_id":"go:GO:0061328","description":"\"The process whose specific outcome is the progression of the posterior Malpighian tubule over time, from its formation to the mature structure. The pair of posterior tubules arise from a ventrolateral region of the embryonic hindgut and project backwards through the body cavity. A Malpighian tubule is a fine, thin-walled excretory tubule in insects which connects with the posterior part of the gut.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"3cc7fba277ab430fb901e9a5ceb07a56","type":"GO_TERM","name":"posterior abdomen determination","canonical_id":"go:GO:0007359","description":"\"The regionalization process in which the posterior (abdominal) regions of the embryo are specified by the gap genes.\" [GOC:dph, GOC:isa_complete, http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"e120ef14c9094331be1eee2ec5e0073a","type":"GO_TERM","name":"posterior cell cortex","canonical_id":"go:GO:0061803","description":"\"The region that lies just beneath the plasma membrane in the part of a cell that is closest to the posterior as defined by the developing, or existing, anterior/posterior axis.\" [GOC:dph, GOC:kmv, PMID:15666355, PMID:17981131]","metadata":null},{"id":"bfc8c8f78ba243f49b6c4bda2cae9725","type":"GO_TERM","name":"posterior cibarial plate development","canonical_id":"go:GO:0048727","description":"\"The process whose specific outcome is the progression of the posterior cibarial plate over time, from its formation to the mature structure.\" [GOC:rc]","metadata":null},{"id":"952117f00a424c758a8fb4c9f291e5e1","type":"GO_TERM","name":"posterior cibarial plate morphogenesis","canonical_id":"go:GO:0048720","description":"\"The process in which the anatomical structures of the posterior cibarial plate are generated and organized.\" [GOC:rc]","metadata":null},{"id":"025aa58639e3415db673f6e6fb81f3ca","type":"GO_TERM","name":"posterior commissure morphogenesis","canonical_id":"go:GO:0021961","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the midbrain towards target cells in the diencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9e0820ec1314463c94db4dc41eb2c006","type":"GO_TERM","name":"posterior compartment specification","canonical_id":"go:GO:0007388","description":"\"The process involved in the specification of cell identity in the posterior compartments of the segmented embryo.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"2e55c2e80ef345098ff1a65af2c09960","type":"GO_TERM","name":"posterior head segmentation","canonical_id":"go:GO:0035289","description":"\"Partitioning the posterior region of the insect head anlage into gnathal (mandibular, maxillary and labial) segments. Unlike the anterior head (procephalic) segments, formation of the posterior head (gnathal) segments occurs by a similar mechanism to trunk segmentation, where a cascade of gap genes, pair-rule genes and segment-polarity genes subdivide the embryo into progressively smaller domains.\" [PMID:15382136]","metadata":null},{"id":"a89265209094468b92e39ef2febba374","type":"GO_TERM","name":"posterior lateral line development","canonical_id":"go:GO:0048916","description":"\"The process whose specific outcome is the progression of the posterior lateral line over time, from its formation to the mature structure. The posterior lateral line consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the body and trunk of all fishes and most amphibians. The posterior lateral line develops from cranial ectodermal placodes situated behind the ear.\" [ISBN:0125296509]","metadata":null},{"id":"b01e0016e75447679edd663a768637b3","type":"GO_TERM","name":"posterior lateral line ganglion development","canonical_id":"go:GO:0048917","description":"\"The process whose specific outcome is the progression of the posterior lateral line ganglion over time, from its formation to the mature structure. The posterior lateral line ganglion develops from cranial ectodermal placodes situated behind the ear.\" [ISBN:0125296509, ISBN:0387968377]","metadata":null},{"id":"7fb91475de2b47e6b6cf969c22ca1861","type":"GO_TERM","name":"posterior lateral line ganglion neuron differentiation","canonical_id":"go:GO:0048928","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron of the posterior lateral line ganglion.\" [PMID:15018940]","metadata":null},{"id":"a517395a5172480ca8889064fa2f75e4","type":"GO_TERM","name":"posterior lateral line nerve development","canonical_id":"go:GO:0048918","description":"\"The process whose specific outcome is the progression of the posterior lateral line nerve over time, from its formation to the mature structure. The posterior lateral line nerve innervates hair cells of the PLL and projects to an octavolateralis column in the hindbrain that consists of the medial octavolateralis nucleus (MON), the caudal octavolateralis nucleus, and the magnocellular nucleus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0125296509]","metadata":null},{"id":"961a59734c864a12907364a8c1eccc1c","type":"GO_TERM","name":"posterior lateral line nerve glial cell development","canonical_id":"go:GO:0048941","description":"\"The process aimed at the progression of a glial cell in the posterior lateral line nerve over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dgh]","metadata":null},{"id":"68ea9c5128d64a709b6ee061624e7a9f","type":"GO_TERM","name":"posterior lateral line nerve glial cell differentiation","canonical_id":"go:GO:0048931","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a glial cell in the posterior lateral line nerve.\" [PMID:15832385]","metadata":null},{"id":"a5e2df20cc4840eebb71d67a29fca7c7","type":"GO_TERM","name":"posterior lateral line nerve glial cell morphogenesis involved in differentiation","canonical_id":"go:GO:0048942","description":"\"The process in which the structures of a glial cell in the posterior lateral line nerve are generated and organized. This process occurs while the initially relatively unspecialized cell is acquiring the specialized features of a glial cell in the posterior lateral line nerve.\" [GOC:dgh]","metadata":null},{"id":"de8efed698814e6e89941623f00cd542","type":"GO_TERM","name":"posterior lateral line neuromast cupula development","canonical_id":"go:GO:0048921","description":"\"The process whose specific outcome is the progression of the posterior lateral line neuromast cupula over time, from its formation to the mature structure. The cupula is secreted by mantle cells and the ciliary bundles of all of the hair cells of the neuromast are embedded in it. The cupula provides a mechanical linkage between the hair cells and the external hydrodynamic environment. The cupula of superficial neuromasts grows continuously, while the height of the cupula of canal neuromasts is limited by canal diameter.\" [ISBN:0125296509]","metadata":null},{"id":"afd23b91507c450ab3b83f0e3f5e3f14","type":"GO_TERM","name":"posterior lateral line neuromast deposition","canonical_id":"go:GO:0048922","description":"\"The process in which a migrating neuromast primordium deposits clusters of undifferentiated cells (proneuromasts) along its migratory path in the developing posterior lateral line.\" [PMID:15832385]","metadata":null},{"id":"ecad81ae100d4ec18c6a259056c2e435","type":"GO_TERM","name":"posterior lateral line neuromast development","canonical_id":"go:GO:0048919","description":"\"The process whose specific outcome is the progression of the posterior lateral line neuromast over time, from its formation to the mature structure. The neuromast is the sensory receptor of the anterior lateral line system and is composed of a population of sensory hair cells, and nonsensory supporting cells and mantle cells. Neuromast are located superficially on the epithelium or in lateral line canals.\" [ISBN:0125296509]","metadata":null},{"id":"40e9109debc94b0aa555ad7af2efa140","type":"GO_TERM","name":"posterior lateral line neuromast hair cell development","canonical_id":"go:GO:0035677","description":"\"The process whose specific outcome is the progression of a posterior lateral line neuromast hair cell over time, from its formation to the mature structure. A neuromast hair cell is a hair cell that acts as a sensory receptor of the neuromast; it is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface. Cell development does not include the steps involved in committing a cell to a specific fate.\" [ISBN:0125296509]","metadata":null},{"id":"70e327b173f040e78857c8d401c5acd4","type":"GO_TERM","name":"posterior lateral line neuromast hair cell differentiation","canonical_id":"go:GO:0048923","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a posterior lateral line neuromast hair cell. (N.B. This may be development of neuromast hair cell type or a set of cell of neuromast hair cell type. This will involve the change of a cell or set of cells from one cell identity to another). Hair cells are the sensory receptors of the neuromast and are located in a portion of the neuromast called the sensory strip. Each hair cell of the neuromast is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface. There are approximately seven hair cells within each neuromast, with each hair cell innervated by afferent and efferent neurons.\" [ISBN:0125296509]","metadata":null},{"id":"38bd8a7fda2e459da63e9b3478679fa5","type":"GO_TERM","name":"posterior lateral line neuromast hair cell morphogenesis","canonical_id":"go:GO:0035680","description":"\"The change in form (cell shape and size) that occurs when a posterior lateral line neuromast hair cell progresses from its initial formation to its mature state. A neuromast hair cell is a hair cell that acts as a sensory receptor of the neuromast; it is morphologically polarized as a result of the relative position of the single kinocilium and the clusters of stereocilia on its apical surface.\" [ISBN:0125296509]","metadata":null},{"id":"801553cc6ffa4f2d9327d7010460bd97","type":"GO_TERM","name":"posterior lateral line neuromast mantle cell differentiation","canonical_id":"go:GO:0048924","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a posterior lateral line neuromast mantle cell. (N.B. This may be development of neuromast mantle cell type or a set of cells of neuromast mantle cell type. This will involve the change of a cell or set of cells from one cell identity to another). Mantle cells are non-sensory cells that surround the sensory strip, separating the neuromast from the epidermis. Mantle cells secrete the cupula in which the ciliary bundles of all of the hair cells are embedded.\" [ISBN:0125296509]","metadata":null},{"id":"5365682615d9446b9ce88d0f0746ea0c","type":"GO_TERM","name":"posterior lateral line neuromast primordium migration","canonical_id":"go:GO:0048920","description":"\"The migration of a relatively undifferentiated cell along the developing posterior lateral line, originating from cranial ectodermal placodes situated behind the ear. The neuromast primordium deposits proneuromasts along the lateral line, from which the neuromasts will develop.\" [GOC:dgh, PMID:15832385]","metadata":null},{"id":"63d0a32c62ff409f9456b7a331fd5cd1","type":"GO_TERM","name":"posterior lateral line neuromast support cell differentiation","canonical_id":"go:GO:0048927","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a posterior lateral line neuromast support cell. Support cells are non-sensory cells of the neuromast that extend between the sensory hair cells from the basement membrane to the apical surface; they are surrounded by mantle cells.\" [ISBN:0387968377]","metadata":null},{"id":"e360fbe398ed461b900589fb866d93bb","type":"GO_TERM","name":"posterior lateral line system development","canonical_id":"go:GO:0048915","description":"\"The process whose specific outcome is the progression of the posterior lateral line system over time, from its formation to the mature structure. The posterior lateral line system develops from cranial ectodermal placodes, situated behind the ear, that give rise to both the neuromasts and the posterior lateral line sensory nerves that innervate the neuromasts. The posterior lateral line system consists of small sensory patches (neuromasts) located superficially on the skin or just under the skin in fluid-filled canals on the head of all fishes and most amphibians. The neuromasts are innervated by several lateral line nerves, which project primarily to the hindbrain. The posterior mechanosensory lateral line system is stimulated by local water displacements and vibrations, and detects propulsion of the fish through the water, as well as facilitating shoaling, prey capture, and predator and obstacle avoidance.\" [ISBN:0125296509, PMID:15018940]","metadata":null},{"id":"5ba73ebc5dfc430d80852260c96dfc2c","type":"GO_TERM","name":"posterior mRNA localization involved in anterior/posterior axis specification","canonical_id":"go:GO:0060814","description":"\"Any process in which a mRNA is transported to and maintained in the oocyte and/or syncytial embryo contributing to the specification of the anterior/posterior axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"1bc0a521ae0d4ac4a54c35da92b7be8c","type":"GO_TERM","name":"posterior mesonephric tubule development","canonical_id":"go:GO:0072166","description":"\"The progression of the posterior mesonephric tubule over time, from its initial formation to the mature structure. The posterior mesonephric tubule is an epithelial tube that is part of the mesonephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ad026ecde6244ab3b67d73c055127a78","type":"GO_TERM","name":"posterior midgut development","canonical_id":"go:GO:0007497","description":"\"The process whose specific outcome is the progression of the posterior midgut over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"9beff19252d54967849e9c3140665c4c","type":"GO_TERM","name":"posterior midgut invagination","canonical_id":"go:GO:0007374","description":"\"Formation of a cup-shaped invagination at the posterior end of the embryo, bringing the posterior midgut and hindgut primordia into the interior.\" [ISBN:0879694238]","metadata":null},{"id":"4552ccec85244c749a0695f38b1c838c","type":"GO_TERM","name":"posterior neural plate formation","canonical_id":"go:GO:0090018","description":"\"The formation of posterior end of the flat, thickened layer of ectodermal cells known as the neural plate.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"ae1dc715c4fd42f290f4d523468fa2d7","type":"GO_TERM","name":"posterior neuropore closure","canonical_id":"go:GO:0021507","description":"\"The joining together of the neural folds of the caudal opening of the neural tube. The posterior neuropore appears before the process of neural tube closure is complete.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"dad21b0388cf41eeb21f8b75185d2ccb","type":"GO_TERM","name":"posterior semicircular canal development","canonical_id":"go:GO:0060874","description":"\"The progession of the posterior semicircular canal from its initial formation to the mature structure.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3e4356c38e08439cbd2dea66cbfd97c5","type":"DISEASE","name":"posterior uveitis","canonical_id":"mondo:0006918","description":null,"metadata":null},{"id":"90fffbd4af584bd582f54e21a2facadc","type":"GO_TERM","name":"postganglionic parasympathetic fiber development","canonical_id":"go:GO:0021784","description":"\"The process whose specific outcome is the progression of the postganglionic portion of the parasympathetic fiber over time, from its formation to the mature structure. The parasympathetic fiber is one of the two divisions of the vertebrate autonomic nervous system. Parasympathetic nerves emerge cranially as pre ganglionic fibers from oculomotor, facial, glossopharyngeal and vagus and from the sacral region of the spinal cord. Most neurons are cholinergic and responses are mediated by muscarinic receptors. The parasympathetic system innervates, for example: salivary glands, thoracic and abdominal viscera, bladder and genitalia.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2bbd666aa45244f5b5b45d6763bebaec","type":"DISEASE","name":"postherpetic neuralgia","canonical_id":"mondo:0041052","description":null,"metadata":null},{"id":"dee9aa13984d43f5a0233d8b0b205396","type":"DISEASE","name":"postmenopausal osteoporosis","canonical_id":"mondo:0008159","description":null,"metadata":null},{"id":"0343e40e1b5e42f5b523a0c53876295a","type":"GO_TERM","name":"postnatal olfactory bulb interneuron migration","canonical_id":"go:GO:0021827","description":"\"The migration of olfactory bulb interneuron precursors in the cerebral cortex that occurs after birth.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"3b87f07a5c2f417fa6ab1b3b91c106bc","type":"DISEASE","name":"postpartum depression","canonical_id":"mondo:0005929","description":null,"metadata":null},{"id":"b542f253bc634f1580c1f2e21b2e043a","type":"DISEASE","name":"postpartum hemorrhage","canonical_id":"efo:0009579","description":null,"metadata":null},{"id":"bb8f9d7af27446c3b5bde1b704fde5f9","type":"DISEASE","name":"postpartum hemorrhage","canonical_id":"mesh:D006473","description":null,"metadata":null},{"id":"783c3b6818d84d4c85d575576e5969f2","type":"GO_TERM","name":"postsynapse","canonical_id":"go:GO:0098794","description":"\"The part of a synapse that is part of the post-synaptic cell.\" [GOC:dos]","metadata":null},{"id":"77ff42cdddaa4b7297a88edd915b57bf","type":"GO_TERM","name":"postsynapse assembly","canonical_id":"go:GO:0099068","description":"\"The aggregation, arrangement and bonding together of a set of components to form a postsynapse.\" [GOC:bf, GOC:dos, GOCL:PARL]","metadata":null},{"id":"684562ef9634475fbe002a1bc9a85a1f","type":"GO_TERM","name":"postsynapse of neuromuscular junction","canonical_id":"go:GO:0098975","description":"\"The postsynapse of a neuromuscular junction. In vertebrate muscles this includes the motor end-plate, consisting of postjunctional folds of the sarcolemma.\" [GOC:dos, Wikipedia:Neuromuscular_junction&oldid=723623502]","metadata":null},{"id":"614501fabd1840f897e4ab6189458b21","type":"GO_TERM","name":"postsynapse organization","canonical_id":"go:GO:0099173","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a postsynapse.\" [GOC:dos]","metadata":null},{"id":"9f3e63a2832f41b5abb0bfca061a8c97","type":"GO_TERM","name":"postsynapse to nucleus signaling pathway","canonical_id":"go:GO:0099527","description":"\"The series of molecular signals that conveys information from the postsynapse to the nucleus via cytoskeletal transport of a protein from a postsynapse to the component to the nucleus where it affects biochemical processes that occur in the nucleus (e.g DNA transcription, mRNA splicing, or DNA/histone modifications).\" [GOC:dos, PMID:24317321, PMID:25652077]","metadata":null},{"id":"c016ca41de6c4fb8adec222d86fa4f53","type":"GO_TERM","name":"postsynaptic Golgi apparatus","canonical_id":"go:GO:0150051","description":"\"The network of the Golgi apparatus structures located within the postsynapse.\" [GOC:aruk, GOC:bc, PMID:23838184]","metadata":null},{"id":"e9f93010a1f04f069f8a01c59d65fbf6","type":"GO_TERM","name":"postsynaptic actin cytoskeleton","canonical_id":"go:GO:0098871","description":"\"The actin cytoskeleton that is part of a postsynapse.\" [GOC:dos]","metadata":null},{"id":"51a07166c1bb4a45b657b3bd154cb878","type":"GO_TERM","name":"postsynaptic actin cytoskeleton organization","canonical_id":"go:GO:0098974","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins in the postsynaptic actin cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"101a907104f041c2b7d3213ad8189a58","type":"DISEASE","name":"postsynaptic congenital myasthenic syndrome","canonical_id":"mondo:0020344","description":null,"metadata":null},{"id":"9953d547ef114575bcb7ce77b4c57ab9","type":"GO_TERM","name":"postsynaptic cytoskeleton","canonical_id":"go:GO:0099571","description":"\"The portion of the cytoskeleton contained within the postsynapse.\" [GOC:dos, PMID:19889835]","metadata":null},{"id":"aed668672f6740d2ae66c8649cdeec7a","type":"GO_TERM","name":"postsynaptic cytoskeleton organization","canonical_id":"go:GO:0099188","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising cytoskeletal filaments and their associated proteins in the postsynaptic cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"7bcf0d5190c049719318b1489db8be9d","type":"GO_TERM","name":"postsynaptic cytosol","canonical_id":"go:GO:0099524","description":"\"The region of the cytosol consisting of all cytosol that is part of the postsynapse.\" [GOC:dos]","metadata":null},{"id":"52433f22398148ad8ac979e35104eff1","type":"GO_TERM","name":"postsynaptic dense core vesicle exocytosis","canonical_id":"go:GO:0150038","description":"\"The secretion of molecules (e.g. neuropeptides, insulin-related peptides or neuromodulators such as serotonin and dopamine) contained within a postsynaptic dense core vesicle by fusion of the granule with the plasma membrane of the postsynapse in response to increased cytosolic calcium levels.\" [GOC:aruk, GOC:bc, PMID:19448629]","metadata":null},{"id":"25a038d1b2a4402c88f5e9bd903c5948","type":"GO_TERM","name":"postsynaptic density","canonical_id":"go:GO:0014069","description":"\"An electron dense network of proteins within and adjacent to the postsynaptic membrane of an asymmetric, neuron-neuron synapse. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize them such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components.\" [GOC:BHF, GOC:dos, GOC:ef, GOC:jid, GOC:pr, GOC:sjp, PMID:14532281, Wikipedia:Postsynaptic_density]","metadata":null},{"id":"5cf23eab6d944ce796a9bbc4c122e20c","type":"GO_TERM","name":"postsynaptic density assembly","canonical_id":"go:GO:0097107","description":"\"The aggregation, arrangement and bonding together of a set of components to form a postsynaptic density, a region that lies adjacent to the cytoplasmic face of the postsynaptic membrane at excitatory synapse.\" [GOC:BHF, GOC:sjp, PMID:21525273]","metadata":null},{"id":"a39a237485fe40fda0d10abd2874baf0","type":"GO_TERM","name":"postsynaptic density membrane","canonical_id":"go:GO:0098839","description":"\"The membrane component of the postsynaptic density. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated.\" [GOC:dos]","metadata":null},{"id":"ca77de76efe2415ea33887f5ec50777a","type":"GO_TERM","name":"postsynaptic density organization","canonical_id":"go:GO:0097106","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of a postsynaptic density, a region that lies adjacent to the cytoplasmic face of the postsynaptic membrane at excitatory synapse.\" [GOC:BHF, GOC:sjp, PMID:21525273]","metadata":null},{"id":"90bab2ce6c52475592d1b2051956a6c7","type":"GO_TERM","name":"postsynaptic density protein 95 clustering","canonical_id":"go:GO:0097119","description":"\"The clustering process in which postsynaptic density protein 95 (PSD-95) molecules are localized to distinct domains in the cell membrane. PSD-95 is mostly located in the post synaptic density of neurons, and is involved in anchoring synaptic proteins.\" [GOC:BHF, GOC:sjp, PMID:10433269]","metadata":null},{"id":"0d2428a8bd3941fcaff2925e163137a1","type":"GO_TERM","name":"postsynaptic density, intracellular component","canonical_id":"go:GO:0099092","description":"\"A network of proteins adjacent to the postsynaptic membrane forming an electron dense disc. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize neurotransmitter receptors in the adjacent membrane, such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components.\" [GOC:dos]","metadata":null},{"id":"4b07612e9ab049e88a42b49ac6fbdf6f","type":"GO_TERM","name":"postsynaptic early endosome","canonical_id":"go:GO:0098842","description":"\"An early endosome of the postsynapse. It acts as the major sorting station on the endocytic pathway, targeting neurotransmitter receptors for degregation or recycling.\" [PMID:19603039, PMID:20820847, PMID:24727350]","metadata":null},{"id":"42b108875021469db1c6a369a87f043c","type":"GO_TERM","name":"postsynaptic early endosome membrane","canonical_id":"go:GO:0098896","description":"\"The lipid bilayer surrounding a postsynaptic early endosome.\" [GOC:pz]","metadata":null},{"id":"b6f0a0835a4e4036bbe1362f19e96002","type":"GO_TERM","name":"postsynaptic endocytic zone","canonical_id":"go:GO:0098843","description":"\"A stably positioned site of clathrin adjacent and physically attached to the postsynaptic specialization, which is the site of endocytosis of post-synaptic proteins.\" [PMID:17880892]","metadata":null},{"id":"4b34f9c5d142499e9c4ee3962fae7253","type":"GO_TERM","name":"postsynaptic endocytic zone cytoplasmic component","canonical_id":"go:GO:0099631","description":"\"The cytoplasmic component of the postsynaptic endocytic zone.\" [GOC:dos]","metadata":null},{"id":"2a632becceee464689e705d58bc16794","type":"GO_TERM","name":"postsynaptic endocytic zone membrane","canonical_id":"go:GO:0098844","description":"\"The region of the postsynaptic membrane that is part of the postsynaptic endocytic zone. This region of membrane is associated with stable clathrin puncta.\" [PMID:17880892]","metadata":null},{"id":"7c69c2085b164ffab4841997a8dbea08","type":"GO_TERM","name":"postsynaptic endocytosis","canonical_id":"go:GO:0140239","description":"\"A vesicle-mediated transport process in which the postsynapse take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.\" [PMID:12839988]","metadata":null},{"id":"8410572615114dbd98bfdb4a797584a4","type":"GO_TERM","name":"postsynaptic endosome","canonical_id":"go:GO:0098845","description":"\"An endosomal compartment that is part of the post-synapse. Only early and recycling endosomes are typically present in the postsynapse.\" [PMID:20820847]","metadata":null},{"id":"6ed548f60a2e4bc3a3875fa93a56b59b","type":"GO_TERM","name":"postsynaptic endosome membrane","canonical_id":"go:GO:0098895","description":"\"The lipid bilayer surrounding a postsynaptic endosome.\" [GOC:pz]","metadata":null},{"id":"caa55443766a4292b22a4a46dca18c74","type":"GO_TERM","name":"postsynaptic intermediate filament cytoskeleton","canonical_id":"go:GO:0099160","description":"\"The intermediate filament cytoskeleton that is part of a postsynapse.\" [GOC:dos, PMID:25869803]","metadata":null},{"id":"124b1f50b4714408b1ec34ead38f0404","type":"GO_TERM","name":"postsynaptic intermediate filament cytoskeleton organization","canonical_id":"go:GO:0099185","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprised of intermediate filament and their associated proteins in the postsynaptic cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"f7b8b67d50ef4a2d8d2d773fc36e6dd1","type":"GO_TERM","name":"postsynaptic membrane","canonical_id":"go:GO:0045211","description":"\"A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane.\" [ISBN:0198506732]","metadata":null},{"id":"43e08eb6ea884e42b508e6228c8b75b9","type":"GO_TERM","name":"postsynaptic membrane assembly","canonical_id":"go:GO:0097104","description":"\"The aggregation, arrangement and bonding together of a set of components to form a postsynaptic membrane, a specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft).\" [GOC:BHF, GOC:sjp, PMID:21424692]","metadata":null},{"id":"9d338da8e3844e5aa22435f9076ec2e7","type":"GO_TERM","name":"postsynaptic membrane organization","canonical_id":"go:GO:0001941","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of a postsynaptic membrane, the specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft).\" [GOC:dph, GOC:pr]","metadata":null},{"id":"c2fab1a02e674ca69756ee9104d12dbc","type":"GO_TERM","name":"postsynaptic modulation of chemical synaptic transmission","canonical_id":"go:GO:0099170","description":"\"Any process, acting in the postsynapse that results in modulation of chemical synaptic transmission.\" [GOC:dos]","metadata":null},{"id":"7eb31fe7f0414c6ea51fe5aae1c2b0fd","type":"GO_TERM","name":"postsynaptic neurotransmitter receptor activity","canonical_id":"go:GO:0098960","description":"\"Neurotransmitter receptor activity occurring in the postsynaptic membrane during synaptic transmission.\" [GOC:dos, GOC:signaling]","metadata":null},{"id":"0f8681decb694f7f9650cffe7a02736e","type":"GO_TERM","name":"postsynaptic neurotransmitter receptor cycle","canonical_id":"go:GO:0099630","description":"\"The process during which neurotransmitter receptors in the postsynaptic specialization membrane are recycled via the endosome. This cycle includes release from anchoring (trapping), diffusion in the synaptic membrane to the postsynaptic endocytic region, endocytosis, transport to the endosome, recycling in the endosome, transport back the synaptic membrane and subsequent trapping in the postsynaptic specialization membrane.\" [PMID:18832033]","metadata":null},{"id":"7e193ed8245d4c7e8b436906b190a830","type":"GO_TERM","name":"postsynaptic neurotransmitter receptor diffusion trapping","canonical_id":"go:GO:0098970","description":"\"The process by which diffusing neurotransmitter receptor becomes trapped at the postsynaptic specialization membrane. This is typically due to interaction with components of the post-synaptic specialization.\" [PMID:18832033]","metadata":null},{"id":"e66019986c2f4fecbcefe3e196ff217d","type":"GO_TERM","name":"postsynaptic neurotransmitter receptor internalization","canonical_id":"go:GO:0098884","description":"\"A receptor-mediated endocytosis process that results in the internalization of a neurotransmitter receptor from the postsynaptic membrane endocytic zone into an endocytic vesicle.\" [GOC:dos]","metadata":null},{"id":"0075a3e5225740b5aa00f301eac68610","type":"GO_TERM","name":"postsynaptic recycling endosome","canonical_id":"go:GO:0098837","description":"\"A recycling endosome of the postsynapse. In postsynaptic terminals with dendritic spines, it is typically located at the base of a dendritic spine. It is involved in recycling of neurotransmitter receptors to the postsynaptic membrane. In some cases at least, this recycling is activated by postsynaptic signaling and so can play a role in long term potentiation.\" [PMID:20820847]","metadata":null},{"id":"19958bb63cfa47d3aaa149685309b508","type":"GO_TERM","name":"postsynaptic recycling endosome membrane","canonical_id":"go:GO:0098944","description":"\"The lipid bilayer surrounding a postsynaptic recycling endosome.\" [GOC:pz]","metadata":null},{"id":"b6dc9690ca1d41d88a40cff5094c1904","type":"GO_TERM","name":"postsynaptic septin cytoskeleton","canonical_id":"go:GO:0150050","description":"\"The portion of the septin cytoskeleton contained within the postsynapse.\" [GOC:aruk, GOC:bc, PMID:28065648]","metadata":null},{"id":"51ec14fbe16243a49f50355df59e7c17","type":"GO_TERM","name":"postsynaptic signal transduction","canonical_id":"go:GO:0098926","description":"\"Signal transduction in which the initial step occurs in a postsynapse.\" [GOC:dos]","metadata":null},{"id":"c659ab5d2a454fe38f0af8387eec5974","type":"GO_TERM","name":"postsynaptic specialization","canonical_id":"go:GO:0099572","description":"\"A network of proteins within and adjacent to the postsynaptic membrane. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize them such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components.\" [PMID:22046028]","metadata":null},{"id":"14b8e307deac461f9feaf27b6f5e43dd","type":"GO_TERM","name":"postsynaptic specialization assembly","canonical_id":"go:GO:0098698","description":"\"The aggregation, arrangement and bonding together of a set of components to form a postsynaptic specialization, a region that lies adjacent to the cytoplasmic face of the postsynaptic membrane.\" [GOC:dos]","metadata":null},{"id":"b2fbb3caa60f40ec890bbf38030427b1","type":"GO_TERM","name":"postsynaptic specialization membrane","canonical_id":"go:GO:0099634","description":"\"The membrane component of the postsynaptic specialization. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated.\" [GOC:dos]","metadata":null},{"id":"825486ec48b24eb1a07ed6077ecda3a9","type":"GO_TERM","name":"postsynaptic specialization membrane of symmetric synapse","canonical_id":"go:GO:0099164","description":"\"The membrane component of the postsynaptic specialization of a symmetric synapse. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated.\" [GOC:dos]","metadata":null},{"id":"9b86eb249ca94c2488f3a748d1e55d8a","type":"GO_TERM","name":"postsynaptic specialization of symmetric synapse","canonical_id":"go:GO:0099629","description":"\"A network of proteins within and adjacent to the postsynaptic membrane of a symmetric synapse, consisting of anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components that spatially and functionally organize the neurotransmitter receptors at the synapse. This structure is not as thick or electron dense as the postsynaptic densities found in asymmetric synapses.\" [PMID:18832033]","metadata":null},{"id":"6c7ac9f3863c4be79cc869e31b13fd42","type":"GO_TERM","name":"postsynaptic specialization of symmetric synapse, intracellular component","canonical_id":"go:GO:0099165","description":"\"A network of proteins adjacent to the postsynaptic membrane of a symmetric synapse. Its major components include that spatially and functionally organize neurotransmitter receptors in the adjacent membrane, such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components. This structure is not as thick or electron dense as the postsynaptic density found in asymmetric synapses.\" [GOC:dos]","metadata":null},{"id":"7562de7f35134b63a4f183a7668e050a","type":"GO_TERM","name":"postsynaptic specialization organization","canonical_id":"go:GO:0099084","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of a postsynaptic specialization, a structure that lies adjacent to the cytoplasmic face of the postsynaptic membrane.\" [GOC:BHF, GOC:sjp, PMID:21525273, PMID:26834556]","metadata":null},{"id":"bd76973c96e74dbf96d8f5d001c4439b","type":"GO_TERM","name":"postsynaptic specialization, intracellular component","canonical_id":"go:GO:0099091","description":"\"A network of proteins adjacent to the postsynaptic membrane. Its major components include the proteins that spatially and functionally organize neurotransmitter receptors in the adjacent membrane, such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components.\" [GOC:dos]","metadata":null},{"id":"bcdf73197bef4e308eaa47bc424ef184","type":"GO_TERM","name":"postsynaptic spectrin-associated cytoskeleton","canonical_id":"go:GO:0099189","description":"\"The portion of the spectrin-associated cytoskeleton contained within the postsynapse.\" [GOC:dos, PMID:28576936]","metadata":null},{"id":"d150e5042be3426ab0f80a9a366f8194","type":"GO_TERM","name":"postsynaptic spectrin-associated cytoskeleton organization","canonical_id":"go:GO:0099190","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of spectrin-associated cytoskeleton and associated proteins in the postsynapse.\" [GOC:dos, PMID:28576936]","metadata":null},{"id":"2c05db4d7cc34d2ba0779f844cefbdcc","type":"GO_TERM","name":"potassium channel activator activity","canonical_id":"go:GO:0099104","description":"\"Binds to and increases the activity of a potassium channel, resulting in its opening.\" [GOC:dos]","metadata":null},{"id":"8c3477ead68b46cb929d17f90db5b2b5","type":"GO_TERM","name":"potassium channel activity","canonical_id":"go:GO:0005267","description":"\"Enables the energy-independent facilitated diffusion of a potassium ion through a transmembrane aqueous pore or channel.\" [GOC:BHF, GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"ec04baf890154785aae03b6afaa80a18","type":"GO_TERM","name":"potassium channel complex","canonical_id":"go:GO:0034705","description":"\"An ion channel complex through which potassium ions pass.\" [GOC:mah]","metadata":null},{"id":"a0b2f373d39e4ce1b56dbc559391b3b8","type":"GO_TERM","name":"potassium channel inhibitor activity","canonical_id":"go:GO:0019870","description":"\"Binds to and stops, prevents, or reduces the activity of a potassium channel.\" [GOC:mah]","metadata":null},{"id":"4a7e93e0f77b43718e61c3a490e937e2","type":"GO_TERM","name":"potassium channel regulator activity","canonical_id":"go:GO:0015459","description":"\"Binds to and modulates the activity of a potassium channel.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"200373a57783457387bcf5f22b6cb86e","type":"DRUG","name":"potassium citrate","canonical_id":"mesh:D019357","description":null,"metadata":null},{"id":"7a0cbc1abd8b44d2a7cc8c3efb6b6f57","type":"DISEASE","name":"potassium deficiency disease","canonical_id":"mondo:0003019","description":null,"metadata":null},{"id":"501e14f33a5944d9ad1a701a298fcd80","type":"DRUG","name":"potassium iodide","canonical_id":"mesh:D011193","description":null,"metadata":null},{"id":"60142ab0344744cfb79cbe4bedb1f448","type":"GO_TERM","name":"potassium ion binding","canonical_id":"go:GO:0030955","description":"\"Binding to a potassium ion (K+).\" [GOC:mah]","metadata":null},{"id":"29ef7de8c40e4ce2849deea16e3553e1","type":"GO_TERM","name":"potassium ion export across plasma membrane","canonical_id":"go:GO:0097623","description":"\"The directed movement of potassium ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:vw, PMID:11932440]","metadata":null},{"id":"669368cfdf7a4fefa110dd1910f8f4a8","type":"GO_TERM","name":"potassium ion homeostasis","canonical_id":"go:GO:0055075","description":"\"Any process involved in the maintenance of an internal steady state of potassium ions within an organism or cell.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"a8d38b23aa29446ab65fe6edf09316cf","type":"GO_TERM","name":"potassium ion import across plasma membrane","canonical_id":"go:GO:1990573","description":"\"The directed movement of potassium ions from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:9139127]","metadata":null},{"id":"22869453b71b48f7b980888d3a1d8c58","type":"GO_TERM","name":"potassium ion leak channel activity","canonical_id":"go:GO:0022841","description":"\"Enables the transport of a potassium ion across a membrane via a narrow pore channel that is open even in an unstimulated or 'resting' state.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"939ff64519e44cfe979698dfb76b2d5d","type":"GO_TERM","name":"potassium ion transmembrane transport","canonical_id":"go:GO:0071805","description":"\"A process in which a potassium ion is transported from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"5772c85c9d3645b1899f40104c91b8e8","type":"GO_TERM","name":"potassium ion transmembrane transporter activity","canonical_id":"go:GO:0015079","description":"\"Enables the transfer of potassium ions (K+) from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"460608c207d740c1a8782d0c5f872aa7","type":"GO_TERM","name":"potassium ion transport","canonical_id":"go:GO:0006813","description":"\"The directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"5d6acd7904204b14831c4eb56d9beb95","type":"GO_TERM","name":"potassium ion uniporter activity","canonical_id":"go:GO:0022819","description":"\"Catalysis of the active transport of a potassium ion across a membrane by a mechanism involving conformational change, where energy for active transport is derived from membrane potential if the solute is charged.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"af8aabf0718d48dcafd522ae5db6aadf","type":"GO_TERM","name":"potassium ion-transporting ATPase complex","canonical_id":"go:GO:0031004","description":"\"Protein complex that carries out the reaction: ATP + H2O + K+(out) = ADP + phosphate + K+(in). It is a high affinity potassium uptake system. The E. coli complex consists of 4 proteins: KdpA is the potassium ion translocase, KdpB is the ATPase, and KdpC and KdpF seem to be involved in assembly and stabilization of the complex.\" [PMID:10608856, PMID:9858692]","metadata":null},{"id":"8fbcf42e972e476dbb989a5557d758fe","type":"DISEASE","name":"potassium-aggravated myotonia","canonical_id":"mondo:0018959","description":null,"metadata":null},{"id":"a372e0f9bee44b73a8ceae91ffd1229f","type":"GO_TERM","name":"potassium:chloride symporter activity","canonical_id":"go:GO:0015379","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: K+(out) + Cl-(out) = K+(in) + Cl-(in).\" [TC:2.A.30.1.5]","metadata":null},{"id":"4c0af0cdbea043f7901c19215ab8a0c8","type":"GO_TERM","name":"potassium:proton antiporter activity","canonical_id":"go:GO:0015386","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: K+(in) + H+(out) = K+(out) + H+(in).\" [TC:2.A.37.-.-]","metadata":null},{"id":"37e521ec87f440b6981b359a1c84c7aa","type":"GO_TERM","name":"potassium:proton antiporter complex","canonical_id":"go:GO:1903103","description":"\"A protein complex which is capable of potassium:proton antiporter activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:21041667]","metadata":null},{"id":"bfb4c04117ff42209ae145393285228a","type":"GO_TERM","name":"potassium:proton exchanging ATPase complex","canonical_id":"go:GO:0005889","description":"\"A protein complex that possesses hydrogen:potassium-exchanging ATPase activity; characterized in animal cells, where it maintains ionic gradients of K+ at the expense of ATP hydrolysis; The complex contains two obligatory subunits, the catalytic alpha subunit and a glycosylated beta subunit; two additional subunits, gamma and channel-inducing factor (CHIF), may also be present.\" [PMID:11756431]","metadata":null},{"id":"94e88c63886548209ee7e08d2f0883c7","type":"GO_TERM","name":"potassium:proton symporter activity","canonical_id":"go:GO:0015387","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: K+(out) + H+(out) = K+(in) + H+(in).\" [TC:2.A.38.-.-]","metadata":null},{"id":"c8df4663d0ba47f8b7cd80e6875809a5","type":"GO_TERM","name":"potassium:sodium symporter activity","canonical_id":"go:GO:0009674","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: K+(out) + Na+(out) = K+(in) + Na+(in).\" [TC:2.A.38.3.1]","metadata":null},{"id":"65bb7a54770a46d7aed042bbe9abd56b","type":"DRUG","name":"practolol","canonical_id":"gtopdb:555","description":null,"metadata":null},{"id":"66df2a03354644858d780e0735b20a36","type":"DRUG","name":"practolol","canonical_id":"chembl:CHEMBL6995","description":null,"metadata":null},{"id":"f1e32d9421694d48a678f269ae38dcd0","type":"DRUG","name":"pralatrexate","canonical_id":"gtopdb:6840","description":null,"metadata":null},{"id":"b888024d72544970a1fe2139d2cf0309","type":"DRUG","name":"pralatrexate","canonical_id":"mesh:C418863","description":null,"metadata":null},{"id":"f8d26a771eea4e4eb6450e911df9d097","type":"DRUG","name":"pralatrexate","canonical_id":"chembl:CHEMBL1201746","description":null,"metadata":null},{"id":"1e89c0cc9d4848be9cfa3ba766cf67f7","type":"COMBINATION_TREATMENT","name":"pralatrexate + probenecid","canonical_id":"ctgov_combo:ctgov-combo-62e589686ed7338a","description":null,"metadata":null},{"id":"bb2a60a8c3ab4178b9ec33de9bbc2413","type":"COMBINATION_TREATMENT","name":"pralatrexate + romidepsin","canonical_id":"ctgov_combo:ctgov-combo-8d5d580e8f1d9b6f","description":null,"metadata":null},{"id":"0860f2f309744d3a94baa0c41653e2f5","type":"COMBINATION_TREATMENT","name":"pralatrexate + romidepsin","canonical_id":"ctgov_combo:ctgov-combo-a7f429383dfe1c23","description":null,"metadata":null},{"id":"21e2623f8e954a648ea16ef3e4d22ed0","type":"DRUG","name":"pralidoxime","canonical_id":"gtopdb:7597","description":null,"metadata":null},{"id":"ca12ae7544fe45eda9bdc1ca43fc7fbf","type":"DRUG","name":"pralsetinib","canonical_id":"gtopdb:10033","description":null,"metadata":null},{"id":"cc3eb3e8901041c9bdbb8145cb4989ac","type":"DRUG","name":"pralsetinib","canonical_id":"chembl:CHEMBL4582651","description":null,"metadata":null},{"id":"6f4ea2831adb47b6935c2ba4d692584c","type":"DRUG","name":"pramipexole","canonical_id":"gtopdb:953","description":null,"metadata":null},{"id":"90b293177d874306ad17ec2a9513394f","type":"DRUG","name":"pramipexole","canonical_id":"mesh:C061333","description":null,"metadata":null},{"id":"7db19fc015be41dba8601960fad65a5d","type":"COMBINATION_TREATMENT","name":"pramipexole + quetiapine","canonical_id":"ctgov_combo:ctgov-combo-e0c33c8b39c277ab","description":null,"metadata":null},{"id":"bf369eba445e4a12afcd74bc4ec26b90","type":"COMBINATION_TREATMENT","name":"pramipexole + rasagiline","canonical_id":"ctgov_combo:ctgov-combo-5069690d4cda5e98","description":null,"metadata":null},{"id":"7b6da32b330d4ee0a4dfaf3debd5a3ae","type":"COMBINATION_TREATMENT","name":"pramipexole + rasagiline","canonical_id":"ctgov_combo:ctgov-combo-618e74525a85ecbd","description":null,"metadata":null},{"id":"a94c136426804c3c900905f6a5c769ef","type":"COMBINATION_TREATMENT","name":"pramipexole + trihexyphenidyl","canonical_id":"ctgov_combo:ctgov-combo-9b4443bccd938743","description":null,"metadata":null},{"id":"6d059ec12fb14bd698f6268763eec154","type":"COMBINATION_TREATMENT","name":"pramipexole + warfarin","canonical_id":"ctgov_combo:ctgov-combo-6bf32f8d5ad06684","description":null,"metadata":null},{"id":"59492a1851f3483cb9cc8495607bfa20","type":"DRUG","name":"pramocaine","canonical_id":"mesh:C005548","description":null,"metadata":null},{"id":"a70d69ffe60d495b8342d68ee7076667","type":"DRUG","name":"pranlukast","canonical_id":"gtopdb:3634","description":null,"metadata":null},{"id":"5076d19fc9954c6cb121929b75333135","type":"DRUG","name":"pranlukast","canonical_id":"mesh:C047681","description":null,"metadata":null},{"id":"665615d782c349ed852c0dc4ed533725","type":"DRUG","name":"pranlukast","canonical_id":"chembl:CHEMBL21333","description":null,"metadata":null},{"id":"7a63ec52cd2244d89d8cd872c3236e12","type":"DRUG","name":"pravastatin","canonical_id":"gtopdb:2953","description":null,"metadata":null},{"id":"d60a0f377c654f6dad77d88c5f16d61b","type":"COMBINATION_TREATMENT","name":"pravastatin + rosuvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-493380426089ac69","description":null,"metadata":null},{"id":"770499d5e9224052851918143137b6c5","type":"COMBINATION_TREATMENT","name":"pravastatin + rosuvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-dc2e1d1ded8648fd","description":null,"metadata":null},{"id":"48236f4026bd4b8c832090a0a3f738db","type":"COMBINATION_TREATMENT","name":"pravastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-f929fb2b7124ff9f","description":null,"metadata":null},{"id":"7e3889aa0ff044dc91f5c563c04289d8","type":"COMBINATION_TREATMENT","name":"pravastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-01f69c042c1e1f6a","description":null,"metadata":null},{"id":"0cba1b3ec0ec46e0bc7b30257eea6238","type":"COMBINATION_TREATMENT","name":"pravastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-136e8dd63d8bb104","description":null,"metadata":null},{"id":"e920de8b081c44ea918cc28d65a56875","type":"COMBINATION_TREATMENT","name":"pravastatin + valsartan","canonical_id":"ctgov_combo:ctgov-combo-d0b73e6d24d7fb70","description":null,"metadata":null},{"id":"cce5f15cb36b4eabb7644669c79a9c8c","type":"DRUG","name":"prazepam","canonical_id":"mesh:D011222","description":null,"metadata":null},{"id":"8e53b677d9624d88b9241ddfa9e042cd","type":"DRUG","name":"prazosin","canonical_id":"gtopdb:503","description":null,"metadata":null},{"id":"5b850388402b44519d076b4f96182c52","type":"DRUG","name":"prazosin","canonical_id":"mesh:D011224","description":null,"metadata":null},{"id":"feee03db202d46b5956f7d4cffab973c","type":"COMBINATION_TREATMENT","name":"prazosin + varenicline","canonical_id":"ctgov_combo:ctgov-combo-7d08562479c9b3b5","description":null,"metadata":null},{"id":"d5dc368b245848b89ef75f83a43a45ad","type":"GO_TERM","name":"pre-B cell allelic exclusion","canonical_id":"go:GO:0002331","description":"\"Expression of a single heavy chain allele during pre-B cell differentiation.\" [GOC:add, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"0a15848dd7de4f628deded4b7d214429","type":"GO_TERM","name":"pre-B cell differentiation","canonical_id":"go:GO:0002329","description":"\"The process in which a precursor cell type acquires the specialized features of a pre-B cell. Pre-B cells follow the pro-B cell stage of immature B cell differentiation and undergo rearrangement of heavy chain V, D, and J gene segments.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"e4baa2296eb14c5d88fa393beb13d666","type":"GO_TERM","name":"pre-B cell receptor complex","canonical_id":"go:GO:0035369","description":"\"An immunoglobulin-like complex that is present in at least the plasma membrane of pre-B cells, and that is composed of two identical immunoglobulin heavy chains and two surrogate light chains, each composed of the lambda-5 and VpreB proteins, and a signaling subunit, a heterodimer of the Ig-alpha and Ig-beta proteins.\" [GOC:add, ISBN:0781765196, PMID:16464608, PMID:17306522]","metadata":null},{"id":"caa0d233c4384330b6191bbfad6d66d1","type":"GO_TERM","name":"pre-B cell receptor expression","canonical_id":"go:GO:0002330","description":"\"The process leading up to expression of the pre-B cell receptor on the surface of pre-B cells, starting with the recombination of an immunuglobulin heavy chain locus, including expression of the surrogate light chain, the association of the surrogate light chain with the heavy chain, and expression of the complete pre-B cell receptor on the cell surface. pre-B cell receptor expression is a key checkpoint in the transition of pro-B cell to pre-B cell.\" [GOC:add, GOC:jal, PMID:15263090, PMID:22949502, PMID:9834086]","metadata":null},{"id":"48c5c8edceb6405abb31dced0f11a0c8","type":"GO_TERM","name":"pre-T cell receptor complex","canonical_id":"go:GO:0043384","description":"\"A receptor complex found on immature T cells consisting of a T cell receptor beta chain and the pre-TCR-alpha chain, along with additional signaling components including CD3 family members and additional signaling proteins.\" [ISBN:0781735149, PMID:12220932]","metadata":null},{"id":"e65893fa1fa445a99fc484215d32b927","type":"GO_TERM","name":"pre-mRNA 3'-splice site binding","canonical_id":"go:GO:0030628","description":"\"Binding to a pre-mRNA 3' splice site sequence.\" [GOC:jl]","metadata":null},{"id":"e700626d5e8c4b6e8cbc3176e3e73c9e","type":"GO_TERM","name":"pre-mRNA 5'-splice site binding","canonical_id":"go:GO:0030627","description":"\"Binding to a pre-mRNA 5' splice site sequence.\" [GOC:jl]","metadata":null},{"id":"6db28824064641e6818579ca7b60b0eb","type":"GO_TERM","name":"pre-mRNA binding","canonical_id":"go:GO:0036002","description":"\"Binding to a pre-messenger RNA (pre-mRNA), an intermediate molecule between DNA and protein that may contain introns and, at least in part, encodes one or more proteins. Introns are removed from pre-mRNA to form a mRNA molecule.\" [GOC:bf, GOC:kmv, PMID:21901112, SO:0000120]","metadata":null},{"id":"660f758eb3e14d7dadb66e9f6cdf33a8","type":"GO_TERM","name":"pre-mRNA branch point binding","canonical_id":"go:GO:0045131","description":"\"Binding to a pre-mRNA branch point sequence, located upstream of the 3' splice site.\" [PMID:11691992, PMID:9722632]","metadata":null},{"id":"6da522ae093e40f7b87d4246d2d57a47","type":"GO_TERM","name":"pre-mRNA catabolic process","canonical_id":"go:GO:1990261","description":"\"The chemical reactions and pathways resulting in the breakdown of the unspliced pre-mRNA (pre-messenger RNA).\" [GOC:rb, PMID:22844259]","metadata":null},{"id":"bc4d6865b6944c8e8359790529d1d117","type":"GO_TERM","name":"pre-mRNA intronic binding","canonical_id":"go:GO:0097157","description":"\"Binding to an intronic sequence of a pre-messenger RNA (pre-mRNA).\" [GOC:ans, PMID:16260624]","metadata":null},{"id":"0fadc31a4ca94cdbab71409b5ebfe964","type":"GO_TERM","name":"pre-mRNA intronic pyrimidine-rich binding","canonical_id":"go:GO:0097158","description":"\"Binding to a pyrimidine-rich (CU-rich) intronic sequence of a pre-messenger RNA (pre-mRNA).\" [GOC:ans, PMID:16260624, PMID:16777844]","metadata":null},{"id":"b142302eea0f4325862d1a0789966b34","type":"GO_TERM","name":"pre-miRNA 3'-end processing","canonical_id":"go:GO:0044747","description":"\"Any process involved in forming distinct miRNA isoforms from a mature miRNA that differ at their 3'-ends.\" [PMID:22055292, PMID:22055293]","metadata":null},{"id":"9580df4768b14697a029967edb2037d9","type":"GO_TERM","name":"pre-miRNA binding","canonical_id":"go:GO:0070883","description":"\"Binding to a precursor microRNA (pre-miRNA) transcript, a stem-loop-containing precursor of microRNA.\" [PMID:18951094]","metadata":null},{"id":"03268271aa4040a4bbfd4f1541eedbd7","type":"GO_TERM","name":"pre-miRNA export from nucleus","canonical_id":"go:GO:0035281","description":"\"Transport of pre-microRNAs (pre-miRNAs) from the nucleus to the cytoplasm. Pre-miRNAs are a ~60-70 nucleotide stem loop intermediate in miRNA production, produced by the nuclear cleavage of a primary miRNA (pri-mRNA) transcript. Pre-miRNAs are transported from the nucleus to the cytoplasm where further cleavage occurs to produce a mature miRNA product.\" [GOC:sl, PMID:14744438]","metadata":null},{"id":"bfc8523924084a419a1421137dbf9fbf","type":"GO_TERM","name":"pre-miRNA processing","canonical_id":"go:GO:0031054","description":"\"A process involved in the conversion of a pre-microRNA transcript into a mature microRNA molecule.\" [GOC:sl, PMID:15211354]","metadata":null},{"id":"127f213c47d14249ada5932f59583c94","type":"GO_TERM","name":"pre-primosome complex","canonical_id":"go:GO:1990099","description":"\"Any of the protein-DNA complexes that contain a DNA helicase and associated protein(s) at the origin of replication, and build up to assembling the core primosome. The associated protein(s) chaperone the helicase to the DNA, and assembly of the pre-primosome is essential for the initiation or restart of replication. Pre-primosome complexes lack a primase component.\" [GOC:bhm, PMID:18179598, PMID:20129058, PMID:8663105]","metadata":null},{"id":"c630d47fc76746949c1d7d1cf43238ce","type":"GO_TERM","name":"pre-replicative complex","canonical_id":"go:GO:0036387","description":"\"A protein-DNA complex that forms at the origin of replication during the initial step of DNA replication and allows the origin to become competent, or 'licensed', for replication.\" [GOC:bf, GOC:bhm, GOC:jh2, Wikipedia:Pre-replication_complex]","metadata":null},{"id":"55574c1f0ed34c71b60d5e7a49bb0353","type":"GO_TERM","name":"pre-replicative complex assembly","canonical_id":"go:GO:0036388","description":"\"The aggregation, arrangement and bonding together of a set of components to form the pre-replicative complex, a protein-DNA complex that forms at the origin of replication during the initial step of DNA replication and allows the origin to become competent, or 'licensed', for replication.\" [GOC:bf, GOC:bhm, GOC:jh2]","metadata":null},{"id":"c213ca0fb5574fe8b80171a25ca2c0f8","type":"GO_TERM","name":"pre-replicative complex assembly involved in cell cycle DNA replication","canonical_id":"go:GO:1902299","description":"\"Any pre-replicative complex assembly that is involved in cell cycle DNA replication.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"a41969ee60a148f5bceddd91cf062d6d","type":"GO_TERM","name":"pre-replicative complex assembly involved in nuclear cell cycle DNA replication","canonical_id":"go:GO:0006267","description":"\"The aggregation, arrangement and bonding together of a set of components to form the nuclear pre-replicative complex, a protein-DNA complex that forms at the eukaryotic DNA replication origin and is required for replication initiation.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"ace5f0fdd61c46c89c455ec26b36e86f","type":"GO_TERM","name":"pre-snoRNP complex","canonical_id":"go:GO:0070761","description":"\"A ribonucleoprotein complex that contains a precursor small nucleolar RNA (pre-snoRNA) and associated proteins, and forms during small nucleolar ribonucleoprotein complex (snoRNP) assembly. Pre-snoRNP complexes may contain proteins not found in the corresponding mature snoRNP complexes.\" [GOC:BHF, GOC:mah, GOC:rl, PMID:17636026, PMID:17709390]","metadata":null},{"id":"52e5b1a5ff8341529b3c9514d967e86b","type":"GO_TERM","name":"pre-tubular aggregate formation","canonical_id":"go:GO:0072035","description":"\"The cell adhesion process in which mesenchyme cells adhere to one another in the initial stages of the formation of the pre-tubular aggregate, the earliest recognizable structure of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"52891a3268794afea6d126fb7fa7c055","type":"GO_TERM","name":"preQ1 synthase activity","canonical_id":"go:GO:0033739","description":"\"Catalysis of the reaction: 7-aminomethyl-7-carbaguanine + 2 NADP+ = 7-cyano-7-deazaguanine + 2 NADPH + 3 H+.\" [RHEA:13409]","metadata":null},{"id":"da9701f8c90545fd9c5c73e3ca0203bc","type":"GO_TERM","name":"preantral ovarian follicle growth","canonical_id":"go:GO:0001546","description":"\"Increase in size of follicles surrounded by two or more layers of granulosa cells up to the onset of antrum formation.\" [https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"c49ae00b61524f5786fb5050cbe27885","type":"GO_TERM","name":"prebend segment development","canonical_id":"go:GO:0072066","description":"\"The process whose specific outcome is the progression of the prebend segment over time, from its formation to the mature structure. The prebend segment is a part of the descending thin limb that lies before the bend and exhibits permeabilities characteristic of the ascending limb, especially negligible water permeability.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e22843b5d4394b179ed3ad354701b753","type":"GO_TERM","name":"preblastoderm mitotic cell cycle","canonical_id":"go:GO:0035185","description":"\"The first nine mitotic division cycles of the insect embryo, during which the dividing nuclei lie deep in the interior of the egg and divide nearly synchronously. This is the first phase of the syncytial period where nuclei divide in a common cytoplasm without cytokinesis.\" [ISBN:0879694238]","metadata":null},{"id":"e5a3a269011340ff98353c22d20a1c3d","type":"GO_TERM","name":"precatalytic spliceosome","canonical_id":"go:GO:0071011","description":"\"A spliceosomal complex that is formed by the recruitment of a preassembled U5-containing tri-snRNP to the prespliceosome. Although all 5 snRNPs are present, the precatalytic spliceosome is catalytically inactive. The precatalytic spliceosome includes many proteins in addition to those found in the associated snRNPs.\" [GOC:ab, GOC:krc, GOC:mah, PMID:18322460, PMID:19239890]","metadata":null},{"id":"917297cafb664322ae2d4517f9f5dd34","type":"GO_TERM","name":"prechordal plate formation","canonical_id":"go:GO:0021501","description":"\"The formation of the prechordal plate. The prechordal plate is a thickening of the endoderm at the cranial end of the primitive streak formed by the involution of Spemann's organizer cells. The prechordal plate and the notochord induce the formation of the neural plate from the overlying ectodermal cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"837cba2be13b4162bd248f4a9306dade","type":"DISEASE","name":"precocious puberty","canonical_id":"mondo:0000088","description":null,"metadata":null},{"id":"ed7ec8da4deb4bcb93058008beea008e","type":"GO_TERM","name":"precorrin-2 C20-methyltransferase activity","canonical_id":"go:GO:0030788","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + precorrin-2 = S-adenosyl-L-homocysteine + H+ + precorrin-3A.\" [EC:2.1.1.130, RHEA:16841]","metadata":null},{"id":"b0d69cafe4e348ff8d94830c116da4ca","type":"GO_TERM","name":"precorrin-2 dehydrogenase activity","canonical_id":"go:GO:0043115","description":"\"Catalysis of the reaction: NAD+ + precorrin-2 = 2 H+ + NADH + sirohydrochlorin.\" [EC:1.3.1.76, RHEA:15613]","metadata":null},{"id":"f7c80d1570c4413688c4f8ea2be22099","type":"GO_TERM","name":"precorrin-3B C17-methyltransferase activity","canonical_id":"go:GO:0030789","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + precorrin-3B = S-adenosyl-L-homocysteine + precorrin 4.\" [EC:2.1.1.131]","metadata":null},{"id":"f7bb5e3050b141009cc20d8f83e6a5a9","type":"GO_TERM","name":"precorrin-3B synthase activity","canonical_id":"go:GO:0043818","description":"\"Catalysis of the reaction: H+ + NADH + O2 + precorrin-3A = H2O + NAD+ + precorrin-3B.\" [EC:1.14.13.83, RHEA:17293]","metadata":null},{"id":"25c7fbb9029948509c5cd24edc1513b8","type":"GO_TERM","name":"precorrin-4 C11-methyltransferase activity","canonical_id":"go:GO:0046026","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + precorrin-4 = S-adenosyl-L-homocysteine + precorrin 5.\" [EC:2.1.1.133]","metadata":null},{"id":"962ae632f8c24811837e702b7095c0c5","type":"GO_TERM","name":"precorrin-6A reductase activity","canonical_id":"go:GO:0016994","description":"\"Catalysis of the reaction: precorrin-6B + NADP+ = precorrin-6A + NADPH + H+.\" [EC:1.3.1.54]","metadata":null},{"id":"b1717b03a30349cc9099031aec2e8cc5","type":"GO_TERM","name":"precorrin-6A synthase (deacetylating) activity","canonical_id":"go:GO:0043819","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + H2O + precorrin-5 = S-adenosyl-L-homocysteine + acetate + 2 H+ + precorrin-6X.\" [EC:2.1.1.152, RHEA:18261]","metadata":null},{"id":"abf38544cebd467981577846946c0548","type":"GO_TERM","name":"precorrin-6Y C5,15-methyltransferase (decarboxylating) activity","canonical_id":"go:GO:0046025","description":"\"Catalysis of the reaction: 2 S-adenosyl-L-methionine + precorrin-6Y = 2 S-adenosyl-L-homocysteine + precorrin-8X + CO2.\" [EC:2.1.1.132]","metadata":null},{"id":"313da3e6d19e425a99880dd78f5eb461","type":"GO_TERM","name":"precorrin-8X methylmutase activity","canonical_id":"go:GO:0016993","description":"\"Catalysis of the reaction: precorrin-8X = hydrogenobyrinate.\" [EC:5.4.99.61]","metadata":null},{"id":"e4558621fcc54658a3950393ce07d102","type":"DRUG","name":"prednisolone","canonical_id":"gtopdb:2866","description":null,"metadata":null},{"id":"04ad91484b974d8ebe9694e9a50d7863","type":"DRUG","name":"prednisolone","canonical_id":"mesh:D011239","description":null,"metadata":null},{"id":"4e865b8bc4a547e5bdc4a7f4f2602379","type":"DRUG","name":"prednisolone","canonical_id":"chembl:CHEMBL1201014","description":null,"metadata":null},{"id":"cfa35b50e4b84d3aab77b62ea2891069","type":"COMBINATION_TREATMENT","name":"prednisolone + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-72765f904200030a","description":null,"metadata":null},{"id":"b15baf117aae4e1e874eea6db68adeac","type":"DRUG","name":"prednisolone acetate","canonical_id":"mesh:C009935","description":null,"metadata":null},{"id":"1c2cbc92541f43a2b557159abe209fc8","type":"DRUG","name":"prednisolone phosphate","canonical_id":"mesh:C009022","description":null,"metadata":null},{"id":"cb708c24ad8646089d17308f1cfbfb6f","type":"DRUG","name":"prednisone","canonical_id":"gtopdb:7096","description":null,"metadata":null},{"id":"af5d4dfe07ac4832b140af830ece3e12","type":"DRUG","name":"prednisone","canonical_id":"mesh:D011241","description":null,"metadata":null},{"id":"ab7a61804e1f4c81a695addae34cd544","type":"DRUG","name":"prednisone","canonical_id":"chembl:CHEMBL635","description":null,"metadata":null},{"id":"0c3b445e496c4a86ba9422801299507d","type":"COMBINATION_TREATMENT","name":"prednisone + rituximab + vincristine","canonical_id":"ctgov_combo:ctgov-combo-8acc2e5cfc85dc1e","description":null,"metadata":null},{"id":"218af777b92a43ba949622a5e5fd7fc0","type":"COMBINATION_TREATMENT","name":"prednisone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-83f8a0b2d8141581","description":null,"metadata":null},{"id":"946e66c0d9c34492a8b2ba103201b464","type":"COMBINATION_TREATMENT","name":"prednisone + vincristine","canonical_id":"ctgov_combo:ctgov-combo-5af773222cdfb152","description":null,"metadata":null},{"id":"5edc8ebf95d640ddb1da162fc7d687f7","type":"DISEASE","name":"preeclampsia","canonical_id":"mondo:0005081","description":null,"metadata":null},{"id":"2533624d99794c3ca0592c5b917f12b7","type":"GO_TERM","name":"prefoldin complex","canonical_id":"go:GO:0016272","description":"\"A multisubunit chaperone that is capable of delivering unfolded proteins to cytosolic chaperonin, which it acts as a cofactor for. In humans, the complex is a heterohexamer of two PFD-alpha and four PFD-beta type subunits. In Saccharomyces cerevisiae, it also acts in the nucleus to regulate the rate of elongation by RNA polymerase II via a direct effect on histone dynamics.\" [GOC:jl, PMID:17384227, PMID:24068951, PMID:9630229]","metadata":null},{"id":"1647b8f56f744387a13e7d5a7ab48d5c","type":"GO_TERM","name":"preganglionic parasympathetic fiber development","canonical_id":"go:GO:0021783","description":"\"The process whose specific outcome is the progression of a preganglionic parasympathetic fiber over time, from its formation to the mature structure. A preganglionic parasympathetic fiber is a cholinergic axonal fiber projecting from the CNS to a parasympathetic ganglion.\" [GO_REF:0000021, GOC:cjm, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"38fc04c975de443184a134ee0d2f9bf6","type":"GO_TERM","name":"pregnan-21-ol dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047007","description":"\"Catalysis of the reaction: NAD+ + pregnan-21-ol = H+ + NADH + pregnan-21-al.\" [RHEA:11448]","metadata":null},{"id":"012c15b622fe406cb6ad51701cdf03b2","type":"GO_TERM","name":"pregnan-21-ol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047008","description":"\"Catalysis of the reaction: NADP+ + pregnan-21-ol = H+ + NADPH + pregnan-21-al.\" [RHEA:23712]","metadata":null},{"id":"7ae5aa83c7b24d77aa9280bc5c46c383","type":"DISEASE","name":"pregnancy disorder","canonical_id":"mondo:0024575","description":null,"metadata":null},{"id":"d3c0706100424d0b80772f383bca26d4","type":"DISEASE","name":"prekallikrein deficiency","canonical_id":"mondo:0044744","description":null,"metadata":null},{"id":"fc3d18d8b105480e84e900a942967e6d","type":"GO_TERM","name":"premature acrosome loss","canonical_id":"go:GO:0061948","description":"\"The discharge, by sperm, of a single, anterior secretory granule before the sperm reaches to the zona pellucida of the oocyte. The process begins with the fusion of the outer acrosomal membrane with the sperm plasma membrane and ends with the exocytosis of the acrosomal contents.\" [PMID:19153666, PMID:21380641, PMID:26655718]","metadata":null},{"id":"f53df61265994786a62c1e1607b56bc9","type":"DISEASE","name":"premature ejaculation","canonical_id":"mondo:0001780","description":null,"metadata":null},{"id":"f4f41a34e8c6496f9fb7ae87a25454e6","type":"DISEASE","name":"premature menopause","canonical_id":"mondo:0001119","description":null,"metadata":null},{"id":"e0a920cf885143be9b9a465f014f8b60","type":"GO_TERM","name":"premeiotic DNA replication","canonical_id":"go:GO:0006279","description":"\"The replication of DNA that precedes meiotic cell division.\" [GO_REF:0000060, GOC:ai, GOC:TermGenie]","metadata":null},{"id":"7230428b486a4e66b4da3fd204272444","type":"GO_TERM","name":"premeiotic DNA replication preinitiation complex assembly","canonical_id":"go:GO:1902976","description":"\"Any DNA replication preinitiation complex assembly that is involved in meiotic cell cycle.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"d0a071d56f8249e587ca09f15662df2e","type":"GO_TERM","name":"premeiotic DNA replication termination","canonical_id":"go:GO:1902978","description":"\"Any DNA replication termination involved in meiotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:TermGenie]","metadata":null},{"id":"9a6e16a2590c442f8b0c2c4cc56c6f1c","type":"GO_TERM","name":"prenol biosynthetic process","canonical_id":"go:GO:0016091","description":"\"The chemical reactions and pathways resulting in the formation of prenols, isoprenoids of general formula (H-CH2-C(CH3)=CH-CH2-)n-OH, any primary monohydroxy alcohol whose carbon skeleton consists of two or more isoprenoid residues linked head to tail.\" [GOC:curators]","metadata":null},{"id":"5a0342f9da7d4d13afca428ecf9dc9b2","type":"GO_TERM","name":"prenol catabolic process","canonical_id":"go:GO:0016092","description":"\"The chemical reactions and pathways resulting in the breakdown of prenols, isoprenoids of general formula (H-CH2-C(CH3)=CH-CH2-)n-OH, any primary monohydroxy alcohol whose carbon skeleton consists of two or more isoprenoid residues linked head to tail.\" [GOC:curators]","metadata":null},{"id":"1fc925170ea84a0895b01e28103f55fb","type":"GO_TERM","name":"prenol kinase activity","canonical_id":"go:GO:0052673","description":"\"Catalysis of the reaction: prenol + nucleoside triphosphate = prenyl phosphate + nucleoside diphosphate activity.\" [GOC:ai, GOC:kd]","metadata":null},{"id":"f409a163f1164c86b76b1851d7e8bcbc","type":"GO_TERM","name":"prenyl diphosphate synthase activity","canonical_id":"go:GO:0120531","description":"\"Catalysis of chain elongation of prenyl diphosphate substrates via one or more condensation reactions with isopentenyl diphosphate to generate linear polymers with defined chain lengths.\" [PMID:12135472, PMID:26216239]","metadata":null},{"id":"84c001af7cc742e080d7d7c2bd68d687","type":"GO_TERM","name":"prenyl-FMNH2 binding","canonical_id":"go:GO:0120233","description":"\"Binding to prenyl-FMNH2, a flavin mononucleotide obtained by prenylation of the N-10 position of FMNH2 followed by cyclisation. An essential cofactor for the decarboxylase enzymes UbiD and Fdc1.\" [GOC:krc, PMID:25647642, PMID:26083743, PMID:26083754]","metadata":null},{"id":"795c7ad7e9ce40e6bd83ac3f575d5b8b","type":"GO_TERM","name":"prenyl-FMNH2 biosynthetic process","canonical_id":"go:GO:0120232","description":"\"The chemical reactions and pathways resulting in prenyl-FMNH2, an essential cofactor for the decarboxylase enzymes UbiD and Fdc1.\" [GOC:krc, PMID:25647642, PMID:26083743, PMID:26083754]","metadata":null},{"id":"5ce1563e47f641be8b6adc4f9b15eb42","type":"GO_TERM","name":"prenyl-diphosphatase activity","canonical_id":"go:GO:0050210","description":"\"Catalysis of the reaction: dimethylallyl diphosphate + H2O = diphosphate + prenol.\" [RHEA:21496]","metadata":null},{"id":"2682525d293443e2a74632c1c5b9f9b0","type":"GO_TERM","name":"prenylated protein catabolic process","canonical_id":"go:GO:0030327","description":"\"The chemical reactions and pathways resulting in the breakdown of prenylated proteins.\" [GOC:mah]","metadata":null},{"id":"e938fabb11804dd0924faa737607cdbf","type":"GO_TERM","name":"prenylation","canonical_id":"go:GO:0097354","description":"\"The covalent attachment of a prenyl group to a molecule; geranyl, farnesyl, or geranylgeranyl groups may be added.\" [GOC:di, PMID:18029206, PMID:21351751, PMID:22123822, PMID:22642693, PMID:22660767]","metadata":null},{"id":"d284bdbf5c1249e58f1dd734a029817d","type":"GO_TERM","name":"prenylcysteine biosynthetic process","canonical_id":"go:GO:0046311","description":"\"The chemical reactions and pathways resulting in the formation of prenylcysteine, 3-methyl-2-buten-1-yl-cysteine, a derivative of the amino acid cysteine formed by the covalent addition of a prenyl residue.\" [GOC:ai]","metadata":null},{"id":"0c6b74bbb28a432995a9d6ccd2ed3b29","type":"GO_TERM","name":"prenylcysteine catabolic process","canonical_id":"go:GO:0030328","description":"\"The chemical reactions and pathways resulting in the breakdown of prenylcysteine, 3-methyl-2-buten-1-yl-cysteine, a derivative of the amino acid cysteine formed by the covalent addition of a prenyl residue.\" [GOC:ai]","metadata":null},{"id":"ca6fd03ab95a4b3a8e12121746377cc7","type":"GO_TERM","name":"prenylcysteine methylesterase activity","canonical_id":"go:GO:0010296","description":"\"Catalysis of the reaction: protein C-terminal S-farnesyl-L-cysteine methyl ester + H2O = protein C-terminal S-farnesyl-L-cysteine + methanol + H+.\" [PMID:16870359, RHEA:48520]","metadata":null},{"id":"b2b00a7621ac4c638d1cfea3f06eec8e","type":"GO_TERM","name":"prenylcysteine oxidase activity","canonical_id":"go:GO:0001735","description":"\"Catalysis of the reaction: S-prenyl-L-cysteine + O2 + H2O = a prenal + L-cysteine + H2O2.\" [GOC:hjd, RHEA:53892]","metadata":null},{"id":"6868371ce52445a09541e7ba06110a70","type":"GO_TERM","name":"prenyltransferase activity","canonical_id":"go:GO:0004659","description":"\"Catalysis of the transfer of a prenyl group from one compound (donor) to another (acceptor).\" [GOC:mah]","metadata":null},{"id":"48ed2129d4114f96aa7ba4049da88229","type":"GO_TERM","name":"prephenate dehydratase activity","canonical_id":"go:GO:0004664","description":"\"Catalysis of the reaction: prephenate = phenylpyruvate + H2O + CO2.\" [EC:4.2.1.51]","metadata":null},{"id":"ac700de85ab14faf87424b38b866eb9d","type":"GO_TERM","name":"prephenate dehydrogenase (NAD+) activity","canonical_id":"go:GO:0008977","description":"\"Catalysis of the reaction: NAD+ + prephenate = (4-hydroxyphenyl)pyruvate + CO2 + NADH.\" [EC:1.3.1.12, RHEA:13869]","metadata":null},{"id":"558831f5f8e444be95b4edc1beee4b12","type":"GO_TERM","name":"prephenate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004665","description":"\"Catalysis of the reaction: NADP+ + prephenate = (4-hydroxyphenyl)pyruvate + CO2 + NADPH.\" [EC:1.3.1.13, RHEA:21640]","metadata":null},{"id":"4d30756501624da98ae3b686280087db","type":"GO_TERM","name":"prephenate(2-) biosynthetic process","canonical_id":"go:GO:1901747","description":"\"The chemical reactions and pathways resulting in the formation of prephenate(2-).\" [GOC:TermGenie, GOC:yaf, PMID:16752890, UniPathway:UPA00120]","metadata":null},{"id":"966654beaf5b41bebca2771088c43cad","type":"GO_TERM","name":"prephenate(2-) catabolic process","canonical_id":"go:GO:1901746","description":"\"The chemical reactions and pathways resulting in the breakdown of prephenate(2-).\" [GOC:TermGenie, GOC:yaf, PMID:16752890]","metadata":null},{"id":"4da37c10f62248fea0e5acd4cc6f5a06","type":"GO_TERM","name":"preprophase band","canonical_id":"go:GO:0009574","description":"\"A dense band of microtubules, 1-3 pm wide, that appears just beneath the cell membrane before the start of cell division in the cells of higher plants. It precedes the onset of prophase and then disappears as mitosis begins, yet it somehow determines the plane of orientation of the new cell plate forming in late telophase and marks the zone of the parental cell wall where fusion with the growing cell plate ultimately occurs.\" [ISBN:0198506732]","metadata":null},{"id":"b10f059302604b9f84f9b191fe193f18","type":"GO_TERM","name":"preprophase band assembly","canonical_id":"go:GO:0000913","description":"\"The aggregation, arrangement and bonding together of a set of components to form the preprophase band, a dense band of microtubules that marks the position in the cell where cytokinesis will occur in cells that perform cytokinesis by cell plate formation.\" [GOC:clt, GOC:mah]","metadata":null},{"id":"7b0aba78bfc44c36b2b8cd3f4e6488b1","type":"GO_TERM","name":"preprotein binding","canonical_id":"go:GO:0070678","description":"\"Binding to a preprotein, the unprocessed form of a protein destined to undergo co- or post-translational processing.\" [GOC:imk, GOC:mah, PMID:12914940]","metadata":null},{"id":"ad9ceb969d2f4b56b9f9f2a27552cdc5","type":"GO_TERM","name":"prepulse inhibition","canonical_id":"go:GO:0060134","description":"\"The process in which a startle magnitude is reduced when the startling stimulus is preceded by a low-intensity prepulse.\" [GOC:dph, PMID:10341260]","metadata":null},{"id":"e5dcdb0e38764e2089564f1a27ff1fbd","type":"GO_TERM","name":"prepupal development","canonical_id":"go:GO:0035210","description":"\"The process whose specific outcome is the progression of the prepupa over time, from its formation to the mature structure. The prepupal stage is a life stage interposed between the larval and the pupal stages in insects that undergo a complete metamorphosis. The start of the pre-pupal stage is marked by pupariation, and the end is marked by pupation.\" [GOC:mtg_sensu, http://sdb.bio.purdue.edu/fly/aimain/1adult.htm]","metadata":null},{"id":"ce12f9db7f9e4ef2a2348023b9bd3917","type":"GO_TERM","name":"preribosome","canonical_id":"go:GO:0030684","description":"\"Any complex of pre-rRNAs, ribosomal proteins, and associated proteins formed during ribosome biogenesis.\" [PMID:10567516]","metadata":null},{"id":"af0fcb0b691f41259b70028db45dbd88","type":"GO_TERM","name":"preribosome binding","canonical_id":"go:GO:1990275","description":"\"Binding to a preribosome.\" [GOC:di, PMID:22735702]","metadata":null},{"id":"7b7ec1d730c0458286d5adbed708e189","type":"GO_TERM","name":"preribosome, large subunit precursor","canonical_id":"go:GO:0030687","description":"\"A preribosomal complex consisting of 27SA, 27SB, and/or 7S pre-rRNA, 5S rRNA, ribosomal proteins including late-associating large subunit proteins, and associated proteins; a precursor of the eukaryotic cytoplasmic large ribosomal subunit.\" [PMID:10567516]","metadata":null},{"id":"2bb3ffa42b484c62822f5b7f97792f94","type":"GO_TERM","name":"preribosome, small subunit precursor","canonical_id":"go:GO:0030688","description":"\"A preribosomal complex consisting of 20S pre-rRNA, ribosomal proteins including late-associating small subunit proteins, and associated proteins; a precursor of the eukaryotic cytoplasmic small ribosomal subunit.\" [PMID:10567516]","metadata":null},{"id":"2cfdb1aa3c1640eb8d11425d0dff2d08","type":"GO_TERM","name":"prespliceosome","canonical_id":"go:GO:0071010","description":"\"A spliceosomal complex that is formed by association of the 5' splice site and the branch point sequence with specific snRNPs. The prespliceosome includes many proteins in addition to those found in the bound snRNPs. Commitment to a given pair of 5' and 3' splice sites occurs at the time of prespliceosome formation. Prespliceosome complexes are not active for splicing, but are instead an early step in the assembly of a spliceosomal complex.\" [GOC:ab, GOC:krc, GOC:mah, PMID:17332742, PMID:19239890]","metadata":null},{"id":"e2f3707cf1b44b2883b44753d3427581","type":"GO_TERM","name":"pressure natriuresis","canonical_id":"go:GO:0003095","description":"\"The process in which the volume of blood increases renal pressure and thereby results in both an increase in urine volume (diuresis) and an increase in the amount of sodium excreted in the urine (natriuresis).\" [GOC:mtg_cardio]","metadata":null},{"id":"b9af1f432cb04fb6963364843685b29d","type":"GO_TERM","name":"presynapse","canonical_id":"go:GO:0098793","description":"\"The part of a synapse that is part of the presynaptic cell.\" [GOC:dos]","metadata":null},{"id":"002d4991a89a422f9066bc5f461b3aed","type":"GO_TERM","name":"presynapse assembly","canonical_id":"go:GO:0099054","description":"\"The aggregation, arrangement and bonding together of a set of components to form a presynapse.\" [GOC:bf, GOC:dos, GOC:PARL, PMID:24449494]","metadata":null},{"id":"383f499abe15424eabb50a4da16255db","type":"GO_TERM","name":"presynapse organization","canonical_id":"go:GO:0099172","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a presynapse.\" [GOC:dos]","metadata":null},{"id":"9e5656179bea4042b4b6ffc7293fe0d1","type":"GO_TERM","name":"presynapse to nucleus signaling pathway","canonical_id":"go:GO:0099526","description":"\"The series of molecular signals that conveys information from the presynapse to the nucleus via cytoskeletal transport of a protein from a presynapse to the component to the nucleus where it affects biochemical processes that occur in the nucleus (e.g DNA transcription, mRNA splicing, or DNA/histone modifications).\" [GOC:dos, PMID:24317321, PMID:25652077]","metadata":null},{"id":"525ef58efc1e4623b52a0851ba01434a","type":"GO_TERM","name":"presynaptic actin cytoskeleton","canonical_id":"go:GO:0099143","description":"\"The actin cytoskeleton that is part of a presynapse.\" [GOC:dos]","metadata":null},{"id":"08fef0396c1349c3a80ef522ce3973ea","type":"GO_TERM","name":"presynaptic actin cytoskeleton organization","canonical_id":"go:GO:0099140","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins in the presynaptic actin cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"6769c0d112d34ea79a13bd0421e60dd1","type":"GO_TERM","name":"presynaptic active zone","canonical_id":"go:GO:0048786","description":"\"A specialized region of the plasma membrane and cell cortex of a presynaptic neuron; encompasses a region of the plasma membrane where synaptic vesicles dock and fuse, and a specialized cortical cytoskeletal matrix.\" [GOC:dh, GOC:dl, GOC:ef, GOC:jid, GOC:pr, PMID:3152289]","metadata":null},{"id":"5caee2ef7d454bb28a4a92818db3d1b4","type":"GO_TERM","name":"presynaptic active zone assembly","canonical_id":"go:GO:1904071","description":"\"The aggregation, arrangement and bonding together of a set of components to form a presynaptic active zone. The presynaptic active zone is a specialized region of the plasma membrane and cell cortex of a presynaptic neuron; encompasses a region of the plasma membrane where synaptic vesicles dock and fuse, and a specialized cortical cytoskeletal matrix.\" [GO_REF:0000079, GOC:pr, GOC:TermGenie, PMID:10769383]","metadata":null},{"id":"5ad9ebe5962b4e0fa8c075dc31a7368d","type":"GO_TERM","name":"presynaptic active zone cytoplasmic component","canonical_id":"go:GO:0098831","description":"\"A specialized region below the presynaptic membrane, characterized by electron-dense material, a specialized cytoskeletal matrix and accumulated (associated) synaptic vesicles.\" [GOC:dos]","metadata":null},{"id":"f3021b7ce9a14616859ca961c5e8d7f8","type":"GO_TERM","name":"presynaptic active zone dense projection","canonical_id":"go:GO:0097445","description":"\"Electron dense projection extending from the cytomatrix into the cytoplasm on which synaptic vesicles are tethered.\" [NIF_Subcellular:sao494258938, PMID:15381754]","metadata":null},{"id":"59ec1e713a904b00bce4d54ea94efdf4","type":"GO_TERM","name":"presynaptic active zone disassembly","canonical_id":"go:GO:1904072","description":"\"The disaggregation of a presynaptic active zone into its constituent components.\" [GO_REF:0000079, GOC:pr, GOC:TermGenie, ISBN:9780387325606]","metadata":null},{"id":"5cb4193f2c7544d296770cbc939d9bb4","type":"GO_TERM","name":"presynaptic active zone membrane","canonical_id":"go:GO:0048787","description":"\"The membrane portion of the presynaptic active zone; it is the site where docking and fusion of synaptic vesicles occurs for the release of neurotransmitters.\" [PMID:12812759, PMID:12923177, PMID:3152289]","metadata":null},{"id":"5d6dc282a7c04491bbc647770ed5d8fa","type":"GO_TERM","name":"presynaptic active zone organization","canonical_id":"go:GO:1990709","description":"\"A process that results in the assembly, arrangement of constituent parts, or disassembly of a presynaptic active zone.\" [GOC:pr, PMID:16865347, PMID:17068967]","metadata":null},{"id":"bed46cdbc6aa478aa5fa1daddd7f4126","type":"GO_TERM","name":"presynaptic cytoskeleton","canonical_id":"go:GO:0099569","description":"\"The portion of the cytoskeleton contained within the presynapse.\" [GOC:dos]","metadata":null},{"id":"b3a5dec852ac4d1fa8d81fa1fddb4023","type":"GO_TERM","name":"presynaptic cytoskeleton organization","canonical_id":"go:GO:0099187","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures and their associated proteins in the presynaptic cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"3c344eeb6b6b46b38686c478beffb1fb","type":"GO_TERM","name":"presynaptic cytosol","canonical_id":"go:GO:0099523","description":"\"The region of the cytosol consisting of all cytosol that is part of the presynapse.\" [GOC:dos]","metadata":null},{"id":"f8a71edcf3cb4ffe901fddc0e2e34099","type":"GO_TERM","name":"presynaptic dense core vesicle exocytosis","canonical_id":"go:GO:0099525","description":"\"The secretion of molecules (e.g. neuropeptides and neuromodulators such as serotonin and dopamine) contained within a membrane-bounced dense in response to increased presynaptic cytosolic calcium levels.\" [PMID:17553987, PMID:24653208]","metadata":null},{"id":"a9de07188d8f49938aa9f31648340e99","type":"GO_TERM","name":"presynaptic density","canonical_id":"go:GO:0098980","description":"\"An electron dense specialization of the presynaptic active zone cytoskeleton.\" [GOC:dos, PMID:26780543]","metadata":null},{"id":"f4a59054144842f993377da744d0a380","type":"GO_TERM","name":"presynaptic endocytic zone","canonical_id":"go:GO:0098833","description":"\"A specialized region of the plasma membrane and underlying cytoplasm which surround the the active zone, into which synaptic vesicle membranes are recycled following exocytosis. It is especially enriched in endocytic proteins following intense activity.\" [PMID:17455288]","metadata":null},{"id":"119e4c228a8d46659fa257fc53459b3d","type":"GO_TERM","name":"presynaptic endocytic zone cytoplasmic component","canonical_id":"go:GO:0098834","description":"\"The cytoplasmic component of the presynaptic endocytic zone.\" [GOC:dos]","metadata":null},{"id":"790f1d1f24c34b878f2956f266277906","type":"GO_TERM","name":"presynaptic endocytic zone membrane","canonical_id":"go:GO:0098835","description":"\"The region of the presynaptic membrane that is part of the presynaptic endocytic zone - where synaptic vesicles are endocytosed and recycled following release.\" [GOC:dos]","metadata":null},{"id":"758b4e75e2a04d749f48af59e6117dd1","type":"GO_TERM","name":"presynaptic endocytosis","canonical_id":"go:GO:0140238","description":"\"A vesicle-mediated transport process in which the presynapse take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.\" [PMID:24719103]","metadata":null},{"id":"047a47d49ab54c3c99e95e1883a0392a","type":"GO_TERM","name":"presynaptic endosome","canonical_id":"go:GO:0098830","description":"\"An endosome present in the presynapse that fuses with endocytic vesicles arising in the presynaptic endocytic zone. This organelle is believed to be involved in regeneration of synaptic vesicles.\" [PMID:20200227, PMID:25939282]","metadata":null},{"id":"b650fdbaaebe4e26b7c5f40e39f2cbb5","type":"GO_TERM","name":"presynaptic endosome membrane","canonical_id":"go:GO:0098954","description":"\"The lipid bilayer surrounding a presynaptic endosome.\" [GOC:pz]","metadata":null},{"id":"7b239087c6de4fdf9a174ccbbdab391e","type":"GO_TERM","name":"presynaptic grid","canonical_id":"go:GO:1990013","description":"\"A hexagonal array of electron dense particles attached to the cytoplasmic face of the presynaptic membrane.\" [ISBN:0716723808, NIF_Subcellular:sao1730664005]","metadata":null},{"id":"2a5e19565e844ca4b37458629acf925c","type":"GO_TERM","name":"presynaptic intermediate filament cytoskeleton","canonical_id":"go:GO:0099182","description":"\"The intermediate filament cytoskeleton that is part of a presynapse.\" [GOC:dos]","metadata":null},{"id":"bb675f261c014470934a7d816e50ae5b","type":"GO_TERM","name":"presynaptic membrane","canonical_id":"go:GO:0042734","description":"\"A specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane.\" [GOC:jl, ISBN:0815316194]","metadata":null},{"id":"64c20db161d4420a8da8a54abb13c6f3","type":"GO_TERM","name":"presynaptic membrane assembly","canonical_id":"go:GO:0097105","description":"\"The aggregation, arrangement and bonding together of a set of components to form a presynaptic membrane, including any proteins associated with the membrane, but excluding other cellular components. A presynaptic membrane is a specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction.\" [GOC:BHF, GOC:pr, GOC:sjp, PMID:15797875, PMID:18550748]","metadata":null},{"id":"e4ecf0f29af249c5bb807462977c938e","type":"GO_TERM","name":"presynaptic membrane organization","canonical_id":"go:GO:0097090","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of a presynaptic membrane, including any proteins associated with the membrane, but excluding other cellular components. A presynaptic membrane is a specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction.\" [GOC:BHF, GOC:pr, GOC:sjp, PMID:19730411]","metadata":null},{"id":"41025c2cf37a451989cb02f68bc5ce22","type":"GO_TERM","name":"presynaptic modulation of chemical synaptic transmission","canonical_id":"go:GO:0099171","description":"\"Any process, acting in the presynapse that results in modulation of chemical synaptic transmission.\" [GOC:dos]","metadata":null},{"id":"16d63a42a79045beaf226c9b5f6cd643","type":"GO_TERM","name":"presynaptic periactive zone","canonical_id":"go:GO:0036062","description":"\"A region that surrounds the active zone of the presynaptic plasma membrane, and is specialized for the control of synaptic development.\" [GOC:sart, PMID:10976048, PMID:18439406]","metadata":null},{"id":"ef6830fcdb8c4938be38fafa03611ad4","type":"GO_TERM","name":"presynaptic signal transduction","canonical_id":"go:GO:0098928","description":"\"Signal transduction in which the initial step occurs in a presynapse.\" [GOC:dos]","metadata":null},{"id":"35c24c5ef06444ee94345b422797f138","type":"GO_TERM","name":"prevention of polyspermy","canonical_id":"go:GO:0060468","description":"\"The negative regulation of fertilization process that takes place as part of egg activation, ensuring that only a single sperm fertilizes the egg.\" [GOC:dph]","metadata":null},{"id":"36571845be4142b7a46d172edadce9d6","type":"GO_TERM","name":"prevention of polyspermy during double fertilization","canonical_id":"go:GO:0160071","description":"\"The regulation of double fertilization forming a zygote and endosperm process that ensures that only a single sperm cell fertilizes one egg cell and another single sperm cell fertilizes one central cell.\" [PMID:27951463]","metadata":null},{"id":"f1ea9a36a4444ba187d1f3240551fb8d","type":"GO_TERM","name":"priRNA 3'-end processing","canonical_id":"go:GO:1990431","description":"\"The process of forming the mature 3' end of a priRNA molecule.\" [PMID:24095277]","metadata":null},{"id":"2b81b975130748a7b7adbe419c4f565b","type":"DRUG","name":"primaquine","canonical_id":"mesh:D011319","description":null,"metadata":null},{"id":"67d73908f6b94a9d842d84611fcfc522","type":"GO_TERM","name":"primary active transmembrane transporter activity","canonical_id":"go:GO:0015399","description":"\"Enables the transfer of a solute from one side of a membrane to the other, up the solute's concentration gradient, by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction and is powered by a primary energy source. Primary energy sources known to be coupled to transport are chemical such as ATP hydrolysis, redox energy and photon energy.\" [GOC:mtg_transport, PMID:31613498]","metadata":null},{"id":"e7f8cc0401a24d269d095af44e386d97","type":"GO_TERM","name":"primary adaptive immune response","canonical_id":"go:GO:0090720","description":"\"An adaptive immune response against an antigen not previously encountered by immune system.\" [GOC:add, PMID:26831526]","metadata":null},{"id":"89274b20b55747f19a84724262e8a6f0","type":"GO_TERM","name":"primary adaptive immune response involving T cells and B cells","canonical_id":"go:GO:0090721","description":"\"An adaptive immune response mediated by naive T or B cells against an antigen not previously encountered by immune system.\" [GOC:add, PMID:26831526]","metadata":null},{"id":"ebec1c740f4e410792b4ffd4b8430be8","type":"DISEASE","name":"primary adrenal insufficiency","canonical_id":"mondo:0015128","description":null,"metadata":null},{"id":"a1360f90578347eba4aaa6ba0503aff6","type":"GO_TERM","name":"primary alcohol biosynthetic process","canonical_id":"go:GO:0034309","description":"\"The chemical reactions and pathways resulting in the formation of primary alcohols. A primary alcohol is any alcohol in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.\" [GOC:mah]","metadata":null},{"id":"62b68ca190d94cb088adacce4851dd8b","type":"GO_TERM","name":"primary alcohol catabolic process","canonical_id":"go:GO:0034310","description":"\"The chemical reactions and pathways resulting in the breakdown of primary alcohols. A primary alcohol is any alcohol in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.\" [GOC:mah]","metadata":null},{"id":"9d026854a1124046b8071012b2a35b3a","type":"GO_TERM","name":"primary alcohol metabolic process","canonical_id":"go:GO:0034308","description":"\"The chemical reactions and pathways involving primary alcohols. A primary alcohol is any alcohol in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.\" [GOC:mah]","metadata":null},{"id":"1ccbbcb37ebd48aeb29f99beded8a26c","type":"GO_TERM","name":"primary amine secretion","canonical_id":"go:GO:0061531","description":"\"The regulated release of a primary amine by a cell.\" [GOC:dph]","metadata":null},{"id":"802a9562ddca4ce38f8ead116445baf6","type":"GO_TERM","name":"primary amine secretion, neurotransmission","canonical_id":"go:GO:0061532","description":"\"The regulated release of a primary amine by a cell, in which the primary amine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"cb515ac2c5bd4d28aa417e4959baeccc","type":"GO_TERM","name":"primary amino compound biosynthetic process","canonical_id":"go:GO:1901162","description":"\"The chemical reactions and pathways resulting in the formation of primary amino compound.\" [GOC:TermGenie]","metadata":null},{"id":"2577fff7fb8641f298c1fcdc5b51d8e6","type":"GO_TERM","name":"primary amino compound catabolic process","canonical_id":"go:GO:1901161","description":"\"The chemical reactions and pathways resulting in the breakdown of primary amino compound.\" [GOC:TermGenie]","metadata":null},{"id":"64b5cfcebe394159b61385c7491e664e","type":"DISEASE","name":"primary biliary cholangitis","canonical_id":"mondo:0005388","description":null,"metadata":null},{"id":"c128b22ef9f74a7da5bc97a3a16dcbd0","type":"GO_TERM","name":"primary branching, open tracheal system","canonical_id":"go:GO:0007428","description":"\"Formation of primary branches in the open tracheal system. These form from small groups of cells that migrate out at specific positions, organizing into tubes as they migrate. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:29844090]","metadata":null},{"id":"8bf11f9f9e2341789bf69aba8de8426b","type":"GO_TERM","name":"primary cell septum","canonical_id":"go:GO:0000936","description":"\"A cell septum that forms following nuclear division.\" [GOC:clt, ISBN:0471940526]","metadata":null},{"id":"e925d4dc5e1a4da49c38dc16bec9e04b","type":"GO_TERM","name":"primary cell septum biogenesis","canonical_id":"go:GO:0031671","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a primary cell septum following nuclear division.\" [GOC:jl]","metadata":null},{"id":"dc856e140dfe4958b3799378b113cdfd","type":"GO_TERM","name":"primary cell septum disassembly","canonical_id":"go:GO:0030994","description":"\"Dissolution of the primary septum during cell separation.\" [PMID:12665550]","metadata":null},{"id":"5704e8d8b4dd42379d84b09e6c4f9e4d","type":"GO_TERM","name":"primary cell wall","canonical_id":"go:GO:0009530","description":"\"A plant cell wall that is still able to expand, permitting cell growth. Primary cell walls contain more pectin than secondary walls and no lignin is present.\" [GOC:jid, PMID:39878232, PMID:9442872]","metadata":null},{"id":"145b6bf3ba7e4d1b8523d0f509047304","type":"GO_TERM","name":"primary cell wall cellulose synthase complex","canonical_id":"go:GO:0044567","description":"\"A large, multimeric protein complex which catalyzes the biosynthesis of cellulose for the plant primary cell wall. In Arabidopsis, contains the essential component proteins CESA1 and -3, and a CESA6-related protein.\" [GOC:mengo_curators, GOC:tt, PMID:17878302, PMID:21307367]","metadata":null},{"id":"534e6da6fbe34fc5be8c9ba40114559c","type":"DISEASE","name":"primary cutaneous T-cell non-Hodgkin lymphoma","canonical_id":"mondo:0000607","description":null,"metadata":null},{"id":"8cdfd966d78d49edb4e533ac2367a577","type":"GO_TERM","name":"primary dendrite","canonical_id":"go:GO:0150001","description":"\"A dendrite emerging from the cell body (the soma) of a neuron.\" [GOC:aruk, GOC:bc]","metadata":null},{"id":"fdd1ddb79ad34c7682103ab0db6f588e","type":"GO_TERM","name":"primary endosperm nucleus","canonical_id":"go:GO:0048353","description":"\"Nucleus resulting from the fusion of the male gamete and two polar nuclei in the central cell of the embryo sac.\" [ISBN:0471245208]","metadata":null},{"id":"156f1d45edd34f41965dfdfb5c0cc6ac","type":"DISEASE","name":"primary erythermalgia","canonical_id":"mondo:0007571","description":null,"metadata":null},{"id":"6385d8f67d3f49ff97923bcf1dbc979d","type":"DISEASE","name":"primary failure of tooth eruption","canonical_id":"mondo:0007434","description":null,"metadata":null},{"id":"e05b0ea6ddf942ef9a8afd2ef8643faf","type":"DISEASE","name":"primary familial polycythemia due to EPO receptor mutation","canonical_id":"mondo:0007572","description":null,"metadata":null},{"id":"7b5a8fb9ffad449dae917c3aad523d9f","type":"GO_TERM","name":"primary fluorescent dioxobilin-type chlorophyll catabolite methylesterase activity","canonical_id":"go:GO:0106372","description":"\"Catalysis of the reaction: H2O + primary fluorescent dioxobilin-type chlorophyll catabolite = H+ + methanol + O13(4)-desmethyl pFCC.\" [PMID:23723324, RHEA:67176]","metadata":null},{"id":"f705a94297fd4d29b2458f84216c15cc","type":"GO_TERM","name":"primary follicle stage","canonical_id":"go:GO:0048160","description":"\"The stage in oogenesis when a single layer of cuboidal follicle cells surrounds the oocyte. The oocyte nucleus is large.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"933cb5d936044220a71a720ae0eac194","type":"GO_TERM","name":"primary growth","canonical_id":"go:GO:0080189","description":"\"Growth of a plant structure from the time of its initiation by an apical meristem until its expansion is completed.\" [ISBN:0471245208]","metadata":null},{"id":"c084a21e216c474f8f040ce6d852678f","type":"GO_TERM","name":"primary heart field specification","canonical_id":"go:GO:0003138","description":"\"The process that results in the delineation of a specific region of the lateral mesoderm into the area which will form the primary beating heart tube. In mammals the primary heart field gives rise to the left ventricle.\" [GOC:mtg_heart, GOC:rl]","metadata":null},{"id":"66c2bbc28fd742cc8a5a75bc26699cd1","type":"DISEASE","name":"primary hyperparathyroidism","canonical_id":"mondo:0010837","description":null,"metadata":null},{"id":"3b5026da246749f6b47448891093e45f","type":"GO_TERM","name":"primary leaflet morphogenesis","canonical_id":"go:GO:0060778","description":"\"The process in which the primary leaflet attains its shape. A primary leaflet is a leaflet that develops directly from the rachis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"6fce3a087d4b4e50b3aaf5f784c15aba","type":"GO_TERM","name":"primary lung bud formation","canonical_id":"go:GO:0060431","description":"\"The morphogenetic process in which the foregut region specified to become the lung forms the initial left and right buds.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"a48e4deb38a7429d97ff80519a6c89a8","type":"GO_TERM","name":"primary lysosome","canonical_id":"go:GO:0005766","description":"\"A lysosome before it has fused with a vesicle or vacuole.\" [GOC:jl, ISBN:0815316194]","metadata":null},{"id":"513698f5ca0a4af5b1b2626e08999884","type":"GO_TERM","name":"primary meristem tissue development","canonical_id":"go:GO:0010065","description":"\"The process whose specific outcome is the progression of the primary meristem over time, from formation to the mature structure, as it occurs during plant embryogenesis. The primary meristem tissue is the protoderm, ground meristem and procambium.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"99387f31ab8c4348b4ad18506695bc6b","type":"GO_TERM","name":"primary metabolic process","canonical_id":"go:GO:0044238","description":"\"The chemical reactions and pathways involving those compounds which are formed as a part of the normal anabolic and catabolic processes. These processes take place in most, if not all, cells of the organism.\" [GOC:curators]","metadata":null},{"id":"6dbb95204e1242afa7a72e0e50d2fb80","type":"GO_TERM","name":"primary methylamine oxidase activity","canonical_id":"go:GO:0008131","description":"\"Catalysis of the reaction: a primary methyl amine + H2O + O2 = an aldehyde + H2O2 + NH4+.\" [RHEA:16153]","metadata":null},{"id":"eedd593348aa46b2a5b6f901925815bb","type":"GO_TERM","name":"primary miRNA binding","canonical_id":"go:GO:0070878","description":"\"Binding to a primary microRNA (pri-miRNA) transcript, an RNA molecule that is processed into a short hairpin-shaped structure called a pre-miRNA and finally into a functional miRNA. Both double-stranded and single-stranded regions of a pri-miRNA are required for binding.\" [GOC:sl, PMID:15531877, PMID:15574589]","metadata":null},{"id":"417fef38c4534942b8ac11d698335386","type":"GO_TERM","name":"primary miRNA processing","canonical_id":"go:GO:0031053","description":"\"A process involved in the conversion of a primary microRNA transcript into a pre-microRNA molecule.\" [GOC:sl, PMID:15211354, PMID:25799998]","metadata":null},{"id":"69774b3e03854f54a35ba73310e02ff9","type":"DISEASE","name":"primary myelofibrosis","canonical_id":"mondo:0009692","description":null,"metadata":null},{"id":"38234f7230d8436dbafeb698e8e109fc","type":"GO_TERM","name":"primary neural tube formation","canonical_id":"go:GO:0014020","description":"\"The formation of the neural tube from an epithelial cell sheet (the neuroepithelium or neural plate). In primary neurulation, the cells surrounding the neural plate direct the neural plate cells to proliferate, invaginate, and pinch off from the surface to form a hollow epithelial tube. Primary neurulation is the typical mechanism of formation of the anterior neural tube.\" [GOC:ef, ISBN:0878932585, PMID:15327780]","metadata":null},{"id":"b91cb8969d1c41f5bc1fd6be641e57cb","type":"GO_TERM","name":"primary oocyte stage","canonical_id":"go:GO:0048159","description":"\"The stage in oogenesis when the oocyte has a nucleus slightly larger than those of the adjacent cells and is surrounded by a layer of loose squamous epithelial cells.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"371498097f6c454bafdbc1052c734454","type":"DISEASE","name":"primary ovarian failure","canonical_id":"mondo:0005387","description":null,"metadata":null},{"id":"87e4dfdcc59045de961b3a69e2160349","type":"DISEASE","name":"primary ovarian failure","canonical_id":"mesh:D016649","description":null,"metadata":null},{"id":"a539564d96604af285c508b817ba2a77","type":"GO_TERM","name":"primary ovarian follicle growth","canonical_id":"go:GO:0001545","description":"\"Increase in size of primary follicles including oocyte growth and granulosa and/or theca cell proliferation until more than one layer of granulosa cells is present (preantral follicle).\" [GOC:mtg_mpo, https://www.ncbi.nlm.nih.gov/books/NBK279054/]","metadata":null},{"id":"f68f2acfe7884da9a2f083b466b6e3d7","type":"GO_TERM","name":"primary palate development","canonical_id":"go:GO:1903929","description":"\"The process whose specific outcome is the progression of a primary palate over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:mgi_curators, GOC:TermGenie, PMID:24644145, PMID:25504820]","metadata":null},{"id":"6ad1cc1e6a0148dd8ebdf1c358b7fc45","type":"DISEASE","name":"primary peritoneal carcinoma","canonical_id":"mondo:0015686","description":null,"metadata":null},{"id":"126fd9884f714eaeb185c15f84aaca4c","type":"GO_TERM","name":"primary piRNA processing","canonical_id":"go:GO:0140990","description":"\"The process involved in converting precursor piRNAs into non-overlapping, contiguous primary piRNAs (approximately 24-30-nt piRNAs with a preference for a 5' uridine (U) via the endonucleolytic activity of cytosolic PIWI. This may include pre-piRNA maturation of 3' ends by trimming and 2'-O-methylation.\" [PMID:22907665, PMID:26166577, PMID:34469728]","metadata":null},{"id":"dd2ecd7187b243b1acbe444912f69f06","type":"GO_TERM","name":"primary plasmodesma","canonical_id":"go:GO:0009550","description":"\"A plasmodesma that consists of a simple, single channel; found predominantly in young tissue and formed as a function of cell plate formation during cytokinesis.\" [PMID:15012255]","metadata":null},{"id":"c1f1d9bc20904272b6be46ba26cc253d","type":"DISEASE","name":"primary progressive multiple sclerosis","canonical_id":"mondo:0000451","description":null,"metadata":null},{"id":"3468fab69dce4d48bfe4c5844d482521","type":"GO_TERM","name":"primary prostatic bud elongation","canonical_id":"go:GO:0060516","description":"\"The increase in size of the prostatic bud as it forms.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"e27f1c8cfa5f4c18962ade38922addf8","type":"GO_TERM","name":"primary root development","canonical_id":"go:GO:0080022","description":"\"The process whose specific outcome is the progression of the primary root over time, from its formation to the mature structure. The primary root develops directly from the embryonic radicle.\" [GOC:dhl]","metadata":null},{"id":"12ff92ad7a7c4d5bafb8f445e8b7f79d","type":"GO_TERM","name":"primary sex determination","canonical_id":"go:GO:0007538","description":"\"The sex determination process that results in the initial specification of sexual status of an individual organism.\" [GOC:mah]","metadata":null},{"id":"f9a9bb4fda5649159bf468a0bbe22e67","type":"GO_TERM","name":"primary sex determination, germ-line","canonical_id":"go:GO:0007542","description":"\"The transmission of information about sexual status, from the initial general determination, to signals specific to the germ-line.\" [GOC:ems]","metadata":null},{"id":"754f6d6bd3a64202b543f33cd41af6e6","type":"GO_TERM","name":"primary sex determination, soma","canonical_id":"go:GO:0007539","description":"\"The transmission of information about sexual status from the initial, general, determination to signals specific to the soma.\" [GOC:ems]","metadata":null},{"id":"28ba64d769554b43a7c068f9437d99c5","type":"GO_TERM","name":"primary shoot apical meristem specification","canonical_id":"go:GO:0010072","description":"\"The specification of the meristem which will give rise to all post-embryonic above-ground structures of the plant as well as the non-root below-ground structures, such as rhizomes and tubers.\" [GOC:ascb_2009, GOC:dph, GOC:tair_curators, GOC:tb]","metadata":null},{"id":"86bccd72d11e4623bebea05fd22cfd5d","type":"DISEASE","name":"primary short bowel syndrome","canonical_id":"efo:0700081","description":null,"metadata":null},{"id":"fdac83a4cec645b59b610b965d931552","type":"GO_TERM","name":"primary spermatocyte growth","canonical_id":"go:GO:0007285","description":"\"The phase of growth and gene expression that male germ cells undergo as they enter the spermatocyte stage. The cells grow in volume and transcribe most of the gene products needed for the morphological events that follow meiosis.\" [GOC:jid, ISBN:0879694238]","metadata":null},{"id":"4c25173203364aefb8f4a5356bea82e0","type":"GO_TERM","name":"primary thickening","canonical_id":"go:GO:0080192","description":"\"Lateral growth of a plant axis (shoot axis or root) that is an increase in thickness resulting from the activity of a primary thickening meristem.\" [ISBN:0471245208, JSTOR:4354165, PO:0005039, PO:0025004]","metadata":null},{"id":"18c8b23128db4baa9313c9f7fb7f53f3","type":"GO_TERM","name":"primary ureteric bud growth","canonical_id":"go:GO:0060682","description":"\"The process in which the primary ureteric bud grows along its axis dorsally toward the metanephric blastema.\" [GOC:dph, PMID:16916378]","metadata":null},{"id":"b60ba5f82b93499b9f7c603bb23a6bed","type":"DRUG","name":"primidone","canonical_id":"mesh:D011324","description":null,"metadata":null},{"id":"0d7642fe460b44389bc36bbbeee09b75","type":"GO_TERM","name":"priming of cellular response to stress","canonical_id":"go:GO:0080136","description":"\"The process that enables cells to respond in a more rapid and robust manner than nonprimed cells to much lower levels of a stimulus indicating the organism is under stress.\" [PMID:19318610]","metadata":null},{"id":"726defcced464da9bd49102aa69f2101","type":"GO_TERM","name":"primitive erythrocyte differentiation","canonical_id":"go:GO:0060319","description":"\"Erythrocyte differentiation which occurs as part of the process of primitive hemopoiesis.\" [GOC:add, GOC:BHF, GOC:dph]","metadata":null},{"id":"5bf255cdaeaa4e44aaedc66374aff0b8","type":"GO_TERM","name":"primitive hemopoiesis","canonical_id":"go:GO:0060215","description":"\"A first transient wave of blood cell production that, in vertebrates, gives rise to erythrocytes (red blood cells) and myeloid cells.\" [GOC:bf, GOC:dph, PMID:15378083, PMID:15617691]","metadata":null},{"id":"acdbc0f129ee4b33a1f83340e17b93f5","type":"GO_TERM","name":"primitive palate development","canonical_id":"go:GO:0062010","description":"\"The biological process whose specific outcome is the progression of the primitive palate from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure.\" [GOC:dph]","metadata":null},{"id":"e4c8697ad9d14fe7abaad10c9c6b8a86","type":"GO_TERM","name":"primitive streak formation","canonical_id":"go:GO:0090009","description":"\"The developmental process pertaining to the initial formation of the primitive streak from unspecified parts. The primitive streak is a ridge of cells running along the midline of the embryo where the mesoderm ingresses. It defines the anterior-posterior axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"8ae3e773b757461d9688ff0128a9be0c","type":"GO_TERM","name":"primordial germ cell migration","canonical_id":"go:GO:0008354","description":"\"The orderly movement of a cell specialized to produce haploid gametes through the embryo from its site of production to the place where the gonads will form.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"fed517afde934f109335f87f682f60d5","type":"GO_TERM","name":"primosome complex","canonical_id":"go:GO:1990077","description":"\"Any of a family of protein complexes that form at the origin of replication or stalled replication forks and function in replication primer synthesis in all organisms. Early complexes initiate double-stranded DNA unwinding. The core unit consists of a replicative helicase and a primase. The helicase further unwinds the DNA and recruits the polymerase machinery. The primase synthesizes RNA primers that act as templates for complementary stand replication by the polymerase machinery. The primosome contains a number of associated proteins and protein complexes and contributes to the processes of replication initiation, lagging strand elongation, and replication restart.\" [GOC:bhm, GOC:mah, PMID:21856207]","metadata":null},{"id":"0721c96fa4a244ea895cacc821745dfc","type":"GO_TERM","name":"principal sensory nucleus of trigeminal nerve development","canonical_id":"go:GO:0021740","description":"\"The process whose specific outcome is the progression of the pontine nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"458897c47fbb47af9605ee4d2b94fbae","type":"GO_TERM","name":"pristanate-CoA ligase activity","canonical_id":"go:GO:0070251","description":"\"Catalysis of the reaction: ATP + pristanate + CoA = AMP + diphosphate + pristanoyl-CoA.\" [GOC:pde, PMID:10198260]","metadata":null},{"id":"3f9e31a7a9c74c7e9826584772334eb2","type":"GO_TERM","name":"pristanoyl-CoA oxidase activity","canonical_id":"go:GO:0016402","description":"\"Catalysis of the reaction: (2S)-pristanoyl-CoA + O2 = (2E)-pristenoyl-CoA + H2O2.\" [RHEA:40459]","metadata":null},{"id":"adb932e3d260421c8a6a7bf9ed7d55a2","type":"GO_TERM","name":"pro-B cell differentiation","canonical_id":"go:GO:0002328","description":"\"The process in which a precursor cell type acquires the specialized features of a pro-B cell. Pro-B cells are the earliest stage of the B cell lineage and undergo heavy chain D and J gene rearrangements, although they are not fully committed.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"dd5151710c4f465bae440390cb909c17","type":"GO_TERM","name":"pro-T cell differentiation","canonical_id":"go:GO:0002572","description":"\"The process in which a precursor cell type acquires the specialized features of a pro-T cell. Pro-T cells are the earliest stage of the T cell lineage but are not fully committed.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f9026c24505e46518f2b1cfd11bce613","type":"GO_TERM","name":"pro-T cell lineage commitment","canonical_id":"go:GO:0002680","description":"\"The process in which a lymphoid progenitor cell becomes committed to becoming a pro-T cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"8407b5a62fdb46ee8eb3e513a602db6a","type":"GO_TERM","name":"proacrosomal vesicle fusion","canonical_id":"go:GO:0120211","description":"\"Fusion of the membrane of proacrosomal vesicle with the membrane of another proacrosomal vesicle to form the acrosome.\" [GOC:krc, PMID:29991750]","metadata":null},{"id":"69074c313e214021b184bee4d235b30d","type":"GO_TERM","name":"proanthocyanidin biosynthetic process","canonical_id":"go:GO:0010023","description":"\"The chemical reactions and pathways resulting in the formation of proanthocyanidin.\" [GOC:lm]","metadata":null},{"id":"3dfce869110a490cbe9d2329aa9bb1d8","type":"DRUG","name":"probenecid","canonical_id":"gtopdb:4357","description":null,"metadata":null},{"id":"bdcdc75d8ce8403d85a512ec32f00c21","type":"DRUG","name":"probenecid","canonical_id":"chembl:CHEMBL897","description":null,"metadata":null},{"id":"c47019130fb2412a8cbe93f86c73eece","type":"COMBINATION_TREATMENT","name":"probenecid + verapamil","canonical_id":"ctgov_combo:ctgov-combo-c2eaee1e6142fdbf","description":null,"metadata":null},{"id":"fca2af4a754c48ff86e53e8b30f7f497","type":"GO_TERM","name":"proboscis development","canonical_id":"go:GO:0048728","description":"\"The process whose specific outcome is the progression of the proboscis over time, from its formation to the mature structure.\" [GOC:rc]","metadata":null},{"id":"83991baecf66426caaba6e99fc71ccc9","type":"GO_TERM","name":"proboscis extension reflex","canonical_id":"go:GO:0007637","description":"\"The extension, through direct muscle actions, of the proboscis (the trunk-like extension of the mouthparts on the adult external head) in response to a nutritional stimulus.\" [FB:FBrf0044924, GOC:jid]","metadata":null},{"id":"22151a0a2ba1417b9cb46c8db7c10d70","type":"GO_TERM","name":"proboscis morphogenesis","canonical_id":"go:GO:0048734","description":"\"The process in which the anatomical structures of the proboscis are generated and organized. The proboscis is the trunk-like extension of the mouthparts on the adult head.\" [GOC:jid, GOC:rc]","metadata":null},{"id":"0026da2bf75444d7b7f06606496290ef","type":"GO_TERM","name":"proboscis morphogenesis, clypeo-labral disc-derived","canonical_id":"go:GO:0010784","description":"\"The process in which the anatomical structures of the proboscis that are derived from the clypeo-labral disc are generated and organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"79509176a5544721a25387800cd694da","type":"GO_TERM","name":"proboscis morphogenesis, eye-antennal disc-derived","canonical_id":"go:GO:0010783","description":"\"The process in which the anatomical structures of the proboscis that are derived from the eye-antennal disc are generated and organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"90db489cfe3c40c38131ad3dd1f4bdb9","type":"GO_TERM","name":"proboscis morphogenesis, labial disc-derived","canonical_id":"go:GO:0010782","description":"\"The process in which the anatomical structures of the proboscis that are derived from the labial disc are generated and organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c7e49cffa1d648508cb9ead07744a500","type":"DRUG","name":"probucol","canonical_id":"gtopdb:7277","description":null,"metadata":null},{"id":"9c5f40f7e699466c8aa780f15c7558a5","type":"DRUG","name":"probucol","canonical_id":"mesh:D011341","description":null,"metadata":null},{"id":"a5b82fb4ce5d44dab29cd30638854deb","type":"DRUG","name":"probucol","canonical_id":"chembl:CHEMBL608","description":null,"metadata":null},{"id":"47a0df3f33404ecc850a1ac573e8a351","type":"GO_TERM","name":"procambium histogenesis","canonical_id":"go:GO:0010067","description":"\"The formation of the primary meristem or meristematic tissue that gives rise to the primary vascular tissue.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"63741b3754524c83977949aebf344482","type":"DRUG","name":"procarbazine","canonical_id":"mesh:D011344","description":null,"metadata":null},{"id":"e1314080824a4aada5e3910549843bf2","type":"DRUG","name":"procaterol","canonical_id":"gtopdb:3464","description":null,"metadata":null},{"id":"f4cffb680ab641fcafdab7295a6470a1","type":"DRUG","name":"procaterol","canonical_id":"chembl:CHEMBL160519","description":null,"metadata":null},{"id":"16eb3344382044ea8f0cc971a48f1be6","type":"GO_TERM","name":"procentriole","canonical_id":"go:GO:0120098","description":"\"A cellular structure that is the site of a developing centriole, which will become a microtubule organizing center. During the canonical pathway of centriole duplication that occurs during the cell division cycle, procentrioles grow at the proximal ends of both mother and daughter centrioles. In the newly divided cells, the original mother and daughter centrioles become mother centrioles while the procentrioles become the new daughter centrioles. Procentrioles can also arise from de novo pathways that occur in multiciliated cells. In ciliated epithelial cells, numerous procentrioles arise form electron dense material referred to as fibrous granules and deuterosomes. The pathway of procentriole formation in multiciliated protists appears to be similar to that in mammalian multiciliated epithelium. In sperm of primitive land plants, multiple procentrioles are formed from a blepharoplast giving rise to multicilated sperm cells.\" [GOC:bhm, GOC:krc, PMID:18620859, PMID:21289083, PMID:25047614]","metadata":null},{"id":"798bb2bf4d6f43db90a9a3b24596e5ea","type":"GO_TERM","name":"procentriole replication complex","canonical_id":"go:GO:0120099","description":"\"A protein complex that acts as a chaperone or scaffold for centriolar proteins during the maturation of the procentriole. Some of its members may become integrated into the growing centriole. Examples are the CPAP(CENPJ)-STIL complex, CEP192-PLK4 complex or CEP152-PLK4 complex in vertebrates.\" [GOC:bhm, PMID:17576815, PMID:18207742, PMID:21059844, PMID:22020124, PMID:24997597]","metadata":null},{"id":"cd561a729ebc42488a00f27528de303c","type":"GO_TERM","name":"process utilizing autophagic mechanism","canonical_id":"go:GO:0061919","description":"\"A cellular process involving delivery of a portion of the cytoplasm to lysosomes or to the plant or fungal vacuole that does not involve direct transport through the endocytic or vacuolar protein sorting (Vps) pathways. This process typically leads to degradation of the cargo; however, it can also be used to deliver resident proteins, such as in the cytoplasm-to-vacuole targeting (Cvt) pathway.\" [PMID:21997368, PMID:22966490, PMID:28596378]","metadata":null},{"id":"d9d5b11d775e41219d06bfaab180b1a3","type":"DRUG","name":"prochlorperazine","canonical_id":"gtopdb:7279","description":null,"metadata":null},{"id":"d3754752a7124a49856d631d59e42d3c","type":"DRUG","name":"prochlorperazine","canonical_id":"mesh:D011346","description":null,"metadata":null},{"id":"0dc97ba078894c25993cacff0447bd14","type":"DRUG","name":"prochlorperazine","canonical_id":"chembl:CHEMBL728","description":null,"metadata":null},{"id":"032ed4a8c4cf492fbf5b67050dc9db9c","type":"GO_TERM","name":"proclavaminate amidinohydrolase activity","canonical_id":"go:GO:0033972","description":"\"Catalysis of the reaction: amidinoproclavaminate + H2O = proclavaminate + urea.\" [EC:3.5.3.22, RHEA:17001]","metadata":null},{"id":"c13961b00373427c9c9baee131b4fb96","type":"GO_TERM","name":"procollagen galactosyltransferase activity","canonical_id":"go:GO:0050211","description":"\"Catalysis of the reaction: UDP-galactose + procollagen 5-hydroxy-L-lysine = UDP + procollagen 5-(D-galactosyloxy)-L-lysine.\" [EC:2.4.1.50, MetaCyc:PROCOLLAGEN-GALACTOSYLTRANSFERASE-RXN]","metadata":null},{"id":"35ac77a6387e452ab01fdc41c294d630","type":"GO_TERM","name":"procollagen glucosyltransferase activity","canonical_id":"go:GO:0033823","description":"\"Catalysis of the reaction: UDP-glucose + 5-(D-galactosyloxy)-L-lysine-procollagen = UDP + 1,2-D-glucosyl-5-D-(galactosyloxy)-L-lysine-procollagen.\" [EC:2.4.1.66]","metadata":null},{"id":"e73e2028c3fc4103b04fa976bedd1992","type":"GO_TERM","name":"procollagen-lysine 5-dioxygenase activity","canonical_id":"go:GO:0008475","description":"\"Catalysis of the reaction: L-lysyl-[collagen] + 2-oxoglutarate + O2 = (5R)-5-hydroxy-L-lysyl-[collagen] + succinate + CO2.\" [RHEA:16569]","metadata":null},{"id":"c2585879591e4492af9c3dcd095ed5c9","type":"GO_TERM","name":"procollagen-proline 3-dioxygenase activity","canonical_id":"go:GO:0019797","description":"\"Catalysis of the reaction: procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-3-hydroxy-L-proline + succinate + CO2.\" [EC:1.14.11.7, RHEA:22872]","metadata":null},{"id":"9d2943ad80d54a0fa1e2d524da47030e","type":"GO_TERM","name":"procollagen-proline 4-dioxygenase activity","canonical_id":"go:GO:0004656","description":"\"Catalysis of the reaction: procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-4-hydroxy-L-proline + succinate + CO2.\" [EC:1.14.11.2]","metadata":null},{"id":"f76f8fe09d954e4baa5e5cde3d8a848d","type":"GO_TERM","name":"procollagen-proline 4-dioxygenase complex","canonical_id":"go:GO:0016222","description":"\"A protein complex that catalyzes the formation of procollagen trans-4-hydroxy-L-proline and succinate from procollagen L-proline and 2-oxoglutarate, requiring Fe2+ and ascorbate. Contains two alpha subunits that contribute to most parts of the catalytic sites, and two beta subunits that are identical to protein-disulfide isomerase.\" [PMID:14500733, PMID:7753822]","metadata":null},{"id":"c85d0efd13354c0fbc70ca291c0f0fa9","type":"GO_TERM","name":"procollagen-proline 4-dioxygenase complex, alpha(I) type","canonical_id":"go:GO:0070386","description":"\"A procollagen-proline 4-dioxygenase complex that contains alpha subunits of the type I isoform; its activity is readily inhibited by poly(L-proline).\" [PMID:14500733, PMID:7753822]","metadata":null},{"id":"1baf2fb006d74a83b8b07cdab8ed9d7f","type":"GO_TERM","name":"procollagen-proline 4-dioxygenase complex, alpha(II) type","canonical_id":"go:GO:0070387","description":"\"A procollagen-proline 4-dioxygenase complex that contains alpha subunits of the type II isoform; its activity is inhibited by poly(L-proline) only at high concentrations.\" [PMID:14500733, PMID:7753822]","metadata":null},{"id":"221559ab5ef0491eb4a2fe387a65c1d0","type":"GO_TERM","name":"procollagen-proline 4-dioxygenase complex, alpha(III) type","canonical_id":"go:GO:0070388","description":"\"A procollagen-proline 4-dioxygenase complex that contains alpha subunits of the type III isoform.\" [PMID:14500733]","metadata":null},{"id":"af49a570627d47fcbf17222f0144446f","type":"GO_TERM","name":"procollagen-proline dioxygenase activity","canonical_id":"go:GO:0019798","description":"\"Catalysis of the reaction: procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-hydroxy-L-proline + succinate + CO2.\" [GOC:mah, PMID:4371784]","metadata":null},{"id":"5f794676d72f4a13b279361423e9665f","type":"DISEASE","name":"proctitis","canonical_id":"mondo:0005538","description":null,"metadata":null},{"id":"77a0b45f520049a5826b6b9ad9ae3632","type":"GO_TERM","name":"proctolin receptor activity","canonical_id":"go:GO:0035236","description":"\"Combining with the neuropeptide proctolin, to initiate a change in cell activity.\" [GOC:bf]","metadata":null},{"id":"4386ef43e8c340d89e3b4b8848bf8361","type":"GO_TERM","name":"proctolin receptor binding","canonical_id":"go:GO:0071860","description":"\"Binding to a proctolin receptor.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"518ddf64a1884d1986d09758aa0302e4","type":"GO_TERM","name":"procyclogenesis","canonical_id":"go:GO:0120324","description":"\"The morphological, biochemical and genetic changes that induce the differentiation of bloodstream form trypomastigotes into procyclic trypomastigotes in some of the Trypanosomatidae species such as Trypanosoma brucei. This process occurs inside the midgut of the tsetse fly vectors in T. brucei.\" [GOC:ach, PMID:10593184, PMID:1698624, PMID:17997129, PMID:3194362, PMID:3194363]","metadata":null},{"id":"160ec671c216428c99f7845a585bed2a","type":"GO_TERM","name":"production of molecular mediator involved in inflammatory response","canonical_id":"go:GO:0002532","description":"\"The synthesis or release of any molecular mediator of the inflammatory response following an inflammatory stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, GOC:dph, GOC:tb, ISBN:0781735149]","metadata":null},{"id":"89d3d21ce3d84537abab08e17727e911","type":"GO_TERM","name":"production of molecular mediator of immune response","canonical_id":"go:GO:0002440","description":"\"The synthesis or release of any molecular mediator of the immune response, resulting in an increase in its intracellular or extracellular levels.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"096b93e6a1314c12a897e8a2857484fe","type":"GO_TERM","name":"proepicardium cell migration involved in pericardium morphogenesis","canonical_id":"go:GO:0003345","description":"\"The coordinated movement of a mesenchymal proepicardial cell to the surface of the developing heart.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"e9ed2e84a7e249568144824b0a1e5376","type":"GO_TERM","name":"proepicardium development","canonical_id":"go:GO:0003342","description":"\"The progression of the proepicardium from its formation to the mature structure. The proepicardium is an outpouching of the septum transversum.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"c85ad359a0c442449ffd758af6863d30","type":"GO_TERM","name":"proestrus","canonical_id":"go:GO:0060208","description":"\"The estrous cycle phase in which there is heightened follicular activity.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"531bbb5f7b1d441795289b627835965c","type":"GO_TERM","name":"profilin binding","canonical_id":"go:GO:0005522","description":"\"Binding to profilin, an actin-binding protein that forms a complex with G-actin and prevents it from polymerizing to form F-actin.\" [ISBN:0721662544]","metadata":null},{"id":"c6051346f91141a6b2415fe10f0dcafb","type":"DRUG","name":"progesterone","canonical_id":"gtopdb:2377","description":null,"metadata":null},{"id":"2336930d6505484cbf9897dcf558b7e7","type":"DRUG","name":"progesterone","canonical_id":"chembl:CHEMBL103","description":null,"metadata":null},{"id":"7ff6f04480324eecaaf6ce209bb202da","type":"GO_TERM","name":"progesterone 11-alpha-monooxygenase activity","canonical_id":"go:GO:0050212","description":"\"Catalysis of the reaction: progesterone + reduced [NADPH-hemoprotein reductase] + O2 = 11alpha-hydroxyprogesterone + oxidized [NADPH-hemoprotein reductase] + H2O + H+.\" [PMID:39766209, RHEA:86055]","metadata":null},{"id":"ad13f28e4ca44eec99d19402587c829b","type":"GO_TERM","name":"progesterone 21-hydroxylase activity","canonical_id":"go:GO:0106309","description":"\"Catalysis of the reaction: O2 + progesterone + reduced [NADPH--hemoprotein reductase] = 21-hydroxyprogesterone + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [PMID:25855791, RHEA:50304]","metadata":null},{"id":"2b2c45a5015c4b96ae48a3d1cc9a238c","type":"GO_TERM","name":"progesterone biosynthetic process","canonical_id":"go:GO:0006701","description":"\"The chemical reactions and pathways resulting in the formation of progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants.\" [GOC:jl, PMID:14613534]","metadata":null},{"id":"d8ae900e0ad04ddb9e66ed22d67d636a","type":"GO_TERM","name":"progesterone catabolic process","canonical_id":"go:GO:0006709","description":"\"The chemical reactions and pathways resulting in the breakdown of progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants.\" [GOC:jl, PMID:11392024]","metadata":null},{"id":"e634da73081c44a0b29f3c677e6ab7f4","type":"GO_TERM","name":"progesterone metabolic process","canonical_id":"go:GO:0042448","description":"\"The chemical reactions and pathways involving progesterone, a steroid hormone produced in the ovary which prepares and maintains the uterus for pregnancy. Also found in plants.\" [GOC:jl, PMID:11392024]","metadata":null},{"id":"4552aec1f77f411d999c4b452a943c08","type":"GO_TERM","name":"progesterone monooxygenase activity","canonical_id":"go:GO:0050214","description":"\"Catalysis of the reaction: AH2 + O2 + progesterone = A + H2O + testosterone acetate.\" [PMID:5950688, RHEA:11984]","metadata":null},{"id":"4b3beab346844c04bc6aecba3742d737","type":"GO_TERM","name":"progesterone receptor signaling pathway","canonical_id":"go:GO:0050847","description":"\"A nuclear receptor-mediated signaling pathway initiated by a progesterone binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [PMID:14744870]","metadata":null},{"id":"857f28a84694425f975149e374308a64","type":"GO_TERM","name":"progesterone secretion","canonical_id":"go:GO:0042701","description":"\"The regulated release of progesterone, a steroid hormone, by the corpus luteum of the ovary and by the placenta.\" [GOC:jl, ISBN:0395825172]","metadata":null},{"id":"6d79bdf42b96480fb7ded4de804be2ee","type":"GO_TERM","name":"programmed DNA elimination","canonical_id":"go:GO:0031049","description":"\"A process in which genomic fragments or entire chromosomes are eliminated from somatic cells or from micronuclei of ciliates. This process occurs in the developing macronucleus (anlage) of a ciliate, as well as in other species, including vertebrates and is an irreversible mechanism of gene silencing.\" [GOC:mah, GOC:ns, PMID:18708581, PMID:24886889, PMID:32986476]","metadata":null},{"id":"d10ce07c0dcb42deb683d09ea245b010","type":"GO_TERM","name":"programmed DNA elimination by chromosome breakage","canonical_id":"go:GO:0031052","description":"\"Regulated cleavage of the developing macronuclear genome at a limited number of chromosome breakage sites (CBS). The macronuclear destined segment (MDS) sequence adjacent to the CBS (or separated from it by a BES) receives a macronuclear telomere following chromosome breakage.\" [GOC:ns, PMID:15956677, PMID:25303953, PMID:32165395]","metadata":null},{"id":"c9a560f2f58a4a6bb947bb892c97bb72","type":"GO_TERM","name":"programmed DNA elimination by elimination of internal DNA segments","canonical_id":"go:GO:0140763","description":"\"A programmed DNA elimination mechanism in which specific sequences, namely, internal eliminated sequences (IES) and breakage eliminated sequences (BES) are removed from the genome. This process is known to occur in ciliates.\" [PMID:18708581]","metadata":null},{"id":"53468d85ceb94f4796e1dba93f7ef6f6","type":"GO_TERM","name":"programmed cell death","canonical_id":"go:GO:0012501","description":"\"A process which begins when a cell receives an internal or external signal and activates a series of biochemical events (signaling pathway). The process ends with the death of the cell.\" [GOC:lr, GOC:mtg_apoptosis]","metadata":null},{"id":"9cc9cba4e3834363b582841ab92461d4","type":"GO_TERM","name":"programmed cell death in response to reactive oxygen species","canonical_id":"go:GO:0097468","description":"\"Cell death resulting from activation of endogenous cellular processes and occurring as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"95c46a9447f7470995bd509fb322c531","type":"GO_TERM","name":"programmed cell death in response to retinoic acid","canonical_id":"go:GO:0160059","description":"\"Cell death resulting from activation of endogenous cellular processes and occurring as a result of a retinoic acid.\" [PMID:17869331, PMID:9187263]","metadata":null},{"id":"87abe9f311c148e1b9133328032d5895","type":"GO_TERM","name":"programmed cell death involved in cell development","canonical_id":"go:GO:0010623","description":"\"The activation of endogenous cellular processes that result in the death of a cell as part of its development.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"6c020fd0f28d4b938152b23094deab05","type":"GO_TERM","name":"programmed necrotic cell death","canonical_id":"go:GO:0097300","description":"\"A necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors.\" [GOC:mtg_apoptosis, PMID:21760595]","metadata":null},{"id":"a165c0d4cd3040739b0782c971751588","type":"GO_TERM","name":"programmed necrotic cell death in response to starvation","canonical_id":"go:GO:0097385","description":"\"A programmed necrotic cell death occurring as a result of a starvation stimulus (deprivation of nourishment).\" [GOC:mtg_apoptosis, GOC:pg, PMID:13679856]","metadata":null},{"id":"c197813fb65b4d9ebb93c23df95aef47","type":"GO_TERM","name":"progression of morphogenetic furrow involved in compound eye morphogenesis","canonical_id":"go:GO:0007458","description":"\"The morphogenetic furrow is a dorsoventral indentation which sweeps anteriorly across the eye disc. Ommatidia begin to form along the furrow, resulting in a graded series of ommatidial development across the anterior/posterior axis of the disc.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"3c45a46b7ecb4470aadbd9e840442a6f","type":"GO_TERM","name":"progression of neural tube closure","canonical_id":"go:GO:0021994","description":"\"The process in which the neural folds are fused extending from the initial closure points.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"614d2fe9b2bb46ca93683db4c2252b94","type":"DISEASE","name":"progressive familial heart block","canonical_id":"mondo:0019490","description":null,"metadata":null},{"id":"0a2123c731ae49d0949911ea0c12181e","type":"DISEASE","name":"progressive familial heart block, type 1A","canonical_id":"mondo:0007240","description":null,"metadata":null},{"id":"cea1e58cb4434d718ead4ef69f3a5716","type":"DISEASE","name":"progressive familial intrahepatic cholestasis","canonical_id":"mondo:0015762","description":null,"metadata":null},{"id":"4dba0f5b4c2840e29083f412aaa6a97f","type":"DISEASE","name":"progressive familial intrahepatic cholestasis type 1","canonical_id":"mondo:0008892","description":null,"metadata":null},{"id":"ea04e3720c734f3f8d17c52b156f0871","type":"GO_TERM","name":"prolactin metabolic process","canonical_id":"go:GO:0120122","description":"\"The chemical reactions and pathways involving prolactin, a protein hormone of the anterior pituitary gland that promotes lactation in response to the suckling stimulus of hungry young mammals.\" [PMID:11015620]","metadata":null},{"id":"7ddaec91dada419ebaf83ab773382d9e","type":"GO_TERM","name":"prolactin receptor activity","canonical_id":"go:GO:0004925","description":"\"Combining with prolactin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"e7a7946b5dbb45a797a86d60d3138aa7","type":"GO_TERM","name":"prolactin receptor binding","canonical_id":"go:GO:0005148","description":"\"Binding to a prolactin receptor.\" [GOC:ai]","metadata":null},{"id":"4e9c92f9f7ae4a58b71ab65a040e31fb","type":"GO_TERM","name":"prolactin secreting cell development","canonical_id":"go:GO:0060132","description":"\"The process whose specific outcome is the progression of a prolactin secreting cell over time, from its formation to the mature structure. A prolactin secreting cell is an acidophilic cell of the anterior pituitary that produces prolactin.\" [GOC:dph]","metadata":null},{"id":"43c21c7c4138488e99118e6f44bb1e51","type":"GO_TERM","name":"prolactin secreting cell differentiation","canonical_id":"go:GO:0060127","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a prolactin secreting cell. A prolactin secreting cell is an acidophilic cell of the anterior pituitary that produces prolactin.\" [GOC:dph]","metadata":null},{"id":"bc446e534fd14ff48fa7a9cc4422d6f1","type":"GO_TERM","name":"prolactin secretion","canonical_id":"go:GO:0070459","description":"\"The regulated release of prolactin, a peptide hormone that stimulates lactation, from secretory granules in the anterior pituitary.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"b75afd78068746798b617d08994293bd","type":"GO_TERM","name":"prolactin signaling pathway","canonical_id":"go:GO:0038161","description":"\"The series of molecular signals initiated by the binding of the peptide hormone prolactin to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:21664429]","metadata":null},{"id":"5963c7b00bc74e43a4d9a315179651d3","type":"GO_TERM","name":"prolactin-releasing peptide receptor binding","canonical_id":"go:GO:0031861","description":"\"Binding to a prolactin-releasing peptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a01f349c2f0e47a7b889a4475e742e89","type":"GO_TERM","name":"proline 3-hydroxylase activity","canonical_id":"go:GO:0033763","description":"\"Catalysis of the reaction: L-proline + 2-oxoglutarate + O2 = cis-3-hydroxy-L-proline + succinate + CO2.\" [EC:1.14.11.28]","metadata":null},{"id":"75321ce706c546fd8a92edb604884d58","type":"GO_TERM","name":"proline binding","canonical_id":"go:GO:1901973","description":"\"Binding to proline.\" [GOC:pm, GOC:TermGenie, PMID:7730362]","metadata":null},{"id":"64be23bc14164de396bf58d40094839d","type":"GO_TERM","name":"proline dehydrogenase activity","canonical_id":"go:GO:0004657","description":"\"Catalysis of the reaction: L-proline + a quinone = (S)-1-pyrroline-5-carboxylate + a quinol + H+.\" [RHEA:23784]","metadata":null},{"id":"fd9d8e97aa3f417d96b393e3b9d2d5ba","type":"GO_TERM","name":"proline dipeptidase activity","canonical_id":"go:GO:0102009","description":"\"Catalysis of the reaction: H2O + a dipeptide with proline at the C-terminal = L-proline + a standard alpha amino acid.\" [EC:3.4.13.9]","metadata":null},{"id":"78fd960838db41c6b637ac2ba916d131","type":"GO_TERM","name":"proline import across plasma membrane","canonical_id":"go:GO:1905647","description":"\"The directed movement of proline from outside of a cell into the cytoplasmic compartment.\" [GO_REF:0000075, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"4db91e2d31634181bde654c6a6210996","type":"GO_TERM","name":"proline racemase activity","canonical_id":"go:GO:0018112","description":"\"Catalysis of the reaction: L-proline = D-proline.\" [EC:5.1.1.4, RHEA:10680]","metadata":null},{"id":"d48c405270874fafbf46d8b52dc82041","type":"GO_TERM","name":"proline transmembrane transport","canonical_id":"go:GO:0035524","description":"\"The directed movement of proline, pyrrolidine-2-carboxylic acid, across a membrane by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"dcffb625c75b46538c5ff528f32b2764","type":"GO_TERM","name":"proline transport","canonical_id":"go:GO:0015824","description":"\"The directed movement of proline, pyrrolidine-2-carboxylic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"ef7775db153e410fb9f3c39af3dc5ec2","type":"GO_TERM","name":"proline-rich region binding","canonical_id":"go:GO:0070064","description":"\"Binding to a proline-rich region, i.e. a region that contains a high proportion of proline residues, in a protein.\" [GOC:mah]","metadata":null},{"id":"41171bd68f4847218d76b08d5de267c2","type":"GO_TERM","name":"proline-tRNA ligase activity","canonical_id":"go:GO:0004827","description":"\"Catalysis of the reaction: ATP + L-proline + tRNA(Pro) = AMP + diphosphate + L-prolyl-tRNA(Pro).\" [EC:6.1.1.15]","metadata":null},{"id":"2d0a1e4448ef4e65b182d47d90bad8f2","type":"GO_TERM","name":"proline:proton symporter activity","canonical_id":"go:GO:0005297","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: proline(out) + H+(out) = proline(in) + H+(in).\" [GOC:ai]","metadata":null},{"id":"c926e7b152484060b0d5a009e3b6ee03","type":"GO_TERM","name":"proline:sodium symporter activity","canonical_id":"go:GO:0005298","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: proline(out) + Na+(out) = proline(in) + Na+(in).\" [TC:2.A.22.2.1]","metadata":null},{"id":"35b22009b5b044769c00c92e3cd994db","type":"GO_TERM","name":"prolyl-tRNA aminoacylation","canonical_id":"go:GO:0006433","description":"\"The process of coupling proline to prolyl-tRNA, catalyzed by prolyl-tRNA synthetase. The prolyl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of a methionine-accetping tRNA.\" [GOC:mah, ISBN:0716730510]","metadata":null},{"id":"d7cf1887281a4878b5b77b943a9b20cb","type":"DRUG","name":"promazine","canonical_id":"gtopdb:7281","description":null,"metadata":null},{"id":"c19ad4a123684579900bdbf8608fbabd","type":"DRUG","name":"promazine","canonical_id":"mesh:D011395","description":null,"metadata":null},{"id":"cbcacaebc6d04c4f8f50c497d5df284a","type":"DRUG","name":"promethazine","canonical_id":"gtopdb:7282","description":null,"metadata":null},{"id":"2122d29dd882449cb0b5ed8a4add6bf6","type":"DRUG","name":"promethazine","canonical_id":"mesh:D011398","description":null,"metadata":null},{"id":"08919fde20d34935813466ebf8ff8333","type":"GO_TERM","name":"prominosome","canonical_id":"go:GO:0071914","description":"\"An extracellular membrane-bounded vesicle that contains prominin proteins (in mouse Prom1/CD33 or Prom2) and are found in body fluids including ventricular fluid, saliva, urine and seminal fluid. In the ventricular fluid of the developing mouse brain two major classes of these particles have been observed (P2 particles of 500-1000 nm and P4 particles of 50-80 nm) which likely originate from microvilli, primary cilia and/or the midbody of neuroepithelial cells. The physiological role is not known.\" [GOC:vesicles, PMID:15976444, PMID:17109118, PMID:17283184]","metadata":null},{"id":"779d8f7c80224713b07c535359f33a42","type":"GO_TERM","name":"promoter clearance during DNA-templated transcription","canonical_id":"go:GO:0001109","description":"\"Any process involved in the transition from the initiation to the elongation phases of transcription by a DNA-dependent RNA polymerase, generally including a conformational change from the initiation conformation to the elongation conformation. Promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors.\" [GOC:txnOH, PMID:15020047, PMID:18280161]","metadata":null},{"id":"c2903062b9d3415593cb0117219c30e9","type":"GO_TERM","name":"promoter-enhancer loop anchoring activity","canonical_id":"go:GO:0140585","description":"\"Bridging together two cis-regulatory elements, colloquially referred to as promoters and/or enhancers, holding two loop anchors together to maintain a chromatin loop.\" [PMID:32213323]","metadata":null},{"id":"b31311bb3c40496e9b37cb7ea9d3e5de","type":"GO_TERM","name":"promoter-specific chromatin binding","canonical_id":"go:GO:1990841","description":"\"Binding to a section of chromatin that is associated with gene promoter sequences of DNA.\" [PMID:19948729]","metadata":null},{"id":"f7b74f05630549d78a7e81bb2b1c4554","type":"GO_TERM","name":"promoter-terminator loop anchoring activity","canonical_id":"go:GO:0140586","description":"\"Bridging together a cis-regulatory element and a terminator DNA sequences on the chromatin, holding two loop anchors together, maintaining a chromatin loop.\" [PMID:19933151]","metadata":null},{"id":"ff4a9a6bb6d0455785df3e4d45677661","type":"GO_TERM","name":"pronephric distal tubule development","canonical_id":"go:GO:0035777","description":"\"The process whose specific outcome is the progression of the pronephric distal tubule over time, from its formation to the mature structure. A pronephric nephron tubule is an epithelial tube that is part of the pronephros.\" [GOC:mtg_kidney_jan10, GOC:yaf, PMID:18787069]","metadata":null},{"id":"7299e772d5fd4455b31efc5f25181d48","type":"GO_TERM","name":"pronephric distal tubule morphogenesis","canonical_id":"go:GO:0039013","description":"\"The process in which the anatomical structures of a pronephric nephron distal tubule are generated and organized. A pronephric nephron tubule is an epithelial tube that is part of the pronephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"46a858187cb842deb22fa85b8ca9763e","type":"GO_TERM","name":"pronephric duct development","canonical_id":"go:GO:0039022","description":"\"The process whose specific outcome is the progression of the pronephric duct over time, from its formation to the mature structure. The pronephric duct collects the filtrate from the pronephric tubules and opens to the exterior of the pronephric kidney.\" [GOC:mtg_kidney_jan10, PMID:15647339, XAO:0000063, ZFA:0000150]","metadata":null},{"id":"b5d465b1839d4496a7977f5395bb2eff","type":"GO_TERM","name":"pronephric duct morphogenesis","canonical_id":"go:GO:0039023","description":"\"The process in which the anatomical structures of the pronephric duct are generated and organized. The pronephric duct collects the filtrate from the pronephric tubules and opens to the exterior of the kidney.\" [GOC:mtg_kidney_jan10, XAO:0000063, ZFA:0000150]","metadata":null},{"id":"96958eca75764cb4865b76487db57dea","type":"GO_TERM","name":"pronephric field specification","canonical_id":"go:GO:0039003","description":"\"The process in which regions of the embryo are delineated into the area in which the pronephric kidney will develop.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"48a61de112ab4eed82661deb84bcb32e","type":"GO_TERM","name":"pronephric glomerulus development","canonical_id":"go:GO:0039021","description":"\"The progression of the glomerulus of the pronephric kidney over time from its initial formation until its mature state. The pronephric glomerulus is part of the pronephric nephron and is restricted to one body segment.\" [GOC:dgh, GOC:mtg_kidney_jan10, ZFA:00001557]","metadata":null},{"id":"28e4c428099f4760b9adcbee73abc68f","type":"GO_TERM","name":"pronephric glomerulus morphogenesis","canonical_id":"go:GO:0035775","description":"\"The process in which the anatomical structures of the pronephric glomerulus are generated and organized. The pronephric glomerulus is part of the pronephric nephron and is restricted to one body segment.\" [GOC:mtg_kidney_jan10, GOC:yaf, PMID:18787069]","metadata":null},{"id":"c021576c2cff4004ae02c3aefd105a06","type":"GO_TERM","name":"pronephric nephron development","canonical_id":"go:GO:0039019","description":"\"The process whose specific outcome is the progression of the pronephric nephron over time, from its formation to the mature structure. A pronephric nephron is the functional unit of the pronephros.\" [GOC:mtg_kidney_jan10, XAO:00002785]","metadata":null},{"id":"baa42eb241e6494d8d9d008df61a4328","type":"GO_TERM","name":"pronephric nephron morphogenesis","canonical_id":"go:GO:0039007","description":"\"The process in which the anatomical structures of the pronephric nephron are generated and organized. A pronephric nephron is the functional unit of the pronephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e16ac3c99130440ba4c3b622e7eca544","type":"GO_TERM","name":"pronephric nephron tubule development","canonical_id":"go:GO:0039020","description":"\"The process whose specific outcome is the progression of a pronephric nephron tubule over time, from its formation to the mature structure. The pronephric nephron tubule is an epithelial tube that is part of the pronephric nephron and connects the filtration unit (glomerulus or glomus) of the pronephros to the pronephric duct.\" [GOC:mtg_kidney_jan10, PMID:19909807, PMID:9268568]","metadata":null},{"id":"3668fd11b2d840c2875bb0faaca9e88c","type":"GO_TERM","name":"pronephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0035778","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the pronephric nephron tubule as it progresses from its formation to the mature state.\" [GOC:mtg_kidney_jan10, GOC:yaf, PMID:18787069]","metadata":null},{"id":"4a44b13a285f4d16af7fd63937b70c3a","type":"GO_TERM","name":"pronephric nephron tubule formation","canonical_id":"go:GO:0039006","description":"\"The developmental process pertaining to the initial formation of a pronephric nephron tubule from unspecified parts. A pronephric nephron tubule is an epithelial tube that is part of a nephron in the pronephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b48b386a78a94a3ab1d4662c42cadc31","type":"GO_TERM","name":"pronephric nephron tubule morphogenesis","canonical_id":"go:GO:0039008","description":"\"The process in which the anatomical structures of a pronephric nephron tubule are generated and organized from an epithelium. A pronephric nephron tubule is an epithelial tube that is part of the pronephric nephron.\" [GOC:mtg_kidney_jan10, ZFA:00001558]","metadata":null},{"id":"983c1fa09281408ab338f72effaa08a2","type":"GO_TERM","name":"pronephric proximal tubule development","canonical_id":"go:GO:0035776","description":"\"The progression of the pronephric proximal tubule over time, from its formation to the mature structure. A pronephric nephron tubule is an epithelial tube that is part of the pronephros.\" [GOC:mtg_kidney_jan10, GOC:yaf, PMID:18787069]","metadata":null},{"id":"c79d1f452e0c425e98af68a9e4cf20da","type":"GO_TERM","name":"pronephric proximal tubule morphogenesis","canonical_id":"go:GO:0039011","description":"\"The process in which the anatomical structures of a pronephric nephron proximal tubule are generated and organized. A pronephric nephron tubule is an epithelial tube that is part of the pronephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6ce6a37c7423471f84d7856e3f7811e4","type":"GO_TERM","name":"pronephric sinus development","canonical_id":"go:GO:0039012","description":"\"The process whose specific outcome is the progression of the pronephric sinus over time, from its formation to the mature structure. The pronephric sinus is an ill-defined capillary network that lies between the pronephric tubules.\" [GOC:mtg_kidney_jan10, PMID:10535314, XAO:0000385]","metadata":null},{"id":"5d94d10e0b9c4d16bcca3c4e822fce1c","type":"GO_TERM","name":"pronephros development","canonical_id":"go:GO:0048793","description":"\"The process whose specific outcome is the progression of the pronephros over time, from its formation to the mature structure. In mammals, the pronephros is the first of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the pronephros is the fully functional embryonic kidney and is indispensable for larval life.\" [GOC:bf, GOC:mtg_kidney_jan10, PMID:10535314, PMID:15968585, PMID:18322540, XAO:00002000, ZFA:0000151]","metadata":null},{"id":"b010f643e16d40c4a053d1d622fc0941","type":"GO_TERM","name":"pronephros formation","canonical_id":"go:GO:0072116","description":"\"The developmental process pertaining to the initial formation of the pronephros. In mammals, the pronephros is the first of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the pronephros is the fully functional embryonic kidney and is indispensable for larval life.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ae2d4b9171f44c9ea11437d085ae1f1b","type":"GO_TERM","name":"pronephros maturation","canonical_id":"go:GO:0072120","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the pronephros to attain its fully functional state. In mammals, the pronephros is the first of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the pronephros is the fully functional embryonic kidney and is indispensable for larval life.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"71f6a676816944eda1afe1e498b13e28","type":"GO_TERM","name":"pronephros morphogenesis","canonical_id":"go:GO:0072114","description":"\"The process in which the anatomical structures of the pronephros are generated and organized. In mammals, the pronephros is the first of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the pronephros is the fully functional embryonic kidney and is indispensable for larval life.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b5c5a511f319476185152ace004074f4","type":"GO_TERM","name":"pronephros structural organization","canonical_id":"go:GO:0072118","description":"\"The process that contributes to the act of creating the structural organization of the pronephros. This process pertains to the physical shaping of a rudimentary structure. In mammals, the pronephros is the first of the three embryonic kidneys to be established and exists only transiently. In lower vertebrates such as fish and amphibia, the pronephros is the fully functional embryonic kidney and is indispensable for larval life.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d892accadce94bcbbbd442bea710dd41","type":"GO_TERM","name":"pronuclear envelope synthesis","canonical_id":"go:GO:0018985","description":"\"Synthesis and ordering of the envelope of pronuclei.\" [GOC:ems]","metadata":null},{"id":"d3e2769f880745a39a85f8d262255306","type":"GO_TERM","name":"pronuclear fusion","canonical_id":"go:GO:0007344","description":"\"The merging of two pronuclei in a fertilized egg to fuse and produce a single zygotic genome.\" [GOC:ems, ISBN:087969307X]","metadata":null},{"id":"bebaec65fae6431d85054ee8b23e0732","type":"GO_TERM","name":"pronuclear migration","canonical_id":"go:GO:0035046","description":"\"The directed movement of the male and female pronuclei towards each other prior to their fusion.\" [GOC:bf, PMID:9199363]","metadata":null},{"id":"3b99d76d231146a29621152692cf226a","type":"GO_TERM","name":"pronucleus","canonical_id":"go:GO:0045120","description":"\"The nucleus of either the ovum or the spermatozoon following fertilization. Thus, in the fertilized ovum, there are two pronuclei, one originating from the ovum, the other from the spermatozoon that brought about fertilization; they approach each other, but do not fuse until just before the first cleavage, when each pronucleus loses its membrane to release its contents.\" [ISBN:0198506732]","metadata":null},{"id":"ae0771f426aa4b67bc3a70298323a408","type":"DRUG","name":"propafenone","canonical_id":"gtopdb:2561","description":null,"metadata":null},{"id":"e5ab65b197c644d29db29b16719f112f","type":"DRUG","name":"propafenone","canonical_id":"mesh:D011405","description":null,"metadata":null},{"id":"26aa8af51c5547f5bef55f3188ebf7cb","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-7956e32ab6d84332","description":null,"metadata":null},{"id":"eaf383975e70437ea75709906ec669b6","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-e1a7b047343c314a","description":null,"metadata":null},{"id":"6c57d3d6c7314c8f9699643e12cba313","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-d582c7609077bfbf","description":null,"metadata":null},{"id":"0108617b5e6245d191d5faae034160d0","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-0cca21b98ff26f9d","description":null,"metadata":null},{"id":"78b3fac16a1943e0b175fedfc76e24d1","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-b6de8b3e4f5db972","description":null,"metadata":null},{"id":"95ab366741df4fb9ba90aedf139e7217","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-57ca89b974688d7b","description":null,"metadata":null},{"id":"021262229d4f404e8898025636dd5913","type":"COMBINATION_TREATMENT","name":"propafenone + sotalol","canonical_id":"ctgov_combo:ctgov-combo-90a6200d12cfea9c","description":null,"metadata":null},{"id":"f2dd2017250b46c09a42ebe6d683a1e3","type":"GO_TERM","name":"propan-2-ol biosynthetic process","canonical_id":"go:GO:1902640","description":"\"The chemical reactions and pathways resulting in the formation of propan-2-ol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:16346237]","metadata":null},{"id":"3363f3c30f4b4fefa7156bc4eba28801","type":"GO_TERM","name":"propan-2-ol:coenzyme F420 oxidoreductase activity","canonical_id":"go:GO:0052753","description":"\"Catalysis of the reaction: propan-2-ol + coenzyme F420 = acetone + reduced coenzyme F420.\" [GOC:mengo_curators, PMID:15016352, PMID:1879431, PMID:8706724]","metadata":null},{"id":"4f63feabd1fb421684786e4c49120906","type":"GO_TERM","name":"propane 1,3-diol transport","canonical_id":"go:GO:0015799","description":"\"The directed movement of 1,3-propanediol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Propanediol is a sweet colorless, viscous, hygroscopic liquid used as an antifreeze and in brake fluid; it is also as a humectant in cosmetics and personal care items, although it can be absorbed through the skin with harmful effects.\" [PMID:24002752]","metadata":null},{"id":"60a935d6d319447b9faccd067891369d","type":"GO_TERM","name":"propanediol degradation polyhedral organelle","canonical_id":"go:GO:0031472","description":"\"An organelle found in bacteria consisting of a proteinaceous coat containing enzymes for the degradation of 1,2-propanediol whose purpose is the protection of the rest of the cell from the toxic propionaldehyde product of the enzyme diol dehydratase.\" [GOC:js, PMID:10498708, PMID:11844753, PMID:12923081]","metadata":null},{"id":"5ab17b81f5334e08b094825888517eca","type":"GO_TERM","name":"propanediol dehydratase activity","canonical_id":"go:GO:0050215","description":"\"Catalysis of the reaction: propane-1,2-diol = H2O + propanal.\" [EC:4.2.1.28, RHEA:14569]","metadata":null},{"id":"a0b00dad57e94f49b6a82d5b33bf6973","type":"GO_TERM","name":"propanediol-phosphate dehydrogenase activity","canonical_id":"go:GO:0050216","description":"\"Catalysis of the reaction: NAD+ + propane-1,2-diol 1-phosphate = H+ + hydroxyacetone phosphate + NADH.\" [EC:1.1.1.7, RHEA:21584]","metadata":null},{"id":"52ab9ab354d04380a091c8cc184886dd","type":"GO_TERM","name":"propanoate transmembrane transport","canonical_id":"go:GO:0015730","description":"\"The directed movement of propionate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"b8a47949e7ad4080b3661b658746a005","type":"GO_TERM","name":"propanoyl-CoA C-acyltransferase activity","canonical_id":"go:GO:0033814","description":"\"Catalysis of the reaction: choloyl-CoA + propanoyl-CoA = 3alpha,7alpha,12alpha-trihydroxy-24-oxo-5beta-cholestan-26-oyl-CoA + CoA.\" [RHEA:16865]","metadata":null},{"id":"389b91ae93b745d98b94d6c81f765ca8","type":"DRUG","name":"propantheline","canonical_id":"gtopdb:329","description":null,"metadata":null},{"id":"323e6d6930b4451e9690122bedb62aae","type":"GO_TERM","name":"prophage integrase activity","canonical_id":"go:GO:0008979","description":"\"Catalysis of the integration of prophage DNA into a target DNA molecule, usually a bacterial chromosome, via a sequence-specific recombination event which involves the formation of an intasome, a DNA-protein-complex designed for site-specific recombination of the phage and host DNA.\" [GOC:jl]","metadata":null},{"id":"527f4796df2641e1b19978f04add5cf7","type":"GO_TERM","name":"prophase","canonical_id":"go:GO:0051324","description":"\"The cell cycle phase which is the first stage of M phase of meiosis and mitosis and during which chromosomes condense and the two daughter centrioles and their asters migrate toward the poles of the cell.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"0cec2c9f8eb3417aa8e7ba7c56497ed9","type":"GO_TERM","name":"propioin synthase activity","canonical_id":"go:GO:0050217","description":"\"Catalysis of the reaction: 4-hydroxyhexan-3-one = 2 propanal.\" [EC:4.1.2.35, RHEA:11100]","metadata":null},{"id":"8458ef9605334ffaad15fc1793fd53b6","type":"GO_TERM","name":"propionate CoA-transferase activity","canonical_id":"go:GO:0018729","description":"\"Catalysis of the reaction: acetyl-CoA + propanoate = acetate + propanoyl-CoA.\" [RHEA:23520]","metadata":null},{"id":"658559fb40944189b1642dc414bd583e","type":"GO_TERM","name":"propionate biosynthetic process","canonical_id":"go:GO:0019542","description":"\"The chemical reactions and pathways resulting in the formation of propionate, the anion derived from propionic acid.\" [GOC:curators]","metadata":null},{"id":"14666b2945b443f3be7190f2890ed743","type":"GO_TERM","name":"propionate catabolic process","canonical_id":"go:GO:0019543","description":"\"The chemical reactions and pathways resulting in the breakdown of propionate, the anion derived from propionic acid.\" [GOC:curators]","metadata":null},{"id":"e70adda43648416ab91ffcbeab17ce74","type":"GO_TERM","name":"propionate kinase activity","canonical_id":"go:GO:0008980","description":"\"Catalysis of the reaction: ATP + propanoate = ADP + propanoyl phosphate.\" [EC:2.7.2.15]","metadata":null},{"id":"9d4b552d2e0a4eab968bd6ea99b72196","type":"GO_TERM","name":"propionate metabolic process","canonical_id":"go:GO:0019541","description":"\"The chemical reactions and pathways involving propionate, the anion derived from propionic (propanoic) acid, a carboxylic acid important in the energy metabolism of ruminants.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f174afd512cd4dbf846fdeda83aba620","type":"GO_TERM","name":"propionate transmembrane transporter activity","canonical_id":"go:GO:0015552","description":"\"Enables the transfer of propionate from one side of a membrane to the other. Propionate (or propanoate) is the organic acid CH3-CH2-COOH.\" [GOC:ai]","metadata":null},{"id":"8f8e662a946d4f289a4ed5afeec004be","type":"GO_TERM","name":"propionate-CoA ligase activity","canonical_id":"go:GO:0050218","description":"\"Catalysis of the reaction: ATP + propanoate + CoA = AMP + diphosphate + propanoyl-CoA.\" [EC:6.2.1.17, MetaCyc:PROPIONATE--COA-LIGASE-RXN]","metadata":null},{"id":"9b1a69153c524366bb896affc1ba7af1","type":"GO_TERM","name":"propionyl-CoA C2-trimethyltridecanoyltransferase activity","canonical_id":"go:GO:0050632","description":"\"Catalysis of the reaction: 4,8,12-trimethyltridecanoyl-CoA + propanoyl-CoA = 3-oxopristanoyl-CoA + CoA.\" [RHEA:10408]","metadata":null},{"id":"1986b3a3c4804ce3ae92c3d7a9cbd36c","type":"GO_TERM","name":"propionyl-CoA biosynthetic process","canonical_id":"go:GO:1902860","description":"\"The chemical reactions and pathways resulting in the formation of propionyl-CoA.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:15514053]","metadata":null},{"id":"9ae98cba4ba04a61bd1dd7e2b266855d","type":"GO_TERM","name":"propionyl-CoA carboxylase activity","canonical_id":"go:GO:0004658","description":"\"Catalysis of the reaction: ATP + propanoyl-CoA + HCO3- = ADP + phosphate + (S)-methylmalonyl-CoA.\" [EC:6.4.1.3]","metadata":null},{"id":"7b3272a0667a4c3c860e2e2c110f02c3","type":"GO_TERM","name":"propionyl-CoA catabolic process","canonical_id":"go:GO:1902859","description":"\"The chemical reactions and pathways resulting in the breakdown of propionyl-CoA.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:15514053]","metadata":null},{"id":"deebca970b5b4c22b93d360bb313fb8d","type":"GO_TERM","name":"propionyl-CoA metabolic process","canonical_id":"go:GO:1902858","description":"\"The chemical reactions and pathways involving propionyl-CoA.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:15514053]","metadata":null},{"id":"3e7b52c6204947079f64e0bab662bb5c","type":"GO_TERM","name":"propionyl-CoA:succinate CoA-transferase activity","canonical_id":"go:GO:0043821","description":"\"Catalysis of the reaction: succinate + propionyl-CoA = succinyl-CoA + propionate.\" [PMID:10769117, RHEA:28010]","metadata":null},{"id":"91c0ce7c8f814ab2841dd4884dd394a2","type":"GO_TERM","name":"proplastid","canonical_id":"go:GO:0009537","description":"\"The precursor of other plastids.\" [ISBN:0943088399]","metadata":null},{"id":"296faf8b32074822b14d51b55af3b09c","type":"GO_TERM","name":"proplastid nucleoid","canonical_id":"go:GO:0042647","description":"\"The region of a proplastid to which the DNA is confined.\" [GOC:jl]","metadata":null},{"id":"37a128efc6064f25b6939c061388d63e","type":"GO_TERM","name":"proplastid stroma","canonical_id":"go:GO:0009571","description":"\"The space enclosed by the double membrane of a proplastid.\" [GOC:jl]","metadata":null},{"id":"f617e2e4df97483abad45f9ebbd2892d","type":"DRUG","name":"propranolol","canonical_id":"gtopdb:564","description":null,"metadata":null},{"id":"c456494dc0bd47f099146f43c73b6e26","type":"COMBINATION_TREATMENT","name":"propranolol + sintilimab","canonical_id":"ctgov_combo:ctgov-combo-7c4a4aa8a6e25dc2","description":null,"metadata":null},{"id":"3c23b58223104df5971ae9b1ade49b32","type":"GO_TERM","name":"proprioception","canonical_id":"go:GO:0019230","description":"\"The series of events by which an organism senses the position, location, orientation, and movement of the body and its parts. Proprioception is mediated by proprioceptors, sensory nerve terminals found in muscles, tendons, and joint capsules, which give information concerning movements and position of the body. The receptors in the labyrinth are sometimes also considered proprioceptors.\" [ISBN:072168677X]","metadata":null},{"id":"716f028400ba41719f7cd888e8048d67","type":"GO_TERM","name":"proprioception involved in equilibrioception","canonical_id":"go:GO:0051355","description":"\"The series of events contributing to equilibrioception by which an organism senses the position, location, orientation, and movement of the body and its parts. Proprioception plays an important role in the ability of an organism to perceive its orientation with respect to gravity.\" [GOC:ai]","metadata":null},{"id":"5b8a27695bcd47e8adb04132713326dc","type":"GO_TERM","name":"propylene catabolic process","canonical_id":"go:GO:0042208","description":"\"The chemical reactions and pathways resulting in the breakdown of propylene, an alkene produced by catalytic or thermal cracking of hydrocarbons or as a by-product of petroleum refining.\" [GOC:jl]","metadata":null},{"id":"102c85040718473d87e597eaa606fbd4","type":"GO_TERM","name":"propylene metabolic process","canonical_id":"go:GO:0018964","description":"\"The chemical reactions and pathways involving propylene, an alkene produced by catalytic or thermal cracking of hydrocarbons or as a by-product of petroleum refining. It is used mainly in the preparation of alkylates for gasoline and in the production of polypropylene, acrylonitrile, propylene oxide and a number of other industrial chemicals.\" [GOC:jl]","metadata":null},{"id":"25a7862140c445bcb44b3ed564db320b","type":"DRUG","name":"propylthiouracil","canonical_id":"gtopdb:6650","description":null,"metadata":null},{"id":"d1829016f4e747b68f69c810a17a045a","type":"DRUG","name":"propylthiouracil","canonical_id":"mesh:D011441","description":null,"metadata":null},{"id":"f4e40692f9414711b0fb0b09a3514da3","type":"DRUG","name":"propylthiouracil","canonical_id":"chembl:CHEMBL1518","description":null,"metadata":null},{"id":"8d5284e60aa9433b90b82ab9e0f9a0f6","type":"GO_TERM","name":"prosaposin receptor activity","canonical_id":"go:GO:0036505","description":"\"Combining with prosaposin to initiate a change in cell activity. Prosaposin is the glycoprotein precursor of four cleavage products (saposins A, B, C and D).\" [GOC:bf, GOC:PARL, PMID:23690594, PMID:9388493]","metadata":null},{"id":"8bc1f50961ac43159a0cd5dfd516194f","type":"GO_TERM","name":"prospore contractile ring","canonical_id":"go:GO:0032157","description":"\"A contractile ring, i.e. a cytoskeletal structure composed of actin filaments and myosin, that forms beneath the plasma membrane of the prospore envelope in meiotic cells in preparation for completing cytokinesis.\" [GOC:krc, PMID:16009555]","metadata":null},{"id":"6b2ba9b9f8fa4c68bd69302da713dfa6","type":"GO_TERM","name":"prospore membrane","canonical_id":"go:GO:0005628","description":"\"The prospore membrane is a double-membraned structure that extends from the cytoplasmic face of the spindle pole bodies to encompass the spindle pole bodies and the four nuclear lobes that are formed during meiosis. It helps isolate the meiotic nuclei from the cytoplasm during spore formation and serves as a foundation for the formation of the spore walls. An example of this component is found in Schizosaccharomyces pombe.\" [ISBN:0879693649]","metadata":null},{"id":"bc195735f933484892a3e6ccffb10dbc","type":"GO_TERM","name":"prospore membrane leading edge","canonical_id":"go:GO:0070056","description":"\"The region of the prospore membrane that extends to surround the spore nucleus; coated with specific proteins that are thought to play a role in prospore membrane organization.\" [GOC:mah, PMID:14702385]","metadata":null},{"id":"d5a467560edd484db38a6104c921f831","type":"GO_TERM","name":"prospore membrane spindle pole body attachment site","canonical_id":"go:GO:0070057","description":"\"The region of the prospore membrane to which the spindle pole body (SPB) is anchored; the prospore membrane extends from the SPB attachment site to surround the spore nucleus.\" [GOC:mah, PMID:14702385]","metadata":null},{"id":"69609249e1214edd8ffc25bdda143671","type":"GO_TERM","name":"prospore septin filament array","canonical_id":"go:GO:0032165","description":"\"Arrays of septin filaments, or bars, found in a series of filamentous structures; observed in the prospore membrane during spore formation.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"3bb8e385c9ab45c4a096dec5c6065b63","type":"GO_TERM","name":"prospore septin ring","canonical_id":"go:GO:0032169","description":"\"A tight ring-shaped structure that forms in the division plane at the site of cytokinesis in a prospore; composed of septins as well as septin-associated proteins.\" [GOC:krc, GOC:mah, PMID:16151244]","metadata":null},{"id":"3caf4a489ba74acf9f81cb8f00a02353","type":"GO_TERM","name":"prostacyclin receptor activity","canonical_id":"go:GO:0016501","description":"\"Combining with prostacyclin (PGI(2)) to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"81dd77a8520841ce97e5650f105bc8b4","type":"GO_TERM","name":"prostacyclin receptor binding","canonical_id":"go:GO:0031869","description":"\"Binding to a prostacyclin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9a67028cc7344743bbc3b2a65767eb14","type":"GO_TERM","name":"prostaglandin D receptor activity","canonical_id":"go:GO:0004956","description":"\"Combining with prostaglandin D (PGD(2)) to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"65c9ce466511471683de07b9e1ee08c3","type":"GO_TERM","name":"prostaglandin D2 11-ketoreductase activity","canonical_id":"go:GO:0036131","description":"\"Catalysis of the reaction: prostaglandin D2 + H+ + NADPH = 11-epi-prostaglandin F2alpha + NADP+.\" [PMID:1504718, PMID:3862115, RHEA:45316]","metadata":null},{"id":"e370fba4f378457d848d79b39275bae9","type":"GO_TERM","name":"prostaglandin D2 receptor binding","canonical_id":"go:GO:0031863","description":"\"Binding to a prostaglandin D2 receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cf5e8c1f39604970810ba4eaa409b451","type":"GO_TERM","name":"prostaglandin E receptor activity","canonical_id":"go:GO:0004957","description":"\"Combining with prostaglandin E (PGE(2)) to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"2895b0773b68447e80d66679d645b84d","type":"GO_TERM","name":"prostaglandin E2 9-reductase activity","canonical_id":"go:GO:0050221","description":"\"Catalysis of the reaction: (5Z,13E)-(15S)-9-alpha,11-alpha,15-trihydroxyprosta-5,13-dienoate + NADP+ = (5Z,13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate + NADPH.\" [EC:1.1.1.189, MetaCyc:PROSTAGLANDIN-E2-9-REDUCTASE-RXN]","metadata":null},{"id":"08433cd065a0442b90881db9e148f6e1","type":"GO_TERM","name":"prostaglandin F receptor activity","canonical_id":"go:GO:0004958","description":"\"Combining with prostaglandin F (PGF (2-alpha)) to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"1fa65f89634d49e59776e76de8052410","type":"GO_TERM","name":"prostaglandin F synthase activity","canonical_id":"go:GO:0047017","description":"\"Catalysis of the reaction: NADP+ + prostaglandin F2alpha = H+ + NADPH + prostaglandin D2.\" [RHEA:10140]","metadata":null},{"id":"eafd3bfb55fa435bbdca70c767f94d60","type":"GO_TERM","name":"prostaglandin F2-alpha receptor binding","canonical_id":"go:GO:0031868","description":"\"Binding to a prostaglandin F2-alpha receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"b4b45bef51f64977b66ce67d15da8373","type":"GO_TERM","name":"prostaglandin H2 endoperoxidase reductase activity","canonical_id":"go:GO:0036130","description":"\"Catalysis of the reaction: prostaglandin F2alpha + NADP+ = prostaglandin H2 + NADPH + H+.\" [PMID:10622721, PMID:14979715, PMID:16475787, RHEA:45312]","metadata":null},{"id":"a7cfe32020934c6fb13ec7defcf90ffc","type":"GO_TERM","name":"prostaglandin J receptor activity","canonical_id":"go:GO:0001785","description":"\"Combining with prostaglandin J (PGJ(2)), a metabolite of prostaglandin D (PGD(2)) to initiate a change in cell activity.\" [PMID:12878180]","metadata":null},{"id":"0161872a1bc84edbb1549ba60aff6a03","type":"GO_TERM","name":"prostaglandin binding","canonical_id":"go:GO:1904593","description":"\"Binding to prostaglandin.\" [GO_REF:0000067, GOC:TermGenie, PMID:21445266]","metadata":null},{"id":"1d28e74c334e48e3b48c0b4728678890","type":"GO_TERM","name":"prostaglandin biosynthetic process","canonical_id":"go:GO:0001516","description":"\"The chemical reactions and pathways resulting in the formation of prostaglandins, any of a group of biologically active metabolites which contain a cyclopentane ring.\" [GOC:ai]","metadata":null},{"id":"8003f2333c8441f392e3230ac05d0b76","type":"GO_TERM","name":"prostaglandin catabolic process","canonical_id":"go:GO:1905344","description":"\"The chemical reactions and pathways resulting in the breakdown of prostaglandin.\" [GO_REF:0000068, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:25290914]","metadata":null},{"id":"e07bca82ee724043826c97ee9ae5cff8","type":"GO_TERM","name":"prostaglandin metabolic process","canonical_id":"go:GO:0006693","description":"\"The chemical reactions and pathways involving prostaglandins, any of a group of biologically active metabolites which contain a cyclopentane ring due to the formation of a bond between two carbons of a fatty acid. They have a wide range of biological activities.\" [ISBN:0198506732]","metadata":null},{"id":"50e6af95c342485f8ac4647ddebb07f5","type":"GO_TERM","name":"prostaglandin production involved in inflammatory response","canonical_id":"go:GO:0002539","description":"\"The synthesis or release of any prostaglandin following a stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"78c21db9f68e4d8ebfacf3b48b8d5870","type":"GO_TERM","name":"prostaglandin receptor activity","canonical_id":"go:GO:0004955","description":"\"Combining with a prostaglandin (PG) to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"5fd9aa7180404ed7bfdd99479078f41e","type":"GO_TERM","name":"prostaglandin receptor internalization","canonical_id":"go:GO:1990767","description":"\"The process that results in the uptake of a prostaglandin receptor into an endocytic vesicle.\" [PMID:15937517]","metadata":null},{"id":"3313042ffb7247fe9801e8450883d077","type":"GO_TERM","name":"prostaglandin secretion","canonical_id":"go:GO:0032310","description":"\"The regulated release of a prostaglandin, any of a group of biologically active metabolites which contain a cyclopentane ring, from a cell or a tissue.\" [GOC:mah]","metadata":null},{"id":"d51f2dbb3b6b4d87bb753da2eed3d096","type":"GO_TERM","name":"prostaglandin transmembrane transporter activity","canonical_id":"go:GO:0015132","description":"\"Enables the transfer of prostaglandins from one side of a membrane to the other. A prostaglandin is any of a group of biologically active metabolites which contain a cyclopentane ring due to the formation of a bond between two carbons of a fatty acid. They have a wide range of biological activities.\" [GOC:ai]","metadata":null},{"id":"abbe4cdcd9704a7ba6ad7bee19dbec72","type":"GO_TERM","name":"prostaglandin transport","canonical_id":"go:GO:0015732","description":"\"The directed movement of prostaglandins into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"cb5ffad5090940c096dd6e6dec8dacba","type":"GO_TERM","name":"prostaglandin-A1 delta-isomerase activity","canonical_id":"go:GO:0050219","description":"\"Catalysis of the reaction: prostaglandin A1 = prostaglandin C1.\" [RHEA:10460]","metadata":null},{"id":"b64e2ef821144b72826d6b0620573ea8","type":"GO_TERM","name":"prostaglandin-D synthase activity","canonical_id":"go:GO:0004667","description":"\"Catalysis of the reaction: prostaglandin H(2) = prostaglandin D(2).\" [EC:5.3.99.2, RHEA:10600]","metadata":null},{"id":"05017bf63da9464e9738c43c8fd1e6c6","type":"GO_TERM","name":"prostaglandin-E synthase activity","canonical_id":"go:GO:0050220","description":"\"Catalysis of the reaction: prostaglandin H(2) = prostaglandin E(2).\" [EC:5.3.99.3, RHEA:12893]","metadata":null},{"id":"efcb3c87ed6a4c5f97514ced1727fdf1","type":"GO_TERM","name":"prostaglandin-I synthase activity","canonical_id":"go:GO:0008116","description":"\"Catalysis of the reaction: prostaglandin H(2) = prostaglandin I(2).\" [EC:5.3.99.4, RHEA:23580]","metadata":null},{"id":"e7b22458a6f24d86b49428a3015f4834","type":"GO_TERM","name":"prostaglandin-endoperoxide synthase activity","canonical_id":"go:GO:0004666","description":"\"Catalysis of the reaction: (5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + 2 O2 = A + H2O + prostaglandin H2.\" [RHEA:23728]","metadata":null},{"id":"c6cd839042fc4ef49892dba3725f2a13","type":"GO_TERM","name":"prostanoid biosynthetic process","canonical_id":"go:GO:0046457","description":"\"The chemical reactions and pathways resulting in the formation of prostanoids, any compound based on or derived from the prostanoate structure.\" [GOC:ai]","metadata":null},{"id":"92b992e2222e452fbd9f3fc0d1f05214","type":"GO_TERM","name":"prostanoid catabolic process","canonical_id":"go:GO:0062232","description":"\"The chemical reactions and pathways resulting in the breakdown of prostanoids.\" [PMID:25449649]","metadata":null},{"id":"98d5d06c7c344b5482b8064b130da4b7","type":"GO_TERM","name":"prostanoid metabolic process","canonical_id":"go:GO:0006692","description":"\"The chemical reactions and pathways involving prostanoids, any compound based on or derived from the prostanoate structure.\" [ISBN:0198506732]","metadata":null},{"id":"e84e320ae80a44bbb887298c5d7dcbe6","type":"GO_TERM","name":"prostanoid receptor activity","canonical_id":"go:GO:0004954","description":"\"Combining with a prostanoid, any compound based on or derived from the prostanoate structure, to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"43d9af7e4f9d48ccb83063182f750ae8","type":"GO_TERM","name":"prostanoid receptor binding","canonical_id":"go:GO:0031862","description":"\"Binding to a prostanoid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e909ab445dab43759ed6b461b7897b1d","type":"DISEASE","name":"prostate adenocarcinoma","canonical_id":"mondo:0005082","description":null,"metadata":null},{"id":"76dd3475f4fe4736a6cdd4a9533e189f","type":"DISEASE","name":"prostate cancer","canonical_id":"mondo:0008315","description":null,"metadata":null},{"id":"8b82f7af6f8f404f8a3e0f4a1545d4f0","type":"DISEASE","name":"prostate carcinoma","canonical_id":"mondo:0005159","description":null,"metadata":null},{"id":"460c49f8e5c94256b5ffed1bfa86a367","type":"GO_TERM","name":"prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis","canonical_id":"go:GO:0060527","description":"\"The branching morphogenesis process in which the prostate epithelial cords branch freely to create the structure of the prostate acini.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"e44bca1352634987bbeca7f57eb348a9","type":"GO_TERM","name":"prostate epithelial cord elongation","canonical_id":"go:GO:0060523","description":"\"The developmental growth process in which solid chords of prostate epithelium increase in length.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"548c8e9a71dc498c92a9777809efea92","type":"GO_TERM","name":"prostate field specification","canonical_id":"go:GO:0060515","description":"\"The process that results in the delineation of a specific region of the urogenital sinus epithelium into the area in which the prostate gland will develop.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"c6eed8f4eb584d0d8328eedcbddb51b5","type":"GO_TERM","name":"prostate gland development","canonical_id":"go:GO:0030850","description":"\"The process whose specific outcome is the progression of the prostate gland over time, from its formation to the mature structure. The prostate gland is a partly muscular, partly glandular body that is situated near the base of the mammalian male urethra and secretes an alkaline viscid fluid which is a major constituent of the ejaculatory fluid.\" [PMID:11839751]","metadata":null},{"id":"aca9e4afe454486bb725b28557d9e413","type":"GO_TERM","name":"prostate gland epithelium morphogenesis","canonical_id":"go:GO:0060740","description":"\"The process in which the anatomical structures of epithelia of the prostate gland are generated and organized. An epithelium consists of closely packed cells arranged in one or more layers, that covers the outer surfaces of the body or lines any internal cavity or tube.\" [GOC:dph]","metadata":null},{"id":"74df427ca9234004a67864d3377c3ca2","type":"GO_TERM","name":"prostate gland growth","canonical_id":"go:GO:0060736","description":"\"The increase in size or mass of the prostate gland where the increase in size or mass has the specific outcome of the progression of the gland, from its formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"8b1f6288027242b38193eb9697f96b8a","type":"GO_TERM","name":"prostate gland morphogenesis","canonical_id":"go:GO:0060512","description":"\"The process in which the anatomical structures of a prostate gland are generated and organized.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"0ac161051e6a47c99585bd110207d241","type":"GO_TERM","name":"prostate gland morphogenetic growth","canonical_id":"go:GO:0060737","description":"\"The differential increase in size or mass of the prostate gland that contributes to the gland attaining its form.\" [GOC:dph]","metadata":null},{"id":"cbd3a6f2cb224f38816da769ad179294","type":"GO_TERM","name":"prostate gland stromal morphogenesis","canonical_id":"go:GO:0060741","description":"\"The process in which the prostate gland stroma is generated and organized. The prostate gland stroma is made up of the mesenchymal or fibroblast cells of the prostate gland.\" [GOC:dph]","metadata":null},{"id":"cb7a42acb4bf40ad886ac007d7312939","type":"GO_TERM","name":"prostate glandular acinus development","canonical_id":"go:GO:0060525","description":"\"The progression of a glandular acinus of the prostate gland over time, from its initial formation to the mature structure. The glandular acini are the saclike structures of the gland.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"10fa558633dd4e408b0939323c1b57da","type":"GO_TERM","name":"prostate glandular acinus morphogenesis","canonical_id":"go:GO:0060526","description":"\"The process in which the prostate glandular acini are generated and organized. The glandular acini are the saclike structures of the gland.\" [GOC:dph]","metadata":null},{"id":"0ef73171d5124c7aba4533a63a27f165","type":"GO_TERM","name":"prostate induction","canonical_id":"go:GO:0060514","description":"\"The close range interaction of the urogenital sinus mesenchyme and the urogenital sinus epithelium that causes the cells of the urogenital sinus epithelium to change their fates and specify the development of the prostate gland.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"28cdd10246f447e8ba15457f83c278bc","type":"DISEASE","name":"prostate neoplasm","canonical_id":"mondo:0021259","description":null,"metadata":null},{"id":"2c3b530c23dd4077a6db1a9c18f5ea81","type":"GO_TERM","name":"prostatic bud formation","canonical_id":"go:GO:0060513","description":"\"The morphogenetic process in which a region of the fetal urogenital sinus epithelium is specified to become the prostate, resulting in prostate bud outgrowth.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"ec3eacbb9cb9449faa56626a285c4038","type":"GO_TERM","name":"prosthetic group binding","canonical_id":"go:GO:0051192","description":"\"Binding to a prosthetic group, the non-amino acid portion of certain protein molecules. Prosthetic groups may be inorganic or organic and are usually required for the biological activity of the protein.\" [GOC:ai, GOC:vw]","metadata":null},{"id":"cd718d7a682d47e4b6975187366d88f6","type":"GO_TERM","name":"prosthetic group biosynthetic process","canonical_id":"go:GO:0051191","description":"\"The chemical reactions and pathways resulting in the formation of a prosthetic group, the non-amino acid portion of certain protein molecules. Prosthetic groups may be inorganic or organic and are usually required for the biological activity of the protein.\" [GOC:ai]","metadata":null},{"id":"b7e675b7f7d143f38755e9e2aa29e0eb","type":"GO_TERM","name":"prosthetic group catabolic process","canonical_id":"go:GO:0051190","description":"\"The chemical reactions and pathways resulting in the breakdown of a prosthetic group, the non-amino acid portion of certain protein molecules. Prosthetic groups may be inorganic or organic and are usually required for the biological activity of the protein.\" [GOC:ai]","metadata":null},{"id":"bf8a551413ca4e5887aa9041dfd10885","type":"GO_TERM","name":"prosthetic group metabolic process","canonical_id":"go:GO:0051189","description":"\"The chemical reactions and pathways involving a prosthetic group, the non-amino acid portion of certain protein molecules. Prosthetic groups may be inorganic or organic and are usually required for the biological activity of the protein.\" [GOC:ai]","metadata":null},{"id":"b0a54dcd50ea49d59281953651a1acd7","type":"GO_TERM","name":"proteaphagy","canonical_id":"go:GO:0061816","description":"\"The selective degradation of proteasomes by macroautophagy.\" [GOC:dph, GOC:se, PMID:26670610, PMID:27477278]","metadata":null},{"id":"7b8e9f40e967496ab468ca2152bbbd30","type":"GO_TERM","name":"protease binding","canonical_id":"go:GO:0002020","description":"\"Binding to a protease or a peptidase.\" [GOC:hjd]","metadata":null},{"id":"f2910ffa3ae3489b8a06fd253baada71","type":"GO_TERM","name":"protease inhibitor complex","canonical_id":"go:GO:0097179","description":"\"A heterodimeric protein complex that contains a protease inhibitor and a protease; formation of the complex inhibits protease activity.\" [GOC:ans, PMID:6323392]","metadata":null},{"id":"7ba742b41a474552a7977c41df33c6a6","type":"GO_TERM","name":"protease localization to T cell secretory granule","canonical_id":"go:GO:0033375","description":"\"Any process in which a protease is transported to, or maintained in, a location within a secretory granule in a T cell.\" [GOC:mah]","metadata":null},{"id":"858c3043f724410da8142afde937516b","type":"GO_TERM","name":"protease localization to mast cell secretory granule","canonical_id":"go:GO:0033368","description":"\"Any process in which a protease is transported to, or maintained in, a location within a secretory granule in a mast cell.\" [GOC:mah]","metadata":null},{"id":"4d84cb9ea5a64f36afd2612200cbb54c","type":"GO_TERM","name":"proteasomal protein catabolic process","canonical_id":"go:GO:0010498","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome.\" [GOC:tb]","metadata":null},{"id":"dc29d7655de94d5493f0e54b9524df6f","type":"GO_TERM","name":"proteasomal proteolysis associated with antigen processing and presentation","canonical_id":"go:GO:0002497","description":"\"The hydrolysis of a peptide bond or bonds within a protein by the proteasome complex contributing to antigen processing and presentation.\" [GOC:add, ISBN:0781735149, PMID:15224092, PMID:15771591]","metadata":null},{"id":"7c6fdd5bb80744c09102818eaef4aa5a","type":"GO_TERM","name":"proteasomal ubiquitin-independent protein catabolic process","canonical_id":"go:GO:0010499","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome but do not involve ubiquitin.\" [GOC:tb]","metadata":null},{"id":"3b3c29701f4b442eaa116264016f4f00","type":"GO_TERM","name":"proteasome accessory complex","canonical_id":"go:GO:0022624","description":"\"A protein complex, that caps one or both ends of the proteasome core complex and regulates entry into, or exit from, the proteasome core complex.\" [GOC:mtg_sensu]","metadata":null},{"id":"cf255dd090354a92b04b702bd5abc355","type":"GO_TERM","name":"proteasome activator complex","canonical_id":"go:GO:0008537","description":"\"A multisubunit complex that activates the hydrolysis of small nonubiquitinated peptides by binding to the proteasome core complex.\" [GOC:rb]","metadata":null},{"id":"d4aeb5c57aa84129b7469ad86dd89959","type":"GO_TERM","name":"proteasome assembly","canonical_id":"go:GO:0043248","description":"\"The aggregation, arrangement and bonding together of a mature, active proteasome complex.\" [GOC:curators, PMID:10872471]","metadata":null},{"id":"3f17576132d347649045610e4927b44f","type":"GO_TERM","name":"proteasome binding","canonical_id":"go:GO:0070628","description":"\"Binding to a proteasome, a large multisubunit protein complex that catalyzes protein degradation.\" [GOC:mah]","metadata":null},{"id":"dfd39abe07fc4041a732ff87f139277c","type":"GO_TERM","name":"proteasome complex","canonical_id":"go:GO:0000502","description":"\"A large multisubunit complex which catalyzes protein degradation, found in eukaryotes, archaea and some bacteria. In eukaryotes, this complex consists of the barrel shaped proteasome core complex and one or two associated proteins or complexes that act in regulating entry into or exit from the core.\" [GOC:rb, Wikipedia:Proteasome]","metadata":null},{"id":"a494aca4479842799582d65d6522cca2","type":"GO_TERM","name":"proteasome complex disassembly","canonical_id":"go:GO:1903009","description":"\"The disaggregation of a proteasome complex into its constituent components.\" [GO_REF:0000079, GOC:TermGenie]","metadata":null},{"id":"cc8f3d2ac59b40599b4c7ebe874c494d","type":"GO_TERM","name":"proteasome core complex","canonical_id":"go:GO:0005839","description":"\"A multisubunit barrel shaped endoprotease complex, which is the core of the proteasome complex.\" [GOC:rb, PMID:10806206]","metadata":null},{"id":"68d58a0e8390469392787bac8f668834","type":"GO_TERM","name":"proteasome core complex assembly","canonical_id":"go:GO:0080129","description":"\"The aggregation, arrangement and bonding together of a mature, active 20S proteasome core particle complex that does not contain any regulatory particles.\" [PMID:12401807, PMID:17971041]","metadata":null},{"id":"588d55d56aed49d3af9e39d118404b44","type":"GO_TERM","name":"proteasome core complex binding","canonical_id":"go:GO:1904854","description":"\"Binding to a proteasome core complex.\" [GOC:TermGenie, PMID:16096059]","metadata":null},{"id":"e2e159a2670744518525e301a403b3d6","type":"GO_TERM","name":"proteasome core complex import into nucleus","canonical_id":"go:GO:1990236","description":"\"The directed movement of the proteasome core complex (AKA core particle (CP)) from the cytoplasm into the nucleus.\" [GOC:dos, GOC:rb, PMID:23982732]","metadata":null},{"id":"6f9247d8396243b5aaf7f941ad8464b2","type":"GO_TERM","name":"proteasome core complex, alpha-subunit complex","canonical_id":"go:GO:0019773","description":"\"The proteasome core subcomplex that constitutes the two outer rings of the proteasome core complex. An example of this component is found in Mus musculus.\" [GOC:jl, GOC:mtg_sensu, GOC:rb, PMID:10854779]","metadata":null},{"id":"f1fa269b8dfe43918fadd94726c760f3","type":"GO_TERM","name":"proteasome core complex, beta-subunit complex","canonical_id":"go:GO:0019774","description":"\"The proteasome core subcomplex that constitutes the two inner rings of the proteasome core complex. An example of this component is found in Mus musculus.\" [GOC:jl, GOC:mtg_sensu, GOC:rb, PMID:10854779]","metadata":null},{"id":"fe9c6655a7af4aa3832d82ccaaf4eb16","type":"GO_TERM","name":"proteasome localization","canonical_id":"go:GO:0031144","description":"\"Any process in which the proteasome is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"17b5b064638946c99a643bca70eb9414","type":"GO_TERM","name":"proteasome regulatory particle","canonical_id":"go:GO:0005838","description":"\"A multisubunit complex, which caps one or both ends of the proteasome core complex. This complex recognizes and unfolds ubiquitinated proteins, and translocates them to the proteasome core complex.\" [GOC:mtg_sensu, GOC:rb]","metadata":null},{"id":"4c299b1460114457aa14ec9460779461","type":"GO_TERM","name":"proteasome regulatory particle assembly","canonical_id":"go:GO:0070682","description":"\"The aggregation, arrangement and bonding together of a mature, active proteasome regulatory particle complex.\" [GOC:mah, GOC:rb, PMID:19412159]","metadata":null},{"id":"7d9e589649e54aaea18d58f8ea22652a","type":"GO_TERM","name":"proteasome regulatory particle binding","canonical_id":"go:GO:1904855","description":"\"Binding to a proteasome regulatory particle.\" [GOC:TermGenie, PMID:16096059]","metadata":null},{"id":"56fda7fbab1045398d6abd28c85a62b6","type":"GO_TERM","name":"proteasome regulatory particle, base subcomplex","canonical_id":"go:GO:0008540","description":"\"The subcomplex of the proteasome regulatory particle that directly associates with the proteasome core complex.\" [GOC:mtg_sensu, GOC:rb]","metadata":null},{"id":"c76e2ce43e934fe2b7ca86ef4bf64519","type":"GO_TERM","name":"proteasome regulatory particle, lid subcomplex","canonical_id":"go:GO:0008541","description":"\"The subcomplex of the proteasome regulatory particle that forms the peripheral lid, which is added on top of the base subcomplex.\" [GOC:rb]","metadata":null},{"id":"63870ad6e0944944a0858d554545f34e","type":"GO_TERM","name":"proteasome storage granule","canonical_id":"go:GO:0034515","description":"\"An aggregation of proteasome core protease (CP) and regulatory particle (RP) complexes that localizes in the cytoplasm as dot-like structures when cells are in a quiescent state.\" [GOC:krc, GOC:rb, PMID:18504300, PMID:30204036]","metadata":null},{"id":"108932f3f16f44fa822584ff25acd074","type":"GO_TERM","name":"proteasome storage granule assembly","canonical_id":"go:GO:1902906","description":"\"The aggregation, arrangement and bonding together of a set of components to form a proteasome storage granule.\" [GO_REF:0000079, GOC:di, GOC:TermGenie, PMID:23690178]","metadata":null},{"id":"b8d0672485a943f3bd3dabd7b84e8610","type":"GO_TERM","name":"proteasome storage granule disassembly","canonical_id":"go:GO:1902907","description":"\"The disaggregation of a proteasome storage granule into its constituent components.\" [GO_REF:0000079, GOC:di, GOC:TermGenie, PMID:23690178]","metadata":null},{"id":"3459f30d4759460ea7172d6f2c61af1a","type":"GO_TERM","name":"proteasome-activating activity","canonical_id":"go:GO:0036402","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate, which promotes unfolding of protein substrates, and channel opening of the core proteasome.\" [GOC:rb, PMID:11430818]","metadata":null},{"id":"9612e89e198e44718d24081d3d01578e","type":"GO_TERM","name":"proteasome-activating nucleotidase complex","canonical_id":"go:GO:0022623","description":"\"A homohexameric complex that recognizes and unfolds core proteasome substrate proteins, and translocates them to the core complex in an ATP dependent manner.\" [GOC:bf, GOC:mtg_sensu, PMID:19363223, PMID:19481528]","metadata":null},{"id":"4739a48f73184e4c9d3e33604c2758e5","type":"GO_TERM","name":"proteasome-mediated ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0043161","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.\" [GOC:curators]","metadata":null},{"id":"79a1c85227f74139a8a0de74c9c9cbc6","type":"GO_TERM","name":"proteasome-nuclear membrane anchor activity","canonical_id":"go:GO:1990919","description":"\"The binding activity of a molecule that brings together a proteasome complex and a nuclear inner membrane, to maintain the nuclear membrane localization of the proteasome.\" [PMID:16096059]","metadata":null},{"id":"8af001c7590c45728c1881a1c88f91ee","type":"GO_TERM","name":"protection from natural killer cell mediated cytotoxicity","canonical_id":"go:GO:0042270","description":"\"The process of protecting a cell from natural killer cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7c71fbf554694c18952f6ee661606636","type":"GO_TERM","name":"protection from non-homologous end joining at telomere","canonical_id":"go:GO:0031848","description":"\"A process that prevents non-homologous end joining at telomere, thereby ensuring that telomeres do not fuse.\" [GOC:mah]","metadata":null},{"id":"af15dbb079434497baf5b8e131791580","type":"GO_TERM","name":"protein ADP-ribosyltransferase-substrate adaptor activity","canonical_id":"go:GO:0140768","description":"\"An enzyme-substrate adaptor that bings together a protein ADP-ribosyl transferase and its substrate.\" [PMID:32028527]","metadata":null},{"id":"ca72cb0ac5814f0d9d6303dda0dfeedb","type":"GO_TERM","name":"protein C inhibitor-KLK3 complex","canonical_id":"go:GO:0036029","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and prostate-specific antigen (KLK3); formation of the complex inhibits the serine protease activity of prostate-specific antigen.\" [GOC:ans, PMID:1725227]","metadata":null},{"id":"49ea42ba394b44fabbfc40ed7ce2a598","type":"GO_TERM","name":"protein C inhibitor-PLAT complex","canonical_id":"go:GO:0036026","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and tissue-type plasminogen activator (PLAT); formation of the complex inhibits the serine protease activity of tissue-type plasminogen activator.\" [GOC:ans, PMID:10340997]","metadata":null},{"id":"186b0d684449426a96d6f38613b1500e","type":"GO_TERM","name":"protein C inhibitor-PLAU complex","canonical_id":"go:GO:0036027","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and urokinase-type plasminogen activator (PLAU); formation of the complex inhibits the serine protease activity of urokinase-type plasminogen activator.\" [GOC:ans, PMID:10340997, PMID:3501295, PMID:8536714]","metadata":null},{"id":"02cde74c0042411b943b8869ecb03b49","type":"GO_TERM","name":"protein C inhibitor-TMPRSS11E complex","canonical_id":"go:GO:0036025","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and transmembrane protease serine 11E (TMPRSS11E); formation of the complex inhibits the serine protease activity of transmembrane protease serine 11E.\" [GOC:ans, PMID:15328353]","metadata":null},{"id":"b26cb33565e3422e958ac5be8232fabf","type":"GO_TERM","name":"protein C inhibitor-TMPRSS7 complex","canonical_id":"go:GO:0036024","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and transmembrane protease serine 7 (TMPRSS7); formation of the complex inhibits the serine protease activity of transmembrane protease serine 7.\" [GOC:ans, PMID:15853774]","metadata":null},{"id":"11724af0df8b41a9ad5003d51ec917e3","type":"GO_TERM","name":"protein C inhibitor-acrosin complex","canonical_id":"go:GO:0033282","description":"\"A heterodimeric protein complex of protein C inhibitor (SERPINA5) and acrosin; formation of the complex inhibits the protease activity of acrosin.\" [GOC:pr, PMID:11120760, PMID:7521127]","metadata":null},{"id":"6b363174b5084889893984fb21851365","type":"GO_TERM","name":"protein C inhibitor-coagulation factor V complex","canonical_id":"go:GO:0097181","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and coagulation factor V (F5); formation of the complex inhibits the serine protease activity of coagulation factor V.\" [GOC:ans, PMID:6323392]","metadata":null},{"id":"ba23c0a995724642be81f58f1530c04d","type":"GO_TERM","name":"protein C inhibitor-coagulation factor XI complex","canonical_id":"go:GO:0097183","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and coagulation factor XI (F11); formation of the complex inhibits the serine protease activity of coagulation factor XI.\" [GOC:ans, PMID:2844223]","metadata":null},{"id":"31b2988b3ae44be68767bd6061c03780","type":"GO_TERM","name":"protein C inhibitor-coagulation factor Xa complex","canonical_id":"go:GO:0097182","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and coagulation factor Xa (F10); formation of the complex inhibits the serine protease activity of coagulation factor Xa.\" [GOC:ans, PMID:6323392]","metadata":null},{"id":"528e119185ed41dfa3701bf4149c2b12","type":"GO_TERM","name":"protein C inhibitor-plasma kallikrein complex","canonical_id":"go:GO:0036030","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and plasma kallikrein (KLK1B); formation of the complex inhibits the serine protease activity of plasma kallikrein.\" [GOC:ans, PMID:2844223, PMID:8536714]","metadata":null},{"id":"686612be1df142eba184ac738d77897d","type":"GO_TERM","name":"protein C inhibitor-thrombin complex","canonical_id":"go:GO:0036028","description":"\"A heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and thrombin (F2); formation of the complex inhibits the serine protease activity of thrombin.\" [GOC:ans, PMID:6323392]","metadata":null},{"id":"c636dc017db54ff3b8176f5b934886a7","type":"GO_TERM","name":"protein C-linked glycosylation","canonical_id":"go:GO:0018103","description":"\"A protein glycosylation process in which a carbohydrate or carbohydrate derivative unit is added to a protein via a C atom.\" [PMID:35536965, PMID:7947762]","metadata":null},{"id":"8c9843e16f8740ec879337d706ed1abc","type":"GO_TERM","name":"protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activity","canonical_id":"go:GO:0004671","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester.\" [EC:2.1.1.100]","metadata":null},{"id":"37e62f301ad648a18240cba0e2c870c1","type":"GO_TERM","name":"protein C-terminal carboxyl O-methyltransferase activity","canonical_id":"go:GO:0003880","description":"\"Catalysis of the transfer of a methyl group to the oxygen atom of a carboxyl group at the C-terminal of a protein.\" [PMID:8428937]","metadata":null},{"id":"788c53d87641472980c176add60e13db","type":"GO_TERM","name":"protein C-terminal leucine carboxyl O-methyltransferase activity","canonical_id":"go:GO:0018423","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + [protein]-L-leucine = S-adenosyl-L-homocysteine + [protein]-L-leucine methyl ester. This modification occurs only at the oxygen atoms of the free alpha carboxyl group of a leucine residue at the C-terminus of the protein.\" [PMID:8514774]","metadata":null},{"id":"a256835c89c947d3a7f4cf26cd4bcdd9","type":"GO_TERM","name":"protein K11-linked deubiquitination","canonical_id":"go:GO:0035871","description":"\"A protein deubiquitination process in which a K11-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 11 of the ubiquitin monomers, is removed from a protein.\" [GOC:sp, PMID:21596315]","metadata":null},{"id":"4ebac44f48034232a3861d1abc552a4e","type":"GO_TERM","name":"protein K11-linked ubiquitination","canonical_id":"go:GO:0070979","description":"\"A protein ubiquitination process in which ubiquitin monomers are attached to a protein, and then ubiquitin polymers are formed by linkages between lysine residues at position 11 of the ubiquitin monomers. K11-linked polyubiquitination targets the substrate protein for degradation. The anaphase-promoting complex promotes the degradation of mitotic regulators by assembling K11-linked polyubiquitin chains.\" [GOC:jsg, GOC:pr, GOC:sp, PMID:18485873, PMID:20655260, PMID:21113135]","metadata":null},{"id":"a4b6c4b6efab46d8be384b3c17406a32","type":"GO_TERM","name":"protein K27-linked deubiquitination","canonical_id":"go:GO:1990167","description":"\"A protein deubiquitination process in which a K27-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 27 of the ubiquitin monomers, is removed from a protein.\" [PMID:23827681]","metadata":null},{"id":"9aed3adce4c64a698d2f9a51ef7edefd","type":"GO_TERM","name":"protein K27-linked ubiquitination","canonical_id":"go:GO:0044314","description":"\"A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 27 of the ubiquitin monomers, is added to a protein.\" [PMID:19345326]","metadata":null},{"id":"ab5807501fb3462d9b33474731480abc","type":"GO_TERM","name":"protein K29-linked deubiquitination","canonical_id":"go:GO:0035523","description":"\"A protein deubiquitination process in which a K29-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 29 of the ubiquitin monomers, is removed from a protein.\" [GOC:bf]","metadata":null},{"id":"740d441809454c27bde4cd6a5efbe92e","type":"GO_TERM","name":"protein K29-linked ubiquitination","canonical_id":"go:GO:0035519","description":"\"A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 29 of the ubiquitin monomers, is added to a protein. K29-linked ubiquitination targets the substrate protein for degradation.\" [PMID:17028573]","metadata":null},{"id":"fa8cf04d917d4b0ebe0acb39c4ddf98b","type":"GO_TERM","name":"protein K33-linked deubiquitination","canonical_id":"go:GO:1990168","description":"\"A protein deubiquitination process in which a K33-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 33 of the ubiquitin monomers, is removed from a protein.\" [PMID:23827681]","metadata":null},{"id":"123bf4d273564edf84fdc8ebeb3ac581","type":"GO_TERM","name":"protein K33-linked ubiquitination","canonical_id":"go:GO:1990390","description":"\"A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 33 of the ubiquitin monomers, is added to a protein.\" [PMID:24768539]","metadata":null},{"id":"629fd6b29f78462ab0e187d9baaff254","type":"GO_TERM","name":"protein K48-linked deubiquitination","canonical_id":"go:GO:0071108","description":"\"A protein deubiquitination process in which a K48-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is removed from a protein.\" [GOC:mah]","metadata":null},{"id":"da428a881f694f6aafbd04a35ff4c0dc","type":"GO_TERM","name":"protein K48-linked ubiquitination","canonical_id":"go:GO:0070936","description":"\"A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is added to a protein. K48-linked ubiquitination targets the substrate protein for degradation.\" [GOC:cvs, PMID:15556404]","metadata":null},{"id":"18025ba45ca044adbeacf85191e62ae4","type":"GO_TERM","name":"protein K6-linked deubiquitination","canonical_id":"go:GO:0044313","description":"\"A protein deubiquitination process in which a K6-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 6 of the ubiquitin monomers, is removed from a protein.\" [GOC:sp]","metadata":null},{"id":"b941deef51a84cf3ab79d5f2a0c208b2","type":"GO_TERM","name":"protein K6-linked ubiquitination","canonical_id":"go:GO:0085020","description":"\"A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 6 of the ubiquitin monomers, is added to a protein. K6-linked ubiquitination is involved in DNA repair.\" [GOC:sp]","metadata":null},{"id":"0427c8bf7f1442408ec984ca11e5939d","type":"GO_TERM","name":"protein K63-linked deubiquitination","canonical_id":"go:GO:0070536","description":"\"A protein deubiquitination process in which a K63-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 63 of the ubiquitin monomers, is removed from a protein.\" [GOC:mah, PMID:19202061, PMID:19214193]","metadata":null},{"id":"5ad980cbf2be412f9b099173a3525e4e","type":"GO_TERM","name":"protein K63-linked ubiquitination","canonical_id":"go:GO:0070534","description":"\"A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 63 of the ubiquitin monomers, is added to a protein. K63-linked ubiquitination does not target the substrate protein for degradation, but is involved in several pathways, notably as a signal to promote error-free DNA postreplication repair.\" [GOC:mah, PMID:15556404]","metadata":null},{"id":"45f0cd416921499eae451a24ee373961","type":"GO_TERM","name":"protein K69-linked ufmylation","canonical_id":"go:GO:1990592","description":"\"A protein ufmylation process in which a polymer of the ubiquitin-like protein UFM1 is formed by linkages between lysine residues at position 69 of the UFM1 monomers, is added to a protein.\" [PMID:25219498]","metadata":null},{"id":"4da8d01fab5340c4979966627795bbc2","type":"GO_TERM","name":"protein N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0016262","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + protein = UDP + 4-N-(N-acetyl-D-glucosaminyl)-protein.\" [EC:2.4.1.94]","metadata":null},{"id":"da056754f4824c448bec3f781b13b2f2","type":"GO_TERM","name":"protein N-acetylglucosaminyltransferase complex","canonical_id":"go:GO:0017122","description":"\"A protein complex capable of protein N-acetylglucosaminyltransferase activity, the addition of nucleotide-activated sugars onto the polypeptide according to reaction: UDP-N-acetyl-D-glucosamine + protein = UDP + 4-N-(N-acetyl-D-glucosaminyl)-protein. The complex has different compositions in different species: In mammals it is often a homotrimer, in bacteria a heterotetramer of 2 different subunits.\" [PMID:15247246]","metadata":null},{"id":"30b15e248d264667b2c7d1d19a812e84","type":"GO_TERM","name":"protein N-acetyltransferase activity","canonical_id":"go:GO:0034212","description":"\"Catalysis of the acetylation of an amino acid residue of a peptide or protein, according to the reaction: acetyl-CoA + peptide = CoA + N-acetylpeptide.\" [GOC:mah]","metadata":null},{"id":"3e80b712fb3c42f0b87c5d38eabf6082","type":"GO_TERM","name":"protein N-acyltransferase activity","canonical_id":"go:GO:0140186","description":"\"Catalysis of the reaction: an acyl-CoA + L-lysyl-[protein] = N6-acyl-L-lysyl-[protein] + CoA + H+.\" [RHEA:53916]","metadata":null},{"id":"824c31823ee34e9d86499010b3a6415b","type":"GO_TERM","name":"protein N-linked glycosylation","canonical_id":"go:GO:0006487","description":"\"A protein glycosylation process in which a carbohydrate or carbohydrate derivative unit is added to a protein via the N4 atom of an asparagine residue.\" [PMID:35536965]","metadata":null},{"id":"bd6bf75fcb28454d93d549caa13f0d30","type":"GO_TERM","name":"protein N-terminal-methionine acetyltransferase activity","canonical_id":"go:GO:0120518","description":"\"Catalysis of the reaction: acetyl-CoA + N-terminal L-methionyl-[protein] = CoA + H+ + N-terminal N(alpha)-acetyl-L-methionyl-[protein].\" [RHEA:75239]","metadata":null},{"id":"30d565237bb642808f55bc064d0095a1","type":"GO_TERM","name":"protein N-terminal-serine acetyltransferase activity","canonical_id":"go:GO:1990189","description":"\"Catalysis of the reaction: acetyl-CoA + N-terminal L-seryl-[protein] = CoA + H+ + N-terminal Nalpha-acetyl-L-seryl-[protein].\" [PMID:23912279, RHEA:50504]","metadata":null},{"id":"13e6f5a2927c41e582c45dc3bce8fb69","type":"GO_TERM","name":"protein O-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0097363","description":"\"Catalysis of the reaction: UDP-N-acetyl-D-glucosamine + [protein]-L-serine = UDP + [protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine, or UDP-N-acetyl-D-glucosamine + [protein]-L-threonine = UDP + [protein]-3-O-(N-acetyl-D-glucosaminyl)-L-threonine.\" [GOC:jsg, GOC:sart, PMID:22158438]","metadata":null},{"id":"b59dbd54557145bb963ec829ad1e8800","type":"GO_TERM","name":"protein O-linked glycosylation","canonical_id":"go:GO:0006493","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of carbohydrate or carbohydrate derivative unit via a glycosidic bond to the oxygen atom of a serine, threonine, hydroxylysine, hydroxyproline or tyrosine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan.\" [PMID:33775405]","metadata":null},{"id":"145fccf3b08d48a1ad73b9f08d53a3f8","type":"GO_TERM","name":"protein O-linked glycosylation via N-acetylgalactosamine","canonical_id":"go:GO:0016266","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of an N-acetyl-galactosamine via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan.\" [PMID:10580130, PMID:35536936]","metadata":null},{"id":"784ab2005e9f47fe841b6d4f97eadb9e","type":"GO_TERM","name":"protein O-linked glycosylation via N-acetylglucosamine","canonical_id":"go:GO:7770074","description":"\"A glycoprotein biosynthetic process in which a single N-acetylglucosamine is covalently linked via a beta-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, resulting in the formation of a protein O-linked glycan. The sugar is not elongated into a larger oligosaccharide chain.\" [PMID:35536957]","metadata":null},{"id":"c4b1685bfa9e44ea923ebef34366be10","type":"GO_TERM","name":"protein O-linked glycosylation via arabinose","canonical_id":"go:GO:0180063","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of an arabinose via a beta-glycosidic bond to the oxygen atom of the hydroxyl group of a hydroxyproline in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan.\" [PMID:33815452]","metadata":null},{"id":"3fc27d65d7204526b63f44d225f4ed3f","type":"GO_TERM","name":"protein O-linked glycosylation via fucose","canonical_id":"go:GO:0036066","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of a fucose via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan. This modification typically occurs within specific motifs, such as EGF-like or thrombospondin type-1 repeats.\" [PMID:16899492, PMID:35536928]","metadata":null},{"id":"a62a1d12db9e4767b7544f9dff895d09","type":"GO_TERM","name":"protein O-linked glycosylation via galactose","canonical_id":"go:GO:0180062","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of galactose via a beta-glycosidic bond to the oxygen atom of the hydroxyl group of a hydroxyproline, a hydroxylysine, a serine or a threonine in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan. Hydroxylysine modification occurs in the endoplasmic reticulum and is predominantly found in collagen. Hydroxyproline modification occurs in the Golgi and is found only in plant proteins.\" [PMID:17516569, PMID:30822656, PMID:33815452]","metadata":null},{"id":"8bfdb9ecbf8b41d98a27f9f11dddf91b","type":"GO_TERM","name":"protein O-linked glycosylation via glucose","canonical_id":"go:GO:0180059","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of a glucose via a beta-glycosidic bond to the oxygen atom of a serine, threonine or tyrosine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan.\" [PMID:35536928]","metadata":null},{"id":"696837d308fb41668d1220896277a374","type":"GO_TERM","name":"protein O-linked glycosylation via mannose","canonical_id":"go:GO:0035269","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of a mannose via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan.\" [PMID:35536928]","metadata":null},{"id":"873790cf71fe4174b3fdf9223b41649b","type":"GO_TERM","name":"protein O-linked glycosylation via xylose","canonical_id":"go:GO:0180064","description":"\"A glycoprotein biosynthetic process starting with the covalent linkage of a xylose via a beta-glycosidic bond to the oxygen atom of a serine or a threonine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan.\" [PMID:22117070]","metadata":null},{"id":"daf5e0c9601e4736a36d62628aa292b5","type":"GO_TERM","name":"protein S-linked glycosylation","canonical_id":"go:GO:0018280","description":"\"A protein glycosylation process in which a carbohydrate or carbohydrate derivative unit is added to a protein via a sulfur atom of a peptidyl-amino-acid such as cysteine or methionine.\" [GOC:ai, GOC:jsg, GOC:pr]","metadata":null},{"id":"54caca24ef564633bf6821e8611efe03","type":"GO_TERM","name":"protein acetylation","canonical_id":"go:GO:0006473","description":"\"The addition of an acetyl group to a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [GOC:ai]","metadata":null},{"id":"851ecf48eeb84cda85066abc1c172d53","type":"GO_TERM","name":"protein acetyltransferase complex","canonical_id":"go:GO:0031248","description":"\"A complex that catalyzes the transfer of an acetyl group to a protein acceptor molecule.\" [GOC:bf]","metadata":null},{"id":"b255b82e83b946aa9a00fdcb752743ee","type":"GO_TERM","name":"protein activation cascade","canonical_id":"go:GO:0072376","description":"\"A sequential series of modifications to a set of proteins where the product of one reaction catalyzes the following reaction, ultimately leading to the generation of a mature protein. Modifications typically include proteolysis or covalent modification, and may also include binding events.\" [GOC:add, GOC:mah, GOC:pde]","metadata":null},{"id":"a2d5836221424cf3a8a7132cc5c0746b","type":"GO_TERM","name":"protein acylation","canonical_id":"go:GO:0043543","description":"\"The addition of an acyl group, any group or radical of the form RCO- where R is an organic group, to a protein amino acid.\" [GOC:jl]","metadata":null},{"id":"4da3726bef4345f9907ec04d8fbdc42c","type":"GO_TERM","name":"protein adenylylation","canonical_id":"go:GO:0018117","description":"\"The addition of an adenylyl group (adenosine 5'-monophosphate; AMP) to a protein amino acid.\" [GOC:ai, GOC:jsg, GOC:sart, PMID:21607083]","metadata":null},{"id":"34f0241462074bacb24772f40f25d0cc","type":"GO_TERM","name":"protein adenylylhydrolase activity","canonical_id":"go:GO:0044603","description":"\"Catalysis of the reaction: adenylyl-protein+ H2O = adenylate + protein; mediates the removal of an adenylyl (adenosine 5'-monophosphate; AMP group) from specific residues of target proteins.\" [PMID:21734656]","metadata":null},{"id":"ea1a0400777b4361a81165930c97f231","type":"GO_TERM","name":"protein aggregate center","canonical_id":"go:GO:0140453","description":"\"Reversible aggregate of misfolded proteins and chaperones formed to shield thermosensitive proteins from degradation until conditions allow disaggregation and refolding.\" [PMID:32075773]","metadata":null},{"id":"d90103e6e2ed4248aa9830fb981fb52b","type":"GO_TERM","name":"protein aggregate center assembly","canonical_id":"go:GO:0140454","description":"\"The reversible aggregation of misfolded proteins and chaperones, formed to shield thermosensitive proteins from degradation until conditions allow disaggregation and refolding.\" [PMID:32075773]","metadata":null},{"id":"82140af8cfef46fe9ca643f4243377bd","type":"GO_TERM","name":"protein alkylation","canonical_id":"go:GO:0008213","description":"\"The addition of an alkyl group to a protein amino acid. Alkyl groups are derived from alkanes by removal of one hydrogen atom.\" [GOC:ma]","metadata":null},{"id":"06c53c6f3102449fa4d5fea717633b88","type":"GO_TERM","name":"protein alpha-1,2-demannosylation","canonical_id":"go:GO:0036508","description":"\"The removal of one or more alpha 1,2-linked mannose residues from a mannosylated protein.\" [GOC:bf, GOC:PARL, PMID:21062743, PMID:25092655]","metadata":null},{"id":"e90d128e179f4fb5ba2d9d6431e52a92","type":"GO_TERM","name":"protein antigen binding","canonical_id":"go:GO:1990405","description":"\"Binding to a protein antigen.\" [PMID:9360996]","metadata":null},{"id":"7c6dbdc5c06442dab5c59d7cf24a2c8e","type":"GO_TERM","name":"protein arginine N5-methyltransferase activity","canonical_id":"go:GO:0019702","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the delta-nitrogen atom of peptidyl-arginine residues. The reaction is S-adenosyl-L-methionine + [protein]-L-arginine = S-adenosyl-L-homocysteine + [protein]-N5-methyl-L-arginine.\" [EC:2.1.1.322, PMID:11856739, PMID:9873020]","metadata":null},{"id":"bdbcf99327b34a4181af7e425d073063","type":"GO_TERM","name":"protein arginine kinase activity","canonical_id":"go:GO:1990424","description":"\"Catalysis of the reaction: ATP + a protein arginine = ADP + protein arginine phosphate.\" [PMID:22517742, RHEA:43384]","metadata":null},{"id":"26c7b1e1100a455988e2c2a701ad5e3f","type":"GO_TERM","name":"protein arginine phosphatase activity","canonical_id":"go:GO:0098627","description":"\"Catalysis of the reaction: phospho-L-arginyl-[protein] +H2O = L-arginyl-[protein] + phosphate.\" [PMID:23770242, RHEA:43380]","metadata":null},{"id":"9276f44924ee40df84756e7eec325373","type":"GO_TERM","name":"protein arginylation","canonical_id":"go:GO:0016598","description":"\"The conjugation of arginine to the N-terminal aspartate or glutamate of a protein; required for the degradation of the protein via the ubiquitin pathway.\" [PMID:17896865]","metadata":null},{"id":"c770e650cf954f01b7c1cd385aebde62","type":"GO_TERM","name":"protein asparagine deamidase activity","canonical_id":"go:GO:0160260","description":"\"Catalysis of the reaction: L-asparaginyl-[protein] + H2O = L-aspartyl-[protein] + NH4+.\" [PMID:25752576, PMID:30092200, PMID:39719712, PMID:40240600, RHEA:57416]","metadata":null},{"id":"ebd7f5982d294993a74acdd77f98b54d","type":"GO_TERM","name":"protein auto-ADP-ribosylation","canonical_id":"go:GO:0070213","description":"\"The ADP-ribosylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"bb412a78722b481482e386f966c8ab43","type":"GO_TERM","name":"protein autophosphorylation","canonical_id":"go:GO:0046777","description":"\"The phosphorylation by a protein of one or more of its own amino acid residues (cis-autophosphorylation), or residues on an identical protein (trans-autophosphorylation).\" [ISBN:0198506732]","metadata":null},{"id":"ee4338c7f77649239545320aebe23818","type":"GO_TERM","name":"protein autoprocessing","canonical_id":"go:GO:0016540","description":"\"Processing which a protein carries out itself. This involves actions such as the autolytic removal of residues to generate the mature form of the protein.\" [GOC:ai, PMID:9335337]","metadata":null},{"id":"07a016a3b7d34bf8a7ac700b22a10590","type":"GO_TERM","name":"protein autosumoylation","canonical_id":"go:GO:1990466","description":"\"The sumoylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.\" [PMID:21518767, PMID:23443663]","metadata":null},{"id":"aa0567443fcc4cac8342bbd3c823119d","type":"GO_TERM","name":"protein autoubiquitination","canonical_id":"go:GO:0051865","description":"\"The ubiquitination by a protein of one or more of its own amino acid residues, or residues on an identical protein. Ubiquitination occurs on the lysine residue by formation of an isopeptide crosslink.\" [GOC:ai]","metadata":null},{"id":"31daa2a760a34111bad2875b376b50c6","type":"GO_TERM","name":"protein binding","canonical_id":"go:GO:0005515","description":"\"Binding to a protein.\" [GOC:curators]","metadata":null},{"id":"d2bb1dc2ece843d196690bb9b9b33a1f","type":"GO_TERM","name":"protein binding involved in heterotypic cell-cell adhesion","canonical_id":"go:GO:0086080","description":"\"Binding to a protein or protein complex contributing to the adhesion of two different types of cells.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"0162ac8447704f469be419b4d7210c42","type":"GO_TERM","name":"protein biosynthetic process","canonical_id":"go:GO:0160307","description":"\"The chemical reactions and pathways resulting in the formation of protein.\" [Wikipedia:Protein_biosynthesis]","metadata":null},{"id":"2cd7a1af448b4f19a2e40841928cca1a","type":"GO_TERM","name":"protein branched polyubiquitination","canonical_id":"go:GO:0141198","description":"\"A protein ubiquitination process in which ubiquitin monomers are attached to a protein, and then ubiquitin polymers are formed by linkages between lysine residues at various positions of the ubiquitin monomers, forming branched linkages, such as K11/K48- or K11/K63-linked chains.\" [PMID:29033132, PMID:29378950, PMID:31998699, PMID:37325469]","metadata":null},{"id":"5ff9652d41ff44628409edc37934dfaf","type":"DISEASE","name":"protein c deficiency","canonical_id":"efo:0009316","description":null,"metadata":null},{"id":"4b7790d3d5624032ae93948608b24c52","type":"GO_TERM","name":"protein carbamoylation","canonical_id":"go:GO:0046944","description":"\"The addition of a carbamoyl group to a protein amino acid. A carbamoyl group is the acyl group -CO-NH2.\" [GOC:ai]","metadata":null},{"id":"f752b5e0d62148d784e719b2cea1f2bd","type":"GO_TERM","name":"protein carboxyl O-methyltransferase activity","canonical_id":"go:GO:0051998","description":"\"Catalysis of the transfer of a methyl group to a carboxyl group on a protein.\" [GOC:ai]","metadata":null},{"id":"a6b8622f70b44c7e8fda1427115016b6","type":"GO_TERM","name":"protein carboxylation","canonical_id":"go:GO:0018214","description":"\"The addition of a carboxy group to a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"9a7c5b897cc14d09954799d174e49fa6","type":"GO_TERM","name":"protein carrier activity","canonical_id":"go:GO:0140597","description":"\"Directly binding to a protein and delivering it either to an acceptor molecule or to a specific location.\" [PMID:7628437]","metadata":null},{"id":"5e3d914a863348d58c392643a9363a95","type":"GO_TERM","name":"protein catabolic process","canonical_id":"go:GO:0030163","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.\" [GOC:mah]","metadata":null},{"id":"1c027f2891144965bcf6fdc2e0271295","type":"GO_TERM","name":"protein catabolic process at postsynapse","canonical_id":"go:GO:0140249","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein at a postsynapse.\" [PMID:17062563]","metadata":null},{"id":"7ac0134d8d7d4fc3addea04c8b1d9959","type":"GO_TERM","name":"protein catabolic process at presynapse","canonical_id":"go:GO:0140247","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein at a presynapse.\" [PMID:27764673]","metadata":null},{"id":"84706504c30148f1bd59fc1f3f2fc7c6","type":"GO_TERM","name":"protein catabolic process at synapse","canonical_id":"go:GO:0140246","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein at a synapse.\" [PMID:17062563]","metadata":null},{"id":"78705746818949b2ad023d8272ece2f3","type":"GO_TERM","name":"protein catabolic process in the vacuole","canonical_id":"go:GO:0007039","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein in the vacuole, usually by the action of vacuolar proteases.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"ed0d78bc530446c3a9fd588920531d5e","type":"GO_TERM","name":"protein catabolic process, modulating synaptic transmission","canonical_id":"go:GO:0099546","description":"\"Any protein degradation process, occurring at a presynapse, that regulates synaptic transmission.\" [GOC:dos, PMID:23083742]","metadata":null},{"id":"64d24e0fb97e43518dcc63cde5fbd1d7","type":"GO_TERM","name":"protein catenane formation","canonical_id":"go:GO:0018419","description":"\"The aggregation, arrangement and bonding together of a protein structure comprising two or more rings that are interlocked but not covalently joined; resembling the links of a chain.\" [ISBN:0198506732]","metadata":null},{"id":"9f2321bf4c9d4c1d8e07116cb11beb31","type":"GO_TERM","name":"protein co-translational transfer of dolichol-linked oligosaccharide","canonical_id":"go:GO:0180058","description":"\"A N-linked protein glycosylation process in which the preassembled dolichol-linked oligosaccharide precursor is transfered post-translationally to an asparagine residue within the motif Asn-X-Ser/Thr of the target protein. This is mediated by the OSTA complex.\" [PMID:19167329]","metadata":null},{"id":"dc743bb477904f10a85bf4847a39ce1a","type":"GO_TERM","name":"protein complex involved in cell adhesion","canonical_id":"go:GO:0098636","description":"\"Any protein complex that is capable of carrying out some part of the process of cell adhesion to the cell matrix or to another cell.\" [GOC:dos]","metadata":null},{"id":"ffc8c9c9f6654c16a744fd593f166057","type":"GO_TERM","name":"protein complex involved in cell-cell adhesion","canonical_id":"go:GO:0098635","description":"\"Any protein complex that is capable of carrying out some part of the process of cell-cell adhesion.\" [GOC:dos]","metadata":null},{"id":"65f0229bf2d147669e118ea6d077d782","type":"GO_TERM","name":"protein complex involved in cell-matrix adhesion","canonical_id":"go:GO:0098637","description":"\"Any protein complex that is capable of carrying out some part of the process of cell-matrix adhesion.\" [GOC:dos]","metadata":null},{"id":"fe4c09ed72e04d5485680337d83650fd","type":"GO_TERM","name":"protein complex oligomerization","canonical_id":"go:GO:0051259","description":"\"The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of component monomers; protein oligomers may be composed of different or identical monomers. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer.\" [GOC:ai, PMID:18293929]","metadata":null},{"id":"06534f862cfb49db916bdbfb29abffab","type":"GO_TERM","name":"protein complex scaffold activity","canonical_id":"go:GO:0140378","description":"\"A structural molecule activity of a protein-containing complex component that serves to hold the complex together. Protein complex scaffolds are integral members of complexes.\" [PMID:41298522]","metadata":null},{"id":"ada58b175716481e993fc286880f7ede","type":"GO_TERM","name":"protein de-2-hydroxyisobutyrylase activity","canonical_id":"go:GO:0160010","description":"\"Catalysis of the reaction: H2O + N6-(2-hydroxyisobutanoyl)-L-lysyl-[protein] = 2-hydroxy-2-methylpropanoate + L-lysyl-[protein].\" [PMID:29192674]","metadata":null},{"id":"497a6c9880964e8dbb130d26bcf3ec2e","type":"GO_TERM","name":"protein de-ADP-ribosylation","canonical_id":"go:GO:0051725","description":"\"The process of removing one or more ADP-ribose residues from a protein.\" [GOC:ai]","metadata":null},{"id":"71396f98947542019654bb3e0fd5017a","type":"GO_TERM","name":"protein deacetylation","canonical_id":"go:GO:0006476","description":"\"The removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [GOC:ai]","metadata":null},{"id":"8b01b9b7c497471cb5e3ff826564ca62","type":"GO_TERM","name":"protein deacylation","canonical_id":"go:GO:0035601","description":"\"The removal of an acyl group, any group or radical of the form RCO- where R is an organic group, from a protein amino acid.\" [GOC:se, PMID:12080046]","metadata":null},{"id":"73f69ac6eef74facb21b5ab16ef3a91d","type":"GO_TERM","name":"protein deadenylylation","canonical_id":"go:GO:0044602","description":"\"The removal of an adenylyl group (adenosine 5'-monophosphate; AMP) from a protein amino acid.\" [GOC:sp, PMID:21734656]","metadata":null},{"id":"6d9be1ae429b461394ca446ba51f13ce","type":"GO_TERM","name":"protein dealkylation","canonical_id":"go:GO:0008214","description":"\"The removal of an alkyl group from a protein amino acid. Alkyl groups are derived from alkanes by removal of one hydrogen atom.\" [GOC:ai]","metadata":null},{"id":"34945126fb9c46cab3a2cf07a284bb19","type":"GO_TERM","name":"protein deamination","canonical_id":"go:GO:0018277","description":"\"The removal of an amino group from a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"ee3e8bf6ebf6491cb1b7b23c8cc5a405","type":"GO_TERM","name":"protein decanoylation","canonical_id":"go:GO:0051366","description":"\"The modification of a protein amino acid by formation of an ester or amide with decanoic acid.\" [GOC:jsg]","metadata":null},{"id":"3a080b2b2e2f4d06b72bfa507e11564d","type":"GO_TERM","name":"protein decrotonylase activity","canonical_id":"go:GO:0160008","description":"\"Catalysis of the reaction: H2O + N6-(2E)-butenoyl-L-lysyl-[protein] = (2E)-2-butenoate + L-lysyl-[protein].\" [PMID:28497810, PMID:30279482, PMID:34608293]","metadata":null},{"id":"f7e7fccde973401bacb36a9e9896e49e","type":"GO_TERM","name":"protein deglutamylation","canonical_id":"go:GO:0035608","description":"\"The removal of a glutamate residue from a protein. Glutamate residues in proteins can be gene-encoded, or added as side chains during the protein modification process of polyglutamylation.\" [GOC:sp, PMID:21074048]","metadata":null},{"id":"0f346c059f634e5bb5b7cb390d050fc3","type":"GO_TERM","name":"protein deglutarylation","canonical_id":"go:GO:0061698","description":"\"The removal of a glutaryl group (CO-CH2-CH2-CH2-CO) from a residue in a peptide or protein.\" [GOC:dph, PMID:24703693]","metadata":null},{"id":"7c7f5ae8e0d947038de3662fb20e10c9","type":"GO_TERM","name":"protein deglutathionylation","canonical_id":"go:GO:0080058","description":"\"The protein modification process in which a glutathione molecule is removed from a protein amino acid by breaking a disulfide linkage.\" [GOC:tb]","metadata":null},{"id":"9be85b42529f4e3bbf27df063e0bdf9a","type":"GO_TERM","name":"protein deglycase activity","canonical_id":"go:GO:0036524","description":"\"Catalysis of the removal of a sugar or dicarbonyl from a glycated L-arginine, L-lysine or L-cysteine residue within proteins that have been attacked and modified by glyoxal or 2-oxopropanal.\" [EC:3.5.1.124, GOC:bf, GOC:PARL, PMID:14568004, PMID:25416785, PMID:26873906]","metadata":null},{"id":"eead9ed9a41b4a1a8802be2fd5276913","type":"GO_TERM","name":"protein deglycation","canonical_id":"go:GO:0036525","description":"\"The removal of a sugar or dicarbonyl from a glycated protein.\" [GOC:bf, GOC:PARL, PMID:14568004, PMID:25416785]","metadata":null},{"id":"36d58aa0762e42fca239d55faf3acbc7","type":"GO_TERM","name":"protein deglycation, glyoxal removal","canonical_id":"go:GO:0036529","description":"\"The removal of glyoxal from a glycated protein, to form glycolate and a deglycated protein.\" [GOC:bf, GOC:PARL, PMID:25416785]","metadata":null},{"id":"cec9da00b13d49a5bab278ac09389afa","type":"GO_TERM","name":"protein deglycation, methylglyoxal removal","canonical_id":"go:GO:0036530","description":"\"The removal of methylglyoxal from a glycated protein, to form lactate and a deglycated protein.\" [GOC:bf, GOC:PARL, PMID:25416785]","metadata":null},{"id":"d49397140011429781374c87fa991b78","type":"GO_TERM","name":"protein deglycosylation","canonical_id":"go:GO:0006517","description":"\"The removal of sugar residues from a glycosylated protein.\" [GOC:mah]","metadata":null},{"id":"580b085a248349e78feb37b8a8e406f3","type":"GO_TERM","name":"protein deglycosylation involved in glycoprotein catabolic process","canonical_id":"go:GO:0035977","description":"\"The removal of sugar residues from a glycosylated protein that contributes to the breakdown of a glycoprotein.\" [GOC:bf, GOC:vw]","metadata":null},{"id":"8d66d1c544374ebda70cea0ec17b9772","type":"GO_TERM","name":"protein dehydration","canonical_id":"go:GO:0018249","description":"\"The removal of a water group from a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"787879ef1ea84a558deacfda42213628","type":"GO_TERM","name":"protein delipidation","canonical_id":"go:GO:0051697","description":"\"The breakage of covalent bonds to detach lipid groups from a protein.\" [GOC:ai]","metadata":null},{"id":"f06e3fc23c694d0aa496448d1fd07842","type":"GO_TERM","name":"protein demalonylation","canonical_id":"go:GO:0036046","description":"\"The removal of a malonyl group (CO-CH2-CO), from an amino acid residue within a protein or peptide.\" [GOC:sp, PMID:22076378]","metadata":null},{"id":"e6949f39e13f4a6d911dff0d2af33d79","type":"GO_TERM","name":"protein demannosylation","canonical_id":"go:GO:0036507","description":"\"The removal of one or more mannose residues from a mannosylated protein.\" [GOC:bf, GOC:PARL, PMID:25092655]","metadata":null},{"id":"dfcaec815fbe4339abcf675e462938ef","type":"GO_TERM","name":"protein demethylase activity","canonical_id":"go:GO:0140457","description":"\"Catalysis of the removal of a methyl group from a protein.\" [PMID:24498420, PMID:28360925]","metadata":null},{"id":"5d4300a54412499e916f565a8aec5313","type":"GO_TERM","name":"protein demethylation","canonical_id":"go:GO:0006482","description":"\"The removal of a methyl group, from a protein amino acid. A methyl group is derived from methane by the removal of a hydrogen atom.\" [GOC:mah]","metadata":null},{"id":"dc4eb612fe584d7bad585188ce33dab5","type":"GO_TERM","name":"protein denaturation","canonical_id":"go:GO:0030164","description":"\"Structural change in proteins which destroys the native, active configuration without rupture of peptide bonds.\" [GOC:kd, ISBN:3110145359]","metadata":null},{"id":"b9c045a699304ba8afeed5f1950e387d","type":"GO_TERM","name":"protein deneddylation","canonical_id":"go:GO:0000338","description":"\"The removal of a ubiquitin-like protein of the NEDD8 type from a protein.\" [GOC:krc]","metadata":null},{"id":"7e7a6941ddd643d6be70fda4e0ca7141","type":"GO_TERM","name":"protein denucleotidylation","canonical_id":"go:GO:0044601","description":"\"The removal of a nucleotide from a protein amino acid.\" [GOC:sp, PMID:21734656]","metadata":null},{"id":"aa120816c62048528a3c63a025c61f37","type":"GO_TERM","name":"protein depalmitoleylation","canonical_id":"go:GO:1990697","description":"\"The removal of palmitoleyl group, a 16-carbon monounsaturated fatty acid (C16:1), from a lipoprotein.\" [PMID:25731175]","metadata":null},{"id":"02c63d16299d427782ab012f680d291d","type":"GO_TERM","name":"protein depalmitoylation","canonical_id":"go:GO:0002084","description":"\"The removal of palymitoyl groups from a lipoprotein.\" [GOC:hjd]","metadata":null},{"id":"79b6bd9578a546bf85cf1644a2312c7a","type":"GO_TERM","name":"protein dephosphorylation","canonical_id":"go:GO:0006470","description":"\"The process of removing one or more phosphoric residues from a protein.\" [GOC:hb]","metadata":null},{"id":"b9508f7a28cd4630a7d51a41717cb0e5","type":"GO_TERM","name":"protein depolymerization","canonical_id":"go:GO:0051261","description":"\"The process in which protein polymers, compounds composed of a large number of component monomers, are broken down. Depolymerization occurs by the successive removal of monomers from an existing poly- or oligomeric protein.\" [GOC:ai]","metadata":null},{"id":"160c413fb09f4c819f89c219ecf63162","type":"GO_TERM","name":"protein depropionylation","canonical_id":"go:GO:0106230","description":"\"The removal of a propionyl group from a residue in a peptide or protein.\" [GOC:sp, PMID:30026585]","metadata":null},{"id":"e266e457ec36427489375bb4b0022885","type":"GO_TERM","name":"protein destabilization","canonical_id":"go:GO:0031648","description":"\"Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation.\" [GOC:mah]","metadata":null},{"id":"4a9a71ee032945429bccbf928a038d9a","type":"GO_TERM","name":"protein desuccinylation","canonical_id":"go:GO:0036048","description":"\"The removal of a succinyl group (CO-CH2-CH2-CO) from a residue in a peptide or protein.\" [GOC:sp, PMID:22076378]","metadata":null},{"id":"a2cdf44b699e4d3a925c055cb56d8eaa","type":"GO_TERM","name":"protein desumoylation","canonical_id":"go:GO:0016926","description":"\"The process in which a SUMO protein (small ubiquitin-related modifier) is cleaved from its target protein.\" [GOC:jl, PMID:11265250]","metadata":null},{"id":"515a6e910850408f8ff933359a4a03d2","type":"GO_TERM","name":"protein deubiquitination","canonical_id":"go:GO:0016579","description":"\"The removal of one or more ubiquitin groups from a protein.\" [GOC:ai]","metadata":null},{"id":"f33cb532cfb245a1912ed2030aafb929","type":"GO_TERM","name":"protein deubiquitination involved in ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0071947","description":"\"The removal of one or more ubiquitin groups from a protein as part of a process of ubiquitin-dependent protein catabolism.\" [GOC:mah]","metadata":null},{"id":"56f945c5bd4c445a9b2cf9ebe7f1c37f","type":"GO_TERM","name":"protein digestion","canonical_id":"go:GO:0044256","description":"\"The whole of the physical, chemical, and biochemical processes carried out by living organisms to break down ingested proteins into components that may be easily absorbed and directed into metabolism.\" [GOC:curators]","metadata":null},{"id":"c986805e3865448c8fa5c5ae85453e7d","type":"GO_TERM","name":"protein dimerization activity","canonical_id":"go:GO:0046983","description":"\"The formation of a protein dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.\" [ISBN:0198506732]","metadata":null},{"id":"883a7240ed8b4b8f82a530e8f73151d2","type":"GO_TERM","name":"protein disulfide isomerase activity","canonical_id":"go:GO:0003756","description":"\"Catalysis of the rearrangement of both intrachain and interchain disulfide bonds in proteins.\" [EC:5.3.4.1, GOC:vw, Wikipedia:Protein_disulfide-isomerase#Function]","metadata":null},{"id":"b5672bfd0ecc4377a1fb12255e7f64ff","type":"GO_TERM","name":"protein domain specific binding","canonical_id":"go:GO:0019904","description":"\"Binding to a specific domain of a protein.\" [GOC:curators]","metadata":null},{"id":"a5c102a8402a4db1810c6ab60a180e7e","type":"GO_TERM","name":"protein export from nucleus","canonical_id":"go:GO:0006611","description":"\"The directed movement of a protein from the nucleus into the cytoplasm.\" [GOC:jl]","metadata":null},{"id":"455ccd59c4464f928ec5af8c82689f22","type":"GO_TERM","name":"protein farnesylation","canonical_id":"go:GO:0018343","description":"\"The covalent attachment of a farnesyl group to a protein.\" [GOC:jl]","metadata":null},{"id":"a14c11b744f6418ca7ad35def3c79d96","type":"GO_TERM","name":"protein farnesyltransferase activity","canonical_id":"go:GO:0004660","description":"\"Catalysis of the reaction: L-cysteinyl-[protein] + (2E,6E)-farnesyl diphosphate = S-(2E,6E)-farnesyl-L-cysteinyl-[protein] + diphosphate.\" [PMID:8621375, RHEA:13345]","metadata":null},{"id":"e38bd18bf49c4d3ab87e19014a03e85d","type":"GO_TERM","name":"protein farnesyltransferase complex","canonical_id":"go:GO:0005965","description":"\"A protein complex that possesses protein farnesyltransferase activity.\" [GOC:mah]","metadata":null},{"id":"d62734f5a9ab4117b0af090872132cbf","type":"GO_TERM","name":"protein flavinylation","canonical_id":"go:GO:0017013","description":"\"The addition of a flavin group to a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"e74ee01a06174ab78130cbcca80c776a","type":"GO_TERM","name":"protein folding","canonical_id":"go:GO:0006457","description":"\"The process of assisting in the covalent and noncovalent assembly of single chain polypeptides or multisubunit complexes into the correct tertiary structure.\" [GOC:curators, GOC:rb]","metadata":null},{"id":"63d8511fd2e042b4a1e4f904487b2e41","type":"GO_TERM","name":"protein folding chaperone","canonical_id":"go:GO:0044183","description":"\"Binding to a protein or a protein-containing complex to assist the protein folding process.\" [GOC:mtg_cambridge_2009]","metadata":null},{"id":"c552b84689e54c24b3e89b9f461ff469","type":"GO_TERM","name":"protein folding chaperone complex","canonical_id":"go:GO:0101031","description":"\"A protein complex required for the non-covalent folding or unfolding, maturation, stabilization or assembly or disassembly of macromolecular structures. Usually active during or immediately after completion of translation. Many chaperone complexes contain heat shock proteins.\" [GOC:bhm, PMID:21855797]","metadata":null},{"id":"f0f8041d359643ce8c1d2b9d51ba5a2a","type":"GO_TERM","name":"protein folding in endoplasmic reticulum","canonical_id":"go:GO:0034975","description":"\"A protein folding process that takes place in the endoplasmic reticulum (ER). Secreted, plasma membrane and organelle proteins are folded in the ER, assisted by chaperones and foldases (protein disulphide isomerases), and additional factors required for optimal folding (ATP, Ca2+ and an oxidizing environment to allow disulfide bond formation).\" [GOC:mah, GOC:vw]","metadata":null},{"id":"06e4596b4bbf48f9ade15348f41714ff","type":"GO_TERM","name":"protein formylation","canonical_id":"go:GO:0018256","description":"\"The addition of a formyl group to a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"e8441159ce7d46ca9ccb6405231573b2","type":"GO_TERM","name":"protein geranylgeranylation","canonical_id":"go:GO:0018344","description":"\"The covalent attachment of a geranylgeranyl group to a protein.\" [GOC:jl]","metadata":null},{"id":"d21ce973661a4a589bf54ba58f71ee00","type":"GO_TERM","name":"protein geranylgeranyltransferase activity","canonical_id":"go:GO:0004661","description":"\"Catalysis of the covalent addition of a geranylgeranyl (20-carbon isoprenoid) group via thioether linkages to a cysteine residue at or near the C terminus of a protein.\" [PMID:8621375]","metadata":null},{"id":"9a64707459e64432b8d5574c8ab4be85","type":"GO_TERM","name":"protein glutathionylation","canonical_id":"go:GO:0010731","description":"\"The protein modification process in which a glutathione molecule is added to a protein amino acid through a disulfide linkage.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"59eaac38df4944d5ab03021d780366a1","type":"GO_TERM","name":"protein guanylylation","canonical_id":"go:GO:0018260","description":"\"The addition of phospho-guanosine to a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"0d9184fd2c514045bbdd6b8741febd65","type":"GO_TERM","name":"protein guanylyltransferase activity","canonical_id":"go:GO:0044600","description":"\"Catalysis of the reaction: GTP + protein = diphosphate + guanylyl-protein; mediates the addition of an guanylyl (guanosine 5'-monophosphate; GMP group) to specific residues of target proteins.\" [GOC:sp, PMID:20651120]","metadata":null},{"id":"ad5ce5e22966471eb831f105b026122b","type":"GO_TERM","name":"protein heterodimerization activity","canonical_id":"go:GO:0046982","description":"\"Binding to a nonidentical protein to form a heterodimer.\" [GOC:ai]","metadata":null},{"id":"00079507a33e4f50863459d31bfcd0dd","type":"GO_TERM","name":"protein heterooligomerization","canonical_id":"go:GO:0051291","description":"\"The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of component monomers that are not all identical. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer.\" [GOC:ai]","metadata":null},{"id":"2248939d2fc14a66888ebb4feee039a3","type":"GO_TERM","name":"protein heterotetramerization","canonical_id":"go:GO:0051290","description":"\"The formation of a protein heterotetramer, a macromolecular structure consisting of four noncovalently associated subunits, of which not all are identical.\" [GOC:curators]","metadata":null},{"id":"37cd3100d5674a79bedce90abfab15a4","type":"GO_TERM","name":"protein heterotrimerization","canonical_id":"go:GO:0070208","description":"\"The formation of a protein heterotrimer, a macromolecular structure consisting of three noncovalently associated subunits, of which not all are identical.\" [GOC:hjd]","metadata":null},{"id":"87f05a02c8f04c2183ebc1492eca9e31","type":"GO_TERM","name":"protein hexamerization","canonical_id":"go:GO:0034214","description":"\"The formation of a protein hexamer, a macromolecular structure consisting of six noncovalently associated identical or nonidentical subunits.\" [GOC:ecd]","metadata":null},{"id":"73201dcb3e474497b50f8a5e1acbf436","type":"GO_TERM","name":"protein histidine kinase activity","canonical_id":"go:GO:0004673","description":"\"Catalysis of the reaction: ATP + protein L-histidine = ADP + protein phospho-L-histidine.\" [EC:2.7.13.3, GOC:mah]","metadata":null},{"id":"f759bd2dbeec4efbad4d3a5b4ff8987f","type":"GO_TERM","name":"protein histidine kinase binding","canonical_id":"go:GO:0043424","description":"\"Binding to a protein histidine kinase.\" [GOC:jl]","metadata":null},{"id":"e9cd5d7729e54a5f957883a4151a8f67","type":"GO_TERM","name":"protein histidine kinase complex","canonical_id":"go:GO:0009365","description":"\"A complex that possesses protein histidine kinase activity.\" [GOC:mah]","metadata":null},{"id":"b51f7de6920641dca61fd4290f2b5bb6","type":"GO_TERM","name":"protein histidine phosphatase activity","canonical_id":"go:GO:0101006","description":"\"Catalysis of the reaction: protein histidine phosphate + H2O = protein histidine + phosphate.\" [EC:3.9.1.3]","metadata":null},{"id":"a3262380be74465a86e794ce24d62cdc","type":"GO_TERM","name":"protein histidine pros-kinase activity","canonical_id":"go:GO:0008256","description":"\"Catalysis of the reaction: ATP + protein L-histidine = ADP + protein N(pi)-phospho-L-histidine.\" [EC:2.7.13.1]","metadata":null},{"id":"e65303301eca4c7897a246f613224b9f","type":"GO_TERM","name":"protein histidine tele-kinase activity","canonical_id":"go:GO:0008257","description":"\"Catalysis of the reaction: ATP + protein L-histidine = ADP + protein N(tau)-phospho-L-histidine.\" [EC:2.7.13.2]","metadata":null},{"id":"fcd08708f96347df9cf2710f32a69664","type":"GO_TERM","name":"protein histidyl modification to diphthamide","canonical_id":"go:GO:0017183","description":"\"The modification of peptidyl-histidine to 2'-(3-carboxamido-3-(trimethylammonio)propyl)-L-histidine, known as diphthamide, found in translation elongation factor EF-2. The process occurs in eukaryotes and archaea but not eubacteria.\" [GOC:pde, PMID:20559380]","metadata":null},{"id":"22b2ede9f6c1418287edea86790b9a56","type":"GO_TERM","name":"protein homodimerization activity","canonical_id":"go:GO:0042803","description":"\"Binding to an identical protein to form a homodimer.\" [GOC:jl]","metadata":null},{"id":"844bfcda39d746ada32bd2e7bcf294a7","type":"GO_TERM","name":"protein homooligomerization","canonical_id":"go:GO:0051260","description":"\"The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of identical component monomers. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer.\" [GOC:ai]","metadata":null},{"id":"a7acdbf0eba94d1389cd12cbd122f0bf","type":"GO_TERM","name":"protein homotetramerization","canonical_id":"go:GO:0051289","description":"\"The formation of a protein homotetramer, a macromolecular structure consisting of four noncovalently associated identical subunits.\" [GOC:curators]","metadata":null},{"id":"118c6d69456c4bfba7bcb46cec0074d3","type":"GO_TERM","name":"protein homotrimerization","canonical_id":"go:GO:0070207","description":"\"The formation of a protein homotrimer, a macromolecular structure consisting of three noncovalently associated identical subunits.\" [GOC:hjd]","metadata":null},{"id":"bfeec1d876434f8ca73db602ca141b08","type":"GO_TERM","name":"protein hydroxylation","canonical_id":"go:GO:0018126","description":"\"The addition of a hydroxy group to a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"5a99681ee2154f9a850e58728b4aa75c","type":"GO_TERM","name":"protein import","canonical_id":"go:GO:0017038","description":"\"The targeting and directed movement of proteins into a cell or organelle. Not all import involves an initial targeting event.\" [GOC:ai]","metadata":null},{"id":"e3fa7b3844a64f6f938726e31baf5017","type":"GO_TERM","name":"protein import into chloroplast stroma","canonical_id":"go:GO:0045037","description":"\"The targeting and import of proteins into the chloroplast stroma. Import depends on ATP hydrolysis catalyzed by stromal chaperones. Chloroplast stromal proteins, such as the S subunit of rubisco, have a N-terminal stromal-import sequence of about 44 amino acids which is cleaved from the protein precursor after import.\" [ISBN:0716731363]","metadata":null},{"id":"a5e9c54634a14480860da10133469af2","type":"GO_TERM","name":"protein import into chloroplast thylakoid membrane","canonical_id":"go:GO:0045038","description":"\"The import of proteins into the chloroplast thylakoid membranes. Proteins that are destined for the thylakoid lumen require two uptake-targeting sequences: the first targets the protein to the stroma, and the second targets the protein from the stroma to the thylakoid lumen. Four separate thylakoid-import systems deal with the proteins once they are in the stroma.\" [ISBN:0716731363]","metadata":null},{"id":"48bed1af69a0497eab4059dd93ffd163","type":"GO_TERM","name":"protein import into mitochondrial intermembrane space","canonical_id":"go:GO:0045041","description":"\"The import of proteins from the cytosol across the outer mitochondrial membrane into the intermembrane space.\" [ISBN:0716731363]","metadata":null},{"id":"62e8536d6506467baf6820dee55e163d","type":"GO_TERM","name":"protein import into mitochondrial matrix","canonical_id":"go:GO:0030150","description":"\"The import of proteins with mitochondrial targeting sequence from the cytosol across the mitochondrial outer and inner membranes into the matrix via TOM-TIM23-PAM.\" [ISBN:0716731363, PMID:36931257]","metadata":null},{"id":"4ef40156a09547ec9048300a98868165","type":"GO_TERM","name":"protein import into nucleus","canonical_id":"go:GO:0006606","description":"\"The directed movement of a protein from the cytoplasm to the nucleus.\" [GOC:jl]","metadata":null},{"id":"2bbc5b92253542e78c34c6e7f0f05fe2","type":"GO_TERM","name":"protein import into peroxisome matrix","canonical_id":"go:GO:0016558","description":"\"The import of proteins into the peroxisomal matrix. A peroxisome targeting signal (PTS) binds to a soluble receptor protein in the cytosol, and the resulting complex then binds to a receptor protein in the peroxisome membrane and is imported. The cargo protein is then released into the peroxisome matrix.\" [ISBN:0716731363, PMID:11687502, PMID:11988772]","metadata":null},{"id":"3522fcc85d9d46399c0ca289ebd49ad5","type":"GO_TERM","name":"protein import into peroxisome matrix, docking","canonical_id":"go:GO:0016560","description":"\"The process in which a complex formed of a peroxisome targeting sequence (PTS) receptor bound to a PTS-bearing protein docks with translocation machinery in the peroxisomal membrane.\" [PMID:11687502, PMID:11988772, PMID:14754507]","metadata":null},{"id":"6ff71eeb99bf40f0bac3647350db9b8a","type":"GO_TERM","name":"protein import into peroxisome matrix, receptor recycling","canonical_id":"go:GO:0016562","description":"\"The process in which peroxisome targeting sequence receptors dissociates from cargo proteins and are returned to the cytosol.\" [PMID:11687502]","metadata":null},{"id":"3a127f0fc5604283815bda83c28532a9","type":"GO_TERM","name":"protein import into peroxisome matrix, substrate release","canonical_id":"go:GO:0044721","description":"\"The process by which the cargo protein is released into the peroxisomal matrix, following translocation across the membrane.\" [PMID:21976670]","metadata":null},{"id":"2532b7fc0feb46da8570682c157361cc","type":"GO_TERM","name":"protein import into peroxisome matrix, translocation","canonical_id":"go:GO:0016561","description":"\"The process in which proteins are moved across the peroxisomal membrane into the matrix. It is likely that the peroxisome targeting sequence receptor remains associated with cargo proteins during translocation.\" [PMID:11687502]","metadata":null},{"id":"e2c525237d634bd8b1cde13de6b8a3df","type":"GO_TERM","name":"protein import into peroxisome membrane","canonical_id":"go:GO:0045046","description":"\"The targeting of proteins into the peroxisomal membrane. The process is not well understood, but both signals and mechanism differ from those involved in peroxisomal matrix protein import.\" [ISBN:0716731363, PMID:11687502]","metadata":null},{"id":"d444eead4f76494ca1d9e666d9128099","type":"GO_TERM","name":"protein import into the intermembrane space via the disulfide relay system","canonical_id":"go:GO:0160203","description":"\"The import of small cysteine-containing proteins from the cytosol across the outer mitochondrial membrane via the TOM complex driven by oxidative folding.\" [PMID:32936885, PMID:37159021]","metadata":null},{"id":"693280b2a497402c9e95ac6f59b6ec2b","type":"GO_TERM","name":"protein insertion into ER membrane","canonical_id":"go:GO:0045048","description":"\"The process that results in incorporation of a protein into an endoplasmic reticulum (ER) membrane. It depends on specific topogenic sequences of amino acids that ensure that a protein acquires the proper orientation during its insertion into the ER membrane.\" [ISBN:0716731363]","metadata":null},{"id":"3a9b131faf4642b78207e483c747f205","type":"GO_TERM","name":"protein insertion into ER membrane by N-terminal cleaved signal sequence","canonical_id":"go:GO:0045049","description":"\"A process of protein insertion into the endoplasmic reticulum (ER) membrane in which N-terminal cleaved signal sequences direct polypeptides to the ER.\" [ISBN:0716731363]","metadata":null},{"id":"ecca84006d1e43148beb8ff39a463c4d","type":"GO_TERM","name":"protein insertion into ER membrane by internal uncleaved signal-anchor sequence","canonical_id":"go:GO:0045051","description":"\"A process of protein insertion into the endoplasmic reticulum (ER) membrane in which signal anchor sequences function as both ER signal sequences and membrane anchor sequences.\" [ISBN:0716731363]","metadata":null},{"id":"968c7f0d29af476ca34c2bb662ff8bab","type":"GO_TERM","name":"protein insertion into ER membrane by stop-transfer membrane-anchor sequence","canonical_id":"go:GO:0045050","description":"\"A process of protein insertion into the endoplasmic reticulum (ER) membrane in which stop-transfer membrane-anchor sequences become an ER membrane spanning helix.\" [ISBN:0716731363]","metadata":null},{"id":"8fb12f9f19984b85905bf3ad30822ae1","type":"GO_TERM","name":"protein insertion into membrane","canonical_id":"go:GO:0051205","description":"\"The process that results in the incorporation of a protein into a biological membrane. Incorporation in this context means having some part or covalently attached group that is inserted into the the hydrophobic region of one or both bilayers.\" [GOC:ai]","metadata":null},{"id":"7f9ff953b8804c65b2b0cf1c14e7d295","type":"GO_TERM","name":"protein insertion into membrane raft","canonical_id":"go:GO:0071210","description":"\"The process in which a protein is incorporated into a membrane raft. Membrane rafts are small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes.\" [GOC:mah]","metadata":null},{"id":"22ec98ceb8404f45a820ddb9de1329ce","type":"GO_TERM","name":"protein insertion into mitochondrial inner membrane","canonical_id":"go:GO:0045039","description":"\"The processes mediating the insertion of proteins into the mitochondrial inner membrane. Mitochondrial inner membrane proteins can get inserted from the cytosol, by crossing the outer membrane and being guided by an inner membrane translocase complex into their final destination in the inner membrane. Some proteins present in the intermembrane space can get inserted into the inner mitochondrial membrane. Finally, some proteins are inserted into the inner membrane from the matrix side of the membrane.\" [GOC:mcc, GOC:vw, PMID:18672008]","metadata":null},{"id":"ec542a4cee414f098607d44e1faeb008","type":"GO_TERM","name":"protein insertion into mitochondrial inner membrane from matrix","canonical_id":"go:GO:0032979","description":"\"The process in which a protein is incorporated into the mitochondrial inner membrane from the matrix side. This includes membrane insertion of newly synthesized mitochondrially-encoded proteins, and insertion of nuclear-encoded proteins after their import into the mitochondrial matrix.\" [GOC:vw, PMID:12880202, PMID:15473843]","metadata":null},{"id":"8502afa34a444196a22aa04412d51cac","type":"GO_TERM","name":"protein insertion into mitochondrial membrane","canonical_id":"go:GO:0051204","description":"\"The process that results in the incorporation of a protein into a mitochondrial membrane.\" [GOC:ai]","metadata":null},{"id":"303b8a2fe417439fb5baf428829798e5","type":"GO_TERM","name":"protein insertion into mitochondrial outer membrane","canonical_id":"go:GO:0045040","description":"\"The process comprising the insertion of proteins from outside the organelle into the mitochondrial outer membrane, mediated by large outer membrane translocase complexes.\" [GOC:mcc, GOC:vw, PMID:18672008]","metadata":null},{"id":"dc41655bcc004dd285bbe40735aeccc5","type":"GO_TERM","name":"protein insertion into plasma membrane","canonical_id":"go:GO:0098737","description":"\"The process that results in the incorporation of a protein into a plasma membrane. Incorporation in this context means having some part or covalently attached group that is inserted into the the hydrophobic region of one or both bilayers.\" [GOC:DOS]","metadata":null},{"id":"c3990b2efdc74acfbf770476f3abe18e","type":"GO_TERM","name":"protein insertion into plasma membrane raft","canonical_id":"go:GO:0044859","description":"\"The process in which a protein is incorporated into a plasma membrane raft.\" [GOC:jl]","metadata":null},{"id":"e3d0ef5a03ab4355b127af34e3d0d877","type":"GO_TERM","name":"protein kinase 5 complex","canonical_id":"go:GO:0016533","description":"\"A protein complex that has protein serine/threonine kinase activity; in mammals composed of catalytic subunit CDK5 and regulatory subunits CDK5R1 or CDK5R2. Contrary to its gene symbol, CDK5 is not cyclin-dependent.\" [PMID:15689152]","metadata":null},{"id":"81bd9988de4c494eb0a10e45dc6a7a98","type":"GO_TERM","name":"protein kinase A binding","canonical_id":"go:GO:0051018","description":"\"Binding to a protein kinase A.\" [GOC:ai]","metadata":null},{"id":"fcdb9650cabd48cf9d1f730af74d45a8","type":"GO_TERM","name":"protein kinase A catalytic subunit binding","canonical_id":"go:GO:0034236","description":"\"Binding to one or both of the catalytic subunits of protein kinase A.\" [GOC:mah]","metadata":null},{"id":"ed19a3174ffa48f592393b8480bb3ecb","type":"GO_TERM","name":"protein kinase A regulatory subunit binding","canonical_id":"go:GO:0034237","description":"\"Binding to one or both of the regulatory subunits of protein kinase A.\" [GOC:mah]","metadata":null},{"id":"22e8ba9a46914fbca8173b715e0bfeaf","type":"GO_TERM","name":"protein kinase B binding","canonical_id":"go:GO:0043422","description":"\"Binding to protein kinase B, an intracellular kinase that is important in regulating glucose metabolism.\" [GOC:jl, https://doi.org/10.1016/S0092-8674(02)01083-8]","metadata":null},{"id":"1b706baac3934135892c0e01fd4f7c19","type":"GO_TERM","name":"protein kinase C binding","canonical_id":"go:GO:0005080","description":"\"Binding to protein kinase C.\" [GOC:jl]","metadata":null},{"id":"8bb9e20a4c6f45f38ce18a9a62bf74d7","type":"GO_TERM","name":"protein kinase C deactivation","canonical_id":"go:GO:0042313","description":"\"Any process resulting in the inhibition or termination of the activity of protein kinase C.\" [GOC:bf]","metadata":null},{"id":"f615b3c79b51493c9845ea6463419db3","type":"GO_TERM","name":"protein kinase C inhibitor activity","canonical_id":"go:GO:0008426","description":"\"Binds to and stops, prevents or reduces the activity of protein kinase C, an enzyme which phosphorylates a protein.\" [GOC:ai]","metadata":null},{"id":"8fc28449673d4684a3eae78b7bc8e738","type":"GO_TERM","name":"protein kinase C signaling","canonical_id":"go:GO:0070528","description":"\"A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1e43f85d58c346d2bd43f23dde1757aa","type":"GO_TERM","name":"protein kinase CK2 complex","canonical_id":"go:GO:0005956","description":"\"A protein complex that possesses protein serine/threonine kinase activity, and contains two catalytic alpha subunits and two regulatory beta subunits. Protein kinase CK2 complexes are found in nearly every subcellular compartment, and can phosphorylate many protein substrates in addition to casein.\" [GOC:mah, PMID:10994779]","metadata":null},{"id":"2db9d55f3cfd46f5a1ca1753c08540ae","type":"GO_TERM","name":"protein kinase activator activity","canonical_id":"go:GO:0030295","description":"\"Binds to and increases the activity of a protein kinase, an enzyme which phosphorylates a protein.\" [GOC:ai]","metadata":null},{"id":"d2845c053c954784b3c06434fbc6001e","type":"GO_TERM","name":"protein kinase activity","canonical_id":"go:GO:0004672","description":"\"Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.\" [PMID:25399640]","metadata":null},{"id":"7a75e3713e994f5d9ffd7601a40c005a","type":"GO_TERM","name":"protein kinase binding","canonical_id":"go:GO:0019901","description":"\"Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.\" [GOC:jl]","metadata":null},{"id":"a3d4486f45904bc083a8d3b36ade7bc0","type":"GO_TERM","name":"protein kinase complex","canonical_id":"go:GO:1902911","description":"\"A protein complex which is capable of protein kinase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:24606918]","metadata":null},{"id":"c04de36a454541228cf2dd8e79687ef1","type":"GO_TERM","name":"protein kinase inhibitor activity","canonical_id":"go:GO:0004860","description":"\"Binds to and stops, prevents or reduces the activity of a protein kinase.\" [GOC:ai]","metadata":null},{"id":"abf6842d8ccd4c98a9369130063ac3eb","type":"GO_TERM","name":"protein kinase regulator activity","canonical_id":"go:GO:0019887","description":"\"Modulates the activity of a protein kinase, an enzyme which phosphorylates a protein.\" [GOC:ai]","metadata":null},{"id":"21f6ebfcd31d4beb986f35467866a427","type":"GO_TERM","name":"protein linear deubiquitination","canonical_id":"go:GO:1990108","description":"\"A protein deubiquitination process in which a linear polymer of ubiquitin, formed by the amino-terminal methionine (M1) of one ubiquitin molecule and by the carboxy-terminal glycine (G76) of the next, is removed from a protein.\" [PMID:23708998]","metadata":null},{"id":"396e88b6c8814330a68c949ebf01c68d","type":"GO_TERM","name":"protein linear polyubiquitination","canonical_id":"go:GO:0097039","description":"\"A protein ubiquitination process in which a linear polymer of ubiquitin, formed by the amino-terminal methionine (M1) of one ubiquitin molecule and by the carboxy-terminal glycine (G76) of the next, is added to a protein.\" [GOC:jsg, GOC:sp, PMID:21455173, PMID:21455180, PMID:21455181, PMID:31998699]","metadata":null},{"id":"e0d9aa80ea45494ba3a9338b65c86e57","type":"GO_TERM","name":"protein lipidation","canonical_id":"go:GO:0006497","description":"\"The covalent attachment of lipid groups to an amino acid in a protein.\" [GOC:jl]","metadata":null},{"id":"c9303c17c8e04cf3b3aebeaaab6c4ea4","type":"GO_TERM","name":"protein lipidation involved in autophagosome assembly","canonical_id":"go:GO:0061739","description":"\"The protein lipidation process by which phosphatidylethanolamine is conjugated to a protein of the ATG8 family, leading to membrane insertion of the protein as a step in autophagosome assembly.\" [GOC:autophagy, GOC:dph, PMID:11096062, PMID:11100732, PMID:15277523]","metadata":null},{"id":"7a406eaeea2449e5971ceb35e401a926","type":"GO_TERM","name":"protein lipoylation","canonical_id":"go:GO:0009249","description":"\"The lipoylation of peptidyl-lysine to form peptidyl-N6-lipoyl-L-lysine.\" [RESID:AA0118]","metadata":null},{"id":"24dff3b3df5241d8a3aa2d5549797900","type":"GO_TERM","name":"protein localization involved in acrosome reaction","canonical_id":"go:GO:0060476","description":"\"The actin-based process in which a protein is transported to, or maintained in, a specific location in the sperm as part of the acrosome reaction.\" [GOC:dph]","metadata":null},{"id":"0927473d584543f09ba353c2acef4e97","type":"GO_TERM","name":"protein localization involved in auxin polar transport","canonical_id":"go:GO:1901703","description":"\"Any protein localization that is involved in auxin polar transport.\" [GOC:TermGenie, PMID:23163883]","metadata":null},{"id":"2cb83b9ec3fd44a4a13a72afde47425e","type":"GO_TERM","name":"protein localization involved in establishment of planar polarity","canonical_id":"go:GO:0090251","description":"\"Any process in which a protein is transported to, and/or maintained in, a specific location in a cell that contributes to the establishment of planar polarity.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"65a875a1f06c4080a26226ab718adcda","type":"GO_TERM","name":"protein localization to CENP-A containing chromatin","canonical_id":"go:GO:0061644","description":"\"Any process in which a protein is transported to, or maintained at, CENP-A containing chromatin.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"3673f321df724b0f9370ec41e278fff6","type":"GO_TERM","name":"protein localization to Cajal body","canonical_id":"go:GO:1904867","description":"\"A process in which a protein is transported to, or maintained in, a location within a Cajal body.\" [GO_REF:0000087, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"2fae0b3d9ffd40b4aff5e9f0412d7fd0","type":"GO_TERM","name":"protein localization to ERGIC","canonical_id":"go:GO:0106272","description":"\"A process in which a protein is transported to, or maintained in, a location within the endoplasmic reticulum-Golgi intermediate compartment (ERGIC).\" [PMID:32272059]","metadata":null},{"id":"c793b30287134208a5122b3e393f9231","type":"GO_TERM","name":"protein localization to Golgi apparatus","canonical_id":"go:GO:0034067","description":"\"A process in which a protein is transported to, or maintained in, a location within the Golgi apparatus.\" [GOC:mah]","metadata":null},{"id":"75eab178091444f48899d3bbe8df7a1f","type":"GO_TERM","name":"protein localization to Golgi membrane","canonical_id":"go:GO:1903292","description":"\"A process in which a protein is transported to, or maintained in, a location within a Golgi membrane.\" [GO_REF:0000087, GOC:TermGenie, PMID:11378902]","metadata":null},{"id":"0da5dc779b0b42a28d9738ffa5149560","type":"GO_TERM","name":"protein localization to M-band","canonical_id":"go:GO:0036309","description":"\"Any process in which a protein is transported to, and/or maintained in, the M band. The M band is the midline of aligned thick filaments in a sarcomere.\" [GOC:BHF, GOC:rl, PMID:18782775]","metadata":null},{"id":"dcf16897dcc74d1b93d93bd5a0c98503","type":"GO_TERM","name":"protein localization to Mei2 nuclear dot","canonical_id":"go:GO:1902549","description":"\"A process in which a protein is transported to, or maintained in, a location within a Mei2 nuclear dot.\" [GOC:TermGenie, PMID:23980030]","metadata":null},{"id":"9d2319c4022a4361a57986901244c2ba","type":"GO_TERM","name":"protein localization to P-body","canonical_id":"go:GO:0110012","description":"\"Any process in which a protein is transported to, or maintained at, a P-body.\" [GOC:mah, PMID:28031482]","metadata":null},{"id":"1541b63aea594cbb910ba9c85742f4fb","type":"GO_TERM","name":"protein localization to T cell secretory granule","canonical_id":"go:GO:0033374","description":"\"A process in which a protein is transported to, or maintained in, a location within a secretory granule in a T cell.\" [GOC:mah]","metadata":null},{"id":"c67ef95a11c7485e93e4d744266688cb","type":"GO_TERM","name":"protein localization to T-tubule","canonical_id":"go:GO:0036371","description":"\"A process in which a protein is transported to, or maintained in, the T-tubule. The T-tubule is an invagination of the plasma membrane of a muscle cell that extends inward from the cell surface around each myofibril.\" [GOC:BHF, GOC:rl, PMID:16292983]","metadata":null},{"id":"88fe52a2c16c42af970552ea0b410cdd","type":"GO_TERM","name":"protein localization to actin cortical patch","canonical_id":"go:GO:0044379","description":"\"A process in which a protein is transported to, or maintained in, an actin cortical patch.\" [GOC:mah, PMID:21620704]","metadata":null},{"id":"829d8bd276db401fad21f6f558edd12d","type":"GO_TERM","name":"protein localization to actin cytoskeleton","canonical_id":"go:GO:1903119","description":"\"A process in which a protein is transported to, or maintained in, the location of an actin cytoskeleton.\" [GO_REF:0000087, GOC:TermGenie, PMID:24798735]","metadata":null},{"id":"060381967f2c48e09fd0282537c5cf4a","type":"GO_TERM","name":"protein localization to actin filament bundle","canonical_id":"go:GO:1903120","description":"\"A process in which a protein is transported to, or maintained in, the location of an actin filament bundle.\" [GO_REF:0000087, GOC:TermGenie, PMID:24798735]","metadata":null},{"id":"c9838944e6aa49a8b302449e5afb8a0d","type":"GO_TERM","name":"protein localization to actomyosin contractile ring","canonical_id":"go:GO:1990179","description":"\"A process in which a protein is transported to, or maintained at, the actomyosin contractile ring.\" [GOC:mah, PMID:23349808]","metadata":null},{"id":"4f7c5924b6fb4d4eb44109fe2765c464","type":"GO_TERM","name":"protein localization to adherens junction","canonical_id":"go:GO:0071896","description":"\"Any process in which a protein is transported to, and/or maintained at the adherens junction.\" [GOC:aruk, GOC:bc, GOC:BHF, GOC:mah, PMID:26412237]","metadata":null},{"id":"6bf3ced3bd9042489e2c9656ef0f0beb","type":"GO_TERM","name":"protein localization to ascospore wall","canonical_id":"go:GO:1904853","description":"\"A process in which a protein is transported to, or maintained in, a location within an ascospore wall.\" [GO_REF:0000087, GOC:TermGenie, PMID:24623719]","metadata":null},{"id":"b64e0ddbe2ef41baafd6bbe51956d82a","type":"GO_TERM","name":"protein localization to astral microtubule","canonical_id":"go:GO:1902888","description":"\"A process in which a protein is transported to, or maintained in, a location within an astral microtubule.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:16054030]","metadata":null},{"id":"2fe438f270804c34a5bcb47d05d82029","type":"GO_TERM","name":"protein localization to axon","canonical_id":"go:GO:0099612","description":"\"A process in which a protein is transported to or maintained in a location within an axon.\" [GOC:dos, PMID:26157139]","metadata":null},{"id":"5c43751e807c466bb0dc4246413ef47a","type":"GO_TERM","name":"protein localization to basal ectoplasmic specialization","canonical_id":"go:GO:0120145","description":"\"A process in which a protein is transported to, or maintained in, a location within a basal ectoplasmic specialization.\" [PMID:22872576]","metadata":null},{"id":"7ac2644ce382477c9dd115fd13ed53f1","type":"GO_TERM","name":"protein localization to basolateral plasma membrane","canonical_id":"go:GO:1903361","description":"\"Any process in which a protein is transported to, or maintained in, basolateral regions of the plasma membrane.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:24785082, PMID:9425351]","metadata":null},{"id":"836a1642eb1c4d6bb9111ecdbe696170","type":"GO_TERM","name":"protein localization to bicellular tight junction","canonical_id":"go:GO:1902396","description":"\"A process in which a protein is transported to, or maintained in, a location within a bicellular tight junction.\" [GOC:TermGenie, PMID:18332111]","metadata":null},{"id":"136e67dd10de4cceb12cb8e63c35477b","type":"GO_TERM","name":"protein localization to bud neck","canonical_id":"go:GO:0097271","description":"\"A process in which a protein is transported to, or maintained at, a location within a cellular bud neck.\" [GOC:rb, PMID:22344253]","metadata":null},{"id":"ff86db43cfc14f5984fe0cdac4e945fb","type":"GO_TERM","name":"protein localization to cell cortex","canonical_id":"go:GO:0072697","description":"\"A process in which a protein is transported to, or maintained in, the cell cortex.\" [GOC:mah]","metadata":null},{"id":"6b70172acb81416a981b2ce40f511e62","type":"GO_TERM","name":"protein localization to cell cortex of cell tip","canonical_id":"go:GO:1990896","description":"\"A process in which a protein is transported to, or maintained in, the cell cortex of the cell tip.\" [PMID:26150232]","metadata":null},{"id":"67dffc9ea8b8469a8c3d9d2a860fa65a","type":"GO_TERM","name":"protein localization to cell division site","canonical_id":"go:GO:0072741","description":"\"A cellular protein localization process in which a protein is transported to, or maintained at, the site of cell division.\" [GOC:mah, PMID:19756689]","metadata":null},{"id":"0e24a197286d44f3bc1da8adf371da5b","type":"GO_TERM","name":"protein localization to cell division site after cytokinesis","canonical_id":"go:GO:0098841","description":"\"A cellular protein localization process in which a protein is transported to, or maintained at, the site of cell division following cytokinesis.\" [PMID:25411334]","metadata":null},{"id":"592710ed3c8c4773b4056c03a9ef8cab","type":"GO_TERM","name":"protein localization to cell division site involved in mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:1903476","description":"\"Any protein localization to cell division site that is involved in mitotic actomyosin contractile ring assembly.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"ff4fad48dc654e58919fa44a1cc0358e","type":"GO_TERM","name":"protein localization to cell junction","canonical_id":"go:GO:1902414","description":"\"A process in which a protein is transported to, or maintained in, a location within a cell junction.\" [GOC:TermGenie, PMID:18332111]","metadata":null},{"id":"24adcea6a96e4e2d902811c3ba17cc78","type":"GO_TERM","name":"protein localization to cell leading edge","canonical_id":"go:GO:1902463","description":"\"A process in which a protein is transported to, or maintained in, a location within a cell leading edge.\" [GOC:lb, GOC:TermGenie, PMID:21543326]","metadata":null},{"id":"e502c89b47314c67989e16b601e48d7c","type":"GO_TERM","name":"protein localization to cell periphery","canonical_id":"go:GO:1990778","description":"\"A process in which a protein is transported to, or maintained in, the cell periphery.\" [PMID:18216290]","metadata":null},{"id":"f73ff8e1105b4b1db045ee2b840e2298","type":"GO_TERM","name":"protein localization to cell surface","canonical_id":"go:GO:0034394","description":"\"A process in which a protein is transported to, or maintained in, a location within the external part of the cell wall and/or plasma membrane.\" [GOC:mah]","metadata":null},{"id":"dace9335ac2b4b71aaa40aaf26a38a2a","type":"GO_TERM","name":"protein localization to cell tip","canonical_id":"go:GO:1990151","description":"\"A process in which a protein is transported to, or maintained in, a location at the cell tip.\" [PMID:22768263]","metadata":null},{"id":"9399e3fc74054e699215083d0f9e0c6c","type":"GO_TERM","name":"protein localization to cell wall","canonical_id":"go:GO:0099613","description":"\"The process of directing proteins towards the cell-wall.\" [ISBN:0716731363]","metadata":null},{"id":"eaf6cc7782a54ba1b2c4031cb5b6ac3e","type":"GO_TERM","name":"protein localization to cell-cell junction","canonical_id":"go:GO:0150105","description":"\"A process in which a protein is transported to, or maintained, in a location within a cell-cell junction.\" [GOC:aruk, GOC:bc, PMID:26706435]","metadata":null},{"id":"b709c6655f324ae09d3d2fa4c04c955a","type":"GO_TERM","name":"protein localization to centriolar satellite","canonical_id":"go:GO:0120329","description":"\"A process in which a protein is transported to, or maintained in, a location within a centriolar satellite.\" [PMID:34782749]","metadata":null},{"id":"9e0924929f174790bb141d20cd9d98ea","type":"GO_TERM","name":"protein localization to centrosome","canonical_id":"go:GO:0071539","description":"\"A process in which a protein is transported to, or maintained at, the centrosome.\" [GOC:ecd]","metadata":null},{"id":"a35499728d9e4cdc83d50f1aea376413","type":"GO_TERM","name":"protein localization to chloroplast","canonical_id":"go:GO:0072598","description":"\"A process in which a protein is transported to, or maintained at, a location in a chloroplast.\" [GOC:ecd]","metadata":null},{"id":"d1a4c01c539949a9a0971260cab8d32b","type":"GO_TERM","name":"protein localization to chloroplast starch grain","canonical_id":"go:GO:1904160","description":"\"A process in which a protein is transported to, or maintained in, a location within a chloroplast starch grain.\" [GO_REF:0000087, GOC:TermGenie, PMID:25710501]","metadata":null},{"id":"899bf6b31bd844b7aaa90b90484c6857","type":"GO_TERM","name":"protein localization to chromatin","canonical_id":"go:GO:0071168","description":"\"Any process in which a protein is transported to, or maintained at, a part of a chromosome that is organized into chromatin.\" [GOC:mah]","metadata":null},{"id":"7e567d189da540148fcb7b2e2708a445","type":"GO_TERM","name":"protein localization to chromosome","canonical_id":"go:GO:0034502","description":"\"Any process in which a protein is transported to, or maintained at, a specific location on a chromosome.\" [GOC:mah]","metadata":null},{"id":"cd180ac0950049cb8b870ef01d4f426d","type":"GO_TERM","name":"protein localization to chromosome, centromeric region","canonical_id":"go:GO:0071459","description":"\"Any process in which a protein is transported to, or maintained at, the centromeric region of a chromosome.\" [GOC:mah]","metadata":null},{"id":"78fb1b47e559479c914fc5309bce5379","type":"GO_TERM","name":"protein localization to chromosome, telomeric region","canonical_id":"go:GO:0070198","description":"\"Any process in which a protein is transported to, or maintained at, the telomeric region of a chromosome.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"f7e2894938b44098bc369f9b24d67dac","type":"GO_TERM","name":"protein localization to ciliary inversin compartment","canonical_id":"go:GO:1904108","description":"\"A process in which a protein is transported to, or maintained in, a location within a ciliary inversin compartment.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:25335890]","metadata":null},{"id":"4905219ae647491da2e55bb8d61cbf8b","type":"GO_TERM","name":"protein localization to ciliary membrane","canonical_id":"go:GO:1903441","description":"\"A process in which a protein is transported to, or maintained in, a location within a ciliary membrane.\" [GO_REF:0000087, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22139371]","metadata":null},{"id":"48c8500e302e429e93473e54579eea77","type":"GO_TERM","name":"protein localization to ciliary transition zone","canonical_id":"go:GO:1904491","description":"\"A process in which a protein is transported to, or maintained in, a location within a ciliary transition zone.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:21422230]","metadata":null},{"id":"cac5b65c5c94415c8f97136639ac3e27","type":"GO_TERM","name":"protein localization to cilium","canonical_id":"go:GO:0061512","description":"\"A process in which a protein is transported to, or maintained in, a location within a cilium.\" [GOC:dph]","metadata":null},{"id":"c3a71ee95dd44b789e1060fa6bcc56e8","type":"GO_TERM","name":"protein localization to cleavage furrow","canonical_id":"go:GO:1905345","description":"\"A process in which a protein is transported to, or maintained in, a location within a cleavage furrow.\" [GO_REF:0000087, GOC:TermGenie, PMID:27082518]","metadata":null},{"id":"484404e2ce1d410ba996342c440829d8","type":"GO_TERM","name":"protein localization to cleavage furrow rim","canonical_id":"go:GO:1905346","description":"\"A process in which a protein is transported to, or maintained in, a location within a cleavage furrow rim.\" [GO_REF:0000087, GOC:TermGenie, PMID:27082518]","metadata":null},{"id":"d874bdab8ba345d19513330da4c9cc46","type":"GO_TERM","name":"protein localization to condensed chromosome","canonical_id":"go:GO:1903083","description":"\"A process in which a protein is transported to, or maintained in, a location within a condensed chromosome.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:12707312]","metadata":null},{"id":"7c921b9ff1134021a14c63ac5fa13706","type":"GO_TERM","name":"protein localization to condensed nuclear chromosome","canonical_id":"go:GO:1903084","description":"\"A process in which a protein is transported to, or maintained in, a location within a condensed nuclear chromosome.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:12707312]","metadata":null},{"id":"56573fd3eeda423a8ac4daab550da58a","type":"GO_TERM","name":"protein localization to cortical endoplasmic reticulum","canonical_id":"go:GO:1903419","description":"\"A process in which a protein is transported to, or maintained in, a location within a cortical endoplasmic reticulum.\" [GO_REF:0000087, GOC:TermGenie, PMID:25103238]","metadata":null},{"id":"4924e3ebe234456b80b16fbf83d552f5","type":"GO_TERM","name":"protein localization to cortical microtubule cytoskeleton","canonical_id":"go:GO:0072699","description":"\"A process in which a protein is transported to, or maintained at, a location within the cortical microtubule cytoskeleton.\" [GOC:mah]","metadata":null},{"id":"1936af892dd1459594f7362ba21f2189","type":"GO_TERM","name":"protein localization to cytoplasmic microtubule","canonical_id":"go:GO:1905755","description":"\"A process in which a protein is transported to, or maintained in, a location within a cytoplasmic microtubule.\" [GO_REF:0000087, GOC:TermGenie, PMID:15177031]","metadata":null},{"id":"8288b1f0230f4822899e0796a55ad471","type":"GO_TERM","name":"protein localization to cytoplasmic microtubule plus-end","canonical_id":"go:GO:1904518","description":"\"A process in which a protein is transported to, or maintained in, a location at a cytoplasmic microtubule plus-end.\" [GO_REF:0000087, GOC:TermGenie, PMID:15772152]","metadata":null},{"id":"ea6a76ff7156415891d2517d5564a3eb","type":"GO_TERM","name":"protein localization to cytoplasmic stress granule","canonical_id":"go:GO:1903608","description":"\"A process in which a protein is transported to, or maintained in, a location within a cytoplasmic stress granule.\" [GO_REF:0000087, GOC:TermGenie, PMID:24755092]","metadata":null},{"id":"ca8bcb5a30514b36b441c2ab468795c4","type":"GO_TERM","name":"protein localization to cytoskeleton","canonical_id":"go:GO:0044380","description":"\"A process in which a protein is transported to, or maintained in, a location within the cytoskeleton.\" [GOC:jl]","metadata":null},{"id":"a18b4c43bf1f4854848d7d37ee84f406","type":"GO_TERM","name":"protein localization to cytosolic proteasome complex","canonical_id":"go:GO:1904327","description":"\"A process in which a protein is transported to, or maintained in, a location within a cytosolic proteasome complex.\" [GO_REF:0000087, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:17000876]","metadata":null},{"id":"f9ce8fe444734e3eb12738fd099f2933","type":"GO_TERM","name":"protein localization to division septum","canonical_id":"go:GO:1902432","description":"\"A process in which a protein is transported to, or maintained in, a location within a division septum.\" [GOC:TermGenie, PMID:9367977]","metadata":null},{"id":"87d2e22306934f418f15b0c3336e48bf","type":"GO_TERM","name":"protein localization to early endosome","canonical_id":"go:GO:1902946","description":"\"A process in which a protein is transported to, or maintained in, a location within an early endosome.\" [GO_REF:0000087, GOC:sjp, GOC:TermGenie, PMID:22621900]","metadata":null},{"id":"9659a7751fdd467ca6e7e6754362f0f7","type":"GO_TERM","name":"protein localization to eisosome filament","canonical_id":"go:GO:0097446","description":"\"A process in which a protein is transported to, and/or maintained in, a specific location in a eisosome filament (also called linear eisosome), a filamentous cortical structure formed, in S. pombe, by the eisosome component Pil1.\" [GOC:mah, GOC:vw, PMID:22869600, PMID:23722945]","metadata":null},{"id":"bdc821916bc94245ac01517a29258aae","type":"GO_TERM","name":"protein localization to endoplasmic reticulum","canonical_id":"go:GO:0070972","description":"\"A process in which a protein is transported to, or maintained in, a location within the endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"d0ec2d87abe247cc80a6d56141e95dfc","type":"GO_TERM","name":"protein localization to endoplasmic reticulum tubular network","canonical_id":"go:GO:1903420","description":"\"A process in which a protein is transported to, or maintained in, a location within an endoplasmic reticulum tubular network.\" [GO_REF:0000087, GOC:TermGenie, PMID:25103238]","metadata":null},{"id":"2565ea82fd4b4087845b30fdc01b135d","type":"GO_TERM","name":"protein localization to endosome","canonical_id":"go:GO:0036010","description":"\"A process in which a protein is transported to, or maintained in, a location within an endosome.\" [GOC:yaf]","metadata":null},{"id":"8e31b47f6eaf4f0aa91427074789cd79","type":"GO_TERM","name":"protein localization to equatorial microtubule organizing center","canonical_id":"go:GO:1904759","description":"\"A process in which a protein is transported to, or maintained in, a location within an equatorial microtubule organizing center.\" [GO_REF:0000087, GOC:TermGenie, PMID:16611237]","metadata":null},{"id":"c84c3887113e44368e266eab4e6a8156","type":"GO_TERM","name":"protein localization to euchromatin","canonical_id":"go:GO:1905632","description":"\"A process in which a protein is transported to, or maintained in, a location within an euchromatin.\" [GO_REF:0000087, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"ac735f8991354b07891f4902ba2b6fb3","type":"GO_TERM","name":"protein localization to extracellular region","canonical_id":"go:GO:0071692","description":"\"Any process in which a protein is transported from one specific location in the extracellular region to another, or maintained in a specific extracellular location.\" [GOC:mah]","metadata":null},{"id":"0f54b714b7e0455f9fa57b7628364707","type":"GO_TERM","name":"protein localization to growing cell tip","canonical_id":"go:GO:1902486","description":"\"A process in which a protein is transported to, or maintained in, a location within a growing cell tip.\" [GOC:TermGenie, PMID:23041194]","metadata":null},{"id":"8a8d7cb911e74a9f854810b21a779079","type":"GO_TERM","name":"protein localization to heterochromatin","canonical_id":"go:GO:0097355","description":"\"Any process in which a protein is transported to, or maintained at, a part of a chromosome that is organized into heterochromatin.\" [GOC:mah]","metadata":null},{"id":"f93c194b628f431b8fa075b6e757c583","type":"GO_TERM","name":"protein localization to horsetail-astral microtubule array","canonical_id":"go:GO:1903696","description":"\"A process in which a protein is transported to, or maintained in, a location within a horsetail-astral microtubule array.\" [GO_REF:0000087, GOC:TermGenie, PMID:11907273]","metadata":null},{"id":"ad8328c2abfa4a19b4706086f3c0b58d","type":"GO_TERM","name":"protein localization to interphase microtubule organizing center","canonical_id":"go:GO:1905509","description":"\"A process in which a protein is transported to, or maintained in, a location within an interphase microtubule organizing center.\" [GO_REF:0000087, GOC:TermGenie, PMID:19001497]","metadata":null},{"id":"173f25463c8b49198b3766dd5a825483","type":"GO_TERM","name":"protein localization to juxtaparanode region of axon","canonical_id":"go:GO:0071205","description":"\"Any process in which a protein is transported to, or maintained at, the juxtaparanode region of an axon.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"acf8706ef05e4939b66cdd0a6a8541a2","type":"GO_TERM","name":"protein localization to kinetochore","canonical_id":"go:GO:0034501","description":"\"Any process in which a protein is transported to, or maintained at, the kinetochore.\" [GOC:mah]","metadata":null},{"id":"12a2903e15c1498bbbf2c97a72deac84","type":"GO_TERM","name":"protein localization to kinetochore involved in kinetochore assembly","canonical_id":"go:GO:1903394","description":"\"Any protein localization to kinetochore that is involved in kinetochore assembly.\" [GO_REF:0000060, GOC:TermGenie, PMID:15369671]","metadata":null},{"id":"d51be6870f624ce790f4327c8a1b0dea","type":"GO_TERM","name":"protein localization to lateral cortical node","canonical_id":"go:GO:1903360","description":"\"A process in which a protein is transported to, or maintained in, a location within a lateral cortical node.\" [GO_REF:0000087, GOC:TermGenie, PMID:25009287]","metadata":null},{"id":"2c0b720436c047c7bd1878937c9f134e","type":"GO_TERM","name":"protein localization to linear element","canonical_id":"go:GO:0036181","description":"\"A cellular protein localization process in which a protein is transported to, or maintained at, a linear element. A linear element is a proteinaceous scaffold associated with S. pombe chromosomes during meiotic prophase.\" [GOC:mah, PMID:19756689]","metadata":null},{"id":"033a8eb823324e69906c8271e776bf19","type":"GO_TERM","name":"protein localization to lipid droplet","canonical_id":"go:GO:1990044","description":"\"A process in which a protein is transported to, or maintained in, a location on or within a lipid droplet.\" [GOC:sart, PMID:22505614]","metadata":null},{"id":"2a823f821a9a4816baae565cfaff999d","type":"GO_TERM","name":"protein localization to lysosome","canonical_id":"go:GO:0061462","description":"\"A process in which a protein is transported to, or maintained in, a location within a lysosome.\" [GOC:dph]","metadata":null},{"id":"910692c3f5e5462982e23f24b5ae0f24","type":"GO_TERM","name":"protein localization to mast cell secretory granule","canonical_id":"go:GO:0033367","description":"\"A process in which a protein is transported to, or maintained in, a location within a secretory granule in a mast cell.\" [GOC:mah]","metadata":null},{"id":"9d1fa6cc233c4647ada911f3ad9ff9a7","type":"GO_TERM","name":"protein localization to mating projection tip","canonical_id":"go:GO:1903260","description":"\"A process in which a protein is transported to, or maintained in, a location within a mating projection tip.\" [GO_REF:0000087, GOC:TermGenie, PMID:11952834]","metadata":null},{"id":"8ada98c2c79743bb998bf9aa4ab401c4","type":"GO_TERM","name":"protein localization to medial cortex","canonical_id":"go:GO:0071574","description":"\"A process in which a protein is transported to, or maintained in, the medial cortex.\" [GOC:mah]","metadata":null},{"id":"27d3aeb8601e40ef81585f4617bd3b8f","type":"GO_TERM","name":"protein localization to medial cortical node","canonical_id":"go:GO:1902577","description":"\"A process in which a protein is transported to, or maintained in, a location within a medial cortical node.\" [GOC:TermGenie, PMID:24127216]","metadata":null},{"id":"de02909832dd4f44b12d38c1f3d687df","type":"GO_TERM","name":"protein localization to meiotic spindle","canonical_id":"go:GO:1905359","description":"\"A process in which a protein is transported to, or maintained in, a location within a meiotic spindle.\" [GO_REF:0000087, GOC:TermGenie, PMID:26696398]","metadata":null},{"id":"6f166cfedb1a4cae9980dd0baa0210f2","type":"GO_TERM","name":"protein localization to meiotic spindle midzone","canonical_id":"go:GO:1903096","description":"\"A process in which a protein is transported to, or maintained in, a location within a meiotic spindle midzone.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:12707312]","metadata":null},{"id":"baa9baada7704e6da1a997e9fa2f4a42","type":"GO_TERM","name":"protein localization to meiotic spindle pole body","canonical_id":"go:GO:1902441","description":"\"A process in which a protein is transported to, or maintained in, a location within a meiotic spindle pole body.\" [PMID:20833892]","metadata":null},{"id":"ac1bb14ab8e14f2fa9291b6cab4d6b25","type":"GO_TERM","name":"protein localization to membrane","canonical_id":"go:GO:0072657","description":"\"A process in which a protein is transported to, or maintained in, a specific location in a membrane.\" [GOC:mah]","metadata":null},{"id":"a40d4d880e73408dbf32f0e02235b319","type":"GO_TERM","name":"protein localization to membrane raft","canonical_id":"go:GO:1903044","description":"\"A process in which a protein is transported to, or maintained in, a location within a membrane raft.\" [GO_REF:0000087, GOC:dl, GOC:TermGenie, PMID:19414744]","metadata":null},{"id":"78c105697a9340ffad32228bda61edd1","type":"GO_TERM","name":"protein localization to microtubule","canonical_id":"go:GO:0035372","description":"\"A process in which a protein is transported to, or maintained at, a microtubule.\" [GOC:bf, GOC:lb]","metadata":null},{"id":"1b4909ee7a24415b8cfbed393eb69d30","type":"GO_TERM","name":"protein localization to microtubule cytoskeleton","canonical_id":"go:GO:0072698","description":"\"A cellular protein localization process in which a protein is transported to, or maintained at, a location within the microtubule cytoskeleton.\" [GOC:mah]","metadata":null},{"id":"fcbda9de5b36408e8aa24917078ef244","type":"GO_TERM","name":"protein localization to microtubule end","canonical_id":"go:GO:1905725","description":"\"A process in which a protein is transported to, or maintained in, a location at a microtubule end.\" [GO_REF:0000087, GOC:TermGenie, PMID:12034771]","metadata":null},{"id":"c169fcb286d243e8b2284fc29fdf5876","type":"GO_TERM","name":"protein localization to microtubule minus-end","canonical_id":"go:GO:1904519","description":"\"A process in which a protein is transported to, or maintained in, a location at a microtubule minus-end.\" [GO_REF:0000087, GOC:TermGenie, PMID:25987607]","metadata":null},{"id":"7ad3e89553d44ae6824e56af18a0e703","type":"GO_TERM","name":"protein localization to microtubule organizing center","canonical_id":"go:GO:1905508","description":"\"A process in which a protein is transported to, or maintained in, a location within a microtubule organizing center.\" [GO_REF:0000087, GOC:TermGenie, PMID:19001497]","metadata":null},{"id":"bc659aec75a24067a79fce52f0cdff34","type":"GO_TERM","name":"protein localization to microtubule plus-end","canonical_id":"go:GO:1904825","description":"\"A process in which a protein is transported to, or maintained in, a location at a microtubule plus-end.\" [GO_REF:0000087, GOC:TermGenie, PMID:24039245]","metadata":null},{"id":"cbe82fbc591846f6823841cf8adfdda2","type":"GO_TERM","name":"protein localization to microvillus","canonical_id":"go:GO:1904106","description":"\"A process in which a protein is transported to, or maintained in, a location within a microvillus.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:25335890]","metadata":null},{"id":"d9b631260e3c4576af4eefa496e4a105","type":"GO_TERM","name":"protein localization to microvillus membrane","canonical_id":"go:GO:1904107","description":"\"A process in which a protein is transported to, or maintained in, a location within a microvillus membrane.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:25335890]","metadata":null},{"id":"e6374aac439e46b693cca48d3c877b80","type":"GO_TERM","name":"protein localization to mitochondrion","canonical_id":"go:GO:0070585","description":"\"A process in which a protein is transported to, or maintained in, a location within the mitochondrion.\" [GOC:ecd]","metadata":null},{"id":"6ffd4afe12da4d40a864242322cb4001","type":"GO_TERM","name":"protein localization to mitotic actomyosin contractile ring","canonical_id":"go:GO:1904498","description":"\"Any protein localization to actomyosin contractile ring that is involved in mitotic cytokinesis.\" [GO_REF:0000060, GOC:TermGenie, PMID:25688133]","metadata":null},{"id":"b807d3f40cb94a04a4c9fd721960430f","type":"GO_TERM","name":"protein localization to mitotic spindle","canonical_id":"go:GO:1902480","description":"\"A process in which a protein is transported to, or maintained in, a location within a mitotic spindle.\" [GOC:TermGenie, PMID:23885124]","metadata":null},{"id":"36f17463d98f485abd83e85011c4fcc8","type":"GO_TERM","name":"protein localization to mitotic spindle midzone","canonical_id":"go:GO:1902967","description":"\"A process in which a protein is transported to, or maintained in, a location within a mitotic spindle midzone.\" [GO_REF:0000087, GOC:TermGenie, PMID:16824200]","metadata":null},{"id":"7dffb81eed694b46be913c3103109a8c","type":"GO_TERM","name":"protein localization to mitotic spindle pole body","canonical_id":"go:GO:1902440","description":"\"A process in which a protein is transported to, or maintained in, a location within a mitotic spindle pole body.\" [GOC:TermGenie, PMID:22438582]","metadata":null},{"id":"c156fde010e7426294ad27d9ed80cf49","type":"GO_TERM","name":"protein localization to motile cilium","canonical_id":"go:GO:0120229","description":"\"A process in which a protein is transported to, or maintained in, a location within a motile cilium.\" [GOC:krc, PMID:27486780]","metadata":null},{"id":"f8a91c794f9c4eb9a0fb03eab30d51c9","type":"GO_TERM","name":"protein localization to myelin sheath abaxonal region","canonical_id":"go:GO:0035750","description":"\"Any process in which a protein is transported to, and/or maintained in, the abaxonal region of the myelin sheath. The abaxonal region is the region of the myelin sheath furthest from the axon.\" [GOC:BHF, PMID:20237282]","metadata":null},{"id":"df6b90983241442fa5625a3c111a76d6","type":"GO_TERM","name":"protein localization to new growing cell tip","canonical_id":"go:GO:1904758","description":"\"A process in which a protein is transported to, or maintained in, a location within a new growing cell tip.\" [GO_REF:0000087, GOC:TermGenie, PMID:19431238]","metadata":null},{"id":"48edcd5ca8dc4724ac0e178c1a2bfb20","type":"GO_TERM","name":"protein localization to non-growing cell tip","canonical_id":"go:GO:1902487","description":"\"A process in which a protein is transported to, or maintained in, a location within a non-growing cell tip.\" [GOC:TermGenie, PMID:21652630, PMID:23041194]","metadata":null},{"id":"8a44f4a44746451ebc8c4b97988b116a","type":"GO_TERM","name":"protein localization to non-motile cilium","canonical_id":"go:GO:0097499","description":"\"A process in which a protein is transported to, or maintained in, a location within a non-motile cilium.\" [GOC:cilia, GOC:kmv, PMID:23128241]","metadata":null},{"id":"af66d330666a431fae4f966eb4110004","type":"GO_TERM","name":"protein localization to nuclear body","canonical_id":"go:GO:1903405","description":"\"A process in which a protein is transported to, or maintained in, a location within a nuclear body.\" [GO_REF:0000087, GOC:TermGenie, PMID:24713849]","metadata":null},{"id":"56ee5875c5c34f8dab4a70c6650680fb","type":"GO_TERM","name":"protein localization to nuclear envelope","canonical_id":"go:GO:0090435","description":"\"A process in which a protein is transported to, or maintained at, a location within a nuclear envelope.\" [GOC:tb]","metadata":null},{"id":"74d1b6962235458db3157bc74f0ac279","type":"GO_TERM","name":"protein localization to nuclear inner membrane","canonical_id":"go:GO:0036228","description":"\"A process in which a protein is transported to, or maintained in, a location within the nuclear inner membrane.\" [GOC:dgf, PMID:16929305]","metadata":null},{"id":"cc4a46c633c94c97b13fe473c145bfd9","type":"GO_TERM","name":"protein localization to nuclear periphery","canonical_id":"go:GO:1990139","description":"\"A process in which a protein is transported to, or maintained in, a location within the nuclear periphery.\" [GOC:mah, PMID:23703609]","metadata":null},{"id":"89991e0dbe9848f788d70ef780adee05","type":"GO_TERM","name":"protein localization to nuclear pore","canonical_id":"go:GO:0090204","description":"\"A process in which a protein is transported to, or maintained in, a nuclear pore.\" [GOC:dph, GOC:rb, GOC:tb]","metadata":null},{"id":"091a2877d31d4655927900cc246e28c2","type":"GO_TERM","name":"protein localization to nucleolar rDNA repeats","canonical_id":"go:GO:0034503","description":"\"Any process in which a protein is transported to, or maintained at, the rDNA repeats on a chromosome in the nucleolus.\" [GOC:mah]","metadata":null},{"id":"eb35554c49d243b9838b9f64b32a6c22","type":"GO_TERM","name":"protein localization to nucleolus","canonical_id":"go:GO:1902570","description":"\"A process in which a protein is transported to, or maintained in, a location within a nucleolus.\" [GOC:TermGenie, PMID:22809626]","metadata":null},{"id":"a5cd410c5c494433b16fd4383fce50c3","type":"GO_TERM","name":"protein localization to nucleoplasm","canonical_id":"go:GO:1990173","description":"\"A process in which a protein is transported to, or maintained in, a location within the nucleoplasm.\" [GOC:mah, PMID:22918952]","metadata":null},{"id":"9e07835e2e5f47cda4f49a3641b36d89","type":"GO_TERM","name":"protein localization to nucleus","canonical_id":"go:GO:0034504","description":"\"A process in which a protein transports or maintains the localization of another protein to the nucleus.\" [GOC:ecd]","metadata":null},{"id":"6479456e661444c398469057b6a8b5e7","type":"GO_TERM","name":"protein localization to old growing cell tip","canonical_id":"go:GO:1903858","description":"\"A process in which a protein is transported to, or maintained in, a location within an old growing cell tip.\" [GO_REF:0000087, GOC:TermGenie, PMID:17895368]","metadata":null},{"id":"639a64e22a4a4604b86f7f938f21a019","type":"GO_TERM","name":"protein localization to organelle","canonical_id":"go:GO:0033365","description":"\"A process in which a protein is transported to, or maintained in, a location within an organelle.\" [GOC:mah]","metadata":null},{"id":"2b0fa623e1994a18a8b9c6fc516c82e9","type":"GO_TERM","name":"protein localization to outer membrane","canonical_id":"go:GO:0089705","description":"\"A process in which a protein is transported to, or maintained in, a specific location the cell outer membrane.\" [GOC:dos, PMID:12823819]","metadata":null},{"id":"5d2e22c6911c44bfb2514be9fe984499","type":"GO_TERM","name":"protein localization to paranode region of axon","canonical_id":"go:GO:0002175","description":"\"A cellular protein localization process in which a protein is transported to, or maintained at, the paranode region of an axon.\" [PMID:18803321]","metadata":null},{"id":"9b0f8087b7af420d9b49bab8d0a5d37a","type":"GO_TERM","name":"protein localization to pericentric heterochromatin","canonical_id":"go:GO:1902682","description":"\"A process in which a protein is transported to, or maintained in the pericentric heterochromatin.\" [GO_REF:0000087, GOC:TermGenie, PMID:20211136]","metadata":null},{"id":"afd50db359f84c408c8179b723f351b7","type":"GO_TERM","name":"protein localization to pericentriolar material","canonical_id":"go:GO:1905793","description":"\"A process in which a protein is transported to, or maintained in, a location within a pericentriolar material.\" [GO_REF:0000087, GOC:TermGenie, PMID:21694707, PMID:24385583]","metadata":null},{"id":"460225989e1f44aca771cd5ed0e2c110","type":"GO_TERM","name":"protein localization to perinuclear region of cytoplasm","canonical_id":"go:GO:1905719","description":"\"A process in which a protein is transported to, or maintained in, a location within the perinuclear region of the cytoplasm.\" [GO_REF:0000087, GOC:TermGenie, PMID:15177031]","metadata":null},{"id":"23d09a7e30c04cd0be81f1bf6d986619","type":"GO_TERM","name":"protein localization to peroxisome","canonical_id":"go:GO:0072662","description":"\"A process in which a protein is transported to, or maintained at, a location in a peroxisome.\" [GOC:ecd]","metadata":null},{"id":"120ed1ac2c6d436b866c670796e88798","type":"GO_TERM","name":"protein localization to phagocytic vesicle","canonical_id":"go:GO:1905161","description":"\"A process in which a protein is transported to, or maintained in, a location within a phagocytic vesicle.\" [GO_REF:0000087, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23303671]","metadata":null},{"id":"af3e33a33bde46bba5d12c46bc2ed49e","type":"GO_TERM","name":"protein localization to phagophore assembly site","canonical_id":"go:GO:0034497","description":"\"Any process in which a protein is transported to, or maintained at, the phagophore assembly site (PAS).\" [GOC:rb]","metadata":null},{"id":"82e24c1e3d3c41158de6e0bfc1c869c7","type":"GO_TERM","name":"protein localization to photoreceptor connecting cilium","canonical_id":"go:GO:1903621","description":"\"A process in which a protein is transported to, or maintained in, a location within a photoreceptor connecting cilium.\" [GO_REF:0000087, GOC:lb, GOC:TermGenie, PMID:25398945]","metadata":null},{"id":"30d30ac77ff7407db319f5e640bc0c91","type":"GO_TERM","name":"protein localization to photoreceptor outer segment","canonical_id":"go:GO:1903546","description":"\"A process in which a protein is transported to, or maintained in, a location within a photoreceptor outer segment.\" [GO_REF:0000087, GOC:TermGenie, PMID:11481257, PMID:21867699]","metadata":null},{"id":"8cccb20f33064fa58db07ca8cebb9c34","type":"GO_TERM","name":"protein localization to plasma membrane","canonical_id":"go:GO:0072659","description":"\"A process in which a protein is transported to, or maintained in, a specific location in the plasma membrane.\" [GOC:mah]","metadata":null},{"id":"bcd71582d397423bb90bb5ee7aeabfb2","type":"GO_TERM","name":"protein localization to plasma membrane of cell tip","canonical_id":"go:GO:1903418","description":"\"A process in which a protein is transported to, or maintained in, a location within a plasma membrane of cell tip.\" [GO_REF:0000087, GOC:TermGenie, PMID:25157670, PMID:27852900]","metadata":null},{"id":"3176d48496c34c668a149955a00e3ef8","type":"GO_TERM","name":"protein localization to plasma membrane raft","canonical_id":"go:GO:0044860","description":"\"A process in which a protein is transported to, or maintained in, a location within a plasma membrane raft.\" [GOC:jl]","metadata":null},{"id":"440aa34baeb74d23933b0ffbd5063f7d","type":"GO_TERM","name":"protein localization to polar microtubule","canonical_id":"go:GO:0160086","description":"\"A process in which a protein is transported to, or maintained in, a location within a polar microtubule.\" [PMID:34080538]","metadata":null},{"id":"7d23c968629b4fef8d5be28525e3203a","type":"GO_TERM","name":"protein localization to postsynapse","canonical_id":"go:GO:0062237","description":"\"Any process in which a protein is transported to, and/or maintained at the postsynapse, the part of a synapse that is part of the post-synaptic cell.\" [PMID:31189538]","metadata":null},{"id":"7f0c4fbf37d54c0aa6049c07a23f8ea4","type":"GO_TERM","name":"protein localization to postsynaptic membrane","canonical_id":"go:GO:1903539","description":"\"A process in which a protein is transported to, or maintained in, a location within a postsynaptic membrane.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:9753322]","metadata":null},{"id":"eceede81c5c1443199e223ebec6a357b","type":"GO_TERM","name":"protein localization to postsynaptic specialization membrane","canonical_id":"go:GO:0099633","description":"\"A process in which a protein is transported to, or maintained in, a location within the membrane adjacent to a postsynaptic specialization (e.g. post synaptic density).\" [GOC:dos]","metadata":null},{"id":"84ea8e0f5f4e47c3bb76508d4767eeda","type":"GO_TERM","name":"protein localization to presynapse","canonical_id":"go:GO:1905383","description":"\"A process in which a protein is transported to, or maintained in, a location within a presynapse.\" [GO_REF:0000087, GOC:TermGenie, PMID:24449494]","metadata":null},{"id":"a7f0c8d53567496aa3de11746052727f","type":"GO_TERM","name":"protein localization to presynaptic membrane","canonical_id":"go:GO:0099644","description":"\"A process in which a protein is transported to, or maintained in, a location within a presynaptic membrane.\" [GOC:dos]","metadata":null},{"id":"82522c33e515454ca6473c82541fdc60","type":"GO_TERM","name":"protein localization to prospore membrane","canonical_id":"go:GO:1902657","description":"\"A process in which a protein is transported to, or maintained in, a location within a prospore membrane.\" [GO_REF:0000087, GOC:dph, GOC:TermGenie, PMID:24036347]","metadata":null},{"id":"f3e5e5fbe94747c18c20052d11a91499","type":"GO_TERM","name":"protein localization to rhabdomere","canonical_id":"go:GO:1990146","description":"\"A process in which a protein is transported to, or maintained in, a location within a rhabdomere.\" [GOC:sart, PMID:8335687]","metadata":null},{"id":"aaa650dcf4c54ebe911858b044da9c90","type":"GO_TERM","name":"protein localization to secretory granule","canonical_id":"go:GO:0033366","description":"\"A process in which a protein is transported to, or maintained in, a location within a secretory granule.\" [GOC:mah]","metadata":null},{"id":"37d7c1b9d2cb4ca9974a7237aa673387","type":"GO_TERM","name":"protein localization to septin ring","canonical_id":"go:GO:1902935","description":"\"A process in which a protein is transported to, or maintained in, a location within a septin ring.\" [GO_REF:0000087, GOC:TermGenie, PMID:16325501]","metadata":null},{"id":"d3db871b847f4d48beb1ccdff4294f29","type":"GO_TERM","name":"protein localization to site of double-strand break","canonical_id":"go:GO:1990166","description":"\"Any process in which a protein is transported to, or maintained at, a region of a chromosome at which a DNA double-strand break has occurred.\" [GOC:mah, PMID:23080121]","metadata":null},{"id":"5e8c46335ffd4beab68f253ae8da4b73","type":"GO_TERM","name":"protein localization to somatodendritic compartment","canonical_id":"go:GO:0061938","description":"\"A process in which a protein is transported to or maintained in a location within the somatodendritic compartment.\" [PMID:18341993]","metadata":null},{"id":"49eb7c9be80849bab03e56ce6ad4f900","type":"GO_TERM","name":"protein localization to spindle microtubule","canonical_id":"go:GO:1902889","description":"\"A process in which a protein is transported to, or maintained in, a location within a spindle microtubule.\" [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:16054030]","metadata":null},{"id":"a153edf57b484be3b27a80533548a197","type":"GO_TERM","name":"protein localization to spindle pole body","canonical_id":"go:GO:0071988","description":"\"A process in which a protein is transported to, or maintained at, the spindle pole body.\" [GOC:mah]","metadata":null},{"id":"3578d741c37f44849ecec2cd713cebae","type":"GO_TERM","name":"protein localization to spore cell wall","canonical_id":"go:GO:0099614","description":"\"A process in which a protein is transported, tethered to or otherwise maintained in a spore cell wall.\" [GOC:dos]","metadata":null},{"id":"543668d711674e8db9f2ed2b7e4d0845","type":"GO_TERM","name":"protein localization to subtelomeric heterochromatin","canonical_id":"go:GO:1903213","description":"\"A process in which a protein is transported to, or maintained in, a location within a subtelomeric heterochromatin.\" [GO_REF:0000087, GOC:TermGenie, PMID:21300781, SO:0001997]","metadata":null},{"id":"9ac8ebf4e1ce4b838f55d6921dbd5234","type":"GO_TERM","name":"protein localization to synapse","canonical_id":"go:GO:0035418","description":"\"Any process in which a protein is transported to, and/or maintained at the synapse, the junction between a nerve fiber of one neuron and another neuron or muscle fiber or glial cell.\" [GOC:bf]","metadata":null},{"id":"d4cbfb6844c248e28c58bb6b84c10d7a","type":"GO_TERM","name":"protein localization to trailing edge","canonical_id":"go:GO:0036051","description":"\"A process in which a protein is transported to, or maintained at, the trailing edge. The trailing edge is the area of a motile cell opposite to the direction of movement.\" [GOC:pf, GOC:pg]","metadata":null},{"id":"b19fc7f3cc2f4076b629507d7d56b876","type":"GO_TERM","name":"protein localization to tricellular tight junction","canonical_id":"go:GO:0061833","description":"\"A process in which a protein is transported to, or maintained in, a location within a tricellular tight junction.\" [PMID:24889144]","metadata":null},{"id":"631b83229a3e43899d77f61a3ac45919","type":"GO_TERM","name":"protein localization to uropod","canonical_id":"go:GO:0036052","description":"\"A process in which a protein is transported to, or maintained in, a uropod. A uropod is a membrane projection with related cytoskeletal components at the trailing edge of a migrating cell.\" [GOC:add, GOC:pf, ISBN:0781735149, PMID:12714569, PMID:12787750]","metadata":null},{"id":"6e8a4996ee754f8bb69a4f02dfc3dccf","type":"GO_TERM","name":"protein localization to vacuolar membrane","canonical_id":"go:GO:1903778","description":"\"A process in which a protein is transported to, or maintained in, a location within a vacuolar membrane.\" [GO_REF:0000087, GOC:TermGenie, PMID:25378562]","metadata":null},{"id":"e459a9d8be984dedbe684f36fffecdb5","type":"GO_TERM","name":"protein localization to vacuole","canonical_id":"go:GO:0072665","description":"\"A process in which a protein is transported to, or maintained at, a location in a vacuole.\" [GOC:ecd]","metadata":null},{"id":"449052bb2e054827bb434414c265c107","type":"GO_TERM","name":"protein lysine deacetylase activity","canonical_id":"go:GO:0033558","description":"\"Catalysis of the reaction: Removal of an acetyl group from a lysine residue in a protein.\" [PMID:27296530, RHEA:58108]","metadata":null},{"id":"3d412731c535420fbda9b23676f1dce0","type":"GO_TERM","name":"protein lysine delactylase activity","canonical_id":"go:GO:0160216","description":"\"Catalysis of the reaction: H2O + N6-lactoyl-L-lysyl-[protein] = (S)-lactate + L-lysyl-[protein].\" [PMID:35044827, RHEA:81387]","metadata":null},{"id":"1b978dbf3d5e473d8d209eb92a5b2a09","type":"GO_TERM","name":"protein malonylation","canonical_id":"go:GO:0044394","description":"\"The modification of a protein amino acid by the addition of a malonyl (CO-CH2-CO) group.\" [GOC:sp]","metadata":null},{"id":"d99413bf9a8c4dd5a2ee9a3b3fbbe2c8","type":"GO_TERM","name":"protein maturation","canonical_id":"go:GO:0051604","description":"\"Any process leading to the attainment of the full functional capacity of a protein.\" [GOC:ai]","metadata":null},{"id":"3a07aff44f5848dbb2619d0e765ccbf4","type":"GO_TERM","name":"protein metabolic process","canonical_id":"go:GO:0019538","description":"\"The chemical reactions and pathways involving a protein. Includes protein modification.\" [GOC:ma]","metadata":null},{"id":"8da5464de9e84241a0c901a716a9afcc","type":"GO_TERM","name":"protein methylation","canonical_id":"go:GO:0006479","description":"\"The addition of a methyl group to a protein amino acid. A methyl group is derived from methane by the removal of a hydrogen atom.\" [GOC:ai]","metadata":null},{"id":"4a10b76acc864fbca5e92702cc711fb5","type":"GO_TERM","name":"protein methylesterase activity","canonical_id":"go:GO:0051723","description":"\"Catalysis of the reaction: protein amino acid methyl ester + H2O = protein amino acid + methanol.\" [GOC:ai]","metadata":null},{"id":"02d6cc95388c4e32a6d528496a482bff","type":"GO_TERM","name":"protein methylthiotransferase activity","canonical_id":"go:GO:0103039","description":"\"Catalysis of the reaction: 2 S-adenosyl-L-methionine + a [ribosomal protein S12] L-aspartate89 + a sulfurated [sulfur carrier] + a reduced electron acceptor = S-adenosyl-L-homocysteine + L-methionine + 5'-deoxyadenosine + 2 H+ + a [ribosomal protein S12] 3-methylthio-L-aspartate89 + an unsulfurated [sulfur carrier] + an oxidized electron acceptor.\" [EC:2.8.4.4, GOC:pz]","metadata":null},{"id":"a799c02a20744d648376fd8034ee990e","type":"GO_TERM","name":"protein methyltransferase activity","canonical_id":"go:GO:0008276","description":"\"Catalysis of the transfer of a methyl group (CH3-) to a protein.\" [GOC:jl]","metadata":null},{"id":"7471f72b02e34efe83d18692fb45b456","type":"GO_TERM","name":"protein modification by small protein conjugation","canonical_id":"go:GO:0032446","description":"\"A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to a target protein.\" [GOC:mah]","metadata":null},{"id":"482e903740c3481ea8badc84b2868803","type":"GO_TERM","name":"protein modification by small protein conjugation or removal","canonical_id":"go:GO:0070647","description":"\"A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to or removed from a target protein.\" [GOC:mah]","metadata":null},{"id":"6e72cc58017e4178861dca0f266dd029","type":"GO_TERM","name":"protein modification by small protein removal","canonical_id":"go:GO:0070646","description":"\"A protein modification process in which one or more covalently attached groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are removed from a target protein.\" [GOC:mah]","metadata":null},{"id":"1ee924ef9674424cad15286205bb250b","type":"GO_TERM","name":"protein modification process","canonical_id":"go:GO:0036211","description":"\"The covalent alteration of one or more amino acids occurring in proteins, peptides and nascent polypeptides (co-translational, post-translational modifications). Includes the modification of charged tRNAs that are destined to occur in a protein (pre-translation modification).\" [GOC:bf, GOC:jl]","metadata":null},{"id":"f9d51e8ac15641599bb6c9e5475fc09a","type":"GO_TERM","name":"protein monoubiquitination","canonical_id":"go:GO:0006513","description":"\"Addition of a single ubiquitin group to a protein.\" [GOC:ai]","metadata":null},{"id":"d1dc358fa3d04810b88828a0e81da85a","type":"GO_TERM","name":"protein myristoylation","canonical_id":"go:GO:0018377","description":"\"The covalent attachment of a myristoyl group to a protein.\" [GOC:ai]","metadata":null},{"id":"f8caf18485084ec8ad2b9f5c0ae1f862","type":"GO_TERM","name":"protein neddylation","canonical_id":"go:GO:0045116","description":"\"Covalent attachment of the ubiquitin-like protein NEDD8 (RUB1) to another protein.\" [PMID:11698580]","metadata":null},{"id":"de42670f4f934594b966ebf3e9e99ee8","type":"GO_TERM","name":"protein nitrosylation","canonical_id":"go:GO:0017014","description":"\"The covalent addition of a nitric oxide group to an amino acid within a protein.\" [GOC:ai, PMID:20972426]","metadata":null},{"id":"7a0066d690814b1c9a8fb23daf77e620","type":"GO_TERM","name":"protein nucleotidylation","canonical_id":"go:GO:0018175","description":"\"The addition of a nucleotide to a protein amino acid.\" [GOC:ai]","metadata":null},{"id":"1c8fce32a34e48559d5837a5cb413cf5","type":"GO_TERM","name":"protein octanoylation","canonical_id":"go:GO:0018190","description":"\"The modification of a protein amino acid by formation of an ester or amide with octanoic acid.\" [GOC:jsg]","metadata":null},{"id":"64505e485f454fc6a7418b266f7e3872","type":"GO_TERM","name":"protein oxidation","canonical_id":"go:GO:0018158","description":"\"The modification of a protein amino acid by oxidation.\" [GOC:ai]","metadata":null},{"id":"27af61ec5edf4c27ac0613c69ab8e238","type":"GO_TERM","name":"protein palmitoleylation","canonical_id":"go:GO:0045234","description":"\"The covalent attachment of a palmitoleyl group to a protein.\" [GOC:ai]","metadata":null},{"id":"bbf1e0595d1948d9ba28dca16a41a50c","type":"GO_TERM","name":"protein palmitoylation","canonical_id":"go:GO:0018345","description":"\"The covalent attachment of a palmitoyl group to a protein.\" [GOC:jl, PMID:15520806]","metadata":null},{"id":"ca96ad0cc47b49e3bb424c515b0d0e8e","type":"GO_TERM","name":"protein peptidyl-prolyl isomerization","canonical_id":"go:GO:0000413","description":"\"The modification of a protein by cis-trans isomerization of a proline residue.\" [GOC:krc, PMID:16959570]","metadata":null},{"id":"6acf6d8c206a4c4fb582edd372be00ad","type":"GO_TERM","name":"protein phosphatase 1 binding","canonical_id":"go:GO:0008157","description":"\"Binding to a protein phosphatase 1.\" [GOC:jl]","metadata":null},{"id":"7a52d5403e574ab0b5ff88895625fed9","type":"GO_TERM","name":"protein phosphatase 2A binding","canonical_id":"go:GO:0051721","description":"\"Binding to protein phosphatase 2A.\" [GOC:ai]","metadata":null},{"id":"c80704d14d5a4fafaec4c1f863120485","type":"GO_TERM","name":"protein phosphatase 2B binding","canonical_id":"go:GO:0030346","description":"\"Binding to a protein phosphatase 2B.\" [GOC:jl]","metadata":null},{"id":"728e295d1da84faa9f7391a583ef965c","type":"GO_TERM","name":"protein phosphatase 4 complex","canonical_id":"go:GO:0030289","description":"\"A protein serine/threonine phosphatase complex formed by the catalytic subunit of protein phosphatase 4 plus one or more regulatory subunits.\" [GOC:bhm, PMID:10026142]","metadata":null},{"id":"15cf517ff3e94cab9de270fcc04ef939","type":"GO_TERM","name":"protein phosphatase 5 binding","canonical_id":"go:GO:1990634","description":"\"Binding to protein phosphatase 5.\" [PMID:8943293]","metadata":null},{"id":"7b9b9b8df96b4b02903587fbc2afc230","type":"GO_TERM","name":"protein phosphatase activator activity","canonical_id":"go:GO:0072542","description":"\"Binds to and increases the activity of a protein phosphatase.\" [GOC:mah]","metadata":null},{"id":"b894bcb7cbe741ef9db92db0a7cd6304","type":"GO_TERM","name":"protein phosphatase binding","canonical_id":"go:GO:0019903","description":"\"Binding to a protein phosphatase.\" [GOC:jl]","metadata":null},{"id":"47735d147a484e4096771e157861e84a","type":"GO_TERM","name":"protein phosphatase inhibitor activity","canonical_id":"go:GO:0004864","description":"\"Binds to and stops, prevents or reduces the activity of a protein phosphatase.\" [GOC:ai]","metadata":null},{"id":"a2eaa3a2b9be48418cd86c354fd0d45c","type":"GO_TERM","name":"protein phosphatase inhibitor complex","canonical_id":"go:GO:0062049","description":"\"A protein-containing complex that inhibits protein phosphatase activity by directly binding to a protein phosphatase.\" [GOC:bhm, PMID:19407142, PMID:19933100]","metadata":null},{"id":"b4def2ed339d4180b5cef06c1bb66461","type":"GO_TERM","name":"protein phosphatase regulator activity","canonical_id":"go:GO:0019888","description":"\"Binds to and modulates the activity of a protein phosphatase.\" [GOC:ai]","metadata":null},{"id":"99ea1a31d2e64dd0b19d2d7c43548fb3","type":"GO_TERM","name":"protein phosphatase type 1 complex","canonical_id":"go:GO:0000164","description":"\"A protein complex that possesses magnesium-dependent protein serine/threonine phosphatase (AMD phosphatase) activity, and consists of a catalytic subunit and one or more regulatory subunits that dictates the phosphatase's substrate specificity, function, and activity.\" [GOC:mah, GOC:ssd]","metadata":null},{"id":"6a28c5496d7b43a498165e2a8c5edb2c","type":"GO_TERM","name":"protein phosphatase type 2A complex","canonical_id":"go:GO:0000159","description":"\"A protein complex that has protein serine/threonine phosphatase activity that is polycation-stimulated (PCS), being directly stimulated by protamine, polylysine, or histone H1; it constitutes a subclass of several enzymes activated by different histones and polylysine, and consists of catalytic, scaffolding, and regulatory subunits. The catalytic and scaffolding subunits form the core enzyme, and the holoenzyme also includes the regulatory subunit.\" [GOC:mah, ISBN:0198547684, PMID:17245430]","metadata":null},{"id":"db9e193af335432abe8b2626403c9569","type":"GO_TERM","name":"protein phosphate-linked glycosylation","canonical_id":"go:GO:0042076","description":"\"The glycosylation of peptidyl-amino acids through a phosphoester bond forming, for example, GlcNAc-alpha-1-P-Ser residues.\" [PMID:7499424]","metadata":null},{"id":"25da2366f6a4418a896482e660fe81d5","type":"GO_TERM","name":"protein phosphopantetheinylation","canonical_id":"go:GO:0018215","description":"\"The modification of a protein amino acid by phosphopantetheinylation.\" [GOC:ai]","metadata":null},{"id":"b948613a252b4a8db55cc14a9b4d5baa","type":"GO_TERM","name":"protein phosphorylated amino acid binding","canonical_id":"go:GO:0045309","description":"\"Binding to a phosphorylated amino acid residue within a protein.\" [GOC:curators]","metadata":null},{"id":"baa423fa1c444eebb72a987d5579d947","type":"GO_TERM","name":"protein phosphorylation","canonical_id":"go:GO:0006468","description":"\"The process of introducing a phosphate group on to a protein.\" [GOC:hb]","metadata":null},{"id":"f3b3f86914b64995aa4761fb92762989","type":"GO_TERM","name":"protein poly-ADP-ribosylation","canonical_id":"go:GO:0070212","description":"\"The transfer of multiple ADP-ribose residues from NAD to a protein amino acid, forming a poly(ADP-ribose) chain.\" [GOC:BHF, GOC:mah, GOC:rl, PMID:25043379]","metadata":null},{"id":"461ed63bd2144f399c2412b010e378de","type":"GO_TERM","name":"protein polyamination","canonical_id":"go:GO:0018184","description":"\"The modification of a protein amino acid by polyamination.\" [GOC:ai]","metadata":null},{"id":"fc4b3eea30ff43059ede9a3f09de4842","type":"GO_TERM","name":"protein polyglutamylation","canonical_id":"go:GO:0018095","description":"\"The addition of one or more alpha-linked glutamyl units to the gamma carboxyl group of peptidyl-glutamic acid.\" [RESID:AA0202]","metadata":null},{"id":"5442095d2a2240de8293818f7d905ec9","type":"GO_TERM","name":"protein polyglycylation","canonical_id":"go:GO:0018094","description":"\"The addition of glycyl units covalently bound to the gamma carboxyl group peptidyl-glutamic acid.\" [RESID:AA0201]","metadata":null},{"id":"817c215c903d4fff8175d1471e164617","type":"GO_TERM","name":"protein polymerization","canonical_id":"go:GO:0051258","description":"\"The process of creating protein polymers, compounds composed of a large number of component monomers; polymeric proteins may be made up of different or identical monomers. Polymerization occurs by the addition of extra monomers to an existing poly- or oligomeric protein.\" [GOC:ai]","metadata":null},{"id":"4e52cd2fa77644058e8a12835ccbd3ac","type":"GO_TERM","name":"protein polyubiquitination","canonical_id":"go:GO:0000209","description":"\"Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain.\" [PMID:26906419]","metadata":null},{"id":"9f870a7e25764ccfbcff046ba05d2de2","type":"GO_TERM","name":"protein polyufmylation","canonical_id":"go:GO:1990564","description":"\"Covalent attachment of the ubiquitin-like protein UFM1 to a protein, forming an UFM1 chain.\" [PMID:25219498]","metadata":null},{"id":"9795392ad9984b75a2ae16a6c68be82b","type":"GO_TERM","name":"protein post-translational transfer of dolichol-linked oligosaccharide","canonical_id":"go:GO:0180057","description":"\"A N-linked protein glycosylation process in which the preassembled dolichol-linked oligosaccharide precursor is transfered co-translationally to an asparagine residue within the motif Asn-X-Ser/Thr of the target protein. This is mediated by the OSTB complex.\" [PMID:19167329]","metadata":null},{"id":"42b96036bbde4655b82d02bdbef050be","type":"GO_TERM","name":"protein prenylation","canonical_id":"go:GO:0018342","description":"\"The covalent attachment of a prenyl group to a protein; geranyl, farnesyl, or geranylgeranyl groups may be added.\" [GOC:di, ISBN:0198506732]","metadata":null},{"id":"90e7abba65f346cf83a1652683820569","type":"GO_TERM","name":"protein prenyltransferase activity","canonical_id":"go:GO:0008318","description":"\"Catalysis of the covalent addition of an isoprenoid group such as a farnesyl or geranylgeranyl group via thioether linkages to a cysteine residue in a protein.\" [GOC:mah]","metadata":null},{"id":"af256bf859fa4ab8baf51502f1ed30ba","type":"GO_TERM","name":"protein processing","canonical_id":"go:GO:0016485","description":"\"Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a protein. Protein maturation is the process leading to the attainment of the full functional capacity of a protein.\" [GOC:curators, GOC:jl, GOC:jsg]","metadata":null},{"id":"e53b4686ecc74d7587ef499fde7d2534","type":"GO_TERM","name":"protein processing in phagocytic vesicle","canonical_id":"go:GO:1900756","description":"\"Protein processing that takes place in the phagosome. Most protein processing in the phagosome represents protein degradation.\" [GOC:rjd, GOC:TermGenie]","metadata":null},{"id":"f31c57c1df724742976f9ab188ea87b3","type":"GO_TERM","name":"protein propionyltransferase activity","canonical_id":"go:GO:0061920","description":"\"Catalysis of the reaction: propionyl-CoA + lysine in peptide = CoA + N-propionyl-lysine-peptide.\" [PMID:17267393]","metadata":null},{"id":"d39d4178b06c4070ab8fb7867ec36300","type":"GO_TERM","name":"protein pupylation","canonical_id":"go:GO:0070490","description":"\"The process in which a Pup protein is conjugated to a target protein via an isopeptide bond between the carboxy-terminus of Pup and the epsilon-amino group of a lysine residue of the target protein.\" [PMID:18980670]","metadata":null},{"id":"3c22444f66fd412994e5ccb2e4d75880","type":"GO_TERM","name":"protein quality control for misfolded or incompletely synthesized proteins","canonical_id":"go:GO:0006515","description":"\"The chemical reactions and pathways resulting in the breakdown of misfolded or attenuated proteins.\" [GOC:jl]","metadata":null},{"id":"4de4f20a79e443c897cc623cb618defe","type":"GO_TERM","name":"protein refolding","canonical_id":"go:GO:0042026","description":"\"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.\" [GOC:mb]","metadata":null},{"id":"3c09fd55cfc64334a10e8e7581b6bb35","type":"GO_TERM","name":"protein repair","canonical_id":"go:GO:0030091","description":"\"The process of restoring a protein to its original state after damage by such things as oxidation or spontaneous decomposition of residues.\" [GOC:mlg]","metadata":null},{"id":"4ca848cc298a433ba86613f9d980b380","type":"GO_TERM","name":"protein retention in ER lumen","canonical_id":"go:GO:0006621","description":"\"The retention in the endoplasmic reticulum (ER) lumen of soluble resident proteins. Sorting receptors retrieve proteins with ER localization signals, such as KDEL and HDEL sequences or some transmembrane domains, that have escaped to the cis-Golgi network and return them to the ER. Abnormally folded proteins and unassembled subunits are also selectively retained in the ER.\" [ISBN:0716731363, PMID:12972550]","metadata":null},{"id":"118c4728df1a4a94a7a096b2bb756da9","type":"GO_TERM","name":"protein retention in Golgi apparatus","canonical_id":"go:GO:0045053","description":"\"The retention of proteins within the Golgi apparatus. Golgi-localized carbohydrate-modifying enzymes have a short N-terminal domain that faces the cytosol, a single transmembrane alpha helix, and a large C-terminal domain that faces the Golgi lumen and that contains the catalytic site. How the membrane-spanning alpha helix in a Golgi enzyme causes its localization and prevents its movement to the plasma membrane is not known.\" [ISBN:0716731363]","metadata":null},{"id":"231ebb6b8ddb4299aafb166003d70f02","type":"GO_TERM","name":"protein secretion","canonical_id":"go:GO:0009306","description":"\"The controlled release of proteins from a cell.\" [GOC:ai]","metadata":null},{"id":"e37c208e994440df9cb3fbf0b5991893","type":"GO_TERM","name":"protein secretion by platelet","canonical_id":"go:GO:0070560","description":"\"The regulated release of proteins by a platelet or group of platelets.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"bbfe8a95005843048a20fde75b88ae79","type":"GO_TERM","name":"protein secretion by the type I secretion system","canonical_id":"go:GO:0030253","description":"\"The process in which proteins are secreted into the extracellular milieu via the type I secretion system; secretion occurs in a continuous process without the distinct presence of periplasmic intermediates and does not involve proteolytic processing of secreted proteins.\" [GOC:pamgo_curators]","metadata":null},{"id":"f2df70ef9a79474db46989484b00e3cc","type":"GO_TERM","name":"protein secretion by the type II secretion system","canonical_id":"go:GO:0015628","description":"\"The process in which proteins are secreted across the outer membrane of Gram-negative bacteria by the type II secretion system. Proteins using this pathway are first translocated across the cytoplasmic membrane via the Sec or Tat pathways.\" [GOC:pamgo_curators]","metadata":null},{"id":"c79d1f6df196479a88df0c81dedbdeb8","type":"GO_TERM","name":"protein secretion by the type III secretion system","canonical_id":"go:GO:0030254","description":"\"The process in which proteins are transferred into the extracellular milieu or directly into host cells by the bacterial type III secretion system; secretion occurs in a continuous process without the distinct presence of periplasmic intermediates and does not involve proteolytic processing of secreted proteins.\" [GOC:pamgo_curators]","metadata":null},{"id":"1aa65d6fecb54b9a9ca8355ce8c51e72","type":"GO_TERM","name":"protein secretion by the type IV secretion system","canonical_id":"go:GO:0030255","description":"\"The process in which proteins are transferred into the extracellular milieu or directly into host cells, via the type IV protein secretion system.\" [GOC:pamgo_curators]","metadata":null},{"id":"137ebb975b004751a9736f1bd2770e91","type":"GO_TERM","name":"protein secretion by the type IX secretion system","canonical_id":"go:GO:0160303","description":"\"The process by which proteins are transported from the periplasmic space across the outer membrane of Bacteroidota bacteria via the type IX secretion system (T9SS).\" [PMID:19966289, PMID:37043368, PMID:40490843]","metadata":null},{"id":"a4d65b75ee70459a9328fe796032402b","type":"GO_TERM","name":"protein secretion by the type V secretion system","canonical_id":"go:GO:0046819","description":"\"The process in which proteins mediate their own secretion across the outer membrane through a beta-barrel pore structure formed by the C-terminal domain of the protein precursor. Following passage across the outer membrane, the mature protein is released from the pore by an autocatalytic activity. Proteins secreted by the Type V system are first translocated across the plasma membrane by the Sec pathway.\" [GOC:pamgo_curators]","metadata":null},{"id":"e778f097a780425d8a7c75936ed5ad2a","type":"GO_TERM","name":"protein secretion by the type VI secretion system","canonical_id":"go:GO:0033103","description":"\"The process in which proteins are transferred into the extracellular milieu or directly into host cells by the type VI secretion system. Proteins secreted by this system do not require an N-terminal signal sequence.\" [GOC:mlg, PMID:16432199, PMID:16763151]","metadata":null},{"id":"8e581e1e5de848a3a40b7a93c1de29ed","type":"GO_TERM","name":"protein secretion by the type VII secretion system","canonical_id":"go:GO:0044315","description":"\"The process in which proteins are transferred into the extracellular milieu or directly into host cells, via the type VII protein secretion system.\" [PMID:17922044, PMID:19876390]","metadata":null},{"id":"a67460ada4ad49539353906ed072af72","type":"GO_TERM","name":"protein secretion by the type VIII secretion system","canonical_id":"go:GO:0098777","description":"\"Protein secretion through the outer membrane via the mechanism used for the secretion of curli subunits.\" [PMID:19299134, PMID:24080089]","metadata":null},{"id":"575500c19ec14df6961bccf8173a2211","type":"GO_TERM","name":"protein sequestering activity","canonical_id":"go:GO:0140311","description":"\"Binding to a protein to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:1493333]","metadata":null},{"id":"066319fef7924d9499fe59b8d9e1dabe","type":"GO_TERM","name":"protein serine kinase activity","canonical_id":"go:GO:0106310","description":"\"Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate.\" [RHEA:17989]","metadata":null},{"id":"a93fd9bcdecb4c64800303c363c4b37b","type":"GO_TERM","name":"protein serine kinase activity (using GTP as donor)","canonical_id":"go:GO:0106264","description":"\"Catalysis of the reactions: GTP + L-seryl-[protein] = GDP + H+ + O-phospho-L-seryl-[protein].\" [GOC:sp, PMID:32322062, RHEA:64020]","metadata":null},{"id":"1e166809477a457fa6d873c15f9a1d09","type":"GO_TERM","name":"protein serine pyrophosphorylase activity","canonical_id":"go:GO:0141090","description":"\"Catalysis of the reaction: protein phospho-serine + inositol 5-triphosphate pentakisphosphate = protein diphospho-serine + inositol 5-diphosphate pentakisphosphate.\" [PMID:36603579, RHEA:64104]","metadata":null},{"id":"f51aff59dc79466fa2c59eb73d42e843","type":"GO_TERM","name":"protein serine/threonine kinase activator activity","canonical_id":"go:GO:0043539","description":"\"Binds to and increases the activity of a protein serine/threonine kinase.\" [GOC:curators]","metadata":null},{"id":"5667614e70a54a3ba5b8273cbf1e5c44","type":"GO_TERM","name":"protein serine/threonine kinase activity","canonical_id":"go:GO:0004674","description":"\"Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.\" [EC:2.7.11.-, GOC:bf, PMID:2956925]","metadata":null},{"id":"ed64dfc7eb9d46228e572d501c539108","type":"GO_TERM","name":"protein serine/threonine kinase binding","canonical_id":"go:GO:0120283","description":"\"Binding to a protein serine/threonine kinase.\" [GOC:krc, GOC:sl, PMID:28608965]","metadata":null},{"id":"bb96b38ec1ad4ccea3cb663e35f4b6e7","type":"GO_TERM","name":"protein serine/threonine kinase inhibitor activity","canonical_id":"go:GO:0030291","description":"\"Binds to and stops, prevents or reduces the activity of a protein serine/threonine kinase.\" [GOC:mah]","metadata":null},{"id":"075ccf47ab36419bbd0ecb5c0af4758c","type":"GO_TERM","name":"protein serine/threonine phosphatase activity","canonical_id":"go:GO:0004722","description":"\"Catalysis of the reaction: protein serine phosphate + H2O = protein serine + phosphate, and protein threonine phosphate + H2O = protein threonine + phosphate.\" [GOC:bf]","metadata":null},{"id":"c2bc2b2e1eed4e588410783fac828e84","type":"GO_TERM","name":"protein serine/threonine phosphatase complex","canonical_id":"go:GO:0008287","description":"\"A complex, normally consisting of a catalytic and a regulatory subunit, which catalyzes the removal of a phosphate group from a serine or threonine residue of a protein.\" [GOC:bf]","metadata":null},{"id":"27e73ea588ba4a20baff5d4acae50af1","type":"GO_TERM","name":"protein serine/threonine phosphatase inhibitor activity","canonical_id":"go:GO:0004865","description":"\"Binds to and stops, prevents or reduces the activity of a serine/threonine protein phosphatase, an enzyme that catalyzes the reaction: protein serine/threonine phosphate + H2O = protein serine/threonine + phosphate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a071ced545894e11a4fb2b58f9c3d00f","type":"GO_TERM","name":"protein serine/threonine/tyrosine kinase activity","canonical_id":"go:GO:0004712","description":"\"Catalysis of the reactions: ATP + a protein serine = ADP + protein serine phosphate; ATP + a protein threonine = ADP + protein threonine phosphate; and ATP + a protein tyrosine = ADP + protein tyrosine phosphate.\" [GOC:mah]","metadata":null},{"id":"8323d2d037e842e3b64edf0c27f7c4f3","type":"GO_TERM","name":"protein sialylation","canonical_id":"go:GO:1990743","description":"\"A protein modification process that results in the addition of a sialic acid unit to the end of an oligosaccharide chain in a glycoprotein.\" [PMID:21930713]","metadata":null},{"id":"82b6311fb45a4b9d87438f0a27e52f68","type":"GO_TERM","name":"protein side chain deglutamylation","canonical_id":"go:GO:0035610","description":"\"The removal of a glutamate residue from the side chain of a protein. Glutamate side chains are added to glutamic acid residues within the primary protein sequence during polyglutamylation.\" [GOC:sp, PMID:21074048]","metadata":null},{"id":"a4c0cd11e0844babb11d3564fb2a6df6","type":"GO_TERM","name":"protein splicing","canonical_id":"go:GO:0030908","description":"\"The post-translational removal of peptide sequences from within a protein sequence.\" [GOC:mah]","metadata":null},{"id":"4455704286ad45508c87f5782cb8b042","type":"GO_TERM","name":"protein stabilization","canonical_id":"go:GO:0050821","description":"\"Any process involved in maintaining the structure and integrity of a protein and preventing it from degradation or aggregation.\" [GOC:ai]","metadata":null},{"id":"9a329f65d902466d8f33b590852e5cf6","type":"GO_TERM","name":"protein stearoylation","canonical_id":"go:GO:0140438","description":"\"The covalent attachment of a stearoyl group to an amino acid in a protein.\" [PMID:26214738]","metadata":null},{"id":"1b724699d54d4950b66c50495e65861e","type":"GO_TERM","name":"protein storage","canonical_id":"go:GO:0140089","description":"\"The accumulation and maintenance in cells of proteins. Protein reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.\" [PMID:37922900]","metadata":null},{"id":"e10be74a9b5646c286e9dcea7cb25624","type":"GO_TERM","name":"protein storage vacuole","canonical_id":"go:GO:0000326","description":"\"A storage vacuole that contains a lytic vacuole; identified in plants.\" [PMID:11739409]","metadata":null},{"id":"61ae1b8fe0a24acaa262e587004ff719","type":"GO_TERM","name":"protein storage vacuole lumen","canonical_id":"go:GO:0034495","description":"\"The volume enclosed by the protein storage vacuole membrane.\" [GOC:rph]","metadata":null},{"id":"259156404d9d40aaa86e5f510a350177","type":"GO_TERM","name":"protein storage vacuole membrane","canonical_id":"go:GO:0032586","description":"\"The lipid bilayer surrounding a protein storage vacuole.\" [GOC:mah]","metadata":null},{"id":"3cd5653591094a718a447641b9211b61","type":"GO_TERM","name":"protein storage vacuole organization","canonical_id":"go:GO:1990019","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a protein storage vacuole, a storage vacuole that contains a lytic vacuole.\" [GOC:tb, PMID:21670741]","metadata":null},{"id":"6be340a37aa6426c8ad1821d04a5b752","type":"GO_TERM","name":"protein succinylation","canonical_id":"go:GO:0018335","description":"\"The modification of a protein by the addition of a succinyl group (CO-CH2-CH2-CO) to an amino acid residue.\" [GOC:bf]","metadata":null},{"id":"4447437b4993481db0fea67bdef0908e","type":"GO_TERM","name":"protein sulfation","canonical_id":"go:GO:0006477","description":"\"The addition of a sulfate group as an ester to a protein amino acid.\" [GOC:curators]","metadata":null},{"id":"38801f19840446adb99b3c7f9bc2374e","type":"GO_TERM","name":"protein sulfhydration","canonical_id":"go:GO:0044524","description":"\"The modification of a protein amino acid by the addition of sulfur.\" [GOC:jl, GOC:jsg, PMID:19903941, PMID:22169477, PMID:8161529]","metadata":null},{"id":"17a2c2b0b5004dea8632501280db5107","type":"GO_TERM","name":"protein sumoylation","canonical_id":"go:GO:0016925","description":"\"The process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxy-terminus of SUMO with an epsilon-amino group of a lysine residue of the target protein.\" [GOC:jl, PMID:11265250]","metadata":null},{"id":"15ba2a4239aa48a986a3c2f007d6dd9b","type":"GO_TERM","name":"protein tag activity","canonical_id":"go:GO:0031386","description":"\"A molecular function exhibited by a protein that is covalently attached (AKA tagged or conjugated) to another protein where it acts as a marker, recognized by the cellular apparatus to target the tagged protein for some cellular process such as modification, sequestration, transport or degradation.\" [GOC:dos, PMID:19028679, PMID:20054389, PMID:6305978]","metadata":null},{"id":"d01e499b0f7f4284bdf41bde6fc10c33","type":"GO_TERM","name":"protein targeting","canonical_id":"go:GO:0006605","description":"\"The process of targeting specific proteins to particular regions of the cell, typically membrane-bounded subcellular organelles. Usually requires an organelle specific protein sequence motif.\" [GOC:ma]","metadata":null},{"id":"1fc509213335499e87bc8ef4413accc1","type":"GO_TERM","name":"protein targeting to ER","canonical_id":"go:GO:0045047","description":"\"The process of directing proteins towards the endoplasmic reticulum (ER) using signals contained within the protein. One common mechanism uses a 16- to 30-residue signal sequence, typically located at the N-terminus of the protein and containing positively charged amino acids followed by a continuous stretch of hydrophobic residues, which directs the ribosome to the ER membrane and initiates transport of the growing polypeptide across the ER membrane.\" [ISBN:0716731363]","metadata":null},{"id":"3bd2cd81b44245bbbfa941b03ec7765c","type":"GO_TERM","name":"protein targeting to Golgi apparatus","canonical_id":"go:GO:0140450","description":"\"The process of targeting specific proteins to the Golgi apparatus. Usually requires an organelle-specific protein sequence motif or a protein modification (for example a palmitoylation).\" [PMID:18817523]","metadata":null},{"id":"e96c617ea65a49f680e0e6de2f4bc398","type":"GO_TERM","name":"protein targeting to chloroplast","canonical_id":"go:GO:0045036","description":"\"The process of directing proteins towards the chloroplast, usually using signals contained within the protein. Imported proteins are synthesized as cytosolic precursors containing N-terminal uptake-targeting sequences that direct each protein to its correct subcompartment and are subsequently cleaved.\" [ISBN:0716731363]","metadata":null},{"id":"d787ca945fe5412293140deec485996e","type":"GO_TERM","name":"protein targeting to lysosome","canonical_id":"go:GO:0006622","description":"\"The process of directing proteins towards the lysosome using signals contained within the protein.\" [GOC:curators]","metadata":null},{"id":"5e2466b33d0042a48c2f31e47e1ae6d2","type":"GO_TERM","name":"protein targeting to lysosome involved in chaperone-mediated autophagy","canonical_id":"go:GO:0061740","description":"\"The targeting of a protein to the lysosome process in which an input protein binds to a chaperone and subsequently to a lysosomal receptor.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:22748206]","metadata":null},{"id":"2c5627408f44478fa909a747236a0886","type":"GO_TERM","name":"protein targeting to membrane","canonical_id":"go:GO:0006612","description":"\"The process of directing proteins towards a membrane, usually using signals contained within the protein.\" [GOC:curators]","metadata":null},{"id":"ac9453e2599a481bbdee9ac20d3896ce","type":"GO_TERM","name":"protein targeting to peroxisome","canonical_id":"go:GO:0006625","description":"\"The process of directing proteins towards the peroxisome, usually using signals contained within the protein.\" [GOC:ai]","metadata":null},{"id":"61ff9463bc814d06b53eb976809921ed","type":"GO_TERM","name":"protein targeting to vacuolar membrane","canonical_id":"go:GO:0044395","description":"\"The process of directing proteins towards the vacuolar membrane; usually uses signals contained within the protein.\" [GOC:jl]","metadata":null},{"id":"58c2aa5a34ab4c7dbad48aed6c2193f8","type":"GO_TERM","name":"protein targeting to vacuole","canonical_id":"go:GO:0006623","description":"\"The process of directing proteins towards the vacuole, usually using signals contained within the protein.\" [GOC:curators]","metadata":null},{"id":"161da8a3ff6144919864f58e700b980f","type":"GO_TERM","name":"protein targeting to vacuole involved in autophagy","canonical_id":"go:GO:0071211","description":"\"The process of directing proteins towards the vacuole using signals contained within the protein, occurring as part of autophagy, the process in which cells digest parts of their own cytoplasm.\" [GOC:mah]","metadata":null},{"id":"ce1040a707f3433c804432ad0b0ff1b8","type":"GO_TERM","name":"protein tetramerization","canonical_id":"go:GO:0051262","description":"\"The formation of a protein tetramer, a macromolecular structure consisting of four noncovalently associated identical or nonidentical subunits.\" [GOC:ecd]","metadata":null},{"id":"0c22ccd884954b11af4ba2849deb79c7","type":"GO_TERM","name":"protein to membrane docking","canonical_id":"go:GO:0022615","description":"\"The initial attachment of a protein to a target membrane, mediated by a proteins protruding from the target membrane. Docking requires only that the proteins come close enough to interact and adhere.\" [GOC:isa_complete]","metadata":null},{"id":"71c475690d0c4468a017ba5891548de4","type":"GO_TERM","name":"protein trans-autophosphorylation","canonical_id":"go:GO:0036290","description":"\"The phosphorylation by a protein of a residue on an identical protein. For example, phosphorylation by the other kinase within a homodimer.\" [GOC:jsg, PMID:20516151]","metadata":null},{"id":"9e5901635edb4e98b97e5d269ac9b8a9","type":"GO_TERM","name":"protein translocation chaperone activity","canonical_id":"go:GO:0140388","description":"\"Binding to the exposed unfolded portion of a polypeptide as it emerges from a membrane translocation channel/pore to drive its unidirectional transport across a membrane. Iterative cycles of ATP-dependent binding/rebinding by the chaperone prevents back sliding and drive vectorial transport.\" [PMID:11733493]","metadata":null},{"id":"48d9e108f723459e87bfb8fa2e3aa8e3","type":"GO_TERM","name":"protein transmembrane import into intracellular organelle","canonical_id":"go:GO:0044743","description":"\"The directed movement of proteins into an intracellular organelle, across a membrane.\" [GOC:jl]","metadata":null},{"id":"fb076de0321549f9963895cdb8094ee7","type":"GO_TERM","name":"protein transmembrane transport","canonical_id":"go:GO:0071806","description":"\"The process in which a protein is transported across a membrane.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"b8fbafc4d1874ae3bf5f03548139a066","type":"GO_TERM","name":"protein transport","canonical_id":"go:GO:0015031","description":"\"The directed movement of proteins into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"9bc3fd5a3d514f579cf73b3aa75ec493","type":"GO_TERM","name":"protein transport across periplasmic space","canonical_id":"go:GO:0072322","description":"\"The directed movement of proteins from the plasma membrane across the periplasmic space to the outer membrane or cell wall.\" [GOC:mah, PMID:20378773]","metadata":null},{"id":"92d85d16eaf14c9daf728dbc8bd75cb7","type":"GO_TERM","name":"protein transport across the cell outer membrane","canonical_id":"go:GO:0098776","description":"\"The directed movement of proteins across the cell outer membrane.\" [GOC:dos]","metadata":null},{"id":"f283fdf3872d44daa081486fe8f841c1","type":"GO_TERM","name":"protein transport along microtubule","canonical_id":"go:GO:0098840","description":"\"The directed movement of a protein along a microtubule, mediated by motor proteins.\" [PMID:25987607]","metadata":null},{"id":"f4164c55dc5e4dedab57420ada4e3853","type":"GO_TERM","name":"protein transport along microtubule to cell tip","canonical_id":"go:GO:0099117","description":"\"The movement of a protein along a microtubule to the cell-tip, mediated by motor proteins.\" [PMID:15177031]","metadata":null},{"id":"7e4b02111a0f4ecba98c0ab6e7d820d0","type":"GO_TERM","name":"protein transport along microtubule to kinetochore","canonical_id":"go:GO:0140210","description":"\"Any process in which a protein is transported to the kinetochore along a microtubule.\" [PMID:25472718]","metadata":null},{"id":"549133d1fad94df6b14223e409b115ea","type":"GO_TERM","name":"protein transport along microtubule to mitotic spindle pole body","canonical_id":"go:GO:1990976","description":"\"The directed movement of a protein along a microtubule to the mitotic spindle pole body, mediated by motor proteins.\" [PMID:25987607]","metadata":null},{"id":"728c1f0e44404358ba19b9a064821804","type":"GO_TERM","name":"protein transport along microtubule to spindle pole body","canonical_id":"go:GO:1990852","description":"\"The directed movement of a protein along a microtubule to the spindle pole body, mediated by motor proteins.\" [PMID:25987607]","metadata":null},{"id":"63f799c1080a471b918e513fc0168dab","type":"GO_TERM","name":"protein transport by the Sec complex","canonical_id":"go:GO:0043952","description":"\"The process in which unfolded proteins are transported across the cytoplasmic membrane in Gram-positive and Gram-negative bacteria by the Sec complex, in a process involving proteolytic cleavage of an N-terminal signal peptide.\" [GOC:pamgo_curators]","metadata":null},{"id":"f1fda6f281fd4675aa3ed98dab11ea46","type":"GO_TERM","name":"protein transport by the Tat complex","canonical_id":"go:GO:0043953","description":"\"The process in which folded proteins are transported across cytoplasmic membranes of bacteria and membranes of organelles derived from bacteria (chloroplasts and mitochondria) by the TAT complex.\" [GOC:pamgo_curators]","metadata":null},{"id":"b1ceba3fae1949429832ca613ca65cb3","type":"GO_TERM","name":"protein transport from ciliary membrane to plasma membrane","canonical_id":"go:GO:1903445","description":"\"The directed movement of protein from ciliary membrane to plasma membrane.\" [GO_REF:0000078, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22139371]","metadata":null},{"id":"52a208395d434698a26c21fde1b632f8","type":"GO_TERM","name":"protein transport into membrane raft","canonical_id":"go:GO:0032596","description":"\"The directed movement of a protein into a membrane raft. Membrane rafts are small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes.\" [GOC:mah]","metadata":null},{"id":"0fa9105ce01d41559363b9f9b9912490","type":"GO_TERM","name":"protein transport into plasma membrane raft","canonical_id":"go:GO:0044861","description":"\"The directed movement of a protein into a plasma membrane raft.\" [GOC:jl]","metadata":null},{"id":"c72738b276f94588afcc59613be2576d","type":"GO_TERM","name":"protein transport out of membrane raft","canonical_id":"go:GO:0032599","description":"\"The directed movement of a protein out of a membrane raft. Membrane rafts are small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes.\" [GOC:mah]","metadata":null},{"id":"ae4bae20123a403485b1fdff7dc6b96d","type":"GO_TERM","name":"protein transport out of plasma membrane raft","canonical_id":"go:GO:0044862","description":"\"The directed movement of a protein out of a plasma membrane raft.\" [GOC:jl]","metadata":null},{"id":"ef587beb1acf46b5a27a6168a4b7f643","type":"GO_TERM","name":"protein transport to mating projection actin fusion focus","canonical_id":"go:GO:1904601","description":"\"A process in which a protein is transported to a location within an actin fusion focus.\" [GO_REF:0000087, GOC:TermGenie, PMID:25825517]","metadata":null},{"id":"2c0bd789578a472d9163ec221e4cf28d","type":"GO_TERM","name":"protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway","canonical_id":"go:GO:0043328","description":"\"The process of directing proteins towards the vacuole that contributes to protein catabolism via the multivesicular body (MVB) pathway.\" [GOC:jl, PMID:11511343]","metadata":null},{"id":"b39f2df0fdae4e59b62799b0574573de","type":"GO_TERM","name":"protein transport within extracellular region","canonical_id":"go:GO:0071693","description":"\"The directed movement of proteins in the extracellular region, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"676fed8832e546519fb137924e553910","type":"GO_TERM","name":"protein transport within lipid bilayer","canonical_id":"go:GO:0032594","description":"\"The directed movement of a protein from one location to another within a lipid bilayer.\" [GOC:mah]","metadata":null},{"id":"0af908914d6b452b86ff859d86cf360d","type":"GO_TERM","name":"protein transport within plasma membrane","canonical_id":"go:GO:0099632","description":"\"A process in which protein is transported from one region of the plasma membrane to another.\" [GOC:dos]","metadata":null},{"id":"0dfd627e3e6c42d6b4e45684c8e50067","type":"GO_TERM","name":"protein transporter activity","canonical_id":"go:GO:0140318","description":"\"Directly binding to a specific protein and delivering it to a specific cellular location.\" [PMID:18706423]","metadata":null},{"id":"977f1e68be7f4c0c9e54191989f9374a","type":"GO_TERM","name":"protein trimerization","canonical_id":"go:GO:0070206","description":"\"The formation of a protein trimer, a macromolecular structure consisting of three noncovalently associated identical or nonidentical subunits.\" [GOC:hjd]","metadata":null},{"id":"6ef6aba69fab4ad09d427cb35717def4","type":"GO_TERM","name":"protein tyrosine kinase activator activity","canonical_id":"go:GO:0030296","description":"\"Increases the activity of a protein tyrosine kinase, an enzyme which phosphorylates a tyrosyl phenolic group on a protein.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"262e8e38a91642f7875d222e4a34e170","type":"GO_TERM","name":"protein tyrosine kinase activity","canonical_id":"go:GO:0004713","description":"\"Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.\" [RHEA:10596]","metadata":null},{"id":"2fd8b6a15af443a0a6c150f7a1f10238","type":"GO_TERM","name":"protein tyrosine kinase binding","canonical_id":"go:GO:1990782","description":"\"Binding to protein tyrosine kinase.\" [PMID:25499537]","metadata":null},{"id":"308ca471bfe74eac89a5581512d3db58","type":"GO_TERM","name":"protein tyrosine kinase collagen receptor activity","canonical_id":"go:GO:0038062","description":"\"Combining with collagen and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.\" [GOC:bf, GOC:uh, PMID:16626936, PMID:21568710]","metadata":null},{"id":"c9f8f604361543288a57ca216f690aaa","type":"GO_TERM","name":"protein tyrosine kinase inhibitor activity","canonical_id":"go:GO:0030292","description":"\"Stops, prevents or reduces the activity of a protein tyrosine kinase.\" [GOC:mah]","metadata":null},{"id":"114719a8196643f8a34bf9e82eb679de","type":"GO_TERM","name":"protein tyrosine phosphatase activator activity","canonical_id":"go:GO:0008160","description":"\"Binds to and increases the activity of a phosphotyrosine phosphatase, an enzyme which catalyzes of the removal of a phosphate group from a tyrosyl phenolic group of a protein.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"1a54336e052b47aeb2fae0dc3cf96d7e","type":"GO_TERM","name":"protein tyrosine phosphatase activity","canonical_id":"go:GO:0004725","description":"\"Catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate.\" [EC:3.1.3.48]","metadata":null},{"id":"6afea5b3e5bc4695a9512e389789ae04","type":"GO_TERM","name":"protein tyrosine phosphatase activity, metal-dependent","canonical_id":"go:GO:0030946","description":"\"Catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate. This reaction requires metal ions.\" [GOC:mah]","metadata":null},{"id":"7b7a6b53387d4c2da2a3ba788403e591","type":"GO_TERM","name":"protein tyrosine phosphatase complex","canonical_id":"go:GO:1904096","description":"\"A protein complex which is capable of protein tyrosine phosphatase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:22389722]","metadata":null},{"id":"7b0469fd69214f51a198de44e6237893","type":"GO_TERM","name":"protein tyrosine/serine/threonine phosphatase activity","canonical_id":"go:GO:0008138","description":"\"Catalysis of the reactions: protein serine + H2O = protein serine + phosphate; protein threonine phosphate + H2O = protein threonine + phosphate; and protein tyrosine phosphate + H2O = protein tyrosine + phosphate.\" [GOC:mah]","metadata":null},{"id":"703426a393e847519f5fbdf660d5e9db","type":"GO_TERM","name":"protein tyrosine/threonine phosphatase activity","canonical_id":"go:GO:0008330","description":"\"Catalysis of the reactions: protein threonine phosphate + H2O = protein threonine + phosphate; and protein tyrosine phosphate + H2O = protein tyrosine + phosphate.\" [GOC:mah]","metadata":null},{"id":"0d1a27e19018433b8f693ab430dc09c0","type":"GO_TERM","name":"protein ubiquitination","canonical_id":"go:GO:0016567","description":"\"The process in which one or more ubiquitin groups are added to a protein.\" [PMID:26906419]","metadata":null},{"id":"8c0f377dd2ac42e48d30ed19eec7a0a5","type":"GO_TERM","name":"protein ufmylation","canonical_id":"go:GO:0071569","description":"\"Covalent attachment of the ubiquitin-like protein UFM1 to another protein.\" [GOC:vw, PMID:20018847]","metadata":null},{"id":"4bf9dfaca233456785ce4c5829776e96","type":"GO_TERM","name":"protein unfolding","canonical_id":"go:GO:0043335","description":"\"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.\" [GOC:mlg]","metadata":null},{"id":"0815d48810e34849a4332c27ba784665","type":"GO_TERM","name":"protein uridylylation","canonical_id":"go:GO:0018177","description":"\"The addition of phospho-uridine to a protein amino acid.\" [GOC:jsg]","metadata":null},{"id":"745d13c689774304ba898390d3173e58","type":"GO_TERM","name":"protein urmylation","canonical_id":"go:GO:0032447","description":"\"Covalent attachment of the ubiquitin-like protein URM1 to another protein.\" [GOC:vw]","metadata":null},{"id":"661370485e1b42429bf221ec5a97579c","type":"GO_TERM","name":"protein xylosyltransferase activity","canonical_id":"go:GO:0030158","description":"\"Catalysis of the transfer of a beta-D-xylosyl residue from UDP-D-xylose to the serine hydroxyl group of an acceptor protein substrate.\" [EC:2.4.2.26]","metadata":null},{"id":"3373744569c34b9ba9d6f75cd7f6953e","type":"GO_TERM","name":"protein-DNA ISRE complex","canonical_id":"go:GO:0097522","description":"\"A protein-DNA complex formed through interaction of the protein(s) with an interferon-stimulated response element (ISRE) in the DNA.\" [GOC:amm, GOC:cjm, PMID:11747630]","metadata":null},{"id":"a05691414cc5433fba0088412b9f8dd9","type":"GO_TERM","name":"protein-DNA ISRE complex assembly","canonical_id":"go:GO:0035362","description":"\"The aggregation, arrangement and bonding together of proteins and DNA molecules to form a protein-DNA complex, in which the complex is formed through interaction of the protein(s) with a interferon-stimulated response element (ISRE) in the DNA.\" [GOC:amm, PMID:11747630]","metadata":null},{"id":"0b837d9aaea04a41905c4be8d9f87c59","type":"GO_TERM","name":"protein-DNA complex","canonical_id":"go:GO:0032993","description":"\"A macromolecular complex containing both protein and DNA molecules.\" [GOC:mah]","metadata":null},{"id":"edc12227da4044cd909cfc17420434ad","type":"GO_TERM","name":"protein-DNA complex assembly","canonical_id":"go:GO:0065004","description":"\"The aggregation, arrangement and bonding together of proteins and DNA molecules to form a protein-DNA complex.\" [GOC:jl]","metadata":null},{"id":"cd28261908914245a65dcf0db2901ebd","type":"GO_TERM","name":"protein-DNA complex disassembly","canonical_id":"go:GO:0032986","description":"\"The disaggregation of a protein-DNA complex into its constituent components.\" [GOC:mah]","metadata":null},{"id":"cf9309034efe4477b96f7c4ca5edc50d","type":"GO_TERM","name":"protein-DNA complex organization","canonical_id":"go:GO:0071824","description":"\"Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a protein-DNA complex.\" [GOC:mah]","metadata":null},{"id":"4ef37411884149b3ad7b48f8496c64d7","type":"GO_TERM","name":"protein-DNA complex remodeling","canonical_id":"go:GO:0001120","description":"\"The acquisition, loss, or modification of macromolecules within a protein-DNA complex, resulting in the alteration of an existing complex.\" [GOC:txnOH]","metadata":null},{"id":"8198556f58964666bb69326cc5196aad","type":"GO_TERM","name":"protein-DNA complex transport","canonical_id":"go:GO:0015869","description":"\"The directed movement of protein-DNA complexes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"919c9302f9e0454793aba156b2330e3d","type":"GO_TERM","name":"protein-DNA covalent cross-linking activity","canonical_id":"go:GO:0160129","description":"\"Catalysis of the cross-link between a protein and a DNA abasic site, forming a thiazolidine linkage between a DNA ring-opened abasic site and the alpha-amino and sulfhydryl substituents of cysteine residue of the protein.\" [PMID:30554877, PMID:31235913]","metadata":null},{"id":"c8cfdf7c09eb4257a9530328ad8d7aef","type":"GO_TERM","name":"protein-DNA covalent cross-linking repair","canonical_id":"go:GO:0106300","description":"\"The removal of covalent cross-link between DNA and a protein.\" [PMID:31921408]","metadata":null},{"id":"968e1dce48ca41cba61c26b774e523f7","type":"GO_TERM","name":"protein-DNA-RNA complex","canonical_id":"go:GO:0001114","description":"\"A macromolecular complex containing protein, DNA, and RNA molecules.\" [GOC:txnOH]","metadata":null},{"id":"5b5b6fae90ce44fab6fd035b5e491fdd","type":"GO_TERM","name":"protein-DNA-RNA complex assembly","canonical_id":"go:GO:0001116","description":"\"The aggregation, arrangement and bonding together of proteins, DNA, and RNA molecules to form a protein-DNA-RNA complex.\" [GOC:txnOH]","metadata":null},{"id":"86855ee0d35143efa0fa09542f323fa9","type":"GO_TERM","name":"protein-DNA-RNA complex disassembly","canonical_id":"go:GO:0001117","description":"\"The disaggregation of a protein-DNA-RNA complex into its constituent components.\" [GOC:txnOH]","metadata":null},{"id":"821ff854d38a44769f054f4d77cde51f","type":"GO_TERM","name":"protein-DNA-RNA complex organization","canonical_id":"go:GO:0001115","description":"\"Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a protein-DNA-RNA complex.\" [GOC:txnOH]","metadata":null},{"id":"a8e36fb6cad5418299dcdc691b002d93","type":"GO_TERM","name":"protein-DNA-RNA complex remodeling","canonical_id":"go:GO:0001119","description":"\"The acquisition, loss, or modification of macromolecules within a protein-DNA-RNA complex, resulting in the alteration of an existing complex.\" [GOC:txnOH]","metadata":null},{"id":"f74cb41ec514421b9372a39ca6cb7f8c","type":"GO_TERM","name":"protein-FAD linkage","canonical_id":"go:GO:0018293","description":"\"The formation of a linkage between a protein amino acid and flavin-adenine dinucleotide (FAD).\" [GOC:ai]","metadata":null},{"id":"3d28d33723de44c6a705f8b09441fb7b","type":"GO_TERM","name":"protein-L-histidine N-pros-methyltransferase activity","canonical_id":"go:GO:0106370","description":"\"Catalysis of the reaction: L-histidyl-[protein] + S-adenosyl-L-methionine = N(pros)-methyl-L-histidyl-[protein] + S-adenosyl-L-homocysteine.\" [PMID:33563959, RHEA:67076]","metadata":null},{"id":"504ba94f58424899a1445f3afb608072","type":"GO_TERM","name":"protein-L-histidine N-tele-methyltransferase activity","canonical_id":"go:GO:0018064","description":"\"Catalysis of the reaction: L-histidyl-[protein] + S-adenosyl-L-methionine = N(tele)-methyl-L-histidyl-[protein] + S-adenosyl-L-homocysteine.\" [RHEA:19369]","metadata":null},{"id":"ceefff13cc0f48a8bbc5d75be662dac5","type":"GO_TERM","name":"protein-L-isoaspartate (D-aspartate) O-methyltransferase activity","canonical_id":"go:GO:0004719","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + protein L-beta-aspartate = S-adenosyl-L-homocysteine + protein L-beta-aspartate methyl ester.\" [EC:2.1.1.77]","metadata":null},{"id":"16a8513f6a8e484191e2f7a6a9fa8388","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-N,N'-diacetylchitobiose phosphotransferase system transporter activity","canonical_id":"go:GO:0090562","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + N,N'-diacetylchitobiose(out) = protein histidine + N,N'-diacetylchitobiose phosphate(in).\" [GOC:am, PMID:10913119]","metadata":null},{"id":"e4afa5be1d0840d0a200c70397ce482c","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-N-acetyl-mannosamine phosphotransferase system transporter activity","canonical_id":"go:GO:0090591","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + N-acetyl-mannosamine(out) = protein histidine +N-acetyl- mannosamine-6-phosphate(in).\" [PMID:9864311]","metadata":null},{"id":"1e0bc864eef847d79f05d33b22a55e22","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-N-acetylgalactosamine phosphotransferase system transporter activity","canonical_id":"go:GO:0022881","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + N-acetylgalactosamine(out) = protein histidine + N-acetylgalactosamine phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"fd54b1098b24423eb94b2602874415e5","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-N-acetylglucosamine phosphotransferase system transporter activity","canonical_id":"go:GO:0022880","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane by the reaction: N(pros)-phospho-L-histidyl-[protein] + N-acetyl-D-glucosamine(out) = L-histidyl-[protein] + N-acetyl-D-glucosamine 6-phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, RHEA:49240]","metadata":null},{"id":"b4ab48900f8c4de485e760c2e36aaeeb","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-beta-glucoside phosphotransferase system transporter activity","canonical_id":"go:GO:0022882","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + beta-glucoside(out) = protein histidine + beta-glucoside phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, PMID:19251853]","metadata":null},{"id":"a5fafc6c74fe426393f6ad6250fdfaf5","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-carbohydrate phosphotransferase activity","canonical_id":"go:GO:0008982","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + sugar(out) = protein histidine + sugar phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, PMID:16339738, PMID:31214989]","metadata":null},{"id":"cc468606488b4c5ca6b0cac0f5ba7977","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-cellobiose phosphotransferase system transporter activity","canonical_id":"go:GO:0022874","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane according to the reaction: D-cellobiose(out) + N(pros)-phospho-L-histidyl-[protein] = 6-phospho-beta-D-glucosyl-(1->4)-D-glucose(in) + L-histidyl-[protein]. This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, RHEA:49292]","metadata":null},{"id":"7e811916587f411bbd93f3ecae3a4f55","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-fructose phosphotransferase system transporter activity","canonical_id":"go:GO:0022877","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + fructose(out) = protein histidine + fructose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b6214c3941b0471daf1bc7d827369fd6","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-galactitol phosphotransferase system transmembrane transporter activity","canonical_id":"go:GO:0022875","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + galactitol(out) = protein histidine + galactitol phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"a2b8360da8d64926b2a375e36f405534","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-galactosamine phosphotransferase system transporter activity","canonical_id":"go:GO:0022876","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + galactosamine(out) = protein histidine + galactosamine phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"5a03994457fe4601bdae57dfdc39f0dd","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-glucose phosphotransferase system transporter activity","canonical_id":"go:GO:0022855","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + glucose(out) = protein histidine + glucose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"06296f205a7142539e93d04a480d92c1","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-lactose phosphotransferase system transporter activity","canonical_id":"go:GO:0022869","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + lactose(out) = protein histidine + lactose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"e8f31c4f10094d4a8dfb7affd8996d7e","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-maltose phosphotransferase system transporter activity","canonical_id":"go:GO:0022873","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + maltose(out) = protein histidine + maltose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ad9315a136704097a7367fc2f70c45cb","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-mannitol phosphotransferase system transmembrane transporter activity","canonical_id":"go:GO:0022872","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + mannitol(out) = protein histidine + mannitol phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"439eeeec9cc74dfd878e6d61c70c04b8","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-mannose phosphotransferase system transporter activity","canonical_id":"go:GO:0022870","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane according to the reaction: D-mannose(out) + N(pros)-phospho-L-histidyl-[protein] = D-mannose 6-phosphate(in) + L-histidyl-[protein]. This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, RHEA:49232]","metadata":null},{"id":"eeb011780dc442d7b22d5a39fb49fad9","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-sorbitol phosphotransferase system transporter activity","canonical_id":"go:GO:0022856","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + sorbitol(out) = protein histidine + sorbitol phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"494a88eaf87b47bb8196c77428e4ea8d","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-sorbose phosphotransferase system transporter activity","canonical_id":"go:GO:0022871","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + sorbose(out) = protein histidine + sorbose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, PMID:10613875, RHEA:49296]","metadata":null},{"id":"ce46f34562664d238ab796413f9d2c6a","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-sucrose phosphotransferase system transporter activity","canonical_id":"go:GO:0022878","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + sucrose(out) = protein histidine + sucrose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"4adaecc7b49a4a1eb0f62e3494932c90","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-sugar phosphotransferase complex","canonical_id":"go:GO:0009357","description":"\"An enzyme complex that catalyzes the transfer of a phosphate from protein N(PI)-phosphohistidine to a sugar molecule. It is enzyme II of the phosphotransferase system.\" [PMID:2951378]","metadata":null},{"id":"f25b9c06290b4896ad1b522b0dcc504b","type":"GO_TERM","name":"protein-N(PI)-phosphohistidine-trehalose phosphotransferase system transporter activity","canonical_id":"go:GO:0022879","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein N-phosphohistidine + trehalose(out) = protein histidine + trehalose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"00551f59ceb5413097e707d2f8401a2d","type":"GO_TERM","name":"protein-N-terminal amino-acid acetyltransferase activity","canonical_id":"go:GO:0004596","description":"\"Catalysis of the reaction: acetyl-CoA + an N-terminal L-alpha-aminoacyl-[protein] = CoA + H+ + N-terminal Nalpha-acetyl-L-alpha-aminoacyl-[protein].\" [PMID:30054468, RHEA:21028]","metadata":null},{"id":"e58be8a6c9c341cda6300886f5302b4d","type":"GO_TERM","name":"protein-N-terminal asparagine amidohydrolase activity","canonical_id":"go:GO:0008418","description":"\"Catalysis of the reaction: N-terminal L-asparaginyl-[protein] + H+ + H2O = N-terminal L-aspartyl-[protein] + NH4+. This reaction is the deamidation of an N-terminal asparagine residue in a peptide or protein.\" [PMID:8910481, RHEA:50676]","metadata":null},{"id":"3e1ca5eec0844c56bb663da98a91a6af","type":"GO_TERM","name":"protein-N-terminal glutamine amidohydrolase activity","canonical_id":"go:GO:0070773","description":"\"Catalysis of the reaction: N-terminal L-glutaminyl-[protein] + H2O = N-terminal L-glutamyl-[protein] + NH4+. This reaction is the deamidation of an N-terminal glutamine residue of a protein.\" [PMID:19560421, RHEA:50680]","metadata":null},{"id":"3e72f0099bfa48ea9e737abce308f1a0","type":"GO_TERM","name":"protein-N-terminal-alanine acetyltransferase activity","canonical_id":"go:GO:0008999","description":"\"Catalysis of the reaction: acetyl-CoA + N-terminal L-alanyl-[protein] = CoA + H+ + N-terminal N(alpha)-acetyl-L-alanyl-[protein].\" [RHEA:50500]","metadata":null},{"id":"470845f7a3254b8cb4cd5f37dce007c9","type":"GO_TERM","name":"protein-N-terminal-glutamate acetyltransferase activity","canonical_id":"go:GO:1990190","description":"\"Catalysis of the reaction: acetyl-CoA + N-terminal L-glutamate in peptide = CoA + N-acetyl-L-glutamate-peptide.\" [GOC:al, PMID:23912279]","metadata":null},{"id":"a1f08218c36f4f239eb2cfd99209800c","type":"GO_TERM","name":"protein-RNA adaptor activity","canonical_id":"go:GO:0140517","description":"\"The binding activity of a protein that brings together another protein and an RNA, permitting those molecules to function in a coordinated way.\" [PMID:24470144]","metadata":null},{"id":"6b681ccaef944b089df702d2788a71f4","type":"GO_TERM","name":"protein-RNA complex assembly","canonical_id":"go:GO:0022618","description":"\"The aggregation, arrangement and bonding together of proteins and RNA molecules to form a ribonucleoprotein complex.\" [GOC:jl]","metadata":null},{"id":"3a56c5d5fe5940868041337b6813901f","type":"GO_TERM","name":"protein-RNA complex disassembly","canonical_id":"go:GO:0032988","description":"\"The disaggregation of a protein-RNA complex into its constituent components.\" [GOC:mah]","metadata":null},{"id":"2da55955788f4004ae2f0fa161964d51","type":"GO_TERM","name":"protein-RNA complex organization","canonical_id":"go:GO:0071826","description":"\"Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a ribonucleoprotein complex.\" [GOC:mah]","metadata":null},{"id":"68f818e7b73343b7889f5bb07414abca","type":"GO_TERM","name":"protein-RNA complex remodeling","canonical_id":"go:GO:0110136","description":"\"The acquisition, loss, or modification of macromolecules within a protein-RNA complex, resulting in the alteration of an existing complex.\" [GOC:rn, PMID:19737519, PMID:20542003, PMID:24240281]","metadata":null},{"id":"0987865635d24a8ab3afcbdbb2f22879","type":"GO_TERM","name":"protein-RNA covalent cross-linking repair","canonical_id":"go:GO:0160127","description":"\"A process that rescues stalled ribosomes by removing the covalent cross-link between RNA and a protein.\" [PMID:37951215, PMID:37951216]","metadata":null},{"id":"30df4d9dd2844cf3a1bb0f7de65d2360","type":"GO_TERM","name":"protein-RNA sequence-specific adaptor activity","canonical_id":"go:GO:0160134","description":"\"A protein adaptor activity characterized by the capacity to selectively recognize and interact with RNA molecules in a sequence-specific manner. Entities possessing this activity typically exhibit discerning binding preferences for specific nucleotide sequences within RNA molecules, enabling the identification and engagement of distinct RNA motifs or structural elements. This function is integral to various biological processes, including RNA processing, transport, and regulatory mechanisms, contributing to the specificity and precision of cellular RNA-related activities.\" [PMID:14749727, PMID:17036044]","metadata":null},{"id":"9d47728c704a47c8a7de885ffb686b84","type":"GO_TERM","name":"protein-arginine C-methyltransferase activity","canonical_id":"go:GO:0035244","description":"\"Catalysis of the transfer of a methyl group to the carbon atom of an arginine residue in a protein. This modification has been detected in anaerobic bacteria.\" [GOC:bf, PMID:29743535, PMID:33162960, RHEA:66028]","metadata":null},{"id":"b15de9f33bac4f7f82c99bbcf8779a6e","type":"GO_TERM","name":"protein-arginine N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0106362","description":"\"Catalysis of the reaction: L-arginyl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = H+ + N(omega)-(N-acetyl-beta-D-glucosaminyl)-L-arginyl-[protein] + UDP.\" [GOC:sp, PMID:23955153, PMID:30619781, RHEA:66632]","metadata":null},{"id":"088e12cfc3244cc090629daabc3d572a","type":"GO_TERM","name":"protein-arginine N-methyltransferase activity","canonical_id":"go:GO:0016274","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + (protein)-arginine = S-adenosyl-L-homocysteine + (protein)-N-methyl-arginine.\" [GOC:mah, PMID:12351636, PMID:31284549]","metadata":null},{"id":"9549cb2548f94e5db2093182d11dc55f","type":"GO_TERM","name":"protein-arginine deiminase activity","canonical_id":"go:GO:0004668","description":"\"Catalysis of the reaction: H2O + L-arginyl-[protein] = L-citrullyl-[protein] + NH4+, resulting in citrullination of the target protein. This reaction is calcium-dependent.\" [PMID:27393304]","metadata":null},{"id":"29df5a782cbe4af893503de98916061c","type":"GO_TERM","name":"protein-arginine omega-N asymmetric methyltransferase activity","canonical_id":"go:GO:0035242","description":"\"Catalysis of the addition of a second methyl group to methylated peptidyl-arginine. Methylation is on the same terminal nitrogen (omega nitrogen) residue that was previously methylated, resulting in asymmetrical peptidyl-N(omega),N(omega)-dimethylated arginine residues.\" [PMID:14705965]","metadata":null},{"id":"b36ed6a2d3344691b761cd9ef63ef091","type":"GO_TERM","name":"protein-arginine omega-N monomethyltransferase activity","canonical_id":"go:GO:0035241","description":"\"Catalysis of the addition of a methyl group to either of the unmethylated terminal nitrogen atoms (also called omega nitrogen) in peptidyl-arginine to form an omega-N-G-monomethylated arginine residue. The reaction is S-adenosyl-L-methionine + [protein]-L-arginine = S-adenosyl-L-homocysteine + [protein]-Nomega-methyl-L-arginine.\" [EC:2.1.1.321, PMID:14705965, RESID:AA0069]","metadata":null},{"id":"831afa97d15549708a50127f33287b76","type":"GO_TERM","name":"protein-arginine omega-N symmetric methyltransferase activity","canonical_id":"go:GO:0035243","description":"\"Catalysis of the addition of a second methyl group to methylated peptidyl-arginine. Methylation is on the terminal nitrogen (omega nitrogen) residue that is not already methylated, resulting in symmetrical peptidyl-N(omega),N'(omega)-dimethyled arginine residues.\" [EC:2.1.1.320, PMID:14705965, RESID:AA0067, RESID:AA0069]","metadata":null},{"id":"bddc344385d24cf9b5cc4fdf03c6f2de","type":"GO_TERM","name":"protein-arginine rhamnosyltransferase activity","canonical_id":"go:GO:0106361","description":"\"Catalysis of the reaction: dTDP-beta-L-rhamnose + L-arginyl-[protein] = dTDP + H+ + N(omega)-(L-rhamnosyl)-L-arginyl-[protein].\" [GOC:sp, PMID:25686373, PMID:26060278, RHEA:66692]","metadata":null},{"id":"cd4cfff8db074ca7844d12b6d0ec0eaf","type":"GO_TERM","name":"protein-bilin linkage","canonical_id":"go:GO:0017007","description":"\"The covalent linkage of bilin and a protein.\" [GOC:ai]","metadata":null},{"id":"d3430f81f44a4705ba7e4193ba7236eb","type":"GO_TERM","name":"protein-carbohydrate complex","canonical_id":"go:GO:0032992","description":"\"A macromolecular complex containing separate protein and carbohydrate molecules. Separate in this context means not covalently bound to each other.\" [GOC:mah]","metadata":null},{"id":"2443a1724d2941d2b1c3e1c96d807524","type":"GO_TERM","name":"protein-carbohydrate complex disassembly","canonical_id":"go:GO:0032985","description":"\"The disaggregation of a protein-carbohydrate complex into its constituent components.\" [GOC:mah]","metadata":null},{"id":"33144a74a53d4b70923875ab9e413c96","type":"GO_TERM","name":"protein-carbohydrate complex subunit organization","canonical_id":"go:GO:0071823","description":"\"Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a protein-carbohydrate complex.\" [GOC:mah]","metadata":null},{"id":"2cf2475846d84996a9009500f8054533","type":"GO_TERM","name":"protein-coenzyme A linkage","canonical_id":"go:GO:0018246","description":"\"The formation of a linkage between a protein amino acid and coenzyme A.\" [GOC:mah]","metadata":null},{"id":"f43d3cbb235b4c99975c358c5d10dd52","type":"GO_TERM","name":"protein-containing complex","canonical_id":"go:GO:0032991","description":"\"A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together.\" [GOC:dos, GOC:mah]","metadata":null},{"id":"30ba5a0622bd4edf93ee593f6236a46d","type":"GO_TERM","name":"protein-containing complex assembly","canonical_id":"go:GO:0065003","description":"\"The aggregation, arrangement and bonding together of a set of macromolecules to form a protein-containing complex.\" [GOC:jl]","metadata":null},{"id":"821cc90159b0438ca85ffbcade62f5c4","type":"GO_TERM","name":"protein-containing complex assembly involved in synapse maturation","canonical_id":"go:GO:0090126","description":"\"The aggregation, arrangement and bonding together of a set of components to form a protein complex that contributes to synapse maturation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"57643e059c7649d48945bf8ecc2cd111","type":"GO_TERM","name":"protein-containing complex binding","canonical_id":"go:GO:0044877","description":"\"Binding to a macromolecular complex.\" [GOC:jl]","metadata":null},{"id":"bf238a7b795049fa8ba67d294fbf4eb3","type":"GO_TERM","name":"protein-containing complex destabilizing activity","canonical_id":"go:GO:0140776","description":"\"A molecular function that involves direct binding to one of the subunits of a protein-containing complex and promoting the dissociation of one or many subunits. This often happens by changing the conformation of the protein being bound, which decreases its affinity for the rest of the complex.\" [PMID:23727094, PMID:29779865, PMID:34836783]","metadata":null},{"id":"8059ed5bc3f04413b64d6869f174c17a","type":"GO_TERM","name":"protein-containing complex disassembly","canonical_id":"go:GO:0032984","description":"\"The disaggregation of a protein-containing macromolecular complex into its constituent components.\" [GOC:mah]","metadata":null},{"id":"2a928b283754409d8a8a43bf7da4f47a","type":"GO_TERM","name":"protein-containing complex localization","canonical_id":"go:GO:0031503","description":"\"A localization process that acts on a protein complex; the complex is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"4bcd972c5b504b66a8dabeb120720a21","type":"GO_TERM","name":"protein-containing complex localization to centriolar satellite","canonical_id":"go:GO:0140706","description":"\"A protein-containing complex localization by which the complex is transported to, or maintained in, the centriolar satellite.\" [PMID:27979967]","metadata":null},{"id":"a116a01952d5445192e2ff82e5d43f39","type":"GO_TERM","name":"protein-containing complex organization","canonical_id":"go:GO:0043933","description":"\"Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a protein complex.\" [GOC:mah]","metadata":null},{"id":"f54dbbf493b64401be7d61378fa1b5f7","type":"GO_TERM","name":"protein-containing complex remodeling","canonical_id":"go:GO:0034367","description":"\"The acquisition, loss, or modification of macromolecules within a complex, resulting in the alteration of an existing complex.\" [GOC:BHF, GOC:mah, GOC:mtg_mpo, GOC:rl]","metadata":null},{"id":"f9114cdcf55c45e9b0c0be66971aca24","type":"GO_TERM","name":"protein-containing complex stabilizing activity","canonical_id":"go:GO:0140777","description":"\"A molecular function that involves direct binding to one of the subunits of a protein-containing complex, thus preventing an interaction with a factor that would promote dissociation of the complex.\" [PMID:34040253]","metadata":null},{"id":"a6a0c1c5b33947a3ae9f155afdb046aa","type":"GO_TERM","name":"protein-cysteine S-acyltransferase activity","canonical_id":"go:GO:0019707","description":"\"Catalysis of the transfer of an acyl group to a sulfur atom on the cysteine of a protein molecule.\" [GOC:ai, RHEA:63372]","metadata":null},{"id":"9fbb4b4461bf46bb8765524990f5d841","type":"GO_TERM","name":"protein-cysteine S-arachidonoyltransferase activity","canonical_id":"go:GO:0140441","description":"\"Catalysis of the transfer of an arachidonoyl (systematic name, (5Z,8Z,11Z,14Z)-eicosatetraenoyl) group to a sulfur atom on the cysteine of a protein molecule, in the reaction: in the reaction: (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + L-cysteinyl-[protein] = CoA + S-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-L-cysteinyl-[protein].\" [PMID:12681491, PMID:22247542, PMID:22968831, RHEA:59748]","metadata":null},{"id":"ad1dc2c18a274e8c86136eed720424c6","type":"GO_TERM","name":"protein-cysteine S-myristoyltransferase activity","canonical_id":"go:GO:0019705","description":"\"Catalysis of the transfer of a myristoyl (systematic name, tetradecanoyl) group to a sulfur atom on a cysteine residue of a protein molecule in the reaction: tetradecanoyl-CoA + L-cysteinyl-[protein] = CoA + S-tetradecanoyl-L-cysteinyl-[protein].\" [GOC:ai, PMID:22247542, RHEA:59736]","metadata":null},{"id":"98c1b595f24a403e8efd5d82c58decef","type":"GO_TERM","name":"protein-cysteine S-oleoyltransferase activity","canonical_id":"go:GO:0140440","description":"\"Catalysis of the transfer of an oleoyl (systematic name, (9Z)-octadecenoyl) group to a sulfur atom on the cysteine of a protein molecule, in the reaction: (9Z)-octadecenoyl-CoA + L-cysteinyl-[protein] = CoA + S-(9Z-octadecenoyl)-L-cysteinyl-[protein].\" [PMID:22247542, RHEA:59744]","metadata":null},{"id":"72abf25c52794de9abf67802a5845799","type":"GO_TERM","name":"protein-cysteine S-palmitoyltransferase activity","canonical_id":"go:GO:0019706","description":"\"Catalysis of the transfer of a palmitoyl (systematic name, hexadecanoyl) group to a sulfur atom on the cysteine of a protein molecule, in the reaction hexadecanoyl-CoA + L-cysteinyl-[protein] = CoA + S-hexadecanoyl-L-cysteinyl-[protein].\" [GOC:ai, GOC:pr, RHEA:36683]","metadata":null},{"id":"03a63cf040134921948ac71b6e35696e","type":"GO_TERM","name":"protein-cysteine S-palmitoyltransferase complex","canonical_id":"go:GO:1905961","description":"\"A protein complex which is capable of protein-cysteine S-palmitoyltransferase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:20851885]","metadata":null},{"id":"5d01177b8ccb4e7eb21917c62eded335","type":"GO_TERM","name":"protein-cysteine S-stearoyltransferase activity","canonical_id":"go:GO:0140439","description":"\"Catalysis of the transfer of a stearoyl (systematic name, octadecanoyl) group to a sulfur atom on the cysteine of a protein molecule, in the reaction: octadecanoyl-CoA + L-cysteinyl-[protein] = CoA + S-octadecanoyl-L-cysteinyl-[protein].\" [PMID:12681491, PMID:22247542, PMID:22968831, RHEA:59740]","metadata":null},{"id":"97a0fc519677405382a1a30751e149a6","type":"GO_TERM","name":"protein-cysteine methyltransferase activity","canonical_id":"go:GO:0106363","description":"\"Catalysis of the reaction: L-cysteinyl-[protein] + S-adenosyl-L-methionine = H+ + S-adenosyl-L-homocysteine + S-methyl-L-cysteinyl-[protein].\" [GOC:sp, PMID:21481189, PMID:22158122, PMID:24235145, PMID:25412445, RHEA:66544]","metadata":null},{"id":"4e303af470de42e583d41495ed7239b4","type":"GO_TERM","name":"protein-disulfide reductase (glutathione) activity","canonical_id":"go:GO:0019153","description":"\"Catalysis of the reaction: 2 glutathione + protein-disulfide = glutathione disulfide+ protein-dithiol.\" [RHEA:21064]","metadata":null},{"id":"8bc774d2d48440fe9f08e200111375c5","type":"GO_TERM","name":"protein-disulfide reductase [NAD(P)H] activity","canonical_id":"go:GO:0047134","description":"\"Catalysis of the reaction: protein-dithiol + NAD(P)+ = protein-disulfide + NAD(P)H + H+.\" [EC:1.8.1.8]","metadata":null},{"id":"1c1090d6e4554d2f8ca63d7dd7f0cc9f","type":"GO_TERM","name":"protein-disulfide reductase activity","canonical_id":"go:GO:0015035","description":"\"Catalysis of the reaction: a protein with reduced sulfide groups = a protein with oxidized disulfide bonds.\" [PMID:18331844]","metadata":null},{"id":"6017ebfe56bc40df9f4c45535d42615c","type":"GO_TERM","name":"protein-exporting ATPase activity","canonical_id":"go:GO:0008564","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: ATP + H2O + protein+(in) = ADP + phosphate + protein+(out); drives the concomitant secretion of proteins.\" [EC:7.4.2.8, PMID:30346996]","metadata":null},{"id":"a55b68aac1934e1abb78a36c96f7644b","type":"GO_TERM","name":"protein-folding chaperone binding","canonical_id":"go:GO:0051087","description":"\"Binding to a chaperone protein, a class of proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport.\" [PMID:10585443]","metadata":null},{"id":"0bdf5f84d34a4427b285fe5db08b52d8","type":"GO_TERM","name":"protein-fructosamine 3-kinase activity","canonical_id":"go:GO:0102194","description":"\"Catalysis of the reaction: ATP + a [protein]-N6-D-fructosyl-L-lysine = ADP + H+ + a [protein]-N6-(3-O-phospho-D-fructosyl)-L-lysine.\" [EC:2.7.1.171, GOC:pz, PMID:11016445]","metadata":null},{"id":"57f494f07c9b4a0f9c9e01c58b1f26dc","type":"GO_TERM","name":"protein-glucosylgalactosylhydroxylysine glucosidase activity","canonical_id":"go:GO:0047402","description":"\"Catalysis of the reaction: H2O + protein alpha-D-glucosyl-1,2-beta-D-galactosyl-L-hydroxylysine = protein beta-D-galactosyl-L-hydroxylysine + beta-D-glucose. The enzyme specifically hydrolyzes glucose from alpha-D-glucosyl- (1->2)-beta-D-galactosyl disaccharide units that are linked to hydroxylysine residues of collagen and collagen-like proteins.\" [EC:3.2.1.107, MetaCyc:3.2.1.107-RXN]","metadata":null},{"id":"f3b978881b254300bec6506f89902d86","type":"GO_TERM","name":"protein-glutamate O-methyltransferase activity","canonical_id":"go:GO:0008983","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + protein L-glutamate = S-adenosyl-L-homocysteine + protein L-glutamate 5-methyl ester; this reaction is the methylation of peptidyl-L-glutamate to form peptidyl-L-glutamate 5-methyl ester.\" [EC:2.1.1.80]","metadata":null},{"id":"7673b3c445ef446db5cc5b41b0dbe500","type":"GO_TERM","name":"protein-glutamate methylesterase activity","canonical_id":"go:GO:0008984","description":"\"Catalysis of the reaction: protein L-glutamate O(5)-methyl ester + H2O = protein L-glutamate + methanol.\" [EC:3.1.1.61, RESID:AA0072]","metadata":null},{"id":"1a11afcb4fbb44748b8f8aa2d77d33d4","type":"GO_TERM","name":"protein-glutamic acid ligase activity","canonical_id":"go:GO:0070739","description":"\"Catalysis of the posttranslational transfer of one or more glutamate residues to a specific residue on a target protein.\" [GOC:mah, PMID:19524510]","metadata":null},{"id":"714b61d3c7064aab800b188e6ee3e6fe","type":"GO_TERM","name":"protein-glutamic acid ligase activity, elongating","canonical_id":"go:GO:0106438","description":"\"Catalytic reaction :(L-glutamyl)n-L-gamma-glutamyl-L-glutamyl-[protein] + ATP + L-glutamate = (L-glutamyl)n+1-L-gamma-glutamyl-L-glutamyl-[protein] + ADP + H+ + phosphate.\" [PMID:32747782, RHEA:60148]","metadata":null},{"id":"783a386721284424bf3a0d5374ad5213","type":"GO_TERM","name":"protein-glutamic acid ligase activity, initiating","canonical_id":"go:GO:0106437","description":"\"Catalytic reaction: ATP + L-glutamate + L-glutamyl-[protein] = ADP + H+ + L-gamma-glutamyl-L-glutamyl-[protein] + phosphate.\" [PMID:32747782, RHEA:60144]","metadata":null},{"id":"8c508f7c8c854e6ba18a2491f9d45c43","type":"GO_TERM","name":"protein-glutaminase activity","canonical_id":"go:GO:0050170","description":"\"Catalysis of the reaction: [protein]-C-terminal-L-glutamine + H2O = [protein]-C-terminal-L-glutamate + NH4+.\" [RHEA:10032]","metadata":null},{"id":"5bbb25282cbc4bce8b02072c4e54f512","type":"GO_TERM","name":"protein-glutamine N-methyltransferase activity","canonical_id":"go:GO:0036009","description":"\"Catalysis of the reaction: L-glutaminyl-[protein] + S-adenosyl-L-methionine = N(5)-methyl-L-glutaminyl-[protein] + S-adenosyl-L-homocysteine + H+.\" [PMID:11847124, RHEA:57452]","metadata":null},{"id":"37b7e7f95a254e578874e3fed15e9fe5","type":"GO_TERM","name":"protein-glutamine gamma-glutamyltransferase activity","canonical_id":"go:GO:0003810","description":"\"Catalysis of the reaction: L-glutaminyl-[protein] + L-lysyl-[protein] = [protein]-L-lysyl-N(6)-5-L-glutamyl-[protein] + NH4+. This reaction is the formation of the N6-(L-isoglutamyl)-L-lysine isopeptide, resulting in cross-linking polypeptide chains; the gamma-carboxamide groups of peptidyl-glutamine residues act as acyl donors, and the 6-amino-groups of peptidyl-lysine residues act as acceptors, to give intra- and intermolecular N6-(5-glutamyl)lysine cross-links.\" [EC:2.3.2.13]","metadata":null},{"id":"4a291024b2c44d76a60979cc054e75da","type":"GO_TERM","name":"protein-glutamine glutaminase activity","canonical_id":"go:GO:0050568","description":"\"Catalysis of the reaction: L-glutaminyl-[protein] + H2O = L-glutamyl-[protein] + NH4+.\" [RHEA:16441]","metadata":null},{"id":"65e88000d26346cfaf06ffd6100fe019","type":"GO_TERM","name":"protein-glutaryllysine deglutarylase activity","canonical_id":"go:GO:0061697","description":"\"Catalysis of the reaction: N(6)-glutaryl-L-lysyl-[protein] + NAD+ + H2O = 2''-O-glutaryl-ADP-D-ribose + nicotinamide + L-lysyl-[protein].\" [PMID:24703693, RHEA:47664]","metadata":null},{"id":"ac503571ccd84bd48a13ae05f4137d39","type":"GO_TERM","name":"protein-glutathione oxidoreductase (glutathione) activity","canonical_id":"go:GO:0141049","description":"\"Catalysis of the reaction: glutathionylated protein (PSSG) + glutathione (GSH) = protein-thiol (PSH) + glutathione disulfide (GSSG). The reaction may proceed via a 'monothiol' or 'dithiol' mechanism.\" [PMID:23397885, PMID:33932870, PMID:36771108]","metadata":null},{"id":"5346aa70b9b94dc09f8cbbb81949827c","type":"GO_TERM","name":"protein-glycine ligase activity","canonical_id":"go:GO:0070735","description":"\"Catalysis of the reaction: ATP + glycine + L-glutamyl-[protein] = ADP + glycyl-L-glutamyl-[protein] + H+ + phosphate.\" [RHEA:67180]","metadata":null},{"id":"eec5e545da734e2db4d584f6eecadb49","type":"GO_TERM","name":"protein-glycine ligase activity, elongating","canonical_id":"go:GO:0070737","description":"\"Catalysis of the posttranslational transfer of one or more glycine residues to a glycine residue covalently attached to the gamma-carboxyl group of a glutamate residue on a target protein, resulting in the elongation of a polyglycine side chain.\" [GOC:mah, PMID:19524510]","metadata":null},{"id":"0d5e93cf86fb458a8abb370dd4a2cd23","type":"GO_TERM","name":"protein-glycine ligase activity, initiating","canonical_id":"go:GO:0070736","description":"\"Catalysis of the posttranslational transfer of a glycine residue to the gamma-carboxyl group(s) of one or more specific glutamate residues on a target protein.\" [GOC:mah, PMID:19524510]","metadata":null},{"id":"0c7af6ab5777493f91fcfd2dd54de434","type":"GO_TERM","name":"protein-heme P460 linkage","canonical_id":"go:GO:0018174","description":"\"The linkage of protein to heme P460.\" [RESID:AA0266, RESID:AA0271]","metadata":null},{"id":"4f3db7926f614805822385684bb4c974","type":"GO_TERM","name":"protein-heme linkage","canonical_id":"go:GO:0017003","description":"\"The covalent linkage of heme and a protein.\" [GOC:ma]","metadata":null},{"id":"13d3befe00d844c583b088d9a99864ee","type":"GO_TERM","name":"protein-hormone receptor activity","canonical_id":"go:GO:0016500","description":"\"Combining with a protein hormone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"2d8161889fb84f6c8c1b2f851ce1311b","type":"GO_TERM","name":"protein-lipid complex","canonical_id":"go:GO:0032994","description":"\"A macromolecular complex containing separate protein and lipid molecules. Separate in this context means not covalently bound to each other.\" [GOC:mah]","metadata":null},{"id":"18fb8b82a5fd412c9c129fe0038ffdd0","type":"GO_TERM","name":"protein-lipid complex assembly","canonical_id":"go:GO:0065005","description":"\"The aggregation, arrangement and bonding together of proteins and lipids to form a protein-lipid complex.\" [GOC:jl]","metadata":null},{"id":"60713dac68314f2087a2414414adf318","type":"GO_TERM","name":"protein-lipid complex binding","canonical_id":"go:GO:0071814","description":"\"Binding to a protein-lipid complex, any macromolecular complex that contains both protein and lipid molecules.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"561aebb465f04777b156945fdbe05207","type":"GO_TERM","name":"protein-lipid complex disassembly","canonical_id":"go:GO:0032987","description":"\"The disaggregation of a protein-lipid complex into its constituent components.\" [GOC:mah]","metadata":null},{"id":"8518d54174c04732895a515f8b0c2a9f","type":"GO_TERM","name":"protein-lipid complex organization","canonical_id":"go:GO:0071825","description":"\"Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a protein-lipid complex.\" [GOC:mah]","metadata":null},{"id":"9e4eb957d22d4963a0a7f2ae9cee9fab","type":"GO_TERM","name":"protein-lipid complex remodeling","canonical_id":"go:GO:0034368","description":"\"The acquisition, loss or modification of a protein or lipid within a protein-lipid complex.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"5bd3033855f340b5994ee0e771582c06","type":"GO_TERM","name":"protein-lipid-RNA complex","canonical_id":"go:GO:1990684","description":"\"A macromolecular complex containing separate protein, lipid and RNA molecules. Separate in this context means not covalently bound to each other.\" [GOC:vesicles, PMID:21423178, PMID:22028337, PMID:23559634]","metadata":null},{"id":"69ac7746a6034366bd9ebbee8642d14d","type":"GO_TERM","name":"protein-lysine 6-oxidase activity","canonical_id":"go:GO:0004720","description":"\"Catalysis of the reaction: L-lysyl-[protein] + O2 + H2O = (S)-2-amino-6-oxohexanoyl-[protein] + H2O2 + NH4+.\" [RHEA:24544]","metadata":null},{"id":"a52012e9595e439282cc55883f3b6907","type":"GO_TERM","name":"protein-lysine N-methyltransferase activity","canonical_id":"go:GO:0016279","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the epsilon-amino group of a lysine residue in a protein substrate.\" [PMID:12054878]","metadata":null},{"id":"cbb4563155b14f9bba7b21e43dfced23","type":"GO_TERM","name":"protein-lysine lysyltransferase activity","canonical_id":"go:GO:0052868","description":"\"Catalysis of the reaction: D-beta-lysine + L-lysyl-[protein] + ATP = N6-((3R)-3,6-diaminohexanoyl)-L-lysyl-[protein] + AMP + diphosphate + H+n. This reaction is the addition of lysine group from one protein to a lysine residue in a second protein, producing N6-(lysyl)-L-lysine.\" [PMID:20729861, RHEA:83435]","metadata":null},{"id":"83456f5ad4ca45aebd0f3da75671340c","type":"GO_TERM","name":"protein-lysine-acetyltransferase activity","canonical_id":"go:GO:0061733","description":"\"Catalysis of the reaction: L-lysyl-[protein] + acetyl-CoA = N6-acetyl-L-lysyl-[protein] + CoA + H+.\" [RHEA:45948]","metadata":null},{"id":"3a5a9b65390a4b989c5fc00d4057edbc","type":"GO_TERM","name":"protein-macromolecule adaptor activity","canonical_id":"go:GO:0030674","description":"\"An adaptor activity that brings together two or more macromolecules in contact, permitting those molecules to function in a coordinated way. The adaptor can bring together two proteins, or a protein and another macromolecule such as a lipid or a nucleic acid.\" [GOC:bf, GOC:mah, GOC:vw]","metadata":null},{"id":"6ca63392a44141008439a0f72cdf83dd","type":"GO_TERM","name":"protein-malonyllysine demalonylase activity","canonical_id":"go:GO:0036054","description":"\"Catalysis of the reaction: N(6)-malonyl-L-lysyl-[protein] + NAD+ + H2O = 2''-O-malonyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein].\" [PMID:21908771, PMID:22076378, RHEA:47672]","metadata":null},{"id":"6a3df9341af34f87b98f65212c2671cf","type":"GO_TERM","name":"protein-membrane adaptor activity","canonical_id":"go:GO:0043495","description":"\"The binding activity of a molecule that brings together a protein or a protein complex with a membrane, either via membrane lipid binding or by interacting with a membrane protein, to establish or maintain the localization of the protein, protein complex or organelle.\" [GOC:curators]","metadata":null},{"id":"e61092c2d84b48dfb893239c90486b4a","type":"GO_TERM","name":"protein-mitochondrial outer membrane tethering activity","canonical_id":"go:GO:0180050","description":"\"The binding activity of a molecule that brings together a protein or protein complex and a mitochondrial outer membrane lipid or membrane-associated protein, in order to maintain the localization of the protein, or protein complex at a specific mitochondrial outer membrane location.\" [GOC:vw]","metadata":null},{"id":"d57888026dba42dd954ec2ff0e63ecbb","type":"GO_TERM","name":"protein-phosphatidylethanolamide deconjugating activity","canonical_id":"go:GO:0019786","description":"\"Catalysis of the reaction: [protein]-C-terminal L-amino acid-glycyl-phosphatidylethanolamide + H2O = [protein]-C-terminal L-amino acid-glycine + a 1,2-diacyl-sn-glycero-3-phosphoethanolamine. An example of this reaction is the removal of ATG8 from membranes to which it is covalently linked to a phosphatidylethanolamid via its terminal glycine residue.\" [PMID:22240591, PMID:22652539, PMID:28330855, PMID:2882172, PMID:28901328]","metadata":null},{"id":"a651de17d7c047beac63d4ddc9eb9f5a","type":"GO_TERM","name":"protein-phosphocysteine-D-fructose-phosphotransferase system transporter activity","canonical_id":"go:GO:0090582","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + D-fructose(out) = protein cysteine + D-fructose-1-phosphate(in).\" [PMID:8626640]","metadata":null},{"id":"df2b471dc68f44d2b168efe64c56dd8d","type":"GO_TERM","name":"protein-phosphocysteine-D-sorbitol-phosphotransferase system transporter activity","canonical_id":"go:GO:0090583","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + D-sorbitol(out) = protein cysteine + D-sorbitol-1-phosphate(in).\" [PMID:8875915]","metadata":null},{"id":"9ad33f0d1f89481185952eb3aaf0081e","type":"GO_TERM","name":"protein-phosphocysteine-L-ascorbate-phosphotransferase system transporter activity","canonical_id":"go:GO:0090585","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + L-ascorbate(out) = protein cysteine + L-ascorbate-6-phosphate(in).\" [PMID:15153772]","metadata":null},{"id":"48de7f97818941d090efe9844a2fc428","type":"GO_TERM","name":"protein-phosphocysteine-N,N'-diacetylchitobiose phosphotransferase system transporter activity","canonical_id":"go:GO:0090566","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + N,N'-diacetylchitobiose(out) = protein cysteine + N,N'-diacetylchitobiose phosphate(in).\" [GOC:am, PMID:10913119]","metadata":null},{"id":"b57538ca02df4189b8fbff4883d01c24","type":"GO_TERM","name":"protein-phosphocysteine-N-acetylglucosamine phosphotransferase system transporter activity","canonical_id":"go:GO:0090586","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + N-acetylglucosamine (out) = protein cysteine + N-acetylglucosamine-6-phosphate (in).\" [PMID:8246840]","metadata":null},{"id":"2bff4915fcf24ffe9e7367ca6dc3ceab","type":"GO_TERM","name":"protein-phosphocysteine-N-acetylmuramate phosphotransferase system transporter activity","canonical_id":"go:GO:0090588","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + N-acetylmuramate (out) = protein cysteine + N-acetylmuramate-6-phosphate (in).\" [PMID:15060041]","metadata":null},{"id":"fbd2525263e143c78f61ab5640173e43","type":"GO_TERM","name":"protein-phosphocysteine-galactitol-phosphotransferase system transporter activity","canonical_id":"go:GO:0090584","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + galactitol(out) = protein cysteine + galactitol-6-phosphate(in).\" [PMID:8955298]","metadata":null},{"id":"bbad580fea8c4b6e9b5a98ed764f884c","type":"GO_TERM","name":"protein-phosphocysteine-glucosamine phosphotransferase system transporter activity","canonical_id":"go:GO:0090587","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + glucosamine (out) = protein cysteine + glucosamine-6-phosphate (in).\" [PMID:8246840]","metadata":null},{"id":"89a60fd478e54f49852fe0aa89597df9","type":"GO_TERM","name":"protein-phosphocysteine-glucose phosphotransferase system transporter activity","canonical_id":"go:GO:0090564","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + glucose(out) = protein cysteine + glucose phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:am]","metadata":null},{"id":"ac90d14f71ee47dfaab8648deb17e214","type":"GO_TERM","name":"protein-phosphocysteine-mannitol phosphotransferase system transporter activity","canonical_id":"go:GO:0090565","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + mannitol(out) = protein cysteine + mannitol phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:am]","metadata":null},{"id":"49ce684fdf524cf4896340d65377d5b2","type":"GO_TERM","name":"protein-phosphocysteine-mannosylglycerate-phosphotransferase system transporter activity","canonical_id":"go:GO:0090581","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + mannosylglycerate(out) = protein cysteine + mannosylglycerate phosphate(in).\" [PMID:14645248]","metadata":null},{"id":"c70b7489cae34ed9ad3cd83a54db59ad","type":"GO_TERM","name":"protein-phosphocysteine-sugar phosphotransferase activity","canonical_id":"go:GO:0090563","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + sugar(out) = protein cysteine + sugar phosphate(in). This differs from primary and secondary active transport in that the solute is modified during transport.\" [GOC:am]","metadata":null},{"id":"a2ad9a77d3ff421c9a58ec6c6095a2ea","type":"GO_TERM","name":"protein-phosphocysteine-trehalose phosphotransferase system transporter activity","canonical_id":"go:GO:0090589","description":"\"Catalysis of the PEP-dependent, phosphoryl transfer-driven transport of substances across a membrane. The transport happens by catalysis of the reaction: protein S-phosphocysteine + trehalose (out) = protein cysteine + trehalose-6-phosphate (in).\" [PMID:7608078]","metadata":null},{"id":"66b2bcd0d7ce41c5a292d0fcd587d28e","type":"GO_TERM","name":"protein-phosphoribosyl dephospho-coenzyme A linkage","canonical_id":"go:GO:0018247","description":"\"The linkage of phosphoribosyl dephospho-coenzyme A to protein via peptidyl-serine, to form O-(phosphoribosyl dephospho-coenzyme A)-L-serine; it is uncertain whether the phosphoribosyl glycosidic attachment to the dephospho-coenzyme A is alpha or beta, and through the 2' or the 3' position.\" [RESID:AA0167]","metadata":null},{"id":"2bafe4e56ff94f18bfa14fcbca11bff6","type":"GO_TERM","name":"protein-phycobiliviolin linkage","canonical_id":"go:GO:0017008","description":"\"The linkage of the chromophore phycobiliviolin to phycoerythrocyanin.\" [RESID:AA0258]","metadata":null},{"id":"61e01f777af94d10a3772cc0cc17ecb1","type":"GO_TERM","name":"protein-phycocyanobilin linkage","canonical_id":"go:GO:0017009","description":"\"The linkage of the chromophore phycocyanobilin to phycocyanin or allophycocyanin.\" [RESID:AA0131]","metadata":null},{"id":"d92a85c65fec4c5d8b7c9152a0bea0fc","type":"GO_TERM","name":"protein-phycoerythrobilin linkage","canonical_id":"go:GO:0017011","description":"\"The linkage of the chromophore phycoerythrobilin to phycoerythrins.\" [RESID:AA0132, RESID:AA0259]","metadata":null},{"id":"109932aaf76846fea6eea12fb2615368","type":"GO_TERM","name":"protein-phycourobilin linkage","canonical_id":"go:GO:0017010","description":"\"The linkage of the chromophore phycourobilin to phycoerythrins.\" [RESID:AA0260]","metadata":null},{"id":"1dca6ff39784490e8fcc8c48a86ca8e7","type":"GO_TERM","name":"protein-phytochromobilin linkage","canonical_id":"go:GO:0017012","description":"\"The linkage of the chromophore phytochromobilin to phycocyanin or allophycocyanin.\" [RESID:AA0133]","metadata":null},{"id":"0d3a00ad95fc4b44af5b48452836e606","type":"GO_TERM","name":"protein-pyridoxal-5-phosphate linkage","canonical_id":"go:GO:0018352","description":"\"The formation of a linkage between a protein amino acid and pyridoxal-5-phosphate.\" [GOC:mah]","metadata":null},{"id":"e711efc1477e4cd3b0b244b92840bf2d","type":"GO_TERM","name":"protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysine","canonical_id":"go:GO:0018272","description":"\"The modification of peptidyl-lysine to form N6-pyridoxal phosphate-L-lysine.\" [RESID:AA0119]","metadata":null},{"id":"0c352e41487846a6a3a8e1b08329a285","type":"GO_TERM","name":"protein-ribulosamine 3-kinase activity","canonical_id":"go:GO:0102193","description":"\"Catalysis of the reaction: ATP + a [protein]-N6-D-ribulosyl-L-lysine = ADP + a [protein]-N6-(3-O-phospho-D-ribulosyl)-L-lysine.\" [EC:2.7.1.172, GOC:pz]","metadata":null},{"id":"68877dd2b0cb4104904388812c285d0d","type":"GO_TERM","name":"protein-serine epimerase activity","canonical_id":"go:GO:0018365","description":"\"Catalysis of the reaction: (protein)-L-serine = (protein)-D-serine.\" [EC:5.1.1.16]","metadata":null},{"id":"f7729c48e7c74311aa96f0cde545ee54","type":"GO_TERM","name":"protein-succinyllysine desuccinylase activity","canonical_id":"go:GO:0036055","description":"\"Catalysis of the reaction: N(6)-succinyl-L-lysyl-[protein] + NAD+ + H2O = 2''-O-succinyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein].\" [PMID:22076378, RHEA:47668]","metadata":null},{"id":"2599951eb6b74cc68c9b7431c5f1c031","type":"GO_TERM","name":"protein-tRNA adaptor activity","canonical_id":"go:GO:0180014","description":"\"The binding activity of a protein that brings together another protein and a tRNA, permitting those molecules to function in a coordinated way.\" [PMID:31048492]","metadata":null},{"id":"f49164b43f2844219ede4b22a1e452cb","type":"GO_TERM","name":"protein-tetrapyrrole linkage","canonical_id":"go:GO:0017006","description":"\"The covalent linking of a tetrapyrrole to a protein.\" [GOC:ai]","metadata":null},{"id":"c63068fa21c44b1cbc5c10759ca96666","type":"GO_TERM","name":"protein-transporting ATPase activity","canonical_id":"go:GO:0015450","description":"\"Primary active carrier-mediated transport of a protein across a membrane, driven by the hydrolysis of the diphosphate bond of inorganic pyrophosphate, ATP, or another nucleoside triphosphate. The transport protein may or may not be transiently phosphorylated, but the substrate is not phosphorylated.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"fdc5e108681f49be8392cf6451856d83","type":"GO_TERM","name":"protein-tyrosine sulfotransferase activity","canonical_id":"go:GO:0008476","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + protein tyrosine = adenosine 3',5'-bisphosphate + protein tyrosine-O-sulfate.\" [EC:2.8.2.20]","metadata":null},{"id":"4d5aa4404055461b8de425aeedcc4ba0","type":"GO_TERM","name":"proteinase activated receptor binding","canonical_id":"go:GO:0031871","description":"\"Binding to a proteinase activated receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"19507a96ff9c4a29b5dac297348d59ce","type":"GO_TERM","name":"proteinase-activated receptor activity","canonical_id":"go:GO:0001648","description":"\"A G protein-coupled receptor activity that is activated by cleavage by a serine protease, exposing a tethered ligand corresponding to the new N-terminus, which binds to the receptor and activates it.\" [GOC:mah, PMID:11356985, PMID:33742547]","metadata":null},{"id":"bf2747ea669a4875ab583046c5c662f3","type":"GO_TERM","name":"proteinogenic amino acid biosynthetic process","canonical_id":"go:GO:0170038","description":"\"The chemical reactions and pathways resulting in the formation of any amino acid that is incorporated into protein naturally by ribosomal translation of mRNA, and that has a specific codon for translation from mRNA to protein.\" [GOC:ew]","metadata":null},{"id":"e4733d866708463690bfdb5d80426bfb","type":"GO_TERM","name":"proteinogenic amino acid catabolic process","canonical_id":"go:GO:0170040","description":"\"The chemical reactions and pathways resulting in the breakdown of any amino acid that is incorporated into protein naturally by ribosomal translation of mRNA, and that has a specific codon for translation from mRNA to protein.\" [GOC:ew]","metadata":null},{"id":"8f385e17141c4d06bb02c79ea8fc21cf","type":"GO_TERM","name":"proteinogenic amino acid metabolic process","canonical_id":"go:GO:0170039","description":"\"The chemical reactions and pathways involving any amino acid that is incorporated into protein naturally by ribosomal translation of mRNA, and that has a specific codon for translation from mRNA to protein.\" [GOC:ew]","metadata":null},{"id":"e18a5d56513e42efa110d575a283f4ee","type":"GO_TERM","name":"proteinoplast","canonical_id":"go:GO:0031986","description":"\"A leucoplast in which protein is stored.\" [GOC:pz]","metadata":null},{"id":"61ee5ab17674497d84057ddc2649fb30","type":"GO_TERM","name":"proteoglycan binding","canonical_id":"go:GO:0043394","description":"\"Binding to a proteoglycan, any glycoprotein in which the carbohydrate units are glycosaminoglycans.\" [ISBN:0198506732]","metadata":null},{"id":"47a695bffa8d474a8289bf7925cfeecd","type":"GO_TERM","name":"proteoglycan biosynthetic process","canonical_id":"go:GO:0030166","description":"\"The chemical reactions and pathways resulting in the formation of proteoglycans, any glycoprotein in which the carbohydrate units are glycosaminoglycans.\" [PMID:35536939]","metadata":null},{"id":"a90cd739eb39418da5f3a9b40765607a","type":"GO_TERM","name":"proteoglycan catabolic process","canonical_id":"go:GO:0030167","description":"\"The chemical reactions and pathways resulting in the breakdown of proteoglycans, any glycoprotein in which the carbohydrate units are glycosaminoglycans.\" [PMID:35536982]","metadata":null},{"id":"c94f9434f9ca41fcb8d9c67ca7948cb4","type":"GO_TERM","name":"proteoglycan metabolic process","canonical_id":"go:GO:0006029","description":"\"The chemical reactions and pathways involving proteoglycans, any glycoprotein in which the carbohydrate units are glycosaminoglycans.\" [PMID:35536939]","metadata":null},{"id":"996671e57158418cba2ca412a88e96e5","type":"GO_TERM","name":"proteoglycan sulfotransferase activity","canonical_id":"go:GO:0050698","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + proteoglycan = adenosine 3',5'-bisphosphate + proteoglycan sulfate. A proteoglycan is a glycoprotein whose carbohydrate units are glycosaminoglycans.\" [GOC:ai]","metadata":null},{"id":"24a2ac822f8c4fb68bcce42c45681c1a","type":"GO_TERM","name":"proteolysis","canonical_id":"go:GO:0006508","description":"\"The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.\" [GOC:bf, GOC:mah]","metadata":null},{"id":"5e1e04cbe6bf4f1dbe214001d7e6d311","type":"GO_TERM","name":"proteolysis associated with antigen processing and presentation","canonical_id":"go:GO:0002496","description":"\"The hydrolysis of a peptide bond or bonds within a protein contributing to antigen processing and presentation.\" [GOC:add, ISBN:0781735149, PMID:15224092, PMID:15771591]","metadata":null},{"id":"11fc9cb65a0d45138edab8eaa3cc0fad","type":"GO_TERM","name":"proteolysis by cytosolic proteases associated with antigen processing and presentation","canonical_id":"go:GO:0002203","description":"\"The hydrolysis of a peptide bond or bonds within a protein by cytosolic resident proteases during antigen processing and presentation.\" [GOC:add, ISBN:0781735149, PMID:15224092, PMID:15771591]","metadata":null},{"id":"44921e902eb84507b379810489bae503","type":"GO_TERM","name":"proteolysis within endoplasmic reticulum associated with antigen processing and presentation","canonical_id":"go:GO:0002498","description":"\"The hydrolysis of a peptide bond or bonds within a protein by ER resident proteases contributing to antigen processing and presentation.\" [GOC:add, ISBN:0781735149, PMID:15224092, PMID:15771591]","metadata":null},{"id":"b82c8597f9d64f6db15f9632bc4f9399","type":"GO_TERM","name":"proteolysis within endosome associated with antigen processing and presentation","canonical_id":"go:GO:0002499","description":"\"The hydrolysis of a peptide bond or bonds within a protein by endosomal resident proteases contributing to antigen processing and presentation.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"c7d776b21e33412abca6eb2a938edf5c","type":"GO_TERM","name":"proteolysis within lysosome associated with antigen processing and presentation","canonical_id":"go:GO:0002500","description":"\"The hydrolysis of a peptide bond or bonds within a protein by lysosomal resident proteases contributing to antigen processing and presentation.\" [GOC:add, ISBN:0781735149, PMID:15771591]","metadata":null},{"id":"5e9db001af0f4dea82922c7e455998ed","type":"GO_TERM","name":"prothoracic disc development","canonical_id":"go:GO:0035219","description":"\"Progression of the prothoracic disc over time, from its initial formation through to its metamorphosis to form the adult humerous and anterior spiracle.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"153c89db067d4a30b4fc93af7f21b841","type":"GO_TERM","name":"prothoracic disc morphogenesis","canonical_id":"go:GO:0007470","description":"\"The process in which the anatomical structures derived from the prothoracic disc are generated and organized. This includes the transformation of a prothoracic imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into the recognizable adult humerous and anterior spiracle.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"bfbc61f2bc264907a0c9e652bff73c42","type":"GO_TERM","name":"prothoracicotrophic hormone activity","canonical_id":"go:GO:0018445","description":"\"The action characteristic of prothoracicotrophic hormone, a peptide hormone that is secreted by the brain and, upon receptor binding, acts on the prothoracic gland to stimulate the release of ecdysone in insects.\" [GOC:mah, PMID:3301403]","metadata":null},{"id":"37410fa5b7e44549ae45cc96b366598f","type":"DISEASE","name":"prothrombin deficiency","canonical_id":"mondo:0024307","description":null,"metadata":null},{"id":"d23c7de33dea4efb939c4c721c8a796b","type":"GO_TERM","name":"prothylakoid","canonical_id":"go:GO:0042649","description":"\"Underdeveloped thylakoids found in etioplasts, lacking competent photosynthetic membranes. Rapidly develop into mature thylakoids in the presence of light.\" [GOC:jl, PMID:11532175]","metadata":null},{"id":"974c2569f3be461180452f6f8d7799df","type":"GO_TERM","name":"prothylakoid membrane","canonical_id":"go:GO:0042650","description":"\"The membrane of prothylakoids, underdeveloped thylakoids found in etioplasts, lacking competent photosynthetic membranes.\" [GOC:jl, PMID:11532175]","metadata":null},{"id":"2c3730c0977446ac9e7c40d31997b226","type":"GO_TERM","name":"protoaphin-aglucone dehydratase (cyclizing) activity","canonical_id":"go:GO:0047452","description":"\"Catalysis of the reaction: protoaphin aglucone = H2O + xanthoaphin.\" [EC:4.2.1.73, RHEA:23876]","metadata":null},{"id":"35c8b0ffd7b540d883bb11e471e8781f","type":"GO_TERM","name":"protocadherin-alpha-protocadherin-gamma complex","canonical_id":"go:GO:0071183","description":"\"A protein complex that contains two cell adhesion molecules, a protocadherin-alpha and a protocadherin-gamma, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"05ef92a21fe5497db07e7df62f3de325","type":"GO_TERM","name":"protocadherin-alpha-v4-protocadherin-gamma-a1 complex","canonical_id":"go:GO:0071184","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v4 and protocadherin-gamma-a1, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"c25bca77a3e149bd97f013d1408a3d4a","type":"GO_TERM","name":"protocadherin-alpha-v4-protocadherin-gamma-a3 complex","canonical_id":"go:GO:0071185","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v4 and protocadherin-gamma-a3, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"d4fe97625b374ff6954884234066910b","type":"GO_TERM","name":"protocadherin-alpha-v4-protocadherin-gamma-b2 complex","canonical_id":"go:GO:0071186","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v4 and protocadherin-gamma-b2, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"d53c637694e9472688705940cc764435","type":"GO_TERM","name":"protocadherin-alpha-v4-protocadherin-gamma-b4 complex","canonical_id":"go:GO:0071187","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v4 and protocadherin-gamma-b4, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"2840f39e843a454ab5679463219ef448","type":"GO_TERM","name":"protocadherin-alpha-v7-protocadherin-gamma-a1 complex","canonical_id":"go:GO:0071188","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v7 and protocadherin-gamma-a1, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"cb833214c26a4061907d9be594e3c61d","type":"GO_TERM","name":"protocadherin-alpha-v7-protocadherin-gamma-a3 complex","canonical_id":"go:GO:0071189","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v7 and protocadherin-gamma-a3, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"4d0d27db9a1e4ed78d93bc7ab4cfe80c","type":"GO_TERM","name":"protocadherin-alpha-v7-protocadherin-gamma-b2 complex","canonical_id":"go:GO:0071190","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v7 and protocadherin-gamma-b2, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"5b2838d2176546c0b6d1fc1c7d0bce0a","type":"GO_TERM","name":"protocadherin-alpha-v7-protocadherin-gamma-b4 complex","canonical_id":"go:GO:0071191","description":"\"A protein complex that contains the cell adhesion molecules protocadherin-alpha-v7 and protocadherin-gamma-b4, and is involved in the regulation of protein localization to the plasma membrane.\" [PMID:15347688]","metadata":null},{"id":"756271fe626d49b0bb89680d343e6c04","type":"GO_TERM","name":"protocatechuate 3,4-dioxygenase activity","canonical_id":"go:GO:0018578","description":"\"Catalysis of the reaction: 3,4-dihydroxybenzoate + O2 = 3-carboxy-cis,cis-muconate.\" [EC:1.13.11.3]","metadata":null},{"id":"7ea02dc8007c41c38602affc92f7ff4d","type":"GO_TERM","name":"protocatechuate 3,4-dioxygenase complex","canonical_id":"go:GO:7770085","description":"\"A protein complex which is capable of protocatechuate 3,4-dioxygenase activity. It consists of an alpha subunit (PcaG) and a beta subunit (PcaH), with the non-heme iron active site formed at the alpha-beta interface.\" [PMID:25558786]","metadata":null},{"id":"24188b2aa9fd416e84654ee9e72da50a","type":"GO_TERM","name":"protocatechuate 4,5-dioxygenase activity","canonical_id":"go:GO:0018579","description":"\"Catalysis of the reaction: protocatechuate + O2 = 4-carboxy-2-hydroxymuconate semialdehyde.\" [EC:1.13.11.8]","metadata":null},{"id":"7509e91a98ac4923b6597d5db3e59bbc","type":"GO_TERM","name":"protocatechuate catabolic process, meta-cleavage","canonical_id":"go:GO:0019617","description":"\"The chemical reactions and pathways resulting in the breakdown of protocatechuate, the anion of 3,4-dihydroxybenzoic acid, to yield oxaloacetate and pyruvate.\" [MetaCyc:P184-PWY]","metadata":null},{"id":"c57f551ad45a4f5daa767c77d60b560f","type":"GO_TERM","name":"protocatechuate catabolic process, ortho-cleavage","canonical_id":"go:GO:0019618","description":"\"The chemical reactions and pathways resulting in the breakdown of protocatechuate, the anion of 3,4-dihydroxybenzoic acid, to yield beta-ketoadipate.\" [MetaCyc:PROTOCATECHUATE-ORTHO-CLEAVAGE-PWY]","metadata":null},{"id":"38bb599ae83640f0bbcaf13d48866952","type":"GO_TERM","name":"protocatechuate decarboxylase activity","canonical_id":"go:GO:0050223","description":"\"Catalysis of the reaction: 3,4-dihydroxybenzoate + H+ = catechol + CO2.\" [EC:4.1.1.63, RHEA:22416]","metadata":null},{"id":"0d2f1e11cfda4cdd882a60c69d791cf9","type":"GO_TERM","name":"protochlorophyllide reductase activity","canonical_id":"go:GO:0016630","description":"\"Catalysis of the reaction: chlorophyllide a + NADP+ = protochlorophyllide + NADPH + H+.\" [EC:1.3.1.33]","metadata":null},{"id":"3433bef09f15486b8124463b5f8714c2","type":"GO_TERM","name":"protoderm histogenesis","canonical_id":"go:GO:0010068","description":"\"The formation of the primary meristem or meristematic tissue that gives rise to the epidermis.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"6634446f4d3840fab091e24c39023b1f","type":"GO_TERM","name":"protoheme IX farnesyltransferase activity","canonical_id":"go:GO:0008495","description":"\"Catalysis of the reaction: protoheme IX + (2E,6E)-farnesyl diphosphate + H2O = heme O + diphosphate.\" [RHEA:28070]","metadata":null},{"id":"652edfc9cac04732a18c307a3865199e","type":"GO_TERM","name":"proton binding","canonical_id":"go:GO:1901691","description":"\"Binding to proton.\" [GOC:TermGenie]","metadata":null},{"id":"e3724c1fa274466780d68bf6290ce3ca","type":"GO_TERM","name":"proton channel activity","canonical_id":"go:GO:0015252","description":"\"Enables the facilitated diffusion of a hydrogen ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.\" [GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"c7d419c8b1544c04acf00b384789b518","type":"GO_TERM","name":"proton export across plasma membrane","canonical_id":"go:GO:0120029","description":"\"The directed movement of hydrogen ions (protons) from inside a cell, across the plasma membrane and into the extracellular region.\" [GOC:mah, PMID:9762918]","metadata":null},{"id":"810f821237d84f928de28814408f3f4f","type":"GO_TERM","name":"proton motive force dependent protein transmembrane transporter activity","canonical_id":"go:GO:0009977","description":"\"Catalysis of the transfer of proteins from one side of a membrane to the other. Transportation is dependent on pH gradient across the membrane.\" [PMID:11526245, PMID:25494301]","metadata":null},{"id":"7cfe43598e61462584344cdde410692f","type":"GO_TERM","name":"proton motive force-driven ATP synthesis","canonical_id":"go:GO:0015986","description":"\"The chemical reactions and pathways resulting in the formation of ATP driven by transport of protons across a membrane to generate an electrochemical gradient (proton-motive force).\" [GOC:vw]","metadata":null},{"id":"fafe683998db4554905181381f8bd3b6","type":"GO_TERM","name":"proton motive force-driven mitochondrial ATP synthesis","canonical_id":"go:GO:0042776","description":"\"The chemical reactions and pathways resulting in the formation of ATP driven by transport of protons across a mitochondrial membrane to generate an electrochemical gradient (proton-motive force).\" [GOC:vw]","metadata":null},{"id":"d47e9c08925c42e89ed5f4172eb4ed87","type":"GO_TERM","name":"proton motive force-driven motor activity","canonical_id":"go:GO:0140605","description":"\"A motor activity driven by an electrochemical proton gradient (proton-motive force). PMF-driven motors are used by bacterial flagella.\" [PMID:18216858]","metadata":null},{"id":"cd83ab05adf7438b8ebdb3edd29d2267","type":"GO_TERM","name":"proton motive force-driven plasma membrane ATP synthesis","canonical_id":"go:GO:0042777","description":"\"The chemical reactions and pathways resulting in the formation of ATP driven by transport of protons across a plasma membrane to generate an electrochemical gradient (proton-motive force).\" [GOC:vw]","metadata":null},{"id":"1260f3be0b4847b696c3f3d8cdae6461","type":"GO_TERM","name":"proton transmembrane transport","canonical_id":"go:GO:1902600","description":"\"The directed movement of a proton across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"fa73eb47cf4b4e12a9e14a23bc2bff51","type":"GO_TERM","name":"proton transmembrane transporter activity","canonical_id":"go:GO:0015078","description":"\"Enables the transfer of a proton from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"297db106f32f47b8bc0b58b812497284","type":"GO_TERM","name":"proton-dependent oligopeptide secondary active transmembrane transporter activity","canonical_id":"go:GO:0005427","description":"\"Enables the transfer of a oligopeptide from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by proton movement.\" [GOC:mtg_transport, OMIM:600544]","metadata":null},{"id":"196d4d152a30463e98240054b1ea3896","type":"GO_TERM","name":"proton-translocating NAD(P)+ transhydrogenase activity","canonical_id":"go:GO:0008750","description":"\"Catalysis of the reaction: H+(in) + NAD+ + NADPH = H+(out) + NADH + NADP+.\" [RHEA:47992]","metadata":null},{"id":"691262a1107e43909df7f544643a3fbc","type":"GO_TERM","name":"proton-transporting ATP synthase activity, rotational mechanism","canonical_id":"go:GO:0046933","description":"\"Enables the synthesis of ATP from ADP and phosphate by the transfer of protons from one side of a membrane to the other by a rotational mechanism driven by a gradient according to the reaction: ADP + phosphate + 5 H+(out) => ATP + H2O + 4 H+(in).\" [RHEA:57722]","metadata":null},{"id":"8f9d61c711244e00b77b68e1f051529b","type":"GO_TERM","name":"proton-transporting ATP synthase complex","canonical_id":"go:GO:0045259","description":"\"A proton-transporting two-sector ATPase complex that catalyzes the phosphorylation of ADP to ATP during oxidative phosphorylation. The complex comprises a membrane sector (F0) that carries out proton transport and a cytoplasmic compartment sector (F1) that catalyzes ATP synthesis by a rotational mechanism; the extramembrane sector (containing 3 a and 3 b subunits) is connected via the d-subunit to the membrane sector by several smaller subunits. Within this complex, the g and e subunits and the 9-12 c subunits rotate by consecutive 120 degree angles and perform parts of ATP synthesis. This movement is driven by the hydrogen ion electrochemical potential gradient.\" [ISBN:0198547684, ISBN:0716743663]","metadata":null},{"id":"6f910de7c4cd45db99ae7d2cdb454ebf","type":"GO_TERM","name":"proton-transporting ATP synthase complex assembly","canonical_id":"go:GO:0043461","description":"\"The aggregation, arrangement and bonding together of a proton-transporting ATP synthase (also known as F-type ATPase), a two-sector ATPase found in the inner membrane of mitochondria and chloroplasts, and in bacterial plasma membranes.\" [GOC:jl, GOC:mah, PMID:29514954]","metadata":null},{"id":"9d59319c4e7c4f7a906aa2071b33ac0d","type":"GO_TERM","name":"proton-transporting ATPase activity, rotational mechanism","canonical_id":"go:GO:0046961","description":"\"Enables the transfer of protons from one side of a membrane to the other by a rotational mechanism according to the reaction: ATP + H2O + 4 H+(in) => ADP + phosphate + 5 H+(out).\" [RHEA:57721]","metadata":null},{"id":"652a99e6ea2441378a2509f8a9291987","type":"GO_TERM","name":"proton-transporting V-type ATPase complex","canonical_id":"go:GO:0033176","description":"\"A proton-transporting two-sector ATPase complex that couples ATP hydrolysis to the transport of protons across a concentration gradient. The resulting transmembrane electrochemical potential of H+ is used to drive a variety of (i) secondary active transport systems via H+-dependent symporters and antiporters and (ii) channel-mediated transport systems. The complex comprises a membrane sector (V0) that carries out proton transport and a cytoplasmic compartment sector (V1) that catalyzes ATP hydrolysis. V-type ATPases are found in the membranes of organelles such as vacuoles, endosomes, and lysosomes, and in the plasma membrane.\" [GOC:mah, ISBN:0716743663, PMID:16449553]","metadata":null},{"id":"92311ad20bdb4c7e9a6557cff9d5a4b6","type":"GO_TERM","name":"proton-transporting V-type ATPase complex assembly","canonical_id":"go:GO:0070070","description":"\"The aggregation, arrangement and bonding together of a proton-transporting V-type ATPase complex, proton-transporting two-sector ATPase complex that couples ATP hydrolysis to the transport of protons across a concentration gradient.\" [GOC:mah]","metadata":null},{"id":"9dd7a588dd1447c1a63f5e06fead38f8","type":"GO_TERM","name":"proton-transporting V-type ATPase, V0 domain","canonical_id":"go:GO:0033179","description":"\"A protein complex that forms part of a proton-transporting V-type ATPase and mediates proton transport across a membrane. The V0 complex consists of at least four different subunits (a,c,d and e); six or more c subunits form a proton-binding rotor ring.\" [GOC:mah, ISBN:0716743663, PMID:16449553]","metadata":null},{"id":"a90055bd9847497da7b48980b282f9bf","type":"GO_TERM","name":"proton-transporting V-type ATPase, V1 domain","canonical_id":"go:GO:0033180","description":"\"A protein complex that forms part of a proton-transporting V-type ATPase and catalyzes ATP hydrolysis. The V1 complex consists of: (1) a globular headpiece with three alternating copies of subunits A and B that form a ring, (2) a central rotational stalk composed of single copies of subunits D and F, and (3) a peripheral stalk made of subunits C, E, G and H. Subunits A and B mediate the hydrolysis of ATP at three reaction sites associated with subunit A.\" [GOC:mah, ISBN:0716743663, PMID:16449553]","metadata":null},{"id":"c323d5a8313c43ca8c8a0ac0577548b5","type":"GO_TERM","name":"proton-transporting two-sector ATPase complex","canonical_id":"go:GO:0016469","description":"\"A large protein complex that catalyzes the synthesis or hydrolysis of ATP by a rotational mechanism, coupled to the transport of protons across a membrane. The complex comprises a membrane sector (F0, V0, or A0) that carries out proton transport and a cytoplasmic compartment sector (F1, V1, or A1) that catalyzes ATP synthesis or hydrolysis. Two major types have been characterized: V-type ATPases couple ATP hydrolysis to the transport of protons across a concentration gradient, whereas F-type ATPases, also known as ATP synthases, normally run in the reverse direction to utilize energy from a proton concentration or electrochemical gradient to synthesize ATP. A third type, A-type ATPases have been found in archaea, and are closely related to eukaryotic V-type ATPases but are reversible.\" [GOC:mah, ISBN:0716743663, PMID:16691483]","metadata":null},{"id":"c714c6c08b8746beb5c9e2e663bf4e73","type":"GO_TERM","name":"proton-transporting two-sector ATPase complex assembly","canonical_id":"go:GO:0070071","description":"\"The aggregation, arrangement and bonding together of a proton-transporting two-sector ATPase complex, a large protein complex that catalyzes the synthesis or hydrolysis of ATP by a rotational mechanism, coupled to the transport of protons across a membrane.\" [GOC:mah]","metadata":null},{"id":"9b918ef47ad042059ca2f7ddfc33dd19","type":"GO_TERM","name":"proton-transporting two-sector ATPase complex, catalytic domain","canonical_id":"go:GO:0033178","description":"\"A protein complex that forms part of a proton-transporting two-sector ATPase complex and catalyzes ATP hydrolysis or synthesis. The catalytic domain (F1, V1, or A1) comprises a hexameric catalytic core and a central stalk, and is peripherally associated with the membrane when the two-sector ATPase is assembled.\" [GOC:mah, PMID:10838056]","metadata":null},{"id":"9534658941714f2ca317d872803652bd","type":"GO_TERM","name":"proton-transporting two-sector ATPase complex, proton-transporting domain","canonical_id":"go:GO:0033177","description":"\"A protein complex that forms part of a proton-transporting two-sector ATPase complex and carries out proton transport across a membrane. The proton-transporting domain (F0, V0, or A0) includes integral and peripheral membrane proteins.\" [GOC:mah, PMID:10838056]","metadata":null},{"id":"07158e66bf8f40de9114bd0f21b88ac1","type":"GO_TERM","name":"protopanaxadiol 6-hydroxylase activity","canonical_id":"go:GO:0102557","description":"\"Catalysis of the reaction: (20S)-protopanaxadiol + O2 + reduced [NADPH--hemoprotein reductase] = (20S)-protopanaxatriol + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [EC:1.14.14.121]","metadata":null},{"id":"062c76431cf4452185b6d87c611310a5","type":"GO_TERM","name":"protoperithecium formation","canonical_id":"go:GO:0120166","description":"\"The process of producing fruiting body precursors, called protoperithecia. Protoperitheicium is a spherical structure that is formed in the sexual phase of ascomycetous fungi such as Neurospora crassa and Sordaria macrospora. Protoperithecium is formed by the enveloping of ascogonia cells by sterile hyphae and it develops into perithecium.\" [DOI:10.1007/978-3-642-00286-1_2, PMID:125266, PMID:20739093, PMID:25311923, PMID:4410944, PMID:6235211, PMID:6235212]","metadata":null},{"id":"4739445aaa4642e49334bf6e4f8abebd","type":"GO_TERM","name":"protopine 6-monooxygenase activity","canonical_id":"go:GO:0047087","description":"\"Catalysis of the reaction: O2 + protopine + reduced [NADPH--hemoprotein reductase] = 6-hydroxyprotopine + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:22644]","metadata":null},{"id":"75d69be6a5a444cc997a4e42ea0d64fd","type":"GO_TERM","name":"protoporphyrin ferrochelatase activity","canonical_id":"go:GO:0004325","description":"\"Catalysis of the reaction: heme B (protoheme) + H+ = Fe(2+) + protoporphyrin IX.\" [RHEA:22584]","metadata":null},{"id":"44452f7aa9cd4192a1d793fe46d28998","type":"GO_TERM","name":"protoporphyrinogen oxidase activity","canonical_id":"go:GO:0070818","description":"\"Catalysis of the reaction: protoporphyrinogen IX + 3 acceptor = protoporphyrin IX + 3 reduced acceptor.\" [PMID:19583219, RHEA:62000]","metadata":null},{"id":"cd5e623d0365472d9c0b26bdbb2e29fd","type":"GO_TERM","name":"protoporphyrinogen oxidase activity, oxygen as acceptor","canonical_id":"go:GO:0004729","description":"\"Catalysis of the reaction: 3 O2 + protoporphyrinogen IX = 3 H2O2 + protoporphyrin IX.\" [RHEA:25576]","metadata":null},{"id":"5f3ae605c1084764b7721fa9e81afd2e","type":"GO_TERM","name":"protoporphyrinogen oxidase activity, quinone as acceptor","canonical_id":"go:GO:0070819","description":"\"Catalysis of the reaction: protoporphyrinogen IX + 3 a quinone = protoporphyrin IX + 3 a quinol.\" [PMID:19583219, RHEA:65032]","metadata":null},{"id":"c11b19c662cc422c8d6eb195db68f376","type":"GO_TERM","name":"protoxylem development","canonical_id":"go:GO:0090059","description":"\"The process whose specific outcome is the progression of the protoxylem over time, from its formation to the mature structure. The protoxylem comprises the first formed elements of the primary xylem.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"97be404316d4467b8c5dd5bde7155aea","type":"DRUG","name":"protriptyline","canonical_id":"gtopdb:7285","description":null,"metadata":null},{"id":"1a47002441fc4716a53f8fb0ef77dae0","type":"DRUG","name":"protriptyline","canonical_id":"mesh:D011530","description":null,"metadata":null},{"id":"c94de684ded441eda80b855d7a40e4d9","type":"GO_TERM","name":"provirus excision","canonical_id":"go:GO:0032359","description":"\"The molecular events that lead to the excision of a viral genome from the host genome.\" [GOC:mlg, VZ:3969]","metadata":null},{"id":"bcb0d356deec416c9834a6c8e91a37b4","type":"GO_TERM","name":"proximal convoluted tubule development","canonical_id":"go:GO:0072019","description":"\"The process whose specific outcome is the progression of the proximal convoluted tubule over time, from its formation to the mature structure. The proximal convoluted tubule is the most proximal portion of the proximal tubule and extends from the glomerular capsule to the proximal straight tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"10059bb37d5d422aa108a067748c4110","type":"GO_TERM","name":"proximal convoluted tubule segment 1 cell development","canonical_id":"go:GO:0072145","description":"\"The process whose specific outcome is the progression of an S1 cell in the kidney over time, from its formation to the mature structure.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"ee1ab356522142a691b212cd50b39f3f","type":"GO_TERM","name":"proximal convoluted tubule segment 1 cell differentiation","canonical_id":"go:GO:0072062","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the S1 cells of the kidney as it progresses from its formation to the mature state.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"a272968e8029459f80f40d4579467cb4","type":"GO_TERM","name":"proximal convoluted tubule segment 1 cell fate commitment","canonical_id":"go:GO:0072154","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into an S1 cell in the kidney.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"5385cb5fbdc84aaa8e31e16de393f44a","type":"GO_TERM","name":"proximal convoluted tubule segment 1 development","canonical_id":"go:GO:0072031","description":"\"The process whose specific outcome is the progression of the S1 portion of the proximal convoluted tubule over time, from its formation to the mature structure. The S1 portion is the initial portion of the proximal convoluted tubule and is responsible for avid reabsorption of water and solutes.\" [GOC:mtg_kidney_jan10, MA:0002612]","metadata":null},{"id":"e1068dc15707436bb6d9770e7f56dab4","type":"GO_TERM","name":"proximal convoluted tubule segment 2 development","canonical_id":"go:GO:0072032","description":"\"The process whose specific outcome is the progression of the S2 portion of the proximal convoluted tubule over time, from its formation to the mature structure. The S2 portion of the tubule is involved in reabsorption of water and sodium chloride.\" [GOC:mtg_kidney_jan10, MA:0002613]","metadata":null},{"id":"fcf2b2da99a7445a9ebcaba0b342386c","type":"GO_TERM","name":"proximal dendrite","canonical_id":"go:GO:1990635","description":"\"The dendrite of the dendritic tree that is closest to the neuronal cell body (the soma).\" [GOC:aruk, GOC:bc, PMID:16899232]","metadata":null},{"id":"7a7d8762e34546dbac25584a6b8ae44a","type":"GO_TERM","name":"proximal neuron projection","canonical_id":"go:GO:1990769","description":"\"The portion of an axon or dendrite that is close to the neuronal cell body.\" [PMID:21104189]","metadata":null},{"id":"92ec9bb1140f4db8bc3618ee8102a96a","type":"GO_TERM","name":"proximal portion of axoneme","canonical_id":"go:GO:0120134","description":"\"The portion of the axoneme that is close to the base of the cilium.\" [GOC:krc]","metadata":null},{"id":"574fb2f27e97495b95f7576d5f57988d","type":"GO_TERM","name":"proximal stomach smooth muscle contraction","canonical_id":"go:GO:0014847","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the proximal stomach. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The proximal stomach, composed of the fundus and upper body, shows low frequency, sustained tonic contractions that are responsible for generating a basal pressure within the stomach.\" [GOC:mtg_muscle, PMID:30252381]","metadata":null},{"id":"33a26bd514cf4f43b2d33e82f9273e06","type":"GO_TERM","name":"proximal straight tubule development","canonical_id":"go:GO:0072020","description":"\"The process whose specific outcome is the progression of the proximal straight tubule over time, from its formation to the mature structure. The proximal straight tubule is the part of the descending limb that extends from the proximal convoluted tubule to the descending thin tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"26e9515848654855979fbf5a32a598df","type":"GO_TERM","name":"proximal tubule development","canonical_id":"go:GO:0072014","description":"\"The process whose specific outcome is the progression of the proximal tubule over time, from its formation to the mature structure. In mammals, the proximal tubule is a nephron tubule that connects Bowman's capsule to the descending thin limb of the loop of Henle. It has a brush border epithelial morphology.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d0254715cf7944a1b1635fec07564d29","type":"GO_TERM","name":"proximal tubule morphogenesis","canonical_id":"go:GO:0072158","description":"\"The process in which the anatomical structures of a proximal tubule are generated and organized. The proximal tubule is a nephron tubule that connects Bowman's capsule to the descending thin limb of the loop of Henle. It has a brush border epithelial morphology.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"dfbbf8880ce4421b8fa61e42e266479e","type":"GO_TERM","name":"proximal/distal axis specification","canonical_id":"go:GO:0009946","description":"\"The establishment, maintenance and elaboration of the proximal/distal axis. The proximal/distal axis is defined by a line that runs from main body (proximal end) of an organism outward (distal end).\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"d69efd7e47514c509bf7fb93f72c86bf","type":"GO_TERM","name":"proximal/distal pattern formation","canonical_id":"go:GO:0009954","description":"\"The regionalization process in which specific areas of cell differentiation are determined along a proximal/distal axis. The proximal/distal axis is defined by a line that runs from main body (proximal end) of an organism outward (distal end).\" [GOC:curators, GOC:dph, GOC:isa_complete]","metadata":null},{"id":"f031617084b44935b3bb737b7b980cf3","type":"GO_TERM","name":"proximal/distal pattern formation involved in metanephric nephron development","canonical_id":"go:GO:0072272","description":"\"The regionalization process in which specific areas of cell differentiation are determined along a proximal/distal axis of a nephron in the metanephros. The proximal/distal axis is defined by a line that runs from the center of the kidney (proximal end) outward (distal end).\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0d8983a06ce94f6d9ddd7e09c3b2b476","type":"GO_TERM","name":"proximal/distal pattern formation involved in nephron development","canonical_id":"go:GO:0072047","description":"\"The regionalization process in which specific areas of cell differentiation are determined along a proximal/distal axis of a nephron. The proximal/distal axis is defined by a line that runs from the center of the kidney (proximal end) outward (distal end).\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"442ab9bc514e46b9a5daf6366ec28e98","type":"GO_TERM","name":"proximal/distal pattern formation involved in pronephric nephron development","canonical_id":"go:GO:0072196","description":"\"The regionalization process in which specific areas of cell differentiation are determined along a proximal/distal axis of the pronephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ecf3e2bf4c1240d7ab58be4bd6c5ad09","type":"GO_TERM","name":"proximal/distal pattern formation, imaginal disc","canonical_id":"go:GO:0007449","description":"\"The establishment, maintenance and elaboration of the proximal/distal axis of the imaginal disc. Imaginal disks are masses of hypodermic cells, carried by the larvae of some insects after leaving the egg, from which masses the wings and legs of the adult are subsequently formed.\" [GOC:jid, ISBN:0879694238]","metadata":null},{"id":"25d65ca1d4e646239dad5bd872afd9d1","type":"DRUG","name":"prucalopride","canonical_id":"mesh:C406662","description":null,"metadata":null},{"id":"bf8aa4f275a94cd3bdc4336255dd61cb","type":"GO_TERM","name":"prunasin beta-glucosidase activity","canonical_id":"go:GO:0050224","description":"\"Catalysis of the reaction: (R)-prunasin + H2O = D-glucose + mandelonitrile.\" [EC:3.2.1.118, RHEA:16489]","metadata":null},{"id":"0018f5a657774a8482bf6543daf0fc9a","type":"DISEASE","name":"prune belly syndrome","canonical_id":"mondo:0007032","description":null,"metadata":null},{"id":"f5f6b62839814ef181493ca9ac759580","type":"DISEASE","name":"prurigo","canonical_id":"mondo:0021739","description":null,"metadata":null},{"id":"25446023c9f742658fe715c5f3d8dfc4","type":"DISEASE","name":"prurigo nodularis","canonical_id":"mondo:0026045","description":null,"metadata":null},{"id":"420442a297254553b0b80a8dc51ace0b","type":"GO_TERM","name":"pseudocleavage","canonical_id":"go:GO:0030588","description":"\"Partial constriction of the cytoplasm of a cell to form a furrow that resembles a cleavage furrow but does not complete cytokinesis.\" [GOC:mah, PMID:10751167, PMID:30990821, PMID:7729583]","metadata":null},{"id":"0cf8768e4c82497692e0277a0ddc85df","type":"GO_TERM","name":"pseudocleavage involved in syncytial blastoderm formation","canonical_id":"go:GO:0030589","description":"\"Formation of furrows in the cytoplasm between nuclei during cell cycles in embryos that contribute to the formation of the syncytial blastoderm. An example of this process is found in Drosophila melanogaster.\" [GOC:mtg_sensu]","metadata":null},{"id":"2f23c29b078e4ebf92ad42f7fea98ff9","type":"DISEASE","name":"pseudohyperaldosteronism type 2","canonical_id":"mondo:0011517","description":null,"metadata":null},{"id":"2ecd5aff16c44fe3b589a028373beafc","type":"GO_TERM","name":"pseudohyphal growth","canonical_id":"go:GO:0007124","description":"\"The process in which cells grow as a chain of physically attached, elongated cells in response to an environmental stimulus or stimuli.\" [GOC:krc, PMID:11104818, PMID:19347739, PMID:24710476]","metadata":null},{"id":"2a35c406b5ff4ecbaf8d3ae6b87ffac4","type":"GO_TERM","name":"pseudohyphal septin ring","canonical_id":"go:GO:0032170","description":"\"A tight ring-shaped structure that forms in the division plane at the junction between the mother cell and a pseudohyphal projection; composed of septins as well as septin-associated proteins.\" [GOC:krc, GOC:mah, PMID:16151244]","metadata":null},{"id":"80dd860400fa4eb5b4d6e0929571b591","type":"GO_TERM","name":"pseudohyphal septin ring assembly","canonical_id":"go:GO:0062163","description":"\"The aggregation, arrangement and bonding together of septins and associated proteins to form a tight ring-shaped structure that forms in the division plane at the junction between the mother cell and a pseudohyphal projection.\" [PMID:29567712]","metadata":null},{"id":"c9ff8703caa647d8abf09bfd2bffcda3","type":"GO_TERM","name":"pseudophosphatase activity","canonical_id":"go:GO:0001691","description":"\"Maintains the phosphorylation state of certain molecules by associating with them and preventing them from associating with active phosphatases, and thus inhibiting the enzyme activity without interacting with the enzyme. Often pertains to proteins belonging to dual-specificity phosphatase family but lacking critical active site residues.\" [GOC:ajp]","metadata":null},{"id":"3a316a5ccf1e48c79ab6b7908ce23e74","type":"GO_TERM","name":"pseudopodium","canonical_id":"go:GO:0031143","description":"\"A temporary protrusion or retractile process of a cell, associated with flowing movements of the protoplasm, and serving for locomotion and feeding.\" [ISBN:0198506732]","metadata":null},{"id":"b055c2a6a534459fb66c3dafcb17164a","type":"GO_TERM","name":"pseudopodium assembly","canonical_id":"go:GO:0031269","description":"\"The assembly of a pseudopodium by rearrangement of the actin cytoskeleton and overlying membrane.\" [GOC:dph, GOC:mah, GOC:pg, GOC:tb]","metadata":null},{"id":"a3afce1c158d4dbaad5caff45f8182dc","type":"GO_TERM","name":"pseudopodium membrane","canonical_id":"go:GO:0031260","description":"\"The portion of the plasma membrane surrounding a pseudopodium.\" [GOC:mah]","metadata":null},{"id":"69d4f6fd17f8425dbe1a749a947221d5","type":"GO_TERM","name":"pseudopodium organization","canonical_id":"go:GO:0031268","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a pseudopodium, a temporary protrusion or retractile process of a cell, associated with cellular movement.\" [GOC:pg]","metadata":null},{"id":"1997c6d738be41d3b7c666a1521821a8","type":"GO_TERM","name":"pseudopodium retraction","canonical_id":"go:GO:0031270","description":"\"The myosin-based contraction and retraction of a pseudopodium.\" [GOC:pg]","metadata":null},{"id":"aa08e76006414468931847d397c7e714","type":"GO_TERM","name":"pseudouridine 5'-phosphatase activity","canonical_id":"go:GO:1990738","description":"\"Catalysis of the reaction: pseudouridine 5'-phosphate + H2O = pseudouridine + phosphate.\" [EC:3.1.3.96, PMID:20722631]","metadata":null},{"id":"faa4ce66c68f4f309ea37953a551ff97","type":"GO_TERM","name":"pseudouridine kinase activity","canonical_id":"go:GO:0050225","description":"\"Catalysis of the reaction: ATP + pseudouridine = ADP + 2 H+ + pseudouridine 5'-phosphate.\" [EC:2.7.1.83, RHEA:22448]","metadata":null},{"id":"af54337726b24a42a237f7713fc13951","type":"GO_TERM","name":"pseudouridine synthase activity","canonical_id":"go:GO:0009982","description":"\"Catalysis of the reaction: a uridine in RNA = a pseudouridine in RNA. Conversion of uridine in an RNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.\" [GOC:mah, RHEA:48348]","metadata":null},{"id":"dc8fb662b58e44ca8fcea89b86ac39ca","type":"GO_TERM","name":"pseudouridine synthesis","canonical_id":"go:GO:0001522","description":"\"The intramolecular conversion of uridine to pseudouridine within an RNA molecule.\" [GOC:hjd, GOC:mah]","metadata":null},{"id":"ee480d34da914c1385715651fd132d22","type":"GO_TERM","name":"pseudouridylate synthase activity","canonical_id":"go:GO:0004730","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + uracil = H2O + pseudouridine 5'-phosphate.\" [EC:4.2.1.70, RHEA:18337]","metadata":null},{"id":"8954e55c8b39473eb041faed1b90efeb","type":"GO_TERM","name":"pseurotin A biosynthetic process","canonical_id":"go:GO:1900790","description":"\"The chemical reactions and pathways resulting in the formation of pseurotin A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ba66859e062143a793299365adcfdbf9","type":"GO_TERM","name":"pseurotin A catabolic process","canonical_id":"go:GO:1900789","description":"\"The chemical reactions and pathways resulting in the breakdown of pseurotin A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"dba3724354224d6fb7dae076ec70901d","type":"GO_TERM","name":"psilocybin biosynthetic process","canonical_id":"go:GO:0140380","description":"\"The chemical reactions and pathways resulting in the formation of psilocybin, a psychotropic tryptamine-derived natural product.\" [MetaCyc:PWY-7936, PMID:28763571]","metadata":null},{"id":"a400f29110184b15bad9b19aae48031f","type":"GO_TERM","name":"psoralen synthase (NADPH) activity","canonical_id":"go:GO:0102876","description":"\"Catalysis of the reaction: (+)-marmesin + NADPH + H+ + O2 = psoralen + NADP + acetone + 2 H2O.\" [EC:1.14.14.141]","metadata":null},{"id":"7281f559d9e74e39aa54168594b6b798","type":"DISEASE","name":"psoriasis","canonical_id":"mondo:0005083","description":null,"metadata":null},{"id":"129fd9858e2d4d708df4ddb4ea03fe7c","type":"DISEASE","name":"psoriasis vulgaris","canonical_id":"efo:1001494","description":null,"metadata":null},{"id":"680f6071553b42389fa7a28b502039f6","type":"DISEASE","name":"psoriatic arthritis","canonical_id":"mondo:0011849","description":null,"metadata":null},{"id":"3e15d6e0a78d4b32b0342aad43df9750","type":"GO_TERM","name":"psychomotor behavior","canonical_id":"go:GO:0036343","description":"\"The specific behavior of an organism that combines cognitive functions and physical movement. For example, driving a car, throwing a ball, or playing a musical instrument.\" [GOC:nhn, GOC:pr, PMID:17159989, Wikipedia:Psychomotor_learning]","metadata":null},{"id":"6b3eca38b46b44e28abc91d4eae596b4","type":"GO_TERM","name":"psychosine sulfotransferase activity","canonical_id":"go:GO:0050226","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + galactosylsphingosine = adenosine 3',5'-bisphosphate + psychosine sulfate.\" [EC:2.8.2.13, MetaCyc:PSYCHOSINE-SULFOTRANSFERASE-RXN]","metadata":null},{"id":"e6544bfaa5384a8088e013b9f9df3229","type":"DISEASE","name":"psychotic disorder","canonical_id":"mondo:0005485","description":null,"metadata":null},{"id":"720da25a6e5a4c3382d7d6d514edda97","type":"GO_TERM","name":"pteridine biosynthetic process","canonical_id":"go:GO:0006728","description":"\"The chemical reactions and pathways resulting in the formation of pteridine, pyrazino(2,3-dipyrimidine), the parent structure of pterins and the pteroyl group.\" [ISBN:0198506732]","metadata":null},{"id":"835ce5605d694f4488209c3e6a369249","type":"GO_TERM","name":"pteridine catabolic process","canonical_id":"go:GO:0019990","description":"\"The chemical reactions and pathways resulting in the breakdown of pteridine, pyrazino(2,3-dipyrimidine), the parent structure of pterins and the pteroyl group.\" [ISBN:0198506732]","metadata":null},{"id":"423521f4d0a24fce9093a32b0d151715","type":"GO_TERM","name":"pteridine metabolic process","canonical_id":"go:GO:0019889","description":"\"The chemical reactions and pathways involving pteridine, pyrazino(2,3-dipyrimidine), the parent structure of pterins and the pteroyl group.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"23f317b0bb064a568ed1d36e863520bd","type":"GO_TERM","name":"pteridine oxidase activity","canonical_id":"go:GO:0050227","description":"\"Catalysis of the reaction: 2-amino-4-hydroxypteridine + O2 = 2-amino-4,7-dihydroxypteridine + unknown.\" [RHEA:12777]","metadata":null},{"id":"36aec9fa98c743e5b0030e5c7cfd6825","type":"GO_TERM","name":"pteridine reductase activity","canonical_id":"go:GO:0047040","description":"\"Catalysis of the reaction: 5,6,7,8-tetrahydrobiopterin + 2 NADP+ = biopterin + 2 H+ + 2 NADPH.\" [EC:1.5.1.33, RHEA:19509]","metadata":null},{"id":"7f777d1e1017466eb2ad1aa715a2d3f4","type":"GO_TERM","name":"pteridine-containing compound biosynthetic process","canonical_id":"go:GO:0042559","description":"\"The chemical reactions and pathways resulting in the formation of any compound containing pteridine (pyrazino(2,3-dipyrimidine)), e.g. pteroic acid, xanthopterin and folic acid.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"fea05999b92c41a38e6ac1f327d92dc7","type":"GO_TERM","name":"pteridine-containing compound catabolic process","canonical_id":"go:GO:0042560","description":"\"The chemical reactions and pathways resulting in the breakdown of any compound containing pteridine (pyrazino(2,3-dipyrimidine)), e.g. pteroic acid, xanthopterin and folic acid.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"bf7187e0853249448032240147508749","type":"GO_TERM","name":"pteridine-containing compound metabolic process","canonical_id":"go:GO:0042558","description":"\"The chemical reactions and pathways involving any compound containing pteridine (pyrazino(2,3-dipyrimidine)), e.g. pteroic acid, xanthopterin and folic acid.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"99a56013ffbd4e1f82b73469d0a67b30","type":"GO_TERM","name":"pterin deaminase activity","canonical_id":"go:GO:0050228","description":"\"Catalysis of the reaction: a 2-amino-4-hydroxypteridine + H2O + H+ = a 2,4-dihydroxypteridine + NH4+.\" [RHEA:36055]","metadata":null},{"id":"80503eaec4f244669d99c05c078096ee","type":"GO_TERM","name":"pterin-4alpha-carbinolamine dehydratase activity","canonical_id":"go:GO:0102434","description":"\"Catalysis of the reaction: a 10-formyltetrahydrofolate-4a-carbinolamine = H2O + a 10-formyldihydrofolate.\" [GOC:pz, PMID:18245455, PMID:20959559]","metadata":null},{"id":"e35d1725a84644d2a546827cbf7d7bfa","type":"GO_TERM","name":"pterinosome","canonical_id":"go:GO:0043700","description":"\"A tissue-specific, membrane-bounded cytoplasmic organelle within which pteridine pigments are synthesized and stored. Pterinosomes are synthesized in xanthophores and erythrophore cells and are yellow, orange or red in appearance.\" [GOC:mh]","metadata":null},{"id":"5b3e0cb5166f4f09b3f887932517479b","type":"GO_TERM","name":"pterocarpan synthase activity","canonical_id":"go:GO:0140859","description":"\"Catalysis of the reaction: H2O + medicarpin = 4'-methoxyisoflavan-2',4,7-triol.\" [PMID:7805842, RHEA:35407]","metadata":null},{"id":"dcfd173452724fef9bab1ca4ed7dbbee","type":"DRUG","name":"pucolentimab","canonical_id":"gtopdb:13886","description":null,"metadata":null},{"id":"aedf4fff4d554447b8a1cac691c4f61a","type":"GO_TERM","name":"pullulan binding","canonical_id":"go:GO:2001067","description":"\"Binding to pullulan.\" [GOC:mengo_curators]","metadata":null},{"id":"e8e464d6000e4a5ba3db840f8cbc527d","type":"GO_TERM","name":"pullulan biosynthetic process","canonical_id":"go:GO:0051677","description":"\"The chemical reactions and pathways resulting in the formation of pullulan, a neutral linear polysaccharide composed of repeating units of maltotriose joined by alpha-(1,6)-linkages.\" [GOC:ai]","metadata":null},{"id":"ebca491a3911481798b0a51bcff12d36","type":"GO_TERM","name":"pullulan catabolic process","canonical_id":"go:GO:0051678","description":"\"The chemical reactions and pathways resulting in the breakdown of pullulan, a neutral linear polysaccharide composed of repeating units of maltotriose joined by alpha-(1,6)-linkages.\" [GOC:ai]","metadata":null},{"id":"b894fe57fc0e47f4a0f4c817acc7d08f","type":"GO_TERM","name":"pullulan metabolic process","canonical_id":"go:GO:0051676","description":"\"The chemical reactions and pathways involving pullulan, a neutral linear polysaccharide composed of repeating units of maltotriose joined by alpha-(1,6)-linkages.\" [PMID:15013381]","metadata":null},{"id":"279ae9a703a646ba9dde445645288630","type":"GO_TERM","name":"pullulanase activity","canonical_id":"go:GO:0051060","description":"\"Catalysis of the hydrolysis of (1,6)-alpha-D-glucosidic linkages in pullulan (a linear polymer of alpha-(1,6)-linked maltotriose units) and in amylopectin and glycogen, and the a- and b-limit dextrins of amylopectin and glycogen.\" [EC:3.2.1.41]","metadata":null},{"id":"909d3d7eefd5483fb098cd65d25f9e29","type":"DISEASE","name":"pulmonary arterial hypertension","canonical_id":"mondo:0015924","description":null,"metadata":null},{"id":"c112f0516d7f40b78213860ddc8cb4fc","type":"GO_TERM","name":"pulmonary artery endothelial tube morphogenesis","canonical_id":"go:GO:0061155","description":"\"The process in which the anatomical structures of a tube are generated and organized from the pulmonary artery endothelium. An pulmonary artery endothelium is an epithelium that lines the pulmonary artery.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"c1b50ccb916d46d4b44e153e42bf67c5","type":"GO_TERM","name":"pulmonary artery morphogenesis","canonical_id":"go:GO:0061156","description":"\"The process in which the anatomical structures of the pulmonary artery are generated and organized. The pulmonary artery is the artery that carries blood from the heart to the lungs.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"166f2c0cc0af4d9a99cf0ba526f5adac","type":"GO_TERM","name":"pulmonary blood vessel remodeling","canonical_id":"go:GO:0101010","description":"\"The reorganization or renovation of existing pulmonary blood vessels.\" [GOC:mec]","metadata":null},{"id":"f78c51c31d00443093e3e19804feaa71","type":"DISEASE","name":"pulmonary edema","canonical_id":"mondo:0006932","description":null,"metadata":null},{"id":"2392b0b6e54e409988cee6681c60367d","type":"DISEASE","name":"pulmonary embolism","canonical_id":"mondo:0005279","description":null,"metadata":null},{"id":"e58072993ff544c1a31c5b7c37bdbf31","type":"DISEASE","name":"pulmonary emphysema","canonical_id":"mondo:0004849","description":null,"metadata":null},{"id":"a8fa6ab3e2744db4a82a33771ff32ec1","type":"DISEASE","name":"pulmonary fibrosis","canonical_id":"mondo:0002771","description":null,"metadata":null},{"id":"fca6b3433a4d4547b36c7579f6573bed","type":"DISEASE","name":"pulmonary hypertension","canonical_id":"mondo:0005149","description":null,"metadata":null},{"id":"c823fb6cf8fc45f48009063c52b7b64b","type":"DISEASE","name":"pulmonary hypertension, primary, 1","canonical_id":"mondo:0024533","description":null,"metadata":null},{"id":"85ed56d0bc7347d18f07c4e53acf8eea","type":"GO_TERM","name":"pulmonary myocardium development","canonical_id":"go:GO:0003350","description":"\"The progression of the pulmonary myocardium over time, from its initial formation to the mature structure. The pulmonary myocardium is the myocardial tissue present in the pulmonary vein.\" [GOC:dph, PMID:17638577]","metadata":null},{"id":"60343d1c9c284cd3b17c26490d464a6b","type":"DISEASE","name":"pulmonary tuberculosis","canonical_id":"mondo:0006052","description":null,"metadata":null},{"id":"780c4d2871b343f7b2fe340478a20487","type":"GO_TERM","name":"pulmonary valve development","canonical_id":"go:GO:0003177","description":"\"The progression of the pulmonary valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"fbc0d48a3d0041ce950edbbec38433ce","type":"GO_TERM","name":"pulmonary valve formation","canonical_id":"go:GO:0003193","description":"\"The developmental process pertaining to the initial formation of the pulmonary valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"d4d068b595954324ad758402d16ff7c3","type":"GO_TERM","name":"pulmonary valve morphogenesis","canonical_id":"go:GO:0003184","description":"\"The process in which the structure of the pulmonary valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"5e13ebe8cba440feac3c62cc07945017","type":"GO_TERM","name":"pulmonary vein morphogenesis","canonical_id":"go:GO:0060577","description":"\"The process in which the anatomical structure of the pulmonary venous blood vessels are generated and organized. Pulmonary veins are blood vessels that transport blood from the lungs to the heart.\" [GOC:dph]","metadata":null},{"id":"df1463ba8c5f45e8ac07fa7cb177cf24","type":"GO_TERM","name":"pumilio-response element binding","canonical_id":"go:GO:0062104","description":"\"Binding to a region of RNA containing a Pumilio-response element element. The consensus sequence for the element is UGUAAAUA.\" [PMID:30601114]","metadata":null},{"id":"f628d93d29a24063a9f38c3bd89edbe7","type":"GO_TERM","name":"puncta adhaerentia","canonical_id":"go:GO:0044288","description":"\"A small version of the zonula adherens type junction, characterized by a symmetrical adherent point between two cells.\" [NIF_Subcellular:sao257629430]","metadata":null},{"id":"be8bd729aefa431297e28314322d4e89","type":"GO_TERM","name":"pupal chitin-based cuticle development","canonical_id":"go:GO:0008364","description":"\"Synthesis and deposition of a chitin-based pupal cuticle. At the end of the prepupal period the insect is covered by the pupal cuticle which continues to be elaborated into the pupal period. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"21f5b45039ad4c4fb2e6d638b63f6a02","type":"GO_TERM","name":"pupal development","canonical_id":"go:GO:0035209","description":"\"The process whose specific outcome is the progression of the pupa over time, from its formation to the mature structure. The pupa is a dormant life stage interposed between the larval and the adult stages in insects that undergo a complete metamorphosis.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"c466612a7a7141379593a03e1920699d","type":"GO_TERM","name":"puparial adhesion","canonical_id":"go:GO:0007594","description":"\"The adhesion of the puparia of Diptera to their substrate; normally effected by a 'glue' secreted by the larval salivary gland and expectorated at the time of pupariation.\" [GOC:ma]","metadata":null},{"id":"1a40bdeb5ad74627b43d12059a29ba35","type":"GO_TERM","name":"pupariation","canonical_id":"go:GO:0035073","description":"\"The onset of prepupal development when the larval stops crawling, everts its spiracles and the larval cuticle becomes the puparium or pupal case that surrounds the organism for the duration of metamorphosis.\" [GOC:bf, ISBN:0879694238, PMID:9409683]","metadata":null},{"id":"a273fd2a04ba4f95aaa189a95ad50f18","type":"GO_TERM","name":"pupation","canonical_id":"go:GO:0035074","description":"\"The act of becoming a pupa, a resting stage in the life cycle of organisms with complete metamorphosis. This event marks the end of the prepupal period and the beginning of the pupal period.\" [GOC:bf, ISBN:0582227089, ISBN:0879694238]","metadata":null},{"id":"c8e97a5cc4e047688479c4fcb8563fa2","type":"GO_TERM","name":"purine alkaloid biosynthetic process","canonical_id":"go:GO:0009711","description":"\"The chemical reactions and pathways resulting in the breakdown of purine alkaloids, compounds derived from purine and composed of an N-containing double ring structure.\" [GOC:ai]","metadata":null},{"id":"8dd0cc1448a5430e8e782c1b6bab1207","type":"GO_TERM","name":"purine alkaloid metabolic process","canonical_id":"go:GO:0046446","description":"\"The chemical reactions and pathways involving purine alkaloids, compounds derived from purine and composed of an N-containing double ring structure.\" [GOC:ai]","metadata":null},{"id":"ea2473afd5dd4e67a8aa250c15e7f4b1","type":"GO_TERM","name":"purine deoxyribonucleoside binding","canonical_id":"go:GO:0032547","description":"\"Binding to a purine deoxyribonucleoside, a compound consisting of a purine base linked to deoxyribose.\" [GOC:mah]","metadata":null},{"id":"50e7613a95774f8f8f94129627de6947","type":"GO_TERM","name":"purine deoxyribonucleoside biosynthetic process","canonical_id":"go:GO:0046123","description":"\"The chemical reactions and pathways resulting in the formation of any purine deoxyribonucleoside, one of a family of organic molecules consisting of a purine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"da46da2dd8fe472f887bf328183db8bf","type":"GO_TERM","name":"purine deoxyribonucleoside catabolic process","canonical_id":"go:GO:0046124","description":"\"The chemical reactions and pathways resulting in the breakdown of any one of a family of organic molecules consisting of a purine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"533f6ce316504031b1d14fd4b30aaed9","type":"GO_TERM","name":"purine deoxyribonucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009183","description":"\"The chemical reactions and pathways resulting in the formation of purine deoxyribonucleoside diphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"61c68eaaa61a4ec894de35c86b946b5f","type":"GO_TERM","name":"purine deoxyribonucleoside diphosphate catabolic process","canonical_id":"go:GO:0009184","description":"\"The chemical reactions and pathways resulting in the breakdown of purine deoxyribonucleoside diphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"43b5ca4740bd4b83a62d6b6df9996ea4","type":"GO_TERM","name":"purine deoxyribonucleoside diphosphate metabolic process","canonical_id":"go:GO:0009182","description":"\"The chemical reactions and pathways involving purine deoxyribonucleoside diphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a5d52781916043db877af7ee26c0fe63","type":"GO_TERM","name":"purine deoxyribonucleoside interconversion","canonical_id":"go:GO:0019688","description":"\"The chemical reactions and pathways by which a purine deoxyribonucleoside is synthesized from another purine deoxyribonucleoside.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"ca5d11e011f64ee9b272c6f5636f72ab","type":"GO_TERM","name":"purine deoxyribonucleoside metabolic process","canonical_id":"go:GO:0046122","description":"\"The chemical reactions and pathways involving any one of a family of organic molecules consisting of a purine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"9618260ccbd5474d956677f57f145f10","type":"GO_TERM","name":"purine deoxyribonucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009171","description":"\"The chemical reactions and pathways resulting in the formation of purine deoxyribonucleoside monophosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"247c427651f64dd0b726edacd3dcc0f2","type":"GO_TERM","name":"purine deoxyribonucleoside monophosphate catabolic process","canonical_id":"go:GO:0009172","description":"\"The chemical reactions and pathways resulting in the breakdown of purine deoxyribonucleoside monophosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"40ca963c5c964a70b62d5bc65fd6ddda","type":"GO_TERM","name":"purine deoxyribonucleoside monophosphate metabolic process","canonical_id":"go:GO:0009170","description":"\"The chemical reactions and pathways involving purine deoxyribonucleoside monophosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"2c488a84b814450e8afe32b075f1e0ce","type":"GO_TERM","name":"purine deoxyribonucleoside salvage","canonical_id":"go:GO:0043098","description":"\"Any process which produces a purine deoxyribonucleoside from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"cd1791d658e343b48006020cf0ef3fee","type":"GO_TERM","name":"purine deoxyribonucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009216","description":"\"The chemical reactions and pathways resulting in the formation of purine deoxyribonucleoside triphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5016a34cef144d31bba7c36d58ef2c4a","type":"GO_TERM","name":"purine deoxyribonucleoside triphosphate catabolic process","canonical_id":"go:GO:0009217","description":"\"The chemical reactions and pathways resulting in the breakdown of purine deoxyribonucleoside triphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f9b97631fad2410493a7b0c2ceccddfa","type":"GO_TERM","name":"purine deoxyribonucleoside triphosphate metabolic process","canonical_id":"go:GO:0009215","description":"\"The chemical reactions and pathways involving purine deoxyribonucleoside triphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"df83cded8bb44714a13ff4a692196e77","type":"GO_TERM","name":"purine deoxyribonucleotide binding","canonical_id":"go:GO:0032554","description":"\"Binding to a purine deoxyribonucleotide, any compound consisting of a purine deoxyribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety.\" [GOC:mah]","metadata":null},{"id":"d369d7f8b965478e9c68a9413affc3dc","type":"GO_TERM","name":"purine deoxyribonucleotide biosynthetic process","canonical_id":"go:GO:0009153","description":"\"The chemical reactions and pathways resulting in the formation of purine deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a purine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"aca78aa8ff0f4479bb8e98d1e666a0d0","type":"GO_TERM","name":"purine deoxyribonucleotide catabolic process","canonical_id":"go:GO:0009155","description":"\"The chemical reactions and pathways resulting in the breakdown of purine deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a purine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"69f1da69cc0f471b9f7d21aaf3cd5e76","type":"GO_TERM","name":"purine deoxyribonucleotide interconversion","canonical_id":"go:GO:0015952","description":"\"The chemical reactions and pathways by which a purine deoxyribonucleotide is synthesized from another purine deoxyribonucleotide.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"4f49739be2d5432a958f9aa3256e98c8","type":"GO_TERM","name":"purine deoxyribonucleotide metabolic process","canonical_id":"go:GO:0009151","description":"\"The chemical reactions and pathways involving purine deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a purine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"07d22fbfe99a4deb991b45a03dbc1cf0","type":"GO_TERM","name":"purine deoxyribonucleotide salvage","canonical_id":"go:GO:0106381","description":"\"Any process which produces a purine deoxyribonucleotide from derivatives of it, without de novo synthesis.\" [PMID:6605343]","metadata":null},{"id":"7c19fdf6ef114f1eb4b7b972237333da","type":"GO_TERM","name":"purine deoxyribosyltransferase activity","canonical_id":"go:GO:0044102","description":"\"Catalysis of deoxyribose exchange between purine deoxyribonucleoside as a donor and purine base as an acceptor.\" [GOC:jl, PMID:11836245]","metadata":null},{"id":"79aff10eeb624eaaa49ecf952ebb2f2c","type":"GO_TERM","name":"purine fermentation","canonical_id":"go:GO:0019653","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of purine nucleobases, yielding acetate and CO2.\" [GOC:mah]","metadata":null},{"id":"b064bf9e351a4789bc3d4eb3ee75a50a","type":"GO_TERM","name":"purine imidazole-ring cyclase activity","canonical_id":"go:GO:0050230","description":"\"Catalysis of the reaction: DNA 4,6-diamino-5-formamidopyrimidine = DNA adenine + H2O.\" [EC:4.3.2.4, MetaCyc:PURINE-IMIDAZOLE-RING-CYCLASE-RXN]","metadata":null},{"id":"98841056b9cc490faad5fe0344a462ed","type":"GO_TERM","name":"purine nucleobase binding","canonical_id":"go:GO:0002060","description":"\"Binding to a purine nucleobase, an organic nitrogenous base with a purine skeleton.\" [GOC:hjd]","metadata":null},{"id":"bdcfaabf22234e6893de0ebd4566dab4","type":"GO_TERM","name":"purine nucleobase biosynthetic process","canonical_id":"go:GO:0009113","description":"\"The chemical reactions and pathways resulting in the formation of purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, which include adenine and guanine.\" [ISBN:0198506732]","metadata":null},{"id":"dbb5215f24a14765b811eb90c4831cec","type":"GO_TERM","name":"purine nucleobase catabolic process","canonical_id":"go:GO:0006145","description":"\"The chemical reactions and pathways resulting in the breakdown of purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, which include adenine and guanine.\" [GOC:curators]","metadata":null},{"id":"da828d0f2fe04a4c8ea5b030cb2102b3","type":"GO_TERM","name":"purine nucleobase metabolic process","canonical_id":"go:GO:0006144","description":"\"The chemical reactions and pathways involving purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, which include adenine and guanine.\" [GOC:curators]","metadata":null},{"id":"979372495bb84120b4e30924b258a2db","type":"GO_TERM","name":"purine nucleobase salvage","canonical_id":"go:GO:0043096","description":"\"Any process that generates purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, from derivatives of them without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"206847ebfc2e47c79879dd54996c8a64","type":"GO_TERM","name":"purine nucleobase transmembrane transport","canonical_id":"go:GO:1904823","description":"\"The process in which a purine nucleobase is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie]","metadata":null},{"id":"25a2143ab73a40939d2ad66bb5462fa0","type":"GO_TERM","name":"purine nucleobase transmembrane transporter activity","canonical_id":"go:GO:0005345","description":"\"Enables the transfer of purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"d1f3eacc549745c5bfa4d17c0ccbfc16","type":"GO_TERM","name":"purine nucleobase transport","canonical_id":"go:GO:0006863","description":"\"The directed movement of purine bases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [ISBN:0198506732]","metadata":null},{"id":"7d8e7907c350443e90c23fdf951f8edb","type":"GO_TERM","name":"purine nucleosidase activity","canonical_id":"go:GO:0008477","description":"\"Catalysis of the reaction: a N-D-ribosylpurine + H2O = a purine + D-ribose.\" [EC:3.2.2.1]","metadata":null},{"id":"9f5d0bb8a14b4d9bb84a232cfc6985c0","type":"GO_TERM","name":"purine nucleoside binding","canonical_id":"go:GO:0001883","description":"\"Binding to a purine nucleoside, a compound consisting of a purine base linked either to ribose or deoxyribose.\" [GOC:hjd]","metadata":null},{"id":"7ad10068cb6a4aa5bc32562ec46b4d4b","type":"GO_TERM","name":"purine nucleoside biosynthetic process","canonical_id":"go:GO:0042451","description":"\"The chemical reactions and pathways resulting in the formation of any purine nucleoside, one of a family of organic molecules consisting of a purine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:curators]","metadata":null},{"id":"d193fb40d01d4af19621d4f900cecf52","type":"GO_TERM","name":"purine nucleoside bisphosphate biosynthetic process","canonical_id":"go:GO:0034033","description":"\"The chemical reactions and pathways resulting in the formation of a purine nucleoside bisphosphate, a compound consisting of a purine base linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"e0145e3e128645aa8a4f85332c3b1998","type":"GO_TERM","name":"purine nucleoside bisphosphate catabolic process","canonical_id":"go:GO:0034034","description":"\"The chemical reactions and pathways resulting in the breakdown of a purine nucleoside bisphosphate, a compound consisting of a purine base linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"0d6738657e6c41f4b3dbc6c7e10bbd0f","type":"GO_TERM","name":"purine nucleoside bisphosphate metabolic process","canonical_id":"go:GO:0034032","description":"\"The chemical reactions and pathways involving a purine nucleoside bisphosphate, a compound consisting of a purine base linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"b6da4aaae87f4c2facb39587c6e063e9","type":"GO_TERM","name":"purine nucleoside catabolic process","canonical_id":"go:GO:0006152","description":"\"The chemical reactions and pathways resulting in the breakdown of purine nucleoside, one of a family of organic molecules consisting of a purine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:curators]","metadata":null},{"id":"d8429b2a23ad457983d3b3b11a4c7c9a","type":"GO_TERM","name":"purine nucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009136","description":"\"The chemical reactions and pathways resulting in the formation of purine nucleoside diphosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c0f572cbca604ce89783a412438477ea","type":"GO_TERM","name":"purine nucleoside diphosphate catabolic process","canonical_id":"go:GO:0009137","description":"\"The chemical reactions and pathways resulting in the breakdown of purine nucleoside diphosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5dbcd0cb7aaf4929a471f99d6c9ed640","type":"GO_TERM","name":"purine nucleoside diphosphate metabolic process","canonical_id":"go:GO:0009135","description":"\"The chemical reactions and pathways involving purine nucleoside diphosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d194f7fdc8e243aaa793d8a83deb27dc","type":"GO_TERM","name":"purine nucleoside interconversion","canonical_id":"go:GO:0019686","description":"\"The chemical reactions and pathways by which a purine nucleoside is synthesized from another purine nucleoside.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"0e6157d2d87b4d7384d30ca5da0ecf32","type":"GO_TERM","name":"purine nucleoside metabolic process","canonical_id":"go:GO:0042278","description":"\"The chemical reactions and pathways involving one of a family of organic molecules consisting of a purine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:jl, ISBN:0140512713]","metadata":null},{"id":"3ee7a03b6e0344a9892bef98168914da","type":"GO_TERM","name":"purine nucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009127","description":"\"The chemical reactions and pathways resulting in the formation of purine nucleoside monophosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0a00af3708c24e44878af6a2ba983bef","type":"GO_TERM","name":"purine nucleoside monophosphate catabolic process","canonical_id":"go:GO:0009128","description":"\"The chemical reactions and pathways resulting in the breakdown of purine nucleoside monophosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f7ed3854f28244e7a0adca0af85aa4f8","type":"GO_TERM","name":"purine nucleoside monophosphate metabolic process","canonical_id":"go:GO:0009126","description":"\"The chemical reactions and pathways involving purine nucleoside monophosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"6b49e863ae1247019b82763acaaf0af0","type":"GO_TERM","name":"purine nucleoside transmembrane transport","canonical_id":"go:GO:0015860","description":"\"The process in which a purine nucleoside is transported across a membrane. A purine nucleoside is a purine base covalently bonded to a ribose or deoxyribose sugar.\" [GOC:ai, GOC:vw]","metadata":null},{"id":"ea139cca6a64462481d17e926c381ba9","type":"GO_TERM","name":"purine nucleoside transmembrane transporter activity","canonical_id":"go:GO:0015211","description":"\"Enables the transfer of a purine nucleoside, a purine base covalently bonded to a ribose or deoxyribose sugar, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"2436a9b2bda44c9bb8308a1f3f127557","type":"GO_TERM","name":"purine nucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009145","description":"\"The chemical reactions and pathways resulting in the formation of purine nucleoside triphosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"1968c798d6e24c04a0e00479847a7419","type":"GO_TERM","name":"purine nucleoside triphosphate catabolic process","canonical_id":"go:GO:0009146","description":"\"The chemical reactions and pathways resulting in the breakdown of purine nucleoside triphosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"348b193755674fea8e33927aacff4743","type":"GO_TERM","name":"purine nucleoside triphosphate metabolic process","canonical_id":"go:GO:0009144","description":"\"The chemical reactions and pathways involving purine nucleoside triphosphate, a compound consisting of a purine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"56e8eb5159c149dba3edf62ea5ed60be","type":"GO_TERM","name":"purine nucleotide binding","canonical_id":"go:GO:0017076","description":"\"Binding to a purine nucleotide, a compound consisting of a purine nucleoside esterified with (ortho)phosphate.\" [GOC:ai]","metadata":null},{"id":"3bc4663a46504e0d8f1476871f5b3132","type":"GO_TERM","name":"purine nucleotide biosynthetic process","canonical_id":"go:GO:0006164","description":"\"The chemical reactions and pathways resulting in the formation of a purine nucleotide, a compound consisting of nucleoside (a purine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"2bd21db833454cf1a31fa1f1e13e5db4","type":"GO_TERM","name":"purine nucleotide catabolic process","canonical_id":"go:GO:0006195","description":"\"The chemical reactions and pathways resulting in the breakdown of a purine nucleotide, a compound consisting of nucleoside (a purine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d99fb18b3ac0484892800b14a3ee66fb","type":"GO_TERM","name":"purine nucleotide import into lysosome","canonical_id":"go:GO:0141013","description":"\"The directed import of purine nucleotide from the cytosol, across the lysosomal membrane, into the lysosome.\" [PMID:18375752, PMID:23876310]","metadata":null},{"id":"77cb7b0fceee4610b2b6bf1e08f4f0cb","type":"GO_TERM","name":"purine nucleotide interconversion","canonical_id":"go:GO:0015950","description":"\"The chemical reactions and pathways by which a purine nucleotide is synthesized from another purine nucleotide.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"527ee17e835c4a2390ad46aaa40b0ffd","type":"GO_TERM","name":"purine nucleotide metabolic process","canonical_id":"go:GO:0006163","description":"\"The chemical reactions and pathways involving a purine nucleotide, a compound consisting of nucleoside (a purine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5251733400a24c73a3d809057fbaae32","type":"GO_TERM","name":"purine nucleotide salvage","canonical_id":"go:GO:0032261","description":"\"Any process which produces a purine nucleotide from derivatives of it, without de novo synthesis.\" [GOC:jp]","metadata":null},{"id":"684c99c8f9ae47abb0e069eca9bae00f","type":"GO_TERM","name":"purine nucleotide transmembrane transporter activity","canonical_id":"go:GO:0015216","description":"\"Enables the transfer of a purine nucleotide, any compound consisting of a purine nucleoside esterified with (ortho)phosphate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"2e034dd3279540fe9f98421e0511f31f","type":"GO_TERM","name":"purine nucleotide transport","canonical_id":"go:GO:0015865","description":"\"The directed movement of a purine nucleotide, any compound consisting of a purine nucleoside esterified with (ortho)phosphate, into, out of or within a cell.\" [GOC:ai]","metadata":null},{"id":"058a3e6321b04067a9abd6c0259f0fe9","type":"GO_TERM","name":"purine nucleotide uniporter activity","canonical_id":"go:GO:0160042","description":"\"Catalysis of the active transport of purine nucleotides across a membrane by a mechanism involving conformational change, where energy for active transport is derived from membrane potential if the solute is charged.\" [PMID:18375752, PMID:27477609]","metadata":null},{"id":"bc29d62bc1984801a54fcd3457b23aa5","type":"GO_TERM","name":"purine nucleotide-sugar transmembrane transport","canonical_id":"go:GO:0090480","description":"\"The process in which a purine nucleotide-sugar is transported across a membrane. Purine nucleotide-sugars are purine nucleotides in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [GOC:tb]","metadata":null},{"id":"0329145654b44f4298362cd231a5ca70","type":"GO_TERM","name":"purine nucleotide-sugar transmembrane transporter activity","canonical_id":"go:GO:0036080","description":"\"Enables the transfer of a purine nucleotide-sugar from one side of a membrane to the other. Purine nucleotide-sugars are purine nucleotides in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [GOC:sart, PMID:19948734]","metadata":null},{"id":"50d21020b2304339983315100f655736","type":"GO_TERM","name":"purine phosphoribosyltransferase activity","canonical_id":"go:GO:0106130","description":"\"Catalysis of the reaction: RMP + diphosphate = R + 5-phospho-alpha-D-ribose 1-diphosphate.\" [PMID:5123876]","metadata":null},{"id":"606d476604264022bb972cdf013a49d0","type":"GO_TERM","name":"purine ribonucleoside binding","canonical_id":"go:GO:0032550","description":"\"Binding to a purine ribonucleoside, a compound consisting of a purine base linked to ribose.\" [GOC:mah]","metadata":null},{"id":"3abcc9985e734ccb80ed32a74148d26d","type":"GO_TERM","name":"purine ribonucleoside biosynthetic process","canonical_id":"go:GO:0046129","description":"\"The chemical reactions and pathways resulting in the formation of any purine ribonucleoside, a nucleoside in which purine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:ai]","metadata":null},{"id":"70105b0b4e8b4f359643e4d9de585af2","type":"GO_TERM","name":"purine ribonucleoside bisphosphate biosynthetic process","canonical_id":"go:GO:0034036","description":"\"The chemical reactions and pathways resulting in the formation of a purine ribonucleoside bisphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"9eb24f6ffe254d93adc70330d32b268c","type":"GO_TERM","name":"purine ribonucleoside bisphosphate catabolic process","canonical_id":"go:GO:0034037","description":"\"The chemical reactions and pathways resulting in the breakdown of a purine ribonucleoside bisphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"4276d5d55fd245b5bf0c4847c47475ba","type":"GO_TERM","name":"purine ribonucleoside bisphosphate metabolic process","canonical_id":"go:GO:0034035","description":"\"The chemical reactions and pathways involving a purine ribonucleoside bisphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"8398d47a9a454925b760fd27d463b383","type":"GO_TERM","name":"purine ribonucleoside catabolic process","canonical_id":"go:GO:0046130","description":"\"The chemical reactions and pathways resulting in the breakdown of any purine ribonucleoside, a nucleoside in which purine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:ai]","metadata":null},{"id":"0313c3f4798b4ca4ba4dd2cb5047f707","type":"GO_TERM","name":"purine ribonucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009180","description":"\"The chemical reactions and pathways resulting in the formation of purine ribonucleoside diphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"706433a725c54a3cb4939f677f459b62","type":"GO_TERM","name":"purine ribonucleoside diphosphate catabolic process","canonical_id":"go:GO:0009181","description":"\"The chemical reactions and pathways resulting in the breakdown of purine ribonucleoside diphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"8d8762b1401f478f95511b11bbbf3e66","type":"GO_TERM","name":"purine ribonucleoside diphosphate metabolic process","canonical_id":"go:GO:0009179","description":"\"The chemical reactions and pathways involving purine ribonucleoside diphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"3db10fcb93b84d40933c9849f43c2f4c","type":"GO_TERM","name":"purine ribonucleoside metabolic process","canonical_id":"go:GO:0046128","description":"\"The chemical reactions and pathways involving any ribonucleoside, a nucleoside in which purine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:ai]","metadata":null},{"id":"12d3bdb0f657451fb5223f68e2fb9d96","type":"GO_TERM","name":"purine ribonucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009168","description":"\"The chemical reactions and pathways resulting in the formation of purine ribonucleoside monophosphate, a compound consisting of a purine base linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"a5ce3196624f4471aa9375a8821ff70d","type":"GO_TERM","name":"purine ribonucleoside monophosphate catabolic process","canonical_id":"go:GO:0009169","description":"\"The chemical reactions and pathways resulting in the breakdown of purine ribonucleoside monophosphate, a compound consisting of a purine base linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"4d3b3ad5540c480da8fd08430f76a454","type":"GO_TERM","name":"purine ribonucleoside monophosphate metabolic process","canonical_id":"go:GO:0009167","description":"\"The chemical reactions and pathways involving purine ribonucleoside monophosphate, a compound consisting of a purine base linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"829733c4832747ceb45bad4ff50a3ae6","type":"GO_TERM","name":"purine ribonucleoside salvage","canonical_id":"go:GO:0006166","description":"\"Any process which produces a purine nucleoside from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"63004669db9f4867bc552c4a256c246b","type":"GO_TERM","name":"purine ribonucleoside triphosphate binding","canonical_id":"go:GO:0035639","description":"\"Binding to a purine ribonucleoside triphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:BHF, GOC:ebc, ISBN:0198506732]","metadata":null},{"id":"36eaddb9b6474bb6921f97f139bf10a9","type":"GO_TERM","name":"purine ribonucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009206","description":"\"The chemical reactions and pathways resulting in the formation of purine ribonucleoside triphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c6a32cc00d4344a78e14b08dbb45472b","type":"GO_TERM","name":"purine ribonucleoside triphosphate catabolic process","canonical_id":"go:GO:0009207","description":"\"The chemical reactions and pathways resulting in the breakdown of purine ribonucleoside triphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"13df4bd0f17e416eb814846dca5be505","type":"GO_TERM","name":"purine ribonucleoside triphosphate metabolic process","canonical_id":"go:GO:0009205","description":"\"The chemical reactions and pathways involving purine ribonucleoside triphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"fe7040990d1842fbbe50358a14624008","type":"GO_TERM","name":"purine ribonucleotide binding","canonical_id":"go:GO:0032555","description":"\"Binding to a purine ribonucleotide, any compound consisting of a purine ribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety.\" [GOC:mah]","metadata":null},{"id":"524fdc0a62ee4fec9484b7673417f77f","type":"GO_TERM","name":"purine ribonucleotide biosynthetic process","canonical_id":"go:GO:0009152","description":"\"The chemical reactions and pathways resulting in the formation of a purine ribonucleotide, a compound consisting of ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"adc239bc563a4af5ac28abf74bb1ffaa","type":"GO_TERM","name":"purine ribonucleotide catabolic process","canonical_id":"go:GO:0009154","description":"\"The chemical reactions and pathways resulting in the breakdown of a purine ribonucleotide, a compound consisting of ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"05ec876a45a0442fb54591f0ae11e7ed","type":"GO_TERM","name":"purine ribonucleotide interconversion","canonical_id":"go:GO:0015951","description":"\"The chemical reactions and pathways by which a purine ribonucleotide is synthesized from another purine ribonucleotide.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"17a6549f4d504d8bb14440be36072a4e","type":"GO_TERM","name":"purine ribonucleotide metabolic process","canonical_id":"go:GO:0009150","description":"\"The chemical reactions and pathways involving a purine ribonucleotide, a compound consisting of ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"557573d51898421484b7261877b8251d","type":"GO_TERM","name":"purine ribonucleotide salvage","canonical_id":"go:GO:0106380","description":"\"Any process which produces a purine ribonucleotide from derivatives of it, without de novo synthesis.\" [PMID:8864750]","metadata":null},{"id":"d9eef5f0b3e74c3797bccc8e77f9a7df","type":"GO_TERM","name":"purine ribonucleotide transmembrane transporter activity","canonical_id":"go:GO:0005346","description":"\"Enables the transfer of a purine ribonucleotide, any compound consisting of a purine ribonucleoside (a purine organic base attached to a ribose sugar) esterified with (ortho)phosphate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"cd68aef7834749a38068478b7e3cc80e","type":"GO_TERM","name":"purine ribonucleotide transport","canonical_id":"go:GO:0015868","description":"\"The directed movement of a purine ribonucleotide, any compound consisting of a purine ribonucleoside (a purine organic base attached to a ribose sugar) esterified with (ortho)phosphate, into, out of or within a cell.\" [GOC:ai]","metadata":null},{"id":"08f760a8597249d28e319d07ef535ab5","type":"GO_TERM","name":"purine-containing compound biosynthetic process","canonical_id":"go:GO:0072522","description":"\"The chemical reactions and pathways resulting in the formation of a purine-containing compound, i.e. any compound that contains purine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"87fe020913a648b399aa934c536504c1","type":"GO_TERM","name":"purine-containing compound catabolic process","canonical_id":"go:GO:0072523","description":"\"The chemical reactions and pathways resulting in the breakdown of a purine-containing compound, i.e. any compound that contains purine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"473e8c90880c4f439d63484725e7a9e1","type":"GO_TERM","name":"purine-containing compound metabolic process","canonical_id":"go:GO:0072521","description":"\"The chemical reactions and pathways involving a purine-containing compound, i.e. any compound that contains purine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"b59a8117417a4308880dad1199300b4a","type":"GO_TERM","name":"purine-containing compound salvage","canonical_id":"go:GO:0043101","description":"\"Any process that generates a purine-containing compound, any nucleobase, nucleoside, nucleotide or nucleic acid that contains a purine base, from derivatives of them without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"9254158246e04ee5bf0f8fbf52ddb184","type":"GO_TERM","name":"purine-containing compound transmembrane transport","canonical_id":"go:GO:0072530","description":"\"The process in which a purine-containing compound is transported across a membrane. A purine-containing compound is any compound that contains purine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"d0c1163f32b4412b9d30067f4a207192","type":"GO_TERM","name":"purine-nucleoside phosphorylase activity","canonical_id":"go:GO:0004731","description":"\"Catalysis of the reaction: purine nucleoside + phosphate = purine + alpha-D-ribose 1-phosphate.\" [EC:2.4.2.1]","metadata":null},{"id":"b1a57865660f426ea653200e196d1784","type":"GO_TERM","name":"purine-rich negative regulatory element binding","canonical_id":"go:GO:0032422","description":"\"Binding to a 30-bp purine-rich negative regulatory element; the best characterized such element is found in the first intronic region of the rat cardiac alpha-myosin heavy chain gene, and contains two palindromic high-affinity Ets-binding sites (CTTCCCTGGAAG). The presence of this element restricts expression of the gene containing it to cardiac myocytes.\" [GOC:mah, PMID:9819411]","metadata":null},{"id":"6bff483f79c14e258b03404d068071b2","type":"GO_TERM","name":"purine-specific mismatch base pair DNA N-glycosylase activity","canonical_id":"go:GO:0000701","description":"\"Catalysis of the removal of purines present in mismatches, especially opposite oxidized purines, by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic (AP) site.\" [GOC:elh, PMID:9224623]","metadata":null},{"id":"644f0e634c5245848fe89a4b00975176","type":"GO_TERM","name":"purine-specific nucleoside:sodium symporter activity","canonical_id":"go:GO:0015390","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: purine(out) + Na+(out) = nucleoside(in) + Na+(in).\" [TC:2.A.41.2.1]","metadata":null},{"id":"a82398193ec04dd58c325223ecce0e7e","type":"GO_TERM","name":"purinergic nucleotide receptor activity","canonical_id":"go:GO:0001614","description":"\"Combining with a purine nucleotide and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"b6dfe37ce2e1469aa6b6b5e8e801142b","type":"GO_TERM","name":"purinergic nucleotide receptor signaling pathway","canonical_id":"go:GO:0035590","description":"\"The series of molecular signals initiated by an extracellular purine nucleotide binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, PMID:9755289]","metadata":null},{"id":"583f914f4faf446796a84fdc2616e13c","type":"GO_TERM","name":"puromycin biosynthetic process","canonical_id":"go:GO:0043638","description":"\"The chemical reactions and pathways resulting in the formation of puromycin, an aminonucleoside antibiotic that is a potent inhibitor of translation; produced by the bacterium Streptomyces alboniger.\" [GOC:jl, Wikipedia:Puromycin]","metadata":null},{"id":"b2337714b0e740c2810da1caea6dd23c","type":"DISEASE","name":"pustular psoriasis","canonical_id":"mondo:0022205","description":null,"metadata":null},{"id":"898e40f18ab24f8c8b495d8fe2ae19f6","type":"GO_TERM","name":"putamen development","canonical_id":"go:GO:0021758","description":"\"The progression of the putamen over time from its initial formation until its mature state. The putamen is the lens-shaped basal ganglion involved with control of voluntary movement in the brain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"6447940ddf10444f8ef5f94cc796027f","type":"GO_TERM","name":"putrescine N-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047174","description":"\"Catalysis of the reaction: caffeoyl-CoA + putrescine = N-caffeoylputrescine + CoA + H+.\" [EC:2.3.1.138, RHEA:12436]","metadata":null},{"id":"1010d9cc15c84f94af4702665e76deb3","type":"GO_TERM","name":"putrescine N-methyltransferase activity","canonical_id":"go:GO:0030750","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + putrescine = N-methylputrescine + S-adenosyl-L-homocysteine + H+.\" [EC:2.1.1.53, RHEA:15037]","metadata":null},{"id":"76484706c14140b4a15b26c6f79d6132","type":"GO_TERM","name":"putrescine binding","canonical_id":"go:GO:0019810","description":"\"Binding to putrescine, 1,4-diaminobutane, the polyamine formed by decarboxylation of ornithine and the metabolic precursor of spermidine and spermine.\" [GOC:ai]","metadata":null},{"id":"fdcb532123f64e3481c1c16d5806a45e","type":"GO_TERM","name":"putrescine biosynthetic process","canonical_id":"go:GO:0009446","description":"\"The chemical reactions and pathways resulting in the formation of putrescine, 1,4-diaminobutane; putrescine can be synthesized from arginine or ornithine and is the metabolic precursor of spermidine and spermine.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"66ccadddce4e4b008b2f3737f56d8eab","type":"GO_TERM","name":"putrescine carbamoyltransferase activity","canonical_id":"go:GO:0050231","description":"\"Catalysis of the reaction: carbamoyl phosphate + putrescine = N-carbamoylputrescine + H+ + phosphate.\" [EC:2.1.3.6, RHEA:21936]","metadata":null},{"id":"98e6cef03aab4101bcc12ef7c35b1de4","type":"GO_TERM","name":"putrescine catabolic process","canonical_id":"go:GO:0009447","description":"\"The chemical reactions and pathways resulting in the breakdown of putrescine, 1,4-diaminobutane; putrescine is the metabolic precursor of spermidine and spermine.\" [GOC:ai]","metadata":null},{"id":"6547aa8bb49c4eeabf4d789a27225ca3","type":"GO_TERM","name":"putrescine metabolic process","canonical_id":"go:GO:0009445","description":"\"The chemical reactions and pathways involving putrescine, 1,4-diaminobutane; putrescine can be formed by decarboxylation of ornithine and is the metabolic precursor of spermidine and spermine.\" [GOC:ai]","metadata":null},{"id":"039ae5da0b7f4ffeaa6a1f00a38b2808","type":"GO_TERM","name":"putrescine oxidase activity","canonical_id":"go:GO:0050232","description":"\"Catalysis of the reaction: H2O + O2 + putrescine = 4-aminobutanal + H2O2 + NH4+.\" [RHEA:18273]","metadata":null},{"id":"5e69faa6f44149e2924a8b0901ba0c26","type":"GO_TERM","name":"putrescine transmembrane transporter activity","canonical_id":"go:GO:0015489","description":"\"Enables the transfer of putrescine from one side of a membrane to the other. Putrescine is 1,4-diaminobutane, the polyamine formed by decarboxylation of ornithine and the metabolic precursor of spermidine and spermine.\" [GOC:ai]","metadata":null},{"id":"73606226c6354f55aada50d24f2f6f86","type":"GO_TERM","name":"putrescine transport","canonical_id":"go:GO:0015847","description":"\"The directed movement of putrescine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Putrescine is 1,4-diaminobutane, the polyamine formed by decarboxylation of ornithine and the metabolic precursor of spermidine and spermine.\" [GOC:krc, ISBN:0198506732]","metadata":null},{"id":"07a58037de9e4da2ab7220f6c11b7559","type":"GO_TERM","name":"putrescine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0033094","description":"\"Catalysis of the reaction: putrescine + 2-oxoglutarate = L-glutamate + 1-pyrroline + H2O. The enzymatic part of the reaction produces 4-aminobutanal that spontaneously cyclizes to form 1-pyrroline.\" [EC:2.6.1.82, RHEA:12268]","metadata":null},{"id":"493b9b0058e341b9baa7fa3f5c47ac36","type":"GO_TERM","name":"putrescine:ornithine antiporter activity","canonical_id":"go:GO:0015496","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: putrescine(out) + ornithine(in) = putrescine(in) + ornithine(out).\" [TC:2.A.3.2.1]","metadata":null},{"id":"1afa7412fa194201bbf17815c0e94f95","type":"GO_TERM","name":"pyloric antrum smooth muscle contraction","canonical_id":"go:GO:0120065","description":"\"A process in which force is generated within gastric smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the widest part of the pylorus that is continuous with the body of the stomach.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"4b063c2bc338401db255e72fc948a21c","type":"GO_TERM","name":"pyloric canal smooth muscle contraction","canonical_id":"go:GO:0120066","description":"\"A process in which force is generated within gastric smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the distal part of the pylorus between the pyloric antrum and the pyloric sphincter.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"ba017cf67cda48ee8c4bdd878bba0399","type":"GO_TERM","name":"pyloric sphincter smooth muscle contraction","canonical_id":"go:GO:0120067","description":"\"A process in which force is generated within gastric smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the narrowest part of the pylorus that separates the stomach from the duodenum.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"13dfb791c61b49d5b46a51a40124fa4d","type":"GO_TERM","name":"pyochelin biosynthetic process","canonical_id":"go:GO:0042864","description":"\"The chemical reactions and pathways resulting in the formation of the siderochrome pyochelin (2-(2-o-hydroxyphenyl-2-thiazolin-4-yl)-3-methylthiazolidine-4-carboxylic acid).\" [GOC:jl, PMID:6794030]","metadata":null},{"id":"9438b7d98b53479a80db276ed93a3bd5","type":"GO_TERM","name":"pyochelin catabolic process","canonical_id":"go:GO:0042865","description":"\"The chemical reactions and pathways resulting in the breakdown of the siderochrome pyochelin (2-(2-o-hydroxyphenyl-2-thiazolin-4-yl)-3-methylthiazolidine-4-carboxylic acid).\" [GOC:jl, PMID:6794030]","metadata":null},{"id":"27e6c06a35e04815b087431170dea4ee","type":"GO_TERM","name":"pyocyanine biosynthetic process","canonical_id":"go:GO:0106220","description":"\"The chemical reactions and pathways resulting in the formation of pyrocyanin, an iminium betaine that is 5-methylphenazin-5-ium which is substituted at position 1 by an oxidanidyl group.\" [PMID:28715477]","metadata":null},{"id":"b4187c09f5be47bfae2fd09ee9931d99","type":"GO_TERM","name":"pyoverdine biosynthetic process","canonical_id":"go:GO:0002049","description":"\"The chemical reactions and pathways resulting in the formation of the siderochrome pyoverdine.\" [PMID:15317763]","metadata":null},{"id":"142f9b0efb9b494480530d818beadd91","type":"GO_TERM","name":"pyoverdine catabolic process","canonical_id":"go:GO:0002050","description":"\"The chemical reactions and pathways resulting in the breakdown of the siderochrome pyoverdine.\" [PMID:15317763]","metadata":null},{"id":"92f1b4fba2824803b42c58fe9ac52ddf","type":"GO_TERM","name":"pyramid development","canonical_id":"go:GO:0072056","description":"\"The process whose specific outcome is the progression of the kidney pyramids over time, from its formation to the mature structure. Kidney pyramids are the conical masses that constitute the renal medulla in a multi-lobed mammalian kidney; they contain the loops of Henle and the medullary collecting ducts.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"441e6477ead84e3a914d38647f603449","type":"GO_TERM","name":"pyramidal neuron development","canonical_id":"go:GO:0021860","description":"\"The progression of a pyramidal neuron from its initial formation to its mature state.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6297e606e6704e389dc2ae3ab89be4a6","type":"GO_TERM","name":"pyramidal neuron differentiation","canonical_id":"go:GO:0021859","description":"\"The process in which a neuroblast or one of its progeny commits to a pyramidal neuron fate, migrates from the ventricular zone to the appropriate layer in the cortex and develops into a mature neuron.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"563936485a154e83a530d451e142ecf9","type":"GO_TERM","name":"pyramidal neuron migration to cerebral cortex","canonical_id":"go:GO:0021852","description":"\"The migration of a pyramidal neuron precursor from the ventricular zone to the correct layer of the cerebral cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695, PMID:22192824]","metadata":null},{"id":"9ef8159ce3bc442a9ae623e0ebb7d1d5","type":"GO_TERM","name":"pyranose dehydrogenase (acceptor) activity","canonical_id":"go:GO:0033718","description":"\"Catalysis of the reactions: pyranose + acceptor = 2-dehydropyranose (or 3-dehydropyranose or 2,3-didehydropyranose) + reduced acceptor, and a pyranoside + acceptor = a 3-dehydropyranoside (or 3,4-didehydropyranoside) + reduced acceptor.\" [EC:1.1.99.29]","metadata":null},{"id":"2f1b50e49adc49a48ab16cf06ee47056","type":"GO_TERM","name":"pyranose oxidase activity","canonical_id":"go:GO:0050233","description":"\"Catalysis of the reaction: D-glucose + O2 = 2-dehydro-D-glucose + H2O2.\" [EC:1.1.3.10, RHEA:10552]","metadata":null},{"id":"5801e2126e91493ab7d0adf11f35fc5a","type":"GO_TERM","name":"pyrazolylalanine synthase activity","canonical_id":"go:GO:0050234","description":"\"Catalysis of the reaction: L-serine + pyrazole = 3-(pyrazol-1-yl)-L-alanine + H2O.\" [EC:4.2.1.50, RHEA:24512]","metadata":null},{"id":"c1a92596373042a0b7b4ade9a0ab282b","type":"GO_TERM","name":"pyrenoid","canonical_id":"go:GO:1990732","description":"\"A non-membrane-bounded organelle found within the chloroplasts of algae and hornworts; responsible for carbon dioxide fixation.\" [GOC:cjm, GOC:pr, PMID:23345319, Wikipedia:Pyrenoid]","metadata":null},{"id":"89c59a1ba9904db09718c900cba8b660","type":"GO_TERM","name":"pyrenoid tubule","canonical_id":"go:GO:0160223","description":"\"A specialized membranous structure that extends from the photosynthetic thylakoid membrane into and transverses the matrix of a pyrenoid.\" [PMID:32428480]","metadata":null},{"id":"2f14dc26287740d2ad805ddb300d18b4","type":"GO_TERM","name":"pyridine N-methyltransferase activity","canonical_id":"go:GO:0030760","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + pyridine = N-methylpyridinium + S-adenosyl-L-homocysteine.\" [EC:2.1.1.87, RHEA:16893]","metadata":null},{"id":"0c03cb0170e24cf8bf134a11ae87d765","type":"GO_TERM","name":"pyridine biosynthetic process","canonical_id":"go:GO:0046220","description":"\"The chemical reactions and pathways resulting in the formation of pyridine, a nitrogenous base (C5H5N) obtained from the distillation of bone oil or coal tar, and by the decomposition of certain alkaloids, as a colorless liquid with a peculiar pungent odor.\" [GOC:ai]","metadata":null},{"id":"c3b022e0703846548640f891805f0827","type":"GO_TERM","name":"pyridine catabolic process","canonical_id":"go:GO:0046221","description":"\"The chemical reactions and pathways resulting in the breakdown of pyridine, a nitrogenous base (C5H5N) obtained from the distillation of bone oil or coal tar, and by the decomposition of certain alkaloids, as a colorless liquid with a peculiar pungent odor.\" [GOC:ai]","metadata":null},{"id":"8d61b2cdba304d758b60641628e9244b","type":"GO_TERM","name":"pyridine nucleoside biosynthetic process","canonical_id":"go:GO:0071589","description":"\"The chemical reactions and pathways resulting in the formation of any pyridine nucleoside, one of a family of organic molecules consisting of a pyridine base covalently bonded to a sugar, usually ribose.\" [GOC:mah]","metadata":null},{"id":"09bd561aed9d49cda6ba0d2fbda4ecd2","type":"GO_TERM","name":"pyridine nucleoside catabolic process","canonical_id":"go:GO:0070638","description":"\"The chemical reactions and pathways resulting in the breakdown of any pyridine nucleoside, a nucleoside in which a pyridine base covalently bonded to a sugar, usually ribose.\" [GOC:mah]","metadata":null},{"id":"93881bdb76ec4cd4bb6b3f76a7709da0","type":"GO_TERM","name":"pyridine nucleoside metabolic process","canonical_id":"go:GO:0070637","description":"\"The chemical reactions and pathways involving any pyridine nucleoside, a nucleoside in which a pyridine base covalently bonded to a sugar, usually ribose.\" [GOC:mah]","metadata":null},{"id":"20e56db1e9144c9ab40802506a79def6","type":"GO_TERM","name":"pyridine nucleotide biosynthetic process","canonical_id":"go:GO:0019363","description":"\"The chemical reactions and pathways resulting in the formation of a pyridine nucleotide, a nucleotide characterized by a pyridine derivative as a nitrogen base.\" [GOC:jl, GOC:pde, GOC:vw]","metadata":null},{"id":"c6165bf0c1564c509f8b779112d56367","type":"GO_TERM","name":"pyridine nucleotide catabolic process","canonical_id":"go:GO:0019364","description":"\"The chemical reactions and pathways resulting in the breakdown of a pyridine nucleotide, a nucleotide characterized by a pyridine derivative as a nitrogen base.\" [GOC:jl, GOC:pde, GOC:vw]","metadata":null},{"id":"fc284c8227dd413fac203703bd456404","type":"GO_TERM","name":"pyridine nucleotide salvage","canonical_id":"go:GO:0019365","description":"\"Any process that generates a pyridine nucleotide, a nucleotide characterized by a pyridine derivative as a nitrogen base, from derivatives of them without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"058456c108d14276b2e1d86dcfd15850","type":"GO_TERM","name":"pyridine-containing compound biosynthetic process","canonical_id":"go:GO:0072525","description":"\"The chemical reactions and pathways resulting in the formation of a pyridine-containing compound, i.e. any compound that contains pyridine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"cd5b9d947a994b49a0a335d8e2cfd197","type":"GO_TERM","name":"pyridine-containing compound catabolic process","canonical_id":"go:GO:0072526","description":"\"The chemical reactions and pathways resulting in the breakdown of a pyridine-containing compound, i.e. any compound that contains pyridine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"33ac7c640ff140ee918d12ebf282b9ba","type":"GO_TERM","name":"pyridine-containing compound metabolic process","canonical_id":"go:GO:0072524","description":"\"The chemical reactions and pathways involving a pyridine-containing compound, i.e. any compound that contains pyridine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"41c96843af0845e28a71c0204d26350b","type":"GO_TERM","name":"pyridinol guanylyltransferase activity","canonical_id":"go:GO:0160298","description":"\"Catalysis of the reaction: 6-carboxymethyl-3,5-dimethyl-4-hydroxypyridin-2-ol + GTP + H+ = guanylylpyridinol + diphosphate.\" [PMID:24249552, RHEA:85479]","metadata":null},{"id":"1a212e796e264eb2a4291f1b62e468ed","type":"DRUG","name":"pyridostigmine","canonical_id":"mesh:D011729","description":null,"metadata":null},{"id":"21b227b9545e4563b51cac13becd2b01","type":"GO_TERM","name":"pyridoxal 4-dehydrogenase activity","canonical_id":"go:GO:0050235","description":"\"Catalysis of the reaction: NAD+ + pyridoxal = 4-pyridoxolactone + H+ + NADH.\" [EC:1.1.1.107, RHEA:21336]","metadata":null},{"id":"aac7a136dec04a56a2e212251435163b","type":"GO_TERM","name":"pyridoxal 5'-phosphate biosynthetic process","canonical_id":"go:GO:0042823","description":"\"The chemical reactions and pathways resulting in the formation of pyridoxal phosphate, pyridoxal phosphorylated at the hydroxymethyl group of C-5, the active form of vitamin B6.\" [GOC:jl]","metadata":null},{"id":"b618006cb9b64839bd4c6895666da030","type":"GO_TERM","name":"pyridoxal 5'-phosphate catabolic process","canonical_id":"go:GO:0032361","description":"\"The chemical reactions and pathways resulting in the breakdown of pyridoxal phosphate, pyridoxal phosphorylated at the hydroxymethyl group of C-5, the active form of vitamin B6.\" [GOC:mah]","metadata":null},{"id":"0644fec87b8349b0a8e46ffd103689aa","type":"GO_TERM","name":"pyridoxal 5'-phosphate metabolic process","canonical_id":"go:GO:0042822","description":"\"The chemical reactions and pathways involving pyridoxal phosphate, pyridoxal phosphorylated at the hydroxymethyl group of C-5, the active form of vitamin B6.\" [GOC:jl]","metadata":null},{"id":"1a3325e5bab8463ea76250467fb48f6d","type":"GO_TERM","name":"pyridoxal 5'-phosphate salvage","canonical_id":"go:GO:0009443","description":"\"Any process that generates pyridoxal 5'-phosphate, the active form of vitamin B6, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"44a23639d3ac43b5b2e8333cd351b31c","type":"GO_TERM","name":"pyridoxal 5'-phosphate synthase (glutamine hydrolysing) activity","canonical_id":"go:GO:0036381","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + D-glyceraldehyde 3-phosphate + L-glutamine = pyridoxal 5'-phosphate + L-glutamate + 3 H2O + phosphate. The reaction occurs in two steps: L-glutamine + H2O = L-glutamate + NH4+, and subsequently D-ribose 5-phosphate + D-glyceraldehyde 3-phosphate + NH4+ = pyridoxal 5'-phosphate + 4 H2O + phosphate.\" [EC:4.3.3.6, GOC:rs]","metadata":null},{"id":"02a841291c8f48ea98973e5293cf7742","type":"GO_TERM","name":"pyridoxal binding","canonical_id":"go:GO:0070280","description":"\"Binding to pyridoxal, 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carbaldehyde, a form of vitamin B6.\" [CHEBI:17310, GOC:mah]","metadata":null},{"id":"dcb47693dd844605826b76a58ce4e7a4","type":"GO_TERM","name":"pyridoxal biosynthetic process","canonical_id":"go:GO:0042821","description":"\"The chemical reactions and pathways resulting in the formation of 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde, one of the vitamin B6 compounds.\" [GOC:jl, PMID:21767669]","metadata":null},{"id":"cb66274385d84eab810de0ef3eba5a1c","type":"GO_TERM","name":"pyridoxal import across plasma membrane","canonical_id":"go:GO:0140204","description":"\"The directed movement of pyridoxal from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:vw]","metadata":null},{"id":"f99632c32e044568a3bf229d3390ef49","type":"GO_TERM","name":"pyridoxal kinase activity","canonical_id":"go:GO:0008478","description":"\"Catalysis of the reaction: ATP + pyridoxal = ADP + pyridoxal 5'-phosphate.\" [EC:2.7.1.35]","metadata":null},{"id":"62123c1013d04669a80a3e974765b6dd","type":"GO_TERM","name":"pyridoxal metabolic process","canonical_id":"go:GO:0042817","description":"\"The chemical reactions and pathways involving 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde, one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:jl, PMID:21767669]","metadata":null},{"id":"fd3c6c919c4940d8b7341fd1842fe2f9","type":"GO_TERM","name":"pyridoxal oxidase activity","canonical_id":"go:GO:0004732","description":"\"Catalysis of the reaction:  pyridoxal + H2O + O2 = 4-pyridoxate + H+ + H2O2.\" [RHEA:23724]","metadata":null},{"id":"2e5effcf46254bfabca7c0421b78feac","type":"GO_TERM","name":"pyridoxal phosphatase activity","canonical_id":"go:GO:0033883","description":"\"Catalysis of the reaction: pyridoxal 5'-phosphate + H2O = pyridoxal + phosphate.\" [EC:3.1.3.74]","metadata":null},{"id":"89ada64299464c8aa24af28899503b4f","type":"GO_TERM","name":"pyridoxal phosphate binding","canonical_id":"go:GO:0030170","description":"\"Binding to pyridoxal 5' phosphate, 3-hydroxy-5-(hydroxymethyl)-2-methyl4-pyridine carboxaldehyde 5' phosphate, the biologically active form of vitamin B6.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"e0f67b66c2e84aba8ce0cce185790368","type":"GO_TERM","name":"pyridoxal phosphate transmembrane transporter activity","canonical_id":"go:GO:0031926","description":"\"Enables the transfer of pyridoxal phosphate from one side of a membrane to the other. Pyridoxal phosphate is pyridoxal phosphorylated at the hydroxymethyl group of C-5, and is the active form of vitamin B6.\" [GOC:mah]","metadata":null},{"id":"bd74de952e74426f881858a3cea53246","type":"GO_TERM","name":"pyridoxal phosphate transport","canonical_id":"go:GO:0031921","description":"\"The directed movement of pyridoxal phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore; pyridoxal phosphate is pyridoxal phosphorylated at the hydroxymethyl group of C-5, and is the active form of vitamin B6.\" [GOC:mah]","metadata":null},{"id":"e7e99ff474984aa8bdc275635e609973","type":"GO_TERM","name":"pyridoxal transmembrane transport","canonical_id":"go:GO:1903090","description":"\"The process in which pyridoxal is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:15701794]","metadata":null},{"id":"c271d3a004b84ac69e69855164722193","type":"GO_TERM","name":"pyridoxal transmembrane transporter activity","canonical_id":"go:GO:0031925","description":"\"Enables the transfer of pyridoxal from one side of a membrane to the other. Pyridoxal, 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde, is one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"451824f7f8f145879383f0f518f56a5c","type":"GO_TERM","name":"pyridoxal transport","canonical_id":"go:GO:0031920","description":"\"The directed movement of pyridoxal into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Pyridoxal, 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde, is one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"20826fb95d2d45ccbc69bf77e7132a17","type":"GO_TERM","name":"pyridoxamine binding","canonical_id":"go:GO:0070281","description":"\"Binding to pyridoxamine, 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, a form of vitamin B6.\" [CHEBI:16410, GOC:mah]","metadata":null},{"id":"891e944613de4978934e1c273a3ac413","type":"GO_TERM","name":"pyridoxamine metabolic process","canonical_id":"go:GO:0042818","description":"\"The chemical reactions and pathways involving 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:jl]","metadata":null},{"id":"a14f5221f894410690e0f7fdad8f9571","type":"GO_TERM","name":"pyridoxamine phosphate oxidase activity","canonical_id":"go:GO:0004733","description":"\"Catalysis of the reaction: pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + NH4+ + H2O2. This activity can also oxidize pyridoxine 5'-phosphate to pyridoxal 5'-phosphate + H2O2.\" [EC:1.4.3.5, PMID:11786019]","metadata":null},{"id":"81e11f8b18134717a249a06695df7c9c","type":"GO_TERM","name":"pyridoxamine transmembrane transport","canonical_id":"go:GO:1903091","description":"\"The process in which pyridoxamine is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:15701794]","metadata":null},{"id":"c465e3d4647843d08587eb3916665d0e","type":"GO_TERM","name":"pyridoxamine transmembrane transporter activity","canonical_id":"go:GO:0031927","description":"\"Enables the transfer of pyridoxamine from one side of a membrane to the other. Pyridoxamine, 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, is one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"105ef90116cf4def98b6c0beef42c14a","type":"GO_TERM","name":"pyridoxamine transport","canonical_id":"go:GO:0031922","description":"\"The directed movement of pyridoxamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Pyridoxamine, 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol, is one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"a4037e8eb3354b978beea854a600a7f8","type":"GO_TERM","name":"pyridoxamine-phosphate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0019163","description":"\"Catalysis of the reaction: pyridoxamine 5'-phosphate + 2-oxoglutarate = pyridoxal 5'-phosphate + D-glutamate.\" [RHEA:15877]","metadata":null},{"id":"adef1c25939c43dcaa1442d9a2dd5f2d","type":"GO_TERM","name":"pyridoxamine:oxaloacetate transaminase activity","canonical_id":"go:GO:0019162","description":"\"Catalysis of the reaction: oxaloacetate + pyridoxamine = L-aspartate + pyridoxal.\" [RHEA:10844]","metadata":null},{"id":"395d9f9446534da59cce957a104245c1","type":"GO_TERM","name":"pyridoxamine:pyruvate transaminase activity","canonical_id":"go:GO:0047300","description":"\"Catalysis of the reaction: pyridoxamine + pyruvate = L-alanine + pyridoxal.\" [RHEA:12841]","metadata":null},{"id":"cc539279857f4d48b5236c227ecf1265","type":"DRUG","name":"pyridoxine","canonical_id":"mesh:D011736","description":null,"metadata":null},{"id":"4f9e073669bf4bf9a714b49e5583a449","type":"GO_TERM","name":"pyridoxine 4-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050236","description":"\"Catalysis of the reaction: NADP+ + pyridoxine = H+ + NADPH + pyridoxal.\" [RHEA:16129]","metadata":null},{"id":"aaab3ad24cc14964a57252328a1a3258","type":"GO_TERM","name":"pyridoxine 4-oxidase activity","canonical_id":"go:GO:0050237","description":"\"Catalysis of the reaction: pyridoxine + O2 = pyridoxal + H2O2.\" [EC:1.1.3.12, MetaCyc:PYRIDOXINE-4-OXIDASE-RXN]","metadata":null},{"id":"b2fe98185a85477c9bb36c804639f16a","type":"GO_TERM","name":"pyridoxine 5'-O-beta-D-glucosyltransferase activity","canonical_id":"go:GO:0047231","description":"\"Catalysis of the reaction: pyridoxine + UDP-D-glucose = 5'-O-beta-D-glucosylpyridoxine + H+ + UDP.\" [EC:2.4.1.160, RHEA:20177]","metadata":null},{"id":"de539ccd53fb4abfbb8e9e0aad883de1","type":"GO_TERM","name":"pyridoxine 5'-phosphate synthase activity","canonical_id":"go:GO:0033856","description":"\"Catalysis of the reaction: 1-deoxy-D-xylulose 5-phosphate + 3-amino-2-oxopropyl phosphate = 2 H2O + H+ + phosphate + pyridoxine 5'-phosphate.\" [RHEA:15265]","metadata":null},{"id":"fdb34a88d238415c88da45ec80835e6d","type":"GO_TERM","name":"pyridoxine 5-dehydrogenase activity","canonical_id":"go:GO:0050238","description":"\"Catalysis of the reaction: pyridoxine + acceptor = isopyridoxal + reduced acceptor.\" [EC:1.1.99.9, MetaCyc:PYRIDOXINE-5-DEHYDROGENASE-RXN]","metadata":null},{"id":"15bac449cf0d4fa599b79d292483bbf4","type":"GO_TERM","name":"pyridoxine binding","canonical_id":"go:GO:0070282","description":"\"Binding to pyridoxine, 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol, a form of vitamin B6.\" [CHEBI:16709, GOC:mah]","metadata":null},{"id":"26b2432830c4467abc9f6c7844858cd4","type":"GO_TERM","name":"pyridoxine biosynthetic process","canonical_id":"go:GO:0008615","description":"\"The chemical reactions and pathways resulting in the formation of pyridoxine, 2-methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine, one of the vitamin B6 compounds.\" [GOC:ai]","metadata":null},{"id":"8e8b9e635b30466b8320beba030dda5d","type":"GO_TERM","name":"pyridoxine import across plasma membrane","canonical_id":"go:GO:1903075","description":"\"The directed movement of pyridoxine from outside of a cell, across the plasma membrane and into the cytosol.\" [GO_REF:0000075, GOC:TermGenie, PMID:15701794]","metadata":null},{"id":"65ad063c61aa420784c7691bd726fdcc","type":"GO_TERM","name":"pyridoxine metabolic process","canonical_id":"go:GO:0008614","description":"\"The chemical reactions and pathways involving pyridoxine, 2-methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine, one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:curators]","metadata":null},{"id":"b7e9c3e1f59144e8b467f2d553b0326e","type":"GO_TERM","name":"pyridoxine transmembrane transport","canonical_id":"go:GO:1903092","description":"\"The process in which pyridoxine is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:15701794]","metadata":null},{"id":"64a9b680d6bd41b6bd5efc86afa8b102","type":"GO_TERM","name":"pyridoxine transmembrane transporter activity","canonical_id":"go:GO:0031928","description":"\"Enables the transfer of pyridoxine from one side of a membrane to the other. Pyridoxine, 2-methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine, is one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"35abd58884a84d05b90d97e5c37482a0","type":"GO_TERM","name":"pyridoxine transport","canonical_id":"go:GO:0031923","description":"\"The directed movement of pyridoxine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Pyridoxine, 2-methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine, is one of the vitamin B6 compounds. Pyridoxal, pyridoxamine and pyridoxine are collectively known as vitamin B6, and are efficiently converted to the biologically active form of vitamin B6, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"43d1a13d38da4c0eb50ec4fe3067bc0c","type":"DRUG","name":"pyrimethamine","canonical_id":"mesh:D011739","description":null,"metadata":null},{"id":"df29de6f989549659338b516e0a8a299","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside binding","canonical_id":"go:GO:0032548","description":"\"Binding to a pyrimidine deoxyribonucleoside, a compound consisting of a pyrimidine base linked to deoxyribose.\" [GOC:mah]","metadata":null},{"id":"4826898939db4a238d9d0b89d7c9bbc9","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside biosynthetic process","canonical_id":"go:GO:0046126","description":"\"The chemical reactions and pathways resulting in the formation of any one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"063be2fb76da43dea64ce778ce6b391a","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside catabolic process","canonical_id":"go:GO:0046127","description":"\"The chemical reactions and pathways resulting in the breakdown of any one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"3c1c8628ff994e0ca25abd6b2dc43441","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009197","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine deoxyribonucleoside diphosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"9481a411031c4e96a473f5577f0b28f3","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside diphosphate catabolic process","canonical_id":"go:GO:0009198","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine deoxynucleoside diphosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"352aefec0e3948b9ab019ac372a3ff63","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside diphosphate metabolic process","canonical_id":"go:GO:0009196","description":"\"The chemical reactions and pathways involving pyrimidine deoxynucleoside diphosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"17fb9c783eb749a998707d5b55215405","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside interconversion","canonical_id":"go:GO:0019690","description":"\"The chemical reactions and pathways by which a pyrimidine deoxyribonucleoside is synthesized from another deoxyribopyrimidine nucleoside.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"dde325bf401240748e8ab9bee8a980e6","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside metabolic process","canonical_id":"go:GO:0046125","description":"\"The chemical reactions and pathways involving any one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"0edf77b4517f4d9a8f4082427a2d8e52","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009177","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine deoxynucleoside monophosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"1d5dd79aa23d4bf49e220a52ff7601c3","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside monophosphate catabolic process","canonical_id":"go:GO:0009178","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine deoxynucleoside monophosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"6116c817a1f94e919a95759a513041cd","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside monophosphate metabolic process","canonical_id":"go:GO:0009176","description":"\"The chemical reactions and pathways involving pyrimidine deoxynucleoside monophosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"33dbe33bb8dd4ed5b5b22ed4de58bd26","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside salvage","canonical_id":"go:GO:0043099","description":"\"Any process that generates a pyrimidine deoxyribonucleoside from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"2019350215b44005aa68990f77ba60dc","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009212","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine deoxyribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"4f4261cf59904a5fb72f42e287fafab7","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside triphosphate catabolic process","canonical_id":"go:GO:0009213","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine deoxyribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0e28730e94bf4c9e9203612caeab219c","type":"GO_TERM","name":"pyrimidine deoxyribonucleoside triphosphate metabolic process","canonical_id":"go:GO:0009211","description":"\"The chemical reactions and pathways involving pyrimidine deoxyribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0d17108095474c06a1a12104b59a76f4","type":"GO_TERM","name":"pyrimidine deoxyribonucleotide binding","canonical_id":"go:GO:0032556","description":"\"Binding to a pyrimidine deoxyribonucleotide, any compound consisting of a pyrimidine deoxyribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety.\" [GOC:mah]","metadata":null},{"id":"e9810f3fd127406ebd81725471f785ee","type":"GO_TERM","name":"pyrimidine deoxyribonucleotide biosynthetic process","canonical_id":"go:GO:0009221","description":"\"The chemical reactions and pathways resulting in the formation of a pyrimidine deoxyribonucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"7a79f67054154e709194f0493b67c11c","type":"GO_TERM","name":"pyrimidine deoxyribonucleotide catabolic process","canonical_id":"go:GO:0009223","description":"\"The chemical reactions and pathways resulting in the breakdown of a pyrimidine deoxyribonucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"224889b50d5b4f10be37983c34b93e0d","type":"GO_TERM","name":"pyrimidine deoxyribonucleotide interconversion","canonical_id":"go:GO:0015955","description":"\"The chemical reactions and pathways by which a pyrimidine deoxyribonucleotide is synthesized from another pyrimidine deoxyribonucleotide.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"1f0b42e7719249cb8a2a9c9af3e4983b","type":"GO_TERM","name":"pyrimidine deoxyribonucleotide metabolic process","canonical_id":"go:GO:0009219","description":"\"The chemical reactions and pathways involving a pyrimidine deoxynucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"bc763bc5c74d49cda7c5a7660430b2ee","type":"GO_TERM","name":"pyrimidine deoxyribonucleotide salvage","canonical_id":"go:GO:0010139","description":"\"The pathway by which pyrimidine bases or pyrimidine deoxyribonucleotides from pyrimidine nucleotide breakdown are converted back to pyrimidine deoxyribonucleotides. The salvage pathway is important where there is no de novo pyrimidine deoxyribonucleotide biosynthesis.\" [GOC:pz]","metadata":null},{"id":"2dbc4dcefe3949af923e57bc6e5cc5f1","type":"GO_TERM","name":"pyrimidine dimer DNA N-glycosylase activity","canonical_id":"go:GO:0000704","description":"\"Catalysis of the removal of pyrimidine dimers by removing the 5' pyrimidine of the dimer by cleaving the N-C1' glycosidic bond between the 5' pyrimidine of the dimer and the deoxyribose sugar. The reaction releases the 5' pyrimidine of the dimer and leaves an apurinic (AP) site. The reaction involves the formation of a covalent enzyme substrate intermediate. Release of the enzyme and free base by a beta-elimination or a beta, gamma-elimination mechanism results in the cleavage of the DNA backbone 3' of the apyrimidinic (AP) site.\" [GOC:elh, PMID:9224623]","metadata":null},{"id":"c95ff2074e004c84b165eb9167b175f6","type":"GO_TERM","name":"pyrimidine dimer repair","canonical_id":"go:GO:0006290","description":"\"The repair of UV-induced T-T, C-T and C-C dimers.\" [ISBN:0815316194]","metadata":null},{"id":"2578050448e842eaa20b59930e8350a3","type":"GO_TERM","name":"pyrimidine dimer repair by nucleotide-excision repair","canonical_id":"go:GO:0000720","description":"\"The repair of UV-induced T-T, C-T, and C-C dimers by the recognition and removal of the damaged DNA strand from the DNA helix as an oligonucleotide. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase.\" [GOC:elh]","metadata":null},{"id":"d90ad5840c1b45c790ccda2b467fc0bc","type":"GO_TERM","name":"pyrimidine nucleobase binding","canonical_id":"go:GO:0002061","description":"\"Binding to a pyrimidine nucleobase, an organic nitrogenous base with a pyrimidine skeleton.\" [GOC:hjd]","metadata":null},{"id":"7ba4809a0f3849c7b736bfe76e619049","type":"GO_TERM","name":"pyrimidine nucleobase biosynthetic process","canonical_id":"go:GO:0019856","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine nucleobases, 1,3-diazine, organic nitrogenous bases.\" [GOC:curators]","metadata":null},{"id":"46fdef93fa8f4a589c0a5e4dd4a5dc09","type":"GO_TERM","name":"pyrimidine nucleobase catabolic process","canonical_id":"go:GO:0006208","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine nucleobases, 1,3-diazine, organic nitrogenous bases.\" [GOC:curators]","metadata":null},{"id":"0e58be59a8a844c7b6632453351934c6","type":"GO_TERM","name":"pyrimidine nucleobase metabolic process","canonical_id":"go:GO:0006206","description":"\"The chemical reactions and pathways involving pyrimidine nucleobases, 1,3-diazine, organic nitrogenous bases.\" [GOC:curators]","metadata":null},{"id":"f6290547af4c4c99bc6a4b0ee0115235","type":"GO_TERM","name":"pyrimidine nucleobase salvage","canonical_id":"go:GO:0043100","description":"\"Any process that generates pyrimidine nucleobases, 1,3-diazine organic nitrogenous bases, from derivatives of them without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"8517ae6fbeb24ec88c22a13fbf9202ee","type":"GO_TERM","name":"pyrimidine nucleobase transmembrane transport","canonical_id":"go:GO:1904082","description":"\"The process in which pyrimidine is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie]","metadata":null},{"id":"e5d9d0fd739748cbb008a1ea27f42a5f","type":"GO_TERM","name":"pyrimidine nucleobase transmembrane transporter activity","canonical_id":"go:GO:0005350","description":"\"Enables the transfer of pyrimidine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"4dd8ca55c9c747f59d3880b196b68147","type":"GO_TERM","name":"pyrimidine nucleobase transport","canonical_id":"go:GO:0015855","description":"\"The directed movement of pyrimidine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"3dcc13e396c244efa8c2860f6557fee7","type":"GO_TERM","name":"pyrimidine nucleoside binding","canonical_id":"go:GO:0001884","description":"\"Binding to a pyrimidine nucleoside, a compound consisting of a pyrimidine base linked either to ribose or deoxyribose.\" [GOC:hjd]","metadata":null},{"id":"1fb72a3d9dc94fadbd8bc1791e5d5b02","type":"GO_TERM","name":"pyrimidine nucleoside biosynthetic process","canonical_id":"go:GO:0046134","description":"\"The chemical reactions and pathways resulting in the formation of one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"dd5ef15f93494164975e9157111642bb","type":"GO_TERM","name":"pyrimidine nucleoside catabolic process","canonical_id":"go:GO:0046135","description":"\"The chemical reactions and pathways resulting in the breakdown of one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:ai]","metadata":null},{"id":"5bf4d96015f44d23af93678effb1cbf8","type":"GO_TERM","name":"pyrimidine nucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009139","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine nucleoside diphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"bc70d39778c8405aae3d93cd7c5df1af","type":"GO_TERM","name":"pyrimidine nucleoside diphosphate catabolic process","canonical_id":"go:GO:0009140","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine nucleoside diphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"9a9f94e106574ca3b72503967a64ad13","type":"GO_TERM","name":"pyrimidine nucleoside diphosphate metabolic process","canonical_id":"go:GO:0009138","description":"\"The chemical reactions and pathways involving pyrimidine nucleoside diphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c63f905d9c6e439199eebd50d7c42ac3","type":"GO_TERM","name":"pyrimidine nucleoside interconversion","canonical_id":"go:GO:0019689","description":"\"The chemical reactions and pathways by which a pyrimidine nucleoside is synthesized from another pyrimidine nucleoside.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"1c9775c228f543c2bd894965aa5a8ea6","type":"GO_TERM","name":"pyrimidine nucleoside metabolic process","canonical_id":"go:GO:0006213","description":"\"The chemical reactions and pathways involving any pyrimidine nucleoside, one of a family of organic molecules consisting of a pyrimidine base covalently bonded to ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).\" [GOC:jl, ISBN:0140512713]","metadata":null},{"id":"e26953351dc24629a81e116a8faf5aae","type":"GO_TERM","name":"pyrimidine nucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009130","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine nucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"ca52f2c685c149de8a078d03a9c44b9a","type":"GO_TERM","name":"pyrimidine nucleoside monophosphate catabolic process","canonical_id":"go:GO:0009131","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine nucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"399f31865201404bbc53576cadd6214c","type":"GO_TERM","name":"pyrimidine nucleoside monophosphate metabolic process","canonical_id":"go:GO:0009129","description":"\"The chemical reactions and pathways involving pyrimidine nucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"4c5df96e60174c4396ff891a64a07c84","type":"GO_TERM","name":"pyrimidine nucleoside salvage","canonical_id":"go:GO:0043097","description":"\"Any process that generates a pyrimidine nucleoside, one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar ribose, from derivatives of it, without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"62fe260b9c90404fa16ae42b07409fa5","type":"GO_TERM","name":"pyrimidine nucleoside transmembrane transporter activity","canonical_id":"go:GO:0015214","description":"\"Enables the transfer of a pyrimidine nucleoside, a pyrimidine base covalently bonded to a ribose or deoxyribose sugar from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"549f5dc3163443ab9766a395489d425a","type":"GO_TERM","name":"pyrimidine nucleoside transport","canonical_id":"go:GO:0015864","description":"\"The directed movement of a pyrimidine nucleoside, a pyrimidine base covalently bonded to a ribose or deoxyribose sugar, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"7f7cb0c91e6f43cc996e026d7f0c254d","type":"GO_TERM","name":"pyrimidine nucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009148","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine nucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"487ea273d7514baf98a843ebac9f4974","type":"GO_TERM","name":"pyrimidine nucleoside triphosphate catabolic process","canonical_id":"go:GO:0009149","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine nucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"96d4d303cd254ceb9ccf970640e76439","type":"GO_TERM","name":"pyrimidine nucleoside triphosphate metabolic process","canonical_id":"go:GO:0009147","description":"\"The chemical reactions and pathways involving pyrimidine nucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"3e8f57533f43453584520dcfbcf74159","type":"GO_TERM","name":"pyrimidine nucleotide binding","canonical_id":"go:GO:0019103","description":"\"Binding to a pyrimidine nucleotide, a pyrimidine nucleoside esterified with (ortho)phosphate.\" [GOC:ai]","metadata":null},{"id":"961da221bea24c829cd09fa418afa194","type":"GO_TERM","name":"pyrimidine nucleotide biosynthetic process","canonical_id":"go:GO:0006221","description":"\"The chemical reactions and pathways resulting in the formation of a pyrimidine nucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f9dbe419170d4644807277e64559862b","type":"GO_TERM","name":"pyrimidine nucleotide catabolic process","canonical_id":"go:GO:0006244","description":"\"The chemical reactions and pathways resulting in the breakdown of a pyrimidine nucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"53b1f3b0499648c684972d5cfdb1a30c","type":"GO_TERM","name":"pyrimidine nucleotide import into mitochondrion","canonical_id":"go:GO:1990519","description":"\"The process in which a pyrimidine nucleotide is transported across the mitochondrial inner membrane, into the mitochondrial matrix.\" [PMID:16194150]","metadata":null},{"id":"fecd817a9e1c416485b50dc8f684c258","type":"GO_TERM","name":"pyrimidine nucleotide interconversion","canonical_id":"go:GO:0015953","description":"\"The chemical reactions and pathways by which a pyrimidine nucleotide is synthesized from another pyrimidine nucleotide.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"18ee3d11102e4901914f7d80ccb37370","type":"GO_TERM","name":"pyrimidine nucleotide metabolic process","canonical_id":"go:GO:0006220","description":"\"The chemical reactions and pathways involving a pyrimidine nucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5efc8d72ad1342a38d43dda9d0b36af7","type":"GO_TERM","name":"pyrimidine nucleotide salvage","canonical_id":"go:GO:0032262","description":"\"Any process which produces a pyrimidine nucleotide from derivatives of it, without de novo synthesis.\" [GOC:mah]","metadata":null},{"id":"7167a4e4ff99457a812d5538c4be88c1","type":"GO_TERM","name":"pyrimidine nucleotide transmembrane transporter activity","canonical_id":"go:GO:0015218","description":"\"Enables the transfer of a pyrimidine nucleotide, any compound consisting of a pyrimidine nucleoside esterified with (ortho)phosphate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"24a8753614084845b27c723a9d7190dd","type":"GO_TERM","name":"pyrimidine nucleotide transport","canonical_id":"go:GO:0006864","description":"\"The directed movement of a pyrimidine nucleotide, any compound consisting of a pyrimidine nucleoside esterified with (ortho)phosphate, into, out of or within a cell.\" [GOC:ai]","metadata":null},{"id":"d8ae14bd924449a48d8e6c351510e011","type":"GO_TERM","name":"pyrimidine nucleotide-sugar transmembrane transport","canonical_id":"go:GO:0090481","description":"\"The process in which a pyrimidine nucleotide-sugar is transported across a membrane. Pyrimidine nucleotide-sugars are pyrimidine nucleotides in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [GOC:tb]","metadata":null},{"id":"7faede7069b14c9eb605fede2c7bca42","type":"GO_TERM","name":"pyrimidine nucleotide-sugar transmembrane transporter activity","canonical_id":"go:GO:0015165","description":"\"Enables the transfer of a pyrimidine nucleotide-sugar from one side of a membrane to the other. Pyrimidine nucleotide-sugars are pyrimidine nucleotides in glycosidic linkage with a monosaccharide or monosaccharide derivative.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"89fe17933d264642a3b20b3d346f2f69","type":"GO_TERM","name":"pyrimidine ribonucleoside binding","canonical_id":"go:GO:0032551","description":"\"Binding to a pyrimidine ribonucleoside, a compound consisting of a pyrimidine base linked to ribose.\" [GOC:mah]","metadata":null},{"id":"822c77bad9b642ecb0f092d13525dac9","type":"GO_TERM","name":"pyrimidine ribonucleoside biosynthetic process","canonical_id":"go:GO:0046132","description":"\"The chemical reactions and pathways resulting in the formation of any ribonucleoside, a nucleoside in which a pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:ai]","metadata":null},{"id":"937283d4758c4cde988873d0345b08c6","type":"GO_TERM","name":"pyrimidine ribonucleoside catabolic process","canonical_id":"go:GO:0046133","description":"\"The chemical reactions and pathways resulting in the breakdown of any ribonucleoside, a nucleoside in which a pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:ai]","metadata":null},{"id":"d5bda6b93d6141009753de8bb31bf10e","type":"GO_TERM","name":"pyrimidine ribonucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009194","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine ribonucleoside diphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"7bcd7babafee411dbc173cfbd7524d12","type":"GO_TERM","name":"pyrimidine ribonucleoside diphosphate catabolic process","canonical_id":"go:GO:0009195","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine ribonucleoside diphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"cc51636fe7a74fc093b838fc31f43ed0","type":"GO_TERM","name":"pyrimidine ribonucleoside diphosphate metabolic process","canonical_id":"go:GO:0009193","description":"\"The chemical reactions and pathways involving pyrimidine ribonucleoside diphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"ca67890eb02446aba3d9a3b2fa75a98e","type":"GO_TERM","name":"pyrimidine ribonucleoside metabolic process","canonical_id":"go:GO:0046131","description":"\"The chemical reactions and pathways involving any ribonucleoside, a nucleoside in which pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:ai]","metadata":null},{"id":"f7820e40432d420eb40e1c66b075b4e8","type":"GO_TERM","name":"pyrimidine ribonucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009174","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine ribonucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"358de9fde28d4fe58f3d94458a0eb117","type":"GO_TERM","name":"pyrimidine ribonucleoside monophosphate catabolic process","canonical_id":"go:GO:0009175","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine ribonucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"1cbcfc395d7e4f4a94382b97a3a89705","type":"GO_TERM","name":"pyrimidine ribonucleoside monophosphate metabolic process","canonical_id":"go:GO:0009173","description":"\"The chemical reactions and pathways involving pyrimidine ribonucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b6c2b87dc0104a16b08b5b38c73b6f2e","type":"GO_TERM","name":"pyrimidine ribonucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009209","description":"\"The chemical reactions and pathways resulting in the formation of pyrimidine ribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c3d4a9f0e86e4253a609afae76504db6","type":"GO_TERM","name":"pyrimidine ribonucleoside triphosphate catabolic process","canonical_id":"go:GO:0009210","description":"\"The chemical reactions and pathways resulting in the breakdown of pyrimidine ribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d4e07450c035454fba2785eeb91ae51e","type":"GO_TERM","name":"pyrimidine ribonucleoside triphosphate metabolic process","canonical_id":"go:GO:0009208","description":"\"The chemical reactions and pathways involving pyrimidine ribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"c74ad455649547d3a96c1bdd09da8e37","type":"GO_TERM","name":"pyrimidine ribonucleotide binding","canonical_id":"go:GO:0032557","description":"\"Binding to a pyrimidine ribonucleotide, any compound consisting of a pyrimidine ribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety.\" [GOC:mah]","metadata":null},{"id":"d5107013f7e94e3f9eb500952fd1c5d0","type":"GO_TERM","name":"pyrimidine ribonucleotide biosynthetic process","canonical_id":"go:GO:0009220","description":"\"The chemical reactions and pathways resulting in the formation of a pyrimidine ribonucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b23b2bd9000c45068f9cd8abdfdee698","type":"GO_TERM","name":"pyrimidine ribonucleotide catabolic process","canonical_id":"go:GO:0009222","description":"\"The chemical reactions and pathways resulting in the breakdown of a pyrimidine ribonucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"15273ec6f8b446b9bf7c762e3c791d4a","type":"GO_TERM","name":"pyrimidine ribonucleotide interconversion","canonical_id":"go:GO:0015954","description":"\"The chemical reactions and pathways by which a pyrimidine ribonucleotide is synthesized from another pyrimidine ribonucleotide.\" [GOC:mah, ISBN:0306444747, ISBN:0471394831]","metadata":null},{"id":"ef5e703db85a47a3b78d11161f9d963e","type":"GO_TERM","name":"pyrimidine ribonucleotide metabolic process","canonical_id":"go:GO:0009218","description":"\"The chemical reactions and pathways involving a pyrimidine ribonucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"df111133a0624b4c86ecdcfdc0a054d6","type":"GO_TERM","name":"pyrimidine ribonucleotide salvage","canonical_id":"go:GO:0010138","description":"\"The pathway by which pyrimidine bases or pyrimidine ribonucleosides from pyrimidine nucleotide breakdown are converted back to pyrimidine ribonucleotides. The salvage pathway is important where there is no de novo pyrimidine nucleotide biosynthesis.\" [GOC:pz]","metadata":null},{"id":"5083d26e07b249adbc567f15aa1acd7c","type":"GO_TERM","name":"pyrimidine- and adenosine-specific:sodium symporter activity","canonical_id":"go:GO:0015389","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: (pyrimidine nucleoside or adenosine)(out) + Na+(out) = (pyrimidine nucleoside or adenosine)(in) + Na+(in).\" [TC:2.A.41.2.3]","metadata":null},{"id":"6a1341c091e7427cbbe494e54ba6668b","type":"GO_TERM","name":"pyrimidine-5'-nucleotide nucleosidase activity","canonical_id":"go:GO:0047405","description":"\"Catalysis of the reaction: H2O + a pyrimidine 5'-nucleotide = ribose-5-phosphate + a pyrimidine.\" [EC:3.2.2.10, MetaCyc:3.2.2.10-RXN]","metadata":null},{"id":"8fdb3132deed42a5a82fbbfec40b1289","type":"GO_TERM","name":"pyrimidine-containing compound biosynthetic process","canonical_id":"go:GO:0072528","description":"\"The chemical reactions and pathways resulting in the formation of a pyrimidine-containing compound, i.e. any compound that contains pyrimidine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"807efc3dd945432c97276650f4836138","type":"GO_TERM","name":"pyrimidine-containing compound catabolic process","canonical_id":"go:GO:0072529","description":"\"The chemical reactions and pathways resulting in the breakdown of a pyrimidine-containing compound, i.e. any compound that contains pyrimidine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"17ae69838c3c45979aa01b33176ed31b","type":"GO_TERM","name":"pyrimidine-containing compound metabolic process","canonical_id":"go:GO:0072527","description":"\"The chemical reactions and pathways involving a pyrimidine-containing compound, i.e. any compound that contains pyrimidine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"b2d24235186d4316aa959349c1902a60","type":"GO_TERM","name":"pyrimidine-containing compound salvage","canonical_id":"go:GO:0008655","description":"\"Any process that generates a pyrimidine-containing compound, a nucleobase, nucleoside, nucleotide or nucleic acid that contains a pyrimidine base, from derivatives of them without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"12a7409534304fe492cdc75f51fc9799","type":"GO_TERM","name":"pyrimidine-containing compound transmembrane transport","canonical_id":"go:GO:0072531","description":"\"The process in which a pyrimidine-containing compound is transported across a membrane. A pyrimidine-containing compound is any compound that contains pyrimidine or a formal derivative thereof.\" [GOC:mah]","metadata":null},{"id":"2c5b7af0416247de8e515e90762bc8f0","type":"GO_TERM","name":"pyrimidine-nucleoside phosphorylase activity","canonical_id":"go:GO:0016154","description":"\"Catalysis of the reaction: pyrimidine nucleoside + phosphate = pyrimidine + alpha-D-ribose 1-phosphate.\" [EC:2.4.2.2]","metadata":null},{"id":"555037351d464f1aa469143870e12b3c","type":"GO_TERM","name":"pyrimidine-specific mismatch base pair DNA N-glycosylase activity","canonical_id":"go:GO:0008263","description":"\"Catalysis of the removal of mismatched pyrimidine bases in DNA. Enzymes with this activity recognize and remove pyrimidines present in mismatches by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apyrimidinic (AP) site.\" [GOC:elh, PMID:9224623]","metadata":null},{"id":"f55d33719ce549f3a2cc4fb6f02d9691","type":"GO_TERM","name":"pyrimidodiazepine synthase activity","canonical_id":"go:GO:0004734","description":"\"Catalysis of the reaction: a pyrimidodiazepine + oxidized glutathione = 6-pyruvoyltetrahydropterin + 2 glutathione.\" [EC:1.5.4.1]","metadata":null},{"id":"cf225bd7dbc14b0b8d7fe5500f96c686","type":"GO_TERM","name":"pyripyropene A biosynthetic process","canonical_id":"go:GO:0140652","description":"\"The chemical reactions and pathways resulting in the formation of pyripyropene A.\" [GOC:ach, PMID:21224862, PMID:26019565]","metadata":null},{"id":"249e4364dbdd4694a9082a7248681de1","type":"GO_TERM","name":"pyrithiamine deaminase activity","canonical_id":"go:GO:0050239","description":"\"Catalysis of the reaction: 1-(4-amino-2-methylpyrimid-5-ylmethyl)-3-(2-hydroxyethyl)-2-methylpyridinium + H2O + H+ = 1-(4-hydroxy-2-methylpyrimid-5-ylmethyl)-3-(2-hydroxyethyl)-2-methylpyridinium + NH4+.\" [RHEA:14537]","metadata":null},{"id":"92f19b14f3e6494ca9027077e49710a4","type":"GO_TERM","name":"pyrogallol 1,2-oxygenase activity","canonical_id":"go:GO:0050240","description":"\"Catalysis of the reaction: O2 + pyrogallol = (Z)-5-oxohex-2-enedioate + 2 H+.\" [EC:1.13.11.35, RHEA:19673]","metadata":null},{"id":"481df1739dcf43ea8c78609ec5a223a2","type":"GO_TERM","name":"pyrogallol hydroxytransferase activity","canonical_id":"go:GO:0018706","description":"\"Catalysis of the reaction: 1,2,3,5-tetrahydroxybenzene + 1,2,3-trihydroxybenzene = 1,3,5-trihydroxybenzene + 1,2,3,5-tetrahydroxybenzene.\" [RHEA:21000]","metadata":null},{"id":"cd458a3f237e4661824624df70cc25ef","type":"GO_TERM","name":"pyroglutamyl-peptidase activity","canonical_id":"go:GO:0016920","description":"\"Catalysis of the release of the N-terminal pyroglutamyl group from a peptide or protein.\" [GOC:mah, PMID:9920379]","metadata":null},{"id":"d41a27a413874b3aa03ac36ce30f344c","type":"GO_TERM","name":"pyrokinin receptor activity","canonical_id":"go:GO:0036401","description":"\"Combining with a pyrokinin and transmitting the signal within the cell to induce a change in cell activity. Pyrokinins are a group of insect neuropeptides that share the common C-terminal pentapeptide sequence Phe-X-Pro-Arg-Leu-NH2 (X = S, T, K, A, or G). They play a central role in diverse physiological processes including stimulation of gut motility, production and release of sex pheromones, diapause, and pupariation.\" [GOC:ha, PMID:12951076, PMID:19186060]","metadata":null},{"id":"6dc63218bb5e475e92bcbf4d4ab7e33c","type":"GO_TERM","name":"pyrophosphatase activity","canonical_id":"go:GO:0016462","description":"\"Catalysis of the hydrolysis of a pyrophosphate bond (diphosphate bond) between two phosphate groups.\" [GOC:curators, https://en.wikipedia.org/wiki/Pyrophosphatase]","metadata":null},{"id":"5f7f7ce79fc6418ba2e312c5dcc58d3f","type":"GO_TERM","name":"pyrophosphate-dependent phosphofructokinase complex","canonical_id":"go:GO:0010316","description":"\"Heterodimeric complex that catalyzes the pyrophosphate-dependent phosphorylation of D-fructose 6-phosphate into D-fructose 1,6-bisphosphate.\" [PMID:2170409]","metadata":null},{"id":"307bee83d5d84ef3be53b1703e2bd556","type":"GO_TERM","name":"pyrophosphate-dependent phosphofructokinase complex, alpha-subunit complex","canonical_id":"go:GO:0010317","description":"\"Refers to the alpha subunit of the heterodimeric complex that possesses pyrophosphate-dependent phosphofructokinase activity.\" [PMID:2170409]","metadata":null},{"id":"1539dd4bbc6e4ec7a21e90d4ca5fcb94","type":"GO_TERM","name":"pyrophosphate-dependent phosphofructokinase complex, beta-subunit complex","canonical_id":"go:GO:0010318","description":"\"Refers to the beta subunit of the heterodimeric complex that possesses pyrophosphate-dependent phosphofructokinase activity.\" [PMID:2170409]","metadata":null},{"id":"b3a26c6fbf9e43a0bc2746e228880ec0","type":"GO_TERM","name":"pyroptosome complex","canonical_id":"go:GO:0061703","description":"\"A protein complex that consists of an assemble of ASC dimers that is capable of inducing pyroptosis.\" [GOC:dph, PMID:17599095]","metadata":null},{"id":"09e2a11c0f344bb7ac29413244cbf33e","type":"GO_TERM","name":"pyroptosome complex assembly","canonical_id":"go:GO:1904270","description":"\"The aggregation, arrangement and bonding together of a set of components to form a pyroptosome complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:17964261]","metadata":null},{"id":"042d8cebd5f84ad58adfdd8779e97925","type":"GO_TERM","name":"pyroptotic cell death","canonical_id":"go:GO:0141201","description":"\"A inflammatory cell death process associated with the generation of pyrogenic mediators that result from the activation of gasdermins.\" [PMID:18846107, PMID:21760595, PMID:33883744]","metadata":null},{"id":"d0612f26087648f9afbbda68273eea00","type":"GO_TERM","name":"pyroptotic inflammatory response","canonical_id":"go:GO:0070269","description":"\"A gasdermin-dependent inflammatory response that is associated with the generation of pyrogenic mediators such as IL-1beta and IL-18. Gasdermins are activated by caspase-1 or caspase-4/11, or by certain granzymes. In some, but not all cells, it can lead to pyroptotic programmed cell death.\" [PMID:18846107, PMID:21760595, PMID:33883744]","metadata":null},{"id":"d2a242a9c825441ba44f76424031181c","type":"GO_TERM","name":"pyrrole-2-carboxylate decarboxylase activity","canonical_id":"go:GO:0034941","description":"\"Catalysis of the reaction: pryrole-2-carboxylate + H+ = pyrrole + CO2.\" [UM-BBD_reactionID:r0970]","metadata":null},{"id":"3615b698b2b040e19d04b6d40dcbadd7","type":"GO_TERM","name":"pyrrole-2-carboxylate monooxygenase (NADH) activity","canonical_id":"go:GO:0034938","description":"\"Catalysis of the reaction: H+ + NADH + O2 + pyrrole-2-carboxylate = 5-hydroxypyrrole-2-carboxylate + H2O + NAD+.\" [RHEA:30351]","metadata":null},{"id":"03c7393c287044269f5c18432b4e8209","type":"GO_TERM","name":"pyrroline-2-carboxylate reductase activity","canonical_id":"go:GO:0050241","description":"\"Catalysis of the reaction: L-proline + NAD(P)+ = 1-pyrroline-2-carboxylate + NAD(P)H + H+.\" [EC:1.5.1.1, MetaCyc:PYRROLINE-2-CARBOXYLATE-REDUCTASE-RXN]","metadata":null},{"id":"0eebf98a2573455cb7745cb57423e6fb","type":"GO_TERM","name":"pyrroline-5-carboxylate reductase activity","canonical_id":"go:GO:0004735","description":"\"Catalysis of the reaction: L-proline + NADP+ = 1-pyrroline-5-carboxylate + NADPH + H+.\" [EC:1.5.1.2]","metadata":null},{"id":"338fe7b125e14a30b8ae123158327952","type":"GO_TERM","name":"pyrroline-5-carboxylate reductase complex","canonical_id":"go:GO:1902792","description":"\"A protein complex which is capable of pyrroline-5-carboxylate reductase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:2722838]","metadata":null},{"id":"e8e4b7738d04423db7bd04bc5e69027a","type":"GO_TERM","name":"pyrrolizidine alkaloid biosynthetic process","canonical_id":"go:GO:1901085","description":"\"The chemical reactions and pathways resulting in the formation of pyrrolizidine alkaloid.\" [GOC:TermGenie, GOC:yaf, PMID:30001795]","metadata":null},{"id":"2f9e342795d14684ab5ec5c6e7fe3bf3","type":"GO_TERM","name":"pyrroloquinoline quinone binding","canonical_id":"go:GO:0070968","description":"\"Binding to pyrroloquinoline quinone, PQQ, the coenzyme or the prosthetic group of certain alcohol dehydrogenases and glucose dehydrogenases.\" [GOC:dh]","metadata":null},{"id":"b817a8812fc6430799e063cd123b0956","type":"GO_TERM","name":"pyrroloquinoline quinone biosynthetic process","canonical_id":"go:GO:0018189","description":"\"The chemical reactions and pathways resulting in the formation of the cofactor pyrroloquinoline quinone (PQQ); it is synthesized from a small peptide containing tyrosine and glutamic acid; these amino acids in the peptide are multiply cross-linked and the rest of the peptide is removed.\" [PMID:7665488, RESID:AA0283]","metadata":null},{"id":"9d6c8f7ea641416694af1148c07cb952","type":"GO_TERM","name":"pyrroloquinoline-quinone synthase activity","canonical_id":"go:GO:0033732","description":"\"Catalysis of the reaction: 6-(2-amino-2-carboxyethyl)-7,8-dioxo-1,2,3,4,7,8-hexahydroquinoline-2,4-dicarboxylate + 3 O2 = 2 H2O + 2 H2O2 + H+ + pyrroloquinoline quinone.\" [EC:1.3.3.11, RHEA:10692]","metadata":null},{"id":"ea48b85534674d6e95e05e9fb5a1d4bb","type":"GO_TERM","name":"pyrrolysine biosynthetic process","canonical_id":"go:GO:0071524","description":"\"The chemical reactions and pathways resulting in the formation of pyrrolysine.\" [GOC:curators, PMID:17204561]","metadata":null},{"id":"b7cbd69b8204429193a679734193d51e","type":"GO_TERM","name":"pyrrolysine incorporation","canonical_id":"go:GO:0030631","description":"\"The incorporation of pyrrolysine, also known as lysine methylamine methyltransferase cofactor adduct, into a peptide; uses a special tRNA that recognizes the UAG codon as a modified lysine, rather than as a termination codon. Pyrrolysine may be synthesized as a free amino acid or synthesized from a lysine charged tRNA before its incorporation; it is not a posttranslational modification of peptidyl-lysine; this modification is found in several Methanosarcina methylamine methyltransferases.\" [PMID:11435424, PMID:17204561, RESID:AA0321]","metadata":null},{"id":"a5af0b144f164ef499edb7d361aa1b08","type":"GO_TERM","name":"pyrrolysyl-tRNA synthetase activity","canonical_id":"go:GO:0043767","description":"\"Catalysis of the reaction: ATP + L-pyrrolysine + tRNA(Pyl) = AMP + diphosphate + L-pyrrolysyl-tRNA(Pyl).\" [PMID:15314242, RHEA:19277]","metadata":null},{"id":"be26cbd912194b2a84d1c2e0c89d50e2","type":"GO_TERM","name":"pyruvate biosynthetic process","canonical_id":"go:GO:0042866","description":"\"The chemical reactions and pathways resulting in the formation of pyruvate, 2-oxopropanoate.\" [GOC:curators]","metadata":null},{"id":"4b04f59e55d141ea9fa3e4acfc1fa242","type":"GO_TERM","name":"pyruvate carboxylase activity","canonical_id":"go:GO:0004736","description":"\"Catalysis of the reaction: ATP + bicarbonate + pyruvate = ADP + 2 H+ + oxaloacetate + phosphate.\" [EC:6.4.1.1, RHEA:20844]","metadata":null},{"id":"b71b3bafe8b443bf84f7fbed0e4ee3e2","type":"GO_TERM","name":"pyruvate catabolic process","canonical_id":"go:GO:0042867","description":"\"The chemical reactions and pathways resulting in the breakdown of pyruvate, 2-oxopropanoate.\" [GOC:curators]","metadata":null},{"id":"0bc3cd5c9ac5475287018793b2682056","type":"GO_TERM","name":"pyruvate decarboxylase activity","canonical_id":"go:GO:0004737","description":"\"Catalysis of the reaction: a 2-oxo acid = an aldehyde + CO2.\" [EC:4.1.1.1]","metadata":null},{"id":"c38a09cd939c45e0a28cd90301a29f08","type":"GO_TERM","name":"pyruvate decarboxylation to acetyl-CoA","canonical_id":"go:GO:0006086","description":"\"The chemical reactions and pathways resulting in the formation of acetyl-CoA from pyruvate.  In most organisms, this pathway links glycolysis to the TCA cycle, by a series of three reactions carried out by a multisubunit complex called the 'pyruvate dehydrogenase complex', even though pyruvate dehydrogenase activity describes only one of those reactions. The combination of the three reactions can be summarized as: pyruvate + coenzyme A + NAD+ -> acetyl-CoA + CO2 + NADH.\" [MetaCyc:PYRUVDEHYD-PWY]","metadata":null},{"id":"36ec169706714e71a92ec746edb3c97e","type":"GO_TERM","name":"pyruvate dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050243","description":"\"Catalysis of the reaction: CoA + NADP+ + pyruvate = acetyl-CoA + CO2 + NADPH.\" [RHEA:17425]","metadata":null},{"id":"652da7dcc79e4ab7b7f0a0f11a22884c","type":"GO_TERM","name":"pyruvate dehydrogenase (acetyl-transferring) activity","canonical_id":"go:GO:0004739","description":"\"Catalysis of the reaction: N(6)-[(R)-lipoyl]-L-lysyl-[protein] + pyruvate + H+ = N(6)-[(R)-S(8)-acetyldihydrolipoyl]-L-lysyl-[protein] + CO2.\" [RHEA:19189]","metadata":null},{"id":"4de5bb3f25714fbf8300d6b6249572f9","type":"GO_TERM","name":"pyruvate dehydrogenase (acetyl-transferring) kinase activity","canonical_id":"go:GO:0004740","description":"\"Catalysis of the reaction: ATP + L-seryl-[pyruvate dehydrogenase E1 alpha subunit] = ADP + H+ + O-phospho-L-seryl-[pyruvate dehydrogenase E1 alpha subunit].\" [RHEA:23052]","metadata":null},{"id":"eb93fc4f035549bfa4cc97a6896ce13b","type":"GO_TERM","name":"pyruvate dehydrogenase (lipoamide) phosphatase complex","canonical_id":"go:GO:0045253","description":"\"A complex of a regulatory and catalytic subunit that catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex.\" [PMID:9395502]","metadata":null},{"id":"a50217f40760468f9b570b89ab4892a9","type":"GO_TERM","name":"pyruvate dehydrogenase (quinone) activity","canonical_id":"go:GO:0052737","description":"\"Catalysis of the reaction: a ubiquinone + H2O + pyruvate = a ubiquinol + acetate + CO2.\" [EC:1.2.5.1]","metadata":null},{"id":"71d8ac701e2e428ca50da010b4c3afd7","type":"GO_TERM","name":"pyruvate dehydrogenase complex","canonical_id":"go:GO:0045254","description":"\"A multi-enzyme complex that catalyzes the oxidative decarboxylation of pyruvate to form acetyl-CoA. The complex comprises multiple copies of three enzymes referred to as E1, E2 and E3: pyruvate dehydrogenase (E1, which may be a homodimer or a heterotetramer of two alpha and two beta subunits, depending on species), dihydrolipoamide S-acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). Additional proteins may also be present.\" [PMID:36863425]","metadata":null},{"id":"edec537d74e14121a5332e79c2b2aee3","type":"GO_TERM","name":"pyruvate family amino acid biosynthetic process","canonical_id":"go:GO:0009079","description":"\"The chemical reactions and pathways resulting in the formation of an L-amino acid derived from pyruvate (L-alanine, L-valine, and L-leucine).\" [GOC:curators]","metadata":null},{"id":"67cac9807a5e42f5834e2d8574eaebce","type":"GO_TERM","name":"pyruvate fermentation","canonical_id":"go:GO:0019660","description":"\"The fermentation process resulting in the oxygen-independent conversion of pyruvate to reduced end products (e.g., lactate, ethanol, and acetate), accompanied by the concomitant oxidation of NADH to NAD.\" [GOC:curators]","metadata":null},{"id":"9dc3f44103ac4d2285f39bebbdcf3732","type":"GO_TERM","name":"pyruvate fermentation to acetate","canonical_id":"go:GO:0019654","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of acetate, yielding energy in the form of ATP.\" [GOC:jl, MetaCyc:P142-PWY]","metadata":null},{"id":"d4f0ff081d924da8aa6b68a9bdf391d0","type":"GO_TERM","name":"pyruvate fermentation to butanoate","canonical_id":"go:GO:0044813","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of pyruvate into butanoate. This pathway is found in strict anaerobes such as Clostridia species.\" [GOC:mengo_curators, PMID:20395274, PMID:20692761]","metadata":null},{"id":"9794ce48f14744d7a8e6199590e9cb14","type":"GO_TERM","name":"pyruvate fermentation to ethanol","canonical_id":"go:GO:0019655","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of pyruvate into ethanol and carbon dioxide (CO2).\" [GOC:dph, GOC:nr, ISBN:0716720094]","metadata":null},{"id":"e85e8ecfbd7149438a32d6742215343f","type":"GO_TERM","name":"pyruvate fermentation to lactate","canonical_id":"go:GO:0019244","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of pyruvate into D-lactate or L-lactate.\" [GOC:curators]","metadata":null},{"id":"7ec6e52288c445389f38bacb15883f0f","type":"GO_TERM","name":"pyruvate fermentation to propionate","canonical_id":"go:GO:0019657","description":"\"The anaerobic chemical reactions and pathways resulting in the breakdown of pyruvate into to propionate, an alternative to the acrylate pathway to produce propionate.\" [GOC:dph, GOC:nr, MetaCyc:P108-PWY]","metadata":null},{"id":"cdc9f0df31f94811840aa2a8addd661e","type":"GO_TERM","name":"pyruvate import into mitochondria","canonical_id":"go:GO:0006850","description":"\"The process in which pyruvate is transported from the cytosol into the mitochondrial matrix.\" [GOC:vw, PMID:22628558]","metadata":null},{"id":"3044b7501bac47d0b699295499462c6d","type":"GO_TERM","name":"pyruvate kinase activity","canonical_id":"go:GO:0004743","description":"\"Catalysis of the reaction: ADP + H+ + phosphoenolpyruvate = ATP + pyruvate.\" [RHEA:18157]","metadata":null},{"id":"8d7eedea72ba4b52ad383530ea77234f","type":"GO_TERM","name":"pyruvate kinase complex","canonical_id":"go:GO:1902912","description":"\"A protein complex which is capable of pyruvate kinase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:24606918]","metadata":null},{"id":"b4411b1b46c043bfa8f020964778b4f1","type":"GO_TERM","name":"pyruvate metabolic process","canonical_id":"go:GO:0006090","description":"\"The chemical reactions and pathways involving pyruvate, 2-oxopropanoate.\" [GOC:curators]","metadata":null},{"id":"7b9847b8fe0a44658f179c208ca3a444","type":"GO_TERM","name":"pyruvate oxidase (CoA-acetylating) activity","canonical_id":"go:GO:0050244","description":"\"Catalysis of the reaction: CoA + H+ + O2 + pyruvate = acetyl-CoA + CO2 + H2O2.\" [RHEA:21912]","metadata":null},{"id":"2cb7610ccc3f44e4b8e3cc2cd3a2060d","type":"GO_TERM","name":"pyruvate oxidase activity","canonical_id":"go:GO:0047112","description":"\"Catalysis of the reaction: H+ + O2 + phosphate + pyruvate = acetyl phosphate + CO2 + H2O2.\" [RHEA:20848]","metadata":null},{"id":"53fbe9ff800e443db0be28fd96aae2b4","type":"GO_TERM","name":"pyruvate secondary active transmembrane transporter activity","canonical_id":"go:GO:0005477","description":"\"Enables the transfer of pyruvate from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport]","metadata":null},{"id":"96d21db3a59f4af29497efdd7d53bc17","type":"GO_TERM","name":"pyruvate synthase activity","canonical_id":"go:GO:0019164","description":"\"Catalysis of the reaction: pyruvate + CoA + 2 oxidized ferredoxin = acetyl-CoA + CO2 + 2 reduced ferredoxin + 2 H+.\" [KEGG_REACTION:R01196]","metadata":null},{"id":"8c56c36d68b94ecc9c1ea96698db3864","type":"GO_TERM","name":"pyruvate transmembrane transport","canonical_id":"go:GO:1901475","description":"\"The directed movement of pyruvate across a membrane.\" [GOC:TermGenie]","metadata":null},{"id":"40f6060da6f54bda9cfb5b41e717b72e","type":"GO_TERM","name":"pyruvate transmembrane transporter activity","canonical_id":"go:GO:0050833","description":"\"Enables the transfer of pyruvate, 2-oxopropanoate, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"6a2e7b9483354ae09bf609c1282e869d","type":"GO_TERM","name":"pyruvate transport","canonical_id":"go:GO:0006848","description":"\"The directed movement of pyruvate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"08947cc351d44eb9b6423d94c322d3a9","type":"GO_TERM","name":"pyruvate, phosphate dikinase activity","canonical_id":"go:GO:0050242","description":"\"Catalysis of the reaction: ATP + phosphate + pyruvate = AMP + diphosphate + 2 H+ + phosphoenolpyruvate.\" [RHEA:10756]","metadata":null},{"id":"0cb0d018771342409b7041c4049af2f9","type":"GO_TERM","name":"pyruvate, water dikinase activity","canonical_id":"go:GO:0008986","description":"\"Catalysis of the reaction: ATP + H2O + pyruvate = AMP + 2 H+ + phosphate + phosphoenolpyruvate.\" [RHEA:11364]","metadata":null},{"id":"ac56e576c32f40baa76e7dbbd07c7fff","type":"GO_TERM","name":"pyruvate-flavodoxin oxidoreductase activity","canonical_id":"go:GO:0043873","description":"\"Catalysis of the reaction: pyruvate + CoA + oxidized flavodoxin = acetyl-CoA + CO2 + reduced flavodoxin.\" [PMID:6352705]","metadata":null},{"id":"b6309e36bea9420496ea13a9d5cd942f","type":"GO_TERM","name":"pyruvyltransferase activity","canonical_id":"go:GO:0046919","description":"\"Catalysis of the transfer of a pyruvyl (oxopropanoyl) group from one compound to another.\" [GOC:ai]","metadata":null},{"id":"9b5507aa9b904bd6905c5519eeadefa0","type":"GO_TERM","name":"quaternary ammonium group binding","canonical_id":"go:GO:0050997","description":"\"Binding to a quaternary ammonium group, including glycine betaine, choline, carnitine and proline. A quaternary ammonium group is any compound that can be regarded as derived from ammonium hydroxide or an ammonium salt by replacement of all four hydrogen atoms of the NH4+ ion by organic groups.\" [GOC:ai]","metadata":null},{"id":"7d41183915cc4d5fad78388c95d2159e","type":"GO_TERM","name":"quaternary ammonium group transmembrane transporter activity","canonical_id":"go:GO:0015651","description":"\"Enables the transfer of quaternary ammonium groups from one side of a membrane to the other. Quaternary ammonium groups are any compound that can be regarded as derived from ammonium hydroxide or an ammonium salt by replacement of all four hydrogen atoms of the NH4+ ion by organic groups.\" [ISBN:0198506732]","metadata":null},{"id":"98944ccfa8cf4850917206d3a3e5d3ea","type":"GO_TERM","name":"quaternary ammonium group transport","canonical_id":"go:GO:0015697","description":"\"The directed movement into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore of quaternary ammonium compounds, any compound that can be regarded as derived from ammonium hydroxide or an ammonium salt by replacement of all four hydrogen atoms of the NH4+ ion by organic groups.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"798bdb7676a64eb2a237f86068116c1c","type":"GO_TERM","name":"quaternary ammonium group:proton symporter activity","canonical_id":"go:GO:0015652","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: quaternary ammonium group(out) + H+(out) = quaternary ammonium group(in) + H+(in).\" [GOC:ai]","metadata":null},{"id":"eebcee5e8f064249aaf61470843c3751","type":"GO_TERM","name":"quercetin 2,3-dioxygenase activity","canonical_id":"go:GO:0008127","description":"\"Catalysis of the reaction: H+ + O2 + quercetin = 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoate + CO.\" [EC:1.13.11.24, RHEA:15381]","metadata":null},{"id":"f690166598b64bc98a3bf1fedef28036","type":"GO_TERM","name":"quercetin 3'-O-glucosyltransferase activity","canonical_id":"go:GO:0080045","description":"\"Catalysis of the transfer of a glucosyl group from UDP-glucose to the 3'-hydroxy group of a quercetin molecule.\" [PMID:15352060]","metadata":null},{"id":"e9ebdc18d25d4dc29d16969ed019bc49","type":"GO_TERM","name":"quercetin 3-O-glucosyltransferase activity","canonical_id":"go:GO:0080043","description":"\"Catalysis of the transfer of a glucosyl group from UDP-glucose to the 3-hydroxy group of a quercetin molecule.\" [PMID:15352060]","metadata":null},{"id":"4145cf60a3b2404fb0366a37bb8b146f","type":"GO_TERM","name":"quercetin 3-O-methyltransferase activity","canonical_id":"go:GO:0030755","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 3,5,7,3',4'-pentahydroxyflavone = S-adenosyl-L-homocysteine + 3-methoxy-5,7,3',4'-tetrahydroxy-flavone.\" [EC:2.1.1.76]","metadata":null},{"id":"0e2f7a471930497e8d5867b75fdc6d17","type":"GO_TERM","name":"quercetin 4'-O-glucosyltransferase activity","canonical_id":"go:GO:0080046","description":"\"Catalysis of the transfer of a glucosyl group from UDP-glucose to the 4'-hydroxy group of a quercetin molecule.\" [PMID:15352060]","metadata":null},{"id":"618c9b5eb23f4eccb59653cf1faaec35","type":"GO_TERM","name":"quercetin 7-O-glucosyltransferase activity","canonical_id":"go:GO:0080044","description":"\"Catalysis of the transfer of a glucosyl group from UDP-glucose to the 7-hydroxy group of a quercetin molecule.\" [PMID:15352060]","metadata":null},{"id":"74110cb54d17427c8a5aa63487ec7c58","type":"GO_TERM","name":"quercetin 7-O-methyltransferase activity","canonical_id":"go:GO:0102432","description":"\"Catalysis of the reaction: quercetin + S-adenosyl-L-methionine = H+ + rhamnetin + S-adenosyl-L-homocysteine.\" [RHEA:73115]","metadata":null},{"id":"97b7f65f694749b28715173c243034d0","type":"GO_TERM","name":"quercetin O-glucoside biosynthetic process","canonical_id":"go:GO:0033303","description":"\"The chemical reactions and pathways leading to the formation of O-glucosylated derivatives of quercetin.\" [GOC:mah, MetaCyc:PWY-5321]","metadata":null},{"id":"34f06027492844e8b8ae0cbc3b1aa63c","type":"GO_TERM","name":"quercetin biosynthetic process","canonical_id":"go:GO:1901734","description":"\"The chemical reactions and pathways resulting in the formation of quercetin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00724]","metadata":null},{"id":"879459dec6ab406c97d4c1ab4888553b","type":"GO_TERM","name":"quercetin catabolic process","canonical_id":"go:GO:1901733","description":"\"The chemical reactions and pathways resulting in the breakdown of quercetin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00724]","metadata":null},{"id":"e4df5fa9fea44455b33bf947af4ee982","type":"GO_TERM","name":"quercetin-3,3'-bissulfate 7-sulfotransferase activity","canonical_id":"go:GO:0047367","description":"\"Catalysis of the reaction: quercetin 3,3'-bissulfate + 3'-phosphoadenosine 5'-phosphosulfate = quercetin 3,3',7-trissulfate + adenosine 3',5'-bisphosphate.\" [EC:2.8.2.28, MetaCyc:2.8.2.28-RXN]","metadata":null},{"id":"ee34dd1d34c64c259730c1bbc33d3993","type":"GO_TERM","name":"quercetin-3-sulfate 3'-sulfotransferase activity","canonical_id":"go:GO:0047365","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + quercetin 3-sulfate = adenosine 3',5'-diphosphate + H+ + quercetin 3,3'-disulfate.\" [EC:2.8.2.26, RHEA:22504]","metadata":null},{"id":"283c799856bb41d9a018ea3e8b6d3429","type":"GO_TERM","name":"quercetin-3-sulfate 4'-sulfotransferase activity","canonical_id":"go:GO:0047366","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + quercetin 3-sulfate = adenosine 3',5'-diphosphate + H+ + quercetin 3,4'-disulfate.\" [EC:2.8.2.27, RHEA:17205]","metadata":null},{"id":"71296a2ddde7457c8c8bb7c0f1aca707","type":"GO_TERM","name":"quercitrin binding","canonical_id":"go:GO:2001227","description":"\"Binding to quercitrin.\" [GOC:obol]","metadata":null},{"id":"bfacc88dba274041a48e6732f376213f","type":"GO_TERM","name":"questin hydroquinone dioxygenase activity","canonical_id":"go:GO:7770081","description":"\"Catalysis of the reaction: questin hydroquinone + O2 = demethylsulochrin + 2 H+.\" [PMID:34586791, RHEA:86143]","metadata":null},{"id":"8f940142aa1d4bda9ed962b082f80bfd","type":"GO_TERM","name":"questin reductase (NADPH) activity","canonical_id":"go:GO:7770080","description":"\"Catalysis of the reaction: questin hydroquinone + NADP+ = questin + NADPH + 2 H+.\" [PMID:34586791, RHEA:86147]","metadata":null},{"id":"7da55abd39014fa1835ed10e7aef12b1","type":"DRUG","name":"quetiapine","canonical_id":"gtopdb:50","description":null,"metadata":null},{"id":"0d7689b25c3a4543bbf9f9d71cceb8e5","type":"DRUG","name":"quetiapine","canonical_id":"mesh:D000069348","description":null,"metadata":null},{"id":"29f917e899564289bff2c7ef16415040","type":"GO_TERM","name":"queuine import across plasma membrane","canonical_id":"go:GO:0160284","description":"\"The directed movement of queuine from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:40526720]","metadata":null},{"id":"c6468f87a0634ce2beae13c2d12ffb84","type":"GO_TERM","name":"queuine transmembrane transporter activity","canonical_id":"go:GO:0160283","description":"\"Enables the transfer of queuine from one side of a membrane to the other according to the reaction: queuine(out) = queuine(in).\" [PMID:40526720, RHEA:85679]","metadata":null},{"id":"2c770cc295d849969568e7f3d0d90bc6","type":"GO_TERM","name":"queuosine import across plasma membrane","canonical_id":"go:GO:0160287","description":"\"The directed movement of queuosine from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:40526720]","metadata":null},{"id":"d59e66bc69dc4737aa8bca6eb9eca543","type":"GO_TERM","name":"queuosine nucleosidase activity","canonical_id":"go:GO:0106432","description":"\"Catalysis of the reaction: queuosine 5'-phosphate + H2O = queuine + D-ribose 5-phosphate.\" [PMID:35940128, RHEA:75387]","metadata":null},{"id":"adc276f9401a4910bb08d76adc354753","type":"GO_TERM","name":"queuosine transmembrane transporter activity","canonical_id":"go:GO:0160286","description":"\"Enables the transfer of queuosine from one side of a membrane to the other according to the reaction: queuosine(out) = queuosine(in).\" [PMID:40526720, RHEA:85683]","metadata":null},{"id":"515dae4e9a894732bb6ac861e4c208ba","type":"GO_TERM","name":"quiescent center organization","canonical_id":"go:GO:1904961","description":"\"The process that contributes to the act of creating the structural organization of the quiescent center. This process pertains to the physical shaping of a rudimentary structure.\" [GO_REF:0000084, GOC:TermGenie, PMID:21233333]","metadata":null},{"id":"d9707e9d27c54c09903cb8473ce67c67","type":"GO_TERM","name":"quinaldate 4-oxidoreductase activity","canonical_id":"go:GO:0047122","description":"\"Catalysis of the reaction: A + H2O + quinaldate = AH(2) + kynurenate.\" [EC:1.3.99.18, RHEA:16697]","metadata":null},{"id":"2ba3f0667e5e4af9ba91fb66872a96ab","type":"DRUG","name":"quinapril","canonical_id":"mesh:D000077583","description":null,"metadata":null},{"id":"03832ee88ad846b7801296d763dd000c","type":"DRUG","name":"quinaprilat","canonical_id":"gtopdb:6352","description":null,"metadata":null},{"id":"a7a93efa6f124a4891394d649b4fec61","type":"GO_TERM","name":"quinate 3-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0030266","description":"\"Catalysis of the reaction: (-)-quinate + NAD+ = (-)-3-dehydroquinate + NADH + H+.\" [EC:1.1.1.24]","metadata":null},{"id":"fe40824d271d417681a0c1f6e86efb69","type":"GO_TERM","name":"quinate 3-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0052733","description":"\"Catalysis of the reaction: quinate + NADP+ = 3-dehydroquinate + NADPH + H+.\" [RHEA:18425]","metadata":null},{"id":"70e27378f4084225aa6e7e5afbb45b64","type":"GO_TERM","name":"quinate O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047205","description":"\"Catalysis of the reaction: feruloyl-CoA + quinate = O-feruloylquinate + CoA.\" [EC:2.3.1.99, MetaCyc:2.3.1.99-RXN]","metadata":null},{"id":"e8ae2bcb23164782af239336f131dd20","type":"GO_TERM","name":"quinate biosynthetic process","canonical_id":"go:GO:0042194","description":"\"The chemical reactions and pathways resulting in the formation of quinate, the anion of quinic acid.\" [GOC:curators]","metadata":null},{"id":"d04446d6046649f49ea7ba2fcc9390ff","type":"GO_TERM","name":"quinate catabolic process","canonical_id":"go:GO:0019631","description":"\"The chemical reactions and pathways resulting in the breakdown of quinate, the anion of quinic acid.\" [GOC:jl]","metadata":null},{"id":"8b72f634316646ee9eef19ee3e7284db","type":"GO_TERM","name":"quinate dehydrogenase (quinone) activity","canonical_id":"go:GO:0047519","description":"\"Catalysis of the reaction: (-)-quinate + pyrroloquinoline-quinone = (-)-3-dehydroquinate + pyrroloquinoline-quinol.\" [RHEA:23672]","metadata":null},{"id":"bd77c693ac5448a297b938121acb0408","type":"DRUG","name":"quinestrol","canonical_id":"mesh:D011800","description":null,"metadata":null},{"id":"5929cfd347ac420f9a7b595e2e9fb8bd","type":"DRUG","name":"quinfamide","canonical_id":"mesh:C026546","description":null,"metadata":null},{"id":"57cfdd9ebeaa4772ae1a20fd3a3f38a6","type":"DRUG","name":"quinidine","canonical_id":"mesh:D011802","description":null,"metadata":null},{"id":"9ea36027cffa4ea3bfeb14070a56e046","type":"GO_TERM","name":"quinine 3-monooxygenase activity","canonical_id":"go:GO:0050591","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + quinine = 3-hydroxyquinine + H2O + NADP+.\" [EC:1.14.14.55, RHEA:20149]","metadata":null},{"id":"1813d0ee5f1a461e84adefe4065fc5c8","type":"GO_TERM","name":"quinol-cytochrome-c reductase activity","canonical_id":"go:GO:0008121","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: a quinol + 2 Fe(III)-cytochrome c = a quinone + 2 Fe(II)-cytochrome c + 2 H+(out).\" [RHEA:11484]","metadata":null},{"id":"5b29cb0b494b4259ac389c6c984a599d","type":"GO_TERM","name":"quinolinate biosynthetic process","canonical_id":"go:GO:0019805","description":"\"The chemical reactions and pathways resulting in the formation of quinolinate, the anion of quinolinic acid, also known as 2,3-pyridinedicarboxylic acid.\" [GOC:ai]","metadata":null},{"id":"e593e6be43c049e185ee59381bd5a2ea","type":"GO_TERM","name":"quinolinate catabolic process","canonical_id":"go:GO:0034213","description":"\"The chemical reactions and pathways resulting in the breakdown of quinolinate, the anion of quinolinic acid, also known as 2,3-pyridinedicarboxylic acid.\" [GOC:mah]","metadata":null},{"id":"2ed43f43fc0147f097c7b7e1e64db23d","type":"GO_TERM","name":"quinolinate metabolic process","canonical_id":"go:GO:0046874","description":"\"The chemical reactions and pathways involving quinolinate, the anion of quinolinic acid, also known as 2,3-pyridinedicarboxylic acid.\" [GOC:ai]","metadata":null},{"id":"d6d68bd4755b4199bd2290ff895f3992","type":"GO_TERM","name":"quinolinate synthetase A activity","canonical_id":"go:GO:0008987","description":"\"Catalysis of the reaction: iminoaspartate + dihydroxy-acetone-phosphate = quinolinate + 2 H2O + phosphate.\" [GOC:jl, MetaCyc:QUINOLINATE-SYNTHA-RXN]","metadata":null},{"id":"9fbbab51be03448285aeabdf59745613","type":"GO_TERM","name":"quinoline 2-oxidoreductase activity","canonical_id":"go:GO:0018523","description":"\"Catalysis of the reaction: quinoline + acceptor + H2O = isoquinolin-1(2H)-one + reduced acceptor.\" [EC:1.3.99.17]","metadata":null},{"id":"83de7ed6f61943da8b88c388aba9de4e","type":"GO_TERM","name":"quinoline-4-carboxylate 2-oxidoreductase activity","canonical_id":"go:GO:0047123","description":"\"Catalysis of the reaction: A + H2O + quinoline-4-carboxylate = 2-oxo-1,2-dihydroquinoline-4-carboxylate + AH(2).\" [EC:1.3.99.19, RHEA:14949]","metadata":null},{"id":"04ccc13f36fb458d9a24beeb7e2b54ab","type":"GO_TERM","name":"quinolinic acid transmembrane transport","canonical_id":"go:GO:1903222","description":"\"The process in which quinolinic acid is transported across a membrane.\" [GO_REF:0000069, GOC:di, GOC:TermGenie, PMID:23457190]","metadata":null},{"id":"a65149c365b64d1f9828bbc66ceef34a","type":"GO_TERM","name":"quinone binding","canonical_id":"go:GO:0048038","description":"\"Binding to a quinone, any member of a class of diketones derivable from aromatic compounds by conversion of two CH groups into CO groups with any necessary rearrangement of double bonds.\" [ISBN:0198506732]","metadata":null},{"id":"9d450ef5828d4014bde87037e1a69759","type":"GO_TERM","name":"quinone biosynthetic process","canonical_id":"go:GO:1901663","description":"\"The chemical reactions and pathways resulting in the formation of quinone.\" [GOC:mb, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"122f5d8d9c9243d69a4ad9948b091fde","type":"GO_TERM","name":"quinone catabolic process","canonical_id":"go:GO:1901662","description":"\"The chemical reactions and pathways resulting in the breakdown of quinone.\" [GOC:curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"7377cacbab9c43e3b07bff9d8cd2237f","type":"GO_TERM","name":"quinone metabolic process","canonical_id":"go:GO:1901661","description":"\"The chemical reactions and pathways involving quinone.\" [GOC:curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"6a32ee886b9b4e83a64811089a305bef","type":"GO_TERM","name":"quinone reductase (NADPH) activity","canonical_id":"go:GO:0003960","description":"\"Catalysis of the reaction: 2 a quinone + NADPH + H+ = 2 a 1,4-benzosemiquinone + NADP+.\" [RHEA:14269]","metadata":null},{"id":"ec823e44773b406992276724223d625b","type":"GO_TERM","name":"quinoprotein glucose dehydrogenase activity","canonical_id":"go:GO:0008876","description":"\"Catalysis of the reaction: D-glucose + ubiquinone = D-glucono-1,5-lactone + ubiquinol.\" [RHEA:22152]","metadata":null},{"id":"f8373ff8d9d34b18bd8618c972921181","type":"DRUG","name":"quinupristin","canonical_id":"mesh:C113825","description":null,"metadata":null},{"id":"d77790ee2862468f90ec2f0ce7263c14","type":"DRUG","name":"quizartinib","canonical_id":"gtopdb:5658","description":null,"metadata":null},{"id":"0b2129846b704be0b8cf44381d5928e8","type":"DRUG","name":"quizartinib","canonical_id":"chembl:CHEMBL576982","description":null,"metadata":null},{"id":"1ed7a9ec2859412793663efe614153a7","type":"GO_TERM","name":"quorum sensing","canonical_id":"go:GO:0009372","description":"\"The cell-cell signaling process in which single-celled organisms carry out coordinated responses by monitoring their own population density, and often also that of other microbes, by producing small, diffusible, signal molecules, detecting the concentration of these molecules, and triggering a signal transduction pathway when a certain threshold is reached. Quorum sensing can occur amongst microbial communities in the environment or within host organisms.\" [GOC:krc, GOC:mlg, PMID:10607620, PMID:15716452, PMID:16497924, PMID:16630813, PMID:8288518]","metadata":null},{"id":"b80b1d0c0feb41e7aed7a87fef454367","type":"TRIAL","name":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","canonical_id":"clinicaltrials.gov:NCT04833907","description":"Canavan Disease","metadata":null},{"id":"cd6afa5096b4445493c698c86c307468","type":"GO_TERM","name":"rDNA binding","canonical_id":"go:GO:0000182","description":"\"Binding to a DNA sequence encoding a ribosomal RNA.\" [GOC:mah]","metadata":null},{"id":"c9922c36996346f6b6b224069b4baabe","type":"GO_TERM","name":"rDNA chromatin condensation","canonical_id":"go:GO:0070550","description":"\"The process in which the chromatin structure of the rDNA repeats is compacted. In S. cerevisiae, condensation and resolution of the rDNA occurs during anaphase.\" [GOC:dgf, PMID:10811823, PMID:15137940]","metadata":null},{"id":"76e749cdb76a4bcd8ba9de931210a4fe","type":"GO_TERM","name":"rDNA heterochromatin","canonical_id":"go:GO:0033553","description":"\"A region of heterochromatin located at the rDNA repeats in a chromosome.\" [GOC:mah, PMID:20661445]","metadata":null},{"id":"1ec6722613424ee596c7e63ae00be009","type":"GO_TERM","name":"rDNA heterochromatin formation","canonical_id":"go:GO:0000183","description":"\"The formation of heterochromatin at ribosomal DNA, characterized by the modified histone H3K9me3.\" [PMID:10219245]","metadata":null},{"id":"f9b307b3ee0a4929bba95b56ed0f623b","type":"GO_TERM","name":"rDNA protrusion","canonical_id":"go:GO:0030875","description":"\"Any of the tandem arrays of rDNA localized at the periphery of the nucleus and protruding into the nucleolus, and associated proteins. May be visible as a single or double spot by DAPI staining.\" [PMID:1629244]","metadata":null},{"id":"323b1731fc8e45e08e5e6c515f184310","type":"GO_TERM","name":"rDNA spacer replication fork barrier binding","canonical_id":"go:GO:0043110","description":"\"Binding to replication fork barriers found in rDNA spacers, sites that inhibit replication forks in the direction opposite to rDNA transcription.\" [GOC:jl, GOC:mah, PMID:14645529]","metadata":null},{"id":"6547713b55ad41cdb57107c9b3924a45","type":"GO_TERM","name":"rRNA (adenine(2503)-C2-)-methyltransferase activity","canonical_id":"go:GO:0070040","description":"\"Catalysis of the reaction: adenosine2503 in 23S rRNA + 2 reduced [2Fe-2S]-[ferredoxin] + 2 S-adenosyl-L-methionine = 2-methyladenosine2503 in 23S rRNA + 5'-deoxyadenosine + L-methionine + 2 oxidized [2Fe-2S]-[ferredoxin] + S-adenosyl-L-homocysteine.\" [GOC:imk, PMID:20007606, PMID:20184321, PMID:21368151, PMID:21415317, PMID:21527678, RHEA:42916]","metadata":null},{"id":"28b40a5e8e4e4667802986f4046a0c29","type":"GO_TERM","name":"rRNA (adenine) methyltransferase activity","canonical_id":"go:GO:0016433","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing methyladenine.\" [GOC:curators]","metadata":null},{"id":"d24060f68d844d728baec23a4214015a","type":"GO_TERM","name":"rRNA (adenine-N1-)-methyltransferase activity","canonical_id":"go:GO:0106142","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + adenine(645) in 25S rRNA = S-adenosyl-L-homocysteine + N(1)-methyladenine(645) in 25S rRNA.\" [EC:2.1.1.287, PMID:23180764]","metadata":null},{"id":"2360fa4b5e534155944921d61e39ded6","type":"GO_TERM","name":"rRNA (adenine-N6,N6-)-dimethyltransferase activity","canonical_id":"go:GO:0000179","description":"\"Catalysis of the dimethylation of two adjacent adenine residues in a rRNA, using S-adenosyl-L-methionine as a methyl donor.\" [ISBN:1555811337, PMID:10690410]","metadata":null},{"id":"2624445a98b042ca9b8f092d7c53be8d","type":"GO_TERM","name":"rRNA (adenine-N6-)-methyltransferase activity","canonical_id":"go:GO:0008988","description":"\"Catalysis of the reaction: adenosine in rRNA + S-adenosyl-L-methionine = H+ + N(6)-methyladenosine in rRNA + S-adenosyl-L-homocysteine.\" [RHEA:58728]","metadata":null},{"id":"3d1c979e7125460c8565a56cfe16d6ac","type":"GO_TERM","name":"rRNA (cytosine) methyltransferase activity","canonical_id":"go:GO:0016434","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing methylcytosine.\" [GOC:curators]","metadata":null},{"id":"f917b595577a4f44961914a8c09f2452","type":"GO_TERM","name":"rRNA (cytosine-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0070677","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing 2'-O-methylcytosine.\" [GOC:mah, PMID:19400805]","metadata":null},{"id":"78651fe2cf544d97a863280ed365aa53","type":"GO_TERM","name":"rRNA (cytosine-C5-)-methyltransferase activity","canonical_id":"go:GO:0009383","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to cytosine to form 5-methylcytosine in small subunit ribosomal RNA.\" [GOC:imk, PMID:10026269, PMID:18786544]","metadata":null},{"id":"ffe96fd38b204762b60309606e68bf67","type":"GO_TERM","name":"rRNA (cytosine-N4-)-methyltransferase activity","canonical_id":"go:GO:0071424","description":"\"Catalysis of the reaction: a cytidine in rRNA + S-adenosyl-L-methionine = an N(4)-methylcytidine in rRNA + H+ + S-adenosyl-L-homocysteine.\" [GOC:imk, PMID:19965768, RHEA:62520]","metadata":null},{"id":"122d62848d034fec92c1303caf00cd67","type":"GO_TERM","name":"rRNA (guanine) methyltransferase activity","canonical_id":"go:GO:0016435","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing methylguanine.\" [GOC:curators]","metadata":null},{"id":"d52c8d3355ca45108fee453ab4c1a372","type":"GO_TERM","name":"rRNA (guanine-N1-)-methyltransferase activity","canonical_id":"go:GO:0008989","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing N1-methylguanine.\" [GOC:curators]","metadata":null},{"id":"429dfba234a540018717aec35249cb73","type":"GO_TERM","name":"rRNA (guanine-N2-)-methyltransferase activity","canonical_id":"go:GO:0008990","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing N2-methylguanine.\" [PMID:17389639]","metadata":null},{"id":"f3e23397b02c494391ea04297ad4eb69","type":"GO_TERM","name":"rRNA (guanine-N7)-methylation","canonical_id":"go:GO:0070476","description":"\"The addition of a methyl group to the N7 atom in the base portion of a guanine nucleotide residue in an rRNA molecule.\" [GOC:mah]","metadata":null},{"id":"7e6c1ca0eee448d58adb80bd2f387177","type":"GO_TERM","name":"rRNA (guanine-N7-)-methyltransferase activity","canonical_id":"go:GO:0070043","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing N7-methylguanine.\" [GOC:imk, GOC:mah]","metadata":null},{"id":"9dc5f145063a40f096228dbbccb1fe4f","type":"GO_TERM","name":"rRNA (guanosine-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0070039","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing 2'-O-methylguanosine.\" [GOC:imk, GOC:mah]","metadata":null},{"id":"87e1b2a9f7c342ed950af6b42cc852b2","type":"GO_TERM","name":"rRNA (pseudouridine) methyltransferase activity","canonical_id":"go:GO:0070037","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to a pseudouridine residue in an rRNA molecule.\" [GOC:imk, GOC:mah]","metadata":null},{"id":"85d01cdd79b34ad58906b5d7d9b36412","type":"GO_TERM","name":"rRNA (pseudouridine-N3-)-methyltransferase activity","canonical_id":"go:GO:0070038","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing N3-methylpseudouridine.\" [GOC:imk, GOC:mah]","metadata":null},{"id":"a647904c88234947bd5a19dc9ca802c4","type":"GO_TERM","name":"rRNA (uridine) methyltransferase activity","canonical_id":"go:GO:0016436","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing methyluridine.\" [GOC:curators]","metadata":null},{"id":"1833c54f555540628f4597e8e458c94e","type":"GO_TERM","name":"rRNA (uridine-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0008650","description":"\"Catalysis of the reaction: a uridine in rRNA + S-adenosyl-L-methionine = a 2'-O-methyluridine in rRNA + S-adenosyl-L-homocysteine + H+.\" [RHEA:54152]","metadata":null},{"id":"679d4fbef8bb4ce4ababc8583916119d","type":"GO_TERM","name":"rRNA (uridine-C5-)-methyltransferase activity","canonical_id":"go:GO:0070041","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing C5-methyluridine.\" [GOC:imk, GOC:mah]","metadata":null},{"id":"73dab9287eb74616a45484ba779d9a2a","type":"GO_TERM","name":"rRNA (uridine-N3-)-methyltransferase activity","canonical_id":"go:GO:0070042","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + rRNA = S-adenosyl-L-homocysteine + rRNA containing N3-methyluridine.\" [GOC:imk, GOC:mah]","metadata":null},{"id":"d6483b9afadf454fbdb711d5d79f880b","type":"GO_TERM","name":"rRNA 2'-O-methylation","canonical_id":"go:GO:0000451","description":"\"The addition of a methyl group to the 2'-oxygen atom of a nucleotide residue in an rRNA molecule during ribosome biogenesis.\" [GOC:curators, ISBN:1555811337]","metadata":null},{"id":"8b8e016b28d84398be4af4886905c2c3","type":"GO_TERM","name":"rRNA 2'-O-ribose methylation guide activity","canonical_id":"go:GO:0030562","description":"\"Specifies the site of 2'-O-ribose methylation in an rRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"9253e24172424ad1aca5cc5d01d8cac2","type":"GO_TERM","name":"rRNA 3'-end processing","canonical_id":"go:GO:0031125","description":"\"Any process involved in forming the mature 3' end of an rRNA molecule.\" [GOC:mah]","metadata":null},{"id":"b241c78135bf4a389f1325c535c1acef","type":"GO_TERM","name":"rRNA 5'-end processing","canonical_id":"go:GO:0000967","description":"\"Any process involved in forming the mature 5' end of an rRNA molecule.\" [GOC:krc]","metadata":null},{"id":"de828ecb0553498496666a32e2a03aae","type":"GO_TERM","name":"rRNA N-glycosylase activity","canonical_id":"go:GO:0030598","description":"\"Catalysis of the hydrolysis of the N-glycosylic bond at A-4324 in 28S rRNA from rat ribosomes or corresponding sites in 28S RNA from other species.\" [EC:3.2.2.22, GOC:mah]","metadata":null},{"id":"40dd2146ec9d4c28987968fd97ee2156","type":"GO_TERM","name":"rRNA acetylation","canonical_id":"go:GO:1990882","description":"\"The modification of rRNA structure by addition of an acetyl group to rRNA. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [PMID:25402480]","metadata":null},{"id":"6e5fcb9e00f64cf5bcb22392391d2695","type":"GO_TERM","name":"rRNA acetylation involved in maturation of SSU-rRNA","canonical_id":"go:GO:1904812","description":"\"Any rRNA acetylation that is involved in maturation of SSU-rRNA.\" [GO_REF:0000060, GOC:TermGenie, PMID:25402480]","metadata":null},{"id":"6095d314856c4b0ca20739f51ea2dd7d","type":"GO_TERM","name":"rRNA base methylation","canonical_id":"go:GO:0070475","description":"\"The addition of a methyl group to an atom in the nucleoside base portion of a nucleotide residue in an rRNA molecule.\" [GOC:mah]","metadata":null},{"id":"7c484ae1a1e34efe821a40317439d555","type":"GO_TERM","name":"rRNA binding","canonical_id":"go:GO:0019843","description":"\"Binding to a ribosomal RNA.\" [GOC:jl]","metadata":null},{"id":"a3ff7e9fa6714a9f93ff90c42864f574","type":"GO_TERM","name":"rRNA catabolic process","canonical_id":"go:GO:0016075","description":"\"The chemical reactions and pathways resulting in the breakdown of rRNA, ribosomal RNA, a structural constituent of ribosomes.\" [GOC:ai]","metadata":null},{"id":"654a57474bc84b51b1bb4da45157c4a4","type":"GO_TERM","name":"rRNA endonuclease activity","canonical_id":"go:GO:0033902","description":"\"Catalysis of the reaction: a 28S rRNA containing guanosine-adenosine pair + H2O = an [RNA fragment]-3'-adenosine-3'-phosphate + a 5'-a hydroxy-guanosine-3'-[RNA fragment].\" [EC:4.6.1.23]","metadata":null},{"id":"0a278deb53da47929b513df39d7e0003","type":"GO_TERM","name":"rRNA import into mitochondrion","canonical_id":"go:GO:0035928","description":"\"The process in which a rRNA, ribosomal ribonucleic acid, transported from the cytosol into the mitochondrial matrix.\" [GOC:ans, PMID:20691904]","metadata":null},{"id":"c9dcc3d940084b859b7fe7dab14a8821","type":"GO_TERM","name":"rRNA metabolic process","canonical_id":"go:GO:0016072","description":"\"The chemical reactions and pathways involving rRNA, ribosomal RNA, a structural constituent of ribosomes.\" [ISBN:0198506732]","metadata":null},{"id":"0279ce18255e46e39211cef1ae2140ac","type":"GO_TERM","name":"rRNA methylation","canonical_id":"go:GO:0031167","description":"\"The posttranscriptional addition of methyl groups to specific residues in an rRNA molecule.\" [GOC:mah]","metadata":null},{"id":"58adca5c03d54e759e759192ab77f427","type":"GO_TERM","name":"rRNA methyltransferase activity","canonical_id":"go:GO:0008649","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to a nucleoside residue in an rRNA molecule. The methyl group can be transfered to the nucleobase or to the ribose group of the nucleoside.\" [GOC:mah]","metadata":null},{"id":"c0f0378830f544e195893adf4d3d7a5f","type":"GO_TERM","name":"rRNA modification","canonical_id":"go:GO:0000154","description":"\"The covalent alteration of one or more nucleotides within an rRNA molecule to produce an rRNA molecule with a sequence that differs from that coded genetically.\" [GOC:curators]","metadata":null},{"id":"52c03834e9214abd85636be55f83cf3d","type":"GO_TERM","name":"rRNA modification guide activity","canonical_id":"go:GO:0030556","description":"\"Specifies the site of a posttranscriptional modification in an rRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"674e8c8af1d048cd9c86984d096d008a","type":"GO_TERM","name":"rRNA primary transcript binding","canonical_id":"go:GO:0042134","description":"\"Binding to an unprocessed ribosomal RNA transcript.\" [GOC:jl]","metadata":null},{"id":"ff4cf81cce3248b69183894c72b18bbc","type":"GO_TERM","name":"rRNA processing","canonical_id":"go:GO:0006364","description":"\"Any process involved in the conversion of a primary ribosomal RNA (rRNA) transcript into one or more mature rRNA molecules.\" [GOC:curators]","metadata":null},{"id":"8c68cdd9834c4ef2b7bf9b40a36a156c","type":"GO_TERM","name":"rRNA pseudouridine synthase activity","canonical_id":"go:GO:0120159","description":"\"Catalysis of the reaction: a uridine in rRNA = a pseudouridine in rRNA. Conversion of uridine in an rRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.\" [PMID:28432181, RHEA:54568]","metadata":null},{"id":"23cf53cf66b247129537be992ee94ef9","type":"GO_TERM","name":"rRNA pseudouridine synthesis","canonical_id":"go:GO:0031118","description":"\"The intramolecular conversion of uridine to pseudouridine in an rRNA molecule.\" [GOC:mah]","metadata":null},{"id":"26f9ba3754b44a6eb3703e74abfdc787","type":"GO_TERM","name":"rRNA pseudouridylation guide activity","canonical_id":"go:GO:0030559","description":"\"Specifies the site of pseudouridylation in an rRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"98defeee8a0841dd9e66a761cafd4f2a","type":"GO_TERM","name":"rRNA small subunit aminocarboxypropyltransferase activity","canonical_id":"go:GO:0106388","description":"\"Catalysis of the reaction: N1-methylpseudouridine in small subunit rRNA + S-adenosyl-L-methionine = H+ + N1-methyl-N3-[(3S)-3-amino-3-carboxypropyl]pseudouridine in small subunit rRNA + S-methyl-5'-thioadenosine.\" [PMID:27084949, RHEA:63296]","metadata":null},{"id":"78849bb46ebd4d51a1cb826468fe97f1","type":"GO_TERM","name":"rRNA transcription","canonical_id":"go:GO:0009303","description":"\"The synthesis of ribosomal RNA (rRNA), any RNA that forms part of the ribosomal structure, from a DNA template.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"bc03640bda4b42fca116cd073f989476","type":"GO_TERM","name":"rRNA transport","canonical_id":"go:GO:0051029","description":"\"The directed movement of rRNA, ribosomal ribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"62fd5c1a47c24edea2dc6befac067781","type":"TRIAL","name":"rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT04180969","description":"Stress; Healthy","metadata":null},{"id":"3e3597981c7744bbabff76cd7d586f9e","type":"DRUG","name":"rabeprazole","canonical_id":"mesh:D064750","description":null,"metadata":null},{"id":"a4b317be23214a88875cb1fb9483a782","type":"GO_TERM","name":"racemase and epimerase activity","canonical_id":"go:GO:0016854","description":"\"Catalysis of a reaction that alters the configuration of one or more chiral centers in a molecule.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"2e1b5496e53948f4aec1873e7dca9aac","type":"GO_TERM","name":"racemase and epimerase activity, acting on amino acids and derivatives","canonical_id":"go:GO:0016855","description":"\"Catalysis of a reaction that alters the configuration of one or more chiral centers in an amino acid.\" [GOC:mah]","metadata":null},{"id":"627de81b11a943fcb56a770650ccd830","type":"GO_TERM","name":"racemase and epimerase activity, acting on carbohydrates and derivatives","canonical_id":"go:GO:0016857","description":"\"Catalysis of a reaction that alters the configuration of one or more chiral centers in a carbohydrate molecule.\" [EC:5.1.3.-, GOC:mah]","metadata":null},{"id":"37b4fff670e543cd8359c7a62612f6c3","type":"GO_TERM","name":"racemase and epimerase activity, acting on hydroxy acids and derivatives","canonical_id":"go:GO:0016856","description":"\"Catalysis of a reaction that alters the configuration of one or more chiral centers in a hydroxy acid molecule.\" [GOC:mah]","metadata":null},{"id":"6b7ed7626ed3479a8f9fc4b71756ed52","type":"GO_TERM","name":"radial axis specification","canonical_id":"go:GO:0009945","description":"\"The establishment, maintenance and elaboration of an axis that initiates at a point and radiates outward from the point.\" [GOC:curators, GOC:dph, GOC:isa_complete]","metadata":null},{"id":"47bfa53597ef4fea9938347b7dee353c","type":"GO_TERM","name":"radial glia guided migration of Purkinje cell","canonical_id":"go:GO:0021942","description":"\"The migration of postmitotic a Purkinje cell along radial glial cells from the ventricular zone to the Purkinje cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"51286c00f3c746919d198449b61fc603","type":"GO_TERM","name":"radial glia guided migration of cerebellar granule cell","canonical_id":"go:GO:0021933","description":"\"The inward migration of postmitotic granule cells along a radial glial cell from the external granule layer to the internal granule cell layer.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"a6266e5adde649b5aa01f5f3d8899866","type":"GO_TERM","name":"radial glia-guided pyramidal neuron migration","canonical_id":"go:GO:0140650","description":"\"The radial migration of a pyramidal neuron along radial glial cells.\" [PMID:3760547]","metadata":null},{"id":"057908177c014ac1b976f12019cede9d","type":"GO_TERM","name":"radial glial cell differentiation","canonical_id":"go:GO:0060019","description":"\"The process in which neuroepithelial cells of the neural tube give rise to radial glial cells, specialized bipotential progenitors cells of the brain. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GOC:dph]","metadata":null},{"id":"ab8c4119a0ca4296b36a14e2ba84d69b","type":"GO_TERM","name":"radial glial cell division in pallium","canonical_id":"go:GO:0022015","description":"\"The division of a radial glial cell in the pallium. A radial glial cell is a precursor cell that gives rise to neurons and astrocytes.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d2c2b930df144d2da47aa2d65048f8c3","type":"GO_TERM","name":"radial glial cell fate commitment in forebrain","canonical_id":"go:GO:0022023","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a radial glial cell in the forebrain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6b0e0c3b39f54282ad81da018058145b","type":"GO_TERM","name":"radial microtubular system formation","canonical_id":"go:GO:0010245","description":"\"Formation of radial microtubular systems during male meiotic cytokinesis in plants.\" [GOC:syr]","metadata":null},{"id":"e8382811fe8b4481a233175298e43d61","type":"GO_TERM","name":"radial pattern formation","canonical_id":"go:GO:0009956","description":"\"The regionalization process that results in defined areas around a point in which specific types of cell differentiation will occur.\" [GOC:curators, GOC:dph, GOC:isa_complete]","metadata":null},{"id":"de273b0b0c664e5a8085302c88fb4945","type":"GO_TERM","name":"radial spoke","canonical_id":"go:GO:0001534","description":"\"Protein complex that links the outer microtubule doublet of a 9+2 type ciliary or flagellar axoneme with the sheath that surrounds the central pair of microtubules. Composed of a stalk that attaches to each doublet microtubule and a globular structure (spoke head) that projects toward the central pair of microtubules.\" [GOC:krc, ISBN:0124325653, PMID:22118931, PMID:25694453, PMID:34871179, PMID:9450971]","metadata":null},{"id":"98a2a2bd9cc34b5194839a05e9a95cce","type":"GO_TERM","name":"radial spoke 1","canonical_id":"go:GO:0120333","description":"\"The radial spoke of each group of radial spokes, whether grouped as triplets or doublets, that is most proximal to the base of the cilium. Radial spoke 1 (RS1), similarly to radial spoke 2, is comprised of four domains: 1) a very short base anchored to the A microtubule, 2) an elongaged stalk, 3) a bifurcated neck, and 4) an orthogonal head. The base of RS1 is connected to the tail of the inner dynein arm a/d.\" [GOC:krc, PMID:22754630]","metadata":null},{"id":"47a4c54b654d426a92418818c0322cf7","type":"GO_TERM","name":"radial spoke 2","canonical_id":"go:GO:0120334","description":"\"The radial spoke of each group of radial spokes, whether grouped as triplets or doublets, that is immediately distal to radial spoke 1 (RS1). Radial spoke 2 (RS2), similarly to RS1, is comprised of four domains: 1) a very short base anchored to the A microtubule, 2) an elongaged stalk, 3) a bifurcated neck, and 4) an orthogonal head. The base of RS2 is connected to the tail of the inner dynein arm c.\" [GOC:krc, PMID:22754630]","metadata":null},{"id":"e21a2d3ae346491f8ed41e2b8e5d8da5","type":"GO_TERM","name":"radial spoke 3","canonical_id":"go:GO:0120335","description":"\"Radial spoke 3 (RS3), when present, is the most distal of each group of radial spokes, whether grouped as triplets or doublets. RS3 has significantly different morphology and protein composition than RS1 and RS2 and also extends at a slant from the microtubule doublet, rather than perpendicularly like RS1 and RS2. In some organisms (e.g. Chlamydomonas and Sarcophaga bullata), RS3 is represented only as a stump attached to the A-microtubule lacking the rest of the stalk structure and entirely lacking the head structure.\" [GOC:krc, ISBN:0124325653, PMID:22754630, PMID:25694453, PMID:9450971]","metadata":null},{"id":"144ec3afae184d68851ab50d61e799d0","type":"GO_TERM","name":"radial spoke assembly","canonical_id":"go:GO:0062177","description":"\"The aggregation, arrangement and bonding together of a set of components to form the radial spoke, a protein complex that links the outer microtubule doublet of the ciliary or flagellum axoneme with the sheath that surrounds the central pair of microtubules.\" [PMID:21613541, PMID:21692193, PMID:24124175, PMID:27940518, PMID:8408197]","metadata":null},{"id":"eae94dca8f28468eaf801c84965da4d1","type":"GO_TERM","name":"radial spoke base","canonical_id":"go:GO:0120339","description":"\"The short portion of the radial spoke that is directly anchored to the A microtubule of an axonemal microtubule doublet.\" [GOC:krc, PMID:22754630, PMID:25694453]","metadata":null},{"id":"d7f9045ec92b410fadda81006a5714c6","type":"GO_TERM","name":"radial spoke base 1","canonical_id":"go:GO:0120340","description":"\"The short portion of the radial spoke 1 (RS1) that is directly anchored to the A microtubule of an axonemal microtubule doublet.\" [GOC:krc, PMID:22754630, PMID:25694453]","metadata":null},{"id":"ebe52d65b1984199b6a99a1e38630d0f","type":"GO_TERM","name":"radial spoke base 2","canonical_id":"go:GO:0120341","description":"\"The short portion of the radial spoke 2 (RS2) that is directly anchored to the A microtubule of an axonemal microtubule doublet.\" [GOC:krc, PMID:22754630, PMID:25694453]","metadata":null},{"id":"c48bfd5f6bb34b88836823ef3c348fc8","type":"GO_TERM","name":"radial spoke base 3","canonical_id":"go:GO:0120342","description":"\"The short portion of the radial spoke 3 (RS3 )that is directly anchored to the A microtubule of an axonemal microtubule doublet.\" [GOC:krc, PMID:22754630, PMID:25694453]","metadata":null},{"id":"dde8d5c7b7e94be9918cd0bb3099b7d0","type":"GO_TERM","name":"radial spoke head","canonical_id":"go:GO:0001535","description":"\"Protein complex forming portion of the radial spoke that is orthogonal to the elongated stalk and which projects towards the central pair of microtubules within the ciliary or flagellum axoneme.\" [GOC:cilia, GOC:hjd, GOC:krc, PMID:22754630, PMID:34871179]","metadata":null},{"id":"e1a2ac6ff80242168d5ccb65953d62d7","type":"GO_TERM","name":"radial spoke head 1","canonical_id":"go:GO:0120336","description":"\"The portion of the radial spoke 1 that is orthogonal to the elongated stalk and which projects towards the central pair of microtubules within the ciliary axoneme.\" [GOC:krc, PMID:22754630, PMID:348711799]","metadata":null},{"id":"1c0efa19199a4587a6946564a6f1b1b4","type":"GO_TERM","name":"radial spoke head 2","canonical_id":"go:GO:0120337","description":"\"The portion of the radial spoke 2 that is orthogonal to the elongated stalk and which projects towards the central pair of microtubules within the ciliary axoneme.\" [GOC:krc, PMID:22754630, PMID:348711799]","metadata":null},{"id":"f8e64c54f0474283a26fed1e6e770ec7","type":"GO_TERM","name":"radial spoke head 3","canonical_id":"go:GO:0120338","description":"\"The portion of the radial spoke 3 that is orthogonal to the elongated stalk and which projects towards the central pair of microtubules within the ciliary axoneme.\" [GOC:krc, PMID:22754630, PMID:348711799]","metadata":null},{"id":"dbf1151c3ba84690a7b572bf9379359f","type":"GO_TERM","name":"radial spoke neck","canonical_id":"go:GO:0120343","description":"\"The radial spoke neck is a complex that connects the spoke stalk to the head.\" [GOC:krc, PMID:22754630]","metadata":null},{"id":"274e0c5b177f4ad0894b4277cf38901f","type":"GO_TERM","name":"radial spoke stalk","canonical_id":"go:GO:0001536","description":"\"Protein complex forming the elongated portion of the radial spoke between the base which binds to the A-tubule of each microtubule outer doublet and the neck which connects to the spoke head within the ciliary or flagellum axoneme.\" [GOC:hjd, GOC:krc, PMID:22754630, PMID:34871179]","metadata":null},{"id":"90dfd916bb414fa0b53031c2ebcf6fda","type":"DRUG","name":"radium Ra 223 dichloride","canonical_id":"mesh:C581106","description":null,"metadata":null},{"id":"47b69377e7a14d1a815287fcf89c98ad","type":"GO_TERM","name":"raffinose alpha-galactosidase activity","canonical_id":"go:GO:0052692","description":"\"Catalysis of the reaction: raffinose + H2O = alpha-D-galactose + sucrose.\" [PMID:20739305, RHEA:70275]","metadata":null},{"id":"f021b111be1341b6ba7c1b76c96ed4f0","type":"GO_TERM","name":"raffinose biosynthetic process","canonical_id":"go:GO:0033529","description":"\"The chemical reactions and pathways resulting in the formation of raffinose, the trisaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"79689e4f006b47238f60066d5f7293b3","type":"GO_TERM","name":"raffinose catabolic process","canonical_id":"go:GO:0034484","description":"\"The chemical reactions and pathways resulting in the breakdown of raffinose, the trisaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"56771c3ebd6a44d9a97e05b3dbe7110c","type":"GO_TERM","name":"raffinose family oligosaccharide biosynthetic process","canonical_id":"go:GO:0010325","description":"\"The chemical reactions and pathways resulting in the formation of raffinose family oligosaccharides (RFOs, such as raffinose, stachyose, verbascose and other molecules with a higher degree of galactosyl polymerization).\" [GOC:tair_curators]","metadata":null},{"id":"dac2872ee59a45399354f311f6957b85","type":"GO_TERM","name":"raffinose metabolic process","canonical_id":"go:GO:0033530","description":"\"The chemical reactions and pathways involving raffinose, the trisaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"c4672c3aeb7043c0b1f0f163cdc43b20","type":"GO_TERM","name":"raffinose transmembrane transporter activity","canonical_id":"go:GO:0015158","description":"\"Enables the transfer of raffinose from one side of a membrane to the other. Raffinose occurs in plants almost as commonly as sucrose and is present in cereal grains, cotton seeds, and many legumes. It is synthesized from sucrose by transfer of a galactopyranoside from myo-inositol.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"22f0467cc86a41da8a55f7a37d772584","type":"GO_TERM","name":"raffinose transport","canonical_id":"go:GO:0015773","description":"\"The directed movement of raffinose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Raffinose occurs in plants almost as commonly as sucrose and is present in cereal grains, cotton seeds, and many legumes. It is synthesized from sucrose by transfer of a galactopyranoside from myo-inositol.\" [ISBN:0198506732]","metadata":null},{"id":"cfbc6b1717ea46b99751d6d7c65d0524","type":"GO_TERM","name":"raffinose-raffinose alpha-galactotransferase activity","canonical_id":"go:GO:0047234","description":"\"Catalysis of the reaction: 2 raffinose = sucrose + 1F-alpha-D-galactosylraffinose.\" [EC:2.4.1.166]","metadata":null},{"id":"48476bd7c8564ac29bffa2781536b8b9","type":"GO_TERM","name":"raffinose:proton symporter activity","canonical_id":"go:GO:0015529","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: raffinose(out) + H+(out) = raffinose(in) + H+(in).\" [TC:2.A.1.5.2]","metadata":null},{"id":"42ca6df718f34e6a8f16126b689721d1","type":"DRUG","name":"raloxifene","canonical_id":"gtopdb:2820","description":null,"metadata":null},{"id":"8de89a7ea3b9432d9d7dda29235e9020","type":"DRUG","name":"raloxifene","canonical_id":"mesh:D020849","description":null,"metadata":null},{"id":"66388fd26444400f894af8f6fa5980e6","type":"DRUG","name":"raloxifene","canonical_id":"chembl:CHEMBL81","description":null,"metadata":null},{"id":"85abf4e90bcc4ef7a036ef88949b8dc8","type":"COMBINATION_TREATMENT","name":"raloxifene + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-72fa2edbb9993676","description":null,"metadata":null},{"id":"4a830bd596a444b69616e7410dc6d853","type":"COMBINATION_TREATMENT","name":"raloxifene + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-845c7cf6c159020c","description":null,"metadata":null},{"id":"fcaa546722b54dc7951e16af9945853d","type":"DRUG","name":"raltegravir","canonical_id":"mesh:D000068898","description":null,"metadata":null},{"id":"d4ab62b9994c400bb2d57c65b8b765fd","type":"DRUG","name":"raltitrexed","canonical_id":"gtopdb:7403","description":null,"metadata":null},{"id":"485adb86563a4e648e18ba1981c93050","type":"DRUG","name":"raltitrexed","canonical_id":"chembl:CHEMBL225071","description":null,"metadata":null},{"id":"2d4ae3bbb9ed42b08ea3c463dcad8c0f","type":"COMBINATION_TREATMENT","name":"raltitrexed + ramucirumab","canonical_id":"ctgov_combo:ctgov-combo-5e2527640c8c86f0","description":null,"metadata":null},{"id":"0edb06747768476c8f564f245456fda0","type":"COMBINATION_TREATMENT","name":"raltitrexed + tuvonralimab","canonical_id":"ctgov_combo:ctgov-combo-e90c9da911550c15","description":null,"metadata":null},{"id":"8974a50c6eb64aefa2a35f84a3b060d5","type":"DRUG","name":"ramelteon","canonical_id":"gtopdb:1356","description":null,"metadata":null},{"id":"defc7a71e77b4205a9cbb513c9417216","type":"DRUG","name":"ramelteon","canonical_id":"chembl:CHEMBL1218","description":null,"metadata":null},{"id":"02bd2035923f4139bcd927d4b9626c03","type":"COMBINATION_TREATMENT","name":"ramelteon + triazolam","canonical_id":"ctgov_combo:ctgov-combo-c3bc5e644ec529a0","description":null,"metadata":null},{"id":"7d8f7b678927464ca05c1f4e97e4d7bf","type":"COMBINATION_TREATMENT","name":"ramelteon + zolpidem","canonical_id":"ctgov_combo:ctgov-combo-6dbeb6e4c767c61c","description":null,"metadata":null},{"id":"1dbb2c1f00b14eaca84e38c89a213b0d","type":"COMBINATION_TREATMENT","name":"ramelteon + zolpidem","canonical_id":"ctgov_combo:ctgov-combo-540ada3bf0119b11","description":null,"metadata":null},{"id":"b2d7591323ef4b08a6234d048d222e10","type":"COMBINATION_TREATMENT","name":"ramelteon + zolpidem","canonical_id":"ctgov_combo:ctgov-combo-70047093f1222a0c","description":null,"metadata":null},{"id":"c49df2d5312e4c2ea251f9bfcf714e49","type":"DRUG","name":"ramipril","canonical_id":"gtopdb:6339","description":null,"metadata":null},{"id":"184ffec092d248d2823a70b5204aceb5","type":"DRUG","name":"ramipril","canonical_id":"mesh:D017257","description":null,"metadata":null},{"id":"295ce2457dd2427f8b5f6c8d33c856ae","type":"DRUG","name":"ramipril","canonical_id":"chembl:CHEMBL1168","description":null,"metadata":null},{"id":"642383d0540242bf8c2ec06795ab1b3f","type":"COMBINATION_TREATMENT","name":"ramipril + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-ea07d27075542077","description":null,"metadata":null},{"id":"ef5777a979184cffa972f1ddedc0ab1d","type":"COMBINATION_TREATMENT","name":"ramipril + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-b0b69e1420b67a95","description":null,"metadata":null},{"id":"f4af3b07ac7f4d44b2d7b99beec5706f","type":"COMBINATION_TREATMENT","name":"ramipril + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-3b6477472783d25b","description":null,"metadata":null},{"id":"18d671798ad247e8af8919d0db82d4cc","type":"COMBINATION_TREATMENT","name":"ramipril + telmisartan","canonical_id":"ctgov_combo:ctgov-combo-63142c4f731f2aeb","description":null,"metadata":null},{"id":"6c02b7d799cd4d93b4bbf1e014376da9","type":"COMBINATION_TREATMENT","name":"ramipril + valsartan","canonical_id":"ctgov_combo:ctgov-combo-faa9acf4ba6e0962","description":null,"metadata":null},{"id":"ab0c93ac4ac8494bbf3f7323a3681db8","type":"DRUG","name":"ramiprilat","canonical_id":"gtopdb:6344","description":null,"metadata":null},{"id":"b99ec3f19ab7494fabf73dad34d32ca4","type":"DRUG","name":"ramucirumab","canonical_id":"gtopdb:7390","description":null,"metadata":null},{"id":"3e9a4dcde05242e3b832485026458bcc","type":"DRUG","name":"ramucirumab","canonical_id":"mesh:C543333","description":null,"metadata":null},{"id":"8f9666e22b8241809512e14114e00207","type":"DRUG","name":"ramucirumab","canonical_id":"chembl:CHEMBL1743062","description":null,"metadata":null},{"id":"4ea1534a10214c2bb9d385a4312e530b","type":"TRIAL","name":"randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure","canonical_id":"clinicaltrials.gov:NCT02900378","description":"Chronic Heart Failure With Reduced Ejection Fraction","metadata":null},{"id":"119065eb161442ae8f437e7ee77aad39","type":"GO_TERM","name":"random inactivation of X chromosome","canonical_id":"go:GO:0060816","description":"\"Compensating for the two-fold variation in X-chromosome:autosome ratios between sexes by a global inactivation of all, or most of, the genes on either the paternal or maternal X-chromosome in the XX sex.\" [GOC:dph, GOC:sdb_2009, GOC:tb, PMID:32189388]","metadata":null},{"id":"d829acd883db46a2b1478dac166131e2","type":"DRUG","name":"ranibizumab","canonical_id":"gtopdb:6779","description":null,"metadata":null},{"id":"5f3ae89f5b3446abac36816a7c70917f","type":"DRUG","name":"ranibizumab","canonical_id":"chembl:CHEMBL1201825","description":null,"metadata":null},{"id":"2419bed4159e4b49b4f559484c6390eb","type":"COMBINATION_TREATMENT","name":"ranibizumab + sirolimus","canonical_id":"ctgov_combo:ctgov-combo-f86e6ee3393a3cd5","description":null,"metadata":null},{"id":"19dc6a2eb4bf44feac795d96e2dfedc3","type":"COMBINATION_TREATMENT","name":"ranibizumab + triamcinolone","canonical_id":"ctgov_combo:ctgov-combo-5b8c24c54b9bbc57","description":null,"metadata":null},{"id":"17e04d58a11f4d208fac0795f599fafb","type":"DRUG","name":"ranitidine","canonical_id":"gtopdb:1234","description":null,"metadata":null},{"id":"7bd3b65032f848ef84d2b0f7d205067a","type":"DRUG","name":"ranitidine","canonical_id":"mesh:D011899","description":null,"metadata":null},{"id":"bf3183bdb69c4869beb9f23318e449b4","type":"DRUG","name":"ranitidine","canonical_id":"chembl:CHEMBL1790041","description":null,"metadata":null},{"id":"c1256cbef7754a8a9a3c57c2d86b5d4e","type":"DRUG","name":"ranolazine","canonical_id":"mesh:D000069458","description":null,"metadata":null},{"id":"6cccee4ca3f74b30aa570f5222f5a47f","type":"GO_TERM","name":"rapid tRNA decay","canonical_id":"go:GO:0180037","description":"\"A cytoplasmic tRNA surveillance pathway that targets mature hypomodified tRNAs, catalyzed by 5'-3' exonucleases Xrn1 (S. cerevisiae/human) and Rat1 (S. cerevisiae) XRN2 human, and regulated by adenosine 3',5' bisphosphate (pAp).\" [GOC:vw, PMID:35901126]","metadata":null},{"id":"767cc85eaac347a287559f7ee78f2a72","type":"GO_TERM","name":"raps-insc complex","canonical_id":"go:GO:1990499","description":"\"Protein complex required for the asymmetric division of neuroblasts in Drosophila. Coordinates asymmetric localization of cell fate determinants with orientation of the mitotic spindle resulting in different daughter cells upon division. Localizes at the apical cortex of the neuroblast: Raps maintains, but does not initiate, Insc apically, while Insc segregates Raps asymmetrically. Complex appears to be conserved in mammals (composed of INSC and GPSM1 or GPSM2).\" [GOC:bhm, PMID:22171003]","metadata":null},{"id":"fe8559a1e9fc460398d85c70f89a66f8","type":"DRUG","name":"rasagiline","canonical_id":"gtopdb:6641","description":null,"metadata":null},{"id":"fb04e3785375402393d571d7dda144ec","type":"DRUG","name":"rasagiline","canonical_id":"mesh:C031967","description":null,"metadata":null},{"id":"02173f30c2c94ffbadf03cd808d9c29a","type":"DRUG","name":"rasburicase","canonical_id":"mesh:C469709","description":null,"metadata":null},{"id":"a4118def50b24504b4a1bd057ebc2d7d","type":"GO_TERM","name":"raucaffricine beta-glucosidase activity","canonical_id":"go:GO:0050247","description":"\"Catalysis of the reaction: H2O + raucaffricine = D-glucose + vomilenine.\" [EC:3.2.1.125, RHEA:14557]","metadata":null},{"id":"39f4fac501d34ea8987d374574d5d1b0","type":"DRUG","name":"ravulizumab","canonical_id":"gtopdb:10168","description":null,"metadata":null},{"id":"6b48e527e49d44c19df9804a77d79c07","type":"DRUG","name":"ravulizumab","canonical_id":"chembl:CHEMBL3989986","description":null,"metadata":null},{"id":"04004d38d59e49f2a8d0ba6f604a9d44","type":"DRUG","name":"raxibacumab","canonical_id":"mesh:C542124","description":null,"metadata":null},{"id":"9221e699cafd49b0b386c405f47051d7","type":"GO_TERM","name":"re-entry into mitotic cell cycle","canonical_id":"go:GO:0000320","description":"\"The resumption of the mitotic cell division cycle by cells that were in a quiescent or other non-dividing state.\" [GOC:krc]","metadata":null},{"id":"a280e1b871f94a83b38797bd0c922638","type":"GO_TERM","name":"re-entry into mitotic cell cycle after pheromone arrest","canonical_id":"go:GO:0000321","description":"\"The resumption of the mitotic cell division cycle by pheromone-arrested cells that have not mated. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:krc, PMID:9927449]","metadata":null},{"id":"af46951d1a284f6da67ac80f94aa2b24","type":"GO_TERM","name":"reactive gliosis","canonical_id":"go:GO:0150103","description":"\"A coordinated response of central nervous system (CNS) glial cells-including astrocytes, microglia, and NG2 glia-to injury, infection, or disease, characterized by changes in gene expression, morphology, proliferation, and extracellular matrix production. Reactive gliosis can range from transient glial activation to the formation of a persistent glial scar border.\" [GOC:aruk, GOC:bc, PMID:20012068, PMID:24267886, PMID:24462092, PMID:27049947]","metadata":null},{"id":"bde9dd0ef9704297947322c7eecc476a","type":"GO_TERM","name":"reactive nitrogen species metabolic process","canonical_id":"go:GO:2001057","description":"\"The chemical reactions and pathways involving a reactive nitrogen species.\" [GOC:obol]","metadata":null},{"id":"e180eb80e8374e53bb17c188f806d7f3","type":"GO_TERM","name":"reactive oxygen species biosynthetic process","canonical_id":"go:GO:1903409","description":"\"The chemical reactions and pathways resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.\" [GO_REF:0000068, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24252804]","metadata":null},{"id":"21da11977c1a4130b46f9b8f4c06d16d","type":"GO_TERM","name":"reactive oxygen species metabolic process","canonical_id":"go:GO:0072593","description":"\"The chemical reactions and pathways involving a reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen. They contribute to the microbicidal activity of phagocytes, regulation of signal transduction and gene expression, and the oxidative damage to biopolymers.\" [GOC:mah]","metadata":null},{"id":"e54ceef2727841a09ccbe3c79c95763f","type":"TRIAL","name":"realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL","canonical_id":"clinicaltrials.gov:NCT04981795","description":"Diffuse Large B-cell Lymphoma","metadata":null},{"id":"f203c98d42dc431694aa9883e8429bc5","type":"DRUG","name":"rebamipide","canonical_id":"mesh:C052785","description":null,"metadata":null},{"id":"2476532452994a52b101e07361b3d00d","type":"GO_TERM","name":"rebaudioside B glucosyltransferase activity","canonical_id":"go:GO:0102382","description":"\"Catalysis of the reaction: rebaudioside B + UDP-alpha-D-glucose = rebaudioside A + UDP.\" [RHEA:61760]","metadata":null},{"id":"b7705dff0f354d3fbdfb215eb6abf501","type":"DRUG","name":"reboxetine","canonical_id":"gtopdb:4808","description":null,"metadata":null},{"id":"df0452fc926e4ab398a94e33c47995ac","type":"DRUG","name":"reboxetine","canonical_id":"mesh:C074679","description":null,"metadata":null},{"id":"0753419d6fd14e91b0805cbd6de5eb3a","type":"DRUG","name":"reboxetine","canonical_id":"chembl:CHEMBL14370","description":null,"metadata":null},{"id":"8c4b797c51c34747ac8fa1baf33190c6","type":"COMBINATION_TREATMENT","name":"reboxetine + rivastigmine","canonical_id":"ctgov_combo:ctgov-combo-e2025b808f90a208","description":null,"metadata":null},{"id":"9a47652f8583404782110812e9fd6f38","type":"DRUG","name":"recaticimab","canonical_id":"gtopdb:14196","description":null,"metadata":null},{"id":"034714f7ceaa4be7ac7586d93b04d5ec","type":"COMBINATION_TREATMENT","name":"recaticimab + vunakizumab","canonical_id":"ctgov_combo:ctgov-combo-671058b1a03235e4","description":null,"metadata":null},{"id":"51531865e85442c0824477bb51f96388","type":"GO_TERM","name":"receptor antagonist activity","canonical_id":"go:GO:0048019","description":"\"The activity of a gene product that interacts with a receptor to decrease the ability of the receptor agonist to bind and activate the receptor.\" [GOC:ceb, ISBN:0198506732]","metadata":null},{"id":"c8587f49dcda476db759f6cf35d37235","type":"GO_TERM","name":"receptor catabolic process","canonical_id":"go:GO:0032801","description":"\"The chemical reactions and pathways resulting in the breakdown of a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.\" [GOC:mah]","metadata":null},{"id":"7d068f7232634d2a830af3bf06fae1f8","type":"GO_TERM","name":"receptor clustering","canonical_id":"go:GO:0043113","description":"\"The receptor metabolic process that results in grouping of a set of receptors at a cellular location, often to amplify the sensitivity of a signaling response.\" [GOC:bf, GOC:jl, GOC:pr, PMID:19747931, PMID:21453460]","metadata":null},{"id":"fb77d7b9084642a4a7a6afe011b5c15f","type":"GO_TERM","name":"receptor clustering activity","canonical_id":"go:GO:0141175","description":"\"A protein-protein adaptor that acts as a platform for receptor clustering, often serving to amplify the sensitivity of a signaling response.\" [PMID:19747931, PMID:21453460, PMID:33597156]","metadata":null},{"id":"776d98d30943428897efbb465e015961","type":"GO_TERM","name":"receptor decoy activity","canonical_id":"go:GO:0140319","description":"\"Binding and sequestering a specific receptor ligand to prevent it from binding to its regular receptor.\" [Wikipedia:Decoy_receptors]","metadata":null},{"id":"26e7e1a63be646118e5594f597d0dd64","type":"GO_TERM","name":"receptor diffusion trapping","canonical_id":"go:GO:0098953","description":"\"The process by which a membrane receptor, diffusing freely within the plasma membeane, becomes trapped in some plasma membrane region. This can happen when a receptor bind, directly or indirectly, to some component of the underlying matrix.\" [PMID:18832033]","metadata":null},{"id":"7e902d825793464ca06bf6f4214b3261","type":"GO_TERM","name":"receptor guanylyl cyclase signaling pathway","canonical_id":"go:GO:0007168","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses guanylyl cyclase activity, and converts GTP to cGMP upon activation, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling, PMID:16815030]","metadata":null},{"id":"f6e462c942284da9899594e9bd924285","type":"GO_TERM","name":"receptor internalization","canonical_id":"go:GO:0031623","description":"\"A receptor-mediated endocytosis process that results in the movement of receptors from the plasma membrane to the inside of the cell. The process begins when cell surface receptors are monoubiquitinated following ligand-induced activation. Receptors are subsequently taken up into endocytic vesicles from where they are either targeted to the lysosome or vacuole for degradation or recycled back to the plasma membrane.\" [GOC:bf, GOC:mah, GOC:signaling, PMID:15006537, PMID:19643732]","metadata":null},{"id":"7e4956fb26884a3f970c5399b173161e","type":"GO_TERM","name":"receptor ligand activity","canonical_id":"go:GO:0048018","description":"\"The activity of a gene product that interacts with a receptor to effect a change in the activity of the receptor. Ligands may be produced by the same cell that expresses the receptor. Ligands may also be expressed at the plasma membrane of an adjacent cell (e.g. Notch ligands) or be secreted and diffuse extracellularly from their point of origin to the receiving cell (e.g. interleukins).\" [GOC:kv, GOC:molecular_function_refactoring, GOC:pdt]","metadata":null},{"id":"f97de6e4effa4de593554b7ca73d96f4","type":"GO_TERM","name":"receptor ligand inhibitor activity","canonical_id":"go:GO:0141069","description":"\"Binds to and decreases the activity of the ligand of a signaling receptor.\" [PMID:12478285, PMID:1721860]","metadata":null},{"id":"addb7beb77894780b1d77d25606c2e7c","type":"GO_TERM","name":"receptor localization to non-motile cilium","canonical_id":"go:GO:0097500","description":"\"A process in which a receptor is transported to, or maintained in, a location within a non-motile cilium.\" [GOC:cilia, GOC:kmv, PMID:23128241]","metadata":null},{"id":"f40ce28c7cce40b38ee93db3c2322cb0","type":"GO_TERM","name":"receptor localization to synapse","canonical_id":"go:GO:0097120","description":"\"Any process in which a receptor is transported to, and/or maintained at the synapse, the junction between a nerve fiber of one neuron and another neuron or muscle fiber or glial cell.\" [GOC:BHF, GOC:sjp, PMID:21525273]","metadata":null},{"id":"5be67baffb694794aa512c571813ec6e","type":"GO_TERM","name":"receptor metabolic process","canonical_id":"go:GO:0043112","description":"\"The chemical reactions and pathways involving a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.\" [GOC:jl]","metadata":null},{"id":"9c8aaae659d9450d930de5ac659c013a","type":"GO_TERM","name":"receptor recycling","canonical_id":"go:GO:0001881","description":"\"The process that results in the return of receptor molecules to an active state and an active cellular location after they have been stimulated by a ligand. An active state is when the receptor is ready to receive a signal.\" [GOC:dph]","metadata":null},{"id":"9786f50ee9144d31a75a0d1ccd20695b","type":"GO_TERM","name":"receptor serine/threonine kinase binding","canonical_id":"go:GO:0033612","description":"\"Binding to a receptor that possesses protein serine/threonine kinase activity.\" [GOC:mah]","metadata":null},{"id":"12d5ddbd4f8a41b0aba0c23767c7cd9f","type":"GO_TERM","name":"receptor signaling protein tyrosine kinase activator activity","canonical_id":"go:GO:0030298","description":"\"Binds to and increases the activity of a receptor signaling protein tyrosine kinase.\" [GOC:mah]","metadata":null},{"id":"b391fe1e65d54fc9b5046cb48cd46aaa","type":"GO_TERM","name":"receptor signaling protein tyrosine kinase inhibitor activity","canonical_id":"go:GO:0030294","description":"\"Stops, prevents or reduces the activity of a receptor signaling protein tyrosine kinase.\" [GOC:mah]","metadata":null},{"id":"d2052f8a63ea4841bb361d342d96d79a","type":"GO_TERM","name":"receptor tyrosine kinase binding","canonical_id":"go:GO:0030971","description":"\"Binding to a receptor that possesses protein tyrosine kinase activity.\" [GOC:mah]","metadata":null},{"id":"5027627408344e55b5f461dc558ca5c1","type":"GO_TERM","name":"receptor tyrosine kinase-like orphan receptor binding","canonical_id":"go:GO:0005115","description":"\"Binding to a receptor tyrosine kinase-like orphan receptor (Ror).\" [GOC:ceb, GOC:vw]","metadata":null},{"id":"3da6b295a20c465aad5051592b6ad500","type":"GO_TERM","name":"receptor-mediated bacteriophage irreversible attachment to host cell","canonical_id":"go:GO:0098002","description":"\"The processes by which a bacteriophage initially commits to infection by binding the host receptor irreversibly. Disruption of the phage:cell complex at this step results in the loss of infective phage virions since the process is characterized by conformational changes of bacteriophage head and tail proteins and injection of bacteriophage proteins into the infected cell.\" [GOC:bm]","metadata":null},{"id":"8563210998af464b962bd24612a53c4c","type":"GO_TERM","name":"receptor-mediated bacteriophage reversible attachment to host cell","canonical_id":"go:GO:0098001","description":"\"Process by which a bacteriophage, using its tail fibers, spikes or a baseplate component, initially recognizes and binds to its specific receptor on the host cell surface. This process is reversible and allows the release of a bacteriophage without affecting infection.\" [GOC:bm]","metadata":null},{"id":"fcce8943283943d58d7f25268afddc0e","type":"GO_TERM","name":"receptor-mediated endocytosis","canonical_id":"go:GO:0006898","description":"\"An endocytosis process in which cell surface receptors ensure specificity of transport. A specific receptor on the cell surface binds tightly to the extracellular macromolecule (the ligand) that it recognizes; the plasma-membrane region containing the receptor-ligand complex then undergoes endocytosis, forming a transport vesicle containing the receptor-ligand complex and excluding most other plasma-membrane proteins. Receptor-mediated endocytosis generally occurs via clathrin-coated pits and vesicles.\" [GOC:mah, ISBN:0716731363]","metadata":null},{"id":"5a4b41f4bced4ee9b1a893e925eecfa3","type":"GO_TERM","name":"receptor-mediated endocytosis involved in cholesterol transport","canonical_id":"go:GO:0090118","description":"\"A receptor-mediated endocytosis process involved in intracellular cholesterol transport.\" [GOC:ascb_2009, GOC:dph, GOC:pr, GOC:tb]","metadata":null},{"id":"1a154e8609db47b9820c4c450ccbf8d9","type":"GO_TERM","name":"receptor-mediated endocytosis of virus by host cell","canonical_id":"go:GO:0019065","description":"\"Any receptor-mediated endocytosis that is involved in the uptake of a virus into a host cell; successive instances of virus endocytosis result in the accumulation of virus particles within the cell.\" [GOC:bf, GOC:jl, ISBN:0781702534]","metadata":null},{"id":"19f25d7185944d94b329ace5dceec968","type":"GO_TERM","name":"receptor-mediated virion attachment to host cell","canonical_id":"go:GO:0046813","description":"\"The process by which a virion attaches to a host cell by binding to a receptor on the host cell surface.\" [ISBN:0879694971]","metadata":null},{"id":"3c17d1e9545343fea867aceb54c1a06c","type":"GO_TERM","name":"receptor-receptor interaction","canonical_id":"go:GO:0090722","description":"\"The aggregation, arrangement and bonding together of two or more different receptor complexes that individually undergo combination with a hormone, neurotransmitter, drug or intracellular messenger to form a higher level receptor complex. The formation of the higher level complex initiates a change in cell function.\" [GOC:dox, GOC:pad, GOC:PARL, PMID:22035699, PMID:24157794]","metadata":null},{"id":"17a24f0f86cf4c5281ae7e88bc78d013","type":"GO_TERM","name":"reciprocal homologous recombination","canonical_id":"go:GO:0140527","description":"\"A DNA recombination process that results in the bidirectional exchange of genetic material between highly homologous DNA molecules.\" [PMID:17846636]","metadata":null},{"id":"61f7a263c6e74e628db376525691d5df","type":"GO_TERM","name":"reciprocal meiotic recombination","canonical_id":"go:GO:0007131","description":"\"The cell cycle process in which double strand breaks are formed and repaired through a single or double Holliday junction intermediate. This results in the equal exchange of genetic material between non-sister chromatids in a pair of homologous chromosomes. These reciprocal recombinant products ensure the proper segregation of homologous chromosomes during meiosis I and create genetic diversity.\" [PMID:2087779]","metadata":null},{"id":"958bb42d55564f0eb020f712d5eaedad","type":"GO_TERM","name":"recognition of apoptotic cell","canonical_id":"go:GO:0043654","description":"\"The process in which a cell interprets signals (in the form of specific proteins and lipids) on the surface of a dying cell which it will engulf and remove by phagocytosis.\" [GOC:rk, PMID:15536015]","metadata":null},{"id":"c031531a106c48b3b179627101c29587","type":"GO_TERM","name":"recognition of pollen","canonical_id":"go:GO:0048544","description":"\"A cell recognition process in which pollen is recognized and either accepted or rejected by cells in the stigma.\" [GOC:dph, GOC:pj, GOC:tb]","metadata":null},{"id":"361d2d018d8a40da9267ae6e4c30aee3","type":"GO_TERM","name":"recombinase activator activity","canonical_id":"go:GO:0120230","description":"\"Binds to and increases the activity of a recombinase.\" [GOC:mah, PMID:32414915]","metadata":null},{"id":"1597a12b7f5f4d139c94b8b926f41331","type":"GO_TERM","name":"recombination hotspot binding","canonical_id":"go:GO:0010844","description":"\"Binding to a genomic region which promotes recombination.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ed6996f08ce24f5aaf123e827e984154","type":"GO_TERM","name":"recombination nodule","canonical_id":"go:GO:0005713","description":"\"An electron dense structure that is associated with meiotic chromosomes.\" [GOC:elh]","metadata":null},{"id":"2aeb995c450345a19cf922544b7d3b33","type":"GO_TERM","name":"recombination within rDNA repeats","canonical_id":"go:GO:0045458","description":"\"Genetic recombination within the DNA of the genes coding for ribosomal RNA.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5dc8aaca85eb4ea38cb27f5cbd677b9e","type":"GO_TERM","name":"recombinational interstrand cross-link repair","canonical_id":"go:GO:0036298","description":"\"Removal of a DNA interstrand crosslink (a covalent attachment of DNA bases on opposite strands of the DNA) and restoration of the DNA by a mechanism that involves the exchange, reciprocal or nonreciprocal, of genetic material between the broken DNA molecule and a homologous DNA region.\" [GOC:vw, PMID:20658649]","metadata":null},{"id":"f9c21eed5920460f9d6c4d14fb941ecb","type":"GO_TERM","name":"recombinational repair","canonical_id":"go:GO:0000725","description":"\"A DNA repair process that involves the exchange, reciprocal or nonreciprocal, of genetic material between the broken DNA molecule and a homologous DNA region.\" [GOC:elh]","metadata":null},{"id":"a174cbfe00e344808ccf921a6d63998b","type":"GO_TERM","name":"rectal diverticulum development","canonical_id":"go:GO:0039009","description":"\"The process whose specific outcome is the progression of the rectal diverticulum over time, from its formation to the mature structure. The rectal diverticulum is an outgrowth of the cloaca and links the pronephric kidney to the exterior.\" [GOC:mtg_kidney_jan10, PMID:10535314, PMID:18226983, XAO:0001015]","metadata":null},{"id":"a26e4fdac73e4a5db3d61c56ddcf0e8b","type":"DISEASE","name":"rectum adenocarcinoma","canonical_id":"mondo:0002169","description":null,"metadata":null},{"id":"706dee2574514039a82d978050d3ff37","type":"GO_TERM","name":"recurrent axon collateral","canonical_id":"go:GO:1990020","description":"\"Axon collateral that ramifies in the area of the soma of the cell of origin.\" [NIF_Subcellular:sao1642494436]","metadata":null},{"id":"735b490f581944cfab3d3e192dbe797b","type":"DISEASE","name":"recurrent infections associated with rare immunoglobulin isotypes deficiency","canonical_id":"mondo:0013576","description":null,"metadata":null},{"id":"7b619b55f4ed4b7fb99b770de491f095","type":"GO_TERM","name":"recycling endosome","canonical_id":"go:GO:0055037","description":"\"An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane.\" [GOC:dph, GOC:jid, GOC:kmv, GOC:rph, PMID:10930469, PMID:15601896, PMID:16246101, PMID:21556374, PMID:21562044]","metadata":null},{"id":"d4c6dc58106442f584ae5a8fce2227df","type":"GO_TERM","name":"recycling endosome lumen","canonical_id":"go:GO:0034777","description":"\"The volume enclosed by the membranes of a recycling endosome.\" [GOC:rph]","metadata":null},{"id":"d27e2d9492e54264936e38eccb06c537","type":"GO_TERM","name":"recycling endosome membrane","canonical_id":"go:GO:0055038","description":"\"The lipid bilayer surrounding a recycling endosome.\" [GOC:jid, GOC:rph, PMID:10930469, PMID:15601896, PMID:16246101]","metadata":null},{"id":"8cadd2d3836b4cc7b3f3e4f3c85ba63e","type":"GO_TERM","name":"recycling endosome to Golgi transport","canonical_id":"go:GO:0071955","description":"\"The directed movement of substances from recycling endosomes to the Golgi.\" [GOC:lb]","metadata":null},{"id":"77e2fcc216744c0395642e222fb211f4","type":"GO_TERM","name":"recycling of RNA polymerase","canonical_id":"go:GO:0140182","description":"\"The process of freeing aborted or stalled RNA polymerase (RNAP), which dissociates it from nucleic acids and allows RNAP to reinitiate another transcription cycle. The freed mRNA is not used for further transcription.\" [PMID:33339820, PMID:33339823, PMID:33339827, PMID:39384756]","metadata":null},{"id":"8687258684e548c989d40ed2205237ea","type":"GO_TERM","name":"red chlorophyll catabolite reductase activity","canonical_id":"go:GO:0051743","description":"\"Catalysis of the reaction: primary fluorescent chlorophyll catabolite + 2 oxidized [2Fe-2S]-[ferredoxin] = red chlorophyll catabolite + 2 reduced [2Fe-2S]-[ferredoxin] + 3 H+. This reaction is the reduction of the C20/C1 double bond in the pyrrole system of red chlorophyll catabolite (RCC) to a colorless tetrapyrrole (pFCC) with a strong blue fluorescence.\" [PMID:10743659, RHEA:24752]","metadata":null},{"id":"55173fdf57754e0fb7957cccfcad63b4","type":"GO_TERM","name":"red light photoreceptor activity","canonical_id":"go:GO:0031517","description":"\"The function of absorbing and responding to electromagnetic radiation with a wavelength of approximately 660nm. The response may involve a change in conformation.\" [GOC:nln]","metadata":null},{"id":"b048d0ca15a142cbaf370c94131d2f58","type":"GO_TERM","name":"red light signaling pathway","canonical_id":"go:GO:0010161","description":"\"The series of molecular signals initiated upon sensing of red light by a photoreceptor molecule. Red light is electromagnetic radiation of wavelength of 580-700nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"bc75117f9fe54f1595626e12f1f7476f","type":"GO_TERM","name":"red or far-red light photoreceptor activity","canonical_id":"go:GO:0009883","description":"\"The function of absorbing and responding to electromagnetic radiation with a wavelength of approximately 660-730nm. The response may involve a change in conformation.\" [GOC:lr]","metadata":null},{"id":"f64a40f26da842268d581be9cf6d493b","type":"GO_TERM","name":"red or far-red light signaling pathway","canonical_id":"go:GO:0010017","description":"\"The series of molecular signals initiated upon sensing by photoreceptor molecules of red light or far red light. Red light is electromagnetic radiation of wavelength of 580-700nm. Far red light is electromagnetic radiation of wavelength 700-800nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:lr, GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"173712fa7387408390de23a4dffead5c","type":"GO_TERM","name":"red, far-red light phototransduction","canonical_id":"go:GO:0009585","description":"\"The sequence of reactions within a cell required to convert absorbed photons from red or far-red light into a molecular signal; the red, far-red light range is defined as having a wavelength within the range 660-730 nm.\" [GOC:mah]","metadata":null},{"id":"4efc5e8de571424e9d35b1719d35a6b9","type":"GO_TERM","name":"redox taxis","canonical_id":"go:GO:0009455","description":"\"The directed movement of a motile cell or organism in response to redox potential.\" [GOC:jl, PMID:11029423]","metadata":null},{"id":"410fc8d7d06f48058ec8f9bbdd931ccc","type":"GO_TERM","name":"reduced coenzyme F420 dehydrogenase activity","canonical_id":"go:GO:0043738","description":"\"Catalysis of the reaction: methanophenazine + reduced coenzyme F420 = dihydromethanophenazine + coenzyme F420.\" [RHEA:54752]","metadata":null},{"id":"6dc8fe08c5654492904a344d914f98ed","type":"GO_TERM","name":"reduction of food intake in response to dietary excess","canonical_id":"go:GO:0002023","description":"\"An eating behavior process whereby detection of a dietary excess results in a decrease in intake of nutrients.\" [GOC:pg, GOC:pr, PMID:12161655, PMID:12840200]","metadata":null},{"id":"ce117b64abeb42a3aa352b3b591ff3ca","type":"GO_TERM","name":"reductive iron assimilation","canonical_id":"go:GO:0033215","description":"\"A process in which iron is solubilized by reduction from Fe3+ to Fe2+ via a cell surface reductase and subsequent transport of the iron across the membrane by iron uptake proteins.\" [GOC:cjm, GOC:mah, PMID:16963626]","metadata":null},{"id":"ca9f3ff58d3b402bbc1cda66f1b43629","type":"GO_TERM","name":"reductive pentose-phosphate cycle","canonical_id":"go:GO:0019253","description":"\"The fixation of carbon dioxide (CO2) as glucose in the chloroplasts of C3 plants; uses ATP and NADPH formed in the light reactions of photosynthesis; carbon dioxide reacts with ribulose 1,5-bisphosphate (catalyzed by the function of ribulose-bisphosphate carboxylase) to yield two molecules of 3-phosphoglycerate; these are then phosphorylated by ATP to 1,3-bisphosphateglyceraldehyde which, in turn, is then reduced by NADPH to glyceraldehyde 3-phosphate. The glyceraldehyde 3-phosphate is converted to fructose 5-phosphate and ribulose 5-phosphate by aldolase and other enzymes; the ribulose 5-phosphate is phosphorylated by ATP to ribulose 1,5-bisphosphate.\" [ISBN:0198547684]","metadata":null},{"id":"87720eee49f54856a613bb40b906aea8","type":"GO_TERM","name":"reductive tricarboxylic acid cycle","canonical_id":"go:GO:0019643","description":"\"A pathway leading to the fixation of two molecules of CO2 and the production of one molecule of acetyl-CoA; essentially the oxidative TCA cycle running in reverse. Acetyl-CoA is reductively carboxylated to pyruvate, from which all other central metabolites can be formed. Most of the enzymes of reductive and oxidative TCA cycle are shared, with the exception of three key enzymes that allow the cycle to run in reverse: ATP citrate lyase, 2-oxoglutarate:ferredoxin oxidoreductase, and fumarate reductase. 2-oxoglutarate:ferredoxin oxidoreductase catalyzes the carboxylation of succinyl-CoA to 2-oxoglutarate, ATP citrate lyase the ATP-dependent cleavage of citrate to acetyl-CoA and oxaloacetate, and fumarate reductase the reduction of fumarate forming succinate.\" [GOC:jl, PMID:15838028]","metadata":null},{"id":"581db2c2319f4df6b02605186721c1d9","type":"GO_TERM","name":"reelin complex","canonical_id":"go:GO:0110157","description":"\"An extracellular complex that binds lipoprotein receptors VLDLR and APOER2, cadherin-related neuronal receptors (CNRs) or alpha3beta1 integrin and induces various downstream, reelin-dependent, phosphorylation cascades. It ultimately affects polarization, differentiation, neuronal migration and layer formation in the embryonic brain and neuron growth, maturation, and synaptic activity in the postnatal and adult brain.\" [GOC:bhm, PMID:21844191, PMID:28887403]","metadata":null},{"id":"11ebd46405604245a92e1cc7caf4ebcb","type":"GO_TERM","name":"reelin receptor activity","canonical_id":"go:GO:0038025","description":"\"Combining with the secreted glycoprotein reelin, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, PMID:12827279, PMID:20223215]","metadata":null},{"id":"4d9cb0bf4eb14d2c8192da29f557960c","type":"GO_TERM","name":"reelin-mediated signaling pathway","canonical_id":"go:GO:0038026","description":"\"The series of molecular signals initiated by the binding of reelin (a secreted glycoprotein) to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, PMID:12827279, PMID:20223215]","metadata":null},{"id":"bf14611458ae4f1189ff02734d1e89a9","type":"GO_TERM","name":"reflex","canonical_id":"go:GO:0060004","description":"\"An automatic response to a stimulus beginning with a nerve impulse from a receptor and ending with the action of an effector such as a gland or a muscle. Signaling never reaches a level of consciousness.\" [GOC:dph, ISBN:0877797099]","metadata":null},{"id":"b2fb2fe052ec474789171f80d3a85a38","type":"DISEASE","name":"refractive error","canonical_id":"mondo:0004892","description":null,"metadata":null},{"id":"1244cae239a544559239f1a55990cf89","type":"DRUG","name":"regadenoson","canonical_id":"gtopdb:5596","description":null,"metadata":null},{"id":"598072bb01fd495e8d43d5450ccb67f9","type":"DRUG","name":"regadenoson","canonical_id":"chembl:CHEMBL3989695","description":null,"metadata":null},{"id":"b1b3c28245d148808b9aa8107a3f7393","type":"GO_TERM","name":"regeneration","canonical_id":"go:GO:0031099","description":"\"The regrowth of a lost or destroyed body part, such as an organ or tissue. This process may occur via renewal, repair, and/or growth alone (i.e. increase in size or mass).\" [GOC:mah, GOC:pr]","metadata":null},{"id":"b75188c4ab5849b7bd0020d424b9b3c7","type":"GO_TERM","name":"regionalization","canonical_id":"go:GO:0003002","description":"\"The pattern specification process that results in the subdivision of an axis or axes in space to define an area or volume in which specific patterns of cell differentiation will take place or in which cells interpret a specific environment.\" [GOC:dph, GOC:isa_complete]","metadata":null},{"id":"86b100e127554fcd89506a42ac604b96","type":"DRUG","name":"regorafenib","canonical_id":"gtopdb:5891","description":null,"metadata":null},{"id":"df6cc075076c49dc872f73aef2bec66f","type":"DRUG","name":"regorafenib","canonical_id":"mesh:C559147","description":null,"metadata":null},{"id":"796767734ee749b0bfe0ed79f783893b","type":"DRUG","name":"regorafenib","canonical_id":"chembl:CHEMBL1946170","description":null,"metadata":null},{"id":"9103e42bf5b54fd5b9784760b6876fe4","type":"COMBINATION_TREATMENT","name":"regorafenib + tislelizumab","canonical_id":"ctgov_combo:ctgov-combo-518191cfc1fe6a93","description":null,"metadata":null},{"id":"b7f7d78d43d94860946fb9dab6ce0106","type":"GO_TERM","name":"regulated exocytosis","canonical_id":"go:GO:0045055","description":"\"A process of exocytosis in which soluble proteins and other substances are initially stored in secretory vesicles for later release. It is found mainly in cells that are specialized for secreting products such as hormones, neurotransmitters, or digestive enzymes rapidly on demand.\" [GOC:mah, ISBN:0716731363]","metadata":null},{"id":"5e0c9301106c466c877f1e7597926452","type":"GO_TERM","name":"regulation by virus of viral protein levels in host cell","canonical_id":"go:GO:0046719","description":"\"Any virus-mediated process that modulates the levels of viral proteins in a cell.\" [GOC:ai]","metadata":null},{"id":"cfa6811c307643189afb3144847af680","type":"GO_TERM","name":"regulation of 'de novo' NAD biosynthetic process from L-tryptophan","canonical_id":"go:GO:1905012","description":"\"Any process that modulates the frequency, rate or extent of 'de novo' NAD biosynthetic process from L-tryptophan.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:12140278, PMID:19843166]","metadata":null},{"id":"94698266b50a4d6a8baed74c70e581dd","type":"GO_TERM","name":"regulation of (+)-kotanin biosynthetic process","canonical_id":"go:GO:1900692","description":"\"Any process that modulates the frequency, rate or extent of (+)-kotanin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c8d9ead426e64db7b670635c3af40660","type":"GO_TERM","name":"regulation of (1->3)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070606","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->3)-alpha-D-glucans, compounds composed of glucose residues linked by (1->3)-alpha-D-glucosidic bonds.\" [GOC:mah]","metadata":null},{"id":"a0721eecc75b4ee4acaf24110c78db50","type":"GO_TERM","name":"regulation of (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0032953","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans.\" [GOC:mah]","metadata":null},{"id":"d145d4656b3645a2bc1124bd760d99e6","type":"GO_TERM","name":"regulation of (1->6)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0060917","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->6)-beta-D-glucans.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a6c99d122974487397aa24585329b953","type":"GO_TERM","name":"regulation of (R)-carnitine transmembrane transport","canonical_id":"go:GO:1902272","description":"\"Any process that modulates the frequency, rate or extent of (R)-carnitine transmembrane transport.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"b13532f52ea249f892e6d7177adb7b9c","type":"GO_TERM","name":"regulation of (R)-mevalonic acid biosynthetic process","canonical_id":"go:GO:0106107","description":"\"Any process that modulates the frequency, rate or extent of (R)-mevalonic acid biosynthetic process.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:24296663]","metadata":null},{"id":"7b040299ee9a4a149ad40aea7dfee9d1","type":"GO_TERM","name":"regulation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process","canonical_id":"go:GO:1902646","description":"\"Any process that modulates the frequency, rate or extent of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"c4d6617dcece459aabf830094fe06407","type":"GO_TERM","name":"regulation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process","canonical_id":"go:GO:1902641","description":"\"Any process that modulates the frequency, rate or extent of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate catabolic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22562153]","metadata":null},{"id":"9f4b75c176ac42eb85d445c0aff289b0","type":"GO_TERM","name":"regulation of 3'-UTR-mediated mRNA stabilization","canonical_id":"go:GO:1905868","description":"\"Any process that modulates the frequency, rate or extent of 3'-UTR-mediated mRNA stabilization.\" [GO_REF:0000058, GOC:TermGenie, PMID:19737525]","metadata":null},{"id":"c7924707e762415daeee99689cc9c3d1","type":"GO_TERM","name":"regulation of 4,6-pyruvylated galactose residue biosynthetic process","canonical_id":"go:GO:0060634","description":"\"Any process that modulates the rate, frequency, or extent of 4,6-pyruvylated galactose residue biosynthetic process, the chemical reactions and pathways resulting in the formation of the pyruvylated galactose residue 4-6-O-[(R)(1-carboxyethylidine)]-Gal-beta-(1->3)-. The galactose residue is part of a larger polysaccharide chain.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ef4b90d2fb234a69a734b92db23a729e","type":"GO_TERM","name":"regulation of AIM2 inflammasome complex assembly","canonical_id":"go:GO:0140971","description":"\"Any process that modulates the frequency, rate or extent of AIM2 inflammasome complex assembly.\" [PMID:33467177]","metadata":null},{"id":"2c483950edbf47c4a6f682b57f3bb898","type":"GO_TERM","name":"regulation of AMPA glutamate receptor clustering","canonical_id":"go:GO:1904717","description":"\"Any process that modulates the frequency, rate or extent of AMPA glutamate receptor clustering.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:21558424]","metadata":null},{"id":"3ef60d3d54f44b258b010ee1e48cb803","type":"GO_TERM","name":"regulation of AMPA receptor activity","canonical_id":"go:GO:2000311","description":"\"Any process that modulates the frequency, rate or extent of AMPA selective glutamate receptor activity.\" [GOC:BHF]","metadata":null},{"id":"2250e6c6486e42228b01762ff0b70744","type":"GO_TERM","name":"regulation of ARF protein signal transduction","canonical_id":"go:GO:0032012","description":"\"Any process that modulates the frequency, rate or extent of ARF protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"33e5fdb223574d2ba459f8695cb4de6a","type":"GO_TERM","name":"regulation of ATF6-mediated unfolded protein response","canonical_id":"go:GO:1903891","description":"\"Any process that modulates the frequency, rate or extent of the ATF6-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"8ba7abdad4c14fdcb4a7d576b54ca0cc","type":"GO_TERM","name":"regulation of ATP biosynthetic process","canonical_id":"go:GO:2001169","description":"\"Any process that modulates the frequency, rate or extent of ATP biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"9d6696c0df244a26853c252b4743fbe4","type":"GO_TERM","name":"regulation of ATP citrate synthase activity","canonical_id":"go:GO:2000983","description":"\"Any process that modulates the frequency, rate or extent of ATP citrate synthase activity.\" [GOC:BHF]","metadata":null},{"id":"9f15614f93a14afd82432501a5037a37","type":"GO_TERM","name":"regulation of ATP metabolic process","canonical_id":"go:GO:1903578","description":"\"Any process that modulates the frequency, rate or extent of ATP metabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:20695849]","metadata":null},{"id":"6c278148e1534cd8ad0ff331eb072e4b","type":"GO_TERM","name":"regulation of ATP-dependent activity","canonical_id":"go:GO:0043462","description":"\"Any process that modulates the rate of an ATP-dependent activity.\" [GOC:jl]","metadata":null},{"id":"7ccafa861e0e412d93231815947b6db7","type":"GO_TERM","name":"regulation of ATPase-coupled calcium transmembrane transporter activity","canonical_id":"go:GO:1901894","description":"\"Any process that modulates the frequency, rate or extent of an ATPase-coupled calcium transmembrane transporter activity.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671]","metadata":null},{"id":"9f494321011440ddb64b0c714a6df860","type":"GO_TERM","name":"regulation of AV node cell action potential","canonical_id":"go:GO:0098904","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in an atrioventricular node myocyte. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"60100a68cbfc4bd78c6892c3b57a3b48","type":"GO_TERM","name":"regulation of Arp2/3 complex-mediated actin nucleation","canonical_id":"go:GO:0034315","description":"\"Any process that modulates the frequency, rate or extent of actin nucleation mediated by the Arp2/3 complex and interacting proteins.\" [GOC:mah]","metadata":null},{"id":"0f08efa8d95c4af7bcad5c95999cbb8b","type":"GO_TERM","name":"regulation of Atg1/ULK1 kinase complex assembly","canonical_id":"go:GO:1905864","description":"\"Any process that modulates the frequency, rate or extent of Atg1/ULK1 kinase complex assembly.\" [GO_REF:0000058, GOC:autophagy, GOC:mf, GOC:TermGenie, PMID:26567215]","metadata":null},{"id":"abd7232ab56c4f8f9dc8ecd9411db326","type":"GO_TERM","name":"regulation of B cell activation","canonical_id":"go:GO:0050864","description":"\"Any process that modulates the frequency, rate or extent of B cell activation.\" [GOC:ai]","metadata":null},{"id":"be03004da3144285a3cc540943543dfc","type":"GO_TERM","name":"regulation of B cell anergy","canonical_id":"go:GO:0002670","description":"\"Any process that modulates the frequency, rate, or extent of B cell anergy.\" [GOC:add]","metadata":null},{"id":"65184605c8f740e4b27af88387b6414f","type":"GO_TERM","name":"regulation of B cell antigen processing and presentation","canonical_id":"go:GO:0002622","description":"\"Any process that modulates the frequency, rate, or extent of B cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"3ce67efb1b0d4d01b68e9f82c9b93d3d","type":"GO_TERM","name":"regulation of B cell apoptotic process","canonical_id":"go:GO:0002902","description":"\"Any process that modulates the frequency, rate, or extent of B cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"664819f1ec224bf38c7295359cee0746","type":"GO_TERM","name":"regulation of B cell chemotaxis","canonical_id":"go:GO:2000537","description":"\"Any process that modulates the frequency, rate or extent of B cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"5c63be96286b4ecdae46402126e832a0","type":"GO_TERM","name":"regulation of B cell cytokine production","canonical_id":"go:GO:0002721","description":"\"Any process that modulates the frequency, rate, or extent of B cell cytokine production.\" [GOC:add]","metadata":null},{"id":"a736835b72fa4f35869b98065acc8fb7","type":"GO_TERM","name":"regulation of B cell deletion","canonical_id":"go:GO:0002867","description":"\"Any process that modulates the frequency, rate, or extent of B cell deletion.\" [GOC:add]","metadata":null},{"id":"7e16a66035bf41e8b7d93f49b5b75d54","type":"GO_TERM","name":"regulation of B cell differentiation","canonical_id":"go:GO:0045577","description":"\"Any process that modulates the frequency, rate or extent of B cell differentiation.\" [GOC:curators]","metadata":null},{"id":"4d7cd7b00406410aa501ed546a34f563","type":"GO_TERM","name":"regulation of B cell mediated immunity","canonical_id":"go:GO:0002712","description":"\"Any process that modulates the frequency, rate, or extent of B cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"c3746740703a4cdeaea359ca7e7c5926","type":"GO_TERM","name":"regulation of B cell proliferation","canonical_id":"go:GO:0030888","description":"\"Any process that modulates the frequency, rate or extent of B cell proliferation.\" [GOC:mah]","metadata":null},{"id":"7a89748d26e243a2ba0af47577bc8004","type":"GO_TERM","name":"regulation of B cell receptor signaling pathway","canonical_id":"go:GO:0050855","description":"\"Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell.\" [GOC:ai]","metadata":null},{"id":"16e7062003474eb596a33d6c59cd339e","type":"GO_TERM","name":"regulation of B cell tolerance induction","canonical_id":"go:GO:0002661","description":"\"Any process that modulates the frequency, rate, or extent of B cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"0d7a3d262c76400688c7eea1e90e197a","type":"GO_TERM","name":"regulation of B-1 B cell differentiation","canonical_id":"go:GO:0001924","description":"\"Any process that modulates the frequency, rate, or extent of B-1 B cell differentiation. B-1 B cells are a distinct subset of B cells characterized as being CD5 positive, found predominantly in the peritoneum, pleural cavities, and spleen, and enriched for self-reactivity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"5118cd694b4148a49d6e49ea03a14bd6","type":"GO_TERM","name":"regulation of BMP secretion","canonical_id":"go:GO:2001284","description":"\"Any process that modulates the frequency, rate or extent of BMP secretion.\" [GOC:sart]","metadata":null},{"id":"fc645aac08e74f97a1ee1f91576306ab","type":"GO_TERM","name":"regulation of BMP signaling pathway","canonical_id":"go:GO:0030510","description":"\"Any process that modulates the frequency, rate or extent of the activity of any BMP receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"4e595d1efc044244a458dfcb7bd12386","type":"GO_TERM","name":"regulation of C-C chemokine receptor CCR7 signaling pathway","canonical_id":"go:GO:1903080","description":"\"Any process that modulates the frequency, rate or extent of C-C chemokine receptor CCR7 signaling pathway.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11602640]","metadata":null},{"id":"05e16c33b7d44bc69ebc1f5490a497a6","type":"GO_TERM","name":"regulation of CAMKK-AMPK signaling cascade","canonical_id":"go:GO:1905289","description":"\"Any process that modulates the frequency, rate or extent of CAMKK-AMPK signaling cascade.\" [GO_REF:0000058, GOC:TermGenie, PMID:22128786]","metadata":null},{"id":"08c7e2500c2f4266859acbdbc9d918f2","type":"GO_TERM","name":"regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation","canonical_id":"go:GO:0032829","description":"\"Any process that modulates the frequency, rate or extent of differentiation of CD4-positive, CD25-positive, alpha-beta regulatory T cells.\" [GOC:mah]","metadata":null},{"id":"e6fc51310a8044e69996b97740b62220","type":"GO_TERM","name":"regulation of CD4-positive, alpha-beta T cell activation","canonical_id":"go:GO:2000514","description":"\"Any process that modulates the frequency, rate or extent of CD4-positive, alpha-beta T cell activation.\" [GOC:obol]","metadata":null},{"id":"b6740e26eb2c4616a10a610f8818b50c","type":"GO_TERM","name":"regulation of CD4-positive, alpha-beta T cell costimulation","canonical_id":"go:GO:1900279","description":"\"Any process that modulates the frequency, rate or extent of CD4-positive, alpha-beta T cell costimulation.\" [GOC:BHF, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"af800b992aa14b5eac68a8759155d340","type":"GO_TERM","name":"regulation of CD4-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043370","description":"\"Any process that modulates the frequency, rate, or extent of CD4-positive, alpha-beta T cell differentiation.\" [GOC:add, GOC:pr, ISBN:0781735149]","metadata":null},{"id":"55c6b271142744aaa6299b2b1cac1676","type":"GO_TERM","name":"regulation of CD4-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:2000561","description":"\"Any process that modulates the frequency, rate or extent of CD4-positive, alpha-beta T cell proliferation.\" [GOC:obol]","metadata":null},{"id":"8509b7a0ce454fe881dddbe3c3e9ea63","type":"GO_TERM","name":"regulation of CD40 signaling pathway","canonical_id":"go:GO:2000348","description":"\"Any process that modulates the frequency, rate or extent of signaling via the CD40 signaling pathway.\" [GOC:mah]","metadata":null},{"id":"4eb953be40e94b329ff747a2e5ab0c25","type":"GO_TERM","name":"regulation of CD8-positive, alpha-beta T cell activation","canonical_id":"go:GO:2001185","description":"\"Any process that modulates the frequency, rate or extent of CD8-positive, alpha-beta T cell activation.\" [GOC:obol]","metadata":null},{"id":"1319527452e04ab189e6fb5ca24385bb","type":"GO_TERM","name":"regulation of CD8-positive, alpha-beta T cell differentiation","canonical_id":"go:GO:0043376","description":"\"Any process that modulates the frequency, rate, or extent of CD8-positive, alpha-beta T cell differentiation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1aba1523f98a4a968b29c689dd8dca99","type":"GO_TERM","name":"regulation of CD8-positive, alpha-beta T cell extravasation","canonical_id":"go:GO:2000449","description":"\"Any process that modulates the frequency, rate or extent of CD8-positive, alpha-beta T cell extravasation.\" [GOC:obol]","metadata":null},{"id":"785af67d51c2438bb4d81b01c1d6b9d3","type":"GO_TERM","name":"regulation of CD8-positive, alpha-beta T cell proliferation","canonical_id":"go:GO:2000564","description":"\"Any process that modulates the frequency, rate or extent of CD8-positive, alpha-beta T cell proliferation.\" [GOC:obol]","metadata":null},{"id":"e4f865922d9246db8986eb24e705bc41","type":"GO_TERM","name":"regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation","canonical_id":"go:GO:2000452","description":"\"Any process that modulates the frequency, rate or extent of CD8-positive, alpha-beta cytotoxic T cell extravasation.\" [GOC:obol]","metadata":null},{"id":"fae536ad9756444daad4821b6a48605f","type":"GO_TERM","name":"regulation of COPII vesicle uncoating","canonical_id":"go:GO:0090111","description":"\"Any process that modulates the frequency, rate or extent of COPII vesicle uncoating, the process in which COPII vesicle coat proteins are disassembled, and released.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"91f8de375ef54de4a11c82e8fa0640c2","type":"GO_TERM","name":"regulation of Cdc42 protein signal transduction","canonical_id":"go:GO:0032489","description":"\"Any process that modulates the frequency, rate or extent of Cdc42 protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"80ebdfd22b864138b4930f7a174f3b57","type":"GO_TERM","name":"regulation of D-aspartate import across plasma membrane","canonical_id":"go:GO:0140215","description":"\"Any process that modulates the frequency, rate or extent of the directed import of D-aspartate from the extracellular region across the plasma membrane and into the cytosol.\" [PMID:27663541]","metadata":null},{"id":"95e2d08a1574410aa1bebeaa1dcd5f67","type":"GO_TERM","name":"regulation of D-glucose import across plasma membrane","canonical_id":"go:GO:0046324","description":"\"Any process that modulates the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell.\" [GOC:ai]","metadata":null},{"id":"be2cde4571d64711b52a889c195c3535","type":"GO_TERM","name":"regulation of D-glucose transmembrane transport","canonical_id":"go:GO:0010827","description":"\"Any process that modulates the frequency, rate or extent of glucose transport across a membrane. Glucose transport is the directed movement of the hexose monosaccharide glucose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"250b6777c6034b4185315dff633a7a61","type":"GO_TERM","name":"regulation of D-xylose catabolic process","canonical_id":"go:GO:0043469","description":"\"Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of xylose.\" [GOC:mlg]","metadata":null},{"id":"64c91ac9305c4af7a3770bc8a8eeffed","type":"GO_TERM","name":"regulation of DNA amplification","canonical_id":"go:GO:1904523","description":"\"Any process that modulates the frequency, rate or extent of DNA amplification.\" [GO_REF:0000058, GOC:TermGenie, PMID:26195783]","metadata":null},{"id":"0621644e2e404e2da599d71a09813475","type":"GO_TERM","name":"regulation of DNA binding","canonical_id":"go:GO:0051101","description":"\"Any process that modulates the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid).\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"5b2d166628454e7b842594af60f2f2cb","type":"GO_TERM","name":"regulation of DNA biosynthetic process","canonical_id":"go:GO:2000278","description":"\"Any process that modulates the frequency, rate or extent of DNA biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"fb860af83a5f41338dbd7d02a11d3ebc","type":"GO_TERM","name":"regulation of DNA catabolic process","canonical_id":"go:GO:1903624","description":"\"Any process that modulates the frequency, rate or extent of DNA catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:2001740]","metadata":null},{"id":"ac8c310b56f74f8bbab20738a4875ce2","type":"GO_TERM","name":"regulation of DNA damage checkpoint","canonical_id":"go:GO:2000001","description":"\"Any process that modulates the frequency, rate or extent of a DNA damage checkpoint.\" [GOC:obol]","metadata":null},{"id":"ba97ff47470e45bbb6038ec11d5c04ed","type":"GO_TERM","name":"regulation of DNA damage response, signal transduction by p53 class mediator","canonical_id":"go:GO:0043516","description":"\"Any process that modulates the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.\" [GOC:jl]","metadata":null},{"id":"091289836e0c4c29ac0b8afe502f0ed0","type":"GO_TERM","name":"regulation of DNA double-strand break processing","canonical_id":"go:GO:1903775","description":"\"Any process that modulates the frequency, rate or extent of DNA double-strand break processing.\" [GO_REF:0000058, GOC:TermGenie, PMID:25203555]","metadata":null},{"id":"ad4d5c8b3908464fb8790c461abb572b","type":"GO_TERM","name":"regulation of DNA endoreduplication","canonical_id":"go:GO:0032875","description":"\"Any process that modulates the frequency, rate or extent of DNA endoreduplication.\" [GOC:mah]","metadata":null},{"id":"a44fee930d4d4863867ed534d0be2a81","type":"GO_TERM","name":"regulation of DNA metabolic process","canonical_id":"go:GO:0051052","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving DNA.\" [GOC:ai]","metadata":null},{"id":"9989655bcb5e4115aa857ba5b7661657","type":"GO_TERM","name":"regulation of DNA recombinase disassembly","canonical_id":"go:GO:0062109","description":"\"Any process that modulates the rate, frequency or extent of DNA recombinase disassembly, the disaggregation of a DNA recombinase complex into its constituent components.\" [PMID:30297419]","metadata":null},{"id":"51ebe43103874a4c937f0d177aa29c49","type":"GO_TERM","name":"regulation of DNA recombinase mediator complex assembly","canonical_id":"go:GO:1903872","description":"\"Any process that modulates the frequency, rate or extent of DNA recombinase mediator complex assembly.\" [GO_REF:0000058, GOC:rb, GOC:TermGenie, PMID:18347097]","metadata":null},{"id":"f4f1bad73eb04cb8852de76fb76591ed","type":"GO_TERM","name":"regulation of DNA recombination","canonical_id":"go:GO:0000018","description":"\"Any process that modulates the frequency, rate or extent of DNA recombination, a DNA metabolic process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"928a1a12631f43fbb2d75375d7017fd9","type":"GO_TERM","name":"regulation of DNA recombination at centromere","canonical_id":"go:GO:0061806","description":"\"Any process that modulates the frequency, rate or extent of DNA recombination within centromeric DNA.\" [GOC:dph, GOC:mah, PMID:27697832]","metadata":null},{"id":"c9f708171e374d4faa2c7cdb382345c8","type":"GO_TERM","name":"regulation of DNA recombination at telomere","canonical_id":"go:GO:0072695","description":"\"Any process that modulates the frequency, rate or extent of DNA recombination within the telomere.\" [GOC:mah]","metadata":null},{"id":"a7be9bd00b2c4f0394a72f01b82ad1ef","type":"GO_TERM","name":"regulation of DNA repair","canonical_id":"go:GO:0006282","description":"\"Any process that modulates the frequency, rate or extent of DNA repair.\" [GOC:curators]","metadata":null},{"id":"eb8a1346f3b841af8d7d3536a0cb9ef9","type":"GO_TERM","name":"regulation of DNA replication","canonical_id":"go:GO:0006275","description":"\"Any process that modulates the frequency, rate or extent of DNA replication.\" [GOC:curators]","metadata":null},{"id":"bcd32792b89e400e9f318897f53c9282","type":"GO_TERM","name":"regulation of DNA replication termination","canonical_id":"go:GO:2000621","description":"\"Any process that modulates the frequency, rate or extent of DNA replication termination.\" [GOC:obol]","metadata":null},{"id":"f6e812a31cf1477ba38daa6afbf6ef26","type":"GO_TERM","name":"regulation of DNA stability","canonical_id":"go:GO:0097752","description":"\"Any process that modulates the stability of DNA.\" [GOC:pr]","metadata":null},{"id":"4d030a1e2b1c436ab04b1cbc1d3baec9","type":"GO_TERM","name":"regulation of DNA strand elongation","canonical_id":"go:GO:0060382","description":"\"Any process that modulates the rate, frequency or extent of DNA strand elongation. DNA strand elongation is the DNA metabolic process in which an existing DNA strand is extended by activities including the addition of nucleotides to the 3' end of the strand.\" [GOC:mah]","metadata":null},{"id":"d4abed955d0e4773b53c6498e8c6e79a","type":"GO_TERM","name":"regulation of DNA strand resection involved in replication fork processing","canonical_id":"go:GO:0110026","description":"\"Any process that modulates the frequency, rate or extent of DNA strand resection involved in replication fork processing.\" [GOC:mah, PMID:28475874]","metadata":null},{"id":"c59908fa71bc44738f54c71d09e58311","type":"GO_TERM","name":"regulation of DNA-templated DNA replication","canonical_id":"go:GO:0090329","description":"\"Any process that modulates the rate, frequency, or extent of DNA-templated DNA replication, the process in which new strands of DNA are synthesized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"077689e7b7834c75bc768d6029691f0d","type":"GO_TERM","name":"regulation of DNA-templated DNA replication initiation","canonical_id":"go:GO:0030174","description":"\"Any process that modulates the frequency, rate or extent of initiation of DNA-dependent DNA replication; the process in which DNA becomes competent to replicate. In eukaryotes, replication competence is established in early G1 and lost during the ensuing S phase.\" [GOC:mah]","metadata":null},{"id":"47f25b65f41548fda8fc6aa52602f883","type":"GO_TERM","name":"regulation of DNA-templated transcription","canonical_id":"go:GO:0006355","description":"\"Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"1d5e7c9bd0e949cdb3e292b6ec0fabce","type":"GO_TERM","name":"regulation of DNA-templated transcription elongation","canonical_id":"go:GO:0032784","description":"\"Any process that modulates the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides catalyzed by a DNA-dependent RNA polymerase.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"d4882cc146c449b7b12ecf62ea0c95a8","type":"GO_TERM","name":"regulation of DNA-templated transcription initiation","canonical_id":"go:GO:2000142","description":"\"Any process that modulates the frequency, rate or extent of DNA-templated transcription initiation.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"c9a7297d4066493294994bce8bbf3868","type":"GO_TERM","name":"regulation of ER to Golgi vesicle-mediated transport","canonical_id":"go:GO:0060628","description":"\"Any process that modulates the rate, frequency, or extent of ER to Golgi vesicle-mediated transport, the directed movement of substances from the endoplasmic reticulum (ER) to the Golgi, mediated by COP II vesicles. Small COP II coated vesicles form from the ER and then fuse directly with the cis-Golgi. Larger structures are transported along microtubules to the cis-Golgi.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f8d87a03077243f2a08471583f23ad1d","type":"GO_TERM","name":"regulation of ERAD pathway","canonical_id":"go:GO:1904292","description":"\"Any process that modulates the frequency, rate or extent of ERAD pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"188d83f4af1c47cf87e90051be9069b9","type":"GO_TERM","name":"regulation of ERBB signaling pathway","canonical_id":"go:GO:1901184","description":"\"Any process that modulates the frequency, rate or extent of ERBB signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"a575319b3404413db8270b843f7844c1","type":"GO_TERM","name":"regulation of ERBB3 signaling pathway","canonical_id":"go:GO:1905578","description":"\"Any process that modulates the frequency, rate or extent of ERBB3 signaling pathway.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:27353365]","metadata":null},{"id":"fca970d8aad3466d8e90d5ba34a145da","type":"GO_TERM","name":"regulation of ERK1 and ERK2 cascade","canonical_id":"go:GO:0070372","description":"\"Any process that modulates the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.\" [GOC:add, ISBN:0121245462, ISBN:0896039986]","metadata":null},{"id":"40fbece4b09a4e1cab63b29059f5342a","type":"GO_TERM","name":"regulation of ERK5 cascade","canonical_id":"go:GO:0070376","description":"\"Any process that modulates the frequency, rate or extent of signal transduction mediated by the ERK5 cascade.\" [GOC:add, ISBN:0121245462, ISBN:0896039986]","metadata":null},{"id":"29227a55c2d248448a9f3bdf04c92339","type":"GO_TERM","name":"regulation of F-9775A biosynthetic process","canonical_id":"go:GO:1900670","description":"\"Any process that modulates the frequency, rate or extent of F-9775A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"02ae188c179b4960a6d57b9f9755bc3a","type":"GO_TERM","name":"regulation of F-9775B biosynthetic process","canonical_id":"go:GO:1900675","description":"\"Any process that modulates the frequency, rate or extent of F-9775B biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5bd1a918f7e84ea7837fb532f55dcded","type":"GO_TERM","name":"regulation of FACT complex assembly","canonical_id":"go:GO:1905644","description":"\"Any process that modulates the frequency, rate or extent of FACT complex assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"b5557b6539ac427bba1944bbfbe625da","type":"GO_TERM","name":"regulation of Fas signaling pathway","canonical_id":"go:GO:1902044","description":"\"Any process that modulates the frequency, rate or extent of Fas signaling pathway.\" [GOC:TermGenie, PMID:17245429]","metadata":null},{"id":"fceb330ca77647bdab1d68fc7d624eca","type":"GO_TERM","name":"regulation of Fc receptor mediated stimulatory signaling pathway","canonical_id":"go:GO:0060368","description":"\"Any process that modulates the rate, frequency or extent of the Fc receptor mediated stimulatory signaling pathway..\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6fe1ba689e9f4a5eb97399039ec5a0b7","type":"GO_TERM","name":"regulation of Frizzled Nuclear Import pathway","canonical_id":"go:GO:0140710","description":"\"Any process that modulates the frequency, rate or extent of a Frizzled Nuclear Import pathway.\" [PMID:22510459, PMID:22579286]","metadata":null},{"id":"14dff0f34c9244569b294c541b145328","type":"GO_TERM","name":"regulation of FtsZ-dependent cytokinesis","canonical_id":"go:GO:2000244","description":"\"Any process that modulates the frequency, rate or extent of FtsZ-dependent cytokinesis.\" [GOC:mah]","metadata":null},{"id":"fabc3d2239ad4b61b6085b52efa8b844","type":"GO_TERM","name":"regulation of G protein-coupled receptor internalization","canonical_id":"go:GO:1904020","description":"\"Any process that modulates the frequency, rate or extent of G protein-coupled receptor internalization.\" [GO_REF:0000058, GOC:TermGenie, PMID:24732013]","metadata":null},{"id":"11d4e380386d4aad923df673c54720e8","type":"GO_TERM","name":"regulation of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0008277","description":"\"Any process that modulates the frequency, rate or extent of G protein-coupled receptor signaling pathway.\" [GOC:curators]","metadata":null},{"id":"68873e1b3f9b44d2adb4754db4fad782","type":"GO_TERM","name":"regulation of G0 to G1 transition","canonical_id":"go:GO:0070316","description":"\"A cell cycle process that modulates the rate or extent of the transition from the G0 quiescent state to the G1 phase.\" [GOC:mah]","metadata":null},{"id":"4ac263b73ac841d1b89888a38524a281","type":"GO_TERM","name":"regulation of G1 to G0 transition","canonical_id":"go:GO:1903450","description":"\"Any process that modulates the frequency, rate or extent of G1 to G0 transition.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:24088570]","metadata":null},{"id":"a9ba2f3d1fed45b49d182962cbb690be","type":"GO_TERM","name":"regulation of G1/S transition of mitotic cell cycle","canonical_id":"go:GO:2000045","description":"\"Any signaling pathway that modulates the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the mitotic cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"1aba05d67bdb40969a30fa272f0a81ab","type":"GO_TERM","name":"regulation of G2/M transition of mitotic cell cycle","canonical_id":"go:GO:0010389","description":"\"Any signaling pathway that modulates the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the mitotic cell cycle.\" [GOC:mtg_cell_cycle, PMID:17329565]","metadata":null},{"id":"1449945875674e0bac42f1980bfaac3d","type":"GO_TERM","name":"regulation of G2/MI transition of meiotic cell cycle","canonical_id":"go:GO:0110030","description":"\"Any signaling pathway that modulates the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to MI phase of the meiotic cell cycle.\" [GOC:vw]","metadata":null},{"id":"76a92520064f4bcb99c023f8f0ba0dc3","type":"GO_TERM","name":"regulation of GABA catabolic process","canonical_id":"go:GO:1901715","description":"\"Any process that modulates the frequency, rate or extent of gamma-aminobutyric acid catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"080822279129435a8ee390eb559bdf8a","type":"GO_TERM","name":"regulation of GABA-A receptor activity","canonical_id":"go:GO:0106040","description":"\"Any process that modulates the frequency, rate or extent of GABA-A receptor activity.\" [PMID:24044036]","metadata":null},{"id":"a1f278c338bc4771819b532be50a4f62","type":"GO_TERM","name":"regulation of GTPase activity","canonical_id":"go:GO:0043087","description":"\"Any process that modulates the rate of GTP hydrolysis by a GTPase.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"a40ad29e651e4b89aa40c417f4d0781b","type":"GO_TERM","name":"regulation of Golgi calcium ion export","canonical_id":"go:GO:1901472","description":"\"Any process that modulates the frequency, rate or extent of Golgi calcium ion export.\" [GOC:TermGenie]","metadata":null},{"id":"61d7407d0da34502b7dcfe9f07fa47c7","type":"GO_TERM","name":"regulation of Golgi inheritance","canonical_id":"go:GO:0090170","description":"\"Any process that modulates the rate, frequency or extent of Golgi inheritance. Golgi inheritance is the partitioning of Golgi apparatus between daughter cells at cell division.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"9feca65147f6407c94b900a72b0d4641","type":"GO_TERM","name":"regulation of Golgi organization","canonical_id":"go:GO:1903358","description":"\"Any process that modulates the frequency, rate or extent of Golgi organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:17562788]","metadata":null},{"id":"74a7ed3172c14351b0cd32e718d48011","type":"GO_TERM","name":"regulation of Golgi to plasma membrane protein transport","canonical_id":"go:GO:0042996","description":"\"Any process that modulates the frequency, rate or extent of the transport of proteins from the Golgi to the plasma membrane.\" [GOC:jl]","metadata":null},{"id":"d3439076e4b640fea32bda47fae2feaf","type":"GO_TERM","name":"regulation of Golgi vesicle fusion to target membrane","canonical_id":"go:GO:0048214","description":"\"Any process that modulates the frequency, rate or extent of Golgi vesicle fusion to target membrane.\" [GOC:jid, ISBN:0716731363, PMID:10219233]","metadata":null},{"id":"275617b1665a4e509270986c823b0191","type":"GO_TERM","name":"regulation of Hulle cell development","canonical_id":"go:GO:0070808","description":"\"Any process that modulates the frequency, rate or extent of Hulle cell development, a process that leads to the formation of Hulle cells. Hulle cells are specialized multinucleate cells that originate from a nest-like aggregation of hyphae during sexual development and serve as nurse cells to the developing cleistothecium, or fruiting body.\" [GOC:mah]","metadata":null},{"id":"3156c3205e074b5cb93696c151b6da3e","type":"GO_TERM","name":"regulation of I-kappaB phosphorylation","canonical_id":"go:GO:1903719","description":"\"Any process that modulates the frequency, rate or extent of I-kappaB phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23675531]","metadata":null},{"id":"19f490f57ed3422592dd819a0052e27b","type":"GO_TERM","name":"regulation of IP-10 production","canonical_id":"go:GO:0071658","description":"\"Any process that modulates the frequency, rate, or extent of production of IP-10.\" [GOC:mah]","metadata":null},{"id":"fd107c38c63c41279c78e1047ddbcfa6","type":"GO_TERM","name":"regulation of IRE1-mediated unfolded protein response","canonical_id":"go:GO:1903894","description":"\"Any process that modulates the frequency, rate or extent of the IRE1-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"03770c632f604300a26c88a08bec4d3a","type":"GO_TERM","name":"regulation of JNK cascade","canonical_id":"go:GO:0046328","description":"\"Any process that modulates the frequency, rate or extent of signal transduction mediated by the JNK cascade.\" [GOC:bf]","metadata":null},{"id":"b0261b24d8304b3f877ff36a4de44466","type":"GO_TERM","name":"regulation of JUN kinase activity","canonical_id":"go:GO:0043506","description":"\"Any process that modulates the frequency, rate or extent of JUN kinase activity.\" [GOC:jl]","metadata":null},{"id":"aa84dcc2503d4f3196d905ce718ab067","type":"GO_TERM","name":"regulation of Kit signaling pathway","canonical_id":"go:GO:1900234","description":"\"Any process that modulates the frequency, rate or extent of Kit signaling pathway.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"48ecd57d0053470cb2795e30555794f4","type":"GO_TERM","name":"regulation of L-arginine import across plasma membrane","canonical_id":"go:GO:1905541","description":"\"Any process that modulates the frequency, rate or extent of L-arginine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:14718525]","metadata":null},{"id":"fd5e20ec035f4188befaa42b8651469e","type":"GO_TERM","name":"regulation of L-ascorbic acid biosynthetic process","canonical_id":"go:GO:2000082","description":"\"Any process that modulates the frequency, rate or extent of L-ascorbic acid biosynthetic process.\" [PMID:19395407]","metadata":null},{"id":"2a5b521e45184f59bcdbff32841c6553","type":"GO_TERM","name":"regulation of L-fucose catabolic process","canonical_id":"go:GO:0043468","description":"\"Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of L-fucose.\" [GOC:mlg]","metadata":null},{"id":"063f4f517b964f77aa2f3182176034df","type":"GO_TERM","name":"regulation of L-glutamate import across plasma membrane","canonical_id":"go:GO:0002036","description":"\"Any process that modulates the frequency, rate or extent of L-glutamate import into a cell.\" [GOC:TermGenie]","metadata":null},{"id":"01c41d41fd7b4730a2566d10f6cb8904","type":"GO_TERM","name":"regulation of L-glutamine biosynthetic process","canonical_id":"go:GO:0062132","description":"\"Any process that modulates the rate, frequency or extent of L-glutamine biosynthesis.\" [GOC:ha, PMID:19755423]","metadata":null},{"id":"e4e230237db447a5919ddeba13cc0b5d","type":"GO_TERM","name":"regulation of L-glutamine import across plasma membrane","canonical_id":"go:GO:1901034","description":"\"Any process that modulates the frequency, rate or extent of L-glutamine import into cell.\" [GOC:TermGenie]","metadata":null},{"id":"0caf8fb1d73e4b0392cb5cf8be44cb4e","type":"GO_TERM","name":"regulation of L-leucine biosynthetic process","canonical_id":"go:GO:2001276","description":"\"Any process that modulates the frequency, rate or extent of L-leucine biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"b2365fff40174a23a519a75658ef4ec1","type":"GO_TERM","name":"regulation of L-leucine import across plasma membrane","canonical_id":"go:GO:1905532","description":"\"Any process that modulates the frequency, rate or extent of L-leucine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:10467003]","metadata":null},{"id":"4a666a259ed1475da53d0e68cbd4c012","type":"GO_TERM","name":"regulation of L-lysine import across plasma membrane","canonical_id":"go:GO:1905008","description":"\"Any process that modulates the frequency, rate or extent of L-lysine import into cell.\" [GO_REF:0000058, GOC:TermGenie, PMID:7499219]","metadata":null},{"id":"f973366300794c08901921d63aab2136","type":"GO_TERM","name":"regulation of L-methionine import across plasma membrane","canonical_id":"go:GO:1905624","description":"\"Any process that modulates the frequency, rate or extent of L-methionine import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:17556368]","metadata":null},{"id":"2ca5f1f1c6894da2aa04fe00f40805de","type":"GO_TERM","name":"regulation of L-proline biosynthetic process","canonical_id":"go:GO:1902005","description":"\"Any process that modulates the frequency, rate or extent of L-proline biosynthetic process.\" [GOC:TermGenie, PMID:23415322]","metadata":null},{"id":"dbc9ea98b7d242babc85a0adc52422cc","type":"GO_TERM","name":"regulation of L-proline catabolic process","canonical_id":"go:GO:2001156","description":"\"Any process that modulates the frequency, rate or extent of L-proline catabolic process.\" [GOC:obol]","metadata":null},{"id":"66a9599147a143618010cc7a7ea5a2c5","type":"GO_TERM","name":"regulation of L-proline import across plasma membrane","canonical_id":"go:GO:1905735","description":"\"Any process that modulates the frequency, rate or extent of L-proline import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"7bd48d1c10364b3ca4ddb376b9ab51c5","type":"GO_TERM","name":"regulation of L-threonine import across plasma membrane","canonical_id":"go:GO:1900926","description":"\"Any process that modulates the frequency, rate or extent of L-threonine import into cell.\" [GOC:TermGenie]","metadata":null},{"id":"d80511f368a04e859338e1d9a74a68b4","type":"GO_TERM","name":"regulation of L-tyrosine import across plasma membrane","canonical_id":"go:GO:1900929","description":"\"Any process that modulates the frequency, rate or extent of L-tyrosine import into the cell.\" [GOC:TermGenie]","metadata":null},{"id":"d138baa325c64392b198450383cd24e3","type":"GO_TERM","name":"regulation of Lewy body formation","canonical_id":"go:GO:0140122","description":"\"Any process that modulates the frequency, rate or extent of Lewy body formation.\" [GOC:sl]","metadata":null},{"id":"d142bce4a83041dcb6b4113f220783b0","type":"GO_TERM","name":"regulation of MAP kinase activity","canonical_id":"go:GO:0043405","description":"\"Any process that modulates the frequency, rate or extent of MAP kinase activity.\" [GOC:curators, GOC:dph]","metadata":null},{"id":"e4d51e71886b4254a86c8cbe72a79ff6","type":"GO_TERM","name":"regulation of MAPK cascade","canonical_id":"go:GO:0043408","description":"\"Any process that modulates the frequency, rate or extent of signal transduction mediated by the MAP kinase (MAPK) cascade.\" [GOC:curators]","metadata":null},{"id":"da9187603b1348e5a34cbc1ddc745570","type":"GO_TERM","name":"regulation of MDA-5 signaling pathway","canonical_id":"go:GO:0039533","description":"\"Any process that modulates the frequency, rate or extent of the series of molecular signals generated as a consequence of the cytoplasmic pattern recognition receptor (PRR) MDA-5 (also known as IFIH1) binding to viral RNA.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"686c5af8c6a84a4796ca71b26657f319","type":"GO_TERM","name":"regulation of MHC class I biosynthetic process","canonical_id":"go:GO:0045343","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class I.\" [GOC:curators]","metadata":null},{"id":"9ed057b081284455a38664a095b500ed","type":"GO_TERM","name":"regulation of MHC class II biosynthetic process","canonical_id":"go:GO:0045346","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class II.\" [GOC:curators]","metadata":null},{"id":"0d2143d10c2b49aa9dfa5ac2ce84ffa7","type":"GO_TERM","name":"regulation of Malpighian tubule diameter","canonical_id":"go:GO:0035297","description":"\"Ensuring that the Malpighian tubule is the correct width. Malpighian tubules have a uniform circumference along their length; the circumference of the tubes is eight cells during the time the cells are dividing, after which the cells rearrange producing tubes with a cirumference of two cells.\" [PMID:9286684]","metadata":null},{"id":"3a07db1ae2d2457f8a3bbda915e86b39","type":"GO_TERM","name":"regulation of Malpighian tubule size","canonical_id":"go:GO:0035298","description":"\"Ensuring that a Malpighian tubule is the correct length and diameter.\" [GOC:bf]","metadata":null},{"id":"b153ddd9e7924a23ae24e74270f5e902","type":"GO_TERM","name":"regulation of MyD88-dependent toll-like receptor signaling pathway","canonical_id":"go:GO:0034124","description":"\"Any process that modulates the frequency, rate, or extent of MyD88-dependent toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"88af16198d6141aab486b8fab0ab0f93","type":"GO_TERM","name":"regulation of MyD88-independent toll-like receptor signaling pathway","canonical_id":"go:GO:0034127","description":"\"Any process that modulates the frequency, rate, or extent of MyD88-independent toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"90c69c53b8dc4e38ad2a5f3f4e5094e2","type":"GO_TERM","name":"regulation of N',N'',N'''-triacetylfusarinine C biosynthetic process","canonical_id":"go:GO:1900695","description":"\"Any process that modulates the frequency, rate or extent of N',N'',N'''-triacetylfusarinine C biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4092507d6180481299ad61652ea87442","type":"GO_TERM","name":"regulation of N-terminal peptidyl-lysine acetylation","canonical_id":"go:GO:2000759","description":"\"Any process that modulates the frequency, rate or extent of N-terminal peptidyl-lysine acetylation.\" [GOC:obol]","metadata":null},{"id":"7409edf5c0534762bfbc4e76e13a2115","type":"GO_TERM","name":"regulation of N-terminal peptidyl-methionine acetylation","canonical_id":"go:GO:1904663","description":"\"Any process that modulates the frequency, rate or extent of N-terminal peptidyl-methionine acetylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:20807799]","metadata":null},{"id":"dccdbd93ad9e4744b0e1b529f1b7cf26","type":"GO_TERM","name":"regulation of N-terminal protein palmitoylation","canonical_id":"go:GO:0060254","description":"\"Any process that modulates the rate frequency or extent of the covalent attachment of a palmitoyl group to the N-terminal amino acid residue of a protein.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"780a35abe17e4ed4bf2d7972846112dc","type":"GO_TERM","name":"regulation of NAD metabolic process","canonical_id":"go:GO:1902688","description":"\"Any process that modulates the frequency, rate or extent of NAD metabolic process.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:19846558]","metadata":null},{"id":"ce11cec6f3a54e63829d82735de3c04c","type":"GO_TERM","name":"regulation of NADP metabolic process","canonical_id":"go:GO:1902031","description":"\"Any process that modulates the frequency, rate or extent of NADP metabolic process.\" [GOC:TermGenie, PMID:23334421]","metadata":null},{"id":"de887672a2ab44e4be190d76cb58848e","type":"GO_TERM","name":"regulation of NK T cell activation","canonical_id":"go:GO:0051133","description":"\"Any process that modulates the frequency, rate or extent of natural killer T cell activation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"962a9564d3f54348ab53fcea87b32421","type":"GO_TERM","name":"regulation of NK T cell differentiation","canonical_id":"go:GO:0051136","description":"\"Any process that modulates the frequency, rate or extent of natural killer T cell differentiation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"143896414a564c5ba765036b5629baa9","type":"GO_TERM","name":"regulation of NK T cell proliferation","canonical_id":"go:GO:0051140","description":"\"Any process that modulates the frequency, rate or extent of natural killer T cell proliferation.\" [ISBN:0781735149, PMID:12154375, PMID:9133426]","metadata":null},{"id":"7d022ce812a14f98ae37c3276b3b803c","type":"GO_TERM","name":"regulation of NLRP3 inflammasome complex assembly","canonical_id":"go:GO:1900225","description":"\"Any process that modulates the frequency, rate or extent of NLRP3 inflammasome complex assembly.\" [GOC:TermGenie]","metadata":null},{"id":"58c0f9d2c97e400387b85199758f4c16","type":"GO_TERM","name":"regulation of NMDA receptor activity","canonical_id":"go:GO:2000310","description":"\"Any process that modulates the frequency, rate or extent of N-methyl-D-aspartate selective glutamate receptor activity.\" [GOC:BHF]","metadata":null},{"id":"ca021f20c58242ee900785a4a6a61723","type":"GO_TERM","name":"regulation of Notch signaling pathway","canonical_id":"go:GO:0008593","description":"\"Any process that modulates the frequency, rate or extent of the Notch signaling pathway.\" [GOC:curators]","metadata":null},{"id":"084fd58b1594461990f9c80525e40edc","type":"GO_TERM","name":"regulation of P-type sodium:potassium-exchanging transporter activity","canonical_id":"go:GO:1903406","description":"\"Any process that modulates the frequency, rate or extent of sodium:potassium-exchanging ATPase activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:8160880]","metadata":null},{"id":"382d58911f624d6d86763d6c6fbbe634","type":"GO_TERM","name":"regulation of PERK-mediated unfolded protein response","canonical_id":"go:GO:1903897","description":"\"Any process that modulates the frequency, rate or extent of the PERK-mediated unfolded protein response.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22013210]","metadata":null},{"id":"aaccf09b45694edbb734342ebd421887","type":"GO_TERM","name":"regulation of PSII associated light-harvesting complex II catabolic process","canonical_id":"go:GO:0010550","description":"\"Any process that modulates the chemical reactions and pathways resulting in the breakdown of one or more components of the light-harvesting complex of photosystem II.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c2a8572221734ded8b71c2ead8baedf7","type":"GO_TERM","name":"regulation of Purkinje myocyte action potential","canonical_id":"go:GO:0098906","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a Purkinje myocyte. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"2d63c1689009431d9b12f317ee1b5915","type":"GO_TERM","name":"regulation of R7 cell differentiation","canonical_id":"go:GO:0045676","description":"\"Any process that modulates the frequency, rate or extent of R7 differentiation.\" [GOC:curators]","metadata":null},{"id":"81e3ea79f23a46ddac870d2006e34777","type":"GO_TERM","name":"regulation of R7 cell fate commitment","canonical_id":"go:GO:0106396","description":"\"Any process that modulates the frequency, rate or extent of R7 cell fate commitment.\" [GOC:ha, PMID:22878552]","metadata":null},{"id":"7be7304bd78c4d5bbd3265a68432b5c1","type":"GO_TERM","name":"regulation of R8 cell differentiation","canonical_id":"go:GO:0045679","description":"\"Any process that modulates the frequency, rate or extent of R8 differentiation.\" [GOC:curators]","metadata":null},{"id":"70cae84c1aa2464290d142e1cc2b0f97","type":"GO_TERM","name":"regulation of R8 cell spacing in compound eye","canonical_id":"go:GO:0045468","description":"\"Any process that ensures that the R8 cells are selected in a precise progressive pattern so that they are evenly spaced throughout the eye disc.\" [GOC:dph, GOC:tb, PMID:11880339]","metadata":null},{"id":"c4a6fab8dd39485bbfe21b23e3363577","type":"GO_TERM","name":"regulation of RIG-I signaling pathway","canonical_id":"go:GO:0039535","description":"\"Any process that modulates the frequency, rate or extent of the RIG-I signaling pathway.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"30af639307d648b38d7061a560f39f79","type":"GO_TERM","name":"regulation of RNA biosynthetic process","canonical_id":"go:GO:2001141","description":"\"Any process that modulates the frequency, rate or extent of RNA biosynthetic process.\" [GOC:dph]","metadata":null},{"id":"4010440c93c449aaacfd4119963194bf","type":"GO_TERM","name":"regulation of RNA export from nucleus","canonical_id":"go:GO:0046831","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of RNA from the nucleus to the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"7f9077a05e3349eea24f8791ee483174","type":"GO_TERM","name":"regulation of RNA helicase activity","canonical_id":"go:GO:1902280","description":"\"Any process that modulates the frequency, rate or extent of ATP-dependent RNA helicase activity.\" [GOC:rb, GOC:TermGenie, PMID:23721653]","metadata":null},{"id":"c29273f96a024377b4506c5a8c8e2c97","type":"GO_TERM","name":"regulation of RNA import into nucleus","canonical_id":"go:GO:0046828","description":"\"Any process that modulates the frequency, rate or extent of movement of RNA from the cytoplasm to the nucleus.\" [GOC:bf]","metadata":null},{"id":"4fa6a6b7133e44c08e3beaeb39794fe6","type":"GO_TERM","name":"regulation of RNA metabolic process","canonical_id":"go:GO:0051252","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving RNA.\" [GOC:ai]","metadata":null},{"id":"4a6ff799670746c097a6a62dfdda8f47","type":"GO_TERM","name":"regulation of RNA polymerase II regulatory region sequence-specific DNA binding","canonical_id":"go:GO:1903025","description":"\"Any process that modulates the frequency, rate or extent of RNA polymerase II regulatory region sequence-specific DNA binding.\" [GO_REF:0000059, GOC:dph, GOC:krc, GOC:TermGenie, PMID:20026326]","metadata":null},{"id":"3fa6f41405f441f8b25545f9616ef30d","type":"GO_TERM","name":"regulation of RNA polymerase II transcription preinitiation complex assembly","canonical_id":"go:GO:0045898","description":"\"Any process that modulates the frequency, rate or extent of RNA polymerase II transcriptional preinitiation complex assembly.\" [GOC:curators]","metadata":null},{"id":"71c49968ed954116a442eb7e8328ac33","type":"GO_TERM","name":"regulation of RNA splicing","canonical_id":"go:GO:0043484","description":"\"Any process that modulates the frequency, rate or extent of RNA splicing, the process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.\" [GOC:jl]","metadata":null},{"id":"9979288ec52a49eca38a470e3990fe59","type":"GO_TERM","name":"regulation of RNA stability","canonical_id":"go:GO:0043487","description":"\"Any process that modulates the propensity of RNA molecules to degradation. Includes processes that both stabilize and destabilize RNAs.\" [GOC:jl]","metadata":null},{"id":"24ead5347d924cabb696f4e78fadb41f","type":"GO_TERM","name":"regulation of Rab protein signal transduction","canonical_id":"go:GO:0032483","description":"\"Any process that modulates the frequency, rate or extent of Rab protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"c3ec25334bd343f8801f4bb0a25b7cf3","type":"GO_TERM","name":"regulation of Rac protein signal transduction","canonical_id":"go:GO:0035020","description":"\"Any process that modulates the frequency, rate or extent of Rac protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"0dcc51d1bfd24dfcb631273399322e13","type":"GO_TERM","name":"regulation of Ral protein signal transduction","canonical_id":"go:GO:0032485","description":"\"Any process that modulates the frequency, rate or extent of Ral protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"21b42ef0286e4264a075ccaf3bfab565","type":"GO_TERM","name":"regulation of Rap protein signal transduction","canonical_id":"go:GO:0032487","description":"\"Any process that modulates the frequency, rate or extent of Rap protein signal transduction.\" [GOC:mah]","metadata":null},{"id":"11933e710fc64701a16754fd76545318","type":"GO_TERM","name":"regulation of Ras protein signal transduction","canonical_id":"go:GO:0046578","description":"\"Any process that modulates the frequency, rate or extent of Ras protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"ba78965e3ff64aa2aedc334b8d381630","type":"GO_TERM","name":"regulation of Rho protein signal transduction","canonical_id":"go:GO:0035023","description":"\"Any process that modulates the frequency, rate or extent of Rho protein signal transduction.\" [GOC:bf]","metadata":null},{"id":"f4d330d6cd89446ca160cbf46ee97429","type":"GO_TERM","name":"regulation of Roundabout signaling pathway","canonical_id":"go:GO:0035386","description":"\"Any process that modulates the frequency, rate or extent of the Roundabout signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"88611ba781d147a08737f125987fda42","type":"GO_TERM","name":"regulation of SA node cell action potential","canonical_id":"go:GO:0098907","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in an SA node cardiac myocyte. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"952c97856362402d9eb1905ce44eca3f","type":"GO_TERM","name":"regulation of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0062025","description":"\"Any process that modualtes the rate, frequency or extent of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process, the chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by an SCF (Skp1/Cul1/F-box protein) complex, and mediated by the proteasome.\" [PMID:28007894]","metadata":null},{"id":"03dc306e58f947ef8b8ced790c5e64b1","type":"GO_TERM","name":"regulation of SMAD protein signal transduction","canonical_id":"go:GO:0060390","description":"\"Any process that modulates the rate, frequency or extent of SMAD protein signal transduction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"64a9df94c80446b8a201c54f05e1e813","type":"GO_TERM","name":"regulation of SNARE complex assembly","canonical_id":"go:GO:0035542","description":"\"Any process that modulates the frequency, rate or extent of assembly of the SNARE complex. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb]","metadata":null},{"id":"829e2befd0424588a2400bdd4ace3664","type":"GO_TERM","name":"regulation of SNARE complex disassembly","canonical_id":"go:GO:0035495","description":"\"Any process that modulates the frequency, rate or extent of disassembly of the SNARE complex. The SNARE complex is a protein complex involved in membrane fusion; a stable ternary complex consisting of a four-helix bundle, usually formed from one R-SNARE and three Q-SNAREs with an ionic layer sandwiched between hydrophobic layers.\" [GOC:rb]","metadata":null},{"id":"c75e1a7dd27b4cbdb60e607fc2231791","type":"GO_TERM","name":"regulation of SREBP signaling pathway","canonical_id":"go:GO:2000638","description":"\"Any process that modulates the frequency, rate or extent of the SREBP signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"01cf022e07dc44549a8f1be0d1259f4a","type":"GO_TERM","name":"regulation of Schwann cell chemotaxis","canonical_id":"go:GO:1904266","description":"\"Any process that modulates the frequency, rate or extent of Schwann cell chemotaxis.\" [GO_REF:0000058, GOC:TermGenie, PMID:16203995]","metadata":null},{"id":"29605a5112f34b09b0824b6ffed6954b","type":"GO_TERM","name":"regulation of Schwann cell differentiation","canonical_id":"go:GO:0014038","description":"\"Any process that modulates the frequency, rate or extent of Schwann cell differentiation.\" [GOC:ef]","metadata":null},{"id":"2b7ed294216f43ce9b5351c249afca30","type":"GO_TERM","name":"regulation of Schwann cell migration","canonical_id":"go:GO:1900147","description":"\"Any process that modulates the frequency, rate or extent of Schwann cell migration.\" [GOC:sjw, GOC:TermGenie]","metadata":null},{"id":"d395cf5695774e2d92522952b27f3d8b","type":"GO_TERM","name":"regulation of Schwann cell proliferation","canonical_id":"go:GO:0010624","description":"\"Any process that modulates the frequency or rate of multiplication or reproduction of Schwann cells, resulting in the expansion of their population. Schwann cells are a type of glial cell in the peripheral nervous system.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"66f96937f27143a993e9dd5050ba3e7d","type":"GO_TERM","name":"regulation of T cell activation","canonical_id":"go:GO:0050863","description":"\"Any process that modulates the frequency, rate or extent of T cell activation.\" [GOC:ai]","metadata":null},{"id":"d873efcfcc6f4ab68d962d1bf414634b","type":"GO_TERM","name":"regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell","canonical_id":"go:GO:2001188","description":"\"Any process that modulates the frequency, rate or extent of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell.\" [GOC:obol]","metadata":null},{"id":"3d8bda37616443da824c55744f78c696","type":"GO_TERM","name":"regulation of T cell anergy","canonical_id":"go:GO:0002667","description":"\"Any process that modulates the frequency, rate, or extent of T cell anergy.\" [GOC:add]","metadata":null},{"id":"49751a7cf969407eb4aa4587185efbd5","type":"GO_TERM","name":"regulation of T cell antigen processing and presentation","canonical_id":"go:GO:0002625","description":"\"Any process that modulates the frequency, rate, or extent of T cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"02ca3471c9aa4cb2958e1d99f198cbfd","type":"GO_TERM","name":"regulation of T cell apoptotic process","canonical_id":"go:GO:0070232","description":"\"Any process that modulates the occurrence or rate of T cell death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"0cd6898d12ce4ceea04b967dfeaa22bc","type":"GO_TERM","name":"regulation of T cell chemotaxis","canonical_id":"go:GO:0010819","description":"\"Any process that modulates the rate, frequency or extent of T cell chemotaxis. T cell chemotaxis is the directed movement of a T cell in response to an external stimulus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"97dadec73d0c4c86ba8455d79e825aa9","type":"GO_TERM","name":"regulation of T cell costimulation","canonical_id":"go:GO:2000523","description":"\"Any process that modulates the frequency, rate or extent of T cell costimulation.\" [GOC:obol]","metadata":null},{"id":"62f5d17e86b7450abff052ff254c35c0","type":"GO_TERM","name":"regulation of T cell cytokine production","canonical_id":"go:GO:0002724","description":"\"Any process that modulates the frequency, rate, or extent of T cell cytokine production.\" [GOC:add]","metadata":null},{"id":"9c14e2ccf97646b883c046b42097822c","type":"GO_TERM","name":"regulation of T cell differentiation","canonical_id":"go:GO:0045580","description":"\"Any process that modulates the frequency, rate or extent of T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"86a304cbea024fce8d958d579ed13fbe","type":"GO_TERM","name":"regulation of T cell differentiation in thymus","canonical_id":"go:GO:0033081","description":"\"Any process that modulates the frequency, rate or extent of T cell differentiation in the thymus.\" [GOC:add, GOC:mah]","metadata":null},{"id":"dd3fa33ba67e4cacadee01b0959b6bf9","type":"GO_TERM","name":"regulation of T cell extravasation","canonical_id":"go:GO:2000407","description":"\"Any process that modulates the frequency, rate or extent of T cell extravasation.\" [GOC:mah]","metadata":null},{"id":"75330b9db6564d408608d37a216a0baf","type":"GO_TERM","name":"regulation of T cell homeostatic proliferation","canonical_id":"go:GO:0046013","description":"\"Any process that modulates the frequency, rate or extent of resting T cell proliferation.\" [GOC:curators]","metadata":null},{"id":"85396a76d31a4eb6ae059feea701c888","type":"GO_TERM","name":"regulation of T cell mediated cytotoxicity","canonical_id":"go:GO:0001914","description":"\"Any process that modulates the frequency, rate, or extent of T cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ff80d63c4fba434da81a8466393fac8d","type":"GO_TERM","name":"regulation of T cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002852","description":"\"Any process that modulates the frequency, rate, or extent of T cell mediated cytotoxicity directed against a tumor cell target.\" [GOC:add]","metadata":null},{"id":"51f5204931384f658c2978c66b5ecc2c","type":"GO_TERM","name":"regulation of T cell mediated immune response to tumor cell","canonical_id":"go:GO:0002840","description":"\"Any process that modulates the frequency, rate, or extent of a T cell mediated immune response to tumor cell.\" [GOC:add]","metadata":null},{"id":"f1cf2b13e90545d28448fe68701aca1d","type":"GO_TERM","name":"regulation of T cell mediated immunity","canonical_id":"go:GO:0002709","description":"\"Any process that modulates the frequency, rate, or extent of T cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"73d8d52822d9477e8e91faa33650bd03","type":"GO_TERM","name":"regulation of T cell migration","canonical_id":"go:GO:2000404","description":"\"Any process that modulates the frequency, rate or extent of T cell migration.\" [GOC:mah]","metadata":null},{"id":"1e97eab7744c4499b41e112f2ff011a8","type":"GO_TERM","name":"regulation of T cell proliferation","canonical_id":"go:GO:0042129","description":"\"Any process that modulates the frequency, rate or extent of T cell proliferation.\" [GOC:jl]","metadata":null},{"id":"738747c6dac846808d62b2747a8e9997","type":"GO_TERM","name":"regulation of T cell receptor signaling pathway","canonical_id":"go:GO:0050856","description":"\"Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.\" [GOC:ai]","metadata":null},{"id":"0a33b1221cee48af9d80fff26e46c2b3","type":"GO_TERM","name":"regulation of T cell tolerance induction","canonical_id":"go:GO:0002664","description":"\"Any process that modulates the frequency, rate, or extent of T cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"51bca7166ab94b5e84ab00e69e202da0","type":"GO_TERM","name":"regulation of T cell tolerance induction to tumor cell","canonical_id":"go:GO:0002846","description":"\"Any process that modulates the frequency, rate, or extent of T cell tolerance induction to tumor cell.\" [GOC:add]","metadata":null},{"id":"d758a1a88c654d2b9708e7307fb66e83","type":"GO_TERM","name":"regulation of T-helper 1 cell activation","canonical_id":"go:GO:2000517","description":"\"Any process that modulates the frequency, rate or extent of T-helper 1 cell activation.\" [GOC:obol]","metadata":null},{"id":"34fe6997f16342c49f49c3767cf08336","type":"GO_TERM","name":"regulation of T-helper 1 cell cytokine production","canonical_id":"go:GO:2000554","description":"\"Any process that modulates the frequency, rate or extent of T-helper 1 cell cytokine production.\" [GOC:obol]","metadata":null},{"id":"cfbddc0f2e1048b680aba24c127c9f01","type":"GO_TERM","name":"regulation of T-helper 1 cell differentiation","canonical_id":"go:GO:0045625","description":"\"Any process that modulates the frequency, rate or extent of T-helper 1 cell differentiation.\" [GOC:curators]","metadata":null},{"id":"3b98b7392a33480e9f9d987bfeb9685e","type":"GO_TERM","name":"regulation of T-helper 1 type immune response","canonical_id":"go:GO:0002825","description":"\"Any process that modulates the frequency, rate, or extent of a T-helper 1 type immune response.\" [GOC:add]","metadata":null},{"id":"0a223499c92642818b1910cce48f9108","type":"GO_TERM","name":"regulation of T-helper 17 cell differentiation","canonical_id":"go:GO:2000319","description":"\"Any process that modulates the frequency, rate or extent of T-helper 17 cell differentiation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"068b7d80cf044e028f6877bec9a800a2","type":"GO_TERM","name":"regulation of T-helper 17 cell extravasation","canonical_id":"go:GO:2000455","description":"\"Any process that modulates the frequency, rate or extent of T-helper 17 cell extravasation.\" [GOC:obol]","metadata":null},{"id":"6b4009cb50d7496893ccad7d9f1d8dbf","type":"GO_TERM","name":"regulation of T-helper 17 cell lineage commitment","canonical_id":"go:GO:2000328","description":"\"Any process that modulates the frequency, rate or extent of T-helper 17 cell lineage commitment.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"6ae3ce4e359846adba0c00457b3af489","type":"GO_TERM","name":"regulation of T-helper 17 type immune response","canonical_id":"go:GO:2000316","description":"\"Any process that modulates the frequency, rate or extent of T-helper 17 type immune response.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ae0e434674694bf199689faab619c9cb","type":"GO_TERM","name":"regulation of T-helper 2 cell activation","canonical_id":"go:GO:2000569","description":"\"Any process that modulates the frequency, rate or extent of T-helper 2 cell activation.\" [GOC:obol]","metadata":null},{"id":"8ef2d5e815474415ac9ce56a99f27a04","type":"GO_TERM","name":"regulation of T-helper 2 cell cytokine production","canonical_id":"go:GO:2000551","description":"\"Any process that modulates the frequency, rate or extent of T-helper 2 cell cytokine production.\" [GOC:obol]","metadata":null},{"id":"e70a0f7ffe8e463bbbb01b05022be51a","type":"GO_TERM","name":"regulation of T-helper 2 cell differentiation","canonical_id":"go:GO:0045628","description":"\"Any process that modulates the frequency, rate or extent of T-helper 2 cell differentiation.\" [GOC:curators]","metadata":null},{"id":"5d3ced043e9b4f0f9765295b205a6843","type":"GO_TERM","name":"regulation of T-helper cell differentiation","canonical_id":"go:GO:0045622","description":"\"Any process that modulates the frequency, rate or extent of T-helper cell differentiation.\" [GOC:curators]","metadata":null},{"id":"b537abb1d81047b4a2b82b9328f63512","type":"GO_TERM","name":"regulation of TOR signaling","canonical_id":"go:GO:0032006","description":"\"Any process that modulates the frequency, rate or extent of TOR signaling.\" [GOC:mah]","metadata":null},{"id":"338b852c61c3421f999aa0c1d49583aa","type":"GO_TERM","name":"regulation of TORC1 signaling","canonical_id":"go:GO:1903432","description":"\"Any process that modulates the frequency, rate or extent of TORC1 signaling.\" [GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"26ca1cb7c91d4008923522ffd1d47b4b","type":"GO_TERM","name":"regulation of TORC2 signaling","canonical_id":"go:GO:1903939","description":"\"Any process that modulates the frequency, rate or extent of TORC2 signaling.\" [GO_REF:0000058, GOC:TermGenie, PMID:24247430]","metadata":null},{"id":"ebdd8711d68c41b59701f6dc08a8e88f","type":"GO_TERM","name":"regulation of TRAIL production","canonical_id":"go:GO:0032679","description":"\"Any process that modulates the frequency, rate, or extent of TRAIL production.\" [GOC:mah]","metadata":null},{"id":"51383c0dc0e3416ba30ce961a8243bc2","type":"GO_TERM","name":"regulation of TRAIL-activated apoptotic signaling pathway","canonical_id":"go:GO:1903121","description":"\"Any process that modulates the frequency, rate or extent of TRAIL-activated apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"c6b3c2f8e42344bca2415f7d3da8a3ff","type":"GO_TERM","name":"regulation of Toll receptor ligand protein activation cascade","canonical_id":"go:GO:0160033","description":"\"Any process that modulates the frequency, rate or extent of the Toll receptor ligand protein activation cascade.\" [PMID:23632253]","metadata":null},{"id":"46d6ce14fba94aaea86e31a6d5581d0b","type":"GO_TERM","name":"regulation of Toll signaling pathway","canonical_id":"go:GO:0008592","description":"\"Any process that modulates the frequency, rate or extent of the Tl signaling pathway.\" [GOC:curators]","metadata":null},{"id":"f818f538de484d3f869417577c4b0727","type":"GO_TERM","name":"regulation of UDP-N-acetylglucosamine biosynthetic process","canonical_id":"go:GO:0106278","description":"\"Any process that modulates the frequency, rate or extent of the UDP-N_acetylglucosamine biosynthetic process.\" [PMID:32579556]","metadata":null},{"id":"aa468815c22b413d9e2a62e7c5e6ec3b","type":"GO_TERM","name":"regulation of VCP-NPL4-UFD1 AAA ATPase complex assembly","canonical_id":"go:GO:1904239","description":"\"Any process that modulates the frequency, rate or extent of VCP-NPL4-UFD1 AAA ATPase complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"0f0cffb1c3e446eba5d5a1b124c81083","type":"GO_TERM","name":"regulation of Wnt protein secretion","canonical_id":"go:GO:0061356","description":"\"Any process that modulates the frequency, rate or extent of the controlled release of a Wnt protein from a cell.\" [GOC:bf, PMID:19223472]","metadata":null},{"id":"72cd479426b04448b8343557895abf16","type":"GO_TERM","name":"regulation of Wnt signaling pathway","canonical_id":"go:GO:0030111","description":"\"Any process that modulates the frequency, rate or extent of the activity of the Wnt signal transduction pathway.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"943164fe12d04291aed62002887e96a9","type":"GO_TERM","name":"regulation of Wnt signaling pathway, calcium modulating pathway","canonical_id":"go:GO:0008591","description":"\"Any process that modulates the frequency, rate or extent of the series of molecular signals initiated by binding of a Wnt protein to a receptor on the surface of the target cell where activated receptors leads to an increase in intracellular calcium and activation of protein kinase C (PKC).\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"8d1e47aca5cb44c1a0d894f1029470ad","type":"GO_TERM","name":"regulation of Wnt signaling pathway, planar cell polarity pathway","canonical_id":"go:GO:2000095","description":"\"Any process that modulates the frequency, rate or extent of Wnt signaling pathway, planar cell polarity pathway.\" [GOC:BHF]","metadata":null},{"id":"353386d98bb7403f871e7a602041776f","type":"GO_TERM","name":"regulation of Wnt-Frizzled-LRP5/6 complex assembly","canonical_id":"go:GO:1904711","description":"\"Any process that modulates the frequency, rate or extent of Wnt-Frizzled-LRP5/6 complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"9aaf180cda894de9a42686df398bf2f5","type":"GO_TERM","name":"regulation of [2Fe-2S] cluster assembly","canonical_id":"go:GO:1900487","description":"\"Any process that modulates the frequency, rate or extent of [2Fe-2S] cluster assembly.\" [GOC:mengo_curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"db2376e149c94c269ff2dd5364d29dc2","type":"GO_TERM","name":"regulation of [4Fe-4S] cluster assembly","canonical_id":"go:GO:1900491","description":"\"Any process that modulates the frequency, rate or extent of [4Fe-4S] cluster assembly.\" [GOC:mengo_curators, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"7931f9c90cd24759994b106663cdfc97","type":"GO_TERM","name":"regulation of abscisic acid biosynthetic process","canonical_id":"go:GO:0010115","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of abscisic acid.\" [GOC:sm]","metadata":null},{"id":"12a530613a514d8080db4dfbebbe2921","type":"GO_TERM","name":"regulation of abscisic acid-activated signaling pathway","canonical_id":"go:GO:0009787","description":"\"Any process that modulates the frequency, rate or extent of abscisic acid (ABA) signaling.\" [GOC:lr]","metadata":null},{"id":"0c518a9413e44c67ac4fb1e3877f17e8","type":"GO_TERM","name":"regulation of acetate catabolic process","canonical_id":"go:GO:0045734","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of acetate, the anion of acetic acid.\" [GOC:curators]","metadata":null},{"id":"9764d84852174767abcb6c114651be3a","type":"GO_TERM","name":"regulation of acetylcholine biosynthetic process","canonical_id":"go:GO:1905921","description":"\"Any process that modulates the frequency, rate or extent of acetylcholine biosynthetic process.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:20164328]","metadata":null},{"id":"de82bb17f2c74537b5c3cbfd6a4d0f21","type":"GO_TERM","name":"regulation of acetylcholine metabolic process","canonical_id":"go:GO:0060408","description":"\"Any process that modulates the rate, frequency or extent of the chemical reactions and pathways involving acetylcholine, the acetic acid ester of the organic base choline. Acetylcholine is a major neurotransmitter and neuromodulator both in the central and peripheral nervous systems. It also acts as a paracrine signal in various non-neural tissues.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"905dbe70dd8e4164bad922b27cbc72c1","type":"GO_TERM","name":"regulation of acetylcholine secretion, neurotransmission","canonical_id":"go:GO:0014056","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of acetylcholine.\" [GOC:ef]","metadata":null},{"id":"306a50b5f43d46a4aa47ee63298b2032","type":"GO_TERM","name":"regulation of acetylcholine uptake","canonical_id":"go:GO:0051631","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of the neurotransmitter acetylcholine into a cell.\" [GOC:ai]","metadata":null},{"id":"ab1649a76cd64258ac8d5338bb129b76","type":"GO_TERM","name":"regulation of acinar cell proliferation","canonical_id":"go:GO:1904697","description":"\"Any process that modulates the frequency, rate or extent of acinar cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:9788538]","metadata":null},{"id":"6a3c7927976045f89cc8fcd449e2c368","type":"GO_TERM","name":"regulation of acrosomal vesicle exocytosis","canonical_id":"go:GO:2000367","description":"\"Any process that modulates the frequency, rate or extent of acrosomal vesicle exocytosis.\" [GOC:obol]","metadata":null},{"id":"f89e52f5cdc540c5803e6b1de995af9f","type":"GO_TERM","name":"regulation of acrosome reaction","canonical_id":"go:GO:0060046","description":"\"Any process that modulates the frequency, rate or extent of the acrosome reaction.\" [GOC:dph]","metadata":null},{"id":"fac6a0dbb97b40cba8e7f73ea5033ac3","type":"GO_TERM","name":"regulation of actin cortical patch localization","canonical_id":"go:GO:0060583","description":"\"Any process that modulates the localization of an actin cortical patch. An actin cortical patch is a discrete actin-containing structure found just beneath the plasma membrane in fungal cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"15becfead1e046fb95ed231ad638a5a1","type":"GO_TERM","name":"regulation of actin cytoskeleton organization","canonical_id":"go:GO:0032956","description":"\"Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.\" [GOC:mah]","metadata":null},{"id":"77bfd2116c4d46d0b235904d0cc9fb84","type":"GO_TERM","name":"regulation of actin cytoskeleton organization by cell-cell adhesion","canonical_id":"go:GO:0090138","description":"\"Any cell-cell adhesion process that modulates the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"6f7f4a6aea55462d8c43ce2914994c1c","type":"GO_TERM","name":"regulation of actin filament annealing","canonical_id":"go:GO:0110054","description":"\"Any process that modulates the frequency, rate or extent of actin filament annealing, i.e. the end-to-end joining of existing actin filaments.\" [GOC:mah, PMID:10585915, PMID:11575927, PMID:15743909, PMID:19244341]","metadata":null},{"id":"ea576f6c37b1490fa147184b5d802d49","type":"GO_TERM","name":"regulation of actin filament bundle assembly","canonical_id":"go:GO:0032231","description":"\"Any process that modulates the frequency, rate or extent of the assembly of actin filament bundles.\" [GOC:mah]","metadata":null},{"id":"29cebb7c2b5d48a093931c91b6942b52","type":"GO_TERM","name":"regulation of actin filament depolymerization","canonical_id":"go:GO:0030834","description":"\"Any process that modulates the frequency, rate or extent of the disassembly of actin filaments by the removal of actin monomers from a filament.\" [GOC:mah]","metadata":null},{"id":"10bd816c6a564f4b860f37e0cdf7613e","type":"GO_TERM","name":"regulation of actin filament length","canonical_id":"go:GO:0030832","description":"\"Any process that controls the length of actin filaments in a cell.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"49dca26fd50a4a3fba5ec597a5205317","type":"GO_TERM","name":"regulation of actin filament organization","canonical_id":"go:GO:0110053","description":"\"Any process that modulates the frequency, rate or extent of actin filament organization.\" [GOC:kmv]","metadata":null},{"id":"8ca5a4de70c44e459a3990ecb9011fa3","type":"GO_TERM","name":"regulation of actin filament polymerization","canonical_id":"go:GO:0030833","description":"\"Any process that modulates the frequency, rate or extent of the assembly of actin filaments by the addition of actin monomers to a filament.\" [GOC:mah]","metadata":null},{"id":"3ca4084f79ff42e3810a7024c8044860","type":"GO_TERM","name":"regulation of actin filament severing","canonical_id":"go:GO:1903918","description":"\"Any process that modulates the frequency, rate or extent of actin filament severing.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23325791]","metadata":null},{"id":"cd59f56299c141338863328343d059e8","type":"GO_TERM","name":"regulation of actin filament-based movement","canonical_id":"go:GO:1903115","description":"\"Any process that modulates the frequency, rate or extent of actin filament-based movement.\" [GO_REF:0000058, GOC:TermGenie, PMID:24798735]","metadata":null},{"id":"094389498d6945e3a3e0baeed3c7b875","type":"GO_TERM","name":"regulation of actin filament-based process","canonical_id":"go:GO:0032970","description":"\"Any process that modulates the frequency, rate or extent of any cellular process that depends upon or alters the actin cytoskeleton.\" [GOC:mah]","metadata":null},{"id":"5774cf4109b4457cbf00e4e62f29187b","type":"GO_TERM","name":"regulation of actin nucleation","canonical_id":"go:GO:0051125","description":"\"Any process that modulates the frequency, rate or extent of actin nucleation, the initial step in the formation of an actin filament in which actin monomers combine to form a new filament.\" [GOC:ai]","metadata":null},{"id":"ccf3001c26ef4db4b3d00b4bfa64dc95","type":"GO_TERM","name":"regulation of actin polymerization or depolymerization","canonical_id":"go:GO:0008064","description":"\"Any process that modulates the frequency, rate or extent of the assembly or disassembly of actin filaments by the addition or removal of actin monomers from a filament.\" [GOC:mah]","metadata":null},{"id":"175f801a955c492baaf52adb1adbc561","type":"GO_TERM","name":"regulation of action potential","canonical_id":"go:GO:0098900","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:curators, GOC:dos, GOC:dph, GOC:tb, ISBN:978-0-07-139011-8]","metadata":null},{"id":"636f200fcc3844b5a9ba0a84d29b6eba","type":"GO_TERM","name":"regulation of action potential firing pattern","canonical_id":"go:GO:0099608","description":"\"Any process that regulates the temporal pattern of a sequence of action potentials in a neuron.\" [ISBN:978-0071390118]","metadata":null},{"id":"3a66dc131f584137a2f4852bb7c0be24","type":"GO_TERM","name":"regulation of action potential firing rate","canonical_id":"go:GO:0099605","description":"\"Any process that regulates the frequency of action potentials in a spike train.\" [ISBN:978-0071390118]","metadata":null},{"id":"8053c054c01e40cd891f907a2ea7de79","type":"GO_TERM","name":"regulation of action potential firing threshold","canonical_id":"go:GO:0099611","description":"\"Any process that regulates the potential at which an axon potential is triggered.\" [ISBN:978-0071390118]","metadata":null},{"id":"cd29ac6fa1e44d96ba177bbe5b3f13aa","type":"GO_TERM","name":"regulation of activated CD4-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905399","description":"\"Any process that modulates the frequency, rate or extent of activated CD4-positive, alpha-beta T cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"3f6c29958d9a4015b15e7346ef8ddc14","type":"GO_TERM","name":"regulation of activated CD8-positive, alpha-beta T cell apoptotic process","canonical_id":"go:GO:1905402","description":"\"Any process that modulates the frequency, rate or extent of activated CD8-positive, alpha-beta T cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"eb49f1b271844362a5783d804f2d6e0f","type":"GO_TERM","name":"regulation of activated T cell autonomous cell death","canonical_id":"go:GO:0070239","description":"\"Any process that modulates the occurrence or rate of activated T cell autonomous cell death.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"f943e85b232841db848e67ebcf9a1501","type":"GO_TERM","name":"regulation of activated T cell proliferation","canonical_id":"go:GO:0046006","description":"\"Any process that modulates the frequency, rate or extent of activated T cell proliferation.\" [GOC:curators]","metadata":null},{"id":"90f81c8ee2424eccba0d1d3209a81246","type":"GO_TERM","name":"regulation of activation of membrane attack complex","canonical_id":"go:GO:0001969","description":"\"Any process that modulates the frequency, rate or extent of the activation of the membrane attack complex components of the complement cascade.\" [GOC:hjd]","metadata":null},{"id":"eac468b513f444eaa2e202ed29099a3d","type":"GO_TERM","name":"regulation of activation-induced cell death of T cells","canonical_id":"go:GO:0070235","description":"\"Any process that modulates the occurrence or rate of activation-induced cell death of T cells.\" [GOC:add, ISBN:0781765196]","metadata":null},{"id":"328abfca04d94b8bb9f5e19054bb0a37","type":"GO_TERM","name":"regulation of activin receptor signaling pathway","canonical_id":"go:GO:0032925","description":"\"Any process that modulates the frequency, rate or extent of the activity of any activin receptor signaling pathway.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"ec8bebf1df244137b3fb5089f37cd401","type":"GO_TERM","name":"regulation of activin secretion","canonical_id":"go:GO:0032335","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of activin from a cell.\" [GOC:mah]","metadata":null},{"id":"da373eb59c494e51b447c2e30f9a77b6","type":"GO_TERM","name":"regulation of actomyosin contractile ring contraction","canonical_id":"go:GO:0031991","description":"\"Any process that modulates the frequency, rate or extent of contraction of the actomyosin ring involved in cytokinesis that takes place as part of a cell cycle.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"2c07fc073bbd453bab40cb8ad394f98a","type":"GO_TERM","name":"regulation of actomyosin structure organization","canonical_id":"go:GO:0110020","description":"\"Any process that modulates the frequency, rate or extent of the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures containing both actin and myosin or paramyosin.\" [GOC:lf, PMID:22790195]","metadata":null},{"id":"6e56df3abaae44839ff570ba07785bc6","type":"GO_TERM","name":"regulation of acute inflammatory response","canonical_id":"go:GO:0002673","description":"\"Any process that modulates the frequency, rate, or extent of an acute inflammatory response.\" [GOC:add]","metadata":null},{"id":"8babf1e0392b4d69a2a40a6e800dcac0","type":"GO_TERM","name":"regulation of acute inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002864","description":"\"Any process that modulates the frequency, rate, or extent of an acute inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"0f1df4fa7ea247c9bc261800ab6fd4ba","type":"GO_TERM","name":"regulation of acute inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002877","description":"\"Any process that modulates the frequency, rate, or extent of an acute inflammatory response to a non-antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"28ed36738b984f448e49d21ef4df8854","type":"GO_TERM","name":"regulation of acyl-CoA biosynthetic process","canonical_id":"go:GO:0050812","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acyl-CoA.\" [GOC:ai]","metadata":null},{"id":"81bfedbc94d8440ea59ff3a1affd5da1","type":"GO_TERM","name":"regulation of acylglycerol transport","canonical_id":"go:GO:1901506","description":"\"Any process that modulates the frequency, rate or extent of acylglycerol transport.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"48036faea80947228474ba6cfad403d1","type":"GO_TERM","name":"regulation of adaptive immune effector response","canonical_id":"go:GO:1905677","description":"\"Any process that modulates the frequency, rate or extent of adaptive immune effector response.\" [GO_REF:0000058, GOC:TermGenie, ISBN:9781405196833]","metadata":null},{"id":"06085b541f614e2fb18dfa278d3b8454","type":"GO_TERM","name":"regulation of adaptive immune memory response","canonical_id":"go:GO:1905674","description":"\"Any process that modulates the frequency, rate or extent of adaptive immune memory response.\" [GO_REF:0000058, GOC:TermGenie, PMID:26831526]","metadata":null},{"id":"fe619d0c25fb437980e90129f6757a05","type":"GO_TERM","name":"regulation of adaptive immune response","canonical_id":"go:GO:0002819","description":"\"Any process that modulates the frequency, rate, or extent of an adaptive immune response.\" [GOC:add]","metadata":null},{"id":"3ddfc76d33814560a3fcdc7777b274a7","type":"GO_TERM","name":"regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains","canonical_id":"go:GO:0002822","description":"\"Any process that modulates the frequency, rate, or extent of an adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. An example of this process is found in the Gnathostomata.\" [GOC:add, GOC:mtg_sensu]","metadata":null},{"id":"20c882da6e8945dc9dfb86d2b305893c","type":"GO_TERM","name":"regulation of adaxial/abaxial pattern formation","canonical_id":"go:GO:2000011","description":"\"Any process that modulates the frequency, rate or extent of adaxial/abaxial pattern formation.\" [GOC:obol]","metadata":null},{"id":"9c754508c83645b082ccb3d7579103af","type":"GO_TERM","name":"regulation of adenine biosynthetic process","canonical_id":"go:GO:0061934","description":"\"Any process that modulates the frequency, rate or extent of an adenine biosynthetic process.\" [PMID:19933844]","metadata":null},{"id":"ca0a0b2758fa48cdb8219ef686c0dee5","type":"GO_TERM","name":"regulation of adenosine receptor signaling pathway","canonical_id":"go:GO:0060167","description":"\"Any process that modulates the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands.\" [GOC:dph]","metadata":null},{"id":"46d56a37374a4a3cb0ef62d62f4b77bb","type":"GO_TERM","name":"regulation of adenosine transport","canonical_id":"go:GO:0032249","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of adenosine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"c7a8e9477e57413b9ed097d0cc2da6e0","type":"GO_TERM","name":"regulation of adenylate cyclase activity","canonical_id":"go:GO:0045761","description":"\"Any process that modulates the frequency, rate or extent of adenylate cyclase activity.\" [GOC:curators]","metadata":null},{"id":"dc54da88d21b4718a3f377ebc6ce0fd2","type":"GO_TERM","name":"regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0106070","description":"\"Any process that modulates the frequency, rate or extent of an adenylate cyclase-activating G protein-coupled receptor signaling pathway.\" [GOC:hjd, PMID:19246489]","metadata":null},{"id":"13d07085e89d404f96bee00fb9de5248","type":"GO_TERM","name":"regulation of adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0110033","description":"\"Any process that modulates the frequency, rate or extent of the adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway, the series of molecular signals generated as a consequence of glucose binding to a G protein-coupled receptor, where the pathway proceeds with activation of adenylyl cyclase and a subsequent increase in the concentration of cyclic AMP (cAMP).\" [GOC:al, PMID:24297439]","metadata":null},{"id":"578b09f4ddba4f45973867e042171584","type":"GO_TERM","name":"regulation of adenylate cyclase-inhibiting adrenergic receptor signaling pathway","canonical_id":"go:GO:0071877","description":"\"Any process that modulates the frequency, rate or extent of an adenylate cyclase-inhibiting adrenergic receptor signaling pathway activity. An adrenergic receptor signaling pathway is the series of molecular signals generated as a consequence of an adrenergic receptor binding to one of its physiological ligands.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a5f82b93c96e4849ab1d0d6fb6775ee5","type":"GO_TERM","name":"regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway","canonical_id":"go:GO:1904990","description":"\"Any process that modulates the frequency, rate or extent of adenylate cyclase-inhibiting dopamine receptor signaling pathway.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26554819]","metadata":null},{"id":"f77139ef7df341889e09f85ce158f77a","type":"GO_TERM","name":"regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway","canonical_id":"go:GO:1900729","description":"\"Any process that modulates the frequency, rate or extent of adenylate cyclase-inhibiting opioid receptor signaling pathway.\" [GOC:sjw, GOC:TermGenie, PMID:17157995]","metadata":null},{"id":"0827e8d6da304fd1bc1a967834f4a32d","type":"GO_TERM","name":"regulation of adherens junction organization","canonical_id":"go:GO:1903391","description":"\"Any process that modulates the frequency, rate or extent of adherens junction organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:21724833]","metadata":null},{"id":"3c3f464d680d48b2bc953d34c4b43b68","type":"GO_TERM","name":"regulation of adiponectin secretion","canonical_id":"go:GO:0070163","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of adiponectin from a cell.\" [GOC:mah]","metadata":null},{"id":"f0b1faf329ac449aa3b07209504d8b59","type":"GO_TERM","name":"regulation of adipose tissue development","canonical_id":"go:GO:1904177","description":"\"Any process that modulates the frequency, rate or extent of adipose tissue development.\" [GO_REF:0000058, GOC:TermGenie, PMID:23081848]","metadata":null},{"id":"0feea103af0a48b1898b52a950f3b18e","type":"GO_TERM","name":"regulation of adult chitin-containing cuticle pigmentation","canonical_id":"go:GO:0048082","description":"\"Any process that modulates the frequency, rate or extent of establishment of the adult pattern of pigmentation in the cuticle of an organism.\" [GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"234793fad33047faa4731bfa7a6a76a1","type":"GO_TERM","name":"regulation of adult salivary gland boundary specification","canonical_id":"go:GO:0045707","description":"\"Any process that modulates the frequency, rate or extent of salivary gland determination in an adult organism.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"a5e99f73d3f64cd2a90fadff7ce66898","type":"GO_TERM","name":"regulation of adult somatic muscle development","canonical_id":"go:GO:0062226","description":"\"Any process that modulates the rate, frequency or extent of adult somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"ebcca55c07634c60a1ec55e9111bc093","type":"GO_TERM","name":"regulation of aeciospore formation","canonical_id":"go:GO:0075248","description":"\"Any process that modulates the frequency, rate or extent of aeciospore formation, a process in which a dikaryotic spore of typically a rust fungus is produced in an aecium.\" [GOC:pamgo_curators]","metadata":null},{"id":"88a8c8515c1b4c8a97632e33e73f4cd3","type":"GO_TERM","name":"regulation of aecium development","canonical_id":"go:GO:0075268","description":"\"Any process that modulates the frequency, rate or extent of aecium development, a process in which a cuplike structure containing chains of aeciospores is formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"8e5257daa90745f6bc7f392d347ca7b5","type":"GO_TERM","name":"regulation of aerobic respiration","canonical_id":"go:GO:1903715","description":"\"Any process that modulates the frequency, rate or extent of aerobic respiration.\" [GO_REF:0000058, GOC:TermGenie, PMID:19266076]","metadata":null},{"id":"930058edb43f4c0a9c6f909ea50f3a72","type":"GO_TERM","name":"regulation of aflatoxin biosynthetic process","canonical_id":"go:GO:1900177","description":"\"Any process that modulates the frequency, rate or extent of aflatoxin biosynthetic process.\" [GOC:di]","metadata":null},{"id":"7e2af4eff113437493b2a88d2bd251a7","type":"GO_TERM","name":"regulation of age-related resistance","canonical_id":"go:GO:1904248","description":"\"Any process that modulates the extent of age-related resistance.\" [GO_REF:0000058, GOC:TermGenie, PMID:19694953]","metadata":null},{"id":"c791d1acb8824acfa24100668e2329e7","type":"GO_TERM","name":"regulation of aggregate size involved in sorocarp development","canonical_id":"go:GO:0031157","description":"\"Any process that modulates the size of the aggregate formed during sorocarp formation.\" [GOC:mah, GOC:mtg_sensu, GOC:pg, PMID:4338436]","metadata":null},{"id":"b3c6e5c95d85428fa60c3c3beeab60f4","type":"GO_TERM","name":"regulation of aggregation involved in sorocarp development","canonical_id":"go:GO:0060176","description":"\"Any process that modulates the frequency, rate or extent of aggregation during sorocarp development. Aggregation involved in sorocarp development is the process whose specific outcome is the progression of the aggregate over time, from its formation to the point when a slug is formed. Aggregate development begins in response to starvation and continues by the chemoattractant-mediated movement of cells toward each other. The aggregate is a multicellular structure that gives rise to the slug.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b5e40fbe3213466b9657b5bdc605bd66","type":"GO_TERM","name":"regulation of aggrephagy","canonical_id":"go:GO:1905335","description":"\"Any process that modulates the frequency, rate or extent of aggrephagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:25686248]","metadata":null},{"id":"d417c203f61d451d982863985a451fe0","type":"GO_TERM","name":"regulation of alcohol biosynthetic process","canonical_id":"go:GO:1902930","description":"\"Any process that modulates the frequency, rate or extent of alcohol biosynthetic process.\" [GO_REF:0000058, GOC:mengo_curators, GOC:TermGenie, PMID:23332010]","metadata":null},{"id":"f627913815e64fe4a73dad0e752709c8","type":"GO_TERM","name":"regulation of alcohol catabolic process","canonical_id":"go:GO:1900419","description":"\"Any process that modulates the frequency, rate or extent of alcohol catabolic process within a cell.\" [GOC:TermGenie]","metadata":null},{"id":"d25636d024804a37b26af745bcbc2a72","type":"GO_TERM","name":"regulation of aldosterone biosynthetic process","canonical_id":"go:GO:0032347","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of aldosterone.\" [GOC:mah]","metadata":null},{"id":"3490842563d14f718cbf80fc0f9c4fb4","type":"GO_TERM","name":"regulation of aldosterone metabolic process","canonical_id":"go:GO:0032344","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving aldosterone.\" [GOC:mah]","metadata":null},{"id":"57a1abcf759b478d8c2ff0e2e0b02e6e","type":"GO_TERM","name":"regulation of aldosterone secretion","canonical_id":"go:GO:2000858","description":"\"Any process that modulates the frequency, rate or extent of aldosterone secretion.\" [GOC:sl]","metadata":null},{"id":"93b5b17945b04ccfa2515c2e8fbaec2a","type":"GO_TERM","name":"regulation of alkane biosynthetic process","canonical_id":"go:GO:1901577","description":"\"Any process that modulates the frequency, rate or extent of alkane biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"0d94c509b587492f8da692a3708a1b0a","type":"GO_TERM","name":"regulation of alpha-beta T cell activation","canonical_id":"go:GO:0046634","description":"\"Any process that modulates the frequency, rate or extent of alpha-beta T cell activation.\" [GOC:ai]","metadata":null},{"id":"be1eacc6a3194cc991108085090273c0","type":"GO_TERM","name":"regulation of alpha-beta T cell differentiation","canonical_id":"go:GO:0046637","description":"\"Any process that modulates the frequency, rate or extent of alpha-beta T cell differentiation.\" [GOC:ai]","metadata":null},{"id":"5c5cd6eb311f4e67baf65b478a1654a8","type":"GO_TERM","name":"regulation of alpha-beta T cell proliferation","canonical_id":"go:GO:0046640","description":"\"Any process that modulates the frequency, rate or extent of alpha-beta T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"2a2e4cfe73ec46af95750a0f1ef90392","type":"GO_TERM","name":"regulation of alpha-glucan biosynthetic process","canonical_id":"go:GO:0032949","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways relusting in the formation of alpha-glucans.\" [GOC:mah]","metadata":null},{"id":"1887fe507b074149a876a1d3276eccb9","type":"GO_TERM","name":"regulation of alpha-glucan metabolic process","canonical_id":"go:GO:0032948","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving alpha-glucans.\" [GOC:mah]","metadata":null},{"id":"50366774e6274ebe8b42582310b60767","type":"GO_TERM","name":"regulation of alternative mRNA splicing, via spliceosome","canonical_id":"go:GO:0000381","description":"\"Any process that modulates the frequency, rate or extent of alternative splicing of nuclear mRNAs.\" [GOC:krc]","metadata":null},{"id":"01dd5e48cccb4279aaebdae91609ac3e","type":"GO_TERM","name":"regulation of amacrine cell differentiation","canonical_id":"go:GO:1902869","description":"\"Any process that modulates the frequency, rate or extent of amacrine cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"83201bf666de497a9a51061836e27305","type":"GO_TERM","name":"regulation of amine catabolic process","canonical_id":"go:GO:0033241","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of amines.\" [GOC:mah]","metadata":null},{"id":"4acb2a6c76164848adb21189fc09a26f","type":"GO_TERM","name":"regulation of amine metabolic process","canonical_id":"go:GO:0033238","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform amines.\" [GOC:mah]","metadata":null},{"id":"941a74ed5ad048c89ae54f3edb8f43a3","type":"GO_TERM","name":"regulation of amine transport","canonical_id":"go:GO:0051952","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"f081c448d3774687b100153626e9520f","type":"GO_TERM","name":"regulation of amino acid biosynthetic process","canonical_id":"go:GO:2000282","description":"\"Any process that modulates the frequency, rate or extent of cellular amino acid biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"b47ddcbdf0fc4421b267eb6610815ed0","type":"GO_TERM","name":"regulation of amino acid export","canonical_id":"go:GO:0080143","description":"\"Any process that modulates the frequency, rate or extent of amino acid export. Amino acid export is the directed movement of amino acids out of a cell or organelle.\" [PMID:20018597]","metadata":null},{"id":"06921e8de65740b9a7544000f01a6538","type":"GO_TERM","name":"regulation of amino acid import across plasma membrane","canonical_id":"go:GO:0010958","description":"\"Any process that modulates the frequency, rate or extent of amino acid import into a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0c9ff7632aef4178981b1e31ccc97f30","type":"GO_TERM","name":"regulation of amino acid metabolic process","canonical_id":"go:GO:0006521","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving amino acids.\" [GOC:curators]","metadata":null},{"id":"47c9490a873843a5aeeefbd4448ca111","type":"GO_TERM","name":"regulation of amino acid transmembrane transport","canonical_id":"go:GO:1903789","description":"\"Any process that modulates the frequency, rate or extent of amino acid transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:16115814]","metadata":null},{"id":"49477d6454734139881b90336fa156b4","type":"GO_TERM","name":"regulation of amino acid transport","canonical_id":"go:GO:0051955","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"286092d3f64b4b209fb6dcbd9888674b","type":"GO_TERM","name":"regulation of ammonia assimilation cycle","canonical_id":"go:GO:2001248","description":"\"Any process that modulates the frequency, rate or extent of ammonia assimilation cycle.\" [GOC:BHF]","metadata":null},{"id":"2a865a0c923e4eda85691cee602cc00c","type":"GO_TERM","name":"regulation of amniotic stem cell differentiation","canonical_id":"go:GO:2000797","description":"\"Any process that modulates the frequency, rate or extent of amniotic stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"f560e778986a4235a65b0da54689ebf7","type":"GO_TERM","name":"regulation of amoeboid sperm motility","canonical_id":"go:GO:1905416","description":"\"Any process that modulates the frequency, rate or extent of amoeboid sperm motility.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie]","metadata":null},{"id":"42c85700b73b43308ce448591ed33883","type":"GO_TERM","name":"regulation of amphiregulin production","canonical_id":"go:GO:0140731","description":"\"Any process that modulates the frequency, rate, or extent of production of amphiregulin.\" [PMID:24463227]","metadata":null},{"id":"f2dd75bc3947499fb693c8c3ddacc00d","type":"GO_TERM","name":"regulation of amyloid fibril formation","canonical_id":"go:GO:1905906","description":"\"Any process that modulates the frequency, rate or extent of amyloid fibril formation.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:23106396]","metadata":null},{"id":"36bf63a3a10b48f0bb805f497846d4d3","type":"GO_TERM","name":"regulation of amyloid precursor protein biosynthetic process","canonical_id":"go:GO:0042984","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of amyloid precursor protein (APP), the precursor of amyloid-beta.\" [GOC:curators]","metadata":null},{"id":"dd61388906624445a5874c042ecf36ff","type":"GO_TERM","name":"regulation of amyloid precursor protein catabolic process","canonical_id":"go:GO:1902991","description":"\"Any process that modulates the frequency, rate or extent of amyloid precursor protein catabolic process.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:24499793]","metadata":null},{"id":"bafe9c6275064a0b9d46c21581d2ba09","type":"GO_TERM","name":"regulation of amyloid-beta clearance","canonical_id":"go:GO:1900221","description":"\"Any process that modulates the frequency, rate or extent of amyloid-beta clearance.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"1f7f391851c942d2b1616d79360e7ee1","type":"GO_TERM","name":"regulation of amyloid-beta formation","canonical_id":"go:GO:1902003","description":"\"Any process that modulates the frequency, rate or extent of amyloid-beta formation.\" [GOC:dph, GOC:TermGenie, PMID:17098871]","metadata":null},{"id":"a4ef24996383439d80fe79ee4c94380d","type":"GO_TERM","name":"regulation of amylopectin catabolic process","canonical_id":"go:GO:2000945","description":"\"Any process that modulates the frequency, rate or extent of amylopectin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"4d6f9c4fb0c3408ba56557ebd01ca202","type":"GO_TERM","name":"regulation of anaphase-promoting complex-dependent catabolic process","canonical_id":"go:GO:1905784","description":"\"Any process that modulates the frequency, rate or extent of anaphase-promoting complex-dependent catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:10921876]","metadata":null},{"id":"153565361986494682a4a5a73ee926a4","type":"GO_TERM","name":"regulation of anatomical structure morphogenesis","canonical_id":"go:GO:0022603","description":"\"Any process that modulates the frequency, rate or extent of anatomical structure morphogenesis.\" [GOC:mah]","metadata":null},{"id":"63b08ae1f7574d4cac63cbaf9f2d92ec","type":"GO_TERM","name":"regulation of anatomical structure size","canonical_id":"go:GO:0090066","description":"\"Any process that modulates the size of an anatomical structure.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"64c1f6a410514fecb2bd229dced6cad7","type":"GO_TERM","name":"regulation of androgen receptor signaling pathway","canonical_id":"go:GO:0060765","description":"\"Any process that modulates the rate, frequency, or extent of the androgen receptor signaling pathway.\" [GOC:dph]","metadata":null},{"id":"856535de65304ded88afe218637637d7","type":"GO_TERM","name":"regulation of androgen secretion","canonical_id":"go:GO:2000834","description":"\"Any process that modulates the frequency, rate or extent of androgen secretion.\" [GOC:sl]","metadata":null},{"id":"75148abc6a04458e93ca87f4830631c7","type":"GO_TERM","name":"regulation of androst-4-ene-3,17-dione biosynthetic process","canonical_id":"go:GO:1903454","description":"\"Any process that modulates the frequency, rate or extent of androst-4-ene-3,17-dione biosynthetic process.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:24399684]","metadata":null},{"id":"267cb15009904cd8ae576db02b6ff037","type":"GO_TERM","name":"regulation of androstenedione secretion","canonical_id":"go:GO:2000837","description":"\"Any process that modulates the frequency, rate or extent of androstenedione secretion.\" [GOC:sl]","metadata":null},{"id":"f9686d0e311348daac185c2227a399c3","type":"GO_TERM","name":"regulation of angioblast cell migration involved in selective angioblast sprouting","canonical_id":"go:GO:0035477","description":"\"Any process that modulates the frequency, rate or extent of angioblast cell migration involved in selective angioblast sprouting.\" [GOC:dgh, PMID:19815777]","metadata":null},{"id":"8c66182e4c0c401a9d6eac665a3d87c6","type":"GO_TERM","name":"regulation of angiogenesis","canonical_id":"go:GO:0045765","description":"\"Any process that modulates the frequency, rate or extent of angiogenesis.\" [GOC:curators]","metadata":null},{"id":"e2de1813c6834712a386d965d7c3a3d2","type":"GO_TERM","name":"regulation of angiotensin levels in blood","canonical_id":"go:GO:0002002","description":"\"The process that modulates the level of any of the various angiotensinogen proteolytic products in the blood. This occurs by the proteolytic cleavage of angiotensinogen, and its proteolytic products, to create a variety of active peptide hormones, such as angiotensin I and angiotensin II, as well as through the removal of these peptides from the circulation.\" [GOC:rl, PMID:21951628, Wikipedia:Angiotensin]","metadata":null},{"id":"0b9c55f8763a4ef3a08741ef1b4e54a8","type":"GO_TERM","name":"regulation of angiotensin metabolic process","canonical_id":"go:GO:0060177","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving angiotensin.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9ec76608fc1640f19f106aecdc1cc647","type":"GO_TERM","name":"regulation of angiotensin-activated signaling pathway","canonical_id":"go:GO:0110061","description":"\"Any process that modulates the frequency, rate or extent of the angiotensin-activated signaling pathway.\" [GOC:lf, PMID:28784619]","metadata":null},{"id":"832c84549e574f21aaf0abb7cdf06096","type":"GO_TERM","name":"regulation of animal organ formation","canonical_id":"go:GO:0003156","description":"\"Any process that modulates the rate, frequency or extent of animal organ formation. Organ formation is the process pertaining to the initial formation of an organ from unspecified parts. The process begins with the specific processes that contribute to the appearance of the discrete structure, such as inductive events, and ends when the structural rudiment of the organ is recognizable, such as a condensation of mesenchymal cells into the organ rudiment.\" [GOC:dph, GOC:mtg_heart, GOC:tb]","metadata":null},{"id":"31ec7852d2fd4b9fa61aafa57b613605","type":"GO_TERM","name":"regulation of animal organ morphogenesis","canonical_id":"go:GO:2000027","description":"\"Any process that modulates the frequency, rate or extent of animal organ morphogenesis.\" [GOC:obol]","metadata":null},{"id":"824ed53433634150a5e9c28810c349e4","type":"GO_TERM","name":"regulation of anoikis","canonical_id":"go:GO:2000209","description":"\"Any process that modulates the frequency, rate or extent of anoikis.\" [GOC:mah]","metadata":null},{"id":"fa084508d01c4b418690a37c0eb2343e","type":"GO_TERM","name":"regulation of anterior head development","canonical_id":"go:GO:2000742","description":"\"Any process that modulates the frequency, rate or extent of anterior head development.\" [GOC:obol]","metadata":null},{"id":"7cf4370726d64776bb5b74f7ef813682","type":"GO_TERM","name":"regulation of anterior/posterior axon guidance","canonical_id":"go:GO:1905486","description":"\"Any process that modulates the frequency, rate or extent of anterior/posterior axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"5d5451c59271455da233a54cbb18ce9d","type":"GO_TERM","name":"regulation of anterograde axonal transport of mitochondrion","canonical_id":"go:GO:0061880","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of mitochondria along microtubules in axons away from the cell body and towards the presynapse.\" [PMID:24302729]","metadata":null},{"id":"f5a3ac479ed449d1ad2222a6914ae930","type":"GO_TERM","name":"regulation of anterograde dense core granule transport","canonical_id":"go:GO:1901951","description":"\"Any process that modulates the frequency, rate or extent of anterograde dense core granule transport.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"65b1d9ae00bc47d7b8cf08c5456e2a61","type":"GO_TERM","name":"regulation of anterograde synaptic vesicle transport","canonical_id":"go:GO:1903742","description":"\"Any process that modulates the frequency, rate or extent of anterograde synaptic vesicle transport.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:25329901]","metadata":null},{"id":"966f88ecd88a4f498fa0a565c5a6e65e","type":"GO_TERM","name":"regulation of anther dehiscence","canonical_id":"go:GO:0120194","description":"\"Any process involved in the dehiscence of an anther to release the pollen grains contained within it.\" [GOC:lr, PMID:30911018]","metadata":null},{"id":"0a57bc238b114376a24091d87f6c04b1","type":"GO_TERM","name":"regulation of anthocyanin biosynthetic process","canonical_id":"go:GO:0031540","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of anthocyanins.\" [GOC:mah]","metadata":null},{"id":"fbc936801b294065ace5655efde75ac0","type":"GO_TERM","name":"regulation of anthocyanin catabolic process","canonical_id":"go:GO:1900000","description":"\"Any process that modulates the frequency, rate or extent of anthocyanin catabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"d24ceef2cab541c696ead5cb015a6cf7","type":"GO_TERM","name":"regulation of anthocyanin metabolic process","canonical_id":"go:GO:0031537","description":"\"Any process that modulates the frequency, rate or extent of chemical reactions and pathways involving anthocyanins.\" [GOC:mah]","metadata":null},{"id":"9e59f21f824a4ee59449ab609739fb4a","type":"GO_TERM","name":"regulation of anti-Mullerian hormone signaling pathway","canonical_id":"go:GO:1902612","description":"\"Any process that modulates the frequency, rate or extent of anti-Mullerian hormone signaling pathway.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:23624077]","metadata":null},{"id":"9bd2a9f0d2d341cb8a205c3674290b10","type":"GO_TERM","name":"regulation of antibacterial peptide biosynthetic process","canonical_id":"go:GO:0002808","description":"\"Any process that modulates the frequency, rate, or extent of antibacterial peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"f5fc93d27109434a9178ca7fccfd8567","type":"GO_TERM","name":"regulation of antibacterial peptide production","canonical_id":"go:GO:0002786","description":"\"Any process that modulates the frequency, rate, or extent of antibacterial peptide production.\" [GOC:add]","metadata":null},{"id":"c087ba659672453692de59c2c49afb2c","type":"GO_TERM","name":"regulation of antibacterial peptide secretion","canonical_id":"go:GO:0002797","description":"\"Any process that modulates the frequency, rate, or extent of antibacterial peptide secretion.\" [GOC:add]","metadata":null},{"id":"a0dceefaf7a14e4791b6da0ad5dba2db","type":"GO_TERM","name":"regulation of antibody-dependent cellular cytotoxicity","canonical_id":"go:GO:0001813","description":"\"Any process that modulates the frequency, rate, or extent of antibody-dependent cellular cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"900b8a0b7292447da9a0f43ca0323731","type":"GO_TERM","name":"regulation of antifungal innate immune response","canonical_id":"go:GO:1905034","description":"\"Any process that modulates the frequency, rate or extent of an antifungal innate immune response.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:22470487]","metadata":null},{"id":"94da24ab737e44d8bbf62b75034152d4","type":"GO_TERM","name":"regulation of antifungal peptide biosynthetic process","canonical_id":"go:GO:0002810","description":"\"Any process that modulates the frequency, rate, or extent of antifungal peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"d849b9274dec44fdbedae208d4033e8e","type":"GO_TERM","name":"regulation of antifungal peptide production","canonical_id":"go:GO:0002788","description":"\"Any process that modulates the frequency, rate, or extent of antifungal peptide production.\" [GOC:add]","metadata":null},{"id":"f86e83c734dd4aec89aa82b7a68a7364","type":"GO_TERM","name":"regulation of antifungal peptide secretion","canonical_id":"go:GO:0002800","description":"\"Any process that modulates the frequency, rate, or extent of antifungal peptide secretion.\" [GOC:add]","metadata":null},{"id":"dd97a21268214e6fb1eaf4a638f37f8a","type":"GO_TERM","name":"regulation of antigen processing and presentation","canonical_id":"go:GO:0002577","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"b07139f2450e4c59a76e69a581866d92","type":"GO_TERM","name":"regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I","canonical_id":"go:GO:1904282","description":"\"Any process that modulates the frequency, rate or extent of antigen processing and presentation of endogenous peptide antigen via MHC class I.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24643698]","metadata":null},{"id":"bc8d471fa53c450187491674e5fa65ea","type":"GO_TERM","name":"regulation of antigen processing and presentation of lipid antigen via MHC class Ib","canonical_id":"go:GO:0002598","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of lipid antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"680d9ec67f374fa7a3f72f65ea7c929e","type":"GO_TERM","name":"regulation of antigen processing and presentation of peptide antigen","canonical_id":"go:GO:0002583","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of peptide antigen.\" [GOC:add]","metadata":null},{"id":"48ef7168b30841e5b815d1d7b1e16953","type":"GO_TERM","name":"regulation of antigen processing and presentation of peptide antigen via MHC class I","canonical_id":"go:GO:0002589","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class I.\" [GOC:add]","metadata":null},{"id":"81847966f28b4d438f53e51d9f675c5d","type":"GO_TERM","name":"regulation of antigen processing and presentation of peptide antigen via MHC class II","canonical_id":"go:GO:0002586","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class II.\" [GOC:add]","metadata":null},{"id":"205423119c2c4ba38360b2eafeff17fc","type":"GO_TERM","name":"regulation of antigen processing and presentation of peptide antigen via MHC class Ib","canonical_id":"go:GO:0002595","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of peptide antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"91bcc849c664436396b2f9fd4d47d020","type":"GO_TERM","name":"regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002580","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of antigen (peptide or polysaccharide) via MHC class II.\" [GOC:add]","metadata":null},{"id":"16922a05866e48bfb457ba7b59d6bc37","type":"GO_TERM","name":"regulation of antigen processing and presentation of polysaccharide antigen via MHC class II","canonical_id":"go:GO:0002601","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of polysaccharide antigen via MHC class II.\" [GOC:add]","metadata":null},{"id":"796d3c51e6394820bf614ea1a29360f9","type":"GO_TERM","name":"regulation of antigen processing and presentation via MHC class Ib","canonical_id":"go:GO:0002592","description":"\"Any process that modulates the frequency, rate, or extent of antigen processing and presentation of antigen via MHC class Ib.\" [GOC:add]","metadata":null},{"id":"8f388582d11b44109951f4872e35339b","type":"GO_TERM","name":"regulation of antigen receptor-mediated signaling pathway","canonical_id":"go:GO:0050854","description":"\"Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B- or T cell.\" [GOC:ai]","metadata":null},{"id":"c3891ef7fea549d380447de427874c35","type":"GO_TERM","name":"regulation of antimicrobial humoral response","canonical_id":"go:GO:0002759","description":"\"Any process that modulates the frequency, rate, or extent of an antimicrobial humoral response.\" [GOC:add]","metadata":null},{"id":"a3da6b0d2e1d4042b953cb950f8bf74a","type":"GO_TERM","name":"regulation of antimicrobial peptide biosynthetic process","canonical_id":"go:GO:0002805","description":"\"Any process that modulates the frequency, rate, or extent of antimicrobial peptide biosynthesis.\" [GOC:add]","metadata":null},{"id":"43b8f77a8e58484eac5d536c7648dc9c","type":"GO_TERM","name":"regulation of antimicrobial peptide production","canonical_id":"go:GO:0002784","description":"\"Any process that modulates the frequency, rate, or extent of antimicrobial peptide production.\" [GOC:add]","metadata":null},{"id":"73b132c802cf4f03a374e1f8264be336","type":"GO_TERM","name":"regulation of antimicrobial peptide secretion","canonical_id":"go:GO:0002794","description":"\"Any process that modulates the frequency, rate, or extent of antimicrobial peptide secretion.\" [GOC:add]","metadata":null},{"id":"de341bd00c5c432a8833153d007693d5","type":"GO_TERM","name":"regulation of antipodal cell differentiation","canonical_id":"go:GO:0045688","description":"\"Any process that modulates the frequency, rate or extent of antipodal cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"845c83f02c2648aa949dcadd79c5a147","type":"GO_TERM","name":"regulation of antisense RNA transcription","canonical_id":"go:GO:0060194","description":"\"Any process that modulates the frequency, rate or extent of the synthesis of antisense RNA, an RNA molecule complementary in sequence to another RNA or DNA molecule, which, by binding the latter, acts to inhibit its function and/or completion of synthesis, on a template of DNA.\" [GOC:dph, GOC:jp, GOC:tb, PMID:18075583]","metadata":null},{"id":"7b6c9ca256b140e39411674560d63cf6","type":"GO_TERM","name":"regulation of antral ovarian follicle growth","canonical_id":"go:GO:2000387","description":"\"Any process that modulates the frequency, rate or extent of antral ovarian follicle growth.\" [GOC:obol]","metadata":null},{"id":"33509ead594d4f41936b594a039f3389","type":"GO_TERM","name":"regulation of aorta morphogenesis","canonical_id":"go:GO:1903847","description":"\"Any process that modulates the frequency, rate or extent of aorta morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"ec5aea3a2f6d494b8d2d618839c8f0a0","type":"GO_TERM","name":"regulation of aortic smooth muscle cell differentiation","canonical_id":"go:GO:1904829","description":"\"Any process that modulates the frequency, rate or extent of aortic smooth muscle cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22034194]","metadata":null},{"id":"fcdf2789641b47a193f60cd1684b8d5b","type":"GO_TERM","name":"regulation of apical constriction involved in ventral furrow formation","canonical_id":"go:GO:0110073","description":"\"Any process that modulates the frequency, rate or extent of apical constriction involved in ventral furrow formation.\" [GOC:ha, PMID:28495958]","metadata":null},{"id":"e1d83c233c8647eea93fc547e705b1dd","type":"GO_TERM","name":"regulation of apical ectodermal ridge formation","canonical_id":"go:GO:1905140","description":"\"Any process that modulates the frequency, rate or extent of apical ectodermal ridge formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:18359901]","metadata":null},{"id":"345567f28ff84daf88c5e8759cb86c22","type":"GO_TERM","name":"regulation of aplanospore formation","canonical_id":"go:GO:0075290","description":"\"Any process that modulates the frequency, rate or extent of aplanospore formation, a process in which a nonmotile, asexual spore is formed within a cell in certain algae and fungi (commonly in the Phycomycetes), the wall of aplanospore is distinct from that of the parent cell.\" [GOC:pamgo_curators]","metadata":null},{"id":"3a5c9ec54a75490c83cc2e82bc19648a","type":"GO_TERM","name":"regulation of apolipoprotein A-I-mediated signaling pathway","canonical_id":"go:GO:1905094","description":"\"Any process that modulates the frequency, rate or extent of apolipoprotein A-I-mediated signaling pathway.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25084135]","metadata":null},{"id":"db528949b466444da4309cf757c08652","type":"GO_TERM","name":"regulation of apoptosis involved in tissue homeostasis","canonical_id":"go:GO:0060785","description":"\"Any process that modulates the occurrence or rate of cell death by apoptosis that results in the maintenance of the steady-state number of cells within a tissue.\" [GOC:dph]","metadata":null},{"id":"756447d9ef9541fba38540f999a85b8f","type":"GO_TERM","name":"regulation of apoptosome assembly","canonical_id":"go:GO:1905100","description":"\"Any process that modulates the frequency, rate or extent of apoptosome assembly.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:26265044]","metadata":null},{"id":"678a4169585944b292631adbcdd0618b","type":"GO_TERM","name":"regulation of apoptotic DNA fragmentation","canonical_id":"go:GO:1902510","description":"\"Any process that modulates the frequency, rate or extent of apoptotic DNA fragmentation.\" [GOC:hjd, GOC:TermGenie, PMID:15572351, PMID:15723341]","metadata":null},{"id":"d969f8b8da904c92b57e86c5fa7ada82","type":"GO_TERM","name":"regulation of apoptotic cell clearance","canonical_id":"go:GO:2000425","description":"\"Any process that modulates the frequency, rate or extent of apoptotic cell clearance.\" [GOC:obol]","metadata":null},{"id":"227db4269d2a4a81a8d939124e03f356","type":"GO_TERM","name":"regulation of apoptotic process","canonical_id":"go:GO:0042981","description":"\"Any process that modulates the occurrence or rate of cell death by apoptotic process.\" [GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"a216f1f062a44fe782b9cb0beb6937b7","type":"GO_TERM","name":"regulation of apoptotic process in bone marrow cell","canonical_id":"go:GO:0071865","description":"\"Any process that modulates the occurrence or rate of cell death by apoptotic process in the bone marrow.\" [GOC:mah, GOC:mtg_apoptosis, GOC:yaf, PMID:17063141]","metadata":null},{"id":"de44beb085b14e09a73cbcf913751c76","type":"GO_TERM","name":"regulation of apoptotic process involved in development","canonical_id":"go:GO:1904748","description":"\"Any process that modulates the frequency, rate or extent of apoptotic process involved in development.\" [GO_REF:0000058, GOC:TermGenie, PMID:22801495]","metadata":null},{"id":"116fefa3c0fb4baebadbe4dd2dcfedde","type":"GO_TERM","name":"regulation of apoptotic process involved in outflow tract morphogenesis","canonical_id":"go:GO:1902256","description":"\"Any process that modulates the frequency, rate or extent of apoptotic process involved in outflow tract morphogenesis.\" [GOC:dph, GOC:mtg_apoptosis, GOC:TermGenie, PMID:16839542]","metadata":null},{"id":"2d69b3b48d364225ae7863fe8eb5e493","type":"GO_TERM","name":"regulation of apoptotic signaling pathway","canonical_id":"go:GO:2001233","description":"\"Any process that modulates the frequency, rate or extent of apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"0bcfdd62ca154a4590399ede19feadcc","type":"GO_TERM","name":"regulation of appetite","canonical_id":"go:GO:0032098","description":"\"Any process which modulates appetite, the desire or physical craving for food.\" [GOC:add]","metadata":null},{"id":"f80bb76330564f70b004006896458418","type":"GO_TERM","name":"regulation of appressorium formation","canonical_id":"go:GO:0075017","description":"\"Any process that modulates the frequency, rate or extent of symbiont appressorium formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"ad287141ee144727bc82dcfe265e7201","type":"GO_TERM","name":"regulation of arabinoxylan-containing compound catabolic process","canonical_id":"go:GO:2000921","description":"\"Any process that modulates the frequency, rate or extent of arabinoxylan-containing compound catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"530bd408aa1848a38a333e041cfc3ccc","type":"GO_TERM","name":"regulation of arachidonate secretion","canonical_id":"go:GO:0090237","description":"\"Any process that modulates the rate, frequency, or extent of arachidonic acid secretion, the controlled release of arachidonic acid from a cell or a tissue.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"270a9e1635bf499eb0cd562dffcd9cac","type":"GO_TERM","name":"regulation of arbuscule formation for nutrient acquisition from host","canonical_id":"go:GO:0075329","description":"\"Any process that modulates the frequency, rate or extent of symbiont arbuscule formation for nutrient acquisition from host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"cab9b6678bff4dd3982b6754716bf8cb","type":"GO_TERM","name":"regulation of arginine biosynthetic process","canonical_id":"go:GO:1900079","description":"\"Any process that modulates the frequency, rate or extent of arginine biosynthetic process.\" [GOC:dgf, GOC:TermGenie]","metadata":null},{"id":"b1f7c33b18d14f138b6c493a0e2e8cea","type":"GO_TERM","name":"regulation of arginine catabolic process","canonical_id":"go:GO:1900081","description":"\"Any process that modulates the frequency, rate or extent of arginine catabolic process.\" [GOC:dgf, GOC:TermGenie]","metadata":null},{"id":"573ed6b7968c401bacc0e2b48457318c","type":"GO_TERM","name":"regulation of artery morphogenesis","canonical_id":"go:GO:1905651","description":"\"Any process that modulates the frequency, rate or extent of artery morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:27389411]","metadata":null},{"id":"5c85a9970bc441b296bb5066d170ae18","type":"GO_TERM","name":"regulation of artery smooth muscle contraction","canonical_id":"go:GO:1905654","description":"\"Any process that modulates the frequency, rate or extent of artery smooth muscle contraction.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:27389411]","metadata":null},{"id":"f411de7436d44d6aad96866f7013c262","type":"GO_TERM","name":"regulation of arugosin biosynthetic process","canonical_id":"go:GO:1900626","description":"\"Any process that modulates the frequency, rate or extent of arugosin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4966838ec45d4cb998cc5ec9067381f5","type":"GO_TERM","name":"regulation of ascospore formation","canonical_id":"go:GO:0034307","description":"\"Any process that modulates the frequency, rate or extent of ascospore formation. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:mah]","metadata":null},{"id":"8dfdb2f26c164200bd644b89d19b3908","type":"GO_TERM","name":"regulation of ascospore wall (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0060624","description":"\"Any process that modulates the rate, frequency, or extent of ascospore wall (1->3)-beta-D-glucan biosynthetic process, the chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D--glucosidic bonds, found in the walls of ascospores.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4c6fce6aeef1415fa6a23099379b1b7b","type":"GO_TERM","name":"regulation of ascospore wall beta-glucan biosynthetic process","canonical_id":"go:GO:0060622","description":"\"Any process that modulates the rate, frequency or extent of ascospore wall beta-glucan biosynthetic process, the chemical reactions and pathways resulting in the formation of beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of ascospores.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a82a3d48143d4bf2a47ecb0e39a94fef","type":"GO_TERM","name":"regulation of ascospore-type prospore membrane formation","canonical_id":"go:GO:1903023","description":"\"Any process that modulates the frequency, rate or extent of formation of an ascospore-type prospore membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:11405625]","metadata":null},{"id":"249e2c5f8a344f1da078519fbec2b348","type":"GO_TERM","name":"regulation of ascus development","canonical_id":"go:GO:0075318","description":"\"Any process that modulates the frequency, rate or extent of ascus development, a process that leads to the formation of basidium, a sac-like structure produced by fungi of the phylum Ascomycota (sac fungi) in which sexually produced spores (ascospores), usually four or eight in number, are formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"42c6c79c63a648a7824b4ed0f84479c6","type":"GO_TERM","name":"regulation of asexual reproduction","canonical_id":"go:GO:1903664","description":"\"Any process that modulates the frequency, rate or extent of asexual reproduction.\" [GO_REF:0000058, GOC:TermGenie, PMID:24390142]","metadata":null},{"id":"962ab9259d174e949a9bcaaea9108d50","type":"GO_TERM","name":"regulation of asexual sporulation","canonical_id":"go:GO:0034305","description":"\"Any process that modulates the frequency, rate or extent of spore formation from the products of mitosis.\" [GOC:mah]","metadata":null},{"id":"37c4dbed7f8e491eaf35d16939c64ff8","type":"GO_TERM","name":"regulation of asexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043943","description":"\"Any process that modulates the frequency, rate or extent of the formation of a cellular spore derived from the products of mitosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"3a41bbc3e805427296cbeb30442d086a","type":"GO_TERM","name":"regulation of aspartate secretion","canonical_id":"go:GO:1904448","description":"\"Any process that modulates the frequency, rate or extent of aspartate secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:2342602]","metadata":null},{"id":"1ccd4d13f37d423dbf180614f64edd0e","type":"GO_TERM","name":"regulation of asperfuranone biosynthetic process","canonical_id":"go:GO:1900637","description":"\"Any process that modulates the frequency, rate or extent of asperfuranone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5d50b3370f7a4764a6fde41be6dc8be7","type":"GO_TERM","name":"regulation of asperthecin biosynthetic process","canonical_id":"go:GO:1900379","description":"\"Any process that modulates the frequency, rate or extent of asperthecin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7bedd709151d496f9d7e00890a24cf7d","type":"GO_TERM","name":"regulation of assembly of large subunit precursor of preribosome","canonical_id":"go:GO:1902627","description":"\"Any process that modulates the frequency, rate or extent of assembly of a large subunit precursor of preribosome.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:22735702]","metadata":null},{"id":"80e23e13948e48999d4d970fc15c22b1","type":"GO_TERM","name":"regulation of astrocyte activation","canonical_id":"go:GO:0061888","description":"\"Any process that modulates the frequency, rate or extent of astrocyte activation.\" [GOC:aruk, GOC:bc, PMID:20005821]","metadata":null},{"id":"c48ef9a2b8f44fe1ab1bbf89d4aa93c8","type":"GO_TERM","name":"regulation of astrocyte chemotaxis","canonical_id":"go:GO:2000458","description":"\"Any process that modulates the frequency, rate or extent of astrocyte chemotaxis.\" [GOC:obol]","metadata":null},{"id":"cbc6e463b21343a18c502fcb85175dde","type":"GO_TERM","name":"regulation of astrocyte differentiation","canonical_id":"go:GO:0048710","description":"\"Any process that modulates the frequency, rate or extent of astrocyte differentiation.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"efbd53b5e8f6400d9c608d3f5f43c208","type":"GO_TERM","name":"regulation of asymmetric cell division","canonical_id":"go:GO:0009786","description":"\"Any process that modulates the frequency, rate or extent of asymmetric cell division.\" [GOC:lr]","metadata":null},{"id":"a65c92a833054d249e0b945260d2f8bc","type":"GO_TERM","name":"regulation of asymmetric protein localization involved in cell fate determination","canonical_id":"go:GO:1904785","description":"\"Any process that modulates the frequency, rate or extent of asymmetric protein localization involved in cell fate determination.\" [GO_REF:0000058, GOC:TermGenie, PMID:17476329]","metadata":null},{"id":"99e1734790e34831abd7acad64fa46f7","type":"GO_TERM","name":"regulation of atrial cardiac muscle cell action potential","canonical_id":"go:GO:0098910","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in an atrial cardiac muscle cell contributing to the regulation of its contraction. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"b0a4e12437a24340b247975384ee8aa1","type":"GO_TERM","name":"regulation of atrial cardiac muscle cell membrane depolarization","canonical_id":"go:GO:0060371","description":"\"Any process that modulates the establishment or extent of a membrane potential in the depolarizing direction away from the resting potential in an atrial cardiomyocyte.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"94247900bff644cca14f749cb49a72c3","type":"GO_TERM","name":"regulation of atrial cardiac muscle cell membrane repolarization","canonical_id":"go:GO:0060372","description":"\"Any process that modulates the establishment or extent of a membrane potential in the polarizing direction towards the resting potential in an atrial cardiomyocyte.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"03e0f4ac0ffc42d384336086c835dcb1","type":"GO_TERM","name":"regulation of atrichoblast fate specification","canonical_id":"go:GO:0010058","description":"\"Any process that modulates atrichoblast fate specification.\" [GOC:tb]","metadata":null},{"id":"2796a4a22e9d434eb8611e38f769b0a0","type":"GO_TERM","name":"regulation of attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:1902423","description":"\"Any process that modulates the frequency, rate or extent of attachment of spindle microtubules to kinetochore involved in mitotic sister chromatid segregation.\" [GOC:TermGenie, GOC:vw, PMID:22065639]","metadata":null},{"id":"fa8412c7c0d440d0929fc158b05663a0","type":"GO_TERM","name":"regulation of attachment of spindle microtubules to kinetochore","canonical_id":"go:GO:0051988","description":"\"Any process that modulates the frequency, rate or extent of the attachment of spindle microtubules to the kinetochore.\" [GOC:ai]","metadata":null},{"id":"faa2ea2e89944a38b0788486b1b1a077","type":"GO_TERM","name":"regulation of austinol biosynthetic process","canonical_id":"go:GO:1900640","description":"\"Any process that modulates the frequency, rate or extent of austinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"468f6f49e93f40cebb66de8d9218697c","type":"GO_TERM","name":"regulation of autophagic cell death","canonical_id":"go:GO:1904092","description":"\"Any process that modulates the frequency, rate or extent of autophagic cell death.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25736836]","metadata":null},{"id":"e5306b983ff3428ba1fd1db182d96087","type":"GO_TERM","name":"regulation of autophagosome assembly","canonical_id":"go:GO:2000785","description":"\"Any process that modulates the frequency, rate or extent of autophagosome assembly.\" [GOC:autophagy, GOC:BHF]","metadata":null},{"id":"97f3905bd4ae4951ace91b1d3419d955","type":"GO_TERM","name":"regulation of autophagosome maturation","canonical_id":"go:GO:1901096","description":"\"Any process that modulates the frequency, rate or extent of autophagosome maturation.\" [GOC:autophagy, GOC:TermGenie, PMID:10436019, PMID:21383079]","metadata":null},{"id":"6e677b9f43fd44a8b37459b044dabc97","type":"GO_TERM","name":"regulation of autophagosome size","canonical_id":"go:GO:0016243","description":"\"Any process that modulates the size of the autophagosome.\" [GOC:autophagy, GOC:krc]","metadata":null},{"id":"41ce8735437d48a48b5b2a880144b751","type":"GO_TERM","name":"regulation of autophagy","canonical_id":"go:GO:0010506","description":"\"Any process that modulates the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"233563951184407384e6eb815d3c7f10","type":"GO_TERM","name":"regulation of autophagy of mitochondrion","canonical_id":"go:GO:1903146","description":"\"Any process that modulates the frequency, rate or extent of mitochondrion degradation by an autophagic process.\" [GO_REF:0000058, GOC:autophagy, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24600391]","metadata":null},{"id":"e65c7191c1704b8caf3cc4e7fbcc6454","type":"GO_TERM","name":"regulation of auxin biosynthetic process","canonical_id":"go:GO:0010600","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of auxins, plant hormones that regulate aspects of plant growth.\" [PMID:18287041]","metadata":null},{"id":"2c3bd602a239437f8b0663dda79773f2","type":"GO_TERM","name":"regulation of auxin mediated signaling pathway","canonical_id":"go:GO:0010928","description":"\"Any process that modulates the rate, frequency or extent of auxin mediated signaling pathway. Auxin mediated signaling pathway is the series of molecular signals generated in response to detection of auxin.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d30d9fd11a924a9db1239c440bd3e715","type":"GO_TERM","name":"regulation of auxin metabolic process","canonical_id":"go:GO:0090354","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving auxins, plant hormones that regulate aspects of plant growth.\" [GOC:tb]","metadata":null},{"id":"21d1eab0a9f9408580464bee71b09365","type":"GO_TERM","name":"regulation of auxin polar transport","canonical_id":"go:GO:2000012","description":"\"Any process that modulates the frequency, rate or extent of auxin polar transport.\" [GOC:obol]","metadata":null},{"id":"63bd69a0052c44f6802e6b86fa5673e1","type":"GO_TERM","name":"regulation of axial mesodermal cell fate determination","canonical_id":"go:GO:0048324","description":"\"Any process that modulates the frequency, rate or extent of axial mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"3743b88135df4d81b53dbb43a5769cd8","type":"GO_TERM","name":"regulation of axial mesodermal cell fate specification","canonical_id":"go:GO:0048328","description":"\"Any process that modulates the frequency, rate or extent of axial mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"2e0d7c4a751240749d171f4d53c3681a","type":"GO_TERM","name":"regulation of axo-dendritic protein transport","canonical_id":"go:GO:1905126","description":"\"Any process that modulates the frequency, rate or extent of axo-dendritic protein transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20694152]","metadata":null},{"id":"e06f8e5b95934d11a223dc435f16f6eb","type":"GO_TERM","name":"regulation of axon diameter","canonical_id":"go:GO:0031133","description":"\"Any process that modulates the rate, direction or extent of axon growth such that the correct diameter is attained and maintained.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"d956bbd7f3f945709c1db075244b14d2","type":"GO_TERM","name":"regulation of axon extension","canonical_id":"go:GO:0030516","description":"\"Any process that modulates the rate, direction or extent of axon extension.\" [GOC:curators]","metadata":null},{"id":"7042376f6cbe428285dbcdfbc2f91753","type":"GO_TERM","name":"regulation of axon extension involved in axon guidance","canonical_id":"go:GO:0048841","description":"\"Any process that modulates the frequency, rate or extent of axon extension involved in axon guidance.\" [GOC:devbiol]","metadata":null},{"id":"04f5055b919d493cb13a8d23a213dd43","type":"GO_TERM","name":"regulation of axon guidance","canonical_id":"go:GO:1902667","description":"\"Any process that modulates the frequency, rate or extent of axon guidance.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:23006775]","metadata":null},{"id":"3d1ded2bf4b64a818cf8f27750b27dc8","type":"GO_TERM","name":"regulation of axon regeneration","canonical_id":"go:GO:0048679","description":"\"Any process that modulates the frequency, rate or extent of axon regeneration.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"cc5dc53a0570485fbcda420f4ab058f5","type":"GO_TERM","name":"regulation of axonogenesis","canonical_id":"go:GO:0050770","description":"\"Any process that modulates the frequency, rate or extent of axonogenesis, the generation of an axon, the long process of a neuron.\" [GOC:ai]","metadata":null},{"id":"d590a681419c4a5b8c508dd60382d63f","type":"GO_TERM","name":"regulation of backward locomotion","canonical_id":"go:GO:0043058","description":"\"Any process that modulates the speed, mechanical force, or rhythm of the posterior movement of an organism.\" [GOC:curators]","metadata":null},{"id":"4e7cd88650654e5683256c618b1a2fd6","type":"GO_TERM","name":"regulation of bacterial-type flagellum assembly","canonical_id":"go:GO:1902208","description":"\"Any process that modulates the frequency, rate or extent of bacterial-type flagellum assembly.\" [GOC:jl, GOC:TermGenie]","metadata":null},{"id":"95fb6971ceef4b76b8ac1ed8ebdd680c","type":"GO_TERM","name":"regulation of bacterial-type flagellum-dependent cell motility","canonical_id":"go:GO:1902021","description":"\"Any process that modulates the frequency, rate or extent of bacterial-type flagellum-dependent cell motility.\" [GOC:cilia, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"0e62a6fcafa3457cabfbaaf5f54cefcf","type":"GO_TERM","name":"regulation of bacterial-type flagellum-dependent cell motility by regulation of motor speed","canonical_id":"go:GO:0071945","description":"\"A process that modulates flagellum-dependent motility in bacteria by modulating the speed or direction of rotation of a rotary flagellar motor, mediated by interactions between the braking protein.\" [GOC:cilia, GOC:jl, PMID:20371342]","metadata":null},{"id":"c13a1063eb7e4eae8ddfc6f5a422dc0a","type":"GO_TERM","name":"regulation of barbed-end actin filament capping","canonical_id":"go:GO:2000812","description":"\"Any process that modulates the frequency, rate or extent of barbed-end actin filament capping.\" [GOC:BHF]","metadata":null},{"id":"684f7c3cb89045bf992b056d0614902d","type":"GO_TERM","name":"regulation of base-excision repair","canonical_id":"go:GO:1905051","description":"\"Any process that modulates the frequency, rate or extent of base-excision repair.\" [GO_REF:0000058, GOC:ah, GOC:TermGenie, PMID:18973764]","metadata":null},{"id":"84fec41ccbe8437a85bf4eddc1ea5f66","type":"GO_TERM","name":"regulation of basement membrane organization","canonical_id":"go:GO:0110011","description":"\"Any process that modulates the frequency, rate or extent of the assembly, disassembly or arrangement of constituent parts of the basement membrane.\" [GOC:ha, PMID:27404358]","metadata":null},{"id":"ccc7ccd830fb4f1b9c322b8391e15d32","type":"GO_TERM","name":"regulation of basidiospore formation","canonical_id":"go:GO:0075302","description":"\"Any process that modulates the frequency, rate or extent of basidiospore formation, a process in which a sexually produced fungal spore is formed on a basidium in the fungi Basidiomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"6c3d3e447ba54b6d90f038c678762309","type":"GO_TERM","name":"regulation of basidium development","canonical_id":"go:GO:0075314","description":"\"Any process that modulates the frequency, rate or extent of basidium development, a process that leads to the formation of a basidium, a small, specialized club-shaped structure typically bearing four basidiospores at the tips of minute projections. The basidium is unique to Basidiomycetes and distinguishes them from other kinds of fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"369ddc11edc245f9a04cf539ed6d268a","type":"GO_TERM","name":"regulation of basophil degranulation","canonical_id":"go:GO:1903581","description":"\"Any process that modulates the frequency, rate or extent of basophil degranulation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10880837]","metadata":null},{"id":"616fabd8a08d4103a3d06f8749023493","type":"GO_TERM","name":"regulation of basophil differentiation","canonical_id":"go:GO:0045640","description":"\"Any process that modulates the frequency, rate or extent of basophil differentiation.\" [GOC:curators]","metadata":null},{"id":"d0bdad2d84ba4769b9c5512dac25e787","type":"GO_TERM","name":"regulation of behavior","canonical_id":"go:GO:0050795","description":"\"Any process that modulates the frequency, rate or extent of behavior, the internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or external stimuli.\" [GOC:curators, GOC:pr]","metadata":null},{"id":"510ee5f7f66a4637887c9ff688675c84","type":"GO_TERM","name":"regulation of behavioral fear response","canonical_id":"go:GO:2000822","description":"\"Any process that modulates the frequency, rate or extent of behavioral fear response.\" [GOC:BHF]","metadata":null},{"id":"b0270128b1e4482eb3cbb716afca5d3a","type":"GO_TERM","name":"regulation of beta 2 integrin biosynthetic process","canonical_id":"go:GO:0045115","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of beta 2 integrins.\" [GOC:curators]","metadata":null},{"id":"aee7b42b456c4ff2b66f20a1a2803378","type":"GO_TERM","name":"regulation of beta-catenin-TCF complex assembly","canonical_id":"go:GO:1904863","description":"\"Any process that modulates the frequency, rate or extent of beta-catenin-TCF complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"651bc76050714645afd9dea0ec8381d8","type":"GO_TERM","name":"regulation of beta-glucan biosynthetic process","canonical_id":"go:GO:0032951","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways relusting in the formation of beta-glucans.\" [GOC:mah]","metadata":null},{"id":"35aac9405bf74f80af0a9b409379f0f3","type":"GO_TERM","name":"regulation of beta-glucan metabolic process","canonical_id":"go:GO:0032950","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving beta-glucans.\" [GOC:mah]","metadata":null},{"id":"90ca67b1bf154c088104292c5b6cb8ee","type":"GO_TERM","name":"regulation of beta-lactamase activity","canonical_id":"go:GO:0033252","description":"\"Any process that modulates the frequency, rate or extent of beta-lactamase activity, the hydrolysis of a beta-lactam to yield a substituted beta-amino acid.\" [GOC:mah]","metadata":null},{"id":"97ef93cc9cb545bea6130479218840f0","type":"GO_TERM","name":"regulation of bicellular tight junction assembly","canonical_id":"go:GO:2000810","description":"\"Any process that modulates the frequency, rate or extent of tight junction assembly.\" [GOC:BHF]","metadata":null},{"id":"c0a6432692044ce5b7362a816b0f2a94","type":"GO_TERM","name":"regulation of bicoid mRNA localization","canonical_id":"go:GO:0008359","description":"\"Any process that modulates the frequency, rate or extent of the process in which bicoid mRNA is transported to, or maintained in, a specific location.\" [GOC:hb]","metadata":null},{"id":"d44b3c2a45c74daf97a3a6e542ab08e1","type":"GO_TERM","name":"regulation of bile acid biosynthetic process","canonical_id":"go:GO:0070857","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"49c650458135418fabc0285f25593f9c","type":"GO_TERM","name":"regulation of bile acid secretion","canonical_id":"go:GO:0120188","description":"\"Any process that modulates the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:22767443]","metadata":null},{"id":"d3bcc072dae54146ac9c63c88f8b5aab","type":"GO_TERM","name":"regulation of binding","canonical_id":"go:GO:0051098","description":"\"Any process that modulates the frequency, rate or extent of binding, the selective interaction of a molecule with one or more specific sites on another molecule.\" [GOC:ai]","metadata":null},{"id":"044cc04c52a541949ad5c762930a698e","type":"GO_TERM","name":"regulation of binding of sperm to zona pellucida","canonical_id":"go:GO:2000359","description":"\"Any process that modulates the frequency, rate or extent of binding of sperm to the zona pellucida.\" [GOC:obol]","metadata":null},{"id":"787259c212fc47f39e6238fe62d19d2e","type":"GO_TERM","name":"regulation of biological process","canonical_id":"go:GO:0050789","description":"\"Any process that modulates the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule.\" [GOC:ai, GOC:curators]","metadata":null},{"id":"64da1f3cebf746278f2b4d57441c066b","type":"GO_TERM","name":"regulation of biological process involved in symbiotic interaction","canonical_id":"go:GO:0043903","description":"\"Any process that modulates the frequency, rate or extent of symbiosis, an interaction between two organisms living together in more or less intimate association.\" [GOC:jl]","metadata":null},{"id":"ac6834d494eb4bf082bb30bf0799f354","type":"GO_TERM","name":"regulation of biological quality","canonical_id":"go:GO:0065008","description":"\"Any process that modulates a qualitative or quantitative trait of a biological quality. A biological quality is a measurable attribute of an organism or part of an organism, such as size, mass, shape, color, etc.\" [GOC:dph, GOC:isa_complete, GOC:mah, GOC:pr, GOC:vw]","metadata":null},{"id":"a65e24e231c94416b566c00bda55ce34","type":"GO_TERM","name":"regulation of bioluminescence","canonical_id":"go:GO:1905085","description":"\"Any process that modulates the frequency, rate or extent of bioluminescence.\" [GO_REF:0000058, GOC:BHF, GOC:rph, GOC:TermGenie, PMID:10913092]","metadata":null},{"id":"d6b65b270f17421eba05eb8ec2eb9a87","type":"GO_TERM","name":"regulation of biomineral tissue development","canonical_id":"go:GO:0070167","description":"\"Any process that modulates the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds.\" [GOC:mah]","metadata":null},{"id":"b459bbb2e19840b2ade516636d38d940","type":"GO_TERM","name":"regulation of biosynthetic process","canonical_id":"go:GO:0009889","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances.\" [GOC:curators]","metadata":null},{"id":"9b934e56cda24538ace19fed1b7541d5","type":"GO_TERM","name":"regulation of biosynthetic process of antibacterial peptides active against Gram-negative bacteria","canonical_id":"go:GO:0002813","description":"\"Any process that modulates the frequency, rate, or extent of biosynthesis of antibacterial peptides active against Gram-negative bacteria.\" [GOC:add]","metadata":null},{"id":"668feeb4c4704a52b7d038850fe75a3f","type":"GO_TERM","name":"regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria","canonical_id":"go:GO:0002816","description":"\"Any process that modulates the frequency, rate, or extent of biosynthesis of antibacterial peptides active against Gram-positive bacteria.\" [GOC:add]","metadata":null},{"id":"5c024c0ff82b420bb986baff6b640a03","type":"GO_TERM","name":"regulation of bipolar cell growth","canonical_id":"go:GO:0051516","description":"\"Any process that modulates the frequency, rate or extent of bipolar cell growth, polarized growth from both ends of a cell.\" [GOC:ai]","metadata":null},{"id":"4e350f1bf1c4476f9a27a3921f718380","type":"GO_TERM","name":"regulation of blastocyst development","canonical_id":"go:GO:0120222","description":"\"Any process that modulates the frequency, rate or extent of blastocyst development.\" [GOC:krc, PMID:29593216]","metadata":null},{"id":"a6122140a9ca48bd8791f07f86b1ab75","type":"GO_TERM","name":"regulation of bleb assembly","canonical_id":"go:GO:1904170","description":"\"Any process that modulates the frequency, rate or extent of bleb assembly.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:25651887]","metadata":null},{"id":"753a4fe825ed4e85bb2102c673cb52f4","type":"GO_TERM","name":"regulation of blood circulation","canonical_id":"go:GO:1903522","description":"\"Any process that modulates the frequency, rate or extent of blood circulation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:10659969]","metadata":null},{"id":"0a0b3a8896294a1caaa703d08a131fd8","type":"GO_TERM","name":"regulation of blood coagulation","canonical_id":"go:GO:0030193","description":"\"Any process that modulates the frequency, rate or extent of blood coagulation.\" [GOC:mah]","metadata":null},{"id":"b7aa80259cd54ecfa3792c0a62b81d55","type":"GO_TERM","name":"regulation of blood coagulation, common pathway","canonical_id":"go:GO:2000260","description":"\"Any process that modulates the frequency, rate or extent of blood coagulation, common pathway.\" [GOC:mah]","metadata":null},{"id":"9f678f0832a442d1b94e94c279e266ac","type":"GO_TERM","name":"regulation of blood coagulation, extrinsic pathway","canonical_id":"go:GO:2000263","description":"\"Any process that modulates the frequency, rate or extent of blood coagulation, extrinsic pathway.\" [GOC:mah]","metadata":null},{"id":"45390e21d18a45efa481e00ef7a01739","type":"GO_TERM","name":"regulation of blood coagulation, intrinsic pathway","canonical_id":"go:GO:2000266","description":"\"Any process that modulates the frequency, rate or extent of blood coagulation, intrinsic pathway.\" [GOC:mah]","metadata":null},{"id":"5d84252a75384caf8538542577be6178","type":"GO_TERM","name":"regulation of blood microparticle formation","canonical_id":"go:GO:2000332","description":"\"Any process that modulates the frequency, rate or extent of blood microparticle formation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ae75d64ec5de4a57886597b89a5d0845","type":"GO_TERM","name":"regulation of blood pressure","canonical_id":"go:GO:0008217","description":"\"Any process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure.\" [GOC:dph, GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"5102b6d2d8bf483795cee12470e91b9a","type":"GO_TERM","name":"regulation of blood pressure by chemoreceptor signaling pathway","canonical_id":"go:GO:0010850","description":"\"A series of reactions within the cell that occur as a result of a single trigger reaction or compound interacting with a chemoreceptor resulting in a modulation of the force with which blood travels through the circulatory system. Chemoreceptors respond to oxygen, carbon dioxide and hydrogen ions.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9fb09cc968b84e3191130710ee6a399b","type":"GO_TERM","name":"regulation of blood vessel branching","canonical_id":"go:GO:1905553","description":"\"Any process that modulates the frequency, rate or extent of blood vessel branching.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23201774]","metadata":null},{"id":"89d8a8e9c6d64479bea5429f1e70fb90","type":"GO_TERM","name":"regulation of blood vessel endothelial cell differentiation","canonical_id":"go:GO:0110057","description":"\"Any process that modulates the frequency, rate or extent of blood vessel endothelial cell differentiation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:23072816]","metadata":null},{"id":"2a5a9e43bd03464d939d67ab29a7cc26","type":"GO_TERM","name":"regulation of blood vessel endothelial cell migration","canonical_id":"go:GO:0043535","description":"\"Any process that modulates the frequency, rate or extent of the migration of the endothelial cells of blood vessels.\" [GOC:curators]","metadata":null},{"id":"513c519009f44bb9a00d688da3db9a51","type":"GO_TERM","name":"regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis","canonical_id":"go:GO:1903587","description":"\"Any process that modulates the frequency, rate or extent of blood vessel endothelial cell proliferation involved in sprouting angiogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:23388056]","metadata":null},{"id":"2f79518d42174071a9a8bd7f5db3532d","type":"GO_TERM","name":"regulation of blood vessel remodeling","canonical_id":"go:GO:0060312","description":"\"Any process that modulates the rate, frequency or extent of blood vessel remodeling, the reorganization or renovation of existing blood vessels.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"7a47050dae0a4c429f43bf69eb2883ed","type":"GO_TERM","name":"regulation of blood volume by renal aldosterone","canonical_id":"go:GO:0002017","description":"\"The process in which the hormone aldosterone decreases the rate of diuresis and natriuresis resulting in increased blood volume.\" [GOC:dph, GOC:tb, ISBN:0721643949]","metadata":null},{"id":"4d438f2601614b09b5f4992230dd8481","type":"GO_TERM","name":"regulation of blood volume by renin-angiotensin","canonical_id":"go:GO:0002016","description":"\"The process in which the renin-angiotensin system controls the rate of fluid intake and output into the blood.\" [GOC:dph, GOC:mtg_cardio, GOC:tb, ISBN:0721643949]","metadata":null},{"id":"59febe2ef6c34394878066feee36a776","type":"GO_TERM","name":"regulation of blood-brain barrier permeability","canonical_id":"go:GO:1905603","description":"\"Any process that modulates blood-brain barrier permeability, the quality of the blood-brain barrier that allows for a controlled passage of substances (e.g. macromolecules, small molecules, ions) into and out of the brain.\" [GO_REF:0000058, GOC:als, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:22524708, PMID:30280653]","metadata":null},{"id":"bc9fe399c1244ac599d8fc06a334801a","type":"GO_TERM","name":"regulation of body fluid levels","canonical_id":"go:GO:0050878","description":"\"Any process that modulates the levels of body fluids.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"3953fe90f86347c8be5575fedc0db108","type":"GO_TERM","name":"regulation of bone development","canonical_id":"go:GO:1903010","description":"\"Any process that modulates the frequency, rate or extent of bone development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:22510437]","metadata":null},{"id":"3788877995364c6fb367c263bf2388d8","type":"GO_TERM","name":"regulation of bone mineralization","canonical_id":"go:GO:0030500","description":"\"Any process that modulates the frequency, rate or extent of bone mineralization.\" [GOC:curators]","metadata":null},{"id":"ab29bf9c1f344722999a9a4c854ea42a","type":"GO_TERM","name":"regulation of bone remodeling","canonical_id":"go:GO:0046850","description":"\"Any process that modulates the frequency, rate or extent of bone remodeling, the processes of bone formation and resorption that combine to maintain skeletal integrity.\" [GOC:ai]","metadata":null},{"id":"b72e16b1e3cf4393ba14d7d205a5c1fc","type":"GO_TERM","name":"regulation of bone resorption","canonical_id":"go:GO:0045124","description":"\"Any process that modulates the frequency, rate or extent of bone tissue loss (resorption).\" [GOC:ai]","metadata":null},{"id":"0ffd52382761453293c4e0029da43fe8","type":"GO_TERM","name":"regulation of bone trabecula formation","canonical_id":"go:GO:1900154","description":"\"Any process that modulates the frequency, rate or extent of bone trabecula formation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"73a66906c5ec46c890a0a275431a37a0","type":"GO_TERM","name":"regulation of border follicle cell delamination","canonical_id":"go:GO:0030710","description":"\"Any process that regulates the frequency, rate or extent of border cell delamination.\" [PMID:10822261]","metadata":null},{"id":"adc9700c0d874af0a66736d5a16142b0","type":"GO_TERM","name":"regulation of border follicle cell migration","canonical_id":"go:GO:1903684","description":"\"Any process that modulates the frequency, rate or extent of border follicle cell migration.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18394891]","metadata":null},{"id":"c29439470fd0456389f3cc31b4d41914","type":"GO_TERM","name":"regulation of brain-derived neurotrophic factor receptor signaling pathway","canonical_id":"go:GO:0031548","description":"\"Any process that modulates the frequency, rate or extent of signaling via the brain-derived neurotrophic factor receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"acca7ad0d09144b0840aa27cc01cb91f","type":"GO_TERM","name":"regulation of branch elongation involved in ureteric bud branching","canonical_id":"go:GO:0072095","description":"\"Any process that modulates the frequency, rate or extent of branch elongation involved in ureteric bud branching, the growth of a branch of the ureteric bud along its axis.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a279310159bd4848b42b222be9289efa","type":"GO_TERM","name":"regulation of branching involved in lung morphogenesis","canonical_id":"go:GO:0061046","description":"\"Any process that modulates the rate, frequency, or extent of the process in which a highly ordered sequence of patterning events generates the branched structures of the lung, consisting of reiterated combinations of bud outgrowth, elongation, and dichotomous subdivision of terminal units.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"4c4d772467554f4bb3d1e173338f2446","type":"GO_TERM","name":"regulation of branching involved in mammary gland duct morphogenesis","canonical_id":"go:GO:0060762","description":"\"Any process that modulates the rate, frequency, or extent of branching involved in mammary gland duct morphogenesis.\" [GOC:dph]","metadata":null},{"id":"b03499758817499297c061fd7d1c2079","type":"GO_TERM","name":"regulation of branching involved in prostate gland morphogenesis","canonical_id":"go:GO:0060687","description":"\"Any process that modulates the rate, frequency, or extent of prostate gland branching, the process in which the branching structure of the prostate gland is generated and organized. A branch is a division or offshoot from a main stem.\" [GOC:dph]","metadata":null},{"id":"980073bd69fc4c1abb7e9466d18e71cd","type":"GO_TERM","name":"regulation of branching involved in salivary gland morphogenesis","canonical_id":"go:GO:0060693","description":"\"Any process that modulates the rate, frequency, or extent of branching morphogenesis in the salivary gland epithelium.\" [GOC:dph]","metadata":null},{"id":"98986eab57d04545aa331d3cd9ed93c6","type":"GO_TERM","name":"regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling","canonical_id":"go:GO:0060683","description":"\"Any process that modulates the rate, frequency, or extent of salivary gland branching as a result of the transfer of information from the epithelial cells to the mesenchymal cells of the salivary gland.\" [GOC:dph, PMID:18559345]","metadata":null},{"id":"cdd457975c4d4245a9f1873a70a76c0a","type":"GO_TERM","name":"regulation of branching involved in salivary gland morphogenesis by extracellular matrix-epithelial cell signaling","canonical_id":"go:GO:0060668","description":"\"Any process that modulates the rate, frequency, or extent of salivary gland branching as a result of the transfer of information from the extracellular matrix to the epithelium of the salivary gland.\" [GOC:dph]","metadata":null},{"id":"db3dd05f4f694fb4b58cba5912009fea","type":"GO_TERM","name":"regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling","canonical_id":"go:GO:0060665","description":"\"Any process that modulates the rate, frequency, or extent of branching involved in salivary gland morphogenesis as a result of signals being generated by the mesenchyme and received and interpreted by the salivary gland epithelium.\" [GOC:dph, PMID:17336109]","metadata":null},{"id":"493122e39577422eb768cfd260b05ec5","type":"GO_TERM","name":"regulation of branching involved in ureteric bud morphogenesis","canonical_id":"go:GO:0090189","description":"\"Any process that modulates the rate, frequency or extent of branching involved in ureteric bud morphogenesis, the process in which the branching structure of the ureteric bud is generated and organized. The ureteric bud is an epithelial tube that grows out from the metanephric duct. The bud elongates and branches to give rise to the ureter and kidney collecting tubules.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"dfdc4bc8591d4c15927f69d1a5dfc6bc","type":"GO_TERM","name":"regulation of branching morphogenesis of a nerve","canonical_id":"go:GO:2000172","description":"\"Any process that modulates the frequency, rate or extent of branching morphogenesis of a nerve.\" [GOC:BHF]","metadata":null},{"id":"291d979a446f4b4b91a8ad517df29e67","type":"GO_TERM","name":"regulation of branchiomeric skeletal muscle development","canonical_id":"go:GO:0014711","description":"\"Any process that modulates the frequency, rate or extent of branchiomeric skeletal muscle development. Branchiomeric skeletal muscle development is the process whose specific outcome is the progression of the branchiomeric skeletal muscle over time, from its formation to the mature structure.\" [GOC:mtg_muscle]","metadata":null},{"id":"4890239b1a814276ac8274559952405f","type":"GO_TERM","name":"regulation of brassinosteroid biosynthetic process","canonical_id":"go:GO:0010422","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of brassinosteroids.\" [PMID:16857903]","metadata":null},{"id":"3a54f3533eb448268e5051c5f762db92","type":"GO_TERM","name":"regulation of brassinosteroid mediated signaling pathway","canonical_id":"go:GO:1900457","description":"\"Any process that modulates the frequency, rate or extent of brassinosteroid mediated signaling pathway.\" [GOC:TermGenie, PMID:21855796]","metadata":null},{"id":"7338cd5a879c48b0a7a1eb12115956d1","type":"GO_TERM","name":"regulation of brood size","canonical_id":"go:GO:0060378","description":"\"Any process that modulates brood size. Brood size is the number of progeny that survive embryogenesis and are cared for at one time.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b04b6d60619f402a9a6804cc418ee0b3","type":"GO_TERM","name":"regulation of brown fat cell differentiation","canonical_id":"go:GO:0090335","description":"\"Any process that modulates the rate, frequency, or extent of brown fat cell differentiation. Brown fat cell differentiation is the process in which a relatively unspecialized cell acquires specialized features of a brown adipocyte, an animal connective tissue cell involved in adaptive thermogenesis. Brown adipocytes contain multiple small droplets of triglycerides and a high number of mitochondria.\" [GOC:tb]","metadata":null},{"id":"ec0bdd1405b64f9f9e2995cf6b139b58","type":"GO_TERM","name":"regulation of brown fat cell proliferation","canonical_id":"go:GO:0070347","description":"\"Any process that modulates the frequency, rate or extent of brown fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"f2875707bddf4116a1e13a374159b0fa","type":"GO_TERM","name":"regulation of budding cell apical bud growth","canonical_id":"go:GO:0010568","description":"\"Any process that modulates the frequency, rate or extent of growth at the tip of a bud, in a cell that reproduces by budding.\" [GOC:dph, GOC:jp, GOC:tb, PMID:17417630]","metadata":null},{"id":"98718e1c37fd48b99f0b64f62041451c","type":"GO_TERM","name":"regulation of bundle of His cell action potential","canonical_id":"go:GO:0098905","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a cardiac muscle cell of the bundle of His. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"2ffd85f2a1c64b8ab24f3ef43be5cd7a","type":"GO_TERM","name":"regulation of buoyancy","canonical_id":"go:GO:0031413","description":"\"Any process that modulates an organism's tendency or ability to rise or float in a fluid medium such as water or air, often through the use of stored gases.\" [GOC:mah, PATO:0001420]","metadata":null},{"id":"176ba2b165d24cb9a273ae8427d895c8","type":"GO_TERM","name":"regulation of c-di-GMP signaling","canonical_id":"go:GO:0061940","description":"\"Any process that modulates the rate frequency or extent of c-di-GMP signaling.\" [PMID:22864416]","metadata":null},{"id":"cf6f12f61dbe4068921ac669e8c8a97e","type":"GO_TERM","name":"regulation of cAMP-dependent protein kinase activity","canonical_id":"go:GO:2000479","description":"\"Any process that modulates the frequency, rate or extent of cAMP-dependent protein kinase activity.\" [GOC:obol]","metadata":null},{"id":"1eefac280bc64e5fb64b508afc370ab0","type":"GO_TERM","name":"regulation of cAMP/PKA signal transduction","canonical_id":"go:GO:0141161","description":"\"Any process that modulates the frequency, rate or extent of cAMP/PKA signal transduction.\" [GOC:curators]","metadata":null},{"id":"84e5d972e8b84963bb06d22eed1f4380","type":"GO_TERM","name":"regulation of calcineurin-NFAT signaling cascade","canonical_id":"go:GO:0070884","description":"\"Any process that modulates the frequency, rate or extent of the calcineurin-NFAT signaling cascade.\" [GOC:ai]","metadata":null},{"id":"f25652c1884b4e228adc9117099186ca","type":"GO_TERM","name":"regulation of calcineurin-mediated signaling","canonical_id":"go:GO:0106056","description":"\"Any process that modulates the frequency, rate or extent of calcineurin-mediated signaling.\" [PMID:25081204]","metadata":null},{"id":"4a0b5b97fdf949459bdf986e342294ea","type":"GO_TERM","name":"regulation of calcitonin secretion","canonical_id":"go:GO:1904362","description":"\"Any process that modulates the frequency, rate or extent of calcitonin secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11278900]","metadata":null},{"id":"957732d3880c4135a85da259e33662ba","type":"GO_TERM","name":"regulation of calcium import into the mitochondrion","canonical_id":"go:GO:0110097","description":"\"Any process that modulates the frequency, rate or extent of calcium import into the mitochondrion.\" [GOC:sl, PMID:24085037]","metadata":null},{"id":"dc4c9b3c44314c3784f3ad93615368a3","type":"GO_TERM","name":"regulation of calcium ion binding","canonical_id":"go:GO:1901876","description":"\"Any process that modulates the frequency, rate or extent of calcium ion binding.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16432188]","metadata":null},{"id":"58fe75d546ed4b33abb6e12624238d79","type":"GO_TERM","name":"regulation of calcium ion export across plasma membrane","canonical_id":"go:GO:1905912","description":"\"Any process that modulates the frequency, rate or extent of calcium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22362515]","metadata":null},{"id":"5188bfe0e9f84dc3b4c57d9394cfc477","type":"GO_TERM","name":"regulation of calcium ion import","canonical_id":"go:GO:0090279","description":"\"Any process that modulates the rate, frequency, or extent of the directed movement of calcium ions into a cell or organelle.\" [GOC:BHF]","metadata":null},{"id":"8a0086cae8cb4483809e4a9f0a1170b8","type":"GO_TERM","name":"regulation of calcium ion import across plasma membrane","canonical_id":"go:GO:1905664","description":"\"Any process that modulates the frequency, rate or extent of calcium ion import across plasma membrane.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:17640527]","metadata":null},{"id":"4424e658b63d47f280634720a9e376a2","type":"GO_TERM","name":"regulation of calcium ion import into sarcoplasmic reticulum","canonical_id":"go:GO:1902080","description":"\"Any process that modulates the frequency, rate or extent of calcium ion import into sarcoplasmic reticulum.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:8349590]","metadata":null},{"id":"28a69f46e92d4608a51f9243c4172974","type":"GO_TERM","name":"regulation of calcium ion transmembrane transport","canonical_id":"go:GO:1903169","description":"\"Any process that modulates the frequency, rate or extent of calcium ion transmembrane transport.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24125847]","metadata":null},{"id":"c79fbb50aa1f49c38606bc77335e5ee5","type":"GO_TERM","name":"regulation of calcium ion transmembrane transport via high voltage-gated calcium channel","canonical_id":"go:GO:1902514","description":"\"Any process that modulates the frequency, rate or extent of generation of calcium ion transmembrane transport via high voltage-gated calcium channel.\" [GOC:dph, GOC:pg, GOC:TermGenie, PMID:1611048]","metadata":null},{"id":"5e5818a91202480d873230ddefdcf952","type":"GO_TERM","name":"regulation of calcium ion transport","canonical_id":"go:GO:0051924","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"9a2d58e2443949e2bb42517b69f4ed54","type":"GO_TERM","name":"regulation of calcium ion transport into cytosol","canonical_id":"go:GO:0010522","description":"\"Any process that modulates the rate of the directed movement of calcium ions into the cytosol of a cell. The cytosol is that part of the cytoplasm that does not contain membranous or particulate subcellular components.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"dc06e6570b7f4b698ff0f9083fbb1443","type":"GO_TERM","name":"regulation of calcium ion-dependent exocytosis","canonical_id":"go:GO:0017158","description":"\"Any process that modulates the frequency, rate or extent of calcium ion-dependent exocytosis.\" [GOC:curators]","metadata":null},{"id":"ba036b922034423ba9cf0b3d153312be","type":"GO_TERM","name":"regulation of calcium ion-dependent exocytosis of neurotransmitter","canonical_id":"go:GO:1903233","description":"\"Any process that modulates the frequency, rate or extent of calcium ion-dependent exocytosis of neurotransmitter.\" [GO_REF:0000058, GOC:TermGenie, PMID:16782817]","metadata":null},{"id":"e4efbeca37ae41bf8c6425a96a215762","type":"GO_TERM","name":"regulation of calcium-dependent activation of synaptic vesicle fusion","canonical_id":"go:GO:0150037","description":"\"Any process that modulates the frequency, rate or extent of calcium-dependent activation of synaptic vesicle fusion.\" [GOC:aruk, GOC:bc, PMID:27052163]","metadata":null},{"id":"18d9e6ae888344a792077f9c6bf4953b","type":"GO_TERM","name":"regulation of calcium-dependent cell-cell adhesion","canonical_id":"go:GO:0046586","description":"\"Any process that modulates the frequency, rate or extent of the attachment of one cell to another cell via adhesion molecules that require the presence of calcium for the interaction.\" [GOC:ai]","metadata":null},{"id":"14dba17e856d4765b15caaefb790a8c5","type":"GO_TERM","name":"regulation of calcium-independent cell-cell adhesion","canonical_id":"go:GO:0051040","description":"\"Any process that modulates the frequency, rate or extent of the attachment of one cell to another cell via adhesion molecules that do not require the presence of calcium for the interaction.\" [GOC:ai]","metadata":null},{"id":"2f9bf18c0d5a4c6198fe0706e19e9231","type":"GO_TERM","name":"regulation of calcium-mediated signaling","canonical_id":"go:GO:0050848","description":"\"Any process that modulates the frequency, rate or extent of calcium-mediated signaling, the process in which a cell uses calcium ions to convert an extracellular signal into a response.\" [GOC:ai]","metadata":null},{"id":"dc5f77b366694f2abf150745005e8e41","type":"GO_TERM","name":"regulation of canonical NF-kappaB signal transduction","canonical_id":"go:GO:0043122","description":"\"Any process that modulates the canonical NF-kappaB signaling cascade.\" [GOC:jl, PMID:12773372]","metadata":null},{"id":"d4eb9ada0cf1417294c4934b5178ef86","type":"GO_TERM","name":"regulation of canonical Wnt signaling pathway","canonical_id":"go:GO:0060828","description":"\"Any process that modulates the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"b3b251909faf490da87cd1840dda6f0e","type":"GO_TERM","name":"regulation of cap-dependent translational initiation","canonical_id":"go:GO:1903674","description":"\"Any process that modulates the frequency, rate or extent of cap-dependent translational initiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"3c518c13fcde4a88b1e0b0bd9eaeef40","type":"GO_TERM","name":"regulation of cap-independent translational initiation","canonical_id":"go:GO:1903677","description":"\"Any process that modulates the frequency, rate or extent of cap-independent translational initiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"a9c3b54f787f450c844b908d76267216","type":"GO_TERM","name":"regulation of capsule organization","canonical_id":"go:GO:1901913","description":"\"Any process that modulates the frequency, rate or extent of capsule organization.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"72758bdafca4407389117c9f2904826b","type":"GO_TERM","name":"regulation of capsule polysaccharide biosynthetic process","canonical_id":"go:GO:0062084","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of polysaccharides that make up the capsule, a protective structure surrounding some species of bacteria and fungi.\" [PMID:21917918]","metadata":null},{"id":"5a2acf49363a4ea3a6f1aa5c7d570c33","type":"GO_TERM","name":"regulation of carbohydrate biosynthetic process","canonical_id":"go:GO:0043255","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of carbohydrates.\" [GOC:jl]","metadata":null},{"id":"a0eddae99dda4b91b654b273b4b39d2f","type":"GO_TERM","name":"regulation of carbohydrate catabolic process","canonical_id":"go:GO:0043470","description":"\"Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of carbohydrates.\" [GOC:mlg]","metadata":null},{"id":"f85dd4f8334042b897379c76b309748f","type":"GO_TERM","name":"regulation of carbohydrate metabolic process","canonical_id":"go:GO:0006109","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates.\" [GOC:curators]","metadata":null},{"id":"59d81f0819c54858ab2fe8bf167c5a7a","type":"GO_TERM","name":"regulation of carbohydrate utilization","canonical_id":"go:GO:0043610","description":"\"Any process that modulates the frequency, rate or extent of carbohydrate utilization.\" [GOC:jl]","metadata":null},{"id":"3fb8764d6fc64b77adc056f411fd675f","type":"GO_TERM","name":"regulation of carbon utilization","canonical_id":"go:GO:0043609","description":"\"Any process that modulates the frequency, rate, or extent of carbon utilization.\" [GOC:jl]","metadata":null},{"id":"a50e1aa7f4494d60b73fa8ba9c5bbc1e","type":"GO_TERM","name":"regulation of cardiac cell fate specification","canonical_id":"go:GO:2000043","description":"\"Any process that modulates the frequency, rate or extent of cardiac cell fate specification.\" [GOC:BHF]","metadata":null},{"id":"fc92ca9f8a99436187db6f4ae5cb131e","type":"GO_TERM","name":"regulation of cardiac chamber formation","canonical_id":"go:GO:1901210","description":"\"Any process that modulates the frequency, rate or extent of cardiac chamber formation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"5bc7473fbabc4556995b998353947261","type":"GO_TERM","name":"regulation of cardiac chamber morphogenesis","canonical_id":"go:GO:1901219","description":"\"Any process that modulates the frequency, rate or extent of cardiac chamber morphogenesis.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"cd506fb1fdb34421818cfad13174d10d","type":"GO_TERM","name":"regulation of cardiac conduction","canonical_id":"go:GO:1903779","description":"\"Any process that modulates the frequency, rate or extent of cardiac conduction.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:12967627]","metadata":null},{"id":"96519a2c9470478caa60fe7dca3c3c58","type":"GO_TERM","name":"regulation of cardiac endothelial to mesenchymal transition","canonical_id":"go:GO:0061999","description":"\"Any process that modulates the frequency, rate or extent of cardiac endothelial to mesenchymal transition.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26857067]","metadata":null},{"id":"a6a4380e2cad48fcb224d076c19f0b27","type":"GO_TERM","name":"regulation of cardiac epithelial to mesenchymal transition","canonical_id":"go:GO:0062042","description":"\"Any process that modulates the rate, frequency or extent of cardiac epithelial to mesenchymal transition, a transition where a cardiac epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BHF, GOC:rph, PMID:20951801]","metadata":null},{"id":"5063b0cb2b0b405fa94efc045c113d9d","type":"GO_TERM","name":"regulation of cardiac muscle adaptation","canonical_id":"go:GO:0010612","description":"\"Any process that modulates the rate, extent or frequency of the process in which cardiac muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"908b4f74c6894467912ae5fc0ea8565d","type":"GO_TERM","name":"regulation of cardiac muscle cell action potential","canonical_id":"go:GO:0098901","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a cardiac muscle cell. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:dos, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"219945efef6949c3bc276d2f1d5a8879","type":"GO_TERM","name":"regulation of cardiac muscle cell action potential involved in regulation of contraction","canonical_id":"go:GO:0098909","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a cardiac muscle cell contributing to the regulation of its contraction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"eff5895857ec4d17acc02c52d5bcbdd8","type":"GO_TERM","name":"regulation of cardiac muscle cell apoptotic process","canonical_id":"go:GO:0010665","description":"\"Any process that modulates the rate or extent of cardiac cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a cardiac muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"be3c6762f73d4c5199198962621d4b39","type":"GO_TERM","name":"regulation of cardiac muscle cell contraction","canonical_id":"go:GO:0086004","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle cell contraction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"31ec046d8fb44a62bd2207d845c409b6","type":"GO_TERM","name":"regulation of cardiac muscle cell differentiation","canonical_id":"go:GO:2000725","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"a18068b5ca874ce0acb3c6c6a6ba0602","type":"GO_TERM","name":"regulation of cardiac muscle cell membrane potential","canonical_id":"go:GO:0086036","description":"\"Any process that modulates the establishment or extent of a membrane potential in a cardiac muscle cell (a cardiomyocyte). A membrane potential is the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f85595418cd7472c973b349ad6eacf8e","type":"GO_TERM","name":"regulation of cardiac muscle cell membrane repolarization","canonical_id":"go:GO:0099623","description":"\"Any process that modulates the establishment or extent of a change in membrane potential in the polarizing direction towards the resting potential in a cardiomyocyte.\" [GOC:BHF, GOC:dos, GOC:rl]","metadata":null},{"id":"eeefd688b61f4b41af4bf6e1d4ca5e4d","type":"GO_TERM","name":"regulation of cardiac muscle cell myoblast differentiation","canonical_id":"go:GO:2000690","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle cell myoblast differentiation.\" [GOC:obol]","metadata":null},{"id":"3026fe4d7aaf405387740a1819b689ae","type":"GO_TERM","name":"regulation of cardiac muscle cell proliferation","canonical_id":"go:GO:0060043","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle cell proliferation.\" [GOC:dph, GOC:rph]","metadata":null},{"id":"a48f7bbbf4d442558f97ed00fdc897f7","type":"GO_TERM","name":"regulation of cardiac muscle contraction","canonical_id":"go:GO:0055117","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle contraction.\" [GOC:ecd]","metadata":null},{"id":"15e584c8fd20434791307761fe9c37cf","type":"GO_TERM","name":"regulation of cardiac muscle contraction by calcium ion signaling","canonical_id":"go:GO:0010882","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle contraction by changing the calcium ion signals that trigger contraction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"79e78a465ab343e1bcbf7bd6d81b86df","type":"GO_TERM","name":"regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion","canonical_id":"go:GO:0010881","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle contraction via the regulation of the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol. The sarcoplasmic reticulum is the endoplasmic reticulum of striated muscle, specialised for the sequestration of calcium ions that are released upon receipt of a signal relayed by the T tubules from the neuromuscular junction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d2bd6aaba8904b2c82cd195317523e2f","type":"GO_TERM","name":"regulation of cardiac muscle fiber development","canonical_id":"go:GO:0055018","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle fiber development.\" [GOC:vk]","metadata":null},{"id":"5d90a40b34e6460d9ad97675817b5a5c","type":"GO_TERM","name":"regulation of cardiac muscle hypertrophy","canonical_id":"go:GO:0010611","description":"\"Any process that modulates the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"dfabb766dddc4da49756d0b0783e2783","type":"GO_TERM","name":"regulation of cardiac muscle hypertrophy in response to stress","canonical_id":"go:GO:1903242","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle hypertrophy in response to stress.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19287093]","metadata":null},{"id":"b93d2e35b38e48058b3a6b7edc7e139f","type":"GO_TERM","name":"regulation of cardiac muscle myoblast proliferation","canonical_id":"go:GO:0110022","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle myoblast proliferation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26512644]","metadata":null},{"id":"38ff9c1c16f84b4c8dddc31ab07438dd","type":"GO_TERM","name":"regulation of cardiac muscle tissue development","canonical_id":"go:GO:0055024","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle tissue development.\" [GOC:vk]","metadata":null},{"id":"946aaef41633403693eb04f335753de9","type":"GO_TERM","name":"regulation of cardiac muscle tissue growth","canonical_id":"go:GO:0055021","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle growth.\" [GOC:vk]","metadata":null},{"id":"9c42d15bda83498d84d41064f818299a","type":"GO_TERM","name":"regulation of cardiac muscle tissue regeneration","canonical_id":"go:GO:1905178","description":"\"Any process that modulates the frequency, rate or extent of cardiac muscle tissue regeneration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23222520]","metadata":null},{"id":"e07f389601b0456b9505100cd59cea99","type":"GO_TERM","name":"regulation of cardiac myofibril assembly","canonical_id":"go:GO:1905304","description":"\"Any process that modulates the frequency, rate or extent of cardiac myofibril assembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16151019]","metadata":null},{"id":"a1e2457bd2e8492c81e978ae03452e4f","type":"GO_TERM","name":"regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis","canonical_id":"go:GO:1905310","description":"\"Any process that modulates the frequency, rate or extent of cardiac neural crest cell migration involved in outflow tract morphogenesis.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17628518]","metadata":null},{"id":"fdc6f14ef44c48ec8be6309b871d5f22","type":"GO_TERM","name":"regulation of cardiac vascular smooth muscle cell differentiation","canonical_id":"go:GO:2000722","description":"\"Any process that modulates the frequency, rate or extent of cardiac vascular smooth muscle cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"f729cea446a5490fb4440a02eecab11e","type":"GO_TERM","name":"regulation of cardiac ventricle development","canonical_id":"go:GO:1904412","description":"\"Any process that modulates the frequency, rate or extent of cardiac ventricle development.\" [GO_REF:0000058, GOC:TermGenie, PMID:19590510]","metadata":null},{"id":"9bac2d5e3b2541028a419bd57e7d8b74","type":"GO_TERM","name":"regulation of cardiac ventricle formation","canonical_id":"go:GO:1904942","description":"\"Any process that modulates the frequency, rate or extent of cardiac ventricle formation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23575307]","metadata":null},{"id":"ab1f7e096f6a43a4a802445b3ab2eac8","type":"GO_TERM","name":"regulation of cardioblast cell fate specification","canonical_id":"go:GO:0042686","description":"\"Any process that mediates the specification of a cell into a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:curators]","metadata":null},{"id":"f2f98262c324410cb880c16140942b7c","type":"GO_TERM","name":"regulation of cardioblast differentiation","canonical_id":"go:GO:0051890","description":"\"Any process that modulates the frequency, rate or extent of cardioblast differentiation, the process in which a relatively unspecialized mesodermal cell acquires the specialized structural and/or functional features of a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:ai]","metadata":null},{"id":"959f8d3b79064893bff2de3464b189ff","type":"GO_TERM","name":"regulation of cardioblast proliferation","canonical_id":"go:GO:0003264","description":"\"Any process that modulates the frequency, rate or extent of cardioblast proliferation. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"d9973eb8ecf14482939d524152008d75","type":"GO_TERM","name":"regulation of cardiocyte differentiation","canonical_id":"go:GO:1905207","description":"\"Any process that modulates the frequency, rate or extent of cardiocyte differentiation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23069713]","metadata":null},{"id":"d6efadc676d143aeb61a578d5e51e1c0","type":"GO_TERM","name":"regulation of cardiolipin metabolic process","canonical_id":"go:GO:1900208","description":"\"Any process that modulates the frequency, rate or extent of cardiolipin metabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"7c87bb9c11fa4342ab60050a43fc03a3","type":"GO_TERM","name":"regulation of cargo loading into COPII-coated vesicle","canonical_id":"go:GO:1901301","description":"\"Any process that modulates the frequency, rate or extent of cargo loading into COPII-coated vesicle.\" [GOC:lb, GOC:TermGenie, PMID:15899885]","metadata":null},{"id":"d1a23d22aeeb4b9da23c8ca138a1aa57","type":"GO_TERM","name":"regulation of cartilage condensation","canonical_id":"go:GO:1902026","description":"\"Any process that modulates the frequency, rate or extent of cartilage condensation.\" [GOC:TermGenie, PMID:17202865]","metadata":null},{"id":"bb768b67aee3415aa9496f5b31480d17","type":"GO_TERM","name":"regulation of cartilage development","canonical_id":"go:GO:0061035","description":"\"Any process that modulates the rate, frequency, or extent of cartilage development, the process whose specific outcome is the progression of the cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.\" [GOC:dph]","metadata":null},{"id":"78fedc2f11b3447b877fd3d0116afd6d","type":"GO_TERM","name":"regulation of catabolic process","canonical_id":"go:GO:0009894","description":"\"Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of substances.\" [GOC:curators]","metadata":null},{"id":"d63fb1914ab54fec964e3fd86aca84fb","type":"GO_TERM","name":"regulation of catalytic activity","canonical_id":"go:GO:0050790","description":"\"Any process that modulates the activity of an enzyme.\" [GOC:ai, GOC:ebc, GOC:vw]","metadata":null},{"id":"dc61150d56d74e3e9adad6d9ea77b1a6","type":"GO_TERM","name":"regulation of catecholamine metabolic process","canonical_id":"go:GO:0042069","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving catecholamines.\" [GOC:curators]","metadata":null},{"id":"32cccbaceba54601ab0f506cfc5dda81","type":"GO_TERM","name":"regulation of catecholamine secretion","canonical_id":"go:GO:0050433","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of catecholamines.\" [GOC:ai]","metadata":null},{"id":"d2d52ed9a72b4a1da5969b967f4217c9","type":"GO_TERM","name":"regulation of caveolin-mediated endocytosis","canonical_id":"go:GO:2001286","description":"\"Any process that modulates the frequency, rate or extent of caveolin-mediated endocytosis.\" [GOC:obol]","metadata":null},{"id":"7307bbb6059e4635be23d2c77d30da4a","type":"GO_TERM","name":"regulation of cell activation","canonical_id":"go:GO:0050865","description":"\"Any process that modulates the frequency, rate or extent of cell activation, the change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand.\" [GOC:ai]","metadata":null},{"id":"be9d09252b974cb5bc32fb3f7440aca0","type":"GO_TERM","name":"regulation of cell adhesion","canonical_id":"go:GO:0030155","description":"\"Any process that modulates the frequency, rate or extent of attachment of a cell to another cell or to the extracellular matrix.\" [GOC:mah]","metadata":null},{"id":"835fd1e1c14c4ac095cf4ccc3686e425","type":"GO_TERM","name":"regulation of cell adhesion involved in heart morphogenesis","canonical_id":"go:GO:0061344","description":"\"Any process that modulates the extent of cell adhesion contributing to the shaping of the heart.\" [GOC:dph, GOC:mtg_heart, PMID:16860783]","metadata":null},{"id":"abfd6cece38a4915b4f7a7ff53318884","type":"GO_TERM","name":"regulation of cell adhesion mediated by integrin","canonical_id":"go:GO:0033628","description":"\"Any process that modulates the frequency, rate, or extent of cell adhesion mediated by integrin.\" [GOC:add]","metadata":null},{"id":"532021ae75e14c84bf984883c8a430d2","type":"GO_TERM","name":"regulation of cell adhesion molecule production","canonical_id":"go:GO:0060353","description":"\"Any process that modulates the rate, frequency or extent of cell adhesion molecule production. Cell adhesion molecule production is the appearance of a cell adhesion molecule as a result of its biosynthesis or a decrease in its catabolism.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"4f6a46925e694372b6bf0c40440518ab","type":"GO_TERM","name":"regulation of cell budding","canonical_id":"go:GO:0007116","description":"\"Any process that modulates the frequency, rate or extent of the formation and growth of cell buds.\" [GOC:mah]","metadata":null},{"id":"b7eb88748f014064829a68bcca97517a","type":"GO_TERM","name":"regulation of cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:1904847","description":"\"Any process that modulates the frequency, rate or extent of cell chemotaxis to fibroblast growth factor.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23233752]","metadata":null},{"id":"e84d90ea87684912800a77708057d5a7","type":"GO_TERM","name":"regulation of cell communication","canonical_id":"go:GO:0010646","description":"\"Any process that modulates the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"69ecbd6e514c425d811061849646148d","type":"GO_TERM","name":"regulation of cell communication by chemical coupling","canonical_id":"go:GO:0010645","description":"\"Any process that modulates the frequency, rate or extent of cell communication via chemical coupling. Cell communication by chemical coupling is the process that mediates signaling interactions between one cell and another cell by the transfer of small, water-soluble molecules or metabolites between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"6e0561a57387406981bfca834a93e092","type":"GO_TERM","name":"regulation of cell communication by electrical coupling","canonical_id":"go:GO:0010649","description":"\"Any process that modulates the frequency, rate or extent of cell communication via electrical coupling. Cell communication via electrical coupling is the process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"e8324badd42a4f7cb0f4ae1189525ba9","type":"GO_TERM","name":"regulation of cell communication by electrical coupling involved in cardiac conduction","canonical_id":"go:GO:1901844","description":"\"Any process that modulates the frequency, rate or extent of cell communication by electrical coupling involved in cardiac conduction.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17130302]","metadata":null},{"id":"9bfc6ab487004d7cb3ae2dd7ce506bbe","type":"GO_TERM","name":"regulation of cell cycle","canonical_id":"go:GO:0051726","description":"\"Any process that modulates the rate or extent of progression through the cell cycle.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"e77314a7bb304e188aacb1bbe0d4450a","type":"GO_TERM","name":"regulation of cell cycle G1/S phase transition","canonical_id":"go:GO:1902806","description":"\"Any signaling pathway that modulates the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the cell cycle.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"3b4837476a964f309cab7bc6f921803f","type":"GO_TERM","name":"regulation of cell cycle G2/M phase transition","canonical_id":"go:GO:1902749","description":"\"Any signaling pathway that modulates the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the cell cycle.\" [GO_REF:0000058, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"c1740bc65f10415294454afee4a57766","type":"GO_TERM","name":"regulation of cell cycle checkpoint","canonical_id":"go:GO:1901976","description":"\"Any process that modulates the frequency, rate or extent of cell cycle checkpoint.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:23028116]","metadata":null},{"id":"552972b744cc42e6ba73e1bbeff6f0e3","type":"GO_TERM","name":"regulation of cell cycle phase transition","canonical_id":"go:GO:1901987","description":"\"Any process that modulates the frequency, rate or extent of cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"e8291768451f4f02a0b60f457d766984","type":"GO_TERM","name":"regulation of cell cycle process","canonical_id":"go:GO:0010564","description":"\"Any process that modulates a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7b6e5c1cd0774553beb73d816b381153","type":"GO_TERM","name":"regulation of cell cycle switching, mitotic to meiotic cell cycle","canonical_id":"go:GO:0110044","description":"\"Any process that modulates the frequency, rate, or extent of mitotic to meiotic cell cycle switching, the process in which a cell switches cell cycle mode from mitotic to meiotic division.\" [GOC:al, PMID:17674143]","metadata":null},{"id":"05779dc16f8a4a3ca37cb3a4c9959e11","type":"GO_TERM","name":"regulation of cell development","canonical_id":"go:GO:0060284","description":"\"Any process that modulates the rate, frequency or extent of the progression of the cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b0b7350890134c2f94c6bdf71a055965","type":"GO_TERM","name":"regulation of cell diameter","canonical_id":"go:GO:0060305","description":"\"Any process that modulates the diameter of a cell, the length of a line segment that crosses through the center of a circular section through a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"271ac87163604687b24e9ef03dac9198","type":"GO_TERM","name":"regulation of cell differentiation","canonical_id":"go:GO:0045595","description":"\"Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features.\" [GOC:curators]","metadata":null},{"id":"d2dc89b0b64e40aebd74da2de6140f70","type":"GO_TERM","name":"regulation of cell differentiation involved in embryonic placenta development","canonical_id":"go:GO:0060800","description":"\"Any process that modulates the rate, frequency or extent of cell differentiation that contributes to the progression of the placenta over time, from its initial condition to its mature state.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3ba42725f96a437aad406d736f30f9ae","type":"GO_TERM","name":"regulation of cell differentiation involved in tissue homeostasis","canonical_id":"go:GO:0060786","description":"\"Any process that modulates the frequency, rate or extent of cell differentiation that contributes to the maintenance of a steady state of a cell type within a tissue.\" [GOC:dph]","metadata":null},{"id":"c4ac369faf6947e0bdd28071fb4d0e85","type":"GO_TERM","name":"regulation of cell division","canonical_id":"go:GO:0051302","description":"\"Any process that modulates the frequency, rate or extent of the physical partitioning and separation of a cell into daughter cells.\" [GOC:curators]","metadata":null},{"id":"f10ae359a0384724a561ed91ca0c55d3","type":"GO_TERM","name":"regulation of cell fate commitment","canonical_id":"go:GO:0010453","description":"\"Any process that modulates the frequency, rate or extent of cell fate commitment. Cell fate commitment is the commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"edca1ece80fb427291f224685abb70c1","type":"GO_TERM","name":"regulation of cell fate determination","canonical_id":"go:GO:1905933","description":"\"Any process that modulates the frequency, rate or extent of cell fate determination.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25793578]","metadata":null},{"id":"f500d7f16c9c4667be23649ec185bc61","type":"GO_TERM","name":"regulation of cell fate specification","canonical_id":"go:GO:0042659","description":"\"Any process that mediates the adoption of a specific fate by a cell.\" [GOC:curators]","metadata":null},{"id":"d3a969b6de7044368687dd6db1a35368","type":"GO_TERM","name":"regulation of cell growth","canonical_id":"go:GO:0001558","description":"\"Any process that modulates the frequency, rate, extent or direction of cell growth.\" [GOC:curators]","metadata":null},{"id":"6060c58f054b4a1994ecac9b2c953858","type":"GO_TERM","name":"regulation of cell growth by extracellular stimulus","canonical_id":"go:GO:0001560","description":"\"Any process in which external signals modulate the frequency, rate or extent of cell growth, the irreversible increase in size of a cell over time.\" [GOC:dph]","metadata":null},{"id":"43b7824ff008483ea03fe55e0539a4e2","type":"GO_TERM","name":"regulation of cell growth involved in cardiac muscle cell development","canonical_id":"go:GO:0061050","description":"\"Any process that modulates the rate, frequency, or extent of the growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"1f0ab2bffe5e473b9e4af26870a3e433","type":"GO_TERM","name":"regulation of cell integrity MAPK cascade","canonical_id":"go:GO:1903137","description":"\"Any process that modulates the frequency, rate or extent of a cell integrity MAPK cascade.\" [GOC:vw]","metadata":null},{"id":"11a3839eab944500864630be122f2c4d","type":"GO_TERM","name":"regulation of cell junction assembly","canonical_id":"go:GO:1901888","description":"\"Any process that modulates the frequency, rate or extent of cell junction assembly.\" [GOC:TermGenie]","metadata":null},{"id":"d8771cdebd8345798d204f656258187a","type":"GO_TERM","name":"regulation of cell killing","canonical_id":"go:GO:0031341","description":"\"Any process that modulates the frequency, rate or extent of cell killing, the process in which a cell brings about the death of another cell, either in the same or a different organism.\" [GOC:mah]","metadata":null},{"id":"73f84605ac4e4a36b8e81210bf77bc97","type":"GO_TERM","name":"regulation of cell maturation","canonical_id":"go:GO:1903429","description":"\"Any process that modulates the frequency, rate or extent of cell maturation.\" [GO_REF:0000058, GOC:TermGenie, PMID:17459944]","metadata":null},{"id":"9bcf47a34c2d4f6bb836b46863cb73b9","type":"GO_TERM","name":"regulation of cell migration","canonical_id":"go:GO:0030334","description":"\"Any process that modulates the frequency, rate or extent of cell migration.\" [GOC:curators]","metadata":null},{"id":"1e6f12f110584bda814e45730d666b66","type":"GO_TERM","name":"regulation of cell migration involved in somitogenic axis elongation","canonical_id":"go:GO:0090249","description":"\"Any process that modulates the frequency, rate, or extent of the controlled self-propelled movement of a cell that contributes to somitogenic axis elongation.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"77c91518d010498bb69b3577d957faa7","type":"GO_TERM","name":"regulation of cell migration involved in sprouting angiogenesis","canonical_id":"go:GO:0090049","description":"\"Any process that modulates the frequency, rate or extent of cell migration involved in sprouting angiogenesis. Cell migration involved in sprouting angiogenesis is the orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels contributing to the process of sprouting angiogenesis.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"c2f95e99004244e482fc53e31b0fc10b","type":"GO_TERM","name":"regulation of cell morphogenesis","canonical_id":"go:GO:0022604","description":"\"Any process that modulates the frequency, rate or extent of cell morphogenesis. Cell morphogenesis is the developmental process in which the shape of a cell is generated and organized.\" [GOC:isa_complete]","metadata":null},{"id":"a59e90d6323c4916b5d4356ac1633aca","type":"GO_TERM","name":"regulation of cell motility","canonical_id":"go:GO:2000145","description":"\"Any process that modulates the frequency, rate or extent of cell motility.\" [GOC:mah]","metadata":null},{"id":"e02e1b4d03cf4249bafbda95dbdf589c","type":"GO_TERM","name":"regulation of cell population proliferation","canonical_id":"go:GO:0042127","description":"\"Any process that modulates the frequency, rate or extent of cell proliferation.\" [GOC:jl]","metadata":null},{"id":"1bf0588c062d49a7a786403f52cbf4b7","type":"GO_TERM","name":"regulation of cell projection assembly","canonical_id":"go:GO:0060491","description":"\"Any process that modulates the rate, frequency, or extent of cell projection assembly.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"293fa533df194da9988bc338a8f7b158","type":"GO_TERM","name":"regulation of cell projection organization","canonical_id":"go:GO:0031344","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell projections.\" [GOC:mah]","metadata":null},{"id":"65eebe815e374903903ea95d82d9cdf5","type":"GO_TERM","name":"regulation of cell projection size","canonical_id":"go:GO:0032536","description":"\"A process that modulates the size of a cell projection.\" [GOC:mah]","metadata":null},{"id":"0f505b21fa4048c98fdf8fbe11ef10df","type":"GO_TERM","name":"regulation of cell proliferation in bone marrow","canonical_id":"go:GO:0071863","description":"\"A process that modulates the frequency, rate or extent of cell proliferation in the bone marrow.\" [GOC:mah, GOC:yaf, PMID:17063141]","metadata":null},{"id":"5b7e7592eff1408ab91093819f8e8d14","type":"GO_TERM","name":"regulation of cell proliferation in dorsal spinal cord","canonical_id":"go:GO:0021921","description":"\"The process that modulates the frequency, rate or extent of cell proliferation in the dorsal spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7c51196190fc4a32b1bd500c2f425c83","type":"GO_TERM","name":"regulation of cell proliferation in midbrain","canonical_id":"go:GO:1904933","description":"\"Any process that modulates the frequency, rate or extent of cell proliferation in midbrain.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18953410, PMID:24431302]","metadata":null},{"id":"54e0ece4d38c4bd0a2e61ce2b9e99d42","type":"GO_TERM","name":"regulation of cell proliferation involved in compound eye morphogenesis","canonical_id":"go:GO:2000495","description":"\"Any process that modulates the frequency, rate or extent of cell proliferation involved in compound eye morphogenesis.\" [GOC:obol]","metadata":null},{"id":"1885f771142d45f28a6f86bf1d4e89b8","type":"GO_TERM","name":"regulation of cell proliferation involved in embryonic placenta development","canonical_id":"go:GO:0060723","description":"\"Any process that modulates the rate, frequency, or extent of cell proliferation involved in embryonic placenta development.\" [GOC:dph]","metadata":null},{"id":"4c2be993431f49e2be31e9fc96fedb2b","type":"GO_TERM","name":"regulation of cell proliferation involved in heart morphogenesis","canonical_id":"go:GO:2000136","description":"\"Any process that modulates the frequency, rate or extent of cell proliferation involved in heart morphogenesis.\" [GOC:dph]","metadata":null},{"id":"6aa1485996ee46a8ac2fe0155822b8a7","type":"GO_TERM","name":"regulation of cell proliferation involved in imaginal disc-derived wing morphogenesis","canonical_id":"go:GO:0090256","description":"\"Any process that modulates the frequency, rate, or extent of the multiplication or reproduction of cells, resulting in the expansion of a cell population that contributes to imaginal disc-derived wing morphogenesis.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"9fb88bd5f778448681c3849cd0b9d62c","type":"GO_TERM","name":"regulation of cell proliferation involved in kidney morphogenesis","canonical_id":"go:GO:0061006","description":"\"Any process that modulates the frequency, rate or extent of cell proliferation that contributes to the shaping of the kidney.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"e26e83ec5a72424fa6f1847a4b91ed83","type":"GO_TERM","name":"regulation of cell proliferation involved in tissue homeostasis","canonical_id":"go:GO:0060784","description":"\"Any process that modulates the frequency, rate or extent of cell proliferation resulting in the maintenance of a steady-state number of cells within a tissue.\" [GOC:dph]","metadata":null},{"id":"eaf9e784b6f945b39f5a6e788f9927b6","type":"GO_TERM","name":"regulation of cell septum assembly","canonical_id":"go:GO:1901891","description":"\"Any process that modulates the frequency, rate or extent of cell septum assembly.\" [GOC:TermGenie]","metadata":null},{"id":"dc32a609fa4f4a39b0d82b4c6007e0e4","type":"GO_TERM","name":"regulation of cell shape","canonical_id":"go:GO:0008360","description":"\"Any process that modulates the surface configuration of a cell.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"e42a4c1153ec49ad800f15384f839237","type":"GO_TERM","name":"regulation of cell size","canonical_id":"go:GO:0008361","description":"\"Any process that modulates the size of a cell.\" [GOC:curators]","metadata":null},{"id":"1817f54b56bd487ea238925f1293d8a7","type":"GO_TERM","name":"regulation of cell wall (1->3)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070608","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->3)-alpha-D-glucans, compounds composed of glucose residues linked by (1->3)-alpha-D-glucosidic bonds, found in the walls of cells.\" [GOC:mah]","metadata":null},{"id":"cba80fdfef424c9fb61f020536f1fb9c","type":"GO_TERM","name":"regulation of cell wall (1->3)-beta-D-glucan biosynthetic process","canonical_id":"go:GO:0090334","description":"\"Any process that modulates the rate, frequency, or extent of the chemical reactions and pathways resulting in the formation of (1->3)-beta-D-glucans, compounds composed of glucose residues linked by (1->3)-beta-D-glucosidic bonds, found in the walls of cells.\" [GOC:tb]","metadata":null},{"id":"3307f119675f4a1d89e211e801904489","type":"GO_TERM","name":"regulation of cell wall macromolecule metabolic process","canonical_id":"go:GO:0010981","description":"\"Any process that modulates the rate, frequency or extent of cell wall macromolecule metabolism. Cell wall macromolecule metabolic processes are the chemical reactions and pathways involving macromolecules forming, or destined to form, part of the cell wall. A cell wall is a rigid or semi-rigid envelope lying outside the cell membrane of plant, fungal and most prokaryotic cells, maintaining their shape and protecting them from osmotic lysis.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c8d7b3e114fa49288614448fb03a1b66","type":"GO_TERM","name":"regulation of cell wall organization or biogenesis","canonical_id":"go:GO:1903338","description":"\"Any process that modulates the frequency, rate or extent of cell wall organization or biogenesis.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"6357e939ddc847e48e99227b9e6598ac","type":"GO_TERM","name":"regulation of cell wall pectin metabolic process","canonical_id":"go:GO:1902066","description":"\"Any process that modulates the frequency, rate or extent of cell wall pectin metabolic process.\" [GOC:TermGenie, PMID:23453954]","metadata":null},{"id":"3f8c76b00f624bf5a8e275d7d91fc7eb","type":"GO_TERM","name":"regulation of cell wall polysaccharide catabolic process","canonical_id":"go:GO:2000966","description":"\"Any process that modulates the frequency, rate or extent of cell wall polysaccharide catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"454ec9ef1dac405fb509fbda2d946c5d","type":"GO_TERM","name":"regulation of cell-cell adhesion","canonical_id":"go:GO:0022407","description":"\"Any process that modulates the frequency, rate or extent of attachment of a cell to another cell.\" [GOC:isa_complete]","metadata":null},{"id":"016bab70978d46e5a9b3e710ed1449d2","type":"GO_TERM","name":"regulation of cell-cell adhesion involved in gastrulation","canonical_id":"go:GO:0070587","description":"\"Any process that modulates the frequency, rate, or extent of attachment of a cell to another cell affecting gastrulation.\" [GOC:dsf, PMID:19091770]","metadata":null},{"id":"c100a83067784f9a9d771156ed654af3","type":"GO_TERM","name":"regulation of cell-cell adhesion mediated by cadherin","canonical_id":"go:GO:2000047","description":"\"Any process that modulates the frequency, rate or extent of cell-cell adhesion mediated by cadherin.\" [GOC:obol]","metadata":null},{"id":"a0bacfb29acb4c8486cb98c607fa32b7","type":"GO_TERM","name":"regulation of cell-cell adhesion mediated by integrin","canonical_id":"go:GO:0033632","description":"\"Any process that modulates the frequency, rate, or extent of cell-cell adhesion mediated by integrin.\" [GOC:add]","metadata":null},{"id":"b0cc0d9eb3e64509a7fa4ea84a6bf20f","type":"GO_TERM","name":"regulation of cell-matrix adhesion","canonical_id":"go:GO:0001952","description":"\"Any process that modulates the frequency, rate or extent of attachment of a cell to the extracellular matrix.\" [GOC:hjd]","metadata":null},{"id":"b08715444ffd467f8e131c3d3d73da84","type":"GO_TERM","name":"regulation of cell-substrate adhesion","canonical_id":"go:GO:0010810","description":"\"Any process that modulates the frequency, rate or extent of cell-substrate adhesion. Cell-substrate adhesion is the attachment of a cell to the underlying substrate via adhesion molecules.\" [GOC:dph, GOC:pf, GOC:tb]","metadata":null},{"id":"ce73678f5458467d8af0e615a82e4372","type":"GO_TERM","name":"regulation of cell-substrate junction assembly","canonical_id":"go:GO:0090109","description":"\"Any process that modulates the rate, frequency, or extent of cell-substrate junction assembly. Cell-substrate junction assembly is the aggregation, arrangement and bonding together of a set of components to form a junction between a cell and its substrate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"846cd01595ad48b7954c5ecdf242fd1c","type":"GO_TERM","name":"regulation of cell-substrate junction organization","canonical_id":"go:GO:0150116","description":"\"Any process that modulates the frequency, rate or extent of cell-substrate junction organization.\" [GOC:aruk]","metadata":null},{"id":"466cd10348b640cf8a2ce6542b99e40d","type":"GO_TERM","name":"regulation of cellobiose catabolic process","canonical_id":"go:GO:1900282","description":"\"Any process that modulates the frequency, rate or extent of cellobiose catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"ea1be2c21f6a4575b7db6f946df7db72","type":"GO_TERM","name":"regulation of cellodextrin catabolic process","canonical_id":"go:GO:2000927","description":"\"Any process that modulates the frequency, rate or extent of cellodextrin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"0ba5db3a3e584f8eaa637274339b64cf","type":"GO_TERM","name":"regulation of cellooligosaccharide catabolic process","canonical_id":"go:GO:2000963","description":"\"Any process that modulates the frequency, rate or extent of cellooligosaccharide catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"dd08a767239747569be4a79414d39aef","type":"GO_TERM","name":"regulation of cellotriose catabolic process","canonical_id":"go:GO:2000936","description":"\"Any process that modulates the frequency, rate or extent of cellotriose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"aaa96ca144ac46288a3d2caec31c3f65","type":"GO_TERM","name":"regulation of cellotriose transport","canonical_id":"go:GO:1900285","description":"\"Any process that modulates the frequency, rate or extent of cellotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f6593836a4714a7792630d6a37a79611","type":"GO_TERM","name":"regulation of cellular component biogenesis","canonical_id":"go:GO:0044087","description":"\"Any process that modulates the frequency, rate or extent of cellular component biogenesis, a process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cellular component.\" [GOC:jl]","metadata":null},{"id":"26ce1d0ef5864c7f8e31c5c0e7033508","type":"GO_TERM","name":"regulation of cellular component organization","canonical_id":"go:GO:0051128","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell structures, including the plasma membrane and any external encapsulating structures such as the cell wall and cell envelope.\" [GOC:ai]","metadata":null},{"id":"bebd34ff862f45858b67d9def04fbc6a","type":"GO_TERM","name":"regulation of cellular component size","canonical_id":"go:GO:0032535","description":"\"A process that modulates the size of a cellular component.\" [GOC:mah]","metadata":null},{"id":"3818d67de6904d66b60ef0111075651f","type":"GO_TERM","name":"regulation of cellular defense response","canonical_id":"go:GO:0010185","description":"\"Any process that modulates the frequency, rate or extent of cellular defense response.\" [GOC:sm]","metadata":null},{"id":"4d241738208342aa9f5e55b1d96bdeb0","type":"GO_TERM","name":"regulation of cellular extravasation","canonical_id":"go:GO:0002691","description":"\"Any process that modulates the frequency, rate, or extent of cellular extravasation.\" [GOC:add]","metadata":null},{"id":"27e575d9e8bc4e479a153a9aa78635ce","type":"GO_TERM","name":"regulation of cellular hyperosmotic salinity response","canonical_id":"go:GO:1900069","description":"\"Any process that modulates the frequency, rate or extent of cellular hyperosmotic salinity response.\" [GOC:dgf, GOC:TermGenie, PMID:16278455]","metadata":null},{"id":"5b6d3b9f66df45129d133971623f8126","type":"GO_TERM","name":"regulation of cellular localization","canonical_id":"go:GO:0060341","description":"\"Any process that modulates the frequency, rate or extent of a process in which a cell, a substance, or a cellular entity is transported to, or maintained in a specific location within or in the membrane of a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8097563c33c24c3ebbe30d775a8aa260","type":"GO_TERM","name":"regulation of cellular process","canonical_id":"go:GO:0050794","description":"\"Any process that modulates the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.\" [GOC:curators]","metadata":null},{"id":"6fa19447f96a4a65a10144798b59e660","type":"GO_TERM","name":"regulation of cellular respiration","canonical_id":"go:GO:0043457","description":"\"Any process that modulates the frequency, rate or extent of cellular respiration, the enzymatic release of energy from organic compounds.\" [GOC:jl]","metadata":null},{"id":"dde64dd5b33f4c2f8b4b8ee7cd7bd78a","type":"GO_TERM","name":"regulation of cellular response to X-ray","canonical_id":"go:GO:2000683","description":"\"Any process that modulates the frequency, rate or extent of cellular response to X-ray.\" [GOC:obol]","metadata":null},{"id":"48b57806520f4f4489144ac2b9ce141c","type":"GO_TERM","name":"regulation of cellular response to alcohol","canonical_id":"go:GO:1905957","description":"\"Any process that modulates the frequency, rate or extent of cellular response to alcohol.\" [GO_REF:0000058, GOC:TermGenie, PMID:26434723]","metadata":null},{"id":"035165add1fb4b5c9ae7b55cbacc3faa","type":"GO_TERM","name":"regulation of cellular response to alkaline pH","canonical_id":"go:GO:1900067","description":"\"Any process that modulates the frequency, rate or extent of cellular response to alkalinity.\" [GOC:dgf, GOC:TermGenie, PMID:12509465, PMID:17023428]","metadata":null},{"id":"71adaef920a24bbc84ae03df03bb5f17","type":"GO_TERM","name":"regulation of cellular response to amino acid starvation","canonical_id":"go:GO:1903832","description":"\"Any process that modulates the frequency, rate or extent of cellular response to amino acid starvation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25002487, PMID:7623840]","metadata":null},{"id":"76160f64208b4358881126fd4bb4fc91","type":"GO_TERM","name":"regulation of cellular response to drug","canonical_id":"go:GO:2001038","description":"\"Any process that modulates the frequency, rate or extent of cellular response to drug.\" [GOC:obol]","metadata":null},{"id":"fd2fc826ee37430689bffe50900bcdab","type":"GO_TERM","name":"regulation of cellular response to gamma radiation","canonical_id":"go:GO:1905843","description":"\"Any process that modulates the frequency, rate or extent of cellular response to gamma radiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23505386]","metadata":null},{"id":"0a55ddb6c32c408d80d6182eb47ad9f3","type":"GO_TERM","name":"regulation of cellular response to glucose starvation","canonical_id":"go:GO:1904547","description":"\"Any process that modulates the frequency, rate or extent of cellular response to glucose starvation.\" [GO_REF:0000058, GOC:TermGenie, PMID:21118717]","metadata":null},{"id":"77461dfd0b4a4ab0936a2bda428e9bd5","type":"GO_TERM","name":"regulation of cellular response to growth factor stimulus","canonical_id":"go:GO:0090287","description":"\"Any process that modulates the rate, frequency, or extent of a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.\" [GOC:tb]","metadata":null},{"id":"5f76b25d7c0040c499e0a735ea3ac6e8","type":"GO_TERM","name":"regulation of cellular response to heat","canonical_id":"go:GO:1900034","description":"\"Any process that modulates the frequency, rate or extent of cellular response to heat.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"dfda4eeea2ad4d1e87af1fc5e3ffff48","type":"GO_TERM","name":"regulation of cellular response to hepatocyte growth factor stimulus","canonical_id":"go:GO:2001112","description":"\"Any process that modulates the frequency, rate or extent of cellular response to hepatocyte growth factor stimulus.\" [GOC:obol]","metadata":null},{"id":"6ffabfe7da9c448ca674975aa0e980fc","type":"GO_TERM","name":"regulation of cellular response to hypoxia","canonical_id":"go:GO:1900037","description":"\"Any process that modulates the frequency, rate or extent of cellular response to hypoxia.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"e68510b104fb4cb89dfe95224a1e62bb","type":"GO_TERM","name":"regulation of cellular response to insulin stimulus","canonical_id":"go:GO:1900076","description":"\"Any process that modulates the frequency, rate or extent of cellular response to insulin stimulus.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"093228d6b8f542b9baaf5471894dd4e1","type":"GO_TERM","name":"regulation of cellular response to iron ion starvation","canonical_id":"go:GO:1901966","description":"\"Any process that modulates the frequency, rate or extent of cellular response to iron ion starvation.\" [GOC:TermGenie, PMID:23115244]","metadata":null},{"id":"c8b7c347d2db409897e2477e8d4ade0c","type":"GO_TERM","name":"regulation of cellular response to macrophage colony-stimulating factor stimulus","canonical_id":"go:GO:1903972","description":"\"Any process that modulates the frequency, rate or extent of cellular response to macrophage colony-stimulating factor stimulus.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"ed8c22b200ad4ae884a728a657cf2bce","type":"GO_TERM","name":"regulation of cellular response to manganese ion","canonical_id":"go:GO:1905802","description":"\"Any process that modulates the frequency, rate or extent of cellular response to manganese ion.\" [GO_REF:0000058, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"0d429d72b6cd4b77a15c3543aab2286c","type":"GO_TERM","name":"regulation of cellular response to osmotic stress","canonical_id":"go:GO:0106049","description":"\"Any process that modulates the frequency, rate or extent of the cellular response to osmotic stress.\" [PMID:10398679]","metadata":null},{"id":"fbe8b7f35b3c495cb8305ecd2761f675","type":"GO_TERM","name":"regulation of cellular response to oxidative stress","canonical_id":"go:GO:1900407","description":"\"Any process that modulates the frequency, rate or extent of cellular response to oxidative stress.\" [GOC:mah, GOC:TermGenie]","metadata":null},{"id":"70da18e383fb4025a56f688edab2c2c9","type":"GO_TERM","name":"regulation of cellular response to oxidopamine","canonical_id":"go:GO:1905846","description":"\"Any process that modulates the frequency, rate or extent of cellular response to oxidopamine.\" [GO_REF:0000058, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"ab9491ef08aa435c919619c70db0e055","type":"GO_TERM","name":"regulation of cellular response to phosphate starvation","canonical_id":"go:GO:0140255","description":"\"Any process that modulates the frequency, rate or extent of cellular response to phosphate starvation.\" [PMID:29414789]","metadata":null},{"id":"c1f4a7abfd6b4a19aa7a16bc9abe6b35","type":"GO_TERM","name":"regulation of cellular response to stress","canonical_id":"go:GO:0080135","description":"\"Any process that modulates the frequency, rate or extent of a cellular response to stress. Cellular response to stress is a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:dhl]","metadata":null},{"id":"13e26322dc4d477181c95e4ae273e543","type":"GO_TERM","name":"regulation of cellular response to testosterone stimulus","canonical_id":"go:GO:2000654","description":"\"Any process that modulates the frequency, rate or extent of cellular response to testosterone stimulus.\" [GOC:BHF]","metadata":null},{"id":"d8c680c0e5e749d7818564c79bb0b8c6","type":"GO_TERM","name":"regulation of cellular response to transforming growth factor beta stimulus","canonical_id":"go:GO:1903844","description":"\"Any process that modulates the frequency, rate or extent of cellular response to transforming growth factor beta stimulus.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"3c69dfe0298449d2b1343e1e552bde42","type":"GO_TERM","name":"regulation of cellular response to vascular endothelial growth factor stimulus","canonical_id":"go:GO:1902547","description":"\"Any process that modulates the frequency, rate or extent of cellular response to vascular endothelial growth factor stimulus.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17895370]","metadata":null},{"id":"cd91697cfa3d447ab36e82973e44c645","type":"GO_TERM","name":"regulation of cellular response to very-low-density lipoprotein particle stimulus","canonical_id":"go:GO:1905890","description":"\"Any process that modulates the frequency, rate or extent of cellular response to very-low-density lipoprotein particle stimulus.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:7592957]","metadata":null},{"id":"0e101e769d504d87a69891c3f0882c57","type":"GO_TERM","name":"regulation of cellular senescence","canonical_id":"go:GO:2000772","description":"\"Any process that modulates the frequency, rate or extent of cellular senescence.\" [GOC:BHF]","metadata":null},{"id":"4fad975522924adf9e9d952745e5fde7","type":"GO_TERM","name":"regulation of cellulose biosynthetic process","canonical_id":"go:GO:2001006","description":"\"Any process that modulates the frequency, rate or extent of cellulose biosynthetic process.\" [GOC:mengo_curators]","metadata":null},{"id":"015669544b5b4568bdea6916ca50dade","type":"GO_TERM","name":"regulation of cellulose catabolic process","canonical_id":"go:GO:2000997","description":"\"Any process that modulates the frequency, rate or extent of cellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"5e1158efa20d457890a4dc9b40e1b520","type":"GO_TERM","name":"regulation of cellulosome assembly","canonical_id":"go:GO:1900503","description":"\"Any process that modulates the frequency, rate or extent of cellulosome assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"e23d1cab485f4d9a88356063ae6c84f5","type":"GO_TERM","name":"regulation of central B cell anergy","canonical_id":"go:GO:0002914","description":"\"Any process that modulates the frequency, rate, or extent of central B cell anergy.\" [GOC:add]","metadata":null},{"id":"0e1494024f5d436ba96bb6e204de02bb","type":"GO_TERM","name":"regulation of central B cell deletion","canonical_id":"go:GO:0002898","description":"\"Any process that modulates the frequency, rate, or extent of central B cell deletion.\" [GOC:add]","metadata":null},{"id":"21987b35004c455d8cbe001b83b1a3ef","type":"GO_TERM","name":"regulation of central B cell tolerance induction","canonical_id":"go:GO:0002895","description":"\"Any process that modulates the frequency, rate, or extent of central B cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"16200906eb0246948ded7edd5f938858","type":"GO_TERM","name":"regulation of central tolerance induction","canonical_id":"go:GO:0002646","description":"\"Any process that modulates the frequency, rate, or extent of central tolerance induction.\" [GOC:add]","metadata":null},{"id":"cc73f03cbd984e92b1a339d5c06586a7","type":"GO_TERM","name":"regulation of centriole elongation","canonical_id":"go:GO:1903722","description":"\"Any process that modulates the frequency, rate or extent of centriole elongation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:20616062]","metadata":null},{"id":"a681e0c33b6c45079c15933d4f61edec","type":"GO_TERM","name":"regulation of centriole replication","canonical_id":"go:GO:0046599","description":"\"Any process that modulates the frequency, rate or extent of the formation of a daughter centriole of an existing centriole.\" [GOC:ai]","metadata":null},{"id":"83904c73941f4258842bc69662479809","type":"GO_TERM","name":"regulation of centriole-centriole cohesion","canonical_id":"go:GO:0030997","description":"\"Any process that modulates the extent to which the two centrioles within a centrosome remain tightly paired; may be mediated by the assembly and disassembly of a proteinaceous linker.\" [PMID:11076968]","metadata":null},{"id":"ce7d3833eef64b3e9865c8018d520915","type":"GO_TERM","name":"regulation of centromeric sister chromatid cohesion","canonical_id":"go:GO:0070602","description":"\"Any process that modulates the frequency, rate or extent of sister chromatid cohesion in the centromeric region of a chromosome.\" [GOC:mah]","metadata":null},{"id":"e12ddf8e1f834a3bae2abf60d420f084","type":"GO_TERM","name":"regulation of centrosome cycle","canonical_id":"go:GO:0046605","description":"\"Any process that modulates the frequency, rate or extent of the centrosome cycle, the processes of centrosome duplication and separation.\" [GOC:ai]","metadata":null},{"id":"e4798206f0104b74aa70a3d924110e50","type":"GO_TERM","name":"regulation of centrosome duplication","canonical_id":"go:GO:0010824","description":"\"Any process that modulates the frequency, rate or extent of centrosome duplication. Centrosome duplication is the replication of a centrosome, a structure comprised of a pair of centrioles and peri-centriolar material from which a microtubule spindle apparatus is organized.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"25716618189a4356b30d6c43516c6f18","type":"GO_TERM","name":"regulation of ceramide biosynthetic process","canonical_id":"go:GO:2000303","description":"\"Any process that modulates the frequency, rate or extent of a ceramide biosynthetic process.\" [GOC:dph]","metadata":null},{"id":"3c1ef870fe964fe5bd30addf489a3de4","type":"GO_TERM","name":"regulation of cerebellar granule cell precursor proliferation","canonical_id":"go:GO:0021936","description":"\"The process that modulates the frequency, rate or extent of granule cell precursor proliferation.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"bcea02385ad840d1ba4021db6c134379","type":"GO_TERM","name":"regulation of cerebellar neuron development","canonical_id":"go:GO:1905079","description":"\"Any process that modulates the frequency, rate or extent of cerebellar neuron development.\" [GO_REF:0000058, GOC:TermGenie, PMID:26609159]","metadata":null},{"id":"e78f0955d09844a48b54612325d6fab1","type":"GO_TERM","name":"regulation of cerebral blood circulation","canonical_id":"go:GO:0120276","description":"\"Any process that modulates the frequency, rate or extent of cerebral blood circulation.\" [GOC:krc, PMID:25397684]","metadata":null},{"id":"740faa25479247d4b9b6dc46a45fb7e7","type":"GO_TERM","name":"regulation of chanoclavine-I aldehyde biosynthetic process","canonical_id":"go:GO:1900646","description":"\"Any process that modulates the frequency, rate or extent of chanoclavine-I aldehyde biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"2a5d37ba71c847609163180f90e87a90","type":"GO_TERM","name":"regulation of chaperone-mediated autophagy","canonical_id":"go:GO:1904714","description":"\"Any process that modulates the frequency, rate or extent of chaperone-mediated autophagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20176123]","metadata":null},{"id":"90312c8586ea4b7689ccfcdfb7d5f9d1","type":"GO_TERM","name":"regulation of chaperone-mediated protein complex assembly","canonical_id":"go:GO:0090034","description":"\"Any process that modulates the frequency, rate, or extent of chaperone-mediated protein complex assembly. Chaperone-mediated protein complex assembly is the aggregation, arrangement and bonding together of a set of components to form a protein complex, mediated by chaperone molecules that do not form part of the finished complex.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"ec7afd9726404a2795f61814e8299a8a","type":"GO_TERM","name":"regulation of chemokine (C-C motif) ligand 1 production","canonical_id":"go:GO:0071652","description":"\"Any process that modulates the frequency, rate, or extent of production of chemokine (C-C motif) ligand 1.\" [GOC:mah]","metadata":null},{"id":"2bc848be13494d60b758328b2805377c","type":"GO_TERM","name":"regulation of chemokine (C-C motif) ligand 20 production","canonical_id":"go:GO:1903884","description":"\"Any process that modulates the frequency, rate or extent of chemokine (C-C motif) ligand 20 production.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:20054338]","metadata":null},{"id":"4ea7867c5521489ab2ecedbb3ba4f00e","type":"GO_TERM","name":"regulation of chemokine (C-C motif) ligand 4 production","canonical_id":"go:GO:0071643","description":"\"Any process that modulates the frequency, rate, or extent of production of chemokine (C-C motif) ligand 4.\" [GOC:mah]","metadata":null},{"id":"83bb10b57aa14a07bea9edfb51a16612","type":"GO_TERM","name":"regulation of chemokine (C-C motif) ligand 5 production","canonical_id":"go:GO:0071649","description":"\"Any process that modulates the frequency, rate, or extent of production of chemokine (C-C motif) ligand 5.\" [GOC:mah]","metadata":null},{"id":"12e8310ddb784da8ad572118650cfa14","type":"GO_TERM","name":"regulation of chemokine (C-C motif) ligand 6 production","canonical_id":"go:GO:0035531","description":"\"Any process that modulates the frequency, rate, or extent of production of chemokine (C-C motif) ligand 6 (CCL6).\" [GOC:add, GOC:bf]","metadata":null},{"id":"982b266d81e44d0aace27234c2b621e9","type":"GO_TERM","name":"regulation of chemokine (C-X-C motif) ligand 1 production","canonical_id":"go:GO:2000338","description":"\"Any process that modulates the frequency, rate or extent of chemokine (C-X-C motif) ligand 1 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"9d5be74cbb514902ad42df4fb76f8632","type":"GO_TERM","name":"regulation of chemokine (C-X-C motif) ligand 2 production","canonical_id":"go:GO:2000341","description":"\"Any process that modulates the frequency, rate or extent of chemokine (C-X-C motif) ligand 2 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"79c9b68080ea42348010a920c0373aa5","type":"GO_TERM","name":"regulation of chemokine (C-X-C motif) ligand 9 production","canonical_id":"go:GO:0035394","description":"\"Any process that modulates the frequency, rate, or extent of production of chemokine (C-X-C motif) ligand 9.\" [GOC:bf]","metadata":null},{"id":"5afd56e44db44b5cb12afa7e8dcfb4b8","type":"GO_TERM","name":"regulation of chemokine activity","canonical_id":"go:GO:1900136","description":"\"Any process that modulates the frequency, rate or extent of chemokine activity.\" [GOC:TermGenie]","metadata":null},{"id":"07a5cc2a272840ed864feaf3396ab9d1","type":"GO_TERM","name":"regulation of chemokine production","canonical_id":"go:GO:0032642","description":"\"Any process that modulates the frequency, rate, or extent of chemokine production.\" [GOC:mah]","metadata":null},{"id":"c3eca4e754fc4b47b032f619b77f2c20","type":"GO_TERM","name":"regulation of chemokine-mediated signaling pathway","canonical_id":"go:GO:0070099","description":"\"Any process that modulates the rate, frequency or extent of a chemokine-mediated signaling pathway.\" [GOC:mah]","metadata":null},{"id":"c83e2840c3ba44568a9563d098b970a2","type":"GO_TERM","name":"regulation of chemokinesis","canonical_id":"go:GO:1904365","description":"\"Any process that modulates the frequency, rate or extent of chemokinesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:8679543]","metadata":null},{"id":"c3a8d31ae1eb4ad08960fc6a65f5c599","type":"GO_TERM","name":"regulation of chemotaxis","canonical_id":"go:GO:0050920","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a motile cell or organism in response to a specific chemical concentration gradient.\" [GOC:ai]","metadata":null},{"id":"50d7173f4d8d4e76accc96cfcde2679f","type":"GO_TERM","name":"regulation of chemotaxis to arachidonate","canonical_id":"go:GO:1904552","description":"\"Any process that modulates the frequency, rate or extent of chemotaxis to arachidonic acid.\" [GO_REF:0000058, GOC:TermGenie, PMID:16382163]","metadata":null},{"id":"7c1f232b45df4a4a8d0e4c66a3820ae6","type":"GO_TERM","name":"regulation of chitin biosynthetic process","canonical_id":"go:GO:0032883","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of chitin.\" [GOC:mah]","metadata":null},{"id":"0646d8df153849c794b035731ea1eb9f","type":"GO_TERM","name":"regulation of chitin metabolic process","canonical_id":"go:GO:0032882","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving chitin.\" [GOC:mah]","metadata":null},{"id":"8a52eccdfa6d47228b2e8e30fc6e8462","type":"GO_TERM","name":"regulation of chitin-based cuticle tanning","canonical_id":"go:GO:0007564","description":"\"Any process that modulates the frequency, rate or extent of chitin-based cuticular tanning.\" [GOC:curators, GOC:jid, GOC:mtg_sensu]","metadata":null},{"id":"239014a635ce40adb552065ad096f9a2","type":"GO_TERM","name":"regulation of chloride transport","canonical_id":"go:GO:2001225","description":"\"Any process that modulates the frequency, rate or extent of chloride transport.\" [GOC:dph]","metadata":null},{"id":"c2c3bbdf5f5f477f9e83980d5f9d1400","type":"GO_TERM","name":"regulation of chlorophyll biosynthetic process","canonical_id":"go:GO:0010380","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of chlorophyll, any compound of magnesium complexed in a porphyrin (tetrapyrrole) ring and which functions as a photosynthetic pigment, from less complex precursors.\" [PMID:17291312]","metadata":null},{"id":"3f364cc509114b619336e0ba4c675c35","type":"GO_TERM","name":"regulation of chlorophyll catabolic process","canonical_id":"go:GO:0010271","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of chlorophyll.\" [PMID:16361392]","metadata":null},{"id":"f9a0cca6a1cf4269b64743a25e5cbba4","type":"GO_TERM","name":"regulation of chlorophyll metabolic process","canonical_id":"go:GO:0090056","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving chlorophyll.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6859489d441546c0884088e8661390d7","type":"GO_TERM","name":"regulation of chloroplast fission","canonical_id":"go:GO:1905192","description":"\"Any process that modulates the frequency, rate or extent of chloroplast fission.\" [GO_REF:0000058, GOC:TermGenie, PMID:26862170]","metadata":null},{"id":"acee90b368aa48bab98706a1e75ff80f","type":"GO_TERM","name":"regulation of cholangiocyte apoptotic process","canonical_id":"go:GO:1904192","description":"\"Any process that modulates the frequency, rate or extent of cholangiocyte apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24498161]","metadata":null},{"id":"954488bb95b04e0e9e79c91117661f28","type":"GO_TERM","name":"regulation of cholangiocyte proliferation","canonical_id":"go:GO:1904054","description":"\"Any process that modulates the frequency, rate or extent of cholangiocyte proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24434010]","metadata":null},{"id":"0ace4586bddf4a7886c531cf0e780d28","type":"GO_TERM","name":"regulation of cholesterol biosynthetic process","canonical_id":"go:GO:0045540","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of cholesterol.\" [GOC:curators]","metadata":null},{"id":"d6553bf0a453475f892e1eb9bc2073b8","type":"GO_TERM","name":"regulation of cholesterol efflux","canonical_id":"go:GO:0010874","description":"\"Any process that modulates the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"90498d74b1be451b8925e4f2f5b4d9c5","type":"GO_TERM","name":"regulation of cholesterol import","canonical_id":"go:GO:0060620","description":"\"Any process that modulates the rate, frequency or extent of cholesterol import. Cholesterol import is the directed movement of cholesterol into a cell or organelle.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"fb9cc8e3637743da8a807e2060c2a0c0","type":"GO_TERM","name":"regulation of cholesterol metabolic process","canonical_id":"go:GO:0090181","description":"\"Any process that modulates the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"54e995117a424b75bfaff8933979dd3b","type":"GO_TERM","name":"regulation of cholesterol storage","canonical_id":"go:GO:0010885","description":"\"Any process that modulates the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5c5c67042e0b45a0b3bec8f227b31ef9","type":"GO_TERM","name":"regulation of cholesterol transport","canonical_id":"go:GO:0032374","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of cholesterol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"ac83ed70ae114777a5ee1344b4a27e28","type":"GO_TERM","name":"regulation of chondrocyte development","canonical_id":"go:GO:0061181","description":"\"Any process that modulates the rate, frequency, or extent of the process whose specific outcome is the progression of a chondrocyte over time, from its commitment to its mature state. Chondrocyte development does not include the steps involved in committing a chondroblast to a chondrocyte fate.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"79a7501cf2a641e5a171db1966768709","type":"GO_TERM","name":"regulation of chondrocyte differentiation","canonical_id":"go:GO:0032330","description":"\"Any process that modulates the frequency, rate or extent of chondrocyte differentiation.\" [GOC:mah]","metadata":null},{"id":"0203bb0ddf134bfdb6d0381f2c9aa529","type":"GO_TERM","name":"regulation of chondrocyte differentiation involved in endochondral bone morphogenesis","canonical_id":"go:GO:1902738","description":"\"Any process that modulates the rate, frequency, or extent of the process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte that will contribute to the development of a bone. A chondrocyte is a polymorphic cell that forms cartilage.\" [GO_REF:0000058, GOC:TermGenie, PMID:8662546]","metadata":null},{"id":"0de6461dac83482ba5f5d242b3e3fb23","type":"GO_TERM","name":"regulation of chondrocyte hypertrophy","canonical_id":"go:GO:1903041","description":"\"Any process that modulates the frequency, rate or extent of chondrocyte hypertrophy.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:23928032]","metadata":null},{"id":"85deb6ce91254779993cca40ecbaad45","type":"GO_TERM","name":"regulation of chorionic trophoblast cell proliferation","canonical_id":"go:GO:1901382","description":"\"Any process that modulates the frequency, rate or extent of chorionic trophoblast cell proliferation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"94d3ddc335d44fe284e328a76eaab4ab","type":"GO_TERM","name":"regulation of chromatin organization","canonical_id":"go:GO:1902275","description":"\"Any process that modulates the frequency, rate or extent of chromatin organization.\" [GO_REF:0000058, GOC:bf, GOC:TermGenie, GOC:vw, PMID:18314879]","metadata":null},{"id":"2e36754bb7ea4f2bac004500deaa9004","type":"GO_TERM","name":"regulation of chromosome attachment to the nuclear envelope","canonical_id":"go:GO:0120264","description":"\"Any process that modulates the frequency, rate, extent or location of chromosome attachment to the nuclear envelope.\" [GOC:krc]","metadata":null},{"id":"04b38bf1caee4a028121dbfe28558cd7","type":"GO_TERM","name":"regulation of chromosome condensation","canonical_id":"go:GO:0060623","description":"\"Any process that modulates the rate, frequency, or extent of chromosome condensation, the progressive compaction of dispersed interphase chromatin into threadlike chromosomes prior to mitotic or meiotic nuclear division, or during apoptosis, in eukaryotic cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4283668329d44374b9358a3c8164b9f8","type":"GO_TERM","name":"regulation of chromosome organization","canonical_id":"go:GO:0033044","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a chromosome.\" [GOC:mah]","metadata":null},{"id":"ebc115200ede4fecb6ec406d30aa0f62","type":"GO_TERM","name":"regulation of chromosome segregation","canonical_id":"go:GO:0051983","description":"\"Any process that modulates the frequency, rate or extent of chromosome segregation, the process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets.\" [GOC:ai]","metadata":null},{"id":"0936f11c27c543568f672716a8ca1a51","type":"GO_TERM","name":"regulation of chromosome separation","canonical_id":"go:GO:1905818","description":"\"Any process that modulates the frequency, rate or extent of chromosome separation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:21795393]","metadata":null},{"id":"45f14c1b41f44c82aa165c5fa029e505","type":"GO_TERM","name":"regulation of chronic inflammatory response","canonical_id":"go:GO:0002676","description":"\"Any process that modulates the frequency, rate, or extent of a chronic inflammatory response.\" [GOC:add]","metadata":null},{"id":"35ae7a0be4684097b54bd37df562a72a","type":"GO_TERM","name":"regulation of chronic inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002874","description":"\"Any process that modulates the frequency, rate, or extent of a chronic inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"dee09262fab2465f878b824760bee339","type":"GO_TERM","name":"regulation of chronic inflammatory response to non-antigenic stimulus","canonical_id":"go:GO:0002880","description":"\"Any process that modulates the frequency, rate, or extent of a chronic inflammatory response to a non-antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"1f3c06f53c474de0881cac0fe5528c09","type":"GO_TERM","name":"regulation of chylomicron remnant clearance","canonical_id":"go:GO:0090320","description":"\"Any process that modulates the rate, frequency or extent of chylomicron remnant clearance. Chylomicron clearance is the process in which a chylomicron remnant is removed from the blood via receptor-mediated endocytosis into liver cells and its constituent parts degraded.\" [GOC:tb]","metadata":null},{"id":"c3d834d7d0db4a4bb6cf98be96fadbef","type":"GO_TERM","name":"regulation of chylomicron remodeling","canonical_id":"go:GO:0090318","description":"\"Any process that modulates the rate, frequency, or extent of chylomicron remodeling. Chylomicron remodeling is the acquisition, loss or modification of a protein or lipid within a chylomicron, including the hydrolysis of triglyceride by lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:tb]","metadata":null},{"id":"fbfa28e182d14af2848aece38ad41b2c","type":"GO_TERM","name":"regulation of cilium assembly","canonical_id":"go:GO:1902017","description":"\"Any process that modulates the frequency, rate or extent of cilium assembly.\" [GOC:cilia, GOC:dph, GOC:TermGenie, PMID:17719545]","metadata":null},{"id":"7f48c4af51db4c3eb39f5b12711f77df","type":"GO_TERM","name":"regulation of cilium beat frequency","canonical_id":"go:GO:0003356","description":"\"Any process that modulates the frequency of cilium movement, the directed, self-propelled movement of a cilium.\" [GOC:dph]","metadata":null},{"id":"0f136da30f5f4c4e901a90e51b3a8122","type":"GO_TERM","name":"regulation of cilium beat frequency involved in ciliary motility","canonical_id":"go:GO:0060296","description":"\"Any process that modulates the frequency of cilium beating involved in ciliary motility.\" [GOC:BHF, GOC:cilia, GOC:dph, GOC:krc, GOC:tb]","metadata":null},{"id":"27232d54c5ae48aaa6a58d0f7df98f97","type":"GO_TERM","name":"regulation of cilium movement","canonical_id":"go:GO:0003352","description":"\"Any process that modulates the rate, frequency, or extent of cilium movement, the directed, self-propelled movement of a cilium.\" [GOC:dph]","metadata":null},{"id":"203abf91db834eaabf3c72f588e17386","type":"GO_TERM","name":"regulation of cilium movement involved in cell motility","canonical_id":"go:GO:0060295","description":"\"Any process that modulates the rate frequency or extent of cilium movement involved in ciliary motility.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"88517f2810754a48be114723934335bc","type":"GO_TERM","name":"regulation of cilium-dependent cell motility","canonical_id":"go:GO:1902019","description":"\"Any process that modulates the frequency, rate or extent of cilium-dependent cell motility.\" [GOC:cilia, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"2f9f661207ac42dea90967c01bc4dd00","type":"GO_TERM","name":"regulation of circadian rhythm","canonical_id":"go:GO:0042752","description":"\"Any process that modulates the frequency, rate or extent of a circadian rhythm. A circadian rhythm is a biological process in an organism that recurs with a regularity of approximately 24 hours.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"ea81d433298240bab91f779d658574c2","type":"GO_TERM","name":"regulation of circadian sleep/wake cycle","canonical_id":"go:GO:0042749","description":"\"Any process that modulates the frequency, rate or extent of the circadian sleep/wake cycle.\" [GOC:jl]","metadata":null},{"id":"197062d1e16f48c9a23319c2e8d46049","type":"GO_TERM","name":"regulation of circadian sleep/wake cycle, REM sleep","canonical_id":"go:GO:0042320","description":"\"Any process that modulates the frequency, rate or extent of rapid eye movement (REM) sleep.\" [GOC:jl, PMID:11506998]","metadata":null},{"id":"69d43798d3234b8e9632d29552e1e382","type":"GO_TERM","name":"regulation of circadian sleep/wake cycle, non-REM sleep","canonical_id":"go:GO:0045188","description":"\"Any process that modulates the frequency, rate or extent of non-rapid eye movement sleep.\" [GOC:curators]","metadata":null},{"id":"81421da645384cda9ee11e347424a0ff","type":"GO_TERM","name":"regulation of circadian sleep/wake cycle, sleep","canonical_id":"go:GO:0045187","description":"\"Any process that modulates the frequency, rate or extent of sleep; a readily reversible state of reduced awareness and metabolic activity that occurs periodically in many animals.\" [GOC:jl, ISBN:0192800981]","metadata":null},{"id":"2da75fd6af6346b4ba5e4236854bc056","type":"GO_TERM","name":"regulation of circadian sleep/wake cycle, wakefulness","canonical_id":"go:GO:0010840","description":"\"Any process that modulates the rate, frequency, or extent of the wakeful phase of the circadian sleep/wake cycle. The wakeful phase is the part of the circadian sleep/wake cycle where the organism is not asleep.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"904cd85050df4312806d6529e8460eea","type":"GO_TERM","name":"regulation of circulating fibrinogen levels","canonical_id":"go:GO:0044537","description":"\"Any process that modulates the quantity of fibrinogen circulating in the bloodstream.\" [GOC:jl]","metadata":null},{"id":"624c10af1a634f088d447814a3933b04","type":"GO_TERM","name":"regulation of citrulline biosynthetic process","canonical_id":"go:GO:1903248","description":"\"Any process that modulates the frequency, rate or extent of citrulline biosynthetic process.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19278978]","metadata":null},{"id":"c780bf4d5c0d42b3b2b9b7ec0da05db9","type":"GO_TERM","name":"regulation of clathrin coat assembly","canonical_id":"go:GO:1905443","description":"\"Any process that modulates the frequency, rate or extent of clathrin coat assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:15533940]","metadata":null},{"id":"f3b5877b70f947ed83d8ddd32972a981","type":"GO_TERM","name":"regulation of clathrin-dependent endocytosis","canonical_id":"go:GO:2000369","description":"\"Any process that modulates the frequency, rate or extent of clathrin-mediated endocytosis.\" [GOC:mah]","metadata":null},{"id":"d91d3184433749ccb1fd13a83bbc0234","type":"GO_TERM","name":"regulation of cleistothecium development","canonical_id":"go:GO:0070796","description":"\"Any process that modulates the frequency, rate or extent of cleistothecium development, a process that leads to the formation of a cleistothecium. The cleistothecium is a closed sexual fruiting body that contains ascospores in linear asci, characteristic of some filamentous Ascomycete fungi such as members of the genera Aspergillus and Emericella.\" [GOC:mah]","metadata":null},{"id":"b620a81a97c64a0e811454fc1dd85060","type":"GO_TERM","name":"regulation of coagulation","canonical_id":"go:GO:0050818","description":"\"Any process that modulates the frequency, rate or extent of coagulation, the process in which a fluid solution, or part of it, changes into a solid or semisolid mass.\" [GOC:ai]","metadata":null},{"id":"f71fa97c28bc4887a8f614f9f561d12e","type":"GO_TERM","name":"regulation of cobalamin catabolic process","canonical_id":"go:GO:0106064","description":"\"Any process that modulates the frequency, rate or extent of cobalamin (vitamin B12) catabolic process.\" [PMID:29056341]","metadata":null},{"id":"726dfa0839a8464d889f4c0f96be7fdc","type":"GO_TERM","name":"regulation of coenzyme A biosynthetic process","canonical_id":"go:GO:0080020","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving coenzyme A.\" [PMID:18621975]","metadata":null},{"id":"8e6f71a906c247118c1440ecfdea701a","type":"GO_TERM","name":"regulation of coenzyme F420-dependent bicyclic nitroimidazole catabolic process","canonical_id":"go:GO:1900288","description":"\"Any process that modulates the frequency, rate or extent of coenzyme F420-dependent bicyclic nitroimidazole catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"30ed45c6d58a4b759b365c13e8d1a205","type":"GO_TERM","name":"regulation of cold-induced thermogenesis","canonical_id":"go:GO:0120161","description":"\"Any process that modulates the frequency, rate or extent of cold-induced thermogenesis.\" [PMID:27876809]","metadata":null},{"id":"b7c61665b56640c0aeb73cdd6eebeb33","type":"GO_TERM","name":"regulation of collagen biosynthetic process","canonical_id":"go:GO:0032965","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.\" [GOC:mah]","metadata":null},{"id":"75929466757248e19b0fb0235f6ca91e","type":"GO_TERM","name":"regulation of collagen catabolic process","canonical_id":"go:GO:0010710","description":"\"Any process that modulates the rate, frequency or extent of collagen catabolism. Collagen catabolism is the proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"a22b4fd2bbeb48d283416e91344f98cb","type":"GO_TERM","name":"regulation of collagen fibril organization","canonical_id":"go:GO:1904026","description":"\"Any process that modulates the frequency, rate or extent of collagen fibril organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:25451920]","metadata":null},{"id":"5ef51c7082f74219be4ca4a85e412323","type":"GO_TERM","name":"regulation of collagen metabolic process","canonical_id":"go:GO:0010712","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the metabolism of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9dc90dc2d6654414a936610057eccd0d","type":"GO_TERM","name":"regulation of collateral sprouting","canonical_id":"go:GO:0048670","description":"\"Any process that modulates the frequency, rate or extent of collateral sprouting.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"fc92cf2d21074b71b9845b67aa0fce43","type":"GO_TERM","name":"regulation of collateral sprouting in absence of injury","canonical_id":"go:GO:0048696","description":"\"Any process that modulates the frequency, rate or extent of collateral sprouting in the absence of injury.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"53887a25fb11467489944cf80d972d2a","type":"GO_TERM","name":"regulation of collateral sprouting of injured axon","canonical_id":"go:GO:0048693","description":"\"Any process that modulates the frequency, rate or extent of collateral sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"c94d57050b414d76809d3ec83588478f","type":"GO_TERM","name":"regulation of collateral sprouting of intact axon in response to injury","canonical_id":"go:GO:0048683","description":"\"Any process that modulates the frequency, rate or extent of collateral sprouting of an intact axon as a result of injury to an axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"362b0c2f02e045a5acaefb6b30fe6ce0","type":"GO_TERM","name":"regulation of collecting lymphatic vessel constriction","canonical_id":"go:GO:1903814","description":"\"Any process that modulates the frequency, rate or extent of collecting lymphatic vessel constriction.\" [GO_REF:0000058, GOC:TermGenie, PMID:23897233]","metadata":null},{"id":"1bb256b94e2b4f43a93cc6336c63bdff","type":"GO_TERM","name":"regulation of colon smooth muscle contraction","canonical_id":"go:GO:1904341","description":"\"Any process that modulates the frequency, rate or extent of colon smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:24170253]","metadata":null},{"id":"f9dda133f66e4ea1bd8455a3be3c2e07","type":"GO_TERM","name":"regulation of complement activation","canonical_id":"go:GO:0030449","description":"\"Any process that modulates the frequency, rate or extent of complement activation.\" [GOC:curators]","metadata":null},{"id":"0182686326f14b3eb24f5551ae234b20","type":"GO_TERM","name":"regulation of complement activation, alternative pathway","canonical_id":"go:GO:0030451","description":"\"Any process that modulates the frequency, rate or extent of the alternative pathway of complement activation.\" [GOC:curators]","metadata":null},{"id":"c75390165e3a46a4ae7ec8123635871a","type":"GO_TERM","name":"regulation of complement activation, classical pathway","canonical_id":"go:GO:0030450","description":"\"Any process that modulates the frequency, rate or extent of the classical pathway of complement activation.\" [GOC:curators]","metadata":null},{"id":"28b8500b53564ba090740fb793599691","type":"GO_TERM","name":"regulation of complement activation, lectin pathway","canonical_id":"go:GO:0001868","description":"\"Any process that modulates the frequency, rate or extent of the lectin pathway of complement activation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c9d69ab3a66c47e0b325d836ce96ceaf","type":"GO_TERM","name":"regulation of complement-dependent cytotoxicity","canonical_id":"go:GO:1903659","description":"\"Any process that modulates the frequency, rate or extent of complement-dependent cytotoxicity.\" [GO_REF:0000058, GOC:TermGenie, PMID:24280217]","metadata":null},{"id":"6cd57d41c1bc46aab151f7a5adaed33e","type":"GO_TERM","name":"regulation of compound eye cone cell fate specification","canonical_id":"go:GO:0042682","description":"\"Any process that mediates the specification of a cell into a compound eye cone cell.\" [GOC:mtg_sensu]","metadata":null},{"id":"d1345754ddde4d10a265277eb681fa0c","type":"GO_TERM","name":"regulation of compound eye photoreceptor cell differentiation","canonical_id":"go:GO:0110116","description":"\"Any process that modulates the frequency, rate or extent of compound eye photoreceptor cell differentiation.\" [GOC:ha, PMID:16377567]","metadata":null},{"id":"5ded0f008f71481e82951b70b6ad83cf","type":"GO_TERM","name":"regulation of compound eye photoreceptor development","canonical_id":"go:GO:0045314","description":"\"Any process that modulates the frequency, rate or extent of compound eye photoreceptor development.\" [GOC:bf]","metadata":null},{"id":"a98b250813474f7595fd0f46f60736b5","type":"GO_TERM","name":"regulation of compound eye pigmentation","canonical_id":"go:GO:0048076","description":"\"Any process that modulates the frequency, rate or extent of establishment of a pattern of pigment in the compound eye.\" [GOC:jid]","metadata":null},{"id":"7b5299ff4cf94e1e9981a14213d41f7f","type":"GO_TERM","name":"regulation of compound eye retinal cell apoptotic process","canonical_id":"go:GO:1901692","description":"\"Any process that modulates the frequency, rate or extent of compound eye retinal cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:TermGenie, PMID:12021768]","metadata":null},{"id":"4b548afec4514196b4ea74e9c5cfceaa","type":"GO_TERM","name":"regulation of compound eye retinal cell programmed cell death","canonical_id":"go:GO:0046669","description":"\"Any process that modulates the frequency, rate or extent of programmed cell death that occurs in the compound eye retina.\" [GOC:ai]","metadata":null},{"id":"5a3c036be1c847edb26cfaaa6e1fe5fd","type":"GO_TERM","name":"regulation of conidiophore development","canonical_id":"go:GO:0070793","description":"\"Any process that modulates the frequency, rate or extent of conidiophore development, a process that leads to the formation of a conidiophore. The conidiophore is a specialized hypha that extends aerially from the growth substrate and bears conidia, or asexual spores.\" [GOC:mah]","metadata":null},{"id":"7a014f784d4d4ae3b11cf37a5fd8f316","type":"GO_TERM","name":"regulation of conidiophore stalk development","canonical_id":"go:GO:0070799","description":"\"Any process that modulates the frequency, rate or extent of conidiophore stalk development, a process that leads to the formation of a conidiophore stalk. The conidiophore stalk is part of a specialized hypha that extends aerially from the growth substrate and supports structures from which conidia, or asexual spores, develop.\" [GOC:mah]","metadata":null},{"id":"878408d434134716acc28c622c6701d8","type":"GO_TERM","name":"regulation of conidium formation","canonical_id":"go:GO:0075306","description":"\"Any process that modulates the frequency, rate or extent of conidium formation, a process of producing non-motile spores, called conidia, via mitotic asexual reproduction in higher fungi. Conidia are haploid cells genetically identical to their haploid parent. They are produced by conversion of hyphal elements, or are borne on sporogenous cells on or within specialized structures termed conidiophores, and participate in dispersal of the fungus.\" [GOC:di, GOC:pamgo_curators]","metadata":null},{"id":"61e44fc868974071bda22f972e9af2dc","type":"GO_TERM","name":"regulation of conjugation with cellular fusion","canonical_id":"go:GO:0031137","description":"\"Any process that modulates the rate or frequency of conjugation with cellular fusion.\" [GOC:mah]","metadata":null},{"id":"815dbe9643344ee297fc073cd88f29ad","type":"GO_TERM","name":"regulation of connective tissue growth factor production","canonical_id":"go:GO:0032643","description":"\"Any process that modulates the frequency, rate, or extent of connective tissue growth factor production.\" [GOC:mah]","metadata":null},{"id":"d7ef9bd1a19d48229b3c64021e89b7df","type":"GO_TERM","name":"regulation of connective tissue replacement","canonical_id":"go:GO:1905203","description":"\"Any process that modulates the frequency, rate or extent of connective tissue replacement.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25590961]","metadata":null},{"id":"012bb779833e4e948d85f6471561065e","type":"GO_TERM","name":"regulation of constitutive secretory pathway","canonical_id":"go:GO:1903433","description":"\"Any process that modulates the frequency, rate or extent of constitutive secretory pathway.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22899725]","metadata":null},{"id":"e21da3265a2440fb8c10dc39bcd89706","type":"GO_TERM","name":"regulation of convergent extension involved in axis elongation","canonical_id":"go:GO:1901232","description":"\"Any process that modulates the frequency, rate or extent of convergent extension involved in axis elongation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"19a6600b54014d39b302430d00dd795a","type":"GO_TERM","name":"regulation of convergent extension involved in gastrulation","canonical_id":"go:GO:1904103","description":"\"Any process that modulates the frequency, rate or extent of convergent extension involved in gastrulation.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:24892953]","metadata":null},{"id":"dfeffee4f5ef4c60ba9838ab57ee2338","type":"GO_TERM","name":"regulation of copper ion transmembrane transport","canonical_id":"go:GO:1902311","description":"\"Any process that modulates the frequency, rate or extent of copper ion transmembrane transport.\" [GOC:di, GOC:TermGenie, PMID:21489137]","metadata":null},{"id":"b79bab2682ba429e9b951308f40065d3","type":"GO_TERM","name":"regulation of cornification","canonical_id":"go:GO:1905715","description":"\"Any process that modulates the frequency, rate or extent of cornification.\" [GO_REF:0000058, GOC:TermGenie, PMID:26014679]","metadata":null},{"id":"3c049e838e724a8f904df8945d5f84f1","type":"GO_TERM","name":"regulation of corticosteroid hormone secretion","canonical_id":"go:GO:2000846","description":"\"Any process that modulates the frequency, rate or extent of corticosteroid hormone secretion.\" [GOC:sl]","metadata":null},{"id":"6dfc608a1ade4c5ca8a3b834e9f8d112","type":"GO_TERM","name":"regulation of corticosterone secretion","canonical_id":"go:GO:2000852","description":"\"Any process that modulates the frequency, rate or extent of corticosterone secretion.\" [GOC:sl]","metadata":null},{"id":"45d50e8216b34ef4aa50113d5e866a00","type":"GO_TERM","name":"regulation of corticotropin secretion","canonical_id":"go:GO:0051459","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of corticotropic hormone from a cell.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"c30b93370b264f6da424607e362f8dfc","type":"GO_TERM","name":"regulation of corticotropin-releasing hormone secretion","canonical_id":"go:GO:0043397","description":"\"Any process that modulates the frequency, rate or extent of corticotropin-releasing hormone secretion.\" [GOC:curators, PMID:11027914]","metadata":null},{"id":"7fcb39fa777b412da9f0b48c06f772b8","type":"GO_TERM","name":"regulation of cortisol biosynthetic process","canonical_id":"go:GO:2000064","description":"\"Any process that modulates the frequency, rate or extent of cortisol biosynthetic process.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"f15b579653f44be49ea1065e7a675ce9","type":"GO_TERM","name":"regulation of cortisol secretion","canonical_id":"go:GO:0051462","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of cortisol from a cell.\" [GOC:ai]","metadata":null},{"id":"39395a0309bd4a8ea5e9efe45a8f8522","type":"GO_TERM","name":"regulation of cristae formation","canonical_id":"go:GO:1903850","description":"\"Any process that modulates the frequency, rate or extent of cristae formation.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:19279012]","metadata":null},{"id":"3f8657f2138d46a982eaab1eeab75588","type":"GO_TERM","name":"regulation of crystal cell differentiation","canonical_id":"go:GO:0042689","description":"\"Any process that modulates the frequency, rate or extent of crystal cell differentiation.\" [GOC:curators]","metadata":null},{"id":"3d8b48ac29ad4c30b88da69928de405d","type":"GO_TERM","name":"regulation of cumulus cell differentiation","canonical_id":"go:GO:0045592","description":"\"Any process that modulates the frequency, rate or extent of ovarian cumulus cell differentiation.\" [GOC:curators]","metadata":null},{"id":"ef5cbfbe82c243f2ba9e2336913df5b4","type":"GO_TERM","name":"regulation of cuticle pigmentation","canonical_id":"go:GO:0048079","description":"\"Any process that modulates the frequency, rate or extent of establishment of a pattern of pigment in the cuticle of an organism.\" [GOC:jid]","metadata":null},{"id":"9e785ebfc01646009098f8a5d3041f3f","type":"GO_TERM","name":"regulation of cutin biosynthetic process","canonical_id":"go:GO:1901957","description":"\"Any process that modulates the frequency, rate or extent of cutin biosynthetic process.\" [GOC:tb, GOC:TermGenie, PMID:23243127]","metadata":null},{"id":"21732b0b49cb417ab229085a220ec84b","type":"GO_TERM","name":"regulation of cyanophore differentiation","canonical_id":"go:GO:0048781","description":"\"Any process that modulates the frequency, rate or extent of cyanophore differentiation.\" [GOC:mh]","metadata":null},{"id":"986bfbbfa25a470f9688c6db026bcebf","type":"GO_TERM","name":"regulation of cyclic nucleotide catabolic process","canonical_id":"go:GO:0030805","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of cyclic nucleotides.\" [GOC:mah]","metadata":null},{"id":"f7341653c5bd47ea91af18a6cc191515","type":"GO_TERM","name":"regulation of cyclic nucleotide-gated ion channel activity","canonical_id":"go:GO:1902159","description":"\"Any process that modulates the frequency, rate or extent of cyclic nucleotide-gated ion channel activity.\" [GOC:TermGenie, PMID:11420311]","metadata":null},{"id":"71827d65ae434f419f37d0dc4ebaef7a","type":"GO_TERM","name":"regulation of cyclin-dependent protein serine/threonine kinase activity","canonical_id":"go:GO:0000079","description":"\"Any process that modulates the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity.\" [GOC:curators, GOC:pr]","metadata":null},{"id":"044290eaf8954841ac37291f3e73f680","type":"GO_TERM","name":"regulation of cyclodextrin catabolic process","canonical_id":"go:GO:2000957","description":"\"Any process that modulates the frequency, rate or extent of cyclodextrin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"2afeb1f1304d4d758ebcfdd618ba615b","type":"GO_TERM","name":"regulation of cytochrome-c oxidase activity","canonical_id":"go:GO:1904959","description":"\"Any process that modulates the frequency, rate or extent of cytochrome-c oxidase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:26734017]","metadata":null},{"id":"b070adbd72664136bccda427ac69c82a","type":"GO_TERM","name":"regulation of cytokine activity","canonical_id":"go:GO:0060300","description":"\"Any process that modulates the rate, frequency or extent of the activity of a molecule that controls the survival, growth, differentiation and effector function of tissues and cells.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"580bf1fe421c4e5fac5df23a55776cb6","type":"GO_TERM","name":"regulation of cytokine production","canonical_id":"go:GO:0001817","description":"\"Any process that modulates the frequency, rate, or extent of production of a cytokine.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"93f5551434484640aa708a582b557d0f","type":"GO_TERM","name":"regulation of cytokine production involved in immune response","canonical_id":"go:GO:0002718","description":"\"Any process that modulates the frequency, rate, or extent of cytokine production that contributes to an immune response.\" [GOC:add]","metadata":null},{"id":"6603c60f7c4740979e925c167b23af3c","type":"GO_TERM","name":"regulation of cytokine production involved in inflammatory response","canonical_id":"go:GO:1900015","description":"\"Any process that modulates the frequency, rate or extent of cytokine production involved in inflammatory response.\" [GOC:TermGenie]","metadata":null},{"id":"63873da532f14c17ac969717b7c37446","type":"GO_TERM","name":"regulation of cytokine-mediated signaling pathway","canonical_id":"go:GO:0001959","description":"\"Any process that modulates the frequency, rate or extent of the cytokine mediated signaling pathway.\" [GOC:hjd]","metadata":null},{"id":"ccf24650e21c42f28a642144e5874361","type":"GO_TERM","name":"regulation of cytokinesis","canonical_id":"go:GO:0032465","description":"\"Any process that modulates the frequency, rate or extent of the division of the cytoplasm of a cell and its separation into two daughter cells.\" [GOC:mah]","metadata":null},{"id":"9567946f3747412ea942180aa942b251","type":"GO_TERM","name":"regulation of cytokinesis, actomyosin contractile ring assembly","canonical_id":"go:GO:2000431","description":"\"Any process that modulates the frequency, rate or extent of cytokinesis, actomyosin contractile ring assembly.\" [GOC:obol]","metadata":null},{"id":"186704ea4b3242518762f38b5fa51c7f","type":"GO_TERM","name":"regulation of cytokinesis, site selection","canonical_id":"go:GO:2000073","description":"\"Any process that modulates the frequency, rate or extent of site selection that occurs as part of cytokinesis.\" [GOC:mtg_cell_cycle, GOC:obol]","metadata":null},{"id":"0b01757893a64feba9d884c0d2703c9b","type":"GO_TERM","name":"regulation of cytokinetic process","canonical_id":"go:GO:0032954","description":"\"Any process that modulates the frequency, rate or extent of a cytokinetic process.\" [GOC:mah]","metadata":null},{"id":"2141e2aaa08b4821bcf48129368269fa","type":"GO_TERM","name":"regulation of cytokinin-activated signaling pathway","canonical_id":"go:GO:0080036","description":"\"Any process that modulates the frequency, rate or extent of cytokinin signaling.\" [GOC:dhl]","metadata":null},{"id":"ce7be50efcda4963a1e05789e0fb48ad","type":"GO_TERM","name":"regulation of cytolysis","canonical_id":"go:GO:0042268","description":"\"Any process that modulates the frequency, rate or extent of the rupture of cell membranes and the loss of cytoplasm.\" [GOC:jl, GOC:mtg_apoptosis]","metadata":null},{"id":"c6bc934e62544576a2010765a04a0385","type":"GO_TERM","name":"regulation of cytoplasmic mRNA processing body assembly","canonical_id":"go:GO:0010603","description":"\"Any process that modulates the rate, frequency, or extent of the aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic mRNA processing body.\" [GOC:dph, GOC:krc, GOC:tb]","metadata":null},{"id":"cb455fe1ac28448e937d1b07c08163ca","type":"GO_TERM","name":"regulation of cytoplasmic microtubule depolymerization","canonical_id":"go:GO:0010937","description":"\"Any process that modulates the frequency, rate or extent of cytoplasmic microtubule depolymerization.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2437f89e524041719cd94f234af7bfbc","type":"GO_TERM","name":"regulation of cytoplasmic pattern recognition receptor signaling pathway","canonical_id":"go:GO:0039531","description":"\"Any process that modulates the frequency, rate or extent of a cytoplasmic pattern recognition receptor signaling pathway.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"b5605e65b8024980a142c5f27ec07039","type":"GO_TERM","name":"regulation of cytoplasmic stress granule assembly","canonical_id":"go:GO:0062028","description":"\"Any process that modulates the rate, frequency or extent of cytoplasmic stress granule assembly, the aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic stress granule.\" [PMID:20180778]","metadata":null},{"id":"6c7c077ede044138895c7f9c1986a0df","type":"GO_TERM","name":"regulation of cytoplasmic translation","canonical_id":"go:GO:2000765","description":"\"Any process that modulates the frequency, rate or extent of cytoplasmic translation.\" [GOC:obol]","metadata":null},{"id":"72f94e5707b84ed598c4bf0332419a63","type":"GO_TERM","name":"regulation of cytoplasmic translation in response to stress","canonical_id":"go:GO:1990497","description":"\"Modulation of the frequency, rate or extent of cytoplasmic translation as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:vw, PMID:16278445]","metadata":null},{"id":"d27157d2e1984a208146fe9ee2ac3e05","type":"GO_TERM","name":"regulation of cytoplasmic translational elongation","canonical_id":"go:GO:1900247","description":"\"Any process that modulates the frequency, rate or extent of cytoplasmic translational elongation.\" [GOC:TermGenie]","metadata":null},{"id":"f091243a501148b083341ccbb472df6d","type":"GO_TERM","name":"regulation of cytoplasmic translational elongation through polyproline stretches","canonical_id":"go:GO:1903270","description":"\"Any process that modulates the frequency, rate or extent of cytoplasmic translational elongation through polyproline stretches.\" [GO_REF:0000058, GOC:TermGenie, PMID:24923804]","metadata":null},{"id":"81b16231dd8d4fcfa71ac9a6aba63eb3","type":"GO_TERM","name":"regulation of cytoplasmic translational fidelity","canonical_id":"go:GO:0140018","description":"\"Any process that modulates the ability of the cytoplasmic translational apparatus to interpret the genetic code.\" [PMID:22768388]","metadata":null},{"id":"cc8db6a929c94bd9b0119643d77d25de","type":"GO_TERM","name":"regulation of cytoplasmic translational initiation","canonical_id":"go:GO:1904688","description":"\"Any process that modulates the frequency, rate or extent of cytoplasmic translational initiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:12242291]","metadata":null},{"id":"18a85ef86ea446d4839c7cfc894d2e56","type":"GO_TERM","name":"regulation of cytoplasmic translational initiation in response to stress","canonical_id":"go:GO:1990611","description":"\"Modulation of the frequency, rate or extent of cytoplasmic translational initiation as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [PMID:16278445]","metadata":null},{"id":"a14cf85f16e349748b03d3044a2696d8","type":"GO_TERM","name":"regulation of cytoplasmic translational termination","canonical_id":"go:GO:1990580","description":"\"Any process that modulates the frequency, rate or extent of cytoplasmic translational termination.\" [PMID:11570975]","metadata":null},{"id":"292030a08d91442e94a6bbd69712321c","type":"GO_TERM","name":"regulation of cytoskeleton organization","canonical_id":"go:GO:0051493","description":"\"Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures.\" [GOC:ai]","metadata":null},{"id":"36d1b033a0ff422296ea4a5cd471043a","type":"GO_TERM","name":"regulation of cytosolic calcium ion concentration","canonical_id":"go:GO:0051480","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions within the cytosol of a cell or between the cytosol and its surroundings.\" [GOC:ai, GOC:mah, GOC:rph]","metadata":null},{"id":"bdacc7c7dbcb46118d25adc78cade503","type":"GO_TERM","name":"regulation of cytotoxic T cell degranulation","canonical_id":"go:GO:0043317","description":"\"Any process that modulates the frequency, rate, or extent of cytotoxic T cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"c4c209cc756145e0b85d2d9f7ae00027","type":"GO_TERM","name":"regulation of cytotoxic T cell differentiation","canonical_id":"go:GO:0045583","description":"\"Any process that modulates the frequency, rate or extent of cytotoxic T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"60d7270bf83643f6b44aa571bfd6311a","type":"GO_TERM","name":"regulation of dCDP biosynthetic process","canonical_id":"go:GO:1903528","description":"\"Any process that modulates the frequency, rate or extent of dCDP biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:16317005]","metadata":null},{"id":"a4266b798b7e4378b70f6fda2e068d71","type":"GO_TERM","name":"regulation of dauer entry","canonical_id":"go:GO:1905909","description":"\"Any process that modulates the frequency, rate or extent of dauer entry.\" [GO_REF:0000058, GOC:TermGenie, PMID:21531333]","metadata":null},{"id":"1a6be7d041714663bd92a1fc1b672c31","type":"GO_TERM","name":"regulation of dauer larval development","canonical_id":"go:GO:0061065","description":"\"Any process that modulates the rate, frequency, or extent of dauer larval development, the process whose specific outcome is the progression of the dauer larva over time, through the facultative diapause of the dauer (enduring) larval stage, with specialized traits adapted for dispersal and long-term survival, with elevated stress resistance and without feeding.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"fd84e0e97036498dbc9cfa28003d7694","type":"GO_TERM","name":"regulation of deacetylase activity","canonical_id":"go:GO:0150065","description":"\"Any process that modulates the frequency, rate or extent of deacetylase activity.\" [GOC:aruk, GOC:bc, PMID:19457097]","metadata":null},{"id":"73679b426c1746d097106e1b3d6a42c6","type":"GO_TERM","name":"regulation of deadenylation-dependent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:0106288","description":"\"Any process that modulates the frequency, rate or extent of deadenylation-dependent decapping of nuclear-transcribed mRNA.\" [PMID:32354837]","metadata":null},{"id":"060f9059063c45218c0a95b52eca1652","type":"GO_TERM","name":"regulation of deadenylation-independent decapping of nuclear-transcribed mRNA","canonical_id":"go:GO:1901834","description":"\"Any process that modulates the frequency, rate or extent of deadenylation-independent decapping of nuclear-transcribed mRNA.\" [GOC:TermGenie]","metadata":null},{"id":"0a223cbebaaf482fa1c8914d3208876a","type":"GO_TERM","name":"regulation of death-inducing signaling complex assembly","canonical_id":"go:GO:1903072","description":"\"Any process that modulates the frequency, rate or extent of death-inducing signaling complex assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21785459]","metadata":null},{"id":"9e37846d9f43481eb211c1fcdf8229dc","type":"GO_TERM","name":"regulation of defecation","canonical_id":"go:GO:2000292","description":"\"Any process that modulates the frequency, rate or extent of defecation.\" [GOC:obol]","metadata":null},{"id":"835ff6ada25d405f9e1c93f019846930","type":"GO_TERM","name":"regulation of defecation rhythm","canonical_id":"go:GO:2000746","description":"\"Any process that modulates the frequency, rate or extent of defecation rhythm.\" [GOC:kmv]","metadata":null},{"id":"03bdb1592d6144bda6867922384b563f","type":"GO_TERM","name":"regulation of defense response","canonical_id":"go:GO:0031347","description":"\"Any process that modulates the frequency, rate or extent of a defense response.\" [GOC:mah]","metadata":null},{"id":"61bdd29ebd9146d5985dd40ab71aaf82","type":"GO_TERM","name":"regulation of defense response by callose deposition","canonical_id":"go:GO:2000071","description":"\"Any process that modulates the frequency, rate or extent of defense response by callose deposition.\" [GOC:obol]","metadata":null},{"id":"23ef9f9497074cb2bfd9c40752cdd52b","type":"GO_TERM","name":"regulation of defense response to bacterium","canonical_id":"go:GO:1900424","description":"\"Any process that modulates the frequency, rate or extent of defense response to bacterium.\" [GOC:TermGenie, PMID:22346749]","metadata":null},{"id":"8870b4d63afc4ede97b57353842a65c9","type":"GO_TERM","name":"regulation of defense response to fungus","canonical_id":"go:GO:1900150","description":"\"Any process that modulates the frequency, rate or extent of defense response to fungus.\" [GOC:dhl, GOC:TermGenie, PMID:22242006]","metadata":null},{"id":"b5e05091f9204a3db2bcba81365c8cb1","type":"GO_TERM","name":"regulation of defense response to insect","canonical_id":"go:GO:2000068","description":"\"Any process that modulates the frequency, rate or extent of defense response to insect.\" [GOC:obol]","metadata":null},{"id":"566042f574b64364a9e17c32b3f13f2c","type":"GO_TERM","name":"regulation of defense response to oomycetes","canonical_id":"go:GO:1902288","description":"\"Any process that modulates the frequency, rate or extent of defense response to oomycetes.\" [GOC:TermGenie, PMID:16040633]","metadata":null},{"id":"92cd2fca66114fe3977cddc496c5ea78","type":"GO_TERM","name":"regulation of defense response to virus","canonical_id":"go:GO:0050688","description":"\"Any process that modulates the frequency, rate or extent of the antiviral response of a cell or organism.\" [GOC:ai]","metadata":null},{"id":"eb035c1be59445ca876aa75f2cbd974b","type":"GO_TERM","name":"regulation of defense response to virus by host","canonical_id":"go:GO:0050691","description":"\"Any host process that modulates the frequency, rate, or extent of the antiviral response of a host cell or organism.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"9f524d9966664086887d696826e1d88d","type":"GO_TERM","name":"regulation of definitive erythrocyte differentiation","canonical_id":"go:GO:0010724","description":"\"Any process that modulates the rate, frequency, or extent of definitive erythrocyte differentiation. Definitive erythrocyte differentiation occurs as part of the process of definitive hemopoiesis.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"41b84cfd3de34990a1cc5065d6098d6b","type":"GO_TERM","name":"regulation of dehydroaustinol biosynthetic process","canonical_id":"go:GO:1900649","description":"\"Any process that modulates the frequency, rate or extent of dehydroaustinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"9036e42a3399400daca9aa3e73a98aee","type":"GO_TERM","name":"regulation of dehydroepiandrosterone secretion","canonical_id":"go:GO:2000840","description":"\"Any process that modulates the frequency, rate or extent of dehydroepiandrosterone secretion.\" [GOC:sl]","metadata":null},{"id":"6d72ecc29aba4a769bddce1022aa0ddb","type":"GO_TERM","name":"regulation of delayed rectifier potassium channel activity","canonical_id":"go:GO:1902259","description":"\"Any process that modulates the frequency, rate or extent of delayed rectifier potassium channel activity.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11299204]","metadata":null},{"id":"cf452ca6374042efa1ac421039d07aea","type":"GO_TERM","name":"regulation of demethylkotanin biosynthetic process","canonical_id":"go:GO:1900652","description":"\"Any process that modulates the frequency, rate or extent of demethylkotanin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"9b69208477c246f1b6d6076b3d7f17f6","type":"GO_TERM","name":"regulation of dendrite development","canonical_id":"go:GO:0050773","description":"\"Any process that modulates the frequency, rate or extent of dendrite development.\" [GOC:ai]","metadata":null},{"id":"5ca2b50f9eba4cd3be15bd03afbbb582","type":"GO_TERM","name":"regulation of dendrite extension","canonical_id":"go:GO:1903859","description":"\"Any process that modulates the frequency, rate or extent of dendrite extension.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24898855]","metadata":null},{"id":"fc9810e918434c8280307e9e394a0cad","type":"GO_TERM","name":"regulation of dendrite morphogenesis","canonical_id":"go:GO:0048814","description":"\"Any process that modulates the frequency, rate or extent of dendrite morphogenesis.\" [GOC:ai]","metadata":null},{"id":"1ef8df68b27e47699781d296637f1d56","type":"GO_TERM","name":"regulation of dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002604","description":"\"Any process that modulates the frequency, rate, or extent of dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"5e8d117882ec46a9845a83a213d169af","type":"GO_TERM","name":"regulation of dendritic cell apoptotic process","canonical_id":"go:GO:2000668","description":"\"Any process that modulates the frequency, rate or extent of dendritic cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"50dcb2f0ea964783b2162982e4da6f51","type":"GO_TERM","name":"regulation of dendritic cell chemotaxis","canonical_id":"go:GO:2000508","description":"\"Any process that modulates the frequency, rate or extent of dendritic cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"02d729aabd8c4bfe9da6cdfa09042e57","type":"GO_TERM","name":"regulation of dendritic cell cytokine production","canonical_id":"go:GO:0002730","description":"\"Any process that modulates the frequency, rate, or extent of dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"8f103a771c0945d38319b9eec6e102fc","type":"GO_TERM","name":"regulation of dendritic cell dendrite assembly","canonical_id":"go:GO:2000547","description":"\"Any process that modulates the frequency, rate or extent of dendritic cell dendrite assembly.\" [GOC:obol]","metadata":null},{"id":"b4f2616e7e1f4967a99576493def8957","type":"GO_TERM","name":"regulation of dendritic cell differentiation","canonical_id":"go:GO:2001198","description":"\"Any process that modulates the frequency, rate or extent of dendritic cell differentiation.\" [GOC:obol]","metadata":null},{"id":"2c82844af2484bb2bd1eaf0cb987cfa3","type":"GO_TERM","name":"regulation of dendritic spine development","canonical_id":"go:GO:0060998","description":"\"Any process that modulates the rate, frequency, or extent of dendritic spine development, the process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"2bc564c30f2c4d0d8e6b1067cdb87d5d","type":"GO_TERM","name":"regulation of dendritic spine maintenance","canonical_id":"go:GO:1902950","description":"\"Any process that modulates the frequency, rate or extent of dendritic spine maintenance.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24328732]","metadata":null},{"id":"c3747ac3168448e8a90f02346c5b9413","type":"GO_TERM","name":"regulation of dendritic spine morphogenesis","canonical_id":"go:GO:0061001","description":"\"Any process that modulates the rate, frequency, or extent of dendritic spine morphogenesis, the process in which the anatomical structures of a dendritic spine are generated and organized. A dendritic spine is a protrusion from a dendrite and a specialized subcellular compartment involved in synaptic transmission.\" [GOC:dph]","metadata":null},{"id":"6ce149342bcf4004ad4f21e1766cbf85","type":"GO_TERM","name":"regulation of dense core granule biogenesis","canonical_id":"go:GO:2000705","description":"\"Any process that modulates the frequency, rate or extent of dense core granule biogenesis.\" [GOC:obol]","metadata":null},{"id":"3d8fc328d90241a8b083cd45f5a5a974","type":"GO_TERM","name":"regulation of dense core granule exocytosis","canonical_id":"go:GO:1905413","description":"\"Any process that modulates the frequency, rate or extent of dense core granule exocytosis.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18468511]","metadata":null},{"id":"ab89649ad7744653805c70aeaaa8d469","type":"GO_TERM","name":"regulation of dense core granule transport","canonical_id":"go:GO:1904809","description":"\"Any process that modulates the frequency, rate or extent of dense core granule transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22699897]","metadata":null},{"id":"4fb3d07019ef4a858fcba967155c7905","type":"GO_TERM","name":"regulation of dephosphorylation","canonical_id":"go:GO:0035303","description":"\"Any process that modulates the frequency, rate or extent of removal of phosphate groups from a molecule.\" [GOC:bf]","metadata":null},{"id":"c38ceed7ba404039a14fe418e689dc3a","type":"GO_TERM","name":"regulation of dermatome development","canonical_id":"go:GO:0061183","description":"\"Any process that modulates the rate, frequency, or extent of the progression of the dermatome over time, from its initial formation to the mature structure. The dermatome is the portion of a somite that will form skin.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"573251c725d84fee85de9500000b19e4","type":"GO_TERM","name":"regulation of detection of glucose","canonical_id":"go:GO:2000970","description":"\"Any process that modulates the frequency, rate or extent of detection of glucose.\" [GOC:BHF]","metadata":null},{"id":"60ae5ed3989941ed8d41b06166ed0ecc","type":"GO_TERM","name":"regulation of determination of dorsal identity","canonical_id":"go:GO:2000015","description":"\"Any process that modulates the frequency, rate or extent of determination of dorsal identity.\" [GOC:obol]","metadata":null},{"id":"218a189bbff747e3bc392810c05dfd32","type":"GO_TERM","name":"regulation of development of symbiont in host","canonical_id":"go:GO:0044127","description":"\"Any process in which the symbiont regulates its progression from an initial condition to a later condition, within the cells or tissues of the host organism. This may (but not necessarily) include a filamentous growth form, and also can include secretion of proteases and lipases to break down. The host is defined as the larger of the organisms involved in the symbiotic interaction.\" [GOC:jl, GOC:pamgo_curators]","metadata":null},{"id":"0b6253481f5d4aa2be9410c62d5e654a","type":"GO_TERM","name":"regulation of development, heterochronic","canonical_id":"go:GO:0040034","description":"\"Any process that modulates the consistent predetermined time point at which an integrated living unit or organism progresses from an initial condition to a later condition and the rate at which this time point is reached.\" [PMID:9442909]","metadata":null},{"id":"e18b80b2b4eb41d0aafd7d4224d53010","type":"GO_TERM","name":"regulation of developmental growth","canonical_id":"go:GO:0048638","description":"\"Any process that modulates the frequency, rate or extent of developmental growth.\" [GOC:curators]","metadata":null},{"id":"28967d5557324bb493b14b405a2280f7","type":"GO_TERM","name":"regulation of developmental pigmentation","canonical_id":"go:GO:0048070","description":"\"Any process that modulates the frequency, rate or extent of the developmental process that results in the deposition of coloring matter in an organism.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"177320e51fc5480da9037d6cb6d5cfd5","type":"GO_TERM","name":"regulation of developmental process","canonical_id":"go:GO:0050793","description":"\"Any process that modulates the frequency, rate or extent of development, the biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote, or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).\" [GOC:curators]","metadata":null},{"id":"5eee58eaa2b94f6fbe59492bce4217a1","type":"GO_TERM","name":"regulation of developmental vegetative growth","canonical_id":"go:GO:1905613","description":"\"Any process that modulates the frequency, rate or extent of developmental vegetative growth.\" [GO_REF:0000058, GOC:TermGenie, PMID:11606552]","metadata":null},{"id":"4579ff1e4b2f447db5b9191eaf836109","type":"GO_TERM","name":"regulation of diacylglycerol biosynthetic process","canonical_id":"go:GO:1900480","description":"\"Any process that modulates the frequency, rate or extent of diacylglycerol biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"a82449e282ee4effabb5ebaaf8c409b3","type":"GO_TERM","name":"regulation of digestive system process","canonical_id":"go:GO:0044058","description":"\"Any process that modulates the frequency, rate or extent of a digestive system process, a physical, chemical, or biochemical process carried out by living organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.\" [GOC:jl]","metadata":null},{"id":"62f2fad49ca045168b28111be2af0b92","type":"GO_TERM","name":"regulation of dipeptide transmembrane transport","canonical_id":"go:GO:2001148","description":"\"Any process that modulates the frequency, rate or extent of dipeptide transmembrane transport.\" [GOC:obol]","metadata":null},{"id":"61482391133f4eb482877997ca478f0e","type":"GO_TERM","name":"regulation of dipeptide transport","canonical_id":"go:GO:0090089","description":"\"Any process that modulates the rate, frequency or extent of dipeptide transport. Dipeptide transport is the directed movement of a dipeptide, a combination of two amino acids by means of a peptide (-CO-NH-) link, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9537e2d80b1b42268655c562acc67a56","type":"GO_TERM","name":"regulation of direction of cell growth","canonical_id":"go:GO:0061389","description":"\"Any process that modulates the direction of cell growth.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"98bb8cc194b346eca5e58870fe2a13e2","type":"GO_TERM","name":"regulation of distal tip cell migration","canonical_id":"go:GO:1903354","description":"\"Any process that modulates the frequency, rate or extent of distal tip cell migration.\" [GO_REF:0000058, GOC:mm2, GOC:TermGenie, PMID:24968003]","metadata":null},{"id":"41ae924243ba4591ae13d918030f238d","type":"GO_TERM","name":"regulation of division septum assembly","canonical_id":"go:GO:0032955","description":"\"Any process that modulates the frequency, rate or extent of division septum formation. Division septum formation is the assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis.\" [GOC:mtg_cell_cycle, PMID:19959363, PMID:21246752, PMID:22786806]","metadata":null},{"id":"121a185aea1d4eab9a2de76c07fa45f3","type":"GO_TERM","name":"regulation of dolichyl monophosphate biosynthetic process","canonical_id":"go:GO:0010794","description":"\"Any process that modulates the frequency, rate or extent of dolichol biosynthesis. Dolichol biosynthesis consists of the chemical reactions and pathways resulting in the formation of dolichols, any 2,3-dihydropolyprenol derived from four or more linked isoprene units.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4bb8110157184ee18b928c7b76df711b","type":"GO_TERM","name":"regulation of dopamine biosynthetic process","canonical_id":"go:GO:1903179","description":"\"Any process that modulates the frequency, rate or extent of dopamine biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"4233440ad54247be85c8b29ef44d8927","type":"GO_TERM","name":"regulation of dopamine metabolic process","canonical_id":"go:GO:0042053","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving dopamine.\" [GOC:curators]","metadata":null},{"id":"ce4d3c37c66b433a9b9ea9b6f44de086","type":"GO_TERM","name":"regulation of dopamine receptor signaling pathway","canonical_id":"go:GO:0060159","description":"\"Any process that modulates the frequency, rate or extent of a dopamine receptor signaling pathway activity. A dopamine receptor signaling pathway is the series of molecular signals generated as a consequence of a dopamine receptor binding to one of its physiological ligands.\" [GOC:dph]","metadata":null},{"id":"46ef1ad6e9714255854a46e49a765783","type":"GO_TERM","name":"regulation of dopamine secretion","canonical_id":"go:GO:0014059","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of dopamine.\" [GOC:ef]","metadata":null},{"id":"227e0a878f654104b5b4bf5c0a4d4ece","type":"GO_TERM","name":"regulation of dopamine uptake involved in synaptic transmission","canonical_id":"go:GO:0051584","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of the catecholamine neurotransmitter dopamine into a cell.\" [GOC:ai]","metadata":null},{"id":"543b2842e60a459d88dfc10147cf5987","type":"GO_TERM","name":"regulation of dopaminergic neuron differentiation","canonical_id":"go:GO:1904338","description":"\"Any process that modulates the frequency, rate or extent of dopaminergic neuron differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15522889]","metadata":null},{"id":"8c0913b8f01c4f0c9a6b2c01dcd428b7","type":"GO_TERM","name":"regulation of dorsal/ventral axon guidance","canonical_id":"go:GO:1905815","description":"\"Any process that modulates the frequency, rate or extent of dorsal/ventral axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:18434533]","metadata":null},{"id":"0ac1ed097fb04490b9723c62e4f9a8b3","type":"GO_TERM","name":"regulation of double fertilization forming a zygote and endosperm","canonical_id":"go:GO:0080155","description":"\"Any process that modulates the rate, frequency or extent of double fertilization forming a zygote and endosperm. Double fertilization forming a zygote and endosperm is a type of fertilization where one of the two sperm nuclei from the pollen tube fuses with the egg nucleus to form a 2n zygote, and the other fuses with the two polar nuclei to form the 3n primary endosperm nucleus and then develops into the endosperm. The ploidy level of the 2n zygote and 3n primary endosperm nucleus is determined by the ploidy level of the parents involved. An example of this component is found in Arabidopsis thaliana.\" [GOC:DHL, PMID:20478994]","metadata":null},{"id":"ec6505782d7542bcb6553b9d34af763a","type":"GO_TERM","name":"regulation of double-strand break repair","canonical_id":"go:GO:2000779","description":"\"Any process that modulates the frequency, rate or extent of double-strand break repair.\" [GOC:BHF]","metadata":null},{"id":"5d1c6e3adaef4d86b420d127e39f321e","type":"GO_TERM","name":"regulation of double-strand break repair via break-induced replication","canonical_id":"go:GO:1901591","description":"\"Any process that modulates the frequency, rate or extent of double-strand break repair via break-induced replication.\" [GOC:TermGenie]","metadata":null},{"id":"42aba721d52346b29d46515b818a8d2e","type":"GO_TERM","name":"regulation of double-strand break repair via homologous recombination","canonical_id":"go:GO:0010569","description":"\"Any process that modulates the frequency, rate or extent of the error-free repair of a double-strand break in DNA in which the broken DNA molecule is repaired using homologous sequences.\" [GOC:dph, GOC:jp, GOC:tb]","metadata":null},{"id":"1c3a8061549f4bacb805e3ed061a52c9","type":"GO_TERM","name":"regulation of double-strand break repair via nonhomologous end joining","canonical_id":"go:GO:2001032","description":"\"Any process that modulates the frequency, rate or extent of double-strand break repair via nonhomologous end joining.\" [GOC:obol]","metadata":null},{"id":"f731d91002db4b83bd9a193a4f0de960","type":"GO_TERM","name":"regulation of double-strand break repair via single-strand annealing, removal of nonhomologous ends","canonical_id":"go:GO:1903776","description":"\"Any process that modulates the frequency, rate or extent of double-strand break repair via single-strand annealing, removal of nonhomologous ends.\" [GO_REF:0000058, GOC:TermGenie, PMID:25203555]","metadata":null},{"id":"386841d217f84abe823209e343869899","type":"GO_TERM","name":"regulation of ductus arteriosus closure","canonical_id":"go:GO:1904335","description":"\"Any process that modulates the frequency, rate or extent of ductus arteriosus closure.\" [GO_REF:0000058, GOC:TermGenie, PMID:16303610]","metadata":null},{"id":"f63de0ef01e8459494e3961dfd3b57c8","type":"GO_TERM","name":"regulation of eIF2 alpha phosphorylation by dsRNA","canonical_id":"go:GO:0060735","description":"\"Any process that modulates the rate, frequency, or extent of eIF2 alpha phosphorylation as a cellular response to double-stranded RNA.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2fbe2d755aa445f895412989985c4f61","type":"GO_TERM","name":"regulation of eIF2 alpha phosphorylation by heme","canonical_id":"go:GO:0010999","description":"\"Any process that modulates the rate, frequency, or extent of eIF2 alpha phosphorylation as a result of heme levels.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"ffa3dd87d9ad4772b6a27c745486f1e2","type":"GO_TERM","name":"regulation of early endosome to late endosome transport","canonical_id":"go:GO:2000641","description":"\"Any process that modulates the frequency, rate or extent of early endosome to late endosome transport.\" [GOC:BHF]","metadata":null},{"id":"3791d655716a443881026a02e1fb06fd","type":"GO_TERM","name":"regulation of early stripe melanocyte differentiation","canonical_id":"go:GO:0050939","description":"\"Any process that modulates the frequency, rate or extent of early stripe melanocyte differentiation.\" [GOC:ai]","metadata":null},{"id":"e0d2bb67b491431bb023d99998c731a6","type":"GO_TERM","name":"regulation of eating behavior","canonical_id":"go:GO:1903998","description":"\"Any process that modulates the frequency, rate or extent of eating behavior.\" [GO_REF:0000058, GOC:TermGenie, PMID:11961051]","metadata":null},{"id":"40413a3952624149b3403dccca47ab97","type":"GO_TERM","name":"regulation of ecdysone receptor signaling pathway","canonical_id":"go:GO:0120141","description":"\"Any process that modulates the frequency, rate or extent of the activity of any ecdysone receptor signaling pathway.\" [GOC:ha, PMID:23072462]","metadata":null},{"id":"d2ffdfef198b454fb1f5d2bda24d525b","type":"GO_TERM","name":"regulation of ecdysteroid biosynthetic process","canonical_id":"go:GO:0007554","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ecdysteroids.\" [GOC:curators]","metadata":null},{"id":"c8a81f6862614462982151e9a34b89c1","type":"GO_TERM","name":"regulation of ecdysteroid metabolic process","canonical_id":"go:GO:0007553","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving ecdysteroids, a group of polyhydroxylated ketosteroids which initiate post-embryonic development, including the metamorphosis of immature forms and the development of the reproductive system and the maturation of oocytes in adult females.\" [ISBN:0198506732]","metadata":null},{"id":"829d0461a1d7448f9298142e65990d98","type":"GO_TERM","name":"regulation of ecdysteroid secretion","canonical_id":"go:GO:0007555","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of ecdysteroid from a cell.\" [GOC:curators]","metadata":null},{"id":"e25a762ac00949a6bd29455b747fa4e9","type":"GO_TERM","name":"regulation of eclosion","canonical_id":"go:GO:0007563","description":"\"Any process that modulates the frequency, rate or extent of the emergence of an insect from a pupa-case or of a larva from an egg.\" [GOC:curators, ISBN:0198600461]","metadata":null},{"id":"c7f561aa45cf4a46af6a0f214aa89c4f","type":"GO_TERM","name":"regulation of ectoderm development","canonical_id":"go:GO:2000383","description":"\"Any process that modulates the frequency, rate or extent of ectoderm development.\" [GOC:BHF]","metadata":null},{"id":"18b537e8bde748a9b3f070bfcd5053c5","type":"GO_TERM","name":"regulation of ectodermal cell fate specification","canonical_id":"go:GO:0042665","description":"\"Any process that mediates the specification of a cell into an ectoderm cell.\" [GOC:curators]","metadata":null},{"id":"912b65a6142a492fa9157f4aabc29914","type":"GO_TERM","name":"regulation of egg-laying behavior","canonical_id":"go:GO:0046662","description":"\"Any process that modulates the frequency, rate or extent of the deposition of eggs, either fertilized or not, upon a surface or into a medium.\" [GOC:dph, GOC:tb, PMID:11932766]","metadata":null},{"id":"28f0e8c3c21945268c81b1af909b623a","type":"GO_TERM","name":"regulation of elastin catabolic process","canonical_id":"go:GO:0060310","description":"\"Any process that modulates the rate, frequency or extent of elastin catabolism, the chemical reactions and pathways resulting in the breakdown of elastin.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"725fc8127bd944ec99ef110407c99ed4","type":"GO_TERM","name":"regulation of embryo sac central cell differentiation","canonical_id":"go:GO:0045691","description":"\"Any process that modulates the frequency, rate or extent of female gametophyte central cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"2995ca898dab4a8487dcfae7c0ff9110","type":"GO_TERM","name":"regulation of embryo sac egg cell differentiation","canonical_id":"go:GO:0045694","description":"\"Any process that modulates the frequency, rate or extent of embryo sac egg cell differentiation.\" [GOC:curators, GOC:mtg_plant]","metadata":null},{"id":"87243de726be4cd88308a09590b84962","type":"GO_TERM","name":"regulation of embryonic camera-type eye development","canonical_id":"go:GO:1902863","description":"\"Any process that modulates the frequency, rate or extent of embryonic camera-type eye development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"3c26e98816374f24a1586c7fe88518c3","type":"GO_TERM","name":"regulation of embryonic cell shape","canonical_id":"go:GO:0016476","description":"\"Any process that modulates the surface configuration of an embryonic cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d1223aeb08764404a7fc097ef6eb54c4","type":"GO_TERM","name":"regulation of embryonic development","canonical_id":"go:GO:0045995","description":"\"Any process that modulates the frequency, rate or extent of embryonic development.\" [GOC:curators]","metadata":null},{"id":"eae6fe2746e54cb2885937305bc18f94","type":"GO_TERM","name":"regulation of embryonic pattern specification","canonical_id":"go:GO:1902875","description":"\"Any process that modulates the frequency, rate or extent of embryonic pattern specification.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"8af3505508064b18bdfd7192542feb2f","type":"GO_TERM","name":"regulation of embryonic skeletal joint development","canonical_id":"go:GO:1902762","description":"\"Any process that modulates the frequency, rate or extent of embryonic skeletal joint development.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16575901]","metadata":null},{"id":"5cb404ee2f4a4492be4335db9eab8937","type":"GO_TERM","name":"regulation of emericellamide A biosynthetic process","canonical_id":"go:GO:1900661","description":"\"Any process that modulates the frequency, rate or extent of emericellamide A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"bd2c1e2f86c64c6b972ddee5e23ccf35","type":"GO_TERM","name":"regulation of emericellamide biosynthetic process","canonical_id":"go:GO:1900658","description":"\"Any process that modulates the frequency, rate or extent of emericellamide biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3a7ce5dfa191467f8ab65ab021d123c4","type":"GO_TERM","name":"regulation of emericellin biosynthetic process","canonical_id":"go:GO:1900834","description":"\"Any process that modulates the frequency, rate or extent of emericellin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"954db0e08b14434a945ec0dcc5324756","type":"GO_TERM","name":"regulation of emodin biosynthetic process","canonical_id":"go:GO:1900664","description":"\"Any process that modulates the frequency, rate or extent of emodin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"bbaa3acfe1e94ab190942a16fd9b029f","type":"GO_TERM","name":"regulation of enamel mineralization","canonical_id":"go:GO:0070173","description":"\"Any process that modulates the frequency, rate or extent of enamel mineralization, the deposition of calcium salts in tooth enamel.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"465da327d63343aa9fbb11d4ae17ea32","type":"GO_TERM","name":"regulation of encysted zoospore germination","canonical_id":"go:GO:0075227","description":"\"Any process that modulates the frequency, rate or extent of an encysted zoospore germination.\" [GOC:pamgo_curators]","metadata":null},{"id":"4b7c5eb501d942f88e5f22799888adbf","type":"GO_TERM","name":"regulation of endocannabinoid signaling pathway","canonical_id":"go:GO:2000124","description":"\"Any process that modulates the frequency, rate or extent of endocannabinoid signaling pathway.\" [GOC:mah, PMID:15550444]","metadata":null},{"id":"e8f94badf4434105b334e508297e516a","type":"GO_TERM","name":"regulation of endocardial cushion cell differentiation","canonical_id":"go:GO:0120074","description":"\"Any process that modulates the frequency, rate or extent of cell differentiation, the process in which a relatively unspecialized cell acquires the specialized structural and/or functional features of an endocardial cushion cell.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"4dd6cfede0a84f4eb485a76ae7ad63d9","type":"GO_TERM","name":"regulation of endocardial cushion to mesenchymal transition","canonical_id":"go:GO:0140049","description":"\"Any process that modulates the frequency, rate or extent of endocardial cushion to mesenchymal transition.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:21778427]","metadata":null},{"id":"9770997ace994fd9a47fbc96a85a0d26","type":"GO_TERM","name":"regulation of endocardial cushion to mesenchymal transition involved in heart valve formation","canonical_id":"go:GO:2000800","description":"\"Any process that modulates the frequency, rate or extent of endocardial cushion to mesenchymal transition involved in heart valve formation.\" [GOC:BHF]","metadata":null},{"id":"61098f0902374deb8c745c3b88eee07e","type":"GO_TERM","name":"regulation of endocrine process","canonical_id":"go:GO:0044060","description":"\"Any process that modulates the frequency, rate or extent of an endocrine process, a process involving the secretion of or response to endocrine hormones. An endocrine hormone is a hormone released into the circulatory system.\" [GOC:jl]","metadata":null},{"id":"15240c5a3279471da946f13a2d2fe576","type":"GO_TERM","name":"regulation of endocrocin biosynthetic process","canonical_id":"go:GO:1900667","description":"\"Any process that modulates the frequency, rate or extent of endocrocin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"abdf07110db84a4f9637e1c3b9691e04","type":"GO_TERM","name":"regulation of endocytic recycling","canonical_id":"go:GO:2001135","description":"\"Any process that modulates the frequency, rate or extent of endocytic recycling.\" [GOC:obol]","metadata":null},{"id":"b3cdd76c3c704a17a518bb4f13b4921a","type":"GO_TERM","name":"regulation of endocytosis","canonical_id":"go:GO:0030100","description":"\"Any process that modulates the frequency, rate or extent of endocytosis.\" [GOC:curators]","metadata":null},{"id":"ff7d0951d3b9417c83d94fef0ea79a02","type":"GO_TERM","name":"regulation of endodeoxyribonuclease activity","canonical_id":"go:GO:0032071","description":"\"Any process that modulates the frequency, rate or extent of endodeoxyribonuclease activity, the hydrolysis of ester linkages within deoxyribonucleic acid by creating internal breaks.\" [GOC:mah]","metadata":null},{"id":"8f8912f92b294f1ca76202039f5ebacc","type":"GO_TERM","name":"regulation of endodermal cell differentiation","canonical_id":"go:GO:1903224","description":"\"Any process that modulates the frequency, rate or extent of endodermal cell differentiation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23154389]","metadata":null},{"id":"11e23158b92849ec9a13745445361fff","type":"GO_TERM","name":"regulation of endodermal cell fate specification","canonical_id":"go:GO:0042663","description":"\"Any process that mediates the specification of a cell into an endoderm cell.\" [GOC:curators]","metadata":null},{"id":"ec1390c8c57e445183e6ecee4f221ce4","type":"GO_TERM","name":"regulation of endopeptidase activity","canonical_id":"go:GO:0052548","description":"\"Any process that modulates the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins.\" [GOC:ai, GOC:hjd]","metadata":null},{"id":"233f4822c8f3461cb9b9cf4a0de3e6ed","type":"GO_TERM","name":"regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation","canonical_id":"go:GO:0060734","description":"\"Any process that modulates the rate, frequency, or extent of eIF2 alpha phosphorylation as a cellular response to endoplasmic reticulum stress.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bd75017dda6e45159f744caf9a75bdc0","type":"GO_TERM","name":"regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1902235","description":"\"Any process that modulates the frequency, rate or extent of an endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:20160352]","metadata":null},{"id":"04251256f47445c0b6c7b5fb39eb2a6b","type":"GO_TERM","name":"regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903381","description":"\"Any process that modulates the frequency, rate or extent of an endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"5bda87779bb948a280ba80bc35302912","type":"GO_TERM","name":"regulation of endoplasmic reticulum tubular network organization","canonical_id":"go:GO:1903371","description":"\"Any process that modulates the frequency, rate or extent of endoplasmic reticulum tubular network organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24891604]","metadata":null},{"id":"4dcdcb9a089545ad8e7ceb92a74f2cb6","type":"GO_TERM","name":"regulation of endoplasmic reticulum unfolded protein response","canonical_id":"go:GO:1900101","description":"\"Any process that modulates the frequency, rate or extent of endoplasmic reticulum unfolded protein response.\" [GOC:TermGenie]","metadata":null},{"id":"6993a8ba0b664312b99b7d5b84e4d464","type":"GO_TERM","name":"regulation of endoribonuclease activity","canonical_id":"go:GO:0060699","description":"\"Any process that modulates the rate, frequency or extent of the catalysis of the hydrolysis of ester linkages within ribonucleic acid by creating internal breaks.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b1793ba27c57431fbddad4e14fa05332","type":"GO_TERM","name":"regulation of endosomal vesicle fusion","canonical_id":"go:GO:1905364","description":"\"Any process that modulates the frequency, rate or extent of endosomal vesicle fusion.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"d517862aae5d45f8a49194433ce02100","type":"GO_TERM","name":"regulation of endosome organization","canonical_id":"go:GO:1904978","description":"\"Any process that modulates the frequency, rate or extent of endosome organization.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22511594]","metadata":null},{"id":"51c704a54e4f479183fe40a45bfaf871","type":"GO_TERM","name":"regulation of endosome size","canonical_id":"go:GO:0051036","description":"\"Any process that modulates the volume of an endosome, a membrane-bounded organelle that carries materials newly ingested by endocytosis.\" [GOC:ai]","metadata":null},{"id":"45f055be4a3f4ab5815e58f6512020a9","type":"GO_TERM","name":"regulation of endosome to plasma membrane protein transport","canonical_id":"go:GO:1905749","description":"\"Any process that modulates the frequency, rate or extent of endosome to plasma membrane protein transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:22869721]","metadata":null},{"id":"80972957e7354945a116fcc69c7a4bd6","type":"GO_TERM","name":"regulation of endosperm development","canonical_id":"go:GO:2000014","description":"\"Any process that modulates the frequency, rate or extent of endosperm development.\" [GOC:obol]","metadata":null},{"id":"984a3b8836db4fbca8a3acc0546d72ce","type":"GO_TERM","name":"regulation of endothelial cell activation","canonical_id":"go:GO:1904987","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell activation.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:24255059]","metadata":null},{"id":"c3e6ac69635b4cb0bea5b24cd17e542b","type":"GO_TERM","name":"regulation of endothelial cell apoptotic process","canonical_id":"go:GO:2000351","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell apoptotic process.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"90b59f63efea45b1a4339e0bcec5d2a4","type":"GO_TERM","name":"regulation of endothelial cell chemotaxis","canonical_id":"go:GO:2001026","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell chemotaxis.\" [GOC:BHF]","metadata":null},{"id":"cfef67b8f3314286ae86f322960c6da5","type":"GO_TERM","name":"regulation of endothelial cell chemotaxis to fibroblast growth factor","canonical_id":"go:GO:2000544","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell chemotaxis to fibroblast growth factor.\" [GOC:obol]","metadata":null},{"id":"6e18aa206d8943eeb54dea810331aff1","type":"GO_TERM","name":"regulation of endothelial cell chemotaxis to vascular endothelial growth factor","canonical_id":"go:GO:1904857","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell chemotaxis to vascular endothelial growth factor.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:21885851]","metadata":null},{"id":"f85db2407ffa40f2a09b4862ab8e3024","type":"GO_TERM","name":"regulation of endothelial cell development","canonical_id":"go:GO:1901550","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell development.\" [GOC:pr, GOC:TermGenie, PMID:19470579]","metadata":null},{"id":"c6fa5278007a4764937bc3d395132b3f","type":"GO_TERM","name":"regulation of endothelial cell differentiation","canonical_id":"go:GO:0045601","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell differentiation.\" [GOC:curators]","metadata":null},{"id":"60be541cb88f46c9a3980353683ab704","type":"GO_TERM","name":"regulation of endothelial cell migration","canonical_id":"go:GO:0010594","description":"\"Any process that modulates the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"49aea6b6b73a46cab1b0ce99bdc77dae","type":"GO_TERM","name":"regulation of endothelial cell proliferation","canonical_id":"go:GO:0001936","description":"\"Any process that modulates the frequency, rate, or extent of endothelial cell proliferation.\" [GOC:add]","metadata":null},{"id":"cc6d7eadab4f4e07b0c46332808143be","type":"GO_TERM","name":"regulation of endothelial cell-matrix adhesion","canonical_id":"go:GO:1904904","description":"\"Any process that modulates the frequency, rate or extent of endothelial cell-matrix adhesion.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:19460962]","metadata":null},{"id":"b47c607c81944c798b2d38900bba30da","type":"GO_TERM","name":"regulation of endothelial microparticle formation","canonical_id":"go:GO:2000335","description":"\"Any process that modulates the frequency, rate or extent of endothelial microparticle formation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"4cc384eab8974e79874c98caf25ecd77","type":"GO_TERM","name":"regulation of endothelial tube morphogenesis","canonical_id":"go:GO:1901509","description":"\"Any process that modulates the frequency, rate or extent of endothelial tube morphogenesis.\" [GOC:dph, GOC:TermGenie]","metadata":null},{"id":"9090403677104293aaff32e0f416389b","type":"GO_TERM","name":"regulation of endothelin production","canonical_id":"go:GO:1904470","description":"\"Any process that modulates the frequency, rate or extent of endothelin production.\" [GO_REF:0000058, GOC:TermGenie, PMID:15560120]","metadata":null},{"id":"02108c9d322648819393f6f65cf5602d","type":"GO_TERM","name":"regulation of engulfment of apoptotic cell","canonical_id":"go:GO:1901074","description":"\"Any process that modulates the frequency, rate or extent of engulfment of apoptotic cell.\" [GO:kmv, GOC:TermGenie, PMID:19402756]","metadata":null},{"id":"bef19e86daff4f9c98fa8c233f71f49f","type":"GO_TERM","name":"regulation of ent-pimara-8(14),15-diene biosynthetic process","canonical_id":"go:GO:1901542","description":"\"Any process that modulates the frequency, rate or extent of ent-pimara-8(14),15-diene biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"fc7615361f274694b9f7c9b8f5556e33","type":"GO_TERM","name":"regulation of entry into reproductive diapause","canonical_id":"go:GO:0061963","description":"\"Any process that modulates the rate or extent of the dormancy process that results in entry into reproductive diapause. Reproductive diapause is a form of diapause where the organism itself will remain fully active, including feeding and other routine activities, but the reproductive organs experience a tissue-specific reduction in metabolism, with characteristic triggering and releasing stimuli.\" [GOC:ha, PMID:27689881]","metadata":null},{"id":"d8f48d52bd62497f8024e8150972c08b","type":"GO_TERM","name":"regulation of entry of bacterium into host cell","canonical_id":"go:GO:2000535","description":"\"Any process that modulates the frequency, rate or extent of entry of bacterium into host cell.\" [GOC:obol]","metadata":null},{"id":"c73bd64e08ef4851a2ba701913a312bf","type":"GO_TERM","name":"regulation of eosinophil activation","canonical_id":"go:GO:1902566","description":"\"Any process that modulates the frequency, rate or extent of eosinophil activation.\" [GOC:TermGenie, PMID:16254138]","metadata":null},{"id":"f3c6e8abaeab43c6aaebe0844edbbbf1","type":"GO_TERM","name":"regulation of eosinophil chemotaxis","canonical_id":"go:GO:2000422","description":"\"Any process that modulates the frequency, rate or extent of eosinophil chemotaxis.\" [GOC:obol]","metadata":null},{"id":"cb2e860c14ae42a6bb055a3cc04e7e85","type":"GO_TERM","name":"regulation of eosinophil degranulation","canonical_id":"go:GO:0043309","description":"\"Any process that modulates the frequency, rate, or extent of eosinophil degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"46be6f74853a41319bba82963fb2ad55","type":"GO_TERM","name":"regulation of eosinophil differentiation","canonical_id":"go:GO:0045643","description":"\"Any process that modulates the frequency, rate or extent of eosinophil differentiation.\" [GOC:curators]","metadata":null},{"id":"9d65a781f7ee4940871697f9815c444c","type":"GO_TERM","name":"regulation of eosinophil extravasation","canonical_id":"go:GO:2000419","description":"\"Any process that modulates the frequency, rate or extent of eosinophil extravasation.\" [GOC:mah]","metadata":null},{"id":"65d255769e3b400cbedb96c6bfd8eb56","type":"GO_TERM","name":"regulation of eosinophil migration","canonical_id":"go:GO:2000416","description":"\"Any process that modulates the frequency, rate or extent of eosinophil migration.\" [GOC:mah]","metadata":null},{"id":"35281999311c4aff8473f2f515dcc60d","type":"GO_TERM","name":"regulation of ephrin receptor signaling pathway","canonical_id":"go:GO:1901187","description":"\"Any process that modulates the frequency, rate or extent of ephrin receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"5ce416f6d027417cb2a4234939f89425","type":"GO_TERM","name":"regulation of epiboly involved in gastrulation with mouth forming second","canonical_id":"go:GO:1904086","description":"\"Any process that modulates the frequency, rate or extent of epiboly involved in gastrulation with mouth forming second.\" [GO_REF:0000058, GOC:TermGenie, PMID:24892953]","metadata":null},{"id":"3277f146a76e485b9c80437cb434f7a9","type":"GO_TERM","name":"regulation of epidermal cell differentiation","canonical_id":"go:GO:0045604","description":"\"Any process that modulates the frequency, rate or extent of epidermal cell differentiation.\" [GOC:curators]","metadata":null},{"id":"6f590786196e4f91aed107a606547e7b","type":"GO_TERM","name":"regulation of epidermal cell division","canonical_id":"go:GO:0010482","description":"\"Any process that modulates the frequency, rate or extent of the physical partitioning and separation of an epidermal cell into daughter cells. An epidermal cell is any of the cells that make up the epidermis.\" [PMID:17450124]","metadata":null},{"id":"caa74d2be34e430697632fe46f2f42c3","type":"GO_TERM","name":"regulation of epidermal growth factor receptor signaling pathway","canonical_id":"go:GO:0042058","description":"\"Any process that modulates the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"0cd853354fe64013886ec455c4bb8c8e","type":"GO_TERM","name":"regulation of epidermis development","canonical_id":"go:GO:0045682","description":"\"Any process that modulates the frequency, rate or extent of epidermis development.\" [GOC:curators]","metadata":null},{"id":"290c61ed7bfe425781774da01f0d990a","type":"GO_TERM","name":"regulation of epinephrine secretion","canonical_id":"go:GO:0014060","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of epinephrine.\" [GOC:ef]","metadata":null},{"id":"a98e312ebe2a4b14a16f0eeb2030e960","type":"GO_TERM","name":"regulation of epinephrine uptake","canonical_id":"go:GO:0051626","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of the neurotransmitter epinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"576af0df63dd4d5b90252cc1f9e68553","type":"GO_TERM","name":"regulation of epithelial cell apoptotic process","canonical_id":"go:GO:1904035","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:19137015]","metadata":null},{"id":"2c5e485301fa4f67bc0b662a07212f69","type":"GO_TERM","name":"regulation of epithelial cell differentiation","canonical_id":"go:GO:0030856","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell differentiation.\" [GOC:mah]","metadata":null},{"id":"c56ea4b485bc4d69b741cfb67fc48bf2","type":"GO_TERM","name":"regulation of epithelial cell differentiation involved in kidney development","canonical_id":"go:GO:2000696","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell differentiation involved in kidney development.\" [GOC:mtg_kidney_jan10, GOC:yaf]","metadata":null},{"id":"8b35df0a76d94ffb985a17cdab7d9762","type":"GO_TERM","name":"regulation of epithelial cell migration","canonical_id":"go:GO:0010632","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell migration.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"73c827b40aa44e06b92e9ac1de8865cb","type":"GO_TERM","name":"regulation of epithelial cell migration, open tracheal system","canonical_id":"go:GO:2000274","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell migration, open tracheal system.\" [GOC:obol]","metadata":null},{"id":"72b282e7bb474c52b16ef87cf7574a0f","type":"GO_TERM","name":"regulation of epithelial cell proliferation","canonical_id":"go:GO:0050678","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell proliferation.\" [GOC:ai]","metadata":null},{"id":"59ecb33ada7141f6947afc8e40166caa","type":"GO_TERM","name":"regulation of epithelial cell proliferation involved in lung morphogenesis","canonical_id":"go:GO:2000794","description":"\"Any process that modulates the frequency, rate or extent of epithelial cell proliferation involved in lung morphogenesis.\" [PMID:21513708]","metadata":null},{"id":"46aec4a841bd430c9d185f03df9204b1","type":"GO_TERM","name":"regulation of epithelial cell proliferation involved in prostate gland development","canonical_id":"go:GO:0060768","description":"\"Any process that modulates the rate, frequency or extent of epithelial cell proliferation that contributes to the progression of the prostate gland over time.\" [GOC:dph]","metadata":null},{"id":"0e9d6b3de2604951a12a2dab81786ba7","type":"GO_TERM","name":"regulation of epithelial to mesenchymal transition","canonical_id":"go:GO:0010717","description":"\"Any process that modulates the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"95a8637faa8f402cac9fd167db14021a","type":"GO_TERM","name":"regulation of epithelial to mesenchymal transition involved in endocardial cushion formation","canonical_id":"go:GO:1905005","description":"\"Any process that modulates the frequency, rate or extent of epithelial to mesenchymal transition involved in endocardial cushion formation.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"9f0fc3d342e74789b62a3412dd921919","type":"GO_TERM","name":"regulation of epithelial tube formation","canonical_id":"go:GO:1905276","description":"\"Any process that modulates the frequency, rate or extent of epithelial tube formation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25745997]","metadata":null},{"id":"91f37c6ebc1f4021916fe7127b1fba84","type":"GO_TERM","name":"regulation of epithelium regeneration","canonical_id":"go:GO:1905041","description":"\"Any process that modulates the frequency, rate or extent of epithelium regeneration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23221517]","metadata":null},{"id":"8ef3afc708724275b3a0616ca03cc35f","type":"GO_TERM","name":"regulation of ergosterol biosynthetic process","canonical_id":"go:GO:0032443","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ergosterol.\" [GOC:mah]","metadata":null},{"id":"be2a26586e274487a822344f17a8e7e6","type":"GO_TERM","name":"regulation of ergot alkaloid biosynthetic process","canonical_id":"go:GO:1900822","description":"\"Any process that modulates the frequency, rate or extent of ergot alkaloid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ab7d6636eff84a548bb221ab7614c6e6","type":"GO_TERM","name":"regulation of error-prone translesion synthesis","canonical_id":"go:GO:1904331","description":"\"Any process that modulates the frequency, rate or extent of error-prone translesion synthesis.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22761594]","metadata":null},{"id":"1888a2575466482dbc7d9c961f288a06","type":"GO_TERM","name":"regulation of erythrocyte aggregation","canonical_id":"go:GO:0034118","description":"\"Any process that modulates the frequency, rate, or extent of erythrocyte aggregation.\" [GOC:add]","metadata":null},{"id":"7d4fb264c47044d3ae924c2983857c93","type":"GO_TERM","name":"regulation of erythrocyte apoptotic process","canonical_id":"go:GO:1902250","description":"\"Any process that modulates the frequency, rate or extent of erythrocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"0166f8c711d04f988d5d595300b97b56","type":"GO_TERM","name":"regulation of erythrocyte clearance","canonical_id":"go:GO:0034106","description":"\"Any process that modulates the frequency, rate, or extent of erythrocyte clearance.\" [GOC:add, PMID:12905029, PMID:14754397]","metadata":null},{"id":"45485b7ea1a14ff09d9d71402f3d9abb","type":"GO_TERM","name":"regulation of erythrocyte differentiation","canonical_id":"go:GO:0045646","description":"\"Any process that modulates the frequency, rate or extent of erythrocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"3ffae079c5e14dde932944676281a2cb","type":"GO_TERM","name":"regulation of erythrocyte enucleation","canonical_id":"go:GO:0061930","description":"\"Any process that modulates the frequency, rate or extent of erythrocyte enucleation.\" [PMID:25241935]","metadata":null},{"id":"d1ef358e6b26477a9d38618b8d0e920c","type":"GO_TERM","name":"regulation of erythrophore differentiation","canonical_id":"go:GO:0048778","description":"\"Any process that modulates the frequency, rate or extent of erythrophore differentiation.\" [GOC:mh]","metadata":null},{"id":"e4aa22fedd5548d1be3f14c3ec90e183","type":"GO_TERM","name":"regulation of establishment of RNA localization to telomere","canonical_id":"go:GO:1904910","description":"\"Any process that modulates the frequency, rate or extent of establishment of RNA localization to telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"9432f418112c4d62ab5202f97bd7d56d","type":"GO_TERM","name":"regulation of establishment of Sertoli cell barrier","canonical_id":"go:GO:1904444","description":"\"Any process that modulates the frequency, rate or extent of establishment of Sertoli cell barrier.\" [GO_REF:0000058, GOC:TermGenie, PMID:18057314]","metadata":null},{"id":"cabf6b844bd343b5bd866054f5e535f9","type":"GO_TERM","name":"regulation of establishment of T cell polarity","canonical_id":"go:GO:1903903","description":"\"Any process that modulates the frequency, rate or extent of establishment of T cell polarity.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"c92a2194add14da99f7bc9aa3ac22205","type":"GO_TERM","name":"regulation of establishment of bipolar cell polarity","canonical_id":"go:GO:0061172","description":"\"Any process that modulates the rate, frequency or extent of the establishment of bipolar cell polarity. Bipolar organization is the organization that is a mirror image along an axis from a plane.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"b2674695ed1c41d5a11acf32434a98fe","type":"GO_TERM","name":"regulation of establishment of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:0061160","description":"\"Any process that modulates the rate, frequency or extent of the establishment of bipolar cell polarity that contributes to the shape of a cell.\" [GOC:dph, GOC:vw]","metadata":null},{"id":"3ff710cd82db43be917e6e690f3d4133","type":"GO_TERM","name":"regulation of establishment of blood-brain barrier","canonical_id":"go:GO:0090210","description":"\"Any process that modulates the rate, frequency or extent of the establishment of the blood-brain barrier, a selectively permeable structural and functional barrier that exists between the capillaries and the brain.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"656b11ecc5ba472ba46bfdbcae9f06cc","type":"GO_TERM","name":"regulation of establishment of cell polarity","canonical_id":"go:GO:2000114","description":"\"Any process that modulates the frequency, rate or extent of establishment of cell polarity.\" [GOC:dph]","metadata":null},{"id":"0cc178f9cf204a89ab878ae848230df2","type":"GO_TERM","name":"regulation of establishment of cell polarity regulating cell shape","canonical_id":"go:GO:2000782","description":"\"Any process that modulates the frequency, rate or extent of establishment of cell polarity regulating cell shape.\" [GOC:Mah]","metadata":null},{"id":"dd0ac07dc8984d0f9d24141ed07db30c","type":"GO_TERM","name":"regulation of establishment of competence for transformation","canonical_id":"go:GO:0045304","description":"\"Any process that modulates the frequency, rate or extent of the process in which a cell becomes able to take up and incorporate extracellular DNA into its genome.\" [GOC:mlg]","metadata":null},{"id":"7c76df23d5c44cf2b3db323e8aa75b73","type":"GO_TERM","name":"regulation of establishment of endothelial barrier","canonical_id":"go:GO:1903140","description":"\"Any process that modulates the frequency, rate or extent of establishment of endothelial barrier.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24851274]","metadata":null},{"id":"22d709ee47044c8ba0e0a4de9d8121e2","type":"GO_TERM","name":"regulation of establishment of planar polarity","canonical_id":"go:GO:0090175","description":"\"Any process that modulates the rate, frequency or extent of the establishment of planar polarity, the coordinated organization of groups of cells in a tissue, such that they all orient to similar coordinates.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d1c466d7513f4564951dedb6471df001","type":"GO_TERM","name":"regulation of establishment of planar polarity involved in neural tube closure","canonical_id":"go:GO:0090178","description":"\"Any process that modulates the rate, frequency, or extent of the establishment of planar polarity involved in neural tube closure, the coordinated organization of groups of cells in the plane of an epithelium that contributes to the closure of the neural tube.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1e348621ba704c3987373a1e5c67ce37","type":"GO_TERM","name":"regulation of establishment of protein localization","canonical_id":"go:GO:0070201","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a protein to a specific location.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"798a05536dd64df09ff49dcccf9b5ff4","type":"GO_TERM","name":"regulation of establishment of protein localization to chromosome","canonical_id":"go:GO:0070202","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a protein to a specific location on a chromosome.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1d99699fe4be4523809e8aa9e7018a82","type":"GO_TERM","name":"regulation of establishment of protein localization to telomere","canonical_id":"go:GO:0070203","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a protein to a specific location in the telomeric region of a chromosome.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"ad69fd38295e405f99dd38704fd7684d","type":"GO_TERM","name":"regulation of establishment of protein-containing complex localization to telomere","canonical_id":"go:GO:1904913","description":"\"Any process that modulates the frequency, rate or extent of establishment of the localization of a protein-containing macromolecular complex to a telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"9de3bcd299094e4bba4b2321a65c49a9","type":"GO_TERM","name":"regulation of establishment or maintenance of bipolar cell polarity","canonical_id":"go:GO:2000099","description":"\"Any process that modulates the frequency, rate or extent of establishment or maintenance of bipolar cell polarity.\" [GOC:obol]","metadata":null},{"id":"6d5194791e8148ef86da70092b5b0617","type":"GO_TERM","name":"regulation of establishment or maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:2000100","description":"\"Any process that modulates the frequency, rate or extent of establishment or maintenance of bipolar cell polarity regulating cell shape.\" [GOC:obol]","metadata":null},{"id":"4fbc11e7ec4142eb85efe3a7fc6cda5b","type":"GO_TERM","name":"regulation of establishment or maintenance of cell polarity","canonical_id":"go:GO:0032878","description":"\"Any process that modulates the frequency, rate or extent of the specification, formation or maintenance of anisotropic intracellular organization or cell growth patterns.\" [GOC:mah]","metadata":null},{"id":"c1a5ee405883465c814ca5672c7a2b99","type":"GO_TERM","name":"regulation of establishment or maintenance of cell polarity regulating cell shape","canonical_id":"go:GO:2000769","description":"\"Any process that modulates the frequency, rate or extent of establishment or maintenance of cell polarity regulating cell shape.\" [GOC:mah]","metadata":null},{"id":"5e85deabc3344344b18a3b0e118f86a9","type":"GO_TERM","name":"regulation of estradiol secretion","canonical_id":"go:GO:2000864","description":"\"Any process that modulates the frequency, rate or extent of estradiol secretion.\" [GOC:sl]","metadata":null},{"id":"d0a988db2ba446d9939c3ea033df7260","type":"GO_TERM","name":"regulation of estrogen biosynthetic process","canonical_id":"go:GO:1904076","description":"\"Any process that modulates the frequency, rate or extent of estrogen biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24530842]","metadata":null},{"id":"b54fc4fda1c34a82bd84c588527f848a","type":"GO_TERM","name":"regulation of estrogen secretion","canonical_id":"go:GO:2000861","description":"\"Any process that modulates the frequency, rate or extent of estrogen secretion.\" [GOC:sl]","metadata":null},{"id":"1494f268883046dfa3e48a84051bc226","type":"GO_TERM","name":"regulation of estrone secretion","canonical_id":"go:GO:2000867","description":"\"Any process that modulates the frequency, rate or extent of estrone secretion.\" [GOC:sl]","metadata":null},{"id":"89ee6c4b21f5416bbde7372dfc8e683e","type":"GO_TERM","name":"regulation of ethanol catabolic process","canonical_id":"go:GO:1900065","description":"\"Any process that modulates the frequency, rate or extent of ethanol catabolic process.\" [GOC:TermGenie, PMID:10608811, PMID:7760841]","metadata":null},{"id":"6dd7245a0098493dbbf4665bf6f02b95","type":"GO_TERM","name":"regulation of ethylene biosynthetic process","canonical_id":"go:GO:0010364","description":"\"Any process that modulates the frequency, rate, or extent of an ethylene biosynthetic process.\" [GOC:tair_curators]","metadata":null},{"id":"01bcd40f98fd4262a967dc57bc931aa6","type":"GO_TERM","name":"regulation of ethylene-activated signaling pathway","canonical_id":"go:GO:0010104","description":"\"Any process that modulates the frequency, rate or extent of ethylene (ethene) signal transduction.\" [GOC:tb]","metadata":null},{"id":"b1ad3261565e43d2aa3ec668757ba70d","type":"GO_TERM","name":"regulation of eukaryotic translation initiation factor 4F complex assembly","canonical_id":"go:GO:1905535","description":"\"Any process that modulates the frequency, rate or extent of eukaryotic translation initiation factor 4F complex assembly.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:18426977]","metadata":null},{"id":"dc2d919ec93b4f13b7037fb41e652c8d","type":"GO_TERM","name":"regulation of excitatory postsynaptic membrane potential involved in skeletal muscle contraction","canonical_id":"go:GO:0014853","description":"\"Any process, involved in skeletal muscle contraction, that modulates the establishment or extent of the excitatory postsynaptic potential (EPSP). Excitatory postsynaptic potential (EPSP) is a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"54fab33db3734b0f89b581d2b60f8576","type":"GO_TERM","name":"regulation of excitatory synapse assembly","canonical_id":"go:GO:1904889","description":"\"Any process that modulates the frequency, rate or extent of excitatory synapse assembly.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"6fb24d628bab434790e25bf67beb05a8","type":"GO_TERM","name":"regulation of excitatory synapse pruning","canonical_id":"go:GO:1905810","description":"\"Any process that modulates the frequency, rate or extent of excitatory synapse pruning.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"53858716e5824b3f80055a77b5e96a6f","type":"GO_TERM","name":"regulation of excretion","canonical_id":"go:GO:0044062","description":"\"Any process that modulates the frequency, rate, or extent of excretion, the elimination by an organism of the waste products that arise as a result of metabolic activity.\" [GOC:jl]","metadata":null},{"id":"95f5bb3a84e2473a84adcb1116f7b73e","type":"GO_TERM","name":"regulation of execution phase of apoptosis","canonical_id":"go:GO:1900117","description":"\"Any process that modulates the frequency, rate or extent of execution phase of apoptosis.\" [GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"3a8b1745b6c84db1aecd74bc7a6b593c","type":"GO_TERM","name":"regulation of exit from meiosis","canonical_id":"go:GO:0106060","description":"\"Any process that modulates the frequency, rate or extent of exit from mitosis.\" [GOC:al, PMID:11493649]","metadata":null},{"id":"f06f2d4220e4479db31192b3f9ba58ad","type":"GO_TERM","name":"regulation of exit from mitosis","canonical_id":"go:GO:0007096","description":"\"Any process involved in the progression from anaphase/telophase to G1 that is associated with a conversion from high to low mitotic CDK activity.\" [GOC:rn]","metadata":null},{"id":"40f612be2c3c4c8eb618028b1c748ec4","type":"GO_TERM","name":"regulation of exocyst assembly","canonical_id":"go:GO:0001928","description":"\"Any process that modulates the frequency, rate or extent of exocyst assembly.\" [GOC:hjd]","metadata":null},{"id":"d5c9236ffebf479b90e58b46b15b3a52","type":"GO_TERM","name":"regulation of exocyst localization","canonical_id":"go:GO:0060178","description":"\"Any process that modulates the localization of exocysts. An exocyst is a protein complex peripherally associated with the plasma membrane that determines where vesicles dock and fuse.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"644033a56de34476857f80396a1dad63","type":"GO_TERM","name":"regulation of exocytic insertion of neurotransmitter receptor to postsynaptic membrane","canonical_id":"go:GO:0099145","description":"\"Any process that modulates the frequency, rate or extent of exocytic fusion of neurotransmitter receptor containing vesicles into the postsynaptic membrane.\" [GOC:dos]","metadata":null},{"id":"497cf6237b924c6e81f11aabf2a19180","type":"GO_TERM","name":"regulation of exocytosis","canonical_id":"go:GO:0017157","description":"\"Any process that modulates the frequency, rate or extent of exocytosis.\" [GOC:curators]","metadata":null},{"id":"f9cc0001f1c54396a89cbd865c6bad89","type":"GO_TERM","name":"regulation of exosomal secretion","canonical_id":"go:GO:1903541","description":"\"Any process that modulates the frequency, rate or extent of exosomal secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:24105262]","metadata":null},{"id":"2cef82202c244033b7b1d4cf00f487e6","type":"GO_TERM","name":"regulation of extent of cell growth","canonical_id":"go:GO:0061387","description":"\"Any process that modulates the extent of cell growth.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"3481e56a731c46c6a92c99925e100fdf","type":"GO_TERM","name":"regulation of extracellular exosome assembly","canonical_id":"go:GO:1903551","description":"\"Any process that modulates the frequency, rate or extent of extracellular vesicular exosome assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:24105262]","metadata":null},{"id":"0815c9cdbdd54bc9a53303206277dda2","type":"GO_TERM","name":"regulation of extracellular matrix assembly","canonical_id":"go:GO:1901201","description":"\"Any process that modulates the frequency, rate or extent of extracellular matrix assembly.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"d809674744b94a8d92c16383fa1cb80d","type":"GO_TERM","name":"regulation of extracellular matrix constituent secretion","canonical_id":"go:GO:0003330","description":"\"Any process that modulates the rate, frequency, or extent of the controlled release of molecules that form the extracellular matrix, including carbohydrates and glycoproteins by a cell or a group of cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c2252462f2e44a7d959bf566a41421e9","type":"GO_TERM","name":"regulation of extracellular matrix disassembly","canonical_id":"go:GO:0010715","description":"\"Any process that modulates the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d1e3545a44a3442d802f68f2a10401c8","type":"GO_TERM","name":"regulation of extracellular matrix organization","canonical_id":"go:GO:1903053","description":"\"Any process that modulates the frequency, rate or extent of extracellular matrix organization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22357537]","metadata":null},{"id":"5acb5e58f3394b63966ec0d67de93f44","type":"GO_TERM","name":"regulation of extraocular skeletal muscle development","canonical_id":"go:GO:0014725","description":"\"Any process that modulates the frequency, rate or extent of extraocular skeletal muscle development. Extraocular skeletal muscle development is the process whose specific outcome is the progression of the extraocular skeletal muscle over time, from its formation to the mature structure. The extraocular muscle is derived from cranial mesoderm and controls eye movements. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle.\" [GOC:mtg_muscle]","metadata":null},{"id":"4aae278734dc4d3cbf5c25bc450dd487","type":"GO_TERM","name":"regulation of extrathymic T cell differentiation","canonical_id":"go:GO:0033082","description":"\"Any process that modulates the frequency, rate or extent of extrathymic T cell differentiation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"aa73e78d8e2f44c589cd7bfd8bcabdd8","type":"GO_TERM","name":"regulation of extrinsic apoptotic signaling pathway","canonical_id":"go:GO:2001236","description":"\"Any process that modulates the frequency, rate or extent of extrinsic apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"44c5a7a7af124a5ea3f297864f3769b1","type":"GO_TERM","name":"regulation of extrinsic apoptotic signaling pathway in absence of ligand","canonical_id":"go:GO:2001239","description":"\"Any process that modulates the frequency, rate or extent of extrinsic apoptotic signaling pathway in absence of ligand.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"8f15642217724ec5b541729a24e2e37b","type":"GO_TERM","name":"regulation of extrinsic apoptotic signaling pathway via death domain receptors","canonical_id":"go:GO:1902041","description":"\"Any process that modulates the frequency, rate or extent of extrinsic apoptotic signaling pathway via death domain receptors.\" [GOC:TermGenie, PMID:17245429]","metadata":null},{"id":"1306389865774f4a83d31fb81131d649","type":"GO_TERM","name":"regulation of eye photoreceptor cell development","canonical_id":"go:GO:0042478","description":"\"Any process that modulates the frequency, rate or extent of eye photoreceptor development.\" [GOC:jl]","metadata":null},{"id":"e7c16c076d8946999f90ef2c3c3e852c","type":"GO_TERM","name":"regulation of eye pigmentation","canonical_id":"go:GO:0048073","description":"\"Any process that modulates the frequency, rate or extent of establishment of a pattern of pigment in the eye of an organism.\" [GOC:jid]","metadata":null},{"id":"cbb46eefc15a4039a513b4a3f90160e9","type":"GO_TERM","name":"regulation of fast-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031446","description":"\"Any process that modulates the frequency, rate or extent of fast-twitch skeletal muscle contraction.\" [GOC:dph, GOC:ef, GOC:mah, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"8c4631b9723e4fc994422ded6807c397","type":"GO_TERM","name":"regulation of fat cell apoptotic process","canonical_id":"go:GO:1904649","description":"\"Any process that modulates the frequency, rate or extent of fat cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:17024416]","metadata":null},{"id":"7e2b5102e8ef486f8989a816956aa9ca","type":"GO_TERM","name":"regulation of fat cell differentiation","canonical_id":"go:GO:0045598","description":"\"Any process that modulates the frequency, rate or extent of adipocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"4c2ec4a293b24550b9a8cdcaf86ff6cd","type":"GO_TERM","name":"regulation of fat cell proliferation","canonical_id":"go:GO:0070344","description":"\"Any process that modulates the frequency, rate or extent of fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"6908a8dc4b5e486db36e7073b163c863","type":"GO_TERM","name":"regulation of fatty acid beta-oxidation","canonical_id":"go:GO:0031998","description":"\"Any process that modulates the frequency, rate or extent of fatty acid bbeta-oxidation.\" [GOC:mah]","metadata":null},{"id":"c00b656b49f24f5d8ead0c3294af5e8b","type":"GO_TERM","name":"regulation of fatty acid biosynthetic process","canonical_id":"go:GO:0042304","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils.\" [GOC:curators, GOC:jl]","metadata":null},{"id":"a275dd96fe66409c8fe2d839d56234bb","type":"GO_TERM","name":"regulation of fatty acid metabolic process","canonical_id":"go:GO:0019217","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving fatty acids.\" [GOC:curators]","metadata":null},{"id":"d2512598032741b4b4489cf2c11e032b","type":"GO_TERM","name":"regulation of fatty acid oxidation","canonical_id":"go:GO:0046320","description":"\"Any process that modulates the frequency, rate or extent of fatty acid oxidation.\" [GOC:ai]","metadata":null},{"id":"221dc623278b452891116df2a499b68b","type":"GO_TERM","name":"regulation of fatty acid transport","canonical_id":"go:GO:2000191","description":"\"Any process that modulates the frequency, rate or extent of fatty acid transport.\" [GOC:BHF]","metadata":null},{"id":"355c3e63a8ff49deb9c6fa16231c1e2b","type":"GO_TERM","name":"regulation of fear response","canonical_id":"go:GO:1903365","description":"\"Any process that modulates the frequency, rate or extent of fear response.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:8677262]","metadata":null},{"id":"91d193ee3cb946caa6661011436ba6fd","type":"GO_TERM","name":"regulation of feeding behavior","canonical_id":"go:GO:0060259","description":"\"Any process that modulates the rate, frequency or extent of the behavior associated with the intake of food.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"353e0efc4c464c3b9276961b3fa3bbc5","type":"GO_TERM","name":"regulation of female gonad development","canonical_id":"go:GO:2000194","description":"\"Any process that modulates the frequency, rate or extent of female gonad development.\" [GOC:obol]","metadata":null},{"id":"177a75a52262403ba88a6b6977d111ba","type":"GO_TERM","name":"regulation of female pigmentation","canonical_id":"go:GO:0048089","description":"\"Any process that modulates the frequency, rate or extent of establishment of a pattern of pigment in females.\" [GOC:jid]","metadata":null},{"id":"087f1e5ec42d41f1adfebe80242a8ee7","type":"GO_TERM","name":"regulation of female receptivity","canonical_id":"go:GO:0045924","description":"\"Any process that modulates the frequency, rate or extent of the willingness or readiness of a female to receive male advances.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"c51b10a606ad44c5b3e593d32c40a90c","type":"GO_TERM","name":"regulation of female receptivity, post-mating","canonical_id":"go:GO:0046008","description":"\"Any process that modulates the receptiveness of a female to male advances subsequent to mating.\" [GOC:curators]","metadata":null},{"id":"e7310e7ff551446f968527aa631b6330","type":"GO_TERM","name":"regulation of fermentation","canonical_id":"go:GO:0043465","description":"\"Any process that modulates the frequency, rate or extent of fermentation, the anaerobic enzymatic conversion of organic compounds, especially carbohydrates, to other compounds, especially to ethyl alcohol, resulting in energy in the form of adenosine triphosphate (ATP).\" [GOC:jl]","metadata":null},{"id":"ec720167c0174b388651d53992924e0a","type":"GO_TERM","name":"regulation of ferrichrome biosynthetic process","canonical_id":"go:GO:1905568","description":"\"Any process that modulates the frequency, rate or extent of ferrichrome biosynthetic process.\" [GO_REF:0000058, GOC:al, GOC:TermGenie]","metadata":null},{"id":"8eb387460e1446d38abdf2d7d034e672","type":"GO_TERM","name":"regulation of ferricrocin biosynthetic process","canonical_id":"go:GO:1900678","description":"\"Any process that modulates the frequency, rate or extent of ferricrocin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"232356034b55441791247666ba2da979","type":"GO_TERM","name":"regulation of ferroptosis","canonical_id":"go:GO:0110075","description":"\"Any process that modulates the frequency, rate or extent of ferroptosis.\" [GOC:sp, PMID:24439385, PMID:25402683, PMID:29290465]","metadata":null},{"id":"126dac47d5fe40889ff91a50a7867d8f","type":"GO_TERM","name":"regulation of fertilization","canonical_id":"go:GO:0080154","description":"\"Any process that modulates the rate, frequency or extent of fertilization. Fertilization is the union of gametes of opposite sexes during the process of sexual reproduction to form a zygote. It involves the fusion of the gametic nuclei (karyogamy) and cytoplasm (plasmogamy).\" [GOC:DHL, PMID:20478994]","metadata":null},{"id":"cf3da2d4641e4b7182c552a1ce7ea74c","type":"GO_TERM","name":"regulation of ferulate catabolic process","canonical_id":"go:GO:1901466","description":"\"Any process that modulates the frequency, rate or extent of ferulate catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b1bec5472fe64e2583088756b7574504","type":"GO_TERM","name":"regulation of fever generation","canonical_id":"go:GO:0031620","description":"\"Any process that modulates the rate or extent of fever generation.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"b2d011d5c1e342c59241b197e07866a3","type":"GO_TERM","name":"regulation of fever generation by prostaglandin biosynthetic process","canonical_id":"go:GO:0100008","description":"\"Any prostaglandin biosynthetic process process that regulates fever generation.\" [GOC:cjm, GOC:obol]","metadata":null},{"id":"a1f2986a0f714e5ea5e5325477c1013f","type":"GO_TERM","name":"regulation of fever generation by prostaglandin secretion","canonical_id":"go:GO:0100009","description":"\"Any prostaglandin secretion process that regulates fever generation.\" [GOC:cjm, GOC:obol]","metadata":null},{"id":"1fe7104e0ccf4ef2a4b2f7372ead625c","type":"GO_TERM","name":"regulation of fever generation by regulation of prostaglandin biosynthesis","canonical_id":"go:GO:0071809","description":"\"Any process that modulates the rate or extent of fever generation via regulation of the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.\" [GOC:BHF, GOC:dph, GOC:mah]","metadata":null},{"id":"911b1812e03b4057b9610f9c79a050e0","type":"GO_TERM","name":"regulation of fever generation by regulation of prostaglandin secretion","canonical_id":"go:GO:0071810","description":"\"Any process that modulates the rate or extent of fever generation via regulation of the frequency, rate or extent of the regulated release of a prostaglandin from a cell.\" [GOC:BHF, GOC:dph, GOC:mah]","metadata":null},{"id":"e291562a34904953ac944679ac261472","type":"GO_TERM","name":"regulation of fibrinolysis","canonical_id":"go:GO:0051917","description":"\"Any process that modulates the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.\" [GOC:ai]","metadata":null},{"id":"4fed246f1eb24a1fa15c0a28780b9baa","type":"GO_TERM","name":"regulation of fibroblast apoptotic process","canonical_id":"go:GO:2000269","description":"\"Any process that modulates the frequency, rate or extent of fibroblast apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol, GOC:yaf]","metadata":null},{"id":"ab387f60f3704bf59c2cb0c4f9a2699a","type":"GO_TERM","name":"regulation of fibroblast chemotaxis","canonical_id":"go:GO:1905210","description":"\"Any process that modulates the frequency, rate or extent of fibroblast chemotaxis.\" [GO_REF:0000058, GOC:TermGenie, PMID:8760137]","metadata":null},{"id":"024b4d78fbb244e19048baee6512933a","type":"GO_TERM","name":"regulation of fibroblast growth factor production","canonical_id":"go:GO:0090270","description":"\"Any process that modulates the rate, frequency or extent of the appearance of a fibroblast growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"5bf0f55e272e4593a7221010d92bf139","type":"GO_TERM","name":"regulation of fibroblast growth factor receptor signaling pathway","canonical_id":"go:GO:0040036","description":"\"Any process that modulates the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity.\" [GOC:curators]","metadata":null},{"id":"eafe7d40084b4499a068a1432551b1dc","type":"GO_TERM","name":"regulation of fibroblast migration","canonical_id":"go:GO:0010762","description":"\"Any process that modulates the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"afbfbf646d7849a092494438fd71c0f7","type":"GO_TERM","name":"regulation of fibroblast proliferation","canonical_id":"go:GO:0048145","description":"\"Any process that modulates the frequency, rate or extent of multiplication or reproduction of fibroblast cells.\" [GOC:jid]","metadata":null},{"id":"35f9e28ec9c948cab06551ca6fd7aa39","type":"GO_TERM","name":"regulation of fibronectin-dependent thymocyte migration","canonical_id":"go:GO:2000413","description":"\"Any process that modulates the frequency, rate or extent of fibronectin-dependent thymocyte migration.\" [GOC:mah]","metadata":null},{"id":"1b61981bd70344e29808f97b2352367d","type":"GO_TERM","name":"regulation of filamentous growth","canonical_id":"go:GO:0010570","description":"\"Any process that modulates the frequency, rate or extent of the process in which a multicellular organism or a group of unicellular organisms grow in a threadlike, filamentous shape.\" [GOC:dph, GOC:jp, GOC:tb]","metadata":null},{"id":"88df9fb57e764b2b84e683feb85e7335","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms","canonical_id":"go:GO:1900428","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3302f98ea57b4fa9b610b1bee5c8c061","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms in response to biotic stimulus","canonical_id":"go:GO:1900443","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to biotic stimulus.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"cad30441466b4730b08c31f06d5d2cbd","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms in response to chemical stimulus","canonical_id":"go:GO:1900437","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to chemical stimulus.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"93844ad137624fda84b513cb4f98cb09","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms in response to heat","canonical_id":"go:GO:1900431","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to heat.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"74e09e312a9142089295a21dd81c3e13","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms in response to neutral pH","canonical_id":"go:GO:1900440","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to neutral pH.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"fd0335ddeb3047cfab50578c8cd5c652","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms in response to pH","canonical_id":"go:GO:1900741","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to pH.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5699880202494ead826f9b2116e0e12f","type":"GO_TERM","name":"regulation of filamentous growth of a population of unicellular organisms in response to starvation","canonical_id":"go:GO:1900434","description":"\"Any process that modulates the frequency, rate or extent of filamentous growth of a population of unicellular organisms in response to starvation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"12ca84b9b12f4baeb05a57b7815bf27c","type":"GO_TERM","name":"regulation of filopodium assembly","canonical_id":"go:GO:0051489","description":"\"Any process that modulates the frequency, rate or extent of the assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"0d32635620b4469cb49cb1c4cd6d4f57","type":"GO_TERM","name":"regulation of flagellated sperm motility","canonical_id":"go:GO:1901317","description":"\"Any process that modulates the frequency, rate or extent of flagellated sperm motility.\" [GOC:cilia, GOC:krc, GOC:TermGenie]","metadata":null},{"id":"36bb46b63bc649b2aa6242fc67b4eb52","type":"GO_TERM","name":"regulation of flavonoid biosynthetic process","canonical_id":"go:GO:0009962","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of flavonoids.\" [GOC:tb]","metadata":null},{"id":"15ac06592dcf4b55995f94199f8a818e","type":"GO_TERM","name":"regulation of flavonol biosynthetic process","canonical_id":"go:GO:1900384","description":"\"Any process that modulates the frequency, rate or extent of flavonol biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"72724807483a453689c43eced322795e","type":"GO_TERM","name":"regulation of flocculation","canonical_id":"go:GO:0060256","description":"\"Any process that modulates the rate, frequency or extent of the non-sexual aggregation of single-celled organisms.\" [PMID:10591965, PMID:15466424, PMID:16568252]","metadata":null},{"id":"e891bde770c847c696eb7ede0ccc139b","type":"GO_TERM","name":"regulation of floral meristem growth","canonical_id":"go:GO:0010080","description":"\"Any process involved in maintaining the size and shape of a floral meristem.\" [GOC:tb]","metadata":null},{"id":"e32bd0d49cfb4c5588ebe10ef867ef44","type":"GO_TERM","name":"regulation of floral organ abscission","canonical_id":"go:GO:0060860","description":"\"Any process that modulates the rate, frequency, or extent of floral organ abscission, the controlled shedding of floral organs.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"087956cbabc646efbc73dcb90e3355f3","type":"GO_TERM","name":"regulation of floral organ abscission by signal transduction","canonical_id":"go:GO:0060863","description":"\"The cascade of processes by which a signal interacts with a receptor, causing a change in the level or activity of a second messenger or other downstream target, and ultimately modulating the rate, or extent of floral organ abscission.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"ff8764ceebcc44bd906fd51d9d6aebe8","type":"GO_TERM","name":"regulation of flower development","canonical_id":"go:GO:0009909","description":"\"Any process that modulates the frequency, rate or extent of flower development.\" [GOC:curators]","metadata":null},{"id":"b3d6350074fb4e32a9edb950e6c88c11","type":"GO_TERM","name":"regulation of focal adhesion assembly","canonical_id":"go:GO:0051893","description":"\"Any process that modulates the frequency, rate or extent of focal adhesion formation, the establishment and maturation of focal adhesions.\" [GOC:ai]","metadata":null},{"id":"39a2d4c2928e4b21840edea93616c95d","type":"GO_TERM","name":"regulation of focal adhesion disassembly","canonical_id":"go:GO:0120182","description":"\"Any process that modulates the frequency, rate or extent of disaggregation of a focal adhesion into its constituent components.\" [PMID:25490267]","metadata":null},{"id":"5d65069b2d5b4fa898d5516fb71d7086","type":"GO_TERM","name":"regulation of follicle cell microvillus length","canonical_id":"go:GO:0032533","description":"\"A process that modulates the length of a microvillus on a follicle cell.\" [GOC:sart, PMID:16260500]","metadata":null},{"id":"fa64805f8a344763bc7accaee1b3287a","type":"GO_TERM","name":"regulation of follicle cell microvillus organization","canonical_id":"go:GO:0032531","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a microvillus on a follicle cell.\" [GOC:mah]","metadata":null},{"id":"062db28460f441b4a420d06df474f13c","type":"GO_TERM","name":"regulation of follicle-stimulating hormone secretion","canonical_id":"go:GO:0046880","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of follicle-stimulating hormone.\" [GOC:ai]","metadata":null},{"id":"66faa9ac126d4f9c8fe2789ff197a733","type":"GO_TERM","name":"regulation of foraging behavior","canonical_id":"go:GO:1903368","description":"\"Any process that modulates the frequency, rate or extent of foraging behavior.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:8677262]","metadata":null},{"id":"3b7003b75bd9434da24dd64a453f3c8d","type":"GO_TERM","name":"regulation of forebrain neuron differentiation","canonical_id":"go:GO:2000977","description":"\"Any process that modulates the frequency, rate or extent of forebrain neuron differentiation.\" [GOC:obol]","metadata":null},{"id":"342761eac84c4151ae7f5f77c8ae4048","type":"GO_TERM","name":"regulation of formation by symbiont of haustorium for nutrient acquisition from host","canonical_id":"go:GO:0075045","description":"\"Any process that modulates the frequency, rate or extent of symbiont haustorium formation for nutrient acquisition from host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"548d98bfb2f24efa988fa26f51474fd1","type":"GO_TERM","name":"regulation of formation of growth cone in injured axon","canonical_id":"go:GO:1905942","description":"\"Any process that modulates the frequency, rate or extent of formation of growth cone in injured axon.\" [GO_REF:0000058, GOC:TermGenie, PMID:19737525]","metadata":null},{"id":"b2d61a6f6157461c84e8a39939c1e036","type":"GO_TERM","name":"regulation of formation of radial glial scaffolds","canonical_id":"go:GO:0061924","description":"\"Any process that modulates the frequency, rate or extent of the formation of radial glial scaffolds. The scaffolds are used as a substrate for the radial migration of cells.\" [PMID:22076441]","metadata":null},{"id":"805f1a9c646045b2b875f203eb6a1b5a","type":"GO_TERM","name":"regulation of formation of translation initiation ternary complex","canonical_id":"go:GO:1901190","description":"\"Any process that modulates the frequency, rate or extent of formation of translation initiation ternary complex.\" [GOC:TermGenie]","metadata":null},{"id":"f8ce4c30556744a08cfe53db6a39dbc9","type":"GO_TERM","name":"regulation of formation of translation preinitiation complex","canonical_id":"go:GO:1901193","description":"\"Any process that modulates the frequency, rate or extent of formation of translation preinitiation complex.\" [GOC:TermGenie]","metadata":null},{"id":"6d2124f50de6495bb9e82a1e190495d7","type":"GO_TERM","name":"regulation of formin-nucleated actin cable assembly","canonical_id":"go:GO:0090337","description":"\"Any process that modulates the rate, frequency, or extent of formin-nucleated actin cable assembly. Formin-nucleated actin cable assembly is the aggregation, arrangement and bonding together of a set of components to form a formin-nucleated actin cable. A formin-nucleated actin cable is an actin filament bundle that consists of short filaments organized into bundles of uniform polarity, and is nucleated by formins.\" [GOC:jh, GOC:tb, PMID:12810699, PMID:15923184]","metadata":null},{"id":"548bdeb0c29d46c29743a2b12c04396f","type":"GO_TERM","name":"regulation of forward locomotion","canonical_id":"go:GO:0043059","description":"\"Any process that modulates the speed, mechanical force, or rhythm of the anterior movement of an organism.\" [GOC:curators]","metadata":null},{"id":"e791be79878c467d8f46fc815ddcffc4","type":"GO_TERM","name":"regulation of fractalkine production","canonical_id":"go:GO:0032644","description":"\"Any process that modulates the frequency, rate, or extent of fractalkine production.\" [GOC:mah]","metadata":null},{"id":"4a5f329878684fab8f337e30dbfaaca8","type":"GO_TERM","name":"regulation of free ubiquitin chain polymerization","canonical_id":"go:GO:1904542","description":"\"Any process that modulates the frequency, rate or extent of free ubiquitin chain polymerization.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:24660806]","metadata":null},{"id":"facae8f8aa5e487c9897f9dbf0291181","type":"GO_TERM","name":"regulation of fumagillin biosynthetic process","canonical_id":"go:GO:1902090","description":"\"Any process that modulates the frequency, rate or extent of fumagillin biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:23488861]","metadata":null},{"id":"ddb232c1f5724e2897f518ee8e945744","type":"GO_TERM","name":"regulation of fumigaclavine C biosynthetic process","canonical_id":"go:GO:1900837","description":"\"Any process that modulates the frequency, rate or extent of fumigaclavine C biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3de7118e9f7d4243b2bc70d632d4e569","type":"GO_TERM","name":"regulation of fumonisin biosynthetic process","canonical_id":"go:GO:1900683","description":"\"Any process that modulates the frequency, rate or extent of fumonisin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5b247feed1694bbe93443bd347a9391e","type":"GO_TERM","name":"regulation of fungal-type cell wall (1->3)-alpha-glucan biosynthetic process","canonical_id":"go:GO:0070610","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of (1->3)-alpha glucans, compounds composed of glucose residues linked by (1->3)-alpha-D-glucosidic bonds, found in fungal-type cell walls, including those of ascospores.\" [GOC:mah]","metadata":null},{"id":"4ecd6792a6de4331a3fef4a5dbf6d263","type":"GO_TERM","name":"regulation of fungal-type cell wall beta-glucan biosynthetic process","canonical_id":"go:GO:0090093","description":"\"Any process that modulates the frequency, rate or extent of fungal-type cell wall beta-glucan biosynthesis, the chemical reactions and pathways resulting in the formation of beta-glucans, compounds composed of glucose residues linked by beta-D-glucosidic bonds, found in the walls of fungal cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3efb989fa3ce42ee916f428e10e46530","type":"GO_TERM","name":"regulation of fungal-type cell wall biogenesis","canonical_id":"go:GO:0032995","description":"\"Any process that modulates the process in which a cell wall is synthesized, aggregates, and bonds together. The fungal-type cell wall contains beta-glucan and may contain chitin.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"c8ebf3957f154876a99e746f31afc23a","type":"GO_TERM","name":"regulation of fungal-type cell wall organization","canonical_id":"go:GO:0060237","description":"\"Any process that modulates the rate, frequency or extent of the formation, arrangement of constituent parts, or disassembly of the fungal-type cell wall.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a773e31bad5545f5a12dc7368fcb35f9","type":"GO_TERM","name":"regulation of fusion of sperm to egg plasma membrane","canonical_id":"go:GO:0043012","description":"\"Any process that modulates the binding and fusion of a sperm to the oocyte plasma membrane.\" [GOC:jl, PMID:11483596]","metadata":null},{"id":"3a6a497b906f40109ff2a1dacc0206d9","type":"GO_TERM","name":"regulation of fusion of virus membrane with host plasma membrane","canonical_id":"go:GO:1903913","description":"\"Any process that modulates the frequency, rate or extent of fusion of virus membrane with host plasma membrane.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"716805bf562c438aa44ac6a430550765","type":"GO_TERM","name":"regulation of galactoglucomannan catabolic process","canonical_id":"go:GO:2000912","description":"\"Any process that modulates the frequency, rate or extent of galactoglucomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"4d1953cefbf1499380107d672caacc15","type":"GO_TERM","name":"regulation of galactomannan catabolic process","canonical_id":"go:GO:2000991","description":"\"Any process that modulates the frequency, rate or extent of galactomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"35080c1ba89748eebf92dc44abb777bc","type":"GO_TERM","name":"regulation of galactotriose transport","canonical_id":"go:GO:1900291","description":"\"Any process that modulates the frequency, rate or extent of galactotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"990c0a91188a4d47a0ee3691ebd29897","type":"GO_TERM","name":"regulation of gamma-aminobutyric acid secretion","canonical_id":"go:GO:0014052","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of gamma-aminobutyric acid.\" [GOC:ef]","metadata":null},{"id":"41f10c672a4d475d903777376413734e","type":"GO_TERM","name":"regulation of gamma-delta T cell activation","canonical_id":"go:GO:0046643","description":"\"Any process that modulates the frequency, rate or extent of gamma-delta T cell activation.\" [GOC:ai]","metadata":null},{"id":"88eced76cd3d437aa964ef482e73b8a6","type":"GO_TERM","name":"regulation of gamma-delta T cell differentiation","canonical_id":"go:GO:0045586","description":"\"Any process that modulates the frequency, rate or extent of gamma-delta T cell differentiation.\" [GOC:curators]","metadata":null},{"id":"7f9dbe61edc24037b6b3a71a5f2fde32","type":"GO_TERM","name":"regulation of gamma-delta T cell proliferation","canonical_id":"go:GO:0046646","description":"\"Any process that modulates the frequency, rate or extent of gamma-delta T cell proliferation.\" [GOC:ai]","metadata":null},{"id":"cec041af97df49f48af9da7599f44e06","type":"GO_TERM","name":"regulation of gap junction assembly","canonical_id":"go:GO:1903596","description":"\"Any process that modulates the frequency, rate or extent of gap junction assembly.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:25017399]","metadata":null},{"id":"283ad7a5909041bbbbd61e809f80d504","type":"GO_TERM","name":"regulation of gastric acid secretion","canonical_id":"go:GO:0060453","description":"\"Any process that modulates the rate frequency or extent of gastric secretion. Gastric secretion is the regulated release of gastric acid (hydrochloric acid) by parietal or oxyntic cells during digestion.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2a0a6868f9634f86b1936177d66f34fe","type":"GO_TERM","name":"regulation of gastric emptying","canonical_id":"go:GO:0120060","description":"\"Any process that modulates the frequency, rate or extent of any gastric emptying process, the process in which the liquid and liquid-suspended solid contents of the stomach exit through the pylorus into the duodenum.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"3356932f2595496193eacbd656e33dcb","type":"GO_TERM","name":"regulation of gastric motility","canonical_id":"go:GO:1905333","description":"\"Any process that modulates the frequency, rate or extent of gastric motility.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:9924029]","metadata":null},{"id":"4b866f34fe3245368f63a87b509e5d17","type":"GO_TERM","name":"regulation of gastric mucosal blood circulation","canonical_id":"go:GO:1904344","description":"\"Any process that modulates the frequency, rate or extent of gastric mucosal blood circulation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10807413]","metadata":null},{"id":"08220462e9874f96a330ad2a09cb6651","type":"GO_TERM","name":"regulation of gastrin-induced gastric acid secretion","canonical_id":"go:GO:1903639","description":"\"Any process that modulates the frequency, rate or extent of gastrin-induced gastric acid secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11123201]","metadata":null},{"id":"ca19659fd6f7475f99bc7fbe86c527c2","type":"GO_TERM","name":"regulation of gastro-intestinal system smooth muscle contraction","canonical_id":"go:GO:1904304","description":"\"Any process that modulates the frequency, rate or extent of gastro-intestinal system smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:10821044]","metadata":null},{"id":"7bbb79a38442467e914453b80ad8184e","type":"GO_TERM","name":"regulation of gastrulation","canonical_id":"go:GO:0010470","description":"\"Any process that modulates the rate or extent of gastrulation. Gastrulation is the complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6a4f9c0389e545a5af2460bb1772eda0","type":"GO_TERM","name":"regulation of gene expression","canonical_id":"go:GO:0010468","description":"\"Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).\" [GOC:txnOH-2018]","metadata":null},{"id":"2789dfa9a3b54d329bb3ba55112ab8a8","type":"GO_TERM","name":"regulation of gene silencing by regulatory ncRNA","canonical_id":"go:GO:0060966","description":"\"Any process that regulates the rate, frequency, or extent of gene silencing by RNA. Gene silencing by RNA is the process in which RNA molecules inactivate expression of target genes.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"abb847dc12cb452db89aed68c2b50ad5","type":"GO_TERM","name":"regulation of generation of precursor metabolites and energy","canonical_id":"go:GO:0043467","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances.\" [GOC:jl]","metadata":null},{"id":"e3ad60cc03b7493586420c352bb63716","type":"GO_TERM","name":"regulation of gerfelin biosynthetic process","canonical_id":"go:GO:1900686","description":"\"Any process that modulates the frequency, rate or extent of gerfelin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"575dae6a16054383aa75eec4c8baece7","type":"GO_TERM","name":"regulation of germ cell proliferation","canonical_id":"go:GO:1905936","description":"\"Any process that modulates the frequency, rate or extent of germ cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15342467]","metadata":null},{"id":"c4c28ae394c448cfbb566cda4dd1d14a","type":"GO_TERM","name":"regulation of germ plasm oskar mRNA localization","canonical_id":"go:GO:0007317","description":"\"Any process that modulates the frequency, rate or extent of the process in which oskar mRNA is transported to, or maintained in, the germ plasm.\" [GOC:hb]","metadata":null},{"id":"c4e1502deb284346b849714f3d2c482b","type":"GO_TERM","name":"regulation of germ tube formation","canonical_id":"go:GO:0075010","description":"\"Any process that modulates the frequency, rate or extent of germ tube formation on or near host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"2ba56c582a65411f8f551855c5496851","type":"GO_TERM","name":"regulation of germinal center formation","canonical_id":"go:GO:0002634","description":"\"Any process that modulates the frequency, rate, or extent of germinal center formation.\" [GOC:add]","metadata":null},{"id":"c02def082fb247588d702971648c9cbd","type":"GO_TERM","name":"regulation of gibberellic acid mediated signaling pathway","canonical_id":"go:GO:0009937","description":"\"Any process that modulates the frequency, rate or extent of gibberellic acid mediated signaling.\" [GOC:curators]","metadata":null},{"id":"c05129c8280b43f9886483b0d6571ba9","type":"GO_TERM","name":"regulation of gibberellin biosynthetic process","canonical_id":"go:GO:0010371","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of gibberellins.\" [GOC:tair_curators]","metadata":null},{"id":"1a492cbd2153411f8aa219cf1bdb5316","type":"GO_TERM","name":"regulation of glial cell apoptotic process","canonical_id":"go:GO:0034350","description":"\"Any process that modulates the frequency, rate, or extent of glial cell apoptotic process.\" [GOC:mah, GOC:mtg_apoptosis]","metadata":null},{"id":"7d42b298a172499c9a11b9f76a6cde3a","type":"GO_TERM","name":"regulation of glial cell differentiation","canonical_id":"go:GO:0045685","description":"\"Any process that modulates the frequency, rate or extent of glia cell differentiation.\" [GOC:curators]","metadata":null},{"id":"519f830b41834491a07f17a38dcce720","type":"GO_TERM","name":"regulation of glial cell migration","canonical_id":"go:GO:1903975","description":"\"Any process that modulates the frequency, rate or extent of glial cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"a3c769714ec245bfacb5081a5cd66235","type":"GO_TERM","name":"regulation of glial cell proliferation","canonical_id":"go:GO:0060251","description":"\"Any process that modulates the frequency, rate or extent of glial cell proliferation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8875d652633a4ad2a488c9c1096a13f5","type":"GO_TERM","name":"regulation of glial cell-derived neurotrophic factor production","canonical_id":"go:GO:1900166","description":"\"Any process that modulates the frequency, rate or extent of glial cell-derived neurotrophic factor production.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"8d1cd23368084862b5d14c208728d2b2","type":"GO_TERM","name":"regulation of gliogenesis","canonical_id":"go:GO:0014013","description":"\"Any process that modulates the frequency, rate or extent of gliogenesis, the formation of mature glia.\" [GOC:ef]","metadata":null},{"id":"91a3d881df7a446080b1725acbf47e5e","type":"GO_TERM","name":"regulation of gliotoxin biosynthetic process","canonical_id":"go:GO:1900689","description":"\"Any process that modulates the frequency, rate or extent of gliotoxin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"138ebf8b346e42c2938b9d6a6688159b","type":"GO_TERM","name":"regulation of glomerular filtration","canonical_id":"go:GO:0003093","description":"\"Any process that modulates the frequency, rate or extent of glomerular filtration. Glomerular filtration is the process in which blood is filtered by the glomerulus into the renal tubule.\" [GOC:mtg_cardio]","metadata":null},{"id":"46190ac398ca473ea619b21ad626b5a2","type":"GO_TERM","name":"regulation of glomerular mesangial cell proliferation","canonical_id":"go:GO:0072124","description":"\"Any process that modulates the frequency, rate or extent of glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d5f636cc9e434dee87011538240cfa12","type":"GO_TERM","name":"regulation of glomerulus development","canonical_id":"go:GO:0090192","description":"\"Any process that modulates the rate, frequency or extent of glomerulus development, the progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"887be579e8324f2ab5bc4ef9f417fb84","type":"GO_TERM","name":"regulation of glucagon secretion","canonical_id":"go:GO:0070092","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of glucagon.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"555d52aac3e64d7987e01bdc7e48ae30","type":"GO_TERM","name":"regulation of glucan biosynthetic process","canonical_id":"go:GO:0010962","description":"\"Any process that modulates the rate, frequency, or extent of glucan biosynthesis. Glucan biosynthetic processes are the chemical reactions and pathways resulting in the formation of glucans, polysaccharides consisting only of glucose residues.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"fd758bcc56c441c28e45201259244c12","type":"GO_TERM","name":"regulation of glucocorticoid biosynthetic process","canonical_id":"go:GO:0031946","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"3799762f14064f5db920840f5c7f59ef","type":"GO_TERM","name":"regulation of glucocorticoid catabolic process","canonical_id":"go:GO:0031949","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"dcb0893cfe034a03af1410243587e6fa","type":"GO_TERM","name":"regulation of glucocorticoid metabolic process","canonical_id":"go:GO:0031943","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving glucocorticoids.\" [GOC:mah]","metadata":null},{"id":"ac2ac0f1947649bfbffb6616130b2337","type":"GO_TERM","name":"regulation of glucocorticoid secretion","canonical_id":"go:GO:2000849","description":"\"Any process that modulates the frequency, rate or extent of glucocorticoid secretion.\" [GOC:sl]","metadata":null},{"id":"08a60c7c4ad74fdfba73879ca7008ffa","type":"GO_TERM","name":"regulation of glucomannan catabolic process","canonical_id":"go:GO:2000898","description":"\"Any process that modulates the frequency, rate or extent of glucomannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"c6d445fa89e64828a50541f642dd3e7f","type":"GO_TERM","name":"regulation of gluconate transmembrane transport","canonical_id":"go:GO:0035430","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a gluconate across a membrane by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"349081cfa1314634ae7ea15f2475d062","type":"GO_TERM","name":"regulation of gluconeogenesis","canonical_id":"go:GO:0006111","description":"\"Any process that modulates the frequency, rate or extent of gluconeogenesis, the formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol.\" [GOC:curators]","metadata":null},{"id":"add7fd2a7fd74ff486e60887846b0515","type":"GO_TERM","name":"regulation of glucose catabolic process to lactate via pyruvate","canonical_id":"go:GO:1904023","description":"\"Any process that modulates the frequency, rate or extent of glucose catabolic process to lactate via pyruvate.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:20935145]","metadata":null},{"id":"ab574defb6dd4ea2b0f01798f1531d02","type":"GO_TERM","name":"regulation of glucose mediated signaling pathway","canonical_id":"go:GO:1902659","description":"\"Any process that modulates the frequency, rate or extent of glucose mediated signaling pathway.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:24277933]","metadata":null},{"id":"dd4ba1d0ff4544e2b73ea9f833fd060e","type":"GO_TERM","name":"regulation of glucose metabolic process","canonical_id":"go:GO:0010906","description":"\"Any process that modulates the rate, frequency or extent of glucose metabolism. Glucose metabolic processes are the chemical reactions and pathways involving glucose, the aldohexose gluco-hexose.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"389ca079358444e5ab1e11d8ec7b9405","type":"GO_TERM","name":"regulation of glucosinolate biosynthetic process","canonical_id":"go:GO:0010439","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosinolates, substituted thioglucosides found in rapeseed products and related cruciferae.\" [PMID:17420480]","metadata":null},{"id":"6c4aad2026214793945888eb572b2315","type":"GO_TERM","name":"regulation of glucosylceramide biosynthetic process","canonical_id":"go:GO:0046317","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide.\" [GOC:ai, GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"dd62670e7d5e4c43b944ad796f13a2cc","type":"GO_TERM","name":"regulation of glucosylceramide catabolic process","canonical_id":"go:GO:2000752","description":"\"Any process that modulates the frequency, rate or extent of glucosylceramide catabolic process.\" [GOC:BHF]","metadata":null},{"id":"4703d5db9c1f4c60a40dd9e82239dc3a","type":"GO_TERM","name":"regulation of glucuronoarabinoxylan catabolic process","canonical_id":"go:GO:2000918","description":"\"Any process that modulates the frequency, rate or extent of glucuronoarabinoxylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"7e1836aa7747432b9aef4608ac91f188","type":"GO_TERM","name":"regulation of glucuronoxylan catabolic process","canonical_id":"go:GO:2000915","description":"\"Any process that modulates the frequency, rate or extent of glucuronoxylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"97440fe648e3444b83730a3e7ab8e3b4","type":"GO_TERM","name":"regulation of glutamate receptor clustering","canonical_id":"go:GO:0106104","description":"\"Any process that modulates the frequency, rate or extent of glutamate receptor clustering.\" [GOC:ha, PMID:28455372]","metadata":null},{"id":"522adb659b37449789ff4b39dfd0fdf4","type":"GO_TERM","name":"regulation of glutamate receptor signaling pathway","canonical_id":"go:GO:1900449","description":"\"Any process that modulates the frequency, rate or extent of glutamate receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"d4fd8d238f244258b740a7c899d6160b","type":"GO_TERM","name":"regulation of glutamate secretion","canonical_id":"go:GO:0014048","description":"\"Any process that modulates the frequency, rate or extent of the controlled release of glutamate.\" [GOC:ef]","metadata":null},{"id":"0afce55241a54c7693606d3e2e3ed3ae","type":"GO_TERM","name":"regulation of glutamate secretion, neurotransmission","canonical_id":"go:GO:1903294","description":"\"Any process that modulates the frequency, rate or extent of glutamate secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:16782817]","metadata":null},{"id":"58e92f0f1a044581860f759d208e8b81","type":"GO_TERM","name":"regulation of glutamate uptake involved in transmission of nerve impulse","canonical_id":"go:GO:0051946","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of L-glutamate into a neuron or glial cell.\" [GOC:ai]","metadata":null},{"id":"d9dccbbb5b044698ba20d7853b05cb8c","type":"GO_TERM","name":"regulation of glutamatergic neuron differentiation","canonical_id":"go:GO:0120006","description":"\"Any process that modulates the frequency, rate or extent of glutamatergic neuron differentiation.\" [PMID:24030726]","metadata":null},{"id":"ccb5a40b157c4211b1c676864c3a23e1","type":"GO_TERM","name":"regulation of glutamine transport","canonical_id":"go:GO:2000485","description":"\"Any process that modulates the frequency, rate or extent of glutamine transport.\" [GOC:obol]","metadata":null},{"id":"ec1a6d2869414815a4164ec0d8902ebc","type":"GO_TERM","name":"regulation of glutathione biosynthetic process","canonical_id":"go:GO:1903786","description":"\"Any process that modulates the frequency, rate or extent of glutathione biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"d26e6f6376884ec3a499dc488f6774ad","type":"GO_TERM","name":"regulation of glycerol transport","canonical_id":"go:GO:0090371","description":"\"Any process that modulates the rate, frequency, or extent of the directed movement of glycerol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:jh, GOC:tb]","metadata":null},{"id":"1cd483b81ba547968b7df51da6853864","type":"GO_TERM","name":"regulation of glycine import across plasma membrane","canonical_id":"go:GO:1900923","description":"\"Any process that modulates the frequency, rate or extent of glycine import into a cell.\" [GOC:TermGenie]","metadata":null},{"id":"4eed503959054f6abd61e7d71fa28fe4","type":"GO_TERM","name":"regulation of glycine secretion, neurotransmission","canonical_id":"go:GO:1904624","description":"\"Any process that modulates the frequency, rate or extent of glycine secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:22988142]","metadata":null},{"id":"f8fe5202aee141feb5e6bc50170c1cdb","type":"GO_TERM","name":"regulation of glycogen (starch) synthase activity","canonical_id":"go:GO:2000465","description":"\"Any process that modulates the frequency, rate or extent of glycogen (starch) synthase activity.\" [GOC:obol]","metadata":null},{"id":"7a657e8b233f4426b6073c7b82e475db","type":"GO_TERM","name":"regulation of glycogen biosynthetic process","canonical_id":"go:GO:0005979","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen.\" [GOC:curators]","metadata":null},{"id":"7b9c8ddf039f464880d008b8037f3a30","type":"GO_TERM","name":"regulation of glycogen catabolic process","canonical_id":"go:GO:0005981","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen.\" [GOC:curators]","metadata":null},{"id":"46a8b40520aa4e218b1452bd71e60d8d","type":"GO_TERM","name":"regulation of glycogen metabolic process","canonical_id":"go:GO:0070873","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving glycogen.\" [GOC:mah]","metadata":null},{"id":"c291caa888864c6bb3e60cc52bbb54f3","type":"GO_TERM","name":"regulation of glycolytic fermentation to ethanol","canonical_id":"go:GO:2001154","description":"\"Any process that modulates the frequency, rate or extent of glucose catabolic process to ethanol.\" [GOC:obol]","metadata":null},{"id":"db5d0ac3b2a346e9bd7d4f2507c5c927","type":"GO_TERM","name":"regulation of glycolytic process","canonical_id":"go:GO:0006110","description":"\"Any process that modulates the frequency, rate or extent of glycolysis.\" [GOC:curators]","metadata":null},{"id":"20867653c0354e4f9ba63866f7bfb32d","type":"GO_TERM","name":"regulation of glycoprotein biosynthetic process","canonical_id":"go:GO:0010559","description":"\"Any process that modulates the rate, frequency, or extent of the chemical reactions and pathways resulting in the formation of a glycoprotein, a protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b82c969fbbf141969459659ab063b41c","type":"GO_TERM","name":"regulation of glycoprotein metabolic process","canonical_id":"go:GO:1903018","description":"\"Any process that modulates the frequency, rate or extent of glycoprotein metabolic process.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23544079]","metadata":null},{"id":"8d57eb0d632d469c85beb3744e458043","type":"GO_TERM","name":"regulation of glyoxylate cycle","canonical_id":"go:GO:2000874","description":"\"Any process that modulates the frequency, rate or extent of glyoxylate cycle.\" [GOC:dgf]","metadata":null},{"id":"301c451b157b4edbab46a142a80edeb8","type":"GO_TERM","name":"regulation of gonad development","canonical_id":"go:GO:1905939","description":"\"Any process that modulates the frequency, rate or extent of gonad development.\" [GO_REF:0000058, GOC:TermGenie, PMID:15342467]","metadata":null},{"id":"022fbc98db374beeafb95f2d818e6ca0","type":"GO_TERM","name":"regulation of gonadotropin secretion","canonical_id":"go:GO:0032276","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of a gonadotropin.\" [GOC:mah]","metadata":null},{"id":"0ff5eca7e59d4c24b278d3e233ac8f98","type":"GO_TERM","name":"regulation of granulocyte chemotaxis","canonical_id":"go:GO:0071622","description":"\"Any process that modulates the rate, frequency or extent of granulocyte chemotaxis. Granulocyte chemotaxis is the movement of a granulocyte in response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"28f9ccc924cb4ba49bebc0d8c631edf2","type":"GO_TERM","name":"regulation of granulocyte colony-stimulating factor production","canonical_id":"go:GO:0071655","description":"\"Any process that modulates the frequency, rate, or extent of production of granulocyte colony-stimulating factor.\" [GOC:mah]","metadata":null},{"id":"891db2e71cf14c26abfe6d1b85671f80","type":"GO_TERM","name":"regulation of granulocyte differentiation","canonical_id":"go:GO:0030852","description":"\"Any process that modulates the frequency, rate or extent of granulocyte differentiation.\" [GOC:mah]","metadata":null},{"id":"690c4a07c63d44428edf7cdb4cc45de2","type":"GO_TERM","name":"regulation of granulocyte macrophage colony-stimulating factor production","canonical_id":"go:GO:0032645","description":"\"Any process that modulates the frequency, rate, or extent of granulocyte macrophage colony-stimulating factor production.\" [GOC:mah]","metadata":null},{"id":"2fbccf0ce4384ac8869c6a208d2a01ba","type":"GO_TERM","name":"regulation of granuloma formation","canonical_id":"go:GO:0002631","description":"\"Any process that modulates the frequency, rate, or extent of granuloma formation.\" [GOC:add]","metadata":null},{"id":"6c2d33dd031a48e9aa7346eb2b343089","type":"GO_TERM","name":"regulation of granulosa cell apoptotic process","canonical_id":"go:GO:1904708","description":"\"Any process that modulates the frequency, rate or extent of granulosa cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:19208546]","metadata":null},{"id":"532910da6609463e9edf78418f4943a1","type":"GO_TERM","name":"regulation of granulosa cell proliferation","canonical_id":"go:GO:1904195","description":"\"Any process that modulates the frequency, rate or extent of granulosa cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22383759]","metadata":null},{"id":"88581e0a6cd94e7a893f5f233d2b9250","type":"GO_TERM","name":"regulation of granzyme A production","canonical_id":"go:GO:2000511","description":"\"Any process that modulates the frequency, rate or extent of granzyme A production.\" [GOC:obol]","metadata":null},{"id":"956555b3aa044a178c2e7a82a58f6e53","type":"GO_TERM","name":"regulation of granzyme B production","canonical_id":"go:GO:0071661","description":"\"Any process that modulates the frequency, rate, or extent of production of granzyme B.\" [GOC:mah]","metadata":null},{"id":"707a69e5ddf04d4ea71c7fb888fb95ad","type":"GO_TERM","name":"regulation of grooming behavior","canonical_id":"go:GO:2000821","description":"\"Any process that modulates the frequency, rate or extent of grooming behavior.\" [GOC:BHF]","metadata":null},{"id":"df3460aeb7c145c9a316709967de6cf8","type":"GO_TERM","name":"regulation of growth","canonical_id":"go:GO:0040008","description":"\"Any process that modulates the frequency, rate or extent of the growth of all or part of an organism so that it occurs at its proper speed, either globally or in a specific part of the organism's development.\" [GOC:ems, GOC:mah]","metadata":null},{"id":"7c07d4bfb66b45299dab7d6caccc14c7","type":"GO_TERM","name":"regulation of growth hormone receptor signaling pathway","canonical_id":"go:GO:0060398","description":"\"Any process that modulates the rate, frequency or extent of the growth hormone receptor signaling pathway. The growth hormone receptor signaling pathway is the series of molecular signals generated as a consequence of growth hormone receptor binding to its physiological ligand.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"ec26d359eb3b4f3fb6cc02734009d6ae","type":"GO_TERM","name":"regulation of growth hormone secretion","canonical_id":"go:GO:0060123","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of growth hormone from a cell.\" [GOC:dph]","metadata":null},{"id":"aa32a0713e864cbd9de89ab98c444fd3","type":"GO_TERM","name":"regulation of growth of unicellular organism as a thread of attached cells","canonical_id":"go:GO:0070784","description":"\"Any process that modulates the frequency, rate or extent of the process in which cells remain attached after division and form thread-like filaments that may penetrate into a solid growth medium.\" [GOC:mah]","metadata":null},{"id":"d47a6c17e0654ce693cb53150a8104d6","type":"GO_TERM","name":"regulation of growth plate cartilage chondrocyte differentiation","canonical_id":"go:GO:1902733","description":"\"Any process that modulates the rate, frequency, or extent of the process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte that will contribute to the growth of a bone. A chondrocyte is a polymorphic cell that forms cartilage.\" [GO_REF:0000058, GOC:TermGenie, PMID:23212449]","metadata":null},{"id":"0ab05d0288d341a1a15173c53a20d476","type":"GO_TERM","name":"regulation of growth plate cartilage chondrocyte proliferation","canonical_id":"go:GO:0003420","description":"\"Any process that modulates the rate, frequency, or extent of the multiplication or reproduction of chondrocytes in a growing endochondral bone, resulting in the expansion of a cell population.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"4fd52d1f26024b7d8f3798b69c338152","type":"GO_TERM","name":"regulation of growth rate","canonical_id":"go:GO:0040009","description":"\"Any process that modulates the rate of growth of all or part of an organism.\" [GOC:mah]","metadata":null},{"id":"69ee0b8d2efd400fad8204d1233d334b","type":"GO_TERM","name":"regulation of gut granule assembly","canonical_id":"go:GO:1904755","description":"\"Any process that modulates the frequency, rate or extent of gut granule assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:17535251]","metadata":null},{"id":"459110866d054582806039109136dd98","type":"GO_TERM","name":"regulation of hair cycle","canonical_id":"go:GO:0042634","description":"\"Any process that modulates the frequency, rate or extent of the cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair.\" [GOC:curators, PMID:12230507]","metadata":null},{"id":"7e854de065dc4c6c8f715db6be40253d","type":"GO_TERM","name":"regulation of hair follicle cell proliferation","canonical_id":"go:GO:0071336","description":"\"Any process that modulates the frequency, rate or extent of hair follicle cell proliferation.\" [GOC:mah]","metadata":null},{"id":"f55410e90d7044c2b2281efea1992a95","type":"GO_TERM","name":"regulation of hair follicle development","canonical_id":"go:GO:0051797","description":"\"Any process that modulates the frequency, rate or extent of hair follicle development.\" [GOC:ai]","metadata":null},{"id":"c50aaa277e604b5d885125c642450813","type":"GO_TERM","name":"regulation of hair follicle maturation","canonical_id":"go:GO:0048819","description":"\"Any process that modulates the frequency, rate or extent of hair follicle maturation.\" [GOC:devbiol]","metadata":null},{"id":"4a665f405ae940babd419aec068b51f1","type":"GO_TERM","name":"regulation of hair follicle placode formation","canonical_id":"go:GO:0061168","description":"\"Any process that modulates the rate, frequency, or extent of hair follicle placode formation, the developmental process in which a hair placode forms. An hair follicle placode is a thickening of the ectoderm that will give rise to the hair follicle bud.\" [GOC:dph]","metadata":null},{"id":"26ccb4d4e28b4cd580024beac120432f","type":"GO_TERM","name":"regulation of haustorium mother cell formation","canonical_id":"go:GO:0075193","description":"\"Any process that modulates the frequency, rate or extent of symbiont haustorium mother cell formation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"4f998c545b67437091d7f9b582c09289","type":"GO_TERM","name":"regulation of heart contraction","canonical_id":"go:GO:0008016","description":"\"Any process that modulates the frequency, rate or extent of heart contraction. Heart contraction is the process in which the heart decreases in volume in a characteristic way to propel blood through the body.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"f0352ccad37b45dbbde9933f3a14eccd","type":"GO_TERM","name":"regulation of heart growth","canonical_id":"go:GO:0060420","description":"\"Any process that modulates the rate or extent of heart growth. Heart growth is the increase in size or mass of the heart.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6129ca7348264c44badf7e5870719618","type":"GO_TERM","name":"regulation of heart induction","canonical_id":"go:GO:0090381","description":"\"Any process that modulates the rate, frequency, or extent of heart induction. Heart induction is the close range interaction between mesoderm and endoderm or ectoderm that causes cells to change their fates and specify the development of the heart.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0e008200312a48cabfe2eed4a3e35b4e","type":"GO_TERM","name":"regulation of heart looping","canonical_id":"go:GO:1901207","description":"\"Any process that modulates the frequency, rate or extent of heart looping.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"c021ef306a8e40d183d08d2a6d6fb145","type":"GO_TERM","name":"regulation of heart morphogenesis","canonical_id":"go:GO:2000826","description":"\"Any process that modulates the frequency, rate or extent of heart morphogenesis.\" [GOC:BHF]","metadata":null},{"id":"702d1f87e944470da0f78fed3f2bf87f","type":"GO_TERM","name":"regulation of heart rate","canonical_id":"go:GO:0002027","description":"\"Any process that modulates the frequency or rate of heart contraction.\" [GOC:dph, GOC:tb, PMID:10358008]","metadata":null},{"id":"7043ded921f34a6b9f11b0f92ac0975a","type":"GO_TERM","name":"regulation of heart rate by cardiac conduction","canonical_id":"go:GO:0086091","description":"\"A cardiac conduction process that modulates the frequency or rate of heart contraction.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"8fc01197d5434592b710cf15479f5a83","type":"GO_TERM","name":"regulation of heart rate by chemical signal","canonical_id":"go:GO:0003062","description":"\"The regulation of the rate of heart contraction mediated by chemical signaling, hormonal, autocrine or paracrine.\" [GOC:dph, GOC:mtg_cardio, GOC:rl, GOC:tb]","metadata":null},{"id":"c957482b87b9434ea33acfa4c9673e4b","type":"GO_TERM","name":"regulation of heart rate by hormone","canonical_id":"go:GO:0003064","description":"\"The process in which the hormones modulates the rate of heart muscle contraction. A hormone is one of a group of substances formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells, in the same organism, upon which they have a specific regulatory action.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"b16e8a620337401c9b8c51a2e2cde7da","type":"GO_TERM","name":"regulation of heat dissipation","canonical_id":"go:GO:0031654","description":"\"Any process that modulates the rate or extent of heat dissipation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"7d8a5723b7074740aef37ef6ec406805","type":"GO_TERM","name":"regulation of heat generation","canonical_id":"go:GO:0031650","description":"\"Any process that modulates the rate or extent of heat generation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"1ee8d4ca974844389b917aeeedf59f13","type":"GO_TERM","name":"regulation of helvolic acid biosynthetic process","canonical_id":"go:GO:1900840","description":"\"Any process that modulates the frequency, rate or extent of helvolic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7e7ce08b5af3492f87316fa588fdbb07","type":"GO_TERM","name":"regulation of hematopoietic progenitor cell differentiation","canonical_id":"go:GO:1901532","description":"\"Any process that modulates the frequency, rate or extent of hematopoietic progenitor cell differentiation.\" [GOC:BHF, GOC:rl, GOC:TermGenie]","metadata":null},{"id":"2f5b8011898a4647a0bc27508f0c599a","type":"GO_TERM","name":"regulation of hematopoietic stem cell differentiation","canonical_id":"go:GO:1902036","description":"\"Any process that modulates the frequency, rate or extent of hematopoietic stem cell differentiation.\" [GOC:TermGenie, PMID:23403623]","metadata":null},{"id":"2af6255f2dcb4228a24a7e7ed9133813","type":"GO_TERM","name":"regulation of hematopoietic stem cell migration","canonical_id":"go:GO:2000471","description":"\"Any process that modulates the frequency, rate or extent of hematopoietic stem cell migration.\" [GOC:obol]","metadata":null},{"id":"2a15235bbf094ab7bb436ba5335fe746","type":"GO_TERM","name":"regulation of hematopoietic stem cell proliferation","canonical_id":"go:GO:1902033","description":"\"Any process that modulates the frequency, rate or extent of hematopoietic stem cell proliferation.\" [GOC:TermGenie, PMID:23403623]","metadata":null},{"id":"2138d58b752549db8c6a7274c06eed51","type":"GO_TERM","name":"regulation of heme biosynthetic process","canonical_id":"go:GO:0070453","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of heme.\" [GOC:mah]","metadata":null},{"id":"55c76e713d9b4589bc7359975044809b","type":"GO_TERM","name":"regulation of hemicellulose catabolic process","canonical_id":"go:GO:2000988","description":"\"Any process that modulates the frequency, rate or extent of hemicellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"fcf554d35af94636b35a7f16ed0f82b8","type":"GO_TERM","name":"regulation of hemocyte differentiation","canonical_id":"go:GO:0045610","description":"\"Any process that modulates the frequency, rate or extent of hemocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"8f4388f2a5b549488fba8dba6eefa552","type":"GO_TERM","name":"regulation of hemocyte proliferation","canonical_id":"go:GO:0035206","description":"\"Any process that modulates the frequency, rate or extent of hemocyte proliferation. Hemocytes are blood cells associated with a hemocoel (the cavity containing most of the major organs of the arthropod body) which are involved in defense and clotting of hemolymph, but not involved in transport of oxygen. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"524e242f8c9546ab9e112caef1072a6a","type":"GO_TERM","name":"regulation of hemoglobin biosynthetic process","canonical_id":"go:GO:0046984","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of hemoglobin, an oxygen carrying, conjugated protein containing four heme groups and globin.\" [GOC:ai]","metadata":null},{"id":"f8888e1e1be948499687b881e69c172e","type":"GO_TERM","name":"regulation of hemopoiesis","canonical_id":"go:GO:1903706","description":"\"Any process that modulates the frequency, rate or extent of hemopoiesis.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:20080761]","metadata":null},{"id":"df640bbafab844308ec3a43dc43be0d7","type":"GO_TERM","name":"regulation of hemostasis","canonical_id":"go:GO:1900046","description":"\"Any process that modulates the frequency, rate or extent of hemostasis.\" [GOC:TermGenie]","metadata":null},{"id":"9b3cf7173e4747999436a0358437b866","type":"GO_TERM","name":"regulation of heparan sulfate proteoglycan biosynthetic process","canonical_id":"go:GO:0010908","description":"\"Any process that modulates the rate, frequency or extent of heparan sulfate proteoglycan biosynthesis. Heparan sulfate proteoglycan biosynthetic processes are the chemical reactions and pathways resulting in the formation of the heparan sulfate proteoglycan, which consists of a core protein linked to a heparan sulfate glycosaminoglycan. The heparan sulfate chain is composed of the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid.\" [GOC:curators]","metadata":null},{"id":"3d22c91ca8c64ebd99aa9d7bf0c9a1ac","type":"GO_TERM","name":"regulation of hepatic stellate cell activation","canonical_id":"go:GO:2000489","description":"\"Any process that modulates the frequency, rate or extent of hepatic stellate cell activation.\" [GOC:obol]","metadata":null},{"id":"04ccea849cf34166bfa6bf43d302f8d7","type":"GO_TERM","name":"regulation of hepatic stellate cell contraction","canonical_id":"go:GO:0061873","description":"\"Any process that modulates the frequency, rate or extent of hepatic stellate cell contraction.\" [PMID:24204762]","metadata":null},{"id":"fbab4a6f46c84ee4b622ea6f7bd8ea55","type":"GO_TERM","name":"regulation of hepatic stellate cell migration","canonical_id":"go:GO:0061869","description":"\"Any process that modulates the frequency, rate or extent of hepatic stellate cell migration.\" [PMID:24204762]","metadata":null},{"id":"de9dceac701c439b8a4c6936e35fb52e","type":"GO_TERM","name":"regulation of hepatic stellate cell proliferation","canonical_id":"go:GO:1904897","description":"\"Any process that modulates the frequency, rate or extent of hepatic stellate cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15358192]","metadata":null},{"id":"5ef7a9c00d42419f9c16c91b19b2bd72","type":"GO_TERM","name":"regulation of hepatocyte apoptotic process","canonical_id":"go:GO:1903943","description":"\"Any process that modulates the frequency, rate or extent of hepatocyte apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:8649852]","metadata":null},{"id":"2e67a9097dad43758d86f7997efab375","type":"GO_TERM","name":"regulation of hepatocyte differentiation","canonical_id":"go:GO:0070366","description":"\"Any process that modulates the frequency, rate or extent of hepatocyte differentiation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"c6728ab7c6b740b29fd897d022644a24","type":"GO_TERM","name":"regulation of hepatocyte growth factor production","canonical_id":"go:GO:0032646","description":"\"Any process that modulates the frequency, rate, or extent of hepatocyte growth factor production.\" [GOC:mah, PMID:1838014]","metadata":null},{"id":"8611a04b26bd42babb340b8a3730437d","type":"GO_TERM","name":"regulation of hepatocyte growth factor receptor signaling pathway","canonical_id":"go:GO:1902202","description":"\"Any process that modulates the frequency, rate or extent of hepatocyte growth factor receptor signaling pathway.\" [GOC:TermGenie, PMID:18819921]","metadata":null},{"id":"e9ce0c8921984d99a52dbbea2f3dfe56","type":"GO_TERM","name":"regulation of hepatocyte proliferation","canonical_id":"go:GO:2000345","description":"\"Any process that modulates the frequency, rate or extent of hepatocyte proliferation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"706e58de5f644aaf8c8efa9307026c83","type":"GO_TERM","name":"regulation of heptadecane biosynthetic process","canonical_id":"go:GO:1900896","description":"\"Any process that modulates the frequency, rate or extent of heptadecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"96748ed9a4b64c6fa76a808764e46b63","type":"GO_TERM","name":"regulation of heptasaccharide transport","canonical_id":"go:GO:1900294","description":"\"Any process that modulates the frequency, rate or extent of heptasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"11d1f0af15f1463c9553977536ef6769","type":"GO_TERM","name":"regulation of heterochromatin formation","canonical_id":"go:GO:0031445","description":"\"Any process that modulates the frequency, rate, extent or location of heterochromatin formation.\" [GOC:mah]","metadata":null},{"id":"a0f9f5f732b140c990b7bd5a1e951944","type":"GO_TERM","name":"regulation of heterochromatin organization","canonical_id":"go:GO:0120261","description":"\"Any process that modulates the frequency, rate, extent or location of heterochromatin organization.\" [GOC:krc]","metadata":null},{"id":"5650b765a7e345e8bd55de1f33a6201a","type":"GO_TERM","name":"regulation of heterotypic cell-cell adhesion","canonical_id":"go:GO:0034114","description":"\"Any process that modulates the frequency, rate, or extent of heterotypic cell-cell adhesion.\" [GOC:add]","metadata":null},{"id":"86fda38a8bcb4f2abfaedf3756657a70","type":"GO_TERM","name":"regulation of hexadecanal biosynthetic process","canonical_id":"go:GO:1900902","description":"\"Any process that modulates the frequency, rate or extent of hexadecanal biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"cbf9b5ac1c3c4efeb903cd8b757740e7","type":"GO_TERM","name":"regulation of hexasaccharide transport","canonical_id":"go:GO:1900297","description":"\"Any process that modulates the frequency, rate or extent of hexasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"0b210c51947e48ca8ec2112b8b5a0e24","type":"GO_TERM","name":"regulation of high-density lipoprotein particle assembly","canonical_id":"go:GO:0090107","description":"\"Any process that modulates the frequency, rate, or extent of high-density lipoprotein particle assembly. High-density lipoprotein particle assembly is the aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2bad0c3a870c45dcba3c807757275eb8","type":"GO_TERM","name":"regulation of high-density lipoprotein particle clearance","canonical_id":"go:GO:0010982","description":"\"Any process that modulates the rate, frequency or extent of high-density lipoprotein particle clearance. High-density lipoprotein particle clearance is the process in which a high-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5e08c71d9ce74d5898b2cef7a2c61060","type":"GO_TERM","name":"regulation of hindgut contraction","canonical_id":"go:GO:0043134","description":"\"Any process that modulates the frequency, rate or extent of muscle contraction of the hindgut, the posterior part of the alimentary canal, including the rectum, and the large intestine.\" [GOC:jl, UBERON:0001046]","metadata":null},{"id":"2a25ba97ecb041b2b025439376275023","type":"GO_TERM","name":"regulation of hippo signaling","canonical_id":"go:GO:0035330","description":"\"Any process that modulates the frequency, rate or extent of hippo signaling.\" [GOC:bf]","metadata":null},{"id":"5fd82fb3fa1e4662b881ef2bdaf6965d","type":"GO_TERM","name":"regulation of hippocampal neuron apoptotic process","canonical_id":"go:GO:0110089","description":"\"Any process that modulates the occurrence or rate of cell death by apoptotic process in hippocampal neurons.\" [GOC:sl, PMID:18940801]","metadata":null},{"id":"691fd02a39fb4271afc5930bc6fe027a","type":"GO_TERM","name":"regulation of histamine secretion by mast cell","canonical_id":"go:GO:1903593","description":"\"Any process that modulates the frequency, rate or extent of histamine secretion by mast cell.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18253931]","metadata":null},{"id":"1b42e00b0d8a41d08c02d5ca1f671ffb","type":"GO_TERM","name":"regulation of histamine uptake","canonical_id":"go:GO:0051616","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of the neurotransmitter histamine into a cell.\" [GOC:ai]","metadata":null},{"id":"c814f1f416db4b22806820cb199069ae","type":"GO_TERM","name":"regulation of histidine biosynthetic process","canonical_id":"go:GO:0120213","description":"\"Any process that modulates the frequency, rate or extent of histidine biosynthetic process.\" [GOC:krc]","metadata":null},{"id":"a4a381cdd1c346a496a58ca5db2b05ea","type":"GO_TERM","name":"regulation of homologous chromosome segregation","canonical_id":"go:GO:0060629","description":"\"Any process that modulates the rate, frequency, or extent of homologous chromosome segregation, the cell cycle process in which replicated homologous chromosomes are organized and then physically separated and apportioned to two sets during the first division of the meiotic cell cycle. Each replicated chromosome, composed of two sister chromatids, aligns at the cell equator, paired with its homologous partner; this pairing off, referred to as synapsis, permits genetic recombination. One homolog (both sister chromatids) of each morphologic type goes into each of the resulting chromosome sets.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"0b45d376aff1459b97151600ab3cc663","type":"GO_TERM","name":"regulation of homophilic cell adhesion","canonical_id":"go:GO:1903385","description":"\"Any process that modulates the frequency, rate or extent of homophilic cell adhesion.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:21724833]","metadata":null},{"id":"0bffb6c884714361a11433a1b42e66e5","type":"GO_TERM","name":"regulation of homoserine biosynthetic process","canonical_id":"go:GO:1901710","description":"\"Any process that modulates the frequency, rate or extent of homoserine biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"d2ffc686ef1e4d238410cd3ae3d133cc","type":"GO_TERM","name":"regulation of homotypic cell-cell adhesion","canonical_id":"go:GO:0034110","description":"\"Any process that modulates the frequency, rate, or extent of homotypic cell-cell adhesion.\" [GOC:add]","metadata":null},{"id":"d2a446793da2448499557dbe075be82a","type":"GO_TERM","name":"regulation of horizontal cell localization","canonical_id":"go:GO:1902872","description":"\"Any process that modulates the frequency, rate or extent of horizontal cell localization.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"7d67e488a4774624a05463a1b1a2c20b","type":"GO_TERM","name":"regulation of hormone biosynthetic process","canonical_id":"go:GO:0046885","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of hormones.\" [GOC:ai]","metadata":null},{"id":"9e5d3e5c3bbf45fdb92d230b8a8c92c1","type":"GO_TERM","name":"regulation of hormone levels","canonical_id":"go:GO:0010817","description":"\"Any process that modulates the levels of hormone within an organism or a tissue. A hormone is any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"9e3268aa9655456bb81780dec9747954","type":"GO_TERM","name":"regulation of hormone metabolic process","canonical_id":"go:GO:0032350","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving any hormone.\" [GOC:mah]","metadata":null},{"id":"6d4df189200247bbb84cb8cf5218fc1b","type":"GO_TERM","name":"regulation of hormone secretion","canonical_id":"go:GO:0046883","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of a hormone from a cell.\" [GOC:ai]","metadata":null},{"id":"b1983389fc9740cdb385305463e333de","type":"GO_TERM","name":"regulation of host-seeking behavior","canonical_id":"go:GO:0032538","description":"\"Any process that modulates the frequency, rate or extent of any behavior associated with finding a host organism.\" [GOC:mah]","metadata":null},{"id":"959b165c90d6423cb85c6b44bde41e45","type":"GO_TERM","name":"regulation of humoral immune response","canonical_id":"go:GO:0002920","description":"\"Any process that modulates the frequency, rate, or extent of a humoral immune response.\" [GOC:add]","metadata":null},{"id":"0db23ee6d85f45acbdde134109e62f95","type":"GO_TERM","name":"regulation of humoral immune response mediated by circulating immunoglobulin","canonical_id":"go:GO:0002923","description":"\"Any process that modulates the frequency, rate, or extent of a humoral immune response mediated by circulating immunoglobulin.\" [GOC:add]","metadata":null},{"id":"7110e90710794036929a98bbd12cea49","type":"GO_TERM","name":"regulation of hyaluranon cable assembly","canonical_id":"go:GO:1900104","description":"\"Any process that modulates the frequency, rate or extent of hyaluranon cable assembly.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"1e53c0de40ab4e2d8b5b9c97da956d64","type":"GO_TERM","name":"regulation of hyaluronan biosynthetic process","canonical_id":"go:GO:1900125","description":"\"Any process that modulates the frequency, rate or extent of hyaluronan biosynthetic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"20076945dc344b8e87e0024adec62616","type":"GO_TERM","name":"regulation of hydrogen peroxide biosynthetic process","canonical_id":"go:GO:0010728","description":"\"Any process that modulates the rate, frequency or extent of hydrogen peroxide biosynthesis. The chemical reactions and pathways resulting in the formation of hydrogen peroxide (H2O2), a potentially harmful byproduct of aerobic cellular respiration which can cause damage to DNA.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"5f49e8aef06440449f61244587d74308","type":"GO_TERM","name":"regulation of hydrogen peroxide catabolic process","canonical_id":"go:GO:2000295","description":"\"Any process that modulates the frequency, rate or extent of hydrogen peroxide catabolic process.\" [GOC:BHF]","metadata":null},{"id":"8a266cf79ce4487b9bf151d0855d545f","type":"GO_TERM","name":"regulation of hydrogen peroxide metabolic process","canonical_id":"go:GO:0010310","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving hydrogen peroxide.\" [PMID:14765119]","metadata":null},{"id":"c2372b9ed99f4404a88bcc205bea3065","type":"GO_TERM","name":"regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903383","description":"\"Any process that modulates the frequency, rate or extent of a hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"1e3a2d5778c849b7b2286bdefb670895","type":"GO_TERM","name":"regulation of hydrogen peroxide-mediated programmed cell death","canonical_id":"go:GO:1901298","description":"\"Any process that modulates the frequency, rate or extent of hydrogen peroxide-mediated programmed cell death.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"572fde744acd4fd3937768e4c842daee","type":"GO_TERM","name":"regulation of hydrogen sulfide biosynthetic process","canonical_id":"go:GO:1904826","description":"\"Any process that modulates the frequency, rate or extent of hydrogen sulfide biosynthetic process.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22034194]","metadata":null},{"id":"e8ef4067e7ff4e5ba26274d17dcf2e48","type":"GO_TERM","name":"regulation of hydrolase activity","canonical_id":"go:GO:0051336","description":"\"Any process that modulates the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.\" [GOC:ai]","metadata":null},{"id":"6a5a2fcbbf524417b902d75bc98eb24b","type":"GO_TERM","name":"regulation of hypersensitivity","canonical_id":"go:GO:0002883","description":"\"Any process that modulates the frequency, rate, or extent of hypersensitivity.\" [GOC:add]","metadata":null},{"id":"c18a5bcefed64050b033f14d7e3dbf04","type":"GO_TERM","name":"regulation of hyphopodium formation","canonical_id":"go:GO:0075188","description":"\"Any process that modulates the frequency, rate or extent of symbiont hyphopodium formation on or near its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"6298bc52bbc14809908dc88c754a2d80","type":"GO_TERM","name":"regulation of hypoxanthine transport","canonical_id":"go:GO:0035345","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of hypoxanthine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"3783594819934449b0142cdfdd7e4689","type":"GO_TERM","name":"regulation of hypoxia-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903297","description":"\"Any process that modulates the frequency, rate or extent of hypoxia-induced intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"979226ab02bc425f878df2a9bae24cf5","type":"GO_TERM","name":"regulation of hypoxia-inducible factor-1alpha signaling pathway","canonical_id":"go:GO:1902071","description":"\"Any process that modulates the frequency, rate or extent of hypoxia-inducible factor-1alpha signaling pathway.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"8dfe617bbd0542eba4b9f80aedcda69f","type":"GO_TERM","name":"regulation of icosanoid secretion","canonical_id":"go:GO:0032303","description":"\"Any process that modulates the frequency, rate or extent of the controlled release of an icosanoid from a cell.\" [GOC:mah]","metadata":null},{"id":"84b16ef613b743bf950118de8a14e0c7","type":"GO_TERM","name":"regulation of imaginal disc growth","canonical_id":"go:GO:0045570","description":"\"Any process that modulates the frequency, rate or extent of the growth of the imaginal disc.\" [GOC:curators]","metadata":null},{"id":"8bc639a484164005ac4d30bf0faf8af4","type":"GO_TERM","name":"regulation of imaginal disc-derived leg joint morphogenesis","canonical_id":"go:GO:0110137","description":"\"Any process that modulates the frequency, rate or extent of imaginal disc-derived leg joint morphogenesis, the process in which the anatomical structure of the imaginal disc-derived leg joint is generated and organized.\" [GOC:ha, PMID:25329825]","metadata":null},{"id":"8af0255d93b84f0185bae4a731aa1eae","type":"GO_TERM","name":"regulation of imaginal disc-derived wing size","canonical_id":"go:GO:0044719","description":"\"Any process that modulates the size of an imaginal disc-derived wing.\" [PMID:21393605]","metadata":null},{"id":"c3136f626eec4162b8fbdb49292e3764","type":"GO_TERM","name":"regulation of imaginal disc-derived wing vein specification","canonical_id":"go:GO:0110107","description":"\"Any process that modulates the frequency, rate or extent of imaginal disc-derived wing vein specification.\" [GOC:ha, PMID:11861482]","metadata":null},{"id":"0d54f32c062346c69e5c2ed06fc9f526","type":"GO_TERM","name":"regulation of immature T cell proliferation","canonical_id":"go:GO:0033083","description":"\"Any process that modulates the frequency, rate or extent of immature T cell proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"7e8348092e284164b949a163b54cabed","type":"GO_TERM","name":"regulation of immature T cell proliferation in thymus","canonical_id":"go:GO:0033084","description":"\"Any process that modulates the frequency, rate or extent of immature T cell proliferation in the thymus.\" [GOC:add, GOC:mah]","metadata":null},{"id":"27e9f5576df54f099725a2bc760a3345","type":"GO_TERM","name":"regulation of immune complex clearance by monocytes and macrophages","canonical_id":"go:GO:0090264","description":"\"Any process that modulates the rate, frequency, or extent of the process of immune complex clearance by monocytes or macrophages.\" [GOC:tb]","metadata":null},{"id":"da813629960a4607a1dd7e73294d2530","type":"GO_TERM","name":"regulation of immune effector process","canonical_id":"go:GO:0002697","description":"\"Any process that modulates the frequency, rate, or extent of an immune effector process.\" [GOC:add]","metadata":null},{"id":"2988f09bc7fe42f1811f776985bd97a6","type":"GO_TERM","name":"regulation of immune response","canonical_id":"go:GO:0050776","description":"\"Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.\" [GOC:ai]","metadata":null},{"id":"a81394d91d5b451ea78788ddd0a3078f","type":"GO_TERM","name":"regulation of immune response to tumor cell","canonical_id":"go:GO:0002837","description":"\"Any process that modulates the frequency, rate, or extent of an immune response to tumor cell.\" [GOC:add]","metadata":null},{"id":"3d5b876d32e54bc48e8730bac1d0e423","type":"GO_TERM","name":"regulation of immune system process","canonical_id":"go:GO:0002682","description":"\"Any process that modulates the frequency, rate, or extent of an immune system process.\" [GOC:add]","metadata":null},{"id":"3c3aec86ba9246638e1ec7c7120d1bb7","type":"GO_TERM","name":"regulation of immunoglobulin mediated immune response","canonical_id":"go:GO:0002889","description":"\"Any process that modulates the frequency, rate, or extent of an immunoglobulin mediated immune response.\" [GOC:add]","metadata":null},{"id":"b6a44bcf151d4558be9cfd817c9298ba","type":"GO_TERM","name":"regulation of immunoglobulin production","canonical_id":"go:GO:0002637","description":"\"Any process that modulates the frequency, rate, or extent of immunoglobulin production.\" [GOC:add]","metadata":null},{"id":"e12bf578e56846919f710c36ce659007","type":"GO_TERM","name":"regulation of immunoglobulin production in mucosal tissue","canonical_id":"go:GO:2000557","description":"\"Any process that modulates the frequency, rate or extent of immunoglobulin production in mucosal tissue.\" [GOC:obol]","metadata":null},{"id":"faafc69a3bf04c2ca8e903715b58efd2","type":"GO_TERM","name":"regulation of immunological synapse formation","canonical_id":"go:GO:2000520","description":"\"Any process that modulates the frequency, rate or extent of immunological synapse formation.\" [GOC:obol]","metadata":null},{"id":"f865b621649f4452a65347a90d50f989","type":"GO_TERM","name":"regulation of inclusion body assembly","canonical_id":"go:GO:0090083","description":"\"Any process that modulates the rate, frequency, or extent of inclusion body assembly. Inclusion body assembly is the aggregation, arrangement and bonding together of a set of components to form an inclusion body.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"66add5b00ba64872b32a0d16182e604b","type":"GO_TERM","name":"regulation of induction of conjugation upon nitrogen starvation","canonical_id":"go:GO:0060905","description":"\"Any process that modulates the frequency of induction of conjugation upon nitrogen starvation, the process in which a cell initiates conjugation with cellular fusion upon nitrogen starvation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"562d5c611cea422793606d874b90aed6","type":"GO_TERM","name":"regulation of infection cushion formation","canonical_id":"go:GO:0075184","description":"\"Any process that modulates the frequency, rate or extent of symbiont infection cushion formation.\" [GOC:pamgo_curators]","metadata":null},{"id":"bd498a4ac6454c15bf26c5b6e422eee5","type":"GO_TERM","name":"regulation of inflammasome-mediated signaling pathway","canonical_id":"go:GO:0141085","description":"\"Any process that modulates the frequency, rate or extent of an inflammasome-mediated signaling pathway.\" [PMID:33467177]","metadata":null},{"id":"07edb35c863740ea94dc9162dd6eba9a","type":"GO_TERM","name":"regulation of inflammatory response","canonical_id":"go:GO:0050727","description":"\"Any process that modulates the frequency, rate or extent of the inflammatory response, the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents.\" [GOC:ai]","metadata":null},{"id":"a54d6926dce143d7a1d2d93c90e843b5","type":"GO_TERM","name":"regulation of inflammatory response to antigenic stimulus","canonical_id":"go:GO:0002861","description":"\"Any process that modulates the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.\" [GOC:add]","metadata":null},{"id":"9ac83e46b03b4dc2b5c233a0b464f6c3","type":"GO_TERM","name":"regulation of inflammatory response to wounding","canonical_id":"go:GO:0106014","description":"\"Any process that modulates the frequency, rate or extent of the inflammatory response to wounding.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:26022821]","metadata":null},{"id":"68da03ff14cb45e5be34cee6490e8b8a","type":"GO_TERM","name":"regulation of inflorescence meristem growth","canonical_id":"go:GO:0010081","description":"\"Any process involved in maintaining the size and shape of an inflorescence meristem.\" [GOC:tb]","metadata":null},{"id":"d65b5291c53045ec9ddd0baa48bf188d","type":"GO_TERM","name":"regulation of inhibin secretion","canonical_id":"go:GO:0032338","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of inhibin from a cell.\" [GOC:mah]","metadata":null},{"id":"6bfa0210054b42a280e73e5c78ee67ca","type":"GO_TERM","name":"regulation of inhibitory G protein-coupled receptor phosphorylation","canonical_id":"go:GO:1904323","description":"\"Any process that modulates the frequency, rate or extent of inhibitory G protein-coupled receptor phosphorylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:15937517]","metadata":null},{"id":"d2bd7ddf730c481db1f63fe39252fbd6","type":"GO_TERM","name":"regulation of inhibitory synapse assembly","canonical_id":"go:GO:1905702","description":"\"Any process that modulates the frequency, rate or extent of inhibitory synapse assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"138b72a99d8044cea45a0827932fbbd7","type":"GO_TERM","name":"regulation of initiation of mating projection growth","canonical_id":"go:GO:0031384","description":"\"Any process that modulates the frequency, rate, or extent of the start of mating projection formation by unicellular fungi.\" [PMID:14734532]","metadata":null},{"id":"1abf379593244add87513a90df423d8b","type":"GO_TERM","name":"regulation of initiation of premeiotic DNA replication","canonical_id":"go:GO:1904512","description":"\"Any process that modulates the frequency, rate or extent of initiation of premeiotic DNA replication.\" [GO_REF:0000058, GOC:TermGenie, PMID:25891897]","metadata":null},{"id":"a35982f1faf94f54a40941842e7f9544","type":"GO_TERM","name":"regulation of innate immune response","canonical_id":"go:GO:0045088","description":"\"Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.\" [GOC:ebc]","metadata":null},{"id":"69cffb211bd54986b775c3d5abbf2871","type":"GO_TERM","name":"regulation of innate immunity memory response","canonical_id":"go:GO:1905680","description":"\"Any process that modulates the frequency, rate or extent of innate immunity memory response.\" [GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"0041ec576782429da1fe02919dbdd70e","type":"GO_TERM","name":"regulation of inner ear auditory receptor cell differentiation","canonical_id":"go:GO:0045607","description":"\"Any process that modulates the frequency, rate or extent of auditory hair cell differentiation.\" [GOC:curators]","metadata":null},{"id":"c83847919bbc489ab4c93bfa536bd59d","type":"GO_TERM","name":"regulation of inner ear auditory receptor cell fate specification","canonical_id":"go:GO:0042669","description":"\"Any process that mediates the specification of a cell into an auditory hair cell.\" [GOC:curators]","metadata":null},{"id":"1be1e5b6a44a42989fd461294366962a","type":"GO_TERM","name":"regulation of inner ear receptor cell differentiation","canonical_id":"go:GO:2000980","description":"\"Any process that modulates the frequency, rate or extent of inner ear receptor cell differentiation.\" [GOC:obol]","metadata":null},{"id":"f8affd5ca35743f888725d9093b64890","type":"GO_TERM","name":"regulation of inosine transport","canonical_id":"go:GO:0035341","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of inosine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf]","metadata":null},{"id":"643f24f2dd3f48e6be130d528ac6cc2e","type":"GO_TERM","name":"regulation of inositol biosynthetic process","canonical_id":"go:GO:1900088","description":"\"Any process that modulates the frequency, rate or extent of inositol biosynthetic process.\" [GOC:TermGenie, PMID:22307851]","metadata":null},{"id":"a29ac489c67f4a079b7b3109708f38e9","type":"GO_TERM","name":"regulation of inositol phosphate biosynthetic process","canonical_id":"go:GO:0010919","description":"\"Any process that modulates the rate, frequency or extent of inositol phosphate biosynthesis. Inositol phosphate biosynthetic processes are the chemical reactions and pathways resulting in the formation of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5f072f779c0d4c8595aa1be3931ceb3c","type":"GO_TERM","name":"regulation of inositol trisphosphate biosynthetic process","canonical_id":"go:GO:0032960","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of inositol trisphosphate.\" [GOC:mah]","metadata":null},{"id":"afacb17adf3844e9919ef7963106a71e","type":"GO_TERM","name":"regulation of insulin receptor signaling pathway","canonical_id":"go:GO:0046626","description":"\"Any process that modulates the frequency, rate or extent of insulin receptor signaling.\" [GOC:bf]","metadata":null},{"id":"17634b11279f4a11a3aa54f0e0d7dc20","type":"GO_TERM","name":"regulation of insulin secretion","canonical_id":"go:GO:0050796","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of insulin.\" [GOC:ai]","metadata":null},{"id":"466ad8558275417fa6f9b896bb277b2b","type":"GO_TERM","name":"regulation of insulin secretion involved in cellular response to glucose stimulus","canonical_id":"go:GO:0061178","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"6b0a19b699904049aa24f3a2c5c7df1c","type":"GO_TERM","name":"regulation of insulin-like growth factor receptor signaling pathway","canonical_id":"go:GO:0043567","description":"\"Any process that modulates the frequency, rate or extent of insulin-like growth factor receptor signaling.\" [GOC:bf]","metadata":null},{"id":"e59b548fc7e24d86ba818eaa7062fc85","type":"GO_TERM","name":"regulation of integrin activation","canonical_id":"go:GO:0033623","description":"\"Any process that modulates the frequency, rate, or extent of integrin activation.\" [GOC:add]","metadata":null},{"id":"1a41e4356deb4449973e6a0097cf2032","type":"GO_TERM","name":"regulation of integrin biosynthetic process","canonical_id":"go:GO:0045113","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of integrins.\" [GOC:curators]","metadata":null},{"id":"b5646dd765ab4db992259fedd282f6bb","type":"GO_TERM","name":"regulation of integrin-mediated signaling pathway","canonical_id":"go:GO:2001044","description":"\"Any process that modulates the frequency, rate or extent of integrin-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"8df2dcd16c44493fa4484fc37ef228ef","type":"GO_TERM","name":"regulation of interferon-alpha production","canonical_id":"go:GO:0032647","description":"\"Any process that modulates the frequency, rate, or extent of interferon-alpha production.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"dd05cd9619134060bf83c4cb2256b62e","type":"GO_TERM","name":"regulation of interferon-beta production","canonical_id":"go:GO:0032648","description":"\"Any process that modulates the frequency, rate, or extent of interferon-beta production.\" [GOC:mah, PMID:15546383]","metadata":null},{"id":"6a0407272ec34c0690269ba345d03305","type":"GO_TERM","name":"regulation of interleukin-1 alpha production","canonical_id":"go:GO:0032650","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-1 alpha production.\" [GOC:mah]","metadata":null},{"id":"1c0b4ce60b244ff58cb11a80c18110d9","type":"GO_TERM","name":"regulation of interleukin-1 beta production","canonical_id":"go:GO:0032651","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-1 beta production.\" [GOC:mah]","metadata":null},{"id":"0794f110e6d54c278975948a27e9dac7","type":"GO_TERM","name":"regulation of interleukin-1 production","canonical_id":"go:GO:0032652","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-1 production.\" [GOC:mah]","metadata":null},{"id":"e28822ebf80b4b35a3f9c6ce791e9119","type":"GO_TERM","name":"regulation of interleukin-1-mediated signaling pathway","canonical_id":"go:GO:2000659","description":"\"Any process that modulates the frequency, rate or extent of interleukin-1-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"647a846d88b24541b5a3b29696815d09","type":"GO_TERM","name":"regulation of interleukin-10 production","canonical_id":"go:GO:0032653","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-10 production.\" [GOC:mah]","metadata":null},{"id":"b9ef2b7c0db041a4a7d114218bd1b7fe","type":"GO_TERM","name":"regulation of interleukin-11 production","canonical_id":"go:GO:0032654","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-11 production.\" [GOC:mah, PMID:29286137]","metadata":null},{"id":"fd226e06fb8f48fab25cebe570ca7c7a","type":"GO_TERM","name":"regulation of interleukin-12 production","canonical_id":"go:GO:0032655","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-12 production.\" [GOC:mah]","metadata":null},{"id":"6573e1a688da42ca9a4aa690993187df","type":"GO_TERM","name":"regulation of interleukin-13 production","canonical_id":"go:GO:0032656","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-13 production.\" [GOC:mah]","metadata":null},{"id":"584fa66016ad4b5fbf3dafa1e4d9694b","type":"GO_TERM","name":"regulation of interleukin-15 production","canonical_id":"go:GO:0032658","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-15 production.\" [GOC:mah]","metadata":null},{"id":"d22ff055025d413590f575a45eddc376","type":"GO_TERM","name":"regulation of interleukin-16 production","canonical_id":"go:GO:0032659","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-16 production.\" [GOC:mah]","metadata":null},{"id":"19e6ee87ff83452f80b48c2958b26e50","type":"GO_TERM","name":"regulation of interleukin-17 production","canonical_id":"go:GO:0032660","description":"\"Any process that modulates the frequency, rate, or extent of production of any member of the interleukin-17 family of cytokines.\" [GOC:add, GOC:mah, PMID:16482511]","metadata":null},{"id":"80c085b21a184f85a14a8c71010389d1","type":"GO_TERM","name":"regulation of interleukin-17-mediated signaling pathway","canonical_id":"go:GO:1903881","description":"\"Any process that modulates the frequency, rate or extent of interleukin-17-mediated signaling pathway.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:20054338]","metadata":null},{"id":"05a670961e4f4e328f951c0184f6023b","type":"GO_TERM","name":"regulation of interleukin-17A production","canonical_id":"go:GO:0150151","description":"\"Any process that modulates the frequency, rate or extent of interleukin-17A production.\" [GOC:aruk, PMID:27901018]","metadata":null},{"id":"13dabd7b18cf40c88c5c6aa1b65c1892","type":"GO_TERM","name":"regulation of interleukin-18 production","canonical_id":"go:GO:0032661","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-18 production.\" [GOC:mah, PMID:23710316]","metadata":null},{"id":"e49bbb97da494c25a3da2e219f3e7c04","type":"GO_TERM","name":"regulation of interleukin-18-mediated signaling pathway","canonical_id":"go:GO:2000492","description":"\"Any process that modulates the frequency, rate or extent of interleukin-18-mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"ec8ecb49606b47c6b0ca7d7b80a72abe","type":"GO_TERM","name":"regulation of interleukin-19 production","canonical_id":"go:GO:0032662","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-19 production.\" [GOC:mah]","metadata":null},{"id":"dad0bced23394e9ea2757afb941158e0","type":"GO_TERM","name":"regulation of interleukin-2 production","canonical_id":"go:GO:0032663","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-2 production.\" [GOC:mah]","metadata":null},{"id":"bc4d88e0f2f7466dbc17c2424c952fbb","type":"GO_TERM","name":"regulation of interleukin-2-mediated signaling pathway","canonical_id":"go:GO:1902205","description":"\"Any process that modulates the frequency, rate or extent of interleukin-2-mediated signaling pathway.\" [GOC:TermGenie, PMID:11909529]","metadata":null},{"id":"7dd544285ebf49aba5232860caaa4ff7","type":"GO_TERM","name":"regulation of interleukin-20 production","canonical_id":"go:GO:0032664","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-20 production.\" [GOC:mah]","metadata":null},{"id":"5921c74eb372496c9015d3a50633265f","type":"GO_TERM","name":"regulation of interleukin-21 production","canonical_id":"go:GO:0032665","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-21 production.\" [GOC:mah]","metadata":null},{"id":"339bec8012f344e8862c9224b4950d34","type":"GO_TERM","name":"regulation of interleukin-22 production","canonical_id":"go:GO:0032666","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-22 production.\" [GOC:mah]","metadata":null},{"id":"ef8b03ebfb32477da9b9e4ce63370737","type":"GO_TERM","name":"regulation of interleukin-23 production","canonical_id":"go:GO:0032667","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-23 production.\" [GOC:mah]","metadata":null},{"id":"c09f4e36c1544c45ac2e8b4120650f88","type":"GO_TERM","name":"regulation of interleukin-24 production","canonical_id":"go:GO:0032668","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-24 production.\" [GOC:mah]","metadata":null},{"id":"6b7d48069c6b4135847239b8c8f0419e","type":"GO_TERM","name":"regulation of interleukin-25 production","canonical_id":"go:GO:0032669","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-25 production.\" [GOC:mah, PMID:27901018]","metadata":null},{"id":"b68cbf69cbd147c2a727945d13f0f0e8","type":"GO_TERM","name":"regulation of interleukin-26 production","canonical_id":"go:GO:0032670","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-26 production.\" [GOC:mah]","metadata":null},{"id":"1ce6ced1bf104881a3b12718f1649433","type":"GO_TERM","name":"regulation of interleukin-27 production","canonical_id":"go:GO:0032671","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-27 production.\" [GOC:mah]","metadata":null},{"id":"8506ef33e08241adb5760cfb8ecc32e4","type":"GO_TERM","name":"regulation of interleukin-27-mediated signaling pathway","canonical_id":"go:GO:0070107","description":"\"Any process that modulates the rate, frequency or extent of an interleukin-27-mediated signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"182f836d554748a4a6911a5652749edc","type":"GO_TERM","name":"regulation of interleukin-3 production","canonical_id":"go:GO:0032672","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-3 production.\" [GOC:mah]","metadata":null},{"id":"b95bb62aec0b4b37911ef6f4e20c6735","type":"GO_TERM","name":"regulation of interleukin-32 production","canonical_id":"go:GO:0150189","description":"\"Any process that modulates the frequency, rate or extent of interleukin-32 production.\" [GOC:aruk, PMID:23729669]","metadata":null},{"id":"3aac7ca6bd044cde8c27acf0a0e040ce","type":"GO_TERM","name":"regulation of interleukin-33 production","canonical_id":"go:GO:0150127","description":"\"Any process that modulates the frequency, rate or extent of interleukin-33 production.\" [GOC:aruk, PMID:29778524]","metadata":null},{"id":"7b73d2960f9a4aefa527bce8a375c94f","type":"GO_TERM","name":"regulation of interleukin-34 production","canonical_id":"go:GO:0150157","description":"\"Any process that modulates the frequency, rate or extent of interleukin-34 production.\" [GOC:aruk, PMID:26754294]","metadata":null},{"id":"1504a3cc16324ae9b7241771122c667c","type":"GO_TERM","name":"regulation of interleukin-35 production","canonical_id":"go:GO:0070754","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-35 production.\" [GOC:mah]","metadata":null},{"id":"6f23540921f74a6aa3b70a199e2e73ca","type":"GO_TERM","name":"regulation of interleukin-35-mediated signaling pathway","canonical_id":"go:GO:0070758","description":"\"Any process that modulates the rate, frequency or extent of an interleukin-35-mediated signaling pathway.\" [GOC:mah]","metadata":null},{"id":"5dcb195ce5074e8b88ab940d8a35f705","type":"GO_TERM","name":"regulation of interleukin-37 production","canonical_id":"go:GO:0150136","description":"\"Any process that modulates the frequency, rate or extent of interleukin-37 production.\" [GOC:aruk, PMID:30362558]","metadata":null},{"id":"81e9ee7308df49fb8b7d691f93c6eff6","type":"GO_TERM","name":"regulation of interleukin-4 production","canonical_id":"go:GO:0032673","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-4 production.\" [GOC:mah, PMID:29778524]","metadata":null},{"id":"d96ebc8f767a46f8952be171c5a84c5c","type":"GO_TERM","name":"regulation of interleukin-4-dependent isotype switching to IgE isotypes","canonical_id":"go:GO:2000571","description":"\"Any process that modulates the frequency, rate or extent of interleukin-4-dependent isotype switching to IgE isotypes.\" [GOC:obol]","metadata":null},{"id":"7208ab9cea0d45ef91070c7c246a2fb7","type":"GO_TERM","name":"regulation of interleukin-4-mediated signaling pathway","canonical_id":"go:GO:1902214","description":"\"Any process that modulates the frequency, rate or extent of interleukin-4-mediated signaling pathway.\" [GOC:TermGenie, PMID:17210636]","metadata":null},{"id":"f95c96ad81ea4db8a634cbb7fa3b2f52","type":"GO_TERM","name":"regulation of interleukin-5 production","canonical_id":"go:GO:0032674","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-5 production.\" [GOC:mah]","metadata":null},{"id":"2b08f8976d514edbbc66ecfe9e797bc5","type":"GO_TERM","name":"regulation of interleukin-6 production","canonical_id":"go:GO:0032675","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-6 production.\" [GOC:mah]","metadata":null},{"id":"3c0100ff4b8440b2b44dfd795d5852f1","type":"GO_TERM","name":"regulation of interleukin-6-mediated signaling pathway","canonical_id":"go:GO:0070103","description":"\"Any process that modulates the rate, frequency or extent of an interleukin-6-mediated signaling pathway.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"8f55e2bd44ef4e9aa21330a24c139db7","type":"GO_TERM","name":"regulation of interleukin-7 production","canonical_id":"go:GO:0032676","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-7 production.\" [GOC:mah, PMID:25962782]","metadata":null},{"id":"e1032841664a4919b2035b7a54531f0b","type":"GO_TERM","name":"regulation of interleukin-8 production","canonical_id":"go:GO:0032677","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-8 production.\" [GOC:mah]","metadata":null},{"id":"a812c4b88f0045d781fe9b3e57899365","type":"GO_TERM","name":"regulation of interleukin-9 production","canonical_id":"go:GO:0032678","description":"\"Any process that modulates the frequency, rate, or extent of interleukin-9 production.\" [GOC:mah]","metadata":null},{"id":"ee44b67e61e94a16a251cac3bf6acfe6","type":"GO_TERM","name":"regulation of intermediate filament depolymerization","canonical_id":"go:GO:0030842","description":"\"Any process that modulates the frequency, rate or extent of the disassembly of intermediate filaments by the removal of monomers from a filament.\" [GOC:mah]","metadata":null},{"id":"066780daa15d48288a6817acedd9f06b","type":"GO_TERM","name":"regulation of intermediate filament polymerization","canonical_id":"go:GO:0030839","description":"\"Any process that modulates the frequency, rate or extent of the assembly of intermediate filaments by the addition of monomers to a filament.\" [GOC:mah]","metadata":null},{"id":"86c75516a384473596bba6f4602a7dba","type":"GO_TERM","name":"regulation of intermediate filament polymerization or depolymerization","canonical_id":"go:GO:0045108","description":"\"Any process that modulates the frequency, rate or extent of the assembly or disassembly of intermediate filaments by the addition or removal of monomers from a filament; this usually occurs through the opposing action of kinases and phosphatases.\" [ISBN:0716731363]","metadata":null},{"id":"d61ca849e28c4bd58ebc27f49eb81ba0","type":"GO_TERM","name":"regulation of intermediate mesodermal cell fate determination","canonical_id":"go:GO:0048395","description":"\"Any process that modulates the frequency, rate or extent of intermediate mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"4c2661d96b364cd586bcd685711d754a","type":"GO_TERM","name":"regulation of intermediate mesodermal cell fate specification","canonical_id":"go:GO:0048399","description":"\"Any process that modulates the frequency, rate or extent of intermediate mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"673037d69f1245d6b4242da3e15c4198","type":"GO_TERM","name":"regulation of interphase mitotic telomere clustering","canonical_id":"go:GO:0110065","description":"\"Any process that modulates the frequency, rate or extent of mitotic telomere clustering during interphase.\" [GOC:vw, PMID:25778919]","metadata":null},{"id":"d058172f0cb14319b42f948eb48f93e8","type":"GO_TERM","name":"regulation of intestinal D-glucose absorption","canonical_id":"go:GO:1903985","description":"\"Any process that modulates the frequency, rate or extent of intestinal D-glucose absorption.\" [GO_REF:0000058, GOA:als, GOC:TermGenie, PMID:22114352]","metadata":null},{"id":"eadfe7424ae84bc68cb8461b099a2695","type":"GO_TERM","name":"regulation of intestinal absorption","canonical_id":"go:GO:1904478","description":"\"Any process that modulates the frequency, rate or extent of intestinal absorption.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12469120]","metadata":null},{"id":"5b8e937d45e44c41bc8a8cf238138fcb","type":"GO_TERM","name":"regulation of intestinal cholesterol absorption","canonical_id":"go:GO:0030300","description":"\"Any process that modulates the frequency, rate or extent of absorption of cholesterol into the blood, and the exclusion of other sterols from absorption.\" [GOC:mah, PMID:11099417]","metadata":null},{"id":"883528ab99144ca6a7b8de8801755265","type":"GO_TERM","name":"regulation of intestinal epithelial cell development","canonical_id":"go:GO:1905298","description":"\"Any process that modulates the frequency, rate or extent of intestinal epithelial cell development.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23904268]","metadata":null},{"id":"89bc6a367bfe4f25804739e7b52dff31","type":"GO_TERM","name":"regulation of intestinal epithelial structure maintenance","canonical_id":"go:GO:0060730","description":"\"Any process that modulates the rate, frequency, or extent of intestinal epithelial structure maintenance, a tissue homeostatic process required for the maintenance of the structure of the intestinal epithelium.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"915b281116664598b45d7fd2cd9f6df4","type":"GO_TERM","name":"regulation of intestinal lipid absorption","canonical_id":"go:GO:1904729","description":"\"Any process that modulates the frequency, rate or extent of intestinal lipid absorption.\" [GO_REF:0000058, GOC:TermGenie, PMID:18768481]","metadata":null},{"id":"d74925f12dd34c3dbec6201391cddfbe","type":"GO_TERM","name":"regulation of intracellular cholesterol transport","canonical_id":"go:GO:0032383","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of cholesterol within cells.\" [GOC:mah]","metadata":null},{"id":"198615d81b3e4e3c8d637dab30aca3d9","type":"GO_TERM","name":"regulation of intracellular estrogen receptor signaling pathway","canonical_id":"go:GO:0033146","description":"\"Any process that modulates the frequency, rate or extent of the activity of an intracellular estrogen receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"1997fd1e17ab43039ba6ae06f787124a","type":"GO_TERM","name":"regulation of intracellular lipid transport","canonical_id":"go:GO:0032377","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of lipids within cells.\" [GOC:mah]","metadata":null},{"id":"4379f7d898c94471915cb50eefa2eea4","type":"GO_TERM","name":"regulation of intracellular mRNA localization","canonical_id":"go:GO:1904580","description":"\"Any process that modulates the frequency, rate or extent of intracellular mRNA localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:21471000]","metadata":null},{"id":"4c4e4b4096c04693b3252f2686446afd","type":"GO_TERM","name":"regulation of intracellular pH","canonical_id":"go:GO:0051453","description":"\"Any process that modulates the internal pH of a cell, corresponding to a change in hydrogen ion concentration.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"c1deb8a5f41e4ffe88187a35129969f1","type":"GO_TERM","name":"regulation of intracellular protein transport","canonical_id":"go:GO:0033157","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of proteins within cells.\" [GOC:mah]","metadata":null},{"id":"f98ca8091c704bed881e31fcacff8aaa","type":"GO_TERM","name":"regulation of intracellular signal transduction","canonical_id":"go:GO:1902531","description":"\"Any process that modulates the frequency, rate or extent of intracellular signal transduction.\" [GOC:dph, GOC:signaling, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"36032720ebc344df8ae8855db6b9f090","type":"GO_TERM","name":"regulation of intracellular steroid hormone receptor signaling pathway","canonical_id":"go:GO:0033143","description":"\"Any process that modulates the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"c9fb898fdadb4faf958aca2892bae232","type":"GO_TERM","name":"regulation of intracellular sterol transport","canonical_id":"go:GO:0032380","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of sterols within cells.\" [GOC:mah]","metadata":null},{"id":"91b7d2e059ee457bb9fb1f35cb0780ef","type":"GO_TERM","name":"regulation of intracellular transport","canonical_id":"go:GO:0032386","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of substances within cells.\" [GOC:mah]","metadata":null},{"id":"9cd382e62563408faef882d97dd53e13","type":"GO_TERM","name":"regulation of intracellular transport of viral material","canonical_id":"go:GO:1901252","description":"\"Any process that modulates the frequency, rate or extent of egress of virus within host cell.\" [GOC:bf, GOC:jl, GOC:TermGenie]","metadata":null},{"id":"cec4aa8193f94587ab2e3359dff47a8e","type":"GO_TERM","name":"regulation of intraciliary anterograde transport","canonical_id":"go:GO:1905796","description":"\"Any process that modulates the frequency, rate or extent of intraciliary anterograde transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:27930654]","metadata":null},{"id":"4fd6735fd2fa42d89a9c614bf3e21129","type":"GO_TERM","name":"regulation of intraciliary retrograde transport","canonical_id":"go:GO:1905799","description":"\"Any process that modulates the frequency, rate or extent of intraciliary retrograde transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:27930654]","metadata":null},{"id":"c7d0bbfa653149fdaaa7ecd6f33c378b","type":"GO_TERM","name":"regulation of intralumenal vesicle formation","canonical_id":"go:GO:1905365","description":"\"Any process that modulates the frequency, rate or extent of intralumenal vesicle formation.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"25d88e82f38b4e9980a10532264c0cea","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway","canonical_id":"go:GO:2001242","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway.\" [GOC:mtg_apoptosis]","metadata":null},{"id":"65031c1441bc463ba20edfdd11b8de58","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway by p53 class mediator","canonical_id":"go:GO:1902253","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway by p53 class mediator.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15705871]","metadata":null},{"id":"80400c9259904d03802cc03d432fda35","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway in response to DNA damage","canonical_id":"go:GO:1902229","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:15314165]","metadata":null},{"id":"3a09f8b9bc9c4fae8d4a2a22abca06cc","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator","canonical_id":"go:GO:1902165","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator.\" [GOC:TermGenie, PMID:17719541]","metadata":null},{"id":"7049db3e7d844643b8994f7035769cd7","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide","canonical_id":"go:GO:1903750","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to hydrogen peroxide.\" [GO_REF:0000058, GOC:TermGenie, PMID:18681888]","metadata":null},{"id":"f219f97fb6c74f70bce76db9c5e4773d","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway in response to osmotic stress","canonical_id":"go:GO:1902218","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to osmotic stress.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:14569084]","metadata":null},{"id":"374b2996dce746a787667dba0ac293cb","type":"GO_TERM","name":"regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator","canonical_id":"go:GO:1902238","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator.\" [GOC:krc, GOC:mtg_apoptosis, GOC:TermGenie, PMID:16571598]","metadata":null},{"id":"4308626c65e64553896eaa3435d0fb63","type":"GO_TERM","name":"regulation of invasive growth in response to glucose limitation","canonical_id":"go:GO:2000217","description":"\"Any process that modulates the frequency, rate or extent of invasive growth in response to glucose limitation.\" [GOC:mah]","metadata":null},{"id":"3c4ae56bae694a7c84faa7753350a4cc","type":"GO_TERM","name":"regulation of iodide transmembrane transport","canonical_id":"go:GO:1904212","description":"\"Any process that modulates the frequency, rate or extent of iodide transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"91134367f71549e5a5a368aae1785b26","type":"GO_TERM","name":"regulation of iodide transport","canonical_id":"go:GO:1904201","description":"\"Any process that modulates the frequency, rate or extent of iodide transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:20392814]","metadata":null},{"id":"90a0f8f36d4f414d88c957c1bcd982a3","type":"GO_TERM","name":"regulation of iridophore differentiation","canonical_id":"go:GO:0050937","description":"\"Any process that modulates the frequency, rate or extent of iridophore differentiation.\" [GOC:ai]","metadata":null},{"id":"8e003b5d9c21426f81045ec502c896a5","type":"GO_TERM","name":"regulation of iron export across plasma membrane","canonical_id":"go:GO:1904038","description":"\"Any process that modulates the frequency, rate or extent of export of iron ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GO_REF:0000058, GOC:BHF, GOC:kom, GOC:TermGenie, PMID:15514116]","metadata":null},{"id":"2911e95ba7914828831cff26b53cb88e","type":"GO_TERM","name":"regulation of iron ion import across plasma membrane","canonical_id":"go:GO:1904438","description":"\"Any process that modulates the frequency, rate or extent of iron ions import across plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:kom, GOC:TermGenie, PMID:18353247]","metadata":null},{"id":"b99e431515374994bb04df299dc1a5e3","type":"GO_TERM","name":"regulation of iron ion transmembrane transport","canonical_id":"go:GO:0034759","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of iron ions (Fe) from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"24f5c7c9dc92471e81d91e7fc43accf2","type":"GO_TERM","name":"regulation of iron ion transport","canonical_id":"go:GO:0034756","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of iron ions (Fe) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"79863303cb1c409a987e641d7a2dc6bd","type":"GO_TERM","name":"regulation of iron-sulfur cluster assembly","canonical_id":"go:GO:1903329","description":"\"Any process that modulates the frequency, rate or extent of iron-sulfur cluster assembly.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"7c292aabf1974cae8fb0a300e86aa3d2","type":"GO_TERM","name":"regulation of iron-sulfur-molybdenum cofactor assembly","canonical_id":"go:GO:1900506","description":"\"Any process that modulates the frequency, rate or extent of iron-sulfur-molybdenum cofactor assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f0a476e432b2439098c3832f217a7f1c","type":"GO_TERM","name":"regulation of isopentenyl diphosphate biosynthetic process, methylerythritol phosphate pathway","canonical_id":"go:GO:0010322","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of isopentenyl diphosphate produced via the methylerythritol (MEP) pathway (mevalonate-independent).\" [PMID:16531478]","metadata":null},{"id":"cfe6ac1c113643efa292d961ad0ae2d6","type":"GO_TERM","name":"regulation of isopentenyl diphosphate biosynthetic process, mevalonate pathway","canonical_id":"go:GO:2001210","description":"\"Any process that modulates the frequency, rate or extent of isopentenyl diphosphate biosynthetic process, mevalonate pathway.\" [GOC:al]","metadata":null},{"id":"d7c78a11d15340ed8bf76751a0d8af7d","type":"GO_TERM","name":"regulation of isoprenoid metabolic process","canonical_id":"go:GO:0019747","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving isoprenoids.\" [GOC:curators]","metadata":null},{"id":"1edd5b71f1b14d98960ec2718a22a7e3","type":"GO_TERM","name":"regulation of isotype switching","canonical_id":"go:GO:0045191","description":"\"Any process that modulates the frequency, rate or extent of isotype switching.\" [GOC:ai]","metadata":null},{"id":"26c694449fc94472b73cfd93a3e3c746","type":"GO_TERM","name":"regulation of isotype switching to IgA isotypes","canonical_id":"go:GO:0048296","description":"\"Any process that modulates the frequency, rate or extent of isotype switching to IgA isotypes.\" [GOC:jid]","metadata":null},{"id":"30b08fb7e90046aebf8c5732b52085bf","type":"GO_TERM","name":"regulation of isotype switching to IgD isotypes","canonical_id":"go:GO:0048299","description":"\"Any process that modulates the frequency, rate or extent of isotype switching to IgD isotypes.\" [GOC:jid]","metadata":null},{"id":"a34cf14340544d4fb9b3293a43ff5e2e","type":"GO_TERM","name":"regulation of isotype switching to IgE isotypes","canonical_id":"go:GO:0048293","description":"\"Any process that modulates the frequency, rate or extent of isotype switching to IgE isotypes.\" [GOC:jid]","metadata":null},{"id":"bd473790afcd4f44bf4dac8854e4e8c9","type":"GO_TERM","name":"regulation of isotype switching to IgG isotypes","canonical_id":"go:GO:0048302","description":"\"Any process that modulates the frequency, rate or extent of isotype switching to IgG isotypes.\" [GOC:jid]","metadata":null},{"id":"632e417c793e4eebace0531a0867a4c5","type":"GO_TERM","name":"regulation of jasmonic acid biosynthetic process","canonical_id":"go:GO:0080141","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of jasmonic acid.\" [GOC:dhl]","metadata":null},{"id":"0f73507106ef4874a8f8e2a47e24d012","type":"GO_TERM","name":"regulation of jasmonic acid mediated signaling pathway","canonical_id":"go:GO:2000022","description":"\"Any process that modulates the frequency, rate or extent of jasmonic acid mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"87efd7259ef04989b50e91a5bb8bdff0","type":"GO_TERM","name":"regulation of jasmonic acid metabolic process","canonical_id":"go:GO:0080140","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving jasmonic acid.\" [GOC:dhl]","metadata":null},{"id":"af36a5054f564d1fbfc106f5640e832a","type":"GO_TERM","name":"regulation of juvenile hormone biosynthetic process","canonical_id":"go:GO:0007557","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"a3d5ba0e76f943f7882ad3e6f1b5d50f","type":"GO_TERM","name":"regulation of juvenile hormone catabolic process","canonical_id":"go:GO:0045952","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of juvenile hormone.\" [GOC:curators]","metadata":null},{"id":"df2b6bc384e0455faf9eb40c2adb73eb","type":"GO_TERM","name":"regulation of juvenile hormone secretion","canonical_id":"go:GO:0007558","description":"\"Any process that modulates the frequency, rate or extent of juvenile hormone secretion.\" [GOC:curators]","metadata":null},{"id":"d3a802ada19f41ceb4451c388f14ffea","type":"GO_TERM","name":"regulation of kainate selective glutamate receptor signaling pathway","canonical_id":"go:GO:0106426","description":"\"Any process that modulates the frequency, rate or extent of the kainate selective glutamate receptor signaling pathway.\" [PMID:12597860]","metadata":null},{"id":"30e874108a264a5bba56c73c1f9ccd7f","type":"GO_TERM","name":"regulation of karyogamy","canonical_id":"go:GO:0032871","description":"\"Any process that modulates the frequency, rate or extent of karyogamy, the creation of a single nucleus from multiple nuclei as a result of membrane fusion.\" [GOC:mah]","metadata":null},{"id":"97f1946fe0f0481f8e77f76d03ac0eb5","type":"GO_TERM","name":"regulation of keratinocyte apoptotic process","canonical_id":"go:GO:1902172","description":"\"Any process that modulates the frequency, rate or extent of keratinocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl, GOC:TermGenie, PMID:18938133]","metadata":null},{"id":"49df027508434c3c8beb83278dc08abf","type":"GO_TERM","name":"regulation of keratinocyte differentiation","canonical_id":"go:GO:0045616","description":"\"Any process that modulates the frequency, rate or extent of keratinocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"9d86f33dbf4844afb46c41fdae4aaa98","type":"GO_TERM","name":"regulation of keratinocyte migration","canonical_id":"go:GO:0051547","description":"\"Any process that modulates the frequency, rate or extent of keratinocyte migration.\" [GOC:ai]","metadata":null},{"id":"7b58533d7fda4776bd36ca46f8780c2e","type":"GO_TERM","name":"regulation of keratinocyte proliferation","canonical_id":"go:GO:0010837","description":"\"Any process that modulates the rate, frequency or extent of keratinocyte proliferation. Keratinocyte proliferation is the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d295a0c33a5d4a9285a8f995c51b4a07","type":"GO_TERM","name":"regulation of ketone biosynthetic process","canonical_id":"go:GO:0010566","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of a ketone, carried out by individual cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"42c9b76bd8164254945fdb7f4721ae7a","type":"GO_TERM","name":"regulation of ketone catabolic process","canonical_id":"go:GO:0010567","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a ketone, carried out by individual cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6b1ec1fc43df4855a9ce78b8794d772d","type":"GO_TERM","name":"regulation of ketone metabolic process","canonical_id":"go:GO:0010565","description":"\"Any process that modulates the chemical reactions and pathways involving any of a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"78e4236d08324e6eb90d8ef65c33dc81","type":"GO_TERM","name":"regulation of kidney development","canonical_id":"go:GO:0090183","description":"\"Any process that modulates the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"bebb7efa1e2942a388195b68142e6438","type":"GO_TERM","name":"regulation of kidney size","canonical_id":"go:GO:0035564","description":"\"Any process that modulates the size of a kidney.\" [GOC:bf]","metadata":null},{"id":"c88c2d8330cf4c62b53058a037a90e20","type":"GO_TERM","name":"regulation of kidney smooth muscle cell differentiation","canonical_id":"go:GO:2000356","description":"\"Any process that modulates the frequency, rate or extent of kidney smooth muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"3d20ce9fde044ff1a4a01a9684d2db55","type":"GO_TERM","name":"regulation of killing of cells of another organism","canonical_id":"go:GO:0051709","description":"\"Any process that modulates the frequency, rate or extent of the killing by an organism of cells in another organism.\" [GOC:ai]","metadata":null},{"id":"c8e542f9b73b4df0842094d9e2574830","type":"GO_TERM","name":"regulation of kinase activity","canonical_id":"go:GO:0043549","description":"\"Any process that modulates the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.\" [GOC:bf]","metadata":null},{"id":"d72029a345f04881a3ba43e44281aef0","type":"GO_TERM","name":"regulation of kinetochore assembly","canonical_id":"go:GO:0090234","description":"\"Any process that modulates the rate, frequency, or extent of kinetochore assembly, the aggregation, arrangement and bonding together of a set of components to form the kinetochore, a multisubunit complex that is located at the centromeric region of DNA and provides an attachment point for the spindle microtubules.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"fc05dd827d1549398ccf50f236634408","type":"GO_TERM","name":"regulation of kinin cascade","canonical_id":"go:GO:0002256","description":"\"Any process that modulates the frequency, rate, or extent of the kinin cascade.\" [GOC:jal]","metadata":null},{"id":"327ba206c7b543ee9bd51ab2ceb4f35e","type":"GO_TERM","name":"regulation of kojic acid biosynthetic process","canonical_id":"go:GO:1900394","description":"\"Any process that modulates the frequency, rate or extent of kojic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"18f354526e82441f8b0d5fc3ba020694","type":"GO_TERM","name":"regulation of lactation","canonical_id":"go:GO:1903487","description":"\"Any process that modulates the frequency, rate or extent of lactation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19563620]","metadata":null},{"id":"e8a024fe8d1e4448b10f0aafc00c0603","type":"GO_TERM","name":"regulation of lactose biosynthetic process","canonical_id":"go:GO:1903534","description":"\"Any process that modulates the frequency, rate or extent of lactose biosynthetic process.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:12018418]","metadata":null},{"id":"8b7589032dad49e4989151d53ce0c228","type":"GO_TERM","name":"regulation of lamellipodium assembly","canonical_id":"go:GO:0010591","description":"\"Any process that modulates the rate, frequency or extent of the formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"64dafedd406342189a2260b115998e72","type":"GO_TERM","name":"regulation of lamellipodium morphogenesis","canonical_id":"go:GO:2000392","description":"\"Any process that modulates the frequency, rate or extent of lamellipodium morphogenesis.\" [GOC:mah]","metadata":null},{"id":"86667e0153fd43c1b18eb2e0a6e1c3e5","type":"GO_TERM","name":"regulation of lamellipodium organization","canonical_id":"go:GO:1902743","description":"\"Any process that modulates the frequency, rate or extent of lamellipodium organization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:16054028]","metadata":null},{"id":"de84de4aadf0434ea5a910437235c4cf","type":"GO_TERM","name":"regulation of lamellocyte differentiation","canonical_id":"go:GO:0035203","description":"\"Any process that modulates the frequency, rate or extent of lamellocyte differentiation. Lamellocytes differentiate massively in the lymph glands after parasitization and are large flat cells devoted to encapsulation of invaders too large to be phagocytosed by plasmatocytes.\" [PMID:14734104]","metadata":null},{"id":"956346b8bd5944dfa19c3e0b361daae2","type":"GO_TERM","name":"regulation of laminaritriose transport","canonical_id":"go:GO:1900303","description":"\"Any process that modulates the frequency, rate or extent of laminaritriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2c0ee5c9cf324f2795d720533931a94c","type":"GO_TERM","name":"regulation of larval salivary gland boundary specification","canonical_id":"go:GO:0045708","description":"\"Any process that modulates the frequency, rate or extent of salivary gland determination in a larval organism.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"154ee022b6004fd09396bb183b958e8c","type":"GO_TERM","name":"regulation of larval somatic muscle development","canonical_id":"go:GO:0062229","description":"\"Any process that modulates the rate, frequency or extent of larval somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"bd1ec440343d4032ad46b014ab60a54b","type":"GO_TERM","name":"regulation of late endosome to lysosome transport","canonical_id":"go:GO:1902822","description":"\"Any process that modulates the frequency, rate or extent of late endosome to lysosome transport.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:23949442]","metadata":null},{"id":"bb70188f6b4d4bc4a9f93cea3f3fc840","type":"GO_TERM","name":"regulation of late stripe melanocyte differentiation","canonical_id":"go:GO:0050940","description":"\"Any process that modulates the frequency, rate or extent of late stripe melanocyte differentiation.\" [GOC:ai]","metadata":null},{"id":"00b15ae36f3e4a70af9e883be00720f9","type":"GO_TERM","name":"regulation of lateral attachment of mitotic spindle microtubules to kinetochore","canonical_id":"go:GO:1905115","description":"\"Any process that modulates the frequency, rate or extent of lateral attachment of mitotic spindle microtubules to kinetochore.\" [GO_REF:0000058, GOC:TermGenie, PMID:22375062]","metadata":null},{"id":"39f30762036644a0aae22f8cc687d609","type":"GO_TERM","name":"regulation of lateral mesodermal cell fate determination","canonical_id":"go:GO:0048374","description":"\"Any process that modulates the frequency, rate or extent of lateral mesoderm cell fate determination.\" [GOC:jid]","metadata":null},{"id":"3b72237025c14b20b2f8316c21f012e3","type":"GO_TERM","name":"regulation of lateral mesodermal cell fate specification","canonical_id":"go:GO:0048378","description":"\"Any process that modulates the frequency, rate or extent of lateral mesoderm cell fate specification.\" [GOC:jid]","metadata":null},{"id":"07bc9369edfe496287ec2f4ec8d8c56d","type":"GO_TERM","name":"regulation of lateral motor column neuron migration","canonical_id":"go:GO:1902076","description":"\"Any process that modulates the frequency, rate or extent of lateral motor column neuron migration.\" [GOC:TermGenie, GOC:yaf, PMID:20711475]","metadata":null},{"id":"b5fbdb288a23460fa815cabb87bce6cf","type":"GO_TERM","name":"regulation of lateral root development","canonical_id":"go:GO:2000023","description":"\"Any process that modulates the frequency, rate or extent of lateral root development.\" [GOC:obol]","metadata":null},{"id":"13404663bafb4b47abcc8ec93a007024","type":"GO_TERM","name":"regulation of leaf development","canonical_id":"go:GO:2000024","description":"\"Any process that modulates the frequency, rate or extent of leaf development.\" [GOC:obol]","metadata":null},{"id":"445d6ca2700343d188015c89d932cd37","type":"GO_TERM","name":"regulation of leaf formation","canonical_id":"go:GO:2000025","description":"\"Any process that modulates the frequency, rate or extent of leaf formation.\" [GOC:obol]","metadata":null},{"id":"40131a5225844b8cba8375faa2263395","type":"GO_TERM","name":"regulation of leaf morphogenesis","canonical_id":"go:GO:1901371","description":"\"Any process that modulates the frequency, rate or extent of leaf morphogenesis.\" [GOC:TermGenie]","metadata":null},{"id":"e1dedfff6ab04439992f1fb87e9c96eb","type":"GO_TERM","name":"regulation of leaf senescence","canonical_id":"go:GO:1900055","description":"\"Any process that modulates the frequency, rate or extent of leaf senescence.\" [GOC:TermGenie]","metadata":null},{"id":"1b1817c264874f79be50be5b84629043","type":"GO_TERM","name":"regulation of leaflet formation","canonical_id":"go:GO:0090016","description":"\"Any process that modulates the frequency, rate or extent of leaflet formation.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"e3ec6e5e493b4a68bc5cc060abf62cc7","type":"GO_TERM","name":"regulation of lens epithelial cell proliferation","canonical_id":"go:GO:2001109","description":"\"Any process that modulates the frequency, rate or extent of lens epithelial cell proliferation.\" [GOC:obol]","metadata":null},{"id":"5a0994efd1b1458aa25de47f08bf0037","type":"GO_TERM","name":"regulation of lens fiber cell differentiation","canonical_id":"go:GO:1902746","description":"\"Any process that modulates the frequency, rate or extent of lens fiber cell differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17592637]","metadata":null},{"id":"24e3d8342cf948b6b1030e3ce9f0aea6","type":"GO_TERM","name":"regulation of leucophore differentiation","canonical_id":"go:GO:0048775","description":"\"Any process that modulates the frequency, rate or extent of leucophore differentiation.\" [GOC:mh]","metadata":null},{"id":"cc5f8f06cbb746b9bf8227ef5e89df04","type":"GO_TERM","name":"regulation of leukocyte activation","canonical_id":"go:GO:0002694","description":"\"Any process that modulates the frequency, rate, or extent of leukocyte activation.\" [GOC:add]","metadata":null},{"id":"8c0ba73e3c3943e1909c0edd2cb0a13a","type":"GO_TERM","name":"regulation of leukocyte adhesion to arterial endothelial cell","canonical_id":"go:GO:1904997","description":"\"Any process that modulates the frequency, rate or extent of leukocyte adhesion to arterial endothelial cell.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22267480]","metadata":null},{"id":"e5f39dcaab254bb2b4c70e33b93b61c1","type":"GO_TERM","name":"regulation of leukocyte adhesion to vascular endothelial cell","canonical_id":"go:GO:1904994","description":"\"Any process that modulates the frequency, rate or extent of leukocyte adhesion to vascular endothelial cell.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:23897866]","metadata":null},{"id":"407b6f89993b46ab9aea212371565974","type":"GO_TERM","name":"regulation of leukocyte apoptotic process","canonical_id":"go:GO:2000106","description":"\"Any process that modulates the frequency, rate or extent of leukocyte apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis]","metadata":null},{"id":"fb2ff39db5d64dd29a8716e4ca0a8fc4","type":"GO_TERM","name":"regulation of leukocyte cell-cell adhesion","canonical_id":"go:GO:1903037","description":"\"Any process that modulates the frequency, rate or extent of leukocyte cell-cell adhesion.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21106532]","metadata":null},{"id":"fedc33d58f534852a52a7bf053d1aefd","type":"GO_TERM","name":"regulation of leukocyte chemotaxis","canonical_id":"go:GO:0002688","description":"\"Any process that modulates the frequency, rate, or extent of leukocyte chemotaxis.\" [GOC:add]","metadata":null},{"id":"c83b52ccf27c470dbb8db72c6c347df2","type":"GO_TERM","name":"regulation of leukocyte degranulation","canonical_id":"go:GO:0043300","description":"\"Any process that modulates the frequency, rate, or extent of leukocyte degranulation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"9136ffe81b4e4e13accd2d4a0e16f668","type":"GO_TERM","name":"regulation of leukocyte differentiation","canonical_id":"go:GO:1902105","description":"\"Any process that modulates the frequency, rate or extent of leukocyte differentiation.\" [GOC:add, GOC:TermGenie]","metadata":null},{"id":"7ed8e00e1f34431699e1904163674b25","type":"GO_TERM","name":"regulation of leukocyte mediated cytotoxicity","canonical_id":"go:GO:0001910","description":"\"Any process that modulates the frequency, rate, or extent of leukocyte mediated cytotoxicity.\" [GOC:add, ISBN:0781735149, PMID:11911826]","metadata":null},{"id":"96cd5193ac654f53ad2f4d5b967af556","type":"GO_TERM","name":"regulation of leukocyte mediated immunity","canonical_id":"go:GO:0002703","description":"\"Any process that modulates the frequency, rate, or extent of leukocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"67dc0560f1fd43aa9019cb0515f695dd","type":"GO_TERM","name":"regulation of leukocyte migration","canonical_id":"go:GO:0002685","description":"\"Any process that modulates the frequency, rate, or extent of leukocyte migration.\" [GOC:add]","metadata":null},{"id":"a1b1d67a24854de0a5ce8f5055722632","type":"GO_TERM","name":"regulation of leukocyte proliferation","canonical_id":"go:GO:0070663","description":"\"Any process that modulates the frequency, rate or extent of leukocyte proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"881112039ae543dfb425ecf2e55df044","type":"GO_TERM","name":"regulation of leukocyte tethering or rolling","canonical_id":"go:GO:1903236","description":"\"Any process that modulates the frequency, rate or extent of leukocyte tethering or rolling.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18308860]","metadata":null},{"id":"052895cd509840d4b0b3fe48dfbbba5c","type":"GO_TERM","name":"regulation of leukotriene production involved in inflammatory response","canonical_id":"go:GO:0035490","description":"\"Any process that modulates the rate, frequency or extent of the synthesis or release of any leukotriene following a stimulus as part of an inflammatory response.\" [GOC:bf]","metadata":null},{"id":"9e20484b10b9461f8fbbcd0bbecc8dad","type":"GO_TERM","name":"regulation of lignin biosynthetic process","canonical_id":"go:GO:1901141","description":"\"Any process that modulates the frequency, rate or extent of lignin biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"49484b0a5dff4fceaebbc063c1e17048","type":"GO_TERM","name":"regulation of linear element assembly","canonical_id":"go:GO:0090006","description":"\"Any process that modulates the rate, frequency or extent of linear element assembly. Linear element assembly is the cell cycle process in which a proteinaceous scaffold, related to the synaptonemal complex, is assembled in association with S. pombe chromosomes during meiotic prophase.\" [GOC:tb]","metadata":null},{"id":"bdc81a1a37ce4bf1af9282d083dd4210","type":"GO_TERM","name":"regulation of linear element maturation","canonical_id":"go:GO:0062123","description":"\"Any process that modulates the rate, frequency or extent of linear element maturation.\" [PMID:30640914]","metadata":null},{"id":"e5497791078f4c6c9efba35eb49c8c39","type":"GO_TERM","name":"regulation of lipid biosynthetic process","canonical_id":"go:GO:0046890","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.\" [GOC:ai]","metadata":null},{"id":"ca657096d42640e28d04df74cd574927","type":"GO_TERM","name":"regulation of lipid catabolic process","canonical_id":"go:GO:0050994","description":"\"Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of lipids.\" [GOC:ai]","metadata":null},{"id":"9c4485b47f71464da47985db66a79776","type":"GO_TERM","name":"regulation of lipid kinase activity","canonical_id":"go:GO:0043550","description":"\"Any process that modulates the frequency, rate or extent of lipid kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a simple or complex lipid.\" [GOC:bf]","metadata":null},{"id":"8d9ae402b9f04d70b78c884a081a72e5","type":"GO_TERM","name":"regulation of lipid localization","canonical_id":"go:GO:1905952","description":"\"Any process that modulates the frequency, rate or extent of lipid localization.\" [GO_REF:0000058, GOC:TermGenie, PMID:17564681]","metadata":null},{"id":"fa48b8ecb85c41fdbd291971a84f7581","type":"GO_TERM","name":"regulation of lipid metabolic process","canonical_id":"go:GO:0019216","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.\" [GOC:curators]","metadata":null},{"id":"791cfa1a122446789d5259cda1357e52","type":"GO_TERM","name":"regulation of lipid storage","canonical_id":"go:GO:0010883","description":"\"Any process that modulates the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"24a8203cb74944c790f203abe282952e","type":"GO_TERM","name":"regulation of lipid transport","canonical_id":"go:GO:0032368","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"ef716295ee2d44ecaa299c9f2daf102f","type":"GO_TERM","name":"regulation of lipid transport across blood-brain barrier","canonical_id":"go:GO:1903000","description":"\"Any process that modulates the frequency, rate or extent of lipid transport across blood-brain barrier.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:24345162]","metadata":null},{"id":"e025f4631f314b63953ac89287daed6d","type":"GO_TERM","name":"regulation of lipophagy","canonical_id":"go:GO:1904502","description":"\"Any process that modulates the frequency, rate or extent of lipophagy.\" [GO_REF:0000058, GOC:autophagy, GOC:dph, GOC:TermGenie, PMID:25383539]","metadata":null},{"id":"fee87397703b43c587e3943ae7e5969b","type":"GO_TERM","name":"regulation of lipopolysaccharide-mediated signaling pathway","canonical_id":"go:GO:0031664","description":"\"Any process that modulates the frequency, rate or extent of signaling in response to detection of lipopolysaccharide.\" [GOC:mah]","metadata":null},{"id":"b3e46b09a1544fa8845ec027dc42bfc9","type":"GO_TERM","name":"regulation of lipoprotein lipid oxidation","canonical_id":"go:GO:0060587","description":"\"Any process that modulates the rate, frequency or extent of lipoprotein lipid oxidation. Lipoprotein lipid oxidation is the modification of a lipoprotein by oxidation of the lipid group.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"b57b346aa7b64446a3e46faed0a58821","type":"GO_TERM","name":"regulation of lipoprotein metabolic process","canonical_id":"go:GO:0050746","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipoproteins, any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.\" [GOC:ai]","metadata":null},{"id":"34305d5cfe4a4bb0a59e576a5dad10a8","type":"GO_TERM","name":"regulation of lipoprotein oxidation","canonical_id":"go:GO:0034442","description":"\"Any process that modulates the frequency, rate or extent of lipoprotein oxidation.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"a4f9112c3d134ad6982b953d2342e6df","type":"GO_TERM","name":"regulation of lipoprotein particle clearance","canonical_id":"go:GO:0010984","description":"\"Any process that modulates the rate, frequency, or extent of lipoprotein particle clearance. Lipoprotein particle clearance is the process in which a lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"88febafb707b43ca8cc6d9b30c89cee5","type":"GO_TERM","name":"regulation of lipoprotein transport","canonical_id":"go:GO:0140075","description":"\"Any process that controls lipoprotein transport.\" [GOC:BHF, GOC:BHF_miRNA, GOC:RPH, PMID:26501192]","metadata":null},{"id":"f120c7ab0904408aa6bd323e68581b27","type":"GO_TERM","name":"regulation of lncRNA transcription","canonical_id":"go:GO:0140743","description":"\"Any process that modulates the frequency, rate or extent of the synthesis of a lncRNA.\" [PMID:33767452, PMID:33913806]","metadata":null},{"id":"508577cdd61b48639bdf847f3c4e895d","type":"GO_TERM","name":"regulation of localization","canonical_id":"go:GO:0032879","description":"\"Any process that modulates the frequency, rate or extent of any process in which a cell, a substance, or a cellular entity is transported to, or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"a257471a80cf4d52aca5cb610ade3681","type":"GO_TERM","name":"regulation of locomotion","canonical_id":"go:GO:0040012","description":"\"Any process that modulates the frequency, rate or extent of locomotion of a cell or organism.\" [GOC:ems]","metadata":null},{"id":"785f734d336c45579f6923d6e8f19a62","type":"GO_TERM","name":"regulation of locomotion involved in locomotory behavior","canonical_id":"go:GO:0090325","description":"\"Any process that modulates the frequency, rate, or extent of the self-propelled movement of a cell or organism from one location to another in a behavioral context; the aspect of locomotory behavior having to do with movement.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"bb07c7d6a69d4941914890922d01be9b","type":"GO_TERM","name":"regulation of locomotor rhythm","canonical_id":"go:GO:1904059","description":"\"Any process that modulates the frequency, rate or extent of locomotor rhythm.\" [GO_REF:0000058, GOC:TermGenie, PMID:16310969]","metadata":null},{"id":"d07583ff4d56414284aaf57bc0f40df6","type":"GO_TERM","name":"regulation of long-chain fatty acid import across plasma membrane","canonical_id":"go:GO:0010746","description":"\"Any process that modulates the rate, frequency or extent of plasma membrane long-chain fatty acid transport. Plasma membrane long-chain fatty acid transport is the directed movement of long-chain fatty acids across the plasma membrane. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"0c42a15caade4731900471c394772a3f","type":"GO_TERM","name":"regulation of long-chain fatty acid import into cell","canonical_id":"go:GO:0140212","description":"\"Any process that modulates the frequency, rate or extent of long-chain fatty acid import into a cell.\" [PMID:28178239]","metadata":null},{"id":"4fb8e95286b34be4b91ac3b42851aefb","type":"GO_TERM","name":"regulation of long-day photoperiodism, flowering","canonical_id":"go:GO:0048586","description":"\"Any process that modulates the frequency, rate or extent of long-day photoperiodism, where the response associated with the photoperiodism is flowering. Flowering is defined by the switch from the vegetative to the reproductive phase.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"9c798c5e70af481b83eea245063147c8","type":"GO_TERM","name":"regulation of long-term neuronal synaptic plasticity","canonical_id":"go:GO:0048169","description":"\"A process that modulates long-term neuronal synaptic plasticity, the ability of neuronal synapses to change long-term as circumstances require. Long-term neuronal synaptic plasticity generally involves increase or decrease in actual synapse numbers.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"12438fa4afcd4b099ad305f24dc883cb","type":"GO_TERM","name":"regulation of long-term synaptic depression","canonical_id":"go:GO:1900452","description":"\"Any process that modulates the frequency, rate or extent of long term synaptic depression.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"99ad61f949bd45bdb3257ccd16b0f19c","type":"GO_TERM","name":"regulation of long-term synaptic potentiation","canonical_id":"go:GO:1900271","description":"\"Any process that modulates the frequency, rate or extent of long-term synaptic potentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"8b6ad81d6b834cd3a588a503208c7c64","type":"GO_TERM","name":"regulation of low-density lipoprotein particle clearance","canonical_id":"go:GO:0010988","description":"\"Any process that modulates the rate, frequency or extent of low-density lipoprotein particle clearance. Low-density lipoprotein particle clearance is the process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"25bf643df5394249a99279c3a331cdcb","type":"GO_TERM","name":"regulation of low-density lipoprotein particle receptor catabolic process","canonical_id":"go:GO:0032803","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of low-density lipoprotein particle receptors.\" [GOC:mah]","metadata":null},{"id":"2aa66b11e7cd4f7396bda62648bcf641","type":"GO_TERM","name":"regulation of lung alveolus development","canonical_id":"go:GO:1904653","description":"\"Any process that modulates the frequency, rate or extent of lung alveolus development.\" [GO_REF:0000058, GOC:TermGenie, PMID:23962064]","metadata":null},{"id":"9f2ddfe2d66a42ab98bb155c328c4869","type":"GO_TERM","name":"regulation of lung blood pressure","canonical_id":"go:GO:0014916","description":"\"The process that modulates the force with which blood travels through the lungs. The process is controlled by a balance of processes that increase pressure and decrease pressure.\" [GOC:mtg_cardio]","metadata":null},{"id":"be63c9da78944df6b4e1b0bf73c9cea8","type":"GO_TERM","name":"regulation of lung ciliated cell differentiation","canonical_id":"go:GO:1901246","description":"\"Any process that modulates the frequency, rate or extent of lung ciliated cell differentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"7a5002d7b94149ed9bd669890e39ed57","type":"GO_TERM","name":"regulation of lung goblet cell differentiation","canonical_id":"go:GO:1901249","description":"\"Any process that modulates the frequency, rate or extent of lung goblet cell differentiation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"6b5182cec62c4fadb72e6f45dfa88301","type":"GO_TERM","name":"regulation of luteinizing hormone secretion","canonical_id":"go:GO:0033684","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of luteinizing hormone.\" [GOC:mah]","metadata":null},{"id":"ea97f4c9363a4b298226325895750bf9","type":"GO_TERM","name":"regulation of lymphangiogenesis","canonical_id":"go:GO:1901490","description":"\"Any process that modulates the frequency, rate or extent of lymphangiogenesis.\" [GOC:dph, GOC:TermGenie, PMID:20133819]","metadata":null},{"id":"6db11ebf688d41e994fc4d4b3b2e33e2","type":"GO_TERM","name":"regulation of lymphatic vascular permeability","canonical_id":"go:GO:1990185","description":"\"Any process that modulates the extent to which lymphatic vessels can be pervaded by fluid.\" [PMID:23897233]","metadata":null},{"id":"f16ebe788000457d92239f9b2c330ac4","type":"GO_TERM","name":"regulation of lymphatic vessel size","canonical_id":"go:GO:1990186","description":"\"Any process that modulates the size of lymphatic vessels.\" [PMID:23897233]","metadata":null},{"id":"1908a727b5ec4204a06c02349e4e70b1","type":"GO_TERM","name":"regulation of lymphocyte activation","canonical_id":"go:GO:0051249","description":"\"Any process that modulates the frequency, rate or extent of lymphocyte activation.\" [GOC:ai]","metadata":null},{"id":"11d948d051694300ae0d4c64ba24d572","type":"GO_TERM","name":"regulation of lymphocyte anergy","canonical_id":"go:GO:0002911","description":"\"Any process that modulates the frequency, rate, or extent of lymphocyte anergy.\" [GOC:add]","metadata":null},{"id":"2858c3acc5744ad2b843c06c07f32e7d","type":"GO_TERM","name":"regulation of lymphocyte apoptotic process","canonical_id":"go:GO:0070228","description":"\"Any process that modulates the occurrence or rate of lymphocyte death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"ba9bdf1457af473891897f5b9dbb9ca5","type":"GO_TERM","name":"regulation of lymphocyte chemotaxis","canonical_id":"go:GO:1901623","description":"\"Any process that modulates the frequency, rate or extent of lymphocyte chemotaxis.\" [GOC:TermGenie]","metadata":null},{"id":"b3ca2653a1ae4ab5af259b4f2bdd2d09","type":"GO_TERM","name":"regulation of lymphocyte differentiation","canonical_id":"go:GO:0045619","description":"\"Any process that modulates the frequency, rate or extent of lymphocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"a663e824c2b545a9a11261fe67909051","type":"GO_TERM","name":"regulation of lymphocyte mediated immunity","canonical_id":"go:GO:0002706","description":"\"Any process that modulates the frequency, rate, or extent of lymphocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"aed704f194b84d4b9f3183d0d0f7171a","type":"GO_TERM","name":"regulation of lymphocyte migration","canonical_id":"go:GO:2000401","description":"\"Any process that modulates the frequency, rate or extent of lymphocyte migration.\" [GOC:mah]","metadata":null},{"id":"88680935fdbe4c1b8d0534149a9621db","type":"GO_TERM","name":"regulation of lymphocyte proliferation","canonical_id":"go:GO:0050670","description":"\"Any process that modulates the frequency, rate or extent of lymphocyte proliferation.\" [GOC:ai]","metadata":null},{"id":"4491e2974ed7465e94171099d752772e","type":"GO_TERM","name":"regulation of lymphoid progenitor cell differentiation","canonical_id":"go:GO:1905456","description":"\"Any process that modulates the frequency, rate or extent of lymphoid progenitor cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27010503]","metadata":null},{"id":"94a6cb15d30045f7b0a8dc3a1aab06a0","type":"GO_TERM","name":"regulation of lymphotoxin A production","canonical_id":"go:GO:0032681","description":"\"Any process that modulates the frequency, rate, or extent of lymphotoxin A production.\" [GOC:mah]","metadata":null},{"id":"1436afd76b454469ade3b11adbe4ee72","type":"GO_TERM","name":"regulation of lysine biosynthetic process via aminoadipic acid","canonical_id":"go:GO:1902986","description":"\"Any process that modulates the frequency, rate or extent of lysine biosynthetic process via aminoadipic acid.\" [GO_REF:0000058, GOC:TermGenie, PMID:8590464]","metadata":null},{"id":"865c108b9ab74f799a28cfdfa34b0b04","type":"GO_TERM","name":"regulation of lysosomal membrane permeability","canonical_id":"go:GO:0097213","description":"\"Any process that modulates the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane.\" [GOC:yaf, PMID:20544854]","metadata":null},{"id":"43d11d48606044e0af40bb1da001eb19","type":"GO_TERM","name":"regulation of lysosomal protein catabolic process","canonical_id":"go:GO:1905165","description":"\"Any process that modulates the frequency, rate or extent of lysosomal protein catabolic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23499937]","metadata":null},{"id":"978a2358cae941a1b1217660b0aff106","type":"GO_TERM","name":"regulation of lysosome organization","canonical_id":"go:GO:1905671","description":"\"Any process that modulates the frequency, rate or extent of lysosome organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:25561470]","metadata":null},{"id":"ba15be4076884717a0b50fb2895c0c07","type":"GO_TERM","name":"regulation of lysosome size","canonical_id":"go:GO:0062196","description":"\"Any process that modulates the size of a lysosome.\" [PMID:31314175]","metadata":null},{"id":"5f37fba8737e4e49bd8b63b0e4c3ab7e","type":"GO_TERM","name":"regulation of mRNA 3'-end processing","canonical_id":"go:GO:0031440","description":"\"Any process that modulates the frequency, rate or extent of mRNA 3'-end processing, any process involved in forming the mature 3' end of an mRNA molecule.\" [GOC:mah]","metadata":null},{"id":"2cb8f13708f34ed798d8185adce72a37","type":"GO_TERM","name":"regulation of mRNA alternative polyadenylation","canonical_id":"go:GO:0140408","description":"\"Any process that modulates the frequency, rate or extent of mRNA alternative polyadenylation.\" [PMID:29507755]","metadata":null},{"id":"0e43f65b41f7489bb00a28c84b43a19c","type":"GO_TERM","name":"regulation of mRNA binding","canonical_id":"go:GO:1902415","description":"\"Any process that modulates the frequency, rate or extent of mRNA binding.\" [GOC:rb, GOC:TermGenie, PMID:22890846]","metadata":null},{"id":"3132060657b94ef486ff3a90c24413f1","type":"GO_TERM","name":"regulation of mRNA catabolic process","canonical_id":"go:GO:0061013","description":"\"Any process that modulates the rate, frequency, or extent of a mRNA catabolic process, the chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1bb1adf781d2445c96f009a7a76bbca3","type":"GO_TERM","name":"regulation of mRNA cis splicing, via spliceosome","canonical_id":"go:GO:1905744","description":"\"Any process that modulates the frequency, rate or extent of mRNA cis splicing, via spliceosome.\" [GO_REF:0000058, GOC:TermGenie, PMID:2880558]","metadata":null},{"id":"a20d5c72e976473cadfc98e39be1aa27","type":"GO_TERM","name":"regulation of mRNA export from nucleus","canonical_id":"go:GO:0010793","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of mRNA from the nucleus to the cytoplasm.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7e04df983d374ea290b60e8c24e24f93","type":"GO_TERM","name":"regulation of mRNA export from nucleus in response to heat stress","canonical_id":"go:GO:2000728","description":"\"Any process that modulates the frequency, rate or extent of mRNA export from nucleus in response to heat stress.\" [PMID:15210706]","metadata":null},{"id":"e473b7a214d647879a13e7a400308c68","type":"GO_TERM","name":"regulation of mRNA metabolic process","canonical_id":"go:GO:1903311","description":"\"Any process that modulates the frequency, rate or extent of mRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"ac3e3f06ff164e4c8772084bdb9ff6a5","type":"GO_TERM","name":"regulation of mRNA modification","canonical_id":"go:GO:0090365","description":"\"Any process that modulates the rate, frequency, or extent of the covalent alteration of one or more nucleotides within an mRNA molecule to produce an mRNA molecule with a sequence that differs from that coded genetically.\" [GOC:dph, GOC:sl, GOC:tb, PMID:14559896]","metadata":null},{"id":"6cbabaa51e154fb393242c490191be90","type":"GO_TERM","name":"regulation of mRNA processing","canonical_id":"go:GO:0050684","description":"\"Any process that modulates the frequency, rate or extent of mRNA processing, those processes involved in the conversion of a primary mRNA transcript into a mature mRNA prior to its translation into polypeptide.\" [GOC:ai]","metadata":null},{"id":"c8768ea59ec7446d8c180ca86e7b0c85","type":"GO_TERM","name":"regulation of mRNA splicing, via spliceosome","canonical_id":"go:GO:0048024","description":"\"Any process that modulates the frequency, rate or extent of mRNA splicing via a spliceosomal mechanism.\" [GOC:jid]","metadata":null},{"id":"b20fc8e732b142059e8363c13679fa93","type":"GO_TERM","name":"regulation of mRNA stability","canonical_id":"go:GO:0043488","description":"\"Any process that modulates the propensity of mRNA molecules to degradation. Includes processes that both stabilize and destabilize mRNAs.\" [GOC:jl]","metadata":null},{"id":"7b09ddd830bd42369dc74dd311533a95","type":"GO_TERM","name":"regulation of mRNA stability involved in cellular response to UV","canonical_id":"go:GO:1902629","description":"\"Any regulation of mRNA stability that is involved in cellular response to UV.\" [GO_REF:0000060, GOC:TermGenie, PMID:10954610]","metadata":null},{"id":"1cb0df7c07d648bd92e2ddaccf91c3ed","type":"GO_TERM","name":"regulation of mRNA stability involved in response to oxidative stress","canonical_id":"go:GO:2000815","description":"\"A process of regulation of mRNA stability that is involved in a response to oxidative stress.\" [GOC:obol]","metadata":null},{"id":"2ef159356ca74eeca8ff9c0a65466df7","type":"GO_TERM","name":"regulation of mRNA stability involved in response to stress","canonical_id":"go:GO:0010610","description":"\"Any process that modulates the propensity of mRNA molecules to degradation that is part of a change in state or activity of a cell as a result of an exogenous disturbance.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4c4f0b17afb9444594282b010c0be9a1","type":"GO_TERM","name":"regulation of macroautophagy","canonical_id":"go:GO:0016241","description":"\"Any process that modulates the frequency, rate or extent of macroautophagy.\" [GOC:krc]","metadata":null},{"id":"830e6e58ff47416bb15154d603dd1a31","type":"GO_TERM","name":"regulation of macromolecule biosynthetic process","canonical_id":"go:GO:0010556","description":"\"Any process that modulates the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"81cff7b277ed48dbbdb84f4e8e99f0a5","type":"GO_TERM","name":"regulation of macromolecule metabolic process","canonical_id":"go:GO:0060255","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b2fa9f5662b7476e9c74b539e4938827","type":"GO_TERM","name":"regulation of macrophage activation","canonical_id":"go:GO:0043030","description":"\"Any process that modulates the frequency or rate of macrophage activation.\" [GOC:jl]","metadata":null},{"id":"e4fe7b6e461b4813b577f7e79eeffe57","type":"GO_TERM","name":"regulation of macrophage antigen processing and presentation","canonical_id":"go:GO:0002616","description":"\"Any process that modulates the frequency, rate, or extent of macrophage antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"5e2abdbdea704034a9f64c30fc733246","type":"GO_TERM","name":"regulation of macrophage apoptotic process","canonical_id":"go:GO:2000109","description":"\"Any process that modulates the frequency, rate or extent of macrophage apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis]","metadata":null},{"id":"c6a091b813c54f7e9288142537c7d568","type":"GO_TERM","name":"regulation of macrophage chemotaxis","canonical_id":"go:GO:0010758","description":"\"Any process that modulates the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"9f070416e4d749cba05fad130d7d4e8f","type":"GO_TERM","name":"regulation of macrophage colony-stimulating factor production","canonical_id":"go:GO:1901256","description":"\"Any process that modulates the frequency, rate or extent of macrophage colony-stimulating factor production.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"c7e95f8617da4c9788b0a8ef60d634de","type":"GO_TERM","name":"regulation of macrophage colony-stimulating factor signaling pathway","canonical_id":"go:GO:1902226","description":"\"Any process that modulates the frequency, rate or extent of macrophage colony-stimulating factor signaling pathway.\" [GOC:TermGenie, PMID:16705167]","metadata":null},{"id":"625a54bd734442cb84b2ab7927946578","type":"GO_TERM","name":"regulation of macrophage cytokine production","canonical_id":"go:GO:0010935","description":"\"Any process that modulates the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"17644fdcfa72479a86e0e7fb35085df6","type":"GO_TERM","name":"regulation of macrophage derived foam cell differentiation","canonical_id":"go:GO:0010743","description":"\"Any process that modulates the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.\" [GOC:add, GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1b6ad385f40846318729d97d9f46b31c","type":"GO_TERM","name":"regulation of macrophage differentiation","canonical_id":"go:GO:0045649","description":"\"Any process that modulates the frequency, rate or extent of macrophage differentiation.\" [GOC:curators]","metadata":null},{"id":"e5c296aa03f54e57827061cb78691914","type":"GO_TERM","name":"regulation of macrophage fusion","canonical_id":"go:GO:0034239","description":"\"Any process that modulates the frequency, rate or extent of macrophage fusion.\" [GOC:mah]","metadata":null},{"id":"3d9b49b4133d470b9d6c37e70afee872","type":"GO_TERM","name":"regulation of macrophage inflammatory protein 1 alpha production","canonical_id":"go:GO:0071640","description":"\"Any process that modulates the frequency, rate, or extent of production of macrophage inflammatory protein 1 alpha.\" [GOC:mah]","metadata":null},{"id":"2a210509bab2401c89b25fee0215ce2e","type":"GO_TERM","name":"regulation of macrophage inflammatory protein-1 gamma production","canonical_id":"go:GO:0071646","description":"\"Any process that modulates the frequency, rate, or extent of production of macrophage inflammatory protein-1 gamma.\" [GOC:mah]","metadata":null},{"id":"80b7dbc2daba4a71b18b65211ba07be8","type":"GO_TERM","name":"regulation of macrophage migration","canonical_id":"go:GO:1905521","description":"\"Any process that modulates the frequency, rate or extent of macrophage migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:25749876]","metadata":null},{"id":"5a719048759846ef8f326e92df4fde9c","type":"GO_TERM","name":"regulation of macrophage migration inhibitory factor signaling pathway","canonical_id":"go:GO:2000446","description":"\"Any process that modulates the frequency, rate or extent of macrophage migration inhibitory factor signaling pathway.\" [GOC:obol]","metadata":null},{"id":"b9a927cf3a714b7486c7bc5fdda6bec5","type":"GO_TERM","name":"regulation of macrophage proliferation","canonical_id":"go:GO:0120040","description":"\"Any process that modulates the frequency, rate or extent of macrophage proliferation.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph]","metadata":null},{"id":"f345ebda12714d8c92047a49d87ed1d8","type":"GO_TERM","name":"regulation of macrophage tolerance induction","canonical_id":"go:GO:0010932","description":"\"Any process that modulates the frequency, rate, or extent of macrophage tolerance induction.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"9cbd163a3ebe45c38184e4f9350e3267","type":"GO_TERM","name":"regulation of macropinocytosis","canonical_id":"go:GO:1905301","description":"\"Any process that modulates the frequency, rate or extent of macropinocytosis.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:18691641]","metadata":null},{"id":"e2f3e25c1db1479b91bc9fb76a24bc63","type":"GO_TERM","name":"regulation of maintenance of bipolar cell polarity regulating cell shape","canonical_id":"go:GO:2000115","description":"\"Any process that modulates the frequency, rate or extent of maintenance of bipolar cell polarity regulating in cell shape.\" [GOC:obol]","metadata":null},{"id":"ff68aa315d0a4625891643c9a79e827c","type":"GO_TERM","name":"regulation of maintenance of meiotic sister chromatid cohesion","canonical_id":"go:GO:0034094","description":"\"Any process that modulates the extent to which the association between sister chromatids of a replicated chromosome is maintained during a meiotic cell cycle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"aa7a71ea4e8340b1b5a73a489953788d","type":"GO_TERM","name":"regulation of maintenance of meiotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:2000709","description":"\"Any process that modulates the frequency, rate or extent of maintenance of meiotic sister chromatid cohesion in the centromeric region.\" [GOC:mah]","metadata":null},{"id":"002852e5a2844ae8883e2e62e0aa2e8a","type":"GO_TERM","name":"regulation of maintenance of mitotic sister chromatid cohesion","canonical_id":"go:GO:0034182","description":"\"Any process that modulates the extent to which the association between sister chromatids of a replicated chromosome is maintained during a mitotic cell cycle.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"21f3b74c84f641849b4e213ed6a11166","type":"GO_TERM","name":"regulation of maintenance of mitotic sister chromatid cohesion, arms","canonical_id":"go:GO:2000715","description":"\"Any process that modulates the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion along the chromosome arms.\" [GOC:mah]","metadata":null},{"id":"39b36cb53edb404e8ff38b5dff9dd3d3","type":"GO_TERM","name":"regulation of maintenance of mitotic sister chromatid cohesion, centromeric","canonical_id":"go:GO:2000718","description":"\"Any process that modulates the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion in the centromeric region.\" [GOC:mah]","metadata":null},{"id":"01665e6abeeb49268e5733ff13d52ad8","type":"GO_TERM","name":"regulation of maintenance of mitotic sister chromatid cohesion, telomeric","canonical_id":"go:GO:1904907","description":"\"Any process that modulates the frequency, rate or extent of maintenance of mitotic sister chromatid cohesion, telomeric.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26373281]","metadata":null},{"id":"3ca215cbb2a04a08b62dd51aa2e2f1bc","type":"GO_TERM","name":"regulation of maintenance of sister chromatid cohesion","canonical_id":"go:GO:0034091","description":"\"Any process that modulates the extent to which the association between sister chromatids of a replicated chromosome is maintained.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"cf566ecf69424d56a24d82bd33dcbfd5","type":"GO_TERM","name":"regulation of male germ cell proliferation","canonical_id":"go:GO:2000254","description":"\"Any process that modulates the frequency, rate or extent of male germ cell proliferation.\" [GOC:obol]","metadata":null},{"id":"4a4c90fc103c4c1f908f91f4954e1c09","type":"GO_TERM","name":"regulation of male germ-line stem cell asymmetric division","canonical_id":"go:GO:1904838","description":"\"Any process that modulates the frequency, rate or extent of male germ-line stem cell asymmetric division.\" [GO_REF:0000058, GOC:TermGenie, PMID:19339709]","metadata":null},{"id":"a957a218f8514675be1d1b0b0505c93b","type":"GO_TERM","name":"regulation of male gonad development","canonical_id":"go:GO:2000018","description":"\"Any process that modulates the frequency, rate or extent of male gonad development.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"cbeef81361bc473b8e225d61c54fd10e","type":"GO_TERM","name":"regulation of male mating behavior","canonical_id":"go:GO:1902435","description":"\"Any process that modulates the frequency, rate or extent of male mating behavior.\" [GOC:TermGenie, PMID:24089208]","metadata":null},{"id":"6bd7f44c998948f0bef3f99ebbf5c47a","type":"GO_TERM","name":"regulation of male pigmentation","canonical_id":"go:GO:0048088","description":"\"Any process that modulates the frequency, rate or extent of establishment of a pattern of pigment in males.\" [GOC:jid]","metadata":null},{"id":"f9e53bd61b184034a6251047c929bc5b","type":"GO_TERM","name":"regulation of maltoheptaose transport","canonical_id":"go:GO:1900306","description":"\"Any process that modulates the frequency, rate or extent of maltoheptaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"6ba3135949074967aa68eb5929ef398d","type":"GO_TERM","name":"regulation of maltohexaose transport","canonical_id":"go:GO:1900312","description":"\"Any process that modulates the frequency, rate or extent of maltohexaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"edbd7b0f449c497997421095692f5b6e","type":"GO_TERM","name":"regulation of maltopentaose transport","canonical_id":"go:GO:1900315","description":"\"Any process that modulates the frequency, rate or extent of maltopentaose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4dc3dece29524b43aa6958db1a2af81a","type":"GO_TERM","name":"regulation of maltose transport","canonical_id":"go:GO:1902343","description":"\"Any process that modulates the frequency, rate or extent of maltose transport.\" [GOC:dph, GOC:TermGenie, PMID:23770568]","metadata":null},{"id":"6c60f15302834c15ab6135844c7739d5","type":"GO_TERM","name":"regulation of maltotetraose transport","canonical_id":"go:GO:1900321","description":"\"Any process that modulates the frequency, rate or extent of maltotetraose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"ecc2f329b8ea4902b5f273220f85650e","type":"GO_TERM","name":"regulation of maltotriulose transport","canonical_id":"go:GO:1900324","description":"\"Any process that modulates the frequency, rate or extent of maltotriulose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"a4addce5f23e47e3892d69031231fd8a","type":"GO_TERM","name":"regulation of mammary gland cord elongation by mammary fat precursor cell-epithelial cell signaling","canonical_id":"go:GO:0060657","description":"\"Any process that modulates the rate, frequency, or extent of mammary gland cord elongation as a result of a signal being created by a mesenchymal cell that is a precursor to the mammary fat and its subsequent reception and interpretation by an mammary cord epithelial cell.\" [GOC:dph, PMID:12558599]","metadata":null},{"id":"77015942d46b4207ac3e11760858f6d6","type":"GO_TERM","name":"regulation of mammary gland epithelial cell proliferation","canonical_id":"go:GO:0033599","description":"\"Any process that modulates the frequency, rate or extent of mammary gland epithelial cell proliferation.\" [GOC:mah]","metadata":null},{"id":"a46cbc2fdb54412c865550ef78e0ea48","type":"GO_TERM","name":"regulation of mammary gland involution","canonical_id":"go:GO:1903519","description":"\"Any process that modulates the frequency, rate or extent of mammary gland involution.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:23164222]","metadata":null},{"id":"c8e45dad10dd43e99db13cf87fec9040","type":"GO_TERM","name":"regulation of mammary stem cell proliferation","canonical_id":"go:GO:2000101","description":"\"Any process that modulates the frequency, rate or extent of mammary stem cell proliferation.\" [GOC:obol]","metadata":null},{"id":"57583987c30145378efd0c78349ee389","type":"GO_TERM","name":"regulation of mannan catabolic process","canonical_id":"go:GO:2000994","description":"\"Any process that modulates the frequency, rate or extent of mannan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"1538f5ac89f6492088f4c271fa33f1b7","type":"GO_TERM","name":"regulation of mannotriose transport","canonical_id":"go:GO:1900327","description":"\"Any process that modulates the frequency, rate or extent of mannotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"21e370b332f2424eb164f184ad7b6e26","type":"GO_TERM","name":"regulation of mast cell activation","canonical_id":"go:GO:0033003","description":"\"Any process that modulates the frequency, rate, or extent of mast cell activation.\" [GOC:mah]","metadata":null},{"id":"38fea1f829e24178b80e174e15155638","type":"GO_TERM","name":"regulation of mast cell apoptotic process","canonical_id":"go:GO:0033025","description":"\"Any process that modulates the frequency, rate, or extent of mast cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"196d19a13f3742fbb0e6106d59d0037a","type":"GO_TERM","name":"regulation of mast cell chemotaxis","canonical_id":"go:GO:0060753","description":"\"Any process that modulates the rate, frequency or extent of mast cell chemotaxis. Mast cell chemotaxis is the movement of a mast cell in response to an external stimulus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b5f160b1a3f2479a8b74e55fbf637b15","type":"GO_TERM","name":"regulation of mast cell cytokine production","canonical_id":"go:GO:0032763","description":"\"Any process that modulates the frequency, rate, or extent of mast cell cytokine production.\" [GOC:mah]","metadata":null},{"id":"9c4475779816450f95a7095ff7345bff","type":"GO_TERM","name":"regulation of mast cell degranulation","canonical_id":"go:GO:0043304","description":"\"Any process that modulates the frequency, rate, or extent of mast cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"f77eb635dde94f7e85f9b3cc6d756b1d","type":"GO_TERM","name":"regulation of mast cell differentiation","canonical_id":"go:GO:0060375","description":"\"Any process that modulates the rate, frequency or extent of mast cell differentiation, the process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a mast cell. A mast cell is a cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9c5c5151243342b3888a86b5564040b6","type":"GO_TERM","name":"regulation of mast cell proliferation","canonical_id":"go:GO:0070666","description":"\"Any process that modulates the frequency, rate or extent of mast cell proliferation.\" [GOC:add, GOC:mah]","metadata":null},{"id":"38b4e8309f4e4cf583311da9b8989292","type":"GO_TERM","name":"regulation of mating projection assembly","canonical_id":"go:GO:0031383","description":"\"Any process that modulates the frequency, rate, or extent of mating projection formation by unicellular fungi.\" [PMID:14734532]","metadata":null},{"id":"5712137526bd439eb79f5fbf2d987177","type":"GO_TERM","name":"regulation of mating type switching","canonical_id":"go:GO:0031494","description":"\"Any process that modulates the frequency, rate or extent of mating type switching, the conversion of a single-cell organism from one mating type to another by the precise replacement of a DNA sequence at the expressed mating type locus with a copy of a sequence from a donor locus.\" [GOC:mah]","metadata":null},{"id":"0b3121de8a814f98ab29733382525900","type":"GO_TERM","name":"regulation of mating-type specific transcription, DNA-templated","canonical_id":"go:GO:0007532","description":"\"Any mating-type specific process that modulates the frequency, rate or extent of cellular DNA-templated transcription.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"ecf8d93d2b3146d587c0ca143855359b","type":"GO_TERM","name":"regulation of matrix metallopeptidase secretion","canonical_id":"go:GO:1904464","description":"\"Any process that modulates the frequency, rate or extent of matrix metallopeptidase secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:8679543]","metadata":null},{"id":"03d386bea1094cfea599c9ec9d9ad9d5","type":"GO_TERM","name":"regulation of mature B cell apoptotic process","canonical_id":"go:GO:0002905","description":"\"Any process that modulates the frequency, rate, or extent of mature B cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"22d5e880d43f44069e732711470585b0","type":"GO_TERM","name":"regulation of mechanoreceptor differentiation","canonical_id":"go:GO:0045631","description":"\"Any process that modulates the frequency, rate or extent of mechanoreceptor differentiation.\" [GOC:curators]","metadata":null},{"id":"515fc7e5b7b14814aea257361d29205e","type":"GO_TERM","name":"regulation of mechanosensory behavior","canonical_id":"go:GO:1905790","description":"\"Any process that modulates the frequency, rate or extent of mechanosensory behavior.\" [GO_REF:0000058, GOC:TermGenie, PMID:8692859]","metadata":null},{"id":"96547d65226a4502afe459b3350cf338","type":"GO_TERM","name":"regulation of mediator complex assembly","canonical_id":"go:GO:2001176","description":"\"Any process that modulates the frequency, rate or extent of mediator complex assembly.\" [GOC:obol]","metadata":null},{"id":"2cb002a77fae469886b578189e6121a8","type":"GO_TERM","name":"regulation of megakaryocyte differentiation","canonical_id":"go:GO:0045652","description":"\"Any process that modulates the frequency, rate or extent of megakaryocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"9a8120d64f9d485783678e9462f9c48d","type":"GO_TERM","name":"regulation of meiosis I","canonical_id":"go:GO:0060631","description":"\"Any process that modulates the rate, frequency, or extent of meiosis I, a cell cycle process comprising the steps by which a cell progresses through the first phase of meiosis, in which cells divide and homologous chromosomes are paired and segregated from each other, producing two daughter cells.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3d08658070f641d2ad4fbe11bf24b6ad","type":"GO_TERM","name":"regulation of meiosis I spindle assembly checkpoint","canonical_id":"go:GO:1905325","description":"\"Any process that modulates the frequency, rate or extent of the meiosis I spindle assembly checkpoint.\" [GO_REF:0000058, GOC:TermGenie, PMID:26483559]","metadata":null},{"id":"6decf2b7fb0144d38e17641c4ace82d8","type":"GO_TERM","name":"regulation of meiotic DNA double-strand break formation","canonical_id":"go:GO:1903341","description":"\"Any process that modulates the frequency, rate or extent of meiotic DNA double-strand break formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25103240]","metadata":null},{"id":"55f273409b1b4993884776388b0d384c","type":"GO_TERM","name":"regulation of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination","canonical_id":"go:GO:1905261","description":"\"Any process that modulates the frequency, rate or extent of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination.\" [GO_REF:0000058, GOC:TermGenie, PMID:26653857]","metadata":null},{"id":"0c1cd602f99e450eb511b5e702bc52ad","type":"GO_TERM","name":"regulation of meiotic cell cycle","canonical_id":"go:GO:0051445","description":"\"Any process that modulates the rate or extent of progression through the meiotic cell cycle.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"3e2e7b555d254faaa387f6659b98356b","type":"GO_TERM","name":"regulation of meiotic cell cycle phase transition","canonical_id":"go:GO:1901993","description":"\"Any process that modulates the frequency, rate or extent of meiotic cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"552679c2c7514d7883ccfa7eeac60ded","type":"GO_TERM","name":"regulation of meiotic cell cycle process involved in oocyte maturation","canonical_id":"go:GO:1903538","description":"\"Any process that modulates the frequency, rate or extent of meiotic cell cycle process involved in oocyte maturation.\" [GO_REF:0000058, GOC:jz, GOC:TermGenie, PMID:25212395]","metadata":null},{"id":"af8854363d704818aa39007e1de86f47","type":"GO_TERM","name":"regulation of meiotic chromosome separation","canonical_id":"go:GO:1905132","description":"\"Any process that modulates the frequency, rate or extent of meiotic chromosome separation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw, PMID:15620645]","metadata":null},{"id":"06836319440c495ab69c29b30f2de1a1","type":"GO_TERM","name":"regulation of meiotic joint molecule formation","canonical_id":"go:GO:0010946","description":"\"Any process that modulates the frequency, rate or extent of meiotic joint molecule formation. Meiotic joint molecule formation is the conversion of the paired broken DNA and homologous duplex DNA into a four-stranded branched intermediate, known as a joint molecule, formed during meiotic recombination.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f0da09b2100847438d6cf94235cfa7ef","type":"GO_TERM","name":"regulation of meiotic nuclear division","canonical_id":"go:GO:0040020","description":"\"Any process that modulates the frequency, rate or extent of meiotic nuclear division, the process in which the nucleus of a diploid cell divides twice forming four haploid cells, one or more of which usually function as gametes.\" [GOC:ems, GOC:ma]","metadata":null},{"id":"ef36844f13354ffe8bec716abf65c0fa","type":"GO_TERM","name":"regulation of meiotic spindle elongation","canonical_id":"go:GO:1902119","description":"\"Any process that modulates the frequency, rate or extent of meiotic spindle elongation.\" [GOC:TermGenie, PMID:23370392]","metadata":null},{"id":"7009aec758be4e7196413d516d646f83","type":"GO_TERM","name":"regulation of melanin biosynthetic process","canonical_id":"go:GO:0048021","description":"\"Any process that alters the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of melanin.\" [GOC:jid]","metadata":null},{"id":"87208de441514b82b2b29f05e397a383","type":"GO_TERM","name":"regulation of melanization defense response","canonical_id":"go:GO:0035007","description":"\"Any process that affects the rate, extent or location of the melanization defense response during injury or invasion.\" [GOC:bf]","metadata":null},{"id":"a870902e09e74d14a77fc8ca67141e5e","type":"GO_TERM","name":"regulation of melanocyte differentiation","canonical_id":"go:GO:0045634","description":"\"Any process that modulates the frequency, rate or extent of melanocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"e560289fb2534e4886cd944342ff7440","type":"GO_TERM","name":"regulation of melanosome organization","canonical_id":"go:GO:1903056","description":"\"Any process that modulates the frequency, rate or extent of melanosome organization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:24769727]","metadata":null},{"id":"3b47f135274c415bbfc74dee1ae2f4c2","type":"GO_TERM","name":"regulation of melanosome transport","canonical_id":"go:GO:1902908","description":"\"Any process that modulates the frequency, rate or extent of melanosome transport.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23334344]","metadata":null},{"id":"9fbeee881b974294a9a557b887b3f50c","type":"GO_TERM","name":"regulation of melanotic encapsulation of foreign target","canonical_id":"go:GO:0140539","description":"\"Any process that modulates the frequency, rate or extent of melanotic encapsulation of foreign target.\" [PMID:15749104, PMID:18457993]","metadata":null},{"id":"73fb49f666fb4c5bb5503661948507d3","type":"GO_TERM","name":"regulation of membrane depolarization","canonical_id":"go:GO:0003254","description":"\"Any process that modulates the rate, frequency or extent of membrane depolarization. Membrane depolarization is the process in which membrane potential changes in the depolarizing direction from the resting potential, usually from negative to positive.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4e117229044b4b57be55be3a373e364c","type":"GO_TERM","name":"regulation of membrane depolarization during AV node cell action potential","canonical_id":"go:GO:1905027","description":"\"Any process that modulates the frequency, rate or extent of membrane depolarization during AV node cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:19726871]","metadata":null},{"id":"7c8d9bab1f6346ec90941f99fbfd966f","type":"GO_TERM","name":"regulation of membrane depolarization during action potential","canonical_id":"go:GO:0098902","description":"\"Any process that modulates the rate, frequency or extent of membrane depolarization during an action potential. Membrane depolarization is the process in which membrane potential changes in the depolarizing direction from the resting potential.\" [GOC:dos, GOC:dph, GOC:tb, ISBN:978-0-07-139011-8]","metadata":null},{"id":"fca2212f182b4303a27651fc23148f89","type":"GO_TERM","name":"regulation of membrane depolarization during cardiac muscle cell action potential","canonical_id":"go:GO:1900825","description":"\"Any process that modulates the frequency, rate or extent of membrane depolarization during a cardiac muscle cell action potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:TermGenie]","metadata":null},{"id":"ee89c64bedb440fa9c68e56e9cc682bd","type":"GO_TERM","name":"regulation of membrane disassembly","canonical_id":"go:GO:0010549","description":"\"Any process that modulates the frequency, rate or extent of membrane disassembly.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7e57e71dc0e845f88c95f7b18637eda5","type":"GO_TERM","name":"regulation of membrane hyperpolarization","canonical_id":"go:GO:1902630","description":"\"Any process that modulates the frequency, rate or extent of membrane hyperpolarization.\" [GO_REF:0000058, GOC:TermGenie, PMID:23223304]","metadata":null},{"id":"81389f0085ac45b68af982fce833ae58","type":"GO_TERM","name":"regulation of membrane invagination","canonical_id":"go:GO:1905153","description":"\"Any process that modulates the frequency, rate or extent of membrane invagination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:26589353]","metadata":null},{"id":"9c4d4475cee1496a9c0828d9075c9c07","type":"GO_TERM","name":"regulation of membrane lipid distribution","canonical_id":"go:GO:0097035","description":"\"Any process that modulates the proportions or spatial arrangement of lipids in a cellular membrane.\" [GOC:mah, PMID:18441123, PMID:20823909]","metadata":null},{"id":"6890033b3b894e8aaec4fe5e336fb41d","type":"GO_TERM","name":"regulation of membrane permeability","canonical_id":"go:GO:0090559","description":"\"Any process that modulates the frequency, rate or extent of the passage or uptake of molecules by a membrane.\" [GOC:kmv, PMID:22677064]","metadata":null},{"id":"28e81deb35df45ce9e5af17021f251d8","type":"GO_TERM","name":"regulation of membrane potential","canonical_id":"go:GO:0042391","description":"\"Any process that modulates the establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:jl, GOC:mtg_cardio, GOC:tb, ISBN:0198506732]","metadata":null},{"id":"de148a898ed24a3f869178d9c1e359b4","type":"GO_TERM","name":"regulation of membrane potential in photoreceptor cell","canonical_id":"go:GO:0016057","description":"\"Hyperpolarization (vertebrates) or depolarization (invertebrates) of the photoreceptor cell membrane via closing/opening of cation specific channels as a result of signals generated by rhodopsin activation by a photon.\" [GOC:dph, GOC:hb, GOC:tb]","metadata":null},{"id":"b4c224e105d04713aa13d53630628884","type":"GO_TERM","name":"regulation of membrane protein ectodomain proteolysis","canonical_id":"go:GO:0051043","description":"\"Any process that modulates the frequency, rate or extent of the proteolytic cleavage of transmembrane proteins and release of their ectodomain (extracellular domain).\" [GOC:ai]","metadata":null},{"id":"1f3f419cb46e4b0fbbf062480afa7019","type":"GO_TERM","name":"regulation of membrane repolarization","canonical_id":"go:GO:0060306","description":"\"Any process that modulates the establishment or extent of a membrane potential in the polarizing direction towards the resting potential, usually from positive to negative.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb]","metadata":null},{"id":"c9e7613a7ddc4b99bc75cfa4592479af","type":"GO_TERM","name":"regulation of membrane repolarization during action potential","canonical_id":"go:GO:0098903","description":"\"Any process that modulates the rate, frequency or extent of membrane repolarization during an action potential. Membrane repolarization is the process in which membrane potential changes in the repolarizing direction, towards the resting potential.\" [GOC:dos, GOC:dph, GOC:tb, ISBN:978-0-07-139011-8]","metadata":null},{"id":"4de2ccda543c4a0184cf10d4af7c4015","type":"GO_TERM","name":"regulation of membrane repolarization during atrial cardiac muscle cell action potential","canonical_id":"go:GO:1905000","description":"\"Any process that modulates the frequency, rate or extent of membrane repolarization during atrial cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:21098446]","metadata":null},{"id":"6f0762be0ade4e6c8ed0a9c5bc7d2f19","type":"GO_TERM","name":"regulation of membrane repolarization during cardiac muscle cell action potential","canonical_id":"go:GO:1905031","description":"\"Any process that modulates the frequency, rate or extent of membrane repolarization during cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:23157812]","metadata":null},{"id":"3ca62dcd80d441d8b3b0f72650db6052","type":"GO_TERM","name":"regulation of membrane repolarization during ventricular cardiac muscle cell action potential","canonical_id":"go:GO:1905024","description":"\"Any process that modulates the frequency, rate or extent of membrane repolarization during ventricular cardiac muscle cell action potential.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:mtg_cardiac_conduct_nov11, GOC:rph, GOC:TermGenie, PMID:19893015]","metadata":null},{"id":"91148b772d464b5ebb9e1c55069b4c9b","type":"GO_TERM","name":"regulation of membrane tubulation","canonical_id":"go:GO:1903525","description":"\"Any process that modulates the frequency, rate or extent of membrane tubulation.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:18388313]","metadata":null},{"id":"7e366b4865474c41ab4d42c449d8b95b","type":"GO_TERM","name":"regulation of memory T cell activation","canonical_id":"go:GO:2000567","description":"\"Any process that modulates the frequency, rate or extent of memory T cell activation.\" [GOC:obol]","metadata":null},{"id":"34bac2147101480aad5e0771348a321e","type":"GO_TERM","name":"regulation of memory T cell differentiation","canonical_id":"go:GO:0043380","description":"\"Any process that modulates the frequency, rate, or extent of memory T cell differentiation.\" [ISBN:0781735149]","metadata":null},{"id":"363b01f0819d4db980a0b3536032ae7e","type":"GO_TERM","name":"regulation of meristem development","canonical_id":"go:GO:0048509","description":"\"Any process that modulates the frequency, rate or extent of meristem development, the biological process whose specific outcome is the progression of the meristem over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"2b9da31f3eb44fd89f1023a942076919","type":"GO_TERM","name":"regulation of meristem growth","canonical_id":"go:GO:0010075","description":"\"Any process involved in maintaining the size and shape of a meristem.\" [GOC:tb]","metadata":null},{"id":"15e1b249501f422ea80e106f922b57ec","type":"GO_TERM","name":"regulation of meristem structural organization","canonical_id":"go:GO:0009934","description":"\"Any process that modulates the frequency, rate or extent of meristem organization.\" [GOC:jid]","metadata":null},{"id":"171dd9e3f4f54bd1b453d3630127f934","type":"GO_TERM","name":"regulation of mesenchymal cell apoptotic process","canonical_id":"go:GO:2001053","description":"\"Any process that modulates the frequency, rate or extent of mesenchymal cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"b1d3e80cc3114dac8b32f99de2fdfd38","type":"GO_TERM","name":"regulation of mesenchymal cell proliferation","canonical_id":"go:GO:0010464","description":"\"Any process that modulates the frequency, rate or extent of mesenchymal cell proliferation. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"c60c6f4b6c964fd18f372e0c4e0b675b","type":"GO_TERM","name":"regulation of mesenchymal stem cell differentiation","canonical_id":"go:GO:2000739","description":"\"Any process that modulates the frequency, rate or extent of mesenchymal stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"4e42e68c8d694154abe161e7c661aeb7","type":"GO_TERM","name":"regulation of mesenchymal stem cell migration","canonical_id":"go:GO:1905320","description":"\"Any process that modulates the frequency, rate or extent of mesenchymal stem cell migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:26846297]","metadata":null},{"id":"09fac98362894736b49311b756f3979f","type":"GO_TERM","name":"regulation of mesenchymal stem cell proliferation","canonical_id":"go:GO:1902460","description":"\"Any process that modulates the frequency, rate or extent of mesenchymal stem cell proliferation.\" [GOC:pm, GOC:TermGenie, PMID:18672106]","metadata":null},{"id":"36828cd3dcd7415ea6c2a516f9b5afd3","type":"GO_TERM","name":"regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis","canonical_id":"go:GO:0003339","description":"\"Any process that modulates the rate, frequency or extent of the transition where a mesenchymal cell establishes apical/basolateral polarity,forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell that will contribute to the shaping of the metanephros.\" [GOC:dph]","metadata":null},{"id":"935b43f0b09a430bbd299edb26d74a9f","type":"GO_TERM","name":"regulation of mesoderm development","canonical_id":"go:GO:2000380","description":"\"Any process that modulates the frequency, rate or extent of mesoderm development.\" [GOC:BHF]","metadata":null},{"id":"adcca6f7a2f842129068a4dfb20ff4e9","type":"GO_TERM","name":"regulation of mesoderm formation","canonical_id":"go:GO:1905902","description":"\"Any process that modulates the frequency, rate or extent of mesoderm formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23939491]","metadata":null},{"id":"acedab0b1dbc4dddb230b592766d27fb","type":"GO_TERM","name":"regulation of mesodermal cell differentiation","canonical_id":"go:GO:1905770","description":"\"Any process that modulates the frequency, rate or extent of mesodermal cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23765923]","metadata":null},{"id":"ace8655df51b46b386ce7f8175e22cc5","type":"GO_TERM","name":"regulation of mesodermal cell fate determination","canonical_id":"go:GO:0048334","description":"\"Any process that modulates the frequency, rate or extent of mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"f8098b79710c4ba789b178a9ab2487c3","type":"GO_TERM","name":"regulation of mesodermal cell fate specification","canonical_id":"go:GO:0042661","description":"\"Any process that modulates the frequency, rate or extent of mesoderm cell fate specification.\" [GOC:curators]","metadata":null},{"id":"8e000fc3213440c6afeaf42c788bac1d","type":"GO_TERM","name":"regulation of mesonephric glomerular mesangial cell proliferation","canonical_id":"go:GO:2000090","description":"\"Any process that modulates the frequency, rate or extent of mesonephric glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bd244493721347d9b35fd13efebbc82f","type":"GO_TERM","name":"regulation of mesonephric glomerulus development","canonical_id":"go:GO:2000087","description":"\"Any process that modulates the frequency, rate or extent of mesonephric glomerulus development.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8e3e03c22e6c4000ab17918ba331482c","type":"GO_TERM","name":"regulation of mesonephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:2000093","description":"\"Any process that modulates the frequency, rate or extent of mesonephric nephron tubule epithelial cell differentiation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"121bf89834e14b469bb927f78df70d3d","type":"GO_TERM","name":"regulation of mesonephros development","canonical_id":"go:GO:0061217","description":"\"Any process that modulates the rate, frequency or extent of mesonephros development. Mesonephros development is the process whose specific outcome is the progression of the mesonephros over time, from its formation to the mature structure. The mesonephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"083945dfe8814421b7f525e664f0df54","type":"GO_TERM","name":"regulation of metabolic process","canonical_id":"go:GO:0019222","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.\" [GOC:curators]","metadata":null},{"id":"71542f1f18994c93a7d121cd107156e1","type":"GO_TERM","name":"regulation of metal ion transport","canonical_id":"go:GO:0010959","description":"\"Any process that modulates the frequency, rate, or extent of metal ion transport. Metal ion transport is the directed movement of metal ions, any metal ion with an electric charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"67b1f7f38765498ba5b30a5514179ff5","type":"GO_TERM","name":"regulation of metallopeptidase activity","canonical_id":"go:GO:1905048","description":"\"Any process that modulates the frequency, rate or extent of metallopeptidase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:26473732]","metadata":null},{"id":"8f25b9e06af540dbab179b749a6f1b73","type":"GO_TERM","name":"regulation of metanephric DCT cell differentiation","canonical_id":"go:GO:2000592","description":"\"Any process that modulates the frequency, rate or extent of metanephric DCT cell differentiation.\" [GOC:obol]","metadata":null},{"id":"caa4b5f1fa4f45d7bf1df59e86e028d5","type":"GO_TERM","name":"regulation of metanephric S-shaped body morphogenesis","canonical_id":"go:GO:2000004","description":"\"Any process that modulates the frequency, rate or extent of metanephric S-shaped body morphogenesis.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"bcd606537adc4f6bb91b6935f10ce31b","type":"GO_TERM","name":"regulation of metanephric cap mesenchymal cell proliferation","canonical_id":"go:GO:0090095","description":"\"Any process that modulates the frequency, rate, or extent of metanephric cap mesenchymal cell proliferation. Metanephric cap mesenchymal cell proliferation is the multiplication or reproduction of metanephric cap mesenchymal cells, resulting in the expansion of the cell population. A metanephric cap mesenchymal cell is a mesenchymal cell that has condensed with other mesenchymal cells surrounding the ureteric bud tip.\" [GOC:dph, GOC:tb, GOC:yaf]","metadata":null},{"id":"fa7b1e0e2eea491caafbd660579b5e15","type":"GO_TERM","name":"regulation of metanephric comma-shaped body morphogenesis","canonical_id":"go:GO:2000006","description":"\"Any process that modulates the frequency, rate or extent of metanephric comma-shaped body morphogenesis.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"21db8a67efc446589f76346c8392418a","type":"GO_TERM","name":"regulation of metanephric glomerular mesangial cell proliferation","canonical_id":"go:GO:0072301","description":"\"Any process that modulates the frequency, rate or extent of metanephric glomerular mesangial cell proliferation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1ef61a1ce49743da8acea694c0da35ac","type":"GO_TERM","name":"regulation of metanephric glomerulus development","canonical_id":"go:GO:0072298","description":"\"Any process that modulates the rate, frequency or extent of metanephric glomerulus development, the progression of the metanephric glomerulus over time from its initial formation until its mature state. The metanephric glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney, or metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"7b0732d323df497f90b0bf539dc6882d","type":"GO_TERM","name":"regulation of metanephric mesenchymal cell migration","canonical_id":"go:GO:2000589","description":"\"Any process that modulates the frequency, rate or extent of metanephric mesenchymal cell migration.\" [GOC:obol]","metadata":null},{"id":"910bf31b93be44fab0c6b44bc8689f94","type":"GO_TERM","name":"regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:1900238","description":"\"Any process that modulates the frequency, rate or extent of regulation of metanephric mesenchymal cell migration, by platelet-derived growth factor receptor-beta signaling pathway.\" [GOC:mtg_kidney_jan10, GOC:TermGenie, GOC:yaf, PMID:19019919]","metadata":null},{"id":"0c7902130f624287aadfb200e708fbaf","type":"GO_TERM","name":"regulation of metanephric nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0072307","description":"\"Any process that modulates the frequency, rate or extent of metanephric nephron tubule epithelial cell differentiation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1bf6d6cb44a0483f8abd3e26b439741b","type":"GO_TERM","name":"regulation of metanephric podocyte development","canonical_id":"go:GO:2000477","description":"\"Any process that modulates the frequency, rate or extent of metanephric glomerular visceral epithelial cell development.\" [GOC:obol]","metadata":null},{"id":"a5b9d62f0a50443aa716541fe0328908","type":"GO_TERM","name":"regulation of metanephric ureteric bud development","canonical_id":"go:GO:2001074","description":"\"Any process that modulates the frequency, rate or extent of metanephric ureteric bud development.\" [GOC:obol]","metadata":null},{"id":"d3ed74352ec347e39ca44fa47f51f02d","type":"GO_TERM","name":"regulation of metanephros development","canonical_id":"go:GO:0072215","description":"\"Any process that modulates the rate, frequency or extent of metanephros development. Metanephros development is the process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. The metanephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"808768a44b4b458a9b76f370d2756e4e","type":"GO_TERM","name":"regulation of metanephros size","canonical_id":"go:GO:0035566","description":"\"Any process that modulates the size of a metanephric kidney.\" [GOC:bf]","metadata":null},{"id":"ebccd5d3d71447919ea8297948a5d227","type":"GO_TERM","name":"regulation of metaphase plate congression","canonical_id":"go:GO:0090235","description":"\"Any process that modulates the rate, frequency, or extent of metaphase plate congression, the alignment of chromosomes at the metaphase plate, a plane halfway between the poles of the spindle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"2b4ef39087ac4ab8ab43a6f2d67c6de4","type":"GO_TERM","name":"regulation of metaphase/anaphase transition of cell cycle","canonical_id":"go:GO:1902099","description":"\"Any process that modulates the frequency, rate or extent of metaphase/anaphase transition of cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"97a9ab36414047f89ef01a40f3bbb361","type":"GO_TERM","name":"regulation of metaphase/anaphase transition of meiosis I","canonical_id":"go:GO:1905186","description":"\"Any process that modulates the frequency, rate or extent of metaphase/anaphase transition of meiosis I.\" [GO_REF:0000058, GOC:TermGenie, PMID:21389117]","metadata":null},{"id":"5009514c420a414fa8e2fc7abd39bfaf","type":"GO_TERM","name":"regulation of metaphase/anaphase transition of meiosis II","canonical_id":"go:GO:1905189","description":"\"Any process that modulates the frequency, rate or extent of metaphase/anaphase transition of meiosis II.\" [GO_REF:0000058, GOC:TermGenie, PMID:21389117]","metadata":null},{"id":"9c1e3cfb9c074d36bdb7b34cd7b9394a","type":"GO_TERM","name":"regulation of metaphase/anaphase transition of meiotic cell cycle","canonical_id":"go:GO:1902102","description":"\"Any process that modulates the frequency, rate or extent of metaphase/anaphase transition of meiotic cell cycle.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"7b7db205d4c34c0188d4219bbd812597","type":"GO_TERM","name":"regulation of metaxylem development","canonical_id":"go:GO:0090060","description":"\"Any process that modulates the frequency, rate, or extent of metaxylem development. Metaxylem development is the process whose specific outcome is the progression of the metaxylem over time, from its formation to the mature structure. The metaxylem is the part of the primary xylem that differentiates after the protoxylem and before the secondary xylem, if any of the latter is formed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"35e561d72a2344df88c70918a4717b76","type":"GO_TERM","name":"regulation of methanofuran biosynthetic process","canonical_id":"go:GO:1900351","description":"\"Any process that modulates the frequency, rate or extent of methanofuran biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c0261eac9c254a5a8463be8d7a5d2b2a","type":"GO_TERM","name":"regulation of methanophenazine biosynthetic process","canonical_id":"go:GO:1900962","description":"\"Any process that modulates the frequency, rate or extent of methanophenazine biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4df9aefe1f004a2baec9ad43f82fae4d","type":"GO_TERM","name":"regulation of methyl-branched fatty acid biosynthetic process","canonical_id":"go:GO:1902322","description":"\"Any process that modulates the frequency, rate or extent of methyl-branched fatty acid biosynthetic process.\" [GOC:kmv, GOC:TermGenie, PMID:15340492]","metadata":null},{"id":"a947ee1e5c144f8bab623554fe487a08","type":"GO_TERM","name":"regulation of metula development","canonical_id":"go:GO:0070802","description":"\"Any process that modulates the frequency, rate or extent of metula development, a process that leads to the formation of metulae. Metulae are elongated mononucleate cells that bud from the surface of the conidiophore tip.\" [GOC:mah]","metadata":null},{"id":"3e3fe59a13a840028a8519128cc83686","type":"GO_TERM","name":"regulation of miRNA catabolic process","canonical_id":"go:GO:2000625","description":"\"Any process that modulates the frequency, rate or extent of miRNA catabolic process.\" [GOC:dph]","metadata":null},{"id":"433d2da3dedb46bcbe5a5b7b72451572","type":"GO_TERM","name":"regulation of miRNA metabolic process","canonical_id":"go:GO:2000628","description":"\"Any process that modulates the frequency, rate or extent of miRNA metabolic process.\" [GOC:dph]","metadata":null},{"id":"0bc3cd8ca3ae4e4198e277d4cac2463c","type":"GO_TERM","name":"regulation of miRNA processing","canonical_id":"go:GO:1903798","description":"\"Any process that modulates the frequency, rate or extent of microRNA processing.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:22269326]","metadata":null},{"id":"9df48f803f884063b56e81025dde4e6a","type":"GO_TERM","name":"regulation of miRNA transcription","canonical_id":"go:GO:1902893","description":"\"Any process that modulates the frequency, rate or extent of microRNA (miRNA) gene transcription.\" [GO_REF:0000058, GOC:dph, GOC:kmv, GOC:TermGenie, PMID:24699545]","metadata":null},{"id":"51cec844e77c4aadb61897a88d61d7d4","type":"GO_TERM","name":"regulation of miRNA-mediated gene silencing","canonical_id":"go:GO:0060964","description":"\"A process that modulates the rate, frequency, or extent of the downregulation of gene expression through the action of microRNAs (miRNAs).\" [GOC:aruk, GOC:bc, GOC:dph, GOC:rl, GOC:tb, PMID:23985560, PMID:28379604]","metadata":null},{"id":"19a779db79644ebfa00acf6cb541a62d","type":"GO_TERM","name":"regulation of microglia differentiation","canonical_id":"go:GO:0014006","description":"\"Any process that modulates the frequency, rate or extent of microglia differentiation, the process in which a relatively unspecialized cell acquires specialized features of a microglial cell.\" [GOC:ef]","metadata":null},{"id":"2d6cddbe986245e287c2391fd29dcfa4","type":"GO_TERM","name":"regulation of microglial cell activation","canonical_id":"go:GO:1903978","description":"\"Any process that modulates the frequency, rate or extent of microglial cell activation.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"1194b60a7bff4ecdad07c10f6211f6c9","type":"GO_TERM","name":"regulation of microglial cell mediated cytotoxicity","canonical_id":"go:GO:1904149","description":"\"Any process that modulates the frequency, rate or extent of microglial cell mediated cytotoxicity.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"4ae12d52f3454e538dc20d97ebdfc952","type":"GO_TERM","name":"regulation of microglial cell migration","canonical_id":"go:GO:1904139","description":"\"Any process that modulates the frequency, rate or extent of microglial cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"43d1744523394c85807a6acabf0ae700","type":"GO_TERM","name":"regulation of microlipophagy","canonical_id":"go:GO:0140505","description":"\"Any process that modulates the frequency, rate or extent of microlipophagy, the microautophagy-mediated direct internalization of lipid droplets into a lysosome-like vacuole during nutrient depletion.\" [PMID:28394250, PMID:29601311]","metadata":null},{"id":"f69571fa740548e49b20eb2e61bfb38e","type":"GO_TERM","name":"regulation of microtubule anchoring at centrosome","canonical_id":"go:GO:0150101","description":"\"Any process that modulates the frequency, rate or extent of microtubule anchoring at centrosome.\" [GOC:aruk, GOC:bc, PMID:17139249]","metadata":null},{"id":"d01c4cbb3d3f472d84eec38566a122d9","type":"GO_TERM","name":"regulation of microtubule cytoskeleton organization","canonical_id":"go:GO:0070507","description":"\"Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising microtubules and their associated proteins.\" [GOC:mah]","metadata":null},{"id":"6877ba7a504b419bb37addc5b15f601f","type":"GO_TERM","name":"regulation of microtubule depolymerization","canonical_id":"go:GO:0031114","description":"\"Any process that modulates the frequency, rate or extent of microtubule depolymerization.\" [GOC:mah]","metadata":null},{"id":"353bc38a850c47a0afede02579dc07be","type":"GO_TERM","name":"regulation of microtubule nucleation","canonical_id":"go:GO:0010968","description":"\"Any process that modulates the rate, frequency or extent of microtubule nucleation. Microtubule nucleation is the 'de novo' formation of a microtubule, in which tubulin heterodimers form metastable oligomeric aggregates, some of which go on to support formation of a complete microtubule. Microtubule nucleation usually occurs from a specific site within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"bdce17b6e4f54a2f879d8ca9efc2408a","type":"GO_TERM","name":"regulation of microtubule polymerization","canonical_id":"go:GO:0031113","description":"\"Any process that modulates the frequency, rate or extent of microtubule polymerization.\" [GOC:mah]","metadata":null},{"id":"cf34e135891e43ee93117c256a7132fa","type":"GO_TERM","name":"regulation of microtubule polymerization or depolymerization","canonical_id":"go:GO:0031110","description":"\"Any process that modulates the frequency, rate or extent of microtubule polymerization or depolymerization by the addition or removal of tubulin heterodimers from a microtubule.\" [GOC:mah]","metadata":null},{"id":"303172aff84f4f5c96bf9683f5969870","type":"GO_TERM","name":"regulation of microtubule-based movement","canonical_id":"go:GO:0060632","description":"\"Any process that modulates the rate, frequency, or extent of microtubule-based movement, the movement of organelles, other microtubules and other particles along microtubules, mediated by motor proteins.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7e4db1bf63464097a63985e614706a00","type":"GO_TERM","name":"regulation of microtubule-based process","canonical_id":"go:GO:0032886","description":"\"Any process that modulates the frequency, rate or extent of any cellular process that depends upon or alters the microtubule cytoskeleton.\" [GOC:mah]","metadata":null},{"id":"2206edf6da77435e8a3a5050bcc1af79","type":"GO_TERM","name":"regulation of microvillus assembly","canonical_id":"go:GO:0032534","description":"\"A process that modulates the formation of a microvillus.\" [GOC:mah]","metadata":null},{"id":"6368ef4d2fa74871afa0733811c43d26","type":"GO_TERM","name":"regulation of microvillus length","canonical_id":"go:GO:0032532","description":"\"A process that modulates the length of a microvillus.\" [GOC:mah]","metadata":null},{"id":"d4adbd2b4fb649d39cf284ce91043219","type":"GO_TERM","name":"regulation of microvillus organization","canonical_id":"go:GO:0032530","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a microvillus.\" [GOC:mah]","metadata":null},{"id":"dbc39373d4ef4336badd6f63713ac8d0","type":"GO_TERM","name":"regulation of midbrain dopaminergic neuron differentiation","canonical_id":"go:GO:1904956","description":"\"Any process that modulates the frequency, rate or extent of midbrain dopaminergic neuron differentiation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:21347250]","metadata":null},{"id":"5fc63ced37164fcd855accdaa449ac0a","type":"GO_TERM","name":"regulation of mineralocorticoid secretion","canonical_id":"go:GO:2000855","description":"\"Any process that modulates the frequency, rate or extent of mineralocorticoid secretion.\" [GOC:sl]","metadata":null},{"id":"dd94605ebe6a43e0afccf5f8c0e8f2e8","type":"GO_TERM","name":"regulation of mini excitatory postsynaptic potential","canonical_id":"go:GO:0061884","description":"\"Any process that modulates the frequency, rate or extent of mini excitatory postsynaptic potential. Mini excitatory postsynaptic potential is a process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell, induced by the spontaneous release of a single vesicle of an excitatory neurotransmitter into the synapse.\" [GOC:aruk, GOC:bc, PMID:20395454]","metadata":null},{"id":"6630071eeda9406a8dc457061c4b3c87","type":"GO_TERM","name":"regulation of mismatch repair","canonical_id":"go:GO:0032423","description":"\"Any process that modulates the frequency, rate or extent of mismatch repair.\" [GOC:vk]","metadata":null},{"id":"9714585652114d5597dbf5d3e84c3f4a","type":"GO_TERM","name":"regulation of mitochondrial ATP synthesis coupled electron transport","canonical_id":"go:GO:1905446","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial ATP synthesis coupled electron transport.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:23707074]","metadata":null},{"id":"d7c2c89ea1af48fc8b324cf8f8367724","type":"GO_TERM","name":"regulation of mitochondrial ATP synthesis coupled proton transport","canonical_id":"go:GO:1905706","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial ATP synthesis coupled proton transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:12809520, PMID:15294286]","metadata":null},{"id":"5ff108840c074ccb977cd03a2efc820f","type":"GO_TERM","name":"regulation of mitochondrial DNA metabolic process","canonical_id":"go:GO:1901858","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial DNA metabolic process.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"a331321441f74f6493e79e23faa859dc","type":"GO_TERM","name":"regulation of mitochondrial DNA replication","canonical_id":"go:GO:0090296","description":"\"Any process that modulates the rate, frequency or extent of the process in which new strands of DNA are synthesized in the mitochondrion.\" [GOC:tb]","metadata":null},{"id":"ded09ce4ff614d6b8e7f17f9d2463d70","type":"GO_TERM","name":"regulation of mitochondrial RNA catabolic process","canonical_id":"go:GO:0000960","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving catabolism in the mitochondrion of RNA transcribed from the mitochondrial genome.\" [GOC:krc, GOC:mah]","metadata":null},{"id":"a2e8bb3e8dda4614ada08c2cc80ac2fe","type":"GO_TERM","name":"regulation of mitochondrial depolarization","canonical_id":"go:GO:0051900","description":"\"Any process that modulates the frequency, rate or extent of the change in the membrane potential of the mitochondria from negative to positive.\" [GOC:ai]","metadata":null},{"id":"1f6429b62d0849539b93e7192074d42f","type":"GO_TERM","name":"regulation of mitochondrial electron transport, NADH to ubiquinone","canonical_id":"go:GO:1902956","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:23530063]","metadata":null},{"id":"b9eb49d1b4014a22b97d5d2a128055dd","type":"GO_TERM","name":"regulation of mitochondrial fission","canonical_id":"go:GO:0090140","description":"\"Any process that modulates the rate, frequency or extent of mitochondrial fission. Mitochondrial fission is the division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d55ea0d75ee145a18fc2291f7df8df54","type":"GO_TERM","name":"regulation of mitochondrial fusion","canonical_id":"go:GO:0010635","description":"\"Any process that modulates the frequency, rate or extent of merging of two or more mitochondria within a cell to form a single compartment.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"ea5b76dcee29474280442dbcbd8c9bc7","type":"GO_TERM","name":"regulation of mitochondrial gene expression","canonical_id":"go:GO:0062125","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).\" [PMID:28285835]","metadata":null},{"id":"25d8e383db9343ca942a4da8984c0253","type":"GO_TERM","name":"regulation of mitochondrial mRNA catabolic process","canonical_id":"go:GO:1905637","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial mRNA catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:27122350]","metadata":null},{"id":"18e5a75e0bca4827a186e419e2eeb95d","type":"GO_TERM","name":"regulation of mitochondrial mRNA stability","canonical_id":"go:GO:0044528","description":"\"Any process that modulates the propensity of mitochondrial mRNA molecules to degradation. Includes processes that both stabilize and destabilize mitochondrial mRNAs.\" [GOC:al, GOC:jl]","metadata":null},{"id":"6f15ea6db20f4f0585f39a805c1eb71e","type":"GO_TERM","name":"regulation of mitochondrial membrane permeability","canonical_id":"go:GO:0046902","description":"\"Any process that modulates the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.\" [GOC:bf]","metadata":null},{"id":"f795fa743f604bce99147251a90f0441","type":"GO_TERM","name":"regulation of mitochondrial membrane permeability involved in apoptotic process","canonical_id":"go:GO:1902108","description":"\"Any regulation of mitochondrial membrane permeability that is involved in apoptotic process.\" [GOC:mtg_apoptosis, GOC:pm, GOC:TermGenie, PMID:19168129]","metadata":null},{"id":"c8e24a9362ab413ca8d15e9f86b00ce0","type":"GO_TERM","name":"regulation of mitochondrial membrane permeability involved in programmed necrotic cell death","canonical_id":"go:GO:1902445","description":"\"Any regulation of mitochondrial membrane permeability that is involved in programmed necrotic cell death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:TermGenie, PMID:22493254]","metadata":null},{"id":"d23a895994344461b73e555966c6858c","type":"GO_TERM","name":"regulation of mitochondrial membrane potential","canonical_id":"go:GO:0051881","description":"\"Any process that modulates the establishment or extent of the mitochondrial membrane potential, the electric potential existing across the mitochondrial membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:ai]","metadata":null},{"id":"8cc53ff8c97049678dd0c3773c134a34","type":"GO_TERM","name":"regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway","canonical_id":"go:GO:1901028","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:TermGenie]","metadata":null},{"id":"813611870099417e8f9ff9b4db0d3bc9","type":"GO_TERM","name":"regulation of mitochondrial rRNA stability","canonical_id":"go:GO:0044529","description":"\"Any process that modulates the propensity of mitochondrial rRNA molecules to degradation. Includes processes that both stabilize and destabilize mitochondrial rRNAs.\" [GOC:al, GOC:jl]","metadata":null},{"id":"340440fb4f104d24b7bf632d059d0610","type":"GO_TERM","name":"regulation of mitochondrial transcription","canonical_id":"go:GO:1903108","description":"\"Any process that modulates the frequency, rate or extent of transcription occurring in the mitochondrion.\" [GO_REF:0000058, GOC:TermGenie, PMID:21357609]","metadata":null},{"id":"074e0a47828b461f8556a304bc0792b9","type":"GO_TERM","name":"regulation of mitochondrial translation","canonical_id":"go:GO:0070129","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"fb91882b725d4194a78c3f9bb42d207f","type":"GO_TERM","name":"regulation of mitochondrial translational elongation","canonical_id":"go:GO:1905082","description":"\"Any process that modulates the frequency, rate or extent of mitochondrial translational elongation.\" [GO_REF:0000058, GOC:TermGenie, PMID:25738458]","metadata":null},{"id":"5275fc4227ed4b958b34a31e4d063ef6","type":"GO_TERM","name":"regulation of mitochondrial translational initiation","canonical_id":"go:GO:0070132","description":"\"Any process that modulates the frequency, rate or extent of the process preceding formation of the peptide bond between the first two amino acids of a protein in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"28277557968f472cb789ebde35d52166","type":"GO_TERM","name":"regulation of mitochondrion organization","canonical_id":"go:GO:0010821","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a mitochondrion.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4c4232518f2d4559a117e3837d17a75b","type":"GO_TERM","name":"regulation of mitophagy","canonical_id":"go:GO:1901524","description":"\"Any process that modulates the frequency, rate or extent of macromitophagy.\" [GOC:TermGenie]","metadata":null},{"id":"091c28ae097d4cef8014c8294e3a2be2","type":"GO_TERM","name":"regulation of mitotic DNA damage checkpoint","canonical_id":"go:GO:1904289","description":"\"Any process that modulates the frequency, rate or extent of mitotic DNA damage checkpoint.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:16549501]","metadata":null},{"id":"97c30c92cb144c8bb246a1e79ed68842","type":"GO_TERM","name":"regulation of mitotic DNA replication initiation","canonical_id":"go:GO:1903466","description":"\"Any process that modulates the frequency, rate or extent of DNA replication initiation involved in mitotic DNA replication.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"94461217940842f882f5fa94ed2e3fa3","type":"GO_TERM","name":"regulation of mitotic DNA replication initiation from early origin","canonical_id":"go:GO:0062212","description":"\"Any process that modulates the frequency, rate or extent of firing from an early origin of replication involved in mitotic DNA replication.\" [PMID:22279046]","metadata":null},{"id":"d650bcc4ce18476191e32ac9bc60a7dd","type":"GO_TERM","name":"regulation of mitotic DNA replication initiation from late origin","canonical_id":"go:GO:0101017","description":"\"Any process that modulates the frequency, rate or extent of firing from a late origin of replication involved in mitotic DNA replication.\" [PMID:26436827]","metadata":null},{"id":"ba146ba1b2174c12a2086e7df58ce46a","type":"GO_TERM","name":"regulation of mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:1903499","description":"\"Any process that modulates the frequency, rate or extent of mitotic actomyosin contractile ring assembly.\" [GO_REF:0000058, GOC:al, GOC:mtg_cell_cycle, GOC:TermGenie, GOC:vw, PMID:18256290]","metadata":null},{"id":"ca310f8a10284dea8e3e87ce5be5c11a","type":"GO_TERM","name":"regulation of mitotic actomyosin contractile ring contraction","canonical_id":"go:GO:1903471","description":"\"Any process that modulates the frequency, rate or extent of mitotic actomyosin contractile ring contraction.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"bae0efd986604c35b27b22164078aaaf","type":"GO_TERM","name":"regulation of mitotic cell cycle","canonical_id":"go:GO:0007346","description":"\"Any process that modulates the rate or extent of progress through the mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"bcf819de033f4198bb54b457e0eb30c9","type":"GO_TERM","name":"regulation of mitotic cell cycle DNA replication","canonical_id":"go:GO:1903463","description":"\"Any process that modulates the frequency, rate or extent of mitotic cell cycle DNA replication.\" [GO_REF:0000058, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"99447ec4fcf742e79325b4266fc3d00f","type":"GO_TERM","name":"regulation of mitotic cell cycle phase transition","canonical_id":"go:GO:1901990","description":"\"Any process that modulates the frequency, rate or extent of mitotic cell cycle phase transition.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:22841721]","metadata":null},{"id":"25842bb97fbf4fe786a4f0b299444628","type":"GO_TERM","name":"regulation of mitotic cell cycle spindle assembly checkpoint","canonical_id":"go:GO:0090266","description":"\"Any process that modulates the rate, frequency, or extent of the mitotic cell cycle spindle assembly checkpoint, a cell cycle checkpoint that delays the metaphase/anaphase transition of a mitotic nuclear division until the spindle is correctly assembled and chromosomes are attached to the spindle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d106a3b3ba1e45fab2318f9a380f38d4","type":"GO_TERM","name":"regulation of mitotic cell cycle, embryonic","canonical_id":"go:GO:0009794","description":"\"Any process that modulates the frequency, rate or extent of replication and segregation of genetic material in the embryo.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"fe6cbbaa9b7948ee92e630c4670e1d8c","type":"GO_TERM","name":"regulation of mitotic centrosome separation","canonical_id":"go:GO:0046602","description":"\"Any process that modulates the frequency, rate or extent of the separation of duplicated centrosome components at the beginning of mitosis.\" [GOC:ai]","metadata":null},{"id":"9e068afdb9724701b9b37dd67f77fbb2","type":"GO_TERM","name":"regulation of mitotic chromosome condensation","canonical_id":"go:GO:1903379","description":"\"Any process that modulates the frequency, rate or extent of mitotic chromosome condensation.\" [GO_REF:0000058, GOC:TermGenie, PMID:9490640]","metadata":null},{"id":"432fa420da104ba79233915ee1056861","type":"GO_TERM","name":"regulation of mitotic cytokinesis","canonical_id":"go:GO:1902412","description":"\"Any process that modulates the frequency, rate or extent of mitotic cytokinesis.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"417ce06c3bd9454abed3bcb1cb5e69ba","type":"GO_TERM","name":"regulation of mitotic cytokinesis, division site positioning","canonical_id":"go:GO:1902472","description":"\"Any process that modulates the frequency, rate or extent of mitotic cytokinesis, division site positioning.\" [PMID:9852154]","metadata":null},{"id":"7cda8bcfa0104656a9eb129327a9a393","type":"GO_TERM","name":"regulation of mitotic cytokinetic process","canonical_id":"go:GO:1903436","description":"\"Any process that modulates the frequency, rate or extent of mitotic cytokinetic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"27d4f587959941aeabd3a55bb2d0d624","type":"GO_TERM","name":"regulation of mitotic division septum assembly","canonical_id":"go:GO:0140279","description":"\"Any process that modulates the frequency, rate or extent of mitotic division septum formation. Division septum formation is the assembly and arrangement of a septum that spans the plasma membrane interface between progeny cells following cytokinesis.\" [PMID:22786806]","metadata":null},{"id":"3ed99dc6b1ac401b94bcf2e29b7057ca","type":"GO_TERM","name":"regulation of mitotic metaphase/anaphase transition","canonical_id":"go:GO:0030071","description":"\"Any process that modulates the frequency, rate or extent of the cell cycle process in which a cell progresses from metaphase to anaphase during mitosis, triggered by the activation of the anaphase promoting complex by Cdc20/Sleepy homolog which results in the degradation of Securin.\" [GOC:mah]","metadata":null},{"id":"40874402e0f544c89025c9cfbfb50fc5","type":"GO_TERM","name":"regulation of mitotic nuclear division","canonical_id":"go:GO:0007088","description":"\"Any process that modulates the frequency, rate or extent of mitosis.\" [GOC:curators]","metadata":null},{"id":"ab97ac6b07bc4d6ca5ad574f9d85dfb4","type":"GO_TERM","name":"regulation of mitotic nuclear envelope disassembly","canonical_id":"go:GO:1905557","description":"\"Any process that modulates the frequency, rate or extent of mitotic nuclear envelope disassembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"66360c2b32874d28aa519b2c8c5ed885","type":"GO_TERM","name":"regulation of mitotic recombination","canonical_id":"go:GO:0000019","description":"\"Any process that modulates the frequency, rate or extent of DNA recombination during mitosis.\" [GOC:curators]","metadata":null},{"id":"15681c06a42d4f2e81b0b72076cf5dad","type":"GO_TERM","name":"regulation of mitotic recombination-dependent replication fork processing","canonical_id":"go:GO:1903221","description":"\"Any process that modulates the frequency, rate or extent of mitotic recombination-dependent replication fork processing. Regulation of mitotic recombination prevents recombination between inappropriate homologous sequences.\" [GO_REF:0000058, GOC:TermGenie, PMID:23093942]","metadata":null},{"id":"441436fdf56a4eb69ed5b063f0d2eb9a","type":"GO_TERM","name":"regulation of mitotic sister chromatid arm separation","canonical_id":"go:GO:1905822","description":"\"Any process that modulates the frequency, rate or extent of mitotic sister chromatid arm separation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18765790]","metadata":null},{"id":"c96636042c7247faa51eb669f8a8f702","type":"GO_TERM","name":"regulation of mitotic sister chromatid segregation","canonical_id":"go:GO:0033047","description":"\"Any process that modulates the frequency, rate or extent of sister chromatid segregation during mitosis.\" [GOC:mah]","metadata":null},{"id":"53710ab6108d42f28b179bc5a3d0a59a","type":"GO_TERM","name":"regulation of mitotic sister chromatid separation","canonical_id":"go:GO:0010965","description":"\"Any process that modulates the frequency, rate or extent of mitotic sister chromatid separation. Mitotic sister chromatid separation is the process in which sister chromatids are physically detached from each other during mitosis.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"624498bfc1f147acb8c5add9bf7fd7a4","type":"GO_TERM","name":"regulation of mitotic spindle assembly","canonical_id":"go:GO:1901673","description":"\"Any process that modulates the frequency, rate or extent of mitotic spindle assembly.\" [GOC:TermGenie]","metadata":null},{"id":"a75d5673dd664d4b9fb4ec34c60e62ba","type":"GO_TERM","name":"regulation of mitotic spindle checkpoint","canonical_id":"go:GO:1903504","description":"\"Any process that modulates the frequency, rate or extent of mitotic spindle checkpoint.\" [GO_REF:0000058, GOC:TermGenie, PMID:23442800]","metadata":null},{"id":"906365377ab34cb6ae3fc9e3f87bc682","type":"GO_TERM","name":"regulation of mitotic spindle disassembly","canonical_id":"go:GO:1904686","description":"\"Any process that modulates the frequency, rate or extent of mitotic spindle disassembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:25963819]","metadata":null},{"id":"77ff9c2d4ef24f94b0e3bb671f8c2244","type":"GO_TERM","name":"regulation of mitotic spindle elongation","canonical_id":"go:GO:0032888","description":"\"Any process that modulates the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle.\" [GOC:mah]","metadata":null},{"id":"54171e385c244b27a7d98cbc942e0e85","type":"GO_TERM","name":"regulation of mitotic spindle elongation (spindle phase three)","canonical_id":"go:GO:0110162","description":"\"Any process that modulates the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic anaphase B (spindle phase three).\" [GOC:vw, PMID:27697865]","metadata":null},{"id":"685d999f6f0f4909b97bf6023657059c","type":"GO_TERM","name":"regulation of mitotic spindle formation (spindle phase one)","canonical_id":"go:GO:0110159","description":"\"Any process that modulates the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the mitotic spindle during mitotic prophase (spindle phase one).\" [GOC:vw, PMID:27697865]","metadata":null},{"id":"23c65f39710f4432956d030199f01375","type":"GO_TERM","name":"regulation of mitotic spindle organization","canonical_id":"go:GO:0060236","description":"\"Any process that modulates the rate, frequency or extent of the assembly, arrangement of constituent parts, or disassembly of the microtubule spindle during a mitotic cell cycle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1bcbf989e7f6411bbc4d2a37304b9e8f","type":"GO_TERM","name":"regulation of mitotic spindle pole body separation","canonical_id":"go:GO:0010695","description":"\"Any process that modulates the rate, frequency or extent of the process involving the release of duplicated mitotic spindle pole bodies (SPBs) and their migration away from each other within the nuclear membrane.\" [GOC:dph, GOC:tb, PMID:16792804, PMID:18500339]","metadata":null},{"id":"7a60585946214fc3a21a02d63e914212","type":"GO_TERM","name":"regulation of mitotic telomere tethering at nuclear periphery","canonical_id":"go:GO:1904536","description":"\"Any process that modulates the frequency, rate or extent of mitotic telomere tethering at nuclear periphery.\" [GO_REF:0000058, GOC:TermGenie, PMID:22959349]","metadata":null},{"id":"b098ee93788f4864b04513b28b886e6f","type":"GO_TERM","name":"regulation of modification of postsynaptic actin cytoskeleton","canonical_id":"go:GO:1905274","description":"\"Any process that modulates the frequency, rate or extent of modification of postsynaptic actin cytoskeleton.\" [GO_REF:0000058, GOC:TermGenie, PMID:21068295]","metadata":null},{"id":"92cd7c1c913a4c6ca3f7f7bb3e9ab121","type":"GO_TERM","name":"regulation of modification of postsynaptic structure","canonical_id":"go:GO:0099159","description":"\"Any process that modulates the frequency, rate or extent of modification of postsynaptic structure.\" [GOC:dos]","metadata":null},{"id":"7bd51bf5e1b741bfb916b0d887fad0ca","type":"GO_TERM","name":"regulation of modification of synapse structure, modulating synaptic transmission","canonical_id":"go:GO:0098987","description":"\"Any process that regulates the modification of synaptic structure and as a result regulates synaptic transmission.\" [GOC:dos]","metadata":null},{"id":"6e856638ea274ec7a0d77a1b06a3e6f7","type":"GO_TERM","name":"regulation of modification of synaptic structure","canonical_id":"go:GO:1905244","description":"\"Any process that modulates the frequency, rate or extent of modification of synaptic structure.\" [GO_REF:0000058, GOC:TermGenie, PMID:25164660]","metadata":null},{"id":"0b33036fe563411d8b6e313a3b8049d5","type":"GO_TERM","name":"regulation of molecular function","canonical_id":"go:GO:0065009","description":"\"Any process that modulates the frequency, rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding.\" [GOC:isa_complete]","metadata":null},{"id":"5bd1d4d74cd045949fddbb7c4c5f0593","type":"GO_TERM","name":"regulation of monoatomic anion transmembrane transport","canonical_id":"go:GO:1903959","description":"\"Any process that modulates the frequency, rate or extent of anion transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"85941c488916441088bd3a75f1dca2c3","type":"GO_TERM","name":"regulation of monoatomic anion transport","canonical_id":"go:GO:0044070","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of anions, atoms or small molecules with a net negative charge into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"aadc5a2fd0bc46c1a4aa57b590df364a","type":"GO_TERM","name":"regulation of monoatomic cation transmembrane transport","canonical_id":"go:GO:1904062","description":"\"Any process that modulates the frequency, rate or extent of cation transmembrane transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:15304482]","metadata":null},{"id":"51b67f5210aa4eec817bb782040fdfcd","type":"GO_TERM","name":"regulation of monoatomic ion transmembrane transport","canonical_id":"go:GO:0034765","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of ions from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"171019758ed84b1bbf62edc849bb5c37","type":"GO_TERM","name":"regulation of monoatomic ion transport","canonical_id":"go:GO:0043269","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"9ba1ad3afe084e74874b56563a1a5a0a","type":"GO_TERM","name":"regulation of monocyte aggregation","canonical_id":"go:GO:1900623","description":"\"Any process that modulates the frequency, rate or extent of monocyte aggregation.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"f71d472bd6a24d309ccd702e5b0d49bc","type":"GO_TERM","name":"regulation of monocyte antigen processing and presentation","canonical_id":"go:GO:0002613","description":"\"Any process that modulates the frequency, rate, or extent of monocyte antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"50577812dacc49aaa885e44f279a983b","type":"GO_TERM","name":"regulation of monocyte chemotactic protein-1 production","canonical_id":"go:GO:0071637","description":"\"Any process that modulates the frequency, rate, or extent of production of monocyte chemotactic protein-1.\" [GOC:mah]","metadata":null},{"id":"c4f61a3a9dfd49c09ae3756c27766103","type":"GO_TERM","name":"regulation of monocyte chemotaxis","canonical_id":"go:GO:0090025","description":"\"Any process that modulates the frequency, rate, or extent of monocyte chemotaxis.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"60c30fdb031c43dbbd60e82cc86f8372","type":"GO_TERM","name":"regulation of monocyte differentiation","canonical_id":"go:GO:0045655","description":"\"Any process that modulates the frequency, rate or extent of monocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"47dd27ddaf6b4a62b74e2c7c571e07b3","type":"GO_TERM","name":"regulation of monocyte extravasation","canonical_id":"go:GO:2000437","description":"\"Any process that modulates the frequency, rate or extent of monocyte extravasation.\" [GOC:obol]","metadata":null},{"id":"e5f791c26cae417a830aa1e6bb06bb06","type":"GO_TERM","name":"regulation of monodictyphenone biosynthetic process","canonical_id":"go:GO:1900843","description":"\"Any process that modulates the frequency, rate or extent of monodictyphenone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"281c765bf7f4426db755d09eba989e8e","type":"GO_TERM","name":"regulation of mononuclear cell migration","canonical_id":"go:GO:0071675","description":"\"Any process that modulates the rate, frequency or extent of mononuclear cell migration. Mononuclear cell migration is the movement of a mononuclear cell within or between different tissues and organs of the body.\" [GOC:mah]","metadata":null},{"id":"e2197b39b68b4ca5bada25df3a7dfcd6","type":"GO_TERM","name":"regulation of mononuclear cell proliferation","canonical_id":"go:GO:0032944","description":"\"Any process that modulates the frequency, rate or extent of mononuclear cell proliferation.\" [GOC:add]","metadata":null},{"id":"e0076493c6be437c97a6afc322745dfa","type":"GO_TERM","name":"regulation of monopolar cell growth","canonical_id":"go:GO:0051513","description":"\"Any process that modulates the frequency, rate or extent of monopolar cell growth, polarized growth from one end of a cell.\" [GOC:ai]","metadata":null},{"id":"59bfee67a61a4a42869353fb128e5b29","type":"GO_TERM","name":"regulation of morphogenesis of a branching structure","canonical_id":"go:GO:0060688","description":"\"Any process that modulates the rate, frequency, or extent of branching morphogenesis, the process in which the anatomical structures of branches are generated and organized.\" [GOC:dph]","metadata":null},{"id":"2b088acb643e4e71a8c11efb17d46b3a","type":"GO_TERM","name":"regulation of morphogenesis of an epithelium","canonical_id":"go:GO:1905330","description":"\"Any process that modulates the frequency, rate or extent of morphogenesis of an epithelium.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:25745997]","metadata":null},{"id":"9f7cbb423b6046cc9b461b7942670b5e","type":"GO_TERM","name":"regulation of motile cilium assembly","canonical_id":"go:GO:1905503","description":"\"Any process that modulates the frequency, rate or extent of motile cilium assembly.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:25294941]","metadata":null},{"id":"561a25386efe42f4b604ad684d4ed846","type":"GO_TERM","name":"regulation of motor neuron apoptotic process","canonical_id":"go:GO:2000671","description":"\"Any process that modulates the frequency, rate or extent of motor neuron apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"b03aa67575534f229c135192a8f2b042","type":"GO_TERM","name":"regulation of motor neuron axon guidance","canonical_id":"go:GO:1905812","description":"\"Any process that modulates the frequency, rate or extent of motor neuron axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:18434533]","metadata":null},{"id":"ed0b59fcc5494cdab947f2f690957bf9","type":"GO_TERM","name":"regulation of motor neuron migration","canonical_id":"go:GO:1905483","description":"\"Any process that modulates the frequency, rate or extent of motor neuron migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"d2013ee39356483b8a8f33fbdb0c0bef","type":"GO_TERM","name":"regulation of mucus secretion","canonical_id":"go:GO:0070255","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of mucus from a cell or a tissue.\" [GOC:add]","metadata":null},{"id":"b3fd2e868f414d249f0005f7b2443b6d","type":"GO_TERM","name":"regulation of multicellular organism growth","canonical_id":"go:GO:0040014","description":"\"Any process that modulates the frequency, rate or extent of growth of the body of an organism so that it reaches its usual body size.\" [GOC:dph, GOC:ems, GOC:tb]","metadata":null},{"id":"815688006e38487f97db64ee0013bcfc","type":"GO_TERM","name":"regulation of multicellular organismal development","canonical_id":"go:GO:2000026","description":"\"Any process that modulates the frequency, rate or extent of multicellular organismal development.\" [GOC:obol]","metadata":null},{"id":"0ae4b49eb2de4682a4588cfbcf7c8002","type":"GO_TERM","name":"regulation of multicellular organismal process","canonical_id":"go:GO:0051239","description":"\"Any process that modulates the frequency, rate or extent of a multicellular organismal process, the processes pertinent to the function of a multicellular organism above the cellular level; includes the integrated processes of tissues and organs.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"62eb6f259ffe427f834da3c0cbcf709a","type":"GO_TERM","name":"regulation of muscle adaptation","canonical_id":"go:GO:0043502","description":"\"Any process that modulates the frequency, rate or extent of muscle adaptation.\" [GOC:curators, GOC:mtg_muscle]","metadata":null},{"id":"ee9a140300b94dc796317a5dcd733696","type":"GO_TERM","name":"regulation of muscle atrophy","canonical_id":"go:GO:0014735","description":"\"Any process that modulates the frequency, rate or extent of muscle atrophy.\" [GOC:mtg_muscle]","metadata":null},{"id":"dfc2ce06f6f944019fb784be75eabcd9","type":"GO_TERM","name":"regulation of muscle cell apoptotic process","canonical_id":"go:GO:0010660","description":"\"Any process that modulates the rate or frequency of muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"3f5af24f91044995808aed7a7d9637a3","type":"GO_TERM","name":"regulation of muscle cell chemotaxis toward tendon cell","canonical_id":"go:GO:2001281","description":"\"Any process that modulates the frequency, rate or extent of muscle cell chemotaxis toward tendon cell.\" [GOC:sart]","metadata":null},{"id":"01aadc5589d2485ba389729731f39773","type":"GO_TERM","name":"regulation of muscle cell differentiation","canonical_id":"go:GO:0051147","description":"\"Any process that modulates the frequency, rate or extent of muscle cell differentiation.\" [CL:0000187, GOC:ai]","metadata":null},{"id":"01d006c8182142c6827e5d015ee3cf49","type":"GO_TERM","name":"regulation of muscle contraction","canonical_id":"go:GO:0006937","description":"\"Any process that modulates the frequency, rate or extent of muscle contraction.\" [GOC:curators]","metadata":null},{"id":"becaa5ebefce45c2a597f2b3925f6e26","type":"GO_TERM","name":"regulation of muscle filament sliding","canonical_id":"go:GO:0032971","description":"\"Any process that modulates the frequency, rate or extent of muscle filament sliding.\" [GOC:ecd]","metadata":null},{"id":"7fe7b81526c4484f8744457f74363e8c","type":"GO_TERM","name":"regulation of muscle filament sliding speed","canonical_id":"go:GO:0032972","description":"\"Any process that modulates the velocity of muscle filament sliding.\" [GOC:dph, GOC:ecd, GOC:tb]","metadata":null},{"id":"5209dcd1a39b43e1ad2d6e6de5fbb51d","type":"GO_TERM","name":"regulation of muscle hyperplasia","canonical_id":"go:GO:0014738","description":"\"Any process that modulates the frequency, rate or extent of muscle hyperplasia.\" [GOC:mtg_muscle]","metadata":null},{"id":"eff48d8b695a4315933b19f7b466bc75","type":"GO_TERM","name":"regulation of muscle hypertrophy","canonical_id":"go:GO:0014743","description":"\"Any process that modulates the frequency, rate or extent of muscle hypertrophy.\" [GOC:mtg_muscle]","metadata":null},{"id":"c098a0c054d745d7bfc760978c307841","type":"GO_TERM","name":"regulation of muscle organ development","canonical_id":"go:GO:0048634","description":"\"Any process that modulates the frequency, rate or extent of muscle development.\" [GOC:curators]","metadata":null},{"id":"30f37e565705468eb77422808aa8d8f4","type":"GO_TERM","name":"regulation of muscle system process","canonical_id":"go:GO:0090257","description":"\"Any process that modulates the frequency, rate or extent of a muscle system process, a multicellular organismal process carried out by any of the organs or tissues in a muscle system.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6662e66509cd47a6a8ad20b5affb79e4","type":"GO_TERM","name":"regulation of muscle tissue development","canonical_id":"go:GO:1901861","description":"\"Any process that modulates the frequency, rate or extent of muscle tissue development.\" [GOC:TermGenie, GOC:yaf, PMID:23150719]","metadata":null},{"id":"0e51ca539b864b849bd4903729dc114d","type":"GO_TERM","name":"regulation of myelination","canonical_id":"go:GO:0031641","description":"\"Any process that modulates the frequency, rate or extent of the formation of a myelin sheath around nerve axons.\" [GOC:mah]","metadata":null},{"id":"f40329f781144e019cf3020e9854d70c","type":"GO_TERM","name":"regulation of myeloid cell apoptotic process","canonical_id":"go:GO:0033032","description":"\"Any process that modulates the frequency, rate, or extent of myeloid cell apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"720cefee9430432d9f952858414aee5c","type":"GO_TERM","name":"regulation of myeloid cell differentiation","canonical_id":"go:GO:0045637","description":"\"Any process that modulates the frequency, rate or extent of myeloid cell differentiation.\" [GOC:curators]","metadata":null},{"id":"c8a5af626fe04ad899c10ca72091a610","type":"GO_TERM","name":"regulation of myeloid dendritic cell activation","canonical_id":"go:GO:0030885","description":"\"Any process that modulates the frequency or rate of myeloid dendritic cell activation.\" [GOC:mah]","metadata":null},{"id":"49d0cc51be2843b3acec93add9f4f336","type":"GO_TERM","name":"regulation of myeloid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002607","description":"\"Any process that modulates the frequency, rate, or extent of myeloid dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"7d78c5a05f0440398f688197896d1d7a","type":"GO_TERM","name":"regulation of myeloid dendritic cell chemotaxis","canonical_id":"go:GO:2000527","description":"\"Any process that modulates the frequency, rate or extent of myeloid dendritic cell chemotaxis.\" [GOC:obol]","metadata":null},{"id":"6c447eb19d234b299c68c88bc325205f","type":"GO_TERM","name":"regulation of myeloid dendritic cell cytokine production","canonical_id":"go:GO:0002733","description":"\"Any process that modulates the frequency, rate, or extent of myeloid dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"70a29abbcec345299b22cd0d701a37fe","type":"GO_TERM","name":"regulation of myeloid leukocyte differentiation","canonical_id":"go:GO:0002761","description":"\"Any process that modulates the frequency, rate, or extent of myeloid leukocyte differentiation.\" [GOC:add]","metadata":null},{"id":"c1fc8c47bcbe4506abac2cea758d4af6","type":"GO_TERM","name":"regulation of myeloid leukocyte mediated immunity","canonical_id":"go:GO:0002886","description":"\"Any process that modulates the frequency, rate, or extent of myeloid leukocyte mediated immunity.\" [GOC:add]","metadata":null},{"id":"662c20222764408ab52d7a5826d331f3","type":"GO_TERM","name":"regulation of myeloid progenitor cell differentiation","canonical_id":"go:GO:1905453","description":"\"Any process that modulates the frequency, rate or extent of myeloid progenitor cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:27010503]","metadata":null},{"id":"0ece8cbfcff94073a6b26ca431bf2f03","type":"GO_TERM","name":"regulation of myoblast differentiation","canonical_id":"go:GO:0045661","description":"\"Any process that modulates the frequency, rate or extent of myoblast differentiation. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.\" [CL:0000056, GOC:curators, GOC:mtg_muscle]","metadata":null},{"id":"eb476111c4ff43869a60122bc701c87d","type":"GO_TERM","name":"regulation of myoblast fusion","canonical_id":"go:GO:1901739","description":"\"Any process that modulates the frequency, rate or extent of myoblast fusion.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21364645]","metadata":null},{"id":"070b0a2806cd4dea9e486241541e272c","type":"GO_TERM","name":"regulation of myoblast proliferation","canonical_id":"go:GO:2000291","description":"\"Any process that modulates the frequency, rate or extent of myoblast proliferation.\" [GOC:mah]","metadata":null},{"id":"56d73ba81da24bdf90d9f1e9962420b2","type":"GO_TERM","name":"regulation of myofibril number","canonical_id":"go:GO:0014882","description":"\"Any process that modulates the number of myofibrils. A myofibril is the contractile element of skeletal and cardiac muscle. It is a long, highly organized bundle of actin, myosin, and other proteins that contracts by a sliding filament mechanism.\" [GOC:dph, GOC:ef, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"17029f75201b4d8f9ef51354371e77ba","type":"GO_TERM","name":"regulation of myofibril size","canonical_id":"go:GO:0014881","description":"\"Any process that modulates the size of myofibrils. A myofibril is the contractile element of skeletal and cardiac muscle. It is a long, highly organized bundle of actin, myosin, and other proteins that contracts by a sliding filament mechanism.\" [GOC:dph, GOC:ef, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"f844b0228a88473fb63bc53bab53c9fe","type":"GO_TERM","name":"regulation of myofibroblast cell apoptotic process","canonical_id":"go:GO:1904520","description":"\"Any process that modulates the frequency, rate or extent of myofibroblast cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:26119034]","metadata":null},{"id":"4edc42670bd14e95b35ddb24345c3684","type":"GO_TERM","name":"regulation of myofibroblast contraction","canonical_id":"go:GO:1904328","description":"\"Any process that modulates the frequency, rate or extent of myofibroblast contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:19239477]","metadata":null},{"id":"a3848e2fd0e84a84b4a34b3846b0af7a","type":"GO_TERM","name":"regulation of myofibroblast differentiation","canonical_id":"go:GO:1904760","description":"\"Any process that modulates the frequency, rate or extent of myofibroblast differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20533548]","metadata":null},{"id":"d72f9f0e27b045528254bfd4e7a4b34b","type":"GO_TERM","name":"regulation of myosin II filament assembly","canonical_id":"go:GO:0043520","description":"\"Any process that modulates the frequency, rate or extent of the formation of a bipolar filament composed of myosin II molecules.\" [GOC:jl]","metadata":null},{"id":"f83797eab9834741b121a478a7cd1a34","type":"GO_TERM","name":"regulation of myosin II filament disassembly","canonical_id":"go:GO:0043521","description":"\"Any process that modulates the frequency, rate or extent of the disassembly of a bipolar filament composed of myosin II molecules.\" [GOC:jl]","metadata":null},{"id":"db25cbe3888b46a789c316b99d6ef751","type":"GO_TERM","name":"regulation of myosin II filament organization","canonical_id":"go:GO:0043519","description":"\"Any process that modulates the frequency, rate or extent of the assembly, arrangement of constituent parts, or disassembly of a bipolar filament composed of myosin II molecules.\" [GOC:jl]","metadata":null},{"id":"faf126f9c4b64de4abbcccaf9dc72c08","type":"GO_TERM","name":"regulation of myotome development","canonical_id":"go:GO:2000290","description":"\"Any process that modulates the frequency, rate or extent of myotome development.\" [GOC:mah]","metadata":null},{"id":"4beecbcd9ed642cbbe44bfbb6e364e08","type":"GO_TERM","name":"regulation of myotube cell migration","canonical_id":"go:GO:0110123","description":"\"Any process that modulates the frequency, rate or extent of myotube cell migration.\" [GOC:ha, PMID:29122742]","metadata":null},{"id":"8606316843cc43cea57086f48920028b","type":"GO_TERM","name":"regulation of myotube differentiation","canonical_id":"go:GO:0010830","description":"\"Any process that modulates the frequency, rate or extent of myotube differentiation. Myotube differentiation is the process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f6af99850d064171995dd5214d7ba277","type":"GO_TERM","name":"regulation of naphtho-gamma-pyrone biosynthetic process","canonical_id":"go:GO:1900846","description":"\"Any process that modulates the frequency, rate or extent of naphtho-gamma-pyrone biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5f1e00a8e6764b34ab0ac165cbddec0e","type":"GO_TERM","name":"regulation of natural killer cell activation","canonical_id":"go:GO:0032814","description":"\"Any process that modulates the frequency, rate or extent of natural killer cell activation.\" [GOC:mah]","metadata":null},{"id":"cefeeebc53704d2381ba3e15a4cf0451","type":"GO_TERM","name":"regulation of natural killer cell apoptotic process","canonical_id":"go:GO:0070247","description":"\"Any process that modulates the occurrence or rate of natural killer cell death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"bee64622cb1e4083a6da6ff6af58a6d4","type":"GO_TERM","name":"regulation of natural killer cell chemotaxis","canonical_id":"go:GO:2000501","description":"\"Any process that modulates the frequency, rate or extent of natural killer cell chemotaxis.\" [GOC:BHF]","metadata":null},{"id":"e0f410b2413c4a3383c5fec8fcfea18d","type":"GO_TERM","name":"regulation of natural killer cell cytokine production","canonical_id":"go:GO:0002727","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell cytokine production.\" [GOC:add]","metadata":null},{"id":"97d01b528d4a4921b00eac12354e49c8","type":"GO_TERM","name":"regulation of natural killer cell degranulation","canonical_id":"go:GO:0043321","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"f50f6c066a1b40f4bfffd3f0c5fd3275","type":"GO_TERM","name":"regulation of natural killer cell differentiation","canonical_id":"go:GO:0032823","description":"\"Any process that modulates the frequency, rate or extent of natural killer cell differentiation.\" [GOC:mah]","metadata":null},{"id":"230f06098e45478091757c0ab7d262a2","type":"GO_TERM","name":"regulation of natural killer cell mediated cytotoxicity","canonical_id":"go:GO:0042269","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"715fa87cd2b34295b41fb5159818ca6d","type":"GO_TERM","name":"regulation of natural killer cell mediated cytotoxicity directed against tumor cell target","canonical_id":"go:GO:0002858","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell mediated cytotoxicity directed against tumor cell target.\" [GOC:add]","metadata":null},{"id":"97e054acb77744628a83f24fe52b54f9","type":"GO_TERM","name":"regulation of natural killer cell mediated immune response to tumor cell","canonical_id":"go:GO:0002855","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell mediated immune response to a tumor cell.\" [GOC:add]","metadata":null},{"id":"971087b5b63643dfa285f02f2624ee29","type":"GO_TERM","name":"regulation of natural killer cell mediated immunity","canonical_id":"go:GO:0002715","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell mediated immunity.\" [GOC:add]","metadata":null},{"id":"9f8627004c2c4c39b1b6c150cd204c96","type":"GO_TERM","name":"regulation of natural killer cell proliferation","canonical_id":"go:GO:0032817","description":"\"Any process that modulates the frequency, rate or extent of natural killer cell proliferation.\" [GOC:mah]","metadata":null},{"id":"2fa9ed7cf7124bd49110aab35aea750c","type":"GO_TERM","name":"regulation of natural killer cell tolerance induction","canonical_id":"go:GO:0002871","description":"\"Any process that modulates the frequency, rate, or extent of natural killer cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"7c7ebfe1134f4aae9e250cd9e0938acf","type":"GO_TERM","name":"regulation of necroptotic process","canonical_id":"go:GO:0060544","description":"\"Any process that modulates the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors.\" [GOC:BHF, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"0902c9f0b8ec4101b5ecdd5abbb3ec1b","type":"GO_TERM","name":"regulation of negative chemotaxis","canonical_id":"go:GO:0050923","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"87a3db77c0f54df5804c46ddcefa0b22","type":"GO_TERM","name":"regulation of nematode larval development","canonical_id":"go:GO:0061062","description":"\"Any process that modulates the rate, frequency, or extent of nematode larval development, the process whose specific outcome is the progression of the nematode larva over time, from its formation to the mature structure. Nematode larval development begins with the newly hatched first-stage larva (L1) and ends with the end of the last larval stage (for example the fourth larval stage (L4) in C. elegans). Each stage of nematode larval development is characterized by proliferation of specific cell lineages and an increase in body size without alteration of the basic body plan. Nematode larval stages are separated by molts in which each stage-specific exoskeleton, or cuticle, is shed and replaced anew.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"0cb9e24e9fb64d3b8df71666c508dd23","type":"GO_TERM","name":"regulation of nematode larval development, heterochronic","canonical_id":"go:GO:0090444","description":"\"Any process that modulates the consistent predetermined time point at which a nematode larva progresses from an initial condition to a later condition and the rate at which this time point is reached.\" [PMID:17550772]","metadata":null},{"id":"1a6843751f97487db1a55fdebd2f680f","type":"GO_TERM","name":"regulation of nematode male tail tip morphogenesis","canonical_id":"go:GO:0110037","description":"\"Any process that modulates the frequency, rate or extent of nematode male tail tip morphogenesis, the process in which the anatomical structure of the adult male tail tip is generated and organized.\" [GOC:rz, PMID:28068334]","metadata":null},{"id":"feae093b14944b57a40a0166d98cdc3e","type":"GO_TERM","name":"regulation of nematode pharyngeal pumping","canonical_id":"go:GO:0043051","description":"\"Any process that modulates the contraction and relaxation movements of the pharyngeal muscle that mediates feeding in nematodes.\" [GOC:cab1, PMID:2181052]","metadata":null},{"id":"8368d9237f1e4499a45b78bcb69a8899","type":"GO_TERM","name":"regulation of nematode pharynx morphogenesis","canonical_id":"go:GO:0110041","description":"\"Any process that modulates the frequency, rate or extent of nematode pharynx morphogenesis, the process in which the anatomical structure of the pharynx is generated and organized.\" [GOC:rz, PMID:20805556]","metadata":null},{"id":"047aca11e0ce423a8714b6d9ed5d553a","type":"GO_TERM","name":"regulation of neosartoricin biosynthetic process","canonical_id":"go:GO:1902053","description":"\"Any process that modulates the frequency, rate or extent of neosartoricin biosynthetic process.\" [GOC:di, GOC:TermGenie, PMID:23368997]","metadata":null},{"id":"8cd15080fbc74e2da109e3b64dd24d68","type":"GO_TERM","name":"regulation of nephron tubule epithelial cell differentiation","canonical_id":"go:GO:0072182","description":"\"Any process that modulates the frequency, rate or extent of nephron tubule epithelial cell differentiation.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"876aa99b2613462cbbbe30b349bcbeb9","type":"GO_TERM","name":"regulation of nerve growth factor production","canonical_id":"go:GO:0032903","description":"\"Any process that modulates the frequency, rate, or extent of production of nerve growth factor (NGF).\" [GOC:mah]","metadata":null},{"id":"ab5e4f19a3684fc08b6889c0b4cb7f73","type":"GO_TERM","name":"regulation of nerve growth factor receptor activity","canonical_id":"go:GO:0051394","description":"\"Any process that modulates the frequency, rate or extent of the activity of the nerve growth factor (NGF) receptor.\" [GOC:ai]","metadata":null},{"id":"30e72a24e77b438c858f73fdd18f46fb","type":"GO_TERM","name":"regulation of nervous system development","canonical_id":"go:GO:0051960","description":"\"Any process that modulates the frequency, rate or extent of nervous system development, the origin and formation of nervous tissue.\" [GOC:ai]","metadata":null},{"id":"79cfc604d69244afb63df2f4605ffa1c","type":"GO_TERM","name":"regulation of nervous system process","canonical_id":"go:GO:0031644","description":"\"Any process that modulates the frequency, rate or extent of a neurophysiological process, an organ system process carried out by any of the organs or tissues of the nervous system.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"33efc9c3c69e4422925e54f7d20657b5","type":"GO_TERM","name":"regulation of netrin-activated signaling pathway","canonical_id":"go:GO:1902841","description":"\"Any process that modulates the frequency, rate or extent of netrin-activated signaling pathway.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:24004945]","metadata":null},{"id":"2420324b893f4fc5acff70e7a44dc18f","type":"GO_TERM","name":"regulation of neural crest cell differentiation","canonical_id":"go:GO:1905292","description":"\"Any process that modulates the frequency, rate or extent of neural crest cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15073157]","metadata":null},{"id":"62d71c4f219447e2aff09ca13cdf270f","type":"GO_TERM","name":"regulation of neural crest cell fate specification","canonical_id":"go:GO:1905295","description":"\"Any process that modulates the frequency, rate or extent of neural crest cell fate specification.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15073157]","metadata":null},{"id":"55139ab9b46f4356b613aa504c053e24","type":"GO_TERM","name":"regulation of neural crest formation","canonical_id":"go:GO:0090299","description":"\"Any process that modulates the rate, frequency, or extent of neural crest formation. Neural crest formation is the formation of the specialized region of ectoderm between the neural ectoderm (neural plate) and non-neural ectoderm. The neural crest gives rise to the neural crest cells that migrate away from this region as neural tube formation proceeds.\" [GOC:tb]","metadata":null},{"id":"8e129bab1ae84c0da170558c41e06e04","type":"GO_TERM","name":"regulation of neural precursor cell proliferation","canonical_id":"go:GO:2000177","description":"\"Any process that modulates the frequency, rate or extent of neural precursor cell proliferation.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"a1bcf685be6243c7b00027301ddf9b69","type":"GO_TERM","name":"regulation of neural retina development","canonical_id":"go:GO:0061074","description":"\"Any process that modulates the rate, frequency, or extent of neural retina development, the progression of the neural retina over time from its initial formation to the mature structure. The neural retina is the part of the retina that contains neurons and photoreceptor cells.\" [GOC:dph]","metadata":null},{"id":"da6b3d201a844b03b08094532a4cf72e","type":"GO_TERM","name":"regulation of neuroblast migration","canonical_id":"go:GO:0061853","description":"\"Any process that modulates the frequency, rate or extent of neuroblast migration.\" [PMID:23149556]","metadata":null},{"id":"4571b45558a54bc1ae23d2c69f0af669","type":"GO_TERM","name":"regulation of neuroblast proliferation","canonical_id":"go:GO:1902692","description":"\"Any process that modulates the frequency, rate or extent of neuroblast proliferation.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:21168496]","metadata":null},{"id":"02ca535d0c6743e8b8cc0595e9785eba","type":"GO_TERM","name":"regulation of neurofibrillary tangle assembly","canonical_id":"go:GO:1902996","description":"\"Any process that modulates the frequency, rate or extent of neurofibrillary tangle assembly.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:15897157]","metadata":null},{"id":"c239f9cf84234ebe894299bf26246ced","type":"GO_TERM","name":"regulation of neurogenesis","canonical_id":"go:GO:0050767","description":"\"Any process that modulates the frequency, rate or extent of neurogenesis, the generation of cells in the nervous system.\" [GOC:ai]","metadata":null},{"id":"b0fd95fe962141fd9ced917ed2de3c3e","type":"GO_TERM","name":"regulation of neuroinflammatory response","canonical_id":"go:GO:0150077","description":"\"Any process that modulates the frequency, rate or extent of neuroinflammatory response.\" [GOC:aruk, GOC:bc, PMID:10981966, PMID:11099416, PMID:18164423]","metadata":null},{"id":"468b49680d694123a5e2af86291e0cfd","type":"GO_TERM","name":"regulation of neuromuscular junction development","canonical_id":"go:GO:1904396","description":"\"Any process that modulates the frequency, rate or extent of neuromuscular junction development.\" [GO_REF:0000058, GOC:TermGenie, PMID:7722643]","metadata":null},{"id":"5d5465e6ae994b6ba0a54714f5eedd37","type":"GO_TERM","name":"regulation of neuromuscular synaptic transmission","canonical_id":"go:GO:1900073","description":"\"Any process that modulates the frequency, rate or extent of neuromuscular synaptic transmission.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"4fbb2786dfde4babaa5a402979b9d3d9","type":"GO_TERM","name":"regulation of neuron apoptotic process","canonical_id":"go:GO:0043523","description":"\"Any process that modulates the occurrence or rate of cell death by apoptotic process in neurons.\" [GOC:curators, GOC:mtg_apoptosis]","metadata":null},{"id":"178c1f744c0d4bd2a66fcf0c4f729c0e","type":"GO_TERM","name":"regulation of neuron differentiation","canonical_id":"go:GO:0045664","description":"\"Any process that modulates the frequency, rate or extent of neuron differentiation.\" [GOC:curators]","metadata":null},{"id":"9f949cc148a946e981e24aff78864881","type":"GO_TERM","name":"regulation of neuron maturation","canonical_id":"go:GO:0014041","description":"\"Any process that modulates the frequency, rate or extent of neuron maturation, the process leading to the attainment of the full functional capacity of a neuron. This process is independent of morphogenetic change.\" [GOC:ef]","metadata":null},{"id":"d50baecd701a40568c90ecc489063696","type":"GO_TERM","name":"regulation of neuron migration","canonical_id":"go:GO:2001222","description":"\"Any process that modulates the frequency, rate or extent of neuron migration.\" [GOC:obol]","metadata":null},{"id":"02169d30659647a9968c260fe95f02fc","type":"GO_TERM","name":"regulation of neuron projection arborization","canonical_id":"go:GO:0150011","description":"\"Any process that modulates the frequency, rate or extent of the process in which the anatomical structures of a neuron projection are generated and organized into branches.\" [GOC:aruk, GOC:bc, PMID:17114044]","metadata":null},{"id":"a8e6fb59663443028d0dd797e3e36dab","type":"GO_TERM","name":"regulation of neuron projection development","canonical_id":"go:GO:0010975","description":"\"Any process that modulates the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6e2e0a3325f24f9e8c0da1fd21de0ee4","type":"GO_TERM","name":"regulation of neuron projection regeneration","canonical_id":"go:GO:0070570","description":"\"Any process that modulates the rate, frequency or extent of neuron projection regeneration, the regrowth of neuronal processes such as axons or dendrites following their loss or damage.\" [GOC:mah]","metadata":null},{"id":"955e449f57ab487aba84b5059f9ccfa5","type":"GO_TERM","name":"regulation of neuron remodeling","canonical_id":"go:GO:1904799","description":"\"Any process that modulates the frequency, rate or extent of neuron remodeling.\" [GO_REF:0000058, GOC:TermGenie, PMID:21609829]","metadata":null},{"id":"d71c99fca3d842f89721c10b31b22d74","type":"GO_TERM","name":"regulation of neuronal action potential","canonical_id":"go:GO:0098908","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a neuron. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"4adb31cb5f184664a5e1ccfef1502204","type":"GO_TERM","name":"regulation of neuronal signal transduction","canonical_id":"go:GO:1902847","description":"\"Any process that modulates the frequency, rate or extent of neuronal signal transduction.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie]","metadata":null},{"id":"2941e5593a294aecbc96745ab22caafc","type":"GO_TERM","name":"regulation of neuronal synaptic plasticity","canonical_id":"go:GO:0048168","description":"\"A process that modulates neuronal synaptic plasticity, the ability of neuronal synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"51ec832a82bb4c2589302b5817b3a379","type":"GO_TERM","name":"regulation of neuronal synaptic plasticity in response to neurotrophin","canonical_id":"go:GO:0031637","description":"\"The process in which a neurotrophic factor induces neuronal synaptic plasticity, the ability of neuronal synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.\" [GOC:mah, PMID:8703078]","metadata":null},{"id":"137fb2bc07a94ef18103a64e99c651a5","type":"GO_TERM","name":"regulation of neurotransmitter loading into synaptic vesicle","canonical_id":"go:GO:0099162","description":"\"Any process that modulates the frequency, rate or extent of neurotransmitter loading into synaptic vesicles.\" [GOC:dos, PMID:25176177]","metadata":null},{"id":"c6f25444537a439a95f151bc7b5690e0","type":"GO_TERM","name":"regulation of neurotransmitter receptor activity","canonical_id":"go:GO:0099601","description":"\"Any process that modulates the frequency, rate or extent of neurotransmitter receptor activity. Modulation may be via an effect on ligand affinity, or effector function such as ion selectivity or pore opening/closing in ionotropic receptors.\" [GOC:dos]","metadata":null},{"id":"ccd30d92e4e84d63b30d64043a0b5550","type":"GO_TERM","name":"regulation of neurotransmitter receptor localization to postsynaptic specialization membrane","canonical_id":"go:GO:0098696","description":"\"Any process that modulates the frequency, rate or extent of neurotransmitter receptor localization to postsynaptic specialization membrane.\" [GOC:dos]","metadata":null},{"id":"cba44f79bed945a0bfd292642ff4f0d4","type":"GO_TERM","name":"regulation of neurotransmitter receptor transport, endosome to postsynaptic membrane","canonical_id":"go:GO:0099152","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of neurotransmitter receptor from the postsynaptic endosome to the postsynaptic membrane in transport vesicles.\" [GOC:dos, PMID:20098723]","metadata":null},{"id":"aacd53c2839b4c8a8e39a9752b86bbb8","type":"GO_TERM","name":"regulation of neurotransmitter secretion","canonical_id":"go:GO:0046928","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of a neurotransmitter from a cell.\" [GOC:ai]","metadata":null},{"id":"bc38af7e194640438aeba051a0a0059b","type":"GO_TERM","name":"regulation of neurotransmitter transport","canonical_id":"go:GO:0051588","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"cf49e6136c7d4cdf9451ee3ddd25c3ea","type":"GO_TERM","name":"regulation of neurotransmitter uptake","canonical_id":"go:GO:0051580","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell.\" [GOC:ai]","metadata":null},{"id":"6305c166cadd47a893eead7bc16afccb","type":"GO_TERM","name":"regulation of neurotrophin TRK receptor signaling pathway","canonical_id":"go:GO:0051386","description":"\"Any process that modulates the frequency, rate or extent of the neurotrophin TRK receptor signaling pathway.\" [GOC:ai]","metadata":null},{"id":"2bfa1a81110a421ebfc4bb61fa37f46f","type":"GO_TERM","name":"regulation of neurotrophin production","canonical_id":"go:GO:0032899","description":"\"Any process that modulates the frequency, rate, or extent of production of a neurotrophin.\" [GOC:mah]","metadata":null},{"id":"e9d2892ecbac4b57bfd6fc41db8397d7","type":"GO_TERM","name":"regulation of neutrophil activation","canonical_id":"go:GO:1902563","description":"\"Any process that modulates the frequency, rate or extent of neutrophil activation.\" [GOC:TermGenie, PMID:17588661]","metadata":null},{"id":"48de57e5d86f4c10a0782c8de4f7f24f","type":"GO_TERM","name":"regulation of neutrophil aggregation","canonical_id":"go:GO:2000428","description":"\"Any process that modulates the frequency, rate or extent of neutrophil aggregation.\" [GOC:BHF]","metadata":null},{"id":"24e742ced64e46c19598dfda629c5374","type":"GO_TERM","name":"regulation of neutrophil apoptotic process","canonical_id":"go:GO:0033029","description":"\"Any process that modulates the frequency, rate, or extent of neutrophil apoptotic process.\" [GOC:add, GOC:mtg_apoptosis]","metadata":null},{"id":"d0ca530a53904a4fbb0af137f0f4c485","type":"GO_TERM","name":"regulation of neutrophil chemotaxis","canonical_id":"go:GO:0090022","description":"\"Any process that modulates the frequency, rate, or extent of neutrophil chemotaxis. Neutrophil chemotaxis is the directed movement of a neutrophil cell, the most numerous polymorphonuclear leukocyte found in the blood, in response to an external stimulus, usually an infection or wounding.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3e12097ed33d4d6abcf3f414a0832375","type":"GO_TERM","name":"regulation of neutrophil degranulation","canonical_id":"go:GO:0043313","description":"\"Any process that modulates the frequency, rate, or extent of neutrophil degranulation.\" [ISBN:0781735149]","metadata":null},{"id":"c24c02363f0e44e9babe2d4d663491d5","type":"GO_TERM","name":"regulation of neutrophil differentiation","canonical_id":"go:GO:0045658","description":"\"Any process that modulates the frequency, rate or extent of neutrophil differentiation.\" [GOC:curators]","metadata":null},{"id":"a9d8a35c2f3041b39f3db0f0930c8b51","type":"GO_TERM","name":"regulation of neutrophil extravasation","canonical_id":"go:GO:2000389","description":"\"Any process that modulates the frequency, rate or extent of neutrophil extravasation.\" [GOC:mah]","metadata":null},{"id":"13c1801006a44a9e9abee2b01e90cd42","type":"GO_TERM","name":"regulation of neutrophil mediated cytotoxicity","canonical_id":"go:GO:0070948","description":"\"Any process that modulates the rate, frequency or extent of neutrophil mediated killing of a target cell, the directed killing of a target cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"936b428b66b34d0c9d3d9ec937547717","type":"GO_TERM","name":"regulation of neutrophil mediated killing of bacterium","canonical_id":"go:GO:0070950","description":"\"Any process that modulates the rate, frequency or extent of neutrophil mediated killing of a bacterium, the directed killing of a bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"27f48b95aeff4270a6c486d955165b4b","type":"GO_TERM","name":"regulation of neutrophil mediated killing of fungus","canonical_id":"go:GO:0070953","description":"\"Any process that modulates the rate, frequency or extent of neutrophil mediated killing of a fungal cell, the directed killing of a fungal cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"4de05c244760430193cc4a005ec1f87b","type":"GO_TERM","name":"regulation of neutrophil mediated killing of gram-negative bacterium","canonical_id":"go:GO:0070951","description":"\"Any process that modulates the rate, frequency or extent of neutrophil mediated killing of a gram-negative bacterium, the directed killing of a gram-negative bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"223798f33bc84ce9a2244a5a95915c5d","type":"GO_TERM","name":"regulation of neutrophil mediated killing of gram-positive bacterium","canonical_id":"go:GO:0070952","description":"\"Any process that modulates the rate, frequency or extent of neutrophil mediated killing of a gram-positive bacterium, the directed killing of a gram-positive bacterium by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"a8b79b3bb44a494d967fe2b161882608","type":"GO_TERM","name":"regulation of neutrophil mediated killing of symbiont cell","canonical_id":"go:GO:0070949","description":"\"Any process that modulates the rate, frequency or extent of neutrophil mediated killing of a symbiont cell, the directed killing of a symbiont target cell by a neutrophil.\" [GOC:add, GOC:mah]","metadata":null},{"id":"ad3bc76c81f34b63ab876a77db841e34","type":"GO_TERM","name":"regulation of neutrophil migration","canonical_id":"go:GO:1902622","description":"\"Any process that modulates the frequency, rate or extent of neutrophil migration.\" [GO_REF:0000058, GOC:TermGenie, PMID:1826836]","metadata":null},{"id":"b25709ac270f4ae78704eb2eca7ce353","type":"GO_TERM","name":"regulation of nigerotriose transport","canonical_id":"go:GO:1900357","description":"\"Any process that modulates the frequency, rate or extent of nigerotriose transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"e2efcf584280437cadacad5066347cb5","type":"GO_TERM","name":"regulation of nitrate assimilation","canonical_id":"go:GO:0090352","description":"\"Any process that modulates the rate, frequency, or extent of the uptake, from the environment, of nitrates, inorganic or organic salts and esters of nitric acid and the subsequent reduction of nitrate ion to other, less highly oxidized, inorganic nitrogenous substances.\" [GOC:tb]","metadata":null},{"id":"7b77038e4e574dd79aee2cb9d8fa7492","type":"GO_TERM","name":"regulation of nitric oxide biosynthetic process","canonical_id":"go:GO:0045428","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.\" [GOC:curators]","metadata":null},{"id":"421feee613154ef7825c958705ce00ae","type":"GO_TERM","name":"regulation of nitric oxide metabolic process","canonical_id":"go:GO:0080164","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nitric oxide, nitrogen monoxide (NO), a colorless gas only slightly soluble in water.\" [GOC:DHL]","metadata":null},{"id":"6334866330ef4a74b62f966564a8fa76","type":"GO_TERM","name":"regulation of nitric oxide-cGMP mediated signal transduction","canonical_id":"go:GO:0141149","description":"\"Any process that modulates the rate, frequency or extent of nitric oxide-cGMP mediated signal transduction.\" [PMID:35931019]","metadata":null},{"id":"2def6dfdbf8142599725c514ca5ca585","type":"GO_TERM","name":"regulation of nitric-oxide synthase activity","canonical_id":"go:GO:0050999","description":"\"Any process that modulates the activity of the enzyme nitric-oxide synthase.\" [GOC:ai]","metadata":null},{"id":"959444a1515b46eca9581fc401da8aa5","type":"GO_TERM","name":"regulation of nitrogen utilization","canonical_id":"go:GO:0006808","description":"\"Any process that modulates the frequency, rate or extent of nitrogen utilization.\" [GOC:curators]","metadata":null},{"id":"2a803741ae2849e0836c519b323b79ba","type":"GO_TERM","name":"regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1905258","description":"\"Any process that modulates the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to nitrosative stress.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:14752510]","metadata":null},{"id":"b068427ddaf54c1aaed11d5b6d94834e","type":"GO_TERM","name":"regulation of nodal receptor complex assembly","canonical_id":"go:GO:1900123","description":"\"Any process that modulates the frequency, rate or extent of nodal receptor complex assembly.\" [GOC:signaling, GOC:TermGenie, PMID:15062104]","metadata":null},{"id":"8ff3675b6fc34a13ad1de114cc0e7670","type":"GO_TERM","name":"regulation of nodal signaling pathway","canonical_id":"go:GO:1900107","description":"\"Any process that modulates the frequency, rate or extent of nodal signaling pathway.\" [GOC:BHF, GOC:TermGenie, GOC:vk]","metadata":null},{"id":"ee3ec7ee843f4c6cbe18b100268be6ef","type":"GO_TERM","name":"regulation of non-canonical NF-kappaB signal transduction","canonical_id":"go:GO:1901222","description":"\"Any process that modulates the frequency, rate or extent of the non-canonical NF-kappaB signaling cascade.\" [GOC:TermGenie]","metadata":null},{"id":"dc0264e72eb948e580e3f9bafc652d27","type":"GO_TERM","name":"regulation of non-canonical Wnt signaling pathway","canonical_id":"go:GO:2000050","description":"\"Any process that modulates the frequency, rate or extent of non-canonical Wnt signaling pathway.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"33cf7dc29e0149e2a0b1742c989890c4","type":"GO_TERM","name":"regulation of non-motile cilium assembly","canonical_id":"go:GO:1902855","description":"\"Any process that modulates the frequency, rate or extent of non-motile cilium assembly.\" [GO_REF:0000058, GOC:cilia, GOC:kmv, GOC:TermGenie, PMID:23807208]","metadata":null},{"id":"d2fe6ffa03814b3c8634fe59b27c1ffa","type":"GO_TERM","name":"regulation of non-professional antigen presenting cell antigen processing and presentation","canonical_id":"go:GO:0002619","description":"\"Any process that modulates the frequency, rate, or extent of non-professional antigen presenting cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"9a6653bfbd8d46289d8822ab3686ec60","type":"GO_TERM","name":"regulation of norepinephrine secretion","canonical_id":"go:GO:0014061","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of norepinephrine.\" [GOC:ef]","metadata":null},{"id":"3f387e6685004f2e8861e7952681d232","type":"GO_TERM","name":"regulation of norepinephrine uptake","canonical_id":"go:GO:0051621","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of the neurotransmitter norepinephrine into a cell.\" [GOC:ai]","metadata":null},{"id":"c8cd5a7801a14a5c9bbbdb2f1a3ae9ee","type":"GO_TERM","name":"regulation of nuclear cell cycle DNA replication","canonical_id":"go:GO:0033262","description":"\"Any process that modulates the frequency, rate or extent of The DNA-dependent DNA replication that occurs in the nucleus of eukaryotic organisms as part of the cell cycle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"c5b389dd1f7548ada553c983da54def5","type":"GO_TERM","name":"regulation of nuclear division","canonical_id":"go:GO:0051783","description":"\"Any process that modulates the frequency, rate or extent of nuclear division, the partitioning of the nucleus and its genetic information.\" [GOC:ai]","metadata":null},{"id":"470b1c1cb6ba47529fa7c48ba058f48c","type":"GO_TERM","name":"regulation of nuclear mRNA surveillance of meiosis-specific transcripts","canonical_id":"go:GO:0120270","description":"\"Any process that modulates the rate, frequency, or extent of selective degradation of meiosis-specific nuclear transcribed transcripts during vegetative growth, by a mechanism that requires determinant of selective removal (DSR) sequences in the targeted mRNAs and involves a YTH family protein.\" [GOC:krc, PMID:24920274]","metadata":null},{"id":"b85b2170f8a54da8b4d1d830854dd08b","type":"GO_TERM","name":"regulation of nuclear migration along microtubule","canonical_id":"go:GO:1902838","description":"\"Any process that modulates the frequency, rate or extent of nuclear migration along microtubule.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"0f749e7a6fc84d50adc31c18f2be1e47","type":"GO_TERM","name":"regulation of nuclear migration during mitotic telophase","canonical_id":"go:GO:1902852","description":"\"Any process that modulates the frequency, rate or extent of nuclear migration during mitotic telophase.\" [GO_REF:0000058, GOC:TermGenie, PMID:23087209]","metadata":null},{"id":"90a7ac8838a6403cbbb664f23d495aed","type":"GO_TERM","name":"regulation of nuclear receptor-mediated glucocorticoid signaling pathway","canonical_id":"go:GO:2000322","description":"\"Any process that modulates the frequency, rate or extent of nuclear receptor-mediated glucocorticoid signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"7e2d4b929b714c3fab97fa71ba301f34","type":"GO_TERM","name":"regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay","canonical_id":"go:GO:1900151","description":"\"Any process that modulates the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay.\" [GOC:mcc, GOC:TermGenie]","metadata":null},{"id":"55be182b287b48c2b31c795a5d258edb","type":"GO_TERM","name":"regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay","canonical_id":"go:GO:2000622","description":"\"Any process that modulates the frequency, rate or extent of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay.\" [GOC:obol]","metadata":null},{"id":"89922156c4ce413b8b28fe2d07ad7fe8","type":"GO_TERM","name":"regulation of nuclear-transcribed mRNA poly(A) tail shortening","canonical_id":"go:GO:0060211","description":"\"Any process that modulates the frequency, rate or extent of poly(A) tail shortening of a nuclear-transcribed mRNA. Poly(A) tail shortening is the decrease in length of the poly(A) tail of an mRNA from full length to an oligo(A) length.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"712850f619cc4a47bc5b29b809497549","type":"GO_TERM","name":"regulation of nucleobase-containing compound metabolic process","canonical_id":"go:GO:0019219","description":"\"Any cellular process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids.\" [GOC:curators]","metadata":null},{"id":"2709d86d12a847cba8b01bc5d7efc996","type":"GO_TERM","name":"regulation of nucleobase-containing compound transport","canonical_id":"go:GO:0032239","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of nucleobases, nucleosides, nucleotides and nucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"feae8441f87f404ba64ef353475f3dee","type":"GO_TERM","name":"regulation of nucleocytoplasmic transport","canonical_id":"go:GO:0046822","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of substances between the nucleus and the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"1b41b6e5fc1e4c66af214f1832b57775","type":"GO_TERM","name":"regulation of nucleoside metabolic process","canonical_id":"go:GO:0009118","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleosides.\" [GOC:curators]","metadata":null},{"id":"779b3eae38cc400db992e177062950f9","type":"GO_TERM","name":"regulation of nucleoside transport","canonical_id":"go:GO:0032242","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"f743bd8cc1864ce48b8715e92196293d","type":"GO_TERM","name":"regulation of nucleotide biosynthetic process","canonical_id":"go:GO:0030808","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nucleotides.\" [GOC:mah]","metadata":null},{"id":"1424dfb462a2418d87cc5d309fa596ed","type":"GO_TERM","name":"regulation of nucleotide catabolic process","canonical_id":"go:GO:0030811","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of nucleotides.\" [GOC:mah]","metadata":null},{"id":"b60fce4d9eab4e8199e7ade3529e9519","type":"GO_TERM","name":"regulation of nucleotide metabolic process","canonical_id":"go:GO:0006140","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleotides.\" [GOC:curators]","metadata":null},{"id":"5ec3a51e714d4cf1b40c8c416c5c11d8","type":"GO_TERM","name":"regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway","canonical_id":"go:GO:0070424","description":"\"Any process that modulates the frequency, rate, or extent of a nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (NLR) pathway.\" [GOC:add]","metadata":null},{"id":"03cddf6ace3a4a3398e8fca559c23172","type":"GO_TERM","name":"regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway","canonical_id":"go:GO:0070428","description":"\"Any process that modulates the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 1 (NOD1) pathway.\" [GOC:add]","metadata":null},{"id":"84620e47835d444ab9415c70131e2098","type":"GO_TERM","name":"regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway","canonical_id":"go:GO:0070432","description":"\"Any process that modulates the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 2 (NOD2) pathway.\" [GOC:add]","metadata":null},{"id":"590c31f9c4f94eb89c31f3860c6cc5cd","type":"GO_TERM","name":"regulation of nucleotide-excision repair","canonical_id":"go:GO:2000819","description":"\"Any process that modulates the frequency, rate or extent of nucleotide-excision repair.\" [GOC:jp, PMID:18836076]","metadata":null},{"id":"d173621d056d40898915935d5cdbc798","type":"GO_TERM","name":"regulation of nucleus organization","canonical_id":"go:GO:1903353","description":"\"Any process that modulates the frequency, rate or extent of nucleus organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:16943282]","metadata":null},{"id":"3947626cc0924961bd2fdcf7224ee254","type":"GO_TERM","name":"regulation of nucleus size","canonical_id":"go:GO:0097298","description":"\"Any process that modulates the size of the nucleus.\" [GOC:al, GOC:mah, PMID:19366728]","metadata":null},{"id":"4cc0f3c48bc0496ea8f61e84c2e6dbf0","type":"GO_TERM","name":"regulation of nurse cell apoptotic process","canonical_id":"go:GO:0045477","description":"\"Any process that modulates the frequency, rate or extent of nurse cell apoptotic process.\" [GOC:mtg_apoptosis, PMID:11973306]","metadata":null},{"id":"4b7269b272b54b13b3bbfbeef2c527e4","type":"GO_TERM","name":"regulation of o-orsellinic acid biosynthetic process","canonical_id":"go:GO:1900698","description":"\"Any process that modulates the frequency, rate or extent of o-orsellinic acid biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"edde5bbdce0b4b74a5bcde94b123a656","type":"GO_TERM","name":"regulation of octopamine or tyramine signaling pathway","canonical_id":"go:GO:2000125","description":"\"Any process that modulates the frequency, rate or extent of octopamine or tyramine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"a97d380e671b4d7c811baac1c4d34abc","type":"GO_TERM","name":"regulation of octopamine signaling pathway","canonical_id":"go:GO:2000128","description":"\"Any process that modulates the frequency, rate or extent of octopamine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"fad4002f615e4970a2165f43c4d13cd7","type":"GO_TERM","name":"regulation of odontoblast differentiation","canonical_id":"go:GO:1901329","description":"\"Any process that modulates the frequency, rate or extent of odontoblast differentiation.\" [GOC:TermGenie]","metadata":null},{"id":"2294c8614785450ea56b523de3eb67b7","type":"GO_TERM","name":"regulation of odontogenesis","canonical_id":"go:GO:0042481","description":"\"Any process that modulates the frequency, rate or extent of the formation and development of a tooth or teeth.\" [GOC:jl]","metadata":null},{"id":"29b6775b1fa64b2d966f450ac49ba61b","type":"GO_TERM","name":"regulation of odontogenesis of dentin-containing tooth","canonical_id":"go:GO:0042487","description":"\"Any process that modulates the frequency, rate or extent of the formation and development of teeth, the hard, bony appendages which are borne on the jaws, or on other bones in the walls of the mouth or pharynx of most vertebrates.\" [GOC:jl, GOC:mtg_sensu, PMID:15355794]","metadata":null},{"id":"b2e565ff4ed7413ca55e48ca1efacd8c","type":"GO_TERM","name":"regulation of olefin biosynthetic process","canonical_id":"go:GO:1900911","description":"\"Any process that modulates the frequency, rate or extent of olefin biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"d1447e4d73df4b669c2506eea7586b9f","type":"GO_TERM","name":"regulation of olfactory learning","canonical_id":"go:GO:0090328","description":"\"Any process that modulates the rate, frequency, or extent of olfactory learning. Olfactory learning is any process in an organism in which a relatively long-lasting adaptive behavioral change occurs in response to (repeated) exposure to an olfactory cue.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"51eab5e362244fd39614a992d4f41417","type":"GO_TERM","name":"regulation of oligodendrocyte apoptotic process","canonical_id":"go:GO:1900141","description":"\"Any process that modulates the frequency, rate or extent of oligodendrocyte apoptotic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"0173fb8fda2f4f89b97d587d07642fc8","type":"GO_TERM","name":"regulation of oligodendrocyte differentiation","canonical_id":"go:GO:0048713","description":"\"Any process that modulates the frequency, rate or extent of oligodendrocyte differentiation.\" [GOC:vp, PMID:15139015]","metadata":null},{"id":"2b968bc320bd42ce9abbe178150a1dcd","type":"GO_TERM","name":"regulation of oligodendrocyte progenitor proliferation","canonical_id":"go:GO:0070445","description":"\"Any process that modulates the frequency, rate or extent of oligodendrocyte progenitor proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"6876994365b3496896538eb0176333c9","type":"GO_TERM","name":"regulation of oligopeptide transport","canonical_id":"go:GO:0090088","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of oligopeptides into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Oligopeptides are molecules that contain a small number (2 to 20) of amino-acid residues connected by peptide linkages.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3206d4d601c64f3facb64054af57d713","type":"GO_TERM","name":"regulation of oocyte development","canonical_id":"go:GO:0060281","description":"\"Any process that modulates the rate or extent of the process whose specific outcome is the progression of an oocyte over time, from initial commitment of the cell to its specific fate, to the fully functional differentiated cell.\" [GOC:dph, GOC:tb, PMID:2394318]","metadata":null},{"id":"ae53115210134554b1f0dcf7616b4263","type":"GO_TERM","name":"regulation of oocyte karyosome formation","canonical_id":"go:GO:0120313","description":"\"Any process that modulates the frequency, rate or extent of oocyte karyosome formation, the chromosome organization process in which meiotic chromosomes in the oocyte nucleus cluster together to form a compact spherical structure called the karyosome.\" [GOC:ha, GOC:krc, PMID:33382409]","metadata":null},{"id":"9d2fca0c9bb041e282a442a7a9b62078","type":"GO_TERM","name":"regulation of oocyte maturation","canonical_id":"go:GO:1900193","description":"\"Any process that modulates the frequency, rate or extent of oocyte maturation.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"7de9eee595b545209e103af427254e8e","type":"GO_TERM","name":"regulation of oogenesis","canonical_id":"go:GO:1905879","description":"\"Any process that modulates the frequency, rate or extent of oogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:26434723]","metadata":null},{"id":"4478b919b30a403eaa930602a8099e17","type":"GO_TERM","name":"regulation of oogonium development","canonical_id":"go:GO:0075264","description":"\"Any process that modulates the frequency, rate or extent of oogonium development, a process that leads to the formation of a female gametangium of oomycetes, containing one or more gametes.\" [GOC:pamgo_curators]","metadata":null},{"id":"72d21836c7c14558a384e0f247d3d9b4","type":"GO_TERM","name":"regulation of oomycete sporangium development","canonical_id":"go:GO:0075322","description":"\"Any process that modulates the frequency, rate or extent of oomycete sporangium development, a process that leads to the formation of oomycete sporangium, a single-celled or many-celled structure that germinates directly to form an infection hypha or differentiate, through specialized cleavage vesicles, into between 10 and 30 zoospores, which is laterally flagellated.\" [GOC:pamgo_curators]","metadata":null},{"id":"cfceaf3f29734ddeab62dc09db72c0a2","type":"GO_TERM","name":"regulation of oospore formation","canonical_id":"go:GO:0075244","description":"\"Any process that modulates the frequency, rate or extent of oospore formation, a process in which male and female gametangia develop and fuse to form a thick-walled resting spore of oomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"35bb17255cb94355b194490fa7a16c2c","type":"GO_TERM","name":"regulation of opioid receptor signaling pathway","canonical_id":"go:GO:2000474","description":"\"Any process that modulates the frequency, rate or extent of opioid receptor signaling pathway.\" [GOC:obol]","metadata":null},{"id":"65c3b46b72fb44af8532a41db19c7d1a","type":"GO_TERM","name":"regulation of opsin-mediated signaling pathway","canonical_id":"go:GO:0022400","description":"\"Any process that modulates the frequency, rate or extent of opsin-mediated signaling.\" [GOC:mah]","metadata":null},{"id":"a163088477fa4e649a41a12e5b37fcf6","type":"GO_TERM","name":"regulation of opsonization","canonical_id":"go:GO:1903027","description":"\"Any process that modulates the frequency, rate or extent of opsonization.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22333221]","metadata":null},{"id":"7d7ca3074b8f48368573b919e0de0aee","type":"GO_TERM","name":"regulation of optic nerve formation","canonical_id":"go:GO:2000595","description":"\"Any process that modulates the frequency, rate or extent of optic nerve formation.\" [GOC:obol]","metadata":null},{"id":"9656552156a04865b49f47e2fa24938e","type":"GO_TERM","name":"regulation of optical nerve axon regeneration","canonical_id":"go:GO:1905591","description":"\"Any process that modulates the frequency, rate or extent of optical nerve axon regeneration.\" [GO_REF:0000058, GOC:TermGenie, PMID:16699509]","metadata":null},{"id":"a73f7021df7b4854a3bd1bc672e65aba","type":"GO_TERM","name":"regulation of orcinol biosynthetic process","canonical_id":"go:GO:1900701","description":"\"Any process that modulates the frequency, rate or extent of orcinol biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"60874608b78e4d238e5a2c47bd86a7f9","type":"GO_TERM","name":"regulation of organ growth","canonical_id":"go:GO:0046620","description":"\"Any process that modulates the frequency, rate or extent of growth of an organ of an organism.\" [GOC:bf, GOC:tb]","metadata":null},{"id":"e99abfd3cbe3494ab8fa8f16976a618f","type":"GO_TERM","name":"regulation of organelle assembly","canonical_id":"go:GO:1902115","description":"\"Any process that modulates the frequency, rate or extent of organelle assembly.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"ac66086cc98c4740bd0452b01d0121e5","type":"GO_TERM","name":"regulation of organelle organization","canonical_id":"go:GO:0033043","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of an organelle.\" [GOC:mah]","metadata":null},{"id":"e87889cb00b9423f8c8fee123db5a853","type":"GO_TERM","name":"regulation of organelle transport along microtubule","canonical_id":"go:GO:1902513","description":"\"Any process that modulates the frequency, rate or extent of organelle transport along microtubule.\" [GOC:dph, GOC:TermGenie, PMID:21147087]","metadata":null},{"id":"6ee27394315b44469a27be1ed44144eb","type":"GO_TERM","name":"regulation of organic acid transport","canonical_id":"go:GO:0032890","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of organic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"846b5e5059c646459b1483b81832a3ba","type":"GO_TERM","name":"regulation of organohalogen metabolic process","canonical_id":"go:GO:0090347","description":"\"Any process that modulates the rate, frequency or extent of the chemical reactions and pathways involving organohalogen compounds, as carried out by individual cells.\" [GOC:BHF]","metadata":null},{"id":"16a61588b4504c9c974828018c13043c","type":"GO_TERM","name":"regulation of ornithine catabolic process","canonical_id":"go:GO:1903266","description":"\"Any process that modulates the frequency, rate or extent of ornithine catabolic process.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:12679340]","metadata":null},{"id":"25676a61ede34e749f1ec8fed5b7caf1","type":"GO_TERM","name":"regulation of oskar mRNA translation","canonical_id":"go:GO:0046011","description":"\"Any process that modulates the frequency, rate or extent of oskar mRNA translation. To ensure the localization of Oskar protein at the posterior pole of the oocyte, translation of oskar mRNA is repressed during its transport to the posterior pole and activated upon localization of the mRNA at the posterior cortex.\" [GOC:curators, PMID:12538512]","metadata":null},{"id":"249a993315d6430394825471fc86c9fb","type":"GO_TERM","name":"regulation of ossification","canonical_id":"go:GO:0030278","description":"\"Any process that modulates the frequency, rate or extent of ossification, the formation of bone or of a bony substance or the conversion of fibrous tissue or of cartilage into bone or a bony substance.\" [GOC:curators]","metadata":null},{"id":"d7df1b9cf1964314bcf15247bd9dd239","type":"GO_TERM","name":"regulation of osteoblast differentiation","canonical_id":"go:GO:0045667","description":"\"Any process that modulates the frequency, rate or extent of osteoblast differentiation.\" [GOC:curators]","metadata":null},{"id":"666bbba03b114f45b188c716bb8f9a3c","type":"GO_TERM","name":"regulation of osteoblast proliferation","canonical_id":"go:GO:0033688","description":"\"Any process that modulates the frequency, rate or extent of osteoblast proliferation.\" [GOC:mah]","metadata":null},{"id":"2acf5ca942a14f5381b8f052c8e37ca9","type":"GO_TERM","name":"regulation of osteoclast development","canonical_id":"go:GO:2001204","description":"\"Any process that modulates the frequency, rate or extent of osteoclast development.\" [GOC:obol]","metadata":null},{"id":"7fced516286c4f16818bad0d2965280b","type":"GO_TERM","name":"regulation of osteoclast differentiation","canonical_id":"go:GO:0045670","description":"\"Any process that modulates the frequency, rate or extent of osteoclast differentiation.\" [GOC:curators]","metadata":null},{"id":"1afc132aac9f4d5a9d50102359f3a487","type":"GO_TERM","name":"regulation of osteoclast proliferation","canonical_id":"go:GO:0090289","description":"\"Any process that modulates the rate, frequency, or extent of the multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population.\" [GOC:tb]","metadata":null},{"id":"6f966f83e62247969dd43a9822d38c46","type":"GO_TERM","name":"regulation of otic vesicle morphogenesis","canonical_id":"go:GO:1904118","description":"\"Any process that modulates the frequency, rate or extent of otic vesicle morphogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:25677106]","metadata":null},{"id":"be558dc047fd46e49f0ba4bf78f47a2a","type":"GO_TERM","name":"regulation of outer hair cell apoptotic process","canonical_id":"go:GO:1905585","description":"\"Any process that modulates the frequency, rate or extent of outer hair cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24472721]","metadata":null},{"id":"8817745163a5406cbb6f402bf6d4232b","type":"GO_TERM","name":"regulation of ovarian follicle development","canonical_id":"go:GO:2000354","description":"\"Any process that modulates the frequency, rate or extent of ovarian follicle development.\" [GOC:obol]","metadata":null},{"id":"378833f49c2d424ca119bb15b0ba26eb","type":"GO_TERM","name":"regulation of ovulation","canonical_id":"go:GO:0060278","description":"\"Any process that modulates the frequency, rate or extent of ovulation, the release of a mature ovum/oocyte from an ovary.\" [GOC:dph, GOC:kmv, GOC:tb]","metadata":null},{"id":"87afb3f97d24492584bf3030bc2afaab","type":"GO_TERM","name":"regulation of oxidative phosphorylation","canonical_id":"go:GO:0002082","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.\" [GOC:dph]","metadata":null},{"id":"0f3e35d31e974322be1862a22a01f24f","type":"GO_TERM","name":"regulation of oxidative stress-induced intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1902175","description":"\"Any process that modulates the frequency, rate or extent of an oxidative stress-induced intrinsic apoptotic signaling pathway.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:TermGenie, PMID:11672522]","metadata":null},{"id":"c0a93cbf31e14d65a0fd40a9a54d4dc5","type":"GO_TERM","name":"regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway","canonical_id":"go:GO:1903376","description":"\"Any process that modulates the frequency, rate or extent of oxidative stress-induced neuron intrinsic apoptotic signaling pathway.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"fa732ba44d584602852d742f6aa73072","type":"GO_TERM","name":"regulation of oxidoreductase activity","canonical_id":"go:GO:0051341","description":"\"Any process that modulates the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.\" [GOC:ai]","metadata":null},{"id":"24e84cea178840dea8ca6bcffa87e835","type":"GO_TERM","name":"regulation of oxygen metabolic process","canonical_id":"go:GO:2000374","description":"\"Any process that modulates the frequency, rate or extent of oxygen metabolic process.\" [GOC:mah]","metadata":null},{"id":"640bf5c568d945d6848eae7a846ba073","type":"GO_TERM","name":"regulation of oxytocin production","canonical_id":"go:GO:0140667","description":"\"Any process that modulates the frequency, rate, or extent of production of oxytocin.\" [PMID:25096581]","metadata":null},{"id":"2cef17bc8d804986bfb10f3d9d537a33","type":"GO_TERM","name":"regulation of p38MAPK cascade","canonical_id":"go:GO:1900744","description":"\"Any process that modulates the frequency, rate or extent of p38MAPK cascade.\" [GOC:TermGenie]","metadata":null},{"id":"9a919f0fc37848b69658c7f5a230359f","type":"GO_TERM","name":"regulation of pH","canonical_id":"go:GO:0006885","description":"\"Any process involved in the maintenance of an internal equilibrium of hydrogen ions, thereby modulating the internal pH, within an organism or cell.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"b1f2dc57c1744d6c832d1a2ec59a50b0","type":"GO_TERM","name":"regulation of pancreatic A cell differentiation","canonical_id":"go:GO:2000226","description":"\"Any process that modulates the frequency, rate or extent of pancreatic A cell differentiation.\" [GOC:mah]","metadata":null},{"id":"bcc39fa7f2db4f4b8e00e83828481942","type":"GO_TERM","name":"regulation of pancreatic amylase secretion","canonical_id":"go:GO:1902276","description":"\"Any process that modulates the frequency, rate or extent of pancreatic amylase secretion.\" [GOC:jc, GOC:TermGenie]","metadata":null},{"id":"2fb7ded601664fd6a063f88abe31a8b9","type":"GO_TERM","name":"regulation of pancreatic juice secretion","canonical_id":"go:GO:0090186","description":"\"Any process that modulates the rate, frequency or extent of pancreatic juice secretion, the regulated release of pancreatic juice by the exocrine pancreas into the upper part of the intestine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e8008ef95d02495ab36815874a1c4d16","type":"GO_TERM","name":"regulation of pancreatic stellate cell proliferation","canonical_id":"go:GO:2000229","description":"\"Any process that modulates the frequency, rate or extent of pancreatic stellate cell proliferation.\" [GOC:mah]","metadata":null},{"id":"76d7a92dd8074978a16f5a90cf989abc","type":"GO_TERM","name":"regulation of pancreatic trypsinogen secretion","canonical_id":"go:GO:1904242","description":"\"Any process that modulates the frequency, rate or extent of pancreatic trypsinogen secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:12771515]","metadata":null},{"id":"77365fa434424929a7252d75ec305006","type":"GO_TERM","name":"regulation of parathyroid hormone secretion","canonical_id":"go:GO:2000828","description":"\"Any process that modulates the frequency, rate or extent of parathyroid hormone secretion.\" [GOC:obol]","metadata":null},{"id":"883e462ff76240fdac62227881fc5bac","type":"GO_TERM","name":"regulation of paraxial mesodermal cell fate determination","canonical_id":"go:GO:0048345","description":"\"Any process that modulates the frequency, rate or extent of paraxial mesoderm cell fate determination.\" [GOC:dgh]","metadata":null},{"id":"acde2cf179514044ad7f8325533ee77b","type":"GO_TERM","name":"regulation of paraxial mesodermal cell fate specification","canonical_id":"go:GO:0048349","description":"\"Any process that modulates the frequency, rate or extent of paraxial mesoderm cell fate specification.\" [GOC:dgh]","metadata":null},{"id":"2e8451ed0dc44fcaadcb52d76316cde6","type":"GO_TERM","name":"regulation of pattern recognition receptor signaling pathway","canonical_id":"go:GO:0062207","description":"\"Any process that modulates the rate, frequency or extent of a pattern recognition receptor signaling pathway.\" [PMID:30610168]","metadata":null},{"id":"f721de07c2f84790af1695c6ab7232d2","type":"GO_TERM","name":"regulation of pectin biosynthetic process","canonical_id":"go:GO:1900030","description":"\"Any process that modulates the frequency, rate or extent of pectin biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"8779de2f8bb84b8aa0d89892c89ec3a1","type":"GO_TERM","name":"regulation of pectin catabolic process","canonical_id":"go:GO:2001003","description":"\"Any process that modulates the frequency, rate or extent of pectin catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"3698f3c6eede4a509be4613212630900","type":"GO_TERM","name":"regulation of penetration hypha formation","canonical_id":"go:GO:0075202","description":"\"Any process that modulates the frequency, rate or extent of symbiont penetration hypha formation for entry into host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"e49bc8ffecd34b86b291398802b655e1","type":"GO_TERM","name":"regulation of penicillin biosynthetic process","canonical_id":"go:GO:1900196","description":"\"Any process that modulates the frequency, rate or extent of penicillin biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"de0a3b3bb0c546a59ce556a3365cb950","type":"GO_TERM","name":"regulation of penicillin catabolic process","canonical_id":"go:GO:0033247","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways leading to the breakdown of any antibiotic that contains the condensed beta-lactamthiazolidine ring system.\" [GOC:mah]","metadata":null},{"id":"67375efe7eae4f289a7b26d48c18852b","type":"GO_TERM","name":"regulation of penile erection","canonical_id":"go:GO:0060405","description":"\"Any process that modulates the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"8864e4c7b09e4fd9845270408bfc0f0d","type":"GO_TERM","name":"regulation of pentadecane biosynthetic process","canonical_id":"go:GO:1900887","description":"\"Any process that modulates the frequency, rate or extent of pentadecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c3e0d9b3b73c4334b8e13430aa4ae945","type":"GO_TERM","name":"regulation of pentasaccharide transport","canonical_id":"go:GO:1900360","description":"\"Any process that modulates the frequency, rate or extent of pentasaccharide transport.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9764df0876e44d24921561964df7c95a","type":"GO_TERM","name":"regulation of pentose-phosphate shunt","canonical_id":"go:GO:0043456","description":"\"Any process that modulates the frequency, rate or extent of the pentose-phosphate shunt, the process in which glucose is oxidized, coupled to NADPH synthesis.\" [GOC:jl]","metadata":null},{"id":"f3c2a3abd4f64258a38784aca317ae8e","type":"GO_TERM","name":"regulation of peptidase activity","canonical_id":"go:GO:0052547","description":"\"Any process that modulates the frequency, rate or extent of peptidase activity, the hydrolysis of peptide bonds within proteins.\" [GOC:ai]","metadata":null},{"id":"e1eb483c6de447158cbe008d4857729c","type":"GO_TERM","name":"regulation of peptide antigen transport","canonical_id":"go:GO:1901039","description":"\"Any process that modulates the frequency, rate or extent of peptide antigen transport.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"2b75183c1416416383f9106e40877258","type":"GO_TERM","name":"regulation of peptide hormone processing","canonical_id":"go:GO:0060568","description":"\"Any process that modulates the rate, frequency or extent of peptide hormone processing. Peptide hormone processing is the generation of a mature peptide hormone by posttranslational processing of a prohormone.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3b0be9033e154bc48230485e21133b45","type":"GO_TERM","name":"regulation of peptide hormone secretion","canonical_id":"go:GO:0090276","description":"\"Any process that modulates the rate, frequency, or extent of the regulated release of a peptide hormone from secretory granules.\" [GOC:tb]","metadata":null},{"id":"ea283eed8eea4811aa0cdb3b0458ae6c","type":"GO_TERM","name":"regulation of peptide secretion","canonical_id":"go:GO:0002791","description":"\"Any process that modulates the frequency, rate, or extent of peptide secretion.\" [GOC:add]","metadata":null},{"id":"1b2980cffdd74e0381f71b9a4f2671a9","type":"GO_TERM","name":"regulation of peptide transport","canonical_id":"go:GO:0090087","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of peptides, compounds of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b913058eadc247fd9452323abff74628","type":"GO_TERM","name":"regulation of peptidoglycan recognition protein signaling pathway","canonical_id":"go:GO:0061058","description":"\"Any process that modulates the rate, frequency, or extent of the peptidoglycan recognition protein signaling pathway.\" [GOC:dph]","metadata":null},{"id":"e820f954e203461b8795c2d1cf29e64b","type":"GO_TERM","name":"regulation of peptidyl-L-cysteine S-palmitoylation","canonical_id":"go:GO:1902662","description":"\"Any process that modulates the frequency, rate or extent of peptidyl-L-cysteine S-palmitoylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23444136]","metadata":null},{"id":"73741cdda882477c9b644f14ecebda04","type":"GO_TERM","name":"regulation of peptidyl-cysteine S-nitrosylation","canonical_id":"go:GO:2000169","description":"\"Any process that modulates the frequency, rate or extent of peptidyl-cysteine S-nitrosylation.\" [GOC:obol]","metadata":null},{"id":"9809eee197a54b739d64e6e56a2e890c","type":"GO_TERM","name":"regulation of peptidyl-lysine acetylation","canonical_id":"go:GO:2000756","description":"\"Any process that modulates the frequency, rate or extent of peptidyl-lysine acetylation.\" [GOC:obol]","metadata":null},{"id":"eb63c0c0131341d9905031b491dbd72b","type":"GO_TERM","name":"regulation of peptidyl-lysine crotonylation","canonical_id":"go:GO:0120093","description":"\"Any process that modulates the frequency, rate or extent of crotonylation of a lysine residue in a protein.\" [PMID:28803779]","metadata":null},{"id":"6c36c7e19943403b81ef86c8196bbf6d","type":"GO_TERM","name":"regulation of peptidyl-serine phosphorylation","canonical_id":"go:GO:0033135","description":"\"Any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-serine.\" [GOC:mah]","metadata":null},{"id":"1343b9ee2bfb4398b59553ff2f39c70a","type":"GO_TERM","name":"regulation of peptidyl-serine phosphorylation of STAT protein","canonical_id":"go:GO:0033139","description":"\"Any process that modulates the frequency, rate or extent of the phosphorylation of a serine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:mah]","metadata":null},{"id":"4af3e72b72d04e8da6cf7aa6450974c4","type":"GO_TERM","name":"regulation of peptidyl-threonine phosphorylation","canonical_id":"go:GO:0010799","description":"\"Any process that modulates the frequency, rate or extent of peptidyl-threonine phosphorylation. Peptidyl-threonine phosphorylation is the phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"89d9600d450f424999a759579ff4c5f0","type":"GO_TERM","name":"regulation of peptidyl-tyrosine autophosphorylation","canonical_id":"go:GO:1900084","description":"\"Any process that modulates the frequency, rate or extent of peptidyl-tyrosine autophosphorylation.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"6300d7d9a8b4416bbd837e29cc85c7af","type":"GO_TERM","name":"regulation of peptidyl-tyrosine phosphorylation","canonical_id":"go:GO:0050730","description":"\"Any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.\" [GOC:ai]","metadata":null},{"id":"818e1ec3fce14715aa9987e7f65cd51e","type":"GO_TERM","name":"regulation of pericentric heterochromatin formation","canonical_id":"go:GO:0090052","description":"\"Any process that modulates the frequency, rate or extent of heterochromatin formation at the centromere. Chromatin silencing at the centromere is the repression of transcription of centromeric DNA by altering the structure of chromatin.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"42366ef9c8be4bec956f2979ccd0a7ad","type":"GO_TERM","name":"regulation of peripheral B cell anergy","canonical_id":"go:GO:0002917","description":"\"Any process that modulates the frequency, rate, or extent of peripheral B cell anergy.\" [GOC:add]","metadata":null},{"id":"3827f28825154f7e9348eef26de2b777","type":"GO_TERM","name":"regulation of peripheral B cell deletion","canonical_id":"go:GO:0002908","description":"\"Any process that modulates the frequency, rate, or extent of peripheral B cell deletion.\" [GOC:add]","metadata":null},{"id":"a05ada374bf74c23bee42dd12c80221e","type":"GO_TERM","name":"regulation of peripheral T cell tolerance induction","canonical_id":"go:GO:0002849","description":"\"Any process that modulates the frequency, rate, or extent of peripheral T cell tolerance induction.\" [GOC:add]","metadata":null},{"id":"293b776347e94d9e85a60e804f1ccb85","type":"GO_TERM","name":"regulation of peripheral tolerance induction","canonical_id":"go:GO:0002658","description":"\"Any process that modulates the frequency, rate, or extent of peripheral tolerance induction.\" [GOC:add]","metadata":null},{"id":"041614ab62c64b4d928c18187337c2e6","type":"GO_TERM","name":"regulation of peroxisome organization","canonical_id":"go:GO:1900063","description":"\"Any process that modulates the frequency, rate or extent of peroxisome organization.\" [GOC:TermGenie, PMID:7500953]","metadata":null},{"id":"d9e524a5bf75440fa1bc48b88c5b7144","type":"GO_TERM","name":"regulation of peroxisome proliferator activated receptor signaling pathway","canonical_id":"go:GO:0035358","description":"\"Any process that modulates the frequency, rate or extent of the peroxisome proliferator activated receptor signaling pathway.\" [GOC:bf]","metadata":null},{"id":"ce1ccce9799848c785a0b6918800ddf6","type":"GO_TERM","name":"regulation of peroxisome size","canonical_id":"go:GO:0044375","description":"\"Any process that modulates the volume of a peroxisome, a small, membrane-bounded organelle that uses dioxygen (O2) to oxidize organic molecules.\" [GOC:jl]","metadata":null},{"id":"06330cb7cbb943a8985334428e208245","type":"GO_TERM","name":"regulation of phagocytosis","canonical_id":"go:GO:0050764","description":"\"Any process that modulates the frequency, rate or extent of phagocytosis, the process in which phagocytes engulf external particulate material.\" [GOC:ai]","metadata":null},{"id":"746bdd20071c4dc2a515f1dd97f97e29","type":"GO_TERM","name":"regulation of phagocytosis, engulfment","canonical_id":"go:GO:0060099","description":"\"Any process that modulates the frequency, rate or extent of the internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis.\" [GOC:dph]","metadata":null},{"id":"03f015912e70457ba880ff9a82752cab","type":"GO_TERM","name":"regulation of phagosome maturation","canonical_id":"go:GO:1905162","description":"\"Any process that modulates the frequency, rate or extent of phagosome maturation.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:16908865, PMID:23303671]","metadata":null},{"id":"793cce5f432f4d36af6bfff553f5eb72","type":"GO_TERM","name":"regulation of phenazine biosynthetic process","canonical_id":"go:GO:1900980","description":"\"Any process that modulates the frequency, rate or extent of phenazine biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2eb1061b82014ed78a867674cb098451","type":"GO_TERM","name":"regulation of phenotypic switching","canonical_id":"go:GO:1900239","description":"\"Any process that modulates the frequency, rate or extent of phenotypic switching.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"edc63de690a240689f1c172cd9dc2f59","type":"GO_TERM","name":"regulation of phenylpropanoid metabolic process","canonical_id":"go:GO:2000762","description":"\"Any process that modulates the frequency, rate or extent of phenylpropanoid metabolic process.\" [GOC:obol]","metadata":null},{"id":"4b835211673846fa9694d30170507087","type":"GO_TERM","name":"regulation of pheromone response MAPK cascade","canonical_id":"go:GO:0180039","description":"\"Any process that modulates the frequency, rate or extent of a pheromone response MAPK cascade.\" [GOC:vw]","metadata":null},{"id":"bd74b6165fbd43c98ef80fd527a17f17","type":"GO_TERM","name":"regulation of phialide development","canonical_id":"go:GO:0070805","description":"\"Any process that modulates the frequency, rate or extent of phialide development, a process that leads to the formation of phialides. Phialides are specialized cells that bud from the ends of metulae on the conidiophore tip.\" [GOC:mah]","metadata":null},{"id":"ff03749f3f4145fa9a4528bcb9cc442e","type":"GO_TERM","name":"regulation of phosphatase activity","canonical_id":"go:GO:0010921","description":"\"Any process that modulates the rate or frequency of phosphatase activity. Phosphatases catalyze the hydrolysis of phosphoric monoesters, releasing phosphate.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"f5f593bc4d8441fd9631e20c49204ca1","type":"GO_TERM","name":"regulation of phosphate transmembrane transport","canonical_id":"go:GO:2000185","description":"\"Any process that modulates the frequency, rate or extent of phosphate transmembrane transport.\" [GOC:obol]","metadata":null},{"id":"0da0d43a4056461595054a72ab249ae2","type":"GO_TERM","name":"regulation of phosphate transport","canonical_id":"go:GO:0010966","description":"\"Any process that modulates the frequency, rate or extent of phosphate transport. Phosphate transport is the directed movement of phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"01a06509ba024a26867e49bbf9dda58f","type":"GO_TERM","name":"regulation of phosphatidic acid biosynthetic process","canonical_id":"go:GO:1905693","description":"\"Any process that modulates the frequency, rate or extent of phosphatidic acid biosynthetic process.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:23767959]","metadata":null},{"id":"bac2b53b60e046ac89e567afa2a75b5a","type":"GO_TERM","name":"regulation of phosphatidylcholine biosynthetic process","canonical_id":"go:GO:2001245","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylcholine biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"83c0587905f14cc49f0827c4eaee712f","type":"GO_TERM","name":"regulation of phosphatidylcholine catabolic process","canonical_id":"go:GO:0010899","description":"\"Any process that modulates the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"c4931fb139dd414e91460d33d7c297c7","type":"GO_TERM","name":"regulation of phosphatidylcholine metabolic process","canonical_id":"go:GO:0150172","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylcholine metabolic process.\" [GOC:aruk, GOC:bc, PMID:30074985]","metadata":null},{"id":"31602656c6cc4e57b2fec8a0b715a97b","type":"GO_TERM","name":"regulation of phosphatidylethanolamine metabolic process","canonical_id":"go:GO:0150175","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylethanolamine metabolic process.\" [GOC:aruk, GOC:bc, PMID:30074985]","metadata":null},{"id":"30b92e6cb8a442678e1cc997fa83873f","type":"GO_TERM","name":"regulation of phosphatidylglycerol biosynthetic process","canonical_id":"go:GO:1901351","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylglycerol biosynthetic process.\" [GOC:dgf, GOC:TermGenie, PMID:12869188]","metadata":null},{"id":"e0d734407bed43159c065a8d5139c682","type":"GO_TERM","name":"regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction","canonical_id":"go:GO:0051896","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction.\" [GOC:ai]","metadata":null},{"id":"f8ff81070d3541e993705e8ee11f841d","type":"GO_TERM","name":"regulation of phosphatidylinositol biosynthetic process","canonical_id":"go:GO:0010511","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phosphatidylinositol.\" [GOC:dph, GOC:tb, GOC:vw]","metadata":null},{"id":"d8a271d51dd34ec5918ea850fe5f749c","type":"GO_TERM","name":"regulation of phosphatidylinositol dephosphorylation","canonical_id":"go:GO:0060304","description":"\"Any process that modulates the frequency, rate or extent of the chemical reaction involving the removal of one or more phosphate groups from a phosphatidylinositol.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7d206cdc2770477db64bde543a727602","type":"GO_TERM","name":"regulation of phosphatidylserine biosynthetic process","canonical_id":"go:GO:1900468","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylserine biosynthetic process.\" [GOC:dgf, GOC:TermGenie, PMID:8056324, PMID:8614637]","metadata":null},{"id":"8f89ef9d84b64fd6b62bba021a04aaa9","type":"GO_TERM","name":"regulation of phosphatidylserine exposure on apoptotic cell surface","canonical_id":"go:GO:1905780","description":"\"Any process that modulates the frequency, rate or extent of phosphatidylserine exposure on apoptotic cell surface.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:17401362]","metadata":null},{"id":"391ea378812d47e7bf0e0f8a453e30d2","type":"GO_TERM","name":"regulation of phospholipase C-activating G protein-coupled receptor signaling pathway","canonical_id":"go:GO:1900736","description":"\"Any process that modulates the frequency, rate or extent of phospholipase C-activating G protein-coupled receptor signaling pathway.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"b5c604eba50d4501a6490aba06f8d253","type":"GO_TERM","name":"regulation of phospholipase activity","canonical_id":"go:GO:0010517","description":"\"Any process that modulates the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"fd9c2e06fb53452187c3246cd49f645b","type":"GO_TERM","name":"regulation of phospholipid biosynthetic process","canonical_id":"go:GO:0071071","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.\" [GOC:mah]","metadata":null},{"id":"74ebc73e2a314bf9b5ca040d57014c8d","type":"GO_TERM","name":"regulation of phospholipid catabolic process","canonical_id":"go:GO:0060696","description":"\"Any process that modulates the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"daed3796814f4784a3fc51f4e64be253","type":"GO_TERM","name":"regulation of phospholipid efflux","canonical_id":"go:GO:1902994","description":"\"Any process that modulates the frequency, rate or extent of phospholipid efflux.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:12042316]","metadata":null},{"id":"c7b3fc0bd3994006a027b0c58dd3b665","type":"GO_TERM","name":"regulation of phospholipid metabolic process","canonical_id":"go:GO:1903725","description":"\"Any process that modulates the frequency, rate or extent of phospholipid metabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:10657240]","metadata":null},{"id":"76c1dc3ba2b341abb3c6ff51f4c54afd","type":"GO_TERM","name":"regulation of phospholipid translocation","canonical_id":"go:GO:0061091","description":"\"Any process that modulates the frequency, rate or extent of the translocation, or flipping, of phospholipid molecules from one monolayer of a membrane bilayer to the opposite monolayer.\" [GOC:dph, GOC:jh, GOC:tb, PMID:19966303]","metadata":null},{"id":"2b2539a5a120452280073ce784323f43","type":"GO_TERM","name":"regulation of phospholipid transport","canonical_id":"go:GO:2001138","description":"\"Any process that modulates the frequency, rate or extent of phospholipid transport.\" [GOC:obol]","metadata":null},{"id":"643bb0947ff44f8ea91ea81f89543acf","type":"GO_TERM","name":"regulation of phosphorelay signal transduction system","canonical_id":"go:GO:0070297","description":"\"Any process that modulates the frequency, rate or extent of signal transduction via a phosphorelay signal transduction system.\" [GOC:mah]","metadata":null},{"id":"a669d8ba30b34cbbb692df6c970f76d3","type":"GO_TERM","name":"regulation of phosphorus metabolic process","canonical_id":"go:GO:0051174","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving phosphorus or compounds containing phosphorus.\" [GOC:ai]","metadata":null},{"id":"16517c8fcd334f0ba9b34276f3409769","type":"GO_TERM","name":"regulation of phosphorus utilization","canonical_id":"go:GO:0006795","description":"\"Any process that modulates the frequency, rate or extent of phosphorus utilization.\" [GOC:curators]","metadata":null},{"id":"2c7b423ed9d4428c8cb3ffceec5d986e","type":"GO_TERM","name":"regulation of phosphorylation","canonical_id":"go:GO:0042325","description":"\"Any process that modulates the frequency, rate or extent of addition of phosphate groups into a molecule.\" [GOC:jl]","metadata":null},{"id":"ec05bf1eed5f4a06bf1cbd44e9f26530","type":"GO_TERM","name":"regulation of photomorphogenesis","canonical_id":"go:GO:0010099","description":"\"Any process that modulates the rate or extent of photomorphogenesis.\" [GOC:tb]","metadata":null},{"id":"2607c625e3254130840a03d59dfa941e","type":"GO_TERM","name":"regulation of photoperiodism, flowering","canonical_id":"go:GO:2000028","description":"\"Any process that modulates the frequency, rate or extent of photoperiodism, flowering.\" [GOC:obol]","metadata":null},{"id":"61b27cdafb344a3f988bcf1a37a06513","type":"GO_TERM","name":"regulation of photoreceptor cell axon guidance","canonical_id":"go:GO:2000289","description":"\"Any process that modulates the frequency, rate or extent of photoreceptor cell axon guidance.\" [GOC:mah]","metadata":null},{"id":"7ce5598610a746a79475baca44e27ee8","type":"GO_TERM","name":"regulation of photoreceptor cell differentiation","canonical_id":"go:GO:0046532","description":"\"Any process that modulates the frequency, rate or extent of photoreceptor cell differentiation. An example of this process is found in Drosophila melanogaster.\" [GOC:curators]","metadata":null},{"id":"1639ce3f37ea41f3a9f9ebca77ace17e","type":"GO_TERM","name":"regulation of photorespiration","canonical_id":"go:GO:0080093","description":"\"Any process that modulates the rate, frequency or extent of photorespiration. Photorespiration is a light-dependent catabolic process occurring concomitantly with photosynthesis in plants (especially C3 plants) whereby dioxygen (O2) is consumed and carbon dioxide (CO2) is evolved.\" [GOC:tb]","metadata":null},{"id":"ff8d2d6f1c274855a93f89fdf83c5216","type":"GO_TERM","name":"regulation of photosynthesis","canonical_id":"go:GO:0010109","description":"\"Any process that modulates the frequency, rate or extent of photosynthesis.\" [GOC:sm]","metadata":null},{"id":"eb4b6d673cd94130959597dee9869a53","type":"GO_TERM","name":"regulation of photosynthesis, dark reaction","canonical_id":"go:GO:0010110","description":"\"Any process that modulates the frequency, rate or extent of photosynthesis dark reaction.\" [GOC:sm]","metadata":null},{"id":"c76bd3438a814223a62f2dbdfa9b8914","type":"GO_TERM","name":"regulation of photosynthesis, light reaction","canonical_id":"go:GO:0042548","description":"\"Any process that modulates the frequency, rate or extent of the light-dependent reaction of photosynthesis.\" [GOC:jl]","metadata":null},{"id":"cfb26113d67a4cea9be9be5ffb8926b2","type":"GO_TERM","name":"regulation of phragmoplast microtubule organization","canonical_id":"go:GO:2000694","description":"\"Any process that modulates the frequency, rate or extent of phragmoplast microtubule organization.\" [GOC:obol]","metadata":null},{"id":"61c54cebd3c44baca9ad4f2c2f8939c0","type":"GO_TERM","name":"regulation of phytol biosynthetic process","canonical_id":"go:GO:1904963","description":"\"Any process that modulates the frequency, rate or extent of phytol biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24275650]","metadata":null},{"id":"785d8f2e1c9844e08b1629ec11dd73e5","type":"GO_TERM","name":"regulation of piRNA transcription","canonical_id":"go:GO:0140542","description":"\"Any process that modulates the frequency, rate or extent of the synthesis of a piRNA.\" [PMID:28847004]","metadata":null},{"id":"8f94778f0a864b53b389f32d67e26c88","type":"GO_TERM","name":"regulation of pigment cell differentiation","canonical_id":"go:GO:0050932","description":"\"Any process that modulates the frequency, rate or extent of pigmented cell differentiation.\" [GOC:ai]","metadata":null},{"id":"cba1dd25bbf549fc86d50a058655951c","type":"GO_TERM","name":"regulation of pigmentation","canonical_id":"go:GO:0120305","description":"\"Any process that modulates the frequency, rate or extent of the deposition or modulates the distribution of coloring matter in an organism.\" [GOC:krc]","metadata":null},{"id":"c6a451d1946c4bf68dafb06a4fc5b1dc","type":"GO_TERM","name":"regulation of pinocytosis","canonical_id":"go:GO:0048548","description":"\"Any process that modulates the frequency, rate or extent of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes.\" [GOC:curators]","metadata":null},{"id":"2530f71cfdad4c819762d2549f343b31","type":"GO_TERM","name":"regulation of placenta blood vessel development","canonical_id":"go:GO:0110079","description":"\"Any process that modulates the frequency, rate or extent of placenta blood vessel development.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:27748453]","metadata":null},{"id":"5e82fedd50c54c5e879e287bd678098a","type":"GO_TERM","name":"regulation of plant epidermal cell differentiation","canonical_id":"go:GO:1903888","description":"\"Any process that modulates the frequency, rate or extent of plant epidermal cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:123345]","metadata":null},{"id":"f5dd51ee5eb44e33847cc5e7489f269a","type":"GO_TERM","name":"regulation of plant organ formation","canonical_id":"go:GO:1905428","description":"\"Any process that modulates the frequency, rate or extent of plant organ formation.\" [GO_REF:0000058, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"31189615e8a041a2ad704048e1938e87","type":"GO_TERM","name":"regulation of plant organ morphogenesis","canonical_id":"go:GO:1905421","description":"\"Any process that modulates the frequency, rate or extent of plant organ morphogenesis.\" [GO_REF:0000058, GOC:tb, GOC:TermGenie]","metadata":null},{"id":"d9543ecf4437426bad0ee3d931d0f275","type":"GO_TERM","name":"regulation of plant-type cell wall cellulose biosynthetic process","canonical_id":"go:GO:2001009","description":"\"Any process that modulates the frequency, rate or extent of plant-type cell wall cellulose biosynthetic process.\" [GOC:mengo_curators]","metadata":null},{"id":"ef38e4f6fab8430ea341dbd92575fffe","type":"GO_TERM","name":"regulation of plant-type cell wall cellulose catabolic process","canonical_id":"go:GO:2000939","description":"\"Any process that modulates the frequency, rate or extent of plant-type cell wall cellulose catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"430ab16c2fa14dbf96a77d352bb818bc","type":"GO_TERM","name":"regulation of plant-type cell wall organization or biogenesis","canonical_id":"go:GO:0080157","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving plant-type cell wall organization or biogenesis. Plant-type cell wall organization or biogenesis is a process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cellulose- and pectin-containing cell wall.\" [PMID:20530756]","metadata":null},{"id":"e84c5a06403a459ab018a58b7139385f","type":"GO_TERM","name":"regulation of plant-type hypersensitive response","canonical_id":"go:GO:0010363","description":"\"Any endogenous process that modulates the frequency, rate or extent of the plant hypersensitive response.\" [PMID:16255244]","metadata":null},{"id":"30e2869cd4324332b126e1097866f6c0","type":"GO_TERM","name":"regulation of plasma cell differentiation","canonical_id":"go:GO:1900098","description":"\"Any process that modulates the frequency, rate or extent of plasma cell differentiation.\" [GOC:TermGenie]","metadata":null},{"id":"cbfef27e3fcb4bab91b24554e3447dcd","type":"GO_TERM","name":"regulation of plasma kallikrein-kinin cascade","canonical_id":"go:GO:0002529","description":"\"Any process that modulates the frequency, rate, or extent of the plasma kallikrein-kinin cascade.\" [GOC:add]","metadata":null},{"id":"33ed6851dd6f4d20a1b089f2b35cf524","type":"GO_TERM","name":"regulation of plasma lipoprotein oxidation","canonical_id":"go:GO:0034444","description":"\"Any process that modulates the frequency, rate or extent of lipoprotein oxidation, occurring in the blood plasma.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"111506e061344d50a3354cc3dc5dd307","type":"GO_TERM","name":"regulation of plasma lipoprotein particle levels","canonical_id":"go:GO:0097006","description":"\"Any process involved in the maintenance of internal levels of plasma lipoprotein particles within an organism.\" [GOC:BHF]","metadata":null},{"id":"25b9e164dfea4a6fa44c5970e764462c","type":"GO_TERM","name":"regulation of plasma membrane bounded cell projection assembly","canonical_id":"go:GO:0120032","description":"\"Any process that modulates the rate, frequency, or extent of plasma membrane bounded cell projection assembly.\" [GOC:krc]","metadata":null},{"id":"a75014db24234c4eb98f02fbabaad0d8","type":"GO_TERM","name":"regulation of plasma membrane bounded cell projection organization","canonical_id":"go:GO:0120035","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of plasma membrane bounded cell projections.\" [GOC:krc]","metadata":null},{"id":"c14e5d7971034c619ea8caae3323b39c","type":"GO_TERM","name":"regulation of plasma membrane organization","canonical_id":"go:GO:1903729","description":"\"Any process that modulates the frequency, rate or extent of plasma membrane organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:24514900]","metadata":null},{"id":"5e6cf54797144e98bc0575c56e731881","type":"GO_TERM","name":"regulation of plasma membrane raft polarization","canonical_id":"go:GO:1903906","description":"\"Any process that modulates the frequency, rate or extent of plasma membrane raft polarization.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"fba6dadb23144af8a6ccf7881c615085","type":"GO_TERM","name":"regulation of plasma membrane repair","canonical_id":"go:GO:1905684","description":"\"Any process that modulates the frequency, rate or extent of plasma membrane repair.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:22940583]","metadata":null},{"id":"bab9a168d7e0456082840d09d20f98cb","type":"GO_TERM","name":"regulation of plasma membrane sterol distribution","canonical_id":"go:GO:0097036","description":"\"Any process that modulates the proportions or spatial arrangement of sterols in the plasma membrane.\" [GOC:mah, PMID:18441123, PMID:20823909]","metadata":null},{"id":"125ff3be3dd54a03a30d21486c6ea6fe","type":"GO_TERM","name":"regulation of plasmacytoid dendritic cell antigen processing and presentation","canonical_id":"go:GO:0002610","description":"\"Any process that modulates the frequency, rate, or extent of plasmacytoid dendritic cell antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"5a57520c3a074298882fdac8d0cd2930","type":"GO_TERM","name":"regulation of plasmacytoid dendritic cell cytokine production","canonical_id":"go:GO:0002736","description":"\"Any process that modulates the frequency, rate, or extent of plasmacytoid dendritic cell cytokine production.\" [GOC:add]","metadata":null},{"id":"4a14d97c4aba49b68b91c4b4f9e1283d","type":"GO_TERM","name":"regulation of plasmatocyte differentiation","canonical_id":"go:GO:0045613","description":"\"Any process that modulates the frequency, rate or extent of plasmatocyte differentiation.\" [GOC:curators]","metadata":null},{"id":"aeaa45e2c65647518a174f9baf34d79b","type":"GO_TERM","name":"regulation of plasminogen activation","canonical_id":"go:GO:0010755","description":"\"Any process that modulates the rate, frequency or extent of plasminogen activation. Plasminogen activation is the process in which plasminogen is processed to plasmin.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d89a226d4d524228b92a188e9e132f6b","type":"GO_TERM","name":"regulation of platelet activation","canonical_id":"go:GO:0010543","description":"\"Any process that modulates the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"1ba9016550fa4e0480ee0ca0f7f65aa2","type":"GO_TERM","name":"regulation of platelet aggregation","canonical_id":"go:GO:0090330","description":"\"Any process that modulates the rate, frequency or extent of platelet aggregation. Platelet aggregation is the adhesion of one platelet to one or more other platelets via adhesion molecules.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b6a182f021884176a3baf3641526bd3c","type":"GO_TERM","name":"regulation of platelet formation","canonical_id":"go:GO:1905219","description":"\"Any process that modulates the frequency, rate or extent of platelet formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:10606160]","metadata":null},{"id":"a7b94451dc924e6399bacae3bb375bab","type":"GO_TERM","name":"regulation of platelet rolling","canonical_id":"go:GO:0160017","description":"\"Any process that modulates the frequency, rate or extent of platelet rolling.\" [GO_REF:0000058, GOC:sl]","metadata":null},{"id":"2b2b536e46a54cc2959232e46331af04","type":"GO_TERM","name":"regulation of platelet-derived growth factor production","canonical_id":"go:GO:0090361","description":"\"Any process that modulates the rate, frequency, or extent of the appearance of any platelet-derived growth factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF]","metadata":null},{"id":"3b3473259e4c4fc98d35166e081cff4a","type":"GO_TERM","name":"regulation of platelet-derived growth factor receptor signaling pathway","canonical_id":"go:GO:0010640","description":"\"Any process that modulates the frequency, rate or extent of the platelet-derived growth factor receptor signaling pathway.\" [GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"193cfae2709f4e44b30b80d226b80fed","type":"GO_TERM","name":"regulation of platelet-derived growth factor receptor-alpha signaling pathway","canonical_id":"go:GO:2000583","description":"\"Any process that modulates the frequency, rate or extent of platelet-derived growth factor receptor-alpha signaling pathway.\" [GOC:obol]","metadata":null},{"id":"3f60fad9010a43deadb63b9671219960","type":"GO_TERM","name":"regulation of platelet-derived growth factor receptor-beta signaling pathway","canonical_id":"go:GO:2000586","description":"\"Any process that modulates the frequency, rate or extent of platelet-derived growth factor receptor-beta signaling pathway.\" [GOC:obol]","metadata":null},{"id":"730955f4da1c409f96c502f9b54f27a1","type":"GO_TERM","name":"regulation of plus-end directed microtubule sliding","canonical_id":"go:GO:0062169","description":"\"Any process that mediates the frequency, rate, or extent of plus-end directed microtubule sliding.\" [PMID:21892183]","metadata":null},{"id":"50275e2e64aa4c2087b8a34f0f45c613","type":"GO_TERM","name":"regulation of podocyte apoptotic process","canonical_id":"go:GO:1904633","description":"\"Any process that modulates the frequency, rate or extent of glomerular visceral epithelial cell apoptotic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:23692924]","metadata":null},{"id":"0c325c4301274690840d07e8790fe14d","type":"GO_TERM","name":"regulation of podosome assembly","canonical_id":"go:GO:0071801","description":"\"Any process that modulates the frequency, rate or extent of podosome assembly.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"16bdfc0e3ea240b3b31e03e6d11bdb39","type":"GO_TERM","name":"regulation of polarized epithelial cell differentiation","canonical_id":"go:GO:0030860","description":"\"Any process that modulates the frequency, rate or extent of polarized epithelial cell differentiation.\" [GOC:mah]","metadata":null},{"id":"05fcd0c453bb4dcd8d94f25e29fed6c2","type":"GO_TERM","name":"regulation of pollen tube growth","canonical_id":"go:GO:0080092","description":"\"Any process that modulates the frequency, rate or extent of pollen tube growth.\" [PMID:19208902]","metadata":null},{"id":"15602534edeb485f9cad97e2ef8f721e","type":"GO_TERM","name":"regulation of poly(3-hydroxyalkanoate) biosynthetic process","canonical_id":"go:GO:0043286","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of poly(3-hydroxyalkanoates), polyesters of 3-hydroxyacids produced as intracellular granules by a large variety of bacteria.\" [GOC:jl]","metadata":null},{"id":"30529853e14045f08ca55bedcfa2c816","type":"GO_TERM","name":"regulation of polyamine biosynthetic process","canonical_id":"go:GO:0010967","description":"\"Any process that modulates the frequency, rate or extent of polyamine biosynthesis. Polyamine biosynthesis is the chemical reactions and pathways resulting in the formation of polyamines, any organic compound containing two or more amino groups.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8d47c7a604af4fb685e45fe4fdb71820","type":"GO_TERM","name":"regulation of polyamine transmembrane transport","canonical_id":"go:GO:1902267","description":"\"Any process that modulates the frequency, rate or extent of polyamine transmembrane transport.\" [GOC:TermGenie, PMID:23755272]","metadata":null},{"id":"cb45daa2d2014867bd910a6cdde1e2da","type":"GO_TERM","name":"regulation of polyketide biosynthetic process","canonical_id":"go:GO:1900732","description":"\"Any process that modulates the frequency, rate or extent of polyketide biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"c63ab43a9feb4b87bc1c217ce22b822a","type":"GO_TERM","name":"regulation of polysaccharide biosynthetic process","canonical_id":"go:GO:0032885","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of polysaccharides.\" [GOC:mah]","metadata":null},{"id":"15ab1bff892f40c6b2919131a7b34086","type":"GO_TERM","name":"regulation of polysaccharide metabolic process","canonical_id":"go:GO:0032881","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving polysaccharides.\" [GOC:mah]","metadata":null},{"id":"be5d74040c8b471f92f5ee4e33a7d7da","type":"GO_TERM","name":"regulation of positive chemotaxis","canonical_id":"go:GO:0050926","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.\" [GOC:ai]","metadata":null},{"id":"354d727d3a864e4fa60cc4b5b6bb0b0a","type":"GO_TERM","name":"regulation of positive chemotaxis to cAMP","canonical_id":"go:GO:0061118","description":"\"Any process that modulates the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP.\" [GOC:dph]","metadata":null},{"id":"a291805e3ceb494ba6376151723c1652","type":"GO_TERM","name":"regulation of positive chemotaxis to cAMP by DIF-1","canonical_id":"go:GO:0061120","description":"\"Any process that modulates the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of DIF-1. DIF-1 is a chlorinated alkylphenone.\" [GOC:dph]","metadata":null},{"id":"95dbc5f0fbfa4d57970acaed7caf6d0e","type":"GO_TERM","name":"regulation of positive chemotaxis to cAMP by DIF-2","canonical_id":"go:GO:0061121","description":"\"Any process that modulates the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of DIF-2. DIF-2 is a chlorinated alkylphenone.\" [GOC:dph]","metadata":null},{"id":"e9d9f8c494fa4f15beb56c1275402b9f","type":"GO_TERM","name":"regulation of positive chemotaxis to cAMP by chlorinated alkylphenone","canonical_id":"go:GO:0061119","description":"\"Any process that modulates the rate, frequency, or extent of directed movement of a motile cell or organism up a concentration gradient of 3',5'-cAMP by the action of a chlorinated alkylphenone. An alkylphenone is an aromatic polyketide with methyl and chlorine substitutions.\" [GOC:dph, PMID:19684855]","metadata":null},{"id":"c7cdfed4cca14ef29a088090e6936c6f","type":"GO_TERM","name":"regulation of positive thymic T cell selection","canonical_id":"go:GO:1902232","description":"\"Any process that modulates the frequency, rate or extent of positive thymic T cell selection.\" [GOC:TermGenie, PMID:22080863]","metadata":null},{"id":"e221e42bc7734ad4a62e70abe3d0d7e0","type":"GO_TERM","name":"regulation of post-embryonic development","canonical_id":"go:GO:0048580","description":"\"Any process that modulates the frequency, rate or extent of post-embryonic development. Post-embryonic development is defined as the process whose specific outcome is the progression of the organism over time, from the completion of embryonic development to the mature structure.\" [GOC:jid]","metadata":null},{"id":"d31635957d06418a9273889095a7d221","type":"GO_TERM","name":"regulation of post-embryonic root development","canonical_id":"go:GO:2000069","description":"\"Any process that modulates the frequency, rate or extent of post-embryonic root development.\" [GOC:obol]","metadata":null},{"id":"f0cdc7296ebd4e30ba347ff8c2defade","type":"GO_TERM","name":"regulation of post-lysosomal vacuole size","canonical_id":"go:GO:0044656","description":"\"Any process that modulates the volume of a post-lysosomal vacuole, a membrane-bounded intracellular vesicle formed late in the endocytic pathway when the pH in the vacuole becomes neutral prior to exocytosis.\" [GOC:rjd, PMID:22008230]","metadata":null},{"id":"4f2193896fbe4a509ea7c2a5ac7f1a1a","type":"GO_TERM","name":"regulation of post-transcriptional gene silencing","canonical_id":"go:GO:0060147","description":"\"Any process that modulates the frequency, rate or extent of the inactivation of gene expression by a posttranscriptional mechanism.\" [GOC:dph]","metadata":null},{"id":"57f9ef4eb7724bb49696194a05ea57e9","type":"GO_TERM","name":"regulation of post-transcriptional gene silencing by regulatory ncRNA","canonical_id":"go:GO:1900368","description":"\"Any process that modulates the frequency, rate or extent of post-transcriptional gene silencing by a non-coding RNA.\" [GOC:kmv, GOC:TermGenie, PMID:22412382]","metadata":null},{"id":"0634caba21704b308430ca3601810f8d","type":"GO_TERM","name":"regulation of post-translational protein modification","canonical_id":"go:GO:1901873","description":"\"Any process that modulates the frequency, rate or extent of post-translational protein modification.\" [GOC:TermGenie, GOC:yaf, PMID:21209915]","metadata":null},{"id":"a47f557253eb4604ab2872b8bb1630e1","type":"GO_TERM","name":"regulation of post-translational protein targeting to membrane, translocation","canonical_id":"go:GO:0120235","description":"\"Any process that modulates the frequency, rate or extent of posttranslational protein translocation through the ER membrane.\" [GOC:krc, GOC:rn, PMID:32513868]","metadata":null},{"id":"df8279d77593401ba204439a27104153","type":"GO_TERM","name":"regulation of postsynapse assembly","canonical_id":"go:GO:0150052","description":"\"Any process that modulates the frequency, rate or extent of postsynapse assembly, the aggregation, arrangement and bonding together of a set of components to form a postsynapse.\" [GOC:aruk, GOC:bc, PMID:16394100, PMID:16672654, PMID:28185854]","metadata":null},{"id":"267192ac0a8e413882b926c46bf58666","type":"GO_TERM","name":"regulation of postsynapse organization","canonical_id":"go:GO:0099175","description":"\"Any process that modulates the physical form of a postsynapse.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"ee0af539b7164c45a865f1983d84bb4f","type":"GO_TERM","name":"regulation of postsynapse to nucleus signaling pathway","canonical_id":"go:GO:1905539","description":"\"Any process that modulates the frequency, rate or extent of postsynapse to nucleus signaling pathway.\" [GO_REF:0000058, GOC:TermGenie, ISBN:9780071120005]","metadata":null},{"id":"d2b854dc38b044628f6c4c20b4352a05","type":"GO_TERM","name":"regulation of postsynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:0099566","description":"\"Any process that regulates the concentration of calcium in the postsynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"5b149f7cf71e443bb5d789a6a89fc264","type":"GO_TERM","name":"regulation of postsynaptic dense core vesicle exocytosis","canonical_id":"go:GO:0150044","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic dense core vesicle exocytosis.\" [GOC:aruk, GOC:bc, PMID:19448629]","metadata":null},{"id":"29addad7bee3498ca981f22db6bcb5d8","type":"GO_TERM","name":"regulation of postsynaptic density assembly","canonical_id":"go:GO:0099151","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic density assembly, the aggregation, arrangement and bonding together of a set of components to form a postsynaptic density.\" [GOC:dos]","metadata":null},{"id":"5e6acf70a6394038b6b77d162444daee","type":"GO_TERM","name":"regulation of postsynaptic density organization","canonical_id":"go:GO:1905874","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic density organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:21887379]","metadata":null},{"id":"f86adc95443f4b8fb04d98c584a1fc6b","type":"GO_TERM","name":"regulation of postsynaptic density protein 95 clustering","canonical_id":"go:GO:1902897","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic density protein 95 clustering.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:10570482]","metadata":null},{"id":"ed1b8a9f5a2f4e9685dea21e21caea05","type":"GO_TERM","name":"regulation of postsynaptic membrane neurotransmitter receptor levels","canonical_id":"go:GO:0099072","description":"\"Any process that regulates the the local concentration of neurotransmitter receptor at the postsynaptic membrane.\" [GOC:dos]","metadata":null},{"id":"7ee3594efd6f4d51aa1718b7f63e5e67","type":"GO_TERM","name":"regulation of postsynaptic membrane organization","canonical_id":"go:GO:1901626","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"bb441df61b92446b8a70d93f6bcb5343","type":"GO_TERM","name":"regulation of postsynaptic membrane potential","canonical_id":"go:GO:0060078","description":"\"Any process that modulates the potential difference across a post-synaptic membrane.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"2c1ce164d30e413da3807ae121f8ed76","type":"GO_TERM","name":"regulation of postsynaptic neurotransmitter receptor diffusion trapping","canonical_id":"go:GO:0150054","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic neurotransmitter receptor diffusion trapping.\" [GOC:aruk, GOC:bc, PMID:20935643]","metadata":null},{"id":"82d775ff0594478c8cd072e3b5624a32","type":"GO_TERM","name":"regulation of postsynaptic neurotransmitter receptor internalization","canonical_id":"go:GO:0099149","description":"\"Any process that modulates the frequency, rate or extent of endocytosis of neurotransmitter receptor at the postsynapse.\" [GOC:ai]","metadata":null},{"id":"13dd589f16b44711bf382b8aad87955b","type":"GO_TERM","name":"regulation of postsynaptic specialization assembly","canonical_id":"go:GO:0099150","description":"\"Any process that modulates the frequency, rate or extent of postsynaptic specialization assembly, the aggregation, arrangement and bonding together of a set of components to form a postsynaptic specialization.\" [GOC:dos]","metadata":null},{"id":"3166d91e9565430eb3cf015228e3a239","type":"GO_TERM","name":"regulation of potassium ion export across plasma membrane","canonical_id":"go:GO:1903764","description":"\"Any process that modulates the frequency, rate or extent of potassium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:19646991]","metadata":null},{"id":"b545dffd10ba457bbc51c9692ca0730d","type":"GO_TERM","name":"regulation of potassium ion import","canonical_id":"go:GO:1903286","description":"\"Any process that modulates the frequency, rate or extent of potassium ion import.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:10636900]","metadata":null},{"id":"3ed779a8265f4700ae2890dea2bfba67","type":"GO_TERM","name":"regulation of potassium ion transmembrane transport","canonical_id":"go:GO:1901379","description":"\"Any process that modulates the frequency, rate or extent of potassium ion transmembrane transport.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"5f741f4ec1e14135baa3070fc76d4553","type":"GO_TERM","name":"regulation of potassium ion transport","canonical_id":"go:GO:0043266","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"b597a549566740e19ec28b472cdd3525","type":"GO_TERM","name":"regulation of potassium:proton exchanging ATPase activity","canonical_id":"go:GO:1904451","description":"\"Any process that modulates the frequency, rate or extent of hydrogen:potassium-exchanging ATPase activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:11897793]","metadata":null},{"id":"bf78e908659b42a5a851ddb23742ad23","type":"GO_TERM","name":"regulation of pre-miRNA processing","canonical_id":"go:GO:2000631","description":"\"Any process that modulates the frequency, rate or extent of pre-microRNA processing.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"701d01e5c8004c6097cf20111554b8e9","type":"GO_TERM","name":"regulation of pre-tubular aggregate formation by cell-cell signaling","canonical_id":"go:GO:0072043","description":"\"Any process that mediates the transfer of information from one cell to another that modulates the rate, frequency, or extent of pre-tubular aggregate formation. Pre-tubular aggregate formation is the cell adhesion process in which mesenchymal cells adhere to one another in the initial stages of the formation of the pre-tubular aggregate, the earliest recognizable structure of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"308156ba092d4d60b5d1190e6773fccc","type":"GO_TERM","name":"regulation of preblastoderm mitotic cell cycle","canonical_id":"go:GO:0007347","description":"\"A cell cycle process that modulates the rate or extent of the progression through the preblastoderm mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"a8f5cd5c99414c15a93ef31be63762aa","type":"GO_TERM","name":"regulation of premature acrosome loss","canonical_id":"go:GO:0061949","description":"\"Any process that modulates the rate, frequency or extent of the discharge, by sperm, of a single, anterior secretory granule before the sperm reaches to the zona pellucida of the oocyte. The process begins with the fusion of the outer acrosomal membrane with the sperm plasma membrane and ends with the exocytosis of the acrosomal contents.\" [PMID:22228629, PMID:23430248]","metadata":null},{"id":"02867d65929f4060881d380044dc1711","type":"GO_TERM","name":"regulation of presynapse assembly","canonical_id":"go:GO:1905606","description":"\"Any process that modulates the frequency, rate or extent of presynapse assembly.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:25533483]","metadata":null},{"id":"3c71f236f54f40d19accb1248b85a64c","type":"GO_TERM","name":"regulation of presynapse organization","canonical_id":"go:GO:0099174","description":"\"Any process that modulates the physical form of a presynapse.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"a8f0cfaaf2e745a2bc08d13cca474baf","type":"GO_TERM","name":"regulation of presynaptic active zone assembly","canonical_id":"go:GO:1905518","description":"\"Any process that modulates the frequency, rate or extent of presynaptic active zone assembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:15797875]","metadata":null},{"id":"6b2ef7f0737147c18e3d0e93270ef7b4","type":"GO_TERM","name":"regulation of presynaptic cytosolic calcium ion concentration","canonical_id":"go:GO:0099509","description":"\"Any process that regulates the concentration of calcium in the presynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"8d5c3daef1da46f59a0b18b77e8824b6","type":"GO_TERM","name":"regulation of presynaptic dense core granule exocytosis","canonical_id":"go:GO:0099161","description":"\"Any process that modulates the frequency, rate or extent of presynaptic dense core granule exocytosis.\" [GOC:dos, PMID:17881523]","metadata":null},{"id":"c2c778b21e044b169773b6c9563e9681","type":"GO_TERM","name":"regulation of presynaptic membrane organization","canonical_id":"go:GO:1901629","description":"\"Any process that modulates the frequency, rate or extent of presynaptic membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"96601fd6e7ad4a87a38dab92c201c8d4","type":"GO_TERM","name":"regulation of presynaptic membrane potential","canonical_id":"go:GO:0099505","description":"\"Any process that modulates the potential difference across a presynaptic membrane.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"3d9c68d8bc5c45968b41fe7744cac278","type":"GO_TERM","name":"regulation of primary cell septum biogenesis","canonical_id":"go:GO:1905756","description":"\"Any process that modulates the frequency, rate or extent of primary cell septum biogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:27898700]","metadata":null},{"id":"b2fb8ec8e6e54cd69ebaafbc64edcb95","type":"GO_TERM","name":"regulation of primary heart field cardioblast proliferation","canonical_id":"go:GO:0003265","description":"\"Any process that modulates the frequency, rate or extent of cardioblast proliferation in the primary heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating. In mammals the primary heart field gives rise to the left ventricle.\" [GOC:mtg_heart, GOC:rl]","metadata":null},{"id":"d3682f8b8ac449df8a19c3b565d4af0d","type":"GO_TERM","name":"regulation of primary metabolic process","canonical_id":"go:GO:0080090","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism involving those compounds formed as a part of the normal anabolic and catabolic processes. These processes take place in most, if not all, cells of the organism.\" [PMID:19211694]","metadata":null},{"id":"94a23bde68d24d37802d991f152fdcdc","type":"GO_TERM","name":"regulation of primary miRNA processing","canonical_id":"go:GO:2000634","description":"\"Any process that modulates the frequency, rate or extent of primary microRNA processing.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"2481db9ea41b42d58f414351338836bd","type":"GO_TERM","name":"regulation of primitive erythrocyte differentiation","canonical_id":"go:GO:0010725","description":"\"Any process that modulates the rate, frequency, or extent of primitive erythrocyte differentiation. Primitive erythrocyte differentiation occurs as part of the process of primitive hemopoiesis.\" [GOC:add, GOC:dph, GOC:tb]","metadata":null},{"id":"02c44aa48f224d6da5c26eab7190ee3d","type":"GO_TERM","name":"regulation of pro-B cell differentiation","canonical_id":"go:GO:2000973","description":"\"Any process that modulates the frequency, rate or extent of pro-B cell differentiation.\" [GOC:obol]","metadata":null},{"id":"467cfd9a146f46a481aeae730832ea16","type":"GO_TERM","name":"regulation of pro-T cell differentiation","canonical_id":"go:GO:2000174","description":"\"Any process that modulates the frequency, rate or extent of pro-T cell differentiation.\" [GOC:BHF]","metadata":null},{"id":"ef197afa7b194975bc69538114046c43","type":"GO_TERM","name":"regulation of proanthocyanidin biosynthetic process","canonical_id":"go:GO:2000029","description":"\"Any process that modulates the frequency, rate or extent of proanthocyanidin biosynthetic process.\" [GOC:obol]","metadata":null},{"id":"0f69d3cd6f9d48d08945e8312527ca3d","type":"GO_TERM","name":"regulation of production of molecular mediator of immune response","canonical_id":"go:GO:0002700","description":"\"Any process that modulates the frequency, rate, or extent of the production of molecular mediator of immune response.\" [GOC:add]","metadata":null},{"id":"4fe6043b4c1043b0badafd1a0fc43203","type":"GO_TERM","name":"regulation of progesterone biosynthetic process","canonical_id":"go:GO:2000182","description":"\"Any process that modulates the frequency, rate or extent of progesterone biosynthetic process.\" [GOC:dph]","metadata":null},{"id":"16c706c5b91a4d0c93269abfad4212ce","type":"GO_TERM","name":"regulation of progesterone secretion","canonical_id":"go:GO:2000870","description":"\"Any process that modulates the frequency, rate or extent of progesterone secretion.\" [GOC:sl]","metadata":null},{"id":"ce1bb148fd60424d8896a6cda69ea7d6","type":"GO_TERM","name":"regulation of programmed cell death","canonical_id":"go:GO:0043067","description":"\"Any process that modulates the frequency, rate or extent of programmed cell death, cell death resulting from activation of endogenous cellular processes.\" [GOC:jl]","metadata":null},{"id":"4d0649b54bc94109bf5e4307516de9bd","type":"GO_TERM","name":"regulation of programmed necrotic cell death","canonical_id":"go:GO:0062098","description":"\"Any process that modulates the frequency, rate or extent of programmed necrotic cell death.\" [GOC:aruk, GOC:rph, PMID:27258785]","metadata":null},{"id":"b6ff0a2711c544c0bd6d7bf39240d125","type":"GO_TERM","name":"regulation of prolactin signaling pathway","canonical_id":"go:GO:1902211","description":"\"Any process that modulates the frequency, rate or extent of prolactin signaling pathway.\" [GOC:TermGenie, PMID:11773439]","metadata":null},{"id":"13b8bad84915497aab8ea316cdac404f","type":"GO_TERM","name":"regulation of proline import across plasma membrane","canonical_id":"go:GO:1902834","description":"\"Any process that modulates the frequency, rate or extent of proline import into cell.\" [GO_REF:0000058, GOC:TermGenie, PMID:24344203]","metadata":null},{"id":"41612960502b4cb39d4c1b4a0f0c8620","type":"GO_TERM","name":"regulation of proline transport","canonical_id":"go:GO:0070881","description":"\"Any process that modulates the frequency, rate or extent of proline transport.\" [GOC:mah]","metadata":null},{"id":"5abebc9b49c142f1a08b44a18d07ee12","type":"GO_TERM","name":"regulation of promoter clearance from RNA polymerase II promoter","canonical_id":"go:GO:0140845","description":"\"A process that modulates the frequency, rate or extent of the transition from the initiation to the elongation phases of transcription by RNA polymerase II.\" [PMID:28248323]","metadata":null},{"id":"32ed6b1d83e842389b1656e3bb26a56e","type":"GO_TERM","name":"regulation of pronephric nephron tubule development","canonical_id":"go:GO:1900206","description":"\"Any process that modulates the frequency, rate or extent of pronephric nephron tubule development.\" [GOC:TermGenie]","metadata":null},{"id":"53560e7896b84e9dbdc9808697ea6efa","type":"GO_TERM","name":"regulation of pronephros size","canonical_id":"go:GO:0035565","description":"\"Any process that modulates the size of a pronephric kidney.\" [GOC:bf]","metadata":null},{"id":"7236b91032df48afa8807776e0e09283","type":"GO_TERM","name":"regulation of prostaglandin biosynthetic process","canonical_id":"go:GO:0031392","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.\" [GOC:mah]","metadata":null},{"id":"22e5758f3e614bd8893b5e33a9ee8c27","type":"GO_TERM","name":"regulation of prostaglandin catabolic process","canonical_id":"go:GO:1905828","description":"\"Any process that modulates the frequency, rate or extent of prostaglandin catabolic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:12432938]","metadata":null},{"id":"0a8a5ac7068745d0b4bf3c87de29826f","type":"GO_TERM","name":"regulation of prostaglandin secretion","canonical_id":"go:GO:0032306","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of a prostaglandin from a cell.\" [GOC:mah]","metadata":null},{"id":"35bb51d93e244e01850613cc56613fcd","type":"GO_TERM","name":"regulation of prostatic bud formation","canonical_id":"go:GO:0060685","description":"\"Any process that modulates the rate, frequency, or extent of prostatic bud formation, the morphogenetic process in which a region of the fetal urogenital sinus epithelium is specified to become the prostate, resulting in prostate bud outgrowth.\" [GOC:dph]","metadata":null},{"id":"0ccae9eecd6e49deb09ff0811d82b5bb","type":"GO_TERM","name":"regulation of proteasomal protein catabolic process","canonical_id":"go:GO:0061136","description":"\"Any process that modulates the rate, frequency, or extent of the chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"89fe48bf716a4647839a626c190c8b27","type":"GO_TERM","name":"regulation of proteasomal ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0032434","description":"\"Any process that modulates the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.\" [GOC:mah]","metadata":null},{"id":"019fc24632234c5b95a3bbf223f7d469","type":"GO_TERM","name":"regulation of proteasome assembly","canonical_id":"go:GO:0090364","description":"\"Any process that modulates the rate, frequency, or extent of the aggregation, arrangement and bonding together of a mature, active proteasome complex.\" [GOC:dph, GOC:elh, GOC:tb]","metadata":null},{"id":"f223787c3add4af5b8940ff8dd730e12","type":"GO_TERM","name":"regulation of protection from non-homologous end joining at telomere","canonical_id":"go:GO:1905764","description":"\"Any process that modulates the frequency, rate or extent of protection from non-homologous end joining at telomere.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:14690602]","metadata":null},{"id":"c894a767594349109f8748f54ff8abed","type":"GO_TERM","name":"regulation of protein ADP-ribosylation","canonical_id":"go:GO:0010835","description":"\"Any process that modulates the frequency, rate or extent of protein ADP-ribosylation. Protein ADP-ribosylation is the transfer, from NAD, of ADP-ribose to protein amino acids.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"02e5ae22f0854b5e9b15489d82a9785f","type":"GO_TERM","name":"regulation of protein K48-linked deubiquitination","canonical_id":"go:GO:1903093","description":"\"Any process that modulates the frequency, rate or extent of protein K48-linked deubiquitination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"e37d1108442442b6b542dd1e7d95ef5e","type":"GO_TERM","name":"regulation of protein K48-linked ubiquitination","canonical_id":"go:GO:0061945","description":"\"Any process that modulates the rate, frequency or extent of protein K-48-linked ubiquitination, a protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is added to a protein. K48-linked ubiquitination targets the substrate protein for degradation.\" [PMID:23460740]","metadata":null},{"id":"2b83eea3ca4e475daf92a8ddf292325a","type":"GO_TERM","name":"regulation of protein K63-linked deubiquitination","canonical_id":"go:GO:1903004","description":"\"Any process that modulates the frequency, rate or extent of protein K63-linked deubiquitination.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:22970133]","metadata":null},{"id":"b7c4c8159a4949d3af5bf36ebecd9329","type":"GO_TERM","name":"regulation of protein K63-linked ubiquitination","canonical_id":"go:GO:1900044","description":"\"Any process that modulates the frequency, rate or extent of protein K63-linked ubiquitination.\" [GOC:TermGenie]","metadata":null},{"id":"99c0a07f719e44d19da0f2f5709bfbbf","type":"GO_TERM","name":"regulation of protein O-linked glycosylation","canonical_id":"go:GO:1904098","description":"\"Any process that modulates the frequency, rate or extent of protein O-linked glycosylation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24509081]","metadata":null},{"id":"5138d6d296cb4270aaa261a6929fdf37","type":"GO_TERM","name":"regulation of protein acetylation","canonical_id":"go:GO:1901983","description":"\"Any process that modulates the frequency, rate or extent of protein acetylation.\" [GOC:TermGenie, PMID:22117195]","metadata":null},{"id":"09024274ac464e349e38febc28647083","type":"GO_TERM","name":"regulation of protein activation cascade","canonical_id":"go:GO:2000257","description":"\"Any process that modulates the frequency, rate or extent of protein activation cascade.\" [GOC:mah]","metadata":null},{"id":"a7229f68cbd14877bc228d6e26d6e0bf","type":"GO_TERM","name":"regulation of protein adenylylation","canonical_id":"go:GO:1900722","description":"\"Any process that modulates the frequency, rate or extent of protein adenylylation.\" [GOC:TermGenie]","metadata":null},{"id":"9d66e203ff984ac3aae0a16203e2276c","type":"GO_TERM","name":"regulation of protein autophosphorylation","canonical_id":"go:GO:0031952","description":"\"Any process that modulates the frequency, rate or extent of addition of the phosphorylation by a protein of one or more of its own residues.\" [GOC:mah]","metadata":null},{"id":"54882d1c98c849bf82da6a4333a26557","type":"GO_TERM","name":"regulation of protein autoubiquitination","canonical_id":"go:GO:1902498","description":"\"Any process that modulates the frequency, rate or extent of protein autoubiquitination.\" [GOC:rb, GOC:TermGenie, PMID:24069405]","metadata":null},{"id":"14fa068c2e404f098e3c06db9489c163","type":"GO_TERM","name":"regulation of protein binding","canonical_id":"go:GO:0043393","description":"\"Any process that modulates the frequency, rate or extent of protein binding.\" [GOC:curators]","metadata":null},{"id":"edddc598a2ad4cbea668aa189b5ebf71","type":"GO_TERM","name":"regulation of protein catabolic process","canonical_id":"go:GO:0042176","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.\" [GOC:curators, GOC:jl]","metadata":null},{"id":"9ac9b7a9f0be4d9190e77235be70eb97","type":"GO_TERM","name":"regulation of protein catabolic process at postsynapse, modulating synaptic transmission","canonical_id":"go:GO:0099576","description":"\"Any process that modulates synaptic transmission by regulating a catabolic process occurring at a postsynapse.\" [GOC:dos]","metadata":null},{"id":"ea210431daf94108bc49e2a6a3402023","type":"GO_TERM","name":"regulation of protein catabolic process at presynapse, modulating synaptic transmission","canonical_id":"go:GO:0099575","description":"\"Any process that modulates synaptic transmission by regulating a catabolic process occurring at a presynapse.\" [GOC:dos]","metadata":null},{"id":"019cfbeabf2f441d818448fda1e2b4d0","type":"GO_TERM","name":"regulation of protein catabolic process at synapse, modulating synaptic transmission","canonical_id":"go:GO:0099574","description":"\"Any process that modulates synaptic transmission by regulating protein degradation at the synapse.\" [GOC:dos]","metadata":null},{"id":"86ed39a014cb4b69a25a2a39d95d0c39","type":"GO_TERM","name":"regulation of protein catabolic process in the vacuole","canonical_id":"go:GO:1904350","description":"\"Any process that modulates the frequency, rate or extent of protein catabolic process in the vacuole.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:25635054]","metadata":null},{"id":"de663c56e3fb4893affbfbc2e95143d8","type":"GO_TERM","name":"regulation of protein complex stability","canonical_id":"go:GO:0061635","description":"\"Any process that affects the structure and integrity of a protein complex by altering the likelihood of its assembly or disassembly.\" [GOC:dph]","metadata":null},{"id":"0329f878da754f62b4359f7ce99d02ac","type":"GO_TERM","name":"regulation of protein deacetylation","canonical_id":"go:GO:0090311","description":"\"Any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [GOC:tb]","metadata":null},{"id":"ca22aed853c144698be614d04166190b","type":"GO_TERM","name":"regulation of protein deneddylation","canonical_id":"go:GO:0060625","description":"\"Any process that modulates the rate, frequency, or extent of protein deneddylation, the removal of a ubiquitin-like protein of the NEDD8 type from a protein.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7ea57e4ddb0e43838510958c4cbdaecd","type":"GO_TERM","name":"regulation of protein depolymerization","canonical_id":"go:GO:1901879","description":"\"Any process that modulates the frequency, rate or extent of protein depolymerization.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:12032137]","metadata":null},{"id":"07964ea4f1fc44f4adefe39c6d37df57","type":"GO_TERM","name":"regulation of protein desumoylation","canonical_id":"go:GO:0060188","description":"\"Any process that modulates the frequency, rate or extent of protein desumoylation. Protein desumoylation is the process in which a SUMO protein (small ubiquitin-related modifier) is cleaved from its target protein.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"180289bd6a5b47ec9d7ed21f0aaa7ba6","type":"GO_TERM","name":"regulation of protein deubiquitination","canonical_id":"go:GO:0090085","description":"\"Any process that modulates the frequency, rate or extent of protein deubiquitination. Protein deubiquitination is the removal of one or more ubiquitin groups from a protein.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"0678e129e8fe4728a7318a2e335b95dc","type":"GO_TERM","name":"regulation of protein export from nucleus","canonical_id":"go:GO:0046825","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of proteins from the nucleus to the cytoplasm.\" [GOC:bf]","metadata":null},{"id":"f25f53694c184499ba1977bb6e13a440","type":"GO_TERM","name":"regulation of protein folding","canonical_id":"go:GO:1903332","description":"\"Any process that modulates the frequency, rate or extent of protein folding.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"375307a97ff3464cb400c3294f704b90","type":"GO_TERM","name":"regulation of protein folding in endoplasmic reticulum","canonical_id":"go:GO:0060904","description":"\"Any process that modulates the rate, frequency or extent of the protein folding process that takes place in the endoplasmic reticulum (ER). Secreted, plasma membrane and organelle proteins are folded in the ER, assisted by chaperones and foldases (protein disulphide isomerases), and additional factors required for optimal folding (ATP, Ca2+ and an oxidizing environment to allow disulfide bond formation).\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8d7fa4607daa417490381fa59d2ef632","type":"GO_TERM","name":"regulation of protein geranylgeranylation","canonical_id":"go:GO:2000539","description":"\"Any process that modulates the frequency, rate or extent of protein geranylgeranylation.\" [GOC:obol]","metadata":null},{"id":"a7799a8d25a141a4ac9e9ec2c15edd0b","type":"GO_TERM","name":"regulation of protein glutathionylation","canonical_id":"go:GO:0010732","description":"\"Any process that modulates the rate, frequency, or extent of protein glutathionylation. Protein glutathionylation is the protein modification process in which a glutathione molecule is added to a protein amino acid through a disulfide linkage.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"f5df7991c2e4462297b14fc64c708494","type":"GO_TERM","name":"regulation of protein homooligomerization","canonical_id":"go:GO:0032462","description":"\"Any process that modulates the frequency, rate or extent of protein homooligomerization.\" [GOC:mah]","metadata":null},{"id":"4cf2f2a5daee473584614ac60109ea07","type":"GO_TERM","name":"regulation of protein homotetramerization","canonical_id":"go:GO:1901093","description":"\"Any process that modulates the frequency, rate or extent of protein homotetramerization.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"38d62d20ec384bf48726034a41f378b7","type":"GO_TERM","name":"regulation of protein import","canonical_id":"go:GO:1904589","description":"\"Any process that modulates the frequency, rate or extent of protein import.\" [GO_REF:0000058, GOC:TermGenie, PMID:11406629]","metadata":null},{"id":"314643202dc7466a939a2588f3a28a64","type":"GO_TERM","name":"regulation of protein import into chloroplast stroma","canonical_id":"go:GO:1904215","description":"\"Any process that modulates the frequency, rate or extent of protein import into chloroplast stroma.\" [GO_REF:0000058, GOC:TermGenie, PMID:25901327]","metadata":null},{"id":"3973e804d5d34a348bd7276f508f2778","type":"GO_TERM","name":"regulation of protein import into nucleus","canonical_id":"go:GO:0042306","description":"\"Any process that modulates the frequency, rate or extent of movement of proteins from the cytoplasm to the nucleus.\" [GOC:jl]","metadata":null},{"id":"754432b2640042b0bc5f3e8224097ad7","type":"GO_TERM","name":"regulation of protein kinase C activity","canonical_id":"go:GO:1900019","description":"\"Any process that modulates the frequency, rate or extent of protein kinase C activity.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"0891f13a07924506a98ebc6102b6a375","type":"GO_TERM","name":"regulation of protein kinase C signaling","canonical_id":"go:GO:0090036","description":"\"Any process that modulates the frequency, rate, or extent of a series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3023da3c33854aba8eed0e03086898b1","type":"GO_TERM","name":"regulation of protein kinase activity","canonical_id":"go:GO:0045859","description":"\"Any process that modulates the frequency, rate or extent of protein kinase activity.\" [GOC:curators]","metadata":null},{"id":"f53c59f5e24e48149fe0a1543908bc1f","type":"GO_TERM","name":"regulation of protein linear polyubiquitination","canonical_id":"go:GO:1902528","description":"\"Any process that modulates the frequency, rate or extent of protein linear polyubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"8ff5423cefe840b2b445b053cc65cef6","type":"GO_TERM","name":"regulation of protein lipidation","canonical_id":"go:GO:1903059","description":"\"Any process that modulates the frequency, rate or extent of protein lipidation.\" [GO_REF:0000058, GOC:rph, GOC:TermGenie, PMID:21909394]","metadata":null},{"id":"ed7ca36ab1544c719b3a6fa6c5d31f43","type":"GO_TERM","name":"regulation of protein localization","canonical_id":"go:GO:0032880","description":"\"Any process that modulates the frequency, rate or extent of any process in which a protein is transported to, or maintained in, a specific location.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"b18882c5820c43c18f2eeee19312d6fa","type":"GO_TERM","name":"regulation of protein localization by the Cvt pathway","canonical_id":"go:GO:2001159","description":"\"Any process that modulates the frequency, rate or extent of protein localization by the Cvt pathway.\" [GOC:obol]","metadata":null},{"id":"3d1b465d3a03450393a530ebc858f43f","type":"GO_TERM","name":"regulation of protein localization to Cajal body","canonical_id":"go:GO:1904869","description":"\"Any process that modulates the frequency, rate or extent of protein localization to Cajal body.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"b132d4abb2bf4b60bfc4197f6f6d8498","type":"GO_TERM","name":"regulation of protein localization to actin cortical patch","canonical_id":"go:GO:1904370","description":"\"Any process that modulates the frequency, rate or extent of protein localization to actin cortical patch.\" [GO_REF:0000058, GOC:TermGenie, PMID:18216290]","metadata":null},{"id":"4e874cf6435a40599dc89f466d940cee","type":"GO_TERM","name":"regulation of protein localization to adherens junction","canonical_id":"go:GO:1904702","description":"\"Any process that modulates the frequency, rate or extent of protein localization to adherens junction. An adherens junction is a cell-cell junction composed of the epithelial cadherin-catenin complex at which the cytoplasmic face of the plasma membrane is attached to actin filaments.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:kmv, GOC:TermGenie, PMID:26412237]","metadata":null},{"id":"8df311f32bcb415f9bf86df92d8dc0ee","type":"GO_TERM","name":"regulation of protein localization to basolateral plasma membrane","canonical_id":"go:GO:1904508","description":"\"Any process that modulates the frequency, rate or extent of protein localization to basolateral plasma membrane.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26115433]","metadata":null},{"id":"e34e8855052844edaec2352e1a6d24a8","type":"GO_TERM","name":"regulation of protein localization to cell cortex","canonical_id":"go:GO:1904776","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell cortex.\" [GO_REF:0000058, GOC:TermGenie, PMID:17115027]","metadata":null},{"id":"5fb7b75e8d1e4ae0a29d5c693310fb08","type":"GO_TERM","name":"regulation of protein localization to cell cortex of cell tip","canonical_id":"go:GO:1990895","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell cortex of cell tip.\" [GOC:vw, PMID:26150232]","metadata":null},{"id":"42989b69ae6a4a64a8898574bffd7f69","type":"GO_TERM","name":"regulation of protein localization to cell division site","canonical_id":"go:GO:1901900","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell division site.\" [GOC:dph, GOC:TermGenie, PMID:22573892]","metadata":null},{"id":"3266238aa8d244b996719a231dd85bfe","type":"GO_TERM","name":"regulation of protein localization to cell division site involved in cell separation after cytokinesis","canonical_id":"go:GO:1905391","description":"\"Any regulation of protein localization to cell division site that is involved in cell separation after cytokinesis.\" [GO_REF:0000060, GOC:TermGenie, PMID:25411334]","metadata":null},{"id":"451fe062d09340aba2c2e646636fe2d9","type":"GO_TERM","name":"regulation of protein localization to cell division site involved in cytokinesis","canonical_id":"go:GO:1901901","description":"\"Any regulation of protein localization to cell division site that is involved in cytokinesis.\" [GOC:dph, GOC:TermGenie, PMID:22573892]","metadata":null},{"id":"9d2f4b8d7dff4200a4b23a23ac927e34","type":"GO_TERM","name":"regulation of protein localization to cell division site involved in mitotic actomyosin contractile ring assembly","canonical_id":"go:GO:0110082","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell division site involved in mitotic actomyosin contractile ring assembly.\" [GOC:vw, PMID:29343550]","metadata":null},{"id":"6d06c6dffbe84fa9bbe52a5f4bfd0d2a","type":"GO_TERM","name":"regulation of protein localization to cell leading edge","canonical_id":"go:GO:1905871","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell leading edge.\" [GO_REF:0000058, GOC:TermGenie, PMID:26324884]","metadata":null},{"id":"e08cf67c6d8f41968f3b1ad60f51a613","type":"GO_TERM","name":"regulation of protein localization to cell periphery","canonical_id":"go:GO:1904375","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell periphery.\" [GO_REF:0000058, GOC:TermGenie, PMID:18216290]","metadata":null},{"id":"d2c9d4f25d3c46acb47031dfab33e195","type":"GO_TERM","name":"regulation of protein localization to cell surface","canonical_id":"go:GO:2000008","description":"\"Any process that modulates the frequency, rate or extent of protein localization to the cell surface.\" [GOC:obol]","metadata":null},{"id":"2d4cd74aa9294e40af1f24c3c73c8e26","type":"GO_TERM","name":"regulation of protein localization to cell tip","canonical_id":"go:GO:1903066","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell tip.\" [GO_REF:0000058, GOC:TermGenie, PMID:24554432]","metadata":null},{"id":"9191cee2bc31433db7bc4207fa01f927","type":"GO_TERM","name":"regulation of protein localization to cell-cell junction","canonical_id":"go:GO:0150106","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cell-cell junction.\" [GOC:aruk, GOC:bc, PMID:26706435]","metadata":null},{"id":"c3a0f5c51f954579b332296e2cacf917","type":"GO_TERM","name":"regulation of protein localization to centrosome","canonical_id":"go:GO:1904779","description":"\"Any process that modulates the frequency, rate or extent of protein localization to centrosome.\" [GO_REF:0000058, GOC:TermGenie, PMID:17115027]","metadata":null},{"id":"6f0f9ad26bd54c71bab54a56a927f448","type":"GO_TERM","name":"regulation of protein localization to chromatin","canonical_id":"go:GO:1905634","description":"\"Any process that modulates the frequency, rate or extent of protein localization to chromatin.\" [GO_REF:0000058, GOC:TermGenie, PMID:20889714]","metadata":null},{"id":"cb2b716c5cc6484d860eac44b2d82ef2","type":"GO_TERM","name":"regulation of protein localization to chromosome, telomeric region","canonical_id":"go:GO:1904814","description":"\"Any process that modulates the frequency, rate or extent of protein localization to chromosome, telomeric region.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:19487455]","metadata":null},{"id":"d371a5fcbe2f44e6962d4fb753d4ea58","type":"GO_TERM","name":"regulation of protein localization to ciliary membrane","canonical_id":"go:GO:1903567","description":"\"Any process that modulates the frequency, rate or extent of protein localization to ciliary membrane.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22072986]","metadata":null},{"id":"83fef7176fdd498c95be846d543de5d2","type":"GO_TERM","name":"regulation of protein localization to cilium","canonical_id":"go:GO:1903564","description":"\"Any process that modulates the frequency, rate or extent of protein localization to cilium.\" [GO_REF:0000058, GOC:cilia, GOC:krc, GOC:TermGenie, PMID:22072986]","metadata":null},{"id":"e25097ccc4834286b66c9fec180a288f","type":"GO_TERM","name":"regulation of protein localization to early endosome","canonical_id":"go:GO:1902965","description":"\"Any process that modulates the frequency, rate or extent of protein localization to early endosome.\" [GO_REF:0000058, GOC:sjp, GOC:TermGenie, PMID:22621900]","metadata":null},{"id":"cc0293291134420a9fc5d7c83dd04513","type":"GO_TERM","name":"regulation of protein localization to endoplasmic reticulum","canonical_id":"go:GO:1905550","description":"\"Any process that modulates the frequency, rate or extent of protein localization to endoplasmic reticulum.\" [GO_REF:0000058, GOC:TermGenie, PMID:22768340]","metadata":null},{"id":"8873599f20884b7a8e9611e41cc8b2a5","type":"GO_TERM","name":"regulation of protein localization to endosome","canonical_id":"go:GO:1905666","description":"\"Any process that modulates the frequency, rate or extent of protein localization to endosome.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:22732145]","metadata":null},{"id":"c0e1a3385bd54a24a6e69aaac427f1fc","type":"GO_TERM","name":"regulation of protein localization to kinetochore","canonical_id":"go:GO:1905340","description":"\"Any process that modulates the frequency, rate or extent of protein localization to kinetochore.\" [GO_REF:0000058, GOC:TermGenie, PMID:22581055]","metadata":null},{"id":"77c5c471dc8a4e5faa4e35f7665837c5","type":"GO_TERM","name":"regulation of protein localization to lysosome","canonical_id":"go:GO:0150031","description":"\"Any process that modulates the frequency, rate or extent of protein localization to lysosome.\" [GOC:aruk, GOC:bc, PMID:24305806]","metadata":null},{"id":"b815db12fb2f4f86b34032c4d31a3ca3","type":"GO_TERM","name":"regulation of protein localization to medial cortex","canonical_id":"go:GO:0106011","description":"\"Any process that regulates the localization of a protein to the medial cortex.\" [GOC:hjd]","metadata":null},{"id":"369d979a819f4e629f182d1f2cacf217","type":"GO_TERM","name":"regulation of protein localization to medial cortical node","canonical_id":"go:GO:0120046","description":"\"Any process that modulates the frequency, rate or extent of protein localization to a medial cortical node.\" [PMID:19474789]","metadata":null},{"id":"0f462924a14748a1add86f2a0cb65267","type":"GO_TERM","name":"regulation of protein localization to meiotic spindle pole body","canonical_id":"go:GO:0140433","description":"\"Any process that modulates the frequency, rate or extent of protein localization to a meiotic spindle pole body.\" [PMID:22438582]","metadata":null},{"id":"b56115d3f4e7420fba47384604e2ad5f","type":"GO_TERM","name":"regulation of protein localization to membrane","canonical_id":"go:GO:1905475","description":"\"Any process that modulates the frequency, rate or extent of protein localization to membrane.\" [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:26911690]","metadata":null},{"id":"089ecb13c18a49f2a45569e3cbc3b388","type":"GO_TERM","name":"regulation of protein localization to microtubule","canonical_id":"go:GO:1902816","description":"\"Any process that modulates the frequency, rate or extent of protein localization to microtubule.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw, PMID:23087209]","metadata":null},{"id":"fdf6e928f2e04f1aa8745e5cf7d1a58a","type":"GO_TERM","name":"regulation of protein localization to mitochondrion","canonical_id":"go:GO:1903747","description":"\"Any process that modulates the frequency, rate or extent of protein localization to mitochondrion.\" [GO_REF:0000058, GOC:TermGenie, PMID:16857185]","metadata":null},{"id":"a9116c4942034ea08536e04e83fb059d","type":"GO_TERM","name":"regulation of protein localization to mitotic spindle pole body","canonical_id":"go:GO:1902542","description":"\"Any process that modulates the frequency, rate or extent of protein localization to mitotic spindle pole body.\" [GOC:TermGenie, PMID:22809626]","metadata":null},{"id":"25599c44cb3f4abc88b5fc41ababac3e","type":"GO_TERM","name":"regulation of protein localization to non-growing cell tip","canonical_id":"go:GO:0062107","description":"\"Any process that modulates the frequency, rate or extent of protein localization to a non-growing cell tip.\" [PMID:18328707]","metadata":null},{"id":"ca225dc4e4e24fb099192599229baa38","type":"GO_TERM","name":"regulation of protein localization to nucleolus","canonical_id":"go:GO:1904749","description":"\"Any process that modulates the frequency, rate or extent of protein localization to nucleolus.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24415760]","metadata":null},{"id":"acc2af3869ff4aabbd084e43c8d689ea","type":"GO_TERM","name":"regulation of protein localization to nucleus","canonical_id":"go:GO:1900180","description":"\"Any process that modulates the frequency, rate or extent of protein localization to nucleus.\" [GOC:TermGenie]","metadata":null},{"id":"68c0b7969a714e1a9ecada2fb7272f91","type":"GO_TERM","name":"regulation of protein localization to phagocytic vesicle","canonical_id":"go:GO:1905169","description":"\"Any process that modulates the frequency, rate or extent of protein localization to phagocytic vesicle.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie]","metadata":null},{"id":"694e183758284fd3b25cddfc40c9e1b7","type":"GO_TERM","name":"regulation of protein localization to plasma membrane","canonical_id":"go:GO:1903076","description":"\"Any process that modulates the frequency, rate or extent of protein localization to plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:11602640]","metadata":null},{"id":"95f5f380d09a4346b69e06399b5f2272","type":"GO_TERM","name":"regulation of protein localization to presynapse","canonical_id":"go:GO:1905384","description":"\"Any process that modulates the frequency, rate or extent of protein localization to presynapse.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24449494]","metadata":null},{"id":"7d1cb97ef44a4ae49ade37aa7c535195","type":"GO_TERM","name":"regulation of protein localization to prospore membrane","canonical_id":"go:GO:2001231","description":"\"Any process that modulates the frequency, rate or extent of protein localization to prospore membrane.\" [GOC:mah]","metadata":null},{"id":"96e4b6ed6a0e4afc9ee80f2c12593c2d","type":"GO_TERM","name":"regulation of protein localization to spindle pole body","canonical_id":"go:GO:1902363","description":"\"Any process that modulates the frequency, rate or extent of protein localization to spindle pole body.\" [GOC:TermGenie, PMID:21131906]","metadata":null},{"id":"8fed04e8f4574ca89e96a90e102b744f","type":"GO_TERM","name":"regulation of protein localization to synapse","canonical_id":"go:GO:1902473","description":"\"Any process that modulates the frequency, rate or extent of protein localization to synapse.\" [GOC:kmv, GOC:TermGenie, PMID:22588719]","metadata":null},{"id":"bfcc9a999f2b4095b0bde29f3d35a9a9","type":"GO_TERM","name":"regulation of protein maturation","canonical_id":"go:GO:1903317","description":"\"Any process that modulates the frequency, rate or extent of protein maturation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"0467575c43944e0bae13754b2a77632d","type":"GO_TERM","name":"regulation of protein metabolic process","canonical_id":"go:GO:0051246","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving a protein.\" [GOC:ai]","metadata":null},{"id":"c1087d893d094876a26e237ca8cfe1b6","type":"GO_TERM","name":"regulation of protein modification by small protein conjugation or removal","canonical_id":"go:GO:1903320","description":"\"Any process that modulates the frequency, rate or extent of protein modification by small protein conjugation or removal.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"f963b53c2cec4aee9bc910a4e682401a","type":"GO_TERM","name":"regulation of protein modification process","canonical_id":"go:GO:0031399","description":"\"Any process that modulates the frequency, rate or extent of the covalent alteration of one or more amino acid residues within a protein.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"1f851167f5164ae293d5753a3926a0f6","type":"GO_TERM","name":"regulation of protein monoubiquitination","canonical_id":"go:GO:1902525","description":"\"Any process that modulates the frequency, rate or extent of protein monoubiquitination.\" [GOC:TermGenie, PMID:21931591]","metadata":null},{"id":"8b494b43da934c38b215e32cbb654ffb","type":"GO_TERM","name":"regulation of protein neddylation","canonical_id":"go:GO:2000434","description":"\"Any process that modulates the frequency, rate or extent of protein neddylation.\" [GOC:obol]","metadata":null},{"id":"b19b3f502c44466d8fe862e20f2db4b4","type":"GO_TERM","name":"regulation of protein oligomerization","canonical_id":"go:GO:0032459","description":"\"Any process that modulates the frequency, rate or extent of protein oligomerization.\" [GOC:mah]","metadata":null},{"id":"c944eba389a04e8795366a8fd2cbc2e8","type":"GO_TERM","name":"regulation of protein oxidation","canonical_id":"go:GO:1904806","description":"\"Any process that modulates the frequency, rate or extent of protein oxidation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22719267]","metadata":null},{"id":"7ba36d5d164e45de84b8558db00de21b","type":"GO_TERM","name":"regulation of protein phosphorylation","canonical_id":"go:GO:0001932","description":"\"Any process that modulates the frequency, rate or extent of addition of phosphate groups into an amino acid in a protein.\" [GOC:hjd]","metadata":null},{"id":"5304f4ec43064fb09d406a252fa21071","type":"GO_TERM","name":"regulation of protein polyglycylation","canonical_id":"go:GO:1903344","description":"\"Any process that modulates the frequency, rate or extent of protein polyglycylation.\" [GO_REF:0000058, GOC:sart, GOC:TermGenie]","metadata":null},{"id":"397eff651b7541ef8d0edc1442678cbb","type":"GO_TERM","name":"regulation of protein polymerization","canonical_id":"go:GO:0032271","description":"\"Any process that modulates the frequency, rate or extent of the process of creating protein polymers.\" [GOC:mah]","metadata":null},{"id":"4b1b9d9cfce442bf9d4f871d051ce652","type":"GO_TERM","name":"regulation of protein polyubiquitination","canonical_id":"go:GO:1902914","description":"\"Any process that modulates the frequency, rate or extent of protein polyubiquitination.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:23645667]","metadata":null},{"id":"5f7b238117b844268a50eb305a0c7800","type":"GO_TERM","name":"regulation of protein processing","canonical_id":"go:GO:0070613","description":"\"Any process that modulates the frequency, rate or extent of protein processing, a protein maturation process achieved by the cleavage of a peptide bond or bonds within a protein.\" [GOC:mah]","metadata":null},{"id":"1617099e98ed46d5bdb961dd3fc6db0c","type":"GO_TERM","name":"regulation of protein processing in phagocytic vesicle","canonical_id":"go:GO:1903921","description":"\"Any process that modulates the frequency, rate or extent of protein processing in phagocytic vesicle.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23325791]","metadata":null},{"id":"b799194d62124e3aa743a5628363d7ff","type":"GO_TERM","name":"regulation of protein refolding","canonical_id":"go:GO:0061083","description":"\"Any process that regulates the rate, frequency, or extent of protein refolding. Protein refolding is the process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"eccf59e991204ee096485037d3e40ad5","type":"GO_TERM","name":"regulation of protein secretion","canonical_id":"go:GO:0050708","description":"\"Any process that modulates the frequency, rate or extent of the controlled release of a protein from a cell.\" [GOC:ai]","metadata":null},{"id":"68079fbd5c9d4cefa4cf4a46a65168bd","type":"GO_TERM","name":"regulation of protein serine/threonine kinase activity","canonical_id":"go:GO:0071900","description":"\"Any process that modulates the rate, frequency, or extent of protein serine/threonine kinase activity.\" [GOC:mah]","metadata":null},{"id":"188d8a3bb8a549a9b6b970a9199913aa","type":"GO_TERM","name":"regulation of protein stability","canonical_id":"go:GO:0031647","description":"\"Any process that affects the structure and integrity of a protein, altering the likelihood of its degradation or aggregation.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"cee5f4d562274ca2a0a5112e4a8026c4","type":"GO_TERM","name":"regulation of protein sumoylation","canonical_id":"go:GO:0033233","description":"\"Any process that modulates the frequency, rate or extent of the addition of SUMO groups to a protein.\" [GOC:mah]","metadata":null},{"id":"bcdb3c5b1fae49839291e4903277a5ee","type":"GO_TERM","name":"regulation of protein targeting","canonical_id":"go:GO:1903533","description":"\"Any process that modulates the frequency, rate or extent of protein targeting.\" [GO_REF:0000058, GOC:TermGenie]","metadata":null},{"id":"66150af9908042c08cff30ed6baef5ff","type":"GO_TERM","name":"regulation of protein targeting to membrane","canonical_id":"go:GO:0090313","description":"\"Any process that modulates the frequency, rate or extent of the process of directing proteins towards a membrane, usually using signals contained within the protein.\" [GOC:tb]","metadata":null},{"id":"acafdd7ca3194e9d83f4de24efe7de31","type":"GO_TERM","name":"regulation of protein targeting to vacuolar membrane","canonical_id":"go:GO:1900483","description":"\"Any process that modulates the frequency, rate or extent of protein targeting to vacuolar membrane.\" [GOC:TermGenie]","metadata":null},{"id":"369fb1bfc5ad4de99e149e9736aa00a9","type":"GO_TERM","name":"regulation of protein tetramerization","canonical_id":"go:GO:1901090","description":"\"Any process that modulates the frequency, rate or extent of protein tetramerization.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"c7f29ec71cec4d55b0f35b5dd7588a5a","type":"GO_TERM","name":"regulation of protein transport","canonical_id":"go:GO:0051223","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a protein into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"8dee411ea83b45a59943af7b3fdf1e68","type":"GO_TERM","name":"regulation of protein tyrosine kinase activity","canonical_id":"go:GO:0061097","description":"\"Any process that modulates the rate, frequency, or extent of protein tyrosine kinase activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"cf7966a8734b48749d66a89459bf3ad3","type":"GO_TERM","name":"regulation of protein ubiquitination","canonical_id":"go:GO:0031396","description":"\"Any process that modulates the frequency, rate or extent of the addition of ubiquitin groups to a protein.\" [GOC:mah]","metadata":null},{"id":"87ca9f30961a447ab60a9990ddb04aeb","type":"GO_TERM","name":"regulation of protein-containing complex assembly","canonical_id":"go:GO:0043254","description":"\"Any process that modulates the frequency, rate or extent of protein complex assembly.\" [GOC:jl]","metadata":null},{"id":"4f31e0fd445142689f265126e1eacde6","type":"GO_TERM","name":"regulation of protein-containing complex disassembly","canonical_id":"go:GO:0043244","description":"\"Any process that modulates the frequency, rate or extent of protein complex disassembly, the disaggregation of a protein complex into its constituent components.\" [GOC:jl]","metadata":null},{"id":"9a1a997447e94b1e8fd3169418016528","type":"GO_TERM","name":"regulation of protein-pyridoxal-5-phosphate linkage","canonical_id":"go:GO:1904285","description":"\"Any process that modulates the frequency, rate or extent of protein-pyridoxal-5-phosphate linkage.\" [GO_REF:0000058, GOC:TermGenie, PMID:25957689]","metadata":null},{"id":"f7d58878a3e04928a8f882915eaf25da","type":"GO_TERM","name":"regulation of proteolysis","canonical_id":"go:GO:0030162","description":"\"Any process that modulates the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.\" [GOC:mah]","metadata":null},{"id":"056ce7513e9943208a6c2892c10fca5e","type":"GO_TERM","name":"regulation of proteolysis associated with antigen processing and presentation","canonical_id":"go:GO:0002628","description":"\"Any process that modulates the frequency, rate, or extent of proteolysis associated with antigen processing and presentation.\" [GOC:add]","metadata":null},{"id":"6042a94195da4b56864375c077df3b9f","type":"GO_TERM","name":"regulation of proton transport","canonical_id":"go:GO:0010155","description":"\"Any process that modulates the frequency, rate or extent of proton transport into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:sm]","metadata":null},{"id":"869072f7d6b24618b5acf75f405a40b6","type":"GO_TERM","name":"regulation of pseudohyphal growth","canonical_id":"go:GO:2000220","description":"\"Any process that modulates the frequency, rate or extent of pseudohyphal growth.\" [GOC:mah]","metadata":null},{"id":"c69415ef55f84f2fbacbd7f32fa9b8da","type":"GO_TERM","name":"regulation of pseudohyphal septin ring assembly","canonical_id":"go:GO:0062164","description":"\"Any process that modulates the rate, frequency or extent of pseudohyphal septin ring assembly.\" [PMID:29567712]","metadata":null},{"id":"c837ce3877aa417a887f6340f0b4b124","type":"GO_TERM","name":"regulation of pseudopodium assembly","canonical_id":"go:GO:0031272","description":"\"Any process that modulates the frequency, rate or extent of the assembly of pseudopodia.\" [GOC:pg]","metadata":null},{"id":"ccd2ab87e3bd4349aa4b59f271c86fc7","type":"GO_TERM","name":"regulation of pseurotin A biosynthetic process","canonical_id":"go:GO:1900849","description":"\"Any process that modulates the frequency, rate or extent of pseurotin A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"006ca63894374c0794bae5d3f68be477","type":"GO_TERM","name":"regulation of pulmonary blood vessel remodeling","canonical_id":"go:GO:1905109","description":"\"Any process that modulates the frequency, rate or extent of pulmonary blood vessel remodeling.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22161164]","metadata":null},{"id":"3ce9782812044179a5040bf874b1d9ad","type":"GO_TERM","name":"regulation of pupariation","canonical_id":"go:GO:0106023","description":"\"Any process that modulates the onset of pupariation.\" [PMID:26510564]","metadata":null},{"id":"041df39e5fd64c90bfb4205be1060917","type":"GO_TERM","name":"regulation of purine nucleobase metabolic process","canonical_id":"go:GO:0006141","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving purines.\" [GOC:curators]","metadata":null},{"id":"f797c2a270dd486eb1a152395c30ccea","type":"GO_TERM","name":"regulation of purine nucleoside transport","canonical_id":"go:GO:0032245","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a purine nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"84ff4fdf00fe48f29b6d6d71551934f4","type":"GO_TERM","name":"regulation of purine nucleotide biosynthetic process","canonical_id":"go:GO:1900371","description":"\"Any process that modulates the frequency, rate or extent of purine nucleotide biosynthetic processes.\" [GOC:curators, GOC:TermGenie]","metadata":null},{"id":"174af9b4004f4e0ea2cb726d421297a7","type":"GO_TERM","name":"regulation of purine nucleotide catabolic process","canonical_id":"go:GO:0033121","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of purine nucleotides.\" [GOC:mah]","metadata":null},{"id":"b50e9f4c561b4f07852323808746ca45","type":"GO_TERM","name":"regulation of purine nucleotide metabolic process","canonical_id":"go:GO:1900542","description":"\"Any process that modulates the frequency, rate or extent of purine nucleotide metabolic process.\" [GOC:TermGenie]","metadata":null},{"id":"19a15b4b344a463db6dd913b610b7d90","type":"GO_TERM","name":"regulation of pyloric antrum smooth muscle contraction","canonical_id":"go:GO:0120071","description":"\"Any process that modulates the frequency, rate or extent of any pyloric antrum smooth muscle contraction.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"d51dba3be19743dabab8e6153dc960c6","type":"GO_TERM","name":"regulation of pyocyanine biosynthetic process","canonical_id":"go:GO:0062161","description":"\"Any process that modulates the frequency, rate or extent of a pyocyanine biosynthetic process.\" [PMID:28715477]","metadata":null},{"id":"32d785b4a99b4c1997b9d38774673db3","type":"GO_TERM","name":"regulation of pyrimidine nucleoside transport","canonical_id":"go:GO:0032246","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a pyrimidine nucleoside into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"ef85025426064361b86c10af4756be57","type":"GO_TERM","name":"regulation of pyrimidine nucleotide biosynthetic process","canonical_id":"go:GO:1900397","description":"\"Any process that modulates the frequency, rate or extent of pyrimidine nucleotide biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"02faa69cd2114a68bb990b57ede568b9","type":"GO_TERM","name":"regulation of pyrimidine-containing compound salvage","canonical_id":"go:GO:1903930","description":"\"Any process that modulates the frequency, rate or extent of pyrimidine-containing compound salvage.\" [GO_REF:0000058, GOC:TermGenie, PMID:23695302]","metadata":null},{"id":"da64b59cb5884e748c55ecd2b5053fee","type":"GO_TERM","name":"regulation of pyruvate decarboxylation to acetyl-CoA","canonical_id":"go:GO:0010510","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acetyl-CoA from pyruvate. In most organisms, this pathway links glycolysis to the TCA cycle, by a series of three reactions carried out by a multisubunit complex called the 'pyruvate dehydrogenase complex', even though pyruvate dehydrogenase activity describes only one of those reactions.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9ef5365ff1624c28a6222ea23aa77aa3","type":"GO_TERM","name":"regulation of pyruvate kinase activity","canonical_id":"go:GO:1903302","description":"\"Any process that modulates the frequency, rate or extent of pyruvate kinase activity.\" [GO_REF:0000059, GOC:mr, GOC:TermGenie, PMID:15804508]","metadata":null},{"id":"d87d9d0ecaaf40738ed6b3eda835d2f3","type":"GO_TERM","name":"regulation of quinolinate biosynthetic process","canonical_id":"go:GO:1904984","description":"\"Any process that modulates the frequency, rate or extent of quinolinate biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:12140278, PMID:19843166]","metadata":null},{"id":"33f64d06a3224856a2fc993d538a2f5d","type":"GO_TERM","name":"regulation of rDNA heterochromatin formation","canonical_id":"go:GO:0061187","description":"\"Any process that modulates the rate, frequency, or extent of rDNA heterochromatin formation.\" [PMID:10388812]","metadata":null},{"id":"786c54c099dc4aaca28003cc0d192089","type":"GO_TERM","name":"regulation of rRNA catabolic process","canonical_id":"go:GO:1902374","description":"\"Any process that modulates the frequency, rate or extent of rRNA catabolic process.\" [GOC:bf, GOC:TermGenie, PMID:20160119]","metadata":null},{"id":"d2926ef10f5f468b9b1ec6bf39be62cc","type":"GO_TERM","name":"regulation of rRNA processing","canonical_id":"go:GO:2000232","description":"\"Any process that modulates the frequency, rate or extent of rRNA processing.\" [GOC:mah]","metadata":null},{"id":"489c01cddca14cbf8f36f7bd454b600c","type":"GO_TERM","name":"regulation of rRNA stability","canonical_id":"go:GO:0044357","description":"\"Any process that modulates the propensity of rRNA molecules to degradation. Includes processes that both stabilize and destabilize rRNAs.\" [GOC:jl]","metadata":null},{"id":"516d1087e6cc4d3682eb12028dc447de","type":"GO_TERM","name":"regulation of radial pattern formation","canonical_id":"go:GO:0090213","description":"\"Any process that modulates the rate, frequency or extent of radial pattern formation, the regionalization process that results in defined areas around a point in which specific types of cell differentiation will occur.\" [GOC:tb]","metadata":null},{"id":"14c772515ff14aea84566dc765888cec","type":"GO_TERM","name":"regulation of raffinose biosynthetic process","canonical_id":"go:GO:1900091","description":"\"Any process that modulates the frequency, rate or extent of raffinose biosynthetic process.\" [GOC:TermGenie, PMID:22307851]","metadata":null},{"id":"08a3df98da5a48c09bd242fc00b2cc26","type":"GO_TERM","name":"regulation of raffinose metabolic process","canonical_id":"go:GO:0080091","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving raffinose.\" [PMID:19211694]","metadata":null},{"id":"a2ac1a7e74204d71a97f11072d9c7bf4","type":"GO_TERM","name":"regulation of rate of cell growth","canonical_id":"go:GO:0061388","description":"\"Any process that modulates the rate of cell growth.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"9a3d7c5c007844c08838fc5169b511da","type":"GO_TERM","name":"regulation of reactive oxygen species biosynthetic process","canonical_id":"go:GO:1903426","description":"\"Any process that modulates the frequency, rate or extent of reactive oxygen species biosynthetic process.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:24252804]","metadata":null},{"id":"51fdcfff44b94809be84cf8ef365717d","type":"GO_TERM","name":"regulation of reactive oxygen species metabolic process","canonical_id":"go:GO:2000377","description":"\"Any process that modulates the frequency, rate or extent of reactive oxygen species metabolic process.\" [GOC:mah]","metadata":null},{"id":"c35f3f31f6ae47d8826aa6d3eb5b9a41","type":"GO_TERM","name":"regulation of receptor binding","canonical_id":"go:GO:1900120","description":"\"Any process that modulates the frequency, rate or extent of a protein or other molecule binding to a receptor.\" [GOC:signaling, GOC:TermGenie]","metadata":null},{"id":"eca13c3cb4164b01bf1665b1c452c9b0","type":"GO_TERM","name":"regulation of receptor catabolic process","canonical_id":"go:GO:2000644","description":"\"Any process that modulates the frequency, rate or extent of receptor catabolic process.\" [GOC:BHF]","metadata":null},{"id":"7efda7d8a5ff431b98a832f3745d5dee","type":"GO_TERM","name":"regulation of receptor clustering","canonical_id":"go:GO:1903909","description":"\"Any process that modulates the frequency, rate or extent of receptor clustering.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:23575248]","metadata":null},{"id":"1caf746a325b44bcb7812c2a35c1c1ac","type":"GO_TERM","name":"regulation of receptor internalization","canonical_id":"go:GO:0002090","description":"\"Any process that modulates the frequency, rate or extent of receptor internalization.\" [GOC:hjd]","metadata":null},{"id":"758821820ac04330ba2ae590e47b42be","type":"GO_TERM","name":"regulation of receptor localization to synapse","canonical_id":"go:GO:1902683","description":"\"Any process that modulates the frequency, rate or extent of receptor localization to synapse.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22252129]","metadata":null},{"id":"c04bd4156fac4fc5a4d5886fe8407c57","type":"GO_TERM","name":"regulation of receptor recycling","canonical_id":"go:GO:0001919","description":"\"Any process that modulates the frequency, rate, or extent of receptor recycling.\" [GOC:add]","metadata":null},{"id":"ab3d85359fb64cb682de64ff57e4e328","type":"GO_TERM","name":"regulation of receptor signaling pathway via JAK-STAT","canonical_id":"go:GO:0046425","description":"\"Any process that modulates the frequency, rate or extent of receptor signaling via JAK-STAT.\" [GOC:bf]","metadata":null},{"id":"e64b4a32386e43baa8d0630903991730","type":"GO_TERM","name":"regulation of receptor signaling pathway via STAT","canonical_id":"go:GO:1904892","description":"\"Any process that modulates the frequency, rate or extent of receptor signaling via STAT.\" [GO_REF:0000058, GOC:rjd, GOC:TermGenie, PMID:24587195]","metadata":null},{"id":"a04b3fb64ea74189aa6f6252cbf04a4a","type":"GO_TERM","name":"regulation of receptor-mediated endocytosis","canonical_id":"go:GO:0048259","description":"\"Any process that modulates the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"218cc13e8c5642e3a297030fd09729aa","type":"GO_TERM","name":"regulation of receptor-mediated virion attachment to host cell","canonical_id":"go:GO:1902734","description":"\"Any process that modulates the frequency, rate or extent of receptor-mediated virion attachment to host cell.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18385238]","metadata":null},{"id":"f8a333ce7b89454eaa243921be0f4c41","type":"GO_TERM","name":"regulation of reciprocal meiotic recombination","canonical_id":"go:GO:0010520","description":"\"Any process that modulates the frequency, rate or extent of recombination during meiosis. Reciprocal meiotic recombination is the cell cycle process in which double strand breaks are formed and repaired through a double Holliday junction intermediate.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8e7e3f3d788449f384c97af7cda71f94","type":"GO_TERM","name":"regulation of recycling endosome localization within postsynapse","canonical_id":"go:GO:0099158","description":"\"Any process that modulates the frequency, rate or extent of transport or maintenance of location of a postsynaptic recycling endosome within the postsynapse.\" [GOC:dos, PMID:20098723]","metadata":null},{"id":"b46e11e9b8264375bd16e3da7c447140","type":"GO_TERM","name":"regulation of red or far-red light signaling pathway","canonical_id":"go:GO:0090227","description":"\"Any process that modulates the rate, frequency or extent of the red or far-red signaling pathway, the series of molecular signals initiated upon sensing by photoreceptor molecules of red light or far red light.\" [GOC:tb]","metadata":null},{"id":"f437d8de3bd948979bd735ab67358546","type":"GO_TERM","name":"regulation of reductive pentose-phosphate cycle","canonical_id":"go:GO:0080152","description":"\"Any process that modulates the frequency, rate or extent of reductive pentose-phosphate cycle.\" [PMID:17031544]","metadata":null},{"id":"ce8c771f225a47b5994024d43a0a6a1e","type":"GO_TERM","name":"regulation of regulated secretory pathway","canonical_id":"go:GO:1903305","description":"\"Any process that modulates the frequency, rate or extent of regulated secretory pathway.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:12526776]","metadata":null},{"id":"1923365787c04081a39d6c3fc997ebf9","type":"GO_TERM","name":"regulation of regulatory T cell differentiation","canonical_id":"go:GO:0045589","description":"\"Any process that modulates the frequency, rate or extent of differentiation of regulatory T cells.\" [ISBN:0781735149]","metadata":null},{"id":"b0f6d1d41039430d8ade177cdb42e136","type":"GO_TERM","name":"regulation of regulatory ncRNA processing","canonical_id":"go:GO:0070920","description":"\"Any process that modulates the frequency, rate or extent of regulatory non-coding RNA processing.\" [GOC:mah]","metadata":null},{"id":"331b65978d314357b1b7f310468496c4","type":"GO_TERM","name":"regulation of regulatory ncRNA-mediated heterochromatin formation","canonical_id":"go:GO:0010964","description":"\"Any process that modulates the frequency, rate or extent of small non-coding RNA-mediated heterochromatin formation.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"05377585020149e499fa944551713c6c","type":"GO_TERM","name":"regulation of relaxation of cardiac muscle","canonical_id":"go:GO:1901897","description":"\"Any process that modulates the frequency, rate or extent of relaxation of cardiac muscle.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671]","metadata":null},{"id":"66e7a1e6b80c4084bfe83867254f426d","type":"GO_TERM","name":"regulation of relaxation of muscle","canonical_id":"go:GO:1901077","description":"\"Any process that modulates the frequency, rate or extent of relaxation of muscle.\" [GOC:TermGenie]","metadata":null},{"id":"c8209599cb4a4758ba83b94b51b9ccfa","type":"GO_TERM","name":"regulation of relaxation of smooth muscle","canonical_id":"go:GO:1901080","description":"\"Any process that modulates the frequency, rate or extent of relaxation of smooth muscle.\" [GOC:TermGenie]","metadata":null},{"id":"dce767b0946a4fdc804fe0ec17022c40","type":"GO_TERM","name":"regulation of release of cytochrome c from mitochondria","canonical_id":"go:GO:0090199","description":"\"Any process that modulates the rate, frequency or extent of release of cytochrome c from mitochondria, the process in which cytochrome c is enabled to move from the mitochondrial intermembrane space into the cytosol, which is an early step in apoptosis and leads to caspase activation.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"e576fd26332c45f0a4b4dc4ea11d4529","type":"GO_TERM","name":"regulation of release of sequestered calcium ion into cytosol","canonical_id":"go:GO:0051279","description":"\"Any process that modulates the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"01ec816c0f40403bad1d472e00e39e44","type":"GO_TERM","name":"regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum","canonical_id":"go:GO:0010880","description":"\"Any process that modulates the rate, frequency or extent of release of sequestered calcium ion into cytosol by the sarcoplasmic reticulum, the process in which the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol occurs via calcium release channels.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"46e6739525494291993556739eaf056e","type":"GO_TERM","name":"regulation of removal of superoxide radicals","canonical_id":"go:GO:2000121","description":"\"Any process that modulates the frequency, rate or extent of removal of superoxide radicals.\" [GOC:obol]","metadata":null},{"id":"c13ac4f0dc8e47c69381882be91a7572","type":"GO_TERM","name":"regulation of renal albumin absorption","canonical_id":"go:GO:2000532","description":"\"Any process that modulates the frequency, rate or extent of renal albumin absorption.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"92a07d0a44144073bfd78e9175bf0083","type":"GO_TERM","name":"regulation of renal amino acid absorption","canonical_id":"go:GO:1902752","description":"\"Any process that modulates the frequency, rate or extent of renal amino acid absorption.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:1526373]","metadata":null},{"id":"7dcbe925f0e3498aa4786074b69c7bf7","type":"GO_TERM","name":"regulation of renal output by angiotensin","canonical_id":"go:GO:0002019","description":"\"The process in which angiotensin directly modulates the rate of urine output by the kidney.\" [GOC:dph, GOC:mtg_cardio, GOC:tb, ISBN:0721643949]","metadata":null},{"id":"650d95daea4448b2a6e3d9ca6356c9e9","type":"GO_TERM","name":"regulation of renal phosphate excretion","canonical_id":"go:GO:1903402","description":"\"Any process that modulates the frequency, rate or extent of renal phosphate excretion.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:8700837]","metadata":null},{"id":"39c16aafe994420f8419064b8d950379","type":"GO_TERM","name":"regulation of renal sodium excretion","canonical_id":"go:GO:0035813","description":"\"Any process that modulates the amount of sodium excreted in urine over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"fcb38244232340bbb006edb26b9cbb91","type":"GO_TERM","name":"regulation of renal system process","canonical_id":"go:GO:0098801","description":"\"Any process that modulates the frequency, rate or extent of a system process, a multicellular organismal process carried out by the renal system.\" [GOC:dos]","metadata":null},{"id":"a19182bf6e8a4039a69130a58db4e85a","type":"GO_TERM","name":"regulation of renal water transport","canonical_id":"go:GO:2001151","description":"\"Any process that modulates the frequency, rate or extent of renal water transport.\" [GOC:obol]","metadata":null},{"id":"72a6e2a87f974e8b9cda6d0f103603c4","type":"GO_TERM","name":"regulation of renin secretion into blood stream","canonical_id":"go:GO:1900133","description":"\"Any process that modulates the frequency, rate or extent of renin secretion into blood stream.\" [GOC:TermGenie]","metadata":null},{"id":"f7047e2151c84b3cad8febbe605b38bb","type":"GO_TERM","name":"regulation of replication fork arrest at rDNA repeats","canonical_id":"go:GO:1902681","description":"\"Any process that modulates the frequency, rate or extent of replication fork arrest at rDNA repeats.\" [GO_REF:0000058, GOC:TermGenie, PMID:23260662]","metadata":null},{"id":"4c046ea413944eb8b6404c75bcbc0e19","type":"GO_TERM","name":"regulation of replicative senescence","canonical_id":"go:GO:1904726","description":"\"Any process that modulates the frequency, rate or extent of replicative senescence.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:23496142]","metadata":null},{"id":"f9c5ffa13ba84f89bf5b1cbed6132ca1","type":"GO_TERM","name":"regulation of reproductive fruiting body development","canonical_id":"go:GO:0031155","description":"\"Any process that modulates the frequency, rate or extent of reproductive fruiting body development.\" [GOC:mah]","metadata":null},{"id":"2d794e8b5b81422c8014bdbe03ba8a96","type":"GO_TERM","name":"regulation of reproductive process","canonical_id":"go:GO:2000241","description":"\"Any process that modulates the frequency, rate or extent of reproductive process.\" [GOC:mah]","metadata":null},{"id":"5af17d8624e947229970cf01a5841c22","type":"GO_TERM","name":"regulation of respiratory burst","canonical_id":"go:GO:0060263","description":"\"Any process that modulates the rate frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"3e58ee0e9d3448f997f2a4b9a271a205","type":"GO_TERM","name":"regulation of respiratory burst involved in inflammatory response","canonical_id":"go:GO:0060264","description":"\"Any process that modulates the rate, frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases made as a defense response ; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"266b2e84d219418ca6e07f131afcf35f","type":"GO_TERM","name":"regulation of respiratory gaseous exchange","canonical_id":"go:GO:0043576","description":"\"Any process that modulates the frequency, rate or extent of the process of gaseous exchange between an organism and its environment.\" [GOC:jl]","metadata":null},{"id":"fb6ffd4027314bd799929d0df02c2677","type":"GO_TERM","name":"regulation of respiratory gaseous exchange by nervous system process","canonical_id":"go:GO:0002087","description":"\"A process carried out by the nervous system that is required for the proper control of respiratory gaseous exchange. This process occurs in the respiratory center of the brain in vertebrates.\" [GOC:dph, GOC:tb, PMID:12458206]","metadata":null},{"id":"eb4784595acf4b57bb082bd524e4aee2","type":"GO_TERM","name":"regulation of respiratory system process","canonical_id":"go:GO:0044065","description":"\"Any process that modulates the frequency, rate or extent of a respiratory system process, an organ system process carried out by any of the organs or tissues of the respiratory system.\" [GOC:jl]","metadata":null},{"id":"e24e24cd01064535aee8f91c48162118","type":"GO_TERM","name":"regulation of response to DNA damage checkpoint signaling","canonical_id":"go:GO:1902153","description":"\"Any process that modulates the frequency, rate or extent of response to DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"7fb9b51532594ba4b09df06399ed0bb7","type":"GO_TERM","name":"regulation of response to DNA integrity checkpoint signaling","canonical_id":"go:GO:1902151","description":"\"Any process that modulates the frequency, rate or extent of response to DNA integrity checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"6ffd0f681f0b402caf39d1fa72da6d48","type":"GO_TERM","name":"regulation of response to G1 DNA damage checkpoint signaling","canonical_id":"go:GO:1902155","description":"\"Any process that modulates the frequency, rate or extent of response to G1 DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"c74bfc4719c54d44a7dfd5d334438abc","type":"GO_TERM","name":"regulation of response to G2 DNA damage checkpoint signaling","canonical_id":"go:GO:1902157","description":"\"Any process that modulates the frequency, rate or extent of response to G2 DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"648c30a8de2340af9ecb54253840cebf","type":"GO_TERM","name":"regulation of response to acetate","canonical_id":"go:GO:1901457","description":"\"Any process that modulates the frequency, rate or extent of response to acetate.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"a54d46e7f00548caaf28f1aa70e099a2","type":"GO_TERM","name":"regulation of response to alcohol","canonical_id":"go:GO:1901419","description":"\"Any process that modulates the frequency, rate or extent of response to alcohol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"00d19a493b354d08bc3e1e9c578f5b19","type":"GO_TERM","name":"regulation of response to amylopectin","canonical_id":"go:GO:1900521","description":"\"Any process that modulates the frequency, rate or extent of response to amylopectin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"1033542c04bb4afbac0769683557823b","type":"GO_TERM","name":"regulation of response to benzene","canonical_id":"go:GO:1901451","description":"\"Any process that modulates the frequency, rate or extent of response to benzene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"d779c89e6b27433fabd2f730ec0611ee","type":"GO_TERM","name":"regulation of response to biotic stimulus","canonical_id":"go:GO:0002831","description":"\"Any process that modulates the frequency, rate, or extent of a response to biotic stimulus.\" [GOC:add]","metadata":null},{"id":"e737b5b84dcc4ed18f04b6e6aff7eb93","type":"GO_TERM","name":"regulation of response to butan-1-ol","canonical_id":"go:GO:1901448","description":"\"Any process that modulates the frequency, rate or extent of response to butan-1-ol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"aed5dfd161024bdf92c7cc44502d9cad","type":"GO_TERM","name":"regulation of response to calcium ion","canonical_id":"go:GO:1905945","description":"\"Any process that modulates the frequency, rate or extent of response to calcium ion.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:11404397]","metadata":null},{"id":"54376b2246ad487584fb3d3287aae910","type":"GO_TERM","name":"regulation of response to cell cycle checkpoint signaling","canonical_id":"go:GO:1902145","description":"\"Any process that modulates the frequency, rate or extent of response to cell cycle checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"d5d947d3b0bd4825a9166807256101aa","type":"GO_TERM","name":"regulation of response to cycloalkane","canonical_id":"go:GO:1901431","description":"\"Any process that modulates the frequency, rate or extent of response to cycloalkane.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"441ed67948d34765b3e46145f8c04164","type":"GO_TERM","name":"regulation of response to cytokine stimulus","canonical_id":"go:GO:0060759","description":"\"Any process that modulates the rate, frequency, or extent of a response to cytokine stimulus.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"7d882e38e8ba456ebc2eb005d48c647e","type":"GO_TERM","name":"regulation of response to cytokinesis checkpoint signaling","canonical_id":"go:GO:1902147","description":"\"Any process that modulates the frequency, rate or extent of response to cytokinesis checkpoint signaling.\" [GOC:mtg_cell_cycle, GOC:TermGenie]","metadata":null},{"id":"fbd17c3f19be4a2181f2b0150e842e78","type":"GO_TERM","name":"regulation of response to drug","canonical_id":"go:GO:2001023","description":"\"Any process that modulates the frequency, rate or extent of response to drug.\" [GOC:obol]","metadata":null},{"id":"e9d439bd8b214ecca5b7d0ab8642c11a","type":"GO_TERM","name":"regulation of response to endoplasmic reticulum stress","canonical_id":"go:GO:1905897","description":"\"Any process that modulates the frequency, rate or extent of response to endoplasmic reticulum stress.\" [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:21803450]","metadata":null},{"id":"249d899d8d9f4debaf04f461e275ac1e","type":"GO_TERM","name":"regulation of response to ethanol","canonical_id":"go:GO:1901416","description":"\"Any process that modulates the frequency, rate or extent of response to ethanol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"a2c95906c7254836994c1caa63c1928c","type":"GO_TERM","name":"regulation of response to external stimulus","canonical_id":"go:GO:0032101","description":"\"Any process that modulates the frequency, rate or extent of a response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"7e37e04747504c6eadf7bcc932e9c1a8","type":"GO_TERM","name":"regulation of response to food","canonical_id":"go:GO:0032095","description":"\"Any process that modulates the frequency, rate or extent of a response to a food stimulus.\" [GOC:add]","metadata":null},{"id":"87b109e3fdb64533ba091d4a221f7aef","type":"GO_TERM","name":"regulation of response to formic acid","canonical_id":"go:GO:1901460","description":"\"Any process that modulates the frequency, rate or extent of response to formic acid.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"78494016265f42b88c6b6bf908b977ec","type":"GO_TERM","name":"regulation of response to furfural","canonical_id":"go:GO:1901442","description":"\"Any process that modulates the frequency, rate or extent of response to furfural.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4f418c95051a4f3fab78be474af3d0d2","type":"GO_TERM","name":"regulation of response to gamma radiation","canonical_id":"go:GO:2001228","description":"\"Any process that modulates the frequency, rate or extent of response to gamma radiation.\" [GOC:obol]","metadata":null},{"id":"7c48fd0130934e74a0c271208fcf19f2","type":"GO_TERM","name":"regulation of response to macrophage colony-stimulating factor","canonical_id":"go:GO:1903969","description":"\"Any process that modulates the frequency, rate or extent of response to macrophage colony-stimulating factor.\" [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]","metadata":null},{"id":"63b5fc8911ce440ca298a75fa1d49616","type":"GO_TERM","name":"regulation of response to nutrient levels","canonical_id":"go:GO:0032107","description":"\"Any process that modulates the frequency, rate or extent of a response to nutrient levels.\" [GOC:mah]","metadata":null},{"id":"b1d2fdf784a24c2297da058f778a77c9","type":"GO_TERM","name":"regulation of response to osmotic stress","canonical_id":"go:GO:0047484","description":"\"Any process that modulates the rate or extent of the response to osmotic stress.\" [GOC:ai]","metadata":null},{"id":"94a9e811b4a648f8929118b59b60fdc2","type":"GO_TERM","name":"regulation of response to oxidative stress","canonical_id":"go:GO:1902882","description":"\"Any process that modulates the frequency, rate or extent of response to oxidative stress.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:16899554]","metadata":null},{"id":"213fe565087845e993a402b69109c221","type":"GO_TERM","name":"regulation of response to propan-1-ol","canonical_id":"go:GO:1901445","description":"\"Any process that modulates the frequency, rate or extent of response to propan-1-ol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"2fb6ef801f964911afb56abde067ca91","type":"GO_TERM","name":"regulation of response to pullulan","canonical_id":"go:GO:1900518","description":"\"Any process that modulates the frequency, rate or extent of response to pullulan.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c365dd55d28e4655b8e8f446353c1acf","type":"GO_TERM","name":"regulation of response to reactive oxygen species","canonical_id":"go:GO:1901031","description":"\"Any process that modulates the frequency, rate or extent of response to reactive oxygen species.\" [GOC:kmv, GOC:TermGenie]","metadata":null},{"id":"af0dbd33d2b748c39bdc5e2e9e3c0117","type":"GO_TERM","name":"regulation of response to red or far red light","canonical_id":"go:GO:2000030","description":"\"Any process that modulates the frequency, rate or extent of response to red or far red light.\" [GOC:obol]","metadata":null},{"id":"fdff85cd33084cdfbc4e9acdeb3f8997","type":"GO_TERM","name":"regulation of response to salt stress","canonical_id":"go:GO:1901000","description":"\"Any process that modulates the frequency, rate or extent of response to salt stress.\" [GOC:TermGenie, PMID:22627139]","metadata":null},{"id":"5d82251b4dbf4810ab362dfb7042a104","type":"GO_TERM","name":"regulation of response to stimulus","canonical_id":"go:GO:0048583","description":"\"Any process that modulates the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.\" [GOC:jid]","metadata":null},{"id":"96dde01207484fec81a07429a573b602","type":"GO_TERM","name":"regulation of response to stress","canonical_id":"go:GO:0080134","description":"\"Any process that modulates the frequency, rate or extent of a response to stress. Response to stress is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:dhl]","metadata":null},{"id":"2fca6b73c7274fa2aad7ffe38fd2ab33","type":"GO_TERM","name":"regulation of response to toluene","canonical_id":"go:GO:1901454","description":"\"Any process that modulates the frequency, rate or extent of response to toluene.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"7765f5ecf8cd45f99320a8a009564449","type":"GO_TERM","name":"regulation of response to tumor cell","canonical_id":"go:GO:0002834","description":"\"Any process that modulates the frequency, rate, or extent of a response to tumor cell.\" [GOC:add]","metadata":null},{"id":"25c5ad8cdaec417090879e9fd6a42663","type":"GO_TERM","name":"regulation of response to type II interferon","canonical_id":"go:GO:0060330","description":"\"Any process that modulates the rate, frequency or extent of a response to type II interferon (interferon-gamma). Response to interferon gamma is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus.\" [GOC:dph]","metadata":null},{"id":"69b566f336a04bca991a5af9ba41dbf5","type":"GO_TERM","name":"regulation of response to water deprivation","canonical_id":"go:GO:2000070","description":"\"Any process that modulates the frequency, rate or extent of response to water deprivation.\" [GOC:obol]","metadata":null},{"id":"dceed243b81b440aa32fc7870b2c2b09","type":"GO_TERM","name":"regulation of response to wounding","canonical_id":"go:GO:1903034","description":"\"Any process that modulates the frequency, rate or extent of response to wounding.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:19164535]","metadata":null},{"id":"41571d64bb7942298cf1472587c48df9","type":"GO_TERM","name":"regulation of resting membrane potential","canonical_id":"go:GO:0060075","description":"\"Any process that modulates the establishment or extent of a resting potential, the electrical charge across the plasma membrane, with the interior of the cell negative with respect to the exterior. The resting potential is the membrane potential of a cell that is not stimulated to be depolarized or hyperpolarized.\" [GOC:dph, GOC:ef, ISBN:0195088433]","metadata":null},{"id":"d309caa5e18345928a996ed479097493","type":"GO_TERM","name":"regulation of reticulophagy","canonical_id":"go:GO:0140500","description":"\"Any process that modulates the frequency, rate or extent of reticulophagy.\" [PMID:32735772]","metadata":null},{"id":"4dd801e9c4884d32a09841b08bb32e30","type":"GO_TERM","name":"regulation of retina development in camera-type eye","canonical_id":"go:GO:1902866","description":"\"Any process that modulates the frequency, rate or extent of retina development in camera-type eye.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:16872597]","metadata":null},{"id":"5af470a6049741dd9c483ad492accc42","type":"GO_TERM","name":"regulation of retinal cell programmed cell death","canonical_id":"go:GO:0046668","description":"\"Any process that modulates the frequency, rate or extent of programmed cell death that occurs in the retina.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"77af76093c134923abe179133f5db3c7","type":"GO_TERM","name":"regulation of retinal cone cell fate commitment","canonical_id":"go:GO:0060222","description":"\"Any process that modulates the process in which a cell becomes committed to a retinal cone cell fate. Retinal cone cell fate commitment is the process in which the developmental fate of a cell becomes restricted such that it will develop into a retinal cone cell.\" [GOC:dph]","metadata":null},{"id":"6673380b92d240b1b4995fd925b5f914","type":"GO_TERM","name":"regulation of retinal cone cell fate specification","canonical_id":"go:GO:0042673","description":"\"Any process that mediates the specification of a cell into a retinal cone cell.\" [GOC:curators]","metadata":null},{"id":"340b713d61c6462e854f0e455e6ef9b8","type":"GO_TERM","name":"regulation of retinal ganglion cell axon guidance","canonical_id":"go:GO:0090259","description":"\"Any process that modulates the frequency, rate, or extent of retinal ganglion cell axon guidance, the process in which the migration of an axon growth cone of a retinal ganglion cell (RGC) is directed to its target in the brain in response to a combination of attractive and repulsive cues.\" [GOC:tb, GOC:yaf]","metadata":null},{"id":"fa75d69467ad462cb7840a987afc2afb","type":"GO_TERM","name":"regulation of retinal rod cell fate commitment","canonical_id":"go:GO:0060224","description":"\"Any process that modulates the process in which the developmental fate of a cell becomes restricted such that it will develop into a retinal rod cell. A retinal rod cell is one of the two photoreceptor subtypes in a camera-type eye.\" [GOC:dph]","metadata":null},{"id":"3bfd2ebd5efd468ab121923ace69954e","type":"GO_TERM","name":"regulation of retinoic acid biosynthetic process","canonical_id":"go:GO:1900052","description":"\"Any process that modulates the frequency, rate or extent of retinoic acid biosynthetic process.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"13901aabdd974f4798a8d6273f864577","type":"GO_TERM","name":"regulation of retinoic acid receptor signaling pathway","canonical_id":"go:GO:0048385","description":"\"Any process that modulates the frequency, rate or extent of retinoic acid receptor signaling pathway activity.\" [GOC:dgh]","metadata":null},{"id":"abf43e7884134bb6b8615ee41f3088b5","type":"GO_TERM","name":"regulation of retrograde axon cargo transport","canonical_id":"go:GO:2001017","description":"\"Any process that modulates the frequency, rate or extent of retrograde axon cargo transport.\" [GOC:obol]","metadata":null},{"id":"94e153b0b62e407bac6e9d2c745025cf","type":"GO_TERM","name":"regulation of retrograde dense core granule transport","canonical_id":"go:GO:1901954","description":"\"Any process that modulates the frequency, rate or extent of retrograde dense core granule transport.\" [GOC:kmv, GOC:TermGenie, PMID:23358451]","metadata":null},{"id":"be18c69f89404c22bfc6eeca1cef9e5a","type":"GO_TERM","name":"regulation of retrograde protein transport, ER to cytosol","canonical_id":"go:GO:1904152","description":"\"Any process that modulates the frequency, rate or extent of retrograde protein transport, ER to cytosol.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:18555783]","metadata":null},{"id":"2671181cd9e64cefb5be5d3acf6ae9ad","type":"GO_TERM","name":"regulation of retrograde trans-synaptic signaling by endocanabinoid","canonical_id":"go:GO:0099178","description":"\"Any process that modulates the frequency, rate or extent of retrograde trans-synaptic signaling by an endocannabinoid.\" [GOC:dos, PMID:15664177]","metadata":null},{"id":"6c773d6ba6f04a35890e9dbb77b25f33","type":"GO_TERM","name":"regulation of retrograde trans-synaptic signaling by neuropeptide","canonical_id":"go:GO:1905432","description":"\"Any process that modulates the frequency, rate or extent of retrograde trans-synaptic signaling by neuropeptide.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:19448629]","metadata":null},{"id":"d2a9678cdc7742ed86b51cacb23a3ab3","type":"GO_TERM","name":"regulation of retrograde trans-synaptic signaling by trans-synaptic protein complex","canonical_id":"go:GO:0099176","description":"\"Any process that modulates the frequency, rate or extent of retrograde trans-synaptic signaling by a trans-synaptic complex.\" [GOC:dos, PMID:23209303]","metadata":null},{"id":"b85ca535d2b64533b15ff4918cbef269","type":"GO_TERM","name":"regulation of retrograde transport, endosome to Golgi","canonical_id":"go:GO:1905279","description":"\"Any process that modulates the frequency, rate or extent of retrograde transport, endosome to Golgi.\" [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23395371]","metadata":null},{"id":"1ed0dc8c66ce47148648a40e84db65ee","type":"GO_TERM","name":"regulation of retrograde vesicle-mediated transport, Golgi to ER","canonical_id":"go:GO:2000156","description":"\"Any process that modulates the frequency, rate or extent of retrograde vesicle-mediated transport, Golgi to ER.\" [GOC:mah]","metadata":null},{"id":"9b717bfbf0b64f27952ec8fe6bc70704","type":"GO_TERM","name":"regulation of reverse cholesterol transport","canonical_id":"go:GO:1903062","description":"\"Any process that modulates the frequency, rate or extent of reverse cholesterol transport.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:23931754]","metadata":null},{"id":"81ae8b30a67b49c5a5d382c88bf4c87b","type":"GO_TERM","name":"regulation of reverse transcription","canonical_id":"go:GO:1900268","description":"\"Any process that modulates the frequency, rate or extent of reverse transcription.\" [GOC:TermGenie]","metadata":null},{"id":"347f52d62e7e4374a5b0f572daf9a0bb","type":"GO_TERM","name":"regulation of rhamnose catabolic process","canonical_id":"go:GO:0043463","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of rhamnose, the hexose 6-deoxy-L-mannose.\" [GOC:jl]","metadata":null},{"id":"bac3814830e7450fb6fd98969d7d2bcd","type":"GO_TERM","name":"regulation of ribonuclease activity","canonical_id":"go:GO:0060700","description":"\"Any process that modulates the rate, frequency, or extent of ribonuclease activity, catalysis of the hydrolysis of phosphodiester bonds in chains of RNA.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"4612ee1068104f2d8c8a90d5744e0a11","type":"GO_TERM","name":"regulation of ribonucleoprotein complex localization","canonical_id":"go:GO:2000197","description":"\"Any process that modulates the frequency, rate or extent of ribonucleoprotein complex localization.\" [GOC:mah]","metadata":null},{"id":"a5da8f44e94b4b05bb89e4da20d1f6f3","type":"GO_TERM","name":"regulation of ribosomal large subunit export from nucleus","canonical_id":"go:GO:2000203","description":"\"Any process that modulates the frequency, rate or extent of ribosomal large subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"b25f839593524a84b8cf369757fd5ced","type":"GO_TERM","name":"regulation of ribosomal protein gene transcription by RNA polymerase II","canonical_id":"go:GO:0060962","description":"\"Any process that modulates the frequency, rate or extent of the synthesis of RNA from ribosomal protein genes mediated by RNA polymerase II.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"7729043f25ab49d39a5f94754bb30449","type":"GO_TERM","name":"regulation of ribosomal small subunit export from nucleus","canonical_id":"go:GO:2000206","description":"\"Any process that modulates the frequency, rate or extent of ribosomal small subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"9130da5b6d924ebda445e4b398f6d63b","type":"GO_TERM","name":"regulation of ribosomal subunit export from nucleus","canonical_id":"go:GO:2000200","description":"\"Any process that modulates the frequency, rate or extent of ribosomal subunit export from nucleus.\" [GOC:mah]","metadata":null},{"id":"e124a31777d44ef4be75400c27ea3618","type":"GO_TERM","name":"regulation of ribosome biogenesis","canonical_id":"go:GO:0090069","description":"\"Any process that modulates the rate, frequency or extent of ribosome biogenesis. Ribosome biogenesis is the cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of ribosome subunits.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"753f911bc04845ed85d070581b5ca671","type":"GO_TERM","name":"regulation of root development","canonical_id":"go:GO:2000280","description":"\"Any process that modulates the frequency, rate or extent of root development.\" [GOC:obol]","metadata":null},{"id":"b96c1bdde6c94496a64b5aae837fc4b2","type":"GO_TERM","name":"regulation of root hair elongation","canonical_id":"go:GO:1902890","description":"\"Any process that modulates the frequency, rate or extent of root hair elongation.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:22329353]","metadata":null},{"id":"805a7aca061147689afbf3c1a5e1ebef","type":"GO_TERM","name":"regulation of root meristem growth","canonical_id":"go:GO:0010082","description":"\"Any process involved in maintaining the size and shape of a root meristem.\" [GOC:tb]","metadata":null},{"id":"d233701791144021b58b11c3ac0f8309","type":"GO_TERM","name":"regulation of root morphogenesis","canonical_id":"go:GO:2000067","description":"\"Any process that modulates the frequency, rate or extent of root morphogenesis.\" [GOC:obol]","metadata":null},{"id":"c083dc374b534bada5948b4843fcc12a","type":"GO_TERM","name":"regulation of ruffle assembly","canonical_id":"go:GO:1900027","description":"\"Any process that modulates the frequency, rate or extent of ruffle assembly.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"20ce2eac1f004299aaf40fd3b0ff1101","type":"GO_TERM","name":"regulation of ryanodine-sensitive calcium-release channel activity","canonical_id":"go:GO:0060314","description":"\"Any process that modulates the activity of a ryanodine-sensitive calcium-release channel. The ryanodine-sensitive calcium-release channel catalyzes the transmembrane transfer of a calcium ion by a channel that opens when a ryanodine class ligand has been bound by the channel complex or one of its constituent parts.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"d192472415134f4e851d68b55bf3a4d8","type":"GO_TERM","name":"regulation of salicylic acid biosynthetic process","canonical_id":"go:GO:0080142","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of salicylic acid.\" [GOC:dhl]","metadata":null},{"id":"53f8f2a1490f4e83a4d6a7820838ef05","type":"GO_TERM","name":"regulation of salicylic acid mediated signaling pathway","canonical_id":"go:GO:2000031","description":"\"Any process that modulates the frequency, rate or extent of salicylic acid mediated signaling pathway.\" [GOC:obol]","metadata":null},{"id":"2d7dc992c97d4af5ba6693ea5db993fe","type":"GO_TERM","name":"regulation of salicylic acid metabolic process","canonical_id":"go:GO:0010337","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving salicylic acid.\" [PMID:14765119]","metadata":null},{"id":"54c44d0701344684a1b8cdd8e394fd0a","type":"GO_TERM","name":"regulation of saliva secretion","canonical_id":"go:GO:0046877","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of saliva from a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"bb1ec080438247599e70b94761ead3b1","type":"GO_TERM","name":"regulation of salivary gland boundary specification","canonical_id":"go:GO:0045704","description":"\"Any process that modulates the frequency, rate or extent of salivary gland determination.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"7bfd6bedb843417ba3e2e60f9856daeb","type":"GO_TERM","name":"regulation of sarcinapterin biosynthetic process","canonical_id":"go:GO:1900971","description":"\"Any process that modulates the frequency, rate or extent of sarcinapterin biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"eedff2da02c74a56a0e90680ef68d44d","type":"GO_TERM","name":"regulation of sarcomere organization","canonical_id":"go:GO:0060297","description":"\"Any process that modulates the rate, frequency or extent of myofibril assembly by organization of muscle actomyosin into sarcomeres. The sarcomere is the repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"93bfc056a5ce4cf68e04cb6b7567503a","type":"GO_TERM","name":"regulation of satellite cell activation involved in skeletal muscle regeneration","canonical_id":"go:GO:0014717","description":"\"Any process that modulates the frequency, rate or extent of satellite cell activation. The satellite cell activation is the process that initiates satellite cell division by causing it to move from quiescence to the G1 stage of the cell cycle. The cell swells and there are a number of other small changes. The cells then start to divide. Following cell division the cells will differentiate.\" [GOC:mtg_muscle]","metadata":null},{"id":"fd7497234fd1461c9e2ab6c7ac98669f","type":"GO_TERM","name":"regulation of sclerenchyma cell differentiation","canonical_id":"go:GO:1904368","description":"\"Any process that modulates the frequency, rate or extent of sclerenchyma cell differentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:26025534]","metadata":null},{"id":"2dc23789c0514f1ba43cc7309d6c3545","type":"GO_TERM","name":"regulation of sclerotium development","canonical_id":"go:GO:1901922","description":"\"Any process that modulates the frequency, rate or extent of sclerotium development.\" [GOC:di, GOC:TermGenie, PMID:21148914]","metadata":null},{"id":"6941ed14ce4844669ae27e7bdda3ad51","type":"GO_TERM","name":"regulation of sclerotome development","canonical_id":"go:GO:0061190","description":"\"Any process that modulates the rate, frequency, or extent of the progression of the sclerotome over time, from its initial formation to the mature structure. The sclerotome is the portion of the somite that will give rise to a vertebra.\" [GOC:dph]","metadata":null},{"id":"4126e2cabe534c3097af041fddc8d696","type":"GO_TERM","name":"regulation of sebum secreting cell proliferation","canonical_id":"go:GO:1904002","description":"\"Any process that modulates the frequency, rate or extent of sebum secreting cell proliferation.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:16901790]","metadata":null},{"id":"d7a9da8bdf8545a49e413679399bf3fb","type":"GO_TERM","name":"regulation of secondary cell septum biogenesis","canonical_id":"go:GO:1903395","description":"\"Any process that modulates the frequency, rate or extent of secondary cell septum biogenesis.\" [GO_REF:0000058, GOC:di, GOC:TermGenie, PMID:23878277]","metadata":null},{"id":"e79bb2799a734f5bab39b5c69882b7d7","type":"GO_TERM","name":"regulation of secondary cell wall biogenesis","canonical_id":"go:GO:2000652","description":"\"Any process that modulates the frequency, rate or extent of secondary cell wall biogenesis.\" [GOC:obol]","metadata":null},{"id":"87b7cd2e41f44b4aa9b2829d041ce7be","type":"GO_TERM","name":"regulation of secondary growth","canonical_id":"go:GO:2000603","description":"\"Any process that modulates the frequency, rate or extent of secondary growth.\" [GOC:obol]","metadata":null},{"id":"673d01e9c875441485b3b65aaf6248b9","type":"GO_TERM","name":"regulation of secondary heart field cardioblast proliferation","canonical_id":"go:GO:0003266","description":"\"Any process that modulates the frequency, rate or extent of cardioblast proliferation in the second heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating. The secondary heart field is the region of the heart that will form the majority of the mesodermal component of the right ventricle, the arterial pole (outflow tract) and the venous pole (inflow tract).\" [GOC:mtg_heart, GOC:rl, PMID:17276708]","metadata":null},{"id":"a3a5e83888de40c487f2cf4d3d13da19","type":"GO_TERM","name":"regulation of secondary metabolic process","canonical_id":"go:GO:0043455","description":"\"Any process that modulates the frequency, rate or extent of secondary metabolism, the chemical reactions and pathways involving compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon.\" [GOC:jl]","metadata":null},{"id":"0a32c587aea842e696b794c4554ade62","type":"GO_TERM","name":"regulation of secondary metabolite biosynthetic process","canonical_id":"go:GO:1900376","description":"\"Any process that modulates the frequency, rate or extent of secondary metabolite biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"ef535b62313d40e4805fe3b4fd82aac7","type":"GO_TERM","name":"regulation of secondary shoot formation","canonical_id":"go:GO:2000032","description":"\"Any process that modulates the frequency, rate or extent of secondary shoot formation.\" [GOC:obol]","metadata":null},{"id":"726dc086421a438e9ad0774936eefd6f","type":"GO_TERM","name":"regulation of secretion","canonical_id":"go:GO:0051046","description":"\"Any process that modulates the frequency, rate or extent of the controlled release of a substance from a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"1ee111ad6ff7425489b54fd637fcec5a","type":"GO_TERM","name":"regulation of secretion by asymmetric Golgi ribbon formation","canonical_id":"go:GO:0090165","description":"\"The asymmetric formation of a continuous ribbon of interconnected Golgi stacks of flat cisternae that modulates the controlled release of a substance from a polarized epithelial cell.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"941ac2f249a74b38beca67110f046332","type":"GO_TERM","name":"regulation of secretion by cell","canonical_id":"go:GO:1903530","description":"\"Any process that modulates the frequency, rate or extent of secretion by cell.\" [GO_REF:0000058, GOC:pm, GOC:TermGenie, PMID:12130530]","metadata":null},{"id":"8cfca853348d44bebeb3d401289f4056","type":"GO_TERM","name":"regulation of secretion of lysosomal enzymes","canonical_id":"go:GO:0090182","description":"\"Any process that modulates the rate, frequency or extent of secretion of lysosomal enzymes, the controlled release of lysosomal enzymes by a cell.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"2b20c4053b8b45c9bd683bdd6b61a347","type":"GO_TERM","name":"regulation of secretory granule organization","canonical_id":"go:GO:1904409","description":"\"Any process that modulates the frequency, rate or extent of secretory granule organization.\" [GO_REF:0000058, GOC:TermGenie, PMID:15039777]","metadata":null},{"id":"380c6672162e4a279637c4460ebd3b2f","type":"GO_TERM","name":"regulation of seed development","canonical_id":"go:GO:0080050","description":"\"Any process that modulates the frequency, rate or extent of seed development.\" [PMID:19141706]","metadata":null},{"id":"5f43cebcaced48718173b15c695ab296","type":"GO_TERM","name":"regulation of seed dormancy process","canonical_id":"go:GO:2000033","description":"\"Any process that modulates the frequency, rate or extent of seed dormancy process.\" [GOC:obol, GOC:pr, ISBN:9781405139830]","metadata":null},{"id":"d189f1232e294f97b48c9f24e7bd0c84","type":"GO_TERM","name":"regulation of seed germination","canonical_id":"go:GO:0010029","description":"\"Any process that modulates the frequency, rate or extent of seed germination.\" [GOC:sm]","metadata":null},{"id":"ac8d15859125490f889f4f167fe1853d","type":"GO_TERM","name":"regulation of seed growth","canonical_id":"go:GO:0080113","description":"\"Any process that modulates the frequency, rate or extent of growth of the seed of an plant.\" [PMID:19141706]","metadata":null},{"id":"7ecf973262dc4572abe33ad3b7469eff","type":"GO_TERM","name":"regulation of seed maturation","canonical_id":"go:GO:2000034","description":"\"Any process that modulates the frequency, rate or extent of seed maturation.\" [GOC:obol]","metadata":null},{"id":"1f1f6987cf754106971aa0b20efa24de","type":"GO_TERM","name":"regulation of seedling development","canonical_id":"go:GO:1900140","description":"\"Any process that modulates the frequency, rate or extent of seedling development.\" [GOC:TermGenie]","metadata":null},{"id":"b76d7d259a9c42f3912483c2f8e7cc6e","type":"GO_TERM","name":"regulation of selenocysteine incorporation","canonical_id":"go:GO:1904569","description":"\"Any process that modulates the frequency, rate or extent of selenocysteine incorporation.\" [GO_REF:0000058, GOC:TermGenie, PMID:21685449]","metadata":null},{"id":"bcbd18b42787456691527c15029086af","type":"GO_TERM","name":"regulation of semaphorin-plexin signaling pathway","canonical_id":"go:GO:2001260","description":"\"Any process that modulates the frequency, rate or extent of semaphorin-plexin signaling pathway.\" [GOC:BHF]","metadata":null},{"id":"9cbadbf7e1b54752be759541475223d6","type":"GO_TERM","name":"regulation of sensory neuron axon guidance","canonical_id":"go:GO:1905489","description":"\"Any process that modulates the frequency, rate or extent of sensory neuron axon guidance.\" [GO_REF:0000058, GOC:TermGenie, PMID:16516839]","metadata":null},{"id":"0ba8b1f78dab4c8eab1aa597a5672354","type":"GO_TERM","name":"regulation of sensory perception","canonical_id":"go:GO:0051931","description":"\"Any process that modulates the frequency, rate or extent of sensory perception, the series of events required for an organism to receive a sensory stimulus, convert it to a molecular signal, and recognize and characterize the signal.\" [GOC:ai]","metadata":null},{"id":"281885aee5024b44acece8bd6279c3a4","type":"GO_TERM","name":"regulation of sensory perception of bitter taste","canonical_id":"go:GO:1904660","description":"\"Any process that modulates the frequency, rate or extent of sensory perception of bitter taste.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:1716172]","metadata":null},{"id":"ef2961d7abe64da3a075a0d5bdaedeea","type":"GO_TERM","name":"regulation of sensory perception of pain","canonical_id":"go:GO:0051930","description":"\"Any process that modulates the frequency, rate or extent of the sensory perception of pain, the series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal.\" [GOC:ai]","metadata":null},{"id":"45a09d0c6e8b477cacd81ac1628e9512","type":"GO_TERM","name":"regulation of sensory perception of sweet taste","canonical_id":"go:GO:1904656","description":"\"Any process that modulates the frequency, rate or extent of sensory perception of sweet taste.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:1716172]","metadata":null},{"id":"a4714810cb34401f9717efeb81063f2f","type":"GO_TERM","name":"regulation of septation initiation signaling","canonical_id":"go:GO:0031029","description":"\"Any process that modulates the frequency, rate or extent of septation initiation signaling.\" [GOC:mah]","metadata":null},{"id":"22491e6421ed484e8e1cebf2292e08b5","type":"GO_TERM","name":"regulation of septum digestion after cytokinesis","canonical_id":"go:GO:0010590","description":"\"Any process that modulates the rate, frequency or extent of the process of physically separating the septal cell wall material by enzymatic digestion, that occurs after daughter cells are separated by cytokinesis.\" [GOC:mtg_cell_cycle, GOC:TermGenie, PMID:19959363, PMID:21246752, PMID:22786806]","metadata":null},{"id":"84ba0ce757e94506907aead518df2955","type":"GO_TERM","name":"regulation of serine-type endopeptidase activity","canonical_id":"go:GO:1900003","description":"\"Any process that modulates the frequency, rate or extent of serine-type endopeptidase activity.\" [GOC:TermGenie]","metadata":null},{"id":"56ad0ae24c0643999b7e4d64fbedfd0d","type":"GO_TERM","name":"regulation of serotonin biosynthetic process","canonical_id":"go:GO:1905627","description":"\"Any process that modulates the frequency, rate or extent of serotonin biosynthetic process.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:25642596]","metadata":null},{"id":"eaa3492fb35649f1b14a6855b8558901","type":"GO_TERM","name":"regulation of serotonin secretion","canonical_id":"go:GO:0014062","description":"\"Any process that modulates the frequency, rate or extent of the regulated release of serotonin.\" [GOC:ef]","metadata":null},{"id":"c1d950eaaa7b481b9ac585370880c81b","type":"GO_TERM","name":"regulation of serotonin uptake","canonical_id":"go:GO:0051611","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of the monoamine neurotransmitter serotonin into a cell.\" [GOC:ai]","metadata":null},{"id":"de227effcbc04ba7be6ad9ff7071f96a","type":"GO_TERM","name":"regulation of sevenless signaling pathway","canonical_id":"go:GO:0045501","description":"\"Any process that modulates the frequency, rate or extent of the sevenless signaling pathway.\" [GOC:curators]","metadata":null},{"id":"f7dd7ecc8d86493ea5e860955eb93ccc","type":"GO_TERM","name":"regulation of sexual sporulation","canonical_id":"go:GO:0034306","description":"\"Any process that modulates the frequency, rate or extent of spore formation from the products of meiosis. An example of this is found in Saccharomyces cerevisiae.\" [GOC:mah]","metadata":null},{"id":"740af1aa2ab1486788ab06148b8d204c","type":"GO_TERM","name":"regulation of sexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043940","description":"\"Any process that modulates the frequency, rate or extent of the formation of cellular spores derived from the products of meiosis.\" [GOC:pamgo_curators]","metadata":null},{"id":"d59630021968465a860fdc6c61b2a580","type":"GO_TERM","name":"regulation of shade avoidance","canonical_id":"go:GO:1902446","description":"\"Any process that modulates the frequency, rate or extent of shade avoidance.\" [GOC:TermGenie, PMID:23763263]","metadata":null},{"id":"af968ccb437a4fb19c18ca7f3bf966d9","type":"GO_TERM","name":"regulation of shell calcification","canonical_id":"go:GO:1905648","description":"\"Any process that modulates the frequency, rate or extent of shell calcification.\" [GO_REF:0000058, GOC:TermGenie, PMID:14648763]","metadata":null},{"id":"d6d6b5cc4bac4915b11435a71130eb48","type":"GO_TERM","name":"regulation of shelterin complex assembly","canonical_id":"go:GO:1904790","description":"\"Any process that modulates the frequency, rate or extent of shelterin complex assembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24270157]","metadata":null},{"id":"707580b6f11341bca68a3e5cb82c1d0b","type":"GO_TERM","name":"regulation of shoot apical meristem development","canonical_id":"go:GO:1902183","description":"\"Any process that modulates the frequency, rate or extent of shoot apical meristem development.\" [GOC:TermGenie, PMID:21496644]","metadata":null},{"id":"043abfc760b74945b61f7b53669fb361","type":"GO_TERM","name":"regulation of shoot system development","canonical_id":"go:GO:0048831","description":"\"Any process that modulates the frequency, rate or extent of shoot development.\" [GOC:tb, PMID:16361392]","metadata":null},{"id":"58fd65e6e7ba4e93bdaded1b14c43d53","type":"GO_TERM","name":"regulation of shoot system morphogenesis","canonical_id":"go:GO:1900618","description":"\"Any process that modulates the frequency, rate or extent of shoot morphogenesis.\" [GOC:TermGenie]","metadata":null},{"id":"7d3f46de3ae34a2a91bf695fef5d0d56","type":"GO_TERM","name":"regulation of short-day photoperiodism, flowering","canonical_id":"go:GO:0048587","description":"\"Any process that modulates the frequency, rate or extent of short-day photoperiodism, where the response associated with the photoperiodism is flowering. Flowering is defined by the switch from the vegetative to the reproductive phase.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"10750c97bedb4983bb1e7750fcd99da1","type":"GO_TERM","name":"regulation of short-term neuronal synaptic plasticity","canonical_id":"go:GO:0048172","description":"\"A process that modulates short-term neuronal synaptic plasticity, the ability of neuronal synapses to change in the short-term as circumstances require. Short-term neuronal synaptic plasticity generally involves increasing or decreasing synaptic sensitivity.\" [GOC:jid, PMID:11891290]","metadata":null},{"id":"157b4ec8a48e46c3aa89d1045344bf02","type":"GO_TERM","name":"regulation of short-term synaptic potentiation","canonical_id":"go:GO:1905512","description":"\"Any process that modulates the frequency, rate or extent of short-term synaptic potentiation.\" [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:15470145]","metadata":null},{"id":"a2ca9bb570e445cf8c3976e6402886f6","type":"GO_TERM","name":"regulation of siRNA processing","canonical_id":"go:GO:0070921","description":"\"Any process that modulates the frequency, rate or extent of siRNA processing.\" [GOC:mah]","metadata":null},{"id":"8902c22d49bd41ffa2ab53a92c053526","type":"GO_TERM","name":"regulation of siRNA-independent facultative heterochromatin formation","canonical_id":"go:GO:1902801","description":"\"Any process that modulates the frequency, rate or extent of siRNA-independent facultative heterochromatin assembly.\" [GO_REF:0000058, GOC:TermGenie, PMID:24210919]","metadata":null},{"id":"2a893e2699aa463494dfb73abd0c6971","type":"GO_TERM","name":"regulation of siRNA-mediated facultative heterochromatin formation","canonical_id":"go:GO:1902802","description":"\"Any process that modulates the frequency, rate or extent of siRNA-dependent facultative heterochromatin formation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24210919]","metadata":null},{"id":"07e0a665de5441f5a674f6b5d25869f4","type":"GO_TERM","name":"regulation of siderophore biosynthetic process","canonical_id":"go:GO:1900704","description":"\"Any process that modulates the frequency, rate or extent of siderophore biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"255256d4beba4b4394d23c2131760009","type":"GO_TERM","name":"regulation of signal transduction","canonical_id":"go:GO:0009966","description":"\"Any process that modulates the frequency, rate or extent of signal transduction.\" [GOC:sm]","metadata":null},{"id":"0e45011387c74701a2833c613452500f","type":"GO_TERM","name":"regulation of signal transduction by p53 class mediator","canonical_id":"go:GO:1901796","description":"\"Any process that modulates the frequency, rate or extent of signal transduction by p53 class mediator.\" [GOC:TermGenie]","metadata":null},{"id":"f790d65ae409450289048d627969e42d","type":"GO_TERM","name":"regulation of signal transduction by receptor internalization","canonical_id":"go:GO:0038009","description":"\"Any process that modulates the frequency, rate or extent of signal transduction by the movement of a signaling receptor from the plasma membrane to the inside of the cell. Receptor internalization can have a positive or negative effect on a signaling pathway.\" [GOC:bf, GOC:signaling, PMID:17011816, PMID:19696798]","metadata":null},{"id":"44a6e91123ee4bfca2cdb544ae81fc70","type":"GO_TERM","name":"regulation of signaling","canonical_id":"go:GO:0023051","description":"\"Any process that modulates the frequency, rate or extent of a signaling process.\" [GOC:mtg_signal]","metadata":null},{"id":"6884ebe3615e456a82a32761180dd34a","type":"GO_TERM","name":"regulation of signaling receptor activity","canonical_id":"go:GO:0010469","description":"\"Any process that modulates the frequency, rate or extent of a signaling receptor activity. Receptor activity is when a molecule combines with an extracellular or intracellular messenger to initiate a change in cell activity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"b1a0250160c240beaa43c047410cdbd7","type":"GO_TERM","name":"regulation of silent mating-type cassette heterochromatin formation","canonical_id":"go:GO:0090054","description":"\"Any process that modulates the frequency, rate, or extent of heterochromatin formation at silent mating-type cassette.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"aca6d790b0c24ea2b892a795d6833966","type":"GO_TERM","name":"regulation of sinapate ester biosynthetic process","canonical_id":"go:GO:1903085","description":"\"Any process that modulates the frequency, rate or extent of sinapate ester biosynthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:11080161]","metadata":null},{"id":"a0bd2b2834ac428dac07576aa4a651cd","type":"GO_TERM","name":"regulation of single strand break repair","canonical_id":"go:GO:1903516","description":"\"Any process that modulates the frequency, rate or extent of single strand break repair.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17395247]","metadata":null},{"id":"14a386f5b9244d2a94f31c88a3aeb90f","type":"GO_TERM","name":"regulation of single stranded viral RNA replication via double stranded DNA intermediate","canonical_id":"go:GO:0045091","description":"\"Any process that modulates the frequency, rate or extent of single stranded viral RNA replication via double stranded DNA intermediate.\" [GOC:curators]","metadata":null},{"id":"a20636f906b948ccbae45574e9954764","type":"GO_TERM","name":"regulation of single-species biofilm formation","canonical_id":"go:GO:1900190","description":"\"Any process that modulates the frequency, rate or extent of single-species biofilm formation.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"9bb375649e464d1fb1913231e66992b3","type":"GO_TERM","name":"regulation of single-species biofilm formation in or on host organism","canonical_id":"go:GO:1900228","description":"\"Any process that modulates the frequency, rate or extent of single-species biofilm formation in or on host organism.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5e5fa5aedc74476bb0ffd56976c3e80b","type":"GO_TERM","name":"regulation of single-species biofilm formation on inanimate substrate","canonical_id":"go:GO:1900231","description":"\"Any process that modulates the frequency, rate or extent of single-species biofilm formation on inanimate substrate.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"4ac4281856c140f38c20bbd0d2b3d8c6","type":"GO_TERM","name":"regulation of single-strand break repair via homologous recombination","canonical_id":"go:GO:1903110","description":"\"Any process that modulates the frequency, rate or extent of single-strand break repair via homologous recombination.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:24339919]","metadata":null},{"id":"d228101eaa50435398bfc4634b400210","type":"GO_TERM","name":"regulation of sister chromatid cohesion","canonical_id":"go:GO:0007063","description":"\"Any process that modulates the frequency, rate or extent of sister chromatid cohesion.\" [GOC:curators]","metadata":null},{"id":"5076d0244b6b49ceb70fee2c49465f92","type":"GO_TERM","name":"regulation of sister chromatid segregation","canonical_id":"go:GO:0033045","description":"\"Any process that modulates the frequency, rate or extent of sister chromatid segregation.\" [GOC:mah]","metadata":null},{"id":"da1c06a9d1de4105b24aa3839dfe5f00","type":"GO_TERM","name":"regulation of skeletal muscle acetylcholine-gated channel clustering","canonical_id":"go:GO:1904393","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle acetylcholine-gated channel clustering.\" [GO_REF:0000058, GOC:TermGenie, PMID:7722643]","metadata":null},{"id":"862044e3d7d245f88384b3d227cf33d3","type":"GO_TERM","name":"regulation of skeletal muscle adaptation","canonical_id":"go:GO:0014733","description":"\"Any process in which skeletal muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors. These adaptive events occur in both muscle fibers and associated structures (motoneurons and capillaries), and they involve alterations in regulatory mechanisms, contractile properties and metabolic capacities.\" [GOC:mtg_muscle]","metadata":null},{"id":"fffb25c2b007416faf0fe21fc053bc7b","type":"GO_TERM","name":"regulation of skeletal muscle cell differentiation","canonical_id":"go:GO:2001014","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"f3eac4abdc6746d8aaeaaee6d1f6d6c0","type":"GO_TERM","name":"regulation of skeletal muscle cell proliferation","canonical_id":"go:GO:0014857","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle cell proliferation.\" [CL:0000188, GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"482506a927e74f06b2ea71489174d6ca","type":"GO_TERM","name":"regulation of skeletal muscle contraction","canonical_id":"go:GO:0014819","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"a7210a1a366f44e49948995e0be8a97e","type":"GO_TERM","name":"regulation of skeletal muscle contraction by action potential","canonical_id":"go:GO:0100001","description":"\"Any action potential process that regulates skeletal muscle contraction.\" [GOC:cjm, GOC:obol]","metadata":null},{"id":"3043bbc4d32c4a5d8bbac771cc5daa2e","type":"GO_TERM","name":"regulation of skeletal muscle contraction by calcium ion signaling","canonical_id":"go:GO:0014722","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction by changing the calcium ion signals that trigger contraction.\" [GOC:mtg_muscle]","metadata":null},{"id":"88c59778dd1444eeb948e7bb52a4d9c0","type":"GO_TERM","name":"regulation of skeletal muscle contraction by chemo-mechanical energy conversion","canonical_id":"go:GO:0014862","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction by regulating force and velocity of shortening. The force of skeletal muscle contraction is produced by acto-myosin interaction processes through formation of cross bridges. The shortening leads to reduction of length of muscle fiber and sarcomeres.\" [GOC:mtg_muscle]","metadata":null},{"id":"c2497738d5874b97bc77c05d71239bf1","type":"GO_TERM","name":"regulation of skeletal muscle contraction by modulation of calcium ion sensitivity of myofibril","canonical_id":"go:GO:0014723","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction by changing calcium ion binding affinity of the myofibril.\" [GOC:mtg_muscle]","metadata":null},{"id":"c2974195b69649f1b2873cded5f68460","type":"GO_TERM","name":"regulation of skeletal muscle contraction by neural stimulation via neuromuscular junction","canonical_id":"go:GO:0014852","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction by variation of the pattern of stimulation by nervous system.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"fb35ae7c60ba43ee803b663e91b3699e","type":"GO_TERM","name":"regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion","canonical_id":"go:GO:0014809","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction via the regulation of the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol. The sarcoplasmic reticulum is the endoplasmic reticulum of striated muscle, specialised for the sequestration of calcium ions that are released upon receipt of a signal relayed by the T tubules from the neuromuscular junction.\" [GOC:mtg_muscle]","metadata":null},{"id":"b2ddbe96d5ba4bd486b42a780ca8ea4a","type":"GO_TERM","name":"regulation of skeletal muscle contraction via regulation of action potential","canonical_id":"go:GO:0014861","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle contraction by depolarization of muscle membrane and ionic fluxes.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:mtg_muscle]","metadata":null},{"id":"66771935f52e443db54a8a3389357bcd","type":"GO_TERM","name":"regulation of skeletal muscle fiber development","canonical_id":"go:GO:0048742","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle fiber development. Muscle fibers are formed by the maturation of myotubes. They can be classed as slow, intermediate/fast or fast.\" [GOC:dph, GOC:jid, GOC:mtg_muscle, GOC:sm]","metadata":null},{"id":"988db1b82faa4745834acf8668d1faba","type":"GO_TERM","name":"regulation of skeletal muscle fiber differentiation","canonical_id":"go:GO:1902809","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle fiber differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:17879321]","metadata":null},{"id":"821395ba25224f39bdff3dd977bfebee","type":"GO_TERM","name":"regulation of skeletal muscle hypertrophy","canonical_id":"go:GO:1904204","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle hypertrophy.\" [GO_REF:0000058, GOC:TermGenie, PMID:23470307]","metadata":null},{"id":"5d439a2ad392473885584b2b2cf4cfff","type":"GO_TERM","name":"regulation of skeletal muscle satellite cell proliferation","canonical_id":"go:GO:0014842","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle satellite cell proliferation.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"2d2b129fe66a4a349c1a60565fbd6b41","type":"GO_TERM","name":"regulation of skeletal muscle tissue development","canonical_id":"go:GO:0048641","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle tissue development.\" [GOC:curators]","metadata":null},{"id":"c2c8bce542fd4cbab548f587bfae9d3d","type":"GO_TERM","name":"regulation of skeletal muscle tissue growth","canonical_id":"go:GO:0048631","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle growth.\" [GOC:lm, PMID:15726494, PMID:15907921]","metadata":null},{"id":"05939f2718d14cafb1ab86766f0f6c45","type":"GO_TERM","name":"regulation of skeletal muscle tissue regeneration","canonical_id":"go:GO:0043416","description":"\"Any process that modulates the frequency, rate or extent of skeletal muscle.\" [GOC:jl]","metadata":null},{"id":"3258d41aa7f645f587f4a646712a8bde","type":"GO_TERM","name":"regulation of slow-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031449","description":"\"Any process that modulates the frequency, rate or extent of slow-twitch skeletal muscle contraction.\" [GOC:dph, GOC:ef, GOC:mah, GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"56273be42a604aa0990a2f2112d5701c","type":"GO_TERM","name":"regulation of small GTPase mediated signal transduction","canonical_id":"go:GO:0051056","description":"\"Any process that modulates the frequency, rate or extent of small GTPase mediated signal transduction.\" [GOC:curators]","metadata":null},{"id":"8b61678b957245d1958c69cda183e75c","type":"GO_TERM","name":"regulation of small intestinal transit","canonical_id":"go:GO:0120057","description":"\"Any process that modulates the frequency, rate or extent of any small intestinal transit process, the migration of ingested material along the length of the small intestine.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"6ac85ce9dbb44b21b3aaa2660d7881d3","type":"GO_TERM","name":"regulation of small intestine smooth muscle contraction","canonical_id":"go:GO:1904347","description":"\"Any process that modulates the frequency, rate or extent of small intestine smooth muscle contraction.\" [GO_REF:0000058, GOC:TermGenie, PMID:11991626]","metadata":null},{"id":"6a2780722e0440d8abcd5c89aadb8844","type":"GO_TERM","name":"regulation of small molecule metabolic process","canonical_id":"go:GO:0062012","description":"\"Any process that modulates the rate, frequency or extent of a small molecule metabolic process.\" [GOC:vw]","metadata":null},{"id":"f752b0ecf58d4119bf62332febce8130","type":"GO_TERM","name":"regulation of smooth muscle cell apoptotic process","canonical_id":"go:GO:0034391","description":"\"Any process that modulates the frequency, rate, or extent of smooth muscle cell apoptotic process.\" [GOC:BHF, GOC:mtg_apoptosis, GOC:rl]","metadata":null},{"id":"3653f6df3e6c479988ef6668f6f03fa3","type":"GO_TERM","name":"regulation of smooth muscle cell chemotaxis","canonical_id":"go:GO:0071671","description":"\"Any process that modulates the frequency, rate, or extent of smooth muscle cell chemotaxis.\" [GOC:mah]","metadata":null},{"id":"86dd3002969a4c3d985214f6351c64d8","type":"GO_TERM","name":"regulation of smooth muscle cell differentiation","canonical_id":"go:GO:0051150","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle cell differentiation.\" [CL:0000192, GOC:ai]","metadata":null},{"id":"d2ec7f566108496ba74dfe37f632741b","type":"GO_TERM","name":"regulation of smooth muscle cell migration","canonical_id":"go:GO:0014910","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle cell migration.\" [CL:0000192, GOC:mtg_muscle]","metadata":null},{"id":"9952e338d47d435cb694c9e439573f8c","type":"GO_TERM","name":"regulation of smooth muscle cell proliferation","canonical_id":"go:GO:0048660","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle cell proliferation.\" [CL:0000192, GOC:ebc]","metadata":null},{"id":"8e3dcfe9fa454f24a57774433baead6b","type":"GO_TERM","name":"regulation of smooth muscle cell-matrix adhesion","canonical_id":"go:GO:2000097","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle cell-matrix adhesion.\" [GOC:BHF]","metadata":null},{"id":"6f80fb4f1e2241ee8ebd309123f6042f","type":"GO_TERM","name":"regulation of smooth muscle contraction","canonical_id":"go:GO:0006940","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle contraction.\" [GOC:curators]","metadata":null},{"id":"0b6d1fbba57e41edb8ef464e7b37c9bf","type":"GO_TERM","name":"regulation of smooth muscle hypertrophy","canonical_id":"go:GO:1905147","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle hypertrophy.\" [GO_REF:0000058, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:22161164]","metadata":null},{"id":"0c01e5813e0f4d8aae58e847c8a5cc74","type":"GO_TERM","name":"regulation of smooth muscle tissue development","canonical_id":"go:GO:1905899","description":"\"Any process that modulates the frequency, rate or extent of smooth muscle tissue development.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:14709716]","metadata":null},{"id":"a48fea13b069444c95d42e0d0bf1eee6","type":"GO_TERM","name":"regulation of smoothened signaling pathway","canonical_id":"go:GO:0008589","description":"\"Any process that modulates the frequency, rate or extent of smoothened signaling.\" [GOC:curators]","metadata":null},{"id":"e628d3f1f2d843a29d920e3309bf659c","type":"GO_TERM","name":"regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning","canonical_id":"go:GO:1901620","description":"\"Any process that modulates the frequency, rate or extent of smoothened signaling pathway involved in dorsal/ventral neural tube patterning.\" [GOC:TermGenie]","metadata":null},{"id":"7a55ecb92d28493ebab084a98c4dad86","type":"GO_TERM","name":"regulation of snRNA pseudouridine synthesis","canonical_id":"go:GO:1905356","description":"\"Any process that modulates the frequency, rate or extent of snRNA pseudouridine synthesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:27268497]","metadata":null},{"id":"40923506439748938c8c5abf0b7b95b2","type":"GO_TERM","name":"regulation of snRNA transcription by RNA polymerase II","canonical_id":"go:GO:1905380","description":"\"Any process that modulates the frequency, rate or extent of snRNA transcription mediated by RNA polymerase II.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:10022900]","metadata":null},{"id":"b3e249af94eb4c488012167b463b69fa","type":"GO_TERM","name":"regulation of snoRNA metabolic process","canonical_id":"go:GO:1903323","description":"\"Any process that modulates the frequency, rate or extent of snoRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"7d8f532176ef453aa8ee0bc6f76ba001","type":"GO_TERM","name":"regulation of snoRNA processing","canonical_id":"go:GO:1902796","description":"\"Any process that modulates the frequency, rate or extent of snoRNA processing.\" [GO_REF:0000058, GOC:TermGenie, PMID:24210919]","metadata":null},{"id":"590430d70b8347e6a3ffc3904072e43e","type":"GO_TERM","name":"regulation of sodium ion export across plasma membrane","canonical_id":"go:GO:1903276","description":"\"Any process that modulates the frequency, rate or extent of sodium ion export across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17095720]","metadata":null},{"id":"2232137b9fc14209ae4a14f1cda1aa52","type":"GO_TERM","name":"regulation of sodium ion import across plasma membrane","canonical_id":"go:GO:1903782","description":"\"Any process that modulates the frequency, rate or extent of sodium ion import across the plasma membrane.\" [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nc, GOC:TermGenie, PMID:19376779]","metadata":null},{"id":"421e51eae4004a4699e2cd117ea673d8","type":"GO_TERM","name":"regulation of sodium ion transmembrane transport","canonical_id":"go:GO:1902305","description":"\"Any process that modulates the frequency, rate or extent of sodium ion transmembrane transport.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:18591664]","metadata":null},{"id":"d8790ec9e3b64689828338aa51db4667","type":"GO_TERM","name":"regulation of sodium ion transmembrane transporter activity","canonical_id":"go:GO:2000649","description":"\"Any process that modulates the frequency, rate or extent of sodium ion transmembrane transporter activity.\" [GOC:obol]","metadata":null},{"id":"4597d8b9335f4c4d9909b0897bedae9e","type":"GO_TERM","name":"regulation of sodium ion transport","canonical_id":"go:GO:0002028","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:dph]","metadata":null},{"id":"860581e9cc7a442794bf3f5505f28d12","type":"GO_TERM","name":"regulation of sodium-dependent phosphate transport","canonical_id":"go:GO:2000118","description":"\"Any process that modulates the frequency, rate or extent of sodium-dependent phosphate transport.\" [GOC:BHF]","metadata":null},{"id":"404911dd337248ba9315d4f5d9b7e400","type":"GO_TERM","name":"regulation of somatic muscle development","canonical_id":"go:GO:0062223","description":"\"Any process that regulates the rate, frequency or extent of somatic muscle development.\" [PMID:16643882, PMID:25758712]","metadata":null},{"id":"230a66e725ba4ccaa510fa45c4718e48","type":"GO_TERM","name":"regulation of somatic stem cell division","canonical_id":"go:GO:1904675","description":"\"Any process that modulates the frequency, rate or extent of somatic stem cell division.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19409607]","metadata":null},{"id":"57d767e7d8d64c45844db101dffc3007","type":"GO_TERM","name":"regulation of somatic stem cell population maintenance","canonical_id":"go:GO:1904672","description":"\"Any process that modulates the frequency, rate or extent of somatic stem cell population maintenance.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19409607]","metadata":null},{"id":"e69f17bda660414f9bd46931de551866","type":"GO_TERM","name":"regulation of somatostatin secretion","canonical_id":"go:GO:0090273","description":"\"Any process that modulates the rate, frequency, extent of the regulated release of somatostatin from secretory granules in the D cells of the pancreas.\" [GOC:BHF]","metadata":null},{"id":"4895195733e7461bb48fbde3643d9051","type":"GO_TERM","name":"regulation of somitogenesis","canonical_id":"go:GO:0014807","description":"\"Any process that modulates the frequency, rate or extent of somitogenesis.\" [GOC:mtg_muscle]","metadata":null},{"id":"ae50bfc30ef849e59ca044a5f088282c","type":"GO_TERM","name":"regulation of somitomeric trunk muscle development","canonical_id":"go:GO:0014708","description":"\"Any process that modulates the frequency, rate or extent of somitomeric trunk muscle development.\" [GOC:mtg_muscle]","metadata":null},{"id":"94ce5223126140459e542af8709fb68e","type":"GO_TERM","name":"regulation of sorocarp development","canonical_id":"go:GO:0031156","description":"\"Any process that modulates the frequency, rate or extent of sorocarp development. An example of this process is found in Dictyostelium discoideum.\" [GOC:mah, GOC:mtg_sensu, PMID:4332228]","metadata":null},{"id":"a0bce8aaa6f949df93e2aae9975bf4f5","type":"GO_TERM","name":"regulation of sorocarp spore cell differentiation","canonical_id":"go:GO:1901261","description":"\"Any process that modulates the frequency, rate or extent of sorocarp spore cell differentiation.\" [GOC:rjd, GOC:TermGenie]","metadata":null},{"id":"0b4d89e46126464aabc9178d1fbe8b72","type":"GO_TERM","name":"regulation of sorocarp stalk cell differentiation","canonical_id":"go:GO:0031285","description":"\"Any process that modulates the frequency, rate or extent of sorocarp stalk cell differentiation. An example of this process is found in Dictyostelium discoideum.\" [GOC:kp, GOC:mtg_sensu, PMID:4338436]","metadata":null},{"id":"9e3c97b88c6249ca89fa364ca638d729","type":"GO_TERM","name":"regulation of sperm capacitation","canonical_id":"go:GO:1902490","description":"\"Any process that modulates the frequency, rate or extent of sperm capacitation.\" [GOC:hjd, GOC:TermGenie, PMID:22539676]","metadata":null},{"id":"6d51fb636c7c4feb822f2142640fae41","type":"GO_TERM","name":"regulation of spermatid nuclear differentiation","canonical_id":"go:GO:0045700","description":"\"Any process that modulates the frequency, rate or extent of spermatid nuclear differentiation.\" [GOC:curators]","metadata":null},{"id":"94a9d09468174b769ba56fa996a2da06","type":"GO_TERM","name":"regulation of spermidine biosynthetic process","canonical_id":"go:GO:1901304","description":"\"Any process that modulates the frequency, rate or extent of spermidine biosynthetic process.\" [GOC:pm, GOC:TermGenie]","metadata":null},{"id":"23cc488399ac42aa8a07834eb9494138","type":"GO_TERM","name":"regulation of sphingolipid biosynthetic process","canonical_id":"go:GO:0090153","description":"\"Any process that modulates the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"1ff746703795472c8d10ad53e62d845e","type":"GO_TERM","name":"regulation of sphingolipid mediated signaling pathway","canonical_id":"go:GO:1902068","description":"\"Any process that modulates the frequency, rate or extent of sphingolipid signaling.\" [GOC:TermGenie, PMID:20870412]","metadata":null},{"id":"80ef8231eb4640bfa3829749d5511575","type":"GO_TERM","name":"regulation of sphingomyelin catabolic process","canonical_id":"go:GO:2000754","description":"\"Any process that modulates the frequency, rate or extent of sphingomyelin catabolic process.\" [GOC:BHF]","metadata":null},{"id":"391a36e4df8447a5986afa5152df5373","type":"GO_TERM","name":"regulation of spinal cord association neuron differentiation","canonical_id":"go:GO:1902829","description":"\"Any process that modulates the frequency, rate or extent of spinal cord association neuron differentiation.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:21730158]","metadata":null},{"id":"bbdac3679fc441e29493161b641eba99","type":"GO_TERM","name":"regulation of spindle assembly","canonical_id":"go:GO:0090169","description":"\"Any process that modulates the rate, frequency or extent of spindle assembly. Spindle assembly is the aggregation, arrangement and bonding together of a set of components to form the spindle, the array of microtubules and associated molecules that serves to move duplicated chromosomes apart.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"68608cd223e14be09daa973c20387db9","type":"GO_TERM","name":"regulation of spindle attachment to meiosis I kinetochore","canonical_id":"go:GO:1904967","description":"\"Any process that modulates the frequency, rate or extent of attachment of spindle microtubules to kinetochore involved in homologous chromosome segregation.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw, PMID:21920317, PMID:23770679]","metadata":null},{"id":"61de293f3c274833ba709c701d496148","type":"GO_TERM","name":"regulation of spindle checkpoint","canonical_id":"go:GO:0090231","description":"\"Any process that modulates the rate, frequency, or extent of the spindle checkpoint, a cell cycle checkpoint that delays the metaphase/anaphase transition until the spindle is correctly assembled and oriented, and chromosomes are attached to the spindle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"cd12f83145694cd39e0893e12e164fd6","type":"GO_TERM","name":"regulation of spindle elongation","canonical_id":"go:GO:0032887","description":"\"Any process that modulates the frequency, rate or extent of the cell cycle process in which the distance is lengthened between poles of the spindle.\" [GOC:mah]","metadata":null},{"id":"e30e731a50c340dfa60b22a66b86c2c3","type":"GO_TERM","name":"regulation of spindle organization","canonical_id":"go:GO:0090224","description":"\"Any process that modulates the rate, frequency or extent of the assembly, arrangement of constituent parts, or disassembly of the microtubule spindle.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"2d582e72d946465c8be2cded70676781","type":"GO_TERM","name":"regulation of spongiotrophoblast cell proliferation","canonical_id":"go:GO:0060721","description":"\"Any process that modulates the rate, frequency or extent of spongiotrophoblast cell proliferation.\" [GOC:dph]","metadata":null},{"id":"e55f063319f449df890b17f0cceecddb","type":"GO_TERM","name":"regulation of spontaneous neurotransmitter secretion","canonical_id":"go:GO:1904048","description":"\"Any process that modulates the frequency, rate or extent of spontaneous neurotransmitter secretion.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22314364]","metadata":null},{"id":"7c5cc2b26e1346e797185f083f96f25f","type":"GO_TERM","name":"regulation of spontaneous synaptic transmission","canonical_id":"go:GO:0150003","description":"\"Any process that modulates the frequency, rate or extent of spontaneous synaptic transmission.\" [GOC:aruk, GOC:bc, PMID:15457210]","metadata":null},{"id":"2a97beaf21004346bd44a6a7e5edb4ee","type":"GO_TERM","name":"regulation of sporangiospore formation","canonical_id":"go:GO:0075286","description":"\"Any process that modulates the frequency, rate or extent of sporangiospore formation, a process in which sporangiospores, a type of asexual spore found in fungi, are formed. Sporangiospores are formed within sac-like structure, the sporangium, following the division of the cytoplasm.\" [GOC:pamgo_curators]","metadata":null},{"id":"1a0e1679119f4e23b03647aa5b37eda3","type":"GO_TERM","name":"regulation of sporangium development","canonical_id":"go:GO:0075310","description":"\"Any process that modulates the frequency, rate or extent of sporangium development, a process that leads to the formation of sporangium, a single-celled or many-celled structure in which spores are produced, as in fungi, algae, mosses, and ferns, gymnosperms, angiosperms.\" [GOC:pamgo_curators]","metadata":null},{"id":"a6b6ca67cbd14754bda71ea090591957","type":"GO_TERM","name":"regulation of sporangium germination","canonical_id":"go:GO:0075223","description":"\"Any process that modulates the frequency, rate or extent of sporangium germination.\" [GOC:pamgo_curators]","metadata":null},{"id":"ed82207602af4de48d3a6d4b207dbb51","type":"GO_TERM","name":"regulation of spore germination","canonical_id":"go:GO:1904359","description":"\"Any process that modulates the frequency, rate or extent of spore germination.\" [GO_REF:0000058, GOC:TermGenie, PMID:14718564, PMID:8798577]","metadata":null},{"id":"d5e65de28a1f417c8d642d647f5cde7a","type":"GO_TERM","name":"regulation of spore-bearing organ development","canonical_id":"go:GO:0075260","description":"\"Any process that modulates the frequency, rate or extent of spore-bearing organ development, a process in which hyphae grow into special aggregates called fruiting bodies that produce new spores.\" [GOC:pamgo_curators]","metadata":null},{"id":"cdc5f28cbdb64df7885165fd664e9ff9","type":"GO_TERM","name":"regulation of sporulation","canonical_id":"go:GO:0043937","description":"\"Any process that modulates the frequency, rate or extent of sporulation, the process whose specific outcome is the progression of a spore over time, from its initiation to the mature structure.\" [GOC:pamgo_curators]","metadata":null},{"id":"f2827697ef3245af863b01e81814289d","type":"GO_TERM","name":"regulation of sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0042173","description":"\"Any process that modulates the frequency, rate or extent of spore formation.\" [GOC:jl]","metadata":null},{"id":"74d5aa404c834f7c938f1725ba8120b1","type":"GO_TERM","name":"regulation of sprouting angiogenesis","canonical_id":"go:GO:1903670","description":"\"Any process that modulates the frequency, rate or extent of sprouting angiogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:16756958]","metadata":null},{"id":"fa72d5a4b5e34e9ca6928ca0787de0c0","type":"GO_TERM","name":"regulation of sprouting of injured axon","canonical_id":"go:GO:0048686","description":"\"Any process that modulates the frequency, rate or extent of sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"9671e48a528f48639637f077d14080f9","type":"GO_TERM","name":"regulation of starch biosynthetic process","canonical_id":"go:GO:0010581","description":"\"An process which modulate the frequency, rate or extent of starch biosynthesis, the chemical reactions and pathways resulting in the formation of starch.\" [GOC:tb]","metadata":null},{"id":"0f01deaa9c024625925dc42699cc98ab","type":"GO_TERM","name":"regulation of starch catabolic process","canonical_id":"go:GO:2000881","description":"\"Any process that modulates the frequency, rate or extent of starch catabolic process.\" [GOC:obol]","metadata":null},{"id":"edb3979c700d42899348fbf35f9ad18b","type":"GO_TERM","name":"regulation of starch metabolic process","canonical_id":"go:GO:2000904","description":"\"Any process that modulates the frequency, rate or extent of starch metabolic process.\" [GOC:obol]","metadata":null},{"id":"a687c85c7ec747709f6ede53d294dce4","type":"GO_TERM","name":"regulation of starch utilization system complex assembly","canonical_id":"go:GO:1900512","description":"\"Any process that modulates the frequency, rate or extent of starch utilization system complex assembly.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"c3e24a535a784c0ca03c8271eb8764c8","type":"GO_TERM","name":"regulation of stem cell differentiation","canonical_id":"go:GO:2000736","description":"\"Any process that modulates the frequency, rate or extent of stem cell differentiation.\" [GOC:obol]","metadata":null},{"id":"dfa33ad1789c43e6a12f5a2955969e3a","type":"GO_TERM","name":"regulation of stem cell division","canonical_id":"go:GO:2000035","description":"\"Any process that modulates the frequency, rate or extent of stem cell division.\" [GOC:obol]","metadata":null},{"id":"940782f0e6114f8f9c7686da6e204661","type":"GO_TERM","name":"regulation of stem cell population maintenance","canonical_id":"go:GO:2000036","description":"\"Any process that modulates the frequency, rate or extent of stem cell population maintenance.\" [GOC:obol]","metadata":null},{"id":"17fd0d8acfa249fe89b40d78d806f9ef","type":"GO_TERM","name":"regulation of stem cell proliferation","canonical_id":"go:GO:0072091","description":"\"Any process that modulates the frequency, rate or extent of stem cell proliferation. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d5631eec68c84258a0d7aef45a0cc5b9","type":"GO_TERM","name":"regulation of sterigmatocystin biosynthetic process","canonical_id":"go:GO:0010913","description":"\"Any process that modulates the rate, frequency, or extent of sterigmatocystin biosynthesis. Sterigmatocystin biosynthetic processes are the chemical reactions and pathways resulting in the formation of sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"88e5b9129dab46dfbcdb02ce6d5d8658","type":"GO_TERM","name":"regulation of steroid biosynthetic process","canonical_id":"go:GO:0050810","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.\" [GOC:ai]","metadata":null},{"id":"58f81a4d0c7a427d9caa0b06f602db12","type":"GO_TERM","name":"regulation of steroid hormone biosynthetic process","canonical_id":"go:GO:0090030","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroid hormones,compounds with a 1, 2, cyclopentanoperhydrophenanthrene nucleus that act as hormones.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"903863cd805a4050939de14fea056ad5","type":"GO_TERM","name":"regulation of steroid hormone secretion","canonical_id":"go:GO:2000831","description":"\"Any process that modulates the frequency, rate or extent of steroid hormone secretion.\" [GOC:sl]","metadata":null},{"id":"0ef6e8bdb3714330885973d3a40db547","type":"GO_TERM","name":"regulation of steroid metabolic process","canonical_id":"go:GO:0019218","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving steroids.\" [GOC:curators]","metadata":null},{"id":"d52a5a9968824153a85f312d2839d292","type":"GO_TERM","name":"regulation of sterol biosynthetic process","canonical_id":"go:GO:0106118","description":"\"Any process that modulates the frequency, rate or extent of a sterol biosynthetic process.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:16459310]","metadata":null},{"id":"a27445668b844b1586fbeced521cd6eb","type":"GO_TERM","name":"regulation of sterol import","canonical_id":"go:GO:2000909","description":"\"Any process that modulates the frequency, rate or extent of sterol import.\" [GOC:obol]","metadata":null},{"id":"6baa821cecf14ee4817548908fc94537","type":"GO_TERM","name":"regulation of sterol transport","canonical_id":"go:GO:0032371","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of sterols into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"1bcdb99a33734436ac8a2734dafe7921","type":"GO_TERM","name":"regulation of stomach fundus smooth muscle contraction","canonical_id":"go:GO:0120068","description":"\"Any process that modulates the frequency, rate or extent of any stomach fundus smooth muscle contraction.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"66d13c2eff17456aa33362ca050c3813","type":"GO_TERM","name":"regulation of stomach neuroendocrine cell differentiation","canonical_id":"go:GO:0061105","description":"\"Any process that modulates the rate, frequency or extent of the differentiation of a neuroendocrine cell in the stomach.\" [GOC:dph]","metadata":null},{"id":"cdcac169aa7c410ebb5ad48b72075acf","type":"GO_TERM","name":"regulation of stomatal closure","canonical_id":"go:GO:0090333","description":"\"Any process that modulates the rate, frequency, or extent of stomatal closure. Stomatal closure is the process of closing of stomata, pores in the epidermis of leaves and stems bordered by two guard cells and serving in gas exchange.\" [GOC:tb]","metadata":null},{"id":"cd87b71ed7b6404ea66ff368a07c1ed8","type":"GO_TERM","name":"regulation of stomatal complex development","canonical_id":"go:GO:2000038","description":"\"Any process that modulates the frequency, rate or extent of stomatal complex development.\" [GOC:obol]","metadata":null},{"id":"f5a9ff1e2e7f4ae39ecd826a2a07c8c3","type":"GO_TERM","name":"regulation of stomatal complex patterning","canonical_id":"go:GO:2000037","description":"\"Any process that modulates the frequency, rate or extent of stomatal complex patterning.\" [GOC:obol]","metadata":null},{"id":"f51588a62cb946eb9dad177800cb1055","type":"GO_TERM","name":"regulation of stomatal movement","canonical_id":"go:GO:0010119","description":"\"Any process that modulates the frequency, rate or extent of stomatal movement.\" [GOC:sm]","metadata":null},{"id":"f568f999da944754927dfe5d8a490b73","type":"GO_TERM","name":"regulation of stomatal opening","canonical_id":"go:GO:1902456","description":"\"Any process that modulates the frequency, rate or extent of stomatal opening.\" [GOC:TermGenie, PMID:23766366]","metadata":null},{"id":"52db01ae275143278076879e10a14a43","type":"GO_TERM","name":"regulation of store-operated calcium channel activity","canonical_id":"go:GO:1901339","description":"\"Any process that modulates the frequency, rate or extent of store-operated calcium channel activity.\" [GOC:TermGenie]","metadata":null},{"id":"928526b5e6994427af3ab9105f45cb15","type":"GO_TERM","name":"regulation of store-operated calcium entry","canonical_id":"go:GO:2001256","description":"\"Any process that modulates the frequency, rate or extent of store-operated calcium entry.\" [GOC:BHF]","metadata":null},{"id":"25caa4d2fa51426aa07a671c7652aad1","type":"GO_TERM","name":"regulation of strand invasion","canonical_id":"go:GO:0060542","description":"\"Any process that modulates the rate, frequency or extent of strand invasion. Strand invasion is the process in which the nucleoprotein complex (composed of the broken single-strand DNA and the recombinase) searches and identifies a region of homology in intact duplex DNA. The broken single-strand DNA displaces the like strand and forms Watson-Crick base pairs with its complement, forming a duplex in which each strand is from one of the two recombining DNA molecules.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"d842f6c7b321432195516a8f56973036","type":"GO_TERM","name":"regulation of stress fiber assembly","canonical_id":"go:GO:0051492","description":"\"Any process that modulates the frequency, rate or extent of the assembly of a stress fiber, a bundle of microfilaments and other proteins found in fibroblasts.\" [GOC:ai]","metadata":null},{"id":"05b97128502645d782a71b1140b83180","type":"GO_TERM","name":"regulation of stress response to copper ion","canonical_id":"go:GO:1903853","description":"\"Any process that modulates the frequency, rate or extent of stress response to copper ion.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:23437011]","metadata":null},{"id":"efa982143d1b44049d42e95f87b94b81","type":"GO_TERM","name":"regulation of stress-activated MAPK cascade","canonical_id":"go:GO:0032872","description":"\"Any process that modulates the frequency, rate or extent of signal transduction mediated by the stress-activated MAPK cascade.\" [GOC:mah]","metadata":null},{"id":"1e4409299b254a4995632d7197145517","type":"GO_TERM","name":"regulation of stress-activated protein kinase signaling cascade","canonical_id":"go:GO:0070302","description":"\"Any process that modulates the frequency, rate or extent of signaling via a stress-activated protein kinase signaling cascade.\" [GOC:mah]","metadata":null},{"id":"4297f6bf149f45e7b10aeb6c1c45de33","type":"GO_TERM","name":"regulation of striated muscle cell apoptotic process","canonical_id":"go:GO:0010662","description":"\"Any process that modulates the rate or extent of striated muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a striated muscle cell and result in its death.\" [GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"463afd8011154907be333678430afd2f","type":"GO_TERM","name":"regulation of striated muscle cell differentiation","canonical_id":"go:GO:0051153","description":"\"Any process that modulates the frequency, rate or extent of striated muscle cell differentiation.\" [CL:0000737, GOC:ai]","metadata":null},{"id":"b32bf7933e114842a00414b4914a8a79","type":"GO_TERM","name":"regulation of striated muscle contraction","canonical_id":"go:GO:0006942","description":"\"Any process that modulates the frequency, rate or extent of striated muscle contraction.\" [GOC:curators]","metadata":null},{"id":"68e0ea12e90b4b1ab157f510b23ff43c","type":"GO_TERM","name":"regulation of striated muscle tissue development","canonical_id":"go:GO:0016202","description":"\"Any process that modulates the frequency, rate or extent of striated muscle development.\" [GOC:curators]","metadata":null},{"id":"9352a79d2a0840fdba1f4c6f86cf3fe6","type":"GO_TERM","name":"regulation of substance P secretion","canonical_id":"go:GO:1904458","description":"\"Any process that modulates the frequency, rate or extent of substance P secretion.\" [GO_REF:0000058, GOC:TermGenie, PMID:11278900]","metadata":null},{"id":"1e95a8a42a7b4655bb34defa5223f0b6","type":"GO_TERM","name":"regulation of substance P secretion, neurotransmission","canonical_id":"go:GO:1904494","description":"\"Any process that modulates the frequency, rate or extent of substance P secretion, neurotransmission.\" [GO_REF:0000058, GOC:TermGenie, PMID:15292051]","metadata":null},{"id":"1bd4588250354c0abfaf455c1f7a36da","type":"GO_TERM","name":"regulation of substrate adhesion-dependent cell spreading","canonical_id":"go:GO:1900024","description":"\"Any process that modulates the frequency, rate or extent of substrate adhesion-dependent cell spreading.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"87f294e95d334964bc473599f6529a96","type":"GO_TERM","name":"regulation of substrate-dependent cell migration, cell attachment to substrate","canonical_id":"go:GO:1904235","description":"\"Any process that modulates the frequency, rate or extent of substrate-dependent cell migration, cell attachment to substrate.\" [GO_REF:0000058, GOC:TermGenie, PMID:25834989]","metadata":null},{"id":"36192b57174d4119867a8c02d6e1f579","type":"GO_TERM","name":"regulation of sulfate assimilation","canonical_id":"go:GO:1900058","description":"\"Any process that modulates the frequency, rate or extent of sulfate assimilation.\" [GOC:TermGenie, PMID:7601277, PMID:7891681]","metadata":null},{"id":"3ec8d82af1114ad6b7e0d4b31c642e66","type":"GO_TERM","name":"regulation of sulfite transmembrane transport","canonical_id":"go:GO:1900071","description":"\"Any process that modulates the frequency, rate or extent of sulfite transmembrane transport.\" [GOC:TermGenie, PMID:10234785, PMID:10870099]","metadata":null},{"id":"78356a1d7bda42738edb1fde2b533db8","type":"GO_TERM","name":"regulation of sulfur metabolic process","canonical_id":"go:GO:0042762","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving sulfur, the nonmetallic element sulfur or compounds that contain sulfur.\" [GOC:curators]","metadata":null},{"id":"b312fe30061d40fb89dbbf73667fbfe7","type":"GO_TERM","name":"regulation of sulfur utilization","canonical_id":"go:GO:0006792","description":"\"Any process that modulates the frequency, rate or extent of sulfur utilization.\" [GOC:curators]","metadata":null},{"id":"a88630d51ddc4d1fbc08554394dbd677","type":"GO_TERM","name":"regulation of superoxide anion generation","canonical_id":"go:GO:0032928","description":"\"Any process that modulates the frequency, rate or extent of enzymatic generation of superoxide by a cell.\" [GOC:mah]","metadata":null},{"id":"999e41b1027e4230a13da381a72bd11e","type":"GO_TERM","name":"regulation of superoxide dismutase activity","canonical_id":"go:GO:1901668","description":"\"Any process that modulates the frequency, rate or extent of superoxide dismutase activity.\" [GOC:TermGenie]","metadata":null},{"id":"b70d0529cc164a7f8ccb83b768f72012","type":"GO_TERM","name":"regulation of superoxide metabolic process","canonical_id":"go:GO:0090322","description":"\"Any process that modulates the rate, frequency, or extent of superoxide metabolism, the chemical reactions and pathways involving superoxide, the superoxide anion O2- (superoxide free radical), or any compound containing this species.\" [GOC:tb]","metadata":null},{"id":"d8e84fa0ac284b3ab7a4781ef609eafc","type":"GO_TERM","name":"regulation of supramolecular fiber organization","canonical_id":"go:GO:1902903","description":"\"Any process that modulates the frequency, rate or extent of supramolecular fiber organization.\" [GO_REF:0000058, GOC:PARL, GOC:rl, GOC:TermGenie, PMID:23921388]","metadata":null},{"id":"d4d61a886dde41d5b2281b4452a13189","type":"GO_TERM","name":"regulation of synapse assembly","canonical_id":"go:GO:0051963","description":"\"Any process that modulates the frequency, rate or extent of synapse assembly, the aggregation, arrangement and bonding together of a set of components to form a synapse.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"178765e88a5d4bc8a0fdff09edc9eaee","type":"GO_TERM","name":"regulation of synapse maturation","canonical_id":"go:GO:0090128","description":"\"Any process that modulates the extent of synapse maturation, the process that organizes a synapse so that it attains its fully functional state.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"79c10d4772aa4de5acd820413013f246","type":"GO_TERM","name":"regulation of synapse organization","canonical_id":"go:GO:0050807","description":"\"Any process that modulates the physical form of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell).\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"284915807af340b3a151704bd1050036","type":"GO_TERM","name":"regulation of synapse pruning","canonical_id":"go:GO:1905806","description":"\"Any process that modulates the frequency, rate or extent of synapse pruning.\" [GO_REF:0000058, GOC:TermGenie, PMID:27779093]","metadata":null},{"id":"096d498000d642c4afa91b55a9c1606a","type":"GO_TERM","name":"regulation of synapse structural plasticity","canonical_id":"go:GO:0051823","description":"\"Any process that modulates the frequency, rate or extent of synapse structural plasticity. Synapse structural plasticity is a type of cytoskeletal remodeling; this remodeling is induced by stimuli that can lead to long term potentiation and it can be activity-dependent or -independent. Examples of cytoskeletal changes include the formation of new spines and increase in spine size; this can be accompanied by the insertion of greater numbers of glutamate (or other neurotransmitter) receptors into the post-synaptic membrane.\" [PMID:11063967, PMID:14976517, PMID:9884123]","metadata":null},{"id":"64ec07cf3be84e07b3b56a82f92e528c","type":"GO_TERM","name":"regulation of synapse structure or activity","canonical_id":"go:GO:0050803","description":"\"Any process that modulates the physical form or the activity of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell).\" [GOC:ai]","metadata":null},{"id":"bb25bd6ed87b49a5a5e9c540d50c82c7","type":"GO_TERM","name":"regulation of synaptic activity","canonical_id":"go:GO:0060025","description":"\"Any process that modulates the frequency, rate or extent of synaptic activity, the controlled release of neurotransmitters into the synaptic cleft and their subsequent detection by a postsynaptic cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f97545efc1444cfebbe6c6226f36c4b9","type":"GO_TERM","name":"regulation of synaptic assembly at neuromuscular junction","canonical_id":"go:GO:0008582","description":"\"Any process that modulates the frequency, rate or extent of synaptic assembly at neuromuscular junctions.\" [GOC:curators]","metadata":null},{"id":"6abf88aa9fc947cb8e69f575fd3c34b7","type":"GO_TERM","name":"regulation of synaptic membrane adhesion","canonical_id":"go:GO:0099179","description":"\"Any process that modulates the frequency, rate or extent of adhesion between pre- and post-synaptic membranes.\" [GOC:dos]","metadata":null},{"id":"3f6becce7e614f0e95768871f7fe142b","type":"GO_TERM","name":"regulation of synaptic metaplasticity","canonical_id":"go:GO:0031916","description":"\"A process that modulates synaptic metaplasticity. Metaplasticity is a higher-order form of plasticity and is manifest as a change in the ability to induce subsequent synaptic plasticity that is the ability of synapses to change as circumstances require.\" [GOC:mah, PMID:8658594]","metadata":null},{"id":"3c21297393924f6ca09eb74769dfb81b","type":"GO_TERM","name":"regulation of synaptic plasticity","canonical_id":"go:GO:0048167","description":"\"A process that modulates synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.\" [GOC:dph, GOC:jid, GOC:tb, PMID:11891290]","metadata":null},{"id":"28b2acd3844c4b6dbfa4494e5913274e","type":"GO_TERM","name":"regulation of synaptic plasticity by chemical substance","canonical_id":"go:GO:0051913","description":"\"The process in which a chemical substance modulates synaptic plasticity, the ability of synapses to change as circumstances require.\" [GOC:ai]","metadata":null},{"id":"e6043dbb8ba5450bbc08b5aa2f073a9d","type":"GO_TERM","name":"regulation of synaptic plasticity by receptor localization to synapse","canonical_id":"go:GO:1900383","description":"\"Any process that modulates synaptic plasticity, the ability of synapses to change as circumstances require, via receptor localization to the synapse, the junction between a nerve fiber of one neuron and another neuron or muscle fiber or glial cell. Processes may include receptor transport to, and/or maintenance at, the synapse.\" [GOC:kmv, GOC:TermGenie, PMID:22464329]","metadata":null},{"id":"47f345a97d834413bfad164124e1d6c2","type":"GO_TERM","name":"regulation of synaptic scaling","canonical_id":"go:GO:0150092","description":"\"A process that modulates synaptic scaling. Synaptic scaling is a form of synaptic plasticity, which entails uniform adjustments in the strength of all synapses on a cell in response to prolonged changes in the electrical activity of the cell.\" [GOC:aruk, GOC:bc, PMID:14630218, PMID:14735113, PMID:16547515]","metadata":null},{"id":"b68fa93e183b4ef691f495a6cb074a06","type":"GO_TERM","name":"regulation of synaptic signaling by nitric oxide","canonical_id":"go:GO:0150045","description":"\"Any process that modulates the frequency, rate or extent of synaptic signaling by nitric oxide.\" [GOC:aruk, GOC:bc, PMID:26311509]","metadata":null},{"id":"0424b2ecb4694ed4b82a33908afe147c","type":"GO_TERM","name":"regulation of synaptic transmission, GABAergic","canonical_id":"go:GO:0032228","description":"\"Any process that modulates the frequency, rate or extent of GABAergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter gamma-aminobutyric acid (GABA).\" [GOC:mah]","metadata":null},{"id":"f4c8bfcdf75449a7a37a9972910eac4d","type":"GO_TERM","name":"regulation of synaptic transmission, cholinergic","canonical_id":"go:GO:0032222","description":"\"Any process that modulates the frequency, rate or extent of cholinergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter acetylcholine.\" [GOC:mah]","metadata":null},{"id":"aeb5ffda0f954078a0b01089bce4e519","type":"GO_TERM","name":"regulation of synaptic transmission, dopaminergic","canonical_id":"go:GO:0032225","description":"\"Any process that modulates the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine.\" [GOC:mah]","metadata":null},{"id":"53d0dcc97a414285bbe14e9be417a190","type":"GO_TERM","name":"regulation of synaptic transmission, glutamatergic","canonical_id":"go:GO:0051966","description":"\"Any process that modulates the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate.\" [GOC:ai]","metadata":null},{"id":"311db2fba13f49cd89606fa185358bda","type":"GO_TERM","name":"regulation of synaptic transmission, glycinergic","canonical_id":"go:GO:0060092","description":"\"Any process that modulates the frequency, rate or extent of glycinergic synaptic transmission. Glycinergic synaptic transmission is the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glycine.\" [GOC:dms, GOC:dph]","metadata":null},{"id":"952e6e4a29344922a1073207ccbc9a6a","type":"GO_TERM","name":"regulation of synaptic vesicle budding from presynaptic endocytic zone membrane","canonical_id":"go:GO:0098694","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle budding from presynaptic endocytic zone membrane.\" [GOC:dos]","metadata":null},{"id":"4e97f07a7c17432ca0a1d88444d57584","type":"GO_TERM","name":"regulation of synaptic vesicle clustering","canonical_id":"go:GO:2000807","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle clustering.\" [PMID:21513708]","metadata":null},{"id":"2a16df43901445ddaaea1adb9fcb0b5a","type":"GO_TERM","name":"regulation of synaptic vesicle cycle","canonical_id":"go:GO:0098693","description":"\"Any process that modulates the frequency, rate or extent of the synaptic vesicle cycle.\" [GOC:dos]","metadata":null},{"id":"cf8483ef98aa4f7fbe144d502587f060","type":"GO_TERM","name":"regulation of synaptic vesicle endocytosis","canonical_id":"go:GO:1900242","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle endocytosis.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"4177e4c8f99d470aa0a837d7ef93f81b","type":"GO_TERM","name":"regulation of synaptic vesicle exocytosis","canonical_id":"go:GO:2000300","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle exocytosis.\" [GOC:obol]","metadata":null},{"id":"ec6c0788a2154ce4a266bdf70eb9e165","type":"GO_TERM","name":"regulation of synaptic vesicle fusion to presynaptic active zone membrane","canonical_id":"go:GO:0031630","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle fusion to the presynaptic membrane.\" [GOC:mah]","metadata":null},{"id":"ede9cc1bcc1c442eac25116e22980cef","type":"GO_TERM","name":"regulation of synaptic vesicle lumen acidification","canonical_id":"go:GO:1901546","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle lumen acidification.\" [GOC:TermGenie]","metadata":null},{"id":"12d7b5ea9fdf496e8bc5a3c7f77441f4","type":"GO_TERM","name":"regulation of synaptic vesicle membrane organization","canonical_id":"go:GO:1901632","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle membrane organization.\" [GOC:TermGenie, PMID:22426000]","metadata":null},{"id":"e0c42ae9ca8b48b8bb72c36d897bd620","type":"GO_TERM","name":"regulation of synaptic vesicle priming","canonical_id":"go:GO:0010807","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle priming. Synaptic vesicle priming is the formation of SNARE-containing complexes, bringing synaptic vesicle membrane and plasma membranes into close proximity and thereby facilitating membrane fusion.\" [GOC:dph, GOC:kmv, GOC:tb, PMID:15489511]","metadata":null},{"id":"9d145c40e38d4ca59bf9d931f75db44b","type":"GO_TERM","name":"regulation of synaptic vesicle recycling","canonical_id":"go:GO:1903421","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle recycling.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:22745285]","metadata":null},{"id":"fce855e18b8448e3b304c26851d84b2c","type":"GO_TERM","name":"regulation of synaptic vesicle transport","canonical_id":"go:GO:1902803","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle transport.\" [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:23527112]","metadata":null},{"id":"0e738ad84fd747ca958ea4bd4a2d48e3","type":"GO_TERM","name":"regulation of synaptic vesicle uncoating","canonical_id":"go:GO:1903388","description":"\"Any process that modulates the frequency, rate or extent of synaptic vesicle uncoating.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21563316]","metadata":null},{"id":"a89b858203634834858e32fcdff88631","type":"GO_TERM","name":"regulation of synaptonemal complex assembly","canonical_id":"go:GO:0090173","description":"\"Any process that modulates the frequency, rate or extent of synaptonemal complex assembly. Synaptonemal complex assembly is the cell cycle process in which the synaptonemal complex, a structure that holds paired chromosomes together during prophase I of meiosis and that promotes genetic recombination, is formed.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"fbc7e900b7b74b99ab110510d821eb66","type":"GO_TERM","name":"regulation of syncytial blastoderm mitotic cell cycle","canonical_id":"go:GO:0007348","description":"\"A cell cycle process that modulates the rate or extent of the progression through the syncytial blastoderm mitotic cell cycle.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"5f925d1cbb33416bb65d54dbdb81960f","type":"GO_TERM","name":"regulation of syncytium formation by plasma membrane fusion","canonical_id":"go:GO:0060142","description":"\"Any process that modulates the frequency, rate or extent of the formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by the fusion of the plasma membranes of two or more individual cells.\" [GOC:dph]","metadata":null},{"id":"227f192b55c1410bae9043be5350ab23","type":"GO_TERM","name":"regulation of synergid differentiation","canonical_id":"go:GO:0045697","description":"\"Any process that modulates the frequency, rate or extent of synergid cell differentiation.\" [GOC:curators]","metadata":null},{"id":"87c8e72a4da24f22a987069900613cb4","type":"GO_TERM","name":"regulation of synoviocyte proliferation","canonical_id":"go:GO:1901645","description":"\"Any process that modulates the frequency, rate or extent of synoviocyte proliferation.\" [GOC:TermGenie]","metadata":null},{"id":"fcd9cf4907f1405481075ddeb711025b","type":"GO_TERM","name":"regulation of syringal lignin biosynthetic process","canonical_id":"go:GO:1901428","description":"\"Any process that modulates the frequency, rate or extent of syringal lignin biosynthetic process.\" [GOC:TermGenie]","metadata":null},{"id":"d880339efbea4a7d89c8d1915ceab20f","type":"GO_TERM","name":"regulation of syringal lignin catabolic process","canonical_id":"go:GO:1901469","description":"\"Any process that modulates the frequency, rate or extent of syringal lignin catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"67b5de18bc3c4af3be402e5132a27e2b","type":"GO_TERM","name":"regulation of system process","canonical_id":"go:GO:0044057","description":"\"Any process that modulates the frequency, rate or extent of a system process, a multicellular organismal process carried out by any of the organs or tissues in an organ system.\" [GOC:jl]","metadata":null},{"id":"e58edb9a6a6e456cac0f5a9462a4ba61","type":"GO_TERM","name":"regulation of systemic acquired resistance","canonical_id":"go:GO:0010112","description":"\"Any process that modulates the frequency, rate or extent of systemic acquired resistance.\" [GOC:sm]","metadata":null},{"id":"806e7bd1ef134d7b9fd6aa5b6fe91ba3","type":"GO_TERM","name":"regulation of systemic arterial blood pressure","canonical_id":"go:GO:0003073","description":"\"The process that modulates the force with which blood travels through the systemic arterial circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure.\" [GOC:mtg_cardio]","metadata":null},{"id":"93f4ae7df04548b1b31cdff917ec3f3f","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by acetylcholine","canonical_id":"go:GO:0003068","description":"\"The regulation of blood pressure mediated by acetylcholine signaling. Acetylcholine is an acetic acid ester of the organic base choline and functions as a neurotransmitter.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"4c6a1324a69a475a9b2fadf0b7d1d8d2","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by aortic arch baroreceptor feedback","canonical_id":"go:GO:0003026","description":"\"The process that modulates blood pressure by sensing the amount of stretch occurring in the aorta and responding to the input via central nervous system control.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"497422640da245dba638485e2b3dd719","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by aortic body chemoreceptor signaling","canonical_id":"go:GO:0003028","description":"\"The process that modulates blood pressure by the action of chemoreceptors found in the aortic bodies and their resultant modulation of the vasomotor center. Chemoreceptors respond to oxygen, carbon dioxide and hydrogen ions.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"0cf208dba77644f9bb71c99d55174096","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by atrial baroreceptor feedback","canonical_id":"go:GO:0002015","description":"\"A process that controls blood pressure by sensing the amount of stretch occurring in the atria.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"fa938bad1ed44ad8abaa6a6667d9d614","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by atrial natriuretic peptide","canonical_id":"go:GO:0003050","description":"\"The regulation of blood pressure mediated by the signaling molecule atrial natriuretic peptide.\" [GOC:mtg_cardio]","metadata":null},{"id":"b6a76472fd824e108d64d000e39bc85f","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by baroreceptor feedback","canonical_id":"go:GO:0003025","description":"\"The neural regulation of blood pressure in which baroreceptors sense the amount of stretch occurring in vessels and respond to the input via central nervous system control.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"4b5900f58f9d45319795b43014819827","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by capillary fluid shift","canonical_id":"go:GO:0003049","description":"\"The intrinsic circulatory process resulting from capillary fluid shift that modulates the force with which blood travels through the systemic arterial circulatory system. Capillary fluid shift is the movement of fluid across the capillary membrane between the blood and the interstitial fluid compartment.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"9dd47f456998485aab36dc5dd3db598f","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by carotid body chemoreceptor signaling","canonical_id":"go:GO:0003027","description":"\"The process that modulates blood pressure by the action of chemoreceptors found in the carotid bodies and their resultant modulation of the vasomotor center. Chemoreceptors respond to oxygen, carbon dioxide and hydrogen ions.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"145463f0a95b46399ee7b5ebf158bc2f","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by carotid sinus baroreceptor feedback","canonical_id":"go:GO:0001978","description":"\"The process that modulates blood pressure by sensing the amount of stretch occurring in large arteries and responding to the input via central nervous system control.\" [GOC:dph, GOC:tb, ISBN:0721643949]","metadata":null},{"id":"5bbb601a697c4a008abebc519d22ec7b","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by chemoreceptor signaling","canonical_id":"go:GO:0001979","description":"\"The process that modulates blood pressure by the action of chemoreceptors found in the carotid and aortic bodies and their resultant modulation of the vasomotor center. Chemoreceptors respond to oxygen, carbon dioxide and hydrogen ions.\" [GOC:dph, GOC:tb, ISBN:0721643949]","metadata":null},{"id":"70c7aed4fe204c259994d3b4ca269f0f","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by circulatory epinephrine-norepinephrine","canonical_id":"go:GO:0003101","description":"\"The process in which epinephrine-norepinephrine modulate the force with which blood passes through the circulatory system.\" [GOC:mtg_cardio]","metadata":null},{"id":"9dfe3ff1b17b47a296abde73272112f1","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by circulatory renin-angiotensin","canonical_id":"go:GO:0001991","description":"\"The process in which angiotensinogen metabolites in the bloodstream modulate the force with which blood passes through the circulatory system. The process begins when renin is released and cleaves angiotensinogen.\" [ISBN:0721643949]","metadata":null},{"id":"62248416c99443a9b2953b88a8f18337","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by endothelin","canonical_id":"go:GO:0003100","description":"\"The process in which endothelin modulates the force with which blood passes through the circulatory system. Endothelin is a hormone that is released by the endothelium, and it is a vasoconstrictor.\" [GOC:mtg_cardio]","metadata":null},{"id":"ecf4ffffc7a743a998086ddd3fcba965","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by epinephrine","canonical_id":"go:GO:0003047","description":"\"The regulation of blood pressure mediated by the catecholamine signaling molecule epinephrine.\" [GOC:mtg_cardio]","metadata":null},{"id":"087e1f1784f34efc9301c8414bc8d931","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by hormone","canonical_id":"go:GO:0001990","description":"\"The process in which hormones modulate the force with which blood passes through the circulatory system. A hormone is one of a group of substances formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells, in the same organism, upon which they have a specific regulatory action.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"51497bc4c84f4e7c95698b9eedd42721","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by ischemic conditions","canonical_id":"go:GO:0001980","description":"\"The process that modulates blood pressure by the detection of carbon dioxide levels in the brain stem. Increased levels activate the sympathetic vasoconstrictor mechanism increasing the force with which blood flows through the circulatory system.\" [GOC:dph, GOC:tb, ISBN:0721643949]","metadata":null},{"id":"ee56c9b01c1647cd9cee14f2d9de618b","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by local renal renin-angiotensin","canonical_id":"go:GO:0003086","description":"\"The process in which angiotensinogen metabolites in the kidney modulate the force with which blood passes through the renal circulatory system. The process begins when renin cleaves angiotensinogen.\" [GOC:mtg_cardio]","metadata":null},{"id":"6de6e3e42d11477ab5348d45acbd71c4","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by neurotransmitter","canonical_id":"go:GO:0003070","description":"\"The regulation of blood pressure mediated by a neurotransmitter. A neurotransmitter is any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell.\" [GOC:mtg_cardio]","metadata":null},{"id":"28b76d4993c14969bb8c68f9faa690c2","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by norepinephrine","canonical_id":"go:GO:0003048","description":"\"The regulation of blood pressure mediated by the catecholamine signaling molecule norepinephrine.\" [GOC:mtg_cardio]","metadata":null},{"id":"6b43f6d278474797860ae7a35341088b","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by norepinephrine-epinephrine","canonical_id":"go:GO:0001993","description":"\"The process in which the secretion of norepinephrine or epinephrine into the bloodstream modulates the force with which blood passes through the circulatory system.\" [ISBN:0721643949]","metadata":null},{"id":"f7a655328f87419aa2a8671efc0326ca","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by physical factors","canonical_id":"go:GO:0003045","description":"\"The regulation of blood pressure mediated by detection of forces within the circulatory system.\" [GOC:mtg_cardio]","metadata":null},{"id":"4b1ec9c7299d4b6dbf3acc388f5ec644","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by renin-angiotensin","canonical_id":"go:GO:0003081","description":"\"The process in which renin-angiotensin modulates the force with which blood passes through the circulatory system.\" [GOC:mtg_cardio]","metadata":null},{"id":"e8dec60eaf454f3595bb662877cf7632","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by stress relaxation","canonical_id":"go:GO:0003046","description":"\"The intrinsic circulatory process resulting from stress relaxation that modulates the force with which blood travels through the systemic arterial circulatory system. Stress relaxation is the adaptation of vessels to a new size as a result of changes in pressure in storage areas such as veins, the liver, the spleen, and the lungs.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"dab3626acc89457caf6e916a8f98a77a","type":"GO_TERM","name":"regulation of systemic arterial blood pressure by vasopressin","canonical_id":"go:GO:0001992","description":"\"The regulation of blood pressure mediated by the signaling molecule vasopressin. Vasopressin is produced in the hypothalamus, and affects vasoconstriction, and renal water transport.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"9ebd9245cc084507a3bbf9d2025bc93f","type":"GO_TERM","name":"regulation of systemic arterial blood pressure mediated by a chemical signal","canonical_id":"go:GO:0003044","description":"\"The regulation of blood pressure mediated by biochemical signaling: hormonal, autocrine or paracrine.\" [GOC:mtg_cardio]","metadata":null},{"id":"99c393825b3e4e7ca916be1b773f3929","type":"GO_TERM","name":"regulation of t-SNARE clustering","canonical_id":"go:GO:1904032","description":"\"Any process that modulates the frequency, rate or extent of t-SNARE clustering.\" [GO_REF:0000058, GOC:TermGenie, PMID:22528485]","metadata":null},{"id":"7f1e3d8afa0742a386ab5b67007cba71","type":"GO_TERM","name":"regulation of t-circle formation","canonical_id":"go:GO:1904429","description":"\"Any process that modulates the frequency, rate or extent of t-circle formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"ba2f0249505148bc81a05ac90bef3534","type":"GO_TERM","name":"regulation of tRNA C5-cytosine methylation","canonical_id":"go:GO:0110003","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving tRNA C5-cytosine methylation.\" [GOC:vw, PMID:23074192]","metadata":null},{"id":"8133262105f943d490ade94f50baaed5","type":"GO_TERM","name":"regulation of tRNA catabolic process","canonical_id":"go:GO:1902370","description":"\"Any process that modulates the frequency, rate or extent of tRNA catabolic process.\" [GOC:bf, GOC:TermGenie]","metadata":null},{"id":"8187518def3544f384f8f5d16196220b","type":"GO_TERM","name":"regulation of tRNA export from nucleus","canonical_id":"go:GO:2000238","description":"\"Any process that modulates the frequency, rate or extent of tRNA export from nucleus.\" [GOC:mah]","metadata":null},{"id":"18d92dfecdea41b6bf37be2f35728bb7","type":"GO_TERM","name":"regulation of tRNA metabolic process","canonical_id":"go:GO:1903326","description":"\"Any process that modulates the frequency, rate or extent of tRNA metabolic process.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"1548e4a4a792459e8c6428f9f861ad5d","type":"GO_TERM","name":"regulation of tRNA methylation","canonical_id":"go:GO:0110002","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving tRNA methylation.\" [GOC:vw, PMID:23074192]","metadata":null},{"id":"ce6201d9e8d94336a605c806f54edbbf","type":"GO_TERM","name":"regulation of tRNA processing","canonical_id":"go:GO:2000235","description":"\"Any process that modulates the frequency, rate or extent of tRNA processing.\" [GOC:mah]","metadata":null},{"id":"15c3a406b73b423fba82367f83d3b43b","type":"GO_TERM","name":"regulation of tRNA stability","canonical_id":"go:GO:0036415","description":"\"Any process that modulates the propensity of transfer RNA (tRNA) molecules to degradation. Includes processes that both stabilize and destabilize tRNAs.\" [GOC:aa, PMID:21502523, PMID:23572593]","metadata":null},{"id":"132075f073854a5e9d9985cc8c2f33be","type":"GO_TERM","name":"regulation of taurine biosynthetic process","canonical_id":"go:GO:0062089","description":"\"Any process that modulates the rate, frequency or extent of taurine biosynthesis.\" [GOC:BHF, PMID:18648510, PMID:24911144]","metadata":null},{"id":"d7246dd7d64c4d6d9268abd26e73d1f3","type":"GO_TERM","name":"regulation of teliospore formation","canonical_id":"go:GO:0075256","description":"\"Any process that modulates the frequency, rate or extent of teliospore formation, which is the formation of a thick-walled resting or over-wintering spore produced by the rust fungi (Uredinales) and smut fungi (Ustilaginales) in which karyogamy occurs.\" [GOC:pamgo_curators]","metadata":null},{"id":"1b729ef24d2a4cce825938f6d9045608","type":"GO_TERM","name":"regulation of telium development","canonical_id":"go:GO:0075276","description":"\"Any process that modulates the frequency, rate or extent of telium development, a process that leads to the formation of a teliospore-bearing sorus of the rust fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"99dc240542744f1e9c22ecdee532d0d8","type":"GO_TERM","name":"regulation of telomerase RNA localization to Cajal body","canonical_id":"go:GO:1904872","description":"\"Any process that modulates the frequency, rate or extent of telomerase RNA localization to Cajal body.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:25467444]","metadata":null},{"id":"0ae3f8a3d8d140eeb82f761aa7780b68","type":"GO_TERM","name":"regulation of telomerase catalytic core complex assembly","canonical_id":"go:GO:1904882","description":"\"Any process that modulates the frequency, rate or extent of telomerase catalytic core complex assembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"9aec9062b25945959f85fb1ce7eb60bd","type":"GO_TERM","name":"regulation of telomere capping","canonical_id":"go:GO:1904353","description":"\"Any process that modulates the frequency, rate or extent of telomere capping.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23959892]","metadata":null},{"id":"68dfbf2c63e243dd85506627d5591b8a","type":"GO_TERM","name":"regulation of telomere maintenance","canonical_id":"go:GO:0032204","description":"\"Any process that modulates the frequency, rate or extent of a process that affects and monitors the activity of telomeric proteins and the length of telomeric DNA.\" [GOC:mah]","metadata":null},{"id":"c4526295f7a547348afcd712c7d7b273","type":"GO_TERM","name":"regulation of telomere maintenance in response to DNA damage","canonical_id":"go:GO:1904505","description":"\"Any process that modulates the frequency, rate or extent of telomere maintenance in response to DNA damage.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"058d0bb6d97c49e8979daa9a045e7882","type":"GO_TERM","name":"regulation of telomere maintenance via recombination","canonical_id":"go:GO:0032207","description":"\"Any process that modulates the frequency, rate or extent of a recombinational process involved in the maintenance of proper telomeric length.\" [GOC:mah]","metadata":null},{"id":"8debe1a2be4a41d882d4116357a8ef6e","type":"GO_TERM","name":"regulation of telomere maintenance via semi-conservative replication","canonical_id":"go:GO:0032213","description":"\"Any process that modulates the frequency, rate or extent of the semi-conservative replication of telomeric DNA.\" [GOC:mah]","metadata":null},{"id":"949e52456808409482064d14531a7639","type":"GO_TERM","name":"regulation of telomere maintenance via telomerase","canonical_id":"go:GO:0032210","description":"\"Any process that modulates the frequency, rate or extent of the addition of telomeric repeats by telomerase.\" [GOC:mah]","metadata":null},{"id":"6df6adcfc8ac472abfa6567bd835021f","type":"GO_TERM","name":"regulation of telomere maintenance via telomere lengthening","canonical_id":"go:GO:1904356","description":"\"Any process that modulates the frequency, rate or extent of telomere maintenance via telomere lengthening.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23959892]","metadata":null},{"id":"c529021cb221429aba0c2f234fb96186","type":"GO_TERM","name":"regulation of telomeric D-loop disassembly","canonical_id":"go:GO:1905838","description":"\"Any process that modulates the frequency, rate or extent of telomeric D-loop disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:15200954]","metadata":null},{"id":"d921e489c7574d55ba4b03fd5b42508c","type":"GO_TERM","name":"regulation of telomeric loop disassembly","canonical_id":"go:GO:1904533","description":"\"Any process that modulates the frequency, rate or extent of telomeric loop disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"d79bf06a7def4e3fb1bf6ef4fbcad1db","type":"GO_TERM","name":"regulation of telomeric loop formation","canonical_id":"go:GO:1904418","description":"\"Any process that modulates the frequency, rate or extent of telomeric loop formation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:22579284]","metadata":null},{"id":"0edbf5641ac54fecb818df587256b092","type":"GO_TERM","name":"regulation of tendon cell differentiation","canonical_id":"go:GO:2001049","description":"\"Any process that modulates the frequency, rate or extent of tendon cell differentiation.\" [GOC:obol]","metadata":null},{"id":"aeeedb5b8e79486085b7d16ac4fb349e","type":"GO_TERM","name":"regulation of tensidol A biosynthetic process","canonical_id":"go:GO:1900707","description":"\"Any process that modulates the frequency, rate or extent of tensidol A biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"6964d556853f4fb9b1e9bad73dbcfb12","type":"GO_TERM","name":"regulation of tensidol B biosynthetic process","canonical_id":"go:GO:1900710","description":"\"Any process that modulates the frequency, rate or extent of tensidol B biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"0d985a0156f04555b82c28af4b7e324a","type":"GO_TERM","name":"regulation of terminal button organization","canonical_id":"go:GO:2000331","description":"\"Any process that modulates the frequency, rate or extent of terminal button organization.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"cbd6906e0b06443ab76d4bc102bb40d2","type":"GO_TERM","name":"regulation of termination of DNA-templated transcription","canonical_id":"go:GO:0031554","description":"\"Any process that modulates the frequency, rate, extent, or location of DNA-templated transcription termination, the process in which transcription is completed; the formation of phosphodiester bonds ceases, the RNA-DNA hybrid dissociates, and RNA polymerase releases the DNA.\" [GOC:mlg, GOC:txnOH]","metadata":null},{"id":"2e76ac7d7a724438a35db6603d39cb64","type":"GO_TERM","name":"regulation of termination of RNA polymerase I transcription","canonical_id":"go:GO:2000730","description":"\"Any process that modulates the frequency, rate or extent of termination of RNA polymerase I transcription.\" [GOC:obol]","metadata":null},{"id":"9c7813f601de415d9bac1ae093f659cb","type":"GO_TERM","name":"regulation of termination of RNA polymerase II transcription","canonical_id":"go:GO:1904594","description":"\"Any process that modulates the frequency, rate or extent of termination of RNA polymerase II transcription.\" [GO_REF:0000058, GOC:TermGenie, PMID:25417108]","metadata":null},{"id":"bb80f231f9f847e8b379cdf71c62c404","type":"GO_TERM","name":"regulation of termination of RNA polymerase II transcription, poly(A)-coupled","canonical_id":"go:GO:2000804","description":"\"Any process that modulates the frequency, rate or extent of termination of RNA polymerase II transcription, poly(A)-coupled.\" [GOC:obol]","metadata":null},{"id":"4583cfdd5e504f7e98c18e27b802613f","type":"GO_TERM","name":"regulation of termination of mating projection growth","canonical_id":"go:GO:0031385","description":"\"Any process that modulates the frequency, rate, or extent of the end of mating projection formation by unicellular fungi.\" [PMID:14734532]","metadata":null},{"id":"03602b2c44bd41da9e3f93f4f195b7bf","type":"GO_TERM","name":"regulation of testosterone biosynthetic process","canonical_id":"go:GO:2000224","description":"\"Any process that modulates the frequency, rate or extent of testosterone biosynthetic process.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"4cd7d187d9b440e0af369c26ebb8851c","type":"GO_TERM","name":"regulation of testosterone secretion","canonical_id":"go:GO:2000843","description":"\"Any process that modulates the frequency, rate or extent of testosterone secretion.\" [GOC:sl]","metadata":null},{"id":"53d26aaf153b4ec285eef0cbdaf1747f","type":"GO_TERM","name":"regulation of tetrapyrrole biosynthetic process","canonical_id":"go:GO:1901463","description":"\"Any process that modulates the frequency, rate or extent of tetrapyrrole biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f8c8913bff534eef830d780a377d745d","type":"GO_TERM","name":"regulation of tetrapyrrole catabolic process","canonical_id":"go:GO:1901404","description":"\"Any process that modulates the frequency, rate or extent of tetrapyrrole catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b986df187021491ca8d9a73f24c03937","type":"GO_TERM","name":"regulation of tetrapyrrole metabolic process","canonical_id":"go:GO:1901401","description":"\"Any process that modulates the frequency, rate or extent of tetrapyrrole metabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"7c65a83500844168a0c113dd29f500b8","type":"GO_TERM","name":"regulation of thalamus size","canonical_id":"go:GO:0090067","description":"\"Any process that modulates the size of the thalamus. The thalamus is a part of the diencephalon that is composed of the dorsal thalamus and the ventral thalamus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"39cfc999e1ea4c06993a20d41cabcaba","type":"GO_TERM","name":"regulation of the force of heart contraction","canonical_id":"go:GO:0002026","description":"\"Any process that modulates the extent of heart contraction, changing the force with which blood is propelled.\" [GOC:dph, GOC:tb, PMID:10358008]","metadata":null},{"id":"7d8244c2fa7d4699be5a912184c243b7","type":"GO_TERM","name":"regulation of the force of heart contraction by cardiac conduction","canonical_id":"go:GO:0086092","description":"\"A cardiac conduction process that modulates the extent of heart contraction, changing the force with which blood is propelled.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"48d618f5ec8742239248d9e53f46b5d5","type":"GO_TERM","name":"regulation of the force of heart contraction by chemical signal","canonical_id":"go:GO:0003057","description":"\"The regulation of the force of heart muscle contraction mediated by chemical signaling, hormonal, autocrine or paracrine.\" [GOC:mtg_cardio, GOC:rl]","metadata":null},{"id":"986ca50f8696459db1e17b04db0e30c3","type":"GO_TERM","name":"regulation of the force of skeletal muscle contraction","canonical_id":"go:GO:0014728","description":"\"Any process that modulates the frequency, rate or extent of the force of skeletal muscle contraction. The force of skeletal muscle contraction is produced by acto-myosin interaction processes through the formation of cross bridges.\" [GOC:mtg_muscle]","metadata":null},{"id":"b015f5b826914bb88fed67e0f69d9b1f","type":"GO_TERM","name":"regulation of the velocity of shortening of skeletal muscle modulating contraction","canonical_id":"go:GO:0014729","description":"\"Any process that modulates velocity of shortening of a skeletal muscle contraction. The shortening leads to reduction of the length of muscle fibers and sarcomeres.\" [GOC:mtg_muscle]","metadata":null},{"id":"e5b63d88707a4f9196f3f156793afba1","type":"GO_TERM","name":"regulation of thermomorphogenesis","canonical_id":"go:GO:0140920","description":"\"Any process that modulates the frequency, rate or extent of thermomorphogenesis.\" [PMID:27250752]","metadata":null},{"id":"392c12f105f748dcaeb943f85bef905a","type":"GO_TERM","name":"regulation of thiamine biosynthetic process","canonical_id":"go:GO:0070623","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of thiamine.\" [GOC:mah]","metadata":null},{"id":"7f0f7d0e898743c7a297bd7f39f5ec02","type":"GO_TERM","name":"regulation of thiamine diphosphate biosynthetic process","canonical_id":"go:GO:0070616","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of thiamine diphosphate.\" [GOC:mah]","metadata":null},{"id":"9b255d58cc444b1583042a03dbd6b5b1","type":"GO_TERM","name":"regulation of thrombin-activated receptor signaling pathway","canonical_id":"go:GO:0070494","description":"\"Any process that modulates the frequency, rate or extent of a thrombin-activated receptor signaling pathway activity. A thrombin receptor signaling pathway is the series of molecular signals generated as a consequence of a thrombin-activated receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"14ef01d711ff400ea1369ff52d62b0ea","type":"GO_TERM","name":"regulation of thylakoid membrane disassembly","canonical_id":"go:GO:0010548","description":"\"Any process that modulates the frequency, rate or extent of thylakoid membrane disassembly.\" [GOC:dph, GOC:tb, PMID:17416733]","metadata":null},{"id":"065ce355697143e880c7c9b8d04c600c","type":"GO_TERM","name":"regulation of thymine transport","canonical_id":"go:GO:0035365","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of thymine, 5-methyluracil, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:bf, GOC:sl]","metadata":null},{"id":"dbf5f4778f1f4be3988d049f5963b879","type":"GO_TERM","name":"regulation of thymocyte aggregation","canonical_id":"go:GO:2000398","description":"\"Any process that modulates the frequency, rate or extent of thymocyte aggregation.\" [GOC:mah]","metadata":null},{"id":"5cdb8d1c9b4f46e8bcc5f2e37da777ef","type":"GO_TERM","name":"regulation of thymocyte apoptotic process","canonical_id":"go:GO:0070243","description":"\"Any process that modulates the occurrence or rate of thymocyte death by apoptotic process.\" [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"4a5ce1984f7940cbb5090e7e00f869a9","type":"GO_TERM","name":"regulation of thymocyte migration","canonical_id":"go:GO:2000410","description":"\"Any process that modulates the frequency, rate or extent of thymocyte migration.\" [GOC:mah]","metadata":null},{"id":"cdd0322ba5ab43dd9fe60dc9479edec2","type":"GO_TERM","name":"regulation of thyroid gland epithelial cell proliferation","canonical_id":"go:GO:1904441","description":"\"Any process that modulates the frequency, rate or extent of thyroid gland epithelial cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:17646383]","metadata":null},{"id":"48e493284ae148acb8c7557e87562fe9","type":"GO_TERM","name":"regulation of thyroid hormone generation","canonical_id":"go:GO:2000609","description":"\"Any process that modulates the frequency, rate or extent of thyroid hormone generation.\" [GOC:obol]","metadata":null},{"id":"2f6d6fd629774bc2a5b268d4d1e3da5d","type":"GO_TERM","name":"regulation of thyroid hormone receptor signaling pathway","canonical_id":"go:GO:0002155","description":"\"Any process that modulates the frequency, rate or extent of a thyroid hormone mediated signaling pathway.\" [GOC:hjd]","metadata":null},{"id":"9d8f2a2d9e514485a40e6fd6166c7c08","type":"GO_TERM","name":"regulation of thyroid-stimulating hormone secretion","canonical_id":"go:GO:2000612","description":"\"Any process that modulates the frequency, rate or extent of thyroid-stimulating hormone secretion.\" [GOC:obol]","metadata":null},{"id":"0f9ff01c177f40048417e340f2fd181a","type":"GO_TERM","name":"regulation of tight junction disassembly","canonical_id":"go:GO:1905073","description":"\"Any process that modulates the frequency, rate or extent of tight junction disassembly.\" [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"f93a57ecc19d4ecf85228fce354dd3db","type":"GO_TERM","name":"regulation of timing of anagen","canonical_id":"go:GO:0051884","description":"\"Any process that modulates the frequency, rate or extent of timing of anagen, the growth phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"14fce9f6834242c68ec20c69cffbe02e","type":"GO_TERM","name":"regulation of timing of animal organ formation","canonical_id":"go:GO:0048504","description":"\"Any process that modulates the rate, frequency or extent of animal organ formation at a consistent predetermined time point during development.\" [GOC:bf, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"d0c82c82af0c4b6ab10e360856f940f6","type":"GO_TERM","name":"regulation of timing of catagen","canonical_id":"go:GO:0051794","description":"\"Any process that modulates the frequency, rate or extent of timing of catagen, the regression phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"74cc2f9684704e49a59f7d00bfcedbc9","type":"GO_TERM","name":"regulation of timing of cell differentiation","canonical_id":"go:GO:0048505","description":"\"The process controlling the activation and/or rate at which relatively unspecialized cells acquire specialized features. Any process that modulates the rate, frequency or extent of the XXX at a consistent predetermined time point during its development.\" [GOC:bf, GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"11f5948b587a4cbbb4a2d731bbc3fdff","type":"GO_TERM","name":"regulation of timing of exogen","canonical_id":"go:GO:0051887","description":"\"Any process that modulates the frequency, rate or extent of timing of exogen, the shedding phase of the hair cycle.\" [GOC:ai, GOC:pr]","metadata":null},{"id":"8e702923968947d2846f995dbeea55c5","type":"GO_TERM","name":"regulation of timing of meristematic phase transition","canonical_id":"go:GO:0048506","description":"\"Any process that modulates the rate, frequency or extent of a change in identity of a meristem at a characteristic predetermined time point.\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"6156fa475bbb4089b81c5d85adcdb499","type":"GO_TERM","name":"regulation of timing of neuron differentiation","canonical_id":"go:GO:0060164","description":"\"The process controlling the activation and/or rate at which a relatively unspecialized cell acquires features of a neuron.\" [GOC:dph]","metadata":null},{"id":"f6db5bab2a5c492eb6e6dab3e53b8f83","type":"GO_TERM","name":"regulation of timing of plant organ formation","canonical_id":"go:GO:0090709","description":"\"Any process that modulates the rate, frequency or extent of plant organ formation at a consistent predetermined time point during development.\" [GOC:tb]","metadata":null},{"id":"e47d8e216a7d40a3a47bf4282301d7a6","type":"GO_TERM","name":"regulation of timing of subpallium neuron differentiation","canonical_id":"go:GO:0060165","description":"\"The process controlling the timing and/or rate at which a relatively unspecialized cell in the subpallium acquires features of a neuron. The subpallium is the base region of the telencephalon.\" [GOC:dph]","metadata":null},{"id":"712a9d0a1455487ab9549479b48b984a","type":"GO_TERM","name":"regulation of timing of transition from vegetative to reproductive phase","canonical_id":"go:GO:0048510","description":"\"The process controlling the point in time during development when a vegetative meristem will change its identity to become an inflorescence or floral meristem, and/or the rate at which the change occurs.\" [GOC:jid, PMID:8974397]","metadata":null},{"id":"e425d9bc00194959be3db755fb238aa9","type":"GO_TERM","name":"regulation of tissue kallikrein-kinin cascade","canonical_id":"go:GO:0002382","description":"\"Any process that modulates the frequency, rate, or extent of the tissue kallikrein-kinin cascade.\" [GOC:add]","metadata":null},{"id":"890b3398164b49d3b9b60aeb8edece2d","type":"GO_TERM","name":"regulation of tissue remodeling","canonical_id":"go:GO:0034103","description":"\"Any process that modulates the frequency, rate, or extent of tissue remodeling.\" [GOC:add]","metadata":null},{"id":"decfa93cb6b043158cb8e2450193fdb5","type":"GO_TERM","name":"regulation of tocopherol cyclase activity","canonical_id":"go:GO:1902171","description":"\"Any process that modulates the frequency, rate or extent of tocopherol cyclase activity.\" [GOC:TermGenie, PMID:23632854]","metadata":null},{"id":"080a714743c347c28b07a9a453a27836","type":"GO_TERM","name":"regulation of tolerance induction","canonical_id":"go:GO:0002643","description":"\"Any process that modulates the frequency, rate, or extent of tolerance induction.\" [GOC:add]","metadata":null},{"id":"8552aae20d3f4d47896ed0b9d3cc1823","type":"GO_TERM","name":"regulation of tolerance induction dependent upon immune response","canonical_id":"go:GO:0002652","description":"\"Any process that modulates the frequency, rate, or extent of tolerance induction dependent upon immune response.\" [GOC:add]","metadata":null},{"id":"aecc3e5fcc1744099101efd471777c46","type":"GO_TERM","name":"regulation of tolerance induction to nonself antigen","canonical_id":"go:GO:0002655","description":"\"Any process that modulates the frequency, rate, or extent of tolerance induction to nonself antigen.\" [GOC:add]","metadata":null},{"id":"8333d6a58e5049c087419690d6149c1a","type":"GO_TERM","name":"regulation of tolerance induction to self antigen","canonical_id":"go:GO:0002649","description":"\"Any process that modulates the frequency, rate, or extent of tolerance induction to self antigen.\" [GOC:add]","metadata":null},{"id":"75b91d843cd44ddc8969c9a71997fa21","type":"GO_TERM","name":"regulation of tolerance induction to tumor cell","canonical_id":"go:GO:0002843","description":"\"Any process that modulates the frequency, rate, or extent of tolerance induction to tumor cell.\" [GOC:add]","metadata":null},{"id":"069864b64711461987db062d4fbe0cda","type":"GO_TERM","name":"regulation of toll-like receptor 1 signaling pathway","canonical_id":"go:GO:0034131","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 1 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"2dfa863000b946fd9b1461e72e8f04fd","type":"GO_TERM","name":"regulation of toll-like receptor 10 signaling pathway","canonical_id":"go:GO:0034167","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 10 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"6468580c88c64fe5a9847bc94c07c15f","type":"GO_TERM","name":"regulation of toll-like receptor 11 signaling pathway","canonical_id":"go:GO:0034171","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 11 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"a3ced5ebf24244698d044afe0e323d21","type":"GO_TERM","name":"regulation of toll-like receptor 12 signaling pathway","canonical_id":"go:GO:0034175","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 12 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"12bedb2c4b47493793b32595a86a3b85","type":"GO_TERM","name":"regulation of toll-like receptor 13 signaling pathway","canonical_id":"go:GO:0034179","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 13 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"8f80dd2e134642e1bf8428b3ca3b6bf1","type":"GO_TERM","name":"regulation of toll-like receptor 15 signaling pathway","canonical_id":"go:GO:2000440","description":"\"Any process that modulates the frequency, rate or extent of toll-like receptor 15 signaling pathway.\" [GOC:obol]","metadata":null},{"id":"eb293ad133874402ae34a512b86b915a","type":"GO_TERM","name":"regulation of toll-like receptor 2 signaling pathway","canonical_id":"go:GO:0034135","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 2 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"b94efa7dc4774b82be21f6e5b0f2a705","type":"GO_TERM","name":"regulation of toll-like receptor 21 signaling pathway","canonical_id":"go:GO:2000443","description":"\"Any process that modulates the frequency, rate or extent of toll-like receptor 21 signaling pathway.\" [GOC:obol]","metadata":null},{"id":"9f1be1abe2854cd798d3b94ac1cc7d8b","type":"GO_TERM","name":"regulation of toll-like receptor 3 signaling pathway","canonical_id":"go:GO:0034139","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 3 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"12bf1b860e324324afc838c3db3a6df1","type":"GO_TERM","name":"regulation of toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0034143","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 4 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"8ec938696e084d02a5ca2226e8fe5505","type":"GO_TERM","name":"regulation of toll-like receptor 5 signaling pathway","canonical_id":"go:GO:0034147","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 5 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"daee5c3feb5945f39bde74b773c2289b","type":"GO_TERM","name":"regulation of toll-like receptor 6 signaling pathway","canonical_id":"go:GO:0034151","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 6 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"095abe49555d4f46bf9268c5203375b5","type":"GO_TERM","name":"regulation of toll-like receptor 7 signaling pathway","canonical_id":"go:GO:0034155","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 7 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"05c9d0f2c8eb4fd0893a21b2d97b96ae","type":"GO_TERM","name":"regulation of toll-like receptor 8 signaling pathway","canonical_id":"go:GO:0034159","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 8 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"0027457a7d024b8dae1779cbb35860ca","type":"GO_TERM","name":"regulation of toll-like receptor 9 signaling pathway","canonical_id":"go:GO:0034163","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor 9 signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"dd750483954046b0949e0860d8fa0c2e","type":"GO_TERM","name":"regulation of toll-like receptor signaling pathway","canonical_id":"go:GO:0034121","description":"\"Any process that modulates the frequency, rate, or extent of toll-like receptor signaling pathway.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"4f7b0418a4474e31b517b98ca97815da","type":"GO_TERM","name":"regulation of toluene catabolic process","canonical_id":"go:GO:1901434","description":"\"Any process that modulates the frequency, rate or extent of toluene catabolic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"3bc1ff9a26ce4ca4afea362851f5e8fb","type":"GO_TERM","name":"regulation of tongue muscle cell differentiation","canonical_id":"go:GO:2001035","description":"\"Any process that modulates the frequency, rate or extent of tongue muscle cell differentiation.\" [GOC:obol]","metadata":null},{"id":"4fa0f057c6a04579a3c29e24e38c5983","type":"GO_TERM","name":"regulation of tonic skeletal muscle contraction","canonical_id":"go:GO:0014746","description":"\"Any process that modulates the frequency, rate or extent of tonic skeletal muscle contraction.\" [GOC:mtg_muscle]","metadata":null},{"id":"27ab51f8b60044c5bd757cf46d30f97f","type":"GO_TERM","name":"regulation of tooth mineralization","canonical_id":"go:GO:0070170","description":"\"Any process that modulates the frequency, rate or extent of tooth mineralization, the deposition of calcium salts in tooth structures.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b0ad4b90be0f4cf3bf3cd1e550f294da","type":"GO_TERM","name":"regulation of torso signaling pathway","canonical_id":"go:GO:0120175","description":"\"Any process that modulates the frequency, rate or extent of the torso signaling pathway.\" [GOC:ha, PMID:23732470]","metadata":null},{"id":"2ea661ec05b047fdaa3070c4dcc64fcd","type":"GO_TERM","name":"regulation of trans-synaptic signaling","canonical_id":"go:GO:0099177","description":"\"Any process that modulates the frequency, rate or extent of trans-synaptic signaling.\" [GOC:dos]","metadata":null},{"id":"00b9d3d47a09449aa719e660bc593776","type":"GO_TERM","name":"regulation of trans-synaptic signaling by BDNF, modulating synaptic transmission","canonical_id":"go:GO:0150035","description":"\"Any process that modulates the frequency, rate or extent of trans-synaptic signaling by BDNF, modulating synaptic transmission.\" [GOC:aruk, GOC:bc, PMID:19448629]","metadata":null},{"id":"85978354ec5647cb963d58953501f270","type":"GO_TERM","name":"regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission","canonical_id":"go:GO:0150036","description":"\"Any process that modulates the frequency, rate or extent of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission.\" [GOC:aruk, GOC:bc, PMID:27296803]","metadata":null},{"id":"cbb673033c4d47d99216fb52193bab91","type":"GO_TERM","name":"regulation of transcription by RNA polymerase I","canonical_id":"go:GO:0006356","description":"\"Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase I.\" [GOC:curators]","metadata":null},{"id":"396c3819d5b9421190e05f3c94054ff8","type":"GO_TERM","name":"regulation of transcription by RNA polymerase II","canonical_id":"go:GO:0006357","description":"\"Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II.\" [GOC:curators, GOC:txnOH]","metadata":null},{"id":"481702dabb7648b98dc08a028c418c1d","type":"GO_TERM","name":"regulation of transcription by RNA polymerase III","canonical_id":"go:GO:0006359","description":"\"Any process that modulates the frequency, rate or extent of transcription mediated by RNA ploymerase III.\" [GOC:curators]","metadata":null},{"id":"93a073f82c1a4d7aa08287747d2fb80b","type":"GO_TERM","name":"regulation of transcription by RNA polymerase V","canonical_id":"go:GO:1904279","description":"\"Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase V.\" [GO_REF:0000058, GOC:TermGenie, PMID:24726328]","metadata":null},{"id":"5f8f3fe9098e484691dcd705ee737060","type":"GO_TERM","name":"regulation of transcription by galactose","canonical_id":"go:GO:0000409","description":"\"Any process involving galactose that modulates the frequency, rate or extent or transcription.\" [GOC:curators]","metadata":null},{"id":"3d4596fdc93646b684125807ab0cc189","type":"GO_TERM","name":"regulation of transcription by glucose","canonical_id":"go:GO:0046015","description":"\"Any process involving glucose that modulates the frequency, rate or extent or transcription.\" [GOC:curators]","metadata":null},{"id":"28989469c56b4b349fe1b72d783924f5","type":"GO_TERM","name":"regulation of transcription elongation by RNA polymerase I","canonical_id":"go:GO:2001207","description":"\"Any process that modulates the frequency, rate or extent of transcription elongation from RNA polymerase I promoter.\" [PMID:20299458]","metadata":null},{"id":"2ac337c32dfb47cd8d7662161791dac0","type":"GO_TERM","name":"regulation of transcription elongation by RNA polymerase II","canonical_id":"go:GO:0034243","description":"\"Any process that modulates the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"ccdd4c57c78b44938d9668cfe3eeefde","type":"GO_TERM","name":"regulation of transcription from RNA polymerase II promoter by galactose","canonical_id":"go:GO:0000431","description":"\"Any process involving galactose that modulates the frequency, rate or extent of transcription from an RNA polymerase II promoter.\" [GOC:krc]","metadata":null},{"id":"b6c016826cdb4b2c9d714d1c06790bd4","type":"GO_TERM","name":"regulation of transcription from RNA polymerase II promoter by glucose","canonical_id":"go:GO:0000430","description":"\"Any process involving glucose that modulates the frequency, rate or extent of transcription from an RNA polymerase II promoter.\" [GOC:krc]","metadata":null},{"id":"5a262899491f4759b2b7e4c3cfc524a7","type":"GO_TERM","name":"regulation of transcription initiation by RNA polymerase I","canonical_id":"go:GO:1903357","description":"\"Any process that modulates the frequency, rate or extent of transcription initiation from RNA polymerase I promoter.\" [GO_REF:0000058, GOC:TermGenie, PMID:9092673]","metadata":null},{"id":"7bef7c36fc3948048ec1928dd4a6d0d0","type":"GO_TERM","name":"regulation of transcription initiation by RNA polymerase II","canonical_id":"go:GO:0060260","description":"\"Any process that modulates the rate, frequency or extent of a process involved in starting transcription from an RNA polymerase II promoter.\" [GOC:dph, GOC:tb, GOC:txnOH]","metadata":null},{"id":"fb0b20cd472545099c228c624f592ec6","type":"GO_TERM","name":"regulation of transcription of nucleolar large rRNA by RNA polymerase I","canonical_id":"go:GO:1901836","description":"\"Any process that modulates the frequency, rate or extent of transcription of nuclear large rRNA mediated by RNA polymerase I.\" [GOC:sart, GOC:TermGenie]","metadata":null},{"id":"fb810513115a46c3b65a7c6af38e5084","type":"GO_TERM","name":"regulation of transcription open complex formation at RNA polymerase II promoter","canonical_id":"go:GO:0001177","description":"\"Any process that modulates the rate, frequency or extent of a process involved the melting of the DNA hybrid of the core promoter region within the transcriptional closed complex of an RNA polymerase II preinitiation complex (PIC) to produce an open complex where the DNA duplex around the transcription initiation site is unwound to form the transcription bubble.\" [GOC:txnOH]","metadata":null},{"id":"a3bc04f8655440edb6e6c680e163d008","type":"GO_TERM","name":"regulation of transcription regulatory region DNA binding","canonical_id":"go:GO:2000677","description":"\"Any process that modulates the frequency, rate or extent of transcription regulatory region DNA binding.\" [GOC:obol]","metadata":null},{"id":"99b367c7838d4ca3a215862bfc0f3489","type":"GO_TERM","name":"regulation of transcription, start site selection","canonical_id":"go:GO:0010630","description":"\"Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA by a mechanism that selects the start site along that template.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"f001d4a3b2334fa6b899efb9e1d065da","type":"GO_TERM","name":"regulation of transcription-coupled nucleotide-excision repair","canonical_id":"go:GO:0090262","description":"\"Any process that modulates the frequency, rate, or extent of the nucleotide-excision repair process that carries out preferential repair of DNA lesions on the actively transcribed strand of the DNA duplex. In addition, the transcription-coupled nucleotide-excision repair pathway is required for the recognition and repair of a small subset of lesions that are not recognized by the global genome nucleotide excision repair pathway.\" [GOC:tb]","metadata":null},{"id":"0dbb608295c243169c014f0686eb1b1a","type":"GO_TERM","name":"regulation of transcriptional start site selection at RNA polymerase II promoter","canonical_id":"go:GO:0001178","description":"\"Any process that modulates the rate, frequency or extent of a process involved in the selection of the specific location within the template strand of an RNA polymerase II promoter for hybridization of the cognate ribonucleotides and formation of first phosphodiester bond within the nascent transcript.\" [GOC:txnOH]","metadata":null},{"id":"3aaca7dbe9744f26854acaaa08b7d6b1","type":"GO_TERM","name":"regulation of transcytosis","canonical_id":"go:GO:1904298","description":"\"Any process that modulates the frequency, rate or extent of transcytosis.\" [GO_REF:0000058, GOC:TermGenie, PMID:9664076]","metadata":null},{"id":"929adcaf653e4dcfab1d63209e242ad3","type":"GO_TERM","name":"regulation of transdifferentiation","canonical_id":"go:GO:1903618","description":"\"Any process that modulates the frequency, rate or extent of transdifferentiation.\" [GO_REF:0000058, GOC:TermGenie, PMID:22118091]","metadata":null},{"id":"339b06eb3d3543e4bcf725572a6b9796","type":"GO_TERM","name":"regulation of transepithelial transport","canonical_id":"go:GO:0150111","description":"\"Any process that modulates the frequency, rate or extent of transepithelial transport.\" [GOC:aruk, PMID:27593915]","metadata":null},{"id":"283d5cc168e84f3bb309292494de7b5f","type":"GO_TERM","name":"regulation of transferase activity","canonical_id":"go:GO:0051338","description":"\"Any process that modulates the frequency, rate or extent of transferase activity, the catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.\" [GOC:ai]","metadata":null},{"id":"b9735101f6b94ed098f27f848080ad31","type":"GO_TERM","name":"regulation of transformation of host cell by virus","canonical_id":"go:GO:1904187","description":"\"Any process that modulates the frequency, rate or extent of transformation of host cell by virus.\" [GO_REF:0000058, GOC:TermGenie, PMID:12200142]","metadata":null},{"id":"1e8c4c2641ee41a58dc48c941864033b","type":"GO_TERM","name":"regulation of transforming growth factor beta production","canonical_id":"go:GO:0071634","description":"\"Any process that modulates the frequency, rate, or extent of production of transforming growth factor-beta.\" [GOC:mah]","metadata":null},{"id":"e9197ad400484bd7909070e5b0f4335e","type":"GO_TERM","name":"regulation of transforming growth factor beta receptor signaling pathway","canonical_id":"go:GO:0017015","description":"\"Any process that modulates the frequency, rate or extent of activity of any TGF-beta receptor signaling pathway.\" [GOC:mah]","metadata":null},{"id":"54599ae7ff4a4978a9ecde625aeb9651","type":"GO_TERM","name":"regulation of transforming growth factor beta1 production","canonical_id":"go:GO:0032908","description":"\"Any process that modulates the frequency, rate, or extent of production of transforming growth factor-beta1.\" [GOC:mah]","metadata":null},{"id":"1396e37024554b0fb1b1504a2b79de20","type":"GO_TERM","name":"regulation of transforming growth factor beta2 production","canonical_id":"go:GO:0032909","description":"\"Any process that modulates the frequency, rate, or extent of production of transforming growth factor-beta2.\" [GOC:mah]","metadata":null},{"id":"61211920a0ab4abab14ae6bc9e7ec736","type":"GO_TERM","name":"regulation of transforming growth factor beta3 production","canonical_id":"go:GO:0032910","description":"\"Any process that modulates the frequency, rate, or extent of production of transforming growth factor-beta3.\" [GOC:mah]","metadata":null},{"id":"895ca439138c4e2290758a45fbd83e4d","type":"GO_TERM","name":"regulation of translation","canonical_id":"go:GO:0006417","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.\" [GOC:isa_complete]","metadata":null},{"id":"8f7607f5aec94f8790d64cb48d05d851","type":"GO_TERM","name":"regulation of translation at postsynapse","canonical_id":"go:GO:0140245","description":"\"Any process that regulates translation occurring at the postsynapse.\" [PMID:20427644]","metadata":null},{"id":"91ba1bb3c8f549728433c22fa05c16e4","type":"GO_TERM","name":"regulation of translation at postsynapse, modulating synaptic transmission","canonical_id":"go:GO:0099578","description":"\"Any process that modulates synaptic transmission by regulating translation occurring at the postsynapse.\" [GOC:dos]","metadata":null},{"id":"3781fb4ed24646fca294f5c7fcbf4c68","type":"GO_TERM","name":"regulation of translation at presynapse","canonical_id":"go:GO:0140244","description":"\"Any process that regulates translation occurring at the presynapse.\" [PMID:20427644]","metadata":null},{"id":"9a7f287346a7486098effafde552a488","type":"GO_TERM","name":"regulation of translation at presynapse, modulating synaptic transmission","canonical_id":"go:GO:0099577","description":"\"Any process that modulates synaptic transmission by regulating translation occurring at the presynapse.\" [GOC:dos]","metadata":null},{"id":"34f0106bf8fe40f9bd0d6a44fc09eecd","type":"GO_TERM","name":"regulation of translation at synapse","canonical_id":"go:GO:0140243","description":"\"Any process that regulates translation occurring at the synapse.\" [PMID:20427644]","metadata":null},{"id":"b4ed4ff5e77f4e4f808a6e88f95296d0","type":"GO_TERM","name":"regulation of translation at synapse, modulating synaptic transmission","canonical_id":"go:GO:0099547","description":"\"Any process that modulates synaptic transmission by regulating translation occurring at the synapse.\" [GOC:dos]","metadata":null},{"id":"43865e7efd2e49c18103e25bf1574765","type":"GO_TERM","name":"regulation of translation by machinery localization","canonical_id":"go:GO:0043143","description":"\"Any process in which proteins and protein complexes involved in translation are transported to, or maintained in, a specific location.\" [GOC:jl]","metadata":null},{"id":"d716238c2c2348d689e686bc129d88e7","type":"GO_TERM","name":"regulation of translation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036490","description":"\"Modulation of the frequency, rate or extent of translation as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL, PMID:14676213, PMID:16835242]","metadata":null},{"id":"0c792508dcaf42bd8d085b040efcf712","type":"GO_TERM","name":"regulation of translation in response to osmotic stress","canonical_id":"go:GO:0043557","description":"\"Any process that modulates the frequency, rate or extent of the frequency, rate or extent of translation as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:jl]","metadata":null},{"id":"5f5aa096fb214835a0628618dbbd3c59","type":"GO_TERM","name":"regulation of translation in response to oxidative stress","canonical_id":"go:GO:0043556","description":"\"Any process that modulates the frequency, rate or extent of translation as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.\" [GOC:jl]","metadata":null},{"id":"32897d5f265747478e48a6675ddab885","type":"GO_TERM","name":"regulation of translation in response to stress","canonical_id":"go:GO:0043555","description":"\"Modulation of the frequency, rate or extent of translation as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:jl]","metadata":null},{"id":"3351106b032e4ecf947f512856055543","type":"GO_TERM","name":"regulation of translation initiation in response to endoplasmic reticulum stress","canonical_id":"go:GO:0036491","description":"\"Any process that modulates the frequency, rate or extent of translation initiation, as a result of endoplasmic reticulum stress.\" [GOC:bf, GOC:PARL, PMID:14676213, PMID:16835242]","metadata":null},{"id":"12de251e49214f74bb1af861f4ae4586","type":"GO_TERM","name":"regulation of translation involved in cellular response to UV","canonical_id":"go:GO:1904803","description":"\"Any regulation of translation that is involved in cellular response to UV.\" [GO_REF:0000060, GOC:TermGenie, PMID:17369398]","metadata":null},{"id":"f6b40c8880ca4024b738f51b6883630c","type":"GO_TERM","name":"regulation of translation, ncRNA-mediated","canonical_id":"go:GO:0045974","description":"\"Any process, mediated by small non-coding RNAs, that modulates the frequency, rate or extent that mRNAs are effectively translated into protein.\" [GOC:curators, GOC:dph, GOC:tb]","metadata":null},{"id":"3177905fc8ff4c8189a36a5197a762a6","type":"GO_TERM","name":"regulation of translational elongation","canonical_id":"go:GO:0006448","description":"\"Any process that modulates the frequency, rate, extent or accuracy of translational elongation.\" [GOC:curators]","metadata":null},{"id":"bdb8b29a9d3a4c69960b5210ddeb8be7","type":"GO_TERM","name":"regulation of translational fidelity","canonical_id":"go:GO:0006450","description":"\"Any process that modulates the ability of the translational apparatus to interpret the genetic code.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"2f2c055cbe6f49bc9bfbfbee05b7f40e","type":"GO_TERM","name":"regulation of translational frameshifting","canonical_id":"go:GO:2001124","description":"\"Any process that modulates the frequency, rate or extent of translational frameshifting.\" [GOC:obol]","metadata":null},{"id":"7f839f3dee6f4aa4a58e2f5883f9696b","type":"GO_TERM","name":"regulation of translational initiation","canonical_id":"go:GO:0006446","description":"\"Any process that modulates the frequency, rate or extent of translational initiation.\" [GOC:curators]","metadata":null},{"id":"e55304ed4cf9448c853ae841161a1c1e","type":"GO_TERM","name":"regulation of translational initiation by eIF2 alpha dephosphorylation","canonical_id":"go:GO:0036496","description":"\"Any process that modulates the frequency, rate or extent of translation initiation in response to stress by the dephosphorylation of eIF2 alpha.\" [GOC:bf, GOC:PARL]","metadata":null},{"id":"df553e7d5d2d441382ea0831222f705a","type":"GO_TERM","name":"regulation of translational initiation by eIF2 alpha phosphorylation","canonical_id":"go:GO:0010998","description":"\"Any process that modulates the frequency, rate or extent of translation initiation in response to stress by the phosphorylation of eIF2 alpha.\" [GOC:BHF, GOC:dph, GOC:hjd, GOC:tb]","metadata":null},{"id":"113356a78d224940bdb7dc12b756153e","type":"GO_TERM","name":"regulation of translational initiation by iron","canonical_id":"go:GO:0006447","description":"\"Any process that modulates the frequency, rate or extent of the translation of certain mRNAs involved in iron metabolism; regulated by the concentration of iron.\" [GOC:jl]","metadata":null},{"id":"d2acbd66e19a437995e3cd79f5e0d325","type":"GO_TERM","name":"regulation of translational initiation by tRNA modification","canonical_id":"go:GO:1990983","description":"\"A process in which translation initiation is regulated by post-translation modifications of a tRNA molecule.\" [PMID:27745969]","metadata":null},{"id":"8be75404fd7148ada154bab5f3b954b3","type":"GO_TERM","name":"regulation of translational initiation in response to osmotic stress","canonical_id":"go:GO:0043561","description":"\"Any process that modulates the frequency, rate or extent of translation initiation, as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:dph, GOC:jl, GOC:tb]","metadata":null},{"id":"f8d048eca66e4efc9fdb759c6d494e23","type":"GO_TERM","name":"regulation of translational initiation in response to starvation","canonical_id":"go:GO:0071262","description":"\"Any process that modulates the frequency, rate or extent of translation initiation, as a result of deprivation of nourishment.\" [GOC:mah]","metadata":null},{"id":"86ee041871fd4cd9a6ba631c81d95952","type":"GO_TERM","name":"regulation of translational initiation in response to stress","canonical_id":"go:GO:0043558","description":"\"Any process that modulates the frequency, rate or extent of translation initiation, as a result of a stimulus indicating the organism is under stress.\" [GOC:jl]","metadata":null},{"id":"8a6d3530e167414dae5b64f91c7671ab","type":"GO_TERM","name":"regulation of translational termination","canonical_id":"go:GO:0006449","description":"\"Any process that modulates the frequency, rate or extent of translational termination.\" [GOC:curators]","metadata":null},{"id":"0efd6fc0c2bf4d28ae58b37aa623cbea","type":"GO_TERM","name":"regulation of transmembrane receptor protein serine/threonine kinase signaling pathway","canonical_id":"go:GO:0090092","description":"\"Any process that modulates the rate, frequency, or extent of the series of molecular signals generated as a consequence of a transmembrane receptor serine/threonine kinase binding to its physiological ligand.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"651f820ec4f342f785f6e721b77edb91","type":"GO_TERM","name":"regulation of transmembrane transport","canonical_id":"go:GO:0034762","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of a solute from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"5195b0031ae6424983a0810087ce74e6","type":"GO_TERM","name":"regulation of transmembrane transporter activity","canonical_id":"go:GO:0022898","description":"\"Any process that modulates the frequency, rate or extent of transmembrane transporter activity.\" [GOC:dph, GOC:mtg_cardio, GOC:mtg_transport]","metadata":null},{"id":"b902f34c92c44b05a06f071daa22aca5","type":"GO_TERM","name":"regulation of transmission of nerve impulse","canonical_id":"go:GO:0051969","description":"\"Any process that modulates the frequency, rate or extent of transmission of a nerve impulse, the sequential electrochemical polarization and depolarization that travels across the membrane of a neuron in response to stimulation.\" [GOC:ai]","metadata":null},{"id":"8dca57ce3bb846e0819b8da2db5d4a7e","type":"GO_TERM","name":"regulation of transport","canonical_id":"go:GO:0051049","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"0a1ae808469348c7b2bdf895f0b5bebe","type":"GO_TERM","name":"regulation of transport across blood-brain barrier","canonical_id":"go:GO:0150200","description":"\"Any process that modulates the frequency, rate or extent of transport across the blood-brain barrier.\" [GOC:aruk, GOC:bc, PMID:29377008, PMID:30280653]","metadata":null},{"id":"8e5b2d50499340929753b6428e110424","type":"GO_TERM","name":"regulation of trehalose metabolic process","canonical_id":"go:GO:0090062","description":"\"Any process that modulates the frequency, rate or extent of trehalose metabolism, the chemical reactions and pathways involving trehalose, a disaccharide that consists of two molecules of glucose and is isomeric with sucrose.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"cd7110adf0d44ac6b5ebfcf0c0de55c1","type":"GO_TERM","name":"regulation of trichoblast fate specification","canonical_id":"go:GO:0010061","description":"\"Any process that modulates trichoblast fate specification.\" [GOC:tb]","metadata":null},{"id":"d88b8075e14544e3bbd33b932e2723c9","type":"GO_TERM","name":"regulation of trichome morphogenesis","canonical_id":"go:GO:2000039","description":"\"Any process that modulates the frequency, rate or extent of trichome morphogenesis.\" [GOC:obol]","metadata":null},{"id":"4dbaf27340f74b52a1e5b840d3052335","type":"GO_TERM","name":"regulation of trichome patterning","canonical_id":"go:GO:1900032","description":"\"Any process that modulates the frequency, rate or extent of trichome patterning.\" [GOC:TermGenie]","metadata":null},{"id":"481d8350efe149ebaedf0a01e12dd53f","type":"GO_TERM","name":"regulation of tridecane biosynthetic process","canonical_id":"go:GO:1900884","description":"\"Any process that modulates the frequency, rate or extent of tridecane biosynthetic process.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"39619b3f563f4d6680a22cfd1b1f88c3","type":"GO_TERM","name":"regulation of triglyceride biosynthetic process","canonical_id":"go:GO:0010866","description":"\"Any process that modulates the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol.\" [GOC:BHF, GOC:tb]","metadata":null},{"id":"1ac51c30dda3463fb672b4ee118d5f85","type":"GO_TERM","name":"regulation of triglyceride catabolic process","canonical_id":"go:GO:0010896","description":"\"Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride.\" [GOC:rn, GOC:tb]","metadata":null},{"id":"b525984805d1474689d14649967d5e18","type":"GO_TERM","name":"regulation of triglyceride metabolic process","canonical_id":"go:GO:0090207","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving triglyceride, any triester of glycerol.\" [GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"ed0e96f720bb4008afb22bf78f211928","type":"GO_TERM","name":"regulation of triglyceride storage","canonical_id":"go:GO:0010889","description":"\"Any process that modulates the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"8bbd17bf05904f4cbfd6396f5090f320","type":"GO_TERM","name":"regulation of triglyceride transport","canonical_id":"go:GO:1905883","description":"\"Any process that modulates the frequency, rate or extent of triglyceride transport.\" [GO_REF:0000058, GOC:TermGenie, PMID:25849533]","metadata":null},{"id":"7576ea7e219e419895393d9f6296a80a","type":"GO_TERM","name":"regulation of trophectodermal cell proliferation","canonical_id":"go:GO:1904073","description":"\"Any process that modulates the frequency, rate or extent of trophectodermal cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:24508636]","metadata":null},{"id":"3550d9c17c7e4a24aecc64edf5082781","type":"GO_TERM","name":"regulation of trophoblast cell migration","canonical_id":"go:GO:1901163","description":"\"Any process that modulates the frequency, rate or extent of trophoblast cell migration.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"cb8479df9fbb4c4aac915a76822204a3","type":"GO_TERM","name":"regulation of trypanothione biosynthetic process","canonical_id":"go:GO:1905722","description":"\"Any process that modulates the frequency, rate or extent of trypanothione biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:18949025]","metadata":null},{"id":"16c4b81a268147a2b257b99311118c55","type":"GO_TERM","name":"regulation of tube architecture, open tracheal system","canonical_id":"go:GO:0035152","description":"\"Ensuring that tracheal cells form and maintain tubular structures with the correct size and shape for their position in the network. This is essential for efficient flow of gases through the tracheal network.\" [GOC:mtg_sensu, PMID:14570584]","metadata":null},{"id":"777fb0fe665440779a59b862791248e2","type":"GO_TERM","name":"regulation of tube diameter","canonical_id":"go:GO:0035296","description":"\"Any process that modulates the diameter of a tube.\" [GOC:bf]","metadata":null},{"id":"2cb40d667d394b4790c4d1d856c76eea","type":"GO_TERM","name":"regulation of tube diameter, open tracheal system","canonical_id":"go:GO:0035158","description":"\"Ensuring that a tube in an open tracheal system is of the correct diameter. When primary branches form their lumens are small (less than 2 micrometers) in caliber and must undergo regulated expansion during larval life to reach their mature size.\" [GOC:mtg_sensu, PMID:14570584]","metadata":null},{"id":"295e1c18c8db45f0b125e50422fff747","type":"GO_TERM","name":"regulation of tube length, open tracheal system","canonical_id":"go:GO:0035159","description":"\"Ensuring that a tube in an open tracheal system is of the correct length.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"aa33457f2d1e44f59339bf14d2b86854","type":"GO_TERM","name":"regulation of tube lumen cavitation","canonical_id":"go:GO:1903132","description":"\"Any process that modulates the frequency, rate or extent of tube lumen cavitation.\" [GO_REF:0000058, GOC:dph, GOC:TermGenie, PMID:22898778]","metadata":null},{"id":"75a1702d1bb448ad81c7270a1d4f4a62","type":"GO_TERM","name":"regulation of tube size","canonical_id":"go:GO:0035150","description":"\"Ensuring that a tube is of the correct length and diameter. Tube size must be maintained not only during tube formation, but also throughout development and in some physiological processes.\" [PMID:10887083]","metadata":null},{"id":"65acc47610694125afcdd8a6a785762c","type":"GO_TERM","name":"regulation of tube size, open tracheal system","canonical_id":"go:GO:0035151","description":"\"Ensuring that an epithelial tube in an open tracheal system is of the correct length and diameter. Tracheal tubes undergo highly regulated tube-size increases during development, expanding up to 40 times their initial size by the end of larval life. Tube size appears to be controlled by regulation of apical membrane expansion and secretion, rather than by changes in cell number, size or shape.\" [GOC:mtg_sensu, PMID:10887083, PMID:12930776, PMID:12973360]","metadata":null},{"id":"0e2c98090a614e1aaf38fe5f3036e76b","type":"GO_TERM","name":"regulation of tubulin deacetylation","canonical_id":"go:GO:0090043","description":"\"Any process that modulates the frequency, rate or extent of tubulin deacetylation. Tubulin deacetylation is the removal of an acetyl group from a protein amino acid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"4646e17aa519460c9b29a33b18dc0e9b","type":"GO_TERM","name":"regulation of tumor necrosis factor (ligand) superfamily member 11 production","canonical_id":"go:GO:2000307","description":"\"Any process that modulates the frequency, rate or extent of tumor necrosis factor (ligand) superfamily member 11 production.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d5c86028c93e49f48ed598f29785888e","type":"GO_TERM","name":"regulation of tumor necrosis factor production","canonical_id":"go:GO:0032680","description":"\"Any process that modulates the frequency, rate or extent of tumor necrosis factor production.\" [GOC:mah, PMID:10891884, PMID:15560120]","metadata":null},{"id":"b68a52952acc4447b059cea03c083b61","type":"GO_TERM","name":"regulation of tumor necrosis factor superfamily cytokine production","canonical_id":"go:GO:1903555","description":"\"Any process that modulates the frequency, rate or extent of tumor necrosis factor superfamily cytokine production.\" [GO_REF:0000058, GOC:TermGenie, PMID:24187568]","metadata":null},{"id":"d567eb20b8ae4105b9d06344ca375ba0","type":"GO_TERM","name":"regulation of tumor necrosis factor-mediated signaling pathway","canonical_id":"go:GO:0010803","description":"\"Any process that modulates the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"a2705c6965ca4d6b9d9e644ed5b42fc6","type":"GO_TERM","name":"regulation of turning behavior involved in mating","canonical_id":"go:GO:0061094","description":"\"Any process that modulates the rate, frequency or extent of turning behavior involved in mating. Turning behavior is the sharp ventral turn performed by the male as he approaches either the hermaphrodite head or tail, whilst trying to locate his partner's vulva. Turning occurs via a sharp ventral coil of the male's tail.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6a71292f47d24d3d9e36a8983ee78316","type":"GO_TERM","name":"regulation of twitch skeletal muscle contraction","canonical_id":"go:GO:0014724","description":"\"Any process that modulates the frequency, rate or extent of twitch skeletal muscle contraction.\" [GOC:mtg_muscle]","metadata":null},{"id":"490d1b9e987e4929afccd89f89d717d4","type":"GO_TERM","name":"regulation of type 2 immune response","canonical_id":"go:GO:0002828","description":"\"Any process that modulates the frequency, rate, or extent of a type 2 immune response.\" [GOC:add]","metadata":null},{"id":"c76ae39becd14dc591748c9f38c5cd97","type":"GO_TERM","name":"regulation of type 2 mitophagy","canonical_id":"go:GO:1905089","description":"\"Any process that modulates the frequency, rate or extent of type 2 mitophagy.\" [PMID:26942284]","metadata":null},{"id":"a5970bf828d041f98ccd9219def7a72e","type":"GO_TERM","name":"regulation of type B pancreatic cell apoptotic process","canonical_id":"go:GO:2000674","description":"\"Any process that modulates the frequency, rate or extent of type B pancreatic cell apoptotic process.\" [GOC:mtg_apoptosis, GOC:obol]","metadata":null},{"id":"5e42c1b922fd44acbc6d647eff5ce247","type":"GO_TERM","name":"regulation of type B pancreatic cell development","canonical_id":"go:GO:2000074","description":"\"Any process that modulates the frequency, rate or extent of pancreatic B cell development.\" [GOC:obol, GOC:yaf]","metadata":null},{"id":"6024b8c54917413e8ad1b62016b3d36e","type":"GO_TERM","name":"regulation of type B pancreatic cell proliferation","canonical_id":"go:GO:0061469","description":"\"Any process that modulates the frequency, rate or extent of type B pancreatic cell proliferation.\" [GOC:dph]","metadata":null},{"id":"994b479539a248a7b0f018a41814b1be","type":"GO_TERM","name":"regulation of type I hypersensitivity","canonical_id":"go:GO:0001810","description":"\"Any process that modulates the frequency, rate, or extent of type I hypersensitivity, a type of inflammatory response.\" [ISBN:0781735149]","metadata":null},{"id":"cd378789affb4c81b9fbda631af488cd","type":"GO_TERM","name":"regulation of type I interferon production","canonical_id":"go:GO:0032479","description":"\"Any process that modulates the frequency, rate, or extent of interferon type I production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, GOC:mah]","metadata":null},{"id":"9ee75136787441b182e2ecc84613f356","type":"GO_TERM","name":"regulation of type I interferon-mediated signaling pathway","canonical_id":"go:GO:0060338","description":"\"Any process that modulates the rate, frequency or extent of a type I interferon-mediated signaling pathway.\" [GOC:dph]","metadata":null},{"id":"0c9dd7ca8ba041f1ba83fbd46595db67","type":"GO_TERM","name":"regulation of type II hypersensitivity","canonical_id":"go:GO:0002892","description":"\"Any process that modulates the frequency, rate, or extent of type II hypersensitivity.\" [GOC:add]","metadata":null},{"id":"6dfa86d2fa9c485e8ad792f26e9e73c3","type":"GO_TERM","name":"regulation of type II interferon production","canonical_id":"go:GO:0032649","description":"\"Any process that modulates the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.\" [GOC:add, GOC:mah, PMID:15546383]","metadata":null},{"id":"4f562468a22e4f46bae9c6b0487f6ec2","type":"GO_TERM","name":"regulation of type II interferon-mediated signaling pathway","canonical_id":"go:GO:0060334","description":"\"Any process that modulates the rate, frequency or extent of an interferon-gamma-mediated signaling pathway.\" [GOC:dph]","metadata":null},{"id":"87a7437aaad84f6e82fffd5f88389db2","type":"GO_TERM","name":"regulation of type III hypersensitivity","canonical_id":"go:GO:0001803","description":"\"Any process that modulates the frequency, rate, or extent of type III hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f086e81758a249e99686567a975cdc8c","type":"GO_TERM","name":"regulation of type III interferon production","canonical_id":"go:GO:0034344","description":"\"Any process that modulates the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"cb2225b21e8b4c10a48171054d7a93c0","type":"GO_TERM","name":"regulation of type IIa hypersensitivity","canonical_id":"go:GO:0001796","description":"\"Any process that modulates the frequency, rate, or extent of type IIa hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"ec669cc7bba94ffe85eac49c0f2fc750","type":"GO_TERM","name":"regulation of type IIb hypersensitivity","canonical_id":"go:GO:0001799","description":"\"Any process that modulates the frequency, rate, or extent of type IIb hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1710a1330ca94cb28c4543bce2e2a271","type":"GO_TERM","name":"regulation of type IV hypersensitivity","canonical_id":"go:GO:0001807","description":"\"Any process that modulates the frequency, rate, or extent of type IV hypersensitivity, a type of inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"31f27d62d8994c1b8bc88ed3e78e2327","type":"GO_TERM","name":"regulation of type IV pilus biogenesis","canonical_id":"go:GO:1903656","description":"\"Any process that modulates the frequency, rate or extent of type IV pilus biogenesis.\" [GO_REF:0000058, GOC:TermGenie, PMID:25049409]","metadata":null},{"id":"716c1017ce7745ddaf614ecfaed4fcdb","type":"GO_TERM","name":"regulation of tyramine signaling pathway","canonical_id":"go:GO:2000131","description":"\"Any process that modulates the frequency, rate or extent of tyramine signaling pathway.\" [GOC:mah]","metadata":null},{"id":"60c38bf2973249678804b86cb18893b8","type":"GO_TERM","name":"regulation of tyrosine phosphorylation of STAT protein","canonical_id":"go:GO:0042509","description":"\"Any process that modulates the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:jl, PMID:11426647]","metadata":null},{"id":"5fbdd394cc61420abbe91dd5af865458","type":"GO_TERM","name":"regulation of ubiquinone biosynthetic process","canonical_id":"go:GO:0010795","description":"\"Any process that modulates the frequency, rate or extent of ubiquinone biosynthesis. Ubiquinone biosynthesis consists of the chemical reactions and pathways resulting in the formation of ubiquinone, a lipid-soluble electron-transporting coenzyme.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"459577023bda4ac7bf1e9d4c0c0244d8","type":"GO_TERM","name":"regulation of ubiquitin protein ligase activity","canonical_id":"go:GO:1904666","description":"\"Any process that modulates the frequency, rate or extent of ubiquitin protein ligase activity.\" [GO_REF:0000059, GOC:dph, GOC:TermGenie, GOC:vw, PMID:10921876, PMID:26216882]","metadata":null},{"id":"432484ceaf9a4b9b864a702f1cdb0ad0","type":"GO_TERM","name":"regulation of ubiquitin-dependent endocytosis","canonical_id":"go:GO:2000395","description":"\"Any process that modulates the frequency, rate or extent of ubiquitin-dependent endocytosis.\" [GOC:mah]","metadata":null},{"id":"ecc50a69b30044a4b4ed5036e68415f8","type":"GO_TERM","name":"regulation of ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:2000058","description":"\"Any process that modulates the frequency, rate or extent of ubiquitin-dependent protein catabolic process.\" [GOC:BHF]","metadata":null},{"id":"19397fd5e8d6457d8a536e7c24dd22cc","type":"GO_TERM","name":"regulation of ubiquitin-protein transferase activity","canonical_id":"go:GO:0051438","description":"\"Any process that modulates the frequency, rate or extent of ubiquitin transferase activity.\" [GOC:ai, GOC:tb]","metadata":null},{"id":"f4222542e89544deb96a0e1339f55ae0","type":"GO_TERM","name":"regulation of unidimensional cell growth","canonical_id":"go:GO:0051510","description":"\"Any process that modulates the frequency, rate or extent of unidimensional cell growth, the process in which a cell irreversibly increases in size in one [spatial] dimension or along one axis.\" [GOC:ai]","metadata":null},{"id":"17d370d657c144bdb45151484dfb8916","type":"GO_TERM","name":"regulation of unsaturated fatty acid biosynthetic process","canonical_id":"go:GO:2001279","description":"\"Any process that modulates the frequency, rate or extent of unsaturated fatty acid biosynthetic process.\" [GO:0006636]","metadata":null},{"id":"3139f99c6161416e8d30388f783466ec","type":"GO_TERM","name":"regulation of uracil import across plasma membrane","canonical_id":"go:GO:1905529","description":"\"Any process that modulates the frequency, rate or extent of uracil import across plasma membrane.\" [GO_REF:0000058, GOC:TermGenie, PMID:26536126]","metadata":null},{"id":"60ae91ddc3164cd1abd759edd9e07c4c","type":"GO_TERM","name":"regulation of urea catabolic process","canonical_id":"go:GO:0034254","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of urea.\" [GOC:mah]","metadata":null},{"id":"ce6f37835bd94f5b8410450c5cd80ab4","type":"GO_TERM","name":"regulation of uredinium development","canonical_id":"go:GO:0075280","description":"\"Any process that modulates the frequency, rate or extent of uredinium development, a process that leads to the formation of a reddish, pustule-like structure formed by a rust fungus and consisting of uredospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"a854134ab7274824a75e4a96a41ec403","type":"GO_TERM","name":"regulation of uredospore formation","canonical_id":"go:GO:0075252","description":"\"Any process that modulates the frequency, rate or extent of uredospore formation, a process in which an asexual, dikaryotic, often rusty-colored spore, is formed in a structure called a uredinium.\" [GOC:pamgo_curators]","metadata":null},{"id":"91bea73c17884d07aee02f5851b127e3","type":"GO_TERM","name":"regulation of ureter smooth muscle cell differentiation","canonical_id":"go:GO:2000061","description":"\"Any process that modulates the frequency, rate or extent of ureter smooth muscle cell differentiation.\" [GOC:mtg_kidney_jan10, GOC:obol, GOC:yaf]","metadata":null},{"id":"72018c78900a4b6ba94b3ff5dbb7f98a","type":"GO_TERM","name":"regulation of ureteric bud formation","canonical_id":"go:GO:0072106","description":"\"Any process that modulates the developmental process pertaining to the initial formation of the ureteric bud from the Wolffian duct.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"58e383f0e6c444fca09d14560b73725a","type":"GO_TERM","name":"regulation of urine volume","canonical_id":"go:GO:0035809","description":"\"Any process that modulates the amount of urine excreted from the body over a unit of time.\" [GOC:mtg_25march11, GOC:yaf]","metadata":null},{"id":"79521dac18494956a9c50b924371ed36","type":"GO_TERM","name":"regulation of urothelial cell proliferation","canonical_id":"go:GO:0050675","description":"\"Any process that modulates the frequency, rate or extent of urothelial cell proliferation.\" [GOC:ai]","metadata":null},{"id":"32a1bd05f93a4c6fa6da2108ab01707f","type":"GO_TERM","name":"regulation of uterine smooth muscle contraction","canonical_id":"go:GO:0070472","description":"\"Any process that modulates the frequency, rate or extent of uterine smooth muscle contraction.\" [GOC:curators]","metadata":null},{"id":"bf059c34bb6e44ff874bd3d1a80e9e74","type":"GO_TERM","name":"regulation of uterine smooth muscle relaxation","canonical_id":"go:GO:1900719","description":"\"Any process that modulates the frequency, rate or extent of uterine smooth muscle relaxation.\" [GOC:TermGenie]","metadata":null},{"id":"b1cdaa2a825c4ec9a0f6016cb2121411","type":"GO_TERM","name":"regulation of vacuolar transport","canonical_id":"go:GO:1903335","description":"\"Any process that modulates the frequency, rate or extent of vacuolar transport.\" [GO_REF:0000058, GOC:TermGenie, GOC:vw]","metadata":null},{"id":"dac32875092b420b905cc75708c5e573","type":"GO_TERM","name":"regulation of vacuole fusion, non-autophagic","canonical_id":"go:GO:0032889","description":"\"Any process that modulates the frequency, rate or extent of the fusion of two vacuole membranes to form a single vacuole.\" [GOC:mah]","metadata":null},{"id":"2ebfc3fd197148488d6d1dfb9ad606f8","type":"GO_TERM","name":"regulation of vacuole organization","canonical_id":"go:GO:0044088","description":"\"Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a vacuole.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"7107611d65e0490fb7452a3d951b139d","type":"GO_TERM","name":"regulation of vascular associated smooth muscle cell apoptotic process","canonical_id":"go:GO:1905459","description":"\"Any process that modulates the frequency, rate or extent of vascular associated smooth muscle cell apoptotic process.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:26493107]","metadata":null},{"id":"7e0baf0fd7244082ba81db165d556446","type":"GO_TERM","name":"regulation of vascular associated smooth muscle cell dedifferentiation","canonical_id":"go:GO:1905174","description":"\"Any process that modulates the frequency, rate or extent of vascular smooth muscle cell dedifferentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19088079]","metadata":null},{"id":"0375ed39e6964d36b2525593a03ec03c","type":"GO_TERM","name":"regulation of vascular associated smooth muscle cell differentiation","canonical_id":"go:GO:1905063","description":"\"Any process that modulates the frequency, rate or extent of vascular smooth muscle cell differentiation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:19088079]","metadata":null},{"id":"ccfa92c017eb49298467d859dc75f43e","type":"GO_TERM","name":"regulation of vascular associated smooth muscle cell membrane depolarization","canonical_id":"go:GO:1990736","description":"\"Any process that modulates the establishment or extent of a membrane potential in the depolarizing direction away from the resting potential in a vascular smooth muscle cell.\" [PMID:20826763]","metadata":null},{"id":"fd52acd5ea3c4f6a9b1bb3f5725fa7d3","type":"GO_TERM","name":"regulation of vascular associated smooth muscle cell migration","canonical_id":"go:GO:1904752","description":"\"Any process that modulates the frequency, rate or extent of vascular associated smooth muscle cell migration.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20693317]","metadata":null},{"id":"7d3d7da3ce354ae1b2eabc4071a2fc82","type":"GO_TERM","name":"regulation of vascular associated smooth muscle cell proliferation","canonical_id":"go:GO:1904705","description":"\"Any process that modulates the frequency, rate or extent of vascular smooth muscle cell proliferation.\" [GO_REF:0000058, GOC:TermGenie, PMID:23246467]","metadata":null},{"id":"c4bc83c6145444ab84c508113442924b","type":"GO_TERM","name":"regulation of vascular associated smooth muscle contraction","canonical_id":"go:GO:0003056","description":"\"Any process that increases the frequency, rate or extent of vascular smooth muscle contraction.\" [GOC:mtg_cardio, GOC:mtg_sensu, GOC:rl]","metadata":null},{"id":"bc95e06266c040a9a56bfff47130956c","type":"GO_TERM","name":"regulation of vascular endothelial cell proliferation","canonical_id":"go:GO:1905562","description":"\"Any process that modulates the frequency, rate or extent of vascular endothelial cell proliferation.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:23201774]","metadata":null},{"id":"676b401c0be946ae9b769e0a1db99d34","type":"GO_TERM","name":"regulation of vascular endothelial growth factor production","canonical_id":"go:GO:0010574","description":"\"Any process that modulates the frequency, rate, or extent of production of vascular endothelial growth factor.\" [GOC:rl]","metadata":null},{"id":"0a8fdd22c1984c82b974905aa45870ef","type":"GO_TERM","name":"regulation of vascular endothelial growth factor receptor signaling pathway","canonical_id":"go:GO:0030947","description":"\"Any process that modulates the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.\" [GOC:dgh]","metadata":null},{"id":"0ffd5cdf4e054a6dae95bf160ebb2c0c","type":"GO_TERM","name":"regulation of vascular endothelial growth factor signaling pathway","canonical_id":"go:GO:1900746","description":"\"Any process that modulates the frequency, rate or extent of vascular endothelial growth factor signaling pathway.\" [GOC:TermGenie]","metadata":null},{"id":"320dfdd99e404fa6a16965d17da92106","type":"GO_TERM","name":"regulation of vascular permeability","canonical_id":"go:GO:0043114","description":"\"Any process that modulates the extent to which blood vessels can be pervaded by fluid.\" [GOC:jl]","metadata":null},{"id":"5126042c1e464c4c8ae17dbec5d2ba8a","type":"GO_TERM","name":"regulation of vascular permeability involved in acute inflammatory response","canonical_id":"go:GO:0002528","description":"\"Any process that modulates the extent to which blood vessels can be pervaded by fluid contributing to an acute inflammatory response.\" [GOC:jal]","metadata":null},{"id":"adcc358cbbbb413f86182766d67104b6","type":"GO_TERM","name":"regulation of vascular wound healing","canonical_id":"go:GO:0061043","description":"\"Any process that modulates the rate, frequency, or extent of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature.\" [GOC:dph]","metadata":null},{"id":"8b2607cadf3b4c45a9948eec5bd6e072","type":"GO_TERM","name":"regulation of vasculature development","canonical_id":"go:GO:1901342","description":"\"Any process that modulates the frequency, rate or extent of vasculature development.\" [GOC:TermGenie]","metadata":null},{"id":"cbcc25b486f44da1a00b83910aefb476","type":"GO_TERM","name":"regulation of vasculogenesis","canonical_id":"go:GO:2001212","description":"\"Any process that modulates the frequency, rate or extent of vasculogenesis.\" [GOC:obol]","metadata":null},{"id":"e6bbd7bf5eea440f88b3526cf2776d00","type":"GO_TERM","name":"regulation of vasoconstriction","canonical_id":"go:GO:0019229","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels.\" [GOC:jl]","metadata":null},{"id":"b223ac82ce144169ac289e86d407ce04","type":"GO_TERM","name":"regulation of vasoconstriction by circulating epinephrine","canonical_id":"go:GO:0003120","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels as a result of secretion of epinephrine into the bloodstream.\" [GOC:mtg_cardio]","metadata":null},{"id":"fe997dc797e545db8155f9ca34b3c8dc","type":"GO_TERM","name":"regulation of vasoconstriction by circulating norepinephrine","canonical_id":"go:GO:0003117","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels as a result of secretion of norepinephrine into the bloodstream.\" [GOC:mtg_cardio]","metadata":null},{"id":"1637d0272a024e39bb4dcad1517e9c10","type":"GO_TERM","name":"regulation of vasoconstriction by epinephrine","canonical_id":"go:GO:0003115","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels as a result of secretion of epinephrine into the bloodstream or released by nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"a252ca38fc1347598ead752903084640","type":"GO_TERM","name":"regulation of vasoconstriction by neuronal epinephrine","canonical_id":"go:GO:0003119","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels as a result of epinephrine released by nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"ff9236498745417394fe0dbfe679ea96","type":"GO_TERM","name":"regulation of vasoconstriction by neuronal norepinephrine","canonical_id":"go:GO:0003118","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels as a result of norepinephrine released by nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"0a74746785b24278abc24f9b586b5db8","type":"GO_TERM","name":"regulation of vasoconstriction by norepinephrine","canonical_id":"go:GO:0003116","description":"\"Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels as a result of secretion of norepinephrine into the bloodstream or released by nerve endings.\" [GOC:mtg_cardio]","metadata":null},{"id":"85f5317a3e0d4636b3d167a13d27b70b","type":"GO_TERM","name":"regulation of vegetative meristem growth","canonical_id":"go:GO:0010083","description":"\"Any process involved in maintaining the size and shape of a vegetative meristem.\" [GOC:tb]","metadata":null},{"id":"981765142620406ca3a4e159b449e00f","type":"GO_TERM","name":"regulation of vegetative phase change","canonical_id":"go:GO:0010321","description":"\"Any process that modulates the frequency, rate or extent of vegetative phase change. Vegetative phase change is the set of post-embryonic processes involved in the transition of a plant from a juvenile phase of vegetative development to an adult phase of vegetative development.\" [GOC:tair_curators]","metadata":null},{"id":"bda16e3d353c44329ca12046facb0f08","type":"GO_TERM","name":"regulation of vein smooth muscle contraction","canonical_id":"go:GO:0062086","description":"\"Any process that modulates the frequency, rate or extent of vein smooth muscle contraction.\" [PMID:8428203]","metadata":null},{"id":"e95a437a1fcd447c9b9d767550d97e85","type":"GO_TERM","name":"regulation of venous endothelial cell fate commitment","canonical_id":"go:GO:2000787","description":"\"Any process that modulates the frequency, rate or extent of venous endothelial cell fate commitment.\" [PMID:11585794]","metadata":null},{"id":"5fcd0c45d8d34cb49c1e0411697d9503","type":"GO_TERM","name":"regulation of ventricular cardiac muscle cell action potential","canonical_id":"go:GO:0098911","description":"\"Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a ventricular cardiac muscle cell contributing to the regulation of its contraction. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f8f8057ead0d4f6ebecec242af1afe9b","type":"GO_TERM","name":"regulation of ventricular cardiac muscle cell membrane depolarization","canonical_id":"go:GO:0060373","description":"\"Any process that modulates the establishment or extent of a membrane potential in the depolarizing direction away from the resting potential in a ventricular cardiomyocyte.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"e19aeae5b58a447ba5ee2005a2022355","type":"GO_TERM","name":"regulation of ventricular cardiac muscle cell membrane repolarization","canonical_id":"go:GO:0060307","description":"\"Any process that modulates the establishment or extent of a membrane potential in the polarizing direction towards the resting potential in a ventricular cardiomyocyte.\" [GOC:BHF, GOC:dph, GOC:mtg_cardiac_conduct_nov11, GOC:tb]","metadata":null},{"id":"cc6998f8e63742e89e222a021a7391be","type":"GO_TERM","name":"regulation of vernalization response","canonical_id":"go:GO:0010219","description":"\"Any process that modulates the frequency, rate or extent of the vernalization response, by which induction of flowering is normally caused by extended exposure to cold temperatures.\" [GOC:sm]","metadata":null},{"id":"93f016c6e3114aea8d1574f71cf09135","type":"GO_TERM","name":"regulation of very-low-density lipoprotein particle clearance","canonical_id":"go:GO:0010915","description":"\"Any process that modulates the rate, frequency or extent of very-low-density lipoprotein particle clearance. Very-low-density lipoprotein particle clearance is the process in which a very-low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"5eba94dcf0604f2aa4027f2515e73468","type":"GO_TERM","name":"regulation of very-low-density lipoprotein particle remodeling","canonical_id":"go:GO:0010901","description":"\"Any process that modulates the rate, frequency or extent of very-low-density lipoprotein particle remodeling. Very-low-density lipoprotein particle remodeling is the acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:tb]","metadata":null},{"id":"fe5aa527ef244adcb1c40ca233a9b3af","type":"GO_TERM","name":"regulation of vesicle fusion","canonical_id":"go:GO:0031338","description":"\"Any process that modulates the frequency, rate or extent of vesicle fusion.\" [GOC:mah]","metadata":null},{"id":"59667c7e69c1485bafe659c2ff831375","type":"GO_TERM","name":"regulation of vesicle fusion with Golgi apparatus","canonical_id":"go:GO:0106214","description":"\"Any process that modulates the frequency, rate or extent of vesicle fusion with Golgi apparatus.\" [GOC:se, PMID:26195667]","metadata":null},{"id":"45ba955a835f415ca96c7637319fd59a","type":"GO_TERM","name":"regulation of vesicle size","canonical_id":"go:GO:0097494","description":"\"Any process that modulates the size of a vesicle.\" [GOC:pm, PMID:20007772]","metadata":null},{"id":"4bbf313f884549f9a9c5346933d7270f","type":"GO_TERM","name":"regulation of vesicle transport along microtubule","canonical_id":"go:GO:1901608","description":"\"Any process that modulates the frequency, rate or extent of vesicle transport along microtubule.\" [GOC:TermGenie]","metadata":null},{"id":"6c0016eaee444349b5984670d5dace56","type":"GO_TERM","name":"regulation of vesicle-mediated transport","canonical_id":"go:GO:0060627","description":"\"Any process that modulates the rate, frequency, or extent of vesicle-mediated transport, the directed movement of substances, either within a vesicle or in the vesicle membrane, into, out of or within a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"5948cdfc1195460497e3725f86cd649a","type":"GO_TERM","name":"regulation of violaceol I biosynthetic process","canonical_id":"go:GO:1900713","description":"\"Any process that modulates the frequency, rate or extent of violaceol I biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7c408ac86b4048fdb26fb8cf18b7fedb","type":"GO_TERM","name":"regulation of violaceol II biosynthetic process","canonical_id":"go:GO:1900716","description":"\"Any process that modulates the frequency, rate or extent of violaceol II biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"b5af57b76d7d4a9f8ec140dad4976ba9","type":"GO_TERM","name":"regulation of viral DNA genome packaging via site-specific sequence recognition","canonical_id":"go:GO:1905137","description":"\"Any process that modulates the frequency, rate or extent of viral DNA genome packaging via site-specific sequence recognition.\" [GO_REF:0000058, GOC:TermGenie, PMID:24711378]","metadata":null},{"id":"ebb1e454347e41709d4020e197286729","type":"GO_TERM","name":"regulation of viral budding via host ESCRT complex","canonical_id":"go:GO:1903772","description":"\"Any process that modulates the frequency, rate or extent of viral budding via host ESCRT complex.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24878737]","metadata":null},{"id":"2e7c5620994d46aca9903b26b7a71674","type":"GO_TERM","name":"regulation of viral entry into host cell","canonical_id":"go:GO:0046596","description":"\"Any process that modulates the frequency, rate or extent of the viral entry into the host cell.\" [GOC:jl]","metadata":null},{"id":"642bf35876514652a656ef40a7b07a70","type":"GO_TERM","name":"regulation of viral genome replication","canonical_id":"go:GO:0045069","description":"\"Any process that modulates the frequency, rate or extent of viral genome replication.\" [GOC:ai]","metadata":null},{"id":"183ce19760474be9a3c357b565288d67","type":"GO_TERM","name":"regulation of viral life cycle","canonical_id":"go:GO:1903900","description":"\"Any process that modulates the frequency, rate or extent of viral life cycle.\" [GO_REF:0000058, GOC:TermGenie, PMID:18005716]","metadata":null},{"id":"e94b539a5620423f993e1f3ec8f00c85","type":"GO_TERM","name":"regulation of viral process","canonical_id":"go:GO:0050792","description":"\"Any process that modulates the rate or extent of the viral life cycle, the set of processes by which a virus reproduces and spreads among hosts.\" [GOC:curators, GOC:tb]","metadata":null},{"id":"81c4c12db9b84150b689425cebac588e","type":"GO_TERM","name":"regulation of viral transcription","canonical_id":"go:GO:0046782","description":"\"Any process that modulates the frequency, rate or extent of the transcription of the viral genome.\" [GOC:ai]","metadata":null},{"id":"36ba08a5fdc94dfe8f1074be6e2bce35","type":"GO_TERM","name":"regulation of viral translation","canonical_id":"go:GO:1904971","description":"\"Any process that modulates the frequency, rate or extent of viral translation.\" [GO_REF:0000058, GOC:bhm, GOC:TermGenie, PMID:19666601]","metadata":null},{"id":"d3505e4fb95d4dc3ab8d9268234dc59f","type":"GO_TERM","name":"regulation of vitamin A metabolic process","canonical_id":"go:GO:1901738","description":"\"Any process that modulates the frequency, rate or extent of vitamin A metabolic process.\" [GOC:TermGenie, PMID:18093975]","metadata":null},{"id":"03134a4458064fa696a9587c717089ca","type":"GO_TERM","name":"regulation of vitamin D biosynthetic process","canonical_id":"go:GO:0060556","description":"\"Any process that modulates the rate frequency or extent of a vitamin D biosynthetic process. Vitamin D biosynthesis is the chemical reactions and pathways resulting in the formation of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [CHEBI:27300, GOC:BHF, GOC:mah, ISBN:0471331309]","metadata":null},{"id":"86d109163d244239adb8a660e2e93aca","type":"GO_TERM","name":"regulation of vitamin D receptor signaling pathway","canonical_id":"go:GO:0070562","description":"\"Any process that modulates the frequency, rate or extent of vitamin D receptor signaling pathway activity.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"137be3bc233a4f6395c3be6fdd642129","type":"GO_TERM","name":"regulation of vitamin E biosynthetic process","canonical_id":"go:GO:1904965","description":"\"Any process that modulates the frequency, rate or extent of vitamin E biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:20823244]","metadata":null},{"id":"4ccaf796adcf4ad8aba334bb85644e0f","type":"GO_TERM","name":"regulation of vitamin metabolic process","canonical_id":"go:GO:0030656","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:mah]","metadata":null},{"id":"42ba4a827bad41deac9e28866eb6ec4d","type":"GO_TERM","name":"regulation of vitellogenesis","canonical_id":"go:GO:1903186","description":"\"Any process that modulates the frequency, rate or extent of vitellogenesis.\" [GO_REF:0000058, GOC:mr, GOC:TermGenie, PMID:19467235]","metadata":null},{"id":"9c49e2dd07e24d60ab085d5f5ddfd14b","type":"GO_TERM","name":"regulation of voltage-gated calcium channel activity","canonical_id":"go:GO:1901385","description":"\"Any process that modulates the frequency, rate or extent of voltage-gated calcium channel activity.\" [GOC:BHF, GOC:TermGenie]","metadata":null},{"id":"ce55addc86bc401998910de350883074","type":"GO_TERM","name":"regulation of voltage-gated sodium channel activity","canonical_id":"go:GO:1905150","description":"\"Any process that modulates the frequency, rate or extent of voltage-gated sodium channel activity.\" [GO_REF:0000059, GOC:TermGenie, PMID:24198377]","metadata":null},{"id":"e66798f6b80c46c1948c0f446e9042cf","type":"GO_TERM","name":"regulation of vulval development","canonical_id":"go:GO:0040028","description":"\"Any process that modulates the frequency, rate or extent of development of the vulva. Vulval development is the process whose specific outcome is the progression of the egg-laying organ of female and hermaphrodite nematodes over time, from its formation to the mature structure. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed vulva in the adult.\" [GOC:kmv, GOC:ma]","metadata":null},{"id":"b8cf9df3956a47f6ac55eed9483746e9","type":"GO_TERM","name":"regulation of water channel activity","canonical_id":"go:GO:1902427","description":"\"Any process that modulates the frequency, rate or extent of water channel activity.\" [GOC:nhn, GOC:TermGenie, PMID:22095752]","metadata":null},{"id":"038f95bbf01747b5a8a9ddccc512b19c","type":"GO_TERM","name":"regulation of wax biosynthetic process","canonical_id":"go:GO:1904276","description":"\"Any process that modulates the frequency, rate or extent of wax biosynthetic process.\" [GO_REF:0000058, GOC:TermGenie, PMID:24692420]","metadata":null},{"id":"356a44df345c4732ae4b15e71a4e4362","type":"GO_TERM","name":"regulation of white fat cell proliferation","canonical_id":"go:GO:0070350","description":"\"Any process that modulates the frequency, rate or extent of white fat cell proliferation.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"66aa94e0c5514d20a58c6407d64ebac1","type":"GO_TERM","name":"regulation of wound healing","canonical_id":"go:GO:0061041","description":"\"Any process that modulates the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"66d0cae1a83648fd9f12b282bd88c158","type":"GO_TERM","name":"regulation of wound healing, spreading of epidermal cells","canonical_id":"go:GO:1903689","description":"\"Any process that modulates the frequency, rate or extent of wound healing, spreading of epidermal cells.\" [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:18394891]","metadata":null},{"id":"5f1f569b2a1f460e9b6d3b726c04aea7","type":"GO_TERM","name":"regulation of xanthone-containing compound biosynthetic process","canonical_id":"go:GO:1900183","description":"\"Any process that modulates the frequency, rate or extent of xanthone-containing compound biosynthetic process.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"77e4ab3f40d541f39a655f4d1ff9eaef","type":"GO_TERM","name":"regulation of xanthophore differentiation","canonical_id":"go:GO:0050938","description":"\"Any process that modulates the frequency, rate or extent of xanthophore differentiation.\" [GOC:ai]","metadata":null},{"id":"4d422e0e2d1042f390f07026f8d6ba93","type":"GO_TERM","name":"regulation of xenobiotic detoxification by transmembrane export across the plasma membrane","canonical_id":"go:GO:1905699","description":"\"Any process that modulates the frequency, rate or extent of xenobiotic transmembrane export. A xenobiotic is a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GO_REF:0000058, GOC:krc, GOC:TermGenie, PMID:15198509]","metadata":null},{"id":"f3739c6f5c0a46e78761cef744062004","type":"GO_TERM","name":"regulation of xenophagy","canonical_id":"go:GO:1904415","description":"\"Any process that modulates the frequency, rate or extent of xenophagy.\" [GO_REF:0000058, GOC:pad, GOC:PARL, GOC:TermGenie, PMID:21617041]","metadata":null},{"id":"bfc3320e14a3465e91a450971c73dfce","type":"GO_TERM","name":"regulation of xylan catabolic process","canonical_id":"go:GO:2001000","description":"\"Any process that modulates the frequency, rate or extent of xylan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"8452cab3917a4c7aa06d243679e3e47a","type":"GO_TERM","name":"regulation of xyloglucan catabolic process","canonical_id":"go:GO:2000951","description":"\"Any process that modulates the frequency, rate or extent of xyloglucan catabolic process.\" [GOC:mengo_curators]","metadata":null},{"id":"cfc53fbdcd594288bcfb568cffffc977","type":"GO_TERM","name":"regulation of xylose catabolic process to ethanol","canonical_id":"go:GO:1900515","description":"\"Any process that modulates the frequency, rate or extent of xylose catabolic process to ethanol.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4f4fa4a25e8848b1bb9c53406cf50e67","type":"GO_TERM","name":"regulation of zinc ion transmembrane import","canonical_id":"go:GO:0071581","description":"\"Any process that modulates the frequency, rate or extent of zinc ion import.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"debfedf4cc7c43c1b046e7f24e01559b","type":"GO_TERM","name":"regulation of zinc ion transmembrane transport","canonical_id":"go:GO:0071580","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of zinc ions (Zn2+) from one side of a membrane to the other.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d4e826491a344e468ee055663adbbbde","type":"GO_TERM","name":"regulation of zinc ion transport","canonical_id":"go:GO:0071579","description":"\"Any process that modulates the frequency, rate or extent of the directed movement of zinc ions (Zn2+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d9fc598de07249a98462ddcae7b482e3","type":"GO_TERM","name":"regulation of zoospore formation","canonical_id":"go:GO:0075240","description":"\"Any process that modulates the frequency, rate or extent of zoospore formation, a process in which a diploid cell undergoes meiosis, and the meiotic products acquire specialized features of asexual motile mononucleate flagellated spores called zoospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"3aae460c2a4b4290967d1edace66977c","type":"GO_TERM","name":"regulation of zygosporangium development","canonical_id":"go:GO:0075272","description":"\"Any process that modulates the frequency, rate or extent of zygosporangium development, a process in which a fruiting body called zygosporangium is formed.\" [GOC:pamgo_curators]","metadata":null},{"id":"f924bf3b43df43dba369587d783f4439","type":"GO_TERM","name":"regulation of zygospore formation","canonical_id":"go:GO:0075298","description":"\"Any process that modulates the frequency, rate or extent of zygospore formation, a process in which a thick-walled spore of some algae and fungi is formed by union of two similar sexual cells, usually serves as a resting spore, and produces the sporophytic phase.\" [GOC:pamgo_curators]","metadata":null},{"id":"205a7327a8e14289a44c31e531a1b837","type":"GO_TERM","name":"regulation protein catabolic process at postsynapse","canonical_id":"go:GO:0140252","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein at the postsynapse.\" [PMID:17062563]","metadata":null},{"id":"f5e39e6f6ce84d84b90f2cf1de07efda","type":"GO_TERM","name":"regulation protein catabolic process at presynapse","canonical_id":"go:GO:0140251","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein at the presynapse.\" [PMID:27764673]","metadata":null},{"id":"e16b0d3e03cf44e6b32db3ce253f336f","type":"GO_TERM","name":"regulation protein catabolic process at synapse","canonical_id":"go:GO:0140250","description":"\"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein at the synapse.\" [PMID:23083742]","metadata":null},{"id":"63ad3defd09c45f2abd6d30bc68dfb34","type":"GO_TERM","name":"regulatory RNA binding","canonical_id":"go:GO:0061980","description":"\"Binding to a small regulatory RNA, a short RNA (usually 50-200 nt long) that is either independently transcribed or processed from a longer RNA by an RNAse enzyme.\" [PMID:14622403, PMID:23475961]","metadata":null},{"id":"0efe0441607c4f55b8cfb00fea2abd78","type":"GO_TERM","name":"regulatory T cell apoptotic process","canonical_id":"go:GO:1902482","description":"\"Any apoptotic process in a regulatory T cell.\" [GOC:nhn, GOC:TermGenie, PMID:20471291]","metadata":null},{"id":"823a9f3c425e4ca285f324e8f7eee4c4","type":"GO_TERM","name":"regulatory T cell differentiation","canonical_id":"go:GO:0045066","description":"\"The process in which a relatively unspecialized T cell acquires specialized features of a regulatory T cell. Regulatory T cells control or suppress immune responses through a variety of mechanisms and subsets include the CD4+CD25+ cell type as well as certain CD8+ cell types.\" [ISBN:0781735149]","metadata":null},{"id":"57afb46198414f8ba1a21faeaa41218a","type":"GO_TERM","name":"regulatory ncRNA 3'-end processing","canonical_id":"go:GO:0043628","description":"\"Any process involved in forming the mature 3' end of a regulatory non-coding RNA molecule.\" [GOC:jl]","metadata":null},{"id":"700cc56e28bd43c8bb1ad30da11f12a4","type":"GO_TERM","name":"regulatory ncRNA processing","canonical_id":"go:GO:0070918","description":"\"A process leading to the generation of a functional regulatory non-coding RNA.\" [GOC:mah, PMID:15196465, PMID:19239886]","metadata":null},{"id":"2748df995b1f4115bb9d3a5cc84a69ce","type":"GO_TERM","name":"regulatory ncRNA-mediated gene silencing","canonical_id":"go:GO:0031047","description":"\"A process in which an regulatory non-coding RNA molecule reduces expression of target genes. This can occur pre-transcriptionally by assembly of heterochromatin and prevention of transcription or co- or post-transcriptionally by targeting RNAs for degradation or by interfering with splicing or translation. This process starts once the inhibitory RNA molecule has been transcribed, and includes processing of the RNA such as cleavage, modifications, transport from the nucleus to the cytoplasm, loading onto the RISC complex, and the effect on transcription or translation.\" [PMID:15020054]","metadata":null},{"id":"cf51dbfe1c0849058e9dd537e933a9c4","type":"GO_TERM","name":"regulatory ncRNA-mediated heterochromatin formation","canonical_id":"go:GO:0031048","description":"\"A heterochromatin formation-based gene silencing process mediated by a regulatory non-coding RNA molecule that occur before the beginning of trancription.\" [PMID:19239886, PMID:21420348]","metadata":null},{"id":"955fde7966bc473aa506ccf34a7bac5a","type":"GO_TERM","name":"regulatory ncRNA-mediated post-transcriptional gene silencing","canonical_id":"go:GO:0035194","description":"\"A posttranscriptional gene silencing pathway in which regulatory RNAs elicit silencing of specific target genes, either by mRNA destabilization or inhibition of translation.\" [GOC:ems, PMID:11201747, PMID:11713190, PMID:15020054, PMID:15066275, PMID:18771919, PMID:32885814, PMID:33184244]","metadata":null},{"id":"d87a8289728842cc902878ac379932aa","type":"GO_TERM","name":"regulatory region RNA binding","canonical_id":"go:GO:0001069","description":"\"Binding to a RNA region that regulates a nucleic acid-based process. Such processes include transcription, DNA replication, and DNA repair.\" [GOC:txnOH]","metadata":null},{"id":"1d32dc6ef9104b4cb282a244dd20a201","type":"GO_TERM","name":"rejection of pollen from other species","canonical_id":"go:GO:1990109","description":"\"The recognition and rejection of pollen of one species by cells in the stigma of another species.\" [PMID:21205670]","metadata":null},{"id":"1e8a4bd67c074fa3bda7194843364c01","type":"GO_TERM","name":"rejection of self pollen","canonical_id":"go:GO:0060320","description":"\"The recognition and rejection of self pollen by cells in the stigma, mediated by the sharing and interaction of the single locus incompatibility haplotypes.\" [GOC:dph, GOC:tb, PMID:34848142]","metadata":null},{"id":"fad79ba935d94f9db3216652480a97c2","type":"DISEASE","name":"relapsing-remitting multiple sclerosis","canonical_id":"mondo:0005314","description":null,"metadata":null},{"id":"6d6e73d9fbd74e0298ee53e02c9cd195","type":"DRUG","name":"relatlimab","canonical_id":"gtopdb:9536","description":null,"metadata":null},{"id":"6062bb9e5fb743f795afd3a4a831eb43","type":"DRUG","name":"relatlimab","canonical_id":"chembl:CHEMBL3990044","description":null,"metadata":null},{"id":"4415585f563d4003ac3f1d79dada58f5","type":"COMBINATION_TREATMENT","name":"relatlimab + sacituzumab govitecan","canonical_id":"ctgov_combo:ctgov-combo-2f5468db6a063bd1","description":null,"metadata":null},{"id":"e142ef667c8d49f5a0a88ad31d769a0d","type":"COMBINATION_TREATMENT","name":"relatlimab + sarilumab","canonical_id":"ctgov_combo:ctgov-combo-61197763d7d9590a","description":null,"metadata":null},{"id":"87861f53f69147ba96da3f1ab6e70fdc","type":"GO_TERM","name":"relaxation of cardiac muscle","canonical_id":"go:GO:0055119","description":"\"The process in which the extent of cardiac muscle contraction is reduced.\" [GOC:ecd]","metadata":null},{"id":"cb8031d8675546efa8d5d396a6295ae1","type":"GO_TERM","name":"relaxation of muscle","canonical_id":"go:GO:0090075","description":"\"A process in which the extent of muscle contraction is reduced. Muscle relaxation can involve a number of processes including the removal of calcium from the cytoplasm to the sarcoplasmic reticulum lumen through the action of Ca2+ ATPases. In some muscles, calcium-independent pathways also play a role in muscle relaxation by decreasing the phosphorylation state of myosin light chain.\" [GOC:BHF, GOC:rl, PMID:19996365]","metadata":null},{"id":"3e989c23e87c4fe394882420319a44fc","type":"GO_TERM","name":"relaxation of skeletal muscle","canonical_id":"go:GO:0090076","description":"\"A process in which the extent of skeletal muscle tissue contraction is reduced. Muscle relaxation involves the removal of calcium from the cytoplasm to the sarcoplasmic reticulum lumen through the action of Ca2+ ATPases.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"e8371516a4b14c28ba9bea0c56f863ef","type":"GO_TERM","name":"relaxation of smooth muscle","canonical_id":"go:GO:0044557","description":"\"A process in which the extent of smooth muscle contraction is reduced. Smooth muscle differs from striated muscle in the much higher actin/myosin ratio, the absence of conspicuous sarcomeres and the ability to contract to a much smaller fraction of its resting length.\" [GOC:jl]","metadata":null},{"id":"c4c0297618fe4f729148a7bcfeb8786a","type":"GO_TERM","name":"relaxation of vascular associated smooth muscle","canonical_id":"go:GO:0060087","description":"\"A negative regulation of smooth muscle contraction resulting in relaxation of vascular smooth muscle. The relaxation is mediated by a decrease in the phosphorylation state of myosin light chain. This can be achieved by removal of calcium from the cytoplasm to the sarcoplasmic reticulum lumen through the action of Ca2+ ATPases leading to a decrease myosin light chain kinase activity, and through calcium-independent pathways leading to a increase in myosin light chain phosphatase activity.\" [GO_REF:0000058, GOC:BHF, GOC:BHF_miRNA, GOC:dph, GOC:rph, GOC:TermGenie, PMID:15867178, PMID:19996365, PMID:27389411]","metadata":null},{"id":"b0bac660c809440eba0b7d7c8f7bc492","type":"GO_TERM","name":"release from viral latency","canonical_id":"go:GO:0019046","description":"\"The process by which a virus begins to replicate following a latency replication decision (switch).\" [GOC:dos, GOC:jl]","metadata":null},{"id":"71428ea5c2b44a4bb0f957087e9cfc76","type":"GO_TERM","name":"release of cytochrome c from mitochondria","canonical_id":"go:GO:0001836","description":"\"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.\" [GOC:add, GOC:mah, GOC:mtg_apoptosis, ISBN:0721639976, PMID:12925707, PMID:9560217]","metadata":null},{"id":"bae3505418ed4a69bd4df116bec0fafc","type":"GO_TERM","name":"release of matrix enzymes from mitochondria","canonical_id":"go:GO:0032976","description":"\"The process in which enzymes, such as aspartate aminotransferase, are enabled to move from the mitochondrial matrix into the cytosol, as part of the apoptotic process.\" [GOC:mah, GOC:mtg_apoptosis, PMID:9843949]","metadata":null},{"id":"0e0786446b5249299027c218b4d2bbe9","type":"GO_TERM","name":"release of seed from dormancy","canonical_id":"go:GO:0048838","description":"\"The process in which the dormant state is broken in a seed. Dormancy is characterized by a suspension of physiological activity that can be reactivated upon release.\" [GOC:dph, GOC:jid, GOC:tb, ISBN:9781405139830]","metadata":null},{"id":"77262ee0be6c4771a41f8256171d8875","type":"GO_TERM","name":"release of sequestered calcium ion into cytosol","canonical_id":"go:GO:0051209","description":"\"The process in which calcium ions sequestered in the endoplasmic reticulum, Golgi apparatus or mitochondria are released into the cytosolic compartment.\" [GOC:dph, GOC:hjd, GOC:mtg_lung, PMID:1814929]","metadata":null},{"id":"68a222d7449f4574bdfe3961817e4bde","type":"GO_TERM","name":"release of sequestered calcium ion into cytosol by Golgi","canonical_id":"go:GO:0061454","description":"\"The directed movement of calcium ions (Ca2+) out of the Golgi apparatus into the cytosol.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"6d2a4a3239f942869439eb2fdca3dce4","type":"GO_TERM","name":"release of sequestered calcium ion into cytosol by endoplasmic reticulum","canonical_id":"go:GO:1903514","description":"\"The directed movement of calcium ion from endoplasmic reticulum to cytosol.\" [GO_REF:0000078, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:16402920]","metadata":null},{"id":"dee0f83a21754924a6bc17c4cca21df4","type":"GO_TERM","name":"release of sequestered calcium ion into cytosol by sarcoplasmic reticulum","canonical_id":"go:GO:0014808","description":"\"The process in which the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol occurs via calcium release channels.\" [GOC:mtg_muscle]","metadata":null},{"id":"f971855406ff4074a3656391335b938a","type":"GO_TERM","name":"release of sequestered calcium ion into postsynaptic cytosol","canonical_id":"go:GO:0099586","description":"\"The process in which calcium ions sequestered in the endoplasmic reticulum, Golgi apparatus or mitochondria are released into the postsynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"18a734053c5e4a76bf6d2c0f78872856","type":"GO_TERM","name":"release of sequestered calcium ion into presynaptic cytosol","canonical_id":"go:GO:0099585","description":"\"The process in which calcium ions sequestered in the endoplasmic reticulum, Golgi apparatus or mitochondria are released into the presynaptic cytosol.\" [GOC:dos]","metadata":null},{"id":"01862f1f251d463facd528cbbf7408ad","type":"GO_TERM","name":"removal of RNA primer involved in mitotic DNA replication","canonical_id":"go:GO:1903469","description":"\"Any DNA replication, removal of RNA primer that is involved in mitotic cell cycle DNA replication.\" [GO_REF:0000060, GOC:mtg_cell_cycle, GOC:TermGenie, PMID:1234]","metadata":null},{"id":"44d50c9f1ef4432db9901481df12413f","type":"GO_TERM","name":"removal of nonhomologous ends","canonical_id":"go:GO:0000735","description":"\"The removal of nonhomologous sequences at the broken 3' single-strand DNA end before DNA repair synthesis can occur.\" [PMID:10357855]","metadata":null},{"id":"b5b7084246ec44508ab49de0cc727db6","type":"GO_TERM","name":"removal of superoxide radicals","canonical_id":"go:GO:0019430","description":"\"Any process, acting at the cellular level, involved in removing superoxide radicals (O2-) from a cell or organism, e.g. by conversion to dioxygen (O2) and hydrogen peroxide (H2O2).\" [GOC:jl]","metadata":null},{"id":"614f2b1a71ad4557bb92ed210f136151","type":"GO_TERM","name":"renal D-glucose absorption","canonical_id":"go:GO:0035623","description":"\"A renal system process in which D-glucose is taken up from the collecting ducts and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures.\" [GOC:yaf, PMID:11269503]","metadata":null},{"id":"4833bae31677405985f56cf5b0f63133","type":"GO_TERM","name":"renal absorption","canonical_id":"go:GO:0070293","description":"\"A renal system process in which water, ions, glucose and proteins are taken up from the collecting ducts, glomerulus and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures (e.g. protein absorption is observed in nephrocytes in Drosophila, see PMID:23264686).\" [GOC:dph, GOC:mah, GOC:yaf]","metadata":null},{"id":"3797013bcc8148eba214ea1269a61b4c","type":"DISEASE","name":"renal agenesis","canonical_id":"mondo:0018470","description":null,"metadata":null},{"id":"a56ac613859b411a8eab38e2b131f5fe","type":"GO_TERM","name":"renal albumin absorption","canonical_id":"go:GO:0097018","description":"\"A renal system process in which albumin is taken up from the collecting ducts, glomerulus and proximal and distal loops of the nephron.\" [GOC:yaf, PMID:18431508]","metadata":null},{"id":"c41faeca45bc46c28fb3bf788d5aca9c","type":"GO_TERM","name":"renal amino acid absorption","canonical_id":"go:GO:1990297","description":"\"A renal system process in which amino acids are taken up from the collecting ducts, glomerulus and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures.\" [GOC:hjd, PMID:1526373]","metadata":null},{"id":"560ea9d12ffb4a85928a7810083d03ef","type":"GO_TERM","name":"renal artery morphogenesis","canonical_id":"go:GO:0061441","description":"\"The process in which the anatomical structure of a renal artery is generated and organized. Renal arteries supply the kidneys with blood.\" [GOC:mtg_kidney_jan10, PMID:11891195]","metadata":null},{"id":"e5973d31a14144fd9c1112e591527bb1","type":"GO_TERM","name":"renal capsule development","canonical_id":"go:GO:0072127","description":"\"The process whose specific outcome is the progression of the renal capsule over time, from its formation to the mature structure. The renal capsule is the tough fibrous layer surrounding the kidney, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage. During development, it comprises a single layer of flattened cells that lie just above the cortical stroma and the condensed mesenchyme of the nephrogenic zone. It is in this region that the early stages of nephron induction and formation of new generations ureteric bud branches occur, as the kidney expands.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"346eee9debb94a13a9669430bcbd1944","type":"GO_TERM","name":"renal capsule formation","canonical_id":"go:GO:0072129","description":"\"The developmental process pertaining to the initial formation of a renal capsule from unspecified parts. The renal capsule is the tough fibrous layer surrounding the kidney, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage. During development, it comprises a single layer of flattened cells that lie just above the cortical stroma and the condensed mesenchyme of the nephrogenic zone. It is in this region that the early stages of nephron induction and formation of new generations ureteric bud branches occur, as the kidney expands.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5045bbf0cb74480daf898485d50601e3","type":"GO_TERM","name":"renal capsule morphogenesis","canonical_id":"go:GO:0072128","description":"\"The process in which the anatomical structures of the renal capsule are generated and organized. The renal capsule is the tough fibrous layer surrounding the kidney, covered in a thick layer of perinephric adipose tissue. It provides some protection from trauma and damage. During development, it comprises a single layer of flattened cells that lie just above the cortical stroma and the condensed mesenchyme of the nephrogenic zone. It is in this region that the early stages of nephron induction and formation of new generations ureteric bud branches occur, as the kidney expands.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3a6fbf48f9e3407ea90656add666b36f","type":"GO_TERM","name":"renal capsule specification","canonical_id":"go:GO:0072130","description":"\"The regionalization process in which the identity of the renal capsule is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"c1a09d49d5cf4c34bfee92570834d71c","type":"DISEASE","name":"renal carcinoma","canonical_id":"mondo:0005206","description":null,"metadata":null},{"id":"6e257407b89242bb80609c545c7efa83","type":"DISEASE","name":"renal cell carcinoma","canonical_id":"mondo:0005086","description":null,"metadata":null},{"id":"7bd4fb63556f40ae950f07a49026eed2","type":"GO_TERM","name":"renal cortex development","canonical_id":"go:GO:0072055","description":"\"The process whose specific outcome is the progression of the renal cortex over time, from its formation to the mature structure. The renal cortex is the outer region of the kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b0367aefce9f48d58c29f1a18b841014","type":"GO_TERM","name":"renal filtration","canonical_id":"go:GO:0097205","description":"\"A renal system process in which fluid circulating through the body is filtered through a barrier system.\" [GOC:pr, GOC:sart]","metadata":null},{"id":"a74e5f428bb9410fae59c8dc9b324331","type":"GO_TERM","name":"renal filtration cell differentiation","canonical_id":"go:GO:0061318","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a renal filtration cell. Renal filtration cells are specialized cells of the renal system that filter fluids by charge, size or both. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"6fa3f7e8427b4bb8b167e6aad68f68e5","type":"DISEASE","name":"renal glycosuria","canonical_id":"efo:1001151","description":null,"metadata":null},{"id":"dcb935cf30114b398df0d4bbecc402d6","type":"DISEASE","name":"renal hypodysplasia/aplasia 1","canonical_id":"mondo:0024519","description":null,"metadata":null},{"id":"3ccf25aca0174a13a4b35e2c511a982a","type":"GO_TERM","name":"renal inner medulla development","canonical_id":"go:GO:0072053","description":"\"The process whose specific outcome is the progression of the renal inner medulla over time, from its formation to the mature structure. The renal inner medulla is unique to mammalian kidneys and is the innermost region of the mammalian kidney.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"9018a22f4e014daf8b40d543926c475c","type":"GO_TERM","name":"renal interstitial fibroblast development","canonical_id":"go:GO:0072141","description":"\"The process whose specific outcome is the progression of a renal interstitial fibroblast over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"cf1bb6fbe0454303bc843c14280cc78e","type":"GO_TERM","name":"renal interstitial fibroblast fate commitment","canonical_id":"go:GO:0072153","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a renal fibroblast.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3cd637e4cbaa4dde89c6a4ac527e7d00","type":"GO_TERM","name":"renal outer medulla development","canonical_id":"go:GO:0072054","description":"\"The process whose specific outcome is the progression of the renal outer medulla over time, from its formation to the mature structure. The renal outer medulla is the region of the kidney that lies between the renal cortex and the renal inner medulla.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"36b83ccab99b4c73afea51b3c3341d5b","type":"GO_TERM","name":"renal phosphate excretion","canonical_id":"go:GO:0044722","description":"\"The elimination of phosphate ions from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine.\" [GOC:jl, PMID:25287933]","metadata":null},{"id":"0334ef38777a47069a7c9493f7828f67","type":"GO_TERM","name":"renal phosphate ion absorption","canonical_id":"go:GO:0097291","description":"\"A renal system process in which phosphate ions are taken up from the collecting ducts and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures.\" [GOC:lb, PMID:18784102, PMID:22506049]","metadata":null},{"id":"807d9c80a65d4563a10d5f909fc70174","type":"GO_TERM","name":"renal potassium excretion","canonical_id":"go:GO:0036359","description":"\"The elimination of potassium ions from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine.\" [GOC:gap, PMID:15034090, PMID:25287933]","metadata":null},{"id":"2f869c176f9f4d80986184d2e4a82537","type":"GO_TERM","name":"renal protein absorption","canonical_id":"go:GO:0097017","description":"\"A renal system process in which proteins are taken up from the collecting ducts, glomerulus and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures (e.g. protein absorption is observed in nephrocytes in Drosophila, see PMID:23264686).\" [GOC:yaf, PMID:18431508]","metadata":null},{"id":"c4433500cc4d4ba0acc893d47883ce04","type":"GO_TERM","name":"renal response to blood flow involved in circulatory renin-angiotensin regulation of systemic arterial blood pressure","canonical_id":"go:GO:0001999","description":"\"The physiological response of the kidneys to a decrease in blood flow.\" [GOC:dph]","metadata":null},{"id":"555903871d5b4673bb763f9087aa4d92","type":"GO_TERM","name":"renal sodium excretion","canonical_id":"go:GO:0035812","description":"\"The elimination of sodium ions from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine.\" [GOC:mtg_25march11, GOC:yaf, PMID:25287933]","metadata":null},{"id":"ea791d1dc929426a91314925e8bca1df","type":"GO_TERM","name":"renal sodium ion absorption","canonical_id":"go:GO:0070294","description":"\"A renal system process in which sodium ions are taken up from the collecting ducts and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"9aea23892e0740a2a00fad677ac9bd90","type":"GO_TERM","name":"renal sodium ion transport","canonical_id":"go:GO:0003096","description":"\"The directed movement of sodium ions (Na+) by the renal system.\" [GOC:mtg_cardio]","metadata":null},{"id":"421869c4afbf49d69f73830c625df1d4","type":"GO_TERM","name":"renal system development","canonical_id":"go:GO:0072001","description":"\"The process whose specific outcome is the progression of the renal system over time, from its formation to the mature structure. The renal system maintains fluid balance and contributes to electrolyte balance, acid/base balance, and disposal of nitrogenous waste products. In humans, the renal system comprises a pair of kidneys, a pair of ureters, urinary bladder, urethra, sphincter muscle and associated blood vessels.\" [GOC:mtg_kidney_jan10, GOC:yaf, PMID:6996269]","metadata":null},{"id":"6faa753cddea42759cefcd49bccd55fe","type":"GO_TERM","name":"renal system pattern specification","canonical_id":"go:GO:0072048","description":"\"Any developmental process that results in the creation of defined areas or spaces within an organism to which cells respond and eventually are instructed to differentiate into the anatomical structures of the renal system.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6e8bdfc35e2449dea0563b6c9e702de9","type":"GO_TERM","name":"renal system process","canonical_id":"go:GO:0003014","description":"\"An organ system process carried out by any of the organs or tissues of the renal system. The renal system maintains fluid balance, and contributes to electrolyte balance, acid/base balance, and disposal of nitrogenous waste products. In humans, the renal system comprises a pair of kidneys, a pair of ureters, urinary bladder, urethra, sphincter muscle and associated blood vessels; in other species, the renal system may comprise related structures (e.g., nephrocytes and malpighian tubules in Drosophila).\" [GOC:cjm, GOC:mtg_cardio, GOC:mtg_kidney_jan10]","metadata":null},{"id":"c8fac5a32af74783a27c383228443d8e","type":"GO_TERM","name":"renal system process involved in regulation of systemic arterial blood pressure","canonical_id":"go:GO:0003071","description":"\"Renal process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"06ab681415594f6bbfa683ff31252552","type":"GO_TERM","name":"renal system segmentation","canonical_id":"go:GO:0061150","description":"\"The regionalization process that divides an the renal system into a series of segments along its proximal/distal axis.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"87e56d3759974adfab598614ebeee751","type":"GO_TERM","name":"renal system vasculature development","canonical_id":"go:GO:0061437","description":"\"The process whose specific outcome is the progression of vasculature of the renal system over time, from its formation to the mature structure.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:11891195]","metadata":null},{"id":"42ed90a7865048fd8979cd7d3ae5274e","type":"GO_TERM","name":"renal system vasculature morphogenesis","canonical_id":"go:GO:0061438","description":"\"The process in which the renal system vasculature is generated and organized. Morphogenesis pertains to the creation of form.\" [GOC:dph, GOC:mtg_kidney_jan10, PMID:11891195]","metadata":null},{"id":"1d67a01186cb4942ba498ed66400b349","type":"DISEASE","name":"renal tubular dysgenesis","canonical_id":"mondo:0017609","description":null,"metadata":null},{"id":"983a02fc54054deaaac1ef6c05eab571","type":"DISEASE","name":"renal tubular dysgenesis of genetic origin","canonical_id":"mondo:0009970","description":null,"metadata":null},{"id":"8a96fda1620c47f8b6ca16f64de54c5c","type":"GO_TERM","name":"renal tubular secretion","canonical_id":"go:GO:0097254","description":"\"The elimination of substances from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine. Substances that are secreted include organic anions, ammonia, potassium and drugs.\" [GOC:rph, PMID:25287933, Wikipedia:Renal_secretion#Secretion]","metadata":null},{"id":"31dee2835f2c40609c1981b8d144113d","type":"GO_TERM","name":"renal tubule development","canonical_id":"go:GO:0061326","description":"\"The progression of the renal tubule over time from its formation to the mature form. A renal tubule is a tube that filters, re-absorbs and secretes substances to rid an organism of waste and to play a role in fluid homeostasis.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"ec806ce1ef7e46ef87076ee5fd49d477","type":"GO_TERM","name":"renal tubule morphogenesis","canonical_id":"go:GO:0061333","description":"\"The process in which the renal tubule is generated by specification of cell fate, through the maintenance of cell polarity, regulated cell proliferation and morphogenetic cell rearrangements, shape changes and growth. A renal tubule is a tube that filters, re-absorbs and secretes substances to rid an organism of waste and to play a role in fluid homeostasis.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"a7ceb3a4d5a442f29af8656042548bae","type":"GO_TERM","name":"renal urate salt excretion","canonical_id":"go:GO:0097744","description":"\"The elimination of urate salt or uric acid from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine.\" [GOC:jl, PMID:25287933, PMID:3906799, Wikipedia:Renal_physiology#Secretion]","metadata":null},{"id":"ceddbf8fee084e06a8c5de3f215e790d","type":"GO_TERM","name":"renal vesicle development","canonical_id":"go:GO:0072087","description":"\"The process whose specific outcome is the progression of the renal vesicle over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure. The renal vesicle is the primordial structure of the nephron epithelium, and is formed by the condensation of mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"46a6e24d03534664bb0630fdb834b291","type":"GO_TERM","name":"renal vesicle formation","canonical_id":"go:GO:0072033","description":"\"The developmental process pertaining to the initial formation of the renal vesicle from condensed mesenchymal cells. The renal vesicle is the primordial structure of the nephron epithelium, and is formed by the condensation of mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"45f1869a3491411382e8a7b97541ce49","type":"GO_TERM","name":"renal vesicle induction","canonical_id":"go:GO:0072034","description":"\"Signaling at short range between cells of the ureteric bud terminus and the kidney mesenchyme that positively regulates the formation of the renal vesicle.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"adfaa31988c24023b383be3ba0b1e77d","type":"GO_TERM","name":"renal vesicle morphogenesis","canonical_id":"go:GO:0072077","description":"\"The process in which the anatomical structures of the renal vesicle are generated and organized. The renal vesicle is the primordial structure of the nephron epithelium, and is formed by the condensation of mesenchymal cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bc71607fad7c4f94b492a4f142ebe317","type":"GO_TERM","name":"renal vesicle progenitor cell differentiation","canonical_id":"go:GO:0072184","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the renal vesicle progenitor cells of the kidney as it progresses from its formation to the mature state. A renal vesicle progenitor cell is a cell that will give rise to terminally differentiated cells of the renal vesicle without self-renewing.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1f91fe0b6eae4849aedce91d40fb9e2b","type":"GO_TERM","name":"renal water absorption","canonical_id":"go:GO:0070295","description":"\"A renal system process in which water is taken up from the collecting ducts and proximal and distal loops of the nephron. In non-mammalian species, absorption may occur in related structures.\" [GOC:dph, GOC:mah]","metadata":null},{"id":"dd7477ca9c2e4e92b1035d1532acb9b1","type":"GO_TERM","name":"renal water homeostasis","canonical_id":"go:GO:0003091","description":"\"Renal process involved in the maintenance of an internal steady state of water in the body.\" [GOC:mtg_cardio]","metadata":null},{"id":"8fb9c257e1c24cc0bb6291e4e1d7526f","type":"GO_TERM","name":"renal water retention","canonical_id":"go:GO:0003092","description":"\"The process in which renal water excretion is decreased.\" [GOC:mtg_cardio]","metadata":null},{"id":"5667df6979c0498a8505077bee1c00a6","type":"GO_TERM","name":"renal water transport","canonical_id":"go:GO:0003097","description":"\"The directed movement of water (H2O) by the renal system.\" [GOC:mtg_cardio]","metadata":null},{"id":"c3cc6dda6f2245099b03f9b1cfa078ac","type":"GO_TERM","name":"renal zinc excretion","canonical_id":"go:GO:0180002","description":"\"The elimination of zinc ions from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine.\" [PMID:28196538]","metadata":null},{"id":"592b2aa0e249458ca7a2ac69080a99c9","type":"GO_TERM","name":"renin secretion into blood stream","canonical_id":"go:GO:0002001","description":"\"The regulated release of renin into the blood stream by juxtoglomerular cells.\" [ISBN:0721643949]","metadata":null},{"id":"c8bae3c3a9e243d19214af10e603b450","type":"GO_TERM","name":"renin-angiotensin regulation of aldosterone production","canonical_id":"go:GO:0002018","description":"\"The process in which an increase in active angiotensin stimulates the adrenal cortices to secrete aldosterone.\" [ISBN:0721643949]","metadata":null},{"id":"492878287a68431aaa1fa64f828cdd70","type":"GO_TERM","name":"reorganization of cellular membranes to establish viral sites of replication","canonical_id":"go:GO:0140754","description":"\"A process in intracellular membranes are reorganized by viral proteins that perturb membrane integrity and can cause an extensive rearrangement of cellular membranes, forming membranous webs, which are thought to be the site of replication or certain viruses, for example the HPV virus.\" [PMID:19376974]","metadata":null},{"id":"122362f7e6a846e284dd8f76de834c91","type":"GO_TERM","name":"reorganization of host cellular membranes to establish sites of replication","canonical_id":"go:GO:0140755","description":"\"A process in which a virus triggers host intracellular membranes to be reorganized, forming membranous webs, which are thought to be the site of replication or certain viruses, for example the HPV virus.\" [PMID:34699787, PMID:4372566]","metadata":null},{"id":"666ab089b2384fb2baa82fba0f9a9add","type":"DRUG","name":"repaglinide","canonical_id":"gtopdb:6841","description":null,"metadata":null},{"id":"9c9e596c1c7a473eb6a8d362acf07d86","type":"DRUG","name":"repaglinide","canonical_id":"mesh:C072379","description":null,"metadata":null},{"id":"feb8b6f679f54bf0a3fcf73452285b81","type":"DRUG","name":"repaglinide","canonical_id":"chembl:CHEMBL1272","description":null,"metadata":null},{"id":"bd6120aaf6264ca7a8afafe90af547f0","type":"COMBINATION_TREATMENT","name":"repaglinide + tazemetostat","canonical_id":"ctgov_combo:ctgov-combo-215ef408c7ed9105","description":null,"metadata":null},{"id":"b7e8d467b5d34c5d9cf560d6a4038cde","type":"GO_TERM","name":"repair of kinetochore microtubule attachment defect","canonical_id":"go:GO:0140274","description":"\"The cell cycle process where kinetochore microtubule attachment defects are corrected.\" [PMID:15525536]","metadata":null},{"id":"14b62f3894be4ebc9b20906da80b0c8a","type":"GO_TERM","name":"repair of mitotic kinetochore microtubule attachment defect","canonical_id":"go:GO:0140273","description":"\"The mitotic cell cycle process where kinetochore microtubule attachment defects are corrected.\" [PMID:15525536]","metadata":null},{"id":"80c9962d3b03401f93c7bc48fd7b01ff","type":"GO_TERM","name":"replacement bone morphogenesis","canonical_id":"go:GO:0061971","description":"\"The process in which bones are generated and organized as a result of the conversion of another structural tissue into bone.\" [PMID:29852585]","metadata":null},{"id":"2a8913d5840c4c3caaba5ceac809684b","type":"GO_TERM","name":"replacement ossification","canonical_id":"go:GO:0036075","description":"\"Ossification that requires the replacement of a preexisting tissue prior to bone tissue formation.\" [GO_REF:0000034]","metadata":null},{"id":"805378296110430480394edf1fac69f8","type":"GO_TERM","name":"replication compartment","canonical_id":"go:GO:0046809","description":"\"Globular nuclear domains where the transcription and replication of the viral genome occurs. More than one site can be present simultaneously.\" [PMID:9499108, VZ:1951]","metadata":null},{"id":"c327c178856146af9f65849aee201287","type":"GO_TERM","name":"replication fork","canonical_id":"go:GO:0005657","description":"\"The Y-shaped region of a replicating DNA molecule, resulting from the separation of the DNA strands and in which the synthesis of new strands takes place. Also includes associated protein complexes.\" [GOC:mah, ISBN:0198547684]","metadata":null},{"id":"6d0f3e3b2f6242a899fd856726060592","type":"GO_TERM","name":"replication fork arrest","canonical_id":"go:GO:0043111","description":"\"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA replication by impeding the progress of the DNA replication fork. Replication fork arrest is one of the 'quality control' processes ensuring that DNA-dependent DNA replication occurs correctly. DNA replication fork arrest during DNA-dependent DNA replication is not known to occur outside of cases where a replication error needs to be prevented or corrected.\" [GOC:jl, GOC:pr, PMID:14645529]","metadata":null},{"id":"8d65b4d19fb648c7860ccad38f6a36c1","type":"GO_TERM","name":"replication fork arrest at mating type locus","canonical_id":"go:GO:0011000","description":"\"A process that impedes the progress of the DNA replication fork at natural replication fork pausing sites within the mating type locus.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"9139f8c45bfe45588f8eb95238b3698b","type":"GO_TERM","name":"replication fork arrest at rDNA repeats","canonical_id":"go:GO:0031582","description":"\"A process that impedes the progress of the DNA replication fork at natural replication fork pausing sites within the eukaryotic rDNA repeat spacer.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"e7e022243f974c71b98bdabdc41c4d2d","type":"GO_TERM","name":"replication fork arrest at tRNA locus","canonical_id":"go:GO:0090001","description":"\"A process that impedes the progress of the DNA replication fork at natural replication fork pausing sites within the eukaryotic tRNA transcription unit.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"7219b6a1ccb0447f947731d505a99094","type":"GO_TERM","name":"replication fork arrest involved in DNA replication termination","canonical_id":"go:GO:0071807","description":"\"A replication fork arrest process that contributes to the termination of DNA replication.\" [GOC:mah, PMID:17347517, PMID:20797631]","metadata":null},{"id":"6f79befa8998471e9b1cf4b8398033f3","type":"GO_TERM","name":"replication fork barrier binding","canonical_id":"go:GO:0031634","description":"\"Binding to replication fork barriers, sites that inhibit the progress of replication forks.\" [GOC:mah]","metadata":null},{"id":"1a221adb04f5492285709780af67839c","type":"GO_TERM","name":"replication fork processing","canonical_id":"go:GO:0031297","description":"\"The process in which a DNA replication fork that has stalled is restored to a functional state and replication is restarted. The stalling may be due to DNA damage, DNA secondary structure, bound proteins, dNTP shortage, or other causes.\" [GOC:vw, PMID:11459955, PMID:15367656, PMID:17660542]","metadata":null},{"id":"4d9decb2cb544f06adad138148518592","type":"GO_TERM","name":"replication fork progression beyond termination site","canonical_id":"go:GO:0097046","description":"\"Regulation of DNA replication by a mechanism that allows a DNA replication fork to progress beyond a termination site, which is a region containing fork pausing elements that influence the progression and merging of DNA replication forks.\" [GOC:bf, GOC:mcc, GOC:pr, PMID:20797631]","metadata":null},{"id":"1499d3ac3eda48ac8ea7bca2163b21d1","type":"GO_TERM","name":"replication fork protection complex","canonical_id":"go:GO:0031298","description":"\"A heterotrimeric replication-pausing complex conserved in eukaryotes and associated with the replication fork; the complex stabilizes stalled replication forks and is thought to be involved in coordinating leading- and lagging-strand synthesis and in replication checkpoint signaling. Required for maximal fork speed both in vivo and in vitro.\" [PMID:12944972, PMID:15367656, PMID:19819872]","metadata":null},{"id":"81f3d199113f485c8edec2b9156917d0","type":"GO_TERM","name":"replication fork reversal","canonical_id":"go:GO:0071932","description":"\"Replication fork processing that involves the unwinding of blocked forks to form four-stranded structures resembling Holliday junctions, which are subsequently resolved.\" [PMID:19406929]","metadata":null},{"id":"5f96b6671fe341fd91961b6ef98ba59d","type":"GO_TERM","name":"replication inhibiting complex","canonical_id":"go:GO:1990078","description":"\"A protein complex that inhibits multiple events of replication initiation during one replication cycle.\" [GOC:bhm, PMID:21708944]","metadata":null},{"id":"304de6cfdf3543b6b5388dc3ac1c3487","type":"GO_TERM","name":"replication of extrachromosomal circular DNA","canonical_id":"go:GO:0001326","description":"\"Replication of circular DNA following excision from the chromosome; replication of extrachromosomal circular DNA generally occurs independently of chromosomal replication.\" [GOC:jh, PMID:33867825]","metadata":null},{"id":"e1d7b3cb669d4467b01b9cd8f8bf5120","type":"GO_TERM","name":"replication-born double-strand break repair via sister chromatid exchange","canonical_id":"go:GO:1990414","description":"\"The repair of a replication-born double-strand DNA break in which the DNA molecule is repaired using the homologous sequence of the sister chromatid which serves as a template to repair the breaks.\" [GOC:rb, PMID:12820977, PMID:16888651]","metadata":null},{"id":"6f98fd55e8d646988d1e380037c0f28c","type":"GO_TERM","name":"replicative DNA transposition","canonical_id":"go:GO:0098039","description":"\"Process of transposition in which the existing element is replicated and one of the copies is excised and integrated at a new target site. Also referred to as copy-and-paste transposition.\" [GOC:bm, PMID:10540284, PMID:1660177]","metadata":null},{"id":"2e266a6d00764a289e1636b5a5ad6742","type":"GO_TERM","name":"replicative senescence","canonical_id":"go:GO:0090399","description":"\"The process by which normal somatic cells reach an irreversible stage of cell cycle arrest following multiple rounds of replication; this end stage is associated with marked changes in gene expression and function. This is a natural barrier to unlimited proliferation of somatic cells, and is believed to be contolled by telomere shortening.\" [PMID:17014937, PMID:23061726]","metadata":null},{"id":"c9f14a1293c849a2b45e6c9b4dc3097b","type":"GO_TERM","name":"replisome","canonical_id":"go:GO:0030894","description":"\"A multi-component enzymatic machine at the replication fork which mediates DNA replication. Includes DNA primase, one or more DNA polymerases, DNA helicases, and other proteins.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"d11ae7b3503f4f94b2d6b877a898a7bb","type":"GO_TERM","name":"repressor ecdysone receptor complex","canonical_id":"go:GO:0008231","description":"\"A protein complex consisting of a heterodimer of Ecdysone receptor (EcR) and ultraspiracle (usp) plus an associated corepressor such as SMRTER, which represses transcription of target genes.\" [PMID:10488333]","metadata":null},{"id":"8523bc829d6d409f8cb0b892cee2c916","type":"GO_TERM","name":"repressor of RNA polymerase inhibitor activity","canonical_id":"go:GO:0140871","description":"\"Binds to and stops, prevents or reduces the activity of an RNA polymerase inhibitor.\" [PMID:28475895, PMID:31048766]","metadata":null},{"id":"bc4d7a16654742fe97357958013f491c","type":"GO_TERM","name":"reproductive behavior","canonical_id":"go:GO:0019098","description":"\"The specific behavior of an organism that is associated with reproduction.\" [GOC:jl, GOC:pr]","metadata":null},{"id":"287698e720124b44afd09d6801c493a1","type":"GO_TERM","name":"reproductive blastospore formation","canonical_id":"go:GO:0034299","description":"\"The formation of a spore following the marked enlargement of part of a cell before separation by a septum. Blastospores are a type of asexual spore found in some fungi, most notably the class Glomeromycota.\" [GOC:mah, PMID:30910084]","metadata":null},{"id":"171209466cc040ddaa3862960824f954","type":"GO_TERM","name":"reproductive fruiting body development","canonical_id":"go:GO:0030582","description":"\"The process whose specific outcome is the progression of a reproductive fruiting body over time, from its formation to the mature structure. A reproductive fruiting body is a multicellular reproductive structure that contains spores.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"a36a6325193d4850b45ce5c81a796ae1","type":"GO_TERM","name":"reproductive process","canonical_id":"go:GO:0022414","description":"\"A biological process that directly contributes to the process of producing new individuals by one or two organisms. The new individuals inherit some proportion of their genetic material from the parent or parents.\" [GOC:dph, GOC:isa_complete]","metadata":null},{"id":"10810eb271eb402ba90535a09b04b7df","type":"GO_TERM","name":"reproductive process in single-celled organism","canonical_id":"go:GO:0022413","description":"\"A process, occurring at the cellular level, that is involved in the reproductive function of a single-celled organism.\" [GOC:isa_complete]","metadata":null},{"id":"b0bab8ce2b7544f98544195b9d2e20f5","type":"GO_TERM","name":"reproductive senescence","canonical_id":"go:GO:1990636","description":"\"A life cycle stage during which the reproductive capacity and fitness of an organism declines.\" [PMID:24914937, PMID:25523082, PMID:27353257]","metadata":null},{"id":"a4de01ef3b5c40fab5095c09dc764c87","type":"GO_TERM","name":"reproductive shoot system development","canonical_id":"go:GO:0090567","description":"\"The process whose specific outcome is the progression of a reproductive shoot system over time, from its formation to the mature structure.\" [GOC:pj]","metadata":null},{"id":"1a053f1645374b06b2e30cdb2cca1321","type":"GO_TERM","name":"reproductive structure development","canonical_id":"go:GO:0048608","description":"\"The reproductive developmental process whose specific outcome is the progression of somatic structures that will be used in the process of creating new individuals from one or more parents, from their formation to the mature structures.\" [GOC:dph, GOC:isa_complete, GOC:jid]","metadata":null},{"id":"0083e9d868e64978bd3104deaf8e9203","type":"GO_TERM","name":"reproductive system development","canonical_id":"go:GO:0061458","description":"\"The progression of the reproductive system over time from its formation to the mature structure. The reproductive system consists of the organs that function in reproduction.\" [GOC:dph]","metadata":null},{"id":"4ba06af7b9274881819f6573613e7c78","type":"DRUG","name":"reproterol","canonical_id":"mesh:C014792","description":null,"metadata":null},{"id":"79418f773c9d4f33acb6b83966da618c","type":"GO_TERM","name":"rescue of stalled cytosolic ribosome","canonical_id":"go:GO:0072344","description":"\"A process of cytosolic translational elongation that takes place when a cytosolic ribosome has stalled during translation, and results in freeing the ribosome from the stalled translation complex.\" [GOC:jh2, GOC:mah, PMID:18557701, PMID:19170872, PMID:20117091, PMID:20185543]","metadata":null},{"id":"2378f90656584b91918b8a1766e2f83d","type":"GO_TERM","name":"rescue of stalled mitochondrial ribosome","canonical_id":"go:GO:7770016","description":"\"A process of mitochondrial translational elongation that takes place when a mitochondrial ribosome has stalled during translation, and results in freeing the ribosome from the stalled translation complex.\" [PMID:33243891]","metadata":null},{"id":"8a8122ad18b040a19bccffdab73cfcb9","type":"DRUG","name":"reserpine","canonical_id":"gtopdb:4823","description":null,"metadata":null},{"id":"afbc0f24bc2d475a9221d6cbb4c36e13","type":"DRUG","name":"reserpine","canonical_id":"mesh:D012110","description":null,"metadata":null},{"id":"bb37a2877b0640b7874c2a15cae33777","type":"DRUG","name":"reserpine","canonical_id":"chembl:CHEMBL772","description":null,"metadata":null},{"id":"c62b0f93099a4c30ab625509bfaee53a","type":"GO_TERM","name":"reservosome","canonical_id":"go:GO:0106123","description":"\"A large membrane-bound endocytic organelle present only in members of the Schizotrypanum subgenus of the Trypanosoma genus and is defined as the site of storage of endocytosed macromolecules and lysosomal enzymes. It is found at the posterior end of epimastigote forms of Trypanosoma cruzi, but absent in amastigotes and trypomastigotes.\" [GOC:ach, PMID:12204365, PMID:15521631, PMID:1845219, PMID:19288526, PMID:21818313, PMID:22425988]","metadata":null},{"id":"b3a77e50a1a6430bbd85994f59a2cf0b","type":"GO_TERM","name":"reservosome lumen","canonical_id":"go:GO:0106124","description":"\"The volume enclosed by the membranes of a reservosome.\" [GOC:ach, PMID:12204365, PMID:15521631, PMID:18452191, PMID:19288526, PMID:21818313, PMID:22425988]","metadata":null},{"id":"fcdfa49e280c424eb0ec98adbc084360","type":"GO_TERM","name":"reservosome matrix","canonical_id":"go:GO:0106125","description":"\"A matrix composed of planar membranes, vesicles and lipid inclusions within the reservosome.\" [GOC:ach, PMID:12204365, PMID:15521631, PMID:18452191, PMID:19288526, PMID:21818313, PMID:22425988]","metadata":null},{"id":"b214b78c008a41c7a4016e04ed7e9c95","type":"GO_TERM","name":"reservosome membrane","canonical_id":"go:GO:0106126","description":"\"The lipid bilayer surrounding a reservosome.\" [GOC:ach, PMID:12204365, PMID:15521631, PMID:18452191, PMID:19288526, PMID:21818313, PMID:22425988]","metadata":null},{"id":"4cc600271bc047d68f6763d3c0b0976b","type":"DISEASE","name":"resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta","canonical_id":"mondo:0700478","description":null,"metadata":null},{"id":"5ff7171a66d64a2e8a5314320065776c","type":"DRUG","name":"reslizumab","canonical_id":"gtopdb:8091","description":null,"metadata":null},{"id":"b471b98380e74418a44a165ca92fd781","type":"DRUG","name":"reslizumab","canonical_id":"chembl:CHEMBL2107884","description":null,"metadata":null},{"id":"2e86f9068d2d4e41a631c321122a43a4","type":"GO_TERM","name":"resolution of DNA recombination intermediates","canonical_id":"go:GO:0071139","description":"\"The cleavage and rejoining of intermediates, such as Holliday junctions, formed during DNA recombination to produce two intact molecules in which genetic material has been exchanged.\" [GOC:elh, GOC:mah, GOC:vw]","metadata":null},{"id":"1a12da7940fc4879a95a08fdfc66b2f5","type":"GO_TERM","name":"resolution of meiotic recombination intermediates","canonical_id":"go:GO:0000712","description":"\"The cleavage and rejoining of intermediates, such as Holliday junctions, formed during meiotic recombination to produce two intact molecules in which genetic material has been exchanged.\" [GOC:elh, PMID:11733053]","metadata":null},{"id":"c8ea62a6c0f6446a862108610746fcc1","type":"GO_TERM","name":"resolution of mitotic recombination intermediates","canonical_id":"go:GO:0071140","description":"\"The cleavage and rejoining of intermediates, mitotic recombination to produce two intact molecules in which genetic material has been exchanged.\" [GOC:elh, GOC:mah, GOC:vw]","metadata":null},{"id":"d5b7cc7daf084b2bbf8ca1e2f3dc2638","type":"GO_TERM","name":"resolution phase response","canonical_id":"go:GO:0106299","description":"\"An active host response phase of acute inflammation driven by specialized pro-resolving mediators (SPMs) and signaling pathways, enabling timely tissue regeneration and return of function.\" [PMID:28087575]","metadata":null},{"id":"1f7060f49e86431294ec5949e3ab4625","type":"GO_TERM","name":"resolvin biosynthetic process","canonical_id":"go:GO:0106295","description":"\"The chemical reactions and pathways resulting in the formation of resolvins, di- or trihydroxy fatty acids derived from omega-3 polyunsaturated fatty acids, specifically icosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid.\" [PMID:24899309]","metadata":null},{"id":"faf4540095354df5a28a1bb0db7abad6","type":"GO_TERM","name":"resorcinol metabolic process","canonical_id":"go:GO:0019505","description":"\"The chemical reactions and pathways involving resorcinol (C6H4(OH)2), a benzene derivative with many applications, including dyes, explosives, resins and as an antiseptic.\" [GOC:jl, PMID:33145, PMID:7217008]","metadata":null},{"id":"b69cad9ae8be465886afb28ba47adf03","type":"GO_TERM","name":"respiratory basal cell differentiation","canonical_id":"go:GO:1902691","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a respiratory basal cell.\" [GO_REF:0000086, GOC:TermGenie, MP:0011114, PMID:17909629]","metadata":null},{"id":"02ffb59f109048e0b458d4fb34a849a1","type":"GO_TERM","name":"respiratory burst","canonical_id":"go:GO:0045730","description":"\"A phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [ISBN:0198506732]","metadata":null},{"id":"045c6ab9b983447cbdf6791d4a57f684","type":"GO_TERM","name":"respiratory burst after phagocytosis","canonical_id":"go:GO:0045728","description":"\"A phase of elevated metabolic activity, during which oxygen consumption increases, that occurs in neutrophils, monocytes, and macrophages shortly after phagocytosing material. An enhanced uptake of oxygen leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals, which play a part in microbiocidal activity.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"e24e2d9f897e4657be7acc8a478fbfbf","type":"GO_TERM","name":"respiratory burst at fertilization","canonical_id":"go:GO:0045729","description":"\"The phase of elevated metabolic activity, during which oxygen consumption increases, that occurs at fertilization. An enhanced uptake of oxygen leads to the production of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals. Capacitation, a necessary prerequisite event to successful fertilization, can be induced by reactive oxygen species in vitro; hydrogen peroxide is used as an extracellular oxidant to cross-link the protective surface envelopes.\" [ISBN:0198506732, PMID:2537493, PMID:9013127]","metadata":null},{"id":"37c632c750544c3f96316875acd62d28","type":"GO_TERM","name":"respiratory burst involved in defense response","canonical_id":"go:GO:0002679","description":"\"A phase of elevated metabolic activity, during which oxygen consumption increases made as part of a defense response ; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.\" [GOC:add, ISBN:0781735149, PMID:12789499]","metadata":null},{"id":"8031895eb39a4b7daaba6973351a1aed","type":"GO_TERM","name":"respiratory burst involved in inflammatory response","canonical_id":"go:GO:0002536","description":"\"A phase of elevated metabolic activity, during which oxygen consumption increases following a stimulus as part of an inflammatory response; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals, resulting in an increase in their intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"96fa43d427df45b9abb3431701489d8e","type":"GO_TERM","name":"respiratory chain complex","canonical_id":"go:GO:0098803","description":"\"Any protein complex that is part of a respiratory chain.\" [GOC:dos]","metadata":null},{"id":"8fc39c1d5e3249f58feb16d8ff9d873c","type":"GO_TERM","name":"respiratory chain complex I","canonical_id":"go:GO:0045271","description":"\"Respiratory chain complex I is an enzyme of the respiratory chain. It consists of several polypeptide chains and is L-shaped, with a horizontal arm lying in the membrane and a vertical arm that projects into the matrix. The electrons of NADH enter the chain at this complex.\" [GOC:imk, GOC:jid, ISBN:0716749556]","metadata":null},{"id":"4565e90d8829466ea836ac96106fcdaf","type":"GO_TERM","name":"respiratory chain complex II (succinate dehydrogenase)","canonical_id":"go:GO:0045273","description":"\"A part of the respiratory chain, containing the four polypeptide subunits of succinate dehydrogenase, flavin-adenine dinucleotide and iron-sulfur. Catalyzes the oxidation of succinate by ubiquinone. Connects the TCA cycle with the respiratory chain.\" [ISBN:0198547684]","metadata":null},{"id":"8e7fc7747bb54aaf8e760dc3b799bb5e","type":"GO_TERM","name":"respiratory chain complex II assembly","canonical_id":"go:GO:0034552","description":"\"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex II.\" [GOC:dgf]","metadata":null},{"id":"86530ca7fdcb49a8bb293f6d265ea97c","type":"GO_TERM","name":"respiratory chain complex III","canonical_id":"go:GO:0045275","description":"\"A protein complex that transfers electrons from ubiquinol to cytochrome c and translocates two protons across a membrane. The complex contains a core structure of three catalytic subunits: cytochrome b, the Rieske iron sulfur protein (ISP), and cytochrome c1, which are arranged in an integral membrane-bound dimeric complex; additional subunits are present, and vary among different species.\" [PMID:16228398, PMID:16352458, PMID:17200733]","metadata":null},{"id":"28bdd9bf5068441cb2d89eb35cf16f89","type":"GO_TERM","name":"respiratory chain complex III assembly","canonical_id":"go:GO:0017062","description":"\"The aggregation, arrangement and bonding together of a set of components to form the cytochrome bc(1) complex, a transmembrane lipoprotein complex that it catalyzes the reduction of cytochrome c by accepting reducing equivalents from Coenzyme Q, by the aggregation, arrangement and bonding together of its constituents.\" [GOC:jl, PMID:12833641, PMID:20116362]","metadata":null},{"id":"25e0a6eb02e64e98aad9c614dd3bdc2d","type":"GO_TERM","name":"respiratory chain complex IV","canonical_id":"go:GO:0045277","description":"\"A part of the respiratory chain, containing the 13 polypeptide subunits of cytochrome c oxidase, including cytochrome a and cytochrome a3. Catalyzes the oxidation of reduced cytochrome c by dioxygen (O2).\" [ISBN:0198547684]","metadata":null},{"id":"fdb5b40e037b4ca696a90c024e8be0d3","type":"GO_TERM","name":"respiratory chain complex IV assembly","canonical_id":"go:GO:0008535","description":"\"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase), the terminal member of the respiratory chain of the mitochondrion and some aerobic bacteria. Cytochrome c oxidases are multi-subunit enzymes containing from 13 subunits in the mammalian mitochondrial form to 3-4 subunits in the bacterial forms.\" [GOC:jl, PMID:32311046]","metadata":null},{"id":"1d4873a45def4a38af0f9176135fde2f","type":"GO_TERM","name":"respiratory chemosensitivity","canonical_id":"go:GO:0160061","description":"\"A homeostatic process by which the sensing of CO2 and/or H+ by the brain leads to appropriate altering in breathing to regulate blood gas and tissue pH.\" [PMID:26068853]","metadata":null},{"id":"a85de78cc6694b33bd2d7b2adf5cf380","type":"GO_TERM","name":"respiratory electron transport chain","canonical_id":"go:GO:0022904","description":"\"A process in which a series of electron carriers operate together to transfer electrons from donors such as NADH and FADH2 to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.\" [GOC:mtg_electron_transport, ISBN:0716720094]","metadata":null},{"id":"c5776d65cd93466bacb0b01dfb1bed08","type":"DISEASE","name":"respiratory failure","canonical_id":"mondo:0021113","description":null,"metadata":null},{"id":"5229bcb6349845749dacd8c783c8ebbc","type":"GO_TERM","name":"respiratory gaseous exchange by respiratory system","canonical_id":"go:GO:0007585","description":"\"The process of gaseous exchange between an organism and its environment. In plants, microorganisms, and many small animals, air or water makes direct contact with the organism's cells or tissue fluids, and the processes of diffusion supply the organism with dioxygen (O2) and remove carbon dioxide (CO2). In larger animals the efficiency of gaseous exchange is improved by specialized respiratory organs, such as lungs and gills, which are ventilated by breathing mechanisms.\" [ISBN:0198506732]","metadata":null},{"id":"73fad20fb93b4bb18ca008e0039d1500","type":"DISEASE","name":"respiratory system cancer","canonical_id":"mondo:0000376","description":null,"metadata":null},{"id":"358ab7bcdec040b9bfa1ec902180cf49","type":"GO_TERM","name":"respiratory system development","canonical_id":"go:GO:0060541","description":"\"The progression of the respiratory system over time from its formation to its mature structure. The respiratory system carries out respiratory gaseous exchange.\" [GOC:dph]","metadata":null},{"id":"ad881ae4e7794fce95552d3c7c709c3a","type":"DISEASE","name":"respiratory system disorder","canonical_id":"mondo:0005087","description":null,"metadata":null},{"id":"48fcd5409ce748bb8db853ebc2e060a8","type":"GO_TERM","name":"respiratory system process","canonical_id":"go:GO:0003016","description":"\"A process carried out by the organs or tissues of the respiratory system. The respiratory system is an organ system responsible for respiratory gaseous exchange.\" [GOC:dph, GOC:mtg_cardio, GOC:tb]","metadata":null},{"id":"588e388cb0204ad898455cbb0175ed7f","type":"GO_TERM","name":"respiratory tube development","canonical_id":"go:GO:0030323","description":"\"The process whose specific outcome is the progression of the respiratory tube over time, from its formation to the mature structure. The respiratory tube is assumed to mean any tube in the respiratory tract.\" [GOC:jid]","metadata":null},{"id":"3c06ed44dfc74cbfbc322ecc538ac938","type":"GO_TERM","name":"response to (R)-carnitine","canonical_id":"go:GO:0061959","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an (R)-carnitine stimulus.\" [PMID:28102299]","metadata":null},{"id":"926e4181c97c40829068bcad419d6e39","type":"GO_TERM","name":"response to 1-aminocyclopropane-1-carboxylic acid","canonical_id":"go:GO:0009961","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-aminocyclopropane-1-carboxylic acid stimulus.\" [GOC:jl]","metadata":null},{"id":"90801d54e93e44c2a276bb78830e0e46","type":"GO_TERM","name":"response to 1-oleoyl-sn-glycerol 3-phosphate","canonical_id":"go:GO:1904565","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-oleoyl-sn-glycerol 3-phosphate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12139919]","metadata":null},{"id":"aee9765d7ea14b97a643825477bee21c","type":"GO_TERM","name":"response to 11-deoxycorticosterone","canonical_id":"go:GO:1903496","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 11-deoxycorticosterone stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:3585228]","metadata":null},{"id":"cb45b663cb004d9d8682e4df34d6063e","type":"GO_TERM","name":"response to 2,3,7,8-tetrachlorodibenzodioxine","canonical_id":"go:GO:1904612","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 2,3,7,8-tetrachlorodibenzodioxine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23196670]","metadata":null},{"id":"198fc4878bf64236ba92b9ac9cc4054a","type":"GO_TERM","name":"response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine","canonical_id":"go:GO:1904316","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:9321918]","metadata":null},{"id":"66771ddcf5a14df29105716f3f693997","type":"GO_TERM","name":"response to 3,3',4,4',5-pentachlorobiphenyl","canonical_id":"go:GO:1904610","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 3,3',4,4',5-pentachlorobiphenyl stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23196670]","metadata":null},{"id":"767a3b1df9eb40019b827357d40c5c4c","type":"GO_TERM","name":"response to 3,3',5-triiodo-L-thyronine","canonical_id":"go:GO:1905242","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 3,3',5-triiodo-L-thyronine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21382270]","metadata":null},{"id":"18f1a9e08d314c0a8ebb2b6d3b5f52ed","type":"GO_TERM","name":"response to 3-methylcholanthrene","canonical_id":"go:GO:1904681","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 3-methylcholanthrene stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:9224771]","metadata":null},{"id":"b1271600aa81453fa2fb9cdca2bb437c","type":"GO_TERM","name":"response to 4'-epidoxorubicin","canonical_id":"go:GO:1902522","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 4'-epidoxorubicin stimulus.\" [GOC:dw, GOC:TermGenie, PMID:23648065]","metadata":null},{"id":"9e7691aec76f4489b7ee605b04c47b0a","type":"GO_TERM","name":"response to 4-nitroquinoline N-oxide","canonical_id":"go:GO:0072724","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 4-nitroquinoline N-oxide stimulus.\" [GOC:mah]","metadata":null},{"id":"c42953b9e6114a87a545a0fdb55d4767","type":"GO_TERM","name":"response to 5-fluoro-2'-deoxyuridine","canonical_id":"go:GO:0097330","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 5-fluoro-2'-deoxyuridine stimulus. 5-fluoro-2'-deoxyuridine is a pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; it is used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.\" [GOC:pr]","metadata":null},{"id":"cff8056d217e43d2a889516483e14d96","type":"GO_TERM","name":"response to 5-fluorouracil","canonical_id":"go:GO:0036275","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 5-fluorouracil stimulus.\" [GOC:hp]","metadata":null},{"id":"8113aa8212d942369d8d648ef81a1742","type":"GO_TERM","name":"response to ATP","canonical_id":"go:GO:0033198","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ATP (adenosine 5'-triphosphate) stimulus.\" [GOC:sl]","metadata":null},{"id":"de18e7c0ab8b4ad28076e2b1059401b6","type":"GO_TERM","name":"response to Aroclor 1254","canonical_id":"go:GO:1904010","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an Aroclor 1254 stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18602130]","metadata":null},{"id":"eba418d36d9d453897a2570767b143d5","type":"GO_TERM","name":"response to BMP","canonical_id":"go:GO:0071772","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bone morphogenetic protein (BMP) stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"34608f766d9c43ba96219c1953cc2b25","type":"GO_TERM","name":"response to D-galactosamine","canonical_id":"go:GO:1904421","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a D-galactosamine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12057922]","metadata":null},{"id":"b797aa84e0ce4e7d86307b8b67002382","type":"GO_TERM","name":"response to D-galactose","canonical_id":"go:GO:1905377","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a D-galactose stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26261574]","metadata":null},{"id":"d18460479db0479f96a154e23320b73c","type":"GO_TERM","name":"response to DDT","canonical_id":"go:GO:0046680","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a DDT stimulus. DDT, dichlorodiphenyltrichloroethane, is a chlorinated hydrocarbon pesticide moderately toxic to humans and other animals.\" [ISBN:0721662544]","metadata":null},{"id":"1ad25859edf0449387f6cd520ed00bc4","type":"GO_TERM","name":"response to DNA damage checkpoint signaling","canonical_id":"go:GO:0072423","description":"\"A process that occurs in response to signals generated as a result of DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"7525b137d3f342c7abf3539d8b3c9b99","type":"GO_TERM","name":"response to DNA integrity checkpoint signaling","canonical_id":"go:GO:0072402","description":"\"A process that occurs in response to signals generated as a result of DNA integrity checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"588c5d155495498eb00b49a9afbc5bca","type":"GO_TERM","name":"response to DNA replication checkpoint signaling","canonical_id":"go:GO:0072438","description":"\"A process that occurs in response to signals generated as a result of DNA replication checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"43249a6f593146968e703b96630ce252","type":"GO_TERM","name":"response to G1 DNA damage checkpoint signaling","canonical_id":"go:GO:0072432","description":"\"A process that occurs in response to signals generated as a result of G1/S transition DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"00b8034b27844ee9aa13dddad06a23dc","type":"GO_TERM","name":"response to G1 cell size control checkpoint signaling","canonical_id":"go:GO:0072449","description":"\"A process that occurs in response to signals generated as a result of mitotic cell cycle G1/S transition size control checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"407f3bc4569740adac8ae8eafe9f24f0","type":"GO_TERM","name":"response to G2 DNA damage checkpoint signaling","canonical_id":"go:GO:0072426","description":"\"A process that occurs in response to signals generated as a result of G2/M transition DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"92d43d2b2e3242b4b3f064fd774fc6db","type":"GO_TERM","name":"response to G2 transition size control checkpoint signaling","canonical_id":"go:GO:0072452","description":"\"A process that occurs in response to signals generated as a result of G2/M transition size control checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"9b08fce8bcbe4dabb27aeedddbf36ef6","type":"GO_TERM","name":"response to GW 7647","canonical_id":"go:GO:1901593","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a GW 7647 stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"12217d4129344280bd5357be846fd107","type":"GO_TERM","name":"response to Gentian violet","canonical_id":"go:GO:0072728","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Gentian violet stimulus.\" [GOC:mah]","metadata":null},{"id":"07244e6d9bc54c5ebcbb4265f140782a","type":"GO_TERM","name":"response to Gram-negative bacterium","canonical_id":"go:GO:0140460","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a Gram-negative bacterium.\" [PMID:23664307]","metadata":null},{"id":"4f9e7bfb01834e76acc35684cd0ce2c6","type":"GO_TERM","name":"response to Gram-positive bacterium","canonical_id":"go:GO:0140459","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a Gram-positive bacterium.\" [PMID:23664307]","metadata":null},{"id":"55a387a001b34c32b9fc9d6d09509183","type":"GO_TERM","name":"response to L-arginine","canonical_id":"go:GO:1903576","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-arginine stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:6394628]","metadata":null},{"id":"31119c4d40f94b6e9b765626216e0b3f","type":"GO_TERM","name":"response to L-ascorbic acid","canonical_id":"go:GO:0033591","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an L-ascorbic acid (vitamin C) stimulus.\" [GOC:sl]","metadata":null},{"id":"6f2ac74269414e05b53c2e4aea29df0d","type":"GO_TERM","name":"response to L-canavanine","canonical_id":"go:GO:1901354","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-canavanine stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"f2d70427d07b4e62a3821c7fcd332e2f","type":"GO_TERM","name":"response to L-cysteine","canonical_id":"go:GO:1901367","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-cysteine stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"a44c6c98c2654fa3909acf1d92de0016","type":"GO_TERM","name":"response to L-dopa","canonical_id":"go:GO:1904473","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-dopa stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25044243]","metadata":null},{"id":"d1a3566d56014f54a6c7def96d3e71f0","type":"GO_TERM","name":"response to L-glutamate","canonical_id":"go:GO:1902065","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an L-glutamate stimulus.\" [GOC:TermGenie, PMID:23574009]","metadata":null},{"id":"e3269dc1ebf94464a7929908a1ab95f4","type":"GO_TERM","name":"response to L-glutamine","canonical_id":"go:GO:1904844","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-glutamine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23185570]","metadata":null},{"id":"94f0109bf0ff42428b385652e35bcb9a","type":"GO_TERM","name":"response to L-leucine","canonical_id":"go:GO:0043201","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-leucine stimulus.\" [GOC:mlg]","metadata":null},{"id":"2a7d7910b60f428fbecba85c82ea86fa","type":"GO_TERM","name":"response to L-phenylalanine derivative","canonical_id":"go:GO:1904386","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-phenylalanine derivative stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12112407]","metadata":null},{"id":"5237987924d44751b15ee3bb4ddcb059","type":"GO_TERM","name":"response to L-thialysine","canonical_id":"go:GO:1901345","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-thialysine stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"61b74ba5c3a649ed96e984ad0840fd71","type":"GO_TERM","name":"response to N-acetyl-D-glucosamine","canonical_id":"go:GO:0097315","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an N-acetyl-D-glucosamine stimulus.\" [GOC:di, PMID:21700702]","metadata":null},{"id":"49cbe13cb7ee4273bc574fca420d9b88","type":"GO_TERM","name":"response to N-phenylthiourea","canonical_id":"go:GO:1902610","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a N-phenylthiourea stimulus.\" [GO_REF:0000071, GOC:rjd, GOC:TermGenie, PMID:24006265]","metadata":null},{"id":"b4d14ca439be4fe3a075dff4c6f3df76","type":"GO_TERM","name":"response to TNF agonist","canonical_id":"go:GO:0061481","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a TNF agonist stimulus.\" [GOC:dph]","metadata":null},{"id":"5b859bc64a7b4d649fae28a9161d99e3","type":"GO_TERM","name":"response to Thyroglobulin triiodothyronine","canonical_id":"go:GO:1904016","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Thyroglobulin triiodothyronine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:7531505]","metadata":null},{"id":"9056a21024054c3a9fa74d2ec63a8682","type":"GO_TERM","name":"response to Thyroid stimulating hormone","canonical_id":"go:GO:1904400","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a Thyroid stimulating hormone stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:11238928]","metadata":null},{"id":"3733c4efb5b942ea9754a5713689b4df","type":"GO_TERM","name":"response to UV","canonical_id":"go:GO:0009411","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ultraviolet radiation (UV light) stimulus. Ultraviolet radiation is electromagnetic radiation with a wavelength in the range of 10 to 380 nanometers.\" [GOC:hb]","metadata":null},{"id":"3dd5b0925b954fb68758b9e8edec70ba","type":"GO_TERM","name":"response to UV-A","canonical_id":"go:GO:0070141","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-A radiation stimulus. UV-A radiation (UV-A light) spans the wavelengths 315 to 400 nm.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"04b9fe596ca84bcb91822be1ac18f3a5","type":"GO_TERM","name":"response to UV-B","canonical_id":"go:GO:0010224","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-B radiation stimulus. UV-B radiation (UV-B light) spans the wavelengths 280 to 315 nm.\" [GOC:tb]","metadata":null},{"id":"738a635f941c48b89c2acede54e6d007","type":"GO_TERM","name":"response to UV-C","canonical_id":"go:GO:0010225","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-C radiation stimulus. UV-C radiation (UV-C light) spans the wavelengths 100 to 280 nm.\" [GOC:tb]","metadata":null},{"id":"0729e31495704640a01603c00f4be940","type":"GO_TERM","name":"response to X-ray","canonical_id":"go:GO:0010165","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of X-ray radiation. An X-ray is a form of electromagnetic radiation with a wavelength in the range of 10 nanometers to 100 picometers (corresponding to frequencies in the range 30 PHz to 3 EHz).\" [GOC:sm, Wikipedia:X-ray]","metadata":null},{"id":"3bd09419f7914c37a79a8643b409f59e","type":"GO_TERM","name":"response to abiotic stimulus","canonical_id":"go:GO:0009628","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an abiotic (not derived from living organisms) stimulus.\" [GOC:hb]","metadata":null},{"id":"d0d932b0a0f44867bc63ca45611045b9","type":"GO_TERM","name":"response to abscisic acid","canonical_id":"go:GO:0009737","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an abscisic acid stimulus.\" [GOC:jl]","metadata":null},{"id":"2517bf1a3f774d40834262767b32ba2a","type":"GO_TERM","name":"response to absence of light","canonical_id":"go:GO:0009646","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an absence of light stimuli.\" [GOC:curators]","metadata":null},{"id":"dbde8de200f043489cadb6d4706bc701","type":"GO_TERM","name":"response to acadesine","canonical_id":"go:GO:1904101","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acadesine stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:20802119]","metadata":null},{"id":"d4a38a288a494712a872cc588671ebf0","type":"GO_TERM","name":"response to acetaldehyde","canonical_id":"go:GO:1905640","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acetaldehyde stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:27687866]","metadata":null},{"id":"a9275aa9f590471d81825ac4b22dd277","type":"GO_TERM","name":"response to acetate","canonical_id":"go:GO:0010034","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acetate stimulus.\" [GOC:sm]","metadata":null},{"id":"2943206433a24d2d9ace1de129fdb608","type":"GO_TERM","name":"response to acetylcholine","canonical_id":"go:GO:1905144","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acetylcholine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21238497]","metadata":null},{"id":"d8558099b5144ee591508f96412b0e6f","type":"GO_TERM","name":"response to acetylsalicylate","canonical_id":"go:GO:1903492","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aspirin (acetylsalicylate) stimulus. Aspirin is a non-steroidal anti-inflammatory drug with moA cyclooxygenase inhibitor activity.\" [GO_REF:0000071, GOC:TermGenie, PMID:23392654]","metadata":null},{"id":"78aea2d454b24662be8073ebf737bf01","type":"GO_TERM","name":"response to acid chemical","canonical_id":"go:GO:0001101","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by the chemical structure of the anion portion of a dissociated acid (rather than the acid acting as a proton donor). The acid chemical may be in gaseous, liquid or solid form.\" [GOC:curators, GOC:rn]","metadata":null},{"id":"7dbbe1641bac4ead913b1eb4f6f757b7","type":"GO_TERM","name":"response to acidic pH","canonical_id":"go:GO:0010447","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus with pH < 7. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:curators, GOC:tb, Wikipedia:PH]","metadata":null},{"id":"a79aaeab215d4273b5ac6079f19e516e","type":"GO_TERM","name":"response to acrylamide","canonical_id":"go:GO:1903937","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acrylamide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16292499]","metadata":null},{"id":"2caff404dd9040bb8f446a51b4f8d0f8","type":"GO_TERM","name":"response to actinomycin D","canonical_id":"go:GO:0072716","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an actinomycin D stimulus.\" [GOC:mah]","metadata":null},{"id":"c8d04272619448ee932c829ddc58386a","type":"GO_TERM","name":"response to activity","canonical_id":"go:GO:0014823","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an activity stimulus.\" [GOC:mtg_muscle]","metadata":null},{"id":"f01e9dbe000e44b0bd741cef454af540","type":"GO_TERM","name":"response to alcohol","canonical_id":"go:GO:0097305","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alcohol stimulus.\" [GOC:pr, PMID:24014527]","metadata":null},{"id":"167a0c556bd045d3ba20edbf25d92f00","type":"GO_TERM","name":"response to aldosterone","canonical_id":"go:GO:1904044","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aldosterone stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17644563]","metadata":null},{"id":"dd7f15a27cbc4e54b444018a8cc46da8","type":"GO_TERM","name":"response to alkaline pH","canonical_id":"go:GO:0010446","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus with pH > 7. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:curators, GOC:tb, Wikipedia:PH]","metadata":null},{"id":"2126908653fe4ccc80289e329b50f3a7","type":"GO_TERM","name":"response to alkaloid","canonical_id":"go:GO:0043279","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkaloid stimulus. Alkaloids are a large group of nitrogenous substances found in naturally in plants, many of which have extracts that are pharmacologically active.\" [GOC:jl]","metadata":null},{"id":"8b92b13fe24240ef9cadf0394a2318af","type":"GO_TERM","name":"response to alkane","canonical_id":"go:GO:1902778","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:22958739, PMID:23826995]","metadata":null},{"id":"319244af49334c5da2b0e327ff29e271","type":"GO_TERM","name":"response to alkyl hydroperoxide","canonical_id":"go:GO:0033195","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkyl hydroperoxide stimulus. Alkyl hydroperoxides are monosubstitution products of hydrogen peroxide, HOOH, where the substituent is an alkyl group.\" [GOC:mah]","metadata":null},{"id":"f8c44b740e8640019aa1f39b5e0bfd92","type":"GO_TERM","name":"response to aluminum ion","canonical_id":"go:GO:0010044","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aluminum ion stimulus.\" [GOC:sm]","metadata":null},{"id":"f4f13865e1c54fb7aa4cffba4f4ec577","type":"GO_TERM","name":"response to amine","canonical_id":"go:GO:0014075","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amine stimulus. An amine is a compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.\" [GOC:ef]","metadata":null},{"id":"0127ea60e8c14cbfab4df437965b396a","type":"GO_TERM","name":"response to amino acid","canonical_id":"go:GO:0043200","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amino acid stimulus. An amino acid is a carboxylic acids containing one or more amino groups.\" [GOC:ef, GOC:mlg]","metadata":null},{"id":"c324912efe944ee78804496c019d2b8d","type":"GO_TERM","name":"response to amino acid starvation","canonical_id":"go:GO:1990928","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of amino acids.\" [PMID:7765311]","metadata":null},{"id":"6cc08fd355984a08b299f42585bf532e","type":"GO_TERM","name":"response to amitrole","canonical_id":"go:GO:0072722","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amitrole stimulus.\" [GOC:mah]","metadata":null},{"id":"2bfa877407984379a3b4332bd057f44f","type":"GO_TERM","name":"response to ammonium ion","canonical_id":"go:GO:0060359","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ammonium stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23509267]","metadata":null},{"id":"0177ffb819604349a1d461ccefbafd84","type":"GO_TERM","name":"response to amphetamine","canonical_id":"go:GO:0001975","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"c15e3c49514542d986435adbc06aa2eb","type":"GO_TERM","name":"response to amyloid-beta","canonical_id":"go:GO:1904645","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23555824]","metadata":null},{"id":"a41d7f86c8f24f188138591da3ef2874","type":"GO_TERM","name":"response to amylopectin","canonical_id":"go:GO:0044591","description":"\"A process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of amylopectin stimulus.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"09ab5daa1f6049bd8bb77beacfd18534","type":"GO_TERM","name":"response to anesthetic","canonical_id":"go:GO:0072347","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anesthetic stimulus. An anesthetic is a substance that causes loss of feeling, awareness, or sensation.\" [GOC:sart]","metadata":null},{"id":"4a90336160bd42bfb26ca0c19a1eb2a4","type":"GO_TERM","name":"response to angiotensin","canonical_id":"go:GO:1990776","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an angiotensin stimulus. Angiotensin is any of three physiologically active peptides (angiotensin II, III, or IV) processed from angiotensinogen.\" [PMID:22982863]","metadata":null},{"id":"86cd52adc963473a928a53ef2d3706da","type":"GO_TERM","name":"response to anion stress","canonical_id":"go:GO:0072342","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of anion stress, an increase or decrease in the concentration of negatively charged ions in the environment.\" [GOC:cvs, PMID:19641131]","metadata":null},{"id":"e7718fc568d74ae4ab7f61f4d695927e","type":"GO_TERM","name":"response to anisomycin","canonical_id":"go:GO:0072739","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anisomycin stimulus.\" [GOC:mah]","metadata":null},{"id":"d444705b77b54adbbc36cfb3f12a1f7f","type":"GO_TERM","name":"response to anoxia","canonical_id":"go:GO:0034059","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating a decline in oxygen levels to trace amounts, <0.1%.\" [GOC:kmv]","metadata":null},{"id":"9223b28057224716af3245edede2118c","type":"GO_TERM","name":"response to antibiotic","canonical_id":"go:GO:0046677","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antibiotic stimulus. An antibiotic is a chemical substance produced by a microorganism which has the capacity to inhibit the growth of or to kill other microorganisms.\" [GOC:ai, GOC:ef]","metadata":null},{"id":"59fd0b7cc3d24668b1818e0261359406","type":"GO_TERM","name":"response to anticoagulant","canonical_id":"go:GO:0061476","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anticoagulant stimulus.\" [GOC:dph]","metadata":null},{"id":"d0010842c6b14240bf69db16ccc01e27","type":"GO_TERM","name":"response to anticonvulsant","canonical_id":"go:GO:0036277","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an anticonvulsant stimulus, a drug used to prevent seizures or reduce their severity.\" [GOC:hp]","metadata":null},{"id":"88cd2ea83fe149ccbd9cde922f8c946b","type":"GO_TERM","name":"response to antidepressant","canonical_id":"go:GO:0036276","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antidepressant stimulus, a mood-stimulating drug.\" [GOC:hp]","metadata":null},{"id":"87563255b23748288cd20246d7ce9e02","type":"GO_TERM","name":"response to antimetabolite","canonical_id":"go:GO:0097329","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antimetabolite stimulus. An antimetabolite is a substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.\" [GOC:pr]","metadata":null},{"id":"a9da85003e5b41c7adce913f975a7e8c","type":"GO_TERM","name":"response to antimycin A","canonical_id":"go:GO:1901325","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antimycin A stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"e1da41fc9b4b42699fbd92cb6929456d","type":"GO_TERM","name":"response to antineoplastic agent","canonical_id":"go:GO:0097327","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antineoplastic agent stimulus. An antineoplastic agent is a substance that inhibits or prevents the proliferation of neoplasms.\" [GOC:pr]","metadata":null},{"id":"75d31b20a7344fb4a31d634e192a7d3a","type":"GO_TERM","name":"response to antipsychotic drug","canonical_id":"go:GO:0097332","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antipsychotic drug stimulus. Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.\" [GOC:pr]","metadata":null},{"id":"f758bf5a6ac74f0bb20505825825fd3c","type":"GO_TERM","name":"response to arachidonate","canonical_id":"go:GO:1904550","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arachidonic acid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16382163]","metadata":null},{"id":"0930fa4f69f047928a988493140fce0e","type":"GO_TERM","name":"response to aromatase inhibitor","canonical_id":"go:GO:0061477","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aromatase inhibitor stimulus.\" [GOC:dph]","metadata":null},{"id":"d3c587b763fe46008c01c7ec5c569625","type":"GO_TERM","name":"response to arsenic-containing substance","canonical_id":"go:GO:0046685","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenic stimulus from compounds containing arsenic, including arsenates, arsenites, and arsenides.\" [GOC:hjd, ISBN:0721662544]","metadata":null},{"id":"24a8b19639744e73bda466db44affe2c","type":"GO_TERM","name":"response to arsenite ion","canonical_id":"go:GO:1903842","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenite ion stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:12106899]","metadata":null},{"id":"a96f5afc607b4ab6b90955c4d0e1f169","type":"GO_TERM","name":"response to arsenite(3-)","canonical_id":"go:GO:1903840","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenite(3-) stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:12106899]","metadata":null},{"id":"7e96bf4d7d834b3fbcdf99ee5c108816","type":"GO_TERM","name":"response to asparaginase","canonical_id":"go:GO:0061480","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an asparaginase stimulus.\" [GOC:dph]","metadata":null},{"id":"1565cf4b8d2746de95e3119210879b9a","type":"GO_TERM","name":"response to astaxanthin","canonical_id":"go:GO:1905217","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an astaxanthin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22309505]","metadata":null},{"id":"b40e67b57777428c9be0b99f20ba28ec","type":"GO_TERM","name":"response to auditory stimulus","canonical_id":"go:GO:0010996","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an auditory stimulus.\" [GOC:BHF, GOC:dph, GOC:sl, GOC:tb]","metadata":null},{"id":"47e2c5ddf08b4d0fbaa2a09806bad47b","type":"GO_TERM","name":"response to auxin","canonical_id":"go:GO:0009733","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an auxin stimulus.\" [GOC:jl]","metadata":null},{"id":"1021825387274c7fb17fb3cc08bd0803","type":"GO_TERM","name":"response to axon injury","canonical_id":"go:GO:0048678","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an axon injury stimulus.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"4c42c9f58a464851988510e5a7ec3773","type":"GO_TERM","name":"response to azide","canonical_id":"go:GO:0097184","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an azide stimulus.\" [GOC:yaf, PMID:16846222]","metadata":null},{"id":"1ffc875e09a04a97b08fa49b218a0d8b","type":"GO_TERM","name":"response to bacterial lipopeptide","canonical_id":"go:GO:0070339","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bacterial lipopeptide stimulus.\" [GOC:add, PMID:12077222]","metadata":null},{"id":"d723fa60a5f543b4b5e93ce8af7fff63","type":"GO_TERM","name":"response to bacterial lipoprotein","canonical_id":"go:GO:0032493","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bacterial lipoprotein stimulus.\" [GOC:add, PMID:12077222]","metadata":null},{"id":"c136de144f8c4336843ad6a52df84711","type":"GO_TERM","name":"response to bacteriocin","canonical_id":"go:GO:0046678","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bacteriocin stimulus. A bacteriocin is a protein substance released by certain bacteria that kills but does not lyse closely related strains of bacteria. Specific bacteriocins attach to specific receptors on cell walls and induce specific metabolic block, e.g. cessation of nucleic acid or protein synthesis of oxidative phosphorylation.\" [ISBN:0721662544]","metadata":null},{"id":"3e3e8bbadf034ae6af25ce0bc0370322","type":"GO_TERM","name":"response to bacterium","canonical_id":"go:GO:0009617","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a bacterium.\" [GOC:hb]","metadata":null},{"id":"ea8f95a5e30644fb90b87d3f5dd8709c","type":"GO_TERM","name":"response to benzene","canonical_id":"go:GO:1901423","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a benzene stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"aa85d9f633f643339374c01796a9c71a","type":"GO_TERM","name":"response to benzoic acid","canonical_id":"go:GO:0080021","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a benzoic acid stimulus.\" [PMID:18753285]","metadata":null},{"id":"1c8099d8c4b4478b9f2f8d2c7f617fde","type":"GO_TERM","name":"response to beta-carotene","canonical_id":"go:GO:1905387","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a beta-carotene stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16771696]","metadata":null},{"id":"391939bc5e2e44deb2bf5e7ccf5a39cb","type":"GO_TERM","name":"response to bile acid","canonical_id":"go:GO:1903412","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bile acid stimulus.\" [GO_REF:0000071, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:21757002]","metadata":null},{"id":"4622668049f54558a9a9186a6f6c3630","type":"GO_TERM","name":"response to biotic stimulus","canonical_id":"go:GO:0009607","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biotic stimulus, a stimulus caused or produced by a living organism.\" [GOC:hb]","metadata":null},{"id":"c6d9623669144f5583e127d12f4c602a","type":"GO_TERM","name":"response to biotin","canonical_id":"go:GO:0070781","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biotin stimulus.\" [GOC:sl]","metadata":null},{"id":"a8b743c45adc452e8b898dcd170cc38b","type":"GO_TERM","name":"response to biphenyl","canonical_id":"go:GO:1904614","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biphenyl stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23196670]","metadata":null},{"id":"6739d7c9089d4dc2a238143d53d28749","type":"GO_TERM","name":"response to bismuth","canonical_id":"go:GO:0072700","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bismuth (Bi) stimulus.\" [GOC:mah]","metadata":null},{"id":"e743b30363f945e78b0f1cbfea1b52cd","type":"GO_TERM","name":"response to bisphenol A","canonical_id":"go:GO:1903925","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bisphenol A stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22957036]","metadata":null},{"id":"5e183ea3b3eb421991599343b7fd01f0","type":"GO_TERM","name":"response to bleomycin","canonical_id":"go:GO:1904975","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bleomycin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:11553781]","metadata":null},{"id":"8212e2c2da294cc485d0a06e6068dbfa","type":"GO_TERM","name":"response to blue light","canonical_id":"go:GO:0009637","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a blue light stimulus. Blue light is electromagnetic radiation with a wavelength of between 440 and 500nm.\" [GOC:ai, GOC:mtg_far_red]","metadata":null},{"id":"e4748dfa3515478292eb356490f9ddc5","type":"GO_TERM","name":"response to borneol","canonical_id":"go:GO:1905230","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a borneol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26593909]","metadata":null},{"id":"8dedcbc75b3b48fa8f8d3c3b3fd315fe","type":"GO_TERM","name":"response to boron-containing substance","canonical_id":"go:GO:0010036","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a boron-containing substance stimulus.\" [GOC:sm]","metadata":null},{"id":"c4c2b42e09e943b6bb7becec33a62a42","type":"GO_TERM","name":"response to brassinosteroid","canonical_id":"go:GO:0009741","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a brassinosteroid stimulus.\" [GOC:jl]","metadata":null},{"id":"43ca7abc6d454fa8ae903fca5e457df6","type":"GO_TERM","name":"response to brefeldin A","canonical_id":"go:GO:0031001","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a brefeldin A stimulus.\" [GOC:mah]","metadata":null},{"id":"38f4210f6eaf450888bb63570864416d","type":"GO_TERM","name":"response to bronchodilator","canonical_id":"go:GO:0097366","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bronchodilator stimulus. A bronchodilator is a chemical that causes an increase in the expansion of a bronchus or bronchial tubes.\" [GOC:hp]","metadata":null},{"id":"6486e8bd713c4ac3a9636b8f3ec21a35","type":"GO_TERM","name":"response to butan-1-ol","canonical_id":"go:GO:1901422","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a butan-1-ol stimulus.\" [GOC:mengo_curators, GOC:TermGenie, PMID:24014527]","metadata":null},{"id":"70fa60a2b4d14ed4b4765e0a1e76f1f0","type":"GO_TERM","name":"response to butyrate","canonical_id":"go:GO:1903544","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a butyrate stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:9734870]","metadata":null},{"id":"f5fdda974830485a853164943f0d8612","type":"GO_TERM","name":"response to cAMP","canonical_id":"go:GO:0051591","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus.\" [GOC:ai]","metadata":null},{"id":"054fee94704f4007b99d761595e32ace","type":"GO_TERM","name":"response to cGMP","canonical_id":"go:GO:0070305","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cGMP (cyclic GMP, guanosine 3',5'-cyclophosphate) stimulus.\" [GOC:sl]","metadata":null},{"id":"653e03ee94874041a854e4cd06c28108","type":"GO_TERM","name":"response to cadmium ion","canonical_id":"go:GO:0046686","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus.\" [GOC:ai]","metadata":null},{"id":"9c4d15ee68e34de9bec9a827bb0e3a87","type":"GO_TERM","name":"response to caffeine","canonical_id":"go:GO:0031000","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a caffeine stimulus. Caffeine is an alkaloid found in numerous plant species, where it acts as a natural pesticide that paralyzes and kills certain insects feeding upon them.\" [GOC:ef, GOC:mah]","metadata":null},{"id":"00ce7ae872854f8fb6addbdd2b318392","type":"GO_TERM","name":"response to calcium ion","canonical_id":"go:GO:0051592","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a calcium ion stimulus.\" [GOC:ai]","metadata":null},{"id":"c16a46ee1d3543ebbf849333f41b3d73","type":"GO_TERM","name":"response to caloric restriction","canonical_id":"go:GO:0061771","description":"\"A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a caloric restriction, insufficient food energy intake.\" [GOC:dph, PMID:15520862]","metadata":null},{"id":"c57222a559414502a75c98dca25613a0","type":"GO_TERM","name":"response to camptothecin","canonical_id":"go:GO:1901563","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a camptothecin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"1d1564aae932422ca3a7b05bec5e4086","type":"GO_TERM","name":"response to candesartan","canonical_id":"go:GO:1901556","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a candesartan stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"5cc4f2d369da45b883e8e67110919436","type":"GO_TERM","name":"response to capsazepine","canonical_id":"go:GO:1901594","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a capsazepine stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"0f2cbf4c7418428682fe35d4368021d0","type":"GO_TERM","name":"response to carbamate","canonical_id":"go:GO:0046681","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbamate stimulus. Carbamates are a group of insecticides and parasiticides that act by inhibiting cholinesterase.\" [ISBN:0721662544]","metadata":null},{"id":"ae4550123e804155ae6e1807bf4bf062","type":"GO_TERM","name":"response to carbendazim","canonical_id":"go:GO:1901597","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbendazim stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"ed6eed1daf014a57b14372ca5d28b38d","type":"GO_TERM","name":"response to carbohydrate","canonical_id":"go:GO:0009743","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbohydrate stimulus.\" [GOC:jl]","metadata":null},{"id":"942347c26e254d1ea77793c49d8c820f","type":"GO_TERM","name":"response to carbon dioxide","canonical_id":"go:GO:0010037","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbon dioxide (CO2) stimulus.\" [GOC:sm]","metadata":null},{"id":"055b92f4b65a449aa461cece4d520657","type":"GO_TERM","name":"response to carbon monoxide","canonical_id":"go:GO:0034465","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbon monoxide (CO) stimulus.\" [GOC:ecd]","metadata":null},{"id":"de39830276ce4f8bbf32f6b548299f1a","type":"GO_TERM","name":"response to carbon starvation","canonical_id":"go:GO:0090549","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of a carbon source.\" [GOC:tair_curators, PMID:18245858]","metadata":null},{"id":"7f22b2da677749bea020e58eb5fd7b4e","type":"GO_TERM","name":"response to carboplatin","canonical_id":"go:GO:0097328","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carboplatin stimulus.\" [GOC:pr]","metadata":null},{"id":"1d87e3c0f8514b3a9ee718e4bafd0d89","type":"GO_TERM","name":"response to catechin","canonical_id":"go:GO:1902168","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a catechin stimulus.\" [GOC:rjd, GOC:TermGenie, PMID:23516620]","metadata":null},{"id":"ca61f1e60b974ad19585ec37d5140ddc","type":"GO_TERM","name":"response to catecholamine","canonical_id":"go:GO:0071869","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a catecholamine stimulus. A catecholamine is any of a group of biogenic amines that includes 4-(2-aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"8221375f66694ae090e38c7fc04df46f","type":"GO_TERM","name":"response to cation stress","canonical_id":"go:GO:0043157","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of cation stress, an increase or decrease in the concentration of positively charged ions in the environment.\" [GOC:jl, PMID:14762213]","metadata":null},{"id":"92a1e82d7ff8432abf2cbd2e034c38f1","type":"GO_TERM","name":"response to cell cycle checkpoint signaling","canonical_id":"go:GO:0072396","description":"\"A process that occurs in response to signals generated as a result of cell cycle checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"672b69a7eaee48f9b7e0985f3847ef61","type":"GO_TERM","name":"response to cell size control checkpoint signaling","canonical_id":"go:GO:0072470","description":"\"A process that occurs in response to signals generated as a result of cell size control checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"8d02f233341e470cb1bd515b20c6035b","type":"GO_TERM","name":"response to ceramide","canonical_id":"go:GO:0106096","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ceramide stimulus.\" [PMID:18006463]","metadata":null},{"id":"20717e41a81e4360b371d666c72d1581","type":"GO_TERM","name":"response to cesium ion","canonical_id":"go:GO:0010164","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cesium stimulus.\" [GOC:sm]","metadata":null},{"id":"191ceda62f3c42dd8c8b22eaaacf85f5","type":"GO_TERM","name":"response to chemical","canonical_id":"go:GO:0042221","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chemical stimulus.\" [GOC:jl]","metadata":null},{"id":"6cabe28eae1a4e9f996ec930e56f8834","type":"GO_TERM","name":"response to chemokine","canonical_id":"go:GO:1990868","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chemokine stimulus.\" [PMID:11113082]","metadata":null},{"id":"0a9ba60d5a23410eadf4d30741ec8798","type":"GO_TERM","name":"response to chitin","canonical_id":"go:GO:0010200","description":"\"A process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chitin stimulus.\" [GOC:sm]","metadata":null},{"id":"cf155872332a4a56973e733e69903e3e","type":"GO_TERM","name":"response to chloramphenicol","canonical_id":"go:GO:1901322","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chloramphenicol stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"3b1c18ed21ab4752b6dde9dcd46561fa","type":"GO_TERM","name":"response to chlorate","canonical_id":"go:GO:0010157","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chlorate stimulus.\" [GOC:sm]","metadata":null},{"id":"b5e3c85e1e234f4a8f6e356d19680b51","type":"GO_TERM","name":"response to chloroquine","canonical_id":"go:GO:1902349","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chloroquine stimulus.\" [GOC:kmv, GOC:TermGenie, PMID:23922869]","metadata":null},{"id":"04aa7b370336435bb83fb099d7d1fa11","type":"GO_TERM","name":"response to cholecystokinin","canonical_id":"go:GO:0061847","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholecystokinin stimulus.\" [PMID:14622258]","metadata":null},{"id":"019d44116ac940c58273e7319c11522e","type":"GO_TERM","name":"response to cholesterol","canonical_id":"go:GO:0070723","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cholesterol stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"84d575e0bcf24baa8493635b9e170535","type":"GO_TERM","name":"response to chondroitin 4'-sulfate","canonical_id":"go:GO:1905441","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chondroitin 4'-sulfate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22365850]","metadata":null},{"id":"b6057ef30295461b863a6e6b239d27d8","type":"GO_TERM","name":"response to chondroitin 6'-sulfate","canonical_id":"go:GO:1905439","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chondroitin 6'-sulfate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22365850]","metadata":null},{"id":"cf2e9cea831a4c33ab1bd1a531a2d8a9","type":"GO_TERM","name":"response to chromate","canonical_id":"go:GO:0046687","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a chromate stimulus.\" [ISBN:0721662544]","metadata":null},{"id":"550a471fdb0a4f8782f6e89bbb3f744e","type":"GO_TERM","name":"response to ciliary neurotrophic factor","canonical_id":"go:GO:1904391","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ciliary neurotrophic factor stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16914133]","metadata":null},{"id":"364d6816b6bc4d09a592196836a22051","type":"GO_TERM","name":"response to cisplatin","canonical_id":"go:GO:0072718","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cisplatin stimulus.\" [GOC:mah]","metadata":null},{"id":"0875b53fad614768bd0a7a315056564a","type":"GO_TERM","name":"response to clopidogrel","canonical_id":"go:GO:1903493","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a clopidogrel stimulus. Clopidogrel is a is an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.\" [GO_REF:0000071, GOC:TermGenie, PMID:23392654]","metadata":null},{"id":"2caf008b4d8b40bbba3deb4c60315711","type":"GO_TERM","name":"response to clozapine","canonical_id":"go:GO:0097338","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a clozapine stimulus.\" [GOC:pr]","metadata":null},{"id":"b8ac71fabbac4a4f8843ec20d716f11b","type":"GO_TERM","name":"response to cobalamin","canonical_id":"go:GO:0033590","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cobalamin (vitamin B12) stimulus.\" [GOC:sl]","metadata":null},{"id":"06ab52cc7e1e4937990240b7ae6a3aa3","type":"GO_TERM","name":"response to cobalt ion","canonical_id":"go:GO:0032025","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cobalt ion (Co2+) stimulus.\" [GOC:mah]","metadata":null},{"id":"f6c45cada4ac4529a304eb32a5ba267c","type":"GO_TERM","name":"response to cocaine","canonical_id":"go:GO:0042220","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cocaine stimulus. Cocaine is a crystalline alkaloid obtained from the leaves of the coca plant.\" [GOC:ef, GOC:jl]","metadata":null},{"id":"49b7bef513e941d3a7d243897fbf400d","type":"GO_TERM","name":"response to codeine","canonical_id":"go:GO:1905233","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a codeine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24914722]","metadata":null},{"id":"4c18049cb8f9429ea717a9358b4510ba","type":"GO_TERM","name":"response to cold","canonical_id":"go:GO:0009409","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cold stimulus, a temperature stimulus below the optimal temperature for that organism.\" [GOC:lr]","metadata":null},{"id":"ea5dcc2a29ce42b2a798596e65fef2da","type":"GO_TERM","name":"response to continuous far red light stimulus by the high-irradiance response system","canonical_id":"go:GO:0010201","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the detection of a continuous far red light stimulus by the high-irradiance response system. Far red light is electromagnetic radiation of wavelength 700-800nm. The activity of the high-irradiance response system is characterized by stronger effects of continuous than pulsed light at equal total fluence.\" [GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"2919ba68b8fc494ca0b8f58ae18b5a22","type":"GO_TERM","name":"response to copper ion","canonical_id":"go:GO:0046688","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a copper ion stimulus.\" [GOC:ai]","metadata":null},{"id":"2cafbf2389fa4c71a84198f0c26731ff","type":"GO_TERM","name":"response to copper ion starvation","canonical_id":"go:GO:0120126","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of copper ion.\" [GOC:sl, PMID:24024382]","metadata":null},{"id":"992e17348b5a4579be968db157207ccb","type":"GO_TERM","name":"response to cordycepin","canonical_id":"go:GO:1904309","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cordycepin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21597460]","metadata":null},{"id":"742ba1c25c284ccabba0737de1f8016e","type":"GO_TERM","name":"response to corticosteroid","canonical_id":"go:GO:0031960","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosteroid hormone stimulus. A corticosteroid is a steroid hormone that is produced in the adrenal cortex. Corticosteroids are involved in a wide range of physiologic systems such as stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. They include glucocorticoids and mineralocorticoids.\" [GOC:mah, PMID:11027914]","metadata":null},{"id":"df3ec222026e49d899b8a57e22ed302c","type":"GO_TERM","name":"response to corticosterone","canonical_id":"go:GO:0051412","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosterone stimulus. Corticosterone is a 21 carbon steroid hormone of the corticosteroid type, produced in the cortex of the adrenal glands. In many species, corticosterone is the principal glucocorticoid, involved in regulation of fuel metabolism, immune reactions, and stress responses.\" [PMID:15240347]","metadata":null},{"id":"de976f9b62c14eeba64663be8cdf492c","type":"GO_TERM","name":"response to corticotropin-releasing hormone","canonical_id":"go:GO:0043435","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticotropin-releasing hormone stimulus. Corticotropin-releasing hormone is a peptide hormone involved in the stress response.\" [PMID:11027914, PMID:15134857, Wikipedia:Corticotropin-releasing_hormone]","metadata":null},{"id":"d75b8d0c104246e1af07330b143871c8","type":"GO_TERM","name":"response to cortisol","canonical_id":"go:GO:0051414","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cortisol stimulus. Cortisol is the major natural glucocorticoid synthesized in the zona fasciculata of the adrenal cortex; it affects the metabolism of glucose, protein, and fats and has appreciable mineralocorticoid activity. It also regulates the immune system and affects many other functions.\" [ISBN:0721662544, PMID:11276391]","metadata":null},{"id":"18d2834932d04638b854bcced93893cd","type":"GO_TERM","name":"response to cortisone","canonical_id":"go:GO:0051413","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cortisone stimulus. Cortisone is a natural glucocorticoid steroid hormone that is metabolically convertible to cortisol. Cortisone is synthesized from cholesterol in the cortex of the adrenal gland under the stimulation of adrenocorticotropin hormone (ACTH). The main physiological effect of cortisone is on carbohydrate metabolism; it can stimulate increased glucose release from the liver, increased liver glycogen synthesis, and decreased utilization of glucose by the tissues.\" [ISBN:0721662544, PMID:11276391]","metadata":null},{"id":"474296e1943c4fc1ab2793ab8c143317","type":"GO_TERM","name":"response to curcumin","canonical_id":"go:GO:1904643","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a curcumin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24755072]","metadata":null},{"id":"944d0723bbe441dca54c82a4e40d8204","type":"GO_TERM","name":"response to cyanide","canonical_id":"go:GO:1903927","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyanide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:21854848]","metadata":null},{"id":"f85c64c2cdf84b4d9275550b29e7cd07","type":"GO_TERM","name":"response to cycloalkane","canonical_id":"go:GO:0014071","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cycloalkane stimulus. A cycloalkane is a cyclic saturated hydrocarbon having the general formula CnH2n.\" [GOC:ef]","metadata":null},{"id":"c3858a146d22481fbd690484d7bcf350","type":"GO_TERM","name":"response to cyclodiene","canonical_id":"go:GO:0046682","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyclodiene stimulus. A cyclodiene is any organic insecticide (as dieldrin or chlordane) with a chlorinated methylene group forming a bridge across a 6-membered carbon ring.\" [ISBN:0877797099]","metadata":null},{"id":"fb484372dbfd45909438b7ae43d50ea4","type":"GO_TERM","name":"response to cycloheximide","canonical_id":"go:GO:0046898","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cycloheximide stimulus. Cycloheximide (actidione) is an antibiotic produced by some Streptomyces species which interferes with protein synthesis in eukaryotes.\" [GOC:ef, ISBN:0198506732]","metadata":null},{"id":"db730a23d0394f75991359bdbbab7fba","type":"GO_TERM","name":"response to cyclopentenone","canonical_id":"go:GO:0010583","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyclopentenone stimulus. Cyclopentenones are oxylipins derived from polyunsaturated fatty acids. They are structurally similar to jasmonic acid, but contain a reactive unsaturated carbonyl structure in the cyclo-ring. Cyclopentenones include phytoprostanes and 12-oxo-phytodienoic acid.\" [PMID:18334669]","metadata":null},{"id":"63adcabec0dc4b1483aab7c50aefd4fb","type":"GO_TERM","name":"response to cyclophosphamide","canonical_id":"go:GO:1902518","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyclophosphamide stimulus.\" [GOC:dw, GOC:TermGenie, PMID:23648065]","metadata":null},{"id":"6b96eb27c1e345e791b4f00078d9a0ea","type":"GO_TERM","name":"response to cyclosporin A","canonical_id":"go:GO:1905237","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cyclosporin A stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24914722]","metadata":null},{"id":"e7f4d05f90074015b01cdb98d22d148a","type":"GO_TERM","name":"response to cytarabine","canonical_id":"go:GO:0097331","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytarabine stimulus.\" [GOC:pr]","metadata":null},{"id":"922cac547dd74fccaadfeaeca79883c7","type":"GO_TERM","name":"response to cytochalasin B","canonical_id":"go:GO:1901328","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytochalasin B stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"4b34c0b0396f43a4a5bf21355a07f30a","type":"GO_TERM","name":"response to cytokine","canonical_id":"go:GO:0034097","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokine stimulus.\" [GOC:sl]","metadata":null},{"id":"cad8c8f258944c8ab0a1c4cc7be45ba2","type":"GO_TERM","name":"response to cytokinesis checkpoint signaling","canonical_id":"go:GO:0072399","description":"\"A process that occurs in response to signals generated as a result of cytokinesis checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"6e58a3007514456aa8b7b2f7a7cf6f6e","type":"GO_TERM","name":"response to cytokinin","canonical_id":"go:GO:0009735","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokinin stimulus.\" [GOC:jl]","metadata":null},{"id":"5ed344ca72ad421f938b833e2380fd18","type":"GO_TERM","name":"response to decalin","canonical_id":"go:GO:1901493","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a decalin stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"a82ef87a4a9e4ae2a76b6e026ab3e439","type":"GO_TERM","name":"response to decane","canonical_id":"go:GO:1902782","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a decane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:23826995]","metadata":null},{"id":"cac7717a0e804915a06af928d1abca1b","type":"GO_TERM","name":"response to decreased oxygen levels","canonical_id":"go:GO:0036293","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting a decline in the level of oxygen.\" [GOC:al]","metadata":null},{"id":"dc18189e125747b69d5c7dab41c40eff","type":"GO_TERM","name":"response to deep water","canonical_id":"go:GO:0030912","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a deep water stimulus, being immersed in standing deep water throughout the life cycle.\" [GOC:mah]","metadata":null},{"id":"f8133fa79ed64fd6a839da6c12eccecc","type":"GO_TERM","name":"response to dehydroepiandrosterone","canonical_id":"go:GO:1903494","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dehydroepiandrosterone stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:3585228]","metadata":null},{"id":"6bfdd5c498d846329833f0cfa0fdadf8","type":"GO_TERM","name":"response to denervation involved in regulation of muscle adaptation","canonical_id":"go:GO:0014894","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a denervation stimulus. This process occurs as part of the regulation of muscle adaptation.\" [GOC:mtg_muscle]","metadata":null},{"id":"98f15ffead48499b9e3b6a789d17064c","type":"GO_TERM","name":"response to desiccation","canonical_id":"go:GO:0009269","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a desiccation stimulus, extreme dryness resulting from the prolonged deprivation of water.\" [GOC:jl]","metadata":null},{"id":"1bb941ff149340a191c66f0621decd26","type":"GO_TERM","name":"response to desipramine","canonical_id":"go:GO:1904307","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a desipramine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20549303]","metadata":null},{"id":"ede90ca321b74b41ac72ab7eb7bf2847","type":"GO_TERM","name":"response to dexamethasone","canonical_id":"go:GO:0071548","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dexamethasone stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"5f1635fb05fe44709aeaea68d6d5276f","type":"GO_TERM","name":"response to dextromethorphan","canonical_id":"go:GO:1904558","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dextromethorphan stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:25796330]","metadata":null},{"id":"719f0cf69e5f448e9ae2b8742ecab5f6","type":"GO_TERM","name":"response to diacyl bacterial lipopeptide","canonical_id":"go:GO:0071724","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diacylated bacterial lipopeptide stimulus.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"0dcb870f66d04571876158f7032273ad","type":"GO_TERM","name":"response to diamide","canonical_id":"go:GO:0072737","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diamide (N,N,N',N'-tetramethyldiazene-1,2-dicarboxamide) stimulus.\" [GOC:mah]","metadata":null},{"id":"6706621a61d848d5b99dae982332d4d6","type":"GO_TERM","name":"response to dietary excess","canonical_id":"go:GO:0002021","description":"\"The physiological process in which dietary excess is sensed by the central nervous system, resulting in a reduction in food intake and increased energy expenditure.\" [GOC:pg, GOC:pr, PMID:12161655]","metadata":null},{"id":"e0fc26ba552f498ab864a26003bbe598","type":"GO_TERM","name":"response to diethyl maleate","canonical_id":"go:GO:1902111","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diethyl maleate stimulus.\" [GOC:TermGenie, PMID:12100563]","metadata":null},{"id":"909eb2f4a7b041e9ac899edd69c85157","type":"GO_TERM","name":"response to differentiation-inducing factor 1","canonical_id":"go:GO:1903013","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22365144]","metadata":null},{"id":"fb46b752dca4432bb5f8ade11047ff47","type":"GO_TERM","name":"response to differentiation-inducing factor 2","canonical_id":"go:GO:1905960","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)pentan-1-one stimulus.\" [GO_REF:0000071, GOC:rjd, GOC:TermGenie, PMID:19684855, PMID:3355503]","metadata":null},{"id":"ac4e58615866448394dd13a2f4c000ed","type":"GO_TERM","name":"response to dimethyl sulfoxide","canonical_id":"go:GO:1904619","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dimethyl sulfoxide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:12873812]","metadata":null},{"id":"a07e35e96f6b4dd7b942a1a176264dbd","type":"GO_TERM","name":"response to dinitrophenol","canonical_id":"go:GO:1904641","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dinitrophenol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24336883]","metadata":null},{"id":"9ce3d264f5bd4aa38aae446ca8b680d8","type":"GO_TERM","name":"response to diosgenin","canonical_id":"go:GO:1905092","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diosgenin stimulus.\" [GO_REF:0000071, GOC:bc, GOC:BHF, GOC:BHF_miRNA, GOC:TermGenie, PMID:25765596]","metadata":null},{"id":"f61677955ca64e7880c3c5bfe456bfd6","type":"GO_TERM","name":"response to diphenidol","canonical_id":"go:GO:1904560","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diphenidol stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:25796330]","metadata":null},{"id":"57a2b16738364366bdf1e7f5289ddff2","type":"GO_TERM","name":"response to diphenyl ether","canonical_id":"go:GO:1901497","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diphenyl ether stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"4d6bbbf62101498d9d01b3837e1af9ae","type":"GO_TERM","name":"response to disaccharide","canonical_id":"go:GO:0034285","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disaccharide stimulus.\" [GOC:sart]","metadata":null},{"id":"93227fbd9f694868ba45413130620444","type":"GO_TERM","name":"response to diterpene","canonical_id":"go:GO:1904629","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diterpene stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:19765580]","metadata":null},{"id":"59ce2273bfb44b70bc4142ce55674486","type":"GO_TERM","name":"response to dithiothreitol","canonical_id":"go:GO:0072720","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dithiothreitol stimulus.\" [GOC:mah]","metadata":null},{"id":"cbc7715ca88a487cacb9fe14effd2f08","type":"GO_TERM","name":"response to diuretic","canonical_id":"go:GO:0036270","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a diuretic stimulus. A diuretic is an agent that promotes the excretion of urine through its effects on kidney function.\" [GOC:hp]","metadata":null},{"id":"897526c6a8fb4560aee886f84f142527","type":"GO_TERM","name":"response to docetaxel trihydrate","canonical_id":"go:GO:1902519","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a docetaxel trihydrate stimulus.\" [GOC:dw, GOC:TermGenie, PMID:23648065]","metadata":null},{"id":"0b9e83a5671649d7a381a12c1f3457e5","type":"GO_TERM","name":"response to dodecane","canonical_id":"go:GO:1902786","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dodecane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:23826995]","metadata":null},{"id":"44e48caa8167458cb16f3d75973cb351","type":"GO_TERM","name":"response to dopamine","canonical_id":"go:GO:1903350","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dopamine stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:11118945]","metadata":null},{"id":"7e5e65639a9646ae97672009608ec56a","type":"GO_TERM","name":"response to doxorubicin","canonical_id":"go:GO:1902520","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a doxorubicin stimulus.\" [GOC:dw, GOC:TermGenie, PMID:23648065]","metadata":null},{"id":"65a54981b6804c9ea61ad086b77dcded","type":"GO_TERM","name":"response to dsDNA","canonical_id":"go:GO:1990784","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a double-stranded DNA stimulus.\" [PMID:10051633]","metadata":null},{"id":"ffc6d7ac2439496c8726e943482a26e6","type":"GO_TERM","name":"response to dsRNA","canonical_id":"go:GO:0043331","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a double-stranded RNA stimulus.\" [GOC:jl]","metadata":null},{"id":"fe61e684f8f5489293e884979ebb9ec5","type":"GO_TERM","name":"response to ecdysone","canonical_id":"go:GO:0035075","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ecdysone stimulus.\" [GOC:bf]","metadata":null},{"id":"a2d3b195a63f44b5b90780b75480d09a","type":"GO_TERM","name":"response to electrical stimulus","canonical_id":"go:GO:0051602","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus.\" [GOC:ai]","metadata":null},{"id":"08cb98a6af5a46eaa60a366bf8053a75","type":"GO_TERM","name":"response to electrical stimulus involved in regulation of muscle adaptation","canonical_id":"go:GO:0014878","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus. This process occurs as part of the regulation of muscle adaptation.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"307f7388b1624abb898c79d12cc8825c","type":"GO_TERM","name":"response to endogenous stimulus","canonical_id":"go:GO:0009719","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus arising within the organism.\" [GOC:sm]","metadata":null},{"id":"d73bba4590c140308c2cc9a1c650a176","type":"GO_TERM","name":"response to endoplasmic reticulum stress","canonical_id":"go:GO:0034976","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.\" [GOC:cjm, GOC:mah]","metadata":null},{"id":"8ae369252c3b4249b4a31541ea1e1781","type":"GO_TERM","name":"response to endothelin","canonical_id":"go:GO:1990839","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an endothelin stimulus. Endothelin is any of three secretory vasoconstrictive peptides (endothelin-1, -2, -3).\" [PMID:16365184]","metadata":null},{"id":"2cdac3d8042d4294b6adc5bbefb02ca8","type":"GO_TERM","name":"response to environmental enrichment","canonical_id":"go:GO:0090648","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the provision of a combination of complex inanimate and social stimulations in the organism's housing environment.\" [GOC:sl, PMID:23644055, PMID:25934034]","metadata":null},{"id":"ab7aea854c704b43b0f54eeafbb6e461","type":"GO_TERM","name":"response to epidermal growth factor","canonical_id":"go:GO:0070849","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth factor stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"764ad01b46c649eb8fb6f824dae0aca4","type":"GO_TERM","name":"response to epinephrine","canonical_id":"go:GO:0071871","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epinephrine stimulus. Epinephrine is a catecholamine that has the formula C9H13NO3; it is secreted by the adrenal medulla to act as a hormone, and released by certain neurons to act as a neurotransmitter active in the central nervous system.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"1677515d1745436eb59fa43bd27c77ad","type":"GO_TERM","name":"response to erythromycin","canonical_id":"go:GO:1901323","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an erythromycin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"f46a2698945f4ddb86161355f09b5236","type":"GO_TERM","name":"response to erythropoietin","canonical_id":"go:GO:0036017","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an erythropoietin stimulus. Erythropoietin is a glycoprotein hormone that controls erythropoiesis.\" [GOC:yaf]","metadata":null},{"id":"dfd07a76669140229e608c7328c13995","type":"GO_TERM","name":"response to estradiol","canonical_id":"go:GO:0032355","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.\" [GOC:mah, ISBN:0911910123]","metadata":null},{"id":"aab9b8aac840413782e0c96ec901ee8c","type":"GO_TERM","name":"response to estrogen","canonical_id":"go:GO:0043627","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"9513d030a03e43258fb7e124f4a056fb","type":"GO_TERM","name":"response to ethanol","canonical_id":"go:GO:0045471","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus.\" [GOC:curators]","metadata":null},{"id":"7edcfbd11f944d2cbe6d2557b70eb077","type":"GO_TERM","name":"response to ether","canonical_id":"go:GO:0045472","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ether stimulus.\" [GOC:curators]","metadata":null},{"id":"348393ba25d848dda21f8d9c2273cc05","type":"GO_TERM","name":"response to ethylene","canonical_id":"go:GO:0009723","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethylene (ethene) stimulus.\" [GOC:jl]","metadata":null},{"id":"43f904c16c0248fd9be7bf853dbe28bd","type":"GO_TERM","name":"response to etoposide","canonical_id":"go:GO:1902521","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an etoposide stimulus.\" [GOC:dw, GOC:TermGenie, PMID:23648065]","metadata":null},{"id":"7aa10e70c99b4166a19d4b51fc6ad150","type":"GO_TERM","name":"response to exogenous dsRNA","canonical_id":"go:GO:0043330","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an exogenous double-stranded RNA stimulus.\" [GOC:curators]","metadata":null},{"id":"ceac2a56552943d4a64f5e6223b3d6ee","type":"GO_TERM","name":"response to external biotic stimulus","canonical_id":"go:GO:0043207","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external biotic stimulus, an external stimulus caused by, or produced by living things.\" [GOC:curators]","metadata":null},{"id":"8119062f954144eaaa60b9688a962bbb","type":"GO_TERM","name":"response to external stimulus","canonical_id":"go:GO:0009605","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus.\" [GOC:hb]","metadata":null},{"id":"83b01c98506b485b9a1aeff0537e7f3a","type":"GO_TERM","name":"response to far red light","canonical_id":"go:GO:0010218","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of far red light stimulus. Far red light is electromagnetic radiation of wavelength 700-800nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:mtg_far_red, GOC:tb]","metadata":null},{"id":"0a2356a3440f4b2ea872ff3d0573815c","type":"GO_TERM","name":"response to farnesol","canonical_id":"go:GO:0097307","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a farnesol stimulus.\" [GOC:pr]","metadata":null},{"id":"9f93990e3724466e9d05b72acbbb42d3","type":"GO_TERM","name":"response to fatty acid","canonical_id":"go:GO:0070542","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fatty acid stimulus.\" [GOC:lp]","metadata":null},{"id":"3927dc4b1ee3461083a924f520097384","type":"GO_TERM","name":"response to fenofibrate","canonical_id":"go:GO:1901557","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fenofibrate stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"e931d7cd3eb14c89b12c335a218ec1da","type":"GO_TERM","name":"response to fibroblast growth factor","canonical_id":"go:GO:0071774","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fibroblast growth factor stimulus.\" [GOC:mah]","metadata":null},{"id":"f5c26fe9a6dd4925a7da4395c6fa3ba9","type":"GO_TERM","name":"response to flavonoid","canonical_id":"go:GO:1905395","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a flavonoid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22700048]","metadata":null},{"id":"d3481037e3cc47019e2972aba28d0e75","type":"GO_TERM","name":"response to flooding","canonical_id":"go:GO:0009413","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating flooding, short-term immersion in water.\" [GOC:lr]","metadata":null},{"id":"4ff164252aa346e28d17b840f4e6ffc1","type":"GO_TERM","name":"response to fluid shear stress","canonical_id":"go:GO:0034405","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluid shear stress stimulus. Fluid shear stress is the force acting on an object in a system where the fluid is moving across a solid surface.\" [GOC:sl]","metadata":null},{"id":"5774649fad04493d8150ee22164d5763","type":"GO_TERM","name":"response to fluoride","canonical_id":"go:GO:1902617","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluoride stimulus.\" [GO_REF:0000071, GOC:kmv, GOC:TermGenie, PMID:8138152]","metadata":null},{"id":"4c686efa7a7a4fe2a6c1542d6737c997","type":"GO_TERM","name":"response to fluoxetine","canonical_id":"go:GO:0014076","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluoxetine stimulus. Fluoxetine increases the extracellular level of the neurotransmitter serotonin by inhibiting its reuptake into the presynaptic cell, increasing the level of serotonin available to bind to the postsynaptic receptor.\" [GOC:ef, GOC:pr]","metadata":null},{"id":"3a6188564c0c4ea29b5ab3d7f36ff577","type":"GO_TERM","name":"response to folic acid","canonical_id":"go:GO:0051593","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a folic acid stimulus.\" [GOC:ai]","metadata":null},{"id":"09d7447cb7b24922bd8fbea71f2f621e","type":"GO_TERM","name":"response to follicle-stimulating hormone","canonical_id":"go:GO:0032354","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a follicle-stimulating hormone stimulus.\" [GOC:mah]","metadata":null},{"id":"500eda2f6c7346b2965ff1d59ead0c4c","type":"GO_TERM","name":"response to food","canonical_id":"go:GO:0032094","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a food stimulus; food is anything which, when taken into the body, serves to nourish or build up the tissues or to supply body heat.\" [GOC:add, ISBN:0721601464]","metadata":null},{"id":"7584e3ae3eff43f4a80d9ec838753d0e","type":"GO_TERM","name":"response to formaldehyde","canonical_id":"go:GO:1904404","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a formaldehyde stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:9149109]","metadata":null},{"id":"4caa71a833794cfd8bd7a1bddbef49f7","type":"GO_TERM","name":"response to formic acid","canonical_id":"go:GO:1901425","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a formic acid stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"12e9cb0c58a54ffeaaed7e722ef74182","type":"GO_TERM","name":"response to forskolin","canonical_id":"go:GO:1904321","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a forskolin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:15937517]","metadata":null},{"id":"3e90b172d4244db98346d9e71d1041f1","type":"GO_TERM","name":"response to freezing","canonical_id":"go:GO:0050826","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a freezing stimulus, temperatures below 0 degrees Celsius.\" [GOC:jl]","metadata":null},{"id":"352364d17e974fefa435b8f158390033","type":"GO_TERM","name":"response to fructose","canonical_id":"go:GO:0009750","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fructose stimulus.\" [GOC:jl]","metadata":null},{"id":"1aa016ed2dfe41eb9ea1f088df56a6a2","type":"GO_TERM","name":"response to fungicide","canonical_id":"go:GO:0060992","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fungicide stimulus. Fungicides are chemicals used to kill fungi.\" [GOC:dph]","metadata":null},{"id":"82ee52b97653439fb6ea3fce27dc8c6c","type":"GO_TERM","name":"response to fungus","canonical_id":"go:GO:0009620","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a fungus.\" [GOC:hb]","metadata":null},{"id":"3c2c546dd4b7469abff239d5d387d0bd","type":"GO_TERM","name":"response to furfural","canonical_id":"go:GO:1901426","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a furfural stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"b17e603219d54bbba7592fcb1b9e4d2d","type":"GO_TERM","name":"response to gamma radiation","canonical_id":"go:GO:0010332","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gamma radiation stimulus. Gamma radiation is a form of electromagnetic radiation (EMR) or light emission of a specific frequency produced from sub-atomic particle interaction, such as electron-positron annihilation and radioactive decay. Gamma rays are generally characterized as EMR having the highest frequency and energy, and also the shortest wavelength, within the electromagnetic radiation spectrum.\" [GOC:tair_curators]","metadata":null},{"id":"8645c79ddab24c52885a48044c027ff4","type":"GO_TERM","name":"response to gastrin","canonical_id":"go:GO:1990867","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gastrin stimulus.\" [PMID:10348814]","metadata":null},{"id":"97a74e3c1d244c9ea6e67492b0c4b142","type":"GO_TERM","name":"response to gemcitabine","canonical_id":"go:GO:0036272","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gemcitabine stimulus. Gemcitabine is a 2'-deoxycytidine having geminal fluoro substituents in the 2'-position, and is used as a drug in the treatment of various carcinomas.\" [GOC:hp, Wikipedia:Gemcitabine]","metadata":null},{"id":"0d9a0e84ee0e4f2a87e80186ee78e4c3","type":"GO_TERM","name":"response to genistein","canonical_id":"go:GO:0033595","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a genistein stimulus.\" [GOC:mah]","metadata":null},{"id":"f9d91161a02a4874b9346e1b3104086c","type":"GO_TERM","name":"response to gibberellin","canonical_id":"go:GO:0009739","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gibberellin stimulus.\" [GOC:jl]","metadata":null},{"id":"5c399e88c6b845c48de3821548be7b98","type":"GO_TERM","name":"response to glial cell derived neurotrophic factor","canonical_id":"go:GO:1990790","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glial cell derived neurotrophic factor stimulus.\" [PMID:20877310]","metadata":null},{"id":"8627f4a5cb5e4825bad5f4da981bfefe","type":"GO_TERM","name":"response to glucagon","canonical_id":"go:GO:0033762","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucagon stimulus.\" [GOC:sl]","metadata":null},{"id":"9345c43a235d4df19bf53a1919375f5f","type":"GO_TERM","name":"response to glucocorticoid","canonical_id":"go:GO:0051384","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucocorticoid stimulus. Glucocorticoids are hormonal C21 corticosteroids synthesized from cholesterol with the ability to bind with the cortisol receptor and trigger similar effects. Glucocorticoids act primarily on carbohydrate and protein metabolism, and have anti-inflammatory effects.\" [GOC:ai, PMID:9884123]","metadata":null},{"id":"a50725b1ace04425b5c4cf636208e5b5","type":"GO_TERM","name":"response to glucose","canonical_id":"go:GO:0009749","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucose stimulus.\" [GOC:jl]","metadata":null},{"id":"fde2ed699bdf445c9b3aedc978967447","type":"GO_TERM","name":"response to glucoside","canonical_id":"go:GO:1904631","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucoside stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16842873]","metadata":null},{"id":"45cd27145c0647809b14c6f042b03b7c","type":"GO_TERM","name":"response to glutathione","canonical_id":"go:GO:1901370","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glutathione stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"69ac5343e33d4943a4efff033703ee21","type":"GO_TERM","name":"response to glyceraldehyde","canonical_id":"go:GO:1905630","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glyceraldehyde stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:11377826]","metadata":null},{"id":"58ac859ec53b40f285dcdad4a59b060a","type":"GO_TERM","name":"response to glycine","canonical_id":"go:GO:1905429","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glycine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18984164]","metadata":null},{"id":"600d4f5f391e42eca2ffdfee2c63782e","type":"GO_TERM","name":"response to glycoprotein","canonical_id":"go:GO:1904587","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glycoprotein stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:14597422]","metadata":null},{"id":"b6694baaa8a8489fa87be7ed7cbc3fa5","type":"GO_TERM","name":"response to glycoside","canonical_id":"go:GO:1903416","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glycoside stimulus.\" [GO_REF:0000071, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:12027881, PMID:16243970]","metadata":null},{"id":"f47694285c5948ddb5246e5495cf12fd","type":"GO_TERM","name":"response to gold nanoparticle","canonical_id":"go:GO:1990268","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gold nanoparticle stimulus.\" [PMID:23150627]","metadata":null},{"id":"ccaa0f46af2a42cd9b8209568cebb15b","type":"GO_TERM","name":"response to gold(3+)","canonical_id":"go:GO:1904311","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gold(3+) stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16206274]","metadata":null},{"id":"ccb6f8f19bb84a45be65c7fa9f5dcd4a","type":"GO_TERM","name":"response to gonadotropin","canonical_id":"go:GO:0034698","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gonadotropin stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"827ca9b20b4b4f82850be75ee93fdd74","type":"GO_TERM","name":"response to gonadotropin-releasing hormone","canonical_id":"go:GO:0097210","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gonadotropin-releasing hormone stimulus. Gonadotropin-releasing hormone (GnRH) is a peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released by the hypothalamus.\" [GOC:yaf, PMID:15976007]","metadata":null},{"id":"00496e45b1674332846f041d50a8ad7b","type":"GO_TERM","name":"response to granulocyte colony-stimulating factor","canonical_id":"go:GO:1990638","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a granulocyte colony-stimulating factor stimulus.\" [PMID:9488469]","metadata":null},{"id":"34ba61130808433da24b968fd516d19b","type":"GO_TERM","name":"response to granulocyte macrophage colony-stimulating factor","canonical_id":"go:GO:0097012","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a granulocyte macrophage colony-stimulating factor stimulus.\" [GOC:pr]","metadata":null},{"id":"7798f613fc2f4369a9d022578905969b","type":"GO_TERM","name":"response to gravity","canonical_id":"go:GO:0009629","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gravitational stimulus.\" [GOC:hb]","metadata":null},{"id":"8299fcc5d66a4dfa8e0b7488c10e69b6","type":"GO_TERM","name":"response to growth factor","canonical_id":"go:GO:0070848","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b8ed4000e8334359a5dbd1f734af28d8","type":"GO_TERM","name":"response to growth hormone","canonical_id":"go:GO:0060416","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth hormone stimulus. Growth hormone is a peptide hormone that binds to the growth hormone receptor and stimulates growth.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"24d427cd8bf749e5b75473e368306374","type":"DISEASE","name":"response to growth hormone","canonical_id":"efo:0010969","description":null,"metadata":null},{"id":"3a57188ad50a4b41b5d38027556f7c07","type":"GO_TERM","name":"response to growth hormone-releasing hormone","canonical_id":"go:GO:1990864","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth hormone-releasing hormone stimulus. Growth hormone-releasing hormone regulates the release of growth hormone, as well as some pancreatic proteins, and possibly other proteins.\" [PMID:7720628]","metadata":null},{"id":"846b3cc6cec441a8bbae4953b994bb0a","type":"GO_TERM","name":"response to haloperidol","canonical_id":"go:GO:1905119","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a haloperidol stimulus.\" [GO_REF:0000071, GOC:dw, GOC:TermGenie, PMID:24751813]","metadata":null},{"id":"c097bb960ac34dfa9110c3c1a2673a43","type":"GO_TERM","name":"response to heat","canonical_id":"go:GO:0009408","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heat stimulus, a temperature stimulus above the optimal temperature for that organism.\" [GOC:lr]","metadata":null},{"id":"5d1485c865974a649ceacfffd50aef2c","type":"GO_TERM","name":"response to heparin","canonical_id":"go:GO:0071503","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heparin stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"0b6d1a613ee94d61bad5b19a78eeffed","type":"GO_TERM","name":"response to hepatocyte growth factor","canonical_id":"go:GO:0035728","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hepatocyte growth factor stimulus.\" [GOC:bf]","metadata":null},{"id":"750fdd9a98fc4479871c5eb9bc2c3afe","type":"GO_TERM","name":"response to herbicide","canonical_id":"go:GO:0009635","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a herbicide stimulus. Herbicides are chemicals used to kill or control the growth of plants.\" [GOC:curators]","metadata":null},{"id":"3b3fe05b32e142f8a3088bf90292e075","type":"GO_TERM","name":"response to herbivore","canonical_id":"go:GO:0080027","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a herbivore.\" [PMID:18987211]","metadata":null},{"id":"362b551cf7104c55a722feb19a2975e7","type":"GO_TERM","name":"response to hermaphrodite contact","canonical_id":"go:GO:0034606","description":"\"The response by the male to a hermaphrodite after initial contact following mate finding. The male stops forward locomotion, presses the ventral side of his tail against his partner's body, and begins moving backward along the hermaphrodite. Male response behavior is initiated when sensory neurons located in the rays of his tail contact a potential mate.\" [PMID:18050467, WB_REF:WBPaper00002109]","metadata":null},{"id":"dbe1d74765a845d68c83daea6e56bbf5","type":"GO_TERM","name":"response to hesperadin","canonical_id":"go:GO:1901595","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hesperadin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"b5ca20c115de4389b21c017011a878ea","type":"GO_TERM","name":"response to hexane","canonical_id":"go:GO:1901499","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hexane stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"887df2e512c2411f81cc5f34d2f5a6c7","type":"GO_TERM","name":"response to hexose","canonical_id":"go:GO:0009746","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hexose stimulus.\" [GOC:jl]","metadata":null},{"id":"0e48db9c56d2440db187112717ea6b2f","type":"GO_TERM","name":"response to high fluence blue light stimulus by blue high-fluence system","canonical_id":"go:GO:0055121","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the detection of a high fluence blue light stimulus by the blue high-fluence system. Blue light is electromagnetic radiation with a wavelength of between 440 and 500nm. The blue high-fluence system responds to blue light at levels between 100 and 1000 micromols/m2.\" [GOC:mtg_far_red]","metadata":null},{"id":"7700961f3c4749edbd202d48c4c9ab07","type":"GO_TERM","name":"response to high light intensity","canonical_id":"go:GO:0009644","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a high light intensity stimulus.\" [GOC:curators]","metadata":null},{"id":"36293cf8d5bd4e678577bf35fd023484","type":"GO_TERM","name":"response to high population density","canonical_id":"go:GO:0090664","description":"\"Any process that results in a change in state or activity of a cell or a multicellular organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a higher than normal number of multicellular organisms living per unit area.\" [GOC:mr, PMID:26439857]","metadata":null},{"id":"48b25b8d565e4bbdaf94ac12a58b3e2b","type":"GO_TERM","name":"response to histamine","canonical_id":"go:GO:0034776","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a histamine stimulus. Histamine, the biogenic amine 2-(1H-imidazol-4-yl)ethanamine, is involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.\" [GOC:BHF, GOC:mah, GOC:vk]","metadata":null},{"id":"e936266a76164672a6bc9d41e5be673d","type":"GO_TERM","name":"response to histidine","canonical_id":"go:GO:0080052","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a histidine stimulus.\" [PMID:15889294]","metadata":null},{"id":"224eba6156eb47e4873bd4f997948833","type":"GO_TERM","name":"response to homocysteine","canonical_id":"go:GO:1905374","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a homocysteine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26722473]","metadata":null},{"id":"62416b6814884ab58c829a0e6a375937","type":"GO_TERM","name":"response to hormone","canonical_id":"go:GO:0009725","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus.\" [GOC:jl]","metadata":null},{"id":"324a7ba5cd644a2dbc13dc009268301f","type":"GO_TERM","name":"response to host","canonical_id":"go:GO:0075136","description":"\"Any process that results in a change in state or activity of the symbiont or its cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detecting molecules of its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"eb556d31fd4849b5a85d705cf0b784bf","type":"GO_TERM","name":"response to host immune response","canonical_id":"go:GO:0052572","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detecting the immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"86a398e12bdb49bb9e95779aae2a6820","type":"GO_TERM","name":"response to host iron concentration","canonical_id":"go:GO:0075139","description":"\"Any process that results in a change in state or activity of the symbiont or its cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detecting iron concentration in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"73724bfcd9d94e2f9bb63aa29e445c5f","type":"GO_TERM","name":"response to host osmotic environment","canonical_id":"go:GO:0075000","description":"\"Any process that results in a change in state or activity of the symbiont or its cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the osmotic conditions in or around its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"69020d58826543bf9f408fa962bd718f","type":"GO_TERM","name":"response to host oxygen tension environment","canonical_id":"go:GO:0075138","description":"\"Any process that results in a change in state or activity of the symbiont or its cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detecting oxygen tension in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"da31f245e3a14cfc9aeebb5b552adb97","type":"GO_TERM","name":"response to host pH environment","canonical_id":"go:GO:0075293","description":"\"Any process that results in a change in state or activity of the symbiont or its cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the pH conditions in or around its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"266bf1432f924457bbfd2a8e36a57259","type":"GO_TERM","name":"response to host redox environment","canonical_id":"go:GO:0075137","description":"\"Any process that results in a change in state or activity of the symbiont organism or its cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detecting the redox environment in host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"941152068b5a45e596ed540d63999fce","type":"GO_TERM","name":"response to human chorionic gonadotropin","canonical_id":"go:GO:0044752","description":"\"Any process that results in a change in state or activity of a cell or organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a human chorionic gonadotropin stimulus.\" [PMID:21325635]","metadata":null},{"id":"f4d7cbf8336b449ba74a461ad54fb7e6","type":"GO_TERM","name":"response to humidity","canonical_id":"go:GO:0009270","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a humidity stimulus, moisture in the atmosphere.\" [GOC:jl]","metadata":null},{"id":"109ea451749642878c08b7c00a12fe0d","type":"GO_TERM","name":"response to hydrogen peroxide","canonical_id":"go:GO:0042542","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus.\" [GOC:jl]","metadata":null},{"id":"90b2ece35d47485f937d038c598c2384","type":"GO_TERM","name":"response to hydrogen sulfide","canonical_id":"go:GO:1904880","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen sulfide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24012591]","metadata":null},{"id":"b9837fe314524f9d867c9d238a00bc63","type":"GO_TERM","name":"response to hydroperoxide","canonical_id":"go:GO:0033194","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroperoxide stimulus. Hydroperoxides are monosubstitution products of hydrogen peroxide, HOOH.\" [GOC:mah]","metadata":null},{"id":"87c10ec6d6e74f02a7c62cd83cb12ec5","type":"GO_TERM","name":"response to hydrostatic pressure","canonical_id":"go:GO:0051599","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrostatic pressure stimulus. Hydrostatic pressure is the force acting on an object in a system where the fluid is at rest (as opposed to moving). The weight of the fluid above the object creates pressure on it.\" [Wikipedia:Hydrostatic_pressure]","metadata":null},{"id":"ba42cfdec1804cc69f4b7345f439cceb","type":"GO_TERM","name":"response to hydroxyisoflavone","canonical_id":"go:GO:0033594","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroxyisoflavone stimulus.\" [GOC:mah]","metadata":null},{"id":"a82763c930a342d193f6b3fd0333332a","type":"GO_TERM","name":"response to hydroxyurea","canonical_id":"go:GO:0072710","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydroxyurea stimulus.\" [GOC:mah]","metadata":null},{"id":"21eb261c8dcb4cb585dda459f64b592c","type":"GO_TERM","name":"response to hyperoxia","canonical_id":"go:GO:0055093","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating increased oxygen tension.\" [GOC:kmv]","metadata":null},{"id":"54b7630894224a6ca1ed2e6f7b417ef0","type":"GO_TERM","name":"response to hypobaric hypoxia","canonical_id":"go:GO:1990910","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension combined with low atmospheric pressure. Hypoxia is defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95% and hypobaric is defined as atmospheric pressure below 0.74 atm (greater than 2,500 m above sea level).\" [PMID:24590457]","metadata":null},{"id":"2c35228d8ff04a63836732b00084d3b6","type":"GO_TERM","name":"response to hypochlorite","canonical_id":"go:GO:1901530","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hypochlorite stimulus.\" [GOC:pr, GOC:TermGenie, PMID:22223481]","metadata":null},{"id":"c0a78bc33f784890b3e7a42db7329722","type":"GO_TERM","name":"response to hypoxia","canonical_id":"go:GO:0001666","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.\" [GOC:hjd]","metadata":null},{"id":"7fe79ff080e3476585237e93071d8168","type":"GO_TERM","name":"response to iloperidone","canonical_id":"go:GO:0036287","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iloperidone stimulus.\" [GOC:hp]","metadata":null},{"id":"f494411abed04b5f8dab17ee13c286d4","type":"GO_TERM","name":"response to imidacloprid","canonical_id":"go:GO:1902351","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an imidacloprid stimulus.\" [GOC:kmv, GOC:TermGenie, PMID:23922869]","metadata":null},{"id":"87d06936e91a4636b61ed0d0243f638b","type":"GO_TERM","name":"response to immobilization stress","canonical_id":"go:GO:0035902","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of being rendered immobile.\" [GOC:bf, PMID:17683801, PMID:19893991]","metadata":null},{"id":"fb1ab1c866b04b75937f60b1e45818b4","type":"GO_TERM","name":"response to immobilization stress combined with electrical stimulus","canonical_id":"go:GO:1990781","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus given while being held immobile.\" [PMID:17008368]","metadata":null},{"id":"4cd9b7e1d5ea4d4ebbf336594faba575","type":"GO_TERM","name":"response to inactivity","canonical_id":"go:GO:0014854","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inactivity stimulus.\" [GOC:mtg_muscle]","metadata":null},{"id":"84581c1371b74c73bd434364cef37d85","type":"GO_TERM","name":"response to increased oxygen levels","canonical_id":"go:GO:0036296","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting an increase in the level of oxygen.\" [GOC:al]","metadata":null},{"id":"ebf405cf8ff949eb961049279be75b42","type":"GO_TERM","name":"response to indole-3-methanol","canonical_id":"go:GO:0071680","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an indole-3-methanol stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"4770d65315524ddeb0d4794b5c34f0c5","type":"GO_TERM","name":"response to indolebutyric acid","canonical_id":"go:GO:0080026","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an indolebutyric acid stimulus.\" [PMID:18725356]","metadata":null},{"id":"2609c667bb114975a130658354eb71cf","type":"GO_TERM","name":"response to injury involved in regulation of muscle adaptation","canonical_id":"go:GO:0014876","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a injury. This process occurs as part of the regulation of muscle adaptation.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"2913c9a156d74e7da34cfc764f7613ee","type":"GO_TERM","name":"response to inositol","canonical_id":"go:GO:1902140","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inositol stimulus.\" [GOC:TermGenie, PMID:16496115]","metadata":null},{"id":"cabe660eb30b4aa8911a34c5173654b0","type":"GO_TERM","name":"response to insect","canonical_id":"go:GO:0009625","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from an insect.\" [GOC:hb]","metadata":null},{"id":"73946e6b67b6404d944a414004821e2e","type":"GO_TERM","name":"response to insecticide","canonical_id":"go:GO:0017085","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insecticide stimulus. Insecticides are chemicals used to kill insects.\" [GOC:curators]","metadata":null},{"id":"ffc8a287d7ae424594a951ada22b938f","type":"GO_TERM","name":"response to insulin","canonical_id":"go:GO:0032868","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"c91a0d2e98b74e2abfcac49e5c25a8c7","type":"GO_TERM","name":"response to insulin-like growth factor stimulus","canonical_id":"go:GO:1990418","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin-like growth factor stimulus.\" [PMID:21932665]","metadata":null},{"id":"13635f0013b444b89001ed83ba8c394d","type":"GO_TERM","name":"response to interferon-alpha","canonical_id":"go:GO:0035455","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-alpha stimulus. Interferon-alpha is a type I interferon.\" [GOC:sl, PMID:11356686]","metadata":null},{"id":"70e3001bca444e5cae8f36925d47bfb6","type":"GO_TERM","name":"response to interferon-beta","canonical_id":"go:GO:0035456","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-beta stimulus. Interferon-beta is a type I interferon.\" [GOC:sl, PMID:9561374]","metadata":null},{"id":"88b8b0e506194b27987861e9b12cb007","type":"GO_TERM","name":"response to interleukin-1","canonical_id":"go:GO:0070555","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"988a543867f842a0a5256219b65f1768","type":"GO_TERM","name":"response to interleukin-11","canonical_id":"go:GO:0071105","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-11 stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"13f74bcc827c4a70be3a1c12348e2387","type":"GO_TERM","name":"response to interleukin-12","canonical_id":"go:GO:0070671","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-12 stimulus.\" [GOC:mah]","metadata":null},{"id":"94d690d25e854683ae703f350ba32ecf","type":"GO_TERM","name":"response to interleukin-13","canonical_id":"go:GO:0035962","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-13 stimulus.\" [GOC:sjw, PMID:20100461]","metadata":null},{"id":"13c4076946be4482853ce1647f080901","type":"GO_TERM","name":"response to interleukin-15","canonical_id":"go:GO:0070672","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-15 stimulus.\" [GOC:mah]","metadata":null},{"id":"1f753b4768b04712b81bab27847c4e31","type":"GO_TERM","name":"response to interleukin-17","canonical_id":"go:GO:0097396","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-17 stimulus.\" [GOC:pr]","metadata":null},{"id":"30150b10c8bc4397a72ef5cdf8d176ba","type":"GO_TERM","name":"response to interleukin-18","canonical_id":"go:GO:0070673","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-18 stimulus.\" [GOC:mah]","metadata":null},{"id":"59a2d3fb607b4752866a1af4f11fc407","type":"GO_TERM","name":"response to interleukin-2","canonical_id":"go:GO:0070669","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-2 stimulus.\" [GOC:mah]","metadata":null},{"id":"7060da58fcfb42b2a38d1f5a182fe532","type":"GO_TERM","name":"response to interleukin-21","canonical_id":"go:GO:0098756","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-21 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"0ae41ac720034ffd9fd547b05103ba6b","type":"GO_TERM","name":"response to interleukin-3","canonical_id":"go:GO:0036015","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-3 stimulus.\" [GOC:yaf]","metadata":null},{"id":"13eac852018d4e53ae34e84cc868e675","type":"GO_TERM","name":"response to interleukin-32","canonical_id":"go:GO:0097395","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-32 stimulus.\" [GOC:pr]","metadata":null},{"id":"2ba2e38b2f6b480f8d8d850cdcebb80e","type":"GO_TERM","name":"response to interleukin-4","canonical_id":"go:GO:0070670","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus.\" [GOC:mah]","metadata":null},{"id":"903cb0da04434fcfb98dae221c58fc71","type":"GO_TERM","name":"response to interleukin-6","canonical_id":"go:GO:0070741","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-6 stimulus.\" [GOC:mah]","metadata":null},{"id":"7467fe21a23544cba30650dbd3e4a453","type":"GO_TERM","name":"response to interleukin-7","canonical_id":"go:GO:0098760","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-7 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"c2c488e7bdb445d6a7c667f8eef3ce9b","type":"GO_TERM","name":"response to interleukin-8","canonical_id":"go:GO:0098758","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-8 stimulus.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"e49524ba265840638337c1a1eb8bc624","type":"GO_TERM","name":"response to interleukin-9","canonical_id":"go:GO:0071104","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-9 stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"317f16d5bc3441f29098acd9187b7cee","type":"GO_TERM","name":"response to intra-S DNA damage checkpoint signaling","canonical_id":"go:GO:0072429","description":"\"A process that occurs in response to signals generated as a result of intra-S DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"00f1927955424e649e9b85bbfa7a23b6","type":"GO_TERM","name":"response to ionizing radiation","canonical_id":"go:GO:0010212","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays.\" [PMID:12509526]","metadata":null},{"id":"d3873ecf908948a1bc0664eebf07c946","type":"GO_TERM","name":"response to ionomycin","canonical_id":"go:GO:1904636","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ionomycin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17516843]","metadata":null},{"id":"4b8a92f049b3481d946e8051a81c209c","type":"GO_TERM","name":"response to irinotecan","canonical_id":"go:GO:0061482","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an irinotecan stimulus.\" [GOC:dph]","metadata":null},{"id":"7efad7084b644681b2f6a75e2b03bcb6","type":"GO_TERM","name":"response to iron ion","canonical_id":"go:GO:0010039","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron ion stimulus.\" [GOC:sm]","metadata":null},{"id":"59f77d9780374248bd76705151a1085d","type":"GO_TERM","name":"response to iron ion starvation","canonical_id":"go:GO:1990641","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of iron ion.\" [PMID:16208485]","metadata":null},{"id":"2e41bce9b83c45f4919a3afb3b4a023b","type":"GO_TERM","name":"response to iron(II) ion","canonical_id":"go:GO:0010040","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(II) ion stimulus.\" [GOC:sm]","metadata":null},{"id":"6fcc9c4b80c94be88c6d7cc3222091d5","type":"GO_TERM","name":"response to iron(III) ion","canonical_id":"go:GO:0010041","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(III) ion stimulus.\" [GOC:sm]","metadata":null},{"id":"ef78ea9d8bb441408454559e36385f29","type":"GO_TERM","name":"response to ischemia","canonical_id":"go:GO:0002931","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a inadequate blood supply.\" [GOC:hjd]","metadata":null},{"id":"771f45f82cbb432e82c86a36226e5b2d","type":"GO_TERM","name":"response to isobutanol","canonical_id":"go:GO:1902665","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an isobutanol stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:24014527]","metadata":null},{"id":"e0b89ecf97f645969b26b8e7af0fa66f","type":"GO_TERM","name":"response to isolation stress","canonical_id":"go:GO:0035900","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lack of contact with other members of the same species.\" [GOC:bf, PMID:20203532]","metadata":null},{"id":"8f727e7369f444679a4ca87d2606231f","type":"GO_TERM","name":"response to isooctane","canonical_id":"go:GO:1902788","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an isooctane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:22328008]","metadata":null},{"id":"bc9830830b034997b5e099f42fbea69e","type":"GO_TERM","name":"response to isoquinoline alkaloid","canonical_id":"go:GO:0014072","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an isoquinoline alkaloid stimulus. An isoquinoline alkaloid is any member of a group of compounds with the heterocyclic ring structure of benzo(c)pyridine which is a structure characteristic of the group of opium alkaloids.\" [GOC:ef]","metadata":null},{"id":"f5b97a888c3842018c264463af9f498b","type":"GO_TERM","name":"response to jasmonic acid","canonical_id":"go:GO:0009753","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a jasmonic acid stimulus.\" [GOC:jl]","metadata":null},{"id":"72e1ea6dd2674686836ad3ab5a386b63","type":"GO_TERM","name":"response to jasmonic acid stimulus involved in jasmonic acid and ethylene-dependent systemic resistance","canonical_id":"go:GO:0032260","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a jasmonic acid stimulus received in the context of the jasmonic acid- and ethylene (ethene)-dependent process that confers broad spectrum systemic resistance to disease in response to wounding or a pathogen.\" [GOC:mah]","metadata":null},{"id":"3ec7f400ae0540e3b5eed3842d4d64cb","type":"GO_TERM","name":"response to kainic acid","canonical_id":"go:GO:1904373","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a kainic acid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17443789]","metadata":null},{"id":"583bc35d8299486db51e6b8ef0640ce6","type":"GO_TERM","name":"response to karrikin","canonical_id":"go:GO:0080167","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a karrikin stimulus. Karrikins are signaling molecules in smoke from burning vegetation that trigger seed germination for many angiosperms (flowering plants).\" [PMID:20351290]","metadata":null},{"id":"1adec7f59f7341efb2b2f6a3f51394e8","type":"GO_TERM","name":"response to ketamine","canonical_id":"go:GO:1901986","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ketamine stimulus.\" [GOC:TermGenie, PMID:11251190]","metadata":null},{"id":"c754ba3b98834ff9bb691c88d429df23","type":"GO_TERM","name":"response to ketone","canonical_id":"go:GO:1901654","description":"\"A response that results in a state of tolerance to ketone.\" [GOC:mengo_curators, PMID:23356676]","metadata":null},{"id":"9a11732766ee443cabd53537eb28ca18","type":"GO_TERM","name":"response to laminar fluid shear stress","canonical_id":"go:GO:0034616","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a laminar fluid shear stress stimulus. Laminar fluid flow is the force acting on an object in a system where the fluid is moving across a solid surface in parallel layers. As an example, laminar shear stress can be seen where blood flows against the luminal side of blood vessel walls.\" [GOC:ecd]","metadata":null},{"id":"11aad850ae2d445dace6ccc19fefbd09","type":"GO_TERM","name":"response to lapatinib","canonical_id":"go:GO:0036274","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lapatinib stimulus.\" [GOC:hp]","metadata":null},{"id":"b53971c06a7f488b94c301bd50c526f9","type":"GO_TERM","name":"response to lead ion","canonical_id":"go:GO:0010288","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lead ion stimulus.\" [GOC:tair_curators, PMID:16461380]","metadata":null},{"id":"e02aa5e675044aa39e5d2224752c401c","type":"GO_TERM","name":"response to lectin","canonical_id":"go:GO:1990840","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lectin stimulus. A lectin is a carbohydrate-binding protein, highly specific for binding sugar moieties.\" [PMID:25996210, PMID:26306444]","metadata":null},{"id":"2ab352914e1c424580b91c25bd64bc29","type":"GO_TERM","name":"response to leptin","canonical_id":"go:GO:0044321","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leptin stimulus. Leptin is a hormone manufactured primarily in the adipocytes of white adipose tissue, and the level of circulating leptin is directly proportional to the total amount of fat in the body. It plays a key role in regulating energy intake and energy expenditure, including appetite and metabolism].\" [GOC:yaf]","metadata":null},{"id":"f9c8a2cca41a4c94b4bc4a50263c030c","type":"GO_TERM","name":"response to leptomycin B","canonical_id":"go:GO:1901344","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leptomycin B stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"64c88a95e4884b3ca6e4d47353ac0318","type":"GO_TERM","name":"response to leukemia inhibitory factor","canonical_id":"go:GO:1990823","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukemia inhibitory factor stimulus.\" [PMID:12801913]","metadata":null},{"id":"c144e0a489374a46aa9e9f9028fd54b0","type":"GO_TERM","name":"response to leukotriene B4","canonical_id":"go:GO:1905389","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukotriene B4 stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:14656734]","metadata":null},{"id":"d20d9f9899d74306867fa1240c815e07","type":"GO_TERM","name":"response to light intensity","canonical_id":"go:GO:0009642","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a light intensity stimulus.\" [GOC:curators]","metadata":null},{"id":"0c4bf9d3d39c4a94b414adecbcb91ba2","type":"GO_TERM","name":"response to light stimulus","canonical_id":"go:GO:0009416","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a light stimulus, electromagnetic radiation of wavelengths classified as infrared, visible or ultraviolet light.\" [GOC:curators, ISBN:0582227089]","metadata":null},{"id":"1027d04cf8414f74a35c10ebe87f0cf4","type":"GO_TERM","name":"response to linoleic acid","canonical_id":"go:GO:0070543","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a linoleic acid stimulus.\" [GOC:lp]","metadata":null},{"id":"5571e5315e6c4712ad37c56b5315ecbb","type":"GO_TERM","name":"response to lipid","canonical_id":"go:GO:0033993","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid stimulus.\" [GOC:sl]","metadata":null},{"id":"71f6462cf00a4f8eaa5fa8b0d0b46b53","type":"GO_TERM","name":"response to lipid hydroperoxide","canonical_id":"go:GO:0006982","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid hydroperoxide stimulus. Lipid hydroperoxide is the highly reactive primary oxygenated products of polyunsaturated fatty acids.\" [GOC:jl, PMID:10944149]","metadata":null},{"id":"c6d14f078d9144e3ad40a866ae9fe65d","type":"GO_TERM","name":"response to lipoic acid","canonical_id":"go:GO:1903442","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoic acid stimulus.\" [GO_REF:0000071, GOC:sl, GOC:TermGenie, PMID:23232760]","metadata":null},{"id":"86c377b1dd0c4d59a6932c29ee48078e","type":"GO_TERM","name":"response to lipopolysaccharide","canonical_id":"go:GO:0032496","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.\" [GOC:add, ISBN:0721601464]","metadata":null},{"id":"ac971cc3864b4df6922f92e1328fc92d","type":"GO_TERM","name":"response to lipoprotein particle","canonical_id":"go:GO:0055094","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoprotein particle stimulus.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"2a6cd05f5cdc43ecbb2bf396fffa535b","type":"GO_TERM","name":"response to lipoteichoic acid","canonical_id":"go:GO:0070391","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoteichoic acid stimulus; lipoteichoic acid is a major component of the cell wall of gram-positive bacteria and typically consists of a chain of glycerol-phosphate repeating units linked to a glycolipid anchor.\" [GOC:add, PMID:14665680, PMID:16020688]","metadata":null},{"id":"ff446344fec44b25bce08bac37910d6d","type":"GO_TERM","name":"response to lithium ion","canonical_id":"go:GO:0010226","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lithium (Li+) ion stimulus.\" [GOC:tb]","metadata":null},{"id":"c7e1270658704c9095fd9e7a199af1c3","type":"GO_TERM","name":"response to low fluence blue light stimulus by blue low-fluence system","canonical_id":"go:GO:0010244","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the detection of a low fluence blue light stimulus by the blue low-fluence system. Blue light is electromagnetic radiation with a wavelength of between 440 and 500nm. The blue low-fluence system responds to blue light at or below 0.1 micromols/m2. In certain species excitation of the blue low fluence system induces the transcription of a number of nuclear and plastid coded genes.\" [GOC:mtg_far_red, PMID:10398709]","metadata":null},{"id":"bc84b567012a4967a897ca718eb0e949","type":"GO_TERM","name":"response to low fluence red light stimulus","canonical_id":"go:GO:0010202","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a low fluence red light stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm. Low fluence red light is defined in this case as short pulses of red light followed by darkness, providing a light level of 0.001-0.1 mmol/m2/sec.\" [GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"ac965fb075874ce98879cfd3e713e08c","type":"GO_TERM","name":"response to low humidity","canonical_id":"go:GO:0090547","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of low humidity stimulus, reduced moisture in the atmosphere.\" [GOC:tb]","metadata":null},{"id":"39495309b06b44e186ae63505606eaf0","type":"GO_TERM","name":"response to low light intensity stimulus","canonical_id":"go:GO:0009645","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a low light intensity stimulus. Low light intensity is defined as a level of electromagnetic radiation at or below 0.1 micromols/m2.\" [GOC:curators, GOC:mtg_far_red]","metadata":null},{"id":"cc1a412ee31741d3bf2bbeed6d8d9414","type":"GO_TERM","name":"response to luteinizing hormone","canonical_id":"go:GO:0034699","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a luteinizing hormone stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"8440ff692ce74c27ad5aae582e8f3760","type":"GO_TERM","name":"response to macrophage colony-stimulating factor","canonical_id":"go:GO:0036005","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a macrophage colony-stimulating factor stimulus.\" [GOC:yaf, PMID:14687666]","metadata":null},{"id":"ed8d160dc37b4abe97ec77fd960488d4","type":"GO_TERM","name":"response to magnesium ion","canonical_id":"go:GO:0032026","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnesium ion stimulus.\" [GOC:mah]","metadata":null},{"id":"0570435ae2284acab55ee32b1795e917","type":"GO_TERM","name":"response to magnetism","canonical_id":"go:GO:0071000","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnetic stimulus.\" [GOC:sl]","metadata":null},{"id":"ce30293d50a54ce395968c36bc636389","type":"GO_TERM","name":"response to maltose","canonical_id":"go:GO:0034286","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a maltose stimulus.\" [GOC:sart]","metadata":null},{"id":"bf8402fe764642d1bac4f6daa5eccf00","type":"GO_TERM","name":"response to manganese ion","canonical_id":"go:GO:0010042","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a manganese ion stimulus.\" [GOC:sm]","metadata":null},{"id":"7be3fc009c9d4f2caacb4b4f6375d6bb","type":"GO_TERM","name":"response to manganese ion starvation","canonical_id":"go:GO:0090551","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of manganese.\" [GOC:tair_curators]","metadata":null},{"id":"56250358b7764ed48156dd45355fe6ef","type":"GO_TERM","name":"response to manganese-induced endoplasmic reticulum stress","canonical_id":"go:GO:1990737","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of endoplasmic reticulum stress caused by a manganese stimulus.\" [GOC:bf, GOC:PARL, PMID:23934647]","metadata":null},{"id":"c181f78673794549beccdcd29928bd86","type":"GO_TERM","name":"response to mannitol","canonical_id":"go:GO:0010555","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mannitol stimulus.\" [PMID:17999646]","metadata":null},{"id":"00f06d152ccb413592fefc415ab34b6c","type":"GO_TERM","name":"response to mannose","canonical_id":"go:GO:1905582","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mannose stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16699509]","metadata":null},{"id":"b0aa2519119d4dcb8178a029c265eb11","type":"GO_TERM","name":"response to mechanical stimulus","canonical_id":"go:GO:0009612","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus.\" [GOC:hb]","metadata":null},{"id":"3d8e7aad832048a78e4ac44076ab02d4","type":"GO_TERM","name":"response to meiotic DNA replication checkpoint signaling","canonical_id":"go:GO:0072441","description":"\"A process that occurs in response to signals generated as a result of meiotic DNA replication checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"735af40aa80b4e43bd765b1ec0d3cdc2","type":"GO_TERM","name":"response to meiotic cell cycle checkpoint signaling","canonical_id":"go:GO:0072410","description":"\"A process that acts directly to delay or stop progression through the cell cycle in response to signals generated as a result of meiotic cell cycle checkpoint signaling; contributes to a meiotic cell cycle checkpoint.\" [GOC:mah]","metadata":null},{"id":"9c3fc6cde4e24b3db798a04ffd0ac87b","type":"GO_TERM","name":"response to meiotic recombination checkpoint signaling","canonical_id":"go:GO:0072461","description":"\"A process that occurs in response to signals generated as a result of meiotic recombination checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"be218d8ae7604a11979cb2a054fdf0ef","type":"GO_TERM","name":"response to meiotic spindle assembly checkpoint signaling","canonical_id":"go:GO:0072464","description":"\"A process that occurs in response to signals generated as a result of meiotic spindle assembly checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"4b62a52bd255441da09ee5356a8bcc19","type":"GO_TERM","name":"response to melanocyte-stimulating hormone","canonical_id":"go:GO:1990680","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a melanocyte-stimulating hormone stimulus. The binding of any one of three melanocyte-stimulating hormones causes dispersal of melanosomes in melanophores of poikilothermic vertebrates.\" [PMID:17036007]","metadata":null},{"id":"fd40ccd58b0044af881fc2b416477a85","type":"GO_TERM","name":"response to menaquinone","canonical_id":"go:GO:0032572","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a menaquinone (vitamin K2) stimulus.\" [GOC:sl]","metadata":null},{"id":"bc5a5a8d49c44f32845693a7e5fa4ec9","type":"GO_TERM","name":"response to mercaptoethanol","canonical_id":"go:GO:0072704","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mercaptoethanol stimulus.\" [GOC:mah]","metadata":null},{"id":"f8cc0f061a1d40b6b513a76a59a4eef2","type":"GO_TERM","name":"response to mercury ion","canonical_id":"go:GO:0046689","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mercury ion stimulus.\" [GOC:ai]","metadata":null},{"id":"ee86e10a60bb4a62b1b71925f5d8022d","type":"GO_TERM","name":"response to metal ion","canonical_id":"go:GO:0010038","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a metal ion stimulus.\" [GOC:sm]","metadata":null},{"id":"36ada04aabff40019e4bd53aca382cf3","type":"GO_TERM","name":"response to metal ion starvation","canonical_id":"go:GO:0180055","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of some metal ion.\" [PMID:24024382]","metadata":null},{"id":"8937218c65de4e83a8561e8ead01bbe3","type":"GO_TERM","name":"response to metformin","canonical_id":"go:GO:1901558","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a metformin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"d88db4ecbb6d4d04ad40a4b04a9b0cb1","type":"GO_TERM","name":"response to methamphetamine hydrochloride","canonical_id":"go:GO:1904313","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methamphetamine hydrochloride stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22174933]","metadata":null},{"id":"e1c54390b0af4aa2a3b96f183e775753","type":"GO_TERM","name":"response to methanol","canonical_id":"go:GO:0033986","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methanol stimulus.\" [GOC:sl]","metadata":null},{"id":"7582bb07257d4a6699eb79bd42cba12d","type":"GO_TERM","name":"response to methionine","canonical_id":"go:GO:1904640","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methionine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17716000]","metadata":null},{"id":"fc1c849720834029ae9d21ab4aba71ef","type":"GO_TERM","name":"response to methotrexate","canonical_id":"go:GO:0031427","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methotrexate stimulus. Methotrexate is 4-amino-10-methylformic acid, a folic acid analogue that is a potent competitive inhibitor of dihydrofolate reductase.\" [GOC:ef, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"bc9dc7cee27048788b57a12cac3f02c5","type":"GO_TERM","name":"response to methyl methanesulfonate","canonical_id":"go:GO:0072702","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methyl methanesulfonate (MMS) stimulus.\" [GOC:mah]","metadata":null},{"id":"cf3df72c8c474cd88133db96483b1bba","type":"GO_TERM","name":"response to methylamine","canonical_id":"go:GO:0036255","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylamine stimulus.\" [GOC:mah]","metadata":null},{"id":"6cb4272cf9764855a62fa1c4bb7b0bdd","type":"GO_TERM","name":"response to methylglyoxal","canonical_id":"go:GO:0051595","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylglyoxal stimulus. Methylglyoxal is a 2-oxoaldehyde derived from propanal.\" [GOC:ai]","metadata":null},{"id":"51a6422e8fe8487989f8e97a4c2604a2","type":"GO_TERM","name":"response to methylmercury","canonical_id":"go:GO:0051597","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylmercury stimulus.\" [GOC:ai]","metadata":null},{"id":"7aee48be897540deb13512dfa9a609ca","type":"GO_TERM","name":"response to methylphenidate","canonical_id":"go:GO:0036271","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylphenidate stimulus.\" [GOC:hp, Wikipedia:Methylphenidate]","metadata":null},{"id":"9c54392c4b1b4719b24472abc371e7b6","type":"GO_TERM","name":"response to micafungin","canonical_id":"go:GO:1903967","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a micafungin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:16928959]","metadata":null},{"id":"9609701afba94d9e8da9281aa2e61560","type":"GO_TERM","name":"response to miconazole","canonical_id":"go:GO:1905307","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a miconazole stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:26108447]","metadata":null},{"id":"69d3a890997b4e839fd3c1364a290f76","type":"GO_TERM","name":"response to microbial phytotoxin","canonical_id":"go:GO:0010188","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a microbial phytotoxin stimulus. A microbial phytotoxin is a chemical substance produced by microbes which is toxic to plants.\" [GOC:sm]","metadata":null},{"id":"b1eb0c88b6f84edb882a509176f87715","type":"GO_TERM","name":"response to mineralocorticoid","canonical_id":"go:GO:0051385","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mineralocorticoid stimulus. Mineralocorticoids are hormonal C21 corticosteroids synthesized from cholesterol and characterized by their similarity to aldosterone. Mineralocorticoids act primarily on water and electrolyte balance.\" [GOC:ai, PMID:9884123]","metadata":null},{"id":"06d67b3c67c14224922c8f30bd2a1fbc","type":"GO_TERM","name":"response to misfolded protein","canonical_id":"go:GO:0051788","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a misfolded protein stimulus.\" [GOC:curators]","metadata":null},{"id":"ea47d2ffc4cc4758b4879499213156cd","type":"GO_TERM","name":"response to mitochondrial depolarisation","canonical_id":"go:GO:0098780","description":"\"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) in response to the depolarization of one or more mitochondria.\" [GOC:dos]","metadata":null},{"id":"c944d797d6ee4d979c3b088dab75dd54","type":"GO_TERM","name":"response to mitotic DNA integrity checkpoint signaling","canonical_id":"go:GO:1990820","description":"\"A process that occurs in response to signals generated as a result of mitotic DNA integrity checkpoint signaling.\" [PMID:7548844]","metadata":null},{"id":"4fbf3ca982d74e62b66f9222d2b89f92","type":"GO_TERM","name":"response to mitotic DNA replication checkpoint signaling","canonical_id":"go:GO:0072444","description":"\"A process that occurs in response to signals generated as a result of mitotic DNA replication checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"5fdf7f13d4994aa8bf22d7048d7b108f","type":"GO_TERM","name":"response to mitotic G2 DNA damage checkpoint signaling","canonical_id":"go:GO:0072435","description":"\"A process that occurs in response to signals generated as a result of mitotic G2/M transition DNA damage checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"014ccc90068d45cc85ff1ccca34cfd7a","type":"GO_TERM","name":"response to mitotic cell cycle checkpoint signaling","canonical_id":"go:GO:0072414","description":"\"A process that occurs in response to signals generated as a result of mitotic cell cycle checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"125b5893826640b7a81eb9731b516f72","type":"GO_TERM","name":"response to mitotic cell cycle spindle assembly checkpoint signaling","canonical_id":"go:GO:0072479","description":"\"A process that occurs in response to signals generated as a result of mitotic cell cycle spindle assembly checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"4b69dde312494fc3818a5e73280baadb","type":"GO_TERM","name":"response to mitotic cell cycle spindle orientation checkpoint signaling","canonical_id":"go:GO:0072482","description":"\"A process that occurs in response to signals generated as a result of mitotic cell cycle spindle orientation checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"ee9389dd91944c30942554d21956d1bb","type":"GO_TERM","name":"response to mitotic spindle checkpoint signaling","canonical_id":"go:GO:0072476","description":"\"A process that occurs in response to signals generated as a result of mitotic cell cycle spindle checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"6644cd817089470a979b3d459b2d473f","type":"GO_TERM","name":"response to molecule of bacterial origin","canonical_id":"go:GO:0002237","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of bacterial origin such as peptides derived from bacterial flagellin.\" [GOC:rl, GOC:sm]","metadata":null},{"id":"972223cc551f4241ada0b575d3a1084a","type":"GO_TERM","name":"response to molecule of fungal origin","canonical_id":"go:GO:0002238","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of fungal origin such as chito-octamer oligosaccharide.\" [GOC:rl, GOC:sm]","metadata":null},{"id":"41392f52c85b4b908b38024b2742ff72","type":"GO_TERM","name":"response to molecule of oomycetes origin","canonical_id":"go:GO:0002240","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of oomycetes origin.\" [GOC:rl, GOC:sm]","metadata":null},{"id":"82ee3468a0694ffb842d63980270f869","type":"GO_TERM","name":"response to molybdenum starvation","canonical_id":"go:GO:0090550","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of molybdenum.\" [GOC:tair_curators]","metadata":null},{"id":"3f0a8bc401734574a9493419a91eb36f","type":"GO_TERM","name":"response to monoamine","canonical_id":"go:GO:0071867","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a monoamine stimulus. A monoamine is any of a group of molecular messengers that contain one amino group that is connected to an aromatic ring by ethylene group (-CH2-CH2-). Monoamines are derived from the aromatic amino acids phenylalanine, tyrosine, histidine and tryptophan.\" [GOC:mah]","metadata":null},{"id":"10e22ec6bc554c8ba438c095c5a0b564","type":"GO_TERM","name":"response to monosaccharide","canonical_id":"go:GO:0034284","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a monosaccharide stimulus.\" [GOC:mah]","metadata":null},{"id":"efa5be52172c4f5dbbd38f176f370143","type":"GO_TERM","name":"response to morphine","canonical_id":"go:GO:0043278","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a morphine stimulus. Morphine is an opioid alkaloid, isolated from opium, with a complex ring structure.\" [GOC:ef, GOC:jl]","metadata":null},{"id":"93f383064ed84e3db96e4422c472adbc","type":"GO_TERM","name":"response to muramyl dipeptide","canonical_id":"go:GO:0032495","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muramyl dipeptide stimulus. Muramyl dipeptide is derived from peptidoglycan.\" [GOC:add]","metadata":null},{"id":"b27005ae51764df18c270dc1afabeef4","type":"GO_TERM","name":"response to muscle activity","canonical_id":"go:GO:0014850","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muscle activity stimulus.\" [GOC:mtg_muscle]","metadata":null},{"id":"c091818bf2924a7eac9b799a14337736","type":"GO_TERM","name":"response to muscle activity involved in regulation of muscle adaptation","canonical_id":"go:GO:0014873","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muscle activity stimulus. This process occurs as part of the regulation of muscle adaptation.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"189bc52ddd234955ae2d703f5cf24e92","type":"GO_TERM","name":"response to muscle inactivity","canonical_id":"go:GO:0014870","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muscle inactivity stimulus.\" [GOC:mtg_muscle]","metadata":null},{"id":"7f46f8da37384b98aad647f3a79ffbbe","type":"GO_TERM","name":"response to muscle stretch","canonical_id":"go:GO:0035994","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a myofibril being extended beyond its slack length.\" [GOC:BHF, GOC:vk, PMID:14583192]","metadata":null},{"id":"76f241f55a924ea887d9e3bbb36e1ff3","type":"GO_TERM","name":"response to mycophenolic acid","canonical_id":"go:GO:0071505","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mycophenolic acid stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"dac2057f679f4ba7a352457bfc06b416","type":"GO_TERM","name":"response to mycotoxin","canonical_id":"go:GO:0010046","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mycotoxin stimulus. A mycotoxin is a toxic chemical substance produced by fungi.\" [GOC:sm]","metadata":null},{"id":"4e480835630e4c6a808d6f8c339e74fa","type":"GO_TERM","name":"response to nematicide","canonical_id":"go:GO:0093002","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nematicide stimulus. Nematicides are chemicals used to kill nematodes.\" [GOC:kvm, PMID:22301316]","metadata":null},{"id":"0c719fd99adc41deb1745369f590d645","type":"GO_TERM","name":"response to nematode","canonical_id":"go:GO:0009624","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a nematode.\" [GOC:hb]","metadata":null},{"id":"2b9abfd72f674548a549220ac672c484","type":"GO_TERM","name":"response to nerve growth factor","canonical_id":"go:GO:1990089","description":"\"A process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nerve growth factor stimulus.\" [PMID:22399805]","metadata":null},{"id":"7045490a6d5b4d4384a32d4e9f1447d0","type":"GO_TERM","name":"response to neutral pH","canonical_id":"go:GO:0036176","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a neutral pH (pH close to 7) stimulus. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:di, Wikipedia:PH]","metadata":null},{"id":"da18a367e45c4240a56c4314e580294b","type":"GO_TERM","name":"response to nickel cation","canonical_id":"go:GO:0010045","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nickel cation stimulus.\" [GOC:sm]","metadata":null},{"id":"62e0b136a2e54b9081df3c87d6ff1fce","type":"GO_TERM","name":"response to nicotine","canonical_id":"go:GO:0035094","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nicotine stimulus.\" [GOC:bf, GOC:ef, ISBN:0198506732, ISBN:0582227089]","metadata":null},{"id":"6ee12eb5e1d74e42a34fc597381f874a","type":"GO_TERM","name":"response to nitrate","canonical_id":"go:GO:0010167","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrate stimulus.\" [GOC:sm]","metadata":null},{"id":"bcebb71170fd4e86a0e1892e0e5add77","type":"GO_TERM","name":"response to nitrate starvation","canonical_id":"go:GO:0090548","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of nitrate.\" [GOC:tair_curators]","metadata":null},{"id":"007b8cd1388f4c10a90d32472b0b47c0","type":"GO_TERM","name":"response to nitric oxide","canonical_id":"go:GO:0071731","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitric oxide stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"774f350d6d174549b38b147f7a081631","type":"GO_TERM","name":"response to nitrite","canonical_id":"go:GO:0080033","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrite stimulus.\" [GOC:dhl, PMID:17951451]","metadata":null},{"id":"ddaee9a403d842af96193fe78df186bf","type":"GO_TERM","name":"response to nitrogen compound","canonical_id":"go:GO:1901698","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrogen compound stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"cf2680db2c5f48d481f0d016c4f6608a","type":"GO_TERM","name":"response to nitrogen dioxide","canonical_id":"go:GO:0035713","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrogen dioxide (NO2) stimulus.\" [GOC:BHF]","metadata":null},{"id":"19d45a49c8ff4bbeac11674c9a27d558","type":"GO_TERM","name":"response to nitroglycerin","canonical_id":"go:GO:1904842","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitroglycerin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25626975]","metadata":null},{"id":"26f517e4ecd649e397c7dfbf790566d7","type":"GO_TERM","name":"response to nitrosative stress","canonical_id":"go:GO:0051409","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrosative stress stimulus. Nitrosative stress is a state often resulting from exposure to high levels of nitric oxide (NO) or the highly reactive oxidant peroxynitrite, which is produced following interaction of NO with superoxide anions.\" [PMID:15925705]","metadata":null},{"id":"642c616a4e8b490bb73c2612940c473e","type":"GO_TERM","name":"response to nocodazole","canonical_id":"go:GO:1904402","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nocodazole stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:17822405]","metadata":null},{"id":"404588dfccb44f90b4d3ec405f76047d","type":"GO_TERM","name":"response to non-ionic osmotic stress","canonical_id":"go:GO:0010335","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of non-ionic solutes (e.g. mannitol, sorbitol) in the environment.\" [GOC:tair_curators]","metadata":null},{"id":"ada7d342844e49b9972f19b4c557a4d9","type":"GO_TERM","name":"response to nonane","canonical_id":"go:GO:1902780","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nonane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:22958739]","metadata":null},{"id":"42bfc77b8a044689b38471c13b0dbe13","type":"GO_TERM","name":"response to nonylphenol","canonical_id":"go:GO:1904147","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nonylphenol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:19260726]","metadata":null},{"id":"3ef4336ed0314eb391c01105ed039950","type":"GO_TERM","name":"response to norepinephrine","canonical_id":"go:GO:0071873","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a norepinephrine stimulus. Norepinephrine is a catecholamine that has the formula C8H11NO3; it acts as a hormone, and as a neurotransmitter in most of the sympathetic nervous system.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"50689217aba74dce8a66f3a41b349358","type":"GO_TERM","name":"response to nutrient","canonical_id":"go:GO:0007584","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nutrient stimulus.\" [GOC:curators]","metadata":null},{"id":"b5b8d41ae7494463855fe8742ccdb74a","type":"GO_TERM","name":"response to nutrient levels","canonical_id":"go:GO:0031667","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of nutrients.\" [GOC:mah]","metadata":null},{"id":"d56d5c5d3c434e88bae1791863ac18eb","type":"GO_TERM","name":"response to odorant","canonical_id":"go:GO:1990834","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an odorant stimulus. An odorant is any substance capable of stimulating the sense of smell.\" [PMID:11268007]","metadata":null},{"id":"d6281d4aae004957a70779c843e8d77b","type":"GO_TERM","name":"response to olanzapine","canonical_id":"go:GO:0097333","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an olanzapine stimulus.\" [GOC:pr]","metadata":null},{"id":"83f5fd226e9942c4b4a46da603fc7919","type":"GO_TERM","name":"response to oleic acid","canonical_id":"go:GO:0034201","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oleic acid stimulus.\" [GOC:lp]","metadata":null},{"id":"1fdd97ebe7a54685bfdf55375b324487","type":"GO_TERM","name":"response to oomycetes","canonical_id":"go:GO:0002239","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from an oomycetes.\" [GOC:add, PMID:16497589]","metadata":null},{"id":"f53a70a02eab4f2e960d8a946e9fbf24","type":"GO_TERM","name":"response to organophosphorus","canonical_id":"go:GO:0046683","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organophosphorus stimulus. Organophosphorus is a compound containing phosphorus bound to an organic molecule; several organophosphorus compounds are used as insecticides, and they are highly toxic cholinesterase inhibitors.\" [ISBN:0721662544]","metadata":null},{"id":"3485a82e4829464686ba6d9e251adc60","type":"GO_TERM","name":"response to oscillatory fluid shear stress","canonical_id":"go:GO:0097702","description":"\"Any response to fluid shear stress where the fluid is moving across a solid surface with an oscillatory flow. Disturbed flow patterns at the arterial bifurcations and curvatures may cause endothelial dysfunction, which initiates atherosclerosis.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"f0b6942aa5bc42d699d770a59d9ac337","type":"GO_TERM","name":"response to osmotic stress","canonical_id":"go:GO:0006970","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.\" [GOC:jl]","metadata":null},{"id":"7207d6cf51b44a8fa054be1d10b24040","type":"GO_TERM","name":"response to other organism","canonical_id":"go:GO:0051707","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from another living organism.\" [GOC:ai]","metadata":null},{"id":"d662792b1548448ab21050890d755ad0","type":"GO_TERM","name":"response to oxidative stress","canonical_id":"go:GO:0006979","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.\" [GOC:jl, PMID:12115731]","metadata":null},{"id":"38309f5e18c046338e660859db94773f","type":"GO_TERM","name":"response to oxidopamine","canonical_id":"go:GO:1905841","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxidopamine stimulus.\" [GO_REF:0000071, GOC:rz, GOC:TermGenie, PMID:23721876]","metadata":null},{"id":"6cbd261f739a40ea9d40d3d7f09d4233","type":"GO_TERM","name":"response to oxygen levels","canonical_id":"go:GO:0070482","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of oxygen.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"132816bafcc1400bb7114d1d995b246f","type":"GO_TERM","name":"response to oxygen radical","canonical_id":"go:GO:0000305","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxygen radical stimulus. An oxygen radical is any oxygen species that carries a free electron; examples include hydroxyl radicals and the superoxide anion.\" [GOC:krc, ISBN:0124325653]","metadata":null},{"id":"ecdaae90ad344312838c3f2a74f25648","type":"GO_TERM","name":"response to oxygen-containing compound","canonical_id":"go:GO:1901700","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxygen-containing compound stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"68d2603fe691461d85382e1b4e806e16","type":"GO_TERM","name":"response to oxygen-glucose deprivation","canonical_id":"go:GO:0090649","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the deprivation of oxygen and glucose.\" [GOC:sl, PMID:21525936]","metadata":null},{"id":"e89db064ae7a434f8d01a662a46b3061","type":"GO_TERM","name":"response to ozone","canonical_id":"go:GO:0010193","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ozone stimulus.\" [GOC:sm]","metadata":null},{"id":"585620db3f344ed382dcdfb32096b4f8","type":"GO_TERM","name":"response to p-xylene","canonical_id":"go:GO:1901500","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a p-xylene stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"f8cde4f763e84cbf920044b8a7cbe98c","type":"GO_TERM","name":"response to pH","canonical_id":"go:GO:0009268","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus. pH is a measure of the acidity or basicity of an aqueous solution.\" [GOC:jl, Wikipedia:PH]","metadata":null},{"id":"b63ab96662aa47d88393cbc97c54fd42","type":"GO_TERM","name":"response to pain","canonical_id":"go:GO:0048265","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pain stimulus. Pain stimuli cause activation of nociceptors, peripheral receptors for pain, include receptors which are sensitive to painful mechanical stimuli, extreme heat or cold, and chemical stimuli.\" [GOC:jid, PMID:10203867, PMID:12723742, PMID:12843304, Wikipedia:Pain]","metadata":null},{"id":"9a731e3b03054276a642faf63aff649d","type":"GO_TERM","name":"response to palmitoleic acid","canonical_id":"go:GO:1904926","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a palmitoleic acid stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:25429233]","metadata":null},{"id":"f36ae45ce3564c6aaf021eadba627622","type":"GO_TERM","name":"response to papulacandin B","canonical_id":"go:GO:0072730","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a papulacandin B stimulus.\" [GOC:mah]","metadata":null},{"id":"a43aa813dd104b3da9e6c2ab462162d9","type":"GO_TERM","name":"response to paracetamol","canonical_id":"go:GO:1901554","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a paracetamol stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"bdfb2fd38d6c477784f7c0b1e003aa8c","type":"GO_TERM","name":"response to paraquat","canonical_id":"go:GO:1901562","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a paraquat stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"ab71aa85470246b1b2ec628fe2a6997b","type":"GO_TERM","name":"response to parasitic plant","canonical_id":"go:GO:0002241","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a parasitic plant.\" [GOC:add, PMID:16547862]","metadata":null},{"id":"9ba74c7bc7fb46a3ab3280ceae5282be","type":"GO_TERM","name":"response to parathyroid hormone","canonical_id":"go:GO:0071107","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a parathyroid hormone stimulus.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"ddcea48c311949f6aed8921944d3c5ca","type":"GO_TERM","name":"response to peptide","canonical_id":"go:GO:1901652","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptide stimulus.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"86df3c459e754ca294c4f8e1623c5491","type":"GO_TERM","name":"response to peptide hormone","canonical_id":"go:GO:0043434","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptide hormone stimulus. A peptide hormone is any of a class of peptides that are secreted into the blood stream and have endocrine functions in living animals.\" [PMID:11027914, PMID:15134857, Wikipedia:Peptide_hormone]","metadata":null},{"id":"a98c47989f3941969454b0f4ec7e6b55","type":"GO_TERM","name":"response to peptidoglycan","canonical_id":"go:GO:0032494","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptidoglycan stimulus. Peptidoglycan is a bacterial cell wall macromolecule.\" [GOC:add, ISBN:0721601464]","metadata":null},{"id":"43ef2df610204c3f942f99109e47e370","type":"GO_TERM","name":"response to perphenazine","canonical_id":"go:GO:0097334","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a perphenazine stimulus. Perphenazine is a phenothiazine derivative having a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position.\" [GOC:pr]","metadata":null},{"id":"a9be6ab335e84609a82b1cbc0b77a3d1","type":"GO_TERM","name":"response to phenylalanine","canonical_id":"go:GO:0080053","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phenylalanine stimulus.\" [PMID:15889294]","metadata":null},{"id":"f993f0c64aa648248d38a932417bd030","type":"GO_TERM","name":"response to phenylpropanoid","canonical_id":"go:GO:0080184","description":"\"Any process that results in a change in state or activity of a cell or organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as the result of a phenylpropanoid stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism. A phenylpropanoid is any of secondary metabolites with structures based on a phenylpropane skeleton. The class includes phenylpropanoid esters, flavonoids, anthocyanins, coumarins and many small phenolic molecules. Phenylpropanoids are also precursors of lignin.\" [GOC:tb]","metadata":null},{"id":"a6cc39593d6442a2af8fdbd636c5f694","type":"GO_TERM","name":"response to pheromone","canonical_id":"go:GO:0019236","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pheromone stimulus.\" [GOC:jl]","metadata":null},{"id":"15ba8f04a373426cacc8844db2b4aff7","type":"GO_TERM","name":"response to pheromone regulating conjugation with mutual genetic exchange","canonical_id":"go:GO:0000756","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pheromone stimulus regulating the process of conjugation without cellular fusion.\" [GOC:clt]","metadata":null},{"id":"60332acf182146ba9fb6f7c60384428e","type":"GO_TERM","name":"response to pheromone regulating pheromone-induced unidirectional conjugation","canonical_id":"go:GO:0000765","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pheromone stimulus that regulates the process of pheromone-induced unidirectional conjugation.\" [GOC:clt]","metadata":null},{"id":"df383633fc334003bff289cedc651ea1","type":"GO_TERM","name":"response to pheromone triggering conjugation with cellular fusion","canonical_id":"go:GO:0000749","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pheromone stimulus that positively regulates the process of conjugation with cellular fusion. An example of this process is found in Saccharomyces cerevisiae.\" [GOC:clt]","metadata":null},{"id":"6410d6f9d3334e09b460bedd8968b08b","type":"GO_TERM","name":"response to phorbol 13-acetate 12-myristate","canonical_id":"go:GO:1904627","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phorbol 13-acetate 12-myristate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:2200903]","metadata":null},{"id":"711fb62d26684ebe9dcd1f9fded1ed17","type":"GO_TERM","name":"response to phosphatidylethanolamine","canonical_id":"go:GO:1905711","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phosphatidylethanolamine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:1657995]","metadata":null},{"id":"216561ca485d484da5a4d118f8d2edcb","type":"GO_TERM","name":"response to photooxidative stress","canonical_id":"go:GO:0080183","description":"\"Any process that results in a change in state or activity of a cell or organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as the result of a photooxidative stress, the light-dependent generation of active oxygen species. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism.\" [DOI:10.1111/j.1399-3054.1994.tb03042.x]","metadata":null},{"id":"c8de65867fe5438092de6ef4d079b71a","type":"GO_TERM","name":"response to photoperiod, blue light","canonical_id":"go:GO:0009906","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of the detection of a blue light photoperiod stimulus. Blue light is electromagnetic radiation with a wavelength of between 440 and 500nm.\" [GOC:curators, GOC:mtg_far_red]","metadata":null},{"id":"8c0cddf4e4894e8caa959a7192376ed9","type":"GO_TERM","name":"response to photoperiod, red light","canonical_id":"go:GO:0009907","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a red light photoperiod stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm.\" [GOC:curators, GOC:mtg_far_red]","metadata":null},{"id":"0a1d7cf6124a40ddbd9cac89f8fb2048","type":"GO_TERM","name":"response to phylloquinone","canonical_id":"go:GO:0032573","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a phylloquinone (vitamin K1) stimulus.\" [GOC:sl]","metadata":null},{"id":"1ac0f21b8bf148709c58a52f4d5246fc","type":"GO_TERM","name":"response to platelet aggregation inhibitor","canonical_id":"go:GO:0061478","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platelet aggregation inhibitor stimulus.\" [GOC:dph]","metadata":null},{"id":"b49d9875c45f4afb876fe448dd302056","type":"GO_TERM","name":"response to platelet-derived growth factor","canonical_id":"go:GO:0036119","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platelet-derived growth factor stimulus.\" [GOC:yaf]","metadata":null},{"id":"03d7906c20624630ad800f5c286500ec","type":"GO_TERM","name":"response to platinum ion","canonical_id":"go:GO:0070541","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platinum stimulus.\" [GOC:sl]","metadata":null},{"id":"eeb72a63c5294303a7b8bc43d8df85cc","type":"GO_TERM","name":"response to plumbagin","canonical_id":"go:GO:1902708","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a plumbagin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23028742]","metadata":null},{"id":"0e2766ae6e8e426a9c49e9658ca22508","type":"GO_TERM","name":"response to polyamine macromolecule","canonical_id":"go:GO:1904583","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a polyamine macromolecule stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20805360]","metadata":null},{"id":"3843360ea22b4f16ae70c965c7c2f86b","type":"GO_TERM","name":"response to polycyclic arene","canonical_id":"go:GO:1903165","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a polycyclic arene stimulus.\" [GO_REF:0000071, GOC:mr, GOC:TermGenie, PMID:10998501]","metadata":null},{"id":"04bfb9c0ec10492db8c1963da50f4cce","type":"GO_TERM","name":"response to potassium ion","canonical_id":"go:GO:0035864","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a potassium ion stimulus.\" [GOC:yaf]","metadata":null},{"id":"a924b11bd36e4ea49a1a46d7c08cf4f3","type":"GO_TERM","name":"response to progesterone","canonical_id":"go:GO:0032570","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a progesterone stimulus.\" [GOC:sl]","metadata":null},{"id":"46a6a1af3de744d6a1d7249de9267f29","type":"GO_TERM","name":"response to prolactin","canonical_id":"go:GO:1990637","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prolactin stimulus. The anterior pituitary hormone prolactin has a number of roles including being essential for lactation.\" [PMID:7760850]","metadata":null},{"id":"19c770c707004565b1c4c9d6f8fee1ed","type":"GO_TERM","name":"response to proline","canonical_id":"go:GO:0010238","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a proline stimulus.\" [GOC:sm]","metadata":null},{"id":"d5a74942c36c4c3e86ad25f53de28d1e","type":"GO_TERM","name":"response to propan-1-ol","canonical_id":"go:GO:1901427","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a propan-1-ol stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9f3834ed20ab481e9825e594a4b7226a","type":"GO_TERM","name":"response to prostaglandin","canonical_id":"go:GO:0034694","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"7bfa6fb667484cc7a228a11391838697","type":"GO_TERM","name":"response to prostaglandin D","canonical_id":"go:GO:0071798","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin D stimulus.\" [GOC:sl]","metadata":null},{"id":"8844918ea59b4213bd8accca1652f14e","type":"GO_TERM","name":"response to prostaglandin E","canonical_id":"go:GO:0034695","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin E stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"16481dab7c814f28b166379ff71d2255","type":"GO_TERM","name":"response to prostaglandin F","canonical_id":"go:GO:0034696","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin F stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"e2587115be66460086fdd809f3816592","type":"GO_TERM","name":"response to prostaglandin I","canonical_id":"go:GO:0034697","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin I stimulus.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"211ae50a0960482092666a0f09a970e2","type":"GO_TERM","name":"response to protozoan","canonical_id":"go:GO:0001562","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a protozoan.\" [GOC:ai]","metadata":null},{"id":"00fd74db95a448edbde2d81aa5c4a859","type":"GO_TERM","name":"response to psychosocial stress","canonical_id":"go:GO:1990911","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of exposure to aversive or demanding psychological and social conditions that tax or exceed the behavioral resources of the organism.\" [PMID:22922217, PMID:26458179]","metadata":null},{"id":"b6205a574e8e4511938bb2abb1f5ac16","type":"GO_TERM","name":"response to pullulan","canonical_id":"go:GO:0044592","description":"\"A process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of pullulan stimulus.\" [GOC:mengo_curators, GOC:tt]","metadata":null},{"id":"a545f2103a1844959b8a0c5aa0191a41","type":"GO_TERM","name":"response to pulsatile fluid shear stress","canonical_id":"go:GO:0097701","description":"\"Any response to fluid shear stress where the fluid is flowing across a solid surface with periodic variations. For example, the endothelium in straight parts of the artery tree is subjected to pulsatile shear stress with a significant forward direction, which is believed to be an important physiological stimulus enhancing vessel compliance and conferring anti-thrombotic, anti-adhesive, and anti-inflammatory effects.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"3d02a92ce7f74f558c3f109288dab18b","type":"GO_TERM","name":"response to purine-containing compound","canonical_id":"go:GO:0014074","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purine-containing compound stimulus.\" [GOC:ef]","metadata":null},{"id":"1d26d714cc684346b1e5b2d2a3acf9e0","type":"GO_TERM","name":"response to puromycin","canonical_id":"go:GO:1905794","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a puromycin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:25736288]","metadata":null},{"id":"0d0125df5e4a48b09fc7c936ea54bd0c","type":"GO_TERM","name":"response to purvalanol A","canonical_id":"go:GO:1901560","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purvalanol A stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"f3eb4fddaef14d698448896e1051c94b","type":"GO_TERM","name":"response to putrescine","canonical_id":"go:GO:1904585","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a putrescine stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20805360]","metadata":null},{"id":"825aafcf86904f1dbe3503e7267d85cd","type":"GO_TERM","name":"response to pyrethroid","canonical_id":"go:GO:0046684","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pyrethroid stimulus. Pyrethroids are a group of growth regulators, analogous to insect juvenile hormones, that interfere with the development of insect larvae and are used in the control of insects that are harmful in the adult stage.\" [ISBN:0721662544]","metadata":null},{"id":"b5666bf8c9ac45ccaf2997e03c174710","type":"GO_TERM","name":"response to pyrimidine ribonucleotide","canonical_id":"go:GO:1905834","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pyrimidine ribonucleotide stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22065602]","metadata":null},{"id":"4956ecc64e764942a10d3dd0b4dab943","type":"GO_TERM","name":"response to quercetin","canonical_id":"go:GO:1905235","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a quercetin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24914722]","metadata":null},{"id":"1834da77b3c3440e914359448e7fb092","type":"GO_TERM","name":"response to quetiapine","canonical_id":"go:GO:0097335","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a quetiapine stimulus.\" [GOC:pr]","metadata":null},{"id":"772446a58c794e909ae43684e7adabe6","type":"GO_TERM","name":"response to radiation","canonical_id":"go:GO:0009314","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electromagnetic radiation stimulus. Electromagnetic radiation is a propagating wave in space with electric and magnetic components. These components oscillate at right angles to each other and to the direction of propagation.\" [GOC:jl, Wikipedia:Electromagnetic_radiation]","metadata":null},{"id":"92bd3a1411fe459bb7a29e01a2220e92","type":"GO_TERM","name":"response to raffinose","canonical_id":"go:GO:1901545","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a raffinose stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"20d21141f9414c23b10765fd63cc4150","type":"GO_TERM","name":"response to rapamycin","canonical_id":"go:GO:1901355","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rapamycin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"b06ffee07bb14435905060ffbb4d221c","type":"GO_TERM","name":"response to reactive oxygen species","canonical_id":"go:GO:0000302","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals.\" [GOC:krc]","metadata":null},{"id":"e7321b1c019a4257830e4dd52372f99b","type":"GO_TERM","name":"response to red light","canonical_id":"go:GO:0010114","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a red light stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"04680a057443456dbb582eeaa569d964","type":"GO_TERM","name":"response to red or far red light","canonical_id":"go:GO:0009639","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a red or far red light stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm. Far red light is electromagnetic radiation of wavelength 700-800nm. An example of this response is seen at the beginning of many plant species developmental stages. These include germination, and the point when cotyledon expansion is triggered. In certain species these processes take place in response to absorption of red light by the pigment molecule phytochrome, but the signal can be reversed by exposure to far red light. During the initial phase the phytochrome molecule is only present in the red light absorbing form, but on absorption of red light it changes to a far red light absorbing form, triggering progress through development. An immediate short period of exposure to far red light entirely returns the pigment to its initial state and prevents triggering of the developmental process. A thirty minute break between red and subsequent far red light exposure renders the red light effect irreversible, and development then occurs regardless of whether far red light exposure subsequently occurs.\" [GOC:ai, GOC:mtg_far_red]","metadata":null},{"id":"1c21586a5c3b42afb445ca205dd10cc1","type":"GO_TERM","name":"response to redox state","canonical_id":"go:GO:0051775","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating redox state. Redox state refers to the balance of oxidized versus reduced forms of electron donors and acceptors in an organelle, cell or organ; plastoquinone, glutathione (GSH/GSSG), and nicotinamide nucleotides (NAD+/NADH and NADP+/NADPH) are among the most important.\" [GOC:mah, PMID:15131240, PMID:16987039]","metadata":null},{"id":"f8b5737dda304130bbb28a7a97079786","type":"GO_TERM","name":"response to resveratrol","canonical_id":"go:GO:1904638","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a resveratrol stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:23555824]","metadata":null},{"id":"9899c8ea0b8a4cf0942081955d92571c","type":"GO_TERM","name":"response to retinoic acid","canonical_id":"go:GO:0032526","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus.\" [GOC:sl]","metadata":null},{"id":"fa7aea00d0924883acb93389edfd58cc","type":"GO_TERM","name":"response to reverse transcriptase inhibitor","canonical_id":"go:GO:0061479","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reverse transcriptase inhibitor stimulus.\" [GOC:dph]","metadata":null},{"id":"a46235b5324241f2bacc359dee8e3254","type":"GO_TERM","name":"response to reversine","canonical_id":"go:GO:1901596","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reversine stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"d2bd7caac89147ff9a275dd1ddfd8fff","type":"GO_TERM","name":"response to rhamnose","canonical_id":"go:GO:0032149","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rhamnose stimulus.\" [GOC:mlg]","metadata":null},{"id":"871ee53a035147498899f96c304da0d2","type":"GO_TERM","name":"response to ribavirin","canonical_id":"go:GO:1901559","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ribavirin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"599ba4a232304b30b6dec259f0913ccf","type":"GO_TERM","name":"response to risperidone","canonical_id":"go:GO:0097336","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a risperidone stimulus.\" [GOC:pr]","metadata":null},{"id":"d67254b0ef7d4586ae9788b6562a69e1","type":"GO_TERM","name":"response to rotenone","canonical_id":"go:GO:1904647","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rotenone stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18538940]","metadata":null},{"id":"b46cbb73d52a496c9f210ccbe168a683","type":"GO_TERM","name":"response to salicylic acid","canonical_id":"go:GO:0009751","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a salicylic acid stimulus.\" [GOC:jl]","metadata":null},{"id":"8e7eff08a11f481ab516a981a68f3339","type":"GO_TERM","name":"response to salt","canonical_id":"go:GO:1902074","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a salt stimulus.\" [GOC:mls, GOC:TermGenie, PMID:16666921]","metadata":null},{"id":"718c098ff72a439c86626104d640724b","type":"GO_TERM","name":"response to salt stress","canonical_id":"go:GO:0009651","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.\" [GOC:jl]","metadata":null},{"id":"2e372b714f7343f69873071554a877e0","type":"GO_TERM","name":"response to selenite ion","canonical_id":"go:GO:0072714","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a selenite ion stimulus.\" [GOC:mah]","metadata":null},{"id":"e76539726a2349d7a8501c9a5d8430bc","type":"GO_TERM","name":"response to selenium ion","canonical_id":"go:GO:0010269","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from selenium ion.\" [GOC:mg]","metadata":null},{"id":"c4e4f49fb81d47308c39356936fcf743","type":"GO_TERM","name":"response to serotonin","canonical_id":"go:GO:1904014","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a serotonin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:1505525]","metadata":null},{"id":"75355fb1721340d88dc6ca01934983f8","type":"GO_TERM","name":"response to silicon dioxide","canonical_id":"go:GO:0034021","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a silicon dioxide stimulus.\" [GOC:sl]","metadata":null},{"id":"b44f486a82ba4c15b61561ac6a0256e4","type":"GO_TERM","name":"response to silver ion","canonical_id":"go:GO:0010272","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a silver ion stimulus.\" [PMID:16367966]","metadata":null},{"id":"9ed6222e060245a1a78d39c45ca3b471","type":"GO_TERM","name":"response to simvastatin","canonical_id":"go:GO:1903491","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a simvastatin stimulus. Simvastatin is a statin used as a cholesterol-lowering and anti-cardiovascular disease drug.\" [GO_REF:0000071, GOC:sl, GOC:TermGenie, PMID:23100282]","metadata":null},{"id":"8d0aeb4f879b4364a6a84bd2b8eacc96","type":"GO_TERM","name":"response to singlet oxygen","canonical_id":"go:GO:0000304","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a singlet oxygen stimulus. Singlet oxygen is a dioxygen (O2) molecule in which two 2p electrons have similar spin. Singlet oxygen is more highly reactive than the form in which these electrons are of opposite spin, and it is produced in mutant chloroplasts lacking carotenoids and by leukocytes during metabolic burst.\" [GOC:krc, ISBN:0124325653, ISBN:0198506732]","metadata":null},{"id":"5bd864b5870f438c96a3b9127a02d0dd","type":"GO_TERM","name":"response to sodium arsenite","canonical_id":"go:GO:1903935","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium arsenite stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:18674524]","metadata":null},{"id":"bff0efd3053a4e93a0c06e4b2d7372d0","type":"GO_TERM","name":"response to sodium dodecyl sulfate","canonical_id":"go:GO:0072706","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium dodecyl sulfate (SDS) stimulus.\" [GOC:mah]","metadata":null},{"id":"c4a5e9a4ca8f48df9fb24b9d88424271","type":"GO_TERM","name":"response to sodium phosphate","canonical_id":"go:GO:1904383","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sodium phosphate stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:24625659]","metadata":null},{"id":"181be47fae7248a3adc3d8fbb9cce97c","type":"GO_TERM","name":"response to sorbitol","canonical_id":"go:GO:0072708","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sorbitol stimulus.\" [GOC:mah]","metadata":null},{"id":"dac063e279594d11af8c6a5c2d5c7eb5","type":"GO_TERM","name":"response to spindle assembly checkpoint signaling","canonical_id":"go:GO:0072485","description":"\"A process that occurs in response to signals generated as a result of spindle assembly checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"36f338c6cc634111a1d899287b6aad52","type":"GO_TERM","name":"response to spindle checkpoint signaling","canonical_id":"go:GO:0072417","description":"\"A process that occurs in response to signals generated as a result of spindle checkpoint signaling.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"13ccf4c7c5af42fc9596fa69a9976b44","type":"GO_TERM","name":"response to starvation","canonical_id":"go:GO:0042594","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of nourishment.\" [GOC:curators]","metadata":null},{"id":"0b2f4c295c2146cb8f6fc1b6a6849405","type":"GO_TERM","name":"response to statin","canonical_id":"go:GO:0036273","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a statin stimulus. Statins are organooxygen compounds whose structure is related to compactin (mevastatin) and which may be used as an anticholesteremic drug due its EC:1.1.1.34/EC:1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitory properties.\" [GOC:hp]","metadata":null},{"id":"8b91331c0a7d4351956cae675424b73a","type":"DISEASE","name":"response to statin","canonical_id":"go:0036273","description":null,"metadata":null},{"id":"83c4a366412645838c768477ac7ea784","type":"GO_TERM","name":"response to staurosporine","canonical_id":"go:GO:0072733","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a staurosporine stimulus.\" [GOC:mah]","metadata":null},{"id":"19be26dec2d54b1e93405b9c473499af","type":"GO_TERM","name":"response to stem cell factor","canonical_id":"go:GO:0036215","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stem cell factor (SCF) stimulus.\" [GOC:uh]","metadata":null},{"id":"26eca49d756e4a299c9e8fe8dbe70b56","type":"GO_TERM","name":"response to steroid hormone","canonical_id":"go:GO:0048545","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a steroid hormone stimulus.\" [GOC:curators]","metadata":null},{"id":"7b3c6cf65f244adeba4e187a4547f6e5","type":"GO_TERM","name":"response to sterol","canonical_id":"go:GO:0036314","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sterol stimulus.\" [GOC:bf]","metadata":null},{"id":"fe9cd1537e394150a2d58049a2ee4033","type":"GO_TERM","name":"response to sterol depletion","canonical_id":"go:GO:0006991","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating deprivation of sterols. Sterols are a group of steroids characterized by the presence of one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"c41ba41340944a159ccade4dcd59572d","type":"GO_TERM","name":"response to stilbenoid","canonical_id":"go:GO:0035634","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of exposure to a stilbenoid. Stilbenoids are secondary products of heartwood formation in trees that can act as phytoalexins. Stilbenoids are hydroxylated derivatives of stilbene. They belong to the family of phenylpropanoids and share most of their biosynthesis pathway with chalcones.\" [GOC:yaf, Wikipedia:Stilbenoid]","metadata":null},{"id":"bff6f4fb00fc4c11bf2a367379eeba93","type":"GO_TERM","name":"response to stimulus","canonical_id":"go:GO:0050896","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism.\" [GOC:ai, GOC:bf]","metadata":null},{"id":"504eafca4e6749e1b6470a366a908d71","type":"GO_TERM","name":"response to streptomycin","canonical_id":"go:GO:0046679","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a streptomycin stimulus. Streptomycin is a commonly used antibiotic in cell culture media which acts only on prokaryotes and blocks transition from initiation complex to chain elongating ribosome.\" [GOC:curators]","metadata":null},{"id":"8234fd5d1f9643adac287444f9f11c16","type":"GO_TERM","name":"response to stress","canonical_id":"go:GO:0006950","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).\" [GOC:mah]","metadata":null},{"id":"3f3f050253f541108ce9ac068d439edf","type":"GO_TERM","name":"response to strigolactone","canonical_id":"go:GO:1902347","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a strigolactone stimulus.\" [GOC:TermGenie, PMID:23893171]","metadata":null},{"id":"1ccbee7b0fc34c8f95fe51251a5a78a4","type":"GO_TERM","name":"response to sucrose","canonical_id":"go:GO:0009744","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sucrose stimulus.\" [GOC:jl]","metadata":null},{"id":"0e99e785dbf74f51b338144ca3954adb","type":"GO_TERM","name":"response to sulfur dioxide","canonical_id":"go:GO:0010477","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sulfur dioxide (SO2) stimulus.\" [PMID:17425719]","metadata":null},{"id":"b10f4763c7c845e1bad08b6b37aa2843","type":"GO_TERM","name":"response to superoxide","canonical_id":"go:GO:0000303","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a superoxide stimulus. Superoxide is the anion, oxygen-, formed by addition of one electron to dioxygen (O2) or any compound containing the superoxide anion.\" [GOC:krc, ISBN:0198506732]","metadata":null},{"id":"c1ae4584c864403a86212cc10969e5d7","type":"GO_TERM","name":"response to symbiont","canonical_id":"go:GO:0009608","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a symbiont, an organism living with an organism of a different species in close physical association. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"7790430808b6460691239bb063cfa69b","type":"GO_TERM","name":"response to symbiotic bacterium","canonical_id":"go:GO:0009609","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a symbiotic bacterium, a bacterium living in close physical association with another organism.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"9469f03e4fff451faf9dcda097ab812e","type":"GO_TERM","name":"response to symbiotic fungus","canonical_id":"go:GO:0009610","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a symbiotic fungus, a fungus living in close physical association with another organism.\" [GOC:hb, ISBN:0198506732]","metadata":null},{"id":"b2475ee210fc45ea8fc9c139bf36af12","type":"GO_TERM","name":"response to tacrolimus","canonical_id":"go:GO:1901327","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tacrolimus stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"767cf1a89e1f4f8a8999bea4c2febfea","type":"GO_TERM","name":"response to tamsulosin","canonical_id":"go:GO:1901905","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tamsulosin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"a5267161b058429b8943945e908f1b2b","type":"GO_TERM","name":"response to tellurium ion","canonical_id":"go:GO:0046690","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tellurium ion stimulus.\" [GOC:ai]","metadata":null},{"id":"7edb20c2b50c4489b0f3354f21a23b16","type":"GO_TERM","name":"response to temozolomide","canonical_id":"go:GO:1990054","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a temozolomide stimulus.\" [GOC:hp]","metadata":null},{"id":"0d92e8b3e80944488488679f9dec0771","type":"GO_TERM","name":"response to temperature stimulus","canonical_id":"go:GO:0009266","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a temperature stimulus.\" [GOC:hb]","metadata":null},{"id":"f1111ce31af84ff689f4bfbf7a7af09b","type":"GO_TERM","name":"response to tert-butyl hydroperoxide","canonical_id":"go:GO:0072735","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tert-butyl hydroperoxide (t-BOOH) stimulus.\" [GOC:mah]","metadata":null},{"id":"a47a63d3044a4576a1a9b7eef5e72a9a","type":"GO_TERM","name":"response to testosterone","canonical_id":"go:GO:0033574","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a testosterone stimulus.\" [GOC:sl]","metadata":null},{"id":"ef57e90d26ca48059f02bfcf215354e6","type":"GO_TERM","name":"response to tetrachloromethane","canonical_id":"go:GO:1904772","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetrachloromethane stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:7852267]","metadata":null},{"id":"62ad15fd79a9424ab2369fe3cb21ecd0","type":"GO_TERM","name":"response to tetracycline","canonical_id":"go:GO:1901326","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetracycline stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"418c4abdf80344f18616d1344eccbf0c","type":"GO_TERM","name":"response to tetrahydrofolate","canonical_id":"go:GO:1904481","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetrahydrofolate stimulus.\" [GO_REF:0000071, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:24698160]","metadata":null},{"id":"c11b64ee63184041906508bd7697ec66","type":"GO_TERM","name":"response to tetralin","canonical_id":"go:GO:1901498","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tetralin stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"dd887b2e995546359905131769cc0236","type":"GO_TERM","name":"response to thiabendazole","canonical_id":"go:GO:0072712","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thiabendazole stimulus.\" [GOC:mah]","metadata":null},{"id":"0ae69e4af88f4cf1939b64dd6c1720ca","type":"GO_TERM","name":"response to thyroid hormone","canonical_id":"go:GO:0097066","description":"\"A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyroid hormone stimulus.\" [GOC:sjw, PMID:9916872]","metadata":null},{"id":"2ecca3d0433d4c99948f17bae40ef0cf","type":"GO_TERM","name":"response to thyrotropin-releasing hormone","canonical_id":"go:GO:1905225","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyrotropin-releasing hormone (TRH) stimulus. TRH increases the secretion of thyroid-stimulating hormone by the anterior pituitary.\" [GO_REF:0000071, GOC:sl, GOC:TermGenie, PMID:21382270]","metadata":null},{"id":"02da1dd0738549d5aca4efa9725af186","type":"GO_TERM","name":"response to thyroxine","canonical_id":"go:GO:0097068","description":"\"A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyroxine stimulus.\" [GOC:sjw, PMID:9916872]","metadata":null},{"id":"b6ead5baf4d44c84b309cbe163f8f810","type":"GO_TERM","name":"response to toluene","canonical_id":"go:GO:1901424","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toluene stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"8cad5a40ae0846c4a4a189d4dad32ded","type":"GO_TERM","name":"response to topoisomerase inhibitor","canonical_id":"go:GO:0072758","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a topoisomerase inhibitor stimulus.\" [GOC:mah]","metadata":null},{"id":"153fd7319afa4786aaee7f63f0b82099","type":"GO_TERM","name":"response to topologically incorrect protein","canonical_id":"go:GO:0035966","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a protein that is not folded in its correct three-dimensional structure.\" [GOC:bf]","metadata":null},{"id":"8474676d84cf47a0a75da4b16037ac9d","type":"GO_TERM","name":"response to toxic substance","canonical_id":"go:GO:0009636","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus.\" [GOC:lr]","metadata":null},{"id":"220f48ffcdd04410bf5e1008fadd54f5","type":"DISEASE","name":"response to tramadol","canonical_id":"efo:0022041","description":null,"metadata":null},{"id":"9556050206434e8ba09f52ad9a6d0372","type":"GO_TERM","name":"response to transforming growth factor beta","canonical_id":"go:GO:0071559","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus.\" [GOC:mah]","metadata":null},{"id":"3c0a066417b04140aa72605fb0c014ee","type":"GO_TERM","name":"response to transition metal nanoparticle","canonical_id":"go:GO:1990267","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transition metal nanoparticle.\" [PMID:23150627]","metadata":null},{"id":"0db6e9dff0054699bfa8eccf146f74bb","type":"GO_TERM","name":"response to trehalose","canonical_id":"go:GO:0010353","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trehalose stimulus.\" [PMID:17031512]","metadata":null},{"id":"ac71f1ec2ed0464886e6c100c6b5189d","type":"GO_TERM","name":"response to trehalose-6-phosphate","canonical_id":"go:GO:0080094","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trehalose-6-phosphate stimulus.\" [PMID:19193861]","metadata":null},{"id":"7788628ccd08436c8e41dadd38568225","type":"GO_TERM","name":"response to triacyl bacterial lipopeptide","canonical_id":"go:GO:0071725","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a triacylated bacterial lipopeptide stimulus.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"2ca4514e7b334b409c53c4f534bb4cd0","type":"GO_TERM","name":"response to trichodermin","canonical_id":"go:GO:1901324","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trichodermin stimulus.\" [GOC:TermGenie]","metadata":null},{"id":"2ed5b54a7d2d4a9fb28f96917869030f","type":"GO_TERM","name":"response to trichostatin A","canonical_id":"go:GO:0035983","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a trichostatin A stimulus.\" [GOC:yaf, PMID:20181743]","metadata":null},{"id":"a212292032594b9eb905ef58c80de203","type":"GO_TERM","name":"response to triglyceride","canonical_id":"go:GO:0034014","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a triglyceride stimulus.\" [GOC:sl]","metadata":null},{"id":"fa38d2c487b04145a3e06176ea16b816","type":"GO_TERM","name":"response to triterpenoid","canonical_id":"go:GO:1905836","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a triterpenoid stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:28078994]","metadata":null},{"id":"753d46fafb28463694b654cd5a9eb1a5","type":"GO_TERM","name":"response to tropane","canonical_id":"go:GO:0014073","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tropane stimulus. Tropane is a nitrogenous bicyclic organic compound mainly known for a group of alkaloids derived from it (called tropane alkaloids), which include, among others, atropine and cocaine.\" [GOC:ef]","metadata":null},{"id":"aeb687793ba34a68906ba58b7226768c","type":"GO_TERM","name":"response to tumor cell","canonical_id":"go:GO:0002347","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a tumor cell.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"5c99805fea404130820c28df97a6513d","type":"GO_TERM","name":"response to tumor necrosis factor","canonical_id":"go:GO:0034612","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus.\" [GOC:mah]","metadata":null},{"id":"ae15957037284965866a76e7a293406b","type":"GO_TERM","name":"response to type I interferon","canonical_id":"go:GO:0034340","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type I interferon stimulus. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16681834]","metadata":null},{"id":"8ac02cf967a04844bccbac686f6d3b7d","type":"GO_TERM","name":"response to type II interferon","canonical_id":"go:GO:0034341","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon-gamma is also known as type II interferon.\" [GOC:add, ISBN:0126896631, PMID:15546383]","metadata":null},{"id":"183f134c996f4cc1826967f01937138b","type":"GO_TERM","name":"response to type III interferon","canonical_id":"go:GO:0034342","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type III interferon stimulus. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"9ed8ef5cd67343d48ea363daf9a347e9","type":"DISEASE","name":"response to tyrosine kinase inhibitor","canonical_id":"efo:0009170","description":null,"metadata":null},{"id":"1883f1798082420d88e2b81928076935","type":"GO_TERM","name":"response to ultrasound","canonical_id":"go:GO:1990478","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ultrasonic stimulus.\" [PMID:20950932]","metadata":null},{"id":"c19c0f7d285e4082b7cc8a672c4eec59","type":"GO_TERM","name":"response to undecane","canonical_id":"go:GO:1902784","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an undecane stimulus.\" [GO_REF:0000071, GOC:mengo_curators, GOC:TermGenie, PMID:23826995]","metadata":null},{"id":"4d85d67be0dd4857a59971332152203e","type":"GO_TERM","name":"response to unfolded protein","canonical_id":"go:GO:0006986","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an unfolded protein stimulus.\" [GOC:jl]","metadata":null},{"id":"17370f499885406c919afb60187ee595","type":"GO_TERM","name":"response to vanadate(3-)","canonical_id":"go:GO:1902438","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vanadate(3-) stimulus.\" [GOC:di, GOC:TermGenie, PMID:7489911]","metadata":null},{"id":"cc1923d27b9f40b38cea5025b9e0cb19","type":"GO_TERM","name":"response to vasopressin","canonical_id":"go:GO:1904116","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vasopressin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:22811487]","metadata":null},{"id":"a96c7a6532584ba7b3441a4d7d00b5f7","type":"GO_TERM","name":"response to very low fluence red light stimulus","canonical_id":"go:GO:0010203","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a very low fluence red light stimulus. Red light is electromagnetic radiation of wavelength of 580-700nm. Very low fluence red light is defined in this case as short pulses of red light followed by darkness, providing light levels of less than 0.001 mmol/m2/sec.\" [GOC:mtg_far_red, GOC:sm]","metadata":null},{"id":"a3d31cc679a2496da0a50544df1d04e1","type":"GO_TERM","name":"response to very low light intensity stimulus","canonical_id":"go:GO:0055122","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a very low light intensity stimulus. A very low light intensity stimulus is defined as a level of electromagnetic radiation below 0.001 mmol/m2/sec.\" [GOC:mtg_far_red]","metadata":null},{"id":"1ba79cc5ae6747ebb466eb84b3cdd51a","type":"GO_TERM","name":"response to virus","canonical_id":"go:GO:0009615","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus.\" [GOC:hb]","metadata":null},{"id":"dd6ae76a304c41798be7e75016793e67","type":"GO_TERM","name":"response to viscosity","canonical_id":"go:GO:0097714","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a viscosity stimulus.\" [GOC:sl, PMID:7061416]","metadata":null},{"id":"bb252dcfd59c416d972a5a501e9323b7","type":"GO_TERM","name":"response to vitamin","canonical_id":"go:GO:0033273","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin stimulus.\" [GOC:sl]","metadata":null},{"id":"0d635a9329d145c88b61ae221ce019f1","type":"GO_TERM","name":"response to vitamin A","canonical_id":"go:GO:0033189","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin A stimulus.\" [GOC:sl]","metadata":null},{"id":"0e01ff57af8f48d1a82d34df4606f419","type":"GO_TERM","name":"response to vitamin B1","canonical_id":"go:GO:0010266","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B1 stimulus.\" [GOC:pz]","metadata":null},{"id":"50f442ca702b46e390a34178e0f54520","type":"GO_TERM","name":"response to vitamin B2","canonical_id":"go:GO:0033274","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B2 stimulus.\" [GOC:sl]","metadata":null},{"id":"17c1354f173f44b18df4e528b667ba12","type":"GO_TERM","name":"response to vitamin B3","canonical_id":"go:GO:0033552","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B3 stimulus.\" [GOC:sl]","metadata":null},{"id":"7f07f42fb99f497cae7a35eb06e2815c","type":"GO_TERM","name":"response to vitamin B6","canonical_id":"go:GO:0034516","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin B6 stimulus. Vitamin B6 encompasses pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate.\" [GOC:mah, GOC:rph]","metadata":null},{"id":"4bd621b33f9345a780256ee6af499a29","type":"GO_TERM","name":"response to vitamin D","canonical_id":"go:GO:0033280","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin D stimulus.\" [GOC:sl]","metadata":null},{"id":"f7b427e253c6454aba8fd576b42cf1b6","type":"GO_TERM","name":"response to vitamin E","canonical_id":"go:GO:0033197","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin E stimulus.\" [GOC:sl]","metadata":null},{"id":"f2fcbc1024454d42bf86679ae4b13ef8","type":"GO_TERM","name":"response to vitamin K","canonical_id":"go:GO:0032571","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin K stimulus.\" [GOC:sl]","metadata":null},{"id":"0408f00125b04342ac43f6e4b24d61ad","type":"GO_TERM","name":"response to water","canonical_id":"go:GO:0009415","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of water.\" [GOC:jl]","metadata":null},{"id":"79e0773834a149f791b7adfce6bfe37b","type":"GO_TERM","name":"response to water deprivation","canonical_id":"go:GO:0009414","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a water deprivation stimulus, prolonged deprivation of water.\" [GOC:lr]","metadata":null},{"id":"8f49478e2d814859ad7beb4fbfb0234f","type":"GO_TERM","name":"response to water-immersion restraint stress","canonical_id":"go:GO:1990785","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of water immersion while being held immobile.\" [PMID:10882227]","metadata":null},{"id":"742250b2d251424db801fd3065e2f8d0","type":"GO_TERM","name":"response to wortmannin","canonical_id":"go:GO:1904567","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a wortmannin stimulus.\" [GO_REF:0000071, GOC:TermGenie, PMID:20629186]","metadata":null},{"id":"bb585df1706d4bd4925cb28e9d9b3d0c","type":"GO_TERM","name":"response to wounding","canonical_id":"go:GO:0009611","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to the organism.\" [GOC:curators]","metadata":null},{"id":"d197e2531daf4c06991cd7ca3720cb58","type":"GO_TERM","name":"response to xenobiotic stimulus","canonical_id":"go:GO:0009410","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:jl, GOC:krc]","metadata":null},{"id":"f9053fef49194fb9879bd88d04a24a30","type":"GO_TERM","name":"response to ximelagatran","canonical_id":"go:GO:0036288","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ximelagatran stimulus.\" [GOC:hp]","metadata":null},{"id":"3e72a1014205490fa299873a0979f810","type":"GO_TERM","name":"response to xylene","canonical_id":"go:GO:1901501","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a xylene stimulus.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"5b5b553000e44a68b135fb036cfc5f3f","type":"GO_TERM","name":"response to yeast","canonical_id":"go:GO:0001878","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a yeast species.\" [PMID:14707091]","metadata":null},{"id":"1dfa3c71309542019d425f102fb8c112","type":"GO_TERM","name":"response to zinc ion","canonical_id":"go:GO:0010043","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a zinc ion stimulus.\" [GOC:sm]","metadata":null},{"id":"ee1e08987a4a4627aab5168a235c0419","type":"GO_TERM","name":"response to zinc ion starvation","canonical_id":"go:GO:0120127","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a starvation stimulus, deprivation of zinc ion.\" [GOC:sl, PMID:24024381]","metadata":null},{"id":"860663b2dc8d4cc0b117277ff03845d1","type":"GO_TERM","name":"response to ziprasidone","canonical_id":"go:GO:0097337","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ziprasidone stimulus. Ziprasidone is a piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.\" [GOC:pr]","metadata":null},{"id":"9221d8dcf53b4795a3b91e62fbfcee5a","type":"DISEASE","name":"restless legs syndrome","canonical_id":"mondo:0005391","description":null,"metadata":null},{"id":"d899ae26440e462885a87b5393d23cbe","type":"GO_TERM","name":"restriction endodeoxyribonuclease activity","canonical_id":"go:GO:0015666","description":"\"Catalysis of endonucleolytic cleavage of DNA in a site-specific manner, resulting in double-strand breaks.\" [GOC:mlg]","metadata":null},{"id":"fd0ae9e2659348219ab30be56846a4e0","type":"GO_TERM","name":"resveratrol 3,5-O-dimethyltransferase activity","canonical_id":"go:GO:0102303","description":"\"Catalysis of the reaction: 2 S-adenosyl-L-methionine + trans-resveratrol = 2 S-adenosyl-L-homocysteine + pterostilbene + 2 H+.\" [EC:2.1.1.240, GOC:pz]","metadata":null},{"id":"c2fc0354d1544952810c677559255579","type":"GO_TERM","name":"resveratrol dioxygenase activity","canonical_id":"go:GO:7770086","description":"\"Catalysis of the reaction: trans-resveratrol + O2 = 3,5-dihydroxybenzaldehyde + 4-hydroxybenzaldehyde.\" [PMID:28493664, RHEA:73735]","metadata":null},{"id":"d4f9981a5f0444079bf827e8fcd5ff66","type":"GO_TERM","name":"reticuline oxidase activity","canonical_id":"go:GO:0050468","description":"\"Catalysis of the reaction: (S)-reticuline + O2 = (S)-scoulerine + H2O2 + H+. Also acts on related compounds, converting the N-methyl group into the methylene bridge ('berberine bridge') of (S)- tetrahydroprotoberberines.\" [RHEA:19885]","metadata":null},{"id":"60786deee73545ab916877e30fb8d937","type":"GO_TERM","name":"reticulophagy","canonical_id":"go:GO:0061709","description":"\"The selective autohagy process in which parts of the endoplasmic reticulum are loaded into autophagosomes, delivered to the vacuole, and degraded in response to changing cellular conditions.\" [GOC:autophagy, GOC:dph, PMID:22481944, PMID:24060720, PMID:26040717]","metadata":null},{"id":"ca73a104802844e1b77409f253457c7a","type":"DRUG","name":"retigabine","canonical_id":"gtopdb:2601","description":null,"metadata":null},{"id":"ebfcbf439cd54ff28a267742104a00ed","type":"DRUG","name":"retigabine","canonical_id":"chembl:CHEMBL41355","description":null,"metadata":null},{"id":"23901f9ca92949a581ce306807ce91c8","type":"GO_TERM","name":"retina blood vessel maintenance","canonical_id":"go:GO:0097601","description":"\"A retina homeostatic process preventing the degeneration of a retina blood vessel.\" [GOC:jh2, PMID:23093773]","metadata":null},{"id":"f86abed84a0f46c68027127442aea699","type":"GO_TERM","name":"retina development in camera-type eye","canonical_id":"go:GO:0060041","description":"\"The process whose specific outcome is the progression of the retina over time, from its formation to the mature structure. The retina is the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates.\" [GOC:bf, GOC:dph, ISBN:0815340729]","metadata":null},{"id":"dadd902124b8427cbf96347a0104f561","type":"GO_TERM","name":"retina homeostasis","canonical_id":"go:GO:0001895","description":"\"A tissue homeostatic process involved in the maintenance of an internal equilibrium within the retina of the eye, including control of cellular proliferation and death and control of metabolic function.\" [GOC:add, GOC:dph, GOC:tb, PMID:15365173, PMID:15365178]","metadata":null},{"id":"8461c0d57e7b4db58de62e677184c855","type":"GO_TERM","name":"retina layer formation","canonical_id":"go:GO:0010842","description":"\"The process in which the vertebrate retina is organized into three laminae: the outer nuclear layer (ONL), which contains photoreceptor nuclei; the inner nuclear layer (INL), which contains amacrine, bipolar and horizontal cells; and the retinal ganglion cell (RGC) layer. Between the inner and outer nuclear layers, the outer plexiform layer (OPL) contains connections between the photoreceptors and bipolar and horizontal cells. The inner plexiform layer (IPL) is positioned between the INL and the ganglion cell layer and contains the dendrites of RGCs and processes of bipolar and amacrine cells. Spanning all layers of the retina are the radially oriented Mueller glia.\" [GOC:ascb_2009, GOC:dph, GOC:tb, PMID:1270266]","metadata":null},{"id":"a621483288ea45d79355543b3a9d2002","type":"GO_TERM","name":"retina morphogenesis in camera-type eye","canonical_id":"go:GO:0060042","description":"\"The process in which the anatomical structure of the retina is generated and organized.\" [GOC:bf, GOC:dph, GOC:mtg_sensu]","metadata":null},{"id":"36d48f92470a4a3fa9246d74cd11cfbd","type":"GO_TERM","name":"retina vasculature development in camera-type eye","canonical_id":"go:GO:0061298","description":"\"The process whose specific outcome is the progression of the vasculature of the retina over time, from its formation to the mature structure.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"afc81d6e4d5447218a93152f647e31a8","type":"GO_TERM","name":"retina vasculature morphogenesis in camera-type eye","canonical_id":"go:GO:0061299","description":"\"The process in which the vasculature of the retina is generated and organized.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"822480fb714c4b2da9271a9dbd503f0a","type":"GO_TERM","name":"retinal binding","canonical_id":"go:GO:0016918","description":"\"Binding to retinal, one of the forms of vitamin A. Retinal plays an important role in the visual process in most vertebrates, combining with opsins to form visual pigments in the retina.\" [ISBN:0198506732]","metadata":null},{"id":"7adc9d3ecafe4dcca891f4f82c474ad9","type":"GO_TERM","name":"retinal bipolar neuron differentiation","canonical_id":"go:GO:0060040","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a bipolar cell, the last neuron to be generated in the retina.\" [GOC:ascb_2009, GOC:bf, GOC:dph, GOC:tb]","metadata":null},{"id":"567dac6a76d44f5e95d97cce72cb26d6","type":"GO_TERM","name":"retinal blood vessel morphogenesis","canonical_id":"go:GO:0061304","description":"\"The process whose specific outcome is the progression of a blood vessel of the retina over time, from its formation to the mature structure.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"f62d4b13007a4616ae217263f8805d32","type":"GO_TERM","name":"retinal cell apoptotic process","canonical_id":"go:GO:1990009","description":"\"Any apoptotic process in a retinal cell.\" [GOC:mtg_apoptosis, PMID:15558487, PMID:24664675]","metadata":null},{"id":"1abd884b37174ebebdc9a037992e6a38","type":"GO_TERM","name":"retinal cell programmed cell death","canonical_id":"go:GO:0046666","description":"\"Programmed cell death that occurs in the developing retina.\" [GOC:bf]","metadata":null},{"id":"465fb2fb9eef4da689d87f8b2be40555","type":"GO_TERM","name":"retinal cone cell apoptotic process","canonical_id":"go:GO:0097474","description":"\"Any apoptotic process in a retinal cone cell, one of the two photoreceptor cell types of the vertebrate retina.\" [CL:0000573, GOC:jc]","metadata":null},{"id":"ea990099d2984c289c31db1b420d7828","type":"GO_TERM","name":"retinal cone cell development","canonical_id":"go:GO:0046549","description":"\"Development of a cone cell, one of the sensory cells in the eye that reacts to the presence of light. Cone cells contain the photopigment iodopsin or cyanopsin and are responsible for photopic (daylight) vision.\" [ISBN:0198506732]","metadata":null},{"id":"4059b1a16c6447d489945a015a2c36ff","type":"GO_TERM","name":"retinal cone cell differentiation","canonical_id":"go:GO:0042670","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a retinal cone cell.\" [GOC:curators]","metadata":null},{"id":"0e2f39be72184c8c9e3c37a4d07290b3","type":"GO_TERM","name":"retinal cone cell fate commitment","canonical_id":"go:GO:0046551","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a retinal cone cell. A retinal cone cell is one of the two photoreceptor subtypes in a camera-type eye.\" [GOC:mtg_sensu, PMID:3076112, PMID:3937883]","metadata":null},{"id":"a7052c743c794330bd303f1ade70d578","type":"GO_TERM","name":"retinal cone cell fate determination","canonical_id":"go:GO:0042671","description":"\"The process in which a cell becomes capable of differentiating autonomously into a retinal cone cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators]","metadata":null},{"id":"e13b60a538184edfa92d967dcc8189cb","type":"GO_TERM","name":"retinal cone cell fate specification","canonical_id":"go:GO:0042672","description":"\"The process in which a cell becomes capable of differentiating autonomously into a retinal cone cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed.\" [GOC:curators]","metadata":null},{"id":"f5392e0940f94535a981e8445140702b","type":"GO_TERM","name":"retinal dehydrogenase (NAD+) activity","canonical_id":"go:GO:0001758","description":"\"Catalysis of the reaction: retinal + NAD+ + H2O = retinoate + NADH. Acts on both 11-trans and 13-cis forms of retinal.\" [EC:1.2.1.36]","metadata":null},{"id":"2f15325ab093435c9b7ebafc4ba2ff3c","type":"GO_TERM","name":"retinal ganglion cell axon guidance","canonical_id":"go:GO:0031290","description":"\"The process in which the migration of an axon growth cone of a retinal ganglion cell (RGC) is directed to its target in the brain in response to a combination of attractive and repulsive cues.\" [GOC:ejs]","metadata":null},{"id":"bac1c85090424105b0de757700250933","type":"GO_TERM","name":"retinal isomerization","canonical_id":"go:GO:0106434","description":"\"The reactions involved in isomerization of all trans to all cis retnal.\" [PMID:21447403]","metadata":null},{"id":"aa512fcc64e641ce9effe19f58f810c4","type":"GO_TERM","name":"retinal metabolic process","canonical_id":"go:GO:0042574","description":"\"The chemical reactions and pathways involving retinal, a compound that plays an important role in the visual process in most vertebrates. In the retina, retinal combines with opsins to form visual pigments. Retinal is one of the forms of vitamin A.\" [ISBN:0198506732]","metadata":null},{"id":"4581ad31a1614c4b914f4b6afc4e158d","type":"GO_TERM","name":"retinal pigment epithelium development","canonical_id":"go:GO:0003406","description":"\"The progression of the retinal pigment epithelium over time, from its initial formation to the mature structure. The retinal pigment epithelium is the melanin-containing layer of cells between the retina and the choroid that absorbs scattered and reflected light and removes waste products produced by the photoreceptor cells.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"0df74916763b4bcba73c22200355cd5c","type":"GO_TERM","name":"retinal rod cell apoptotic process","canonical_id":"go:GO:0097473","description":"\"Any apoptotic process in a retinal rod cell, one of the two photoreceptor cell types of the vertebrate retina.\" [CL:0000604, GOC:jc, PMID:17202487]","metadata":null},{"id":"2cf52a0af7b5434db390ad65c8982d89","type":"GO_TERM","name":"retinal rod cell development","canonical_id":"go:GO:0046548","description":"\"Development of a rod cell, one of the sensory cells in the eye that reacts to the presence of light. Rod cells contain the photopigment rhodopsin or porphyropsin and are responsible for vision in dim light.\" [ISBN:0198506732]","metadata":null},{"id":"faf02bf3cd6e4de8ac94ada8de696acf","type":"GO_TERM","name":"retinal rod cell differentiation","canonical_id":"go:GO:0060221","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a retinal rod cell.\" [GOC:dph]","metadata":null},{"id":"bc9ab240bbd940a8b06f8e1ff406edde","type":"GO_TERM","name":"retinal rod cell fate commitment","canonical_id":"go:GO:0060223","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a retinal rod cell. A retinal rod cell is one of the two photoreceptor subtypes in a camera-type eye.\" [GOC:dph]","metadata":null},{"id":"e4d2fd1831ac452c951950698df3eb1e","type":"DISEASE","name":"retinal vein occlusion","canonical_id":"mondo:0006951","description":null,"metadata":null},{"id":"7ece6a05afbb4a04ae90e5fddfbe9c79","type":"DISEASE","name":"retinitis pigmentosa","canonical_id":"mondo:0019200","description":null,"metadata":null},{"id":"88b1e103aaeb4b29b1926aff6e0e8b72","type":"DISEASE","name":"retinitis pigmentosa 10","canonical_id":"mondo:0008379","description":null,"metadata":null},{"id":"ff30b37a90e249d38044b2a0d068dac1","type":"DISEASE","name":"retinitis pigmentosa 26","canonical_id":"mondo:0012024","description":null,"metadata":null},{"id":"14f09d4f65b34e5ca3043f02631dddbb","type":"DISEASE","name":"retinitis pigmentosa 85","canonical_id":"mondo:0032689","description":null,"metadata":null},{"id":"7625e7708b564823beab96a1c27b8c1c","type":"GO_TERM","name":"retinoic acid 4-hydroxylase activity","canonical_id":"go:GO:0008401","description":"\"Catalysis of the conversion of retinoic acid to 4-hydroxy-retinoic acid.\" [PMID:19519282, PMID:9250660]","metadata":null},{"id":"4d7c6cbdc6ce4a8c8b319951ce6a6eae","type":"GO_TERM","name":"retinoic acid binding","canonical_id":"go:GO:0001972","description":"\"Binding to retinoic acid, 3,7-dimethyl-9-(2,6,-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid.\" [GOC:hjd]","metadata":null},{"id":"6e092ca57da546528b4fd88e4e1d39cf","type":"GO_TERM","name":"retinoic acid biosynthetic process","canonical_id":"go:GO:0002138","description":"\"The chemical reactions and pathways resulting in the biosynthesis of retinoic acid, one of the three components that makes up vitamin A.\" [GOC:hjd]","metadata":null},{"id":"9f86d1b462fe4a1d933ab74c4832d8c1","type":"GO_TERM","name":"retinoic acid catabolic process","canonical_id":"go:GO:0034653","description":"\"The chemical reactions and pathways resulting in the breakdown of retinoic acid, one of the three components that makes up vitamin A.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"3221876181bb42a789f2b8ffc87cc944","type":"GO_TERM","name":"retinoic acid metabolic process","canonical_id":"go:GO:0042573","description":"\"The chemical reactions and pathways involving retinoic acid, one of the three components that makes up vitamin A.\" [GOC:jl, PMID:12570742]","metadata":null},{"id":"1fa286f44c624a1f99f83bbad24e0341","type":"GO_TERM","name":"retinoic acid receptor signaling pathway","canonical_id":"go:GO:0048384","description":"\"A nuclear receptor-mediated signaling pathway initiated by a retinoic acid binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:dgh]","metadata":null},{"id":"6d1d22903e40483fb5373aaaccba3f8b","type":"GO_TERM","name":"retinoic acid-responsive element binding","canonical_id":"go:GO:0044323","description":"\"Binding to a retinoic acid-responsive element, a variable direct repeat of the sequence PuGGTCA spaced by five nucleotides (DR5) found in the promoters of retinoic acid-responsive genes, to which retinoic acid receptors bind.\" [GOC:jl, GOC:vw, GOC:yaf, PMID:11327309, PMID:19917671]","metadata":null},{"id":"033450606e1e41d7b355eaaab65ca305","type":"GO_TERM","name":"retinoid binding","canonical_id":"go:GO:0005501","description":"\"Binding to a retinoid, a class of isoprenoids that contain or are derived from four prenyl groups linked head-to-tail. Retinoids include retinol and retinal and structurally similar natural derivatives or synthetic compounds, but need not have vitamin A activity.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"25a842fe8d39409395efe9143b86565d","type":"GO_TERM","name":"retinoid metabolic process","canonical_id":"go:GO:0001523","description":"\"The chemical reactions and pathways involving retinoids, any member of a class of isoprenoids that contain or are derived from four prenyl groups linked head-to-tail. Retinoids include retinol and retinal and structurally similar natural derivatives or synthetic compounds, but need not have vitamin A activity.\" [ISBN:0198506732]","metadata":null},{"id":"e9c12f8fbbb84456bde9ff82bc8d8342","type":"GO_TERM","name":"retinol O-fatty-acyltransferase activity","canonical_id":"go:GO:0050252","description":"\"Catalysis of the reaction: acyl-CoA + retinol = CoA + retinyl ester.\" [EC:2.3.1.76, MetaCyc:RETINOL-O-FATTY-ACYLTRANSFERASE-RXN]","metadata":null},{"id":"c33a8f48c29c432cb418f552e2e28075","type":"GO_TERM","name":"retinol binding","canonical_id":"go:GO:0019841","description":"\"Binding to retinol, vitamin A1, 2,6,6-trimethyl-1-(9'-hydroxy-3',7'-dimethylnona-1',3',5',7'-tetraenyl)cyclohex-1-ene, one of the three components that makes up vitamin A. Retinol is an intermediate in the vision cycle and it also plays a role in growth and differentiation.\" [GOC:curators]","metadata":null},{"id":"3941c65b2b0545bca230b5cd310c4717","type":"GO_TERM","name":"retinol dehydratase activity","canonical_id":"go:GO:0017051","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + retinol = adenosine 3',5'-bisphosphate + anhydroretinol.\" [PMID:9857081]","metadata":null},{"id":"06943e047e114e6a9b6f9cf3a80e4e70","type":"GO_TERM","name":"retinol isomerase activity","canonical_id":"go:GO:0050251","description":"\"Catalysis of the reaction: all-trans-retinol = 11-cis-retinol.\" [GOC:pde, RHEA:19141]","metadata":null},{"id":"0e9c54c1a2154acc89cbc5b2ef60ac19","type":"GO_TERM","name":"retinol metabolic process","canonical_id":"go:GO:0042572","description":"\"The chemical reactions and pathways involving retinol, one of the three compounds that makes up vitamin A.\" [GOC:jl, PMID:1924551]","metadata":null},{"id":"4df25bc39d454993af85edb190ba30fb","type":"GO_TERM","name":"retinol transmembrane transporter activity","canonical_id":"go:GO:0034632","description":"\"Enables the transfer of retinol from one side of a membrane to the other. Retinol is vitamin A1, 2,6,6-trimethyl-1-(9'-hydroxy-3',7'-dimethylnona-1',3',5',7'-tetraenyl)cyclohex-1-ene, one of the three components that makes up vitamin A.\" [GOC:BHF, GOC:mah, GOC:vk]","metadata":null},{"id":"660cc182fbed4096a95142a5d29cc747","type":"GO_TERM","name":"retinol transport","canonical_id":"go:GO:0034633","description":"\"The directed movement of retinol into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Retinol is vitamin A1, 2,6,6-trimethyl-1-(9'-hydroxy-3',7'-dimethylnona-1',3',5',7'-tetraenyl)cyclohex-1-ene, one of the three components that makes up vitamin A.\" [GOC:BHF, GOC:mah, GOC:vk]","metadata":null},{"id":"c64233ecb03d4427b4b0bae7477db662","type":"GO_TERM","name":"retinyl-palmitate esterase activity","canonical_id":"go:GO:0050253","description":"\"Catalysis of the reaction: retinyl palmitate + H2O = retinol + palmitate + H+.\" [RHEA:21508]","metadata":null},{"id":"dadaf7ea4c8e43348ac896c72d899ea2","type":"GO_TERM","name":"retrograde axonal protein transport","canonical_id":"go:GO:0099642","description":"\"The directed movement of proteins along microtubules from the cell periphery toward the cell body in nerve cell axons.\" [ISBN:0815316194]","metadata":null},{"id":"638040c94c3d411a8f50ca15934648bf","type":"GO_TERM","name":"retrograde axonal transport","canonical_id":"go:GO:0008090","description":"\"The directed movement of organelles or molecules along microtubules from the cell periphery toward the cell body in nerve cell axons.\" [ISBN:0815316194]","metadata":null},{"id":"c08c4bc0ee7f4095b788f19f097d3a63","type":"GO_TERM","name":"retrograde axonal transport of mitochondrion","canonical_id":"go:GO:0098958","description":"\"The directed movement of mitochondria along microtubules in axons towards the cell body and away from the presynapse.\" [GOC:dos]","metadata":null},{"id":"c92f7c426f634fa9b52959ea8bd0e206","type":"GO_TERM","name":"retrograde cargo receptor complex, Golgi to ER","canonical_id":"go:GO:0061852","description":"\"Cargo receptor complex that recognizes, binds and returns endoplasmic reticulum (ER) resident proteins that have trafficked to Golgi compartments. Targets proteins lacking the HDEL motif recognised by COPI-coated vesicles.\" [GOC:bhm, PMID:16093310]","metadata":null},{"id":"c2def115235246f89d5ce7d1feafecc8","type":"GO_TERM","name":"retrograde dendritic transport","canonical_id":"go:GO:0098934","description":"\"The directed movement of organelles or molecules along microtubules in a dendrite from the postsynapse towards the cell body.\" [GOC:dos]","metadata":null},{"id":"4e1e4a3cbf5b43b394ae157aa6297f91","type":"GO_TERM","name":"retrograde dendritic transport of mitochondrion","canonical_id":"go:GO:0098959","description":"\"The directed movement of mitochondria along microtubules in dendrites towards the cell body and away from the postsynapse.\" [GOC:dos]","metadata":null},{"id":"65c777f9512c44caac6250c43f0fa291","type":"GO_TERM","name":"retrograde extension","canonical_id":"go:GO:0003389","description":"\"The progression of a neuronal projection over time by the attachment of a part of the cell to an anchor and the subsequent migration of the cell body away from the anchor point.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"4753f78e1025493dad56a0fa1c92572f","type":"GO_TERM","name":"retrograde neuronal dense core vesicle transport","canonical_id":"go:GO:1990049","description":"\"The directed movement of neuronal dense core vesicles along axonal microtubules towards the cell body.\" [GOC:kmv, PMID:23358451, PMID:24762653]","metadata":null},{"id":"c315bd3fac6049d18d8cb704d9afa02c","type":"GO_TERM","name":"retrograde protein transport, ER to cytosol","canonical_id":"go:GO:0030970","description":"\"The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon.\" [PMID:11994744]","metadata":null},{"id":"895aeb49f9ce48d7bc84e3ebda727600","type":"GO_TERM","name":"retrograde synaptic vesicle transport","canonical_id":"go:GO:0048491","description":"\"The directed movement of synaptic vesicle along axonal microtubules from the presynapse to the cell body.\" [GOC:jid, GOC:lmg, PMID:24762653]","metadata":null},{"id":"67503baf97ad499cb976185cfe4330b7","type":"GO_TERM","name":"retrograde trans-synaptic signaling","canonical_id":"go:GO:0098917","description":"\"Cell-cell signaling from post to pre-synapse, across the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"0a363d1189f344f0804e69ee27aff982","type":"GO_TERM","name":"retrograde trans-synaptic signaling by endocannabinoid","canonical_id":"go:GO:0098921","description":"\"Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by an endocannabinoid ligand.\" [GOC:dos]","metadata":null},{"id":"fb89bfbd6bd6449f972dd5257ae5c659","type":"GO_TERM","name":"retrograde trans-synaptic signaling by lipid","canonical_id":"go:GO:0098920","description":"\"Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by a lipid ligand.\" [GOC:dos]","metadata":null},{"id":"9b46cc889923487bbc3289a1d31821e6","type":"GO_TERM","name":"retrograde trans-synaptic signaling by neuropeptide","canonical_id":"go:GO:0099082","description":"\"Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by a neuropeptide.\" [GOC:bf, GOC:dos, GOC:PARL, PMID:19448629]","metadata":null},{"id":"91f202aa010e438cb646c5216e310b54","type":"GO_TERM","name":"retrograde trans-synaptic signaling by neuropeptide, modulating synaptic transmission","canonical_id":"go:GO:0099083","description":"\"Modulation of synaptic transmission by cell-cell signaling across the synaptic cleft from postsynapse to presynapse, mediated by a neuropeptide.\" [GOC:bf, GOC:dos, GOC:PARL, PMID:19448629]","metadata":null},{"id":"688e940e2345444983adc62e290c1d10","type":"GO_TERM","name":"retrograde trans-synaptic signaling by nitric oxide","canonical_id":"go:GO:0098924","description":"\"Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by nitric oxide.\" [GOC:dos]","metadata":null},{"id":"ee551b8c47744e9ca3de4b2179ce26a0","type":"GO_TERM","name":"retrograde trans-synaptic signaling by nitric oxide, modulating synaptic transmission","canonical_id":"go:GO:0098925","description":"\"Modulation of synaptic transmission by cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by nitric oxide.\" [GOC:dos]","metadata":null},{"id":"1fcd1eabc9f145d09b4bd0db6a3c9a45","type":"GO_TERM","name":"retrograde trans-synaptic signaling by soluble gas","canonical_id":"go:GO:0098923","description":"\"Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by an soluble gas ligand.\" [GOC:dos]","metadata":null},{"id":"4224a4dbcd724d7eab2c9150eec49300","type":"GO_TERM","name":"retrograde trans-synaptic signaling by trans-synaptic protein complex","canonical_id":"go:GO:0098942","description":"\"Cell-cell signaling from postsynapse to presynapse, across the synaptic cleft, mediated by trans-synaptic protein complex.\" [GOC:dos]","metadata":null},{"id":"6ff259c53a0e43608085caa11509afac","type":"GO_TERM","name":"retrograde transport, endosome to Golgi","canonical_id":"go:GO:0042147","description":"\"The directed movement of membrane-bounded vesicles from endosomes back to the trans-Golgi network where they are recycled for further rounds of transport.\" [GOC:jl, PMID:10873832, PMID:16936697]","metadata":null},{"id":"33d45cbeb46e419396b7b9ec1f635b09","type":"GO_TERM","name":"retrograde transport, plasma membrane to Golgi","canonical_id":"go:GO:0035526","description":"\"The directed movement of substances from the plasma membrane back to the trans-Golgi network, mediated by vesicles.\" [GOC:lb, PMID:17488291]","metadata":null},{"id":"a97ee416ab464c0b9f81e299854b7486","type":"GO_TERM","name":"retrograde transport, vacuole to Golgi","canonical_id":"go:GO:0045018","description":"\"The directed movement of substances from the vacuole to the trans-Golgi network; this occurs in yeast via the prevacuolar/endosomal compartment.\" [PMID:9700156]","metadata":null},{"id":"3c6298a0648c4397a8ac74c364da02a1","type":"GO_TERM","name":"retrograde transport, vesicle recycling within Golgi","canonical_id":"go:GO:0000301","description":"\"The retrograde movement of substances within the Golgi, mediated by COP I vesicles. Cis-Golgi vesicles are constantly moving forward through the Golgi stack by cisternal progression, eventually becoming trans-Golgi vesicles. They then selectively transport membrane and luminal proteins from the trans- to the medial-Golgi while leaving others behind in the trans-Golgi cisternae; similarly, they selectively move proteins from the medial- to the cis-Golgi.\" [ISBN:0716731363]","metadata":null},{"id":"04e0e219886c45cb9d009b65eaa73bd4","type":"GO_TERM","name":"retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum","canonical_id":"go:GO:0006890","description":"\"The directed movement of substances from the Golgi back to the endoplasmic reticulum, mediated by vesicles bearing specific protein coats such as COPI or COG.\" [ISBN:0716731363, PMID:16510524]","metadata":null},{"id":"ba2ed39811e34c3ba2825aa0a4d57b35","type":"GO_TERM","name":"retromer complex","canonical_id":"go:GO:0030904","description":"\"A conserved hetero-pentameric membrane-associated complex involved in retrograde transport from endosomes to the Golgi apparatus. The budding yeast retromer comprises Vps35p, Vps29p, Vps26p, Vps5p, and Vps17p. The mammalian complex shows slight variation in composition compared to yeast, and comprises SNX1 or SNX2, SNX5 or SNX6, VPS26A or VPS26B, VPS29, and VPS35.\" [GOC:bf, PMID:26220253, PMID:27385586, PMID:9700157]","metadata":null},{"id":"4aedddb3fcc54793b8bc55bdbf1c30bb","type":"GO_TERM","name":"retromer complex binding","canonical_id":"go:GO:1905394","description":"\"Binding to a retromer complex.\" [GOC:bc, GOC:PARL, GOC:TermGenie, PMID:27385586]","metadata":null},{"id":"2594782077b840278b3ce9d1c42f673d","type":"GO_TERM","name":"retromer, cargo-selective complex","canonical_id":"go:GO:0030906","description":"\"The trimeric subcomplex of the retromer, believed to be closely associated with the membrane. This trimeric complex is responsible for recognizing and binding to cargo molecules. The complex comprises three Vps proteins in both yeast and mammalian cells: Vps35p, Vps29p, and Vps26p in yeast, and VPS35, VPS29 and VPS26A or VPS26B in mammals.\" [GOC:bf, PMID:11102511, PMID:26220253, PMID:9700157]","metadata":null},{"id":"001301072c624821ae0cc498415d6548","type":"GO_TERM","name":"retromer, tubulation complex","canonical_id":"go:GO:0030905","description":"\"The dimeric subcomplex of the retromer, believed to be peripherally associated with the membrane. This dimeric complex is responsible for remodeling endosomal membranes to form a tube-structure to which cargo molecules are selected for recycling. The budding yeast complex comprises Vps5p and Vps17p, and may contain multiple copies of a Vps5p/Vps17p dimer. The mammalian complex contains SNX1 or SNX2 dimerized with SNX5 or SNX6.\" [GOC:bf, PMID:26220253, PMID:9700157]","metadata":null},{"id":"8b070a7ddd1f400eb2a5ca2d91bbd05d","type":"GO_TERM","name":"retrotransposition","canonical_id":"go:GO:0032197","description":"\"A type of transposition in which a transposable element (transposon) copies and pastes itself into a different genomic location by transcription and convertsion of the transcribed RNA back into DNA through reverse transcription.\" [ISBN:1555812090, PMID:26912865, PMID:30416149, PMID:30958115, PMID:32588192]","metadata":null},{"id":"7b119ccc9b1c468fa21488086d4661d0","type":"GO_TERM","name":"retrotransposon nucleocapsid","canonical_id":"go:GO:0000943","description":"\"A complex of the retrotransposon RNA genome, reverse transcriptase, integrase, and associated molecules required for reproduction and integration of the retrotransposon into the host genome; the main structural molecule of the nucleocapsid is often a gag protein homolog.\" [GOC:clt, PMID:10861903]","metadata":null},{"id":"94f731ddc0de4e4195af7cd8f6483c5a","type":"GO_TERM","name":"retrotrapezoid nucleus development","canonical_id":"go:GO:0061451","description":"\"The progression of the retrotrapezoid nucleus (RTN) over time from it's initial formation to its mature state. The retrotrapezoid nucleus is a group of neurons in the rostral medulla, which are responsible regulating respiration.\" [GOC:dph]","metadata":null},{"id":"22d2ae765e7e4e4bbde2466b20da5ebb","type":"GO_TERM","name":"retrotrapezoid nucleus neuron differentiation","canonical_id":"go:GO:0061452","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuron whose cell body resides in the retrotrapezoid nucleus.\" [GOC:dph]","metadata":null},{"id":"781d9f6ee9604909a19082faaa602810","type":"GO_TERM","name":"retroviral 3' processing activity","canonical_id":"go:GO:0044824","description":"\"The catalysis of the removal of two di- or tri-nucleotides from each 3' end of double-stranded viral DNA, exposing recessed 3' hydroxyls.\" [PMID:22580823]","metadata":null},{"id":"98bdc2593ca44b3fb4d67de05b5d1fb2","type":"GO_TERM","name":"retroviral intasome","canonical_id":"go:GO:0044834","description":"\"A tetramer of retroviral integrase subunits tightly associated with a pair of viral DNA ends. Functions to insert viral DNA into a host cell chromosome.\" [PMID:20118915]","metadata":null},{"id":"8a5897d86e4143d2905bb24685508134","type":"GO_TERM","name":"retroviral integrase activity","canonical_id":"go:GO:0044823","description":"\"Catalysis of the covalent insertion of double-stranded retroviral DNA into host DNA. Proceeds by an endonucleolytic cleavage at each 3'-OH extremity of the viral genome, named 3'-processing, followed by a strand transfer reaction leading to the insertion of the processed viral DNA into the target DNA by a trans-esterification mechanism.\" [PMID:19091057]","metadata":null},{"id":"49143378e17d49518e98bc76dbe188f7","type":"GO_TERM","name":"reuteran biosynthetic process","canonical_id":"go:GO:0052784","description":"\"The chemical reactions and pathways resulting in the formation of reuteran, a soluble glucan polymer with mainly alpha-(1->4) glycosidic linkages and significant amounts of alpha-(1->6) and alpha-(1->4,6) glucosidic linkages.\" [GOC:mengo_curators, PMID:15256553, PMID:16000808]","metadata":null},{"id":"fca1af1d045c4be58572be987797c55c","type":"GO_TERM","name":"reverse cholesterol transport","canonical_id":"go:GO:0043691","description":"\"The directed movement of peripheral cell cholesterol, cholest-5-en-3-beta-ol, towards the liver for catabolism.\" [GOC:ecd, PMID:7751809]","metadata":null},{"id":"8300014977df49b49e5b56132694d7f2","type":"GO_TERM","name":"reverse gyrase activity","canonical_id":"go:GO:0160097","description":"\"Catalysis of a DNA topological transformation by transiently cleaving one DNA strand at a time to allow passage of another strand; changes the linking number by +1 per catalytic cycle, is driven by ATP hydrolysis.\" [PMID:25013168]","metadata":null},{"id":"6735cfb3a0be425aa13967b48d353512","type":"GO_TERM","name":"reverse transcription","canonical_id":"go:GO:0001171","description":"\"A DNA synthesis process that uses RNA as the initial template for synthesis of DNA, but which also includes an RNase activity to remove the RNA strand of an RNA-DNA heteroduplex produced by the RNA-dependent synthesis step and use of the initial DNA strand as a template for DNA synthesis.\" [GOC:txnOH, PMID:20358252]","metadata":null},{"id":"b4ce6e73879344eeacb968bcf43e8743","type":"GO_TERM","name":"reversible differentiation","canonical_id":"go:GO:0090677","description":"\"A phenotypic switching process where a cell reversibly differentiates and dedifferentiates from one cell type into another.\" [GOC:curators]","metadata":null},{"id":"98b0d12a27054a91aa82a9b46e8a2368","type":"TRIAL","name":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","canonical_id":"clinicaltrials.gov:NCT07476846","description":"Primary Immune Thrombocytopenia (ITP)","metadata":null},{"id":"4fbb2ef41ebe43e6a3b199c135464c56","type":"GO_TERM","name":"rhabdomere","canonical_id":"go:GO:0016028","description":"\"The specialized microvilli-containing organelle on the apical surfaces of a photoreceptor cell containing the visual pigment rhodopsin and most of the proteins involved in phototransduction.\" [GOC:hb, GOC:sart, PMID:8646774]","metadata":null},{"id":"e62a69e49cbd438d8fb9c9855f3fd222","type":"GO_TERM","name":"rhabdomere development","canonical_id":"go:GO:0042052","description":"\"The assembly and arrangement of a rhabdomere within a cell. The rhabdomere is the organelle on the apical surface of a photoreceptor cell that contains the visual pigments.\" [PMID:3076112, PMID:3937883]","metadata":null},{"id":"e1b683277c7a4f6f8bcba0d7f45320e0","type":"GO_TERM","name":"rhabdomere membrane","canonical_id":"go:GO:0033583","description":"\"The portion of the plasma membrane surrounding the rhabdomere.\" [GOC:mah]","metadata":null},{"id":"88481c1a904d442d993e2121bfa541db","type":"GO_TERM","name":"rhabdomere membrane biogenesis","canonical_id":"go:GO:0045313","description":"\"A process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a rhabdomere membrane.\" [GOC:jl]","metadata":null},{"id":"010e3d49f10945b2937eda9e67d74c94","type":"GO_TERM","name":"rhabdomere microvillus","canonical_id":"go:GO:0035996","description":"\"Thin cylindrical membrane-covered projection on the surface of a rhabdomere.\" [GOC:bf, GOC:sart, PMID:14744998]","metadata":null},{"id":"fd16cd4816594c5182a0185a78e2bc35","type":"GO_TERM","name":"rhabdomere microvillus membrane","canonical_id":"go:GO:0035997","description":"\"The portion of the plasma membrane surrounding a microvillus of a rhabdomere.\" [GOC:bf, GOC:sart, PMID:14744998]","metadata":null},{"id":"413916536697430db496cd9985b4e2da","type":"GO_TERM","name":"rhabdomere morphogenesis","canonical_id":"go:GO:0061541","description":"\"The process in which the anatomical structures of a rhabdomere are generated and organized. The rhabdomere is the organelle on the apical surface of a photoreceptor cell that contains the visual pigments.\" [GOC:dph, PMID:22113834]","metadata":null},{"id":"ae3baee3cc22441685b212c6c72bd7f0","type":"GO_TERM","name":"rhamnetin 3'-O-methyltransferase activity","canonical_id":"go:GO:0102447","description":"\"Catalysis of the reaction: rhamnetin + S-adenosyl-L-methionine = H+ + rhamnacene + S-adenosyl-L-homocysteine.\" [RHEA:73271]","metadata":null},{"id":"5de9b6a1137c46cb902f695a88689aa0","type":"GO_TERM","name":"rhamnetin 3-O-methyltransferase activity","canonical_id":"go:GO:0102446","description":"\"Catalysis of the reaction: rhamnetin + S-adenosyl-L-methionine = 3',4',5-trihydroxy-3,7-dimethoxyflavone + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74763]","metadata":null},{"id":"20c76138597a45718d2f9e455b7037cc","type":"GO_TERM","name":"rhamnetin 4'-O-methyltransferase activity","canonical_id":"go:GO:0102448","description":"\"Catalysis of the reaction: rhamnetin + S-adenosyl-L-methionine = 7,4'-O-dimethylquercetin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74731]","metadata":null},{"id":"97d6eb0ad82e4d5da7077aae38699e6d","type":"GO_TERM","name":"rhamnogalacturonan I biosynthetic process","canonical_id":"go:GO:0010246","description":"\"The chemical reactions and pathways resulting in the formation of rhamnogalacturonan I component of pectin, a rhamnose-rich pectic polysaccharide.\" [GOC:pz]","metadata":null},{"id":"2df52e753f5d4c82b889d3b2bb309b76","type":"GO_TERM","name":"rhamnogalacturonan I metabolic process","canonical_id":"go:GO:0010395","description":"\"The chemical reactions and pathways involving rhamnogalacturonan I (RGI), a branched pectin with a backbone of alternating alpha-(1->2)-linked rhamnose and alpha-(1->4)-linked D-galacturonic acid residues that carries neutral side-chains of predominantly beta-(1->4)-D-galactose and/or alpha-(1->5)-L-arabinose residues attached to the rhamnose residues of the RGI backbone.\" [GOC:tair_curators]","metadata":null},{"id":"748d4a80b77f45bb938a0ef74570a590","type":"GO_TERM","name":"rhamnogalacturonan I side chain metabolic process","canonical_id":"go:GO:0010400","description":"\"The chemical reactions and pathways involving the side chains of the pectin, rhamnogalacturonan I.\" [GOC:tair_curators]","metadata":null},{"id":"87714340a8ac4f66856c3e26af0adb9f","type":"GO_TERM","name":"rhamnogalacturonan II biosynthetic process","canonical_id":"go:GO:0010306","description":"\"The chemical reactions and pathways resulting in the formation of rhamnogalacturonan II, a low molecular mass (5 - 10KDa) pectic polysaccharide, conserved in the primary walls of dicotyledenous and monocotyledenous plants and gymnosperms.\" [PMID:12754267]","metadata":null},{"id":"c500af5bfc5a4367bd24d97752234f80","type":"GO_TERM","name":"rhamnogalacturonan acetylesterase activity","canonical_id":"go:GO:0046575","description":"\"Catalysis of the removal of acetylesters (as acetate) from galacturonic acid residues in the backbone of rhamnogalacturonan.\" [PMID:10801485]","metadata":null},{"id":"1cf30df672b8490da9fca347e7ddade8","type":"GO_TERM","name":"rhamnogalacturonan alpha-L-rhamnopyranosyl-(1->4)-alpha-D-galactopyranosyluronide lyase activity","canonical_id":"go:GO:0046576","description":"\"Catalysis of the cleavage of rhamnogalacturonan, generating oligosaccharides of the form alpha-D-us-galacturonic acid-(1,2)-alpha-L-rhamnose-(1,4)-alpha-D-galacturonate-(1,2)-L-rhamnose-(1,2)-alpha-L-rhamnose-p-(1,4)-alpha-D-galacturonic acid, terminating at the non-reducing end with a hex-4-enopyranosyluronic acid residue.\" [PMID:8587995, PMID:8720076]","metadata":null},{"id":"cb967ed17fd24f168309b36d284c6ab5","type":"GO_TERM","name":"rhamnogalacturonan endolyase activity","canonical_id":"go:GO:0102210","description":"\"Catalysis of the reaction: H2O + a rhamnogalacturonan type I = [rhamnogalacturonan I oligosaccharide]-alpha-L-rhamnose + 4-deoxy-4,5-unsaturated D-galactopyranosyluronate-[rhamnogalacturonan I oligosaccharide].\" [EC:4.2.2.23, GOC:pz]","metadata":null},{"id":"ea3e6bcccbff4127b349e369eb1b445f","type":"GO_TERM","name":"rhamnolipid biosynthesis","canonical_id":"go:GO:0106236","description":"\"The chemical reactions and pathways resulting in the formation/production of a glycolipid surfactant that acts as a bacterial biofilm dispersal.\" [GOC:vw, PMID:28715477]","metadata":null},{"id":"cc8af32f0fd94a2e81274dd4d134ee74","type":"GO_TERM","name":"rhamnose binding","canonical_id":"go:GO:0033296","description":"\"Binding to the D- or L-enantiomer of rhamnose.\" [GOC:mah]","metadata":null},{"id":"571339a2c6184febbe19479e680a0ec0","type":"GO_TERM","name":"rhamnose biosynthetic process","canonical_id":"go:GO:0019300","description":"\"The chemical reactions and pathways resulting in the formation of rhamnose, the hexose 6-deoxy-L-mannose.\" [ISBN:0198506732]","metadata":null},{"id":"d39b698c80a04a36baa9b684ea89ba1b","type":"GO_TERM","name":"rhamnose catabolic process","canonical_id":"go:GO:0019301","description":"\"The chemical reactions and pathways resulting in the breakdown of rhamnose, the hexose 6-deoxy-L-mannose.\" [ISBN:0198506732]","metadata":null},{"id":"c192a3e01caf45c081c22cf7da9a0708","type":"GO_TERM","name":"rhamnose transmembrane transport","canonical_id":"go:GO:0015762","description":"\"The process in which rhamnose is transported across a lipid bilayer, from one side of a membrane to the other. Rhamnose occurs commonly as a compound of plant glycosides, in polysaccharides of gums and mucilages, and in bacterial polysaccharides. It is also a component of some plant cell wall polysaccharides and frequently acts as the sugar components of flavonoids.\" [GOC:ai]","metadata":null},{"id":"1dafde09721f44e192b70df7ee6a0b8e","type":"GO_TERM","name":"rhamnose transmembrane transporter activity","canonical_id":"go:GO:0015153","description":"\"Enables the transfer of rhamnose from one side of a membrane to the other. Rhamnose occurs commonly as a compound of plant glycosides, in polysaccharides of gums and mucilages, and in bacterial polysaccharides. It is also a component of some plant cell wall polysaccharides and frequently acts as the sugar components of flavonoids.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"92a21ef573284ec0b5c6596dc9ec73cb","type":"GO_TERM","name":"rhamnose:proton symporter activity","canonical_id":"go:GO:0015561","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: rhamnose(out) + H+(out) = rhamnose(in) + H+(in).\" [TC:2.A.7.6]","metadata":null},{"id":"08b3f783f8ab49aba6aa0c8ea3b65825","type":"GO_TERM","name":"rhamnulokinase activity","canonical_id":"go:GO:0008993","description":"\"Catalysis of the reaction: ATP + L-rhamnulose = ADP + L-rhamnulose 1-phosphate.\" [EC:2.7.1.5]","metadata":null},{"id":"dca0b3e298e74c9d8417762e6abe5311","type":"GO_TERM","name":"rhamnulose-1-phosphate aldolase activity","canonical_id":"go:GO:0008994","description":"\"Catalysis of the reaction: L-rhamnulose 1-phosphate = glycerone phosphate + (S)-lactaldehyde.\" [EC:4.1.2.19]","metadata":null},{"id":"16e273d0f3f64ac7b2e4319768fb1ed2","type":"DISEASE","name":"rheumatic disorder","canonical_id":"mondo:0005554","description":null,"metadata":null},{"id":"6af726815e90424988465d26073e37f7","type":"DISEASE","name":"rheumatoid arthritis","canonical_id":"mondo:0008383","description":null,"metadata":null},{"id":"f97ca74291fc482883967016fd924496","type":"DISEASE","name":"rhinitis","canonical_id":"mondo:0003014","description":null,"metadata":null},{"id":"a0e3f22af9be4fa1aab963b29b64725e","type":"GO_TERM","name":"rhizobactin 1021 biosynthetic process","canonical_id":"go:GO:0019289","description":"\"The chemical reactions and pathways resulting in the formation of rhizobactin 1021, (E)-4-((3-(acetylhydroxyamino)propyl)-amino)-2-hydroxy-(2-(2-(3-(hydroxy(1-oxo-2-decenyl)amino)propyl)amino)-2-oxoethyl)-4-oxobutanoic acid, a siderophore produced by Sinorhizobium meliloti.\" [PMID:11274118]","metadata":null},{"id":"52a042d513d8487cb3450677e078523c","type":"GO_TERM","name":"rhodopsin biosynthetic process","canonical_id":"go:GO:0016063","description":"\"The chemical reactions and pathways resulting in the formation of rhodopsin, a brilliant purplish-red, light-sensitive visual pigment found in the rod cells of the retinas.\" [ISBN:0198506732]","metadata":null},{"id":"4bb1589f5a464696bd6bd3e38afb4e7f","type":"GO_TERM","name":"rhodopsin catabolic process","canonical_id":"go:GO:0046155","description":"\"The chemical reactions and pathways resulting in the breakdown of rhodopsin, a brilliant purplish-red, light-sensitive visual pigment found in the rod cells of the retinas.\" [ISBN:0198506732]","metadata":null},{"id":"887feda90c0e43568a9d777d7b148327","type":"GO_TERM","name":"rhodopsin kinase activity","canonical_id":"go:GO:0050254","description":"\"Catalysis of the reaction: ATP + rhodopsin = ADP + phosphorhodopsin.\" [PMID:14654303]","metadata":null},{"id":"8bfdf057fe47414497679d158602865e","type":"GO_TERM","name":"rhodopsin metabolic process","canonical_id":"go:GO:0046154","description":"\"The chemical reactions and pathways involving rhodopsin, a brilliant purplish-red, light-sensitive visual pigment found in the rod cells of the retinas.\" [ISBN:0198506732]","metadata":null},{"id":"628641acd5064f1a83666231368c469e","type":"GO_TERM","name":"rhombomere 1 development","canonical_id":"go:GO:0021567","description":"\"The process whose specific outcome is the progression of rhombomere 1 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"39123cd682f64a678776c981cde61892","type":"GO_TERM","name":"rhombomere 1 formation","canonical_id":"go:GO:0021652","description":"\"The process that gives rise to rhombomere 1. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"da20981784fd4ef3b59ca0b70e06f3a4","type":"GO_TERM","name":"rhombomere 1 morphogenesis","canonical_id":"go:GO:0021651","description":"\"The process in which the anatomical structure of rhombomere 1 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a99dce1caa2d40b38e396dc3c1f98de8","type":"GO_TERM","name":"rhombomere 1 structural organization","canonical_id":"go:GO:0021653","description":"\"The process that contributes to creating the structural organization of rhombomere 1. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"4ea66be534054268b0e8d507bed81864","type":"GO_TERM","name":"rhombomere 2 development","canonical_id":"go:GO:0021568","description":"\"The process whose specific outcome is the progression of rhombomere 2 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6f341af409164cafb8e22745db891f0d","type":"GO_TERM","name":"rhombomere 2 formation","canonical_id":"go:GO:0021657","description":"\"The process that gives rise to rhombomere 2. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5657e1811aae488396f6a1671bf65ac9","type":"GO_TERM","name":"rhombomere 2 morphogenesis","canonical_id":"go:GO:0021655","description":"\"The process in which the anatomical structure of rhombomere 2 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"87915b92d88e4b7e8692761c3a2ad00c","type":"GO_TERM","name":"rhombomere 2 structural organization","canonical_id":"go:GO:0021656","description":"\"The process that contributes to creating the structural organization of rhombomere 2. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2853bee8f31a4ddfb58321f28c9d3d8e","type":"GO_TERM","name":"rhombomere 3 development","canonical_id":"go:GO:0021569","description":"\"The process whose specific outcome is the progression of rhombomere 3 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e9dbb36f2973416ca806194bb5adbcd0","type":"GO_TERM","name":"rhombomere 3 formation","canonical_id":"go:GO:0021660","description":"\"The process that gives rise to rhombomere 3. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"87a8be1499544900b91b7dc8729c2934","type":"GO_TERM","name":"rhombomere 3 morphogenesis","canonical_id":"go:GO:0021658","description":"\"The process in which the anatomical structure of rhombomere 3 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7b5c2ea660b6436389f47311893777eb","type":"GO_TERM","name":"rhombomere 3 structural organization","canonical_id":"go:GO:0021659","description":"\"The process that contributes to creating the structural organization of rhombomere 3. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"205c0138456b4a6095929b8cf1d8310e","type":"GO_TERM","name":"rhombomere 4 development","canonical_id":"go:GO:0021570","description":"\"The process whose specific outcome is the progression of rhombomere 4 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b27dfc11ad7b4524b0d9eca869b45f42","type":"GO_TERM","name":"rhombomere 4 formation","canonical_id":"go:GO:0021663","description":"\"The process that gives rise to rhombomere 4. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2af1fd34e6544dafac469556821c9c98","type":"GO_TERM","name":"rhombomere 4 morphogenesis","canonical_id":"go:GO:0021661","description":"\"The process in which the anatomical structure of rhombomere 4 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"95591da390ad40a6b5abea4ccb1b0194","type":"GO_TERM","name":"rhombomere 4 structural organization","canonical_id":"go:GO:0021662","description":"\"The process that contributes to creating the structural organization of rhombomere 4. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"40a64fc9814e49de9fda03372b13dea6","type":"GO_TERM","name":"rhombomere 5 development","canonical_id":"go:GO:0021571","description":"\"The process whose specific outcome is the progression of rhombomere 5 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"321a9c195ea5407fbfbd287be4c1af99","type":"GO_TERM","name":"rhombomere 5 formation","canonical_id":"go:GO:0021666","description":"\"The process that gives rise to rhombomere 5. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b13b9f2e31a242f7a472571da3d4e250","type":"GO_TERM","name":"rhombomere 5 morphogenesis","canonical_id":"go:GO:0021664","description":"\"The process in which the anatomical structures of rhombomere 5 are generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"61e170b5bac44f0ab2b02327f5a10405","type":"GO_TERM","name":"rhombomere 5 structural organization","canonical_id":"go:GO:0021665","description":"\"The process that contributes to creating the structural organization of rhombomere 5. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2b4df7ac364f40e596ec53b1b0e77091","type":"GO_TERM","name":"rhombomere 6 development","canonical_id":"go:GO:0021572","description":"\"The process whose specific outcome is the progression of rhombomere 6 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"da7be49740e448f0bdb3aea1675867d1","type":"GO_TERM","name":"rhombomere 6 formation","canonical_id":"go:GO:0021669","description":"\"The process that gives rise to rhombomere 6. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"48504a0a5c404ec48ded846f190a5121","type":"GO_TERM","name":"rhombomere 6 morphogenesis","canonical_id":"go:GO:0021667","description":"\"The process in which the anatomical structure of rhombomere 6 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"8c798ab3a72947bdaadcaa534bd0c118","type":"GO_TERM","name":"rhombomere 6 structural organization","canonical_id":"go:GO:0021668","description":"\"The process that contributes to creating the structural organization of rhombomere 6. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d151b797c7244cdbb59bd1a126a65727","type":"GO_TERM","name":"rhombomere 7 development","canonical_id":"go:GO:0021573","description":"\"The process whose specific outcome is the progression of rhombomere 7 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b05760653383492d83fe7121285fa51f","type":"GO_TERM","name":"rhombomere 7 formation","canonical_id":"go:GO:0021673","description":"\"The process that gives rise to rhombomere 7. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b5c56363591d472383fb6bcb6cef01d9","type":"GO_TERM","name":"rhombomere 7 morphogenesis","canonical_id":"go:GO:0021671","description":"\"The process in which the anatomical structure of rhombomere 7 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5badf7b07b274163b7402e5839be21f1","type":"GO_TERM","name":"rhombomere 7 structural organization","canonical_id":"go:GO:0021672","description":"\"The process that contributes to creating the structural organization of rhombomere 7. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"aa1b382dbd144fceb8394848f0f88a2d","type":"GO_TERM","name":"rhombomere 8 development","canonical_id":"go:GO:0021574","description":"\"The process whose specific outcome is the progression of rhombomere 8 over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"9e88e40dfe05449dbdf1d5fdc48af943","type":"GO_TERM","name":"rhombomere 8 formation","canonical_id":"go:GO:0021677","description":"\"The process that gives rise to rhombomere 8. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"7ffc1161093643829d4f33be5a889a17","type":"GO_TERM","name":"rhombomere 8 morphogenesis","canonical_id":"go:GO:0021674","description":"\"The process in which the anatomical structure of rhombomere 8 is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"cdb47d6b037249599987387e056b46d7","type":"GO_TERM","name":"rhombomere 8 structural organization","canonical_id":"go:GO:0021676","description":"\"The process that contributes to creating the structural organization of rhombomere 8. This process pertains to the physical shaping of a rudimentary structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in an anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"26237913094b4c64aec234bd96446047","type":"GO_TERM","name":"rhombomere boundary formation","canonical_id":"go:GO:0021654","description":"\"The process that gives rise to a rhombomere boundary. This process pertains to the initial formation of a boundary delimiting a rhombomere. Rhombomeres are transverse segments of the developing rhombencephalon that are lineage restricted, express different genes from one another, and adopt different developmental fates. Rhombomeres are numbered in anterior to posterior order.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6ef6e8efd3394601bc08947169d21342","type":"GO_TERM","name":"rhombomere cell differentiation","canonical_id":"go:GO:0022036","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a rhombomere cell.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3a5e7c485e2449c7918f3c23283d31c9","type":"GO_TERM","name":"rhombomere cell migration","canonical_id":"go:GO:0022035","description":"\"The movement of a cell within a rhombomere. This process is known to occur as an early step in the generation of anatomical structure from a rhombomere.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15629700]","metadata":null},{"id":"a9069be43798462c9d846297887da29f","type":"GO_TERM","name":"rhombomere cell proliferation","canonical_id":"go:GO:0022034","description":"\"The multiplication or reproduction of rhombomere cells, resulting in the expansion of the cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"931a479ede4948a0ba0b300e1a0b228c","type":"GO_TERM","name":"rhombomere development","canonical_id":"go:GO:0021546","description":"\"The process whose specific outcome is the progression of the rhombomere over time, from its formation to the mature structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8abdec5fa9a14909889c69a8c99b17d7","type":"GO_TERM","name":"rhombomere formation","canonical_id":"go:GO:0021594","description":"\"The process that gives rise to the rhombomere. This process pertains to the initial formation of a structure from unspecified parts. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"1fdff0988ae2401393c7d026ce12cb02","type":"GO_TERM","name":"rhombomere morphogenesis","canonical_id":"go:GO:0021593","description":"\"The process in which the anatomical structure of the rhombomere is generated and organized. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"11c7f95ae7bb49e89d9f0328df189556","type":"GO_TERM","name":"rhombomere structural organization","canonical_id":"go:GO:0021595","description":"\"The process that contributes to the act of creating the structural organization of the rhombomere structure. Rhombomeres are transverse segments of the developing rhombencephalon. Rhombomeres are lineage restricted, express different genes from one another, and adopt different developmental fates.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"7e86be62c95042a1a9eab36c1e73cf61","type":"GO_TERM","name":"rhoptry","canonical_id":"go:GO:0020008","description":"\"A large, club-shaped secretory organelle that forms part of the apical complex of an apicomplexan parasite, and consists of a bulbous body and a narrow electron-dense neck that extends through the conoid at the apical tip of the parasite. The rhoptry necks serve as ducts through which the contents of the rhoptries are secreted after attachment to the host has been completed and at the commencement of invasion. Rhoptry proteins function in the biogenesis and host organellar association of the parasitophorous vacuole.\" [ISBN:0521664470, PMID:11801218, PMID:16002398]","metadata":null},{"id":"8e80893c9de2451fa68b29f9d43296c1","type":"GO_TERM","name":"rhoptry lumen","canonical_id":"go:GO:0034591","description":"\"The volume enclosed by the rhoptry membrane.\" [GOC:rph, PMID:17997128]","metadata":null},{"id":"1ec0d4f33d854f839a4e6af6b2f0235f","type":"GO_TERM","name":"rhoptry membrane","canonical_id":"go:GO:0033016","description":"\"The lipid bilayer surrounding a rhoptry.\" [GOC:mah]","metadata":null},{"id":"4a1966d86f1c4fd196e3a0939089ae1d","type":"GO_TERM","name":"rhoptry neck","canonical_id":"go:GO:1990225","description":"\"Narrow, electron-dense part of the rhoptry that extends through the conoid at the apical tip of an apicomplexan parasite. The rhoptry neck serves as a duct through which the contents of the rhoptry are secreted after attachment to the host has been completed and at the commencement of invasion.\" [GOC:giardia, GOC:pr, PMID:23499754, PMID:23937520, PMID:24002067, PMID:24070999]","metadata":null},{"id":"aac74d1bdf774f6a912b6611bf511785","type":"GO_TERM","name":"rhythmic behavior","canonical_id":"go:GO:0007622","description":"\"The specific behavior of an organism that recur with measured regularity.\" [GOC:jl, GOC:pr]","metadata":null},{"id":"ce99ff59d3f14a0bbc7453b5a656f760","type":"GO_TERM","name":"rhythmic excitation","canonical_id":"go:GO:0043179","description":"\"Any process involved in the generation of rhythmic, synchronous excitatory synaptic inputs in a neural circuit.\" [GOC:curators, ISBN:0195088433]","metadata":null},{"id":"da9ee47e8e7047cf833b409a90ad0293","type":"GO_TERM","name":"rhythmic inhibition","canonical_id":"go:GO:0043180","description":"\"Any process involved in the generation of rhythmic, synchronous inhibitory synaptic inputs in a neural circuit.\" [GOC:curators]","metadata":null},{"id":"328324fd4b604de1ae17e82ccb214abd","type":"GO_TERM","name":"rhythmic process","canonical_id":"go:GO:0048511","description":"\"Any process pertinent to the generation and maintenance of rhythms in the physiology of an organism.\" [GOC:jid]","metadata":null},{"id":"29595ea6fd9f42568e71a30a9e5ecd41","type":"GO_TERM","name":"rhythmic synaptic transmission","canonical_id":"go:GO:0060024","description":"\"Any process involved in the generation of rhythmic, synchronous synaptic inputs in a neural circuit.\" [GOC:dph]","metadata":null},{"id":"6261a42b74d54cc5882df2cef2aabf7e","type":"DRUG","name":"ribavirin","canonical_id":"gtopdb:6842","description":null,"metadata":null},{"id":"63cca04b1b7740c7af23e9a54a73f223","type":"DRUG","name":"ribavirin","canonical_id":"mesh:D012254","description":null,"metadata":null},{"id":"666dd4fb9c3f4ba6b8ea35450cd6d8f0","type":"DRUG","name":"ribavirin","canonical_id":"chembl:CHEMBL1643","description":null,"metadata":null},{"id":"4b759f61834142219bb852b67df27f51","type":"COMBINATION_TREATMENT","name":"ribavirin + rosiglitazone","canonical_id":"ctgov_combo:ctgov-combo-20c377b3fc7d1831","description":null,"metadata":null},{"id":"2a456482ef064f40bf96ececebdc22d5","type":"GO_TERM","name":"ribbon synapse","canonical_id":"go:GO:0097470","description":"\"Type of synapse characterized by an electron-dense ribbon, lamella (bar) or spherical body in the presynaptic process cytoplasm.\" [NIF_Subcellular:sao1884931180, PMID:15626493]","metadata":null},{"id":"ce31376690ea4e9a9069a56ffe5e2538","type":"GO_TERM","name":"ribitol 2-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050255","description":"\"Catalysis of the reaction: D-ribitol + NAD+ = D-ribulose + H+ + NADH.\" [EC:1.1.1.56, RHEA:20053]","metadata":null},{"id":"71ebed05cf374ae888b386c56760da68","type":"GO_TERM","name":"ribitol beta-1,4-xylosyltransferase activity","canonical_id":"go:GO:0120053","description":"\"Catalysis of the reaction: UDP-D-xylose + D-ribitol 5-phosphate-R = UDP + beta1,4-xylosyl-D-ribitol 5-phosphate-R.\" [PMID:27733679]","metadata":null},{"id":"7e6dcd83561743689fdfb49da0f6b1ac","type":"GO_TERM","name":"ribitol biosynthetic process","canonical_id":"go:GO:0046362","description":"\"The chemical reactions and pathways resulting in the formation of ribitol, a pentitol derived formally by reduction of the -CHO group of either D- or L-ribose.\" [ISBN:0198506732]","metadata":null},{"id":"023b0827fcb34e54b35e6f62eb3e3ca4","type":"GO_TERM","name":"ribitol catabolic process","canonical_id":"go:GO:0046363","description":"\"The chemical reactions and pathways resulting in the breakdown of ribitol, a pentitol derived formally by reduction of the -CHO group of either D- or L-ribose.\" [ISBN:0198506732]","metadata":null},{"id":"7506079ecea941adb558ad19dd533f4c","type":"GO_TERM","name":"ribitol-5-phosphatase activity","canonical_id":"go:GO:0110130","description":"\"Catalysis of the reaction: ribitol-5-phosphate + H20 = ribitol + phosphate.\" [GOC:rn, PMID:30240188]","metadata":null},{"id":"1a128103c2104d65978b693ef305e55b","type":"GO_TERM","name":"ribitol-5-phosphate 2-dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0050256","description":"\"Catalysis of the reaction: D-ribitol 5-phosphate + NAD(P)+ = D-ribulose 5-phosphate + NAD(P)H + H+.\" [EC:1.1.1.137]","metadata":null},{"id":"7a9bd5db94624809ba6129359073b2cf","type":"DRUG","name":"ribociclib","canonical_id":"gtopdb:7383","description":null,"metadata":null},{"id":"4b76db16d38e472fabf58547290d8b55","type":"DRUG","name":"ribociclib","canonical_id":"chembl:CHEMBL3545110","description":null,"metadata":null},{"id":"a8e9c5c722c84d72a923dcbac30ab0de","type":"COMBINATION_TREATMENT","name":"ribociclib + trametinib","canonical_id":"ctgov_combo:ctgov-combo-1c283e1276ebcb0d","description":null,"metadata":null},{"id":"386198dbc8c1408b9266ccce35605b01","type":"COMBINATION_TREATMENT","name":"ribociclib + trastuzumab","canonical_id":"ctgov_combo:ctgov-combo-a78071e87f881167","description":null,"metadata":null},{"id":"d759e4cc1e474db093660c1259ff6081","type":"GO_TERM","name":"riboflavin binding","canonical_id":"go:GO:1902444","description":"\"Binding to riboflavin.\" [GOC:TermGenie, PMID:12083520]","metadata":null},{"id":"827de5da9f4a481c98ede10f34a44156","type":"GO_TERM","name":"riboflavin biosynthetic process","canonical_id":"go:GO:0009231","description":"\"The chemical reactions and pathways resulting in the formation of riboflavin (vitamin B2), the precursor for the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).\" [GOC:jl, PMID:10940330]","metadata":null},{"id":"807cbb9e53194fd49b27d31151c474de","type":"GO_TERM","name":"riboflavin catabolic process","canonical_id":"go:GO:0009232","description":"\"The chemical reactions and pathways resulting in the breakdown of riboflavin (vitamin B2), the precursor for the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).\" [GOC:jl, PMID:10961912]","metadata":null},{"id":"dfc7fb3acfb942c3a531487558e96c59","type":"GO_TERM","name":"riboflavin kinase activity","canonical_id":"go:GO:0008531","description":"\"Catalysis of the reaction: ATP + riboflavin = ADP + FMN + 2 H+.\" [EC:2.7.1.26, RHEA:14357]","metadata":null},{"id":"b2c53958ce1c4167ab03f417504334de","type":"GO_TERM","name":"riboflavin metabolic process","canonical_id":"go:GO:0006771","description":"\"The chemical reactions and pathways involving riboflavin (vitamin B2), the precursor for the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD).\" [GOC:jl, PMID:11153262, PMID:24764086]","metadata":null},{"id":"5f48bdc830e24cd4853eb5e4a3081c01","type":"GO_TERM","name":"riboflavin phosphotransferase activity","canonical_id":"go:GO:0050257","description":"\"Catalysis of the reaction: alpha-D-glucose 1-phosphate + riboflavin = D-glucose + FMN.\" [EC:2.7.1.42, RHEA:20409]","metadata":null},{"id":"660ab18288394064b48b10cdae1a56b7","type":"GO_TERM","name":"riboflavin reductase (NADPH) activity","canonical_id":"go:GO:0042602","description":"\"Catalysis of the reaction: reduced riboflavin + NADP+ = riboflavin + NADPH + 2 H+.\" [RHEA:19377]","metadata":null},{"id":"4fe87fd74f454b33aaebe09b6ca6217e","type":"GO_TERM","name":"riboflavin reductase [NAD(P)H] activity","canonical_id":"go:GO:0052875","description":"\"Catalysis of the reaction: reduced riboflavin + NAD(P)+ = riboflavin + NAD(P)H + 2 H+. This reaction can utilize NADH and NADPH.\" [EC:1.5.1.41]","metadata":null},{"id":"0b4d93a33fa840c9b13f02ea0eb7894e","type":"GO_TERM","name":"riboflavin synthase activity","canonical_id":"go:GO:0004746","description":"\"Catalysis of the reaction: 2 6,7-dimethyl-8-(1-D-ribityl)lumazine + H+ = 5-amino-6-(D-ribitylamino)uracil + riboflavin.\" [EC:2.5.1.9, RHEA:20772]","metadata":null},{"id":"7192c6b252164c5fbdc682a5e93f9c68","type":"GO_TERM","name":"riboflavin synthase complex","canonical_id":"go:GO:0009349","description":"\"An flavoprotein that catalyzes the reaction the breakdown of dimethyl(ribityl)lumazine to form riboflavin and ribitylamino-amino-dihydroxypyrimidine.\" [PMID:18298940]","metadata":null},{"id":"fe028df745b54a2a87354c3fa930051b","type":"GO_TERM","name":"riboflavin transmembrane transporter activity","canonical_id":"go:GO:0032217","description":"\"Enables the transfer of riboflavin from one side of a membrane to the other. Riboflavin (vitamin B2) is a water-soluble B-complex vitamin, converted in the cell to FMN and FAD, cofactors required for the function of flavoproteins.\" [GOC:rn, PMID:16204239]","metadata":null},{"id":"637ca1ed008f44d5bf28411ffd940ced","type":"GO_TERM","name":"riboflavin transport","canonical_id":"go:GO:0032218","description":"\"The directed movement of riboflavin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Riboflavin (vitamin B2) is a water-soluble B-complex vitamin, converted in the cell to FMN and FAD, cofactors required for the function of flavoproteins.\" [GOC:rn, PMID:16204239]","metadata":null},{"id":"ab32e29bda114e63ad094c41950b5d46","type":"GO_TERM","name":"riboflavinase activity","canonical_id":"go:GO:0050258","description":"\"Catalysis of the reaction: H2O + H+ + riboflavin = D-ribitol + lumichrome.\" [EC:3.5.99.1, RHEA:11408]","metadata":null},{"id":"d8f96f15cd524cfab8ccaf963b1e8494","type":"GO_TERM","name":"ribokinase activity","canonical_id":"go:GO:0004747","description":"\"Catalysis of the reaction: ATP + D-ribose = ADP + D-ribose 5-phosphate.\" [EC:2.7.1.15]","metadata":null},{"id":"fe06b48fa5cd4d2ca59f8fef22412416","type":"GO_TERM","name":"ribonuclease A activity","canonical_id":"go:GO:0004522","description":"\"Catalysis of the endonucleolytic cleavage of RNA to 3'-phosphomononucleotides and 3'-phosphooligonucleotides ending in C-P or U-P with 2',3'-cyclic phosphate intermediates.\" [EC:4.6.1.18]","metadata":null},{"id":"8e933b37b4f0417babd18138127630be","type":"GO_TERM","name":"ribonuclease D activity","canonical_id":"go:GO:0033890","description":"\"Catalysis of the exonucleolytic cleavage that removes extra residues from the 3'-terminus of tRNA to produce 5'-mononucleotides.\" [EC:3.1.13.5]","metadata":null},{"id":"59633fde6080426e95ec76965feba38f","type":"GO_TERM","name":"ribonuclease E activity","canonical_id":"go:GO:0008995","description":"\"Catalysis of the cleavage of single-stranded RNA that is monophosphorylated at its 5'-end; cleavage occurs predominantly at 5 nucleotides from the 5'-end and in A + U-rich regions, and is blocked by the presence of a 5'-triphosphate group.\" [EC:3.1.26.12, PMID:10722715, PMID:16854990]","metadata":null},{"id":"440e6423fd8145dfa6ab73ccf17b2070","type":"GO_TERM","name":"ribonuclease F activity","canonical_id":"go:GO:0033900","description":"\"Catalysis of the endonucleolytic cleavage of RNA precursor into two, leaving 5'-hydroxy and 3'-phosphate groups.\" [EC:3.1.27.7]","metadata":null},{"id":"1bd8d0dddb114ddb97e7e456f8125523","type":"GO_TERM","name":"ribonuclease H2 complex","canonical_id":"go:GO:0032299","description":"\"A protein complex that possesses ribonuclease H activity, in which the catalytic subunit is a member of the RNase H2 (or HII) class. For example, in Saccharomyces the complex contains Rnh201p, Rnh202p and Rnh203p.\" [GOC:mah, PMID:14734815]","metadata":null},{"id":"90a61279dbe14c52a45f7ac2377fc6a3","type":"GO_TERM","name":"ribonuclease III activity","canonical_id":"go:GO:0004525","description":"\"Catalysis of the endonucleolytic cleavage of RNA with 5'-phosphomonoesters and 3'-OH termini; makes two staggered cuts in both strands of dsRNA, leaving a 3' overhang of 2 nt.\" [PMID:11157775, PMID:15242644]","metadata":null},{"id":"cafb665f9ddf4e3fbf2a1000ddb3d16f","type":"GO_TERM","name":"ribonuclease III complex","canonical_id":"go:GO:1903095","description":"\"A protein complex which is capable of ribonuclease III activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:22393237]","metadata":null},{"id":"660f610c97d34a7da075629319ceddd0","type":"GO_TERM","name":"ribonuclease IV activity","canonical_id":"go:GO:0033893","description":"\"Catalysis of the endonucleolytic cleavage of poly(A) to fragments terminated by 3'-hydroxy and 5'-phosphate groups.\" [EC:3.1.26.6]","metadata":null},{"id":"19a0be2a49df4d1c9834245a6eb0d404","type":"GO_TERM","name":"ribonuclease IX activity","canonical_id":"go:GO:0033896","description":"\"Catalysis of the endonucleolytic cleavage of poly(U) or poly(C) to fragments terminated by 3'-hydroxy and 5'-phosphate groups.\" [EC:3.1.26.10]","metadata":null},{"id":"b6a160337d8646eaa629da7e22e163f2","type":"GO_TERM","name":"ribonuclease M5 activity","canonical_id":"go:GO:0043822","description":"\"Catalysis of the endonucleolytic cleavage of RNA, removing 21 and 42 nucleotides, respectively, from the 5'- and 3'-termini of a 5S-rRNA precursor.\" [PMID:402365]","metadata":null},{"id":"058619b35d0843de987c31cb9ddb4960","type":"GO_TERM","name":"ribonuclease MRP activity","canonical_id":"go:GO:0000171","description":"\"Catalysis of the site-specific cleavage of RNA by a catalytic RNA-mediated mechanism; substrates include the A3 site in the ITS1 of pre-rRNA.\" [PMID:17881380]","metadata":null},{"id":"34927d323ebd42509fbc1e8e964c7ed2","type":"GO_TERM","name":"ribonuclease MRP complex","canonical_id":"go:GO:0000172","description":"\"A ribonucleoprotein complex that contains an RNA molecule of the snoRNA family, and cleaves the rRNA precursor as part of rRNA transcript processing. It also has other roles: In S. cerevisiae it is involved in cell cycle-regulated degradation of daughter cell-specific mRNAs, while in mammalian cells it also enters the mitochondria and processes RNAs to create RNA primers for DNA replication.\" [GOC:sgd_curators, PMID:10690410, PMID:14729943, PMID:7510714]","metadata":null},{"id":"e0b9ab8da6604abbb26eb5749534c989","type":"GO_TERM","name":"ribonuclease P RNA binding","canonical_id":"go:GO:0033204","description":"\"Binding to RNA subunit of ribonuclease P.\" [GOC:pg, PMID:11455963]","metadata":null},{"id":"c92d6be320d445dd89e96041ed5e8348","type":"GO_TERM","name":"ribonuclease P activity","canonical_id":"go:GO:0004526","description":"\"Catalysis of the endonucleolytic cleavage of RNA, removing 5' extra nucleotides from tRNA precursor.\" [EC:3.1.26.5]","metadata":null},{"id":"5c61b6b98505474087b9b40edec6a101","type":"GO_TERM","name":"ribonuclease P complex","canonical_id":"go:GO:0030677","description":"\"A ribonucleoprotein complex that catalyzes cleavage of the leader sequence of precursor tRNAs (pre-tRNAs), generating the mature 5' end of tRNAs.\" [GOC:mah, PMID:12045094]","metadata":null},{"id":"ad1f20d5cdc54915a67ca2540283f519","type":"GO_TERM","name":"ribonuclease P4 activity","canonical_id":"go:GO:0033894","description":"\"Catalysis of the endonucleolytic cleavage of RNA, removing 3'-extranucleotides from tRNA precursor.\" [EC:3.1.26.7]","metadata":null},{"id":"1e00543d0d3d4828acda28f9193247e3","type":"GO_TERM","name":"ribonuclease T1 activity","canonical_id":"go:GO:0046589","description":"\"Catalysis of the endonucleolytic cleavage to nucleoside 3'-phosphates and 3'-phosphooligonucleotides ending in Gp with 2',3'-cyclic phosphate intermediates.\" [EC:4.6.1.24]","metadata":null},{"id":"d5560189b7104b3390b10526070fa610","type":"GO_TERM","name":"ribonuclease T2 activity","canonical_id":"go:GO:0033897","description":"\"Catalysis of the reaction: a ribonucleotidyl-ribonucleotide-RNA + H2O = a 3'-end 3'-phospho-ribonucleotide-RNA + a 5'-end dephospho-ribonucleoside-RNA + H+. This reaction is a two-stage endonucleolytic cleavage to nucleoside 3'-phosphates and 3'-phosphooligonucleotides with 2',3'-cyclic phosphate intermediates.\" [EC:4.6.1.19, RHEA:68052]","metadata":null},{"id":"870ddf6f2b404e31855467ed82ce1710","type":"GO_TERM","name":"ribonuclease U2 activity","canonical_id":"go:GO:0033899","description":"\"Catalysis of the two-stage endonucleolytic cleavage to nucleoside 3'-phosphates and 3'-phosphooligonucleotides ending in Ap or Gp with 2',3'-cyclic phosphate intermediates.\" [EC:4.6.1.20]","metadata":null},{"id":"25d72d32521c412fbd719ea266ad334d","type":"GO_TERM","name":"ribonuclease V activity","canonical_id":"go:GO:0033901","description":"\"Catalysis of the hydrolysis of poly(A), forming oligoribonucleotides and ultimately 3'-AMP.\" [EC:3.1.27.8]","metadata":null},{"id":"5edef95bc59c450aa8609d4dee361056","type":"GO_TERM","name":"ribonuclease [poly-(U)-specific] activity","canonical_id":"go:GO:0033895","description":"\"Catalysis of the endonucleolytic cleavage of poly(U) to fragments terminated by 3'-hydroxy and 5'-phosphate groups.\" [EC:3.1.26.9]","metadata":null},{"id":"c4ba6cc4e58c454a8a8cc1d267d334b6","type":"GO_TERM","name":"ribonuclease activator activity","canonical_id":"go:GO:0170054","description":"\"Binds to and increases the activity of a ribonuclease.\" [PMID:24736845]","metadata":null},{"id":"66159a34d4964b7588565b8f1ea88b79","type":"GO_TERM","name":"ribonuclease inhibitor activity","canonical_id":"go:GO:0008428","description":"\"Binds to and stops, prevents or reduces the activity of ribonuclease.\" [GOC:ai]","metadata":null},{"id":"b3adae2009dc4d66aa28c8b598009de2","type":"GO_TERM","name":"ribonucleoprotein complex","canonical_id":"go:GO:1990904","description":"\"A macromolecular complex that contains both RNA and protein molecules.\" [GOC:krc, GOC:vesicles]","metadata":null},{"id":"a46a60993f594327a07fba24e8f5446c","type":"GO_TERM","name":"ribonucleoprotein complex binding","canonical_id":"go:GO:0043021","description":"\"Binding to a complex of RNA and protein.\" [GOC:bf, GOC:curators, GOC:vk]","metadata":null},{"id":"43b4d76549694d6cb596851959201676","type":"GO_TERM","name":"ribonucleoprotein complex biogenesis","canonical_id":"go:GO:0022613","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a complex containing RNA and proteins. Includes the biosynthesis of the constituent RNA and protein molecules, and those macromolecular modifications that are involved in synthesis or assembly of the ribonucleoprotein complex.\" [GOC:isa_complete, GOC:mah]","metadata":null},{"id":"a1a67d693eee41148a9b7bc5ae5fa8e8","type":"GO_TERM","name":"ribonucleoprotein complex localization","canonical_id":"go:GO:0071166","description":"\"Any process in which a ribonucleoprotein complex is transported to, or maintained in, a specific location within a cell.\" [GOC:mah]","metadata":null},{"id":"6bb381f12f5f46f0a27ab8e991b7bd84","type":"GO_TERM","name":"ribonucleoprotein granule","canonical_id":"go:GO:0035770","description":"\"A non-membranous macromolecular complex containing proteins and translationally silenced mRNAs. RNA granules contain proteins that control the localization, stability, and translation of their RNA cargo. Different types of RNA granules (RGs) exist, depending on the cell type and cellular conditions.\" [GOC:curators, GOC:sp, PMID:16520386, PMID:20368989, PMID:21436445]","metadata":null},{"id":"2d059b1b0cd041f2867e3d2152ab4942","type":"GO_TERM","name":"ribonucleoside binding","canonical_id":"go:GO:0032549","description":"\"Binding to a ribonucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked to ribose.\" [GOC:mah]","metadata":null},{"id":"b1d2c00616c54122b444226c6a5aa77a","type":"GO_TERM","name":"ribonucleoside biosynthetic process","canonical_id":"go:GO:0042455","description":"\"The chemical reactions and pathways resulting in the formation of any ribonucleoside, a nucleoside in which purine or pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:jl]","metadata":null},{"id":"cdb21e47d40c44d896a75ffb7f48878a","type":"GO_TERM","name":"ribonucleoside bisphosphate biosynthetic process","canonical_id":"go:GO:0034030","description":"\"The chemical reactions and pathways resulting in the formation of a ribonucleoside bisphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"5d2c05d3343a4ac4808b11517730087a","type":"GO_TERM","name":"ribonucleoside bisphosphate catabolic process","canonical_id":"go:GO:0034031","description":"\"The chemical reactions and pathways resulting in the breakdown of a ribonucleoside bisphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"4c6e189f38d5486aafe1eb63b9c953c1","type":"GO_TERM","name":"ribonucleoside bisphosphate metabolic process","canonical_id":"go:GO:0033875","description":"\"The chemical reactions and pathways involving a ribonucleoside bisphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.\" [GOC:mah, GOC:pde]","metadata":null},{"id":"da8560a70ac941859598aeab38d93a1d","type":"GO_TERM","name":"ribonucleoside catabolic process","canonical_id":"go:GO:0042454","description":"\"The chemical reactions and pathways resulting in the breakdown of any ribonucleoside, a nucleoside in which purine or pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:jl]","metadata":null},{"id":"f38c1a1a90d24833ab627b64874abf33","type":"GO_TERM","name":"ribonucleoside diphosphate biosynthetic process","canonical_id":"go:GO:0009188","description":"\"The chemical reactions and pathways resulting in the formation of a ribonucleoside diphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"088dafd17e4346b0aa36e88bdd0aba89","type":"GO_TERM","name":"ribonucleoside diphosphate catabolic process","canonical_id":"go:GO:0009191","description":"\"The chemical reactions and pathways resulting in the breakdown of a ribonucleoside diphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"5ef31ec04cff4518a2eefe0b27201614","type":"GO_TERM","name":"ribonucleoside diphosphate metabolic process","canonical_id":"go:GO:0009185","description":"\"The chemical reactions and pathways involving a ribonucleoside diphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with diphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"91496ec5760d42f4a5188b8db1185010","type":"GO_TERM","name":"ribonucleoside metabolic process","canonical_id":"go:GO:0009119","description":"\"The chemical reactions and pathways involving any ribonucleoside, a nucleoside in which purine or pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.\" [GOC:jl]","metadata":null},{"id":"8cb6f79de1864aeebce31213eafb330e","type":"GO_TERM","name":"ribonucleoside monophosphate biosynthetic process","canonical_id":"go:GO:0009156","description":"\"The chemical reactions and pathways resulting in the formation of a ribonucleoside monophosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"1e0653942ca64c0b9b5949591b52f68f","type":"GO_TERM","name":"ribonucleoside monophosphate catabolic process","canonical_id":"go:GO:0009158","description":"\"The chemical reactions and pathways resulting in the breakdown of a ribonucleoside monophosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with phosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"7f624980436c45609e4a0cac939df195","type":"GO_TERM","name":"ribonucleoside triphosphate biosynthetic process","canonical_id":"go:GO:0009201","description":"\"The chemical reactions and pathways resulting in the formation of a ribonucleoside triphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"f1c1a704314d4c0da5b2220ca2256149","type":"GO_TERM","name":"ribonucleoside triphosphate catabolic process","canonical_id":"go:GO:0009203","description":"\"The chemical reactions and pathways resulting in the breakdown of a ribonucleoside triphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with triphosphate on the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"b7aa8249170f412098dacbe86392ec0a","type":"GO_TERM","name":"ribonucleoside triphosphate phosphatase activity","canonical_id":"go:GO:0017111","description":"\"Catalysis of the reaction: a ribonucleoside triphosphate + H2O = a ribonucleoside diphosphate + H+ + phosphate.\" [RHEA:23680]","metadata":null},{"id":"eaf941bef2164a968728025d673789f6","type":"GO_TERM","name":"ribonucleoside-diphosphate reductase activity","canonical_id":"go:GO:0061731","description":"\"Catalysis of the formation of 2'-deoxyribonucleoside diphosphate from ribonucleoside diphosphate, using either thioredoxin disulfide or glutaredoxin disulfide as an acceptor.\" [GOC:dph, GOC:vw, PMID:16756507]","metadata":null},{"id":"be626db09a804fec8aea7259319affd2","type":"GO_TERM","name":"ribonucleoside-diphosphate reductase activity, glutaredoxin disulfide as acceptor","canonical_id":"go:GO:0036175","description":"\"Catalysis of the reaction: 2'-deoxyribonucleoside diphosphate + glutaredoxin disulfide + H2O = ribonucleoside diphosphate + glutaredoxin.\" [GOC:bf, GOC:pde, PMID:19176520, PMID:31266802, PMID:7476363]","metadata":null},{"id":"74f8c18aa2a4471899120c6d3cbbc4f8","type":"GO_TERM","name":"ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor","canonical_id":"go:GO:0004748","description":"\"Catalysis of the reaction: 2'-deoxyribonucleoside diphosphate + thioredoxin disulfide + H2O = ribonucleoside diphosphate + thioredoxin. Thioredoxin disulfide is the oxidized form of thioredoxin.\" [EC:1.17.4.1]","metadata":null},{"id":"ff18696e997b450db8c13f4a0c4d46f0","type":"GO_TERM","name":"ribonucleoside-diphosphate reductase complex","canonical_id":"go:GO:0005971","description":"\"An enzyme complex composed of 2-4 or more subunits, which usually contains nonheme iron and requires ATP for catalysis. Catalyzes the formation of 2'-deoxyribonucleoside diphosphate from ribonucleoside diphosphate, using either thioredoxin disulfide or glutaredoxin disulfide as an acceptor.\" [PMID:10716984, PMID:21336276]","metadata":null},{"id":"4a99707ba3f1442eb9dad33cbcb67995","type":"GO_TERM","name":"ribonucleoside-diphosphate reductase inhibitor activity","canonical_id":"go:GO:1990846","description":"\"Binds to and stops, prevents or reduces the activity of ribonucleoside-diphosphate reductase.\" [PMID:16317005]","metadata":null},{"id":"665ff482202a48abb31ef0dc2dab15ef","type":"GO_TERM","name":"ribonucleoside-triphosphate reductase (thioredoxin) activity","canonical_id":"go:GO:0008998","description":"\"Catalysis of the reaction: [thioredoxin]-disulfide + a 2'-deoxyribonucleoside 5'-triphosphate + H2O = [thioredoxin]-dithiol + a ribonucleoside 5'-triphosphate.\" [RHEA:12701]","metadata":null},{"id":"eaae5268d8b44147b8ecaa0eebbd535b","type":"GO_TERM","name":"ribonucleotide binding","canonical_id":"go:GO:0032553","description":"\"Binding to a ribonucleotide, any compound consisting of a ribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety.\" [GOC:mah]","metadata":null},{"id":"e733c84b0ea84b1f986f070eb5396301","type":"GO_TERM","name":"ribonucleotide biosynthetic process","canonical_id":"go:GO:0009260","description":"\"The chemical reactions and pathways resulting in the formation of a ribonucleotide, a compound consisting of ribonucleoside (a base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"e1c401d404e34f289073a2391852ea4f","type":"GO_TERM","name":"ribonucleotide catabolic process","canonical_id":"go:GO:0009261","description":"\"The chemical reactions and pathways resulting in the breakdown of a ribonucleotide, a compound consisting of ribonucleoside (a base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d959742434b443febf72d3c1104d8d04","type":"GO_TERM","name":"ribonucleotide excision repair","canonical_id":"go:GO:1990516","description":"\"The pathway by which a ribonucleotide is removed from DNA and replaced by a deoxyribonucleotide. The ribonucleotide is incised by RNase H2, and further excised by an endonuclease. The resulting 1 nt gap is then repaired by DNA polymerase and DNA ligase.\" [PMID:12475934, PMID:22864116]","metadata":null},{"id":"250bf43437c449ca9b544855707add15","type":"GO_TERM","name":"ribonucleotide metabolic process","canonical_id":"go:GO:0009259","description":"\"The chemical reactions and pathways involving a ribonucleotide, a compound consisting of ribonucleoside (a base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"4a5ce68ff20e4f0f9a5c9ffe6223c363","type":"GO_TERM","name":"ribophagy","canonical_id":"go:GO:0034517","description":"\"The selective degradation of mature ribosomes by macroautophagy.\" [GOC:autophagy, PMID:18391941]","metadata":null},{"id":"95ab2b8d35b441329c9b567058a1d849","type":"GO_TERM","name":"ribose 1,5-bisphosphate isomerase activity","canonical_id":"go:GO:0043917","description":"\"Catalysis of the reaction: alpha-D-ribose 1,5-bisphosphate = D-ribulose 1,5-bisphosphate.\" [RHEA:32243]","metadata":null},{"id":"b636916cd02f4ec2a059dc9b3d30deb1","type":"GO_TERM","name":"ribose 1,5-bisphosphate phosphokinase activity","canonical_id":"go:GO:0033863","description":"\"Catalysis of the reaction: D-ribose 1,5-diphosphate + ATP = 5-phospho-alpha-D-ribose 1-diphosphate + ADP + H+.\" [EC:2.7.4.23, RHEA:20109]","metadata":null},{"id":"9af75e6296f44b51bf92fe56ce2aead5","type":"GO_TERM","name":"ribose 1-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050259","description":"\"Catalysis of the reaction: H2O + NADP+ + ribofuranose = D-ribonate + 2 H+ + NADPH.\" [EC:1.1.1.115, RHEA:11676]","metadata":null},{"id":"75f1d3ef8840431e9a529c76f76edfc0","type":"GO_TERM","name":"ribose isomerase activity","canonical_id":"go:GO:0050261","description":"\"Catalysis of the reaction: aldehydo-D-ribose = D-ribulose.\" [RHEA:20796]","metadata":null},{"id":"5327621aac544ebdbcc5e5f77a690d35","type":"GO_TERM","name":"ribose phosphate biosynthetic process","canonical_id":"go:GO:0046390","description":"\"The chemical reactions and pathways resulting in the formation of ribose phosphate, any phosphorylated ribose sugar.\" [GOC:ai]","metadata":null},{"id":"770b3c1589354cbca6b7db4c08a4412c","type":"GO_TERM","name":"ribose phosphate diphosphokinase activity","canonical_id":"go:GO:0004749","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + ATP = 5-phospho-alpha-D-ribose 1-diphosphate + AMP + 2 H+.\" [RHEA:15609]","metadata":null},{"id":"3f30a5c7a83e428d8dcb8dd129b12a1d","type":"GO_TERM","name":"ribose phosphate diphosphokinase complex","canonical_id":"go:GO:0002189","description":"\"A protein complex having ribose phosphate diphosphokinase activity.\" [GO:hjd, PMID:9348095]","metadata":null},{"id":"8e2e923de81a4a52904b83b69fb2831d","type":"GO_TERM","name":"ribose phosphate metabolic process","canonical_id":"go:GO:0019693","description":"\"The chemical reactions and pathways involving ribose phosphate, any phosphorylated ribose sugar.\" [GOC:ai]","metadata":null},{"id":"091cb98d34754555af655ee396b00760","type":"GO_TERM","name":"ribose-5-phosphate adenylyltransferase activity","canonical_id":"go:GO:0047345","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + ADP + H+ = ADP-ribose + phosphate.\" [EC:2.7.7.35, RHEA:14529]","metadata":null},{"id":"c3e5f34c4f5a4fa4ba3b969c842c53df","type":"GO_TERM","name":"ribose-5-phosphate isomerase activity","canonical_id":"go:GO:0004751","description":"\"Catalysis of the reaction: aldehydo-D-ribose 5-phosphate = D-ribulose 5-phosphate.\" [RHEA:14657]","metadata":null},{"id":"72980e5eb00447b1b93330ca0f97e9f2","type":"GO_TERM","name":"ribose-5-phosphate-ammonia ligase activity","canonical_id":"go:GO:0050260","description":"\"Catalysis of the reaction: D-ribose 5-phosphate + ATP + NH4 = 5-phospho-D-ribosylamine + ADP + 2 H+ + phosphate.\" [EC:6.3.4.7, RHEA:13777]","metadata":null},{"id":"7e78653d5bb846778732a8769f591b60","type":"GO_TERM","name":"ribosomal S6-glutamic acid ligase activity","canonical_id":"go:GO:0018169","description":"\"Catalysis of the posttranslational transfer of one or more glutamic acid residues to the C-terminus of ribosomal protein S6.\" [GOC:mah, PMID:2570347]","metadata":null},{"id":"386d98a5d8b74bfaafa57e4b92f35dd5","type":"GO_TERM","name":"ribosomal large subunit assembly","canonical_id":"go:GO:0000027","description":"\"The aggregation, arrangement and bonding together of constituent RNAs and proteins to form the large ribosomal subunit.\" [GOC:jl, PMID:30467428]","metadata":null},{"id":"273a1d32ab9148bf9e1b48b3ffa9f1f9","type":"GO_TERM","name":"ribosomal large subunit binding","canonical_id":"go:GO:0043023","description":"\"Binding to a large ribosomal subunit.\" [GOC:curators]","metadata":null},{"id":"87ea7086356b4d34af0b3bd14ff7f033","type":"GO_TERM","name":"ribosomal large subunit biogenesis","canonical_id":"go:GO:0042273","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a large ribosomal subunit; includes transport to the sites of protein synthesis.\" [GOC:jl]","metadata":null},{"id":"2e3841d53fd3408288b90bf2c3c6c493","type":"GO_TERM","name":"ribosomal large subunit export from nucleus","canonical_id":"go:GO:0000055","description":"\"The directed movement of a ribosomal large subunit from the nucleus into the cytoplasm.\" [GOC:mah]","metadata":null},{"id":"e5f7efde93b447d88333ccb13aceaf28","type":"GO_TERM","name":"ribosomal protein S6 kinase activity","canonical_id":"go:GO:0004711","description":"\"Catalysis of the reaction: ribosomal protein S6 + ATP = ribosomal protein S6 phosphate + ATP.\" [GOC:mah, PMID:9822608]","metadata":null},{"id":"1574a868b6b54b3c91b5552543318798","type":"GO_TERM","name":"ribosomal protein import into nucleus","canonical_id":"go:GO:0006610","description":"\"The directed movement of a ribosomal protein from the cytoplasm into the nucleus, across the nuclear membrane. At least some ribosomal proteins, including rpl12, uses the importin 11 pathway as a major route into the nucleus.\" [GOC:ai, PMID:11809816]","metadata":null},{"id":"f979f22431c744fb9148a040eeb50be5","type":"GO_TERM","name":"ribosomal skipping","canonical_id":"go:GO:0075524","description":"\"A translation process in which a specific viral peptide prevents the ribosome from covalently linking a new inserted amino acid, and lets it continue translation, thereby cleaving the nascent protein while allowing translation to continue.\" [GOC:bf, GOC:ch, GOC:jl, VZ:914]","metadata":null},{"id":"e86353c91c3d404b89bfdf1c775ff5e7","type":"GO_TERM","name":"ribosomal small subunit assembly","canonical_id":"go:GO:0000028","description":"\"The aggregation, arrangement and bonding together of constituent RNAs and proteins to form the small ribosomal subunit.\" [GOC:jl, PMID:30467428]","metadata":null},{"id":"f328d1c612ed4755a9957bab273aeec3","type":"GO_TERM","name":"ribosomal small subunit binding","canonical_id":"go:GO:0043024","description":"\"Binding to a small ribosomal subunit.\" [GOC:curators]","metadata":null},{"id":"33c0b113b1ce4569b442c9bf796d6e03","type":"GO_TERM","name":"ribosomal small subunit biogenesis","canonical_id":"go:GO:0042274","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a small ribosomal subunit; includes transport to the sites of protein synthesis.\" [GOC:jl]","metadata":null},{"id":"219a835234e74ff2864544663733c324","type":"GO_TERM","name":"ribosomal small subunit export from nucleus","canonical_id":"go:GO:0000056","description":"\"The directed movement of a ribosomal small subunit from the nucleus into the cytoplasm.\" [GOC:mah]","metadata":null},{"id":"573eff8476cf40ad90e03dd57fe0d3df","type":"GO_TERM","name":"ribosomal subunit","canonical_id":"go:GO:0044391","description":"\"Either of the two subunits of a ribosome: the ribosomal large subunit or the ribosomal small subunit.\" [GOC:jl]","metadata":null},{"id":"cb7acaa609b641d9b66dc40943d2a3e9","type":"GO_TERM","name":"ribosomal subunit export from nucleus","canonical_id":"go:GO:0000054","description":"\"The directed movement of a ribosomal subunit from the nucleus into the cytoplasm.\" [GOC:ai]","metadata":null},{"id":"205505ec92744762bbde13cd11294ede","type":"GO_TERM","name":"ribosome","canonical_id":"go:GO:0005840","description":"\"An intracellular organelle, about 200 A in diameter, consisting of RNA and protein. It is the site of protein biosynthesis resulting from translation of messenger RNA (mRNA). It consists of two subunits, one large and one small, each containing only protein and RNA. Both the ribosome and its subunits are characterized by their sedimentation coefficients, expressed in Svedberg units (symbol: S). Hence, the prokaryotic ribosome (70S) comprises a large (50S) subunit and a small (30S) subunit, while the eukaryotic ribosome (80S) comprises a large (60S) subunit and a small (40S) subunit. Two sites on the ribosomal large subunit are involved in translation, namely the aminoacyl site (A site) and peptidyl site (P site). Ribosomes from prokaryotes, eukaryotes, mitochondria, and chloroplasts have characteristically distinct ribosomal proteins.\" [ISBN:0198506732]","metadata":null},{"id":"f9c8951946f44a218ee285355a325b4d","type":"GO_TERM","name":"ribosome assembly","canonical_id":"go:GO:0042255","description":"\"The aggregation, arrangement and bonding together of the mature ribosome and of its subunits.\" [GOC:ma, PMID:30467428]","metadata":null},{"id":"5c5fb709251c4848a212e8a3e088ac18","type":"GO_TERM","name":"ribosome binding","canonical_id":"go:GO:0043022","description":"\"Binding to a ribosome.\" [GOC:curators]","metadata":null},{"id":"0cbe22776974436ca0792bfcfafe20e6","type":"GO_TERM","name":"ribosome biogenesis","canonical_id":"go:GO:0042254","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of ribosome subunits; includes transport to the sites of protein synthesis.\" [GOC:ma, PMID:26404467, Wikipedia:Ribosome_biogenesis]","metadata":null},{"id":"b9819816c7cf433d9e0b24fdbb5f0532","type":"GO_TERM","name":"ribosome disassembly","canonical_id":"go:GO:0032790","description":"\"The disaggregation of a ribosome into its constituent components; includes the dissociation of ribosomal subunits.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"1506aa03cebd4acdbf24821ce53d1f92","type":"GO_TERM","name":"ribosome localization","canonical_id":"go:GO:0033750","description":"\"A process in which a ribosome is transported to, and/or maintained in, a specific location.\" [GOC:mah]","metadata":null},{"id":"77cd649e52e94a8f855f3264f75a92d3","type":"GO_TERM","name":"ribosome translocase activity","canonical_id":"go:GO:0180054","description":"\"A motor activity that generates movement of a ribosome one codon forward along the mRNA, driven by GTP hydrolysis.\" [PMID:19173642]","metadata":null},{"id":"03c49e8bc7414313989ea7720489bfda","type":"GO_TERM","name":"ribosome-associated ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:1990116","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide encoded by an aberrant message and associated with a stalled ribosome. Degradation is initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the ribosome-associated protein.\" [GOC:dgf, PMID:23358411]","metadata":null},{"id":"a608802d035f4dddaa0f523784580496","type":"GO_TERM","name":"ribosylnicotinamide kinase activity","canonical_id":"go:GO:0050262","description":"\"Catalysis of the reaction: beta-nicotinamide D-riboside + ATP = beta-nicotinamide D-ribonucleotide + ADP + H+.\" [PMID:17914902, RHEA:14017]","metadata":null},{"id":"3c93374215b84a74af4c976fb0c742fb","type":"GO_TERM","name":"ribosylpyrimidine nucleosidase activity","canonical_id":"go:GO:0050263","description":"\"Catalysis of the reaction: an N-D-ribosylpyrimidine + H2O = D-ribose + a pyrimidine.\" [EC:3.2.2.8, MetaCyc:RIBOSYLPYRIMIDINE-NUCLEOSIDASE-RXN]","metadata":null},{"id":"d467094978e241ed9d60607a9f6aa13b","type":"GO_TERM","name":"ribulokinase activity","canonical_id":"go:GO:0008741","description":"\"Catalysis of the reaction: ATP + L(or D)-ribulose = ADP + L(or D)-ribulose 5-phosphate.\" [EC:2.7.1.16]","metadata":null},{"id":"5584fa3b5bb04632b0d243cb53359a14","type":"GO_TERM","name":"ribulose bisphosphate carboxylase complex","canonical_id":"go:GO:0048492","description":"\"A complex containing either both large and small subunits or just small subunits which carries out the activity of producing 3-phosphoglycerate from carbon dioxide and ribulose-1,5-bisphosphate.\" [GOC:mlg]","metadata":null},{"id":"0a5fb9b2ac7c452aadd98346fae4f646","type":"GO_TERM","name":"ribulose bisphosphate carboxylase complex assembly","canonical_id":"go:GO:0110102","description":"\"The aggregation, arrangement and bonding together of a set of components to form a ribulose bisphosphate carboxylase complex.\" [GOC:krc, GOC:tb, PMID:29396988, PMID:29589905]","metadata":null},{"id":"84df0c9ec7924fcb963c2b362e71e67b","type":"GO_TERM","name":"ribulose-1,5-bisphosphate carboxylase/oxygenase activator activity","canonical_id":"go:GO:0046863","description":"\"Binds to and iincreases the activity of rubisco by the removal of otherwise inhibitory sugar phosphates: RuBP, and in some plants, 2-carboxyarabinitol 1-phosphate.\" [PMID:10430961, PMID:10965036, PMID:2404515]","metadata":null},{"id":"cf182871ce4941049727e49cedeb0126","type":"GO_TERM","name":"ribulose-bisphosphate carboxylase activity","canonical_id":"go:GO:0016984","description":"\"Catalysis of the reaction: 2 (2R)-3-phosphoglycerate + 2 H+ = CO2 + D-ribulose 1,5-bisphosphate + H2O.\" [RHEA:23124]","metadata":null},{"id":"dfe59a2963844c9b8bc285f89ab42211","type":"GO_TERM","name":"ricinine nitrilase activity","canonical_id":"go:GO:0047426","description":"\"Catalysis of the reaction: ricinine + 2 H2O = 4-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate + NH4+.\" [RHEA:22704]","metadata":null},{"id":"9f28def1e2f540eebb74cb8cb9bb37b0","type":"GO_TERM","name":"rifamycin-B oxidase activity","canonical_id":"go:GO:0050264","description":"\"Catalysis of the reaction: 2 H+ + O2 + rifamycin B = H2O2 + rifamycin O.\" [EC:1.10.3.6, RHEA:11292]","metadata":null},{"id":"8ae5bb63cf364328a9589a85359512da","type":"DRUG","name":"rifapentine","canonical_id":"mesh:C018421","description":null,"metadata":null},{"id":"27522e67dfcf4a0596a39413005252d3","type":"GO_TERM","name":"right anterior basal body","canonical_id":"go:GO:1902672","description":"\"Any ciliary basal body that is part of a right anterior flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"a78256762d9d4f67ae35bab18c4d736d","type":"GO_TERM","name":"right anterior flagellum","canonical_id":"go:GO:0097555","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It originates at the right anterior basal body, extends laterally through the cytoplasm, crosses the left anterior axoneme, and exits as a membrane-bound flagellum on the anterior right side of the cell.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"a20678d5c65840a4b887aa776d508b9a","type":"GO_TERM","name":"right caudal basal body","canonical_id":"go:GO:1902678","description":"\"Any ciliary basal body that is part of a right caudal flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"a91de5d9dc2d4b99b2c8c600d8ff4d35","type":"GO_TERM","name":"right caudal flagellum","canonical_id":"go:GO:0097561","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It is nucleated by the right caudal basal body, extending cytoplasmically and exiting at the posterior end of the cell body.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"cd1713cc87c242b6822bc937b746aaa8","type":"GO_TERM","name":"right horn of sinus venosus development","canonical_id":"go:GO:0061080","description":"\"The progression of the right horn of the sinus venosus from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"3e2b772f218b4634a5fe00ed49737411","type":"GO_TERM","name":"right lateral basal body pair","canonical_id":"go:GO:0097564","description":"\"Set of two basal bodies found in Giardia species (trophozoite stage). It comprises the anterior and ventral basal bodies located to the left of the right nucleus of the trophozoite when viewed dorsally.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"ec30e20be66842ad9e16b3f6b925ffeb","type":"GO_TERM","name":"right lung development","canonical_id":"go:GO:0060458","description":"\"The biological process whose specific outcome is the progression of a right lung from an initial condition to its mature state. This process begins with the formation of the right lung and ends with the mature structure. The right lung is the lung which is on the right side of the anterior posterior axis looking from a dorsal to ventral aspect.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"27ada03f09c54b3188031c3de91f6672","type":"GO_TERM","name":"right lung morphogenesis","canonical_id":"go:GO:0060461","description":"\"The process in which anatomical structures of the right lung are generated and organized.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"d666e5bc91ba42f5a3f829d8a555236f","type":"GO_TERM","name":"right middle basal body pair","canonical_id":"go:GO:0097565","description":"\"Set of two basal bodies found in Giardia species (trophozoite stage). It comprises the caudal and posteriolateral basal bodies located to the left of the right nucleus of the trophozoite when viewed dorsally.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"f8333f36dacd48eeaf51d3505ee89372","type":"GO_TERM","name":"right nucleus","canonical_id":"go:GO:0097572","description":"\"One of the two nuclei found in Giardia species (trophozoite stage). It is located on the right side of the cell when viewed from the dorsal side.\" [GOC:giardia, ISBN:0-444-81258-X]","metadata":null},{"id":"14d3c79cde974287960303957db9bc8a","type":"GO_TERM","name":"right posteriolateral basal body","canonical_id":"go:GO:1902674","description":"\"Any ciliary basal body that is part of a right posteriolateral flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"430f7281a8e740f8ba9ec3e2888f1af9","type":"GO_TERM","name":"right posteriolateral flagellum","canonical_id":"go:GO:0097557","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It is nucleated by the right posteriolateral basal body and extends cytoplasmically toward the cell posterior, marking the right anterior boundary of the lateral shield and the right lateral region of the funis before exiting at the right lateral region of the cell body.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"7da6237ea2c74c9f9cf3c662b3dd2c09","type":"GO_TERM","name":"right tetrad","canonical_id":"go:GO:0097567","description":"\"Set of four basal bodies found in Giardia species (trophozoite stage). It comprises the right lateral basal body pair and the right middle basal body pair (i.e. the anterior, ventral, caudal and posteriolateral basal bodies located to the left of the right nucleus of the trophozoite when viewed dorsally).\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"8c7a2aa638f348b58ed7cb3da4d5a0f0","type":"GO_TERM","name":"right ventral basal body","canonical_id":"go:GO:1902676","description":"\"Any ciliary basal body that is part of a right ventral flagellum found in Giardia species (trophozoite stage).\" [GO_REF:0000064, GOC:giardia, GOC:TermGenie, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"981ea78ff96d416d8ab0424def38c143","type":"GO_TERM","name":"right ventral flagellum","canonical_id":"go:GO:0097559","description":"\"A cilium (also called flagellum) found in Giardia species (trophozoite stage). It is nucleated by the right ventral basal body and exits the cell body proximally and dorsal to the ventral disc.\" [GOC:giardia, ISBN:9780124260207, PMID:16607022, PMID:5961344]","metadata":null},{"id":"4f3ef62c30ec4012979c78c35694a3ec","type":"GO_TERM","name":"right ventricular cardiac muscle tissue morphogenesis","canonical_id":"go:GO:0003221","description":"\"The process in which the anatomical structures of the right cardiac ventricle muscle are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"a145d14ab23b41a98c6292878150451c","type":"GO_TERM","name":"right ventricular compact myocardium morphogenesis","canonical_id":"go:GO:0003226","description":"\"The process in which the anatomical structures of the right ventricular compact myocardium are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"233588332b0646ef9f9d3adc3c26b857","type":"GO_TERM","name":"right ventricular trabecular myocardium morphogenesis","canonical_id":"go:GO:0003227","description":"\"The process in which the anatomical structures of the right ventricular myocardium are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"7f3779a6e6464fc2a325bdbb7634dcd3","type":"GO_TERM","name":"righting reflex","canonical_id":"go:GO:0060013","description":"\"A reflex process in which an animal immediately tries to turn over after being placed in a supine position.\" [GOC:dph, PMID:8635460]","metadata":null},{"id":"4e6741392fd5495ea164c91cef30ee13","type":"DRUG","name":"rilmenidine","canonical_id":"mesh:C032302","description":null,"metadata":null},{"id":"c5c9e1ae3aab4ee282c3ed6e1269db41","type":"DRUG","name":"rilonacept","canonical_id":"gtopdb:6790","description":null,"metadata":null},{"id":"88ab4f92eb7a41ff968f5bcde4e235b0","type":"DRUG","name":"rilonacept","canonical_id":"mesh:C531377","description":null,"metadata":null},{"id":"7e3549f62d8547ddbcb9b9d747372064","type":"DRUG","name":"rilonacept","canonical_id":"chembl:CHEMBL1201830","description":null,"metadata":null},{"id":"2edc048e7eb748fbaf0705f395ff5d4b","type":"DRUG","name":"rimegepant","canonical_id":"gtopdb:10704","description":null,"metadata":null},{"id":"271c8c59dccf404e91977d61f5784be0","type":"DRUG","name":"rimegepant","canonical_id":"chembl:CHEMBL2178422","description":null,"metadata":null},{"id":"fd49d02e30464efabcaac68af7349cdc","type":"COMBINATION_TREATMENT","name":"rimegepant + rizatriptan","canonical_id":"ctgov_combo:ctgov-combo-0413bf23eb4e0600","description":null,"metadata":null},{"id":"296f48fba95b4c42aa168f1a434b2a74","type":"GO_TERM","name":"ring centriole","canonical_id":"go:GO:0061823","description":"\"A ring-like structure observed at the base of the ciliary cap of insect spermatids. This structure may anchor the axoneme to the ciliary cap membrane and/or act as a diffusion barrier, proposed to be analogous to the annulus of mammalian sperm flagellum.\" [PMID:25447994, PMID:4903810]","metadata":null},{"id":"2f60e37f6abc49de8270a7df122eb0a2","type":"GO_TERM","name":"ring gland development","canonical_id":"go:GO:0035271","description":"\"Progression of the ring gland over time, from its formation to a mature structure. The ring gland is a neuroendocrine organ found in higher Dipterans, which is composed of the prothoracic gland, the corpus allatum, and the corpora cardiacum. The ring gland is the site of production and release of ecdysteroids and juvenile hormones.\" [GOC:bf, PMID:11223816, PMID:9584098]","metadata":null},{"id":"268162613ec140a6b2d0d2777639488b","type":"DRUG","name":"riociguat","canonical_id":"mesh:C542595","description":null,"metadata":null},{"id":"de49272611f347d684dfb07d3cec0ba2","type":"DRUG","name":"ripasudil","canonical_id":"gtopdb:10423","description":null,"metadata":null},{"id":"8dd97fa1a31c434f97e5a67f76581cf0","type":"DRUG","name":"ripasudil","canonical_id":"chembl:CHEMBL3426621","description":null,"metadata":null},{"id":"295138e04baa4c22978e582c4111fb47","type":"GO_TERM","name":"ripoptosome","canonical_id":"go:GO:0097342","description":"\"A protein complex whose core components are the receptor-interacting serine/threonine-protein kinases RIPK1 and RIPK3 (also called RIP1 and RIP3). Formation of the ripoptosome can induce an extrinsic apoptotic signaling pathway or a necroptotic signaling pathway. The composition of this protein complex may depend on several factors including nature of the signal, cell type and more.\" [GOC:bhm, GOC:mtg_apoptosis, PMID:22265414, PMID:22274400]","metadata":null},{"id":"4bb100e244f04b41ad1c79d944fd01bd","type":"GO_TERM","name":"ripoptosome assembly","canonical_id":"go:GO:0097343","description":"\"The aggregation, arrangement and bonding together of a set of components to form a ripoptosome, a protein complex whose formation can induce an extrinsic apoptotic signaling pathway or a necroptotic signaling pathway. The composition of this protein complex may depend on several factors including nature of the signal, cell type and more.\" [GOC:mtg_apoptosis, PMID:22274400]","metadata":null},{"id":"c1247f371b0c41fe9278bcaeb9e907d0","type":"GO_TERM","name":"ripoptosome assembly involved in necroptotic process","canonical_id":"go:GO:1901026","description":"\"The aggregation, arrangement and bonding together of ripoptosome components leading to a necroptotic process.\" [GOC:mtg_apoptosis, GOC:TermGenie, PMID:22274400]","metadata":null},{"id":"9f986049f6394cd9a41d4dcc2951e5ad","type":"DRUG","name":"risankizumab","canonical_id":"gtopdb:8922","description":null,"metadata":null},{"id":"4ad8484f2c2245a9b3f9058b4bf93b69","type":"DRUG","name":"risankizumab","canonical_id":"chembl:CHEMBL3990029","description":null,"metadata":null},{"id":"8d92ba17f1e94a848347369d20a0e465","type":"COMBINATION_TREATMENT","name":"risankizumab + secukinumab","canonical_id":"ctgov_combo:ctgov-combo-802ffd1ae69f0a0a","description":null,"metadata":null},{"id":"2a643b102e184e06849e2f56ca395804","type":"COMBINATION_TREATMENT","name":"risankizumab + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-ad8494e898ca0e70","description":null,"metadata":null},{"id":"9243f8a4a2204fdda2f8ecc4cef47c11","type":"DRUG","name":"risedronate","canonical_id":"gtopdb:3176","description":null,"metadata":null},{"id":"ed66010c436a4ba794a49e9555e88830","type":"DRUG","name":"risedronate","canonical_id":"chembl:CHEMBL1654","description":null,"metadata":null},{"id":"438f1cd1f66544808c3d47af955f4ce5","type":"COMBINATION_TREATMENT","name":"risedronate + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-604ef7552775cc2b","description":null,"metadata":null},{"id":"fae72bc3217c45f69d7a3b6db21c94fc","type":"COMBINATION_TREATMENT","name":"risedronate + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-73f742284a666c0e","description":null,"metadata":null},{"id":"e8ea5d909f724a58837449441f325e31","type":"COMBINATION_TREATMENT","name":"risedronate + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-92b36f63ecf6324d","description":null,"metadata":null},{"id":"3b0fd651d3e849cbaecf49ac2a20787f","type":"DRUG","name":"risedronic acid","canonical_id":"mesh:D000068296","description":null,"metadata":null},{"id":"307b946e67944779bc7db5e6246be3a8","type":"DISEASE","name":"risk-taking behaviour","canonical_id":"efo:0008579","description":null,"metadata":null},{"id":"e6aca4f7213946a9968ae6b41131258c","type":"DRUG","name":"risperidone","canonical_id":"gtopdb:96","description":null,"metadata":null},{"id":"abb3471a79c947ec85a047ddea65900c","type":"DRUG","name":"risperidone","canonical_id":"mesh:D018967","description":null,"metadata":null},{"id":"02ff9b682419454baf067cc8348f291d","type":"DRUG","name":"risperidone","canonical_id":"chembl:CHEMBL85","description":null,"metadata":null},{"id":"af8e2b8760304a9e8f3d953077be2aab","type":"COMBINATION_TREATMENT","name":"risperidone + sertraline","canonical_id":"ctgov_combo:ctgov-combo-3617a86c491a6389","description":null,"metadata":null},{"id":"d1ca676b20c14fb0b0907ea05c9c6d73","type":"COMBINATION_TREATMENT","name":"risperidone + tropisetron","canonical_id":"ctgov_combo:ctgov-combo-0ddd22539c046529","description":null,"metadata":null},{"id":"cc01ecdaa06e4e539aa1142feee47545","type":"DRUG","name":"ritlecitinib","canonical_id":"gtopdb:9559","description":null,"metadata":null},{"id":"149f268376d5444293ed76b0ecabff12","type":"DRUG","name":"ritlecitinib","canonical_id":"chembl:CHEMBL4085457","description":null,"metadata":null},{"id":"083b83d81cdd434e8a4ebac2ebe75bf4","type":"COMBINATION_TREATMENT","name":"ritlecitinib + tolbutamide","canonical_id":"ctgov_combo:ctgov-combo-8cb74f0c30aac46f","description":null,"metadata":null},{"id":"45abab919909487da781c4f2e09ed426","type":"DRUG","name":"ritodrine","canonical_id":"mesh:D012312","description":null,"metadata":null},{"id":"8ca703e189fd4898b3c3f9d86727ee04","type":"DRUG","name":"rituximab","canonical_id":"gtopdb:6780","description":null,"metadata":null},{"id":"72a3271179714cd79556a9bc073299bb","type":"DRUG","name":"rituximab","canonical_id":"mesh:D000069283","description":null,"metadata":null},{"id":"db7d436b5b1b40bf8d883494532401e9","type":"DRUG","name":"rituximab","canonical_id":"chembl:CHEMBL1201576","description":null,"metadata":null},{"id":"55ea1ed6ab644028ae645f001cd8f914","type":"COMBINATION_TREATMENT","name":"rituximab + venetoclax","canonical_id":"ctgov_combo:ctgov-combo-3b5214ca58cb7273","description":null,"metadata":null},{"id":"ec1830ff84754ce2ac92f488915ccd57","type":"DRUG","name":"rivaroxaban","canonical_id":"gtopdb:6388","description":null,"metadata":null},{"id":"539f8b94b4134a08acc27c6111b0e28c","type":"DRUG","name":"rivaroxaban","canonical_id":"chembl:CHEMBL198362","description":null,"metadata":null},{"id":"647458719a0646719c8e0f7e7ad40308","type":"COMBINATION_TREATMENT","name":"rivaroxaban + tranexamic acid","canonical_id":"ctgov_combo:ctgov-combo-3d58d64860a4810b","description":null,"metadata":null},{"id":"a51f188a0d5343ed8858b16eea83577d","type":"DRUG","name":"rivastigmine","canonical_id":"gtopdb:6602","description":null,"metadata":null},{"id":"128564e014294e43a9ad4b6b74b2f0cf","type":"DRUG","name":"rivastigmine","canonical_id":"mesh:D000068836","description":null,"metadata":null},{"id":"32fabd74530648188c45934cb2c0b7a9","type":"DRUG","name":"rivastigmine","canonical_id":"chembl:CHEMBL636","description":null,"metadata":null},{"id":"366c4e23c4a249d1a05733830849d150","type":"GO_TERM","name":"rixosome complex","canonical_id":"go:GO:0120330","description":"\"A conserved RNA endonuclease complex required for spreading and epigenetic inheritance of heterochromatin. The rixosome contains six unique subunits: three structural subunits (Crb3, Rix1, and Ipi1) which form the core of the complex, and three catalytic subunits (the endonuclease Las1, the polynucleotide kinase Grc3, and the AAA-type ATPase Mdn1), which are involved in the processing of ribosomal RNA precursors. All subunits are essential for viability and are conserved from yeast to mammals, including humans.\" [GOC:vw, PMID:32491985, PMID:35355014]","metadata":null},{"id":"b9adbeaeab7b4bf087e7756437179e39","type":"DRUG","name":"rizatriptan","canonical_id":"gtopdb:51","description":null,"metadata":null},{"id":"2b0432e889814f0eaf67bf5b060f80cc","type":"COMBINATION_TREATMENT","name":"rizatriptan + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-9c420836615746b9","description":null,"metadata":null},{"id":"11297d56cdd6433daf24d7b8690fd63b","type":"COMBINATION_TREATMENT","name":"rizatriptan + sumatriptan","canonical_id":"ctgov_combo:ctgov-combo-d207286d7c7bfa33","description":null,"metadata":null},{"id":"ad0917b8dd1f45f980e08aeddd2c7650","type":"GO_TERM","name":"rod bipolar cell differentiation","canonical_id":"go:GO:1904389","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a rod bipolar cell.\" [GO_REF:0000086, GOC:TermGenie, PMID:16914133]","metadata":null},{"id":"48afa029bcc84419b3d7781cedcc8de1","type":"GO_TERM","name":"rod bipolar cell terminal bouton","canonical_id":"go:GO:1990795","description":"\"A specialized region of the axon terminus portion of a rod bipolar axon. A rod bipolar cell is a neuron found in the retina and having connections with rod photoreceptor cells and neurons in the inner plexiform layer.\" [PMID:19883736]","metadata":null},{"id":"8c486c994f0146999a518aff8a046e21","type":"GO_TERM","name":"rod photoreceptor disc lumen","canonical_id":"go:GO:0120203","description":"\"The volume enclosed by the membrane of a rod photoreceptor cell disc membrane.\" [GOC:krc, GOC:pde, PMID:19501669, PMID:26574505, PMID:6771304]","metadata":null},{"id":"fe1d7df7d0bb4949b48b0b821c3bfc0c","type":"GO_TERM","name":"rod photoreceptor disc membrane","canonical_id":"go:GO:0120202","description":"\"Stack of disc membranes located inside a rod photoreceptor outer segment, and containing densely packed molecules of rhodopsin photoreceptor proteins that traverse the lipid bilayer. It is thought that rod disc membranes arise as evaginations of the ciliary membrane near the base of the outer segment, which then become completely separated from the ciliary membrane, during the development of the rod outer segment.\" [GOC:krc, GOC:pde, PMID:19501669, PMID:26574505, PMID:6771304]","metadata":null},{"id":"8a008c5816394d9591494317141a13e8","type":"GO_TERM","name":"rod photoreceptor outer segment","canonical_id":"go:GO:0120200","description":"\"The outer segment of a vertebrate rod photoreceptor that contains sealed membrane discs that are not connected to the ciliary membrane and containing rhodopsin photoreceptor proteins.\" [GOC:krc, GOC:pde, PMID:19501669, PMID:26574505, PMID:6771304]","metadata":null},{"id":"6452a11c62964160a0f38a39be45f075","type":"GO_TERM","name":"rod photoreceptor phosphodiesterase 6 complex","canonical_id":"go:GO:7770030","description":"\"A heterotetrameric cGMP phosphodiesterase complex found in the disc membranes of rod photoreceptor outer segments. It consists of two catalytic subunits, PDE6A and PDE6B, and two inhibitory gamma-subunits, PDE6G. In response to activation by transducin, the complex hydrolyzes cyclic GMP, thereby mediating the light-induced closure of cGMP-gated ion channels during rod phototransduction.\" [PMID:38159849]","metadata":null},{"id":"354ea76b2ab341efbd7938745ed99176","type":"GO_TERM","name":"rod spherule","canonical_id":"go:GO:0044317","description":"\"A specialized neuron projection which is the site of synaptic transmission produced by retinal rod cells. Rod spherules are small round enlargements of the axon (3-5 micrometers diameter) or even extensions of the cell body.\" [PMID:26930660]","metadata":null},{"id":"fb73520c751747c99e6d843fa6143d65","type":"GO_TERM","name":"rod telodendria","canonical_id":"go:GO:0120210","description":"\"Rod telodendria are projections that originate from the rod pedicle and form gap junctions with other photoreceptors within the outer plexiform layer of the retina.\" [GOC:cvs, GOC:krc, PMID:14755521]","metadata":null},{"id":"e2ff07c92ad34624aa419234b6ab170a","type":"DRUG","name":"rofecoxib","canonical_id":"gtopdb:2893","description":null,"metadata":null},{"id":"b49fa817ca3940b6bd612d6ae8735e13","type":"DRUG","name":"rofecoxib","canonical_id":"chembl:CHEMBL122","description":null,"metadata":null},{"id":"0f5085c0619749a69bd5cd2c152d8f12","type":"COMBINATION_TREATMENT","name":"rofecoxib + valdecoxib","canonical_id":"ctgov_combo:ctgov-combo-6a00e7f29b76de07","description":null,"metadata":null},{"id":"e6250a2c85f8488f9273ac772ec48a53","type":"COMBINATION_TREATMENT","name":"rofecoxib + valdecoxib","canonical_id":"ctgov_combo:ctgov-combo-f866b425b3bbb163","description":null,"metadata":null},{"id":"0fad887af8b249308e6a5570e2a469f0","type":"COMBINATION_TREATMENT","name":"rofecoxib + valdecoxib","canonical_id":"ctgov_combo:ctgov-combo-8dbc431e30b3d02b","description":null,"metadata":null},{"id":"b1ca53fde3db46b2b53e671c35b3e227","type":"DRUG","name":"roflumilast","canonical_id":"gtopdb:6962","description":null,"metadata":null},{"id":"5c20e8b753054f0bafe0c6fdf882a75b","type":"DRUG","name":"roflumilast","canonical_id":"chembl:CHEMBL193240","description":null,"metadata":null},{"id":"905e4041e1c646ee89c74cb03b969439","type":"COMBINATION_TREATMENT","name":"roflumilast + theophylline","canonical_id":"ctgov_combo:ctgov-combo-255601349b0bb88c","description":null,"metadata":null},{"id":"e7ca2a9b8df44234bc0e8c2a2e8611eb","type":"GO_TERM","name":"rolling circle DNA replication","canonical_id":"go:GO:0070581","description":"\"A DNA-dependent DNA replication process in which a single-stranded DNA molecule is synthesized from a circular duplex template. Replication typically does not cease when one circumference has been replicated, but continues around the circumference several more times, producing a long single strand comprising multimers of the replicon.\" [GOC:cb, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"9b3ff7e408ad4a859298462fe568e311","type":"GO_TERM","name":"rolling circle double-stranded viral DNA replication","canonical_id":"go:GO:0039683","description":"\"A rolling circle viral DNA replication that begins with a double-stranded viral DNA genome.\" [GOC:bf, GOC:jl, VZ:2676]","metadata":null},{"id":"46fe069126624e7aa94df411a1cbb3c9","type":"GO_TERM","name":"rolling circle single-stranded viral DNA replication","canonical_id":"go:GO:0039684","description":"\"A rolling circle viral DNA replication that begins with a single-stranded viral DNA genome.\" [GOC:bf, GOC:jl, VZ:1941]","metadata":null},{"id":"ecf3aa0d982049a488226b3878e5432d","type":"GO_TERM","name":"rolling circle viral DNA replication","canonical_id":"go:GO:0039682","description":"\"A process of unidirectional viral DNA replication that takes place on a circular DNA to rapidly produce numerous copies of the viral genome. Involves creating a nick in one strand of the circular DNA molecule at the origin of replication. DNA is then synthesized by DNA polymerase. Using the non-nicked strand as a template, replication proceeds around the circular DNA molecule, displacing the nicked strand as single-stranded DNA.\" [GOC:bf, GOC:jl, VZ:915, Wikipedia:Rolling_circle_replication]","metadata":null},{"id":"1b9889f699464fc19996df3956cf4378","type":"GO_TERM","name":"rolling hairpin viral DNA replication","canonical_id":"go:GO:0039685","description":"\"A viral DNA replication process where a 3' hairpin structure in the viral single-stranded DNA (ssDNA) template serves as a primer for host enzymes to synthesize DNA.\" [GOC:bf, GOC:jl, VZ:2656]","metadata":null},{"id":"6e0e708afa894034a3b108c55f3af687","type":"DRUG","name":"romidepsin","canonical_id":"gtopdb:7006","description":null,"metadata":null},{"id":"97cb1c474ea44bccbe24c5cafe254e7f","type":"DRUG","name":"romidepsin","canonical_id":"chembl:CHEMBL343448","description":null,"metadata":null},{"id":"96d70d20e98743eaa499ecfa6713f35e","type":"DRUG","name":"romiplostim","canonical_id":"gtopdb:6974","description":null,"metadata":null},{"id":"6c3672c3953a4890a450c9e1df04a812","type":"DRUG","name":"romiplostim","canonical_id":"chembl:CHEMBL1201832","description":null,"metadata":null},{"id":"a1f1e504101746e88fa3d175103cdd78","type":"DRUG","name":"romosozumab","canonical_id":"gtopdb:8092","description":null,"metadata":null},{"id":"3bafd758752e4235aa5602a1afffb003","type":"DRUG","name":"romosozumab","canonical_id":"chembl:CHEMBL2107874","description":null,"metadata":null},{"id":"f5741ff786794b019d707d7295da6633","type":"COMBINATION_TREATMENT","name":"romosozumab + teriparatide","canonical_id":"ctgov_combo:ctgov-combo-fe15f0c69d973b1c","description":null,"metadata":null},{"id":"2e76b11b6b994303bbaeaa2c676a745d","type":"COMBINATION_TREATMENT","name":"romosozumab + zoledronic acid","canonical_id":"ctgov_combo:ctgov-combo-fd1a44a265be841f","description":null,"metadata":null},{"id":"a82e76d8dc0646ce99d6c13e7f7d8397","type":"GO_TERM","name":"roof of mouth development","canonical_id":"go:GO:0060021","description":"\"The biological process whose specific outcome is the progression of the roof of the mouth from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The roof of the mouth is the partition that separates the nasal and oral cavities.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"8cef58a3a4994f738c77607ab2df522f","type":"GO_TERM","name":"roof plate formation","canonical_id":"go:GO:0021509","description":"\"The formation of a single row of glia at the dorsal midline of the developing neural tube. This region provides inductive signals for the specification of neuronal cell types and of the specification of neural crest cells. The cells comprising the roof plate are the precursors to radial glial cells.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15936325]","metadata":null},{"id":"104c823fba724863933d330c977a5143","type":"GO_TERM","name":"root cap development","canonical_id":"go:GO:0048829","description":"\"The process whose specific outcome is the progression of the root cap over time, from its formation to the mature structure. The root cap protects the root meristem from friction as the root grows through the soil. The cap is made up of a group of parenchyma cells which secrete a glycoprotein mucilage as a lubricant.\" [GOC:tb]","metadata":null},{"id":"1dd1c292bf4a48eea68845774aad57ab","type":"GO_TERM","name":"root cap mucilage biosynthetic process","canonical_id":"go:GO:0048355","description":"\"The chemical reactions and pathways resulting in the formation of mucilage that occur in the root cap; mucilage is normally synthesized during root growth.\" [GOC:jid]","metadata":null},{"id":"e26b67b85a0545bd871367c84169d599","type":"GO_TERM","name":"root development","canonical_id":"go:GO:0048364","description":"\"The process whose specific outcome is the progression of the root over time, from its formation to the mature structure. The root is the water- and mineral-absorbing part of a plant which is usually underground, does not bear leaves, tends to grow downwards and is typically derived from the radicle of the embryo.\" [GOC:jid, PO:0009005]","metadata":null},{"id":"8458a52cc3864e04bfd4479bef99813d","type":"GO_TERM","name":"root epidermal cell differentiation","canonical_id":"go:GO:0010053","description":"\"The process in which a relatively unspecialized cell in the root epidermis acquires the specialized features of a trichoblast or atrichoblast.\" [GOC:tb]","metadata":null},{"id":"77f3004c909b4e3881214d37e308a360","type":"GO_TERM","name":"root epithelial mucilage biosynthetic process","canonical_id":"go:GO:0048356","description":"\"The chemical reactions and pathways resulting in the formation of mucilage that occur in the root epithelium; mucilage is normally synthesized during root growth.\" [GOC:jid]","metadata":null},{"id":"b0072fdb333c42ddaccf57a81c97ecec","type":"GO_TERM","name":"root hair","canonical_id":"go:GO:0035618","description":"\"A long, thin projection from a root epidermal cell that contains F-actin and tubulin, and a cell wall.\" [PMID:24982600, PO:0000256]","metadata":null},{"id":"08797237316f4f09ac11ba95f6979280","type":"GO_TERM","name":"root hair cell development","canonical_id":"go:GO:0080147","description":"\"The process whose specific outcome is the progression of a root hair cell over time, from its formation to the mature state.\" [PMID:19675148]","metadata":null},{"id":"ad52c385aad3400a9ce54425134492a9","type":"GO_TERM","name":"root hair cell differentiation","canonical_id":"go:GO:0048765","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a root hair cell.\" [GOC:jid]","metadata":null},{"id":"02658ad4ab4347058893f4b07a4cc1c3","type":"GO_TERM","name":"root hair cell tip growth","canonical_id":"go:GO:0048768","description":"\"Localized growth of a plant root hair tip by extension of the cell wall.\" [GOC:jid, GOC:ki, PMID:12468740]","metadata":null},{"id":"3247e09519eb440c95875ddd526decf2","type":"GO_TERM","name":"root hair elongation","canonical_id":"go:GO:0048767","description":"\"The process in which the root hair grows longer.\" [GOC:jid, PMID:12468740]","metadata":null},{"id":"17cbf84ae816436da0c2c7af51810194","type":"GO_TERM","name":"root hair initiation","canonical_id":"go:GO:0048766","description":"\"The process in which a protrusion or bulge is formed at the site of plant root hair outgrowth.\" [GOC:jid, PMID:12468740]","metadata":null},{"id":"e896f79bf9b2453597e8f09d44b4b79d","type":"GO_TERM","name":"root hair tip","canonical_id":"go:GO:0035619","description":"\"The tip portion of an outgrowth of a root epidermal cell.\" [PMID:16567499]","metadata":null},{"id":"910f198206d4441ca1f1461c166a508b","type":"GO_TERM","name":"root meristem growth","canonical_id":"go:GO:0010449","description":"\"The increase in size or mass of a root meristem, a population of undifferentiated cells in a plant root which maintains a continuous balance between the production of stem cells and the incorporation of their derivatives into the growth of the root.\" [GOC:tb]","metadata":null},{"id":"d1f94fc069ac4f1e8bbabe3c05c214a6","type":"GO_TERM","name":"root meristem specification","canonical_id":"go:GO:0010071","description":"\"The specification of a meristem which will give rise to a primary or lateral root.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"f7b1db841eed4b50a3dd9c64119b77b2","type":"GO_TERM","name":"root morphogenesis","canonical_id":"go:GO:0010015","description":"\"The process in which the anatomical structures of roots are generated and organized. The root is the usually underground part of a seed plant body that originates from the hypocotyl, functions as an organ of absorption, aeration, and food storage or as a means of anchorage and support.\" [GOC:sm, ISBN:0877797099]","metadata":null},{"id":"f6a258c59c414ba9bb7607de61ab6508","type":"GO_TERM","name":"root radial pattern formation","canonical_id":"go:GO:0090057","description":"\"The radial pattern formation process that results in the formation of the different tissues of the root around its radial axis.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"b177c3a3be0e4e59bdadcbbd74e29eed","type":"GO_TERM","name":"root regeneration","canonical_id":"go:GO:0062211","description":"\"The the regeneration process by which a damaged or lost root regrows or re-differentiates. This process may occur via de-differentiation and subsequent reprogramming of somatic cells or activation of existing undifferentiated (meristematic) cells to form a new root meristem and subsequently new root.\" [PMID:27143753]","metadata":null},{"id":"5799b71252d24f7a89244166a37cb99d","type":"GO_TERM","name":"root system development","canonical_id":"go:GO:0022622","description":"\"The process whose specific outcome is the progression of the root system over time, from its formation to the mature structure.\" [GOC:isa_complete]","metadata":null},{"id":"1cdcc558feae40d7a727846e29ad78ae","type":"DRUG","name":"ropinirole","canonical_id":"gtopdb:7295","description":null,"metadata":null},{"id":"d6e770103c0249bbbc51e0ad9e60bbf8","type":"DISEASE","name":"rosacea","canonical_id":"mondo:0006604","description":null,"metadata":null},{"id":"a2292a24578340f1a15ff1516b571a5f","type":"DRUG","name":"rosiglitazone","canonical_id":"gtopdb:1056","description":null,"metadata":null},{"id":"3e06dcfc37c442fc8648f953d84af509","type":"DRUG","name":"rosiglitazone","canonical_id":"chembl:CHEMBL121","description":null,"metadata":null},{"id":"09374b508d17413f8a2db6f128b78fe1","type":"GO_TERM","name":"rosmarinate synthase activity","canonical_id":"go:GO:0050266","description":"\"Catalysis of the reaction: caffeoyl-CoA + 3-(3,4-dihydroxyphenyl)lactate = CoA + rosmarinate.\" [EC:2.3.1.140]","metadata":null},{"id":"7e686beac245465d93bedd2f94c44312","type":"GO_TERM","name":"rostral hindbrain neuronal precursor cell proliferation","canonical_id":"go:GO:0021931","description":"\"The multiplication or reproduction of neuroblasts that will give rise to neurons of the lateral pontine nucleus and the locus ceruleus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"ce8a73c0c55549f297a2f80fc848ea6f","type":"GO_TERM","name":"rostrocaudal neural tube patterning","canonical_id":"go:GO:0021903","description":"\"The process in which the neural tube is divided into specific regions along the rostrocaudal axis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"0faa399b3bdf4769bbb3775920acf1c4","type":"DRUG","name":"rosuvastatin","canonical_id":"gtopdb:2954","description":null,"metadata":null},{"id":"f19f90daf33145ada359c0c50b5e7f4a","type":"COMBINATION_TREATMENT","name":"rosuvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-4f4b87603feb0cb4","description":null,"metadata":null},{"id":"bbd61c242c464088bb535a3d254901df","type":"COMBINATION_TREATMENT","name":"rosuvastatin + simvastatin","canonical_id":"ctgov_combo:ctgov-combo-d2c55df0357a83b4","description":null,"metadata":null},{"id":"993cd2f562c64bfda31cce5d53435961","type":"COMBINATION_TREATMENT","name":"rosuvastatin + warfarin","canonical_id":"ctgov_combo:ctgov-combo-5e3fbc4ea229ed19","description":null,"metadata":null},{"id":"2e936b814b4c4be5af1662ac837ac53a","type":"DRUG","name":"rotigotine","canonical_id":"gtopdb:941","description":null,"metadata":null},{"id":"30c8d0829fed418c8798fc7f8e47e92a","type":"DRUG","name":"rotigotine","canonical_id":"mesh:C047508","description":null,"metadata":null},{"id":"24a9f164c07242bf8fab6684a562445a","type":"DRUG","name":"rotigotine","canonical_id":"chembl:CHEMBL1303","description":null,"metadata":null},{"id":"04b703c3becd4fadad61f9fff899b4d8","type":"GO_TERM","name":"rough endoplasmic reticulum","canonical_id":"go:GO:0005791","description":"\"The rough (or granular) endoplasmic reticulum (ER) has ribosomes adhering to the outer surface; the ribosomes are the site of translation of the mRNA for those proteins which are either to be retained within the cisternae (ER-resident proteins), the proteins of the lysosomes, or the proteins destined for export from the cell. Glycoproteins undergo their initial glycosylation within the cisternae.\" [ISBN:0198506732]","metadata":null},{"id":"b0aa2cd4c08b43cb98a6d4f3237144b8","type":"GO_TERM","name":"rough endoplasmic reticulum cisterna","canonical_id":"go:GO:0120083","description":"\"A subcompartment of the rough endoplasmic reticulum consisting of lumenal expansion into a flattened, disc-shaped cavity.\" [GOC:sl, PMID:12112448]","metadata":null},{"id":"82e5eb4fde7d4b139f7bd64bbfe09d24","type":"GO_TERM","name":"rough endoplasmic reticulum lumen","canonical_id":"go:GO:0048237","description":"\"The volume enclosed by the membranes of the rough endoplasmic reticulum.\" [GOC:jid]","metadata":null},{"id":"73194eac60e04cce94ad8704b94db4e8","type":"GO_TERM","name":"rough endoplasmic reticulum membrane","canonical_id":"go:GO:0030867","description":"\"The lipid bilayer surrounding the rough endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"f4f58d37168249b7964b32074dc52f21","type":"DRUG","name":"rozanolixizumab","canonical_id":"gtopdb:9801","description":null,"metadata":null},{"id":"3fc1197f9f22464fa8f85f7e8211240f","type":"DRUG","name":"rozanolixizumab","canonical_id":"chembl:CHEMBL4297820","description":null,"metadata":null},{"id":"bf01af3c8b9244079c703b30002a1137","type":"PROTEIN","name":"rpsB","canonical_id":"uniprot:P0A7V0","description":null,"metadata":null},{"id":"96188eeeb12341d2aeb9b02b5af66a9a","type":"GO_TERM","name":"rubber cis-polyprenylcistransferase activity","canonical_id":"go:GO:0050267","description":"\"Catalysis of the reaction: (cis-prenyl)n-diphosphate + isopentenyl diphosphate = (cis-prenyl)(n+1)-diphosphate + diphosphate.\" [RHEA:18801]","metadata":null},{"id":"8ba31ea8ece2450db15705d912a8d4af","type":"GO_TERM","name":"rubredoxin-NAD(P)H reductase activity","canonical_id":"go:GO:0015045","description":"\"Catalysis of the reaction: reduced rubredoxin + NAD(P)+ = oxidized rubredoxin + NAD(P)H + H+.\" [EC:1.18.1.4]","metadata":null},{"id":"f26cc468c3984ffea9216e2bd0c61562","type":"GO_TERM","name":"rubredoxin-NAD+ reductase activity","canonical_id":"go:GO:0015044","description":"\"Catalysis of the reaction: 2 reduced [rubredoxin] + NAD+ + H+ = 2 oxidized [rubredoxin] + NADH.\" [RHEA:18597]","metadata":null},{"id":"b0460752f9924906bb6fc31571f88f6f","type":"GO_TERM","name":"rubredoxin-NADP+ reductase activity","canonical_id":"go:GO:0015046","description":"\"Catalysis of the reaction: 2 reduced [rubredoxin] + NADP+ + H+ = 2 oxidized [rubredoxin] + NADPH.\" [RHEA:13949]","metadata":null},{"id":"7bde3fde8fab4c4dbbaebec1b8e56f7d","type":"GO_TERM","name":"rubrospinal tract morphogenesis","canonical_id":"go:GO:0021964","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the red nucleus of the midbrain towards target cells in the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a969466271e24098b7472f5f39e21920","type":"DRUG","name":"rucaparib","canonical_id":"gtopdb:7736","description":null,"metadata":null},{"id":"748d020dcf5e4ee5939a6d799b73bc88","type":"DRUG","name":"rucaparib","canonical_id":"mesh:C531549","description":null,"metadata":null},{"id":"54c4b41b5e484fe7bde24ae1f29bbd1d","type":"DRUG","name":"rucaparib","canonical_id":"chembl:CHEMBL1173055","description":null,"metadata":null},{"id":"2fd1dfde93af41e09241308bf49af67b","type":"COMBINATION_TREATMENT","name":"rucaparib + talazoparib","canonical_id":"ctgov_combo:ctgov-combo-d45f6bf06755e10b","description":null,"metadata":null},{"id":"ce95239b99864d9a8cd0f17fbb92fdc8","type":"GO_TERM","name":"ruffle","canonical_id":"go:GO:0001726","description":"\"Projection at the leading edge of a crawling cell; the protrusions are supported by a microfilament meshwork.\" [ISBN:0124325653]","metadata":null},{"id":"58fe29a65ba74360a58dc86e18b6186d","type":"GO_TERM","name":"ruffle assembly","canonical_id":"go:GO:0097178","description":"\"The aggregation, arrangement and bonding together of a set of components to form a ruffle, a projection at the leading edge of a crawling cell; the protrusions are supported by a microfilament meshwork. The formation of ruffles (also called membrane ruffling) is thought to be controlled by a group of enzymes known as Rho GTPases, specifically RhoA, Rac1 and cdc42.\" [GOC:yaf, PMID:12556481, Wikipedia:Membrane_ruffling]","metadata":null},{"id":"d2d2360fb2f14af38ed74bd1a333987c","type":"GO_TERM","name":"ruffle membrane","canonical_id":"go:GO:0032587","description":"\"The portion of the plasma membrane surrounding a ruffle.\" [GOC:mah]","metadata":null},{"id":"2f413c8d7227447b9405cd999cd12c79","type":"GO_TERM","name":"ruffle organization","canonical_id":"go:GO:0031529","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a ruffle, a projection at the leading edge of a crawling cell.\" [GOC:mah, PMID:10036235]","metadata":null},{"id":"16c944fa0c20419f8733740c61cedfcb","type":"DRUG","name":"rufinamide","canonical_id":"mesh:C079703","description":null,"metadata":null},{"id":"d719bea31f1f4bfe94f87c226f54e434","type":"GO_TERM","name":"rumination","canonical_id":"go:GO:0036147","description":"\"A digestive process in which food, usually grass or hay, is swallowed into a multi-compartmented stomach, regurgitated, chewed again, and swallowed again.\" [GOC:maf, Wikipedia:Rumination]","metadata":null},{"id":"f6543b75f7464dbebb69ade389fb531f","type":"DRUG","name":"rupatadine","canonical_id":"gtopdb:10103","description":null,"metadata":null},{"id":"e6297add026f4fe9b0876f4cdb627d42","type":"DRUG","name":"rupatadine","canonical_id":"mesh:C103639","description":null,"metadata":null},{"id":"1a9adcc9c1c54741b1ef3c36ebc1b467","type":"DRUG","name":"rupatadine","canonical_id":"chembl:CHEMBL91397","description":null,"metadata":null},{"id":"220937b9b80940d3b09549cf7e149e98","type":"DRUG","name":"ruxolitinib","canonical_id":"gtopdb:5688","description":null,"metadata":null},{"id":"85b77cbed9ad4252ac389b2aff1baaf7","type":"GO_TERM","name":"ryanodine receptor complex","canonical_id":"go:GO:1990425","description":"\"A voltage-gated calcium-release channel complex of the sarcoplasmic or endoplasmic reticulum. It plays an important role in the excitation-contraction (E-C) coupling of muscle cells. RyR comprises a family of ryanodine receptors, widely expressed throughout the animal kingdom.\" [GOC:ame, PMID:22822064]","metadata":null},{"id":"ff6f74c906fe4392813088baacc7a1c0","type":"GO_TERM","name":"ryanodine-sensitive calcium-release channel activity","canonical_id":"go:GO:0005219","description":"\"Enables transmembrane transfer of calcium ions from an intracellular store to the cytosol on induction by increased calcium concentration and is sensitive to the plant alkaloid ryanodine.\" [GOC:dph, GOC:tb, PMID:22822064]","metadata":null},{"id":"f81312c366664a428ba86853b23ebb6d","type":"DISEASE","name":"ryr1-related disorders","canonical_id":"efo:0009143","description":null,"metadata":null},{"id":"d8774941d9dd491dba50d7bb17123fcb","type":"GO_TERM","name":"s-triazine compound catabolic process","canonical_id":"go:GO:0042204","description":"\"The chemical reactions and pathways resulting in the breakdown of any s-triazine compound. These compounds include many pesticides of widespread use in agriculture, and are characterized by a symmetrical hexameric ring consisting of alternating carbon and nitrogen atoms.\" [UM-BBD_pathwayID:tria]","metadata":null},{"id":"c0de98a8c7e44a05a679291c885043c5","type":"GO_TERM","name":"sRNA-mediated post-transcriptional gene silencing","canonical_id":"go:GO:0040033","description":"\"A post-transcriptional gene silencing pathway mediated by the action of small regulatory non-coding RNAs (sRNAs). sRNAs are 20-500 nucleotides in length and found in bacteria.\" [PMID:12460531, PMID:2468565, PMID:33963446]","metadata":null},{"id":"08e9e93d11124ed69c0ab31486db5026","type":"GO_TERM","name":"sabinene synthase activity","canonical_id":"go:GO:0080015","description":"\"Catalysis of the reaction: (2E)-geranyl diphosphate = diphosphate + sabinene.\" [PMID:12566586, PMID:9747540, RHEA:68636]","metadata":null},{"id":"4f634164437942e99c8909ab77bdba76","type":"GO_TERM","name":"sabinene-hydrate synthase activity","canonical_id":"go:GO:0050469","description":"\"Catalysis of the reaction: geranyl diphosphate + H2O = diphosphate + sabinene hydrate.\" [EC:4.2.3.11, RHEA:19565]","metadata":null},{"id":"71fe19a06296415b918d317262c2ec41","type":"GO_TERM","name":"saccharopine dehydrogenase (NAD+, L-glutamate-forming) activity","canonical_id":"go:GO:0047131","description":"\"Catalysis of the reaction: L-saccharopine + H2O + NAD+ = L-glutamate + allysine + H+ + NADH.\" [EC:1.5.1.9, RHEA:24520]","metadata":null},{"id":"06fbc2d5f61b47adba82ae2b15ddb9a6","type":"GO_TERM","name":"saccharopine dehydrogenase (NAD+, L-lysine-forming) activity","canonical_id":"go:GO:0004754","description":"\"Catalysis of the reaction: L-saccharopine + H2O + NAD+ = 2-oxoglutarate + L-lysine + H+ + NADH.\" [EC:1.5.1.7, RHEA:12440]","metadata":null},{"id":"997a298d165e445383e78da9b03f32b4","type":"GO_TERM","name":"saccharopine dehydrogenase (NADP+, L-glutamate-forming) activity","canonical_id":"go:GO:0004755","description":"\"Catalysis of the reaction: L-saccharopine + H2O + NADP+ = L-allysine + L-glutamate + H+ + NADPH.\" [EC:1.5.1.10, RHEA:10020]","metadata":null},{"id":"5e35461a1cad4f47893be7968d3bac25","type":"GO_TERM","name":"saccharopine dehydrogenase (NADP+, L-lysine-forming) activity","canonical_id":"go:GO:0047130","description":"\"Catalysis of the reaction: L-saccharopine + H2O + NADP+ = 2-oxoglutarate + L-lysine + H+ + NADPH.\" [EC:1.5.1.8, RHEA:19373]","metadata":null},{"id":"50430bc737ff42999dd2bd49399f38ef","type":"GO_TERM","name":"saccharopine dehydrogenase activity","canonical_id":"go:GO:0004753","description":"\"Catalysis of the cleavage of N6-(L-1,3-dicarboxypropyl)-L-lysine to release an amino acid (lysine or glutamate), with the concomitant reduction of an electron acceptor.\" [GOC:mah]","metadata":null},{"id":"c851cb49f5634a2190ba1a6cf4bfd507","type":"GO_TERM","name":"saccharopine oxidase activity","canonical_id":"go:GO:0051698","description":"\"Catalysis of the reaction: H2O + L-saccharopine + O2 = (S)-2-amino-6-oxohexanoate + H2O2 + L-glutamate.\" [PMID:16233628, RHEA:28210]","metadata":null},{"id":"6c10aff033bd47148639bbe13831f608","type":"DRUG","name":"sacituzumab govitecan","canonical_id":"gtopdb:8253","description":null,"metadata":null},{"id":"283cd13be2e547b486b1b9731df98082","type":"DRUG","name":"sacituzumab govitecan","canonical_id":"chembl:CHEMBL3545262","description":null,"metadata":null},{"id":"b046e10adaf540a5a62914ed585b46f4","type":"DRUG","name":"safinamide","canonical_id":"gtopdb:8291","description":null,"metadata":null},{"id":"1b37561ab6b94cc4a9f96cd2c7f6eabf","type":"DRUG","name":"safinamide","canonical_id":"chembl:CHEMBL396778","description":null,"metadata":null},{"id":"e7c0473b6fc5403eb14230c3c0acbd27","type":"GO_TERM","name":"sagittal suture morphogenesis","canonical_id":"go:GO:0060367","description":"\"The process in which the sagittal suture is generated and organized.\" [GOC:dph, GOC:sl]","metadata":null},{"id":"75d1e2cdb1e94ae98e0e73316e13b1da","type":"GO_TERM","name":"sakuranetin 6-hydroxylase activity","canonical_id":"go:GO:0102536","description":"\"Catalysis of the reaction: (2S)-sakuranetin + O2 + reduced [NADPH--hemoprotein reductase] = (2S)-7-methylcarthamidin + H(+) + H2O + oxidized [NADPH--hemoprotein reductase].\" [PMID:23184958, RHEA:73431]","metadata":null},{"id":"5c64242d565640e890a344eca2e38d96","type":"DRUG","name":"salbutamol","canonical_id":"gtopdb:558","description":null,"metadata":null},{"id":"a33d653ed157459ba9ed780837abce71","type":"DRUG","name":"salbutamol","canonical_id":"chembl:CHEMBL714","description":null,"metadata":null},{"id":"a983a72b8c1f4b07b3ac29da04cf22a3","type":"GO_TERM","name":"salicin transmembrane transporter activity","canonical_id":"go:GO:0042950","description":"\"Enables the transfer of salicin (saligenin-beta-D-glucopyranoside), a glucoside of o-hydroxybenzylalcohol, from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"48847761e0ba4942a3d7df2f9347ff26","type":"GO_TERM","name":"salicin transport","canonical_id":"go:GO:0042948","description":"\"The directed movement of salicin (saligenin-beta-D-glucopyranoside), a glucoside of o-hydroxybenzylalcohol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"2c15cbdb019d4955ae4003d78c972365","type":"GO_TERM","name":"salicyl-alcohol beta-D-glucosyltransferase activity","canonical_id":"go:GO:0050274","description":"\"Catalysis of the reaction: salicyl alcohol + UDP-D-glucose = H+ + salicin + UDP.\" [EC:2.4.1.172, RHEA:11512]","metadata":null},{"id":"7fa402f8c51845cf98961a7e2236ed4d","type":"GO_TERM","name":"salicylaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0018485","description":"\"Catalysis of the reaction: salicylaldehyde + NAD+ + H2O = salicylate + NADH + H+.\" [RHEA:18537]","metadata":null},{"id":"4399658867784eabb605c9a9bab8e6af","type":"GO_TERM","name":"salicylate 1-monooxygenase activity","canonical_id":"go:GO:0018658","description":"\"Catalysis of the reaction: salicylate + NADH + H+ + O2 = catechol + NAD+ + H2O + CO2.\" [EC:1.14.13.1]","metadata":null},{"id":"ea90521c7b6c4535bec5300234692307","type":"GO_TERM","name":"salicylate 5-hydroxylase (NADH) activity","canonical_id":"go:GO:0034785","description":"\"Catalysis of the reaction: salicylate + NADH + O2 + H+ = 2,5-dihydroxybenzoate + NAD+ + H2O.\" [RHEA:35307]","metadata":null},{"id":"e408df399cf74b9380c154d3b014c03e","type":"DRUG","name":"salicylic acid","canonical_id":"mesh:D020156","description":null,"metadata":null},{"id":"6c46c3392c2a42528f6a3aeb99ab6207","type":"GO_TERM","name":"salicylic acid binding","canonical_id":"go:GO:1901149","description":"\"Binding to salicylic acid.\" [GOC:TermGenie, PMID:22699612]","metadata":null},{"id":"5bdd8a4a79fc490da5e8e5ce821f13bd","type":"GO_TERM","name":"salicylic acid biosynthetic process","canonical_id":"go:GO:0009697","description":"\"The chemical reactions and pathways resulting in the formation of salicylic acid (2-hydroxybenzoic acid), a derivative of benzoic acid.\" [ISBN:0943088399]","metadata":null},{"id":"ed0d7e58da704de79527acc60d746aca","type":"GO_TERM","name":"salicylic acid catabolic process","canonical_id":"go:GO:0046244","description":"\"The chemical reactions and pathways resulting in the breakdown of salicylic acid (2-hydroxybenzoic acid), a derivative of benzoic acid.\" [GOC:ai]","metadata":null},{"id":"bee920e8e1d844e39c01d696bc2b4ba0","type":"GO_TERM","name":"salicylic acid glucosyltransferase (ester-forming) activity","canonical_id":"go:GO:0052639","description":"\"Catalysis of the reaction: salicylic acid + UDP-glucose = salicylic acid glucose ester + UDP.\" [MetaCyc:RXN-11659, RHEA:62316]","metadata":null},{"id":"2123ce4e3c0f45288d51120604efe7b0","type":"GO_TERM","name":"salicylic acid glucosyltransferase (glucoside-forming) activity","canonical_id":"go:GO:0052640","description":"\"Catalysis of the reaction: salicylic acid + UDP-glucose = salicylic acid 2-O-glucoside + UDP.\" [MetaCyc:RXN-11658, RHEA:62312]","metadata":null},{"id":"a621711087ec4748ae853ed5024ce1cd","type":"GO_TERM","name":"salicylic acid mediated signaling pathway","canonical_id":"go:GO:0009863","description":"\"The series of molecular signals mediated by salicylic acid.\" [GOC:jy]","metadata":null},{"id":"e85961e520004e54a02f629874053e4c","type":"GO_TERM","name":"salicylic acid metabolic process","canonical_id":"go:GO:0009696","description":"\"The chemical reactions and pathways involving of salicylic acid (2-hydroxybenzoic acid), a derivative of benzoic acid.\" [ISBN:0943088399]","metadata":null},{"id":"42037a3aa53c433188e52e3b8be47967","type":"DRUG","name":"salicylsalicylic acid","canonical_id":"mesh:C014182","description":null,"metadata":null},{"id":"268adfd747934da295f22f60008b7ced","type":"GO_TERM","name":"saliva secretion","canonical_id":"go:GO:0046541","description":"\"The regulated release of saliva from the salivary glands. In man, the saliva is a turbid and slightly viscous fluid, generally of an alkaline reaction, and is secreted by the parotid, submaxillary, and sublingual glands. In the mouth the saliva is mixed with the secretion from the buccal glands. In man and many animals, saliva is an important digestive fluid on account of the presence of the peculiar enzyme, ptyalin.\" [GOC:curators, UBERON:0001836]","metadata":null},{"id":"d3d309c46a8a445a9ce91665024d3638","type":"GO_TERM","name":"salivary gland boundary specification","canonical_id":"go:GO:0007432","description":"\"Determination of where the salivary gland forms, the total number of salivary gland cells and how many cells are allocated to each of the specialised cell types within the salivary gland.\" [PMID:11598957]","metadata":null},{"id":"6326e86f70dc4fa7b7b81c868bee3ea9","type":"GO_TERM","name":"salivary gland cavitation","canonical_id":"go:GO:0060662","description":"\"The process in which the solid core of salivary epithelium gives rise to the hollow tube of the gland.\" [GOC:dph]","metadata":null},{"id":"d7251e56ca1541e4a6962a3c53085e9a","type":"GO_TERM","name":"salivary gland development","canonical_id":"go:GO:0007431","description":"\"The process whose specific outcome is the progression of the salivary gland over time, from its formation to the mature structure. Salivary glands include any of the saliva-secreting exocrine glands of the oral cavity.\" [GOC:jid, UBERON:0001044]","metadata":null},{"id":"57881b6611304eaf8279c1f930f7d8ce","type":"GO_TERM","name":"salivary gland histolysis","canonical_id":"go:GO:0035070","description":"\"The stage-specific break down of the larval salivary glands during Drosophila metamorphosis, to allow replacement of larval structures by tissues and structures that form the adult fly.\" [GOC:bf, GOC:dph, GOC:mtg_apoptosis, PMID:9409683]","metadata":null},{"id":"6ec52cef2e614e87a6e16a2772a55a68","type":"GO_TERM","name":"salivary gland morphogenesis","canonical_id":"go:GO:0007435","description":"\"The process in which the anatomical structures of the salivary gland are generated and organized.\" [GOC:jid]","metadata":null},{"id":"cb4fe73b7d8f488199a2d553bdfc1b8b","type":"GO_TERM","name":"salivary nucleus development","canonical_id":"go:GO:0021751","description":"\"The process whose specific outcome is the progression of a salivary nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"34fe394968bd4df1b7e539a0c402dfeb","type":"DRUG","name":"salmeterol","canonical_id":"gtopdb:559","description":null,"metadata":null},{"id":"7ada2a10b6754c53a8f80a95eb8b37a8","type":"DRUG","name":"salmeterol","canonical_id":"mesh:D000068299","description":null,"metadata":null},{"id":"ec01806d53de4049875b3d8c292c50a0","type":"COMBINATION_TREATMENT","name":"salmeterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-5e1e9cb267b799c1","description":null,"metadata":null},{"id":"20830a39c05c4d2eb98b3944972a2ae3","type":"COMBINATION_TREATMENT","name":"salmeterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-016192067f4c06e8","description":null,"metadata":null},{"id":"666583e0d5f54b7ca5bd54d68e26c11e","type":"COMBINATION_TREATMENT","name":"salmeterol + tiotropium","canonical_id":"ctgov_combo:ctgov-combo-f0b0f1b4f2d2c828","description":null,"metadata":null},{"id":"68a0edd096bf4f2d8ff72c611129c2ea","type":"GO_TERM","name":"salt aversion","canonical_id":"go:GO:0035199","description":"\"The specific avoidance actions or reactions of an organism in response to the perception of salt.\" [GOC:bf]","metadata":null},{"id":"88e5a29941004bc2b2d1d0d4faeb68c6","type":"GO_TERM","name":"salt transmembrane transporter activity","canonical_id":"go:GO:1901702","description":"\"Enables the transfer of salt from one side of a membrane to the other.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"33b7dcc3ee574672a95d1432f98c97de","type":"GO_TERM","name":"salutaridine reductase (NADPH) activity","canonical_id":"go:GO:0047037","description":"\"Catalysis of the reaction: (7S)-salutaridinol + NADP+ = H+ + NADPH + salutaridine.\" [EC:1.1.1.248, RHEA:10108]","metadata":null},{"id":"ab13988c5bff4ed28e56d9b6d61df81a","type":"GO_TERM","name":"salutaridine synthase activity","canonical_id":"go:GO:0047055","description":"\"Catalysis of the reaction: (R)-reticuline + reduced [NADPH--hemoprotein reductase] + O2 = salutaridine + oxidized [NADPH--hemoprotein reductase] + 2 H2O + H+.\" [RHEA:17713]","metadata":null},{"id":"33f16be194a74fec84e1bd343c6a11a8","type":"GO_TERM","name":"salutaridinol 7-O-acetyltransferase activity","canonical_id":"go:GO:0047180","description":"\"Catalysis of the reaction: (7S)-salutaridinol + acetyl-CoA = (7S)-O-acetylsalutaridinol + CoA.\" [EC:2.3.1.150, RHEA:22856]","metadata":null},{"id":"c2dfe636442341afa4b56a733a73e149","type":"GO_TERM","name":"saponin biosynthetic process","canonical_id":"go:GO:0016135","description":"\"The chemical reactions and pathways resulting in the formation of saponins, glycosides of plants in which the aglycan (sapogenin) group is a terpene or steroid and the sugar group is a glucose, a galactose, a pentose, a methylpentose or an oligosaccharide. Saponins are powerful surfactant agents and membrane active; they are, hence, toxic to animals on injection.\" [GOC:curators]","metadata":null},{"id":"cbe9664e84e741c09041913f9515b4b7","type":"GO_TERM","name":"saponin catabolic process","canonical_id":"go:GO:0016136","description":"\"The chemical reactions and pathways resulting in the breakdown of saponins, glycosides of plants in which the aglycan (sapogenin) group is a terpene or steroid and the sugar group is a glucose, a galactose, a pentose, a methylpentose or an oligosaccharide. Saponins are powerful surfactant agents and membrane active; they are, hence, toxic to animals on injection.\" [GOC:curators]","metadata":null},{"id":"3326e5e470704b90ba5bc50f7f44a8ee","type":"GO_TERM","name":"saponin metabolic process","canonical_id":"go:GO:0016134","description":"\"The chemical reactions and pathways involving saponins, glycosides of plants in which the aglycan (sapogenin) group is a terpene or steroid and the sugar group is a glucose, a galactose, a pentose, a methylpentose or an oligosaccharide. Saponins are powerful surfactant agents and membrane active; they are, hence, toxic to animals on injection.\" [ISBN:0198547684]","metadata":null},{"id":"f9e224b2f777433fbab377565d22fc33","type":"DRUG","name":"sapropterin","canonical_id":"gtopdb:5276","description":null,"metadata":null},{"id":"c2bcd14e5f0041408ff0cfe29d6c2b8b","type":"DRUG","name":"sapropterin","canonical_id":"mesh:C003402","description":null,"metadata":null},{"id":"fbbd5010df374ca5b1b78b7f7de61868","type":"DRUG","name":"saquinavir","canonical_id":"mesh:D019258","description":null,"metadata":null},{"id":"a1cbc6faa0864dbb9f00c50f7add0a5c","type":"GO_TERM","name":"sarcinapterin biosynthetic process","canonical_id":"go:GO:1900868","description":"\"The chemical reactions and pathways resulting in the formation of sarcinapterin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"9326ea51b9b440d890695ffff9d673c9","type":"GO_TERM","name":"sarcoglycan complex","canonical_id":"go:GO:0016012","description":"\"A protein complex formed of four sarcoglycans plus sarcospan; there are six known sarcoglycans: alpha-, beta-, gamma-, delta-, epsilon- and zeta-sarcoglycan; all are N-glycosylated single-pass transmembrane proteins. The sarcoglycan-sarcospan complex is a subcomplex of the dystrophin glycoprotein complex, and is fixed to the dystrophin axis by a lateral association with the dystroglycan complex.\" [PMID:15117830, PMID:16710609]","metadata":null},{"id":"678304855aca40cdbe54cdc2d3d1a7bc","type":"DISEASE","name":"sarcoidosis","canonical_id":"mondo:0019338","description":null,"metadata":null},{"id":"09c2ab7774df4f2a8638b32a83adad51","type":"GO_TERM","name":"sarcolemma","canonical_id":"go:GO:0042383","description":"\"The outer membrane of a muscle cell, consisting of the plasma membrane, a covering basement membrane (about 100 nm thick and sometimes common to more than one fiber), and the associated loose network of collagen fibers.\" [ISBN:0198506732]","metadata":null},{"id":"80c47e70a7be437e82adfc7b8761790b","type":"DISEASE","name":"sarcoma","canonical_id":"mondo:0005089","description":null,"metadata":null},{"id":"c859cff26c244cba9420f83e7a513857","type":"GO_TERM","name":"sarcomere","canonical_id":"go:GO:0030017","description":"\"The repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs.\" [ISBN:0815316194]","metadata":null},{"id":"491b2cd18f8046d5ae8ee74ff3574859","type":"GO_TERM","name":"sarcomere organization","canonical_id":"go:GO:0045214","description":"\"The myofibril assembly process that results in the organization of muscle actomyosin into sarcomeres. The sarcomere is the repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs.\" [GOC:bf]","metadata":null},{"id":"baa943388cd64af0898cba785959c0e1","type":"GO_TERM","name":"sarcomerogenesis","canonical_id":"go:GO:0048769","description":"\"The process in which sarcomeres are added in series within a fiber.\" [GOC:jid, GOC:lm, PMID:15947030]","metadata":null},{"id":"50b30b9c6e1c4e9885d4faa992d8c1bc","type":"GO_TERM","name":"sarcoplasm","canonical_id":"go:GO:0016528","description":"\"The cytoplasm of a muscle cell; includes the sarcoplasmic reticulum.\" [ISBN:0198547684]","metadata":null},{"id":"bd26a30352424b59ab72b9d6dfe60406","type":"GO_TERM","name":"sarcoplasmic reticulum","canonical_id":"go:GO:0016529","description":"\"A fine reticular network of membrane-limited elements that pervades the sarcoplasm of a muscle cell; continuous over large portions of the cell and with the nuclear envelope; that part of the endoplasmic reticulum specialized for calcium release, uptake and storage.\" [GOC:mtg_muscle, ISBN:0124325653, ISBN:0198547684]","metadata":null},{"id":"15114036cff04af59ae56c3ab3ace4b4","type":"GO_TERM","name":"sarcoplasmic reticulum calcium ion transport","canonical_id":"go:GO:0070296","description":"\"The directed movement of calcium ions (Ca2+) into, out of or within the sarcoplasmic reticulum.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"dc7e94aa9ab849e8bfe7269c1c71725a","type":"GO_TERM","name":"sarcoplasmic reticulum lumen","canonical_id":"go:GO:0033018","description":"\"The volume enclosed by the membranes of the sarcoplasmic reticulum.\" [GOC:rph]","metadata":null},{"id":"666217f858c145ed95c9717a5a00a278","type":"GO_TERM","name":"sarcoplasmic reticulum membrane","canonical_id":"go:GO:0033017","description":"\"The lipid bilayer surrounding the sarcoplasmic reticulum.\" [GOC:rph]","metadata":null},{"id":"2bfc45b78ca8477e8c2256b82b25742e","type":"GO_TERM","name":"sarcosine N-methyltransferase activity","canonical_id":"go:GO:0052730","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + sarcosine = S-adenosyl-L-homocysteine + N,N-dimethylglycine.\" [RHEA:15453]","metadata":null},{"id":"5214f69689724b3d92a406d606f70e74","type":"GO_TERM","name":"sarcosine dehydrogenase activity","canonical_id":"go:GO:0008480","description":"\"Catalysis of the reaction: sarcosine + H2O + electron-transfer flavoprotein = glycine + formaldehyde + reduced electron-transfer flavoprotein.\" [EC:1.5.8.3, RHEA:19793]","metadata":null},{"id":"9b11bd8b4e924d9aba92b6b0a41edb69","type":"GO_TERM","name":"sarcosine oxidase activity","canonical_id":"go:GO:0008115","description":"\"Catalysis of the reaction: H2O + O2 + sarcosine = formaldehyde + glycine + H2O2.\" [EC:1.5.3.1, RHEA:13313]","metadata":null},{"id":"1e775ade36734b9a991e250383a7cc5c","type":"GO_TERM","name":"sarcosine oxidase complex","canonical_id":"go:GO:0032921","description":"\"A complex consisting of 4 protein subunits as a heterotetramer, that possesses sarcosine oxidase activity.\" [GOC:mah, GOC:mlg]","metadata":null},{"id":"06e70080e3d749368e02573d9fe2735f","type":"GO_TERM","name":"sarcosine reductase activity","canonical_id":"go:GO:0033794","description":"\"Catalysis of the reaction: acetyl phosphate + methylamine + thioredoxin disulfide = N-methylglycine + phosphate + thioredoxin.\" [EC:1.21.4.3]","metadata":null},{"id":"2b88420a40d04cde9881c7e0c87a9fb0","type":"DRUG","name":"sarilumab","canonical_id":"gtopdb:7999","description":null,"metadata":null},{"id":"1b97aa669cc947f79d7fe611d154d758","type":"DRUG","name":"sarilumab","canonical_id":"chembl:CHEMBL2108730","description":null,"metadata":null},{"id":"4e1b9e81a00b4047a3313126ae5919d9","type":"GO_TERM","name":"sarsapogenin 3-beta-glucosyltransferase activity","canonical_id":"go:GO:0047249","description":"\"Catalysis of the reaction: (25S)-5beta-spirostan-3beta-ol + UDP-D-glucose = (25S)-5beta-spirostan-3beta-yl beta-D-glucoside + H+ + UDP.\" [EC:2.4.1.193, RHEA:14461]","metadata":null},{"id":"c02d8b3401ee4fb0aebecbffc692be82","type":"GO_TERM","name":"satellite DNA binding","canonical_id":"go:GO:0003696","description":"\"Binding to satellite DNA, the many tandem repeats (identical or related) of a short basic repeating unit; many have a base composition or other property different from the genome average that allows them to be separated from the bulk (main band) genomic DNA.\" [GOC:jl, SO:0000005]","metadata":null},{"id":"9c82cb5428354eb398c1426321beb9d6","type":"GO_TERM","name":"satellite cell activation involved in skeletal muscle regeneration","canonical_id":"go:GO:0014901","description":"\"The process that initiates skeletal muscle satellite cell division by causing it to move from quiescence to the G1 stage of the cell cycle. The cell swells and there are a number of other small changes. The cells then start to divide. Following cell division the cells will differentiate. In adult muscle, satellite cells become activated to divide and differentiate in response to muscle damage.\" [GOC:mtg_muscle]","metadata":null},{"id":"d2e5dc1599d74efa82de6b90c21d2beb","type":"GO_TERM","name":"satellite fibril","canonical_id":"go:GO:0071808","description":"\"An axoneme part that is found in the flagella of mammalian sperm and is located in the middle piece between the outer dense fibers (on the concave side of outer dense fibers as seen in cross-section).\" [GOC:mah, GOC:sl, PMID:20108326]","metadata":null},{"id":"29197a8bedc44176a387c12399dbd329","type":"DRUG","name":"satralizumab","canonical_id":"gtopdb:9093","description":null,"metadata":null},{"id":"0a892f3bc0b74477a2e83e747e9d99e1","type":"DRUG","name":"satralizumab","canonical_id":"chembl:CHEMBL3833307","description":null,"metadata":null},{"id":"55c543afbe7b458fad69acd98e7919c3","type":"GO_TERM","name":"saturated monocarboxylic acid metabolic process","canonical_id":"go:GO:0032788","description":"\"The chemical reactions and pathways involving saturated monocarboxylic acids, any organic acid containing one carboxyl (COOH) group or anion (COO-) and fully saturated C-C bonds.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"9ee9246424964b26b337bec224e799ac","type":"DRUG","name":"saxagliptin","canonical_id":"gtopdb:6316","description":null,"metadata":null},{"id":"65be6be10ce746fabb72ca3353a5ab1b","type":"DRUG","name":"saxagliptin","canonical_id":"mesh:C502994","description":null,"metadata":null},{"id":"8211d2f40e234e8da3be7812a1e6a2f3","type":"COMBINATION_TREATMENT","name":"saxagliptin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-79d02eef555f4128","description":null,"metadata":null},{"id":"7ae9f57f2d334f2da59a6873ca528749","type":"COMBINATION_TREATMENT","name":"saxagliptin + sitagliptin","canonical_id":"ctgov_combo:ctgov-combo-ae4ef76386df66f3","description":null,"metadata":null},{"id":"af3d84ab3d5b4441989d1cbaee910c51","type":"COMBINATION_TREATMENT","name":"saxagliptin + vildagliptin","canonical_id":"ctgov_combo:ctgov-combo-6f9547db756f9f8f","description":null,"metadata":null},{"id":"1cbfc71a0bfa490492610da85c912a12","type":"GO_TERM","name":"scaRNA localization to Cajal body","canonical_id":"go:GO:0090666","description":"\"A process in which a small Cajal body-specific RNA is transported to, or maintained in, a Cajal body.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:25467444]","metadata":null},{"id":"b5ef0926f2c24bffaa85067383eea10f","type":"GO_TERM","name":"scab formation","canonical_id":"go:GO:0035314","description":"\"Formation of hardened covering (a scab) at a wound site. The scab has multiple functions including limiting blood loss, providing structural stability to the wound and guarding against infection.\" [GOC:bf, PMID:15269788]","metadata":null},{"id":"77fb0dad1d94440b96cc9a6632552997","type":"GO_TERM","name":"scaffold protein binding","canonical_id":"go:GO:0097110","description":"\"Binding to a scaffold protein. Scaffold proteins are crucial regulators of many key signaling pathways. Although not strictly defined in function, they are known to interact and/or bind with multiple members of a signaling pathway, tethering them into complexes.\" [GOC:BHF, GOC:sjp, PMID:10433269, Wikipedia:Scaffold_protein]","metadata":null},{"id":"e6f3d994086149b581910353439bace8","type":"GO_TERM","name":"scattered antral spaces stage","canonical_id":"go:GO:0048163","description":"\"The stage in oogenesis when antral spaces begin to form in the follicle cells. Mitochondria form centers for yolk concentration.\" [GOC:jid, GOC:mtg_sensu, ISBN:0198542771]","metadata":null},{"id":"0a321ca24ca3411bb33ecd8f123864ff","type":"GO_TERM","name":"scavenger receptor activity","canonical_id":"go:GO:0005044","description":"\"Combining with any modified low-density lipoprotein (LDL) or other polyanionic ligand and delivering the ligand into the cell via endocytosis. Ligands include acetylated and oxidized LDL, Gram-positive and Gram-negative bacteria, apoptotic cells, amyloid-beta fibrils, and advanced glycation end products (AGEs).\" [GOC:bf, PMID:11790542, PMID:12379907, PMID:12621157, PMID:20981357]","metadata":null},{"id":"cc13b8509250446abc0f4a17542c1631","type":"GO_TERM","name":"scavenger receptor binding","canonical_id":"go:GO:0005124","description":"\"Binding to scavenger receptors, a family of proteins that are expressed on myeloid cells and are involved in the uptake of effete cellular components and foreign particles.\" [GOC:ceb]","metadata":null},{"id":"44d6e25043ad40b58e2926a36a475f12","type":"DISEASE","name":"schizoaffective disorder","canonical_id":"mondo:0005487","description":null,"metadata":null},{"id":"4dd72d909dcd4250bcdaa334ed812ff3","type":"GO_TERM","name":"schizogony","canonical_id":"go:GO:0020014","description":"\"Cell division by multiple fission in which nuclei and other organelles in the parent cell divide repeatedly and move to the cell periphery before internal membranes develop around them, producing a large number of daughter cells simultaneously.\" [GOC:mb]","metadata":null},{"id":"27d32ce8ad5c409c8b18ca725a5030f8","type":"DISEASE","name":"schizophrenia","canonical_id":"mondo:0005090","description":null,"metadata":null},{"id":"474189f88c854d31b930f005be0442c9","type":"GO_TERM","name":"scintillon","canonical_id":"go:GO:0036007","description":"\"A body present in the cytoplasm of some dinoflagellates, which is the source of bioluminescence; emits light on acidification in the presence of oxygen.\" [GOC:mag, GOC:pr, PMID:4501583, PMID:5642469]","metadata":null},{"id":"a4432baa84604c158e2fc23afabc0fb3","type":"GO_TERM","name":"sclerenchyma cell differentiation","canonical_id":"go:GO:0014001","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a sclerenchyma cell. A sclerenchyma cell is a plant cell with thick lignified walls, normally dead at maturity and specialized for structural strength. Includes fiber cells, that are greatly elongated; and sclereids, that are more isodiametric. Intermediate types exist. Cells may or may not be devoid of protoplasm at maturity. Cell form and size are variable.\" [CL:0000276, GOC:ef, GOC:jid, PO:0000077]","metadata":null},{"id":"36660fb52d9f4c28bf71be1a444d4ab6","type":"DISEASE","name":"sclerosing cholangitis","canonical_id":"mondo:0018646","description":null,"metadata":null},{"id":"e40432179ea247b2b7ed33bceab9365c","type":"GO_TERM","name":"sclerotium development","canonical_id":"go:GO:1990045","description":"\"The process whose specific outcome is the progression of the sclerotium over time, from its formation to the mature structure. A sclerotium is a mycelial resting body, resistant to adverse environmental conditions.\" [GOC:di, PMID:21148914]","metadata":null},{"id":"43ac45bb20c040d1a14b2a3ca369a9e7","type":"GO_TERM","name":"sclerotome development","canonical_id":"go:GO:0061056","description":"\"The progression of the sclerotome over time, from its initial formation to the mature structure. The sclerotome is the portion of the somite that will give rise to a vertebra.\" [GOC:dph]","metadata":null},{"id":"c39dd8715a8c4e45942ef25b036f2819","type":"DISEASE","name":"scoliosis","canonical_id":"mondo:0005392","description":null,"metadata":null},{"id":"eaccbd62717e452d820fcd4506289593","type":"DRUG","name":"scopolamine","canonical_id":"gtopdb:330","description":null,"metadata":null},{"id":"5a9fffbfbbfc4bccb6f4c89f72275420","type":"GO_TERM","name":"scopolamine biosynthetic process","canonical_id":"go:GO:1900991","description":"\"The chemical reactions and pathways resulting in the formation of scopolamine.\" [GOC:TermGenie, GOC:yaf, PMID:16720272, PMID:18251710, PMID:32879484]","metadata":null},{"id":"cebb013c9b0945fdbeb3f7e2e9e2e993","type":"GO_TERM","name":"scopoletin 8-hydroxylase activity","canonical_id":"go:GO:0106145","description":"\"Catalysis of the reaction: scopoletin + 2-oxoglutarate + O2 = fraxetin + succinate + CO2.\" [PMID:29361149, PMID:29581584, RHEA:57848]","metadata":null},{"id":"3b3f923842ed4b268295a84f9f834406","type":"GO_TERM","name":"scopoletin glucosyltransferase activity","canonical_id":"go:GO:0050275","description":"\"Catalysis of the reaction: scopoletin + UDP-D-glucose = H+ + scopolin + UDP.\" [EC:2.4.1.128, RHEA:20453]","metadata":null},{"id":"afddaf0fffab4f46a10459b0e54687ab","type":"GO_TERM","name":"sculpture element","canonical_id":"go:GO:0043675","description":"\"The third layer of the sexine.\" [https://doi.org/10.1007/978-3-319-71365-6_3]","metadata":null},{"id":"f2c38799887c48368e60e529deebbd56","type":"GO_TERM","name":"scutellarein 7-O-glucuronosyltransferase activity","canonical_id":"go:GO:0102467","description":"\"Catalysis of the reaction: scutellarein + UDP-alpha-D-glucuronate = scutellarin + UDP.\" [RHEA:28318]","metadata":null},{"id":"ab7bc7961eec4439a7e2dfa11e76cc87","type":"GO_TERM","name":"scutellarein 7-methyl ether 4'-O-methyltransferase activity","canonical_id":"go:GO:0102624","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + scutellarein 7-methyl ether = H+ + ladanein + S-adenosyl-L-homocysteine.\" [RHEA:73239]","metadata":null},{"id":"671979d12ed54aa0b7d4522e339b277e","type":"GO_TERM","name":"scutellarein 7-methyl ether 6-O-methyltransferase activity","canonical_id":"go:GO:0102623","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + scutellarein 7-methyl ether = cirsimaritin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:73243]","metadata":null},{"id":"3b8b6f1ac47f47ad8e8b91df25d98e2d","type":"GO_TERM","name":"scyllo-inosamine 4-kinase activity","canonical_id":"go:GO:0050276","description":"\"Catalysis of the reaction: 1-amino-1-deoxy-scyllo-inositol + ATP = 1-amino-1-deoxy-scyllo-inositol 4-phosphate + ADP + 2 H+.\" [EC:2.7.1.65, RHEA:18605]","metadata":null},{"id":"e0735d74eb5c4ea5b1d4438b333a1ab8","type":"GO_TERM","name":"scyllo-inosamine-4-phosphate amidinotransferase activity","canonical_id":"go:GO:0015069","description":"\"Catalysis of the reaction: 1-amino-1-deoxy-scyllo-inositol 4-phosphate + L-arginine = 1-guanidino-1-deoxy-scyllo-inositol 4-phosphate + L-ornithine.\" [RHEA:13265]","metadata":null},{"id":"7dae7061e6314ee58c3d1f4c719f7f14","type":"GO_TERM","name":"scyllo-inositol dehydrogenase (NADP+) activity","canonical_id":"go:GO:0102497","description":"\"Catalysis of the reaction: scyllo-inositol + NADP = 2,4,6/3,5-pentahydroxycyclohexanone + NADPH + H+.\" [EC:1.1.1.371, GOC:pz]","metadata":null},{"id":"846e07b6827f43f0950267e82fad28fe","type":"GO_TERM","name":"scymnol sulfotransferase activity","canonical_id":"go:GO:0033874","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + 5beta-scymnol = 5beta-scymnol sulfate + adenosine 3',5'-diphosphate + H+.\" [EC:2.8.2.32, RHEA:15477]","metadata":null},{"id":"c20f688a0ca3433eae4f3a55474911c5","type":"GO_TERM","name":"scytalone dehydratase activity","canonical_id":"go:GO:0030411","description":"\"Catalysis of the reaction: scytalone = 1,3,8-trihydroxynaphthalene + H2O.\" [EC:4.2.1.94, RHEA:24396]","metadata":null},{"id":"f78126c7f92b47969c742ed87253cc6e","type":"DISEASE","name":"seasonal allergic conjunctivitis","canonical_id":"mesh:D003233","description":null,"metadata":null},{"id":"7ea5f844c1904f9e83408318fdd753fe","type":"DISEASE","name":"seasonal allergic rhinitis","canonical_id":"mondo:0005324","description":null,"metadata":null},{"id":"38dc031ea0ea43209f500269a2061c60","type":"GO_TERM","name":"sebaceous gland cell differentiation","canonical_id":"go:GO:0001949","description":"\"The process in which a relatively unspecialized epidermal cell acquires the specialized features of a sebaceous gland cell.\" [GOC:mgi_curators, PMID:15737203]","metadata":null},{"id":"82acdf5c9a8a4e188e853eb6c84aa8cf","type":"GO_TERM","name":"sebaceous gland development","canonical_id":"go:GO:0048733","description":"\"The process whose specific outcome is the progression of the sebaceous gland over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"ac7d493628c94a89ab92e3717c436249","type":"GO_TERM","name":"sebaceous gland placode formation","canonical_id":"go:GO:0060791","description":"\"The developmental process in which a sebaceous gland placode forms. A sebaceous gland placode is a thickening of the ectoderm that will give rise to the sebaceous gland bud.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"0ea873b12b1e448db184ea9e256eb233","type":"DRUG","name":"sebelipase alfa","canonical_id":"mesh:C000603932","description":null,"metadata":null},{"id":"ea17d04f18294e6b948140c546574798","type":"DISEASE","name":"seborrheic dermatitis","canonical_id":"mondo:0006608","description":null,"metadata":null},{"id":"402e024cf9f748188e7b1f4df3cc3c97","type":"DISEASE","name":"seborrheic keratosis","canonical_id":"mondo:0008420","description":null,"metadata":null},{"id":"f3bf7e984d2b451f9f229e8749538fe2","type":"GO_TERM","name":"sebum secreting cell proliferation","canonical_id":"go:GO:1990654","description":"\"The multiplication or reproduction of sebocytes by cell division, resulting in the expansion of their population. A sebocyte is an epithelial cell that makes up the sebaceous glands, and secrete sebum.\" [GOC:hjd, PMID:16901790, PMID:18474083]","metadata":null},{"id":"6f613c9a215846a89f383a0aef10b8cb","type":"GO_TERM","name":"secalciferol 1-monooxygenase activity","canonical_id":"go:GO:0062185","description":"\"Catalysis of the reaction:2 H+ + O2 + 2 reduced [adrenodoxin] + secalciferol = calcitetrol + H2O + 2 oxidized [adrenodoxin].\" [PMID:10518789, RHEA:49064]","metadata":null},{"id":"85496a0f8f6841d6bbacab97210985e1","type":"DRUG","name":"secobarbital","canonical_id":"mesh:D012631","description":null,"metadata":null},{"id":"f94a1973e7c24cbfa939a2837b1d3752","type":"GO_TERM","name":"secoisolariciresinol dehydrogenase activity","canonical_id":"go:GO:0120529","description":"\"Catalysis of the reaction: (-)-secoisolariciresinol + 2 NAD+ = (-)-matairesinol + 2 H(+) + 2 NADH.\" [RHEA:33887]","metadata":null},{"id":"4135cd1d31ed4695b32b5f3133b63267","type":"GO_TERM","name":"secologanin synthase activity","canonical_id":"go:GO:0050616","description":"\"Catalysis of the reaction: loganin + reduced [NADPH--hemoprotein reductase] + O2 = secologanin + oxidized [NADPH--hemoprotein reductase] + 2 H2O + H+.\" [RHEA:20585]","metadata":null},{"id":"3e623ff5ec244f04b5f159e6225387bb","type":"GO_TERM","name":"second mitotic wave involved in compound eye morphogenesis","canonical_id":"go:GO:0016330","description":"\"A discrete cell cycle in the third instar eye imaginal disc after progression of the morphogenetic furrow that contributes to compound eye morphogenesis. It is essential for generation of a sufficient pool of uncommitted cells to develop complete ommatidia.\" [PMID:11257224]","metadata":null},{"id":"7fc822b65c344c49999bbd7615c83866","type":"GO_TERM","name":"second spliceosomal transesterification activity","canonical_id":"go:GO:0000386","description":"\"Catalysis of the second transesterification reaction of spliceosomal mRNA splicing. Ligation of the two exons occurs via a transesterification reaction where the free 3'-hydroxyl group of the 5' exon is the nucleophile attacking the 3' splice site. Non-expressed sequences are now detached from the exons. In cis splicing, the intron is in a lariat structure.\" [GOC:krc, ISBN:0879695897, PMID:19239890]","metadata":null},{"id":"6124bb9d1c934ad1ba1ae871247806be","type":"DISEASE","name":"secondary Parkinson disease","canonical_id":"mondo:0006966","description":null,"metadata":null},{"id":"4038fc8ebcb04c109697b169c47f91fc","type":"GO_TERM","name":"secondary active cyanate transmembrane transporter activity","canonical_id":"go:GO:0015541","description":"\"Enables the transfer of cyanate from one side of a membrane to the other.\" [TC:2.A.1.17.1]","metadata":null},{"id":"878ce929f4dd490bb61435d76e5f5f8f","type":"GO_TERM","name":"secondary active monocarboxylate transmembrane transporter activity","canonical_id":"go:GO:0015355","description":"\"Catalysis of the movement of a monocarboxylate, any compound containing a single carboxyl group (COOH or COO-), by uniport, symport or antiport across a membrane by a carrier-mediated mechanism.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"82d162b0478247d0a385878453015b10","type":"GO_TERM","name":"secondary active p-aminobenzoyl-glutamate transmembrane transporter activity","canonical_id":"go:GO:0015558","description":"\"Enables the transfer of p-aminobenzoyl-glutamate from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters. p-aminobenzoyl-glutamate is the anion of p-aminobenzoyl-glutamic acid.\" [GOC:ai]","metadata":null},{"id":"e4ffc62d394f441981df9709be1cc1d5","type":"GO_TERM","name":"secondary active sulfate transmembrane transporter activity","canonical_id":"go:GO:0008271","description":"\"Enables the secondary active transfer of sulfate from one side of a membrane to the other. Secondary active transport is the transfer of a solute across a membrane, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport]","metadata":null},{"id":"e9dc816829e843f1acf76420d3fb1ad3","type":"GO_TERM","name":"secondary active transmembrane transporter activity","canonical_id":"go:GO:0015291","description":"\"Enables the transfer of a solute from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy, not direct ATP coupling. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729, PMID:10839820]","metadata":null},{"id":"3017c48a995341919c953e594f64ac70","type":"GO_TERM","name":"secondary alcohol biosynthetic process","canonical_id":"go:GO:1902653","description":"\"The chemical reactions and pathways resulting in the formation of secondary alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:11288200]","metadata":null},{"id":"d851086d0cfb43ad9a069426991aa3b6","type":"GO_TERM","name":"secondary alcohol metabolic process","canonical_id":"go:GO:1902652","description":"\"The chemical reactions and pathways involving secondary alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:11288200]","metadata":null},{"id":"5dfb93d1608b41d4973c9b74f79a2952","type":"GO_TERM","name":"secondary branching, open tracheal system","canonical_id":"go:GO:0007429","description":"\"Sprouting of secondary branches in an open tracheal system. These form from the tips of primary branches and are formed by individual cells that roll up into unicellular tubes. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:29844090]","metadata":null},{"id":"51baae56e906429783afd139be9faa29","type":"GO_TERM","name":"secondary cell septum","canonical_id":"go:GO:0051077","description":"\"Cell wall structures composed of linear polysaccharides which are deposited at both sides of the primary septum at 90 degrees to the primary septum.\" [GOC:mtg_sensu, PMID:15194814]","metadata":null},{"id":"b7d9ba71cde0477d99627d1371932c2b","type":"GO_TERM","name":"secondary cell septum biogenesis","canonical_id":"go:GO:1990344","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a secondary cell septum following nuclear division.\" [PMID:22891259]","metadata":null},{"id":"ebeb3c83cdc345d1966e6ac56ff7afb4","type":"GO_TERM","name":"secondary cell wall","canonical_id":"go:GO:0009531","description":"\"A plant cell wall that is no longer able to expand and so does not permit growth. Secondary cell walls contain less pectin that primary cell walls. The secondary cell is mostly composed of cellulose and is strengthened with lignin.\" [GOC:jid, ISBN:0943088399, PMID:39878232]","metadata":null},{"id":"7e1c258c866a4146826af05d16fabf7f","type":"GO_TERM","name":"secondary cell wall biogenesis involved in seed trichome differentiation","canonical_id":"go:GO:0090379","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of inextensible cellulose- and pectin-containing cell walls that are formed between the plasma membrane and primary cell wall of seed trichomes after cell expansion is complete.\" [GOC:tb]","metadata":null},{"id":"d1fb67f53cc74c89bf57ea87fff5432b","type":"GO_TERM","name":"secondary cell wall cellulose synthase complex","canonical_id":"go:GO:0044568","description":"\"A large, multimeric protein complex which catalyzes the biosynthesis of cellulose for the plant secondary cell wall. In Arabidopsis, contains the essential component proteins CESA8, CESA7, and CESA4.\" [GOC:mengo_curators, GOC:tt, PMID:21307367]","metadata":null},{"id":"19dd41fb98bc41b2a751f09604a7a814","type":"GO_TERM","name":"secondary growth","canonical_id":"go:GO:0080117","description":"\"Lateral growth of a plant axis (shoot axis or root) that is an increase in thickness resulting from formation of secondary vascular tissues by the vascular cambium.\" [ISBN:0471245208, PMID:19074290, PO:0005598, PO:0025004]","metadata":null},{"id":"7ac4253ef44444c4a7f5406c6e63ed06","type":"GO_TERM","name":"secondary heart field specification","canonical_id":"go:GO:0003139","description":"\"The process that results in the delineation of a specific region of the lateral mesoderm into the area which will form the majority of the mesodermal component of the right ventricle, arterial pole (outflow tract) and venous pole (inflow tract).\" [GOC:mtg_heart, GOC:rl, PMID:17276708]","metadata":null},{"id":"f258a2728a9846e28401c1e5bce087a6","type":"DISEASE","name":"secondary hyperparathyroidism","canonical_id":"mondo:0006964","description":null,"metadata":null},{"id":"8361523560084895bd06bd362373972f","type":"GO_TERM","name":"secondary leaflet morphogenesis","canonical_id":"go:GO:0060779","description":"\"The process in which the secondary leaflet attains its shape. A secondary leaflet develops by branching or division of a primary leaflet.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"ef939de312e04745946610f21ddeb9e2","type":"GO_TERM","name":"secondary lysosome","canonical_id":"go:GO:0005767","description":"\"Vacuole formed by the fusion of a lysosome with an organelle (autosome) or with a primary phagosome.\" [GOC:jl, ISBN:0815316194]","metadata":null},{"id":"ce1eb1e6c9524d8ba5d59060d88fbdd0","type":"GO_TERM","name":"secondary metabolic process","canonical_id":"go:GO:0019748","description":"\"The chemical reactions and pathways resulting in many of the chemical changes of compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon. In multicellular organisms secondary metabolism is generally carried out in specific cell types, and may be useful for the organism as a whole. In unicellular organisms, secondary metabolism is often used for the production of antibiotics or for the utilization and acquisition of unusual nutrients.\" [GOC:curators]","metadata":null},{"id":"0b0be58d71a947618eb9f7068a3dbeeb","type":"GO_TERM","name":"secondary metabolite biosynthetic process","canonical_id":"go:GO:0044550","description":"\"The chemical reactions and pathways resulting in the formation of secondary metabolites, the compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon.\" [GOC:jl]","metadata":null},{"id":"87f0589368c74f4681335edff8cd5528","type":"GO_TERM","name":"secondary metabolite catabolic process","canonical_id":"go:GO:0090487","description":"\"The chemical reactions and pathways resulting in the breakdown of secondary metabolites, the compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon.\" [GOC:tb]","metadata":null},{"id":"fb2e6b6e55e24b6ab9c7cbc019c51f2d","type":"GO_TERM","name":"secondary neural tube formation","canonical_id":"go:GO:0014021","description":"\"The formation of the neural tube by coalescence of mesenchymal cells followed by their conversion to epithelial cells to form a solid cord that subsequently hollows out (cavitates) to create a hollow tube. Secondary neurulation is the typical mechanism of formation of the neural tube posterior to the posterior neuropore in mammals.\" [GOC:ef, ISBN:0878932585, PMID:15327780]","metadata":null},{"id":"15117dfad8af4fdea71e76972f50d372","type":"GO_TERM","name":"secondary palate development","canonical_id":"go:GO:0062009","description":"\"The biological process whose specific outcome is the progression of the secondary palate from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The secondary palate is the part of the palate formed from the fusion of the two palatine shelves, extensions of the maxillary prominences.\" [PMID:28784960]","metadata":null},{"id":"d73c95f80e70483a98fae336ef4cdba5","type":"GO_TERM","name":"secondary piRNA processing","canonical_id":"go:GO:0140965","description":"\"A process leading to the generation of a functional secondary piRNA, involving a self-perpetuating piRNA loop, often called the ping-pong cycle, in which piRNAs are amplified by pairing with complementary transcripts (for example the transposable element mRNA target). In Drosophila, the processing involves the piwi proteins aubergine and Argonaute 3 and in mice, the piwi proteins Piwil2 and Piwil4.\" [PMID:29281264, PMID:32895365]","metadata":null},{"id":"be693d65d40848d097f4693c8744e49e","type":"GO_TERM","name":"secondary plasmodesma","canonical_id":"go:GO:0009551","description":"\"A plasmodesma with a branched structure, often with many channels leading into a larger central cavity; found in older tissues and usually derived from preexisting primary plasmodesmata.\" [PMID:15012255]","metadata":null},{"id":"471d2279ef5346b8a69a4f990288e6cc","type":"DISEASE","name":"secondary progressive multiple sclerosis","canonical_id":"mondo:0000450","description":null,"metadata":null},{"id":"60685971dc774e7fb0f34d1c33afdc61","type":"GO_TERM","name":"secondary shoot formation","canonical_id":"go:GO:0010223","description":"\"The process that gives rise to secondary (or auxiliary or axillary) shoots in plants. This process pertains to the initial formation of a structure from unspecified parts. These secondary shoots originate from secondary meristems initiated in the axils of leaf primordia. Axillary meristems function like the shoot apical meristem of the primary shoot initiating the development of lateral organs.\" [GOC:tb, PMID:12815068]","metadata":null},{"id":"fa655f598446451ea811a016e784d774","type":"GO_TERM","name":"secondary thickening","canonical_id":"go:GO:0080191","description":"\"Lateral growth of a plant axis (shoot axis or root) that is an increase in thickness resulting from formation of tissue from a secondary thickening meristem.\" [JSTOR:4354165, PO:0025004, PO:0025414]","metadata":null},{"id":"243849302ab94d9599698f31f37b3dc9","type":"GO_TERM","name":"secondary-alcohol oxidase activity","canonical_id":"go:GO:0033714","description":"\"Catalysis of the reaction: secondary alcohol + O2 = H2O2 + ketone.\" [EC:1.1.3.18, RHEA:23180]","metadata":null},{"id":"412308ced2a24f67ac078d1b7cbd2461","type":"DRUG","name":"secretin","canonical_id":"gtopdb:3643","description":null,"metadata":null},{"id":"35a113d44875406e9ea9689863659f3c","type":"DRUG","name":"secretin","canonical_id":"chembl:CHEMBL6067494","description":null,"metadata":null},{"id":"9e3622a1f11043aab6fafbe0ad48076d","type":"GO_TERM","name":"secretin receptor activity","canonical_id":"go:GO:0015055","description":"\"Combining with secretin to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"2bbad18efa854b2aaf30ef8be4624769","type":"GO_TERM","name":"secretin receptor binding","canonical_id":"go:GO:0031876","description":"\"Binding to a secretin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"146eb70a204740b28506d65dd5c43615","type":"GO_TERM","name":"secretion","canonical_id":"go:GO:0046903","description":"\"The controlled release of a substance by a cell or a tissue.\" [GOC:ai]","metadata":null},{"id":"42abdb242c154fd6a933549e8607503f","type":"GO_TERM","name":"secretion by cell","canonical_id":"go:GO:0032940","description":"\"The controlled release of a substance by a cell.\" [GOC:mah]","metadata":null},{"id":"530ab456be8948e7b06cb1c8307c11de","type":"GO_TERM","name":"secretion by lung epithelial cell involved in lung growth","canonical_id":"go:GO:0061033","description":"\"The controlled release of liquid by a lung epithelial cell that contributes to an increase in size of the lung as part of its development.\" [GOC:dph]","metadata":null},{"id":"ba8e797233164454a1b3c474bc015cbc","type":"GO_TERM","name":"secretion by the type IV secretion system","canonical_id":"go:GO:0044097","description":"\"The controlled release of proteins or DNA by a cell, via the type IV secretion system.\" [GOC:pamgo_curators]","metadata":null},{"id":"6b0db231cfd744f8895b8612cc1f8f88","type":"GO_TERM","name":"secretion by tissue","canonical_id":"go:GO:0032941","description":"\"The controlled release of a substance by a tissue.\" [GOC:mah]","metadata":null},{"id":"f0bcfbe766e24d59b58902abc6854d92","type":"GO_TERM","name":"secretion of lysosomal enzymes","canonical_id":"go:GO:0033299","description":"\"The controlled release of lysosomal enzymes by a cell.\" [GOC:mah]","metadata":null},{"id":"59482289ce5a4131977ffb4516adcb96","type":"GO_TERM","name":"secretory IgA immunoglobulin complex","canonical_id":"go:GO:0071751","description":"\"A polymeric IgA immunoglobulin complex that is complexed with one chain of secretory component (SC). Polymeric IgA is present in mucosal areas, having been transported via a transcytosis mechanism in mucosal epithelial cells relying on the polymeric Ig receptor, a portion of which then remains bound to the polymeric IgA as secretory component.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"74ca8f9854384de68f46baeb36d2273b","type":"GO_TERM","name":"secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development","canonical_id":"go:GO:0060528","description":"\"The process in which a relatively unspecialized epithelial cell acquires specialized features of a secretory columnal luminar epithelial cell of the prostate.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"c82f4d6066494376b0c522da889fd64a","type":"GO_TERM","name":"secretory dimeric IgA immunoglobulin complex","canonical_id":"go:GO:0071752","description":"\"A dimeric form of secretory IgA immunoglobulin complex.\" [GOC:add, ISBN:0781765196, PMID:16362985]","metadata":null},{"id":"c5c1e86b649b44d5a7e345e0c38409fb","type":"GO_TERM","name":"secretory granule","canonical_id":"go:GO:0030141","description":"\"A small subcellular vesicle, surrounded by a membrane, that is formed from the Golgi apparatus and contains a highly concentrated protein destined for secretion. Secretory granules move towards the periphery of the cell and upon stimulation, their membranes fuse with the cell membrane, and their protein load is exteriorized. Processing of the contained protein may take place in secretory granules.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"1c96cc2aa93842a789455c366c2e8a8e","type":"GO_TERM","name":"secretory granule localization","canonical_id":"go:GO:0032252","description":"\"Any process in which a secretory granule is transported to, and/or maintained in, a specific location within the cell.\" [GOC:mah]","metadata":null},{"id":"98b46149f7b94afd9332ac420647fa1a","type":"GO_TERM","name":"secretory granule lumen","canonical_id":"go:GO:0034774","description":"\"The volume enclosed by the membrane of a secretory granule.\" [GOC:rph]","metadata":null},{"id":"552dbb768f804c919f169120116db521","type":"GO_TERM","name":"secretory granule maturation","canonical_id":"go:GO:0061792","description":"\"Steps required to transform an immature secretory vesicle into a mature secretory vesicle. Typically proceeds through homotypic membrane fusion and membrane remodeling.\" [GOC:bf, GOC:dph, GOC:PARL, PMID:16618809]","metadata":null},{"id":"ea975978091b4e5c93822827dc0d4fc6","type":"GO_TERM","name":"secretory granule membrane","canonical_id":"go:GO:0030667","description":"\"The lipid bilayer surrounding a secretory granule.\" [GOC:mah]","metadata":null},{"id":"a70323c3d57d48a383522c3b7fcbdfb8","type":"GO_TERM","name":"secretory granule organization","canonical_id":"go:GO:0033363","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a secretory granule. A secretory granule is a small subcellular vesicle, surrounded by a membrane, that is formed from the Golgi apparatus and contains a highly concentrated protein destined for secretion.\" [GOC:mah]","metadata":null},{"id":"096bdd73bd1d488297c250c48de6a6b1","type":"GO_TERM","name":"secretory granule-lysosome fusion","canonical_id":"go:GO:0160156","description":"\"The cellular process that results in the fusion of secretory granules with lysosomes to form crinosomes.\" [PMID:29066608, PMID:35452619]","metadata":null},{"id":"c35ba0c2020f42eea4fc94fa47e96146","type":"GO_TERM","name":"secretory vesicle","canonical_id":"go:GO:0099503","description":"\"A cytoplasmic, membrane bound vesicle that is capable of fusing to the plasma membrane to release its contents into the extracellular space.\" [GOC:dos]","metadata":null},{"id":"d6c49758a0a1423ea21aa273ec72db04","type":"DRUG","name":"secukinumab","canonical_id":"gtopdb:8078","description":null,"metadata":null},{"id":"c3bed16c170c408caea3d460674a1032","type":"DRUG","name":"secukinumab","canonical_id":"chembl:CHEMBL1743068","description":null,"metadata":null},{"id":"bf4d2e2d22d44dafb68f062eac005f38","type":"COMBINATION_TREATMENT","name":"secukinumab + tofacitinib","canonical_id":"ctgov_combo:ctgov-combo-d29f791e6fb51b45","description":null,"metadata":null},{"id":"9c3b2b3fc0ab4cb8b3bd4bb80e73e329","type":"COMBINATION_TREATMENT","name":"secukinumab + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-b634dbfc8c849762","description":null,"metadata":null},{"id":"b3829a46ab4e426593af1b454addd192","type":"GO_TERM","name":"sedoheptulokinase activity","canonical_id":"go:GO:0050277","description":"\"Catalysis of the reaction: ATP + sedoheptulose = ADP + 2 H+ + sedoheptulose 7-phosphate.\" [EC:2.7.1.14, RHEA:23844]","metadata":null},{"id":"23d94edb0a58423abe40f3cded82bd71","type":"GO_TERM","name":"sedoheptulose-bisphosphatase activity","canonical_id":"go:GO:0050278","description":"\"Catalysis of the reaction: sedoheptulose 1,7-bisphosphate + H2O = sedoheptulose 7-phosphate + phosphate.\" [EC:3.1.3.37, MetaCyc:SEDOHEPTULOSE-BISPHOSPHATASE-RXN]","metadata":null},{"id":"0859c7d9f0aa470ea3b7bf5ea6589fd8","type":"GO_TERM","name":"seed abscission","canonical_id":"go:GO:0097548","description":"\"The controlled shedding of a seed.\" [GOC:lmo]","metadata":null},{"id":"0531ca958315479890b69d3c38638aad","type":"GO_TERM","name":"seed coat development","canonical_id":"go:GO:0010214","description":"\"The process whose specific outcome is the progression of the seed coat over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"e9adc70a47264b008aded2be7c4fd328","type":"GO_TERM","name":"seed dehydration","canonical_id":"go:GO:1990068","description":"\"The seed development process whose outcome is the drying of a maturing seed.\" [PMID:20138563]","metadata":null},{"id":"793c66fb1d0141c9aa6ada36a3399961","type":"GO_TERM","name":"seed development","canonical_id":"go:GO:0048316","description":"\"The process whose specific outcome is the progression of the seed over time, from its formation to the mature structure. A seed is a propagating organ formed in the sexual reproductive cycle of gymnosperms and angiosperms, consisting of a protective coat enclosing an embryo and food reserves.\" [GOC:jid, PO:0009010]","metadata":null},{"id":"2fe9be8b4558428d9881fc109548e281","type":"GO_TERM","name":"seed dormancy process","canonical_id":"go:GO:0010162","description":"\"A dormancy process in which dormancy (sometimes called a dormant state) is induced, maintained or broken in a seed. Seed dormancy is a suspension of most physiological activity and growth in a seed, including the embryo contained therein, that can be reactivated. It often requires special conditions for reactivation, such as specific temperature, scarification, or leaching of inhibitors.\" [GOC:lr, GOC:PO_curators, ISBN:9781405139830, PO_REF:00009]","metadata":null},{"id":"0521864e14404a31891bcc2057c98e59","type":"GO_TERM","name":"seed germination","canonical_id":"go:GO:0009845","description":"\"The physiological and developmental changes that occur in a seed commencing with water uptake (imbibition) and terminating with the elongation of the embryonic axis.\" [PMID:8281041]","metadata":null},{"id":"6dbbc3a1246f4c54bd46b32cf4d871ec","type":"GO_TERM","name":"seed germination on parent plant","canonical_id":"go:GO:0048623","description":"\"The process in which a seed germinates before being shed from the parent plant.\" [GOC:curators]","metadata":null},{"id":"fb86ed45cedd46e49cdd866d9e88800d","type":"GO_TERM","name":"seed growth","canonical_id":"go:GO:0080112","description":"\"The increase in size or mass of a seed. A seed is a propagating organ formed in the reproductive cycle of a spermatophyte, derived from the ovule and enclosing an embryo.\" [GOC:dhl, PO:0009010]","metadata":null},{"id":"2e9d4782dc4744649572a4ca38bb4f80","type":"GO_TERM","name":"seed maturation","canonical_id":"go:GO:0010431","description":"\"A process in seed development that occurs after embryogenesis by which a quiescent state is established in a seed. Seed maturation is characterized by storage compound accumulation, acquisition of desiccation tolerance, growth arrest and the entry into a dormancy period of variable length that is broken upon germination.\" [PMID:16096971]","metadata":null},{"id":"b19763e412d04d0ca47f02007995457f","type":"GO_TERM","name":"seed morphogenesis","canonical_id":"go:GO:0048317","description":"\"The process in which the anatomical structures of the seed are generated and organized.\" [GOC:curators]","metadata":null},{"id":"f301848b408a4d74a3c1347c36e26829","type":"GO_TERM","name":"seed oilbody biogenesis","canonical_id":"go:GO:0010344","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a seed oilbody. Seed oilbodies are simple organelles comprising a matrix of triglyceride surrounded by a phospholipid monolayer embedded and covered with unique proteins called oleosins. Seed oilbodies supply the energy requirements for the growth of the seedling after germination.\" [GOC:jl, PMID:16877495]","metadata":null},{"id":"0db0d02da44b4b16b04f8bad505d77d9","type":"GO_TERM","name":"seed trichome differentiation","canonical_id":"go:GO:0090376","description":"\"The process in which a relatively unspecialized epidermal cell acquires the specialized features of a seed trichome. A seed trichome is a trichome that develops from seed coat epidermis and is often long with putative dispersal function.\" [GOC:tb, PMID:17905721]","metadata":null},{"id":"6cfbe63c77f54399ac9e344ac2a7f567","type":"GO_TERM","name":"seed trichome elongation","canonical_id":"go:GO:0090378","description":"\"The process in which a seed trichome irreversibly increases in size in one [spatial] dimension or along one axis, resulting in the morphogenesis of the cell.\" [GOC:tb]","metadata":null},{"id":"d9ffd22d180545a3a55a70554f6a26bd","type":"GO_TERM","name":"seed trichome initiation","canonical_id":"go:GO:0090377","description":"\"The process in which the developmental fate of an epidermal cell becomes restricted such that it will develop into a seed trichome, causing a change in the orientation of cell division in the ovule epidermis at or just before anthesis.\" [PMID:17905721]","metadata":null},{"id":"f847077a64024c5c8314f9f9b1cf5cea","type":"GO_TERM","name":"seed trichome maturation","canonical_id":"go:GO:0090380","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a seed trichome to attain its fully functional state.\" [GOC:tb]","metadata":null},{"id":"a03e65b1ced842fc80736938a75fe3d2","type":"GO_TERM","name":"seedling development","canonical_id":"go:GO:0090351","description":"\"The process whose specific outcome is the progression of the seedling over time, beginning with seed germination and ending when the first adult leaves emerge.\" [GOC:tb, PO:0007131]","metadata":null},{"id":"ae2f39dab1fd4ec4b303935405282b72","type":"GO_TERM","name":"segment polarity determination","canonical_id":"go:GO:0007367","description":"\"Division of the 14 parasegments of the embryo into anterior and posterior compartments; exemplified by the actions of the segment polarity gene products.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0632030488, ISBN:0879694238]","metadata":null},{"id":"7ba0e3effc5b44cba015c9831ad24d27","type":"GO_TERM","name":"segment specification","canonical_id":"go:GO:0007379","description":"\"The process in which segments assume individual identities; exemplified in insects by the actions of the products of the homeotic genes.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"5682905ac0cc47dfa923458fd4723b94","type":"GO_TERM","name":"segmentation","canonical_id":"go:GO:0035282","description":"\"The regionalization process that divides an organism or part of an organism into a series of semi-repetitive parts, or segments, often arranged along a longitudinal axis.\" [PMID:10611687, PMID:9706689]","metadata":null},{"id":"3dee9962fbed41e397ee56c3258e5584","type":"DISEASE","name":"seizures, benign familial infantile, 3","canonical_id":"mondo:0011904","description":null,"metadata":null},{"id":"4a4712d6c6934512b51c671bc567e8b5","type":"DISEASE","name":"seizures, benign familial neonatal, 1","canonical_id":"mondo:0007365","description":null,"metadata":null},{"id":"1c1f9c4b08c544d09c042d677201afe7","type":"DRUG","name":"seladelpar","canonical_id":"gtopdb:11137","description":null,"metadata":null},{"id":"e233bd7cddec46baad957a5b09a840d6","type":"DRUG","name":"seladelpar","canonical_id":"chembl:CHEMBL230158","description":null,"metadata":null},{"id":"32711669c8a242cd803de0705ec2cd4f","type":"GO_TERM","name":"selective angioblast sprouting","canonical_id":"go:GO:0035474","description":"\"The segregation of angioblasts into discrete arterial and venous vessels from one common precursor vessel.\" [GOC:dgh, PMID:19815777]","metadata":null},{"id":"04a3f59311ec40cbaab686940ae974a2","type":"DISEASE","name":"selective pituitary resistance to thyroid hormone","canonical_id":"mondo:0007784","description":null,"metadata":null},{"id":"68f3160d40944a2893a4df223ef4799a","type":"DRUG","name":"selegiline","canonical_id":"gtopdb:6639","description":null,"metadata":null},{"id":"0f23ce24daec42709e395357972b7a2e","type":"DRUG","name":"selegiline","canonical_id":"mesh:D012642","description":null,"metadata":null},{"id":"b45b6f519db743919de64a76c1d4f829","type":"DRUG","name":"selegiline","canonical_id":"chembl:CHEMBL972","description":null,"metadata":null},{"id":"fe754e9c4d9845bc9ff8551fee52bfbe","type":"GO_TERM","name":"selenate adenylyltransferase (ATP) activity","canonical_id":"go:GO:0098616","description":"\"Catalysis of the reaction: ATP + H2SeO4 = diphosphate + adenylylselenate.\" [PMID:2537056]","metadata":null},{"id":"5f8f8407ca6144e38436130f3c632a6a","type":"GO_TERM","name":"selenate reductase activity","canonical_id":"go:GO:0033797","description":"\"Catalysis of the reaction: 2 e(-) + 2 H+ + selenate = H2O + selenite.\" [RHEA:14029]","metadata":null},{"id":"dbb4b60eb6ed4f1db2f90cbe4d636676","type":"GO_TERM","name":"selenate transport","canonical_id":"go:GO:0080160","description":"\"The directed movement of selenate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [PMID:18761637]","metadata":null},{"id":"d29d018324d042c8ac04a13f4b5f3df8","type":"GO_TERM","name":"selenide, water dikinase activity","canonical_id":"go:GO:0004756","description":"\"Catalysis of the reaction: ATP + H2O + hydrogen selenide = AMP + 3 H+ + phosphate + selenophosphorate.\" [EC:2.7.9.3, RHEA:18737]","metadata":null},{"id":"dab1584722534f3d9b90bd358fb078b0","type":"GO_TERM","name":"selenite reductase (NADPH) activity","canonical_id":"go:GO:0098623","description":"\"Catalysis of the reaction: SeO3(2-) + 3 NADPH + 5H+ = H2Se +  3NADP+ + 3H2O.\" [PMID:1321713]","metadata":null},{"id":"77f1411286884fbba27f5d659816f7ca","type":"GO_TERM","name":"selenite:proton symporter activity","canonical_id":"go:GO:0097079","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: selenite(out) + H+(out) = selenite(in) + H+(in).\" [GOC:mcc, PMID:20861301]","metadata":null},{"id":"99d47be3d5044e018fb6ce17f054e879","type":"GO_TERM","name":"selenium binding","canonical_id":"go:GO:0008430","description":"\"Binding to a selenium (Se) ion.\" [GOC:ai]","metadata":null},{"id":"9ff8e75acddd45e38c91d1c72746f1d6","type":"GO_TERM","name":"selenium compound metabolic process","canonical_id":"go:GO:0001887","description":"\"The chemical reactions and pathways involving compounds that contain selenium, such as selenocysteine.\" [PMID:12730456]","metadata":null},{"id":"6af5a0a4fd62428d8d1d8fa2dec9f81b","type":"GO_TERM","name":"selenocystathionine beta-synthase activity","canonical_id":"go:GO:0098605","description":"\"Catalysis of the reaction: L-Serine + Selenohomocysteine = L-Selenocystathionine + H2O.\" [PMID:6456763]","metadata":null},{"id":"d3e9f163bb824a4a8c409e3ae25a8618","type":"GO_TERM","name":"selenocystathionine gamma-lyase activity","canonical_id":"go:GO:0098606","description":"\"Catalysis of the reaction:L-selenocystathionine + H2O = L-selenocysteine + 2-oxobutanoate + NH4+.\" [PMID:6456763, RHEA:31151]","metadata":null},{"id":"3383b178cccb4a95b8b3449447d34801","type":"GO_TERM","name":"selenocysteine incorporation","canonical_id":"go:GO:0001514","description":"\"The incorporation of selenocysteine into a peptide; uses a special tRNA that recognizes the UGA codon as selenocysteine, rather than as a termination codon. Selenocysteine is synthesized from serine before its incorporation; it is not a posttranslational modification of peptidyl-cysteine.\" [RESID:AA0022]","metadata":null},{"id":"6c7dfb332cce49a695924c85bc31c1bc","type":"GO_TERM","name":"selenocysteine insertion sequence binding","canonical_id":"go:GO:0035368","description":"\"Binding to a selenocysteine insertion sequence (SECIS), a regulatory sequence within mRNA which directs incorporation of a selenocysteine at a stop codon (UGA) during translation.\" [GOC:imk, PMID:10760958]","metadata":null},{"id":"d2c6dddbd9004d96b7d0b959887cd41f","type":"GO_TERM","name":"selenocysteine lyase activity","canonical_id":"go:GO:0009000","description":"\"Catalysis of the reaction: L-selenocysteine + reduced acceptor = hydrogen selenide + L-alanine + acceptor.\" [EC:4.4.1.16]","metadata":null},{"id":"3a72e5d9a53c4badb780b6880688e48f","type":"GO_TERM","name":"selenocysteine methyltransferase activity","canonical_id":"go:GO:0016205","description":"\"Catalysis of the reaction: selenocysteine + S-adenosyl-L-methionine = Se-methylselenocysteine + S-adenosyl-homocysteine.\" [EC:2.1.1.280, PMID:10026151]","metadata":null},{"id":"49d64cd7b8ff454d9142286d2879a5cc","type":"GO_TERM","name":"selenocysteine-tRNA ligase activity","canonical_id":"go:GO:0098619","description":"\"Catalysis of the reaction: tRNASec + L-Ser + ATP = Ser-tRNASec + AMP + diphosphate.\" [PMID:8890909, PMID:9431993, PMID:9637248]","metadata":null},{"id":"7d454875fa654da88f5262016a319a0c","type":"GO_TERM","name":"selenodiglutathione-disulfide reductase (NADPH) activity","canonical_id":"go:GO:0098622","description":"\"Catalysis of the reaction: H+ + selenodiglutathione + NADPH = gluthathioselenol + glutathione + NADP+.\" [PMID:1569062, RHEA:34927]","metadata":null},{"id":"7a13c9952ff84ad68d998fa0365bbc1f","type":"GO_TERM","name":"selenol Se-methyltransferase activity","canonical_id":"go:GO:0098603","description":"\"Catalysis of the reaction: R + Se-Adenosylselenomethionine = CH3-R + Se-Adenosyl-L-selenohomocysteine.\" [PMID:1711890]","metadata":null},{"id":"61870452a95846f69f8af205b9b9e196","type":"GO_TERM","name":"selenomethionine adenosyltransferase activity","canonical_id":"go:GO:0098601","description":"\"Catalysis of the reaction: L-selenomethionine + ATP + H2O = L-adenosylselenomethionine + phosphate + diphosphate.\" [PMID:2339986, RHEA:31211]","metadata":null},{"id":"491eb0849d644dd4ac8e63b0f2173502","type":"GO_TERM","name":"selenomethionine gamma-lyase activity","canonical_id":"go:GO:0098600","description":"\"Catalysis of the reaction: L-Selenomethionine + H2O = Methaneselenol + Ammonia + 2-oxobutanoic acid.\" [PMID:11578145, PMID:16037612, PMID:16444005]","metadata":null},{"id":"d4e93f35bde143d88020d26fc8d84d9e","type":"GO_TERM","name":"selenomethionine-tRNA ligase activity","canonical_id":"go:GO:0098618","description":"\"Catalysis of the reaction: ATP + L-selenomethionine + tRNA(Met) = AMP + diphosphate + selenomethionyl-tRNA(Met).\" [PMID:16661668, PMID:16661782]","metadata":null},{"id":"ff4ae86da2c348d7996a239cfcff3281","type":"GO_TERM","name":"selenoneine biosynthetic process","canonical_id":"go:GO:1903257","description":"\"The chemical reactions and pathways resulting in the formation of selenoneine.\" [GO_REF:0000068, GOC:TermGenie, PMID:24828577]","metadata":null},{"id":"12bbff687a2d4fdeb0fe73273b38b93f","type":"GO_TERM","name":"selenotransferase activity","canonical_id":"go:GO:0016785","description":"\"Catalysis of the transfer of a selenium-containing group from one compound (donor) to another (acceptor).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"94be497c1ce849c8bfbd81e40c7f87e4","type":"DRUG","name":"selexipag","canonical_id":"mesh:C523468","description":null,"metadata":null},{"id":"1e93871335f941afa3518e7aead41be5","type":"GO_TERM","name":"self proteolysis","canonical_id":"go:GO:0097264","description":"\"The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their own peptide bonds.\" [GOC:yaf, PMID:18676612, PMID:19144634]","metadata":null},{"id":"462667588f5843e09171b75320f50160","type":"DISEASE","name":"self-limited epilepsy with centrotemporal spikes","canonical_id":"mondo:0007295","description":null,"metadata":null},{"id":"7266ba17731446d9b4df165e7190795a","type":"DRUG","name":"selumetinib","canonical_id":"gtopdb:5665","description":null,"metadata":null},{"id":"ac5e347f90094eef8cc1382dc77c41ee","type":"COMBINATION_TREATMENT","name":"selumetinib + serplulimab","canonical_id":"ctgov_combo:ctgov-combo-34e606f8e285a1e5","description":null,"metadata":null},{"id":"001fb7752c0c4c769e08c9526db15864","type":"DRUG","name":"semaglutide","canonical_id":"gtopdb:9724","description":null,"metadata":null},{"id":"5e0614cea6a9430bb3c8b94f2221529a","type":"DRUG","name":"semaglutide","canonical_id":"chembl:CHEMBL2108724","description":null,"metadata":null},{"id":"6d7aa6b006a647cbac76b9b31da328a3","type":"GO_TERM","name":"semaphorin receptor activity","canonical_id":"go:GO:0017154","description":"\"Combining with a semaphorin, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling, PMID:15239958]","metadata":null},{"id":"bab33c33e5fd4cbcb66b25afe56a48be","type":"GO_TERM","name":"semaphorin receptor binding","canonical_id":"go:GO:0030215","description":"\"Binding to a semaphorin receptor.\" [GOC:ceb, PMID:12001990]","metadata":null},{"id":"475fb5bd1be2404b8d7c091d1ccb1d67","type":"GO_TERM","name":"semaphorin receptor complex","canonical_id":"go:GO:0002116","description":"\"A stable binary complex of a semaphorin and a plexin, together forming a functional semaphorin receptor.\" [GOC:hjd, PMID:10934324, PMID:12367632, PMID:12613544]","metadata":null},{"id":"eab0be319a1248168b07e2c484eb7137","type":"GO_TERM","name":"semaphorin-plexin signaling pathway","canonical_id":"go:GO:0071526","description":"\"The series of molecular signals generated as a consequence of a semaphorin receptor (composed of a plexin and a neurophilin) binding to a semaphorin ligand.\" [GOC:BHF, GOC:mah, GOC:vk, PMID:15239959]","metadata":null},{"id":"95941eead56848cab158badef4b95e69","type":"GO_TERM","name":"semaphorin-plexin signaling pathway involved in axon guidance","canonical_id":"go:GO:1902287","description":"\"Any semaphorin-plexin signaling pathway that is involved in axon guidance.\" [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22790009]","metadata":null},{"id":"b81c64677dfe48c9a120818007795c98","type":"GO_TERM","name":"semi-lunar valve development","canonical_id":"go:GO:1905314","description":"\"The process whose specific outcome is the progression of a semi-lunar valve over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19409885]","metadata":null},{"id":"78228162128848008fc74a13e02f3491","type":"GO_TERM","name":"semicircular canal development","canonical_id":"go:GO:0060872","description":"\"The progression of the semicircular canal from its initial formation to the mature structure.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"8ca41bf760cb4d5ea44e7cd10262a5c5","type":"GO_TERM","name":"semicircular canal formation","canonical_id":"go:GO:0060876","description":"\"The developmental process pertaining to the initial formation of the semicircular canal from the otic vesicle. This process begins with the regionalization of the vesicle that specifies the area where the vesicles will form and continues through the process of fusion which forms the initial tubes.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"4d52144fbbce4cd7ae5271870f0667c2","type":"GO_TERM","name":"semicircular canal fusion","canonical_id":"go:GO:0060879","description":"\"Creation of the central hole of the semicircular canal by sealing the edges of the pouch that forms during the process of semicircular canal formation.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"5bb6d1b076ba49379c6c5b0a5d211e52","type":"GO_TERM","name":"semicircular canal morphogenesis","canonical_id":"go:GO:0048752","description":"\"The process in which the anatomical structures of the semicircular canals are generated and organized.\" [GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"007ed15e554a49f4a7b6c96644eda40c","type":"GO_TERM","name":"seminal clot liquefaction","canonical_id":"go:GO:0070684","description":"\"The reproductive process in which coagulated semen becomes liquid following ejaculation, allowing the progressive release of motile spermatozoa.\" [GOC:mah, PMID:18482984]","metadata":null},{"id":"378419a25038491ab4322b9e57eecc7e","type":"GO_TERM","name":"seminal vesicle development","canonical_id":"go:GO:0061107","description":"\"The progression of the seminal vesicle over time, from its formation to the mature structure. The seminal vesicle is a gland that contributes to the production of semen.\" [GOC:dph]","metadata":null},{"id":"bf9c9eb4fbdb47e48044c7f08bed21b4","type":"GO_TERM","name":"seminal vesicle epithelium development","canonical_id":"go:GO:0061108","description":"\"The progression of the seminal vesicle epithelium over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"98f5bbc7de6e4890bd3e67207caf508f","type":"GO_TERM","name":"seminal vesicle morphogenesis","canonical_id":"go:GO:0061682","description":"\"The process in which the anatomical structures of a seminal vesicle are generated and organized.\" [GOC:dph]","metadata":null},{"id":"8d33183214d2488384cd82f256527160","type":"GO_TERM","name":"seminiferous tubule development","canonical_id":"go:GO:0072520","description":"\"The reproductive developmental process whose specific outcome is the progression of the seminiferous tubule over time, from its formation to the mature structure. Seminiferous tubules are ducts located in the testicles, and are the specific location of meiosis, and the subsequent creation of gametes, namely spermatozoa.\" [GOC:BHF, GOC:mah, UBERON:0001343]","metadata":null},{"id":"15eb549103a948829401de4e22866979","type":"GO_TERM","name":"senecionine N-oxygenase activity","canonical_id":"go:GO:0033784","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + senecionine = H2O + NADP+ + senecionine N-oxide.\" [EC:1.14.13.101, RHEA:11420]","metadata":null},{"id":"15cf0bcefb844ba89b12de36bd514f8c","type":"GO_TERM","name":"senescence-associated heterochromatin focus","canonical_id":"go:GO:0035985","description":"\"A transcriptionally-silent heterochromatin structure present in senescent cells. Contains the condensed chromatin of one chromosome and is enriched for histone modifications. Thought to repress expression of proliferation-promoting genes.\" [GOC:yaf, PMID:15621527, PMID:21248468]","metadata":null},{"id":"d2f24f5ac761433b9621c94323f919e8","type":"GO_TERM","name":"senescence-associated vacuole","canonical_id":"go:GO:0010282","description":"\"A lytic vacuole that is maintained at acidic pH and has different tonoplast composition compared to the central vacuole. Found during leaf senescence and develops in the peripheral cytoplasm of cells that contain chloroplast.\" [PMID:15743448]","metadata":null},{"id":"c94b798bc4f146428f0e5009617a057d","type":"GO_TERM","name":"sensitization","canonical_id":"go:GO:0046960","description":"\"An increased in a behavioral response to a repeated stimulus. For example, a shock to the tail of the marine snail Aplysia, to which the snail responds by withdrawing its gill, will result in increased gill withdrawal the next time the skin is touched.\" [ISBN:0582227089]","metadata":null},{"id":"0a8b6867a8344bf7b13d713992e16927","type":"DISEASE","name":"sensorineural hearing loss disorder","canonical_id":"mondo:0020678","description":null,"metadata":null},{"id":"61325256bfd844ea98a2897097b200cb","type":"GO_TERM","name":"sensory dendrite","canonical_id":"go:GO:0071683","description":"\"A dendrite that is found on a sensory neuron, and directly transduces a sensory signal from the sensory neuron to another neuron.\" [GOC:dos, GOC:kmv, GOC:mah]","metadata":null},{"id":"0c6fb42debfb461b8c62123f08aa485d","type":"GO_TERM","name":"sensory epithelium regeneration","canonical_id":"go:GO:0070654","description":"\"The regrowth of a sensory epithelium following its loss or destruction.\" [GOC:dsf, PMID:19381250]","metadata":null},{"id":"dabb3bf1278f4d2d99e0060d2c6ee831","type":"GO_TERM","name":"sensory neuron axon guidance","canonical_id":"go:GO:0097374","description":"\"The process in which the migration of an axon growth cone of a sensory neuron is directed to a specific target site in response to a combination of attractive and repulsive cues. A sensory neuron is an afferent neuron conveying sensory impulses.\" [CL:0000101, GOC:pr]","metadata":null},{"id":"86cd13314ae64e51bf42d0c4796efdd3","type":"GO_TERM","name":"sensory neuron migration","canonical_id":"go:GO:1904937","description":"\"The orderly movement of a sensory neuron from one site to another.\" [GO_REF:0000091, GOC:ah, GOC:TermGenie, PMID:18622031]","metadata":null},{"id":"66736c7323084a9583b6af7b0a79c693","type":"GO_TERM","name":"sensory organ boundary specification","canonical_id":"go:GO:0008052","description":"\"The process in which boundaries between a sensory organ and the surrounding tissue are established and maintained.\" [GO_REF:0000021]","metadata":null},{"id":"07c7b7593d4346b6a4820a19d2c31b68","type":"GO_TERM","name":"sensory organ development","canonical_id":"go:GO:0007423","description":"\"The process whose specific outcome is the progression of sensory organs over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"c35ceeddae8440a3b83aeb5084349104","type":"GO_TERM","name":"sensory organ morphogenesis","canonical_id":"go:GO:0090596","description":"\"Morphogenesis of a sensory organ. A sensory organ is defined as a tissue or set of tissues that work together to receive and transmit signals from external or internal stimuli. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.\" [GOC:kmv, ISBN:978-0199210893]","metadata":null},{"id":"4ec880d1b9b041a6b3a97dcdb8ce288a","type":"GO_TERM","name":"sensory organ precursor cell division","canonical_id":"go:GO:0045035","description":"\"The series of four asymmetric divisions undergone by the sensory organ precursor cells to generate cells that have distinct cell fates. For example, in the external sensory organ, the precursor cells give rise to one multidendritic neuron and four additional cells (the socket, shaft, sheath cells and the external sense neuron).\" [GOC:mah, PMID:11171389, PMID:18295597]","metadata":null},{"id":"700da5360a194b3aab77768cfabb4b7b","type":"GO_TERM","name":"sensory organ precursor cell fate determination","canonical_id":"go:GO:0016360","description":"\"The process in which a cell becomes capable of differentiating autonomously into a sensory organ precursor cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:curators]","metadata":null},{"id":"588bc0b62fd94f339c920ef90083073a","type":"GO_TERM","name":"sensory perception","canonical_id":"go:GO:0007600","description":"\"The series of events required for an organism to receive a sensory stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai, GOC:dph]","metadata":null},{"id":"b0e1f060db5e44d79ed9f18662077407","type":"GO_TERM","name":"sensory perception of bitter taste","canonical_id":"go:GO:0050913","description":"\"The series of events required to receive a bitter taste stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"9201d59837cf47d1b315dedaa0236c7d","type":"GO_TERM","name":"sensory perception of chemical stimulus","canonical_id":"go:GO:0007606","description":"\"The series of events required for an organism to receive a sensory chemical stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"eb27d54f73b8473cac22efe7cd8939ee","type":"GO_TERM","name":"sensory perception of cold stimulus","canonical_id":"go:GO:0062035","description":"\"The series of events required for an organism to receive a cold temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal.\" [PMID:21335241]","metadata":null},{"id":"dcb5e2009c4447a899e535db4c37a39a","type":"GO_TERM","name":"sensory perception of electrical stimulus","canonical_id":"go:GO:0050952","description":"\"The series of events required for an organism to receive a sensory electrical stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"88a68140f0cc41d390033d6b362ee53f","type":"GO_TERM","name":"sensory perception of fast pain","canonical_id":"go:GO:0019234","description":"\"The series of events required for an organism to receive a fast pain stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process. Fast pain is often subjectively described as a sharp or stabbing pain; in humans, the signals from a fast pain stimulus are perceived and relayed along myelinated A-delta fibers to the central nervous system, reaching their target in about 0.1 seconds.\" [PMID:38704307]","metadata":null},{"id":"6e2bfc0405df4978a7a0bcfe8e3f8ac5","type":"GO_TERM","name":"sensory perception of gravity","canonical_id":"go:GO:0070998","description":"\"The series of events required for an organism to receive a gravitational stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:mah]","metadata":null},{"id":"9765e40393d24f2194d433773704ad12","type":"GO_TERM","name":"sensory perception of high humidity","canonical_id":"go:GO:0098510","description":"\"The series of events required for an organism to detect high environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [PMID:18269908]","metadata":null},{"id":"5766b146d4b74c47a2df943717cb9198","type":"GO_TERM","name":"sensory perception of hot stimulus","canonical_id":"go:GO:0062036","description":"\"The series of events required for an organism to receive a hot temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal.\" [PMID:21335241]","metadata":null},{"id":"bfa97b2abd3741cb89abdec9ea063896","type":"GO_TERM","name":"sensory perception of humidity","canonical_id":"go:GO:0098509","description":"\"The series of events required for an organism to detect some level of humidity in its environment, convert this detection into a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [PMID:18269908, PMID:8650222]","metadata":null},{"id":"ffeb67eb1e1a486195f3daa218d32866","type":"GO_TERM","name":"sensory perception of itch","canonical_id":"go:GO:0160025","description":"\"A sensory perception which causes the desire or reflex to scratch.\" [PMID:26015312, PMID:29723501, PMID:30734045, Wikipedia:Itch]","metadata":null},{"id":"9aed310c0bdb447b85e1a56e21eef40a","type":"GO_TERM","name":"sensory perception of light stimulus","canonical_id":"go:GO:0050953","description":"\"The series of events required for an organism to receive a sensory light stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"a23ef1b4bde643db91ee802deb147735","type":"GO_TERM","name":"sensory perception of low humidity","canonical_id":"go:GO:0098511","description":"\"The series of events required for an organism to detect low environmental humidity, convert this detection into a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [PMID:18269908]","metadata":null},{"id":"b2ff187fc01f4bedad965a28aab68a43","type":"GO_TERM","name":"sensory perception of mechanical stimulus","canonical_id":"go:GO:0050954","description":"\"The series of events required for an organism to receive a sensory mechanical stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"820625efbc914eeeb0ab670b53ad811e","type":"GO_TERM","name":"sensory perception of pain","canonical_id":"go:GO:0019233","description":"\"The series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal. A painful stimulus is any physical or chemical event that has the potential to cause tissue damage (actual or perceived) and activates the nociceptive system.\" [GOC:curators]","metadata":null},{"id":"736e9128d59b43db9dfd3157df005c62","type":"GO_TERM","name":"sensory perception of salty taste","canonical_id":"go:GO:0050914","description":"\"The series of events required to receive a salty taste stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"b777f12e0a734494ba75d35f2e4355b9","type":"GO_TERM","name":"sensory perception of slow pain","canonical_id":"go:GO:0019235","description":"\"The series of events required for an organism to receive a slow pain stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process. Slow pain is often subjectively described as an aching or throbbing pain; in humans, the signals from a slow pain stimulus are perceived and relayed along unmyelinated C fibers to the central nervous system, reaching their target in about 1 second. Slow pain is often associated with tissue destruction.\" [http://www.people.vcu.edu/~mikuleck/ssspain/, PMID:38704307]","metadata":null},{"id":"fdf98d0a1ec14771ab7da9531fb06f62","type":"GO_TERM","name":"sensory perception of smell","canonical_id":"go:GO:0007608","description":"\"The series of events required for an organism to receive an olfactory stimulus, convert it to a molecular signal, and recognize and characterize the signal. Olfaction involves the detection of chemical composition of an organism's ambient medium by chemoreceptors. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"72af53d88c424164b2c87c7092d7d552","type":"GO_TERM","name":"sensory perception of sound","canonical_id":"go:GO:0007605","description":"\"The series of events required for an organism to receive an auditory stimulus, convert it to a molecular signal, and recognize and characterize the signal. Sonic stimuli are detected in the form of vibrations and are processed to form a sound.\" [GOC:ai]","metadata":null},{"id":"ddd73a93cb7b428e9d2ba3610f17eb62","type":"GO_TERM","name":"sensory perception of sour taste","canonical_id":"go:GO:0050915","description":"\"The series of events required to receive a sour taste stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"7b0cf3bc195442f99c8ef27f57ec2e22","type":"GO_TERM","name":"sensory perception of sweet taste","canonical_id":"go:GO:0050916","description":"\"The series of events required to receive a sweet taste stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"cfa06ee1ce9b4d029417f3d54f23f895","type":"GO_TERM","name":"sensory perception of taste","canonical_id":"go:GO:0050909","description":"\"The series of events required for an organism to receive a gustatory stimulus, convert it to a molecular signal, and recognize and characterize the signal. Gustation involves the direct detection of chemical composition, usually through contact with chemoreceptor cells. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"6da849249fd241b48cd7f4206db7f2a3","type":"GO_TERM","name":"sensory perception of temperature stimulus","canonical_id":"go:GO:0050951","description":"\"The series of events required for an organism to receive a sensory temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"76c408e2859c43fab7fa268d1aa7ec77","type":"GO_TERM","name":"sensory perception of touch","canonical_id":"go:GO:0050975","description":"\"The series of events required for an organism to receive a touch stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process. The perception of touch in animals is mediated by mechanoreceptors in the skin and mucous membranes and is the sense by which contact with objects gives evidence as to certain of their qualities. Different types of touch can be perceived (for example, light, coarse, pressure and tickling) and the stimulus may be external or internal (e.g. the feeling of a full stomach).\" [GOC:ai]","metadata":null},{"id":"2d274e9ef68549e199c434a5e7ec3b2e","type":"GO_TERM","name":"sensory perception of umami taste","canonical_id":"go:GO:0050917","description":"\"The series of events required to receive an umami taste stimulus, convert it to a molecular signal, and recognize and characterize the signal. Umami taste is the savory taste of meats and other foods that are rich in glutamates. This is a neurological process.\" [GOC:ai]","metadata":null},{"id":"404035bc01e24728a9558aca9bdf213c","type":"GO_TERM","name":"sensory perception of wind","canonical_id":"go:GO:0071063","description":"\"The series of events required for an organism to receive sensory mechanical stimulus resulting from air flow, convert it to a molecular signal, and recognize and characterize the signal.\" [GOC:mah, PMID:19279637]","metadata":null},{"id":"62dab62e5c994d89beae86f6e10e7ffc","type":"GO_TERM","name":"sensory processing","canonical_id":"go:GO:0050893","description":"\"Any neural process required for an organism to sense and interpret the dimensions of a sensory experience: modality, location, intensity and affect.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"49525a12bf774f0f85b97bd383e32534","type":"GO_TERM","name":"sensory system development","canonical_id":"go:GO:0048880","description":"\"The process whose specific outcome is the progression of a sensory system over time from its formation to the mature structure.\" [GOC:dgh]","metadata":null},{"id":"b0b81a2c2bbe4dc08ecdca8082d47561","type":"GO_TERM","name":"sepal development","canonical_id":"go:GO:0048442","description":"\"The process whose specific outcome is the progression of the sepal over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"5b8597e724bc4029907c7bc520050d1e","type":"GO_TERM","name":"sepal formation","canonical_id":"go:GO:0048453","description":"\"The process that gives rise to the sepal. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid]","metadata":null},{"id":"9fc561cc6b664fe6b8b3a4180f93ade2","type":"GO_TERM","name":"sepal giant cell development","canonical_id":"go:GO:0090393","description":"\"The process aimed at the progression of a sepal giant cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:tb]","metadata":null},{"id":"1e17a5ee93f249d29db4d84d4cc5fb7c","type":"GO_TERM","name":"sepal giant cell differentiation","canonical_id":"go:GO:0090392","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a sepal giant cell. A sepal giant cell is a pavement cell that is part of the sepal epidermis and stretches one fifth the length of the sepal with a chromosome content of 16C.\" [GOC:tb, PMID:20485493]","metadata":null},{"id":"0aafdd9d36b34fb4bba137d46354c88d","type":"GO_TERM","name":"sepal morphogenesis","canonical_id":"go:GO:0048447","description":"\"The process in which the anatomical structures of the sepal are generated and organized.\" [GOC:curators]","metadata":null},{"id":"b98a490dd1e54e8193a9195514be5272","type":"GO_TERM","name":"sepal structural organization","canonical_id":"go:GO:0048454","description":"\"The process that contributes to the act of creating the structural organization of the sepal. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid]","metadata":null},{"id":"ba58734f92a94d4ba9ae9bb09e3804ab","type":"GO_TERM","name":"sepal vascular tissue pattern formation","canonical_id":"go:GO:0080057","description":"\"Vascular tissue pattern formation as it occurs in the sepal of vascular plants.\" [PMID:17369435]","metadata":null},{"id":"a4f7f79966ab428796ed669364344472","type":"GO_TERM","name":"separase-securin complex","canonical_id":"go:GO:1990520","description":"\"A protein complex that includes separase (a protease which cleaves cohesin as part of chromosome separation) and securin, a protease inhibitor. Chromosome separation is inhibited until securin is degraded by the Anaphase Promoting Complex (APC).\" [GOC:dos, GOC:vw, PMID:8978688]","metadata":null},{"id":"a00f467c31284223aca61641f37cd0ba","type":"GO_TERM","name":"sepiapterin deaminase activity","canonical_id":"go:GO:0050279","description":"\"Catalysis of the reaction: L-sepiapterin + H2O + H+ = (S)-xanthopterin-B2 + NH4+.\" [RHEA:14025]","metadata":null},{"id":"c4d1a6245c584a7d9434f3cbb5df1b40","type":"GO_TERM","name":"sepiapterin reductase (NADP+) activity","canonical_id":"go:GO:0004757","description":"\"Catalysis of the reactions: 7,8-dihydrobiopterin + NADP+ = sepiapterin + NADPH + H+ and (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin + 2 NADP+ = 6-pyruvoyl-5,6,7,8-tetrahydropterin + 2 H+ + 2 NADPH.\" [EC:1.1.1.153]","metadata":null},{"id":"2ad6927de1bc4340bdbe9ad48f67a446","type":"GO_TERM","name":"septal cell proliferation","canonical_id":"go:GO:0022022","description":"\"The multiplication or reproduction of septal cells, resulting in the expansion of a cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"a3e7ed9e49f34b8a88833225cab84ca2","type":"GO_TERM","name":"septal periplasm","canonical_id":"go:GO:0036240","description":"\"The region between the plasma membrane and the cell wall, as found in organisms such as filamentous fungi.\" [GOC:di, PMID:21564341]","metadata":null},{"id":"d8e452fb70d04e75bc2de1e279816c6c","type":"GO_TERM","name":"septate junction","canonical_id":"go:GO:0005918","description":"\"A cell-cell junction that forms a continuous band around each cell in an epithelium; within the septate junction the membranes of adjacent cells maintain a constant distance of approximately 15 nm; found in arthropods.\" [ISBN:0815332181, PMID:11700298, PMID:12612641, PMID:20795303, PMID:28636800]","metadata":null},{"id":"313d4fc298b34a9aae99e49ae78e1a94","type":"GO_TERM","name":"septate junction assembly","canonical_id":"go:GO:0019991","description":"\"The assembly of a septate junction, an intercellular junction found in invertebrate epithelia that is characterized by a ladder like appearance in electron micrographs and thought to provide structural strength and to provide a barrier to diffusion of solutes through the intercellular space.\" [GOC:ai, PMID:5272312]","metadata":null},{"id":"4fa47553766a4b01a3effeb287e576fc","type":"GO_TERM","name":"septation initiation signaling","canonical_id":"go:GO:0031028","description":"\"The series of molecular signals, mediated by the small GTPase Ras, that results in the initiation of contraction of the contractile ring, at the beginning of cytokinesis and cell division by septum formation. The pathway coordinates chromosome segregation with mitotic exit and cytokinesis.\" [GOC:mah, GOC:vw, PMID:16775007]","metadata":null},{"id":"777002f53b2a41faaac9a135ff7d4493","type":"DISEASE","name":"septic shock","canonical_id":"efo:0006834","description":null,"metadata":null},{"id":"1fd8252a48454f1fbb7b54c8b46b30fe","type":"GO_TERM","name":"septin band","canonical_id":"go:GO:0032158","description":"\"A diffuse ring composed of a series of septin bars that run parallel to the long axis of the cell. This type of septin structure has been observed in a number of locations associated with polarized grown and/or deposition of new membrane, but not with cytokinesis, such as at the shmoo (mating projection) neck, at the junction between the mother cell and the germ tube (hypha) of a fungal cell growing filamentously.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"c581c9d0f3b9462885127c22fed14f73","type":"GO_TERM","name":"septin cap","canonical_id":"go:GO:0032159","description":"\"A faint structure formed of septins found at the leading edge of growth in germ tubes and hyphae in fungal cells growing filamentously. This cap of septins colocalizes with a region of the plasma membrane that is rich in ergosterol.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"65346d01857940e4bdfe80f7088812c4","type":"GO_TERM","name":"septin collar","canonical_id":"go:GO:0032173","description":"\"A tubular, hourglass-shaped structure composed of highly ordered arrays of septin filaments; in budding yeast cells, the septin collar forms from the initial septin ring by expanding into the daughter cell.\" [GOC:krc, PMID:16009555, PMID:16151244]","metadata":null},{"id":"0915e9c42f2b401eba95270d46e96f2d","type":"GO_TERM","name":"septin collar organization","canonical_id":"go:GO:0140544","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising the septin collar.\" [PMID:21736496, PMID:32386534]","metadata":null},{"id":"d845b246a3ab4e92936790d829c4bd74","type":"GO_TERM","name":"septin complex","canonical_id":"go:GO:0031105","description":"\"A protein complex containing septins. Typically, these complexes contain multiple septins and are oligomeric.\" [GOC:mah, PMID:15385632]","metadata":null},{"id":"ca5fb8ecc0fc4546a8cb5532c61f8f30","type":"GO_TERM","name":"septin cytoskeleton","canonical_id":"go:GO:0032156","description":"\"The part of the cytoskeleton (the internal framework of a cell) composed of septins and associated proteins. Includes septin cytoskeleton-associated complexes.\" [GOC:mah]","metadata":null},{"id":"a886e51bfaa8409e83cd40b487cd17f0","type":"GO_TERM","name":"septin cytoskeleton organization","canonical_id":"go:GO:0032185","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising septin complexes and their associated proteins.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"695ddee16b74489b96da3643b3337a33","type":"GO_TERM","name":"septin filament array","canonical_id":"go:GO:0032160","description":"\"Arrays of septin filaments, or bars, found in a series of filamentous structures. Such structures have been observed in the prospore membrane during spore formation in S. cerevisiae and in the chlamydospore membrane during chlamydospore formation in C. albicans.\" [GOC:krc, PMID:16151244]","metadata":null},{"id":"13b3a2b99aad42cb9d22a2bb6cf9709b","type":"GO_TERM","name":"septin ring","canonical_id":"go:GO:0005940","description":"\"A tight ring-shaped structure that forms in the division plane at the site of cytokinesis; composed of members of the conserved family of filament-forming proteins called septins as well as septin-associated proteins. This type of septin structure is observed at the bud neck of budding fungal cells, at the site of cell division in animal cells, at the junction between the mother cell and a pseudohyphal projection, and also within hyphae of filamentous fungi at sites where a septum will form.\" [GOC:krc, GOC:mah, PMID:16009555, PMID:16151244]","metadata":null},{"id":"8f0b62319ec64569bb1eb98c3f7079b1","type":"GO_TERM","name":"septin ring assembly","canonical_id":"go:GO:0000921","description":"\"The aggregation, arrangement and bonding together of septins and associated proteins to form an organized structure resembling a ring at the cell cortex.\" [GOC:clt]","metadata":null},{"id":"cefcbc1c1b904535af85fe2f5a04a3cd","type":"GO_TERM","name":"septin ring disassembly","canonical_id":"go:GO:0031107","description":"\"The controlled breakdown of a septin ring.\" [GOC:mah]","metadata":null},{"id":"907087b8a4a2427e80ae2e160c8da264","type":"GO_TERM","name":"septin ring organization","canonical_id":"go:GO:0031106","description":"\"Control of the formation, spatial distribution, and breakdown of the septin ring.\" [GOC:mah]","metadata":null},{"id":"43c969b3bd894a4e8d34acf04d0e4c9d","type":"GO_TERM","name":"septum digestion after cytokinesis","canonical_id":"go:GO:0000920","description":"\"The process of physically separating the septal cell wall material by enzymatic digestion, that occurs after daughter cells are separated by cytokinesis.\" [GOC:mtg_cell_cycle, GOC:vw]","metadata":null},{"id":"23cc2127d6d74129990a329321839fdc","type":"GO_TERM","name":"septum primum development","canonical_id":"go:GO:0003284","description":"\"The progression of the septum primum over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"5a0ff226aa804b80958a612cf51cd6c3","type":"GO_TERM","name":"septum secundum development","canonical_id":"go:GO:0003285","description":"\"The progression of the septum secundum over time, from its initial formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"fde4a495f5bf4d7aae1529368116f371","type":"GO_TERM","name":"septum transversum development","canonical_id":"go:GO:0003343","description":"\"The progression of the septum transversum from its initial formation to the mature structure. The septum transversum is a portion of the trunk mesenchyme.\" [GOC:dph, PMID:18722343]","metadata":null},{"id":"cd8efad70ba64be4aaf7d71767cdd26a","type":"GO_TERM","name":"sequence-specific DNA binding","canonical_id":"go:GO:0043565","description":"\"Binding to DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.\" [GOC:jl]","metadata":null},{"id":"67a6e33f572d477889fe4b9313eac986","type":"GO_TERM","name":"sequence-specific DNA binding, bending","canonical_id":"go:GO:0044374","description":"\"The activity of binding selectively and non-covalently to DNA in a sequence-specific manner and distorting the original structure of DNA, typically a straight helix, into a bend, or increasing the bend if the original structure was intrinsically bent due to its sequence.\" [GOC:jl, GOC:vw]","metadata":null},{"id":"fa505bb4916d42cc89cda7c12027ab8b","type":"GO_TERM","name":"sequence-specific double-stranded DNA binding","canonical_id":"go:GO:1990837","description":"\"Binding to double-stranded DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA, e.g. promotor binding or rDNA binding.\" [GOC:dos, GOC:sl]","metadata":null},{"id":"d6fea5def65a49aa94069f1b75007743","type":"GO_TERM","name":"sequence-specific mRNA binding","canonical_id":"go:GO:1990825","description":"\"Binding to messenger RNA (mRNA) of a specific nucleotide composition or a specific sequence motif.\" [PMID:11886857]","metadata":null},{"id":"135b04bd05934958ad39a14a78ad49d5","type":"GO_TERM","name":"sequence-specific single stranded DNA binding","canonical_id":"go:GO:0098847","description":"\"Binding to single-stranded DNA of a specific nucleotide composition.\" [PMID:9531483]","metadata":null},{"id":"1eb3ef4a608b43758b03cf797d769466","type":"GO_TERM","name":"sequoyitol dehydrogenase activity","canonical_id":"go:GO:0050280","description":"\"Catalysis of the reaction: 1D-5-O-methyl-myo-inositol + NAD+ = 2D-5-O-methyl-2,3,5/4,6-pentahydroxycyclohexanone + H+ + NADH.\" [EC:1.1.1.143, RHEA:11300]","metadata":null},{"id":"c7ef186637cc49ee8974757a0ba036dd","type":"GO_TERM","name":"serine 3-dehydrogenase activity","canonical_id":"go:GO:0031132","description":"\"Catalysis of the reaction: L-serine + NADP+ = L-alpha-formylglycine + 2 H+ + NADPH.\" [EC:1.1.1.276, RHEA:21596]","metadata":null},{"id":"3314dc1c530a40709e2f6dbc6e3d4bb3","type":"GO_TERM","name":"serine C-palmitoyltransferase activity","canonical_id":"go:GO:0004758","description":"\"Catalysis of the reaction: L-serine + H+ + palmitoyl-CoA = 3-dehydrosphinganine + CO2 + CoA.\" [EC:2.3.1.50, RHEA:14761]","metadata":null},{"id":"230eef3138b54e6a958a2b8dcb05039b","type":"GO_TERM","name":"serine O-acyltransferase activity","canonical_id":"go:GO:0016412","description":"\"Catalysis of the reaction: a fatty acyl-CoA + L-seryl-[protein] = CoA + O-fatty acyl-L-seryl-[protein].\" [RHEA:68272]","metadata":null},{"id":"f6955752dc6740e99ac1248b8f9d78f6","type":"GO_TERM","name":"serine binding","canonical_id":"go:GO:0070905","description":"\"Binding to 2-amino-3-hydroxypropanoic acid.\" [GOC:rph]","metadata":null},{"id":"3e870835201f4d23bf19a9579541cfe0","type":"GO_TERM","name":"serine decarboxylase activity","canonical_id":"go:GO:0102705","description":"\"Catalysis of the reaction: H+ + L-serine = ethanolaminium(1+) + carbon dioxide.\" [GOC:pz, PMID:11461929, RHEA:45824]","metadata":null},{"id":"9268866fc8214f02822f42db4549d19c","type":"GO_TERM","name":"serine family amino acid biosynthetic process","canonical_id":"go:GO:0009070","description":"\"The chemical reactions and pathways resulting in the formation of an amino acid derived from 3-phosphoglycerate (L-serine, glycine, L-cysteine and L-homocysteine).\" [GOC:curators]","metadata":null},{"id":"cbc9bcbc449f4521b284e5fab5caf595","type":"GO_TERM","name":"serine hydrolase activity","canonical_id":"go:GO:0017171","description":"\"Catalysis of the hydrolysis of a substrate by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).\" [Wikipedia:Serine_hydrolase]","metadata":null},{"id":"6b44c7c6ee544045a20d79367959d269","type":"GO_TERM","name":"serine import across plasma membrane","canonical_id":"go:GO:0098718","description":"\"The directed movement of serine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"5c4cf68cbd114e0fa32077ac181756f7","type":"GO_TERM","name":"serine import into mitochondrion","canonical_id":"go:GO:0140300","description":"\"The process in which serine is transported from the cytosol into the mitochondrial matrix.\" [PMID:30442778]","metadata":null},{"id":"e65c688877d940efa5be6344d981c460","type":"GO_TERM","name":"serine palmitoyltransferase complex","canonical_id":"go:GO:0017059","description":"\"A protein complex that catalyses the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the sphingoid base which is the starting point for all sphingolipids. In bacteria the enzyme is a cytoplasmic homodimer, whereas in eukaryotes the enzyme is a multiprotein complex localised to the endoplasmic reticulum. The eukaryotic complex consists of catalytic components (SPTLC1, SPTLC2 and SPTLC3 in humans; LCB1 and LCB2 in S. cerevisiae) and regulatory components, which include activators (SPTSSA/SPTSSB in humans, TSC3 in S. cerevisiae) and negative regulators (ORMDL1/ORMDL2/ORMDL3 in humans, ORM1/2 in S. cerevisiae ).\" [PMID:29863195, PMID:33558761]","metadata":null},{"id":"5395e00ffb144fae90821fa34c92f946","type":"GO_TERM","name":"serine phosphorylation of STAT protein","canonical_id":"go:GO:0042501","description":"\"The process of introducing a phosphate group to a serine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:jl, PMID:10918594]","metadata":null},{"id":"1092b04b36e84a44ad65aaa3f7813374","type":"GO_TERM","name":"serine protease inhibitor complex","canonical_id":"go:GO:0097180","description":"\"A heterodimeric protein complex that contains a serine protease inhibitor and a protease; formation of the complex inhibits serine protease activity.\" [GOC:ans, PMID:6323392]","metadata":null},{"id":"c774e925009a4746850a959a121a49a3","type":"GO_TERM","name":"serine racemase activity","canonical_id":"go:GO:0030378","description":"\"Catalysis of the reaction: L-serine = D-serine.\" [RHEA:10980]","metadata":null},{"id":"3eff083398b3460591278cd626063d4c","type":"GO_TERM","name":"serine transport","canonical_id":"go:GO:0032329","description":"\"The directed movement of L-serine, 2-amino-3-hydroxypropanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"91df539f88af4500b158a50fc80392fe","type":"GO_TERM","name":"serine-based site-specific recombinase activity","canonical_id":"go:GO:0160053","description":"\"Catalysis of the formation of new phosphodiester bonds between a pair of short, unique DNA target sequences; occurs through a phosphoseryl intermediate in which the target sequence is first cleaved by the nucleophilic attack by a serine in the active site.\" [PMID:16756503, PMID:29316791]","metadata":null},{"id":"9520b3b8e5da4887a68210af6e72c478","type":"GO_TERM","name":"serine-ethanolaminephosphate phosphodiesterase activity","canonical_id":"go:GO:0047387","description":"\"Catalysis of the reaction: H2O + serine phosphoethanolamine = H+ + phosphoethanolamine + serine.\" [EC:3.1.4.13, RHEA:17113]","metadata":null},{"id":"e57b420951d04b51b0b833b036787447","type":"GO_TERM","name":"serine-phosphoethanolamine synthase activity","canonical_id":"go:GO:0047494","description":"\"Catalysis of the reaction: L-serine + CDP-ethanolamine = L-serine-phosphoethanolamine + CMP + H+.\" [EC:2.7.8.4, RHEA:22656]","metadata":null},{"id":"75ab5ec37af645eb9129144b12ef1598","type":"GO_TERM","name":"serine-pyruvate aminotransferase complex","canonical_id":"go:GO:0005969","description":"\"A protein homodimeric complex that catalyzes the formation of hydroxypyruvate and alanine from serine and pyruvate.\" [PMID:22751661, PMID:851432]","metadata":null},{"id":"0fceb8eb2be84eb9b641b36453018b25","type":"GO_TERM","name":"serine-sulfate ammonia-lyase activity","canonical_id":"go:GO:0050283","description":"\"Catalysis of the reaction: -serine O-sulfate + H2O = sulfate + pyruvate + NH4+ + H+.\" [RHEA:15605]","metadata":null},{"id":"4df4cc4be3104b60bcc075b0571f1b96","type":"GO_TERM","name":"serine-tRNA ligase activity","canonical_id":"go:GO:0004828","description":"\"Catalysis of the reaction: ATP + L-serine + tRNA(Ser) = AMP + diphosphate + L-seryl-tRNA(Ser). Also catalyzes the formation of L-seryl-tRNA(Sec) from tRNA(Sec), the special tRNA for selenocysteine.\" [EC:6.1.1.11]","metadata":null},{"id":"f4538ecab6634b0fa95b8e76a487d4ca","type":"GO_TERM","name":"serine-tRNA ligase complex","canonical_id":"go:GO:0140715","description":"\"A heterodimeric enzyme complex that catalyzes the ligation of serine to tRNA(Ser), forming L-seryl-tRNA(Ser).\" [PMID:30943413]","metadata":null},{"id":"08c918bce4dc4878b22c84144b7da11a","type":"GO_TERM","name":"serine-type D-Ala-D-Ala carboxypeptidase activity","canonical_id":"go:GO:0009002","description":"\"Catalysis of the reaction: (Ac)2-L-Lys-D-alanyl-D-alanine + H2O = (Ac)2-L-Lys-D-alanine + D-alanine.\" [EC:3.4.16.4]","metadata":null},{"id":"6411244d9f544c0c8c0cebdd3a2190da","type":"GO_TERM","name":"serine-type aminopeptidase activity","canonical_id":"go:GO:0070009","description":"\"Catalysis of the hydrolysis of a single N-terminal amino acid residue from a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#AMINOPEPTIDASE, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"3a48b8d3ea9743b49ea0901c31f60687","type":"GO_TERM","name":"serine-type carboxypeptidase activity","canonical_id":"go:GO:0004185","description":"\"Catalysis of the hydrolysis of a single C-terminal amino acid residue from the C-terminus of a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#CARBOXYPEPTIDASE]","metadata":null},{"id":"69369c083cc6405aa044437574a3ca76","type":"GO_TERM","name":"serine-type endopeptidase activity","canonical_id":"go:GO:0004252","description":"\"Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"1d537a9ca4c54da1894ce279b370fd98","type":"GO_TERM","name":"serine-type endopeptidase complex","canonical_id":"go:GO:1905370","description":"\"A protein complex which is capable of serine-type endopeptidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:1689240]","metadata":null},{"id":"c2c9a9d675bc472a885c3b0e2d25e735","type":"GO_TERM","name":"serine-type endopeptidase inhibitor activity","canonical_id":"go:GO:0004867","description":"\"Binds to and stops, prevents or reduces the activity of a serine-type endopeptidase.\" [GOC:ai]","metadata":null},{"id":"53a6a110ed7949b78e82910347be2e92","type":"GO_TERM","name":"serine-type exopeptidase activity","canonical_id":"go:GO:0070008","description":"\"Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#EXOPEPTIDASE]","metadata":null},{"id":"d215259dbd4242ca9bb690d6b3f0bb0d","type":"GO_TERM","name":"serine-type peptidase activity","canonical_id":"go:GO:0008236","description":"\"Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).\" [https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"8078452afcad49e3960a6d138c182b73","type":"GO_TERM","name":"serine-type peptidase complex","canonical_id":"go:GO:1905286","description":"\"A protein complex which is capable of serine-type peptidase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:18640965]","metadata":null},{"id":"b5c86ef41a0f452db33c2162ea50ef93","type":"GO_TERM","name":"serine/threonine protein kinase complex","canonical_id":"go:GO:1902554","description":"\"A protein complex which is capable of protein serine/threonine kinase activity.\" [GOC:bhm, GOC:TermGenie, PMID:18191223]","metadata":null},{"id":"c717e826dd754772b88256997bf635cf","type":"DRUG","name":"sermorelin","canonical_id":"gtopdb:6998","description":null,"metadata":null},{"id":"b4fc0c9bd52d43caa24765710b6049b1","type":"DRUG","name":"sermorelin","canonical_id":"chembl:CHEMBL1201490","description":null,"metadata":null},{"id":"ec65b21f22f949c09caca2e4982b1086","type":"GO_TERM","name":"serotonergic neuron axon guidance","canonical_id":"go:GO:0036515","description":"\"The chemotaxis process that directs the migration of an axon growth cone of a serotonergic neuron to a specific target site in response to a combination of attractive and repulsive cues.\" [CL:0000850, GOC:bf, GOC:PARL, PMID:21106844]","metadata":null},{"id":"321da60e618c4bc2b524fe51caa85f15","type":"GO_TERM","name":"serotonergic synapse","canonical_id":"go:GO:0099154","description":"\"A synapse that uses serotonin as a neurotransmitter.\" [GOC:dos]","metadata":null},{"id":"b07431182b5a451e8bcff863fd21d269","type":"GO_TERM","name":"serotonin binding","canonical_id":"go:GO:0051378","description":"\"Binding to serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties.\" [GOC:ai]","metadata":null},{"id":"06974362143c4ddf9d2a80ad3932b36b","type":"GO_TERM","name":"serotonin biosynthetic process","canonical_id":"go:GO:0042427","description":"\"The chemical reactions and pathways resulting in the formation of serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f0512e0a21ba4b878eb30f3dd0dcebd9","type":"GO_TERM","name":"serotonin catabolic process","canonical_id":"go:GO:0042429","description":"\"The chemical reactions and pathways resulting in the breakdown of serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"5a1690d6468c4aa0ae5f63e0bbb67866","type":"GO_TERM","name":"serotonin metabolic process","canonical_id":"go:GO:0042428","description":"\"The chemical reactions and pathways involving serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"99791ef5f22749e2a8c3028a6e7a0b98","type":"GO_TERM","name":"serotonin production involved in inflammatory response","canonical_id":"go:GO:0002351","description":"\"The synthesis or release of serotonin following a stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add, ISBN:0781735149, PMID:16730260]","metadata":null},{"id":"4fcde357c709490e89732acbeeea7b0d","type":"GO_TERM","name":"serotonin receptor activity","canonical_id":"go:GO:0099589","description":"\"Combining with the biogenic amine serotonin and transmitting a signal across a membrane by activating some effector activity. Serotonin (5-hydroxytryptamine) is a neurotransmitter and hormone found in vertebrates and invertebrates.\" [GOC:dos]","metadata":null},{"id":"656daf4904e24951aa4c162135d8ad05","type":"GO_TERM","name":"serotonin receptor complex","canonical_id":"go:GO:0098665","description":"\"A protein complex that is capable of serotonin receptor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16116092]","metadata":null},{"id":"e5404016b3e8463799851ed730a06e88","type":"GO_TERM","name":"serotonin receptor signaling pathway","canonical_id":"go:GO:0007210","description":"\"The series of molecular signals generated as a consequence of a serotonin receptor binding to one of its physiological ligands.\" [GOC:mah]","metadata":null},{"id":"644f8ac9d1f34938ae8ecf42d6b6b1bd","type":"GO_TERM","name":"serotonin secretion","canonical_id":"go:GO:0001820","description":"\"The regulated release of serotonin by a cell. Serotonin (5-hydroxytryptamine, or 5-HT) is a monoamine synthesized in serotonergic neurons in the central nervous system, enterochromaffin cells in the gastrointestinal tract and some immune system cells.\" [GOC:ef, ISBN:0198506732, ISBN:0781735149]","metadata":null},{"id":"606413d625e04cb6bed61acdeb884d31","type":"GO_TERM","name":"serotonin secretion by basophil","canonical_id":"go:GO:0002556","description":"\"The regulated release of serotonin by a basophil or group of basophils.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"1f15bb83f91b469397efe160224d4d4e","type":"GO_TERM","name":"serotonin secretion by mast cell","canonical_id":"go:GO:0002552","description":"\"The regulated release of serotonin by a mast cell or group of mast cells.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"b4ed71aa9eec44cca742e28dee3ed5a3","type":"GO_TERM","name":"serotonin secretion by platelet","canonical_id":"go:GO:0002554","description":"\"The regulated release of serotonin by a platelet or group of platelets.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"0b5600ddf33046bfada4394c2d5d87d7","type":"GO_TERM","name":"serotonin secretion involved in inflammatory response","canonical_id":"go:GO:0002442","description":"\"The regulated release of serotonin by a cell as part of an inflammatory response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6650ca0d41a642d3a1f3eefd1d4ff3b0","type":"GO_TERM","name":"serotonin secretion, neurotransmission","canonical_id":"go:GO:0060096","description":"\"The regulated release of serotonin by a cell, in which released serotonin acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"80b9893202db468781c91ee1a775001d","type":"GO_TERM","name":"serotonin uptake","canonical_id":"go:GO:0051610","description":"\"The directed movement of serotonin into a cell, typically presynaptic neurons or glial cells. Serotonin (5-hydroxytryptamine) is a monoamine neurotransmitter occurring in the peripheral and central nervous systems.\" [GOC:ai]","metadata":null},{"id":"c231156d16ef42bfb0123fe2072a0f4d","type":"GO_TERM","name":"serotonin-activated cation-selective channel complex","canonical_id":"go:GO:1904602","description":"\"A protein complex which is capable of serotonin-activated cation-selective channel activity. Mainly found in pre- and postsynaptic membranes of the brain and gastrointestinal tract. Depending on its location it transports Ca2+, Mg2+, Na+ or K+. It is always a pentamer, containing at least the 5HT3A subunit forming 5HT3A homopentamers or 5HT3A/B heteropentamers. In human, 5HT3A/C, A/D and A/E heteropentamers also exist.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:16116092]","metadata":null},{"id":"4494eb0d470c409b88a7c24229d15a23","type":"GO_TERM","name":"serotonin-gated cation-selective signaling pathway","canonical_id":"go:GO:0140227","description":"\"The series of molecular signals initiated by serotonin binding to a seratonin receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex. Ends with regulation of a downstream cellular process, e.g. transcription.\" [GOC:bhm, PMID:25392484, PMID:27764665]","metadata":null},{"id":"0a6d21a837ea402b9b50ad6e4b5e17a8","type":"GO_TERM","name":"serotonin-gated chloride channel activity","canonical_id":"go:GO:0160039","description":"\"Enables the transmembrane transfer of a chloride ion by a channel that opens when the biogenic amine serotonin has been bound by the channel complex or one of its constituent parts. Serotonin (5-hydroxytryptamine) is a neurotransmitter and hormone found in vertebrates and invertebrates.\" [PMID:11100728]","metadata":null},{"id":"76c2fd26c8534ff49051868f6f940101","type":"GO_TERM","name":"serotonin-gated monoatomic cation channel activity","canonical_id":"go:GO:0022850","description":"\"Enables the transmembrane transfer of a cation by a channel that opens when serotonin has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, PMID:12867984]","metadata":null},{"id":"3615da65aeef46cf851dda93336adb83","type":"GO_TERM","name":"serotonin:sodium:chloride symporter activity","canonical_id":"go:GO:0005335","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: serotonin(out) + Na+(out) + Cl-(out) = serotonin(in) + Na+(in)+ Cl-(in).\" [PMID:21752877, PMID:22519513]","metadata":null},{"id":"ca4f66452d5b415f993f04e730b8208e","type":"GO_TERM","name":"serous membrane development","canonical_id":"go:GO:1904817","description":"\"The process whose specific outcome is the progression of a serous membrane over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:dph, GOC:TermGenie, PMID:15840053]","metadata":null},{"id":"dfd046b07f674128992b2893fb9ce558","type":"GO_TERM","name":"serpin family protein binding","canonical_id":"go:GO:0097655","description":"\"Binding to a member of the serpin protein family (serine protease inhibitors or classified inhibitor family I4). Serpins are a broadly distributed family of protease inhibitors that use a conformational change to inhibit target enzymes. They are central in controlling many important proteolytic cascades. The majority of serpins inhibit serine proteases, but serpins that inhibit caspases and papain-like cysteine proteases have also been identified. Rarely, serpins perform a non-inhibitory function; for example, several human serpins function as hormone transporters and certain serpins function as molecular chaperones or tumor suppressors.\" [GOC:mr, InterPro:IPR000215, PMID:16737556]","metadata":null},{"id":"dca8a1dc19d347ea9618f4bf69595fac","type":"DRUG","name":"serplulimab","canonical_id":"gtopdb:13796","description":null,"metadata":null},{"id":"557f10f478d745adb4b5c85ce8b44443","type":"DRUG","name":"serplulimab","canonical_id":"chembl:CHEMBL4594550","description":null,"metadata":null},{"id":"2bd79d00edc14f3bb020b22425ebd946","type":"DRUG","name":"sertaconazole","canonical_id":"mesh:C061131","description":null,"metadata":null},{"id":"519acb162a6e4c47acc78ef5bfab5423","type":"DRUG","name":"sertindole","canonical_id":"gtopdb:98","description":null,"metadata":null},{"id":"b5ce5bdb8e424b12948a7b59c95cfe8e","type":"DRUG","name":"sertindole","canonical_id":"mesh:C066304","description":null,"metadata":null},{"id":"d2dc90840cd9486b9fa417908a25fe2b","type":"DRUG","name":"sertindole","canonical_id":"chembl:CHEMBL12713","description":null,"metadata":null},{"id":"12b406d6a4a74df0b3113364f4bbe897","type":"DRUG","name":"sertraline","canonical_id":"gtopdb:4798","description":null,"metadata":null},{"id":"c95497a3c00a4884ba7c9fa6b99c47b6","type":"DRUG","name":"sertraline","canonical_id":"mesh:D020280","description":null,"metadata":null},{"id":"21f441c57c784516976549336f77ce65","type":"COMBINATION_TREATMENT","name":"sertraline + ziprasidone","canonical_id":"ctgov_combo:ctgov-combo-93af45d712070e8b","description":null,"metadata":null},{"id":"a6e756c9483a4d32a2984b00b9cf8c6e","type":"DISEASE","name":"serum lipopolysaccharide activity","canonical_id":"efo:0600064","description":null,"metadata":null},{"id":"8f41e8b372d34d7f958f5ea19f8e8f2c","type":"GO_TERM","name":"serum response element binding","canonical_id":"go:GO:0010736","description":"\"Binding to a serum response element (SRE), a short sequence with dyad symmetry found in the promoters of some of the cellular immediate-early genes, regulated by serum.\" [GOC:BHF, GOC:dph, GOC:rl, GOC:tb]","metadata":null},{"id":"0d41fdc4aa964824980467fc485337e2","type":"GO_TERM","name":"seryl-selenocysteinyl-tRNA kinase activity","canonical_id":"go:GO:0098620","description":"\"Catalysis of the reaction: Ser-tRNA(Sec) + ATP = Sep-tRNA(Sec) + ADP.\" [PMID:15317934]","metadata":null},{"id":"50415c0409f6469883e2dae12d3a2118","type":"GO_TERM","name":"seryl-tRNA aminoacylation","canonical_id":"go:GO:0006434","description":"\"The process of coupling serine to seryl-tRNA, catalyzed by seryl-tRNA synthetase. The seryl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of a serine-accetping tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"0749e49d53a940b78b919ba57b8deb13","type":"GO_TERM","name":"sesquarterpene biosynthetic process","canonical_id":"go:GO:1903193","description":"\"The chemical reactions and pathways resulting in the formation of sesquarterpene.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:21627333]","metadata":null},{"id":"234ae10afc8d4cc89b415b7aefdcb7c9","type":"GO_TERM","name":"sesquiterpene biosynthetic process","canonical_id":"go:GO:0051762","description":"\"The chemical reactions and pathways resulting in the formation of sesquiterpenes, any of a class of terpenes of the formula C15H24 or a derivative of such a terpene.\" [GOC:ai]","metadata":null},{"id":"2756468350724b15821504c95a2c3006","type":"GO_TERM","name":"sesquiterpene catabolic process","canonical_id":"go:GO:0051763","description":"\"The chemical reactions and pathways resulting in the breakdown of sesquiterpenes, any of a class of terpenes of the formula C15H24 or a derivative of such a terpene.\" [GOC:ai]","metadata":null},{"id":"c0b890f853a34c2ab16287029e5822b9","type":"GO_TERM","name":"sesquiterpene metabolic process","canonical_id":"go:GO:0051761","description":"\"The chemical reactions and pathways involving sesquiterpenes, any of a class of terpenes of the formula C15H24 or a derivative of such a terpene.\" [GOC:ai]","metadata":null},{"id":"cfa1f51bb09c45959115655da649b1c2","type":"GO_TERM","name":"sesquiterpene synthase activity","canonical_id":"go:GO:0010334","description":"\"Catalysis of the reaction: trans,trans-farnesyl diphosphate = a sesquiterpene + diphosphate. Sesquiterpenes are terpenes containing three isoprene units, i.e. 15 carbons.\" [GOC:tair_curators]","metadata":null},{"id":"dbe053ce63334ea880a094696ea771a4","type":"GO_TERM","name":"sesquiterpenoid biosynthetic process","canonical_id":"go:GO:0016106","description":"\"The chemical reactions and pathways resulting in the formation of sesquiterpenoid compounds, terpenoids with three isoprene units.\" [GOC:curators]","metadata":null},{"id":"1b44cc68737740ffac7ee1d1eb26b362","type":"GO_TERM","name":"sesquiterpenoid catabolic process","canonical_id":"go:GO:0016107","description":"\"The chemical reactions and pathways resulting in the breakdown of sesquiterpenoid compounds, terpenoids with three isoprene units.\" [GOC:curators]","metadata":null},{"id":"f432d658a2eb45c38b3f8e425625b44d","type":"GO_TERM","name":"sesquiterpenoid metabolic process","canonical_id":"go:GO:0006714","description":"\"The chemical reactions and pathways involving sesquiterpenoid compounds, terpenoids with three isoprene units.\" [ISBN:0198547684]","metadata":null},{"id":"20fe42a2f4d84dc2adf78704ee94047a","type":"GO_TERM","name":"sesquithujene synthase activity","canonical_id":"go:GO:0102304","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate(3-) = 7-epi-sesquithujene + diphosphoric acid.\" [EC:4.2.3.102, GOC:pz]","metadata":null},{"id":"265b21c199964946b6eaf94ad92e11a1","type":"DRUG","name":"setiptiline","canonical_id":"mesh:C050605","description":null,"metadata":null},{"id":"49d8c4e9219044b48e0f311dffb9d2a7","type":"GO_TERM","name":"sevenless binding","canonical_id":"go:GO:0005118","description":"\"Binding to a sevenless (sev) protein, a receptor tyrosine kinase.\" [GOC:ceb, PMID:3151175]","metadata":null},{"id":"83a827abcde842c6a93bddd6c765cbb5","type":"GO_TERM","name":"sevenless signaling pathway","canonical_id":"go:GO:0045500","description":"\"The series of molecular signals initiated by an extracellular ligand binding to sevenless (sev; a receptor tyrosine kinase) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:signaling, PMID:10771085]","metadata":null},{"id":"5daf09c9824544dda5e87302afc51f6f","type":"DISEASE","name":"severe achondroplasia-developmental delay-acanthosis nigricans syndrome","canonical_id":"mondo:0014658","description":null,"metadata":null},{"id":"b3602f6741a541cd9179eb38ae0d087b","type":"DISEASE","name":"severe aplastic anemia","canonical_id":"efo:0006927","description":null,"metadata":null},{"id":"0b98bb6453504d9cbaca3c7adf1c509b","type":"DISEASE","name":"severe combined immunodeficiency","canonical_id":"mondo:0015974","description":null,"metadata":null},{"id":"2b1660bf0f1148598d99c5cf70ff8de9","type":"DISEASE","name":"severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency","canonical_id":"mondo:0007064","description":null,"metadata":null},{"id":"2473440e4a994bd7ad7ee2ed4fa33e01","type":"DISEASE","name":"severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive","canonical_id":"mondo:0011086","description":null,"metadata":null},{"id":"ccbf7ce8bb864d7d8f3476d8bf4ddba0","type":"DISEASE","name":"severe congenital neutropenia","canonical_id":"mondo:0018542","description":null,"metadata":null},{"id":"5bc932568ddb4c10a6c82110a2033d24","type":"DISEASE","name":"severe hemophilia A","canonical_id":"mondo:0015719","description":null,"metadata":null},{"id":"5d72e3a5d0e44b32803e1bf11be080f3","type":"GO_TERM","name":"sex chromatin","canonical_id":"go:GO:0001739","description":"\"Chromatin that is part of a sex chromosome.\" [GOC:dos, ISBN:0198506732]","metadata":null},{"id":"b27c9c69f54342d8bc871b8df7035072","type":"GO_TERM","name":"sex chromosome","canonical_id":"go:GO:0000803","description":"\"A chromosome involved in sex determination.\" [GOC:elh]","metadata":null},{"id":"d0f8079b36a04a4fa3fd26e70673f5fa","type":"GO_TERM","name":"sex comb development","canonical_id":"go:GO:0045498","description":"\"The process whose specific outcome is the progression of the sex comb over time, from its formation to the mature structure. The sex combs are the male specific chaetae located on the prothoracic tarsal segment of the prothoracic leg.\" [http://fly.ebi.ac.uk]","metadata":null},{"id":"98e5a153f2744e6baac766e6b8a63cb2","type":"GO_TERM","name":"sex determination","canonical_id":"go:GO:0007530","description":"\"Any process that establishes and transmits the specification of sexual status of an individual organism.\" [ISBN:0198506732]","metadata":null},{"id":"c84947ded9be428bb6da678af88f3e01","type":"GO_TERM","name":"sex determination, establishment of X:A ratio","canonical_id":"go:GO:0007540","description":"\"The developmental process in which an organism senses the number of X chromosomes and autosomes in its genomic complement and responds to it.\" [GOC:isa_complete, GOC:mr, PMID:20622855, Wikipedia:XY_sex-determination_system]","metadata":null},{"id":"0d99f9a612934876aa527681185b1bc6","type":"GO_TERM","name":"sex determination, primary response to X:A ratio","canonical_id":"go:GO:0007541","description":"\"The developmental process in which an organism interprets its X to autosomal chromosomal complement.\" [GOC:isa_complete]","metadata":null},{"id":"18c3ddf165e34d7ca8fcf007d4934600","type":"GO_TERM","name":"sex determination, somatic-gonadal interaction","canonical_id":"go:GO:0007543","description":"\"The process that mediates the interactions between somatic cells and gonadal cells that ultimately results in the specification of sexual status of the organism.\" [GOC:isa_complete]","metadata":null},{"id":"9a125b6ec31d4d53a5218708e2d5def5","type":"GO_TERM","name":"sex differentiation","canonical_id":"go:GO:0007548","description":"\"The establishment of the sex of an organism by physical differentiation.\" [GOC:ai]","metadata":null},{"id":"3c9d4cb3b66349e18b25563cf0d44111","type":"PROTEIN","name":"sex hormone binidng globulin","canonical_id":"uniprot:P04278","description":null,"metadata":null},{"id":"59b05a3bbc5d454fa91131a9da2493f2","type":"GO_TERM","name":"sex-chromosome dosage compensation","canonical_id":"go:GO:0007549","description":"\"Compensating for the variation in the unpaired sex chromosome:autosome chromosome ratios between sexes by activation or inactivation of genes on one or both of the sex chromosomes.\" [GOC:ems, PMID:11498577, PMID:30049999, PMID:35306885]","metadata":null},{"id":"1caae359dc4e4f7d8b478c42db515ba8","type":"GO_TERM","name":"sex-specific pigmentation","canonical_id":"go:GO:0048071","description":"\"Establishment of a pattern of pigment in one sex that is not observed in the other sex.\" [GOC:jid]","metadata":null},{"id":"09f8d3e3b4504f748ae91c3e4e2bb40f","type":"GO_TERM","name":"sexine","canonical_id":"go:GO:0043673","description":"\"The outer, sculptured layer of the exine, which lies above the nexine.\" [PMID:5722147]","metadata":null},{"id":"4cd9f9a01f644ab584a35e8ff2b3d961","type":"DISEASE","name":"sexual dysfunction","canonical_id":"efo:0004714","description":null,"metadata":null},{"id":"daa6091a36f04bd79b470ff041e89f3d","type":"GO_TERM","name":"sexual macrocyst formation","canonical_id":"go:GO:0140084","description":"\"The fusion of haploid amoebae cells with matching mating types to form a larger cell, which ingests additional amoebae and forms a cellulose wall. The resulting macrocyst undergoes recombination and meiosis followed by release of haploid amoebae. An example of this process can be found in Dictyostelium discoideum.\" [PMID:16592095, PMID:20089169]","metadata":null},{"id":"cd7f5096d7574e2c9c7e3339220cab96","type":"GO_TERM","name":"sexual reproduction","canonical_id":"go:GO:0019953","description":"\"A type of reproduction that combines the genetic material of two gametes (such as a sperm or egg cell or fungal spores). The gametes have an haploid genome (with a single set of chromosomes, the product of a meiotic division) and combines with one another to produce a zygote (diploid).\" [Wikipedia:Sexual_reproduction]","metadata":null},{"id":"896c511c9005429d8adb660c99464f6a","type":"GO_TERM","name":"sexual spore wall","canonical_id":"go:GO:0097514","description":"\"A specialized envelope lying outside the cell membrane of a spore derived from a product of meiosis.\" [GOC:cjm, GOC:mah]","metadata":null},{"id":"ef747b2bc0474ebfb427a0346aadaf2c","type":"GO_TERM","name":"sexual spore wall assembly","canonical_id":"go:GO:0034294","description":"\"The aggregation, arrangement and bonding together of a set of components to form a sexual spore wall, the specialized envelope lying outside the cell membrane of a spore derived from a product of meiosis.\" [GOC:mah]","metadata":null},{"id":"1f8f54f5654746d79eb2636c41993c59","type":"GO_TERM","name":"sexual sporulation","canonical_id":"go:GO:0034293","description":"\"The formation of spores derived from the products of meiosis.\" [GOC:mah]","metadata":null},{"id":"b2848bc4a0d0403f9a6ec135d7fb046e","type":"GO_TERM","name":"sexual sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0043935","description":"\"The formation of spores derived from the products of meiosis. A cellular spore is a cell form that can be used for dissemination, for survival of adverse conditions because of its heat and desiccation resistance, and/or for reproduction.\" [GOC:pamgo_curators]","metadata":null},{"id":"223c9996a40c4c2e8625e3c96e49d45a","type":"GO_TERM","name":"sexual sporulation resulting in formation of a multicellular or syncytial spore","canonical_id":"go:GO:0075285","description":"\"The formation of multicellular or syncytial spore via septations derived from meiosis. A multicellular or syncytial spore is a structure that can be used for dissemination, for survival of adverse conditions because of its heat and desiccation resistance, and/or for reproduction.\" [GOC:pamgo_curators]","metadata":null},{"id":"2b39f6dd089c4ab1bd034b25458b116b","type":"GO_TERM","name":"shade avoidance","canonical_id":"go:GO:0009641","description":"\"Shade avoidance is a set of responses that plants display when they are subjected to the shade of another plant. It often includes elongation, altered flowering time, increased apical dominance and altered partitioning of resources. Plants are able to distinguish between the shade of an inanimate object (e.g. a rock) and the shade of another plant due to the altered balance between red and far-red light in the shade of a plant; this balance between red and far-red light is perceived by phytochrome.\" [Wikipedia:Shade_avoidance]","metadata":null},{"id":"f2cdbb9673e44933ae78f28bbd1615dc","type":"GO_TERM","name":"shamixanthone biosynthetic process","canonical_id":"go:GO:1900793","description":"\"The chemical reactions and pathways resulting in the formation of shamixanthone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"8b688dfbcee24755ad5c405d4ac7ab26","type":"GO_TERM","name":"shamixanthone catabolic process","canonical_id":"go:GO:1900792","description":"\"The chemical reactions and pathways resulting in the breakdown of shamixanthone.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"87998f3ab1744685b6bd7c424af70bb6","type":"GO_TERM","name":"shell calcification","canonical_id":"go:GO:0031215","description":"\"The precipitation of calcium carbonate onto the organic matrix of a shell, such as a mollusc shell.\" [GOC:mah, PMID:15132736]","metadata":null},{"id":"42259fb581ae4e5bbddfeb793e794044","type":"GO_TERM","name":"shelterin complex","canonical_id":"go:GO:0070187","description":"\"A nuclear telomere cap complex that is formed by the association of telomeric ssDNA- and dsDNA-binding proteins with telomeric DNA, and is involved in telomere protection and recruitment of telomerase. The complex is known to contain TERF1, TERF2, POT1, RAP1, TINF2 and ACD in mammalian cells, and Pot1, Tpz1, Rap1, Rif1, Rif2 and Taz1 in Saccharomyces. Taz1 and Rap1 (or their mammalian equivalents) form a dsDNA-binding subcomplex, Pot1 and Tpz1 form an ssDNA-binding subcomplex, and the two subcomplexes are bridged by Poz1, which acts as an effector molecule along with Ccq1.\" [GOC:expert_mf, GOC:mah, GOC:vw, PMID:18828880]","metadata":null},{"id":"110ff94ff127453ea1a3a3116adbd7da","type":"GO_TERM","name":"shelterin complex assembly","canonical_id":"go:GO:0071573","description":"\"The aggregation, arrangement and bonding together of a set of components to form a shelterin complex. A shelterin complex is a nuclear telomere cap complex that is formed by the association of telomeric ssDNA- and dsDNA-binding proteins with telomeric DNA, and is involved in telomere protection and recruitment of telomerase.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"eaa83b773ada4a3ea50734c18346af24","type":"GO_TERM","name":"shikimate 3-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0052734","description":"\"Catalysis of the reaction: shikimate + NAD+ = 3-dehydroshikimate + NADH + H+.\" [RHEA:17741]","metadata":null},{"id":"a338275656c74168a37fec5b92e265a4","type":"GO_TERM","name":"shikimate 3-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0004764","description":"\"Catalysis of the reaction: shikimate + NADP+ = 3-dehydroshikimate + NADPH + H+.\" [EC:1.1.1.25]","metadata":null},{"id":"6226364c9cd74ee9a65209b714e91ee7","type":"GO_TERM","name":"shikimate O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047172","description":"\"Catalysis of the reaction: shikimate + coumaroyl-CoA = 4-coumaroylshikimate + CoA.\" [EC:2.3.1.133, MetaCyc:2.3.1.133-RXN]","metadata":null},{"id":"8a68b912fcae44c9a6d93441eefc354c","type":"GO_TERM","name":"shikimate catabolic process","canonical_id":"go:GO:0019633","description":"\"The chemical reactions and pathways resulting in the breakdown of shikimate, (3R,4S,5R)--3,4,5-trihydroxycyclohex-1-ene-1-carboxylate, the anion of shikimic acid.\" [GOC:curators]","metadata":null},{"id":"5ba6073413f44fc3b69c16b4a324598d","type":"GO_TERM","name":"shikimate kinase activity","canonical_id":"go:GO:0004765","description":"\"Catalysis of the reaction: ATP + shikimate = 3-phosphoshikimate + ADP + 2 H+.\" [EC:2.7.1.71, RHEA:13121]","metadata":null},{"id":"5fa1597dd2ee4a7fb32f43147739ad0e","type":"GO_TERM","name":"shikimate metabolic process","canonical_id":"go:GO:0019632","description":"\"The chemical reactions and pathways involving shikimate, (3R,4S,5R)--3,4,5-trihydroxycyclohex-1-ene-1-carboxylate, the anion of shikimic acid. It is an important intermediate in the biosynthesis of aromatic amino acids.\" [GOC:sm, ISBN:0198547684]","metadata":null},{"id":"9a632a3c207b49649ff8bc02641af863","type":"GO_TERM","name":"shikimate transmembrane transport","canonical_id":"go:GO:0015733","description":"\"The process in which shikimate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"074bc32c7399414191edb416b9fd1f1b","type":"GO_TERM","name":"shikimate transmembrane transporter activity","canonical_id":"go:GO:0015530","description":"\"Enables the transfer of shikimate from one side of a membrane to the other. Shikimate is an important intermediate in the biosynthesis of aromatic amino acids.\" [GOC:ai]","metadata":null},{"id":"89073ea50862417a9ac45b20324316e7","type":"GO_TERM","name":"shikimate:proton symporter activity","canonical_id":"go:GO:0015533","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: shikimate(out) + H+(out) = shikimate(in) + H+(in).\" [TC:2.A.1.6.6]","metadata":null},{"id":"77c3697c87724c068cc5fbcf4e4d03b8","type":"GO_TERM","name":"shoot apical meristem development","canonical_id":"go:GO:1902182","description":"\"The process whose specific outcome is the progression of a shoot apical meristem over time, from its formation to the mature structure.\" [GOC:TermGenie, PMID:21496644]","metadata":null},{"id":"6fefb9e4f3e342cdbf9894a15efbd20d","type":"GO_TERM","name":"shoot axis formation","canonical_id":"go:GO:0010346","description":"\"The process that gives rise to a shoot axis. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:tb]","metadata":null},{"id":"e24c93ed11cb4d5b865ffd3c4b3813f1","type":"GO_TERM","name":"shoot organ boundary specification","canonical_id":"go:GO:0090470","description":"\"The process in which the basal boundary between the stem and both vegetative and reproductive organs are established and maintained.\" [PMID:18757555]","metadata":null},{"id":"44c6d8e591624621ab84cfe570638cc1","type":"GO_TERM","name":"shoot regeneration","canonical_id":"go:GO:0062210","description":"\"The regeneration process by which a damaged or lost shoot regrows or re-differentiates. This process may occur via de-differentiation and subsequent reprogramming of somatic cells or activation of existing undifferentiated (meristematic) cells to produce a new shoot meristem and subsequently a new shoot.\" [PMID:27143753]","metadata":null},{"id":"140765c59d18409ea9d3b4701507412b","type":"GO_TERM","name":"shoot system development","canonical_id":"go:GO:0048367","description":"\"The process whose specific outcome is the progression of the shoot system over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"0d3e8eff5ece4e52bc8179fa9bd14004","type":"GO_TERM","name":"shoot system morphogenesis","canonical_id":"go:GO:0010016","description":"\"The process in which the anatomical structures of the shoot are generated and organized. The shoot is the part of a seed plant body that is usually above ground.\" [GOC:sm, ISBN:0877797099]","metadata":null},{"id":"cda648ef6b1c4df7956d1807417b5569","type":"DISEASE","name":"short QT syndrome","canonical_id":"mondo:0000453","description":null,"metadata":null},{"id":"cfd809751a62470f9e505fb12cb05952","type":"DISEASE","name":"short bowel syndrome","canonical_id":"mondo:0015183","description":null,"metadata":null},{"id":"556818a64935413d88065be405331b7f","type":"GO_TERM","name":"short descending thin limb development","canonical_id":"go:GO:0072063","description":"\"The process whose specific outcome is the progression of the short descending thin limb over time, from its formation to the mature structure. The short descending thin limb is the descending thin limb of a short nephron that has a squamous epithelial morphology.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"6306f800cd9743199733957b29268df5","type":"GO_TERM","name":"short nephron development","canonical_id":"go:GO:0072030","description":"\"The process whose specific outcome is the progression of a short nephron over time, from its formation to the mature structure. Short nephrons are associated with mid-cortical and superficial glomeruli, are situated entirely in the outer medulla, and have no thin ascending limb.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a66e08ac743a4dd0af2cef5a98f1e5db","type":"GO_TERM","name":"short neuropeptide F receptor activity","canonical_id":"go:GO:0036400","description":"\"Combining with a short neuropeptide F and transmitting the signal within the cell to initiate a change in cell activity. Short neuropeptide F is an arthropod peptide of less than 28 residues (as small as 8-10 residues in some species) with a C-terminal RFamide or LRFamide.\" [GOC:ha, PMID:16330127, PMID:21440021]","metadata":null},{"id":"0ab42803ee69438aa4e3bef527ba6891","type":"DISEASE","name":"short stature due to GHSR deficiency","canonical_id":"mondo:0014403","description":null,"metadata":null},{"id":"acd6429ebbe243c0875e57de82d1a92c","type":"DISEASE","name":"short stature due to partial GHR deficiency","canonical_id":"mondo:0011420","description":null,"metadata":null},{"id":"720e904cb20b49c3833a6f2e2e60a9d2","type":"DISEASE","name":"short stature with nonspecific skeletal abnormalities","canonical_id":"mondo:0975810","description":null,"metadata":null},{"id":"33c3e682e9014a8a9698cdcb6c08b056","type":"GO_TERM","name":"short tract gene conversion","canonical_id":"go:GO:0035823","description":"\"A gene conversion process in which a segment of about 50-200 base pairs is transferred from the donor to the acceptor.\" [GOC:mah, PMID:16954385]","metadata":null},{"id":"336a980cf66643ec912457ec9a97a293","type":"GO_TERM","name":"short-chain 2-methyl fatty acyl-CoA dehydrogenase activity","canonical_id":"go:GO:0003853","description":"\"Catalysis of the reaction: Catalysis of the reaction: a short-chain 2-methyl fatty acyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = a short-chain (2E)-2-methyl-2-enoyl-CoA + reduced [electron-transfer flavoprotein].\" [PMID:10989435, PMID:6401712]","metadata":null},{"id":"dd2f434eb33146e7830b20e1fb882677","type":"GO_TERM","name":"short-chain carboxylesterase activity","canonical_id":"go:GO:0034338","description":"\"Catalysis of the reaction: a carboxylic ester + H2O = an alcohol + a carboxylic anion, where the carboxylic chain has 8 or fewer carbon atoms.\" [GOC:jp]","metadata":null},{"id":"b6b9058fcb744b9b9d4f33c8345c1b68","type":"GO_TERM","name":"short-chain fatty acid biosynthetic process","canonical_id":"go:GO:0051790","description":"\"The chemical reactions and pathways resulting in the formation of a short-chain fatty acid. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [Wikipedia:Fatty_acid_metabolism]","metadata":null},{"id":"63090cc53e844c22bbce4c24a9a9d865","type":"GO_TERM","name":"short-chain fatty acid catabolic process","canonical_id":"go:GO:0019626","description":"\"The chemical reactions and pathways resulting in the breakdown of a short-chain fatty acid. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [ISBN:0198506732]","metadata":null},{"id":"0cd18f08c4e842eb9e34cd42cf152800","type":"GO_TERM","name":"short-chain fatty acid metabolic process","canonical_id":"go:GO:0046459","description":"\"The chemical reactions and pathways involving a short-chain fatty acid. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [Wikipedia:Fatty_acid_metabolism]","metadata":null},{"id":"de389a5fffd14c688215500ea5478070","type":"GO_TERM","name":"short-chain fatty acid transmembrane transport","canonical_id":"go:GO:0015913","description":"\"The directed movement of short-chain fatty acids into a cell or organelle. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [GOC:ai]","metadata":null},{"id":"a5bb0c5e20f84050b4a07246a4eb8232","type":"GO_TERM","name":"short-chain fatty acid transmembrane transporter activity","canonical_id":"go:GO:0015636","description":"\"Enables the transfer of short-chain fatty acids from one side of a membrane to the other. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [GOC:mah]","metadata":null},{"id":"66b11c2baff24d98923562fd0bed030f","type":"GO_TERM","name":"short-chain fatty acid transport","canonical_id":"go:GO:0015912","description":"\"The directed movement of short-chain fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [GOC:ai]","metadata":null},{"id":"c9835574b2444fffac50a9af3e5b864c","type":"GO_TERM","name":"short-chain fatty acid-CoA ligase activity","canonical_id":"go:GO:0031955","description":"\"Catalysis of the reaction: a short-chain fatty acid + ATP + CoA = a short-chain fatty acyl-CoA + AMP + diphosphate. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [PMID:34904027, RHEA:52860]","metadata":null},{"id":"1ca209fc206d4406bdf817ead83dff3e","type":"GO_TERM","name":"short-chain fatty acyl-CoA dehydrogenase activity","canonical_id":"go:GO:0016937","description":"\"Catalysis of the reaction: a short-chain 2,3-saturated fatty acyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = a short-chain (2E)-enoyl-CoA + reduced [electron-transfer flavoprotein]. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons.\" [RHEA:47196]","metadata":null},{"id":"6c02aa951ccf4c1fb30315208d83c5e2","type":"GO_TERM","name":"short-chain fatty acyl-CoA hydrolase activity","canonical_id":"go:GO:0141126","description":"\"Catalysis of the reaction: a short-chain fatty acyl-CoA + H2O = a short fatty acid + CoA + H+. A short-chain fatty acid has an aliphatic tail of less than 6 carbons.\" [RHEA:68180]","metadata":null},{"id":"b354b0d522ff4b9bb02c01408e3b72ab","type":"GO_TERM","name":"short-chain fatty acyl-CoA oxidase activity","canonical_id":"go:GO:0120522","description":"\"Catalysis of the reaction: a short-chain 2,3-saturated fatty acyl-CoA + O2 = a short-chain (2E)-enoyl-CoA + H2O2.\" [RHEA:78859]","metadata":null},{"id":"755b0067d81b46d58e71a83bcccdd124","type":"GO_TERM","name":"short-day photoperiodism","canonical_id":"go:GO:0048572","description":"\"Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a day length that falls short of a particular duration known as the 'critical day length'. The critical day length varies between species. Although the term short-day is used, most species actually respond to the duration of the night, so that the response will occur when a period of darkness exceeds the number of hours defined by 24 hours minus the critical day length.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"2b9765b566104c6690db9e7dc4410c4a","type":"GO_TERM","name":"short-day photoperiodism, flowering","canonical_id":"go:GO:0048575","description":"\"A change from vegetative to reproductive phase as a result of detection of, or exposure to, a period of light that falls short of the critical day length. The critical day length varies between species. Although the term is short-day is used, most species actually respond to the duration of the night, so that the response will occur when a period of darkness exceeds the number of hours defined by 24 minus the critical day length.\" [GOC:jid, GOC:pj, ISBN:0582015952, ISBN:0697037754, ISBN:0709408862]","metadata":null},{"id":"449223107ea048cb89ccf352603c2bc3","type":"GO_TERM","name":"short-term memory","canonical_id":"go:GO:0007614","description":"\"The memory process that deals with the storage, retrieval and modification of information received a short time (up to about 30 minutes) ago. This type of memory is typically dependent on direct, transient effects of second messenger activation.\" [http://hebb.mit.edu/courses/9.03/lecture4.html, ISBN:0582227089]","metadata":null},{"id":"f131bbffdf0f4fa7b9fb462b12308fb6","type":"GO_TERM","name":"short-term synaptic potentiation","canonical_id":"go:GO:1990926","description":"\"The process by which synaptic transmission, induced by the arrival of a spike (action potential) at a synapse, acts to increase the amount of neurotransmitter released in response to the arrival of subsequent spikes. This effect is seen when a train of closely space spikes arrives at a synapse with a low initial release probability. It occurs in a timeframe of tens to hundreds of milliseconds.\" [GOC:dos, GOC:sp, ISBN:9780071120005, PMID:11826273, PMID:26738595]","metadata":null},{"id":"e4829286c04e49c093c5e954d25981e4","type":"GO_TERM","name":"siRNA 3'-end processing","canonical_id":"go:GO:1990432","description":"\"The process of forming the mature 3' end of a siRNA molecule.\" [PMID:24095277]","metadata":null},{"id":"9d4945d390924c918d549183c2562dab","type":"GO_TERM","name":"siRNA binding","canonical_id":"go:GO:0035197","description":"\"Binding to a small interfering RNA, a 21-23 nucleotide RNA that is processed from double stranded RNA (dsRNA) by an RNAse enzyme.\" [PMID:15066275, PMID:15066283]","metadata":null},{"id":"c5de0fc768be4545a8bd2f99f1b4faac","type":"GO_TERM","name":"siRNA catabolic process","canonical_id":"go:GO:0140746","description":"\"The chemical reactions and pathways resulting in the breakdown of small interfering RNA transcripts (siRNAs).\" [PMID:25928405]","metadata":null},{"id":"d2e6f0dab99f486395bccfa0e9010995","type":"GO_TERM","name":"siRNA processing","canonical_id":"go:GO:0030422","description":"\"A process leading to the generation of a functional small interfering RNA (siRNA). Includes the cleavage of double-stranded RNA to form small interfering RNA molecules (siRNAs) of 21-23 nucleotides. May also include amplification of the siRNA by RNA-directed RNA polymerase.\" [GOC:mah, PMID:11524674, PMID:19239886, PMID:20687832]","metadata":null},{"id":"03dd7b7aaa4b40ed90f48bf2b35502ee","type":"GO_TERM","name":"siRNA transcription","canonical_id":"go:GO:0140745","description":"\"The transcription of a small interfering RNA from an RNA template.\" [PMID:23001036]","metadata":null},{"id":"38e27166c9e945c4a957301eb0879af7","type":"GO_TERM","name":"siRNA-independent facultative heterochromatin formation","canonical_id":"go:GO:1902794","description":"\"The formation of facultative heterochromatin into a heterochromatin domain, enriched in histone H3 methylated on lysine 9 (H3K9me), by a process independent of small interfering RNAs.\" [PMID:22144463, PMID:24210919]","metadata":null},{"id":"6831e37051f1466aade0c4d83902c6c4","type":"GO_TERM","name":"siRNA-mediated facultative heterochromatin formation","canonical_id":"go:GO:1902795","description":"\"The formation of facultative heterochromatin into a heterochromatin domain, enriched in histone H3 methylated on lysine 9 (H3K9me), by a process mediated by a small interfering RNA.\" [GO_REF:0000079, GOC:TermGenie, PMID:23151475, PMID:24210919]","metadata":null},{"id":"a054a01508e9480ab62e41589fac7dc8","type":"GO_TERM","name":"siRNA-mediated gene silencing by inhibition of translation","canonical_id":"go:GO:0070549","description":"\"An siRNA-mediated post-transcriptional gene silencing pathway that blocks the translation of target mRNAs into proteins. Once incorporated into a RNA-induced silencing complex (RISC), an siRNA will typically mediate repression of translation if the siRNA perfectly complements elements located in the 3' untranslated region of target mRNAs.\" [GOC:mah, PMID:18771919]","metadata":null},{"id":"a2680212c14f4339994ffd256dab0301","type":"GO_TERM","name":"siRNA-mediated gene silencing by mRNA destabilization","canonical_id":"go:GO:0090625","description":"\"An siRNA-mediated post-transcriptional gene silencing pathway in which small interfering RNAs (siRNAs) direct the cleavage of target mRNAs. Once incorporated into a RNA-induced silencing complex (RISC), an siRNA will typically direct cleavage by base pairing with perfect or near-perfect complementarity to the target mRNA.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:15260970]","metadata":null},{"id":"a4efb918eb3f4d5a941f82ba2a842f89","type":"GO_TERM","name":"siRNA-mediated heterochromatin formation","canonical_id":"go:GO:0141194","description":"\"The formation of heterochromatin into a heterochromatin domain by a process mediated by a small interfering siRNA.\" [GOC:ha, GOC:pg]","metadata":null},{"id":"53ebb9fc7edc4cf98a76ef6379186db7","type":"GO_TERM","name":"siRNA-mediated long-distance post-transcriptional gene silencing","canonical_id":"go:GO:0010495","description":"\"An siRNA-mediated posttranscriptional gene silencing pathway in which small interfering RNAs (siRNAs) direct the cleavage of target mRNAs, and in which the silencing signal originates in one tissue and occurs in a different tissue.\" [GOC:dph, GOC:tb, PMID:11590235, PMID:17785412]","metadata":null},{"id":"db648f18cf0644fb9398c21b6b8dccb2","type":"GO_TERM","name":"siRNA-mediated pericentric heterochromatin formation","canonical_id":"go:GO:0140727","description":"\"The formation of pericentric heterochromatin by a process mediated by a small interfering RNA (siRNA).\" [PMID:15289661]","metadata":null},{"id":"ca2f0f7903a34ed88c3fe990b8698b02","type":"GO_TERM","name":"siRNA-mediated post-transcriptional gene silencing","canonical_id":"go:GO:0140766","description":"\"A post-transcriptional gene silencing pathway in which small interfering RNAs (siRNAs) elicit silencing of specific target genes. siRNAs are 21-23 nucleotide RNA duplexes that are fully complementary to their target mRNA. siRNAs can be exported and act in other cells, including in germline cells. Once incorporated into a RNA-induced silencing complex (RISC), siRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: endonucleolytic cleavage of the mRNA or mRNA translational repression. siRNAs are present in lower animals and plants, but not found in mammals; whereas miRNAs are present in all the animals and in plants.\" [PMID:26372022]","metadata":null},{"id":"36be0027fac64d278a3fe6363ed803c2","type":"GO_TERM","name":"siRNA-mediated silent mating type cassette region heterochromatin formation","canonical_id":"go:GO:0140185","description":"\"The formation of heterochromatin into a heterochromatin domain by a process mediated by a small interfering siRNA at the silent mating-type loci.\" [PMID:39747188]","metadata":null},{"id":"ce6d476ba53b45b1b80d01531e22103f","type":"GO_TERM","name":"sialate 4-O-acetylesterase activity","canonical_id":"go:GO:0106331","description":"\"Catalysis of the reaction: H2O + N-acetyl-4-O-acetylneuraminate = acetate + H+ + N-acetylneuraminate.\" [PMID:22291594, RHEA:25564]","metadata":null},{"id":"fb3c595653674b1a8dbc75ace8471cfc","type":"GO_TERM","name":"sialate 9-O-acetylesterase activity","canonical_id":"go:GO:0106330","description":"\"Catalysis of the reaction: H2O + N-acetyl-9-O-acetylneuraminate = acetate + H+ + N-acetylneuraminate.\" [PMID:22291594, RHEA:22600]","metadata":null},{"id":"1c75edf3e2c844aeb6b7517e0d76408d","type":"GO_TERM","name":"sialate O-acetylesterase activity","canonical_id":"go:GO:0001681","description":"\"Catalysis of the reaction: N-acetyl-O-acetylneuraminate (free or glycosidically bound) + H2O = N-acetylneuraminate + acetate.\" [EC:3.1.1.53, PMID:1991039]","metadata":null},{"id":"3b6beca0e9e744eca0e83a8aa01ab211","type":"GO_TERM","name":"sialate:monoatomic cation symporter activity","canonical_id":"go:GO:0015306","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sialate(out) + cation(out) = sialate(in) + cation(in).\" [TC:2.A.1.14.10]","metadata":null},{"id":"128d74277a694907af432febe28b3c30","type":"GO_TERM","name":"sialic acid binding","canonical_id":"go:GO:0033691","description":"\"Binding to a sialic acid, a N- or O- substituted derivative of neuraminic acid, a nine carbon monosaccharide. Sialic acids often occur in polysaccharides, glycoproteins, and glycolipids in animals and bacteria.\" [GOC:add, ISBN:9780721601465]","metadata":null},{"id":"286e1c9731bd4e51aa21844e4f28e8b0","type":"GO_TERM","name":"sialic acid transmembrane transporter activity","canonical_id":"go:GO:0015136","description":"\"Enables the transfer of sialic acid from one side of a membrane to the other.\" [GOC:jl, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"20a50b119a01458499b49c0c08940706","type":"GO_TERM","name":"sialic acid transport","canonical_id":"go:GO:0015739","description":"\"The directed movement of sialic acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"cc83115365104b2b903969f3376a3a3d","type":"GO_TERM","name":"sialic acid:proton symporter activity","canonical_id":"go:GO:0015538","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sialate(out) + H+(out) = sialate(in) + H+(in).\" [TC:2.A.1.12.1]","metadata":null},{"id":"e8024f74e2a14831bb5915cb9b5dc4a8","type":"GO_TERM","name":"sialylation","canonical_id":"go:GO:0097503","description":"\"The covalent attachment of sialic acid to a substrate molecule.\" [GOC:cjm]","metadata":null},{"id":"fad2ffdffeda4a1d967689edfc7f7b19","type":"GO_TERM","name":"sialyltransferase activity","canonical_id":"go:GO:0008373","description":"\"Catalysis of the transfer of sialic acid to an acceptor molecule, typically the terminal portions of the sialylated glycolipids (gangliosides) or to the N- or O-linked sugar chains of glycoproteins.\" [GOC:cjm, PMID:26192491]","metadata":null},{"id":"b3c18ccb6fc24a668dd12a308eea7b65","type":"DRUG","name":"sibutramine","canonical_id":"gtopdb:2586","description":null,"metadata":null},{"id":"ae47248ecd5d4a77ad3641fc2e14625b","type":"DRUG","name":"sibutramine","canonical_id":"mesh:C058254","description":null,"metadata":null},{"id":"d69f83e9260b46739c07fca697b98610","type":"COMBINATION_TREATMENT","name":"sibutramine + trandolapril","canonical_id":"ctgov_combo:ctgov-combo-1213b0b9b76792cb","description":null,"metadata":null},{"id":"83b336a7df89439881fbb35637cd08bc","type":"DISEASE","name":"sick sinus syndrome 1","canonical_id":"mondo:0024562","description":null,"metadata":null},{"id":"60972360eaa3470f85f67f5dd2bb9ee9","type":"DISEASE","name":"sickle cell disease","canonical_id":"mondo:0011382","description":null,"metadata":null},{"id":"a96587b9efd949c5ba4364c405408c65","type":"GO_TERM","name":"side of membrane","canonical_id":"go:GO:0098552","description":"\"A cellular component consisting of one leaflet of a membrane bilayer and any protein embedded or anchored in it or attached to its surface.\" [GOC:dos]","metadata":null},{"id":"80242afbdbd34127bc06ba760c04aee1","type":"GO_TERM","name":"sideretin biosynthesis","canonical_id":"go:GO:0106146","description":"\"The chemical reactions and pathways resulting in the formation of sideretin.\" [GOC:lr, PMID:29581584]","metadata":null},{"id":"f979d079f11346fdac54fe1bb94480bd","type":"GO_TERM","name":"siderophore biosynthetic process","canonical_id":"go:GO:0019290","description":"\"The chemical reactions and pathways resulting in the formation of siderophores, low molecular weight Fe(III)-chelating substances made by aerobic or facultatively anaerobic bacteria, especially when growing under iron deficient conditions. The complexes of Fe(3+)-siderophores have very high stability constants and are taken up by specific transport systems by microorganisms; the subsequent release of iron requires enzymatic action.\" [PMID:20376388]","metadata":null},{"id":"a64655059dc44957b8ff3f787a048dcf","type":"GO_TERM","name":"siderophore catabolic process","canonical_id":"go:GO:0046215","description":"\"The chemical reactions and pathways resulting in the breakdown of siderophores, low molecular weight Fe(III)-chelating substances made by aerobic or facultatively anaerobic bacteria, especially when growing under iron deficient conditions. The complexes of Fe(3+)-siderophores have very high stability constants and are taken up by specific transport systems by microorganisms; the subsequent release of iron requires enzymatic action.\" [GOC:ai]","metadata":null},{"id":"dd35c76ca02340d4802fc2c2bba83419","type":"GO_TERM","name":"siderophore metabolic process","canonical_id":"go:GO:0009237","description":"\"The chemical reactions and pathways involving siderophores, low molecular weight Fe(III)-chelating substances made by aerobic or facultatively anaerobic bacteria, especially when growing under iron deficient conditions. The complexes of Fe(3+)-siderophores have very high stability constants and are taken up by specific transport systems by microorganisms; the subsequent release of iron requires enzymatic action.\" [ISBN:0198547684]","metadata":null},{"id":"fc238f2eedb84122a0b2f39822695fb1","type":"GO_TERM","name":"siderophore transmembrane transport","canonical_id":"go:GO:0044718","description":"\"The directed movement of siderophores, low molecular weight Fe(III)-chelating substances, from one side of a membrane to the other, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"4e4daeb6e9d64e33ae02d6331bee72dc","type":"GO_TERM","name":"siderophore transport","canonical_id":"go:GO:0015891","description":"\"The directed movement of siderophores, low molecular weight Fe(III)-chelating substances, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"5a02b56fdc9648fa9497a3ee858f6298","type":"GO_TERM","name":"siderophore uptake transmembrane transporter activity","canonical_id":"go:GO:0015344","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: siderophore-iron(ferrioxamine)(out) + H+(out) = siderophore-iron(ferrioxamine)(in) + H+(in).\" [TC:2.A.1.16.1]","metadata":null},{"id":"e91a8f8eec3a44cdb09e5c7e643de88a","type":"GO_TERM","name":"siderophore-dependent iron import pathway","canonical_id":"go:GO:0180060","description":"\"A process in which iron siderophores (low-molecular-weight, high-affinity iron-chelating compounds) are exported to scavenge iron and the iron-loaded siderophores imported back into the cell by transmembrane transport or endocytosis.\" [GOC:vw]","metadata":null},{"id":"a70f919154384061bb25b0a9bc59229e","type":"GO_TERM","name":"siderophore-iron import into cell","canonical_id":"go:GO:0033214","description":"\"A process in which iron (Fe3+) is solubilized by ferric iron-specific chelators, known as siderophores is imported into the cell by transmembrane transport or endocytosis.\" [GOC:vw, PMID:16963626]","metadata":null},{"id":"8df65884390044a6b49dfdc0524f77c7","type":"GO_TERM","name":"siderophore-iron transmembrane transporter activity","canonical_id":"go:GO:0015343","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: siderophore-iron(out) + H+(out) = siderophore-iron(in) + H+(in).\" [PMID:20376388, PMID:31748738]","metadata":null},{"id":"72660a535f664cc7bd6dd181b9e108cf","type":"GO_TERM","name":"sieve area","canonical_id":"go:GO:0097217","description":"\"A pit-like area in the cell wall of a sieve element; contains pores lined with callose and occupied by strands of protoplasmic material that interconnect the protoplasts of contiguous sieve elements.\" [ISBN:0471738433, POC:curators]","metadata":null},{"id":"95dadc66e6a3415ea8c2884c059982c3","type":"GO_TERM","name":"sieve cell differentiation","canonical_id":"go:GO:0048756","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a sieve cell. A sieve cell is a type of sieve element that has relatively undifferentiated sieve areas (with narrow pores). The sieve areas are rather uniform in structure on all walls; that is, there are no sieve plates. Typical of gymnosperms and lower vascular plants. The sieve element is the cell in the phloem tissue concerned with mainly longitudinal conduction of food materials.\" [GOC:jid, PO:0025415, POC:curators]","metadata":null},{"id":"52c096b113914c39bb9fabf8131b7216","type":"GO_TERM","name":"sieve element differentiation","canonical_id":"go:GO:0090603","description":"\"The process whereby a relatively unspecialized cell acquires specialized features of a sieve element.\" [GOC:tb]","metadata":null},{"id":"4a5aa877bec2426b90e0205c950a1bcf","type":"GO_TERM","name":"sieve element enucleation","canonical_id":"go:GO:0090602","description":"\"The process in which nucleated precursor cells lose their nucleus as part of sieve element differentiation. The nuclear contents are released and degraded in the cytoplasm at the same time as other organelles are rearranged and the cytosol is degraded.\" [GOC:tb, PMID:25081480]","metadata":null},{"id":"d5b214319910496f81a909138ec5a55d","type":"GO_TERM","name":"sieve plate","canonical_id":"go:GO:0097218","description":"\"A part of the cell wall of a sieve tube member that bears one or more highly specialized sieve areas.\" [ISBN:0471738433, POC:curators]","metadata":null},{"id":"da57722fcaf44bdc86724c7b6c08fa31","type":"GO_TERM","name":"sigma factor activity","canonical_id":"go:GO:0016987","description":"\"Sigma factors act as the promoter specificity subunit of eubacterial and plant plastid multisubunit RNA polymerases, whose core subunit composition is often described as alpha(2)-beta-beta-prime. Although sigma does not bind DNA on its own, when combined with the core to form the holoenzyme, the sigma factor binds specifically to promoter elements. The sigma subunit is released once elongation begins.\" [GOC:txnOH-2018]","metadata":null},{"id":"952f3c9592cf4d10b05b7cb97b83e8fa","type":"GO_TERM","name":"sigma factor antagonist activity","canonical_id":"go:GO:0016989","description":"\"The function of binding to a sigma factor and stopping, preventing or reducing the rate of its transcriptional activity.\" [GOC:jl, GOC:txnOH, Wikipedia:Anti-sigma_factors]","metadata":null},{"id":"2e0bb53f14ef4898a240ab241cb06e1b","type":"GO_TERM","name":"sigma factor antagonist complex","canonical_id":"go:GO:1903865","description":"\"A protein complex which is capable of sigma factor antagonist activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:23687042]","metadata":null},{"id":"e695760c6c774dfab08f5d7dbe3c0de8","type":"GO_TERM","name":"signal clustering","canonical_id":"go:GO:1990256","description":"\"Grouping of multiple copies of a signal at a cellular location. May promote receptor clustering and alter the signal transduction response.\" [GOC:als, PMID:12011072, PMID:15603739]","metadata":null},{"id":"227ed15b8aa04f98971874eff0fac3e0","type":"GO_TERM","name":"signal complex assembly","canonical_id":"go:GO:0007172","description":"\"The aggregation, arrangement and bonding together of a set of components to form a complex capable of relaying a signal within a cell.\" [GOC:bf, GOC:signaling, PMID:9646862]","metadata":null},{"id":"624cf4c12ab440f09ab336316600af45","type":"GO_TERM","name":"signal peptidase activity","canonical_id":"go:GO:0009003","description":"\"An endopeptidase that cleaves a hydrophobic, N-terminal signal or leader sequences from mitochondrial, secreted and periplasmic proteins.\" [GOC:vw, PMID:12191769, PMID:28065271]","metadata":null},{"id":"b76f25de0d464510a8b88e4052bd6354","type":"GO_TERM","name":"signal peptidase complex","canonical_id":"go:GO:0005787","description":"\"A protein complex that is located in the endoplasmic reticulum membrane and cleaves the signal sequence from precursor proteins following their transport out of the cytoplasmic space.\" [GOC:sgd_curators, PMID:1846444, PMID:7615509]","metadata":null},{"id":"9c9d0539409041859dd7809edfb9259b","type":"GO_TERM","name":"signal recognition particle","canonical_id":"go:GO:0048500","description":"\"A complex of protein and RNA which facilitates translocation of proteins across membranes.\" [GOC:mlg]","metadata":null},{"id":"93bee9112437469bb1165e8cb9a058d5","type":"GO_TERM","name":"signal recognition particle binding","canonical_id":"go:GO:0005047","description":"\"Binding to a signal recognition particle.\" [ISBN:0198506732]","metadata":null},{"id":"34d5ba0a23624b03837c79bd5e75d895","type":"GO_TERM","name":"signal recognition particle receptor complex","canonical_id":"go:GO:0005785","description":"\"A transmembrane heterodimeric protein located in the membrane of the rough endoplasmic reticulum. Both subunits contain GTPase domains with which signal recognition particle interacts. In the presence of GTP and SRP receptor, SRP is released from the ribosome-nascent chain complex.\" [ISBN:0198506732]","metadata":null},{"id":"0b106ea2bcec41839d1e6ae807622bc0","type":"GO_TERM","name":"signal recognition particle, chloroplast targeting","canonical_id":"go:GO:0080085","description":"\"A complex consisting of a protein and RNA component which binds the signal sequence of some proteins and facilitates their export to the chloroplast.\" [PMID:17513500]","metadata":null},{"id":"aaba8dc7f7df42ba88a74256578fe316","type":"GO_TERM","name":"signal recognition particle, endoplasmic reticulum targeting","canonical_id":"go:GO:0005786","description":"\"A ribonucleoprotein particle of 325 kDa composed of a 7S (300 nucleotide) RNA molecule and a complex of six different polypeptides. This binds both to the N-terminal signal peptide for proteins destined for the endoplasmic reticulum as they emerge from the large ribosomal subunit and also to the ribosome. This binding arrests further translation thereby preventing the proteins from being released into the cytosol. The SRP-ribosome complex then diffuses to the endoplasmic reticulum where it is bound to the signal recognition particle receptor, which allows resumption of protein synthesis and facilitates the passage of the growing polypeptide chain through the translocon. Through a process involving GTP hydrolysis, the SRP-SRP receptor complex dissociates and SRP returns to the cytosol. Of the six polypeptides of SRP the 54 kDa subunit (SRP54) is the central player. It contains an N-terminal GTPase domain and a C-terminal domain that binds directly to the signal peptide and the SRP RNA. Examples of this component are found in Mus musculus, Saccharomyces cerevisiae and Arabidopsis thaliana.\" [GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"1f22a64af9714d32a8a446551ace4639","type":"GO_TERM","name":"signal recognition particle, plasma membrane targeting","canonical_id":"go:GO:0048501","description":"\"A complex consisting of a protein and RNA component which binds the signal sequence of some proteins and facilitates their export to or across the plasma membrane.\" [GOC:mlg, GOC:mtg_sensu]","metadata":null},{"id":"7296444c08024bacb5e5d2d98cee798d","type":"GO_TERM","name":"signal release","canonical_id":"go:GO:0023061","description":"\"The process in which a signal is secreted or discharged into the extracellular medium from a cellular source.\" [GOC:mtg_signal]","metadata":null},{"id":"e0522c9c277f4b23a1ab4f68872a4b14","type":"GO_TERM","name":"signal release from synapse","canonical_id":"go:GO:0099643","description":"\"Any signal release from a synapse.\" [GOC:dos]","metadata":null},{"id":"c9e413b413304b188bc8fc2141d205ab","type":"GO_TERM","name":"signal sequence receptor activity","canonical_id":"go:GO:0005048","description":"\"Binding to a signal sequence, a short stretch of amino acids found in a protein that acts as a signal for its proper localization in the cell.\" [GOC:curators]","metadata":null},{"id":"1b401997479c442ea46de162625d2bf6","type":"GO_TERM","name":"signal transduction","canonical_id":"go:GO:0007165","description":"\"The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.\" [GOC:curators, GOC:mtg_signaling_feb11]","metadata":null},{"id":"a841f82cd7f74cf78adfa3f12421654f","type":"GO_TERM","name":"signal transduction by p53 class mediator","canonical_id":"go:GO:0072331","description":"\"An intracellular signaling process that is induced by the cell cycle regulator phosphoprotein p53 or an equivalent protein.\" [GOC:mah]","metadata":null},{"id":"37c1f2ca3fd349cfa1fd3ceb1b2e080b","type":"GO_TERM","name":"signal transduction in absence of ligand","canonical_id":"go:GO:0038034","description":"\"The series of molecular signals initiated by the absence of a ligand or the withdrawal of a ligand from a receptor.\" [GOC:al, GOC:ppm, GOC:pr, PMID:15044679]","metadata":null},{"id":"f00bb05678ff472498a86c89ca38b5d5","type":"GO_TERM","name":"signal transduction in response to DNA damage","canonical_id":"go:GO:0042770","description":"\"A cascade of processes induced by the detection of DNA damage within a cell.\" [GOC:curators]","metadata":null},{"id":"f961344455874b49b7828bc0a9d83b93","type":"GO_TERM","name":"signal transduction involved in cellular response to ammonium ion","canonical_id":"go:GO:1903831","description":"\"Any signal transduction that is involved in cellular response to ammonium ion.\" [GO_REF:0000060, GOC:TermGenie, PMID:16297994]","metadata":null},{"id":"ccdf6490e5cb415b9085b0ac507f279f","type":"GO_TERM","name":"signal transduction involved in filamentous growth","canonical_id":"go:GO:0001402","description":"\"Relaying of environmental signals promoting filamentous growth.\" [GOC:mcc, PMID:9728395]","metadata":null},{"id":"4bc38b5d70824d089e93ca9098313adb","type":"GO_TERM","name":"signal transduction involved in regulation of gene expression","canonical_id":"go:GO:0023019","description":"\"Any process that modulates the frequency, rate or extent of gene expression as a consequence of a process in which a signal is released and/or conveyed from one location to another.\" [GOC:mtg_signal]","metadata":null},{"id":"32a993f36a5f41ad880060505121a423","type":"GO_TERM","name":"signaling","canonical_id":"go:GO:0023052","description":"\"The entirety of a process in which information is transmitted within a biological system. This process begins with an active signal and ends when a cellular response has been triggered.\" [GOC:mtg_signal, GOC:mtg_signaling_feb11, GOC:signaling]","metadata":null},{"id":"de8552d22970410db847534fe571be29","type":"GO_TERM","name":"signaling adaptor activity","canonical_id":"go:GO:0035591","description":"\"The binding activity of a molecule that brings together two or more molecules in a signaling pathway, permitting those molecules to function in a coordinated way. Adaptor molecules themselves do not have catalytic activity.\" [GOC:bf, PMID:19104498]","metadata":null},{"id":"f058338a9a7545b085a430aeea82f34a","type":"GO_TERM","name":"signaling receptor activator activity","canonical_id":"go:GO:0030546","description":"\"The function of interacting (directly or indirectly) with receptors such that the proportion of receptors in the active form is increased.\" [GOC:ceb]","metadata":null},{"id":"4bf4b2d7293c4307ba514ec04e78f4c4","type":"GO_TERM","name":"signaling receptor activity","canonical_id":"go:GO:0038023","description":"\"Receiving a signal and transmitting it in the cell to initiate a change in cell activity. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.\" [GOC:bf, GOC:signaling]","metadata":null},{"id":"05f6810a8e6a4d139f8d3fab7f6202ae","type":"GO_TERM","name":"signaling receptor binding","canonical_id":"go:GO:0005102","description":"\"Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.\" [GOC:bf, GOC:ceb, ISBN:0198506732]","metadata":null},{"id":"5df9323415b94f96a5360d1d86522400","type":"GO_TERM","name":"signaling receptor complex","canonical_id":"go:GO:0043235","description":"\"Any protein complex that binds a signaling molecule such as a hormone, neurotransmitter, molecular pattern recognition receptor (PAMPs and DAMPS), or an intracellular messenger to initiate a change in cell function.\" [GOC:curators]","metadata":null},{"id":"95e208516771415492177495252d5a99","type":"GO_TERM","name":"signaling receptor complex adaptor activity","canonical_id":"go:GO:0030159","description":"\"The binding activity of a molecule that provides a physical support for the assembly of a multiprotein receptor signaling complex.\" [GOC:mah]","metadata":null},{"id":"6e2d9fbec5a24e8bb21deb9595ed708c","type":"GO_TERM","name":"signaling receptor inhibitor activity","canonical_id":"go:GO:0030547","description":"\"Binds to and modulates the activity of a signaling receptor.\" [GOC:ceb]","metadata":null},{"id":"a44c8fa741c44d25a28a9a39a901d002","type":"GO_TERM","name":"signaling receptor ligand precursor processing","canonical_id":"go:GO:0140448","description":"\"The cleavage of a peptide bond in a precursor form of a signaling receptor ligand, resulting in the mature (active) form of the ligand.\" [PMID:29247995]","metadata":null},{"id":"f5db67ad647446c79aa5c7508217b9a6","type":"GO_TERM","name":"signaling receptor regulator activity","canonical_id":"go:GO:0030545","description":"\"Binds to and modulates the activity of a receptor.\" [GOC:ceb]","metadata":null},{"id":"d5f2906929ee4517bf9bfd0e1c0dcfda","type":"DRUG","name":"sildenafil","canonical_id":"gtopdb:4743","description":null,"metadata":null},{"id":"f44532aa1a624b7fb532b9a90e41d2b5","type":"DRUG","name":"sildenafil","canonical_id":"mesh:D000068677","description":null,"metadata":null},{"id":"5ca58a30d8004522af34ba74c03b6e40","type":"COMBINATION_TREATMENT","name":"sildenafil + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-d2a4f347a9f71697","description":null,"metadata":null},{"id":"3f77c8c4c07244e186be4a135091c352","type":"COMBINATION_TREATMENT","name":"sildenafil + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-29955055f675321f","description":null,"metadata":null},{"id":"ae7fa2192ca74c4b9e84be6baaaa8572","type":"COMBINATION_TREATMENT","name":"sildenafil + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-5006f5a477e74c51","description":null,"metadata":null},{"id":"586e072db758472b987caf2008bf5032","type":"GO_TERM","name":"silent mating-type cassette heterochromatin formation","canonical_id":"go:GO:0030466","description":"\"Repression of transcription at silent mating-type loci by alteration of the structure of chromatin.\" [GOC:mcc]","metadata":null},{"id":"f9a36d47c555458392dae49a1181865a","type":"GO_TERM","name":"silicate transmembrane transporter activity","canonical_id":"go:GO:0015115","description":"\"Enables the transfer of silicates from one side of a membrane to the other. Silicates are the salts of silicic acids, and are usually composed of silicon and oxygen (Si[x]O[y]), one or more metals, and possibly hydrogen. Types of silicate include unisilicates, metasilicates and hydrous silicates.\" [GOC:ai]","metadata":null},{"id":"e15c1a3e372047ebb328f4d8db60c8be","type":"GO_TERM","name":"silicic acid import across plasma membrane","canonical_id":"go:GO:0015708","description":"\"The directed movement of silicates from outside of a cell, across the plasma membrane and into the cytosol. Silicates are the salts of silicic acids, and are usually composed of silicon and oxygen (Si[x]O[y]), one or more metals, and possibly hydrogen. Types of silicate include unisilicates, metasilicates and hydrous silicates.\" [GOC:ai, GOC:krc, PMID:16572174]","metadata":null},{"id":"d80ef9b64e664b218c067a9ab97c32ff","type":"GO_TERM","name":"silicon efflux transmembrane transporter activity","canonical_id":"go:GO:0032523","description":"\"Enables the transfer of silicon from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mah, PMID:17625566]","metadata":null},{"id":"1e1f6703877a47ffa660160c453ef030","type":"DRUG","name":"silodosin","canonical_id":"gtopdb:493","description":null,"metadata":null},{"id":"c95c4f605cc94c758f7387576b7e0d17","type":"DRUG","name":"silodosin","canonical_id":"chembl:CHEMBL24778","description":null,"metadata":null},{"id":"088b962a82004747948e6fdf500152cf","type":"COMBINATION_TREATMENT","name":"silodosin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-5c65b65533b65120","description":null,"metadata":null},{"id":"6e5ecb68b5f8449b94826a5f80832c5b","type":"COMBINATION_TREATMENT","name":"silodosin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-883e60b8e3d1500b","description":null,"metadata":null},{"id":"6233313fa1804d98841f87cd249ef6b1","type":"COMBINATION_TREATMENT","name":"silodosin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-96b9aca73d2b438e","description":null,"metadata":null},{"id":"743a5b8640f741958af06154b00eb778","type":"COMBINATION_TREATMENT","name":"silodosin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-c03c900460098a04","description":null,"metadata":null},{"id":"787709503997430fbfbd5a9fbb1bee20","type":"COMBINATION_TREATMENT","name":"silodosin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-13c5da95bebd2594","description":null,"metadata":null},{"id":"a957937186904156985ccfba08461073","type":"DRUG","name":"siltuximab","canonical_id":"gtopdb:7396","description":null,"metadata":null},{"id":"9e46711c78bd48ada38f090a3a39a259","type":"DRUG","name":"siltuximab","canonical_id":"chembl:CHEMBL1743070","description":null,"metadata":null},{"id":"b23e3484567841de86607a7d9f685222","type":"GO_TERM","name":"silver ion transmembrane transport","canonical_id":"go:GO:1902601","description":"\"The directed movement of silver (Ag+) ions across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"2d2a4cabf9e04d8b9a9398488a0cde09","type":"GO_TERM","name":"silver ion transmembrane transporter activity","canonical_id":"go:GO:0015080","description":"\"Enables the transfer of silver (Ag+) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"8deda1f0fa7c4f8c99e42d9a5d65d570","type":"GO_TERM","name":"silver ion transmembrane transporter complex","canonical_id":"go:GO:1903114","description":"\"A protein complex which is capable of silver ion transmembrane transporter activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:11283292]","metadata":null},{"id":"7f2dc960ab53488d8b0746f36065079a","type":"GO_TERM","name":"silver ion transport","canonical_id":"go:GO:0015673","description":"\"The directed movement of silver (Ag+) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"24785c654ddd4776abc6a1fb311411b6","type":"DRUG","name":"simeprevir","canonical_id":"gtopdb:7367","description":null,"metadata":null},{"id":"69c561c62f014549b2bb128bb688bcd9","type":"DRUG","name":"simeprevir","canonical_id":"mesh:D000069616","description":null,"metadata":null},{"id":"30c705b4abbb426fa3c4916fc522d0ab","type":"GO_TERM","name":"simple leaf morphogenesis","canonical_id":"go:GO:0060776","description":"\"The leaf morphogenesis process which results in the shaping of a simple leaf. A simple leaf is a leaf in which the lamina is undivided.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"5d00f8f62c1646399f457b0e2364eb78","type":"GO_TERM","name":"simple sieve plate","canonical_id":"go:GO:0097220","description":"\"A sieve plate that contains a single specialized sieve area.\" [ISBN:0471738433, POC:curators]","metadata":null},{"id":"9fb3fcae14b24e47908a47d6f4b158ad","type":"DRUG","name":"simvastatin","canonical_id":"gtopdb:2955","description":null,"metadata":null},{"id":"15dfaf6f663a4c099458e628771aaede","type":"DRUG","name":"simvastatin","canonical_id":"chembl:CHEMBL1064","description":null,"metadata":null},{"id":"a51bed5a8f8943eda01d8d1ac89cb4a3","type":"GO_TERM","name":"sinapate 1-glucosyltransferase activity","canonical_id":"go:GO:0050284","description":"\"Catalysis of the reaction: UDP-glucose + sinapate = UDP + 1-sinapoyl-D-glucose.\" [EC:2.4.1.120, MetaCyc:SINAPATE-1-GLUCOSYLTRANSFERASE-RXN]","metadata":null},{"id":"17691becad62474ba267f1fd209e354a","type":"GO_TERM","name":"sinapate biosynthetic process","canonical_id":"go:GO:0033497","description":"\"The chemical reactions and pathways resulting in the formation of sinapate, (2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate.\" [GOC:mah]","metadata":null},{"id":"3d3690dfe582467e9a7d8f5bdbadba7c","type":"GO_TERM","name":"sinapate ester biosynthetic process","canonical_id":"go:GO:0033525","description":"\"The chemical reactions and pathways resulting in the formation of ester derivates of sinapate, (2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate.\" [GOC:mah]","metadata":null},{"id":"57ad83b3977b4273b7a6158cf5a649b7","type":"GO_TERM","name":"sinapine esterase activity","canonical_id":"go:GO:0050285","description":"\"Catalysis of the reaction: O-sinapoylcholine + H2O = choline + H+ + sinapate.\" [EC:3.1.1.49, RHEA:10016]","metadata":null},{"id":"e0b155c2cae248b18f3c706eba76326a","type":"GO_TERM","name":"sinapoyl spermidine:sinapoyl CoA N-acyltransferase activity","canonical_id":"go:GO:0080089","description":"\"Catalysis of the transfer of a sinapoyl group to a nitrogen atom on a sinapoyl spermidine molecule resulting in the formation of a disinapoyl spermidine derivative.\" [PMID:19168716]","metadata":null},{"id":"57e221a4a37b466eabae7f64fd865c37","type":"GO_TERM","name":"sinapoylglucose-choline O-sinapoyltransferase activity","canonical_id":"go:GO:0047202","description":"\"Catalysis of the reaction: 1-O-sinapoyl-beta-D-glucose + choline = O-sinapoylcholine + D-glucose.\" [EC:2.3.1.91, RHEA:12024]","metadata":null},{"id":"84aba4d4ae8f40238c8bbb759c9c97bf","type":"GO_TERM","name":"sinapoylglucose-malate O-sinapoyltransferase activity","canonical_id":"go:GO:0016754","description":"\"Catalysis of the reaction: (S)-malate + 1-O-sinapoyl-beta-D-glucose = D-glucose + sinapoyl (S)-malate.\" [EC:2.3.1.92, RHEA:12625]","metadata":null},{"id":"21a56e784cce4f3cb84eed4a79191e91","type":"GO_TERM","name":"sinapoylglucose-sinapoylglucose O-sinapoyltransferase activity","canonical_id":"go:GO:0047158","description":"\"Catalysis of the reaction: 2 1-O-sinapoyl-beta-D-glucose = 1,2-di-O-sinapoyl-beta-D-glucose + D-glucose.\" [EC:2.3.1.103, RHEA:22664]","metadata":null},{"id":"33198509a9b14753ab92961b30945d63","type":"GO_TERM","name":"sinapoyltransferase activity","canonical_id":"go:GO:0016752","description":"\"Catalysis of the transfer of a sinapoyl group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"5908e6cdf4c745618afebeff714bd757","type":"DRUG","name":"sincalide","canonical_id":"mesh:D012844","description":null,"metadata":null},{"id":"83bda061714448809ee6969ed858eb6a","type":"GO_TERM","name":"single adenine insertion binding","canonical_id":"go:GO:0032140","description":"\"Binding to a double-stranded DNA region containing a single adenine insertion or a deletion that results in an unpaired adenine.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"66903c3890424105818a22969aace44e","type":"GO_TERM","name":"single base insertion or deletion binding","canonical_id":"go:GO:0032138","description":"\"Binding to a double-stranded DNA region containing a single base insertion or deletion.\" [GOC:vk]","metadata":null},{"id":"2411797497cd490f8cc882ca814b7083","type":"GO_TERM","name":"single cytosine insertion binding","canonical_id":"go:GO:0032141","description":"\"Binding to a double-stranded DNA region containing a single cytosine insertion or a deletion that results in an unpaired cytosine.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"8c1c7cfcae1747ab8a8a9e9b07bffe5b","type":"GO_TERM","name":"single fertilization","canonical_id":"go:GO:0007338","description":"\"The union of male and female gametes to form a zygote.\" [GOC:ems, GOC:mtg_sensu]","metadata":null},{"id":"9735e39a304c4369b013b671db168baf","type":"GO_TERM","name":"single guanine insertion binding","canonical_id":"go:GO:0032142","description":"\"Binding to a double-stranded DNA region containing a single guanine insertion or a deletion that results in an unpaired guanine.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"cd16cd0330e44cde88305a4783c5a988","type":"GO_TERM","name":"single strand break repair","canonical_id":"go:GO:0000012","description":"\"The repair of single strand breaks in DNA. Repair of such breaks is mediated by the same enzyme systems as are used in base excision repair.\" [PMID:18626472]","metadata":null},{"id":"9be55509870641ff9e2865986961206f","type":"GO_TERM","name":"single stranded viral RNA replication via double stranded DNA intermediate","canonical_id":"go:GO:0039692","description":"\"A viral genome replication where the template is single-stranded RNA (ssRNA), and which proceeds via a double stranded DNA (dsDNA) intermediate molecule. Viral genomic RNA is first reverse transcribed into dsDNA, which integrates into the host chromosomal DNA, where it is transcribed by host RNA polymerase II.\" [GOC:bf, GOC:jl, ISBN:0198506732, VZ:1937]","metadata":null},{"id":"d671c705962244db8b4635055812dd7f","type":"GO_TERM","name":"single thymine insertion binding","canonical_id":"go:GO:0032143","description":"\"Binding to a double-stranded DNA region containing a single thymine insertion or a deletion that results in an unpaired thymine.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"c83ef3566b5b4ee8bcaac66738cb2c47","type":"GO_TERM","name":"single-celled organism vegetative growth phase","canonical_id":"go:GO:0072690","description":"\"A phase of population growth during which single celled organisms reproduce by budding, fission, or other asexual methods.\" [GOC:mah, GOV:vw]","metadata":null},{"id":"edddc459e9f947ca83c79b99f1bb8f07","type":"GO_TERM","name":"single-species biofilm formation","canonical_id":"go:GO:0044010","description":"\"A process in which planktonically growing microorganisms of the same species grow at a liquid-air interface or on a solid substrate under the flow of a liquid and produce extracellular polymers that facilitate matrix formation, resulting in a change in the organisms' growth rate and gene transcription.\" [GOC:cc, GOC:di, GOC:tb]","metadata":null},{"id":"0fb5798e7b65481688a56e29efb70b76","type":"GO_TERM","name":"single-species biofilm formation in or on host organism","canonical_id":"go:GO:0044407","description":"\"A process in which microorganisms of the same species attach to and grow in or on a host species, and produce extracellular polymers that facilitate attachment and matrix formation, resulting in a change in the microorganisms' growth rate and gene transcription. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"0ec7044e47d043938be72f96f004a4c1","type":"GO_TERM","name":"single-species biofilm formation on inanimate substrate","canonical_id":"go:GO:0044011","description":"\"A process in which microorganisms of the same species attach to and grow on an inanimate surface such as a rock or pipe, and produce extracellular polymers that facilitate attachment and matrix formation, resulting in an alteration in the phenotype of the organisms with respect to growth rate and gene transcription.\" [GOC:cc]","metadata":null},{"id":"88b7eb53a44d494a971d2598c037f1b1","type":"GO_TERM","name":"single-species submerged biofilm formation","canonical_id":"go:GO:0090609","description":"\"A process in which planktonically growing microorganisms of the same species aggregate and grow on solid substrates under the flow of a liquid and produce extracellular polymers that facilitate attachment and matrix formation, resulting in a change in the organisms' growth rate and gene transcription.\" [GOC:di, GOC:tb]","metadata":null},{"id":"c71f497e82b94158950c426ae97de6a8","type":"GO_TERM","name":"single-species surface biofilm formation","canonical_id":"go:GO:0090606","description":"\"A process in which microorganisms produce an extracellular matrix and form multicellular aggregates at an air-liquid interface.\" [GOC:ml]","metadata":null},{"id":"586859dd09eb46c0835cbf4e1e5b229a","type":"GO_TERM","name":"single-strand break repair via homologous recombination","canonical_id":"go:GO:1990396","description":"\"The error-free repair of a single-strand break in DNA in which the broken DNA molecule is repaired using homologous sequences. A strand in the broken DNA searches for a homologous region in an intact chromosome to serve as the template for DNA synthesis. The restoration of two intact DNA molecules results in the exchange, reciprocal or nonreciprocal, of genetic material between the intact DNA molecule and the broken DNA molecule.\" [GOC:bhm, PMID:24339919]","metadata":null},{"id":"16dd8d07ad1a4fbbb5f679321dcb7433","type":"GO_TERM","name":"single-strand break-containing DNA binding","canonical_id":"go:GO:1990165","description":"\"Binding to damaged DNA containing single-strand breaks (SSBs).\" [GOC:al, PMID:21984210]","metadata":null},{"id":"3719771a6cbe4622a1db98604398343b","type":"GO_TERM","name":"single-strand selective uracil DNA N-glycosylase activity","canonical_id":"go:GO:0017065","description":"\"Catalysis of the cleavage of the N-C1' glycosidic bond between the damaged DNA base and the deoxyribose sugar, releasing a free base and leaving an apyrimidinic (AP) site. Enzymes with this activity recognize and remove uracil bases present in single-stranded DNA.\" [GOC:elh, PMID:9224623]","metadata":null},{"id":"ad045fb22eac4d15b132ca1aa10dbb87","type":"GO_TERM","name":"single-stranded 3'-5' DNA helicase activity","canonical_id":"go:GO:1990518","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate, in the presence of single-stranded DNA; drives the unwinding of the DNA helix in the direction 3' to 5'.\" [PMID:25165823]","metadata":null},{"id":"435b49ae0c774ec8bcfb1319760129e4","type":"GO_TERM","name":"single-stranded DNA 3'-5' DNA exonuclease activity","canonical_id":"go:GO:0008310","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 3' terminus of a single-stranded DNA molecule.\" [GOC:mah, PMID:22562358]","metadata":null},{"id":"c318e27886b446d19cc440285b14a865","type":"GO_TERM","name":"single-stranded DNA 5'-3' DNA exonuclease activity","canonical_id":"go:GO:0045145","description":"\"Catalysis of the sequential cleavage of nucleotides (such as mononucleotides or dinucleotides) from a free 5' terminus of a single-stranded DNA molecule.\" [GOC:ai, GOC:elh, PMID:20086101]","metadata":null},{"id":"07bf4937b29b467aa266187b1aa7b62b","type":"GO_TERM","name":"single-stranded DNA binding","canonical_id":"go:GO:0003697","description":"\"Binding to single-stranded DNA.\" [GOC:elh, GOC:vw, PMID:22976174]","metadata":null},{"id":"bbdd9e56d66b489a85f7f0a903e523d2","type":"GO_TERM","name":"single-stranded DNA endodeoxyribonuclease activator activity","canonical_id":"go:GO:1990600","description":"\"Increases the activity of a single-stranded DNA endodeoxyribonuclease activator activity.\" [PMID:25203555]","metadata":null},{"id":"a7dd558a9e2641c4aa34022c8b3429d1","type":"GO_TERM","name":"single-stranded DNA endonuclease activity","canonical_id":"go:GO:0000014","description":"\"Catalysis of the hydrolysis of ester linkages within a single-stranded deoxyribonucleic acid molecule by creating internal breaks.\" [GOC:mah]","metadata":null},{"id":"0d1840df515c4d70949df7fe6dafcb5a","type":"GO_TERM","name":"single-stranded DNA exodeoxyribonuclease activity","canonical_id":"go:GO:0008297","description":"\"Catalysis of the sequential cleavage of mononucleotides from a free 5' or 3' terminus of a single-stranded DNA molecule.\" [GOC:mah]","metadata":null},{"id":"6f10a769ee2e4a86805407ab10986bae","type":"GO_TERM","name":"single-stranded DNA helicase activity","canonical_id":"go:GO:0017116","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate, in the presence of single-stranded DNA; drives the unwinding of a DNA helix.\" [GOC:jl]","metadata":null},{"id":"6cfc2a56caad4d2f84e20a66387ff20e","type":"GO_TERM","name":"single-stranded DNA-binding protein complex","canonical_id":"go:GO:0044777","description":"\"A homotetrameric protein complex that is essential for DNA replication. It supercoils the single-stranded DNA preventing DNA duplexing before the polymerase holoenzyme passes and synthesizes the complementary strand. It is also involved in DNA recombination and repair.\" [GOC:jl, UniProt:P0AGE0]","metadata":null},{"id":"0f965d91b5bb4fdf8298af2ec5bcf21f","type":"GO_TERM","name":"single-stranded DNA-dependent ATP-dependent DNA helicase complex","canonical_id":"go:GO:0017117","description":"\"A protein complex that possesses single-stranded DNA-dependent DNA helicase activity.\" [GOC:mah]","metadata":null},{"id":"db784dfc269f48dd8b86c4d6447e529a","type":"GO_TERM","name":"single-stranded RNA binding","canonical_id":"go:GO:0003727","description":"\"Binding to single-stranded RNA.\" [GOC:jl]","metadata":null},{"id":"dba274d82e8b4ccaa3f8531781a0a581","type":"GO_TERM","name":"single-stranded telomeric DNA binding","canonical_id":"go:GO:0043047","description":"\"Binding to single-stranded telomere-associated DNA.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"146b554fc4ad4b2d9465d19c4b652096","type":"GO_TERM","name":"single-subunit type RNA polymerase binding","canonical_id":"go:GO:0001050","description":"\"Binding to a single subunit RNA polymerase enzyme, which is composed of a single catalytic subunit similar to the RNA polymerase enzymes from phages T3, T7, and SP6.\" [GOC:txnOH, PMID:20701995]","metadata":null},{"id":"01f555b9ec2d46f1a88ea89c002c8be2","type":"GO_TERM","name":"singlet oxygen-mediated programmed cell death","canonical_id":"go:GO:0010343","description":"\"Programmed cell death induced by singlet oxygen. Programmed cell death is the cell death resulting from activation of endogenous cellular processes.\" [GOC:mtg_apoptosis, PMID:17075038]","metadata":null},{"id":"7b0e25c5831f4e2f94989a8239e70b0d","type":"GO_TERM","name":"sinoatrial node cell development","canonical_id":"go:GO:0060931","description":"\"The process whose specific outcome is the progression of a sinoatrial (SA) node cell over time, from its formation to the mature state. SA node cells are pacemaker cells that are found in the sinoatrial node.\" [GOC:mtg_heart]","metadata":null},{"id":"c733a52df49b44cdbdf87ae6e6a342d6","type":"GO_TERM","name":"sinoatrial node cell differentiation","canonical_id":"go:GO:0060921","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a sinoatrial (SA) node cell. SA node cells are pacemaker cells that are found in the sinoatrial node.\" [GOC:mtg_heart]","metadata":null},{"id":"b9ea7bb89c5e483cac9c0fdbe0241599","type":"GO_TERM","name":"sinoatrial node cell fate commitment","canonical_id":"go:GO:0060930","description":"\"The commitment of cells to sinoatrial (SA) node cell fates and their capacity to differentiate into SA node cells. SA node cells are pacemaker cells that are found in the sinoatrial node.\" [GOC:mtg_heart]","metadata":null},{"id":"3e82caa118084618a31377dac058bbf1","type":"GO_TERM","name":"sinoatrial node development","canonical_id":"go:GO:0003163","description":"\"The process whose specific outcome is the progression of the sinoatrial (SA) node over time, from its formation to the mature structure. The SA node is part of the cardiac conduction system that controls the timing of heart muscle contraction. It relays electrical signals to the AV node.\" [GOC:mtg_heart]","metadata":null},{"id":"b301a62055694521b2eb7fd4444d1c94","type":"DISEASE","name":"sinoatrial node dysfunction and deafness","canonical_id":"mondo:0013960","description":null,"metadata":null},{"id":"77cc8543b8b248ab8ba1bc6ab347bb75","type":"GO_TERM","name":"sinoatrial valve development","canonical_id":"go:GO:0003172","description":"\"The progression of the sinoatrial valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"15f2615721d346e1bc4cc9c75914062a","type":"GO_TERM","name":"sinoatrial valve formation","canonical_id":"go:GO:0003194","description":"\"The developmental process pertaining to the initial formation of the sinoatrial valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"cc6d3c31adeb48139b8f40e0f7ededb0","type":"GO_TERM","name":"sinoatrial valve morphogenesis","canonical_id":"go:GO:0003185","description":"\"The process in which the structure of the sinoatrial valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"124d2ec3e7184a5a8ecbcc1fc22d483e","type":"DRUG","name":"sintilimab","canonical_id":"gtopdb:12990","description":null,"metadata":null},{"id":"83821c229f864491802eeada5f47228d","type":"DRUG","name":"sintilimab","canonical_id":"chembl:CHEMBL4297829","description":null,"metadata":null},{"id":"bb4e836734eb494aa4d7581c9fd158bc","type":"GO_TERM","name":"sinus venosus development","canonical_id":"go:GO:0003235","description":"\"The progression of the sinus venosus over time, from its formation to the mature structure. The sinus venosus is a heart chamber attached to the atrium on the venous side of the embryonic heart.\" [GOC:mtg_heart]","metadata":null},{"id":"1f14ef8cf2134f8d9b76362366c2381c","type":"GO_TERM","name":"sinus venosus formation","canonical_id":"go:GO:0003237","description":"\"The developmental process pertaining to the initial formation of the sinus venosus from unspecified parts. The sinus venosus is a heart chamber attached to the atrium on the venous side of the embryonic heart.\" [GOC:mtg_heart]","metadata":null},{"id":"55a6110b332844ee8b9e6c6b8e2a830d","type":"GO_TERM","name":"sinus venosus morphogenesis","canonical_id":"go:GO:0003236","description":"\"The process in which the sinus venosus is generated and organized. The sinus venosus is a heart chamber attached to the atrium on the venous side of the embryonic heart.\" [GOC:mtg_heart]","metadata":null},{"id":"b342bfacc67649f9b4597497c6d73da7","type":"DISEASE","name":"sinusitis","canonical_id":"mondo:0005961","description":null,"metadata":null},{"id":"37305cba071c4ce4bf7c4ca27f85833b","type":"DRUG","name":"siponimod","canonical_id":"gtopdb:9289","description":null,"metadata":null},{"id":"3a97207e61604402b72572314e91e4fe","type":"DRUG","name":"siponimod","canonical_id":"chembl:CHEMBL2336071","description":null,"metadata":null},{"id":"e2f5f3d1984546a2b687822fde096512","type":"GO_TERM","name":"siroheme biosynthetic process","canonical_id":"go:GO:0019354","description":"\"The chemical reactions and pathways resulting in the formation of siroheme, a tetrahydroporphyrin with adjacent, reduced pyrrole rings.\" [ISBN:0198506732]","metadata":null},{"id":"9e6b9931485146e789350d455b87811b","type":"GO_TERM","name":"siroheme catabolic process","canonical_id":"go:GO:0046157","description":"\"The chemical reactions and pathways resulting in the breakdown of siroheme, a tetrahydroporphyrin with adjacent, reduced pyrrole rings.\" [ISBN:0198506732]","metadata":null},{"id":"52170888bcd445baa2439da41cc132da","type":"GO_TERM","name":"sirohydrochlorin cobaltochelatase activity","canonical_id":"go:GO:0016852","description":"\"Catalysis of the reaction: sirohydrochlorin + Co2+ = cobalt-sirohydrochlorin + 2 H+.\" [RHEA:15893]","metadata":null},{"id":"dc0498d556ea497aaac9cdffefc62f5d","type":"GO_TERM","name":"sirohydrochlorin ferrochelatase activity","canonical_id":"go:GO:0051266","description":"\"Catalysis of the reaction: siroheme + 2 H+ = Fe(2+) + sirohydrochlorin.\" [RHEA:24360]","metadata":null},{"id":"fd6b10b2ef6a477d83d69f9cb4dd42e5","type":"DRUG","name":"sirolimus","canonical_id":"gtopdb:6031","description":null,"metadata":null},{"id":"df43061572b84098a9e0d904f979576e","type":"COMBINATION_TREATMENT","name":"sirolimus + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-df9eed0c5ca42df8","description":null,"metadata":null},{"id":"ed6afede97314c41b969af2f8cd4afc9","type":"GO_TERM","name":"sister chromatid biorientation","canonical_id":"go:GO:0031134","description":"\"The cell cycle process in which sister chromatids establish stable attachments to microtubules emanating from opposite spindle poles.\" [PMID:15309047]","metadata":null},{"id":"87da6581affb4acc88a31b4b94fa7266","type":"GO_TERM","name":"sister chromatid cohesion","canonical_id":"go:GO:0007062","description":"\"The cell cycle process in which the sister chromatids of a replicated chromosome become tethered to each other.\" [GOC:jh, GOC:mah, ISBN:0815316194]","metadata":null},{"id":"1aeb546f5d844400bdfcd7b62ed197e1","type":"GO_TERM","name":"sister chromatid segregation","canonical_id":"go:GO:0000819","description":"\"The cell cycle process in which sister chromatids are organized and then physically separated and apportioned to two or more sets.\" [GOC:ai, GOC:elh]","metadata":null},{"id":"7e370b32eb5445858326d186e9c2879e","type":"GO_TERM","name":"sister chromosome movement towards spindle pole involved in meiotic sister chromatid segregation","canonical_id":"go:GO:0051759","description":"\"The directed movement of sister chromosomes from the center of the spindle towards the spindle poles, mediated by the shortening of microtubules attached to the chromosomes, during meiosis II.\" [GOC:ai]","metadata":null},{"id":"5e1e943ca22645fe84cf108890fd3265","type":"DRUG","name":"sitagliptin","canonical_id":"gtopdb:6286","description":null,"metadata":null},{"id":"e94755d898e5488eabcbc3a01aef87a2","type":"DRUG","name":"sitagliptin","canonical_id":"mesh:D000068900","description":null,"metadata":null},{"id":"69b2fbcf0da1495cb1f7a15f28cf9285","type":"COMBINATION_TREATMENT","name":"sitagliptin + vildagliptin","canonical_id":"ctgov_combo:ctgov-combo-655d35672faf71f4","description":null,"metadata":null},{"id":"bb13405a5d9a4d7fbbb8759d9b920cd2","type":"DRUG","name":"sitaxsentan","canonical_id":"gtopdb:3950","description":null,"metadata":null},{"id":"d6e4ee5155f7439b89c6bf6f7acbbae0","type":"DRUG","name":"sitaxsentan","canonical_id":"chembl:CHEMBL2105740","description":null,"metadata":null},{"id":"c6de887d717741b0bcd898e9ef34db76","type":"GO_TERM","name":"site of DNA damage","canonical_id":"go:GO:0090734","description":"\"A region of a chromosome at which DNA damage has occurred. DNA damage signaling and repair proteins accumulate at the lesion to respond to the damage and repair the DNA to form a continuous DNA helix.\" [GOC:pg]","metadata":null},{"id":"c6feaf64f8d9483c8b74a36ebfefeca2","type":"GO_TERM","name":"site of double-strand break","canonical_id":"go:GO:0035861","description":"\"A region of a chromosome at which a DNA double-strand break has occurred. DNA damage signaling and repair proteins accumulate at the lesion to respond to the damage and repair the DNA to form a continuous DNA helix.\" [GOC:bf, GOC:mah, GOC:vw, PMID:20096808, PMID:21035408]","metadata":null},{"id":"084ac7ab675a495da7bc3d28a50f101b","type":"GO_TERM","name":"site of polarized growth","canonical_id":"go:GO:0030427","description":"\"Any part of a cell where non-isotropic growth takes place.\" [GOC:mah]","metadata":null},{"id":"60c80c6cdc244546b621022172d5a677","type":"GO_TERM","name":"site-specific DNA replication termination","canonical_id":"go:GO:0071170","description":"\"A DNA replication termination process that takes place at a specific termination site.\" [GOC:mah, PMID:12009298, PMID:18723894]","metadata":null},{"id":"732b8547b7304bd783ef69b4d45d5e53","type":"GO_TERM","name":"site-specific DNA replication termination at RTS1 barrier","canonical_id":"go:GO:0071171","description":"\"A DNA replication termination process that takes place at the RTS1 termination site in the mating type locus, in a specific direction required for subsequent imprinting and mating-type switching.\" [GOC:vw, PMID:12009298, PMID:18723894]","metadata":null},{"id":"c6acde5c09634a98ae3aef0c73dccdeb","type":"GO_TERM","name":"site-specific DNA-methyltransferase (adenine-specific) activity","canonical_id":"go:GO:0009007","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + DNA adenine = S-adenosyl-L-homocysteine + DNA 6-methylaminopurine.\" [EC:2.1.1.72]","metadata":null},{"id":"5887b82abce7465f818bfeef98434917","type":"GO_TERM","name":"site-specific DNA-methyltransferase (cytosine-N4-specific) activity","canonical_id":"go:GO:0015667","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + DNA cytosine = S-adenosyl-L-homocysteine + DNA N4-methylcytosine.\" [EC:2.1.1.113]","metadata":null},{"id":"9be8788a4ed94a9fba8067195ec641ac","type":"GO_TERM","name":"site-specific recombinase activity","canonical_id":"go:GO:0009009","description":"\"Catalysis of the formation of new phosphodiester bonds between a pair of short, unique target DNA sequences.\" [GOC:elh, PMID:6286142]","metadata":null},{"id":"3be50023dfda421fbe96855bc4200d38","type":"GO_TERM","name":"site-specific telomere resolvase activity","canonical_id":"go:GO:0043336","description":"\"Catalysis of a site-specific breakage and reunion reaction that generates two hairpin telomeres from a replicated telomere substrate. Occurs via a two-step transesterification with a protein-DNA intermediate similar to that used by topoisomerases and site-specific recombinases.\" [GOC:jl, PMID:11804598]","metadata":null},{"id":"418ddba419aa43ecb7e5edf6758f1ab3","type":"DRUG","name":"sivelestat","canonical_id":"gtopdb:6441","description":null,"metadata":null},{"id":"a0bc084b77bf4c4b8fc319dfb79396fa","type":"DRUG","name":"sivelestat","canonical_id":"chembl:CHEMBL76688","description":null,"metadata":null},{"id":"1ee5edddeba642f7969c8b6a08b47357","type":"GO_TERM","name":"skein-like inclusion","canonical_id":"go:GO:0097420","description":"\"Intracytoplasmic filamentous structure frequently encountered in preparations immunostained for ubiquitin.\" [NIF_Subcellular:nlx_subcell_20090103, PMID:18026741]","metadata":null},{"id":"8f64311e4e2d4c1d9fb76099de0a9d54","type":"GO_TERM","name":"skeletal muscle acetylcholine-gated channel clustering","canonical_id":"go:GO:0071340","description":"\"The accumulation of acetylcholine-gated cation channels in a narrow, central region of muscle fibers, in apposition to nerve terminals.\" [GOC:bf, GOC:dsf, PMID:19285469]","metadata":null},{"id":"a4d965a4389f4e3aa07f36b84a8fa34c","type":"GO_TERM","name":"skeletal muscle adaptation","canonical_id":"go:GO:0043501","description":"\"Any process in which skeletal muscles change their phenotypic profiles in response to altered functional demands and a variety of signals.\" [GOC:mtg_muscle, PMID:11181628, PMID:11449884, PMID:12605307]","metadata":null},{"id":"7b7dff8e9e9148f5b3e4732c5a8f863a","type":"GO_TERM","name":"skeletal muscle atrophy","canonical_id":"go:GO:0014732","description":"\"A process, occurring in skeletal muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"f6949198f79046afb07c96c6adbb3df8","type":"GO_TERM","name":"skeletal muscle cell differentiation","canonical_id":"go:GO:0035914","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a skeletal muscle cell, a somatic cell located in skeletal muscle.\" [CL:0000188, GOC:BHF, GOC:vk]","metadata":null},{"id":"5b6fe08a8cf44c82993fee1456f81b24","type":"GO_TERM","name":"skeletal muscle cell proliferation","canonical_id":"go:GO:0014856","description":"\"The multiplication or reproduction of skeletal muscle cells, resulting in the expansion of a cell population.\" [CL:0000188, GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"d0b006cd6fe5406b96922107ba5cd92d","type":"GO_TERM","name":"skeletal muscle contraction","canonical_id":"go:GO:0003009","description":"\"A process in which force is generated within skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. In the skeletal muscle, the muscle contraction takes advantage of an ordered sarcomeric structure and in most cases it is under voluntary control.\" [GOC:mtg_cardio, GOC:mtg_muscle]","metadata":null},{"id":"bc2df6bc99fd4171b73d04d4903ee1da","type":"GO_TERM","name":"skeletal muscle fiber adaptation","canonical_id":"go:GO:0043503","description":"\"Any process in which the skeletal muscle fibers change their phenotypic profiles in response to altered functional demands and a variety of signals. Muscle fibers are formed by the maturation of myotubes. They can be classed as slow, intermediate/fast or fast.\" [GOC:mtg_muscle, PMID:11181628, PMID:11449884, PMID:12605307]","metadata":null},{"id":"a312e51c72f54f2c9594ef62ebb0a67e","type":"GO_TERM","name":"skeletal muscle fiber development","canonical_id":"go:GO:0048741","description":"\"The process whose specific outcome is the progression of the skeletal muscle fiber over time, from its formation to the mature structure. Muscle fibers are formed by the maturation of myotubes. They can be classed as slow, intermediate/fast or fast.\" [GOC:dph, GOC:ef, GOC:jid, GOC:lm, GOC:mtg_muscle]","metadata":null},{"id":"b0a025d8a97c44fabb34246de2989305","type":"GO_TERM","name":"skeletal muscle fiber differentiation","canonical_id":"go:GO:0098528","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a skeletal muscle fiber cell. Skeletal muscle fiber differentiation starts with myoblast fusion and the appearance of specific cell markers (this is the cell development step). Then individual skeletal muscle fibers fuse to form bigger myotubes and start to contract.\" [GOC:dos]","metadata":null},{"id":"6651bbbfeb134287a7544b45bedd8788","type":"GO_TERM","name":"skeletal muscle hypertrophy","canonical_id":"go:GO:0014734","description":"\"The enlargement or overgrowth of all or part of an organ due to an increase in size (not length) of individual muscle fibers without cell division. In the case of skeletal muscle cells this happens due to the additional synthesis of sarcomeric proteins and assembly of myofibrils.\" [GOC:mtg_muscle]","metadata":null},{"id":"a98a25a43fc24c469a1b5e6500d9e695","type":"GO_TERM","name":"skeletal muscle myofibril","canonical_id":"go:GO:0098723","description":"\"A myofibril of a skeletal muscle fiber.\" [GOC:dos]","metadata":null},{"id":"09319feac2524a6093e3bf84d8fd1dc4","type":"GO_TERM","name":"skeletal muscle myosin thick filament assembly","canonical_id":"go:GO:0030241","description":"\"The aggregation, arrangement and bonding together of proteins to form the myosin-based thick filaments of myofibrils in skeletal muscle.\" [GOC:ef, GOC:mah, GOC:mtg_muscle]","metadata":null},{"id":"dd69286a61644d42a6366224c6665713","type":"GO_TERM","name":"skeletal muscle organ development","canonical_id":"go:GO:0060538","description":"\"The progression of a skeletal muscle organ over time from its initial formation to its mature state. A skeletal muscle organ includes the skeletal muscle tissue and its associated connective tissue.\" [GOC:dph]","metadata":null},{"id":"c385e406369340a38992c44f4a189067","type":"GO_TERM","name":"skeletal muscle regeneration at neuromuscular junction","canonical_id":"go:GO:0014730","description":"\"The regrowth of muscle tissue to repair injured or damaged muscle fibers in the postnatal stage at the neuromuscular junction. Regeneration of neuromuscular junctions occurs in an orderly way and relies on communication between nerve and muscle. Skeletal myofibers regenerate after injury and form neuro-muscular junctions with motor axons similar to normal ones. Regenerating myofibers develop within the basal lamina sheaths (satellite cells) of original myofibers.\" [GOC:mtg_muscle]","metadata":null},{"id":"52979746f82b499e9a6ed15edd08b629","type":"GO_TERM","name":"skeletal muscle satellite cell activation","canonical_id":"go:GO:0014719","description":"\"The change of a skeletal muscle satellite cell from a mitotically quiescent to a mitotically active state following exposure to some activating factor such as a cellular or soluble ligand. In adult muscle, satellite cells become activated to divide and differentiate in response to muscle damage.\" [GOC:mtg_muscle, PMID:23303905]","metadata":null},{"id":"dacd8f082ebb4a3dbdd836e240b49930","type":"GO_TERM","name":"skeletal muscle satellite cell commitment","canonical_id":"go:GO:0014813","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a satellite cell.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"e94a3ad9e2694680a4756e350d093ec1","type":"GO_TERM","name":"skeletal muscle satellite cell differentiation","canonical_id":"go:GO:0014816","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a satellite cell.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"b18d3e579d2345e2a0ef42bf47570cc1","type":"GO_TERM","name":"skeletal muscle satellite cell fate determination","canonical_id":"go:GO:0014818","description":"\"The process in which a cell becomes capable of differentiating autonomously into a skeletal muscle satellite cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"520f35731f874756ac233af543554cd1","type":"GO_TERM","name":"skeletal muscle satellite cell fate specification","canonical_id":"go:GO:0014817","description":"\"The process in which a cell becomes capable of differentiating autonomously into a skeletal muscle satellite cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"d3ecf238d53244209f5d1e5a9ead16b9","type":"GO_TERM","name":"skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration","canonical_id":"go:GO:0014834","description":"\"Any process by which the number of skeletal muscle satellite cells in a skeletal muscle is maintained during muscle regeneration. There are at least three mechanisms by which this is achieved. Skeletal muscle satellite stem cell asymmetric division ensures satellite stem cell numbers are kept constant. Symmetric division of these cells amplifies the number of skeletal muscle satellite stem cells. Some adult skeletal muscle myoblasts (descendants of activated satellite cells) can develop back into quiescent satellite cells, replenishing the overall pool of satellite cells.\" [GOC:dph, GOC:ef, GOC:mtg_muscle, GOC:tb, PMID:23303905]","metadata":null},{"id":"bf90f35a82a544bd8f05cc6e0c05b5cb","type":"GO_TERM","name":"skeletal muscle satellite cell migration","canonical_id":"go:GO:1902766","description":"\"The orderly movement of a skeletal muscle satellite cell from one site to another. Migration of these cells is a key step in the process of growth and repair of skeletal muscle cells.\" [GO_REF:0000091, GOC:mr, GOC:TermGenie, PMID:17996437, PMID:19609936]","metadata":null},{"id":"7d6efc35513f44dfab7d4d5dcebadf2e","type":"GO_TERM","name":"skeletal muscle satellite cell proliferation","canonical_id":"go:GO:0014841","description":"\"The multiplication or reproduction of satellite cells, resulting in the expansion of the cell population. Satellite cells are quiescent cells that are located between the basal lamina and the plasmalemma of the muscle fiber, which are the main contributors to postnatal muscle growth. In adult muscle, satellite cells become activated to divide and differentiate in response to muscle damage.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"7485cedd6d3d433fbb67cdc765f1002e","type":"GO_TERM","name":"skeletal muscle satellite stem cell asymmetric division","canonical_id":"go:GO:0014833","description":"\"The asymmetric division of a skeletal muscle satellite stem cell to produce two daughter cells, one of which is destined to differentiate and the other to be a quiescent cell that restocks the satellite cell pool.\" [GOC:ef, GOC:mtg_muscle, PMID:16607119]","metadata":null},{"id":"3901ef42815941bb9b4d502787ef74a3","type":"GO_TERM","name":"skeletal muscle thin filament assembly","canonical_id":"go:GO:0030240","description":"\"The aggregation, arrangement and bonding together of proteins to form the actin-based thin filaments of myofibrils in skeletal muscle.\" [GOC:ef, GOC:mah, GOC:mtg_muscle]","metadata":null},{"id":"00ac8a9ac2f34aa89f0b30e39d972344","type":"GO_TERM","name":"skeletal muscle tissue development","canonical_id":"go:GO:0007519","description":"\"The developmental sequence of events leading to the formation of adult skeletal muscle tissue. The main events are: the fusion of myoblasts to form myotubes that increase in size by further fusion to them of myoblasts, the formation of myofibrils within their cytoplasm and the establishment of functional neuromuscular junctions with motor neurons. At this stage they can be regarded as mature muscle fibers.\" [GOC:mtg_muscle]","metadata":null},{"id":"65d8a894d605406eb28577dd2352ba8d","type":"GO_TERM","name":"skeletal muscle tissue growth","canonical_id":"go:GO:0048630","description":"\"The increase in size or mass of a skeletal muscle. This may be due to a change in the fiber number or size.\" [GOC:lm, PMID:15726494, PMID:15907921]","metadata":null},{"id":"0a0988f37f6e4d1ba76068f2c4eecc58","type":"GO_TERM","name":"skeletal muscle tissue regeneration","canonical_id":"go:GO:0043403","description":"\"The regrowth of skeletal muscle tissue to repair injured or damaged muscle fibers in the postnatal stage.\" [GOC:ef, GOC:mtg_muscle, PMID:12021255, PMID:16607119]","metadata":null},{"id":"60a51f7365a44a88ac8c943539a2f53c","type":"GO_TERM","name":"skeletal myofibril assembly","canonical_id":"go:GO:0014866","description":"\"The process whose specific outcome is the progression of the skeletal myofibril over time, from its formation to the mature structure. A skeletal myofibril is a myofibril specific to skeletal muscle cells.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"85cb35f7464f41db8aa48ff4dfeb9548","type":"DISEASE","name":"skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome","canonical_id":"mondo:0014704","description":null,"metadata":null},{"id":"6d80a0ecdb394bb184274dbf2f83fd3c","type":"GO_TERM","name":"skeletal system development","canonical_id":"go:GO:0001501","description":"\"The process whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure. The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton).\" [GOC:dph, GOC:jid, GOC:tb]","metadata":null},{"id":"554fb1116b254f7d8548d885ac342579","type":"GO_TERM","name":"skeletal system morphogenesis","canonical_id":"go:GO:0048705","description":"\"The process in which the anatomical structures of the skeleton are generated and organized.\" [GOC:dph, GOC:dsf, GOC:jid, GOC:tb]","metadata":null},{"id":"b86e7ec2fb064f0fae9b988cd187f07c","type":"DISEASE","name":"skin cancer","canonical_id":"mondo:0002898","description":null,"metadata":null},{"id":"3df0b6a44a35483f9a8580dc153b63e3","type":"GO_TERM","name":"skin development","canonical_id":"go:GO:0043588","description":"\"The process whose specific outcome is the progression of the skin over time, from its formation to the mature structure. The skin is the external membranous integument of an animal. In vertebrates the skin generally consists of two layers, an outer nonsensitive and nonvascular epidermis (cuticle or skarfskin) composed of cells which are constantly growing and multiplying in the deeper, and being thrown off in the superficial layers, as well as an inner vascular dermis (cutis, corium or true skin) composed mostly of connective tissue.\" [GOC:jl, UBERON:0002097]","metadata":null},{"id":"e0d069c39748437f88c020212171d98f","type":"DISEASE","name":"skin disorder","canonical_id":"mondo:0005093","description":null,"metadata":null},{"id":"9e48dc054ff94d1081f3ab353dece029","type":"GO_TERM","name":"skin epidermis development","canonical_id":"go:GO:0098773","description":"\"The process whose specific outcome is the progression of the skin epidermis over time, from its formation to the mature structure.\" [GOC:dos]","metadata":null},{"id":"8611c9e4511741d58815acc5b22a45df","type":"GO_TERM","name":"skin morphogenesis","canonical_id":"go:GO:0043589","description":"\"The process in which the anatomical structures of the skin are generated and organized. The skin is the external membranous integument of an animal. In vertebrates the skin generally consists of two layers, an outer nonsensitive and nonvascular epidermis (cuticle or skarfskin) composed of cells which are constantly growing and multiplying in the deeper, and being thrown off in the superficial layers, as well as an inner, sensitive and vascular dermis (cutis, corium or true skin) composed mostly of connective tissue.\" [GOC:jl, UBERON:0002097]","metadata":null},{"id":"c92ef6ee64c74e69a0723ae8dbaca4b0","type":"DISEASE","name":"skin neoplasm","canonical_id":"mondo:0002531","description":null,"metadata":null},{"id":"ba40bdef14b44f5a902e677e53fead28","type":"GO_TERM","name":"skotomorphogenesis","canonical_id":"go:GO:0009647","description":"\"The control of plant growth, development, and differentiation in response to growth in darkness.\" [PMID:15012288]","metadata":null},{"id":"1f7216252b7545a5b78158c13712d110","type":"GO_TERM","name":"sleep","canonical_id":"go:GO:0030431","description":"\"Any process in which an organism enters and maintains a periodic, readily reversible state of reduced awareness and metabolic activity. Usually accompanied by physical relaxation, the onset of sleep in humans and other mammals is marked by a change in the electrical activity of the brain.\" [ISBN:0192800981]","metadata":null},{"id":"23cd96fbf24c4f7391b6fc30e226aacf","type":"DISEASE","name":"sleep disorder","canonical_id":"mondo:0100081","description":null,"metadata":null},{"id":"4e8e405697b145ecba2ff0a862730ed8","type":"GO_TERM","name":"sleep homeostasis","canonical_id":"go:GO:0160060","description":"\"A homeostatic process in which the drive for sleep increases sleep propensity with prolonged wakefulness.\" [PMID:30509635]","metadata":null},{"id":"d5cba73458ad4dbead96ef6e28d756cf","type":"DISEASE","name":"sleep-wake disorder","canonical_id":"mondo:0003406","description":null,"metadata":null},{"id":"b74fc84aa16b469ba18d4d4ec50f4457","type":"GO_TERM","name":"slime layer","canonical_id":"go:GO:0030114","description":"\"A slime layer is an easily removed, diffuse, unorganized layer of extracellular material that surrounds a cell. Specifically this consists mostly of exopolysaccharides, glycoproteins, and glycolipids.\" [GOC:mlg, Wikipedia:Slime_layer]","metadata":null},{"id":"4b3b600e735e43a18ea3723942d4f2ee","type":"GO_TERM","name":"slime layer organization","canonical_id":"go:GO:0045231","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a slime layer. A slime layer is an easily removed, diffuse, unorganized layer of extracellular material that surrounds a cell.\" [GOC:ai]","metadata":null},{"id":"0c0f96a4f19343ffaa52791aea8293b6","type":"GO_TERM","name":"slime layer polysaccharide biosynthetic process","canonical_id":"go:GO:0045228","description":"\"The chemical reactions and pathways resulting in the formation of polysaccharides in the slime layer, a diffused layer of polysaccharide exterior to the bacterial cell wall.\" [GOC:curators]","metadata":null},{"id":"467dc6a133c8480faf970d17d52b802f","type":"GO_TERM","name":"slit diaphragm","canonical_id":"go:GO:0036057","description":"\"A specialized cell-cell junction found between the interdigitating foot processes of the glomerular epithelium (the podocytes) in the vertebrate kidney, which is adapted for facilitating glomerular filtration.\" [GOC:mtg_kidney_jan10, GOC:rph, PMID:12386277, PMID:15994232, PMID:18971929, PMID:19478094]","metadata":null},{"id":"2a5979b649ce42ddbc671a403e346cb8","type":"GO_TERM","name":"slit diaphragm assembly","canonical_id":"go:GO:0036060","description":"\"The aggregation, arrangement and bonding together of a set of components to form a slit diaphragm, specialized cell-cell junction found between the interdigitating foot processes of the glomerular epithelium (the podocytes) in the vertebrate kidney, which is adapted for facilitating glomerular filtration.\" [GOC:mtg_kidney_jan10, GOC:rph, PMID:20633639]","metadata":null},{"id":"7296bd25f09b42a893af261266544c99","type":"GO_TERM","name":"slow axonal transport","canonical_id":"go:GO:1990832","description":"\"The directed slow movement of non-membranous molecules in nerve cell axons. It is comprised of a Slow Component a (SCa) and a Slow Component b (SCb) which differ in transport rates and protein composition.\" [PMID:6378920]","metadata":null},{"id":"a67624dbd2f24672849ddac8e309604f","type":"GO_TERM","name":"slow endocytic recycling","canonical_id":"go:GO:0032458","description":"\"The directed movement of membrane-bounded vesicles from deep (non-peripheral) compartments endocytic compartments back to the plasma membrane where they are recycled for further rounds of transport.\" [GOC:ecd, PMID:16473635]","metadata":null},{"id":"6822a22a4f304c9aa8b98863d13b37c9","type":"GO_TERM","name":"slow muscle cell migration","canonical_id":"go:GO:1904969","description":"\"The orderly movement of a slow muscle cell from one site to another.\" [GO_REF:0000091, GOC:TermGenie, GOC:ymb, PMID:14667409, PMID:15572133, PMID:25534553]","metadata":null},{"id":"5c804e8785c74c278893e436dae070b2","type":"GO_TERM","name":"slow, calcium ion-dependent exocytosis of neurotransmitter","canonical_id":"go:GO:0098747","description":"\"The slow, second phase of calcium ion-induced neurotransmitter release, via exocytosis, into the synaptic cleft. This depends on high affinity calcium sensors and decays slowly, typically with a decay constant of over 100ms. The underlying molecular mechanisms of this process are distinct from those of the earlier, fast phase of release.\" [GOC:dos, GOC:pad, GOC:parl, PMID:7809151, PMID:7954835]","metadata":null},{"id":"d7091f6a73274fcdb7af4243fb9d7324","type":"GO_TERM","name":"slow-twitch skeletal muscle fiber contraction","canonical_id":"go:GO:0031444","description":"\"A process in which force is generated within slow-twitch skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The slow-twitch skeletal muscle is characterized by slow time parameters, low force development and resistance to fatigue.\" [GOC:ef, GOC:mah, GOC:mtg_muscle]","metadata":null},{"id":"089dcdb3d2774311b116e6bf7797a4a0","type":"GO_TERM","name":"slug development involved in sorocarp development","canonical_id":"go:GO:0031153","description":"\"The process whose specific outcome is the progression of the slug over time, from its formation to the mature structure. Slug development begins when the aggregate rises upwards to form a finger-shaped structure and ends when culmination begins. Slug development begins after aggregation and ends before culmination in sorocarp development.\" [GOC:mah, GOC:mtg_sensu, ISBN:0521583640]","metadata":null},{"id":"84974901954745979cfe73e2efe70129","type":"GO_TERM","name":"small GTPase binding","canonical_id":"go:GO:0031267","description":"\"Binding to a small monomeric GTPase.\" [GOC:mah, PMID:27218782]","metadata":null},{"id":"74b61e37110e478a85df80154ec5fa87","type":"GO_TERM","name":"small GTPase-mediated signal transduction","canonical_id":"go:GO:0007264","description":"\"An intracellular signaling cassette in which a small monomeric GTPase relays a signal.\" [GOC:mah]","metadata":null},{"id":"0f78f2e5e9ea44c0b2949e67341d0571","type":"GO_TERM","name":"small RNA 2'-O-ribose methyltransferase activity","canonical_id":"go:GO:0090486","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the oxygen atom of a nucleoside residue in a small RNA molecule. Reaction: S-adenosyl-L-methionine + small RNA = S-adenosyl-L-homocysteine + small RNA containing a 3'-terminal 2'-O-methylnucleotide.\" [GOC:tb, GOC:vw, RHEA:37887]","metadata":null},{"id":"5d21b2f5d7984008b7979208927bc344","type":"GO_TERM","name":"small RNA binding translational repressor activity","canonical_id":"go:GO:0140764","description":"\"A translational repressor activity that binds to a single-stranded small regulatory RNA (either a miRNA or a siRNA) to guide it to its target mRNA.\" [PMID:27184117, PMID:34117606]","metadata":null},{"id":"436bd9396f7d43849ce1ebf015466a23","type":"DISEASE","name":"small cell carcinoma","canonical_id":"mondo:0000402","description":null,"metadata":null},{"id":"69036fca57d24df4b67ac6926226db8b","type":"DISEASE","name":"small cell lung carcinoma","canonical_id":"mondo:0008433","description":null,"metadata":null},{"id":"6603eab5727b45aba323c6a6ad7268d4","type":"GO_TERM","name":"small conductance calcium-activated potassium channel activity","canonical_id":"go:GO:0016286","description":"\"Enables the transmembrane transfer of potassium by a channel with a unit conductance of 2 to 20 picoSiemens that opens in response to stimulus by internal calcium ions. Small conductance calcium-activated potassium channels are more sensitive to calcium than are large conductance calcium-activated potassium channels. Transport by a channel involves catalysis of facilitated diffusion of a solute (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel, without evidence for a carrier-mediated mechanism.\" [GOC:mtg_transport, OMIM:602754]","metadata":null},{"id":"b8425513189f43c3b8d5663f92671ee6","type":"GO_TERM","name":"small conductance calcium-activated potassium channel inhibitor activity","canonical_id":"go:GO:0140629","description":"\"Binds to and stops, prevents, or reduces the activity of a small conductance calcium-activated potassium channel.\" [PMID:20562108]","metadata":null},{"id":"39d8fc0477ab414a83da319284c9114e","type":"GO_TERM","name":"small intestinal transit","canonical_id":"go:GO:0120055","description":"\"Migration of ingested material along the length of the small intestine.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"7ec8c128e3f5485d8b4269643fe05e8a","type":"DISEASE","name":"small intestine neoplasm","canonical_id":"mondo:0004251","description":null,"metadata":null},{"id":"ae89b8d09d934867871038bd96da512b","type":"GO_TERM","name":"small intestine smooth muscle contraction","canonical_id":"go:GO:1990770","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry in the intestine between the stomach and the large intestine.\" [PMID:11991626]","metadata":null},{"id":"50d6831795ab41cb8b4dd58470f80a1b","type":"GO_TERM","name":"small molecule binding","canonical_id":"go:GO:0036094","description":"\"Binding to a small molecule, any low molecular weight, monomeric, non-encoded molecule.\" [GOC:curators, GOC:pde, GOC:pm]","metadata":null},{"id":"25d97e9be53b46209f5a9a774293a884","type":"GO_TERM","name":"small molecule biosynthetic process","canonical_id":"go:GO:0044283","description":"\"The chemical reactions and pathways resulting in the formation of small molecules, any low molecular weight, monomeric, non-encoded molecule.\" [GOC:curators, GOC:pde, GOC:vw]","metadata":null},{"id":"c3b5f94716dd4bcfb9f10d895d630ef1","type":"GO_TERM","name":"small molecule catabolic process","canonical_id":"go:GO:0044282","description":"\"The chemical reactions and pathways resulting in the breakdown of small molecules, any low molecular weight, monomeric, non-encoded molecule.\" [GOC:curators, GOC:vw]","metadata":null},{"id":"e9e03d3589aa44dfb32ddea7e437043b","type":"GO_TERM","name":"small molecule metabolic process","canonical_id":"go:GO:0044281","description":"\"The chemical reactions and pathways involving small molecules, any low molecular weight, monomeric, non-encoded molecule.\" [GOC:curators, GOC:pde, GOC:vw]","metadata":null},{"id":"0298eea857ca4686a79cb2d57a9a2c92","type":"GO_TERM","name":"small nuclear ribonucleoprotein complex","canonical_id":"go:GO:0030532","description":"\"A ribonucleoprotein complex that contains at least one RNA of the small nuclear RNA (snRNA) class and as well as its associated proteins. These are typically named after the snRNA(s) they contain, e.g. U1 snRNP, U4/U6 snRNP, or 7SK snRNP. Many, of these complexes become part of the spliceosome involved in splicing of nuclear mRNAs. Others are involved in regulation of transcription elongation or 3'-end processing of replication-dependent histone pre-mRNAs.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"bab5adcd3af143fc88a620d4af6d3676","type":"GO_TERM","name":"small nucleolar ribonucleoprotein complex assembly","canonical_id":"go:GO:0000491","description":"\"The aggregation, arrangement and bonding together of proteins and a snoRNA to form a small nucleolar ribonucleoprotein (snoRNP) complex.\" [GOC:krc]","metadata":null},{"id":"866625903bc44cb58882db4ae5766b88","type":"GO_TERM","name":"small protein activating enzyme binding","canonical_id":"go:GO:0044388","description":"\"Binding to a small protein activating enzyme, such as ubiquitin-activating enzyme.\" [GOC:jl]","metadata":null},{"id":"4f67291e984d4aa4a95a1c09555af0a6","type":"GO_TERM","name":"small ribosomal subunit","canonical_id":"go:GO:0015935","description":"\"The smaller of the two subunits of a ribosome.\" [GOC:mah]","metadata":null},{"id":"1ff4207f61a34e03a454649543c4bf5e","type":"GO_TERM","name":"small ribosomal subunit processing complex","canonical_id":"go:GO:0140638","description":"\"A small heterodimeric protein complex that is required during early maturation of nascent 40S ribosomal subunits. The complex has endonuclease activity, it interacts with the small ribosomal subunit pre-rRNA and cleave it it to produce the mature 18S (or small ribosomal subunit) rRNA. In S. cerevisiae it is composed of Rcl1p and Bms1p.\" [GOC:lnp, PMID:21849504, PMID:25064857]","metadata":null},{"id":"4ba4ab33e69f4f578137cd2ee4ce9a00","type":"GO_TERM","name":"small ribosomal subunit rRNA binding","canonical_id":"go:GO:0070181","description":"\"Binding to small ribosomal subunit RNA (SSU rRNA), a constituent of the small ribosomal subunit. In S. cerevisiae, this is the 18S rRNA.\" [GOC:elh]","metadata":null},{"id":"b1fc4e43f79941c69d5bc9a2acd2d7f6","type":"GO_TERM","name":"small-subunit processome","canonical_id":"go:GO:0032040","description":"\"A large ribonucleoprotein complex that is an early preribosomal complex. In S. cerevisiae, it has a size of 80S and consists of the 35S pre-rRNA, early-associating ribosomal proteins most of which are part of the small ribosomal subunit, the U3 snoRNA and associated proteins.\" [GOC:krc, GOC:vw, PMID:12068309, PMID:12957375, PMID:15120992, PMID:15590835]","metadata":null},{"id":"85436323dadb4eb699ed7d0c5d12f4de","type":"GO_TERM","name":"small-subunit processome assembly","canonical_id":"go:GO:0034462","description":"\"The aggregation, arrangement and bonding together of proteins and RNA molecules to form a small-subunit processome.\" [GOC:mah]","metadata":null},{"id":"cc4594e67c544f9eadbb3fa39fd41154","type":"DISEASE","name":"smoking behavior","canonical_id":"efo:0004318","description":null,"metadata":null},{"id":"628fa306c6fa479e8c4cc83418709ab9","type":"DISEASE","name":"smoking cessation","canonical_id":"efo:0004319","description":null,"metadata":null},{"id":"0859f610861f4945bb3889b9221f0ed0","type":"DISEASE","name":"smoking initiation","canonical_id":"efo:0005670","description":null,"metadata":null},{"id":"c2114413d8e040d7a75c483ff4d3ed50","type":"GO_TERM","name":"smooth endoplasmic reticulum","canonical_id":"go:GO:0005790","description":"\"The smooth endoplasmic reticulum (smooth ER or SER) has no ribosomes attached to it. The smooth ER is the recipient of the proteins synthesized in the rough ER. Those proteins to be exported are passed to the Golgi complex, the resident proteins are returned to the rough ER and the lysosomal proteins after phosphorylation of their mannose residues are passed to the lysosomes. Glycosylation of the glycoproteins also continues. The smooth ER is the site of synthesis of lipids, including the phospholipids. The membranes of the smooth ER also contain enzymes that catalyze a series of reactions to detoxify both lipid-soluble drugs and harmful products of metabolism. Large quantities of certain compounds such as phenobarbital cause an increase in the amount of the smooth ER.\" [ISBN:0198506732]","metadata":null},{"id":"f2d76a51ca774966a145818043701931","type":"GO_TERM","name":"smooth endoplasmic reticulum calcium ion homeostasis","canonical_id":"go:GO:0051563","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions within the smooth endoplasmic reticulum of a cell or between the smooth endoplasmic reticulum and its surroundings.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"3459bb2a37e24d2683c789032b93f0eb","type":"GO_TERM","name":"smooth endoplasmic reticulum cisterna","canonical_id":"go:GO:0120082","description":"\"A subcompartment of the smooth endoplasmic reticulum consisting of lumenal expansion into a flattened, disc-shaped cavity.\" [GOC:sl, PMID:12112448]","metadata":null},{"id":"ac8549b47bd045e1ac596b5d8241ac06","type":"GO_TERM","name":"smooth endoplasmic reticulum lumen","canonical_id":"go:GO:0048238","description":"\"The volume enclosed by the membranes of the smooth endoplasmic reticulum.\" [GOC:jid]","metadata":null},{"id":"3f737836366245be87a3e40e16a2e1fd","type":"GO_TERM","name":"smooth endoplasmic reticulum membrane","canonical_id":"go:GO:0030868","description":"\"The lipid bilayer surrounding the smooth endoplasmic reticulum.\" [GOC:mah]","metadata":null},{"id":"32256abf1c584b06a1e3f59e2d627025","type":"GO_TERM","name":"smooth muscle adaptation","canonical_id":"go:GO:0014805","description":"\"Any process in which smooth muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors. These adaptive events occur in both muscle fibers and associated structures (motoneurons and capillaries), and they involve alterations in regulatory mechanisms, contractile properties and metabolic capacities.\" [GOC:mtg_muscle]","metadata":null},{"id":"7b2073ffbca34e4fb594135a3197781a","type":"GO_TERM","name":"smooth muscle atrophy","canonical_id":"go:GO:0014890","description":"\"A process, occurring in smooth muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"da8deba2446043adb82fad9124e5186b","type":"GO_TERM","name":"smooth muscle cell apoptotic process","canonical_id":"go:GO:0034390","description":"\"Any apoptotic process in a smooth muscle cell. Smooth muscle consists of non-striated, elongated, spindle-shaped cell found lining the digestive tract, uterus, and blood vessels.\" [CL:0000192, GOC:BHF, GOC:mah, GOC:mtg_apoptosis, GOC:rl]","metadata":null},{"id":"e16ed77af9ca4c4d9156e4d642c2d999","type":"GO_TERM","name":"smooth muscle cell chemotaxis","canonical_id":"go:GO:0071670","description":"\"The directed movement of a smooth muscle cell in response to an external stimulus.\" [GOC:mah]","metadata":null},{"id":"22d02deaf48d4416a27251c9d889d5bb","type":"GO_TERM","name":"smooth muscle cell differentiation","canonical_id":"go:GO:0051145","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell; smooth muscle lacks transverse striations in its constituent fibers and are almost always involuntary.\" [CL:0000192, GOC:ai]","metadata":null},{"id":"6495674b94a84545b1b244dfaac56931","type":"GO_TERM","name":"smooth muscle cell migration","canonical_id":"go:GO:0014909","description":"\"The orderly movement of a smooth muscle cell from one site to another, often during the development of a multicellular organism.\" [CL:0000192, GOC:mtg_muscle]","metadata":null},{"id":"dd491f5167db4bb1a835e1b3e08b722c","type":"GO_TERM","name":"smooth muscle cell proliferation","canonical_id":"go:GO:0048659","description":"\"The multiplication or reproduction of smooth muscle cells, resulting in the expansion of a cell population.\" [CL:0000192, GOC:ebc, PMID:1840698]","metadata":null},{"id":"d92367e6a94f420fb68efb56b65ddbe5","type":"GO_TERM","name":"smooth muscle cell-matrix adhesion","canonical_id":"go:GO:0061302","description":"\"The binding of a smooth muscle cell to the extracellular matrix via adhesion molecules.\" [GOC:BHF, GOC:dph, PMID:8837777]","metadata":null},{"id":"306a410c11334f098358f70ab8adb57d","type":"GO_TERM","name":"smooth muscle contractile fiber","canonical_id":"go:GO:0030485","description":"\"The contractile fiber of smooth muscle cells.\" [GOC:mah]","metadata":null},{"id":"f9f176297bab440792964fb0aa812cb2","type":"GO_TERM","name":"smooth muscle contraction","canonical_id":"go:GO:0006939","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Smooth muscle differs from striated muscle in the much higher actin/myosin ratio, the absence of conspicuous sarcomeres and the ability to contract to a much smaller fraction of its resting length.\" [GOC:ef, GOC:jl, GOC:mtg_muscle, ISBN:0198506732]","metadata":null},{"id":"9ce0256cd10a46fd8f3eca056429c44d","type":"GO_TERM","name":"smooth muscle contraction involved in micturition","canonical_id":"go:GO:0060083","description":"\"The process leading to shortening and/or development of tension in the urinary bladder smooth muscle tissue involved in the expulsion urine from the body.\" [GOC:dph, PMID:15827347]","metadata":null},{"id":"3ed86e542c174cf0bc67ec4c91b42767","type":"GO_TERM","name":"smooth muscle dense body","canonical_id":"go:GO:0030486","description":"\"Electron-dense region associated with a smooth muscle contractile fiber.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"4e08d173a5c7475cbe41dccc9e1ec726","type":"GO_TERM","name":"smooth muscle derived foam cell differentiation","canonical_id":"go:GO:0090078","description":"\"The process in which a smooth muscle cell acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.\" [GOC:add, GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"f3129534dfc44fb89e5628d6393d7abb","type":"GO_TERM","name":"smooth muscle hyperplasia","canonical_id":"go:GO:0014806","description":"\"A process, occurring in smooth muscle, in which there is an increase in cell number by cell division, often leading to an increase in the size of an organ.\" [GOC:mtg_muscle]","metadata":null},{"id":"3bca5d357f1b4fddb07658cf49120e1e","type":"GO_TERM","name":"smooth muscle hypertrophy","canonical_id":"go:GO:0014895","description":"\"The enlargement or overgrowth of all or part of an organ due to an increase in size of its smooth muscle cells without cell division. Physiological hypertrophy is a normal process during development, and can also occur in mature structures on demand. In the uterus, smooth muscle cells undergo hypertrophy during pregnancy.\" [GOC:mtg_muscle]","metadata":null},{"id":"067e3beb94934168909636cc27aea665","type":"GO_TERM","name":"smooth muscle relaxation of the bladder outlet","canonical_id":"go:GO:0060085","description":"\"A process in which the extent of smooth muscle contraction is reduced in the bladder outlet that contributes to the expulsion of urine from the body.\" [GOC:dph, PMID:15827347]","metadata":null},{"id":"86d2f5bfd550426ab43813dcd9822ed7","type":"GO_TERM","name":"smooth muscle tissue development","canonical_id":"go:GO:0048745","description":"\"The process whose specific outcome is the progression of smooth muscle over time, from its formation to the mature structure.\" [GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"6c32be20bdfb439eb81fb2ec425573c9","type":"GO_TERM","name":"smooth septate junction","canonical_id":"go:GO:0005920","description":"\"A septate junction that lacks the regular arrays of electron-dense septae found in pleated septate junctions.\" [PMID:11700298]","metadata":null},{"id":"d90b443322864639891991a5da40a2a2","type":"GO_TERM","name":"smooth septate junction assembly","canonical_id":"go:GO:0090528","description":"\"The assembly of a smooth septate junction, a septate junction that lacks the regular arrays of electron-dense septae found in pleated septate junctions.\" [PMID:22854041]","metadata":null},{"id":"d760f4d294cb4b7aa09762939a8c6a45","type":"GO_TERM","name":"smoothened binding","canonical_id":"go:GO:0005119","description":"\"Binding to a smoothened (smo) protein, which interacts with patched to transmit hedgehog signals.\" [GOC:ceb, PMID:11731473]","metadata":null},{"id":"7e453cef0d3b45dcb4f4b599d7edf09b","type":"GO_TERM","name":"smoothened signaling pathway","canonical_id":"go:GO:0007224","description":"\"The series of molecular signals generated as a consequence of activation of the transmembrane protein Smoothened.\" [GOC:mah, PMID:15057936, PMID:15205520]","metadata":null},{"id":"c6b11c9302b8402dab39bdae4a87867f","type":"GO_TERM","name":"smoothened signaling pathway involved in dorsal/ventral neural tube patterning","canonical_id":"go:GO:0060831","description":"\"The series of molecular signals generated as a consequence of activation of the transmembrane protein Smoothened contributing to the dorsal/ventral pattern of the neural tube.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"a02bafe0e0194a2cbd458ec061a667f8","type":"GO_TERM","name":"smoothened signaling pathway involved in lung development","canonical_id":"go:GO:0060506","description":"\"The series of molecular signals generated as a consequence of activation of the transmembrane Smoothened-type protein. This process contributes to lung development.\" [GOC:dph, GOC:mtg_lung]","metadata":null},{"id":"c7634c7d213049459005c078bf078000","type":"GO_TERM","name":"smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation","canonical_id":"go:GO:0003271","description":"\"The series of molecular signals generated as a consequence of activation of the transmembrane protein Smoothened contributing to the modulation of the frequency, rate or extent of cardioblast proliferation in the secondary heart field. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.\" [GOC:mtg_heart]","metadata":null},{"id":"f55c8d8017364b8ab374ebb7d302a421","type":"GO_TERM","name":"smoothened signaling pathway involved in spinal cord motor neuron cell fate specification","canonical_id":"go:GO:0021776","description":"\"The series of molecular signals initiated by binding of a ligand to the transmembrane receptor smoothened in a precursor cell in the spinal cord that contributes to the process of a precursor cell becoming capable of differentiating autonomously into a motor neuron in an environment that is neutral with respect to the developmental pathway.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15936325]","metadata":null},{"id":"fa8b76fba120490792ffe730199b2b93","type":"GO_TERM","name":"smoothened signaling pathway involved in ventral spinal cord interneuron specification","canonical_id":"go:GO:0021775","description":"\"The series of molecular signals initiated by binding of a ligand to the transmembrane receptor smoothened in a precursor cell in the ventral spinal cord that contributes to the commitment of the precursor cell to an interneuron fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"f72db6deeae04118a55a59ed30306b9d","type":"GO_TERM","name":"smoothened signaling pathway involved in ventral spinal cord patterning","canonical_id":"go:GO:0021910","description":"\"The series of molecular signals generated as a consequence of activation of the transmembrane protein Smoothened that results in the spatial identity of regions along the dorsal-ventral axis of the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:tb, PMID:11262869]","metadata":null},{"id":"c0aedb8e07024ffd93ed623972042959","type":"GO_TERM","name":"sn-2 acyl-lipid omega-3 desaturase (ferredoxin) activity","canonical_id":"go:GO:0102993","description":"\"Catalysis of the reaction: a (9Z,12Z)-octadecadienoyl-containing glycerolipid + 2 H+ + O2 + 2 reduced [2Fe-2S]-[ferredoxin] = (9Z,12Z,15Z)-octadecatrienoyl-containing glycerolipid + 2 H2O + 2 oxidized [2Fe-2S]-[ferredoxin]. Also converts a (7Z,10Z)-hexadecadienoyl-containing glycerolipid into a (7Z,10Z,13Z)-hexadecatrienoyl-containing glycerolipid.\" [EC:1.14.19.35]","metadata":null},{"id":"5c934ee88bf74156834ef88499f5ba25","type":"GO_TERM","name":"sn-glycerol 1-phosphatase activity","canonical_id":"go:GO:0000121","description":"\"Catalysis of the reaction: H2O + sn-glycerol 1-phosphate = glycerol + phosphate.\" [RHEA:46084]","metadata":null},{"id":"aa3002281c454ad08432e30e44f2ed2a","type":"GO_TERM","name":"sn-glycerol 3-phosphatase activity","canonical_id":"go:GO:0043136","description":"\"Catalysis of the reaction: H2O + sn-glycerol 3-phosphate = glycerol + phosphate.\" [RHEA:66372]","metadata":null},{"id":"7dcfd7bf87f44db8a79b6853b3f47d4a","type":"GO_TERM","name":"sn-glycerol 3-phosphate binding","canonical_id":"go:GO:1902516","description":"\"Binding to sn-glycerol 3-phosphate.\" [GOC:bhm, GOC:TermGenie, PMID:23013274]","metadata":null},{"id":"5312921de2e54b759137394e43fd32bf","type":"GO_TERM","name":"sn-glycerol-3-phosphate 1-galactosyltransferase activity","canonical_id":"go:GO:0047279","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + UDP-D-galactose = 1-O-alpha-D-galactosyl-sn-glycerol 3-phosphate + H+ + UDP.\" [EC:2.4.1.96, RHEA:20341]","metadata":null},{"id":"095f15ef65a94faab52d7a67c479979a","type":"GO_TERM","name":"sn-glycerol-3-phosphate 2-alpha-galactosyltransferase activity","canonical_id":"go:GO:0047221","description":"\"Catalysis of the reaction: sn-glycerol 3-phosphate + UDP-D-galactose = 2-(alpha-D-galactosyl)-sn-glycerol 3-phosphate + H+ + UDP.\" [EC:2.4.1.137, RHEA:14285]","metadata":null},{"id":"7950fc38c28340a3bb0795a729d79b6c","type":"GO_TERM","name":"snRNA (adenine-N6)-methylation","canonical_id":"go:GO:0120049","description":"\"The posttranscriptional N6-methylation of an adenine residue in an snRNA molecule.\" [PMID:28525753]","metadata":null},{"id":"b21b937d9b3f40fc9a73c7acbdcae220","type":"GO_TERM","name":"snRNA 2'-O-methylation","canonical_id":"go:GO:1990437","description":"\"The posttranscriptional addition of a methyl group to the 2' oxygen atom of a nucleotide residue in an snRNA molecule.\" [PMID:11842100, PMID:9844635]","metadata":null},{"id":"a2e02f3bf2644e3eb3c0b2d636d2aff3","type":"GO_TERM","name":"snRNA 2'-O-ribose methylation guide activity","canonical_id":"go:GO:0030563","description":"\"Activity that provides specificity to a methylase by using base complementarity to guide site-specific 2'-O-ribose methylations to a small nuclear RNA molecule.\" [PMID:11733745]","metadata":null},{"id":"9d87d99caf444b2fbf473f1d898a1245","type":"GO_TERM","name":"snRNA 2,2,7-trimethylguanosine (TMG) capping","canonical_id":"go:GO:1990273","description":"\"The sequence of enzymatic reactions by which a 2,2,7-trimethylguanosine cap structure is added to the 5' end of an snRNA. The snRNA capping process includes the formation of 7-methyl-G caps found on all RNA polymerase II transcripts, followed by hypermethylation at the 2' position of the guanosine residue to convert a mono-methylated cap to a 2,2,7-trimethylguanosine cap structure. Note that the pol III transcribed U6 snRNA is also TMG capped.\" [GOC:vw, PMID:15590684]","metadata":null},{"id":"9d6fec3f22ab427cac2bc1c7e93a4022","type":"GO_TERM","name":"snRNA 3'-end processing","canonical_id":"go:GO:0034472","description":"\"Any process involved in forming the mature 3' end of an snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"f0a39c506e2040c1bc2903c92870aee5","type":"GO_TERM","name":"snRNA binding","canonical_id":"go:GO:0017069","description":"\"Binding to a small nuclear RNA (snRNA).\" [GOC:mah]","metadata":null},{"id":"f433ff9e7e78400383e104c1c641ce36","type":"GO_TERM","name":"snRNA catabolic process","canonical_id":"go:GO:0016076","description":"\"The chemical reactions and pathways resulting in the breakdown of snRNA, small nuclear RNA, low-molecular-mass RNA molecules found in the eukaryotic nucleus as components of the small nuclear ribonucleoprotein.\" [ISBN:0198506732]","metadata":null},{"id":"61d33f078c8b49da83c710a5cdae3598","type":"GO_TERM","name":"snRNA export from nucleus","canonical_id":"go:GO:0006408","description":"\"The directed movement of snRNA from the nucleus to the cytoplasm.\" [GOC:ma]","metadata":null},{"id":"35178652fb9644e6bc9e898cc7f2e153","type":"GO_TERM","name":"snRNA import into nucleus","canonical_id":"go:GO:0061015","description":"\"The directed movement of snRNA, small nuclear ribonucleic acid into the nucleus.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"174e4175681f407da2f64d83290cdc36","type":"GO_TERM","name":"snRNA localization to Cajal body","canonical_id":"go:GO:0061016","description":"\"The directed movement of snRNA, small nuclear ribonucleic acid, to a Cajal body.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"44df7e0c3c024f7cb0780d017033014c","type":"GO_TERM","name":"snRNA metabolic process","canonical_id":"go:GO:0016073","description":"\"The chemical reactions and pathways involving snRNA, small nuclear RNA, any of various low-molecular-mass RNA molecules found in the eukaryotic nucleus as components of the small nuclear ribonucleoprotein.\" [ISBN:0198506732]","metadata":null},{"id":"57aa92e8adec4e329db40b3902d48f79","type":"GO_TERM","name":"snRNA methylation","canonical_id":"go:GO:0106349","description":"\"The posttranscriptional addition of methyl groups to specific residues in an snRNA molecule.\" [PMID:21823225]","metadata":null},{"id":"6ecc221287ad4cfe9dad261d179c61f5","type":"GO_TERM","name":"snRNA methyltransferase activity","canonical_id":"go:GO:0106346","description":"\"Catalysis of the transfer of a methyl group from a donor to a nucleoside residue in an snRNA molecule.\" [PMID:27573892]","metadata":null},{"id":"1f7e939910aa4766becd1412b090cbd9","type":"GO_TERM","name":"snRNA modification","canonical_id":"go:GO:0040031","description":"\"The covalent alteration of one or more nucleotides within snRNA, resulting in a change in the properties of the snRNA.\" [GOC:jl]","metadata":null},{"id":"a25ea2b85aaa44d5bee86243e01f852e","type":"GO_TERM","name":"snRNA modification guide activity","canonical_id":"go:GO:0030566","description":"\"Specifies the site of a posttranscriptional modification in an snRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"7b671dcce62143d3a30222d573f59a19","type":"GO_TERM","name":"snRNA processing","canonical_id":"go:GO:0016180","description":"\"Any process involved in the conversion of a primary small nuclear RNA (snRNA) transcript into a mature snRNA molecule. The primary function of snRNAs is processing pre-messenger RNA in the nucleus. They have also been shown to aid in the regulation of transcription factors (7SK RNA) or RNA polymerase II (B2 RNA), and maintaining the telomeres.\" [PMID:15196465, PMID:31815536]","metadata":null},{"id":"2b111be7fe3b4c8eb68248125d82a703","type":"GO_TERM","name":"snRNA pseudouridine synthase activity","canonical_id":"go:GO:0106032","description":"\"Catalysis of the reaction: uridine in snRNA = pseudouridine in snRNA. Conversion of uridine in an snRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.\" [PMID:28432181, RHEA:51124]","metadata":null},{"id":"cd1ac476d81f4abe900134d67e96cff2","type":"GO_TERM","name":"snRNA pseudouridine synthesis","canonical_id":"go:GO:0031120","description":"\"The intramolecular conversion of uridine to pseudouridine in an snRNA molecule.\" [GOC:mah]","metadata":null},{"id":"390e25bc36244dcdae8d7d76c8550e93","type":"GO_TERM","name":"snRNA pseudouridylation guide activity","canonical_id":"go:GO:0030565","description":"\"Activity that provides specificity to a pseudouridine synthetase by using base complementarity to guide site-specific pseudouridylations to a small nuclear RNA molecule.\" [PMID:11733745]","metadata":null},{"id":"c88d390d7c4148b7869e5e4af00176ae","type":"GO_TERM","name":"snRNA stem-loop binding","canonical_id":"go:GO:0035614","description":"\"Binding to a stem-loop in a small nuclear RNA (snRNA). An RNA stem-loop is a secondary RNA structure consisting of a double-stranded RNA (dsRNA) stem and a terminal loop.\" [GOC:sart, PMID:16568238, PMID:20455544]","metadata":null},{"id":"318d2d721163414b887d8d7bf3f3c482","type":"GO_TERM","name":"snRNA transcription","canonical_id":"go:GO:0009301","description":"\"The synthesis of small nuclear RNA (snRNA) from a DNA template.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"dbad79ee0e3f46508fdf48b3097da78f","type":"GO_TERM","name":"snRNA transcription by RNA polymerase II","canonical_id":"go:GO:0042795","description":"\"The synthesis of small nuclear RNA (snRNA) from a DNA template by RNA Polymerase II (Pol II), originating at a Pol II promoter.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"b95665c8b3aa4163af9c5cc21fe290ae","type":"GO_TERM","name":"snRNA transcription by RNA polymerase III","canonical_id":"go:GO:0042796","description":"\"The synthesis of small nuclear RNA (snRNA) from a DNA template by RNA Polymerase III (Pol III), originating at a Pol III promoter.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"65dc367fa35f4060b84ada5f45cef562","type":"GO_TERM","name":"snRNA transport","canonical_id":"go:GO:0051030","description":"\"The directed movement of snRNA, small nuclear ribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"b188f9368912474c8319f642149a13fa","type":"GO_TERM","name":"snRNA-activating protein complex","canonical_id":"go:GO:0019185","description":"\"A protein complex that recognizes the proximal sequence element of RNA polymerase II and III snRNA promoters.\" [PMID:7715707, PMID:9003788]","metadata":null},{"id":"8312bfba3c3540d3abb368cf0ac01f3c","type":"GO_TERM","name":"snRNP binding","canonical_id":"go:GO:0070990","description":"\"Binding to a small nuclear ribonucleoprotein particle.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"36d0a8e54f8d4a6c897f4c29424ae928","type":"GO_TERM","name":"sneeze reflex","canonical_id":"go:GO:0160023","description":"\"A reflex process that expels air forcibly from the mouth and nose in an explosive, spasmodic involuntary action resulting chiefly from irritation of the nasal mucous membrane.\" [https://www.thefreedictionary.com/sneeze, PMID:34133943]","metadata":null},{"id":"b54ee4a7c99b414688ca5d07dd5345b0","type":"GO_TERM","name":"sno(s)RNA 3'-end cleavage","canonical_id":"go:GO:0043145","description":"\"The endonucleolytic cleavage of snoRNA 3' ends, which is required for mature snoRNAs to be functional.\" [GOC:curators, PMID:12773397]","metadata":null},{"id":"d5df6b4fdd124bf39a0d5890af367985","type":"GO_TERM","name":"sno(s)RNA 3'-end processing","canonical_id":"go:GO:0031126","description":"\"Any process involved in forming the mature 3' end of a snoRNA family molecule, also referred to as an sRNA in Archaea.\" [GOC:krc, GOC:mah, PMID:17284456]","metadata":null},{"id":"591b0e71c1b6403bb9684822451fa568","type":"GO_TERM","name":"sno(s)RNA catabolic process","canonical_id":"go:GO:0016077","description":"\"The chemical reactions and pathways resulting in the breakdown of snoRNA, small nucleolar RNA, any of a class of small RNAs that are associated with the eukaryotic nucleus as components of small nucleolar ribonucleoproteins.\" [GOC:krc, ISBN:0198506732]","metadata":null},{"id":"2b5d9733607a4a9282daea8fa8d3f41e","type":"GO_TERM","name":"sno(s)RNA metabolic process","canonical_id":"go:GO:0016074","description":"\"The chemical reactions and pathways involving snoRNA, small nucleolar RNA, any of a class of small RNAs that are associated with the eukaryotic nucleus as components of small nucleolar ribonucleoproteins. They participate in the processing or modifications of many RNAs, mostly ribosomal RNAs (rRNAs) though snoRNAs are also known to target other classes of RNA, including spliceosomal RNAs, tRNAs, and mRNAs via a stretch of sequence that is complementary to a sequence in the targeted RNA.\" [GOC:krc]","metadata":null},{"id":"7abd5abb2e564491be032aa36db8d898","type":"GO_TERM","name":"sno(s)RNA processing","canonical_id":"go:GO:0043144","description":"\"Any process involved in the conversion of a primary snoRNA family RNA transcript into a mature snoRNA (eukaryota) or sRNA (archaea).\" [GOC:curators, GOC:krc, PMID:12773397]","metadata":null},{"id":"353a988d92e144d5806d741af1dbd232","type":"GO_TERM","name":"sno(s)RNA transcription","canonical_id":"go:GO:0009302","description":"\"The synthesis of snoRNA class RNA (also referred to as sRNA in Archaea) from a DNA template.\" [GOC:jl, GOC:krc, PMID:17284456]","metadata":null},{"id":"0c5544edc5904a6085a23c2fe248895b","type":"GO_TERM","name":"sno(s)RNA-containing ribonucleoprotein complex","canonical_id":"go:GO:0005732","description":"\"A ribonucleoprotein complex that contains an RNA molecule of the snoRNA family and associated proteins. Many are involved in a step of processing of rRNA molecules: cleavage, 2'-O-methylation, or pseudouridylation, but other RNA types can be targets as well. The majority fall into one of two classes, box C/D type or box H/ACA type, which are conserved across eukaryotes and archaea. Other members include the telomerase RNA and the ribonuclease MRP RNA.\" [GOC:krc, GOC:mah, ISBN:0879695897, PMID:17284456]","metadata":null},{"id":"3eaca564a37d4d79b6e4c67c262f7be3","type":"GO_TERM","name":"snoRNA 2,2,7-trimethylguanosine (TMG) capping","canonical_id":"go:GO:0180031","description":"\"The sequence of enzymatic reactions by which a 2,2,7-trimethylguanosine cap structure is added to the 5' end of an snoRNA. The snoRNA capping includes the formation of 7-methyl-G caps found on all RNA polymerase II transcripts, followed by hypermethylation at the 2' position of the guanosine residue to convert a mono-methylated cap to a 2,2,7-trimethylguanosine cap structure. Note that the pol III transcribed snoRNAs are also TMG capped.\" [GOC:vw, PMID:15590684]","metadata":null},{"id":"e90f00727fe14ea5af392a306f752a65","type":"GO_TERM","name":"snoRNA binding","canonical_id":"go:GO:0030515","description":"\"Binding to a small nucleolar RNA.\" [GOC:mah]","metadata":null},{"id":"cebf695403084a2f83e46b3f1242cd42","type":"GO_TERM","name":"snoRNA guided rRNA 2'-O-methylation","canonical_id":"go:GO:0000452","description":"\"The posttranscriptional addition of methyl groups to the 2'-oxygen atom of nucleotide residues in an rRNA molecule during ribosome biogenesis using a snoRNA guide that targets the position of methylation.\" [GOC:curators, ISBN:1555811337]","metadata":null},{"id":"c61c01d4bcdd4db492ae71186a9eace0","type":"GO_TERM","name":"snoRNA guided rRNA pseudouridine synthesis","canonical_id":"go:GO:0000454","description":"\"The intramolecular conversion of uridine to pseudouridine in an rRNA molecule during ribosome biogenesis using a snoRNA guide that targets the position of pseudouridylation.\" [GOC:curators, ISBN:1555811337]","metadata":null},{"id":"f7735414f7474dfba931fc7ea33909a6","type":"GO_TERM","name":"snoRNA localization","canonical_id":"go:GO:0048254","description":"\"Any process in which small nucleolar RNA is transported to, or maintained in, a specific location.\" [ISBN:0716731363]","metadata":null},{"id":"6cb18bd265794b56974b6b754d9eab34","type":"GO_TERM","name":"snoRNA release from pre-rRNA","canonical_id":"go:GO:1990417","description":"\"The release of snoRNA from pre-rRNA.\" [GOC:rb, PMID:16908538]","metadata":null},{"id":"d9601d5ffa1f4804807853c301f1342a","type":"GO_TERM","name":"snoRNA splicing","canonical_id":"go:GO:0034247","description":"\"The process of removing sections of a primary snoRNA transcript to remove sequences not present in the mature form of the snoRNA and joining the remaining sections to form the mature form of the snoRNA.\" [GOC:mah]","metadata":null},{"id":"76db76eab7e44185afabdf10730e3aa5","type":"GO_TERM","name":"snoRNA transcription by RNA polymerase II","canonical_id":"go:GO:0001015","description":"\"The synthesis of small nucleolar RNA (snoRNA) from a DNA template by RNA polymerase II, originating at an RNA polymerase II promoter.\" [GOC:txnOH]","metadata":null},{"id":"d67aafedbdcb4b7096547124a7f605b1","type":"GO_TERM","name":"snoRNA transcription by RNA polymerase III","canonical_id":"go:GO:0001014","description":"\"The synthesis of small nucleolar RNA (snoRNA) from a DNA template by RNA polymerase III, originating at a type 2 RNA polymerase III promoter.\" [GOC:txnOH]","metadata":null},{"id":"88fbd4a31c524c408583724b1f8f6f5d","type":"GO_TERM","name":"snoRNP binding","canonical_id":"go:GO:0030519","description":"\"Binding to a small nucleolar ribonucleoprotein particle.\" [GOC:mah]","metadata":null},{"id":"77f5cbfb81b94e649723b1bd0ae451ba","type":"GO_TERM","name":"social behavior","canonical_id":"go:GO:0035176","description":"\"Behavior directed towards society, or taking place between members of the same species. Occurs predominantly, or only, in individuals that are part of a group.\" [GOC:jh2, PMID:12848939, Wikipedia:Social_behavior]","metadata":null},{"id":"a9003166396f42bc84790e56fb5afefc","type":"GO_TERM","name":"socially cooperative development","canonical_id":"go:GO:0099120","description":"\"The process whose specific outcome is the progression of a non-reproductive fruiting body over time, from its formation to the mature structure. A non-reproductive fruiting body is a colonial multicellular structure consisting of co-operating unicellular organisms, some of which are spores. An example of such a process is found in Dictyostelium discoideum and Myxococcus xanthus colonies.\" [GOC:pf, PMID:12448714]","metadata":null},{"id":"2d3d9fe034f84b068c27d34913bf6745","type":"GO_TERM","name":"socket cell differentiation","canonical_id":"go:GO:0090437","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a socket cell, a shoot epidermal cell that surrounds a trichome and provides its support.\" [GOC:tb]","metadata":null},{"id":"703a9b1da341499cb5662c5860f33da5","type":"DRUG","name":"sodium aurothiomalate","canonical_id":"mesh:D006052","description":null,"metadata":null},{"id":"b174d337809b46c5a116fd00dee309f5","type":"GO_TERM","name":"sodium channel activator activity","canonical_id":"go:GO:7770087","description":"\"Binds to and increases the activity of a sodium channel.\" [PMID:25492945, PMID:27246624]","metadata":null},{"id":"6af31183922b4088812cf1d8be487242","type":"GO_TERM","name":"sodium channel activity","canonical_id":"go:GO:0005272","description":"\"Enables the energy-independent facilitated diffusion of a sodium ion through a transmembrane aqueous pore or channel.\" [GOC:BHF, GOC:mtg_transport, GOC:pr, ISBN:0815340729]","metadata":null},{"id":"0465a38e0c904d109670de33d7fcc9cb","type":"GO_TERM","name":"sodium channel complex","canonical_id":"go:GO:0034706","description":"\"An ion channel complex through which sodium ions pass.\" [GOC:mah]","metadata":null},{"id":"5f52a9f133ce4abc922823a743f59626","type":"GO_TERM","name":"sodium channel inhibitor activity","canonical_id":"go:GO:0019871","description":"\"Binds to and stops, prevents, or reduces the activity of a sodium channel.\" [GOC:mah]","metadata":null},{"id":"152b75d5e5bd4972b5a816626cc372e5","type":"GO_TERM","name":"sodium channel regulator activity","canonical_id":"go:GO:0017080","description":"\"Binds to and modulates the activity of a sodium channel.\" [GOC:mah]","metadata":null},{"id":"d40946d7ca024a65bcf3db302f0c5247","type":"DRUG","name":"sodium fluoride","canonical_id":"mesh:D012969","description":null,"metadata":null},{"id":"c08735d8cb2146ada61f793d7c6fcce3","type":"DRUG","name":"sodium glycerophosphate","canonical_id":"mesh:C029620","description":null,"metadata":null},{"id":"f4c3f577ab2c4338a47b13104a663870","type":"GO_TERM","name":"sodium ion binding","canonical_id":"go:GO:0031402","description":"\"Binding to a sodium ion (Na+).\" [GOC:mah]","metadata":null},{"id":"f36352c9a4d3446aa4054ffcf06edd74","type":"GO_TERM","name":"sodium ion export across plasma membrane","canonical_id":"go:GO:0036376","description":"\"The directed movement of sodium ions from inside of a cell, across the plasma membrane and into the extracellular region.\" [GOC:vw, PMID:14674689]","metadata":null},{"id":"fa90cc4c3c4844a1b36ebc143bfe970c","type":"GO_TERM","name":"sodium ion homeostasis","canonical_id":"go:GO:0055078","description":"\"Any process involved in the maintenance of an internal steady state of sodium ions within an organism or cell.\" [GOC:ai, GOC:jid, GOC:mah]","metadata":null},{"id":"77c4d41dc70f405492f0f34a347d581a","type":"GO_TERM","name":"sodium ion import across plasma membrane","canonical_id":"go:GO:0098719","description":"\"The directed movement of sodium ions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"01ef831cce3f47b99451258e15a42002","type":"GO_TERM","name":"sodium ion sequestering activity","canonical_id":"go:GO:7770031","description":"\"Binding to a sodium ion to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:25689889]","metadata":null},{"id":"ee30102ce74c4590bbb1d6f6756c8a29","type":"GO_TERM","name":"sodium ion transmembrane transport","canonical_id":"go:GO:0035725","description":"\"A process in which a sodium ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:vw]","metadata":null},{"id":"5ad6adcc5bed4580b4fc429212592dd9","type":"GO_TERM","name":"sodium ion transmembrane transporter activity","canonical_id":"go:GO:0015081","description":"\"Enables the transfer of sodium ions (Na+) from one side of a membrane to the other.\" [GOC:ai, GOC:BHF]","metadata":null},{"id":"f5a16a25b80a47f48ce1611570ccbd9d","type":"GO_TERM","name":"sodium ion transport","canonical_id":"go:GO:0006814","description":"\"The directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"14ccde007a5541289662233acfd538f2","type":"GO_TERM","name":"sodium ion uniporter activity","canonical_id":"go:GO:0022818","description":"\"Catalysis of the active transport of a sodium ion across a membrane by a mechanism involving conformational change, where energy for active transport is derived from membrane potential if the solute is charged.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"23d4074a5af448989b5bd118a8c0f097","type":"GO_TERM","name":"sodium ion-transporting F-type ATPase complex","canonical_id":"go:GO:0016473","description":"\"A sodium ion-transporting two-sector ATPase complex that catalyzes the phosphorylation of ADP to ATP. The complex comprises a membrane sector (F0) that carries out proton transport and a cytoplasmic compartment sector (F1) that catalyzes ATP synthesis by a rotational mechanism.\" [GOC:mah, PMID:14656431]","metadata":null},{"id":"dfc763f339954020a6f125d6041c1ebb","type":"GO_TERM","name":"sodium ion-transporting V-type ATPase complex","canonical_id":"go:GO:0016474","description":"\"A sodium ion-transporting two-sector ATPase complex that couples ATP hydrolysis to the transport of sodium ions across a concentration gradient. The complex comprises a membrane sector (V0) that carries out proton transport and a cytoplasmic compartment sector (V1) that catalyzes ATP hydrolysis.\" [GOC:mah, PMID:15802565]","metadata":null},{"id":"e99abe93c3e640f294f6bbbb88e90096","type":"GO_TERM","name":"sodium ion-transporting two-sector ATPase complex","canonical_id":"go:GO:0016472","description":"\"A large protein complex that catalyzes the synthesis or hydrolysis of ATP by a rotational mechanism, coupled to the transport of sodium ions across a membrane. The complex comprises a membrane sector (F0 or V0) that carries out ion transport and a cytoplasmic compartment sector (F1 or V1) that catalyzes ATP synthesis or hydrolysis.\" [GOC:mah, PMID:14656431]","metadata":null},{"id":"faca27c8f70a44ea9d7ca2b6d8e899a7","type":"DRUG","name":"sodium tetradecyl sulfate","canonical_id":"mesh:D012981","description":null,"metadata":null},{"id":"176ffbf9d10048388b51344b9d6587a4","type":"GO_TERM","name":"sodium,bicarbonate:chloride antiporter activity","canonical_id":"go:GO:0140892","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction chloride(in) + 2 hydrogencarbonate(out) + Na+(out) = chloride(out) + 2 hydrogencarbonate(in) + Na+(in).\" [PMID:18577713, PMID:20389022, PMID:8189393]","metadata":null},{"id":"97ff24e93b4b4717800d109a767c629e","type":"GO_TERM","name":"sodium-dependent multivitamin transmembrane transporter activity","canonical_id":"go:GO:0008523","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: multivitamin(out) + Na+(out) = multivitamin(in) + Na+(in). Multivitamins include pantothenate, biotin and lipoate.\" [TC:2.A.21.5.2]","metadata":null},{"id":"be831320c59e4ea3a9b6530b3b2cbe45","type":"GO_TERM","name":"sodium-dependent organic anion transport","canonical_id":"go:GO:0043251","description":"\"The directed, sodium-dependent, movement of organic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"83d6d14e8b8f4a2a8e2cf7883b0bb7a1","type":"GO_TERM","name":"sodium-dependent organic cation transport","canonical_id":"go:GO:0070715","description":"\"The directed, sodium-dependent, movement of organic cations into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"294229f440ef49e280623a8aaeba3eac","type":"GO_TERM","name":"sodium-dependent phosphate transport","canonical_id":"go:GO:0044341","description":"\"The directed movement of phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore, by a mechanism dependent upon sodium ions.\" [GOC:BHF, GOC:jl]","metadata":null},{"id":"3f864ecc15f84836917d234809a44228","type":"GO_TERM","name":"sodium-dependent self proteolysis","canonical_id":"go:GO:1990091","description":"\"The sodium-dependent hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their own peptide bonds.\" [PMID:20460380]","metadata":null},{"id":"bce596088ad841ec9a2dcf4e1a631609","type":"GO_TERM","name":"sodium-independent icosanoid transport","canonical_id":"go:GO:0071718","description":"\"The directed, sodium-independent, movement of icosanoids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Icosanoids are unsaturated C20 fatty acids and skeletally related compounds.\" [GOC:mah, GOC:sl]","metadata":null},{"id":"6b7dca5bfe554fe882fcb8e953d38469","type":"GO_TERM","name":"sodium-independent leukotriene transport","canonical_id":"go:GO:0071719","description":"\"The directed, sodium-independent, movement of leukotrienes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Leukotrienes are linear C20 endogenous metabolites of arachidonic acid (icosa-5,8,11,14-tetraenoic acid) containing a terminal carboxy function and four or more double bonds (three or more of which are conjugated) as well as other functional groups.\" [GOC:mah]","metadata":null},{"id":"23015ceda1c84c8a8ef9cdc88a76fb32","type":"GO_TERM","name":"sodium-independent organic anion transport","canonical_id":"go:GO:0043252","description":"\"The directed, sodium-independent, movement of organic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"072cd809330d41b1bae7e39172866b3b","type":"GO_TERM","name":"sodium-independent prostaglandin transport","canonical_id":"go:GO:0071720","description":"\"The directed, sodium-independent, movement of prostaglandins into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"818bd8bf70784448ae5e6e513be34b1b","type":"GO_TERM","name":"sodium-independent thromboxane transport","canonical_id":"go:GO:0071721","description":"\"The directed, sodium-independent, movement of thromboxanes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A thromboxane is any of a class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.\" [GOC:mah]","metadata":null},{"id":"a068c4b4694f407bb4013c613ef1d0d3","type":"GO_TERM","name":"sodium-translocating NADH-quinone reductase complex assembly","canonical_id":"go:GO:0160293","description":"\"The aggregation, arrangement and bonding together of a set of components to form a sodium-translocating NADH-quinone reductase complex.\" [PMID:26644436]","metadata":null},{"id":"1ddb994050874f9e8011e12ed00e9ced","type":"GO_TERM","name":"sodium-translocating NADH:quinone reductase complex","canonical_id":"go:GO:0160292","description":"\"A bacterial protein complex consisting of six subunits, NqrABCDEF, encoded by the nqr operon, which catalyzes electron transfer from NADH to ubiquinone in the respiratory chain coupled with the transport of sodium ions from the cytoplasm to the periplasm.\" [PMID:38955304]","metadata":null},{"id":"9024fef0399c428d8c4e266b65c5560c","type":"GO_TERM","name":"sodium-transporting ATP synthase activity, rotational mechanism","canonical_id":"go:GO:0046932","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other by a rotational mechanism according to the reaction: 4 Na+(out) + ADP + phosphate + H+ => 4 Na+(in) + ATP + H2O.\" [RHEA:58158]","metadata":null},{"id":"3be40caaba0f42659becf9ff44e41d0f","type":"GO_TERM","name":"sodium-transporting ATPase activity, rotational mechanism","canonical_id":"go:GO:0046962","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other by a rotational mechanism according to the reaction: 4 Na+(in) + ATP + H2O => 4 Na+(out) + ADP + phosphate + H+.\" [PMID:30791207, RHEA:58157]","metadata":null},{"id":"1eb09d9221334c959895986e06aad09f","type":"GO_TERM","name":"sodium:ammonium:chloride symporter activity","canonical_id":"go:GO:7770002","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + NH4+(out) + Cl-(out) = Na+(in) + NH4+(in) + Cl-(in).\" [PMID:12657561, RHEA:85511]","metadata":null},{"id":"2508efa082ee459794cc255847ec8905","type":"GO_TERM","name":"sodium:bicarbonate symporter activity","canonical_id":"go:GO:0008510","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + HCO3-(out) = Na+(in) + HCO3-(in).\" [TC:2.A.31.2.1]","metadata":null},{"id":"22918c468ec44ec398cad0290bb751d2","type":"GO_TERM","name":"sodium:chloride symporter activity","canonical_id":"go:GO:0015378","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + Cl-(out) = Na+(in) + Cl-(in).\" [TC:2.A.30.4.-]","metadata":null},{"id":"fd38908a9a454e0e978a57b50540ddb6","type":"GO_TERM","name":"sodium:dicarboxylate symporter activity","canonical_id":"go:GO:0017153","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: dicarboxylate(out) + Na+(out) = dicarboxylate(in) + Na+(in).\" [GOC:ai]","metadata":null},{"id":"74e6c38810904af18af9964b1551badc","type":"GO_TERM","name":"sodium:galactoside symporter activity","canonical_id":"go:GO:0044669","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sodium(out)+ galactoside(out) = sodium(in) + galactoside(in).\" [GOC:crds]","metadata":null},{"id":"d7f8428a606b4df4893a6a40c555bda9","type":"GO_TERM","name":"sodium:iodide symporter activity","canonical_id":"go:GO:0008507","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: iodide(out) + Na+(out) = iodide(in) + Na+(in).\" [TC:2.A.21.5.1]","metadata":null},{"id":"85f9d9d377d74ba99871588e6ee7a73f","type":"GO_TERM","name":"sodium:malonate symporter activity","canonical_id":"go:GO:0044668","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sodium(out)+ malonate(out) = sodium(in) + malonate(in).\" [GOC:crds]","metadata":null},{"id":"f332ba273a5f4369ab3d2cceee16f8b9","type":"GO_TERM","name":"sodium:phosphate symporter activity","canonical_id":"go:GO:0005436","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + phosphate(out) = Na+(in) + phosphate(in).\" [TC:2.A.1.14.6]","metadata":null},{"id":"3ac6c091c0934a18a498764b40c46d19","type":"GO_TERM","name":"sodium:potassium-exchanging ATPase complex","canonical_id":"go:GO:0005890","description":"\"Sodium:potassium-exchanging ATPases are tetrameric proteins, consisting of two large alpha subunits and two smaller beta subunits. The alpha subunits bear the active site and penetrate the membrane, while the beta subunits carry oligosaccharide groups and face the cell exterior.\" [ISBN:0198506732]","metadata":null},{"id":"25f59c388eaf475590fdaa6080e14f9a","type":"GO_TERM","name":"sodium:potassium:chloride symporter activity","canonical_id":"go:GO:0008511","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + K+(out) + Cl-(out) = Na+(in) + K+(in) + Cl-(in).\" [TC:2.A.30.1.1]","metadata":null},{"id":"71e23241f08947af9bb046f4877a3822","type":"GO_TERM","name":"sodium:proton antiporter activity","canonical_id":"go:GO:0015385","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + H+(in) = Na+(in) + H+(out).\" [TC:2.A.35.1.1, TC:2.A.36.-.-]","metadata":null},{"id":"08884593930b4d0e9e4c7a20ae294385","type":"GO_TERM","name":"sodium:sulfate symporter activity","canonical_id":"go:GO:0015382","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sulfate(out) + Na+(out) = sulfate(in) + Na+(in).\" [TC:2.A.47.1.2]","metadata":null},{"id":"d3a58c2582da49449856e264778ba02a","type":"DRUG","name":"sofosbuvir","canonical_id":"mesh:D000069474","description":null,"metadata":null},{"id":"11b1b88377fc474cad539182505737cb","type":"GO_TERM","name":"soft palate development","canonical_id":"go:GO:0060023","description":"\"The biological process whose specific outcome is the progression of the soft palate from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure, whatever form that may be including its natural destruction. The soft palate is the posterior portion of the palate extending from the posterior edge of the hard palate.\" [GOC:dph, ISBN:0721662544]","metadata":null},{"id":"b182e251a0324053a7b32db51f38ae65","type":"DISEASE","name":"soft tissue sarcoma","canonical_id":"mondo:0018078","description":null,"metadata":null},{"id":"1224a03653044fe8b34bc8ed9e9340bb","type":"GO_TERM","name":"solanapyrone synthase activity","canonical_id":"go:GO:0033190","description":"\"Catalysis of the cyclization of double bonds in prosolanapyrone II to form (-)-solanapyrone A.\" [GOC:cb, PMID:9659400]","metadata":null},{"id":"c66e3b4d47ce457f9e75725a10525bf4","type":"GO_TERM","name":"solid phase of basement membrane","canonical_id":"go:GO:0140139","description":"\"The solid compartment of the basement membrane ECM, including a specific subset of basement membrane collagens and basement membrane glycoproteins like laminins or nidogens.\" [PMID:33972551]","metadata":null},{"id":"aa5c50e93ddf4dc7b1f40840ce840eeb","type":"GO_TERM","name":"solid phase of interstitial matrix","canonical_id":"go:GO:0140151","description":"\"The solid compartment of the interstitial matrix, including interstitial collagens such as fibrillar and fibril-associated collagens and non-collagenous glycoproteins like fibronectin and elastin.\" [PMID:3284468, PMID:34807416]","metadata":null},{"id":"47af79ef5287443a8954bf2388ce96a7","type":"DRUG","name":"solifenacin","canonical_id":"gtopdb:7483","description":null,"metadata":null},{"id":"54afb03c4d1941d4911047be6fd3f5f1","type":"DRUG","name":"solifenacin","canonical_id":"mesh:D000069464","description":null,"metadata":null},{"id":"5b0f97590a66449584755dff22e00421","type":"COMBINATION_TREATMENT","name":"solifenacin + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-2cdda5dfa5794d4e","description":null,"metadata":null},{"id":"d8b289e5787b490bb7a279ff7d6774ec","type":"COMBINATION_TREATMENT","name":"solifenacin + tadalafil","canonical_id":"ctgov_combo:ctgov-combo-0328e6ef569fbc9e","description":null,"metadata":null},{"id":"e9842c9c79ef4e0fa5356589e314274d","type":"COMBINATION_TREATMENT","name":"solifenacin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-27d36f84dbe9d018","description":null,"metadata":null},{"id":"fde3d590656745898ab85b8254e3c123","type":"COMBINATION_TREATMENT","name":"solifenacin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-aa72b5f909e5e26a","description":null,"metadata":null},{"id":"ac70fa27f44b43bb874c84dfba9a7abb","type":"COMBINATION_TREATMENT","name":"solifenacin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-12a96cb494fc2561","description":null,"metadata":null},{"id":"847c3b3d1a694ea5b5e26c9b02899deb","type":"COMBINATION_TREATMENT","name":"solifenacin + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-57e009e09631146b","description":null,"metadata":null},{"id":"8c14b1f713af472c8edde0eadc76e301","type":"GO_TERM","name":"solitary nucleus development","canonical_id":"go:GO:0021746","description":"\"The process whose specific outcome is the progression of the solitary nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"bd60b0974b2b46c9a4115abd1bab10c4","type":"GO_TERM","name":"soluble NSF attachment protein activity","canonical_id":"go:GO:0005483","description":"\"Binding to both N-ethylmaleimide-sensitive fusion protein (NSF) and a cis-SNARE complex (i.e. a SNARE complex in which all proteins are associated with the same membrane) and increasing the ATPase activity of NSF, thereby allowing ATP hydrolysis by NSF to disassemble the cis-SNARE complex.\" [GOC:mah, PMID:14570579, PMID:15556857]","metadata":null},{"id":"682def27a36b45a48d12fc14e9d4edc4","type":"GO_TERM","name":"soluble molecule recognition","canonical_id":"go:GO:0009995","description":"\"The recognition of soluble molecules in the environment.\" [GOC:curators]","metadata":null},{"id":"616e4c23b5454395a46df4bae5a91ced","type":"GO_TERM","name":"solute:inorganic anion antiporter activity","canonical_id":"go:GO:0005452","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: inorganic anion(out) + solute(in) = inorganic anion (in) + solute(out).\" [GOC:mah]","metadata":null},{"id":"5a89683bd8d24451961292069eb645f4","type":"GO_TERM","name":"solute:monoatomic cation symporter activity","canonical_id":"go:GO:0015294","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: solute(out) + cation(out) = solute(in) + cation(in).\" [GOC:ai]","metadata":null},{"id":"68a0e13623a0463287de0784924334e6","type":"GO_TERM","name":"solute:potassium antiporter activity","canonical_id":"go:GO:0022821","description":"\"Catalysis of the active transport of a potassium ion across a membrane by a mechanism whereby two or more species are transported in opposite directions in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"897cb2272f304e4ebde6976b90e3e452","type":"GO_TERM","name":"solute:proton symporter activity","canonical_id":"go:GO:0015295","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: solute(out) + H+(out) = solute(in) + H+(in).\" [GOC:ai]","metadata":null},{"id":"2a048d17cc604bff873dc2b7d88eec43","type":"GO_TERM","name":"solute:sodium symporter activity","canonical_id":"go:GO:0015370","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: solute(out) + Na+(out) = solute(in) + Na+(in).\" [GOC:ai]","metadata":null},{"id":"d752deb1f1ef40bbbf6e0e2e1ea9439c","type":"GO_TERM","name":"somal translocation","canonical_id":"go:GO:0021802","description":"\"The radial migration of cells from the ventricular zone that is independent of radial glial cells. Cells extend processes that terminate at the pial surface and follow the processes as they migrate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"0ffffb93b8184e11b2a13fa76596dfde","type":"GO_TERM","name":"somatic cell DNA recombination","canonical_id":"go:GO:0016444","description":"\"Recombination occurring within or between DNA molecules in somatic cells.\" [GOC:ma]","metadata":null},{"id":"b4d5c22235b2405a921b29d87b78dbeb","type":"GO_TERM","name":"somatic diversification of DSCAM-based immune receptors","canonical_id":"go:GO:0002201","description":"\"The somatic process that results in the generation of sequence diversity of the DSCAM-based immune receptors of insects.\" [GOC:add, PMID:16261174]","metadata":null},{"id":"6700baaa929d4675b8ddf68861b22e7a","type":"GO_TERM","name":"somatic diversification of FREP-based immune receptors","canonical_id":"go:GO:0002567","description":"\"The process that results in the generation of sequence diversity of the FREP-based immune receptors of snails.\" [GOC:add, PMID:16102575]","metadata":null},{"id":"775121266e8942d18fcfa8fdc8f52b8c","type":"GO_TERM","name":"somatic diversification of T cell receptor genes","canonical_id":"go:GO:0002568","description":"\"The somatic process that results in the generation of sequence diversity of T cell receptor genes.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"d4de7c1370d8433ba7d34efe4496f0fc","type":"GO_TERM","name":"somatic diversification of T cell receptor genes by N region addition","canonical_id":"go:GO:0002571","description":"\"The addition of variable numbers of random nucleotides by terminal deoxytransferase in the N regions of T cell receptor genes. N regions are found at the V-D, D-D, V-J, and D-J recombinational junctions, depending on the T cell receptor gene.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"7944d4325197487ca50c5c52d66955d7","type":"GO_TERM","name":"somatic diversification of immune receptors","canonical_id":"go:GO:0002200","description":"\"The somatic process allowing for the production of immune receptors whose specificity is not encoded in the germline genomic sequences.\" [GOC:add, ISBN:0781735149, PMID:16102575, PMID:16166509]","metadata":null},{"id":"985d1d4ff7d34b7c8ab49f9f1f5610b0","type":"GO_TERM","name":"somatic diversification of immune receptors by N region addition","canonical_id":"go:GO:0002569","description":"\"The addition of variable numbers of random nucleotides by terminal deoxytransferase in the N regions of heavy chain immunoglobulin and T cell receptor genes. N regions are found at the V-D, D-D, V-J, and D-J recombinational junctions, depending on the immune receptor gene.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"3554adb1f3244787b8d73e1e81b93037","type":"GO_TERM","name":"somatic diversification of immune receptors via alternate splicing","canonical_id":"go:GO:0002563","description":"\"The process in which immune receptor genes are diversified through alternate splicing.\" [GOC:add, ISBN:0781735149, PMID:16166509]","metadata":null},{"id":"3ae297814e144c548b118fce331d2900","type":"GO_TERM","name":"somatic diversification of immune receptors via gene conversion","canonical_id":"go:GO:0002565","description":"\"The process in which immune receptor genes are diversified through gene conversion.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"35cbfa49c3834a7d964a9821f5bb7b4f","type":"GO_TERM","name":"somatic diversification of immune receptors via germline recombination within a single locus","canonical_id":"go:GO:0002562","description":"\"The process in which immune receptor genes are diversified through recombination of the germline genetic elements within a single genetic locus.\" [GOC:add, ISBN:0781735149, PMID:16102575, PMID:16166509]","metadata":null},{"id":"8e35e82179b84734bef8b501430506ef","type":"GO_TERM","name":"somatic diversification of immune receptors via somatic mutation","canonical_id":"go:GO:0002566","description":"\"The process in which immune receptor genes are diversified through somatic mutation.\" [ISBN:0781735149, PMID:16102575]","metadata":null},{"id":"def15f1d11f748e1ac8e43b2063c6e69","type":"GO_TERM","name":"somatic diversification of immunoglobulin genes by N region addition","canonical_id":"go:GO:0002570","description":"\"The addition of variable numbers of random nucleotides by terminal deoxytransferase in the N regions of heavy chain immunoglobulin genes. N regions are found at the V-D and D-J recombinational junctions.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"e96a89aebf704a68a0e1ae8a0f978586","type":"GO_TERM","name":"somatic diversification of immunoglobulins","canonical_id":"go:GO:0016445","description":"\"The somatic process that results in the generation of sequence diversity of immunoglobulins.\" [GOC:add, GOC:ma, ISBN:0781735149]","metadata":null},{"id":"222bafde3da44732b92ef4e9115d074d","type":"GO_TERM","name":"somatic diversification of immunoglobulins involved in immune response","canonical_id":"go:GO:0002208","description":"\"The somatic process that results in the generation of sequence diversity of immunoglobulins after induction, and contributes to an immune response.\" [GOC:add, ISBN:0781735149, PMID:14991701]","metadata":null},{"id":"77ad5ded88114d11a4d9e13c1a4bce76","type":"GO_TERM","name":"somatic diversification of variable lymphocyte receptors of jawless fish","canonical_id":"go:GO:0002202","description":"\"The somatic process that results in the generation of sequence diversity of the variable lymphocyte receptors (VLR) of jawless fish.\" [GOC:add, PMID:16373579]","metadata":null},{"id":"8760952bf6264781b8f5888eb44ee871","type":"GO_TERM","name":"somatic embryogenesis","canonical_id":"go:GO:0010262","description":"\"Initiation of a somatic embryo-an embryo arising from previously differentiated somatic cells, rather than from fused haploid gametes.\" [GOC:sm, PMID:9611173]","metadata":null},{"id":"7fa983883dfe4c7d9dad3b1ca75572fe","type":"GO_TERM","name":"somatic hypermutation of immunoglobulin genes","canonical_id":"go:GO:0016446","description":"\"Mutations occurring somatically that result in amino acid changes in the rearranged V regions of immunoglobulins.\" [GOC:add, ISBN:0781735149, PMID:11205330, PMID:11205333, PMID:14975236, PMID:7813007]","metadata":null},{"id":"fb13488ce91d486a9077238585732627","type":"GO_TERM","name":"somatic motor neuron differentiation","canonical_id":"go:GO:0021523","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of somatic motor neurons. Somatic motor neurons innervate skeletal muscle targets and are responsible for transmission of motor impulses from the brain to the periphery. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"e1bc48f4a4794059aa31487f6c309801","type":"GO_TERM","name":"somatic motor neuron fate commitment","canonical_id":"go:GO:0021917","description":"\"The commitment of unspecified motor neurons to specific motor neuron cell along the anterior-posterior axis of the spinal cord and their capacity to differentiate into specific motor neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"17055adcffd64fcfa13b092f4d26aaf2","type":"GO_TERM","name":"somatic muscle attachment to chitin-based cuticle","canonical_id":"go:GO:0160175","description":"\"The developmental process in which a somatic muscle attaches to the chitin-based cuticle. In insects, this may occur via a specialized epithelial cell adherence to the chitinous extracellular matrix and to muscle cells through their basement membrane.\" [PMID:35675426]","metadata":null},{"id":"ddc817b4dc8f40b191107fb5c0a7fe63","type":"GO_TERM","name":"somatic muscle development","canonical_id":"go:GO:0007525","description":"\"The process whose specific outcome is the progression of the somatic muscle over time, from its formation to the mature structure. Somatic muscles are striated muscle structures that connect to the exoskeleton or cuticle.\" [GOC:jid, GOC:mtg_muscle]","metadata":null},{"id":"54926fb81bff465c9ca581c27a2be87b","type":"GO_TERM","name":"somatic portion of tanycyte","canonical_id":"go:GO:1990017","description":"\"Portion of a tanycyte that lies within the ependyma and contains the nucleus. A tanycyte is a specialized elongated ventricular ependymal cell that has processes that extend to the outer, or pial, surface of the CNS.\" [ISBN:0195065719, NIF_Subcellular:sao401910342]","metadata":null},{"id":"5e64a2e9335842edba88d360dedd2474","type":"GO_TERM","name":"somatic recombination of T cell receptor gene segments","canonical_id":"go:GO:0002681","description":"\"The process in which T cell receptor genes are formed through recombination of the germline genetic elements, also known as T cell receptor gene segments.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a8e01711d81645268f66dcd82a6097a4","type":"GO_TERM","name":"somatic recombination of immunoglobulin gene segments","canonical_id":"go:GO:0016447","description":"\"The process in which immunoglobulin genes are formed through recombination of the germline genetic elements, as known as immunoglobulin gene segments, within a single locus.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"4ca4b4e211404f56925fba7c532d111b","type":"GO_TERM","name":"somatic recombination of immunoglobulin genes involved in immune response","canonical_id":"go:GO:0002204","description":"\"The process in which immunoglobulin genes are formed through recombination of the germline genetic elements, also known as immunoglobulin gene segments, within a single locus following the induction of and contributing to an immune response.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f4dd6991cfc4437db679319134bec3c0","type":"GO_TERM","name":"somatic ring canal","canonical_id":"go:GO:0098549","description":"\"A stable intercellular bridge between somatic cells. Examples include the intercellular bridges between ovarian follicle cells in insects and between imaginal disc cells in insects.\" [GOC:dos, PMID:22135360, PMID:670316]","metadata":null},{"id":"7bd874abd5844019901008b4c3f0f07c","type":"GO_TERM","name":"somatic sensory system development","canonical_id":"go:GO:0160038","description":"\"The process whose specific outcome is the progression of a somatic sensory system over time from its formation to the mature structure. Somatic sensory system is the sensory system for the sense of touch and pain.\" [PMID:25832476, PMID:31399790]","metadata":null},{"id":"4c4e2458776d401c82d9a4ac311b8222","type":"GO_TERM","name":"somatic sex determination","canonical_id":"go:GO:0018993","description":"\"The determination of sex and sexual phenotypes in an organism's soma.\" [GOC:ems]","metadata":null},{"id":"0291641a796c4ff7bfdaa71e8a13ee50","type":"GO_TERM","name":"somatic spine","canonical_id":"go:GO:0097465","description":"\"Spine emanating from the cell soma of a neuron.\" [NIF_Subcellular:sao2048514053]","metadata":null},{"id":"966c57f3261a406e8ee52d93bfe4fec0","type":"GO_TERM","name":"somatic stem cell division","canonical_id":"go:GO:0048103","description":"\"The self-renewing division of a somatic stem cell, a stem cell that can give rise to cell types of the body other than those of the germ-line.\" [GOC:jid, ISBN:0582227089]","metadata":null},{"id":"ede51bd28eba44eba691ba9667bcf981","type":"GO_TERM","name":"somatic stem cell population maintenance","canonical_id":"go:GO:0035019","description":"\"Any process by which an organism retains a population of somatic stem cells, undifferentiated cells in the embryo or adult which can undergo unlimited division and give rise to cell types of the body other than those of the germ-line.\" [GOC:bf, ISBN:0582227089]","metadata":null},{"id":"d3fb3027cc344f16a554275108910ade","type":"GO_TERM","name":"somato-dendritic dopamine secretion","canonical_id":"go:GO:0099123","description":"\"The regulated release of dopamine from the somatodendritic compartment (cell body or dendrites) of a neuron.\" [GOC:bf, GOC:PARL, PMID:21576241]","metadata":null},{"id":"2d142a848d9b4e2f8201c4c08d368ff4","type":"GO_TERM","name":"somatodendritic compartment","canonical_id":"go:GO:0036477","description":"\"The region of a neuron that includes the cell body (cell soma) and dendrite(s), but excludes the axon.\" [GOC:pad, GOC:PARL]","metadata":null},{"id":"fddb738534f94482ad20735ea6cc4309","type":"GO_TERM","name":"somatostatin binding","canonical_id":"go:GO:0120023","description":"\"Binding to somatostatin, a polypeptide hormone involved in regulating pancreatic alpha and pancreatic beta cells and controlling growth hormone secretion as well as many other functions. Somatostatin is produced by several cell types including pancreatic delta cells. There are several different mature forms of somatostatin.\" [GOC:cvs, PMID:20472043]","metadata":null},{"id":"3707eb3b169b406194923427bac134b8","type":"GO_TERM","name":"somatostatin receptor activity","canonical_id":"go:GO:0004994","description":"\"Combining with somatostatin to initiate a change in cell activity. Somatostatin is a peptide hormone that regulates the endocrine system by signaling via G protein-coupled somatostatin receptors. Somatostatin has two active forms produced by proteolytic cleavage: a 14 amino acid peptide (SST-14) and a 28 amino acid peptide (SST-28).\" [GOC:ai, GOC:bf, Wikipedia:Somatostatin]","metadata":null},{"id":"3370e1c640844a7ea9c6f381cc690db1","type":"GO_TERM","name":"somatostatin receptor binding","canonical_id":"go:GO:0031877","description":"\"Binding to a somatostatin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"2bfd95d98aa345e38658783a80486a09","type":"GO_TERM","name":"somatostatin receptor signaling pathway","canonical_id":"go:GO:0038169","description":"\"A G protein-coupled receptor signaling pathway initiated by somatostatin binding to the somatostatin receptor (SSTR) on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:jc, PMID:18006219, PMID:8769369]","metadata":null},{"id":"efe519ad9d8842eabbaecc901f5f0d33","type":"GO_TERM","name":"somatostatin secretion","canonical_id":"go:GO:0070253","description":"\"The regulated release of somatostatin from secretory granules in the D cells of the pancreas.\" [GOC:mah]","metadata":null},{"id":"c8f91b5a6ed44b6782a94b5587f80d6e","type":"GO_TERM","name":"somatostatin signaling pathway","canonical_id":"go:GO:0038170","description":"\"A G protein-coupled receptor signaling pathway initiated by somatostatin binding to a somatostatin receptor (SSTR), and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:nhn, GOC:signaling, PMID:18006219, Wikipedia:Somatostatin]","metadata":null},{"id":"8c7612f36c9d4b3a801e7f5611ce1bd9","type":"GO_TERM","name":"somatotropin secreting cell development","canonical_id":"go:GO:0060133","description":"\"The process whose specific outcome is the progression of a somatotropin secreting cell over time, from its formation to the mature structure. A somatotropin secreting cell is an acidophilic cell of the anterior pituitary that produces growth hormone, somatotropin.\" [GOC:dph]","metadata":null},{"id":"a63b6a3feb0d4915a865dec2ec4b8894","type":"GO_TERM","name":"somatotropin secreting cell differentiation","canonical_id":"go:GO:0060126","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a somatotropin secreting cell. A somatotropin secreting cell is an acidophilic cell of the anterior pituitary that produces growth hormone, somatotropin.\" [GOC:dph]","metadata":null},{"id":"d4b6d07c9338436f9b72578916313e0f","type":"DRUG","name":"somatropin","canonical_id":"mesh:D019382","description":null,"metadata":null},{"id":"452dfff47a204110ac0c533aecaaa885","type":"GO_TERM","name":"somite development","canonical_id":"go:GO:0061053","description":"\"The progression of a somite from its initial formation to the mature structure. Somites are mesodermal clusters that are arranged segmentally along the anterior posterior axis of an embryo.\" [GOC:dph]","metadata":null},{"id":"1cdca73e1aad41c8ba3d89e74d59e52d","type":"GO_TERM","name":"somite rostral/caudal axis specification","canonical_id":"go:GO:0032525","description":"\"The establishment, maintenance and elaboration of the rostro-caudal axis of a somite, prior to the morphological formation of a somite boundary.\" [GOC:bf, PMID:16326386, PMID:17360776]","metadata":null},{"id":"8e86a4deded14ad493ce309906b2210b","type":"GO_TERM","name":"somite specification","canonical_id":"go:GO:0001757","description":"\"The process in which individual somites establish identity during embryogenesis.\" [GOC:dph]","metadata":null},{"id":"3e6c1547e99f4e63ad914d6559504889","type":"GO_TERM","name":"somitogenesis","canonical_id":"go:GO:0001756","description":"\"The formation of mesodermal clusters that are arranged segmentally along the anterior posterior axis of an embryo.\" [ISBN:0721662544]","metadata":null},{"id":"d25756376dd642dbbb09bead058c550f","type":"GO_TERM","name":"somitomeric trunk muscle development","canonical_id":"go:GO:0002075","description":"\"The process whose specific outcome is the progression of the somitomeric trunk muscle over time, from its formation to the mature structure. The somitomeric trunk muscle is derived from somitomeric mesoderm. The muscle begins its development with the differentiation of the muscle cells and ends with the mature muscle. An example of this process is found in Mus musculus.\" [GOC:dph, PMID:16638982]","metadata":null},{"id":"eeaec5d3abbb48ecad0adfcce1d99c01","type":"DRUG","name":"sonidegib","canonical_id":"gtopdb:8199","description":null,"metadata":null},{"id":"834d7c33b0f844918a4644ee09804121","type":"COMBINATION_TREATMENT","name":"sonidegib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-ebe2ebed650bb04c","description":null,"metadata":null},{"id":"ee04f5131d66430e837c6187f027e8cd","type":"GO_TERM","name":"sophorolipid biosynthetic process","canonical_id":"go:GO:0140377","description":"\"The chemical reactions and pathways resulting in the formation of sophorolipid, a class of glycolipids containing a 2-O-beta-D-glucopyranosyl-D-glucopyranose (sophorose) unit covalently linked to the hydroxyl of a omega-hydroxy long chain fatty acids or (omega-1)-hydroxy long chain fatty acids.\" [PMID:23516968, PMID:27251547, PMID:27317616, PMID:38937850, PMID:39143561]","metadata":null},{"id":"47753357eb844b88a42a65513463ef3d","type":"GO_TERM","name":"sophorose transport","canonical_id":"go:GO:2001087","description":"\"The directed movement of a sophoroseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"f03b841f2fa243218cdb9a58641b080e","type":"GO_TERM","name":"sophorosyloxydocosanoate biosynthetic process","canonical_id":"go:GO:0019435","description":"\"The chemical reactions and pathways resulting in the formation of sophorosyloxydocosanoate, 13-sophorosyloxydocosanoate 6',6''-diacetate.\" [GOC:ai]","metadata":null},{"id":"447679f8fee6408fa0d1d74fef53e19c","type":"GO_TERM","name":"sophorosyloxydocosanoate catabolic process","canonical_id":"go:GO:0019436","description":"\"The chemical reactions and pathways resulting in the breakdown of sophorosyloxydocosanoate, 13-sophorosyloxydocosanoate 6',6''-diacetate.\" [GOC:ai]","metadata":null},{"id":"0fe461108e5442b8b410ce5ebb5ec579","type":"DRUG","name":"sorafenib","canonical_id":"gtopdb:5711","description":null,"metadata":null},{"id":"cc3f808ae291487d9340dba5fd3eb66e","type":"COMBINATION_TREATMENT","name":"sorafenib + temsirolimus","canonical_id":"ctgov_combo:ctgov-combo-6852ed1394de39fe","description":null,"metadata":null},{"id":"519a8b2bb2b04e3c805b9345a5fac970","type":"GO_TERM","name":"sorbitol transmembrane transport","canonical_id":"go:GO:0015795","description":"\"The directed movement of sorbitol across a membrane. Sorbitol, also known as glucitol, is the hexitol derived by the reduction of the aldehyde group of glucose.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"421a604b78ad4ebeaef63d896a9a889b","type":"GO_TERM","name":"sorbitol transmembrane transporter activity","canonical_id":"go:GO:0015576","description":"\"Enables the transfer of sorbitol from one side of a membrane to the other. Sorbitol, also known as glucitol, is the hexitol derived by the reduction of the aldehyde group of glucose.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"fe95c6dc4235427c8646f4bd733ea3f7","type":"GO_TERM","name":"sorbitol-6-phosphatase activity","canonical_id":"go:GO:0050286","description":"\"Catalysis of the reaction: D-glucitol 6-phosphate + H2O = D-glucitol + phosphate.\" [EC:3.1.3.50, RHEA:24580]","metadata":null},{"id":"8b82da6fbf9d434f8d69a72d405fc621","type":"GO_TERM","name":"sorbitol-6-phosphate 2-dehydrogenase activity","canonical_id":"go:GO:0009010","description":"\"Catalysis of the reaction: D-sorbitol 6-phosphate + NAD+ = D-fructose 6-phosphate + NADH + H+.\" [EC:1.1.1.140]","metadata":null},{"id":"af4177354a8b45a58664bcbdea965da6","type":"GO_TERM","name":"sorbose 5-dehydrogenase (NADP+) activity","canonical_id":"go:GO:0050287","description":"\"Catalysis of the reaction: L-sorbose + NADP+ = 5-dehydro-D-fructose + H+ + NADPH.\" [EC:1.1.1.123, RHEA:15001]","metadata":null},{"id":"b069a806caf642699e83ef4a33d9203e","type":"GO_TERM","name":"sorbose dehydrogenase activity","canonical_id":"go:GO:0050288","description":"\"Catalysis of the reaction: L-sorbose + A = 5-dehydro-D-fructose + AH(2).\" [EC:1.1.99.12, RHEA:14713]","metadata":null},{"id":"16bed79a9cd64399abeabdf6229a301f","type":"GO_TERM","name":"sorbose reductase activity","canonical_id":"go:GO:0032115","description":"\"Catalysis of the reaction: D-glucitol + NADP+ = L-sorbose + H+ + NADPH. The reaction may occur, to a minor extent, in the reverse direction.\" [EC:1.1.1.289, RHEA:14609]","metadata":null},{"id":"f0334bb9d7524f1694b16ee10ff11ee7","type":"GO_TERM","name":"sorocarp development","canonical_id":"go:GO:0030587","description":"\"The process whose specific outcome is the progression of the sorocarp over time, from its formation to the mature structure. The process begins with the aggregation of individual cells and ends with the mature sorocarp. The sorocarp is a structure containing a spore-bearing sorus that sits on top of a stalk. An example of this process is found in Dictyostelium discoideum.\" [GOC:mah, GOC:mtg_sensu, ISBN:0521583640, PMID:4332228]","metadata":null},{"id":"76424873afd842369a78edee5847e392","type":"GO_TERM","name":"sorocarp morphogenesis","canonical_id":"go:GO:0031288","description":"\"The process in which the sorocarp is generated and organized. An example of this process is found in Dictyostelium discoideum.\" [GOC:kp, GOC:mtg_sensu, PMID:4332228]","metadata":null},{"id":"5c5c8c3d3b0246cf877bfcf00c0095dc","type":"GO_TERM","name":"sorocarp sorus development","canonical_id":"go:GO:0048837","description":"\"The process whose specific outcome is the progression of the sorocarp sorus over time, from its formation to the mature structure. A sorocarp sorus is the spore containing structure of a sorocarp.\" [GOC:devbiol, GOC:mtg_sensu, PMID:4332228]","metadata":null},{"id":"c58cda18901d44ec9fa7feae299513ca","type":"GO_TERM","name":"sorocarp spore cell differentiation","canonical_id":"go:GO:0044671","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a sorocarp spore cell, a cell of the sorocarp sorus. A sorocarp is the fruiting body characteristic of certain cellular slime moulds (e.g., Dictyosteliida) and consists of both stalk and a sorus (spore mass).\" [GOC:jl, GOC:rjd]","metadata":null},{"id":"9702f3b87121473c976c4688724ba535","type":"GO_TERM","name":"sorocarp stalk cell differentiation","canonical_id":"go:GO:0031149","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a sorocarp stalk cell, any of the cellulose-covered cells that form the stalk of a sorocarp. An example of this process is found in Dictyostelium discoideum.\" [GOC:mah, GOC:mtg_sensu, ISBN:0521583640, PMID:4338436]","metadata":null},{"id":"cb8f08bfc5684c69921fa8289946f96d","type":"GO_TERM","name":"sorocarp stalk development","canonical_id":"go:GO:0031150","description":"\"The process whose specific outcome is the progression of the sorocarp stalk over time, from its formation to the mature structure. The sorocarp stalk is a tubular structure that consists of cellulose-covered cells stacked on top of each other and surrounded by an acellular stalk tube composed of cellulose and glycoprotein. An example of this process is found in Dictyostelium discoideum.\" [GOC:mtg_sensu, ISBN:0521583640, PMID:4338436]","metadata":null},{"id":"4a92bb95ef9c43d0b39490f816dd4624","type":"GO_TERM","name":"sorocarp stalk morphogenesis","canonical_id":"go:GO:0036360","description":"\"The process in which the sorocarp stalk is generated and organized. The sorocarp stalk is a tubular structure that consists of cellulose-covered cells stacked on top of each other and surrounded by an acellular stalk tube composed of cellulose and glycoprotein. An example of this process is found in Dictyostelium discoideum.\" [DDANAT:0000068, GOC:pf, PMID:22902739]","metadata":null},{"id":"4363e8828b534ee8af2471e4f524cd51","type":"GO_TERM","name":"sorting endosome","canonical_id":"go:GO:0097443","description":"\"A multivesicular body surrounded by and connected with multiple tubular compartments with associated vesicles.\" [NIF_Subcellular:sao1028571114]","metadata":null},{"id":"1f4da4384ab8422286a05a81e3a4da60","type":"DRUG","name":"sotagliflozin","canonical_id":"gtopdb:8312","description":null,"metadata":null},{"id":"b748860309f7411fa823aa5fe34419e3","type":"DRUG","name":"sotagliflozin","canonical_id":"chembl:CHEMBL3039507","description":null,"metadata":null},{"id":"2d9892671d6341ce9adbab9228e0d657","type":"DRUG","name":"sotalol","canonical_id":"gtopdb:7297","description":null,"metadata":null},{"id":"58b63d53cf414792b971ea0380237dc2","type":"GO_TERM","name":"sour taste receptor activity","canonical_id":"go:GO:0033040","description":"\"Combining with soluble sour compounds to initiate a change in cell activity. These receptors are responsible for the sense of sour taste.\" [GOC:mah]","metadata":null},{"id":"322aea16a996476e8bc7943693734986","type":"GO_TERM","name":"soyasapogenol B glucuronide galactosyltransferase activity","canonical_id":"go:GO:0102240","description":"\"Catalysis of the reaction: UDP-D-galactose + soyasapogenol B 3-O-beta-glucuronate = H+ + UDP + soyasaponin III.\" [EC:2.4.1.272, GOC:pz]","metadata":null},{"id":"2c6b44f75e11496badccde339a0552a6","type":"GO_TERM","name":"soyasapogenol B glucuronosyltransferase activity","canonical_id":"go:GO:0102793","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate + soyasapogenol B = H+ + UDP + soyasapogenol B 3-O-beta-glucuronate.\" [EC:2.4.1.262, GOC:pz]","metadata":null},{"id":"bbb1f88c7d354fa7ac9b7128d5ec31ca","type":"GO_TERM","name":"soyasaponin III rhamnosyltransferase activity","canonical_id":"go:GO:0102241","description":"\"Catalysis of the reaction: UDP-L-rhamnose + soyasaponin III = H+ + UDP + soyasaponin I.\" [EC:2.4.1.273, GOC:pz]","metadata":null},{"id":"dd7c76085e9640be962fdf0ab0416e37","type":"DRUG","name":"sparsentan","canonical_id":"gtopdb:8448","description":null,"metadata":null},{"id":"04cec989558b4e679f6de5b7703794c3","type":"DRUG","name":"sparsentan","canonical_id":"chembl:CHEMBL539423","description":null,"metadata":null},{"id":"8f98b6d8924b421b91bc6aef91d40230","type":"GO_TERM","name":"spatial regulation of meiotic DNA double-strand break formation involved in reciprocal meiotic recombination","canonical_id":"go:GO:0062209","description":"\"Any process that modulates the distribution of sites along the chromosome where meiotic DNA double-strand break formation takes place as part of reciprocal meiotic recombination.\" [PMID:25324213, PMID:30217891]","metadata":null},{"id":"ff74f5d5a12d407f9b4966ef74451bfc","type":"GO_TERM","name":"specialized extracellular matrix","canonical_id":"go:GO:0140047","description":"\"Species or cell-type specific extracellular matrices that are different from the two main types of extracellular matrices: the interstitial ECM and the basement membrane ECM in metazoa.\" [PMID:28955324, PMID:33605520]","metadata":null},{"id":"d654acb6e7354b00a125536db503b39a","type":"GO_TERM","name":"specific granule","canonical_id":"go:GO:0042581","description":"\"Granule with a membranous, tubular internal structure, found primarily in mature neutrophil cells. Most are released into the extracellular fluid. Specific granules contain lactoferrin, lysozyme, vitamin B12 binding protein and elastase.\" [GOC:jl, ISBN:0721662544, PMID:7334549]","metadata":null},{"id":"10992afaefa84eb6b2d256d23f8392a5","type":"GO_TERM","name":"specific granule lumen","canonical_id":"go:GO:0035580","description":"\"The volume enclosed by the membrane of a specific granule, a granule with a membranous, tubular internal structure, found primarily in mature neutrophil cells. Most are released into the extracellular fluid. Specific granules contain lactoferrin, lysozyme, vitamin B12 binding protein and elastase.\" [GOC:bf, PMID:7334549]","metadata":null},{"id":"974f7e9b872248629e43acb94f4b4e54","type":"GO_TERM","name":"specific granule membrane","canonical_id":"go:GO:0035579","description":"\"The lipid bilayer surrounding a specific granule, a granule with a membranous, tubular internal structure, found primarily in mature neutrophil cells. Most are released into the extracellular fluid. Specific granules contain lactoferrin, lysozyme, vitamin B12 binding protein and elastase.\" [GOC:bf, PMID:7334549]","metadata":null},{"id":"9f977d02800648c3b1e960f75e905175","type":"GO_TERM","name":"specification of animal organ axis polarity","canonical_id":"go:GO:0010084","description":"\"The process in which the polarity of an animal organ axis is specified.\" [GOC:tb]","metadata":null},{"id":"dceb65de27dc46e9a1ab78e99d31b7bd","type":"GO_TERM","name":"specification of animal organ identity","canonical_id":"go:GO:0010092","description":"\"The regionalization process in which the identity of an animal organ primordium is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tb]","metadata":null},{"id":"78dd811d16684452b89414b38ac325de","type":"GO_TERM","name":"specification of animal organ position","canonical_id":"go:GO:0010159","description":"\"The regionalization process in which information that determines the correct position at which animal organ primordia are formed is generated and perceived resulting in correct positioning of the new animal organ.\" [GOC:curators]","metadata":null},{"id":"485e1946614241a7b56b45aa0153ff9e","type":"GO_TERM","name":"specification of anterior mesonephric tubule identity","canonical_id":"go:GO:0072168","description":"\"The process in which the tubules of the anterior mesonephros acquire their identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d65ef50a00c34a66a15747db0507f038","type":"GO_TERM","name":"specification of axis polarity","canonical_id":"go:GO:0065001","description":"\"The pattern specification process in which the polarity of a body or organ axis is established and maintained.\" [GOC:mah]","metadata":null},{"id":"8f115b69d0e9455d899cf0f3d3401a42","type":"GO_TERM","name":"specification of carpel identity","canonical_id":"go:GO:0010094","description":"\"The process in which a floral organ primordium acquires the carpel identity. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tair_curators]","metadata":null},{"id":"cafbfc4b92c344a2bb456380df0e0e40","type":"GO_TERM","name":"specification of connecting tubule identity","canonical_id":"go:GO:0072085","description":"\"The process in which the connecting tubule of the kidney nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"2e18389ca98f4252824901ff37e311a5","type":"GO_TERM","name":"specification of distal tubule identity","canonical_id":"go:GO:0072084","description":"\"The process in which the distal tubule of the kidney nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"d92ea710dba64673b244edb28dedc7ba","type":"GO_TERM","name":"specification of floral organ identity","canonical_id":"go:GO:0010093","description":"\"The process in which the identity of a floral organ primordium is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tb]","metadata":null},{"id":"03b7dc6703c74d7894a169304effd58c","type":"GO_TERM","name":"specification of floral organ number","canonical_id":"go:GO:0048833","description":"\"Any process that modulates the number of floral organs formed in a floral whorl.\" [GOC:tb]","metadata":null},{"id":"5f7c047111d343259642e63b5e1c1998","type":"GO_TERM","name":"specification of loop of Henle identity","canonical_id":"go:GO:0072086","description":"\"The process in which the loop of Henle of the kidney nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"0831ea7039ed4214901ed1d60bdc5da9","type":"GO_TERM","name":"specification of mesonephric connecting tubule identity","canonical_id":"go:GO:0061281","description":"\"The process in which the connecting tubule of the mesonephric nephron acquires its identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"8341e4798f3649e7b8ee98efe667699b","type":"GO_TERM","name":"specification of mesonephric distal tubule identity","canonical_id":"go:GO:0061283","description":"\"The process in which the distal tubule of the mesonephric nephron acquires its identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bad52310a0fa4a539106df61d9197b8c","type":"GO_TERM","name":"specification of mesonephric nephron tubule identity","canonical_id":"go:GO:0061282","description":"\"The process in which the tubules arranged along the proximal/distal axis of the mesonephric nephron acquire their identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"24980fa026f44fa5bbcaec06e92631bc","type":"GO_TERM","name":"specification of mesonephric proximal tubule identity","canonical_id":"go:GO:0061284","description":"\"The process in which the proximal tubule of the mesonephric nephron acquires its identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"38536d8ac36a40b78ae7c4838aaecd41","type":"GO_TERM","name":"specification of mesonephric tubule identity","canonical_id":"go:GO:0072167","description":"\"The process in which the tubules of the mesonephros acquire their identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0f13f4f3e76645989fccb0b7fbac74f9","type":"GO_TERM","name":"specification of metanephric connecting tubule identity","canonical_id":"go:GO:0072294","description":"\"The process in which the connecting tubule of the metanephric nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"69b063e0c0ce4b1fa173cfaad139aee9","type":"GO_TERM","name":"specification of metanephric distal tubule identity","canonical_id":"go:GO:0072295","description":"\"The process in which the distal tubule of the metanephric nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"4b6d4e0397a044b382a36ab2f0b8d28e","type":"GO_TERM","name":"specification of metanephric loop of Henle identity","canonical_id":"go:GO:0072296","description":"\"The process in which the loop of Henle of the metanephric nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"86e6af6b45574632a245198afd7db439","type":"GO_TERM","name":"specification of metanephric nephron tubule identity","canonical_id":"go:GO:0072293","description":"\"The process in which the tubules arranged along the proximal/distal axis of the metanephric nephron acquire their identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"1ed39b6ac5c24a57bd3e5b0c62c899b0","type":"GO_TERM","name":"specification of metanephric proximal tubule identity","canonical_id":"go:GO:0072297","description":"\"The process in which the proximal tubule of the metanephric nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"3f63f2f821e94d2eaa2fb8fb5669fb0a","type":"GO_TERM","name":"specification of nephron tubule identity","canonical_id":"go:GO:0072081","description":"\"The process in which the tubules arranged along the proximal/distal axis of the nephron acquire their identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"6f491ed6a7fe4e7bb80113b568178e55","type":"GO_TERM","name":"specification of ovule identity","canonical_id":"go:GO:0010622","description":"\"The regionalization process in which the identity of an ovule is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tb]","metadata":null},{"id":"6d9186cd888b4d4e8b0e2c8de4d02e4e","type":"GO_TERM","name":"specification of petal identity","canonical_id":"go:GO:0010095","description":"\"The process in which a floral organ primordium acquires petal identity. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tair_curators]","metadata":null},{"id":"49f18b63442b4151b0ec1cb5a5a65e65","type":"GO_TERM","name":"specification of petal number","canonical_id":"go:GO:0048834","description":"\"Any process that modulates the number of petals formed in a flower.\" [GOC:tb]","metadata":null},{"id":"27fd166edb7a435e85af106a8a3b7611","type":"GO_TERM","name":"specification of plant organ axis polarity","canonical_id":"go:GO:0090708","description":"\"The process in which the polarity of a plant organ axis is specified.\" [GOC:tb]","metadata":null},{"id":"1e14032f0ce24343979d1dbd3f60db81","type":"GO_TERM","name":"specification of plant organ identity","canonical_id":"go:GO:0090701","description":"\"The regionalization process in which the identity of a plant organ primordium is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tb]","metadata":null},{"id":"2a5a1056bbb748f1bc2967b8ec52bdbe","type":"GO_TERM","name":"specification of plant organ number","canonical_id":"go:GO:0048832","description":"\"The regionalization process that modulates the quantity of a particular type of plant organ.\" [GOC:dph, GOC:isa_complete, GOC:tb]","metadata":null},{"id":"ef3b33da4f084a9a8b8038b12eaadd8c","type":"GO_TERM","name":"specification of plant organ position","canonical_id":"go:GO:0090706","description":"\"The regionalization process in which information that determines the correct position at which plant organ primordia are formed is generated and perceived resulting in correct positioning of the new plant organ.\" [GOC:tb, PMID:9611175]","metadata":null},{"id":"72cf98dd82d44000a9462e011dc66fd8","type":"GO_TERM","name":"specification of posterior mesonephric tubule identity","canonical_id":"go:GO:0072169","description":"\"The process in which the tubules of the posterior mesonephros acquire their identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"10d4fcf54cf34c44b4cdf5bf99eab18d","type":"GO_TERM","name":"specification of pronephric distal tubule identity","canonical_id":"go:GO:0039010","description":"\"The process in which the distal tubule of the pronephric nephron acquires its identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"d65646fe8e5f43859a1b464d494f3d77","type":"GO_TERM","name":"specification of pronephric proximal tubule identity","canonical_id":"go:GO:0039004","description":"\"The process in which the proximal tubule of the pronephric nephron acquires its identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"a1a80cbce7174ef3ac28d33748d68585","type":"GO_TERM","name":"specification of pronephric tubule identity","canonical_id":"go:GO:0039005","description":"\"The process in which the tubules arranged along the proximal/distal axis of the pronephric nephron acquire their identity.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"41648fd5c1794376a9af62e5670a0073","type":"GO_TERM","name":"specification of proximal tubule identity","canonical_id":"go:GO:0072082","description":"\"The process in which the proximal tubule of the kidney nephron acquires its identity.\" [GOC:bf, GOC:mtg_kidney_jan10]","metadata":null},{"id":"ea19e8cd3dd24586b0d57a08dbb11650","type":"GO_TERM","name":"specification of segmental identity, abdomen","canonical_id":"go:GO:0007385","description":"\"The specification of the characteristic structures of the abdominal segments following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"09970d5bc04f4bf8b898af96b3d926f9","type":"GO_TERM","name":"specification of segmental identity, antennal segment","canonical_id":"go:GO:0007383","description":"\"The specification of the characteristic structures of the antennal segment following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"24d6f6b6de724e69bd989bc03a44720e","type":"GO_TERM","name":"specification of segmental identity, head","canonical_id":"go:GO:0007380","description":"\"The specification of the characteristic structures of the head segments following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"d51ecc896fdf43dfac10ef9234db7198","type":"GO_TERM","name":"specification of segmental identity, intercalary segment","canonical_id":"go:GO:0035291","description":"\"The specification of the characteristic structures of the intercalary segment of the anterior head, following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437, PMID:10477305]","metadata":null},{"id":"91f3aad1cacd4fd3aea89ab6c93d396d","type":"GO_TERM","name":"specification of segmental identity, labial segment","canonical_id":"go:GO:0007381","description":"\"The specification of the characteristic structures of the labial segment following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"14782e47cb2a42cb8888ae7419b602a6","type":"GO_TERM","name":"specification of segmental identity, mandibular segment","canonical_id":"go:GO:0042305","description":"\"The specification of the characteristic structures of the mandibular segment following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"86f2d58458b04935840107e3f5a01ebb","type":"GO_TERM","name":"specification of segmental identity, maxillary segment","canonical_id":"go:GO:0007382","description":"\"The specification of the characteristic structures of the maxillary segment following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"4c9f46ef84b446928a7b22d7d59bafd2","type":"GO_TERM","name":"specification of segmental identity, thorax","canonical_id":"go:GO:0007384","description":"\"The specification of the characteristic structures of the thoracic segments following establishment of segment boundaries. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [ISBN:0878932437]","metadata":null},{"id":"dee9c1466a4d4c95857aa1a98ce3e205","type":"GO_TERM","name":"specification of segmental identity, trunk","canonical_id":"go:GO:0035292","description":"\"The specification of the characteristic structures of trunk segments, following establishment of segment boundaries. In Drosophila, the trunk segments include thoracic segments and abdominal segments A1 to A8. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [PMID:1360402]","metadata":null},{"id":"f38a928436d2401abf2a0d6e3cea9b4b","type":"GO_TERM","name":"specification of sepal identity","canonical_id":"go:GO:0010096","description":"\"The process in which a floral organ primordium acquires sepal identity. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tair_curators]","metadata":null},{"id":"988513ebc7ab4e67a1fdbc4e6c2f4957","type":"GO_TERM","name":"specification of stamen identity","canonical_id":"go:GO:0010097","description":"\"The process in which a floral organ primordium acquires stamen or staminode identity. Identity is considered to be the aggregate of characteristics by which a structure is recognized.\" [GOC:tair_curators]","metadata":null},{"id":"706b69fc73614ff5a70b8a10b32a5a19","type":"GO_TERM","name":"specification of symmetry","canonical_id":"go:GO:0009799","description":"\"The establishment of an organism's body plan or part of an organism such that a similar arrangement in form and relationship of parts around a common axis, or around each side of a plane is created.\" [GOC:curators]","metadata":null},{"id":"b07bcdfe0cb64c4a86d93f06b7d01dd2","type":"GO_TERM","name":"specification of ureteric bud anterior/posterior symmetry","canonical_id":"go:GO:0072100","description":"\"The establishment of the ureteric bud such that there is a similar arrangement in form and relationship of parts along its anterior/posterior axis.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"ba91081169d5464cab838dcdf8548f43","type":"GO_TERM","name":"spectrin","canonical_id":"go:GO:0008091","description":"\"Membrane associated dimeric protein (240 and 220 kDa) of erythrocytes. Forms a complex with ankyrin, actin and probably other components of the membrane cytoskeleton, so that there is a mesh of proteins underlying the plasma membrane, potentially restricting the lateral mobility of integral proteins.\" [GOC:curators, ISBN:0815316194]","metadata":null},{"id":"398b2e2e4dac4715bc63714797ac8e73","type":"GO_TERM","name":"spectrin binding","canonical_id":"go:GO:0030507","description":"\"Binding to spectrin, a protein that is the major constituent of the erythrocyte cytoskeletal network. It associates with band 4.1 (see band protein) and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane. It is composed of nonhomologous chains, alpha and beta, which aggregate side-to-side in an antiparallel fashion to form dimers, tetramers, and higher polymers.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"55aa2858aaf8455e8a424a12065ca884","type":"GO_TERM","name":"spectrin-associated cytoskeleton","canonical_id":"go:GO:0014731","description":"\"The part of the cytoskeleton composed of spectrin, protein 4.1 and ankyrin. Spectrin-associated cytoskeleton is associated with the plasma membrane.\" [GOC:mtg_muscle, PMID:15970557]","metadata":null},{"id":"8012811bacb246ff92c14afcb9089977","type":"GO_TERM","name":"spectrosome","canonical_id":"go:GO:0045170","description":"\"A germline specific spherical organelle, rich in membrane skeletal proteins. Precursor to the fusome.\" [GOC:bf]","metadata":null},{"id":"7564b6223286475aa2b7a85a1820f143","type":"GO_TERM","name":"spectrosome organization","canonical_id":"go:GO:0030721","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the spectrosome, a germline specific spherical organelle that is the precursor to the fusome.\" [PMID:11131529]","metadata":null},{"id":"063d6f5f34d34d1eb0b3d8230ecb9b02","type":"GO_TERM","name":"sperm DNA condensation","canonical_id":"go:GO:0035092","description":"\"The progressive compaction of the spermatid chromatin so that it reaches a level of condensation that is not compatible with nuclear activities such as transcription or DNA replication.\" [GOC:bf, PMID:11735001]","metadata":null},{"id":"a84d20c91ee14e5f97068d0a948b69ab","type":"GO_TERM","name":"sperm DNA decondensation","canonical_id":"go:GO:0035041","description":"\"Unwinding of the condensed nuclear chromatin of an inactive male pronucleus after fertilization.\" [GOC:bf, PMID:11735001, PMID:23352575]","metadata":null},{"id":"342d859852e84b3abae3f63aa86d38ed","type":"GO_TERM","name":"sperm annulus","canonical_id":"go:GO:0097227","description":"\"The ring-like, filamentous structure located at the distal end of the midpiece of the sperm flagellum; the annulus is thought to form a diffusion barrier between the midpiece and the principal piece and serve as a stabilizing structure for tail rigidity.\" [GOC:cjm, MP:0009834]","metadata":null},{"id":"004c59f682444baf812bb7f8109324d8","type":"GO_TERM","name":"sperm aster formation","canonical_id":"go:GO:0035044","description":"\"Formation and organization of an aster composed of microtubule arrays originating from the sperm basal body and extending virtually to the egg periphery. The sperm aster ensures the appropriate positioning of the male and female pronuclei.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"0dec2c8d3c8345cd81caade8812d2dda","type":"GO_TERM","name":"sperm axoneme assembly","canonical_id":"go:GO:0007288","description":"\"The assembly and organization of the sperm flagellar axoneme, the bundle of microtubules and associated proteins that forms the core of the eukaryotic sperm flagellum, and is responsible for movement.\" [GOC:bf, GOC:cilia, ISBN:0198547684]","metadata":null},{"id":"661315ce9f3f4e96aed378ff1f62c84d","type":"GO_TERM","name":"sperm capacitation","canonical_id":"go:GO:0048240","description":"\"A process required for sperm to reach fertilization competence. Sperm undergo an incompletely understood series of morphological and molecular maturational processes, termed capacitation, involving, among other processes, protein tyrosine phosphorylation and increased intracellular calcium.\" [GOC:jid, ISBN:978-3-642-58301-8, PMID:11820818]","metadata":null},{"id":"01cfc3aaa9544c37bb82bdcc5028c2d2","type":"GO_TERM","name":"sperm competition","canonical_id":"go:GO:0046692","description":"\"Any process that contributes to the success of sperm fertilization in multiply-mated females.\" [PMID:10885514]","metadata":null},{"id":"9aa82ddb1c6b4ec38d92b3c896154c7e","type":"GO_TERM","name":"sperm cytoplasmic droplet","canonical_id":"go:GO:0097598","description":"\"A small amount of cytoplasm surrounded by a cell membrane that is generally retained in spermatozoa after spermiogenesis, when the majority of the cytoplasm is phagocytosed by Sertoli cells to produce what are called residual bodies. Initially, the droplet is located at the neck just behind the head of an elongated spermatid. During epididymal transit, the cytoplasmic droplet migrates caudally to the annulus at the end of the midpiece; the exact position and time varies by species. The cytoplasmic droplet consists of lipids, lipoproteins, RNAs, a variety of hydrolytic enzymes, receptors, ion channels, and Golgi-derived vesicles. The droplet may be involved in regulatory volume loss (RVD) at ejaculation, and in most species, though not in humans, the cytoplasmic droplet is lost at ejaculation. Note that the cytoplasmic droplet is distinct from 'excessive residual cytoplasm' that sometimes remains in epididymal spermatozoa, particularly when spermiogenesis has been disrupted.\" [GOC:krc, GOC:vesicles, PMID:12672117, PMID:21076437, PMID:23159014]","metadata":null},{"id":"51a71759fcc9480095caa6edffef895c","type":"GO_TERM","name":"sperm displacement","canonical_id":"go:GO:0007321","description":"\"The physical displacement of sperm stored from previous mating encounters.\" [PMID:10440373]","metadata":null},{"id":"a6d5409ebae94206940365ff51eb0ad5","type":"GO_TERM","name":"sperm ejaculation","canonical_id":"go:GO:0042713","description":"\"The expulsion of seminal fluid, thick white fluid containing spermatozoa, from the male genital tract.\" [GOC:jl, PMID:26385403]","metadata":null},{"id":"e2b761b6a42f4b47a787e3687ec863a3","type":"GO_TERM","name":"sperm end piece","canonical_id":"go:GO:0097229","description":"\"The short tip of the sperm flagellum, adjacent to the sperm principal piece and furthest from the sperm head, which contains only the axoneme surrounded by the plasma membrane.\" [GOC:cjm, GOC:sart, MP:0009837]","metadata":null},{"id":"bba8363dcdbf4111b8dbcb5758d49d0b","type":"GO_TERM","name":"sperm entry","canonical_id":"go:GO:0035037","description":"\"An endocytosis process that results in penetration of the egg shell through the micropyle (a specialized anterior opening in the vitelline envelope) and entry of the entire sperm, including the surrounding plasma membrane and the sperm tail, into the egg cytoplasm. This step in fertilization is seen in Drosophila, where a plasma membrane fusion event between the sperm and the egg does not occur.\" [GOC:bf, PMID:9630751]","metadata":null},{"id":"f18eae4c0add49f191941d947ec5dd20","type":"GO_TERM","name":"sperm fibrous sheath","canonical_id":"go:GO:0035686","description":"\"A cytoskeletal structure surrounding the axoneme and outer dense fibers of the sperm flagellum. Consists of two longitudinal columns connected by closely arrayed semicircular ribs that assemble from distal to proximal throughout spermiogenesis. The fibrous sheath probably influences the degree of flexibility, plane of flagellar motion, and the shape of the flagellar beat.\" [GOC:BHF, GOC:cilia, GOC:krc, PMID:20731842, PMID:3282552]","metadata":null},{"id":"d44d3833e41e4f528d0746a4cb836416","type":"GO_TERM","name":"sperm flagellum","canonical_id":"go:GO:0036126","description":"\"A microtubule-based flagellum (or cilium) that is part of a sperm, a mature male germ cell that develops from a spermatid.\" [GOC:cilia, GOC:sart, PMID:8441407]","metadata":null},{"id":"360f09084f914dba98451821894f3ea2","type":"GO_TERM","name":"sperm flagellum assembly","canonical_id":"go:GO:0120316","description":"\"The assembly and organization of the sperm flagellum, the microtubule-based axoneme and associated structures that are part of a sperm flagellum (or cilium).\" [GOC:krc, PMID:32791035]","metadata":null},{"id":"22ff2bfac4aa4c47b82ec57111ca8d06","type":"GO_TERM","name":"sperm glycocalyx","canonical_id":"go:GO:0120238","description":"\"The carbohydrate rich layer at the outermost periphery of a sperm cell.\" [GOC:krc]","metadata":null},{"id":"f1e5a12b126f41e5926b6f4e54f3eb78","type":"GO_TERM","name":"sperm head","canonical_id":"go:GO:0061827","description":"\"The part of the late spermatid or spermatozoon that contains the nucleus and acrosome.\" [PMID:22797892, PMID:24665388]","metadata":null},{"id":"728127e5087448398f04b7b99af08cf6","type":"GO_TERM","name":"sperm head plasma membrane","canonical_id":"go:GO:1990913","description":"\"The plasma membrane that is part of the head section of a sperm cell.\" [PMID:24478030]","metadata":null},{"id":"09364b7db97f4c57a7d343618f616826","type":"GO_TERM","name":"sperm head-tail coupling apparatus","canonical_id":"go:GO:0120212","description":"\"A centrosome-based structure consisting of two cylindrical microtubule-based centrioles and associated components which anchors the flagellum to the sperm head.\" [GOC:krc, PMID:24415959, PMID:30032984]","metadata":null},{"id":"3290944f65df457688b87638a9af6214","type":"GO_TERM","name":"sperm incapacitation","canonical_id":"go:GO:0046694","description":"\"The process in which the use of stored sperm from the first-mating male is inhibited by the seminal fluid of subsequently mating males.\" [PMID:10440373]","metadata":null},{"id":"66622693b72947f6bd54aa28773331dd","type":"GO_TERM","name":"sperm individualization","canonical_id":"go:GO:0007291","description":"\"The resolution of the male germline syncytium or cyst into individual gametes by packaging each spermatid into its own plasma membrane.\" [GOC:bf, PMID:9550716]","metadata":null},{"id":"c1b3153a5c5748efbf9afd826b856a2f","type":"GO_TERM","name":"sperm individualization complex","canonical_id":"go:GO:0070864","description":"\"A cellular structure that includes cytoskeletal components and part of the cell membrane. Forms at the nuclear end of a male germline syncytium, or cyst, and translocates the over the length of the syncytium in the course of sperm individualization. Each complex contains an array of 64 investment cones, one per nucleus, that move synchronously along the spermatogenic cyst.\" [GOC:sart, PMID:10588662, PMID:9550716]","metadata":null},{"id":"b11fc682e65d47f1ab589a2eb51812f4","type":"GO_TERM","name":"sperm karyosome formation","canonical_id":"go:GO:0061989","description":"\"The chromosome organization process in which meiotic chromosomes in the spem nucleus cluster together to form a compact spherical structure called the karyosome.\" [PMID:19696886]","metadata":null},{"id":"6f88e56caa424f828755c29cac64acee","type":"GO_TERM","name":"sperm midpiece","canonical_id":"go:GO:0097225","description":"\"The highly organized segment of the sperm flagellum which begins at the connecting piece and is characterized by the presence of 9 outer dense fibers (ODFs) that lie outside each of the 9 outer axonemal microtubule doublets and by a sheath of mitochondria that encloses the ODFs and the axoneme; the midpiece terminates about one-fourth of the way down the sperm flagellum at the annulus, which marks the beginning of the principal piece.\" [GOC:cjm, MP:0009831]","metadata":null},{"id":"3bd491cef2d2424ebd304f30084890cf","type":"GO_TERM","name":"sperm migration through the uterotubal junction","canonical_id":"go:GO:0160131","description":"\"The controlled self-propelled movement of a sperm cell from the uterus through the uterotubal junction (UTJ) into the oviduct, where interaction between the sperm and the UTJ acts as a major selective barrier for sperm, allowing only living, motile, uncapacitated, morphologically normal sperm with intact acrosomes to pass from the uterus into the oviduct.\" [GOC:krc, PMID:29353867, PMID:31131960, PMID:32712384, PMID:34057175]","metadata":null},{"id":"f4fb549b37d04056ac8f59b16ca0701e","type":"GO_TERM","name":"sperm mitochondrial sheath","canonical_id":"go:GO:0097226","description":"\"The tightly packed helical sheath of ATP-producing mitochondria restricted to the midpiece of the sperm flagellum.\" [GOC:cjm, MP:0009832, PMID:32791035]","metadata":null},{"id":"dc1b5b82f01640c4a2c5df771eb0ed3e","type":"GO_TERM","name":"sperm mitochondrial sheath assembly","canonical_id":"go:GO:0120317","description":"\"The assembly and organization of the sperm mitochondrial sheath, the tightly packed helical sheath of ATP-producing mitochondria restricted to the midpiece of the sperm flagellum.\" [GOC:krc, PMID:32791035]","metadata":null},{"id":"c5aa5b1670294ade8a716f8c2d029247","type":"GO_TERM","name":"sperm mitochondrion organization","canonical_id":"go:GO:0030382","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of sperm mitochondria; the process in which they take on their characteristic morphology; they are flattened, elongated, and arranged circumferentially into a tight helical coil around the tail-dense fibers of the mature sperm.\" [GOC:dph, GOC:jl, GOC:mah, PMID:8833144]","metadata":null},{"id":"4e4efe2f6e3348508701ce3218a14f4b","type":"GO_TERM","name":"sperm motility","canonical_id":"go:GO:0097722","description":"\"Any process involved in the controlled movement of a sperm cell.\" [GOC:cilia, GOC:krc]","metadata":null},{"id":"11034285cb974f6894dd796691ad241b","type":"GO_TERM","name":"sperm nuclear envelope removal","canonical_id":"go:GO:0035040","description":"\"Removal of the sperm nuclear envelope, allowing entry of maternal factors into the sperm nucleus.\" [GOC:bf, PMID:11735001]","metadata":null},{"id":"c26debb21c044aefb595d3286d24832b","type":"GO_TERM","name":"sperm plasma membrane","canonical_id":"go:GO:0097524","description":"\"A plasma membrane that is part of a sperm cell.\" [GOC:cjm]","metadata":null},{"id":"45345b1af3ad42ef8f3b4c235e78ffd7","type":"GO_TERM","name":"sperm plasma membrane disassembly","canonical_id":"go:GO:0035045","description":"\"The gradual disintegration of the sperm plasma membrane following insemination. This process is seen in Drosophila after entry of the entire sperm, surrounded by its plasma membrane, into the egg.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"f9e012b4fe1640e49da6f72c5a407b5f","type":"GO_TERM","name":"sperm principal piece","canonical_id":"go:GO:0097228","description":"\"The segment of the sperm flagellum where the mitochondrial sheath ends, and the outer dense fibers (ODFs) associated with outer axonemal doublets 3 and 8 are replaced by the 2 longitudinal columns of the fibrous sheath (FS) which run the length of the principal piece and are stabilized by circumferential ribs. The principal piece makes up ~2/3 of the length of the sperm flagellum and is defined by the presence of the FS and of only 7 (rather than 9) ODFs which taper and then terminate near the distal end of the principal piece.\" [GOC:cjm, MP:0009836]","metadata":null},{"id":"fd053997592343138790c1160e5e527c","type":"GO_TERM","name":"sperm storage","canonical_id":"go:GO:0046693","description":"\"The retention of sperm by a female following mating.\" [PMID:10885514]","metadata":null},{"id":"41203c9ffa704371a4b608942179bf81","type":"GO_TERM","name":"sperm-egg recognition","canonical_id":"go:GO:0035036","description":"\"The initial contact step made between the sperm plasma membrane and outer layer of the egg during fertilization.\" [GOC:bf]","metadata":null},{"id":"a31c46a4d3944bd2becd61765a93055e","type":"GO_TERM","name":"spermathecum morphogenesis","canonical_id":"go:GO:0035211","description":"\"The process in which the anatomical structures of a spermathecum, a sperm storage organ, are generated and organized. Paired spermathecae lie at the anterior end of the insect uterus on the dorsal side. Each spermatheca consists of an oval shaped capsule, connected to the uterus by a spermathecal stalk.\" [PMID:12679097]","metadata":null},{"id":"7ab9953ec61741f1b995d234ba20c878","type":"GO_TERM","name":"spermatid cytoplasm removal during spermiation of flagellated sperm","canonical_id":"go:GO:0160087","description":"\"The process of removing the majority of the cytoplasm and organelles from a spermatid as it develops into a mature flagellated sperm cell.\" [PMID:21866274, PMID:23087837]","metadata":null},{"id":"62e7817363b441a880ffc912aec37481","type":"GO_TERM","name":"spermatid development","canonical_id":"go:GO:0007286","description":"\"The process whose specific outcome is the progression of a spermatid over time, from its formation to the mature structure.\" [GOC:curators, GOC:dph]","metadata":null},{"id":"8b28790d1dd143f495ba6e391515ce96","type":"GO_TERM","name":"spermatid differentiation","canonical_id":"go:GO:0048515","description":"\"The process whose specific outcome is the progression of a spermatid over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"f9eca375409e4422a8e9c4b687e6f3d4","type":"GO_TERM","name":"spermatid mitochondrial nucleoid elimination","canonical_id":"go:GO:7770014","description":"\"The process in which spermatids lose their mitochondrial nucleoids during spermatid development. This process involves the controlled elimination of mitochondrial DNA-protein complexes while preserving the mitochondrial membranes and and contributes to maternal mitochondrial inheritance patterns by inhibiting paternal transmission.\" [PMID:28318978]","metadata":null},{"id":"5173dd13ab79459194a6de8bc4f24463","type":"GO_TERM","name":"spermatid nucleus differentiation","canonical_id":"go:GO:0007289","description":"\"The specialization of the spermatid nucleus during the development of a spermatid into a mature male gamete competent for fertilization.\" [GOC:bf, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"19390adf4c7a4c928b0ca2135603641e","type":"GO_TERM","name":"spermatid nucleus elongation","canonical_id":"go:GO:0007290","description":"\"The change in shape of the spermatid nucleus from a spherical structure to an elongated organelle, during the latter part of spermatid differentiation.\" [GOC:bf, GOC:dph, GOC:jl, GOC:mah, ISBN:0879694238]","metadata":null},{"id":"b652c873814144e6bc6d07145558398a","type":"GO_TERM","name":"spermatocyte division","canonical_id":"go:GO:0048137","description":"\"The meiotic divisions undergone by the primary and secondary spermatocytes to produce haploid spermatids.\" [GOC:jid, GOC:pr, ISBN:0879694238]","metadata":null},{"id":"cce37e2379ae4bbfa616532e2a3124cc","type":"GO_TERM","name":"spermatogenesis","canonical_id":"go:GO:0007283","description":"\"The developmental process by which male germ line stem cells self renew or give rise to successive cell types resulting in the development of a spermatozoa.\" [GOC:jid, ISBN:9780878933846, PMID:28073824, PMID:30990821]","metadata":null},{"id":"d754a080dc164d7cb778f0c6fbc70fcb","type":"GO_TERM","name":"spermatogonial cell division","canonical_id":"go:GO:0007284","description":"\"The mitotic divisions of the primary spermatogonial cell (a primordial male germ cell) to form secondary spermatogonia (primary spermatocytes).\" [GOC:bf, GOC:pr, ISBN:0879694238]","metadata":null},{"id":"31f382faef6a45d29c9de22ccca9d004","type":"GO_TERM","name":"spermatoproteasome complex","canonical_id":"go:GO:1990111","description":"\"A proteasome specifically found in mammalian testis. Contains the proteasome activator PA200 in the regulatory particle, and beta1i, beta2i, beta5i and/or alpha4s in the core (20S) subunit. Beta1i, beta2i and beta5i are inducible catalytic subunits, closely related to beta1, beta2 and beta5. Alpha4s is a sperm-specific 20S subunit, but unlike other alternative 20S subunits alpha4s lies in the outer alpha-ring and lacks catalytic activity.\" [GOC:sp, PMID:23706739]","metadata":null},{"id":"543cf9f45c6e41a5bc4b3ba1ae06493c","type":"GO_TERM","name":"spermidine binding","canonical_id":"go:GO:0019809","description":"\"Binding to spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:ai]","metadata":null},{"id":"7c51850eeeba49049a95fa2d3899deec","type":"GO_TERM","name":"spermidine biosynthetic process","canonical_id":"go:GO:0008295","description":"\"The chemical reactions and pathways resulting in the formation of spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"0e90fbd8dc0f4b1d8c1d6739c304a5d1","type":"GO_TERM","name":"spermidine catabolic process","canonical_id":"go:GO:0046203","description":"\"The chemical reactions and pathways resulting in the breakdown of spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:ai]","metadata":null},{"id":"bb4305e8e4764f499f7eba0a567a714f","type":"GO_TERM","name":"spermidine dehydrogenase activity","canonical_id":"go:GO:0050289","description":"\"Catalysis of the reaction: spermidine + acceptor + H2O = 1,3-diaminopropane + 4-aminobutanal + reduced acceptor.\" [EC:1.5.99.6, MetaCyc:SPERMIDINE-DEHYDROGENASE-RXN]","metadata":null},{"id":"731def1c9edd4cbbb1a61c0432054791","type":"GO_TERM","name":"spermidine hydroxycinnamate conjugate biosynthetic process","canonical_id":"go:GO:0080088","description":"\"The chemical reactions and pathways resulting in the formation of spermidine hydroxycinnamate conjugates.\" [PMID:19077165]","metadata":null},{"id":"041f5e43b8f94a60a12d57296603e71e","type":"GO_TERM","name":"spermidine import across plasma membrane","canonical_id":"go:GO:0140203","description":"\"The directed movement of spermidine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:vw]","metadata":null},{"id":"adb4237ba1f9406db3d17b32b1a9723d","type":"GO_TERM","name":"spermidine metabolic process","canonical_id":"go:GO:0008216","description":"\"The chemical reactions and pathways involving spermidine, N-(3-aminopropyl)-1,4-diaminobutane.\" [GOC:ai]","metadata":null},{"id":"fca4e2b39b8e456a8702c8d950863eac","type":"GO_TERM","name":"spermidine synthase activity","canonical_id":"go:GO:0004766","description":"\"Catalysis of the reaction: S-adenosylmethioninamine + putrescine = 5'-methylthioadenosine + spermidine.\" [EC:2.5.1.16]","metadata":null},{"id":"16d4126a4649418fb471fce9ff276307","type":"GO_TERM","name":"spermidine transmembrane transport","canonical_id":"go:GO:1903711","description":"\"The process in which spermidine is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:15637075]","metadata":null},{"id":"4be992aba8114487b9ad452d2d44a935","type":"GO_TERM","name":"spermidine transmembrane transporter activity","canonical_id":"go:GO:0015606","description":"\"Enables the transfer of spermidine, N-(3-aminopropyl)-1,4-diaminobutane, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"8bdb19bdfde149de940c8ce819c803c4","type":"GO_TERM","name":"spermidine transport","canonical_id":"go:GO:0015848","description":"\"The directed movement of spermidine, N-(3-aminopropyl)-1,4-diaminobutane, a polyamine formed by the transfer of a propylamine group from decarboxylated S-adenosylmethionine to putrescine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc, ISBN:0198506732]","metadata":null},{"id":"33fa4e14532f466eaf22557673ceec59","type":"GO_TERM","name":"spermidine:caffeoyl CoA N-acyltransferase activity","canonical_id":"go:GO:0080074","description":"\"Catalysis of the transfer of a caffeoyl group to a nitrogen atom on the spermidine molecule.\" [PMID:19077165]","metadata":null},{"id":"8622823119c7439cb81a3d67908dc772","type":"GO_TERM","name":"spermidine:coumaroyl CoA N-acyltransferase activity","canonical_id":"go:GO:0080073","description":"\"Catalysis of the transfer of a coumaroyl group to a nitrogen atom on the spermidine molecule.\" [PMID:19077165]","metadata":null},{"id":"3cfaf4ddc8fe44cfac62bc12be818f66","type":"GO_TERM","name":"spermidine:feruloyl CoA N-acyltransferase activity","canonical_id":"go:GO:0080075","description":"\"Catalysis of the transfer of a feruloyl group to a nitrogen atom on the spermidine molecule.\" [PMID:19077165]","metadata":null},{"id":"699c04b58fea4b2bad81f2f52d10a0dd","type":"GO_TERM","name":"spermidine:sinapoyl CoA N-acyltransferase activity","canonical_id":"go:GO:0080072","description":"\"Catalysis of the transfer of a sinapoyl group to a nitrogen atom on the spermidine molecule.\" [PMID:19077165]","metadata":null},{"id":"f283cc0292a64ef59d58e18eaaf0cf6c","type":"GO_TERM","name":"spermine biosynthetic process","canonical_id":"go:GO:0006597","description":"\"The chemical reactions and pathways resulting in the formation of spermine, a polybasic amine found in human sperm, in ribosomes and in some viruses and involved in nucleic acid packaging.\" [GOC:curators, MetaCyc:ARGSPECAT-PWY]","metadata":null},{"id":"48512e742d284e419934444059c8c5ec","type":"GO_TERM","name":"spermine catabolic process","canonical_id":"go:GO:0046208","description":"\"The chemical reactions and pathways resulting in the breakdown of spermine, a polybasic amine found in human sperm, in ribosomes and in some viruses and involved in nucleic acid packaging.\" [PMID:12141946]","metadata":null},{"id":"4905e02a066d4505bd05f09707140a0e","type":"GO_TERM","name":"spermine metabolic process","canonical_id":"go:GO:0008215","description":"\"The chemical reactions and pathways involving spermine, a polybasic amine found in human sperm, in ribosomes and in some viruses, which is involved in nucleic acid packaging. Synthesis is regulated by ornithine decarboxylase which plays a key role in control of DNA replication.\" [GOC:curators]","metadata":null},{"id":"743c4f92428f4721b80f12e55d7dc33b","type":"GO_TERM","name":"spermine oxidase activity","canonical_id":"go:GO:0052901","description":"\"Catalysis of the reaction: H2O + O2 + spermine = 3-aminopropanal + H2O2 + spermidine. Weak activity with N(1)-acetylspermine. The Arabidopsis thaliana enzyme converts norspermine to norspermidine.\" [EC:1.5.3.16, RHEA:25804]","metadata":null},{"id":"5a6c2f5fd1b24541b44df6113b4c9d54","type":"GO_TERM","name":"spermine synthase activity","canonical_id":"go:GO:0016768","description":"\"Catalysis of the reaction: S-adenosylmethioninamine + spermidine = 5'-methylthioadenosine + spermine.\" [EC:2.5.1.22]","metadata":null},{"id":"f7d0e15cc37c47de9b91cd7b9d602da9","type":"GO_TERM","name":"spermine transmembrane transport","canonical_id":"go:GO:1903710","description":"\"The process in which spermine is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:15637075]","metadata":null},{"id":"441ae9a5252146708097600736e4cab4","type":"GO_TERM","name":"spermine transmembrane transporter activity","canonical_id":"go:GO:0000297","description":"\"Enables the transfer of spermine from one side of a membrane to the other. Spermine is a polybasic amine found in human sperm, in ribosomes and in some viruses, which is involved in nucleic acid packaging. Synthesis is regulated by ornithine decarboxylase which plays a key role in control of DNA replication.\" [GOC:ai]","metadata":null},{"id":"9989076b9f544aeeb25da2d06bb63712","type":"GO_TERM","name":"spermine transport","canonical_id":"go:GO:0000296","description":"\"The directed movement of spermine, N,N-bis(3-aminopropyl)-1,4-diaminobutane, a polyamine formed by the transfer of a propylamine group from decarboxylated S-adenosylmethionine to spermidine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc, ISBN:0198506732]","metadata":null},{"id":"2b4fcf0229ab4c1c89eea2a7f564ceb2","type":"GO_TERM","name":"sphere organelle","canonical_id":"go:GO:0071601","description":"\"A nuclear body that is found in the germinal vesicles of amphibian oocytes, and consist of three major parts: a remarkably spherical body about 5-10 pm in diameter, smaller spherical or nearly spherical granules on the surface, and inclusions of various sizes that strongly resemble the surface granules. The parts of the sphere organelle have distinct compositions, including splicing snRNAs and proteins.\" [PMID:7758244, PMID:8349728]","metadata":null},{"id":"2298707357e54699955c5a89e2becd76","type":"GO_TERM","name":"spherical high-density lipoprotein particle","canonical_id":"go:GO:0034366","description":"\"A mature high-density lipoprotein (HDL) particle, converted from discoidal HDL particles following the esterification of cholesterol in the particle by phosphatidylcholine-sterol O-acyltransferase (lecithin cholesterol acyltransferase; LCAT).\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"8b01737886b94598aab17dde004b996b","type":"GO_TERM","name":"spheroidene biosynthetic process","canonical_id":"go:GO:1901180","description":"\"The chemical reactions and pathways resulting in the formation of spheroidene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00683]","metadata":null},{"id":"6532d79a97df4410b88436bee1bcc022","type":"GO_TERM","name":"spheroidene catabolic process","canonical_id":"go:GO:1901179","description":"\"The chemical reactions and pathways resulting in the breakdown of spheroidene.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00683]","metadata":null},{"id":"4d86512d16af434fa5e5ed5a71aad34d","type":"GO_TERM","name":"spheroidene monooxygenase activity","canonical_id":"go:GO:0043823","description":"\"Catalysis of the reaction: spheroidene + O2 = spheroidenone + H2O.\" [PMID:16086104, PMID:16158287]","metadata":null},{"id":"32c9fb865db149e88bb8b7eeeb3f23f2","type":"GO_TERM","name":"spherule viral factory","canonical_id":"go:GO:0039717","description":"\"A cytoplasmic viral factory which is a 50-400nm diameter membrane invagination. Spherules can appear on several enveloped cellular components depending on the virus.\" [VZ:1951]","metadata":null},{"id":"634d2f9b791d412d97fa9684a6884034","type":"GO_TERM","name":"sphinganine biosynthetic process","canonical_id":"go:GO:0046511","description":"\"The chemical reactions and pathways resulting in the formation of sphinganine, D-erythro-2-amino-1,3-octadecanediol.\" [GOC:ai]","metadata":null},{"id":"c50923dabb6e4f7086e2a656cde50708","type":"GO_TERM","name":"sphinganine metabolic process","canonical_id":"go:GO:0006667","description":"\"The chemical reactions and pathways involving sphinganine, D-erythro-2-amino-1,3-octadecanediol.\" [PMID:29165427]","metadata":null},{"id":"d180cbd2d43249ebb1d5f1ec9246305c","type":"GO_TERM","name":"sphinganine-1-phosphate aldolase activity","canonical_id":"go:GO:0008117","description":"\"Catalysis of the reaction: sphinganine 1-phosphate = phosphoethanolamine + palmitaldehyde.\" [EC:4.1.2.27]","metadata":null},{"id":"08000f7bcd3f4e42b0e7295982cd290d","type":"GO_TERM","name":"sphinganine-1-phosphate biosynthetic process","canonical_id":"go:GO:0006669","description":"\"The chemical reactions and pathways resulting in the formation of sphinganine-1-phosphate, the phosphorylated derivative of D-erythro-2-amino-1,3-octadecanediol.\" [GOC:ai]","metadata":null},{"id":"deb4c4d922384bc2a35425e962989309","type":"GO_TERM","name":"sphinganine-1-phosphate catabolic process","canonical_id":"go:GO:0051874","description":"\"The chemical reactions and pathways resulting in the breakdown of sphinganine-1-phosphate, the phosphorylated derivative of D-erythro-2-amino-1,3-octadecanediol.\" [GOC:ai]","metadata":null},{"id":"1037d1f6e8a54cfaa977654013af841d","type":"GO_TERM","name":"sphinganine-1-phosphate metabolic process","canonical_id":"go:GO:0006668","description":"\"The chemical reactions and pathways involving sphinganine-1-phosphate, the phosphorylated derivative of D-erythro-2-amino-1,3-octadecanediol.\" [GOC:ai]","metadata":null},{"id":"70ab998da5c8464f9d3ee89a539d3598","type":"GO_TERM","name":"sphingoid biosynthetic process","canonical_id":"go:GO:0046520","description":"\"The chemical reactions and pathways resulting in the formation of sphingoids, any of a class of compounds comprising sphinganine and its homologues and stereoisomers, and derivatives of these compounds.\" [ISBN:0198506732]","metadata":null},{"id":"fb58e9190fcf45cea76f5aecf420364e","type":"GO_TERM","name":"sphingoid catabolic process","canonical_id":"go:GO:0046521","description":"\"The chemical reactions and pathways resulting in the breakdown of sphingoids, any of a class of compounds comprising sphinganine and its homologues and stereoisomers, and derivatives of these compounds.\" [ISBN:0198506732]","metadata":null},{"id":"22116fce9e734c5786961a8458f2a744","type":"GO_TERM","name":"sphingoid long-chain base transport","canonical_id":"go:GO:1905329","description":"\"The directed movement of a sphingoid long-chain base, sometimes referred to as long-chain base, or sphingoid base, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Sphingoid long-chain bases are long-chain aliphatic amines that are the fundamental building blocks of sphingolipids. The main mammalian sphingoid long-chain bases are dihydrosphingosine and sphingosine, while dihydrosphingosine and phytosphingosine are the main sphingoid long-chain bases in yeast.\" [GO_REF:0000065, GOC:rn, GOC:TermGenie, PMID:27136724]","metadata":null},{"id":"6d7a513f0d674f68b26334f99f529726","type":"GO_TERM","name":"sphingoid metabolic process","canonical_id":"go:GO:0046519","description":"\"The chemical reactions and pathways involving sphingoids, any of a class of compounds comprising sphinganine and its homologues and stereoisomers, and derivatives of these compounds.\" [ISBN:0198506732]","metadata":null},{"id":"3b75b3361d49480ab67e4602baff0592","type":"GO_TERM","name":"sphingolipid 8-(E/Z)-desaturase activity","canonical_id":"go:GO:0052631","description":"\"Catalysis of the reaction: an N-acyl-(4R)-4-hydroxysphinganine + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = a (4R,8E)-4-hydroxysphingenine ceramide + 2 Fe(III)-[cytochrome b5] + 2 H2O or an N-acyl-(4R)-4-hydroxysphinganine + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = (4R,8Z)-4-hydroxysphing-8-enine ceramide + 2 Fe(III)-[cytochrome b5] + 2 H2O. This results in the formation of a double bond between C8 and C9 of the long chain base of a sphingolipid.\" [EC:1.14.19.29, PMID:17600137, PMID:9786850]","metadata":null},{"id":"4aee467b4e8046038f51de6c3ccfacf3","type":"GO_TERM","name":"sphingolipid C4-monooxygenase activity","canonical_id":"go:GO:0102772","description":"\"Catalysis of the reaction: a dihydroceramide + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = a phytoceramide + 2 Fe(III)-[cytochrome b5] + H2O.\" [EC:1.14.18.5, GOC:pz]","metadata":null},{"id":"be1237a646344f3f8e9dc5793662e60b","type":"GO_TERM","name":"sphingolipid activator protein activity","canonical_id":"go:GO:0030290","description":"\"Any of a group of peptide cofactors of enzymes for the lysosomal degradation of sphingolipids. They stimulate various enzymes, including glucosylceramidase, galactosylceramidase, cerebroside-sulfatase, alpha-galactosidase, beta-galactosidase, and sphingomyelin phosphodiesterase.\" [ISBN:0198506732]","metadata":null},{"id":"451fe0d8ee3440b5a0ec70e3e2e54845","type":"GO_TERM","name":"sphingolipid alpha-glucuronosyltransferase activity","canonical_id":"go:GO:1990482","description":"\"Catalysis of the reaction: UDP-glucuronate + inositol phosphorylceramide (IPC) = UDP + GlcA-IPC.\" [GOC:tb, PMID:25122154]","metadata":null},{"id":"9466a91a44a646b1926051f46d5b99c2","type":"GO_TERM","name":"sphingolipid binding","canonical_id":"go:GO:0046625","description":"\"Binding to a sphingolipid, a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [ISBN:0198506732]","metadata":null},{"id":"8a5341bda0364583a72da2e8d5072b36","type":"GO_TERM","name":"sphingolipid biosynthetic process","canonical_id":"go:GO:0030148","description":"\"The chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"ab4a73fb9728409b9f8e592644a2cc34","type":"GO_TERM","name":"sphingolipid catabolic process","canonical_id":"go:GO:0030149","description":"\"The chemical reactions and pathways resulting in the breakdown of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"dde85386afbd454db47873fdc50e9abc","type":"GO_TERM","name":"sphingolipid delta-4 desaturase activity","canonical_id":"go:GO:0042284","description":"\"Catalysis of the reaction: an N-acylsphinganine + 2 Fe(II)-[cytochrome b5] + O2 + 2 H+ = an N-acylsphing-4-enine + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [PMID:12417141, RHEA:46544]","metadata":null},{"id":"11bf5098f1654c6a91d8ff4724a9da6c","type":"GO_TERM","name":"sphingolipid floppase activity","canonical_id":"go:GO:0046623","description":"\"Catalysis of the movement of a sphingolipid from the cytosolic to the exoplasmic leaflet of a membrane, using energy from the hydrolysis of ATP.\" [GOC:ai, PMID:12034738]","metadata":null},{"id":"71013052c7874f81b4b9069c2748ac7a","type":"GO_TERM","name":"sphingolipid intramembrane carrier activity","canonical_id":"go:GO:0046624","description":"\"Enables the directed movement of sphingolipids into, out of or within a cell, or between cells. Sphingolipids are a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"9a3a66652eb5492daa7d95b597cb2490","type":"GO_TERM","name":"sphingolipid mediated signaling pathway","canonical_id":"go:GO:0090520","description":"\"The series of molecular signals mediated by a sphingolipid.\" [PMID:9525917]","metadata":null},{"id":"c23d4608bf49405996eb0eab1ba4e034","type":"GO_TERM","name":"sphingolipid metabolic process","canonical_id":"go:GO:0006665","description":"\"The chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"00cfb689c1314782bf8a843457e35da7","type":"GO_TERM","name":"sphingolipid transfer activity","canonical_id":"go:GO:0120016","description":"\"Removes a sphingolipid from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"ab24f04abb964a45baf27d4f16daf782","type":"GO_TERM","name":"sphingolipid translocation","canonical_id":"go:GO:0099039","description":"\"The movement of a sphingolipid molecule from one leaflet of a membrane bilayer to the opposite leaflet.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"ce3512415ec14a99b6762539f7502e87","type":"GO_TERM","name":"sphingomyelin biosynthetic process","canonical_id":"go:GO:0006686","description":"\"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.\" [ISBN:0198506732]","metadata":null},{"id":"2a4b0b26bbc2421980a6bcb14c9e78db","type":"GO_TERM","name":"sphingomyelin catabolic process","canonical_id":"go:GO:0006685","description":"\"The chemical reactions and pathways resulting in the breakdown of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.\" [ISBN:0198506732]","metadata":null},{"id":"2929dd76a37f4814baa24c2d53863181","type":"GO_TERM","name":"sphingomyelin metabolic process","canonical_id":"go:GO:0006684","description":"\"The chemical reactions and pathways involving sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine, any of a class of phospholipids in which the amino group of sphingosine is in amide linkage with one of several fatty acids, while the terminal hydroxyl group of sphingosine is esterified to phosphorylcholine.\" [ISBN:0198506732]","metadata":null},{"id":"f739818d4b9a412f93df341d1adab9fd","type":"GO_TERM","name":"sphingomyelin phosphodiesterase D activity","canonical_id":"go:GO:0050290","description":"\"Catalysis of the reaction: H2O + sphingomyelin = ceramide 1-phosphate + choline + H+.\" [EC:3.1.4.41, RHEA:20984]","metadata":null},{"id":"054d561b7cc04914920ddc358fd7c976","type":"GO_TERM","name":"sphingomyelin phosphodiesterase activator activity","canonical_id":"go:GO:0016230","description":"\"Binds to and increases the activity of the enzyme sphingomyelin phosphodiesterase.\" [GOC:ai]","metadata":null},{"id":"b9b4f74ccff04285ba66c9a9900ef234","type":"GO_TERM","name":"sphingomyelin phosphodiesterase activity","canonical_id":"go:GO:0004767","description":"\"Catalysis of the reaction: H2O + sphingomyelin = ceramide + choline phosphate + H+.\" [EC:3.1.4.12, RHEA:19253]","metadata":null},{"id":"ec34db5fcf124988a6c2b4716b2b8a91","type":"GO_TERM","name":"sphingomyelin synthase activity","canonical_id":"go:GO:0033188","description":"\"Catalysis of the reaction: 1,2-diacyl-sn-glycero-3-phosphocholine + ceramide = 1,2-diacyl-sn-glycerol + sphingomyelin.\" [EC:2.7.8.27, RHEA:18765]","metadata":null},{"id":"9a1544f97ac84cc88ff90544da65b79f","type":"GO_TERM","name":"sphingomyelin transfer activity","canonical_id":"go:GO:0140338","description":"\"Removes a sphingomyelin from the outer leaflet of a donor membrane, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to the outer leaflet of an acceptor membrane.\" [PMID:9132017]","metadata":null},{"id":"61c1aaed241d4af28b749b57697361be","type":"GO_TERM","name":"sphingophospholipase activity","canonical_id":"go:GO:0120570","description":"\"Catalysis of the hydrolysis of a sphingophospholipid.\" [GOC:curators]","metadata":null},{"id":"8a6fbee219b445059055d66609662692","type":"GO_TERM","name":"sphingosine N-acyltransferase activity","canonical_id":"go:GO:0050291","description":"\"Catalysis of the reaction: acyl-CoA + sphingosine = CoA + N-acylsphingosine.\" [EC:2.3.1.24, MetaCyc:SPHINGOSINE-N-ACYLTRANSFERASE-RXN, PMID:12069845]","metadata":null},{"id":"0d1528864d1947eead69018faa5587b2","type":"GO_TERM","name":"sphingosine beta-galactosyltransferase activity","canonical_id":"go:GO:0047258","description":"\"Catalysis of the reaction: sphingosine + UDP-D-galactose = H+ + psychosine + UDP.\" [EC:2.4.1.23, RHEA:19485]","metadata":null},{"id":"58069e420f4647b292c6279b2cfb794e","type":"GO_TERM","name":"sphingosine biosynthetic process","canonical_id":"go:GO:0046512","description":"\"The chemical reactions and pathways resulting in the formation of sphingosine (sphing-4-enine), trans-D-erytho-2-amino-octadec-4-ene-1,3-diol, a long chain amino diol sphingoid base that occurs in most sphingolipids in animal tissues.\" [GOC:ma, ISBN:0198506732]","metadata":null},{"id":"0834aa79cdb64a3dac872793d2ea2275","type":"GO_TERM","name":"sphingosine catabolic process","canonical_id":"go:GO:0051872","description":"\"The chemical reactions and pathways resulting in the breakdown of sphingosine (sphing-4-enine), trans-D-erytho-2-amino-octadec-4-ene-1,3-diol, a long chain amino diol sphingoid base that occurs in most sphingolipids in animal tissues.\" [GOC:ai]","metadata":null},{"id":"f58fa9d51a7f4143a644546bd44ba3b4","type":"GO_TERM","name":"sphingosine cholinephosphotransferase activity","canonical_id":"go:GO:0047354","description":"\"Catalysis of the reaction: CDP-choline + sphingosine = CMP + H+ + sphingosyl-phosphocholine.\" [EC:2.7.8.10, RHEA:21224]","metadata":null},{"id":"f5cb23e48506439f9928b3e741fd46e4","type":"GO_TERM","name":"sphingosine kinase activity","canonical_id":"go:GO:0008481","description":"\"Catalysis of the reaction: a sphingoid base + ATP = a sphingoid 1-phosphate + ADP + H+.\" [RHEA:51496]","metadata":null},{"id":"d9185baaf04d41c3bf4cef10b8665c3e","type":"GO_TERM","name":"sphingosine metabolic process","canonical_id":"go:GO:0006670","description":"\"The chemical reactions and pathways involving sphingosine (sphing-4-enine), trans-D-erytho-2-amino-octadec-4-ene-1,3-diol, a long chain amino diol sphingoid base that occurs in most sphingolipids in animal tissues.\" [GOC:ma, ISBN:0198506732]","metadata":null},{"id":"6d361745a0ca4477b1d3fe1e197f0cbf","type":"GO_TERM","name":"sphingosine-1-phosphate phosphatase activity","canonical_id":"go:GO:0042392","description":"\"Catalysis of the reaction: sphingosine 1-phosphate + H2O = sphingosine + phosphate.\" [GOC:jl, PMID:8663293]","metadata":null},{"id":"43323fada41049998e9177e25eabd307","type":"GO_TERM","name":"sphingosine-1-phosphate receptor activity","canonical_id":"go:GO:0038036","description":"\"Combining with the sphingolipid sphingosine-1-phosphate (S1P), and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:bf, PMID:12728273, Wikipedia:S1PR1]","metadata":null},{"id":"38f1582049634f83a5042a88535e05b4","type":"GO_TERM","name":"sphingosine-1-phosphate receptor signaling pathway","canonical_id":"go:GO:0003376","description":"\"A G protein-coupled receptor signaling pathway initiated by sphingosine-1-phosphate binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ascb_2009, GOC:signaling, PMID:14592418, PMID:22001186]","metadata":null},{"id":"1780f47a16f8484f9b6783f96d61842e","type":"GO_TERM","name":"spicule insertion","canonical_id":"go:GO:0034609","description":"\"Insertion of the male copulatory spicules into the hermaphrodite. Spicule insertion behavior initiates when the male cloaca contacts the vulva. During most mating encounters, the spicule tips will prod the vulva continuously until they partially penetrate, which then causes the protractors to contract completely so that the spicules extend through the vulva.\" [PMID:18050467]","metadata":null},{"id":"b02a1e22e3124875a4505fb91fa33c88","type":"GO_TERM","name":"spike train","canonical_id":"go:GO:0098874","description":"\"A series of sequential, propagated action potentials occurring in a single cell.\" [ISBN:978-0071390118]","metadata":null},{"id":"4753a955c96d462b812987dfed072439","type":"GO_TERM","name":"spinal cord anterior/posterior patterning","canonical_id":"go:GO:0021512","description":"\"The process that regulates the coordinated growth and differentiation that establishes the non-random anterior-posterior spatial arrangement of the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"513b5023250d42d0995403d24a14353a","type":"GO_TERM","name":"spinal cord association neuron differentiation","canonical_id":"go:GO:0021527","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of association neurons. Association neurons are cells located in the dorsal portion of the spinal cord that integrate sensory input. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"a71642224b9d41d39f3ff698a6350a70","type":"GO_TERM","name":"spinal cord association neuron specification","canonical_id":"go:GO:0021519","description":"\"The process in which a cell becomes capable of differentiating autonomously into an association neuron in an environment that is neutral with respect to the developmental pathway.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d6a59c4c0f9244c3bcf85f5813690c25","type":"GO_TERM","name":"spinal cord commissural neuron specification","canonical_id":"go:GO:0021518","description":"\"The process in which a cell becomes capable of differentiating autonomously into a commissural neuron in an environment that is neutral with respect to the developmental pathway.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"b3717aa4c4a44f4ab36908959630086c","type":"GO_TERM","name":"spinal cord development","canonical_id":"go:GO:0021510","description":"\"The process whose specific outcome is the progression of the spinal cord over time, from its formation to the mature structure. The spinal cord primarily conducts sensory and motor nerve impulses between the brain and the peripheral nervous tissues.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"6c11dde574864d9f9568fbd623fb4745","type":"DISEASE","name":"spinal cord disorder","canonical_id":"mondo:0002545","description":null,"metadata":null},{"id":"26c8e9df393e4e899a8897d71745d6f6","type":"GO_TERM","name":"spinal cord dorsal/ventral patterning","canonical_id":"go:GO:0021513","description":"\"The process that regulates the coordinated growth and differentiation that establishes the non-random dorsal-ventral spatial arrangement of the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"108ee656779145de86dae4340ab14744","type":"DISEASE","name":"spinal cord injury","canonical_id":"mondo:0043797","description":null,"metadata":null},{"id":"100c8656676a45269ae8ac8ecbcc5c12","type":"GO_TERM","name":"spinal cord interneuron axon guidance","canonical_id":"go:GO:0097377","description":"\"The process in which the migration of an axon growth cone of a spinal cord interneuron is directed to a specific target site in response to a combination of attractive and repulsive cues. A spinal cord interneuron is a CNS interneuron located in the spinal cord.\" [CL:0005000, GOC:pr]","metadata":null},{"id":"2a2c471936b14c46913ef2b4c12bd4cd","type":"GO_TERM","name":"spinal cord motor neuron cell fate specification","canonical_id":"go:GO:0021520","description":"\"The process in which a cell becomes capable of differentiating autonomously into a motor neuron in an environment that is neutral with respect to the developmental pathway.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e57f8d110ab4401daf408a3025c3f494","type":"GO_TERM","name":"spinal cord motor neuron differentiation","canonical_id":"go:GO:0021522","description":"\"The process in which neuroepithelial cells in the ventral neural tube acquire specialized structural and/or functional features of motor neurons. Motor neurons innervate an effector (muscle or glandular) tissue and are responsible for transmission of motor impulses from the brain to the periphery. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"7da3d8646d93410cbe28bcfeed8a698e","type":"GO_TERM","name":"spinal cord motor neuron migration","canonical_id":"go:GO:0097476","description":"\"The orderly movement of a spinal cord motor neuron from one site to another. A spinal cord motor neuron is a motor neuron that passes from the spinal cord toward or to a muscle and conducts an impulse that causes movement.\" [CL:0011001, GOC:yaf, PMID:20711475]","metadata":null},{"id":"61bddd4300a74cd497edbe8ec1264bd8","type":"GO_TERM","name":"spinal cord oligodendrocyte cell differentiation","canonical_id":"go:GO:0021529","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of oligodendrocytes. Oligodendrocytes are non-neuronal cells. The primary function of oligodendrocytes is the myelination of nerve axons in the central nervous system. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"145b3478ea944e9db3c234b43437def0","type":"GO_TERM","name":"spinal cord oligodendrocyte cell fate specification","canonical_id":"go:GO:0021530","description":"\"The process in which a cell becomes capable of differentiating autonomously into an oligodendrocyte in an environment that is neutral with respect to the developmental pathway.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"931d3738cfd84157b25641ed15d401a8","type":"GO_TERM","name":"spinal cord patterning","canonical_id":"go:GO:0021511","description":"\"The regionalization process that regulates the coordinated growth and establishes the non-random spatial arrangement of the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"097a4b872e5c4fdf93be5cc517ec5b59","type":"GO_TERM","name":"spinal cord radial glial cell differentiation","canonical_id":"go:GO:0021531","description":"\"The process in which neuroepithelial cells in the ventral neural tube acquire specialized structural and/or functional features of radial glial cells. Radial cell precursors differentiate into both neuronal cell types and mature radial glial cells. Mature radial glial cells regulate the axon growth and pathfinding processes that occur during white matter patterning of the developing spinal cord. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16185248]","metadata":null},{"id":"ccec3fd2f0c440d1a5f63063d80b95b2","type":"GO_TERM","name":"spinal cord ventral commissure morphogenesis","canonical_id":"go:GO:0021965","description":"\"The process in which the anatomical structures of the spinal cord ventral commissure are generated and organized.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"39c4b69e05e2450a848b5bbef80b6d93","type":"GO_TERM","name":"spinal sensory neuron axon guidance","canonical_id":"go:GO:0097375","description":"\"The process in which the migration of an axon growth cone of a spinal sensory neuron is directed to a specific target site in response to a combination of attractive and repulsive cues. A spinal sensory neuron is a sensory neuron that project to the spinal cord.\" [CL:0009000, GOC:pr, GOC:yaf]","metadata":null},{"id":"2a6774efbeba4291aec4f5c4428ef904","type":"GO_TERM","name":"spinal trigeminal nucleus development","canonical_id":"go:GO:0021741","description":"\"The process whose specific outcome is the progression of the spinal trigeminal nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3a9a8514896d4d1285213ea469749ee2","type":"GO_TERM","name":"spindle","canonical_id":"go:GO:0005819","description":"\"The array of microtubules and associated molecules that forms between opposite poles of a eukaryotic cell during mitosis or meiosis and serves to move the duplicated chromosomes apart.\" [ISBN:0198547684]","metadata":null},{"id":"c2a65fa86c4f4b478313278c88128518","type":"GO_TERM","name":"spindle assembly","canonical_id":"go:GO:0051225","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle, the array of microtubules and associated molecules that serves to move duplicated chromosomes apart.\" [GOC:ai, GOC:expert_rg, GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"1f84192229f441e2b5102fc052331520","type":"GO_TERM","name":"spindle assembly checkpoint signaling","canonical_id":"go:GO:0071173","description":"\"A signaling process that delays the metaphase/anaphase transition until the spindle is correctly assembled and chromosomes are attached to the spindle.\" [GOC:mah]","metadata":null},{"id":"4f5f9e41bd2f40e0ae25c63a8e7c3ef0","type":"GO_TERM","name":"spindle assembly involved in female meiosis","canonical_id":"go:GO:0007056","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle during a meiotic cell cycle in females. An example of this is found in Drosophila melanogaster.\" [GOC:mah]","metadata":null},{"id":"5fd87d30621a4f62ab5f967b275ca03d","type":"GO_TERM","name":"spindle assembly involved in female meiosis I","canonical_id":"go:GO:0007057","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle during meiosis I of a meiotic cell cycle in females. An example of this is found in Drosophila melanogaster.\" [GOC:mah]","metadata":null},{"id":"456472397f324ae78270b7baf6478f2b","type":"GO_TERM","name":"spindle assembly involved in female meiosis II","canonical_id":"go:GO:0007058","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle during meiosis II of a meiotic cell cycle in females. An example of this is found in Drosophila melanogaster.\" [GOC:mah]","metadata":null},{"id":"db6e13b5924c4dfda9a6cf90880998d9","type":"GO_TERM","name":"spindle assembly involved in male meiosis","canonical_id":"go:GO:0007053","description":"\"The aggregation, arrangement and bonding together of a set of components to form the spindle during a meiotic cell cycle in males. An example of this is found in Drosophila melanogaster.\" [GOC:mah]","metadata":null},{"id":"4a3d2fb71cf747c09486dd3fd711ff80","type":"GO_TERM","name":"spindle assembly involved in male meiosis I","canonical_id":"go:GO:0007054","description":"\"The formation of the spindle during meiosis I of a meiotic cell cycle in males. An example of this is found in Drosophila melanogaster.\" [GOC:mah]","metadata":null},{"id":"ae0911b3719846fe9b9d31ad707491fe","type":"GO_TERM","name":"spindle assembly involved in male meiosis II","canonical_id":"go:GO:0007055","description":"\"The formation of the spindle during meiosis II of a meiotic cell cycle in males. An example of this is found in Drosophila melanogaster.\" [GOC:mah]","metadata":null},{"id":"803eb7c11dd944bf9e9b150607b21abb","type":"GO_TERM","name":"spindle attachment to meiosis I kinetochore","canonical_id":"go:GO:0051455","description":"\"The cellular process in which spindle microtubules become physically associated with the proteins making up the kinetochore complex in meiosis I. During meiosis I sister kinetochores are lying next to each other facing the same spindle pole and monopolar attachment of the chromatid to the spindle occurs.\" [GOC:ai, GOC:clt, GOC:dph, GOC:tb]","metadata":null},{"id":"4f7b238d5c8b42d485fdc291dc385ed7","type":"GO_TERM","name":"spindle checkpoint signaling","canonical_id":"go:GO:0031577","description":"\"A signaling process that that controls a cell cycle checkpoint that originates from the mitotic or meiotic spindle.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"ec2ceda829c64c6bbeb5c948a94ec81b","type":"GO_TERM","name":"spindle disassembly","canonical_id":"go:GO:0051230","description":"\"The controlled breakdown of the spindle, the array of microtubules and associated molecules that serves to move duplicated chromosomes apart.\" [GOC:ai]","metadata":null},{"id":"701f6421551c4c5c817cf24bd0d6212d","type":"GO_TERM","name":"spindle elongation","canonical_id":"go:GO:0051231","description":"\"The cell cycle process in which the distance is lengthened between poles of the spindle.\" [GOC:ai]","metadata":null},{"id":"5d3f8bdb10a04c91ac967742029950a7","type":"GO_TERM","name":"spindle envelope","canonical_id":"go:GO:0070732","description":"\"An organelle envelope that surrounds the chromosomes and the central part of the spindle apparatus during mitosis and meiosis; observed in many invertebrates. The spindle envelope consists of membrane layers, called parafusorial membranes, derived from endoplasmic reticulum membrane; in male meiosis it forms during prometaphase and persists until early in the ensuing interphase.\" [GOC:mah, GOC:sart, PMID:19417004, PMID:6428889]","metadata":null},{"id":"63bbf3dd1d8840c29e087a5ae045f350","type":"GO_TERM","name":"spindle localization","canonical_id":"go:GO:0051653","description":"\"Any process in which is the spindle is transported to, and/or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"e772133751da41b6b5de12446ebc773d","type":"GO_TERM","name":"spindle matrix","canonical_id":"go:GO:1990047","description":"\"A proteinaceous, nuclear-derived structure that embeds the microtubule spindle apparatus from pole to pole in a microtubule-independent manner during mitosis.\" [GOC:ans, PMID:19273613, PMID:22855526]","metadata":null},{"id":"e9946328d7f441d794b9493bec8b9a20","type":"GO_TERM","name":"spindle microtubule","canonical_id":"go:GO:0005876","description":"\"Any microtubule that is part of a mitotic or meiotic spindle; anchored at one spindle pole.\" [ISBN:0815316194]","metadata":null},{"id":"2454bb06d47a4941a5190ec4f2088370","type":"GO_TERM","name":"spindle midzone","canonical_id":"go:GO:0051233","description":"\"The area in the center of the spindle where the spindle microtubules from opposite poles overlap.\" [GOC:ai, PMID:15296749]","metadata":null},{"id":"7a76201c0f2b45bda99ae72cee2e409d","type":"GO_TERM","name":"spindle midzone assembly","canonical_id":"go:GO:0051255","description":"\"The cell cycle process in which aggregation, arrangement and bonding together of a set of components to form the spindle midzone. The spindle midzone is the area in the center of the spindle where the spindle microtubules from opposite poles overlap.\" [GOC:ai, PMID:15296749]","metadata":null},{"id":"f622ae0b810f482992d60456a889ff65","type":"GO_TERM","name":"spindle organization","canonical_id":"go:GO:0007051","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the spindle, the array of microtubules and associated molecules that forms between opposite poles of a eukaryotic cell during DNA segregation and serves to move the duplicated chromosomes apart.\" [GOC:curators, GOC:mah]","metadata":null},{"id":"510796d7d7ce49b0ae7ed3838f3459c8","type":"GO_TERM","name":"spindle pole","canonical_id":"go:GO:0000922","description":"\"Either of the ends of a spindle, where spindle microtubules are organized; usually contains a microtubule organizing center and accessory molecules, spindle microtubules and astral microtubules.\" [GOC:clt]","metadata":null},{"id":"83a734edf32240d49b5aa1d5072841be","type":"GO_TERM","name":"spindle pole body","canonical_id":"go:GO:0005816","description":"\"The microtubule organizing center in fungi; functionally homologous to the animal cell centrosome.\" [ISBN:0879693568]","metadata":null},{"id":"3802c4fed3f7493f8227e6344bf07e57","type":"GO_TERM","name":"spindle pole body anchor activity","canonical_id":"go:GO:0140475","description":"\"The binding activity of a protein that brings together the spindle pole body and one or more other molecules, permitting them to function in a coordinated way.\" [PMID:19942852]","metadata":null},{"id":"4c0834b67703471a85c39d5f3db63a89","type":"GO_TERM","name":"spindle pole body duplication","canonical_id":"go:GO:0030474","description":"\"Construction of a new spindle pole body.\" [GOC:clt]","metadata":null},{"id":"96836e15cd8f486abd88d7c557493edc","type":"GO_TERM","name":"spindle pole body localization","canonical_id":"go:GO:0070631","description":"\"Any process in which a spindle pole body is transported to, or maintained in, a specific location. A spindle pole body is a type of microtubule organizing center found in fungal cells.\" [GOC:mah]","metadata":null},{"id":"ecd0d0e25a8545628f168c112c8e4516","type":"GO_TERM","name":"spindle pole body organization","canonical_id":"go:GO:0051300","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the spindle pole body (SPB). The SPB is the microtubule organizing center in fungi, and is functionally homologous to the animal cell centrosome.\" [GOC:ai, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"8781ae7c3e7344aca55deeb45987cc79","type":"GO_TERM","name":"spindle pole body separation","canonical_id":"go:GO:0110100","description":"\"The release of duplicated spindle pole bodies (SPBs) and their migration away from each other within the nuclear membrane. Duplicated SPBs are connected by a bridge structure that is severed in order to release the SPBs from one another. Following liberation, SPBs diffuse through the nuclear membrane until they are across from each other. SPB separation must take place in order for a bipolar spindle to assemble.\" [GOC:vw]","metadata":null},{"id":"c2b7a75b75d8497db31f172e91e88f88","type":"GO_TERM","name":"spindle pole body-led chromosome movement during mitotic interphase","canonical_id":"go:GO:0140405","description":"\"A microtubule-based process in which chromosomes migrate as a result of rapid spindle pole body (SPB) and centrosome oscillations during mitotic interphase.\" [PMID:31483748]","metadata":null},{"id":"a70d325249ac4f44a8a83d1990bfcbd2","type":"GO_TERM","name":"spindle pole body-nuclear membrane anchor activity","canonical_id":"go:GO:0106166","description":"\"The binding activity of a molecule that brings together a mitotic spindle pole body and the nuclear membrane, in order to maintain specific membrane location of the spindle pole body.\" [GOC:vw, PMID:9763447]","metadata":null},{"id":"08a5c1a3cbab44749cb3747be1519c62","type":"GO_TERM","name":"spindle pole centrosome","canonical_id":"go:GO:0031616","description":"\"A centrosome from which one pole of a mitotic or meiotic spindle is organized.\" [GOC:mah]","metadata":null},{"id":"35f4cb2f8a004c8487655e86dc4291d0","type":"GO_TERM","name":"spine apparatus","canonical_id":"go:GO:0097444","description":"\"A specialization of the endomembrane system found in some classes of dendritic spines consisting of two or more closely apposed lamellae with interspersed electron dense material. The endomembrane component is continuous with the smooth endoplasmic reticulum.\" [NIF_Subcellular:sao725931194, PMID:20400711, PMID:8987748]","metadata":null},{"id":"d459302fbcfa4ab188501a00174e70d3","type":"GO_TERM","name":"spine apparatus assembly","canonical_id":"go:GO:1905355","description":"\"The aggregation, arrangement and bonding together of a set of components to form a spine apparatus.\" [GO_REF:0000079, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:12928494]","metadata":null},{"id":"cc83188df1434e4fbbc0f7d3e62a63e0","type":"GO_TERM","name":"spine apparatus lumen","canonical_id":"go:GO:0098899","description":"\"The volume enclosed by the spine apparatus membrane.\" [GOC:dos]","metadata":null},{"id":"094cf02825ac454393d96511ace76f3e","type":"GO_TERM","name":"spine apparatus membrane","canonical_id":"go:GO:0098897","description":"\"The lipid bilayer surrounding the spine apparatus.\" [GOC:mah]","metadata":null},{"id":"e459718e4eda40978b2fbc9eefee0fd1","type":"GO_TERM","name":"spine mat","canonical_id":"go:GO:0097448","description":"\"A configuration of neuron spines found on ciliary ganglion neurons in the embryonic and adult brain consisting of patches of closely spaced spines lying flat against the soma.\" [NIF_Subcellular:sao2128156969, PMID:10818137]","metadata":null},{"id":"9dce156b108b4f45b779c6c0e85d973a","type":"GO_TERM","name":"spine synapse","canonical_id":"go:GO:0106033","description":"\"A type of synapse occurring between an axon and a dendritic spine.\" [PMID:15028757]","metadata":null},{"id":"b63fd3fefe7743269913b4535769ad75","type":"GO_TERM","name":"spinothalamic tract morphogenesis","canonical_id":"go:GO:0021963","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the spinal cord towards target cells in the thalamus. This axonal process is a member of those that make up the spinothalamic tract, one of the major routes of nociceptive signaling.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"168e82422f64494f91efa13d406d4a09","type":"GO_TERM","name":"spiny bracelet of Nageotte","canonical_id":"go:GO:0097455","description":"\"Paranodal terminations of Schwann cells that do not directly contact the paranodal axon membrane. Usually found in thicker myelin.\" [NIF_Subcellular:sao937871668, PMID:15988042]","metadata":null},{"id":"b5c9eb883d8749bda7676d0ae18a3dad","type":"GO_TERM","name":"spiracle morphogenesis, open tracheal system","canonical_id":"go:GO:0035277","description":"\"The process in which the anatomical structures of a spiracle are generated and organized. Spiracles are the openings in the insect open tracheal system; externally they connect to the epidermis and internally they connect to the tracheal trunk.\" [GOC:mtg_sensu, PMID:10491268]","metadata":null},{"id":"1cda30903c7a45fda100d42ddaf22541","type":"DRUG","name":"spirapril","canonical_id":"gtopdb:6575","description":null,"metadata":null},{"id":"ce4c797162c24d35a596ef53837dd373","type":"DRUG","name":"spiraprilat","canonical_id":"gtopdb:6576","description":null,"metadata":null},{"id":"eab69dceee074603a16f90b5c64976da","type":"DRUG","name":"spironolactone","canonical_id":"gtopdb:2875","description":null,"metadata":null},{"id":"59a565ad22ba4e72b1f6914d84aeb96e","type":"DRUG","name":"spironolactone","canonical_id":"mesh:D013148","description":null,"metadata":null},{"id":"b39be54d96b84f4db9f3c7f1d4ade706","type":"DRUG","name":"spironolactone","canonical_id":"chembl:CHEMBL1393","description":null,"metadata":null},{"id":"75daa2ead1ff4d6784c64507cf95397c","type":"GO_TERM","name":"spitzenkorper","canonical_id":"go:GO:0031521","description":"\"Structure within the hyphal tip of filamentous fungi that acts as an organizing center for hyphal tip growth; may function to supply vesicles to the elongating tip and/or to organize cytoskeletal microfilaments.\" [PMID:15701784, PMID:15976451]","metadata":null},{"id":"51dd357452d34592b355f1b8ba10a928","type":"GO_TERM","name":"spleen development","canonical_id":"go:GO:0048536","description":"\"The process whose specific outcome is the progression of the spleen over time, from its formation to the mature structure. The spleen is a large vascular lymphatic organ composed of white and red pulp, involved both in hemopoietic and immune system functions.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"f09859e979ec4b8f944e126fde20b4b8","type":"GO_TERM","name":"spleen trabecula formation","canonical_id":"go:GO:0060345","description":"\"The process of creating a trabecula in the spleen. A trabecula is a tissue element in the form of a small beam, strut or rod.\" [GOC:dph]","metadata":null},{"id":"d23dabe0f92b449fb4be0763ce730e04","type":"GO_TERM","name":"spliceosomal complex","canonical_id":"go:GO:0005681","description":"\"Any of a series of ribonucleoprotein complexes that contain snRNA(s) and small nuclear ribonucleoproteins (snRNPs), and are formed sequentially during the spliceosomal splicing of one or more substrate RNAs, and which also contain the RNA substrate(s) from the initial target RNAs of splicing, the splicing intermediate RNA(s), to the final RNA products. During cis-splicing, the initial target RNA is a single, contiguous RNA transcript, whether mRNA, snoRNA, etc., and the released products are a spliced RNA and an excised intron, generally as a lariat structure. During trans-splicing, there are two initial substrate RNAs, the spliced leader RNA and a pre-mRNA.\" [GOC:editors, GOC:mah, ISBN:0198547684, PMID:19239890]","metadata":null},{"id":"9359f0fd93c9404788196b2c67d74f72","type":"GO_TERM","name":"spliceosomal complex assembly","canonical_id":"go:GO:0000245","description":"\"The aggregation, arrangement and bonding together of a spliceosomal complex, a ribonucleoprotein apparatus that catalyzes nuclear mRNA splicing via transesterification reactions.\" [PMID:9476892]","metadata":null},{"id":"1ba74799cb144b969de54bc01d4afb06","type":"GO_TERM","name":"spliceosomal complex disassembly","canonical_id":"go:GO:0000390","description":"\"Disassembly of a spliceosomal complex with the ATP-dependent release of the product RNAs, one of which is composed of the joined exons. In cis splicing, the other product is the excised sequence, often a single intron, in a lariat structure.\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"793b39b390434818ac85ec425e6944a9","type":"GO_TERM","name":"spliceosomal conformational changes to generate catalytic conformation","canonical_id":"go:GO:0000393","description":"\"Structural rearrangements of the spliceosome complex, containing RNA to be spliced, to generate a catalytic conformation.\" [GOC:krc]","metadata":null},{"id":"59826cd170a1409f8e41b48c8ed3b573","type":"GO_TERM","name":"spliceosomal snRNP assembly","canonical_id":"go:GO:0000387","description":"\"The aggregation, arrangement and bonding together of one or more snRNA and multiple protein components to form a ribonucleoprotein complex that is involved in formation of the spliceosome.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"66bddd974ba1404d901ba04db98b3d76","type":"GO_TERM","name":"spliceosomal snRNP complex","canonical_id":"go:GO:0097525","description":"\"A small ribonucleoprotein complex involved in formation of the spliceosome.\" [GOC:krc, GOC:pr, ISBN:0879695897]","metadata":null},{"id":"a802fdaf7b0348698a21765493e0c920","type":"GO_TERM","name":"spliceosomal tri-snRNP complex","canonical_id":"go:GO:0097526","description":"\"A spliceosomal snRNP complex that is formed by the association of the U4/U6 (or U4atac/U6atac) snRNP with the U5 snRNP.\" [GOC:krc, GOC:pr, ISBN:0879695897, PMID:9452384]","metadata":null},{"id":"b1ab25532b93442fa2c1cedefcdbe048","type":"GO_TERM","name":"spliceosomal tri-snRNP complex assembly","canonical_id":"go:GO:0000244","description":"\"The formation of a tri-snRNP complex containing U4 and U6 (or U4atac and U6atac) snRNAs and U5 snRNAs and associated proteins. This includes reannealing of U4 and U6 (or U4atac and U6atac) snRNAs released from previous rounds of splicing to reform the U4/U6 snRNP (or U4atac/U6atac snRNP) as well as the subsequent association of the U5 snRNP with the U4/U6 snRNP (or U4atac/U6atac snRNP) to form a tri-snRNP that is ready to reassemble into another spliceosome complex.\" [ISBN:0879695897, PMID:9452384]","metadata":null},{"id":"e588b29927144ecf9385903a0f9fc411","type":"GO_TERM","name":"spliceosome conformational change to release U4 (or U4atac) and U1 (or U11)","canonical_id":"go:GO:0000388","description":"\"Rearrangement of the pre-catalytic spliceosome containing U4 (or U4atac) and U1 (or U11) snRNPs to unpair U4 (or U4atac) from U6 (or U6atac) and release it from the spliceosomal complex along with U1 (or U11).\" [GOC:krc, ISBN:0879695897]","metadata":null},{"id":"d3017ad35a1d49be877f51d84462e2f4","type":"GO_TERM","name":"spliceosome-depend formation of circular RNA","canonical_id":"go:GO:0160091","description":"\"Formation of circular RNAs (circRNAs) by back-splicing circularization of pre-mRNAs in a spliceosome-dependent process.\" [PMID:25768908, PMID:28625552]","metadata":null},{"id":"055a56367b114a25995434440ca4ebfd","type":"GO_TERM","name":"splicing factor binding","canonical_id":"go:GO:1990935","description":"\"Binding to a protein involved in the process of removing sections of the primary RNA transcript to form the mature form of the RNA.\" [PMID:11118435]","metadata":null},{"id":"894a3bfad81649e9aeb9fdf0ab2d0732","type":"GO_TERM","name":"split septin rings","canonical_id":"go:GO:0032176","description":"\"A pair of rings that flank the site of cell division, formed by splitting of the septin ring (or collar) prior to cytokinesis; this double ring structure is thought to trap proteins needed for cytokinesis or the formation of the new membrane or cell wall between the two septin rings. Split septin rings are known to occur in budding yeast cells and probably occur in other cell types as well.\" [GOC:krc, PMID:16009555, PMID:16151244]","metadata":null},{"id":"eca0c4bba5dd47b8a05f9424964bdb4c","type":"DISEASE","name":"spondylitis","canonical_id":"mondo:0003937","description":null,"metadata":null},{"id":"5da04f23c2724538af47445eb2083b1f","type":"DISEASE","name":"spondyloarthropathy","canonical_id":"mondo:0005095","description":null,"metadata":null},{"id":"9de4680630484525b01c0e9e97788102","type":"GO_TERM","name":"spongiome","canonical_id":"go:GO:0062160","description":"\"A cellular anatomical entity which is a network of tubules and vessicles and is part of the contractile vacuole complex. It is involved in the discharge of water externally. One of its functions is osmoregulatory.\" [PMID:23890380]","metadata":null},{"id":"a6921f515b7b4938aa17040c9387aeb9","type":"GO_TERM","name":"spongiotrophoblast cell proliferation","canonical_id":"go:GO:0060720","description":"\"The multiplication or reproduction of spongiotrophoblast cells, resulting in the expansion of the population in the spongiotrophoblast layer.\" [GOC:dph]","metadata":null},{"id":"6bd3557af8024c19aee297d283909c15","type":"GO_TERM","name":"spongiotrophoblast differentiation","canonical_id":"go:GO:0060708","description":"\"The process in which a relatively unspecialized cell of the ectoplacental cone acquires specialized features of a spongiotrophoblast of the placenta. A spongiotrophoblast cell is a basophilic cell.\" [GOC:dph, PMID:16269175]","metadata":null},{"id":"56a630682016483b9bc74f3921217266","type":"GO_TERM","name":"spongiotrophoblast layer development","canonical_id":"go:GO:0060712","description":"\"The process in which the spongiotrophoblast layer of the placenta progresses from its formation to its mature state.\" [GOC:dph]","metadata":null},{"id":"98a92cf96d81453ebd03527fcbcb8b91","type":"GO_TERM","name":"spongiotrophoblast layer developmental growth","canonical_id":"go:GO:0090214","description":"\"The increase in size or mass of the spongiotrophoblast layer of the placenta where the increase in size or mass contributes to the progression of that layer over time from its formation to its mature state.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"115e7a3871d848899d3faabd536ffc1c","type":"GO_TERM","name":"spontaneous exocytosis of neurotransmitter","canonical_id":"go:GO:0048792","description":"\"The release of a neurotransmitter into the synaptic cleft, where the release step is independent of the presence of calcium ions (Ca2+). The neurotransmitter is contained within a membrane-bounded vesicle, and is released by fusion of the vesicle with the presynaptic plasma membrane of a nerve cell.\" [GOC:curators]","metadata":null},{"id":"d496b36053e342e6aed3330353458830","type":"GO_TERM","name":"spontaneous neurotransmitter secretion","canonical_id":"go:GO:0061669","description":"\"Neurotransmitter secretion that occurs in the absence of the action of a secretagogue or a presynaptic action potential.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:21334193]","metadata":null},{"id":"7e1e33aec2b3406697e6b98c5bf4a1fb","type":"GO_TERM","name":"spontaneous synaptic transmission","canonical_id":"go:GO:0098814","description":"\"The low level of synaptic transmission that occurs via spontaneous neurotransmitter release into the synaptic cleft in the absence of a presynaptic action potential.\" [PMID:20200227]","metadata":null},{"id":"f72f3634b3dc4024a7dc670eb7cbaaf0","type":"GO_TERM","name":"sporangiospore formation","canonical_id":"go:GO:0034300","description":"\"The process in which sporangiospores, a type of asexual spore found in fungi, are formed. Sporangiospores are formed within sac-like structure, the sporangium, following the division of the cytoplasm.\" [GOC:ds, GOC:mah, PMID:32839172]","metadata":null},{"id":"853e3856e5da42ca9bcdb57ad23028e2","type":"GO_TERM","name":"sporangium development","canonical_id":"go:GO:0043582","description":"\"The process whose specific outcome is the progression of the sporangium over time, from its formation to the mature structure. A sporangium is a structure producing and containing spores.\" [GOC:jl, Wikipedia:Sporagium]","metadata":null},{"id":"9cf149c21a754d039c765912ff5e6fb4","type":"GO_TERM","name":"sporangium germination","canonical_id":"go:GO:0075222","description":"\"The physiological, developmental and morphological changes that occur in a symbiont sporangium following release from dormancy up to the earliest signs of growth. A sporangium is a structure producing and containing spores.\" [GOC:pamgo_curators]","metadata":null},{"id":"175cf4cb496846f1895ab84aa80ad2b1","type":"GO_TERM","name":"spore dispersal","canonical_id":"go:GO:0075325","description":"\"Any process in which an organism disseminates its spores.\" [Wikipedia:Spore]","metadata":null},{"id":"43a1f79c23734551bb2550dbee5a486d","type":"GO_TERM","name":"spore encystment","canonical_id":"go:GO:0075214","description":"\"The physiological, developmental and morphological changes that occur in a symbiont spore during the process of its encystment. Encystment means to enter a state of essentially suspended animation in which the spore is protected by an outer coating and remains immobile and inactive until favorable conditions for growth occur again. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:kmv, GOC:pamgo_curators]","metadata":null},{"id":"f324ef49bbd4467f971c4f54607b35aa","type":"GO_TERM","name":"spore germination","canonical_id":"go:GO:0009847","description":"\"The physiological and developmental changes that occur in a spore following release from dormancy up to the earliest signs of growth (e.g. emergence from a spore wall).\" [GOC:lr]","metadata":null},{"id":"4f8ab91b81964fa6bd6e08040dbee52e","type":"GO_TERM","name":"spore inner membrane","canonical_id":"go:GO:0140549","description":"\"The membrane surrounding the spore core (endospore core) that separates it from its external environment.\" [PMID:23202530]","metadata":null},{"id":"791f76efd9a54494b2a7d98f24db9add","type":"GO_TERM","name":"spore membrane bending pathway","canonical_id":"go:GO:0070583","description":"\"The process in which a bending force is generated in the prospore membrane to form the characteristic curved shape of the prospore.\" [GOC:dgf, PMID:18756268]","metadata":null},{"id":"3c3eb6a3b45b475bb1093ac5aaa0cd3a","type":"GO_TERM","name":"spore wall","canonical_id":"go:GO:0031160","description":"\"The specialized envelope lying outside the cell membrane of a spore.\" [GOC:mah, GOC:pg]","metadata":null},{"id":"d6280a6893a54d87978c58568380ddc3","type":"GO_TERM","name":"spore wall assembly","canonical_id":"go:GO:0042244","description":"\"The aggregation, arrangement and bonding together of a set of components to form a spore wall; a spore wall is the specialized envelope lying outside the cell membrane of a spore.\" [GOC:mah, GOC:pg]","metadata":null},{"id":"90d58bd78a804effab0b81d3e4f7e73c","type":"GO_TERM","name":"spore wall biogenesis","canonical_id":"go:GO:0070590","description":"\"A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a spore wall. A spore wall is the specialized cell wall lying outside the cell membrane of a spore.\" [GOC:mah]","metadata":null},{"id":"a81853d3a1d44b17aa8ff42340259e7b","type":"GO_TERM","name":"spore-bearing structure development","canonical_id":"go:GO:0075259","description":"\"The process whose specific outcome is the progression of a spore-bearing structure over time, from its formation to the mature structure. A spore-bearing structure is an anatomical structure that produces new spores.\" [GOC:di, GOC:mah, GOC:mcc, GOC:pamgo_curators]","metadata":null},{"id":"a7be9ff1771e42818e142a0f6d9a696f","type":"GO_TERM","name":"spore-bearing structure formation","canonical_id":"go:GO:0097751","description":"\"The process of generating a spore-bearing structure. A spore-bearing structure is an anatomical structure that produces new spores.\" [GOC:di]","metadata":null},{"id":"9eb9e3b33f3b4674bd3c05a3f32c1461","type":"GO_TERM","name":"sporocarp development","canonical_id":"go:GO:0030584","description":"\"The process whose specific outcome is the progression of a sporocarp over time, from its formation to the mature structure. The sporocarp is a spore bearing fruiting body organ. An example of this process is found in the Fungal species Coprinopsis cinerea.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"8a776e2aa9af444ea7e3d2ca941c4687","type":"GO_TERM","name":"sporocarp development involved in asexual reproduction","canonical_id":"go:GO:0000905","description":"\"The formation of a spore-bearing structure by fungus where spores will arise from asexual reproduction.\" [GOC:clt, GOC:mtg_sensu]","metadata":null},{"id":"260470454bde40f8a90bf80f8515e0c5","type":"GO_TERM","name":"sporocarp development involved in sexual reproduction","canonical_id":"go:GO:0000909","description":"\"The process whose specific outcome is the progression of a fruiting body organ over time, from its formation to the mature structure. The fruiting body is a spore bearing structure. In fungi, the sporocarp (also known as fruiting body) is a multicellular structure on which spore-producing structures, such as basidia or asci, are borne. The fruiting body is part of the sexual phase of a fungal life cycle, with the rest of the life cycle being characterized by vegetative mycelial growth. The sporocarp of a basidiomycete is known as a basidiocarp, while the fruiting body of an ascomycete is known as an ascocarp. A significant range of different shapes and morphologies is found in both basidiocarps and ascocarps; these features play an important role in the identification and taxonomy of fungi.\" [GOC:clt, GOC:mtg_sensu]","metadata":null},{"id":"c5a7e65d925f46678c961495dd6e243d","type":"GO_TERM","name":"sporocyte differentiation","canonical_id":"go:GO:0048533","description":"\"The process in which a relatively unspecialized floral cell acquires the specialized features of a sporocyte. Sporocytes are the haploid spores of angiosperms. Once formed, they undergo meiotic divisions to form microspores and megaspores.\" [GOC:tair_curators]","metadata":null},{"id":"7d7778c7f7164afb85511c3e9b7685e6","type":"GO_TERM","name":"sporoplasm","canonical_id":"go:GO:0044100","description":"\"The complex infective apparatus corresponding to the central mass of cytoplasm within a spore that is injected into a host cell by various parasitic microorganisms.\" [GOC:mf, PMID:12076771, PMID:16004371, PMID:9723921]","metadata":null},{"id":"65beccbbedfa47bfb58a718981426827","type":"GO_TERM","name":"sporopollenin biosynthetic process","canonical_id":"go:GO:0080110","description":"\"The chemical reactions and pathways resulting in the formation of sporopollenin, a primary constituent of the pollen exine layer.\" [PMID:19218397]","metadata":null},{"id":"69a8f99d0d8546199a2b11498216dd0a","type":"GO_TERM","name":"sporulation","canonical_id":"go:GO:0043934","description":"\"The process whose specific outcome is the progression of a spore over time, from its initiation to the mature structure. A spore is a structure that can be used for dissemination, for survival of adverse conditions because of its heat and desiccation resistance, and/or for reproduction.\" [GOC:pamgo_curators]","metadata":null},{"id":"426f04ceba5e4de1ac665a6e8c23241c","type":"GO_TERM","name":"sporulation resulting in formation of a cellular spore","canonical_id":"go:GO:0030435","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a cellular spore, a cell form that can be used for dissemination, for survival of adverse conditions because of its heat and desiccation resistance, and/or for reproduction.\" [GOC:mah, GOC:pamgo_curators, ISBN:0072992913]","metadata":null},{"id":"ded7470dba69443aab4396af3bcafc68","type":"GO_TERM","name":"sporulation resulting in formation of a multicellular or syncytial spore","canonical_id":"go:GO:0075283","description":"\"The process whose specific outcome is the progression of a multicellular or syncytial spore via septations over time, from its initiation to the mature structure.\" [GOC:pamgo_curators]","metadata":null},{"id":"cc2ddd47630f4f6fb5f5b4b6770a9ca3","type":"GO_TERM","name":"spot adherens junction","canonical_id":"go:GO:0005914","description":"\"A small cell-cell adherens junction assembled during the cellularization stage of insect embyrogenesis; spot adherens junctions later fuse to form the zonula adherens.\" [PMID:11700298]","metadata":null},{"id":"743b74f6d0a64858b874034a02292d82","type":"DISEASE","name":"spotted fever","canonical_id":"mondo:0001195","description":null,"metadata":null},{"id":"c9067fc738c241f2bc1af2724fcc3175","type":"DISEASE","name":"sprain","canonical_id":"efo:0009582","description":null,"metadata":null},{"id":"7938410307d442c0b819aad88a40c608","type":"GO_TERM","name":"sprouting angiogenesis","canonical_id":"go:GO:0002040","description":"\"The extension of new blood vessels from existing vessels into avascular tissues, this process includes the specialization of endothelial cells into leading tip and stalk cells, proliferation and migration of the endothelial cells and cell adhesion resulting in angiogenic sprout fusion or lumen formation.\" [PMID:16391003, PMID:23031691]","metadata":null},{"id":"d12dd63eec6541939629d1948bc9a06b","type":"GO_TERM","name":"sprouting of injured axon","canonical_id":"go:GO:0048682","description":"\"The process involved in sprouting of an injured axon.\" [GOC:dgh, GOC:dph, GOC:jid, GOC:lm]","metadata":null},{"id":"f3ef40c4eddb4afda17475a0b9a1ad35","type":"GO_TERM","name":"squalene cyclase activity","canonical_id":"go:GO:0034072","description":"\"Catalysis of the reaction: squalene = triterpene.\" [GOC:cb, PMID:18033581]","metadata":null},{"id":"6dfcef77d1d64ae0a2e34608f6f192c9","type":"GO_TERM","name":"squalene monooxygenase activity","canonical_id":"go:GO:0004506","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + squalene = (S)-2,3-epoxysqualene + H2O + NADP+.\" [RHEA:25282]","metadata":null},{"id":"84cd7b53c5cf4caba77f1e1755173805","type":"GO_TERM","name":"squalene synthase [NAD(P)H] activity","canonical_id":"go:GO:0051996","description":"\"Catalysis of the reaction: 2 (2E,6E)-farnesyl diphosphate + H+ + NAD(P)H = 2 diphosphate + NAD(P)+ + squalene.\" [EC:2.5.1.21]","metadata":null},{"id":"e4640b9f23ac43499e6366818e3f6d99","type":"GO_TERM","name":"squalene-hopene cyclase activity","canonical_id":"go:GO:0051007","description":"\"Catalysis of the reaction: squalene = hop-22(29)-ene.\" [EC:5.4.99.17]","metadata":null},{"id":"ae286eeb61944919952d5ad198a6138c","type":"GO_TERM","name":"squamous basal epithelial stem cell differentiation involved in prostate gland acinus development","canonical_id":"go:GO:0060529","description":"\"The process in which a relatively unspecialized epithelial cell acquires specialized features of a squamous basal epithelial stem cell of the prostate.\" [GOC:dph, PMID:18977204]","metadata":null},{"id":"c41a0c53163444c3bacd036298faa69a","type":"DISEASE","name":"squamous cell carcinoma","canonical_id":"mondo:0005096","description":null,"metadata":null},{"id":"a5c21c7c050b48a28091071c5d0d37d9","type":"DISEASE","name":"squamous cell lung carcinoma","canonical_id":"mondo:0005097","description":null,"metadata":null},{"id":"58593d6e04b64a1a943aea880502a7fd","type":"GO_TERM","name":"stabilization of membrane potential","canonical_id":"go:GO:0030322","description":"\"The accomplishment of a non-fluctuating membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"1cec4f8f9aff48079f34bca29d016334","type":"GO_TERM","name":"stachyose biosynthetic process","canonical_id":"go:GO:0033532","description":"\"The chemical reactions and pathways resulting in the formation of stachyose, the tetrasaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"617eec3978b84157af6b000139491c62","type":"GO_TERM","name":"stachyose metabolic process","canonical_id":"go:GO:0033531","description":"\"The chemical reactions and pathways involving stachyose, the tetrasaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"a8b8ba438816438f9a28c02dd2c2bb99","type":"GO_TERM","name":"stachyose synthase activity","canonical_id":"go:GO:0102831","description":"\"Catalysis of the reaction: 2 raffinose = stachyose + sucrose.\" [GOC:pz, PMID:12060258]","metadata":null},{"id":"12871f13ba774788b15e2c13e9f8a8e3","type":"DISEASE","name":"stage 5 chronic kidney disease","canonical_id":"efo:0009909","description":null,"metadata":null},{"id":"855df8f9643e4178af0a9741861afa5d","type":"GO_TERM","name":"stalled replication fork localization to nuclear periphery","canonical_id":"go:GO:0120290","description":"\"A cellular localization process where a DNA replication fork that has stalled is signaled to relocate and anchor to the nuclear periphery for the time necessary to complete recombination-dependent replication.\" [GOC:krc, GOC:mah, PMID:33159083]","metadata":null},{"id":"cd388508fdbc4c77934aaed46c7da849","type":"GO_TERM","name":"stalled ribosome sensor activity","canonical_id":"go:GO:0170011","description":"\"A molecule that recognizes stalled ribosomes and initiates a signaling response.\" [PMID:32289254, PMID:32610081, PMID:36638793]","metadata":null},{"id":"c7e4b5805e7243feb60d0aa5161ab066","type":"GO_TERM","name":"stamen development","canonical_id":"go:GO:0048443","description":"\"The process whose specific outcome is the progression of the stamen over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"cf476ed1cccf451eadf9ceb60e29c9a5","type":"GO_TERM","name":"stamen filament development","canonical_id":"go:GO:0080086","description":"\"The process whose specific outcome is the progression of the filament over time, from its formation to the mature structure. Filament is the stalk of a stamen.\" [PMID:19139039, PO:0009067]","metadata":null},{"id":"4076822a6e254f40813aa3917a9f4174","type":"GO_TERM","name":"stamen formation","canonical_id":"go:GO:0048455","description":"\"The process that contributes to the act of giving rise to the stamen. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:jid]","metadata":null},{"id":"25b36803ac99421caeec2ed8aeab4939","type":"GO_TERM","name":"stamen morphogenesis","canonical_id":"go:GO:0048448","description":"\"The process in which the anatomical structures of the stamen are generated and organized.\" [GOC:curators]","metadata":null},{"id":"b0a0507558fe419585da82eecb1bed1b","type":"GO_TERM","name":"stamen structural organization","canonical_id":"go:GO:0048456","description":"\"The process that contributes to the act of creating the structural organization of the stamen. This process pertains to the physical shaping of a rudimentary structure.\" [GOC:jid]","metadata":null},{"id":"82a8a14400044d9eadbc3208d5bc4f92","type":"DRUG","name":"stanozolol","canonical_id":"mesh:D013197","description":null,"metadata":null},{"id":"d65e2ae70bb6490cb4adc9a56468a456","type":"DRUG","name":"stapokibart","canonical_id":"gtopdb:13785","description":null,"metadata":null},{"id":"e3735798ffb04209b5cbc937169fb6e0","type":"GO_TERM","name":"starch binding","canonical_id":"go:GO:2001070","description":"\"Binding to starch.\" [GOC:mengo_curators]","metadata":null},{"id":"a0a67386e2ef46ebbc23a9a329cb363f","type":"GO_TERM","name":"starch biosynthetic process","canonical_id":"go:GO:0019252","description":"\"The chemical reactions and pathways resulting in the formation of starch, the most important reserve polysaccharide in plants.\" [GOC:ai]","metadata":null},{"id":"1d17866eccfc41f5b2bd908c93358e3d","type":"GO_TERM","name":"starch catabolic process","canonical_id":"go:GO:0005983","description":"\"The chemical reactions and pathways resulting in the breakdown of starch, the most important reserve polysaccharide in plants.\" [GOC:ai]","metadata":null},{"id":"2c47082ce6de4d4193d534c925386efb","type":"GO_TERM","name":"starch grain","canonical_id":"go:GO:0043036","description":"\"Plant storage body for amylose and amylopectin, 1-100um in diameter. Also contains small amounts of enzymes, amino acids, lipids and nucleic acids. The shape of the grain varies widely amongst species, but is often spherical or disk-shaped.\" [GOC:jl, PMID:11217978]","metadata":null},{"id":"57c243cea4a241d18e0b25148af3421d","type":"GO_TERM","name":"starch granule initiation","canonical_id":"go:GO:0062052","description":"\"The sequence of events that initiates (or primes) the synthesis of semi-crystalline starch granules within photosynthetic chloroplasts or non-photosynthetic amyloplasts.\" [PMID:28684429]","metadata":null},{"id":"7a957dda8fb2476fb95c682133c39dbf","type":"GO_TERM","name":"starch metabolic process","canonical_id":"go:GO:0005982","description":"\"The chemical reactions and pathways involving starch, the most important reserve polysaccharide in plants. It is a glucan consisting of two components, amylose and amylopectin, which are both glucose homopolymers. Starch is synthesized as a temporary storage form of carbon and can be catabolized to produce sucrose.\" [ISBN:0198506732]","metadata":null},{"id":"833a982f18414e4ab43124e50adf4d64","type":"GO_TERM","name":"starch utilization system complex","canonical_id":"go:GO:0044570","description":"\"A bacterial cell envelope-associated multiprotein system, which binds and degrades starch.\" [GOC:mengo_curators, GOC:tt, PMID:19553672]","metadata":null},{"id":"70c8ef62f40c47aeb1a1ce162ab21086","type":"GO_TERM","name":"starch utilization system complex assembly","canonical_id":"go:GO:0044574","description":"\"The aggregation, arrangement and bonding together of the starch utilization system complex, a complex of cell envelope-associated proteins that degrades glycan.\" [GOC:mengo_curators, GOC:tt, PMID:19553672, PMID:21219452]","metadata":null},{"id":"0db530afa90e421aa23b3e5d1747190a","type":"GO_TERM","name":"startle response","canonical_id":"go:GO:0001964","description":"\"An action or movement due to the application of a sudden unexpected stimulus.\" [GOC:dph]","metadata":null},{"id":"c16ce89866b7429aa4015bf89448cdb6","type":"GO_TERM","name":"static microtubule bundle","canonical_id":"go:GO:0099070","description":"\"A microtubule bundle that has a constant length, and in which microtubule sliding does not take place.\" [GOC:vw, PMID:26124291]","metadata":null},{"id":"14621062a3c64540ac54924747f00d83","type":"DISEASE","name":"status epilepticus","canonical_id":"efo:0008526","description":null,"metadata":null},{"id":"6da1e53786374bb7a2c0d2236d908037","type":"DRUG","name":"stavudine","canonical_id":"mesh:D018119","description":null,"metadata":null},{"id":"0f54df7abcbe40a397e8f6aa216ec3db","type":"GO_TERM","name":"stearic acid binding","canonical_id":"go:GO:0070540","description":"\"Binding to stearic acid, the 18-carbon saturated fatty acid octadecanoic acid.\" [GOC:lp, GOC:mah]","metadata":null},{"id":"d4d335ed56d94a7798735a32c7c6bf69","type":"GO_TERM","name":"stearoyl-CoA 9-desaturase activity","canonical_id":"go:GO:0004768","description":"\"Catalysis of the reaction: 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 + octadecanoyl-CoA = (9Z)-octadecenoyl-CoA + 2 Fe(III)-[cytochrome b5] + 2 H2O.\" [RHEA:19721]","metadata":null},{"id":"db0a570267aa41fd9a9c73cf791275b5","type":"GO_TERM","name":"stearoyl-[ACP] desaturase activity","canonical_id":"go:GO:0045300","description":"\"Catalysis of the reaction: 2 H+ + O2 + octadecanoyl-[ACP] + 2 reduced [2Fe-2S]-[ferredoxin] = (9Z)-octadecenoyl-[ACP] + 2 H2O + 2 oxidized [2Fe-2S]-[ferredoxin].\" [RHEA:11776]","metadata":null},{"id":"aacb7e6dc3a04f0191653579a0b82d14","type":"GO_TERM","name":"stele development","canonical_id":"go:GO:0010479","description":"\"The process whose specific outcome is the progression of the stele over time, from its formation to the mature structure. The stele is the central column of primary vascular tissue in the root and any tissue that it surrounds.\" [GOC:tb]","metadata":null},{"id":"3c6640ee0f1044219f7af3564b1b9670","type":"GO_TERM","name":"stellate cell precursor proliferation","canonical_id":"go:GO:0021929","description":"\"The multiplication or reproduction of neuroblasts that will give rise to stellate cells. A cerebellar stellate cell is an inhibitory GABAergic interneuron found in the cerebellar cortex.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:15157725]","metadata":null},{"id":"2e826683284948aa8a24a372c867757c","type":"GO_TERM","name":"stem cell development","canonical_id":"go:GO:0048864","description":"\"The process whose specific outcome is the progression of the stem cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to its specific fate.\" [CL:0000034, GOC:isa_complete]","metadata":null},{"id":"109dc2818f9b42e09b6e017a50ddcba6","type":"GO_TERM","name":"stem cell differentiation","canonical_id":"go:GO:0048863","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a stem cell. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.\" [CL:0000034, GOC:isa_complete]","metadata":null},{"id":"12c02b6c28234137bce47fe31518b743","type":"GO_TERM","name":"stem cell division","canonical_id":"go:GO:0017145","description":"\"The self-renewing division of a stem cell. A stem cell is an undifferentiated cell, in the embryo or adult, that can undergo unlimited division and give rise to one or several different cell types.\" [GOC:jid, ISBN:0582227089]","metadata":null},{"id":"6d66c51600794d12aafc737eae7ed715","type":"GO_TERM","name":"stem cell factor receptor activity","canonical_id":"go:GO:0005020","description":"\"Combining with stem cell factor (SCF) receptor ligand and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate. Stem cell factor is a cytokine that stimulates mast cell growth and differentiation.\" [GOC:jl, GOC:signaling, PMID:10698217]","metadata":null},{"id":"d2a9463247b740c88fbdd86738b51ed5","type":"GO_TERM","name":"stem cell factor receptor binding","canonical_id":"go:GO:0005173","description":"\"Binding to a stem cell factor receptor (SCFR), a type III transmembrane kinase receptor.\" [GOC:jl, PMID:10698217]","metadata":null},{"id":"1b9896ce64ea4ccb9425b1e059b6b755","type":"GO_TERM","name":"stem cell fate commitment","canonical_id":"go:GO:0048865","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a stem cell.\" [CL:0000034, GOC:isa_complete]","metadata":null},{"id":"d567aaa2c3c747168d0d3196a27688e6","type":"GO_TERM","name":"stem cell fate determination","canonical_id":"go:GO:0048867","description":"\"The process in which a cell becomes capable of differentiating autonomously into a stem cell regardless of its environment; upon determination, the cell fate cannot be reversed.\" [CL:0000034, GOC:isa_complete]","metadata":null},{"id":"441e671a42e9443eb8dcffdf96254fb6","type":"GO_TERM","name":"stem cell fate specification","canonical_id":"go:GO:0048866","description":"\"The process in which a cell becomes capable of differentiating autonomously into a stem cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.\" [CL:0000034, GOC:isa_complete]","metadata":null},{"id":"756e25a522c3435a88683e2da90f3ca2","type":"GO_TERM","name":"stem cell population maintenance","canonical_id":"go:GO:0019827","description":"\"The process by which an organism or tissue maintains a population of stem cells of a single type. This can be achieved by a number of mechanisms: stem cell asymmetric division maintains stem cell numbers; stem cell symmetric division increases them; maintenance of a stem cell niche maintains the conditions for commitment to the stem cell fate for some types of stem cell; stem cells may arise de novo from other cell types.\" [GOC:mah, ISBN:0878932437]","metadata":null},{"id":"a4189bbfb551428cb7f7882526a9b40e","type":"GO_TERM","name":"stem cell proliferation","canonical_id":"go:GO:0072089","description":"\"The multiplication or reproduction of stem cells, resulting in the expansion of a stem cell population. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"1890e05b9d9c4fc987a1d5528a12837b","type":"GO_TERM","name":"stem vascular tissue pattern formation","canonical_id":"go:GO:0010222","description":"\"Vascular tissue pattern formation as it occurs in the stem of vascular plants.\" [GOC:tb]","metadata":null},{"id":"84043333460747dc9560bdef52305c0b","type":"GO_TERM","name":"stemar-13-ene synthase activity","canonical_id":"go:GO:0034278","description":"\"Catalysis of the reaction: 9-alpha-copalyl diphosphate = stemar-13-ene + diphosphate.\" [RHEA:25552]","metadata":null},{"id":"6208bbbfc2d641da816da5dcab878162","type":"GO_TERM","name":"stereocilia ankle link","canonical_id":"go:GO:0002141","description":"\"A stereocilia coupling link that is composed of a fine filament present in developing stereocilia that couples the bases of individual stereocilia to one another. They are not present in mature stereocilia.\" [PMID:17567809]","metadata":null},{"id":"2f9484b9b3a545679a4bc2b797d78f34","type":"GO_TERM","name":"stereocilia ankle link complex","canonical_id":"go:GO:0002142","description":"\"A complex of proteins that connect growing stereocilia in developing cochlear hair cells, composed of Vlgr1, usherin, vezatin, and whirlin.\" [PMID:16775142]","metadata":null},{"id":"cb6f272ef4e745dc95deb1e4b1174ef1","type":"GO_TERM","name":"stereocilia coupling link","canonical_id":"go:GO:0002139","description":"\"A structure involved in coupling stereocilia to one another in sensory hair cells There are four morphologically distinct types: tip links, horizontal top connectors, shaft connectors and ankle links. Tip links and horizontal top connectors are the only inter-stereocilia links associated with mature cochlea, whereas ankle links appear during development of the auditory hair bundle.\" [PMID:16775142]","metadata":null},{"id":"b3b5dc3b5311499996e664c89d42e1d3","type":"GO_TERM","name":"stereocilia tip link","canonical_id":"go:GO:0002140","description":"\"A stereocilia link that is formed by a fine filament running more or less vertically upward from the tip of each shorter stereocilium to attach at a higher point on its adjacent taller neighbor. Tilting the bundle puts tension on the filaments, which pull on mechanically gated ion channels in the membrane of the stereocilia.\" [PMID:1108787]","metadata":null},{"id":"c0df7bdc508c4307bb899bd328044ac4","type":"GO_TERM","name":"stereocilia tip-link density","canonical_id":"go:GO:1990427","description":"\"An electron-dense plaque at either end of a stereocilia tip link that provides the anchor in the stereocilia membrane.\" [PMID:19447093, PMID:21709241]","metadata":null},{"id":"5fa7f35efedd454d862a1ce642bde362","type":"GO_TERM","name":"stereocilium","canonical_id":"go:GO:0032420","description":"\"An actin-based protrusion from the apical surface of auditory and vestibular hair cells and of neuromast cells. These protrusions are supported by a bundle of cross-linked actin filaments (an actin cable), oriented such that the plus (barbed) ends are at the tip of the protrusion, capped by a tip complex which bridges to the plasma. Bundles of stereocilia act as mechanosensory organelles.\" [GOC:ecd, PMID:15661519, PMID:7840137]","metadata":null},{"id":"4dda00ae53b44d05b92e67ed78f6782d","type":"GO_TERM","name":"stereocilium base","canonical_id":"go:GO:0120044","description":"\"The tapered base of the stereocilium adjacent to where it joins the hair cell body. This region contains a rootlet comprised of bundled actin filaments which spans the joint and stabilizes the stereocilium.\" [GOC:krc, PMID:20170899]","metadata":null},{"id":"c323e22d38e64d648727eae950dc2829","type":"GO_TERM","name":"stereocilium bundle","canonical_id":"go:GO:0032421","description":"\"A bundle of cross-linked stereocilia, arranged around a kinocilium on the apical surface of a sensory hair cell (e.g. a neuromast, auditory or vestibular hair cell). Stereocilium bundles act as mechanosensory organelles by responding to fluid motion or fluid pressure changes.\" [GOC:ecd, PMID:15661519, PMID:7840137]","metadata":null},{"id":"25d30b9f30174df9954bea01e6839d55","type":"GO_TERM","name":"stereocilium bundle organization","canonical_id":"go:GO:0160194","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a sensory hair cell stereocilium bundle.\" [PMID:28266911, PMID:6978627]","metadata":null},{"id":"dd444a04840b468aa290230075aefd2a","type":"GO_TERM","name":"stereocilium coat","canonical_id":"go:GO:0120234","description":"\"A glycocalyx on the the endolymphatic surface of a cochlear hair cell that coats the external surface of each stereocilium and maintains a small distance between adjacent stereocilia in the bundle.\" [GOC:krc, ISBN:9781461268918, PMID:31444330, PMID:3583936]","metadata":null},{"id":"f9e9e2875a12481fac20258b6d7f1e0a","type":"GO_TERM","name":"stereocilium maintenance","canonical_id":"go:GO:0120045","description":"\"The organization process that preserves a stereocilium in a stable functional or structural state.\" [GOC:krc, PMID:27693694]","metadata":null},{"id":"5349c51dcc5945558f831a47558cb18a","type":"GO_TERM","name":"stereocilium membrane","canonical_id":"go:GO:0060171","description":"\"The portion of the plasma membrane surrounding a stereocilium.\" [GOC:dph, GOC:rph]","metadata":null},{"id":"533996b05806446c9427da38dd920b4b","type":"GO_TERM","name":"stereocilium shaft","canonical_id":"go:GO:0120043","description":"\"The shaft comprises the majority of the length of the stereocilium. This region is notable for the extreme stability of actin filaments, which are highly crosslinked into a parallel bundle.\" [GOC:krc, PMID:20170899]","metadata":null},{"id":"90ed3498972746ae9c42ad99fc9e59da","type":"GO_TERM","name":"stereocilium tip","canonical_id":"go:GO:0032426","description":"\"A distinct compartment at the tip of a stereocilium, distal to the site of attachment to the apical cell surface. It consists of a dense matrix bridging the barbed ends of the stereocilium actin filaments with the overlying plasma membrane, is dynamic compared to the shaft, and is required for stereocilium elongation.\" [GOC:ecd, GOC:krc, PMID:17021180, PMID:27565685]","metadata":null},{"id":"d0702327974f4b08ae5e06106c60e97a","type":"GO_TERM","name":"sterigmatocystin 7-O-methyltransferase activity","canonical_id":"go:GO:0047146","description":"\"Catalysis of the reaction: sterigmatocystin + S-adenosyl-L-methionine = 7-O-methylsterigmatocystin + S-adenosyl-homocysteine.\" [EC:2.1.1.110, MetaCyc:2.1.1.110-RXN]","metadata":null},{"id":"275d7a302e2c4dbd8bac3e348102be98","type":"GO_TERM","name":"sterigmatocystin biosynthetic process","canonical_id":"go:GO:0045461","description":"\"The chemical reactions and pathways resulting in the formation of sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.\" [PMID:10618248]","metadata":null},{"id":"fc79b3ba721049b59d054f00b7f61bf0","type":"GO_TERM","name":"sterigmatocystin catabolic process","canonical_id":"go:GO:0045574","description":"\"The chemical reactions and pathways resulting in the breakdown of sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.\" [GOC:curators]","metadata":null},{"id":"5a9463e8b05b42238415227e1bf8f8ab","type":"GO_TERM","name":"sterigmatocystin metabolic process","canonical_id":"go:GO:0045460","description":"\"The chemical reactions and pathways involving sterigmatocystin, a carcinogenic mycotoxin produced in high yields by strains of the common molds.\" [PMID:10618248]","metadata":null},{"id":"3a21f50fbae140f28de3bff81943ec96","type":"GO_TERM","name":"sternite morphogenesis","canonical_id":"go:GO:0007491","description":"\"The process in which the anatomical structures of the sternite are generated and organized. The sternite is the plate or sclerite on the underside of a body segment.\" [GOC:jid, PMID:16451739]","metadata":null},{"id":"60d27c8793524647ade9361f8454f16f","type":"GO_TERM","name":"steroid 11-beta-monooxygenase activity","canonical_id":"go:GO:0004507","description":"\"Catalysis of the reaction: a steroid + reduced adrenal ferredoxin + O2 = an 11-beta-hydroxysteroid + oxidized adrenal ferredoxin + H2O.\" [EC:1.14.15.4]","metadata":null},{"id":"2848b20e6ec0473482083541595c0589","type":"GO_TERM","name":"steroid 15-alpha-hydroxylase activity","canonical_id":"go:GO:0008388","description":"\"Catalysis of the reaction: reduced [NADPH-hemoprotein reductase] + O2 + a steroid = oxidized [NADPH-hemoprotein reductase] + H2O + H+ + 15alpha-hydroxy steroid.\" [PMID:2703500, RHEA:83179]","metadata":null},{"id":"71dc73c00f824121921ba8dbfb38ee06","type":"GO_TERM","name":"steroid 17-alpha-monooxygenase activity","canonical_id":"go:GO:0004508","description":"\"Catalysis of the reaction: a C21-steroid + O2 + reduced [NADPH--hemoprotein reductase] = a 17alpha-hydroxy-C21-steroid + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:65760]","metadata":null},{"id":"a19d657f1eff4edf90f447f47d9f45ed","type":"GO_TERM","name":"steroid 21-monooxygenase activity","canonical_id":"go:GO:0004509","description":"\"Catalysis of the reaction: A C(21) steroid + [reduced NADPH--hemoprotein reductase] + O2 = a 21-hydroxy-C(21)-steroid + [oxidized NADPH--hemoprotein reductase] + H2O.\" [RHEA:65612]","metadata":null},{"id":"2a5eb6ce50644261b1f7ead745f75d4c","type":"GO_TERM","name":"steroid 22S-hydroxylase activity","canonical_id":"go:GO:0160191","description":"\"Catalysis of the reaction: a C28-steroid + O2 + reduced NADPH--hemoprotein reductase = a (22S)-22-hydroxy C28-steroid + H+ + H2O + oxidized NADPH--hemoprotein reductase. Also catalyzes the C-22 hydroxylation of a variety of C27 and C29 steroids.\" [EC:1.14.14.178]","metadata":null},{"id":"419f6120ee39490497a9047f528af3c5","type":"GO_TERM","name":"steroid 7-alpha-hydroxylase activity","canonical_id":"go:GO:0008387","description":"\"Catalysis of the reaction: a steroid + AH2 + O2 = 7-alpha-hydroxysteroid + H2O.\" [GOC:mah]","metadata":null},{"id":"6708403cad224625a4cd3f76a6420736","type":"GO_TERM","name":"steroid 9-alpha-monooxygenase activity","canonical_id":"go:GO:0050292","description":"\"Catalysis of the reaction: AH2 + O2 + pregna-4,9(11)-diene-3,20-dione = 9,11alpha-epoxypregn-4-ene-3,20-dione + A + H2O.\" [RHEA:19557]","metadata":null},{"id":"8c5e6930a3e746e299f81ec4da30db00","type":"GO_TERM","name":"steroid Delta-isomerase activity","canonical_id":"go:GO:0004769","description":"\"Catalysis of the reaction: a 3-oxo-delta(5)-steroid = a 3-oxo-delta(4)-steroid.\" [RHEA:14709]","metadata":null},{"id":"47dc05db7d4b4380a87f634e7946d3ae","type":"GO_TERM","name":"steroid N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0047261","description":"\"Catalysis of the reaction: estradiol-17alpha 3-D-glucuronoside + UDP-N-acetyl-alpha-D-glucosamine = 17alpha-(N-acetyl-D-glucosaminyl)-estradiol 3-D-glucuronoside + H+ + UDP.\" [EC:2.4.1.39, RHEA:14153]","metadata":null},{"id":"26237e00e305458f8e886d77fe3148a1","type":"GO_TERM","name":"steroid binding","canonical_id":"go:GO:0005496","description":"\"Binding to a steroid, any of a large group of substances that have in common a ring system based on 1,2-cyclopentanoperhydrophenanthrene.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"13d51842bccb475aa9f3ba29de509005","type":"GO_TERM","name":"steroid biosynthetic process","canonical_id":"go:GO:0006694","description":"\"The chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus; includes de novo formation and steroid interconversion by modification.\" [GOC:curators]","metadata":null},{"id":"5e6c796582db469abd5f5a68abd146e0","type":"GO_TERM","name":"steroid catabolic process","canonical_id":"go:GO:0006706","description":"\"The chemical reactions and pathways resulting in the breakdown of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.\" [GOC:curators]","metadata":null},{"id":"b246841f1be74af5acaba24d916a0f3a","type":"GO_TERM","name":"steroid dehydrogenase activity","canonical_id":"go:GO:0016229","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which one substrate is a sterol derivative.\" [GOC:mah]","metadata":null},{"id":"ed950465a0ac4f3ea6a1e1389ae660ed","type":"GO_TERM","name":"steroid dehydrogenase activity, acting on the CH-CH group of donors","canonical_id":"go:GO:0033765","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-CH group acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor, and in which one substrate is a sterol derivative.\" [GOC:mah]","metadata":null},{"id":"88ba1e86c6bd457ea30c8e1ac83791af","type":"GO_TERM","name":"steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor","canonical_id":"go:GO:0033764","description":"\"Catalysis of an oxidation-reduction (redox) reaction in which a CH-OH group acts as a hydrogen or electron donor and reduces NAD+ or NADP, and in which one substrate is a sterol derivative.\" [GOC:mah]","metadata":null},{"id":"08543d7bb06242db94d82e25f7f58643","type":"GO_TERM","name":"steroid hormone aporeceptor complex","canonical_id":"go:GO:0005831","description":"\"A protein complex consisting of a steroid receptor associated with nonreceptor proteins, minimally a dimer of Hsp90 and a monomer of hsp56/FKBP59; forms in the absence of bound ligand.\" [PMID:7493981]","metadata":null},{"id":"93e4cb7ea44049478fcfa2d464e321d3","type":"GO_TERM","name":"steroid hormone binding","canonical_id":"go:GO:1990239","description":"\"Binding to a steroid hormone.\" [GOC:ln]","metadata":null},{"id":"51b56900632f4a2a93e01a5c7e70068d","type":"GO_TERM","name":"steroid hormone biosynthetic process","canonical_id":"go:GO:0120178","description":"\"The chemical reactions and pathways resulting in the formation of any steroid hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.\" [GOC:krc, GOC:nln]","metadata":null},{"id":"158d649783e542049f317ac88e80bd89","type":"GO_TERM","name":"steroid hormone receptor complex assembly","canonical_id":"go:GO:0006463","description":"\"The aggregation, arrangement and bonding together of a set of components to form a steroid hormone receptor complex, an intracellular receptor that binds steroid hormones. The complex is often a dimer, and forms after the steroid has bound the receptor.\" [GOC:jl, Wikipedia:Steroid_hormone_receptor]","metadata":null},{"id":"691086d775a54a85b43a5b8a2337e136","type":"GO_TERM","name":"steroid hormone receptor signaling pathway","canonical_id":"go:GO:0043401","description":"\"The series of molecular signals mediated by a steroid hormone binding to a receptor.\" [PMID:12606724]","metadata":null},{"id":"02d613836d664313a61379e54bf92c8d","type":"GO_TERM","name":"steroid hormone secretion","canonical_id":"go:GO:0035929","description":"\"The regulated release of any steroid that acts as a hormone into the circulatory system.\" [GOC:sl]","metadata":null},{"id":"06df764ae18c4a7d957751855900eda5","type":"GO_TERM","name":"steroid hydroxylase activity","canonical_id":"go:GO:0008395","description":"\"Catalysis of the formation of a hydroxyl group on a steroid by incorporation of oxygen from O2.\" [ISBN:0721662544]","metadata":null},{"id":"c2175fc2d39c48f08263be7e8b1c57d3","type":"GO_TERM","name":"steroid metabolic process","canonical_id":"go:GO:0008202","description":"\"The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.\" [ISBN:0198547684]","metadata":null},{"id":"aa7eb09f07e746888f1052fb587ec586","type":"GO_TERM","name":"steroid receptor RNA activator RNA binding","canonical_id":"go:GO:0002153","description":"\"Binding to a steroid receptor RNA activator RNA (SRA). SRA enhances steroid hormone receptor transcriptional activity as an RNA transcript by an indirect mechanism that does not involve SRA-steroid receptor binding.\" [GOC:vw, PMID:10199399, PMID:15180993]","metadata":null},{"id":"e098ffba45f24f749ff624d8040caa8e","type":"GO_TERM","name":"steroid sulfotransferase activity","canonical_id":"go:GO:0050294","description":"\"Catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate + a phenolic steroid = adenosine 3',5'-bisphosphate + steroid O-sulfate.\" [MetaCyc:STEROID-SULFOTRANSFERASE-RXN, RHEA:68460]","metadata":null},{"id":"1bd35be4b2eb49fcb888f114b96ae207","type":"GO_TERM","name":"steroid-lactonase activity","canonical_id":"go:GO:0050293","description":"\"Catalysis of the reaction: H2O + testololactone = H+ + testolate.\" [EC:3.1.1.37, RHEA:13721]","metadata":null},{"id":"c111468029904b8a989168a5ad88afd9","type":"GO_TERM","name":"sterol 12-alpha-hydroxylase activity","canonical_id":"go:GO:0008397","description":"\"Catalysis of the reaction: a steroid + reduced [NADPH--hemoprotein reductase] + O2 = a 12-alpha-hydroxysteroid + oxidized [NADPH--hemoprotein reductase]- H2O +H+.\" [EC:1.14.14.139]","metadata":null},{"id":"e94a02f39d2048d1acb2a7e22edbcb94","type":"GO_TERM","name":"sterol 14-demethylase activity","canonical_id":"go:GO:0008398","description":"\"Catalysis of the reaction: a 14alpha-methyl steroid + 3 O2 + 3 reduced [NADPH-hemoprotein reductase] = a delta14 steroid + formate + 4 H+ + 4 H2O + 3 oxidized [NADPH-hemoprotein reductase].\" [RHEA:54028]","metadata":null},{"id":"7083373da9f24c63b60abfbb07383f9e","type":"PROTEIN","name":"sterol 14a-demethylase","canonical_id":"uniprot:P10613","description":null,"metadata":null},{"id":"fab9c0bd05124a3386bd8790e4ae221e","type":"GO_TERM","name":"sterol 24-C-methyltransferase activity","canonical_id":"go:GO:0003838","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + zymosterol = fecosterol + H+ + S-adenosyl-L-homocysteine.\" [RHEA:21128]","metadata":null},{"id":"c97c25cbed7345c593a64a1588082962","type":"GO_TERM","name":"sterol 3-beta-glucosyltransferase activity","canonical_id":"go:GO:0016906","description":"\"Catalysis of the reaction: UDP-glucose + a sterol = UDP + an O-glucosylsterol.\" [EC:2.4.1.173, RHEA:22724]","metadata":null},{"id":"6d29ad1591484eb9b66ab6d4a23fd637","type":"GO_TERM","name":"sterol O-acyltransferase activity","canonical_id":"go:GO:0004772","description":"\"Catalysis of the reaction: a long-chain fatty acyl-CoA + a sterol = a sterol ester + CoA.\" [RHEA:59816]","metadata":null},{"id":"9d1bf4ee16b64cec9422254007aae625","type":"GO_TERM","name":"sterol binding","canonical_id":"go:GO:0032934","description":"\"Binding to a sterol, a steroid containing a hydroxy group in the 3 position, closely related to cholestan-3-ol.\" [GOC:mah]","metadata":null},{"id":"c652a5a609954a2899a7d44428a03378","type":"GO_TERM","name":"sterol biosynthetic process","canonical_id":"go:GO:0016126","description":"\"The chemical reactions and pathways resulting in the formation of sterols, steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:curators]","metadata":null},{"id":"c4cf2ab0294e48a2b6a064777bfff3b2","type":"GO_TERM","name":"sterol catabolic process","canonical_id":"go:GO:0016127","description":"\"The chemical reactions and pathways resulting in the breakdown of sterols, steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:curators]","metadata":null},{"id":"ec9c4fc73e6a458cb0fd98fc74fe223c","type":"GO_TERM","name":"sterol desaturase activity","canonical_id":"go:GO:0070704","description":"\"Catalysis of the introduction of a double bond into a sterol molecule.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"ff0e210a9e43419f9cc622b3f23ce0a5","type":"GO_TERM","name":"sterol ester esterase activity","canonical_id":"go:GO:0004771","description":"\"Catalysis of the reaction: a sterol ester + H2O = a fatty acid + a sterol + H+.\" [RHEA:10100]","metadata":null},{"id":"7d111e5fa9b74257baa0d8db6f4756e4","type":"GO_TERM","name":"sterol homeostasis","canonical_id":"go:GO:0055092","description":"\"Any process involved in the maintenance of an internal steady state of sterol within an organism or cell.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"06947292e8034815b2ef0424c9cde5a4","type":"GO_TERM","name":"sterol import","canonical_id":"go:GO:0035376","description":"\"The directed movement of a sterol into a cell or organelle. Sterols are steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:bf, PMID:19793923]","metadata":null},{"id":"1b92afa12f574622acdaf4c863ebf96a","type":"GO_TERM","name":"sterol metabolic process","canonical_id":"go:GO:0016125","description":"\"The chemical reactions and pathways involving sterols, steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [ISBN:0198547684]","metadata":null},{"id":"36bccc9c784a477e8d6606690fd4083c","type":"GO_TERM","name":"sterol response element binding","canonical_id":"go:GO:0032810","description":"\"Binding to a sterol response element (SRE), a nonpalindromic sequence found in the promoters of genes involved in lipid metabolism.\" [GOC:vk, PMID:11994399]","metadata":null},{"id":"155b4ab74b3542408a21a8cdbb06cb5c","type":"GO_TERM","name":"sterol sensor activity","canonical_id":"go:GO:0032935","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of a sterol.\" [GOC:mah]","metadata":null},{"id":"5f3e78af6aca4542b870da19f78f08d5","type":"GO_TERM","name":"sterol transfer activity","canonical_id":"go:GO:0120015","description":"\"Removes a sterol from a membrane or a monolayer lipid particle, transports it through the aqueous phase while protected in a hydrophobic pocket, and brings it to an acceptor membrane or lipid particle.\" [GOC:krc, PMID:20823909, PMID:24220498, PMID:25797198]","metadata":null},{"id":"b131c0912e204068b326281d5d31e10c","type":"GO_TERM","name":"sterol transmembrane transport","canonical_id":"go:GO:0035382","description":"\"The process in which a sterol is transported across a membrane. Sterols are steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:vw]","metadata":null},{"id":"0696bddcc8b640a09601bf49e511fcc1","type":"GO_TERM","name":"sterol transport","canonical_id":"go:GO:0015918","description":"\"The directed movement of sterols into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Sterols are steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.\" [GOC:ai]","metadata":null},{"id":"8bdf2c7b299d4fb39efbaa21b843160a","type":"GO_TERM","name":"sterol-dependent protein binding","canonical_id":"go:GO:0070866","description":"\"Binding to a protein or protein complex in the presence of sterols.\" [GOC:ecd]","metadata":null},{"id":"f217400fac284820ae2c210bbf7d9f94","type":"GO_TERM","name":"steryl deacetylase activity","canonical_id":"go:GO:0034084","description":"\"Catalysis of the hydrolysis of an acetyl group or groups from an acetylated sterol.\" [GOC:rb, PMID:18034159]","metadata":null},{"id":"a6ecb67f5233463e9869e9f68ad3302b","type":"GO_TERM","name":"steryl-beta-glucosidase activity","canonical_id":"go:GO:0050295","description":"\"Catalysis of the reaction: cholesteryl-beta-D-glucoside + H2O = D-glucose + cholesterol.\" [EC:3.2.1.104, RHEA:11956]","metadata":null},{"id":"ee106613ae164d1e989a7bc09fc836ca","type":"GO_TERM","name":"steryl-sulfatase activity","canonical_id":"go:GO:0004773","description":"\"Catalysis of the reaction: 3-beta-hydroxyandrost-5-en-17-one 3-sulfate + H2O = 3-beta-hydroxyandrost-5-en-17-one + sulfate.\" [EC:3.1.6.2]","metadata":null},{"id":"bc7ed82f20f647a39ab439b0c0a9b8d6","type":"GO_TERM","name":"steviol 13-O glucosyltransferase activity","canonical_id":"go:GO:0102377","description":"\"Catalysis of the reaction: steviol + UDP-alpha-D-glucose = H+ + steviolmonoside + UDP.\" [RHEA:61732]","metadata":null},{"id":"a01d747bc9f34bf6b909d4c90b190e1f","type":"GO_TERM","name":"steviolbioside glucosyltransferase activity (rebaudioside B forming)","canonical_id":"go:GO:0102380","description":"\"Catalysis of the reaction: steviolbioside + UDP-alpha-D-glucose = H+ + rebaudioside B + UDP.\" [RHEA:61752]","metadata":null},{"id":"9fa6a46911af4fdbb6c039531585f41a","type":"GO_TERM","name":"steviolbioside glucosyltransferase activity (stevioside forming)","canonical_id":"go:GO:0102379","description":"\"Catalysis of the reaction: steviolbioside + UDP-alpha-D-glucose = stevioside + UDP.\" [RHEA:61744]","metadata":null},{"id":"ddbecf4597a141308b55996dbbfd10cc","type":"GO_TERM","name":"steviolmonoside glucosyltransferase activity","canonical_id":"go:GO:0102378","description":"\"Catalysis of the reaction: steviolmonoside + UDP-alpha-D-glucose = rubusoside + UDP.\" [RHEA:61736]","metadata":null},{"id":"579ac174d3da4c5c83233462e6c96172","type":"GO_TERM","name":"stevioside glucosyltransferase activity (rebaudioside A forming)","canonical_id":"go:GO:0102381","description":"\"Catalysis of the reaction: stevioside + UDP-alpha-D-glucose = H+ + rebaudioside A + UDP.\" [RHEA:61756]","metadata":null},{"id":"dc9e9e753bd0464e8fbeaf7686091b09","type":"DISEASE","name":"stiff-person syndrome","canonical_id":"mondo:0008491","description":null,"metadata":null},{"id":"05f79e576e914a79b0114d9fcca90f9c","type":"GO_TERM","name":"stigma development","canonical_id":"go:GO:0048480","description":"\"The process whose specific outcome is the progression of the stigma over time, from its formation to the mature structure. The stigma is the pollen-receptive surface of a carpel or group of fused carpels, usually sticky.\" [GOC:jid, PO:0009073]","metadata":null},{"id":"1a65545ca2764b2999a28b31d0079e66","type":"GO_TERM","name":"stigma papilla","canonical_id":"go:GO:0090397","description":"\"A plant cell papilla that is part of a stigma papilla cell.\" [GOC:tb]","metadata":null},{"id":"6d18d6a6a68142dd85abec869a34149b","type":"GO_TERM","name":"stilbene biosynthetic process","canonical_id":"go:GO:0009811","description":"\"The chemical reactions and pathways resulting in the formation of stilbenes, a class of polyketide compounds formed from cinnamic acid and three molecules of malonyl CoA.\" [GOC:tair_curators, ISBN:3110116251]","metadata":null},{"id":"208d9981de594296bea75b6bfdb6bb3d","type":"GO_TERM","name":"stilbene catabolic process","canonical_id":"go:GO:0046272","description":"\"The chemical reactions and pathways resulting in the breakdown of stilbenes, a class of polyketide compounds formed from cinnamic acid and three molecules of malonyl CoA.\" [GOC:ai]","metadata":null},{"id":"ff0fb09b7add4c108c1fd7d9de96203b","type":"GO_TERM","name":"stimulatory C-type lectin receptor signaling pathway","canonical_id":"go:GO:0002223","description":"\"The series of molecular signals initiated by the binding of C-type lectin to its receptor on the surface of a target cell, and resulting in cellular activation.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"5c8ba6f33ab44f4986f81f7e60fccf4b","type":"GO_TERM","name":"stimulatory killer cell immunoglobulin-like receptor signaling pathway","canonical_id":"go:GO:0002222","description":"\"The series of molecular signals initiated by a ligand binding to a killer cell immunoglobulin-like receptor capable of cellular activation.\" [GO_REF:0000022, GOC:add, ISBN:0781735149]","metadata":null},{"id":"37e101098a7341eda490caaff15a1509","type":"GO_TERM","name":"stipitatonate decarboxylase activity","canonical_id":"go:GO:0050296","description":"\"Catalysis of the reaction: H2O + stipitatonate = CO2 + H+ + stipitatate.\" [EC:4.1.1.60, RHEA:13885]","metadata":null},{"id":"4d1f0b385a444f00bd7472d6014b421d","type":"GO_TERM","name":"stipule development","canonical_id":"go:GO:0010865","description":"\"The process whose specific outcome is the progression of the stipule over time, from its formation to the mature structure. A stipule is one of (usually) a pair of appendages at the bases of leaves in many broad-leaved angiosperms.\" [GOC:tb]","metadata":null},{"id":"8a563ee3484e47ba8b30d4764b7026c0","type":"DRUG","name":"stiripentol","canonical_id":"mesh:C021092","description":null,"metadata":null},{"id":"1f50d003563f4d6fb33ba3cfbcd8292b","type":"GO_TERM","name":"stizolobate synthase activity","canonical_id":"go:GO:0050297","description":"\"Catalysis of the reaction: L-dopa + O2 = 4-(L-alanin-3-yl)-2-hydroxy-cis,cis-muconate 6-semialdehyde + H+.\" [RHEA:21220]","metadata":null},{"id":"89179488a837497498a7d4c95f13a3cb","type":"GO_TERM","name":"stizolobinate synthase activity","canonical_id":"go:GO:0050298","description":"\"Catalysis of the reaction: 3,4-dihydroxy-L-phenylalanine + O2 = 5-(L-alanin-3-yl)-2-hydroxy-cis,cis-muconate 6-semialdehyde.\" [EC:1.13.11.30, MetaCyc:STIZOLOBINATE-SYNTHASE-RXN]","metadata":null},{"id":"0f7065e9519948bab5709c5b76fa0d08","type":"GO_TERM","name":"stomach body smooth muscle contraction","canonical_id":"go:GO:0014845","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the body of stomach. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The body of stomach is the part of the stomach that lies between the fundus above and the pyloric antrum below; its boundaries are poorly defined.\" [GOC:ef, GOC:mtg_muscle, MA:0002559]","metadata":null},{"id":"f61df68c815240c4a8a09a36a17388d5","type":"GO_TERM","name":"stomach development","canonical_id":"go:GO:0062094","description":"\"The process whose specific outcome is the progression of the stomach over time, from its formation to the mature structure. The stomach is an expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ.\" [PMID:11967278]","metadata":null},{"id":"56c24155ec9149508dc28f08c360fe65","type":"GO_TERM","name":"stomach fundus smooth muscle contraction","canonical_id":"go:GO:0014825","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the fundus of stomach. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The fundus is the portion of the stomach that lies above the cardiac notch.\" [GOC:mtg_muscle, MA:0001612]","metadata":null},{"id":"67fca8e4668e4d718d5b158231089a74","type":"GO_TERM","name":"stomach neuroendocrine cell differentiation","canonical_id":"go:GO:0061102","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a neuroendocrine cell of the stomach epithelium.\" [GOC:dph, PMID:18173746]","metadata":null},{"id":"c4ac6f010bf24499a38d7cc756d026d9","type":"GO_TERM","name":"stomach pylorus smooth muscle contraction","canonical_id":"go:GO:0120064","description":"\"A process in which force is generated within gastric smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the most distal part of the stomach.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"cd700c42d80140e09e7b3b0439cd9f7c","type":"GO_TERM","name":"stomach smooth muscle contraction","canonical_id":"go:GO:0120063","description":"\"A process in which force is generated within gastric smooth muscle tissue, resulting in a change in muscle geometry. This process occurs throughout the length of the stomach.\" [GOC:sl, PMID:15890336]","metadata":null},{"id":"0fc5fb52a5604e87adb4d188aa451709","type":"GO_TERM","name":"stomatal closure","canonical_id":"go:GO:0090332","description":"\"The process of closing of stomata, pores in the epidermis of leaves and stems bordered by two guard cells and serving in gas exchange.\" [GOC:tb]","metadata":null},{"id":"78f5df2b791b4e2e8592390461cf3b3d","type":"GO_TERM","name":"stomatal complex development","canonical_id":"go:GO:0010374","description":"\"The process whose specific outcome is the progression of the stomatal complex over time from its formation to the mature structure. The stomatal complex is the stomatal guard cells and their associated epidermal cells.\" [PMID:17259259]","metadata":null},{"id":"89dd9c9a752849a09663ec002fb06f1c","type":"GO_TERM","name":"stomatal complex formation","canonical_id":"go:GO:0010376","description":"\"The process that gives rise to the stomatal complex. This process pertains to the initial formation of a structure from unspecified parts. The stomatal complex is the stomatal guard cells and their associated epidermal cells.\" [PMID:17259259]","metadata":null},{"id":"8fb4ab0732914d98af6b129c55576c33","type":"GO_TERM","name":"stomatal complex morphogenesis","canonical_id":"go:GO:0010103","description":"\"The process in which the anatomical structures of the stomatal complex are generated and organized. The stomatal complex is the stomatal guard cells and their associated epidermal cells.\" [GOC:tair_curators]","metadata":null},{"id":"1ec70ae2d15a4bd994af3d97f979e1db","type":"GO_TERM","name":"stomatal complex patterning","canonical_id":"go:GO:0010375","description":"\"The regionalization process of establishing the non-random spatial arrangement of stomatal complex on the surface of a leaf. The stomatal complex is the stomatal guard cells and their associated epidermal cells.\" [PMID:17259259]","metadata":null},{"id":"4c1043f62cd245c599282375d97169d9","type":"GO_TERM","name":"stomatal lineage progression","canonical_id":"go:GO:0010440","description":"\"The process in which an unspecialized epidermal cell progresses through a series of divisions that culminate in the production of a stomatal complex.\" [GOC:expert_db, GOC:tb]","metadata":null},{"id":"a2ca16abec7444998b8895d4a56ed340","type":"GO_TERM","name":"stomatal movement","canonical_id":"go:GO:0010118","description":"\"The process of opening or closing of stomata, which is directly related to the stomatal conductance (measuring rate of passage of either water vapor or carbon dioxide (CO2) through stomata).\" [GOC:sm]","metadata":null},{"id":"92437853e70542ec9eba29d4912180a2","type":"GO_TERM","name":"stomatal opening","canonical_id":"go:GO:1990069","description":"\"The process of opening of stomata, pores in the epidermis of leaves and stems bordered by two guard cells and serving in gas exchange.\" [PMID:21749899]","metadata":null},{"id":"f0ab1fad25084613b9a0012ed8b3dda4","type":"GO_TERM","name":"stomatogastric nervous system development","canonical_id":"go:GO:0007421","description":"\"The process whose specific outcome is the progression of the stomatogastric nervous system over time, from its formation to the mature structure.\" [GOC:jid]","metadata":null},{"id":"a38c5624c3b94639a855b68cf6e8ef35","type":"GO_TERM","name":"stomium development","canonical_id":"go:GO:0080166","description":"\"The process whose specific outcome is the progression of the stomium over time, from its formation to the mature structure. A stomium is a fissure or pore in the anther lobe through which the pollen is released.\" [GOC:tb]","metadata":null},{"id":"cc9e1cac42724dc9b70e9ffc90219fbb","type":"GO_TERM","name":"storage vacuole","canonical_id":"go:GO:0000322","description":"\"A vacuole that functions primarily in the storage of materials, including nutrients, pigments, waste products, and small molecules.\" [GOC:krc]","metadata":null},{"id":"478d1f27845a46fd8d2af9aad319a14a","type":"GO_TERM","name":"store-operated calcium channel activity","canonical_id":"go:GO:0015279","description":"\"A ligand-gated ion channel activity which transports calcium in response to emptying of intracellular calcium stores.\" [GOC:dph, GOC:tb, PMID:15788710]","metadata":null},{"id":"233719f2eb4e42afb80f1235f0ecd3d1","type":"GO_TERM","name":"store-operated calcium entry","canonical_id":"go:GO:0002115","description":"\"A calcium ion entry mechanism in the plasma membrane activated by the depletion of calcium ion from the internal calcium ion store in the endoplasmic reticulum.\" [GOC:hjd, PMID:11120592, PMID:17956991]","metadata":null},{"id":"db82a31c6d284382bf40e7b989a001de","type":"GO_TERM","name":"streptomycin 3''-kinase activity","canonical_id":"go:GO:0050299","description":"\"Catalysis of the reaction: ATP + streptomycin = ADP + 2 H+ + streptomycin 3''-phosphate.\" [EC:2.7.1.87, RHEA:18377]","metadata":null},{"id":"67ecd6b5f9714c9bb6dbe771178442f5","type":"GO_TERM","name":"streptomycin biosynthetic process","canonical_id":"go:GO:0019872","description":"\"The chemical reactions and pathways resulting in the formation of streptomycin, a commonly used antibiotic in cell culture media; it acts only on prokaryotes and blocks transition from initiation complex to chain elongating ribosome.\" [GOC:curators]","metadata":null},{"id":"7d8611028e69405ea1b49da4dd655cf2","type":"GO_TERM","name":"streptomycin-6-phosphatase activity","canonical_id":"go:GO:0050301","description":"\"Catalysis of the reaction: H2O + streptomycin 6-phosphate = phosphate + streptomycin.\" [EC:3.1.3.39, RHEA:10688]","metadata":null},{"id":"cd5baeb7d8f74ca186fc07ce9f06627f","type":"GO_TERM","name":"stress fiber","canonical_id":"go:GO:0001725","description":"\"A contractile actin filament bundle that consists of short actin filaments with alternating polarity, cross-linked by alpha-actinin and possibly other actin bundling proteins, and with myosin present in a periodic distribution along the fiber.\" [PMID:16651381]","metadata":null},{"id":"88f7d5795ebe437c9e7d26fe0b18fa7d","type":"GO_TERM","name":"stress fiber assembly","canonical_id":"go:GO:0043149","description":"\"The aggregation, arrangement and bonding together of a set of components to form a stress fiber. A stress fiber is a contractile actin filament bundle that consists of short actin filaments with alternating polarity.\" [GOC:curators, GOC:mah, PMID:16651381]","metadata":null},{"id":"ea55d5e52bb34b9aaa6c27d31570fa79","type":"GO_TERM","name":"stress response to acid chemical","canonical_id":"go:GO:0097532","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis caused by the chemical structure of the anion portion of a dissociated acid (rather than the acid acting as a proton donor). The acid chemical may be in gaseous, liquid or solid form.\" [GOC:aa, GOC:BHF, GOC:curators, GOC:rl, PMID:10615049, PMID:19170886, Wikipedia:Acid]","metadata":null},{"id":"a2f28e97c5c543c9ac36357c57fc776a","type":"GO_TERM","name":"stress response to cadmium ion","canonical_id":"go:GO:1990170","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis caused by a cadmium ion stimulus.\" [GOC:kmv]","metadata":null},{"id":"2b9d6d85f52a4f6091ff0afb2effd371","type":"GO_TERM","name":"stress response to copper ion","canonical_id":"go:GO:1990169","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis caused by a copper ion stimulus.\" [GOC:kmv, PMID:23437011]","metadata":null},{"id":"6b4f95c2137e4b23824fdd32adb70614","type":"GO_TERM","name":"stress response to metal ion","canonical_id":"go:GO:0097501","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis caused by a metal ion stimulus.\" [GOC:kmv]","metadata":null},{"id":"90e07e96ee034c9cab6abad8bfe3cc4b","type":"GO_TERM","name":"stress response to nickel ion","canonical_id":"go:GO:1990532","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis caused by a nickel ion stimulus.\" [GOC:kmv, PMID:25330323]","metadata":null},{"id":"8c9130fa3345441ebcb1eff08db2c9b3","type":"GO_TERM","name":"stress response to zinc ion","canonical_id":"go:GO:1990359","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis caused by a zinc ion stimulus.\" [GOC:kmv, PMID:17888400]","metadata":null},{"id":"7c4ef067e7fd4e07bd9c8cb5cfe5d1f4","type":"GO_TERM","name":"stress-activated MAPK cascade","canonical_id":"go:GO:0051403","description":"\"A MAPK cascade that starts with the activation of a stress-activated MAP kinase cascade.\" [GOC:ai, PMID:15936270]","metadata":null},{"id":"fa09425fac85472f84b0d0e4e4986b07","type":"GO_TERM","name":"stress-activated protein kinase signaling cascade","canonical_id":"go:GO:0031098","description":"\"The series of molecular signals in which a stress-activated protein kinase (SAPK) cascade relays a signal.\" [GOC:mah]","metadata":null},{"id":"f8e83a55654c4192b44af06c8111d026","type":"GO_TERM","name":"stress-induced homeostatically regulated protein degradation pathway","canonical_id":"go:GO:0120174","description":"\"A stress-inducible protein catabolic pathway that promotes protein quality control by accelerating the degradation of misfolded ER membrane and cytosolic proteins, as well as native proteins. The pathway starts with the activation, by stress, of the Nma111p/Ynm3p serine protease, which cleaves the stress-induced hydrophilin Roq1p, resulting in the generation of a Roq1p cleavage product that selectively interacts with Ubr1p, an E3 ubiquitin ligase. Interaction with the Ubr1p type-1 substrate binding site reprograms the substrate specificity of this ubiquitin ligase resulting in the selective proteasome-mediated degradation of misfolded and native proteins. The pathway ends with degradation of the protein by the cytoplasmic proteasome. Currently, NMA111, ROQ1, UBR1, RAD6, and CDC48 are considered to be involved in this quality control pathway.\" [GOC:rl, GOC:rn, PMID:29861160]","metadata":null},{"id":"2eaaf3758d1047cc8a8d56f0f2aa0a97","type":"GO_TERM","name":"stress-induced mitochondrial fusion","canonical_id":"go:GO:1990046","description":"\"Merging of two or more mitochondria within a cell to form a single compartment, as a result of a disturbance in cellular homeostasis.\" [GOC:lb, PMID:19360003]","metadata":null},{"id":"b8134091879d472c8b44434b8624b950","type":"GO_TERM","name":"stress-induced premature senescence","canonical_id":"go:GO:0090400","description":"\"A cellular senescence process associated with the dismantling of a cell as a response to environmental factors such as hydrogen peroxide or X-rays.\" [GOC:BHF]","metadata":null},{"id":"4ba45e15f2594b41b4c7ca617d362c45","type":"DISEASE","name":"stress-related disorder","canonical_id":"efo:0010098","description":null,"metadata":null},{"id":"58f1c42c2bee467d9b132cf2a0f3d4ed","type":"GO_TERM","name":"stretch-activated, monoatomic cation-selective, calcium channel activity","canonical_id":"go:GO:0015275","description":"\"Enables the transmembrane transfer of a calcium ion by a channel that opens in response to a mechanical stress in the form of stretching.\" [GOC:mtg_transport]","metadata":null},{"id":"bcec6d866949457eb5e9bf7abbc01cf4","type":"GO_TERM","name":"striatal medium spiny neuron differentiation","canonical_id":"go:GO:0021773","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a medium spiny neuron residing in the striatum.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"d9b24427c3f74619a3cfdc08835376eb","type":"GO_TERM","name":"striated muscle adaptation","canonical_id":"go:GO:0014888","description":"\"Any process in which striated muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors. These adaptive events occur in both muscle fibers and associated structures (motoneurons and capillaries), and they involve alterations in regulatory mechanisms, contractile properties and metabolic capacities.\" [GOC:mtg_muscle]","metadata":null},{"id":"1565dc4d6acc4bb3ba9b98c692a5b563","type":"GO_TERM","name":"striated muscle atrophy","canonical_id":"go:GO:0014891","description":"\"A process, occurring in striated muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse.\" [GOC:mtg_muscle]","metadata":null},{"id":"575107b9415a4b17aa35ff1c859dbfe4","type":"GO_TERM","name":"striated muscle cell apoptotic process","canonical_id":"go:GO:0010658","description":"\"A form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases, whose actions dismantle a striated muscle cell and result in its death. Striated muscle cells make up striated muscle fibers which are divided by transverse bands into striations.\" [CL:0000737, GOC:dph, GOC:mtg_apoptosis, GOC:tb]","metadata":null},{"id":"2d81b27c867e4db5ad685a7c6171cf23","type":"GO_TERM","name":"striated muscle cell development","canonical_id":"go:GO:0055002","description":"\"The process whose specific outcome is the progression of a striated muscle cell over time, from its formation to the mature structure. Striated muscle cells contain fibers that are divided by transverse bands into striations, and cardiac and skeletal muscle are types of striated muscle.\" [CL:0000737, GOC:devbiol]","metadata":null},{"id":"a97b441474074e46aaa3c192d7bac7ef","type":"GO_TERM","name":"striated muscle cell differentiation","canonical_id":"go:GO:0051146","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a striated muscle cell; striated muscle fibers are divided by transverse bands into striations, and cardiac and voluntary muscle are types of striated muscle.\" [CL:0000737, GOC:ai]","metadata":null},{"id":"498f5c07766d46e39296d08942480228","type":"GO_TERM","name":"striated muscle cell proliferation","canonical_id":"go:GO:0014855","description":"\"The multiplication or reproduction of striated muscle cells, resulting in the expansion of a cell population. Striated muscles contain fibers that are divided by transverse bands into striations, and cardiac and skeletal muscle are types of striated muscle.\" [CL:0000737, GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"eff15c8ae5a247ae9056211ec6da39bd","type":"GO_TERM","name":"striated muscle contraction","canonical_id":"go:GO:0006941","description":"\"A process in which force is generated within striated muscle tissue, resulting in the shortening of the muscle. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Striated muscle is a type of muscle in which the repeating units (sarcomeres) of the contractile myofibrils are arranged in registry throughout the cell, resulting in transverse or oblique striations observable at the level of the light microscope.\" [GOC:jl, GOC:mtg_muscle, ISBN:0198506732]","metadata":null},{"id":"1b373ebd90224e6083cf8e18b71a2d7f","type":"GO_TERM","name":"striated muscle contraction involved in embryonic body morphogenesis","canonical_id":"go:GO:0061199","description":"\"The process in which force is generated within striated embryonic muscle tissue, resulting in a contraction of the muscle that contributes to the formation of an embryo's characteristic body morphology.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"e9bb765560ed4eaf8f6baa989e1e5419","type":"GO_TERM","name":"striated muscle dense body","canonical_id":"go:GO:0055120","description":"\"A vinculin-containing myofibril attachment structure of striated muscle that connects sarcomeres to the extracellular matrix. In nematode body wall muscle, the dense body performs the dual role of Z-disk and costamere.\" [GOC:kmv, PMID:17492481]","metadata":null},{"id":"9b9c6a2d6ab446289a35ff76f55607e6","type":"GO_TERM","name":"striated muscle hypertrophy","canonical_id":"go:GO:0014897","description":"\"The enlargement or overgrowth of all or part of an organ due to an increase in size of muscle cells without cell division. In the case of striated muscle, this happens due to the additional synthesis of sarcomeric proteins and assembly of myofibrils.\" [GOC:mtg_muscle]","metadata":null},{"id":"c1c145ae5a974b75955bdfa1fdc9b4b2","type":"GO_TERM","name":"striated muscle myosin thick filament","canonical_id":"go:GO:0005863","description":"\"Bipolar filaments formed of polymers of a muscle-specific myosin II isoform, found in the middle of sarcomeres in myofibrils.\" [GOC:mtg_muscle, ISBN:0815316194]","metadata":null},{"id":"6a1d44aabcf7426397d715835daeca07","type":"GO_TERM","name":"striated muscle myosin thick filament assembly","canonical_id":"go:GO:0071688","description":"\"The aggregation, arrangement and bonding together of proteins to form the myosin-based thick filaments of myofibrils in striated muscle.\" [GOC:mah]","metadata":null},{"id":"0cd9275b516a48668c57ef607b36f33e","type":"GO_TERM","name":"striated muscle paramyosin thick filament assembly","canonical_id":"go:GO:0061203","description":"\"The aggregation, arrangement and bonding together of proteins to form the paramyosin-based thick filaments of myofibrils in striated muscle.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"d59786ee80794e52b1c3bf0e89095ab8","type":"GO_TERM","name":"striated muscle thin filament","canonical_id":"go:GO:0005865","description":"\"Filaments formed of actin and associated proteins; attached to Z discs at either end of sarcomeres in myofibrils.\" [ISBN:0815316194]","metadata":null},{"id":"a0c1cdfe00864751bca44863bc9f57d2","type":"GO_TERM","name":"striated muscle tissue development","canonical_id":"go:GO:0014706","description":"\"The process whose specific outcome is the progression of a striated muscle over time, from its formation to the mature structure. Striated muscle contain fibers that are divided by transverse bands into striations, and cardiac and skeletal muscle are types of striated muscle. Skeletal muscle myoblasts fuse to form myotubes and eventually multinucleated muscle fibers. The fusion of cardiac cells is very rare and can only form binucleate cells.\" [CL:0000737, GOC:dph, GOC:mtg_muscle]","metadata":null},{"id":"a6890aad41cd44eaacee1cff9064bd90","type":"GO_TERM","name":"striatum development","canonical_id":"go:GO:0021756","description":"\"The progression of the striatum over time from its initial formation until its mature state. The striatum is a region of the forebrain consisting of the caudate nucleus, putamen and fundus striati.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"976fb94b2bfa4cf38e3ca70786862688","type":"GO_TERM","name":"strictosidine beta-glucosidase activity","canonical_id":"go:GO:0050422","description":"\"Catalysis of the reaction: 3alpha(S)-strictosidine + H2O = D-glucose + strictosidine aglycone.\" [EC:3.2.1.105, RHEA:12917]","metadata":null},{"id":"299b3d6dbc744ebab33f27a52babec2e","type":"GO_TERM","name":"strictosidine synthase activity","canonical_id":"go:GO:0016844","description":"\"Catalysis of the reaction: 3alpha(S)-strictosidine + H2O = secologanin + tryptamine.\" [RHEA:15013]","metadata":null},{"id":"ce1820b2e9594632b0b62b8fbaeebb4f","type":"GO_TERM","name":"strigolactone biosynthetic process","canonical_id":"go:GO:1901601","description":"\"The chemical reactions and pathways resulting in the formation of strigolactone.\" [GOC:TermGenie]","metadata":null},{"id":"d0df874d42d2477ab24c7e4e81b8f820","type":"GO_TERM","name":"strigolactone metabolic process","canonical_id":"go:GO:1901600","description":"\"The chemical reactions and pathways involving strigolactone.\" [GOC:TermGenie]","metadata":null},{"id":"ec2f8ea8353e4f8faa3c341b7a6a1287","type":"GO_TERM","name":"stringent response","canonical_id":"go:GO:0015968","description":"\"A specific global change in the metabolism of a bacterial cell (the downregulation of nucleic acid and protein synthesis, and the simultaneous upregulation of protein degradation and amino acid synthesis) as a result of starvation.\" [GOC:jl, ISBN:0124325653, PMID:11282471]","metadata":null},{"id":"a9f340e57dc24b27acd679f72d6d0c00","type":"DISEASE","name":"stroke disorder","canonical_id":"mondo:0005098","description":null,"metadata":null},{"id":"61b44774c9fa4ce4859792dfe6a41bf6","type":"GO_TERM","name":"stromal side of plastid inner membrane","canonical_id":"go:GO:0098570","description":"\"The leaflet of the plastid inner membrane that faces the stroma, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"e428688f2e13473bb970c74919f2f44a","type":"GO_TERM","name":"stromal side of plastid thylakoid membrane","canonical_id":"go:GO:0098572","description":"\"The leaflet of the plastid thylakoid membrane that faces the stroma, including any protein embedded in, attached to, or peripherally associated with it.\" [GOC:dos]","metadata":null},{"id":"8f9f116fd13246669f87d5dcaf676ad5","type":"GO_TERM","name":"stromal-epithelial cell signaling involved in prostate gland development","canonical_id":"go:GO:0044345","description":"\"The process of transferring information from a stromal cell to an epithelial cell where it is received and interpreted, as part of prostate gland development.\" [GOC:jl, GOC:yaf]","metadata":null},{"id":"e4d71f5e60d9484f9e07341c41afaf7a","type":"GO_TERM","name":"strombine dehydrogenase activity","canonical_id":"go:GO:0050305","description":"\"Catalysis of the reaction: N-(carboxymethyl)-D-alanine + H2O + NAD+ = glycine + H+ + NADH + pyruvate.\" [EC:1.5.1.22, RHEA:14061]","metadata":null},{"id":"b4b7ec0993f0405fa29456e726c20a29","type":"GO_TERM","name":"stromule","canonical_id":"go:GO:0010319","description":"\"Thin filamentous structure extending from the surface of all plastid types examined so far, including chloroplast, proplastid, etioplast, leucoplast, amyloplast, and chromoplast. In general, stromules are more abundant in tissues containing non-green plastids, and in cells containing smaller plastids. The primary function of stromules is still unresolved, although the presence of stromules markedly increases the plastid surface area, potentially increasing transport to and from the cytosol. Other functions of stromules, such as transfer of macromolecules between plastids and starch granule formation in cereal endosperm, may be restricted to particular tissues and cell types.\" [PMID:15272881, PMID:15699062, PMID:16582010]","metadata":null},{"id":"62b1622f9268478799e14dac33fb9283","type":"DRUG","name":"strontium ranelate","canonical_id":"mesh:C081587","description":null,"metadata":null},{"id":"cb0abc45b5124a068faedf88ae68c811","type":"GO_TERM","name":"structural constituent of adult chitin-based cuticle","canonical_id":"go:GO:0008012","description":"\"The action of a molecule that contributes to the structural integrity of the chitin-based cuticle of an adult organism. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"2270a9ed73c84dd98bef700271cc6eaa","type":"GO_TERM","name":"structural constituent of albumen","canonical_id":"go:GO:0097099","description":"\"The action of a molecule that contributes to the structural integrity of albumen (also called egg white). Albumen is the clear liquid contained within an egg and consists of water and proteins, among which are ovomucin and ovomucoid. It protects the egg yolk and provides additional nutrition for the growth of the embryo.\" [GOC:jj, Wikipedia:Albumen]","metadata":null},{"id":"4938ca733370482fb4b4a21bdb4be749","type":"GO_TERM","name":"structural constituent of ascospore wall","canonical_id":"go:GO:1990915","description":"\"The action of a molecule that contributes to the structural integrity of an ascospore wall.\" [PMID:24623719]","metadata":null},{"id":"6b5affc1aac04022a5e7bdb1a8edfc9e","type":"GO_TERM","name":"structural constituent of bone","canonical_id":"go:GO:0008147","description":"\"The action of a molecule that contributes to the structural integrity of bone.\" [GOC:mah]","metadata":null},{"id":"b0cf6ee6004f446a86df4a2de5ab2e67","type":"GO_TERM","name":"structural constituent of carboxysome shell","canonical_id":"go:GO:0043886","description":"\"The action of a molecule that contributes to the structural integrity of a carboxysome shell, an organelle found in all cyanobacteria and some chemoautotrophs, consisting of a proteinaceous coat and enzymes for the fixation of CO2.\" [GOC:jl, PMID:28934381]","metadata":null},{"id":"bf1701a08fa04b74a1334716a073afea","type":"GO_TERM","name":"structural constituent of cell wall","canonical_id":"go:GO:0005199","description":"\"The action of a molecule that contributes to the structural integrity of a cell wall.\" [GOC:mah]","metadata":null},{"id":"2201c0ca248e4b31a697c6a56b2f40ad","type":"GO_TERM","name":"structural constituent of chitin-based cuticle","canonical_id":"go:GO:0005214","description":"\"The action of a molecule that contributes to the structural integrity of a chitin-based cuticle. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"071feabe291c46f7b31df731ac40ba45","type":"GO_TERM","name":"structural constituent of chitin-based larval cuticle","canonical_id":"go:GO:0008010","description":"\"The action of a molecule that contributes to the structural integrity of the chitin-based cuticle of a larva. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"2aad5d6ad1a94380ac04ed3e76b4b303","type":"GO_TERM","name":"structural constituent of chromatin","canonical_id":"go:GO:0030527","description":"\"The action of a molecule that contributes to the structural integrity of chromatin.\" [GOC:ai]","metadata":null},{"id":"437b73cae56245c089eaae7945d4c240","type":"GO_TERM","name":"structural constituent of collagen and cuticulin-based cuticle","canonical_id":"go:GO:0042329","description":"\"The action of a molecule that contributes to the structural integrity of a collagen and cuticulin-based cuticle. An example of this process is found in Caenorhabditis elegans.\" [GOC:jl, GOC:mtg_sensu]","metadata":null},{"id":"eb7a9f901bf44b5a89d9a4aa12ffc66a","type":"GO_TERM","name":"structural constituent of cutaneous appendage","canonical_id":"go:GO:0030281","description":"\"The action of a molecule that contributes to the structural integrity of cutaneous epidermal structures such as hairs, scales, or feathers.\" [GOC:mah, ISBN:0878932437]","metadata":null},{"id":"55cc5602cbef40c48ea7b3d34e453674","type":"GO_TERM","name":"structural constituent of cuticle","canonical_id":"go:GO:0042302","description":"\"The action of a molecule that contributes to the structural integrity of a cuticle.\" [GOC:jl]","metadata":null},{"id":"ea723cb900f24546a52d7939282aad94","type":"GO_TERM","name":"structural constituent of cytoplasmic lattice","canonical_id":"go:GO:0140094","description":"\"The action of a molecule that contributes to the structural integrity of cytoplasmic lattice of the the mammalian ooplasm.\" [PMID:37922900]","metadata":null},{"id":"469445c2f679477e89a72cc41b730b9b","type":"GO_TERM","name":"structural constituent of cytoskeleton","canonical_id":"go:GO:0005200","description":"\"The action of a molecule that contributes to the structural integrity of a cytoskeletal structure.\" [GOC:mah]","metadata":null},{"id":"469644115c324fcf9d514e7d3cab8f06","type":"GO_TERM","name":"structural constituent of egg chorion","canonical_id":"go:GO:0005213","description":"\"The action of a molecule that contributes to the structural integrity of an egg chorion. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:sensu]","metadata":null},{"id":"4477a3684ab9447496480295c738899d","type":"GO_TERM","name":"structural constituent of egg coat","canonical_id":"go:GO:0035804","description":"\"The action of a molecule that contributes to the structural integrity of an egg coat. An egg coat is a specialized extracellular matrix that surrounds the ovum of animals. The egg coat provides structural support and can play an essential role in oogenesis, fertilization and early development.\" [PMID:16944418, PMID:17163408]","metadata":null},{"id":"fca5f3d6f93946f693d0918c55e56141","type":"GO_TERM","name":"structural constituent of eye lens","canonical_id":"go:GO:0005212","description":"\"The action of a molecule that contributes to the structural integrity of the lens of an eye.\" [GOC:mah]","metadata":null},{"id":"67cbb2a0d241425b9c084c1490f0c1e8","type":"GO_TERM","name":"structural constituent of muscle","canonical_id":"go:GO:0008307","description":"\"The action of a molecule that contributes to the structural integrity of a muscle fiber.\" [GOC:mah]","metadata":null},{"id":"86e6f536a19a4e41b9f29f4a7bdd9cb5","type":"GO_TERM","name":"structural constituent of myelin sheath","canonical_id":"go:GO:0019911","description":"\"The action of a molecule that contributes to the structural integrity of the myelin sheath of a nerve.\" [GOC:mah]","metadata":null},{"id":"6b541caca5b14d7ca630af1040fbfe47","type":"GO_TERM","name":"structural constituent of nuclear lamina","canonical_id":"go:GO:0160123","description":"\"The action of a molecule that contributes to the structural integrity of nuclear lamina.\" [PMID:2824113, PMID:31434876]","metadata":null},{"id":"3ed316cf48f442febf3cd4badfc3dfc1","type":"GO_TERM","name":"structural constituent of nuclear pore","canonical_id":"go:GO:0017056","description":"\"The action of a molecule that contributes to the structural integrity of the nuclear pore complex, a protein-lined channel in the nuclear envelope that allows the transfer of macromolecules.\" [GOC:mah, PMID:25802992]","metadata":null},{"id":"7c9d7a1a6ffa465392ffb7bd3ad9e375","type":"GO_TERM","name":"structural constituent of peritrophic membrane","canonical_id":"go:GO:0016490","description":"\"The action of a molecule that contributes to the structural integrity of the peritrophic membrane, a tubular sheath of cuticle that shields the epithelial cells of the midgut from the gut contents. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, ISBN:0879694238]","metadata":null},{"id":"88d6b91742114afcbe053bae2be23852","type":"GO_TERM","name":"structural constituent of postsynapse","canonical_id":"go:GO:0099186","description":"\"The action of a molecule that contributes to the structural integrity of a postsynapse.\" [GOC:dos]","metadata":null},{"id":"68cc39a18f774db3a6da02683d4f3ef5","type":"GO_TERM","name":"structural constituent of postsynaptic actin cytoskeleton","canonical_id":"go:GO:0098973","description":"\"The action of a molecule that contributes to the structural integrity of a postsynaptic actin cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"e0ad7d5dcd1f4e699414c6c5a8c12904","type":"GO_TERM","name":"structural constituent of postsynaptic density","canonical_id":"go:GO:0098919","description":"\"The action of a molecule that contributes to the structural integrity of a postsynaptic density.\" [GOC:dos]","metadata":null},{"id":"244d2b6a95c3478c864a52a80c022b19","type":"GO_TERM","name":"structural constituent of postsynaptic intermediate filament cytoskeleton","canonical_id":"go:GO:0099184","description":"\"The action of a molecule that contributes to the structural integrity of a postsynaptic intermediate filament cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"e474b8f28dbe4db78393d4c38de82ab7","type":"GO_TERM","name":"structural constituent of postsynaptic specialization","canonical_id":"go:GO:0098879","description":"\"The action of a molecule that contributes to the structural integrity of a postsynaptic specialization.\" [GOC:dos]","metadata":null},{"id":"b6be576432d84aba8fa67b5c09886dd6","type":"GO_TERM","name":"structural constituent of presynapse","canonical_id":"go:GO:0099181","description":"\"The action of a molecule that contributes to the structural integrity of a presynapse.\" [GOC:dos, PMID:23751498]","metadata":null},{"id":"f611daa3c56548928b9a09bb7caa942b","type":"GO_TERM","name":"structural constituent of presynaptic actin cytoskeleton","canonical_id":"go:GO:0098699","description":"\"The action of a molecule that contributes to the structural integrity of a presynaptic actin cytoskeleton.\" [GOC:dos]","metadata":null},{"id":"4187b993568249baa629d8e161a11757","type":"GO_TERM","name":"structural constituent of presynaptic active zone","canonical_id":"go:GO:0098882","description":"\"The action of a molecule that contributes to the structural integrity of a presynaptic active zone.\" [GOC:dos]","metadata":null},{"id":"debcdcf867114b7a8ca833881b9da561","type":"GO_TERM","name":"structural constituent of proteasome","canonical_id":"go:GO:0140756","description":"\"The action of a molecule that contributes to the structural integrity of the proteasome.\" [PMID:10500111, PMID:28525752, PMID:28583440, PMID:29652515]","metadata":null},{"id":"8ed1f048d49c4d458bcfcb11d06dcfde","type":"GO_TERM","name":"structural constituent of pupal chitin-based cuticle","canonical_id":"go:GO:0008011","description":"\"The action of a molecule that contributes to the structural integrity of the chitin-based cuticle of a pupa. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"55692506fbf44b3292d4068c0a4ea39f","type":"GO_TERM","name":"structural constituent of ribosome","canonical_id":"go:GO:0003735","description":"\"The action of a molecule that contributes to the structural integrity of the ribosome.\" [GOC:mah]","metadata":null},{"id":"54d5a0e9aecf4338972c1b1e02d5b97c","type":"GO_TERM","name":"structural constituent of skin epidermis","canonical_id":"go:GO:0030280","description":"\"The action of a molecule that contributes to the structural integrity of an epidermal cutaneous structure.\" [GOC:mah]","metadata":null},{"id":"7735cdf9adb24863ac687d34e48d15d1","type":"GO_TERM","name":"structural constituent of synapse","canonical_id":"go:GO:0098918","description":"\"The action of a molecule that contributes to the structural integrity of a synapse.\" [GOC:dos]","metadata":null},{"id":"1bf6e875e1a54a04be9e466abbf56948","type":"GO_TERM","name":"structural constituent of synapse-associated extracellular matrix","canonical_id":"go:GO:0150043","description":"\"The action of a molecule that contributes to the structural integrity of the extracellular matrix of the perisynaptic space (the extracellular space adjacent to the synapse) and the synaptic cleft.\" [GOC:aruk, GOC:bc, PMID:17189701]","metadata":null},{"id":"bc299d1e3fc84894a1a09405ff356534","type":"GO_TERM","name":"structural constituent of tooth enamel","canonical_id":"go:GO:0030345","description":"\"The action of a molecule that contributes to the structural integrity of tooth enamel.\" [GOC:mah]","metadata":null},{"id":"2f6ef75a678d49ad9a2a6873ccfd91c5","type":"GO_TERM","name":"structural constituent of virion","canonical_id":"go:GO:0039660","description":"\"The action of a molecule that contributes to the structural integrity of a virion.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"744270bb899c479e9f1ca3702ca10d8f","type":"GO_TERM","name":"structural constituent of vitelline membrane","canonical_id":"go:GO:0008316","description":"\"The action of a molecule that contributes to the structural integrity of the vitelline membrane of an egg. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:sensu]","metadata":null},{"id":"525220a6d77e464fa042a00eb834dced","type":"GO_TERM","name":"structural molecule activity","canonical_id":"go:GO:0005198","description":"\"The action of a molecule that contributes to the structural integrity of a complex.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"22a668020d5e49afb3cd649c2963b9e8","type":"GO_TERM","name":"structural molecule activity conferring elasticity","canonical_id":"go:GO:0097493","description":"\"The action of a molecule that contributes to the structural integrity of a complex or assembly within or outside a cell, providing elasticity and recoiling.\" [GOC:BHF, GOC:rl, PMID:23283722]","metadata":null},{"id":"203639c1293f438a8997408674646d40","type":"GO_TERM","name":"style development","canonical_id":"go:GO:0048479","description":"\"The process whose specific outcome is the progression of the style over time, from its formation to the mature structure. The style is an elongated part of a carpel, or group of fused carpels, and it lies between the ovary and the stigma.\" [GOC:jid, PO:0009074]","metadata":null},{"id":"f7e267778455484ba5f22f9c95062698","type":"GO_TERM","name":"styrene catabolic process","canonical_id":"go:GO:0042207","description":"\"The chemical reactions and pathways resulting in the breakdown of styrene, an aromatic hydrocarbon liquid used in the manufacture of polystyrene.\" [GOC:jl]","metadata":null},{"id":"afc9807a53ec45fba4ee44cad6607643","type":"GO_TERM","name":"styrene-oxide isomerase activity","canonical_id":"go:GO:0018846","description":"\"Catalysis of the reaction: styrene oxide = phenylacetaldehyde.\" [EC:5.3.99.7, RHEA:21604]","metadata":null},{"id":"74c6874796a74fdebbcfdb479fc02136","type":"GO_TERM","name":"sub-surface cisterna","canonical_id":"go:GO:1990040","description":"\"Specialization of the hypolemmal cisterna consisting of either single profiles or closely apposed stacks of endoplasmic reticulum in which the lumen is obliterated, lying 10-20 nm beneath the plasma membrane.\" [ISBN:0195065719, NIF_Subcellular:sao128470897]","metadata":null},{"id":"5bccd42815f34a94860221ea92023cd2","type":"DISEASE","name":"subacute thyroiditis","canonical_id":"mondo:0006982","description":null,"metadata":null},{"id":"4b9a7da913464351ab6cb9d9d77348bd","type":"GO_TERM","name":"subapical complex","canonical_id":"go:GO:0035003","description":"\"The most apical region of the lateral plasma membrane of an invertebrate epithelial cell. The subapical complex lies above the zonula adherens and the septate junction, and is comparable to the position of the tight junction of vertebrate cells.\" [PMID:11752566, PMID:12500938]","metadata":null},{"id":"f94876c717b64a1eb135a72551f51bfc","type":"GO_TERM","name":"subapical part of cell","canonical_id":"go:GO:0120219","description":"\"The region of a polarized cell that is just below the apical region. For example, in a polarized epithelial cell, the apical region has an exposed surface and lies opposite to the basal lamina that separates the epithelium from other tissue so the subapical region is further from the exposed surface and closer to the basal lamina.\" [GOC:krc, PMID:29891944]","metadata":null},{"id":"0bf32ecdf33d4a888c03196fd0fd74d8","type":"DISEASE","name":"subarachnoid hemorrhage","canonical_id":"mondo:0005099","description":null,"metadata":null},{"id":"14c62b7b11664c33aeda8fb2d38a9d05","type":"GO_TERM","name":"subcortical maternal complex","canonical_id":"go:GO:0106333","description":"\"Comprised of at least NLRP5, OOEP, TLE6, and KHDC3/KHDC3L with evidence of additional SCMC-associated proteins that interact with one or multiple members of the core complex.\" [PMID:18804437, PMID:28992324]","metadata":null},{"id":"2ed62d8611304383ac59c029c46fa89b","type":"GO_TERM","name":"suberin biosynthetic process","canonical_id":"go:GO:0010345","description":"\"The chemical reactions and pathways resulting in the formation of suberin monomers and suberin polyesters. Suberin monomers are derived from fatty acids and trans-cinnamic acids. The monomers are then cross-linked with glycerols.\" [PMID:17259262]","metadata":null},{"id":"f6a364fcf9c247a1b3a650817cecbfca","type":"GO_TERM","name":"suberin network","canonical_id":"go:GO:0048225","description":"\"An extracellular matrix part that consists of fatty acid-derived polymers, including both aromatic and aliphatic components. The suberin network is found in specialized plant cell walls, where it is laid down between the primary wall and plasma membrane, forms protective and wound-healing layers, and provides a water-impermeable diffusion barrier.\" [GOC:jid, GOC:mah, PMID:18440267, PMID:7706282]","metadata":null},{"id":"b8f54091fa7647a7a5a354529fbb1583","type":"GO_TERM","name":"submandibular salivary gland formation","canonical_id":"go:GO:0060661","description":"\"The developmental process pertaining to the initial formation of a submandibular salivary gland. This process begins with a thickening of the epithelium next to the tongue and ends when a bud linked to the oral surface is formed.\" [GOC:dph, PMID:17336109]","metadata":null},{"id":"f018556eb7e04c9e942ad0e5aee5eed8","type":"GO_TERM","name":"submerged biofilm formation","canonical_id":"go:GO:0090605","description":"\"A process in which planktonically growing microorganisms aggregate and grow on solid substrates under the flow of a liquid and produce extracellular polymers that facilitate attachment and matrix formation, resulting in a change in the organisms' growth rate and gene transcription.\" [GOC:di, GOC:tb]","metadata":null},{"id":"71e306f3567f4857b4855e3b17eabe8a","type":"GO_TERM","name":"subnuclear spatial organization of silent mating-type cassette heterochromatin","canonical_id":"go:GO:0140464","description":"\"The localization of silent mating-type cassette heterochromatin at a specific location in the nucleus.\" [PMID:26744419]","metadata":null},{"id":"dd0e7a95589e45408f2b94890dd47dca","type":"GO_TERM","name":"subpallium cell migration","canonical_id":"go:GO:0021980","description":"\"The orderly movement of cells from one site to another in the subpallium.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3630530688dd4af6b4fbd5924048baac","type":"GO_TERM","name":"subpallium cell proliferation in forebrain","canonical_id":"go:GO:0022012","description":"\"The multiplication or reproduction of subpallium cells in the forebrain, resulting in the expansion of a cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d0032d2889464363969f13d78f7692ce","type":"GO_TERM","name":"subpallium development","canonical_id":"go:GO:0021544","description":"\"The process whose specific outcome is the progression of the subpallium over time, from its formation to the mature structure. The subpallium is the base region of the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"07bac931e1b840d7a765a74190452b13","type":"GO_TERM","name":"subpallium glioblast cell division","canonical_id":"go:GO:0021850","description":"\"The division of glioblasts in the subpallium. These cells will give rise to oligodendrocytes.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"0f6fef341d984eccb3f93fa279973cec","type":"GO_TERM","name":"subpallium neuron fate commitment","canonical_id":"go:GO:0060163","description":"\"The process in which in the subpallium, the developmental fate of a cell becomes restricted such that it will develop into a neuron. The subpallium is the base region of the telencephalon.\" [GOC:dph]","metadata":null},{"id":"067c16cb078540bf968ee7179d62b98d","type":"GO_TERM","name":"subpallium radially oriented migration","canonical_id":"go:GO:0021981","description":"\"The migration of cells in the developing subpallium in which cells move from the ventricular and/or subventricular zone toward the surface of the brain.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"24717cbf329e40eaa0c986e4b4dd8033","type":"GO_TERM","name":"subpellicular microtubule","canonical_id":"go:GO:0020025","description":"\"Singlet microtubule that lie underneath the inner membrane pellicle complex and emanate from the basal ring of the conoid.\" [GOC:mb, PMID:24800253]","metadata":null},{"id":"c5a08a44f6474f2d96e6ad1c1f36c3a8","type":"GO_TERM","name":"subpellicular network","canonical_id":"go:GO:0020038","description":"\"A mechanically stable cytoskeletal structure associated with the cytoplasmic face of the pellicle and surrounding the microtubule-based cytoskeleton.\" [PMID:11420112]","metadata":null},{"id":"7f96c04515bb45b986cd2602a3820b07","type":"GO_TERM","name":"subplasmalemmal coating","canonical_id":"go:GO:0044280","description":"\"Electron dense material observed coating the cytoplasmic face of the plasma membrane in certain regions of a neuron, e.g., the axon initial segment; the nodal membrane at the Node of Ranvier.\" [NIF_Subcellular:sao1938587839]","metadata":null},{"id":"8cbda3c9bcf348758916a97737c56053","type":"GO_TERM","name":"subrhabdomeral cisterna","canonical_id":"go:GO:0016029","description":"\"A membrane-bounded compartment that is found at the base of the rhabdomere and contains stored calcium, InsP3 receptors and smooth endoplasmic reticulum Ca2+-ATPase.\" [PMID:11707492, PMID:8646774]","metadata":null},{"id":"f8823e0fe1d44de09150049493197286","type":"GO_TERM","name":"substance K receptor activity","canonical_id":"go:GO:0016497","description":"\"Combining with substance K, the peptide His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met, to initiate a change in cell activity.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"7d0e9a49dc9e483aa946dcabf33fde91","type":"GO_TERM","name":"substance K receptor binding","canonical_id":"go:GO:0031837","description":"\"Binding to a substance K receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ae6cffc27ce44162be86a934f1cde148","type":"GO_TERM","name":"substance P catabolic process","canonical_id":"go:GO:0010814","description":"\"The chemical reactions and pathways resulting in the breakdown of the neuropeptide substance P.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"1a93d4a96c364720b7782445b339af64","type":"GO_TERM","name":"substance P receptor activity","canonical_id":"go:GO:0016496","description":"\"Combining with substance P, the peptide Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met, to initiate a change in cell activity.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"30e8bb81c80140d7af50ce02ad569d25","type":"GO_TERM","name":"substance P receptor binding","canonical_id":"go:GO:0031835","description":"\"Binding to a substance P receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"96f83355d9834adebdca183923a5ba00","type":"GO_TERM","name":"substance P secretion","canonical_id":"go:GO:1990772","description":"\"The regulated release of substance P, a peptide hormone that is involved in neurotransmission, inflammation, and antimicrobial activity.\" [PMID:11278900]","metadata":null},{"id":"4a81644475c24b028389ebde271b2213","type":"GO_TERM","name":"substance P secretion, neurotransmission","canonical_id":"go:GO:1990793","description":"\"The controlled release of substance P by a cell, in which the substance P acts as a neurotransmitter.\" [PMID:15292051]","metadata":null},{"id":"a25cbd478a4c45a58d6b3b8880bd0c15","type":"DISEASE","name":"substance-related disorder","canonical_id":"mondo:0002494","description":null,"metadata":null},{"id":"1500d73117c640ef976ebeeae81c28c3","type":"GO_TERM","name":"substantia nigra development","canonical_id":"go:GO:0021762","description":"\"The progression of the substantia nigra over time from its initial formation until its mature state. The substantia nigra is the layer of gray substance that separates the posterior parts of the cerebral peduncles (tegmentum mesencephali) from the anterior parts; it normally includes a posterior compact part with many pigmented cells (pars compacta) and an anterior reticular part whose cells contain little pigment (pars reticularis).\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343, ISBN:0878937420]","metadata":null},{"id":"588a441fa50041a1bd1f1e673ae4eebf","type":"GO_TERM","name":"substantia propria of cornea development","canonical_id":"go:GO:1903701","description":"\"The process whose specific outcome is the progression of a substantia propria of cornea over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, PMID:12556382]","metadata":null},{"id":"83f11fb910be46cf9611ddc344511b71","type":"GO_TERM","name":"substituted mannan metabolic process","canonical_id":"go:GO:0006080","description":"\"The chemical reactions and pathways involving a mannan backbone composed of D-mannose unites, substituted with D-glucose and/or D-galactose units.\" [GOC:tair_curators]","metadata":null},{"id":"363315dc7d6a41cfa7482fbcba8a23c1","type":"GO_TERM","name":"substrate adhesion-dependent cell spreading","canonical_id":"go:GO:0034446","description":"\"The morphogenetic process that results in flattening of a cell as a consequence of its adhesion to a substrate.\" [GOC:mah, GOC:pf, PMID:17050732]","metadata":null},{"id":"bbe0d3bd331140c7876f5cdbe25e5489","type":"GO_TERM","name":"substrate localization to autophagosome","canonical_id":"go:GO:0061753","description":"\"The localization process by which an autophagic substrate is delivered to a forming autophagosome.\" [GOC:dph, GOC:pad, GOC:PARL, PMID:23545414]","metadata":null},{"id":"9766676131ae44f1adf680e8009d4371","type":"GO_TERM","name":"substrate mycelium formation","canonical_id":"go:GO:0097738","description":"\"The process by which, in some fungal species, hyphae grow as a network of invasive thread-like filaments formed from chains of attached cells within a solid or semi-solid substrate.\" [GOC:di, PMID:10021365]","metadata":null},{"id":"33be00d56a084685800ecf192b756e9e","type":"GO_TERM","name":"substrate-bound cell migration, adhesion receptor recycling","canonical_id":"go:GO:0006934","description":"\"The directed movement of accumulated adhesion components such as integrins from the rear of a migrating cell toward the cell front, where they are available to form new protrusions and adhesions.\" [PMID:11944043]","metadata":null},{"id":"8bc3cc5a975f4d35b8aa6d5faf06ed16","type":"GO_TERM","name":"substrate-dependent cell migration","canonical_id":"go:GO:0006929","description":"\"The orderly movement of a cell from one site to another along a substrate such as the extracellular matrix; the migrating cell forms a protrusion that attaches to the substrate.\" [ISBN:0815316194, PMID:11944043, PMID:14657486]","metadata":null},{"id":"83adf690567a401e862953eb700198df","type":"GO_TERM","name":"substrate-dependent cell migration, cell attachment to substrate","canonical_id":"go:GO:0006931","description":"\"The formation of adhesions that stabilize protrusions at the leading edge of a migrating cell; involves integrin activation, clustering, and the recruitment of structural and signaling components to nascent adhesions.\" [ISBN:0815316194, PMID:11944043, PMID:14657486]","metadata":null},{"id":"410fc29095d7454fac447f5b01e60f58","type":"GO_TERM","name":"substrate-dependent cell migration, cell contraction","canonical_id":"go:GO:0006932","description":"\"The translocation of the cell body forward during cell migration, mediated by tractional force on its substrate and tension in the cortical cytoskeleton. Adhesions transmit propulsive forces and serve as traction points over which the cell moves.\" [ISBN:0815316194, PMID:11944043, PMID:14657486]","metadata":null},{"id":"4cf225bf34c2493385a7ae1a74653b41","type":"GO_TERM","name":"substrate-dependent cell migration, cell extension","canonical_id":"go:GO:0006930","description":"\"The formation of a cell surface protrusion, such as a lamellipodium or filopodium, at the leading edge of a migrating cell.\" [ISBN:0815316194, PMID:11944043, PMID:14657486]","metadata":null},{"id":"d9773e4c78a340f1b16b5393eeac40ec","type":"GO_TERM","name":"substrate-dependent cerebral cortex tangential migration","canonical_id":"go:GO:0021825","description":"\"The process where neuronal precursors migrate tangentially in the cerebral cortex, primarily guided through physical cell-cell interactions.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"833f78dfc11546a39e0f101b2f8ea31f","type":"GO_TERM","name":"substrate-independent telencephalic tangential interneuron migration","canonical_id":"go:GO:0021843","description":"\"The directional movement of tangentially migrating interneurons that are not guided by attaching to extracellular substrates.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"fc40f93175684e2aa2ab3adf88c0feea","type":"GO_TERM","name":"substrate-independent telencephalic tangential migration","canonical_id":"go:GO:0021826","description":"\"The process where neuronal precursors migrate tangentially in the telencephalon, primarily guided by interactions that do not require cell-cell contact.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"e163251895ba48608e2912bd90e46598","type":"GO_TERM","name":"subsynaptic reticulum","canonical_id":"go:GO:0071212","description":"\"An elaborate tubulolamellar membrane system that underlies the postsynaptic cell membrane.\" [PMID:1460464, PMID:18171947, PMID:19244343, PMID:7946331]","metadata":null},{"id":"82577a30a36e499f95fdadbf4aee73e1","type":"GO_TERM","name":"subsynaptic reticulum organization","canonical_id":"go:GO:1990255","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a subsynaptic reticulum. A subsynaptic reticulum is an elaborate tubulolamellar membrane system that underlies the postsynaptic cell membrane.\" [PMID:21041451]","metadata":null},{"id":"23bc462455514d5c8395b26c675fdf4d","type":"GO_TERM","name":"subtelomeric heterochromatin","canonical_id":"go:GO:0140720","description":"\"Heterochromatin that is located adjacent to the telomere, and characterized by methylated H3 histone at lysine 9 (H3K9me2/H3K9me3).\" [PMID:34576871]","metadata":null},{"id":"c27368841b384a478c3a8e09e5af1cbb","type":"GO_TERM","name":"subtelomeric heterochromatin formation","canonical_id":"go:GO:0031509","description":"\"The compaction of chromatin into heterochromatin at the subtelomeric region.\" [GOC:mah, PMID:10219245, PMID:26205977]","metadata":null},{"id":"fecd4b53d0e8456d910955433b6c7a08","type":"GO_TERM","name":"subthalamic nucleus development","canonical_id":"go:GO:0021763","description":"\"The progression of the subthalamic nucleus over time from its initial formation until its mature state. The subthalamic nucleus is the lens-shaped nucleus located in the ventral part of the subthalamus on the inner aspect of the internal capsule that is concerned with the integration of somatic motor function.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"825383a2a6d7496b866b5db119a4bbb9","type":"GO_TERM","name":"subthalamus development","canonical_id":"go:GO:0021539","description":"\"The process whose specific outcome is the progression of the subthalamus over time, from its formation to the mature structure. The subthalamus is the anterior part of the diencephalon that lies between the thalamus, hypothalamus, and tegmentum of the mesencephalon, including subthalamic nucleus, zona incerta, the fields of Forel, and the nucleus of ansa lenticularis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"24c291fa37094db48049c63b64f1a0ff","type":"GO_TERM","name":"subtype 3 bombesin receptor binding","canonical_id":"go:GO:0031706","description":"\"Binding to a subtype 3 bombesin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"008e44d6e02849879d29f8c53da1abfe","type":"GO_TERM","name":"succinate dehydrogenase (FAD) activity","canonical_id":"go:GO:0160308","description":"\"Catalysis of the reaction: FAD + succinate + H+ = fumarate + FADH2.\" [RHEA:30343, WIKIPEDIA:SDHA]","metadata":null},{"id":"8f174b4d5dbb4de192bf27332e0b9d1a","type":"GO_TERM","name":"succinate dehydrogenase (quinone) activity","canonical_id":"go:GO:0008177","description":"\"Catalysis of the reaction: a quinone + succinate = a quinol + fumarate.\" [RHEA:40523]","metadata":null},{"id":"38d2713452604e9f989962feb78bdcfb","type":"GO_TERM","name":"succinate dehydrogenase activity","canonical_id":"go:GO:0000104","description":"\"Catalysis of the reaction: succinate + acceptor = fumarate + reduced acceptor.\" [RHEA:16357]","metadata":null},{"id":"0aa8893845114bf7906366eae56a0281","type":"GO_TERM","name":"succinate import across plasma membrane","canonical_id":"go:GO:0098720","description":"\"The directed movement of succinate from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"0677059b11524bdb982e3c2555933e92","type":"GO_TERM","name":"succinate metabolic process","canonical_id":"go:GO:0006105","description":"\"The chemical reactions and pathways involving succinate, also known as butanedioate or ethane dicarboxylate, the dianion of succinic acid. Succinate is an important intermediate in metabolism and a component of the TCA cycle.\" [ISBN:0198506732]","metadata":null},{"id":"34fdf6fe2d884936ad9213373d6c2ddd","type":"GO_TERM","name":"succinate transmembrane transport","canonical_id":"go:GO:0071422","description":"\"The process in which succinate is transported across a membrane.\" [GOC:mah]","metadata":null},{"id":"2e293acd428f4972a1cb0e5c4a1b825f","type":"GO_TERM","name":"succinate transmembrane transporter activity","canonical_id":"go:GO:0015141","description":"\"Enables the transfer of succinate, the dianion of ethane dicarboxylic acid, from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"97d29c6eca324ff49a3b9e30020dfd99","type":"GO_TERM","name":"succinate transport","canonical_id":"go:GO:0015744","description":"\"The directed movement of succinate, the dianion of ethane dicarboxylic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"fd9bb8b500a84defb0effec48718ad2a","type":"GO_TERM","name":"succinate-CoA ligase (ADP-forming) activity","canonical_id":"go:GO:0004775","description":"\"Catalysis of the reaction: ATP + succinate + CoA = ADP + succinyl-CoA + phosphate.\" [PMID:9874242, RHEA:17661]","metadata":null},{"id":"1d5904c0233f4f98ab8f12d60c9daa6b","type":"GO_TERM","name":"succinate-CoA ligase (GDP-forming) activity","canonical_id":"go:GO:0004776","description":"\"Catalysis of the reaction: GTP + succinate + CoA = GDP + succinyl-CoA + phosphate.\" [RHEA:22120]","metadata":null},{"id":"8d1fa825e1e942a8a844f74d3ce9e8d6","type":"GO_TERM","name":"succinate-CoA ligase activity","canonical_id":"go:GO:0004774","description":"\"Catalysis of the reaction: succinate + CoA + nucleotide triphosphate = nucleotide diphosphate + phosphate + succinyl-CoA.\" [GOC:ai]","metadata":null},{"id":"876c63a2338a41b5ad7f973bc601f694","type":"GO_TERM","name":"succinate-CoA ligase complex","canonical_id":"go:GO:0042709","description":"\"A heterodimeric enzyme complex, usually composed of an alpha and beta chain. Functions in the TCA cycle, hydrolyzing succinyl-CoA into succinate and CoA, thereby forming ATP or GTP.\" [GOC:jl, PMID:10671455]","metadata":null},{"id":"938b5f59b01d4a7fb15b97f55996b1a8","type":"GO_TERM","name":"succinate-CoA ligase complex (ADP-forming)","canonical_id":"go:GO:0009361","description":"\"A heterodimeric enzyme complex, composed of an alpha and beta chain, most usually found in (but not limited to) bacteria. Functions in the TCA cycle, hydrolyzing succinyl-CoA into succinate and CoA, thereby forming ATP.\" [GOC:jl, PMID:9874242]","metadata":null},{"id":"b937a9795ea546329527af2944748184","type":"GO_TERM","name":"succinate-CoA ligase complex (GDP-forming)","canonical_id":"go:GO:0045244","description":"\"A heterodimeric enzyme complex, usually composed of an alpha and beta chain. Functions in the TCA cycle, hydrolyzing succinyl-CoA into succinate and CoA, thereby forming GTP.\" [GOC:jl, PMID:27487822]","metadata":null},{"id":"b95fbd9f46ef48a9991511f09e35e7e1","type":"GO_TERM","name":"succinate-citramalate CoA-transferase activity","canonical_id":"go:GO:0047370","description":"\"Catalysis of the reaction: S-citramalate + succinyl-CoA = citramalyl-CoA + succinate.\" [PMID:16547052, RHEA:38287]","metadata":null},{"id":"1dff1aec84c24efe925e6247c6dd0411","type":"GO_TERM","name":"succinate-hydroxymethylglutarate CoA-transferase activity","canonical_id":"go:GO:0047369","description":"\"Catalysis of the reaction: 3-hydroxy-3-methylglutarate + succinyl-CoA = (3S)-3-hydroxy-3-methylglutaryl-CoA + succinate.\" [RHEA:12284]","metadata":null},{"id":"a53285e093e84f32823b53fde87e62d5","type":"GO_TERM","name":"succinate-semialdehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0004777","description":"\"Catalysis of the reaction: succinate semialdehyde + NAD+ + H2O = succinate + NADH + H+.\" [RHEA:13217]","metadata":null},{"id":"8201b86bb86d409288c5243332db014c","type":"GO_TERM","name":"succinate-semialdehyde dehydrogenase (NADP+) activity","canonical_id":"go:GO:0036243","description":"\"Catalysis of the reaction: succinate semialdehyde + NADP+ + H2O = succinate + NADPH + 2 H+.\" [GOC:bf, RHEA:13213]","metadata":null},{"id":"efa6a64db6184313922f6f4749b25ebb","type":"GO_TERM","name":"succinate-semialdehyde dehydrogenase [NAD(P)+] activity","canonical_id":"go:GO:0009013","description":"\"Catalysis of the reaction: succinate semialdehyde + NAD(P)+ + H2O = succinate + NAD(P)H + H+.\" [EC:1.2.1.16]","metadata":null},{"id":"625b5a6cf89d4e5bba5009e9fffb830e","type":"GO_TERM","name":"succinate-semialdehyde dehydrogenase binding","canonical_id":"go:GO:0032145","description":"\"Binding to succinate-semialdehyde dehydrogenase.\" [GOC:mah]","metadata":null},{"id":"4888e9059a2f40ddb779a90a415a2627","type":"GO_TERM","name":"succinate:fumarate antiporter activity","canonical_id":"go:GO:0005469","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: succinate(out) + fumarate(in) = succinate(in) + fumarate(out).\" [TC:2.A.29.13.1]","metadata":null},{"id":"41d90583d08c4c3d9e3b22bfd8d3d359","type":"GO_TERM","name":"succinate:proton symporter activity","canonical_id":"go:GO:0097434","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: succinate(out) + H+(out) = succinate(in) + H+(in).\" [GOC:al, PMID:1293882]","metadata":null},{"id":"7608d41617d44b7c9230ab17fc4eb1ee","type":"GO_TERM","name":"succinyl-CoA binding","canonical_id":"go:GO:0120226","description":"\"Binding to succinyl-CoA, an omega-carboxyacyl-CoA having succinoyl as the S-acyl component.\" [GOC:krc]","metadata":null},{"id":"1a8e0574befb48d8b435140b55a8bca4","type":"GO_TERM","name":"succinyl-CoA biosynthetic process","canonical_id":"go:GO:1901290","description":"\"The chemical reactions and pathways resulting in the formation of succinyl-CoA.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00929]","metadata":null},{"id":"ed87ffd388a0497b87f767db76566770","type":"GO_TERM","name":"succinyl-CoA catabolic process","canonical_id":"go:GO:1901289","description":"\"The chemical reactions and pathways resulting in the breakdown of succinyl-CoA.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00929]","metadata":null},{"id":"84affb9a82864576bd8f34cb398e63f1","type":"GO_TERM","name":"succinyl-CoA hydrolase activity","canonical_id":"go:GO:0004778","description":"\"Catalysis of the reaction: H2O + succinyl-CoA = CoA + H+ + succinate.\" [EC:3.1.2.3, RHEA:11516]","metadata":null},{"id":"f59f838509e84ef882aaa9129bb6efb4","type":"GO_TERM","name":"succinyl-CoA metabolic process","canonical_id":"go:GO:0006104","description":"\"The chemical reactions and pathways involving succinyl-CoA, a compound composed of the monovalent acyl group 3-carboxypropanoyl, derived from succinic acid by loss of one OH group, linked to coenzyme A.\" [GOC:ai]","metadata":null},{"id":"d8dc3326d02a4cf28e584a806d8a31b6","type":"GO_TERM","name":"succinyl-CoA pathway","canonical_id":"go:GO:0006781","description":"\"The chemical reactions that utilize succinyl-CoA in the synthesis of protoporphyrin IX.\" [GOC:isa_complete, ISBN:0879010479]","metadata":null},{"id":"5b5708205cb742c0bc211beef80851a5","type":"GO_TERM","name":"succinyl-CoA:(R)-benzylsuccinate CoA-transferase activity","canonical_id":"go:GO:0033877","description":"\"Catalysis of the reaction: (R)-2-benzylsuccinate + succinyl-CoA = (R)-2-benzylsuccinyl-CoA + succinate.\" [RHEA:16469]","metadata":null},{"id":"73c8575dd9b046a3a4c4a8b03289d5e7","type":"GO_TERM","name":"succinyl-CoA:(R)-citramalate CoA-transferase activity","canonical_id":"go:GO:0043961","description":"\"Catalysis of the reaction: succinyl-CoA + (R)-citramalate = succinate + (R)-citramalyl-CoA.\" [PMID:17259315, RHEA:38279]","metadata":null},{"id":"232db32f180c47a0b0b6b36c43bb88f0","type":"GO_TERM","name":"succinyl-CoA:3-oxo-acid CoA-transferase activity","canonical_id":"go:GO:0008260","description":"\"Catalysis of the reaction: succinyl-CoA + a 3-oxo acid = succinate + a 3-oxo-acyl-CoA.\" [GOC:vw, PMID:10964512, PMID:8844009, RHEA:24564]","metadata":null},{"id":"1905effc6cc54c3bad14e3ef196c181f","type":"GO_TERM","name":"succinyl-CoA:oxalate CoA-transferase activity","canonical_id":"go:GO:0050161","description":"\"Catalysis of the reaction: oxalate + succinyl-CoA = oxalyl-CoA + succinate.\" [RHEA:23588]","metadata":null},{"id":"d51193f461904d8d949f8dd9da40e307","type":"GO_TERM","name":"succinyl-diaminopimelate desuccinylase activity","canonical_id":"go:GO:0009014","description":"\"Catalysis of the reaction: N-succinyl-LL-2,6-diaminopimelate + H2O = LL-2,6-diaminopimelate + succinate.\" [EC:3.5.1.18, RHEA:22608]","metadata":null},{"id":"241a3814c591427fa2b38367f91770b5","type":"DRUG","name":"succinylcholine","canonical_id":"gtopdb:4004","description":null,"metadata":null},{"id":"90ad25b34d3d4dff9c3daac83fd41b13","type":"GO_TERM","name":"succinyldiaminopimelate:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0009016","description":"\"Catalysis of the reaction: N-succinyl-(2S,6S)-2,6-diaminopimelate + 2-oxoglutarate = (S)-2-succinylamino-6-oxoheptanedioate + L-glutamate.\" [RHEA:11960]","metadata":null},{"id":"5f1ca720415445eb9d5f1f948bc245cf","type":"GO_TERM","name":"succinylglutamate desuccinylase activity","canonical_id":"go:GO:0009017","description":"\"Catalysis of the reaction: N-succinyl-L-glutamate + H2O = L-glutamate + succinate.\" [EC:3.5.1.96, RHEA:15169]","metadata":null},{"id":"b6ce55861cd142d585dbf5943ac179b2","type":"GO_TERM","name":"succinylglutamate-semialdehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0043824","description":"\"Catalysis of the reaction: N-succinyl-L-glutamate 5-semialdehyde + H2O + NAD+ = N-succinyl-L-glutamate + 2 H+ + NADH.\" [EC:1.2.1.71, RHEA:10812]","metadata":null},{"id":"2247a622ca4d46bbbdb4df54155fd8f8","type":"GO_TERM","name":"succinylornithine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0043825","description":"\"Catalysis of the reaction: N(2)-succinyl-L-ornithine + 2-oxoglutarate = N-succinyl-L-glutamate 5-semialdehyde + L-glutamate.\" [RHEA:16953]","metadata":null},{"id":"c94184bbdb6c4597824988769e2ae776","type":"GO_TERM","name":"succinyltransferase activity","canonical_id":"go:GO:0016748","description":"\"Catalysis of the transfer of a succinyl (3-carboxypropanoyl) group to an acceptor molecule.\" [GOC:ai]","metadata":null},{"id":"bff076baed8046dd8a00fc03ce0fe8cb","type":"GO_TERM","name":"suckling behavior","canonical_id":"go:GO:0001967","description":"\"Specific behavior of a newborn or infant mammal that results in the derivation of nourishment from the breast.\" [GOC:dph, GOC:pr]","metadata":null},{"id":"d33e72c7b7ba4ec1996199c3b7340d57","type":"DRUG","name":"sucralfate","canonical_id":"mesh:D013392","description":null,"metadata":null},{"id":"37973ed6188d4dd19cf57bd9bb2a3642","type":"GO_TERM","name":"sucrase-isomaltase complex","canonical_id":"go:GO:0070014","description":"\"A protein complex that possesses oligo-1,6-glucosidase activity; the complex is a heterodimer located in the cell membrane, and is formed by proteolytic cleavage of a single precursor polypeptide. The two subunits have different substrate specificities.\" [PMID:3366777]","metadata":null},{"id":"5c7a7a56c7d64b3589a8bc1305b0fe96","type":"DRUG","name":"sucroferric oxyhydroxide","canonical_id":"mesh:C000599459","description":null,"metadata":null},{"id":"a840c785f8734f01a0fda206bd7da960","type":"GO_TERM","name":"sucrose 1F-fructosyltransferase activity","canonical_id":"go:GO:0050306","description":"\"Catalysis of the reaction: 2 sucrose = D-glucose + 1F-beta-D-fructosylsucrose.\" [EC:2.4.1.99]","metadata":null},{"id":"4ef1f83b1415428f9cc7e24dba015af4","type":"GO_TERM","name":"sucrose 6F-alpha-galactotransferase activity","canonical_id":"go:GO:0047235","description":"\"Catalysis of the reaction: sucrose + UDP-galactose = 6F-alpha-D-galactosylsucrose + UDP.\" [EC:2.4.1.167, MetaCyc:2.4.1.167-RXN]","metadata":null},{"id":"6b148579a0bc4665ae045757e5d373ca","type":"GO_TERM","name":"sucrose alpha-glucosidase activity","canonical_id":"go:GO:0004575","description":"\"Catalysis of the reaction: sucrose + H2O = alpha-D-glucose + beta-D-fructose.\" [RHEA:33795]","metadata":null},{"id":"f509bd3d6fa14c5788de01204264db0b","type":"GO_TERM","name":"sucrose biosynthetic process","canonical_id":"go:GO:0005986","description":"\"The chemical reactions and pathways resulting in the formation of sucrose, the disaccharide fructofuranosyl-glucopyranoside.\" [GOC:curators]","metadata":null},{"id":"6348b4db355d41acb4d231698fa437f2","type":"GO_TERM","name":"sucrose catabolic process","canonical_id":"go:GO:0005987","description":"\"The chemical reactions and pathways resulting in the breakdown of sucrose, the disaccharide fructofuranosyl-glucopyranoside.\" [GOC:curators]","metadata":null},{"id":"3a2f8f59c53c40f5aed8f6886061219c","type":"GO_TERM","name":"sucrose import across plasma membrane","canonical_id":"go:GO:0106082","description":"\"The directed movement of sucrose from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:11136464]","metadata":null},{"id":"bb2ed75a06014eb6bdb9fe5ff48df77d","type":"GO_TERM","name":"sucrose induced translational repression","canonical_id":"go:GO:0080149","description":"\"Any process that stops, prevents or reduces the rate of translation as a result of increase in sucrose level.\" [PMID:19403731]","metadata":null},{"id":"6325a2885feb4654b3ffd57003c30f7f","type":"GO_TERM","name":"sucrose mediated signaling","canonical_id":"go:GO:0009745","description":"\"The series of molecular signals mediated by the detection of sucrose.\" [GOC:sm]","metadata":null},{"id":"5026590cf5fb45ae8742608374af64fe","type":"GO_TERM","name":"sucrose metabolic process","canonical_id":"go:GO:0005985","description":"\"The chemical reactions and pathways involving sucrose, the disaccharide fructofuranosyl-glucopyranoside.\" [GOC:curators]","metadata":null},{"id":"aa1fb657ceb743d286b7a2fafcb57d86","type":"GO_TERM","name":"sucrose phosphorylase activity","canonical_id":"go:GO:0009018","description":"\"Catalysis of the reaction: sucrose + phosphate = D-fructose + alpha-D-glucose 1-phosphate.\" [RHEA:24048]","metadata":null},{"id":"0dc38086595946568e1bd9b4dbd9d488","type":"GO_TERM","name":"sucrose synthase activity","canonical_id":"go:GO:0016157","description":"\"Catalysis of the reaction: an NDP-alpha-D-glucose + D-fructose = a ribonucleoside 5'-diphosphate + H+ + sucrose. The phosphate acceptor can be UDP or ADP.\" [RHEA:16241]","metadata":null},{"id":"0a72a929b4ea4c96b30f7b1f9ec48a01","type":"GO_TERM","name":"sucrose transmembrane transport","canonical_id":"go:GO:1904982","description":"\"The process in which sucrose is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:11136464]","metadata":null},{"id":"b7af5cce7e2e41b4ba981c94741d8397","type":"GO_TERM","name":"sucrose transmembrane transporter activity","canonical_id":"go:GO:0008515","description":"\"Enables the transfer of sucrose from one side of a membrane to the other. Sucrose is the disaccharide O-beta-D-fructofuranosyl-(2->1)-alpha-D-glucopyranoside, a sweet-tasting, non-reducing sugar isolated industrially from sugar beet or sugar cane.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"ee4975c309e94912b92c38bccec0ccf7","type":"GO_TERM","name":"sucrose transport","canonical_id":"go:GO:0015770","description":"\"The directed movement of sucrose into, out of or within a cell, or between cells by means of some agent such as a transporter or pore. Sucrose is the disaccharide fructofuranosyl-glucopyranoside.\" [GOC:ai]","metadata":null},{"id":"e968b122a2154cef9336fb4b8e12f105","type":"GO_TERM","name":"sucrose-phosphate phosphatase activity","canonical_id":"go:GO:0050307","description":"\"Catalysis of the reaction: sucrose 6F-phosphate + H2O = sucrose + phosphate.\" [EC:3.1.3.24, MetaCyc:SUCROSE-PHOSPHATASE-RXN]","metadata":null},{"id":"0b6529482b2a4bcabdca93dc8a770a1c","type":"GO_TERM","name":"sucrose-phosphate synthase activity","canonical_id":"go:GO:0046524","description":"\"Catalysis of the reaction: UDP-glucose + D-fructose 6-phosphate = UDP + sucrose 6-phosphate.\" [EC:2.4.1.14]","metadata":null},{"id":"3ff9a060657a4b26a8b8b5a0c0f823f1","type":"GO_TERM","name":"sucrose:monoatomic cation symporter activity","canonical_id":"go:GO:0009669","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sucrose(out) + monovalent cation(out) = sucrose(in) + monovalent cation(in).\" [GOC:jy, TC:2.A.2.-.-, TC:2.A.2.4.1]","metadata":null},{"id":"a3a6447be46a4530b5f54b7cf104037d","type":"GO_TERM","name":"sucrose:proton symporter activity","canonical_id":"go:GO:0008506","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sucrose(out) + H+(out) = sucrose(in) + H+(in).\" [TC:2.A.1.5.3]","metadata":null},{"id":"bc735b14cee74f808909d433de1bf9cc","type":"DISEASE","name":"sudden cardiac arrest","canonical_id":"efo:0004278","description":null,"metadata":null},{"id":"272e9451c0e44296a21a890a3ddc1cb3","type":"DISEASE","name":"sudden infant death syndrome","canonical_id":"efo:0005303","description":null,"metadata":null},{"id":"e72b1e0948de4a3cbf0368517ae2c50c","type":"DRUG","name":"sufentanil","canonical_id":"gtopdb:3534","description":null,"metadata":null},{"id":"6f58ba983e7b47178361e3d5c4ed4320","type":"DRUG","name":"sufinpyrazone","canonical_id":"gtopdb:5826","description":null,"metadata":null},{"id":"b19fc24a411740a5a707e2d41eae2175","type":"GO_TERM","name":"sugar mediated signaling pathway","canonical_id":"go:GO:0010182","description":"\"The process in which a change in the level of a mono- or disaccharide such as glucose, fructose or sucrose triggers the expression of genes controlling metabolic and developmental processes.\" [PMID:9014361]","metadata":null},{"id":"5df67c1521c642e49410a4b3b50b03e3","type":"GO_TERM","name":"sugar transmembrane transporter activity","canonical_id":"go:GO:0051119","description":"\"Enables the transfer of a sugar from one side of a membrane to the other. A sugar is any member of a class of sweet, water-soluble, crystallizable carbohydrates, which are the monosaccharides and smaller oligosaccharides.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"3d883c5cc9cb4540b856cf9326db7f65","type":"GO_TERM","name":"sugar-phosphatase activity","canonical_id":"go:GO:0050308","description":"\"Catalysis of the reaction: sugar phosphate + H2O = sugar + phosphate.\" [EC:3.1.3.23]","metadata":null},{"id":"48775384164c473298d3af5c270efd3f","type":"GO_TERM","name":"sugar-terminal-phosphatase activity","canonical_id":"go:GO:0050309","description":"\"Catalysis of the reaction: H2O + sugar phosphorylated on the terminal carbon = a sugar + phosphate.\" [EC:3.1.3.58]","metadata":null},{"id":"bc1006c71d494b58bb6939a8c67cf9da","type":"DISEASE","name":"suicidal ideation","canonical_id":"efo:0004320","description":null,"metadata":null},{"id":"03c209556d8844859348138ec2dcc5c5","type":"DRUG","name":"sulbactam","canonical_id":"mesh:D013407","description":null,"metadata":null},{"id":"4a60cfd50c3d4848b84838641eb6c820","type":"GO_TERM","name":"sulcatone reductase activity","canonical_id":"go:GO:0050491","description":"\"Catalysis of the reaction: NAD+ + sulcatol = H+ + NADH + sulcatone.\" [EC:1.1.1.260, RHEA:24484]","metadata":null},{"id":"fab7d8f9ca8243db932f3e03638e28bd","type":"DRUG","name":"sulconazole","canonical_id":"mesh:C033308","description":null,"metadata":null},{"id":"eb05a82edf9347d5944ad6a0467f3ac4","type":"DRUG","name":"sulfacetamide","canonical_id":"mesh:D013409","description":null,"metadata":null},{"id":"cc75562d521b4f6c9368494b8acfc727","type":"DRUG","name":"sulfadiazine","canonical_id":"mesh:D013411","description":null,"metadata":null},{"id":"ecb42441a5a4408486c035194d982c79","type":"DRUG","name":"sulfafurazole","canonical_id":"mesh:D013444","description":null,"metadata":null},{"id":"7735eb0111744e42bda0380cd51d9e45","type":"DRUG","name":"sulfasalazine","canonical_id":"mesh:D012460","description":null,"metadata":null},{"id":"5f01b28bc45d4257a64f7312a8b68612","type":"GO_TERM","name":"sulfate adenylyltransferase (ADP) activity","canonical_id":"go:GO:0004780","description":"\"Catalysis of the reaction: ADP + H+ + sulfate = 5'-adenylyl sulfate + phosphate.\" [EC:2.7.7.5, RHEA:16529]","metadata":null},{"id":"e17add674e2940dda8e8d9b63b0b1de4","type":"GO_TERM","name":"sulfate adenylyltransferase (ATP) activity","canonical_id":"go:GO:0004781","description":"\"Catalysis of the reaction: sulfate + ATP + H+ = adenosine 5'-phosphosulfate + diphosphate.\" [RHEA:18133]","metadata":null},{"id":"5f51c26cd1d44be983219c0fe5456055","type":"GO_TERM","name":"sulfate adenylyltransferase activity","canonical_id":"go:GO:0004779","description":"\"Catalysis of the transfer of an adenylyl group from an adenosine nucleotide (ATP or ADP) to sulfate, forming adenylylsulfate.\" [GOC:mah]","metadata":null},{"id":"9bead9a44fec4162962bbca4600cdf59","type":"GO_TERM","name":"sulfate adenylyltransferase complex (ATP)","canonical_id":"go:GO:0009336","description":"\"An enzyme complex that catalyzes the formation adenylylsulfate from sulfate and ATP.\" [PMID:15184554]","metadata":null},{"id":"47f9c4dd37394b7db131a351e19acec9","type":"GO_TERM","name":"sulfate assimilation","canonical_id":"go:GO:0000103","description":"\"The pathways by which inorganic sulfate is processed and incorporated into sulfated compounds.\" [GOC:jl]","metadata":null},{"id":"9d6597fdc9654bb284966b9415794569","type":"GO_TERM","name":"sulfate binding","canonical_id":"go:GO:0043199","description":"\"Binding to sulfate, SO4(2-), a negatively charged small molecule.\" [GOC:mlg]","metadata":null},{"id":"8ba03e741cd5497082b37a0d5ae15781","type":"GO_TERM","name":"sulfate import across plasma membrane","canonical_id":"go:GO:1902434","description":"\"The directed movement of sulfate from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:TermGenie, PMID:14723223]","metadata":null},{"id":"181e5d7c351a4f93b0bd6890fdd93254","type":"GO_TERM","name":"sulfate ion homeostasis","canonical_id":"go:GO:0055063","description":"\"Any process involved in the maintenance of an internal steady state of sulfate ions within an organism or cell.\" [GOC:jid, GOC:mah]","metadata":null},{"id":"a0419f2cbc1f41d1991455dd02f1a97c","type":"GO_TERM","name":"sulfate transmembrane transport","canonical_id":"go:GO:1902358","description":"\"The directed movement of sulfate across a membrane.\" [GOC:dph, GOC:TermGenie, PMID:9055073]","metadata":null},{"id":"2fde04a4d3b84d39973e323f730fc9fc","type":"GO_TERM","name":"sulfate transmembrane transporter activity","canonical_id":"go:GO:0015116","description":"\"Enables the transfer of sulfate ions, SO4(2-), from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"c3ec33461150479bbb9ef7ec81075728","type":"GO_TERM","name":"sulfate:bicarbonate antiporter activity","canonical_id":"go:GO:0015383","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sulfate(out) + bicarbonate(in) = sulfate(in) + bicarbonate(out).\" [TC:2.A.53.2.2]","metadata":null},{"id":"18dfe641cb37497f8184175dbd3bae6f","type":"GO_TERM","name":"sulfate:chloride antiporter activity","canonical_id":"go:GO:0160044","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: chloride(in) + sulfate(out) = chloride(out) + sulfate(in).\" [PMID:17442754]","metadata":null},{"id":"e83fc69244724641ab49764364631528","type":"GO_TERM","name":"sulfate:proton symporter activity","canonical_id":"go:GO:0008512","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: sulfate(out) + H+(out) = sulfate(in) + H+(in).\" [TC:2.A.53.-.-]","metadata":null},{"id":"7741d786bc0849a5a3038b63e55d1695","type":"DRUG","name":"sulfathiazole","canonical_id":"mesh:C005312","description":null,"metadata":null},{"id":"6878d5f358eb47b9a8e8efefc839b8bb","type":"GO_TERM","name":"sulfathiazole transmembrane transport","canonical_id":"go:GO:1902599","description":"\"The directed movement of sulfathiazole across a membrane.\" [GO_REF:0000069, GOC:pr, GOC:TermGenie]","metadata":null},{"id":"d7b0cbc73a8f4e47b1b02a38fab24cc2","type":"GO_TERM","name":"sulfathiazole transmembrane transporter activity","canonical_id":"go:GO:0015546","description":"\"Enables the transfer of sulfathiazole from one side of a membrane to the other. Sulfathiazole is an antibacterial agent of the sulfonamide group.\" [GOC:curators]","metadata":null},{"id":"ee38af865f8e47dcbefd7992bf00977a","type":"GO_TERM","name":"sulfatide binding","canonical_id":"go:GO:0120146","description":"\"Binding to sulfatide, also known as 3-O-sulfogalactosylceramide, SM4, or sulfated galactocerebroside. Sulfatide is a class of sulfoglycolipid, which are glycolipids that contain a sulfate group.\" [GOC:krc, PMID:21525289, PMID:22619219, PMID:22977233, PMID:23574804, PMID:29497057, PMID:3549017, Wikipedia:Sulfatide]","metadata":null},{"id":"e7448eac3f5f4325ad42b732370ff658","type":"GO_TERM","name":"sulfation","canonical_id":"go:GO:0051923","description":"\"The addition of a sulfate group to a molecule.\" [Wikipedia:Sulfation]","metadata":null},{"id":"a342f1b5358c4733ae522734257a555a","type":"GO_TERM","name":"sulfide dehydrogenase activity","canonical_id":"go:GO:0070225","description":"\"Catalysis of the reaction: hydrogen sulfide + oxidized cytochrome c = S + reduced cytochrome c.\" [RHEA:30223]","metadata":null},{"id":"dd7a864530874ed6ad536a4b7fc68296","type":"GO_TERM","name":"sulfide oxidation","canonical_id":"go:GO:0019418","description":"\"The chemical reactions and pathways resulting in the conversion of sufide to sulfite or sulfate.\" [MetaCyc:Sulfide-Oxidation]","metadata":null},{"id":"fd380e59de1f498c88d489fc223f96cb","type":"GO_TERM","name":"sulfide:quinone oxidoreductase activity","canonical_id":"go:GO:0070224","description":"\"Catalysis of the reaction: H2S (hydrogen sulfide) + a quinone = S0 (sulfane sulfur) + a hydroquinone.\" [RHEA:30239]","metadata":null},{"id":"ce86a1f475564d6994c4bedbeaf49015","type":"GO_TERM","name":"sulfinoalanine decarboxylase activity","canonical_id":"go:GO:0004782","description":"\"Catalysis of the reaction: 3-sulfino-L-alanine = hypotaurine + CO2.\" [EC:4.1.1.29]","metadata":null},{"id":"e7b52c06b09f445595b6290f21497b1b","type":"GO_TERM","name":"sulfiredoxin activity","canonical_id":"go:GO:0032542","description":"\"Catalysis of the reaction: peroxiredoxin-(S-hydroxy-S-oxocysteine) + ATP + 2 R-SH = peroxiredoxin-(S-hydroxycysteine) + ADP + phosphate + R-S-S-R.\" [EC:1.8.98.2, PMID:16102934]","metadata":null},{"id":"0e63eb08ad1a4a0ca16ec85393e234ab","type":"GO_TERM","name":"sulfite dehydrogenase activity","canonical_id":"go:GO:0050310","description":"\"Catalysis of the reaction: sulfite + 2 ferricytochrome c + H2O = sulfate + 2 ferrocytochrome c.\" [EC:1.8.2.1, MetaCyc:SULFITE-DEHYDROGENASE-RXN]","metadata":null},{"id":"7a9dc4ad5efe4a34a6d0fecab48db37e","type":"GO_TERM","name":"sulfite export across plasma membrane","canonical_id":"go:GO:0160244","description":"\"The directed movement of sulfite from inside of a cell, across the plasma membrane and into the extracellular region.\" [PMID:17322211, PMID:30859719]","metadata":null},{"id":"a47d11a6bb274219ab23a67e2825c37d","type":"GO_TERM","name":"sulfite oxidase activity","canonical_id":"go:GO:0008482","description":"\"Catalysis of the reaction: H2O + O2 + sulfite = H2O2 + H+ + sulfate.\" [RHEA:24600]","metadata":null},{"id":"4c54d57cecdc43d59fbbc70efe597a5a","type":"GO_TERM","name":"sulfite reductase (NADPH) activity","canonical_id":"go:GO:0004783","description":"\"Catalysis of the reaction: hydrogen sulfide + 3 NADP+ + 3 H2O = sulfite + 3 NADPH + 3 H+.\" [RHEA:13801]","metadata":null},{"id":"0f5bbf5b6fd94d779207d19a7f62e467","type":"GO_TERM","name":"sulfite reductase (coenzyme F420) activity","canonical_id":"go:GO:0052806","description":"\"Catalysis of the reaction: 3 oxidized coenzyme F420-(gamma-L-Glu)(n) + hydrogen sulfide + 3 H2O + 2 H+ = 3 reduced coenzyme F420-(gamma-L-Glu)(n) + sulfite.\" [PMID:16048999, RHEA:42808]","metadata":null},{"id":"4876f45abad045b9916f242f8749f901","type":"GO_TERM","name":"sulfite reductase (ferredoxin) activity","canonical_id":"go:GO:0050311","description":"\"Catalysis of the reaction: hydrogen sulfide + 3 oxidized ferredoxin + 3 H2O = sulfite + 3 reduced ferredoxin.\" [EC:1.8.7.1, MetaCyc:SULFITE-REDUCTASE-FERREDOXIN-RXN]","metadata":null},{"id":"8077fb682336405cb880c93de55eb977","type":"GO_TERM","name":"sulfite reductase complex (NADPH)","canonical_id":"go:GO:0009337","description":"\"A multisubunit iron flavoprotein, which in yeast is composed of 2 alpha and 2 beta subunits. Catalyzes the reduction of sulfite to sulfide.\" [GOC:jl, PMID:6751400]","metadata":null},{"id":"95d35aa686ff4c94865bfd9998b5e925","type":"GO_TERM","name":"sulfite transmembrane transport","canonical_id":"go:GO:0000316","description":"\"The directed movement of sulfite into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"40cc9c56e7d74b1982c16345fce00694","type":"GO_TERM","name":"sulfite transmembrane transporter activity","canonical_id":"go:GO:0000319","description":"\"Enables the transfer of sulfite ions from one side of a membrane to the other.\" [GOC:as]","metadata":null},{"id":"8709288c0680425da7a23ba4aecc5687","type":"GO_TERM","name":"sulfoacetaldehyde acetyltransferase activity","canonical_id":"go:GO:0050487","description":"\"Catalysis of the reaction: acetyl phosphate + H+ + sulfite = phosphate + sulfoacetaldehyde.\" [RHEA:24204]","metadata":null},{"id":"52040be1e93c4498872b57900a36b10f","type":"GO_TERM","name":"sulfoacetaldehyde dehydrogenase (NAD+) activity","canonical_id":"go:GO:0102984","description":"\"Catalysis of the reaction: sulfoacetaldehyde + NAD+ + H2O = sulfoacetate + NADH + 2 H+.\" [RHEA:25637]","metadata":null},{"id":"72ffc55b59d44103851575fbe36e9e60","type":"GO_TERM","name":"sulfolactate sulfo-lyase activity","canonical_id":"go:GO:0034010","description":"\"Catalysis of the reaction: 3-sulfolactate = pyruvate + sulfite.\" [EC:4.4.1.24, RHEA:21428]","metadata":null},{"id":"dd7b953e0d4c4350826a3ed66c2d490b","type":"GO_TERM","name":"sulfolipid biosynthetic process","canonical_id":"go:GO:0046506","description":"\"The chemical reactions and pathways resulting in the formation of sulfolipid, a compound containing a sulfonic acid residue joined by a carbon-sulfur bond to a lipid.\" [PMID:9751667]","metadata":null},{"id":"915047518be845a8aa768370b8f3e611","type":"GO_TERM","name":"sulfolipid metabolic process","canonical_id":"go:GO:0046505","description":"\"The chemical reactions and pathways involving sulfolipids, any compound containing a sulfonic acid residue joined by a carbon-sulfur bond to a lipid.\" [PMID:9751667]","metadata":null},{"id":"0d3d5c51f17144178c3ae1adc51e502e","type":"GO_TERM","name":"sulfonate dioxygenase activity","canonical_id":"go:GO:0000907","description":"\"Catalysis of the reaction: sulfonate + 2-oxoglutarate + O2 = sulfite + aminoacetaldehyde + succinate + CO2.\" [GOC:clt, PMID:10482536]","metadata":null},{"id":"7e09c2f43f804912933d73794e33362d","type":"GO_TERM","name":"sulfonylurea receptor activity","canonical_id":"go:GO:0008281","description":"\"Combining with sulfonylurea, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:ai, GOC:signaling]","metadata":null},{"id":"e05bf8c5d18f453d8fe9e6bbcfa257e7","type":"GO_TERM","name":"sulfonylurea receptor binding","canonical_id":"go:GO:0017098","description":"\"Binding to a sulfonylurea receptor, a regulatory subunit of the ATP-sensitive potassium ion channel.\" [GOC:ceb, PMID:11938023]","metadata":null},{"id":"d0359bc549f84a8b8e34ae490d9de622","type":"GO_TERM","name":"sulfopropanediol 3-dehydrogenase activity","canonical_id":"go:GO:0102157","description":"\"Catalysis of the reaction: (2R)-3-sulfopropanediol + 2 NAD+ + H2O = (2R)-3-sulfolactate + 2 NADH + 3 H+.\" [PMID:20150239, RHEA:28074]","metadata":null},{"id":"a9c08ed8a6e041d1883fb0333ca0379d","type":"GO_TERM","name":"sulfopyruvate decarboxylase activity","canonical_id":"go:GO:0050545","description":"\"Catalysis of the reaction: 3-sulfopyruvate + H+ = CO2 + sulfoacetaldehyde.\" [EC:4.1.1.79, RHEA:20948]","metadata":null},{"id":"43779ed3b9ab442b922dfcec5a011378","type":"GO_TERM","name":"sulfopyruvate decarboxylase complex","canonical_id":"go:GO:0044681","description":"\"A complex of two polypeptides which form a dodecamer (A6B6). Catalyzes the decarboxylation of sulfopyruvic acid to sulfoacetaldehyde. This reaction is involved in coenzyme M biosynthesis.\" [GOC:mengo_curators, PMID:10940029]","metadata":null},{"id":"fae0a46350744cacbe49ec0cbe04ac67","type":"GO_TERM","name":"sulfoquinovose isomerase activity","canonical_id":"go:GO:0061593","description":"\"Catalysis of the reaction: 6-sulfo-beta-D-quinovose = 6-deoxy-6-sulfo-D-fructose.\" [PMID:24463506, RHEA:40439]","metadata":null},{"id":"a26daaab3e3f43f1abed9e20cdbf3764","type":"GO_TERM","name":"sulfoquinovosidase activity","canonical_id":"go:GO:1990929","description":"\"Catalysis of the reaction: a 6-sulfo-alpha-D-quinovosyldiacylglycerol + H2O = 6-sulfo-alpha-D-quinovose + a 1,2-diacyl-sn-glycerol.\" [PMID:26878550, RHEA:49452]","metadata":null},{"id":"8a6db6d4dcec4d8e9fc17db891d79572","type":"GO_TERM","name":"sulfotransferase activity","canonical_id":"go:GO:0008146","description":"\"Catalysis of the transfer of a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate to the hydroxyl group of an acceptor, producing the sulfated derivative and 3'-phosphoadenosine 5'-phosphate.\" [EC:2.8.2.-]","metadata":null},{"id":"338bf83c2db3466c8ea70de5776b4829","type":"DRUG","name":"sulfur","canonical_id":"mesh:D013455","description":null,"metadata":null},{"id":"bedbb95e0f0444b68528dba9c2ab2781","type":"GO_TERM","name":"sulfur amino acid biosynthetic process","canonical_id":"go:GO:0000097","description":"\"The chemical reactions and pathways resulting in the formation of amino acids containing sulfur.\" [GOC:curators]","metadata":null},{"id":"4f06975d31d445ccb05de919af995f72","type":"GO_TERM","name":"sulfur amino acid catabolic process","canonical_id":"go:GO:0000098","description":"\"The chemical reactions and pathways resulting in the breakdown of amino acids containing sulfur.\" [GOC:curators]","metadata":null},{"id":"996a020d052f48368fd23f1ed9fa05ab","type":"GO_TERM","name":"sulfur amino acid metabolic process","canonical_id":"go:GO:0000096","description":"\"The chemical reactions and pathways involving amino acids containing sulfur.\" [GOC:curators]","metadata":null},{"id":"000165de86a34b8895979b385642cdfa","type":"GO_TERM","name":"sulfur amino acid transmembrane transporter activity","canonical_id":"go:GO:0000099","description":"\"Enables the transfer of sulfur amino acids from one side of a membrane to the other. Sulphur amino acids contain sulfur in the form of cystine, methionine or their derivatives.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"005c1d1280bf4a27aa9264f4b4b164a4","type":"GO_TERM","name":"sulfur amino acid transport","canonical_id":"go:GO:0000101","description":"\"The directed movement of amino acids containing sulfur (cystine, methionine and their derivatives) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"c177112526e548b68f84184034fb1a11","type":"GO_TERM","name":"sulfur carrier activity","canonical_id":"go:GO:0097163","description":"\"Covalently binding to sulfur and delivering it to an acceptor molecule.\" [GOC:imk, PMID:16387657]","metadata":null},{"id":"b47ca796801742de85b31f0585fb16a5","type":"GO_TERM","name":"sulfur compound binding","canonical_id":"go:GO:1901681","description":"\"Binding to a sulfur compound.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"c5d1b08e5a49411faaa282b964a9d127","type":"GO_TERM","name":"sulfur compound biosynthetic process","canonical_id":"go:GO:0044272","description":"\"The chemical reactions and pathways resulting in the formation of compounds that contain sulfur, such as the amino acids methionine and cysteine or the tripeptide glutathione.\" [GOC:jl]","metadata":null},{"id":"ce12a0965b3a45f49990a729198ff884","type":"GO_TERM","name":"sulfur compound catabolic process","canonical_id":"go:GO:0044273","description":"\"The chemical reactions and pathways resulting in the breakdown of compounds that contain sulfur, such as the amino acids methionine and cysteine or the tripeptide glutathione.\" [GOC:jl]","metadata":null},{"id":"ff9979fea88c4390ac2a8acc994a1c37","type":"GO_TERM","name":"sulfur compound metabolic process","canonical_id":"go:GO:0006790","description":"\"The chemical reactions and pathways involving the nonmetallic element sulfur or compounds that contain sulfur, such as the amino acids methionine and cysteine or the tripeptide glutathione.\" [GOC:ai]","metadata":null},{"id":"8b3d342c8f764ebe9bfe5435cd42d810","type":"GO_TERM","name":"sulfur compound transmembrane transporter activity","canonical_id":"go:GO:1901682","description":"\"Enables the transfer of a sulfur compound from one side of a membrane to the other.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"97aea8cc2c524d1487aa5fac0635a89c","type":"GO_TERM","name":"sulfur compound transport","canonical_id":"go:GO:0072348","description":"\"The directed movement of compounds that contain sulfur, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"16806c3cf078444db14fbef0fc06eb43","type":"GO_TERM","name":"sulfur dioxygenase activity","canonical_id":"go:GO:0050313","description":"\"Catalysis of the reaction: S-sulfanylglutathione + O2 + H2O = sulfite + glutathione + 2 H+.\" [EC:1.13.11.18]","metadata":null},{"id":"37d4cb7c10c4409fa7a2783d715f6325","type":"GO_TERM","name":"sulfur oxidation","canonical_id":"go:GO:0019417","description":"\"The chemical reactions and pathways resulting the addition of oxygen to elemental sulfur.\" [GOC:jl]","metadata":null},{"id":"540bc4aee0064b5794835aa1de1ce8cf","type":"GO_TERM","name":"sulfur oxygenase/reductase activity","canonical_id":"go:GO:0033755","description":"\"Catalysis of the reaction: 4 sulfur + 4 H2O + O2 = 2 hydrogen sulfide + 2 bisulfite + 2 H+.\" [EC:1.13.11.55, PMID:1522063]","metadata":null},{"id":"3e78036ae7c14f1188ab83eb251d308b","type":"GO_TERM","name":"sulfur reductase activity","canonical_id":"go:GO:0033796","description":"\"Catalysis of the reduction of elemental sulfur or polysulfide to hydrogen sulfide, H2 + n sulfur = H+ + hydrogen sulfide + (n-1) sulfur.\" [RHEA:35591]","metadata":null},{"id":"eef0e2245811462fba4209353c2cd4d7","type":"GO_TERM","name":"sulfur utilization","canonical_id":"go:GO:0006791","description":"\"A series of processes that forms an integrated mechanism by which a cell or an organism detects the depletion of primary sulfur sources and then activates genes to scavenge the last traces of the primary sulfur source and to transport and metabolize alternate sulfur sources. The utilization process begins when the cell or organism detects sulfur levels, includes the activation of genes whose products detect, transport or metabolize sulfur-containing compounds, and ends when the sulfur is incorporated into the cell or organism's metabolism.\" [GOC:mah, GOC:mlg]","metadata":null},{"id":"a1d23293a30f4394a219f4dc8c6dcbce","type":"GO_TERM","name":"sulfurated eukaryotic molybdenum cofactor(2-) biosynthetic process","canonical_id":"go:GO:1902756","description":"\"The chemical reactions and pathways resulting in the formation of sulfurated eukaryotic molybdenum cofactor(2-).\" [GO_REF:0000068, GOC:dph, GOC:TermGenie, PMID:18258600]","metadata":null},{"id":"fdceb8841eb141ee89b7660044a860e5","type":"GO_TERM","name":"sulfuric ester hydrolase activity","canonical_id":"go:GO:0008484","description":"\"Catalysis of the reaction: RSO-R' + H2O = RSOOH + R'H. This reaction is the hydrolysis of a sulfuric ester bond, an ester formed from sulfuric acid, O=SO(OH)2.\" [GOC:ai]","metadata":null},{"id":"0f8679cf8b2f4fc28cb9a6b9b027dbb8","type":"GO_TERM","name":"sulfurtransferase activity","canonical_id":"go:GO:0016783","description":"\"Catalysis of the transfer of sulfur atoms from one compound (donor) to another (acceptor).\" [EC:2.8.1.-, GOC:ai]","metadata":null},{"id":"6895f6c1e75a4e7fb51c7beccccfa986","type":"GO_TERM","name":"sulfurtransferase complex","canonical_id":"go:GO:1990228","description":"\"A protein complex capable of catalyzing the transfer of sulfur atoms from one compound (donor) to another (acceptor).\" [GOC:bhm, PMID:17350958]","metadata":null},{"id":"40b06b7a952e4f74b51313b626aaeaed","type":"GO_TERM","name":"sulochrin oxidase [(+)-bisdechlorogeodin-forming] activity","canonical_id":"go:GO:0047064","description":"\"Catalysis of the reaction: O2 + 2 sulochrin = 2 (2S)-bisdechlorogeodin + 2 H2O.\" [EC:1.21.3.4, RHEA:24092]","metadata":null},{"id":"386931835a9a4149abb4a08b72147839","type":"GO_TERM","name":"sulochrin oxidase [(-)-bisdechlorogeodin-forming] activity","canonical_id":"go:GO:0047065","description":"\"Catalysis of the reaction: O2 + 2 sulochrin = 2 (2R)-bisdechlorogeodin + 2 H2O.\" [EC:1.21.3.5, RHEA:22616]","metadata":null},{"id":"9a9937f667014579bd282732ed6f21a3","type":"GO_TERM","name":"sulphoglycolysis","canonical_id":"go:GO:0061722","description":"\"The chemical reactions and pathways resulting in the breakdown of 6-sulfoquinovose(1-) resulting in the formation of glycerone phosphate (DHAP) and pyruvate.\" [GOC:dph, PMID:24463506]","metadata":null},{"id":"67190e804f6144f280c99998cc498c03","type":"DRUG","name":"sulpiride","canonical_id":"gtopdb:5501","description":null,"metadata":null},{"id":"05f694c2d5a247748bb5d661fe21cda9","type":"DRUG","name":"sulpiride","canonical_id":"mesh:D013469","description":null,"metadata":null},{"id":"78c601cbcd3d493c804ac909e4662880","type":"DRUG","name":"sumatriptan","canonical_id":"gtopdb:54","description":null,"metadata":null},{"id":"7b09383061d447568f823c9d3c318c5c","type":"DRUG","name":"sumatriptan","canonical_id":"mesh:D018170","description":null,"metadata":null},{"id":"572de16587864cf796fd54ddee6d1af2","type":"DRUG","name":"sumatriptan","canonical_id":"chembl:CHEMBL128","description":null,"metadata":null},{"id":"bc6c87e46a2c4425b1c56b2106959b60","type":"DISEASE","name":"sunburn","canonical_id":"mondo:0005326","description":null,"metadata":null},{"id":"efcc7592fe6644048dc994c981d6445d","type":"DRUG","name":"sunitinib","canonical_id":"gtopdb:5713","description":null,"metadata":null},{"id":"56d28b34661f44939afe647f10c9e499","type":"DRUG","name":"sunitinib","canonical_id":"mesh:C473478","description":null,"metadata":null},{"id":"399bbc55b25c444bb61f9b223ec2db66","type":"DRUG","name":"sunitinib","canonical_id":"chembl:CHEMBL535","description":null,"metadata":null},{"id":"79cca39778d0453b9241e0a14c7a993d","type":"GO_TERM","name":"super elongation complex","canonical_id":"go:GO:0032783","description":"\"A transcription elongation factor complex that increases the overall rate of RNA polymerase II transcription elongation by suppressing transient polymerase pausing. At minimum, the complex contains a transcription factor of the ELL family, an EAF protein, and an AFF family protein or distant relative and most likely also P-TEFb and AF9 or ENL. The complex is conserved from yeast to humans. In Schizosaccharomyces pombe it contains Ell1, Eaf1, and Ebp1, but it is absent from S. cerevisiae.\" [PMID:17150956, PMID:30102332]","metadata":null},{"id":"95af107930d44a879a1440bc7f71ed69","type":"GO_TERM","name":"supercoiled DNA binding","canonical_id":"go:GO:0097100","description":"\"Binding to supercoiled DNA. For example, during replication and transcription, template DNA is negatively supercoiled in the receding downstream DNA and positively supercoiled in the approaching downstream DNA.\" [GOC:pr, GOC:rph, PMID:20723754, PMID:21345933, Wikipedia:DNA_supercoil]","metadata":null},{"id":"10416aa1eb6644968938ca1638aa648e","type":"GO_TERM","name":"superinfection exclusion","canonical_id":"go:GO:0098669","description":"\"The process by which a preexisting viral infection prevents a secondary infection with the same or a closely related virus. Typically some aspect of viral entry is inhibited, but post entry mechanisms have also been documented.\" [PMID:11985726, PMID:23692331, PMID:24089557, PMID:8012757, VZ:3971]","metadata":null},{"id":"d56ea5f1f0cb458f8a29bd23ebb8ed59","type":"GO_TERM","name":"superior colliculus development","canonical_id":"go:GO:0061380","description":"\"The process whose specific outcome is the progression of the superior colliculus over time, from its formation to the mature structure. The superior colliculus is also known as the optic tectum or simply tectum and is a paired structure that forms a major component of the vertebrate midbrain.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"b8973a57ff8f40aeb80488a2c0803cb0","type":"GO_TERM","name":"superior endocardial cushion morphogenesis","canonical_id":"go:GO:1905316","description":"\"The developmental process by which a superior endocardial cushion is generated and organized.\" [GO_REF:0000083, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17050629]","metadata":null},{"id":"fcada0a2a0304430a8dc4c019c8955f5","type":"GO_TERM","name":"superior olivary nucleus development","canonical_id":"go:GO:0021718","description":"\"The process whose specific outcome is the progression of the superior olivary nucleus over time, from its formation to the mature structure. In mice, the superior olivary nucleus is a small cylindrical mass on the dorsal surface of the lateral part of the trapezoid body of the pons, and it is situated immediately above the inferior olivary nucleus. It receives projections from the cochlear nucleus and thus is involved in the perception of sound.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"41ac547f39f741bea83c3160b133efe4","type":"GO_TERM","name":"superior olivary nucleus formation","canonical_id":"go:GO:0021720","description":"\"The process that gives rise to the superior olivary nucleus. This process pertains to the initial formation of a structure from unspecified parts. In mice, the superior olivary nucleus is a small cylindrical mass on the dorsal surface of the lateral part of the trapezoid body of the pons, and it is situated immediately above the inferior olivary nucleus. It receives projections from the cochlear nucleus and thus is involved in the perception of sound.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"0c8dfcc8fbea4049a0552d77df5ea46e","type":"GO_TERM","name":"superior olivary nucleus maturation","canonical_id":"go:GO:0021722","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the superior olivary nucleus to attain its fully functional state. The superior olivary nucleus is a small cylindrical mass on the dorsal surface of the lateral part of the trapezoid body of the pons, and it is situated immediately above the inferior olivary nucleus. It receives projections from the cochlear nucleus and thus is involved in the perception of sound.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"d210fb9bc3cb4d65adce787c632dfc5f","type":"GO_TERM","name":"superior olivary nucleus morphogenesis","canonical_id":"go:GO:0021719","description":"\"The process in which the anatomical structure of the superior olivary nucleus is generated and organized. In mice, the superior olivary nucleus is a small cylindrical mass on the dorsal surface of the lateral part of the trapezoid body of the pons, and it is situated immediately above the inferior olivary nucleus. It receives projections from the cochlear nucleus and thus is involved in the perception of sound.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"2f1f49478cf947198b4b77ded21fda10","type":"GO_TERM","name":"superior olivary nucleus structural organization","canonical_id":"go:GO:0021721","description":"\"The process that contributes to the act of creating the structural organization of the superior olivary nucleus structure. In mice, the superior olivary nucleus is a small cylindrical mass on the dorsal surface of the lateral part of the trapezoid body of the pons, and it is situated immediately above the inferior olivary nucleus. It receives projections from the cochlear nucleus and thus is involved in the perception of sound.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"4f4d8975268b4b14a2706f949e9f4c11","type":"GO_TERM","name":"superior raphe nucleus development","canonical_id":"go:GO:0021725","description":"\"The process whose specific outcome is the progression of the superior raphe nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cjm, GOC:cls, GOC:curators, GOC:cvs, GOC:dgh, GOC:dph, GOC:jid, PMID:19003874, ZFA:0000440]","metadata":null},{"id":"63ee88ac39614e74bde5c1cfbe65578c","type":"GO_TERM","name":"superior reticular formation development","canonical_id":"go:GO:0021729","description":"\"The process whose specific outcome is the progression of the superior reticular formation over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"0a53d8bd4b554974ae2c0abb8ccca07b","type":"GO_TERM","name":"superior salivary nucleus development","canonical_id":"go:GO:0021753","description":"\"The process whose specific outcome is the progression of the superior salivary nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"0632bf7056b24aaca7746a03d7a1aa83","type":"GO_TERM","name":"superior temporal gyrus development","canonical_id":"go:GO:0071109","description":"\"The process whose specific outcome is the progression of the superior temporal gyrus over time, from its formation to the mature structure. The superior temporal gyrus is a portion of the cerebral cortex that extends from the lateral sulcus to the superior temporal sulcus.\" [FMA:61905, GOC:BHF, GOC:mah, PMID:11484000]","metadata":null},{"id":"7c521398e3d244dc95c1a37179d76964","type":"GO_TERM","name":"superior vena cava morphogenesis","canonical_id":"go:GO:0060578","description":"\"The process in which the anatomical structure of superior vena cava generated and organized. The superior vena cava is a blood vessel that transports blood from the upper body to the heart.\" [GOC:dph]","metadata":null},{"id":"28a0ff6f775b401785c8e3f4e8d9c1a6","type":"GO_TERM","name":"superoxide anion generation","canonical_id":"go:GO:0042554","description":"\"The enzymatic generation of superoxide, the superoxide anion O2- (superoxide free radical), or any compound containing this species, by a cell in response to environmental stress, thereby mediating the activation of various stress-inducible signaling pathways.\" [GOC:jl, PMID:12359750]","metadata":null},{"id":"3d1fb292ff8a4e518547c6f60ada0a6b","type":"GO_TERM","name":"superoxide dismutase activity","canonical_id":"go:GO:0004784","description":"\"Catalysis of the reaction: 2 superoxide + 2 H+ = O2 + H2O2.\" [EC:1.15.1.1, GOC:vw, PMID:15064408]","metadata":null},{"id":"199466e3936e4b2cb17d9ab9a0ff6494","type":"GO_TERM","name":"superoxide dismutase complex","canonical_id":"go:GO:1902693","description":"\"A protein complex which is capable of superoxide dismutase activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:10026301]","metadata":null},{"id":"9f9673d9dad445149665b855d848d164","type":"GO_TERM","name":"superoxide dismutase copper chaperone activity","canonical_id":"go:GO:0016532","description":"\"A copper chaperone activity that specifically delivers copper to the Cu-Zn superoxide dismutase, to activate superoxide dismutase activity.\" [GOC:vw, http://link.springer-ny.com/link/service/journals/00335/papers/0011005/00110409.html, PMID:15064408, PMID:9295278]","metadata":null},{"id":"b0fa491003f2499c9e692dd255077ecd","type":"GO_TERM","name":"superoxide dismutase copper chaperone complex","canonical_id":"go:GO:1902694","description":"\"A protein complex which is capable of superoxide dismutase copper chaperone activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:10426947]","metadata":null},{"id":"3688cff357ce46249128f5418a700093","type":"GO_TERM","name":"superoxide metabolic process","canonical_id":"go:GO:0006801","description":"\"The chemical reactions and pathways involving superoxide, the superoxide anion O2- (superoxide free radical), or any compound containing this species.\" [GOC:jl]","metadata":null},{"id":"07b5f56fc1484d8780f98574088e1c48","type":"GO_TERM","name":"superoxide reductase activity","canonical_id":"go:GO:0050605","description":"\"Catalysis of the reaction: superoxide + reduced rubredoxin + 2 H+ = H2O2 + rubredoxin.\" [EC:1.15.1.2, MetaCyc:1.15.1.2-RXN]","metadata":null},{"id":"49664fb8e28e44b3b8d7bb86bf507ff3","type":"GO_TERM","name":"superoxide-generating NAD(P)H oxidase activity","canonical_id":"go:GO:0016175","description":"\"Catalysis of the reaction: NAD(P)H + O2 = NAD(P)H + O2-.\" [GOC:ai, PMID:10806195]","metadata":null},{"id":"71003fdbc9684071967b9540fa78cdac","type":"GO_TERM","name":"superoxide-generating NADH oxidase activity","canonical_id":"go:GO:0106291","description":"\"Catalysis of the reaction: NADH + 2 O2 = H+ + NAD+ + 2 superoxide.\" [RHEA:63184]","metadata":null},{"id":"20a4edd1759f485ab370d1f946e1dfce","type":"GO_TERM","name":"superoxide-generating NADPH oxidase activator activity","canonical_id":"go:GO:0016176","description":"\"Binds to and increases the activity of the enzyme superoxide-generating NADPH oxidase.\" [GOC:ai]","metadata":null},{"id":"c0781ca3008d40a0912fe46e43950039","type":"GO_TERM","name":"superoxide-generating NADPH oxidase activity","canonical_id":"go:GO:0106292","description":"\"Catalysis of the reaction: NADPH + 2 O2 = H+ + NADP+ + 2 superoxide.\" [RHEA:63180]","metadata":null},{"id":"cf8d72cf4b174b7b813fa9da63bc6171","type":"GO_TERM","name":"suppression by virus of host cell lysis in response to superinfection","canonical_id":"go:GO:0039639","description":"\"The prevention or delay of host cell lysis by a pre-existing virus in response to a subsequent infection of the host cell by second virus.\" [GOC:bm, GOC:jl, PMID:22389108, PMID:9560373]","metadata":null},{"id":"ac40df37d6144062a0845fb078ad6371","type":"GO_TERM","name":"suppression of symbiont entry into host","canonical_id":"go:GO:0052373","description":"\"Any process in which an organism stops, prevents, or reduces the frequency, rate or extent to which it enters into a second organism, where the two organisms are in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"f75027925fcd45f4b93670a0d06063fe","type":"GO_TERM","name":"suppression of viral release by host","canonical_id":"go:GO:0044790","description":"\"A process in which a host organism stops, prevents or reduces the frequency, rate or extent of the release of a virus with which it is infected, from its cells.\" [GOC:jl, PMID:18305167]","metadata":null},{"id":"781e2771cc21481ea1c0f0231e32cdb3","type":"GO_TERM","name":"supramolecular complex","canonical_id":"go:GO:0099080","description":"\"A cellular component that consists of an indeterminate number of proteins or macromolecular complexes, organized into a regular, higher-order structure such as a polymer, sheet, network or a fiber.\" [GOC:dos]","metadata":null},{"id":"f598525e34d84688b7887c8794a51cbe","type":"GO_TERM","name":"supramolecular fiber","canonical_id":"go:GO:0099512","description":"\"A polymer consisting of an indefinite number of protein or protein complex subunits that have polymerised to form a fiber-shaped structure.\" [GOC:dos]","metadata":null},{"id":"c495a482567d4c01ba8fb029d71b78fe","type":"GO_TERM","name":"supramolecular fiber organization","canonical_id":"go:GO:0097435","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a supramolecular fiber, a polymer consisting of an indefinite number of protein or protein complex subunits that have polymerised to form a fiber-shaped structure.\" [GOC:pr]","metadata":null},{"id":"74873c3044694f3d9549bdfd7ed7c46b","type":"GO_TERM","name":"supramolecular polymer","canonical_id":"go:GO:0099081","description":"\"A polymeric supramolecular structure.\" [GOC:dos]","metadata":null},{"id":"14cf4cdd3e6f47b98d1b9348c8af3f56","type":"GO_TERM","name":"supraspliceosomal complex","canonical_id":"go:GO:0044530","description":"\"Multicomponent complex of RNA and proteins that is composed of four active spliceosomes, termed native spliceosomes, connected to each other by the pre-mRNA. The supraspliceosome is the nuclear machine where the pre-mRNA processing takes place, like the 5'-end capping, 3'-end cleavage, splicing and editing.\" [GOC:ans, GOC:jl, PMID:19282290]","metadata":null},{"id":"6ccf97e3a9b04d0a9b5edf6433cddb70","type":"DRUG","name":"suprofen","canonical_id":"gtopdb:7298","description":null,"metadata":null},{"id":"462955d346b14445b047efe3a63601a3","type":"DRUG","name":"suprofen","canonical_id":"chembl:CHEMBL956","description":null,"metadata":null},{"id":"545f3b1fafca4972b2e292c61f768d68","type":"GO_TERM","name":"suramin binding","canonical_id":"go:GO:0043924","description":"\"Binding to suramin, a naphthalenesulfonic acid compound which is used in the treatment of diseases caused by trypanosomes and worms.\" [GOC:jl, Wikipedia:Suramin]","metadata":null},{"id":"d28db49bda0a437eb5fd05444f5fd1c2","type":"GO_TERM","name":"surface biofilm formation","canonical_id":"go:GO:0090604","description":"\"A process in which planktonically growing microorganisms grow at the surface of a liquid-air interface and produce extracellular polymers that facilitate matrix formation, resulting in a change in the organisms' growth rate and gene transcription.\" [GOC:di, GOC:tb]","metadata":null},{"id":"97fd820e86f04155a70784e07e0e0e4e","type":"GO_TERM","name":"surface coat of collagen and cuticulin-based cuticle extracellular matrix","canonical_id":"go:GO:0060104","description":"\"An electron dense, amorphous envelope that comprises the outermost layer of the cuticle. The surface coat is loosely apposed to the epicuticle, has distinct biochemical properties, is synthesized by cells other than the underlying hypodermis, and is labile. In addition to serving as a lubricant to protect against abrasion and dehydration, the surface coat may also play important roles in infection and immune evasion. An example of this component is found in Caenorhabditis elegans.\" [GOC:dph, GOC:kmv, ISSN:15518507]","metadata":null},{"id":"bbf37795d700468cb3090887b82da271","type":"GO_TERM","name":"surfactant homeostasis","canonical_id":"go:GO:0043129","description":"\"Any process involved in the maintenance of a steady-state level of a surface-active agent that maintains the surface tension of a liquid.\" [PMID:23708874, PMID:9751757]","metadata":null},{"id":"84927f41d57246dd9165ca60f751a95f","type":"GO_TERM","name":"surfactant secretion","canonical_id":"go:GO:0160069","description":"\"The regulated release of surfactant by a cell or tissue.\" [PMID:19824815]","metadata":null},{"id":"acb28ab64ef5464cb8d06899a98b63c9","type":"GO_TERM","name":"survivin complex","canonical_id":"go:GO:1990713","description":"\"A protein complex that negatively regulates apoptotic processes. Complex contains a component which belongs to the family of baculoviral IAP (inhibitor of apoptosis) repeat-containing proteins.\" [GOC:bhm, PMID:10929712, PMID:10949038, PMID:16282325, PMID:19153467]","metadata":null},{"id":"968a8fab8d1a4b649beb09577556a9a0","type":"GO_TERM","name":"susceptibility to T cell mediated cytotoxicity","canonical_id":"go:GO:0060370","description":"\"The process of causing a cell to become susceptible to T cell mediated cytotoxicity.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"366fcebbd231404e8933b72469ea35a2","type":"GO_TERM","name":"susceptibility to natural killer cell mediated cytotoxicity","canonical_id":"go:GO:0042271","description":"\"The process of causing a cell to become susceptible to natural killer cell mediated cytotoxicity.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6600665be74f4de58aec7eb0ba6f518f","type":"GO_TERM","name":"suspensor development","canonical_id":"go:GO:0010098","description":"\"The process whose specific outcome is the progression of the suspensor over time, from its formation to the mature structure. The suspensor is the extension at the base of the embryo that anchors the embryo in the embryo sac and pushes it into the endosperm.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"8fae231eb04544668906db1f01ba1aae","type":"DRUG","name":"sutimlimab","canonical_id":"gtopdb:9807","description":null,"metadata":null},{"id":"54127830560541d784f63b813029a8ab","type":"DRUG","name":"sutimlimab","canonical_id":"chembl:CHEMBL4297832","description":null,"metadata":null},{"id":"19113f9051604645b768ac46499d75e7","type":"GO_TERM","name":"suture of dorsal opening","canonical_id":"go:GO:0007396","description":"\"Closure of the dorsal hole. Filopodia extending from each leading edge interdigitate at the dorsal midline and appear to prime the formation of adherens junctions between the two rows of leading edge cells. Newly formed septate junctions are also used to seal the dorsal hole.\" [GOC:bf, PMID:12147138]","metadata":null},{"id":"bb185e41124c4244bf4baaad26875992","type":"DRUG","name":"suvorexant","canonical_id":"gtopdb:2890","description":null,"metadata":null},{"id":"aa27aa9da0e344389bca5583b40d9541","type":"DRUG","name":"suvorexant","canonical_id":"chembl:CHEMBL1083659","description":null,"metadata":null},{"id":"5b546f7f4e3d4a7fa17e6533afe3373f","type":"GO_TERM","name":"swarm social behavior","canonical_id":"go:GO:0160306","description":"\"A social behavior in which multiple individuals of the same animal species coordinate their movement in close spatial proximity, forming a dynamic aggregation typically characterized by collective motion, cohesion, and mutual responsiveness among members of the group.\" [DOI:10.1007/s13592-013-0253-2, PMID:23740485, PMID:32788724]","metadata":null},{"id":"4f5e6e79f4e546348b436f00b81e2b70","type":"GO_TERM","name":"sweat gland development","canonical_id":"go:GO:0060792","description":"\"The progression of the sweat gland over time, from its formation to the mature structure. Sweat glands secrete an aqueous solution that is used in thermoregulation.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"9353fb03b9bb4d968be19da929117c20","type":"GO_TERM","name":"sweat gland placode formation","canonical_id":"go:GO:0060793","description":"\"The developmental process in which the sweat gland placode forms. An sweat gland placode is a thickening of the ectoderm that will give rise to the sweat gland bud.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"19ced2ed7c5848aa90012789d8b0de5f","type":"GO_TERM","name":"sweat secretion","canonical_id":"go:GO:0160269","description":"\"The regulated release of sweat from the sweat glands.\" [PMID:1778649]","metadata":null},{"id":"e26a800fa2d741c1b5fe4adf278fbcdf","type":"GO_TERM","name":"sweet taste receptor activity","canonical_id":"go:GO:0033041","description":"\"Combining with soluble sweet compounds to initiate a change in cell activity. These receptors are responsible for the sense of sweet taste.\" [GOC:mah]","metadata":null},{"id":"c10874fe90bc426ab2340ced84b0ebd3","type":"GO_TERM","name":"sweet taste receptor complex","canonical_id":"go:GO:1903767","description":"\"A protein complex which is capable of sweet taste receptor activity.\" [GO_REF:0000088, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16720576]","metadata":null},{"id":"4209d9de0cb14f898334462311321df6","type":"GO_TERM","name":"swim bladder development","canonical_id":"go:GO:0048794","description":"\"The process whose specific outcome is the progression of the swim bladder over time, from its formation to the mature structure. The swim bladder is used by some fishes to maintain buoyancy and may function in addition as a sound producing organ, a sound receptor, and a respiratory organ.\" [GOC:mh]","metadata":null},{"id":"e75d3a57bdca43d1a0ca805b704daa6f","type":"GO_TERM","name":"swim bladder formation","canonical_id":"go:GO:0048797","description":"\"The process that gives rise to the swim bladder. This process pertains to the initial formation of a structure from unspecified parts. The swim bladder is used by some fishes to maintain buoyancy and may function in addition as a sound producing organ, a sound receptor, and a respiratory organ.\" [GOC:mh]","metadata":null},{"id":"180d426dd86b45ccb0d1b0f7b0c16bcf","type":"GO_TERM","name":"swim bladder inflation","canonical_id":"go:GO:0048798","description":"\"The expansion of the swim bladder by trapped gases. The swim bladder is used by some fishes to maintain buoyancy and may function in addition as a sound producing organ, a sound receptor, and a respiratory organ.\" [GOC:mh]","metadata":null},{"id":"f8402dcc0c814ab8a26e10375e9cc4b5","type":"GO_TERM","name":"swim bladder maturation","canonical_id":"go:GO:0048796","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a swim bladder to attain its fully functional state. The swim bladder is used by some fishes to maintain buoyancy and may function in addition as a sound producing organ, a sound receptor, and a respiratory organ.\" [GOC:devbiol]","metadata":null},{"id":"b182b4ebe4484fe5a4bc755da82a69a0","type":"GO_TERM","name":"swim bladder morphogenesis","canonical_id":"go:GO:0048795","description":"\"The process in which the anatomical structure of the swim bladder is generated and organized. The swim bladder is used by some fishes to maintain buoyancy and may function in addition as a sound producing organ, a sound receptor, and a respiratory organ.\" [GOC:mh]","metadata":null},{"id":"6474d7e26b564fcc90fd5453037e0380","type":"GO_TERM","name":"swimming","canonical_id":"go:GO:0036268","description":"\"Self-propelled movement of an organism from one location to another through water, often by means of active fin movement.\" [GOC:cvs, PMID:22459995]","metadata":null},{"id":"638a72c13abe40159d5f4a454b4fd746","type":"GO_TERM","name":"swimming behavior","canonical_id":"go:GO:0036269","description":"\"The response to external or internal stimuli that results in the locomotory process of swimming. Swimming is the self-propelled movement of an organism through the water.\" [GOC:cvs, PMID:16764679]","metadata":null},{"id":"6f5567e4586f4a068d4367cf2aa3b335","type":"GO_TERM","name":"sym-norspermidine synthase activity","canonical_id":"go:GO:0050314","description":"\"Catalysis of the reaction: 1,3-diaminopropane + S-adenosylmethioninamine = S-methyl-5'-thioadenosine + bis(3-aminopropyl)amine + H+.\" [EC:2.5.1.23, RHEA:23244]","metadata":null},{"id":"9d873a4fbe544563bdb954d78fc00753","type":"GO_TERM","name":"symbiont cell surface","canonical_id":"go:GO:0106139","description":"\"The cell surface of a secondary, endosymbiont organism with which the first organism is interacting. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:rjd, PMID:30049880]","metadata":null},{"id":"6769250170ae4c209cbbe08ca5303324","type":"GO_TERM","name":"symbiont defense to host-produced reactive oxygen species","canonical_id":"go:GO:0052164","description":"\"A process in which a symbiont alters or subverts either the host signal transduction pathways leading to the production of reactive oxygen species as part of the host innate immune response.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"9a90fd745cf140eeb770a441beabae2d","type":"GO_TERM","name":"symbiont entry into host","canonical_id":"go:GO:0044409","description":"\"Entry of a symbiont into the body, tissues, or cells of a host organism as part of the symbiont life cycle. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:vw]","metadata":null},{"id":"9b045d88b060404db9aaf1288c27a9a1","type":"GO_TERM","name":"symbiont entry into host cell","canonical_id":"go:GO:0046718","description":"\"The process by which a symbiont breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the symbiont or its genome is released into the host cell.\" [GOC:jl]","metadata":null},{"id":"027dd7c76ef9475e8e53c84e5592167f","type":"GO_TERM","name":"symbiont entry into host cell via disruption of host cell envelope","canonical_id":"go:GO:0098994","description":"\"The disruption by a symbiont of host cell envelope components to allow entry into the host cell.\" [GOC:dos]","metadata":null},{"id":"fdb6df1f0fc54d4f9026836ff5852377","type":"GO_TERM","name":"symbiont entry into host cell via disruption of host cell envelope lipopolysaccharide","canonical_id":"go:GO:0098995","description":"\"The disruption by a symbiont of host cell wall lipopolysaccharides to allow entry into the host cell. For example a phage entering a Gram-negative bacterium may actively break down outer membrane lipopolysaccharides.\" [GOC:dos, VZ:3940]","metadata":null},{"id":"8bc2b0292063421580bea094a3f66482","type":"GO_TERM","name":"symbiont entry into host cell via disruption of host cell glycocalyx","canonical_id":"go:GO:0098996","description":"\"The disruption by a symbiont of host cell capsule to allow entry into the host cell.\" [GOC:dos]","metadata":null},{"id":"eac9e30b638049bfb1f5c66424f41cae","type":"GO_TERM","name":"symbiont entry into host cell via disruption of host cell wall peptidoglycan","canonical_id":"go:GO:0098932","description":"\"The disruption by a symbiont of host cell wall peptidoglycans to allow entry into the host cell.\" [GOC:dos, VZ:3940]","metadata":null},{"id":"7dc11f0b087a4c74a6949d20ee83843e","type":"GO_TERM","name":"symbiont entry into host cell via permeabilization of endosomal membrane","canonical_id":"go:GO:0099006","description":"\"The entry of a symbiont into a host cell, following endocytosis, via permeabilization of the endosomal membrane by membrane penetration protein(s) of the symbiont. This process mediates the entry of some non-enveloped virus into eukaryotic cells. In some cases, viral membrane-penetration protein requires to be activated to display its membrane penetrating activity. Activation can be due to receptor binding or the acidic pH of the endosomal lumen.\" [PMID:15329727, PMID:25055856]","metadata":null},{"id":"e9652222928741c7a1c7ddd660357fcb","type":"GO_TERM","name":"symbiont entry into host cell via permeabilization of host membrane","canonical_id":"go:GO:0140267","description":"\"The entry of a symbiont into the cytoplasm of a host cell, triggered by an interaction between the bilayer of a host membrane and a membrane-penetration symbiont protein. This process mediates the entry of some non-enveloped virus into host cells, and results in the release of the virus contents into the host cell cytoplasm.\" [PMID:20427561, PMID:25055856, VZ:985]","metadata":null},{"id":"da8db91680f246049ddcd4eee6bc5b94","type":"GO_TERM","name":"symbiont entry into host cell via permeabilization of inner membrane","canonical_id":"go:GO:0099008","description":"\"The entry of a symbiont into the cytoplasm of a host cell, following fusion with the outer membrane, via permeabilization of the plasma (inner) membrane. This process mediates the entry of some non-enveloped viruses into prokaryotic cells. In the case of some double stranded RNA viruses of prokaryotes this occurs via interaction of a membrane-interacting component of the capsid, leading to depolarization and permeabilization of the plasma membrane.\" [PMID:15795287, PMID:20427561]","metadata":null},{"id":"e0c7b9b168e0484399c379b10e0ff727","type":"GO_TERM","name":"symbiont genome ejection through host cell envelope","canonical_id":"go:GO:0039678","description":"\"Entry of a symbiont's genome into the host cell through the host cell envelope. Occurs in non-enveloped prokaryotic viruses. Caudovirales carry an ejection apparatus that can be long and contractile, long and noncontractile, or short, and is able to penetrate the host cell envelope to deliver the viral genome into the host cell cytoplasm.\" [GOC:ch, PMID:23385786, PMID:31663016, VZ:986]","metadata":null},{"id":"209b1006f4ef4734bcfdbca80ad3d39d","type":"GO_TERM","name":"symbiont genome ejection through host cell envelope, contractile tail mechanism","canonical_id":"go:GO:0099000","description":"\"Entry of a symbiont's genome into the host cell through the host cell envelope via a contractile tail ejection system consisting of a baseplate, a central tube and an external contractile sheath. Upon binding to the host cell surface, the baseplate changes its conformation and triggers sheath contraction, driving the rigid internal tail tube through the cell envelope. Occurs in non-enveloped prokaryotic viruses.\" [GOC:dos, PMID:26283379, VZ:3950]","metadata":null},{"id":"e9aacb1a6fcd4c2cb9334a67f91b126d","type":"GO_TERM","name":"symbiont genome ejection through host cell envelope, long flexible tail mechanism","canonical_id":"go:GO:0099001","description":"\"Entry of a symbiont's genome into the host cell through the host cell envelope via a long, flexible tail ejection system consisting a baseplate, a central tube and a terminator complex which attaches the tail to the phage capsid. Upon binding to the host cell surface, the baseplate changes its conformation and triggers genome ejection into the host cell cytoplasm. Occurs in non-enveloped prokaryotic viruses.\" [GOC:dos, PMID:22297512, VZ:3952]","metadata":null},{"id":"1b01db5db32a423eb734702c7c52a195","type":"GO_TERM","name":"symbiont genome ejection through host cell envelope, short tail mechanism","canonical_id":"go:GO:0099002","description":"\"Entry of a symbiont's genome into the host cell through the host cell envelope via a short tail ejection system consisting a central tube, the connector which attaches the tail to the phage capsid and releases inner core proteins. Upon binding to the host cell surface, the phage displays a tube-like extension of its short tail that penetrates both host membranes. This tail extension comes from the release of viral core proteins with channel forming properties. Occurs in non-enveloped prokaryotic viruses.\" [GOC:dos, PMID:22297513, VZ:3954]","metadata":null},{"id":"4d82ddb680924f2b92824213045dcb85","type":"GO_TERM","name":"symbiont genome entry into host cell via pore formation in plasma membrane","canonical_id":"go:GO:0044694","description":"\"Entry of a symbiont's genome into a host cell by a pore formed by the symbiont in the host cell. Examples of this process include injection by a non-enveloped virus of the viral genome into the host cytoplasm, usually mediated by a viral pore-forming peptide associated with the viral capsid or bacteriophage tail.\" [GOC:jl, VZ:979]","metadata":null},{"id":"c8e0efb3b57f4524abc722f189280356","type":"GO_TERM","name":"symbiont intracellular protein transport in host","canonical_id":"go:GO:0030581","description":"\"The directed movement of a symbiont's proteins within a cell of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mb]","metadata":null},{"id":"1ffd2770be01416b8e9876e9cee9e2bb","type":"GO_TERM","name":"symbiont-containing vacuolar membrane network","canonical_id":"go:GO:0020006","description":"\"Tubular network of extensions from the symbiont-containing vacuole membrane that protrude into the host cytoplasm.\" [GOC:jl, PMID:3528173]","metadata":null},{"id":"42cc42ef8f6e405a9bd20cc2bcdb5f95","type":"GO_TERM","name":"symbiont-containing vacuolar space","canonical_id":"go:GO:0020004","description":"\"The space between a symbiont plasma membrane and the symbiont-containing vacuole membrane.\" [GOC:jl, GOC:mb]","metadata":null},{"id":"54be986d8b684b558f12e5a9e32321a2","type":"GO_TERM","name":"symbiont-containing vacuole","canonical_id":"go:GO:0020003","description":"\"Membrane-bounded vacuole within a host cell in which a symbiont organism resides. The vacuole membrane is derived from both the host and symbiont.\" [GOC:jl, GOC:mb]","metadata":null},{"id":"6fcbd1b516ed4536bbeeeb764b51e040","type":"GO_TERM","name":"symbiont-containing vacuole membrane","canonical_id":"go:GO:0020005","description":"\"The lipid bilayer surrounding a symbiont-containing vacuole, derived from both the host and symbiont.\" [GOC:jl, GOC:mb]","metadata":null},{"id":"f0391ee89e1b4389803a60c02f3c9da3","type":"GO_TERM","name":"symbiont-induced defense-related programmed cell death","canonical_id":"go:GO:0034050","description":"\"Cell death resulting from activation of endogenous cellular processes after interaction with a symbiont (defined as the smaller of two, or more, organisms engaged in symbiosis, a close interaction encompassing mutualism through parasitism). This can be triggered by direct interaction with the organism, for example, contact with penetrating hyphae of a fungus; or an indirect interaction such as symbiont-secreted molecules.\" [GOC:pamgo_curators]","metadata":null},{"id":"a5e8b5e601114fa192fcb5d57a6a0fd8","type":"GO_TERM","name":"symbiont-mediated actin polymerization-dependent cell-to-cell migration in host","canonical_id":"go:GO:0070360","description":"\"The directional movement of an organism, usually a bacterial cell, from one place to another within its host organism, by a process involving continuous polymerization of actin at one pole of the symbiont cell. Some bacteria use host actin for migration from cell to cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:jl, GOC:mah, PMID:15773977, PMID:15981456, PMID:26021574, PMID:27997855, PMID:35285700]","metadata":null},{"id":"bc4048567b5f4cc8b418405113c36c30","type":"GO_TERM","name":"symbiont-mediated activation of blood coagulation, intrinsic pathway","canonical_id":"go:GO:0140424","description":"\"A process in which a symbiont initiates, promotes, or enhances blood coagulation in another organism by activation of the intrinsic pathway. A common mechanism is the triggering the activity of host coagulation Factor XIIa (F12), one of the contact activation system (CAS) components, which consists of factor XII (FXII), prekallikrein (PK), and high molecular weight kininogen (HK). FXIIa instigates the coagulation cascade by cutting factor XI (FXI).\" [PMID:17142774, PMID:24910020, PMID:29619369]","metadata":null},{"id":"6a0fc742ae4d4d1aacc4b7dc282318a0","type":"GO_TERM","name":"symbiont-mediated activation of host G protein-coupled receptor signal transduction","canonical_id":"go:GO:0141104","description":"\"A process in which a symbiont initiates, promotes, or enhances a G protein-coupled receptor signal transduction pathway in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15963708, PMID:18978047, PMID:25332123]","metadata":null},{"id":"729cb7e11f7941ba9e5e8a6b6ee21900","type":"GO_TERM","name":"symbiont-mediated activation of host MAPK cascade","canonical_id":"go:GO:0141071","description":"\"A process in which a symbiont subverts a MAPK signal transduction pathway in the host organism by initiating, promoting, or enhancing its activation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:24043761, PMID:25675415, PMID:28166272]","metadata":null},{"id":"5a3e5bff426f4710b9d9efa47043ea8b","type":"GO_TERM","name":"symbiont-mediated activation of host NF-kappaB cascade","canonical_id":"go:GO:0085033","description":"\"A process that initiates, promotes, or enhances a host NF-kappaB-mediated signaling cascade. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11907233, PMID:17490702, PMID:21098302, PMID:21199955, PMID:31311877, PMID:7845680]","metadata":null},{"id":"c84ab25571eb4ad48265bfb9f561c449","type":"GO_TERM","name":"symbiont-mediated activation of host anti-inflammatory cytokine signaling","canonical_id":"go:GO:0141184","description":"\"A process in which a symbiont subverts an anti-inflammatory cytokine signaling pathway in the host organism by initiating, promoting, or enhancing its activation.\" [PMID:23284742, PMID:27437422, PMID:29924996]","metadata":null},{"id":"fc1921e3ead846108ab4b2950efe849b","type":"GO_TERM","name":"symbiont-mediated activation of host apoptosis","canonical_id":"go:GO:0052151","description":"\"A process in which a symbiont initiates, promotes, or enhances the normal execution of host apoptosis, leading to an increase in the frequency, rate or extent of apoptosis in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11805081, PMID:18037263, PMID:19801898, PMID:29571981]","metadata":null},{"id":"aa49b5daa6464e7aa901f4b5745ec8be","type":"GO_TERM","name":"symbiont-mediated activation of host autophagy","canonical_id":"go:GO:0039520","description":"\"A process in which a symbiont initiates, promotes, or enhances the normal execution of autophagy in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction. For example, some viruses are able to activate host autophagy as a cellular survival mechanism, hence delaying or inhibiting apoptosis.\" [GOC:bf, GOC:sp, VZ:846]","metadata":null},{"id":"e2c333566a6d4f15955f6b72db87abdc","type":"GO_TERM","name":"symbiont-mediated activation of host induced systemic resistance","canonical_id":"go:GO:0052103","description":"\"Any process in which a symbiont activates, maintains or increases the frequency, rate or extent of induced systemic resistance in the host organism; induced systemic resistance is a response that confers broad spectrum systemic resistance to disease and that does not depend upon salicylic acid signaling. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06, PMID:31516360]","metadata":null},{"id":"65d61a1542994a65ba680858833ce6b6","type":"GO_TERM","name":"symbiont-mediated activation of host inflammasome-mediated signal transduction","canonical_id":"go:GO:0141079","description":"\"A process in which a symbiont subverts an inflammasome-mediated signal transduction pathway in the host organism by initiating, promoting, or enhancing its activation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:25538194, PMID:28331908, PMID:30872531, PMID:34155776]","metadata":null},{"id":"8074130007ab4b919f273b180413cd27","type":"GO_TERM","name":"symbiont-mediated activation of host interferon signaling pathway","canonical_id":"go:GO:0141080","description":"\"A process in which a symbiont subverts an interferon-mediated signal transduction pathway in the host organism by initiating, promoting, or enhancing its activation.\" [PMID:26553469, PMID:29076073]","metadata":null},{"id":"f8a9d7aab60d47af9e8ef43d5a5a2cdd","type":"GO_TERM","name":"symbiont-mediated activation of host plasminogen","canonical_id":"go:GO:0044542","description":"\"A process in which a symbiont initiates, promotes, or enhances the normal activation of plasminogen, the pathway resulting in the processing of inactive plasminogen to active plasmin in the host organism. This can facilitate the dissemination of the symbiont into host tissues. It can also be used to destroy complement, opsonins as well as antibacterial proteins like histones.\" [PMID:18070889, PMID:27533300, PMID:34305859]","metadata":null},{"id":"c48514919f0649608ebbc0986d1ca923","type":"GO_TERM","name":"symbiont-mediated activation of host programmed cell death","canonical_id":"go:GO:0052042","description":"\"A process in which a symbiont gene product activates host programmed cell death, leading to an increase in the frequency, rate or extent of programmed cell death in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"11d1862a497741cf9d3a25bf3b1e9255","type":"GO_TERM","name":"symbiont-mediated activation of host reticulophagy","canonical_id":"go:GO:0140883","description":"\"A process in which a symbiont initiates, promotes, or enhances the normal execution of host reticulophagy, leading to an increase in the frequency, rate or extent of reticulophagy in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:35239449]","metadata":null},{"id":"5f3dc1e04ea34ce69c0b771c5d74dd42","type":"GO_TERM","name":"symbiont-mediated activation of host signal transduction pathway","canonical_id":"go:GO:0052028","description":"\"A process in which a symbiont subverts a signal transduction pathway in the host organism by initiating, promoting, or enhancing its activation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"6af219cdcb134bc0adc36b00a71c6ae0","type":"GO_TERM","name":"symbiont-mediated activation of host signal transduction pathway via agonism of host cell surface receptor","canonical_id":"go:GO:0141134","description":"\"A process in which a symbiont subverts a signal transduction pathway in the host organism by binding to and enhancing the activation of the receptor of the pathway. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:10221874, PMID:18563600]","metadata":null},{"id":"ed8027489deb4767bd513004c5897915","type":"GO_TERM","name":"symbiont-mediated activation of host transcription","canonical_id":"go:GO:1990216","description":"\"A process in which a symbiont initiates, promotes, or enhances transcription of genes into mRNA in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21994350]","metadata":null},{"id":"296ea7547f8d458885134eabb428e6ef","type":"GO_TERM","name":"symbiont-mediated arrest of host cell cycle during G2/M transition","canonical_id":"go:GO:0039592","description":"\"A process in which a symbiont interferes with the progression of the host mitotic cell cycle from G2 phase to M phase, leading to arrest in G2 phase. The arrest in G2/M allows some viruses to replicate their genome before cells enter mitosis. Alternatively, it can inhibit the antiviral immune response by preventing the clonal expansion of infected lymphocytes.\" [PMID:10946289, PMID:12208959, PMID:9882364, VZ:876]","metadata":null},{"id":"e3da9bc0a30745529e7adbaf42c61d5a","type":"GO_TERM","name":"symbiont-mediated cAMP intoxication of host cell","canonical_id":"go:GO:0141042","description":"\"The production by a symbiont of high levels of cyclic AMP in a host cell, impairing host cellular functions in multiple ways, including ATP depletion, interference with host intracellular signaling, cytoskeletal defects and apoptosis-related cell death. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:16390441, PMID:19516256, PMID:27731909, PMID:33013916]","metadata":null},{"id":"f4c95a2ee38a40a59c183bafca8ac060","type":"GO_TERM","name":"symbiont-mediated cell-to-cell migration by invasive hypha","canonical_id":"go:GO:0140649","description":"\"The directional movement of a hyphal filament from one host cell to another. This process involves the clearance of plant-derived plasmodesmal occlusion materials, cytoskeleton based constriction of invasive hypha to traverse plasmodesmata. Septins and F-actin are reorganized into an hourglass shape at the point of maximum hyphal constriction.\" [PMID:29567712]","metadata":null},{"id":"a5cc2589e300474696f0592b47101f7f","type":"GO_TERM","name":"symbiont-mediated cell-to-cell migration in host","canonical_id":"go:GO:0106259","description":"\"The directional movement of a symbiont from one host cell to another.\" [GOC:vw, PMID:18456802, PMID:19262673, PMID:19816653, PMID:29567712]","metadata":null},{"id":"def9848d83914687960dd7de2b8792bd","type":"GO_TERM","name":"symbiont-mediated cytolysis of host cell","canonical_id":"go:GO:0001897","description":"\"A process mediated by a symbiont that results in the death of a host cell by means of the rupture of cell membranes and the loss of cytoplasm. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11423190, PMID:23748204, PMID:24204713, PMID:27405240]","metadata":null},{"id":"70eb30cf06f64a0281c723063509213c","type":"GO_TERM","name":"symbiont-mediated degradation of host mRNA","canonical_id":"go:GO:0039595","description":"\"The process in which a virus increases the frequency, rate or extent of the breakdown of host messenger RNA (mRNA).\" [PMID:12163576, PMID:16477041, PMID:17360652, PMID:22696660]","metadata":null},{"id":"1b3452d2e38442af8f6eaeb0bcfdd996","type":"GO_TERM","name":"symbiont-mediated detoxification of host-generated reactive oxygen species","canonical_id":"go:GO:0141082","description":"\"A process in which a symbiont interferes with, inhibits or disrupts the host reactive oxygen species (ROS)-mediated innate immune response by directly degrading host ROS. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:19684141, PMID:27825304, PMID:28288207]","metadata":null},{"id":"15ef0862a3c14540bf16225cf2ad8fec","type":"GO_TERM","name":"symbiont-mediated disassembly of host stress granules","canonical_id":"go:GO:0140402","description":"\"The process in which an organism effects a change that impairs the structure or function of the stress granule of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction. Stress granules are dynamic cytoplasmic condensates formed through liquid-liquid phase separation. They act as a critical hub for both cellular stress adaptation and defense against viruses.\" [PMID:32353859, PMID:39345463]","metadata":null},{"id":"5acc4a5376024816822d4c5eb1a3932a","type":"GO_TERM","name":"symbiont-mediated disruption of host anatomical structure","canonical_id":"go:GO:0052111","description":"\"The process in which an organism effects a change that impairs the structure or function of an anatomical structure of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"8c2592443d61482da2f0913ebef0bb72","type":"GO_TERM","name":"symbiont-mediated disruption of host antimicrobial peptide activity","canonical_id":"go:GO:0141059","description":"\"Any process in which a symbiont interferes with a host antimicrobial peptide, for example by cleavage or degradation.\" [PMID:16242332, PMID:19015361, PMID:21335044]","metadata":null},{"id":"adb843647374454c8119dc15b82523d3","type":"GO_TERM","name":"symbiont-mediated disruption of host cell PML body","canonical_id":"go:GO:0075342","description":"\"The process in which an organism effects a change that impairs the structure or function of the host PML body. A PML body is a nuclear body that reacts against SP100 auto-antibodies (PML = promyelocytic leukemia). The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:BHF, GOC:jl]","metadata":null},{"id":"e8d226bd74f14f41bcca0d116c836f0c","type":"GO_TERM","name":"symbiont-mediated disruption of host cell envelope","canonical_id":"go:GO:0098933","description":"\"The process in which a symbiont effects a change that impairs the structure or function of the host cell envelope. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [ISBN:0198547684]","metadata":null},{"id":"7b3862e4c4fb42308686ed32299964ba","type":"GO_TERM","name":"symbiont-mediated disruption of host cell nucleus","canonical_id":"go:GO:0044066","description":"\"The process in which an organism effects a change that impairs the structure or function of the host cell nucleus.\" [MITRE:tk]","metadata":null},{"id":"d8ff1ce0cfbc46189d6a6e8b0f03d13e","type":"GO_TERM","name":"symbiont-mediated disruption of host cell wall","canonical_id":"go:GO:0052009","description":"\"The process in which an organism effects a change that impairs the structure or function of the host cell wall. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [ISBN:0198547684]","metadata":null},{"id":"02db24f15203496abf54101ee532106e","type":"GO_TERM","name":"symbiont-mediated disruption of host cell-cell adhesion","canonical_id":"go:GO:0141023","description":"\"A process in which a symbiont alters or subverts host cell adhesion ito its extracellular matrix. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"cc11409d00c94c7ba44f96b6606981cf","type":"GO_TERM","name":"symbiont-mediated disruption of host cellular anatomical structure","canonical_id":"go:GO:0052008","description":"\"The process in which an organism effects a change that impairs the structure or function of a host cellular anatomical structure. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [ISBN:0198547684]","metadata":null},{"id":"efa2c7ac8cba428cb86dbed9febdae23","type":"GO_TERM","name":"symbiont-mediated disruption of host chloroplast","canonical_id":"go:GO:0033656","description":"\"The process in which an organism effects a change that impairs the structure or function of the host chloroplast. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"db52b3dd21184820a922f2bc5f952265","type":"GO_TERM","name":"symbiont-mediated disruption of host chloroplast thylakoid","canonical_id":"go:GO:0033658","description":"\"The process in which an organism effects a change that impairs the structure or function of the host cell chloroplast thylakoid. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"6bb61e8c21a541ca8ca2a133f0611b75","type":"GO_TERM","name":"symbiont-mediated disruption of host cuticle","canonical_id":"go:GO:0085044","description":"\"The process in which an organism effects a change that impairs the structure or function of the host organism cuticle. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:jl, GOC:pamgo_curators]","metadata":null},{"id":"73354a8b50ab4bfb93eb6c7d513968be","type":"GO_TERM","name":"symbiont-mediated disruption of host extracellular matrix","canonical_id":"go:GO:0141066","description":"\"The process in which an organism effects a change that impairs the structure or function of the host extracellular matrix.\" [PMID:11982763, PMID:21115719, PMID:2404867, PMID:25865874]","metadata":null},{"id":"fc3ddcf3c723446a85ed256bd3f06547","type":"GO_TERM","name":"symbiont-mediated disruption of host focal adhesion","canonical_id":"go:GO:0141029","description":"\"A process in which a symbiont alters or subverts focal adhesion in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:19489119, PMID:24573681, PMID:24905543]","metadata":null},{"id":"55c76ee83bee49f88eaea9319331d840","type":"GO_TERM","name":"symbiont-mediated disruption of host mitochondrion","canonical_id":"go:GO:0033659","description":"\"The process in which an organism effects a change in the structure or function of host cell mitochondria. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators, PMID:35069483, PMID:37175745]","metadata":null},{"id":"510b2211d72b4670abe99f34aacc6221","type":"GO_TERM","name":"symbiont-mediated disruption of host mucosa","canonical_id":"go:GO:0141139","description":"\"The disruption of the host mucosa by a symbiont, leading to damage or temporary subversion of that tissue. The mucosa is a membrane that lines various cavities in the body of an organism and covers the surface of internal organs.\" [PMID:22520462, PMID:28598765, PMID:28764997]","metadata":null},{"id":"85269fcfe0bd4624a667d352275e41de","type":"GO_TERM","name":"symbiont-mediated disruption of host neutrophil extracellular traps","canonical_id":"go:GO:0141144","description":"\"A process in which a symbiont damages or impairs host neutrophil extracellular traps. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:16488875, PMID:21231972, PMID:25605868]","metadata":null},{"id":"7ea24b8739184219bcdc4df21dc0f804","type":"GO_TERM","name":"symbiont-mediated disruption of host phagosome","canonical_id":"go:GO:0141160","description":"\"The process in which an organism effects a change that impairs the structure or function of host phagosomes.\" [PMID:15487949, PMID:21412437, PMID:30057173]","metadata":null},{"id":"5280fee37d3649e980b85a6f299d0ed9","type":"GO_TERM","name":"symbiont-mediated disruption of host tissue","canonical_id":"go:GO:0141146","description":"\"The process in which an organism effects a change that impairs the structure or function of a host tissue. This can occur via the disruption of the extracellular matrix, or the detachment of cells from the extracellular matrix, or the dissociation of the cells composing that tissue. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11982763, PMID:14651638, PMID:26355030]","metadata":null},{"id":"d8966266518c4c8a8a4f30a6c492fd7b","type":"GO_TERM","name":"symbiont-mediated evasion of DNA end degradation by host","canonical_id":"go:GO:0099016","description":"\"A process by which a symbiont evades and ends degradation of its DNA when free DNA ends are exposed. DNA ends are exposed during the life cycle of some viruses and these are targeted by host cells to destroy the virus. For example, some bacteriophages encode proteins that bind to free viral DNA ends, protecting them from degradation by host exonucleases.\" [GOC:dos, PMID:11894948, PMID:16949369, VZ:3963]","metadata":null},{"id":"18dfcd3dfa0f46278e7abe6ae837d4b2","type":"GO_TERM","name":"symbiont-mediated evasion of host immune response","canonical_id":"go:GO:0042783","description":"\"A process by which an organism avoids the effects of the host organism's immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mb, PMID:12439615]","metadata":null},{"id":"4fbe9105a707490589e30171b261240e","type":"GO_TERM","name":"symbiont-mediated evasion of host innate immune response","canonical_id":"go:GO:0141043","description":"\"A process by which a symbiont avoids recognition by host's innate immune response by altering, concealing or destroying a conserved symbiont molecule recognized by the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15014080, PMID:22131330, PMID:26502908, PMID:29101229]","metadata":null},{"id":"0e2040b5f63643cab3ff36ade92bede3","type":"GO_TERM","name":"symbiont-mediated evasion of host restriction-modification system","canonical_id":"go:GO:0099018","description":"\"A process by which a symbiont evades the DNA restriction modification system of its host. This process occurs in phages to protein themselves from bacterial restriction enzyme systems. Some viruses encode their own methyltransferase in order to protect their genome from host restriction enzymes. Others directly inhibit restriction enzymes while some use unusual bases in their genome to avoid restriction.\" [PMID:20348932, PMID:23979432, PMID:24123737, VZ:3966]","metadata":null},{"id":"1399163360f94cce9de8d2d2b0cf667e","type":"GO_TERM","name":"symbiont-mediated evasion of mRNA degradation by host via mRNA cap methylation","canonical_id":"go:GO:0039699","description":"\"An innate immune response evasion mechanism in which a symbiont methylates the 2'-O-ribose of the first or second transcribed nucleotide of its mRNAs. Methylation allows evasion of the host innate immune response, which degrades cap0 (non-methylated) mRNAs. This mechanism of immune evasion is used by viruses.\" [PMID:35215972]","metadata":null},{"id":"c65a2bd990374b7fa0d09b47ac60d079","type":"GO_TERM","name":"symbiont-mediated evasion of recognition by host antimicrobial peptide","canonical_id":"go:GO:0141179","description":"\"A process by which a symbiont avoids the effects of recognition by a host  antimicrobial peptide by altering molecules on the symbiont surface. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11401964, PMID:22966934, PMID:25537831]","metadata":null},{"id":"f259dca0433146d6ae3b08540d22641f","type":"GO_TERM","name":"symbiont-mediated evasion of recognition by host complement","canonical_id":"go:GO:0141178","description":"\"A process by which a symbiont avoids the effects of recognition by host  complement by altering molecules on the symbiont surface. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:22825444, PMID:25537831, PMID:34887398]","metadata":null},{"id":"b303e31ddc874a29bdc235e3f3cc75d0","type":"GO_TERM","name":"symbiont-mediated evasion of recognition by host innate immune effector","canonical_id":"go:GO:0141177","description":"\"A process by which a symbiont mitigates the effects of recognition by a host innate immune effector. Effectors have a direct activity against a symbiont and include complement, antimicrobial peptides, and bacterial restriction enzymes. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:19208801, PMID:33330873]","metadata":null},{"id":"259c2742c97e486388f608f626a0fa2d","type":"GO_TERM","name":"symbiont-mediated evasion of recognition by host pattern recognition receptor","canonical_id":"go:GO:0141141","description":"\"A process by which a symbiont avoids recognition by host's innate immune response by altering or concealing a conserved molecule recognized by the host's cell surface and intracellular pattern recognition receptors, including Toll-like and NOD-like receptors. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:17215377, PMID:26502908, PMID:29101229]","metadata":null},{"id":"066831926c224b91ba014074c0882100","type":"GO_TERM","name":"symbiont-mediated generation of symbiont replication vacuole","canonical_id":"go:GO:0141213","description":"\"A process in which a symbiont alters or subverts vacuole organization in its host organism to form a protected environment in which it can replicate. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21822290, PMID:23186105, PMID:30893609]","metadata":null},{"id":"a6cacbb4c6514a8f85df88956abe2618","type":"GO_TERM","name":"symbiont-mediated hemolysis of host erythrocyte","canonical_id":"go:GO:0019836","description":"\"The cytolytic destruction of red blood cells, with the release of intracellular hemoglobin, in the host organism by a symbiont. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:add, UniProtKB-KW:KW-0354]","metadata":null},{"id":"0b4b789d9cb941f3993e205315cfb079","type":"GO_TERM","name":"symbiont-mediated inactivation of host ribosome","canonical_id":"go:GO:0141130","description":"\"A process in which a symbiont inhibits or disrupts translation of mRNA into protein in its host by inactivating its ribosomes.\" [PMID:1324134]","metadata":null},{"id":"5e89d2c08f6542efb1279e6561eaf4d1","type":"GO_TERM","name":"symbiont-mediated induction of syncytium formation","canonical_id":"go:GO:0060141","description":"\"A process in which a symbiont initiates, promotes, or enhances the formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by the fusion of the plasma membranes of two or more individual host cells. Syncytia are produced by viruses that are able to fuse directly at the cell surface without requiring endocytosis.\" [GOC:dph]","metadata":null},{"id":"e101eed5bd47464c95434fab219a6639","type":"GO_TERM","name":"symbiont-mediated induction of tumor or growth in host","canonical_id":"go:GO:0051819","description":"\"The process in which a symbiont causes the formation of a mass of cells in a host organism. While these growths are often called nodules, they are not formed as nitrogen-fixing structures, but rather to provide an environment for the symbiont to grow. In this sense they are parasitic structures rather than mutualistic.\" [GOC:pg]","metadata":null},{"id":"9335fdaf8f7140dfab64eb376f53f57e","type":"GO_TERM","name":"symbiont-mediated killing of host cell","canonical_id":"go:GO:0001907","description":"\"A process mediated by a symbiont that results in the death of a cell in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:add, PMID:11123917, PMID:22992735, PMID:23230295, PMID:26633512]","metadata":null},{"id":"df048cd5d16d4c40b4a0416faa10858f","type":"GO_TERM","name":"symbiont-mediated migration across host tissue barrier","canonical_id":"go:GO:0141142","description":"\"A process in which a symbiont moves across a tissue barrier of the host to transports itself across an extracellular cellular matrix barrier or between the cells of a tissue. This involves the temporary or permanent breaching of the tissue barrier.\" [PMID:19820089, PMID:20188700, PMID:26681776, PMID:29120408]","metadata":null},{"id":"d703855c885d42b990a030ba56662376","type":"GO_TERM","name":"symbiont-mediated migration across host transepithelium","canonical_id":"go:GO:0035756","description":"\"A process in which a symbiont moves from one side of an epithelium to the other within its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, PMID:10639460]","metadata":null},{"id":"4adfc3ed906e4935b2f0aedaa22e3181","type":"GO_TERM","name":"symbiont-mediated modulation of host ethylene-mediated defense response","canonical_id":"go:GO:0052084","description":"\"Any process in which a symbiont modulates the frequency, rate or extent of the ethylene-mediated defense response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"db1cdf46b1a74b36833d0a9a114b1c60","type":"GO_TERM","name":"symbiont-mediated modulation of host virulence","canonical_id":"go:GO:0098676","description":"\"A process by which a virus improves the virulence of its host for that host's respective host. Common in but not limited to bacteriophages; also occurs in phage-bearing bacteria infecting plants or animals for example. Mechanisms include the expression of factors that modulate a bacterial adhesion to a host cell, spread through host tissues, production of exotoxins or provide protection against host immune defenses.\" [PMID:10913072, PMID:11553559, PMID:22919604, PMID:8658163, VZ:3965]","metadata":null},{"id":"8463a37d4b73489184432e3327e90762","type":"GO_TERM","name":"symbiont-mediated non-specific activation of host T-cells","canonical_id":"go:GO:0141128","description":"\"A process by which a symbiont superantigen elicits a strong immune response by activating a large number of T cells in a non-specific manner. Unlike conventional antigens, which activate T cells by interacting with specific receptors on the surface of these cells, superantigens can stimulate T cells by binding to regions outside the antigen-binding site. Superantigens can activate a large proportion of T cells, leading to an exaggerated immune response. This excessive activation can result in the release of a large amount of cytokines such as tumor necrosis factor and interleukin-2. The massive cytokine release can lead to an acute toxic shock, causing symptoms such as fever and organ damage.\" [PMID:12679262, PMID:17427250, PMID:28880920]","metadata":null},{"id":"5b214e506b184d78983236dbf7bab92c","type":"GO_TERM","name":"symbiont-mediated occlusion of host xylem","canonical_id":"go:GO:0052112","description":"\"The process in which an organism reduces the flow of fluid within the host xylem, the tissue in plants that carries water and nutrients up from the roots to the shoot and leaves. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:28871268]","metadata":null},{"id":"8a48ca4d6fb841e09705520bc8e0811a","type":"GO_TERM","name":"symbiont-mediated perturbation of host B-cell mediated immune response","canonical_id":"go:GO:0052154","description":"\"A process in which a symbiont alters or subverts the B-cell mediated immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"6bb844c1994c43f7b9817b838364a95e","type":"GO_TERM","name":"symbiont-mediated perturbation of host G protein-coupled receptor signal transduction pathway","canonical_id":"go:GO:0075118","description":"\"A process by which a symbiont alters or subverts the normal execution of a host G protein-coupled receptor signal transduction pathway. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"90864dac8ebb41b6b602ef44e8d6753c","type":"GO_TERM","name":"symbiont-mediated perturbation of host MAPK cascade","canonical_id":"go:GO:0052080","description":"\"A process in which a symbiont alters or subverts a MAP kinase-mediated signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"0f34c9966edf4f92bc4877ab7ff396dc","type":"GO_TERM","name":"symbiont-mediated perturbation of host NF-kappaB cascade","canonical_id":"go:GO:0085032","description":"\"A process in which a symbiont alters or subverts an NF-kappaB-mediated signaling cascade in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"d363be139e7e4d1ab40010fd8eb7a97f","type":"GO_TERM","name":"symbiont-mediated perturbation of host Rab small GTPase signal transduction","canonical_id":"go:GO:0141127","description":"\"A process in which a symbiont alters a Rab protein family-mediated signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:24251537, PMID:30181274, PMID:30893609]","metadata":null},{"id":"71306838e9db4df28e7d5c430a906ea8","type":"GO_TERM","name":"symbiont-mediated perturbation of host Rho small GTPase signal transduction","canonical_id":"go:GO:0044083","description":"\"A process in which a symbiont alters a Rho protein family-mediated signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15694861, PMID:17689917, PMID:30201700]","metadata":null},{"id":"433e860e7b6b4cb0b0a758c2c4095ec7","type":"GO_TERM","name":"symbiont-mediated perturbation of host T-cell mediated immune response","canonical_id":"go:GO:0052156","description":"\"A process in which a symbiont alters or subverts the T-cell mediated immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"f77aecf7b127431b8afbdd279491ad09","type":"GO_TERM","name":"symbiont-mediated perturbation of host actin cytoskeleton","canonical_id":"go:GO:0141027","description":"\"The process in which an organism effects a change that impairs the structure or function of the host actin cytoskeleton. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:20688909]","metadata":null},{"id":"6005f2bf822b41de855cf2588ad5d15a","type":"GO_TERM","name":"symbiont-mediated perturbation of host actin cytoskeleton via actin crosslinking","canonical_id":"go:GO:0141031","description":"\"The process in which an organism effects a change that impairs the structure or function of the host actin cytoskeleton by actin crosslinking the host actin filaments. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:14512630, PMID:22814176]","metadata":null},{"id":"b396b2e8e1cf40df90df7baef89e0527","type":"GO_TERM","name":"symbiont-mediated perturbation of host actin cytoskeleton via actin filament reorganization","canonical_id":"go:GO:0141032","description":"\"The process in which an organism effects a change that impairs the structure or function of the host actin cytoskeleton by reorganizing the actin filaments, in a way that keeps the total filementous actin remains approximately constant. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:22212282, PMID:31130928]","metadata":null},{"id":"fddba0016bbd4bdcb47807797dd73865","type":"GO_TERM","name":"symbiont-mediated perturbation of host actin cytoskeleton via actin polymerization","canonical_id":"go:GO:0141033","description":"\"The process in which an organism effects a change that impairs the structure or function of the host actin cytoskeleton by polymerizing the host filamentous actin. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18331467, PMID:25293534]","metadata":null},{"id":"baf61019f190493293ffbb7a9acbc2df","type":"GO_TERM","name":"symbiont-mediated perturbation of host actin cytoskeleton via filamentous actin depolymerization","canonical_id":"go:GO:0141030","description":"\"The process in which an organism effects a change that impairs the structure or function of the host actin cytoskeleton by depolymerizing the host filamentous actin. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11889090, PMID:28800062]","metadata":null},{"id":"d7a3314190164dfaa43c6128d612dc09","type":"GO_TERM","name":"symbiont-mediated perturbation of host actin cytoskeleton via inhibition of actin polymerization","canonical_id":"go:GO:0141034","description":"\"The process in which an organism effects a change that disrupts the host actin cytoskeleton by inhibiting host actin from polymerizing. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:23409096, PMID:24253566, PMID:30297616]","metadata":null},{"id":"2af20af9e5964cf099f435f4144a0aca","type":"GO_TERM","name":"symbiont-mediated perturbation of host apoptosis","canonical_id":"go:GO:0052150","description":"\"A process in which a symbiont gene product affects host apoptosis, leading to a change in the frequency, rate or extent of apoptosis in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"37055473a3984381ad0437d499c7fcc8","type":"GO_TERM","name":"symbiont-mediated perturbation of host autophagy","canonical_id":"go:GO:0075071","description":"\"A process in which a symbiont alters or subverts autophagy in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"b4ff9ff8ffb3421e9e2bded615c59a17","type":"GO_TERM","name":"symbiont-mediated perturbation of host cell cycle G0/G1 transition checkpoint","canonical_id":"go:GO:0039646","description":"\"A process in which a symbiont interferes with the normal execution of the host cell G0/G1 transition checkpoint. The host is defined as the larger of the organisms involved in a symbiotic interaction. Some viruses benefit from keeping cells in resting state (G0), while others favor entry through G1 and subsequent cell division to replicate more efficiently.\" [VZ:880]","metadata":null},{"id":"27b9be75b26b40f780b8490f52632210","type":"GO_TERM","name":"symbiont-mediated perturbation of host cell cycle G1/S transition checkpoint","canonical_id":"go:GO:0039645","description":"\"A process in which a symbiont interferes with the normal execution of the host cell G1/S transition checkpoint. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:24501404, VZ:880]","metadata":null},{"id":"b78cf49c2ee04730baf7dd3b54035e92","type":"GO_TERM","name":"symbiont-mediated perturbation of host cell cycle progression","canonical_id":"go:GO:0044071","description":"\"A process in which a symbiont interferes with the normal progression through the host cell cycle. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [MITRE:tk]","metadata":null},{"id":"086db9cdbbe2464db738461668175949","type":"GO_TERM","name":"symbiont-mediated perturbation of host cell endomembrane system","canonical_id":"go:GO:0052025","description":"\"The process in which an organism effects a change that impairs the structure or function of the host endomembrane system. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"d4cd74aa888d46f0b7d7943ab4c69b6d","type":"GO_TERM","name":"symbiont-mediated perturbation of host cell motility","canonical_id":"go:GO:1903653","description":"\"A process in which a symbiont alters or subverts cell motility in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GO_REF:0000063, GOC:TermGenie, PMID:25049409]","metadata":null},{"id":"8f7669040dc54e659ba3ac245c42a34d","type":"GO_TERM","name":"symbiont-mediated perturbation of host cell-cell junction","canonical_id":"go:GO:0044067","description":"\"The process in which an organism effects a change that impairs the structure or temporarily subverts the host intercellular junction. Intercellular junction include tight junctions and adherens junctions.\" [PMID:16102958]","metadata":null},{"id":"6d6fda06f5da4c4a898548a98183ad3d","type":"GO_TERM","name":"symbiont-mediated perturbation of host cellular process","canonical_id":"go:GO:0044068","description":"\"A process in which a symbiont alters or subverts a cellular biological process in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [MITRE:tk]","metadata":null},{"id":"44a08fde97e74e77ae6c62aa0274e554","type":"GO_TERM","name":"symbiont-mediated perturbation of host cholinergic synaptic transmission","canonical_id":"go:GO:0044760","description":"\"A process in which a symbiont alters or subverts cholinergic synaptic transmission, the communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse via the neurotransmitter choline, in its host organism.\" [GOC:jl]","metadata":null},{"id":"2b3178261b014d5f931c7f94bea1bb4a","type":"GO_TERM","name":"symbiont-mediated perturbation of host chromatin organization","canonical_id":"go:GO:0039525","description":"\"A process in which a symbiont alters or subverts the organization of chromatin in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:sp, PMID:11483770, PMID:16687403]","metadata":null},{"id":"fdba318c26094f14aa62c13e20499945","type":"GO_TERM","name":"symbiont-mediated perturbation of host cytoskeleton","canonical_id":"go:GO:0052039","description":"\"The process in which an organism effects a change that impairs the structure or function of the host cytoskeleton. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"4036a5d52be64ce1a2bfa278b546e1cd","type":"GO_TERM","name":"symbiont-mediated perturbation of host defense response","canonical_id":"go:GO:0052031","description":"\"A process in which a symbiont interferes with the ability of the host to mount a defense in response to its presence. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"3ba9fabf2418457e98377ad7bd279c96","type":"GO_TERM","name":"symbiont-mediated perturbation of host defenses","canonical_id":"go:GO:0030682","description":"\"A process in which a symbiont alters or subverts the normal execution of a host organism's defense response. The host defense response is mounted by the host in response to the presence of the symbiont. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"fd956ff750f94278aa34dee99e0aa18a","type":"GO_TERM","name":"symbiont-mediated perturbation of host erythrocyte aggregation","canonical_id":"go:GO:0020013","description":"\"Any process in which a symbiont organism modulates the frequency, rate or extent of erythrocyte aggregation in its host organism, e.g. the binding of parasite-infected erythrocytes to uninfected erythrocytes.\" [GOC:add, GOC:dgh, GOC:mb, GOC:pr, PMID:19467172, PMID:21305024]","metadata":null},{"id":"b7c6f325e355490dbb924729112560da","type":"GO_TERM","name":"symbiont-mediated perturbation of host exit from mitosis","canonical_id":"go:GO:0039593","description":"\"A process in which a virus interferes with the host cell completing the M phase of the cell cycle.\" [VZ:877]","metadata":null},{"id":"1617e75e7c11492aa6f5940478b19f21","type":"GO_TERM","name":"symbiont-mediated perturbation of host gene expression","canonical_id":"go:GO:0039656","description":"\"A process in which a symbiont alters or subverts the normal execution of host gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf]","metadata":null},{"id":"39780b7c63074ac0a50bd8f8e2aa63aa","type":"GO_TERM","name":"symbiont-mediated perturbation of host heat acclimation","canonical_id":"go:GO:0033638","description":"\"A process in which a symbiont alters or subverts the response of its host to heat acclimation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators, PMID:17425405, PMID:35350854]","metadata":null},{"id":"a60a59462e4a4cc88dab7736d1b0f409","type":"GO_TERM","name":"symbiont-mediated perturbation of host immune response","canonical_id":"go:GO:0052553","description":"\"A process in which a symbiont alters or subverts the immune response of the host organism; the immune response is any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"2edc190ee17e45dba8fe1b8481cf07e7","type":"GO_TERM","name":"symbiont-mediated perturbation of host induced systemic resistance","canonical_id":"go:GO:0052159","description":"\"A process in which a symbiont alters or subverts the induced systemic resistance in the host organism; induced systemic resistance is a response that confers broad spectrum systemic resistance to disease and that does not depend upon salicylic acid signaling. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"1acc367efd9e481898d1fbac9f261f34","type":"GO_TERM","name":"symbiont-mediated perturbation of host inflammatory response","canonical_id":"go:GO:0052032","description":"\"A process in which a symbiont alters or subverts the normal execution of the  inflammatory response of the host organism; the inflammatory response is the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"baa41ec8bd8a4aadb1de9681ed29664d","type":"GO_TERM","name":"symbiont-mediated perturbation of host innate immune response","canonical_id":"go:GO:0052167","description":"\"A process in which a symbiont alters or subverts the innate immune response of the host organism; the innate immune response is the host's first line of defense against infection. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"1c710e614f4b41a8a74b4b0e30f82750","type":"GO_TERM","name":"symbiont-mediated perturbation of host intracellular transport","canonical_id":"go:GO:0052038","description":"\"A process in which a symbiont alters or subverts the directed movement of substances within the cell of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"666cfc9327b145c49c18a6676134ffc2","type":"GO_TERM","name":"symbiont-mediated perturbation of host jasmonic acid signaling","canonical_id":"go:GO:0052088","description":"\"A process in which a symbiont alters or subverts a jasmonic acid-mediated signal transduction pathway in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06, PMID:29222513, PMID:35698792]","metadata":null},{"id":"5911a48159474152a2fb12e66ab88ecf","type":"GO_TERM","name":"symbiont-mediated perturbation of host membrane","canonical_id":"go:GO:0141171","description":"\"The process in which a symbiont effects a change that impairs the structure or function of a host membrane. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:14688136, PMID:17043230, PMID:28855258]","metadata":null},{"id":"e012c3ad321645999f3b3e8f7103f95e","type":"GO_TERM","name":"symbiont-mediated perturbation of host microtubule cytoskeleton","canonical_id":"go:GO:0141028","description":"\"The process in which an organism effects a change that impairs the structure or function of the host microtubule cytoskeleton. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21692747, PMID:26220855]","metadata":null},{"id":"99c42360e97c4fb9aa12ecdad670253e","type":"GO_TERM","name":"symbiont-mediated perturbation of host natural killer cell mediated immune response","canonical_id":"go:GO:0039671","description":"\"A process in which a symbiont alters or subverts the natural killer cell mediated immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:jl, PMID:15640804, PMID:18688275, UniProtKB-KW:KW-1131]","metadata":null},{"id":"1fb887e5053349f6939e05ab5bf75c92","type":"GO_TERM","name":"symbiont-mediated perturbation of host neurotransmitter secretion","canonical_id":"go:GO:0044079","description":"\"A process in which a symbiont alters or subverts the regulated release of a neurotransmitter from a cell in its host organism.\" [MITRE:tk]","metadata":null},{"id":"59f32db9f0a044d9aca65b4358cdc8f2","type":"GO_TERM","name":"symbiont-mediated perturbation of host opsonization","canonical_id":"go:GO:0141073","description":"\"A process in which a symbiont alters or subverts opsonization by the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18068388, PMID:18941224, PMID:2307127, PMID:28860090]","metadata":null},{"id":"f79ac69f0d04458e97a258ea9780c6f9","type":"GO_TERM","name":"symbiont-mediated perturbation of host phagocytosis","canonical_id":"go:GO:0052067","description":"\"A process in which in a symbiont interferes with or inhibits host phagocytosis by targeting phagocytic signaling or the cellular phagocytic machinery. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:23084912, PMID:29114249]","metadata":null},{"id":"34e60be71c454de983a4fc736cacd318","type":"GO_TERM","name":"symbiont-mediated perturbation of host phytoalexin production","canonical_id":"go:GO:0052165","description":"\"Any process in which a symbiont modulates the frequency, rate or extent of production of phytoalexins as part of the defense response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06, PMID:6870275]","metadata":null},{"id":"08daa0f68c884f7aa81f84aaba7416cf","type":"GO_TERM","name":"symbiont-mediated perturbation of host process","canonical_id":"go:GO:0044003","description":"\"A process in which a symbiont alters or subverts a biological process in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"ce9ed05e5a6845429b9a2f311dd4e905","type":"GO_TERM","name":"symbiont-mediated perturbation of host programmed cell death","canonical_id":"go:GO:0052040","description":"\"A process in which a symbiont gene product alters or subverts host programmed cell death, leading to a change in the frequency, rate or extent of host programmed cell death in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"cd5a31013dbb40cc93e9b4e64fc148d7","type":"GO_TERM","name":"symbiont-mediated perturbation of host receptor-mediated endocytosis","canonical_id":"go:GO:0044077","description":"\"A process in which a symbiont initiates, promotes, or enhances host receptor-mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [MITRE:tk]","metadata":null},{"id":"ed4c6e18e5664bbb883415e78bf17c9b","type":"GO_TERM","name":"symbiont-mediated perturbation of host receptor-mediated signal transduction","canonical_id":"go:GO:0075109","description":"\"A process by which a symbiont alters or subverts a receptor-mediated signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"37806bf1bc714069a6a75134bd029514","type":"GO_TERM","name":"symbiont-mediated perturbation of host resistance gene-dependent defense response","canonical_id":"go:GO:0052158","description":"\"Any process in which a symbiont modulates the frequency, rate or extent of the resistance gene-dependent defense response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"265d50ca11b24a06811f94c38965441b","type":"GO_TERM","name":"symbiont-mediated perturbation of host response to abiotic stimulus","canonical_id":"go:GO:0033635","description":"\"A process in which a symbiont alters or subverts the response of its host to an abiotic (non-living) stimulus. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"17e07f93bc1a4cf7bfbad80a152c0cb2","type":"GO_TERM","name":"symbiont-mediated perturbation of host salicylic acid-mediated signal transduction pathway","canonical_id":"go:GO:0052081","description":"\"A process in which a symbiont alters or subverts a salicylic acid-mediated signal transduction pathway in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06, PMID:35698792]","metadata":null},{"id":"caa9280f3d234da2930662a3da2f9004","type":"GO_TERM","name":"symbiont-mediated perturbation of host signal transduction pathway","canonical_id":"go:GO:0052027","description":"\"A process in which a symbiont alters or subverts a signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"11f4deed863c4f3085fa9a64dbb8c227","type":"GO_TERM","name":"symbiont-mediated perturbation of host small GTPase-mediated signal transduction","canonical_id":"go:GO:0044082","description":"\"A process in which a symbiont alters or subverts a small GTPase-mediated signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [MITRE:tk]","metadata":null},{"id":"9119811b1a78421088a0929b9dd24e3a","type":"GO_TERM","name":"symbiont-mediated perturbation of host synaptic transmission","canonical_id":"go:GO:0044758","description":"\"A process in which a symbiont alters or subverts synaptic transmission, the communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse, in its host organism.\" [GOC:jl, PMID:26487282, PMID:31075318]","metadata":null},{"id":"9b26e769187a4332b9619fa4b580133c","type":"GO_TERM","name":"symbiont-mediated perturbation of host systemic acquired resistance","canonical_id":"go:GO:0052160","description":"\"A process in which a symbiont alters or subverts systemic acquired resistance in the host organism; systemic acquired resistance is a salicylic acid-mediated response that confers broad spectrum systemic resistance. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"1d5b9bf8a1954b05a7524353204fd936","type":"GO_TERM","name":"symbiont-mediated perturbation of host tight cell-cell junction","canonical_id":"go:GO:0098865","description":"\"The process in which an organism effects a change that impairs the structure or temporarily subverts the tight cell-cell junctions between cells of the host. Tight cell-cell junctions, a cell-cell junction that seals cells together in an epithelium in a way that prevents even small molecules from leaking from one side of the sheet to the other.\" [PMID:24287273]","metadata":null},{"id":"b1e11d5cd362445ebd3f5f662d776dfc","type":"GO_TERM","name":"symbiont-mediated perturbation of host transcription","canonical_id":"go:GO:0052026","description":"\"A process in which a symbiont alters or subverts transcription in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"174ccd8b60094fa098683bc31c02488a","type":"GO_TERM","name":"symbiont-mediated perturbation of host translation","canonical_id":"go:GO:0019057","description":"\"A process in which a symbiont alters or subverts translation of mRNA into protein in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [ISBN:0781718325]","metadata":null},{"id":"d27f35360b6c44d7a830f8f2ba4a3e55","type":"GO_TERM","name":"symbiont-mediated perturbation of host ubiquitin-like protein modification","canonical_id":"go:GO:0039648","description":"\"A process by which a symbiont alters ubiquitin-like protein modification of target proteins of either host or symbiont proteins. This includes ubiquitination, SUMOylation, NEDDylation, and ISG15ylation. The ubiquitination status of a protein  affects whether it is targeted to the proteasome for degradation. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:25166298, PMID:26483404, PMID:26712804]","metadata":null},{"id":"5a36925c26c24ff2b49331155e284a5b","type":"GO_TERM","name":"symbiont-mediated perturbation of host vacuole organization","canonical_id":"go:GO:0044075","description":"\"A process in which a symbiont alters or subverts vacuole organization in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:25139904]","metadata":null},{"id":"c8c5c711003f4021900c54d63253670c","type":"GO_TERM","name":"symbiont-mediated perturbation of host vesicle-mediated transport","canonical_id":"go:GO:1990215","description":"\"A process in which a symbiont alters or subverts vesicle-mediated transport in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:22319451, PMID:24248335, PMID:30893609, PMID:31492901]","metadata":null},{"id":"f467a353de9f432fbbbd9ba655c9c01f","type":"GO_TERM","name":"symbiont-mediated pore formation in host plasma membrane","canonical_id":"go:GO:0044658","description":"\"The disruption of host plasma membrane integrity by formation of a pore, resulting in deregulated ion homeostasis, and cellular dysfunction that can result in cell death.\" [GOC:jl, PMID:7510043]","metadata":null},{"id":"5bd774106563460394b798eacdc8080b","type":"GO_TERM","name":"symbiont-mediated response to host defenses","canonical_id":"go:GO:0052200","description":"\"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detecting the defenses of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"b9dea4bcb4a34a98b0e85a0afc3517e1","type":"GO_TERM","name":"symbiont-mediated stabilization of host tight cell-cell junction","canonical_id":"go:GO:0098864","description":"\"The process in which a symbiont organism that stabilizes the its host tight cell-cell junctions, making them less dynamic. The tight junction is a cell-cell junction that seals cells together in an epithelium in a way that prevents even small molecules from leaking from one side of the sheet to the other, and plays a role in the inflammatory response of the host.\" [PMID:25838979]","metadata":null},{"id":"65639ec8d61343559a8078aa58fe1506","type":"GO_TERM","name":"symbiont-mediated suppression of defense-related host salicylic acid-mediated signal transduction pathway","canonical_id":"go:GO:0052003","description":"\"A process in which a virus interferes with, inhibits or disrupts a host salicylic acid-mediated signal transduction pathways during the host defense response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"e4bd84b1f36a4cefa367dd0abecede55","type":"GO_TERM","name":"symbiont-mediated suppression of host B-cell mediated immune response","canonical_id":"go:GO:0052086","description":"\"A process by which a symbiont interferes with, inhibits or disrupts the normal execution of the B-cell mediated immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"0847e7746cd94c77a1e4fe214eb2ec0e","type":"GO_TERM","name":"symbiont-mediated suppression of host CRISPR-cas system","canonical_id":"go:GO:0098672","description":"\"A process by which a symbiont inhibits or disrupts the CRISPR-cas system of its host. Bacteria and archaea use CRISPR-Cas adaptive immune systems to defend themselves from infection by bacteriophages (phages), and phages have various mechanisms to counter the CRISPR-cas system.\" [PMID:23242138, PMID:23446421, PMID:26416740, PMID:28749735]","metadata":null},{"id":"137c80893f83467d8631694573ce9d37","type":"GO_TERM","name":"symbiont-mediated suppression of host DNA replication","canonical_id":"go:GO:0098673","description":"\"Any process by which a virus inhibits DNA replication in its host cell. Some bacteriophages are known to do this, possibly as a way of increasing the pool of nucleotides available for virus replication.\" [PMID:17010157, PMID:21205014]","metadata":null},{"id":"b0459c58e6c245a9baf4baeab36a3324","type":"GO_TERM","name":"symbiont-mediated suppression of host G protein-coupled receptor signal transduction","canonical_id":"go:GO:0075120","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a G protein-coupled receptor signal transduction in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators, PMID:17562776, PMID:23027529]","metadata":null},{"id":"7bf357b0670546f7924a7d0d300faba4","type":"GO_TERM","name":"symbiont-mediated suppression of host ISG15-protein conjugation","canonical_id":"go:GO:0039579","description":"\"Any process in which a symbiont inhibits or disrupts a host ubiquitin-like protein ISG15 conjugation to a substrate. ISG15 is a ubiquitin-like protein that is conjugated to lysine residues on various target proteins. For example, some viruses escape the antiviral activity of ISG15 by using different mechanisms; the influenza B virus NS1 protein blocks the covalent linkage of ISG15 to its target proteins by directly interacting with ISG15, while the papain-like protease from the coronavirus cleaves ISG15 derivatives.\" [PMID:11157743, PMID:18078692, PMID:18604270, PMID:32845033]","metadata":null},{"id":"a9326ca7a230456a98f573ac7d3f995a","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade","canonical_id":"go:GO:0039514","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:sp, PMID:20624917, PMID:22919663, PMID:27437422, PMID:29924996, PMID:31413201]","metadata":null},{"id":"d53932a626c340d3b56b77f06f1a62c0","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade via inhibition of JAK1 activity","canonical_id":"go:GO:0039576","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism by reducing the activity of host JAK1 (Janus Kinase 1).\" [PMID:16188985]","metadata":null},{"id":"30dee2aa6a6a466f9f7fd3646daa0658","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade via inhibition of STAT activity","canonical_id":"go:GO:0039562","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism by reducing the activity of host STAT (signal transducer and activator of transcription). STATs are SH2 domain-containing proteins which lie downstream of many signaling receptors. Upon phosphorylation by JAKs, STAT proteins hetero- or homo-dimerize and translocate to the nucleus to activate transcription of target genes.\" [GOC:bf]","metadata":null},{"id":"c1f0000d14304d52997031625e02f70d","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade via inhibition of STAT1 activity","canonical_id":"go:GO:0039563","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism by reducing the activity of host STAT1 (signal transducer and activator of transcription 1).\" [PMID:32699158]","metadata":null},{"id":"29486522f50649dfb47d08b5ccdbc565","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade via inhibition of STAT2 activity","canonical_id":"go:GO:0039564","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism by reducing the activity of host STAT2 (signal transducer and activator of transcription 2).\" [PMID:32699158]","metadata":null},{"id":"7fbbcd32074f451e9745fabfc30cf897","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade via inhibition of host IRF9 activity","canonical_id":"go:GO:0039560","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism by reducing the activity of host IRF9 (interferon regulatory factor-9), a transcription factor involved in the innate immune response. For example, viral infection triggers binding of IRF9 to phosphorylated STAT1 and STAT2, forming the ISGF3 complex. The ISGF3 complex migrates to the nucleus and activates transcription of IFN-responsive genes.\" [PMID:10388655, PMID:19109390]","metadata":null},{"id":"e5034d1c3a444f28a9d7526ce793012e","type":"GO_TERM","name":"symbiont-mediated suppression of host JAK-STAT cascade via inhibition of host TYK2 activity","canonical_id":"go:GO:0039574","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a JAK-STAT signal cascade in the host organism by reducing the activity of host TYK2 (tyrosine kinase 2). TYK2 is an intracellular signal-transducing tyrosine kinase involved in numerous cytokines and interferons signaling pathways and transmits the cytokine signal by phosphorylating receptor subunits.\" [PMID:16987978, PMID:19085955]","metadata":null},{"id":"7aeb517088e640e2b864b51bae3201bf","type":"GO_TERM","name":"symbiont-mediated suppression of host MAPK cascade","canonical_id":"go:GO:0141070","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a MAPK signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18005697]","metadata":null},{"id":"300f7a00934d48b0a3b9b367e20d061c","type":"GO_TERM","name":"symbiont-mediated suppression of host NF-kappaB cascade","canonical_id":"go:GO:0085034","description":"\"A process in which a symbiont interferes with, inhibits or disrupts an NF-kappaB-mediated signaling cascade in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18250452, PMID:22442494, PMID:24648522, PMID:33567255]","metadata":null},{"id":"e03a3b9cbcc74613992f15a984d6b9e4","type":"GO_TERM","name":"symbiont-mediated suppression of host PKR/eIFalpha signaling","canonical_id":"go:GO:0039580","description":"\"A process in which a symbiont inhibits or disrupts host PKR (Protein Kinase regulated by RNA) signaling. PKR phosphorylates host targets such as the translation initiation factor eIF2alpha that inhibits protein synthesis as an antimicrobial response. Inhibition of host PKR signaling maintains the host ability to translate mRNA. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15207627]","metadata":null},{"id":"76bd9cceb91043938633e476cdd71959","type":"GO_TERM","name":"symbiont-mediated suppression of host RNAi-mediated antiviral immune response","canonical_id":"go:GO:0140533","description":"\"A process by which a symbiont inhibits or disrupts the host's RNAi-mediated antiviral immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:17693253]","metadata":null},{"id":"a926b0af3c2740cf9233b4d6977619b9","type":"GO_TERM","name":"symbiont-mediated suppression of host T-cell mediated immune response","canonical_id":"go:GO:0052085","description":"\"A process by which a symbiont interferes with, inhibits or disrupts the normal execution of the T-cell mediated immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"fba94c7250614e008b34fd33d7bda3e0","type":"GO_TERM","name":"symbiont-mediated suppression of host adaptive immune response","canonical_id":"go:GO:0039504","description":"\"A process by which a symbiont inhibits or disrupts the normal execution of the adaptive immune response of the host organism, an immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process, and allowing for enhanced response to subsequent exposures to the same antigen (immunological memory).\" [GOC:add, GOC:bf, GOC:sp]","metadata":null},{"id":"0709822592d3402b96ae24c00788855f","type":"GO_TERM","name":"symbiont-mediated suppression of host anti-inflammatory cytokine signaling","canonical_id":"go:GO:0141174","description":"\"A process by which a symbiont inhibits or disrupts anti-inflammatory cytokine signaling in the host organism, either by disruption of production, sequesteration, or destruction of at least one component of the signaling pathway.  Anti-inflammatory cytokines include: interleukin (IL)-1, IL-4, IL-6, IL-10, IL-11, and IL-13. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:19168731, PMID:29720526, PMID:32754056]","metadata":null},{"id":"b9442397413e440fa84fb4ce219fb37e","type":"GO_TERM","name":"symbiont-mediated suppression of host antigen processing and presentation","canonical_id":"go:GO:0039588","description":"\"A process by which a symbiont inhibits or disrupts the normal processing and presentation of a peptide antigen on its cell surface in association with an MHC protein complex.\" [VZ:815]","metadata":null},{"id":"c76b51da5d374eae8efabd2e47c698d4","type":"GO_TERM","name":"symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I","canonical_id":"go:GO:0046776","description":"\"A process by which a symbiont inhibits or disrupts the normal processing and presentation of a peptide antigen on its cell surface in association with an MHC class I transmembrane protein complex. One mechanism of suppression is by direct inhibition of host tapasin, a type I transmembrane protein essential for the optimal expression of stable MHC class I molecules on the host cell surface. By inhibiting host tapasin activity, some viruses can prevent presentation of their antigens at the cell surface, and thereby evade the host anti-viral immune response.\" [GOC:add, GOC:bf, PMID:10227971, PMID:10859382, PMID:9175839]","metadata":null},{"id":"5bc9ff2f3cc042c987d5f6df2e8ecd61","type":"GO_TERM","name":"symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class II","canonical_id":"go:GO:0039505","description":"\"A process by which a symbiont inhibits or disrupts the normal processing and presentation of a peptide antigen on its cell surface in association with an MHC class II protein complex.\" [GOC:add, GOC:bf, PMID:27832589, VZ:820]","metadata":null},{"id":"a89ca620b82143c6a21ae6a75050f636","type":"GO_TERM","name":"symbiont-mediated suppression of host apoptosis","canonical_id":"go:GO:0033668","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of host apoptosis, leading to a decrease in the frequency, rate or extent of apoptosis in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"3691e50502ef4d6793ad21c13fd1c343","type":"GO_TERM","name":"symbiont-mediated suppression of host autophagy","canonical_id":"go:GO:0140321","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of autophagy in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pg]","metadata":null},{"id":"220c818ee0554a8b831604461e2d1c08","type":"GO_TERM","name":"symbiont-mediated suppression of host cAMP/PKA signal transduction","canonical_id":"go:GO:0075210","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cAMP/PKA signal transduction in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"c13059a945d84407975ffd93faab4186","type":"GO_TERM","name":"symbiont-mediated suppression of host cGAS-STING signal transduction","canonical_id":"go:GO:0141074","description":"\"A process in which a virus interferes with, inhibits or disrupt a cGAS/STING signal transduction in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:26405230, PMID:27234299, PMID:29018427]","metadata":null},{"id":"5adf45784d1144339fb65afda9997019","type":"GO_TERM","name":"symbiont-mediated suppression of host calcium-mediated signal transduction","canonical_id":"go:GO:0075135","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a calcium signal transduction in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"486a70c6564f40669cc47add22679300","type":"GO_TERM","name":"symbiont-mediated suppression of host cell division","canonical_id":"go:GO:0044865","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of cell division in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:24218612]","metadata":null},{"id":"bbb9e33d59d347058e53b556111b4421","type":"GO_TERM","name":"symbiont-mediated suppression of host cell wall biogenesis","canonical_id":"go:GO:0039636","description":"\"Any process in which a virus stops, prevents, or reduces the frequency, rate or extent of cell wall biogenesis in the host organism. Cell wall biogenesis includes the biosynthesis of constituent macromolecules, and the assembly and arrangement of these constituent parts.\" [GOC:bf, GOC:bm, GOC:jl]","metadata":null},{"id":"53ae1bb7e6634de2abcb88bee896ebae","type":"GO_TERM","name":"symbiont-mediated suppression of host chemokine signal transduction pathway","canonical_id":"go:GO:0141135","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a chemokine signaling pathway, a G protein-coupled receptor signal transduction pathway activated by a chemokine. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:16581912]","metadata":null},{"id":"36fad25748204f7197edefe7df08f93f","type":"GO_TERM","name":"symbiont-mediated suppression of host cholinergic synaptic transmission","canonical_id":"go:GO:0044761","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of cholinergic synaptic transmission, communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse via the neurotransmitter choline, in its host organism.\" [GOC:jl, PMID:37157163]","metadata":null},{"id":"1a1f63bca5cb45e2ab98662417c25266","type":"GO_TERM","name":"symbiont-mediated suppression of host complement activation","canonical_id":"go:GO:0042784","description":"\"A process by which a symbiont inhibits or disrupts the normal execution of the activation of complement in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:20194595, PMID:21191012, PMID:25830295, PMID:7745740]","metadata":null},{"id":"ce2a81461b484babb63ef9519688d0f0","type":"GO_TERM","name":"symbiont-mediated suppression of host complement activation by activation of host proteases","canonical_id":"go:GO:0141203","description":"\"A process by which a symbiont prevents host complement activation by recruiting host proteases, destroying the complement before it has its effect on the symbiont.\" [PMID:15792635, PMID:26945067, PMID:34305859]","metadata":null},{"id":"0330dc6354eb4ce0865e0934b78b4105","type":"GO_TERM","name":"symbiont-mediated suppression of host complement activation by complement sequestering","canonical_id":"go:GO:0141116","description":"\"A process by which a symbiont prevents host complement activation by sequestering it away from its surface.\" [PMID:18323455]","metadata":null},{"id":"87437f147b39422e864c094006c74da2","type":"GO_TERM","name":"symbiont-mediated suppression of host complement activation by inactivation of complement proteins","canonical_id":"go:GO:0141115","description":"\"A process by which a symbiont disrupts or prematurely activates host complement so that its microbial-destroying activities fail.\" [PMID:24312361, PMID:34305859]","metadata":null},{"id":"5fc118fac320439492a5e2be56c20d68","type":"GO_TERM","name":"symbiont-mediated suppression of host complement activation by recruitment of complement control protein","canonical_id":"go:GO:0141117","description":"\"A process by which a symbiont prevents the activation of host complement by binding a soluble complement control protein (CCP) of the host and recruiting it to the microbe surface. The normal role of CCPs is to prevent complement activation on 'self' cellular targets. When soluble CCPs are recuited to the surface of a microbe, the complement fails to activate.\" [PMID:17513779, PMID:22540535, PMID:24129254, PMID:27304426]","metadata":null},{"id":"96937e9ba13a41a384da7b7adbf3d7fe","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway","canonical_id":"go:GO:0039537","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway. This is a mechanism by which the virus evades the host innate immune response.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"862e1066a9794b9886e608b6cab66c13","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of IKBKE activity","canonical_id":"go:GO:0039724","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway by reducing the activity of host I-kappa-B kinase epsilon (IKBKE/IKK-epsilon/IKK-E).\" [PMID:19153231, PMID:22532683, PMID:24173023]","metadata":null},{"id":"547d80fe5daf4cb994aae1d8adabb9ae","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of IRF3 activity","canonical_id":"go:GO:0039548","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway in a host organism by reducing the activity of host IRF3 (interferon regulatory factor-3). IRF3 is a transcription factor in the RIG-I/MDA-5 signaling pathway. Viral infection triggers phosphorylation of cytoplasmic IRF3, which allows IRF3 to form a homodimer, migrate to the nucleus, and activate transcription of IFN-alpha and IFN-beta genes.\" [PMID:21632562]","metadata":null},{"id":"471e60fb9e7a4ae2b57034656b13ae8b","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of IRF7 activity","canonical_id":"go:GO:0039557","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway by reducing the activity of IRF7 (interferon regulatory factor-7). IRF7 a transcription factor in the RIG-I/MDA-5 signaling pathway. Viral infection triggers phosphorylation of cytoplasmic IRF7, which allows IRF7 to form a homodimer, migrate to the nucleus, and activate transcription of IFN-alpha and IFN-beta genes.\" [PMID:11943871, PMID:16014964, PMID:19557165]","metadata":null},{"id":"be632f81200e4ad28539c649d09d4bf6","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity","canonical_id":"go:GO:0039545","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway in a host organism by reducing the activity of host MAVS (mitochondrial antiviral signaling protein). MAVS is a signal transducer that lies downstream of the viral RNA receptors MDA-5 and RIG-I to coordinate host innate immune responses.\" [PMID:17438296, PMID:22674996]","metadata":null},{"id":"06ba8eec018840f0aa411520a83274f1","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MDA-5 activity","canonical_id":"go:GO:0039554","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway by inhibiting the activity of MDA-5 (also known as IFIH1). The cytoplasmic pattern recognition receptor MDA-5 detects dsRNA synthesized during active viral replication and triggers a signaling pathway to protect the host against viral infection, for example by inducing the expression of antiviral cytokines.\" [PMID:19019954, PMID:33727702]","metadata":null},{"id":"433333efed834b8c98c65f18d35ed79c","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of RIG-I activity","canonical_id":"go:GO:0039540","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway by inhibiting the activity of RIG-1 (also known as DDX58). The cytoplasmic pattern recognition RIG-I recognizes viral RNA synthesized during active viral replication and signals to protect the host against viral infection, for example by inducing the expression of antiviral cytokines.\" [PMID:19454348, PMID:26138103]","metadata":null},{"id":"ce16dc24783642728fc81b4ca8af2a42","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of TBK1 activity","canonical_id":"go:GO:0039723","description":"\"Any process in which a symbiont stops, prevents, or reduces a cytoplasmic pattern recognition receptor signaling pathway in a host organism by reducing the activity of a host serine/threonine kinase TBK1.\" [PMID:22171259, PMID:34084167]","metadata":null},{"id":"0bd28635e1934b7d80acf6d552377c5a","type":"GO_TERM","name":"symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of TRAF activity","canonical_id":"go:GO:0140476","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a cytoplasmic pattern recognition receptor signaling pathway by reducing the activity of host TRAF activity.\" [PMID:36814922, PMID:36845015]","metadata":null},{"id":"304d47c384b54ff9b83e5cbe12d57b2f","type":"GO_TERM","name":"symbiont-mediated suppression of host defenses","canonical_id":"go:GO:0044414","description":"\"A process in which a symbiont interferes with, inhibits or disrupts the normal execution of host defense(s) by active mechanisms that normally result in the shutting down of a host pathway. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"6c0bc60e96134e58b76856cda98075eb","type":"GO_TERM","name":"symbiont-mediated suppression of host dendritic cell mediated immune response","canonical_id":"go:GO:0039673","description":"\"A process in which a symbiont inhibits or disrupts the dendritic cell mediated immune response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:jl, UniProtKB-KW:KW-1118]","metadata":null},{"id":"65e49a7e840941c78b55129962825fc2","type":"GO_TERM","name":"symbiont-mediated suppression of host ethylene-mediated defense response","canonical_id":"go:GO:0052005","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of the ethylene-mediated defense response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"aaf9f56b8fcc48498894b8a026e67664","type":"GO_TERM","name":"symbiont-mediated suppression of host exocytosis","canonical_id":"go:GO:0141157","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of  host exocytosis. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:17185412]","metadata":null},{"id":"187b4f2880524ad98f41e81b3b4ac9f8","type":"GO_TERM","name":"symbiont-mediated suppression of host gene expression","canonical_id":"go:GO:0039657","description":"\"A process in which a symbiont inhibits or disrupts expression of genes in its host. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [VZ:1582]","metadata":null},{"id":"4ac4dca31feb43a1846bca1f1b02d795","type":"GO_TERM","name":"symbiont-mediated suppression of host immune response","canonical_id":"go:GO:0052562","description":"\"A process in which a symbiont interferes with, inhibits or disrupts the normal execution of an immune response of the host organism. The immune response is any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"08e4a958f3ce449ca730638845c006a4","type":"GO_TERM","name":"symbiont-mediated suppression of host immunoglobulin-mediated immune response","canonical_id":"go:GO:0141140","description":"\"A process in which a symbiont interferes with, inhibits or disrupts the normal execution of the immunoglobulin-mediated immune response of the host organism. One common mechanism by which this happens is the direct inhibition of immunoglobulin activity, by direct binding or modification. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18426869, PMID:22256861, PMID:24753590]","metadata":null},{"id":"30e3b627635c48dba7888dded59896ff","type":"GO_TERM","name":"symbiont-mediated suppression of host immunothrombosis","canonical_id":"go:GO:0140422","description":"\"A process by which a symbiont inhibits or disrupts thrombosis formation induced by host immune cells in response to a pathogenic symbiont. Microbial-associated molecular patterns (MAMPs) are recognized by host signaling receptors, leading to platelet activation. The blood clot formed creates a physical barrier that prevent symbiont dessimination, traps and kills pathogens.\" [PMID:24278414, PMID:40973015, PMID:42049611]","metadata":null},{"id":"8398be81e4ef459ebab82bf540f092ba","type":"GO_TERM","name":"symbiont-mediated suppression of host inflammasome-mediated signal transduction","canonical_id":"go:GO:0141081","description":"\"A process in which a symbiont interferes with, inhibits or stops an inflammasome-mediated signal transduction pathway in the host organism by interfering with its normal execution. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:26687278, PMID:27214553, PMID:29061850, PMID:34324582, PMID:36227980]","metadata":null},{"id":"2dce5b94e21c440ea5eea61cbc4a7dae","type":"GO_TERM","name":"symbiont-mediated suppression of host inflammatory response","canonical_id":"go:GO:0052036","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of  inflammatory response in the host organism; the inflammatory response is the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"a2ae1a10d38440aaa4fa49add46d4a68","type":"GO_TERM","name":"symbiont-mediated suppression of host innate immune response","canonical_id":"go:GO:0052170","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of the innate immune response of the host organism, the host's first line of defense against infection. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"4b7249b39aba49c8bf60ca4557bf6221","type":"GO_TERM","name":"symbiont-mediated suppression of host interferon-mediated signaling pathway","canonical_id":"go:GO:0140886","description":"\"Any process in which a virus stops, prevents, or reduces the frequency, rate or extent of interferon-mediated signaling in the host organism.\" [PMID:31266861, PMID:33097660, PMID:34305858]","metadata":null},{"id":"bfec0b6945144113806da5e23ab78e03","type":"GO_TERM","name":"symbiont-mediated suppression of host mRNA export from nucleus","canonical_id":"go:GO:0039522","description":"\"A process in which a symbiont inhibits or disrupts the normal movement of mRNA from the nucleus to the cytoplasm of the host cell, leading to shutoff of host protein expression. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:sp, PMID:22334672]","metadata":null},{"id":"3a0df695cce2469ea6fb813597ba5028","type":"GO_TERM","name":"symbiont-mediated suppression of host mRNA processing","canonical_id":"go:GO:0039524","description":"\"A process in which a symbiont inhibits or disrupts mRNA processing in its host. mRNA processing is the conversion of a primary mRNA transcript into one or more mature mRNA(s) prior to translation into polypeptide. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:sp, PMID:16571812, VZ:903]","metadata":null},{"id":"fc46755377064402a40d85149dbe7297","type":"GO_TERM","name":"symbiont-mediated suppression of host mRNA splicing","canonical_id":"go:GO:0046780","description":"\"A process in which a symbiont inhibits or disrupts the splicing of host mRNA, thus interfering with normal host protein production. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:12660167, PMID:19729513]","metadata":null},{"id":"24dec65788664f05904be53e42e23218","type":"GO_TERM","name":"symbiont-mediated suppression of host mRNA transcription via inhibition of RNA polymerase II activity","canonical_id":"go:GO:0039523","description":"\"A process in which a symbiont inhibits or disrupts the transcription of genes into mRNA in its host by directly inhibiting host RNA polymerase II activity. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:sp, PMID:25233083, PMID:36144426]","metadata":null},{"id":"cdcf31da75c2485e9b30c5d9b8f0aae5","type":"GO_TERM","name":"symbiont-mediated suppression of host natural killer cell activation","canonical_id":"go:GO:0039672","description":"\"A process in which a symbiont interferes with, inhibits or disrupts natural killer cell activation in the host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:10799855]","metadata":null},{"id":"a5f108c5c83f4512b26d2bf47502fec0","type":"GO_TERM","name":"symbiont-mediated suppression of host neurotransmitter secretion","canonical_id":"go:GO:0044762","description":"\"A process in which a symbiont inhibits or disrupts the regulated release of a neurotransmitter from a cell in its host organism.\" [PMID:1328520, PMID:7901002]","metadata":null},{"id":"3a8733d7f44646da8bb21dd98724f5bc","type":"GO_TERM","name":"symbiont-mediated suppression of host neutrophil extracellular trap formation","canonical_id":"go:GO:0141145","description":"\"A process in which a symbiont inhibits or disrupts the formation of neutrophil extracellular traps by the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:30038902, PMID:34108482]","metadata":null},{"id":"f7e8158b551b4d19a8cff7eee3a04407","type":"GO_TERM","name":"symbiont-mediated suppression of host pathogen-associated molecular pattern receptor signaling pathway","canonical_id":"go:GO:0052078","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a PAMP signaling pathway in its host organism, initiated by a ligand binding of a pattern recognition receptor (PRR) to activate a plant innate immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:18005697]","metadata":null},{"id":"1ecfa65705114a3eaa1f6faf82532c75","type":"GO_TERM","name":"symbiont-mediated suppression of host peptidoglycan biosynthetic process","canonical_id":"go:GO:0039635","description":"\"Any process in which a symbiont stops, prevents, or reduces the frequency, rate or extent of peptidoglycan biosynthesis in the host organism. Peptidoglycans are any of a class of glycoconjugates found in bacterial cell walls, and phages have mechanisms to disrupt their host's cell walls.\" [GOC:bf, GOC:bm, GOC:jl]","metadata":null},{"id":"970869d18036487881ef127b8db8d473","type":"GO_TERM","name":"symbiont-mediated suppression of host phagosome acidification","canonical_id":"go:GO:0141159","description":"\"A process in which a symbiont inhibits or disrupts the normal acidification of host phagosomes. Mechanisms by which a symbiont prevents host phagosome acidification include the inhibitition of host V-ATPase, the proton pump that acidifies the phagosome, or disruption of the phagosome membrane by pore-forming toxin. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:20333253, PMID:22087003, PMID:33505976]","metadata":null},{"id":"cb5cea4170d545488c8f814d742e1876","type":"GO_TERM","name":"symbiont-mediated suppression of host phagosome maturation","canonical_id":"go:GO:0141158","description":"\"A process in which a symbiont inhibits or disrupts the normal maturation of host phagosomes. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21501366, PMID:30181274, PMID:30733336, PMID:30937925]","metadata":null},{"id":"adc4170ac0854f9c9c3003f6a480d7fe","type":"GO_TERM","name":"symbiont-mediated suppression of host phytoalexin production","canonical_id":"go:GO:1990217","description":"\"A process in which a symbiont inhibits or disrupts the production of phytoalexins in the host organism. Phytoalexins are produced by plants to fight against pathogens. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:21402357]","metadata":null},{"id":"b9ff3ef327bc490783bf965ea66a992a","type":"GO_TERM","name":"symbiont-mediated suppression of host pro-inflammatory cytokine signaling","canonical_id":"go:GO:0141173","description":"\"A process by which a symbiont inhibits or disrupts pro-inflammatory cytokine signaling in the host organism, either by disruption of production, sequesteration, or destruction of at least one component of the signaling pathway. Pro-inflammatory cytokines include: IL-1, IL-12, IL-18, TNF, IFN-gamma, and GM-CSF. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:20008527, PMID:24508400, PMID:32117813]","metadata":null},{"id":"0401e78509d94a869c1f86711390df48","type":"GO_TERM","name":"symbiont-mediated suppression of host programmed cell death","canonical_id":"go:GO:0052041","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of host programmed cell death, leading to a decrease in the frequency, rate or extent of programmed cell death in the host cell. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:curators]","metadata":null},{"id":"e062e22cdcd94ab884a6dba9c0adf78e","type":"GO_TERM","name":"symbiont-mediated suppression of host protein localization to phagocytic vesicle","canonical_id":"go:GO:0036522","description":"\"A process in which a symbiont inhibits or disrupts the normal localization of a protein to the host phagosome. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf, GOC:PARL, PMID:25063865]","metadata":null},{"id":"7557273ccc1d4f22a1a66c2ae820b820","type":"GO_TERM","name":"symbiont-mediated suppression of host reactive oxygen species generation","canonical_id":"go:GO:0141083","description":"\"A process in which a symbiont interferes with, inhibits or disrupts the host signal transduction pathways leading to the production of reactive oxygen species as part of the host innate immune response. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:27473656, PMID:31375544]","metadata":null},{"id":"6303deb3d83a4e15966094786314f98a","type":"GO_TERM","name":"symbiont-mediated suppression of host receptor-mediated signal transduction","canonical_id":"go:GO:0075111","description":"\"A process in which a virus interferes with, inhibits or disrupts a receptor-mediated signal transduction pathway in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"91746754db6d4db1bde175830b7a6ecd","type":"GO_TERM","name":"symbiont-mediated suppression of host resistance gene-dependent defense response","canonical_id":"go:GO:0033660","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of the resistance gene-dependent defense response of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"7f4e366335014565abf4a09d19229e07","type":"GO_TERM","name":"symbiont-mediated suppression of host signal transduction pathway","canonical_id":"go:GO:0052029","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a host signal transduction pathway. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:mtg_pamgo_17jul06]","metadata":null},{"id":"94286b1b51b346f5a1715902b48c7bec","type":"GO_TERM","name":"symbiont-mediated suppression of host signal transduction pathway via antagonism of host cell surface receptor","canonical_id":"go:GO:0141129","description":"\"A process by which a symbiont alters or subverts a host cell surface receptor-mediated signal transduction pathway by binding to and inhibiting the receptor of the pathway. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:10221874, PMID:22714643]","metadata":null},{"id":"f6ec42a7f2e248b497e8cb205b260de0","type":"GO_TERM","name":"symbiont-mediated suppression of host stress granule assembly","canonical_id":"go:GO:0140411","description":"\"A process in which a symbiont inhibits or disrupts the normal assembly of stress granule of the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction. Stress granules are dynamic cytoplasmic condensates formed through liquid-liquid phase separation. They act as a critical hub for both cellular stress adaptation and defense against viruses.\" [PMID:32353859, PMID:39345463]","metadata":null},{"id":"ffbbf0f0efab43a3b9d73ee34188504e","type":"GO_TERM","name":"symbiont-mediated suppression of host synaptic transmission","canonical_id":"go:GO:0044759","description":"\"A process in which a symbiont inhibits or disrupts the normal execution of synaptic transmission, communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse, in its host organism.\" [GOC:jl]","metadata":null},{"id":"2822e7610cfa4bf6b7f397ad4db3c374","type":"GO_TERM","name":"symbiont-mediated suppression of host toll-like receptor signaling pathway","canonical_id":"go:GO:0039722","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a toll-like receptor signaling pathway in the host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:15944308, PMID:17299722, PMID:18327267]","metadata":null},{"id":"2282f9e85d7d4681a02d2aa3696eb580","type":"GO_TERM","name":"symbiont-mediated suppression of host toll-like receptor signaling pathway via inhibition of TRAF activity","canonical_id":"go:GO:0140470","description":"\"A process in which a symbiont interferes with, inhibits or disrupt a toll-like receptor signaling pathway in the host organism by reducing the activity of host TRAF.\" [PMID:17349955, PMID:32983084, PMID:36845015]","metadata":null},{"id":"31c877d4eecd40f6a4c8743cb5bc4ad2","type":"GO_TERM","name":"symbiont-mediated suppression of host transcription","canonical_id":"go:GO:0039653","description":"\"A process in which a symbiont inhibits or disrupts transcription of genes into mRNA in its host. For example, symbiont proteins can interfere with host RNA polymerase or with transcription factors. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [VZ:1577]","metadata":null},{"id":"6563aaed7552457399fa6679adb8ce15","type":"GO_TERM","name":"symbiont-mediated suppression of host transcription initiation from RNA polymerase II promoter","canonical_id":"go:GO:0039602","description":"\"Any process in which a virus stops, prevents, or reduces the frequency, rate or extent of the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a host DNA template. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:1316611]","metadata":null},{"id":"11dfffb97d0d49f69ea28fa5f0f9d6d2","type":"GO_TERM","name":"symbiont-mediated suppression of host translation","canonical_id":"go:GO:0039604","description":"\"A process in which a symbiont inhibits or disrupts the translation of host mRNA into protein, for example by cleavage of the host mRNAs. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:22046136, PMID:22174690, PMID:32703221]","metadata":null},{"id":"a26cd392a0b3412984e11eebc8e76b82","type":"GO_TERM","name":"symbiont-mediated suppression of host translation elongation","canonical_id":"go:GO:0141155","description":"\"A process in which a symbiont inhibits or disrupts the translation elongation of host mRNA into protein, for example by directly inhibiting elongation factors. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:10657208, PMID:18281405, PMID:18448518]","metadata":null},{"id":"a15d6e5229c446ef90563f12e62e1936","type":"GO_TERM","name":"symbiont-mediated suppression of host translation initiation","canonical_id":"go:GO:0039606","description":"\"A process in which a symbiont inhibits or disrupts translation initiation in its host. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:bf]","metadata":null},{"id":"42dab13103a9434397139e54bcd8b19c","type":"GO_TERM","name":"symbiont-mediated suppression of host translation termination","canonical_id":"go:GO:0046773","description":"\"A process in which a symbiont inhibits or disrupts translation termination of host mRNAs. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [ISBN:0781718325]","metadata":null},{"id":"b7b3af8cb22f41db9aab407d2044cd2f","type":"GO_TERM","name":"symbiont-mediated suppression of host tumor necrosis factor-mediated signaling pathway","canonical_id":"go:GO:0141072","description":"\"A process in which a virus interferes with, inhibits or disrupts a tumor necrosis factor-mediated signal transduction in its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:11805081, PMID:24736233]","metadata":null},{"id":"b4b052b060af4bb3a5c046bf3f638fdf","type":"GO_TERM","name":"symbiont-mediated suppression of host type I interferon-mediated signaling pathway","canonical_id":"go:GO:0039502","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a type I interferon-mediated signaling in the host organism. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, GOC:bf, GOC:sp, PMID:19802576, PMID:26712804, PMID:32464097, PMID:32733001, PMID:33097660]","metadata":null},{"id":"a05063282e184363905e5835348478fe","type":"GO_TERM","name":"symbiont-mediated suppression of host type II interferon-mediated signaling pathway","canonical_id":"go:GO:0140884","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a type II interferon-mediated signaling in the host organism. Type II interferon is also known as interferon-gamma.\" [PMID:28901902]","metadata":null},{"id":"85a58b18f3f34884b51b9b8a1dff927d","type":"GO_TERM","name":"symbiont-mediated suppression of host type III interferon-mediated signaling pathway","canonical_id":"go:GO:0140885","description":"\"A process in which a symbiont interferes with, inhibits or disrupts a type III interferon-mediated signaling in the host organism. Type III interferon is also known as interferon-lambda.\" [PMID:32464097]","metadata":null},{"id":"2b548c49243f4edb91ded4745ef84c03","type":"GO_TERM","name":"symbiont-mediated suppression of host-directed shutoff of host translation","canonical_id":"go:GO:0141154","description":"\"A process in which a symbiont inhibits or disrupts the host shutoff of host translation, a host response that prevents mRNA in the cell to be translated, to prevent the symbiont from expressing its genes. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [PMID:20563710, PMID:21622569]","metadata":null},{"id":"5f72b26da18942b29ba3b1647ba2fc51","type":"GO_TERM","name":"symbiont-mediated transformation of host cell","canonical_id":"go:GO:0019087","description":"\"A symbiont-induced cellular transformation resulting in immortalized cells, or cells capable of indefinite replication. Usually mediated by viruses.\" [ISBN:0781702534, PMID:11119620, PMID:18366075, PMID:24373315]","metadata":null},{"id":"733390847d444c26aa45ec57fbd326d3","type":"GO_TERM","name":"symbiont-mediated-mediated suppression of host tetherin activity","canonical_id":"go:GO:0039587","description":"\"Any process in which a symbiont stops, prevents, or reduces the activity of host tetherin activity. Tetherin (also known as BST2) is an alpha interferon-inducible cellular factor that impairs the release of many enveloped viruses. By blocking tetherin activity, many viruses circumvent its antiviral effects.\" [PMID:22493439]","metadata":null},{"id":"6757b583290c444c824468a6b1a201c2","type":"GO_TERM","name":"symbiosome","canonical_id":"go:GO:0043659","description":"\"A double-enveloped cell compartment, composed of an endosymbiont with its plasmalemma (as inner envelope) and a non-endosymbiotic outer envelope (the perisymbiontic membrane).\" [GOC:cc]","metadata":null},{"id":"b1df38b99d874a898df5197f30d4acf5","type":"GO_TERM","name":"symbiotic process benefiting host","canonical_id":"go:GO:0085030","description":"\"A process carried out by symbiont gene products that enables a symbiotic interaction with a host organism, that is beneficial to the host organism.\" [GOC:pdt]","metadata":null},{"id":"406f1fc9ad834d84972829c39e8e7a37","type":"GO_TERM","name":"symmetric cell division","canonical_id":"go:GO:0098725","description":"\"Cell division in which both daughter cells are of the same type.\" [GOC:dos]","metadata":null},{"id":"a26bd320c6d640008371a4d9003331c0","type":"GO_TERM","name":"symmetric division of skeletal muscle satellite stem cell","canonical_id":"go:GO:0098726","description":"\"The symmetric division of a skeletal muscle satellite stem cell, resulting in two skeletal muscle satellite stem cells. This process is involved in amplification of the pool of these cells.\" [PMID:23303905]","metadata":null},{"id":"89fb555338cb4627a5ff0e85f07c26ec","type":"GO_TERM","name":"symmetric neuroblast division","canonical_id":"go:GO:0055058","description":"\"The process resulting in the physical partitioning and separation of a neuroblast into two equi-potent daughter cells.\" [GOC:dph]","metadata":null},{"id":"a35bf7e11c4348339f18fb2430023046","type":"GO_TERM","name":"symmetric stem cell division","canonical_id":"go:GO:0098724","description":"\"Symmetric division of a stem cell to produce two stem cells of the same type as the parent. Symmetric stem cell division is necessary for amplification of stem cell populations in the absence of sources of stem cells external to an existing population.\" [PMID:19948499, PMID:23303905]","metadata":null},{"id":"fbdb4fd8ba344a9a91d070eebf2d3f5e","type":"GO_TERM","name":"symmetric synapse","canonical_id":"go:GO:0032280","description":"\"A synapse that lacks an electron dense postsynaptic specialization. In vertebtrates, these occur primarily on dendrite shafts and neuronal cell bodies and involve persynapses containing clusters of predominantly flattened or elongated vesicles and are typically inhibitory.\" [GOC:dgh, GOC:ef]","metadata":null},{"id":"bdfe7d43e8a7431e8632c874ba332d51","type":"GO_TERM","name":"symmetric, GABA-ergic, inhibitory synapse","canonical_id":"go:GO:0098983","description":"\"A neuron to neuron synapse that lacks an electron dense postsynaptic specialization, uses GABA as a neurotransmitter and whose activity results in inhibitory postsynaptic potentials.\" [GOC:dos]","metadata":null},{"id":"4b355dd7d39c432e9ea1b7f04c1fbbd4","type":"GO_TERM","name":"sympathetic ganglion development","canonical_id":"go:GO:0061549","description":"\"The process whose specific outcome is the progression of a sympathetic ganglion over time, from its formation to the mature structure.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"5f9acf8c5a8f4464ab5d58f4fccf9d4c","type":"GO_TERM","name":"sympathetic nervous system development","canonical_id":"go:GO:0048485","description":"\"The process whose specific outcome is the progression of the sympathetic nervous system over time, from its formation to the mature structure. The sympathetic nervous system is one of the two divisions of the vertebrate autonomic nervous system (the other being the parasympathetic nervous system). The sympathetic preganglionic neurons have their cell bodies in the thoracic and lumbar regions of the spinal cord and connect to the paravertebral chain of sympathetic ganglia. Innervate heart and blood vessels, sweat glands, viscera and the adrenal medulla. Most sympathetic neurons, but not all, use noradrenaline as a post-ganglionic neurotransmitter.\" [FMA:9906, GOC:jid, GOC:sr]","metadata":null},{"id":"cc771d79c2f94c80a9ffb5895229d214","type":"GO_TERM","name":"sympathetic neuron axon guidance","canonical_id":"go:GO:0097492","description":"\"The chemotaxis process that directs the migration of a sympathetic neuron axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.\" [GOC:BHF, GOC:rl, PMID:22790009]","metadata":null},{"id":"438a46d4c7a248338debda2bb2576c7e","type":"GO_TERM","name":"sympathetic neuron projection extension","canonical_id":"go:GO:0097490","description":"\"Long distance growth of a single sympathetic neuron projection involved in cellular development. A neuron projection is a prolongation or process extending from a nerve cell, e.g. an axon or dendrite.\" [GOC:BHF, GOC:rl, PMID:22790009]","metadata":null},{"id":"dabbbbc0e5a1462f91c86d88b3064f8a","type":"GO_TERM","name":"sympathetic neuron projection guidance","canonical_id":"go:GO:0097491","description":"\"The process in which the migration of a sympathetic neuron projection is directed to a specific target site in response to a combination of attractive and repulsive cues.\" [GOC:BHF, GOC:rl, PMID:22790009]","metadata":null},{"id":"133476b825d849f4bb2a68ba4247f0b5","type":"DISEASE","name":"sympathetic ophthalmia","canonical_id":"mondo:0019198","description":null,"metadata":null},{"id":"0aa5ac3f8f39425d99794881cc76f6e5","type":"GO_TERM","name":"symplast","canonical_id":"go:GO:0055044","description":"\"The interconnected cell membranes and intracellular regions of a plant. The interconnections occur via the plasmodesmata.\" [GOC:mtg_sensu]","metadata":null},{"id":"a4b441887ee04c5997a4aa8f95a193ce","type":"GO_TERM","name":"symporter activity","canonical_id":"go:GO:0015293","description":"\"Enables the active transport of a solute across a membrane by a mechanism whereby two or more species are transported together in the same direction in a tightly coupled process not directly linked to a form of energy other than chemiosmotic energy.\" [GOC:mtg_transport, ISBN:0815340729, PMID:10839820]","metadata":null},{"id":"fa0c8a6a38d04aa7829364f13bcfbdf5","type":"GO_TERM","name":"syn-copalyl diphosphate synthase activity","canonical_id":"go:GO:0051498","description":"\"Catalysis of the reaction: geranylgeranyl diphosphate = 9alpha-copalyl diphosphate.\" [MetaCyc:RXN-8528]","metadata":null},{"id":"29eefe43082740a8a593189de5c15e50","type":"GO_TERM","name":"syn-isopimara-7,15-diene synthase activity","canonical_id":"go:GO:0106243","description":"\"Catalysis of the reaction: 9alpha-copalyl diphosphate = diphosphate + syn-isopimara-7,15-diene.\" [GOC:emb, PMID:29315936, RHEA:62188]","metadata":null},{"id":"030181b947814f1ba64fd4366724d4b4","type":"GO_TERM","name":"syn-pimara-7,15-diene synthase activity","canonical_id":"go:GO:0034279","description":"\"Catalysis of the reaction: 9-alpha-copalyl diphosphate = 9-beta-pimara-7,15-diene + diphosphate.\" [RHEA:25560]","metadata":null},{"id":"abca0773799b4a439cb12a81d791469b","type":"GO_TERM","name":"syn-pimaradiene 6beta-hydroxylase activity","canonical_id":"go:GO:0102612","description":"\"Catalysis of the reaction: 9beta-pimara-7,15-diene + NADPH + O2 + H+ = 6beta-hydroxy-syn-pimaradiene + NADP + H2O.\" [GOC:pz, PMID:22215681]","metadata":null},{"id":"b81804832b124e04b11b3dea7ccf7c61","type":"GO_TERM","name":"syn-stemod-13(17)-ene synthase activity","canonical_id":"go:GO:0034283","description":"\"Catalysis of the reaction: 9-alpha-copalyl diphosphate = stemod-13(17)-ene + diphosphate.\" [RHEA:25556]","metadata":null},{"id":"15e428021fc44a34be75c059c900c1aa","type":"GO_TERM","name":"synapse","canonical_id":"go:GO:0045202","description":"\"The junction between an axon of one neuron and a dendrite of another neuron, a muscle fiber or a glial cell. As the axon approaches the synapse it enlarges into a specialized structure, the presynaptic terminal bouton, which contains mitochondria and synaptic vesicles. At the tip of the terminal bouton is the presynaptic membrane; facing it, and separated from it by a minute cleft (the synaptic cleft) is a specialized area of membrane on the receiving cell, known as the postsynaptic membrane. In response to the arrival of nerve impulses, the presynaptic terminal bouton secretes molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane.\" [GOC:aruk, ISBN:0198506732, PMID:24619342, PMID:29383328, PMID:31998110]","metadata":null},{"id":"bab39ca44a1148ce82608165294016b8","type":"GO_TERM","name":"synapse assembly","canonical_id":"go:GO:0007416","description":"\"The aggregation, arrangement and bonding together of a set of components to form a synapse. This process ends when the synapse is mature (functional).\" [GOC:mah]","metadata":null},{"id":"d41bf6beb561463d914cde80d935b187","type":"GO_TERM","name":"synapse assembly involved in innervation","canonical_id":"go:GO:0060386","description":"\"The assembly of a synapse within a target tissue in which a nerve is invading.\" [GOC:dph, GOC:pr, GOC:sart]","metadata":null},{"id":"946dffed970b40269513034e2066a80d","type":"GO_TERM","name":"synapse maturation","canonical_id":"go:GO:0060074","description":"\"The process that organizes a synapse so that it attains its fully functional state. Synaptic maturation plays a critical role in the establishment of effective synaptic connections in early development.\" [GOC:dph, GOC:ef]","metadata":null},{"id":"a4eea62acc6a4b95b2a549e65ab2cb4b","type":"GO_TERM","name":"synapse organization","canonical_id":"go:GO:0050808","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell).\" [GOC:ai, GOC:pr]","metadata":null},{"id":"ee2fab726868444dabff28f57bc75ff7","type":"GO_TERM","name":"synapse pruning","canonical_id":"go:GO:0098883","description":"\"A cellular process that results in the controlled breakdown of synapse. After it starts the process is continuous until the synapse has disappeared.\" [GOC:dos, PMID:12062020, PMID:18083105, PMID:22632716, PMID:29844190]","metadata":null},{"id":"d75d7a4be2cf461a82a4a05ca67d09c0","type":"GO_TERM","name":"synapse-associated extracellular matrix","canonical_id":"go:GO:0099535","description":"\"The extracellular matrix of the perisynaptic space (the extracellular space adjacent to the synapse) and the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"10560d7aef5a45ffa502bdbaf32961a3","type":"GO_TERM","name":"synapsis initiation complex","canonical_id":"go:GO:0106069","description":"\"A SUMO-E3 ligase complex capable of promoting synapsis, the meiotic cell cycle process where side by side pairing and physical juxtaposition of homologous chromosomes is created during meiotic prophase.\" [PMID:16847351]","metadata":null},{"id":"4bcd8bd0a48d4a2fbad551bdbbb9175d","type":"GO_TERM","name":"synaptic assembly at neuromuscular junction","canonical_id":"go:GO:0051124","description":"\"The assembly of a synapse at a neuromuscular junction.\" [PMID:20215342]","metadata":null},{"id":"e86faf8411c04f7c87418c35ab00ebb5","type":"GO_TERM","name":"synaptic cleft","canonical_id":"go:GO:0043083","description":"\"The narrow gap that separates the presynaptic and postsynaptic membranes, into which neurotransmitter is released.\" [GOC:jl, PMID:30784960]","metadata":null},{"id":"0fbf0db59bfc461fb2e667b58b0aa3d9","type":"GO_TERM","name":"synaptic membrane","canonical_id":"go:GO:0097060","description":"\"A specialized area of membrane on either the presynaptic or the postsynaptic side of a synapse, the junction between a nerve fiber of one neuron and another neuron or muscle fiber or glial cell.\" [GOC:BHF, PMID:20410104]","metadata":null},{"id":"bc8eda6621764c60b51de260b7714468","type":"GO_TERM","name":"synaptic membrane adhesion","canonical_id":"go:GO:0099560","description":"\"The attachment of presynaptic membrane to postsynaptic membrane via adhesion molecules that are at least partially embedded in the plasma membrane.\" [GOC:dos]","metadata":null},{"id":"ebc71d7cfa9f47549f852a4b53fe1f54","type":"GO_TERM","name":"synaptic membrane adhesion to extracellular matrix","canonical_id":"go:GO:0099561","description":"\"The binding of a synaptic membrane to the extracellular matrix via adhesion molecules.\" [GOC:dos]","metadata":null},{"id":"eab568ce84c84c8a9bafdc19b245e2e8","type":"GO_TERM","name":"synaptic receptor adaptor activity","canonical_id":"go:GO:0030160","description":"\"The binding activity of a molecule that provides a physical support bridging a synaptic signaling receptor and a downstream signaling molecule.\" [PMID:10506216]","metadata":null},{"id":"a0c6ea6a10954ae69b2c4cd762993716","type":"GO_TERM","name":"synaptic ribbon","canonical_id":"go:GO:0098681","description":"\"A non-membrane bound, electron dense structure associated that extends perpendicular to the presynaptic membrane in ribbon synapses. The ribbon's surface is studded with small particles to which synaptic vesicles tether via fine filaments. The tethered vesicles function as a pool, several fold greater than the docked pool available for fast release, which supports sustained release of vesicles. Synaptic ribbons may be plate like or spherical.\" [PMID:15626493]","metadata":null},{"id":"6c23a14b4a3b460c9b7e73106c587da4","type":"GO_TERM","name":"synaptic signaling","canonical_id":"go:GO:0099536","description":"\"Cell-cell signaling to, from or within a synapse.\" [GOC:dos]","metadata":null},{"id":"7acd372fe9964dd4ae87b6ece0508909","type":"GO_TERM","name":"synaptic signaling by nitric oxide","canonical_id":"go:GO:0099163","description":"\"Cell-cell signaling to or from a synapse, mediated by nitric oxide.\" [GOC:dos, PMID:19038221]","metadata":null},{"id":"c35baaa10ffc4605a6ad97521bf83f6f","type":"GO_TERM","name":"synaptic signaling via neuropeptide","canonical_id":"go:GO:0099538","description":"\"Cell-cell signaling to or from a synapse, mediated by a peptide.\" [GOC:dos]","metadata":null},{"id":"80f0e67e00314834b69d272059ec663a","type":"GO_TERM","name":"synaptic target attraction","canonical_id":"go:GO:0016200","description":"\"The process in which a neuronal cell in a multicellular organism recognizes chemoattractant signals from, and grows towards, potential targets.\" [GOC:mah, ISBN:0878932437]","metadata":null},{"id":"8d687567dacf40f8960cf1eba20b2f65","type":"GO_TERM","name":"synaptic target inhibition","canonical_id":"go:GO:0016201","description":"\"The process in which a neuronal cell in a multicellular organism recognizes chemorepellent signals that inhibit its growth toward the source.\" [GOC:mah, ISBN:0878932437]","metadata":null},{"id":"90a51c0d4fb8403e9af4f7d1d0f6f4e9","type":"GO_TERM","name":"synaptic target recognition","canonical_id":"go:GO:0008039","description":"\"The process in which a neuronal cell in a multicellular organism interprets signals produced by potential target cells, with which it may form synapses.\" [GOC:mah, ISBN:0878932437]","metadata":null},{"id":"67d34e42be524a839898fe7027206989","type":"GO_TERM","name":"synaptic transmission involved in micturition","canonical_id":"go:GO:0060084","description":"\"The process of communication from a neuron to a smooth muscle in the bladder that contributes to the expulsion of urine from the body.\" [GOC:dph, PMID:15827347]","metadata":null},{"id":"e900112c10864454b5108d4c20705ba2","type":"GO_TERM","name":"synaptic transmission, GABAergic","canonical_id":"go:GO:0051932","description":"\"The vesicular release of gamma-aminobutyric acid (GABA). from a presynapse, across a chemical synapse, the subsequent activation of GABA receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos, ISBN:0126603030]","metadata":null},{"id":"cb7b35d48fe54076bed2c82912f596f2","type":"GO_TERM","name":"synaptic transmission, cholinergic","canonical_id":"go:GO:0007271","description":"\"The vesicular release of acetylcholine from a presynapse, across a chemical synapse, the subsequent activation of dopamine receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos, Wikipedia:Cholinergic]","metadata":null},{"id":"4c8d83f3ee974517b9c7cc370d45a9fa","type":"GO_TERM","name":"synaptic transmission, dopaminergic","canonical_id":"go:GO:0001963","description":"\"The vesicular release of dopamine. from a presynapse, across a chemical synapse, the subsequent activation of dopamine receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos, GOC:dph]","metadata":null},{"id":"c0cc55bfbf0a4717aae93364e5e2c375","type":"GO_TERM","name":"synaptic transmission, glutamatergic","canonical_id":"go:GO:0035249","description":"\"The vesicular release of glutamate from a presynapse, across a chemical synapse, the subsequent activation of glutamate receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos]","metadata":null},{"id":"ce1c18a4445d4501bfe07ab9ea1937e3","type":"GO_TERM","name":"synaptic transmission, glycinergic","canonical_id":"go:GO:0060012","description":"\"The vesicular release of glycine from a presynapse, across a chemical synapse, the subsequent activation of glycine receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos]","metadata":null},{"id":"52f53e293ef8479c86d127f213a18430","type":"GO_TERM","name":"synaptic transmission, noradrenergic","canonical_id":"go:GO:0099155","description":"\"The vesicular release of noradrenaline (norepinephrine) a presynapse, across a chemical synapse, the subsequent activation of noradrenaline receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos, GOC:dph]","metadata":null},{"id":"d57719abd53548b6a40949a6c71b6032","type":"GO_TERM","name":"synaptic transmission, serotonergic","canonical_id":"go:GO:0099153","description":"\"The vesicular release of serotonin from a presynapse, across a chemical synapse, the subsequent activation of serotonin receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.\" [GOC:dos, GOC:dph]","metadata":null},{"id":"cd51be688e5b4c7fba6c2e270b6caa14","type":"GO_TERM","name":"synaptic vesicle","canonical_id":"go:GO:0008021","description":"\"A secretory organelle, typically 50 nm in diameter, of presynaptic nerve terminals; accumulates in high concentrations of neurotransmitters and secretes these into the synaptic cleft by fusion with the 'active zone' of the presynaptic plasma membrane.\" [PMID:10099709, PMID:12563290]","metadata":null},{"id":"8860a0a487b04bb589680f6d00b26dc2","type":"GO_TERM","name":"synaptic vesicle budding","canonical_id":"go:GO:0070142","description":"\"Evagination of a membrane to form a synaptic vesicle.\" [GOC:mah]","metadata":null},{"id":"d9a3d142a0be44c1b9754be446b9fad3","type":"GO_TERM","name":"synaptic vesicle budding from endosome","canonical_id":"go:GO:0016182","description":"\"Budding of synaptic vesicles during the formation of constitutive recycling vesicles from early endosomes.\" [GOC:curators, PMID:10099709, PMID:24596248]","metadata":null},{"id":"299db30f19644401b93e52280080103c","type":"GO_TERM","name":"synaptic vesicle budding from presynaptic endocytic zone membrane","canonical_id":"go:GO:0016185","description":"\"Evagination of the presynaptic membrane, resulting in the formation of a new synaptic vesicle.\" [GOC:curators, PMID:10099709, PMID:20448150]","metadata":null},{"id":"a0f3a2d42f7948a28146da3620d99cf9","type":"GO_TERM","name":"synaptic vesicle clustering","canonical_id":"go:GO:0097091","description":"\"The process that results in grouping synaptic vesicles in presynaptic structures.\" [GOC:ans, GOC:pr, PMID:19900895, PMID:7568108]","metadata":null},{"id":"d33cef0f7f3f4a35a04cffcc078aea11","type":"GO_TERM","name":"synaptic vesicle coating","canonical_id":"go:GO:0016183","description":"\"The formation of clathrin coated pits in the presynaptic membrane endocytic zone, triggered by the presence of high concentrations of synaptic vesicle components. This process leads to, but does not include budding of the membrane to form new vesicles.\" [GOC:curators, PMID:10099709, PMID:20448150]","metadata":null},{"id":"d3d6f89b79044181849edc6a132d5d99","type":"GO_TERM","name":"synaptic vesicle cycle","canonical_id":"go:GO:0099504","description":"\"A biological process in which synaptic vesicles are loaded with neurotransmitters, move to the active zone, exocytose and are then recycled via endocytosis, ultimately leading to reloading with neurotransmitters.\" [GOC:aruk, GOC:bc, PMID:15217342]","metadata":null},{"id":"609e81eef33041a0a164732002e5c1c2","type":"GO_TERM","name":"synaptic vesicle cytoskeletal transport","canonical_id":"go:GO:0099514","description":"\"The directed movement of synaptic vesicles along cytoskeletal fibers such as microfilaments or microtubules within a cell, powered by molecular motors.\" [GOC:dos]","metadata":null},{"id":"3050c48043cb44fc9e26df784d723a4f","type":"GO_TERM","name":"synaptic vesicle endocytosis","canonical_id":"go:GO:0048488","description":"\"A vesicle-mediated transport process, in which the synaptic vesicle membrane constituents are retrieved from the presynaptic membrane on the axon terminal after neurotransmitter secretion by exocytosis. Synaptic vesicle endocytosis can occur via clathrin-dependent and clathrin-independent mechanisms.\" [GOC:aruk, GOC:bc, GOC:jid, GOC:lmg, GOC:mah, PMID:20448150, PMID:26430111]","metadata":null},{"id":"17009c49c30644249901530d136e509b","type":"GO_TERM","name":"synaptic vesicle endosomal processing","canonical_id":"go:GO:0099532","description":"\"The process in which synaptic vesicles fuse to the presynaptic endosome followed by sorting of synaptic vesicle components and budding of new synaptic vesicles.\" [GOC:aruk, GOC:bc, GOC:dos]","metadata":null},{"id":"f1da289d41794df6899342a043e651d1","type":"GO_TERM","name":"synaptic vesicle exocytosis","canonical_id":"go:GO:0016079","description":"\"Fusion of intracellular membrane-bounded vesicles with the pre-synaptic membrane of the neuronal cell resulting in release of neurotransmitter into the synaptic cleft.\" [GOC:jid, GOC:lmg]","metadata":null},{"id":"1adc08dda925474e9b188cac646b49ea","type":"GO_TERM","name":"synaptic vesicle fusion to presynaptic active zone membrane","canonical_id":"go:GO:0031629","description":"\"Fusion of the membrane of a synaptic vesicle with the presynaptic active zone membrane, thereby releasing its cargo neurotransmitters into the synaptic cleft.\" [GOC:aruk, GOC:bc, ISBN:0071120009, PMID:18618940]","metadata":null},{"id":"84bb7061482e4f70ad447797b58303ed","type":"GO_TERM","name":"synaptic vesicle localization","canonical_id":"go:GO:0097479","description":"\"Any process in which a synaptic vesicle or vesicles are transported to, and/or maintained in, a specific location.\" [GOC:pr]","metadata":null},{"id":"15c0df7ef77b4b9f8fcb74241236e7fe","type":"GO_TERM","name":"synaptic vesicle lumen","canonical_id":"go:GO:0034592","description":"\"The volume enclosed by the synaptic vesicle membrane.\" [GOC:rph]","metadata":null},{"id":"f1aa41c827f7440aa322841ed2c07ec1","type":"GO_TERM","name":"synaptic vesicle lumen acidification","canonical_id":"go:GO:0097401","description":"\"The acidification of the synaptic vesicle lumen via transport of protons into the vesicle. The resulting electrochemical gradient powers neurotransmitter loading.\" [GOC:dsf, PMID:21172605, PMID:22875945]","metadata":null},{"id":"fd2155ed80d446258023f94305cd7509","type":"GO_TERM","name":"synaptic vesicle maturation","canonical_id":"go:GO:0016188","description":"\"Steps required to form an initiated synaptic vesicle into a fully formed and transmissible synaptic vesicle.\" [GOC:curators, PMID:10099709]","metadata":null},{"id":"96e54aa7a33c410d8d0475af842c1752","type":"GO_TERM","name":"synaptic vesicle membrane","canonical_id":"go:GO:0030672","description":"\"The lipid bilayer surrounding a synaptic vesicle.\" [GOC:mah]","metadata":null},{"id":"2526013cb8a842848a2bbfdfae884d6e","type":"GO_TERM","name":"synaptic vesicle membrane organization","canonical_id":"go:GO:0048499","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the membrane surrounding a synaptic vesicle.\" [GOC:dph, GOC:jl, GOC:mah, PMID:10620806]","metadata":null},{"id":"dbef5dd751aa4dd9a389dfdfa6b99e7c","type":"GO_TERM","name":"synaptic vesicle priming","canonical_id":"go:GO:0016082","description":"\"A process that converts synaptic vesicles to a state of competence for calcium triggered fusion with the active zone membrane by bringing the two membranes into very close proximity. Priming typically (but not always) occurs after docking (Jahn and Fasshauer, 2012). Primed vesicles are also capable of spontaneously fusing with the active zone membrane.\" [GOC:mah, PMID:15217342, PMID:23060190]","metadata":null},{"id":"a69f50c1a02b4e1f9c75237c9cdc68aa","type":"GO_TERM","name":"synaptic vesicle protein transport vesicle","canonical_id":"go:GO:0097547","description":"\"A cytoplasmic vesicle composed of both tubulovesicular and clear core vesicles that transport synaptic vesicle-associated proteins. Proteins carried by synaptic vesicle protein transport vesicles (STVs) include synaptophysin, synapsin Ia, synaptotagmin and synaptobrevin/vesicle-associated membrane protein 2 (VAMP2). STVs are packaged via the trans-Golgi network before being transported through the axon.\" [GOC:dr, PMID:21569270]","metadata":null},{"id":"baee8b56a4cb4cfe9e3aac7f8473e968","type":"GO_TERM","name":"synaptic vesicle recycling","canonical_id":"go:GO:0036465","description":"\"The trafficking of synaptic vesicles from the pre-synaptic membrane so the vesicle can dock and prime for another round of exocytosis and neurotransmitter release. Recycling occurs after synaptic vesicle exocytosis, and is necessary to replenish presynaptic vesicle pools, sustain transmitter release and preserve the structural integrity of the presynaptic membrane. Recycling can occur following transient fusion with the presynaptic membrane (kiss and run), or via endocytosis of presynaptic membrane.\" [GOC:bf, GOC:pad, GOC:PARL, PMID:15217342, PMID:22026965, PMID:23245563]","metadata":null},{"id":"307b296634124c249fafbd249182ea9b","type":"GO_TERM","name":"synaptic vesicle recycling via endosome","canonical_id":"go:GO:0036466","description":"\"Synaptic vesicle recycling where vesicles endocytosed via clathrin-coated pits re-acidify and refill with neurotransmitters after passing through an endosomal intermediate.\" [GOC:aruk, GOC:bc, GOC:bf, GOC:dos, GOC:pad, GOC:PARL, PMID:15217342]","metadata":null},{"id":"41f193fdf6bf41f7b2d1d0022aa85a9d","type":"GO_TERM","name":"synaptic vesicle to endosome fusion","canonical_id":"go:GO:0016189","description":"\"Fusion of a synaptic vesicle with an endosome.\" [GOC:curators, PMID:10099709]","metadata":null},{"id":"597dae7ce6314230ada09f79e90420b9","type":"GO_TERM","name":"synaptic vesicle transport","canonical_id":"go:GO:0048489","description":"\"The directed movement of synaptic vesicles.\" [GOC:aruk, GOC:bc, GOC:jid, GOC:lmg, GOC:pr]","metadata":null},{"id":"c838f85e2fdd4c53877e4431a96c1ca9","type":"GO_TERM","name":"synaptic vesicle transport along actin filament","canonical_id":"go:GO:0099506","description":"\"The directed movement of synaptic vesicles along actin filaments within a cell, powered by molecular motors.\" [GOC:dos]","metadata":null},{"id":"90cd665cc4b4420f9adbd9a4f2f673c7","type":"GO_TERM","name":"synaptic vesicle transport along microtubule","canonical_id":"go:GO:0099517","description":"\"The directed movement of synaptic vesicles along microtubules within a cell, powered by molecular motors.\" [GOC:dos]","metadata":null},{"id":"e7af83b7d1514b05963f4771990eb496","type":"GO_TERM","name":"synaptic vesicle uncoating","canonical_id":"go:GO:0016191","description":"\"The removal of the protein coat on a synaptic vesicle following the pinching step at the end of budding from the presynaptic membrane.\" [GOC:curators, PMID:10099709, PMID:24596248]","metadata":null},{"id":"975bcef89a5c4b3f8f27cf49e5820d70","type":"GO_TERM","name":"synaptic vesicle, readily releasable pool","canonical_id":"go:GO:1990474","description":"\"A synaptic vesicle belonging to the pool of vesicles that are the first to be released as a result of chemical or electrical stimulation e.g. by an action potential, have the highest presynaptic membrane fusion probability and correspond to about 1% of the total number of synaptic vesicles at a resting terminal bouton.\" [GOC:pad, PMID:22745285]","metadata":null},{"id":"ac56f91ec1384885b6a021e5de3fbf37","type":"GO_TERM","name":"synaptic vesicle, recycling pool","canonical_id":"go:GO:1990475","description":"\"A synaptic vesicle belonging to the pool that repopulate vacancies within the readily releasable pool (RRP) of synaptic vesicles, and require more significant stimuli than the RRP in order to release neurotransmitter; about 10-15% of the total number of synaptic vesicles at a resting terminal bouton are in this state.\" [GOC:pad, PMID:22745285]","metadata":null},{"id":"79191cfe110343aeb187c7453044c189","type":"GO_TERM","name":"synaptic vesicle, resting pool","canonical_id":"go:GO:1990476","description":"\"A synaptic vesicle belonging to the pool that remain unreleased even after prolonged stimulation causes a saturating degree of vesicular turnover. 50-80% of the total number of synaptic vesicles at a resting terminal bouton are in this pool.\" [GOC:pad, PMID:22745285]","metadata":null},{"id":"1dd1ab00812045ecb0631a0852d120ce","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-1a complex","canonical_id":"go:GO:0070044","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, and syntaxin 1a (or orthologs thereof).\" [PMID:10336434]","metadata":null},{"id":"a6988edfc95f43d5aba4e15cb4820448","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex","canonical_id":"go:GO:0070032","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, syntaxin 1a, and complexin I (or orthologs thereof).\" [PMID:7553862]","metadata":null},{"id":"99d44788ed5e48b6bceecc571398228a","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex","canonical_id":"go:GO:0070033","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, syntaxin 1a, and complexin II (or orthologs thereof).\" [PMID:7553862]","metadata":null},{"id":"079fad6afc5645c98466c98d0e79e238","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-2 complex","canonical_id":"go:GO:0070045","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, and syntaxin 2 (or orthologs thereof).\" [PMID:10336434]","metadata":null},{"id":"1e94251ef49e4215917b22621aa40add","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-3 complex","canonical_id":"go:GO:0070046","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, and syntaxin 3 (or orthologs thereof).\" [PMID:10336434]","metadata":null},{"id":"806f1d53695d4d489499d17244458a90","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-3-complexin complex","canonical_id":"go:GO:0070554","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, syntaxin 3, and a complexin (or orthologs thereof).\" [PMID:8824312]","metadata":null},{"id":"14a0105bcdfd4feea39ffcbb7adfee55","type":"GO_TERM","name":"synaptobrevin 2-SNAP-25-syntaxin-4 complex","canonical_id":"go:GO:0070047","description":"\"A SNARE complex that contains synaptobrevin 2 (VAMP2), SNAP-25, and syntaxin 4 (or orthologs thereof).\" [PMID:10336434]","metadata":null},{"id":"909e59a0a68744709298d29c6be0a426","type":"GO_TERM","name":"synaptonemal complex","canonical_id":"go:GO:0000795","description":"\"A proteinaceous scaffold found between homologous chromosomes during meiosis. It consists of 2 lateral elements and a central element, all running parallel to each other. Transverse filaments connect the lateral elements to the central element.\" [DOI:10.5772/29752, GOC:elh]","metadata":null},{"id":"0ef0be6d347f4b10ae3ab6977c904973","type":"GO_TERM","name":"synaptonemal complex assembly","canonical_id":"go:GO:0007130","description":"\"The cell cycle process in which the synaptonemal complex is formed. This is a structure that holds paired chromosomes together during prophase I of meiosis and that promotes genetic recombination.\" [ISBN:0198506732]","metadata":null},{"id":"768ab58668ca488b81e39034a38f621f","type":"GO_TERM","name":"synaptonemal complex disassembly","canonical_id":"go:GO:0070194","description":"\"The controlled breakdown of a synaptonemal complex.\" [GOC:mah]","metadata":null},{"id":"199f54f91db64013ada07e1356326b7b","type":"GO_TERM","name":"synaptonemal complex organization","canonical_id":"go:GO:0070193","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synaptonemal complex. A synaptonemal complex is a proteinaceous scaffold formed between homologous chromosomes during meiosis.\" [GOC:mah]","metadata":null},{"id":"f0445565ff4a4c84b2ad7ab347c7c8d4","type":"GO_TERM","name":"synaptonemal structure","canonical_id":"go:GO:0099086","description":"\"A proteinaceous scaffold found between homologous chromosomes during meiosis.\" [GOC:elh, GOC:vw]","metadata":null},{"id":"21530a051ccf4468a0e7115b443c35b1","type":"GO_TERM","name":"synaptotagmin-synaptobrevin 2-SNAP-25-syntaxin-1a-syntaxin-1b-Rab3a complex","canonical_id":"go:GO:0070356","description":"\"A SNARE complex that contains synaptotagmin, synaptobrevin 2 (VAMP2), SNAP-25, syntaxin 1a, syntaxin1b, and Rab3a (or orthologs thereof).\" [PMID:7654227]","metadata":null},{"id":"8c94fd83ab234f7982d310beab24735d","type":"GO_TERM","name":"synaptotagmin-synaptobrevin 2-SNAP-25-syntaxin-1a-syntaxin-1b-Rab3a-complexin II complex","canonical_id":"go:GO:0070355","description":"\"A SNARE complex that contains synaptotagmin, synaptobrevin 2 (VAMP2), SNAP-25, syntaxin 1a, syntaxin1b, Rab3a, and complexin II (or orthologs thereof).\" [PMID:7654227]","metadata":null},{"id":"6189d181e78c4814b05e810817b40580","type":"GO_TERM","name":"synaptotagmin-synaptobrevin 2-SNAP-25-syntaxin-1a-syntaxin-1b-Unc13 complex","canonical_id":"go:GO:0070768","description":"\"A SNARE complex that contains synaptotagmin, synaptobrevin 2 (VAMP2), SNAP-25, syntaxin 1a, syntaxin1b, and Unc13b (or orthologs thereof).\" [PMID:8999968]","metadata":null},{"id":"71dbb1ec953c414782f0d0c2ab0be781","type":"GO_TERM","name":"synchronous neurotransmitter secretion","canonical_id":"go:GO:0071911","description":"\"Release of neurotransmitter at the synapse that lasts for just a few milliseconds after action potential invasion.\" [GOC:dsf, PMID:19477156, PMID:20643933]","metadata":null},{"id":"fa77fb0bef174225a35dd5e726ea2412","type":"GO_TERM","name":"syncytial blastoderm mitotic cell cycle","canonical_id":"go:GO:0035186","description":"\"Mitotic division cycles 10 to 13 of the insect embryo. This is the second phase of the syncytial period where nuclei divide in a common cytoplasm without cytokinesis. The majority of migrating nuclei reach the embryo surface during cycle 10, after which they divide less synchronously than before, and the syncytial blastoderm cycles lengthen progressively.\" [ISBN:0879694238]","metadata":null},{"id":"0dee23f026d94c86b86d5230ba7e0a04","type":"GO_TERM","name":"syncytial embryo cellularization","canonical_id":"go:GO:0110069","description":"\"The separation of a syncytial embryo into individual cells.\" [GOC:ha, PMID:27226317]","metadata":null},{"id":"8e9db8e1af7544e0b0867e8fe5e95c05","type":"GO_TERM","name":"syncytial nuclear migration","canonical_id":"go:GO:0035190","description":"\"The directed movement of nuclei within the syncytial embryo of insects. These precise temporal and spatial patterns of nuclear movement are coordinated with mitotic divisions and are required during blastoderm formation to reposition dividing nuclei from the interior of the syncytial embryo to the cortex.\" [GOC:bf, ISBN:0879694238, PMID:8314839]","metadata":null},{"id":"1214b1ea21e74a19bd3718112055c850","type":"GO_TERM","name":"syncytiotrophoblast cell differentiation involved in labyrinthine layer development","canonical_id":"go:GO:0060715","description":"\"The process in which a chorionic trophoblast cell acquires specialized features of a syncytiotrophoblast of the labyrinthine layer of the placenta.\" [GOC:dph]","metadata":null},{"id":"537d46f5edd14605ab38c70276e61974","type":"GO_TERM","name":"syncytium formation by cell-cell fusion","canonical_id":"go:GO:0000768","description":"\"The formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by the fusion of the plasma membranes of two or more individual cells.\" [GOC:mtg_muscle, GOC:tb]","metadata":null},{"id":"5fea53cfb3044f879204c6dffaac6f36","type":"GO_TERM","name":"syncytium formation by mitosis without cytokinesis","canonical_id":"go:GO:0000769","description":"\"The formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by one or more rounds of nuclear division without cytokinesis.\" [GOC:mah, GOC:tb]","metadata":null},{"id":"b7171add5a3e44499c4a74d1dd69c83c","type":"GO_TERM","name":"syndecan binding","canonical_id":"go:GO:0045545","description":"\"Binding to syndecan, an integral membrane proteoglycan (250-300 kDa) associated largely with epithelial cells.\" [GOC:curators, PMID:9355727]","metadata":null},{"id":"76dc774fbfa64b52b09b277f45f0967c","type":"GO_TERM","name":"syndecan-syntenin-ALIX complex","canonical_id":"go:GO:1990562","description":"\"An exosome complex that is assembled in the multivesicular body (MVB) membrane and chaperoned to the exosome by the ESCRT-III machinery.\" [GOC:bhm, PMID:22660413]","metadata":null},{"id":"08dc51155ae44d2aa1fa4e8521a8e92d","type":"DISEASE","name":"syndromic microphthalmia","canonical_id":"mondo:0016073","description":null,"metadata":null},{"id":"e31619ac3910489cbda874cda85aac05","type":"GO_TERM","name":"synephrine dehydratase activity","canonical_id":"go:GO:0050315","description":"\"Catalysis of the reaction: synephrine = (4-hydroxyphenyl)acetaldehyde + methylammonium.\" [EC:4.2.1.88, RHEA:32203]","metadata":null},{"id":"3f612050a29749768a0afc0951bbe622","type":"GO_TERM","name":"synergid death","canonical_id":"go:GO:0010198","description":"\"Synergid cells undergo degeneration and death in response to penetration by the pollen tube. It is an active process that involves a dramatic decrease in cell volume, collapse of the vacuoles, and complete disintegration of the plasma membrane and most organelles.\" [GOC:isa_complete, GOC:sm, PMID:12215516]","metadata":null},{"id":"bfedda6ca9374423a15fb6b7fa0b7940","type":"GO_TERM","name":"synergid differentiation","canonical_id":"go:GO:0009563","description":"\"The process in which an uncellularized nucleus cellularizes and acquires the specialized features of a synergid cell.\" [GOC:jid]","metadata":null},{"id":"990480583cac4778ae4c45acd14f49f0","type":"GO_TERM","name":"synoviocyte proliferation","canonical_id":"go:GO:0002941","description":"\"The multiplication or reproduction of type B synoviocytes by cell division, resulting in the expansion of their population. A type B synoviocyte is a fibroblast-like cell found in synovial tissues.\" [PMID:10770586, PMID:9546370]","metadata":null},{"id":"ae38ee9b357047039e166755b0cb3755","type":"DISEASE","name":"synovitis","canonical_id":"mondo:0002400","description":null,"metadata":null},{"id":"85b3bdaa35984f1881e841a81645ed44","type":"GO_TERM","name":"syntaxin binding","canonical_id":"go:GO:0019905","description":"\"Binding to a syntaxin, a SNAP receptor involved in the docking of vesicles.\" [ISBN:0198506732]","metadata":null},{"id":"27362881540041509d93de14d083523f","type":"GO_TERM","name":"syntaxin-1 binding","canonical_id":"go:GO:0017075","description":"\"Binding to a syntaxin-1 SNAP receptor.\" [GOC:ai]","metadata":null},{"id":"bc290c9207d84e2e889386ed1caeb9c7","type":"GO_TERM","name":"syntaxin-3 binding","canonical_id":"go:GO:0030348","description":"\"Binding to a syntaxin-3 SNAP receptor.\" [GOC:ai]","metadata":null},{"id":"4ffc64a8a3dc4d9a85228f32e4dd81bb","type":"GO_TERM","name":"syntaxin-6-syntaxin-16-Vti1a complex","canonical_id":"go:GO:0070067","description":"\"A SNARE complex that contains syntaxin 6, syntaxin 16, and Vti1a (or orthologs thereof).\" [PMID:11839770]","metadata":null},{"id":"f46e10b6881940dfbb60ae09b0f0814a","type":"GO_TERM","name":"synthetic cannabinoid binding","canonical_id":"go:GO:1904483","description":"\"Binding to synthetic cannabinoid.\" [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10700562]","metadata":null},{"id":"073a88d2f32f48c19809e5d430980f8b","type":"GO_TERM","name":"syntrophin complex","canonical_id":"go:GO:0016013","description":"\"A protein complex that includes alpha-, beta1-, beta2-syntrophins and syntrophin-like proteins; the syntrophin complex binds to the second half of the carboxy-terminal domain of dystrophin; also associates with neuronal nitric oxide synthase.\" [PMID:23263165]","metadata":null},{"id":"34c480e177794c72bada5d4c4536f360","type":"GO_TERM","name":"syringal lignin biosynthetic process","canonical_id":"go:GO:1901066","description":"\"The chemical reactions and pathways resulting in the formation of syringal lignin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"7326e541cce54731bf394cbdef9a1957","type":"GO_TERM","name":"syringal lignin catabolic process","canonical_id":"go:GO:1901065","description":"\"The chemical reactions and pathways resulting in the breakdown of syringal lignin.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"8adc23becc014343beeb9a6ab0316ec2","type":"GO_TERM","name":"syringetin 3-O-methyltransferase activity","canonical_id":"go:GO:0102442","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + syringetin = 3,3',5'-O-trimethylmyricetin + H(+) + S-adenosyl-L-homocysteine.\" [RHEA:74767]","metadata":null},{"id":"f790a245ca574a909ed368a38071af58","type":"GO_TERM","name":"syringetin 7-O-methyltransferase activity","canonical_id":"go:GO:0102441","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + syringetin = 7,3',5'-O-trimethylmyricetin + H+ + S-adenosyl-L-homocysteine.\" [RHEA:74735]","metadata":null},{"id":"457afc0e2dc445ee8d30881a9ae5bc82","type":"GO_TERM","name":"system development","canonical_id":"go:GO:0048731","description":"\"The process whose specific outcome is the progression of an organismal system over time, from its formation to the mature structure. A system is a regularly interacting or interdependent group of organs or tissues that work together to carry out a given biological process.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"c96e2aa36c784d5fb2047e842e3cd568","type":"GO_TERM","name":"system process","canonical_id":"go:GO:0003008","description":"\"A multicellular organismal process carried out by any of the organs or tissues in an organ system. An organ system is a regularly interacting or interdependent group of organs or tissues that work together to carry out a biological objective.\" [GOC:mtg_cardio]","metadata":null},{"id":"7a7bf13d19fb45efaaae541d2ff8fb8e","type":"GO_TERM","name":"systemic acquired resistance","canonical_id":"go:GO:0009627","description":"\"The salicylic acid-mediated response to a pathogen which confers broad spectrum resistance.\" [GOC:lr, Wikipedia:Systemic_acquired_resistance]","metadata":null},{"id":"a9ac61abfdd84a59bac4cc183a2dca21","type":"GO_TERM","name":"systemic acquired resistance, salicylic acid mediated signaling pathway","canonical_id":"go:GO:0009862","description":"\"The series of molecular signals mediated by salicylic acid involved in systemic acquired resistance.\" [GOC:jy]","metadata":null},{"id":"2ae96133caaa4f2493d188af62833f23","type":"DISEASE","name":"systemic lupus erythematosus","canonical_id":"mondo:0007915","description":null,"metadata":null},{"id":"2eb2b93d3bc04bc6af99f333ed5db1b3","type":"DISEASE","name":"systemic lupus erythematosus 17","canonical_id":"mondo:0859083","description":null,"metadata":null},{"id":"5879efe7529f401db1b2d6516f853b7e","type":"DISEASE","name":"systemic mastocytosis","canonical_id":"mondo:0016586","description":null,"metadata":null},{"id":"b8ab891a0f3f40debbdbd96abd61e605","type":"DISEASE","name":"systemic sclerosis","canonical_id":"mondo:0005100","description":null,"metadata":null},{"id":"5c8c559575b64384a7ef4e591d948b47","type":"DISEASE","name":"systolic heart failure","canonical_id":"mondo:0006993","description":null,"metadata":null},{"id":"013152c451c04c9aa2fddc5f5d75344a","type":"GO_TERM","name":"t-SNARE clustering","canonical_id":"go:GO:1990656","description":"\"The clustering process in which t-SNARES are localized to distinct domains in the cell membrane. t-SNAREs are cell surface proteins which are part of secretory microdomain assemblies.\" [PMID:22528485]","metadata":null},{"id":"d023d5f3904b463680b6fe4d524f3c29","type":"GO_TERM","name":"t-UTP complex","canonical_id":"go:GO:0034455","description":"\"A protein complex that forms a subcomplex of the 90S preribosome and is required for the subsequent assembly of the rest of the preribosome. In S. cerevisiae, it is composed of Utp5p, Utp4p, Nan1p, Utp8p, Utp9p, Utp10 and Utp15p.\" [GOC:krc, GOC:mah, GOC:vw, PMID:17515605]","metadata":null},{"id":"eb3fa5991484434fa02b6d1403ebb5cf","type":"GO_TERM","name":"t-circle formation","canonical_id":"go:GO:0090656","description":"\"A telomere maintenance process that results in the formation of a telomeric circle, or t-circle. A t-circle is an extrachromosomal duplex or single-stranded circular DNA molecule composed of t-arrays. T-circles are involved in the control of telomere length via alternative-lengthening of telomeres (ALT) pathway and telomere rapid deletion (TRD).\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:19214183, PMID:19581589, PMID:19809492, PMID:19858100]","metadata":null},{"id":"a99f8c5050144eb786a7ac75edee5b60","type":"GO_TERM","name":"tDNA binding","canonical_id":"go:GO:0071443","description":"\"Binding to DNA sequences encoding transfer RNA.\" [GOC:mah]","metadata":null},{"id":"91a46c5d57fb428e9d87f3abb50b70ed","type":"GO_TERM","name":"tRNA (5-carboxymethoxyuridine(34)-5-O)-methyltransferase activity","canonical_id":"go:GO:0097697","description":"\"Catalysis of the reaction: 5-carboxymethoxyuridine34 in tRNA + S-adenosyl-L-methionine = 5-methoxycarbonylmethoxyuridine34 in tRNA + S-adenosyl-L-homocysteine. The methylation occurs on the modified base.\" [PMID:26681692, RHEA:54080]","metadata":null},{"id":"8985c70a9a834a04bfbc4e4ead78130e","type":"GO_TERM","name":"tRNA (5-carboxymethylaminomethyluridine(34)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0141102","description":"\"Catalysis of the reaction: 5-carboxymethylaminomethyluridine34 in tRNA(Leu) + S-adenosyl-L-methionine = 5-carboxymethylaminomethyl-2'-O-methyluridine34 in tRNA(Leu) + H+ + S-adenosyl-L-homocysteine.\" [PMID:20855540, RHEA:43088]","metadata":null},{"id":"6e1777b45ec148838f28a79abb8d5196","type":"GO_TERM","name":"tRNA (5-carboxymethyluridine(34)-5-O)-methyltransferase activity","canonical_id":"go:GO:0106335","description":"\"Catalysis of the reaction: 5-(carboxymethyl)uridine34 in tRNA + S-adenosyl-L-methionine = 5-(2-methoxy-2-oxoethyl)uridine34 in tRNA + S-adenosyl-L-homocysteine. The methylation occurs on the modified base.\" [PMID:20123966, RHEA:43208]","metadata":null},{"id":"aca625cdac5f4d429c2f3b4e1735b62e","type":"GO_TERM","name":"tRNA (5-methylaminomethyl-2-thiouridylate)(34)-methyltransferase activity","canonical_id":"go:GO:0004808","description":"\"Catalysis of the reaction: 5-aminomethyl-2-thiouridine34 in tRNA + S-adenosyl-L-methionine = 5-methylaminomethyl-2-thiouridine34 in tRNA + H+ + S-adenosyl-L-homocysteine. This enzyme specifically adds the terminal methyl group of 5-[(methylamino)methyl]-2-thiouridylate.\" [RHEA:19569]","metadata":null},{"id":"4c72e2406bd34c1a884eb61b4749e174","type":"GO_TERM","name":"tRNA (L-threonylcarbamoyladenosine(37)-C2) methyltransferase activity","canonical_id":"go:GO:0089715","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + tRNA containing N6-threonylcarbamoyladenosine at position 37 = S-adenosyl-L-homocysteine + tRNA containing N6-methylthreonylcarbamoyladenosine at position 37.\" [PMID:25063302, RHEA:70027]","metadata":null},{"id":"e240ad2ee35f4ea9bd94c813bc3fd9f1","type":"GO_TERM","name":"tRNA (N(6)-L-threonylcarbamoyladenosine(37)-C(2))-methylthiotransferase activity","canonical_id":"go:GO:0035598","description":"\"Catalysis of the reaction: N(6)-L-threonylcarbamoyladenosine(37) in tRNA + [sulfur carrier]-SH + AH2 + 2 S-adenosyl-L-methionine = 2-methylsulfanyl-N(6)-L-threonylcarbamoyladenosine(37) in tRNA + [sulfur carrier]-H + 5'-deoxyadenosine + L-methionine + A + S-adenosyl-L-homocysteine + 2 H+.\" [PMID:20472640, PMID:20584901, RHEA:37075]","metadata":null},{"id":"d23504a0b87e48e583c5303a1ba2e139","type":"GO_TERM","name":"tRNA (adenine(22)-N1)-methyltransferase activity","canonical_id":"go:GO:0160105","description":"\"Catalysis of the reaction: adenosine(22) in tRNA + S-adenosyl-L-methionine = H+ + N(1)-methyladenosine(22) in tRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.217]","metadata":null},{"id":"ddeb124de16a4e73a08ae3c26c7c5bde","type":"GO_TERM","name":"tRNA (adenine(37)-C2)-methyltransferase activity","canonical_id":"go:GO:0002935","description":"\"Catalysis of the reaction: adenosine37 in tRNA + 2 reduced [2Fe-2S]-[ferredoxin] + 2 S-adenosyl-L-methionine = 2-methyladenosine37 in tRNA + 5'-deoxyadenosine + L-methionine + 2 oxidized [2Fe-2S]-[ferredoxin] + S-adenosyl-L-homocysteine.\" [PMID:22891362, RHEA:43332]","metadata":null},{"id":"ebe9b26ec5db44b2afed90e135354b7e","type":"GO_TERM","name":"tRNA (adenine(57)-N1)/(adenine(58)-N1)-methyltransferase activity","canonical_id":"go:GO:0043827","description":"\"Catalysis of the reaction: adenosine57/adenosine58 in tRNA + 2 S-adenosyl-L-methionine = 2 H+ + N1-methyladenosine57/N1-methyladenosine58 in tRNA + 2 S-adenosyl-L-homocysteine.\" [PMID:14739239, PMID:20483913, RHEA:41740]","metadata":null},{"id":"b5b5beb1c3294369924cd07d16f2bb13","type":"GO_TERM","name":"tRNA (adenine(58)-N1)-methyltransferase activity","canonical_id":"go:GO:0160107","description":"\"Catalysis of the reaction: adenosine(58) in tRNA + S-adenosyl-L-methionine = H+ + N(1)-methyladenosine(58) in tRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.220]","metadata":null},{"id":"0c620f77427b4c70b0ec17b34631ed33","type":"GO_TERM","name":"tRNA (adenine(9)-N1)-methyltransferase activity","canonical_id":"go:GO:0160106","description":"\"Catalysis of the reaction: adenosine(9) in tRNA + S-adenosyl-L-methionine = H+ + N(1)-methyladenosine(9) in tRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.218]","metadata":null},{"id":"f07c61bae8804b13a45133444e2ede35","type":"GO_TERM","name":"tRNA (adenine) methyltransferase activity","canonical_id":"go:GO:0016426","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + tRNA = S-adenosyl-L-homocysteine + tRNA containing methyladenine.\" [GOC:curators]","metadata":null},{"id":"33484418658246ee84554c284427e945","type":"GO_TERM","name":"tRNA (cytidine(32)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0106339","description":"\"Catalysis of the reaction: cytidine(32) in tRNA + S-adenosyl-L-methionine = 2'-O-methylcytidine(32) in tRNA + S-adenosyl-L-homocysteine + H+.\" [PMID:25404562, RHEA:42932]","metadata":null},{"id":"8f73494b9c7e40558af798cb79d1011a","type":"GO_TERM","name":"tRNA (cytidine(32)/uridine(32)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0160206","description":"\"Catalysis of the reaction: cytidine(32)/uridine(32) in tRNA + S-adenosyl-L-methionine = 2'-O-methylcytidine(32)/2'-O-methyluridine(32) in tRNA + H+ + S-adenosyl-L-homocysteine.\" [EC:2.1.1.200]","metadata":null},{"id":"78427b564b08497ba569d7470e439c0f","type":"GO_TERM","name":"tRNA (cytidine(34)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0141098","description":"\"Catalysis of the reaction: cytidine(34) in tRNA + S-adenosyl-L-methionine = 2'-O-methylcytidine(34) in tRNA + H+ + S-adenosyl-L-homocysteine.\" [PMID:31943105, RHEA:43084]","metadata":null},{"id":"0d8c9a4239294f3dae02af84606f5628","type":"GO_TERM","name":"tRNA (cytidine(4)/adenine(4)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0140386","description":"\"Catalysis of the reaction: cytidine(4) in tRNA + S-adenosyl-L-methionine = 2'-O-methylcytidine(4) in tRNA + S-adenosyl-L-homocysteine + H+. Acts on  cytidine(4) on tRNAPro and tRNAGly(GCC), and on adenosine(4) in tRNAHis.\" [EC:2.1.1.225, PMID:17242307]","metadata":null},{"id":"d02ea8aa1d9c4e7a8ace2bb871e7a8e9","type":"GO_TERM","name":"tRNA (cytidine(56)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0106059","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + cytidine56 in tRNA= S-adenosyl-L-homocysteine + 2'-O-methylcytidine56 in tRNA.\" [RHEA:42968]","metadata":null},{"id":"4e03ef4b52344e25821fea65e4ef7703","type":"GO_TERM","name":"tRNA (cytidine) methyltransferase activity","canonical_id":"go:GO:0016427","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + tRNA = S-adenosyl-L-homocysteine + tRNA containing methylcytosine.\" [GOC:curators]","metadata":null},{"id":"098d79c58c34431782f30d1e0b0c7f13","type":"GO_TERM","name":"tRNA (cytidine-N3)-methyltransferase activity","canonical_id":"go:GO:0052735","description":"\"Catalysis of the reaction: a cytidine in tRNA + S-adenosyl-L-methionine = an N3-methylcytidine in tRNA + H+ + S-adenosyl-L-homocysteine.\" [RHEA:60908]","metadata":null},{"id":"e25e95deb552459dbb7f9e2111ec171a","type":"GO_TERM","name":"tRNA (cytidine-N5)-methyltransferase activity","canonical_id":"go:GO:0016428","description":"\"Catalysis of the reaction: a cytidine in tRNA + S-adenosyl-L-methionine = a 5-methylcytidine in tRNA + S-adenosyl-L-homocysteine + H+. This modification can occur on several residues, including cytidine(34), cytidine(40), cytidine(48), and cytidine(49).\" [RHEA:61468]","metadata":null},{"id":"b1ad65b53e4e44f39273c0b996ce6ae5","type":"GO_TERM","name":"tRNA (guanine(10)-N2)-dimethyltransferase activity","canonical_id":"go:GO:0160101","description":"\"Catalysis of the reaction: guanosine(10) in tRNA + 2 S-adenosyl-L-methionine = 2 H+ + N(2)-dimethylguanosine(10) in tRNA + 2 S-adenosyl-L-homocysteine.\" [EC:2.1.1.213]","metadata":null},{"id":"76d39fadbfdd41f889b2c22efd775db7","type":"GO_TERM","name":"tRNA (guanine(10)-N2)-methyltransferase activity","canonical_id":"go:GO:0160102","description":"\"Catalysis of the reaction: guanosine(10) in tRNA + S-adenosyl-L-methionine = H+ + N(2)-methylguanosine(10) in tRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.214]","metadata":null},{"id":"9cc22fdb3f8f4646b76d5d2b55f63539","type":"GO_TERM","name":"tRNA (guanine(18)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0141100","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanosine 18 in tRNA= S-adenosyl-L-homocysteine + 2'-O-methylguanosine 18 in tRNA + H+.\" [PMID:25404562]","metadata":null},{"id":"2cdfe12289f34be1bedabff9bf1d13e1","type":"GO_TERM","name":"tRNA (guanine(26)-N2)-dimethyltransferase activity","canonical_id":"go:GO:0160104","description":"\"Catalysis of the reaction:guanosine(26) in tRNA + 2 S-adenosyl-L-methionine = 2 H+ + N(2)-dimethylguanosine(26) in tRNA + 2 S-adenosyl-L-homocysteine.\" [EC:2.1.1.216]","metadata":null},{"id":"6985aa11e1b34baa944d875c5863ff3f","type":"GO_TERM","name":"tRNA (guanine(26)-N2/guanine(27)-N2)-dimethyltransferase activity","canonical_id":"go:GO:0160103","description":"\"Catalysis of the reaction: guanosine(26)/guanosine(27) in tRNA + 4 S-adenosyl-L-methionine = 4 H+ + N(2)-dimethylguanosine(26)/N(2)-dimethylguanosine(27) in tRNA + 4 S-adenosyl-L-homocysteine.\" [EC:2.1.1.215]","metadata":null},{"id":"8e8fb6bf79104d118a840b9125019118","type":"GO_TERM","name":"tRNA (guanine(27)-N2)-dimethyltransferase activity","canonical_id":"go:GO:0160248","description":"\"Catalysis of the reaction: guanosine(27) in tRNA + 2 S-adenosyl-L-methionine = 2 H+ + N(2)-dimethylguanosine(27) in tRNA + 2 S-adenosyl-L-homocysteine.\" [PMID:39786990, PMID:39786998]","metadata":null},{"id":"07a1f324fff24da281cf537b3ce32d58","type":"GO_TERM","name":"tRNA (guanine(37)-N1)-methyltransferase activity","canonical_id":"go:GO:0052906","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanine(37) in tRNA = N(1)-methylguanine(37) in tRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.228]","metadata":null},{"id":"09f80004d74040a48da72c97877e3536","type":"GO_TERM","name":"tRNA (guanine(46)-N7)-methyltransferase activity","canonical_id":"go:GO:0008176","description":"\"Catalysis of the reaction: guanosine46 in tRNA + S-adenosyl-L-methionine = N7-methylguanosine46 in tRNA + S-adenosyl-L-homocysteine.\" [RHEA:42708]","metadata":null},{"id":"bfb21f60c98e468e9064450d19e58dff","type":"GO_TERM","name":"tRNA (guanine(6)-N2)-methyltransferase activity","canonical_id":"go:GO:0160117","description":"\"Catalysis of the reaction: guanosine(6) in tRNA + S-adenosyl-L-methionine = H+ + N(2)-methylguanosine(6) in tRNA + S-adenosyl-L-homocysteine.\" [EC:2.1.1.256, PMID:34669960]","metadata":null},{"id":"2fd4ff1322c34234a4e8a714833fa0ca","type":"GO_TERM","name":"tRNA (guanine(7)-N2)-methyltransferase activity","canonical_id":"go:GO:0160118","description":"\"Catalysis of the reaction: guanosine(7) in tRNA + S-adenosyl-L-methionine = H+ + N(2)-methylguanosine(7) in tRNA + S-adenosyl-L-homocysteine.\" [PMID:34669960]","metadata":null},{"id":"8400b6207a694889aa55e922e856b90d","type":"GO_TERM","name":"tRNA (guanine) methyltransferase activity","canonical_id":"go:GO:0016423","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + guanosine in tRNA = S-adenosyl-L-homocysteine + tRNA containing methylguanine.\" [GOC:curators]","metadata":null},{"id":"956344ee9e7e4ea19029286790217063","type":"GO_TERM","name":"tRNA (guanine-N7)-methylation","canonical_id":"go:GO:0106004","description":"\"The process whereby a guanine in a tRNA is methylated at the N7 position of guanine.\" [GOC:hjd, PMID:17382321]","metadata":null},{"id":"3ecf0e6b8ab8439fa9008078b4fe310b","type":"GO_TERM","name":"tRNA (guanosine(34)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0106340","description":"\"Catalysis of the reaction: guanosine(34) in tRNA + S-adenosyl-L-methionine = 2'-O-methylguanosine(34) in tRNA + H+ + S-adenosyl-L-homocysteine.\" [PMID:31943105, RHEA:85171]","metadata":null},{"id":"cf852b2689c3493e9cbceceeba9ff30e","type":"GO_TERM","name":"tRNA (guanosine(9)-N1)-methyltransferase activity","canonical_id":"go:GO:0052905","description":"\"Catalysis of the reaction: guanosine9 in tRNA + S-adenosyl-L-methionine = H+ + N1-methylguanosine9 in tRNA + S-adenosyl-L-homocysteine.\" [RHEA:43156]","metadata":null},{"id":"a8750033db6b445d957ce4d1a6b8ca2c","type":"GO_TERM","name":"tRNA (m1A) methyltransferase complex","canonical_id":"go:GO:0031515","description":"\"A protein complex involved in the catalysis of the formation of the modified nucleotide 1-methyladenosine (m1A) in tRNA. In yeast, it is a heterotetramer of two subunits, Gcd10p and Gcd14p, while in bacteria and archaea it is a homotetramer.\" [PMID:10779558, PMID:14739239]","metadata":null},{"id":"56b1da3449a54ff2a2016f67480523ea","type":"GO_TERM","name":"tRNA (m2G10) methyltransferase complex","canonical_id":"go:GO:0043528","description":"\"A protein complex required for the methylation of the guanosine nucleotide at position 10 (m2G10) in tRNA. In S. cerevisiae, this complex consists of at least two subunits, Trm11p and Trm112p.\" [PMID:15899842]","metadata":null},{"id":"ced049e063294330ad5608d34c84902f","type":"GO_TERM","name":"tRNA (m7G46) methyltransferase complex","canonical_id":"go:GO:0106143","description":"\"A protein complex involved in the catalysis of the formation of the modified nucleotide 7-methylguanine (at position 46 in certain tRNAs, such as tRNA(phe) and tRNA(met). In yeast, it is a heterotetramer of two subunits, Trm8 (catalytic) and Trm82 (WD repeat).\" [GOC:vw, PMID:15811913, PMID:1738232, PMID:18164779, PMID:18184583]","metadata":null},{"id":"a02b88a58b0b4b9ead05569dfb4d70a4","type":"GO_TERM","name":"tRNA (uracil(54)-C5)-methyltransferase activity, 5,10-methylenetetrahydrofolate-dependent","canonical_id":"go:GO:0047151","description":"\"Catalysis of the reaction: uridine54 in tRNA + (6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + NAD(P)H + H+ = 5-methyluridine54 in tRNA + (6S)-5,6,7,8-tetrahydrofolate + NAD(P)+.\" [EC:2.1.1.74]","metadata":null},{"id":"dd5b5e393e534f559e0586e495b6a4a3","type":"GO_TERM","name":"tRNA (uracil(54)-C5)-methyltransferase activity, S-adenosyl methionine-dependent","canonical_id":"go:GO:0030697","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + uridine54 in tRNA = 5-methyluridine54 in tRNA + H+ + S-adenosyl-L-homocysteine.\" [RHEA:42712]","metadata":null},{"id":"48feadbfc653427b8066e7d12cdfdeb4","type":"GO_TERM","name":"tRNA (uridine) methyltransferase activity","canonical_id":"go:GO:0016300","description":"\"Catalysis of the transfer of a methyl group from a donor to a uracil residue in a tRNA molecule.\" [GOC:mah]","metadata":null},{"id":"f8238c98aa954ef484c98402bc605fd9","type":"GO_TERM","name":"tRNA 2'-O-ribose methylation guide activity","canonical_id":"go:GO:0030564","description":"\"Specifies the site of 2'-O-ribose methylation in a tRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"9019a62841cd4a08a07dd17282c79a9e","type":"GO_TERM","name":"tRNA 2'-phosphotransferase activity","canonical_id":"go:GO:0000215","description":"\"Catalysis of the reaction: 2'-phospho-[ligated tRNA] + NAD+ = mature tRNA + ADP ribose 1'',2''-phosphate + nicotinamide + H2O. This reaction is the transfer of the splice junction 2-phosphate from ligated tRNA to NAD+ to produce ADP-ribose 1'-2' cyclic phosphate.\" [EC:2.7.1.160, PMID:9148937]","metadata":null},{"id":"835ff6266f71472eb7e6ca8d311c5f88","type":"GO_TERM","name":"tRNA 2-(methylsulfanyl)-N(6)-isopentenyladenosine(37) hydroxylase activity","canonical_id":"go:GO:0045301","description":"\"Catalysis of the reaction: 2-methylsulfanyl-N(6)-dimethylallyladenosine(37) in tRNA + acceptor-H2 + O2 = N(6)-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-2-(methylsulfanyl)adenosine(37) in tRNA + acceptor + H2O.\" [PMID:8253666, RHEA:65812]","metadata":null},{"id":"3629c19cde0140a08a7a438628463b27","type":"GO_TERM","name":"tRNA 2-selenouridine synthase activity","canonical_id":"go:GO:0043828","description":"\"Catalysis of the reaction: 5-methylaminomethyl-2-thiouridine + selenophosphate = 5-methylaminomethyl-2-selenouridine + phosphate (at the wobble position in tRNA).\" [PMID:14594807, RHEA:42716]","metadata":null},{"id":"941d71d70e3a4431876c1524ea850d07","type":"GO_TERM","name":"tRNA 3'-end processing","canonical_id":"go:GO:0042780","description":"\"The process in which the 3' end of a pre-tRNA molecule is converted to that of a mature tRNA.\" [GOC:curators]","metadata":null},{"id":"6debfe5fbd2040658bd01ff3a955dfdc","type":"GO_TERM","name":"tRNA 3'-terminal CCA addition","canonical_id":"go:GO:0001680","description":"\"Post-transcriptional addition of the terminal 3' CCA sequence to a tRNA which does not encode this sequence within the primary transcript. CCA addition proceeds by the sequential addition of CTP, CTP, and then ATP to the 3' end of the tRNA, yielding a diphosphate with each nucleotide addition.\" [GOC:curators, PMID:2247609]","metadata":null},{"id":"3a57def5a8eb4f8e82a06beaf71dd114","type":"GO_TERM","name":"tRNA 4-demethylwyosine alpha-amino-alpha-carboxypropyltransferase activity","canonical_id":"go:GO:0102522","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + 4-demethylwyosine37 in tRNAPhe = 5'-S-methyl-5'-thioadenosine + H+ + 7-[(3S)-3-amino-3-carboxypropyl]-4-demethylwyosine37 in tRNAPhe.\" [EC:2.5.1.114, GOC:pz]","metadata":null},{"id":"12e923f8ee9e43e59f3674fc10a3ae44","type":"GO_TERM","name":"tRNA 4-thiouridine biosynthesis","canonical_id":"go:GO:0002937","description":"\"The processes whereby a uridine residue in a tRNA is converted to 4-thiouridine. Typically 4-thiouridine is found at position 8, in many transfer RNAs.\" [ISBN:155581073X]","metadata":null},{"id":"210ae93c9b29406bbb359409321130f2","type":"GO_TERM","name":"tRNA 5'-end processing","canonical_id":"go:GO:0099116","description":"\"The process in which the 5' end of a pre-tRNA molecule is converted to that of a mature tRNA.\" [GOC:dos, GOC:pf, PMID:27484477]","metadata":null},{"id":"7700da8bafd540ad98446749dd991d36","type":"GO_TERM","name":"tRNA 5'-leader removal","canonical_id":"go:GO:0001682","description":"\"Generation of the mature 5'-end of the tRNA, usually via an endonucleolytic cleavage by RNase P.\" [PMID:11592395]","metadata":null},{"id":"413fb1ec382d4203ac5cda54866d26a5","type":"GO_TERM","name":"tRNA 5-taurinomethyluridine synthase activity","canonical_id":"go:GO:0160236","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + taurine + GTP + H2O + uridine34 in tRNA + A = 7,8-dihydrofolate + GDP + phosphate + 5-taurinomethyluridine34 in tRNA + H+ + AH2.\" [PMID:29390138, PMID:33619562, RHEA:83279]","metadata":null},{"id":"53e72e1aad484d9092571ffb6d3a43aa","type":"GO_TERM","name":"tRNA C3-cytosine methylation","canonical_id":"go:GO:0106217","description":"\"The process whereby a cytosine in a tRNA is methylated at position 3 of the cytosine.\" [PMID:28655767]","metadata":null},{"id":"6f93a3b4bd2d47b388701cdcae4d558e","type":"GO_TERM","name":"tRNA C5-cytosine methylation","canonical_id":"go:GO:0002946","description":"\"The process whereby a cytosine in a tRNA is methylated at position 5 of the cytosine.\" [ISBN:155581073X]","metadata":null},{"id":"900a8c17fdd7461a9e7710a31bf0b676","type":"GO_TERM","name":"tRNA N(6)-L-threonylcarbamoyladenine synthase activity","canonical_id":"go:GO:0061711","description":"\"Catalysis of the reaction: L-threonylcarbamoyladenylate + adenine(37) in tRNA = AMP + N(6)-L-threonylcarbamoyladenine(37) in tRNA.\" [EC:2.3.1.234]","metadata":null},{"id":"6e92f261b2ae460dafa8ef912205962b","type":"GO_TERM","name":"tRNA N1-guanine methylation","canonical_id":"go:GO:0002939","description":"\"The process whereby a guanine in tRNA is methylated at position N1 of the guanine.\" [ISBN:155581073X, ISBN:1555811337]","metadata":null},{"id":"ee2015414e5d4130a51f381f7f3e8a0c","type":"GO_TERM","name":"tRNA N2-guanine methylation","canonical_id":"go:GO:0002940","description":"\"The process whereby a guanine in a tRNA is methylated at the N2 position of guanine.\" [ISBN:155581073X, ISBN:1555811337]","metadata":null},{"id":"970c2cab2c2344e2ad93d2bad361b6cd","type":"GO_TERM","name":"tRNA acetylation","canonical_id":"go:GO:0051391","description":"\"The modification of tRNA structure by addition of an acetyl group to tRNA. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [GOC:ai]","metadata":null},{"id":"2edef28a56ba4a7c820133facb9d4a2e","type":"GO_TERM","name":"tRNA adenosine deamination to inosine","canonical_id":"go:GO:0140023","description":"\"The removal of an amine group from an adenosine to produce inosine within a tRNA molecule.\" [PMID:27974624]","metadata":null},{"id":"f27d88a0a0fc43d78a364d6997dff58b","type":"GO_TERM","name":"tRNA adenosine(64)-2'-O-ribosylphosphate transferase activity","canonical_id":"go:GO:0043399","description":"\"Catalysis of the transfer of a phosphoribosyl group from 5'-phosphoribosyl-1'-pyrophosphate to position 64 of initiator tRNA.\" [GOC:jl, PMID:22030622, PMID:7954819]","metadata":null},{"id":"1ae70b5257d142ae971a6c66b70ed072","type":"GO_TERM","name":"tRNA aminoacylation","canonical_id":"go:GO:0043039","description":"\"The chemical reactions and pathways by which the various amino acids become bonded to their corresponding tRNAs. The most common route for synthesis of aminoacyl tRNA is by the formation of an ester bond between the 3'-hydroxyl group of the most 3' adenosine of the tRNA and the alpha carboxylic acid group of an amino acid, usually catalyzed by the cognate aminoacyl-tRNA ligase. A given aminoacyl-tRNA ligase aminoacylates all species of an isoaccepting group of tRNA molecules.\" [GOC:ma, GOC:mah]","metadata":null},{"id":"2de2af47c4f143f6908c96da99279b6c","type":"GO_TERM","name":"tRNA aminoacylation for mitochondrial protein translation","canonical_id":"go:GO:0070127","description":"\"The synthesis of aminoacyl tRNA by the formation of an ester bond between the 3'-hydroxyl group of the most 3' adenosine of the tRNA, to be used in ribosome-mediated polypeptide synthesis in a mitochondrion.\" [GOC:mah]","metadata":null},{"id":"57ba643dfc534cd7b4555ef00e00d4e7","type":"GO_TERM","name":"tRNA aminoacylation for nonribosomal peptide biosynthetic process","canonical_id":"go:GO:0043040","description":"\"The synthesis of aminoacyl tRNA by the formation of an ester bond between the 3'-hydroxyl group of the most 3' adenosine of the tRNA, to be used in nonribosomal peptide synthesis.\" [GOC:jl]","metadata":null},{"id":"3a6427a694f1443da5cc51228658da25","type":"GO_TERM","name":"tRNA aminoacylation for protein translation","canonical_id":"go:GO:0006418","description":"\"The synthesis of aminoacyl tRNA by the formation of an ester bond between the 3'-hydroxyl group of the most 3' adenosine of the tRNA and the alpha carboxylic acid group of an amino acid, to be used in ribosome-mediated polypeptide synthesis.\" [GOC:ma]","metadata":null},{"id":"c2bd7f23500647b0974f474484903f45","type":"GO_TERM","name":"tRNA binding","canonical_id":"go:GO:0000049","description":"\"Binding to a transfer RNA.\" [GOC:ai]","metadata":null},{"id":"da369e9db81547c3bbf7bbe74a578aac","type":"GO_TERM","name":"tRNA cytidine N4-acetyltransferase activity","canonical_id":"go:GO:0051392","description":"\"Catalysis of the reaction: a cytidine in tRNA + acetyl-CoA + ATP + H2O = ADP + an N4-acetylcytidine in tRNA + CoA + H+ + phosphate.\" [PMID:15037780, RHEA:53876]","metadata":null},{"id":"dbc0b0619dca4547b6cbc3c54b791bd8","type":"GO_TERM","name":"tRNA decay","canonical_id":"go:GO:0016078","description":"\"The chemical reactions and pathways resulting in the breakdown of tRNA, transfer RNA, a class of relatively small RNA molecules responsible for mediating the insertion of amino acids into the sequence of nascent polypeptide chains during protein synthesis.\" [GOC:ai]","metadata":null},{"id":"3d8c375678154bf9aa117ad9a5adf5f1","type":"GO_TERM","name":"tRNA demethylase activity","canonical_id":"go:GO:1990984","description":"\"Catalysis of the removal of a methyl group from one or more positions within a tRNA molecule.\" [PMID:27745969]","metadata":null},{"id":"d9c51c32ffe04150b76f12f7646fd05b","type":"GO_TERM","name":"tRNA destabilization","canonical_id":"go:GO:0036417","description":"\"Any process that decreases the stability of a tRNA molecule, making it more vulnerable to degradative processes.\" [GOC:aa, GOC:bf]","metadata":null},{"id":"33aafe215bd94fc5a41e0d9fdf67b0e5","type":"GO_TERM","name":"tRNA dihydrouridine synthase activity","canonical_id":"go:GO:0017150","description":"\"Catalysis of the reaction: a 5,6-dihydrouridine in tRNA + NAD(P)+ = a uridine in tRNA + H+ + NAD(P)H.\" [PMID:11983710, PMID:22123979]","metadata":null},{"id":"a13cc71816c743cba54f391983a97a36","type":"GO_TERM","name":"tRNA dihydrouridine synthesis","canonical_id":"go:GO:0002943","description":"\"The process whereby a uridine in a transfer RNA is converted to dihydrouridine.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"f939502925b94551ab17525ef043329c","type":"GO_TERM","name":"tRNA dimethylallyltransferase activity","canonical_id":"go:GO:0052381","description":"\"Catalysis of the reaction: adenosine(37) in tRNA + dimethylallyl diphosphate = N(6)-dimethylallyladenosine(37) in tRNA + diphosphate.\" [EC:2.5.1.75, RHEA:26482]","metadata":null},{"id":"81b1aa07779c40319d72ec49f3921c04","type":"GO_TERM","name":"tRNA end turnover","canonical_id":"go:GO:0042778","description":"\"The process in which the 3'-terminal CCA of a tRNA is removed and restored. This often happens to uncharged tRNA.\" [GOC:curators]","metadata":null},{"id":"12a14c5ec9c84b93b8d80d59b797ecf5","type":"GO_TERM","name":"tRNA exon ligation","canonical_id":"go:GO:0000968","description":"\"An RNA exon ligation process that rejoins two exons of a pre-tRNA which has had the intron removed.\" [GOC:krc]","metadata":null},{"id":"7bc30014447d407d804c1c7ead0ec073","type":"GO_TERM","name":"tRNA export from nucleus","canonical_id":"go:GO:0006409","description":"\"The directed movement of tRNA from the nucleus to the cytoplasm.\" [GOC:ma]","metadata":null},{"id":"4d55414eab4441acb8ce6aaf33d6c1f5","type":"GO_TERM","name":"tRNA folding","canonical_id":"go:GO:0061818","description":"\"The process of assisting in the folding of tRNAs into the correct tertiary structure.\" [GOC:dph, PMID:27849601]","metadata":null},{"id":"ed43286879fb45c6aa6c28d6f20069ef","type":"GO_TERM","name":"tRNA gene clustering","canonical_id":"go:GO:0070058","description":"\"The process in which tRNA genes, which are not linearly connected on the chromosome, are transported in three dimensions to, and maintained together in, the nucleolus. This clustered positioning leads to transcriptional silencing of nearby RNA polymerase II promoters (termed tRNA gene mediated (tgm) silencing) in S. cerevisiae.\" [GOC:jh, GOC:mah, PMID:18708579]","metadata":null},{"id":"2fe8fb5d2ab044839bc586d78e4f2d11","type":"GO_TERM","name":"tRNA guanine ribose methylation","canonical_id":"go:GO:0002938","description":"\"The process whereby a guanosine residue in a tRNA is methylated on the 2'-hydroxyl group of the ribose moiety.\" [ISBN:1555811337]","metadata":null},{"id":"2cda12eb8c694f60b5b95326460fb45a","type":"GO_TERM","name":"tRNA guanylyltransferase activity","canonical_id":"go:GO:0008193","description":"\"Catalysis of the posttranscriptional addition of a guanyl residue to the 5' end of a tRNA molecule; observed for His tRNAs.\" [PMID:1660461]","metadata":null},{"id":"3a139a55d65641598c605bda4a954f66","type":"GO_TERM","name":"tRNA import into mitochondrion","canonical_id":"go:GO:0016031","description":"\"The process in which a tRNA is transported from the cytosol into the mitochondrial matrix.\" [GOC:ma, PMID:10988073, PMID:11121736]","metadata":null},{"id":"d81f48d37ef84cfda7194c2349e1ac31","type":"GO_TERM","name":"tRNA import into nucleus","canonical_id":"go:GO:0035719","description":"\"The directed movement of tRNA from the cytoplasm to the nucleus.\" [GOC:vw, PMID:20032305]","metadata":null},{"id":"00e86573e0e34a7aa47234228d51a2c8","type":"GO_TERM","name":"tRNA ligase activator activity","canonical_id":"go:GO:0140733","description":"\"Binds to and increases the activity of a tRNA ligase.\" [PMID:30943413]","metadata":null},{"id":"f5fa4456959c45a5a007cda52a73d6f3","type":"GO_TERM","name":"tRNA m2,2-guanine biosynthesis","canonical_id":"go:GO:0002942","description":"\"The process whereby a guanine residue in a transfer RNA is methylated twice at the N2 position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"3bec78f4c38b436999ac7acf6358aa49","type":"GO_TERM","name":"tRNA metabolic process","canonical_id":"go:GO:0006399","description":"\"The chemical reactions and pathways involving tRNA, transfer RNA, a class of relatively small RNA molecules responsible for mediating the insertion of amino acids into the sequence of nascent polypeptide chains during protein synthesis. Transfer RNA is characterized by the presence of many unusual minor bases, the function of which has not been completely established.\" [ISBN:0198506732]","metadata":null},{"id":"e2e02af4259b4fd9a67f1fedce23b2cb","type":"GO_TERM","name":"tRNA methylation","canonical_id":"go:GO:0030488","description":"\"The posttranscriptional addition of methyl groups to specific residues in a tRNA molecule.\" [GOC:mah]","metadata":null},{"id":"32ba612b8a8e4292a516dc01297b8de6","type":"GO_TERM","name":"tRNA methylthiolation","canonical_id":"go:GO:0035600","description":"\"The addition of a methylthioether group (-SCH3) to a nucleotide in a tRNA molecule.\" [PMID:20472640]","metadata":null},{"id":"8f237eebc4d74e068012999d32285fd1","type":"GO_TERM","name":"tRNA methyltransferase activator activity","canonical_id":"go:GO:0141106","description":"\"Binds to and increases the activity of a methyltransferase.\" [GOC:curators]","metadata":null},{"id":"bb44e14ea5964237982d6641ed894aef","type":"GO_TERM","name":"tRNA methyltransferase activity","canonical_id":"go:GO:0008175","description":"\"Catalysis of the transfer of a methyl group from a donor to a nucleoside residue in a tRNA molecule. The methyl group can be transfered to the nucleobase or to the ribose group of the nucleoside.\" [GOC:mah]","metadata":null},{"id":"2a07892a2ff84eb690e77a5a7875c8fe","type":"GO_TERM","name":"tRNA methyltransferase complex","canonical_id":"go:GO:0043527","description":"\"A multimeric protein complex involved in the methylation of specific nucleotides in tRNA.\" [GOC:jl, PMID:24904644, PMID:9851972]","metadata":null},{"id":"5a28e0ff5dac43f4935d5c8c57833465","type":"GO_TERM","name":"tRNA modification","canonical_id":"go:GO:0006400","description":"\"The covalent alteration of one or more nucleotides within a tRNA molecule to produce a tRNA molecule with a sequence that differs from that coded genetically.\" [GOC:curators]","metadata":null},{"id":"19db037b19d74c33b27da968aaa6424b","type":"GO_TERM","name":"tRNA modification guide activity","canonical_id":"go:GO:0030557","description":"\"Specifies the site of a posttranscriptional modification in a tRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"02240a8e26ac4e17978eab2335ff67ca","type":"GO_TERM","name":"tRNA nucleoside ribose methylation","canonical_id":"go:GO:0002128","description":"\"The process that results in the modification of the sugar of a nucleoside in tRNA at the 2'O position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"9a42ae868c5846d2b971431331ce211a","type":"GO_TERM","name":"tRNA nucleotidyltransferase activity","canonical_id":"go:GO:0009022","description":"\"Catalysis of the reaction: tRNA(n+1) + phosphate = tRNA(n) + a nucleoside diphosphate.\" [PMID:2455297, RHEA:10628]","metadata":null},{"id":"884120011d654442a6618409d9712625","type":"GO_TERM","name":"tRNA processing","canonical_id":"go:GO:0008033","description":"\"The process in which a pre-tRNA molecule is converted to a mature tRNA, ready for addition of an aminoacyl group.\" [GOC:jl, PMID:12533506]","metadata":null},{"id":"0974eb9033e044af9506cfcea2a9423a","type":"GO_TERM","name":"tRNA pseudouridine synthase activity","canonical_id":"go:GO:0106029","description":"\"Catalysis of the reaction: tRNA uridine = tRNA pseudouridine. Conversion of uridine in a tRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.\" [PMID:11095668]","metadata":null},{"id":"1125f56c287a4d2f9f191e57f31a4a68","type":"GO_TERM","name":"tRNA pseudouridine synthesis","canonical_id":"go:GO:0031119","description":"\"The intramolecular conversion of uridine to pseudouridine in a tRNA molecule.\" [GOC:mah]","metadata":null},{"id":"4ebc9fd8ff0b4c2e8844f641fb8e3e23","type":"GO_TERM","name":"tRNA pseudouridine(13) synthase activity","canonical_id":"go:GO:0160150","description":"\"Catalysis of the reaction: uridine(13) in tRNA = pseudouridine(13) in tRNA.\" [EC:5.4.99.27]","metadata":null},{"id":"2a5858e840e54dfb961ab2d7a733cca0","type":"GO_TERM","name":"tRNA pseudouridine(31) synthase activity","canonical_id":"go:GO:0160152","description":"\"Catalysis of the reaction: uridine(31) in tRNA = pseudouridine(31) in tRNA.\" [EC:5.4.99.42]","metadata":null},{"id":"6df1ceec60b94523ad2d7b1146308275","type":"GO_TERM","name":"tRNA pseudouridine(32) synthase activity","canonical_id":"go:GO:0160151","description":"\"Catalysis of the reaction: uridine(32) in tRNA = pseudouridine(32) in tRNA.\" [EC:5.4.99.28]","metadata":null},{"id":"3853910f400d40989c05e22645bc4b29","type":"GO_TERM","name":"tRNA pseudouridine(38-40) synthase activity","canonical_id":"go:GO:0160147","description":"\"Catalysis of the reaction: uridine(38/39/40) in tRNA = pseudouridine(38/39/40) in tRNA. Modifies uridine(38), uridine(39) and/or uridine(40) in tRNA.\" [EC:5.4.99.12]","metadata":null},{"id":"b557dcb70e5b49539c29c6f242457629","type":"GO_TERM","name":"tRNA pseudouridine(38/39) synthase activity","canonical_id":"go:GO:0160154","description":"\"Catalysis of the reaction: uridine(38/39) in tRNA = pseudouridine(38/39) in tRNA. Modifies uridine(38) and/or uridine(39) in tRNA.\" [EC:5.4.99.45]","metadata":null},{"id":"4f369f74a18c49f3bc729fb854e284a1","type":"GO_TERM","name":"tRNA pseudouridine(55) synthase activity","canonical_id":"go:GO:0160148","description":"\"Catalysis of the reaction: uridine(55) in tRNA = pseudouridine(55) in tRNA.\" [EC:5.4.99.25]","metadata":null},{"id":"66d819bf8c9c4785b08aece903e8abf7","type":"GO_TERM","name":"tRNA pseudouridine(65) synthase activity","canonical_id":"go:GO:0160149","description":"\"Catalysis of the reaction: uridine(65) in tRNA = pseudouridine(65) in tRNA.\" [EC:5.4.99.26]","metadata":null},{"id":"c6e73ceb25d84d579a86b2dfd0590fb2","type":"GO_TERM","name":"tRNA pseudouridylation guide activity","canonical_id":"go:GO:0030560","description":"\"Specifies the site of pseudouridylation in a tRNA molecule by base pairing with a short sequence around the target residue.\" [GOC:mah, PMID:12457565]","metadata":null},{"id":"52e5ffde42f847afa306cb2ef8b07464","type":"GO_TERM","name":"tRNA queuosine(34) biosynthetic process","canonical_id":"go:GO:0008616","description":"\"The chemical reactions and pathways resulting in the formation of queuosines, a series of nucleosides found in position 34 of tRNA and having an additional pentenyl ring added via an NH group to the methyl group of 7-methylguanosine. The pentenyl ring may carry other substituents. The wobble nucleoside of the tRNA sequence  (position 34) corresponds to the first position of the anticodon.\" [PMID:28208705, PMID:39600051]","metadata":null},{"id":"bf7716f3f99d471baba927f36f533b47","type":"GO_TERM","name":"tRNA queuosine(34) biosynthetic process from salvaged queuine","canonical_id":"go:GO:0160255","description":"\"The chemical reactions and pathways resulting in the formation of tRNA queuosine(34) by salvaging available queuine.\" [MetaCyc:PWY-8105, PMID:28208705, PMID:39600051]","metadata":null},{"id":"cc796c644f4c4e1b83560bea32172ed9","type":"GO_TERM","name":"tRNA queuosine(34) biosynthetic process from salvaged queuosine or its precursors","canonical_id":"go:GO:0160254","description":"\"The chemical reactions and pathways resulting in the formation of tRNA queuosine(34) by salvaging available queuosine or precursors of queuosine (preQ0 or preQ1).\" [MetaCyc:PWY-8106, PMID:28208705, PMID:39600051]","metadata":null},{"id":"161f87b3616146a88146c176102d1aad","type":"GO_TERM","name":"tRNA re-export from nucleus","canonical_id":"go:GO:0071528","description":"\"The directed movement from the nucleus to the cytoplasm of a tRNA that was previously exported to the cytoplasm and then imported back into the nucleus. The processes of primary tRNA export and secondary export (re-export) can be distinguished because in organisms in which tRNA splicing occurs in the cytoplasm, the export of a mature tRNA must occur by re-export.\" [GOC:mcc, PMID:17475781, PMID:20032305]","metadata":null},{"id":"2e6163fe107545d19a7b3b9353401106","type":"GO_TERM","name":"tRNA seleno-modification","canonical_id":"go:GO:0070329","description":"\"The substitution of a selenium atom for a sulfur atom in a ribonucleotide in a tRNA molecule.\" [GOC:jsg, PMID:14594807]","metadata":null},{"id":"5d55c6df15e446a2a340e1811ecd8f2a","type":"GO_TERM","name":"tRNA splicing, via endonucleolytic cleavage and ligation","canonical_id":"go:GO:0006388","description":"\"Splicing of tRNA substrates via recognition of the folded RNA structure that brings the 5' and 3' splice sites into proximity and cleavage of the RNA at both the 3' and 5' splice sites by an endonucleolytic mechanism, followed by ligation of the exons.\" [GOC:krc, ISBN:0879695897, PMID:9582290]","metadata":null},{"id":"d64dc0129e7e4e8f88863d161096b50b","type":"GO_TERM","name":"tRNA stabilization","canonical_id":"go:GO:0036416","description":"\"Prevention of degradation of tRNA molecules.\" [GOC:aa, GOC:bf, PMID:20459084]","metadata":null},{"id":"1e106850ed654551a0cbb2351ad761c1","type":"GO_TERM","name":"tRNA surveillance","canonical_id":"go:GO:0106354","description":"\"The set of processes involved in identifying and degrading defective or aberrant tRNAs.\" [GOC:mah, PMID:32841241]","metadata":null},{"id":"21074690da1d4c3989e6fbd2228b3eaf","type":"GO_TERM","name":"tRNA thio-modification","canonical_id":"go:GO:0034227","description":"\"The addition a sulfur atom to a nucleotide in a tRNA molecule.\" [GOC:mcc, PMID:12549933, PMID:14722066]","metadata":null},{"id":"03b0591266a7446a90ffac0d91b08662","type":"GO_TERM","name":"tRNA threonylcarbamoyladenosine dehydratase activity","canonical_id":"go:GO:0061503","description":"\"Catalysis of the ATP-dependent dehydration of t6A to form cyclic t6A.\" [GOC:dph, PMID:23242255]","metadata":null},{"id":"ea7e3b65552b4a358c9a51fd5ed47dd6","type":"GO_TERM","name":"tRNA threonylcarbamoyladenosine modification","canonical_id":"go:GO:0002949","description":"\"The attachment of a carbonyl group and a threonine to the amino group of the adenine residue immediately 3' of the anticodon, in tRNAs that decode ANN codons (where N is any base).\" [GOC:imk, GOC:mah, PMID:19287007, PMID:21183954, PMID:23258706]","metadata":null},{"id":"dc484af9bc624e7298e7b3235742cede","type":"GO_TERM","name":"tRNA transcription","canonical_id":"go:GO:0009304","description":"\"The synthesis of transfer RNA (tRNA) from a DNA template.\" [GOC:jl]","metadata":null},{"id":"4f96a7ee438e4f1ea203cb804d8342a9","type":"GO_TERM","name":"tRNA transcription by RNA polymerase III","canonical_id":"go:GO:0042797","description":"\"The synthesis of transfer RNA (tRNA) from a DNA template by RNA polymerase III (Pol III), originating at a Pol III promoter.\" [GOC:jl, ISBN:0321000382]","metadata":null},{"id":"84892ca005f6437fb03c1792253841b6","type":"GO_TERM","name":"tRNA transmembrane transporter activity","canonical_id":"go:GO:0051034","description":"\"Enables the transfer of tRNA, transfer ribonucleic acid, from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"dad55fb8bd694bcbbfdbd8e900098808","type":"GO_TERM","name":"tRNA transport","canonical_id":"go:GO:0051031","description":"\"The directed movement of tRNA, transfer ribonucleic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"1e300f5ac73f4f45ad19dddd4942c70d","type":"GO_TERM","name":"tRNA uridine(34) acetyltransferase activity","canonical_id":"go:GO:0106261","description":"\"Catalysis of the reaction: acetyl-CoA + H2O + S-adenosyl-L-methionine + uridine(34) in tRNA = 5'-deoxyadenosine + carboxymethyluridine(34) in tRNA + CoA + 2 H+ + L-methionine.\" [PMID:25151136, PMID:30733442, RHEA:61020]","metadata":null},{"id":"066c71b5bd8f44568707c077e7a99e4b","type":"GO_TERM","name":"tRNA wobble adenosine to inosine editing","canonical_id":"go:GO:0002100","description":"\"The process in which an adenosine at position 34 of a tRNA is post-transcriptionally converted to inosine. The wobble nucleoside of the tRNA sequence  (position 34) corresponds to the first position of the anticodon.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"814ffe21351949e0a2ee80fcba00b4ac","type":"GO_TERM","name":"tRNA wobble base 5-methoxycarbonylmethyl-2-thiouridinylation","canonical_id":"go:GO:0002926","description":"\"The process whereby a wobble base uridine residue in a tRNA is modified to 5-methoxycarbonylmethyl-2-thiouridine.\" [GOC:hjd, PMID:22768388]","metadata":null},{"id":"de6acfb4f9d14f9b836a31b82cc94d96","type":"GO_TERM","name":"tRNA wobble base cytosine methylation","canonical_id":"go:GO:0002127","description":"\"The process in which the base of cytosine at position 34 in the anticodon of a tRNA is post-transcriptionally methylated at the C5 position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"14803fdb5a5e44279fc52967c13e1e8c","type":"GO_TERM","name":"tRNA wobble base lysidine biosynthesis","canonical_id":"go:GO:0002136","description":"\"The process in which the carbonyl of cytosine at position 34 of a tRNA is post-transcriptionally replaced by lysine.\" [PMID:15894617]","metadata":null},{"id":"001c6a04a8824291aff7b1b82ea07956","type":"GO_TERM","name":"tRNA wobble base modification","canonical_id":"go:GO:0002097","description":"\"The process in which the nucleotide at position 34 in the anticodon of a tRNA is post-transcriptionally modified. The wobble nucleoside of the tRNA sequence  (position 34) corresponds to the first position of the anticodon.\" [PMID:28812932]","metadata":null},{"id":"4e739f69af0d4d24b5f39606112dc219","type":"GO_TERM","name":"tRNA wobble cytosine modification","canonical_id":"go:GO:0002101","description":"\"The process in which a cytosine at position 34 of a tRNA is post-transcriptionally modified. The wobble nucleoside of the tRNA sequence  (position 34) corresponds to the first position of the anticodon.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"4483f64edcee4b73a5169f8e1fb82931","type":"GO_TERM","name":"tRNA wobble guanine modification","canonical_id":"go:GO:0002099","description":"\"The process in which a guanine at position 34 of a tRNA is post-transcriptionally modified. The wobble nucleoside of the tRNA sequence  (position 34) corresponds to the first position of the anticodon.\" [GOC:hjd, PMID:39600051]","metadata":null},{"id":"048032368bf34f8cac7a58ae2196ff3f","type":"GO_TERM","name":"tRNA wobble position uridine thiolation","canonical_id":"go:GO:0002143","description":"\"The process in which a uridine residue at position 34 in the anticodon of a tRNA is post-transcriptionally thiolated at the C2 position. This process involves transfer of a sulfur from L-cysteine to position C2 by several steps.\" [PMID:16871210]","metadata":null},{"id":"3c4bca9e779443ff93a0a9771561879e","type":"GO_TERM","name":"tRNA wobble uridine modification","canonical_id":"go:GO:0002098","description":"\"The process in which a uridine at position 34 of a tRNA is post-transcriptionally modified. The wobble nucleoside of the tRNA sequence  (position 34) corresponds to the first position of the anticodon.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"92e8473942124460a85150a0b6a17c4f","type":"GO_TERM","name":"tRNA(Ile)-lysidine synthase activity","canonical_id":"go:GO:0032267","description":"\"Catalysis of the reaction: ATP + cytidine(34) in tRNA(Ile2) + L-lysine = AMP + diphosphate + H+ + lysidine(34) in tRNA(Ile2). This modification converts both the codon specificity of tRNA(Ile) from AUG to AUA and its amino acid specificity from methionine to isoleucine.\" [PMID:14527414, RHEA:43744]","metadata":null},{"id":"582cdcd179e04531809837c7e50b1215","type":"GO_TERM","name":"tRNA(Phe) (7-(3-amino-3-carboxypropyl)wyosine37-C2)-hydroxylase activity","canonical_id":"go:GO:0102524","description":"\"Catalysis of the reaction: 2-oxoglutarate + O2 + 7-[(3S)-(3-amino-3-carboxypropyl)]-wyosine37 in tRNAPhe = succinate + carbon dioxide + 7-(2-hydroxy-3-amino-3-carboxypropyl)-wyosine37 in tRNAPhe.\" [GOC:pz, RHEA:37899]","metadata":null},{"id":"abf14b1c951048f9adea8bf573c02d2f","type":"GO_TERM","name":"tRNA(Ser) (uridine(44)-2'-O-ribose)-methyltransferase activity","canonical_id":"go:GO:0141101","description":"\"Catalysis of the reaction: Catalysis of the reaction: S-adenosyl-L-methionine + uridine44 in tRNASer = 2'-O-methyluridine44 in tRNASer + H+ + S-adenosyl-L-homocysteine.\" [PMID:18025252, RHEA:43100]","metadata":null},{"id":"d94aad1814ee4226afdb8ef217be6038","type":"GO_TERM","name":"tRNA(Val) (adenine(37)-N6)-methyltransferase activity","canonical_id":"go:GO:7770054","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + adenosine(37) in tRNA(Val) = S-adenosyl-L-homocysteine + N(6)-methyladenosine(37) in tRNA(Val) + H+.\" [PMID:19383770, RHEA:43160]","metadata":null},{"id":"5a626b5618bb4dc2a5dc7bb2aaf06508","type":"GO_TERM","name":"tRNA-2-methylthio-N(6)-dimethylallyladenosine(37) synthase activity","canonical_id":"go:GO:0035597","description":"\"Catalysis of the reaction: N(6)-dimethylallyladenosine(37) in tRNA + [sulfur carrier]-SH + AH2 + 2 S-adenosyl-L-methionine = 2-methylsulfanyl-N(6)-dimethylallyladenosine(37) in tRNA + [sulfur carrier]-H + 5'-deoxyadenosine + L-methionine + A + S-adenosyl-L-homocysteine + 2 H+.\" [PMID:20472640, RHEA:37067]","metadata":null},{"id":"17e4438e24204d0c92f7e3820ef32508","type":"GO_TERM","name":"tRNA-4-demethylwyosine synthase activity","canonical_id":"go:GO:0102521","description":"\"Catalysis of the reaction: pyruvate + S-adenosyl-L-methionine + N1-methylguanine37 in tRNAPhe = L-methionine + 5'-deoxyadenosine + carbon dioxide + H2O + 4-demethylwyosine37 in tRNAPhe.\" [GOC:pz, PMID:34184886, RHEA:36347]","metadata":null},{"id":"8dcfaa45248248f7bacbff26ab2a779f","type":"GO_TERM","name":"tRNA-5-taurinomethyluridine 2-sulfurtransferase activity","canonical_id":"go:GO:0061708","description":"\"Catalysis of 5-taurinomethyluridine in tRNA + a [protein]-S-sulfanylcysteine + ATP + a reduced electron acceptor = a 5-taurinomethyl-2-thiouridine in tRNA + a [protein]-L-cysteine + AMP + an oxidized electron acceptor + diphosphate + H+.\" [PMID:15509579, RHEA:47040]","metadata":null},{"id":"917472fbd69141a3ad40b2a53e2d7229","type":"GO_TERM","name":"tRNA-derived regulatory ncRNA processing","canonical_id":"go:GO:0140891","description":"\"A process leading to the generation of a functional small regulatory non-coding RNA derived from a tRNA.\" [PMID:29120263]","metadata":null},{"id":"5407b524c1f9453f8046798a1cca1289","type":"GO_TERM","name":"tRNA-dihydrouridine16 synthase activity","canonical_id":"go:GO:0102262","description":"\"Catalysis of the reaction: a 5,6-dihydrouracil16 in tRNA + NAD(P) = H+ + a uracil16 in tRNA + NAD(P)H.\" [GOC:pz]","metadata":null},{"id":"eb6c602d35d24dd586be8615dd720e7d","type":"GO_TERM","name":"tRNA-dihydrouridine17 synthase activity","canonical_id":"go:GO:0102263","description":"\"Catalysis of the reaction: a 5,6-dihydrouracil17 in tRNA + NAD(P) = H+ + a uracil17 in tRNA + NAD(P)H.\" [GOC:pz]","metadata":null},{"id":"d8d7c4b793a74aa9a851a7607d52307b","type":"GO_TERM","name":"tRNA-dihydrouridine20 synthase activity","canonical_id":"go:GO:0102264","description":"\"Catalysis of the reaction: a 5,6-dihydrouracil20 in tRNA + NAD(P) = H+ + a uracil20 in tRNA + NAD(P)H.\" [EC:1.3.1.91, GOC:pz]","metadata":null},{"id":"571f5ae4ae044b2b90950c1b1e1d71b9","type":"GO_TERM","name":"tRNA-dihydrouridine20a synthase activity","canonical_id":"go:GO:0102266","description":"\"Catalysis of the reaction: a 5,6-dihydrouracil20a in tRNA + NAD(P) = H+ + a uracil20a in tRNA + NAD(P)H.\" [GOC:pz]","metadata":null},{"id":"f5ed69274d784047ac8c05d420f4c7de","type":"GO_TERM","name":"tRNA-dihydrouridine20b synthase activity","canonical_id":"go:GO:0102267","description":"\"Catalysis of the reaction: a 5,6-dihydrouracil20b in tRNA + NAD(P) = H+ + a uracil20b in tRNA + NAD(P)H.\" [GOC:pz]","metadata":null},{"id":"1df1c54e8139492c8e3e0c9c1f8fe81d","type":"GO_TERM","name":"tRNA-dihydrouridine47 synthase activity","canonical_id":"go:GO:0102265","description":"\"Catalysis of the reaction: a 5,6-dihydrouracil47 in tRNA + NAD(P) = H+ + a uracil47 in tRNA + NAD(P)H.\" [EC:1.3.1.89, GOC:pz]","metadata":null},{"id":"e12f583790e64d1abb924d02c43e240f","type":"GO_TERM","name":"tRNA-guanine transglycosylase complex","canonical_id":"go:GO:0120507","description":"\"A protein complex that catalyzes the base-exchange of a guanine residue with queuine at the wobble position of the anticodon of tRNAs. The eukaryotic tRNA-guanine transglycosylase exists as a heterodimer of a catalytic subunit (QTRT1 in humans) and an accessory subunit (QTRT2 in humans), whereas the bacterial enzyme is homodimeric.\" [GOC:sjm, PMID:20354154, PMID:38181786]","metadata":null},{"id":"8a48841df5724cf8ab2dfaee155e2c28","type":"GO_TERM","name":"tRNA-guanosine(34) queuine transglycosylase activity","canonical_id":"go:GO:0008479","description":"\"Catalysis of the reaction: guanosine34 in tRNA + queuine = guanine + queuosine34 in tRNA.\" [RHEA:16633]","metadata":null},{"id":"d8eda5f960f2468fa18b76d760b903ba","type":"GO_TERM","name":"tRNA-intron endonuclease complex","canonical_id":"go:GO:0000214","description":"\"A protein complex that catalyzes the endonucleolytic cleavage of pre-tRNA, producing 5'-hydroxyl and 2',3'-cyclic phosphate termini, and specifically removing the intron.\" [PMID:22391451]","metadata":null},{"id":"d2cdd65f8b844dd597ae3d9621e00dab","type":"GO_TERM","name":"tRNA-intron lyase activity","canonical_id":"go:GO:0000213","description":"\"Catalysis of the reaction: pretRNA = a 3'-half-tRNA molecule with a 5'-OH end + a 5'-half-tRNA molecule with a 2',3'-cyclic phosphate end + an intron with a 2',3'-cyclic phosphate and a 5'-hydroxyl terminus.\" [EC:4.6.1.16]","metadata":null},{"id":"bba351401db64397a9074ea9ea6cb45e","type":"GO_TERM","name":"tRNA-queuosine(34) beta-mannosyltransferase activity","canonical_id":"go:GO:0016438","description":"\"Catalysis of the reaction: GDP-alpha-D-mannose + queuosine34 in tRNA(Asp) = GDP + H+ + O-4''-alpha-D-mannosylqueuosine34 in tRNA(Asp).\" [RHEA:12885]","metadata":null},{"id":"cac8f7d99ae3445a9c27795f137a8fc9","type":"GO_TERM","name":"tRNA-queuosine(34) galactosyltransferase activity","canonical_id":"go:GO:0141125","description":"\"Catalysis of the reaction: queuosine34 in tRNA + UDP-alpha-D-galactose = H+ + O-5''-beta-D-galactosylqueuosine34 in tRNATyr + UDP. Substrates include tRNA(Tyr) and tRNA(Asp).\" [PMID:37992713]","metadata":null},{"id":"09029cfc87f042418b8b4b849b7f6f1b","type":"GO_TERM","name":"tRNA-specific adenosine deaminase activity","canonical_id":"go:GO:0008251","description":"\"Catalysis of the reaction: adenosine + H2O = inosine + NH4+, in a tRNA molecule.\" [GOC:mah]","metadata":null},{"id":"b90e457452a4431eab016389ccfb5b4d","type":"GO_TERM","name":"tRNA-specific adenosine-34 deaminase activity","canonical_id":"go:GO:0052717","description":"\"Catalysis of the reaction: adenosine34 in tRNA + H2O + H+ = inosine34 in tRNA + NH4+.\" [PMID:17875641, RHEA:43168]","metadata":null},{"id":"a531452f616b4724992307cc7e742aa1","type":"GO_TERM","name":"tRNA-specific adenosine-34 deaminase complex","canonical_id":"go:GO:0052718","description":"\"A protein complex that possesses tRNA-specific adenosine-34 deaminase activity. In eukaryotes the complex is a heterodimer; the subunits are known as Tad2p and Tad3p in yeasts and Adat2 and Adat3 in human.\" [PMID:17875641]","metadata":null},{"id":"7d118cea516742aeb1f10fe3fc57df0a","type":"GO_TERM","name":"tRNA-specific adenosine-37 deaminase activity","canonical_id":"go:GO:0043829","description":"\"Catalysis of the reaction: adenosine-37 + H2O = inosine-37 + NH4+, in a tRNA-Ala molecule.\" [PMID:8915538, PMID:9707437, RHEA:50968]","metadata":null},{"id":"e4576c49253046db892121fff5d8f35d","type":"GO_TERM","name":"tRNA-specific ribonuclease activity","canonical_id":"go:GO:0004549","description":"\"Catalysis of the hydrolysis of phosphodiester bonds in tRNA molecules.\" [GOC:mah]","metadata":null},{"id":"c8410554a49a4b6bba2caad63a3bbf21","type":"GO_TERM","name":"tRNA-splicing ligase complex","canonical_id":"go:GO:0072669","description":"\"A protein complex that catalyzes the ligation of cleaved pre-tRNAs by directly joining spliced tRNA halves to mature-sized tRNAs by incorporating the precursor-derived splice junction phosphate into the mature tRNA as a canonical 3',5'-phosphodiester.\" [GOC:sp, PMID:21311021]","metadata":null},{"id":"00deaa7e7b544db7b528ec462d411d7f","type":"GO_TERM","name":"tRNA-type intron splice site recognition and cleavage","canonical_id":"go:GO:0000379","description":"\"RNA processing that begins when the tertiary structure of a tRNA type intron is recognized, and ends when the endonucleolytic cleavage of the RNA at both the 5' and 3' splice sites occurs.\" [GOC:krc, GOC:mah, ISBN:0879695897]","metadata":null},{"id":"fb5b0030eaff4d848776b991b2cbea97","type":"GO_TERM","name":"tRNA-uracil-4 sulfurtransferase activity","canonical_id":"go:GO:0140741","description":"\"Catalyzes the reaction: ATP + [ThiI sulfur-carrier protein]-S-sulfanyl-L-cysteine + uracil in tRNA + 2 reduced ferredoxin [iron-sulfur] cluster = AMP + diphosphate + 4-thiouracil in tRNA + [ThiI sulfur-carrier protein]-L-cysteine + 2 oxidized ferredoxin [iron-sulfur] cluster.\" [PMID:27791189, PMID:5541999, RHEA:24176]","metadata":null},{"id":"219385fb1e614d9486ef9c29a5e3c2e6","type":"GO_TERM","name":"tRNA-uridine 2-sulfurtransferase activity","canonical_id":"go:GO:0103016","description":"\"Catalysis of the reaction: AH2 + ATP + S-sulfanyl-L-cysteinyl-[protein] + uridine(34) in tRNA = 2-thiouridine(34) in tRNA + A + AMP + diphosphate + H+ + L-cysteinyl-[protein].\" [RHEA:47032]","metadata":null},{"id":"08e203e0ddef46debecbc2386bcc7fc7","type":"GO_TERM","name":"tRNA-uridine aminocarboxypropyltransferase activity","canonical_id":"go:GO:0016432","description":"\"Catalysis of the reaction: a uridine in tRNA + S-adenosyl-L-methionine = a 3-[(3S)-3-amino-3-carboxypropyl]uridine in tRNA + S-methyl-5'-thioadenosine + H+.\" [RHEA:62432]","metadata":null},{"id":"edaae7b8509c464e9cd90240ba5c9cd6","type":"GO_TERM","name":"ta-siRNA processing","canonical_id":"go:GO:0010267","description":"\"A process leading to the generation of a functional trans-acting small interfering RNA (ta-siRNA). ta-siRNAs function like miRNAs to guide cleavage of target mRNAs.\" [GOC:tb, PMID:16129836, PMID:20687832]","metadata":null},{"id":"93a7470a5a2c464e8bc71a956a6d5014","type":"GO_TERM","name":"tabersonine 16-hydroxylase activity","canonical_id":"go:GO:0050594","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + tabersonine = 16-hydroxytabersonine + H2O + NADP+.\" [EC:1.14.14.103, RHEA:14133]","metadata":null},{"id":"4ab12da99b4d4aa89c03ba9e628420af","type":"GO_TERM","name":"tachykinin receptor activity","canonical_id":"go:GO:0004995","description":"\"Combining with a tachykinin neuropeptide and transmitting the signal across the membrane by activating an associated G-protein.\" [GOC:ai, GOC:bf, PMID:7639617, Wikipedia:Tachykinin]","metadata":null},{"id":"faade8e91f1f4fedaa167516146a17f4","type":"GO_TERM","name":"tachykinin receptor binding","canonical_id":"go:GO:0071861","description":"\"Binding to a tachykinin receptor.\" [GOC:kmv, GOC:mah]","metadata":null},{"id":"db24ec05c8c34eec93455d333b14a9a9","type":"GO_TERM","name":"tachykinin receptor signaling pathway","canonical_id":"go:GO:0007217","description":"\"A G protein-coupled receptor signaling pathway initiated by tachykinin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. Tachykinin is a short peptide with the terminal sequence (Phe-X-Gly-Leu-Met-NH2).\" [GOC:mah, PMID:14723970]","metadata":null},{"id":"e33a202fe0774d14a5275213f1e943dc","type":"DRUG","name":"tacrine","canonical_id":"gtopdb:6687","description":null,"metadata":null},{"id":"cee1ef44af684b54ac623ee286d0730c","type":"DRUG","name":"tacrolimus","canonical_id":"gtopdb:6784","description":null,"metadata":null},{"id":"d1c3044262034b1dbf540a2d18eb807e","type":"DRUG","name":"tacrolimus","canonical_id":"chembl:CHEMBL3989887","description":null,"metadata":null},{"id":"dab6af696866497b92770a80aef9adbc","type":"COMBINATION_TREATMENT","name":"tacrolimus + triamcinolone","canonical_id":"ctgov_combo:ctgov-combo-4809c305c2af5f1a","description":null,"metadata":null},{"id":"71a732964cf64f37be98a7ead609da13","type":"DRUG","name":"tadalafil","canonical_id":"gtopdb:7299","description":null,"metadata":null},{"id":"697a6486b0144ecbae829bf5b1015d8c","type":"DRUG","name":"tadalafil","canonical_id":"mesh:D000068581","description":null,"metadata":null},{"id":"c1543ae91d80485388ad39f2f63318f5","type":"DRUG","name":"tadalafil","canonical_id":"chembl:CHEMBL779","description":null,"metadata":null},{"id":"f00eeacc32dc4e46a3726dd955aa80ff","type":"COMBINATION_TREATMENT","name":"tadalafil + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-8dc284030f261180","description":null,"metadata":null},{"id":"e4c96573d5284d799f50150a80b15c84","type":"COMBINATION_TREATMENT","name":"tadalafil + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-8c2b3f128a1f2cdb","description":null,"metadata":null},{"id":"ef1d751bd25d46749cfdb5ac2b304c83","type":"COMBINATION_TREATMENT","name":"tadalafil + tamsulosin","canonical_id":"ctgov_combo:ctgov-combo-8a98fbebe144d010","description":null,"metadata":null},{"id":"9a766f27a905414aaa8d2293baf0889a","type":"COMBINATION_TREATMENT","name":"tadalafil + vardenafil","canonical_id":"ctgov_combo:ctgov-combo-7fc0a76aa8a3513b","description":null,"metadata":null},{"id":"17334c251dd645b095376f60517a1055","type":"DRUG","name":"tafamidis","canonical_id":"mesh:C547076","description":null,"metadata":null},{"id":"389b6fe19c114ebd97c24eb64736acb6","type":"DRUG","name":"tafasitamab","canonical_id":"gtopdb:11131","description":null,"metadata":null},{"id":"2f4c159061f04d8b871b5ea2db16fc94","type":"DRUG","name":"tafasitamab","canonical_id":"chembl:CHEMBL4298047","description":null,"metadata":null},{"id":"4a90e662b9494c3b93808c4603a3af29","type":"COMBINATION_TREATMENT","name":"tafasitamab + tazemetostat","canonical_id":"ctgov_combo:ctgov-combo-68f388648293f3eb","description":null,"metadata":null},{"id":"eb357a5fb46740aca03020de691565ef","type":"DRUG","name":"tafluprost","canonical_id":"gtopdb:7451","description":null,"metadata":null},{"id":"d5f3d83ba81442b68947a5ebb147a052","type":"DRUG","name":"tafluprost","canonical_id":"chembl:CHEMBL1963683","description":null,"metadata":null},{"id":"07fa1d3dfa504e66a035a5b9f241783e","type":"COMBINATION_TREATMENT","name":"tafluprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-2562530bda4d9d4b","description":null,"metadata":null},{"id":"89adfbad3f2f474ebca17791efbb0904","type":"COMBINATION_TREATMENT","name":"tafluprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-accc925691aedda8","description":null,"metadata":null},{"id":"0855eed3171c4b4e922e53533a5f7cf3","type":"COMBINATION_TREATMENT","name":"tafluprost + timolol","canonical_id":"ctgov_combo:ctgov-combo-66d962b962574298","description":null,"metadata":null},{"id":"a1cfb57bae41454c878b886b4b253ed9","type":"GO_TERM","name":"tagatose kinase activity","canonical_id":"go:GO:0050317","description":"\"Catalysis of the reaction: D-tagatose + ATP = D-tagatose 6-phosphate + ADP + 2 H+.\" [EC:2.7.1.101, RHEA:15513]","metadata":null},{"id":"9ee170b0770a452292109a3471395ba5","type":"GO_TERM","name":"tagatose-6-phosphate kinase activity","canonical_id":"go:GO:0009024","description":"\"Catalysis of the reaction: ATP + D-tagatose 6-phosphate = ADP + D-tagatose 1,6-bisphosphate.\" [EC:2.7.1.144]","metadata":null},{"id":"63b1c03f397140e98f3606b92592e70c","type":"GO_TERM","name":"tagatose-bisphosphate aldolase activity","canonical_id":"go:GO:0009025","description":"\"Catalysis of the reaction: D-tagatose 1,6-diphosphate = D-glyceraldehyde 3-phosphate + glycerone phosphate.\" [EC:4.1.2.40, RHEA:22948]","metadata":null},{"id":"4edc7782e7ce44b587bfc17e5bc75aa8","type":"GO_TERM","name":"tagaturonate reductase activity","canonical_id":"go:GO:0009026","description":"\"Catalysis of the reaction: D-altronate + NAD+ = D-tagaturonate + H+ + NADH.\" [EC:1.1.1.58, RHEA:17813]","metadata":null},{"id":"bc12639201e142b8b27d09c30ccdc22f","type":"DRUG","name":"tagitanlimab","canonical_id":"gtopdb:13795","description":null,"metadata":null},{"id":"26d330fa76ce4389b4ae4e4773e2859c","type":"GO_TERM","name":"tail portion of tanycyte","canonical_id":"go:GO:1990018","description":"\"Elongated process of a tanycyte, devoid of cytoplasmic extensions, that courses through the hypothalamic nuclei to form small endfoot processes that terminate either on blood vessels or at the pial surface of the brain. A tanycyte is a specialized elongated ventricular ependymal cell.\" [ISBN:0195065719, NIF_Subcellular:sao1749953771]","metadata":null},{"id":"76fb76dc01704500877d801827f70ec9","type":"GO_TERM","name":"tail spike morphogenesis","canonical_id":"go:GO:1990522","description":"\"The process in which the nematode tail spike is generated and organized. An example of this process is seen in C. elegans, where the tapered tail spike is formed during embryogenesis by a filamentous process that passes posteriorly through hyp10, the tail ventral hypodermis; the filamentous process is formed by a binucleate cell, the tail-spike cell, that subsequently undergoes programmed cell death.\" [GOC:kmv, PMID:17329362, PMID:6684600]","metadata":null},{"id":"c2c07dd71c96436289d83acfb6e980b1","type":"GO_TERM","name":"tail-anchored membrane protein insertion into ER membrane","canonical_id":"go:GO:0071816","description":"\"A process of protein insertion into the endoplasmic reticulum (ER) membrane in which a tail-anchored (TA) transmembrane protein is incorporated into an endoplasmic reticulum (ER) membrane. TA transmembrane protein, also named type II transmembrane proteins, contain a single C- terminal transmembrane region.\" [GOC:mah, GOC:sp, PMID:20516149, PMID:20676083]","metadata":null},{"id":"758a70bf5e7a42409a1fdde06e2f3836","type":"DRUG","name":"talazoparib","canonical_id":"gtopdb:8313","description":null,"metadata":null},{"id":"6563279703fc451191d02b91c28fbe96","type":"DRUG","name":"talazoparib","canonical_id":"chembl:CHEMBL3137320","description":null,"metadata":null},{"id":"cc386307b23547e68c0e2372568e6ac9","type":"COMBINATION_TREATMENT","name":"talazoparib + tazemetostat","canonical_id":"ctgov_combo:ctgov-combo-6dc24e0c36bbba45","description":null,"metadata":null},{"id":"e5922df3b6ba4a3397182f0d87ea12cc","type":"GO_TERM","name":"talin binding","canonical_id":"go:GO:1990147","description":"\"Binding to a talin, a family of related cytoskeletal proteins that play a role in assembly of actin filaments and migration of various cell types.\" [GOC:hjd, PMID:23372168]","metadata":null},{"id":"7ed2558c42014f039346b60c709b498f","type":"DISEASE","name":"tall stature-scoliosis-macrodactyly of the great toes syndrome","canonical_id":"mondo:0014401","description":null,"metadata":null},{"id":"b5ded92488504b7396624c30801200a6","type":"DRUG","name":"tamibarotene","canonical_id":"gtopdb:2648","description":null,"metadata":null},{"id":"cce95b3e6fba415eaa4c2e614971f5a5","type":"DRUG","name":"tamibarotene","canonical_id":"mesh:C061133","description":null,"metadata":null},{"id":"9b53d38463cb48a19a20819b50290fd1","type":"DRUG","name":"tamibarotene","canonical_id":"chembl:CHEMBL25202","description":null,"metadata":null},{"id":"375f517e1f8d4d40b12447ab46cc67f4","type":"DRUG","name":"tamoxifen","canonical_id":"gtopdb:1016","description":null,"metadata":null},{"id":"acf6e1f10ad044d8857b4d4baf6b018c","type":"DRUG","name":"tamsulosin","canonical_id":"gtopdb:488","description":null,"metadata":null},{"id":"394e3d4ff2b045b09685b84e1eff179e","type":"DRUG","name":"tandospirone","canonical_id":"mesh:C055267","description":null,"metadata":null},{"id":"14bd69dcbd8c4252b4078c90a6cff3f2","type":"GO_TERM","name":"tangential migration from the subventricular zone to the olfactory bulb","canonical_id":"go:GO:0022028","description":"\"The migration of cells in the telencephalon from the subventricular zone to the olfactory bulb in which cells move orthogonally to the direction of radial migration and do not use radial glial cell processes as substrates for migration.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"4d6ecaed7d774aeab3ee67ced89ae44f","type":"GO_TERM","name":"tannase activity","canonical_id":"go:GO:0050318","description":"\"Catalysis of the reaction: digallate + H2O = 2 gallate + H+.\" [EC:3.1.1.20, RHEA:16365]","metadata":null},{"id":"2d708647a8d74353abdcbbc4cbaa241d","type":"GO_TERM","name":"tapasin binding","canonical_id":"go:GO:0046980","description":"\"Binding to tapasin, a member of the MHC class I loading complex which bridges the TAP peptide transporter to class I molecules.\" [PMID:12594855]","metadata":null},{"id":"61ed1f609d6342f69f0228cfe93e32d8","type":"DRUG","name":"tapentadol","canonical_id":"gtopdb:7477","description":null,"metadata":null},{"id":"314e336a53094bb49898957667d8a063","type":"DRUG","name":"tapinarof","canonical_id":"gtopdb:9686","description":null,"metadata":null},{"id":"92f76b11da024ad793372c8901a0e0aa","type":"DRUG","name":"tapinarof","canonical_id":"chembl:CHEMBL259571","description":null,"metadata":null},{"id":"6e1021abfdba44abb14d08067b6bc68e","type":"GO_TERM","name":"target-directed miRNA degradation","canonical_id":"go:GO:0140958","description":"\"The process in which a miRNA is targeted for degradation by a non-coding RNA or mRNA. The binding of an RNA to a target miRNA within a RISC complex results in either ubiquitin-mediated degradation of AGO protein or the displacement of the 3' end of the miRNA, exposing it to nucleases.\" [PMID:33184237, PMID:36150386]","metadata":null},{"id":"e06d25053bbc4d5c9049b8860ce3e984","type":"GO_TERM","name":"tarsal gland development","canonical_id":"go:GO:1903699","description":"\"The process whose specific outcome is the progression of a tarsal gland over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, PMID:20664693]","metadata":null},{"id":"5c5a0163e7d546b7810d6288a8027fd4","type":"GO_TERM","name":"tartrate biosynthetic process","canonical_id":"go:GO:1901277","description":"\"The chemical reactions and pathways resulting in the formation of tartrate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00839]","metadata":null},{"id":"1959c4baf057480cb2f8da94d445cce4","type":"GO_TERM","name":"tartrate catabolic process","canonical_id":"go:GO:1901276","description":"\"The chemical reactions and pathways resulting in the breakdown of tartrate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00839]","metadata":null},{"id":"d71308f6f4d944009dd8206b77274b4e","type":"GO_TERM","name":"tartrate decarboxylase activity","canonical_id":"go:GO:0050319","description":"\"Catalysis of the reaction: L-tartrate + H+ = D-glycerate + CO2.\" [EC:4.1.1.73, RHEA:13317]","metadata":null},{"id":"9035cac2ba14408c9839a7621d562171","type":"GO_TERM","name":"tartrate dehydrogenase activity","canonical_id":"go:GO:0009027","description":"\"Catalysis of the reaction: tartrate + NAD+ = oxaloglycolate + NADH + H+.\" [EC:1.1.1.93]","metadata":null},{"id":"926f190234944cb4b8ec1586a7b92201","type":"GO_TERM","name":"tartrate epimerase activity","canonical_id":"go:GO:0050320","description":"\"Catalysis of the reaction: L-tartrate = (2R,3S)-tartrate.\" [EC:5.1.2.5, RHEA:22212]","metadata":null},{"id":"374ba953221d41a1aac3dfd4c0b98b09","type":"GO_TERM","name":"tartrate metabolic process","canonical_id":"go:GO:1901275","description":"\"The chemical reactions and pathways involving tartrate.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00839]","metadata":null},{"id":"b699d4a3131c426e942cb495d453b5be","type":"GO_TERM","name":"tartrate transmembrane transport","canonical_id":"go:GO:0015745","description":"\"The process in which tartrate is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"ff047240966e48c3a7e2587e3838c9f4","type":"GO_TERM","name":"tartrate transmembrane transporter activity","canonical_id":"go:GO:0015554","description":"\"Enables the transfer of tartrate from one side of a membrane to the other. Tartrate is the anion of 2,3-dihydroxybutanedioic acid, one of the aldaric acids. The L(+) enantiomer occurs widely in plants, especially in grape juice, and in fungi and bacteria.\" [GOC:ai]","metadata":null},{"id":"a47eb67eeda747028732c6a848fbfd5e","type":"GO_TERM","name":"tartrate:succinate antiporter activity","canonical_id":"go:GO:0015516","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: tartrate(out) + succinate(in) = tartrate(in) + succinate(out).\" [TC:2.A.47.3.3]","metadata":null},{"id":"d941297a0b224a1bbbf443c945e3acc1","type":"GO_TERM","name":"tartronate O-hydroxycinnamoyltransferase activity","canonical_id":"go:GO:0047161","description":"\"Catalysis of the reaction: hydroxymalonate + sinapoyl-CoA = CoA + sinapoyltartronate.\" [EC:2.3.1.106, RHEA:10952]","metadata":null},{"id":"e9c796ca1cbb46f596334166b43117c4","type":"GO_TERM","name":"tartronate-semialdehyde synthase activity","canonical_id":"go:GO:0009028","description":"\"Catalysis of the reaction: 2 glyoxylate + H+ = 2-hydroxy-3-oxopropanoate + CO2.\" [EC:4.1.1.47, RHEA:10136]","metadata":null},{"id":"612f8271b90442199b0faad5dac8a97f","type":"DRUG","name":"tasimelteon","canonical_id":"gtopdb:7393","description":null,"metadata":null},{"id":"4e6d833baeca4fe5858aafa68204c733","type":"DRUG","name":"tasimelteon","canonical_id":"chembl:CHEMBL2103822","description":null,"metadata":null},{"id":"737d437688634ba3934280f8e7abe06d","type":"DRUG","name":"tasosartan","canonical_id":"mesh:C086167","description":null,"metadata":null},{"id":"0c9e726b73f345a895863ec0b9e38f9c","type":"GO_TERM","name":"taste bud development","canonical_id":"go:GO:0061193","description":"\"The progression of the taste bud over time, from its formation to the mature state. The taste bud is a specialized area of the tongue that contains taste receptors.\" [GOC:dph]","metadata":null},{"id":"098ae0fc6e4744a1a89d51e2b1e3a994","type":"GO_TERM","name":"taste bud formation","canonical_id":"go:GO:0061195","description":"\"The developmental process pertaining to the initial formation of the taste bud from unspecified parts. The taste bud is a specialized area of the tongue that contains taste receptors.\" [GOC:dph]","metadata":null},{"id":"9a679710f691469e9cbaa61477374c29","type":"GO_TERM","name":"taste bud morphogenesis","canonical_id":"go:GO:0061194","description":"\"The process in which the anatomical structures of the taste bud are generated and organized. The taste bud is a specialized area of the tongue that contains taste receptors.\" [GOC:dph]","metadata":null},{"id":"3a89a311cc60445d8c63426c581b32bc","type":"GO_TERM","name":"taste receptor activity","canonical_id":"go:GO:0008527","description":"\"Combining with soluble compounds to initiate a change in cell activity. These receptors are responsible for the sense of taste.\" [GOC:dph]","metadata":null},{"id":"5c72427319f447b58e6c0b0c5d4e19be","type":"GO_TERM","name":"taste receptor binding","canonical_id":"go:GO:0031883","description":"\"Binding to a taste receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"135d2b56fbbf4292b4d2a858d5386ae1","type":"GO_TERM","name":"taste receptor complex","canonical_id":"go:GO:1903768","description":"\"A protein complex which is capable of taste receptor activity.\" [GO_REF:0000088, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:16720576]","metadata":null},{"id":"eb37c5716c944dd28a891f9aa5c10abd","type":"GO_TERM","name":"tau protein binding","canonical_id":"go:GO:0048156","description":"\"Binding to tau protein. tau is a microtubule-associated protein, implicated in Alzheimer's disease, Down Syndrome and ALS.\" [GOC:jid]","metadata":null},{"id":"c99bdd803762476d8c7df16162afd71e","type":"GO_TERM","name":"tau-protein kinase activity","canonical_id":"go:GO:0050321","description":"\"Catalysis of the reaction: ATP + tau-protein = ADP + O-phospho-tau-protein on serine and threonine residues.\" [EC:2.7.11.26]","metadata":null},{"id":"18def44ede9c4e41af8d83db2a772da9","type":"GO_TERM","name":"taurine binding","canonical_id":"go:GO:0030977","description":"\"Binding to taurine.\" [GOC:mlg]","metadata":null},{"id":"393b4fa5120b4ea8ad9e84905ea45673","type":"GO_TERM","name":"taurine biosynthetic process","canonical_id":"go:GO:0042412","description":"\"The chemical reactions and pathways resulting in the formation of taurine (2-aminoethanesulfonic acid), a sulphur-containing amino acid derivative important in the metabolism of fats.\" [GOC:jl, ISBN:0198600461]","metadata":null},{"id":"70d1598252734146ae83f6f60da3e877","type":"GO_TERM","name":"taurine catabolic process","canonical_id":"go:GO:0019529","description":"\"The chemical reactions and pathways resulting in the breakdown of taurine (2-aminoethanesulfonic acid), a sulphur-containing amino acid derivative important in the metabolism of fats.\" [GOC:jl, ISBN:0198600461]","metadata":null},{"id":"f001e565cc864fa0a8a9698c1c06acf0","type":"GO_TERM","name":"taurine dehydrogenase activity","canonical_id":"go:GO:0050323","description":"\"Catalysis of the reaction: A + H2O + taurine = AH(2) + NH4 + sulfoacetaldehyde.\" [PMID:15073291, RHEA:18709]","metadata":null},{"id":"79efc80414724a3591131a24d74e8f00","type":"GO_TERM","name":"taurine dioxygenase activity","canonical_id":"go:GO:0000908","description":"\"Catalysis of the reaction: 2-oxoglutarate + O2 + taurine = aminoacetaldehyde + CO2 + succinate + sulfite.\" [EC:1.14.11.17, RHEA:15909]","metadata":null},{"id":"ba71a9b9f16648d29fff8238d5463933","type":"GO_TERM","name":"taurine dioxygenase complex","canonical_id":"go:GO:1990205","description":"\"A protein complex capable of catalyzing the conversion of taurine and alpha-ketoglutarate to sulfite, aminoacetaldehyde and succinate under sulfur or cysteine starvation conditions. Its expression is repressed by the presence of sulfate or cysteine. In E. coli it is a homodimer or homotetramer of the protein TauD.\" [GOC:bhm, PMID:12741810]","metadata":null},{"id":"da5f1f52f36c405b9a84b73b1061d452","type":"GO_TERM","name":"taurine metabolic process","canonical_id":"go:GO:0019530","description":"\"The chemical reactions and pathways involving taurine (2-aminoethanesulfonic acid), a sulphur-containing amino acid derivative important in the metabolism of fats.\" [GOC:jl, ISBN:0198600461]","metadata":null},{"id":"877db47ac3f14ff993a4751b0b5de0ad","type":"GO_TERM","name":"taurine transmembrane transport","canonical_id":"go:GO:0015734","description":"\"The directed movement of taurine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"471b94709dc0488eb20091fa95af2a63","type":"GO_TERM","name":"taurine transmembrane transporter activity","canonical_id":"go:GO:0005368","description":"\"Enables the transfer of taurine from one side of a membrane to the other. Taurine (2-aminoethanesulfonic acid) is a sulphur-containing amino acid derivative which is important in the metabolism of fats.\" [GOC:ai]","metadata":null},{"id":"8fc68008e4d44e32b8597ece54468a1c","type":"GO_TERM","name":"taurine:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0050322","description":"\"Catalysis of the reaction: taurine + 2-oxoglutarate = sulfoacetaldehyde + L-glutamate.\" [PMID:16535664, RHEA:16353]","metadata":null},{"id":"899bd53c1eca4908b22ebbcf4bc0df98","type":"GO_TERM","name":"taurine:pyruvate transaminase activity","canonical_id":"go:GO:0031299","description":"\"Catalysis of the reaction: taurine + pyruvate = sulfoacetaldehyde + L-alanine.\" [PMID:11082195, RHEA:10420]","metadata":null},{"id":"b56aab8db86e47839332ed5029311ef9","type":"GO_TERM","name":"taurine:sodium symporter activity","canonical_id":"go:GO:0005369","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: taurine(out) + Na+(out) = taurine(in) + Na+(in).\" [TC:2.A.22.3.3]","metadata":null},{"id":"bfef61f79db74fc2ab55fcf19e42022e","type":"GO_TERM","name":"taurochenodeoxycholate 6alpha-hydroxylase activity","canonical_id":"go:GO:0033780","description":"\"Catalysis of the reaction: taurochenodeoxycholate + O2 + reduced [NADPH--hemoprotein reductase] +  = taurohyocholate H+ + H2O + oxidized [NADPH--hemoprotein reductase]. Acts on taurochenodeoxycholate, taurodeoxycholate and less readily on lithocholate and chenodeoxycholate.\" [EC:1.14.14.57]","metadata":null},{"id":"9ef42481f85d4aa3bfe561b07de0ed4d","type":"GO_TERM","name":"taurocyamine kinase activity","canonical_id":"go:GO:0050324","description":"\"Catalysis of the reaction: ATP + taurocyamine = N-phosphotaurocyamine + ADP + 2 H+.\" [EC:2.7.3.4, RHEA:22516]","metadata":null},{"id":"d783e376b78e49b8b801a0f8cc8f1fb5","type":"GO_TERM","name":"tauropine dehydrogenase activity","canonical_id":"go:GO:0050325","description":"\"Catalysis of the reaction: H2O + NAD+ + tauropine = H+ + NADH + pyruvate + taurine.\" [EC:1.5.1.23, RHEA:12580]","metadata":null},{"id":"7b8a3184040647929492731bf40a7d17","type":"GO_TERM","name":"taxadien-5-alpha-ol O-acetyltransferase activity","canonical_id":"go:GO:0050638","description":"\"Catalysis of the reaction: acetyl-CoA + taxa-4(20),11-dien-5alpha-ol = CoA + taxa-4(20),11-dien-5alpha-yl acetate.\" [EC:2.3.1.162, RHEA:22028]","metadata":null},{"id":"1b7276dbf02c4ce4aadf827f0a31321e","type":"GO_TERM","name":"taxadiene 5-alpha-hydroxylase activity","canonical_id":"go:GO:0050604","description":"\"Catalysis of the reaction: AH2 + O2 + taxa-4,11-diene = A + H2O + taxa-4(20),11-dien-5alpha-ol.\" [RHEA:14049]","metadata":null},{"id":"3e44120ae6c940e2adab6e099c1ecc8b","type":"GO_TERM","name":"taxadiene synthase activity","canonical_id":"go:GO:0050553","description":"\"Catalysis of the reaction: all-trans-geranylgeranyl diphosphate = diphosphate + taxa-4,11-diene.\" [EC:4.2.3.17, RHEA:20912]","metadata":null},{"id":"89237c50d9d841f6b6d5ebc86e9a01b3","type":"GO_TERM","name":"taxane 10-beta-hydroxylase activity","canonical_id":"go:GO:0050597","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + taxa-4(20),11-dien-5alpha-yl acetate = 10beta-hydroxytaxa-4(20),11-dien-5alpha-yl acetate + H2O + NADP+.\" [EC:1.14.14.105, RHEA:15241]","metadata":null},{"id":"878e7e812ca24457aace8776d8a947f8","type":"GO_TERM","name":"taxane 13-alpha-hydroxylase activity","canonical_id":"go:GO:0050598","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + taxa-4(20),11-dien-5alpha-ol = H2O + NADP+ + taxa-4(20),11-dien-5alpha,13alpha-diol.\" [EC:1.14.14.106, RHEA:18949]","metadata":null},{"id":"27c8e7e29fc04c54b2fa1cfa0c63c6c7","type":"GO_TERM","name":"taxifolin 8-monooxygenase activity","canonical_id":"go:GO:0050326","description":"\"Catalysis of the reaction: taxifolin + NAD(P)H + H+ + O2 = 2,3-dihydrogossypetin + NAD(P)+ + H2O.\" [EC:1.14.13.19, MetaCyc:TAXIFOLIN-8-MONOOXYGENASE-RXN]","metadata":null},{"id":"ee33b447215e46a1981a4be9b0207e9e","type":"GO_TERM","name":"taxis","canonical_id":"go:GO:0042330","description":"\"The directed movement of a motile cell or organism in response to an external stimulus.\" [GOC:jl, ISBN:0192801023]","metadata":null},{"id":"0c014edb4f654fe5ae0edd14c770e27e","type":"GO_TERM","name":"taxis to electron acceptor","canonical_id":"go:GO:0042334","description":"\"The directed movement of a motile cell or organism in response to the presence of an alternative electron acceptor, for example, nitrate.\" [GOC:jl, PMID:11029423]","metadata":null},{"id":"35130491eb04434c94f0ddc80f65368c","type":"GO_TERM","name":"taxoid 14-beta-hydroxylase activity","canonical_id":"go:GO:0036203","description":"\"Catalysis of the reaction: 10beta-hydroxytaxa-4(20),11-dien-5alpha-yl acetate + O2 + NADPH + H+ = 10beta,14beta-dihydroxytaxa-4(20),11-dien-5alpha-yl acetate + NADP+ + H2O.\" [EC:1.14.13.146]","metadata":null},{"id":"6b9ab45d850347edb1672e3bc6adaa36","type":"GO_TERM","name":"taxoid 2alpha-hydroxylase activity","canonical_id":"go:GO:0102365","description":"\"Catalysis of the reaction: taxusin + NADPH + O2 + H+ = 2-alpha-hydroxytaxusin + NADP + H2O. Also converts 7beta-hydroxytaxusin to 2alpha,7beta-dihydroxytaxusin.\" [EC:1.14.14.183, PMID:15178487]","metadata":null},{"id":"6a63912e0ce04c80b48f42f3b66287dd","type":"GO_TERM","name":"taxoid 7beta-hydroxylase activity","canonical_id":"go:GO:0036239","description":"\"Catalysis of the reaction: taxusin + [reduced NADPH-hemoprotein reductase] + O2 = 7beta-hydroxytaxusin + [oxidized NADPH-hemoprotein reductase] + H2O. Also converts 2alpha-hydroxytaxusin to 2alpha,7beta-dihydroxytaxusin.\" [EC:1.14.14.182, PMID:15157877, PMID:15178487]","metadata":null},{"id":"9cf44d815d584eb394dc7baf453fd8a9","type":"DRUG","name":"tazanolast","canonical_id":"mesh:C106301","description":null,"metadata":null},{"id":"21d2af91f809405798c0de33b3f0b83d","type":"DRUG","name":"tazarotene","canonical_id":"gtopdb:6952","description":null,"metadata":null},{"id":"fa2335534c5e4fa485887adaaf30242c","type":"DRUG","name":"tazarotene","canonical_id":"mesh:C086827","description":null,"metadata":null},{"id":"208878b9ac6346e497489035ae50aa82","type":"DRUG","name":"tazarotene","canonical_id":"chembl:CHEMBL1657","description":null,"metadata":null},{"id":"59090147364a4cd286b495d5171e36f2","type":"DRUG","name":"tazemetostat","canonical_id":"gtopdb:7011","description":null,"metadata":null},{"id":"e8443cb15b714d88bca230c935362b6c","type":"COMBINATION_TREATMENT","name":"tazemetostat + ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-3cc1dcefb45342af","description":null,"metadata":null},{"id":"95754c8666ad436f9b12835afecda61d","type":"DRUG","name":"tazobactam","canonical_id":"mesh:C043265","description":null,"metadata":null},{"id":"74f34a5eb0bb4e878517819f0a4d054c","type":"GO_TERM","name":"tear secretion","canonical_id":"go:GO:0070075","description":"\"The regulated release of the aqueous layer of the tear film from the lacrimal glands. Tears are the liquid product of a process of lacrimation to clean and lubricate the eyes. Tear fluid contains water, mucin, lipids, lysozyme, lactoferrin, lipocalin, lacritin, immunoglobulins, glucose, urea, sodium, and potassium.\" [GOC:rph]","metadata":null},{"id":"6d2d42cb516c4d948aace63aced4b7ce","type":"GO_TERM","name":"tectobulbar tract morphogenesis","canonical_id":"go:GO:0034429","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the optic tectum towards target cells in the premotor reticulospinal system in the hindbrain.\" [GOC:dsf, PMID:15065115, PMID:17507550, PMID:8038988]","metadata":null},{"id":"b29cf635eac74cb798a18c40e33115b8","type":"GO_TERM","name":"tectospinal tract morphogenesis","canonical_id":"go:GO:0021977","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the superior colliculus of the midbrain towards target cells in the ventral spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"5497b0f4ca104a20b1a56a9cc2d570b1","type":"GO_TERM","name":"tectum","canonical_id":"go:GO:0043676","description":"\"The layer of sexine which forms a roof over the columella, granules or other infratectal elements.\" [PMID:33706055]","metadata":null},{"id":"d18f893b23914d4798e0f9b89b5704d3","type":"DRUG","name":"teduglutide","canonical_id":"gtopdb:7049","description":null,"metadata":null},{"id":"ed6b09e195184976a70c728ab8a4f40d","type":"DRUG","name":"teduglutide","canonical_id":"chembl:CHEMBL2104987","description":null,"metadata":null},{"id":"cf7c39a2c190462e97e83eea55d3374b","type":"GO_TERM","name":"teichoic acid D-alanylation","canonical_id":"go:GO:0070400","description":"\"The formation of a D-alanyl ester of teichoic acid. Alanylation of teichoic acids modulates the properties of the bacterial cell wall and modulates the inflammatory properties of the teichoic acid.\" [GOC:add, PMID:14665680, PMID:16020688]","metadata":null},{"id":"7d3c4ab67f1c4a2fafb4b02e82b64819","type":"GO_TERM","name":"teichoic acid biosynthetic process","canonical_id":"go:GO:0019350","description":"\"The chemical reactions and pathways resulting in the formation of teichoic acid, any polymer occurring in the cell wall, membrane or capsule of Gram-positive bacteria and containing chains of glycerol phosphate or ribitol phosphate residues.\" [ISBN:0198506732]","metadata":null},{"id":"7f46c797f12945d88e7b303afcbff2ef","type":"GO_TERM","name":"teichoic acid catabolic process","canonical_id":"go:GO:0070393","description":"\"The chemical reactions and pathways resulting in the breakdown of teichoic acid, which is a major component of the cell wall of Gram-positive bacteria and typically consists of a polymer of glycerol-phosphate or ribitol-phosphate to which are attached glycosyl and D-alanyl ester residues.\" [GOC:add, PMID:14665680]","metadata":null},{"id":"067b988ef0bc47eebd3b259dbc707ece","type":"GO_TERM","name":"teichoic acid metabolic process","canonical_id":"go:GO:0046374","description":"\"The chemical reactions and pathways involving teichoic acid, any polymer occurring in the cell wall, membrane or capsule of Gram-positive bacteria and containing chains of glycerol phosphate or ribitol phosphate residues.\" [ISBN:0198506732]","metadata":null},{"id":"55b44809695c4e93894b6f0265b8add3","type":"GO_TERM","name":"teichoic acid transport","canonical_id":"go:GO:0015777","description":"\"The directed movement of teichoic acid into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Teichoic acid is any polymer occurring in the cell wall, membrane or capsule of Gram-positive bacteria and containing chains of glycerol phosphate or ribitol phosphate residues.\" [GOC:ai]","metadata":null},{"id":"bca7943fa18b4af68abda3ca50536122","type":"GO_TERM","name":"teichuronic acid biosynthetic process","canonical_id":"go:GO:0050845","description":"\"The chemical reactions and pathways resulting in the formation of teichuronic acid, a polymer containing chains of uronic acids and N-acetylglucosamine found in the cell wall, membrane or capsule of Gram-positive bacteria.\" [ISBN:0815108893]","metadata":null},{"id":"e1fa45c5336e4cdb9e0d0a7110b7645a","type":"GO_TERM","name":"telencephalon astrocyte cell migration","canonical_id":"go:GO:0022031","description":"\"The orderly movement of an astrocyte cell through the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"e494130cc263479f808f1deee219a1ca","type":"GO_TERM","name":"telencephalon cell migration","canonical_id":"go:GO:0022029","description":"\"The orderly movement of a cell from one site to another at least one of which is located in the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"db91a530ca9547c3b8be28effb386652","type":"GO_TERM","name":"telencephalon development","canonical_id":"go:GO:0021537","description":"\"The process whose specific outcome is the progression of the telencephalon over time, from its formation to the mature structure. The telencephalon is the paired anteriolateral division of the prosencephalon plus the lamina terminalis from which the olfactory lobes, cerebral cortex, and subcortical nuclei are derived.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"97cf5f9f9a2d4feb841f74363b4c264f","type":"GO_TERM","name":"telencephalon glial cell migration","canonical_id":"go:GO:0022030","description":"\"The orderly movement of glial cells through the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"f36c3bb9a4fb4296b08e5b5a99d4d1cc","type":"GO_TERM","name":"telencephalon microglial cell migration","canonical_id":"go:GO:0022033","description":"\"The orderly movement of microglial cells through the telencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"72a380bc66c1404198158e88e60c2b2f","type":"GO_TERM","name":"telencephalon oligodendrocyte cell migration","canonical_id":"go:GO:0022032","description":"\"The multiplication or reproduction of telencephalon oligodendrocyte cells, resulting in the expansion of a cell population.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3bbd57247b7747d88283a09885315b88","type":"GO_TERM","name":"telencephalon regionalization","canonical_id":"go:GO:0021978","description":"\"The regionalization process that creates areas within the forebrain that will direct the behavior of cell migration in differentiation as the telencephalon develops.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, GOC:mgi_curators]","metadata":null},{"id":"7b41c2ac16c949268c2a6e2da4d4ff39","type":"GO_TERM","name":"telethonin binding","canonical_id":"go:GO:0031433","description":"\"Binding to telethonin, a protein found in the Z disc of striated muscle and which is a substrate of the titin kinase.\" [GOC:mah, PMID:10481174]","metadata":null},{"id":"834c73f9f8604382a78c5b881ada1033","type":"GO_TERM","name":"teliospore formation","canonical_id":"go:GO:0075255","description":"\"The set of processes leading to the formation of a thick-walled resting or over-wintering spore produced by the rust fungi (Uredinales) and smut fungi (Ustilaginales) in which karyogamy occurs.\" [GOC:pamgo_curators]","metadata":null},{"id":"757c5ce5f20f4433bbd550a0234adc4c","type":"DRUG","name":"telisotuzumab vedotin","canonical_id":"gtopdb:13908","description":null,"metadata":null},{"id":"93ee4b8e8cb3415fbe03850b3687f3e7","type":"DRUG","name":"telisotuzumab vedotin","canonical_id":"chembl:CHEMBL3990032","description":null,"metadata":null},{"id":"11e1d9d99e1046ab8fb5e5b150224be9","type":"DRUG","name":"telithromycin","canonical_id":"mesh:C106791","description":null,"metadata":null},{"id":"c42cde20d4d6413580d611157903cf0a","type":"GO_TERM","name":"telium development","canonical_id":"go:GO:0075275","description":"\"The process that leads to the development of a telium, which is a teliospore-bearing sorus of the rust fungi.\" [GOC:pamgo_curators]","metadata":null},{"id":"468dfa5c626f42aebb7d788d4a847ca1","type":"GO_TERM","name":"tellurite methyltransferase activity","canonical_id":"go:GO:0035797","description":"\"Catalysis of the reaction: tellurite + S-adenosyl-L-methionine = methanetellurite + S-adenosyl-L-homocysteine.\" [PMID:11053398, PMID:21244361, RHEA:34539]","metadata":null},{"id":"d936e3e65719484cbd5c583835e844b3","type":"GO_TERM","name":"tellurite transmembrane transporter activity","canonical_id":"go:GO:0015654","description":"\"Enables the transfer of tellurite from one side of a membrane to the other. Tellurite is a salt of tellurous acid or an oxide of tellurium which occurs sparingly in tufts of white or yellowish crystals.\" [GOC:ai]","metadata":null},{"id":"2370e8335fd54cc39396612570b6b7cb","type":"GO_TERM","name":"tellurite transport","canonical_id":"go:GO:0015710","description":"\"The directed movement of tellurite into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"62fc06c497dc45589fa50ef39e45a813","type":"DRUG","name":"telmisartan","canonical_id":"gtopdb:592","description":null,"metadata":null},{"id":"c76e479e80844c0284a36d3276c93dbe","type":"DRUG","name":"telmisartan","canonical_id":"chembl:CHEMBL1017","description":null,"metadata":null},{"id":"03501d53c08847f699ff2b46b459a745","type":"COMBINATION_TREATMENT","name":"telmisartan + verapamil","canonical_id":"ctgov_combo:ctgov-combo-5cfac25dc07454b5","description":null,"metadata":null},{"id":"462f9148aaa0440b8a1ec2c05ca3f5b1","type":"GO_TERM","name":"telodendria","canonical_id":"go:GO:0120208","description":"\"Telodendria are projections that originate from the axon pedicle and form gap junctions with other neurons.\" [GOC:cvs, GOC:krc, PMID:11074451, PMID:11506430, PMID:14755521, PMID:1646866, PMID:20533354, PMID:29127712, PMID:451992, PMID:8390352]","metadata":null},{"id":"0dcb73d657684161857a2ae24168a9f4","type":"GO_TERM","name":"telogen","canonical_id":"go:GO:0042639","description":"\"The resting phase of hair cycle.\" [PMID:12230507]","metadata":null},{"id":"27bb126856f14447861a0f7e0106a735","type":"GO_TERM","name":"telomerase RNA binding","canonical_id":"go:GO:0070034","description":"\"Binding to the telomerase RNA template.\" [GOC:krc, PMID:16884717]","metadata":null},{"id":"b141f228859d40a9b8e5052d2d6bd10b","type":"GO_TERM","name":"telomerase RNA localization","canonical_id":"go:GO:0090672","description":"\"Any process in which telomerase RNA is transported to, or maintained in, a specific location.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:25467444]","metadata":null},{"id":"7173dbb2672d49a8a3ec8124e05fc33a","type":"GO_TERM","name":"telomerase RNA localization to Cajal body","canonical_id":"go:GO:0090671","description":"\"A process in which telomerase RNA (TERC) is transported to, or maintained in, a Cajal body.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:25467444]","metadata":null},{"id":"6c12356b944e42af9b5e79ef53e14068","type":"GO_TERM","name":"telomerase RNA stabilization","canonical_id":"go:GO:0090669","description":"\"Prevention of degradation of telomerase RNA (TERC) molecules.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:25467444]","metadata":null},{"id":"e37a192d19f343dd8ef0986b4a8ab770","type":"GO_TERM","name":"telomerase activity","canonical_id":"go:GO:0003720","description":"\"Catalysis of the reaction: a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) = diphosphate + DNA(n+1) using an internal RNA template that encodes the telomeric repeat sequence.\" [GOC:krc, PMID:11812242, PMID:28732250]","metadata":null},{"id":"235a131b818a49ef8d8012b0c919237e","type":"GO_TERM","name":"telomerase catalytic core complex","canonical_id":"go:GO:0000333","description":"\"The minimal catalytic core of telomerase is a ribonucleoprotein complex composed of a catalytic reverse transcriptase subunit and an RNA subunit that provides the template for telomeric DNA addition.\" [GOC:BHF-UCL, PMID:11884619, PMID:1808260]","metadata":null},{"id":"cc03825bc63f42ac89760eb74921a016","type":"GO_TERM","name":"telomerase catalytic core complex assembly","canonical_id":"go:GO:1904868","description":"\"The aggregation, arrangement and bonding together of a set of components to form a telomerase catalytic core complex.\" [GO_REF:0000079, GOC:BHF, GOC:BHF_telomere, GOC:rph, GOC:TermGenie, PMID:26586433]","metadata":null},{"id":"7d77e98a44ba4459a7adfd3250c6d622","type":"GO_TERM","name":"telomerase holoenzyme complex","canonical_id":"go:GO:0005697","description":"\"Telomerase is a ribonucleoprotein enzyme complex, with a minimal catalytic core composed of a catalytic reverse transcriptase subunit and an RNA subunit that provides the template for telomeric DNA addition. In vivo, the holoenzyme complex often contains additional subunits.\" [PMID:11884619]","metadata":null},{"id":"282893b6e30e4da692f3b3e1e8a4e4e5","type":"GO_TERM","name":"telomerase holoenzyme complex assembly","canonical_id":"go:GO:1905323","description":"\"The aggregation, arrangement and bonding together of a set of components to form a telomerase holoenzyme complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:26305931]","metadata":null},{"id":"ea0a1ce4615b438da7780435c356a255","type":"GO_TERM","name":"telomerase inhibitor activity","canonical_id":"go:GO:0010521","description":"\"Binds to and stops, prevents or reduces the activity of telomerase.\" [GOC:dph, GOC:krc, GOC:tb]","metadata":null},{"id":"42e9eb56588f44abb0fcf873e8852095","type":"GO_TERM","name":"telomere assembly","canonical_id":"go:GO:0032202","description":"\"A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a telomere at a non-telomeric double-stranded DNA end. A telomere is a terminal region of a linear chromosome that includes telomeric DNA repeats and associated proteins.\" [GOC:mah, GOC:ns, PMID:11902675, PMID:8622671]","metadata":null},{"id":"7c1ab42b553b4904adcb859a5cdb38d2","type":"GO_TERM","name":"telomere cap complex","canonical_id":"go:GO:0000782","description":"\"A complex of DNA and protein located at the end of a linear chromosome that protects and stabilizes a linear chromosome.\" [GOC:elh]","metadata":null},{"id":"455159375fd74bcf892249aa7e4c9bd1","type":"GO_TERM","name":"telomere capping","canonical_id":"go:GO:0016233","description":"\"A process in which telomeres are protected from degradation and fusion, thereby ensuring chromosome stability by protecting the ends from both degradation and from being recognized as damaged DNA. May be mediated by specific single- or double-stranded telomeric DNA binding proteins.\" [GOC:mah, GOC:rn, PMID:11349150, PMID:11352055]","metadata":null},{"id":"65684f702f934ad7a5fc53c4a69afe9b","type":"GO_TERM","name":"telomere formation via telomerase","canonical_id":"go:GO:0032203","description":"\"A cellular process that results in the formation of a telomere at a non-telomeric double-stranded DNA end that involves the activity of a telomerase enzyme.\" [GOC:cjm, GOC:ns, PMID:11902675, PMID:8622671]","metadata":null},{"id":"8b1bf443277243a4a52218f52043688f","type":"GO_TERM","name":"telomere localization","canonical_id":"go:GO:0034397","description":"\"Any process in which a telomere is transported to, and/or maintained in, a specific location.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"3482d239be9e4ff5a65df3876278ee37","type":"GO_TERM","name":"telomere maintenance","canonical_id":"go:GO:0000723","description":"\"Any process that contributes to the maintenance of proper telomeric length and structure by affecting and monitoring the activity of telomeric proteins, the length of telomeric DNA and the replication and repair of the DNA. These processes includes those that shorten, lengthen, replicate and repair the telomeric DNA sequences.\" [GOC:BHF, GOC:BHF_telomere, GOC:elh, GOC:rl, PMID:11092831]","metadata":null},{"id":"4e48d1e00ef641708218457ab8f0ea56","type":"GO_TERM","name":"telomere maintenance in response to DNA damage","canonical_id":"go:GO:0043247","description":"\"Any process that occur in response to the presence of critically short or damaged telomeres.\" [GOC:BHF, GOC:BHF_telomere, GOC:jbu, PMID:15279784]","metadata":null},{"id":"31c42f3ee41f4295971d8decdb0f0aae","type":"GO_TERM","name":"telomere maintenance via base-excision repair","canonical_id":"go:GO:0097698","description":"\"A telomere maintenance process that occurs by base-excision repair of telomeric DNA in response to DNA damage. Telomeric sequences are particularly susceptible to oxidative DNA damage, due to their G-rich nature.\" [GOC:BHF, GOC:BHF_telomere, GOC:jbu, PMID:24703901]","metadata":null},{"id":"0009f72c10be4bf786caff9364ded2d9","type":"GO_TERM","name":"telomere maintenance via recombination","canonical_id":"go:GO:0000722","description":"\"Any recombinational process that contributes to the maintenance of proper telomeric length.\" [GOC:elh, PMID:11850777]","metadata":null},{"id":"e854df4e55d246878fe9080e346ff35e","type":"GO_TERM","name":"telomere maintenance via semi-conservative replication","canonical_id":"go:GO:0032201","description":"\"The process in which telomeric DNA is synthesized semi-conservatively by the conventional replication machinery and telomeric accessory factors as part of cell cycle DNA replication.\" [GOC:BHF, GOC:BHF_telomere, GOC:rl, GOC:vw, PMID:16598261]","metadata":null},{"id":"37a7055bfe8b45b4a10c46ea75f3a4fa","type":"GO_TERM","name":"telomere maintenance via telomerase","canonical_id":"go:GO:0007004","description":"\"The maintenance of proper telomeric length by the addition of telomeric repeats by telomerase.\" [GOC:elh]","metadata":null},{"id":"48deb4aa3e554823855b1dbd04fefdf2","type":"GO_TERM","name":"telomere maintenance via telomere lengthening","canonical_id":"go:GO:0010833","description":"\"Any process that contributes to the maintenance of proper telomeric length and structure by affecting and monitoring the activity of telomeric proteins and lengthening the telomeric DNA.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"11443499a62e462584ab800fc2e8ac5c","type":"GO_TERM","name":"telomere maintenance via telomere trimming","canonical_id":"go:GO:0090737","description":"\"A process that contributes to the maintenance of proper telomeric length and structure via the activation of telomere shortening pathways that compensate telomerase-dependent excessive telomere elongation. Telomere attrition is mediated by a mechanism which involves the generation of single-stranded C-rich telomeric DNA, and the formation and removal of double-stranded telomeric circular DNA (T-circles). Telomere trimming is an independent pathway to recombination-mediated telomere elongation and the well-documented gradual telomere attrition that accompanies cellular replication.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:27918544]","metadata":null},{"id":"2efd30ab6fea41cb8d46339215bdb644","type":"GO_TERM","name":"telomere organization","canonical_id":"go:GO:0032200","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of telomeres, terminal regions of a linear chromosome that include the telomeric DNA repeats and associated proteins.\" [GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"cfe817198e4f4434bf62d5bcd9380eb2","type":"GO_TERM","name":"telomere single strand break repair","canonical_id":"go:GO:1903823","description":"\"Single strand break repair that takes place in a telomere.\" [GO_REF:0000062, GOC:TermGenie, PMID:24374808]","metadata":null},{"id":"3b6f142489d046b0b16857ff671b2748","type":"GO_TERM","name":"telomere tethering at nuclear periphery","canonical_id":"go:GO:0034398","description":"\"The process in which a telomere is maintained in a specific location at the nuclear periphery.\" [GOC:mah]","metadata":null},{"id":"2c0d0eba1a0441798ab2bc1e540ac440","type":"GO_TERM","name":"telomere-nuclear envelope anchor activity","canonical_id":"go:GO:0140473","description":"\"The binding activity of a molecule that brings together the telomeric region of a chromosome and the inner nuclear membrane by interacting with both the telomere and the nuclear membrane, in order to establish and maintain the telomeric location.\" [PMID:31635174]","metadata":null},{"id":"4b1999c91ec0491394a7675319c988a4","type":"GO_TERM","name":"telomere-telomerase complex","canonical_id":"go:GO:0070565","description":"\"A complex of DNA and protein located at the end of a linear chromosome that enables replication of the telomeric repeat sequences at the end of a linear chromosome.\" [GOC:pde, PMID:19179534]","metadata":null},{"id":"2856d79c291c45b5a4f2eb7cd9cf8322","type":"GO_TERM","name":"telomere-telomerase complex assembly","canonical_id":"go:GO:1905324","description":"\"The aggregation, arrangement and bonding together of a set of components to form a telomere-telomerase complex.\" [GO_REF:0000079, GOC:TermGenie, PMID:26305931]","metadata":null},{"id":"8ad239f0c52443dfac3944225b56f598","type":"GO_TERM","name":"telomeric 3' overhang formation","canonical_id":"go:GO:0031860","description":"\"The formation of the single stranded telomeric 3' overhang, a conserved feature that ranges in length from 12 nt in budding yeast to approximately 500 nt in humans.\" [PMID:16096639]","metadata":null},{"id":"0342292838ef407089219acc55700ff6","type":"GO_TERM","name":"telomeric D-loop binding","canonical_id":"go:GO:0061821","description":"\"Binding to a telomeric D-loop. A telomeric D-loop is a three-stranded DNA displacement loop that forms at the site where the telomeric 3' single-stranded DNA overhang (formed of the repeat sequence TTAGGG in mammals) is tucked back inside the double-stranded component of telomeric DNA molecule, thus forming a t-loop or telomeric-loop and protecting the chromosome terminus.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:19734539]","metadata":null},{"id":"b2fc47d360f34cbe8e7b8103e284b6b0","type":"GO_TERM","name":"telomeric D-loop disassembly","canonical_id":"go:GO:0061820","description":"\"A telomere loop disassembly process that results in the disassembly of telomeric D-loops. A telomeric D-loop is a three-stranded DNA displacement loop that forms at the site where the telomeric 3' single-stranded DNA overhang (formed of the repeat sequence TTAGGG in mammals) is tucked back inside the double-stranded component of telomeric DNA molecule, thus forming a t-loop or telomeric-loop and protecting the chromosome terminus.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:10338204, PMID:24012755]","metadata":null},{"id":"32cbd8aca1ee4b8bb5f637dafbceb471","type":"GO_TERM","name":"telomeric DNA-containing double minutes formation","canonical_id":"go:GO:0061819","description":"\"A telomere maintenance process that results in the formation of small fragments of circular extrachromosomal DNA elements which contain telomeric DNA. It is speculated that telomeric DNA-containing double minutes are formed through a recombination event between the telomere and chromosome-internal TTAGGG-like sequences. Telomeric DNA-containing double minutes appear as two closely positioned dots in metaphase.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:14690602, PMID:2397458]","metadata":null},{"id":"54f5d76fba554c4ab390453b5facd5cc","type":"GO_TERM","name":"telomeric G-quadruplex DNA binding","canonical_id":"go:GO:0061849","description":"\"Binding to telomeric G-quadruplex DNA structures, in which groups of four guanines adopt a flat, cyclic Hoogsteen hydrogen-bonding arrangement known as a guanine tetrad. The stacking of guanine tetrads results in G-quadruplex DNA structures in telomeres.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:16142245, PMID:9512530]","metadata":null},{"id":"2a507f8f47574ff4ae1fd3f4a10c9bdd","type":"GO_TERM","name":"telomeric loop disassembly","canonical_id":"go:GO:0090657","description":"\"The telomere maintenance process in which telomeric loops are disassembled to permit efficient telomere replication.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:22579284]","metadata":null},{"id":"954679004c314737962b0da695aa5b21","type":"GO_TERM","name":"telomeric loop formation","canonical_id":"go:GO:0031627","description":"\"The process in which linear telomeric DNA is remodeled into duplex loops, by the invasion of a 3' single-stranded overhang into the duplex region.\" [GOC:vw, PMID:10338214]","metadata":null},{"id":"e9358171639e4ea5b00f8d6521d9bfff","type":"GO_TERM","name":"telomeric repeat DNA binding","canonical_id":"go:GO:0042162","description":"\"Any molecular function by which a gene product interacts selectively and non-covalently with a telomeric DNA repeat sequence.\" [GOC:vw, SO:0000624]","metadata":null},{"id":"8b678340504547b083bd93ce520e37ed","type":"GO_TERM","name":"telomeric repeat-containing RNA binding","canonical_id":"go:GO:0061752","description":"\"Binding to long non-coding RNA molecules transcribed from subtelomeric regions in most eukaryotes. Telomeric repeat-containing RNA (TERRA) molecules consist of subtelomeric-derived sequences and G-rich telomeric repeats.\" [GOC:BHF, GOC:BHF_telomere, GOC:dph, GOC:jbu, PMID:20655916]","metadata":null},{"id":"58ead293473f4c72b2c9d360989f5bc0","type":"GO_TERM","name":"telomeric repeat-containing RNA transcription","canonical_id":"go:GO:0097393","description":"\"The synthesis of telomeric repeat-containing RNA from a DNA template. A telomere is a complex of DNA and proteins that seals the end of a chromosome.\" [GOC:al, PMID:22139915]","metadata":null},{"id":"9779b7f3f14e4e54b4f02b100396637b","type":"GO_TERM","name":"telophase","canonical_id":"go:GO:0051326","description":"\"The cell cycle phase which follows anaphase during M phase of mitosis and meiosis and during which the chromosomes arrive at the poles of the cell and the division of the cytoplasm starts.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"d4bf1949ae1d456991bc9aa9250ce1c1","type":"GO_TERM","name":"telopode","canonical_id":"go:GO:0120327","description":"\"A telopode is a plasma membrane bounded cell projection that is present on a telocyte and is tens to hundreds of microns long. Telopodes form a labyrinthine system communicating through gap junctions.\" [GOC:krc, MESH:D000067617, PMID:20367664]","metadata":null},{"id":"96426a162239404eac47d20b79fc3d26","type":"DRUG","name":"temocapril hydrochloride","canonical_id":"mesh:C055603","description":null,"metadata":null},{"id":"c1e6d85349ce413995ab10eef3175a62","type":"DRUG","name":"temozolomide","canonical_id":"mesh:C047246","description":null,"metadata":null},{"id":"0ae5914813904c7ea62413336e2727c8","type":"GO_TERM","name":"temperature compensation of the circadian clock","canonical_id":"go:GO:0010378","description":"\"The process in which the circadian clock maintains robust and accurate timing over a broad range of physiological temperatures. The circadian clock is an endogenous 24-h timer found in most eukaryotes and in photosynthetic bacteria. The clock drives rhythms in the physiology, biochemistry, and metabolism of the organisms.\" [PMID:16617099]","metadata":null},{"id":"5ef3b3ea096842da921d50abcf1b2125","type":"GO_TERM","name":"temperature homeostasis","canonical_id":"go:GO:0001659","description":"\"A homeostatic process in which an organism modulates its internal body temperature.\" [GOC:jl]","metadata":null},{"id":"8ecf0b31d7554dccb20922b0e63f1a43","type":"GO_TERM","name":"temperature-gated cation channel activity","canonical_id":"go:GO:0097604","description":"\"Enables the transmembrane transfer of a cation by a channel that opens in response to a temperature stimulus (e.g. exposure to a temperature range different than the optimal temperature for that organism).\" [GOC:ha, GOC:pr, PMID:23027824]","metadata":null},{"id":"f4f9aa9975ed411cb2d1881d3092d0e8","type":"GO_TERM","name":"temperature-gated ion channel activity","canonical_id":"go:GO:0097603","description":"\"Enables the transmembrane transfer of an ion by a channel that opens in response to a temperature stimulus (e.g. exposure to a temperature range different than the optimal temperature for that organism).\" [GOC:ha, GOC:pr, PMID:23027824]","metadata":null},{"id":"543eb5548c964d58bb9ab8a6c3e80df4","type":"GO_TERM","name":"template for synthesis of G-rich strand of telomere DNA activity","canonical_id":"go:GO:0000332","description":"\"Provision of the template used by reverse transcriptase to synthesize the G-rich strand of telomeric DNA.\" [PMID:11812242, PMID:7958872]","metadata":null},{"id":"2ad0015d702c465ea86c667ecbedec6e","type":"GO_TERM","name":"template-free RNA nucleotidyltransferase activity","canonical_id":"go:GO:0098680","description":"\"Catalysis of the reaction: nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1); the addition of a terminal nucleotide to an RNA molecule in the absence of a nucleic acid template.\" [GOC:BHF, GOC:BHF_telomere, GOC:dos, GOC:nc, PMID:15994230]","metadata":null},{"id":"2115b6ed7c1845838ea433f13bc43128","type":"DISEASE","name":"temporal arteritis","canonical_id":"mondo:0008538","description":null,"metadata":null},{"id":"03a8958c2d4547218e8b1a89819c09cd","type":"GO_TERM","name":"temporomandibular joint articular cartilage development","canonical_id":"go:GO:0061976","description":"\"The process whose specific outcome is the progression of temporomandibular joint articular cartilage over time, from its formation to the mature structure.\" [PMID:20679519]","metadata":null},{"id":"8427ad19e6274caf83911165538e7352","type":"DRUG","name":"temsirolimus","canonical_id":"gtopdb:5892","description":null,"metadata":null},{"id":"2860c4d8f51c4cc58faef8087227d8ad","type":"DRUG","name":"temsirolimus","canonical_id":"mesh:C401859","description":null,"metadata":null},{"id":"fa84eff81f9f47ac9e8118bd6e665b99","type":"DRUG","name":"temsirolimus","canonical_id":"chembl:CHEMBL1201182","description":null,"metadata":null},{"id":"a1a3cb1510eb4da8a17a8fe259f28b9f","type":"GO_TERM","name":"tenascin complex","canonical_id":"go:GO:0090733","description":"\"A homotrimeric or homohexameric extracellular matrix complex involved in cell adhesion and cell migration. In mammals, four complexes exist: Tenascin-C, Tenascin-N (also known as Tenascin-W), Tenascin-X and Tenascin-R.\" [PMID:10842355, PMID:11731446, PMID:12845616, PMID:17909022, PMID:23658023]","metadata":null},{"id":"6bc8a2a6b51e4304b2817d55011a6702","type":"DISEASE","name":"tendinitis","canonical_id":"mondo:0004857","description":null,"metadata":null},{"id":"352f8588531a4f33b920f6b7cfa93e39","type":"GO_TERM","name":"tendon cell differentiation","canonical_id":"go:GO:0035990","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a tendon cell. Tendon cell are elongated fibrocytes in which the cytoplasm is stretched between the collagen fibres of the tendon. Tendon cells have a central cell nucleus with a prominent nucleolus, a well-developed rough endoplasmic reticulum, and are responsible for synthesis and turnover of tendon fibres and ground substance.\" [CL:0000388, GOC:yaf, PMID:21412429]","metadata":null},{"id":"fb85cc43a74041c88f17d21fcc9aa436","type":"GO_TERM","name":"tendon development","canonical_id":"go:GO:0035989","description":"\"The process whose specific outcome is the progression of a tendon over time, from its formation to the mature structure. A tendon is a fibrous, strong, connective tissue that connects muscle to bone or integument and is capable of withstanding tension. Tendons and muscles work together to exert a pulling force.\" [GOC:yaf, PMID:21412429, UBERON:0000043]","metadata":null},{"id":"00487da26b294f35a641ad8bbb7493f3","type":"GO_TERM","name":"tendon formation","canonical_id":"go:GO:0035992","description":"\"The process that gives rise to a tendon. This process pertains to the initial formation of a tendon from unspecified parts.\" [GOC:yaf, PMID:17567668, UBERON:0000043]","metadata":null},{"id":"048330cc78f1419da419a6c166518134","type":"GO_TERM","name":"tendon sheath development","canonical_id":"go:GO:0002932","description":"\"The process whose specific outcome is the progression of a tendon sheath over time, from its formation to the mature structure. A tendon sheath is a layer of membrane around a tendon. It permits the tendon to move.\" [PMID:20696843]","metadata":null},{"id":"d90b2fff9e4f45918d1e6ea26be49498","type":"DRUG","name":"teneligliptin","canonical_id":"gtopdb:9906","description":null,"metadata":null},{"id":"f8a5c102789d44c4a86a67839bc8ff5a","type":"DRUG","name":"teneligliptin","canonical_id":"chembl:CHEMBL2147777","description":null,"metadata":null},{"id":"f0dd3e4a64f446d8a2cac77caa41054c","type":"DISEASE","name":"tenosynovial giant cell tumor","canonical_id":"mondo:0002522","description":null,"metadata":null},{"id":"570ff46f480b49cfa9f74a719d59f77d","type":"DISEASE","name":"tenosynovitis","canonical_id":"mondo:0004855","description":null,"metadata":null},{"id":"5b01ffa47f904825860df62e3cb73f90","type":"DRUG","name":"tenoxicam","canonical_id":"mesh:C032801","description":null,"metadata":null},{"id":"3d7cd5c63a5e473f81a0f685372ba92c","type":"GO_TERM","name":"tensidol A biosynthetic process","canonical_id":"go:GO:1900605","description":"\"The chemical reactions and pathways resulting in the formation of tensidol A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1abdd1050aed448cafdbedf9412ac529","type":"GO_TERM","name":"tensidol A catabolic process","canonical_id":"go:GO:1900604","description":"\"The chemical reactions and pathways resulting in the breakdown of tensidol A.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"e7f658a477b24a9db6edd032967c5d56","type":"GO_TERM","name":"tensidol B biosynthetic process","canonical_id":"go:GO:1900608","description":"\"The chemical reactions and pathways resulting in the formation of tensidol B.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"5e2b51451ed24ccb8483d960561ad930","type":"GO_TERM","name":"tensidol B catabolic process","canonical_id":"go:GO:1900607","description":"\"The chemical reactions and pathways resulting in the breakdown of tensidol B.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"66b2f3cef5a346259d4a11e4ceed903d","type":"DRUG","name":"tepotinib","canonical_id":"gtopdb:8293","description":null,"metadata":null},{"id":"44350867baba444ab0599c79aa1611bf","type":"DRUG","name":"tepotinib","canonical_id":"chembl:CHEMBL3402762","description":null,"metadata":null},{"id":"4ce34ac5696c44b0b04fc407e2d682f7","type":"COMBINATION_TREATMENT","name":"tepotinib + vismodegib","canonical_id":"ctgov_combo:ctgov-combo-f9eebb78fb876663","description":null,"metadata":null},{"id":"12e80df173b240c8890ff466a5cf1d9d","type":"DRUG","name":"teprotumumab","canonical_id":"gtopdb:10612","description":null,"metadata":null},{"id":"1334e924120b4cf298bc4bab415567d1","type":"DRUG","name":"teprotumumab","canonical_id":"chembl:CHEMBL1743079","description":null,"metadata":null},{"id":"c3decff8cb784423809aa2c9418daa86","type":"DRUG","name":"terazosin","canonical_id":"gtopdb:7302","description":null,"metadata":null},{"id":"b8330c1ad91346c5b2c8fc1bae322ae8","type":"DRUG","name":"terbinafine","canonical_id":"mesh:C041359","description":null,"metadata":null},{"id":"75a9c0a62dd4493a84696c39c990fbdf","type":"DRUG","name":"terbutaline","canonical_id":"gtopdb:560","description":null,"metadata":null},{"id":"b4a41b845e354f8b8868fd0ae6f00711","type":"DRUG","name":"terbutaline","canonical_id":"mesh:D013726","description":null,"metadata":null},{"id":"a7988577b4434e7e966d063320f36dfc","type":"DRUG","name":"terconazole","canonical_id":"mesh:C037815","description":null,"metadata":null},{"id":"4df75216b03e418b8debf1e58f30e000","type":"GO_TERM","name":"terephthalate 1,2-dioxygenase activity","canonical_id":"go:GO:0018628","description":"\"Catalysis of the reaction: terephthalate + NADH + O2 + H+ = (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate + NAD+.\" [RHEA:10312]","metadata":null},{"id":"a42ccb14d24840739599d7681f8c065c","type":"DRUG","name":"terfenadine","canonical_id":"gtopdb:2608","description":null,"metadata":null},{"id":"dc9a1a852f464f44addc8b273cdf7e7e","type":"DRUG","name":"terfenadine","canonical_id":"mesh:D016593","description":null,"metadata":null},{"id":"b92072d585844292a614cab9a42c6bf5","type":"DRUG","name":"terfenadine","canonical_id":"chembl:CHEMBL17157","description":null,"metadata":null},{"id":"305f3d141fc94f319d533d240ec578b1","type":"GO_TERM","name":"tergite morphogenesis","canonical_id":"go:GO:0007490","description":"\"The process in which the anatomical structures of the tergite are generated and organized. The tergite is the primary plate or sclerite forming the dorsal surface of any insect body segment.\" [GOC:jid, PMID:16451739]","metadata":null},{"id":"933c5a5bb1344c55946be1b63b5d9a4d","type":"DRUG","name":"terguride","canonical_id":"mesh:C006208","description":null,"metadata":null},{"id":"22aab328600f4254b64c605037e3fb49","type":"DRUG","name":"teriflunomide","canonical_id":"gtopdb:6844","description":null,"metadata":null},{"id":"66aac65e3a5343d08bb5c0b58b4f937c","type":"DRUG","name":"teriflunomide","canonical_id":"mesh:C527525","description":null,"metadata":null},{"id":"6b6d7dff65704d70bd7d8d56ad032a5c","type":"DRUG","name":"teriflunomide","canonical_id":"chembl:CHEMBL973","description":null,"metadata":null},{"id":"6ecea67f357b4782b541f05bb598e56a","type":"COMBINATION_TREATMENT","name":"teriflunomide + ublituximab","canonical_id":"ctgov_combo:ctgov-combo-232cb028f0f04668","description":null,"metadata":null},{"id":"ef286a5b16644d2eae9018493fb74669","type":"DRUG","name":"teriparatide","canonical_id":"gtopdb:4448","description":null,"metadata":null},{"id":"d37d385376d2487e9dcf6d1bedaabd18","type":"DRUG","name":"teriparatide","canonical_id":"mesh:D019379","description":null,"metadata":null},{"id":"f36f47dfcb1443a99177d45ae9fd556c","type":"DRUG","name":"teriparatide","canonical_id":"chembl:CHEMBL525610","description":null,"metadata":null},{"id":"0c0ff98149e64d4b921dc11a0834c217","type":"GO_TERM","name":"terminal bouton","canonical_id":"go:GO:0043195","description":"\"Terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters. The axon terminus is considered to be the whole region of thickening and the terminal bouton is a specialized region of it.\" [GOC:dph, GOC:mc, GOC:nln, PMID:10218156, PMID:8409967]","metadata":null},{"id":"05407f3c2086496c9e3c756c808ccea5","type":"GO_TERM","name":"terminal branching, open tracheal system","canonical_id":"go:GO:0007430","description":"\"Formation of terminal branches in the open tracheal system. These are long cytoplasmic extensions that form fine tubules that transport oxygen directly to the tissues. An example of the process is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:29844090]","metadata":null},{"id":"1200681025c048b681c1e17ce8924685","type":"GO_TERM","name":"terminal button organization","canonical_id":"go:GO:0072553","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a terminal button. A terminal button is the terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b111ecb6498a4dea8bbaff89357b7979","type":"GO_TERM","name":"terminal cell fate specification, open tracheal system","canonical_id":"go:GO:0035154","description":"\"The process in which a cell in an open tracheal system becomes capable of differentiating autonomously into a terminal cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. Terminal cells send long and bifurcated hollow branches toward target tissues to allow oxygen exchange.\" [GOC:mtg_sensu, PMID:10684581, PMID:11063940]","metadata":null},{"id":"259eebcff5c7418db6c9bfb8dbe9f18e","type":"GO_TERM","name":"terminal cisterna","canonical_id":"go:GO:0014802","description":"\"The portion of sarcoplasmic reticulum devoted to calcium ion storage and calcium ion release.\" [GOC:mtg_muscle]","metadata":null},{"id":"53be0141365e43f3b0afefa5718d11d2","type":"GO_TERM","name":"terminal cisterna lumen","canonical_id":"go:GO:0014804","description":"\"The region between the inner and outer lipid bilayers of the terminal cisterna envelope. This space is enriched in calsequestrin.\" [GOC:mtg_muscle]","metadata":null},{"id":"a8e98aa2b5dc43fc9fedbca6b319d7af","type":"GO_TERM","name":"terminal loop","canonical_id":"go:GO:0097456","description":"\"Portion of myelin-forming Schwann cell consisting of terminal cytoplasmic extensions adhered to the axon at the beginning and end of the myelin sheath.\" [NIF_Subcellular:sao924713546]","metadata":null},{"id":"384e262effb340d6be3cc13f8a9a57e8","type":"GO_TERM","name":"terminal region determination","canonical_id":"go:GO:0007362","description":"\"Specification of the terminal regions (the two non-segmented ends) of the embryo by the gap genes; exemplified in insects by the actions of huckebein and tailless gene products.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"71426e804e35459b91e7daf07091a657","type":"GO_TERM","name":"terminal web","canonical_id":"go:GO:1990357","description":"\"An actin-rich cytoskeletal network located beneath the microvilli of the apical plasma membrane of polarized epithelial cells. In addition to actin filaments, the terminal web may contain actin-binding proteins, myosin motor proteins, and intermediate filaments. The terminal web can function as a contractile structure that influences the spatial distribution of microvilli as well as the development and morphogenesis of tissues containing polarized epithelial cells.\" [GOC:kmv, PMID:19437512, PMID:24677443, PMID:7511618, Wikipedia:Terminal_web]","metadata":null},{"id":"c843524ced0d4882a18c4fb755975ea9","type":"GO_TERM","name":"terminal web assembly","canonical_id":"go:GO:1902896","description":"\"The aggregation, arrangement and bonding together of a set of components to form a terminal web.\" [GO_REF:0000079, GOC:kmv, GOC:TermGenie, PMID:21949650]","metadata":null},{"id":"328a22e3b02844aca7cd91be2004ff72","type":"GO_TERM","name":"termination of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0038032","description":"\"The signaling process in which G protein-coupled receptor signaling is brought to an end. For example, through the action of GTPase-activating proteins (GAPs) that act to accelerate hydrolysis of GTP to GDP on G-alpha proteins, thereby terminating the transduced signal.\" [GOC:bf, GOC:signaling]","metadata":null},{"id":"804a8bdb8e6f492d84e979d3eff1482c","type":"GO_TERM","name":"termination of RNA polymerase I transcription","canonical_id":"go:GO:0006363","description":"\"A transcription termination process that completes the production of a ribosomal RNA transcript. RNAP I termination requires binding of a terminator protein to specific sequences downstream of the transcription unit.\" [GOC:mah, GOC:txnOH, PMID:10684922, PMID:27371117]","metadata":null},{"id":"52a2063f3eac4a9a983dc6cf5b7ebc3c","type":"GO_TERM","name":"termination of RNA polymerase II transcription","canonical_id":"go:GO:0006369","description":"\"A transcription termination process that completes the production of a primary RNA polymerase II transcript.\" [GOC:mah, GOC:txnOH, PMID:27371117]","metadata":null},{"id":"4f8beb508d314a36b75b4e7a59a739bb","type":"GO_TERM","name":"termination of RNA polymerase II transcription, exosome-dependent","canonical_id":"go:GO:0030847","description":"\"The process in which transcription of nonpolyadenylated RNA polymerase II transcripts is terminated; coupled to the maturation of the RNA 3'-end.\" [GOC:txnOH, PMID:12944462, PMID:18679429, PMID:27371117]","metadata":null},{"id":"dcbef6660aaa41d98e0526877e12e588","type":"GO_TERM","name":"termination of RNA polymerase II transcription, poly(A)-coupled","canonical_id":"go:GO:0030846","description":"\"An RNA polymerase II transcription termination process in which cleavage and polyadenylylation of the mRNA 3' end are coupled to transcription termination.\" [GOC:txnOH, PMID:12944462, PMID:18679429, PMID:27371117]","metadata":null},{"id":"059214fdd38f4a7a8b353720a803d8ec","type":"GO_TERM","name":"termination of RNA polymerase III transcription","canonical_id":"go:GO:0006386","description":"\"A transcription termination process that completes the production of a primary RNA polymerase II transcript. RNA polymerase III has an intrinsic ability to terminate transcription upon incorporation of at least 4 contiguous U residues.\" [GOC:mah, PMID:12944462, PMID:27371117]","metadata":null},{"id":"743f236ece0746dda1d01c5653842b32","type":"GO_TERM","name":"termination of Roundabout signal transduction","canonical_id":"go:GO:0035554","description":"\"The signaling process in which signaling from the receptor ROBO is brought to an end, rather than being reversibly modulated.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"7dafbeddda5c4213a365e439bbd50e95","type":"GO_TERM","name":"termination of T cell signal transduction","canonical_id":"go:GO:0023022","description":"\"The signaling process in which T cell signal transduction is brought to an end rather than being reversibly modulated.\" [GOC:mtg_signal]","metadata":null},{"id":"294cfdf5ec354955aca445e9ee8fff86","type":"GO_TERM","name":"termination of bipolar cell growth","canonical_id":"go:GO:0051520","description":"\"Any process that stops the active process of bipolar cell growth, polarized growth from both ends of a cell.\" [GOC:ai]","metadata":null},{"id":"51f799033b474977a7c26b2ed53759e6","type":"GO_TERM","name":"termination of mitochondrial transcription","canonical_id":"go:GO:0006393","description":"\"A transcription termination process that completes the production of a primary mitochondrial transcript.\" [PMID:29945721]","metadata":null},{"id":"bfe7b1b045e14438882e4fca3f14f414","type":"GO_TERM","name":"termination of monopolar cell growth","canonical_id":"go:GO:0051521","description":"\"Any process that stops the active process of bipolar cell growth, polarized growth from one end of a cell.\" [GOC:ai]","metadata":null},{"id":"2b2d154b409e4ad7a64b6fe903fb1c9f","type":"GO_TERM","name":"termination of signal transduction","canonical_id":"go:GO:0023021","description":"\"The signaling process in which signal transduction is brought to an end rather than being reversibly modulated.\" [GOC:mtg_signal]","metadata":null},{"id":"c827b7226ed34e348e36093967934ac3","type":"GO_TERM","name":"terpene biosynthetic process","canonical_id":"go:GO:0046246","description":"\"The chemical reactions and pathways resulting in the formation of terpenes, any of a large group of hydrocarbons made up of isoprene units.\" [GOC:ai]","metadata":null},{"id":"b5084ab89d2745eeb5652b746308fcbe","type":"GO_TERM","name":"terpene catabolic process","canonical_id":"go:GO:0046247","description":"\"The chemical reactions and pathways resulting in the breakdown of terpenes, any of a large group of hydrocarbons made up of isoprene units.\" [GOC:ai]","metadata":null},{"id":"edb1f768081e458397415940412dfc50","type":"GO_TERM","name":"terpene metabolic process","canonical_id":"go:GO:0042214","description":"\"The chemical reactions and pathways involving terpenes, any of a large group of hydrocarbons that are made up of isoprene (C5H8) units which may be cyclic, acyclic or multicyclic, saturated or unsaturated, and may contain various functional groups.\" [GOC:curators]","metadata":null},{"id":"06a402c55c224ff798c2f60c0977d96f","type":"GO_TERM","name":"terpene synthase activity","canonical_id":"go:GO:0010333","description":"\"Catalysis of the formation of cyclic terpenes through the cyclization of linear terpenes (e.g. isopentenyl-PP, geranyl-PP, farnesyl-PP and geranylgeranyl-PP) containing varying numbers of isoprene units.\" [GOC:tair_curators]","metadata":null},{"id":"a51b65ec241b4be0b82ef247a2d78e92","type":"GO_TERM","name":"terpenoid biosynthetic process","canonical_id":"go:GO:0016114","description":"\"The chemical reactions and pathways resulting in the formation of terpenoids, any member of a class of compounds characterized by an isoprenoid chemical structure.\" [GOC:ai]","metadata":null},{"id":"c2a887e9f76f4942948689f1c49ede7b","type":"GO_TERM","name":"terpenoid catabolic process","canonical_id":"go:GO:0016115","description":"\"The chemical reactions and pathways resulting in the breakdown of terpenoids, any member of a class of compounds characterized by an isoprenoid chemical structure.\" [GOC:ai]","metadata":null},{"id":"651132ec0ee74ee5a0016fd26fd12c1f","type":"GO_TERM","name":"terpenoid indole alkaloid biosynthetic process","canonical_id":"go:GO:0009709","description":"\"The chemical reactions and pathways resulting in the formation of terpenoid indole alkaloids, compounds formed from the condensation of tryptamine (derived from tryptophan) and secologanin (derived from geranyl pyrophosphate).\" [GOC:ai, http://rycomusa.com/aspp2000/public/P29/0525.html]","metadata":null},{"id":"ae42ffc3781b444a8521a66f83c1ebd5","type":"GO_TERM","name":"terpenoid indole alkaloid metabolic process","canonical_id":"go:GO:0046447","description":"\"The chemical reactions and pathways involving terpenoid indole alkaloids, compounds formed from the condensation of tryptamine (derived from tryptophan) and secologanin (derived from geranyl pyrophosphate).\" [GOC:ai]","metadata":null},{"id":"12ad09fbc4104daca41ce3e94f58c400","type":"GO_TERM","name":"terpenoid metabolic process","canonical_id":"go:GO:0006721","description":"\"The chemical reactions and pathways involving terpenoids, any member of a class of compounds characterized by an isoprenoid chemical structure and including derivatives with various functional groups.\" [ISBN:0198506732]","metadata":null},{"id":"168511eb31454461b6db25660ba8acbe","type":"GO_TERM","name":"terpenoid transport","canonical_id":"go:GO:0046865","description":"\"The directed movement of terpenoids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Terpenoids are a class of compounds characterized by an isoprenoid chemical structure and include derivatives with various functional groups.\" [GOC:ai]","metadata":null},{"id":"68f7a0eb86894c8ea46b09207977a31e","type":"GO_TERM","name":"terpentetriene synthase activity","canonical_id":"go:GO:0052679","description":"\"Catalysis of the reaction: terpentedienyl diphosphate = diphosphate + terpentetriene.\" [RHEA:25617]","metadata":null},{"id":"1b289cd18b37484ab4fa61983e524603","type":"GO_TERM","name":"terreate biosynthetic process","canonical_id":"go:GO:0180067","description":"\"The chemical reactions and pathways resulting in the formation of terreate, a fungal metabolite with ecological, antimicrobial, antiproliferative, and antioxidative activities.\" [PMID:25265334]","metadata":null},{"id":"ea4ddc8f318d42a79c0d921c55102337","type":"GO_TERM","name":"terrein biosynthetic process","canonical_id":"go:GO:0140880","description":"\"The chemical reactions and pathways resulting in the formation of terrein, a fungal metabolite with ecological, antimicrobial, antiproliferative, and antioxidative activities.\" [PMID:24816227]","metadata":null},{"id":"b03e62b5ef2e4a62ad9cf4d23495271a","type":"GO_TERM","name":"terrequinone A biosynthetic process","canonical_id":"go:GO:1900796","description":"\"The chemical reactions and pathways resulting in the formation of terrequinone A.\" [GOC:di, GOC:TermGenie, PMID:17291795, PMID:17704773]","metadata":null},{"id":"23f1f451c6944f1f8f8027e9eb883d1d","type":"GO_TERM","name":"territorial aggressive behavior","canonical_id":"go:GO:0002124","description":"\"Aggressive behavior performed in defence of a fixed area against intruders, typically conspecifics.\" [GOC:hjd]","metadata":null},{"id":"47579d1dbead4319af1ec3c255012b9d","type":"GO_TERM","name":"tertiary alcohol biosynthetic process","canonical_id":"go:GO:1902645","description":"\"The chemical reactions and pathways resulting in the formation of tertiary alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:11288200]","metadata":null},{"id":"8c2e1760e39a4f8789edf66cf7ba4ed4","type":"GO_TERM","name":"tertiary alcohol metabolic process","canonical_id":"go:GO:1902644","description":"\"The chemical reactions and pathways involving tertiary alcohol.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:11288200]","metadata":null},{"id":"66c8d75e21c540139b94dcc639ac3057","type":"GO_TERM","name":"tertiary branching involved in mammary gland duct morphogenesis","canonical_id":"go:GO:0060748","description":"\"The branching process in which the mammary gland ducts form tertiary branches off of the secondary branches as part of diestrus and pregnancy.\" [GOC:dph, PMID:18614704]","metadata":null},{"id":"7ea65a96e613475ea5d06bd2c673ab29","type":"GO_TERM","name":"tertiary granule","canonical_id":"go:GO:0070820","description":"\"A secretory granule that contains cathepsin and gelatinase and is readily exocytosed upon cell activation; found primarily in mature neutrophil cells.\" [GOC:BHF, GOC:mah, GOC:rl, PMID:12070036]","metadata":null},{"id":"d5f5f92130ca4da4bb24e5781516d63a","type":"GO_TERM","name":"tertiary granule lumen","canonical_id":"go:GO:1904724","description":"\"Any membrane-enclosed lumen that is part of a tertiary granule.\" [GO_REF:0000064, GOC:TermGenie, PMID:23650620]","metadata":null},{"id":"b495853a7ff64d03ab17357e3ac82033","type":"GO_TERM","name":"tertiary granule membrane","canonical_id":"go:GO:0070821","description":"\"The lipid bilayer surrounding a tertiary granule.\" [GOC:BHF, GOC:mah, GOC:rl, PMID:12070036]","metadata":null},{"id":"9be699dc240041c1862d6223459d672a","type":"DRUG","name":"tesamorelin","canonical_id":"gtopdb:6959","description":null,"metadata":null},{"id":"6135fdf8acba4bd28273e519b690d622","type":"DISEASE","name":"testicular cancer","canonical_id":"mondo:0005447","description":null,"metadata":null},{"id":"ed28b92c11ca465a83b2acf0fc79ad24","type":"GO_TERM","name":"testicular fusome organization","canonical_id":"go:GO:0030724","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the fusome of testicular cells, an organelle derived from the spectrosome.\" [GOC:dph, GOC:jl, GOC:mah, ISBN:0879694238]","metadata":null},{"id":"060536ad553d4defbe1b74b41283c24c","type":"DRUG","name":"testolactone","canonical_id":"gtopdb:7303","description":null,"metadata":null},{"id":"6de2e5fdbd1b4e2f9f01063dde135ecb","type":"DRUG","name":"testolactone","canonical_id":"chembl:CHEMBL1571","description":null,"metadata":null},{"id":"7f6764ffa1674b4db3d9df81760f0110","type":"GO_TERM","name":"testosterone 16-alpha-hydroxylase activity","canonical_id":"go:GO:0008390","description":"\"Catalysis of the reaction: O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 16alpha,17beta-dihydroxyandrost-4-en-3-one + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [RHEA:53196]","metadata":null},{"id":"97be045d2e714d6792c4d6508c1655f6","type":"GO_TERM","name":"testosterone 16-beta-hydroxylase activity","canonical_id":"go:GO:0062184","description":"\"Catalysis of the reaction: O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 16beta,17beta-dihydroxyandrost-4-en-3-one + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [PMID:21289075, RHEA:46304]","metadata":null},{"id":"c5e4f51e59e14cd49c662fb75a53fc5b","type":"GO_TERM","name":"testosterone 6-beta-hydroxylase activity","canonical_id":"go:GO:0050649","description":"\"Catalysis of the reaction: O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 6beta,17beta-dihydroxyandrost-4-en-3-one + H+ + H2O + oxidized [NADPH--hemoprotein reductase].\" [PMID:11726664, RHEA:46296]","metadata":null},{"id":"97c2adee0d7d447194d0f93bc271bd66","type":"GO_TERM","name":"testosterone biosynthetic process","canonical_id":"go:GO:0061370","description":"\"The chemical reactions and pathways resulting in the formation of testosterone, an androgen having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4 C-5.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"81fef73da0c347d5838ab27bd8e26505","type":"GO_TERM","name":"testosterone dehydrogenase (NAD+) activity","canonical_id":"go:GO:0047035","description":"\"Catalysis of the reaction: testosterone + NAD+ = androst-4-ene-3,17-dione + NADH.\" [RHEA:14929]","metadata":null},{"id":"cbb6d4664fc34a94a88b1f0ea616ec26","type":"GO_TERM","name":"testosterone dehydrogenase (NADP+) activity","canonical_id":"go:GO:0047045","description":"\"Catalysis of the reaction: NADP+ + testosterone = NADPH + H+ + androst-4-ene-3,17-dione.\" [EC:1.1.1.64]","metadata":null},{"id":"d3834d11406b4a5fac7150b174650b92","type":"DRUG","name":"testosterone propionate","canonical_id":"gtopdb:7100","description":null,"metadata":null},{"id":"b700ebad402547cdb578ff57e4f34000","type":"DRUG","name":"testosterone propionate","canonical_id":"chembl:CHEMBL1170","description":null,"metadata":null},{"id":"f69d704e842e4faa9868717121c414d6","type":"GO_TERM","name":"testosterone secretion","canonical_id":"go:GO:0035936","description":"\"The regulated release of testosterone into the circulatory system. Testosterone is an androgen having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.\" [GOC:sl, PMID:12606499]","metadata":null},{"id":"4cfce550e91d47c0a6e1a65980948e3e","type":"DRUG","name":"tetrabenazine","canonical_id":"gtopdb:4834","description":null,"metadata":null},{"id":"0c7f1469e4f846afbd63ddfa647f3645","type":"DRUG","name":"tetrabenazine","canonical_id":"chembl:CHEMBL117785","description":null,"metadata":null},{"id":"911e7979cd8a4f139552e49558f3fa70","type":"DRUG","name":"tetracaine","canonical_id":"mesh:D013748","description":null,"metadata":null},{"id":"0ab4e5d251194df7984ac331d9637cec","type":"GO_TERM","name":"tetracenomycin C biosynthetic process","canonical_id":"go:GO:1901106","description":"\"The chemical reactions and pathways resulting in the formation of tetracenomycin C.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00174]","metadata":null},{"id":"01b355e495f34e6788d6d26bd9158975","type":"GO_TERM","name":"tetracenomycin C catabolic process","canonical_id":"go:GO:1901105","description":"\"The chemical reactions and pathways resulting in the breakdown of tetracenomycin C.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00174]","metadata":null},{"id":"8b3c47e585c0457dbe27897ef785b716","type":"GO_TERM","name":"tetrachloroethene reductive dehalogenase activity","canonical_id":"go:GO:0050629","description":"\"Catalysis of the reaction: trichloroethene + chloride + acceptor = tetrachloroethene + reduced acceptor. The reaction occurs in the reverse direction.\" [RHEA:20353]","metadata":null},{"id":"694c6d7b938c476aa65894a7ec5e544d","type":"GO_TERM","name":"tetrachloroethylene catabolic process","canonical_id":"go:GO:0019337","description":"\"The chemical reactions and pathways resulting in the breakdown of tetrachloroethylene, a derivative of ethene with the hydrogen atoms replaced by chlorines.\" [GOC:ai, PMID:7988892, PMID:8663199]","metadata":null},{"id":"7465a4c9dd2042008c1508f648a2ac4d","type":"GO_TERM","name":"tetracyclic triterpenoid biosynthetic process","canonical_id":"go:GO:0010686","description":"\"The chemical reactions and pathways resulting in the formation of tetracyclic triterpenoid compounds, terpenoids with six isoprene units and 4 carbon rings.\" [GOC:tair_curators]","metadata":null},{"id":"2b2d1bdfc7e74e6eaee366386eca85bc","type":"DRUG","name":"tetracycline","canonical_id":"mesh:D013752","description":null,"metadata":null},{"id":"6c1ed0ca37e74e80abf4012b77e466f9","type":"GO_TERM","name":"tetracycline biosynthetic process","canonical_id":"go:GO:0043644","description":"\"The chemical reactions and pathways resulting in the formation of tetracycline, (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, a broad-spectrum antibiotic produced by streptomyces bacteria that blocks binding of aminoacyl tRNA to the ribosomes of both Gram-positive and Gram-negative organisms (and those of organelles).\" [GOC:jl, Wikipedia:Tetracycline]","metadata":null},{"id":"0342ffbf84494c5085138972ba9bb7e2","type":"GO_TERM","name":"tetracycline transmembrane transport","canonical_id":"go:GO:0015904","description":"\"The directed movement of tetracycline from one side of a membrane to the other. Tetracycline is a broad spectrum antibiotic that blocks binding of aminoacyl tRNA to the ribosomes of both Gram-positive and Gram-negative organisms (and those of organelles).\" [GOC:curators]","metadata":null},{"id":"5eaedb2ca15a4702a1966bb3583c34c8","type":"GO_TERM","name":"tetracycline transmembrane transporter activity","canonical_id":"go:GO:0008493","description":"\"Enables the transfer of tetracycline from one side of a membrane to the other. Tetracycline is a broad spectrum antibiotic that blocks binding of aminoacyl tRNA to the ribosomes of both Gram-positive and Gram-negative organisms (and those of organelles).\" [GOC:curators]","metadata":null},{"id":"b350079cdc15402a8b0f2ec1facba336","type":"GO_TERM","name":"tetracycline:proton antiporter activity","canonical_id":"go:GO:0015520","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: H+(out) + tetracycline(in) = H+(in) + tetracycline(out).\" [TC:2.A.1.2.4]","metadata":null},{"id":"4cfaa879b2164835badc75a74abb554a","type":"GO_TERM","name":"tetrahydroberberine oxidase activity","canonical_id":"go:GO:0050328","description":"\"Catalysis of the reaction: (S)-tetrahydroberberine + 2 O2 = berberine + 2 H2O2.\" [EC:1.3.3.8, MetaCyc:TETRAHYDROBERBERINE-OXIDASE-RXN]","metadata":null},{"id":"5f3fcb55e0a046f7a36e77608f47c82f","type":"GO_TERM","name":"tetrahydrobiopterin binding","canonical_id":"go:GO:0034617","description":"\"Binding to a tetrahydrobiopterin, 5,6,7,8-tetrahydrobiopterin or a derivative thereof; tetrahydrobiopterins are enzyme cofactors that carry electrons in redox reactions.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"a235ed15257e4c228f86832a2da3246d","type":"GO_TERM","name":"tetrahydrobiopterin biosynthetic process","canonical_id":"go:GO:0006729","description":"\"The chemical reactions and pathways resulting in the formation of tetrahydrobiopterin, the reduced form of biopterin (2-amino-4-hydroxy-6-(1,2-dihydroxypropyl)-pteridine). It functions as a hydroxylation coenzyme, e.g. in the conversion of phenylalanine to tyrosine.\" [ISBN:0198506732]","metadata":null},{"id":"6f7817ce582b4f5e84405147d26776b7","type":"GO_TERM","name":"tetrahydrobiopterin catabolic process","canonical_id":"go:GO:0046147","description":"\"The chemical reactions and pathways resulting in the breakdown of tetrahydrobiopterin, the reduced form of biopterin (2-amino-4-hydroxy-6-(1,2-dihydroxypropyl)-pteridine). It functions as a hydroxylation coenzyme, e.g. in the conversion of phenylalanine to tyrosine.\" [ISBN:0198506732]","metadata":null},{"id":"78515e0059d74e49b1367df619db966e","type":"GO_TERM","name":"tetrahydrobiopterin metabolic process","canonical_id":"go:GO:0046146","description":"\"The chemical reactions and pathways involving tetrahydrobiopterin, the reduced form of biopterin (2-amino-4-hydroxy-6-(1,2-dihydroxypropyl)-pteridine). It functions as a hydroxylation coenzyme, e.g. in the conversion of phenylalanine to tyrosine.\" [PMID:21871890]","metadata":null},{"id":"701f6992fa014245a70e02a5e2608f0f","type":"GO_TERM","name":"tetrahydrocolumbamine 2-O-methyltransferase activity","canonical_id":"go:GO:0030762","description":"\"Catalysis of the reaction: (S)-tetrahydrocolumbamine + S-adenosyl-L-methionine(1+) = S-adenosyl-L-homocysteine + H+ + tetrahydropalmatine.\" [EC:2.1.1.89, RHEA:22536]","metadata":null},{"id":"d0f48fad8f164a398f3d024e82854148","type":"GO_TERM","name":"tetrahydrodictyopterin binding","canonical_id":"go:GO:0071576","description":"\"Binding to tetrahydrodictyopterin, the pterin 2-amino-6-[(1R,2R)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(3H)-one.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"71c51753a12e44f180f0492974d1cf4e","type":"GO_TERM","name":"tetrahydrodipicolinate N-acetyltransferase activity","canonical_id":"go:GO:0047200","description":"\"Catalysis of the reaction: (S)-2,3,4,5-tetrahydrodipicolinate + acetyl-CoA + H2O = L-2-acetamido-6-oxopimelate + CoA.\" [RHEA:13085]","metadata":null},{"id":"cbbd0c67df654c1ebda1b88876f50ffd","type":"GO_TERM","name":"tetrahydrofolate biosynthetic process","canonical_id":"go:GO:0046654","description":"\"The chemical reactions and pathways resulting in the formation of tetrahydrofolate, 5,6,7,8-tetrahydrofolic acid, a folate derivative bearing additional hydrogens on the pterin group.\" [ISBN:0198506732]","metadata":null},{"id":"9ccf131a55b740598407892ba95c6c48","type":"GO_TERM","name":"tetrahydrofolate interconversion","canonical_id":"go:GO:0035999","description":"\"The chemical reactions and pathways by which one-carbon (C1) units are transferred between tetrahydrofolate molecules, to synthesize other tetrahydrofolate molecules.\" [GOC:yaf, PMID:1825999]","metadata":null},{"id":"8967181d4f594731a7171f28dd6554fc","type":"GO_TERM","name":"tetrahydrofolate metabolic process","canonical_id":"go:GO:0046653","description":"\"The chemical reactions and pathways involving tetrahydrofolate, 5,6,7,8-tetrahydrofolic acid, a folate derivative bearing additional hydrogens on the pterin group.\" [ISBN:0198506732]","metadata":null},{"id":"e6e7e6561f0443f6b3bc95070f643b22","type":"GO_TERM","name":"tetrahydrofolyl-poly(glutamate) polymer binding","canonical_id":"go:GO:1904493","description":"\"Binding to tetrahydrofolyl-poly(glutamate) polymer.\" [GO_REF:0000067, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:24863754]","metadata":null},{"id":"6d94f412ceec49179aa27fd4f67dd051","type":"GO_TERM","name":"tetrahydrofolylpolyglutamate biosynthetic process","canonical_id":"go:GO:0046901","description":"\"The chemical reactions and pathways resulting in the formation of tetrahydrofolylpolyglutamate, a folate derivative comprising tetrahydrofolate attached to a chain of glutamate residues.\" [GOC:ai]","metadata":null},{"id":"efc330bd7aef4eb3a7e66eb748d00cee","type":"GO_TERM","name":"tetrahydrofolylpolyglutamate metabolic process","canonical_id":"go:GO:0046900","description":"\"The chemical reactions and pathways involving tetrahydrofolylpolyglutamate, a folate derivative comprising tetrahydrofolate attached to a chain of glutamate residues.\" [GOC:ai]","metadata":null},{"id":"85860b95951d49ff9de381b7ba0373f8","type":"GO_TERM","name":"tetrahydrofolylpolyglutamate synthase activity","canonical_id":"go:GO:0004326","description":"\"Catalysis of the reaction: ATP + tetrahydrofolyl-(Glu)(n) + L-glutamate = ADP + phosphate + tetrahydrofolyl-(Glu)(n+1).\" [EC:6.3.2.17]","metadata":null},{"id":"627a4830ab51472cba2d82c8e9ec01d1","type":"GO_TERM","name":"tetrahydrofuran catabolic process","canonical_id":"go:GO:0018968","description":"\"The chemical reactions and pathways resulting in the breakdown of tetrahydrofuran, a cyclic 4 carbon ether. It is one of the most polar ethers and is a widely used solvent for polar reagents. Since THF is very soluble in water and has a relatively low boiling point, significant amounts are often released into the environment, causing contamination problems.\" [PMID:12632259, PMID:33362743, PMID:35108100]","metadata":null},{"id":"a5ecb4495f0a4209952ce56361ae2686","type":"GO_TERM","name":"tetrahydromethanopterin S-methyltransferase activity","canonical_id":"go:GO:0030269","description":"\"Catalysis of the reaction: 5-methyl-5,6,7,8-tetrahydromethanopterin + coenzyme M + 2 Na+(in) = 5,6,7,8-tetrahydromethanopterin + methyl-coenzyme M + 2 Na+(out). 2-(methylthio)ethanesulfonate is also known as methyl-CoM.\" [RHEA:53492]","metadata":null},{"id":"eeccae3dc155440f92f9922b6e356e7c","type":"GO_TERM","name":"tetrahydromethanopterin biosynthetic process","canonical_id":"go:GO:2001118","description":"\"The chemical reactions and pathways resulting in the formation of a tetrahydromethanopterin.\" [GOC:mengo_curators]","metadata":null},{"id":"4c74944b6f414d2784c6a0850adcae60","type":"GO_TERM","name":"tetrahydroxybenzophenone synthase activity","canonical_id":"go:GO:0047181","description":"\"Catalysis of the reaction: 3-hydroxybenzoyl-CoA + 3 malonyl-CoA = 3 CO2 + 2,3',4,6-tetrahydroxybenzophenone + 4 coenzyme A.\" [EC:2.3.1.151, MetaCyc:2.3.1.151-RXN]","metadata":null},{"id":"171e6550bd224b72812b06748867bd61","type":"GO_TERM","name":"tetrahydroxynaphthalene reductase activity","canonical_id":"go:GO:0047039","description":"\"Catalysis of the reaction: NADP+ + scytalone = NADPH + H+ + 1,3,6,8-naphthalenetetrol.\" [EC:1.1.1.252, MetaCyc:1.1.1.252-RXN]","metadata":null},{"id":"649a5253dcfd42af9ed10c83516008e6","type":"GO_TERM","name":"tetrahydroxypteridine cycloisomerase activity","canonical_id":"go:GO:0050329","description":"\"Catalysis of the reaction: tetrahydroxypteridine = H+ + xanthine-8-carboxylate.\" [EC:5.5.1.3, RHEA:18097]","metadata":null},{"id":"41cf5b9383e24fc4bf70faa73c22ff1c","type":"GO_TERM","name":"tetrahymanol synthase activity","canonical_id":"go:GO:0034073","description":"\"Catalysis of the reaction: tetrahymanol = squalene + H2O.\" [PMID:18033581, RHEA:30675]","metadata":null},{"id":"746559fa46f242c1ae69c5381b2a7086","type":"GO_TERM","name":"tetraketide alpha-pyrone synthase activity","canonical_id":"go:GO:0090439","description":"\"Catalyzes the reaction: 7-hydroxylauroyl-CoA + 3 malonyl-CoA + 2 H+ = 2-(8-hydroxy-2-oxotridecyl)-6-oxopyran-4-olate + 3 CO2 + 4 coenzyme A.\" [MetaCyc:RXN-16407, PMID:21193570]","metadata":null},{"id":"3a2f36b9f6974ce0b9aefc8cbf534593","type":"GO_TERM","name":"tetrapeptide import across plasma membrane","canonical_id":"go:GO:1901583","description":"\"The directed movement of a tetrapeptide from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:TermGenie, PMID:22226946]","metadata":null},{"id":"b51d8366b71743db81d810820ae81ae2","type":"GO_TERM","name":"tetrapeptide transmembrane transporter activity","canonical_id":"go:GO:1901584","description":"\"Enables the transfer of tetrapeptide from one side of a membrane to the other.\" [GOC:TermGenie]","metadata":null},{"id":"dbfbab2f796d4ef5a49272801e6f0fa6","type":"GO_TERM","name":"tetrapyrrole binding","canonical_id":"go:GO:0046906","description":"\"Binding to a tetrapyrrole, a compound containing four pyrrole nuclei variously substituted and linked to each other through carbons at the alpha position.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"bfedf8e32029479caadf455542c1da8f","type":"GO_TERM","name":"tetrapyrrole biosynthetic process","canonical_id":"go:GO:0033014","description":"\"The chemical reactions and pathways leading to the formation of tetrapyrroles, natural pigments containing four pyrrole rings joined by one-carbon units linking position 2 of one pyrrole ring to position 5 of the next.\" [GOC:mah]","metadata":null},{"id":"f0b472aa55654fc0a48ae1cb2ea692fa","type":"GO_TERM","name":"tetrapyrrole catabolic process","canonical_id":"go:GO:0033015","description":"\"The chemical reactions and pathways leading to the breakdown of tetrapyrroles, natural pigments containing four pyrrole rings joined by one-carbon units linking position 2 of one pyrrole ring to position 5 of the next.\" [GOC:mah]","metadata":null},{"id":"ec1aec45afa947d7a700425f5efebe87","type":"GO_TERM","name":"tetrapyrrole metabolic process","canonical_id":"go:GO:0033013","description":"\"The chemical reactions and pathways involving tetrapyrroles, natural pigments containing four pyrrole rings joined by one-carbon units linking position 2 of one pyrrole ring to position 5 of the next.\" [GOC:mah]","metadata":null},{"id":"516dde033c9343238ef068c5d46a1f90","type":"GO_TERM","name":"tetrasaccharide transport","canonical_id":"go:GO:2001098","description":"\"The directed movement of a tetrasaccharideacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"f5f5e2426dda492685161bc4deb2620b","type":"GO_TERM","name":"tetraspanin-enriched microdomain","canonical_id":"go:GO:0097197","description":"\"A pre-organized unit composed either of adhesion molecules (mainly integrins and members of the Ig superfamily), signaling receptors and/or enzyme-enriched plasma membrane domains that compartmentalizes cellular processes. Tetraspanin-enriched microdomains might be specially suited for the regulation of avidity of adhesion receptors and the compartmentalization of enzymatic activities.\" [GOC:ans, PMID:19709882, PMID:21930792]","metadata":null},{"id":"f621db2ba40d467ca7156cc167a0333b","type":"GO_TERM","name":"tetraterpenoid biosynthetic process","canonical_id":"go:GO:0016109","description":"\"The chemical reactions and pathways resulting in the formation of tetraterpenoid compounds, terpenoids with eight isoprene units.\" [GOC:curators]","metadata":null},{"id":"36d5b8c9174c4bb1918b181e95194356","type":"GO_TERM","name":"tetraterpenoid catabolic process","canonical_id":"go:GO:0016110","description":"\"The chemical reactions and pathways resulting in the breakdown of tetraterpenoid compounds, terpenoids with eight isoprene units.\" [GOC:curators]","metadata":null},{"id":"484e2a3ef46c46ffbcf8693c229c6e89","type":"GO_TERM","name":"tetraterpenoid transport","canonical_id":"go:GO:0046866","description":"\"The directed movement of tetraterpenoids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Tetraterpenoids are terpenoids with eight isoprene units.\" [GOC:ai]","metadata":null},{"id":"60c2aeb863f1406480a6cd7f3e07eab0","type":"GO_TERM","name":"tetrose biosynthetic process","canonical_id":"go:GO:0033348","description":"\"The chemical reactions and pathways resulting in the formation of a tetrose, any monosaccharide with a chain of four carbon atoms in the molecule.\" [GOC:mah]","metadata":null},{"id":"2059eb6403214f72a3e5e2968773a418","type":"GO_TERM","name":"tetrose metabolic process","canonical_id":"go:GO:0033347","description":"\"The chemical reactions and pathways involving a tetrose, any monosaccharide with a chain of four carbon atoms in the molecule.\" [GOC:mah]","metadata":null},{"id":"4c5d6fe45fb749e68cd07f411cbbd3c0","type":"DRUG","name":"tezepelumab","canonical_id":"gtopdb:8933","description":null,"metadata":null},{"id":"7f437fa2b5744815881562491661b8de","type":"DRUG","name":"tezepelumab","canonical_id":"chembl:CHEMBL3707229","description":null,"metadata":null},{"id":"2f4b523fa54147efa24feb4c18e05a29","type":"TRIAL","name":"th2 Modulation CRSwNP","canonical_id":"clinicaltrials.gov:NCT06107101","description":"Chronic Rhinosinusitis With Nasal Polyps","metadata":null},{"id":"dca142ff0a5c4cd58655b00fc2b6cd7a","type":"GO_TERM","name":"thalamus development","canonical_id":"go:GO:0021794","description":"\"The process in which the thalamus changes over time, from its initial formation to its mature state.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"3b79b71ac88b49e889d3cdaa59ccf34c","type":"GO_TERM","name":"thalian-diol desaturase activity","canonical_id":"go:GO:0080004","description":"\"Catalysis of the reaction: a thalian-diol = a desaturated thalian-diol. This reaction is the introduction of a double bond to a thalian-diol molecule at carbon 15.\" [PMID:18356490]","metadata":null},{"id":"ce739476633e43e491021d047955d734","type":"GO_TERM","name":"thalianol hydroxylase activity","canonical_id":"go:GO:0080014","description":"\"Catalysis of the reaction: a thalianol = a thalian-diol. This reaction is the addition of a hydroxyl group to thalianol ((13R,14R,17E)-podioda-8,17,21-trien-3beta-ol) to create a thalian-diol ((13R,14R,17E)-podioda-8,17,21-trien-3beta,X-diol), where the hydroxyl group may be attached at one of several different available carbons in ring B or C of thalianol, indicated by the X.\" [MetaCyc:RXN-9631, PMID:17474751, PMID:18356490]","metadata":null},{"id":"53d7858369304329b47b0f04489c9a6d","type":"GO_TERM","name":"thalianol metabolic process","canonical_id":"go:GO:0080003","description":"\"The chemical reactions and pathways involving the triterpene thalianol.\" [PMID:18356490]","metadata":null},{"id":"68fa986969084af698dd4be5b1f5223d","type":"GO_TERM","name":"thalianol synthase activity","canonical_id":"go:GO:0051746","description":"\"Catalysis of the cyclization of 3(S)-oxidosqualene to (3S,13S,14R)-malabarica-8,17,21-trien-3-ol (thalianol).\" [PMID:15125655, RHEA:26160]","metadata":null},{"id":"e915d7b241cc4f0ba47b5d0d712db95c","type":"DRUG","name":"thalidomide","canonical_id":"mesh:D013792","description":null,"metadata":null},{"id":"e30dd7884c034003bfebf9bc3f8d1982","type":"DISEASE","name":"thanatophoric dysplasia","canonical_id":"mondo:0017042","description":null,"metadata":null},{"id":"817bd74d9a8945588c471f669c08fcf0","type":"DISEASE","name":"thanatophoric dysplasia type 1","canonical_id":"mondo:0008546","description":null,"metadata":null},{"id":"62edb810eb104169a96e5e17c745e16a","type":"DISEASE","name":"thanatophoric dysplasia type 2","canonical_id":"mondo:0008547","description":null,"metadata":null},{"id":"7d474850ec2d4ee782f40540e68914b3","type":"TRIAL","name":"the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris","canonical_id":"clinicaltrials.gov:NCT00419848","description":"Acne","metadata":null},{"id":"14bc5f82ea03403b9ab424548486850a","type":"TRIAL","name":"the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia","canonical_id":"clinicaltrials.gov:NCT02279342","description":"Coronary Artery Disease","metadata":null},{"id":"fe051d7b2a314f3da71f2425d9344a22","type":"TRIAL","name":"the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More","canonical_id":"clinicaltrials.gov:NCT06622603","description":"Gout; Uric Acid","metadata":null},{"id":"0bf376edff484faf8f235a1a72eddf89","type":"TRIAL","name":"the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease","canonical_id":"clinicaltrials.gov:NCT03977441","description":"Parkinson Disease; Depression; Sleep Disorders; Circadian Rhythm Disorders","metadata":null},{"id":"cd53198eae0749c4b23c998f6f2bcc11","type":"TRIAL","name":"the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer","canonical_id":"clinicaltrials.gov:NCT06378840","description":"Locally Advanced Cervical Carcinoma; Concurrent Chemoradiotherapy; Immunotherapy","metadata":null},{"id":"b8b2568a327442268f4f8c1d4e93821d","type":"GO_TERM","name":"theanine hydrolase activity","canonical_id":"go:GO:0050330","description":"\"Catalysis of the reaction: N(5)-ethyl-L-glutamine + H2O = L-glutamate + ethylamine.\" [EC:3.5.1.65, RHEA:18013]","metadata":null},{"id":"4ad6e6f5e7b148538018e104f9e4e9ef","type":"GO_TERM","name":"thebaine 6-O-demethylase activity","canonical_id":"go:GO:0102802","description":"\"Catalysis of the reaction: thebaine + 2-oxoglutarate + O2 = neopinone + formaldehyde + succinate + carbon dioxide.\" [EC:1.14.11.31, GOC:pz]","metadata":null},{"id":"a5c9afd62e6b469cbf3cefbb844bb6a2","type":"GO_TERM","name":"thelarche","canonical_id":"go:GO:0042695","description":"\"The beginning of development of the breasts in the female.\" [GOC:curators, PMID:19117864]","metadata":null},{"id":"48c36f1e4621409fb90bff42f396b5cd","type":"DRUG","name":"theophylline","canonical_id":"gtopdb:413","description":null,"metadata":null},{"id":"580a93e07d8249eeae1a76438c48b731","type":"DRUG","name":"theophylline","canonical_id":"mesh:D013806","description":null,"metadata":null},{"id":"9e0c6d806e84448492fb031fa9323e09","type":"DRUG","name":"theophylline","canonical_id":"chembl:CHEMBL1355736","description":null,"metadata":null},{"id":"37b4e6db72324d5eb1189e6fcb1a6328","type":"GO_TERM","name":"thermoception","canonical_id":"go:GO:0050955","description":"\"The series of events required for an organism to receive a temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal. Thermoception in larger animals is mainly done in the skin; mammals have at least two types of sensor, for detecting heat (temperatures above body temperature) and cold (temperatures below body temperature).\" [GOC:ai, Wikipedia:Thermoception]","metadata":null},{"id":"035a314790154b2cbdbd89083b8e98a6","type":"GO_TERM","name":"thermomorphogenesis","canonical_id":"go:GO:0140919","description":"\"The suite of morphological and architectural changes in an organism induced by high ambient temperatures, below the heat-stress range.\" [PMID:27250752]","metadata":null},{"id":"1cf86641a04a4a45a5b7f15be6401c88","type":"GO_TERM","name":"thermosensory behavior","canonical_id":"go:GO:0040040","description":"\"Behavior that is dependent upon the sensation of temperature.\" [GOC:ems]","metadata":null},{"id":"e72c0a2be60748ea90f0a7ef589a522f","type":"GO_TERM","name":"thermospermine biosynthetic process","canonical_id":"go:GO:1903603","description":"\"The chemical reactions and pathways resulting in the formation of thermospermine.\" [GO_REF:0000068, GOC:TermGenie, PMID:24906355]","metadata":null},{"id":"0dc9a8c2be1b4637a3bed933b8d0b737","type":"GO_TERM","name":"thermospermine catabolic process","canonical_id":"go:GO:1903602","description":"\"The chemical reactions and pathways resulting in the breakdown of thermospermine.\" [GO_REF:0000068, GOC:TermGenie, PMID:24906355]","metadata":null},{"id":"9285d3334b424cc3a870e9c8078b4289","type":"GO_TERM","name":"thermospermine oxidase activity","canonical_id":"go:GO:1990534","description":"\"Catalysis of the reaction: S-methyl-5'-thioadenosine + thermospermine + H+ = S-adenosyl 3-(methylthio)propylamine + spermidine.\" [PMID:24906355, RHEA:57836]","metadata":null},{"id":"2a725ebc41b4400da17d0e251c780509","type":"GO_TERM","name":"thermospermine synthase activity","canonical_id":"go:GO:0010487","description":"\"Catalysis of the reaction: S-adenosyl-L-methioninamine + spermidine = S-methyl-5'-thioadenosine + thermospermine + H+.\" [EC:2.5.1.79, MetaCyc:RXN-11190, PMID:17560575]","metadata":null},{"id":"84e39c1765554ea1b228275ad997fd09","type":"GO_TERM","name":"thermotaxis","canonical_id":"go:GO:0043052","description":"\"The directed movement of a motile cell or organism in response to a temperature gradient. Movement may be towards either a higher or lower temperature.\" [GOC:cab1, WB_REF:cgc467]","metadata":null},{"id":"2f9d32abba9d479f8ffd2e3c8dcdf4e9","type":"GO_TERM","name":"theta DNA replication","canonical_id":"go:GO:0070582","description":"\"A DNA-dependent DNA replication process in which a double-stranded DNA molecule is synthesized from a circular duplex template.\" [GOC:cb, GOC:mah, ISBN:0198506732]","metadata":null},{"id":"12afeca52a674a4388da1da65ce74b16","type":"GO_TERM","name":"thetin-homocysteine S-methyltransferase activity","canonical_id":"go:GO:0047149","description":"\"Catalysis of the reaction: L-homocysteine + dimethylsulfonioacetate = (methylthio)acetate + L-methionine + H+.\" [EC:2.1.1.3, RHEA:22788]","metadata":null},{"id":"f983f3dc5d604fe689d6973830f192b2","type":"GO_TERM","name":"thiaminase activity","canonical_id":"go:GO:0050334","description":"\"Catalysis of the reaction: H2O + thiamine = 4-amino-5-hydroxymethyl-2-methylpyrimidine + 5-(2-hydroxyethyl)-4-methylthiazole + H+.\" [EC:3.5.99.2, RHEA:17509]","metadata":null},{"id":"c7b0fbb63856471591839aa0bc58aeca","type":"GO_TERM","name":"thiamine binding","canonical_id":"go:GO:0030975","description":"\"Binding to thiamine (vitamin B1), a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:mlg]","metadata":null},{"id":"6e38741d336843d28f4af1951fc3f1be","type":"GO_TERM","name":"thiamine biosynthetic process","canonical_id":"go:GO:0009228","description":"\"The chemical reactions and pathways resulting in the formation of thiamine (vitamin B1), a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"1b64ba5a828d4614aab4953124e11823","type":"GO_TERM","name":"thiamine catabolic process","canonical_id":"go:GO:0009230","description":"\"The chemical reactions and pathways resulting in the breakdown of thiamine (vitamin B1), a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a5a317488bb14ff58793e7fa9f38084a","type":"GO_TERM","name":"thiamine diphosphate biosynthetic process","canonical_id":"go:GO:0009229","description":"\"The chemical reactions and pathways resulting in the formation of thiamine diphosphate, a derivative of thiamine (vitamin B1) which acts as a coenzyme in a range of processes including the Krebs cycle.\" [GOC:jl, ISBN:0140512713]","metadata":null},{"id":"be9720608b574f29bcc95b77156cdd89","type":"GO_TERM","name":"thiamine diphosphate catabolic process","canonical_id":"go:GO:0042358","description":"\"The chemical reactions and pathways resulting in the breakdown of thiamine diphosphate, a derivative of thiamine (vitamin B1) which acts as a coenzyme in a range of processes including the Krebs cycle.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"aa68be6e91934e5aba8d097f635e9138","type":"GO_TERM","name":"thiamine diphosphate dephosphorylation","canonical_id":"go:GO:0042370","description":"\"The removal of one or more phosphate groups from thiamine diphosphate, a derivative of thiamine (vitamin B1) which acts as a coenzyme in a range of processes including the Krebs cycle.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"80c09bb64a53477989dd2db2d4360238","type":"GO_TERM","name":"thiamine diphosphate metabolic process","canonical_id":"go:GO:0042357","description":"\"The chemical reactions and pathways involving thiamine diphosphate, a derivative of thiamine (vitamin B1) which acts as a coenzyme in a range of processes including the Krebs cycle.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"c5ae80dd5554458ba1eda42d88432d55","type":"GO_TERM","name":"thiamine diphosphate phosphatase activity","canonical_id":"go:GO:0004787","description":"\"Catalysis of the reaction: thiamine diphosphate + H2O = thiamine monophosphate + phosphate.\" [GOC:ai, RHEA:27998]","metadata":null},{"id":"6489b230ea944d288d4999c858faf230","type":"GO_TERM","name":"thiamine diphosphokinase activity","canonical_id":"go:GO:0004788","description":"\"Catalysis of the reaction: ATP + thiamine = AMP + thiamine diphosphate.\" [RHEA:11576]","metadata":null},{"id":"199ec7522d1249f9b689db10fa6facda","type":"GO_TERM","name":"thiamine import across plasma membrane","canonical_id":"go:GO:0140125","description":"\"The directed movement of thiamine from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:vw]","metadata":null},{"id":"e2b3e5024ec741b685ba2f4958ee8040","type":"GO_TERM","name":"thiamine kinase activity","canonical_id":"go:GO:0019165","description":"\"Catalysis of the reaction: ATP + thiamine = ADP + 2 H+ + thiamine phosphate.\" [EC:2.7.1.89, RHEA:12012]","metadata":null},{"id":"cd80525a6b1b40d7b3cbfd1971e714f9","type":"GO_TERM","name":"thiamine metabolic process","canonical_id":"go:GO:0006772","description":"\"The chemical reactions and pathways involving thiamine (vitamin B1), a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a4e00077827e41b9ad52f3c9da1d6282","type":"GO_TERM","name":"thiamine oxidase activity","canonical_id":"go:GO:0050423","description":"\"Catalysis of the reaction: thiamine + 2 O2 = thiamine acetic acid + 2 H2O2.\" [EC:1.1.3.23, MetaCyc:THIAMIN-OXIDASE-RXN]","metadata":null},{"id":"2ff477c444224fd191de9199fa7547ac","type":"GO_TERM","name":"thiamine phosphate phosphatase activity","canonical_id":"go:GO:0042131","description":"\"Catalysis of the reaction: thiamine phosphate + H2O = thiamine + phosphate.\" [PMID:197075, RHEA:47948]","metadata":null},{"id":"916261b84e9a4b21a8c72845e793ebba","type":"GO_TERM","name":"thiamine pyridinylase activity","canonical_id":"go:GO:0050332","description":"\"Catalysis of the reaction: pyridine + thiamine = 5-(2-hydroxyethyl)-4-methylthiazole + heteropyrithiamine.\" [EC:2.5.1.2, RHEA:17697]","metadata":null},{"id":"56ae66a1310b41d29f9dd8f137fc8813","type":"GO_TERM","name":"thiamine pyrophosphate binding","canonical_id":"go:GO:0030976","description":"\"Binding to thiamine pyrophosphate, the diphosphoric ester of thiamine. Acts as a coenzyme of several (de)carboxylases, transketolases, and alpha-oxoacid dehydrogenases.\" [GOC:mlg]","metadata":null},{"id":"bb847982157844d7a18ce1dcaeaf6fb1","type":"GO_TERM","name":"thiamine pyrophosphate transmembrane transport","canonical_id":"go:GO:0030974","description":"\"The process in which thiamine pyrophosphate is transported across a membrane.\" [GOC:mlg]","metadata":null},{"id":"492ce80fcceb4b7280701caece20f105","type":"GO_TERM","name":"thiamine pyrophosphate transmembrane transporter activity","canonical_id":"go:GO:0090422","description":"\"Enables the transfer of thiamine pyrophosphate a substance from one side of a membrane to the other.\" [GOC:tb]","metadata":null},{"id":"1b19684eed8a480f84533187b626a1a2","type":"GO_TERM","name":"thiamine salvage","canonical_id":"go:GO:0036172","description":"\"A process that generates thiamine (vitamin B1) from derivatives of it without de novo synthesis.\" [PMID:15150256, PMID:16952958]","metadata":null},{"id":"3ffaa335878e49debabae1b8c93fafc1","type":"GO_TERM","name":"thiamine transmembrane transport","canonical_id":"go:GO:0071934","description":"\"The process in which thiamine is transported across a membrane. Thiamine is vitamin B1, a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:mah]","metadata":null},{"id":"1e7aa83f2c334d869fe12c076810e698","type":"GO_TERM","name":"thiamine transmembrane transporter activity","canonical_id":"go:GO:0015234","description":"\"Enables the transfer of thiamine from one side of a membrane to the other. Thiamine is vitamin B1, a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:ai, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"0771b9c4abe447f6af740508a17ebe7f","type":"GO_TERM","name":"thiamine transport","canonical_id":"go:GO:0015888","description":"\"The directed movement of thiamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Thiamine is vitamin B1, a water soluble vitamin present in fresh vegetables and meats, especially liver.\" [GOC:ai]","metadata":null},{"id":"4285cbb1177c447db60f828bf84d3272","type":"GO_TERM","name":"thiamine triphosphate phosphatase activity","canonical_id":"go:GO:0050333","description":"\"Catalysis of the reaction: H2O + thiamine triphosphate = thiamine diphosphate + H+ + phosphate.\" [RHEA:11744]","metadata":null},{"id":"17460e84a1674148bf58ebb7e80eb77f","type":"GO_TERM","name":"thiamine-containing compound biosynthetic process","canonical_id":"go:GO:0042724","description":"\"The chemical reactions and pathways resulting in the formation of thiamine (vitamin B1), and related compounds.\" [GOC:jl]","metadata":null},{"id":"c64d536485094329b3f1cef3b70157bd","type":"GO_TERM","name":"thiamine-containing compound catabolic process","canonical_id":"go:GO:0042725","description":"\"The chemical reactions and pathways resulting in the breakdown of thiamine (vitamin B1), and compounds derived from it.\" [GOC:jl]","metadata":null},{"id":"d95feadef3934333bfbaa11ff01ac9c9","type":"GO_TERM","name":"thiamine-containing compound metabolic process","canonical_id":"go:GO:0042723","description":"\"The chemical reactions and pathways involving thiamine (vitamin B1), and compounds derived from it.\" [GOC:jl]","metadata":null},{"id":"acd853bdb2be4e589dbc7fc51c6e8ac7","type":"GO_TERM","name":"thiamine-diphosphate kinase activity","canonical_id":"go:GO:0050331","description":"\"Catalysis of the reaction: ATP + thiamin diphosphate = ADP + thiamin triphosphate.\" [EC:2.7.4.15, MetaCyc:THIAMIN-DIPHOSPHATE-KINASE-RXN]","metadata":null},{"id":"5ef80067badf4820b054a9ab44a60d2c","type":"GO_TERM","name":"thiamine-phosphate diphosphorylase activity","canonical_id":"go:GO:0004789","description":"\"Catalysis of the reaction: 4-amino-2-methyl-5-diphosphomethylpyrimidine + 4-methyl-5-(2-phosphoethyl)-thiazole + H+ = diphosphate + thiamine phosphate.\" [EC:2.5.1.3, RHEA:22328]","metadata":null},{"id":"808b523880aa490fb1f9226ab54aba2f","type":"GO_TERM","name":"thiamine-phosphate kinase activity","canonical_id":"go:GO:0009030","description":"\"Catalysis of the reaction: ATP + thiamine phosphate = ADP + H+ + thiamine diphosphate.\" [EC:2.7.4.16, RHEA:15913]","metadata":null},{"id":"767f43194f3f4fe08f19bf02cf7c14f9","type":"GO_TERM","name":"thiamine:proton symporter activity","canonical_id":"go:GO:0034215","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: thiamine(out) + H+(out) = thiamine(in) + H+(in).\" [GOC:mah]","metadata":null},{"id":"a65223ac19984235906d2d8054665a67","type":"GO_TERM","name":"thiazole biosynthetic process","canonical_id":"go:GO:0052837","description":"\"The chemical reactions and pathways resulting in the formation of a thiazole, a five-membered heterocyclic ring structure containing a sulfur in the 1-position and a nitrogen in the 3-position.\" [GOC:curators]","metadata":null},{"id":"54aaf9175de44b6e8b80a47a01c88df0","type":"GO_TERM","name":"thiazole metabolic process","canonical_id":"go:GO:0052838","description":"\"The chemical reactions and pathways involving thiazole, a five-membered heterocyclic ring structure containing a sulfur in the 1-position and a nitrogen in the 3-position.\" [GOC:curators]","metadata":null},{"id":"34590ad9d1c048b09c64ff1ec1b79300","type":"GO_TERM","name":"thiazole synthase activity","canonical_id":"go:GO:1990107","description":"\"Catalysis of the reaction: 1-deoxy-D-xylulose 5-phosphate + 2-iminoacetate + [sulfur-carrier protein ThiS]-C-terminal Gly-NH-CH2-C(O)SH = 2-[(2R,5Z)-2-carboxy-4-methylthiazol-5(2H)-ylidene]ethyl phosphate + [sulfur-carrier protein ThiS]-C-terminal Gly-Gly + 2 H+ + 2 H2O.\" [PMID:22031445, RHEA:26297]","metadata":null},{"id":"74c2188c9d5b45afac6e62d5f547c634","type":"GO_TERM","name":"thiazole synthase complex","canonical_id":"go:GO:1902507","description":"\"A protein complex which is capable of thiazole synthase activity.\" [GOC:bhm, GOC:TermGenie, PMID:12650933]","metadata":null},{"id":"82083bbb4af2426dadf8e23ddd6e1860","type":"GO_TERM","name":"thick ascending limb development","canonical_id":"go:GO:0072023","description":"\"The process whose specific outcome is the progression of the thick ascending limb over time, from its formation to the mature structure. The thick ascending limb is the last part of the loop of Henle. Its thick, mitochondria-rich epithelium characterizes the outer medulla, and is responsible for very avid active salt transport. At the macula densa, the thick ascending limb connects to the distal convoluted tubule.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"919d9ffc8d9441489b1cf65cccf81c00","type":"GO_TERM","name":"thienylcyclohexylpiperidine binding","canonical_id":"go:GO:0016596","description":"\"Binding to thienylcyclohexylpiperidine.\" [GOC:jl]","metadata":null},{"id":"044762abbe6143fd9be109b463c40726","type":"DRUG","name":"thiethylperazine","canonical_id":"mesh:D013847","description":null,"metadata":null},{"id":"95e50982b4bb4db4b4e8da1838d21b6d","type":"GO_TERM","name":"thigmotaxis","canonical_id":"go:GO:0001966","description":"\"The directed movement of an organism along a spatial gradient of mechanical contact with solid surfaces, typically manifested as a preference for maintaining proximity to walls, edges, or boundaries.\" [PMID:22197677, PMID:35992075, PMID:7913324]","metadata":null},{"id":"ae2044967bd048039123a78e639f84a0","type":"GO_TERM","name":"thigmotropism","canonical_id":"go:GO:0009652","description":"\"The movement of an organism, or part of an organism, such as leaves or tendrils, in response to a touch stimulus, usually toward or away from it.\" [GOC:jl, PMID:16153165]","metadata":null},{"id":"46cc0bb159274597bb48dc62a74eabfa","type":"GO_TERM","name":"thiocyanate catabolic process","canonical_id":"go:GO:0046265","description":"\"The chemical reactions and pathways resulting in the breakdown of thiocyanate, any anion of thiocyanic acid.\" [GOC:ai]","metadata":null},{"id":"b05f1a3c1adc4365be0afe12d213face","type":"GO_TERM","name":"thiocyanate hydrolase activity","canonical_id":"go:GO:0018760","description":"\"Catalysis of the reaction: H2O + 2 H+ + thiocyanate = carbonyl sulfide + NH4.\" [EC:3.5.5.8, RHEA:21464]","metadata":null},{"id":"8ec26b5921f1466ca82f65bd5e8cc004","type":"GO_TERM","name":"thiocyanate metabolic process","canonical_id":"go:GO:0018969","description":"\"The chemical reactions and pathways involving thiocyanate, the anion of thiocyanic acid, a toxic cyanide derivative commonly formed as a by-product in the production of gas for fuel, coke, and substances for chemical industries.\" [GOC:jl]","metadata":null},{"id":"05d69f1eba0042ecbae4bd814c424c18","type":"GO_TERM","name":"thiocyanate methyltransferase activity","canonical_id":"go:GO:0102215","description":"\"Catalysis of the reaction: thiocyanate + S-adenosyl-L-methionine = methyl thiocyanate + S-adenosyl-L-homocysteine.\" [RHEA:28014]","metadata":null},{"id":"eb1f35f548e447fea2434996b4e2815a","type":"GO_TERM","name":"thiocyanate peroxidase activity","canonical_id":"go:GO:0036393","description":"\"Catalysis of the reaction: thiocyanate + H2O2 + H+ = hypothiocyanous acid + H2O.\" [GOC:pm, PMID:12626341, RHEA:69416]","metadata":null},{"id":"5991f2c3be6f4de5948ef0042635f0e7","type":"GO_TERM","name":"thioester transport","canonical_id":"go:GO:1901337","description":"\"The directed movement of a thioester into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:TermGenie]","metadata":null},{"id":"480d93bfb73f40e897c45d7b69d06b43","type":"GO_TERM","name":"thioesterase binding","canonical_id":"go:GO:0031996","description":"\"Binding to a thioesterase.\" [GOC:dl]","metadata":null},{"id":"9f33e8a6229d483a9165ab50e2af380a","type":"GO_TERM","name":"thioethanolamine S-acetyltransferase activity","canonical_id":"go:GO:0050336","description":"\"Catalysis of the reaction: acetyl-CoA + cysteamine = S-acetylcysteamine + CoA.\" [EC:2.3.1.11, RHEA:23280]","metadata":null},{"id":"b2ec493ad9784758a0ba583c59d0323e","type":"GO_TERM","name":"thioether S-methyltransferase activity","canonical_id":"go:GO:0004790","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + dimethyl sulfide = S-adenosyl-L-homocysteine + trimethylsulfonium.\" [EC:2.1.1.96, RHEA:19613]","metadata":null},{"id":"b0f2f6948c5348ee8f1e51298460436e","type":"GO_TERM","name":"thioglucosidase activity","canonical_id":"go:GO:0019137","description":"\"Catalysis of the reaction: a thioglucoside + H2O = a thiol + a sugar.\" [EC:3.2.1.147]","metadata":null},{"id":"07ce4d0a1fc549f7b9c7dcfd6e017131","type":"GO_TERM","name":"thioglucosidase binding","canonical_id":"go:GO:0010180","description":"\"Binding to a thioglucosidase enzyme.\" [GOC:tb]","metadata":null},{"id":"ee067364ad8248b0b5d99a8aa564c30c","type":"GO_TERM","name":"thioglucosidase complex","canonical_id":"go:GO:0010169","description":"\"A large (200-800 kDa) multiprotein complex formed by 70-kDa and 5-kDa myrosinases, myrosinase- binding proteins (MBPs), MBP-related proteins and myrosinase-associated proteins. The complex has been identified in Brassica napus seeds.\" [PMID:10682349]","metadata":null},{"id":"28a72d346b444232be0c9ed525d0f872","type":"DRUG","name":"thioguanine","canonical_id":"gtopdb:6845","description":null,"metadata":null},{"id":"7b5d6f3116b74751b53cc8ff40f90860","type":"DRUG","name":"thioguanine","canonical_id":"chembl:CHEMBL727","description":null,"metadata":null},{"id":"caf7210cda374d26bf9b0162f7f6bdf8","type":"GO_TERM","name":"thiohydroximate beta-D-glucosyltransferase activity","canonical_id":"go:GO:0047251","description":"\"Catalysis of the reaction: phenylthioacetohydroximate + UDP-D-glucose = desulfoglucotropeolin + UDP.\" [EC:2.4.1.195]","metadata":null},{"id":"5c4fe3fa14624e3b942a3b2a64a0212a","type":"GO_TERM","name":"thiol S-methyltransferase activity","canonical_id":"go:GO:0018708","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a thiol = S-adenosyl-L-homocysteine + a thioether.\" [EC:2.1.1.9]","metadata":null},{"id":"e5917f7d848a4b4bb867b95edef85529","type":"GO_TERM","name":"thiol oxidase activity","canonical_id":"go:GO:0016972","description":"\"Catalysis of the reaction: 2 R'C(R)SH + O2 = R'C(R)S-S(R)CR' + 2 H2O2.\" [RHEA:17357]","metadata":null},{"id":"7b77edbfa4234dd1a054f433bc0dd74e","type":"GO_TERM","name":"thiol sulfotransferase activity","canonical_id":"go:GO:0033870","description":"\"Catalysis of the reaction: 3'-phosphoadenylyl sulfate + a thiol = adenosine 3',5'-bisphosphate + an S-alkyl thiosulfate.\" [EC:2.8.2.16]","metadata":null},{"id":"666a1e59219e4a00ab96a617aa3debcb","type":"GO_TERM","name":"thiolester hydrolase activity","canonical_id":"go:GO:0016790","description":"\"Catalysis of the reaction: RCO-SR' + H2O = RCOOH + HSR'. This reaction is the hydrolysis of a thiolester bond, an ester formed from a carboxylic acid and a thiol (i.e., RCO-SR'), such as that found in acetyl-coenzyme A.\" [EC:3.1.2.-]","metadata":null},{"id":"b884a4628cf14c7c95e4b9b54e491ee6","type":"GO_TERM","name":"thiomorpholine-carboxylate dehydrogenase activity","canonical_id":"go:GO:0047127","description":"\"Catalysis of the reaction: NAD(P)+ + thiomorpholine-3-carboxylate = NAD(P)H + 3,4-dehydro-1,4-thiomorpholine-3-carboxylate.\" [EC:1.5.1.25, MetaCyc:1.5.1.25-RXN]","metadata":null},{"id":"7122b16be5254980b60ab4c50ffbc58c","type":"GO_TERM","name":"thiophene-2-carbonyl-CoA monooxygenase activity","canonical_id":"go:GO:0050603","description":"\"Catalysis of the reaction: AH(2) + O2 + thiophene-2-carbonyl-CoA = 5-hydroxythiophene-2-carbonyl-CoA + A + H2O + H+.\" [EC:1.14.99.35, RHEA:18929]","metadata":null},{"id":"54b8cb9f4ca0486281500c719e4fd2ee","type":"GO_TERM","name":"thiopurine S-methyltransferase activity","canonical_id":"go:GO:0008119","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + a thiopurine = S-adenosyl-L-homocysteine + a thiopurine S-methylether.\" [EC:2.1.1.67]","metadata":null},{"id":"03d62a3198f943baadf639c4627cb35a","type":"GO_TERM","name":"thioredoxin peroxidase activity","canonical_id":"go:GO:0008379","description":"\"Catalysis of the reaction: [thioredoxin]-dithiol + H2O2 = [thioredoxin]-disulfide + H2O.\" [RHEA:63528]","metadata":null},{"id":"473808d347e04840b991d4b45aa5c6b3","type":"GO_TERM","name":"thioredoxin-dependent peroxiredoxin activity","canonical_id":"go:GO:0140824","description":"\"Catalysis of the reaction: [thioredoxin]-dithiol + a hydroperoxide = [thioredoxin]-disulfide + an alcohol + H2O.\" [PMID:12707274, PMID:19820102, RHEA:62620]","metadata":null},{"id":"19a0a2c3d1bf4925857af6805ae1da45","type":"GO_TERM","name":"thioredoxin-disulfide reductase (NADPH) activity","canonical_id":"go:GO:0004791","description":"\"Catalysis of the reaction: thioredoxin-dithiol + NADP+ = thioredoxin-disulfide + H+ + NADPH.\" [RHEA:20345]","metadata":null},{"id":"ce3eb49115b043d28a48fcbc82480728","type":"GO_TERM","name":"thioredoxin-disulfide reductase complex","canonical_id":"go:GO:1902515","description":"\"A protein complex which is capable of thioredoxin-disulfide reductase activity.\" [GOC:bhm, GOC:TermGenie, PMID:10947986]","metadata":null},{"id":"0fc6c47dbe4645bdb3a6b29c3e6e1fdd","type":"DRUG","name":"thioridazine","canonical_id":"gtopdb:100","description":null,"metadata":null},{"id":"50d8089926bf442c9fd03b9b1bba2c5e","type":"DRUG","name":"thioridazine","canonical_id":"chembl:CHEMBL479","description":null,"metadata":null},{"id":"1214cc8e5f9041b0a556cba13804d5ec","type":"GO_TERM","name":"thiosulfate binding","canonical_id":"go:GO:0036173","description":"\"Binding to a thiosulfate, a sulfur oxide that has formula O3S2.\" [GOC:db, PMID:2188959]","metadata":null},{"id":"c76bf4dadbb74f6db6a39858170b0942","type":"GO_TERM","name":"thiosulfate dehydrogenase (quinone) activity","canonical_id":"go:GO:0043831","description":"\"Catalysis of the reaction: 6-decylubiquinone + 2 thiosulfate = 6-decylubiquinol + tetrathionate.\" [RHEA:10936]","metadata":null},{"id":"64c1fa90a229416abae74c3119fb90ef","type":"GO_TERM","name":"thiosulfate dehydrogenase activity","canonical_id":"go:GO:0050338","description":"\"Catalysis of the reaction: 2 thiosulfate + 2 ferricytochrome c = tetrathionate + 2 ferrocytochrome c.\" [EC:1.8.2.2, MetaCyc:THIOSULFATE-DEHYDROGENASE-RXN]","metadata":null},{"id":"057dd6c9f3fa4f39a3196725799f093a","type":"GO_TERM","name":"thiosulfate oxidation","canonical_id":"go:GO:0019416","description":"\"The chemical reactions and pathways resulting in the conversion of thiosulfate to tetrathionate, using cytochrome c as an electron acceptor.\" [MetaCyc:THIOSULFOX-PWY]","metadata":null},{"id":"a0e17d8a54b44cab8ab1b5850ef08ef2","type":"GO_TERM","name":"thiosulfate transmembrane transporter activity","canonical_id":"go:GO:0015117","description":"\"Enables the transfer of thiosulfate ions, HS2O3(1-), from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"84cb81d032d64220b493b2498db7fe48","type":"GO_TERM","name":"thiosulfate transport","canonical_id":"go:GO:0015709","description":"\"The directed movement of thiosulfate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"99e1977a537e489ab6fb34b914ae9ac9","type":"GO_TERM","name":"thiosulfate-cyanide sulfurtransferase activity","canonical_id":"go:GO:0004792","description":"\"Catalysis of the reaction: thiosulfate + hydrogen cyanide = thiocyanate + sulfite + 2 H+.\" [RHEA:16881]","metadata":null},{"id":"a9c344f48c8848b5ad4aea3e43fd612b","type":"GO_TERM","name":"thiosulfate-dithiol sulfurtransferase activity","canonical_id":"go:GO:0047362","description":"\"Catalysis of the reaction: dithioerythritol + thiosulfate = hydrogen sulfide + dithioerythritol disulfide + sulfite.\" [EC:2.8.1.5]","metadata":null},{"id":"5f79598fbc7f4be385168b72e3bdff95","type":"GO_TERM","name":"thiosulfate-thiol sulfurtransferase activity","canonical_id":"go:GO:0050337","description":"\"Catalysis of the reaction: thiosulfate + 2 glutathione = glutathione disulfide + hydrogen sulfide + sulfite + 2 H+.\" [RHEA:14505]","metadata":null},{"id":"57fc162ffddb494d89140b6fdd50108b","type":"GO_TERM","name":"thiosulfate-thioredoxin sulfurtransferase activity","canonical_id":"go:GO:0103041","description":"\"Catalysis of the reaction: thiosulfate + [thioredoxin]-dithiol = sulfite + 2 H+ + [thioredoxin]-disulfide + hydrogen sulfide.\" [GOC:pz, RHEA:83859]","metadata":null},{"id":"3d60c5c746c64c9d94f0cdf31c49afc8","type":"DRUG","name":"thiotepa","canonical_id":"mesh:D013852","description":null,"metadata":null},{"id":"9cd80977da83417ea181e76c8ab6ee2a","type":"DRUG","name":"thiothixene","canonical_id":"gtopdb:212","description":null,"metadata":null},{"id":"433d8a4dada2494fbe406a6e222b3e6d","type":"DRUG","name":"thiothixene","canonical_id":"chembl:CHEMBL1201","description":null,"metadata":null},{"id":"6f37dcb2dfa7470ca34945b8a77440fb","type":"GO_TERM","name":"third ventricle development","canonical_id":"go:GO:0021678","description":"\"The process whose specific outcome is the progression of the third ventricle over time, from its formation to the mature structure. The third ventricle is the narrow cleft inferior to the corpus callosum, within the diencephalon, between the paired thalami. Its floor is formed by the hypothalamus, its anterior wall by the lamina terminalis, and its roof by ependyma, and it communicates with the fourth ventricle by the cerebral aqueduct, and with the lateral ventricles by the interventricular foramina.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"2d6e01ca58334a3689b73514b99e50ef","type":"DRUG","name":"thonzonium","canonical_id":"mesh:C000609116","description":null,"metadata":null},{"id":"2b1809e0995d4377975db138bab72304","type":"GO_TERM","name":"thorax and anterior abdomen determination","canonical_id":"go:GO:0007356","description":"\"Specification of the central (trunk) regions of the embryo by the gap genes; exemplified in insects by the actions of the Kruppel gene product.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"aac4836738214332946d1f9b044d4f32","type":"GO_TERM","name":"thorny excrescence","canonical_id":"go:GO:0097464","description":"\"Large complex spine protruding from a dendrite. Each excrescence is formed by a cluster of spine heads.\" [NIF_Subcellular:nlx_467, PMID:730852]","metadata":null},{"id":"6fb1f0fc838f4dbfb944ce5e77853719","type":"GO_TERM","name":"threo-3-hydroxyaspartate ammonia-lyase activity","canonical_id":"go:GO:0030848","description":"\"Catalysis of the reaction: (3S)-3-hydroxy-L-aspartate = NH4 + oxaloacetate.\" [EC:4.3.1.16, RHEA:12424]","metadata":null},{"id":"4a7fdac4ebb54c71a03ab2a7d45898dc","type":"GO_TERM","name":"threonine aldolase activity","canonical_id":"go:GO:0004793","description":"\"Catalysis of the reaction: L-threonine = glycine + acetaldehyde.\" [RHEA:19625]","metadata":null},{"id":"3216215711214bb285d1a6bb71bfedee","type":"GO_TERM","name":"threonine deaminase activity","canonical_id":"go:GO:0004794","description":"\"Catalysis of the reaction: L-threonine = 2-oxobutanoate + NH4.\" [EC:4.3.1.19]","metadata":null},{"id":"8c69f9665a48483f9aa94ff916b1daab","type":"GO_TERM","name":"threonine efflux transmembrane transporter activity","canonical_id":"go:GO:0015565","description":"\"Enables the transfer of threonine from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"b5c991b0bcb8410d8f11198fe7a9784d","type":"GO_TERM","name":"threonine racemase activity","canonical_id":"go:GO:0018114","description":"\"Catalysis of the reaction: L-threonine = D-threonine.\" [EC:5.1.1.6, RHEA:13913]","metadata":null},{"id":"1dc91d4617ad427385ae0d430d24992c","type":"GO_TERM","name":"threonine synthase activity","canonical_id":"go:GO:0004795","description":"\"Catalysis of the reaction: O-phospho-L-homoserine + H2O = L-threonine + phosphate.\" [EC:4.2.3.1]","metadata":null},{"id":"bc31f0ff1aa04df09222a552e0b9e459","type":"GO_TERM","name":"threonine transport","canonical_id":"go:GO:0015826","description":"\"The directed movement of threonine, (2R*,3S*)-2-amino-3-hydroxybutanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"2394540cea21485a8ece730d90aac3d0","type":"GO_TERM","name":"threonine-phosphate decarboxylase activity","canonical_id":"go:GO:0048472","description":"\"Catalysis of the reaction: O-phospho-L-threonine + H+ = (R)-1-aminopropan-2-yl phosphate + CO2.\" [EC:4.1.1.81, RHEA:11492]","metadata":null},{"id":"92d485492eba416a8624582d910ac12a","type":"GO_TERM","name":"threonine-tRNA ligase activity","canonical_id":"go:GO:0004829","description":"\"Catalysis of the reaction: ATP + L-threonine + tRNA(Thr) = AMP + diphosphate + L-threonyl-tRNA(Thr).\" [EC:6.1.1.3]","metadata":null},{"id":"5b62081b8aa548de8338c8cc66ec9189","type":"GO_TERM","name":"threonine-type endopeptidase activity","canonical_id":"go:GO:0004298","description":"\"Catalysis of the hydrolysis of internal peptide bonds in a polypeptide chain by a mechanism in which the hydroxyl group of a threonine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE]","metadata":null},{"id":"f04b6a262c4041d3b7d829abe965e427","type":"GO_TERM","name":"threonine-type peptidase activity","canonical_id":"go:GO:0070003","description":"\"Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a mechanism in which the hydroxyl group of a threonine residue at the active center acts as a nucleophile.\" [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE]","metadata":null},{"id":"3de85dbf12d4469daa34fd0387d52f42","type":"GO_TERM","name":"threonyl-tRNA aminoacylation","canonical_id":"go:GO:0006435","description":"\"The process of coupling threonine to threonyl-tRNA, catalyzed by threonyl-tRNA synthetase. The threonyl-tRNA synthetase is a class-II synthetase. The activated amino acid is transferred to the 3'-OH group of a threonine-accetping tRNA.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"e82a9cba196d430289c98f1e06e8467a","type":"GO_TERM","name":"thrombin-activated receptor activity","canonical_id":"go:GO:0015057","description":"\"A G protein-coupled receptor activity that is activated by cleavage by thrombin, which exposes a tethered ligand corresponding to the new N-terminus, which binds to the receptor and activates it.\" [GOC:ai, GOC:pg, PMID:20423334]","metadata":null},{"id":"13ffb4102a244f58b9cad07990419ed8","type":"GO_TERM","name":"thrombin-activated receptor signaling pathway","canonical_id":"go:GO:0070493","description":"\"A G protein-coupled receptor signaling pathway initiated by thrombin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process.\" [GOC:mah, PMID:1672265]","metadata":null},{"id":"a876dbb2c9824e0b94b778987c939456","type":"GO_TERM","name":"thrombocyte activation","canonical_id":"go:GO:0071892","description":"\"A cell activation process that occurs in thrombocytes and consists of a series of progressive, overlapping events including shape change, adhesiveness, and aggregation, which, when carried through to completion, lead to the formation of a stable hemostatic plug. Thrombocytes are nucleated cells found in non-mammalian vertebrates and are involved in hemostasis. They are the functional equivalent of the non-nucleated platelets found in mammals.\" [GOC:lb, GOC:mah, PMID:10606877, PMID:15634265, PMID:20180901]","metadata":null},{"id":"9454faedd24846be86f8dbe9e9d58dbc","type":"GO_TERM","name":"thrombocyte differentiation","canonical_id":"go:GO:0002574","description":"\"The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a thrombocyte, a nucleated cell found in all vertebrates but mammals involved in hemostasis.\" [GOC:add]","metadata":null},{"id":"aef75dc759e14d8ebcd59418f3f3c85c","type":"DISEASE","name":"thrombocythemia 2","canonical_id":"mondo:0011173","description":null,"metadata":null},{"id":"059681b1e6524bc3ab06d37d6b64a6ce","type":"DISEASE","name":"thrombocythemia 3","canonical_id":"mondo:0013794","description":null,"metadata":null},{"id":"369ee1b71a1b44858776ca308562e089","type":"DISEASE","name":"thrombocytopenic purpura","canonical_id":"mondo:0043768","description":null,"metadata":null},{"id":"5a4b022c2a944a65bae2c5929d3dacfc","type":"DISEASE","name":"thrombophilia","canonical_id":"mondo:0002305","description":null,"metadata":null},{"id":"94d51a01d9a24ca4a1fcf1356ab338b4","type":"DISEASE","name":"thrombophilia due to activated protein C resistance","canonical_id":"mondo:0008560","description":null,"metadata":null},{"id":"91e2b07d322447c1a55b14104da17e45","type":"DISEASE","name":"thrombophilia due to thrombin defect","canonical_id":"mondo:0008559","description":null,"metadata":null},{"id":"b4c6d33aae364f67b2a541e73a07863e","type":"DISEASE","name":"thrombophilia, X-linked, due to factor 8 defect","canonical_id":"mondo:0859082","description":null,"metadata":null},{"id":"31ab195f647b4aff8acdcbc2a7aa19b6","type":"GO_TERM","name":"thrombopoietin receptor activity","canonical_id":"go:GO:0038164","description":"\"Combining with the glycoprotein thrombopoietin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:bf, GOC:signaling, PMID:19630807]","metadata":null},{"id":"32e3a1c60a34407db5bb2ca47c160d09","type":"GO_TERM","name":"thrombopoietin-mediated signaling pathway","canonical_id":"go:GO:0038163","description":"\"The series of molecular signals initiated by thrombopoietin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:19630807]","metadata":null},{"id":"5b9d7183175148928f4ea3bfed5ca7e9","type":"GO_TERM","name":"thrombospondin complex","canonical_id":"go:GO:1990341","description":"\"A homotrimeric or homopentameric glycoprotein that functions at the interface of the cell membrane and the extracellular matrix through its interactions with proteins and proteoglycans, such as collagens, integrins and fibronectin, to regulate matrix structure and cellular behaviour.\" [GOC:bhm, PMID:15094109, PMID:18193164]","metadata":null},{"id":"a2f4edfdb39146978d322585b5974a6a","type":"GO_TERM","name":"thrombospondin receptor activity","canonical_id":"go:GO:0070053","description":"\"Combining with thrombospondin and transmitting the signal to initiate a change in cell activity.\" [GOC:BHF, GOC:signaling, GOC:vk]","metadata":null},{"id":"35eba5e9acd3425b8b0aa40e0b85af3c","type":"DISEASE","name":"thrombotic disease","canonical_id":"mondo:0000831","description":null,"metadata":null},{"id":"65f6b4fa7936426d8c44db34893cf2f8","type":"DISEASE","name":"thrombotic thrombocytopenic purpura","canonical_id":"mondo:0018896","description":null,"metadata":null},{"id":"82723c80222e40f6a0f8a1cd0485ce55","type":"GO_TERM","name":"thromboxane A2 receptor activity","canonical_id":"go:GO:0004961","description":"\"Combining with thromboxane A2 (TXA(2)) and transmitting the signal across the membrane to activate an associated G-protein.\" [GOC:signaling, ISBN:0198506732]","metadata":null},{"id":"38dfdb0bb9b546af9aa49d6fd85f8fa5","type":"GO_TERM","name":"thromboxane A2 receptor binding","canonical_id":"go:GO:0031870","description":"\"Binding to a thromboxane A2 receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"037b9b5f3f6248b4984af94a849363d4","type":"GO_TERM","name":"thromboxane A2 signaling pathway","canonical_id":"go:GO:0038193","description":"\"A G protein-coupled receptor signaling pathway initiated by thromboxane A2 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, PMID:15893915]","metadata":null},{"id":"e4d50f33dd8544bb96c6159611f3854d","type":"GO_TERM","name":"thromboxane receptor activity","canonical_id":"go:GO:0004960","description":"\"Combining with a thromboxane (TXA) to initiate a change in cell activity.\" [ISBN:0198506732]","metadata":null},{"id":"5398384799d24329b0d0ed7b1bf1a898","type":"GO_TERM","name":"thromboxane transport","canonical_id":"go:GO:0071717","description":"\"The directed movement of thromboxanes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A thromboxane is any of a class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.\" [GOC:mah]","metadata":null},{"id":"57a19316e46d4fa6856297361dc7bdbe","type":"GO_TERM","name":"thromboxane-A synthase activity","canonical_id":"go:GO:0004796","description":"\"Catalysis of the reaction: prostaglandin H(2) = thromboxane A(2).\" [EC:5.3.99.5, RHEA:17137]","metadata":null},{"id":"77485174342e43a29ea617e2a34e5663","type":"GO_TERM","name":"thylakoid","canonical_id":"go:GO:0009579","description":"\"A membranous cellular structure that bears the photosynthetic pigments in plants, algae, and cyanobacteria. In cyanobacteria thylakoids are of various shapes and are attached to, or continuous with, the plasma membrane. In eukaryotes they are flattened, membrane-bounded disk-like structures located in the chloroplasts; in the chloroplasts of higher plants the thylakoids form dense stacks called grana. Isolated thylakoid preparations can carry out photosynthetic electron transport and the associated phosphorylation.\" [GOC:ds, GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"9ae34c6a5bd64476bbe1748246b018ae","type":"GO_TERM","name":"thylakoid light-harvesting complex","canonical_id":"go:GO:0009503","description":"\"A thylakoid membrane complex of chlorophylls a and b together with chlorophyll a-b binding proteins. In addition, LHCs contain a number of other proteins, the function of which is speculative, together with accessory pigments. The LHCs capture and transfer energy to photosystems I and II. An example of this is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, ISBN:0198547684]","metadata":null},{"id":"d7b81a2271a044e8b57c1c9bce6cebb1","type":"GO_TERM","name":"thylakoid lumen","canonical_id":"go:GO:0031977","description":"\"The volume enclosed by a thylakoid membrane.\" [GOC:mah, GOC:pz]","metadata":null},{"id":"c50f16f705ff4679b399dd6cc2e66b30","type":"GO_TERM","name":"thylakoid membrane","canonical_id":"go:GO:0042651","description":"\"The pigmented membrane of any thylakoid.\" [GOC:jl, GOC:pr]","metadata":null},{"id":"7e819c97de8d4aae94030dc405f75631","type":"GO_TERM","name":"thylakoid membrane disassembly","canonical_id":"go:GO:0010547","description":"\"The controlled breakdown of the thylakoid membrane in the context of a normal process.\" [GOC:dph, GOC:tb, PMID:17416733]","metadata":null},{"id":"cd0e05eb5b1341d2aab4e198c7a92b4a","type":"GO_TERM","name":"thylakoid membrane organization","canonical_id":"go:GO:0010027","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the thylakoid membrane.\" [GOC:dph, GOC:jl, GOC:mah, GOC:tb]","metadata":null},{"id":"a63f1156d3964692ae8c1fed4485bef5","type":"GO_TERM","name":"thymic T cell selection","canonical_id":"go:GO:0045061","description":"\"The process of T cell selection that occurs in the thymus.\" [ISBN:0781735149, PMID:12414722]","metadata":null},{"id":"2d4b692b2c4c48c5b6f4abff59e91394","type":"GO_TERM","name":"thymic stromal lymphopoietin production","canonical_id":"go:GO:0071925","description":"\"The appearance of thymic stromal lymphopoietin (TSLP) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah, PMID:17129180]","metadata":null},{"id":"64f0a712d76e46eeae43dfea505ee9f7","type":"GO_TERM","name":"thymidine biosynthetic process","canonical_id":"go:GO:0046105","description":"\"The chemical reactions and pathways resulting in the formation of thymidine, deoxyribosylthymine thymine 2-deoxyriboside, a deoxynucleoside very widely distributed but occurring almost entirely as phosphoric esters in deoxynucleotides and deoxyribonucleic acid, DNA.\" [GOC:curators]","metadata":null},{"id":"0f20d3f5c5244385ba4084120f18dde0","type":"GO_TERM","name":"thymidine catabolic process","canonical_id":"go:GO:0006214","description":"\"The chemical reactions and pathways resulting in the breakdown of thymidine, deoxyribosylthymine thymine 2-deoxyriboside, a deoxynucleoside very widely distributed but occurring almost entirely as phosphoric esters in deoxynucleotides and deoxyribonucleic acid, DNA.\" [GOC:curators]","metadata":null},{"id":"3732fcd8a58940749f4acd867bf809bf","type":"GO_TERM","name":"thymidine kinase activity","canonical_id":"go:GO:0004797","description":"\"Catalysis of the reaction: ATP + thymidine = ADP + thymidine 5'-phosphate.\" [EC:2.7.1.21]","metadata":null},{"id":"957b5b78f58a42a39d199e6eac50b1ea","type":"GO_TERM","name":"thymidine metabolic process","canonical_id":"go:GO:0046104","description":"\"The chemical reactions and pathways involving thymidine, deoxyribosylthymine thymine 2-deoxyriboside, a deoxynucleoside very widely distributed but occurring almost entirely as phosphoric esters in deoxynucleotides and deoxyribonucleic acid, DNA.\" [GOC:curators]","metadata":null},{"id":"3452b34a648047ad838f62f91802189d","type":"GO_TERM","name":"thymidine phosphorylase activity","canonical_id":"go:GO:0009032","description":"\"Catalysis of the reaction: thymidine + phosphate = thymine + 2-deoxy-D-ribose 1-phosphate.\" [RHEA:16037]","metadata":null},{"id":"21818b5aefa64a969c54b7b5831b19d5","type":"GO_TERM","name":"thymidylate synthase (FAD) activity","canonical_id":"go:GO:0050797","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + dUMP + NADPH + H+ = dTMP + tetrahydrofolate + NADP+.\" [EC:2.1.1.148]","metadata":null},{"id":"9f9ddcd20a0841e48fe0f18cdbacf0fd","type":"GO_TERM","name":"thymidylate synthase activity","canonical_id":"go:GO:0004799","description":"\"Catalysis of the reaction: 5,10-methylenetetrahydrofolate + dUMP = 7,8-dihydrofolate + thymidylate.\" [EC:2.1.1.45, RHEA:12104]","metadata":null},{"id":"304a47b009ae49aa901d4724fe111387","type":"GO_TERM","name":"thymine binding","canonical_id":"go:GO:0002059","description":"\"Binding to thymine.\" [GOC:hjd]","metadata":null},{"id":"8a68aa79d0b54e22825b83710c61bc9d","type":"GO_TERM","name":"thymine biosynthetic process","canonical_id":"go:GO:0046106","description":"\"The chemical reactions and pathways resulting in the formation of thymine, 5-methyluracil, one of the two major pyrimidine bases present (as thymidine) in DNA but not found in RNA other than (as ribothymidine) in transfer RNA, where it is a minor base.\" [GOC:curators]","metadata":null},{"id":"eada3754d7b2415aaa538dca655e5994","type":"GO_TERM","name":"thymine catabolic process","canonical_id":"go:GO:0006210","description":"\"The chemical reactions and pathways resulting in the breakdown of thymine, 5-methyluracil, one of the two major pyrimidine bases present (as thymidine) in DNA but not found in RNA other than (as ribothymidine) in transfer RNA, where it is a minor base.\" [GOC:curators]","metadata":null},{"id":"2c1ec67d963b455a98f1bccc7a434bad","type":"GO_TERM","name":"thymine dehydrogenase activity","canonical_id":"go:GO:0052620","description":"\"Catalysis of the reaction: H2O + thymine + acceptor = 5-methyl-barbiturate + donor-H2.\" [RHEA:13469]","metadata":null},{"id":"a8fda6f62d4a4b08aa008ee81b0a72ec","type":"GO_TERM","name":"thymine dioxygenase activity","canonical_id":"go:GO:0050341","description":"\"Catalysis of the reaction: thymine + 2-oxoglutarate + O2 = 5-hydroxymethyluracil + succinate + CO2.\" [EC:1.14.11.6, MetaCyc:THYMINE-DIOXYGENASE-RXN]","metadata":null},{"id":"fa76eaee780444a38096925f3ea6455e","type":"GO_TERM","name":"thymine metabolic process","canonical_id":"go:GO:0019859","description":"\"The chemical reactions and pathways involving thymine, 5-methyluracil, one of the two major pyrimidine bases present (as thymidine) in DNA but not found in RNA other than (as ribothymidine) in transfer RNA, where it is a minor base.\" [GOC:curators]","metadata":null},{"id":"ec1a94f695a84091af76ffc87cf9702a","type":"GO_TERM","name":"thymine transport","canonical_id":"go:GO:0035364","description":"\"The directed movement of thymine, 5-methyluracil, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GO:sl]","metadata":null},{"id":"1fe07f965c444b28b4077830f4bcf150","type":"GO_TERM","name":"thymine/thymine mispair binding","canonical_id":"go:GO:0035487","description":"\"Binding to a double-stranded DNA region containing a T/T mispair.\" [GOC:bf, GOC:jh]","metadata":null},{"id":"539c7561b64d4093ac1aeff3795e1523","type":"GO_TERM","name":"thymocyte aggregation","canonical_id":"go:GO:0071594","description":"\"The adhesion of one thymocyte (an immature T cell) to one or more other thymocytes via adhesion molecules.\" [GOC:sl, PMID:1382990]","metadata":null},{"id":"21b619f019204232bb7c250457b6a80c","type":"GO_TERM","name":"thymocyte apoptotic process","canonical_id":"go:GO:0070242","description":"\"Any apoptotic process in a thymocyte, an immature T cell located in the thymus.\" [CL:0000893, GOC:add, GOC:mtg_apoptosis, ISBN:0781765196]","metadata":null},{"id":"63674e32a10b47319a83a527ab309eb5","type":"GO_TERM","name":"thymocyte migration","canonical_id":"go:GO:0072679","description":"\"The movement of a thymocyte through distinct intrathymic niches (e.g. medulla, cortex), where it receives a unique set of developmental cues required for T-cell development.\" [CL:0000893, GOC:BHF, GOC:mah]","metadata":null},{"id":"794cb335dd98466d8a021d6adbc5fb27","type":"GO_TERM","name":"thymus development","canonical_id":"go:GO:0048538","description":"\"The process whose specific outcome is the progression of the thymus over time, from its formation to the mature structure. The thymus is a symmetric bi-lobed organ involved primarily in the differentiation of immature to mature T cells, with unique vascular, nervous, epithelial, and lymphoid cell components.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"731808dd120e43939e862417293d5747","type":"GO_TERM","name":"thymus epithelium morphogenesis","canonical_id":"go:GO:0097536","description":"\"The process in which the thymus epithelium is generated and organized.\" [GOC:pr, PMID:22342843]","metadata":null},{"id":"00a58f1669bd4938b95c186797f19a6b","type":"DISEASE","name":"thyroid cancer","canonical_id":"mondo:0002108","description":null,"metadata":null},{"id":"030c8a80922a4463a2ae77e65db9aeb0","type":"DISEASE","name":"thyroid gland carcinoma","canonical_id":"mondo:0015075","description":null,"metadata":null},{"id":"dcb13961dda14b6fa62f60e988d42e2d","type":"GO_TERM","name":"thyroid gland development","canonical_id":"go:GO:0030878","description":"\"The process whose specific outcome is the progression of the thyroid gland over time, from its formation to the mature structure. The thyroid gland is an endoderm-derived gland that produces thyroid hormone.\" [GOC:dgh]","metadata":null},{"id":"a7cf7219692c47b6ac28ff0a471fe924","type":"DISEASE","name":"thyroid gland disorder","canonical_id":"mondo:0003240","description":null,"metadata":null},{"id":"59b4104ed0034effbde9d5f7d5cdae8a","type":"GO_TERM","name":"thyroid gland epithelial cell proliferation","canonical_id":"go:GO:1990789","description":"\"The multiplication or reproduction of thyroid gland epithelial cells, resulting in the expansion of the thyroid gland epithelial cell population.\" [PMID:17646383]","metadata":null},{"id":"db54642520234daeacfc6991a81d71a6","type":"GO_TERM","name":"thyroid hormone binding","canonical_id":"go:GO:0070324","description":"\"Binding to thyroxine (T4) or triiodothyronine (T3), tyrosine-based hormones produced by the thyroid gland.\" [GOC:rph]","metadata":null},{"id":"1f653bd37e24439c969d50881196313c","type":"GO_TERM","name":"thyroid hormone catabolic process","canonical_id":"go:GO:0042404","description":"\"The chemical reactions and pathways resulting in the breakdown of any of the compounds secreted by the thyroid gland, largely thyroxine and triiodothyronine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"97064dcbbd904efa94ff082a947650d9","type":"GO_TERM","name":"thyroid hormone generation","canonical_id":"go:GO:0006590","description":"\"The formation of either of the compounds secreted by the thyroid gland, mainly thyroxine and triiodothyronine. This is achieved by the iodination and joining of tyrosine molecules to form the precursor thyroglobin, proteolysis of this precursor gives rise to the thyroid hormones.\" [GOC:jl, ISBN:0716720094]","metadata":null},{"id":"48676d6faabd4cc3b23b613246bafbd9","type":"GO_TERM","name":"thyroid hormone metabolic process","canonical_id":"go:GO:0042403","description":"\"The chemical reactions and pathways involving any of the compounds secreted by the thyroid gland, largely thyroxine and triiodothyronine.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"65f0a2860d2d4804aa6c0b0f0cd60168","type":"GO_TERM","name":"thyroid hormone receptor signaling pathway","canonical_id":"go:GO:0002154","description":"\"A nuclear receptor-mediated signaling pathway initiated by a thyroid hormone  binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:hjd]","metadata":null},{"id":"5abe881d7a8249a991e3d9c3657bf469","type":"DISEASE","name":"thyroid hormone resistance syndrome","canonical_id":"mondo:0001328","description":null,"metadata":null},{"id":"398bdff8c2234ad4b5a3377986d62227","type":"DISEASE","name":"thyroid hormone resistance, generalized, autosomal dominant","canonical_id":"mondo:0008569","description":null,"metadata":null},{"id":"0aa8e077929a48b98022538ee35ca7ca","type":"DISEASE","name":"thyroid hormone resistance, generalized, autosomal recessive","canonical_id":"mondo:0010131","description":null,"metadata":null},{"id":"eff67a4e456f424894807586afaeb27c","type":"GO_TERM","name":"thyroid hormone transmembrane transporter activity","canonical_id":"go:GO:0015349","description":"\"Enables the transfer of thyroid hormones from one side of a membrane to the other. Thyroid hormone are any of the compounds secreted by the thyroid gland, largely thyroxine and triiodothyronine.\" [GOC:ai]","metadata":null},{"id":"f434e94579354b3996762954871a5b85","type":"GO_TERM","name":"thyroid hormone transport","canonical_id":"go:GO:0070327","description":"\"The directed movement of thyroid hormone into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:rph]","metadata":null},{"id":"1bb42cba735c49c4a96e52cd81c3742f","type":"DISEASE","name":"thyroid hypoplasia","canonical_id":"mondo:0019861","description":null,"metadata":null},{"id":"a300e9827d304cb9b18b244e39f8d5f8","type":"DISEASE","name":"thyroid tumor","canonical_id":"mondo:0015074","description":null,"metadata":null},{"id":"af4000d9921f4725954ad6c3406482f8","type":"GO_TERM","name":"thyroid-hormone:2-oxoglutarate transaminase activity","canonical_id":"go:GO:0033852","description":"\"Catalysis of the reaction: 3,3',5-triiodo-L-thyronine + 2-oxoglutarate = 3,5,3'-triiodothyropyruvate + L-glutamate.\" [RHEA:19133]","metadata":null},{"id":"fc658fb68da942ecb971c7d155dc235d","type":"GO_TERM","name":"thyroid-stimulating hormone receptor activity","canonical_id":"go:GO:0004996","description":"\"Combining with thyroid-stimulating hormone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"092744907ed646fd94be3aa1acd3e8db","type":"GO_TERM","name":"thyroid-stimulating hormone secretion","canonical_id":"go:GO:0070460","description":"\"The regulated release of thyroid-stimulating hormone, a peptide hormone that stimulates the activity of the thyroid gland, from secretory granules in the anterior pituitary.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"0468a2ab01ab4768b17603d2b344b3ae","type":"GO_TERM","name":"thyroid-stimulating hormone signaling pathway","canonical_id":"go:GO:0038194","description":"\"A G protein-coupled receptor signaling pathway initiated by thyroid-stimulating hormone (thyrotropin) binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:gap, PMID:10809230]","metadata":null},{"id":"57ccc9468ed04c63985b1fcbaa23e181","type":"GO_TERM","name":"thyroid-stimulating hormone-secreting cell development","canonical_id":"go:GO:0060130","description":"\"The process whose specific outcome is the progression of a thyroid-stimulating hormone-secreting cell over time, from its formation to the mature structure. A thyroid-stimulating hormone-secreting cell is a basophil cell of the anterior pituitary that produces thyroid stimulating hormone, thyrotrophin.\" [GOC:dph]","metadata":null},{"id":"adfa4a8d65424b42b5ea73b74c950a01","type":"GO_TERM","name":"thyroid-stimulating hormone-secreting cell differentiation","canonical_id":"go:GO:0060129","description":"\"The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a thyroid-stimulating hormone-secreting cell. A thyroid-stimulating hormone-secreting cell is a basophil cell of the anterior pituitary that produces thyroid-stimulating hormone, thyrotrophin.\" [GOC:dph]","metadata":null},{"id":"5bd3ac3167f64dd4a6f70308723084ad","type":"DISEASE","name":"thyrotoxicosis","canonical_id":"mondo:0010138","description":null,"metadata":null},{"id":"eb0f2eaa779c480297775ca9343b9c51","type":"DRUG","name":"thyrotropin alfa","canonical_id":"mesh:D057073","description":null,"metadata":null},{"id":"327a0855660347a7a87dd3d489f6bc69","type":"GO_TERM","name":"thyrotropin-releasing hormone activity","canonical_id":"go:GO:0008437","description":"\"The action characteristic of thyrotropin-releasing hormone (TRH), a hormone released by the mammalian hypothalamus into the hypophyseal-portal circulation in response to neural and/or chemical stimuli. Upon receptor binding, TRH increases the secretion of thyroid-stimulating hormone by the anterior pituitary.\" [ISBN:0198506732]","metadata":null},{"id":"30cb93cd08474751bb10ac828ef15952","type":"GO_TERM","name":"thyrotropin-releasing hormone binding","canonical_id":"go:GO:0051449","description":"\"Binding to thyrotropin-releasing hormone, a tripeptide hormone that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin by the anterior pituitary and it is produced by the hypothalamus and travels across the median eminence to the pituitary via the pituitary portal system.\" [GOC:ai]","metadata":null},{"id":"9617e5736bf445e3850b403511fb75a8","type":"GO_TERM","name":"thyrotropin-releasing hormone receptor activity","canonical_id":"go:GO:0004997","description":"\"Combining with thyrotropin-releasing hormone to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"9181675e228a45ac8fbfcb2378f283f4","type":"GO_TERM","name":"thyrotropin-releasing hormone receptor binding","canonical_id":"go:GO:0031531","description":"\"Binding to a receptor for thyrotropin-releasing hormone, a tripeptide hormone that is produced by the hypothalamus and stimulates the release of thyroid-stimulating hormone (TSH) and prolactin by the anterior pituitary.\" [PMID:8592728]","metadata":null},{"id":"f8ea250e7f224fe9a66915a2d1a914a8","type":"GO_TERM","name":"thyroxine 5'-deiodinase activity","canonical_id":"go:GO:0004800","description":"\"Catalysis of the reaction: 3,3',5-triiodo-L-thyronine + iodide + acceptor + H+ = L-thyroxine + acceptor-H2.\" [RHEA:19745]","metadata":null},{"id":"c61f51dbabcf4f49988a802e9cbf1b99","type":"GO_TERM","name":"thyroxine 5-deiodinase activity","canonical_id":"go:GO:0033798","description":"\"Catalysis of the reaction: 3,3',5'-triiodo-L-thyronine + iodide + acceptor + H+ = L-thyroxine + acceptor-H2.\" [RHEA:18897]","metadata":null},{"id":"d045df8880984f8f9b9473b81e3d02ad","type":"DRUG","name":"tiagabine","canonical_id":"gtopdb:4818","description":null,"metadata":null},{"id":"cb13c0992b054ddb87ec402d2cc9c75b","type":"DRUG","name":"tiagabine","canonical_id":"mesh:C059205","description":null,"metadata":null},{"id":"c00bf467904f44f9a77aaff53a84f7fc","type":"DRUG","name":"tiaprofenic acid","canonical_id":"mesh:C021270","description":null,"metadata":null},{"id":"9dfaf7630c1e4534a723917665b59bbe","type":"DRUG","name":"tibolone","canonical_id":"mesh:C027385","description":null,"metadata":null},{"id":"2146dbc6f6154a4baa693927fd0e2c68","type":"DISEASE","name":"tic disorder","canonical_id":"mondo:0002420","description":null,"metadata":null},{"id":"644015e3b5684752aaf00346ae0dad63","type":"DRUG","name":"ticagrelor","canonical_id":"gtopdb:1765","description":null,"metadata":null},{"id":"bce38e956e7642709371225909a04f3c","type":"DRUG","name":"ticagrelor","canonical_id":"chembl:CHEMBL398435","description":null,"metadata":null},{"id":"3dc446f8daeb434abe7aecedb1a605d9","type":"COMBINATION_TREATMENT","name":"ticagrelor + warfarin","canonical_id":"ctgov_combo:ctgov-combo-e0bf44aefd21410a","description":null,"metadata":null},{"id":"b53f22b793d64257ba7ba16af01e07d5","type":"DRUG","name":"ticarcillin","canonical_id":"mesh:D013982","description":null,"metadata":null},{"id":"4221e5423440428581a0e5169814aad2","type":"DRUG","name":"tienilic acid","canonical_id":"mesh:D013989","description":null,"metadata":null},{"id":"2f16946cba184a80894f5051efb40638","type":"GO_TERM","name":"tiggrin receptor activity","canonical_id":"go:GO:0005056","description":"\"Combining with the extracellular matrix ligand tiggrin, and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:mah, GOC:signaling, PMID:9521906]","metadata":null},{"id":"dc4d60a5ba1d4c159b9c4eb84250fc7c","type":"GO_TERM","name":"tight junction","canonical_id":"go:GO:0070160","description":"\"A cell-cell junction that seals cells together in an epithelium in a way that prevents even small molecules from leaking from one side of the sheet to the other.\" [ISBN:0815332181]","metadata":null},{"id":"0fbba8b39b854b669c43e07006043c47","type":"GO_TERM","name":"tight junction assembly","canonical_id":"go:GO:0120192","description":"\"A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a tight junction. A tight junction seals cells together in an epithelium in a way that prevents even small molecules from leaking from one side of the sheet to the other.\" [GOC:rl]","metadata":null},{"id":"3c68b11a57144af48064ec5542b08ee9","type":"GO_TERM","name":"tight junction disassembly","canonical_id":"go:GO:1905071","description":"\"The disaggregation of an tight junction into its constituent components.\" [GO_REF:0000079, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:18718461]","metadata":null},{"id":"d5095a00a21e4862ba5cf2560443b7cf","type":"GO_TERM","name":"tight junction organization","canonical_id":"go:GO:0120193","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a tight junction. A tight junction seals cells together in an epithelium in a way that prevents even small molecules from leaking from one side of the sheet to the other.\" [GOC:krc, GOC:rl]","metadata":null},{"id":"e4685e4c7b544fb4a93076992d39f294","type":"DRUG","name":"tildrakizumab","canonical_id":"gtopdb:8093","description":null,"metadata":null},{"id":"0180527c9f2b457fa2ea349668cd998b","type":"DRUG","name":"tildrakizumab","canonical_id":"chembl:CHEMBL2108681","description":null,"metadata":null},{"id":"e7cb75f4a8fb4815bc8931ed4d060bfa","type":"DRUG","name":"timolol","canonical_id":"gtopdb:565","description":null,"metadata":null},{"id":"7cad33f2b83249b3a1180e9cf2aaa994","type":"DRUG","name":"timolol","canonical_id":"chembl:CHEMBL499","description":null,"metadata":null},{"id":"de340adb751144e3aaab46f715a47576","type":"DRUG","name":"tinoridine","canonical_id":"mesh:C100290","description":null,"metadata":null},{"id":"4537785da0d44e0f8eb6612342976dc3","type":"DRUG","name":"tinzaparin","canonical_id":"gtopdb:6846","description":null,"metadata":null},{"id":"ea9ea59fdf9e4db099310671bf64e654","type":"DRUG","name":"tiotropium","canonical_id":"gtopdb:367","description":null,"metadata":null},{"id":"24d1b944d5a849058edb2827754b3515","type":"DRUG","name":"tiotropium bromide","canonical_id":"mesh:D000069447","description":null,"metadata":null},{"id":"1d19d26f32ae4c379a7a1d9652bf3768","type":"DRUG","name":"tipiracil","canonical_id":"mesh:C000613754","description":null,"metadata":null},{"id":"4cb7f788ee524eb39608c9d1293e0471","type":"DRUG","name":"tipranavir","canonical_id":"mesh:C107201","description":null,"metadata":null},{"id":"db55e2e9899d48eda269fe19687b342d","type":"DRUG","name":"tirabrutinib","canonical_id":"gtopdb:9265","description":null,"metadata":null},{"id":"361901c568ca4185a83951ec36689a8e","type":"DRUG","name":"tirabrutinib","canonical_id":"chembl:CHEMBL4071161","description":null,"metadata":null},{"id":"155381fac6ed4cb391f54406cd6c56b2","type":"DRUG","name":"tirofiban","canonical_id":"gtopdb:6586","description":null,"metadata":null},{"id":"148eaba577d94106afe6d03fda4f0ac3","type":"DRUG","name":"tislelizumab","canonical_id":"gtopdb:9592","description":null,"metadata":null},{"id":"c6409bb123b04b7490967956a4de330b","type":"DRUG","name":"tislelizumab","canonical_id":"chembl:CHEMBL4297840","description":null,"metadata":null},{"id":"1dabc518ba564b4c9a71f5280fabc8bc","type":"COMBINATION_TREATMENT","name":"tislelizumab + tucidinostat","canonical_id":"ctgov_combo:ctgov-combo-b16f3d2bdba375ae","description":null,"metadata":null},{"id":"e6bef6569cb9435b80f4168e74d2d6a2","type":"DRUG","name":"tisotumab vedotin","canonical_id":"gtopdb:11719","description":null,"metadata":null},{"id":"d51f2b3d5d324eca89b36bb10767b3ad","type":"DRUG","name":"tisotumab vedotin","canonical_id":"chembl:CHEMBL4297841","description":null,"metadata":null},{"id":"097bb718078a441db0920267e8c2126a","type":"GO_TERM","name":"tissue development","canonical_id":"go:GO:0009888","description":"\"The process whose specific outcome is the progression of a tissue over time, from its formation to the mature structure.\" [ISBN:0471245208]","metadata":null},{"id":"02c98639205a4afe9cc95973f85002f5","type":"GO_TERM","name":"tissue homeostasis","canonical_id":"go:GO:0001894","description":"\"A homeostatic process involved in the maintenance of an internal steady state within a defined tissue of an organism, including control of cellular proliferation and death and control of metabolic function.\" [GOC:add, GOC:isa_complete]","metadata":null},{"id":"b5002134b55644e2badc8662efffa837","type":"GO_TERM","name":"tissue kallikrein-kinin cascade","canonical_id":"go:GO:0002255","description":"\"A series of reactions that takes place outside the cell initiated by the action of tissue (glandular) kallikreins on low molecular weight kininogen in response to tissue damage. Tissue kallikreins are present in glandular tissues and their fluids, such as the salivary glands, sweat glands, pancreas, and kidney. The ultimate products of the tissue kallikrein-kinin cascade include kallidin and bradykinin, agents known to induce smooth muscle contraction, vasoconstriction, and increased vascular permeability.\" [GOC:add, PMID:11842287, PMID:14501145]","metadata":null},{"id":"89542ea8823f430b99e86aae4a8432d8","type":"GO_TERM","name":"tissue migration","canonical_id":"go:GO:0090130","description":"\"The process in which the population of cells that make up a tissue undergo directed movement.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"119c966142f541dcb4e5eeebe8f3247f","type":"GO_TERM","name":"tissue morphogenesis","canonical_id":"go:GO:0048729","description":"\"The process in which the anatomical structures of a tissue are generated and organized.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"a0bf339223864a999771235469e6678f","type":"GO_TERM","name":"tissue regeneration","canonical_id":"go:GO:0042246","description":"\"The regrowth of lost or destroyed tissues.\" [GOC:curators]","metadata":null},{"id":"580f0794df6746deb6c6572019da6c4f","type":"GO_TERM","name":"tissue remodeling","canonical_id":"go:GO:0048771","description":"\"The reorganization or renovation of existing tissues. This process can either change the characteristics of a tissue such as in blood vessel remodeling, or result in the dynamic equilibrium of a tissue such as in bone remodeling.\" [GOC:ebc]","metadata":null},{"id":"bda424562a174707b34d3a85dd986204","type":"GO_TERM","name":"titin Z domain binding","canonical_id":"go:GO:0070080","description":"\"Binding to a titin Z protein domain, which recognizes and binds to the C-terminal calmodulin-like domain of alpha-actinin-2 (Act-EF34), adopts a helical structure, and binds in a groove formed by the two planes between the helix pairs of Act-EF34.\" [GOC:mah, InterPro:IPR015129]","metadata":null},{"id":"b137fca1cc524e58878807820cfc93d5","type":"GO_TERM","name":"titin binding","canonical_id":"go:GO:0031432","description":"\"Binding to titin, any of a family of giant proteins found in striated and smooth muscle. In striated muscle, single titin molecules span half the sarcomere, with their N- and C-termini in the Z-disc and M-line, respectively.\" [GOC:mah, PMID:10481174]","metadata":null},{"id":"130f2c9330264edc9b776931efbed833","type":"GO_TERM","name":"titin-telethonin complex","canonical_id":"go:GO:1990733","description":"\"A protein complex formed between the N-terminus of the giant sarcomeric filament protein titin and the Z-disk ligand, telethonin. The complex is part of the Z-disk of the skeletal and cardiac sarcomere. Telethonin binding to titin might be essential for the initial assembly, stabilization and functional integrity of the titin filament, and hence important for muscle contraction relaxation in mature myofibrils.\" [GOC:ame, PMID:16407954]","metadata":null},{"id":"871dafe06df9416ca7add34480bcca89","type":"DRUG","name":"tivozanib","canonical_id":"gtopdb:6058","description":null,"metadata":null},{"id":"700e94bab0e04c10898a0f299c5f3e88","type":"DRUG","name":"tivozanib","canonical_id":"chembl:CHEMBL1289494","description":null,"metadata":null},{"id":"1875d3ba3aca4b16a37d5e839530cc57","type":"DRUG","name":"tizanidine","canonical_id":"mesh:C023754","description":null,"metadata":null},{"id":"360dc497749a4ba6822811d0770d1dac","type":"TRIAL","name":"to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers","canonical_id":"clinicaltrials.gov:NCT01134965","description":"Healthy","metadata":null},{"id":"295bda10e2b54dd8aa4e991f19306bab","type":"DRUG","name":"tobramycin","canonical_id":"mesh:D014031","description":null,"metadata":null},{"id":"ed3760bb34034ba0a6d0bbbf1e953b01","type":"GO_TERM","name":"tobramycin biosynthetic process","canonical_id":"go:GO:1901121","description":"\"The chemical reactions and pathways resulting in the formation of tobramycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00971]","metadata":null},{"id":"90401831dc0a457f8c671ab4a9146461","type":"GO_TERM","name":"tobramycin catabolic process","canonical_id":"go:GO:1901120","description":"\"The chemical reactions and pathways resulting in the breakdown of tobramycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00971]","metadata":null},{"id":"f36307aebcac45c0813f727c149d62d4","type":"DRUG","name":"tocilizumab","canonical_id":"gtopdb:6881","description":null,"metadata":null},{"id":"ffae5ee79c9349ca83078a59c8ca92fb","type":"DRUG","name":"tocilizumab","canonical_id":"chembl:CHEMBL1237022","description":null,"metadata":null},{"id":"290c0423cc0b431d9c1c8a1a81171f4b","type":"GO_TERM","name":"tocopherol C-methyltransferase activity","canonical_id":"go:GO:0050342","description":"\"Catalysis of the reaction: gamma-tocopherol + S-adenosyl-L-methionine = (+)-alpha-tocopherol + H+ + S-adenosyl-L-homocysteine. This reaction can also use delta-tocopherol, gamma-tocotrienol and delta-tocotrienol as substrates.\" [EC:2.1.1.95]","metadata":null},{"id":"7c9b929c6feb41a5be205d88c3407fbd","type":"GO_TERM","name":"tocopherol cyclase activity","canonical_id":"go:GO:0009976","description":"\"Catalysis of the reactions: delta-tocopherol = 2-methyl-6-phytyl-1,4-benzene-1,4-diol, gamma-tocopherol = 2,3-dimethyl-6-phytylbenzene-1,4-diol. delta-tocotrienol = 6-geranylgeranyl-2-methylbenzene-1,4-diol gamma-tocotrienol, and = 6-geranylgeranyl-2,3-dimethylbenzene-1,4-diol.\" [EC:5.5.1.24, PMID:12213958]","metadata":null},{"id":"4c52eaf573b94450aa58717755d6df37","type":"DRUG","name":"tofacitinib","canonical_id":"gtopdb:5677","description":null,"metadata":null},{"id":"e48d8f7988834d29bec8f194f93d6996","type":"COMBINATION_TREATMENT","name":"tofacitinib + upadacitinib","canonical_id":"ctgov_combo:ctgov-combo-2822eec9e0590eca","description":null,"metadata":null},{"id":"6454f1ff531c4adea5686b68fa2364bc","type":"COMBINATION_TREATMENT","name":"tofacitinib + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-4133830d422f11cd","description":null,"metadata":null},{"id":"9426a388466240bd9c7921b03215d0a2","type":"COMBINATION_TREATMENT","name":"tofacitinib + ustekinumab + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-76a2128db2c33a4a","description":null,"metadata":null},{"id":"b9f04b5cc6114092af2711a972d194ef","type":"DRUG","name":"tofogliflozin","canonical_id":"gtopdb:9395","description":null,"metadata":null},{"id":"7fec08a1a7b147d3929ec318679b696d","type":"DRUG","name":"tofogliflozin","canonical_id":"chembl:CHEMBL2105711","description":null,"metadata":null},{"id":"ae5ed23c184f44369a3748c20fe2db92","type":"DRUG","name":"tolazamide","canonical_id":"mesh:D014042","description":null,"metadata":null},{"id":"56ed82552f5247ebbfab480399a8d36a","type":"DRUG","name":"tolazoline","canonical_id":"gtopdb:7310","description":null,"metadata":null},{"id":"4840aee809d94729a707551efbb62b64","type":"DRUG","name":"tolazoline","canonical_id":"mesh:D014043","description":null,"metadata":null},{"id":"616eea6603a04ae68ed104f4a996aa81","type":"DRUG","name":"tolbutamide","canonical_id":"gtopdb:6848","description":null,"metadata":null},{"id":"a13fe07dc9614be9a78134c43cde2c7e","type":"DRUG","name":"tolbutamide","canonical_id":"chembl:CHEMBL782","description":null,"metadata":null},{"id":"2adaefd408624160b294d4c37bfa79c7","type":"DRUG","name":"tolcapone","canonical_id":"gtopdb:6646","description":null,"metadata":null},{"id":"bbf98481b25f45b6ad246d8de45e2211","type":"DRUG","name":"tolcapone","canonical_id":"chembl:CHEMBL1324","description":null,"metadata":null},{"id":"4b0f2e2aa7fa42faa4cafe3a1ee3fa3f","type":"GO_TERM","name":"tolerance induction","canonical_id":"go:GO:0002507","description":"\"A process that directly activates any of the steps required for tolerance, a physiologic state in which the immune system does not react destructively against the components of an organism that harbors it or against antigens that are introduced to it.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"c0c4b54e792c437aa79c5cbeea06b159","type":"GO_TERM","name":"tolerance induction dependent upon immune response","canonical_id":"go:GO:0002461","description":"\"Tolerance induction dependent upon an immune response, typically a response by a mature T or B cell in the periphery resulting tolerance towards an antigen via induction of anergy, cellular deletion, or regulatory T cell activation.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"997440698dce477b9752fc692383120e","type":"GO_TERM","name":"tolerance induction in Peyer's patch","canonical_id":"go:GO:0002389","description":"\"Tolerance induction taking place in the Peyer's patches.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"f7602af4f5f64456a76b7f4097ced653","type":"GO_TERM","name":"tolerance induction in gut-associated lymphoid tissue","canonical_id":"go:GO:0002394","description":"\"Tolerance induction taking place in the gut-associated lymphoid tissue (GALT).\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"84223d00f2cd475092b9f65bec40a7a8","type":"GO_TERM","name":"tolerance induction in mucosal-associated lymphoid tissue","canonical_id":"go:GO:0002401","description":"\"Tolerance induction taking place in the mucosal-associated lymphoid tissue (MALT).\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"b390e98e977f47699dd732a4937558c8","type":"GO_TERM","name":"tolerance induction in nasopharyngeal-associated lymphoid tissue","canonical_id":"go:GO:0002400","description":"\"Tolerance induction taking place in the nasopharyngeal-associated lymphoid tissue (NALT).\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"7a8c9ae8d170425daa8e9d8b4f873798","type":"GO_TERM","name":"tolerance induction in urogenital tract","canonical_id":"go:GO:0002425","description":"\"Tolerance induction taking place in the urogenital tract.\" [GOC:jal]","metadata":null},{"id":"483680c22dee4d2cb28e1df8ad92006a","type":"GO_TERM","name":"tolerance induction to lipopolysaccharide","canonical_id":"go:GO:0072573","description":"\"Tolerance induction directed at lipopolysaccharide antigens.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"be5c60c2e8c440829958a9318db63b69","type":"GO_TERM","name":"tolerance induction to nonself antigen","canonical_id":"go:GO:0002462","description":"\"Tolerance induction in response to nonself antigens.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"295d38630e2349cb92d7fb74e543305c","type":"GO_TERM","name":"tolerance induction to self antigen","canonical_id":"go:GO:0002513","description":"\"Tolerance induction directed at self antigens.\" [GO_REF:0000022, GOC:jal, ISBN:0781735149]","metadata":null},{"id":"7eabad36145e4382b7605d25c63fec61","type":"GO_TERM","name":"tolerance induction to tumor cell","canonical_id":"go:GO:0002413","description":"\"A process of tolerance induction which leads to immunological tolerance of a tumor.\" [GOC:add]","metadata":null},{"id":"421b00cd7f0140008f45dee514cad0aa","type":"GO_TERM","name":"toll-like receptor 1 signaling pathway","canonical_id":"go:GO:0034130","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 1.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"9283f166e6ab44dd8ddf04e1ed9e5bae","type":"GO_TERM","name":"toll-like receptor 10 signaling pathway","canonical_id":"go:GO:0034166","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 10.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"d27a444658634738abd7d09fb1d2824d","type":"GO_TERM","name":"toll-like receptor 11 signaling pathway","canonical_id":"go:GO:0034170","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 11.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"ea7eeddd7b3f4a6cb8efb0e1f3efdaff","type":"GO_TERM","name":"toll-like receptor 12 signaling pathway","canonical_id":"go:GO:0034174","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 12.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"37714cd58f1c4b2f8534d8ac1835e1f7","type":"GO_TERM","name":"toll-like receptor 13 signaling pathway","canonical_id":"go:GO:0034178","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 13.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"d8152d1de5614fb695f685477ea62526","type":"GO_TERM","name":"toll-like receptor 15 signaling pathway","canonical_id":"go:GO:0035681","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 15.\" [GOC:pde]","metadata":null},{"id":"05aa767148bf4015a2f9f03dd7b08158","type":"GO_TERM","name":"toll-like receptor 2 signaling pathway","canonical_id":"go:GO:0034134","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 2.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"643e0e3805c44bec981ff7f0eab51fbd","type":"GO_TERM","name":"toll-like receptor 21 signaling pathway","canonical_id":"go:GO:0035682","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 21.\" [GOC:pde]","metadata":null},{"id":"93a2de6bb6d74e7ca9dcbd69e4630f07","type":"GO_TERM","name":"toll-like receptor 3 signaling pathway","canonical_id":"go:GO:0034138","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 3.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"70c63b3d3b4f48bc90265d81f317936e","type":"GO_TERM","name":"toll-like receptor 4 signaling pathway","canonical_id":"go:GO:0034142","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 4.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"e91514f34da9460fa742087b94ef520d","type":"GO_TERM","name":"toll-like receptor 5 signaling pathway","canonical_id":"go:GO:0034146","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 5.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"baa2ee48083140fcaef10d50c611f8df","type":"GO_TERM","name":"toll-like receptor 6 signaling pathway","canonical_id":"go:GO:0034150","description":"\"The series of molecular signals initiated by a ligand binding to toll-like receptor 6.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"562345a98caa405fb8feab75a37bbdb7","type":"GO_TERM","name":"toll-like receptor 7 signaling pathway","canonical_id":"go:GO:0034154","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 7.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"18de24f4273d404c8e2c0904ed09cf8c","type":"GO_TERM","name":"toll-like receptor 8 signaling pathway","canonical_id":"go:GO:0034158","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 8.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"207f5d2cc91849619aff2c2f77ec80dd","type":"GO_TERM","name":"toll-like receptor 9 signaling pathway","canonical_id":"go:GO:0034162","description":"\"The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 9.\" [GOC:add, PMID:16551253, PMID:17328678]","metadata":null},{"id":"4b2601423fe74e079eb4a1fb5c7195bc","type":"GO_TERM","name":"toll-like receptor TLR1:TLR2 signaling pathway","canonical_id":"go:GO:0038123","description":"\"The series of molecular signals initiated by a ligand binding of a heterodimeric TLR1:TLR2 complex, followed by transmission of the signal by the activated receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:17318230]","metadata":null},{"id":"a625c95cf74f4fada2dbd34cefbcca8c","type":"GO_TERM","name":"toll-like receptor TLR6:TLR2 signaling pathway","canonical_id":"go:GO:0038124","description":"\"The series of molecular signals initiated by a ligand binding of a heterodimeric TLR6:TLR2 complex, followed by transmission of the signal by the activated receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:nhn, GOC:signaling, PMID:17318230]","metadata":null},{"id":"2d815d3293444e368efc933e661a07ef","type":"GO_TERM","name":"toll-like receptor signaling pathway","canonical_id":"go:GO:0002224","description":"\"The series of molecular signals initiated by a ligand binding to a toll-like receptor of a target cell. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate an innate immune response.\" [GO_REF:0000022, GOC:add, ISBN:0781735149, PMID:12467241, PMID:12524386, PMID:12855817, PMID:15585605, PMID:15728447]","metadata":null},{"id":"cd98fba626c44742a0b1b915aeb6d55e","type":"DRUG","name":"tolrestat","canonical_id":"gtopdb:7404","description":null,"metadata":null},{"id":"9d325423fdf94bc4b5d3d4a64d51758e","type":"DRUG","name":"tolrestat","canonical_id":"chembl:CHEMBL436","description":null,"metadata":null},{"id":"6c603852933f4d5ea84b85435affb728","type":"GO_TERM","name":"toluene 2-monooxygenase activity","canonical_id":"go:GO:0018644","description":"\"Catalysis of the reaction: toluene + H+ + NADH + O2 = 2-hydroxytoluene + H2O + NAD+.\" [RHEA:20349]","metadata":null},{"id":"a3dfbbcc72f442c9ad2bee5ee834d042","type":"GO_TERM","name":"toluene 4-monooxygenase activity","canonical_id":"go:GO:0018638","description":"\"Catalysis of the reaction: toluene + H+ + NADH + O2 = 4-methylphenol + H2O + NAD+.\" [PMID:15240250, PMID:36593585, RHEA:41380]","metadata":null},{"id":"c5430672112b45e78b607a1ba402971c","type":"GO_TERM","name":"toluene biosynthetic process","canonical_id":"go:GO:0046252","description":"\"The chemical reactions and pathways resulting in the formation of toluene, a volatile monoaromatic hydrocarbon found in crude petroleum and petroleum products.\" [GOC:ai, PMID:6508079]","metadata":null},{"id":"3dcac5c537d14926bbc401ad7a915653","type":"GO_TERM","name":"toluene catabolic process","canonical_id":"go:GO:0042203","description":"\"The chemical reactions and pathways resulting in the breakdown of toluene, a volatile monoaromatic hydrocarbon found in crude petroleum and petroleum products.\" [UM-BBD_pathwayID:tol]","metadata":null},{"id":"c61797c6e9774a11b39f829997a4635f","type":"GO_TERM","name":"toluene dioxygenase activity","canonical_id":"go:GO:0018624","description":"\"Catalysis of the reaction: toluene + NADH + O2 + H+ = (1S,2R)-3-methylcyclohexa-3,5-diene-1,2-diol + NAD+.\" [RHEA:16737]","metadata":null},{"id":"e4e51332ba7843b8a74533bc05b9b16d","type":"GO_TERM","name":"toluene-4-sulfonate catabolic process","canonical_id":"go:GO:0046269","description":"\"The chemical reactions and pathways resulting in the breakdown of toluene-4-sulfonate, 4-methylbenzenesulfonate, the anion of sulfonic acid attached to a methylbenzene molecule.\" [GOC:ai]","metadata":null},{"id":"8e06d0c2d6414e55b01e100c3f9eda20","type":"GO_TERM","name":"toluene-containing compound catabolic process","canonical_id":"go:GO:0072491","description":"\"The chemical reactions and pathways resulting in the breakdown of toluene, methylbenzene (formula C7H8), or any of its derivatives.\" [GOC:mah]","metadata":null},{"id":"a17551ce50ef41f3a5106692d7f9da7c","type":"GO_TERM","name":"toluene-sulfonate methyl-monooxygenase activity","canonical_id":"go:GO:0018652","description":"\"Catalysis of the reaction: toluene-4-sulfonate + NADH + O2 = NAD+ + OH- + 4-sulfobenzyl alcohol.\" [RHEA:51024]","metadata":null},{"id":"6bfb139f738c4ef1b6160546399b351a","type":"DRUG","name":"tolvaptan","canonical_id":"gtopdb:2226","description":null,"metadata":null},{"id":"5ae8d2552daa43f1ad76468e870bcf84","type":"DRUG","name":"tolvaptan","canonical_id":"mesh:C116664","description":null,"metadata":null},{"id":"415ed67a6a9c44648a3e38a1534b54ea","type":"DRUG","name":"tolvaptan","canonical_id":"chembl:CHEMBL344159","description":null,"metadata":null},{"id":"efcb9823ae72429fa51b62b67ee8c770","type":"GO_TERM","name":"tongue development","canonical_id":"go:GO:0043586","description":"\"The process whose specific outcome is the progression of the tongue over time, from its formation to the mature structure. The tongue is the movable, muscular organ on the floor of the mouth of most vertebrates, in many other mammals is the principal organ of taste, aids in the prehension of food, in swallowing, and in modifying the voice as in speech.\" [GOC:jl, UBERON:0001723]","metadata":null},{"id":"31096a341ad549638f4584ac9f222cca","type":"GO_TERM","name":"tongue morphogenesis","canonical_id":"go:GO:0043587","description":"\"The process in which the anatomical structures of the tongue are generated and organized. The tongue is the movable, muscular organ on the floor of the mouth of most vertebrates, in man other mammals is the principal organ of taste, aids in the prehension of food, in swallowing, and in modifying the voice as in speech.\" [GOC:jl, UBERON:0001723]","metadata":null},{"id":"6a0e8334169a417db24b84f0fae587dc","type":"GO_TERM","name":"tongue muscle cell differentiation","canonical_id":"go:GO:0035981","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a tongue muscle cell.\" [CL:0002673, GOC:yaf, PMID:3393851]","metadata":null},{"id":"0607d4a24d2942928bd8b5de7f226a67","type":"GO_TERM","name":"tonic skeletal muscle contraction","canonical_id":"go:GO:0014720","description":"\"A process in which force is generated within tonic skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The tonic skeletal muscle is characterized by long lasting contractile responses and high resistance to fatigue.\" [GOC:mtg_muscle]","metadata":null},{"id":"d8161531b27843f7a21776b35e6c8bcf","type":"GO_TERM","name":"tonic smooth muscle contraction","canonical_id":"go:GO:0014820","description":"\"A process in which force is generated within tonic smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. In the tonic smooth muscle, the muscle contraction occurs without an ordered sarcomeric structure. Tonic smooth muscle contraction occurs as a sustained continuous contraction.\" [GOC:mtg_muscle]","metadata":null},{"id":"e98e0147e6ba480aa991945f2381ec66","type":"GO_TERM","name":"tooth eruption","canonical_id":"go:GO:0044691","description":"\"The tooth development process in which the teeth enter the mouth and become visible.\" [Wikipedia:Tooth_eruption]","metadata":null},{"id":"8c70b1ed4c2640979f18f1b7f5812299","type":"GO_TERM","name":"tooth mineralization","canonical_id":"go:GO:0034505","description":"\"The process in which calcium salts are deposited into calcareous tooth structures such as dental enamel, dentin and cementum.\" [GOC:mah, MP:0002817, MSH:D014074]","metadata":null},{"id":"2918cf44ab6940cfa1fccdf54ca9db84","type":"GO_TERM","name":"tooth placode formation","canonical_id":"go:GO:0060790","description":"\"The developmental process in which the tooth placode forms. A tooth placode is a thickening of the ectoderm that will give rise to the tooth bud.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"8305cb35c8c44539bdf93c0cf30180bf","type":"GO_TERM","name":"tooth replacement","canonical_id":"go:GO:0061648","description":"\"The process whose specific outcome is the replacement of an existing tooth with another tooth.\" [GOC:dph, PMID:15170864]","metadata":null},{"id":"e6af8b187d1e46bf87e3de29bdc2eaf5","type":"DISEASE","name":"toothache","canonical_id":"efo:0010072","description":null,"metadata":null},{"id":"cf83a504266246548504b58fa7910b05","type":"DRUG","name":"topiramate","canonical_id":"mesh:D000077236","description":null,"metadata":null},{"id":"a71e7a384a474274b733dfaeb1852a85","type":"PROTEIN","name":"topoisomerases II, IV","canonical_id":"uniprot:P43702","description":null,"metadata":null},{"id":"a000ad655b8048c59b6710e09e9d689e","type":"DRUG","name":"topotecan","canonical_id":"mesh:D019772","description":null,"metadata":null},{"id":"d02d0c24362e422e9e3da89c7524bede","type":"DRUG","name":"torsemide","canonical_id":"mesh:C026116","description":null,"metadata":null},{"id":"bc6beccef163461b95f88d6579784133","type":"GO_TERM","name":"torso binding","canonical_id":"go:GO:0005122","description":"\"Binding to a torso (tor) protein, a receptor tyrosine kinase.\" [GOC:ceb, PMID:2927509]","metadata":null},{"id":"be1d0fbe54e044149064affd3158d898","type":"GO_TERM","name":"torso signaling pathway","canonical_id":"go:GO:0008293","description":"\"The series of molecular signals initiated by an extracellular ligand binding to torso (a receptor tyrosine kinase) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:curators, PMID:8343949]","metadata":null},{"id":"2ec8687cd61448348e648d24404d27e0","type":"DRUG","name":"tositumomab","canonical_id":"gtopdb:6781","description":null,"metadata":null},{"id":"d4928a93db33413fb55010319c2a8604","type":"DRUG","name":"tositumomab","canonical_id":"chembl:CHEMBL1201604","description":null,"metadata":null},{"id":"b3c5064d71844de7a1b7f2d1abeda4df","type":"GO_TERM","name":"toxic metabolite repair","canonical_id":"go:GO:0110052","description":"\"A cellular process that, through single- or multi-step enzymatic reactions, repairs toxic endogenous compounds, formed as by-products of primary metabolism, by converting them into useful metabolites.\" [GOC:ka, GOC:vw, PMID:23334546]","metadata":null},{"id":"342af6e865444bf6b5b6dbaf3c661cf2","type":"GO_TERM","name":"toxic substance binding","canonical_id":"go:GO:0015643","description":"\"Binding to a toxic substance, a poisonous substance that causes damage to biological systems.\" [GOC:bf, GOC:curators, GOC:jl, GOC:pr]","metadata":null},{"id":"754e57d1644a4befbf2fa70834205029","type":"GO_TERM","name":"toxin activity","canonical_id":"go:GO:0090729","description":"\"Interacting selectively with one or more biological molecules in another (target) organism, initiating pathogenesis (leading to an abnormal, generally detrimental state) in the target organism. The activity should refer to an evolved function of the active gene product, i.e. one that was selected for. Examples include the activity of botulinum toxin, and snake venom.\" [GOC:pt]","metadata":null},{"id":"b773c2a106df4f5b9d1d06066342fc65","type":"GO_TERM","name":"toxin biosynthetic process","canonical_id":"go:GO:0009403","description":"\"The chemical reactions and pathways resulting in the formation of toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.\" [GOC:curators]","metadata":null},{"id":"dc68dcda04df4f6e8b3f803c8b21332e","type":"GO_TERM","name":"toxin catabolic process","canonical_id":"go:GO:0009407","description":"\"The chemical reactions and pathways resulting in the breakdown of toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.\" [GOC:curators]","metadata":null},{"id":"3427dc3cc1b048928282b088415a1e04","type":"GO_TERM","name":"toxin export channel activity","canonical_id":"go:GO:0000269","description":"\"Enables the energy independent passage of toxins, sized less than 1000 Da, across a membrane towards the outside of the cell. The transmembrane portions of porins consist exclusively of beta-strands which form a beta-barrel. They are found in the outer membranes of Gram-negative bacteria, mitochondria, plastids and possibly acid-fast Gram-positive bacteria.\" [GOC:mtg_transport]","metadata":null},{"id":"f25277d745274dd381ed8855a6be4d93","type":"GO_TERM","name":"toxin metabolic process","canonical_id":"go:GO:0009404","description":"\"The chemical reactions and pathways involving a toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.\" [GOC:cab2]","metadata":null},{"id":"48b1c34cf9b7403d8801e4588431a46f","type":"GO_TERM","name":"toxin sequestering activity","canonical_id":"go:GO:0097351","description":"\"Binding to a toxin to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [GOC:rs, PMID:19143615, PMID:19325885, PMID:21819231, PMID:22545240, PMID:24806488, Wikipedia:Toxin-antitoxin_system#Type_II]","metadata":null},{"id":"9579e60ed05542eb8472082522a7bd3a","type":"GO_TERM","name":"toxin transmembrane transporter activity","canonical_id":"go:GO:0019534","description":"\"Enables the transfer of a toxin from one side of a membrane to the other. A toxin is a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.\" [ISBN:0198506732]","metadata":null},{"id":"a7cda08506134c44ad2e560a750340da","type":"GO_TERM","name":"toxin-antitoxin complex","canonical_id":"go:GO:0110001","description":"\"A bacterial protein complex that neutralises its own toxin by complexing the toxin with the antitoxin. The antitoxin can be either a protein or an RNA. The neutralising toxin-antitoxin complex also acts as a transcriptional repressor of the toxin-antitoxin operon.\" [GOC:bhm, PMID:16109374, PMID:25093388]","metadata":null},{"id":"18af8e1aac934e16ae9f184bbde405bc","type":"GO_TERM","name":"trabecula formation","canonical_id":"go:GO:0060343","description":"\"The process of creating a trabecula in an organ. A trabecula is a small, often microscopic, tissue element in the form of a small beam, strut or rod, which generally has a mechanical function. Trabecula are usually but not necessarily, composed of dense collagenous tissue.\" [GOC:dph]","metadata":null},{"id":"bab07f645fb648088aaad77e86483c78","type":"GO_TERM","name":"trabecula morphogenesis","canonical_id":"go:GO:0061383","description":"\"The process of shaping a trabecula in an organ. A trabecula is a small, often microscopic, tissue element in the form of a small beam, strut or rod, which generally has a mechanical function. Trabecula are usually but not necessarily, composed of dense collagenous tissue.\" [GOC:dph]","metadata":null},{"id":"9942ed49222343f0890e0b3ed2cb9be0","type":"GO_TERM","name":"trabecular meshwork development","canonical_id":"go:GO:0002930","description":"\"The progression of the trabecular meshwork over time, from its formation to the mature structure. The trabecular meshwork is a fenestrated endothelial-like tissue situated at the intersection of the cornea and the iris. The trabecular meshwork provides drainage for the aqueous humor.\" [PMID:20568247]","metadata":null},{"id":"b6b9398f52dd4726bc10954d32f1b8f0","type":"GO_TERM","name":"trace-amine receptor activity","canonical_id":"go:GO:0001594","description":"\"Combining with a trace amine to initiate a change in cell activity. Trace amines are biogenic amines that are synthesized from aromatic amino acids and are substrates for monoamine oxidase, and are therefore detectable only at trace levels in mammals.\" [GOC:mah, PMID:19325074]","metadata":null},{"id":"1e73818ce1444453a29b9846f8e4a02c","type":"GO_TERM","name":"trachea cartilage development","canonical_id":"go:GO:0060534","description":"\"The process whose specific outcome is the progression of the tracheal cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.\" [GOC:dph]","metadata":null},{"id":"8f7cccbd55024e4d83c308283446c3ee","type":"GO_TERM","name":"trachea cartilage morphogenesis","canonical_id":"go:GO:0060535","description":"\"The process in which the anatomical structures of cartilage in the trachea are generated and organized.\" [GOC:dph]","metadata":null},{"id":"b440ee84ea224ec8b181fd9020ed9e79","type":"GO_TERM","name":"trachea development","canonical_id":"go:GO:0060438","description":"\"The process whose specific outcome is the progression of a trachea over time, from its formation to the mature structure. The trachea is the portion of the airway that attaches to the bronchi as it branches.\" [GOC:dph]","metadata":null},{"id":"c951096013e44c46bd4b8874b04d61cd","type":"GO_TERM","name":"trachea formation","canonical_id":"go:GO:0060440","description":"\"The process pertaining to the initial formation of a trachea from unspecified parts. The process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the trachea is recognizable. The trachea is the portion of the airway that attaches to the bronchi as it branches.\" [GOC:dph]","metadata":null},{"id":"bbd8acbd60fd4fe3b42ae92cd73bf489","type":"GO_TERM","name":"trachea gland development","canonical_id":"go:GO:0061153","description":"\"The progression of a trachea gland over time, from its formation to the mature structure. Trachea glands are found under the mucus of the trachea and secrete mucus, and agents that help protect the lung from injury and infection.\" [GOC:dph]","metadata":null},{"id":"e835a170e6c54dcc973824bebf06ad75","type":"GO_TERM","name":"trachea morphogenesis","canonical_id":"go:GO:0060439","description":"\"The process in which a trachea is generated and organized. The trachea is the portion of the airway that attaches to the bronchi as it branches.\" [GOC:dph]","metadata":null},{"id":"b22abea1744446ecb166d8830299e465","type":"GO_TERM","name":"trachea submucosa development","canonical_id":"go:GO:0061152","description":"\"The progression of the trachea submucosa over time from its formation to the mature structure. The trachea submucosa is made up of the glands and elastic tissue that lie under the mucosa in the trachea.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"f7d360af523440adb5bab8f4bb33c9d7","type":"GO_TERM","name":"tracheal outgrowth, open tracheal system","canonical_id":"go:GO:0007426","description":"\"The projection of branches of an open tracheal system towards their target tissues. An example of this is found in Drosophila melanogaster.\" [GOC:bf, GOC:mtg_sensu]","metadata":null},{"id":"dcd13c6bf2ba46058972426e3fe37b96","type":"GO_TERM","name":"tracheal pit formation in open tracheal system","canonical_id":"go:GO:0035202","description":"\"Formation of the tracheal pits, the first tube-like structures to form in the open tracheal system. Once cells are determined to their tracheal cell fate, the tracheal pits arise by invagination of each ectodermal cluster of tracheal placode cells, between 5 and 7 hours after egg laying. An example of this is found in Drosophila melanogaster.\" [GOC:mtg_sensu, PMID:11063940, PMID:11992723, PMID:14570584]","metadata":null},{"id":"a59aadf606fe475f9823e0ac668a9b8b","type":"GO_TERM","name":"tracheary element differentiation","canonical_id":"go:GO:1905177","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a tracheary element.\" [GO_REF:0000086, GOC:TermGenie, PMID:20659276]","metadata":null},{"id":"4e64569ea15b4c07b5b50ed1a7cdae22","type":"GO_TERM","name":"tracheoesophageal septum formation","canonical_id":"go:GO:1905327","description":"\"The process that gives rise to the tracheoesophageal septum. This process pertains to the initial formation of a structure from unspecified parts.\" [GO_REF:0000081, GOC:TermGenie, PMID:9731532]","metadata":null},{"id":"9a13f856831e4e608da5f4e9d621d77f","type":"DRUG","name":"tralokinumab","canonical_id":"gtopdb:8001","description":null,"metadata":null},{"id":"3d2e6ab60977412cad01c5cf6ad7f6f0","type":"DRUG","name":"tralokinumab","canonical_id":"chembl:CHEMBL1743081","description":null,"metadata":null},{"id":"09fa619f90d44c77949d43da75d67fb1","type":"DRUG","name":"tramadol","canonical_id":"mesh:D014147","description":null,"metadata":null},{"id":"5412e10b2a934bc581189595827940c9","type":"DRUG","name":"trametinib","canonical_id":"gtopdb:6495","description":null,"metadata":null},{"id":"631055433519413e847d32dbeba48216","type":"DRUG","name":"trametinib","canonical_id":"chembl:CHEMBL2103875","description":null,"metadata":null},{"id":"e2a42fc18a284705854ba5e13b2c9cdc","type":"DRUG","name":"trandolapril","canonical_id":"gtopdb:6453","description":null,"metadata":null},{"id":"ddc4d05a0d1c4f2ba804b658176ee92f","type":"DRUG","name":"trandolapril","canonical_id":"chembl:CHEMBL1519","description":null,"metadata":null},{"id":"f4829d37126c46399780a1b1951429d4","type":"COMBINATION_TREATMENT","name":"trandolapril + verapamil","canonical_id":"ctgov_combo:ctgov-combo-8e2ea06a0e394e5e","description":null,"metadata":null},{"id":"90c95798db564af1a84c389b8627202c","type":"DRUG","name":"trandolaprilat","canonical_id":"gtopdb:6455","description":null,"metadata":null},{"id":"6433bd6316174e499c99dc0961bfb070","type":"DRUG","name":"tranexamic acid","canonical_id":"gtopdb:6573","description":null,"metadata":null},{"id":"a5c1785446e14b328e2be234a428e492","type":"DRUG","name":"tranexamic acid","canonical_id":"mesh:D014148","description":null,"metadata":null},{"id":"0a46ef9185554fb980aaa3cc6179c80a","type":"DRUG","name":"tranexamic acid","canonical_id":"chembl:CHEMBL877","description":null,"metadata":null},{"id":"ff895379dcfd4550ac4e748e92773e71","type":"GO_TERM","name":"trans assembly of SL-containing precatalytic spliceosome","canonical_id":"go:GO:0000352","description":"\"Assembly of a spliceosomal complex containing the SL RNA and the pre-mRNA to be joined, as well as all the spliceosomal snRNPs involved in trans leader splicing. Formation of the trans leader spliceosome brings together the quadruple SL/U4/U5/U6 snRNP and the complex of the U2 snRNP with the splice site of the pre-mRNA.\" [GOC:krc, GOC:mtg_mpo, ISBN:0879695897]","metadata":null},{"id":"cd9adb37b91b460a9a2a9dcbdae094d2","type":"GO_TERM","name":"trans spliceosomal complex","canonical_id":"go:GO:0071023","description":"\"A spliceosomal complex that forms during the addition of a specific spliced leader (SL) sequence to the 5'-end of a messenger RNA primary transcript, a process which occurs in a number of eukaryotic organisms, including trypanosomatid protozoans, euglenoids, nematodes, trematodes, and chordates.\" [GOC:krc, ISBN:0879697393]","metadata":null},{"id":"d02543d4a2b643b7b55bd13af0d2a761","type":"GO_TERM","name":"trans, trans-farnesyl diphosphate biosynthetic process","canonical_id":"go:GO:0045337","description":"\"The chemical reactions and pathways resulting in the formation of 2-trans,6-trans-farnesyl diphosphate from prenyl diphosphate.\" [MetaCyc:PWY-5123]","metadata":null},{"id":"9f6a1430627e4c9fbd41e3550b071b54","type":"GO_TERM","name":"trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity","canonical_id":"go:GO:0047115","description":"\"Catalysis of the reaction: NADP+ + trans-1,2-dihydrobenzene-1,2-diol = NADPH + catechol.\" [EC:1.3.1.20, MetaCyc:1.3.1.20-RXN]","metadata":null},{"id":"6891f835b30647b9afd8c32400120ea9","type":"GO_TERM","name":"trans-2,3-dihydro-3-hydroxy-anthranilate isomerase activity","canonical_id":"go:GO:0102943","description":"\"Catalysis of the reaction: (2S,3S)-2,3-dihydro-3-hydroxyanthranilic acid = (1R,6S)-6-ammonio-5-oxocyclohex-2-ene-1-carboxylate.\" [GOC:pz, RHEA:28182]","metadata":null},{"id":"f3e4c3a25b194f6497a29c0dda61b29b","type":"GO_TERM","name":"trans-2-decenoyl-acyl-carrier-protein isomerase activity","canonical_id":"go:GO:0034017","description":"\"Catalysis of the reaction: trans-dec-2-enoyl-[acyl-carrier protein] = cis-dec-3-enoyl-[acyl-carrier protein].\" [RHEA:23568]","metadata":null},{"id":"48479d2c3130458d8832928d5f87b23a","type":"GO_TERM","name":"trans-2-enoyl-CoA reductase (NADH) activity","canonical_id":"go:GO:0050343","description":"\"Catalysis of the reaction: acyl-CoA + NAD+ = trans-didehydroacyl-CoA + NADH.\" [EC:1.3.1.44]","metadata":null},{"id":"570547c3fcbf4463a8623f6c53c143e5","type":"GO_TERM","name":"trans-2-enoyl-CoA reductase (NADPH) activity","canonical_id":"go:GO:0019166","description":"\"Catalysis of the reaction: acyl-CoA + NADP+ = trans-2,3-dehydroacyl-CoA + NADPH + H+.\" [EC:1.3.1.38]","metadata":null},{"id":"e10b7fa589b64761b3add5c5f2f5c0e9","type":"GO_TERM","name":"trans-4-hexen-3-one reductase activity","canonical_id":"go:GO:0102236","description":"\"Catalysis of the reaction: trans-4-hexen-3-one + NADPH + H+ = hexan-3-one + NADP.\" [GOC:pz, PMID:21169366]","metadata":null},{"id":"e2eb079c5a1349a3b9e0504cd8e3011d","type":"GO_TERM","name":"trans-4-hydroxy-L-proline catabolic process","canonical_id":"go:GO:0019470","description":"\"The chemical reactions and pathways resulting in the breakdown of trans-4-hydroxy-L-proline.\" [GOC:curators]","metadata":null},{"id":"1a6abe0fc91d4de7a24109813b800672","type":"GO_TERM","name":"trans-Golgi network","canonical_id":"go:GO:0005802","description":"\"The network of interconnected tubular and cisternal structures located within the Golgi apparatus on the side distal to the endoplasmic reticulum, from which secretory vesicles emerge. The trans-Golgi network is important in the later stages of protein secretion where it is thought to play a key role in the sorting and targeting of secreted proteins to the correct destination.\" [GOC:vw, ISBN:0815316194, PMID:9695800]","metadata":null},{"id":"4781ef4359e84540a51ae96c31eff1a0","type":"GO_TERM","name":"trans-Golgi network membrane","canonical_id":"go:GO:0032588","description":"\"The lipid bilayer surrounding any of the compartments that make up the trans-Golgi network.\" [GOC:mah]","metadata":null},{"id":"e25d90e143e54ccf93c46cfdab4c5ffa","type":"GO_TERM","name":"trans-Golgi network membrane organization","canonical_id":"go:GO:0098629","description":"\"A process which results in the assembly, arrangement of constituent parts, or disassembly of a trans-Golgi network membrane.\" [GOC:di, GOC:dos, PMID:23345439]","metadata":null},{"id":"27532376b0774563a212b4639225a8c5","type":"GO_TERM","name":"trans-Golgi network to recycling endosome transport","canonical_id":"go:GO:0044795","description":"\"The directed movement of substances, in membrane-bounded vesicles, from the trans-Golgi network to the recycling endosomes.\" [GOC:lb, PMID:18779367]","metadata":null},{"id":"a463777eeb2e4f62a5a53eb137f0af9a","type":"GO_TERM","name":"trans-Golgi network transport vesicle","canonical_id":"go:GO:0030140","description":"\"A vesicle that mediates transport between the trans-Golgi network and other parts of the cell.\" [GOC:mah]","metadata":null},{"id":"a2c85aa835564f52883271a4c3e41695","type":"GO_TERM","name":"trans-Golgi network transport vesicle lumen","canonical_id":"go:GO:0098564","description":"\"The volume enclosed within the membrane of a trans-Golgi network transport vesicle.\" [GOC:dos]","metadata":null},{"id":"0f08403d28414ee5bb3c31c187d782dd","type":"GO_TERM","name":"trans-Golgi network transport vesicle membrane","canonical_id":"go:GO:0012510","description":"\"The lipid bilayer surrounding a vesicle transporting substances between the trans-Golgi network and other parts of the cell.\" [GOC:ai]","metadata":null},{"id":"dce68540774c48c8a93755555cfe224d","type":"GO_TERM","name":"trans-Golgi to periciliary membrane compartment transport","canonical_id":"go:GO:0097712","description":"\"The directed movement of substances from the trans-Golgi network to the periciliary membrane compartment, the specialized region of the plasma membrane surrounding the base of the cilium including the ciliary pocket, via vesicle-mediated transport.\" [PMID:20106869, PMID:23351793, PMID:24814148, PMID:26485645]","metadata":null},{"id":"7e641bb1f59e41a8ba980cb6cfd4669e","type":"GO_TERM","name":"trans-Golgi-derived vesicle fusion with Golgi medial cisterna membrane","canonical_id":"go:GO:1990692","description":"\"The joining of the lipid bilayer membrane around a trans-Golgi-derived vesicle to the lipid bilayer membrane around the medial-Golgi cisterna. Such vesicles include COPI-coated transport vesicles involved in retrograde transport.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"8ee69135b6414393a5cd1d2006a1c551","type":"GO_TERM","name":"trans-L-3-hydroxyproline dehydratase activity","canonical_id":"go:GO:0050346","description":"\"Catalysis of the reaction: trans-L-3-hydroxyproline = 1-pyrroline-2-carboxylate + H2O + H+.\" [EC:4.2.1.77, RHEA:10320]","metadata":null},{"id":"60d46f6003534baeb3220554f90ede4e","type":"GO_TERM","name":"trans-acenaphthene-1,2-diol dehydrogenase activity","canonical_id":"go:GO:0047062","description":"\"Catalysis of the reaction: (+-)-trans-acenaphthene-1,2-diol + 2 NADP+ = acenaphthene-1,2-dione + 2 H+ + 2 NADPH.\" [EC:1.10.1.1, RHEA:22184]","metadata":null},{"id":"0cc8f3a699bf426e88e6789c4191a0aa","type":"GO_TERM","name":"trans-aconitate 2-methyltransferase activity","canonical_id":"go:GO:0030798","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + trans-aconitate = (E)-3-(methoxycarbonyl)pent-2-enedioate + S-adenosyl-L-homocysteine.\" [EC:2.1.1.144, RHEA:14969]","metadata":null},{"id":"389ba3196ab8440f85bffa98549d1d7c","type":"GO_TERM","name":"trans-aconitate 3-methyltransferase activity","canonical_id":"go:GO:0046547","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine(1+) + trans-aconitate = (E)-2-(methoxycarbonylmethyl)but-2-enedioate + S-adenosyl-L-homocysteine.\" [EC:2.1.1.145, RHEA:22200]","metadata":null},{"id":"715865af97ff4242903e0bcc74f846d3","type":"GO_TERM","name":"trans-activation response element binding","canonical_id":"go:GO:1990970","description":"\"Binding to a trans-activation response (TAR) element, a hairpin RNA structure located at the 5' end of all HIV-1 transcripts, and which is required for trans-activation of a viral promoter.\" [GOC:bf, GOC:PARL, PMID:25116364, Wikipedia:Trans-activation_response_element_(TAR)]","metadata":null},{"id":"27ccb5210c0143659c4890918c45f738","type":"GO_TERM","name":"trans-cinnamate 2-monooxygenase activity","canonical_id":"go:GO:0050344","description":"\"Catalysis of the reaction: trans-cinnamate + H+ + NADPH + O2 = 2-coumarate + H2O + NADP+.\" [EC:1.14.13.14, RHEA:10956]","metadata":null},{"id":"3022f6f11d1f4691b11cbfe60c2be94e","type":"GO_TERM","name":"trans-cinnamate 4-monooxygenase activity","canonical_id":"go:GO:0016710","description":"\"Catalysis of the reaction: trans-cinnamate + NADPH + H+ + O2 = 4-hydroxycinnamate + NADP+ + H2O.\" [EC:1.14.14.91]","metadata":null},{"id":"1047de38d61e43efb674be39effa92c2","type":"GO_TERM","name":"trans-cinnamate-CoA ligase activity","canonical_id":"go:GO:0106290","description":"\"Catalysis of the reaction: (E)-cinnamate + ATP + CoA = (E)-cinnamoyl-CoA + AMP + diphosphate.\" [PMID:22649270, RHEA:64788]","metadata":null},{"id":"65e8be99c3a048d09767820ae17530f9","type":"GO_TERM","name":"trans-epoxysuccinate hydrolase activity","canonical_id":"go:GO:0050345","description":"\"Catalysis of the reaction: trans-2,3-epoxysuccinate + H2O = (2R,3S)-tartrate.\" [EC:3.3.2.4, RHEA:20740]","metadata":null},{"id":"9c63a042c1494ff582612a404192574e","type":"GO_TERM","name":"trans-feruloyl-CoA synthase activity","canonical_id":"go:GO:0050563","description":"\"Catalysis of the reaction: ATP + CoA + trans-ferulate = (E)-feruloyl-CoA + ADP + phosphate. ADP + phosphate or AMP + diphosphate may be formed in this reaction.\" [EC:6.2.1.34, PMID:22649270]","metadata":null},{"id":"f5fc31859d494e64bd310d258618c5d2","type":"GO_TERM","name":"trans-o-hydroxybenzylidenepyruvate hydratase-aldolase activity","canonical_id":"go:GO:0018813","description":"\"Catalysis of the reaction: (3E)-4-(2-hydroxyphenyl)-2-oxobut-3-enoate + H2O = salicylaldehyde + pyruvate. A broad range of aldehydes and 4-substituted 2-oxobut-3-enoates are accepted as substrates.\" [EC:4.1.2.45, RHEA:27389]","metadata":null},{"id":"a6e528e0a1b24b7ab6acf3a2b2d0f2cb","type":"GO_TERM","name":"trans-permethrin hydrolase activity","canonical_id":"go:GO:0102209","description":"\"Catalysis of the reaction: (-)-trans-permethrin + H2O = H+ + (3-phenoxyphenyl)methanol + (1S,3R)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate.\" [EC:3.1.1.88, GOC:pz]","metadata":null},{"id":"b0de3bc029ba470e85200fa00ea13f17","type":"GO_TERM","name":"trans-synaptic protein complex","canonical_id":"go:GO:0098820","description":"\"A protein complex that spans the synaptic cleft and has parts in both the pre- and post-synaptic membranes.\" [PMID:20200227]","metadata":null},{"id":"8c52ea724caf4878a37d2528e9a595de","type":"GO_TERM","name":"trans-synaptic signaling","canonical_id":"go:GO:0099537","description":"\"Cell-cell signaling in either direction across the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"886639c68632417f96aa85bcfebb90b7","type":"GO_TERM","name":"trans-synaptic signaling by BDNF","canonical_id":"go:GO:0099191","description":"\"Cell-cell signaling between presynapse and postsynapse mediated by brain-derived neurotrophic factor (BDNF) crossing the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"6c8f524eb558407d9e785bf165017b16","type":"GO_TERM","name":"trans-synaptic signaling by BDNF, modulating synaptic transmission","canonical_id":"go:GO:0099183","description":"\"Cell-cell signaling between presynapse and postsynapse, via the vesicular release and reception of brain derived neurotrophic factor (BDNF), that modulates the synaptic transmission properties of the synapse.\" [GOC:dos]","metadata":null},{"id":"a3ab45a3bcdb4ca69f6d0dd24d9af74c","type":"GO_TERM","name":"trans-synaptic signaling by carbon monoxide","canonical_id":"go:GO:0099549","description":"\"Cell-cell signaling between presynapse and postsynapse mediated by carbon monoxide.\" [GOC:dos]","metadata":null},{"id":"23148416e09a4845a01cc729fd2a4180","type":"GO_TERM","name":"trans-synaptic signaling by carbon monoxide, modulating synaptic transmission","canonical_id":"go:GO:0099556","description":"\"Cell-cell signaling between presynapse and postsynapse, via the release and reception of carbon monoxide molecules, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos]","metadata":null},{"id":"38fcb2961db54725baf3d10327b7fba7","type":"GO_TERM","name":"trans-synaptic signaling by endocannabinoid","canonical_id":"go:GO:0099542","description":"\"Cell-cell signaling in either direction across the synaptic cleft, mediated by an endocannabinoid ligand.\" [GOC:dos]","metadata":null},{"id":"489a71109d4040e1a20c93af23feb647","type":"GO_TERM","name":"trans-synaptic signaling by endocannabinoid, modulating synaptic transmission","canonical_id":"go:GO:0099553","description":"\"Cell-cell signaling between presynapse and postsynapse, via the release and reception of endocannabinoid ligands, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos, PMID:21531987]","metadata":null},{"id":"8d9938789d6e4b218448df723ada41d0","type":"GO_TERM","name":"trans-synaptic signaling by lipid","canonical_id":"go:GO:0099541","description":"\"Cell-cell signaling from post to pre-synapse, across the synaptic cleft, mediated by a lipid.\" [GOC:dos]","metadata":null},{"id":"5009124f179e47ababfed651808f547e","type":"GO_TERM","name":"trans-synaptic signaling by lipid, modulating synaptic transmission","canonical_id":"go:GO:0099552","description":"\"Cell-cell signaling between presynapse and postsynapse, via the release and reception of lipid molecules, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos, PMID:21531987]","metadata":null},{"id":"fdcfc74dc7ef488c967af64b08337355","type":"GO_TERM","name":"trans-synaptic signaling by neuropeptide","canonical_id":"go:GO:0099540","description":"\"Cell-cell signaling between presynapse and postsynapse mediated by a peptide ligand crossing the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"b29a2ea8df364f4b8e53123a10f18368","type":"GO_TERM","name":"trans-synaptic signaling by neuropeptide, modulating synaptic transmission","canonical_id":"go:GO:0099551","description":"\"Cell-cell signaling between presynapse and postsynapse, via the vesicular release and reception of neuropeptide molecules, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos]","metadata":null},{"id":"3e24aee60ff64bfaacea769ee4e44c2f","type":"GO_TERM","name":"trans-synaptic signaling by nitric oxide","canonical_id":"go:GO:0099548","description":"\"Cell-cell signaling between presynapse and postsynapse mediated by nitric oxide.\" [GOC:dos]","metadata":null},{"id":"8cce6c50e3c043b4870d53346bc2788c","type":"GO_TERM","name":"trans-synaptic signaling by nitric oxide, modulating synaptic transmission","canonical_id":"go:GO:0099555","description":"\"Cell-cell signaling between presynapse and postsynapse, via the release and reception of nitric oxide molecules, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos]","metadata":null},{"id":"5c433f4fddba435c9afa1d2b08929658","type":"GO_TERM","name":"trans-synaptic signaling by soluble gas","canonical_id":"go:GO:0099543","description":"\"Cell-cell signaling between presynapse and postsynapse mediated by a soluble gas ligand crossing the synaptic cleft.\" [GOC:dos]","metadata":null},{"id":"480c054d18894bc78e25dbb313cdf896","type":"GO_TERM","name":"trans-synaptic signaling by soluble gas, modulating synaptic transmission","canonical_id":"go:GO:0099554","description":"\"Cell-cell signaling between presynapse and postsynapse, via the release and reception of gaseous molecules, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos]","metadata":null},{"id":"1b9615ccca4b4e9eaedd684e6dc058ea","type":"GO_TERM","name":"trans-synaptic signaling by trans-synaptic complex","canonical_id":"go:GO:0099545","description":"\"Cell-cell signaling between presynapse and postsynapse mediated by a trans-synaptic protein complex.\" [GOC:dos]","metadata":null},{"id":"06169773e91e40d2abade0d47fabeb2a","type":"GO_TERM","name":"trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission","canonical_id":"go:GO:0099557","description":"\"Cell-cell signaling between presynapse and postsynapse, mediated by transynaptic protein complexes, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos, PMID:19029886]","metadata":null},{"id":"2e913cb7d24946cebf35d301dc98d194","type":"GO_TERM","name":"trans-synaptic signaling via exosome","canonical_id":"go:GO:0099157","description":"\"Transynaptic signaling in which the ligand is carried across the synapse by an exosome.\" [GOC:dos, PMID:19837038]","metadata":null},{"id":"e37706a7e7184b18884a28d4ce00f70e","type":"GO_TERM","name":"trans-synaptic signaling, modulating synaptic transmission","canonical_id":"go:GO:0099550","description":"\"Cell-cell signaling between presynapse and postsynapse, across the synaptic cleft, that modulates the synaptic transmission properties of the synapse.\" [GOC:dos]","metadata":null},{"id":"5d72df92292e45b68c644397dba0d6fc","type":"GO_TERM","name":"trans-translation","canonical_id":"go:GO:0070929","description":"\"A translational elongation process in which transfer of a translating ribosome from one mRNA to another RNA template takes place. Trans-translation occurs during tmRNA release of stalled ribosomes.\" [GOC:jh2, GOC:mah]","metadata":null},{"id":"95c2ae8d61c94ff98db863a8adc9116a","type":"GO_TERM","name":"trans-translation-dependent protein tagging","canonical_id":"go:GO:0070930","description":"\"A protein modification process in which a polypeptide is added to a nascent polypeptide cotranslationally by trans-translation.\" [PMID:11395451, PMID:35264790]","metadata":null},{"id":"7b7a8b992dbf4184b746aea54b8a0f92","type":"GO_TERM","name":"trans-zeatin O-beta-D-glucosyltransferase activity","canonical_id":"go:GO:0050403","description":"\"Catalysis of the reaction: trans-zeatin + UDP-D-glucose = O-beta-D-glucosyl-trans-zeatin + H+ + UDP.\" [EC:2.4.1.203, RHEA:23224]","metadata":null},{"id":"a473abb3c2684a3583fdb08b195dbee6","type":"GO_TERM","name":"trans-zeatin biosynthetic process","canonical_id":"go:GO:0033466","description":"\"The chemical reactions and pathways resulting in the formation of trans-zeatin, (2E)-2-methyl-4-(9H-purin-6-ylamino)but-2-en-1-ol.\" [GOC:mah]","metadata":null},{"id":"c27205d85c8e4050b01156c86b14c03d","type":"GO_TERM","name":"transaldolase activity","canonical_id":"go:GO:0004801","description":"\"Catalysis of the reaction: sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate = D-erythrose 4-phosphate + D-fructose 6-phosphate.\" [PMID:7592346, RHEA:17053]","metadata":null},{"id":"b88151969e324e16bd45579a40af9c56","type":"GO_TERM","name":"transaminase activity","canonical_id":"go:GO:0008483","description":"\"Catalysis of the transfer of an amino group to an acceptor, usually a 2-oxo acid.\" [EC:2.6.1.-]","metadata":null},{"id":"7231043e69a145dc9ed039f9b5a3dbcd","type":"GO_TERM","name":"transcription antitermination","canonical_id":"go:GO:0031564","description":"\"A positive regulation of gene expression mechanism that allows RNA polymerase to continue transcription beyond a termination site, thus allowing expression of downstream genes under specific conditions.\" [ISBN:0198577788, PMID:12456320, PMID:21478900, PMID:30191803]","metadata":null},{"id":"9ed6af3cb61e4624889a70b8ee4ab613","type":"GO_TERM","name":"transcription antitermination factor activity, DNA binding","canonical_id":"go:GO:0001073","description":"\"Binds to DNA, typically within region of the promoter and transcribed region, to promote readthrough of a transcription termination site and thus extending the length of the RNA transcript produced. Examples of antitermination factors which bind DNA include the lambda Q protein.\" [GOC:txnOH, PMID:8332211]","metadata":null},{"id":"30e4e77d873243a695cf382bc6094409","type":"GO_TERM","name":"transcription antitermination factor activity, RNA binding","canonical_id":"go:GO:0001072","description":"\"Binds to RNA, typically within the nascent RNA transcript, to promote readthrough of a transcription termination site and thus extending the length of the RNA transcript produced. Examples of antitermination factors which bind the nascent RNA include the lambda N protein and the HIV-1 tat protein.\" [GOC:txnOH, PMID:8332211]","metadata":null},{"id":"c54cf41eebe5495c9962481e91f7aa74","type":"GO_TERM","name":"transcription by RNA polymerase I","canonical_id":"go:GO:0006360","description":"\"The synthesis of RNA from a DNA template by RNA polymerase I (RNAP I), originating at an RNAP I promoter.\" [GOC:jl, GOC:txnOH]","metadata":null},{"id":"6bf01a97332940c8b648f589726b6b12","type":"GO_TERM","name":"transcription by RNA polymerase II","canonical_id":"go:GO:0006366","description":"\"The synthesis of RNA from a DNA template by RNA polymerase II (RNAP II), originating at an RNA polymerase II promoter. Includes transcription of messenger RNA (mRNA) and certain small nuclear RNAs (snRNAs).\" [GOC:jl, GOC:txnOH, ISBN:0321000382]","metadata":null},{"id":"c8384b22e74848f5b101edd65736fa45","type":"GO_TERM","name":"transcription by RNA polymerase III","canonical_id":"go:GO:0006383","description":"\"The synthesis of RNA from a DNA template by RNA polymerase III, originating at an RNAP III promoter.\" [GOC:jl, GOC:txnOH, PMID:12381659]","metadata":null},{"id":"d8c3810862f34136938cc82cd4da2c3c","type":"GO_TERM","name":"transcription by RNA polymerase IV","canonical_id":"go:GO:0001059","description":"\"The synthesis of RNA from a DNA template by RNA polymerase IV, originating at a Pol IV-specific promoter.\" [GOC:txnOH, PMID:19110459]","metadata":null},{"id":"617b9b7cfb254e3cb74229799a4809a0","type":"GO_TERM","name":"transcription by RNA polymerase V","canonical_id":"go:GO:0001060","description":"\"The synthesis of RNA from a DNA template by RNA polymerase V, originating at a Pol V-specific promoter.\" [GOC:txnOH, PMID:19110459]","metadata":null},{"id":"b890b6e5e23c41f18cc25fddb6510fcd","type":"GO_TERM","name":"transcription cis-regulatory region binding","canonical_id":"go:GO:0000976","description":"\"Binding to a specific sequence of DNA that is part of a regulatory region that controls transcription of that section of the DNA. The transcribed region might be described as a gene, cistron, or operon.\" [GOC:txnOH]","metadata":null},{"id":"c0af84b891da434698392f9502766099","type":"GO_TERM","name":"transcription coactivator activity","canonical_id":"go:GO:0003713","description":"\"A transcription coregulator activity that activates or increases the transcription of specific gene sets via binding to a DNA-binding transcription factor at a specific genomic locus, either on its own or as part of a complex. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coactivators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. A fourth class of coactivator activity is the bridging of a DNA-binding transcription factor to the general (basal) transcription machinery. The Mediator complex, which bridges sequence-specific DNA binding transcription factors and RNA polymerase, is also a transcription coactivator.\" [GOC:txnOH-2018, PMID:10213677, PMID:16858867]","metadata":null},{"id":"5c2daa1a50c648858bf9bd792ca0f350","type":"GO_TERM","name":"transcription coactivator binding","canonical_id":"go:GO:0001223","description":"\"Binding to a transcription coactivator, a protein involved in positive regulation of transcription via protein-protein interactions with transcription factors and other proteins that positively regulate transcription. Transcription coactivators do not bind DNA directly, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery.\" [GOC:krc]","metadata":null},{"id":"1faee046b75742e2b2b3fcc3286ff62d","type":"GO_TERM","name":"transcription coregulator activity","canonical_id":"go:GO:0003712","description":"\"A transcription regulator activity that modulates the transcription of specific gene sets via binding to a DNA-binding transcription factor at a specific genomic locus, either on its own or as part of a complex. Coregulators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators.\" [GOC:txnOH-2018, PMID:10213677, PMID:16858867, PMID:24203923, PMID:25957681, Wikipedia:Transcription_coregulator]","metadata":null},{"id":"c3e79390a1304521b4c6270b26cc7e6b","type":"GO_TERM","name":"transcription coregulator binding","canonical_id":"go:GO:0001221","description":"\"Binding to a transcription coregulator, a protein involved in regulation of transcription via protein-protein interactions with transcription factors and other transcription regulatory proteins. Cofactors do not bind DNA directly, but rather mediate protein-protein interactions between regulatory transcription factors and the basal transcription machinery.\" [GOC:krc]","metadata":null},{"id":"d52701d9704e46be8a6c82801db54259","type":"GO_TERM","name":"transcription corepressor activity","canonical_id":"go:GO:0003714","description":"\"A transcription coregulator activity that represses or decreases the transcription of specific gene sets via binding to a DNA-binding transcription factor at a specific genomic locus, either on its own or as part of a complex. Corepressors often act by altering chromatin structure and modifications. For example, one class of transcription corepressors modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators.\" [GOC:txnOH-2018, PMID:10213677, PMID:16858867]","metadata":null},{"id":"a2cd3f4e4a2d45f880dc96e12cac22dd","type":"GO_TERM","name":"transcription corepressor binding","canonical_id":"go:GO:0001222","description":"\"Binding to a transcription corepressor, a protein involved in negative regulation of transcription via protein-protein interactions with transcription factors and other proteins that negatively regulate transcription. Transcription corepressors do not bind DNA directly, but rather mediate protein-protein interactions between repressing transcription factors and the basal transcription machinery.\" [GOC:krc]","metadata":null},{"id":"26af773567574de8b6397149dadac072","type":"GO_TERM","name":"transcription elongation by RNA polymerase I","canonical_id":"go:GO:0006362","description":"\"The extension of an RNA molecule after transcription initiation and promoter clearance at an RNA polymerase I specific promoter by the addition of ribonucleotides catalyzed by RNA polymerase I.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"17f865dea89e4d6da39bb4e25558b46f","type":"GO_TERM","name":"transcription elongation by RNA polymerase II","canonical_id":"go:GO:0006368","description":"\"The extension of an RNA molecule after transcription pausing and promoter clearance at an RNA polymerase II promoter by the addition of ribonucleotides catalyzed by RNA polymerase II.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"0119a60306cd415f89c0d18edba79c37","type":"GO_TERM","name":"transcription elongation by RNA polymerase III","canonical_id":"go:GO:0006385","description":"\"The extension of an RNA molecule after transcription initiation and promoter clearance at an RNA polymerase III promoter by the addition of ribonucleotides catalyzed by RNA polymerase III.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"31a28177f44b4f86ac7ee9010df40efa","type":"GO_TERM","name":"transcription elongation by mitochondrial RNA polymerase","canonical_id":"go:GO:0006392","description":"\"The extension of an RNA molecule after transcription initiation and promoter clearance at mitochondrial promoter by the addition of ribonucleotides catalyzed by a mitchondrial RNA polymerase.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"c7e3a202774a48f5ba6b3779ce81553a","type":"GO_TERM","name":"transcription elongation factor activity","canonical_id":"go:GO:0003711","description":"\"A molecular function that stimulates the elongation properties of the RNA polymerase during the elongation phase of transcription. A subclass of transcription elongation factors enable the transition from transcription initiation to elongation, while another class rescue stalled RNA polymerases.\" [GOC:txnOH-2018, PMID:23878398, PMID:28892040]","metadata":null},{"id":"2c314403c86443a0a6f26cc503710e06","type":"GO_TERM","name":"transcription elongation factor complex","canonical_id":"go:GO:0008023","description":"\"Any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation.\" [GOC:jl]","metadata":null},{"id":"593e7db1ee03449db12341021fa28054","type":"GO_TERM","name":"transcription elongation-coupled chromatin remodeling","canonical_id":"go:GO:0140673","description":"\"A chromatin remodeling process that reestablishes the chromatin structure following the passage of RNA polymerase II during transcription elongation, thus preventing cryptic transcription initiation.\" [PMID:22922743, PMID:28053344]","metadata":null},{"id":"7f73ce9b81664ad2a39849f6c068341f","type":"GO_TERM","name":"transcription export complex","canonical_id":"go:GO:0000346","description":"\"The transcription export (TREX) complex couples transcription elongation by RNA polymerase II to mRNA export. The complex associates with the polymerase and travels with it along the length of the transcribed gene. TREX is composed of the THO transcription elongation complex as well as other proteins that couple THO to mRNA export proteins. The TREX complex is known to be found in a wide range of eukaryotes, including S. cerevisiae and metazoans.\" [GOC:krc, PMID:11979277]","metadata":null},{"id":"79fd2a005e9d4db783e1d9cb18114f12","type":"GO_TERM","name":"transcription export complex 2","canonical_id":"go:GO:0070390","description":"\"A protein complex that couples SAGA-dependent gene expression to mRNA export at the inner side of the nuclear pore complex (NPC). The TREX-2 complex is tethered to the inner side of the NPC via the nucleoporins Nup1 and Nup60; in S. cerevisiae it contains Sac3p, Thp1p, Sem1, Sus1p and Cdc31p.\" [GOC:dgf, GOC:mah, PMID:17786152, PMID:19289793, PMID:28334829]","metadata":null},{"id":"5b1840ae8b474d5c9517b8c9f3f61d2a","type":"GO_TERM","name":"transcription factor AP-1 complex","canonical_id":"go:GO:0035976","description":"\"A heterodimeric transcription factor complex composed of proteins from the c-Fos, c-Jun, activating transcription factor (ATF) or JDP families. The subunits contain a basic leucine zipper (bZIP) domain that is essential for dimerization and DNA binding. Jun-Fos heterodimers bind preferentially to a heptamer consensus sequence (TPA responsive element (TRE)), whereas Jun-ATF dimers bind the cyclic AMP responsive element (CRE) to regulate transcription of target genes.\" [GOC:bf, GOC:BHF, GOC:rl, PMID:20060892, PMID:9069263, Wikipedia:AP-1_transcription_factor]","metadata":null},{"id":"fb58cd49ece94bd080aaf86aa4040426","type":"GO_TERM","name":"transcription factor TFIIA complex","canonical_id":"go:GO:0005672","description":"\"A component of the transcription machinery of RNA Polymerase II. In humans, TFIIA is a heterotrimer composed of an alpha (P35), beta (P19) and gamma subunits (P12).\" [GOC:jl, PMID:17560669]","metadata":null},{"id":"3393121674e048f7a776dc60477181be","type":"GO_TERM","name":"transcription factor TFIID complex","canonical_id":"go:GO:0005669","description":"\"A complex composed of TATA binding protein (TBP) and TBP associated factors (TAFs); the total mass is typically about 800 kDa. Most of the TAFs are conserved across species. In TATA-containing promoters for RNA polymerase II (Pol II), TFIID is believed to recognize at least two distinct elements, the TATA element and a downstream promoter element. TFIID is also involved in recognition of TATA-less Pol II promoters. Binding of TFIID to DNA is necessary but not sufficient for transcription initiation from most RNA polymerase II promoters.\" [GOC:krc, GOC:mah, ISBN:0471953393, ISBN:0879695501]","metadata":null},{"id":"b53a37fd5f6b49d0adfb36e35f7dc38c","type":"GO_TERM","name":"transcription factor TFIIE complex","canonical_id":"go:GO:0005673","description":"\"A transcription factor which in humans consists of a complex of two alpha and two beta chains. Recruits TFIIH to the initiation complex and helps activate both RNA polymerase II and TFIIH.\" [GOC:jl, PMID:16547462]","metadata":null},{"id":"a86db136867c4cb0b644b02c549d58b3","type":"GO_TERM","name":"transcription factor TFIIF complex","canonical_id":"go:GO:0005674","description":"\"A general transcription initiation factor which in humans consists of a heterodimer of an alpha and a beta subunit. Helps recruit RNA polymerase II to the initiation complex and promotes translation elongation.\" [GOC:jl, PMID:7597077]","metadata":null},{"id":"7fa73cbc600e459a99790114e0ae6965","type":"GO_TERM","name":"transcription factor TFIIH core complex","canonical_id":"go:GO:0000439","description":"\"The 7 subunit core of TFIIH that is a part of either the general transcription factor holo-TFIIH or the nucleotide-excision repair factor 3 complex. In S. cerevisiae/humans the complex is composed of: Ssl2/XPB, Tfb1/p62, Tfb2/p52, Ssl1/p44, Tfb4/p34, Tfb5/p8 and Rad3/XPD.\" [GOC:ew, GOC:krc, PMID:14500720, PMID:17215295, PMID:22308316, PMID:22572993, PMID:23028141, PMID:7813015]","metadata":null},{"id":"068e8428490a4bb7a9db3054d2a0e17c","type":"GO_TERM","name":"transcription factor TFIIH holo complex","canonical_id":"go:GO:0005675","description":"\"A complex that is capable of kinase activity directed towards the C-terminal Domain (CTD) of the largest subunit of RNA polymerase II and is essential for initiation at RNA polymerase II promoters in vitro. It is composed of the core TFIIH complex and the TFIIK complex.\" [GOC:ew, GOC:krc, PMID:14500720, PMID:22308316, PMID:22572993, PMID:7813015]","metadata":null},{"id":"6408a17d753846129f643f56bff7a0aa","type":"GO_TERM","name":"transcription factor TFIIH holo complex binding","canonical_id":"go:GO:0062058","description":"\"Binding to a transcription factor TFIIH holo complex.\" [PMID:11259578]","metadata":null},{"id":"7f52ab1d38004037b45d6450d9fc06ac","type":"GO_TERM","name":"transcription factor TFIIIB complex","canonical_id":"go:GO:0000126","description":"\"A transcription factor complex that is involved in regulating transcription from RNA polymerase III (Pol III) promoters. TFIIIB contains the TATA-binding protein (TBP) and two Pol III-specific proteins, B'' and BRF.\" [GOC:mah, PMID:11433012]","metadata":null},{"id":"65ebdfd871cd42468fca631bbb895514","type":"GO_TERM","name":"transcription factor TFIIIB complex assembly","canonical_id":"go:GO:0070217","description":"\"The aggregation, arrangement and bonding together of a set of components to form a transcription factor TFIIIB complex.\" [GOC:mah]","metadata":null},{"id":"4a27ca49badc49c99d2b2bafc8fbf363","type":"GO_TERM","name":"transcription factor TFIIIB-alpha complex","canonical_id":"go:GO:0034732","description":"\"A transcription factor TFIIIB-beta complex that contains the TATA-binding protein (TBP), B'' and a specialized homolog of the conserved subunit BRF referred to as BRFU or TFIIIB50, which found in human but not conserved in yeast; the complex is involved in the regulation of transcription from type 3 (upstream) RNA polymerase III promoters.\" [PMID:11433012]","metadata":null},{"id":"b6462ca8f23a44d3b786ee2190233dc2","type":"GO_TERM","name":"transcription factor TFIIIB-beta complex","canonical_id":"go:GO:0034733","description":"\"A transcription factor TFIIIB-beta complex that contains the TATA-binding protein (TBP), B'' and BRF, and is involved in the regulation of transcription from type 2 RNA polymerase III promoters.\" [PMID:11433012]","metadata":null},{"id":"9f77c261a3624a77beb8de649e4fd9ec","type":"GO_TERM","name":"transcription factor TFIIIC complex","canonical_id":"go:GO:0000127","description":"\"A heterotrimeric transcription factor complex that is involved in regulating transcription from RNA polymerase III (Pol III) promoters. TFIIIC contains three conserved subunits that associate with the proximal Pol III promoter element, and additional subunits that associate with sequence elements downstream of the promoter and are more diverged among species. It also functions as a boundary element to partition genome content into distinct domains outside Pol III promoter regions.\" [GOC:mah, GOC:vw, PMID:11433012, PMID:16751097]","metadata":null},{"id":"59d7e618ce9d47c6a1985844a29ce457","type":"GO_TERM","name":"transcription factor TFIIIC1 complex","canonical_id":"go:GO:0034734","description":"\"A transcription factor complex that forms part of the TFIIIC complex, observed in human. The complex is poorly characterized, but contains the 250-kDa form of HsBdp1, and is thought to include nuclear factor 1 (NF1). It stimulates binding by human TFIIIC2 and is required for transcription activity.\" [GOC:mah, PMID:11433012, PMID:15096501]","metadata":null},{"id":"6815fddb3c9b4947a947db088c8a174b","type":"GO_TERM","name":"transcription factor TFIIIC2 complex","canonical_id":"go:GO:0034735","description":"\"A transcription factor complex that forms part of the TFIIIC complex, observed in human; composed of five subunits (GTF3C1/hTFIIIC220/TFIIICalpha, GTF3C2/hTFIIIC110/TFIIICbeta, GTF3C3/hTFIIIC102/TFIIICgamma, GTF3C4/hTFIIIC90/TFIIICdelta and GTF3C5/hTFIIIC63/TFIIICepsilon in human) that together recognize the type 2 RNA polymerase III promoter.\" [GOC:mah, PMID:11433012]","metadata":null},{"id":"f147be06897d4d018de7848d685c7c56","type":"GO_TERM","name":"transcription factor TFIIIE complex","canonical_id":"go:GO:0070264","description":"\"A transcription factor complex that is involved in regulating transcription from RNA polymerase III (Pol III) promoters. TFIIIE contains a specific subset of ribosomal proteins.\" [GOC:jp, PMID:19116144]","metadata":null},{"id":"8f03897bf18847248f5273aac234a7c5","type":"GO_TERM","name":"transcription factor TFIIK complex","canonical_id":"go:GO:0070985","description":"\"A transcription factor complex that forms part of the holo TFIIH complex. In Saccharomyces/human, TFIIK contains Ccl1p/Cyclin H, Tfb3p/MAT1 and Kin28p/CDK7.\" [GOC:mah, PMID:19818408, PMID:22572993]","metadata":null},{"id":"6f56c39c4bea4a7982bc2763ab163a96","type":"GO_TERM","name":"transcription factor TFTC complex","canonical_id":"go:GO:0033276","description":"\"A protein complex that does not contain either a TATA-binding protein (TBP) or a TBP-like factor, but is composed of several TAFIIs and other proteins, including a histone acetyltransferase. This complex is able to nucleate transcription initiation by RNA polymerase II, can mediate transcriptional activation, and has histone acetyltransferase activity.\" [PMID:10373431, PMID:9603525]","metadata":null},{"id":"c56a5f70d5444a51854fff310518ddbf","type":"GO_TERM","name":"transcription factor binding","canonical_id":"go:GO:0008134","description":"\"Binding to a transcription factor, a protein required to initiate or regulate transcription.\" [ISBN:0198506732]","metadata":null},{"id":"3986e3216aa64c7d8f7814750dfcddd4","type":"GO_TERM","name":"transcription initiation at RNA polymerase I promoter","canonical_id":"go:GO:0006361","description":"\"A transcription initiation process that takes place at a RNA polymerase I gene promoter. Ribosomal RNAs (rRNA) genes are transcribed by RNA polymerase I.\" [GOC:txnOH]","metadata":null},{"id":"cbf7fc1c1c1e4aadaa7ed655b98332c8","type":"GO_TERM","name":"transcription initiation at RNA polymerase II promoter","canonical_id":"go:GO:0006367","description":"\"A transcription initiation process that takes place at a RNA polymerase II gene promoter. Messenger RNAs (mRNA) genes, as well as some non-coding RNAs, are transcribed by RNA polymerase II.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"cfc3eb4fe2ab4502a74ed06d4af4ab02","type":"GO_TERM","name":"transcription initiation at RNA polymerase III promoter","canonical_id":"go:GO:0006384","description":"\"A transcription initiation process that takes place at a RNA polymerase III gene promoter. Transfer RNAs (tRNA) genes, as well as some other non-coding RNAs, are transcribed by RNA polymerase III.\" [GOC:mah, GOC:txnOH]","metadata":null},{"id":"72a1ab8e8d474b80b54b7ab163ec2cea","type":"GO_TERM","name":"transcription initiation at mitochondrial promoter","canonical_id":"go:GO:0006391","description":"\"A transcription initiation process that takes place at a promoter on the mitochondrial chromosome.\" [PMID:33127643]","metadata":null},{"id":"ebac7def60cc4a1ba51166ef77c5e572","type":"GO_TERM","name":"transcription initiation-coupled chromatin remodeling","canonical_id":"go:GO:0045815","description":"\"An epigenetic mechanism of regulation of gene expression that involves chromatin remodeling to capacitate gene expression by either modifying the chromatin fiber, the nucleosomal histones, or the DNA.\" [PMID:34414474]","metadata":null},{"id":"26f4ff94860744659a8ef2cf5cee1187","type":"GO_TERM","name":"transcription open complex formation at RNA polymerase II promoter","canonical_id":"go:GO:0001113","description":"\"Any process involved in the melting of the DNA hybrid of the core promoter region within the transcriptional closed complex of an RNA polymerase II preinitiation complex (PIC) to produce an open complex where the DNA duplex around the transcription initiation site is unwound to form the transcription bubble.\" [GOC:txnOH, PMID:15020047, PMID:18280161]","metadata":null},{"id":"f7c8ac4edeaa4d538369dc8c625d2f39","type":"GO_TERM","name":"transcription pausing by RNA polymerase II","canonical_id":"go:GO:0160239","description":"\"A transcription halt following transcription initiation but prior to elongation, during which RNA polymerase II pauses approximately 20-60 nucleotides downstream of the transcriptional start site before proceeding into productive elongation. Transcription pausing starts following phosphorylation of the C-terminal domain (CTD) of RNA polymerase II subunit POLR2A at Ser-5 and stops following phosphorylation of POLR2A by the P-TEFb complex.\" [PMID:33271312, PMID:35816930]","metadata":null},{"id":"ca15608c2b11493d884fb2529753730f","type":"GO_TERM","name":"transcription preinitiation complex","canonical_id":"go:GO:0097550","description":"\"A protein-DNA complex composed of proteins binding promoter DNA to form the transcriptional preinitiation complex (PIC), the formation of which is a prerequisite for transcription.\" [GOC:di, PMID:22751016]","metadata":null},{"id":"7e0bfb825e3e49e38a4318b5bb54d322","type":"GO_TERM","name":"transcription preinitiation complex assembly","canonical_id":"go:GO:0070897","description":"\"The formation of a large multiprotein-DNA complex that self-assembles on gene promoter through the sequential recruitment of the general initiation factors that compose the preinitiation complex (PIC). The PIC engages the RNA polymerase on its DNA template strand and sparks polymerization of the first few RNA nucleotides.\" [GOC:txnOH]","metadata":null},{"id":"5f2c2284409e451a8a93c155191aa0e8","type":"GO_TERM","name":"transcription regulator activator activity","canonical_id":"go:GO:0140537","description":"\"A molecular function regulator that increases the activity of a transcription regulator via direct binding and/or post-translational modification.\" [PMID:9597751]","metadata":null},{"id":"4e1c253ead4649779a6b0dbd0103e3ba","type":"GO_TERM","name":"transcription regulator activity","canonical_id":"go:GO:0140110","description":"\"A molecular function that controls the rate, timing and/or magnitude of gene transcription. The function of transcriptional regulators is to modulate gene expression at the transcription step so that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism. Genes are transcriptional units, and include bacterial operons.\" [GOC:pg, GOC:txnOH-2018, Wikipedia:Transcription_factor]","metadata":null},{"id":"3523d0d3cc48487d8c3f63d221618d77","type":"GO_TERM","name":"transcription regulator complex","canonical_id":"go:GO:0005667","description":"\"A protein complex that is capable of associating with DNA by direct binding, or via other DNA-binding proteins or complexes, and regulating transcription.\" [GOC:jl]","metadata":null},{"id":"413e0867c813490684b88b44eafd0aec","type":"GO_TERM","name":"transcription regulator inhibitor activity","canonical_id":"go:GO:0140416","description":"\"A molecular function regulator that inhibits the activity of a transcription regulator via direct binding and/or post-translational modification.\" [PMID:10652346]","metadata":null},{"id":"b3e176e9118c487eb69bb917e9ad9da1","type":"GO_TERM","name":"transcription regulatory region RNA binding","canonical_id":"go:GO:0001068","description":"\"Binding to a RNA region within the transcript that regulates the transcription of a gene, cistron, or operon.\" [GOC:txnOH]","metadata":null},{"id":"231ef8d2c4324f188544139e0421a460","type":"GO_TERM","name":"transcription regulatory region nucleic acid binding","canonical_id":"go:GO:0001067","description":"\"Binding to a nucleic acid region that regulates a nucleic acid-based process. Such processes include transcription, DNA replication, and DNA repair.\" [GOC:txnOH]","metadata":null},{"id":"644b3644014d43f0a94aad0bdf445ae5","type":"GO_TERM","name":"transcription repressor complex","canonical_id":"go:GO:0017053","description":"\"A protein complex that possesses activity that prevents or downregulates transcription.\" [GOC:mah]","metadata":null},{"id":"fa3cf3a7756c45478093c4ca8b053f19","type":"GO_TERM","name":"transcription termination site sequence-specific DNA binding","canonical_id":"go:GO:0001147","description":"\"Binding to a sequence of DNA that promotes termination by RNA polymerase. The transcribed region might be described as a gene, cistron, or operon.\" [GOC:txnOH, PMID:18280161, PMID:18391175]","metadata":null},{"id":"12fc6ad67509414d84671bdb027ef519","type":"GO_TERM","name":"transcription ternary complex","canonical_id":"go:GO:0097523","description":"\"A protein-DNA-RNA complex composed of RNA polymerase, template DNA, and an RNA transcript.\" [GOC:cjm, GOC:txnOH]","metadata":null},{"id":"719c409088a648b1bc33ca3f3a5c0fd3","type":"GO_TERM","name":"transcription ternary complex disassembly","canonical_id":"go:GO:0001118","description":"\"The disaggregation of a transcription ternary complex, composed of RNA polymerase, template DNA, and an RNA transcript, into its constituent components.\" [GOC:txnOH]","metadata":null},{"id":"ed60cb00f21f4b91aa698a42c44f5224","type":"GO_TERM","name":"transcription-coupled nucleotide-excision repair","canonical_id":"go:GO:0006283","description":"\"The nucleotide-excision repair process that carries out preferential repair of DNA lesions on the actively transcribed strand of the DNA duplex. In addition, the transcription-coupled nucleotide-excision repair pathway is required for the recognition and repair of a small subset of lesions that are not recognized by the global genome nucleotide excision repair pathway.\" [PMID:10197977, PMID:11900249]","metadata":null},{"id":"bff3cf8c238e4f8b848741b44625d192","type":"GO_TERM","name":"transcription-coupled nucleotide-excision repair, DNA damage recognition","canonical_id":"go:GO:0000716","description":"\"The identification of lesions on the actively transcribed strand of the DNA duplex as well as a small subset of lesions not recognized by the general nucleotide-excision repair pathway.\" [GOC:elh, PMID:10197977]","metadata":null},{"id":"844834c8ec8a41c2ac2028d443d8cd1e","type":"GO_TERM","name":"transcription-coupled nucleotide-excision repair, DNA damage recognition complex","canonical_id":"go:GO:1990250","description":"\"A protein complex that is capable of identifying lesions in DNA on the actively transcribed strand of the DNA duplex as well as a small subset of lesions not recognized by the general nucleotide-excision repair pathway. The wide range of substrate specificity suggests that the repair complex recognizes distortions in the DNA helix. It subsequently recruits a nucleotide-excision repair, preincision complex.\" [GOC:bhm, PMID:22331906]","metadata":null},{"id":"fd8c601b63d04ae6a3239929b6102143","type":"GO_TERM","name":"transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery","canonical_id":"go:GO:0000972","description":"\"The chromosome organization process in which the DNA sequence containing a gene transcribed by RNA polymerase II is maintained in a specific location at the nuclear periphery. In S. cerevisiae, this process involves cis-acting DNA sequences such as the TATA box and upstream activating sequence (UAS) elements, trans-acting transcriptional activators, and also the 3'-UTR of the transcript.\" [GOC:krc, PMID:18614049]","metadata":null},{"id":"f135e8e76d314e3396d28a2157124eff","type":"GO_TERM","name":"transcriptional attenuation","canonical_id":"go:GO:0031555","description":"\"A negative regulation of gene expression mechanism by which bacteria and archae can direct RNA polymerase to prematurely terminate transcription in response to a specific metabolic signal.\" [PMID:12210530, PMID:15851059, PMID:7007895]","metadata":null},{"id":"1599605deda944148c5a30ba7491c321","type":"GO_TERM","name":"transcriptional attenuation by ribosome","canonical_id":"go:GO:0031556","description":"\"A type of transcriptional regulation at the level of early termination. This process can occur only in prokaryotes, where transcription of an operon into messenger RNA and translation of that mRNA into polypeptides occur simultaneously. The general principle is that alternative mRNA secondary structures occur under different physiological conditions such as available amount of a particular amino acid. One set of conditions favors early termination of transcription. In the classic example of the trp biosynthesis operon, translation of the gene for a short, trp-containing polypeptide called the trp operon leader peptide pauses either at a trp codon (if tryptophan is scarce) or the stop codon (if trp is readily available). In the former situation transcription continues, but in the latter a Rho-independent terminator forms and reduces, or attenuates, expression of the tryptophan biosynthesis genes. Although the polypeptides encoded by leader peptide genes appear not to be stable once their translation is complete, it is suggested by recent studies that their nascent polypeptide chains interact specifically with ribosomes, specific uncharged tRNAs, or other cellular components to inhibit release at the stop codon and improve the function of transcriptional attenuation as a regulatory switch.\" [GOC:dh, GOC:mlg, ISBN:0198542682]","metadata":null},{"id":"d799917c73124e5e981b946933fc191d","type":"GO_TERM","name":"transcriptional start site selection at RNA polymerase II promoter","canonical_id":"go:GO:0001174","description":"\"Any process involved in the selection of the specific location within the template strand of an RNA polymerase II promoter for hybridization of the cognate ribonucleotides and formation of first phosphodiester bond within the nascent transcript.\" [GOC:txnOH, PMID:16826228, PMID:18846104]","metadata":null},{"id":"c15f92acc52b4f118e1cebe7833430fa","type":"GO_TERM","name":"transcriptional start site selection at RNA polymerase III promoter","canonical_id":"go:GO:0001175","description":"\"Any process involved in the selection of the specific location within the template strand of an RNA polymerase III promoter for hybridization of the cognate ribonucleotides and formation of first phosphodiester bond within the nascent transcript.\" [GOC:txnOH]","metadata":null},{"id":"c248e01bdde94c00a0719365f9c3f738","type":"GO_TERM","name":"transcytosis","canonical_id":"go:GO:0045056","description":"\"The directed movement of endocytosed material through the cell and its exocytosis from the plasma membrane at the opposite side.\" [ISBN:0716731363]","metadata":null},{"id":"8bba42db58664e1387e54bc3bffae237","type":"GO_TERM","name":"transdifferentiation","canonical_id":"go:GO:0060290","description":"\"The conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate.\" [GOC:dph, GOC:kmv]","metadata":null},{"id":"02e30029b5354990af9a7b2ae38aedf7","type":"GO_TERM","name":"transducin-mediated opsin signaling pathway","canonical_id":"go:GO:0141190","description":"\"A G protein-coupled receptor signaling pathway that starts with an opsin molecule being activated by a photon. Opsins include rhodopsin and others visual receptors bind heterotrimeric transducin G proteins upon activation. Activated transducin alpha-subunit activates cGMP phosphodiesterase, which breaks down cGMP. The decrease in cGMP concentration leads to closure of cGMP-gated (CNG) channels, blockage of Na+ influx, and hyperpolarization of photoreceptor plasma membrane, leading to transmission of signal through synapses. The signal is terminated by phosphorylation of the C-terminal tail of rhodopsin by rhodopsin kinase to allow arrestin to bind and block G protein binding. Typical examples are rhabdomeric photoreceptors in the eyes of deuterostomes.\" [PMID:19720651, PMID:36272560, PMID:36499010, PMID:37159291]","metadata":null},{"id":"1ce00fefa77642a58d914ad2c93905d7","type":"GO_TERM","name":"transduction","canonical_id":"go:GO:0009293","description":"\"A type of horizontal gene transfer in which genetic material is introduced into a cell mediated by a virus.\" [PMID:18265289, PMID:33597173]","metadata":null},{"id":"9939f500d21b45ea84eacd0a273983a6","type":"GO_TERM","name":"transepithelial ammonium transport","canonical_id":"go:GO:0070634","description":"\"The directed movement of ammonium ions from one side of an epithelium to the other.\" [GOC:mah, GOC:yaf]","metadata":null},{"id":"8a19c3c8f56b48aa8973302482599883","type":"GO_TERM","name":"transepithelial chloride transport","canonical_id":"go:GO:0030321","description":"\"The directed movement of chloride ions from one side of an epithelium to the other.\" [GOC:mah]","metadata":null},{"id":"dd0bc8517bc9458b9798b1fa1c7ad7ba","type":"GO_TERM","name":"transepithelial transport","canonical_id":"go:GO:0070633","description":"\"The directed movement of a substance from one side of an epithelium to the other.\" [GOC:mah, GOC:yaf, ISBN:0716731363]","metadata":null},{"id":"88999527ee984698a602627b6b3242e8","type":"GO_TERM","name":"transepithelial water transport","canonical_id":"go:GO:0035377","description":"\"The directed movement of water (H2O) from one side of an epithelium to the other.\" [GOC:yaf]","metadata":null},{"id":"1299b2f8b4d24052a0cf5e77959f82d3","type":"GO_TERM","name":"transferase activity","canonical_id":"go:GO:0016740","description":"\"Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.\" [EC:2.-.-.-]","metadata":null},{"id":"04a8f78ffee1484787e5cf21d32d8554","type":"GO_TERM","name":"transferase activity, transferring alkyl or aryl (other than methyl) groups","canonical_id":"go:GO:0016765","description":"\"Catalysis of the transfer of an alkyl or aryl (but not methyl) group from one compound (donor) to another (acceptor).\" [EC:2.5.1.-]","metadata":null},{"id":"e8f4473a16a24d08a17b4da3bbf4bfda","type":"GO_TERM","name":"transferase activity, transferring nitrogenous groups","canonical_id":"go:GO:0016769","description":"\"Catalysis of the transfer of a nitrogenous group from one compound (donor) to another (acceptor).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"a7b673b92ada4a2fa676027072dd3cf3","type":"GO_TERM","name":"transferase activity, transferring one-carbon groups","canonical_id":"go:GO:0016741","description":"\"Catalysis of the transfer of a one-carbon group from one compound (donor) to another (acceptor).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"e2923404e04d46edb09a44d253826540","type":"GO_TERM","name":"transferase activity, transferring phosphorus-containing groups","canonical_id":"go:GO:0016772","description":"\"Catalysis of the transfer of a phosphorus-containing group from one compound (donor) to another (acceptor).\" [EC:2.7.-.-]","metadata":null},{"id":"63772c4aa31a46bfa0a410edb88cb74b","type":"GO_TERM","name":"transferase activity, transferring sulphur-containing groups","canonical_id":"go:GO:0016782","description":"\"Catalysis of the transfer of a sulfur-containing group from one compound (donor) to another (acceptor).\" [EC:2.8.-.-]","metadata":null},{"id":"ac727267c7b34535938315c547770aa3","type":"GO_TERM","name":"transferase complex","canonical_id":"go:GO:1990234","description":"\"A protein complex capable of catalyzing the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor).\" [GOC:bhm, PMID:16540464]","metadata":null},{"id":"dd6ce3332a834a7697598b9aed3f0c26","type":"GO_TERM","name":"transferase complex, transferring phosphorus-containing groups","canonical_id":"go:GO:0061695","description":"\"A transferase complex capable of catalysis of the transfer of a phosphorus-containing group from one compound (donor) to another (acceptor).\" [GOC:bhm, GOC:dph]","metadata":null},{"id":"ed033297838b4ab6b5a3fe595fb096ff","type":"GO_TERM","name":"transferrin receptor activity","canonical_id":"go:GO:0004998","description":"\"Combining selectively with transferrin, and delivering transferrin into the cell via endocytosis. Transferrin is a major iron carrier protein in vertebrates.\" [GOC:bf, PMID:2678449, PMID:3011819]","metadata":null},{"id":"2aed7cf03b65443ab89f1db681108adb","type":"GO_TERM","name":"transferrin receptor binding","canonical_id":"go:GO:1990459","description":"\"Binding to a transferrin receptor.\" [GOC:pm, PMID:9819414]","metadata":null},{"id":"27400aa5991b497cabf8d3450d1ab81a","type":"GO_TERM","name":"transferrin transport","canonical_id":"go:GO:0033572","description":"\"The directed movement of transferrin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mlg]","metadata":null},{"id":"9a86db3e977d4637a130eff225472729","type":"GO_TERM","name":"transforming growth factor beta activated kinase 1 complex","canonical_id":"go:GO:0097076","description":"\"A protein complex that possesses protein kinase activity and activates the I-kappa B kinase complex (IKK) and mitogen-activated protein (MAP) kinases in response to TRAF6 signaling. It comprises the catalytic subunit TAK1 complexed to the regulatory subunits, termed TABs (TAK1-binding subunits).\" [GOC:cna, PMID:16410796, PMID:17496917, PMID:18021073]","metadata":null},{"id":"4c5e58a0439d4dc28c4f4499051a1a37","type":"GO_TERM","name":"transforming growth factor beta binding","canonical_id":"go:GO:0050431","description":"\"Binding to TGF-beta, transforming growth factor beta, a multifunctional peptide that controls proliferation, differentiation and other functions in many cell types.\" [ISBN:0198506732]","metadata":null},{"id":"237735070c804ca78c300ef5f5248ef5","type":"GO_TERM","name":"transforming growth factor beta complex","canonical_id":"go:GO:0099126","description":"\"A protein complex acting as ligand of the transforming growth factor beta receptor complex, typically a homodimer of any of the TFGbeta isoforms. The precursor of TGFbeta proteins is cleaved into mature TGFbeta and the latency-associated peptide (LAP), which remains non-covalently linked to mature TGFbeta rendering it inactive. TGFbeta is activated by dimerization and dissociation of the LAP.\" [PMID:22943793, PMID:25960420, PMID:27252363, PMID:29217273]","metadata":null},{"id":"bc869b5bf4d44c84b169d817b0d6e45f","type":"GO_TERM","name":"transforming growth factor beta ligand-receptor complex","canonical_id":"go:GO:0070021","description":"\"A protein complex that is formed by the association of a TGF-beta dimeric ligand with 2 molecules of each receptor molecule, TGF-beta type I receptor and TGF-beta type II receptor. The receptor molecules may form homo- or heterodimers but only once bound by the ligand.\" [GOC:curators]","metadata":null},{"id":"b50cc9f68e654297bd6c6668f5067b31","type":"GO_TERM","name":"transforming growth factor beta production","canonical_id":"go:GO:0071604","description":"\"The appearance of any member of the transforming growth factor-beta family of cytokines due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Transforming growth factor-beta family members include TGF-B1, TGF-B2, and TGF-B3.\" [GOC:add, GOC:rv, PMID:16891311, PMID:2022183]","metadata":null},{"id":"1144fcee5fba43f6ad0967e87aeba9a9","type":"GO_TERM","name":"transforming growth factor beta receptor activity","canonical_id":"go:GO:0005024","description":"\"Combining with a transforming growth factor beta (TGFbeta) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"4830ff5da3f549c6921c584a7d4ba014","type":"GO_TERM","name":"transforming growth factor beta receptor activity, type I","canonical_id":"go:GO:0005025","description":"\"Combining with a complex of transforming growth factor beta and a type II TGF-beta receptor to initiate a change in cell activity; upon binding, acts as a downstream transducer of TGF-beta signals.\" [GOC:mah]","metadata":null},{"id":"b40b968d0ae3479290de0066b5c01a8e","type":"GO_TERM","name":"transforming growth factor beta receptor activity, type II","canonical_id":"go:GO:0005026","description":"\"Combining with transforming growth factor beta to initiate a change in cell activity; upon ligand binding, binds to and catalyzes the phosphorylation of a type I TGF-beta receptor.\" [GOC:mah]","metadata":null},{"id":"27b4e9c0b0904988ac0d690bf8a3b868","type":"GO_TERM","name":"transforming growth factor beta receptor activity, type III","canonical_id":"go:GO:0070123","description":"\"Combining with transforming growth factor beta to initiate a change in cell activity; facilitates ligand binding to type I and type II TGF-beta receptors.\" [GOC:BHF, GOC:mah, PMID:9759503]","metadata":null},{"id":"d5b35e21625c44e688ca938fa2c486ba","type":"GO_TERM","name":"transforming growth factor beta receptor binding","canonical_id":"go:GO:0005160","description":"\"Binding to a transforming growth factor beta receptor.\" [GOC:ai]","metadata":null},{"id":"815dc354f2f34f2496aac62d03f6681d","type":"GO_TERM","name":"transforming growth factor beta receptor complex assembly","canonical_id":"go:GO:0007181","description":"\"The aggregation, arrangement and bonding together of a ligand-bound type II transforming growth factor beta (TGF-beta) receptor dimer with a type I TGF-beta receptor dimer, following ligand binding, to form a heterotetrameric TGF-beta receptor complex.\" [GOC:jl, Wikipedia:TGF_beta_signaling_pathway]","metadata":null},{"id":"1d305d3373f14515942368504701da82","type":"GO_TERM","name":"transforming growth factor beta receptor signaling pathway","canonical_id":"go:GO:0007179","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a transforming growth factor beta receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:mah, GOC:signaling]","metadata":null},{"id":"82477799411e4d12af8c6aecf45bd3bf","type":"GO_TERM","name":"transforming growth factor beta receptor superfamily signaling pathway","canonical_id":"go:GO:0141091","description":"\"The series of molecular signals initiated by an extracellular ligand binding to a member of the transforming growth factor receptor superfamily, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [PMID:22651914, PMID:28096268]","metadata":null},{"id":"20d2dcc5b1f34fa9a10fb439b71a9f2f","type":"GO_TERM","name":"transforming growth factor beta1 production","canonical_id":"go:GO:0032905","description":"\"The appearance of transforming growth factor-beta1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"372bca9920d248cb9590a9f783121e71","type":"GO_TERM","name":"transforming growth factor beta2 production","canonical_id":"go:GO:0032906","description":"\"The appearance of transforming growth factor-beta2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"c92e67bf7c504f55b225c6c406c3c80d","type":"GO_TERM","name":"transforming growth factor beta3 production","canonical_id":"go:GO:0032907","description":"\"The appearance of transforming growth factor-beta3 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:mah]","metadata":null},{"id":"eb74eb5b1dd44579944ee6ce8210c3c7","type":"DISEASE","name":"transient ischemic attack","canonical_id":"mondo:0005264","description":null,"metadata":null},{"id":"f215d7a9641a4166a03831f3007df723","type":"DISEASE","name":"transient neonatal diabetes mellitus","canonical_id":"mondo:0020525","description":null,"metadata":null},{"id":"4463fa15018a4c6a8a8972473bd5f1a9","type":"GO_TERM","name":"transition between fast and slow fiber","canonical_id":"go:GO:0014883","description":"\"The process of conversion of fast-contracting muscle fibers to a slower character. This may involve slowing of contractile rate, slow myosin gene induction, increase in oxidative metabolic properties, altered electrophysiology and altered innervation. This process also regulates skeletal muscle adapatation.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"874c038b1bbd4d128713a505d3e3b98d","type":"GO_TERM","name":"transition between slow and fast fiber","canonical_id":"go:GO:0014886","description":"\"The process of conversion of slow-contracting muscle fibers to a faster character. This may involve increasing of contractile rate, fast myosin gene induction, increase in glycolytic metabolic properties, altered electrophysiology and altered innervation. This process also regulates skeletal muscle adapatation.\" [GOC:ef, GOC:mtg_muscle]","metadata":null},{"id":"47af8bb998304d0180c51b6bd47eb5d4","type":"GO_TERM","name":"transition metal ion binding","canonical_id":"go:GO:0046914","description":"\"Binding to a transition metal ions; a transition metal is an element whose atom has an incomplete d-subshell of extranuclear electrons, or which gives rise to a cation or cations with an incomplete d-subshell. Transition metals often have more than one valency state. Biologically relevant transition metals include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum and silver.\" [ISBN:0198506732]","metadata":null},{"id":"41a393377a85484ba2aadcfa5f3f601f","type":"GO_TERM","name":"transition metal ion transmembrane transporter activity","canonical_id":"go:GO:0046915","description":"\"Enables the transfer of transition metal ions from one side of a membrane to the other. A transition metal is an element whose atom has an incomplete d-subshell of extranuclear electrons, or which gives rise to a cation or cations with an incomplete d-subshell. Transition metals often have more than one valency state. Biologically relevant transition metals include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum and silver.\" [ISBN:0198506732]","metadata":null},{"id":"8897495c3fc84f8d8b493a89f053db32","type":"GO_TERM","name":"transition metal ion transport","canonical_id":"go:GO:0000041","description":"\"The directed movement of transition metal ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A transition metal is an element whose atom has an incomplete d-subshell of extranuclear electrons, or which gives rise to a cation or cations with an incomplete d-subshell. Transition metals often have more than one valency state. Biologically relevant transition metals include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum and silver.\" [ISBN:0198506732]","metadata":null},{"id":"226681a5f09e448e99a61cfe0b707c88","type":"DISEASE","name":"transitional cell carcinoma","canonical_id":"mondo:0006474","description":null,"metadata":null},{"id":"248b9896346e4220a44e453e6588bfe2","type":"GO_TERM","name":"transitional one stage B cell differentiation","canonical_id":"go:GO:0002333","description":"\"The process in which immature B cells from the bone marrow acquire the specialized features of T1 stage B cells in the spleen. T1 stage B cells do not express either CD23 or CD21.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"1bda4dcdd06945e4b5d892e0ecbad0c6","type":"GO_TERM","name":"transitional stage B cell differentiation","canonical_id":"go:GO:0002332","description":"\"The process in which immature B cells from the bone marrow become mature B cells in the spleen. Transitional stage B cells are subdivided into transitional one (T1) and transitional two (T2) stages and are short-lived and functionally incompetent.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"b6a9c9e51cfe4ad6ba70108ba59b9734","type":"GO_TERM","name":"transitional two stage B cell differentiation","canonical_id":"go:GO:0002334","description":"\"The process in which immature B cells from the bone marrow acquire the specialized features of T2 stage B cells in the spleen. T2 stage B cells express CD23 but not CD21.\" [GOC:jal, ISBN:0781735149]","metadata":null},{"id":"50279defeb6a401c88e625a4b89aef94","type":"GO_TERM","name":"transitive RNA interference","canonical_id":"go:GO:0036453","description":"\"An RNA interference where the silencing signal spreads along the target mRNA in a 5' or 3' direction, outside of the initial target sequence.\" [GOC:pf, PMID:11719187, PMID:12554873, PMID:23724097, PMID:24369430]","metadata":null},{"id":"242f98eceef64372a3bb246b4c5dbf96","type":"GO_TERM","name":"transketolase activity","canonical_id":"go:GO:0004802","description":"\"Catalysis of the reversible transfer of a 2-carbon ketol group (CH2OH-CO-) from a ketose phosphate donor to an aldose phosphate acceptor.\" [EC:2.2.1.1, GOC:fmc]","metadata":null},{"id":"9017fb719e1e43268aad266be28b373f","type":"GO_TERM","name":"transketolase or transaldolase activity","canonical_id":"go:GO:0016744","description":"\"Catalysis of the transfer of an aldehyde or ketonic group from one compound (donor) to another (acceptor).\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"13f693cc704645c9be81c2f308122f5b","type":"GO_TERM","name":"translation","canonical_id":"go:GO:0006412","description":"\"The cellular metabolic process in which a protein is formed, using the sequence of a mature mRNA or circRNA molecule to specify the sequence of amino acids in a polypeptide chain. Translation is mediated by the ribosome, and begins with the formation of a ternary complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2, which subsequently associates with the small subunit of the ribosome and an mRNA or circRNA. Translation ends with the release of a polypeptide chain from the ribosome.\" [GOC:curators]","metadata":null},{"id":"c765bfad62da495fbf5bcf78eae63fbc","type":"GO_TERM","name":"translation activator activity","canonical_id":"go:GO:0008494","description":"\"Any of a group of soluble proteins functioning in the activation of ribosome-mediated translation of mRNA into a polypeptide.\" [GOC:ai]","metadata":null},{"id":"fdd2cab82efc46339023b6a51a504604","type":"GO_TERM","name":"translation at postsynapse","canonical_id":"go:GO:0140242","description":"\"Translation that occurs at the postsynapse.\" [PMID:20427644]","metadata":null},{"id":"0054d87516ab47ebac1cddaafb7c9e3a","type":"GO_TERM","name":"translation at presynapse","canonical_id":"go:GO:0140236","description":"\"Translation that occurs at the presynapse.\" [PMID:27321671]","metadata":null},{"id":"5593af8c28164648b2167f5dde804879","type":"GO_TERM","name":"translation at presynapse, modulating chemical synaptic transmission","canonical_id":"go:GO:0140237","description":"\"Translation that occurs at the presynapse, and that modulates chemical synaptic transmission.\" [PMID:27321671]","metadata":null},{"id":"0443a3f5d1a04b1ab25994e2cb4bd61b","type":"GO_TERM","name":"translation at synapse","canonical_id":"go:GO:0140241","description":"\"Translation that occurs at the synapse.\" [PMID:23083742]","metadata":null},{"id":"374833ab18264f5ea06a60ad5103ca68","type":"GO_TERM","name":"translation elongation factor activity","canonical_id":"go:GO:0003746","description":"\"Functions in chain elongation during polypeptide synthesis at the ribosome.\" [ISBN:0198506732]","metadata":null},{"id":"fa9c513a14e54939a42c19e43a422c42","type":"GO_TERM","name":"translation elongation factor binding","canonical_id":"go:GO:0061770","description":"\"Binding to a translation elongation factor, any polypeptide factor involved in the peptide elongation in ribosome-mediated translation.\" [GOC:dph]","metadata":null},{"id":"12de779fd27b45b2bc3595bfccbd6c38","type":"GO_TERM","name":"translation factor activity","canonical_id":"go:GO:0180051","description":"\"A molecular function required for translation of a mRNA into a protein functioning as part of initiation, elongation or termination of translation.\" [GOC:pg]","metadata":null},{"id":"86ef63666563439a90d17b74d22981c5","type":"GO_TERM","name":"translation factor activity, RNA binding","canonical_id":"go:GO:0008135","description":"\"Functions during translation by binding to RNA during polypeptide synthesis at the ribosome.\" [GOC:ai, GOC:vw]","metadata":null},{"id":"96b3ceb4d1374b1184186b4434d49d28","type":"GO_TERM","name":"translation factor activity, non-nucleic acid binding","canonical_id":"go:GO:0045183","description":"\"A translation regulator activity that does not involve binding to nucleic acids.\" [GOC:ai, GOC:dph, GOC:tb]","metadata":null},{"id":"cc039f54f7104e52b5f578c2b6a7ee70","type":"GO_TERM","name":"translation initiation complex","canonical_id":"go:GO:0070992","description":"\"A ribonucleoprotein complex that contains a ribosome, mRNA, and initiator tRNA; the functional ribosome is at the AUG, with the methionyl/formyl-methionyl-tRNA positioned at the P site.\" [GOC:hjd, GOC:mah]","metadata":null},{"id":"6ffc20c4765c49a1b987614c7e00060f","type":"GO_TERM","name":"translation initiation factor activity","canonical_id":"go:GO:0003743","description":"\"Functions in the initiation of ribosome-mediated translation of mRNA into a polypeptide.\" [ISBN:0198506732]","metadata":null},{"id":"97631d2f77f24b16b376be489f1e521d","type":"GO_TERM","name":"translation initiation factor binding","canonical_id":"go:GO:0031369","description":"\"Binding to a translation initiation factor, any polypeptide factor involved in the initiation of ribosome-mediated translation.\" [GOC:mah]","metadata":null},{"id":"b3f34a1184f040a78ef4bb0b3224151d","type":"GO_TERM","name":"translation initiation ternary complex","canonical_id":"go:GO:0044207","description":"\"A ribonucleoprotein complex that contains aminoacylated initiator methionine tRNA, GTP, and initiation factor 2 (either eIF2 in eukaryotes, or IF2 in prokaryotes). In prokaryotes, fMet-tRNA (initiator) is used rather than Met-tRNA (initiator).\" [GOC:jl]","metadata":null},{"id":"04fceabeceb5430cb7fb9daec884f99f","type":"GO_TERM","name":"translation regulator activity","canonical_id":"go:GO:0045182","description":"\"Any molecular function involved in the regulation of initiation, activation, perpetuation, repression or termination of polypeptide synthesis at the ribosome.\" [GOC:ai]","metadata":null},{"id":"be8800067ea94fb0bcf7fdac4e5f751e","type":"GO_TERM","name":"translation reinitiation","canonical_id":"go:GO:0002188","description":"\"A gene-specific translational control mechanism where the small ribosomal subunit remains attached to the mRNA following termination of translation, then resumes scanning on the same mRNA molecule and initiates again at a downstream start site. Reinitiation depends on de novo recruitment of the ternary complex that is required to recognize the next AUG codon.\" [PMID:18056426, PMID:18765792]","metadata":null},{"id":"dc770b8f085240d693e869a52bb93053","type":"GO_TERM","name":"translation release factor activity","canonical_id":"go:GO:0003747","description":"\"Involved in catalyzing the release of a nascent polypeptide chain from a ribosome.\" [ISBN:0198547684]","metadata":null},{"id":"a7e8fb7695b645fea95612b76d781b40","type":"GO_TERM","name":"translation release factor activity, codon nonspecific","canonical_id":"go:GO:0016150","description":"\"A translation release factor that is not specific to particular codons; binds to guanine nucleotides.\" [ISBN:0198547684]","metadata":null},{"id":"e6e698a3f04045e5bb87b9cb9d418089","type":"GO_TERM","name":"translation release factor activity, codon specific","canonical_id":"go:GO:0016149","description":"\"A translation release factor that is specific for one or more particular termination codons; acts at the ribosomal A-site and require polypeptidyl-tRNA at the P-site.\" [ISBN:0198547684]","metadata":null},{"id":"69bcb8b2ac5b4f1cb733ec5a85be9dc4","type":"GO_TERM","name":"translation release factor complex","canonical_id":"go:GO:0018444","description":"\"A heterodimeric complex involved in the release of a nascent polypeptide chain from a ribosome.\" [ISBN:0198547684]","metadata":null},{"id":"25e516400b144006869a4ee4d8b09ec8","type":"GO_TERM","name":"translation repressor activity","canonical_id":"go:GO:0030371","description":"\"Antagonizes ribosome-mediated translation of mRNA into a polypeptide.\" [GOC:ai, GOC:clt]","metadata":null},{"id":"5dc27472a59c4f628e82e6756e064f1f","type":"GO_TERM","name":"translation repressor activity, non-nucleic acid binding","canonical_id":"go:GO:0000901","description":"\"Antagonizes the ribosome-mediated translation of mRNA into a polypeptide but does not bind directly to nucleic acid.\" [GOC:clt]","metadata":null},{"id":"b9454f60b1b74ff48766610c0d9707d0","type":"GO_TERM","name":"translation repressor complex","canonical_id":"go:GO:1903502","description":"\"A protein complex which is capable of translation repressor activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:14723848]","metadata":null},{"id":"639671c37bd744849bbfc6d03c72c437","type":"GO_TERM","name":"translation termination factor activity","canonical_id":"go:GO:0008079","description":"\"Functions in the termination of translation.\" [GOC:ma]","metadata":null},{"id":"267bc54be06d4608ace9bd740dbe3244","type":"GO_TERM","name":"translational attenuation","canonical_id":"go:GO:0009386","description":"\"Translational attenuation is a regulatory mechanism analogous to ribosome-mediated transcriptional attenuation. The system requires the presence of a short ORF, called a leader peptide, encoded in the mRNA upstream of the ribosome-binding site and start codon of the gene whose translation is to be regulated. Certain conditions, such as presence of the antibiotic tetracycline in bacteria or amino acid starvation, may cause slowing or stalling of the ribosome translating the leader peptide. The stalled ribosome masks a region of the mRNA and affects which of two alternative mRNA folded structures will form, therefore controlling whether or not a ribosome will bind and initiate translation of the downstream gene. Translational attenuation is analogous to ribosome-mediated transcriptional attenuation, in which mRNA remodeling caused by ribosome stalling regulates transcriptional termination rather than translational initiation.\" [PMID:15694341, PMID:15805513]","metadata":null},{"id":"421312f1e3c845b7b8540467a7faea48","type":"GO_TERM","name":"translational elongation","canonical_id":"go:GO:0006414","description":"\"The successive addition of amino acid residues to a nascent polypeptide chain during protein biosynthesis.\" [GOC:ems]","metadata":null},{"id":"78834d78511f40aeb51d49decbe4ca10","type":"GO_TERM","name":"translational frameshifting","canonical_id":"go:GO:0006452","description":"\"A mechanism whereby different proteins may result from a single mRNA molecule, due to a change in the parsing of three nucleotides per codon relative to an initiating AUG codon.\" [GOC:hjd, ISBN:0195094425]","metadata":null},{"id":"bc13f2cef6b7433f8b11e6478bd58d15","type":"GO_TERM","name":"translational initiation","canonical_id":"go:GO:0006413","description":"\"The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA or circRNA, and an initiation complex that contains the first aminoacyl-tRNA.\" [ISBN:019879276X]","metadata":null},{"id":"5243ea1579dd4089bebf66cf456650fd","type":"GO_TERM","name":"translational readthrough","canonical_id":"go:GO:0006451","description":"\"The continuation of translation beyond a stop codon by the use of a special tRNA that recognizes the UAG and UGA codons as modified amino acids, rather than as termination codons.\" [GOC:jsg, PMID:11179232]","metadata":null},{"id":"93537c1dce994fe69af56d684f82cb2a","type":"GO_TERM","name":"translational termination","canonical_id":"go:GO:0006415","description":"\"The process resulting in the release of a polypeptide chain from the ribosome, usually in response to a termination codon (UAA, UAG, or UGA in the universal genetic code).\" [GOC:hjd, ISBN:019879276X]","metadata":null},{"id":"af29ad9f87ee4d05b7805508ed18f66a","type":"GO_TERM","name":"translesion synthesis","canonical_id":"go:GO:0019985","description":"\"The replication of damaged DNA by synthesis across a lesion in the template strand; a specialized DNA polymerase or replication complex inserts a defined nucleotide across from the lesion which allows DNA synthesis to continue beyond the lesion. This process can be mutagenic depending on the damaged nucleotide and the inserted nucleotide.\" [GOC:elh, GOC:vw, PMID:10535901]","metadata":null},{"id":"79f2c28b70014d8392e20f22f1bd841e","type":"GO_TERM","name":"translocation of molecules into host","canonical_id":"go:GO:0044417","description":"\"The directed movement of a molecule(s) produced by an organism to a location inside its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:cc, PMID:18406478]","metadata":null},{"id":"6d8da5974d7e4b9994ff60a6b500fe82","type":"GO_TERM","name":"translocation of molecules into symbiont","canonical_id":"go:GO:0051862","description":"\"The directed movement of molecule(s) produced by an organism to a location inside the symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"b32650733e964389875dd2902c2b8c4c","type":"GO_TERM","name":"translocation of peptides or proteins into host","canonical_id":"go:GO:0042000","description":"\"The directed movement of peptides or proteins produced by an organism to a location inside its host organism. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:cc, PMID:15953025, PMID:18406478]","metadata":null},{"id":"5f0711858f8a4bf9b036afcf04a563a3","type":"GO_TERM","name":"translocation of peptides or proteins into host cell cytoplasm","canonical_id":"go:GO:0044053","description":"\"The directed movement of peptides or proteins produced by a symbiont organism to a location within the host cell cytoplasm.\" [MITRE:tk]","metadata":null},{"id":"66bbd2c939774124a15f06b5d4d77dba","type":"GO_TERM","name":"translocation of peptides or proteins into symbiont","canonical_id":"go:GO:0051844","description":"\"The directed movement of peptides or proteins produced by an organism to a location inside the symbiont organism. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.\" [GOC:cc]","metadata":null},{"id":"ffbe6e859b9b47b3b205b0f9c1f2eea0","type":"GO_TERM","name":"translocon complex","canonical_id":"go:GO:0071256","description":"\"A protein complex that constitutes a specific site of protein translocation across the endoplasmic reticulum, which involves the signal recognition particle receptor. The complex contains a core heterotrimer of alpha, beta and gamma subunits, and may contain additional proteins.\" [GOC:mah, PMID:10611978, PMID:18166647, PMID:8612571]","metadata":null},{"id":"bda4a0b747a74fcfa585aab37bd86eb7","type":"GO_TERM","name":"transmembrane actin-associated (TAN) line","canonical_id":"go:GO:1990973","description":"\"A linear array of nuclear envelope membrane proteins composed of nesprin-2G and SUN2, which couple the nucleus to moving actin cables, resulting in rearward nuclear transport (away from the leading edge).\" [GOC:hjd, PMID:21173262]","metadata":null},{"id":"eaaaaf2d05b944aab464c76fc3730f45","type":"GO_TERM","name":"transmembrane ascorbate ferrireductase activity","canonical_id":"go:GO:0140571","description":"\"Oxidation of Fe(3+) to Fe(2+) on the outer side of a membrane coupled to the reduction of L-ascorbate to monodehydro-L-ascorbate radical on the inner side of a membrane. Electrons get transferred across the membrane during the reaction.\" [PMID:16911521, PMID:24449903, RHEA:30403]","metadata":null},{"id":"cc827f95f1964425b656519b161aa1fc","type":"GO_TERM","name":"transmembrane collagen trimer","canonical_id":"go:GO:0030936","description":"\"Any collagen trimer that passes through a lipid bilayer membrane.\" [PMID:21421911]","metadata":null},{"id":"75af4176075b4d6791debfafefc73895","type":"GO_TERM","name":"transmembrane histidine kinase cytokinin receptor activity","canonical_id":"go:GO:0009885","description":"\"Combining with a cytokinin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-histidine = ADP + a protein-L-histidine phosphate.\" [GOC:lr, GOC:mah]","metadata":null},{"id":"573dc3445605497499225167f53f31b6","type":"GO_TERM","name":"transmembrane monodehydroascorbate reductase activity","canonical_id":"go:GO:0140575","description":"\"Oxidation of monodehydroascorbate outside of a membrane coupled to the reduction of L-ascorbate to monodehydro-L-ascorbate radical on the inner side of a membrane. Electrons get transferred across the membrane during the reaction.\" [PMID:1623014, RHEA:66524]","metadata":null},{"id":"46b945cf4d024e6780e9d7a4b3b1247b","type":"GO_TERM","name":"transmembrane phosphate ion transport from cytosol to vacuole","canonical_id":"go:GO:1905011","description":"\"The directed movement of phosphate ions from the cytosol across the vacuolar membrane and into the vacuolar lumen.\" [GO_REF:0000078, GOC:TermGenie, PMID:26554016]","metadata":null},{"id":"5dc57235a7d848009eb5d8265c9e72c2","type":"GO_TERM","name":"transmembrane protein transporter activity","canonical_id":"go:GO:0008320","description":"\"Enables the transfer of a protein from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"5f0e783d7af14aa398daaa460e012aaa","type":"GO_TERM","name":"transmembrane receptor histidine kinase activity","canonical_id":"go:GO:0009784","description":"\"Combining with a signal and transmitting the signal from one side of a membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-histidine = ADP + a protein-L-histidine phosphate.\" [GOC:lr, GOC:mah]","metadata":null},{"id":"4a0966f2c81143cd98432d61e7dd611c","type":"GO_TERM","name":"transmembrane receptor protein kinase activity","canonical_id":"go:GO:0019199","description":"\"Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: a protein + ATP = a phosphoprotein + ADP.\" [GOC:mah]","metadata":null},{"id":"eb81418e3eb8466086fdb4983f8df71a","type":"GO_TERM","name":"transmembrane receptor protein phosphatase activity","canonical_id":"go:GO:0019198","description":"\"Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: a phosphoprotein + H2O = a protein + phosphate.\" [GOC:hjd]","metadata":null},{"id":"14ab27e6796b4147802c2ce304d3435f","type":"GO_TERM","name":"transmembrane receptor protein serine/threonine kinase activity","canonical_id":"go:GO:0004675","description":"\"Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.\" [RHEA:18673]","metadata":null},{"id":"19841b063b2c403eb18cabefde0e4991","type":"GO_TERM","name":"transmembrane receptor protein serine/threonine kinase binding","canonical_id":"go:GO:0070696","description":"\"Binding to a receptor that spans a cell membrane and possesses protein serine/threonine kinase activity.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"b69cd76afcd7491187c587ba9dab0693","type":"GO_TERM","name":"transmembrane receptor protein tyrosine kinase activator activity","canonical_id":"go:GO:0030297","description":"\"Binds to and increases the activity of a transmembrane receptor protein tyrosine kinase.\" [GOC:mah]","metadata":null},{"id":"93eb2968d2b54c50b49029da268941bc","type":"GO_TERM","name":"transmembrane receptor protein tyrosine kinase activity","canonical_id":"go:GO:0004714","description":"\"Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.\" [EC:2.7.10.1, GOC:mah]","metadata":null},{"id":"8accb6f7f0ed4742be533bf8a4b3c2f8","type":"GO_TERM","name":"transmembrane receptor protein tyrosine kinase adaptor activity","canonical_id":"go:GO:0005068","description":"\"The binding activity of a molecule that brings together a transmembrane receptor protein tyrosine kinase and one or more other molecules, permitting them to function in a coordinated way.\" [GOC:mtg_MIT_16mar07, PMID:10502414, PMID:20565848]","metadata":null},{"id":"c4892ef5b5bc43ca902210576af2eeb5","type":"GO_TERM","name":"transmembrane receptor protein tyrosine kinase inhibitor activity","canonical_id":"go:GO:0030293","description":"\"Binds to and stops, prevents or reduces the activity of a transmembrane receptor protein tyrosine kinase.\" [GOC:mah]","metadata":null},{"id":"cd18d13727d3469d857674e64f234761","type":"GO_TERM","name":"transmembrane receptor protein tyrosine phosphatase activity","canonical_id":"go:GO:0005001","description":"\"Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate.\" [PMID:34353440]","metadata":null},{"id":"253915bad8df423f9ca9e403e0a8910e","type":"GO_TERM","name":"transmembrane signaling receptor activity","canonical_id":"go:GO:0004888","description":"\"Combining with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction.\" [GOC:curators, Wikipedia:Transmembrane_receptor]","metadata":null},{"id":"f7ca20542a14468384a6b5a16280fa5f","type":"GO_TERM","name":"transmembrane transport","canonical_id":"go:GO:0055085","description":"\"The process in which a solute is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:dph, GOC:jid]","metadata":null},{"id":"4ff0bab81c9f48e38187995ab23317d2","type":"GO_TERM","name":"transmembrane transport from lysosomal lumen to cytosol","canonical_id":"go:GO:0170063","description":"\"The directed movement of a solute from the lysosomal lumen across the lysosomal membrane and into the cytosol.\" [PMID:26631267]","metadata":null},{"id":"25143727ba474526ba04914b29101caf","type":"GO_TERM","name":"transmembrane transporter activity","canonical_id":"go:GO:0022857","description":"\"Enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other.\" [GOC:jid, GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ad27a75762a7418a97c9c0ad8f1171ea","type":"GO_TERM","name":"transmembrane transporter binding","canonical_id":"go:GO:0044325","description":"\"Binding to a transmembrane transporter, a protein or protein complex that enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other.\" [GOC:BHF, GOC:jl, PMID:33199372]","metadata":null},{"id":"a988cb6e668b4741b7982a45da64cce5","type":"GO_TERM","name":"transmembrane transporter complex","canonical_id":"go:GO:1902495","description":"\"A transmembrane protein complex which enables the transfer of a substance from one side of a membrane to the other.\" [GOC:bhm, GOC:TermGenie, PMID:18024586]","metadata":null},{"id":"b2e73d62c5374b5e940fd7efe73eeb22","type":"GO_TERM","name":"transmembrane-ephrin receptor activity","canonical_id":"go:GO:0005005","description":"\"Combining with a transmembrane ephrin to initiate a change in cell activity.\" [GOC:mah, PMID:9530499]","metadata":null},{"id":"4c0b7c4d632d4e2abf56cffa07f9e2f2","type":"GO_TERM","name":"transmission of nerve impulse","canonical_id":"go:GO:0019226","description":"\"The neurological system process in which a signal is transmitted through the nervous system by a combination of action potential propagation and synaptic transmission.\" [GOC:curators, ISBN:0815316194]","metadata":null},{"id":"d1f874c09e7749d0b1689b77083ff712","type":"GO_TERM","name":"transmitter-gated channel activity","canonical_id":"go:GO:0022835","description":"\"Enables the transmembrane transfer of a solute by a channel that opens when a specific neurotransmitter has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"666e89e3737b495cb5f68f08c2904d90","type":"GO_TERM","name":"transmitter-gated monoatomic ion channel activity","canonical_id":"go:GO:0022824","description":"\"Enables the transmembrane transfer of an ion by a channel that opens when a specific neurotransmitter has been bound by the channel complex or one of its constituent parts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"0c0906ef44f44207bf410089bb00c2f2","type":"GO_TERM","name":"transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential","canonical_id":"go:GO:1904315","description":"\"Any transmitter-gated ion channel activity that is involved in regulation of postsynaptic membrane potential.\" [GO_REF:0000061, GOC:TermGenie, PMID:20200227]","metadata":null},{"id":"7d9963f938d84a09b06b8d34c434936b","type":"GO_TERM","name":"transmitting tissue development","canonical_id":"go:GO:0010500","description":"\"The process whose specific outcome is the progression of the transmitting tract over time, from its formation to the mature structure. The transmitting tissue is the tissue in the style of a carpel through which the pollen tube grows; it connects the stigma and the inside of ovary.\" [PMID:17855426]","metadata":null},{"id":"2b1b2aa413d5425bbe9f1ab2629edd01","type":"GO_TERM","name":"transnitrosylase complex","canonical_id":"go:GO:1990658","description":"\"A transferase complex which is capable of transferring nitrogenous groups from one component to another.\" [GOC:bhm, PMID:25417112]","metadata":null},{"id":"7a108a77ed7a4cf5bbcd077e638bb066","type":"GO_TERM","name":"transpiration","canonical_id":"go:GO:0010148","description":"\"Release of water by the plant into the air as water vapor mainly through leaves.\" [GOC:sm, ISBN:0879015322]","metadata":null},{"id":"8c0fedf2795d433c80267799a05ce36a","type":"GO_TERM","name":"transport","canonical_id":"go:GO:0006810","description":"\"The directed movement of substances (such as macromolecules, small molecules, ions) or cellular components (such as complexes and organelles) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or a transporter complex, a pore or a motor protein.\" [GOC:dos, GOC:dph, GOC:jl, GOC:mah]","metadata":null},{"id":"3d82cf261d4f468d9a2c8be38b45a0de","type":"GO_TERM","name":"transport across blood-brain barrier","canonical_id":"go:GO:0150104","description":"\"The directed movement of substances (e.g. macromolecules, small molecules, ions) through the blood-brain barrier.\" [GOC:aruk, GOC:bc, PMID:29377008]","metadata":null},{"id":"f4dc81af515d4245a4fbbd22c675837a","type":"GO_TERM","name":"transport across blood-cerebrospinal fluid barrier","canonical_id":"go:GO:0150195","description":"\"The directed movement of substances (e.g. macromolecules, small molecules, ions) through the blood-cerebrospinal fluid barrier.\" [GOC:aruk, GOC:bc, PMID:21349151]","metadata":null},{"id":"66f94b7b1b2b444cbdddbd711bd0fb8c","type":"GO_TERM","name":"transport along microtubule","canonical_id":"go:GO:0010970","description":"\"The movement of organelles or other particles from one location in the cell to another along microtubules, driven by motor activity.\" [GOC:dph, GOC:mah, GOC:tb]","metadata":null},{"id":"e9e4b7372bac484285d3034e8dbbd12f","type":"GO_TERM","name":"transport of viral material towards nucleus","canonical_id":"go:GO:0075606","description":"\"The directed movement of a virus, or part of a virus, towards the host cell nucleus. The process begins after viral entry, and ends when the viral material is at the nuclear membrane.\" [GOC:bf, GOC:jl, VZ:990]","metadata":null},{"id":"bcc9a9c1924b46e088217bdc3a5b0218","type":"GO_TERM","name":"transport of virus","canonical_id":"go:GO:0046794","description":"\"The directed movement of a virus, or part of a virus, into, out of, or within a host cell.\" [GOC:ai]","metadata":null},{"id":"be9320e966b24c19be86d957f1af8d32","type":"GO_TERM","name":"transport of virus in host, cell to cell","canonical_id":"go:GO:0046740","description":"\"The transport of a virus between adjacent cells in a multicellular organism.\" [GOC:bf, GOC:jl, ISBN:0781718325]","metadata":null},{"id":"35dea01159944b78ab09eb90af77bd61","type":"GO_TERM","name":"transport of virus in host, tissue to tissue","canonical_id":"go:GO:0046741","description":"\"The transport of a virus between tissues in a multicellular organism.\" [GOC:bf, GOC:jl, ISBN:0781718325]","metadata":null},{"id":"f711685e1a0c494a8c8b011d597f2cb5","type":"GO_TERM","name":"transport of virus in multicellular host","canonical_id":"go:GO:0046739","description":"\"The transport of a virus between cells in a multicellular organism. The cells can be adjacent or spatially separated (e.g. in different tissues or organs).\" [GOC:bf, GOC:jl, ISBN:0781718325]","metadata":null},{"id":"2f4a2393f3bc405aa70e801acde0d7fb","type":"GO_TERM","name":"transport vesicle","canonical_id":"go:GO:0030133","description":"\"Any of the vesicles of the constitutive secretory pathway, which carry cargo from the endoplasmic reticulum to the Golgi, between Golgi cisternae, from the Golgi to the ER (retrograde transport) or to destinations within or outside the cell.\" [GOC:mah, PMID:22160157]","metadata":null},{"id":"d74668b7a2e24c97b13188661ef368e9","type":"GO_TERM","name":"transport vesicle lumen","canonical_id":"go:GO:0098566","description":"\"The volume enclosed within the membrane of a transport vesicle.\" [GOC:dos]","metadata":null},{"id":"1c13eb294f094fa5a0b4e4594db20680","type":"GO_TERM","name":"transport vesicle membrane","canonical_id":"go:GO:0030658","description":"\"The lipid bilayer surrounding a transport vesicle.\" [GOC:mah]","metadata":null},{"id":"72e17e80fe2e482b9bbc3e9fa63af7bb","type":"GO_TERM","name":"transport-coupled glycolytic process through glucose-6-phosphate","canonical_id":"go:GO:0061633","description":"\"The chemical reactions and pathways resulting in the breakdown of glucose into pyruvate, in which the glucose is converted to glucose-6-phosphate intermediate coupled to transmembrane transport.\" [GOC:dph]","metadata":null},{"id":"a9f08517a508486b8a237af0982aa077","type":"GO_TERM","name":"transporter activator activity","canonical_id":"go:GO:0141109","description":"\"Binds to and increases the activity of a transporter.\" [GOC:curators]","metadata":null},{"id":"dc8002ddb33a4dd4a695e712f5d9829c","type":"GO_TERM","name":"transporter activity","canonical_id":"go:GO:0005215","description":"\"Enables the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, accross or in between cells.\" [GOC:ai, GOC:dgf]","metadata":null},{"id":"adcf3cb2b41b4952ae3c3639f990d44d","type":"GO_TERM","name":"transporter complex","canonical_id":"go:GO:1990351","description":"\"A protein complex facilitating transport of molecules (proteins, small molecules, nucleic acids) into, out of or within a cell, or between cells.\" [GOC:bhm, PMID:15449578]","metadata":null},{"id":"f8107da6326a4bd6a7689fbf0d92245c","type":"GO_TERM","name":"transporter inhibitor activity","canonical_id":"go:GO:0141110","description":"\"Binds to and stops, prevents, or reduces the activity of a transporter.\" [GOC:curators]","metadata":null},{"id":"a1c119dde20a41b69caa2c40bb2795f1","type":"GO_TERM","name":"transporter regulator activity","canonical_id":"go:GO:0141108","description":"\"Binds to and modulates the activity of a transporter.\" [GOC:curators]","metadata":null},{"id":"fb974f7f0e8c43e08abeee8962682008","type":"GO_TERM","name":"transposable element silencing","canonical_id":"go:GO:0010526","description":"\"Any process that decreases the frequency, rate or extent of transposable element expression. Includes both DNA transposons and retrotransposons.\" [GOC:dph, GOC:tb, PMID:32823517]","metadata":null},{"id":"e1083d07e11340d09dd7affc05522bfd","type":"GO_TERM","name":"transposable element silencing by heterochromatin formation","canonical_id":"go:GO:0141005","description":"\"A transposable element silencing mechanism involving heterochromatin assembly. Heterochromatin is a chromatin conformation that is refractory to transcription.\" [PMID:25247314, PMID:28951459, PMID:32823517]","metadata":null},{"id":"9fc2c956589a44ac9c3ab3a491ede9fd","type":"GO_TERM","name":"transposable element silencing by mRNA destabilization","canonical_id":"go:GO:0141008","description":"\"A transposable element silencing mechanism in which mRNAs transcribed from transposons are targeted for degradation.\" [GOC:curators]","metadata":null},{"id":"746c6e5495dd4b0080be0ca8e5b7453b","type":"GO_TERM","name":"transposable element silencing by piRNA-mediated DNA methylation","canonical_id":"go:GO:0141196","description":"\"A transposable element silencing mechanism mediated by Piwi-associated RNA (piRNA)-directed DNA methylation. This results in a heterochromatin assembly, a chromatin conformation that is refractory to transcription.\" [PMID:32674113]","metadata":null},{"id":"fee63461608145e79f258970149fe0ee","type":"GO_TERM","name":"transposable element silencing by piRNA-mediated heterochromatin formation","canonical_id":"go:GO:0141006","description":"\"A transposable element silencing mechanism in which a Piwi-associated RNA (piRNA) triggers heterochromatin assembly. Heterochromatin is a chromatin conformation that is refractory to transcription.\" [PMID:32381626, PMID:32674113]","metadata":null},{"id":"172be348bf414275865d8326bebc7fca","type":"GO_TERM","name":"transposable element silencing by piRNA-mediated mRNA destabilization","canonical_id":"go:GO:0141009","description":"\"A transposable element silencing mechanism in which mRNAs transcribed from transposons are targeted for degradation by a Piwi-associated RNA (piRNA).\" [PMID:22121019]","metadata":null},{"id":"c99c392cd93b4487acda980abd55968e","type":"GO_TERM","name":"transposable element silencing by siRNA-mediated DNA methylation","canonical_id":"go:GO:0141010","description":"\"A transposable element silencing mechanism mediated by RNA-directed DNA methylation. RNA-directed DNA methylation is a gene silencing process in which small interfering RNAs (siRNAs) guide DNA methylation to the siRNA-generating genomic loci and other loci that are homologous to the siRNAs for de novo DNA methylation. This results in a heterochromatin assembly, a chromatin conformation that is refractory to transcription.\" [PMID:28633017, PMID:32381626, PMID:32719317, PMID:36570931]","metadata":null},{"id":"479b7e3373b74679b4144b2cffae9d07","type":"GO_TERM","name":"transposable element silencing by siRNA-mediated heterochromatin formation","canonical_id":"go:GO:0141007","description":"\"A transposable element silencing mechanism in which a siRNA triggers heterochromatin assembly. Heterochromatin is a chromatin conformation that is refractory to transcription.\" [PMID:36570931]","metadata":null},{"id":"1056b9e0fd0c41aa95ee365c3da5da3f","type":"GO_TERM","name":"transposable element silencing by siRNA-mediated mRNA destabilization","canonical_id":"go:GO:0141011","description":"\"A transposable element silencing mechanism in which mRNAs transcribed from transposons are targeted for degradation by a siRNA.\" [PMID:36570931]","metadata":null},{"id":"4e064f5cf50144bc87051c46ee08bfd6","type":"GO_TERM","name":"transposase activity","canonical_id":"go:GO:0004803","description":"\"Catalysis of the transposition of transposable elements or transposons. Transposases are involved in recombination required for transposition and are site-specific for the transposon/transposable element.\" [GOC:bm, ISBN:0198506732]","metadata":null},{"id":"8407aa87f0a449ef898fd980f019a8b0","type":"GO_TERM","name":"transposition","canonical_id":"go:GO:0032196","description":"\"Any process involved in mediating the movement of discrete segments of DNA between nonhomologous sites. For elements that are transcribed as the first step of transposition, the process starts with the transcription of the transposable element, its translation and maturation, and ending with integration into DNA. For elements that are cut out, the process starts with the excision of the donor DNA and integrated into another site.\" [ISBN:1555812090, PMID:14682279, PMID:25893143]","metadata":null},{"id":"6dedf97079914d24b2b8ba25473565dd","type":"GO_TERM","name":"transsulfuration","canonical_id":"go:GO:0019346","description":"\"The interconversion of homocysteine and cysteine via cystathionine. In contrast with enteric bacteria and mammals, Saccharomyces cerevisiae has two transsulfuration pathways employing two separate sets of enzymes.\" [MetaCyc:PWY-801]","metadata":null},{"id":"17f503dc39354e05896ee223db2da0e7","type":"GO_TERM","name":"transverse filament","canonical_id":"go:GO:0000802","description":"\"A structural unit of the synaptonemal complex that spans the regions between the lateral elements and connects them.\" [GOC:elh]","metadata":null},{"id":"3fa65fed9a524722b9684d2aae50539f","type":"GO_TERM","name":"transverse flagellum","canonical_id":"go:GO:0097608","description":"\"A motile cilium found in dinoflagellates. It coils around the cell and provides the forward thrust for motility. It is often contained in a furrow called the cingulum, and emerges from a flagellar pore located in the cingulum.\" [GOC:at, http://tolweb.org/Dinoflagellates/2445, https://doi.org/10.1038/213421a0, Wikipedia:Dinoflagellate#Morphology]","metadata":null},{"id":"b4c3d13c24304264a4946d9fce35bc8a","type":"DRUG","name":"tranylcypromine","canonical_id":"gtopdb:5281","description":null,"metadata":null},{"id":"572efb54ec824f0abe46a162f5f4f88a","type":"COMBINATION_TREATMENT","name":"tranylcypromine + tretinoin","canonical_id":"ctgov_combo:ctgov-combo-9d00785721849cdf","description":null,"metadata":null},{"id":"1f65588e42c14bccafa999f5d305fefe","type":"DRUG","name":"trastuzumab","canonical_id":"gtopdb:5082","description":null,"metadata":null},{"id":"9f139349bd1642c4badfaa845cdf5105","type":"DRUG","name":"trastuzumab","canonical_id":"chembl:CHEMBL1201585","description":null,"metadata":null},{"id":"565f7550b78b464ca1e906e59fd48245","type":"COMBINATION_TREATMENT","name":"trastuzumab + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-74958d9bc2b1b73d","description":null,"metadata":null},{"id":"345ad2fbed564788aa9a7e658fdd0c01","type":"COMBINATION_TREATMENT","name":"trastuzumab + tucatinib","canonical_id":"ctgov_combo:ctgov-combo-c1bb4de7aa9c6a37","description":null,"metadata":null},{"id":"ac076dd4fc3f4a1199fba4ddc07f734a","type":"GO_TERM","name":"traversing start control point of mitotic cell cycle","canonical_id":"go:GO:0007089","description":"\"A cell cycle process by which a cell commits to entering S phase via a positive feedback mechanism between the regulation of transcription and G1 CDK activity.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"26c869d61e36477883186078854227e4","type":"DRUG","name":"trazodone","canonical_id":"gtopdb:213","description":null,"metadata":null},{"id":"9c497df0d2a1464695f49786f7a3865f","type":"DRUG","name":"trazodone","canonical_id":"mesh:D014196","description":null,"metadata":null},{"id":"a7b49d85f7f14a08bf8ccdca6f6a535a","type":"COMBINATION_TREATMENT","name":"trazodone + zolpidem","canonical_id":"ctgov_combo:ctgov-combo-34ecfb0a354750ec","description":null,"metadata":null},{"id":"1566f100efea48ed96ca202f33d8e0e0","type":"GO_TERM","name":"trehalase activity","canonical_id":"go:GO:0015927","description":"\"Catalysis of the hydrolysis of trehalose or a trehalose derivative.\" [GOC:ai, PMID:31925485]","metadata":null},{"id":"3eaf6e4564de40189e6fa6978bc0aed9","type":"GO_TERM","name":"trehalose 6-phosphate phosphorylase activity","canonical_id":"go:GO:0050503","description":"\"Catalysis of the reaction: trehalose 6-phosphate + phosphate = glucose 6-phosphate + beta-D-glucose 1-phosphate.\" [EC:2.4.1.216, MetaCyc:2.4.1.216-RXN]","metadata":null},{"id":"f142462ca68a43108a875c94651cf763","type":"GO_TERM","name":"trehalose O-mycolyltransferase activity","canonical_id":"go:GO:0050348","description":"\"Catalysis of the reaction: 2 alpha,alpha'-trehalose 6-mycolate = alpha,alpha'-trehalose 6,6'-bismycolate + alpha,alpha-trehalose.\" [EC:2.3.1.122, RHEA:23472]","metadata":null},{"id":"8d2afab74ba940bbacce8afe8e37ce2b","type":"GO_TERM","name":"trehalose biosynthetic process","canonical_id":"go:GO:0005992","description":"\"The chemical reactions and pathways resulting in the formation of trehalose, a disaccharide that consists of two molecules of glucose and is isomeric with sucrose.\" [GOC:jl, ISBN:0028623819]","metadata":null},{"id":"5537b59fccbf42258f5f337a76d45637","type":"GO_TERM","name":"trehalose catabolic process","canonical_id":"go:GO:0005993","description":"\"The chemical reactions and pathways resulting in the breakdown of trehalose, a disaccharide that consists of two molecules of glucose and is isomeric with sucrose.\" [GOC:jl, ISBN:0028623819]","metadata":null},{"id":"35a498cfbddf4dc38c8407035eba4005","type":"GO_TERM","name":"trehalose metabolic process","canonical_id":"go:GO:0005991","description":"\"The chemical reactions and pathways involving trehalose, a disaccharide that consists of two molecules of glucose and is isomeric with sucrose.\" [GOC:jl, ISBN:0028623819]","metadata":null},{"id":"348c5fbd1fca402d8906156f65aa7148","type":"GO_TERM","name":"trehalose synthase activity","canonical_id":"go:GO:0102986","description":"\"Catalysis of the reaction: an NDP-alpha-D-glucose + D-glucose = a ribonucleoside 5'-diphosphate + alpha,alpha-trehalose + H+.\" [RHEA:47416]","metadata":null},{"id":"de466432a34a48929d248041cd06ee92","type":"GO_TERM","name":"trehalose transmembrane transporter activity","canonical_id":"go:GO:0015574","description":"\"Enables the transfer of trehalose from one side of a membrane to the other. Trehalose is the disaccharide alpha-D-glucopyranosyl-alpha-D-glucopyranoside that acts of a reserve carbohydrate in certain fungi, algae and lichens.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"c3d7e4bea6e54bf1abd073d11535d6ff","type":"GO_TERM","name":"trehalose transport","canonical_id":"go:GO:0015771","description":"\"The directed movement of trehalose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Trehalose is a disaccharide that consists of two molecules of glucose and is isomeric with sucrose.\" [GOC:ai, PMID:17606922, PMID:20035867]","metadata":null},{"id":"b4ae1233ca244aadb70ac95efbc1ceda","type":"GO_TERM","name":"trehalose transport in response to desiccation","canonical_id":"go:GO:0072515","description":"\"The directed movement of trehalose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore, that occurs as a result of a desiccation stimulus. A desiccation stimulus signals extreme dryness resulting from the prolonged deprivation of water.\" [GOC:mah]","metadata":null},{"id":"f355dfeeee584271aa8fc4dd40229ff0","type":"GO_TERM","name":"trehalose transport in response to water deprivation","canonical_id":"go:GO:0072514","description":"\"The directed movement of trehalose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore, that occurs as a result of deprivation of water.\" [GOC:mah]","metadata":null},{"id":"232b461ec8ea4f469a9340975411719c","type":"GO_TERM","name":"trehalose-phosphatase activity","canonical_id":"go:GO:0004805","description":"\"Catalysis of the reaction: alpha,alpha-trehalose 6-phosphate + H2O = alpha,alpha-trehalose + phosphate.\" [EC:3.1.3.12, RHEA:23420]","metadata":null},{"id":"75758f319f4c47cb9d239e60d96339d9","type":"GO_TERM","name":"trehalose:proton symporter activity","canonical_id":"go:GO:0044693","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: trehalose(out) + H+(out) = trehalose(in) + H+(in).\" [PMID:11136464]","metadata":null},{"id":"5d89579187594ad8b7dcb3a8a6cbb63a","type":"DRUG","name":"tremelimumab","canonical_id":"gtopdb:8462","description":null,"metadata":null},{"id":"12f0f56394fc43d0a509f5b7cf612a4e","type":"DRUG","name":"tremelimumab","canonical_id":"chembl:CHEMBL2108658","description":null,"metadata":null},{"id":"47ef4f825b854ca0b8a2ae5b85030c94","type":"DRUG","name":"treprostinil","canonical_id":"gtopdb:5820","description":null,"metadata":null},{"id":"35fea755486a4b0e8fc9c4583b02e970","type":"DRUG","name":"treprostinil","canonical_id":"chembl:CHEMBL1237119","description":null,"metadata":null},{"id":"10bc3b9ad0a24474b8972716785e6996","type":"DRUG","name":"tretinoin","canonical_id":"gtopdb:2644","description":null,"metadata":null},{"id":"633bc913906046ab9ef6b84e6cd8e726","type":"DRUG","name":"tretinoin","canonical_id":"mesh:D014212","description":null,"metadata":null},{"id":"26a1ccf168e044fcb7a6af9973d3e8dd","type":"DRUG","name":"tretinoin","canonical_id":"chembl:CHEMBL38","description":null,"metadata":null},{"id":"9ada030fcbef4c55b6728bf8b96c982f","type":"GO_TERM","name":"tri-(coumaroyl or caffeoyl) spermidine meta-hydroxylase activity","canonical_id":"go:GO:0072533","description":"\"Catalysis of the meta-hydroxylation of any of the three phenolic rings on tricoumaroyl spermidine or any of its mono- or dicaffeoyl spermidine derivatives.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"05f84524e0be4da6825e32edc2d1d699","type":"GO_TERM","name":"tri-(feruloyl or hydroxyferuloyl) spermidine meta-hydroxylase activity","canonical_id":"go:GO:0072532","description":"\"Catalysis of the meta-hydroxylation of any of the three phenolic rings on triferuloyl spermidine or any of its mono- or di-(hydroxyferuloyl)-spermidine derivatives.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"0d729c89410447ed8aa2fa288a390689","type":"GO_TERM","name":"triacetate-lactonase activity","canonical_id":"go:GO:0050349","description":"\"Catalysis of the reaction: H2O + triacetate lactone = triacetate.\" [EC:3.1.1.38, RHEA:22260]","metadata":null},{"id":"a4935cb376fa4cc693fc0e6ead0425bd","type":"GO_TERM","name":"triacyl lipopeptide binding","canonical_id":"go:GO:0042497","description":"\"Binding to a lipopeptide containing a nonprotein moiety consisting of three acyl groups.\" [GOC:add, PMID:12077222, PMID:12524386, PMID:2757794]","metadata":null},{"id":"cfbe0e30df994e86b37d8cbbaf6a6ea9","type":"GO_TERM","name":"triacylglycerol lipase activity","canonical_id":"go:GO:0004806","description":"\"Catalysis of the reaction: a triacylglycerol + H2O = a diacylglycerol + a fatty acid + H+.\" [RHEA:12044]","metadata":null},{"id":"1da24959fbcf49f9aa7efbf414d9d328","type":"GO_TERM","name":"trialkylsulfonium hydrolase activity","canonical_id":"go:GO:0016802","description":"\"Catalysis of the hydrolysis of a thioether bond, -S-.\" [EC:3.3.1.-, GOC:ai]","metadata":null},{"id":"eb4f5aaa58854c9c8752de4748a212ba","type":"DRUG","name":"triamcinolone","canonical_id":"gtopdb:2870","description":null,"metadata":null},{"id":"c635da4d4a624ef7aac263828e043104","type":"DRUG","name":"triamcinolone","canonical_id":"chembl:CHEMBL1451","description":null,"metadata":null},{"id":"27537041b4b44da4ae293242fed68676","type":"DRUG","name":"triamcinolone acetonide","canonical_id":"mesh:D014222","description":null,"metadata":null},{"id":"4eb789ba36024609a5c5d3f70275764c","type":"DRUG","name":"triamcinolone diacetate","canonical_id":"mesh:D014221","description":null,"metadata":null},{"id":"41acf08639f0450dbeb3e4db34d5a973","type":"DRUG","name":"triamcinolone diacetate","canonical_id":"mesh:C030262","description":null,"metadata":null},{"id":"e7c0c7fecb524fbb9e6e8e4da9f53b3e","type":"DRUG","name":"triamcinolone hexacetonide","canonical_id":"mesh:C005900","description":null,"metadata":null},{"id":"e1960c30e02b4bf3aae7905d24ed7feb","type":"DRUG","name":"triamterene","canonical_id":"gtopdb:4329","description":null,"metadata":null},{"id":"f83ac0310c424bd78ede979eea71cd80","type":"DRUG","name":"triamterene","canonical_id":"mesh:D014223","description":null,"metadata":null},{"id":"cbc1c37c0dd24fcf9b3b2e88c441c3a4","type":"DRUG","name":"triamterene","canonical_id":"chembl:CHEMBL585","description":null,"metadata":null},{"id":"21ea447afa954844bb4d5087b62fd394","type":"DRUG","name":"triazolam","canonical_id":"gtopdb:7313","description":null,"metadata":null},{"id":"bdb4518528c74fdf8952437b26e29232","type":"DRUG","name":"triazolam","canonical_id":"chembl:CHEMBL646","description":null,"metadata":null},{"id":"ca952556caaa40a0924f393d5063497e","type":"GO_TERM","name":"triazole transport","canonical_id":"go:GO:1901504","description":"\"The directed movement of a triazole into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:pr, GOC:TermGenie]","metadata":null},{"id":"e2a504458bf04e8aaf5daa4e97b1c9ee","type":"GO_TERM","name":"tricaffeoyl spermidine O-methyltransferase activity","canonical_id":"go:GO:0102109","description":"\"Catalysis of the reaction: tricaffeoyl spermidine + 3 S-adenosyl-L-methionine = 3 H+ + triferuloyl spermidine + 3 S-adenosyl-L-homocysteine.\" [GOC:pz, PMID:19077165]","metadata":null},{"id":"ff667c97f2d64cf78b23b79f76c0474b","type":"GO_TERM","name":"tricaffeoyl spermidine:S-adenosyl-L-methionine O-methyltransferase activity","canonical_id":"go:GO:0080078","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the oxygen atom of a tricaffeoyl spermidine molecule.\" [PMID:19077165]","metadata":null},{"id":"4f6851043d3140a49fe50f0039319b13","type":"GO_TERM","name":"tricarboxylate secondary active transmembrane transporter activity","canonical_id":"go:GO:0005371","description":"\"Enables the transfer of tricarboxylate from one side of a membrane to the other, up its concentration gradient. The transporter binds the solute and undergoes a series of conformational changes. Transport works equally well in either direction and is driven by a chemiosmotic source of energy. Secondary active transporters include symporters and antiporters.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"fee76456858a4b36a189aee426fc61f0","type":"GO_TERM","name":"tricarboxylic acid biosynthetic process","canonical_id":"go:GO:0072351","description":"\"The chemical reactions and pathways resulting in the formation of dicarboxylic acids, any organic acid containing three carboxyl (-COOH) groups.\" [GOC:mah]","metadata":null},{"id":"2c9d585ef4574a61975d2fddc3eb7df8","type":"GO_TERM","name":"tricarboxylic acid catabolic process","canonical_id":"go:GO:0072352","description":"\"The chemical reactions and pathways resulting in the breakdown of dicarboxylic acids, any organic acid containing three carboxyl (-COOH) groups.\" [GOC:mah]","metadata":null},{"id":"dfe82bcc8f3141a3a2a8d72d1c00068b","type":"GO_TERM","name":"tricarboxylic acid cycle","canonical_id":"go:GO:0006099","description":"\"A nearly universal metabolic pathway in which the acetyl group of acetyl coenzyme A is effectively oxidized to two CO2 and four pairs of electrons are transferred to coenzymes. The acetyl group combines with oxaloacetate to form citrate, which undergoes successive transformations to isocitrate, 2-oxoglutarate, succinyl-CoA, succinate, fumarate, malate, and oxaloacetate again, thus completing the cycle. In eukaryotes the tricarboxylic acid is confined to the mitochondria. See also glyoxylate cycle.\" [ISBN:0198506732]","metadata":null},{"id":"f9f5503fc601402f898eb15b01804a2c","type":"GO_TERM","name":"tricarboxylic acid cycle heteromeric enzyme complex","canonical_id":"go:GO:0045239","description":"\"Any of the heteromeric enzymes that act in the TCA cycle.\" [GOC:mah]","metadata":null},{"id":"82425494b69b49c69fe0d0d432d8b26c","type":"GO_TERM","name":"tricarboxylic acid metabolic process","canonical_id":"go:GO:0072350","description":"\"The chemical reactions and pathways involving dicarboxylic acids, any organic acid containing three carboxyl (COOH) groups or anions (COO-).\" [GOC:mah]","metadata":null},{"id":"f181ca22c5d344e6a593f009551dc2a4","type":"GO_TERM","name":"tricarboxylic acid transmembrane transport","canonical_id":"go:GO:0035674","description":"\"The process in which a tricarboxylic acid is transported across a membrane.\" [GOC:vw]","metadata":null},{"id":"9124c03057344c269e4a5e8a4eeb100f","type":"GO_TERM","name":"tricarboxylic acid transmembrane transporter activity","canonical_id":"go:GO:0015142","description":"\"Enables the transfer of tricarboxylic acids from one side of a membrane to the other. Tricarboxylic acid are organic acids with three COOH groups.\" [GOC:ai]","metadata":null},{"id":"3c3dac97aa404a22acaa7655f0b30388","type":"GO_TERM","name":"tricarboxylic acid transport","canonical_id":"go:GO:0006842","description":"\"The directed movement of tricarboxylic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"2e07b5c3021f40be9e3bebd222e06c8a","type":"GO_TERM","name":"tricellular tight junction","canonical_id":"go:GO:0061689","description":"\"An specialized occluding junction where three epithelial cells meet. It is composed of a branching network of sealing strands that run perpendicularly to the bicellular tight junction at the point of contact between three epithelial cells in an epithelial sheet.\" [GOC:dk, GOC:dph, PMID:22520461, PMID:25822906]","metadata":null},{"id":"ef43b472bf2841eca1d1ff4567bef4be","type":"GO_TERM","name":"tricellular tight junction assembly","canonical_id":"go:GO:1904274","description":"\"The aggregation, arrangement and bonding together of a set of components to form a tricellular tight junction.\" [GO_REF:0000079, GOC:mr, GOC:TermGenie, PMID:22640933, PMID:25097825, PMID:4203962]","metadata":null},{"id":"e9fe0e867c7d44ce81108a0d53843564","type":"GO_TERM","name":"tricellular tight junction disassembly","canonical_id":"go:GO:1904275","description":"\"The disaggregation of a tricellular tight junction into its constituent components.\" [GO_REF:0000079, GOC:mr, GOC:TermGenie, PMID:22640933, PMID:25097825, PMID:4203962]","metadata":null},{"id":"0a9421df6d8f420fafd218e7ec001ec8","type":"GO_TERM","name":"tricetin O-methytransferase activity","canonical_id":"go:GO:0102146","description":"\"Catalysis of the reaction: tricetin + S-adenosyl-L-methionine = H+ + 3'-O-methyltricetin + S-adenosyl-L-homocysteine.\" [GOC:pz, RHEA:27493]","metadata":null},{"id":"dae6fed4e66246f396bb67f969931f0c","type":"DISEASE","name":"trichinosis","canonical_id":"efo:0007520","description":null,"metadata":null},{"id":"3b205755119b4c1d909f4b03a69d7ab1","type":"GO_TERM","name":"trichloro-p-hydroquinone reductive dehalogenase activity","canonical_id":"go:GO:0052690","description":"\"Catalysis of the reaction: 2,3,6-trichlorohydroquinone + 2 glutathione = 2,6-dichlorohydroquinone + glutathione disulfide + HCl.\" [PMID:1459949, RHEA:56832]","metadata":null},{"id":"3ea6967b2be94b11a94bb3ed08d3a6fb","type":"GO_TERM","name":"trichloroethene reductive dehalogenase activity","canonical_id":"go:GO:0050697","description":"\"Catalysis of the reaction: AH2 + trichloroethene = (Z)-1,2-dichloroethene + A + chloride + H+.\" [RHEA:67992]","metadata":null},{"id":"82b4a048ea444aa9b461b03f8e0d3347","type":"GO_TERM","name":"trichloroethylene catabolic process","canonical_id":"go:GO:0050696","description":"\"The chemical reactions and pathways resulting in the breakdown of trichloroethylene, a toxic, colorless, photoreactive, chlorinated hydrocarbon liquid, commonly used as a metal degreaser and solvent.\" [GOC:ai]","metadata":null},{"id":"198e8fbeac23403f8e9b348b028ac712","type":"GO_TERM","name":"trichloroethylene metabolic process","canonical_id":"go:GO:0018979","description":"\"The chemical reactions and pathways involving trichloroethylene, a toxic, colorless, photoreactive, chlorinated hydrocarbon liquid, commonly used as a metal degreaser and solvent.\" [GOC:jl]","metadata":null},{"id":"dd709346718f448f8735d81c9160a52f","type":"GO_TERM","name":"trichoblast differentiation","canonical_id":"go:GO:0010054","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a trichoblast, a root epidermal cell that will give rise to a root hair.\" [GOC:tb]","metadata":null},{"id":"74fea0815cc44e20ad98eec9f43897b7","type":"GO_TERM","name":"trichoblast fate specification","canonical_id":"go:GO:0010057","description":"\"The process involved in the specification of a trichoblast.\" [GOC:tb]","metadata":null},{"id":"424c59b6b6434f4aacf2de8a96db1297","type":"GO_TERM","name":"trichoblast maturation","canonical_id":"go:GO:0048764","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a trichoblast cell to attain its fully functional state.\" [GOC:jid]","metadata":null},{"id":"de8aa8c4c4d54017b46d7ed0bda5fbfa","type":"GO_TERM","name":"trichocyst","canonical_id":"go:GO:0055039","description":"\"A crystalline exocytotic organelle composed of small, acidic proteins existing primarily as disulphide-linked dimers. The trichocyst is an organelle that releases long filamentous proteins that capture predators in net-like structures, to slow them down when the cell is disturbed. The protein is nontoxic and shaped like a long, striated, fibrous shaft.\" [GOC:jid, GOC:rph, PMID:3667715]","metadata":null},{"id":"59986146a7614496a8117bb63b284ca9","type":"GO_TERM","name":"trichodiene synthase activity","canonical_id":"go:GO:0045482","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = diphosphate + trichodiene.\" [EC:4.2.3.6, RHEA:12052]","metadata":null},{"id":"030aebf6e23f432095daa04b3a309a8d","type":"GO_TERM","name":"trichome branching","canonical_id":"go:GO:0010091","description":"\"Any process involved in the formation of branches in plant hair cells. An example of this process is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tair_curators]","metadata":null},{"id":"3e43cb8241a843438bef66cb4165e943","type":"GO_TERM","name":"trichome differentiation","canonical_id":"go:GO:0010026","description":"\"The process in which a relatively unspecialized epidermal cell acquires the specialized features of a trichome cell. An example of this process is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, PMID:9367433]","metadata":null},{"id":"239e7fb56c634cccb0c9ee5af494b00f","type":"GO_TERM","name":"trichome morphogenesis","canonical_id":"go:GO:0010090","description":"\"The process in which the structures of a hair cell (trichome) cell are generated and organized. This process occurs while the initially relatively unspecialized epidermal cell is acquiring the specialized features of a hair cell. An example of this process is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tair_curators]","metadata":null},{"id":"3521fd9688fd43e389917866e049c242","type":"GO_TERM","name":"trichome papilla","canonical_id":"go:GO:0090705","description":"\"A plant cell papilla that is part of a trichome cell.\" [GOC:tb, PMID:24014871]","metadata":null},{"id":"90674e0f08b04cffa226e0adf4862a85","type":"GO_TERM","name":"trichome papilla formation","canonical_id":"go:GO:1905499","description":"\"The aggregation, arrangement and bonding together of a set of components to form a trichome papilla.\" [GO_REF:0000079, GOC:tb, GOC:TermGenie, PMID:24014871]","metadata":null},{"id":"546bca6b48f44ca88c4747d6879f3a07","type":"GO_TERM","name":"trichome patterning","canonical_id":"go:GO:0048629","description":"\"The regionalization process of establishing the non-random spatial arrangement of trichomes on the surface and margin of a leaf. Process involves signaling between adjacent epidermal cells that results in differentiation of some epidermal cells into trichomes.\" [GOC:jid, GOC:mtg_sensu, GOC:sm, GOC:tb, ISBN:0865427429, PMID:10368181]","metadata":null},{"id":"bc9ec78a471740c1be1b7ce8390fe88a","type":"GO_TERM","name":"trichothecene 3-O-acetyltransferase activity","canonical_id":"go:GO:0045462","description":"\"Catalysis of the 3-O-acetylation of a trichothecene. Trichothecenes are sesquiterpene epoxide mycotoxins that act as potent inhibitors of eukaryotic protein synthesis.\" [PMID:10583973]","metadata":null},{"id":"fedf3951306040cd9567a83ccbdff015","type":"GO_TERM","name":"tricoumaroylspermidine meta-hydroxylase activity","canonical_id":"go:GO:0072547","description":"\"Catalysis of the reaction: tricoumaroyl spermidine + NADPH + O2 = dicoumaroyl monocaffeoyl spermidine + NADP+ + H2O.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"ce3fb602eec5440f80d2255d59a3b089","type":"GO_TERM","name":"tricuspid valve development","canonical_id":"go:GO:0003175","description":"\"The progression of the tricuspid valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"c246fca0a4914765a4fd399c642e3a9f","type":"GO_TERM","name":"tricuspid valve formation","canonical_id":"go:GO:0003195","description":"\"The developmental process pertaining to the initial formation of the tricuspid valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"93a8c5f6de234e8daa9d1e0948b47465","type":"GO_TERM","name":"tricuspid valve morphogenesis","canonical_id":"go:GO:0003186","description":"\"The process in which the structure of the tricuspid valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"fbc8a6169bbf4df6ad5c1ca3993ad4cc","type":"GO_TERM","name":"tricyclene synthase activity","canonical_id":"go:GO:0102701","description":"\"Catalysis of the reaction: geranyl diphosphate(3-) = tricyclene + diphosphoric acid.\" [EC:4.2.3.105, GOC:pz]","metadata":null},{"id":"10f0974604ff42e7a65f3b3d40cd2b85","type":"GO_TERM","name":"tricyclic triterpenoid biosynthetic process","canonical_id":"go:GO:0010263","description":"\"The chemical reactions and pathways resulting in the formation of tricyclic triterpenoid compounds, terpenoids with 6 isoprene units and 3 carbon rings.\" [GOC:ct]","metadata":null},{"id":"6539e6b54d104fafb154fca259fa31ce","type":"GO_TERM","name":"tricyclic triterpenoid catabolic process","canonical_id":"go:GO:0010684","description":"\"The chemical reactions and pathways resulting in the breakdown of tricyclic triterpenoid compounds, terpenoids with six isoprene units and 3 rings.\" [GOC:tair_curators]","metadata":null},{"id":"84a49679399c4430895186d6cd77f55b","type":"GO_TERM","name":"tridecane biosynthetic process","canonical_id":"go:GO:1900632","description":"\"The chemical reactions and pathways resulting in the formation of tridecane.\" [GOC:mengo_curators, GOC:TermGenie]","metadata":null},{"id":"d277448e859245b79b59101fc3208067","type":"DRUG","name":"trifarotene","canonical_id":"gtopdb:9962","description":null,"metadata":null},{"id":"fb645182e41142e59c3c7bbdf300ca7c","type":"DRUG","name":"trifarotene","canonical_id":"chembl:CHEMBL3707313","description":null,"metadata":null},{"id":"d080fb0caf2d4ad1802bfd0e1c877d3a","type":"GO_TERM","name":"triferuloylspermidine meta-hydroxylase activity","canonical_id":"go:GO:0072550","description":"\"Catalysis of the reaction: triferuloyl spermidine + NADPH + O2 = diferuloyl mono-(hydroxyferuloyl) spermidine + NADP+ + H2O.\" [GOC:kad, PMID:19779199]","metadata":null},{"id":"29f9471f39f9442ba7b75bdb7e4bf899","type":"DRUG","name":"trifluoperazine","canonical_id":"gtopdb:214","description":null,"metadata":null},{"id":"0d98def4402244bdb59326fb2e5e0a61","type":"GO_TERM","name":"trigeminal ganglion development","canonical_id":"go:GO:0061551","description":"\"The process whose specific outcome is the progression of a trigeminal ganglion over time, from its formation to the mature structure.\" [GOC:dph]","metadata":null},{"id":"2a22f7f2af0a4b94aa6aa60f2b6ffb99","type":"GO_TERM","name":"trigeminal ganglion formation","canonical_id":"go:GO:0061561","description":"\"The process that gives rise to the trigeminal ganglion. This process pertains to the initial formation of a structure from unspecified parts.\" [GOC:dph]","metadata":null},{"id":"200d116d21f34f4f95ad79aa2f9bc6ff","type":"GO_TERM","name":"trigeminal ganglion maturation","canonical_id":"go:GO:0061557","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a trigeminal ganglion to attain its fully functional state.\" [GOC:dph]","metadata":null},{"id":"4842528c16984241912737257d723d32","type":"GO_TERM","name":"trigeminal ganglion morphogenesis","canonical_id":"go:GO:0061556","description":"\"The process in which the anatomical structure of a trigeminal ganglion is generated and organized.\" [GOC:dph]","metadata":null},{"id":"54ec0ef303a54bdea90ab380f8ebac8b","type":"GO_TERM","name":"trigeminal ganglion structural organization","canonical_id":"go:GO:0061563","description":"\"The process that contributes to creating the structural organization of the trigeminal ganglion This process pertains to the physical shaping of a rudimentary structure.\" [GOC:dph]","metadata":null},{"id":"9e7e177c418648429e25926a7c353cdf","type":"GO_TERM","name":"trigeminal motor nucleus development","canonical_id":"go:GO:0021731","description":"\"The process whose specific outcome is the progression of the trigeminal motor nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"d0e5b1d0887241c0baeb7ff8e44a0b62","type":"GO_TERM","name":"trigeminal nerve development","canonical_id":"go:GO:0021559","description":"\"The process whose specific outcome is the progression of the trigeminal nerve over time, from its formation to the mature structure. The trigeminal nerve is composed of three large branches. They are the ophthalmic (V1, sensory), maxillary (V2, sensory) and mandibular (V3, motor and sensory) branches. The sensory ophthalmic branch travels through the superior orbital fissure and passes through the orbit to reach the skin of the forehead and top of the head. The maxillary nerve contains sensory branches that reach the pterygopalatine fossa via the inferior orbital fissure (face, cheek and upper teeth) and pterygopalatine canal (soft and hard palate, nasal cavity and pharynx). The motor part of the mandibular branch is distributed to the muscles of mastication, the mylohyoid muscle and the anterior belly of the digastric. The mandibular nerve also innervates the tensor veli palatini and tensor tympani muscles. The sensory part of the mandibular nerve is composed of branches that carry general sensory information from the mucous membranes of the mouth and cheek, anterior two-thirds of the tongue, lower teeth, skin of the lower jaw, side of the head and scalp and meninges of the anterior and middle cranial fossae.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"88cf81a958d3497cbe7efac06d886def","type":"GO_TERM","name":"trigeminal nerve formation","canonical_id":"go:GO:0021638","description":"\"The process that gives rise to the trigeminal nerve. This process pertains to the initial formation of a structure from unspecified parts. The trigeminal nerve is composed of three large branches. They are the ophthalmic (V1, sensory), maxillary (V2, sensory) and mandibular (V3, motor and sensory) branches. The sensory ophthalmic branch travels through the superior orbital fissure and passes through the orbit to reach the skin of the forehead and top of the head. The maxillary nerve contains sensory branches that reach the pterygopalatine fossa via the inferior orbital fissure (face, cheek and upper teeth) and pterygopalatine canal (soft and hard palate, nasal cavity and pharynx). The motor part of the mandibular branch is distributed to the muscles of mastication, the mylohyoid muscle and the anterior belly of the digastric. The mandibular nerve also innervates the tensor veli palatini and tensor tympani muscles. The sensory part of the mandibular nerve is composed of branches that carry general sensory information from the mucous membranes of the mouth and cheek, anterior two-thirds of the tongue, lower teeth, skin of the lower jaw, side of the head and scalp and meninges of the anterior and middle cranial fossae.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"58e886c2d46a41188833118f2512d3de","type":"GO_TERM","name":"trigeminal nerve maturation","canonical_id":"go:GO:0021635","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the trigeminal nerve to attain its fully functional state. The trigeminal nerve is composed of three large branches. They are the ophthalmic (V1, sensory), maxillary (V2, sensory) and mandibular (V3, motor and sensory) branches. The sensory ophthalmic branch travels through the superior orbital fissure and passes through the orbit to reach the skin of the forehead and top of the head. The maxillary nerve contains sensory branches that reach the pterygopalatine fossa via the inferior orbital fissure (face, cheek and upper teeth) and pterygopalatine canal (soft and hard palate, nasal cavity and pharynx). The motor part of the mandibular branch is distributed to the muscles of mastication, the mylohyoid muscle and the anterior belly of the digastric. The mandibular nerve also innervates the tensor veli palatini and tensor tympani muscles. The sensory part of the mandibular nerve is composed of branches that carry general sensory information from the mucous membranes of the mouth and cheek, anterior two-thirds of the tongue, lower teeth, skin of the lower jaw, side of the head and scalp and meninges of the anterior and middle cranial fossae.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"60423ada97a24bc3ad13962e305f9527","type":"GO_TERM","name":"trigeminal nerve morphogenesis","canonical_id":"go:GO:0021636","description":"\"The process in which the anatomical structure of the trigeminal nerve is generated and organized. The trigeminal nerve is composed of three large branches. They are the ophthalmic (V1, sensory), maxillary (V2, sensory) and mandibular (V3, motor and sensory) branches. The sensory ophthalmic branch travels through the superior orbital fissure and passes through the orbit to reach the skin of the forehead and top of the head. The maxillary nerve contains sensory branches that reach the pterygopalatine fossa via the inferior orbital fissure (face, cheek and upper teeth) and pterygopalatine canal (soft and hard palate, nasal cavity and pharynx). The motor part of the mandibular branch is distributed to the muscles of mastication, the mylohyoid muscle and the anterior belly of the digastric. The mandibular nerve also innervates the tensor veli palatini and tensor tympani muscles. The sensory part of the mandibular nerve is composed of branches that carry general sensory information from the mucous membranes of the mouth and cheek, anterior two-thirds of the tongue, lower teeth, skin of the lower jaw, side of the head and scalp and meninges of the anterior and middle cranial fossae.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"c9e1e46ff6584d208db78a6cfaf083ab","type":"GO_TERM","name":"trigeminal nerve structural organization","canonical_id":"go:GO:0021637","description":"\"The process that contributes to the act of creating the structural organization of the oculomotor nerve. This process pertains to the physical shaping of a rudimentary structure. The trigeminal nerve is composed of three large branches. They are the ophthalmic (V1, sensory), maxillary (V2, sensory) and mandibular (V3, motor and sensory) branches. The sensory ophthalmic branch travels through the superior orbital fissure and passes through the orbit to reach the skin of the forehead and top of the head. The maxillary nerve contains sensory branches that reach the pterygopalatine fossa via the inferior orbital fissure (face, cheek and upper teeth) and pterygopalatine canal (soft and hard palate, nasal cavity and pharynx). The motor part of the mandibular branch is distributed to the muscles of mastication, the mylohyoid muscle and the anterior belly of the digastric. The mandibular nerve also innervates the tensor veli palatini and tensor tympani muscles. The sensory part of the mandibular nerve is composed of branches that carry general sensory information from the mucous membranes of the mouth and cheek, anterior two-thirds of the tongue, lower teeth, skin of the lower jaw, side of the head and scalp and meninges of the anterior and middle cranial fossae.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8bced44c1c504d1baba506cc245c8ec0","type":"DISEASE","name":"trigeminal neuralgia","canonical_id":"mondo:0008599","description":null,"metadata":null},{"id":"dfec645ebdb64cdabb5ea9e69f660036","type":"GO_TERM","name":"trigeminal sensory nucleus development","canonical_id":"go:GO:0021730","description":"\"The process whose specific outcome is the progression of the trigeminal sensory nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"8ff8225062854ab5b64f150836176d0d","type":"GO_TERM","name":"trigeminothalamic tract morphogenesis","canonical_id":"go:GO:0021974","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in spinal cord towards target cells in the thalamus. This axonal process is a member of those that make up the trigeminothalamic tract, one of the major routes of nociceptive and temperature signaling from the face.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420]","metadata":null},{"id":"94896b4fe603466999019b7585cb14d4","type":"GO_TERM","name":"triglucosylalkylacylglycerol sulfotransferase activity","canonical_id":"go:GO:0047363","description":"\"Catalysis of the reaction: alpha-D-glucosyl-1,6-alpha-D-glucosyl-1,6-alpha-D-glucosyl-1,3-1-O-alkyl-2-O-acylglycerol + 3'-phosphoadenosine 5'-phosphosulfate = 6-sulfo-alpha-D-glucosyl-1,6-alpha-D-glucosyl-1,6-alpha-D-glucosyl-1,3-1-O-alkyl-2-O-acylglycerol + adenosine 3',5'-bisphosphate.\" [EC:2.8.2.19, MetaCyc:2.8.2.19-RXN]","metadata":null},{"id":"578a55a4856e4858a625998971aeecbc","type":"GO_TERM","name":"triglyceride acyl-chain remodeling","canonical_id":"go:GO:0036153","description":"\"Remodeling the acyl chains of triacylglycerol, through sequential deacylation and re-acylation reactions, to generate triacylglycerol containing different types of fatty acid acyl chains.\" [GOC:mw, PMID:15364929]","metadata":null},{"id":"1aff24c20e3948b7aaf199fca5076bf4","type":"GO_TERM","name":"triglyceride binding","canonical_id":"go:GO:0017129","description":"\"Binding to a triester of glycerol.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"f42dea65193c438a859d64173b6b002d","type":"GO_TERM","name":"triglyceride biosynthetic process","canonical_id":"go:GO:0019432","description":"\"The chemical reactions and pathways resulting in the formation of a triglyceride, any triester of glycerol.\" [ISBN:0198506732]","metadata":null},{"id":"bcb41dc23be64c05a462338521389d49","type":"GO_TERM","name":"triglyceride catabolic process","canonical_id":"go:GO:0019433","description":"\"The chemical reactions and pathways resulting in the breakdown of a triglyceride, any triester of glycerol.\" [ISBN:0198506732]","metadata":null},{"id":"1b6749a67fd14f33b365f4fbfadce859","type":"GO_TERM","name":"triglyceride homeostasis","canonical_id":"go:GO:0070328","description":"\"Any process involved in the maintenance of an internal steady state of triglyceride within an organism or cell.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"4101dfad2da34a2eabf6965b3c014a7d","type":"GO_TERM","name":"triglyceride metabolic process","canonical_id":"go:GO:0006641","description":"\"The chemical reactions and pathways involving triglyceride, any triester of glycerol. The three fatty acid residues may all be the same or differ in any permutation. Triglycerides are important components of plant oils, animal fats and animal plasma lipoproteins.\" [ISBN:0198506732]","metadata":null},{"id":"3c2223711ec54841b45412b02f4a7797","type":"GO_TERM","name":"triglyceride mobilization","canonical_id":"go:GO:0006642","description":"\"The release of triglycerides, any triester of glycerol, from storage within cells or tissues, making them available for metabolism.\" [GOC:mah, PMID:11943743, PMID:15713625]","metadata":null},{"id":"af31bb4fb9e643aaa149b6ab85d0ef61","type":"GO_TERM","name":"triglyceride storage","canonical_id":"go:GO:0030730","description":"\"The process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"f5bc364b462b4147b846f99989b080ec","type":"GO_TERM","name":"triglyceride transfer activity","canonical_id":"go:GO:0140344","description":"\"Directly binding to a triglyceride and delivering it either to an acceptor molecule or to a specific location.\" [PMID:23475612]","metadata":null},{"id":"f62840b70fe140d0abc8c1365a0769e2","type":"GO_TERM","name":"triglyceride transport","canonical_id":"go:GO:0034197","description":"\"The directed movement of triglyceride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Triglycerides are important components of plant oils, animal fats and animal plasma lipoproteins.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"231b2955fb5e4a64b2ab70ab5cd2f45b","type":"GO_TERM","name":"triglyceride-rich lipoprotein particle clearance","canonical_id":"go:GO:0071830","description":"\"The process in which a triglyceride-rich lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF]","metadata":null},{"id":"ebb3442f154842bdb5f3fb6756d6a362","type":"GO_TERM","name":"triglyceride-rich lipoprotein particle remodeling","canonical_id":"go:GO:0034370","description":"\"The acquisition, loss or modification of a protein or lipid within a triglyceride-rich lipoprotein particle, including the hydrolysis of triglyceride by lipoprotein lipase, with the subsequent loss of free fatty acid, and the transfer of cholesterol esters to a triglyceride-rich lipoprotein particle by cholesteryl ester transfer protein (CETP), with the simultaneous transfer of triglyceride from a triglyceride-rich lipoprotein particle.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"839d0a6038964adfb768009208641c1b","type":"GO_TERM","name":"triglyceride-rich plasma lipoprotein particle","canonical_id":"go:GO:0034385","description":"\"A plasma lipoprotein particle that has a hydrophobic core enriched in triglycerides surrounded by an amphipathic monolayer of phospholipids, cholesterol and apolipoproteins. Triglyceride-rich lipoprotein particles transport lipids, which are non-covalently associated with the particles, in the blood.\" [GOC:BHF, GOC:mah, GOC:rl]","metadata":null},{"id":"54bcacf07b0e4abdaa2205051d650066","type":"GO_TERM","name":"triglyceride-sterol O-acyltransferase activity","canonical_id":"go:GO:0047197","description":"\"Catalysis of the reaction: a 3-beta-hydroxysterol + triacylglycerol = a 3-beta-hydroxysterol ester + 1,2-diacylglycerol.\" [EC:2.3.1.77, MetaCyc:2.3.1.77-RXN]","metadata":null},{"id":"422e4c3055c9480ca016d32c4746d5c1","type":"DISEASE","name":"trigonocephaly 1","canonical_id":"mondo:0008603","description":null,"metadata":null},{"id":"8548b9f8cc31448b9e6ad06e0a1f6d46","type":"DRUG","name":"trihexyphenidyl","canonical_id":"gtopdb:7315","description":null,"metadata":null},{"id":"0f69d97916024d559e991957b08a953e","type":"DRUG","name":"trihexyphenidyl","canonical_id":"mesh:D014282","description":null,"metadata":null},{"id":"54154f7e3a4c478baab381243e941059","type":"GO_TERM","name":"trihydroxybenzophenone synthase activity","canonical_id":"go:GO:0102735","description":"\"Catalysis of the reaction: benzoyl-CoA + 3 malonyl-CoA + 3 H+ = 2,4,6-trihydroxybenzophenone + 4 coenzyme A + 3 carbon dioxide.\" [GOC:pz, RHEA:35143]","metadata":null},{"id":"4d9d74667206488d9a8260682c7c9717","type":"GO_TERM","name":"trihydroxyferuloyl spermidine O-methyltransferase activity","canonical_id":"go:GO:0080012","description":"\"Catalysis of the reaction: trihydroxyferuloyl spermidine + S-adenosyl-L-methionine = dihydroxyferuloyl-sinapoyl spermidine + S-adenosyl-L-homocysteine + H+.\" [PMID:18557837]","metadata":null},{"id":"95f8de252b5347169a2b023e95624804","type":"GO_TERM","name":"trihydroxyferuloyl spermidine:S-adenosyl-L-methionine O-methyltransferase activity","canonical_id":"go:GO:0080077","description":"\"Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the oxygen atom of a trihydroxyferuloyl spermidine molecule.\" [PMID:19077165]","metadata":null},{"id":"f1e100d57bee4cecb96ee2e607d24ca4","type":"GO_TERM","name":"trihydroxypterocarpan dimethylallyltransferase activity","canonical_id":"go:GO:0047292","description":"\"Catalysis of the reaction: (6AS,11AS)-3,6A,9-trihydroxypterocarpan + dimethylallyl-pyrophosphate = glyceollin + diphosphate.\" [EC:2.5.1.36]","metadata":null},{"id":"43fc1c03c590489f9cce777d56a242e2","type":"GO_TERM","name":"trihydroxystilbene synthase activity","canonical_id":"go:GO:0050350","description":"\"Catalysis of the reaction: 3 malonyl-CoA + 4-coumaroyl-CoA = 4 CoA + 3,4',5-trihydroxy-stilbene + 4 CO2.\" [EC:2.3.1.95]","metadata":null},{"id":"08cbb06e44e44d5095d13518a1989372","type":"GO_TERM","name":"trihydroxytoluene dioxygenase activity","canonical_id":"go:GO:0018616","description":"\"Catalysis of the reaction: 2,3,5-trihydroxytoluene + O2 = 2,4,6-trioxoheptanoate.\" [PMID:1254564, UM-BBD_reactionID:r0093]","metadata":null},{"id":"520dbc2579104dbb8726739cf10982b8","type":"DRUG","name":"triiodothyronine","canonical_id":"gtopdb:2634","description":null,"metadata":null},{"id":"1282772ef782439badc5bf267e2d60b4","type":"DRUG","name":"trilostane","canonical_id":"gtopdb:6850","description":null,"metadata":null},{"id":"58e3ab9b2d984b7b9d6cc5c274091bc9","type":"DRUG","name":"trilostane","canonical_id":"mesh:C009954","description":null,"metadata":null},{"id":"3894a27963564f7eb3ecb69464e1a36c","type":"DRUG","name":"trilostane","canonical_id":"chembl:CHEMBL1200907","description":null,"metadata":null},{"id":"5bbbbd014c7e4dc0beeb148ce2027a7d","type":"DRUG","name":"trimetaphan","canonical_id":"mesh:D014294","description":null,"metadata":null},{"id":"4d2939aee3ff4a3fa103b70437bd86f8","type":"GO_TERM","name":"trimetaphosphatase activity","canonical_id":"go:GO:0050351","description":"\"Catalysis of the reaction: H2O + trimetaphosphate = 2 H+ + triphosphate.\" [EC:3.6.1.2, RHEA:11088]","metadata":null},{"id":"7fdf660cb11c4b0dafc4a1e4ab0d1f38","type":"DRUG","name":"trimetazidine","canonical_id":"mesh:D014292","description":null,"metadata":null},{"id":"dc034210fc6e4786ba81e5716386098b","type":"DRUG","name":"trimethadione","canonical_id":"mesh:D014293","description":null,"metadata":null},{"id":"57e627e8df3648c68f9c37f403cda228","type":"DRUG","name":"trimethoprim","canonical_id":"mesh:D014295","description":null,"metadata":null},{"id":"7daf3c7ebcd5409990e090e5b18331f2","type":"GO_TERM","name":"trimethylamine dehydrogenase activity","canonical_id":"go:GO:0050470","description":"\"Catalysis of the reaction: trimethylamine + H2O + electron-transferring flavoprotein = dimethylamine + formaldehyde + reduced electron-transferring flavoprotein.\" [EC:1.5.8.2, MetaCyc:1.5.8.2-RXN]","metadata":null},{"id":"73052d07d6b24b56b1579c5d240a24fe","type":"GO_TERM","name":"trimethylamine methyltransferase activity","canonical_id":"go:GO:0043834","description":"\"Catalysis of the reaction: Co(I)-[trimethylamine-specific corrinoid protein] + H+ + trimethylamine = dimethylamine + methyl-Co(III)-[trimethylamine-specific corrinoid protein].\" [PMID:9006042, RHEA:39287]","metadata":null},{"id":"d29bb6eea99345bca509a2341c9f4725","type":"GO_TERM","name":"trimethylamine monooxygenase activity","canonical_id":"go:GO:0034899","description":"\"Catalysis of the reaction: N,N,N-trimethylamine + NADPH + H+ + O2 = N,N,N-trimethylamine N-oxide + NADP+ + H2O.\" [EC:1.14.13.148, UM-BBD_reactionID:r1407]","metadata":null},{"id":"a8adde91a7de4846a5b1c83705f86f18","type":"GO_TERM","name":"trimethylamine receptor activity","canonical_id":"go:GO:1990081","description":"\"Combining with the biogenic amine trimethylamine to initiate a change in cell activity.\" [PMID:16878137]","metadata":null},{"id":"50438e910a034742a6cc74c044204e02","type":"GO_TERM","name":"trimethylamine-N-oxide reductase (cytochrome c) activity","canonical_id":"go:GO:0050626","description":"\"Catalysis of the reaction: trimethylamine + 2 (ferricytochrome c)-subunit + H2O = trimethylamine-N-oxide + 2 (ferrocytochrome c)-subunit + 2 H+.\" [EC:1.7.2.3, MetaCyc:1.7.2.3-RXN]","metadata":null},{"id":"b588d87659a84fa4af7934153546cc1d","type":"GO_TERM","name":"trimethylamine-N-oxide reductase (cytochrome c) complex","canonical_id":"go:GO:1904852","description":"\"A protein complex which is capable of trimethylamine-N-oxide reductase (cytochrome c) activity.\" [GO_REF:0000088, GOC:bhm, GOC:TermGenie, PMID:11056172]","metadata":null},{"id":"8c880328c4434aa1a839f58234501293","type":"GO_TERM","name":"trimethylamine-oxide aldolase activity","canonical_id":"go:GO:0050352","description":"\"Catalysis of the reaction: H+ + trimethylamine N-oxide = dimethylamine + formaldehyde.\" [EC:4.1.2.32, RHEA:20217]","metadata":null},{"id":"1b3a09ddd8ad4320806b4ff70aa0e0f3","type":"GO_TERM","name":"trimethylenediamine biosynthetic process","canonical_id":"go:GO:1901057","description":"\"The chemical reactions and pathways resulting in the formation of trimethylenediamine.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00010]","metadata":null},{"id":"c08163410966430b9e29e8cd7706dc9c","type":"GO_TERM","name":"trimethyllysine dioxygenase activity","canonical_id":"go:GO:0050353","description":"\"Catalysis of the reaction: 2-oxoglutarate + N(6),N(6),N(6)-trimethyl-L-lysine + O2 = 3-hydroxy-N(6),N(6),N(6)-trimethyl-L-lysine + CO2 + succinate.\" [EC:1.14.11.8, RHEA:14181]","metadata":null},{"id":"848512f6c1864da6aae9cc17c3dd7aaa","type":"GO_TERM","name":"trimethylsulfonium-tetrahydrofolate N-methyltransferase activity","canonical_id":"go:GO:0047147","description":"\"Catalysis of the reaction: (6S)-5,6,7,8-tetrahydrofolate + trimethylsulfonium = (6S)-5-methyl-5,6,7,8-tetrahydrofolate + dimethyl sulfide + H+.\" [EC:2.1.1.19, RHEA:13693]","metadata":null},{"id":"86393499be0e4215bdb7b5783707afd7","type":"GO_TERM","name":"trimethyluric acid monooxygenase activity","canonical_id":"go:GO:0102613","description":"\"Catalysis of the reaction: 1,3,7-trimethyluric acid + O2 + NADH + 3 H+ = 1,3,7-trimethyl-5-hydroxyisourate + NAD + H2O.\" [GOC:pz, RHEA:48992]","metadata":null},{"id":"279f8b3bee6a48779d5661da56e7cf45","type":"DRUG","name":"trimipramine","canonical_id":"gtopdb:7317","description":null,"metadata":null},{"id":"26afd4c13b3b47b694413f62cc7c40b6","type":"GO_TERM","name":"trimming of terminal mannose on C branch","canonical_id":"go:GO:0036510","description":"\"The removal of an alpha-1,2-linked mannose from the C-chain of a glycoprotein oligosaccharide in the endoplasmic reticulum.\" [GOC:bf, GOC:PARL, PMID:20065073]","metadata":null},{"id":"f074f67c4a474c4394c8524e0c665327","type":"GO_TERM","name":"trinitrotoluene catabolic process","canonical_id":"go:GO:0046260","description":"\"The chemical reactions and pathways resulting in the breakdown of trinitrotoluene, a methylated benzene entity with three NO2 groups attached to it. This includes the explosive TNT, 1-methyl-2,4,6-trinitrobenzene.\" [GOC:ai]","metadata":null},{"id":"4e1b4e4f5e08402b89e18941fa9f4619","type":"GO_TERM","name":"triokinase activity","canonical_id":"go:GO:0050354","description":"\"Catalysis of the reaction: D-glyceraldehyde + ATP = D-glyceraldehyde 3-phosphate + ADP + 2 H+.\" [EC:2.7.1.28, RHEA:13941]","metadata":null},{"id":"b80fe8cfa12043379633c8bdb1f71018","type":"GO_TERM","name":"triose phosphate transmembrane transport","canonical_id":"go:GO:0035436","description":"\"The process in which triose phosphate (glyceraldehyde 3-phosphate) is transported across a membrane. Glyceraldehyde 3-phosphate is any organic three carbon compound phosphate ester.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"5b8a1447f93c477fb78ffd956f189103","type":"GO_TERM","name":"triose phosphate transport","canonical_id":"go:GO:0015717","description":"\"The directed movement of triose phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"3925434e152b49d6946ca853914bc725","type":"GO_TERM","name":"triose-phosphate isomerase activity","canonical_id":"go:GO:0004807","description":"\"Catalysis of the reaction: D-glyceraldehyde 3-phosphate = dihydroxyacetone phosphate.\" [RHEA:18585]","metadata":null},{"id":"af5ca335faf144e9a64852720a075e42","type":"GO_TERM","name":"triose-phosphate transmembrane transporter activity","canonical_id":"go:GO:0071917","description":"\"Enables the transfer of a triose phosphate from one side of a membrane to the other.\" [GOC:mah, GOC:vw]","metadata":null},{"id":"7e4f21ea8b6d477d9f334bc76d5e056b","type":"GO_TERM","name":"triose-phosphate:phosphate antiporter activity","canonical_id":"go:GO:0009670","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: triose-phosphate(out) + phosphate(in) = triose-phosphate(in) + phosphate(out).\" [GOC:bf, GOC:jl, GOC:mtg_transport, ISBN:0815340729, TC:2.A.7.-.-]","metadata":null},{"id":"35c9215b7e2b4384bb6f5ed03b1e0c91","type":"GO_TERM","name":"tripartite ATP-independent periplasmic transporter complex","canonical_id":"go:GO:0031317","description":"\"A complex consisting of two membrane proteins and one extracytoplasmic solute receptor. Such transporters transport a variety of substrates without direct ATP power, instead using energy from ion gradients.\" [GOC:mlg]","metadata":null},{"id":"6ad1bd2a93114c2aa90801279929c094","type":"GO_TERM","name":"tripartite attachment complex","canonical_id":"go:GO:0120121","description":"\"A three-part cytoskeletal structure in kinetoplastid species linking mitochondrial DNA organised in a kinetoplast through the mitochondrial membranes to the basal body.\" [PMID:12802053, PMID:18059470, PMID:24821793, PMID:27168148]","metadata":null},{"id":"2235ea12944a42bbaa6a3c430ec73627","type":"GO_TERM","name":"tripartite regional subdivision","canonical_id":"go:GO:0007351","description":"\"Subdivision of the embryo along the anterior/posterior axis into anterior, posterior and terminal regions.\" [GOC:dph, GOC:isa_complete, http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"c3f15e4bfe5c487aa1673718430897af","type":"DRUG","name":"tripelennamine","canonical_id":"gtopdb:7318","description":null,"metadata":null},{"id":"b7d70520aec148c3b9419d070215f094","type":"DRUG","name":"tripelennamine","canonical_id":"mesh:D014309","description":null,"metadata":null},{"id":"6cb90438230b43a5af2c69e5a3bfc81b","type":"GO_TERM","name":"tripeptidase activity","canonical_id":"go:GO:0034701","description":"\"Catalysis of the hydrolysis of a tripeptide.\" [GOC:mah]","metadata":null},{"id":"a5277de7bf9a49049272e92c71188bf6","type":"GO_TERM","name":"tripeptide aminopeptidase activity","canonical_id":"go:GO:0045148","description":"\"Catalysis of the hydrolysis of a single N-terminal amino acid residue from a tripeptide.\" [EC:3.4.11.4]","metadata":null},{"id":"94dc571cd27d4adab311722081cd50d1","type":"GO_TERM","name":"tripeptide import across plasma membrane","canonical_id":"go:GO:0140207","description":"\"The directed movement of a tripeptide from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:22226946]","metadata":null},{"id":"89a38f98983f4137a6b46d8b8d586e86","type":"GO_TERM","name":"tripeptide transmembrane transport","canonical_id":"go:GO:0035443","description":"\"The directed movement of a tripeptide across a membrane by means of some agent such as a transporter or pore. A tripeptide is a compound containing three amino acids linked together by peptide bonds.\" [GOC:vw]","metadata":null},{"id":"5317372381b3499d802049ccfa876ec0","type":"GO_TERM","name":"tripeptide transmembrane transporter activity","canonical_id":"go:GO:0042937","description":"\"Enables the transfer of a tripeptide, a compound containing three amino acids linked together by peptide bonds, from one side of a membrane to the other.\" [GOC:jl]","metadata":null},{"id":"539280309bf841f8aa9016cb634e40be","type":"GO_TERM","name":"tripeptide transport","canonical_id":"go:GO:0042939","description":"\"The directed movement of a tripeptide, a compound containing three amino acids linked together by peptide bonds, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:jl]","metadata":null},{"id":"f8bcc50708cc44c3af929555445c687d","type":"GO_TERM","name":"tripeptidyl-peptidase activity","canonical_id":"go:GO:0008240","description":"\"Catalysis of the release of an N-terminal tripeptide from a polypeptide.\" [GOC:mah]","metadata":null},{"id":"07c06f2f408a4a15a7f11b5ea05741e3","type":"GO_TERM","name":"triphosphoribosyl-dephospho-CoA synthase activity","canonical_id":"go:GO:0046917","description":"\"Catalysis of the reaction: ATP + 3-dephospho-CoA = 2'-(5''-triphosphoribosyl)-3'-dephospho-CoA + adenine.\" [EC:2.4.2.52]","metadata":null},{"id":"9d020b7cff9e44b89001f0634b3acb37","type":"GO_TERM","name":"triphosphoric monoester hydrolase activity","canonical_id":"go:GO:0016793","description":"\"Catalysis of the hydrolysis of a triphosphoester to give a triphosphate group and a free hydroxyl group.\" [EC:3.1.5.-]","metadata":null},{"id":"69f9fcfeabf546e9a565e0fe6a9eab9c","type":"DISEASE","name":"triple-negative breast carcinoma","canonical_id":"mondo:0005494","description":null,"metadata":null},{"id":"2ba0a66a4536469581ea2e492f326af8","type":"GO_TERM","name":"triplet codon-amino acid adaptor activity","canonical_id":"go:GO:0030533","description":"\"The codon binding activity of a tRNA that positions an activated amino acid, mediating its insertion at the correct point in the sequence of a nascent polypeptide chain during protein synthesis.\" [GOC:hjd, GOC:mtg_MIT_16mar07, ISBN:0198506732]","metadata":null},{"id":"0e09a5bc40044580af6847d49733a5d0","type":"GO_TERM","name":"triplex DNA binding","canonical_id":"go:GO:0045142","description":"\"Binding to a DNA triple helix. The formation of triple helical DNA has been evoked in several cellular processes including transcription, replication, and recombination.\" [PMID:10681538]","metadata":null},{"id":"1cd0ce0cb53243ebbe4a2019d6ccd254","type":"DRUG","name":"triprolidine","canonical_id":"gtopdb:1228","description":null,"metadata":null},{"id":"3d746e2353664a81a2a6fec2ac908fbb","type":"DRUG","name":"triprolidine","canonical_id":"mesh:D014311","description":null,"metadata":null},{"id":"6d43e8f1d86745dc8c98c2fe99a4dc46","type":"GO_TERM","name":"trisaccharide binding","canonical_id":"go:GO:0048031","description":"\"Binding to a trisaccharide. Trisaccharides are sugars composed of three monosaccharide units.\" [GOC:jid]","metadata":null},{"id":"8246e8eae4ad4f759325aeafad56097e","type":"GO_TERM","name":"trisaccharide transport","canonical_id":"go:GO:2001088","description":"\"The directed movement of a trisaccharideacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"175202edb56d4b16a1758ffac185276e","type":"GO_TERM","name":"trisporic acid biosynthetic process","canonical_id":"go:GO:0046842","description":"\"The chemical reactions and pathways resulting in the formation of trisporic acid.\" [GOC:ai]","metadata":null},{"id":"870d34d0c3da49b0ad2e8aec1f55f528","type":"GO_TERM","name":"triterpenoid biosynthetic process","canonical_id":"go:GO:0016104","description":"\"The chemical reactions and pathways resulting in the formation of triterpenoid compounds, terpenoids with six isoprene units.\" [GOC:curators]","metadata":null},{"id":"c00696fee141455bb4b57c9fb5cc7af5","type":"GO_TERM","name":"triterpenoid catabolic process","canonical_id":"go:GO:0016105","description":"\"The chemical reactions and pathways resulting in the breakdown of triterpenoid compounds, terpenoids with six isoprene units.\" [GOC:curators]","metadata":null},{"id":"c2c32c61b7bf4c65a1afa5a5825846e3","type":"GO_TERM","name":"triterpenoid metabolic process","canonical_id":"go:GO:0006722","description":"\"The chemical reactions and pathways involving triterpenoid compounds, terpenoids with six isoprene units.\" [ISBN:0198547684]","metadata":null},{"id":"87f8adca3bf940b0aa6522c037b32d81","type":"GO_TERM","name":"trithionate hydrolase activity","canonical_id":"go:GO:0047401","description":"\"Catalysis of the reaction: H2O + trithionate = H+ + sulfate + thiosulfate.\" [RHEA:21884]","metadata":null},{"id":"3014bca2fe9c498f88586d840756d16e","type":"GO_TERM","name":"trochlear nerve development","canonical_id":"go:GO:0021558","description":"\"The process whose specific outcome is the progression of the trochlear nerve over time, from its formation to the mature structure. The trochlear nerve is a motor nerve and is the only cranial nerve to exit the brain dorsally. The trochlear nerve innervates the superior oblique muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"03066b8d821d4b8286c874caa50cfe5e","type":"GO_TERM","name":"trochlear nerve formation","canonical_id":"go:GO:0021642","description":"\"The process that gives rise to the trochlear nerve. This process pertains to the initial formation of a structure from unspecified parts. The trochlear nerve is a motor nerve and is the only cranial nerve to exit the brain dorsally. The trochlear nerve innervates the superior oblique muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"a6c061152b254a0185395b6cb4d622bd","type":"GO_TERM","name":"trochlear nerve maturation","canonical_id":"go:GO:0021640","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the trochlear nerve to attain its fully functional state. The trochlear nerve is a motor nerve and is the only cranial nerve to exit the brain dorsally. The trochlear nerve innervates the superior oblique muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"dda62da6cb474fd08220d8270f60dfcc","type":"GO_TERM","name":"trochlear nerve morphogenesis","canonical_id":"go:GO:0021639","description":"\"The process in which the anatomical structure of the trochlear nerve is generated and organized. The trochlear nerve is a motor nerve and is the only cranial nerve to exit the brain dorsally. The trochlear nerve innervates the superior oblique muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"9d87577217954230b5516598ccab0ab3","type":"GO_TERM","name":"trochlear nerve structural organization","canonical_id":"go:GO:0021641","description":"\"The process that contributes to the act of creating the structural organization of the trochlear nerve. This process pertains to the physical shaping of a rudimentary structure. The trochlear nerve is a motor nerve and is the only cranial nerve to exit the brain dorsally. The trochlear nerve innervates the superior oblique muscle.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"31efa0c3715b48198500f83bfc0a25b2","type":"DRUG","name":"troglitazone","canonical_id":"gtopdb:2693","description":null,"metadata":null},{"id":"a7bb369054fe492fb961741ce846957e","type":"DRUG","name":"troglitazone","canonical_id":"chembl:CHEMBL408","description":null,"metadata":null},{"id":"4f048d3858d04d6094af9b304de5b369","type":"DRUG","name":"troleandomycin","canonical_id":"mesh:D014217","description":null,"metadata":null},{"id":"d3d8589ef82140f8a3a210370836b3d6","type":"GO_TERM","name":"tropane alkaloid biosynthetic process","canonical_id":"go:GO:0009710","description":"\"The chemical reactions and pathways resulting in the breakdown of tropane alkaloids, compounds containing the 8-methyl-8-azabicyclo(3.2.1)octane ring system.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"6d2264fa39c8402eb95fef1699fc3c74","type":"GO_TERM","name":"trophectodermal cell differentiation","canonical_id":"go:GO:0001829","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a trophectoderm cell.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"20d04201e8454b35ad3eedfecccd9e76","type":"GO_TERM","name":"trophectodermal cell fate commitment","canonical_id":"go:GO:0001830","description":"\"The cell fate commitment of precursor cells that will become trophectoderm cells.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"c785a16f6d554f1db618e1dbe22a2345","type":"GO_TERM","name":"trophectodermal cell proliferation","canonical_id":"go:GO:0001834","description":"\"The proliferation of cells in the trophectoderm.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"e3e36c676b1a4555b90f0f5e37e4b4b8","type":"GO_TERM","name":"trophectodermal cellular morphogenesis","canonical_id":"go:GO:0001831","description":"\"The morphogenesis of trophectoderm cells.\" [GOC:dph, ISBN:0124020607, ISBN:0198542771]","metadata":null},{"id":"08273f51e1284dbfbc819a1c5ece5f73","type":"GO_TERM","name":"trophoblast cell migration","canonical_id":"go:GO:0061450","description":"\"Trophoblast cell migration that is accomplished by extension and retraction of a pseudopodium. Trophoblast cells line the outside of the blastocyst.\" [GOC:dph]","metadata":null},{"id":"138a734ede144b7eb8d5d039a78c9b13","type":"GO_TERM","name":"trophoblast giant cell differentiation","canonical_id":"go:GO:0060707","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a trophoblast giant cell of the placenta. Trophoblast giant cells are the cell of the placenta that line the maternal decidua.\" [GOC:dph, PMID:16269175]","metadata":null},{"id":"9cf0195a8a17462683abd8f1b75ad6f4","type":"DRUG","name":"tropicamide","canonical_id":"gtopdb:7319","description":null,"metadata":null},{"id":"7d4f9c1968004923aef769e2ff445f2b","type":"DRUG","name":"tropicamide","canonical_id":"chembl:CHEMBL1200604","description":null,"metadata":null},{"id":"972f4a1eae7445d8b49ebc1a186666ce","type":"GO_TERM","name":"tropine dehydrogenase activity","canonical_id":"go:GO:0050356","description":"\"Catalysis of the reaction: NADP+ + tropine = H+ + NADPH + tropinone.\" [EC:1.1.1.206, RHEA:18357]","metadata":null},{"id":"a28b90455a114f1697fb12f3bd842348","type":"GO_TERM","name":"tropinesterase activity","canonical_id":"go:GO:0050357","description":"\"Catalysis of the reaction: atropine + H2O = H+ + tropate + tropine.\" [EC:3.1.1.10, RHEA:23304]","metadata":null},{"id":"984bf191eef3416687581d778d5ae11b","type":"GO_TERM","name":"tropinone reductase activity","canonical_id":"go:GO:0050358","description":"\"Catalysis of the reaction: NADP+ + pseudotropine = H+ + NADPH + tropinone.\" [EC:1.1.1.236, RHEA:24244]","metadata":null},{"id":"49a89e625838420b8c0229c63ede2ddc","type":"DRUG","name":"tropisetron","canonical_id":"gtopdb:260","description":null,"metadata":null},{"id":"8c79349ff9744e31b8c1b0bd0922a06e","type":"DRUG","name":"tropisetron","canonical_id":"chembl:CHEMBL56564","description":null,"metadata":null},{"id":"71b96b16719e4106a8ea7f6ad9bae178","type":"GO_TERM","name":"tropism","canonical_id":"go:GO:0009606","description":"\"The movement of an organism, or part of an organism, in response to an external source of stimulus, usually toward or away from it.\" [GOC:curators, ISBN:0877795088]","metadata":null},{"id":"be1f27cbcaa140a391de585bb1d376d9","type":"GO_TERM","name":"tropomyosin binding","canonical_id":"go:GO:0005523","description":"\"Binding to tropomyosin, a protein associated with actin filaments both in cytoplasm and, in association with troponin, in the thin filament of striated muscle.\" [GOC:curators, ISBN:0815316194]","metadata":null},{"id":"c8b076f6db614c60b6a5399d91386c96","type":"GO_TERM","name":"troponin C binding","canonical_id":"go:GO:0030172","description":"\"Binding to troponin C, the calcium-binding subunit of the troponin complex.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"92821c6a7f424526bc13dd064c7430ec","type":"GO_TERM","name":"troponin I binding","canonical_id":"go:GO:0031013","description":"\"Binding to troponin I, the inhibitory subunit of the troponin complex.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"24987f312c4c485390b680b5b39bb077","type":"GO_TERM","name":"troponin T binding","canonical_id":"go:GO:0031014","description":"\"Binding to troponin T, the tropomyosin-binding subunit of the troponin complex.\" [GOC:mah, ISBN:0815316194]","metadata":null},{"id":"f22fb1cc62634471b479e57883b3cec4","type":"GO_TERM","name":"troponin complex","canonical_id":"go:GO:0005861","description":"\"A complex of accessory proteins (typically troponin T, troponin I and troponin C) found associated with actin in muscle thin filaments; involved in calcium regulation of muscle contraction.\" [ISBN:0815316194]","metadata":null},{"id":"c1c2a9172b0b4025b79aa5b5f5040d93","type":"DRUG","name":"trospium","canonical_id":"mesh:C003330","description":null,"metadata":null},{"id":"5d15e060b98a4e49bdef5a51361dbc8e","type":"GO_TERM","name":"trunk neural crest cell migration","canonical_id":"go:GO:0036484","description":"\"The characteristic movement of trunk neural crest cells from the neural tube to other locations in the vertebrate embryo.\" [GOC:bf, GOC:mat, GOC:PARL, PMID:2387238]","metadata":null},{"id":"52c77ea79fdd41e5bb99e88d68a3db2b","type":"GO_TERM","name":"trunk segmentation","canonical_id":"go:GO:0035290","description":"\"Partitioning of the blastoderm embryo into trunk segmental units. In Drosophila, the trunk segments include thoracic segments and abdominal segments A1 to A8.\" [PMID:1360402]","metadata":null},{"id":"44c883092b7d442d812d40c84610d136","type":"DISEASE","name":"trypanosomiasis","canonical_id":"mondo:0000940","description":null,"metadata":null},{"id":"28e4583dc97046ffb05d69b3a4aaefd0","type":"GO_TERM","name":"trypanothione biosynthetic process","canonical_id":"go:GO:0019342","description":"\"The chemical reactions and pathways resulting in the formation of trypanothione (N1,N6,-bis(glutathionyl)spermidine) in two steps from glutathione and spermidine via an N1- or N8-glutathionylspermidine intermediate. Trypanothione appears to be an essential redox intermediate in intracellular thiol redox regulation. It also plays a role in protecting against oxidative stress.\" [MetaCyc:TRYPANOSYN-PWY, PMID:9677355]","metadata":null},{"id":"24f39ff6d9d9425c8cca2fbf6b46c125","type":"GO_TERM","name":"trypanothione catabolic process","canonical_id":"go:GO:0046207","description":"\"The chemical reactions and pathways resulting in the breakdown of trypanothione (N1,N6,-bis(glutathionyl)spermidine), an essential redox intermediate in intracellular thiol redox regulation which also plays a role in protecting against oxidative stress.\" [GOC:ai]","metadata":null},{"id":"a1545a67f7ad443e935a539f432ea713","type":"GO_TERM","name":"trypanothione metabolic process","canonical_id":"go:GO:0046206","description":"\"The chemical reactions and pathways involving trypanothione (N1,N6,-bis(glutathionyl)spermidine), an essential redox intermediate in intracellular thiol redox regulation which also plays a role in protecting against oxidative stress.\" [GOC:ai]","metadata":null},{"id":"e6e5cdd6fb5949a08391d47e9721121e","type":"GO_TERM","name":"trypanothione synthase activity","canonical_id":"go:GO:0047479","description":"\"Catalysis of the reaction: reduced glutathione + glutathionylspermidine + ATP = trypanothione + ADP + phosphate.\" [EC:6.3.1.9, MetaCyc:6.3.1.9-RXN]","metadata":null},{"id":"9bc80f6977d941dab7b60949a07c29d1","type":"GO_TERM","name":"trypanothione-disulfide reductase (NADPH) activity","canonical_id":"go:GO:0015042","description":"\"Catalysis of the reaction: NADP+ + trypanothione = NADPH + H+ + trypanothione disulfide.\" [RHEA:16757]","metadata":null},{"id":"5c792973fefd4a6182504a2a886a31be","type":"GO_TERM","name":"tryparedoxin peroxidase activity","canonical_id":"go:GO:0033196","description":"\"Catalysis of the reaction: tryparedoxin + H2O2 = tryparedoxin disulfide + H2O.\" [GOC:mah, PMID:32388269]","metadata":null},{"id":"974993b217fd4d61b755af01e4e8ca75","type":"GO_TERM","name":"tryprostatin A biosynthetic process","canonical_id":"go:GO:0140654","description":"\"The chemical reactions and pathways resulting in the formation of tryprostatin A.\" [GOC:ach, PMID:19226505]","metadata":null},{"id":"4c2870b01abe47d0b816fe37c6583cbf","type":"GO_TERM","name":"trypsinogen activation","canonical_id":"go:GO:0032023","description":"\"The proteolytic processing of trypsinogen to the active form, trypsin.\" [GOC:mah]","metadata":null},{"id":"e58fdcbaa3634f88ba0713dbb95d0a29","type":"GO_TERM","name":"tryptamine 4-monooxygenase activity","canonical_id":"go:GO:0140382","description":"\"Catalysis of the reaction: tryptamine + reduced acceptor + O2 = 4-hydroxytryptamine + acceptor + H2O.\" [PMID:28763571]","metadata":null},{"id":"8e27966ce5bf46a699813efed8ddb774","type":"GO_TERM","name":"tryptophan 2'-dioxygenase activity","canonical_id":"go:GO:0050360","description":"\"Catalysis of the reaction: L-tryptophan + O2 + H+ = 3-indoleglycolaldehyde + NH4+ + CO2.\" [RHEA:22620]","metadata":null},{"id":"4d9c91d69226423cac0e044edc2cdc28","type":"GO_TERM","name":"tryptophan 2-C-methyltransferase activity","canonical_id":"go:GO:0030772","description":"\"Catalysis of the reaction: L-tryptophan + S-adenosyl-L-methionine = 2-methyl-L-tryptophan + S-adenosyl-L-homocysteine + H+.\" [RHEA:17321]","metadata":null},{"id":"f81611e699144b188c8ca9a84dde9c6d","type":"GO_TERM","name":"tryptophan 2-monooxygenase activity","canonical_id":"go:GO:0050361","description":"\"Catalysis of the reaction: L-tryptophan + O2 = CO2 + H2O + indole-3-acetamide.\" [EC:1.13.12.3, RHEA:16165]","metadata":null},{"id":"b735792e71884475889dfa9ee9b6cd31","type":"GO_TERM","name":"tryptophan 5-monooxygenase activity","canonical_id":"go:GO:0004510","description":"\"Catalysis of the reaction: L-tryptophan + tetrahydrobiopterin + O2 = 5-hydroxy-L-tryptophan + 4-alpha-hydroxytetrahydrobiopterin + H2O.\" [EC:1.14.16.4]","metadata":null},{"id":"9a397d9ed55b4afb9a0e0eb9fa137cdf","type":"GO_TERM","name":"tryptophan N-monooxygenase activity","canonical_id":"go:GO:0090489","description":"\"Catalyzes the multi-step reaction: L-tryptophan + 2 O2 + 2 reduced [NADPH--hemoprotein reductase] = (E)-(indol-3-yl)acetaldehyde oxime + CO2 + 2 H+ + 3 H2O + 2 oxidized [NADPH--hemoprotein reductase].\" [RHEA:33279]","metadata":null},{"id":"3b96fc1f9e2d4ce2870dd2e2cb65b010","type":"GO_TERM","name":"tryptophan alpha,beta-oxidase activity","canonical_id":"go:GO:0050621","description":"\"Catalysis of the reaction: L-tryptophan + O2 = alpha,beta-didehydrotryptophan + H2O2 + H+.\" [EC:1.3.3.10, RHEA:19901]","metadata":null},{"id":"68111999698a458485598d6a494d5244","type":"GO_TERM","name":"tryptophan binding","canonical_id":"go:GO:0120284","description":"\"Binding to 2-amino-3-(1H-indol-3-yl)propanoic acid.\" [GOC:krc]","metadata":null},{"id":"ba7ee2b61e6042e097c99bf795dea36f","type":"GO_TERM","name":"tryptophan dimethylallyltransferase activity","canonical_id":"go:GO:0050364","description":"\"Catalysis of the reaction: dimethylallyl diphosphate + L-tryptophan = diphosphate + 4-(3-methylbut-2-enyl)-L-tryptophan.\" [EC:2.5.1.34, MetaCyc:TRYPTOPHAN-DIMETHYLALLYLTRANSFERASE-RXN]","metadata":null},{"id":"6393fc825f694b8f83722a2d2c359840","type":"GO_TERM","name":"tryptophan hydroxylase activator activity","canonical_id":"go:GO:0016483","description":"\"Increases the activity of the enzyme tryptophase hydroxylase.\" [GOC:ai]","metadata":null},{"id":"9a44e1af72db4d328dac7ebeb23933dd","type":"GO_TERM","name":"tryptophan sensor activity","canonical_id":"go:GO:0120286","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of tryptophan.\" [GOC:krc, PMID:31498992]","metadata":null},{"id":"724518b9d5c74d0ba81f97b76c5807c5","type":"GO_TERM","name":"tryptophan synthase activity","canonical_id":"go:GO:0004834","description":"\"Catalysis of the reaction: L-serine + (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate = L-tryptophan + glyceraldehyde 3-phosphate + H2O.\" [RHEA:10532]","metadata":null},{"id":"b34b10dfd28f405f92058ca4c6ff5b50","type":"GO_TERM","name":"tryptophan transport","canonical_id":"go:GO:0015827","description":"\"The directed movement of tryptophan, 2-amino-3-(1H-indol-3-yl)propanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"c42d6ce4fad445be8c338223a2b2d1b0","type":"GO_TERM","name":"tryptophan-tRNA ligase activity","canonical_id":"go:GO:0004830","description":"\"Catalysis of the reaction: ATP + L-tryptophan + tRNA(Trp) = AMP + diphosphate + L-tryptophanyl-tRNA(Trp).\" [EC:6.1.1.2]","metadata":null},{"id":"c99f9c8357d34884bf82cbb92a9b1323","type":"GO_TERM","name":"tryptophanamidase activity","canonical_id":"go:GO:0050365","description":"\"Catalysis of the reaction: L-tryptophanamide + H2O = L-tryptophan + NH4.\" [EC:3.5.1.57, RHEA:11012]","metadata":null},{"id":"5ef3e24f78554511957f9d6647df12a8","type":"GO_TERM","name":"tryptophanase activity","canonical_id":"go:GO:0009034","description":"\"Catalysis of the reaction: L-tryptophan + H2O = indole + NH4 + pyruvate.\" [RHEA:19553]","metadata":null},{"id":"ecd6b997fe6b4298be83ed7442b2de4f","type":"GO_TERM","name":"tryptophanyl-tRNA aminoacylation","canonical_id":"go:GO:0006436","description":"\"The process of coupling tryptophan to tryptophanyl-tRNA, catalyzed by tryptophanyl-tRNA synthetase. The tryptophanyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a tryptophan-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"7ae9040b0db34e2eaeb81dc514f7d84c","type":"GO_TERM","name":"tube closure","canonical_id":"go:GO:0060606","description":"\"Creation of the central hole of a tube in an anatomical structure by sealing the edges of an epithelial fold.\" [GOC:dph]","metadata":null},{"id":"877b34c974d3428bb2e2374e0adb8b07","type":"GO_TERM","name":"tube development","canonical_id":"go:GO:0035295","description":"\"The process whose specific outcome is the progression of a tube over time, from its initial formation to a mature structure. Epithelial and endothelial tubes transport gases, liquids and cells from one site to another and form the basic structure of many organs and tissues including lung and trachea, kidney, the mammary gland, the vascular system and the gastrointestinal and urinary-genital tracts.\" [PMID:12526790]","metadata":null},{"id":"7c68cb9e9cd14973bea3c3c0a0cf5b93","type":"GO_TERM","name":"tube formation","canonical_id":"go:GO:0035148","description":"\"Creation of the central hole of a tube in an anatomical structure through which gases and/or liquids flow.\" [GOC:bf]","metadata":null},{"id":"a75e2230c1c44d16beea7106a525fb3c","type":"GO_TERM","name":"tube fusion","canonical_id":"go:GO:0035146","description":"\"The joining of specific branches of a tubular system to form a continuous network.\" [GOC:bf]","metadata":null},{"id":"91d769698cc14a48b880c5ddb959b51d","type":"GO_TERM","name":"tube lumen cavitation","canonical_id":"go:GO:0060605","description":"\"The formation of a lumen by hollowing out a solid rod or cord.\" [GOC:dph]","metadata":null},{"id":"11b4282b32dc48abb6b0374a52ecc351","type":"GO_TERM","name":"tube morphogenesis","canonical_id":"go:GO:0035239","description":"\"The process in which the anatomical structures of a tube are generated and organized. Epithelial and endothelial tubes transport gases, liquids and cells from one site to another and form the basic structure of many organs and tissues, with tube shape and organization varying from the single-celled excretory organ in Caenorhabditis elegans to the branching trees of the mammalian kidney and insect tracheal system.\" [GOC:bf, PMID:14624839]","metadata":null},{"id":"ddd93a25fd27497dbd580e1823545c55","type":"GO_TERM","name":"tube viral factory","canonical_id":"go:GO:0039719","description":"\"A cytoplasmic viral factory derived from the Golgi in which Bunyaviridae replication takes place. Tubes are membranous structures close to the assembly and budding sites, and their function may be to connect viral replication and morphogenesis inside viral factories.\" [VZ:1951]","metadata":null},{"id":"d7625fed05374702ae7d2506ae91e08b","type":"GO_TERM","name":"tuberculosinol biosynthetic process","canonical_id":"go:GO:0035440","description":"\"The chemical reactions and pathways resulting in the formation of tuberculosinol (halima-5,6,dien-15-ol), a secondary metabolite in Mycobacteria.\" [MetaCyc:PWY-5935]","metadata":null},{"id":"98d84e4fd27347cbae47517d8951fb64","type":"DISEASE","name":"tuberous sclerosis","canonical_id":"mondo:0001734","description":null,"metadata":null},{"id":"304df2b945f24218af31975f8b1a9a47","type":"GO_TERM","name":"tubovesicular membrane network","canonical_id":"go:GO:0085026","description":"\"A complex, symbiont-induced host-derived organelle that is comprised of multiple protein and lipid domains.\" [GOC:pamgo_curators]","metadata":null},{"id":"9a0c2251e64d4f3ab42f60b43e896f90","type":"GO_TERM","name":"tubular endosome","canonical_id":"go:GO:0097422","description":"\"A network of fine tubules in the vicinity of the Golgi complex and around the centriole.\" [NIF_Subcellular:sao1570660411, NIF_Subcellular:sao694815499, PMID:11896161]","metadata":null},{"id":"bac07214d3374b218aaa0debf3330a2e","type":"GO_TERM","name":"tubulin N-acetyltransferase activity","canonical_id":"go:GO:0019799","description":"\"Catalysis of the reaction: acetyl-CoA + (alpha-tubulin) L-lysine = CoA + (alpha-tubulin) N6-acetyl-L-lysine. In most organisms it acetylates L-lysine at position 40 of alpha- tubulin.\" [EC:2.3.1.108]","metadata":null},{"id":"7a4e01c7035d45198f4e0f85fe159949","type":"GO_TERM","name":"tubulin N-terminal-methionine acetyltransferase activity","canonical_id":"go:GO:0120519","description":"\"Catalysis of the reaction: acetyl-CoA + N-terminal L-methionyl-[tubulin] = CoA + H+ + N-terminal N(alpha)-acetyl-L-methionyl-[tubulin]. The N-terminus of both alpha- and beta-tubulin are acetylated.\" [EC:2.3.1.308, RHEA:69607]","metadata":null},{"id":"abedc663afc84c669d604e757f49e842","type":"GO_TERM","name":"tubulin binding","canonical_id":"go:GO:0015631","description":"\"Binding to monomeric or multimeric forms of tubulin, including microtubules.\" [GOC:clt]","metadata":null},{"id":"b04c79d384e349f1a141e0080b364160","type":"GO_TERM","name":"tubulin complex","canonical_id":"go:GO:0045298","description":"\"A heterodimer of tubulins alpha and beta that constitutes the protomer for microtubule assembly.\" [ISBN:0716731363]","metadata":null},{"id":"74baee3ae5b04da7a9adb5a1b6ae5716","type":"GO_TERM","name":"tubulin complex assembly","canonical_id":"go:GO:0007021","description":"\"The aggregation and bonding together of alpha- and beta-tubulin to form a tubulin heterodimer.\" [GOC:mah]","metadata":null},{"id":"41faf50b53f141b4a6d08e3e4122bedf","type":"GO_TERM","name":"tubulin deacetylase activity","canonical_id":"go:GO:0042903","description":"\"Catalysis of the reaction: N-acetyl(alpha-tubulin) + H2O = alpha-tubulin + acetate.\" [PMID:12024216, PMID:12486003]","metadata":null},{"id":"13f861fab6c2492a971326fe858a8b14","type":"GO_TERM","name":"tubulin deacetylation","canonical_id":"go:GO:0090042","description":"\"The removal of an acetyl group from tubulin. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.\" [GOC:BHF, GOC:dph, GOC:tb]","metadata":null},{"id":"aefe60f2dd7043d4be5b94f81dd4f7cf","type":"GO_TERM","name":"tubulin-dependent ATPase activity","canonical_id":"go:GO:0070463","description":"\"Catalysis of the reaction: ATP + H2O = ADP + phosphate. This reaction requires the presence of a tubulin dimer to accelerate release of ADP and phosphate.\" [GOC:mah, PMID:16906148]","metadata":null},{"id":"b1462bb9b61d446d9d61f5cecdac92a0","type":"GO_TERM","name":"tubulin-glutamic acid ligase activity","canonical_id":"go:GO:0070740","description":"\"Catalysis of the posttranslational transfer of one or more glutamate residues to the gamma-carboxyl group(s) of one or more specific glutamate residues on a tubulin molecule.\" [GOC:mah, PMID:19524510]","metadata":null},{"id":"70c10e2055a8427ab3b2a632f6ac1081","type":"GO_TERM","name":"tubulin-glycine ligase activity","canonical_id":"go:GO:0070738","description":"\"Catalysis of the posttranslational transfer of one or more glycine residues to a specific glutamate residue on a target tubulin molecule; acts on alpha or beta tubulin.\" [GOC:mah, PMID:19524510]","metadata":null},{"id":"ff0702e6498946e9a94bb8c87d54cece","type":"GO_TERM","name":"tubulin-tyrosine carboxypeptidase activity","canonical_id":"go:GO:0106423","description":"\"Catalysis of the reaction: C-terminal L-alpha-aminoacyl-L-glutamyl-L-glutamyl-L-tyrosyl-[tubulin] + H2O = C-terminal L-alpha-aminoacyl-L-glutamyl-L-glutamyl-[tubulin] + L-tyrosine.\" [PMID:29146869, PMID:35482892, RHEA:57444]","metadata":null},{"id":"b7cb2f3c89d34a6abd15cbb8008e6204","type":"GO_TERM","name":"tubulin-tyrosine ligase activity","canonical_id":"go:GO:0004835","description":"\"Catalysis of the reaction: ATP + detyrosinated alpha-tubulin + L-tyrosine = alpha-tubulin + ADP + phosphate.\" [EC:6.3.2.25]","metadata":null},{"id":"1c47ea55deca4e0b902225a8985054b5","type":"GO_TERM","name":"tubulobulbar complex","canonical_id":"go:GO:0036284","description":"\"Actin-based structures involved in establishing close contact between Sertoli-Sertoli cells or Sertoli-spermatids in the seminiferous tubules of the testes.\" [GOC:sl, PMID:22510523]","metadata":null},{"id":"60c73e7cb75c4095910f632a8baf7b65","type":"DRUG","name":"tucatinib","canonical_id":"gtopdb:9922","description":null,"metadata":null},{"id":"edbc1557adda467990227496e341e3e9","type":"DRUG","name":"tucatinib","canonical_id":"chembl:CHEMBL3989868","description":null,"metadata":null},{"id":"75d56ef24a14494782ddb4a584efe62b","type":"DRUG","name":"tucidinostat","canonical_id":"gtopdb:8305","description":null,"metadata":null},{"id":"01715dfd46b544c9a40a5994e9cecfb0","type":"GO_TERM","name":"tuft","canonical_id":"go:GO:0151001","description":"\"A dense cluster of elongated, thick microvilli on the apical surface of tuft cells in epithelial tissues, such as the intestine and respiratory tract. The apical tuft extends further into the lumen than typical microvilli, featuring larger, more compact projections with unique actin cores that penetrate deep into the cytoplasm, often reaching the perinuclear region. This distinctive structure, rich in microfilaments and microtubules, supports the chemosensory functions of the cell.\" [PMID:15817800, PMID:35237268]","metadata":null},{"id":"5fa1cc4604c34b60892f09469c26406d","type":"DISEASE","name":"tufted angioma","canonical_id":"mondo:0011927","description":null,"metadata":null},{"id":"a99c74f63f484b918c96f1d33a1fa9b2","type":"DISEASE","name":"tularemia","canonical_id":"mondo:0018077","description":null,"metadata":null},{"id":"5c6238b8b93643c5b81131ad09ac5504","type":"DRUG","name":"tulobuterol","canonical_id":"mesh:C010809","description":null,"metadata":null},{"id":"33b1aa1a79694dada195910257ba7f6f","type":"GO_TERM","name":"tumor necrosis factor (ligand) superfamily member 11 production","canonical_id":"go:GO:0072535","description":"\"The appearance of tumor necrosis factor superfamily member 11 (TNFSF11; RANKL) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"adbfb9b1969e4f0098abfe9b9673a0f0","type":"GO_TERM","name":"tumor necrosis factor binding","canonical_id":"go:GO:0043120","description":"\"Binding to tumor necrosis factor, a proinflammatory cytokine produced by monocytes and macrophages.\" [GOC:jl, http://lookwayup.com/]","metadata":null},{"id":"e4d07ebe6e9a4f2a90ccba8731ea829b","type":"GO_TERM","name":"tumor necrosis factor production","canonical_id":"go:GO:0032640","description":"\"The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Tumor necrosis factor is an inflammatory cytokine produced by macrophages/monocytes during acute inflammation and which is responsible for a diverse range of signaling events within cells, leading to necrosis or apoptosis.\" [GOC:mah, PMID:10891884, PMID:15560120]","metadata":null},{"id":"77a9fb4112c64c318e39b49824a10c20","type":"GO_TERM","name":"tumor necrosis factor receptor activity","canonical_id":"go:GO:0005031","description":"\"Combining with tumor necrosis factor, a proinflammatory cytokine produced by monocytes and macrophages, to initiate a change in cell function.\" [GOC:jl, http://lookwayup.com/]","metadata":null},{"id":"b5b122d057b44ce5837c850998d52b9d","type":"GO_TERM","name":"tumor necrosis factor receptor binding","canonical_id":"go:GO:0005164","description":"\"Binding to a tumor necrosis factor receptor.\" [GOC:ai]","metadata":null},{"id":"96d3ae2f24a4468a81065905aaee8036","type":"GO_TERM","name":"tumor necrosis factor receptor superfamily binding","canonical_id":"go:GO:0032813","description":"\"Binding to a member of the tumor necrosis factor receptor superfamily.\" [GOC:add]","metadata":null},{"id":"e747e5b9c8044329bcef823a710fe492","type":"GO_TERM","name":"tumor necrosis factor receptor superfamily complex","canonical_id":"go:GO:0002947","description":"\"A receptor complex that contains one or more members of the tumor necrosis factor (TNF) receptor superfamily.\" [GOC:krc]","metadata":null},{"id":"939b36bfc9894ab6b051f629bb6b6b0c","type":"GO_TERM","name":"tumor necrosis factor superfamily cytokine production","canonical_id":"go:GO:0071706","description":"\"The appearance of any member of the TNF superfamily due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:add]","metadata":null},{"id":"c54dd8c7620a4d7ea81e30faf9cd22bf","type":"GO_TERM","name":"tumor necrosis factor-mediated signaling pathway","canonical_id":"go:GO:0033209","description":"\"The series of molecular signals initiated by tumor necrosis factor binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:mah, GOC:signaling]","metadata":null},{"id":"8b204d46f89e4a47a3f012a997157469","type":"DISEASE","name":"tumor of parathyroid gland","canonical_id":"mondo:0021360","description":null,"metadata":null},{"id":"15609292924842269fca784fb8d053e5","type":"GO_TERM","name":"tungstate binding","canonical_id":"go:GO:1901359","description":"\"Binding to tungstate.\" [GOC:TermGenie]","metadata":null},{"id":"8f1bfe3721c24ea6aedc1b65ffdc28aa","type":"GO_TERM","name":"tungstate ion transport","canonical_id":"go:GO:0070614","description":"\"The directed movement of tungstate (WO4 2-) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Tungstate is a bivalent oxoanion of tungsten.\" [GOC:dh]","metadata":null},{"id":"5ad365776f2a414984730291e423e3c0","type":"GO_TERM","name":"tungsten incorporation into tungsten-molybdopterin complex","canonical_id":"go:GO:0042042","description":"\"The incorporation of tungsten into a tungsten-molybdopterin complex.\" [GOC:ai]","metadata":null},{"id":"93cbbbcc76904302b6028a11c0b1379a","type":"GO_TERM","name":"turning behavior","canonical_id":"go:GO:0035178","description":"\"Fine-tuning the spatial position of an organism in response to variability in their environment. For example, reorientation of an organism in the direction of a food source.\" [PMID:10880478]","metadata":null},{"id":"85db561051a34194b2eedb052c143e1d","type":"GO_TERM","name":"turning behavior involved in mating","canonical_id":"go:GO:0034607","description":"\"The sharp ventral turn performed by the male as he approaches either the hermaphrodite head or tail, whilst trying to locate his partner's vulva. Turning occurs via a sharp ventral coil of the male's tail.\" [PMID:18050467, WB_REF:WBPaper00002109]","metadata":null},{"id":"021b933f34df4771a04f6ff7af13d0f6","type":"DRUG","name":"tuvonralimab","canonical_id":"gtopdb:13793","description":null,"metadata":null},{"id":"4f7ce83a1f094cea8908bf5566fd4527","type":"GO_TERM","name":"twitch skeletal muscle contraction","canonical_id":"go:GO:0014721","description":"\"A process in which force is generated within twitch skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The twitch skeletal muscle responds to neurostimulations with a contraction followed by a relaxation.\" [GOC:mtg_muscle]","metadata":null},{"id":"b80d11d0dfad4e289cec5720297cf7ea","type":"GO_TERM","name":"type 1 angiotensin receptor binding","canonical_id":"go:GO:0031702","description":"\"Binding to a type 1 angiotensin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c1f4e4c212e24fb2ba70e0a61b37da47","type":"GO_TERM","name":"type 1 cannabinoid receptor binding","canonical_id":"go:GO:0031718","description":"\"Binding to a type 1 cannabinoid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"52479c30a64f4ea1b0df59cb63e0f56d","type":"GO_TERM","name":"type 1 cysteinyl leukotriene receptor binding","canonical_id":"go:GO:0031746","description":"\"Binding to a type 1 cysteinyl leukotriene receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"0c8b221c816943d2943bbd0e0d103429","type":"DISEASE","name":"type 1 diabetes mellitus","canonical_id":"mondo:0005147","description":null,"metadata":null},{"id":"d4534a8d7cbb41ed94f9ed48607e0520","type":"GO_TERM","name":"type 1 fibroblast growth factor receptor binding","canonical_id":"go:GO:0005105","description":"\"Binding to a type 1 fibroblast growth factor receptor (FGFR1).\" [GOC:ceb, GOC:fb_curators]","metadata":null},{"id":"ff3f5908ac9b4c98b0ec9e7e90d01524","type":"GO_TERM","name":"type 1 galanin receptor binding","canonical_id":"go:GO:0031764","description":"\"Binding to a type 1 galanin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"f1303a784b244c12b6132df477ce3de1","type":"GO_TERM","name":"type 1 melanin-concentrating hormone receptor binding","canonical_id":"go:GO:0031777","description":"\"Binding to a type 1 melanin-concentrating hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"8197bf40055e4f88a0eb67cf01b250d6","type":"GO_TERM","name":"type 1 melanocortin receptor binding","canonical_id":"go:GO:0070996","description":"\"Binding to a type 1 melanocortin receptor.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"685508fec39a480f947663a90f77c1e1","type":"GO_TERM","name":"type 1 member 1 taste receptor binding","canonical_id":"go:GO:0031884","description":"\"Binding to a type 1 member 1 taste receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"875f264b24b34c97bb5a4a3873259386","type":"GO_TERM","name":"type 1 member 2 taste receptor binding","canonical_id":"go:GO:0031885","description":"\"Binding to a type 1 member 2 taste receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"f52702d962a2440f9d294951fb50e2ac","type":"GO_TERM","name":"type 1 member 3 taste receptor binding","canonical_id":"go:GO:0031886","description":"\"Binding to a type 1 member 3 taste receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"baa9f3297c8744aabfc5ce547b53d0c2","type":"GO_TERM","name":"type 1 metabotropic GABA receptor binding","canonical_id":"go:GO:0031796","description":"\"Binding to a type 1 metabotropic GABA receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"aa317a5b05474c84a2345beb5492a37e","type":"GO_TERM","name":"type 1 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031798","description":"\"Binding to a type 1 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"6b7ccee989e94243b6bc355d62630f1f","type":"GO_TERM","name":"type 1 mitophagy","canonical_id":"go:GO:0180045","description":"\"The selective autophagy process in which a functional mitochondrion is degraded by macroautophagy to provide metabolic precursors during nutrient deprivation or to remove mitochondria in excess of metabolic needs.\" [GOC:vw, PMID:25009776]","metadata":null},{"id":"e4952249a77f4eb7bb291f375ae3ad8d","type":"GO_TERM","name":"type 1 neuromedin U receptor binding","canonical_id":"go:GO:0031839","description":"\"Binding to a type 1 neuromedin U receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"00b3cb3ca9ce4a2fbecccf10afbba590","type":"GO_TERM","name":"type 1 neuropeptide Y receptor binding","canonical_id":"go:GO:0031842","description":"\"Binding to a type 1 neuropeptide Y receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"03610e177e4e4883914a166c40ab0550","type":"GO_TERM","name":"type 1 neurotensin receptor binding","canonical_id":"go:GO:0031847","description":"\"Binding to a type 1 neurotensin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"17b086473dca44c98dfdf087cceed3c5","type":"GO_TERM","name":"type 1 orexin receptor binding","canonical_id":"go:GO:0031771","description":"\"Binding to a type 1 orexin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"345a40fb89f840aa91e582a483730a70","type":"GO_TERM","name":"type 1 parathyroid hormone receptor binding","canonical_id":"go:GO:0031857","description":"\"Binding to a type 1 parathyroid hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a9e23f13d62d4ae2b2b38ad8a77394e7","type":"GO_TERM","name":"type 1 proteinase activated receptor binding","canonical_id":"go:GO:0031872","description":"\"Binding to a type 1 proteinase activated receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d6a434e84e104842bec8f2915ef83f69","type":"GO_TERM","name":"type 1 somatostatin receptor binding","canonical_id":"go:GO:0031878","description":"\"Binding to a type 1 somatostatin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"06eb2503b6974d0990685fd23eb54963","type":"GO_TERM","name":"type 1 vasoactive intestinal polypeptide receptor binding","canonical_id":"go:GO:0031891","description":"\"Binding to a type 1 vasoactive intestinal polypeptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"56d865d914774036a4eb3b28c21ff1cf","type":"GO_TERM","name":"type 1A melatonin receptor binding","canonical_id":"go:GO:0031785","description":"\"Binding to a type 1A melatonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c05b5444c53e4010ad86c480fda95e2e","type":"GO_TERM","name":"type 1B melatonin receptor binding","canonical_id":"go:GO:0031786","description":"\"Binding to a type 1B melatonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"12eae7d38f2e4d20aead6a545deecc22","type":"GO_TERM","name":"type 1B serotonin receptor binding","canonical_id":"go:GO:0031822","description":"\"Binding to a type 1B serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"64a727a7db0b4aa89e7640a72084ac6d","type":"GO_TERM","name":"type 1D serotonin receptor binding","canonical_id":"go:GO:0031823","description":"\"Binding to a type 1D serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a143c260094040d0bfb4006b44e25b62","type":"GO_TERM","name":"type 1E serotonin receptor binding","canonical_id":"go:GO:0031824","description":"\"Binding to a type 1E serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"40b35eacd6b44356b479c459851c1c33","type":"GO_TERM","name":"type 1F serotonin receptor binding","canonical_id":"go:GO:0031825","description":"\"Binding to a type 1F serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"e4515b759c4d4fae9f1f90e983471812","type":"GO_TERM","name":"type 2 angiotensin receptor binding","canonical_id":"go:GO:0031703","description":"\"Binding to a type 2 angiotensin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d7b7f110ea2f4574a5c11bbb033ce8be","type":"GO_TERM","name":"type 2 cannabinoid receptor binding","canonical_id":"go:GO:0031719","description":"\"Binding to a type 2 cannabinoid receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ef1eb9c4671a4c5f8418ada75f5306c3","type":"GO_TERM","name":"type 2 cysteinyl leukotriene receptor binding","canonical_id":"go:GO:0031747","description":"\"Binding to a type 2 cysteinyl leukotriene receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"0d6b411a325744bfa7838bfbdb493532","type":"DISEASE","name":"type 2 diabetes mellitus","canonical_id":"mondo:0005148","description":null,"metadata":null},{"id":"c122b25767934683917e21da65053f00","type":"GO_TERM","name":"type 2 fibroblast growth factor receptor binding","canonical_id":"go:GO:0005111","description":"\"Binding to a type 2 fibroblast growth factor receptor (FGFR2).\" [GOC:fb_curators]","metadata":null},{"id":"be36caa76e90462fb6ae4dbe2ae48f6f","type":"GO_TERM","name":"type 2 galanin receptor binding","canonical_id":"go:GO:0031765","description":"\"Binding to a type 2 galanin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"f3d364e0631a483bb2cc6e5d2ac297c0","type":"GO_TERM","name":"type 2 immune response","canonical_id":"go:GO:0042092","description":"\"An immune response which is associated with resistance to extracellular organisms such as helminths and pathological conditions such as allergy, which is orchestrated by the production of particular cytokines, most notably IL-4, IL-5, IL-10, and IL-13, by any of a variety of cell types including T-helper 2 cells, eosinophils, basophils, mast cells, and nuocytes, resulting in enhanced production of certain antibody isotypes and other effects.\" [GOC:add, ISBN:0781735149, PMID:18000958, PMID:18007680, PMID:20065995, PMID:20200518]","metadata":null},{"id":"bc51e3e2abf54a029d3c1c112ef1166b","type":"GO_TERM","name":"type 2 melanin-concentrating hormone receptor binding","canonical_id":"go:GO:0031778","description":"\"Binding to a type 2 melanin-concentrating hormone receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"20ce49b0e8684495a0aa16d0cbc78c26","type":"GO_TERM","name":"type 2 metabotropic GABA receptor binding","canonical_id":"go:GO:0031797","description":"\"Binding to a type 2 metabotropic GABA receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"1cca56ea7fe14046b8e8e71a0de40ea9","type":"GO_TERM","name":"type 2 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031799","description":"\"Binding to a type 2 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"edf21dc6b9594ffd9a84db2da15a4f49","type":"GO_TERM","name":"type 2 mitophagy","canonical_id":"go:GO:0061734","description":"\"The selective autophagy process in which a mitochondrion is degraded by macroautophagy in a process initiated by mitochondrial depolarization (mtDepo) followed by Parkin binding, and ubiquitination of outer membrane proteins, to remove potentially harm-inducing dysfunctional/damaged mitochondria.\" [GOC:vw, PMID:25009776, PMID:25349190]","metadata":null},{"id":"e93ba6fbf31b45e39cb9291b140df152","type":"GO_TERM","name":"type 2 neuromedin U receptor binding","canonical_id":"go:GO:0031840","description":"\"Binding to a type 2 neuromedin U receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"31abae03b4c64d8fb7ba7dfa9f2dcff5","type":"GO_TERM","name":"type 2 neuropeptide Y receptor binding","canonical_id":"go:GO:0031843","description":"\"Binding to a type 2 neuropeptide Y receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"84e9093092824d698b34d81b05a73a5a","type":"GO_TERM","name":"type 2 orexin receptor binding","canonical_id":"go:GO:0031772","description":"\"Binding to a type 2 orexin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cb74d491e6824cde8c79e838a2da0a09","type":"GO_TERM","name":"type 2 proteinase activated receptor binding","canonical_id":"go:GO:0031873","description":"\"Binding to a type 2 proteinase activated receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"68b6a240496a42b384e3ae03489af129","type":"GO_TERM","name":"type 2 somatostatin receptor binding","canonical_id":"go:GO:0031879","description":"\"Binding to a type 2 somatostatin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"ef44c7a621644ef084bd4ad7b8dab7f6","type":"GO_TERM","name":"type 2 vasoactive intestinal polypeptide receptor binding","canonical_id":"go:GO:0031892","description":"\"Binding to a type 2 vasoactive intestinal polypeptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"98df1abac01a40faa004e943d4ed145b","type":"GO_TERM","name":"type 2A serotonin receptor binding","canonical_id":"go:GO:0031826","description":"\"Binding to a type 2A serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"f2bc97300ecb402d8058cc012789fd54","type":"GO_TERM","name":"type 2B serotonin receptor binding","canonical_id":"go:GO:0031827","description":"\"Binding to a type 2B serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"45c6668bc8ba43d59eb252f0a1d24058","type":"GO_TERM","name":"type 2C serotonin receptor binding","canonical_id":"go:GO:0031828","description":"\"Binding to a type 2C serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"9b03a0be903f4741a41f18997754e409","type":"GO_TERM","name":"type 3 galanin receptor binding","canonical_id":"go:GO:0031766","description":"\"Binding to a type 3 galanin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d83a3d16a7fc4b26b93ebe92c4d732ce","type":"GO_TERM","name":"type 3 melanocortin receptor binding","canonical_id":"go:GO:0031781","description":"\"Binding to a type 3 melanocortin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a1315a604efc47d0b358ff1adc37a6a9","type":"GO_TERM","name":"type 3 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031800","description":"\"Binding to a type 3 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"a2b3a09762e1464ab28fe599461dfad6","type":"GO_TERM","name":"type 3 proteinase activated receptor binding","canonical_id":"go:GO:0031874","description":"\"Binding to a type 3 proteinase activated receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c73e19115edf4a84a5560808ab029385","type":"GO_TERM","name":"type 3 somatostatin receptor binding","canonical_id":"go:GO:0031880","description":"\"Binding to a type 3 somatostatin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"4c55d545d7f94d19acc08224198f53f3","type":"GO_TERM","name":"type 4 melanocortin receptor binding","canonical_id":"go:GO:0031782","description":"\"Binding to a type 4 melanocortin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"53103816ef09421a98f60bbc3e9d9995","type":"GO_TERM","name":"type 4 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031801","description":"\"Binding to a type 4 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c9afcd1208164d54a5b08bdca29bd8ee","type":"GO_TERM","name":"type 4 neuropeptide Y receptor binding","canonical_id":"go:GO:0031844","description":"\"Binding to a type 4 neuropeptide Y receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7934c5af3c054bfa8eaef2d6f154e8ae","type":"GO_TERM","name":"type 4 proteinase activated receptor binding","canonical_id":"go:GO:0031875","description":"\"Binding to a type 4 proteinase activated receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"b8e1f7dcf09244068cc5342409899ce8","type":"GO_TERM","name":"type 4 serotonin receptor binding","canonical_id":"go:GO:0031829","description":"\"Binding to a type 4 serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"cab0135e75914f639677bb815d93f975","type":"GO_TERM","name":"type 4 somatostatin receptor binding","canonical_id":"go:GO:0031881","description":"\"Binding to a type 4 somatostatin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"f243ec7efe914503ba5a96a70804328b","type":"GO_TERM","name":"type 5 melanocortin receptor binding","canonical_id":"go:GO:0031783","description":"\"Binding to a type 5 melanocortin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"2576a40c69f248c6a29ffb363a11f45c","type":"GO_TERM","name":"type 5 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031802","description":"\"Binding to a type 5 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"afbbf4c6c2014ec8a9c63cb6893b08ef","type":"GO_TERM","name":"type 5 neuropeptide Y receptor binding","canonical_id":"go:GO:0031845","description":"\"Binding to a type 5 neuropeptide Y receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"75ead9e3be444855bd007719f68ebb59","type":"GO_TERM","name":"type 5 somatostatin receptor binding","canonical_id":"go:GO:0031882","description":"\"Binding to a type 5 somatostatin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"b579ee16452d419fb26cfd75fca7ceb4","type":"GO_TERM","name":"type 5A serotonin receptor binding","canonical_id":"go:GO:0031830","description":"\"Binding to a type 5A serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"0f50be35f4b047f1b84f5c0a8b4775ff","type":"GO_TERM","name":"type 5B serotonin receptor binding","canonical_id":"go:GO:0031831","description":"\"Binding to a type 5B serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"73ffab07ec8a4bc4aad38b871a2a2613","type":"GO_TERM","name":"type 6 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031803","description":"\"Binding to a type 6 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7b58dff808df4cc7bcd470058fd89b5e","type":"GO_TERM","name":"type 6 serotonin receptor binding","canonical_id":"go:GO:0031832","description":"\"Binding to a type 6 serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"bc42a4f386be43b794e82453e1bd8db3","type":"GO_TERM","name":"type 7 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031804","description":"\"Binding to a type 7 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d0f3d032d7b94e81aed4184addf1ac87","type":"GO_TERM","name":"type 7 serotonin receptor binding","canonical_id":"go:GO:0031833","description":"\"Binding to a type 7 serotonin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"2ab1d62f03bc4c9c9943f38bd31ba3c7","type":"GO_TERM","name":"type 8 metabotropic glutamate receptor binding","canonical_id":"go:GO:0031805","description":"\"Binding to a type 8 metabotropic glutamate receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"794cbb5e76aa4c3a9063eb97ffdc75f9","type":"GO_TERM","name":"type A cholecystokinin receptor binding","canonical_id":"go:GO:0031740","description":"\"Binding to a type A cholecystokinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"7095f4bb7f314572a1c4d88ecf96d590","type":"GO_TERM","name":"type B gastrin/cholecystokinin receptor binding","canonical_id":"go:GO:0031741","description":"\"Binding to a type B gastrin/cholecystokinin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"db44a435206b4045814504f79ae069d5","type":"GO_TERM","name":"type B pancreatic cell apoptotic process","canonical_id":"go:GO:0097050","description":"\"Any apoptotic process in a type B pancreatic cell, a cell located towards center of the islets of Langerhans that secretes insulin.\" [CL:0000169, GOC:BHF, GOC:mtg_apoptosis, PMID:16087305]","metadata":null},{"id":"33a8124f4f7f4065b8858014e707655e","type":"GO_TERM","name":"type B pancreatic cell development","canonical_id":"go:GO:0003323","description":"\"The process whose specific outcome is the progression of a type B pancreatic cell over time, from its formation to the mature structure. A type B pancreatic cell is a cell located towards center of the islets of Langerhans that secretes insulin.\" [CL:0000169, GOC:dph]","metadata":null},{"id":"449e45f6d86c4868a873aa3a85912f71","type":"GO_TERM","name":"type B pancreatic cell differentiation","canonical_id":"go:GO:0003309","description":"\"The process in which relatively unspecialized cells acquire specialized structural and/or functional features of a type B pancreatic cell. A type B pancreatic cell is a cell located towards center of the islets of Langerhans that secretes insulin.\" [CL:0000169, GOC:dph, PMID:11076772]","metadata":null},{"id":"cad511fb56034967999b6a46e8c36587","type":"GO_TERM","name":"type B pancreatic cell fate commitment","canonical_id":"go:GO:0003327","description":"\"The commitment of a cell to a type B pancreatic cell fate and its capacity to differentiate into a type B pancreatic cell. A type B pancreatic cell is a cell located towards center of the islets of Langerhans that secretes insulin.\" [CL:0000169, GOC:dph]","metadata":null},{"id":"598852d490af48b092e233efbb9a7941","type":"GO_TERM","name":"type B pancreatic cell maturation","canonical_id":"go:GO:0072560","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for a type B pancreatic cell to attain its fully functional state. A type B pancreatic cell is a cell located towards center of the islets of Langerhans that secretes insulin.\" [CL:0000169, GOC:BHF]","metadata":null},{"id":"7d194e55434a4523a2360a807b94d848","type":"GO_TERM","name":"type B pancreatic cell proliferation","canonical_id":"go:GO:0044342","description":"\"The multiplication or reproduction of pancreatic B cells, resulting in the expansion of an pancreatic B cell population. Pancreatic B cell are cells of the pancreas that secrete insulin.\" [GOC:jl, GOC:yaf]","metadata":null},{"id":"ebea365d6c1b47dc8d1f8c65bbf7eb09","type":"GO_TERM","name":"type I activin receptor binding","canonical_id":"go:GO:0070698","description":"\"Binding to a type I activin receptor.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"7c80bc7327684d9a9d8fd0b177bdc118","type":"GO_TERM","name":"type I hypersensitivity","canonical_id":"go:GO:0016068","description":"\"An inflammatory response driven by antigen recognition by antibodies bound to Fc receptors on mast cells or basophils, occurring within minutes after exposure of a sensitized individual to the antigen, and leading to the release of a variety of inflammatory mediators such as histamines.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"6e5a2f11a48a495aa49e736b5632e6ab","type":"GO_TERM","name":"type I hypersensitivity mediated by basophils","canonical_id":"go:GO:0002559","description":"\"An inflammatory response driven by antigen recognition by antibodies bound to Fc receptors basophils, occurring within minutes after exposure of a sensitized individual to the antigen, and leading to the release of a variety of inflammatory mediators such as histamines.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"bb566fa291124ca89ca7c4d8688d2047","type":"GO_TERM","name":"type I hypersensitivity mediated by mast cells","canonical_id":"go:GO:0002558","description":"\"An inflammatory response driven by antigen recognition by antibodies bound to Fc receptors on mast cells, occurring within minutes after exposure of a sensitized individual to the antigen, and leading to the release of a variety of inflammatory mediators such as histamines.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"daca1190086e4a6180647ce0bc837943","type":"GO_TERM","name":"type I interferon binding","canonical_id":"go:GO:0019962","description":"\"Binding to a type I interferon. Type I interferons include the interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16681834]","metadata":null},{"id":"1981613d405e4514b177755002279913","type":"GO_TERM","name":"type I interferon production","canonical_id":"go:GO:0032606","description":"\"The appearance of type I interferon due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16681834]","metadata":null},{"id":"39638930359c4c43a4bd988bdc461a89","type":"GO_TERM","name":"type I interferon receptor activity","canonical_id":"go:GO:0004905","description":"\"Combining with a type I interferon and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Type I interferons include the interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, GOC:signaling, ISBN:0126896631, PMID:15546383, PMID:16681834]","metadata":null},{"id":"be5880101dd24a05ae3625d1e942f1a2","type":"GO_TERM","name":"type I interferon receptor binding","canonical_id":"go:GO:0005132","description":"\"Binding to an interferon-type I receptor, a heterodimeric complex composed of an alpha subunit (IFNAR1) and a beta subunit (IFNAR2).\" [GOC:ai, GOC:signaling, PMID:17502368]","metadata":null},{"id":"1bb588ab071f40abb27b649ac4211200","type":"GO_TERM","name":"type I interferon receptor complex","canonical_id":"go:GO:0038197","description":"\"A heterodimeric protein complex that binds a type I interferon and transmits the signal across the membrane into the cell. Consists of an alpha subunit (IFNAR1) and a beta subunit (IFNAR2).\" [GOC:cjm, GOC:signaling, PMID:17502368]","metadata":null},{"id":"c42380bdef0f4924b41a1ee46d37c04a","type":"GO_TERM","name":"type I interferon-mediated signaling pathway","canonical_id":"go:GO:0060337","description":"\"The series of molecular signals initiated by type I interferon binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.\" [GOC:add, GOC:dph, GOC:signaling, PMID:32464097]","metadata":null},{"id":"4f060b33bc5b4b9191fcd1e18d1ae943","type":"GO_TERM","name":"type I oncostatin-M receptor complex","canonical_id":"go:GO:0005900","description":"\"A heterodimeric receptor for the cytokine oncostatin-M (OSM). In humans the receptor complex is made up of the gene products gp130 and OSMR-beta.\" [GOC:jl, PMID:8999038]","metadata":null},{"id":"17932d56b9b64c5da328013aeeb13a6d","type":"GO_TERM","name":"type I pilus","canonical_id":"go:GO:0140621","description":"\"A short filamentous structure on the surface of a bacterial cell distinguished from other pili by their D-mannose-sensitive agglutinatination of erythrocytes. In E. coli, type I pili consist of a short tip fibrillum made up of the adhesin protein (FimH) and two minor subunits (FimG and FimF) that is joined to the pilus rod, a homopolymer of ~1000 FimA subunits.\" [PMID:28496159, PMID:29345620]","metadata":null},{"id":"c33fa3b7d21648569735c1fbab668c4e","type":"GO_TERM","name":"type I pilus assembly","canonical_id":"go:GO:0140623","description":"\"The assembly from its constituent parts of a type I pilus.\" [PMID:1679330]","metadata":null},{"id":"1db8b45bc7ff46a586fd934b5e58b67a","type":"GO_TERM","name":"type I pneumocyte differentiation","canonical_id":"go:GO:0060509","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a type I pneumocyte. A type I pneumocyte is a flattened cell with greatly attenuated cytoplasm and a paucity of organelles.\" [GOC:dph, GOC:mtg_lung, ISBN:0721662544]","metadata":null},{"id":"31bebc91eba6430a8b12f6672f8d4749","type":"GO_TERM","name":"type I protein secretion system complex","canonical_id":"go:GO:0030256","description":"\"A complex of three secretory proteins that carry out secretion in the type I secretion system: an inner membrane transport ATPase (termed ABC protein for ATP-binding cassette), which provides the energy for protein secretion; an outer membrane protein, which is exported via the sec pathway; and a membrane fusion protein, which is anchored in the inner membrane and spans the periplasmic space.\" [PMID:9618447]","metadata":null},{"id":"a57f5a354ebf495cae72e1d46c9f5786","type":"GO_TERM","name":"type I site-specific deoxyribonuclease activity","canonical_id":"go:GO:0009035","description":"\"Catalysis of the endonucleolytic cleavage of DNA to give random double-stranded fragments with terminal 5' or 3' protrusions, driven by ATP hydrolysis. Cleavage is dependent on the presence in the DNA of a specific recognition site. Cleavage may occur hundreds or thousands of base pairs away from the recognition site due to translocation of DNA.\" [PMID:15300241, PMID:15788748]","metadata":null},{"id":"a9bbcbf50efe40c6b9aff6271ae5caf3","type":"GO_TERM","name":"type I site-specific deoxyribonuclease complex","canonical_id":"go:GO:0019812","description":"\"A multisubunit complex composed of two copies of a restriction (R) subunit, two copies of a methylation (M) subunit, and one copy of a specificity (S) subunit. This complex recognizes specific short DNA sequences (through the S subunit), and binds to them. If the recognition site is hemimethylated, the complex acts as a methyltransferase which modifies the recognition site, using S-adenosylmethionine as the methyl donor. Only the M and S subunits are required for this reaction. If the complex binds to an unmethylated recognition site, then the complex translocates the DNA bidirectionally in an ATP-dependent manner. When the translocation is stalled by impact with another complex or unusual DNA structure, the enzyme functions as an endonuclease and cleavage of the DNA will occur, hundreds or thousands of base pairs away from the recognition site. These DNA restriction systems are used by bacteria to defend against phage and other foreign DNA that may enter a cell.\" [PMID:12654995, PMID:15788748]","metadata":null},{"id":"07d31c9e0a964c35a59fb154a0e4c77b","type":"GO_TERM","name":"type I terminal bouton","canonical_id":"go:GO:0061174","description":"\"Terminal inflated portion of the axon of a glutamatergic neuron, containing the specialized apparatus necessary to release neurotransmitters that will induce the contraction of muscle. The axon terminus is considered to be the whole region of thickening and the terminal bouton is a specialized region of it.\" [GOC:dph, GOC:mc]","metadata":null},{"id":"20d1a678dc9c48f38b7f99a22f609fad","type":"GO_TERM","name":"type I transforming growth factor beta receptor binding","canonical_id":"go:GO:0034713","description":"\"Binding to a type I transforming growth factor beta receptor.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"5dd2d2afe1844f41b5da3907861698a6","type":"GO_TERM","name":"type II activin receptor binding","canonical_id":"go:GO:0070699","description":"\"Binding to a type II activin receptor.\" [GOC:BHF, GOC:vk]","metadata":null},{"id":"b6d18a1eb42d4dea9761d005fecd958f","type":"GO_TERM","name":"type II hypersensitivity","canonical_id":"go:GO:0002445","description":"\"An inflammatory response resulting in cell death or dysfunction mediated by activation of the classical complement pathway or induction of effector cell phagocytosis, cytolysis mechanisms via complement or Fc receptors following the binding of antibodies to cell surface antigens on a target cell, or mediated by the direct binding of antibody to cellular receptors.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"c26ba8fdf17c4106acbb40b7e1147125","type":"GO_TERM","name":"type II interferon binding","canonical_id":"go:GO:0019964","description":"\"Binding to type II interferon, also known as interferon-gamma.\" [GOC:add, GOC:ai, ISBN:0126896631, PMID:15546383]","metadata":null},{"id":"5a6e9556a6644b00b5622c775c81b0ab","type":"GO_TERM","name":"type II interferon production","canonical_id":"go:GO:0032609","description":"\"The appearance of interferon-gamma due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Interferon-gamma is also known as type II interferon.\" [GOC:add, GOC:mah, PMID:15546383]","metadata":null},{"id":"a95922af395b49ff91bdee332a9e7da8","type":"GO_TERM","name":"type II interferon receptor activity","canonical_id":"go:GO:0004906","description":"\"Combining with interferon-gamma (a type II interferon) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.\" [GOC:add, GOC:ai, GOC:signaling, ISBN:0126896631, PMID:15546383]","metadata":null},{"id":"eccd3da534044495960fde19fe5355b8","type":"GO_TERM","name":"type II interferon receptor binding","canonical_id":"go:GO:0005133","description":"\"Binding to a type II interferon receptor. Type II interferon is also known as interferon-gamma.\" [GOC:ai]","metadata":null},{"id":"117fd9b7d4ed4175bb1db35f441eac90","type":"GO_TERM","name":"type II interferon-mediated signaling pathway","canonical_id":"go:GO:0060333","description":"\"The series of molecular signals initiated by interferon-gamma binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far.\" [GOC:add, GOC:dph, GOC:signaling, PMID:28901902]","metadata":null},{"id":"91f921cec0f64986b6e0f74aa3e07dc7","type":"GO_TERM","name":"type II oncostatin-M receptor complex","canonical_id":"go:GO:0140370","description":"\"A heterodimeric receptor for the cytokine LIF (leukemia inhibitory factor). In humans the receptor complex is made up of the gene products gp130 and LIFR.\" [PMID:36930708, PMID:39532904, PMID:7738033]","metadata":null},{"id":"809ea371adb042199c4472e80edb0129","type":"GO_TERM","name":"type II pneumocyte differentiation","canonical_id":"go:GO:0060510","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a type II pneumocyte. A type II pneumocyte is a surfactant secreting cell that contains abundant cytoplasm containing numerous lipid-rich multilamellar bodies.\" [GOC:dph, GOC:mtg_lung, ISBN:0721662544]","metadata":null},{"id":"dddfe3d311294dca87505d4c9820773b","type":"GO_TERM","name":"type II polyketide synthase complex","canonical_id":"go:GO:0034082","description":"\"A polyketide synthase complex that consists of several different polypeptide chains, each of which catalyzes a single reaction.\" [GOC:cb, GOC:mah, PMID:12636085]","metadata":null},{"id":"8eddd6c9b42a4700b884ba69fe74b86e","type":"GO_TERM","name":"type II protein secretion system complex","canonical_id":"go:GO:0015627","description":"\"A large protein complex, containing 12-15 subunits, that spans the cell envelope of Gram-negative bacteria and mediates the movement of proteins into the extracellular environment. The complex includes a component in the cytoplasm, an inner membrane subcomplex that reaches into the periplasmic compartment and a secretion pore in the outer membrane. Proteins using the Type II pathway are transported across the cytoplasmic membrane by the Sec or Tat complex.\" [PMID:16448494]","metadata":null},{"id":"0e9973404c27402fa480d552e912652f","type":"GO_TERM","name":"type II site-specific deoxyribonuclease activity","canonical_id":"go:GO:0009036","description":"\"Catalysis of the endonucleolytic cleavage of DNA to give specific double-stranded fragments with terminal 5'-phosphates and 3' hydroxyls. Cleavage is dependent on the presence in the DNA of a specific recognition site; cleavage occurs at or very near this recognition site.\" [EC:3.1.21.4, PMID:12654995]","metadata":null},{"id":"5e5c588a1af74c0b9ede2cb370e48874","type":"GO_TERM","name":"type II site-specific deoxyribonuclease complex","canonical_id":"go:GO:0009359","description":"\"A protein complex that functions as an endonuclease to cleave DNA at or near a specific recognition site, when that site is unmethylated. These complexes may be dimers or tetramers; it is also possible for the endonuclease to be in a complex with the corresponding methyltransferase that methylates the recognition site. DNA restriction systems such as this are used by bacteria to defend against phage and other foreign DNA that may enter a cell.\" [PMID:12654995]","metadata":null},{"id":"e1df3f9de98541fd80849e5ea7c92d2d","type":"GO_TERM","name":"type II terminal bouton","canonical_id":"go:GO:0061175","description":"\"Terminal inflated portion of the axon of a non-glutamatergic neuron, containing the specialized apparatus necessary to release neurotransmitters at a regulatory synapse. The axon terminus is considered to be the whole region of thickening and the terminal bouton is a specialized region of it.\" [GOC:dph, GOC:mc]","metadata":null},{"id":"2008b801f1d44ade8bf040819a33c2ec","type":"GO_TERM","name":"type II transforming growth factor beta receptor binding","canonical_id":"go:GO:0005114","description":"\"Binding to a type II transforming growth factor beta receptor.\" [GOC:ceb, GOC:mah, PMID:11252892]","metadata":null},{"id":"f7bc4d01c2ef4fffade8507b2ed4decf","type":"GO_TERM","name":"type III hypersensitivity","canonical_id":"go:GO:0001802","description":"\"An inflammatory response resulting from recognition of immune complexes via complement or Fc receptors on effector cells leading to activation of neutrophils and other leukocytes and damage to bystander tissue.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"51cad86993714be8a476a7c5ede228f6","type":"DISEASE","name":"type III hypersensitivity disease","canonical_id":"mondo:0007004","description":null,"metadata":null},{"id":"6eb4ecb077774d7d963689021c22e7a4","type":"GO_TERM","name":"type III interferon binding","canonical_id":"go:GO:0034347","description":"\"Binding to a type III interferon. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"30d23ae6a7ea4a8590f489970c0820c7","type":"GO_TERM","name":"type III interferon production","canonical_id":"go:GO:0034343","description":"\"The appearance of type III interferon due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"0297174f0d9a47859723655bc8a507d5","type":"GO_TERM","name":"type III interferon receptor activity","canonical_id":"go:GO:0034348","description":"\"Combining with a type III interferon and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:add, GOC:signaling, ISBN:0126896631, PMID:15546383, PMID:16734557]","metadata":null},{"id":"f4a00c0f5f67430a94fb5dab7c71ee37","type":"GO_TERM","name":"type III interferon-mediated signaling pathway","canonical_id":"go:GO:0038196","description":"\"The series of molecular signals initiated by type III interferon binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Interferon lambda is the only member of the type III interferon found so far.\" [GOC:signaling, PMID:32464097]","metadata":null},{"id":"48a556e64ff54ee3b7a538a4fe29c2d2","type":"GO_TERM","name":"type III intermediate filament","canonical_id":"go:GO:0045098","description":"\"A type of intermediate filament, typically made up of one or more of the proteins vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Unlike the keratins, the type III proteins can form both homo- and heteropolymeric IF filaments.\" [ISBN:0716731363]","metadata":null},{"id":"0a750a2a1ac0420ba6eda96d0ea92e91","type":"GO_TERM","name":"type III polyketide synthase complex","canonical_id":"go:GO:0034083","description":"\"A polyketide synthase complex that consists of two identical ketosynthase polypeptides.\" [GOC:cb, PMID:12636085]","metadata":null},{"id":"837b6e9218a94cd2855167556866185b","type":"GO_TERM","name":"type III protein secretion system complex","canonical_id":"go:GO:0030257","description":"\"A complex of approximately 20 proteins, most of which are located in the cytoplasmic membrane that carries out protein secretion in the bacterial type III secretion system; type III secretion also requires a cytoplasmic, probably membrane-associated ATPase.\" [PMID:9618447]","metadata":null},{"id":"edff12020ae448f498d8f39413794e68","type":"GO_TERM","name":"type III site-specific deoxyribonuclease activity","canonical_id":"go:GO:0015668","description":"\"Catalysis of the endonucleolytic cleavage of DNA to give double-stranded fragments with terminal 5'-phosphates. ATP hydrolysis is required. Cleavage is dependent on the presence of two copies of a specific recognition sequence in an inverse orientation in the DNA. Cleavage occurs at a specific distance from one of the recognition sites.\" [EC:3.1.21.5, PMID:12654995]","metadata":null},{"id":"7072a75e369f4abc98a689853e91f22e","type":"GO_TERM","name":"type III site-specific deoxyribonuclease complex","canonical_id":"go:GO:0019813","description":"\"A heterodimeric enzyme complex composed of two subunits, Res and Mod, that functions as an endonuclease and cleaves DNA. Cleavage will only occur when there are two un-methylated copies of a specific recognition site in an inverse orientation on the DNA. Cleavage occurs at a specific distance away from one of the recognition sites. The Mod subunit can act alone as a methyltansferase. DNA restriction systems such as this are used by bacteria to defend against phage and other foreign DNA that may enter a cell.\" [PMID:12654995]","metadata":null},{"id":"34242b4092be4ab6877e3c98ccdf21a6","type":"GO_TERM","name":"type III terminal bouton","canonical_id":"go:GO:0097467","description":"\"Terminal inflated portion of the axon of a non-glutamatergic neuron, containing the specialized apparatus necessary to release neurotransmitters at a regulatory synapse. The axon terminus is considered to be the whole region of thickening and the terminal bouton is a specialized region of it. Type III terminal boutons are larger than type II ones.\" [GOC:mc, PMID:10218156]","metadata":null},{"id":"71dd59d2050846e2a103dd50cccdddec","type":"GO_TERM","name":"type III transforming growth factor beta receptor binding","canonical_id":"go:GO:0034714","description":"\"Binding to a type III transforming growth factor beta receptor.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"bae9768e7771444491a1e956630f86c8","type":"GO_TERM","name":"type IIa hypersensitivity","canonical_id":"go:GO:0001794","description":"\"An inflammatory response resulting in cell death mediated by activation of the classical complement pathway or induction of effector cell phagocytosis or cytolysis mechanisms via complement or Fc receptors following the binding of antibodies to cell surface antigens on a target cell.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"89cc9e7fe96c49f3adebae49dda463cc","type":"GO_TERM","name":"type IIb hypersensitivity","canonical_id":"go:GO:0001795","description":"\"An inflammatory response resulting in cell death or dysfunction mediated by the direct binding of antibody to cellular receptors.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"a445710de8d54273898a9feeddee605d","type":"GO_TERM","name":"type IV hypersensitivity","canonical_id":"go:GO:0001806","description":"\"An inflammatory response driven by T cell recognition of processed soluble or cell-associated antigens leading to cytokine release and leukocyte activation.\" [GOC:add, ISBN:0781735149]","metadata":null},{"id":"63bbf3e723054445b330ca45dd1a6237","type":"GO_TERM","name":"type IV pilus","canonical_id":"go:GO:0044096","description":"\"A short filamentous structure on the surface of a bacterial cell distinguished from other pili by post-translational N-methylation of the pilin monomers.\" [GOC:pamgo_curators, PMID:28496159]","metadata":null},{"id":"d7bf9358239f43c38950457683d0a896","type":"GO_TERM","name":"type IV pilus assembly","canonical_id":"go:GO:0043683","description":"\"The assembly from its constituent parts of a type IV pilus.\" [GOC:jl, GOC:ml, PMID:31784891]","metadata":null},{"id":"872454fed5dc4dceae93832cae6fd76c","type":"GO_TERM","name":"type IV pilus-dependent motility","canonical_id":"go:GO:0043107","description":"\"Any process involved in the controlled movement of a bacterial cell which is dependent on the presence of type IV pili. Includes social gliding motility and twitching motility.\" [GOC:curators, PMID:12704238]","metadata":null},{"id":"5506521b2965461c8c5f5d57def65b44","type":"GO_TERM","name":"type IV secretion system complex","canonical_id":"go:GO:0043684","description":"\"A complex of proteins related to those involved in bacterial DNA conjugative transfer, that permits the transfer of DNA or proteins into the extracellular milieu or directly into host cells. In general the type IV complex forms a multisubunit cell-envelope-spanning structure composed of a secretion channel and often a pilus or other surface filament or protein(s).\" [GOC:ml]","metadata":null},{"id":"5cd5ac10ae0d4c93a7fc0cbf45ea562b","type":"GO_TERM","name":"type IV site-specific deoxyribonuclease activity","canonical_id":"go:GO:0032067","description":"\"Catalysis of the endonucleolytic cleavage of DNA in a site specific manner. Cleavage is dependent on the presence of a specific recognition site in the DNA which must be modified (e.g. methylated, hydroxymethylated, glucosyl-hydroxymethylated).\" [PMID:12654995]","metadata":null},{"id":"c237a0d892154e7bb2b6772dd2eabe5e","type":"GO_TERM","name":"type IV site-specific deoxyribonuclease complex","canonical_id":"go:GO:0032068","description":"\"A complex consisting of two proteins which acts as an endonuclease in DNA sequences containing a specific modified recognition site. Modifications may include methylation, hydroxymethylation, and glucosyl-hydroxymethylation.\" [PMID:12654995]","metadata":null},{"id":"ab16dcb27c984556a226ace408aa148d","type":"GO_TERM","name":"type Ib terminal bouton","canonical_id":"go:GO:0061176","description":"\"Terminal inflated portion of the axon of a glutamatergic neuron, containing the specialized apparatus necessary for the tonic release neurotransmitters that will induce the contraction of muscle. Type Ib terminal boutons are larger than type Is terminal boutons.\" [GOC:dph, GOC:mc]","metadata":null},{"id":"3ff6a5d59cb24e16bda73ff5ea54031c","type":"GO_TERM","name":"type Is terminal bouton","canonical_id":"go:GO:0061177","description":"\"Terminal inflated portion of the axon of a glutamatergic neuron, containing the specialized apparatus necessary for the phasic release neurotransmitters that will induce the contraction of muscle. Type Is terminal boutons are smaller than type Ib terminal boutons.\" [GOC:dph, GOC:mc]","metadata":null},{"id":"dd15cc9129394f52895b96caae6dd7e6","type":"GO_TERM","name":"type V protein secretion system complex","canonical_id":"go:GO:0098046","description":"\"A complex of proteins that permits the translocation of proteins across the outer membrane via a transmembrane pore, formed by a beta-barrel, into the extracellular milieu or directly into host cells; the secreted proteins contain all the information required for translocation of an effector molecule through the cell envelope. The type V secretion systems includes the autotransporters (type Va), the two-partner secretion system (type Vb) and the Oca family (type Vc).\" [GOC:bf, GOC:bhm, PMID:15119822, PMID:15590781]","metadata":null},{"id":"a0719c3b2fbf49d5a624a9f5a93d9b14","type":"GO_TERM","name":"type VI protein secretion system complex","canonical_id":"go:GO:0033104","description":"\"A complex of proteins that permits the transfer of proteins into the extracellular milieu or directly into host cells via the type VI secretion system. Proteins secreted by this complex do not require an N-terminal signal sequence.\" [GOC:mlg, PMID:16432199, PMID:16763151]","metadata":null},{"id":"1713c637cbdf4da78d63746d4ba33e13","type":"GO_TERM","name":"type-I cohesin domain binding","canonical_id":"go:GO:1990311","description":"\"Binding to a type-I cohesin domain of a protein. Type-I cohesin domain is the binding partner of type-I dockerin domain.\" [GOC:mengo_curators, PMID:23195689, PMID:24080387]","metadata":null},{"id":"29c9ce20143c4849a622ffcb18549d27","type":"GO_TERM","name":"type-I dockerin domain binding","canonical_id":"go:GO:1990308","description":"\"Binding to a type-I dockerin domain of a protein. Type-I dockerin domain is the binding partner of type-1 cohesin domain.\" [GOC:mengo_curators, PMID:23195689, PMID:24080387]","metadata":null},{"id":"5493e84f5cad4ef8aab679e3af45f56d","type":"GO_TERM","name":"type-II cohesin domain binding","canonical_id":"go:GO:1990312","description":"\"Binding to a type-II cohesin domain of a protein. Type-II cohesin domain is the binding partner of type-II dockerin domain.\" [GOC:mengo_curators, PMID:23195689, PMID:24080387]","metadata":null},{"id":"6767a778320941509b729286d381bf6b","type":"GO_TERM","name":"type-II dockerin domain binding","canonical_id":"go:GO:1990309","description":"\"Binding to a type-II dockerin domain of a protein. Type-II dockerin domain is the binding partner of type-II cohesin domain.\" [GOC:mengo_curators, PMID:23195689, PMID:24080387]","metadata":null},{"id":"39e8911a36044627a7a6b4da2205aa01","type":"GO_TERM","name":"type-III cohesin domain binding","canonical_id":"go:GO:1990313","description":"\"Binding to a type-III cohesin domain of a protein. Type-III cohesin domain is the binding partner of type-III dockerin domain.\" [GOC:mengo_curators, PMID:23195689, PMID:24080387]","metadata":null},{"id":"6dc13081256f4c2b99f50d0d1d219647","type":"GO_TERM","name":"type-III dockerin domain binding","canonical_id":"go:GO:1990310","description":"\"Binding to a type-III dockerin domain of a protein. Type-III dockerin domain is the binding partner of type-III cohesin domain.\" [GOC:mengo_curators, PMID:23195689, PMID:24080387]","metadata":null},{"id":"f0aadcb0c83a4b50a5df1262d26a9756","type":"GO_TERM","name":"typhasterol C-23 hydroxylase activity","canonical_id":"go:GO:0102733","description":"\"Catalysis of the reaction: typhasterol + O2 + a reduced electron acceptor = castasterone + H2O + an oxidized electron acceptor.\" [GOC:pz, PMID:17138693]","metadata":null},{"id":"00fdc41a640048829b23e07af8c34997","type":"DISEASE","name":"typhus","canonical_id":"mondo:0001246","description":null,"metadata":null},{"id":"b38e609d6a154c0d95cda6fd05b7169e","type":"GO_TERM","name":"tyramine N-feruloyltransferase activity","canonical_id":"go:GO:0050366","description":"\"Catalysis of the reaction: feruloyl-CoA + tyramine = CoA + N-feruloyltyramine.\" [EC:2.3.1.110, MetaCyc:TYRAMINE-N-FERULOYLTRANSFERASE-RXN]","metadata":null},{"id":"cff60ff260ec4093b5f3c3a69de26100","type":"GO_TERM","name":"tyramine N-methyltransferase activity","canonical_id":"go:GO:0030738","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + tyramine = N-methyltyramine + S-adenosyl-L-homocysteine + H+.\" [RHEA:14865]","metadata":null},{"id":"64c1e16991204b9789934730cd16067c","type":"GO_TERM","name":"tyramine biosynthetic process","canonical_id":"go:GO:1901695","description":"\"The chemical reactions and pathways resulting in the formation of tyramine.\" [GOC:TermGenie, PMID:21284755]","metadata":null},{"id":"e4c7098421b043a6ac070f1546e87f79","type":"GO_TERM","name":"tyramine loading into synaptic vesicle","canonical_id":"go:GO:0160311","description":"\"The active transport of tyramine neurotransmitters into a synaptic vesicle.\" [PMID:15849736, PMID:9870940]","metadata":null},{"id":"4b940af4e5a445f5a92587729093ad43","type":"GO_TERM","name":"tyramine receptor activity","canonical_id":"go:GO:0008226","description":"\"Combining with the biogenic amine tyramine to initiate a change in cell activity. Tyramine is a sympathomimetic amine derived from tyrosine with an action resembling that of epinephrine.\" [GOC:curators]","metadata":null},{"id":"2ba698719df34ce8ab75f2a82a10be05","type":"GO_TERM","name":"tyramine secretion","canonical_id":"go:GO:0061545","description":"\"The regulated release of a tyramine by a cell.\" [GOC:dph]","metadata":null},{"id":"e78148830cc3423b8eb5db5d1349380f","type":"GO_TERM","name":"tyramine secretion, neurotransmission","canonical_id":"go:GO:0061546","description":"\"The regulated release of a tyramine by a cell in which the tyramine acts as a neurotransmitter.\" [GOC:dph]","metadata":null},{"id":"a3233966d0514612a4a9e8ad43228b6e","type":"GO_TERM","name":"tyramine signaling pathway","canonical_id":"go:GO:0071928","description":"\"The series of molecular signals generated as a consequence of tyramine binding to a cell surface receptor.\" [GOC:mah, PMID:15355245]","metadata":null},{"id":"968a6d42696e4d549d980b0756bb6c48","type":"GO_TERM","name":"tyramine-beta hydroxylase activity","canonical_id":"go:GO:0004836","description":"\"Catalysis of the reaction: tyramine + L-ascorbate + O2 = (R)-octopamine + L-dehydroascorbate + H2O.\" [PMID:10745161, RHEA:57132]","metadata":null},{"id":"3db700a8b8324a3bbd104e395434efad","type":"GO_TERM","name":"tyrocidine biosynthetic process","canonical_id":"go:GO:1901904","description":"\"The chemical reactions and pathways resulting in the formation of tyrocidine.\" [GOC:TermGenie, GOC:yaf, PMID:9352938, UniPathway:UPA00180]","metadata":null},{"id":"0342fd17f97f455ead99762be872ef71","type":"GO_TERM","name":"tyrocidine catabolic process","canonical_id":"go:GO:1901903","description":"\"The chemical reactions and pathways resulting in the breakdown of tyrocidine.\" [GOC:TermGenie, GOC:yaf, PMID:9352938]","metadata":null},{"id":"1f8278cbe048403c9ba7827e3a3ffb6a","type":"GO_TERM","name":"tyrosinase activity","canonical_id":"go:GO:0004503","description":"\"Catalysis of the reaction: L-tyrosine + O2 = L-DOPAquinone + H2O. This reaction can use both monophenols (such as tyrosine) and catechols (o-diphenols) as substrates.\" [PMID:4965136, RHEA:18117]","metadata":null},{"id":"c5a201a1600f4404bbca9c302df2234f","type":"GO_TERM","name":"tyrosine 3-monooxygenase activator activity","canonical_id":"go:GO:0036470","description":"\"Binds to and increases the activity of tyrosine 3-monooxygenase (tyrosine hydroxylase).\" [GOC:bf, GOC:PARL, PMID:19703902]","metadata":null},{"id":"67156ca97e494bf593d0d925bfd65c55","type":"GO_TERM","name":"tyrosine 3-monooxygenase activity","canonical_id":"go:GO:0004511","description":"\"Catalysis of the reaction: L-tyrosine + tetrahydrobiopterin + O2 = 3,4-dihydroxy-L-phenylalanine + 4-alpha-hydroxytetrahydrobiopterin + H2O.\" [EC:1.14.16.2]","metadata":null},{"id":"929a8ea7b11b44b5af7379c534a87e8b","type":"GO_TERM","name":"tyrosine N-monooxygenase activity","canonical_id":"go:GO:0050370","description":"\"Catalysis of the reaction: L-tyrosine + 2 reduced [NADPH--hemoprotein reductase] + 2 O2 = (E)-4-hydroxyphenylacetaldehyde oxime + 2 oxidized [NADPH--hemoprotein reductase] + CO2 + 3 H2O + 2 H+.\" [RHEA:32311]","metadata":null},{"id":"37a98783c6bb47cdaf3b1090ec36fa33","type":"GO_TERM","name":"tyrosine ammonia-lyase activity","canonical_id":"go:GO:0052883","description":"\"Catalysis of the reaction: L-tyrosine = NH4 + trans-4-coumarate.\" [RHEA:24906]","metadata":null},{"id":"2b1d6e5dced342be9e657d0d3b026768","type":"GO_TERM","name":"tyrosine decarboxylase activity","canonical_id":"go:GO:0004837","description":"\"Catalysis of the reaction: L-tyrosine = tyramine + CO2.\" [EC:4.1.1.25]","metadata":null},{"id":"d2a1ac58d9c4486490c2cfa05b171256","type":"DISEASE","name":"tyrosine hydroxylase deficiency","canonical_id":"mondo:0100064","description":null,"metadata":null},{"id":"5ac0a737335545f69dc56f74f8fde17e","type":"GO_TERM","name":"tyrosine phenol-lyase activity","canonical_id":"go:GO:0050371","description":"\"Catalysis of the reaction: L-tyrosine + H2O = NH4 + phenol + pyruvate.\" [EC:4.1.99.2, RHEA:21704]","metadata":null},{"id":"538d25c609964a27a69cb3b55d2fbf4c","type":"GO_TERM","name":"tyrosine phosphorylation of STAT protein","canonical_id":"go:GO:0007260","description":"\"The process of introducing a phosphate group to a tyrosine residue of a STAT (Signal Transducer and Activator of Transcription) protein.\" [GOC:jl, PMID:10918594]","metadata":null},{"id":"d24525ecfa8449f0b1c32505772a354d","type":"GO_TERM","name":"tyrosine sensor activity","canonical_id":"go:GO:0120285","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of tyrosine.\" [GOC:krc, PMID:31498992]","metadata":null},{"id":"e7ecf6b51920476ebf9352b5cd31fca8","type":"GO_TERM","name":"tyrosine transport","canonical_id":"go:GO:0015828","description":"\"The directed movement of tyrosine, 2-amino-3-(4-hydroxyphenyl)propanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"da4f8a2a7e5e4f1d97022e255a5f08f9","type":"GO_TERM","name":"tyrosine-arginine ligase activity","canonical_id":"go:GO:0050367","description":"\"Catalysis of the reaction: L-arginine + L-tyrosine + ATP = L-tyrosyl-L-arginine + AMP + diphosphate + 2 H+.\" [EC:6.3.2.24, RHEA:15345]","metadata":null},{"id":"6df0ab2085df4f218981b682e3f4e53f","type":"GO_TERM","name":"tyrosine-based site-specific recombinase activity","canonical_id":"go:GO:0009037","description":"\"Catalysis of the formation of new phosphodiester bonds between a pair of short, unique DNA target sequences; occurs through a phosphotyrosyl intermediate in which the target sequence is first cleaved by the nucleophilic attack by a tyrosine in the active site.\" [GOC:elh, PMID:11090626]","metadata":null},{"id":"a88089a364de4ad2ad9d7f06058131e1","type":"GO_TERM","name":"tyrosine-ester sulfotransferase activity","canonical_id":"go:GO:0017067","description":"\"Catalysis of the reaction: 3'-phospho-5'-adenylyl sulfate + L-tyrosine methyl ester = L-tyrosine methyl ester 4-sulfate + adenosine 3',5'-diphosphate + H+.\" [EC:2.8.2.9, RHEA:19977]","metadata":null},{"id":"c7a1a0b249eb4db2ae317fa3e6031789","type":"GO_TERM","name":"tyrosine-tRNA ligase activity","canonical_id":"go:GO:0004831","description":"\"Catalysis of the reaction: L-tyrosine + ATP + tRNA(Tyr) = L-tyrosyl-tRNA(Tyr) + AMP + diphosphate + 2 H+.\" [EC:6.1.1.1, RHEA:10220]","metadata":null},{"id":"e1126e4ba05941bcabf4ad81a8dc4d4f","type":"GO_TERM","name":"tyrosine:tyramine antiporter activity","canonical_id":"go:GO:0070908","description":"\"Catalysis of the reaction: tyrosine(out) + tyramine(in) = tyrosine(in) + tyramine(out).\" [GOC:dh]","metadata":null},{"id":"49debe86cc354e4e84eb761cb2b1f215","type":"DISEASE","name":"tyrosinemia","canonical_id":"mondo:0004741","description":null,"metadata":null},{"id":"ac095714286a467799d2445d2fcd3c28","type":"DISEASE","name":"tyrosinemia type III","canonical_id":"mondo:0010162","description":null,"metadata":null},{"id":"760e29a1fd884c00969b33763cbf520f","type":"GO_TERM","name":"tyrosyl-DNA phosphodiesterase activity","canonical_id":"go:GO:0070259","description":"\"Catalysis of the hydrolysis of phosphotyrosyl groups formed as covalent intermediates (in DNA backbone breakage) between a DNA topoisomerase and DNA.\" [GOC:elh, PMID:16751265]","metadata":null},{"id":"d147dfaa1e224ace91385eb7f29cb5ef","type":"GO_TERM","name":"tyrosyl-RNA phosphodiesterase activity","canonical_id":"go:GO:0036317","description":"\"Catalysis of the hydrolysis of a 5' tyrosyl-RNA phosphodiester bond between a protein and RNA. In picornaviruses, this covalent bond connects VPg, a viral-encoded protein essential for RNA replication, to the 5' end of all nascent picornavirus genomes; it is cleaved from viral RNA prior to its engaging in protein synthesis.\" [GOC:bf, GOC:sp, PMID:21408223, PMID:22908287]","metadata":null},{"id":"7a6424cb1fb54f22bc872e28f4117dd5","type":"GO_TERM","name":"tyrosyl-tRNA aminoacylation","canonical_id":"go:GO:0006437","description":"\"The process of coupling tyrosine to tyrosyl-tRNA, catalyzed by tyrosyl-tRNA synthetase. The tyrosyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a tyrosine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"787e469b9c554039b5e8d151a0cae749","type":"GO_TERM","name":"ubiquinol:oxygen oxidoreductase activity","canonical_id":"go:GO:0102721","description":"\"Catalysis of the reaction: O2 + 2 an ubiquinol = 2 H2O + 2 an ubiquinone.\" [GOC:pz, RHEA:30255]","metadata":null},{"id":"0cec4da7195447c1b395934b9c11a0a9","type":"GO_TERM","name":"ubiquinone binding","canonical_id":"go:GO:0048039","description":"\"Binding to ubiquinone, a quinone derivative with a tail of isoprene units.\" [GOC:jid, ISBN:0582227089]","metadata":null},{"id":"85c9e47198144e1ea2833b763a41b9fc","type":"GO_TERM","name":"ubiquinone biosynthesis complex","canonical_id":"go:GO:0110142","description":"\"A protein complex composed of enzymes and accessory factors of the ubiquinone (CoQ) biosynthesis pathway. In E. coli, the complex is composed of seven proteins: UbiE, F, G, H, I, J and K. In eukaryotes, the complex is located on the matrix face of the inner mitochondrial membrane and includes COQ3, COQ4, COQ5, COQ6, COQ7, COQ9.\" [GOC:imk, PMID:27060254, PMID:28927698, PMID:30686758]","metadata":null},{"id":"2f19e887ce5143e0ade1bfbc52ab0ab5","type":"GO_TERM","name":"ubiquinone biosynthetic process","canonical_id":"go:GO:0006744","description":"\"The chemical reactions and pathways resulting in the formation of ubiquinone, a lipid-soluble electron-transporting coenzyme.\" [GOC:mah]","metadata":null},{"id":"650f6d3199c840a19784ce7ecb5ca895","type":"GO_TERM","name":"ubiquinone catabolic process","canonical_id":"go:GO:0032322","description":"\"The chemical reactions and pathways resulting in the breakdown of ubiquinone, a lipid-soluble electron-transporting coenzyme.\" [GOC:mah]","metadata":null},{"id":"f6b67090901f451cadc492f7358f7ce5","type":"GO_TERM","name":"ubiquinone metabolic process","canonical_id":"go:GO:0006743","description":"\"The chemical reactions and pathways involving ubiquinone, a lipid-soluble electron-transporting coenzyme.\" [GOC:mah]","metadata":null},{"id":"88756270043847cf992dafb68d8adcc7","type":"GO_TERM","name":"ubiquinone-6 binding","canonical_id":"go:GO:1900995","description":"\"Binding to ubiquinone-6. Ubiquinone-6 is a ubiquinone compound having a (2E,6E,10E,14E,18E)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl substituent at position 2.\" [GOC:al, GOC:TermGenie]","metadata":null},{"id":"406c9afea64a4422ad7e523c4ec1fbd2","type":"GO_TERM","name":"ubiquitin activating enzyme activity","canonical_id":"go:GO:0004839","description":"\"Catalysis of the reaction: E1 + ubiquitin + ATP--> E1-ubiquitin + AMP + PPi, where the E1-ubiquitin linkage is a thioester bond between the C-terminal glycine of Ub and a sulfhydryl side group of an E1 cysteine residue. This is the first step in a cascade of reactions in which ubiquitin is ultimately added to a protein substrate.\" [GOC:BioGRID, Wikipedia:Ubiquitin-activating_enzyme]","metadata":null},{"id":"4de5a0be57d242eaa818df2678597b26","type":"GO_TERM","name":"ubiquitin activating enzyme binding","canonical_id":"go:GO:0033134","description":"\"Binding to a ubiquitin activating enzyme, any of the E1 proteins.\" [GOC:mah]","metadata":null},{"id":"2f3ad820e8434328a6b9bbd34a949e33","type":"GO_TERM","name":"ubiquitin activating enzyme complex","canonical_id":"go:GO:0120123","description":"\"A protein complex responsible for the catalysis of the reaction: E1 + ubiquitin + ATP--> E1-ubiquitin + AMP + PPi, where the E1-ubiquitin linkage is a thioester bond between the C-terminal glycine of Ub and a sulfhydryl side group of an E1 cysteine residue. This is the first step in a cascade of reactions in which ubiquitin is ultimately added to a protein substrate.\" [GOC:lnp, PMID:9545234]","metadata":null},{"id":"5a98aaaefd15405e9256aa7339c974d6","type":"GO_TERM","name":"ubiquitin binding","canonical_id":"go:GO:0043130","description":"\"Binding to ubiquitin, a protein that when covalently bound to other cellular proteins marks them for proteolytic degradation.\" [GOC:ecd]","metadata":null},{"id":"90c2a4304b344e7fa5a0a536a53932e7","type":"GO_TERM","name":"ubiquitin conjugating enzyme activity","canonical_id":"go:GO:0061631","description":"\"Isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y = Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.\" [GOC:BioGRID, GOC:dph]","metadata":null},{"id":"231345f7e5774242becd90ff97817674","type":"GO_TERM","name":"ubiquitin conjugating enzyme binding","canonical_id":"go:GO:0031624","description":"\"Binding to a ubiquitin conjugating enzyme, any of the E2 proteins.\" [GOC:vp]","metadata":null},{"id":"f5980f4022a6439db27aca385e55f5f6","type":"GO_TERM","name":"ubiquitin conjugating enzyme complex","canonical_id":"go:GO:0031371","description":"\"Any complex that possesses ubiquitin conjugating enzyme activity.\" [GOC:mah]","metadata":null},{"id":"db361927de494a1b8d3dd57ba8c1318f","type":"GO_TERM","name":"ubiquitin ligase activator activity","canonical_id":"go:GO:1990757","description":"\"Binds to and increases the activity of a ubiquitin ligase.\" [GOC:dph, PMID:25619242]","metadata":null},{"id":"fd1f5c1443974d9c87fa2da5c8eb1ba2","type":"GO_TERM","name":"ubiquitin ligase complex","canonical_id":"go:GO:0000151","description":"\"A protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity. The complex also contains other proteins that may confer substrate specificity on the complex.\" [GOC:jh2, PMID:9529603]","metadata":null},{"id":"2336c70dc5ee4e729363689ccc951a53","type":"GO_TERM","name":"ubiquitin ligase complex scaffold activity","canonical_id":"go:GO:0160072","description":"\"The binding activity of a molecule that brings together an ubiquitin ligase and an ubiquitin ligase-substrate adaptor, permitting those molecules to function in a coordinated way.\" [PMID:27664236]","metadata":null},{"id":"b1c5702c395b4de498ba5ecf6babcf06","type":"GO_TERM","name":"ubiquitin ligase inhibitor activity","canonical_id":"go:GO:1990948","description":"\"Binds to and stops, prevents or reduces the activity of a ubiquitin ligase.\" [GOC:dph, GOC:vw, PMID:21389117]","metadata":null},{"id":"f93ac833b8784f7db8db4262900ba04a","type":"GO_TERM","name":"ubiquitin protein ligase activity","canonical_id":"go:GO:0061630","description":"\"Catalysis of the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S = X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues.\" [GOC:BioGRID, GOC:dph, GOC:mah, GOC:tb, PMID:22863777]","metadata":null},{"id":"3630e0db104f4314873bd7f11b426566","type":"GO_TERM","name":"ubiquitin protein ligase binding","canonical_id":"go:GO:0031625","description":"\"Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins.\" [GOC:vp]","metadata":null},{"id":"2f5500106258480988da0cd2ed3cce78","type":"GO_TERM","name":"ubiquitin recycling","canonical_id":"go:GO:0010992","description":"\"Any process involved in the maintenance of an internal steady state of ubiquitin monomers and free ubiquitin chains at the level of the cell by recycling ubiquitin from proteasome-bound ubiquitinated intermediates.\" [GOC:BHF, GOC:dph, GOC:tb, PMID:19410548]","metadata":null},{"id":"1f9a0556568e4f9d8aee15d2b17e6c48","type":"GO_TERM","name":"ubiquitin-dependent endocytosis","canonical_id":"go:GO:0070086","description":"\"Endocytosis of a protein that requires the substrate to be modified by ubiquitination. Several plasma membrane proteins, including cell surface permeases and some receptors, are targeted for internalization by endocytosis, and are thereafter delivered to the vacuole or lysosome, where they are degraded.\" [GOC:jp, GOC:mah, PMID:9409540]","metadata":null},{"id":"562b017801f44185b8c9e2ae9ba238aa","type":"GO_TERM","name":"ubiquitin-dependent glycoprotein ERAD pathway","canonical_id":"go:GO:0097466","description":"\"An ERAD pathway whereby endoplasmic reticulum (ER)-resident glycoproteins are targeted for degradation. Includes differential processing of the glycoprotein sugar chains, retrotranslocation to the cytosol and degradation by the ubiquitin-proteasome pathway. A glycoprotein is a compound in which a carbohydrate component is covalently bound to a protein component.\" [GOC:al, GOC:bf, PMID:16079177]","metadata":null},{"id":"a6e19ae897ca4dc9817f3cce4c41d718","type":"GO_TERM","name":"ubiquitin-dependent protein catabolic process","canonical_id":"go:GO:0006511","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the protein.\" [GOC:curators]","metadata":null},{"id":"b8d0d608b1dc434cba6f2a631f716dc3","type":"GO_TERM","name":"ubiquitin-dependent protein catabolic process via the C-end degron rule pathway","canonical_id":"go:GO:0140627","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide covalently tagged with ubiquitin, via the DesCEND (destruction via C-end degron) pathway. In the DesCEND pathway, C-terminal residues (C-end degrons) in substrates are recognized by Cul2-RING and Cul4-RING E3 ligases, whereupon the substrates are linked to ubiquitin and then delivered to the proteasome for degradation. C-end degrons can be present in full-length proteins, truncated proteins or proteolytically cleaved forms.\" [PMID:29775578, PMID:29779948]","metadata":null},{"id":"9132241b1be2417ab6ee28c656bc934e","type":"GO_TERM","name":"ubiquitin-dependent protein catabolic process via the N-end rule pathway","canonical_id":"go:GO:0071596","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide covalently tagged with ubiquitin, via the N-end rule pathway. In the N-end rule pathway, destabilizing N-terminal residues (N-degrons) in substrates are recognized by E3 ligases (N-recognins), whereupon the substrates are linked to ubiquitin and then delivered to the proteasome for degradation.\" [GOC:mah, GOC:rb, PMID:19246002, PMID:9112437]","metadata":null},{"id":"59cfc06df539495d838077900d951cc4","type":"GO_TERM","name":"ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway","canonical_id":"go:GO:0043162","description":"\"The chemical reactions and pathways resulting in the breakdown of a protein or peptide covalently tagged with ubiquitin, via the multivesicular body (MVB) sorting pathway; ubiquitin-tagged proteins are sorted into MVBs, and delivered to a lysosome/vacuole for degradation.\" [GOC:jl, PMID:11511343]","metadata":null},{"id":"a9d6c21945974630873d98923b7cdc3a","type":"GO_TERM","name":"ubiquitin-like ligase-substrate adaptor activity","canonical_id":"go:GO:1990756","description":"\"The binding activity of a molecule that brings together a ubiquitin-like ligase (including ubiquitin ligase and UFM1 ligase) and its substrate. Usually mediated by F-box BTB/POZ domain proteins.\" [PMID:24658274]","metadata":null},{"id":"d0a874052b10436595c6c4e5d467e03c","type":"GO_TERM","name":"ubiquitin-like modifier activating enzyme activity","canonical_id":"go:GO:0008641","description":"\"Catalysis of the activation of small proteins, such as ubiquitin or ubiquitin-like proteins, through the formation of an ATP-dependent high-energy thiolester bond.\" [GOC:jl, GOC:mah]","metadata":null},{"id":"77e2aebfc5074d07a3a4f6b0c1eec31f","type":"GO_TERM","name":"ubiquitin-like protein binding","canonical_id":"go:GO:0032182","description":"\"Binding to a small conjugating protein such as ubiquitin or a ubiquitin-like protein.\" [GOC:mah]","metadata":null},{"id":"cdffdd98b52d4661aad82053089f2653","type":"GO_TERM","name":"ubiquitin-like protein conjugating enzyme activity","canonical_id":"go:GO:0061650","description":"\"Isoenergetic transfer of a ubiquitin-like protein (ULP) from one protein to another molecule, usually another protein, via the reaction X-SCP + Y = Y-SCP + X, where both the X-SCP and Y-SCP linkages are thioester bonds between the C-terminal amino acid of SCP and a sulfhydryl side group of a cysteine residue.\" [GOC:dph]","metadata":null},{"id":"96d5a6a870e04423b012cfc9655bc33c","type":"GO_TERM","name":"ubiquitin-like protein conjugating enzyme binding","canonical_id":"go:GO:0044390","description":"\"Binding to a ubiquitin-like protein conjugating enzyme such as ubiquitin conjugating enzyme.\" [GOC:jl]","metadata":null},{"id":"a7b29f4c27694f3aaa025f7165bfba71","type":"GO_TERM","name":"ubiquitin-like protein ligase activity","canonical_id":"go:GO:0061659","description":"\"Catalysis of the transfer of a ubiquitin-like protein (ULP) to a substrate protein via the reaction X-ULP + S = X + S-ULP, where X is either an E2 or E3 enzyme, the X-ULP linkage is a thioester bond, and the S-ULP linkage is an isopeptide bond between the C-terminal glycine of ULP and the epsilon-amino group of lysine residues in the substrate.\" [GOC:dph]","metadata":null},{"id":"8c18959b04ee4e9399d1d31f1743240f","type":"GO_TERM","name":"ubiquitin-like protein ligase binding","canonical_id":"go:GO:0044389","description":"\"Binding to a ubiquitin-like protein ligase, such as ubiquitin-ligase.\" [GOC:jl]","metadata":null},{"id":"de96e73774ab4d45af4b97536288dad3","type":"GO_TERM","name":"ubiquitin-like protein peptidase activity","canonical_id":"go:GO:0019783","description":"\"An isopeptidase activity that cleaves ubiquitin or ubiquitin-like proteins (ULP; e.g. ATG8, ISG15, NEDD8, SUMO) from target proteins.\" [PMID:19489724]","metadata":null},{"id":"e423e2ae9aeb42b88b68f44294cf67d3","type":"GO_TERM","name":"ubiquitin-like protein reader activity","canonical_id":"go:GO:0140035","description":"\"A molecular adaptor that recognizes and binds a target protein containing a ubiquitin-like modification and that brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.\" [PMID:26060076]","metadata":null},{"id":"2298aaca70b3417eba69122c0f1f59be","type":"GO_TERM","name":"ubiquitin-like protein transferase activity","canonical_id":"go:GO:0019787","description":"\"Catalysis of the transfer of a ubiquitin-like from one protein to another via the reaction X-ULP + Y = Y-ULP + X, where both X-ULP and Y-ULP are covalent linkages. ULP represents a ubiquitin-like protein.\" [GOC:mah, GOC:rn, PMID:10806345, PMID:10884686]","metadata":null},{"id":"a204fdd22c474c39891c5470b36e4351","type":"GO_TERM","name":"ubiquitin-like protein-specific endopeptidase activity","canonical_id":"go:GO:0070137","description":"\"Catalysis of the hydrolysis of peptide bonds between an alpha-carboxyl group and an alpha-amino group within a small protein such as ubiquitin or a ubiquitin-like protein (e.g. APG8, ISG15, NEDD8, SUMO).\" [GOC:mah]","metadata":null},{"id":"348fb91a0b7c42079297321e8c46a122","type":"GO_TERM","name":"ubiquitin-modified histone reader activity","canonical_id":"go:GO:0061649","description":"\"A histone reader that recognizes a histone bearing a ubiquinated lysine residue.\" [PMID:24526689]","metadata":null},{"id":"ccc08e3982df4e449853aa8f11894512","type":"GO_TERM","name":"ubiquitin-modified protein reader activity","canonical_id":"go:GO:0140036","description":"\"A molecular adaptor recognizes and binds a target protein containing a ubiquitination modification and brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.\" [PMID:26060076]","metadata":null},{"id":"41ff8e7982a342deaf0eb9eba58d91d7","type":"GO_TERM","name":"ubiquitin-protein transferase activator activity","canonical_id":"go:GO:0097027","description":"\"Binds to and increases the activity of a ubiquitin-protein transferase.\" [GOC:rb, PMID:18321851]","metadata":null},{"id":"6d6b5069385847cb9ada83b74de09280","type":"GO_TERM","name":"ubiquitin-protein transferase activity","canonical_id":"go:GO:0004842","description":"\"Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y = Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages.\" [GOC:BioGRID, GOC:jh2, PMID:9635407]","metadata":null},{"id":"29f09bc7df6d42eb831c102a1f7949dc","type":"GO_TERM","name":"ubiquitin-protein transferase inhibitor activity","canonical_id":"go:GO:0055105","description":"\"Binds to and stops, prevents or reduces the activity of a ubiquitin-protein transferase.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"73ccd46214784990b54283cf0c2d7982","type":"GO_TERM","name":"ubiquitin-protein transferase regulator activity","canonical_id":"go:GO:0055106","description":"\"Binds to and modulates the activity of a ubiquitin-protein transferase, an enzyme that catalyzes the covalent attachment of ubiquitin to lysine in a substrate protein.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"d27e0478cbb0434689c7ce9478b111fe","type":"GO_TERM","name":"ubiquitin-specific protease binding","canonical_id":"go:GO:1990381","description":"\"Binding to a ubiquitin-specific protease.\" [GOC:bf, GOC:PARL, PMID:24063750]","metadata":null},{"id":"7ffdca1ee73e4f28838f4599bf8090e2","type":"GO_TERM","name":"ubiquitin-ubiquitin ligase activity","canonical_id":"go:GO:0034450","description":"\"Isoenergetic transfer of ubiquitin from one protein to an existing ubiquitin chain via the reaction X-ubiquitin + Y-ubiquitin = Y-ubiquitin-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.\" [GOC:mah, GOC:mcc, PMID:10089879, PMID:17190603]","metadata":null},{"id":"a5e2d7c3d3044f8e9f7be8ea5ca517f7","type":"DRUG","name":"ublituximab","canonical_id":"gtopdb:8920","description":null,"metadata":null},{"id":"cc5c7914b09d4a98bb75c6693bb5d143","type":"DRUG","name":"ublituximab","canonical_id":"chembl:CHEMBL2108354","description":null,"metadata":null},{"id":"cf69f903149e45d898b6f03f1b85912d","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-d85665be170160ac","description":null,"metadata":null},{"id":"7d3903be31824cfbb4495a0f2fa892c0","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-70bc917f20f91d30","description":null,"metadata":null},{"id":"3905532722dc4aa2930f869b439fc627","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-84cc806bf46d8b21","description":null,"metadata":null},{"id":"cfb6366332ed4c6aa6ec5f2e8241f95f","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-a6d2fd1c97f4e3b5","description":null,"metadata":null},{"id":"955093b1bfe94476806b66f0c2defcae","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-24d08f6ec22fc026","description":null,"metadata":null},{"id":"b490eb1117b844f68f59993a77f20712","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-0c73a4b63a829307","description":null,"metadata":null},{"id":"c112a0e0ac204eee9cc7a1a304c0ad88","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-3b4f071075393bf1","description":null,"metadata":null},{"id":"c3710d64f26149f1acc8ab174d571458","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-48d2247a95fa0805","description":null,"metadata":null},{"id":"ea1ea662f18b4232bc09d9721982ffd1","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-30063d82c82eed2e","description":null,"metadata":null},{"id":"b4a8e0ba7ae645f088294275e4e7791b","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-d62a9c3b775f1887","description":null,"metadata":null},{"id":"2d1696921e334bdba98475643692db56","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-6af99b56e5f86883","description":null,"metadata":null},{"id":"4e6886b4b4af4957bc13a3902d1d67d2","type":"COMBINATION_TREATMENT","name":"ublituximab + umbralisib","canonical_id":"ctgov_combo:ctgov-combo-9d45f444f790d9fc","description":null,"metadata":null},{"id":"bab1b9560d7c468c99e1aaa615ededec","type":"DISEASE","name":"ulcer disease","canonical_id":"mondo:0043839","description":null,"metadata":null},{"id":"2f6a3333dfae4a6ab33cfb589df94875","type":"DISEASE","name":"ulcerative colitis","canonical_id":"mondo:0005101","description":null,"metadata":null},{"id":"a83460f7b4dd49a49a2caba19c5650a4","type":"DRUG","name":"ulipristal acetate","canonical_id":"gtopdb:7460","description":null,"metadata":null},{"id":"bbf73d7ee00648e2a86ba4c3884e153b","type":"DRUG","name":"ulipristal acetate","canonical_id":"chembl:CHEMBL260538","description":null,"metadata":null},{"id":"ea49ab531dc44ed6a0523a5d43c66f41","type":"GO_TERM","name":"ultradian rhythm","canonical_id":"go:GO:0007624","description":"\"The specific actions or reactions of an organism that recur with a regularity more frequent than every 24 hours.\" [GOC:jl, PMID:19708721]","metadata":null},{"id":"c982b3a2a42b49e0b2109d83ef1c99d1","type":"GO_TERM","name":"ulvan lyase activity","canonical_id":"go:GO:0052763","description":"\"Catalysis of the cleavage of a carbon-oxygen bond in ulvan, a carbohydrate composed of a repeating structure of [->4)-beta-D-GlcA-(1,4)-alpha-L-Rha 3S-(1->4)-alpha-L-IdoA-(1->4)-alpha-L-Rha 3S-(1-]n. Continued digest of ulvan with an enzyme that can catalyze this reaction results in ulvanobiouronic acid A 3-sulfate [->4)-beta-D-GlcpA-(1->4)-alpha-L-Rhap 3-sulfate-(1-]n with 4-deoxy-L-threo-hex-4-enopyranosiduronic acid at the non-reducing end.\" [GOC:mengo_curators, PMID:9468631]","metadata":null},{"id":"5281320c344645cc8b027d8b14c3c997","type":"GO_TERM","name":"umami taste receptor activity","canonical_id":"go:GO:0033042","description":"\"Combining with soluble umami compounds to initiate a change in cell activity. These receptors are responsible for the sense of umami taste, the savory taste of meats and other foods that are rich in glutamates.\" [GOC:mah]","metadata":null},{"id":"097296aac08a4dd29c3cf12e09db6f18","type":"GO_TERM","name":"umbilical cord development","canonical_id":"go:GO:0061027","description":"\"The process whose specific outcome is the development of the umbilical cord, from its formation to the mature structure. The umbilical cord is an organ or embryonic origin consisting of the 2 umbilical arteries and the one umbilical vein. The umbilical cord connects the cardiovascular system of the fetus to the mother via the placenta.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"6c910fd101f1468fa9b4af7c172da232","type":"GO_TERM","name":"umbilical cord morphogenesis","canonical_id":"go:GO:0036304","description":"\"The process in which the anatomical structures of the umbilical cord are generated and organized. The umbilical cord is an organ or embryonic origin consisting of the 2 umbilical arteries and the one umbilical vein. The umbilical cord connects the cardiovascular system of the fetus to the mother via the placenta.\" [GOC:BHF, GOC:gr, PMID:15107403]","metadata":null},{"id":"2e66a0fbec784b8f90db29d11ccd2f3d","type":"DRUG","name":"umbralisib","canonical_id":"gtopdb:8916","description":null,"metadata":null},{"id":"dd2ab96bdb1743d6824364eb6bb9f9e5","type":"DRUG","name":"umeclidinium","canonical_id":"mesh:C573971","description":null,"metadata":null},{"id":"3eec7d90fb27461ab63270f7db559b3b","type":"GO_TERM","name":"uncoating of virus","canonical_id":"go:GO:0019061","description":"\"The process by which an incoming virus is disassembled in the host cell to release a replication-competent viral genome.\" [GOC:plm, ISBN:0781702534, PMID:8162442]","metadata":null},{"id":"e92e5eee45274283835070c5f4ce3ef0","type":"GO_TERM","name":"unconventional myosin complex","canonical_id":"go:GO:0016461","description":"\"A portmanteau term for myosins other than myosin II.\" [GOC:ma]","metadata":null},{"id":"ef04fd3c8857447093234ff0fd7c4367","type":"GO_TERM","name":"undecan-2-one biosynthetic process","canonical_id":"go:GO:1902791","description":"\"The chemical reactions and pathways resulting in the formation of undecan-2-one.\" [GO_REF:0000068, GOC:mengo_curators, GOC:TermGenie, PMID:4950559]","metadata":null},{"id":"8dff61ec075d462e8ac43d87ba62ea76","type":"GO_TERM","name":"undecaprenol kinase activity","canonical_id":"go:GO:0009038","description":"\"Catalysis of the reaction: ATP + undecaprenol = ADP + undecaprenyl phosphate.\" [GOC:curators]","metadata":null},{"id":"a1c5811f8bf4454387ac10b787809f89","type":"GO_TERM","name":"undecaprenyl-diphosphatase activity","canonical_id":"go:GO:0050380","description":"\"Catalysis of the reaction: di-trans,octa-cis-undecaprenyl diphosphate + H2O = di-trans,octa-cis-undecaprenyl phosphate + H+ + phosphate.\" [PMID:18411271, RHEA:28094]","metadata":null},{"id":"7cfb979bd9914b2892f3d89917b5f88b","type":"GO_TERM","name":"undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase activity","canonical_id":"go:GO:0099621","description":"\"Catalysis of the reaction: UDP-4-deoxy-4-formamido-beta-L-arabinopyranose + ditrans,octacis-undecaprenyl phosphate = UDP + 4-deoxy-4-formamido-alpha-L-arabinopyranosyl ditrans,octacis-undecaprenyl phosphate.\" [GOC:al, GOC:dos, PMID:11706007, PMID:15695810]","metadata":null},{"id":"62228a10f9354502827e21592b2a07fb","type":"GO_TERM","name":"undecaprenyl-phosphate galactose phosphotransferase activity","canonical_id":"go:GO:0047360","description":"\"Catalysis of the reaction: all-trans-undecaprenyl phosphate + UDP-D-galactose = alpha-D-galactosyl-diphosphoundecaprenol + UMP.\" [EC:2.7.8.6, RHEA:11652]","metadata":null},{"id":"6a6ce22b6d5f4806a9e3743fd853eda6","type":"GO_TERM","name":"undecaprenyl-phosphate glucose phosphotransferase activity","canonical_id":"go:GO:0089702","description":"\"Catalysis of the reaction: di-trans,octa-cis-undecaprenyl phosphate + UDP-alpha-D-glucose = alpha-D-glucosyl di-trans,octa-cis-undecaprenyl diphosphate + UMP.\" [RHEA:28126]","metadata":null},{"id":"92716c6fa2b04f72bd4be3ed67e506fd","type":"GO_TERM","name":"undecaprenyl-phosphate mannosyltransferase activity","canonical_id":"go:GO:0047267","description":"\"Catalysis of the reaction: GDP-mannose + undecaprenyl phosphate = GDP + D-mannosyl-1-phosphoundecaprenol.\" [EC:2.4.1.54]","metadata":null},{"id":"127a1c66ee7e429d95c1706134440087","type":"GO_TERM","name":"undecaprenyldiphospho-muramoylpentapeptide beta-N-acetylglucosaminyltransferase activity","canonical_id":"go:GO:0050511","description":"\"Catalysis of the reaction: Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl diphosphate + UDP-N-acetyl-alpha-D-glucosamine = beta-D-GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamm-D-Glu-L-Lys-D-Ala-D-Ala)-di-trans,octa-cis-undecaprenyl diphosphate + H+ + UDP.\" [RHEA:23192]","metadata":null},{"id":"ba7c6d0c932e4de3a86c844aa617db2d","type":"GO_TERM","name":"unencapsulated part of cell","canonical_id":"go:GO:0097653","description":"\"The part of a cell encompassing the intracellular environment and the plasma membrane; it excludes any external encapsulating structures.\" [GOC:curators]","metadata":null},{"id":"5e0abe5562b0447f9d3e822dd2b71267","type":"GO_TERM","name":"unfolded protein holdase activity","canonical_id":"go:GO:0140309","description":"\"A protein carrier activity that binds to a protein in an unfolded state and escorts it to an acceptor molecule or to a specific location. The unfolded protein carrier prevents aggregation of the target protein while its being delivers to its final destination.\" [PMID:39488384]","metadata":null},{"id":"c187c5c2a9ef4aa092accd185aee8824","type":"GO_TERM","name":"unicellular trichome apex","canonical_id":"go:GO:0090552","description":"\"A cell projection part that is the apical most portion of a unicellular trichome.\" [GOC:PO_curators, PO:0025537]","metadata":null},{"id":"f4ec146c415b43448ca0fcac6c6e6c8e","type":"GO_TERM","name":"unicellular trichome branch","canonical_id":"go:GO:0090405","description":"\"A cell projection part that is a branch of a unicellular trichome.\" [GOC:tb, PO:0025537]","metadata":null},{"id":"3d0e49e1767446cf9ad08b7ad0f85623","type":"GO_TERM","name":"unicellular trichome tip","canonical_id":"go:GO:0090553","description":"\"A cell projection part that is the apical most portion of a unicellular trichome apex.\" [GOC:PO_curators]","metadata":null},{"id":"6da984c85f3744c2909a39d2ae0005be","type":"GO_TERM","name":"unidimensional cell growth","canonical_id":"go:GO:0009826","description":"\"The process in which a cell irreversibly increases in size in one [spatial] dimension or along one axis, resulting in the morphogenesis of the cell.\" [ISBN:0943088399]","metadata":null},{"id":"484103ec7ec74d23b69ac7bebc19ab92","type":"GO_TERM","name":"unidirectional conjugation","canonical_id":"go:GO:0009291","description":"\"The process of unidirectional (polarized) transfer of genetic information involving direct cellular contact between a donor and recipient cell; the contact is followed by the formation of a cellular bridge that physically connects the cells. Some or all of the chromosome(s) of the donor cell is transferred into the recipient cell.\" [Wikipedia:Bacterial_conjugation]","metadata":null},{"id":"599489e9919a4d39bd7f91c6c82a67cc","type":"GO_TERM","name":"uniplex complex","canonical_id":"go:GO:1990246","description":"\"A calcium channel complex in the mitochondrial inner membrane capable of highly-selective calcium channel activity. Its components include the EF-hand-containing proteins mitochondrial calcium uptake 1 (MICU1) and MICU2, the pore-forming subunit mitochondrial calcium uniporter (MCU) and its paralog MCUb, and the MCU regulator EMRE.\" [PMID:24231807]","metadata":null},{"id":"0dce8a4a33bb4f43b6de7883fee2ff88","type":"GO_TERM","name":"uniporter activity","canonical_id":"go:GO:0015292","description":"\"Catalysis of the transport of a single molecular species across a membrane; transport is independent of the movement of any other molecular species.\" [GOC:mtg_transport, ISBN:0815340729, PMID:10839820]","metadata":null},{"id":"135956d9e2574f5587acae4377d556bc","type":"GO_TERM","name":"unmethylated CpG binding","canonical_id":"go:GO:0045322","description":"\"Binding to uan nmethylated CpG motif. Unmethylated CpG dinucleotides are often associated with gene promoters.\" [GOC:ai, PMID:10688657]","metadata":null},{"id":"f3fdf0785452422b921171d2e47dba9b","type":"GO_TERM","name":"unmodified histone reader activity","canonical_id":"go:GO:0140063","description":"\"A histone reader that specifically binds either to an unmodified histone.\" [GOC:pg]","metadata":null},{"id":"a24f3a7ba4a74db1a84a677ca47d990b","type":"GO_TERM","name":"unsaturated chondroitin disaccharide hydrolase activity","canonical_id":"go:GO:0102212","description":"\"Catalysis of the reaction: beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc6S + H2O = 5-dehydro-4-deoxy-D-glucuronate + N-acetyl-beta-D-galactosamine 6-sulfate.\" [EC:3.2.1.180, GOC:pz]","metadata":null},{"id":"dcb4b650b5fb4ab08a2ba4dacb8bc420","type":"GO_TERM","name":"unsaturated fatty acid biosynthetic process","canonical_id":"go:GO:0006636","description":"\"The chemical reactions and pathways resulting in the formation of an unsaturated fatty acid, any fatty acid containing one or more double bonds between carbon atoms.\" [GOC:mah, MetaCyc:PWY-762, MetaCyc:PWY-782]","metadata":null},{"id":"122fbf919e3546299eb22a91504d5e5d","type":"GO_TERM","name":"unsaturated fatty acid metabolic process","canonical_id":"go:GO:0033559","description":"\"The chemical reactions and pathways involving an unsaturated fatty acid, any fatty acid containing one or more double bonds between carbon atoms.\" [GOC:mah]","metadata":null},{"id":"f1a36a79c9084b43b194290f37982489","type":"GO_TERM","name":"unsaturated monocarboxylic acid metabolic process","canonical_id":"go:GO:0032789","description":"\"The chemical reactions and pathways involving unsaturated monocarboxylic acids, any organic acid containing one carboxyl (COOH) group or anion (COO-) and one or more unsaturated C-C bonds.\" [GOC:mah, GOC:vk]","metadata":null},{"id":"3eadbcb6df04403e9a078e5c4736d4c7","type":"GO_TERM","name":"unsaturated rhamnogalacturonyl hydrolase activity","canonical_id":"go:GO:0102211","description":"\"Catalysis of the reaction: 2-O-(4-deoxy-beta-L-threo-hex-4-enopyranuronosyl)-alpha-L-rhamnopyranose(1-) + H2O = (4S,5S)-4,5-dihydroxy-2,6-dioxohexanoate + alpha-L-rhamnopyranose.\" [EC:3.2.1.172, GOC:pz]","metadata":null},{"id":"9bbc9e8ff52045e4af5b93b9f6ee17f2","type":"DRUG","name":"upadacitinib","canonical_id":"gtopdb:9246","description":null,"metadata":null},{"id":"680f4d7e6cb4469d96297870ea61a3d7","type":"COMBINATION_TREATMENT","name":"upadacitinib + ustekinumab","canonical_id":"ctgov_combo:ctgov-combo-bc0081752b8386fe","description":null,"metadata":null},{"id":"63e476dffb914c9dbd350361170a1a1d","type":"COMBINATION_TREATMENT","name":"upadacitinib + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-d0fea98566f10351","description":null,"metadata":null},{"id":"6ced39ce2080465c9b9caef3effa6859","type":"COMBINATION_TREATMENT","name":"upadacitinib + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-a0fb139fd785245e","description":null,"metadata":null},{"id":"d9f175c70e374479a9a2dd27b791ffcb","type":"COMBINATION_TREATMENT","name":"upadacitinib + vedolizumab","canonical_id":"ctgov_combo:ctgov-combo-f19fcb6947bfe51f","description":null,"metadata":null},{"id":"0dd2ad50267d45e680b11ae801e8ec70","type":"GO_TERM","name":"upper tip-link density","canonical_id":"go:GO:1990435","description":"\"An electron-dense plaque at the upper end of a stereocilia tip link that provides the anchor in the stereocilia membrane on the side of the stereocilium where the tip link ends.\" [PMID:19447093]","metadata":null},{"id":"be528a655acf448ebf5f556f88964dd5","type":"GO_TERM","name":"upstream stimulatory factor complex","canonical_id":"go:GO:1990378","description":"\"A protein complex capable of sequence-specific DNA binding RNA polymerase II transcription factor activity through binding to a symmetrical DNA sequence (E-boxes) (5'-CACGTG-3'). Found in a variety of viral and cellular promoters.\" [GOC:bhm, PMID:8576131]","metadata":null},{"id":"969e50c37cb74f6a8fc12683eb80ba02","type":"GO_TERM","name":"uracil DNA N-glycosylase activity","canonical_id":"go:GO:0004844","description":"\"Catalysis of the cleavage of the N-C1' glycosidic bond between the damaged DNA base and the deoxyribose sugar, releasing a free base and leaving an apyrimidinic (AP) site. Enzymes with this activity recognize and remove uracil bases in DNA that result from the deamination of cytosine or the misincorporation of dUTP opposite an adenine.\" [GOC:elh, GOC:pr, PMID:9224623]","metadata":null},{"id":"2a5644f928bb42d786cee013edcc953b","type":"GO_TERM","name":"uracil binding","canonical_id":"go:GO:0002058","description":"\"Binding to uracil.\" [GOC:hjd]","metadata":null},{"id":"d37f3e34222049809fbb7c398a633740","type":"GO_TERM","name":"uracil biosynthetic process","canonical_id":"go:GO:0046107","description":"\"The chemical reactions and pathways resulting in the formation of uracil, 2,4-dioxopyrimidine, one of the pyrimidine bases occurring in RNA, but not in DNA.\" [GOC:curators]","metadata":null},{"id":"2b456edbaa7743bd821779d77afdcd17","type":"GO_TERM","name":"uracil catabolic process","canonical_id":"go:GO:0006212","description":"\"The chemical reactions and pathways resulting in the breakdown of uracil, 2,4-dioxopyrimidine, one of the pyrimidine bases occurring in RNA, but not in DNA.\" [GOC:curators]","metadata":null},{"id":"0f70ef6b2f334a0a9db5af382188b565","type":"GO_TERM","name":"uracil dehydrogenase activity","canonical_id":"go:GO:0050383","description":"\"Catalysis of the reaction: uracil + acceptor = barbiturate + reduced acceptor.\" [RHEA:22752]","metadata":null},{"id":"c068ddd2409e416e806f081db327819e","type":"GO_TERM","name":"uracil import across plasma membrane","canonical_id":"go:GO:0098721","description":"\"The directed movement of uracil from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:dos]","metadata":null},{"id":"bc6133d92ae24ebd9f08090ac3339953","type":"GO_TERM","name":"uracil metabolic process","canonical_id":"go:GO:0019860","description":"\"The chemical reactions and pathways involving uracil, 2,4-dioxopyrimidine, one of the pyrimidine bases occurring in RNA, but not in DNA.\" [GOC:curators]","metadata":null},{"id":"90fe7097aa0043e6b53c43ecb857717c","type":"DRUG","name":"uracil mustard","canonical_id":"mesh:D014499","description":null,"metadata":null},{"id":"a2de1f007fc545cf9dd95ef01a4edf5d","type":"GO_TERM","name":"uracil oxygenase activity","canonical_id":"go:GO:0052614","description":"\"Catalysis of the reaction: FMNH2 + NADH + O2 + uracil = (Z)-3-ureidoacrylate + FMN + H+ + H2O + NAD+. Can also use thymine as a substrate.\" [PMID:20369853, PMID:20400551, RHEA:31587]","metadata":null},{"id":"bf60952b8f7043a190130dda89d6bbf3","type":"GO_TERM","name":"uracil phosphoribosyltransferase activity","canonical_id":"go:GO:0004845","description":"\"Catalysis of the reaction: diphosphate + UMP = 5-phospho-alpha-D-ribose 1-diphosphate + uracil.\" [EC:2.4.2.9, RHEA:13017]","metadata":null},{"id":"c9c809296bf94b2fb952952c8065d5ee","type":"GO_TERM","name":"uracil salvage","canonical_id":"go:GO:0006223","description":"\"Any process that generates uracil, 2,4-dioxopyrimidine, from derivatives of it without de novo synthesis.\" [GOC:jl]","metadata":null},{"id":"b0596d4615cd494481bf1968f3fc4f1d","type":"GO_TERM","name":"uracil transmembrane transport","canonical_id":"go:GO:1903791","description":"\"The process in which uracil is transported across a membrane.\" [GO_REF:0000069, GOC:TermGenie, PMID:8948441]","metadata":null},{"id":"f3821f58a2644e43b65f725a7dd0377a","type":"GO_TERM","name":"uracil transmembrane transporter activity","canonical_id":"go:GO:0015210","description":"\"Enables the transfer of uracil, 2,4-dioxopyrimidine, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"b122bab10a6b43629640b85a50757617","type":"GO_TERM","name":"uracil transport","canonical_id":"go:GO:0015857","description":"\"The directed movement of uracil, 2,4-dioxopyrimidine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"def9c2d024384f978f2155e9bd71e5a3","type":"GO_TERM","name":"uracil-5-carboxylate decarboxylase activity","canonical_id":"go:GO:0050382","description":"\"Catalysis of the reaction: H+ + uracil 5-carboxylate = CO2 + uracil.\" [EC:4.1.1.66, RHEA:17685]","metadata":null},{"id":"ac0e7f8b7bb24876a95ea15bd26798f2","type":"GO_TERM","name":"uracil:monoatomic cation symporter activity","canonical_id":"go:GO:0015505","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: uracil(out) + cation(out) = uracil(in) + cation(in).\" [GOC:mtg_transport]","metadata":null},{"id":"ceb6d7f774b84e35b298c18495f7adf6","type":"GO_TERM","name":"uracilylalanine synthase activity","canonical_id":"go:GO:0050471","description":"\"Catalysis of the reaction: O3-acetyl-L-serine + uracil = 3-(uracil-1-yl)-L-alanine + acetate.\" [RHEA:11496]","metadata":null},{"id":"a332e19d22654dfc95c2051041e53473","type":"GO_TERM","name":"urate biosynthetic process","canonical_id":"go:GO:0034418","description":"\"The chemical reactions and pathways resulting in the formation of urate, the anion of uric acid, 2,6,8-trioxypurine.\" [GOC:mah]","metadata":null},{"id":"e71275cbb35a4d5fb782361c1ba8a9a6","type":"GO_TERM","name":"urate catabolic process","canonical_id":"go:GO:0019628","description":"\"The chemical reactions and pathways resulting in the breakdown of urate, the anion of uric acid, 2,6,8-trioxypurine.\" [ISBN:0198506732]","metadata":null},{"id":"11925a2c8ce04f3abf3c1107a00e2a89","type":"GO_TERM","name":"urate metabolic process","canonical_id":"go:GO:0046415","description":"\"The chemical reactions and pathways involving urate, the anion of uric acid, 2,6,8-trioxypurine, the end product of purine metabolism in certain mammals and the main excretory product in uricotelic animals.\" [ISBN:0198506732]","metadata":null},{"id":"347890fa4061480da51497d05461e492","type":"GO_TERM","name":"urate oxidase activity","canonical_id":"go:GO:0004846","description":"\"Catalysis of the reaction: urate + O2 + H2O = 5-hydroxyisourate + H2O2.\" [EC:1.7.3.3]","metadata":null},{"id":"9a24de5cfbb347dd9071be7d39efba05","type":"GO_TERM","name":"urate transmembrane transporter activity","canonical_id":"go:GO:0015143","description":"\"Enables the transfer of urate from one side of a membrane to the other. Urate is the anion of uric acid, 2,6,8-trioxypurine, the end product of purine metabolism in certain mammals and the main excretory product in uricotelic animals.\" [GOC:ai]","metadata":null},{"id":"9f4a0f4dc7a94b9b83c616f38cbd5fb9","type":"GO_TERM","name":"urate transport","canonical_id":"go:GO:0015747","description":"\"The directed movement of urate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:krc]","metadata":null},{"id":"9fad704516f043788e63f916a1f0b7e5","type":"GO_TERM","name":"urate-ribonucleotide phosphorylase activity","canonical_id":"go:GO:0050384","description":"\"Catalysis of the reaction: 3-(beta-D-ribofuranosyl)uric acid + phosphate = alpha-D-ribose 1-phosphate + H+ + urate.\" [EC:2.4.2.16, RHEA:13909]","metadata":null},{"id":"651e50df6a304dfa8fedf91c80ead7af","type":"GO_TERM","name":"urate:monoatomic anion antiporter activity","canonical_id":"go:GO:0140813","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: urate(out) + anion (in) = urate (in) + anion (out).\" [PMID:12024214, PMID:18411268]","metadata":null},{"id":"384548b62c6043609c9d940afe25df68","type":"GO_TERM","name":"urea binding","canonical_id":"go:GO:0033219","description":"\"Binding to urea, a water-soluble carboxamide with the structure H2N-CO-NH2.\" [GOC:mah, ISBN:0198506732]","metadata":null},{"id":"6de0f18949a1415fba1ca16491c8fdf7","type":"GO_TERM","name":"urea carboxylase activity","canonical_id":"go:GO:0004847","description":"\"Catalysis of the reaction: ATP + bicarbonate + urea = ADP + 2 H+ + phosphate + urea-1-carboxylate.\" [EC:6.3.4.6, RHEA:20896]","metadata":null},{"id":"148b0f808d9d4e85a23a1572ce306158","type":"GO_TERM","name":"urea catabolic process","canonical_id":"go:GO:0043419","description":"\"The chemical reactions and pathways resulting in the breakdown of urea, the water soluble compound O=C-(NH2)2.\" [GOC:jl]","metadata":null},{"id":"f9e512893ca94588866d4715fe6a44e8","type":"GO_TERM","name":"urea channel activity","canonical_id":"go:GO:0015265","description":"\"Enables the energy-independent facilitated diffusion of urea through a transmembrane aqueous pore or channel.\" [GOC:mtg_transport]","metadata":null},{"id":"70793f82390649e0a2f309c06388de68","type":"GO_TERM","name":"urea cycle","canonical_id":"go:GO:0000050","description":"\"The sequence of reactions by which arginine is synthesized from ornithine, then cleaved to yield urea and regenerate ornithine. The overall reaction equation is NH3 + CO2 + aspartate + 3 ATP + 2 H2O = urea + fumarate + 2 ADP + 2 phosphate + AMP + diphosphate.\" [GOC:pde, GOC:vw, ISBN:0198506732]","metadata":null},{"id":"ae276ec190154e71a284dfedc67340c2","type":"GO_TERM","name":"urea import across plasma membrane","canonical_id":"go:GO:0140201","description":"\"The directed movement of urea from outside of a cell, across the plasma membrane and into the cytosol.\" [PMID:17218313]","metadata":null},{"id":"bbb4b1c442e24509a7eae7bb4eeccca0","type":"GO_TERM","name":"urea metabolic process","canonical_id":"go:GO:0019627","description":"\"The chemical reactions and pathways involving urea, the water soluble compound O=C-(NH2)2.\" [ISBN:0198506732]","metadata":null},{"id":"db398ffb615b40228ef95af7833ba133","type":"GO_TERM","name":"urea transmembrane transport","canonical_id":"go:GO:0071918","description":"\"The process in which urea, the water-soluble compound H2N-CO-NH2, is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"e32ab4abc9db4f5cb01d8214b46630c2","type":"GO_TERM","name":"urea transmembrane transporter activity","canonical_id":"go:GO:0015204","description":"\"Enables the transfer of urea from one side of a membrane to the other. Urea is the water soluble compound H2N-CO-NH2.\" [ISBN:0198506732]","metadata":null},{"id":"8bd607cc64174a9f81c5fa35fe123037","type":"GO_TERM","name":"urea transport","canonical_id":"go:GO:0015840","description":"\"The directed movement of urea into, out of or within the cell. Urea is the water-soluble compound H2N-CO-NH2.\" [GOC:ai, ISBN:0198506732]","metadata":null},{"id":"0877b2b109e24252a37eaf1f0286d33f","type":"GO_TERM","name":"urea:sodium symporter activity","canonical_id":"go:GO:0015401","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: urea(out) + Na+(out) = urea(in) + Na+(in).\" [TC:2.A.21.6.1]","metadata":null},{"id":"916ec678c5294673837ccee55f83ff39","type":"GO_TERM","name":"urease activator activity","canonical_id":"go:GO:0018237","description":"\"Increases the activity of urease by promoting the incorporation of nickel into the active site.\" [GOC:mah, PMID:16244137]","metadata":null},{"id":"b37b852780aa46e9bdc4452e6aabd691","type":"GO_TERM","name":"urease activator complex","canonical_id":"go:GO:0150006","description":"\"A protein complex required for the activation of urease. Activator subunits dissociate before urease has catalytic function.\" [GOC:bhm, PMID:16244137, PMID:28710280]","metadata":null},{"id":"476c649534aa460ca4df0fd1b77c1178","type":"GO_TERM","name":"urease activity","canonical_id":"go:GO:0009039","description":"\"Catalysis of the reaction: urea + 2 H2O + H+ = hydrogencarbonate + 2 NH4+.\" [RHEA:20557]","metadata":null},{"id":"5cd24d85f4f34b14b29dca9fbb41d4dd","type":"GO_TERM","name":"urease complex","canonical_id":"go:GO:0035550","description":"\"A multiprotein nickel-containing complex that possesses urease activity (catalysis of the hydrolysis of urea to ammonia and carbon dioxide).\" [InterPro:IPR008221, PMID:2651866]","metadata":null},{"id":"e7227da7618f48abae841b4cdbf8b219","type":"GO_TERM","name":"uredinium development","canonical_id":"go:GO:0075279","description":"\"The process that leads to the formation of a uredinium, a reddish, pustule-like structure formed by a rust fungus and consisting of uredospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"9d159ea9c88d43f4875caaf0230f9dd4","type":"GO_TERM","name":"uredospore formation","canonical_id":"go:GO:0075251","description":"\"The process which specific outcome is the formation of an asexual, dikaryotic, often rusty-colored spore, produced in a structure called a uredinium; mostly found in the rust fungus.\" [GOC:pamgo_curators]","metadata":null},{"id":"ee19efe3c53a47e58e169e5a73f7f636","type":"GO_TERM","name":"ureide biosynthetic process","canonical_id":"go:GO:0010137","description":"\"The chemical reactions and pathways resulting in the formation of ureide, the organic form of nitrogen in nitrogen fixing and transporting plants, from IMP, which is synthesized de novo during nitrogen fixation by roots.\" [GOC:pz]","metadata":null},{"id":"ef0c0fa963944eadbe9a9b206305bdb9","type":"GO_TERM","name":"ureide catabolic process","canonical_id":"go:GO:0010136","description":"\"The chemical reactions and pathways resulting in the breakdown of ureide, which is the organic form of nitrogen in nitrogen fixing and transporting plants with the release of ammonium.\" [GOC:pz]","metadata":null},{"id":"2ebaee99a22a4dd59aa203a16ac6c4bc","type":"GO_TERM","name":"ureidoglycine aminohydrolase activity","canonical_id":"go:GO:0071522","description":"\"Catalysis of the reaction: (S)-2-ureidoglycine + H2O = (S)-ureidoglycolate + NH4+.\" [PMID:19935661, PMID:20038185, RHEA:25241]","metadata":null},{"id":"6509183be4b54afb877410e022613186","type":"GO_TERM","name":"ureidoglycolate dehydrogenase activity","canonical_id":"go:GO:0009040","description":"\"Catalysis of the reaction: (S)-ureidoglycolate + NAD(P)+ = oxalureate + NAD(P)H + H+.\" [EC:1.1.1.154, PMID:23284870]","metadata":null},{"id":"060bd176929a4b28a066339e40ba4137","type":"GO_TERM","name":"ureidoglycolate hydrolase activity","canonical_id":"go:GO:0004848","description":"\"Catalysis of the reaction: (S)-ureidoglycolate + H2O + 2 H+ = CO2 + glyoxylate + 2 NH4.\" [RHEA:19809]","metadata":null},{"id":"f3f46e00f1764318a3a0f12fc17727d9","type":"GO_TERM","name":"ureidoglycolate lyase activity","canonical_id":"go:GO:0050385","description":"\"Catalysis of the reaction: (S)-ureidoglycolate = glyoxylate + urea.\" [EC:4.3.2.3, RHEA:11304]","metadata":null},{"id":"ce4955dd3ec6431291d0991aa01f233a","type":"GO_TERM","name":"ureidosuccinase activity","canonical_id":"go:GO:0050386","description":"\"Catalysis of the reaction: N-carbamoyl-L-aspartate + H2O + 2 H+ = L-aspartate + CO2 + NH4.\" [EC:3.5.1.7, RHEA:14365]","metadata":null},{"id":"059744b5409d4778a9bf99183eff7140","type":"GO_TERM","name":"ureter development","canonical_id":"go:GO:0072189","description":"\"The process whose specific outcome is the progression of the ureter over time, from its formation to the mature structure. The ureter is a muscular tube that transports urine from the kidney to the urinary bladder or from the Malpighian tubule to the hindgut.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"e946f0246f0f4710be6986d179e4e3c2","type":"GO_TERM","name":"ureter epithelial cell differentiation","canonical_id":"go:GO:0072192","description":"\"The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell in the urothelium. The urothelium is the epithelial tube of the ureter.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"3bd47f3601ab4928b9c05938500c8ccd","type":"GO_TERM","name":"ureter maturation","canonical_id":"go:GO:0035799","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the ureter to attain its fully functional state. The ureter is a muscular tube that transports urine from the kidney to the urinary bladder or from the Malpighian tubule to the hindgut.\" [GOC:bf, GOC:mtg_kidney_jan10, GOC:yaf, PMID:17881463]","metadata":null},{"id":"ec2765e6ebb0468ea71a26a01843fd19","type":"GO_TERM","name":"ureter morphogenesis","canonical_id":"go:GO:0072197","description":"\"The process in which the anatomical structures of the ureter are generated and organized. The ureter is a muscular tube that transports urine from the kidney to the urinary bladder.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b7c73bb50fa54c7d937579ba35112b3d","type":"GO_TERM","name":"ureter part of ureteric bud development","canonical_id":"go:GO:0035503","description":"\"The development of the portion of the ureteric bud that contributes to the morphogenesis of the ureter. The ureter ureteric bud is the initial structure that forms the ureter.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"0aa8342f6d2a4376862e028c296eedab","type":"GO_TERM","name":"ureter smooth muscle cell differentiation","canonical_id":"go:GO:0072193","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell in the ureter.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"bda36190194649fea50a02cbe5f6712f","type":"GO_TERM","name":"ureter smooth muscle contraction","canonical_id":"go:GO:0014849","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the ureter. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The ureter is one of a pair of thick-walled tubes that transports urine from the kidney pelvis to the urinary bladder.\" [GOC:mtg_muscle, MA:0000378]","metadata":null},{"id":"afba6ca28da446329f983a89a2e36777","type":"GO_TERM","name":"ureter smooth muscle development","canonical_id":"go:GO:0072191","description":"\"The process whose specific outcome is the progression of smooth muscle in the ureter over time, from its formation to the mature structure.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"5fbf5ff8d5934e5191203888dbebb9b5","type":"GO_TERM","name":"ureter urothelium development","canonical_id":"go:GO:0072190","description":"\"The process whose specific outcome is the progression of the urothelium of the ureter over time, from its formation to the mature structure. The urothelium is an epithelium that makes up the epithelial tube of the ureter.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"b45cc84b1de2449fa67b14bc37ffb899","type":"GO_TERM","name":"ureteric bud development","canonical_id":"go:GO:0001657","description":"\"The process whose specific outcome is the progression of the ureteric bud over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"fa3ab3fba58a46ba8102304a160b19c7","type":"GO_TERM","name":"ureteric bud elongation","canonical_id":"go:GO:0060677","description":"\"The developmental growth in which the ureteric bud grows along its axis beginning with the growth of the primary ureteric bud and ending when the branches of the bud have elongated.\" [GOC:dph, PMID:16916378]","metadata":null},{"id":"64a6548407bd424e8cdd3ecef7baad01","type":"GO_TERM","name":"ureteric bud formation","canonical_id":"go:GO:0060676","description":"\"The developmental process pertaining to the initial formation of the ureteric bud from the Wolffian duct. This process begins when the bud protrudes from the duct and ends when it is a recognizable bud.\" [GOC:dph, PMID:16916378]","metadata":null},{"id":"ebfec0760aa348adba50bef85758e599","type":"GO_TERM","name":"ureteric bud invasion","canonical_id":"go:GO:0072092","description":"\"The process in which the ureteric bud grows along its axis and contributes to the formation of the metanephros.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"18a7fca3c04e4b629c489e95a211bf0b","type":"GO_TERM","name":"ureteric bud morphogenesis","canonical_id":"go:GO:0060675","description":"\"The process in which the ureteric bud is generated and organized.\" [GOC:dph, GOC:mtg_kidney_jan10]","metadata":null},{"id":"c1c4bfc6c08e41cb96e4d4f2a6be7b32","type":"GO_TERM","name":"ureteric peristalsis","canonical_id":"go:GO:0072105","description":"\"A wavelike sequence of involuntary muscular contraction and relaxation that passes along the ureter, impelling the contents onwards. The ureter is one of a pair of thick-walled tubes that transports urine from the kidney pelvis to the urinary bladder.\" [GOC:mtg_kidney_jan10]","metadata":null},{"id":"772c0072cbfc4ffd98fade3ff62bc812","type":"DISEASE","name":"ureterolithiasis","canonical_id":"mondo:0007009","description":null,"metadata":null},{"id":"a8cde71181694ee4b2650a57ad832214","type":"GO_TERM","name":"urethanase activity","canonical_id":"go:GO:0050387","description":"\"Catalysis of the reaction: H2O + H+ + urethane = CO2 + ethanol + NH4.\" [EC:3.5.1.75, RHEA:21372]","metadata":null},{"id":"b5a4a987067f4d14b8f8b72855723648","type":"GO_TERM","name":"urethra development","canonical_id":"go:GO:0061068","description":"\"The progression of the urethra over time from its initial formation to the mature structure. The urethra is a renal system organ that carries urine from the bladder to outside the body.\" [GOC:dph]","metadata":null},{"id":"0dd5c337ab114e75ba9e03e3b793f2ab","type":"GO_TERM","name":"urethra epithelium development","canonical_id":"go:GO:0061071","description":"\"The progression of the urethra epithelium over time from its initial formation to the mature structure. The urethra is a renal system organ that carries urine from the bladder to outside the body. The epithelium is the tubular, planar layer of cells through which the urine passes.\" [GOC:dph]","metadata":null},{"id":"5d838bbfda094088aae7d19e7d702864","type":"DISEASE","name":"urethritis","canonical_id":"mondo:0005297","description":null,"metadata":null},{"id":"0441fb0a5d244dc3ad4f19a6843928e6","type":"DISEASE","name":"urgency urinary incontinence","canonical_id":"efo:0006865","description":null,"metadata":null},{"id":"7968c762ff494002b2905c0cb690059a","type":"GO_TERM","name":"uridine biosynthetic process","canonical_id":"go:GO:0046109","description":"\"The chemical reactions and pathways resulting in the formation of uridine, uracil riboside, a ribonucleoside very widely distributed but occurring almost entirely as phosphoric esters in ribonucleotides and ribonucleic acids.\" [GOC:curators]","metadata":null},{"id":"4ff9c2f4cd68423185d1d181bfe05f72","type":"GO_TERM","name":"uridine catabolic process","canonical_id":"go:GO:0006218","description":"\"The chemical reactions and pathways resulting in the breakdown of uridine, uracil riboside, a ribonucleoside very widely distributed but occurring almost entirely as phosphoric esters in ribonucleotides and ribonucleic acids.\" [GOC:curators]","metadata":null},{"id":"b06fdb2529cb46849f5355dfcbf141fe","type":"GO_TERM","name":"uridine kinase activity","canonical_id":"go:GO:0004849","description":"\"Catalysis of the reaction: ATP + uridine = ADP + UMP.\" [RHEA:16825]","metadata":null},{"id":"c23c933f2d61489eb66ccdc9e7edec94","type":"GO_TERM","name":"uridine metabolic process","canonical_id":"go:GO:0046108","description":"\"The chemical reactions and pathways involving uridine, uracil riboside, a ribonucleoside very widely distributed but occurring almost entirely as phosphoric esters in ribonucleotides and ribonucleic acids.\" [GOC:curators]","metadata":null},{"id":"77f07a5244104b9bae6a2cad3d67526a","type":"GO_TERM","name":"uridine nucleosidase activity","canonical_id":"go:GO:0045437","description":"\"Catalysis of the reaction: H2O + uridine = ribofuranose + uracil.\" [EC:3.2.2.3, RHEA:15577]","metadata":null},{"id":"211a579b804e473c8093bffaa00a864f","type":"GO_TERM","name":"uridine phosphorylase activity","canonical_id":"go:GO:0004850","description":"\"Catalysis of the reaction: uridine + phosphate = uracil + alpha-D-ribose 1-phosphate.\" [EC:2.4.2.3]","metadata":null},{"id":"0d3d68c357f54d448179412a2adb2feb","type":"GO_TERM","name":"uridine to cytidine editing","canonical_id":"go:GO:0016555","description":"\"The conversion of a uridine residue to cytosine in an RNA molecule by amination.\" [PMID:11092837]","metadata":null},{"id":"60281ad6f9cd4335b96538d4b7b557b3","type":"GO_TERM","name":"uridine transmembrane transport","canonical_id":"go:GO:0015862","description":"\"The directed movement of uridine, uracil riboside, across a lipid bilayer, by means of some agent such as a transporter or pore.\" [GOC:curators]","metadata":null},{"id":"b637e05c40ba4026b4472f9ca6d0ebda","type":"GO_TERM","name":"uridine transmembrane transporter activity","canonical_id":"go:GO:0015213","description":"\"Enables the transfer of uridine, uracil riboside, from one side of a membrane to the other.\" [GOC:curators]","metadata":null},{"id":"144ed883eda34f11abe1aa43a7780d26","type":"GO_TERM","name":"uridine-rich cytoplasmic polyadenylylation element binding","canonical_id":"go:GO:0017131","description":"\"Binding to a U-rich sequence in the 3'-end of nuclear-transcribed mRNAs; required for cytoplasmic polyadenylylation.\" [GOC:krc, PMID:7954828]","metadata":null},{"id":"d8a09cffd5484890b7b09c872d01adc6","type":"GO_TERM","name":"uridine:proton symporter activity","canonical_id":"go:GO:0015394","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: uridine(out) + H+(out) = uridine(in) + H+(in).\" [GOC:mtg_transport]","metadata":null},{"id":"92f486e77fdb4979a7c21447918899ba","type":"GO_TERM","name":"uridylyltransferase activity","canonical_id":"go:GO:0070569","description":"\"Catalysis of the transfer of an uridylyl group to an acceptor.\" [GOC:mah]","metadata":null},{"id":"4009365511ef4db2b7db5f8a6fdcbf9a","type":"DISEASE","name":"urinary bladder cancer","canonical_id":"mondo:0001187","description":null,"metadata":null},{"id":"1a80622aa190468c9148b5a25b59edc3","type":"DISEASE","name":"urinary bladder carcinoma","canonical_id":"mondo:0004986","description":null,"metadata":null},{"id":"e6b4ba7c05e44a8388a926829ccc7853","type":"GO_TERM","name":"urinary bladder development","canonical_id":"go:GO:0060157","description":"\"The process whose specific outcome is the progression of the urinary bladder over time, from its formation to the mature structure. The urinary bladder is an elastic, muscular sac situated in the anterior part of the pelvic cavity in which urine collects before excretion.\" [GOC:dph, GOC:ln, GOC:mr, PMID:11768524, PMID:18276178, PMID:538956]","metadata":null},{"id":"7c9a1478185f4f3181e31e3a1e025db7","type":"GO_TERM","name":"urinary bladder smooth muscle contraction","canonical_id":"go:GO:0014832","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the urinary bladder. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The urinary bladder is a musculomembranous sac along the urinary tract.\" [GOC:mr, GOC:mtg_muscle, PMID:11768524, PMID:18276178, PMID:538956]","metadata":null},{"id":"edf1443ffb9b46258fd368da747474c0","type":"DISEASE","name":"urinary bladder, atony of","canonical_id":"mondo:0008630","description":null,"metadata":null},{"id":"6e9292b361cd4315bda08a298d7e3e58","type":"DISEASE","name":"urinary system disorder","canonical_id":"mondo:0002118","description":null,"metadata":null},{"id":"e3cbef8f450c4318b500f3741ceced38","type":"DISEASE","name":"urinary tract infection","canonical_id":"mondo:0100338","description":null,"metadata":null},{"id":"ade98d8aa871454396b083bd2de5725c","type":"GO_TERM","name":"urinary tract smooth muscle contraction","canonical_id":"go:GO:0014848","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the urinary tract. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The urinary tract consists of organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra.\" [GOC:ef, GOC:mtg_muscle, MA:0000325, MSH:D014551]","metadata":null},{"id":"b415256ff2524f8782520b33306685fb","type":"GO_TERM","name":"urocanate hydratase activity","canonical_id":"go:GO:0016153","description":"\"Catalysis of the reaction: 4-imidazolone-5-propanoate + H+ = trans-urocanate + H2O.\" [EC:4.2.1.49, RHEA:13101]","metadata":null},{"id":"52db182a9f1a40888e8a19dc85820337","type":"GO_TERM","name":"urogenital system development","canonical_id":"go:GO:0001655","description":"\"The process whose specific outcome is the progression of the urogenital system over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"1948c1c60869410495154b3cecc3df53","type":"DRUG","name":"urokinase","canonical_id":"mesh:D014568","description":null,"metadata":null},{"id":"db17e210af134a6c8f78f57f84d8ea8a","type":"GO_TERM","name":"urokinase plasminogen activator receptor activity","canonical_id":"go:GO:0030377","description":"\"Combining with the urokinase plasminogen activator to initiate a change in cell activity.\" [GOC:mah, PMID:16456079]","metadata":null},{"id":"f9a7889081f34e83a89fb28359f47f23","type":"GO_TERM","name":"urokinase plasminogen activator signaling pathway","canonical_id":"go:GO:0038195","description":"\"The series of molecular signals initiated by urokinase plasminogen activator binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:gap, PMID:9417082]","metadata":null},{"id":"cc3d257ac0d14c30ba34b6ec50067a82","type":"DISEASE","name":"urolithiasis","canonical_id":"mondo:0024647","description":null,"metadata":null},{"id":"e6d5d92d57da4839985259fb573049b0","type":"GO_TERM","name":"uronate dehydrogenase activity","canonical_id":"go:GO:0050388","description":"\"Catalysis of the reaction: D-galacturonate + H2O + NAD+ = galactarate + 2 H+ + NADH.\" [EC:1.1.1.203, RHEA:22404]","metadata":null},{"id":"973ddfe2231c41f296a0e73650658865","type":"GO_TERM","name":"uronic acid transmembrane transport","canonical_id":"go:GO:0015735","description":"\"The process in which uronic acid is transported across a lipid bilayer, from one side of a membrane to the other.\" [GOC:krc]","metadata":null},{"id":"87499972182d4b30a06592977296c4bf","type":"GO_TERM","name":"uronic acid transmembrane transporter activity","canonical_id":"go:GO:0015133","description":"\"Enables the transfer of uronic acid from one side of a membrane to the other. Uronic acids are any monocarboxylic acid formally derived by oxidizing to a carboxyl group the terminal hydroxymethylene group of either an aldose with four or more carbon atoms in the molecule, or of any glycoside derived from such an aldose.\" [GOC:ai]","metadata":null},{"id":"e2fc417f7f6c4822a8a4d10ed19d6fba","type":"GO_TERM","name":"uronolactonase activity","canonical_id":"go:GO:0050389","description":"\"Catalysis of the reaction: D-glucurono-6,2-lactone + H2O = D-glucuronate.\" [EC:3.1.1.19, MetaCyc:URONOLACTONASE-RXN]","metadata":null},{"id":"4e438c2b197c4bfa82df5fcac03db23c","type":"GO_TERM","name":"uropod","canonical_id":"go:GO:0001931","description":"\"A membrane projection with related cytoskeletal components at the trailing edge of a cell in the process of migrating or being activated, found on the opposite side of the cell from the leading edge or immunological synapse, respectively.\" [GOC:add, ISBN:0781735149, PMID:12714569, PMID:12787750]","metadata":null},{"id":"571e5d41afed4728bf64cded28b67bbc","type":"GO_TERM","name":"uropod assembly","canonical_id":"go:GO:0034460","description":"\"The assembly of a uropod by rearrangement of the cytoskeleton and overlying membrane.\" [GOC:mah]","metadata":null},{"id":"0617b5bcd39c4cb3937a4d50db9c1e18","type":"GO_TERM","name":"uropod membrane","canonical_id":"go:GO:0031259","description":"\"The portion of the plasma membrane surrounding a uropod.\" [GOC:mah]","metadata":null},{"id":"91b7ad3cf6ce46c0b2b223d63ba46ccc","type":"GO_TERM","name":"uropod organization","canonical_id":"go:GO:0032796","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a uropod, a rigid membrane projection with related cytoskeletal components at the trailing edge of a lymphocyte or other cell in the process of migrating or being activated.\" [GOC:add, ISBN:0781735149, PMID:12714569, PMID:12787750]","metadata":null},{"id":"1853d94f1f2d49e2a44b02219878f4b5","type":"GO_TERM","name":"uropod retraction","canonical_id":"go:GO:0034461","description":"\"The process in which a uropod detaches from the cell substrate and retracts the rear of a migrating cell.\" [GOC:mah, PMID:10704379]","metadata":null},{"id":"4ca43c8fe01647ffb00532a0190483f7","type":"GO_TERM","name":"uroporphyrin-III C-methyltransferase activity","canonical_id":"go:GO:0004851","description":"\"Catalysis of the reaction: uroporphyrinogen III + 2 S-adenosyl-L-methionine = precorrin-2 + 2 S-adenosyl-L-homocysteine + H+.\" [RHEA:32459]","metadata":null},{"id":"1f6f7eff8fdf45d68dc91456c7730070","type":"GO_TERM","name":"uroporphyrinogen III biosynthetic process","canonical_id":"go:GO:0006780","description":"\"The chemical reactions and pathways resulting in the formation of uroporphyrinogen III.\" [GOC:ai]","metadata":null},{"id":"7bb2305c57344142866c9aee0cfdf1c7","type":"GO_TERM","name":"uroporphyrinogen III metabolic process","canonical_id":"go:GO:0046502","description":"\"The chemical reactions and pathways involving uroporphyrinogen III, a precursor for synthesis of vitamin B12, chlorophyll, and heme in organisms that produce these compounds.\" [GOC:ai]","metadata":null},{"id":"3a61c43cbba24a4a905e0acd1555bd7b","type":"GO_TERM","name":"uroporphyrinogen decarboxylase activity","canonical_id":"go:GO:0004853","description":"\"Catalysis of the reaction: uroporphyrinogen-III = coproporphyrinogen + 4 CO2.\" [EC:4.1.1.37]","metadata":null},{"id":"4f4af125f4394050ac96d820240bc047","type":"GO_TERM","name":"uroporphyrinogen-III synthase activity","canonical_id":"go:GO:0004852","description":"\"Catalysis of the reaction: hydroxymethylbilane = H2O + uroporphyrinogen III.\" [EC:4.2.1.75, RHEA:18965]","metadata":null},{"id":"0dfe8706d41742d2a5d216b1a00ed53b","type":"GO_TERM","name":"urotensin II receptor activity","canonical_id":"go:GO:0001604","description":"\"Combining with urotensin II to initiate a change in cell activity.\" [GOC:mah, PMID:15102493]","metadata":null},{"id":"acb967d5b8f548448a4ef9fdd05e6c67","type":"GO_TERM","name":"urotensin receptor binding","canonical_id":"go:GO:0031889","description":"\"Binding to a urotensin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"c3514abaf02c42e6a55372a34c5af9ab","type":"DISEASE","name":"urothelial carcinoma","canonical_id":"mondo:0040679","description":null,"metadata":null},{"id":"4df82a37ca274adf8b20e0265b89977c","type":"GO_TERM","name":"urothelial cell proliferation","canonical_id":"go:GO:0050674","description":"\"The multiplication or reproduction of urothelial cells, resulting in the expansion of a cell population. Urothelial cells make up a layer of transitional epithelium in the wall of the bladder, ureter, and renal pelvis, external to the lamina propria.\" [ISBN:0721662544]","metadata":null},{"id":"a552c659a11f47de968e8ae1186b3317","type":"GO_TERM","name":"ursodeoxycholate 7-beta-dehydrogenase (NAD+) activity","canonical_id":"go:GO:0106283","description":"\"Catalysis of the reaction: NAD+ + ursodeoxycholate = 7-oxolithocholate + H+ + NADH.\" [PMID:12917011, RHEA:42028]","metadata":null},{"id":"e5c575fca3ce4343b406f2b097ff575e","type":"DISEASE","name":"urticaria","canonical_id":"mondo:0005492","description":null,"metadata":null},{"id":"98f5316bc41d4f3c9098c631657fc58f","type":"DRUG","name":"ustekinumab","canonical_id":"gtopdb:6885","description":null,"metadata":null},{"id":"6318e3071abe494b9bd99247dc199206","type":"DRUG","name":"ustekinumab","canonical_id":"mesh:D000069549","description":null,"metadata":null},{"id":"a63b89fc83bb44969b138974aa9ab409","type":"DRUG","name":"ustekinumab","canonical_id":"chembl:CHEMBL1201835","description":null,"metadata":null},{"id":"19eaa7e393e14820af19079af7fa1585","type":"COMBINATION_TREATMENT","name":"ustekinumab + vorinostat","canonical_id":"ctgov_combo:ctgov-combo-2fd70d1b4da1a07c","description":null,"metadata":null},{"id":"d1a6231383ea4787ad52ff3fea6c8c70","type":"DISEASE","name":"uterine corpus leiomyoma","canonical_id":"mondo:0007886","description":null,"metadata":null},{"id":"2f8ec3e0773d4516ba23ce61bb582b0f","type":"GO_TERM","name":"uterine epithelium development","canonical_id":"go:GO:0035847","description":"\"The progression of an epithelium of the uterus over time from its initial formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.\" [GOC:bf, GOC:yaf]","metadata":null},{"id":"add9b4a5bbc8438ead21b8fc0601bc8f","type":"GO_TERM","name":"uterine gland development","canonical_id":"go:GO:1903709","description":"\"The process whose specific outcome is the progression of an uterine gland over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:TermGenie, PMID:23619340]","metadata":null},{"id":"76fadc03cd69422f8c30fd9e767c6b6f","type":"GO_TERM","name":"uterine smooth muscle contraction","canonical_id":"go:GO:0070471","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the uterus. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The uterus is a muscular organ of the female mammal for containing and usually for nourishing the young during development prior to birth.\" [GOC:sl]","metadata":null},{"id":"4f871afba76d43bc9598a2e38e3eafa9","type":"GO_TERM","name":"uterine smooth muscle relaxation","canonical_id":"go:GO:0044558","description":"\"A process in which the extent of smooth muscle contraction is reduced in the uterus.\" [GOC:jl]","metadata":null},{"id":"e57e6cd1b1ed458aba7e2eb38f2ed8e5","type":"GO_TERM","name":"uterine wall breakdown","canonical_id":"go:GO:0042704","description":"\"The sloughing of the endometrium and blood vessels during menstruation that results from a drop in progesterone levels.\" [GOC:dph]","metadata":null},{"id":"ff9c2aa2e21745da8e71ff5e792004f9","type":"GO_TERM","name":"uterine wall growth","canonical_id":"go:GO:0042702","description":"\"The regrowth of the endometrium and blood vessels in the uterus following menstruation, resulting from a rise in progesterone levels.\" [GOC:jl]","metadata":null},{"id":"b539318311e548038016b6c340f8185b","type":"GO_TERM","name":"uterus development","canonical_id":"go:GO:0060065","description":"\"The reproductive developmental process whose specific outcome is the progression of the uterus over time, from its formation to the mature structure.\" [GOC:dph, GOC:ebc]","metadata":null},{"id":"cc271ff635494d95b0ab266ee5596c9e","type":"GO_TERM","name":"uterus morphogenesis","canonical_id":"go:GO:0061038","description":"\"The process in which anatomical structures of the uterus are generated and organized.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"c0376ef0c8e2425187be76790a343d0e","type":"DISEASE","name":"uveitis","canonical_id":"mondo:0020283","description":null,"metadata":null},{"id":"104abb232f574b5d801747e98360d3bf","type":"TRIAL","name":"vMII for Measurement of Oesophageal Bolus Transport and Reflux","canonical_id":"clinicaltrials.gov:NCT00604942","description":"Achalasia; GORD","metadata":null},{"id":"d4546a8220dc406baa27c2ace7db5c5e","type":"GO_TERM","name":"vacuolar HOPS complex","canonical_id":"go:GO:1902500","description":"\"Any HOPS complex that is part of a vacuolar membrane.\" [GOC:TermGenie, PMID:23645161]","metadata":null},{"id":"98b62c92085340179557e2f00800697f","type":"GO_TERM","name":"vacuolar acidification","canonical_id":"go:GO:0007035","description":"\"Any process that reduces the pH of the vacuole, corresponding to an increase in hydrogen ion concentration.\" [GOC:jid]","metadata":null},{"id":"5d375e51274249e3bdb1234dbfce2b7a","type":"GO_TERM","name":"vacuolar amino acid transmembrane transport","canonical_id":"go:GO:0034487","description":"\"The process in which an amino acid is transported from one side of the vacuolar membrane to the other.\" [GOC:mah]","metadata":null},{"id":"c3eb73429a124cccb63f2163183e11fe","type":"GO_TERM","name":"vacuolar calcium ion homeostasis","canonical_id":"go:GO:0007036","description":"\"Any process involved in the maintenance of an internal steady state of calcium ions in the vacuole or between a vacuole and its surroundings.\" [GOC:ai, GOC:mah]","metadata":null},{"id":"58fc127bf34e453ea480ba44256fb1e8","type":"GO_TERM","name":"vacuolar localization","canonical_id":"go:GO:1990849","description":"\"Any process in which the vacuole is transported to, and/or maintained in, a specific location within the cell.\" [PMID:26283797]","metadata":null},{"id":"efc7027f76ba4496bf9c72dfca277aa0","type":"GO_TERM","name":"vacuolar lumen","canonical_id":"go:GO:0005775","description":"\"The volume enclosed within the vacuolar membrane.\" [ISBN:0198506732]","metadata":null},{"id":"c55fc20cd8d4402aa357200cc04beb4e","type":"GO_TERM","name":"vacuolar membrane","canonical_id":"go:GO:0005774","description":"\"The lipid bilayer surrounding the vacuole and separating its contents from the cytoplasm of the cell.\" [GOC:ai]","metadata":null},{"id":"532079c4df1d430db4bee90a17b56463","type":"GO_TERM","name":"vacuolar protein processing","canonical_id":"go:GO:0006624","description":"\"Protein processing that takes place in the vacuole. Most protein processing in the vacuole represents proteolytic cleavage of precursors to form active enzymes.\" [GOC:mah]","metadata":null},{"id":"5c94fa83c5d94dc586a966d280ab9ff2","type":"GO_TERM","name":"vacuolar proton-transporting V-type ATPase complex","canonical_id":"go:GO:0016471","description":"\"A proton-transporting two-sector ATPase complex found in the vacuolar membrane, where it acts as a proton pump to mediate acidification of the vacuolar lumen.\" [GOC:mah, ISBN:0716743663, PMID:16449553]","metadata":null},{"id":"3f36274ef80842c9a5b228332c8ec5e2","type":"GO_TERM","name":"vacuolar proton-transporting V-type ATPase complex assembly","canonical_id":"go:GO:0070072","description":"\"The aggregation, arrangement and bonding together of a vacuolar proton-transporting V-type ATPase complex, proton-transporting two-sector ATPase complex that couples ATP hydrolysis to the transport of protons across the vacuolar membrane.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"38bac99e5ad745558f1208e6fa266789","type":"GO_TERM","name":"vacuolar proton-transporting V-type ATPase, V0 domain","canonical_id":"go:GO:0000220","description":"\"The V0 domain of a proton-transporting V-type ATPase found in the vacuolar membrane.\" [GOC:mah, PMID:16449553]","metadata":null},{"id":"c7d6dddf66034f9287efdf37b0601fee","type":"GO_TERM","name":"vacuolar proton-transporting V-type ATPase, V1 domain","canonical_id":"go:GO:0000221","description":"\"The V1 domain of a proton-transporting V-type ATPase found in the vacuolar membrane.\" [GOC:mah, PMID:16449553]","metadata":null},{"id":"446f3d5a696a416a862657af9ecefa62","type":"GO_TERM","name":"vacuolar sorting signal receptor activity","canonical_id":"go:GO:0010209","description":"\"Binding to a vacuolar sorting signal, a specific peptide sequence that acts as a signal to localize the protein within the vacuole.\" [GOC:mah]","metadata":null},{"id":"4dce31441e0e4c1d9048823a0e7c2206","type":"GO_TERM","name":"vacuolar transmembrane transport","canonical_id":"go:GO:0034486","description":"\"The process in which a solute is transported from one side of the vacuolar membrane to the other.\" [GOC:mah]","metadata":null},{"id":"bb54e22662414cd9a46fd9455bd3c646","type":"GO_TERM","name":"vacuolar transport","canonical_id":"go:GO:0007034","description":"\"The directed movement of substances into, out of or within a vacuole.\" [GOC:ai]","metadata":null},{"id":"b3bdeb017fa340e2a99ef6c4921e6a64","type":"GO_TERM","name":"vacuolar transporter chaperone complex","canonical_id":"go:GO:0033254","description":"\"A protein complex that contains four related proteins that have been implicated in several membrane-related processes, such as sorting of H+-translocating ATPases, endocytosis, ER-Golgi trafficking, vacuole fusion, vacuolar polyphosphate homeostasis and the microautophagic scission of vesicles into the vacuolar lumen. The complex is enriched at the vacuolar membrane, but also found in other cellular compartments, including the ER and the cell periphery. In Saccharomyces, the subunits are Vtc1p, Vtc2p, Vtc3p and Vtc4p.\" [PMID:11823419, PMID:17079729, PMID:34544285]","metadata":null},{"id":"60ed009ad9e14b83abd31654d6ba04e8","type":"GO_TERM","name":"vacuole","canonical_id":"go:GO:0005773","description":"\"A closed structure, found only in eukaryotic cells, that is completely surrounded by unit membrane and contains liquid material. Cells contain one or several vacuoles, that may have different functions from each other. Vacuoles have a diverse array of functions. They can act as a storage organelle for nutrients or waste products, as a degradative compartment, as a cost-effective way of increasing cell size, and as a homeostatic regulator controlling both turgor pressure and pH of the cytosol.\" [GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"10a21235a2434550b4ef38934d0d7de1","type":"GO_TERM","name":"vacuole fission","canonical_id":"go:GO:0140572","description":"\"The division of a vacuole within a cell to form two or more separate vacuoles.\" [PMID:19643199]","metadata":null},{"id":"3a6e8b248f5049418217b56704d1415e","type":"GO_TERM","name":"vacuole fusion","canonical_id":"go:GO:0097576","description":"\"Merging of two or more vacuoles, or of vacuoles and vesicles within a cell to form a single larger vacuole.\" [GOC:pr, GOC:vw, Wikipedia:Vacuole]","metadata":null},{"id":"b1343195349542afa10967f2d6ab1d28","type":"GO_TERM","name":"vacuole fusion, non-autophagic","canonical_id":"go:GO:0042144","description":"\"The fusion of two vacuole membranes to form a single vacuole.\" [GOC:jl]","metadata":null},{"id":"2635a61a98154c179e49d055b0428237","type":"GO_TERM","name":"vacuole inheritance","canonical_id":"go:GO:0000011","description":"\"The distribution of vacuoles into daughter cells after mitosis or meiosis, mediated by interactions between vacuoles and the cytoskeleton.\" [GOC:mcc, PMID:10873824, PMID:14616069]","metadata":null},{"id":"5af1ce7ba46d4aeea64df91e09702f88","type":"GO_TERM","name":"vacuole organization","canonical_id":"go:GO:0007033","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a vacuole.\" [GOC:mah]","metadata":null},{"id":"a4a5d5c5c6e041dc9ecfbac99d7a0027","type":"GO_TERM","name":"vacuole-isolation membrane contact site","canonical_id":"go:GO:0120095","description":"\"An organelle membrane contact site formed at the junction of the vacuolar membrane and the isolation membrane or phagophore in response to starvation or other stresses, leading to the formation of the autophagosome.\" [PMID:23549786]","metadata":null},{"id":"2a5bf5dc2d6041e2acb652a327466afa","type":"GO_TERM","name":"vacuole-mitochondrion membrane contact site","canonical_id":"go:GO:1990816","description":"\"A zone of apposition between the vacuolar membrane and the mitochondrial outer membrane, important for transfer of lipids between the two organelles.\" [PMID:25026035, PMID:25026036]","metadata":null},{"id":"cd152a57b4f94615ad1380358b76d517","type":"GO_TERM","name":"vagina development","canonical_id":"go:GO:0060068","description":"\"The reproductive developmental process whose specific outcome is the progression of the vagina over time, from its formation to the mature structure.\" [GOC:dph, GOC:ebc]","metadata":null},{"id":"1a0a46de703b43a194ef89656f648243","type":"DISEASE","name":"vaginal inflammation","canonical_id":"efo:0005757","description":null,"metadata":null},{"id":"a1e9b9b415f245aa9d6d513cda46bbe3","type":"GO_TERM","name":"vagus nerve development","canonical_id":"go:GO:0021564","description":"\"The process whose specific outcome is the progression of the vagus nerve over time, from its formation to the mature structure. This nerve is primarily sensory but also has visceromotor components. It originates in the brain stem and controls many autonomic functions of the heart, lungs, stomach, pharynx, larynx, trachea, esophagus and other gastrointestinal tract components. It controls some motor functions such as speech. The sensory branches mediate sensation from the pharynx, larynx, thorax and abdomen; it also innervates taste buds in the epiglottis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"68f37e7c446945459e326722a6ac4061","type":"GO_TERM","name":"vagus nerve formation","canonical_id":"go:GO:0021646","description":"\"The process that gives rise to the vagus nerve. This process pertains to the initial formation of a structure from unspecified parts. This nerve is primarily sensory but also has visceromotor components. It originates in the brain stem and controls many autonomic functions of the heart, lungs, stomach, pharynx, larynx, trachea, esophagus and other gastrointestinal tract components. It controls some motor functions such as speech. The sensory branches mediate sensation from the pharynx, larynx, thorax and abdomen; it also innervates taste buds in the epiglottis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"5229e7272e7947f280f804956247fb81","type":"GO_TERM","name":"vagus nerve maturation","canonical_id":"go:GO:0021643","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the vagus nerve to attain its fully functional state. This nerve is primarily sensory but also has visceromotor components. It originates in the brain stem and controls many autonomic functions of the heart, lungs, stomach, pharynx, larynx, trachea, esophagus and other gastrointestinal tract components. It controls some motor functions such as speech. The sensory branches mediate sensation from the pharynx, larynx, thorax and abdomen; it also innervates taste buds in the epiglottis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"593ae089b1d54e2b94235b9a5108dc35","type":"GO_TERM","name":"vagus nerve morphogenesis","canonical_id":"go:GO:0021644","description":"\"The process in which the anatomical structure of the vagus nerve is generated and organized. This nerve is primarily sensory but also has visceromotor components. It originates in the brain stem and controls many autonomic functions of the heart, lungs, stomach, pharynx, larynx, trachea, esophagus and other gastrointestinal tract components. It controls some motor functions such as speech. The sensory branches mediate sensation from the pharynx, larynx, thorax and abdomen; it also innervates taste buds in the epiglottis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"7a4d48128cb448aa9466ef691ae7edeb","type":"GO_TERM","name":"vagus nerve structural organization","canonical_id":"go:GO:0021645","description":"\"The process that contributes to the act of creating the structural organization of the vagus nerve. This process pertains to the physical shaping of a rudimentary structure. This nerve is primarily sensory but also has visceromotor components. It originates in the brain stem and controls many autonomic functions of the heart, lungs, stomach, pharynx, larynx, trachea, esophagus and other gastrointestinal tract components. It controls some motor functions such as speech. The sensory branches mediate sensation from the pharynx, larynx, thorax and abdomen; it also innervates taste buds in the epiglottis.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"e04b24793c914b16b7fa71ba38261f6c","type":"DRUG","name":"valaciclovir","canonical_id":"mesh:C084555","description":null,"metadata":null},{"id":"9d789abe20884f3199cf5613dd16062e","type":"DRUG","name":"valbenazine","canonical_id":"gtopdb:8694","description":null,"metadata":null},{"id":"e6977ccb12a844c39d61f1fb1f38590a","type":"DRUG","name":"valbenazine","canonical_id":"mesh:C000603978","description":null,"metadata":null},{"id":"ae25ae375f124dcb9e6051d9cfa5b7a8","type":"DRUG","name":"valbenazine","canonical_id":"chembl:CHEMBL2364639","description":null,"metadata":null},{"id":"8efec5f09b4d4e0ab0aed7a4ca4b1a83","type":"DRUG","name":"valdecoxib","canonical_id":"gtopdb:2894","description":null,"metadata":null},{"id":"2779ba514a6f421a9e78fd7283161eda","type":"DRUG","name":"valdecoxib","canonical_id":"chembl:CHEMBL865","description":null,"metadata":null},{"id":"0a01004f54cb46fc923c12a2358f0aad","type":"GO_TERM","name":"valencene synthase activity","canonical_id":"go:GO:0102905","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate(3-) = (+)-valencene + diphosphoric acid.\" [EC:4.2.3.73, GOC:pz]","metadata":null},{"id":"4d83738b848d4510a6d5599814a8a757","type":"GO_TERM","name":"valerena-4,7(11)-diene synthase activity","canonical_id":"go:GO:0102412","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate(3-) = valerena-4,7(11)-diene + diphosphoric acid.\" [EC:4.2.3.139, GOC:pz]","metadata":null},{"id":"26efc825c7c74a05906163a01f94e773","type":"DRUG","name":"valganciclovir","canonical_id":"mesh:D000077562","description":null,"metadata":null},{"id":"39d4e948728a4f9598b00f314e66990b","type":"GO_TERM","name":"valine N-monooxygenase (oxime forming) activity","canonical_id":"go:GO:0102002","description":"\"Catalysis of the reaction: L-valine + 2 O2 + 2 NADPH(4-) + 2 H+ = (E)-2-methylpropanal oxime + 2 NADP(3-) + carbon dioxide + 3 H2O.\" [EC:1.14.14.38]","metadata":null},{"id":"a27df5bed21346fba823ff8d85a3e161","type":"GO_TERM","name":"valine decarboxylase activity","canonical_id":"go:GO:0050390","description":"\"Catalysis of the reaction: L-valine + H+ = 2-methylpropanamine + CO2.\" [EC:4.1.1.14, RHEA:18989]","metadata":null},{"id":"f089da85e31e448a8db86ef701106744","type":"GO_TERM","name":"valine sensor activity","canonical_id":"go:GO:0160233","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of valine.\" [PMID:39567688]","metadata":null},{"id":"a43ddac0a0ae45fbb7e2a199879d11fd","type":"GO_TERM","name":"valine transport","canonical_id":"go:GO:0015829","description":"\"The directed movement of valine, 2-amino-3-methylbutanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"dcf6724e7a9a4581ab048f87c1c912d1","type":"GO_TERM","name":"valine-tRNA ligase activity","canonical_id":"go:GO:0004832","description":"\"Catalysis of the reaction: L-valine + ATP + tRNA(Val) = L-valyl-tRNA(Val) + AMP + diphosphate + 2 H+.\" [EC:6.1.1.9, RHEA:10704]","metadata":null},{"id":"79765594fbee43f9ac9ed0d99d778956","type":"DRUG","name":"valrubicin","canonical_id":"mesh:C016163","description":null,"metadata":null},{"id":"c4c937f215ea478c89d7ee6e8328358d","type":"DRUG","name":"valsartan","canonical_id":"gtopdb:3937","description":null,"metadata":null},{"id":"c955eafba9fe4d24b4d277bc1df0b708","type":"DRUG","name":"valsartan","canonical_id":"mesh:D000068756","description":null,"metadata":null},{"id":"9fc309774b4c4d719c9214ff39a90665","type":"DRUG","name":"valsartan","canonical_id":"chembl:CHEMBL1069","description":null,"metadata":null},{"id":"2f990b601cad4cafb1057f106174c583","type":"GO_TERM","name":"valyl-tRNA aminoacylation","canonical_id":"go:GO:0006438","description":"\"The process of coupling valine to valyl-tRNA, catalyzed by valyl-tRNA synthetase. The valyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a valine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.\" [GOC:mcc, ISBN:0716730510]","metadata":null},{"id":"d9375b296528484494e8506a09e054e2","type":"DRUG","name":"vamorolone","canonical_id":"gtopdb:9247","description":null,"metadata":null},{"id":"ed918688d94648a7a243bc96eeb86287","type":"DRUG","name":"vamorolone","canonical_id":"chembl:CHEMBL2348780","description":null,"metadata":null},{"id":"9e535ed7762c437daae419565fd21627","type":"GO_TERM","name":"vanadium ion binding","canonical_id":"go:GO:0051212","description":"\"Binding to a vanadium ion (V).\" [GOC:ai]","metadata":null},{"id":"2ebb37f99b7a499da68da3af9c5551d6","type":"GO_TERM","name":"vanadium ion transmembrane transporter activity","canonical_id":"go:GO:0015100","description":"\"Enables the transfer of vanadium (V) ions from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"d7c2216778a94944ae7012487a921ef3","type":"GO_TERM","name":"vanadium ion transport","canonical_id":"go:GO:0015676","description":"\"The directed movement of vanadium (V) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"ef43109442f74942abbc4aeb82162336","type":"GO_TERM","name":"vanadium-iron nitrogenase complex","canonical_id":"go:GO:0016613","description":"\"An enzyme complex containing a vanadium-iron cluster found in some species, such as Azotobacter vinelandii. It is composed of two proteins, dinitrogenase and nitrogenase reductase; dinitrogenase, the vanadium-iron protein, is tetrameric with an alpha2-beta2 structure, and nitrogenase reductase is a homodimer.\" [PMID:3474027]","metadata":null},{"id":"da850a0b8a254cf19a7d034eedafbde9","type":"DRUG","name":"vancomycin","canonical_id":"mesh:D014640","description":null,"metadata":null},{"id":"220dbe6772854d2aaf47760fea4b25e1","type":"GO_TERM","name":"vancomycin biosynthetic process","canonical_id":"go:GO:0033072","description":"\"The chemical reactions and pathways leading to the formation of vancomycin, (3S,6R,7R,11R,23S,26S,30aS,36R,38aR)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-(N-methyl-D-leucyl)-2,5,24,38,39-pentaoxo-1H,22H-23,36-(epiminomethano)-8,11:18,21-dietheno-13,16:31,35-di(metheno)[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid, a complex glycopeptide from Streptomyces orientalis that inhibits a specific step in the synthesis of the peptidoglycan layer in Gram-positive bacteria.\" [GOC:mah]","metadata":null},{"id":"89e20ef51f42485eb5903c7998907b6b","type":"DRUG","name":"vandetanib","canonical_id":"gtopdb:5717","description":null,"metadata":null},{"id":"b7bbbe9477a446d0b94268864a2e5396","type":"DRUG","name":"vandetanib","canonical_id":"chembl:CHEMBL24828","description":null,"metadata":null},{"id":"6bfba232d06046bc8851cb2a9fdaf3f6","type":"GO_TERM","name":"vanillate monooxygenase activity","canonical_id":"go:GO:0018489","description":"\"Catalysis of the reaction: H+ + NADH + O2 + vanillate = 3,4-dihydroxybenzoate + formaldehyde + H2O + NAD+.\" [EC:1.14.13.82, RHEA:13021]","metadata":null},{"id":"3a8299965c4e45e6a853412530f7eecc","type":"GO_TERM","name":"vanillin biosynthetic process","canonical_id":"go:GO:0042189","description":"\"The chemical reactions and pathways resulting in the formation of vanillin, an aromatic hydrocarbon which occurs naturally in black vanilla bean pods.\" [GOC:jl]","metadata":null},{"id":"0ca911686bcb401bbcc39ae41bb280cb","type":"GO_TERM","name":"vanillin catabolic process","canonical_id":"go:GO:0042190","description":"\"The chemical reactions and pathways resulting in the breakdown of vanillin, an aromatic hydrocarbon which occurs naturally in black vanilla bean pods.\" [GOC:jl]","metadata":null},{"id":"f1384c52a88343619f97c92ce96af7fb","type":"GO_TERM","name":"vanillin dehydrogenase (NAD+) activity","canonical_id":"go:GO:0050608","description":"\"Catalysis of the reaction: H2O + NAD+ + vanillin = 2 H+ + NADH + vanillate.\" [EC:1.2.1.67, RHEA:13309]","metadata":null},{"id":"d6e47e192a714ffc96bc8aa9eff2a5ab","type":"GO_TERM","name":"vanillin metabolic process","canonical_id":"go:GO:0018982","description":"\"The chemical reactions and pathways involving vanillin, an aromatic hydrocarbon which occurs naturally in black vanilla bean pods and can be obtained as a by-product of the pulp and paper industry by the oxidative breakdown of lignin.\" [GOC:jl]","metadata":null},{"id":"9fc196f7a4f843c289e225e2186885e6","type":"GO_TERM","name":"vanillyl-alcohol oxidase activity","canonical_id":"go:GO:0018465","description":"\"Catalysis of the reaction: O2 + vanillyl alcohol = H2O2 + vanillin.\" [EC:1.1.3.38, RHEA:10036]","metadata":null},{"id":"2ad1ab847ed44b699e096aa3d02afaae","type":"DRUG","name":"vapreotide","canonical_id":"gtopdb:2054","description":null,"metadata":null},{"id":"ce5e808e2af640cba8a3fd11ec79987f","type":"DRUG","name":"vapreotide","canonical_id":"chembl:CHEMBL3349523","description":null,"metadata":null},{"id":"a8bc218fce904ab5bab1f2b667372207","type":"DRUG","name":"vardenafil","canonical_id":"gtopdb:7320","description":null,"metadata":null},{"id":"50ae2b6f0f7b48e2ba11db0af4cc6449","type":"DRUG","name":"varenicline","canonical_id":"gtopdb:5459","description":null,"metadata":null},{"id":"7394e2533483494897b950d644369040","type":"DRUG","name":"varenicline","canonical_id":"chembl:CHEMBL1076903","description":null,"metadata":null},{"id":"64b70a37b27d4370a3ec76986f6076b6","type":"GO_TERM","name":"varicosity","canonical_id":"go:GO:0043196","description":"\"Non-terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters.\" [GOC:nln]","metadata":null},{"id":"bd42798fd8df43f081c73e36ba1e996c","type":"GO_TERM","name":"vascular associated smooth muscle cell apoptotic process","canonical_id":"go:GO:1905288","description":"\"Any apoptotic process in a vascular associated smooth muscle cell.\" [GO_REF:0000085, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:26493107]","metadata":null},{"id":"6dff84f50e6147bb8c2d41231e8d05a7","type":"GO_TERM","name":"vascular associated smooth muscle cell dedifferentiation","canonical_id":"go:GO:1990936","description":"\"The process in which a vascular smooth muscle cell (a non-striated, elongated, spindle-shaped cell found lining the blood vessels) loses the structural or functional features that characterize it in the mature organism, or some other relatively stable phase of the organism's life history. Under certain conditions, these cells can revert back to the features of the stem cells that were their ancestors.\" [GOC:BHF, GOC:BHF_miRNA, GOC:rph, PMID:19088079]","metadata":null},{"id":"dacd29f0eee94fa39327f91debaa94d1","type":"GO_TERM","name":"vascular associated smooth muscle cell development","canonical_id":"go:GO:0097084","description":"\"The process aimed at the progression of a vascular smooth muscle cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. A vascular smooth muscle cell is a non-striated, elongated, spindle-shaped cell found lining the blood vessels.\" [GOC:BHF]","metadata":null},{"id":"b7c9e1a9805444e19fa4d0e0797c663d","type":"GO_TERM","name":"vascular associated smooth muscle cell differentiation","canonical_id":"go:GO:0035886","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a vascular smooth muscle cell.\" [GOC:sl, PMID:16151017, PMID:18267954]","metadata":null},{"id":"b1c4c73ebffb4c8c89f85aeec640b228","type":"GO_TERM","name":"vascular associated smooth muscle cell fate commitment","canonical_id":"go:GO:0097081","description":"\"The commitment of cells to a vascular smooth muscle cell fate and their capacity to differentiate into vascular smooth muscle cells. A vascular smooth muscle cell is a non-striated, elongated, spindle-shaped cell found lining the blood vessels.\" [GOC:BHF]","metadata":null},{"id":"adc9619f34024e7bb6b7462f2fcb8b49","type":"GO_TERM","name":"vascular associated smooth muscle cell fate determination","canonical_id":"go:GO:0097083","description":"\"The process in which a cell becomes capable of differentiating autonomously into a vascular smooth muscle cell regardless of its environment; upon determination, the cell fate cannot be reversed. A vascular smooth muscle cell is a non-striated, elongated, spindle-shaped cell found lining the blood vessels.\" [GOC:BHF]","metadata":null},{"id":"630b2796bd17413a9673bff9f399574a","type":"GO_TERM","name":"vascular associated smooth muscle cell fate specification","canonical_id":"go:GO:0097082","description":"\"The process in which a cell becomes capable of differentiating autonomously into a vascular smooth muscle cell in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed. A vascular smooth muscle cell is a non-striated, elongated, spindle-shaped cell found lining the blood vessels.\" [GOC:BHF]","metadata":null},{"id":"66073ee2ff594be09e242724e97851f2","type":"GO_TERM","name":"vascular associated smooth muscle cell migration","canonical_id":"go:GO:1904738","description":"\"The orderly movement of a vascular associated smooth muscle cell from one site to another.\" [GO_REF:0000091, GOC:BHF, GOC:BHF_miRNA, GOC:rph, GOC:TermGenie, PMID:20693317]","metadata":null},{"id":"2ddf74ba3b9e4e29b0b073036482074b","type":"GO_TERM","name":"vascular associated smooth muscle cell proliferation","canonical_id":"go:GO:1990874","description":"\"The multiplication or reproduction of vascular smooth muscle cells, resulting in the expansion of a cell population. A vascular smooth muscle cell is a non-striated, elongated, spindle-shaped cell found lining the blood vessels.\" [PMID:23246467]","metadata":null},{"id":"abdce858d34c4b4584d9a89f98d5d4c0","type":"GO_TERM","name":"vascular associated smooth muscle contraction","canonical_id":"go:GO:0014829","description":"\"A process, occurring in the vascular tissue, whereby actin/myosin complex activity generates force through ATP hydrolysis resulting in a change in smooth muscle geometry. This process is always coupled to chemo-mechanical energy conversion.\" [GOC:mtg_muscle, MA:0002718]","metadata":null},{"id":"b300af2c96104226a493765f0e25997b","type":"GO_TERM","name":"vascular cord development","canonical_id":"go:GO:0072360","description":"\"The progression of the vascular cord over time from its initial formation until its mature state. The vascular cord is the primordial vasculature that will develop into blood vessels by the process of tubulogenesis.\" [GOC:mah, PMID:7084422, ZFA:0005077]","metadata":null},{"id":"e63bbfe39dbf46fc96fd94fb30b83a9d","type":"GO_TERM","name":"vascular endothelial cell proliferation","canonical_id":"go:GO:0101023","description":"\"The multiplication or reproduction of blood vessel endothelial cells, resulting in the expansion of a cell population.\" [GOC:BHF, GOC:BHF_telomere, GOC:nc, PMID:23201774]","metadata":null},{"id":"07e393c746e64ef5ad6e43b763919142","type":"GO_TERM","name":"vascular endothelial cell response to fluid shear stress","canonical_id":"go:GO:0097699","description":"\"Any response to fluid shear stress in a vascular endothelial cell.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"fa9d4ee7bb03479e8006e8599f4c8b74","type":"GO_TERM","name":"vascular endothelial cell response to laminar fluid shear stress","canonical_id":"go:GO:0097700","description":"\"Any response to laminar fluid shear stress in a vascular endothelial cell.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"01f030e3e326443ba11a05badd61bfd1","type":"GO_TERM","name":"vascular endothelial cell response to oscillatory fluid shear stress","canonical_id":"go:GO:0097706","description":"\"Any response to oscillatory fluid shear stress that occurs in a vascular endothelial cell.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"cd56c505a60143098919f3263eee0566","type":"GO_TERM","name":"vascular endothelial cell response to pulsatile fluid shear stress","canonical_id":"go:GO:0097705","description":"\"Any response to pulsatile fluid shear stress that occurs in a vascular endothelial cell.\" [GOC:bc, GOC:BHF, GOC:BHF_miRNA, PMID:21768538]","metadata":null},{"id":"863e185956704771b319b04651174692","type":"GO_TERM","name":"vascular endothelial glycocalyx","canonical_id":"go:GO:0120239","description":"\"The carbohydrate-rich layer lining the vascular endothelium connected to the endothelium through a variety of molecules, mainly proteoglycans and glycoproteins. These form a network in which soluble molecules, either plasma- or endothelium-derived, are incorporated.\" [GOC:krc, PMID:17256154]","metadata":null},{"id":"0e75cadfecce413b87d2375103703447","type":"GO_TERM","name":"vascular endothelial growth factor binding","canonical_id":"go:GO:0038085","description":"\"Binding to a vascular endothelial growth factor.\" [PMID:17470632]","metadata":null},{"id":"3166169526f6405488dc3f02534ddbfc","type":"GO_TERM","name":"vascular endothelial growth factor production","canonical_id":"go:GO:0010573","description":"\"The appearance of vascular endothelial growth factor production due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.\" [GOC:rl]","metadata":null},{"id":"7ad8eeb2b0044c53a58aa8d5cc46b438","type":"GO_TERM","name":"vascular endothelial growth factor receptor 1 binding","canonical_id":"go:GO:0043183","description":"\"Binding to a vascular endothelial growth factor receptor 1.\" [GOC:st]","metadata":null},{"id":"0423e090d4d2434bb52afad153065421","type":"GO_TERM","name":"vascular endothelial growth factor receptor 2 binding","canonical_id":"go:GO:0043184","description":"\"Binding to a vascular endothelial growth factor receptor 2.\" [GOC:st]","metadata":null},{"id":"81b025e83020460c86793fcd765a6e01","type":"GO_TERM","name":"vascular endothelial growth factor receptor 3 binding","canonical_id":"go:GO:0043185","description":"\"Binding to a vascular endothelial growth factor receptor 3.\" [GOC:st]","metadata":null},{"id":"31ed3057df42449a9c4beb02da9e76af","type":"GO_TERM","name":"vascular endothelial growth factor receptor activity","canonical_id":"go:GO:0005021","description":"\"Combining with a vascular endothelial growth factor (VEGF) receptor ligand and transmitting the signal across the plasma membrane to initiate a change in cell activity.\" [GOC:mah, GOC:signaling, PMID:19909239]","metadata":null},{"id":"7b8e96c5902447afa31e88356b707478","type":"GO_TERM","name":"vascular endothelial growth factor receptor binding","canonical_id":"go:GO:0005172","description":"\"Binding to a vascular endothelial growth factor receptor.\" [GOC:ai]","metadata":null},{"id":"9cf6872867524399bc32f50db06f798a","type":"GO_TERM","name":"vascular endothelial growth factor receptor signaling pathway","canonical_id":"go:GO:0048010","description":"\"The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor (VEGFR) on the surface of the target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:ceb, GOC:signaling]","metadata":null},{"id":"d7c285338ce54ba0a7aa3d9000692556","type":"GO_TERM","name":"vascular endothelial growth factor receptor-1 signaling pathway","canonical_id":"go:GO:0036323","description":"\"The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor-1 (VEGFR-1) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:uh, Wikipedia:FLT1, Wikipedia:VEGF_receptors]","metadata":null},{"id":"82160914f1c74adea06314d02a2f19bb","type":"GO_TERM","name":"vascular endothelial growth factor receptor-2 signaling pathway","canonical_id":"go:GO:0036324","description":"\"The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor-2 (VEGFR-2) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:uh, PMID:12967471, Wikipedia:Kinase_insert_domain_receptor, Wikipedia:VEGF_receptors]","metadata":null},{"id":"67b335cc110c4292b2a00f65f1865a78","type":"GO_TERM","name":"vascular endothelial growth factor receptor-3 signaling pathway","canonical_id":"go:GO:0036325","description":"\"The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor-3 (VEGFR-3) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:bf, GOC:uh, Wikipedia:VEGF_receptors, Wikipedia:VEGFR3]","metadata":null},{"id":"ab7e484f035d4766b1bc40f75a9cddc7","type":"GO_TERM","name":"vascular endothelial growth factor signaling pathway","canonical_id":"go:GO:0038084","description":"\"The series of molecular signals initiated by vascular endothelial growth factor (VEGF) binding its receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.\" [GOC:signaling, PMID:17470632]","metadata":null},{"id":"b901a4f087cb468fb53ac83269f6d5d0","type":"DISEASE","name":"vascular malformation","canonical_id":"mondo:0024291","description":null,"metadata":null},{"id":"00136a28700d4dd297d0efe1f8dae6bf","type":"DISEASE","name":"vascular neoplasm","canonical_id":"mondo:0024296","description":null,"metadata":null},{"id":"8e697d9a033e42f28ca5186cd747742e","type":"GO_TERM","name":"vascular process in circulatory system","canonical_id":"go:GO:0003018","description":"\"A circulatory process that occurs at the level of the vasculature.\" [GOC:mtg_cardio]","metadata":null},{"id":"31e2f7c5ec334abea580b5860a1e026d","type":"GO_TERM","name":"vascular transport","canonical_id":"go:GO:0010232","description":"\"The directed movement of substances, into, out of or within a cell, either in a vascular tissue or in the vascular membrane.\" [GOC:sm]","metadata":null},{"id":"5d51aac1453a43dc889fcd3ec36357bf","type":"GO_TERM","name":"vascular wound healing","canonical_id":"go:GO:0061042","description":"\"Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature.\" [GOC:BHF, GOC:dph]","metadata":null},{"id":"654ba7e1f73f4cee870f946b01072016","type":"GO_TERM","name":"vasculature development","canonical_id":"go:GO:0001944","description":"\"The process whose specific outcome is the progression of the vasculature over time, from its formation to the mature structure. The vasculature is an interconnected tubular multi-tissue structure that contains fluid that is actively transported around the organism.\" [GOC:dph, UBERON:0002409]","metadata":null},{"id":"6a720a9655f34857b3fa04da5068fd0c","type":"DISEASE","name":"vasculitis","canonical_id":"mondo:0018882","description":null,"metadata":null},{"id":"a67b551508e24194a02902e531cd0d40","type":"GO_TERM","name":"vasculogenesis","canonical_id":"go:GO:0001570","description":"\"The differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes.\" [PMID:8999798]","metadata":null},{"id":"07c96c41a17341c68ab4b1045729d6fd","type":"GO_TERM","name":"vasculogenesis involved in coronary vascular morphogenesis","canonical_id":"go:GO:0060979","description":"\"The differentiation of endothelial cells from progenitor cells that contributes to blood vessel development in the heart, and the de novo formation of blood vessels and tubes.\" [GOC:mtg_heart]","metadata":null},{"id":"76adad2972604768bdf3285197592520","type":"GO_TERM","name":"vasoactive intestinal polypeptide receptor activity","canonical_id":"go:GO:0004999","description":"\"Combining with vasoactive intestinal polypeptide to initiate a change in cell activity.\" [GOC:mah]","metadata":null},{"id":"b81ad34fa6074be08555b832eadeb717","type":"GO_TERM","name":"vasoactive intestinal polypeptide receptor binding","canonical_id":"go:GO:0031890","description":"\"Binding to a vasoactive intestinal polypeptide receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"35f323de053a45e6bb438b8c298b293f","type":"GO_TERM","name":"vasoconstriction","canonical_id":"go:GO:0042310","description":"\"A decrease in the diameter of blood vessels, especially arteries, due to constriction of smooth muscle cells that line the vessels, and usually causing an increase in blood pressure.\" [GOC:pr, ISBN:0192800752]","metadata":null},{"id":"1d4cc3f5da9e47dab2c99ec1740a7810","type":"GO_TERM","name":"vasoconstriction of artery involved in baroreceptor response to lowering of systemic arterial blood pressure","canonical_id":"go:GO:0001987","description":"\"A process that is triggered by vasomotor excitation and results in a decrease in the diameter of an artery during the baroreceptor response to decreased blood pressure.\" [ISBN:0721643949]","metadata":null},{"id":"d53b12c8557a450284e768368a73b93a","type":"GO_TERM","name":"vasoconstriction of artery involved in ischemic response to lowering of systemic arterial blood pressure","canonical_id":"go:GO:0002014","description":"\"The vasoconstriction that is triggered by vasomotor excitation resulting from the detection of high carbon dioxide levels in the vasomotor center of the central nervous system.\" [GOC:mtg_cardio, ISBN:0721643949]","metadata":null},{"id":"db868af617e54d4da09615e917e0b772","type":"GO_TERM","name":"vasodilation","canonical_id":"go:GO:0042311","description":"\"An increase in the internal diameter of blood vessels, especially arterioles or capillaries, due to relaxation of smooth muscle cells that line the vessels, and usually resulting in a decrease in blood pressure.\" [GOC:pr, ISBN:0192800981]","metadata":null},{"id":"1c58dccf9d0f42daa1b75ced54563979","type":"GO_TERM","name":"vasomotion","canonical_id":"go:GO:1990029","description":"\"The rhythmical contraction and relaxation of arterioles, observed as slow and fast waves, with frequencies of 1-2 and 10-20 cpm.\" [GOC:sl, PMID:14993429, PMID:15678091, PMID:1932763]","metadata":null},{"id":"e8a24244eb7a435982ef086e544815c3","type":"DRUG","name":"vasopressin","canonical_id":"gtopdb:2168","description":null,"metadata":null},{"id":"4d4dc476d480421ab2a7aa743edbdace","type":"DRUG","name":"vasopressin","canonical_id":"chembl:CHEMBL1201528","description":null,"metadata":null},{"id":"6b166cf5964e482b99849cb4be720f1e","type":"GO_TERM","name":"vasopressin receptor activity","canonical_id":"go:GO:0005000","description":"\"Combining with vasopressin to initiate a change in cell activity.\" [GOC:ai]","metadata":null},{"id":"4c734f08de404c0b8a655ec02e1b1727","type":"GO_TERM","name":"vasopressin receptor binding","canonical_id":"go:GO:0031893","description":"\"Binding to a vasopressin receptor.\" [GOC:mah, GOC:nln]","metadata":null},{"id":"d40923a297644d52b3a9813f48e775b4","type":"GO_TERM","name":"vasopressin secretion","canonical_id":"go:GO:0030103","description":"\"The regulated release of vasopressin from secretory granules into the blood.\" [GOC:mah]","metadata":null},{"id":"083fdc5d91ea45788aa8df9d6fcd0b4c","type":"DRUG","name":"vedolizumab","canonical_id":"gtopdb:7437","description":null,"metadata":null},{"id":"6eeda024dfc744edb3a3e27799437e64","type":"DRUG","name":"vedolizumab","canonical_id":"chembl:CHEMBL1743087","description":null,"metadata":null},{"id":"48957d593a854251b002bbde868565d5","type":"GO_TERM","name":"vegetative meristem growth","canonical_id":"go:GO:0010448","description":"\"The increase in size or mass of a vegetative meristem, a population of undifferentiated cells in a plant shoot which maintains a continuous balance between the production of stem cells and the incorporation of their derivatives into lateral organ primordia.\" [GOC:tb, ISBN:0849397928]","metadata":null},{"id":"d0098ccf9e654208bd31d11623f859a7","type":"GO_TERM","name":"vegetative phase change","canonical_id":"go:GO:0010050","description":"\"Any process involved in the transition of a plant from a juvenile phase of vegetative development to an adult phase of vegetative development.\" [GOC:tb]","metadata":null},{"id":"401573a024394942a4cd14b3b59144a3","type":"GO_TERM","name":"vegetative to reproductive phase transition of meristem","canonical_id":"go:GO:0010228","description":"\"The process involved in transforming a meristem that produces vegetative structures, such as leaves, into a meristem that produces reproductive structures, such as a flower or an inflorescence.\" [GOC:tb]","metadata":null},{"id":"cc13be814f00400dbf99b012b879cfba","type":"GO_TERM","name":"vein smooth muscle contraction","canonical_id":"go:GO:0014826","description":"\"A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the vein. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The vein is a vessel carrying blood away from the capillary beds.\" [GOC:mtg_muscle, MA:0000715, MSH:D014680]","metadata":null},{"id":"7730a873e9f14a0cbd97ab854166cf73","type":"DRUG","name":"veligrotug","canonical_id":"gtopdb:14572","description":null,"metadata":null},{"id":"e0e6752b9b2a4a88a4dab0be18978432","type":"DRUG","name":"veligrotug","canonical_id":"chembl:CHEMBL2109357","description":null,"metadata":null},{"id":"c18819ca054e49f08901e80a60bb82f5","type":"GO_TERM","name":"vellosimine dehydrogenase activity","canonical_id":"go:GO:0050579","description":"\"Catalysis of the reaction: 10-deoxysarpagine + NADP+ = H+ + NADPH + vellosimine.\" [EC:1.1.1.273, RHEA:20029]","metadata":null},{"id":"ae263df3353e41d7bcd8a158f308a142","type":"DRUG","name":"velpatasvir","canonical_id":"mesh:C000604171","description":null,"metadata":null},{"id":"50054e7dcc514519b520989fdebbf5ff","type":"DRUG","name":"vemurafenib","canonical_id":"gtopdb:5893","description":null,"metadata":null},{"id":"82096d80cbc24a6d9d2c283c49e9ca8c","type":"DRUG","name":"vemurafenib","canonical_id":"chembl:CHEMBL1229517","description":null,"metadata":null},{"id":"6cdd267daf784b1cbeff958a4190f225","type":"DRUG","name":"venetoclax","canonical_id":"gtopdb:8318","description":null,"metadata":null},{"id":"b9fa36e38cf546dd835d20ac890b47f1","type":"DRUG","name":"venetoclax","canonical_id":"mesh:C579720","description":null,"metadata":null},{"id":"07ea6890775f43289789ed50f3c85216","type":"DRUG","name":"venetoclax","canonical_id":"chembl:CHEMBL3137309","description":null,"metadata":null},{"id":"ba1e345e90584892986aa6faf8f53271","type":"DRUG","name":"venlafaxine","canonical_id":"gtopdb:7321","description":null,"metadata":null},{"id":"b333743da5314573898825379781e447","type":"DRUG","name":"venlafaxine","canonical_id":"mesh:D000069470","description":null,"metadata":null},{"id":"0e55d3007b75434abdfb49eabe0b660b","type":"GO_TERM","name":"venom-mediated activation of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0044514","description":"\"A process in which an organism initiates, promotes, or enhances a G protein-coupled receptor signaling pathway in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:8405712]","metadata":null},{"id":"385fba0d4c6248b4ab8d0586eb3d5820","type":"GO_TERM","name":"venom-mediated activation of inflammatory response","canonical_id":"go:GO:7770071","description":"\"A process by which an organism causes inflammatory response in another organism via the action of a venom.\" [PMID:19000915, PMID:32024243]","metadata":null},{"id":"61e836d8a59143d993930938575dbc6d","type":"GO_TERM","name":"venom-mediated activation of pH-gated ion channel activity","canonical_id":"go:GO:0044734","description":"\"A process in which an organism initiates, promotes, or enhances the activity of a pH-gated (also known as acid-sensing ion channel (ASIC)) in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:23034652]","metadata":null},{"id":"b369367e7f4b4f6d8e03ef8fdc83241f","type":"GO_TERM","name":"venom-mediated activation of voltage-gated sodium channel activity","canonical_id":"go:GO:0044494","description":"\"A process in which an organism initiates, promotes, or enhances the activity of a voltage-gated sodium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:21781281]","metadata":null},{"id":"b7475a33487c46339dbe5cbfc56dd00a","type":"GO_TERM","name":"venom-mediated blood coagulation","canonical_id":"go:GO:0044469","description":"\"A process in which an organism initiates, promotes, or enhances blood coagulation in another organism via the action of a venom.\" [GOC:jl]","metadata":null},{"id":"45f1c4fb9d304500b119c8efd729e658","type":"GO_TERM","name":"venom-mediated depletion of circulating fibrinogen","canonical_id":"go:GO:0044536","description":"\"The process which begins with venom being forced into an organism by the bite or sting of another organism, and ends with a reduction in the quantity of fibrinogen found in the bloodstream of the bitten/stung organism.\" [GOC:fj, GOC:jl, PMID:21130897]","metadata":null},{"id":"361575a5192e40688d797fcbaf2366df","type":"GO_TERM","name":"venom-mediated dermonecrosis in another organism","canonical_id":"go:GO:0141123","description":"\"The disruption of the skin of another organism, leading to damage or temporary subversion of the skin.\" [PMID:28194160]","metadata":null},{"id":"ef7351e6f7f34c0ab2eb61543669532c","type":"GO_TERM","name":"venom-mediated disruption of anatomical structure in another organism","canonical_id":"go:GO:0140138","description":"\"A process by which an organism effects a change that impairs the structure or function of an anatomical structure in another organism via the action of a venom. Venoms are injected into the prey by a bite or a sting.\" [GOC:pg]","metadata":null},{"id":"9db549fbf70941e3b61766fc5b7b26a6","type":"GO_TERM","name":"venom-mediated disruption of cell wall in another organism","canonical_id":"go:GO:0044278","description":"\"The disruption of the cell wall of another organism by a venom, leading to damage or temporary subversion of the cell wall.\" [PMID:36738900]","metadata":null},{"id":"d512eb00b917488f9706c37a428494b2","type":"GO_TERM","name":"venom-mediated disruption of chemical synaptic transmission","canonical_id":"go:GO:0140437","description":"\"A process in which an organism alters or subverts the synaptic transmission in another organism via the action of a venom.\" [PMID:12507705, PMID:16549768, PMID:19481459, PMID:26048991, PMID:26221036]","metadata":null},{"id":"2dbf54b4087a40d78bbe2ded0edbb9ff","type":"GO_TERM","name":"venom-mediated disruption of extracellular matrix in another organism","canonical_id":"go:GO:0044523","description":"\"A process that begins with venom being forced into an organism by the bite or sting of another organism, damaging the extracellular matrix of a cell.\" [GOC:fj, GOC:jl, PMID:20398688, PMID:21150580, PMID:33460638, PMID:37006255, PMID:41241197]","metadata":null},{"id":"c60970f7cf2e4c48b153928a89719938","type":"GO_TERM","name":"venom-mediated disruption of neuromuscular synaptic transmission","canonical_id":"go:GO:0140465","description":"\"A process in which an organism alters or subverts the synaptic transmission at the neuromuscular junction in another organism via the action of a venom.\" [PMID:11091135, PMID:28623170, PMID:34204855]","metadata":null},{"id":"830ba56970ac41469b189fee296255cc","type":"GO_TERM","name":"venom-mediated edema","canonical_id":"go:GO:0044398","description":"\"A process by which an organism causes swelling of soft tissues in another organism via the action of a venom. Edema is the result of excess water accumulation in tissues.\" [PMID:20562011]","metadata":null},{"id":"ab953ad5d4f04531b9e84c60c97fec82","type":"GO_TERM","name":"venom-mediated fibrinogenolysis","canonical_id":"go:GO:0044485","description":"\"A process in which an organism initiates, promotes, or enhances fibrinogenolysis in another organism via the action of a venom. Fibrinogenolysis is the degradation of fibrinogen by proteolytic cleavage.\" [GOC:fj, PMID:17433397, PMID:17544404]","metadata":null},{"id":"66716c088b1044ca9f3eaabb06134dc3","type":"GO_TERM","name":"venom-mediated fibrinolysis","canonical_id":"go:GO:0044484","description":"\"A process in which an organism causes fibrinolysis in another organism via the action of a venom. Fibrinolysis is a process that solubilizes fibrin in the blood, chiefly by the proteolytic action of plasmin.\" [GOC:fj, GOC:jl, PMID:17433397, PMID:17544404]","metadata":null},{"id":"cb0a3c38aff44a1f98d0d0c72446d822","type":"GO_TERM","name":"venom-mediated hemorrhage","canonical_id":"go:GO:0044358","description":"\"A process in which an organism causes vascular damage and hemorrhage in another organism via the action of a venom.\" [PMID:10441379, PMID:20614020]","metadata":null},{"id":"8cbf1ec31ffc462a93cff1a922a3be22","type":"GO_TERM","name":"venom-mediated increase of sensory perception of pain","canonical_id":"go:GO:0044742","description":"\"A process in which an organism initiates, promotes, or enhances sensory perception of pain in another organism via the action of a venom. Can manifest as allodynia, a condition that causes pain when a stimulus that normally wouldn't cause pain, or hyperalgesia, an increased sensitivity to feeling pain and an extreme response to pain.\" [GOC:fj, GOC:jl, PMID:23034652]","metadata":null},{"id":"356103164de24144a2c0aaf5db0ae865","type":"GO_TERM","name":"venom-mediated inhibition of calcium channel activity","canonical_id":"go:GO:0044473","description":"\"A process in which an organism inhibits or disrupts the activity of a calcium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:20920515]","metadata":null},{"id":"1047cb1fdb824d858875fb2a8abe0799","type":"GO_TERM","name":"venom-mediated inhibition of high voltage-gated calcium channel activity","canonical_id":"go:GO:0044475","description":"\"A process in which an organism inhibits or disrupts the activity of a high voltage-gated calcium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:20920515]","metadata":null},{"id":"1dff5592fd63453e95f20fd1af05fc63","type":"GO_TERM","name":"venom-mediated inhibition of low voltage-gated calcium channel activity","canonical_id":"go:GO:0044476","description":"\"A process in which an organism inhibits or disrupts the activity of a low voltage-gated calcium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:20920515]","metadata":null},{"id":"82628571d778465d848e9ef1fa71a6a9","type":"GO_TERM","name":"venom-mediated inhibition of pH-gated ion channel activity","canonical_id":"go:GO:0044735","description":"\"A process in which an organism inhibits or disrupts the activity of a pH-gated (also known as acid-sensing ion channel (ASIC)) in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:23034652]","metadata":null},{"id":"1e2e78ee9d544a88bf79b546bb4985fb","type":"GO_TERM","name":"venom-mediated inhibition of voltage-gated calcium channel activity","canonical_id":"go:GO:0044474","description":"\"A process in which an organism inhibits or disrupts the activity of a voltage-gated calcium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:20920515]","metadata":null},{"id":"4d4271031bbe49728d7a45e0fa53dd97","type":"GO_TERM","name":"venom-mediated inhibition of voltage-gated potassium channel activity","canonical_id":"go:GO:0044562","description":"\"A process in which an organism inhibits or disrupts the activity of a  voltage-gated potassium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"796c80af14624caa842bbc6f06e5a430","type":"GO_TERM","name":"venom-mediated inhibition of voltage-gated sodium channel activity","canonical_id":"go:GO:0044493","description":"\"A process in which an organism inhibits or disrupts the activity of a voltage-gated sodium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:21781281]","metadata":null},{"id":"26563437c07b45748fd286149c2f0da6","type":"GO_TERM","name":"venom-mediated leukocyte migration","canonical_id":"go:GO:7770075","description":"\"A venom-mediated activation of inflammatory response that triggers leukocyte migration in another organism.\" [PMID:19000915, PMID:26072684, PMID:32024243]","metadata":null},{"id":"0b609da663bf4383be1dcd15d08606ba","type":"GO_TERM","name":"venom-mediated mast cell degranulation","canonical_id":"go:GO:0044480","description":"\"A process in which an organism initiates, promotes, or enhances mast cell degranulation in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:21549739]","metadata":null},{"id":"ce6c7f6ee8c64f2db91f05bba834697b","type":"GO_TERM","name":"venom-mediated muscle damage in another organism","canonical_id":"go:GO:0044521","description":"\"A process that begins with venom being forced into an organism by the bite or sting of another organism, and ends with resultant muscle damage in the bitten organism.\" [GOC:fj, GOC:jl, PMID:10620318, PMID:21150580]","metadata":null},{"id":"2d87cde3d35b43b699a7142daf29be78","type":"GO_TERM","name":"venom-mediated myocyte killing in another organism","canonical_id":"go:GO:0044522","description":"\"A process that begins with venom being forced into an organism by the bite or sting of another organism, killing heart myocytes and ultimately resulting in muscle damage in the bitten organism.\" [GOC:fj, GOC:jl, PMID:10620318, PMID:21150580]","metadata":null},{"id":"e62a251b2f194fc4a88cca989b51edfb","type":"GO_TERM","name":"venom-mediated paralysis","canonical_id":"go:GO:0044616","description":"\"A process in which an organism induces paralysis in another organism via the action of a venom. Paralysis is the loss of the ability to voluntarily control muscles. This can occur by blocking nerve signals at the neuromuscular junction or by directly interfering with muscle contraction.\" [PMID:28422078, PMID:36668869]","metadata":null},{"id":"83ddfce21fcf4bd6bffb1c0696747ff6","type":"GO_TERM","name":"venom-mediated perturbation of G protein-coupled receptor signaling pathway","canonical_id":"go:GO:0044513","description":"\"A process in which an organism alters or subverts a G protein-coupled receptor signaling pathway in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:8405712]","metadata":null},{"id":"43db24e0eb714a7393f4e3879da9fb2e","type":"GO_TERM","name":"venom-mediated perturbation of biological process","canonical_id":"go:GO:0035738","description":"\"A process by which an organism alters or subverts a biological process in another organism via the action of a venom. Venoms are injected into the prey by a bite or a sting. Venoms cause their biological effects via the many toxins that they contain; some venoms are complex mixtures of toxins of differing types. Venoms can serve as predation mechanisms or defense responses.\" [Wikipedia:Venom]","metadata":null},{"id":"57099227c3604c44a26a1ed1f0670988","type":"GO_TERM","name":"venom-mediated perturbation of blood circulation","canonical_id":"go:GO:0140134","description":"\"A process in which an organism alters or subverts the circulation of blood in another organism via the action of a venom.\" [PMID:31370142]","metadata":null},{"id":"6eedfd4e4e244039b81a7255cd34bf41","type":"GO_TERM","name":"venom-mediated perturbation of blood coagulation","canonical_id":"go:GO:0044468","description":"\"A process in which an organism alters or subverts blood coagulation in another organism via the action of a venom.\" [GOC:jl]","metadata":null},{"id":"635cb71519a04c18afb08e9491069c45","type":"GO_TERM","name":"venom-mediated perturbation of calcium channel activity","canonical_id":"go:GO:0044472","description":"\"A process in which an organism alters or subverts the activity of a calcium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:20920515]","metadata":null},{"id":"1b7e4070c3c2456d81d0bb6dcf232a52","type":"GO_TERM","name":"venom-mediated perturbation of cholinergic synaptic transmission","canonical_id":"go:GO:0140452","description":"\"A process in which an organism alters or subverts the synaptic transmission mediated by the neurotransmitter acetylcholine in another organism via the action of a venom.\" [PMID:11091135, PMID:28623170, PMID:34204855]","metadata":null},{"id":"c053be26b9114c3c9fe00e25607c51c8","type":"GO_TERM","name":"venom-mediated perturbation of complement activation","canonical_id":"go:GO:0044646","description":"\"A process in which an organism activates or inhibits the complement system in another organism via the action of a venom.\" [GOC:fj, PMID:20417224, PMID:20837040, PMID:27846429, PMID:35622591]","metadata":null},{"id":"be20eaf9a0354c89a4ad596debc6de66","type":"GO_TERM","name":"venom-mediated perturbation of heart contraction","canonical_id":"go:GO:0140342","description":"\"A process in which an organism alters or subverts the heart contractility in another organism via the action of a venom.\" [PMID:38167790]","metadata":null},{"id":"84a70dfc80ef4f5fbe323080369b14ec","type":"GO_TERM","name":"venom-mediated perturbation of hemostasis","canonical_id":"go:GO:0044483","description":"\"A process in which an organism alters or subverts hemostasis in another organism via the action of a venom. Hemostasis is the mechanism that leads to cessation of bleeding from a blood vessel.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"8c53ad89a6b54359bc585d50842391ca","type":"GO_TERM","name":"venom-mediated perturbation of immune response","canonical_id":"go:GO:0140428","description":"\"A process in which an organism induces an immune response in another organism via the action of a venom.\" [PMID:35622591]","metadata":null},{"id":"21095ee1116e47c7bea57d64df2941d1","type":"GO_TERM","name":"venom-mediated perturbation of ion channel activity","canonical_id":"go:GO:0044560","description":"\"A process in which an organism alters or subverts the activity of an ion channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"ecc275cda7854b93878944718129a69a","type":"GO_TERM","name":"venom-mediated perturbation of mast cell degranulation","canonical_id":"go:GO:0044479","description":"\"A process in which an organism alters or subverts mast cell degranulation in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:21549739]","metadata":null},{"id":"b92fe663cd534c858b2e95214fd13aaa","type":"GO_TERM","name":"venom-mediated perturbation of muscle system process","canonical_id":"go:GO:0140137","description":"\"A process in which an organism alters or subverts a muscular process in another organism via the action of a venom.\" [GOC:pg]","metadata":null},{"id":"77a960d4d0df4dfab45fa5de8e7193c3","type":"GO_TERM","name":"venom-mediated perturbation of nervous system process","canonical_id":"go:GO:0140136","description":"\"A process in which an organism alters or subverts a nervous system process in another organism via the action of a venom.\" [GOC:pg]","metadata":null},{"id":"b5cb09a2eb874ba5b798e29b46dad3a2","type":"GO_TERM","name":"venom-mediated perturbation of pH-gated ion channel activity","canonical_id":"go:GO:0044733","description":"\"A process in which an organism alters or subverts the activity of a pH-gated (also known as acid-sensing ion channel (ASIC)) in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:23034652]","metadata":null},{"id":"722509675e8c4ef18c015fa3a1075062","type":"GO_TERM","name":"venom-mediated perturbation of signal transduction","canonical_id":"go:GO:0044509","description":"\"A process in which an organism alters or subverts a signal transduction pathway in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:8405712]","metadata":null},{"id":"3aea1c0d5701415896f86a71ce8ec23c","type":"GO_TERM","name":"venom-mediated perturbation of transmission of nerve impulse","canonical_id":"go:GO:0044487","description":"\"A process in which an organism alters or subverts the transmission of a nerve impulse in another organism via the action of a venom.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"f4172faf7e7941e989198ebb0e75c3ae","type":"GO_TERM","name":"venom-mediated perturbation of voltage-gated potassium channel activity","canonical_id":"go:GO:0044559","description":"\"A process in which an organism alters or subverts the activity of a voltage-gated potassium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"1f2c18881fba40df86c5f28aff63177b","type":"GO_TERM","name":"venom-mediated perturbation of voltage-gated sodium channel activity","canonical_id":"go:GO:0044492","description":"\"A process in which an organism alters or subverts the activity of a voltage-gated sodium channel in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:21781281]","metadata":null},{"id":"c94ed3d7225f4d36b2dd3fd9cfcaea6b","type":"GO_TERM","name":"venom-mediated plasminogen activation","canonical_id":"go:GO:0044544","description":"\"A process in which an organism initiates, promotes, or enhances the activation of plasminogen into plasmin in another organism via the action of a venom. This process includes cleavage at an internal Arg-Val site to form an N-terminal A-chain and C-terminal B-chain held together by a disulfide bond, and can include further proteolytic cleavage events to remove the preactivation peptide.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"c9da49f36b65496da54cf32b69c52903","type":"GO_TERM","name":"venom-mediated platelet aggregation","canonical_id":"go:GO:0044478","description":"\"A process in which an organism initiates, promotes, or enhances platelet aggregation in another organism via the action of a venom.\" [GOC:fj, GOC:jl]","metadata":null},{"id":"fcbf4f6b7a624ec0b24585bf32d11997","type":"GO_TERM","name":"venom-mediated pore formation in membrane of another organism","canonical_id":"go:GO:0044471","description":"\"A process that begins with venom being forced into an organism by the bite or sting of another organism, and ends with the aggregation, arrangement and bonding together of a set of components to form a pore complex in a membrane of the bitten organism.\" [GOC:fj, GOC:jl, PMID:21549739]","metadata":null},{"id":"92160f6de98e4a678f164c3fb8c50e12","type":"GO_TERM","name":"venom-mediated reduction of heart rate","canonical_id":"go:GO:0044556","description":"\"A process in which an organism slows down the heart rate in another organism via the action of a venom.\" [GOC:ecd, GOC:jl, PMID:20923766, PMID:31370142]","metadata":null},{"id":"64cc896071cf4cf59f42ac1889b82d00","type":"GO_TERM","name":"venom-mediated release of inflammatory mediator","canonical_id":"go:GO:7770076","description":"\"A venom-mediated activation of inflammatory response that triggers release of an inflammatory mediator in another organism. Inflammatory mediators include cytokines or interleukins.\" [PMID:26072684, PMID:32024243]","metadata":null},{"id":"9b052f7705084fd9acce618a36fd308d","type":"GO_TERM","name":"venom-mediated smooth muscle relaxation","canonical_id":"go:GO:0044617","description":"\"A process in which an organism initiates, promotes, or enhances the relaxation of smooth muscle in another organism via the action of a venom.\" [GOC:jl]","metadata":null},{"id":"144de939de6e41888b1e52b3a05deba9","type":"GO_TERM","name":"venom-mediated suppression of blood coagulation","canonical_id":"go:GO:0044470","description":"\"A process in which an organism inhibits or disrupts blood coagulation in another organism via the action of a venom.\" [GOC:jl]","metadata":null},{"id":"e1d92fb321bf4ee983c36befc57b1b77","type":"GO_TERM","name":"venom-mediated suppression of blood coagulation, intrinsic pathway","canonical_id":"go:GO:0140184","description":"\"A process in which an organism inhibits or disrupts blood coagulation in another organism by suppression of the intrinsic pathway via the action of a venom. A common mechanism is the blocking the activity of host coagulation Factor XIIa (F12).\" [PMID:25724270]","metadata":null},{"id":"a2b44f7301de4e09ac25fdc5bcdd443f","type":"GO_TERM","name":"venom-mediated suppression of bradykinin-dependent vasodilation","canonical_id":"go:GO:0140163","description":"\"A process in which an organism inhibits or disrupts vasodilation via the action of a venom that suppresses bradykinin-dependent signaling.\" [PMID:21889567, PMID:31370142]","metadata":null},{"id":"c639355030fc446cb60dc41afc23710f","type":"GO_TERM","name":"venom-mediated suppression of fibrinolysis","canonical_id":"go:GO:0140099","description":"\"A process in which an organism inhibits or disrupts fibrinolysis in another organism via the action of a venom. Fibrinolysis is the solubilization of fibrin in the bloodstream. Anti-fibrinolytic proteins reduce bleeding at the bite or sting site of the prey.\" [PMID:19236611, PMID:22359676, PMID:27208884, PMID:35716829]","metadata":null},{"id":"45c2bfd956a74fa4b26b2d5922aa7e18","type":"GO_TERM","name":"venom-mediated suppression of platelet aggregation","canonical_id":"go:GO:0044477","description":"\"A process in which an organism inhibits or disrupts platelet aggregation in another organism via the action of a venom.\" [GOC:fj, PMID:28435120, PMID:37818211]","metadata":null},{"id":"cf21a3a0989a403ea0da3b9250c49257","type":"GO_TERM","name":"venom-mediated suppression of sensory perception of pain","canonical_id":"go:GO:0044741","description":"\"A process in which an organism inhibits or disrupts sensory perception of pain in another organism via the action of a venom.\" [GOC:fj, GOC:jl, PMID:23034652]","metadata":null},{"id":"b325f9614d9e4d19a2b75e3c116ae6db","type":"GO_TERM","name":"venom-mediated vasoconstriction","canonical_id":"go:GO:0044499","description":"\"A process in which an organism initiates, promotes, or enhances the narrowing (constriction) of blood vessels by small muscles in their walls in another organism via the action of a venom, concomittantly increasing blood pressure in the bitten/stung organism.\" [GOC:fj, PMID:19837656]","metadata":null},{"id":"8ed902c2a984417f92833560f28d49d7","type":"GO_TERM","name":"venom-mediated vasoconstriction via activation of endothelin receptor signaling pathway","canonical_id":"go:GO:0140183","description":"\"A process in which an organism promotes the narrowing (constriction) of blood vessels, by inhibiting the widening (dilation) of blood vessels in another organism via the action of a venom that activates endothelin receptor signaling pathway, concomittantly increasing blood pressure in the bitten/stung organism.\" [PMID:16277978]","metadata":null},{"id":"be335db6c39644dfb9c81783cde10e84","type":"GO_TERM","name":"venom-mediated vasodilation","canonical_id":"go:GO:0044551","description":"\"A process in which an organism initiates, promotes, or enhances the widening of blood vessels by small muscles in their walls in another organism via the action of a venom, concomittantly reducing blood pressure in the bitten/stung organism.\" [GOC:ecd, GOC:jl, PMID:21050868]","metadata":null},{"id":"4a325a33fb534e259248e990a19ade7d","type":"GO_TERM","name":"venom-mediated vasodilation by activation of bradykinin receptor signaling pathway","canonical_id":"go:GO:0140162","description":"\"A process in which an organism initiates, promotes, or enhances vasodilation via the action of a venom that activates bradykinin-dependent signaling, concomittantly reducing blood pressure in the bitten/stung organism. This can take place via several mechanisms that affect endogenous bradykinin: either increasing its release by kallikrein-like proteases, increasing bradykinin action by potentiation, or inhibiting bradykinin degradation.\" [PMID:31370142]","metadata":null},{"id":"fea133ef83f14c83b3f0936ec73abecb","type":"GO_TERM","name":"venom-mediated vasodilation by activation of nitric oxide-cGMP-mediated signaling","canonical_id":"go:GO:0140165","description":"\"A process in which an organism initiates, promotes, or enhances vasodilation via the action of a venom that activates nitric oxide-cGMP-mediated signaling, concomittantly reducing blood pressure in the bitten/stung organism.\" [PMID:10512636]","metadata":null},{"id":"7fb30938d2b646faaa0d3a3d4935bc16","type":"GO_TERM","name":"venom-mediated vasodilation via suppression of angiotensin maturation","canonical_id":"go:GO:0140166","description":"\"A process in which an organism initiates, promotes, or enhances vasodilation via the action of a venom that prevents angiotensin maturation, concomittantly reducing blood pressure in the bitten/stung organism.\" [PMID:31370142]","metadata":null},{"id":"48de5638d5714939badb42064ca284c3","type":"GO_TERM","name":"venous blood vessel development","canonical_id":"go:GO:0060841","description":"\"The progression of the venous blood vessel over time from its initial formation to the mature structure. Venous blood vessels carry blood back to the heart after the capillary bed.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"7ffe8bc26f1e40ab9da5400649ac64a9","type":"GO_TERM","name":"venous blood vessel morphogenesis","canonical_id":"go:GO:0048845","description":"\"The process in which the anatomical structures of venous blood vessels are generated and organized. Veins are blood vessels that transport blood from the body and its organs to the heart.\" [GOC:dsf, PMID:16740480]","metadata":null},{"id":"5b2222b0dc424c08ae0c221d15d9c641","type":"GO_TERM","name":"venous endothelial cell differentiation","canonical_id":"go:GO:0060843","description":"\"The process in which a relatively unspecialized endothelial cell acquires specialized features of a venous endothelial cell, a thin flattened cell that lines the inside surfaces of veins.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"cf02bd8dca0b469598e979afaa4baf60","type":"GO_TERM","name":"venous endothelial cell fate commitment","canonical_id":"go:GO:0060845","description":"\"The commitment of a cell to a venous endothelial cell fate and its capacity to differentiate into an venous endothelial cell.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"9520003dc21548acba477bdb2f242590","type":"GO_TERM","name":"venous endothelial cell migration involved in lymph vessel development","canonical_id":"go:GO:0060855","description":"\"The orderly movement of venous endothelial cells out of the veins giving rise to the precursors of lymphatic endothelial cells.\" [GOC:dph, GOC:sdb_2009, GOC:tb]","metadata":null},{"id":"3869a41f7a384aaba0a8ecc01c4b10b3","type":"DISEASE","name":"venous thromboembolism","canonical_id":"mondo:0005399","description":null,"metadata":null},{"id":"22c5985db19044c4b79e20d83d1be0f7","type":"GO_TERM","name":"ventral aorta development","canonical_id":"go:GO:0035908","description":"\"The progression of the ventral aorta over time, from its initial formation to the mature structure. The ventral aorta is a blood vessel in a single-pass circulatory system that carries de-oxygenated blood from the heart to the gills. In a single-pass circulatory system blood passes once through the heart to supply the body once.\" [GOC:bf, GOC:dgh, UBERON:0003085, Wikipedia:Aorta, ZFA:0000604]","metadata":null},{"id":"d73ce6f833ba490ab98cfe60ed6a833d","type":"GO_TERM","name":"ventral aorta morphogenesis","canonical_id":"go:GO:0035913","description":"\"The process in which the anatomical structures of the ventral aorta are generated and organized. The ventral aorta is a blood vessel in a single-pass circulatory system that carries de-oxygenated blood from the heart to the gills. In a single-pass circulatory system blood passes once through the heart to supply the body once.\" [GOC:bf, GOC:dgh, UBERON:0003085, Wikipedia:Aorta, ZFA:0000604]","metadata":null},{"id":"d783907a23fd48f1bcb2f5bdc39c29cc","type":"GO_TERM","name":"ventral cochlear nucleus development","canonical_id":"go:GO:0021749","description":"\"The process whose specific outcome is the progression of the ventral cochlear nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"1c09c561b36b434eacafa5dccf13606d","type":"GO_TERM","name":"ventral cord development","canonical_id":"go:GO:0007419","description":"\"The process whose specific outcome is the progression of the ventral cord over time, from its formation to the mature structure. The ventral cord is one of the distinguishing traits of the central nervous system of all arthropods (such as insects, crustaceans and arachnids) as well as many other invertebrates, such as the annelid worms.\" [GOC:bf, GOC:curators, PMID:30826502]","metadata":null},{"id":"1e376a37a25d4a34a3c86fdd9818099b","type":"GO_TERM","name":"ventral disc","canonical_id":"go:GO:0097597","description":"\"Specialized organelle found in Giardia species (trophozoite stage) and characterized by a spiral array of microtubules and microtubule-associated structures including dorsal microribbons and crossbridges. The edge of the ventral disc narrows into a lateral crest. The ventral disk mediates mechanical attachment of the trophozoite to the host's intestinal wall, and contains the contractile proteins actinin, alpha-actinin, myosin, and tropomyosin working towards contraction of the disk involved in adherence.\" [GOC:giardia, ISBN:9780124260207, PMID:11432808, PMID:4777416, PMID:5961344]","metadata":null},{"id":"308e1d7858694afcaaedc80097e9ad50","type":"GO_TERM","name":"ventral disc crossbridge","canonical_id":"go:GO:0097595","description":"\"Structure horizontally linking adjacent microribbons of the ventral disc in Giardia species (trophozoite stage). The composition of crossbridges is not fully known yet.\" [GOC:giardia]","metadata":null},{"id":"37a49f6ef35744fb905a2369c86110dd","type":"GO_TERM","name":"ventral disc dorsal microribbon","canonical_id":"go:GO:0097594","description":"\"Trilaminar structure extending perpendicularly into the cytoplasm along the length of ventral disc microtubules in Giardia species (trophozoite stage). Constituents of dorsal microribbons (also called dorsal ribbons or microribbons) include alpha-coiled-helix proteins approximately 29 to 38 kDa in size. These proteins line the edges of the microribbons but are not found in microtubules. Tubulins are not found in microribbons.\" [GOC:giardia, PMID:11432808]","metadata":null},{"id":"d166eed72713467a92bba86916f5df63","type":"GO_TERM","name":"ventral disc lateral crest","canonical_id":"go:GO:0097591","description":"\"Fibrillar repetitive structure surrounding the ventral disc edge in Giardia species (trophozoite stage). The composition of the lateral crest is not fully known yet.\" [GOC:giardia]","metadata":null},{"id":"701df4716f4f4a399d6ee3973a30e17d","type":"GO_TERM","name":"ventral disc microtubule array","canonical_id":"go:GO:0097593","description":"\"A part of the ventral disc of Giardia species (trophozoite stage) consisting of a spiral array of microtubules linked to the ventral membrane. These microtubules form the base of the ventral disc dorsal microribbons that extend nearly perpendicular from the membrane.\" [GOC:giardia]","metadata":null},{"id":"1e519c7f440e40bebd01ac772ca812a1","type":"GO_TERM","name":"ventral disc overlap zone","canonical_id":"go:GO:0097592","description":"\"A region of the ventral disc of Giardia species (trophozoite stage) where two portions of the same array of microtubules overlap (the microtubule array makes a complete circle and overlaps on itself).\" [GOC:giardia]","metadata":null},{"id":"dfeeff31319d4b408b9e08f402471d7f","type":"GO_TERM","name":"ventral disc supernumerary microtubule array","canonical_id":"go:GO:0097596","description":"\"A partial left-handed spiral array of microtubules that lies generally dorsal to the main ventral disc microtubule array in Giardia species (trophozoite stage).\" [GOC:giardia, ISBN:9780124260207]","metadata":null},{"id":"245d03eb5622407cbdebfbe812bbc9d6","type":"GO_TERM","name":"ventral furrow formation","canonical_id":"go:GO:0007370","description":"\"Formation of a ventral indentation (furrow) from the blastoderm epithelium, which is internalized to form a tube in the interior of the embryo, marking the start of gastrulation.\" [ISBN:0879694238]","metadata":null},{"id":"c86b0f65d80044a9873589ccc1c8c738","type":"GO_TERM","name":"ventral midline determination","canonical_id":"go:GO:0007371","description":"\"The regionalization process in which the area where the ventral midline will form is specified.\" [GOC:bf, GOC:isa_complete, GOC:vk]","metadata":null},{"id":"57cabcbe232d4a0cb80415871222dc69","type":"GO_TERM","name":"ventral midline development","canonical_id":"go:GO:0007418","description":"\"The process whose specific outcome is the progression of the ventral midline over time, from its formation to the mature structure. In protostomes (such as insects, snails and worms) as well as deuterostomes (vertebrates), the midline is an embryonic region that functions in patterning of the adjacent nervous tissue. The ventral midline in insects is a cell population extending along the ventral surface of the embryo and is the region from which cells detach to form the ventrally located nerve cords. In vertebrates, the midline is originally located dorsally. During development, it folds inwards and becomes the ventral part of the dorsally located neural tube and is then called the ventral midline, or floor plate.\" [GOC:bf, GOC:curators, PMID:12075342]","metadata":null},{"id":"3fc988b1f621414a8aa1a4a49c5e6054","type":"GO_TERM","name":"ventral spinal cord development","canonical_id":"go:GO:0021517","description":"\"The process whose specific outcome is the progression of the ventral region of the spinal cord over time, from its formation to the mature structure. The neurons of the ventral region of the mature spinal cord participate in motor output.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"545a04a34ae44ab5a8fb4c7f72bb422b","type":"GO_TERM","name":"ventral spinal cord interneuron differentiation","canonical_id":"go:GO:0021514","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of ventral spinal cord interneurons. Ventral spinal cord interneurons are cells located in the ventral portion of the spinal cord that transmit signals between sensory and motor neurons and are required for reflexive responses. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"de78e91b79b84b7d954e102f77edeed4","type":"GO_TERM","name":"ventral spinal cord interneuron fate commitment","canonical_id":"go:GO:0060579","description":"\"The process in which the developmental fate of a cell becomes restricted such that it will develop into a ventral spinal cord interneuron. Ventral spinal cord interneurons are cells located in the ventral portion of the spinal cord that transmit signals between sensory and motor neurons and are required for reflexive responses.\" [GOC:dph]","metadata":null},{"id":"66d49af9e6e84d0a9789625f1796fe93","type":"GO_TERM","name":"ventral spinal cord interneuron fate determination","canonical_id":"go:GO:0060580","description":"\"The process in which a cell becomes capable of differentiating autonomously into a ventral spinal cord interneuron regardless of its environment; upon determination, the cell fate cannot be reversed. Ventral spinal cord interneurons are cells located in the ventral portion of the spinal cord that transmit signals between sensory and motor neurons and are required for reflexive responses.\" [GOC:dph]","metadata":null},{"id":"026c18c225464c80bf55d8c95b82ac38","type":"GO_TERM","name":"ventral spinal cord interneuron specification","canonical_id":"go:GO:0021521","description":"\"The process in which a cell becomes capable of differentiating autonomously into a ventral spinal cord interneuron in an environment that is neutral with respect to the developmental pathway.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2cdbc0d998434dc0914a2222d3a85f19","type":"GO_TERM","name":"ventral surface of cell","canonical_id":"go:GO:0061835","description":"\"The surface of a migrating cell that is in contact with the substratum or cell layer.\" [PMID:11598004]","metadata":null},{"id":"fde670564a324685b9d37a798a951f23","type":"GO_TERM","name":"ventral tegmental area development","canonical_id":"go:GO:1904866","description":"\"The process whose specific outcome is the progression of a ventral tegmental area (VTA) over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:26548362]","metadata":null},{"id":"2a465c50e88c4c4ab8c6dc25b9e43713","type":"GO_TERM","name":"ventral trunk neural crest cell migration","canonical_id":"go:GO:0036486","description":"\"The movement of trunk neural crest cells from the neural tube, travelling ventrally through the anterior half of each sclerotome. Trunk neural crest cells that remain in the sclerotome form the dorsal root ganglia containing the sensory neurons. Trunk neural crest cells that continue more ventrally form the sympathetic ganglia, the adrenal medulla, and the nerve clusters surrounding the aorta.\" [GOC:bf, GOC:mat, GOC:PARL, PMID:16319111, PMID:19386662]","metadata":null},{"id":"bc5c28755a324cfba34b5e69a3e86b85","type":"GO_TERM","name":"ventricular cardiac muscle cell action potential","canonical_id":"go:GO:0086005","description":"\"An action potential that occurs in a ventricular cardiac muscle cell.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"c17c135bb12b4f709bd5ab010573dec8","type":"GO_TERM","name":"ventricular cardiac muscle cell development","canonical_id":"go:GO:0055015","description":"\"The process whose specific outcome is the progression of a ventricular cardiac muscle cell over time, from its formation to the mature state. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. The ventricle is the part of the heart that pumps blood out of the organ.\" [GOC:devbiol, GOC:mtg_muscle]","metadata":null},{"id":"7b08f86a07a347789c04c229cf1074fc","type":"GO_TERM","name":"ventricular cardiac muscle cell differentiation","canonical_id":"go:GO:0055012","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a ventricular cardiac muscle cell. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. The ventricle is the part of the heart that pumps blood out of the organ.\" [GOC:devbiol, GOC:mtg_heart]","metadata":null},{"id":"e4713f97571c4d7ea9d08ad3b8654259","type":"GO_TERM","name":"ventricular cardiac muscle cell fate commitment","canonical_id":"go:GO:0060925","description":"\"The commitment of cells to ventricular cardiac muscle cell fates and their capacity to differentiate into cardiac muscle cells of the ventricle. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.\" [GOC:mtg_heart]","metadata":null},{"id":"b4298c455b0d4c51a82552c82deb0130","type":"GO_TERM","name":"ventricular cardiac muscle cell membrane repolarization","canonical_id":"go:GO:0099625","description":"\"The process in which ions are transported across the plasma membrane of a ventricular cardiac muscle cell such that the membrane potential changes in the repolarizing direction, toward the steady state potential. For example, the repolarization during an action potential is from a positive membrane potential towards a negative resting potential.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"15202edb91914178be6e17cabdeacbf8","type":"GO_TERM","name":"ventricular cardiac muscle tissue development","canonical_id":"go:GO:0003229","description":"\"The process whose specific outcome is the progression of ventricular cardiac muscle over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"de73f6b706a14e84962461ebc5a0f49f","type":"GO_TERM","name":"ventricular cardiac muscle tissue morphogenesis","canonical_id":"go:GO:0055010","description":"\"The process in which the anatomical structures of cardiac ventricle muscle is generated and organized.\" [GOC:devbiol]","metadata":null},{"id":"c1da015764d3430faf2e8a52a07d1ab4","type":"GO_TERM","name":"ventricular cardiac myofibril assembly","canonical_id":"go:GO:0055005","description":"\"The process whose specific outcome is the progression of the ventricular cardiac myofibril over time, from its formation to the mature structure. A cardiac myofibril is a myofibril specific to cardiac muscle cells.\" [GOC:devbiol]","metadata":null},{"id":"d7d801fae29346a88e284b3e5a37b493","type":"GO_TERM","name":"ventricular compact myocardium morphogenesis","canonical_id":"go:GO:0003223","description":"\"The process in which the anatomical structures of the compact cardiac ventricle muscle are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"604ee867845d4033bde08c30d7d4a565","type":"DISEASE","name":"ventricular fibrillation","canonical_id":"mondo:0000190","description":null,"metadata":null},{"id":"6af1b59b71e74142ade713fd5e045897","type":"DISEASE","name":"ventricular fibrillation, paroxysmal familial, type 1","canonical_id":"mondo:0011376","description":null,"metadata":null},{"id":"594ee0f699724930915a031a744f5d79","type":"GO_TERM","name":"ventricular septum development","canonical_id":"go:GO:0003281","description":"\"The progression of the ventricular septum over time from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"a3d003003176433990bc2fd6631839bc","type":"GO_TERM","name":"ventricular septum intermedium development","canonical_id":"go:GO:0003282","description":"\"The progression of the ventricular septum intermedium over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"c927854ce4aa4023953404bf556d970f","type":"GO_TERM","name":"ventricular septum intermedium morphogenesis","canonical_id":"go:GO:0003288","description":"\"The developmental process in which a ventricular septum intermedium is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"c0275b94e8a34072afd6fbc9cf7944c2","type":"GO_TERM","name":"ventricular septum morphogenesis","canonical_id":"go:GO:0060412","description":"\"The developmental process in which a ventricular septum is generated and organized. A ventricular septum is an anatomical structure that separates the lower chambers (ventricles) of the heart from one another.\" [GOC:dph]","metadata":null},{"id":"aa9d9e99f4084163b71021ac7be9c4e1","type":"GO_TERM","name":"ventricular system development","canonical_id":"go:GO:0021591","description":"\"The process whose specific outcome is the progression of the brain ventricular system over time, from its formation to the mature structure. The brain ventricular system consists of four communicating cavities within the brain that are continuous with the central canal of the spinal cord. These cavities include two lateral ventricles, the third ventricle and the fourth ventricle. Cerebrospinal fluid fills the ventricles and is produced by the choroid plexus.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"6e7832a7f83c4122915c3e92013cff76","type":"DISEASE","name":"ventricular tachycardia","canonical_id":"mondo:0005477","description":null,"metadata":null},{"id":"9a5f096a094442c08f768da1bd5ca488","type":"GO_TERM","name":"ventricular trabecula myocardium morphogenesis","canonical_id":"go:GO:0003222","description":"\"The process in which the anatomical structures of the trabecular cardiac ventricle muscle are generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"989aa0f6cdab4c51acd6be1ab07a08f8","type":"GO_TERM","name":"ventricular zone cell fate commitment","canonical_id":"go:GO:0021900","description":"\"The commitment of neuroblast to become a basal progenitor cell. Basal progenitor cells are neuronal precursor cells that are committed to becoming neurons.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:16226447]","metadata":null},{"id":"56a19db7704542a4b0617c08f4afc694","type":"GO_TERM","name":"ventricular zone neuroblast division","canonical_id":"go:GO:0021847","description":"\"The proliferation of neuroblasts in the ventricular zone of the cerebral cortex. The neuronal progenitors of these cells will migrate radially.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695]","metadata":null},{"id":"7b32154b7e124a6c84d07e8a4b37b89a","type":"GO_TERM","name":"ventriculo bulbo valve development","canonical_id":"go:GO:0003173","description":"\"The progression of the ventriculo bulbo valve over time, from its formation to the mature structure.\" [GOC:mtg_heart]","metadata":null},{"id":"fe79530e6bd1408eb1ad5eaf577d0701","type":"GO_TERM","name":"ventriculo bulbo valve formation","canonical_id":"go:GO:0003196","description":"\"The developmental process pertaining to the initial formation of the ventriculo bulbo valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.\" [GOC:mtg_heart]","metadata":null},{"id":"dd125bca89d0451c90c9a42f8810a071","type":"GO_TERM","name":"ventriculo bulbo valve morphogenesis","canonical_id":"go:GO:0003187","description":"\"The process in which the structure of the ventriculo bulbo valve is generated and organized.\" [GOC:mtg_heart]","metadata":null},{"id":"b352861ad4b64cefbbeade8253e31637","type":"DRUG","name":"verapamil","canonical_id":"gtopdb:2406","description":null,"metadata":null},{"id":"42711c2efc4d47de8d204d896912538a","type":"DRUG","name":"verapamil","canonical_id":"mesh:D014700","description":null,"metadata":null},{"id":"c2fc331a29204b54a10c4310e62f18e8","type":"GO_TERM","name":"verbascose biosynthetic process","canonical_id":"go:GO:0033534","description":"\"The chemical reactions and pathways resulting in the formation of verbascose, the pentasaccharide beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside.\" [GOC:mah]","metadata":null},{"id":"535f9d363ca1412ead32fbc7a5b0f93b","type":"GO_TERM","name":"verbascose galactinol:ajugose galactosyltransferase activity","canonical_id":"go:GO:0102832","description":"\"Catalysis of the reaction: verbascose + alpha-D-galactosyl-(1->3)-1D-myo-inositol = ajugose + myo-inositol.\" [GOC:pz, PMID:11675396]","metadata":null},{"id":"7a2219f93c3144b08fc636a3c6dad69a","type":"GO_TERM","name":"verbascose synthase activity","canonical_id":"go:GO:0102830","description":"\"Catalysis of the reaction: 2 stachyose = verbascose + raffinose.\" [GOC:pz, PMID:12060258]","metadata":null},{"id":"39d70c596d574faf9af9d4076e889d88","type":"GO_TERM","name":"vernalization response","canonical_id":"go:GO:0010048","description":"\"The process of thermal induction in plants in which flowering is promoted by exposure to low temperatures.\" [GOC:tair_curators, ISBN:0521591392]","metadata":null},{"id":"981cc4ef1ed249a7860a2be3417fc8b1","type":"GO_TERM","name":"verruculogen biosynthetic process","canonical_id":"go:GO:1902181","description":"\"The chemical reactions and pathways resulting in the formation of verruculogen.\" [GOC:di, GOC:TermGenie, PMID:23649274]","metadata":null},{"id":"f1be9c23abda45e687f343ae161e3b89","type":"GO_TERM","name":"versatile peroxidase activity","canonical_id":"go:GO:0052750","description":"\"Catalysis of the reaction: reactive black 5 + H2O2 = oxidized reactive black 5 + 2 H2O.\" [RHEA:22396]","metadata":null},{"id":"5373acb6ef9c4fa6b245260297d7a940","type":"GO_TERM","name":"versicolorin B desaturase activity","canonical_id":"go:GO:0140398","description":"\"Catalyzes the reaction: versicolorin B + NADPH + O2 = versicolorin A + NADP+ + 2 H2O. Uses heme-thiolate as a co-factor. Involved in the synthesis of aflatoxins in the fungus Aspergillus parasiticus.\" [PMID:15006741, PMID:8368837]","metadata":null},{"id":"d8697ba08ba545b9a78eec6954a508aa","type":"GO_TERM","name":"versicolorin B synthase activity","canonical_id":"go:GO:0046572","description":"\"Catalysis of the reaction: (2S-3S)-versiconal hemiacetal = versicolorin B + H2O.\" [PMID:8784203, RHEA:33859]","metadata":null},{"id":"7eaa5c66248b4e23918503f12e3b7fc3","type":"GO_TERM","name":"versicolorin reductase activity","canonical_id":"go:GO:0042469","description":"\"Catalysis of the reduction of versicolorin A to sterigmatocystin.\" [PMID:1339261]","metadata":null},{"id":"062720630bf64d1ca987cd6f61f3d8f6","type":"GO_TERM","name":"versiconal hemiacetal acetate esterase activity","canonical_id":"go:GO:0140397","description":"\"Catalyzes the reactions: versiconal hemiacetal acetate + H2O = versiconal + acetate, as well as versiconol acetate + H2O = versiconol + acetate.\" [EC:3.1.1.94, PMID:15006741, PMID:15932995, PMID:8368837]","metadata":null},{"id":"e672cdee553842b2bf7b2764a0e9f21a","type":"GO_TERM","name":"versiconal hemiacetal acetate reductase activity","canonical_id":"go:GO:0102975","description":"\"Catalysis of the reaction: versiconol acetate + NADP = versiconal hemiacetal acetate + NADPH.\" [RHEA:35695]","metadata":null},{"id":"566b51b38877481e8f14fbb4a788f422","type":"GO_TERM","name":"versiconal reductase activity","canonical_id":"go:GO:0102976","description":"\"Catalysis of the reaction: (2S)-versicolorone + NADP+ = 1'-hydroxyversicolorone + H+ + NADPH.\" [RHEA:35699]","metadata":null},{"id":"7bb96e8dce07475ba352b2d00fd64b31","type":"GO_TERM","name":"vertebrate eye-specific patterning","canonical_id":"go:GO:0150064","description":"\"Early postnatal vertebrate developmental process, during which axons of retinal ganglion cells (RGCs), transmitting overlapping inputs from both eyes, segregate into distinct eye-specific non-overlapping regions in the dorsal lateral geniculate nucleus (dLGN) of the thalamus.\" [GOC:aruk, GOC:bc, PMID:16025107, PMID:22632727, PMID:29322522]","metadata":null},{"id":"e4706289a971456fb90c0b42e875e8e7","type":"GO_TERM","name":"very long-chain (3S)-3-hydroxyacyl-CoA dehydrogenase activity","canonical_id":"go:GO:0035380","description":"\"Catalysis of the reaction: (S)-3-hydroxyacyl-CoA + NAD(P)+ = 3-oxoacyl-CoA + NAD(P)H + H+, where the acyl group is a very long-chain fatty acid residue. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [RHEA:78927]","metadata":null},{"id":"bb3cecd78c29445795e8d3c5474b3f42","type":"GO_TERM","name":"very long-chain fatty acid beta-oxidation","canonical_id":"go:GO:0140493","description":"\"A fatty acid beta-oxidation pathway acting on a very long-chain fatty acid. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons. The partway stars with the conversion of an acyl-CoA to a trans-2-enoyl-CoA, catalyzed by acyl-CoA oxidase; the electrons removed by oxidation pass directly to oxygen and produce hydrogen peroxide, which is cleaved by peroxisomal catalases. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and ends when only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).\" [GOC:ha, PMID:17028011, PMID:32169171]","metadata":null},{"id":"34a91d18825b48fc87cec8c8920b8ba6","type":"GO_TERM","name":"very long-chain fatty acid biosynthetic process","canonical_id":"go:GO:0042761","description":"\"The chemical reactions and pathways resulting in the formation of a very long-chain fatty acid. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [PMID:7744868]","metadata":null},{"id":"0346b17a2db749de998c1f44fd22dfc5","type":"GO_TERM","name":"very long-chain fatty acid catabolic process","canonical_id":"go:GO:0042760","description":"\"The chemical reactions and pathways resulting in the breakdown of a very long-chain fatty acid. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [PMID:7744868]","metadata":null},{"id":"1e9ae23a826f4770a863c98f85f47fe8","type":"GO_TERM","name":"very long-chain fatty acid metabolic process","canonical_id":"go:GO:0000038","description":"\"The chemical reactions and pathways involving a very long-chain fatty acid. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [GOC:hjd]","metadata":null},{"id":"0f0c9f2a9f734aee9671fd85dd4b6c83","type":"GO_TERM","name":"very long-chain fatty acid omega-hydroxylase activity","canonical_id":"go:GO:0140692","description":"\"Catalysis of the reaction: an omega-methyl-very-long-chain fatty acid + O2 + reduced [NADPH-hemoprotein reductase] = an omega-hydroxy-very-long-chain fatty acid + H+ + H2O + oxidized [NADPH-hemoprotein reductase]. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [PMID:16547005, RHEA:67952]","metadata":null},{"id":"c86831ef28ea4bca9f7be5d481c2ad4e","type":"GO_TERM","name":"very long-chain fatty acid-CoA ligase activity","canonical_id":"go:GO:0031957","description":"\"Catalysis of the reaction: a very long-chain fatty acid + ATP + CoA = a very long-chain fatty acyl-CoA + AMP + diphosphate. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [PMID:18024425, RHEA:54536]","metadata":null},{"id":"7a419ec2df7b4d14a738bf086bb2c2a3","type":"GO_TERM","name":"very long-chain fatty acyl-CoA hydrolase activity","canonical_id":"go:GO:0052817","description":"\"Catalysis of the reaction: a very long-chain fatty acyl-CoA + H2O = a very long-chain fatty acid + CoA + H+. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [RHEA:67072]","metadata":null},{"id":"7f30c036510649ebb7410e4a26ae5867","type":"GO_TERM","name":"very long-chain fatty-acyl-CoA catabolic process","canonical_id":"go:GO:0036113","description":"\"The chemical reactions and pathways resulting in the breakdown of very long-chain fatty-acyl-CoAs, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a very long-chain fatty-acyl group. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [GOC:pm]","metadata":null},{"id":"74fff136535b4774a3aa9acac4dc3c2f","type":"GO_TERM","name":"very long-chain fatty-acyl-CoA metabolic process","canonical_id":"go:GO:0036111","description":"\"The chemical reactions and pathways involving very long-chain fatty-acyl-CoAs, any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a very long-chain fatty-acyl group. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [GOC:pm]","metadata":null},{"id":"91b62fc637284f5b8cd571b660057f30","type":"GO_TERM","name":"very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase activity","canonical_id":"go:GO:0102158","description":"\"Catalysis of the reaction: a very-long-chain (3R)-3-hydroxyacyl-CoA = H2O + a very-long-chain (2E)-enoyl-CoA. This reaction is the third (dehydration) step of the four-step fatty acid elongation cycle in the endoplasmic reticulum that extends fatty acids of C-16 or longer with an additional 2-C unit.\" [PMID:16564093, PMID:19763486, RHEA:45812]","metadata":null},{"id":"bbd09ee585e744409ee291be87c2e955","type":"GO_TERM","name":"very-long-chain 3-oxoacyl-CoA reductase activity","canonical_id":"go:GO:0141040","description":"\"Catalysis of the reaction: a very-long-chain (3R)-3-hydroxyacyl-CoA + NADP+ = a very-long-chain 3-oxoacyl-CoA + H+ + NADPH. This reaction is the second (reduction) step of the four-step fatty acid elongation cycle in the endoplasmic reticulum that extends fatty acids of C-16 or longer with an additional 2-C unit.\" [PMID:16564093, PMID:19763486, RHEA:48680]","metadata":null},{"id":"b19987c79d3849388b57e366be31516e","type":"GO_TERM","name":"very-long-chain enoyl-CoA reductase activity","canonical_id":"go:GO:0102758","description":"\"Catalysis of the reaction: a very-long-chain 2,3-saturated fatty acyl-CoA + NADP+ = a very-long-chain (2E)-enoyl-CoA + H+ + NADPH. This reaction is the fourth (reduction) step of the four-step fatty acid elongation cycle in the endoplasmic reticulum that extends fatty acids of C-16 or longer with an additional 2-C unit.\" [PMID:16564093, PMID:19763486, RHEA:14473]","metadata":null},{"id":"4cca39f5ce324cfa8ce3a299e6b83e2f","type":"GO_TERM","name":"very-long-chain fatty acyl-CoA dehydrogenase activity","canonical_id":"go:GO:0017099","description":"\"Catalysis of the reaction: a very-long-chain 2,3-saturated fatty acyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = a very-long-chain (2E)-enoyl-CoA + reduced [electron-transfer flavoprotein]. A very long-chain fatty acid has an aliphatic tail containing more than 22 carbons.\" [RHEA:19181]","metadata":null},{"id":"07ce1d9a9a864e198f1001032db11f51","type":"GO_TERM","name":"very-long-chain fatty acyl-CoA oxidase activity","canonical_id":"go:GO:0044535","description":"\"Catalysis of the reaction: a very-long-chain 2,3-saturated fatty acyl-CoA + O2 = a very-long-chain (2E)-enoyl-CoA + H2O2.\" [PMID:17458872, RHEA:78847]","metadata":null},{"id":"2e9aa6525a824605bc54123017bf33f5","type":"GO_TERM","name":"very-low-density lipoprotein particle","canonical_id":"go:GO:0034361","description":"\"A triglyceride-rich lipoprotein particle that is typically composed of APOB100, APOE and APOCs and has a density of about 1.006 g/ml and a diameter of between 20-80 nm. It is found in blood and transports endogenous products (newly synthesized cholesterol and triglycerides) from the liver.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"8b7b28f2e08f417ca1b6105f7f0337a4","type":"GO_TERM","name":"very-low-density lipoprotein particle assembly","canonical_id":"go:GO:0034379","description":"\"The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"36e1a140e9fd44bba8a4ae957459e689","type":"GO_TERM","name":"very-low-density lipoprotein particle binding","canonical_id":"go:GO:0034189","description":"\"Binding to a very-low-density lipoprotein particle, a triglyceride-rich lipoprotein particle that is typically composed of APOB100, APOE and APOCs and has a density of about 1.006 g/ml and a diameter of between 20-80 nm.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"d4ac8663948b4600af926222498485b0","type":"GO_TERM","name":"very-low-density lipoprotein particle clearance","canonical_id":"go:GO:0034447","description":"\"The process in which a very-low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.\" [GOC:BHF, GOC:rl]","metadata":null},{"id":"fa69fb649f484707a5f72e801372837f","type":"GO_TERM","name":"very-low-density lipoprotein particle receptor activity","canonical_id":"go:GO:0030229","description":"\"Combining with a very-low-density lipoprotein particle and delivering the very-low-density lipoprotein into the cell via endocytosis.\" [GOC:bf, ISBN:0198506732]","metadata":null},{"id":"9aab6c1d94024938897fd6509174725b","type":"GO_TERM","name":"very-low-density lipoprotein particle receptor binding","canonical_id":"go:GO:0070326","description":"\"Binding to a very-low-density lipoprotein receptor.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"3586561e510d4dc48074c58ac8be54f6","type":"GO_TERM","name":"very-low-density lipoprotein particle remodeling","canonical_id":"go:GO:0034372","description":"\"The acquisition, loss or modification of a protein or lipid within a very-low-density lipoprotein particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid.\" [GOC:BHF, GOC:expert_pt, GOC:mah, GOC:rl]","metadata":null},{"id":"0ad8a6917e6742bc903cb82b34045e3d","type":"GO_TERM","name":"vesicle","canonical_id":"go:GO:0031982","description":"\"Any small, fluid-filled, spherical organelle enclosed by membrane.\" [GOC:mah, GOC:pz, GOC:vesicles]","metadata":null},{"id":"1ad94454ce9241c4b3f1fe4a3afb292a","type":"GO_TERM","name":"vesicle budding from membrane","canonical_id":"go:GO:0006900","description":"\"The evagination of a membrane, resulting in formation of a vesicle.\" [GOC:jid, GOC:tb]","metadata":null},{"id":"9c533d7363ef4de7b65a178ce5bb84c7","type":"GO_TERM","name":"vesicle cargo loading","canonical_id":"go:GO:0035459","description":"\"The formation of a macromolecular complex between the coat proteins and proteins and/or lipoproteins that are going to be transported by a vesicle.\" [GOC:bf, GOC:lb]","metadata":null},{"id":"70c5a35a149c4fc7b6523ab30d683e04","type":"GO_TERM","name":"vesicle coat","canonical_id":"go:GO:0030120","description":"\"A membrane coat found on a coated vesicle.\" [GOC:mah]","metadata":null},{"id":"90f45c48c61c42cc9619738bc397eadc","type":"GO_TERM","name":"vesicle coat assembly","canonical_id":"go:GO:0006901","description":"\"A protein coat is added to the vesicle to form the proper shape of the vesicle and to target the vesicle for transport to its destination.\" [GOC:jid]","metadata":null},{"id":"94d374f02a1f4e64b82b4c28e6abc9d5","type":"GO_TERM","name":"vesicle cytoskeletal trafficking","canonical_id":"go:GO:0099518","description":"\"The directed movement of a vesicle along a cytoskeletal fiber such as a microtubule or and actin filament, mediated by motor proteins.\" [GOC:ecd, GOC:rl]","metadata":null},{"id":"7c9f9b79398e434585a2bf02dbd10f81","type":"GO_TERM","name":"vesicle docking activity","canonical_id":"go:GO:0160321","description":"\"The binding activity of a protein that directly mediates the stable attachment of a transport vesicle to a target membrane, bringing the two membranes into close apposition.\" [PMID:28237810]","metadata":null},{"id":"ff920b469da94e9e9530d38135466741","type":"GO_TERM","name":"vesicle fusion","canonical_id":"go:GO:0006906","description":"\"Fusion of the membrane of a transport vesicle with its target membrane.\" [GOC:jid]","metadata":null},{"id":"ae19ac8c717d40e3ad53f6cd452d049d","type":"GO_TERM","name":"vesicle fusion to plasma membrane","canonical_id":"go:GO:0099500","description":"\"Fusion of the membrane of a vesicle with the plasma membrane, thereby releasing its contents into the extracellular space.\" [GOC:aruk, GOC:bc, ISBN:0071120009, PMID:18618940]","metadata":null},{"id":"345ca97b18db4a988f1b83341880a7ee","type":"GO_TERM","name":"vesicle fusion with Golgi apparatus","canonical_id":"go:GO:0048280","description":"\"The joining of the lipid bilayer membrane around a vesicle to the lipid bilayer membrane around the Golgi.\" [GOC:jid]","metadata":null},{"id":"123cc4a23902481594b5d00d14dea431","type":"GO_TERM","name":"vesicle fusion with Golgi cis cisterna membrane","canonical_id":"go:GO:1990670","description":"\"The joining of the lipid bilayer membrane around a vesicle to the lipid bilayer membrane around the Golgi cis cisterna. This can involve anterograde or retrograde transport vesicles.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"fc6ec8ad2b914cfd8ca77cc8dd5ea32b","type":"GO_TERM","name":"vesicle fusion with Golgi medial cisterna membrane","canonical_id":"go:GO:1990671","description":"\"The joining of the lipid bilayer membrane around a vesicle to the lipid bilayer membrane around the Golgi medial cisterna. This can involve anterograde or retrograde transport vesicles.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"ee53b0962c1644c79d83a54b2ac2f08a","type":"GO_TERM","name":"vesicle fusion with endoplasmic reticulum","canonical_id":"go:GO:0048279","description":"\"The joining of the lipid bilayer membrane around a vesicle to the lipid bilayer membrane around the endoplasmic reticulum.\" [GOC:jid]","metadata":null},{"id":"6de38124861e4c46904e9eb5849719f6","type":"GO_TERM","name":"vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane","canonical_id":"go:GO:1990668","description":"\"The joining of the lipid bilayer membrane around a vesicle to the lipid bilayer membrane of the ERGIC. This can involve anterograde or retrograde transport vesicles.\" [GOC:bhm, PMID:16038056, PMID:24119662]","metadata":null},{"id":"b3982c3e5bcb4e31bd50f6845de2229c","type":"GO_TERM","name":"vesicle fusion with peroxisome","canonical_id":"go:GO:0019817","description":"\"The joining of the lipid bilayer membrane around a vesicle with the lipid bilayer membrane around the peroxisome.\" [GOC:jid]","metadata":null},{"id":"755573e35c9e42f4a1f48a0acc90c924","type":"GO_TERM","name":"vesicle fusion with vacuole","canonical_id":"go:GO:0051469","description":"\"The joining of the lipid bilayer membrane around a vesicle with the lipid bilayer membrane around the vacuole.\" [GOC:ai]","metadata":null},{"id":"77f9afb146114686a78781b12119a242","type":"GO_TERM","name":"vesicle fusion with vesicle","canonical_id":"go:GO:0061782","description":"\"Fusion of the membrane of a transport vesicle with a target membrane on another vesicle.\" [GOC:bf, GOC:PARL, PMID:16618809]","metadata":null},{"id":"6035eb028ca545419aeeab5c02152d67","type":"GO_TERM","name":"vesicle localization","canonical_id":"go:GO:0051648","description":"\"Any process in which a vesicle or vesicles are transported to, and/or maintained in, a specific location.\" [GOC:ai]","metadata":null},{"id":"6b58814f218e471c97d99af3abd10858","type":"GO_TERM","name":"vesicle lumen","canonical_id":"go:GO:0031983","description":"\"The volume enclosed by the membrane or protein that forms a vesicle.\" [GOC:mah, GOC:vesicles]","metadata":null},{"id":"f842c5472d334e5880a1f11769beef09","type":"GO_TERM","name":"vesicle membrane","canonical_id":"go:GO:0012506","description":"\"The lipid bilayer surrounding any membrane-bounded vesicle in the cell.\" [GOC:mah, GOC:vesicle]","metadata":null},{"id":"bf0f9614cf3744a8b3fdacca3e635c53","type":"GO_TERM","name":"vesicle membrane tethering activity","canonical_id":"go:GO:7770062","description":"\"A membrane-membrane adaptor activity that provides the first point of contact and physically bridges the vesicle membrane and its target membrane prior to vesicle docking and fusion.\" [PMID:19575650, PMID:19887069]","metadata":null},{"id":"fe7a523a92bb49698b57ee981d929dee","type":"GO_TERM","name":"vesicle organization","canonical_id":"go:GO:0016050","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a vesicle.\" [GOC:mah]","metadata":null},{"id":"680ce8decbc54b48952782ca299f1c9d","type":"GO_TERM","name":"vesicle scission","canonical_id":"go:GO:0099050","description":"\"The membrane scission process that is the final step in the formation of a vesicle, leading to separation from its parent membrane. Vesicle scission involves the constriction of a neck-forming protein complex, consisting e.g. of dynamin, around the budded membrane, leading to vesicle closure during its separation from the parent membrane.\" [PMID:21779028]","metadata":null},{"id":"2d799ad09f05483bb2ee8c75f2c23cfb","type":"GO_TERM","name":"vesicle scission involved in endocytosis","canonical_id":"go:GO:0099051","description":"\"The membrane scission process that is the final step in the formation of an endocytic vesicle: separation from the plasma membrane.\" [PMID:21779028]","metadata":null},{"id":"6ceba12a57524a84a683634cc7ef607c","type":"GO_TERM","name":"vesicle tethering complex","canonical_id":"go:GO:0099023","description":"\"Any protein complex that plays a role in vesicle tethering.\" [GOC:dos, GOC:vw, PMID:27243008]","metadata":null},{"id":"d3b6c874bd3340c89a4f5c61b65cc2c6","type":"GO_TERM","name":"vesicle transport along actin filament","canonical_id":"go:GO:0030050","description":"\"Movement of a vesicle along an actin filament, mediated by motor proteins.\" [GOC:mah]","metadata":null},{"id":"802f28f6d0de4e278ff45b1189b6dd5c","type":"GO_TERM","name":"vesicle transport along microtubule","canonical_id":"go:GO:0047496","description":"\"The directed movement of a vesicle along a microtubule, mediated by motor proteins. This process begins with the attachment of a vesicle to a microtubule, and ends when the vesicle reaches its final destination.\" [GOC:ecd, GOC:rl]","metadata":null},{"id":"addeca58f9cd4c55a6f962fa419ab411","type":"GO_TERM","name":"vesicle uncoating","canonical_id":"go:GO:0072319","description":"\"The disaggregation of a vesicle coat into its constituent components, resulting in removal of the protein coat from a transport vesicle. Uncoating occurs after vesicle budding and can be coupled to vesicle docking and fusion with the target membrane.\" [GOC:mah, PMID:20706600]","metadata":null},{"id":"2d0f03f32d054991991d2021beaf265e","type":"GO_TERM","name":"vesicle-mediated cholesterol transport","canonical_id":"go:GO:0090119","description":"\"The directed movement of cholesterol, cholest-5-en-3-beta-ol, or cholesterol-containing compounds, by membrane-bounded vesicles.\" [GOC:ascb_2009, GOC:dph, GOC:tb]","metadata":null},{"id":"d676d090edd34931bf63ecd068f3bb12","type":"GO_TERM","name":"vesicle-mediated intercellular transport","canonical_id":"go:GO:0110077","description":"\"A cellular transport process in which transported substances are moved in extracellular vesicles between cells; transported substances are enclosed in the vesicle lumen or located in the extracellular vesicle membrane.\" [GOC:sp, PMID:29328915, PMID:29328916]","metadata":null},{"id":"cda38cdb0f3044a482731f2b50554ea9","type":"GO_TERM","name":"vesicle-mediated transport","canonical_id":"go:GO:0016192","description":"\"A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane.\" [GOC:ai, GOC:mah, ISBN:08789310662000]","metadata":null},{"id":"01d39c747c9d4d6cafc6c55b52da6195","type":"GO_TERM","name":"vesicle-mediated transport between endosomal compartments","canonical_id":"go:GO:0098927","description":"\"A cellular transport process in which transported substances are moved in membrane-bounded vesicles between endosomal compartments, e.g, between early endosome and sorting endosome.\" [GOC:dos, PMID:10930469]","metadata":null},{"id":"78f76e4b823b4c3084465810eff610f1","type":"GO_TERM","name":"vesicle-mediated transport in synapse","canonical_id":"go:GO:0099003","description":"\"Any vesicle-mediated transport that occurs in a synapse.\" [GOC:dos]","metadata":null},{"id":"3e4c6d6e1b1d41329647d266e0da0a4c","type":"GO_TERM","name":"vesicle-mediated transport to the plasma membrane","canonical_id":"go:GO:0098876","description":"\"The directed movement of substances to the plasma membrane in transport vesicles that fuse with the plasma membrane by exocytosis.\" [GOC:dos]","metadata":null},{"id":"0b25a56e109f472d8ada9a8c8b4958a9","type":"GO_TERM","name":"vestibular calyx terminal","canonical_id":"go:GO:0099096","description":"\"The giant, cup-shaped axon terminal of a vestibular afferent neuron, serving as a post-synaptic contact to a type I hair cell.\" [PMID:10706428, PMID:25355208]","metadata":null},{"id":"b9e3546a646949dfab59ad1ddfc85492","type":"GO_TERM","name":"vestibular nucleus development","canonical_id":"go:GO:0021750","description":"\"The process whose specific outcome is the progression of the vestibular nucleus over time, from its formation to the mature structure.\" [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid, PMID:16221589]","metadata":null},{"id":"40dca9d7d756427ab5b79d25491cef92","type":"GO_TERM","name":"vestibular receptor cell development","canonical_id":"go:GO:0060118","description":"\"The process whose specific outcome is the progression of a vestibular receptor cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.\" [GOC:dph]","metadata":null},{"id":"a404c567bd794b31bfdc42d7d5c47ae3","type":"GO_TERM","name":"vestibular receptor cell differentiation","canonical_id":"go:GO:0060114","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a vestibular hair cell.\" [GOC:dph]","metadata":null},{"id":"1886a4106afb4c8890daa17043ad3c83","type":"GO_TERM","name":"vestibular receptor cell fate commitment","canonical_id":"go:GO:0060115","description":"\"The process in which a cell becomes committed to become a vestibular receptor cell.\" [GOC:dph]","metadata":null},{"id":"6577a923ffbc45e49d6e42580e966ff1","type":"GO_TERM","name":"vestibular receptor cell morphogenesis","canonical_id":"go:GO:0060116","description":"\"Any process that alters the size or shape of a vestibular receptor cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"50200a19761642628fb42e7ca9e3e07f","type":"GO_TERM","name":"vestibular receptor cell stereocilium organization","canonical_id":"go:GO:0060121","description":"\"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a stereocilium. A stereocilium is an actin-based protrusion from the apical surface of vestibular hair cells.\" [GOC:dph]","metadata":null},{"id":"2384edc601894f4bb36615c1515e97c6","type":"GO_TERM","name":"vestibular reflex","canonical_id":"go:GO:0060005","description":"\"A reflex process in which a response to an angular or linear acceleration stimulus begins with an afferent nerve impulse from a receptor in the inner ear and ends with the compensatory action of eye muscles. Signaling never reaches a level of consciousness.\" [PMID:11784757]","metadata":null},{"id":"b92e95448f3d4aa0bc2fb5d4fb332f99","type":"GO_TERM","name":"vestibulocochlear nerve development","canonical_id":"go:GO:0021562","description":"\"The process whose specific outcome is the progression of the vestibulocochlear nerve over time, from its formation to the mature structure. This sensory nerve innervates the membranous labyrinth of the inner ear. The vestibular branch innervates the vestibular apparatus that senses head position changes relative to gravity. The auditory branch innervates the cochlear duct, which is connected to the three bony ossicles which transduce sound waves into fluid movement in the cochlea.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"8343fb5e2c184e518359c8d107e37623","type":"GO_TERM","name":"vestibulocochlear nerve formation","canonical_id":"go:GO:0021650","description":"\"The process that gives rise to the vestibulocochlear nerve. This process pertains to the initial formation of a structure from unspecified parts. This sensory nerve innervates the membranous labyrinth of the inner ear. The vestibular branch innervates the vestibular apparatus that senses head position changes relative to gravity. The auditory branch innervates the cochlear duct, which is connected to the three bony ossicles which transduce sound waves into fluid movement in the cochlea.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"26e46185bb4f4c5da6c1aa4b39a1931b","type":"GO_TERM","name":"vestibulocochlear nerve maturation","canonical_id":"go:GO:0021647","description":"\"A developmental process, independent of morphogenetic (shape) change, that is required for the vestibulocochlear nerve to attain its fully functional state. This sensory nerve innervates the membranous labyrinth of the inner ear. The vestibular branch innervates the vestibular apparatus that senses head position changes relative to gravity. The auditory branch innervates the cochlear duct, which is connected to the three bony ossicles which transduce sound waves into fluid movement in the cochlea.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"3dfe4d0b51a541828ef20cd7dab04366","type":"GO_TERM","name":"vestibulocochlear nerve morphogenesis","canonical_id":"go:GO:0021648","description":"\"The process in which the anatomical structure of the vestibulocochlear nerve is generated and organized. This sensory nerve innervates the membranous labyrinth of the inner ear. The vestibular branch innervates the vestibular apparatus that senses head position changes relative to gravity. The auditory branch innervates the cochlear duct, which is connected to the three bony ossicles which transduce sound waves into fluid movement in the cochlea.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"89c3c9104c6342868fea343d6dc6a7d2","type":"GO_TERM","name":"vestibulocochlear nerve structural organization","canonical_id":"go:GO:0021649","description":"\"The process that contributes to the act of creating the structural organization of the vestibulocochlear nerve. This process pertains to the physical shaping of a rudimentary structure. This sensory nerve innervates the membranous labyrinth of the inner ear. The vestibular branch innervates the vestibular apparatus that senses head position changes relative to gravity. The auditory branch innervates the cochlear duct, which is connected to the three bony ossicles which transduce sound waves into fluid movement in the cochlea.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]","metadata":null},{"id":"38c09c86faea418d9db801bda4a6a078","type":"GO_TERM","name":"vestibulospinal tract morphogenesis","canonical_id":"go:GO:0021962","description":"\"Generation of a long process of a CNS neuron, that carries efferent (outgoing) action potentials from the cell body in the vestibular nucleus of the pons towards target cells in the spinal cord.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]","metadata":null},{"id":"2d076fe808bc47d9952e66f1d9ae4cdf","type":"GO_TERM","name":"vetispiradiene synthase activity","canonical_id":"go:GO:0034003","description":"\"Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate = diphosphate + vetispiradiene.\" [EC:4.2.3.21, RHEA:10340]","metadata":null},{"id":"01844875505a4e95aac511bccf45d164","type":"DRUG","name":"vibegron","canonical_id":"gtopdb:10100","description":null,"metadata":null},{"id":"7c1a2f9bf8c24ca0a7fcc2e6f9c1d0c2","type":"DRUG","name":"vibegron","canonical_id":"chembl:CHEMBL2107826","description":null,"metadata":null},{"id":"8eea1822082c47838ab8e23bc7b841a0","type":"GO_TERM","name":"vibrational conductance of sound to the inner ear","canonical_id":"go:GO:0055127","description":"\"The transmission of vibrations via ossicles to the inner ear.\" [GOC:mh]","metadata":null},{"id":"6873f2acd5f74ae29e899c3076ce9d0c","type":"DISEASE","name":"vibrio infectious disease","canonical_id":"mondo:0007014","description":null,"metadata":null},{"id":"5448c2226f9a453e8edbc525aa30c5f2","type":"GO_TERM","name":"vibriobactin biosynthetic process","canonical_id":"go:GO:0019537","description":"\"The chemical reactions and pathways resulting in the formation of vibriobactin, the major siderophore produced by Vibrio cholerae.\" [GOC:jl, PMID:11112537]","metadata":null},{"id":"a16f6dcdfdf44b99b273ccf896d1048f","type":"GO_TERM","name":"vibriobactin metabolic process","canonical_id":"go:GO:0019536","description":"\"The chemical reactions and pathways involving vibriobactin, the major siderophore produced by Vibrio cholerae.\" [GOC:jl, PMID:11112537]","metadata":null},{"id":"5bc1e2ad51484e48a46384d074deb998","type":"GO_TERM","name":"vicianin beta-glucosidase activity","canonical_id":"go:GO:0050392","description":"\"Catalysis of the reaction: (R)-vicianin + H2O = mandelonitrile + vicianose.\" [EC:3.2.1.119, RHEA:14041]","metadata":null},{"id":"5a1994cfc4254da7a69bf3725fc8db92","type":"DRUG","name":"vidarabine","canonical_id":"mesh:D014740","description":null,"metadata":null},{"id":"d2e71ce704e5464c9e746539b32683c6","type":"DRUG","name":"vigabatrin","canonical_id":"gtopdb:4821","description":null,"metadata":null},{"id":"5701a4ec7f2a471882aa6673b5f86bf7","type":"DRUG","name":"vigabatrin","canonical_id":"chembl:CHEMBL89598","description":null,"metadata":null},{"id":"006762c1a35c4b85be7d9e341f86ba5b","type":"DRUG","name":"vilanterol","canonical_id":"gtopdb:7353","description":null,"metadata":null},{"id":"051aabf7e24f494da220d0714d70a3f2","type":"DRUG","name":"vilazodone","canonical_id":"gtopdb:7427","description":null,"metadata":null},{"id":"ffc092375a3f438db321a5d95d0559df","type":"DRUG","name":"vilazodone","canonical_id":"mesh:D000069503","description":null,"metadata":null},{"id":"5f0752350fe6422eaeef8fd9fbd67c57","type":"DRUG","name":"vildagliptin","canonical_id":"gtopdb:6310","description":null,"metadata":null},{"id":"681a29124ea54d90aed8dd5722e4d12f","type":"DRUG","name":"vildagliptin","canonical_id":"chembl:CHEMBL142703","description":null,"metadata":null},{"id":"61636619c2484e4c9926d0bcb73cc149","type":"DRUG","name":"vinblastine","canonical_id":"gtopdb:6851","description":null,"metadata":null},{"id":"a4d3df95271d44f0bd91fe45f8bde1a1","type":"DRUG","name":"vinblastine","canonical_id":"mesh:D014747","description":null,"metadata":null},{"id":"512b136b18934a149314b6fb39a428a5","type":"COMBINATION_TREATMENT","name":"vinblastine + vincristine","canonical_id":"ctgov_combo:ctgov-combo-d678b77fb8b9e0fc","description":null,"metadata":null},{"id":"ba6b126d583940fd8ab389d97a46d424","type":"DRUG","name":"vincristine","canonical_id":"gtopdb:6785","description":null,"metadata":null},{"id":"286796dbf85a42e1a0ac76d55040342f","type":"GO_TERM","name":"vinculin binding","canonical_id":"go:GO:0017166","description":"\"Binding to vinculin, a protein found in muscle, fibroblasts, and epithelial cells that binds actin and appears to mediate attachment of actin filaments to integral proteins of the plasma membrane.\" [ISBN:0721662544]","metadata":null},{"id":"ba8508ca2975412baed64c315235bed9","type":"GO_TERM","name":"vindoline biosynthetic process","canonical_id":"go:GO:1900985","description":"\"The chemical reactions and pathways resulting in the formation of vindoline.\" [GOC:TermGenie, GOC:yaf, PMID:12228585]","metadata":null},{"id":"5bc45eac436d433c9d96c57a6424e09b","type":"DRUG","name":"vinorelbine","canonical_id":"mesh:C030852","description":null,"metadata":null},{"id":"053748392d4742229701cfaa9cde6fcd","type":"GO_TERM","name":"vinorine hydroxylase activity","canonical_id":"go:GO:0050596","description":"\"Catalysis of the reaction: H+ + NADPH + O2 + vinorine = H2O + NADP+ + vomilenine.\" [EC:1.14.14.104, RHEA:17257]","metadata":null},{"id":"7e7b4caf040c46ad976d44cf0c900a1c","type":"GO_TERM","name":"vinorine synthase activity","canonical_id":"go:GO:0050636","description":"\"Catalysis of the reaction: 16-epivellosimine + acetyl-CoA = CoA + vinorine.\" [EC:2.3.1.160, RHEA:24016]","metadata":null},{"id":"a24f88344ae04c27b0601bc87653c7d8","type":"DRUG","name":"vinpocetine","canonical_id":"mesh:C013983","description":null,"metadata":null},{"id":"dde221e9bac94e4daab56ee2b8be0c89","type":"GO_TERM","name":"vinylacetate caboxylester hydrolase activity","canonical_id":"go:GO:0102197","description":"\"Catalysis of the reaction: but-3-enoate + H2O = allyl alcohol + formate.\" [GOC:pz, PMID:19555778]","metadata":null},{"id":"d0a1da6fddb046b99fc5ddb1a4b90387","type":"GO_TERM","name":"vinylacetyl-CoA delta-isomerase activity","canonical_id":"go:GO:0050393","description":"\"Catalysis of the reaction: vinylacetyl-CoA = (2E)-butenoyl-CoA.\" [RHEA:10572]","metadata":null},{"id":"0a0abcd0fc3c4870aac0a09acdd1159d","type":"GO_TERM","name":"violaceol I biosynthetic process","canonical_id":"go:GO:1900590","description":"\"The chemical reactions and pathways resulting in the formation of violaceol I.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"7c97cc5bca3b4eeba863610a885c26db","type":"GO_TERM","name":"violaceol I catabolic process","canonical_id":"go:GO:1900589","description":"\"The chemical reactions and pathways resulting in the breakdown of violaceol I.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"f00e0c1967f4416d8e6e668ef39eb257","type":"GO_TERM","name":"violaceol I metabolic process","canonical_id":"go:GO:1900588","description":"\"The chemical reactions and pathways involving violaceol I.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"3953f65f1b774530a80898f7e0250fac","type":"GO_TERM","name":"violaceol II biosynthetic process","canonical_id":"go:GO:1900593","description":"\"The chemical reactions and pathways resulting in the formation of violaceol II.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"1db71df39177411b886524bb036a8a96","type":"GO_TERM","name":"violaceol II catabolic process","canonical_id":"go:GO:1900592","description":"\"The chemical reactions and pathways resulting in the breakdown of violaceol II.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"fabf6acce983485eb5e85d63935ed14a","type":"GO_TERM","name":"violaceol II metabolic process","canonical_id":"go:GO:1900591","description":"\"The chemical reactions and pathways involving violaceol II.\" [GOC:di, GOC:TermGenie]","metadata":null},{"id":"d95363c3112e4299bcdc2f398bbfadf3","type":"GO_TERM","name":"violaxanthin de-epoxidase activity","canonical_id":"go:GO:0046422","description":"\"Catalysis of the reaction: violaxanthin + 2 ascorbate = zeaxanthin + 2 dehydroascorbate + 2 H2O; and antheraxanthin + ascorbate = zeaxanthin + dehydroascorbate + H2O.\" [EC:1.23.5.1, GOC:ai, ISBN:0471331309]","metadata":null},{"id":"f7c3f1f9743a4eca9525ca595a2eff29","type":"GO_TERM","name":"violaxanthin oxygenase activity","canonical_id":"go:GO:0102785","description":"\"Catalysis of the reaction: violaxanthin + 2 O2 = 2 5,6-epoxy-3-hydroxy-9-apo-beta-caroten-9-one + 4,9-dimethyldodeca-2,4,6,8,10-pentaenedial.\" [GOC:pz, PMID:11316814]","metadata":null},{"id":"0defe5dfbccb4671946e4164b18489d3","type":"GO_TERM","name":"viomycin kinase activity","canonical_id":"go:GO:0050394","description":"\"Catalysis of the reaction: ATP + viomycin = ADP + O-phosphoviomycin.\" [EC:2.7.1.103, MetaCyc:VIOMYCIN-KINASE-RXN]","metadata":null},{"id":"7d0da5d35ccd4549ad9b91df4264c910","type":"PROTEIN","name":"viral DNA Polymerase","canonical_id":"uniprot:P08546","description":null,"metadata":null},{"id":"da552c38725a4f92ab0773480d09fbbf","type":"GO_TERM","name":"viral DNA genome packaging","canonical_id":"go:GO:0019073","description":"\"The packing of viral DNA into a capsid.\" [ISBN:0781702534]","metadata":null},{"id":"d170f6717bca4199be1bac3e59dd6c5a","type":"GO_TERM","name":"viral DNA genome packaging via site-specific sequence recognition","canonical_id":"go:GO:0098035","description":"\"The encapsulation of the viral DNA genome within the capsid, which proceeds via cleavage of the viral DNA at specific sites by a viral terminase.\" [GOC:bm]","metadata":null},{"id":"da670c8881ad4110a54c001d0d67eedd","type":"GO_TERM","name":"viral DNA genome packaging, 3' extended cos packaging","canonical_id":"go:GO:0098036","description":"\"The encapsulation of the viral DNA genome within the capsid, which proceeds via cleavage of the viral DNA at specific sites to produce 3' protruding ends.\" [GOC:bm]","metadata":null},{"id":"27d27478f4db46f4b9cd7a15c58aa550","type":"GO_TERM","name":"viral DNA genome packaging, 5' extended cos packaging","canonical_id":"go:GO:0098037","description":"\"The encapsulation of the viral DNA genome within the capsid, which proceeds via cleavage of the viral DNA at specific sites to produce 5' protruding ends.\" [GOC:bm]","metadata":null},{"id":"c252fc115b354f6499ea3a5630e54eef","type":"GO_TERM","name":"viral DNA genome packaging, headful","canonical_id":"go:GO:0098006","description":"\"The encapsulation of the viral genome within the capsid where DNA is packaged into the capsid until the capsid is full.\" [GOC:bm]","metadata":null},{"id":"cf7f1a27f0ab4afb94b3d1a9e89b8c36","type":"GO_TERM","name":"viral DNA genome replication","canonical_id":"go:GO:0039693","description":"\"The replication of a viral DNA genome.\" [GOC:bf, GOC:jl, VZ:915]","metadata":null},{"id":"3dc98ef799674637a3cabf71c207ab02","type":"GO_TERM","name":"viral DNA repair","canonical_id":"go:GO:0046787","description":"\"The process of restoring viral DNA after damage or errors in replication.\" [ISBN:0781718325]","metadata":null},{"id":"6389dbfedae24a73b5b583f4f688d080","type":"GO_TERM","name":"viral DNA strand displacement replication","canonical_id":"go:GO:0039687","description":"\"A viral DNA replication process where only one strand is replicated at once, and which releases a single stranded DNA (ssDNA).\" [GOC:bf, GOC:jl, VZ:1940]","metadata":null},{"id":"7eb8323923a9493c88572bb873046346","type":"GO_TERM","name":"viral RNA editing","canonical_id":"go:GO:0075527","description":"\"The process by which bases in viral mRNA are chemically altered during viral transcription. This is usually the incorporation of 1 - 6 additional nucleotides, which shifts the reading frame, allowing the generation of different protein products or through a specific nucleotide change that eliminates the termination codon.\" [PMID:1629949, VZ:857]","metadata":null},{"id":"c27d0d650f864f07b1727b347fc9761a","type":"GO_TERM","name":"viral RNA genome packaging","canonical_id":"go:GO:0019074","description":"\"The packaging of viral RNA (single-stranded or double-stranded) into a nucleocapsid.\" [ISBN:0781718325]","metadata":null},{"id":"f74ac2d43d73425682e8a5ef988f1d15","type":"GO_TERM","name":"viral RNA genome replication","canonical_id":"go:GO:0039694","description":"\"The replication of a viral RNA genome.\" [GOC:bf, GOC:jl]","metadata":null},{"id":"6745286a6c1b4fc8bc09627e179505a1","type":"GO_TERM","name":"viral RNA-directed RNA polymerase complex","canonical_id":"go:GO:0031381","description":"\"A virus-specific protein complex that possesses RNA-dependent RNA polymerase activity and replicates the genome of an RNA virus.\" [GOC:mah, PMID:15574411, PMID:15613301]","metadata":null},{"id":"3f0ad122e79f4e25a69a54aedba3bc4b","type":"GO_TERM","name":"viral budding","canonical_id":"go:GO:0046755","description":"\"A viral process by which enveloped viruses acquire a host-derived membrane enriched in viral proteins to form their external envelope. The process starts when nucleocapsids, assembled or in the process of being built, induce formation of a membrane curvature in the host plasma or organelle membrane and wrap up in the forming bud. The process ends when the bud is eventually pinched off by membrane scission to release the enveloped particle into the lumenal or extracellular space.\" [ISBN:0781718325, VZ:1947]","metadata":null},{"id":"afe4bab763a84c7494ba261f4fab7dca","type":"GO_TERM","name":"viral budding from Golgi membrane","canonical_id":"go:GO:0046760","description":"\"A viral budding that starts with formation of a membrane curvature in the host Golgi membrane.\" [GOC:bf, ISBN:0072370319, VZ:1947]","metadata":null},{"id":"d6a0c94def8b415e97a5be67115087a6","type":"GO_TERM","name":"viral budding from endoplasmic reticulum membrane","canonical_id":"go:GO:0046762","description":"\"A viral budding that starts with formation of a membrane curvature in the host ER membrane.\" [GOC:bf, GOC:jl, ISBN:0072370319, VZ:1947]","metadata":null},{"id":"5558a7e3c3df4bd59fb80ac9052051db","type":"GO_TERM","name":"viral budding from inner nuclear membrane","canonical_id":"go:GO:0046771","description":"\"The envelopment of a virus, in which the nucleocapsid evaginates from the host inner nuclear membrane system into the perinuclear space, thus acquiring a membrane envelope.\" [ISBN:0072370319]","metadata":null},{"id":"851d766d211d4b8fa6fef71d310a5a7b","type":"GO_TERM","name":"viral budding from nuclear membrane","canonical_id":"go:GO:0046765","description":"\"A viral budding that starts with formation of a membrane curvature in the host nuclear membrane.\" [GOC:bf, ISBN:0072370319]","metadata":null},{"id":"8b1318734e5e412691f9fee7c1edd900","type":"GO_TERM","name":"viral budding from outer nuclear membrane","canonical_id":"go:GO:0046772","description":"\"The envelopment of a virus, in which the naked capsid evaginates from the host outer nuclear membrane system, thus acquiring a membrane envelope.\" [ISBN:0072370319]","metadata":null},{"id":"4d9c56fb2dcd4c528247d6d87d26ce98","type":"GO_TERM","name":"viral budding from plasma membrane","canonical_id":"go:GO:0046761","description":"\"A viral budding that starts with formation of a curvature in the host plasma membrane around which the virion particle assembles.\" [GOC:bf, ISBN:0072370319, PMID:9394621, VZ:1947]","metadata":null},{"id":"863ce55af5244aabbb17b4d8678f8ca1","type":"GO_TERM","name":"viral budding via host ESCRT complex","canonical_id":"go:GO:0039702","description":"\"Viral budding which uses a host ESCRT protein complex, or complexes, to mediate the budding process.\" [UniProtKB-KW:KW-1187, VZ:1536]","metadata":null},{"id":"e018874eda794755a642d03fa8af0450","type":"GO_TERM","name":"viral capsid","canonical_id":"go:GO:0019028","description":"\"The protein coat that surrounds the infective nucleic acid in some virus particles. It comprises numerous regularly arranged subunits, or capsomeres.\" [GOC:mtg_sensu, ISBN:0198506732]","metadata":null},{"id":"0c970f613113409784c7b3cc7b136205","type":"GO_TERM","name":"viral capsid assembly","canonical_id":"go:GO:0019069","description":"\"The assembly of a virus capsid from its protein subunits.\" [ISBN:0781702534, PMID:22615368]","metadata":null},{"id":"719a114f895b482fa862cc0b52516cef","type":"GO_TERM","name":"viral capsid secondary envelopment","canonical_id":"go:GO:0046745","description":"\"The process in which a capsid acquires another membrane envelope, subsequent to acquiring an initial membrane envelope.\" [ISBN:0072370319, ISBN:0781718325, PMID:11533156]","metadata":null},{"id":"17dcf98e107548139cbd3f8c42f15340","type":"GO_TERM","name":"viral capsid, decoration","canonical_id":"go:GO:0098021","description":"\"Component of the virus capsid (head), located on the outer head surface. Involved in the stabilization of the head structure and usually non-essential.\" [GOC:bm, VZ:4398]","metadata":null},{"id":"8b1671b620e246d6903f5efea9010b49","type":"GO_TERM","name":"viral capsid, fiber","canonical_id":"go:GO:0098022","description":"\"A type of capsid decoration composed of fiber structures.\" [GOC:bm]","metadata":null},{"id":"a3fef5b58bc74b28b09f98bc5264fcf3","type":"GO_TERM","name":"viral capsid, internal space","canonical_id":"go:GO:0098061","description":"\"The region of a virus contained within the capsid shell, and usually containing the viral genome and accessory proteins.\" [GOC:bm]","metadata":null},{"id":"34999f2caa284b9c9374d18be287b225","type":"GO_TERM","name":"viral capsid, major subunit","canonical_id":"go:GO:0098017","description":"\"The part of the viral capsid that comprises the most common capsomere type. For example, in a T=3 icosahedral capsid, which is composed of 12 pentameric and 20 hexameric capsomeres, the hexameric capsomeres are major subunits.\" [GOC:bm]","metadata":null},{"id":"5bdfb5013a8b41399b171ab343446bb1","type":"GO_TERM","name":"viral capsid, minor subunit","canonical_id":"go:GO:0098018","description":"\"The part of the viral capsid that comprises the less common capsomere type. For example, in a T=3 icosahedral capsid, which is composed of 12 pentameric and 20 hexameric capsomeres, the pentameric capsomeres are minor subunits.\" [GOC:bm]","metadata":null},{"id":"a176c758b79c4d28b4212b598bfa4046","type":"GO_TERM","name":"viral capsid, turret","canonical_id":"go:GO:0039670","description":"\"A turret-like appendage formed at the vertices of an icosahedral capsid.\" [GOC:jh2, PMID:20592081]","metadata":null},{"id":"6b9abb5eb8b44ccfb50cbd974b6df37a","type":"GO_TERM","name":"viral double stranded DNA replication via reverse transcription","canonical_id":"go:GO:0039688","description":"\"A DNA replication process that uses viral RNA as a template for RNA-dependent DNA polymerases (e.g. reverse transcriptase) that synthesize the new strands.\" [GOC:bf, GOC:jl, VZ:1938]","metadata":null},{"id":"c2f9233ad2c342019b7a23a3e61cef59","type":"GO_TERM","name":"viral envelope","canonical_id":"go:GO:0019031","description":"\"The lipid bilayer of a virion that surrounds the protein capsid. May also contain glycoproteins.\" [GOC:bf, GOC:bm, GOC:jl, ISBN:0781718325, Wikipedia:Viral_envelope]","metadata":null},{"id":"d210157c542843d7a1fc6c6ee3cb3e3e","type":"GO_TERM","name":"viral exocytosis","canonical_id":"go:GO:0046754","description":"\"The exit of a fully formed virion particles from the host cell by exocytosis via a host vesicle.\" [ISBN:0072370319, PMID:33157038]","metadata":null},{"id":"3969cbfbcdbd45f295c0885f6ed79366","type":"GO_TERM","name":"viral extrusion","canonical_id":"go:GO:0099045","description":"\"The process whereby a filamentous phage particle is released from a bacterial host cell via a concerted mechanism of assembly and secretion. Neosynthesized virions are coordinately exported as they are assembled at the cell surface in a secretory process that leaves the host cell fully viable. Non-capsid proteins form structures that facilitate translocation through the inner membrane and outer membranes. A viral single-stranded DNA binding protein coats progeny viral DNA molecules to generate the intracellular precursor for assembly of phage particles as they are extruded through the membranes of the bacterial host. The structural proteins of the virus are anchored in the inner membrane before their incorporation into the phage particle. As assembly proceeds, the phage genome traverses the inner and outer membranes until the entire DNA molecule has been coated and extruded.\" [PMID:15567492, VZ:3951]","metadata":null},{"id":"b517c979af00455897eeda5f15d718d0","type":"GO_TERM","name":"viral factory","canonical_id":"go:GO:0039713","description":"\"An intracellular compartment in a host cell which increases the efficiency of viral replication, and shields the virus from host defenses. Viral factories can be either cytoplasmic or nuclear and often arise from extensive rearrangement of host cell cytoskeletal and/or cell membrane compartments.\" [PMID:22440839, VZ:1951]","metadata":null},{"id":"84d60dbcf27a41c699113c96f2491762","type":"GO_TERM","name":"viral gene expression","canonical_id":"go:GO:0019080","description":"\"A process by which a viral gene is converted into a mature gene product or products (proteins or RNA). This includes viral transcription, processing to produce a mature RNA product, and viral translation.\" [GOC:bf, GOC:jl, ISBN:0121585336]","metadata":null},{"id":"782129159feb407fb54b03bedb43b377","type":"GO_TERM","name":"viral genome circularization","canonical_id":"go:GO:0099009","description":"\"The circularization of a viral genome following infection of a host cell. This is common amongst bacterial viruses to protect the viral genome ends from nucleases, to convert the linear genome to an integrative precursor or to give rise to the replicative form of the genome. It can be mediated by covalent closure of the DNA sticky ends, recombinaison between redundant terminal sequences or via the binding of a protein at the viral DNA extremities.\" [PMID:11894948, PMID:15489417, PMID:19523475, PMID:319596, VZ:3968]","metadata":null},{"id":"18bfd48b520f42b29a537004142d6296","type":"GO_TERM","name":"viral genome integration into host DNA","canonical_id":"go:GO:0044826","description":"\"The insertion into a host genome of viral DNA, usually by the action of an integrase enzyme. Once integrated, the provirus persists in the host cell and serves as a template for the transcription of viral genes and replication of the viral genome, leading to the production of new viruses.\" [PMID:19091057]","metadata":null},{"id":"062af74820d543b2a35e3842b3d38c0e","type":"GO_TERM","name":"viral genome maturation","canonical_id":"go:GO:0019070","description":"\"The processes involved in creating a mature, stable viral genome. Begins after genome replication with a newly synthesized nucleic acid and ends when the genome is ready to be packaged. Includes the addition of proteins to the newly synthesized genome, and DNA repair processes.\" [GOC:pk, PMID:21490093]","metadata":null},{"id":"81657d1ef135425a8cde3d8ab39327cb","type":"GO_TERM","name":"viral genome packaging","canonical_id":"go:GO:0019072","description":"\"The encapsulation of the viral genome within the capsid.\" [ISBN:0121585336]","metadata":null},{"id":"6a0a5a62c5fe4fa8ae1f7da6be5fb049","type":"GO_TERM","name":"viral genome replication","canonical_id":"go:GO:0019079","description":"\"Any process involved directly in viral genome replication, including viral nucleotide metabolism.\" [ISBN:0781702534]","metadata":null},{"id":"e4002f0b927a4e7f93db3f5d32d0d6e0","type":"GO_TERM","name":"viral head-tail joining","canonical_id":"go:GO:0098005","description":"\"Process by which virus heads and tails are attached to each other.\" [GOC:bm]","metadata":null},{"id":"13ee6e67f796499298ed856d73efb639","type":"DISEASE","name":"viral infectious disease","canonical_id":"mondo:0005108","description":null,"metadata":null},{"id":"fa0cada8856d43a094a62aa1c593360c","type":"GO_TERM","name":"viral inner capsid","canonical_id":"go:GO:0039625","description":"\"The inner layer of a double or triple concentric icosahedral capsid. Inner capsids are part of reoviridae and cystoviridae virions.\" [UniProtKB-KW:KW-1153]","metadata":null},{"id":"84e92ecea5ef4db9bd8b9adc428c317c","type":"GO_TERM","name":"viral inner membrane","canonical_id":"go:GO:0039641","description":"\"The lipid bilayer of a virion contained inside the protein capsid.\" [GOC:bm, PMID:15331712]","metadata":null},{"id":"2e447ddf07da4617b22c5a4148c366f9","type":"GO_TERM","name":"viral integration complex","canonical_id":"go:GO:0019035","description":"\"A nucleoprotein complex containing viral genetic material and the viral integrase, required for genome integration into the host's genome. May contain other proteins.\" [PMID:21037296, PMID:2721960, PMID:29900498]","metadata":null},{"id":"e337cbb1d0f34ac08d2d7494e2b017d7","type":"GO_TERM","name":"viral intermediate capsid","canonical_id":"go:GO:0039626","description":"\"The intermediate layer of a triple concentric icosahedral capsid. Intermediate capsids are part of reoviridae virions.\" [UniProtKB-KW:KW-1154]","metadata":null},{"id":"08edfa947a0b444a891de74c81fe4a47","type":"GO_TERM","name":"viral latency","canonical_id":"go:GO:0019042","description":"\"The process by which, after initial infection, a virus lies dormant within a cell and viral production ceases. The process ends when the virus switches from latency and starts to replicate.\" [GOC:jl, VZ:3970]","metadata":null},{"id":"69b936b9e33c4517ac689a84c0620845","type":"GO_TERM","name":"viral life cycle","canonical_id":"go:GO:0019058","description":"\"A set of processes which all viruses follow to ensure survival; includes attachment and entry of the virus particle, decoding of genome information, translation of viral mRNA by host ribosomes, genome replication, and assembly and release of viral particles containing the genome.\" [ISBN:1555811272]","metadata":null},{"id":"e8760bfabfbc47a0b09d480edfeaed27","type":"GO_TERM","name":"viral mRNA export from host cell nucleus","canonical_id":"go:GO:0046784","description":"\"The directed movement of intronless viral mRNA from the host nucleus to the cytoplasm for translation.\" [PMID:11598019]","metadata":null},{"id":"fd4c5badb79e4619b6122140e34d4a21","type":"GO_TERM","name":"viral membrane","canonical_id":"go:GO:0036338","description":"\"The lipid bilayer of a virion, a complete fully infectious extracellular virus particle.\" [GOC:bm]","metadata":null},{"id":"fe5ecc9f2a2a4949b10eab1cdc8d4b86","type":"GO_TERM","name":"viral nucleocapsid","canonical_id":"go:GO:0019013","description":"\"The complete protein-nucleic acid complex that is the packaged form of the genome in a virus particle.\" [ISBN:0781702534]","metadata":null},{"id":"10a5096bd3ec4cbfaf3906f11364ae91","type":"GO_TERM","name":"viral occlusion body","canonical_id":"go:GO:0039679","description":"\"A crystalline protein matrix surrounding the nucleocapsids of some insect viruses after their release in the environment. Produced in the host cell, the occlusion body protects the infectious virion after death of the host.\" [UniProtKB-KW:KW-0842, VZ:1949]","metadata":null},{"id":"052f66c24b494de1a5c160a6979c8d76","type":"GO_TERM","name":"viral outer capsid","canonical_id":"go:GO:0039624","description":"\"The outer layer of a double or triple concentric icosahedral capsid. Outer capsids are part of reoviridae and cystoviridae virions.\" [UniProtKB-KW:KW-1152]","metadata":null},{"id":"e0ae14656fb346b79b20b526a2f1b7be","type":"GO_TERM","name":"viral penetration into host nucleus","canonical_id":"go:GO:0075732","description":"\"The crossing by the virus of the host nuclear membrane, either as naked viral genome or for small viruses as an intact capsid.\" [PMID:22929056, VZ:989]","metadata":null},{"id":"a103b92e3b2d42f1a09b1adf2c263dc5","type":"GO_TERM","name":"viral portal complex","canonical_id":"go:GO:0046798","description":"\"A multimeric ring of proteins through which the DNA enters and exits the viral capsid.\" [PMID:11602732]","metadata":null},{"id":"bd23f67facc04648ac328c1bab35e66a","type":"GO_TERM","name":"viral procapsid","canonical_id":"go:GO:0046729","description":"\"A stable empty viral capsid produced during the assembly of viruses.\" [ISBN:0072370319, ISBN:1555811272]","metadata":null},{"id":"2d8722f6221347fcab90a36baab700d7","type":"GO_TERM","name":"viral procapsid maturation","canonical_id":"go:GO:0046797","description":"\"The refolding and structural rearrangements of individual capsid subunits to transition from the intermediate procapsid, to the more stable capsid structure.\" [GOC:bf, PMID:10627558, PMID:19204733]","metadata":null},{"id":"21015d0011514c8783f1c9b1d7f60c70","type":"GO_TERM","name":"viral process","canonical_id":"go:GO:0016032","description":"\"A multi-organism process in which a virus is a participant. The other participant is the host. Includes infection of a host cell, replication of the viral genome, and assembly of progeny virus particles. In some cases the viral genetic material may integrate into the host genome and only subsequently, under particular circumstances, 'complete' its life cycle.\" [GOC:bf, GOC:jl, GOC:mah]","metadata":null},{"id":"4a4b8762b5d749db9a8ba7a7f922c0e2","type":"GO_TERM","name":"viral protein processing","canonical_id":"go:GO:0019082","description":"\"Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a viral protein.\" [GOC:bf, GOC:jl, ISBN:0781702534]","metadata":null},{"id":"7f403f35e44d4f02a893972cc83350ef","type":"GO_TERM","name":"viral release from host cell","canonical_id":"go:GO:0019076","description":"\"The dissemination of mature viral particles from a host cell, e.g. by cell lysis or the budding of virus particles from the cell membrane.\" [GOC:jl]","metadata":null},{"id":"2c588b838686484fbd617d711c311512","type":"GO_TERM","name":"viral release from host cell by cytolysis","canonical_id":"go:GO:0044659","description":"\"The dissemination of mature viral particles from a host cell by the rupture of cell membranes and the loss of cytoplasm.\" [GOC:jl, PMID:26728778]","metadata":null},{"id":"5ceab062f0fd4df589c4949c5f5144e4","type":"GO_TERM","name":"viral release via disruption of host outer membrane","canonical_id":"go:GO:0090680","description":"\"The dissemination of mature viral particles from a host cell via the destabilization of the cell outer membrane.\" [PMID:17900620]","metadata":null},{"id":"52aa75fc35a44c65aad36021deb93f9c","type":"GO_TERM","name":"viral release via disruption of host peptidoglycan cell wall","canonical_id":"go:GO:0140913","description":"\"The dissemination of mature viral particles from a host cell, caused by a virus hydrolyzing the peptidoglycan cell wall of the host organism. Peptidoglycans are any of a class of glycoconjugates found in bacterial cell walls.\" [PMID:24585055, PMID:26085488, PMID:29495305]","metadata":null},{"id":"2344f1d854004e65ab5d9f75ee527a2c","type":"GO_TERM","name":"viral release via pore formation in host cell membrane","canonical_id":"go:GO:0044660","description":"\"The dissemination of mature viral particles from a host cell via the formation by the virus of pores in its host cell membrane.\" [GOC:jl]","metadata":null},{"id":"298f03f5e49841c89e9c7b98b988e675","type":"GO_TERM","name":"viral release via suppression of host peptidoglycan biosynthetic process","canonical_id":"go:GO:0039640","description":"\"The dissemination of mature viral particles from a host cell, caused by a virus stopping, preventing, or reducing peptidoglycan biosynthesis in the host organism. Peptidoglycans are any of a class of glycoconjugates found in bacterial cell walls.\" [GOC:bf, GOC:bm, PMID:28894177]","metadata":null},{"id":"eeddd851653e4d94891282f27efd6285","type":"GO_TERM","name":"viral replication complex","canonical_id":"go:GO:0019034","description":"\"Specific locations and structures in the virus infected cell involved in replicating the viral genome.\" [ISBN:0781718325]","metadata":null},{"id":"9473fe36e27b4dadb05bed1b4d1f21ee","type":"GO_TERM","name":"viral replication complex formation and maintenance","canonical_id":"go:GO:0046786","description":"\"The process of organizing and assembling viral replication proteins in preparation for viral replication.\" [ISBN:0781718325]","metadata":null},{"id":"bbce6426f9284c37bd9210aecc9e8940","type":"GO_TERM","name":"viral scaffold","canonical_id":"go:GO:0046806","description":"\"A complex of proteins that form a scaffold around which the viral capsid is constructed.\" [ISBN:0072370319]","metadata":null},{"id":"827b15ec73ba4c6ba8c57b0cabc91bdb","type":"GO_TERM","name":"viral scaffold assembly and maintenance","canonical_id":"go:GO:0046807","description":"\"The assembly and maintenance of the viral scaffold around which the viral capsid is constructed.\" [ISBN:0072370319]","metadata":null},{"id":"b7493334216c40168ac49f70f7f52255","type":"GO_TERM","name":"viral tail assembly","canonical_id":"go:GO:0098003","description":"\"The aggregation, arrangement and bonding together of a set of components to form a virus tail.\" [GOC:bm, VZ:3955]","metadata":null},{"id":"ef823522d1a341c0a53ecbd3c79ed15e","type":"GO_TERM","name":"viral tegument","canonical_id":"go:GO:0019033","description":"\"A structure lying between the capsid and envelope of a virus, varying in thickness and often distributed asymmetrically.\" [ISBN:0721662544]","metadata":null},{"id":"c77022544496481197a0df57691bbfff","type":"GO_TERM","name":"viral terminase complex","canonical_id":"go:GO:0043493","description":"\"A complex of a large and small subunit which catalyze the packaging of DNA into viral heads. Note that not all viral terminases have this structure, some exist as single polypeptides.\" [GOC:bf, GOC:bm, GOC:jl, GOC:mlg, PMID:18687036]","metadata":null},{"id":"8427779c707242ddaabe409f56473ff1","type":"GO_TERM","name":"viral terminase, large subunit","canonical_id":"go:GO:0098009","description":"\"The part of the viral terminase complex that contains the translocase and endonuclease activities and allows the translocation of the phage DNA into the procapsid. The large subunit usually assembles as a heterooligomer with the small subunit.\" [GOC:bm, GOC:ch, GOC:jh2, PMID:18687036]","metadata":null},{"id":"0283fc58b31a468189a6019cbe8eeabb","type":"GO_TERM","name":"viral terminase, small subunit","canonical_id":"go:GO:0097710","description":"\"The part of the viral terminase complex that acts as a phage DNA-recognition component and regulates the activity of the large subunit. The small subunit usually assembles as a heterooligomer with the large subunit.\" [GOC:ch, GOC:jh2, PMID:18687036]","metadata":null},{"id":"57735c234da344c3bbcd21d97c02c1f6","type":"GO_TERM","name":"viral transcription","canonical_id":"go:GO:0019083","description":"\"The process by which a viral genome, or part of a viral genome, is transcribed within the host cell.\" [GOC:jl, ISBN:0781702534]","metadata":null},{"id":"ba65fcf737b042c8946b841d417b477e","type":"GO_TERM","name":"viral transcriptional complex","canonical_id":"go:GO:0019036","description":"\"Specific locations and structures in the virus infected cell involved in transcribing the viral genome.\" [ISBN:0781718325]","metadata":null},{"id":"db8964e97f4f463680848528a38ecbf9","type":"GO_TERM","name":"viral translation","canonical_id":"go:GO:0019081","description":"\"A process by which viral mRNA is translated into viral protein, using the host cellular machinery.\" [GOC:bf, GOC:jl, ISBN:0781702534]","metadata":null},{"id":"d5281f9d12054ee4b665217c7a6a0f24","type":"GO_TERM","name":"viral translational frameshifting","canonical_id":"go:GO:0075523","description":"\"A process which occurs during viral translation, which involves a translational recoding mechanism called programmed ribosomal frameshifting. This causes the ribosome to alter its reading of the mRNA to an a different open reading frame to produce alternate viral proteins.\" [GOC:bf, GOC:ch, GOC:jl, PMID:24825891, PMID:8852897, VZ:860]","metadata":null},{"id":"bf0b62b59ef84eea989e33232828a232","type":"GO_TERM","name":"viral translational readthrough","canonical_id":"go:GO:0039705","description":"\"The continuation of translation of a viral mRNA beyond a stop codon by the use of a special tRNA that recognizes the UAG and UGA codons as modified amino acids, rather than as termination codons.\" [GOC:bf, GOC:ch, GOC:jl, PMID:10839817, VZ:859]","metadata":null},{"id":"159f5628e5114aa0959625c66e36b773","type":"GO_TERM","name":"viral translational shunt","canonical_id":"go:GO:0039704","description":"\"A viral translation initiation mechanism where ribosomes are loaded onto viral mRNA at the 5'-cap structure and start scanning for a short distance before by-passing the large internal leader region and initiating at a downstream start site.\" [PMID:15827182, PMID:18195037, VZ:608]","metadata":null},{"id":"0b09bf6d257d46ee8d929e282b029ede","type":"GO_TERM","name":"viral translational termination-reinitiation","canonical_id":"go:GO:0075525","description":"\"A process which occurs as part of viral mRNA translation which allows expression of a downstream open reading frame (ORF) in a dicistronic mRNA. In this process, ribosomes translate the upstream ORF but following termination, a proportion of 40S subunits remain tethered to the mRNA and go on to re-initiate translation at the start codon of the downstream ORF.\" [GOC:bf, GOC:ch, GOC:jl, PMID:18631147, PMID:18824510, VZ:858]","metadata":null},{"id":"95f1575b4eda40b682cc5982bdb6fe4b","type":"GO_TERM","name":"viral tropism switching","canonical_id":"go:GO:0098678","description":"\"A process by which the range of hosts which a virus can bind and infect is changed. Examples include phages that switch between types of fibers via the action of a virally encoded invertase.\" [PMID:6232613, VZ:4498]","metadata":null},{"id":"f5297bbd793b4f4580f286f3031a94d6","type":"GO_TERM","name":"viridicatumtoxin biosynthetic process","canonical_id":"go:GO:0140872","description":"\"The chemical reactions and pathways resulting in the formation of viridicatumtoxin, a tetracycline-like fungal meroterpenoid with a unique, fused spirobicyclic ring system.\" [PMID:20534346, PMID:24161266]","metadata":null},{"id":"adf235ada7e84ff08104c67c639835ba","type":"GO_TERM","name":"virion assembly","canonical_id":"go:GO:0019068","description":"\"A late phase of the viral life cycle during which all the components necessary for the formation of a mature virion collect at a particular site in the cell and the basic structure of the virus particle is formed.\" [ISBN:0121585336]","metadata":null},{"id":"0cf28f5716fd475bb84c35f0993e9e61","type":"GO_TERM","name":"virion attachment to host cell","canonical_id":"go:GO:0019062","description":"\"The process by which a virion protein binds to molecules on the host cellular surface or host cell surface projection.\" [GOC:bf, GOC:jl, UniProtKB-KW:KW-1161, VZ:956]","metadata":null},{"id":"bf7a690321da49cd99542b14ae19fef6","type":"GO_TERM","name":"virion attachment to host cell flagellum","canonical_id":"go:GO:0098931","description":"\"The process by which a virion attaches to a the host cell flagellum. Some DNA bacterial viruses use flagella to attach to the host cell. This contact with the flagellum facilitates concentration of phage particles around the entry receptor on the bacterial cell surface.\" [GOC:dos, VZ:3949]","metadata":null},{"id":"ada094152c3e4288a0688d6739c7b848","type":"GO_TERM","name":"virion attachment to host cell pilus","canonical_id":"go:GO:0039666","description":"\"The process by which a virion attaches to a host cell by binding to a pilus on the host cell surface. Pili are retractile filaments that protrude from gram-negative bacteria. Filamentous viruses can attach to the pilus tip, whereas icosahedral viruses can attach to the pilus side.\" [UniProtKB-KW:KW-1175, VZ:981]","metadata":null},{"id":"38c6d1950a43480da63f06990594689d","type":"GO_TERM","name":"virion binding","canonical_id":"go:GO:0046790","description":"\"Binding to a virion, either by binding to components of the capsid or the viral envelope.\" [GOC:ai]","metadata":null},{"id":"ec02d223f0a94932ab5cca461651d40f","type":"GO_TERM","name":"virion component","canonical_id":"go:GO:0044423","description":"\"Any constituent part of a virion, a complete fully infectious extracellular virus particle.\" [GOC:jl]","metadata":null},{"id":"e7f9325c68384b7186e8432187abb724","type":"GO_TERM","name":"virion maturation","canonical_id":"go:GO:0098677","description":"\"Maturation of a virion after separation from the host cell. Not all viruses mature after separation. In those that do, maturation typically involves rearangement and/or cleavage of viral proteins, resulting in the virion becoming competent for reinfection.\" [ISBN:0781718325, VZ:1946]","metadata":null},{"id":"c4a38da5e2c34047b777ad6f71e7180a","type":"GO_TERM","name":"virion membrane","canonical_id":"go:GO:0055036","description":"\"The lipid bilayer surrounding a virion.\" [GOC:jid, GOC:rph, PMID:213106]","metadata":null},{"id":"0716f4c6b1a7400a8ef859022b005598","type":"GO_TERM","name":"virion nucleoid","canonical_id":"go:GO:0039642","description":"\"The region of a virion in which the nucleic acid is confined.\" [GOC:bm, PMID:14291596]","metadata":null},{"id":"d20bdf9df34243158247b0e16453abb3","type":"GO_TERM","name":"virion transport vesicle","canonical_id":"go:GO:0046816","description":"\"A vesicle used to transport the partial or complete virion between cellular compartments.\" [GOC:vesicles, PMID:7933124]","metadata":null},{"id":"d15471e4348041d696f2cceb099d335e","type":"GO_TERM","name":"virogenic stroma","canonical_id":"go:GO:0039720","description":"\"A nuclear viral factory formed by Baculoviruses. A vesicular structure in which virions are assembled.\" [PMID:13358757, PMID:1433508, VZ:1951]","metadata":null},{"id":"abc659e3871c4e7fb609794d83391455","type":"GO_TERM","name":"viroplasm viral factory","canonical_id":"go:GO:0039716","description":"\"A cytoplasmic viral factory that is electron dense due to high levels of viral RNA. Produced by nucleo-cytoplasmic large DNA viruses (NCLDV) like Poxviridae, Asfarviridae and Iridoviridae, and dsRNA viruses like Reoviridae.\" [VZ:1951, Wikipedia:Viroplasm]","metadata":null},{"id":"fe8c933a39674c14a05b7f41dfae2b79","type":"GO_TERM","name":"virus baseplate assembly","canonical_id":"go:GO:0098045","description":"\"The aggregation, arrangement and bonding together of a set of components to form a virus baseplate.\" [GOC:bm]","metadata":null},{"id":"07679b7e69fe430c9644ff2cdbf65992","type":"GO_TERM","name":"virus coreceptor activity","canonical_id":"go:GO:0120274","description":"\"Combining with a virus component, and in cooperation with a nearby primary receptor, initiating a change in cell activity.\" [GOC:ha, GOC:krc, PMID:16051304]","metadata":null},{"id":"cc3af92653434402b64504e4592c2f85","type":"GO_TERM","name":"virus maturation","canonical_id":"go:GO:0019075","description":"\"The refolding and structural rearrangements of virion parts to transition from the intermediate virion to the more mature virion. Maturation usually involves proteolysis events and changes in the folding of the virion proteins. Can occur inside the host cell or after release.\" [ISBN:0781718325]","metadata":null},{"id":"838ffa8d4c304b3f82ddfe6b04ffcd91","type":"GO_TERM","name":"virus receptor activity","canonical_id":"go:GO:0001618","description":"\"Combining with a virus component and mediating entry of the virus into the cell.\" [GOC:bf, GOC:dph, PMID:7621403, UniProtKB-KW:KW-1183]","metadata":null},{"id":"c098cdd6fa454ac3958902d0a71bf4e7","type":"GO_TERM","name":"virus tail","canonical_id":"go:GO:0098015","description":"\"Part of the virion that may be used to recognize, attach and inject the viral genome and accessory proteins into the host cell.\" [GOC:bm, VZ:3958]","metadata":null},{"id":"92f63a1508024b7c9f0410adb2e18b3b","type":"GO_TERM","name":"virus tail fiber assembly","canonical_id":"go:GO:0098004","description":"\"The aggregation, arrangement and bonding together of a set of components to form a virus tail fiber.\" [GOC:bm, VZ:3956]","metadata":null},{"id":"e467846a331349c1b4171693560ad014","type":"GO_TERM","name":"virus tail, baseplate","canonical_id":"go:GO:0098025","description":"\"Multiprotein component at the distal (head) end of the virus tail to which fibers of tailed viruses may be attached.\" [GOC:bm, VZ:3957]","metadata":null},{"id":"55d4f2cbfb594b5bbd5ff3fd53fd66a2","type":"GO_TERM","name":"virus tail, fiber","canonical_id":"go:GO:0098024","description":"\"The fibrous region of the virus tail used to scan, recognize and attach to the host cell.\" [GOC:bm, VZ:4416]","metadata":null},{"id":"0649301d83014932a6976858d6d51f64","type":"GO_TERM","name":"virus tail, shaft","canonical_id":"go:GO:0098028","description":"\"The tube of the non-contractile tails of some viruses.\" [GOC:bm]","metadata":null},{"id":"d37e04fbaadf481bb85eaaa74a88c8da","type":"GO_TERM","name":"virus tail, sheath","canonical_id":"go:GO:0098027","description":"\"The external contractile envelope of the tail of some viruses. Its contraction ensures ejection of the virus DNA into the host cytoplasm.\" [GOC:bm, VZ:3959]","metadata":null},{"id":"5dd9f9e582c843c6adca4ce74ee12206","type":"GO_TERM","name":"virus tail, tip","canonical_id":"go:GO:0098023","description":"\"The basal end of the virus tail, which is used by the virus to attach to the host cell.\" [GOC:bm]","metadata":null},{"id":"fa8786361be3400aa939c2d4da7aa6c5","type":"GO_TERM","name":"virus tail, tube","canonical_id":"go:GO:0098026","description":"\"The internal tube of the tail of some viruses. The virus tail tube is the channel for DNA ejection into the host cytoplasm.\" [PMID:33188213, VZ:3960]","metadata":null},{"id":"2392d21be4f84ce195aa027f2162979b","type":"GO_TERM","name":"virus-like capsid","canonical_id":"go:GO:0170047","description":"\"A protein coat that surrounds nucleic acid to form a structure similar to a virus capsid. Virus-like capsids are non-infectious and are encoded by endogenous (non-viral) genes. Fly and tetrapod Arc (ancestrally-related to retrotransposon Gag) are examples of proteins that can self-assemble into capsid-like structures which encapsulate Arc mRNA and mediate the intercellular transmission of RNA.\" [PMID:29328916]","metadata":null},{"id":"9c7938c30299496880139bbe36476186","type":"GO_TERM","name":"visceral mesoderm-endoderm interaction involved in midgut development","canonical_id":"go:GO:0007495","description":"\"The process of cell-cell signaling between visceral mesoderm cells and endoderm cells that is involved in the differentiation of cells in the midgut.\" [GOC:dph, GOC:isa_complete]","metadata":null},{"id":"0ce50753f0f44c41bdba7ecc29a95654","type":"GO_TERM","name":"visceral motor neuron differentiation","canonical_id":"go:GO:0021524","description":"\"The process in which neuroepithelial cells in the neural tube acquire specialized structural and/or functional features of visceral motor neurons. Visceral motor neurons innervate glandular targets and are responsible for transmission of motor impulses from the brain to the periphery. Differentiation includes the processes involved in commitment of a cell to a specific fate.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11262869]","metadata":null},{"id":"1b45c170fd904f9dbfb2b3d4d92c8669","type":"GO_TERM","name":"visceral muscle development","canonical_id":"go:GO:0007522","description":"\"The process whose specific outcome is the progression of the visceral muscle over time, from its formation to the mature structure.\" [GOC:curators]","metadata":null},{"id":"1734611ff6804c1a8d0c52673dfc9ee0","type":"DISEASE","name":"visceral neuropathy, familial, 1, autosomal recessive","canonical_id":"mondo:8000011","description":null,"metadata":null},{"id":"457bcc2da60a4fe689dca3a2ddfabc02","type":"GO_TERM","name":"visceral peritoneum development","canonical_id":"go:GO:1904818","description":"\"The process whose specific outcome is the progression of a visceral peritoneum over time, from its formation to the mature structure.\" [GO_REF:0000094, GOC:dph, GOC:TermGenie, PMID:15840053]","metadata":null},{"id":"154ad6e3f928465e8250e86c593ac6b0","type":"GO_TERM","name":"visceral serous pericardium development","canonical_id":"go:GO:0061032","description":"\"The progression of the visceral serous pericardium from its formation to the mature structure. The visceral serous pericardium is the inner layer of the pericardium.\" [GOC:dph, GOC:yaf]","metadata":null},{"id":"6f8c7742396e416ca3d6d0c780542680","type":"DRUG","name":"vismodegib","canonical_id":"gtopdb:6975","description":null,"metadata":null},{"id":"c02a0305e4144343be1b4e150052f693","type":"DRUG","name":"vismodegib","canonical_id":"chembl:CHEMBL473417","description":null,"metadata":null},{"id":"0353db451b5e4049b02d07b5ea05d3d8","type":"GO_TERM","name":"vistamycin biosynthetic process","canonical_id":"go:GO:1901152","description":"\"The chemical reactions and pathways resulting in the formation of vistamycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00972]","metadata":null},{"id":"449594b17bc64f1380cdf2ee44f82d58","type":"GO_TERM","name":"vistamycin catabolic process","canonical_id":"go:GO:1901151","description":"\"The chemical reactions and pathways resulting in the breakdown of vistamycin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00972]","metadata":null},{"id":"6a893fc9213542a790b716debebd0b70","type":"GO_TERM","name":"visual behavior","canonical_id":"go:GO:0007632","description":"\"The behavior of an organism in response to a visual stimulus.\" [GOC:jid, GOC:pr]","metadata":null},{"id":"045e7820c809458c86d12ee14d3895c6","type":"GO_TERM","name":"visual learning","canonical_id":"go:GO:0008542","description":"\"Any process in an organism in which a change in behavior of an individual occurs in response to repeated exposure to a visual cue.\" [GOC:jid, ISBN:0582227089]","metadata":null},{"id":"bc2ab5e6ae2048dc97ed4ab81c018b84","type":"GO_TERM","name":"visual perception","canonical_id":"go:GO:0007601","description":"\"The series of events required for an organism to receive a visual stimulus, convert it to a molecular signal, and recognize and characterize the signal. Visual stimuli are detected in the form of photons and are processed to form an image.\" [GOC:ai]","metadata":null},{"id":"10742b7d1e87438c9894133e09254ba3","type":"GO_TERM","name":"visual system development","canonical_id":"go:GO:0150063","description":"\"The process whose specific outcome is the progression of the visual system over time, from its formation to the mature structure, including the eye, parts of the central nervous system (CNS) involved in processing of visual inputs, and connecting nerve pathways.\" [GOC:aruk, GOC:bc, GOC:krc, PMID:15004427, PMID:20647017, PMID:22632727]","metadata":null},{"id":"8dac2ab5117448fdbae82d105ca48f74","type":"GO_TERM","name":"visually-mediated background adaptation","canonical_id":"go:GO:0120303","description":"\"Any process in which an organism changes its pigmentation (lightening in response to a brighter environment or darkening in response to a dimmer environment) in response to a change in light intensity detected by melanopsin-expressing eye cells.\" [GOC:cvs, GOC:krc, PMID:29239123, PMID:32898924]","metadata":null},{"id":"00273fc691f449e4809cfbacb53eae46","type":"GO_TERM","name":"vitamin A biosynthetic process","canonical_id":"go:GO:0035238","description":"\"The chemical reactions and pathways resulting in the formation of any of the vitamin A compounds, retinol, retinal (retinaldehyde) and retinoic acid. Animals cannot synthesize vitamin A de novo, but form it through oxidative cleavage of carotenoids.\" [PMID:11158606]","metadata":null},{"id":"d1305d3cc6dd459aa8578146cf2720de","type":"GO_TERM","name":"vitamin A import into cell","canonical_id":"go:GO:0071939","description":"\"The directed movement of vitamin A from outside of a cell, across the plasma membrane and into the cytosol. Vitamin A is any of several retinoid derivatives of beta-carotene, primarily retinol, retinal, or retinoic acid.\" [GOC:mah, PMID:16011460, PMID:1924551]","metadata":null},{"id":"3b5e068c7d6345d693ecbfee457ea98b","type":"GO_TERM","name":"vitamin A metabolic process","canonical_id":"go:GO:0006776","description":"\"The chemical reactions and pathways involving any of the vitamin A compounds, retinol, retinal (retinaldehyde) and retinoic acid, all of which are derivatives of beta-carotene.\" [GOC:jl, PMID:1503811]","metadata":null},{"id":"5edac1444cc44ed98e19cb62705064c8","type":"GO_TERM","name":"vitamin A transport","canonical_id":"go:GO:0071938","description":"\"The directed movement any form of vitamin A into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Vitamin A is any of several retinoid derivatives of beta-carotene, primarily retinol, retinal, or retinoic acid.\" [GOC:mah, PMID:16011460, PMID:1924551]","metadata":null},{"id":"922682b316d24c018e86af1f248782e7","type":"GO_TERM","name":"vitamin B6 binding","canonical_id":"go:GO:0070279","description":"\"Binding to a vitamin B6 compound: pyridoxal, pyridoxamine, pyridoxine, or the active form, pyridoxal phosphate.\" [GOC:mah]","metadata":null},{"id":"2de78af7b3214005ab2a764f13bc3c00","type":"GO_TERM","name":"vitamin B6 biosynthetic process","canonical_id":"go:GO:0042819","description":"\"The chemical reactions and pathways resulting in the formation of any of the vitamin B6 compounds; pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate.\" [GOC:jl, PMID:16157873, PMID:30671974]","metadata":null},{"id":"2129f053d03c49f68afacb0209c6549c","type":"GO_TERM","name":"vitamin B6 catabolic process","canonical_id":"go:GO:0042820","description":"\"The chemical reactions and pathways resulting in the breakdown of any of the vitamin B6 compounds; pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate.\" [GOC:jl, PMID:30037155, PMID:30671974]","metadata":null},{"id":"79b92bb9dd79463790653ec5a3ecd334","type":"GO_TERM","name":"vitamin B6 metabolic process","canonical_id":"go:GO:0042816","description":"\"The chemical reactions and pathways involving any of the vitamin B6 compounds: pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate.\" [GOC:jl, PMID:30037155, PMID:30671974]","metadata":null},{"id":"ec0a69738d6a458399defeafaf3613f5","type":"GO_TERM","name":"vitamin B6 transmembrane transporter activity","canonical_id":"go:GO:0031924","description":"\"Enables the transfer of any of the vitamin B6 compounds, pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate, from one side of a membrane to the other.\" [GOC:mah]","metadata":null},{"id":"b1c3b727fdbe4009a50ca8138a9ce220","type":"GO_TERM","name":"vitamin B6 transport","canonical_id":"go:GO:0031919","description":"\"The directed movement of any of the vitamin B6 compounds -- pyridoxal, pyridoxamine and pyridoxine and the active form, pyridoxal phosphate -- into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mah]","metadata":null},{"id":"26c17fcca1484bc280eb3e0f28ff56ed","type":"GO_TERM","name":"vitamin D 23-hydroxylase activity","canonical_id":"go:GO:0062179","description":"\"Catalysis of the hydroxylation of C-23 of any form of vitamin D.\" [PMID:22100522, PMID:30205156]","metadata":null},{"id":"598399af8f6c4e4c94e2cf95e66e18ac","type":"GO_TERM","name":"vitamin D 24-hydroxylase activity","canonical_id":"go:GO:0070576","description":"\"Catalysis of the hydroxylation of C-24 of any form of vitamin D.\" [GOC:BHF, GOC:mah, PMID:15546903]","metadata":null},{"id":"f60808d08e8f4db9a03cf5091bb401d6","type":"GO_TERM","name":"vitamin D 25-hydroxylase activity","canonical_id":"go:GO:0030343","description":"\"Catalysis of the reaction: calciol (vitamin D3) + reduced [NADPH--hemoprotein reductase] + O2 = calcidiol + oxidized [NADPH--hemoprotein reductase] + H2O + H+.\" [RHEA:32903]","metadata":null},{"id":"a8683c8a64df4ad69ab4e777c818e9f4","type":"GO_TERM","name":"vitamin D binding","canonical_id":"go:GO:0005499","description":"\"Binding to vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [GOC:mah, ISBN:0471331309]","metadata":null},{"id":"bbee1169a3534a239741274bd950ef64","type":"GO_TERM","name":"vitamin D biosynthetic process","canonical_id":"go:GO:0042368","description":"\"The chemical reactions and pathways resulting in the formation of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [GOC:mah, ISBN:0471331309]","metadata":null},{"id":"333d4f1562c84e95a9d39de3aa75ccc0","type":"GO_TERM","name":"vitamin D catabolic process","canonical_id":"go:GO:0042369","description":"\"The chemical reactions and pathways resulting in the breakdown of vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [GOC:mah, ISBN:0471331309]","metadata":null},{"id":"e7c17aa2d0074ec9a0fe8e950b7be152","type":"DISEASE","name":"vitamin D deficiency","canonical_id":"efo:0003762","description":null,"metadata":null},{"id":"f23f6c3f29804a17b33edb8097a705f9","type":"GO_TERM","name":"vitamin D metabolic process","canonical_id":"go:GO:0042359","description":"\"The chemical reactions and pathways involving vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).\" [GOC:mah, ISBN:0471331309]","metadata":null},{"id":"d4ac8e6e7b42401e81e44d7c69bb9490","type":"GO_TERM","name":"vitamin D receptor signaling pathway","canonical_id":"go:GO:0070561","description":"\"A nuclear receptor-mediated signaling pathway initiated by vitamin D binding to an intracellular receptor of the nuclear receptor protein family, and ending with regulation of a downstream cellular process, e.g. transcription.\" [GOC:BHF, GOC:mah, PMID:12637589]","metadata":null},{"id":"a2a0949508214c26b6bb958bbe77cf77","type":"GO_TERM","name":"vitamin D response element binding","canonical_id":"go:GO:0070644","description":"\"Binding to a vitamin D response element (VDRE), a short sequence with dyad symmetry found in the promoters of some of the cellular immediate-early genes, regulated by serum.\" [GOC:BHF, GOC:vk, PMID:17426122]","metadata":null},{"id":"8a9f3109571d4be0a4b33efb8cc30a73","type":"DISEASE","name":"vitamin D-dependent rickets, type 2","canonical_id":"mondo:0019642","description":null,"metadata":null},{"id":"e5badea3707f49c7a728a60e6cebbcc6","type":"GO_TERM","name":"vitamin D3 biosynthetic process","canonical_id":"go:GO:1901755","description":"\"The chemical reactions and pathways resulting in the formation of vitamin D3.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-6076, Unipathway:UPA00955]","metadata":null},{"id":"6491a80445be491bbbdb526a4b9b35e2","type":"GO_TERM","name":"vitamin D3 catabolic process","canonical_id":"go:GO:1901754","description":"\"The chemical reactions and pathways resulting in the breakdown of vitamin D3.\" [GOC:TermGenie, GOC:yaf]","metadata":null},{"id":"b78f5bf9849148bc9bdf718d26d2931a","type":"GO_TERM","name":"vitamin D3 metabolic process","canonical_id":"go:GO:0070640","description":"\"The chemical reactions and pathways involving vitamin D3, (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"57c0cb76a2224454bb3f68d1673b5a63","type":"GO_TERM","name":"vitamin E binding","canonical_id":"go:GO:0008431","description":"\"Binding to a vitamin E, tocopherol, which includes a series of eight structurally similar compounds. Alpha-tocopherol is the most active form in humans and is a powerful biological antioxidant.\" [ISBN:0721662544]","metadata":null},{"id":"39029bbf022044a099df7580c2cd42be","type":"GO_TERM","name":"vitamin E biosynthetic process","canonical_id":"go:GO:0010189","description":"\"The chemical reactions and pathways resulting in the formation of vitamin E, tocopherol, which includes a series of eight structurally similar compounds. Alpha-tocopherol is the most active form in humans and is a powerful biological antioxidant.\" [GOC:mg]","metadata":null},{"id":"fb4bf6bf9049429c99dc39febbb53111","type":"GO_TERM","name":"vitamin E metabolic process","canonical_id":"go:GO:0042360","description":"\"The chemical reactions and pathways involving vitamin E, tocopherol, which includes a series of eight structurally similar compounds. Alpha-tocopherol is the most active form in humans and is a powerful biological antioxidant.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"5d3894e30d5146c9b27bf3c1e40c87d5","type":"GO_TERM","name":"vitamin K biosynthetic process","canonical_id":"go:GO:0042371","description":"\"The chemical reactions and pathways resulting in the formation of any of the forms of vitamin K, quinone-derived vitamins which are involved in the synthesis of blood-clotting factors in mammals.\" [GOC:jl, https://en.wikipedia.org/wiki/Vitamin_K, PMID:24489112]","metadata":null},{"id":"900bb3433b674b35a2dba87e9bfcf7a6","type":"GO_TERM","name":"vitamin K catabolic process","canonical_id":"go:GO:0042377","description":"\"The chemical reactions and pathways resulting in the breakdown of any of the forms of vitamin K, quinone-derived vitamins which are involved in the synthesis of blood-clotting factors in mammals.\" [GOC:jl, https://en.wikipedia.org/wiki/Vitamin_K, PMID:24489112]","metadata":null},{"id":"571556f0143f4467b1b85464e97613f8","type":"GO_TERM","name":"vitamin K metabolic process","canonical_id":"go:GO:0042373","description":"\"The chemical reactions and pathways involving any of the forms of vitamin K, quinone-derived vitamins which are involved in the synthesis of blood-clotting factors in mammals. Vitamin K substances share a methylated naphthoquinone ring structure and vary in the aliphatic side chains attached to the molecule.\" [GOC:jl, https://en.wikipedia.org/wiki/Vitamin_K, PMID:24489112]","metadata":null},{"id":"50a1290f81084f6e80364a628d00d8db","type":"DISEASE","name":"vitamin K-dependent clotting factors, combined deficiency of, type 1","canonical_id":"mondo:0010187","description":null,"metadata":null},{"id":"952f0e1b23ce4cc2af150b3012f379c2","type":"DISEASE","name":"vitamin K-dependent clotting factors, combined deficiency of, type 2","canonical_id":"mondo:0011837","description":null,"metadata":null},{"id":"1d0a64d4e1684e99a646104ef2cc1dc7","type":"GO_TERM","name":"vitamin binding","canonical_id":"go:GO:0019842","description":"\"Binding to a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:ai]","metadata":null},{"id":"35a68cd1a5304b0a8dac349b9eedd8b1","type":"GO_TERM","name":"vitamin biosynthetic process","canonical_id":"go:GO:0009110","description":"\"The chemical reactions and pathways resulting in the formation of a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:curators, ISBN:0198506732]","metadata":null},{"id":"d672e33d1072480498ff2cc7f9f4ab72","type":"GO_TERM","name":"vitamin catabolic process","canonical_id":"go:GO:0009111","description":"\"The chemical reactions and pathways resulting in the breakdown of a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body, carried out by individual cells.\" [GOC:ai]","metadata":null},{"id":"cfdd8693202a43f5bd60ea19cced8dc9","type":"GO_TERM","name":"vitamin metabolic process","canonical_id":"go:GO:0006766","description":"\"The chemical reactions and pathways involving vitamins. Vitamin is a general term for a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body. Vitamins may be water-soluble or fat-soluble and usually serve as components of coenzyme systems.\" [GOC:ai]","metadata":null},{"id":"d035c37caa91464c8db80d6e87557a6c","type":"GO_TERM","name":"vitamin transmembrane transport","canonical_id":"go:GO:0035461","description":"\"The process in which a vitamin is transported across a membrane. A vitamin is one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:bf]","metadata":null},{"id":"102ddffe99e54c92a72dca4548f2d385","type":"GO_TERM","name":"vitamin transmembrane transporter activity","canonical_id":"go:GO:0090482","description":"\"Enables the transfer of a vitamin from one side of a membrane to the other.\" [GOC:tb]","metadata":null},{"id":"89323191535b4f91a8a7bf953d5abe32","type":"GO_TERM","name":"vitamin transport","canonical_id":"go:GO:0051180","description":"\"The directed movement of vitamins into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A vitamin is one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.\" [GOC:ai]","metadata":null},{"id":"f2bdb094fb1b4dd4a74a1ac307f48c84","type":"GO_TERM","name":"vitamin-K-epoxide reductase (warfarin-insensitive) activity","canonical_id":"go:GO:0047058","description":"\"Catalysis of the reaction: 3-hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinone + oxidized dithiothreitol + H2O = 2,3-epoxy-2,3-dihydro-2-methyl-3-phytyl-1,4-naphthoquinone + 1,4-dithiothreitol.\" [RHEA:21560]","metadata":null},{"id":"09afada67f4940059ef6d639c2cbb75b","type":"GO_TERM","name":"vitamin-K-epoxide reductase (warfarin-sensitive) activity","canonical_id":"go:GO:0047057","description":"\"Catalysis of the reaction: phylloquinol + a protein with a disulfide bond = phylloquinone + a protein with reduced L-cysteine residues.\" [RHEA:57744]","metadata":null},{"id":"eb0399c7420d46db9f642afee9ac7552","type":"GO_TERM","name":"vitelline envelope","canonical_id":"go:GO:0060388","description":"\"A glycoprotein-based structure that lies outside the plasma membrane and surrounds the egg before fertilization.\" [GOC:dph, ISBN:0878932437]","metadata":null},{"id":"31a6192779f348d9a1a5fa042f76dd9f","type":"GO_TERM","name":"vitelline membrane formation","canonical_id":"go:GO:0030704","description":"\"Construction of the vitelline membrane portion of the egg shell, a rigid structure required to maintain the shape of the egg.\" [ISBN:0879694238]","metadata":null},{"id":"ea12214c728f460790684c60aa57f75d","type":"GO_TERM","name":"vitelline membrane formation involved in chorion-containing eggshell formation","canonical_id":"go:GO:0007305","description":"\"Construction of the vitelline membrane portion of a chorion-containing eggshell. An example of this is found in Drosophila melanogaster.\" [GOC:mah, GOC:mtg_sensu]","metadata":null},{"id":"2456ca769e084a8bb25a02cc505314cd","type":"GO_TERM","name":"vitellogenesis","canonical_id":"go:GO:0007296","description":"\"The production of yolk. Yolk is a mixture of materials used for embryonic nutrition.\" [GOC:dph, ISBN:0879694238]","metadata":null},{"id":"bd2e40f7c17b4104b0c2a0b49422ed5c","type":"GO_TERM","name":"vitellogenin receptor activity","canonical_id":"go:GO:0008196","description":"\"Receiving vitellogenin, and delivering vitellogenin into the cell via endocytosis.\" [GOC:bf, PMID:12429745]","metadata":null},{"id":"ce061c96bc104b19b3c5e125d99cd564","type":"GO_TERM","name":"vitexin 2''-O-rhamnoside 7-O-methyltransferase activity","canonical_id":"go:GO:0033801","description":"\"Catalysis of the reaction: S-adenosyl-L-methionine + vitexin 2''-O-beta-L-rhamnoside = S-adenosyl-L-homocysteine + 7-O-methylvitexin 2''-O-beta-L-rhamnoside.\" [RHEA:11432]","metadata":null},{"id":"8dd38f78270d4f11bc8d6a94b0169f44","type":"GO_TERM","name":"vitexin beta-glucosyltransferase activity","canonical_id":"go:GO:0050395","description":"\"Catalysis of the reaction: UDP-D-glucose + vitexin = H+ + UDP + vitexin 2''-O-beta-D-glucoside.\" [EC:2.4.1.105, RHEA:21956]","metadata":null},{"id":"fff0568ea32648c7a0767bea2a7665bf","type":"DISEASE","name":"vitiligo","canonical_id":"mondo:0008661","description":null,"metadata":null},{"id":"417e6e6fae99452b9b49d77c633fa7f7","type":"GO_TERM","name":"vocal learning","canonical_id":"go:GO:0042297","description":"\"A behavioral process whose outcome is a relatively long-lasting behavioral change whereby an organism modifies innate vocalizations to imitate sounds produced by others.\" [GOC:BHF, GOC:dos, GOC:rl, PMID:16418265, PMID:17035521]","metadata":null},{"id":"f2133b1d2cd04a3dbfabdd5f36e025d7","type":"GO_TERM","name":"vocalization behavior","canonical_id":"go:GO:0071625","description":"\"The behavior in which an organism produces sounds by a mechanism involving its respiratory system.\" [GOC:mah]","metadata":null},{"id":"b9568018e4004bba95130126db7ebf04","type":"DRUG","name":"voclosporin","canonical_id":"gtopdb:11388","description":null,"metadata":null},{"id":"745669ef56f54dc686e8c4d2085d1fc5","type":"DRUG","name":"voclosporin","canonical_id":"mesh:C484071","description":null,"metadata":null},{"id":"a6a09dac640d44169352dfcc4ab56acb","type":"DRUG","name":"voclosporin","canonical_id":"chembl:CHEMBL5314379","description":null,"metadata":null},{"id":"6b13571d37a740eda1852f7ace48ece4","type":"DRUG","name":"voglibose","canonical_id":"mesh:C102817","description":null,"metadata":null},{"id":"71047f46b46c45349be849aa777ce7b0","type":"PROTEIN","name":"voltage dependent T-type calcium channel subunit alpha-1G","canonical_id":"uniprot:O43497","description":null,"metadata":null},{"id":"12816c1ce1564138951f5681c7453618","type":"GO_TERM","name":"voltage-gated calcium channel activity","canonical_id":"go:GO:0005245","description":"\"Enables the transmembrane transfer of a calcium ion by a voltage-gated channel. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, GOC:tb, ISBN:0815340729]","metadata":null},{"id":"b38a2268bb814eab8e4792ead85dfcc7","type":"GO_TERM","name":"voltage-gated calcium channel activity involved SA node cell action potential","canonical_id":"go:GO:0086059","description":"\"Enables the transmembrane transfer of a calcium ion by a voltage-gated channel across the plasma membrane of an SA node cardiac muscle cell that contributes to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"43c475b80426406ebc5a93e40ec15896","type":"GO_TERM","name":"voltage-gated calcium channel activity involved in AV node cell action potential","canonical_id":"go:GO:0086056","description":"\"Enables the transmembrane transfer of a calcium ion by a voltage-gated channel across the plasma membrane of an AV node cardiac muscle cell that contributes to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"3af9c942e5af4c34b3ab6bd9b2274324","type":"GO_TERM","name":"voltage-gated calcium channel activity involved in bundle of His cell action potential","canonical_id":"go:GO:0086057","description":"\"Enables the transmembrane transfer of a calcium ion by a voltage-gated channel across the plasma membrane of a bundle of His cardiac muscle cell that contributes to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"f602b2c5af9a4ac48d7bd84631c2f42a","type":"GO_TERM","name":"voltage-gated calcium channel activity involved in cardiac muscle cell action potential","canonical_id":"go:GO:0086007","description":"\"Enables the transmembrane transfer of a calcium ion by a voltage-gated channel across the plasma membrane of a cardiac muscle cell that contributes to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"8066038b814843bbbe2e52d0208de3ab","type":"GO_TERM","name":"voltage-gated calcium channel activity involved in positive regulation of presynaptic cytosolic calcium levels","canonical_id":"go:GO:0099635","description":"\"Positive regulation of presynaptic cytosolic calcium ion concentrations via the directed movement of calcium ions across the plasma-membrane into the cytosol via the action of voltage-gated calcium ion channels. This is the first step in synaptic transmission.\" [GOC:dos]","metadata":null},{"id":"76c0f78c125240a4970181da90d6cb36","type":"GO_TERM","name":"voltage-gated calcium channel activity involved in regulation of cytosolic calcium levels","canonical_id":"go:GO:0099511","description":"\"Regulation of cytosolic calcium ion concentrations via the directed movement of calcium ions across the plasma-membrane into the cytosol via the action of a voltage-gated calcium ion channel.\" [GOC:dos]","metadata":null},{"id":"ed0568a3a1a04c109fd084c6c15cc2e8","type":"GO_TERM","name":"voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels","canonical_id":"go:GO:0099626","description":"\"Regulation of presynaptic cytosolic calcium ion concentrations via the action of voltage-gated calcium ion channels.\" [GOC:dos, PMID:15548655]","metadata":null},{"id":"64945bb51a574085ae47a09d1bb7bebd","type":"GO_TERM","name":"voltage-gated calcium channel complex","canonical_id":"go:GO:0005891","description":"\"A protein complex that forms a transmembrane channel through which calcium ions may pass in response to changes in membrane potential.\" [GOC:mah]","metadata":null},{"id":"47b82283905541c88a494cace56bbda1","type":"GO_TERM","name":"voltage-gated calcium channel complex assembly","canonical_id":"go:GO:0070978","description":"\"Cellular protein complex assembly that results in the formation of a voltage-gated calcium channel complex.\" [GOC:mh]","metadata":null},{"id":"fd17dd8d307748ff87ab8f3d08aa21ca","type":"GO_TERM","name":"voltage-gated channel activity","canonical_id":"go:GO:0022832","description":"\"Enables the transmembrane transfer of a solute by a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"997e0e0f00fe42c1ada3ceb60c7e60bc","type":"GO_TERM","name":"voltage-gated chloride channel activity","canonical_id":"go:GO:0005247","description":"\"Enables the transmembrane transfer of a chloride ion by a voltage-gated channel. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"37e987718f2445ce9873f86d01e26dff","type":"GO_TERM","name":"voltage-gated monoatomic anion channel activity","canonical_id":"go:GO:0008308","description":"\"Enables the transmembrane transfer of an anion by a voltage-gated channel. An anion is a negatively charged ion. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, GOC:vw, ISBN:0815340729]","metadata":null},{"id":"caf536665c994cb4b93a76575ab1d33d","type":"GO_TERM","name":"voltage-gated monoatomic cation channel activity","canonical_id":"go:GO:0022843","description":"\"Enables the transmembrane transfer of a cation by a voltage-gated channel. A cation is a positively charged ion. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"f1f0f8bae47e42a09728fff3bf6072d2","type":"GO_TERM","name":"voltage-gated monoatomic ion channel activity","canonical_id":"go:GO:0005244","description":"\"Enables the transmembrane transfer of an ion by a voltage-gated channel. An ion is an atom or group of atoms carrying an electric charge by virtue of having gained or lost one or more electrons. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0198506732, ISBN:0815340729]","metadata":null},{"id":"c8556d18bd99471a928da63a4e947478","type":"GO_TERM","name":"voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential","canonical_id":"go:GO:1905030","description":"\"Any voltage-gated ion channel activity that is involved in regulation of postsynaptic membrane potential.\" [GO_REF:0000061, GOC:TermGenie, ISBN:9780071120005]","metadata":null},{"id":"1d5586c33ffc4eb89f272afe02c17139","type":"GO_TERM","name":"voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential","canonical_id":"go:GO:0099508","description":"\"Voltage-gated ion channel activity, occurring in the presynaptic membrane, involved in regulation of presynaptic membrane potential. This is a key step in synaptic transmission, following the arrival of an action potential at the synapse.\" [GOC:dos]","metadata":null},{"id":"bab7d1e84e1b4451af65cf83f270e729","type":"GO_TERM","name":"voltage-gated potassium channel activity","canonical_id":"go:GO:0005249","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"72f8256b4d974e62b0d2adb5c440f8bf","type":"GO_TERM","name":"voltage-gated potassium channel activity involved in SA node cell action potential depolarization","canonical_id":"go:GO:0086041","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of an SA node cardiac muscle cell contributing to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"2a4c478f3a024bbe8f68052bf41d669d","type":"GO_TERM","name":"voltage-gated potassium channel activity involved in SA node cell action potential repolarization","canonical_id":"go:GO:0086090","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of an SA node cell contributing to the repolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"64b6ab9bcbef40fab455793671993e95","type":"GO_TERM","name":"voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization","canonical_id":"go:GO:0086089","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of an atrial cardiomyocyte contributing to the repolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"ce9fd0e0de774ac7938b5aecefa05382","type":"GO_TERM","name":"voltage-gated potassium channel activity involved in bundle of His cell action potential repolarization","canonical_id":"go:GO:0086087","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of a bundle of His cell contributing to the repolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"20be9e16f4d34ecdab09c73fce229b2f","type":"GO_TERM","name":"voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization","canonical_id":"go:GO:0086008","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of a cardiac muscle cell contributing to the repolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"9abe1e11ae04411bab893b34c89a8342","type":"GO_TERM","name":"voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization","canonical_id":"go:GO:1902282","description":"\"Enables the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of a ventricular cardiomyocyte contributing to the repolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:8528244]","metadata":null},{"id":"03508ee0c37c49a6865e3b42749ce238","type":"GO_TERM","name":"voltage-gated potassium channel complex","canonical_id":"go:GO:0008076","description":"\"A protein complex that forms a transmembrane channel through which potassium ions may cross a cell membrane in response to changes in membrane potential.\" [GOC:mah]","metadata":null},{"id":"53de19e262ac48e6b754364ee443afbc","type":"GO_TERM","name":"voltage-gated proton channel activity","canonical_id":"go:GO:0030171","description":"\"Enables the transmembrane transfer of a proton by a voltage-gated channel. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [PMID:28774948]","metadata":null},{"id":"ee03fc9af4254ccf9f41cf238bf71d40","type":"GO_TERM","name":"voltage-gated sodium channel activity","canonical_id":"go:GO:0005248","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"d9e8e57b9e5f4987ba5ba25d7977c76b","type":"GO_TERM","name":"voltage-gated sodium channel activity involved in AV node cell action potential","canonical_id":"go:GO:0086060","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of an AV node cardiac muscle cell contributing to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"ecbb3fb5ba924270acf36960e5c68c7d","type":"GO_TERM","name":"voltage-gated sodium channel activity involved in Purkinje myocyte action potential","canonical_id":"go:GO:0086062","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of a Purkinje myocyte contributing to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"bffa4487e1c742cabdb129751705eec2","type":"GO_TERM","name":"voltage-gated sodium channel activity involved in SA node cell action potential","canonical_id":"go:GO:0086063","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of an SA node cardiac muscle cell contributing to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"a06b922f5b3d4b5e8dcfae0199ccecd2","type":"GO_TERM","name":"voltage-gated sodium channel activity involved in bundle of His cell action potential","canonical_id":"go:GO:0086061","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of a bundle of His cardiac muscle cell contributing to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"affb21945f6e4ad4be86800e1b8a8cab","type":"GO_TERM","name":"voltage-gated sodium channel activity involved in cardiac muscle cell action potential","canonical_id":"go:GO:0086006","description":"\"Enables the transmembrane transfer of a sodium ion by a voltage-gated channel through the plasma membrane of a cardiac muscle cell contributing to the depolarization phase of an action potential. A voltage-gated channel is a channel whose open state is dependent on the voltage across the membrane in which it is embedded.\" [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]","metadata":null},{"id":"8ab9814e979d4c9c9ad5a0276d5bc90e","type":"GO_TERM","name":"voltage-gated sodium channel complex","canonical_id":"go:GO:0001518","description":"\"A sodium channel in a cell membrane whose opening is governed by the membrane potential.\" [ISBN:0198506732]","metadata":null},{"id":"4155516230df4e70857f77ac47b0a2a1","type":"GO_TERM","name":"volume-sensitive anion channel activity","canonical_id":"go:GO:0005225","description":"\"Enables the transmembrane transfer of a monoatomic anion by a volume-sensitive channel. A volume-sensitive channel is a channel that responds to changes in the volume of a cell.\" [GOC:dph, GOC:tb]","metadata":null},{"id":"8a36bcd03e3748299851bdef1abdc509","type":"GO_TERM","name":"volume-sensitive chloride channel activity","canonical_id":"go:GO:0072320","description":"\"Enables the transmembrane transfer of a chloride ion by a volume-sensitive channel. A volume-sensitive channel is a channel that responds to changes in the volume of a cell.\" [GOC:mah]","metadata":null},{"id":"33aa233d568742dc8ae8c31accafffd9","type":"GO_TERM","name":"voluntary musculoskeletal movement","canonical_id":"go:GO:0050882","description":"\"The movement of an organism or part of an organism using mechanoreceptors, the nervous system, striated muscle and/or the skeletal system that can be controlled at will.\" [GOC:dph]","metadata":null},{"id":"e9ad1dbb86f6498ea1fe9efa6eb0cc01","type":"GO_TERM","name":"voluntary skeletal muscle contraction","canonical_id":"go:GO:0003010","description":"\"A process in which force is generated within voluntary skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. In the voluntary skeletal muscle, the muscle contraction takes advantage of an ordered sarcomeric structure and it is under voluntary control. Voluntary skeletal muscle is skeletal muscle that is under conscious control.\" [GOC:mtg_cardio, GOC:mtg_muscle]","metadata":null},{"id":"9d3e7ead02a340c28cd633071955e036","type":"GO_TERM","name":"vomifoliol 4'-dehydrogenase activity","canonical_id":"go:GO:0050396","description":"\"Catalysis of the reaction: (6S,9R)-6-hydroxy-3-oxo-alpha-ionol + NAD+ = (6S)-6-hydroxy-3-oxo-alpha-ionone + H+ + NADH.\" [EC:1.1.1.221, RHEA:22804]","metadata":null},{"id":"cdb8a19d7b854351943e845bae8508f0","type":"GO_TERM","name":"vomilenine glucosyltransferase activity","canonical_id":"go:GO:0050506","description":"\"Catalysis of the reaction: UDP-D-glucose + vomilenine = H+ + raucaffricine + UDP.\" [EC:2.4.1.219, RHEA:19385]","metadata":null},{"id":"087c7a4e0fe74def9d7cf912015a09e2","type":"GO_TERM","name":"vomilenine reductase activity","canonical_id":"go:GO:0050624","description":"\"Catalysis of the reaction: 1,2-dihydrovomilenine + NADP+ = H+ + NADPH + vomilenine.\" [EC:1.5.1.32, RHEA:16409]","metadata":null},{"id":"7f77e04b8a6c494594d99c90165c0b06","type":"GO_TERM","name":"vomitoxin biosynthetic process","canonical_id":"go:GO:0106110","description":"\"The chemical reactions and pathways resulting in the formation of type B trichothecene vomitoxin, also known as deoxynivalenol, a poisonous substance produced by some species of fungi and predominantly occurs in grains such as wheat, barley and oats.\" [https://doi.org/10.1007/BF03356188, PMID:19333439, PMID:25680507, PMID:25758923, PMID:8637056]","metadata":null},{"id":"73ac8cd87e8b435b897818b284d76c71","type":"DISEASE","name":"von Willebrand disease (hereditary or acquired)","canonical_id":"mondo:0024574","description":null,"metadata":null},{"id":"d26230657fca440e9da40da0587a2344","type":"GO_TERM","name":"von-Willerbrand-factor-A-domain-rich collagen trimer","canonical_id":"go:GO:0140158","description":"\"A family of collagens containing multiple von Willebrand factor A (vWA) domains.\" [PMID:21421911]","metadata":null},{"id":"ac15b8b697d948b481eefec58524df6b","type":"DRUG","name":"vonicog alfa","canonical_id":"mesh:D014841","description":null,"metadata":null},{"id":"6dee136cc1d44f15a3f724a6ddb1187f","type":"DRUG","name":"vorapaxar","canonical_id":"gtopdb:4047","description":null,"metadata":null},{"id":"bf438844179d4b3db11916a57ca6c5c4","type":"DRUG","name":"vorapaxar","canonical_id":"mesh:C530299","description":null,"metadata":null},{"id":"caf7979911c3407cb6d0d0292165f20a","type":"DRUG","name":"voriconazole","canonical_id":"mesh:D065819","description":null,"metadata":null},{"id":"7bc01b8d9b4b4c95a009927cd397dde0","type":"DRUG","name":"vorinostat","canonical_id":"gtopdb:6852","description":null,"metadata":null},{"id":"5946c529b6ed49c6b0c6fd26c69bd0ea","type":"DRUG","name":"vorinostat","canonical_id":"mesh:C111237","description":null,"metadata":null},{"id":"5460da62cc284f7fb8bbfbaefaaa1904","type":"DRUG","name":"vorinostat","canonical_id":"chembl:CHEMBL98","description":null,"metadata":null},{"id":"b7b007b104544ac6898ef76510c9e375","type":"DRUG","name":"vornorexant","canonical_id":"gtopdb:14430","description":null,"metadata":null},{"id":"7c693a7e94b74a0a944550dcbb51b2bc","type":"DRUG","name":"vortioxetine","canonical_id":"gtopdb:7351","description":null,"metadata":null},{"id":"92a8aa44f3f0430e8855cc4a6d86be61","type":"DRUG","name":"vortioxetine","canonical_id":"mesh:C557874","description":null,"metadata":null},{"id":"b2adf3bc70484ddc9426bea2a365a086","type":"DRUG","name":"voxilaprevir","canonical_id":"mesh:C000619503","description":null,"metadata":null},{"id":"711cb566fdfe492fa889938945849329","type":"GO_TERM","name":"vulval cell fate commitment","canonical_id":"go:GO:0072325","description":"\"The process in which the cellular identity of nematode vulval cells is acquired and determined. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed adult vulva, which is the egg-laying organ of female and hermaphrodite nematodes.\" [GOC:kmv, GOC:mah, ISBN:087969307X, PMID:11236714]","metadata":null},{"id":"92595a064e7f447a8db1bf2ac648ccf8","type":"GO_TERM","name":"vulval cell fate determination","canonical_id":"go:GO:0072326","description":"\"The process in which a cell becomes capable of differentiating autonomously into a nematode vulval cell regardless of its environment; upon determination, the cell fate cannot be reversed. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed adult vulva, which is the egg-laying organ of female and hermaphrodite nematodes.\" [GOC:kmv, GOC:mah, ISBN:087969307X, PMID:11236714]","metadata":null},{"id":"a592f096c3c64ad892b1f13492e83168","type":"GO_TERM","name":"vulval cell fate specification","canonical_id":"go:GO:0072327","description":"\"The process in which a cell becomes capable of differentiating autonomously into a nematode vulval cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed adult vulva, which is the egg-laying organ of female and hermaphrodite nematodes.\" [GOC:kmv, GOC:mah, ISBN:087969307X, PMID:11236714]","metadata":null},{"id":"ee517e5dafb04b608557504d0c72753e","type":"GO_TERM","name":"vulval development","canonical_id":"go:GO:0040025","description":"\"The process whose specific outcome is the progression of the egg-laying organ of female and hermaphrodite nematodes over time, from its formation to the mature structure. In nematodes, the vulva is formed from ventral epidermal cells during larval stages to give rise to a fully formed vulva in the adult.\" [GOC:ems, GOC:kmv, ISBN:087969307X]","metadata":null},{"id":"6a56d69a9325498bb902b1553f34303b","type":"GO_TERM","name":"vulval location","canonical_id":"go:GO:0034608","description":"\"Location, by the male, of his partner's vulva when backing along the ventral side of the hermaphrodite during mating. The male stops at the vulva, coordinates his movements to the hermaphrodite's, and positions his tail precisely over the vulva so that he may insert his spicules and ejaculate.\" [PMID:18050467]","metadata":null},{"id":"d3ee7251bfb64bbd80379f5ffb24c81a","type":"DRUG","name":"vunakizumab","canonical_id":"gtopdb:9296","description":null,"metadata":null},{"id":"f89cef269dd2412c80bbd8ec38c2a01d","type":"DRUG","name":"vunakizumab","canonical_id":"chembl:CHEMBL4298102","description":null,"metadata":null},{"id":"bcd301d094ec4b6084ac22a2414f9812","type":"GO_TERM","name":"walking behavior","canonical_id":"go:GO:0090659","description":"\"The behavior of an organism relating to the progression of that organism along the ground by the process of lifting and setting down each leg.\" [GOC:tb]","metadata":null},{"id":"ed73e6e7d04345e7927af1804ce95a7f","type":"GO_TERM","name":"wall teichoic acid biosynthetic process","canonical_id":"go:GO:0070398","description":"\"The chemical reactions and pathways resulting in the formation of wall teichoic acid, which is a major component of the cell wall of Gram-positive bacteria and typically consists of a polymer of glycerol-phosphate or ribitol-phosphate to which are attached glycosyl and D-alanyl ester residues and which is covalently linked to peptidoglycan.\" [GOC:add, PMID:14665680, PMID:16020688]","metadata":null},{"id":"b6c2feb287314832ae89fc631de4181c","type":"GO_TERM","name":"wall teichoic acid catabolic process","canonical_id":"go:GO:0070399","description":"\"The chemical reactions and pathways resulting in the breakdown of wall teichoic acid, which is a major component of the cell wall of Gram-positive bacteria and typically consists of a polymer of glycerol-phosphate or ribitol-phosphate to which are attached glycosyl and D-alanyl ester residues and which is covalently linked to peptidoglycan.\" [GOC:add, PMID:14665680]","metadata":null},{"id":"ad4237c57ecb40c8a91103d358feeecd","type":"DRUG","name":"warfarin","canonical_id":"gtopdb:6853","description":null,"metadata":null},{"id":"0a678f5249654f5cb6da17ab75a051c4","type":"DRUG","name":"warfarin","canonical_id":"mesh:D014859","description":null,"metadata":null},{"id":"a0064ecd2f0243b795af1742eb2556be","type":"GO_TERM","name":"water channel activity","canonical_id":"go:GO:0015250","description":"\"Enables the energy-independent facilitated diffusion of water through a transmembrane aqueous pore or channel.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"8c8119e409bc41998b920969f304b34d","type":"GO_TERM","name":"water transmembrane transporter activity","canonical_id":"go:GO:0005372","description":"\"Enables the transfer of water (H2O) from one side of a membrane to the other.\" [GOC:ai]","metadata":null},{"id":"f47a9f65662340f3b6d97f0fe2556a78","type":"GO_TERM","name":"water transport","canonical_id":"go:GO:0006833","description":"\"The directed movement of water (H2O) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"29c59bc137a6412ca2f0634f2e8dbce1","type":"GO_TERM","name":"water-soluble vitamin biosynthetic process","canonical_id":"go:GO:0042364","description":"\"The chemical reactions and pathways resulting in the formation of any of a diverse group of vitamins that are soluble in water.\" [GOC:jl]","metadata":null},{"id":"981b861b903243b795426e33581749fd","type":"GO_TERM","name":"water-soluble vitamin catabolic process","canonical_id":"go:GO:0042365","description":"\"The chemical reactions and pathways resulting in the breakdown of any of a diverse group of vitamins that are soluble in water.\" [GOC:jl, PMID:24365359]","metadata":null},{"id":"0898699b29364824ae7920b22cfa854c","type":"GO_TERM","name":"wax biosynthetic process","canonical_id":"go:GO:0010025","description":"\"The chemical reactions and pathways resulting in the formation of wax, which includes C16 and C18 fatty acids.\" [ISBN:0943088399]","metadata":null},{"id":"88591001726a4d4fbf80a413214c612f","type":"GO_TERM","name":"wax metabolic process","canonical_id":"go:GO:0010166","description":"\"The chemical reactions and pathways involving wax, a compound containing C16 and C18 fatty acids.\" [GOC:sm]","metadata":null},{"id":"15da6f5a8616483887d870c0161265a7","type":"GO_TERM","name":"wax-ester hydrolase activity","canonical_id":"go:GO:0050398","description":"\"Catalysis of the reaction: a wax ester + H2O = a long-chain alcohol + a long-chain carboxylate.\" [EC:3.1.1.50, MetaCyc:WAX-ESTER-HYDROLASE-RXN]","metadata":null},{"id":"ebea11984cfa4ad28b3709ff655895ca","type":"DISEASE","name":"wet macular degeneration","canonical_id":"mondo:0005417","description":null,"metadata":null},{"id":"1c45049386cf45d499a14a1540d67e00","type":"GO_TERM","name":"white fat cell differentiation","canonical_id":"go:GO:0050872","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a white adipocyte, an animal connective tissue cell involved in energy storage. White adipocytes have cytoplasmic lipids arranged in a unique vacuole.\" [PMID:12508945]","metadata":null},{"id":"1694a5c020ad4b59a3fe48a4d843d594","type":"GO_TERM","name":"white fat cell proliferation","canonical_id":"go:GO:0070343","description":"\"The multiplication or reproduction of white fat cells by cell division, resulting in the expansion of their population.\" [CL:0000448, GOC:mah, GOC:sl]","metadata":null},{"id":"6df940de97ef43bcbf8c3db7dfa28af5","type":"GO_TERM","name":"wide pore channel activity","canonical_id":"go:GO:0022829","description":"\"Enables the energy-independent facilitated diffusion of propanediol through a large pore, un-gated channel. Examples include gap junctions, which transport substances from one cell to another; and porins which transport substances in and out of bacteria, mitochondria and chloroplasts.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"48cdd7f20ba347b694af74ded3144841","type":"GO_TERM","name":"wing and notum subfield formation","canonical_id":"go:GO:0035309","description":"\"The regionalization process that subdivides the wing imaginal disc into the wing and notum (body wall) subfields, thus determining whether cells ultimately differentiate wing or notum-specific structures.\" [PMID:10860999]","metadata":null},{"id":"fa5a0ea2c6c947038f827c0d35ab3a83","type":"GO_TERM","name":"wing cell fate specification","canonical_id":"go:GO:0035311","description":"\"The process in which a cell in the larval wing imaginal disc becomes capable of differentiating autonomously into a wing cell, if left in its normal environment.\" [PMID:10860999]","metadata":null},{"id":"a56480c001204a559ccae50adfae69d4","type":"GO_TERM","name":"wing disc anterior/posterior pattern formation","canonical_id":"go:GO:0048100","description":"\"The establishment, maintenance and elaboration of the anterior/posterior axis of the wing disc, a precursor to the wing.\" [GOC:jid, PMID:10625531]","metadata":null},{"id":"7341e61b58b94fbaaf8e1351021f42aa","type":"GO_TERM","name":"wing disc development","canonical_id":"go:GO:0035220","description":"\"Progression of the wing disc over time, from its initial formation through to its metamorphosis to form adult structures including the wing hinge, wing blade and pleura.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"14db046b87d74f7a89d189ce30318d44","type":"GO_TERM","name":"wing disc dorsal/ventral pattern formation","canonical_id":"go:GO:0048190","description":"\"The establishment, maintenance and elaboration of the dorsal/ventral axis of the wing disc, a precursor to the adult wing.\" [GOC:jid]","metadata":null},{"id":"b3363742ba454f36a24fccf007538af4","type":"GO_TERM","name":"wing disc morphogenesis","canonical_id":"go:GO:0007472","description":"\"The process in which the anatomical structures derived from the wing disc are generated and organized. This includes the transformation of a wing imaginal disc from a monolayered epithelium in the larvae of holometabolous insects into recognizable adult structures including the wing hinge, wing blade and pleura.\" [GOC:bf, ISBN:0879694238]","metadata":null},{"id":"558536b0487e48a88d6350fe884ca8f2","type":"GO_TERM","name":"wing disc pattern formation","canonical_id":"go:GO:0035222","description":"\"The process giving rise to the pattern of cell differentiation in the wing imaginal disc.\" [GOC:bf]","metadata":null},{"id":"257a2223db094a1592e0266ee63abc7c","type":"GO_TERM","name":"wing disc proximal/distal pattern formation","canonical_id":"go:GO:0007473","description":"\"The establishment, maintenance and elaboration of the proximal/distal axis of the wing disc, a precursor to the adult wing.\" [GOC:bf]","metadata":null},{"id":"8a3e3f55c61c42d98ac9f6fde43b3db3","type":"GO_TERM","name":"wishful thinking binding","canonical_id":"go:GO:0005117","description":"\"Binding to wishful thinking (Wit), a type II bone morphogenic protein receptor.\" [GOC:ceb, PMID:11856529]","metadata":null},{"id":"02e24a8c5f7b489bb44cab31c68d6397","type":"GO_TERM","name":"wobble position cytosine ribose methylation","canonical_id":"go:GO:0002131","description":"\"The process in which the ribose of cytidine at position 34 in the anticodon of a tRNA is post-transcriptionally methylated at the 2'-O position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"fdc6cd15e8d54d1386ecb0ea75eb4819","type":"GO_TERM","name":"wobble position guanine ribose methylation","canonical_id":"go:GO:0002129","description":"\"The process in which the ribose of guanosine at position 34 in the anticodon of a tRNA is post-transcriptionally methylated at the 2'-O position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"e6ade7f01f8a4793a053547613bef50c","type":"GO_TERM","name":"wobble position ribose methylation","canonical_id":"go:GO:0002130","description":"\"The process in which the ribose base of the nucleotide at position 34 in the anticodon of a tRNA is post-transcriptionally methylated at the 2'O position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"14eb41f8a7da4671b7866a85cdd12483","type":"GO_TERM","name":"wobble position uridine ribose methylation","canonical_id":"go:GO:0002132","description":"\"The process in which the ribose of uridine at position 34 in the anticodon of a tRNA is post-transcriptionally methylated at the 2'-O position.\" [GOC:hjd, ISBN:155581073X]","metadata":null},{"id":"0d4c07c25ce2400d8f519d234e5ff880","type":"GO_TERM","name":"wogonin 7-O-glucuronosyltransferase activity","canonical_id":"go:GO:0102468","description":"\"Catalysis of the reaction: UDP-alpha-D-glucuronate + wogonin = UDP + wogonin 7-O-beta-D-glucuronate + H+.\" [RHEA:28322]","metadata":null},{"id":"b628ee6f4d37453fbf61d93e9e518d6f","type":"GO_TERM","name":"wound healing","canonical_id":"go:GO:0042060","description":"\"The series of events that restore integrity to a damaged tissue, following an injury.\" [GOC:bf, PMID:15269788]","metadata":null},{"id":"9687931f1f874d7ca69a0394cfddfdc7","type":"GO_TERM","name":"wound healing involved in inflammatory response","canonical_id":"go:GO:0002246","description":"\"The series of events that restore integrity to damaged tissue that contribute to an inflammatory response.\" [GOC:jal, ISBN:0721601871]","metadata":null},{"id":"8f544c15c73f4890b80dba583d9e07d4","type":"GO_TERM","name":"wound healing, spreading of cells","canonical_id":"go:GO:0044319","description":"\"The migration of a cell along or through a wound gap that contributes to the reestablishment of a continuous surface.\" [GOC:jl]","metadata":null},{"id":"c9958cb1e39a47d4afc01b5ea330fcf1","type":"GO_TERM","name":"wound healing, spreading of epidermal cells","canonical_id":"go:GO:0035313","description":"\"The migration of an epidermal cell along or through a wound gap that contributes to the reestablishment of a continuous epidermis.\" [GOC:bf, PMID:15269788]","metadata":null},{"id":"d0d1c94508144e3795d4070a939b6b02","type":"GO_TERM","name":"wybutosine biosynthetic process","canonical_id":"go:GO:0031591","description":"\"The chemical reactions and pathways resulting in the formation of wybutosine, 3H-imidazo[1,2-alpha]purine-7-butanoic acid, 4,9-dihydro- alpha-[(methoxycarbonyl)amino]- 4,6-dimethyl-9-oxo- 3-beta-D-ribofuranosyl methyl ester, a modified nucleoside found in some tRNA molecules.\" [GOC:hjd, GOC:mah, RNAmods:037]","metadata":null},{"id":"8c6cbb3b4ada40e3b99e3e2415edd66a","type":"GO_TERM","name":"xanthan lyase activity","canonical_id":"go:GO:0047492","description":"\"Catalysis of the reaction: xanthan = oligosaccharide with 4-deoxy-alpha-L-threo-hex-4-enuronosyl end + pyruvylate mannose. This reaction is the eliminative cleavage of the terminal beta-D-mannosyl-beta-D-1,4-glucuronosyl linkage of the side-chain of the polysaccharide xanthan, leaving a 4-deoxy-alpha-L-threo-hex-4-enuronosyl group at the terminus of the side-chain.\" [EC:4.2.2.12]","metadata":null},{"id":"1170b775cef14ab0bb7f7fe301491e73","type":"GO_TERM","name":"xanthine DNA N-glycosylase activity","canonical_id":"go:GO:0097508","description":"\"DNA N-glycosylase activity acting on deaminated guanine (xanthine).\" [GOC:al, PMID:18789404]","metadata":null},{"id":"44d42c0d780c4393b820c6fca20ae255","type":"GO_TERM","name":"xanthine binding","canonical_id":"go:GO:0160050","description":"\"Binding to xanthine, a purine base.\" [PMID:32345632, PMID:34125892]","metadata":null},{"id":"940ec66309694249ba4635f4f5682644","type":"GO_TERM","name":"xanthine biosynthetic process","canonical_id":"go:GO:0046111","description":"\"The chemical reactions and pathways resulting in the formation of xanthine, 2,6-dihydroxypurine, a purine formed in the metabolic breakdown of guanine but not present in nucleic acids.\" [GOC:curators]","metadata":null},{"id":"964299c1db284c58b93d9ba7744ce11b","type":"GO_TERM","name":"xanthine catabolic process","canonical_id":"go:GO:0009115","description":"\"The chemical reactions and pathways resulting in the breakdown of xanthine, 2,6-dihydroxypurine, a purine formed in the metabolic breakdown of guanine but not present in nucleic acids.\" [GOC:curators]","metadata":null},{"id":"f94298ac7342408b8b1d2b744e48d97a","type":"GO_TERM","name":"xanthine dehydrogenase activity","canonical_id":"go:GO:0004854","description":"\"Catalysis of the reaction: xanthine + NAD+ + H2O = urate + NADH + H+.\" [EC:1.17.1.4]","metadata":null},{"id":"f15949b6efb0463481fc29b74c46fb8a","type":"GO_TERM","name":"xanthine dehydrogenase complex","canonical_id":"go:GO:0002197","description":"\"A homodimeric protein complex having xanthine dehydrogenase activity.\" [GOC:hjd, PMID:8224915]","metadata":null},{"id":"eb96adf842824ec8ab683dc00f016ce7","type":"GO_TERM","name":"xanthine hydrolase activity","canonical_id":"go:GO:0043836","description":"\"Catalysis of the reaction: xanthine + H2O = 4-ureido-5-imidazole carboxylate.\" [MetaCyc:R127-RXN, PMID:13278326]","metadata":null},{"id":"8fa447d726e94d73ac8a676e0e6e86be","type":"GO_TERM","name":"xanthine metabolic process","canonical_id":"go:GO:0046110","description":"\"The chemical reactions and pathways involving xanthine, 2,6-dihydroxypurine, a purine formed in the metabolic breakdown of guanine but not present in nucleic acids.\" [GOC:curators]","metadata":null},{"id":"d48459cae56246458e2c7f011c519d91","type":"GO_TERM","name":"xanthine oxidase activity","canonical_id":"go:GO:0004855","description":"\"Catalysis of the reaction: xanthine + H2O + O2 = urate + H2O2.\" [EC:1.17.3.2]","metadata":null},{"id":"a19487017d724eb0889bda215fddff25","type":"GO_TERM","name":"xanthine phosphoribosyltransferase activity","canonical_id":"go:GO:0000310","description":"\"Catalysis of the reaction: diphosphate + XMP = 5-phospho-alpha-D-ribose 1-diphosphate + xanthine.\" [RHEA:10800]","metadata":null},{"id":"8f0304a5bb9b4d96a30aca7f832c1f19","type":"GO_TERM","name":"xanthine transmembrane transporter activity","canonical_id":"go:GO:0042907","description":"\"Enables the transfer of xanthine from one side of a membrane to the other. Xanthine (2,6-dihydroxypurine) is a purine formed in the metabolic breakdown of guanine, but is not present in nucleic acids.\" [GOC:jl]","metadata":null},{"id":"d0fcd701bb6f448ba3ce2aedb9d50645","type":"GO_TERM","name":"xanthine transport","canonical_id":"go:GO:0042906","description":"\"The directed movement of xanthine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Xanthine (2,6-dihydroxypurine) is a purine formed in the metabolic breakdown of guanine, but is not present in nucleic acids.\" [GOC:jl]","metadata":null},{"id":"3636612d63b7446aa8dec1e0ed66974e","type":"DISEASE","name":"xanthinuria type I","canonical_id":"mondo:0010209","description":null,"metadata":null},{"id":"e77aec751621448bbc764f2b80e8329e","type":"DISEASE","name":"xanthinuria type II","canonical_id":"mondo:0011346","description":null,"metadata":null},{"id":"b1fdcd321b85460da51ecca9e816af20","type":"GO_TERM","name":"xanthommatin reductase activity","canonical_id":"go:GO:0050399","description":"\"Catalysis of the reaction: 5,12-dihydroxanthommatin + NAD+ = H+ + NADH + xanthommatin.\" [EC:1.3.1.41, RHEA:13417]","metadata":null},{"id":"1876534ee895464cb4973832851e60c1","type":"GO_TERM","name":"xanthone-containing compound biosynthetic process","canonical_id":"go:GO:2001307","description":"\"The chemical reactions and pathways resulting in the formation of a xanthone-containing compound.\" [GOC:di]","metadata":null},{"id":"8055857498004bf4afd9a30afb57c046","type":"GO_TERM","name":"xanthophore","canonical_id":"go:GO:0031633","description":"\"A chromatophore containing yellow pigment.\" [ISBN:0395825172]","metadata":null},{"id":"4d6a23388d4140ceba563bbc5a594148","type":"GO_TERM","name":"xanthophore differentiation","canonical_id":"go:GO:0050936","description":"\"The process in which a relatively unspecialized cell acquires the specialized features of a xanthophore cell. Xanthophores are pigment cells derived from the neural crest. They contain pteridine and/or carotenoid pigments in structures called pterinosomes or xanthosomes. This makes them yellow to orange in appearance.\" [GOC:jid, GOC:mh, PMID:11858836]","metadata":null},{"id":"7bf42c9e471847ffa9780d96ef234e5b","type":"GO_TERM","name":"xanthophyll binding","canonical_id":"go:GO:0051738","description":"\"Binding to xanthophylls, any of several neutral yellow to orange carotenoid pigments containing oxygen.\" [ISBN:0122146743]","metadata":null},{"id":"8a207a5dfef24c4aaec1e84db54dd720","type":"GO_TERM","name":"xanthophyll biosynthetic process","canonical_id":"go:GO:0016123","description":"\"The chemical reactions and pathways resulting in the formation of xanthophylls, oxygen-containing carotenoids.\" [GOC:curators]","metadata":null},{"id":"37990120f80d418399f97981ab31909a","type":"GO_TERM","name":"xanthophyll catabolic process","canonical_id":"go:GO:0016124","description":"\"The chemical reactions and pathways resulting in the breakdown of xanthophylls, oxygen-containing carotenoids.\" [GOC:curators]","metadata":null},{"id":"445c67c90ab64af9a1142182e540a559","type":"GO_TERM","name":"xanthophyll cycle","canonical_id":"go:GO:0010028","description":"\"A cyclic series of interconversions involving three xanthophylls, violoxanthin, antheraxanthin, and zeaxanthin. The xanthophyll cycle is involved in regulating energy dissipation in light harvesting complex II.\" [ISBN:0122146743]","metadata":null},{"id":"2d59bf06f6764625893022280d98ba28","type":"GO_TERM","name":"xanthophyll metabolic process","canonical_id":"go:GO:0016122","description":"\"The chemical reactions and pathways involving xanthophylls, oxygen-containing carotenoids.\" [ISBN:0198547684]","metadata":null},{"id":"989dafc478df4b2b83efbb8faddd717b","type":"GO_TERM","name":"xanthosine biosynthetic process","canonical_id":"go:GO:1903229","description":"\"The chemical reactions and pathways resulting in the formation of xanthosine.\" [GO_REF:0000068, GOC:TermGenie, PMID:7007809, PMID:7559336]","metadata":null},{"id":"f3c06864a7c342a09532fcfcaf4f9a92","type":"GO_TERM","name":"xanthosine catabolic process","canonical_id":"go:GO:1903228","description":"\"The chemical reactions and pathways resulting in the breakdown of xanthosine.\" [GO_REF:0000068, GOC:TermGenie, PMID:7007809, PMID:7559336]","metadata":null},{"id":"cf5531f6e3bd4beeb9dbd07759316d1f","type":"GO_TERM","name":"xanthosine nucleotidase activity","canonical_id":"go:GO:0072585","description":"\"Catalysis of the reaction: xanthosine + H2O = D-ribose + xanthine.\" [GOC:kad, MetaCyc:RXN0-363, PMID:21235647]","metadata":null},{"id":"4b12c96999d640e59f13f63ca5b4b832","type":"GO_TERM","name":"xanthosine transmembrane transporter activity","canonical_id":"go:GO:0015553","description":"\"Enables the transfer of xanthosine, xanthine riboside, from one side of a membrane to the other.\" [ISBN:0198506732]","metadata":null},{"id":"e5f11284a94b49e79948e0d6cc7e5a5d","type":"GO_TERM","name":"xanthosine transport","canonical_id":"go:GO:0015863","description":"\"The directed movement of xanthosine, xanthine riboside, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [ISBN:0198506732]","metadata":null},{"id":"9129de61dc404a3ca121d78e043e6032","type":"GO_TERM","name":"xanthosine:proton symporter activity","canonical_id":"go:GO:0015537","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: xanthosine(out) + H+(out) = xanthosine(in) + H+(in).\" [TC:2.A.1.10.2]","metadata":null},{"id":"4cffd7211545489ebc993a7108cd1233","type":"GO_TERM","name":"xanthoxin dehydrogenase (NAD+) activity","canonical_id":"go:GO:0010301","description":"\"Catalysis of the reaction: NAD+ + xanthoxin = (+)-abscisic aldehyde + H+ + NADH.\" [EC:1.1.1.288, RHEA:12548]","metadata":null},{"id":"43ea676b1a4c4d5582be79dd5892d647","type":"DRUG","name":"xeligekimab","canonical_id":"gtopdb:13784","description":null,"metadata":null},{"id":"d2edbb1c10df43518ff68a7f687a9ee7","type":"GO_TERM","name":"xenobiotic catabolic process","canonical_id":"go:GO:0042178","description":"\"The chemical reactions and pathways resulting in the breakdown of a xenobiotic compound, a compound foreign to the organism exposed to it, carried out by individual cells. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:jl, GOC:krc]","metadata":null},{"id":"e07ccc6ea79041eab0cddd1eecc5e353","type":"GO_TERM","name":"xenobiotic detoxification by transmembrane export across the cell outer membrane","canonical_id":"go:GO:0140330","description":"\"A process that reduces or removes the toxicity of a xenobiotic by exporting it outside the cell through the outer membrane.\" [PMID:11948170]","metadata":null},{"id":"c9a29ddce2314d7ca48da80a34ce4b86","type":"GO_TERM","name":"xenobiotic detoxification by transmembrane export across the plasma membrane","canonical_id":"go:GO:1990961","description":"\"A process that reduces or removes the toxicity of a xenobiotic by exporting it outside the cell.\" [PMID:28355133]","metadata":null},{"id":"4669870578774cb1a91a18b5f1b287fc","type":"GO_TERM","name":"xenobiotic export from cell","canonical_id":"go:GO:0046618","description":"\"The directed movement of a xenobiotic from a cell, into the extracellular region. A xenobiotic is a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:curators, GOC:krc]","metadata":null},{"id":"34a74050c76a41098218a213347b2b81","type":"GO_TERM","name":"xenobiotic metabolic process","canonical_id":"go:GO:0006805","description":"\"The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:cab2, GOC:krc]","metadata":null},{"id":"edb4c927abf84d46a03301fefb49f034","type":"GO_TERM","name":"xenobiotic transmembrane transport","canonical_id":"go:GO:0006855","description":"\"The process in which a xenobiotic, a compound foreign to the organism exposed to it, is transported across a membrane. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:ai, GOC:bf, GOC:krc]","metadata":null},{"id":"a066c7ccaafa41cb9b141dbcbd0dca69","type":"GO_TERM","name":"xenobiotic transmembrane transporter activity","canonical_id":"go:GO:0042910","description":"\"Enables the directed movement of a xenobiotic from one side of a membrane to the other. A xenobiotic is a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:curators, GOC:krc]","metadata":null},{"id":"96ff1cc0aeae4b6fa10f2c044c6af7e6","type":"GO_TERM","name":"xenobiotic transport","canonical_id":"go:GO:0042908","description":"\"The directed movement of a xenobiotic into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A xenobiotic is a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.\" [GOC:curators, GOC:krc]","metadata":null},{"id":"678b572db8f24d2db299abb4e2a381c9","type":"GO_TERM","name":"xenobiotic transport across blood-brain barrier","canonical_id":"go:GO:1990962","description":"\"The directed movement of a xenobiotic through the blood-brain barrier.\" [PMID:25053619]","metadata":null},{"id":"ad86404b33ba452e829c2ac2b7f94c2b","type":"GO_TERM","name":"xenobiotic transport across blood-nerve barrier","canonical_id":"go:GO:0061772","description":"\"The directed movement of a xenobiotic through the blood-nerve barrier.\" [GOC:dph, PMID:22733753]","metadata":null},{"id":"b75a23223f62446eafc46cf59d5b3f34","type":"GO_TERM","name":"xenophagy","canonical_id":"go:GO:0098792","description":"\"The selective degradation of intracellular pathogen or some part of an intracellular pathogen (e.g. viral capsid) by macroautophagy.\" [GOC:autophagy, GOC:pad, GOC:PARL, PMID:19802565, PMID:20159618, PMID:25497060]","metadata":null},{"id":"ece8761ff56246a5b1eece5b8acc9800","type":"DISEASE","name":"xerostomia","canonical_id":"efo:0009869","description":null,"metadata":null},{"id":"23360dbd43d645c99dc78fd6a0288b79","type":"GO_TERM","name":"xylan 1,3-beta-xylosidase activity","canonical_id":"go:GO:0033914","description":"\"Catalysis of the hydrolysis of successive xylose residues from the non-reducing termini of (1->3)-beta-D-xylans.\" [EC:3.2.1.72]","metadata":null},{"id":"ff3605d287a74b9a82e1d1c15e9b08fd","type":"GO_TERM","name":"xylan 1,4-beta-xylosidase activity","canonical_id":"go:GO:0009044","description":"\"Catalysis of the hydrolysis of (1->4)-beta-D-xylans so as to remove successive D-xylose residues from the non-reducing termini.\" [EC:3.2.1.37]","metadata":null},{"id":"df73d92a20f94e528d21129faefc7554","type":"GO_TERM","name":"xylan O-acetyltransferase activity","canonical_id":"go:GO:1990538","description":"\"Catalysis of the reaction: acetyl-CoA + a xylan= CoA + an acetylated xylan.\" [PMID:25141999]","metadata":null},{"id":"e3968218ab0f4b2585d0748151c54fb7","type":"GO_TERM","name":"xylan alpha-1,2-glucuronosidase activity","canonical_id":"go:GO:0033939","description":"\"Catalysis of the hydrolysis of alpha-D-(1->2)-(4-O-methyl)glucuronosyl links in the main chain of hardwood xylans.\" [EC:3.2.1.131]","metadata":null},{"id":"0a472c060b9e44729f312dfa94ba6b8e","type":"GO_TERM","name":"xylan binding","canonical_id":"go:GO:2001062","description":"\"Binding to xylan.\" [GOC:mengo_curators]","metadata":null},{"id":"56d28125affb4e06bfb7cfdab4917a9a","type":"GO_TERM","name":"xylan biosynthetic process","canonical_id":"go:GO:0045492","description":"\"The chemical reactions and pathways resulting in the formation of xylan, a polymer containing a beta-1,4-linked D-xylose backbone.\" [GOC:curators, PMID:11931668]","metadata":null},{"id":"17a0217ae46b44e3b90dae7483c3649a","type":"GO_TERM","name":"xylan catabolic process","canonical_id":"go:GO:0045493","description":"\"The chemical reactions and pathways resulting in the breakdown of xylan, a polymer containing a beta-1,4-linked D-xylose backbone.\" [GOC:curators, PMID:11931668]","metadata":null},{"id":"ec756eaeb365435b97c059e7950341eb","type":"GO_TERM","name":"xylan endo-1,3-beta-xylosidase activity","canonical_id":"go:GO:0033905","description":"\"Catalysis of the random hydrolysis of (1->3)-beta-D-glycosidic linkages in (1->3)-beta-D-xylans.\" [EC:3.2.1.32]","metadata":null},{"id":"b61f04e3fe9d46759d5ed9e5166f4a3f","type":"GO_TERM","name":"xylan metabolic process","canonical_id":"go:GO:0045491","description":"\"The chemical reactions and pathways involving xylan, a polymer containing a beta-1,4-linked D-xylose backbone.\" [GOC:curators, PMID:11931668]","metadata":null},{"id":"660817ba037e4cf78fbc3bc6388433c5","type":"GO_TERM","name":"xylanase activity","canonical_id":"go:GO:0097599","description":"\"Catalysis of the hydrolysis of xylans, homopolysaccharides composed of xylose residues.\" [GOC:jh2, ISBN:81-7736-269-0]","metadata":null},{"id":"24462af567844d63a15eefb77e39260b","type":"GO_TERM","name":"xylanosome","canonical_id":"go:GO:1990358","description":"\"A multifunctional supermolecular complex, containing several proteins with hemicellulase activity. Functions to hydrolyze hemicellulose.\" [GOC:mengo_curators, PMID:16769147]","metadata":null},{"id":"f4fb276e447f493f8fc5e7c2168463fa","type":"GO_TERM","name":"xylem and phloem pattern formation","canonical_id":"go:GO:0010051","description":"\"The regionalization process that gives rise to the patterning of the conducting tissues. An example of this process is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tb]","metadata":null},{"id":"95d6c33485c24b17b6759d4384b9a208","type":"GO_TERM","name":"xylem development","canonical_id":"go:GO:0010089","description":"\"The formation of the principal water-conducting tissue of a vascular plant.\" [GOC:tb, ISBN:0471245208]","metadata":null},{"id":"be15f59ec94e4b18936568ca5e08b32a","type":"GO_TERM","name":"xylem vessel member cell differentiation","canonical_id":"go:GO:0048759","description":"\"The process in which a relatively unspecialized cell acquires specialized features of a vessel member cell. A vessel member cell is one of the components of a vessel in the xylem. It is a dead cell with the wall between adjacent members being variously perforated and the walls that persist variously thickened.\" [GOC:jid, PO:0002003]","metadata":null},{"id":"7d71bda8d19644a48d35e16f6e1af271","type":"GO_TERM","name":"xylem-to-phloem iron transport","canonical_id":"go:GO:1990388","description":"\"The directed movement of iron ions into the phloem from the xylem.\" [GOC:tb, PMID:24867923]","metadata":null},{"id":"5304cff17101440eb239fe6021b2266e","type":"GO_TERM","name":"xylene catabolic process","canonical_id":"go:GO:0042184","description":"\"The chemical reactions and pathways resulting in the breakdown of xylene, a mixture of three colorless, aromatic hydrocarbon liquids, ortho-, meta- and para-xylene.\" [GOC:curators]","metadata":null},{"id":"7035a230fb09467bb10347445f87380a","type":"GO_TERM","name":"xylitol catabolic process","canonical_id":"go:GO:0051160","description":"\"The chemical reactions and pathways resulting in the breakdown of xylitol, a five-carbon sugar alcohol derived from xylose by reduction of the carbonyl group.\" [GOC:ai]","metadata":null},{"id":"0f1baef9932845e1995f2f377e6e5a7a","type":"GO_TERM","name":"xylitol catabolic process to D-xylulose 5-phosphate","canonical_id":"go:GO:0019697","description":"\"The chemical reactions and pathways resulting in the breakdown of xylitol to form xylulose 5-phosphate.\" [MetaCyc:LARABITOLUTIL-PWY]","metadata":null},{"id":"c9c719e5149c4c8982bf866037e21803","type":"GO_TERM","name":"xylitol kinase activity","canonical_id":"go:GO:0050400","description":"\"Catalysis of the reaction: ATP + xylitol = ADP + 2 H+ + xylitol 5-phosphate.\" [EC:2.7.1.122, RHEA:20209]","metadata":null},{"id":"efd154c1d5d74e9a86692cdfb5351bab","type":"GO_TERM","name":"xylitol metabolic process","canonical_id":"go:GO:0051164","description":"\"The chemical reactions and pathways involving xylitol, a five-carbon sugar alcohol derived from xylose by reduction of the carbonyl group. It is as sweet as sucrose and is used as a noncariogenic sweetner and as a sugar substitute in diabetic diets.\" [GOC:ai]","metadata":null},{"id":"0138891691c84cefb0834ad736b72753","type":"GO_TERM","name":"xylitol oxidase activity","canonical_id":"go:GO:0050582","description":"\"Catalysis of the reaction: xylitol + O2 = xylose + H2O2. Xylitol (five carbons) and sorbitol (6 carbons) are the preferred substrates.\" [EC:1.1.3.41]","metadata":null},{"id":"cf7fe879c97047c2a4d6409dec829a96","type":"GO_TERM","name":"xylitol transmembrane transport","canonical_id":"go:GO:1902341","description":"\"The directed movement of a xylitol across a membrane. Xylitol is a polyalcohol (pentane-1,2,3,4,5-pentol), produced by hydrogenation of xylose.\" [GOC:TermGenie, PMID:23475614]","metadata":null},{"id":"41fb7d609b944a4f8392a1ea1e54f934","type":"GO_TERM","name":"xylogalacturonan beta-1,3-xylosyltransferase activity","canonical_id":"go:GO:0102983","description":"\"Catalysis of the reaction: UDP-alpha-D-xylose + a homogalacturonan = UDP + 4 H+ + a xylogalacturonan.\" [EC:2.4.2.41, GOC:pz]","metadata":null},{"id":"6689d87ae46645b7ad149538e13c3c9f","type":"GO_TERM","name":"xylogalacturonan metabolic process","canonical_id":"go:GO:0010398","description":"\"The chemical reactions and pathways involving xylogalacturonan, a pectin characterized by a backbone of alpha-(1->4)-linked D-galacturonic acid residues substituted on C-3 with beta-D-xylopyranose residues.\" [GOC:tair_curators]","metadata":null},{"id":"2af262b3daa44f6db240a01f4cdaf0d8","type":"GO_TERM","name":"xyloglucan 1,6-alpha-xylosidase activity","canonical_id":"go:GO:0080176","description":"\"Catalysis of the hydrolysis of xyloglucan side chains so as to remove unsubstituted D-xylose residues attached to the glucose located at the non-reducing terminus.\" [PMID:20801759]","metadata":null},{"id":"ce729aaed9b8440695bc2688f2adbc89","type":"GO_TERM","name":"xyloglucan 4-glucosyltransferase activity","canonical_id":"go:GO:0033826","description":"\"Catalysis of the transfer of a beta-D-glucosyl residue from UDP-glucose on to a glucose residue in xyloglucan, forming a beta-1,4-D-glucosyl-D-glucose linkage.\" [EC:2.4.1.168]","metadata":null},{"id":"869109b03c6b4f9eaf01f09397bd27ef","type":"GO_TERM","name":"xyloglucan 6-xylosyltransferase activity","canonical_id":"go:GO:0033843","description":"\"Catalysis of the transfer of an alpha-D-xylosyl residue from UDP-D-xylose to a glucose residue in xyloglucan, forming an alpha-1,6-D-xylosyl-D-glucose linkage.\" [EC:2.4.2.39]","metadata":null},{"id":"a962db741f5a4368971fb970ab51beaf","type":"GO_TERM","name":"xyloglucan biosynthetic process","canonical_id":"go:GO:0009969","description":"\"The chemical reactions and pathways resulting in the formation of xyloglucan, the cross-linking glycan composed of (1->4)-beta-D glucan backbone substituted at regular intervals with beta-D-xylosyl-(1->6) residues, which is present in the primary cell wall of most higher plants.\" [GOC:sm]","metadata":null},{"id":"ef0838e2acc5428e9f349b39d0047716","type":"GO_TERM","name":"xyloglucan catabolic process","canonical_id":"go:GO:2000899","description":"\"The chemical reactions and pathways resulting in the breakdown of a xyloglucan.\" [GOC:mengo_curators]","metadata":null},{"id":"81eec88b4fb345d0874f6092c16b0d36","type":"GO_TERM","name":"xyloglucan metabolic process","canonical_id":"go:GO:0010411","description":"\"The chemical reactions and pathways involving xyloglucan, the cross-linking glycan composed of (1->4)-beta-D-glucan backbone substituted at regular intervals with beta-D-xylosyl-(1->6) residues, which is present in the primary cell wall of most higher plants.\" [GOC:tair_curators]","metadata":null},{"id":"300135be157f4be8885f9a017cc8d7c7","type":"GO_TERM","name":"xyloglucan-specific endo-beta-1,4-glucanase activity","canonical_id":"go:GO:0033946","description":"\"Catalysis of the reaction: xyloglucan + H2O = xyloglucan oligosaccharides. This reaction is the endohydrolysis of (1->4)-beta-D-glucosidic linkages in xyloglucan.\" [EC:3.2.1.151]","metadata":null},{"id":"73309573187247f49e38b508a6b983c9","type":"GO_TERM","name":"xyloglucan-specific endo-beta-1,4-glucanase inhibitor activity","canonical_id":"go:GO:0140594","description":"\"Stops, prevents or reduces the activity of xyloglucan-specific endo-beta-1,4-glucanase.\" [PMID:28082413]","metadata":null},{"id":"91ade4fae250412eb54a7dbe421dcfc5","type":"GO_TERM","name":"xyloglucan-specific exo-beta-1,4-glucanase activity","canonical_id":"go:GO:0033950","description":"\"Catalysis of the reaction: xyloglucan + H2O = xyloglucan oligosaccharides. This reaction is the exohydrolysis of 1,4-beta-D-glucosidic linkages in xyloglucan.\" [EC:3.2.1.155]","metadata":null},{"id":"273234ae0c6b46c181c2f6f7fd85f95b","type":"GO_TERM","name":"xyloglucan:xyloglucosyl transferase activity","canonical_id":"go:GO:0016762","description":"\"Catalysis of the cleavage of a beta-(1->4) bond in the backbone of a xyloglucan and transfers the xyloglucanyl segment on to O-4 of the non-reducing terminal glucose residue of an acceptor, which can be a xyloglucan or an oligosaccharide of xyloglucan.\" [EC:2.4.1.207, GOC:ask, PMID:1400418, PMID:1554366]","metadata":null},{"id":"dbebc412aab7422699f27663087ff4aa","type":"GO_TERM","name":"xylonate dehydratase activity","canonical_id":"go:GO:0050401","description":"\"Catalysis of the reaction: D-xylonate = 2-dehydro-3-deoxy-D-arabinonate + H2O.\" [EC:4.2.1.82, RHEA:19157]","metadata":null},{"id":"30902f92efe34bbcb2a301a76b196401","type":"GO_TERM","name":"xylono-1,4-lactonase activity","canonical_id":"go:GO:0050402","description":"\"Catalysis of the reaction: D-xylono-1,4-lactone + H2O = D-xylonate.\" [EC:3.1.1.68]","metadata":null},{"id":"b29d4caee86b436d81f3c95b1c235571","type":"GO_TERM","name":"xylose binding","canonical_id":"go:GO:0033222","description":"\"Binding to the D- or L-enantiomer of xylose.\" [GOC:mah]","metadata":null},{"id":"5da0037dad1c4c99b7b303e0f5798e91","type":"GO_TERM","name":"xylose isomerase activity","canonical_id":"go:GO:0009045","description":"\"Catalysis of the reaction: alpha-D-xylose = alpha-D-xylulofuranose.\" [RHEA:22816]","metadata":null},{"id":"f80d47c2ea364ca99a2cc830055b475d","type":"GO_TERM","name":"xylosyl alpha-1,3-xylosyltransferase activity","canonical_id":"go:GO:0140560","description":"\"Catalyzes the reaction: UDP-alpha-D-xylose + [protein with EGF-like domain]-3-O-(alpha-D-xylosyl-(1->3)-beta-D-glucosyl)-L-serine = UDP + [protein with EGF-like domain]-3-O-(alpha-D-xylosyl-(1->3)-alpha-D-xylosyl-(1->3)-beta-D-glucosyl)-L-serine. The enzyme, found in animals and insects, is involved in the biosynthesis of the alpha-D-xylosyl-(1->3)-alpha-D-xylosyl-(1->3)- beta-D-glucosyl trisaccharide on epidermal growth factor-like (EGF- like) domains.\" [PMID:22117070, PMID:8982869, RHEA:22820]","metadata":null},{"id":"f1ecda1e75a64084a1970e3fa38766bb","type":"GO_TERM","name":"xylosylprotein 4-beta-galactosyltransferase activity","canonical_id":"go:GO:0046525","description":"\"Catalysis of the reaction: UDP-galactose + O-beta-D-xylosylprotein = UDP + 4-beta-D-galactosyl-O-beta-D-xylosylprotein.\" [EC:2.4.1.133]","metadata":null},{"id":"aaae9ee86ec64476a85dbb2955c0c825","type":"GO_TERM","name":"xylosyltransferase activity","canonical_id":"go:GO:0042285","description":"\"Catalysis of the transfer of a xylosyl group to an acceptor molecule, typically another carbohydrate or a lipid.\" [GOC:ai]","metadata":null},{"id":"e60623cb358a489d9e78ea40ba7b39b0","type":"GO_TERM","name":"xylotriose transport","canonical_id":"go:GO:2001094","description":"\"The directed movement of a xylotrioseacetate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:mengo_curators]","metadata":null},{"id":"5a2fa95d09904697ae203a41309a0785","type":"GO_TERM","name":"xylulose biosynthetic process","canonical_id":"go:GO:0005999","description":"\"The chemical reactions and pathways resulting in the formation of xylulose, the ketopentose threo-2-pentulose.\" [ISBN:0198547684]","metadata":null},{"id":"e3af38d6e8e44620b9406249da46522f","type":"GO_TERM","name":"xylulose catabolic process","canonical_id":"go:GO:0005998","description":"\"The chemical reactions and pathways resulting in the breakdown of xylulose, the ketopentose threo-2-pentulose.\" [ISBN:0198547684]","metadata":null},{"id":"3d2b328372514f1ba99ac3b2d0b8aed5","type":"GO_TERM","name":"xylulose metabolic process","canonical_id":"go:GO:0005997","description":"\"The chemical reactions and pathways involving xylulose, the ketopentose threo-2-pentulose.\" [ISBN:0198547684]","metadata":null},{"id":"2c2b0f0342cc4044ac3b7106ea1ee7e2","type":"GO_TERM","name":"yeast-form cell wall","canonical_id":"go:GO:0030445","description":"\"The wall surrounding a cell of a dimorphic fungus growing in the single-cell budding yeast form, in contrast to the filamentous or hyphal form.\" [GOC:mah, GOC:mcc, PMID:36266346]","metadata":null},{"id":"c8babdd2cd40441fbacb76a00a1acafd","type":"DRUG","name":"yohimbine","canonical_id":"gtopdb:102","description":null,"metadata":null},{"id":"d5bb650998d3465dbc2c43a15a14986a","type":"GO_TERM","name":"yolk","canonical_id":"go:GO:0060417","description":"\"The cytoplasmic part that serves as a nutrient reserve or energy source for the developing embryo.\" [GOC:dph, GOC:tb, PMID:18046696]","metadata":null},{"id":"a4461491f3bc49a8910cf6612aefad2e","type":"GO_TERM","name":"yolk granule","canonical_id":"go:GO:0042718","description":"\"Discrete structures that partition the water-insoluble portion of the yolk of oocytes and ova, which may or may not be membrane enclosed.\" [GOC:jl, PMID:18046696, PMID:6337890]","metadata":null},{"id":"68f7e56aef504a9988775d51ce151f61","type":"GO_TERM","name":"yolk plasma","canonical_id":"go:GO:0060418","description":"\"Discrete structures that partition the water-soluble portion of the yolk of oocytes and ova, which may or may not be membrane enclosed.\" [GOC:dph, GOC:tb, PMID:18046696]","metadata":null},{"id":"613c798db5224e258bbbf396fd5d975d","type":"GO_TERM","name":"yolk syncytial layer development","canonical_id":"go:GO:0106336","description":"\"The progression of the yolk syncytial layer over time, from its initial formation to the mature structure. The yolk syncytial layer is the peripheral layer of the yolk cell including nuclei and non-yolky cytoplasm.\" [PMID:29180571]","metadata":null},{"id":"88ab8d9a14a04a20a2852dc2391a08df","type":"DRUG","name":"zafirlukast","canonical_id":"gtopdb:3322","description":null,"metadata":null},{"id":"4b8660afc90b4825b64172373af4611c","type":"DRUG","name":"zafirlukast","canonical_id":"chembl:CHEMBL603","description":null,"metadata":null},{"id":"b10ebf94f807402eac14f9d9ee1371cb","type":"DRUG","name":"zaleplon","canonical_id":"mesh:C085665","description":null,"metadata":null},{"id":"bb956040aff64079a293bcb1fe81b013","type":"DRUG","name":"zanamivir","canonical_id":"mesh:D053243","description":null,"metadata":null},{"id":"a9ee9242f1394b2183c140225c43f4fd","type":"GO_TERM","name":"zearalenone biosynthetic process","canonical_id":"go:GO:0106150","description":"\"The chemical reactions and pathways resulting in the formation of zearalenone, a mycotoxin produced by several Fusarium species, is most commonly found as a contaminant in stored grain and has chronic estrogenic effects on mammals.\" [GOC:ach, PMID:16517624, PMID:20578001]","metadata":null},{"id":"99920baaf01845f3ac62437d6ad2c20d","type":"GO_TERM","name":"zeatin 9-aminocarboxyethyltransferase activity","canonical_id":"go:GO:0050447","description":"\"Catalysis of the reaction: O-acetyl-L-serine + zeatin = L-lupinate + acetate + H+.\" [EC:2.5.1.50, RHEA:17333]","metadata":null},{"id":"d87a78a299f4468cbeaf03726fc6ad30","type":"GO_TERM","name":"zeatin O-beta-D-xylosyltransferase activity","canonical_id":"go:GO:0050404","description":"\"Catalysis of the reaction: UDP-alpha-D-xylose + zeatin = O-beta-D-xylosylzeatin + H+ + UDP.\" [EC:2.4.2.40, RHEA:14721]","metadata":null},{"id":"89ae93bc675940ab8b92b18aa0551891","type":"GO_TERM","name":"zeatin biosynthetic process","canonical_id":"go:GO:0033398","description":"\"The chemical reactions and pathways resulting in the formation of zeatin, 2-methyl-4-(9H-purin-6-ylamino)but-2-en-1-ol.\" [GOC:mah]","metadata":null},{"id":"24fb2e1eb46140918634f2867758ae99","type":"GO_TERM","name":"zeatin reductase activity","canonical_id":"go:GO:0050472","description":"\"Catalysis of the reaction: dihydrozeatin + NADP+ = H+ + NADPH + zeatin.\" [EC:1.3.1.69, RHEA:12757]","metadata":null},{"id":"3c903bd2370e4578a2a5a8102115b390","type":"GO_TERM","name":"zeaxanthin 2-beta-hydroxylase activity","canonical_id":"go:GO:0102464","description":"\"Catalysis of the reaction: zeaxanthin + O2 + NADH + H+ = caloxanthin + H2O + NAD.\" [GOC:pz, PMID:22509387]","metadata":null},{"id":"d821d2e04f774ec7bbeb875b71273da6","type":"GO_TERM","name":"zeaxanthin biosynthetic process","canonical_id":"go:GO:1901827","description":"\"The chemical reactions and pathways resulting in the formation of zeaxanthin.\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-5944, UniPathway:UPA00843]","metadata":null},{"id":"38d2b75f7e7d4767ace9747022495294","type":"GO_TERM","name":"zeaxanthin bis(beta-D-glucoside) biosynthetic process","canonical_id":"go:GO:1901830","description":"\"The chemical reactions and pathways resulting in the formation of zeaxanthin bis(beta-D-glucoside).\" [GOC:TermGenie, GOC:yaf, MetaCyc:PWY-6288, PMID:20075616, UniPathway:UPA00798]","metadata":null},{"id":"c974f9d83a2e47adb540afc37fe1bf83","type":"GO_TERM","name":"zeaxanthin catabolic process","canonical_id":"go:GO:1901826","description":"\"The chemical reactions and pathways resulting in the breakdown of zeaxanthin.\" [GOC:TermGenie, GOC:yaf, UniPathway:UPA00843]","metadata":null},{"id":"d1542e8994ad4bd39ab66bc9e4e09f04","type":"GO_TERM","name":"zeaxanthin epoxidase activity","canonical_id":"go:GO:0052662","description":"\"Catalysis of the reaction: all-trans-zeaxanthin + 4 H+ + 2 O2 + 4 reduced [2Fe-2S]-[ferredoxin] = all-trans-violaxanthin + 2 H2O + 4 oxidized [2Fe-2S]-[ferredoxin].\" [RHEA:32443]","metadata":null},{"id":"741ccefac4fe474d90b0aac9cd1e6f27","type":"GO_TERM","name":"zerumbone synthase activity","canonical_id":"go:GO:0102069","description":"\"Catalysis of the reaction: 8-hydroxy-alpha-humulene + NAD = zerumbone + NADH + H+.\" [EC:1.1.1.326, GOC:pz]","metadata":null},{"id":"72f017fc16634eb6af26fead641f3122","type":"GO_TERM","name":"zeta DNA polymerase complex","canonical_id":"go:GO:0016035","description":"\"A heterodimeric DNA polymerase complex that catalyzes error-prone DNA synthesis in contexts such as translesion synthesis and double-stranded break repair. First characterized in Saccharomyces, in which the subunits are Rev3p and Rev7p; a third protein, Rev1p, is often associated with the polymerase dimer.\" [PMID:16631579, PMID:16971464]","metadata":null},{"id":"877ae9107bb342c19150c9a92a9bc2cc","type":"GO_TERM","name":"zf-TRAF domain binding","canonical_id":"go:GO:0044198","description":"\"Binding to a TRAF-type zinc finger domain of a protein.\" [InterPro:IPR001293]","metadata":null},{"id":"b72733397b2549c0afb8cf3d0b942c57","type":"DRUG","name":"zileuton","canonical_id":"gtopdb:5297","description":null,"metadata":null},{"id":"4f4ec7e2095349d8b4e8e67da2766c2e","type":"DRUG","name":"zileuton","canonical_id":"chembl:CHEMBL93","description":null,"metadata":null},{"id":"90dd3a3ea4c747a2946509267d9b7f4f","type":"GO_TERM","name":"zinc D-Ala-D-Ala carboxypeptidase activity","canonical_id":"go:GO:0009046","description":"\"Catalysis of the cleavage of the D-alanyl-D-alanine bond in (Ac)2-L-lysyl-D-alanyl-D-alanine.\" [EC:3.4.17.14]","metadata":null},{"id":"8c1264b5a420439889d7ba51b9517bb7","type":"GO_TERM","name":"zinc chaperone activity","canonical_id":"go:GO:0140827","description":"\"Binding to and delivering zinc ions to a target protein.\" [PMID:35584675]","metadata":null},{"id":"211e37fdd6604d5d86104be61b346aa6","type":"GO_TERM","name":"zinc efflux antiporter activity","canonical_id":"go:GO:0015341","description":"\"Enables the transfer of a zinc ion or zinc ions from the inside of the cell to the outside of the cell across a membrane according to the reaction H+(out) + Zn2+(in) = H+(in) + Zn2+(out). The activity is driven by proton motive force.\" [GOC:mtg_transport, ISBN:0815340729, PMID:35226479, TC:2.A.4.1.4, TC:2.A.4.2.3]","metadata":null},{"id":"a6b00244732b4130b4416423d1e6afaa","type":"GO_TERM","name":"zinc efflux transmembrane transporter activity","canonical_id":"go:GO:0022883","description":"\"Enables the transfer of a zinc ion or zinc ions from the inside of the cell to the outside of the cell across a membrane.\" [GOC:mtg_transport, ISBN:0815340729]","metadata":null},{"id":"ce36ee51b6ba40fca47e002e3d0357f3","type":"GO_TERM","name":"zinc export across plasma membrane","canonical_id":"go:GO:0140882","description":"\"The directed movement of zinc ions from a cell, into the extracellular region.\" [PMID:17355957]","metadata":null},{"id":"96f9271aebad4aeeb85e24b02b502e3c","type":"GO_TERM","name":"zinc ion binding","canonical_id":"go:GO:0008270","description":"\"Binding to a zinc ion (Zn).\" [GOC:ai]","metadata":null},{"id":"a7ac46ed23cf45a89c61dfe17c54d117","type":"GO_TERM","name":"zinc ion export from vacuole","canonical_id":"go:GO:0140147","description":"\"The directed movement of zinc ions from inside the vacuole across the vacuolar membrane and into the cytosol.\" [GOC:vw, PMC:PMC203372]","metadata":null},{"id":"3b000fa933784c7fb4b9ad75d2402d57","type":"GO_TERM","name":"zinc ion import across plasma membrane","canonical_id":"go:GO:0071578","description":"\"The directed movement of zinc(2+) ions from outside of a cell, across the plasma membrane and into the cytosol.\" [GOC:vw, PMID:18637840]","metadata":null},{"id":"75f99ae0d21a4432b66deb2f7032d469","type":"GO_TERM","name":"zinc ion import into Golgi lumen","canonical_id":"go:GO:1904257","description":"\"The directed import of zinc(2+) from the cytosol across the Golgi membrane into the Golgi lumen.\" [GO_REF:0000075, GOC:TermGenie, PMID:25732056]","metadata":null},{"id":"08104fed73254318833ec4ccb20d7b80","type":"GO_TERM","name":"zinc ion import into endoplasmic reticulum","canonical_id":"go:GO:0140209","description":"\"The directed import of zinc(2+) from the cytosol, across the endoplasmic reticulum membrane, into the endoplasmic reticulum.\" [PMID:11886869, PMID:29529046]","metadata":null},{"id":"096056b65d0343b2994d7fb8a99c17db","type":"GO_TERM","name":"zinc ion import into lysosome","canonical_id":"go:GO:0140916","description":"\"The directed import of zinc(2+) from the cytosol, across an organelle membrane, into a lysosome.\" [PMID:25808614]","metadata":null},{"id":"50777fd2e8f84a528e2e0caf9c76759f","type":"GO_TERM","name":"zinc ion import into mitochondrion","canonical_id":"go:GO:0140917","description":"\"The directed import of zinc(2+) from the cytosol, across an organelle membrane, into a mitochondrion.\" [PMID:21289295]","metadata":null},{"id":"5945aa6882234d6f8ba5c9b4d30dcf78","type":"GO_TERM","name":"zinc ion import into organelle","canonical_id":"go:GO:0062111","description":"\"The directed import of zinc(2+) from the cytosol, across an organelle membrane, into the organelle.\" [PMID:29529046]","metadata":null},{"id":"7704343196c44e059a8546e7dcc5f04e","type":"GO_TERM","name":"zinc ion import into secretory vesicle","canonical_id":"go:GO:0140914","description":"\"The directed import of zinc(2+) from the cytosol, across an organelle membrane, into a secretory vesicle.\" [PMID:19496757]","metadata":null},{"id":"b07f3e46b74245c59efdcf9adb6285b7","type":"GO_TERM","name":"zinc ion import into synaptic vesicle","canonical_id":"go:GO:0099180","description":"\"The directed movement of Zn2+ ions from the cytoplasm into the lumen of a cytoplasmic vesicle.\" [PMID:9990090]","metadata":null},{"id":"d0743e6c13144777aaa345b3b8127c78","type":"GO_TERM","name":"zinc ion import into zymogen granule","canonical_id":"go:GO:0140915","description":"\"The directed import of zinc(2+) from the cytosol, across an organelle membrane, into a zymogen granule.\" [PMID:20133611]","metadata":null},{"id":"fe8c7ded06ea4c039b0e4d6641c3719f","type":"GO_TERM","name":"zinc ion sensor activity","canonical_id":"go:GO:0106219","description":"\"Binding to and responding, e.g. by conformational change, to changes in the cellular level of zinc.\" [GOC:vw, PMID:31239353]","metadata":null},{"id":"25e469cffd79467eac1bd98932494f9d","type":"GO_TERM","name":"zinc ion sequestering activity","canonical_id":"go:GO:0140486","description":"\"Binding to a zinc ion to prevent it from interacting with other partners or to inhibit its localization to the area of the cell or complex where it is active.\" [PMID:12050156]","metadata":null},{"id":"6405c51f761349278caacb84b3168f11","type":"GO_TERM","name":"zinc ion transmembrane transport","canonical_id":"go:GO:0071577","description":"\"A process in which a zinc II ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.\" [GOC:BHF, GOC:mah]","metadata":null},{"id":"206700f98ca8453e951fcffc3d57861a","type":"GO_TERM","name":"zinc ion transmembrane transporter activity","canonical_id":"go:GO:0005385","description":"\"Enables the transfer of zinc (Zn) ions from one side of a membrane to the other.\" [GOC:dgf]","metadata":null},{"id":"04347d1f3b8144af8caa18e782fb4ed8","type":"GO_TERM","name":"zinc ion transport","canonical_id":"go:GO:0006829","description":"\"The directed movement of zinc (Zn II) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.\" [GOC:ai]","metadata":null},{"id":"02705ce86fd44ecd98832a93d797e7b6","type":"GO_TERM","name":"zinc potentiation of synaptic transmission, glycinergic","canonical_id":"go:GO:0060095","description":"\"Any process that activates or increases the frequency, rate or extent of glycinergic synaptic transmission in the presence of zinc. Glycinergic synaptic transmission is the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glycine.\" [GOC:dms, GOC:dph]","metadata":null},{"id":"da3037bfabb649b380fb91bb4d9cad1c","type":"GO_TERM","name":"zinc:bicarbonate symporter activity","canonical_id":"go:GO:0140412","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: zinc(out) + HCO3-(out) = zinc(in) + HCO3-(in).\" [PMID:27166256]","metadata":null},{"id":"438c1a3ca6c84ba4bd2cad0173094936","type":"GO_TERM","name":"zinc:bicarbonate:selenite symporter activity","canonical_id":"go:GO:0140413","description":"\"Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: zinc(out) + HCO3-(out) + HO3Se-(out) = zinc(in) + HCO3-(in) + HO3Se-(out).\" [PMID:27166256]","metadata":null},{"id":"2afb7205b479425bbaa5f75e0e465e60","type":"GO_TERM","name":"zinc:proton antiporter activity","canonical_id":"go:GO:0140826","description":"\"Enables the transfer of zinc from one side of a membrane to the other according to the reaction: H+(out) + Zn2+(in) = H+(in) + Zn2+(out).\" [PMID:19366695, PMID:30893306]","metadata":null},{"id":"a92055cc942f4c69993373c4fdcde8f1","type":"DRUG","name":"ziprasidone","canonical_id":"gtopdb:59","description":null,"metadata":null},{"id":"7f6857f0fab349168e6e8d68d6d6286a","type":"DRUG","name":"ziprasidone","canonical_id":"mesh:C092292","description":null,"metadata":null},{"id":"60e74e81506b4523b16988deee060374","type":"DRUG","name":"zofenopril","canonical_id":"gtopdb:6462","description":null,"metadata":null},{"id":"7d84cf3c19a5467597a22b6e3d487cbe","type":"DRUG","name":"zofenopril","canonical_id":"mesh:C044958","description":null,"metadata":null},{"id":"caec71d13ed7465098d68ede3a4f4d98","type":"DRUG","name":"zolbetuximab","canonical_id":"gtopdb:9209","description":null,"metadata":null},{"id":"6df7254c77034279a973da658334aca5","type":"DRUG","name":"zolbetuximab","canonical_id":"chembl:CHEMBL2109427","description":null,"metadata":null},{"id":"5f5de6dc2fa542ecb327046e375a37c2","type":"DRUG","name":"zoledronic acid","canonical_id":"gtopdb:3177","description":null,"metadata":null},{"id":"0433e872904b4f1bae24efedfc1cb037","type":"DRUG","name":"zoledronic acid","canonical_id":"mesh:C088658","description":null,"metadata":null},{"id":"f4559d53ba65496593e2cef4440e2b1a","type":"DRUG","name":"zoledronic acid","canonical_id":"chembl:CHEMBL4303669","description":null,"metadata":null},{"id":"a91f1f6be5f045ceade734ee7480c115","type":"DRUG","name":"zolmitriptan","canonical_id":"gtopdb:60","description":null,"metadata":null},{"id":"c626a0b92dbb4e76999551a98f6bf639","type":"DRUG","name":"zolmitriptan","canonical_id":"mesh:C089750","description":null,"metadata":null},{"id":"ca90f53735ce4b8fb5344be76dca293b","type":"DRUG","name":"zolmitriptan","canonical_id":"chembl:CHEMBL1185","description":null,"metadata":null},{"id":"e43d56f482204c409ef471289d5b5c23","type":"DRUG","name":"zolpidem","canonical_id":"gtopdb:4348","description":null,"metadata":null},{"id":"501c0d52decc4c7097000ec85a523423","type":"GO_TERM","name":"zona limitans intrathalamica formation","canonical_id":"go:GO:0022006","description":"\"The formation of the narrow stripe of cells that lies between the prospective dorsal and ventral thalami. This boundary contains signals that pattern the prethalamic and thalamic territories of the future mid-diencephalon.\" [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:11425897, PMID:16452095]","metadata":null},{"id":"11e92527516f4a26bd1221a222df6501","type":"GO_TERM","name":"zona pellucida receptor complex","canonical_id":"go:GO:0002199","description":"\"A multisubunit complex comprising the chaperonin-containing T-complex and several other components involved in mediating sperm-oocyte Interaction.\" [GOC:hjd, PMID:21880732]","metadata":null},{"id":"62003a88433343e9b983ae41647c0ba7","type":"GO_TERM","name":"zonula adherens","canonical_id":"go:GO:0005915","description":"\"A cell-cell adherens junction which forms a continuous belt near the apex of epithelial cells.\" [ISBN:0815316208]","metadata":null},{"id":"a5c0bcfde0f544a29ee9505a196e2033","type":"GO_TERM","name":"zonula adherens assembly","canonical_id":"go:GO:0045186","description":"\"Assembly of the zonula adherens, a cell-cell adherens junction which forms a continuous belt near the apex of epithelial cells.\" [GOC:bf]","metadata":null},{"id":"be0993b2f3c44b8b93c9d356152380e9","type":"GO_TERM","name":"zonula adherens maintenance","canonical_id":"go:GO:0045218","description":"\"Maintaining the zonula adherens junction, the cell-cell adherens junction formed near the apex of epithelial cells.\" [GOC:bf]","metadata":null},{"id":"350221c5027748e7b47e7190da4c4f37","type":"GO_TERM","name":"zoospore encystment on host","canonical_id":"go:GO:0075218","description":"\"The physiological, developmental and morphological changes that occur in a symbiont zoospore during the process of its encystment. Encystment means to enter a state of essentially suspended animation in which the spore is protected by an outer coating and remains immobile and inactive until favorable conditions for growth occur again. The host is defined as the larger of the organisms involved in a symbiotic interaction.\" [GOC:pamgo_curators]","metadata":null},{"id":"ed6df6d4d0ee470da79d6ed5514a4f4c","type":"GO_TERM","name":"zoospore formation","canonical_id":"go:GO:0075239","description":"\"The process in which a diploid cell undergoes meiosis, and the meiotic products acquire specialized features of asexual motile mononucleate flagellated spores called zoospores.\" [GOC:pamgo_curators]","metadata":null},{"id":"633c20d6414f46aab4d73ea11946b16e","type":"DRUG","name":"zorifertinib","canonical_id":"gtopdb:10456","description":null,"metadata":null},{"id":"88e5e920af544e4588336ffece187bcd","type":"DRUG","name":"zorifertinib","canonical_id":"chembl:CHEMBL3623290","description":null,"metadata":null},{"id":"442efd26c6e046159c4e27960e9def73","type":"DRUG","name":"zuclopenthixol","canonical_id":"mesh:D003006","description":null,"metadata":null},{"id":"870176ac24e549a8b80c71e5e90232a9","type":"GO_TERM","name":"zygosporangium development","canonical_id":"go:GO:0075271","description":"\"The process in which a fruiting body called zygosporangium is formed. A zygosporangium is a thick-walled structure in which spores are produced, and is characteristic of the Zygomycetes.\" [GOC:pamgo_curators]","metadata":null},{"id":"ec0a5c9973e148af9a185fd06ee463e5","type":"GO_TERM","name":"zygospore formation","canonical_id":"go:GO:0034296","description":"\"The process in which zygospores are formed. Zygospores are characteristic of the zygomycete fungi (phylum Zygomycota) thick-walled and darkly colored, and usually heavily ornamented as well, with many spines or ridges. It is formed between two specialized organs called suspensors, which are themselves usually heavily ornamented, one from each mating partner. The zygospore forms between them and then breaks away.\" [GOC:ds, GOC:mah, PMID:21858438]","metadata":null},{"id":"360512edbc124e3f8b4468237f118d17","type":"GO_TERM","name":"zygote asymmetric cell division","canonical_id":"go:GO:0010070","description":"\"The division of the zygote into two daughter cells that will adopt developmentally distinct potentials.\" [GOC:tb]","metadata":null},{"id":"50d0dbabf498408489403720fd0e1164","type":"GO_TERM","name":"zygote asymmetric cytokinesis in embryo sac","canonical_id":"go:GO:0010069","description":"\"The division of the zygote in a plane perpendicular to the long axis of the embryo sac to produce a larger basal cell near the micropyle and a small terminal cell close to what was the central cell and is now the developing endosperm. An example of this process is found in Arabidopsis thaliana.\" [GOC:mtg_sensu, GOC:tb, ISBN:0865427429]","metadata":null},{"id":"dc519b9049964253b40670e5264f57cf","type":"GO_TERM","name":"zygote elongation","canonical_id":"go:GO:0080159","description":"\"The process in which the zygote irreversibly increases in size in one dimension after fertilization. An example of such a process is found in Arabidopsis thaliana.\" [GOC:tb]","metadata":null},{"id":"37a22eefd8ff4b5595b1e763ae6a8cc2","type":"GO_TERM","name":"zygotene","canonical_id":"go:GO:0000238","description":"\"The cell cycle phase which follows leptotene during prophase I of meiosis, and during which each chromosome pairs with its homolog; the two become aligned and crossing over may occur.\" [GOC:mtg_cell_cycle]","metadata":null},{"id":"73a1ee1cf6a848298cc6d3fc211febef","type":"GO_TERM","name":"zygotic determination of anterior/posterior axis, embryo","canonical_id":"go:GO:0007354","description":"\"The specification of the anterior/posterior axis of the embryo by products of genes expressed in the zygote; exemplified in insects by the gap genes, pair rule genes and segment polarity gene cascade.\" [http://fly.ebi.ac.uk/allied-data/lk/interactive-fly/aimain/1aahome.htm, ISBN:0879694238]","metadata":null},{"id":"978ad60efc3d41feb18a2cef7204af05","type":"GO_TERM","name":"zygotic genome activation","canonical_id":"go:GO:0141064","description":"\"A process that contributes to the onset of de novo transcription from the zygotic genome as part of the maternal-to-zygote transition in gene expression. The zygote overcomes the silencing that has been established. The cause of this silencing could be due to several factors: chromatin modifications leading to repression, or lack of adequate transcription machinery.\" [PMID:19204068, PMID:20808952]","metadata":null},{"id":"f5ee1fe974214c4a91f0fd832cc0f8b1","type":"GO_TERM","name":"zygotic specification of dorsal/ventral axis","canonical_id":"go:GO:0007352","description":"\"The specification of the dorsal/ventral axis of the embryo, through the products of genes expressed in the zygote.\" [GOC:bf]","metadata":null},{"id":"1c367100336e467fa993c1c55a111698","type":"GO_TERM","name":"zymogen activation","canonical_id":"go:GO:0031638","description":"\"The proteolytic processing of an inactive enzyme to an active form.\" [GOC:hjd]","metadata":null},{"id":"97362cfb920e48188c2e256b6713bb3f","type":"GO_TERM","name":"zymogen binding","canonical_id":"go:GO:0035375","description":"\"Binding to a zymogen, an enzymatically inactive precursor of an enzyme that is often convertible to an active enzyme by proteolysis.\" [ISBN:0198506732]","metadata":null},{"id":"ba02f3b2e4b3431fa82ae446fe374872","type":"GO_TERM","name":"zymogen granule","canonical_id":"go:GO:0042588","description":"\"A membrane-bounded, cytoplasmic secretory granule found in enzyme-secreting cells and visible by light microscopy. Contain zymogen, an inactive enzyme precursor, often of a digestive enzyme.\" [GOC:jl, ISBN:0198506732]","metadata":null},{"id":"30e8d537ded14556945b100f7fbef9c4","type":"GO_TERM","name":"zymogen granule exocytosis","canonical_id":"go:GO:0070625","description":"\"The release of intracellular molecules contained within the zymogen granule by fusion of the granule with the plasma membrane of the oocyte, requiring calcium ions.\" [GOC:BHF, GOC:vk, PMID:17442889]","metadata":null},{"id":"aaaa7f0de6d94670b570c94c81a1f7aa","type":"GO_TERM","name":"zymogen granule membrane","canonical_id":"go:GO:0042589","description":"\"The lipid bilayer surrounding a zymogen granule.\" [GOC:jl]","metadata":null},{"id":"5a4bc71fb5dc4a728fc2c5c289f7286e","type":"GO_TERM","name":"zymogen inhibition","canonical_id":"go:GO:0097341","description":"\"Any process that prevents the proteolytic processing of an inactive enzyme to an active form.\" [GOC:mtg_apoptosis, PMID:20383739]","metadata":null},{"id":"270c22fcef0e4889b9579aa95e9ce5e8","type":"GO_TERM","name":"zymosterol biosynthetic process","canonical_id":"go:GO:0036197","description":"\"The chemical reactions and pathways resulting in the formation of zymosterol, (5alpha-cholesta-8,24-dien-3beta-ol).\" [GOC:yaf, MetaCyc:PWY-6074]","metadata":null},{"id":"b024701c6c614ac4ab3456e9e47a6146","type":"GO_TERM","name":"zymosterol metabolic process","canonical_id":"go:GO:0036196","description":"\"The chemical reactions and pathways involving zymosterol, (5alpha-cholesta-8,24-dien-3beta-ol).\" [GOC:yaf]","metadata":null},{"id":"22de311cc82848259711414bd92084f0","type":"TRIAL","name":"\u00b5MRI of Therapeutic Intervention in Postmenopausal Osteoporosis","canonical_id":"clinicaltrials.gov:NCT01153425","description":"Osteoporosis, Osteopenia","metadata":null},{"id":"210bd4401c754da5a53373a13160484c","type":"TRIAL","name":"\u00df-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab","canonical_id":"clinicaltrials.gov:NCT02296424","description":"Systemic Juvenile Idiopathic Arthritis (SJIA)","metadata":null},{"id":"9271e24324424f1e91ffe2563e16d21c","type":"TRIAL","name":"\u03a4he Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","canonical_id":"clinicaltrials.gov:NCT07047651","description":"Treatment Resistant Schizophrenia; Treatment Resistant Bipolar Disorder","metadata":null},{"id":"fbd32c63244c47ea8d4c71bcc1b3b0cc","type":"TRIAL","name":"\u03b2-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence","canonical_id":"clinicaltrials.gov:NCT00888797","description":"Colorectal Neoplasms","metadata":null}]